Cancer_type	QTL_type	tag_SNP	LD	SNP	SNP_position	Alleles	Methylation_probe	Methylation_position	Probe_related_gene	Beta	t-stat	Correlation_coefficient (r)	p-value	Traits
BRCA	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	14.31	0.49	1.76e-40	Alzheimer's disease;
BRCA	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg13395646	chr4:1353034	KIAA1530	-0.52	-9.44	-0.35	6.79e-20	Obesity-related traits;
BRCA	cis	rs72772090	0.539	rs2042386	chr5:96156783	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-12.03	-0.43	3.57e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4728302	0.869	rs889825	chr7:133596227	A/G	cg07491979	chr7:133331646	EXOC4	0.36	7.84	0.3	1.88e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg24069376	chr3:38537580	EXOG	-0.31	-8.76	-0.33	1.81e-17	Electrocardiographic conduction measures;
BRCA	cis	rs4776059	1.000	rs12902679	chr15:52881317	C/T	cg25063058	chr15:52860530	ARPP19	-0.37	-8.24	-0.31	9.45e-16	Schizophrenia;
BRCA	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg01420254	chr6:26195488	NA	0.55	8.58	0.32	7.05e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg15083037	chr5:83017644	HAPLN1	0.43	9.21	0.34	4.45e-19	Prostate cancer;
BRCA	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg12661370	chr5:149340060	SLC26A2	0.51	7.81	0.3	2.44e-14	HIV-1 control;
BRCA	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-9.2	-0.34	5.08e-19	Monocyte percentage of white cells;
BRCA	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg17143192	chr8:8559678	CLDN23	0.57	11.15	0.4	1.68e-26	Obesity-related traits;
BRCA	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg25801113	chr15:45476975	SHF	-0.33	-8.06	-0.3	3.9e-15	Uric acid levels;
BRCA	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg16850897	chr7:100343110	ZAN	-0.57	-12.25	-0.44	3.72e-31	Other erythrocyte phenotypes;
BRCA	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg01017244	chr2:74357527	NA	0.57	13.12	0.46	5.33e-35	Gestational age at birth (maternal effect);
BRCA	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.47	0.35	5.16e-20	Tonsillectomy;
BRCA	cis	rs870825	0.929	rs72689272	chr4:185592515	T/C	cg04058563	chr4:185651563	MLF1IP	0.69	11.75	0.42	5.29e-29	Blood protein levels;
BRCA	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg14458575	chr2:238380390	NA	0.74	16.58	0.55	1.26e-51	Prostate cancer;
BRCA	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg18016565	chr1:150552671	MCL1	0.34	8.05	0.3	4.08e-15	Tonsillectomy;
BRCA	cis	rs858239	0.699	rs955187	chr7:23194605	A/G	cg23682824	chr7:23144976	KLHL7	-0.4	-10.38	-0.38	2e-23	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg11766577	chr21:47581405	C21orf56	-0.44	-9.82	-0.36	2.65e-21	Testicular germ cell tumor;
BRCA	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4588572	0.644	rs1428864	chr5:77780263	C/T	cg18281939	chr5:77783895	LHFPL2	0.33	8.0	0.3	5.99e-15	Triglycerides;
BRCA	cis	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg07460842	chr6:66804631	NA	0.6	10.31	0.38	3.63e-23	Type 2 diabetes;
BRCA	cis	rs7537052	0.564	rs6669395	chr1:36653717	A/G	cg24686825	chr1:36642396	MAP7D1	-0.54	-12.38	-0.44	1.07e-31	Schizophrenia;
BRCA	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg11764359	chr7:65958608	NA	-0.64	-11.28	-0.41	4.68e-27	Aortic root size;
BRCA	cis	rs6669919	0.967	rs7513031	chr1:211671900	C/T	cg10512769	chr1:211675356	NA	0.53	14.69	0.5	2.77e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg25754956	chr12:51612065	POU6F1	-0.77	-15.88	-0.53	4.04e-48	Cisplatin-induced ototoxicity;
BRCA	cis	rs36051895	0.559	rs12342390	chr9:5211297	G/A	cg02405213	chr9:5042618	JAK2	-0.44	-8.5	-0.32	1.31e-16	Pediatric autoimmune diseases;
BRCA	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-10.51	-0.38	6.2e-24	Personality dimensions;
BRCA	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	14.16	0.49	8.34e-40	Alzheimer's disease;
BRCA	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg23229984	chr5:148520753	ABLIM3	0.37	9.08	0.34	1.33e-18	Breast cancer;
BRCA	cis	rs4363385	0.818	rs436621	chr1:153005492	A/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.56	-0.32	8.46e-17	Inflammatory skin disease;
BRCA	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg17971929	chr21:40555470	PSMG1	-0.61	-13.49	-0.47	1.17e-36	Cognitive function;
BRCA	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg22705602	chr4:152727874	NA	-0.34	-8.61	-0.32	5.47e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6005807	0.719	rs12168765	chr22:29033308	G/C	cg12565055	chr22:29076175	TTC28	0.49	9.36	0.35	1.35e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg19077165	chr18:44547161	KATNAL2	-0.4	-8.39	-0.31	3.23e-16	Educational attainment;
BRCA	trans	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg13565492	chr6:43139072	SRF	-0.84	-11.44	-0.41	1.02e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.94	0.58	1.34e-58	Colorectal cancer;
BRCA	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg13010199	chr12:38710504	ALG10B	-0.36	-7.95	-0.3	8.19e-15	Morning vs. evening chronotype;
BRCA	cis	rs2120243	0.874	rs2316708	chr3:157150299	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	9.5	0.35	3.97e-20	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs2688608	0.839	rs2633310	chr10:75594050	G/T	cg23231163	chr10:75533350	FUT11	0.31	7.86	0.3	1.68e-14	Inflammatory bowel disease;
BRCA	cis	rs72781680	0.716	rs2712086	chr2:24004739	G/C	cg08917208	chr2:24149416	ATAD2B	0.58	9.58	0.35	2.06e-20	Lymphocyte counts;
BRCA	cis	rs4268898	0.552	rs11125444	chr2:24367205	G/T	cg06627628	chr2:24431161	ITSN2	0.4	8.51	0.32	1.24e-16	Asthma;
BRCA	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg24110177	chr3:50126178	RBM5	-0.44	-9.7	-0.36	7.29e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs75804782	0.641	rs11904390	chr2:239344663	T/A	cg01134436	chr17:81009848	B3GNTL1	0.72	9.3	0.35	2.26e-19	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg11663144	chr21:46675770	NA	-0.45	-10.68	-0.39	1.29e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg24006582	chr15:45444508	DUOX1	-0.55	-11.31	-0.41	3.61e-27	Uric acid levels;
BRCA	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg09184832	chr6:79620586	NA	-0.53	-11.69	-0.42	9.66e-29	Intelligence (multi-trait analysis);
BRCA	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg27661571	chr11:113659931	NA	-0.48	-8.35	-0.31	4.29e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg13256891	chr4:100009986	ADH5	0.5	10.34	0.38	2.72e-23	Alcohol dependence;
BRCA	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg08755490	chr11:65554678	OVOL1	0.55	11.5	0.41	5.88e-28	Acne (severe);
BRCA	trans	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-7.85	-0.3	1.81e-14	Corneal astigmatism;
BRCA	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg25036284	chr2:26402008	FAM59B	0.94	15.84	0.53	6.66e-48	Gut microbiome composition (summer);
BRCA	cis	rs7523050	0.643	rs71655970	chr1:109403895	A/G	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg23888215	chr10:79422304	NA	-0.55	-10.7	-0.39	1.07e-24	Bone mineral density;
BRCA	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg12165864	chr7:66369176	NA	-0.45	-10.15	-0.37	1.58e-22	Corneal structure;
BRCA	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.94	0.4	1.2e-25	Rheumatoid arthritis;
BRCA	cis	rs887829	0.569	rs6431628	chr2:234647478	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.32	-8.17	-0.31	1.7e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg08807101	chr21:30365312	RNF160	-0.6	-15.0	-0.51	8.49e-44	Dental caries;
BRCA	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	10.62	0.39	2.31e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs17253792	0.822	rs74940664	chr14:56135065	A/G	cg01858014	chr14:56050164	KTN1	-0.74	-9.16	-0.34	7.15e-19	Putamen volume;
BRCA	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg24531977	chr5:56204891	C5orf35	-0.52	-10.54	-0.38	4.73e-24	Coronary artery disease;
BRCA	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg03477792	chr4:77819574	ANKRD56	0.66	16.03	0.54	7.83e-49	Emphysema distribution in smoking;
BRCA	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg15556689	chr8:8085844	FLJ10661	0.4	9.78	0.36	3.71e-21	Myopia (pathological);
BRCA	cis	rs735539	0.645	rs1052209	chr13:21216850	C/T	cg04906043	chr13:21280425	IL17D	-0.45	-9.05	-0.34	1.73e-18	Dental caries;
BRCA	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg21747090	chr2:27597821	SNX17	-0.43	-9.43	-0.35	7.24e-20	Total body bone mineral density;
BRCA	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg14196790	chr5:131705035	SLC22A5	0.43	11.14	0.4	1.91e-26	Blood metabolite levels;
BRCA	cis	rs68170813	0.559	rs12538090	chr7:106974647	T/C	cg02696742	chr7:106810147	HBP1	-0.55	-9.02	-0.34	2.24e-18	Coronary artery disease;
BRCA	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg27478167	chr7:817139	HEATR2	0.52	10.16	0.37	1.4e-22	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.63	-12.37	-0.44	1.11e-31	Homoarginine levels;
BRCA	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg04450456	chr4:17643702	FAM184B	0.37	10.97	0.4	8.68e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg26149184	chr10:133730230	NA	-0.4	-8.15	-0.31	1.9e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10802521	chr3:52805072	NEK4	-0.33	-8.47	-0.32	1.64e-16	Bipolar disorder;
BRCA	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg22467129	chr15:76604101	ETFA	-0.41	-9.06	-0.34	1.63e-18	Blood metabolite levels;
BRCA	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg07741184	chr6:167504864	NA	0.33	9.86	0.36	1.89e-21	Primary biliary cholangitis;
BRCA	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg22117172	chr7:91764530	CYP51A1	0.23	7.84	0.3	1.88e-14	Breast cancer;
BRCA	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg02403541	chr12:121454288	C12orf43	-0.53	-10.23	-0.38	7.64e-23	N-glycan levels;
BRCA	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg24110177	chr3:50126178	RBM5	-0.45	-11.46	-0.41	8.7e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7927771	0.524	rs7929014	chr11:47776283	C/T	cg20307385	chr11:47447363	PSMC3	0.42	9.56	0.35	2.48e-20	Subjective well-being;
BRCA	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	15.71	0.53	2.81e-47	Fuchs's corneal dystrophy;
BRCA	trans	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg17830980	chr10:43048298	ZNF37B	0.43	10.04	0.37	4.1e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-13.14	-0.46	4.24e-35	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	16.16	0.54	1.57e-49	Platelet count;
BRCA	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.5	-11.23	-0.41	7.7e-27	Cognitive ability;
BRCA	cis	rs3820928	0.874	rs6718057	chr2:227834349	T/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.43	-0.32	2.26e-16	Pulmonary function;
BRCA	cis	rs6665290	0.594	rs17592479	chr1:227173892	T/A	cg10327440	chr1:227177885	CDC42BPA	-1.09	-37.71	-0.83	1.23e-164	Myeloid white cell count;
BRCA	cis	rs13064411	0.696	rs6438159	chr3:113217341	T/C	cg18753928	chr3:113234510	CCDC52	-0.59	-12.52	-0.44	2.53e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs61990749	0.597	rs2112136	chr14:78248952	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.65	9.87	0.36	1.73e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.44	0.38	1.12e-23	Motion sickness;
BRCA	cis	rs9463078	0.764	rs10948190	chr6:44942300	C/T	cg25276700	chr6:44698697	NA	-0.37	-8.74	-0.33	2.08e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.29	-0.31	6.51e-16	Total body bone mineral density;
BRCA	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg26647111	chr11:31128758	NA	-0.42	-9.6	-0.36	1.78e-20	Red blood cell count;
BRCA	trans	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg26043149	chr18:55253948	FECH	-0.38	-8.35	-0.31	4.17e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg04586622	chr2:25135609	ADCY3	0.46	11.61	0.42	2.11e-28	Body mass index in non-asthmatics;
BRCA	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg03929089	chr4:120376271	NA	-0.7	-13.75	-0.48	7e-38	Coronary artery disease;
BRCA	cis	rs7178424	0.875	rs12912208	chr15:62354570	A/G	cg00456672	chr15:62358751	C2CD4A	0.34	8.03	0.3	4.77e-15	Height;
BRCA	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg09307838	chr4:120376055	NA	0.6	12.42	0.44	7.18e-32	Corneal astigmatism;
BRCA	cis	rs4588572	0.643	rs9293747	chr5:77705567	A/G	cg11547950	chr5:77652471	NA	-0.49	-8.88	-0.33	6.8e-18	Triglycerides;
BRCA	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs12611088	0.600	rs2261316	chr19:44030998	A/G	cg15012607	chr19:44012195	ETHE1	0.34	8.37	0.31	3.66e-16	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs34779708	0.931	rs11010132	chr10:35517265	C/G	cg03585969	chr10:35415529	CREM	0.46	9.54	0.35	2.91e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.41	-0.32	2.58e-16	Monocyte percentage of white cells;
BRCA	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg15352829	chr14:105391018	PLD4	-0.38	-12.39	-0.44	9.37e-32	Rheumatoid arthritis;
BRCA	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg22875332	chr1:76189707	ACADM	-0.65	-15.56	-0.52	1.67e-46	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg24558204	chr6:135376177	HBS1L	0.45	12.35	0.44	1.45e-31	Red blood cell count;
BRCA	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.16	-0.31	1.78e-15	Coronary artery disease;
BRCA	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg03342759	chr3:160939853	NMD3	-0.74	-15.16	-0.51	1.44e-44	Parkinson's disease;
BRCA	cis	rs1003719	0.715	rs6579	chr21:38568308	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.5	-0.5	2.11e-41	Eye color traits;
BRCA	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg17644776	chr2:200775616	C2orf69	0.43	8.12	0.31	2.44e-15	Schizophrenia;
BRCA	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg27147174	chr7:100797783	AP1S1	-0.54	-10.84	-0.39	2.87e-25	Life satisfaction;
BRCA	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg19077165	chr18:44547161	KATNAL2	-0.37	-7.84	-0.3	1.9e-14	Educational attainment;
BRCA	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.45	-10.25	-0.38	6.1e-23	Reticulocyte count;
BRCA	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg03929089	chr4:120376271	NA	-0.52	-10.22	-0.37	7.93e-23	HDL cholesterol;
BRCA	trans	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg26043149	chr18:55253948	FECH	0.4	8.92	0.33	5.05e-18	Bone mineral density;
BRCA	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.6	13.31	0.47	7.59e-36	Eosinophil percentage of white cells;
BRCA	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.08	0.62	6.44e-70	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg14458575	chr2:238380390	NA	0.74	16.58	0.55	1.26e-51	Prostate cancer;
BRCA	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.58	13.53	0.47	7.75e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.4	0.57	8.98e-56	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6545883	0.929	rs2593627	chr2:61618574	T/C	cg15711740	chr2:61764176	XPO1	0.53	13.63	0.47	2.48e-37	Tuberculosis;
BRCA	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg13256891	chr4:100009986	ADH5	0.52	9.67	0.36	1e-20	Alcohol dependence;
BRCA	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.61	-0.45	9.81e-33	Bipolar disorder;
BRCA	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06221963	chr1:154839813	KCNN3	-0.56	-16.1	-0.54	3.26e-49	Prostate cancer;
BRCA	cis	rs2806561	0.929	rs2903545	chr1:23541108	C/T	cg12483005	chr1:23474871	LUZP1	-0.37	-8.1	-0.31	2.77e-15	Height;
BRCA	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg18402987	chr7:1209562	NA	0.59	12.21	0.43	5.92e-31	Longevity;Endometriosis;
BRCA	cis	rs9473147	0.516	rs10456570	chr6:47559451	A/G	cg12968598	chr6:47444699	CD2AP	0.44	9.62	0.36	1.56e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.73	0.57	1.72e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.03	-0.3	4.72e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2797160	1.000	rs77678056	chr6:126019738	A/G	cg05901451	chr6:126070800	HEY2	0.4	9.85	0.36	2.14e-21	Endometrial cancer;
BRCA	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg05564831	chr3:52568323	NT5DC2	0.35	8.38	0.31	3.49e-16	Hemoglobin concentration;
BRCA	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg07636037	chr3:49044803	WDR6	0.94	27.29	0.73	2.81e-109	Parkinson's disease;
BRCA	cis	rs2016266	0.820	rs11170496	chr12:53666195	G/A	cg26875137	chr12:53738046	NA	0.37	9.85	0.36	2.16e-21	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs867371	1.000	rs8037224	chr15:82464530	G/A	cg00614314	chr15:82944287	LOC80154	0.43	9.07	0.34	1.5e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	trans	rs1325195	0.920	rs2816209	chr1:179171494	A/G	cg11624085	chr17:8464688	MYH10	0.27	7.83	0.3	2.09e-14	IgE grass sensitization;
BRCA	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg09537434	chr19:41945824	ATP5SL	-0.95	-22.68	-0.67	5.57e-84	Height;
BRCA	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-10.56	-0.39	3.73e-24	Bladder cancer;
BRCA	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg00071950	chr4:10020882	SLC2A9	0.57	14.08	0.49	2.16e-39	Bone mineral density;
BRCA	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.5	0.5	2.04e-41	Colorectal cancer;
BRCA	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg04414720	chr1:150670196	GOLPH3L	0.35	8.06	0.3	3.82e-15	Tonsillectomy;
BRCA	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg23029597	chr12:123009494	RSRC2	-0.56	-10.93	-0.4	1.27e-25	Body mass index;
BRCA	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg01028140	chr2:1542097	TPO	-0.57	-11.98	-0.43	5.46e-30	IgG glycosylation;
BRCA	cis	rs9297145	0.958	rs11975761	chr7:98766688	G/A	cg05967295	chr7:98741636	SMURF1	-0.86	-20.46	-0.63	6.31e-72	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg11764359	chr7:65958608	NA	-0.64	-13.57	-0.47	5e-37	Aortic root size;
BRCA	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.47	7.89	0.3	1.28e-14	Height;
BRCA	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg21573476	chr21:45109991	RRP1B	-0.37	-9.43	-0.35	7.44e-20	Mean corpuscular volume;
BRCA	cis	rs1941023	0.503	rs4939349	chr11:60135880	G/A	cg08716584	chr11:60157161	MS4A7	-0.44	-10.11	-0.37	2.2e-22	Congenital heart disease (maternal effect);
BRCA	cis	rs36051895	0.659	rs7859390	chr9:5062473	A/T	cg02405213	chr9:5042618	JAK2	-0.46	-8.53	-0.32	1.1e-16	Pediatric autoimmune diseases;
BRCA	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25427524	chr10:38739819	LOC399744	-0.73	-17.56	-0.57	1.24e-56	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.45	-9.23	-0.34	4.01e-19	Resistin levels;
BRCA	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg21724239	chr8:58056113	NA	0.46	8.08	0.3	3.13e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs4908760	0.965	rs1884352	chr1:8537289	G/A	cg20416874	chr1:8611966	RERE	-0.28	-7.97	-0.3	7.1e-15	Vitiligo;
BRCA	cis	rs73086581	1.000	rs73086595	chr20:3983448	A/G	cg02187196	chr20:3869020	PANK2	0.53	9.37	0.35	1.23e-19	Response to antidepressants in depression;
BRCA	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.92	-0.3	1.04e-14	Prostate cancer;
BRCA	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg17524180	chr13:113633600	MCF2L	-0.31	-7.91	-0.3	1.13e-14	Systolic blood pressure;
BRCA	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg07395648	chr5:131743802	NA	0.4	9.97	0.37	7.52e-22	Blood metabolite levels;
BRCA	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg16109817	chr1:16162209	FLJ37453	0.29	8.23	0.31	1.09e-15	Systolic blood pressure;
BRCA	cis	rs10193935	0.901	rs222479	chr2:42656857	T/G	cg27598129	chr2:42591480	NA	-0.78	-13.27	-0.46	1.12e-35	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg27446573	chr6:127587934	RNF146	0.9	21.31	0.64	1.56e-76	Breast cancer;
BRCA	cis	rs112217694	1.000	rs17196218	chr4:104658371	C/T	cg17160751	chr4:104641250	TACR3	-0.78	-8.34	-0.31	4.52e-16	Menarche (age at onset);
BRCA	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg18154014	chr19:37997991	ZNF793	0.61	11.43	0.41	1.22e-27	Coronary artery calcification;
BRCA	cis	rs11585357	0.895	rs72633806	chr1:17617943	A/G	cg08277548	chr1:17600880	PADI3	-0.76	-12.36	-0.44	1.32e-31	Hair shape;
BRCA	cis	rs509477	0.962	rs562412	chr18:32576305	T/C	cg00449728	chr18:32561817	MAPRE2	-0.34	-7.84	-0.3	1.92e-14	Cerebrospinal fluid AB1-42 levels;
BRCA	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.57	13.82	0.48	3.38e-38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg00383909	chr3:49044727	WDR6	0.96	15.69	0.53	3.76e-47	Cognitive function;
BRCA	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	20.05	0.62	9.59e-70	Mean platelet volume;
BRCA	trans	rs208520	0.690	rs207077	chr6:66769855	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-20.94	-0.64	1.57e-74	Exhaled nitric oxide output;
BRCA	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg26384229	chr12:38710491	ALG10B	0.76	16.95	0.56	1.79e-53	Bladder cancer;
BRCA	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg07080220	chr10:102295463	HIF1AN	0.5	10.59	0.39	3.07e-24	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg19318889	chr4:1322082	MAEA	-0.6	-11.97	-0.43	6.25e-30	Longevity;
BRCA	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.76	0.39	6.05e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg27478167	chr7:817139	HEATR2	-0.42	-9.1	-0.34	1.12e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.44	-0.32	2.09e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11764359	chr7:65958608	NA	-0.76	-17.53	-0.57	1.89e-56	Aortic root size;
BRCA	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg21535247	chr6:8435926	SLC35B3	0.42	9.5	0.35	4.14e-20	Motion sickness;
BRCA	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg08422745	chr4:174089978	GALNT7	0.81	15.25	0.52	5.13e-45	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.5	10.45	0.38	1.1e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs7394190	0.748	rs4746151	chr10:75578720	G/T	cg07699608	chr10:75541558	CHCHD1	0.68	9.91	0.36	1.24e-21	Incident atrial fibrillation;
BRCA	cis	rs11051970	0.679	rs2651366	chr12:32560431	T/C	cg02745156	chr12:32552066	NA	0.25	8.31	0.31	5.6e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg20503657	chr10:835505	NA	0.9	16.21	0.54	9.35e-50	Eosinophil percentage of granulocytes;
BRCA	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-14.3	-0.49	1.95e-40	Morning vs. evening chronotype;
BRCA	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23583168	chr7:148888333	NA	-0.85	-19.73	-0.62	4.99e-68	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg15556689	chr8:8085844	FLJ10661	0.35	8.92	0.33	4.87e-18	Neuroticism;
BRCA	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18876405	chr7:65276391	NA	-0.66	-16.81	-0.55	9.26e-53	Aortic root size;
BRCA	cis	rs2625529	0.824	rs12593134	chr15:72303007	G/C	cg16672083	chr15:72433130	SENP8	-0.85	-17.68	-0.57	3.22e-57	Red blood cell count;
BRCA	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg22920501	chr2:26401640	FAM59B	-0.95	-17.06	-0.56	4.64e-54	Gut microbiome composition (summer);
BRCA	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg08847533	chr14:75593920	NEK9	-0.86	-22.01	-0.66	2.57e-80	Height;
BRCA	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg00757033	chr12:89920650	WDR51B	0.53	10.69	0.39	1.16e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	trans	rs1962073	0.528	rs9329223	chr8:10331754	C/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-8.76	-0.33	1.78e-17	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
BRCA	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.8	11.49	0.41	6.35e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs800082	0.698	rs800070	chr3:144346614	A/T	cg24215973	chr2:240111563	HDAC4	-0.61	-14.69	-0.5	2.54e-42	Smoking behavior;
BRCA	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg18512352	chr11:47633146	NA	-0.35	-8.52	-0.32	1.17e-16	Subjective well-being;
BRCA	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg01528321	chr10:82214614	TSPAN14	0.62	14.01	0.48	4.46e-39	Post bronchodilator FEV1;
BRCA	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg11502198	chr6:26597334	ABT1	0.56	12.0	0.43	4.76e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.72	0.39	8.85e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05731713	chr7:157510257	PTPRN2	0.41	10.58	0.39	3.25e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg09436375	chr6:42928200	GNMT	-0.28	-10.58	-0.39	3.38e-24	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11890956	chr21:40555474	PSMG1	-0.81	-19.19	-0.6	3.68e-65	Cognitive function;
BRCA	cis	rs1577917	0.560	rs9450288	chr6:86221586	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.36	9.94	0.37	9.9700000000000009e-22	Response to antipsychotic treatment;
BRCA	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg22907277	chr7:1156413	C7orf50	0.59	9.18	0.34	5.82e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg12463550	chr7:65579703	CRCP	-0.36	-7.83	-0.3	2.02e-14	Aortic root size;
BRCA	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.74	-0.33	2.1e-17	Total body bone mineral density;
BRCA	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg23649088	chr2:200775458	C2orf69	-0.58	-8.59	-0.32	6.42e-17	Schizophrenia;
BRCA	cis	rs897984	0.806	rs8050588	chr16:30937799	G/A	cg02466173	chr16:30829666	NA	-0.5	-11.4	-0.41	1.52e-27	Dementia with Lewy bodies;
BRCA	cis	rs11734570	0.581	rs4461531	chr4:38603576	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.51	9.49	0.35	4.41e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.47	-11.22	-0.41	8.22e-27	IgG glycosylation;
BRCA	cis	rs6495367	1.000	rs755362	chr15:79376601	C/T	cg17916960	chr15:79447300	NA	-0.33	-8.4	-0.32	2.78e-16	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	trans	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg26043149	chr18:55253948	FECH	-0.37	-8.3	-0.31	6.41e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs17021463	0.902	rs2016483	chr4:95229039	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-10.03	-0.37	4.4e-22	Testicular germ cell tumor;
BRCA	cis	rs11585357	0.947	rs72646789	chr1:17610030	C/T	cg19159961	chr1:17633534	PADI4	0.58	9.22	0.34	4.14e-19	Hair shape;
BRCA	cis	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg21252483	chr19:49399788	TULP2	-0.43	-9.38	-0.35	1.09e-19	Red cell distribution width;
BRCA	cis	rs13046373	0.507	rs11088139	chr21:31978884	T/G	cg16812893	chr21:31813075	KRTAP15-1	0.39	9.84	0.36	2.21e-21	HDL cholesterol;
BRCA	trans	rs6479891	0.915	rs9415682	chr10:65033817	G/T	cg14819942	chr15:35414228	NA	-0.35	-8.57	-0.32	7.85e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.33	-10.41	-0.38	1.45e-23	Homoarginine levels;
BRCA	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.38	8.97	0.33	3.38e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg13010199	chr12:38710504	ALG10B	0.5	9.89	0.36	1.54e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg20090143	chr19:45452003	APOC2	0.27	7.89	0.3	1.31e-14	Blood protein levels;
BRCA	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg20628663	chr10:43360327	NA	0.65	12.79	0.45	1.61e-33	Blood protein levels;
BRCA	cis	rs7395581	0.798	rs10769252	chr11:47343955	A/G	cg25783544	chr11:47291846	MADD	0.42	9.52	0.35	3.48e-20	HDL cholesterol;
BRCA	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22509189	chr2:225307070	NA	-0.46	-9.94	-0.37	1e-21	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	ch.11.42038R	chr11:967971	AP2A2	0.5	15.8	0.53	9.98e-48	Alzheimer's disease (late onset);
BRCA	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg26248373	chr2:1572462	NA	-0.56	-12.8	-0.45	1.44e-33	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg16339924	chr4:17578868	LAP3	0.62	15.42	0.52	7.56e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg23750338	chr8:142222470	SLC45A4	-0.52	-12.67	-0.45	5.34e-33	Immature fraction of reticulocytes;
BRCA	trans	rs1459104	1.000	rs36082455	chr11:55271813	A/G	cg15704280	chr7:45808275	SEPT13	0.65	8.14	0.31	2.12e-15	Body mass index;
BRCA	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg14675211	chr2:100938903	LONRF2	0.49	11.2	0.4	1.09e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg26031613	chr14:104095156	KLC1	0.7	15.03	0.51	6.13e-44	Body mass index;
BRCA	cis	rs10492096	0.947	rs11064231	chr12:6604415	T/G	cg13857086	chr12:6580257	VAMP1	0.43	8.41	0.32	2.66e-16	Hip geometry;
BRCA	cis	rs6942756	1.000	rs6467235	chr7:128939150	A/G	cg02491457	chr7:128862824	NA	0.69	12.73	0.45	3.08e-33	White matter hyperintensity burden;
BRCA	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg22800045	chr5:56110881	MAP3K1	0.66	12.38	0.44	1.06e-31	Initial pursuit acceleration;
BRCA	cis	rs62229266	0.804	rs2835259	chr21:37425302	T/C	cg12218747	chr21:37451666	NA	-0.33	-7.91	-0.3	1.11e-14	Mitral valve prolapse;
BRCA	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg04117972	chr1:227635322	NA	0.49	8.91	0.33	5.31e-18	Major depressive disorder;
BRCA	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.59	-14.35	-0.49	1.12e-40	Longevity;Endometriosis;
BRCA	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.32	-7.88	-0.3	1.4e-14	Total body bone mineral density;
BRCA	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	13.0	0.46	1.8e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-10.77	-0.39	5.8e-25	IgG glycosylation;
BRCA	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg24558204	chr6:135376177	HBS1L	0.44	12.2	0.43	6.19e-31	Red blood cell count;
BRCA	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg08917208	chr2:24149416	ATAD2B	1.1	15.84	0.53	6.79e-48	Lymphocyte counts;
BRCA	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg12310025	chr6:25882481	NA	0.52	12.44	0.44	5.51e-32	Blood metabolite levels;
BRCA	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27286337	chr10:134555280	INPP5A	0.61	11.91	0.43	1.14e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs17401966	0.964	rs34215045	chr1:10361679	G/A	cg15208524	chr1:10270712	KIF1B	0.38	8.21	0.31	1.21e-15	Hepatocellular carcinoma;
BRCA	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg12564285	chr5:131593104	PDLIM4	0.38	10.19	0.37	1.08e-22	Breast cancer;
BRCA	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.97	-0.33	3.26e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7246657	0.722	rs2909098	chr19:38204248	G/A	cg18154014	chr19:37997991	ZNF793	-0.51	-9.66	-0.36	1.05e-20	Coronary artery calcification;
BRCA	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02475777	chr4:1388615	CRIPAK	0.66	12.88	0.45	6.35e-34	Longevity;
BRCA	cis	rs1775715	0.707	rs2808079	chr10:32167385	C/T	cg14930904	chr10:32216787	ARHGAP12	0.34	7.88	0.3	1.4e-14	Bipolar disorder with mood-incongruent psychosis;
BRCA	trans	rs9784649	0.641	rs72755823	chr5:25075537	T/C	cg08600765	chr20:34638493	LOC647979	-0.76	-12.32	-0.44	1.87e-31	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg03188948	chr7:1209495	NA	0.73	11.99	0.43	4.92e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg19336497	chr11:14380999	RRAS2	-0.3	-8.08	-0.3	3.3e-15	Mitochondrial DNA levels;
BRCA	trans	rs1547374	0.737	rs178741	chr21:43779408	G/A	cg09521743	chr10:75415752	SYNPO2L	0.42	8.47	0.32	1.7e-16	Pancreatic cancer;
BRCA	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg18230493	chr5:56204884	C5orf35	-0.74	-14.37	-0.49	8.94e-41	Type 2 diabetes;
BRCA	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-8.92	-0.33	4.73e-18	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-19.18	-0.6	4.01e-65	Exhaled nitric oxide output;
BRCA	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg11812906	chr14:75593930	NEK9	0.59	13.65	0.48	2.04e-37	Height;
BRCA	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg10224037	chr5:178157518	ZNF354A	0.76	15.88	0.53	4.32e-48	Neutrophil percentage of white cells;
BRCA	cis	rs17253792	0.822	rs77990307	chr14:56070049	T/C	cg01858014	chr14:56050164	KTN1	-0.76	-10.5	-0.38	6.49e-24	Putamen volume;
BRCA	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-9.78	-0.36	3.73e-21	Tonsillectomy;
BRCA	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg26384229	chr12:38710491	ALG10B	-0.43	-9.99	-0.37	6.12e-22	Bladder cancer;
BRCA	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-13.9	-0.48	1.42e-38	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6669919	0.565	rs10863911	chr1:211686860	C/T	cg10512769	chr1:211675356	NA	-0.4	-10.64	-0.39	1.94e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg20607798	chr8:58055168	NA	0.51	10.9	0.4	1.7e-25	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg03676636	chr4:99064102	C4orf37	0.21	8.01	0.3	5.63e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2658782	0.724	rs2605627	chr11:93259515	A/G	cg15737290	chr11:93063684	CCDC67	0.49	9.56	0.35	2.4e-20	Pulmonary function decline;
BRCA	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg00339695	chr16:24857497	SLC5A11	0.51	11.21	0.41	9.46e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs2835872	0.758	rs1709820	chr21:39035971	A/C	cg06728970	chr21:39037746	KCNJ6	0.44	12.59	0.45	1.22e-32	Electroencephalographic traits in alcoholism;
BRCA	trans	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg25214090	chr10:38739885	LOC399744	0.46	10.46	0.38	9.42e-24	Corneal astigmatism;
BRCA	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg07308232	chr7:1071921	C7orf50	-0.4	-8.79	-0.33	1.33e-17	Longevity;Endometriosis;
BRCA	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg11366901	chr6:160182831	ACAT2	0.78	15.29	0.52	3.18e-45	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.75	-0.55	1.78e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	7.99e-21	Bladder cancer;
BRCA	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.45	-8.71	-0.33	2.5e-17	Body mass index;
BRCA	trans	rs629535	0.821	rs497398	chr8:70037434	A/T	cg21567404	chr3:27674614	NA	1.0	21.1	0.64	2.04e-75	Dupuytren's disease;
BRCA	cis	rs6763687	0.693	rs1353894	chr3:171807514	G/A	cg16233210	chr3:171778391	FNDC3B	0.38	9.09	0.34	1.24e-18	Red cell distribution width;
BRCA	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11764359	chr7:65958608	NA	-0.78	-18.53	-0.59	1.09e-61	Aortic root size;
BRCA	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg22705602	chr4:152727874	NA	-0.37	-9.89	-0.36	1.43e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg14784868	chr12:69753453	YEATS4	0.51	12.47	0.44	4.34e-32	Blood protein levels;
BRCA	trans	rs1912785	1.000	rs4681123	chr3:146405343	C/T	cg18433293	chr15:41576837	LOC729082	-0.26	-8.23	-0.31	1.06e-15	Barrett's esophagus;
BRCA	cis	rs7766436	0.767	rs11754964	chr6:22604737	G/T	cg13666174	chr6:22585274	NA	-0.37	-9.5	-0.35	4.04e-20	Coronary artery disease;
BRCA	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg15017067	chr4:17643749	FAM184B	0.28	8.47	0.32	1.64e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs34779708	0.931	rs7923172	chr10:35309367	G/A	cg03585969	chr10:35415529	CREM	0.49	10.3	0.38	3.94e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg20887711	chr4:1340912	KIAA1530	-0.73	-15.53	-0.52	2.14e-46	Longevity;
BRCA	cis	rs17253792	0.822	rs74051609	chr14:56171132	G/A	cg01858014	chr14:56050164	KTN1	-0.57	-8.78	-0.33	1.47e-17	Putamen volume;
BRCA	trans	rs8073060	0.586	rs72829927	chr17:34049992	A/G	cg19694781	chr19:47549865	TMEM160	1.07	20.64	0.63	6.34e-73	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	trans	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-13.07	-0.46	9e-35	Obesity-related traits;
BRCA	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg26446133	chr18:72167187	CNDP2	-0.79	-19.95	-0.62	3.3e-69	Refractive error;
BRCA	cis	rs2712431	0.554	rs9864772	chr3:128316939	A/G	cg16766828	chr3:128327626	NA	-0.36	-8.2	-0.31	1.29e-15	Monocyte chemoattractant protein-1 levels;
BRCA	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg22638593	chr5:131593259	PDLIM4	0.31	7.85	0.3	1.74e-14	Breast cancer;
BRCA	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg05793240	chr7:2802953	GNA12	-0.32	-8.81	-0.33	1.17e-17	Height;
BRCA	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg01689657	chr7:91764605	CYP51A1	0.22	8.01	0.3	5.31e-15	Breast cancer;
BRCA	trans	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg26043149	chr18:55253948	FECH	1.09	23.21	0.68	7.07e-87	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg03709012	chr19:19516395	GATAD2A	0.91	17.4	0.57	8.79e-56	Nonalcoholic fatty liver disease;
BRCA	cis	rs6456156	1.000	rs9457274	chr6:167520865	G/T	cg07741184	chr6:167504864	NA	0.28	8.54	0.32	9.83e-17	Primary biliary cholangitis;
BRCA	cis	rs73086581	1.000	rs6037708	chr20:3961253	C/G	cg02187196	chr20:3869020	PANK2	0.46	8.29	0.31	6.69e-16	Response to antidepressants in depression;
BRCA	trans	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.37	8.02	0.3	4.99e-15	Schizophrenia;
BRCA	cis	rs6973256	0.865	rs10954424	chr7:133335479	G/A	cg07491979	chr7:133331646	EXOC4	-0.39	-8.91	-0.33	5.11e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7247513	0.866	rs2861405	chr19:12722332	A/C	cg01871581	chr19:12707946	ZNF490	-0.68	-15.15	-0.51	1.56e-44	Bipolar disorder;
BRCA	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg07461501	chr17:79650226	HGS;ARL16	0.39	10.0	0.37	5.83e-22	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.09e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6121246	0.559	rs6087779	chr20:30370566	T/C	cg21427119	chr20:30132790	HM13	-0.36	-8.12	-0.31	2.35e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs4911259	0.513	rs4287835	chr20:31457337	T/C	cg13636640	chr20:31349939	DNMT3B	-0.44	-11.55	-0.42	3.8e-28	Inflammatory bowel disease;
BRCA	cis	rs6430585	0.527	rs1446586	chr2:136407445	C/T	cg07169764	chr2:136633963	MCM6	-0.99	-19.44	-0.61	1.81e-66	Corneal structure;
BRCA	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg22875332	chr1:76189707	ACADM	0.52	9.91	0.37	1.21e-21	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs3824867	0.920	rs3740684	chr11:47468820	C/T	cg20307385	chr11:47447363	PSMC3	0.51	11.35	0.41	2.59e-27	Mean corpuscular hemoglobin;
BRCA	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg01262667	chr19:19385393	TM6SF2	0.34	8.76	0.33	1.71e-17	Tonsillectomy;
BRCA	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg21573476	chr21:45109991	RRP1B	-0.36	-9.23	-0.34	3.85e-19	Mean corpuscular volume;
BRCA	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.09	0.4	2.94e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg23285459	chr7:2802560	GNA12	-0.36	-8.95	-0.33	3.74e-18	Height;
BRCA	cis	rs7512552	0.839	rs1097070	chr1:150332955	A/T	cg15654264	chr1:150340011	RPRD2	0.38	8.4	0.32	2.81e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs11191270	1.000	rs4919624	chr10:104021085	A/G	cg15320455	chr10:103880129	LDB1	0.53	8.74	0.33	1.97e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg20701182	chr2:24300061	SF3B14	0.62	8.83	0.33	9.71e-18	Lymphocyte counts;
BRCA	cis	rs6580649	1.000	rs7132668	chr12:48405860	C/T	cg05342945	chr12:48394962	COL2A1	-0.43	-8.35	-0.31	4.37e-16	Lung cancer;
BRCA	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg20701182	chr2:24300061	SF3B14	0.57	8.72	0.33	2.31e-17	Lymphocyte counts;
BRCA	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06634786	chr22:41940651	POLR3H	-0.52	-9.56	-0.35	2.54e-20	Vitiligo;
BRCA	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg21724239	chr8:58056113	NA	-0.58	-9.33	-0.35	1.66e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg06618935	chr21:46677482	NA	-0.39	-8.63	-0.32	4.85e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg04990556	chr1:26633338	UBXN11	0.54	8.89	0.33	6.19e-18	Obesity-related traits;
BRCA	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg00012203	chr2:219082015	ARPC2	-0.42	-8.23	-0.31	1.08e-15	Ulcerative colitis;
BRCA	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg05343316	chr1:45956843	TESK2	0.65	13.23	0.46	1.66e-35	Platelet count;
BRCA	cis	rs911119	0.913	rs6036465	chr20:23588003	G/T	cg16589663	chr20:23618590	CST3	0.39	7.99	0.3	6.43e-15	Chronic kidney disease;
BRCA	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02018176	chr4:1364513	KIAA1530	0.36	7.94	0.3	9.15e-15	Longevity;
BRCA	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.54	8.15	0.31	1.95e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7020830	0.931	rs1388978	chr9:37144062	G/T	cg14294708	chr9:37120828	ZCCHC7	1.05	31.36	0.78	2.06e-131	Schizophrenia;
BRCA	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg08997352	chr12:9597637	DDX12	-0.54	-10.16	-0.37	1.42e-22	Breast size;
BRCA	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.39	8.33	0.31	5.04e-16	Osteoporosis;
BRCA	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11764359	chr7:65958608	NA	0.77	17.35	0.57	1.46e-55	Aortic root size;
BRCA	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg03060546	chr3:49711283	APEH	0.6	9.83	0.36	2.5e-21	Menarche (age at onset);
BRCA	cis	rs7737355	0.898	rs4706024	chr5:130904163	G/A	cg06307176	chr5:131281290	NA	0.54	10.74	0.39	7.2e-25	Life satisfaction;
BRCA	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	10.02	0.37	4.95e-22	Bipolar disorder;
BRCA	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg00666640	chr1:248458726	OR2T12	0.3	8.42	0.32	2.5e-16	Common traits (Other);
BRCA	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg12379764	chr21:47803548	PCNT	-0.4	-8.98	-0.33	2.9e-18	Testicular germ cell tumor;
BRCA	cis	rs4642101	0.824	rs11717013	chr3:12843862	A/C	cg24848339	chr3:12840334	CAND2	0.41	10.6	0.39	2.8e-24	QRS complex (12-leadsum);
BRCA	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg00530320	chr1:46809349	NSUN4	0.48	9.74	0.36	5.54e-21	Menopause (age at onset);
BRCA	trans	rs9409565	0.855	rs7042481	chr9:97064273	C/A	cg05679027	chr9:99775184	HIATL2	0.41	9.08	0.34	1.33e-18	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.87	0.33	7.22e-18	Motion sickness;
BRCA	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg18705301	chr15:41695430	NDUFAF1	0.6	13.85	0.48	2.34e-38	Ulcerative colitis;
BRCA	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg05083358	chr7:2394359	EIF3B	-0.51	-8.04	-0.3	4.52e-15	Multiple sclerosis;
BRCA	trans	rs8073060	0.516	rs2376177	chr17:33938089	T/G	cg19694781	chr19:47549865	TMEM160	-1.04	-21.61	-0.65	3.85e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs1865721	1.000	rs62089511	chr18:73197629	C/T	cg26385618	chr18:73139727	C18orf62	-0.38	-8.66	-0.32	3.85e-17	Intelligence;
BRCA	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.74	10.05	0.37	3.52e-22	Initial pursuit acceleration;
BRCA	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg26384229	chr12:38710491	ALG10B	0.57	13.37	0.47	4.08e-36	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.97	-0.33	3.26e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg15485101	chr11:133734466	NA	0.4	9.74	0.36	5.55e-21	Childhood ear infection;
BRCA	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg09307838	chr4:120376055	NA	-0.49	-9.27	-0.34	2.75e-19	Corneal astigmatism;
BRCA	cis	rs716316	1.000	rs716316	chr20:14908741	C/T	cg04470754	chr20:14904432	MACROD2	0.44	10.54	0.38	4.57e-24	Advanced glycation end-product levels;
BRCA	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-12.18	-0.43	8.01e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	16.78	0.55	1.31e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs2282802	0.685	rs67813630	chr5:139623592	C/A	cg26211634	chr5:139558579	C5orf32	0.36	8.45	0.32	2.04e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs8073060	0.586	rs226090	chr17:34034059	C/T	cg19694781	chr19:47549865	TMEM160	-1.07	-20.59	-0.63	1.26e-72	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs2712184	0.756	rs2024487	chr2:217663271	C/T	cg05032264	chr2:217675019	NA	0.35	8.61	0.32	5.6e-17	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg20487152	chr13:99095054	FARP1	-0.33	-7.96	-0.3	7.85e-15	Longevity;
BRCA	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-9.77	-0.36	4.33e-21	Morning vs. evening chronotype;
BRCA	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg18270830	chr10:32634957	EPC1	0.6	10.44	0.38	1.1e-23	Sexual dysfunction (female);
BRCA	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.41	0.38	1.45e-23	Bladder cancer;
BRCA	cis	rs1942	0.837	rs12440045	chr15:41782684	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.46	-9.08	-0.34	1.38e-18	Eosinophil percentage of granulocytes;
BRCA	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg00745463	chr17:30367425	LRRC37B	-0.62	-9.94	-0.37	9.63e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg04450456	chr4:17643702	FAM184B	0.37	10.81	0.39	4.03e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg25206134	chr2:45395956	NA	0.52	8.73	0.33	2.2e-17	Bipolar disorder;
BRCA	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.67	-13.02	-0.46	1.47e-34	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6752107	0.503	rs12997325	chr2:234237387	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.38	7.84	0.3	1.84e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg15017067	chr4:17643749	FAM184B	0.35	10.83	0.39	3.2e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs495337	0.736	rs530461	chr20:48467716	A/G	cg17835207	chr20:48524531	SPATA2	0.53	12.06	0.43	2.56e-30	Psoriasis;
BRCA	cis	rs593982	0.920	rs618456	chr11:65475620	C/T	cg08755490	chr11:65554678	OVOL1	1.18	17.51	0.57	2.18e-56	Atopic dermatitis;
BRCA	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-10.26	-0.38	5.69e-23	Systemic lupus erythematosus;
BRCA	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg08000102	chr2:233561755	GIGYF2	-0.63	-13.61	-0.47	3.18e-37	Coronary artery disease;
BRCA	cis	rs3820928	0.839	rs4673174	chr2:227801316	A/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.72	-0.33	2.41e-17	Pulmonary function;
BRCA	trans	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg26043149	chr18:55253948	FECH	0.39	8.44	0.32	2.09e-16	Bone mineral density;
BRCA	cis	rs9790314	0.632	rs778645	chr3:160707459	A/T	cg03342759	chr3:160939853	NMD3	-0.47	-8.84	-0.33	9.1e-18	Morning vs. evening chronotype;
BRCA	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-16.32	-0.54	2.48e-50	Chronic sinus infection;
BRCA	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg16586182	chr3:47516702	SCAP	-0.57	-12.77	-0.45	1.96e-33	Colorectal cancer;
BRCA	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	12.17	0.43	8.91e-31	Mean platelet volume;
BRCA	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.36	-8.08	-0.3	3.32e-15	Longevity;Endometriosis;
BRCA	cis	rs922182	1.000	rs1460546	chr15:64283108	C/A	cg24729988	chr15:64271149	DAPK2	0.44	9.64	0.36	1.3e-20	Blood protein levels;
BRCA	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg13010199	chr12:38710504	ALG10B	0.36	8.65	0.32	4.18e-17	Morning vs. evening chronotype;
BRCA	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	10.25	0.38	6.48e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg04727924	chr7:799746	HEATR2	-0.55	-10.86	-0.39	2.52e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg09455208	chr3:40491958	NA	-0.48	-11.9	-0.43	1.25e-29	Renal cell carcinoma;
BRCA	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg05343316	chr1:45956843	TESK2	0.64	13.01	0.46	1.73e-34	Platelet count;
BRCA	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg23711669	chr6:146136114	FBXO30	0.69	16.02	0.54	7.97e-49	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.44	-0.32	2.15e-16	Bipolar disorder;
BRCA	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00149659	chr3:10157352	C3orf10	0.79	13.66	0.48	1.77e-37	Alzheimer's disease;
BRCA	cis	rs68170813	0.562	rs7810216	chr7:107000353	G/A	cg02696742	chr7:106810147	HBP1	-0.55	-8.51	-0.32	1.22e-16	Coronary artery disease;
BRCA	cis	rs11231017	0.507	rs10792351	chr11:62157472	T/C	cg23876832	chr11:62092739	NA	0.32	8.04	0.3	4.4e-15	HIV-1 viral setpoint;
BRCA	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg08601574	chr20:25228251	PYGB	0.34	8.22	0.31	1.14e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs698833	0.547	rs1067348	chr2:44671409	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	8.44	0.32	2.06e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg21361702	chr7:150065534	REPIN1	0.55	10.03	0.37	4.29e-22	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs34891900	0.507	rs12167823	chr22:18124362	G/A	cg19898043	chr22:18121309	BCL2L13	0.46	9.24	0.34	3.75e-19	Sum neutrophil eosinophil counts;
BRCA	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg01939980	chr4:1354348	KIAA1530	0.3	8.18	0.31	1.49e-15	Longevity;
BRCA	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg20302533	chr7:39170763	POU6F2	0.4	8.45	0.32	1.92e-16	IgG glycosylation;
BRCA	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg27165867	chr14:105738592	BRF1	-0.35	-8.93	-0.33	4.35e-18	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08645402	chr16:4508243	NA	0.37	8.96	0.33	3.46e-18	Schizophrenia;
BRCA	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-8.07	-0.3	3.46e-15	Prostate cancer;
BRCA	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg22875332	chr1:76189707	ACADM	0.8	19.03	0.6	2.6e-64	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10924970	0.781	rs10802590	chr1:235444051	A/G	cg26050004	chr1:235667680	B3GALNT2	0.35	8.74	0.33	2.02e-17	Asthma;
BRCA	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg17211192	chr8:82754475	SNX16	-0.53	-12.1	-0.43	1.69e-30	Diastolic blood pressure;
BRCA	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg09469691	chr10:81107165	PPIF	0.5	10.12	0.37	2e-22	Height;
BRCA	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg03929089	chr4:120376271	NA	0.63	12.45	0.44	5.31e-32	Coronary artery disease;
BRCA	cis	rs732716	0.504	rs9352	chr19:4442336	C/T	cg21934504	chr19:4445085	UBXN6	0.32	8.99	0.34	2.71e-18	Mean corpuscular volume;
BRCA	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg15017067	chr4:17643749	FAM184B	0.28	8.41	0.32	2.64e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg18357645	chr12:58087776	OS9	0.34	9.16	0.34	6.91e-19	Multiple sclerosis;
BRCA	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg11843238	chr5:131593191	PDLIM4	-0.36	-7.85	-0.3	1.73e-14	Breast cancer;
BRCA	cis	rs9790314	0.747	rs1599378	chr3:160874511	A/C	cg03342759	chr3:160939853	NMD3	-0.52	-10.43	-0.38	1.21e-23	Morning vs. evening chronotype;
BRCA	trans	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04565464	chr8:145669602	NFKBIL2	0.38	9.0	0.34	2.63e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg12444411	chr7:2802554	GNA12	-0.34	-8.72	-0.33	2.36e-17	Height;
BRCA	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg26384229	chr12:38710491	ALG10B	0.76	17.17	0.56	1.31e-54	Bladder cancer;
BRCA	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg14847009	chr1:175162515	KIAA0040	0.25	9.67	0.36	1.01e-20	Alcohol dependence;
BRCA	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg13010199	chr12:38710504	ALG10B	0.57	12.58	0.45	1.44e-32	Heart rate;
BRCA	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg11822812	chr5:140052017	DND1	-0.33	-9.02	-0.34	2.21e-18	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs11229555	1.000	rs1938598	chr11:58413910	T/C	cg15696309	chr11:58395628	NA	-0.53	-11.59	-0.42	2.59e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6028335	0.674	rs59096774	chr20:37603529	A/G	cg16355469	chr20:37678765	NA	0.47	8.54	0.32	9.61e-17	Alcohol and nicotine co-dependence;
BRCA	cis	rs7766436	1.000	rs7766436	chr6:22598259	C/T	cg13666174	chr6:22585274	NA	-0.41	-10.07	-0.37	3.07e-22	Coronary artery disease;
BRCA	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg05283184	chr6:79620031	NA	-0.36	-8.17	-0.31	1.66e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg24060327	chr5:131705240	SLC22A5	-0.42	-7.94	-0.3	9.32e-15	Acylcarnitine levels;
BRCA	cis	rs2742234	0.590	rs1254962	chr10:43696992	G/A	cg15436174	chr10:43711423	RASGEF1A	0.57	11.53	0.41	4.62e-28	Hirschsprung disease;
BRCA	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg02734326	chr4:10020555	SLC2A9	0.39	8.19	0.31	1.44e-15	Bone mineral density;
BRCA	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg25019033	chr10:957182	NA	-0.41	-7.88	-0.3	1.45e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-11.61	-0.42	2e-28	Mood instability;
BRCA	cis	rs400736	0.655	rs55634431	chr1:8149549	G/A	cg25007680	chr1:8021821	PARK7	-0.38	-8.94	-0.33	4.12e-18	Response to antidepressants and depression;
BRCA	trans	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.38	0.49	8.24e-41	Exhaled nitric oxide output;
BRCA	trans	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg23762105	chr12:34175262	ALG10	0.35	8.95	0.33	3.75e-18	Morning vs. evening chronotype;
BRCA	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg07741184	chr6:167504864	NA	0.33	10.0	0.37	5.67e-22	Primary biliary cholangitis;
BRCA	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	11.25	0.41	6.7399999999999993e-27	Personality dimensions;
BRCA	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.22	0.34	4.35e-19	Tonsillectomy;
BRCA	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18876405	chr7:65276391	NA	-0.66	-16.98	-0.56	1.24e-53	Aortic root size;
BRCA	trans	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg07817883	chr1:32538562	TMEM39B	-0.44	-8.51	-0.32	1.25e-16	Monocyte percentage of white cells;
BRCA	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.92	-0.3	1.02e-14	Corneal astigmatism;
BRCA	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.11	-0.34	1.01e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12826209	chr6:26865740	GUSBL1	0.59	10.42	0.38	1.36e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg15448220	chr1:150897856	SETDB1	0.36	8.25	0.31	8.93e-16	Melanoma;
BRCA	cis	rs72781680	0.821	rs17046004	chr2:24144873	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	10.7	0.39	1.08e-24	Lymphocyte counts;
BRCA	cis	rs600806	0.778	rs491285	chr1:110019002	C/T	cg20591472	chr1:110008990	SYPL2	-0.31	-7.95	-0.3	8.63e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.94	-0.37	9.36e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs9314323	0.592	rs12165	chr8:26269412	C/T	cg13160058	chr8:26243215	BNIP3L	-0.36	-10.32	-0.38	3.35e-23	Red cell distribution width;
BRCA	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg08885076	chr2:99613938	TSGA10	0.45	10.46	0.38	9.8599999999999993e-24	Chronic sinus infection;
BRCA	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11764359	chr7:65958608	NA	-0.79	-19.02	-0.6	2.87e-64	Aortic root size;
BRCA	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.01	21.57	0.65	5.99e-78	Gut microbiome composition (summer);
BRCA	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg24110177	chr3:50126178	RBM5	-0.45	-9.92	-0.37	1.19e-21	Menarche (age at onset);
BRCA	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg22009923	chr11:832065	CD151	-0.48	-10.6	-0.39	2.69e-24	Mean platelet volume;
BRCA	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg16680214	chr1:154839983	KCNN3	-0.46	-12.9	-0.45	5.3e-34	Prostate cancer;
BRCA	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.18	-0.31	1.49e-15	Depression;
BRCA	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	8.15	0.31	1.94e-15	Mean platelet volume;
BRCA	trans	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-8.14	-0.31	2.03e-15	Menarche (age at onset);
BRCA	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg23018236	chr17:30244563	NA	-0.68	-10.7	-0.39	1.09e-24	Hip circumference adjusted for BMI;
BRCA	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg11752832	chr7:134001865	SLC35B4	-0.4	-9.72	-0.36	6.16e-21	Mean platelet volume;
BRCA	trans	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-10.0	-0.37	5.52e-22	Neuroticism;
BRCA	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-11.87	-0.43	1.67e-29	Electroencephalogram traits;
BRCA	cis	rs7246657	0.525	rs10410594	chr19:37477758	C/T	cg18154014	chr19:37997991	ZNF793	0.49	8.39	0.32	3.11e-16	Coronary artery calcification;
BRCA	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg12160578	chr15:63334699	TPM1	-0.42	-8.48	-0.32	1.59e-16	Platelet count;
BRCA	cis	rs2354432	0.607	rs6658763	chr1:146692373	C/T	cg25205988	chr1:146714368	CHD1L	-0.9	-11.32	-0.41	3.48e-27	Mitochondrial DNA levels;
BRCA	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg05207973	chr5:176823642	SLC34A1	0.42	9.22	0.34	4.1e-19	Urinary electrolytes (magnesium/calcium ratio);
BRCA	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.92	0.33	4.98e-18	Motion sickness;
BRCA	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg16989086	chr20:62203971	PRIC285	0.53	8.91	0.33	5.27e-18	Glioblastoma;
BRCA	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg14440974	chr22:39074834	NA	-0.38	-9.0	-0.34	2.64e-18	Menopause (age at onset);
BRCA	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg00684032	chr4:1343700	KIAA1530	0.31	8.04	0.3	4.35e-15	Obesity-related traits;
BRCA	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg21475434	chr5:93447410	FAM172A	0.67	8.75	0.33	1.94e-17	Diabetic retinopathy;
BRCA	cis	rs7593730	0.636	rs3772071	chr2:161135544	C/T	cg22609984	chr2:161126801	NA	0.38	8.32	0.31	5.4e-16	Type 2 diabetes;
BRCA	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg24692254	chr21:30365293	RNF160	-0.62	-15.86	-0.53	5.22e-48	Dental caries;
BRCA	cis	rs7945718	0.935	rs11022501	chr11:12809314	T/C	cg25843174	chr11:12811716	TEAD1	0.23	8.91	0.33	5.12e-18	Educational attainment (years of education);
BRCA	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg14343924	chr8:8086146	FLJ10661	0.4	8.41	0.32	2.74e-16	Mood instability;
BRCA	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.43	9.67	0.36	9.74e-21	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg13852791	chr20:30311386	BCL2L1	0.84	16.58	0.55	1.35e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs7587476	0.822	rs13018304	chr2:215682218	T/G	cg04004882	chr2:215674386	BARD1	0.67	12.41	0.44	7.73e-32	Neuroblastoma;
BRCA	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg05343316	chr1:45956843	TESK2	0.61	12.49	0.44	3.42e-32	Platelet count;
BRCA	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg14530993	chr4:882597	GAK	0.59	9.54	0.35	2.98e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg17211192	chr8:82754475	SNX16	0.49	11.0	0.4	6.82e-26	Diastolic blood pressure;
BRCA	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg25767906	chr1:53392781	SCP2	0.38	8.7	0.33	2.83e-17	Monocyte count;
BRCA	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.58	0.65	5.31e-78	Lymphocyte percentage of white cells;
BRCA	trans	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	9.24	0.34	3.67e-19	Neuroticism;
BRCA	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	13.0	0.46	1.87e-34	Joint mobility (Beighton score);
BRCA	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg18131467	chr2:239335373	ASB1	0.86	21.85	0.65	1.88e-79	Multiple system atrophy;
BRCA	cis	rs724568	0.527	rs12612262	chr2:67934125	G/C	cg14046302	chr2:67939758	NA	-0.38	-10.14	-0.37	1.72e-22	Major depressive disorder (broad);
BRCA	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg24692254	chr21:30365293	RNF160	0.48	10.6	0.39	2.78e-24	Pancreatic cancer;
BRCA	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg27446573	chr6:127587934	RNF146	0.89	21.1	0.64	2.1e-75	Breast cancer;
BRCA	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg22974920	chr21:40686053	BRWD1	-0.35	-7.99	-0.3	6.32e-15	Menarche (age at onset);
BRCA	cis	rs6684514	0.961	rs12126696	chr1:156241348	C/T	cg16558208	chr1:156270281	VHLL	0.37	7.97	0.3	7.58e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12826209	chr6:26865740	GUSBL1	-0.59	-10.48	-0.38	8.28e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg26384229	chr12:38710491	ALG10B	-0.61	-14.68	-0.5	2.95e-42	Bladder cancer;
BRCA	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.32	-10.32	-0.38	3.51e-23	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs12517041	1.000	rs1428622	chr5:23286204	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.9	-0.3	1.19e-14	Calcium levels;
BRCA	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg08601574	chr20:25228251	PYGB	-0.38	-8.94	-0.33	4.31e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg23283495	chr1:209979779	IRF6	0.38	9.11	0.34	1.02e-18	Cleft lip with or without cleft palate;
BRCA	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.96	21.6	0.65	4.41e-78	Lymphocyte percentage of white cells;
BRCA	cis	rs7523273	0.606	rs2724391	chr1:207953244	T/C	cg22525895	chr1:207977042	MIR29B2	0.47	11.92	0.43	1.02e-29	Schizophrenia;
BRCA	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg21573476	chr21:45109991	RRP1B	-0.35	-9.0	-0.34	2.64e-18	Mean corpuscular volume;
BRCA	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg07636037	chr3:49044803	WDR6	0.68	13.58	0.47	4.29e-37	Menarche (age at onset);
BRCA	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg13319975	chr6:146136371	FBXO30	-0.39	-8.55	-0.32	8.79e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg17691542	chr6:26056736	HIST1H1C	0.53	10.85	0.39	2.74e-25	Iron status biomarkers;
BRCA	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11890956	chr21:40555474	PSMG1	1.06	30.21	0.77	3.46e-125	Cognitive function;
BRCA	cis	rs10189230	0.546	rs6436266	chr2:222357235	T/C	cg14652038	chr2:222343519	EPHA4	0.37	8.89	0.33	6.3e-18	Urate levels in lean individuals;
BRCA	trans	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg11693508	chr17:37793320	STARD3	0.6	11.11	0.4	2.42e-26	Bipolar disorder;
BRCA	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg13770153	chr20:60521292	NA	-0.45	-10.92	-0.4	1.44e-25	Body mass index;
BRCA	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg15145296	chr3:125709740	NA	-0.54	-8.72	-0.33	2.31e-17	Blood pressure (smoking interaction);
BRCA	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg14675211	chr2:100938903	LONRF2	0.52	11.65	0.42	1.37e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs6435161	1.000	rs35202091	chr2:203507663	C/T	cg18429434	chr2:203499731	FAM117B	-0.43	-8.46	-0.32	1.77e-16	Total cholesterol levels;
BRCA	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg03709012	chr19:19516395	GATAD2A	0.72	15.68	0.53	4.14e-47	Tonsillectomy;
BRCA	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.34	-0.35	1.6e-19	Alzheimer's disease (late onset);
BRCA	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18876405	chr7:65276391	NA	0.52	12.21	0.44	5.58e-31	Aortic root size;
BRCA	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg25358565	chr5:93447407	FAM172A	-0.53	-9.87	-0.36	1.79e-21	Diabetic retinopathy;
BRCA	trans	rs12517041	1.000	rs7721619	chr5:23292676	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg07636037	chr3:49044803	WDR6	0.46	9.16	0.34	7.01e-19	Resting heart rate;
BRCA	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	13.58	0.47	4.5e-37	Platelet count;
BRCA	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-16.98	-0.56	1.25e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg03188948	chr7:1209495	NA	0.63	12.83	0.45	1.12e-33	Longevity;Endometriosis;
BRCA	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.59	-12.35	-0.44	1.39e-31	Lymphocyte counts;
BRCA	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg22875332	chr1:76189707	ACADM	0.7	15.05	0.51	4.65e-44	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg24829409	chr8:58192753	C8orf71	-0.48	-9.17	-0.34	6.24e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg17063962	chr7:91808500	NA	0.61	14.56	0.5	1.08e-41	Breast cancer;
BRCA	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05025164	chr4:1340916	KIAA1530	-0.59	-12.28	-0.44	2.81e-31	Obesity-related traits;
BRCA	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg17691542	chr6:26056736	HIST1H1C	0.49	9.29	0.34	2.44e-19	Iron status biomarkers;
BRCA	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg23018236	chr17:30244563	NA	0.61	8.75	0.33	1.95e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg26248373	chr2:1572462	NA	-0.47	-9.29	-0.34	2.48e-19	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7149337	1.000	rs35567150	chr14:51725944	A/G	cg23942311	chr14:51606299	NA	0.36	9.63	0.36	1.39e-20	Cancer;
BRCA	cis	rs7582720	0.887	rs72934591	chr2:204019762	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	12.75	0.45	2.48e-33	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs4803468	1.000	rs13344563	chr19:41945904	G/C	cg09537434	chr19:41945824	ATP5SL	1.02	25.5	0.71	1.75e-99	Height;
BRCA	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg26384229	chr12:38710491	ALG10B	0.43	10.27	0.38	5.16e-23	Heart rate;
BRCA	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg26373071	chr5:1325741	CLPTM1L	0.51	12.63	0.45	8.13e-33	Lung cancer;
BRCA	cis	rs9612	1.000	rs346528	chr19:44259232	G/T	cg08581076	chr19:44259116	C19orf61	0.53	9.74	0.36	5.59e-21	Exhaled nitric oxide output;
BRCA	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg04756594	chr16:24857601	SLC5A11	0.54	12.2	0.43	6.23e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg19628046	chr18:33552617	C18orf21	0.55	10.58	0.39	3.18e-24	Endometriosis;Drug-induced torsades de pointes;
BRCA	trans	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.37	0.38	2.09e-23	Mean corpuscular volume;
BRCA	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg27535305	chr1:53392650	SCP2	-0.38	-9.28	-0.34	2.59e-19	Monocyte count;
BRCA	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg15704280	chr7:45808275	SEPT13	-0.46	-8.91	-0.33	5.46e-18	HDL cholesterol;
BRCA	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg20219911	chr3:52813652	ITIH1	0.3	8.27	0.31	7.65e-16	Bipolar disorder;
BRCA	cis	rs10267417	0.657	rs6963367	chr7:19857873	A/C	cg07541023	chr7:19748670	TWISTNB	0.51	9.08	0.34	1.3e-18	Night sleep phenotypes;
BRCA	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg10556349	chr10:835070	NA	0.59	8.31	0.31	5.59e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs10949834	0.504	rs150862	chr7:73524207	C/T	cg07137043	chr7:73588983	EIF4H	0.51	8.72	0.33	2.42e-17	Verbal memory performance (residualized delayed recall change);
BRCA	trans	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg11693508	chr17:37793320	STARD3	0.52	9.14	0.34	8.43e-19	Neuroticism;
BRCA	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg10523679	chr1:76189770	ACADM	0.78	18.91	0.6	1.14e-63	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	12.34	0.44	1.55e-31	Neuroticism;
BRCA	cis	rs7172677	0.737	rs8025412	chr15:75444033	C/T	cg10253484	chr15:75165896	SCAMP2	-0.41	-7.91	-0.3	1.15e-14	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg25817165	chr18:72167213	CNDP2	-0.77	-19.89	-0.62	6.7e-69	Refractive error;
BRCA	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg24011408	chr12:48396354	COL2A1	-0.42	-9.31	-0.35	1.97e-19	Plateletcrit;
BRCA	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg17063962	chr7:91808500	NA	0.61	14.46	0.5	3.48e-41	Breast cancer;
BRCA	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-10.3	-0.38	3.98e-23	Blood metabolite levels;
BRCA	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-12.8	-0.45	1.47e-33	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg16576597	chr16:28551801	NUPR1	0.33	9.04	0.34	1.88e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg04025307	chr7:1156635	C7orf50	0.59	15.01	0.51	7.24e-44	Longevity;Endometriosis;
BRCA	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg06627628	chr2:24431161	ITSN2	-0.54	-8.81	-0.33	1.15e-17	Lymphocyte counts;
BRCA	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg12193833	chr17:30244370	NA	-0.52	-8.41	-0.32	2.7e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg17063962	chr7:91808500	NA	-0.55	-12.75	-0.45	2.49e-33	Breast cancer;
BRCA	trans	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg25214090	chr10:38739885	LOC399744	0.53	11.67	0.42	1.12e-28	Corneal astigmatism;
BRCA	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05535760	chr7:792225	HEATR2	0.87	14.93	0.51	1.94e-43	Cerebrospinal P-tau181p levels;
BRCA	trans	rs747782	0.527	rs7113857	chr11:48141859	G/T	cg15704280	chr7:45808275	SEPT13	0.56	7.94	0.3	9.45e-15	Intraocular pressure;
BRCA	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg21747090	chr2:27597821	SNX17	-0.41	-9.16	-0.34	7.07e-19	Total body bone mineral density;
BRCA	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.87	0.33	7.45e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10733682	0.715	rs3814119	chr9:129462901	A/G	cg00232160	chr9:129468157	NA	0.37	8.8	0.33	1.22e-17	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs708547	0.581	rs13121027	chr4:57813369	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.44	8.55	0.32	9.34e-17	Response to bleomycin (chromatid breaks);
BRCA	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg01483505	chr11:975446	AP2A2	0.34	9.2	0.34	5.11e-19	Alzheimer's disease (late onset);
BRCA	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg03929089	chr4:120376271	NA	-0.49	-9.5	-0.35	4.01e-20	HDL cholesterol;
BRCA	cis	rs9814567	0.806	rs4074521	chr3:134325536	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.36	8.18	0.31	1.51e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05535760	chr7:792225	HEATR2	0.85	14.37	0.49	8.79e-41	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7555523	0.887	rs6696454	chr1:165707923	T/C	cg24409356	chr1:165738333	TMCO1	0.51	8.19	0.31	1.46e-15	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	cis	rs6032067	0.561	rs6032104	chr20:43932412	G/A	cg06407657	chr20:43937138	MATN4;RBPJL	0.29	8.03	0.3	4.75e-15	Blood protein levels;
BRCA	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg03585969	chr10:35415529	CREM	0.57	11.51	0.41	5.35e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-8.13	-0.31	2.22e-15	Menarche (age at onset);
BRCA	cis	rs13046373	0.507	rs8133828	chr21:32033046	C/G	cg16812893	chr21:31813075	KRTAP15-1	0.36	8.58	0.32	7.03e-17	HDL cholesterol;
BRCA	cis	rs78487399	0.908	rs6749617	chr2:43845329	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.52	8.07	0.3	3.47e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.67	13.0	0.46	1.85e-34	Height;
BRCA	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.39	-8.39	-0.32	3.03e-16	IgG glycosylation;
BRCA	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg09904177	chr6:26538194	HMGN4	0.57	18.49	0.59	1.76e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg08798685	chr6:27730294	NA	-0.4	-7.82	-0.3	2.23e-14	Parkinson's disease;
BRCA	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.38	-9.1	-0.34	1.13e-18	Longevity;Endometriosis;
BRCA	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.13	-0.34	8.58e-19	Menopause (age at onset);
BRCA	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg09915433	chr19:53449742	NA	-0.82	-20.11	-0.62	4.69e-70	Psoriasis;
BRCA	cis	rs2346177	0.875	rs1447565	chr2:46643682	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.41	8.58	0.32	6.92e-17	HDL cholesterol;
BRCA	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg03709012	chr19:19516395	GATAD2A	0.85	12.69	0.45	4.46e-33	Nonalcoholic fatty liver disease;
BRCA	cis	rs6733011	0.578	rs11893888	chr2:99495239	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.35	-8.06	-0.3	3.68e-15	Bipolar disorder;
BRCA	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	18.0	0.58	6.37e-59	Platelet count;
BRCA	trans	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg18876405	chr7:65276391	NA	-0.51	-11.6	-0.42	2.34e-28	Aortic root size;
BRCA	cis	rs7072216	0.763	rs10748729	chr10:100171371	G/C	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.71	-0.36	7.24e-21	Metabolite levels;
BRCA	trans	rs1422110	0.513	rs1422105	chr5:85448371	A/C	cg01787110	chr1:109008453	NBPF6	0.36	8.01	0.3	5.6e-15	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs11229555	1.000	rs2298608	chr11:58404467	A/G	cg15696309	chr11:58395628	NA	0.52	11.48	0.41	7.14e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18404041	chr3:52824283	ITIH1	-0.38	-11.8	-0.42	3.22e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg13770153	chr20:60521292	NA	-0.41	-9.12	-0.34	9.89e-19	Body mass index;
BRCA	trans	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg25214090	chr10:38739885	LOC399744	0.49	10.4	0.38	1.59e-23	Corneal astigmatism;
BRCA	trans	rs61931739	0.635	rs10743836	chr12:33961680	C/T	cg26384229	chr12:38710491	ALG10B	0.39	8.87	0.33	7e-18	Morning vs. evening chronotype;
BRCA	cis	rs858239	0.600	rs10266123	chr7:23136487	G/C	cg23682824	chr7:23144976	KLHL7	0.42	11.32	0.41	3.34e-27	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	13.44	0.47	1.93e-36	Ileal carcinoids;
BRCA	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg17143192	chr8:8559678	CLDN23	0.52	10.06	0.37	3.48e-22	Obesity-related traits;
BRCA	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg00031303	chr3:195681400	NA	0.45	8.55	0.32	9.31e-17	Pancreatic cancer;
BRCA	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	10.1	0.37	2.4e-22	Lung cancer in ever smokers;
BRCA	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11890956	chr21:40555474	PSMG1	-0.82	-20.61	-0.63	9.89e-73	Cognitive function;
BRCA	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.56	13.26	0.46	1.2e-35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg23711669	chr6:146136114	FBXO30	0.72	16.53	0.55	2.2e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-11.12	-0.4	2.26e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg25206134	chr2:45395956	NA	0.55	9.06	0.34	1.55e-18	Bipolar disorder;
BRCA	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	11.23	0.41	7.49e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	11.34	0.41	2.78e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08219700	chr8:58056026	NA	0.44	7.94	0.3	8.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg26149184	chr10:133730230	NA	0.39	7.88	0.3	1.46e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg02659138	chr7:134003124	SLC35B4	0.32	9.78	0.36	3.74e-21	Mean platelet volume;
BRCA	cis	rs1451375	0.755	rs3829897	chr7:50629764	G/T	cg18232548	chr7:50535776	DDC	0.4	9.73	0.36	5.85e-21	Malaria;
BRCA	cis	rs858239	0.539	rs10280815	chr7:23188370	A/C	cg23682824	chr7:23144976	KLHL7	0.42	10.94	0.4	1.21e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg21535247	chr6:8435926	SLC35B3	0.42	9.44	0.35	6.79e-20	Motion sickness;
BRCA	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg04691961	chr3:161091175	C3orf57	-0.52	-12.88	-0.45	6.43e-34	Morning vs. evening chronotype;
BRCA	cis	rs12760731	0.565	rs34593395	chr1:178129488	C/T	cg00404053	chr1:178313656	RASAL2	0.64	7.86	0.3	1.67e-14	Obesity-related traits;
BRCA	cis	rs1971762	0.563	rs7958775	chr12:54077556	T/C	cg23533419	chr12:54090519	NA	-0.33	-8.37	-0.31	3.55e-16	Height;
BRCA	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg26384229	chr12:38710491	ALG10B	0.66	15.22	0.52	7.19e-45	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-11.66	-0.42	1.34e-28	Personality dimensions;
BRCA	trans	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg26043149	chr18:55253948	FECH	-0.41	-8.88	-0.33	6.9e-18	Bone mineral density;
BRCA	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg07549590	chr16:15018862	NA	-0.49	-12.34	-0.44	1.63e-31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs877529	1.000	rs713909	chr22:39532420	G/C	cg12193277	chr22:39547181	CBX7	0.46	12.74	0.45	2.63e-33	Multiple myeloma;
BRCA	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.77	-0.42	4.32e-29	Alcohol dependence;
BRCA	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.57	-0.32	7.64e-17	Total body bone mineral density;
BRCA	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	8.08	0.3	3.12e-15	Diabetic retinopathy;
BRCA	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.33	0.35	1.73e-19	Morning vs. evening chronotype;
BRCA	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg11266682	chr4:10021025	SLC2A9	0.37	9.56	0.35	2.56e-20	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.69	-14.34	-0.49	1.24e-40	HIV-1 control;
BRCA	cis	rs16944613	0.541	rs7494949	chr15:91090394	C/G	cg26821196	chr15:91095069	CRTC3	0.47	8.55	0.32	9.42e-17	Colorectal cancer;
BRCA	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-11.95	-0.43	7.54e-30	Personality dimensions;
BRCA	cis	rs6545883	0.525	rs1729662	chr2:61391305	G/A	cg15711740	chr2:61764176	XPO1	-0.46	-11.27	-0.41	5.43e-27	Tuberculosis;
BRCA	cis	rs586533	0.678	rs669951	chr11:99499468	G/T	cg22878054	chr11:99397252	CNTN5	0.32	8.07	0.3	3.53e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg02353165	chr6:42928485	GNMT	0.88	23.75	0.68	7.12e-90	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6723226	0.750	rs3769597	chr2:32691400	T/G	cg02381751	chr2:32503542	YIPF4	0.48	10.21	0.37	8.62e-23	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg12386194	chr3:101231763	SENP7	0.46	9.76	0.36	4.58e-21	Colorectal cancer;
BRCA	cis	rs9400271	0.527	rs60248809	chr6:109640690	A/C	cg01475377	chr6:109611718	NA	0.36	7.96	0.3	7.97e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg00495681	chr13:53174319	NA	0.42	8.98	0.33	2.98e-18	Lewy body disease;
BRCA	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.12	-0.31	2.39e-15	Menopause (age at onset);
BRCA	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.53	13.53	0.47	7.47e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2066819	1.000	rs17118409	chr12:56630764	G/A	cg26714650	chr12:56694279	CS	-1.18	-15.33	-0.52	2.13e-45	Psoriasis vulgaris;
BRCA	cis	rs2731664	0.792	rs652242	chr5:176873010	C/G	cg23176889	chr5:176863531	GRK6	-0.61	-16.61	-0.55	8.84e-52	Intelligence (multi-trait analysis);
BRCA	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg00106254	chr7:1943704	MAD1L1	-0.35	-9.26	-0.34	3.18e-19	Schizophrenia;
BRCA	cis	rs62380364	0.542	rs2457979	chr5:88039660	T/A	cg22951263	chr5:87985283	NA	-0.38	-10.56	-0.39	3.86e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.41	7.84	0.3	1.93e-14	Tuberculosis;
BRCA	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg03885332	chr11:832357	CD151	-0.33	-9.45	-0.35	6.31e-20	Mean platelet volume;
BRCA	cis	rs113835537	0.597	rs57288351	chr11:66307489	C/T	cg24851651	chr11:66362959	CCS	0.48	8.73	0.33	2.15e-17	Airway imaging phenotypes;
BRCA	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg14440974	chr22:39074834	NA	-0.38	-9.0	-0.34	2.64e-18	Menopause (age at onset);
BRCA	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.12	-0.31	2.39e-15	Menopause (age at onset);
BRCA	trans	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.12	0.31	2.33e-15	Corneal astigmatism;
BRCA	cis	rs858239	0.601	rs73272048	chr7:23152653	C/G	cg23682824	chr7:23144976	KLHL7	0.45	12.04	0.43	3.16e-30	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg23711669	chr6:146136114	FBXO30	-0.75	-15.96	-0.53	1.59e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2455601	0.786	rs11042127	chr11:8947586	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-9.03	-0.34	2.02e-18	Schizophrenia;
BRCA	trans	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg26043149	chr18:55253948	FECH	-0.41	-8.73	-0.33	2.29e-17	Bone mineral density;
BRCA	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.27e-23	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg26043149	chr18:55253948	FECH	-0.37	-8.25	-0.31	8.96e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9392556	0.829	rs619873	chr6:4107455	A/G	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.39	-8.64	-0.32	4.63e-17	Blood metabolite levels;
BRCA	trans	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg25214090	chr10:38739885	LOC399744	0.46	10.6	0.39	2.72e-24	Corneal astigmatism;
BRCA	cis	rs782590	0.533	rs2008040	chr2:55687290	G/C	cg18811423	chr2:55921094	PNPT1	0.46	11.99	0.43	5.35e-30	Metabolic syndrome;
BRCA	cis	rs829883	0.622	rs7302630	chr12:98959577	C/A	cg25150519	chr12:98850993	NA	-0.46	-8.46	-0.32	1.82e-16	Colorectal adenoma (advanced);
BRCA	cis	rs6594499	0.872	rs6865932	chr5:110436852	G/C	cg04022379	chr5:110408740	TSLP	0.35	8.01	0.3	5.51e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg04450456	chr4:17643702	FAM184B	0.42	12.53	0.44	2.21e-32	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg27129171	chr3:47204927	SETD2	-0.64	-14.38	-0.49	8.27e-41	Colorectal cancer;
BRCA	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.57	-0.42	3.14e-28	Bipolar disorder;
BRCA	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg03711944	chr11:47377212	SPI1	-0.43	-11.64	-0.42	1.51e-28	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.26	-9.11	-0.34	1.08e-18	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs365132	1.000	rs35977534	chr5:176335231	T/C	cg16309518	chr5:176445507	NA	-0.52	-13.38	-0.47	3.71e-36	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs7635838	0.596	rs347599	chr3:11258191	C/T	cg00170343	chr3:11313890	ATG7	-0.42	-8.42	-0.32	2.44e-16	HDL cholesterol;
BRCA	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg27170947	chr2:26402098	FAM59B	-0.65	-10.98	-0.4	8.46e-26	Gut microbiome composition (summer);
BRCA	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg21775007	chr8:11205619	TDH	0.71	17.28	0.56	3.32e-55	Retinal vascular caliber;
BRCA	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg25237894	chr2:233734115	C2orf82	0.39	11.1	0.4	2.74e-26	Coronary artery disease;
BRCA	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg25809561	chr17:30822961	MYO1D	0.4	9.26	0.34	2.96e-19	Schizophrenia;
BRCA	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg07211511	chr3:129823064	LOC729375	-0.57	-10.52	-0.38	5.52e-24	Blood pressure (smoking interaction);
BRCA	cis	rs34734847	1.000	rs2948149	chr12:121162854	T/G	cg21892295	chr12:121157589	UNC119B	-0.42	-13.07	-0.46	9.58e-35	Mean corpuscular volume;
BRCA	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg16339924	chr4:17578868	LAP3	0.56	13.9	0.48	1.42e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg08888203	chr3:10149979	C3orf24	0.67	14.45	0.5	3.77e-41	Alzheimer's disease;
BRCA	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg27279351	chr12:120934652	DYNLL1	0.51	12.25	0.44	3.95e-31	High light scatter reticulocyte count;
BRCA	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21545522	chr1:205238299	TMCC2	0.4	8.8	0.33	1.29e-17	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg09526685	chr4:187126073	CYP4V2	-0.96	-11.81	-0.42	2.99e-29	Blood protein levels;
BRCA	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg06115741	chr20:33292138	TP53INP2	-0.37	-8.22	-0.31	1.17e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs7631605	0.905	rs9822082	chr3:37086204	G/A	cg15934958	chr3:37212084	LRRFIP2	0.41	9.33	0.35	1.69e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.83	-0.58	5.25e-58	Chronic sinus infection;
BRCA	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg01874867	chr7:94954059	PON1	-0.39	-7.97	-0.3	7.31e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg05347473	chr6:146136440	FBXO30	0.41	8.07	0.3	3.41e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg11764359	chr7:65958608	NA	0.66	12.08	0.43	2.07e-30	Aortic root size;
BRCA	cis	rs13046373	0.508	rs1911572	chr21:32031648	A/G	cg24082983	chr21:31802169	KRTAP13-4	-0.34	-8.56	-0.32	8.65e-17	HDL cholesterol;
BRCA	cis	rs62005083	0.500	rs10135300	chr14:74574561	G/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.52	8.95	0.33	3.72e-18	Mean corpuscular volume;
BRCA	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg04414720	chr1:150670196	GOLPH3L	0.36	8.28	0.31	7.19e-16	Tonsillectomy;
BRCA	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg08085267	chr17:45401833	C17orf57	0.67	14.61	0.5	6.47e-42	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs3824867	0.920	rs7948705	chr11:47447955	C/G	cg20307385	chr11:47447363	PSMC3	-0.49	-11.0	-0.4	7.1e-26	Mean corpuscular hemoglobin;
BRCA	cis	rs10746514	0.768	rs11122427	chr1:232261085	C/T	cg09506761	chr1:232265262	NA	-0.42	-8.66	-0.32	3.86e-17	Response to statin therapy;
BRCA	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg01939980	chr4:1354348	KIAA1530	0.37	8.73	0.33	2.23e-17	Obesity-related traits;
BRCA	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg04998671	chr14:104000505	TRMT61A	0.41	8.94	0.33	4.31e-18	Coronary artery disease;
BRCA	cis	rs3771570	0.901	rs73008106	chr2:242422446	C/T	cg21155796	chr2:242212141	HDLBP	0.52	8.49	0.32	1.41e-16	Prostate cancer;
BRCA	cis	rs28374715	0.662	rs513280	chr15:41482800	T/C	cg18705301	chr15:41695430	NDUFAF1	0.78	16.93	0.56	2.19e-53	Ulcerative colitis;
BRCA	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg06917634	chr15:78832804	PSMA4	0.58	12.5	0.44	3.28e-32	Sudden cardiac arrest;
BRCA	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg12863693	chr15:85201151	NMB	0.4	9.18	0.34	5.7e-19	P wave terminal force;
BRCA	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.12	0.43	1.37e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg15704280	chr7:45808275	SEPT13	-0.77	-17.34	-0.57	1.8e-55	Coronary artery disease;
BRCA	cis	rs17818399	0.548	rs1989720	chr2:46854364	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.42	8.31	0.31	5.84e-16	Height;
BRCA	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg05234568	chr11:5960015	NA	-0.43	-8.83	-0.33	1.01e-17	DNA methylation (variation);
BRCA	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.98	0.3	6.99e-15	Depression;
BRCA	cis	rs4478858	0.611	rs7527645	chr1:31763787	T/C	cg00250761	chr1:31883323	NA	-0.31	-8.17	-0.31	1.63e-15	Alcohol dependence;
BRCA	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	8.35	0.31	4.22e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg11814155	chr7:99998594	ZCWPW1	0.49	8.77	0.33	1.57e-17	Platelet count;
BRCA	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg11062466	chr8:58055876	NA	0.54	9.15	0.34	7.78e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs7582720	1.000	rs72934537	chr2:203969504	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	12.77	0.45	2.02e-33	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg00677455	chr12:58241039	CTDSP2	0.64	16.16	0.54	1.62e-49	Intelligence (multi-trait analysis);
BRCA	cis	rs7246657	0.524	rs28542490	chr19:37456584	C/A	cg23950597	chr19:37808831	NA	-0.58	-9.19	-0.34	5.47e-19	Coronary artery calcification;
BRCA	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg21747090	chr2:27597821	SNX17	-0.45	-9.65	-0.36	1.2e-20	Total body bone mineral density;
BRCA	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.33	-0.44	1.69e-31	Chronic sinus infection;
BRCA	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-9.83	-0.36	2.47e-21	Tonsillectomy;
BRCA	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg13010199	chr12:38710504	ALG10B	0.41	8.37	0.31	3.59e-16	Bladder cancer;
BRCA	cis	rs5167	0.504	rs73047641	chr19:45457377	G/A	cg20090143	chr19:45452003	APOC2	0.27	7.9	0.3	1.18e-14	Blood protein levels;
BRCA	cis	rs870825	0.616	rs877276	chr4:185621249	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	trans	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg15556689	chr8:8085844	FLJ10661	0.33	8.05	0.3	4.14e-15	Triglycerides;
BRCA	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg11843238	chr5:131593191	PDLIM4	0.36	9.32	0.35	1.81e-19	Breast cancer;
BRCA	trans	rs1493916	0.592	rs1389068	chr18:31312738	G/T	cg27147174	chr7:100797783	AP1S1	-0.42	-8.15	-0.31	1.89e-15	Life satisfaction;
BRCA	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg04981885	chr1:160991156	F11R	-0.55	-10.12	-0.37	2.07e-22	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg05863683	chr7:1912471	MAD1L1	0.37	8.39	0.31	3.21e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs4763879	0.865	rs4763840	chr12:9884410	A/G	cg27502298	chr12:9555721	NA	0.41	7.92	0.3	1.05e-14	Type 1 diabetes;
BRCA	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg13736514	chr6:26305472	NA	-0.36	-12.24	-0.44	4.46e-31	Educational attainment;
BRCA	cis	rs10788264	0.538	rs1998344	chr10:124030137	A/G	cg09507567	chr10:124027408	NA	0.38	7.96	0.3	7.94e-15	Total body bone mineral density;
BRCA	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg24069376	chr3:38537580	EXOG	-0.38	-10.78	-0.39	5.09e-25	Electrocardiographic conduction measures;
BRCA	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg17691542	chr6:26056736	HIST1H1C	0.55	11.56	0.42	3.39e-28	Height;
BRCA	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-13.88	-0.48	1.76e-38	Personality dimensions;
BRCA	cis	rs7617773	0.963	rs6800730	chr3:48174210	C/T	cg11946769	chr3:48343235	NME6	0.38	8.19	0.31	1.44e-15	Coronary artery disease;
BRCA	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg22705602	chr4:152727874	NA	-0.38	-10.16	-0.37	1.41e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6901004	0.935	rs1150078	chr6:111560301	C/T	cg15721981	chr6:111408429	SLC16A10	0.36	7.91	0.3	1.1e-14	Blood metabolite levels;
BRCA	cis	rs4594175	0.886	rs11157802	chr14:51622984	C/T	cg23942311	chr14:51606299	NA	0.33	8.46	0.32	1.83e-16	Cancer;
BRCA	cis	rs13053817	1.000	rs7290855	chr22:29852474	G/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.47	-9.04	-0.34	1.81e-18	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg03342759	chr3:160939853	NMD3	-0.64	-13.47	-0.47	1.36e-36	Morning vs. evening chronotype;
BRCA	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.64	0.61	1.56e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26314531	chr2:26401878	FAM59B	-0.66	-11.2	-0.4	1.08e-26	Gut microbiome composition (summer);
BRCA	cis	rs4642101	0.662	rs4034942	chr3:12836792	C/T	cg24848339	chr3:12840334	CAND2	0.52	14.13	0.49	1.16e-39	QRS complex (12-leadsum);
BRCA	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg00339695	chr16:24857497	SLC5A11	0.49	9.75	0.36	5.07e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg06697600	chr4:7070879	GRPEL1	0.6	10.09	0.37	2.65e-22	Monocyte percentage of white cells;
BRCA	cis	rs7020830	0.861	rs6476622	chr9:37308049	T/A	cg14294708	chr9:37120828	ZCCHC7	1.14	38.09	0.83	1.42e-166	Schizophrenia;
BRCA	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.61	-12.65	-0.45	6.64e-33	Homoarginine levels;
BRCA	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg15605315	chr1:45957053	TESK2	0.46	9.4	0.35	9.8e-20	High light scatter reticulocyte count;
BRCA	cis	rs10193935	0.892	rs13413028	chr2:42394865	C/G	cg27598129	chr2:42591480	NA	-0.93	-14.94	-0.51	1.59e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14240646	chr10:27532245	ACBD5	-0.62	-9.58	-0.35	2.13e-20	Breast cancer;
BRCA	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg05896524	chr21:47604654	C21orf56	0.51	10.35	0.38	2.66e-23	Testicular germ cell tumor;
BRCA	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-10.5	-0.38	6.96e-24	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg16011800	chr17:1958478	HIC1	-0.56	-9.04	-0.34	1.84e-18	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg26384229	chr12:38710491	ALG10B	0.73	17.55	0.57	1.36e-56	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7582720	0.943	rs72934546	chr2:203980033	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	12.77	0.45	2.02e-33	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-12.71	-0.45	3.61e-33	Bipolar disorder and schizophrenia;
BRCA	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg23711669	chr6:146136114	FBXO30	-0.8	-19.25	-0.61	1.69e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg10729496	chr3:10149963	C3orf24	0.49	9.17	0.34	6.54e-19	Alzheimer's disease;
BRCA	cis	rs701145	0.938	rs701135	chr3:154065455	C/G	cg17054900	chr3:154042577	DHX36	0.66	11.41	0.41	1.46e-27	Coronary artery disease;
BRCA	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg24692254	chr21:30365293	RNF160	0.79	21.82	0.65	2.72e-79	Dental caries;
BRCA	cis	rs7131987	0.621	rs6487805	chr12:29457550	A/T	cg09582351	chr12:29534625	ERGIC2	0.41	9.34	0.35	1.5700000000000001e-19	QT interval;
BRCA	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg16482183	chr6:26056742	HIST1H1C	0.5	10.33	0.38	3.04e-23	Height;
BRCA	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg25358565	chr5:93447407	FAM172A	-0.66	-11.52	-0.41	4.79e-28	Diabetic retinopathy;
BRCA	trans	rs4819388	0.915	rs4818892	chr21:45650085	A/G	cg17383793	chr5:52405638	MOCS2	0.48	11.03	0.4	5.02e-26	Celiac disease;
BRCA	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-11.86	-0.42	1.87e-29	Gut microbiome composition (summer);
BRCA	trans	rs10805346	0.531	rs12498927	chr4:10115523	C/T	cg26043149	chr18:55253948	FECH	-0.44	-10.26	-0.38	5.8e-23	Urate levels in overweight individuals;Urate levels in obese individuals;
BRCA	cis	rs365132	1.000	rs353490	chr5:176433063	C/T	cg16309518	chr5:176445507	NA	-0.51	-13.2	-0.46	2.28e-35	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	trans	rs7944735	0.517	rs11039538	chr11:48154990	A/T	cg15704280	chr7:45808275	SEPT13	0.57	8.09	0.3	3.11e-15	Intraocular pressure;
BRCA	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg03585969	chr10:35415529	CREM	0.49	10.09	0.37	2.59e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18876405	chr7:65276391	NA	-0.55	-13.02	-0.46	1.6e-34	Aortic root size;
BRCA	cis	rs7095944	0.614	rs4962697	chr10:126447545	G/C	cg08799069	chr10:126477246	METTL10	-0.4	-9.44	-0.35	7.08e-20	Asthma;
BRCA	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg24920358	chr1:40204285	PPIE	0.33	7.81	0.3	2.3e-14	Blood protein levels;
BRCA	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg21017887	chr14:105400489	NA	-0.64	-17.16	-0.56	1.49e-54	Rheumatoid arthritis;
BRCA	trans	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg23762105	chr12:34175262	ALG10	-0.41	-10.1	-0.37	2.42e-22	Heart rate;
BRCA	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.61	8.47	0.32	1.71e-16	Putamen volume;
BRCA	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg22903471	chr2:27725779	GCKR	-0.39	-9.72	-0.36	6.26e-21	Total body bone mineral density;
BRCA	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg18964960	chr10:1102726	WDR37	-0.51	-8.91	-0.33	5.36e-18	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg10253484	chr15:75165896	SCAMP2	0.48	9.54	0.35	2.92e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	trans	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17712092	chr4:129076599	LARP1B	0.54	13.08	0.46	8.18e-35	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	10.66	0.39	1.53e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg03929089	chr4:120376271	NA	0.47	8.42	0.32	2.55e-16	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	20.88	0.64	3.37e-74	Nonalcoholic fatty liver disease;
BRCA	cis	rs11112613	0.713	rs55646142	chr12:105949557	G/A	cg03607813	chr12:105948248	NA	0.6	11.21	0.41	9.41e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08045932	chr20:61659980	NA	0.49	11.18	0.4	1.31e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg07148914	chr20:33460835	GGT7	0.45	9.65	0.36	1.18e-20	Height;
BRCA	cis	rs11702148	0.552	rs2154583	chr21:34888940	T/G	cg14850771	chr21:34775459	IFNGR2	0.36	8.08	0.3	3.35e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg00530320	chr1:46809349	NSUN4	0.48	9.78	0.36	3.87e-21	Menopause (age at onset);
BRCA	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	19.53	0.61	5.96e-67	Platelet count;
BRCA	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg08601574	chr20:25228251	PYGB	0.35	8.39	0.31	3.21e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg04025307	chr7:1156635	C7orf50	0.47	9.42	0.35	8.26e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg24642844	chr7:1081250	C7orf50	-0.89	-16.0	-0.53	1.07e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.33e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg23422044	chr7:1970798	MAD1L1	-0.56	-9.64	-0.36	1.29e-20	Neuroticism;
BRCA	cis	rs6545883	0.859	rs35760550	chr2:61603865	T/A	cg15711740	chr2:61764176	XPO1	0.5	12.18	0.43	8.05e-31	Tuberculosis;
BRCA	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg05623727	chr3:50126028	RBM5	0.45	8.55	0.32	9.1e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg15017067	chr4:17643749	FAM184B	-0.29	-8.78	-0.33	1.49e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.36	7.91	0.3	1.13e-14	Mean corpuscular volume;
BRCA	cis	rs4919694	1.000	rs58317752	chr10:104799267	T/A	cg04362960	chr10:104952993	NT5C2	0.94	14.5	0.5	2.26e-41	Arsenic metabolism;
BRCA	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg00277334	chr10:82204260	NA	-0.48	-10.1	-0.37	2.42e-22	Post bronchodilator FEV1;
BRCA	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg16179182	chr5:140090404	VTRNA1-1	-0.46	-10.75	-0.39	7.03e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs8038465	0.622	rs17185525	chr15:73885539	T/C	cg15420318	chr15:73925796	NPTN	0.48	10.37	0.38	2.07e-23	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg13256891	chr4:100009986	ADH5	-0.53	-9.85	-0.36	2.13e-21	Alcohol dependence;
BRCA	cis	rs751728	0.717	rs3763258	chr6:33773744	A/G	cg25922239	chr6:33757077	LEMD2	0.51	11.42	0.41	1.24e-27	Crohn's disease;
BRCA	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg11502198	chr6:26597334	ABT1	0.47	9.46	0.35	5.7e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg09065629	chr16:1709722	CRAMP1L	0.36	8.36	0.31	3.8e-16	Coronary artery disease;
BRCA	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg04004882	chr2:215674386	BARD1	0.67	12.38	0.44	1.02e-31	Neuroblastoma;
BRCA	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg18904891	chr8:8559673	CLDN23	0.61	11.98	0.43	5.44e-30	Obesity-related traits;
BRCA	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg05072100	chr8:143858499	LYNX1	-0.41	-8.73	-0.33	2.14e-17	Urinary tract infection frequency;
BRCA	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg03929089	chr4:120376271	NA	0.59	10.1	0.37	2.29e-22	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.54	-0.32	9.62e-17	Total body bone mineral density;
BRCA	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18876405	chr7:65276391	NA	-0.63	-15.65	-0.53	5.9e-47	Aortic root size;
BRCA	cis	rs4722585	0.605	rs10268883	chr7:26200417	C/T	cg07876897	chr7:26191696	NFE2L3	0.43	9.33	0.35	1.71e-19	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
BRCA	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg21427119	chr20:30132790	HM13	-0.43	-9.24	-0.34	3.68e-19	Mean corpuscular hemoglobin;
BRCA	cis	rs2404602	0.575	rs11072611	chr15:76947983	A/G	cg23625390	chr15:77176239	SCAPER	0.56	12.94	0.46	3.66e-34	Blood metabolite levels;
BRCA	cis	rs4074536	0.574	rs10801976	chr1:116295519	A/C	cg21648376	chr1:116311395	CASQ2	-0.5	-8.73	-0.33	2.19e-17	QRS duration;
BRCA	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg06026331	chr20:60912101	LAMA5	0.43	8.22	0.31	1.12e-15	Colorectal cancer;
BRCA	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg03433033	chr1:76189801	ACADM	-0.6	-12.13	-0.43	1.23e-30	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs476633	0.691	rs28735224	chr15:41537539	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.4	-8.8	-0.33	1.32e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg06212747	chr3:49208901	KLHDC8B	0.51	8.0	0.3	5.96e-15	Menarche (age at onset);
BRCA	cis	rs7131987	0.650	rs7301398	chr12:29455390	G/T	cg09582351	chr12:29534625	ERGIC2	-0.46	-10.61	-0.39	2.46e-24	QT interval;
BRCA	cis	rs4363385	0.669	rs4845519	chr1:153003916	G/T	cg24667326	chr1:152973720	SPRR3	0.33	9.45	0.35	6.5e-20	Inflammatory skin disease;
BRCA	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg18252515	chr7:66147081	NA	-1.06	-15.69	-0.53	3.74e-47	Gout;
BRCA	cis	rs4308124	0.708	rs56693625	chr2:111965155	G/A	cg04571233	chr2:111982156	NA	-0.45	-9.67	-0.36	9.81e-21	Vitiligo;
BRCA	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg15017067	chr4:17643749	FAM184B	0.34	10.39	0.38	1.76e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg07741184	chr6:167504864	NA	0.29	8.37	0.31	3.57e-16	Crohn's disease;
BRCA	cis	rs2710642	0.962	rs7567923	chr2:63085848	C/T	cg17519650	chr2:63277830	OTX1	-0.38	-8.72	-0.33	2.47e-17	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg06697600	chr4:7070879	GRPEL1	0.61	10.75	0.39	6.57e-25	Monocyte percentage of white cells;
BRCA	cis	rs4953076	0.573	rs7593987	chr2:44393532	C/T	cg04920474	chr2:44395004	PPM1B	-0.47	-9.54	-0.35	3.04e-20	Height;
BRCA	cis	rs6878727	0.850	rs988410	chr5:123730530	C/T	cg01806427	chr5:123737813	NA	0.42	9.55	0.35	2.73e-20	Breast cancer;
BRCA	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg08885076	chr2:99613938	TSGA10	0.43	10.31	0.38	3.72e-23	Chronic sinus infection;
BRCA	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg14664628	chr15:75095509	CSK	0.83	21.87	0.65	1.39e-79	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs4074536	0.574	rs10754356	chr1:116292469	C/T	cg21648376	chr1:116311395	CASQ2	0.48	8.52	0.32	1.11e-16	QRS duration;
BRCA	cis	rs10267417	0.657	rs12668709	chr7:19858946	T/G	cg07541023	chr7:19748670	TWISTNB	0.51	9.11	0.34	1.05e-18	Night sleep phenotypes;
BRCA	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21659725	chr3:3221576	CRBN	-0.71	-21.61	-0.65	3.69e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg08888203	chr3:10149979	C3orf24	0.67	14.48	0.5	2.56e-41	Alzheimer's disease;
BRCA	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg23711669	chr6:146136114	FBXO30	0.69	16.07	0.54	4.52e-49	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg13010199	chr12:38710504	ALG10B	0.44	9.22	0.34	4.31e-19	Morning vs. evening chronotype;
BRCA	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg21475434	chr5:93447410	FAM172A	0.67	8.75	0.33	1.9e-17	Diabetic retinopathy;
BRCA	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg25427524	chr10:38739819	LOC399744	-0.59	-10.15	-0.37	1.49e-22	Obesity (extreme);
BRCA	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.23	0.41	7.53e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2147904	0.934	rs812487	chr1:42366198	G/A	cg16685388	chr1:42384056	HIVEP3	0.32	9.08	0.34	1.36e-18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
BRCA	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	19.71	0.61	6.07e-68	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6545883	0.965	rs3771258	chr2:61764140	C/T	cg15711740	chr2:61764176	XPO1	-0.56	-14.32	-0.49	1.52e-40	Tuberculosis;
BRCA	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg16931447	chr4:875861	GAK	-0.37	-8.43	-0.32	2.24e-16	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
BRCA	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.76	-0.33	1.79e-17	Colorectal cancer;
BRCA	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg24642439	chr20:33292090	TP53INP2	-0.43	-8.79	-0.33	1.34e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg05340658	chr4:99064831	C4orf37	0.67	16.6	0.55	1.05e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6688613	0.694	rs2075946	chr1:166818566	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.42	8.97	0.33	3.39e-18	Refractive astigmatism;
BRCA	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg20203395	chr5:56204925	C5orf35	-0.49	-10.25	-0.38	6.14e-23	Initial pursuit acceleration;
BRCA	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg17691542	chr6:26056736	HIST1H1C	0.48	9.55	0.35	2.75e-20	Iron status biomarkers;
BRCA	trans	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg21659725	chr3:3221576	CRBN	-0.48	-8.7	-0.33	2.83e-17	Menarche (age at onset);
BRCA	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg23358479	chr7:1110784	C7orf50	-0.49	-8.2	-0.31	1.27e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3815308	0.530	rs12983546	chr19:2195065	G/T	cg09261902	chr19:2140048	AP3D1	0.35	8.55	0.32	8.99e-17	Breast cancer;
BRCA	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg13010199	chr12:38710504	ALG10B	0.43	9.14	0.34	8.49e-19	Bladder cancer;
BRCA	cis	rs7707921	0.881	rs60733727	chr5:81448283	G/A	cg15871215	chr5:81402204	ATG10	-0.41	-8.59	-0.32	6.64e-17	Breast cancer;
BRCA	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	8.1	0.31	2.81e-15	Bipolar disorder;
BRCA	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.64	-0.5	4.62e-42	Chronic sinus infection;
BRCA	cis	rs34779708	0.966	rs11010095	chr10:35395948	A/G	cg03585969	chr10:35415529	CREM	0.44	9.26	0.34	3.1e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-8.63	-0.32	4.87e-17	Tonsillectomy;
BRCA	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg15103426	chr22:29168792	CCDC117	0.51	11.88	0.43	1.43e-29	Lymphocyte counts;
BRCA	trans	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.0	0.3	5.89e-15	Corneal astigmatism;
BRCA	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26314531	chr2:26401878	FAM59B	0.85	13.83	0.48	2.92e-38	Gut microbiome composition (summer);
BRCA	cis	rs6878727	0.614	rs256614	chr5:123660784	T/C	cg01806427	chr5:123737813	NA	-0.35	-7.94	-0.3	9.27e-15	Breast cancer;
BRCA	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg16586182	chr3:47516702	SCAP	0.61	13.73	0.48	9.12e-38	Colorectal cancer;
BRCA	cis	rs9400271	0.632	rs9384704	chr6:109587209	C/T	cg01475377	chr6:109611718	NA	-0.43	-10.24	-0.38	6.9e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg20476274	chr7:133979776	SLC35B4	0.63	17.75	0.57	1.4e-57	Mean platelet volume;
BRCA	cis	rs708547	0.599	rs1718864	chr4:57887471	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.38	9.79	0.36	3.44e-21	Response to bleomycin (chromatid breaks);
BRCA	cis	rs204247	0.565	rs411094	chr6:13718264	C/A	cg02206980	chr6:13574034	SIRT5	-0.34	-9.5	-0.35	4.2e-20	Breast cancer;
BRCA	trans	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	38.9	0.84	1.2e-170	Exhaled nitric oxide output;
BRCA	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg20991723	chr1:152506922	NA	0.39	8.94	0.33	4.28e-18	Hair morphology;
BRCA	cis	rs61863818	0.709	rs10786343	chr10:99159465	C/A	cg08345082	chr10:99160200	RRP12	-0.31	-9.07	-0.34	1.46e-18	Monocyte percentage of white cells;
BRCA	trans	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg07461501	chr17:79650226	HGS;ARL16	0.4	10.11	0.37	2.14e-22	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs35661897	0.920	rs12463838	chr2:227310093	G/A	cg03426602	chr2:227312417	NA	-0.47	-7.98	-0.3	6.63e-15	Urinary tract infection frequency;
BRCA	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg20307385	chr11:47447363	PSMC3	-0.41	-9.7	-0.36	7.83e-21	Subjective well-being;
BRCA	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg09307838	chr4:120376055	NA	0.61	12.31	0.44	2.09e-31	Corneal astigmatism;
BRCA	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg08999081	chr20:33150536	PIGU	-0.45	-12.47	-0.44	4.39e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg16102102	chr5:83017553	HAPLN1	-0.91	-17.84	-0.58	4.48e-58	Prostate cancer;
BRCA	cis	rs11971779	0.715	rs6954219	chr7:139065110	G/C	cg07862535	chr7:139043722	LUC7L2	0.38	10.21	0.37	9.03e-23	Diisocyanate-induced asthma;
BRCA	cis	rs7072216	0.770	rs3830020	chr10:100176615	C/G	cg26618903	chr10:100175079	PYROXD2	0.26	7.91	0.3	1.1e-14	Metabolite levels;
BRCA	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg05340658	chr4:99064831	C4orf37	0.68	17.05	0.56	5.48e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg00106254	chr7:1943704	MAD1L1	-0.38	-9.02	-0.34	2.09e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg03433033	chr1:76189801	ACADM	0.76	17.51	0.57	2.43e-56	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg18252515	chr7:66147081	NA	-0.68	-10.93	-0.4	1.3e-25	Diabetic kidney disease;
BRCA	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-14.13	-0.49	1.2e-39	Personality dimensions;
BRCA	cis	rs57590327	0.555	rs13072957	chr3:81776242	A/G	cg07356753	chr3:81810745	GBE1	0.47	11.11	0.4	2.4e-26	Extraversion;
BRCA	cis	rs4891159	0.548	rs617823	chr18:74120233	A/G	cg24786174	chr18:74118243	ZNF516	0.83	25.25	0.71	4.36e-98	Longevity;
BRCA	cis	rs7520050	0.966	rs12411269	chr1:46271052	C/T	cg24296786	chr1:45957014	TESK2	0.44	9.96	0.37	8.03e-22	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-10.98	-0.4	8.03e-26	Alzheimer's disease;
BRCA	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg01028140	chr2:1542097	TPO	-0.77	-15.31	-0.52	2.73e-45	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12016809	chr21:47604291	C21orf56	0.4	7.94	0.3	9.19e-15	Testicular germ cell tumor;
BRCA	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg25358565	chr5:93447407	FAM172A	1.23	18.97	0.6	5.63e-64	Diabetic retinopathy;
BRCA	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.44	-0.35	6.68e-20	Body mass index;
BRCA	trans	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.39	0.49	7.25e-41	Exhaled nitric oxide output;
BRCA	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.47	10.16	0.37	1.45e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4074536	0.536	rs12140550	chr1:116291025	G/A	cg21648376	chr1:116311395	CASQ2	-0.49	-8.68	-0.32	3.19e-17	QRS duration;
BRCA	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	11.8	0.42	3.22e-29	Schizophrenia;
BRCA	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11890956	chr21:40555474	PSMG1	0.64	14.71	0.5	2.11e-42	Menarche (age at onset);
BRCA	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg26384229	chr12:38710491	ALG10B	0.47	12.21	0.44	5.61e-31	Morning vs. evening chronotype;
BRCA	cis	rs7523050	0.643	rs67567504	chr1:109402580	C/A	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg17420585	chr12:42539391	GXYLT1	-0.38	-8.08	-0.3	3.3e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg17971929	chr21:40555470	PSMG1	-0.49	-10.91	-0.4	1.5e-25	Menarche (age at onset);
BRCA	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg02297831	chr4:17616191	MED28	0.39	9.11	0.34	1.08e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg10811474	chr19:8428787	ANGPTL4	-0.33	-8.35	-0.31	4.15e-16	HDL cholesterol;
BRCA	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.54	11.06	0.4	3.74e-26	Monocyte percentage of white cells;
BRCA	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg25036284	chr2:26402008	FAM59B	-0.88	-15.06	-0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-12.45	-0.44	5.43e-32	Longevity;
BRCA	cis	rs698833	0.819	rs2340809	chr2:44536249	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	9.78	0.36	3.93e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg26769984	chr7:1090371	C7orf50	0.48	9.11	0.34	1.06e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg03954927	chr1:10346856	KIF1B	0.47	14.91	0.51	2.22e-43	Hepatocellular carcinoma;
BRCA	cis	rs4561483	0.801	rs33660	chr16:11961858	A/G	cg08843971	chr16:11963173	GSPT1	-0.51	-11.6	-0.42	2.24e-28	Testicular germ cell tumor;
BRCA	cis	rs7011049	1.000	rs79536146	chr8:53853526	G/A	cg26025543	chr8:53854495	NA	0.55	9.54	0.35	3.03e-20	Systolic blood pressure;
BRCA	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.61	-15.79	-0.53	1.14e-47	Longevity;Endometriosis;
BRCA	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.91	-0.3	1.17e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04565464	chr8:145669602	NFKBIL2	0.37	8.7	0.33	2.73e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg11663144	chr21:46675770	NA	-0.48	-9.81	-0.36	3.08e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg18252515	chr7:66147081	NA	-0.86	-12.34	-0.44	1.55e-31	Diabetic kidney disease;
BRCA	trans	rs783540	0.934	rs7182403	chr15:83297613	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.28	-8.91	-0.33	5.42e-18	Schizophrenia;
BRCA	cis	rs4742903	0.967	rs7048372	chr9:106859738	T/C	cg14250997	chr9:106856677	SMC2	0.34	10.67	0.39	1.48e-24	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg04733989	chr22:42467013	NAGA	-0.36	-8.03	-0.3	4.67e-15	Cognitive function;
BRCA	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg04034577	chr2:241836375	C2orf54	-0.56	-13.46	-0.47	1.51e-36	Urinary metabolites;
BRCA	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14240646	chr10:27532245	ACBD5	-0.72	-16.04	-0.54	6.32e-49	Breast cancer;
BRCA	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.96	-0.3	7.61e-15	Prostate cancer;
BRCA	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg05313129	chr8:58192883	C8orf71	-0.46	-9.17	-0.34	6.37e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg20307385	chr11:47447363	PSMC3	0.76	16.8	0.55	1.04e-52	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03264133	chr6:25882463	NA	-0.53	-11.93	-0.43	9.61e-30	Blood metabolite levels;
BRCA	cis	rs6138458	0.887	rs227622	chr20:24910597	T/C	cg06937882	chr20:24974362	C20orf3	-0.44	-8.38	-0.31	3.34e-16	Blood protein levels;
BRCA	cis	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg07460842	chr6:66804631	NA	0.6	10.43	0.38	1.26e-23	Type 2 diabetes;
BRCA	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.78e-21	Total body bone mineral density;
BRCA	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	14.17	0.49	8.02e-40	Colorectal cancer;
BRCA	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg06627628	chr2:24431161	ITSN2	-0.54	-8.81	-0.33	1.15e-17	Lymphocyte counts;
BRCA	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg17802220	chr15:77601643	NA	-0.46	-10.18	-0.37	1.15e-22	Type 2 diabetes;
BRCA	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.34	-8.69	-0.33	3.02e-17	Total body bone mineral density;
BRCA	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg18252515	chr7:66147081	NA	-0.8	-11.18	-0.4	1.23e-26	Diabetic kidney disease;
BRCA	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg23625390	chr15:77176239	SCAPER	-0.36	-8.7	-0.33	2.91e-17	Blood metabolite levels;
BRCA	cis	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg06521331	chr12:34319734	NA	-0.56	-10.01	-0.37	5.05e-22	Morning vs. evening chronotype;
BRCA	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11644478	chr21:40555479	PSMG1	-0.66	-14.44	-0.5	4.25e-41	Cognitive function;
BRCA	cis	rs6878727	0.626	rs256857	chr5:123659824	T/C	cg01806427	chr5:123737813	NA	-0.36	-8.05	-0.3	4.04e-15	Breast cancer;
BRCA	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.89	0.36	1.54e-21	Bladder cancer;
BRCA	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg21770322	chr7:97807741	LMTK2	0.44	11.53	0.41	4.52e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	19.86	0.62	9.53e-69	Platelet count;
BRCA	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg26168224	chr5:2018326	NA	0.64	17.82	0.58	6.05e-58	Gut microbiome composition (winter);
BRCA	cis	rs4302748	0.862	rs57854543	chr7:36184158	C/G	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23221052	chr5:179740743	GFPT2	-0.64	-13.42	-0.47	2.44e-36	Height;
BRCA	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg11062466	chr8:58055876	NA	0.42	8.1	0.31	2.86e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg13902645	chr11:5959945	NA	-0.54	-11.11	-0.4	2.37e-26	DNA methylation (variation);
BRCA	cis	rs372883	0.532	rs425989	chr21:30715275	T/C	cg08807101	chr21:30365312	RNF160	-0.36	-8.18	-0.31	1.48e-15	Pancreatic cancer;
BRCA	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg05283184	chr6:79620031	NA	-0.43	-11.03	-0.4	4.97e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg21573476	chr21:45109991	RRP1B	-0.35	-8.82	-0.33	1.1e-17	Mean corpuscular volume;
BRCA	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg16482183	chr6:26056742	HIST1H1C	0.47	8.94	0.33	4.11e-18	Iron status biomarkers;
BRCA	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.41	-0.32	2.62e-16	Aortic root size;
BRCA	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.17	-0.31	1.6e-15	Depression;
BRCA	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg08000102	chr2:233561755	GIGYF2	0.62	13.57	0.47	4.67e-37	Coronary artery disease;
BRCA	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.53	0.32	1.09e-16	Rheumatoid arthritis;
BRCA	cis	rs9487051	0.768	rs461487	chr6:109525504	A/G	cg01475377	chr6:109611718	NA	-0.44	-10.99	-0.4	7.28e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs6901250	0.568	rs4946198	chr6:117176599	C/T	cg12892004	chr6:117198278	RFX6	-0.44	-8.89	-0.33	6.11e-18	C-reactive protein levels;
BRCA	cis	rs17433780	0.612	rs7911	chr1:89518120	A/G	cg26827852	chr1:89887630	LOC400759	0.33	7.98	0.3	6.65e-15	Carotid intima media thickness;
BRCA	cis	rs3820928	0.874	rs59630650	chr2:227786514	T/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-9.01	-0.34	2.39e-18	Pulmonary function;
BRCA	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-13.22	-0.46	1.99e-35	Platelet count;
BRCA	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.56	-0.32	8.61e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg12935359	chr14:103987150	CKB	-0.52	-11.26	-0.41	6e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg24562669	chr7:97807699	LMTK2	0.6	17.59	0.57	8.38e-57	Breast cancer;
BRCA	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18404041	chr3:52824283	ITIH1	-0.32	-9.65	-0.36	1.16e-20	Bipolar disorder;
BRCA	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.26	-0.34	3.04e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg20368463	chr18:77673604	PQLC1	0.49	12.34	0.44	1.57e-31	Schizophrenia;
BRCA	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg13256891	chr4:100009986	ADH5	0.52	9.77	0.36	4.15e-21	Alcohol dependence;
BRCA	cis	rs7617773	0.817	rs13100815	chr3:48287449	A/C	cg11946769	chr3:48343235	NME6	0.67	13.67	0.48	1.72e-37	Coronary artery disease;
BRCA	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg13319975	chr6:146136371	FBXO30	0.45	10.38	0.38	1.97e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg24803719	chr17:45855879	NA	-0.33	-8.48	-0.32	1.53e-16	IgG glycosylation;
BRCA	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg02297831	chr4:17616191	MED28	0.34	7.88	0.3	1.41e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg18512352	chr11:47633146	NA	-0.33	-8.15	-0.31	1.94e-15	Subjective well-being;
BRCA	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg20469991	chr17:27169893	C17orf63	-0.45	-8.81	-0.33	1.13e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs847577	0.508	rs12538837	chr7:97684468	C/T	cg21770322	chr7:97807741	LMTK2	0.36	8.28	0.31	7.44e-16	Breast cancer;
BRCA	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg01939980	chr4:1354348	KIAA1530	0.29	8.11	0.31	2.67e-15	Longevity;
BRCA	cis	rs2336384	1.000	rs7551874	chr1:12048130	A/G	cg13216073	chr1:12042593	MFN2	0.44	9.55	0.35	2.6e-20	Platelet count;
BRCA	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg25358565	chr5:93447407	FAM172A	-0.52	-9.41	-0.35	8.75e-20	Diabetic retinopathy;
BRCA	trans	rs3857536	0.740	rs7773577	chr6:66892124	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-9.49	-0.35	4.6e-20	Blood trace element (Cu levels);
BRCA	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg27165867	chr14:105738592	BRF1	-0.36	-8.74	-0.33	2.01e-17	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.98	-0.62	2.26e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg05340658	chr4:99064831	C4orf37	0.68	16.67	0.55	4.69e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg06627628	chr2:24431161	ITSN2	0.45	9.43	0.35	7.53e-20	Asthma;
BRCA	cis	rs7220401	0.512	rs2289629	chr17:27959903	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	10.52	0.38	5.63e-24	Coronary artery disease;
BRCA	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg00745463	chr17:30367425	LRRC37B	-0.52	-8.8	-0.33	1.26e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg15557168	chr22:42548783	NA	-0.32	-8.81	-0.33	1.16e-17	Cognitive function;
BRCA	cis	rs6546550	0.867	rs4852349	chr2:70076954	A/T	cg02498382	chr2:70120550	SNRNP27	-0.5	-10.37	-0.38	2.16e-23	Prevalent atrial fibrillation;
BRCA	cis	rs2797160	1.000	rs1739373	chr6:126011509	A/G	cg05901451	chr6:126070800	HEY2	0.4	9.65	0.36	1.19e-20	Endometrial cancer;
BRCA	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.24	-0.31	9.68e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.72	0.39	9.15e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg04455712	chr21:45112962	RRP1B	0.41	10.7	0.39	1.05e-24	Mean corpuscular volume;
BRCA	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs829883	0.664	rs829874	chr12:98840615	G/A	cg25150519	chr12:98850993	NA	0.67	16.16	0.54	1.57e-49	Colorectal adenoma (advanced);
BRCA	cis	rs7178424	1.000	rs12913951	chr15:62372592	A/G	cg00456672	chr15:62358751	C2CD4A	-0.36	-8.66	-0.32	3.81e-17	Height;
BRCA	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg00106254	chr7:1943704	MAD1L1	-0.36	-9.51	-0.35	3.8e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs495337	0.760	rs1056200	chr20:48556248	A/G	cg17835207	chr20:48524531	SPATA2	-0.69	-16.83	-0.55	6.76e-53	Psoriasis;
BRCA	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg09307838	chr4:120376055	NA	0.69	14.89	0.51	2.79e-43	Corneal astigmatism;
BRCA	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg09658497	chr7:2847517	GNA12	0.39	8.31	0.31	5.54e-16	Height;
BRCA	cis	rs7809615	0.901	rs10808111	chr7:99070884	T/A	cg12290671	chr7:99195819	NA	-0.5	-8.59	-0.32	6.77e-17	Blood metabolite ratios;
BRCA	cis	rs600806	0.888	rs6695482	chr1:109870859	C/G	cg20591472	chr1:110008990	SYPL2	0.32	8.12	0.31	2.5e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg06636001	chr8:8085503	FLJ10661	0.7	15.81	0.53	8.86e-48	Mood instability;
BRCA	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.47	10.99	0.4	7.61e-26	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.72	-0.36	6.63e-21	Body mass index;
BRCA	trans	rs2665103	0.632	rs3902959	chr15:82544927	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.32	-8.69	-0.33	3.06e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg25214090	chr10:38739885	LOC399744	0.57	12.99	0.46	2.06e-34	Corneal astigmatism;
BRCA	trans	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg11693508	chr17:37793320	STARD3	-0.59	-11.12	-0.4	2.17e-26	Bipolar disorder;
BRCA	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.47	0.35	5.16e-20	Tonsillectomy;
BRCA	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	7.15e-19	Alzheimer's disease (late onset);
BRCA	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-12.96	-0.46	2.89e-34	Chronic sinus infection;
BRCA	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg13319975	chr6:146136371	FBXO30	0.42	9.6	0.36	1.74e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg18351406	chr4:77819688	ANKRD56	0.58	12.6	0.45	1.14e-32	Emphysema distribution in smoking;
BRCA	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00166722	chr3:10149974	C3orf24	0.65	11.29	0.41	4.52e-27	Alzheimer's disease;
BRCA	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg11752832	chr7:134001865	SLC35B4	0.53	13.81	0.48	3.87e-38	Mean platelet volume;
BRCA	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03188948	chr7:1209495	NA	0.62	12.76	0.45	2.34e-33	Longevity;Endometriosis;
BRCA	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-12.1	-0.43	1.65e-30	Gut microbiome composition (summer);
BRCA	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.09	0.4	2.94e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg06623918	chr6:96969491	KIAA0776	0.74	12.19	0.43	6.85e-31	Migraine;Coronary artery disease;
BRCA	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg12935359	chr14:103987150	CKB	-0.59	-14.09	-0.49	1.85e-39	Body mass index;
BRCA	trans	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg25214090	chr10:38739885	LOC399744	0.5	10.34	0.38	2.83e-23	Corneal astigmatism;
BRCA	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg00666640	chr1:248458726	OR2T12	0.33	8.66	0.32	3.76e-17	Common traits (Other);
BRCA	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg07988820	chr12:82153109	PPFIA2	-0.63	-10.63	-0.39	2.01e-24	Resting heart rate;
BRCA	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.91	-0.33	5.45e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11764359	chr7:65958608	NA	0.8	19.64	0.61	1.58e-67	Aortic root size;
BRCA	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.48	0.47	1.21e-36	Colorectal cancer;
BRCA	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg08999081	chr20:33150536	PIGU	0.47	13.04	0.46	1.28e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs10751667	0.600	rs11246377	chr11:999796	G/T	cg06064525	chr11:970664	AP2A2	-0.27	-8.06	-0.3	3.65e-15	Alzheimer's disease (late onset);
BRCA	cis	rs9341808	0.718	rs3828754	chr6:80900640	C/G	cg08355045	chr6:80787529	NA	0.39	9.96	0.37	7.9e-22	Sitting height ratio;
BRCA	cis	rs9359856	0.564	rs72915933	chr6:90441464	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.67	-8.43	-0.32	2.28e-16	Bipolar disorder;
BRCA	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11764359	chr7:65958608	NA	0.8	19.35	0.61	5.5000000000000005e-66	Aortic root size;
BRCA	cis	rs68170813	0.559	rs6971675	chr7:106833797	G/A	cg02696742	chr7:106810147	HBP1	-0.52	-8.35	-0.31	4.12e-16	Coronary artery disease;
BRCA	cis	rs7617773	0.817	rs6796490	chr3:48237104	A/C	cg11946769	chr3:48343235	NME6	0.49	11.28	0.41	4.77e-27	Coronary artery disease;
BRCA	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg08885076	chr2:99613938	TSGA10	-0.57	-12.88	-0.45	6.45e-34	Chronic sinus infection;
BRCA	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg02466173	chr16:30829666	NA	0.5	11.31	0.41	3.75e-27	Dementia with Lewy bodies;
BRCA	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg04362960	chr10:104952993	NT5C2	0.43	10.38	0.38	1.93e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg10556349	chr10:835070	NA	0.73	9.85	0.36	2.13e-21	Eosinophil percentage of granulocytes;
BRCA	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg27147174	chr7:100797783	AP1S1	-0.52	-10.49	-0.38	7.33e-24	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg11887960	chr12:57824829	NA	0.53	8.26	0.31	8.2e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.34	-8.6	-0.32	6.06e-17	Personality dimensions;
BRCA	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg22189786	chr22:42395067	WBP2NL	0.41	8.39	0.32	3.1e-16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs6450176	1.000	rs59061738	chr5:53296557	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-14.96	-0.51	1.31e-43	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs4285028	0.851	rs1986368	chr3:121710969	A/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.69	-0.39	1.14e-24	Multiple sclerosis;
BRCA	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg17509989	chr5:176798049	RGS14	-0.75	-11.8	-0.42	3.35e-29	Urate levels in lean individuals;
BRCA	cis	rs72772090	0.539	rs11738115	chr5:96113072	A/T	cg17330273	chr5:96107758	CAST;ERAP1	0.57	11.68	0.42	1.1e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.13	0.31	2.16e-15	Corneal astigmatism;
BRCA	cis	rs877282	0.947	rs7923867	chr10:768094	G/A	cg17470449	chr10:769945	NA	0.49	8.47	0.32	1.72e-16	Uric acid levels;
BRCA	cis	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg23422044	chr7:1970798	MAD1L1	-0.43	-8.87	-0.33	7.36e-18	Neuroticism;
BRCA	cis	rs7179456	0.545	rs507801	chr15:59053345	T/G	cg05156742	chr15:59063176	FAM63B	0.46	9.22	0.34	4.11e-19	Asperger disorder;
BRCA	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	9.67	0.36	9.57e-21	Bipolar disorder;
BRCA	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg10295955	chr4:187884368	NA	0.96	27.99	0.74	3.86e-113	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg19729930	chr2:74357872	NA	0.63	14.74	0.5	1.45e-42	Gestational age at birth (maternal effect);
BRCA	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg22713356	chr15:30763199	NA	1.15	23.14	0.68	1.7e-86	Uric acid levels;
BRCA	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.06	0.46	1.02e-34	Bipolar disorder;
BRCA	cis	rs12474201	0.928	rs12999586	chr2:46938736	C/T	cg06386533	chr2:46925753	SOCS5	0.87	18.83	0.6	3.16e-63	Height;
BRCA	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.37	10.22	0.37	8.54e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs9341808	0.700	rs12215236	chr6:80975058	A/T	cg08355045	chr6:80787529	NA	0.37	9.56	0.35	2.58e-20	Sitting height ratio;
BRCA	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg21138405	chr5:131827807	IRF1	0.4	12.98	0.46	2.4e-34	Asthma (sex interaction);
BRCA	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg03929089	chr4:120376271	NA	0.49	7.98	0.3	6.92e-15	D-dimer levels;
BRCA	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg20387954	chr3:183756860	HTR3D	0.39	8.87	0.33	6.99e-18	Anterior chamber depth;
BRCA	cis	rs12541635	0.677	rs1817939	chr8:107029820	A/G	cg10147462	chr8:107024639	NA	0.39	10.56	0.39	3.85e-24	Age of smoking initiation;
BRCA	cis	rs2070997	0.607	rs2855191	chr9:133708441	C/T	cg11464064	chr9:133710261	ABL1	-0.54	-10.01	-0.37	5.12e-22	Response to amphetamines;
BRCA	cis	rs367943	1.000	rs348930	chr5:112814763	T/C	cg12552261	chr5:112820674	MCC	-0.56	-12.28	-0.44	2.97e-31	Type 2 diabetes;
BRCA	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg10253484	chr15:75165896	SCAMP2	-0.56	-11.7	-0.42	8.59e-29	Breast cancer;
BRCA	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg13770153	chr20:60521292	NA	-0.38	-9.02	-0.34	2.15e-18	Body mass index;
BRCA	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg12365402	chr11:9010492	NRIP3	-0.37	-8.45	-0.32	1.9e-16	Hemoglobin concentration;
BRCA	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg14728415	chr7:32535168	LSM5;AVL9	0.38	8.34	0.31	4.57e-16	Cognitive ability;
BRCA	cis	rs897984	0.609	rs732172	chr16:31050033	C/T	cg02466173	chr16:30829666	NA	-0.44	-9.85	-0.36	2.08e-21	Dementia with Lewy bodies;
BRCA	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.54	8.33	0.31	4.83e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg11663144	chr21:46675770	NA	-0.48	-9.62	-0.36	1.45e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1568889	0.712	rs4567438	chr11:28380051	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.52	9.72	0.36	6.56e-21	Bipolar disorder;
BRCA	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg22139774	chr2:100720529	AFF3	-0.29	-8.21	-0.31	1.18e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg12935359	chr14:103987150	CKB	-0.61	-13.9	-0.48	1.51e-38	Intelligence (multi-trait analysis);
BRCA	trans	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	27.8	0.74	4.4e-112	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs877282	0.898	rs12356709	chr10:763365	A/G	cg17470449	chr10:769945	NA	0.47	7.92	0.3	1.08e-14	Uric acid levels;
BRCA	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg08470875	chr2:26401718	FAM59B	0.72	10.32	0.38	3.51e-23	Gut microbiome composition (summer);
BRCA	cis	rs1003719	0.591	rs2018521	chr21:38517264	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.56	-12.48	-0.44	3.95e-32	Eye color traits;
BRCA	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg03474202	chr17:45855739	NA	-0.46	-12.21	-0.43	5.72e-31	IgG glycosylation;
BRCA	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg21385522	chr1:16154831	NA	0.46	9.86	0.36	1.89e-21	Systolic blood pressure;
BRCA	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08564027	chr20:61660810	NA	0.84	22.84	0.67	7.41e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1451375	1.000	rs10250513	chr7:50621488	T/G	cg18232548	chr7:50535776	DDC	0.43	10.09	0.37	2.54e-22	Malaria;
BRCA	cis	rs9318086	0.935	rs9553083	chr13:24441525	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.29	-8.33	-0.31	4.79e-16	Myopia (pathological);
BRCA	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg24069376	chr3:38537580	EXOG	0.39	11.12	0.4	2.26e-26	Electrocardiographic conduction measures;
BRCA	cis	rs9875589	0.509	rs2731330	chr3:14111588	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.95	0.33	3.7e-18	Ovarian reserve;
BRCA	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg18154014	chr19:37997991	ZNF793	0.63	12.27	0.44	3.28e-31	Coronary artery calcification;
BRCA	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11764359	chr7:65958608	NA	-0.76	-17.64	-0.57	4.74e-57	Aortic root size;
BRCA	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg05283184	chr6:79620031	NA	-0.43	-11.01	-0.4	6.1e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg17063962	chr7:91808500	NA	0.53	12.5	0.44	3.23e-32	Breast cancer;
BRCA	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg00383909	chr3:49044727	WDR6	0.48	9.66	0.36	1.03e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs3125734	0.572	rs3864794	chr10:64041956	A/C	cg19640130	chr10:64028056	RTKN2	-0.33	-9.14	-0.34	8.48e-19	Rheumatoid arthritis;
BRCA	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg06064525	chr11:970664	AP2A2	-0.48	-15.94	-0.53	2.15e-48	Alzheimer's disease (late onset);
BRCA	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.72	0.36	6.67e-21	Bipolar disorder;
BRCA	cis	rs6684514	0.922	rs2075166	chr1:156215562	G/A	cg16558208	chr1:156270281	VHLL	0.36	7.88	0.3	1.42e-14	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg05707623	chr12:122985044	ZCCHC8	0.5	9.65	0.36	1.15e-20	Body mass index;
BRCA	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg19920283	chr7:105172520	RINT1	0.65	12.98	0.46	2.34e-34	Bipolar disorder (body mass index interaction);
BRCA	cis	rs3845702	0.736	rs3845701	chr2:180826781	A/G	cg01881094	chr2:180872142	CWC22	-0.96	-17.49	-0.57	2.83e-56	Schizophrenia;
BRCA	cis	rs6840360	0.533	rs13147021	chr4:152722688	A/C	cg22705602	chr4:152727874	NA	0.39	10.42	0.38	1.41e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.94e-24	Motion sickness;
BRCA	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12923728	chr3:195709715	SDHAP1	-0.59	-12.57	-0.45	1.55e-32	Pancreatic cancer;
BRCA	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19346786	chr7:2764209	NA	-0.32	-9.77	-0.36	3.99e-21	Height;
BRCA	cis	rs733175	0.951	rs7669090	chr4:10028131	C/T	cg00071950	chr4:10020882	SLC2A9	0.41	7.97	0.3	7.25e-15	Psychosis and Alzheimer's disease;
BRCA	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg24692254	chr21:30365293	RNF160	0.66	18.2	0.58	5.71e-60	Dental caries;
BRCA	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	16.26	0.54	5.02e-50	Bone mineral density;
BRCA	cis	rs870825	0.929	rs56106324	chr4:185589901	C/A	cg04058563	chr4:185651563	MLF1IP	0.69	11.72	0.42	7.1e-29	Blood protein levels;
BRCA	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg25809561	chr17:30822961	MYO1D	0.39	9.05	0.34	1.67e-18	Schizophrenia;
BRCA	cis	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg06521331	chr12:34319734	NA	-0.56	-10.02	-0.37	4.62e-22	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg18404041	chr3:52824283	ITIH1	-0.38	-10.37	-0.38	2.14e-23	Bipolar disorder;
BRCA	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg23788917	chr6:8435910	SLC35B3	-0.47	-10.18	-0.37	1.22e-22	Motion sickness;
BRCA	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg24531977	chr5:56204891	C5orf35	0.39	8.16	0.31	1.73e-15	Coronary artery disease;
BRCA	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg24846343	chr22:24311635	DDTL	-0.56	-14.17	-0.49	7.73e-40	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24110177	chr3:50126178	RBM5	0.38	10.57	0.39	3.54e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg06494592	chr3:125709126	NA	-0.53	-8.25	-0.31	9.2e-16	Blood pressure (smoking interaction);
BRCA	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.85	0.45	8.63e-34	Electroencephalogram traits;
BRCA	cis	rs752010	0.967	rs6703597	chr1:42097904	C/T	cg06885757	chr1:42089581	HIVEP3	0.24	8.64	0.32	4.39e-17	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs10463316	0.894	rs6579863	chr5:150761946	A/T	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.22	-0.31	1.12e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg23711669	chr6:146136114	FBXO30	0.75	17.17	0.56	1.3e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg13550731	chr2:172543902	DYNC1I2	0.94	32.12	0.79	1.73e-135	Schizophrenia;
BRCA	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg23285459	chr7:2802560	GNA12	-0.35	-8.83	-0.33	9.77e-18	Height;
BRCA	cis	rs490234	0.902	rs10739662	chr9:128278687	T/C	cg14078157	chr9:128172775	NA	-0.33	-7.87	-0.3	1.55e-14	Mean arterial pressure;
BRCA	cis	rs6433895	1.000	rs59395276	chr2:182020696	T/C	cg00481216	chr2:181971175	NA	0.38	8.78	0.33	1.55e-17	Lymphocyte counts;
BRCA	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg24069376	chr3:38537580	EXOG	0.39	11.4	0.41	1.53e-27	Electrocardiographic conduction measures;
BRCA	trans	rs8073060	0.544	rs225268	chr17:33966224	A/C	cg19694781	chr19:47549865	TMEM160	-1.06	-21.58	-0.65	5.04e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs4780401	0.728	rs7188511	chr16:11773743	G/T	cg01061890	chr16:11836724	TXNDC11	-0.44	-9.73	-0.36	5.68e-21	Rheumatoid arthritis;
BRCA	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	13.85	0.48	2.55e-38	Lymphocyte counts;
BRCA	cis	rs870825	0.616	rs7680779	chr4:185652830	G/C	cg04058563	chr4:185651563	MLF1IP	-0.73	-15.84	-0.53	6.2e-48	Blood protein levels;
BRCA	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg20701182	chr2:24300061	SF3B14	0.67	9.77	0.36	4.1e-21	Lymphocyte counts;
BRCA	cis	rs1451375	0.572	rs745042	chr7:50544138	A/G	cg18232548	chr7:50535776	DDC	-0.41	-8.7	-0.33	2.8e-17	Malaria;
BRCA	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.53	11.41	0.41	1.4e-27	Colorectal cancer;
BRCA	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.6	-0.32	6.05e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08109568	chr15:31115862	NA	-0.45	-10.6	-0.39	2.77e-24	Huntington's disease progression;
BRCA	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.28	-0.31	7.24e-16	Aortic root size;
BRCA	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg04691961	chr3:161091175	C3orf57	-0.4	-9.33	-0.35	1.65e-19	Morning vs. evening chronotype;
BRCA	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg25457927	chr22:38595422	NA	-0.32	-11.89	-0.43	1.38e-29	Cutaneous nevi;
BRCA	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg11764359	chr7:65958608	NA	-0.68	-15.2	-0.52	9.03e-45	Cotinine glucuronidation;
BRCA	cis	rs11971779	0.680	rs66491565	chr7:139088977	C/G	cg07862535	chr7:139043722	LUC7L2	0.4	10.97	0.4	9.39e-26	Diisocyanate-induced asthma;
BRCA	cis	rs6088813	0.961	rs6060371	chr20:33913322	G/T	cg14752227	chr20:34000481	UQCC	0.4	8.4	0.32	2.96e-16	Height;
BRCA	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg23649088	chr2:200775458	C2orf69	0.59	11.9	0.43	1.22e-29	Schizophrenia;
BRCA	trans	rs75804782	0.572	rs112551758	chr2:239299770	A/G	cg01134436	chr17:81009848	B3GNTL1	0.74	7.88	0.3	1.38e-14	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.4	-9.75	-0.36	4.86e-21	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-9.61	-0.36	1.69e-20	Menopause (age at onset);
BRCA	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18876405	chr7:65276391	NA	0.55	13.35	0.47	4.99e-36	Aortic root size;
BRCA	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg11266682	chr4:10021025	SLC2A9	0.49	13.12	0.46	5.22e-35	Bone mineral density;
BRCA	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05890377	chr2:74357713	NA	0.46	11.74	0.42	5.94e-29	Gestational age at birth (maternal effect);
BRCA	trans	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg05926928	chr17:57297772	GDPD1	-0.59	-9.1	-0.34	1.13e-18	Opioid sensitivity;
BRCA	cis	rs7903847	0.642	rs11189179	chr10:99143320	T/C	cg20016023	chr10:99160130	RRP12	-0.27	-8.62	-0.32	5.46e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg24812749	chr6:127587940	RNF146	0.6	13.07	0.46	8.88e-35	Breast cancer;
BRCA	cis	rs4074536	0.548	rs9887923	chr1:116288224	T/C	cg21648376	chr1:116311395	CASQ2	-0.49	-8.71	-0.33	2.5e-17	QRS duration;
BRCA	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg11366901	chr6:160182831	ACAT2	0.81	15.96	0.53	1.75e-48	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7560272	0.512	rs13015885	chr2:73920482	G/T	cg20560298	chr2:73613845	ALMS1	0.35	9.13	0.34	8.62e-19	Schizophrenia;
BRCA	cis	rs4845570	1.000	rs11586946	chr1:151769806	G/A	cg07092448	chr1:151763213	TDRKH	-0.9	-16.07	-0.54	4.64e-49	Coronary artery disease;
BRCA	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15541040	chr2:3486749	NA	-0.42	-9.15	-0.34	7.34e-19	Neurofibrillary tangles;
BRCA	cis	rs36051895	0.632	rs12352022	chr9:5161836	T/G	cg02405213	chr9:5042618	JAK2	-0.48	-8.89	-0.33	6.14e-18	Pediatric autoimmune diseases;
BRCA	cis	rs12541635	0.677	rs55639043	chr8:107055993	C/T	cg10147462	chr8:107024639	NA	0.4	10.89	0.4	1.88e-25	Age of smoking initiation;
BRCA	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03264133	chr6:25882463	NA	-0.53	-11.95	-0.43	7.44e-30	Blood metabolite levels;
BRCA	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg06212747	chr3:49208901	KLHDC8B	0.55	12.15	0.43	1.01e-30	Menarche (age at onset);
BRCA	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-11.04	-0.4	4.5e-26	Resting heart rate;
BRCA	trans	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.43	0.32	2.3e-16	Mean corpuscular volume;
BRCA	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.6	12.57	0.45	1.57e-32	Personality dimensions;
BRCA	cis	rs9815354	0.812	rs73073229	chr3:42007850	T/C	cg03022575	chr3:42003672	ULK4	0.74	10.27	0.38	5.43e-23	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg26647111	chr11:31128758	NA	-0.45	-9.78	-0.36	3.99e-21	Red blood cell count;
BRCA	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg25173405	chr17:45401733	C17orf57	0.48	10.01	0.37	5.23e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9296092	0.538	rs56199698	chr6:33534505	G/C	cg13560919	chr6:33536144	NA	-0.91	-19.42	-0.61	2.12e-66	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs721399	0.924	rs1115784	chr8:18255410	C/T	cg18736775	chr8:18248649	NAT2	0.39	8.44	0.32	2.15e-16	Blood metabolite levels;
BRCA	cis	rs10779751	0.770	rs10864490	chr1:11236410	A/C	cg08854313	chr1:11322531	MTOR	0.76	15.62	0.53	8.33e-47	Body mass index;
BRCA	cis	rs11955398	0.625	rs10939857	chr5:59956801	C/T	cg02684056	chr5:59996105	DEPDC1B	0.38	8.84	0.33	9.1e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs61931739	0.620	rs708143	chr12:33719962	A/C	cg26384229	chr12:38710491	ALG10B	0.41	9.28	0.34	2.69e-19	Morning vs. evening chronotype;
BRCA	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg02659138	chr7:134003124	SLC35B4	0.34	10.71	0.39	9.67e-25	Mean platelet volume;
BRCA	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg08470875	chr2:26401718	FAM59B	-0.52	-8.28	-0.31	7.21e-16	Gut microbiome composition (summer);
BRCA	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg03354898	chr7:1950403	MAD1L1	-0.58	-13.91	-0.48	1.32e-38	Bipolar disorder and schizophrenia;
BRCA	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.57	13.17	0.46	3.31e-35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg04166393	chr7:2884313	GNA12	0.41	8.99	0.34	2.76e-18	Height;
BRCA	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-8.3	-0.31	6.2e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs495337	0.699	rs2982414	chr20:48463058	A/G	cg17835207	chr20:48524531	SPATA2	-0.5	-10.83	-0.39	3.33e-25	Psoriasis;
BRCA	cis	rs870825	0.929	rs72689266	chr4:185591053	T/C	cg04058563	chr4:185651563	MLF1IP	0.69	11.83	0.42	2.39e-29	Blood protein levels;
BRCA	cis	rs2191566	0.576	rs419839	chr19:44495598	C/T	cg20607764	chr19:44506953	ZNF230	0.37	8.02	0.3	5.01e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg25204440	chr1:209979598	IRF6	0.51	13.79	0.48	4.84e-38	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
BRCA	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg01324343	chr3:183735012	ABCC5	0.83	21.18	0.64	8.04e-76	Anterior chamber depth;
BRCA	cis	rs887829	0.569	rs3806596	chr2:234637707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.33	8.5	0.32	1.36e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs4919087	0.810	rs10786321	chr10:99026112	T/C	cg25902810	chr10:99078978	FRAT1	0.41	8.99	0.34	2.69e-18	Monocyte count;
BRCA	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg04450456	chr4:17643702	FAM184B	0.32	9.35	0.35	1.42e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4363385	0.818	rs370162	chr1:153005488	G/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.26	-0.34	3.19e-19	Inflammatory skin disease;
BRCA	cis	rs7301016	0.793	rs11174557	chr12:62979216	C/T	cg01804193	chr12:63026212	NA	0.46	8.36	0.31	3.91e-16	IgG glycosylation;
BRCA	cis	rs7727544	0.582	rs3805681	chr5:131537860	T/G	cg14196790	chr5:131705035	SLC22A5	0.36	9.08	0.34	1.29e-18	Blood metabolite levels;
BRCA	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-19.38	-0.61	3.73e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg04455712	chr21:45112962	RRP1B	0.46	11.34	0.41	2.85e-27	Mean corpuscular volume;
BRCA	cis	rs295140	0.506	rs295136	chr2:201141002	G/C	cg23649088	chr2:200775458	C2orf69	0.4	8.39	0.32	3.08e-16	QT interval;
BRCA	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg22431228	chr1:16359049	CLCNKA	-0.44	-9.82	-0.36	2.75e-21	Dilated cardiomyopathy;
BRCA	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08109568	chr15:31115862	NA	-0.43	-10.26	-0.38	6.01e-23	Huntington's disease progression;
BRCA	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.23	-0.31	1.09e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	16.12	0.54	2.76e-49	Hypertriglyceridemia;
BRCA	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg09307838	chr4:120376055	NA	0.68	14.64	0.5	4.72e-42	Corneal astigmatism;
BRCA	trans	rs4596713	0.508	rs4076287	chr9:71755333	A/G	cg16512924	chr15:28394682	HERC2	0.42	10.03	0.37	4.51e-22	Headache;
BRCA	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-10.14	-0.37	1.7e-22	Alzheimer's disease;
BRCA	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg11301795	chr4:187892539	NA	0.31	10.69	0.39	1.15e-24	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg04944784	chr2:26401820	FAM59B	0.97	15.01	0.51	7.4e-44	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg08470875	chr2:26401718	FAM59B	-0.76	-11.6	-0.42	2.24e-28	Gut microbiome composition (summer);
BRCA	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg13271783	chr10:134563150	INPP5A	-0.5	-9.57	-0.35	2.31e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg15395560	chr15:45543142	SLC28A2	0.29	7.95	0.3	8.65e-15	Glomerular filtration rate;
BRCA	cis	rs7147624	0.683	rs8017258	chr14:66231017	C/G	cg03016385	chr14:66212404	NA	0.55	7.98	0.3	6.74e-15	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg24642439	chr20:33292090	TP53INP2	0.38	7.88	0.3	1.39e-14	Height;
BRCA	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg13271783	chr10:134563150	INPP5A	-0.35	-7.94	-0.3	9.19e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-11.09	-0.4	2.84e-26	Lymphocyte counts;
BRCA	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	12.21	0.43	5.95e-31	Bone mineral density;
BRCA	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg22875332	chr1:76189707	ACADM	-0.51	-9.8	-0.36	3.24e-21	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg00701064	chr4:6280414	WFS1	0.62	14.26	0.49	2.83e-40	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7927771	0.756	rs2856661	chr11:47374998	A/G	cg20307385	chr11:47447363	PSMC3	0.4	8.22	0.31	1.14e-15	Subjective well-being;
BRCA	cis	rs3815700	1.000	rs10404211	chr19:33093565	C/T	cg02997394	chr19:33096574	ANKRD27	0.61	8.65	0.32	4.04e-17	Eosinophilic esophagitis;
BRCA	cis	rs427394	0.659	rs274675	chr5:6755319	C/T	cg10857441	chr5:6722123	POLS	-0.32	-10.02	-0.37	4.87e-22	Menopause (age at onset);
BRCA	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.09	-0.3	2.95e-15	Depression;
BRCA	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg12935359	chr14:103987150	CKB	-0.6	-13.53	-0.47	7.47e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.5e-36	High light scatter reticulocyte count;
BRCA	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg20891283	chr12:69753455	YEATS4	0.37	8.84	0.33	8.93e-18	Blood protein levels;
BRCA	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg08645402	chr16:4508243	NA	0.41	9.86	0.36	1.94e-21	Schizophrenia;
BRCA	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg25036284	chr2:26402008	FAM59B	-0.88	-15.06	-0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg27446573	chr6:127587934	RNF146	0.54	12.09	0.43	1.86e-30	Breast cancer;
BRCA	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg20503657	chr10:835505	NA	1.03	15.66	0.53	5.34e-47	Eosinophil percentage of granulocytes;
BRCA	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg11189052	chr15:85197271	WDR73	0.44	9.05	0.34	1.66e-18	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.37e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg25036284	chr2:26402008	FAM59B	0.94	13.89	0.48	1.53e-38	Gut microbiome composition (summer);
BRCA	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg13010199	chr12:38710504	ALG10B	-0.36	-8.51	-0.32	1.21e-16	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.34	0.31	4.72e-16	Corneal astigmatism;
BRCA	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-11.92	-0.43	1.02e-29	Personality dimensions;
BRCA	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.64e-24	Motion sickness;
BRCA	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg13385794	chr1:248469461	NA	0.29	7.88	0.3	1.44e-14	Common traits (Other);
BRCA	trans	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-20.95	-0.64	1.37e-74	Exhaled nitric oxide output;
BRCA	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13732083	chr21:47605072	C21orf56	0.38	7.85	0.3	1.75e-14	Testicular germ cell tumor;
BRCA	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.91	-0.33	5.45e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg19622623	chr12:86230825	RASSF9	-0.32	-8.98	-0.33	3e-18	Major depressive disorder;
BRCA	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-10.6	-0.39	2.73e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs7737355	0.947	rs6859469	chr5:130962546	C/T	cg06307176	chr5:131281290	NA	0.52	10.11	0.37	2.1e-22	Life satisfaction;
BRCA	cis	rs9463078	0.764	rs9369513	chr6:44789476	T/C	cg25276700	chr6:44698697	NA	-0.36	-8.42	-0.32	2.41e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg11301795	chr4:187892539	NA	-0.28	-9.24	-0.34	3.54e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443189	0.570	rs9341532	chr6:76403674	A/G	cg01950844	chr6:76311363	SENP6	0.84	13.53	0.47	7.52e-37	Prostate cancer;
BRCA	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg22920501	chr2:26401640	FAM59B	0.94	16.16	0.54	1.61e-49	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11764359	chr7:65958608	NA	-0.75	-16.9	-0.56	2.91e-53	Aortic root size;
BRCA	cis	rs7520050	0.966	rs1707336	chr1:46493460	T/G	cg24296786	chr1:45957014	TESK2	0.43	9.59	0.35	1.9e-20	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9880211	0.948	rs34135127	chr3:136226498	T/C	cg21827317	chr3:136751795	NA	-0.44	-7.87	-0.3	1.52e-14	Body mass index;Height;
BRCA	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.35	-8.03	-0.3	4.73e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg06521331	chr12:34319734	NA	-0.47	-8.99	-0.34	2.71e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.85	-0.39	2.67e-25	Bipolar disorder;
BRCA	cis	rs208520	0.802	rs851600	chr6:66893754	T/C	cg07460842	chr6:66804631	NA	-0.93	-16.92	-0.56	2.38e-53	Exhaled nitric oxide output;
BRCA	cis	rs7737355	0.947	rs12656936	chr5:130788642	A/C	cg06307176	chr5:131281290	NA	-0.53	-10.55	-0.39	4.22e-24	Life satisfaction;
BRCA	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.78	-0.58	9.4e-58	Chronic sinus infection;
BRCA	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg24562669	chr7:97807699	LMTK2	0.45	12.09	0.43	1.83e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg24558204	chr6:135376177	HBS1L	0.45	12.41	0.44	8.05e-32	Red blood cell count;
BRCA	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg01819863	chr10:32635814	EPC1	1.15	20.31	0.63	3.9e-71	Sexual dysfunction (female);
BRCA	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg25358565	chr5:93447407	FAM172A	1.19	18.82	0.6	3.54e-63	Diabetic retinopathy;
BRCA	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg05347473	chr6:146136440	FBXO30	0.42	8.39	0.32	3.1e-16	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg23762105	chr12:34175262	ALG10	0.36	8.49	0.32	1.45e-16	Morning vs. evening chronotype;
BRCA	cis	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.4	8.99	0.33	2.89e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4363385	0.747	rs2879489	chr1:152970465	A/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.88	-0.33	6.69e-18	Inflammatory skin disease;
BRCA	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg10862848	chr6:42927986	GNMT	-0.34	-14.49	-0.5	2.36e-41	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9359856	0.529	rs56352205	chr6:90439272	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.71	-8.58	-0.32	7.04e-17	Bipolar disorder;
BRCA	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs6484504	0.576	rs158146	chr11:31210433	G/A	cg26647111	chr11:31128758	NA	-0.42	-9.35	-0.35	1.47e-19	Red blood cell count;
BRCA	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg09184832	chr6:79620586	NA	-0.53	-11.69	-0.42	9.67e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08219700	chr8:58056026	NA	0.59	9.82	0.36	2.69e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs6545883	0.965	rs7421663	chr2:61753786	C/T	cg15711740	chr2:61764176	XPO1	-0.55	-14.2	-0.49	5.44e-40	Tuberculosis;
BRCA	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.05	0.49	2.87e-39	Motion sickness;
BRCA	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg25358565	chr5:93447407	FAM172A	1.22	19.53	0.61	5.73e-67	Diabetic retinopathy;
BRCA	cis	rs2425143	1.000	rs8116836	chr20:34453362	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.47	-0.35	5.22e-20	Blood protein levels;
BRCA	trans	rs629535	0.748	rs689410	chr8:70037558	G/A	cg21567404	chr3:27674614	NA	1.0	21.1	0.64	2.04e-75	Dupuytren's disease;
BRCA	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.18	0.4	1.22e-26	Bipolar disorder;
BRCA	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg20476274	chr7:133979776	SLC35B4	0.6	14.74	0.5	1.56e-42	Mean platelet volume;
BRCA	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg06784218	chr1:46089804	CCDC17	0.51	12.17	0.43	8.34e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26119090	chr2:26468346	HADHA;HADHB	1.05	21.9	0.65	9.95e-80	Gut microbiome composition (summer);
BRCA	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	8.34	0.31	4.49e-16	Schizophrenia;
BRCA	cis	rs6088813	1.000	rs224329	chr20:34019579	C/T	cg14752227	chr20:34000481	UQCC	0.38	8.05	0.3	3.97e-15	Height;
BRCA	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.49	-8.79	-0.33	1.37e-17	Renal function-related traits (BUN);
BRCA	cis	rs12541635	0.677	rs6999580	chr8:107018254	C/T	cg10147462	chr8:107024639	NA	0.38	10.36	0.38	2.32e-23	Age of smoking initiation;
BRCA	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg05283184	chr6:79620031	NA	-0.43	-11.0	-0.4	6.58e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg27446573	chr6:127587934	RNF146	0.89	20.5	0.63	3.86e-72	Breast cancer;
BRCA	cis	rs61612642	0.537	rs73434275	chr6:42156239	G/A	cg01092361	chr6:42185687	MRPS10	0.69	11.89	0.43	1.38e-29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
BRCA	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg08807892	chr2:162101083	NA	0.51	10.1	0.37	2.35e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg06623918	chr6:96969491	KIAA0776	0.9	25.43	0.71	4.24e-99	Headache;
BRCA	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg24812749	chr6:127587940	RNF146	-0.91	-20.9	-0.64	2.5e-74	Breast cancer;
BRCA	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg18512352	chr11:47633146	NA	0.32	8.02	0.3	4.99e-15	Subjective well-being;
BRCA	cis	rs9487051	0.698	rs9374081	chr6:109631782	A/G	cg01475377	chr6:109611718	NA	-0.44	-9.51	-0.35	3.76e-20	Reticulocyte fraction of red cells;
BRCA	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg22875332	chr1:76189707	ACADM	0.81	19.7	0.61	7.26e-68	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg08885076	chr2:99613938	TSGA10	-0.46	-8.65	-0.32	4.1e-17	Chronic sinus infection;
BRCA	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.59	-11.84	-0.42	2.28e-29	Caffeine consumption;
BRCA	trans	rs6479891	1.000	rs2393980	chr10:65224510	C/G	cg14819942	chr15:35414228	NA	0.35	8.59	0.32	6.62e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg06115741	chr20:33292138	TP53INP2	0.39	8.62	0.32	5.23e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg06064525	chr11:970664	AP2A2	-0.48	-16.22	-0.54	8.78e-50	Alzheimer's disease (late onset);
BRCA	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg08085267	chr17:45401833	C17orf57	0.69	15.36	0.52	1.56e-45	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs79387448	0.638	rs11465670	chr2:103034440	A/G	cg09003973	chr2:102972529	NA	0.52	8.0	0.3	6.07e-15	Gut microbiota (bacterial taxa);
BRCA	trans	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.23	0.31	1.05e-15	Mean corpuscular volume;
BRCA	cis	rs7707921	0.881	rs111907176	chr5:81312399	A/G	cg15871215	chr5:81402204	ATG10	-0.4	-8.39	-0.31	3.21e-16	Breast cancer;
BRCA	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg06627628	chr2:24431161	ITSN2	-0.56	-9.05	-0.34	1.69e-18	Lymphocyte counts;
BRCA	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg24562669	chr7:97807699	LMTK2	0.44	11.82	0.42	2.66e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25427524	chr10:38739819	LOC399744	-0.7	-16.9	-0.56	3.01e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs16958440	1.000	rs57928699	chr18:44645593	T/A	cg17192377	chr18:44677553	HDHD2	0.67	9.8	0.36	3.33e-21	Sitting height ratio;
BRCA	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg18230493	chr5:56204884	C5orf35	-0.42	-8.55	-0.32	9.31e-17	Coronary artery disease;
BRCA	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14442939	chr10:27389572	ANKRD26	0.66	10.99	0.4	7.61e-26	Breast cancer;
BRCA	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg04455712	chr21:45112962	RRP1B	0.41	10.79	0.39	4.73e-25	Mean corpuscular volume;
BRCA	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg07423050	chr13:99094983	FARP1	-0.49	-11.01	-0.4	5.94e-26	Longevity;
BRCA	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22455342	chr2:225449267	CUL3	0.65	17.04	0.56	5.88e-54	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg20607287	chr7:12443886	VWDE	-0.58	-8.19	-0.31	1.46e-15	Coronary artery disease;
BRCA	cis	rs113835537	0.529	rs75003264	chr11:66256099	G/A	cg24851651	chr11:66362959	CCS	0.5	8.69	0.32	3.12e-17	Airway imaging phenotypes;
BRCA	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.47	-0.35	5.51e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg13334819	chr7:99746414	C7orf59	-0.34	-8.11	-0.31	2.68e-15	Coronary artery disease;
BRCA	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	10.03	0.37	4.25e-22	Bipolar disorder;
BRCA	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.31	-0.31	5.88e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg26384229	chr12:38710491	ALG10B	0.77	17.41	0.57	7.15e-56	Bladder cancer;
BRCA	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.72	0.57	1.98e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.64	-0.32	4.36e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs7786808	0.776	rs11983316	chr7:158209742	A/G	cg02030672	chr11:45687055	CHST1	0.51	11.37	0.41	2.15e-27	Obesity-related traits;
BRCA	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-10.04	-0.37	4.13e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs7633770	0.786	rs1520489	chr3:46677519	A/G	cg11219411	chr3:46661640	NA	-0.64	-17.25	-0.56	5e-55	Coronary artery disease;
BRCA	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	11.42	0.41	1.25e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.54	13.64	0.47	2.21e-37	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg05340658	chr4:99064831	C4orf37	0.68	16.9	0.56	3.04e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg15017067	chr4:17643749	FAM184B	0.32	9.79	0.36	3.54e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-13.96	-0.48	7.8e-39	Blood metabolite levels;
BRCA	trans	rs1459104	1.000	rs35218816	chr11:55087104	C/A	cg15704280	chr7:45808275	SEPT13	0.7	8.7	0.33	2.73e-17	Body mass index;
BRCA	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.31	-0.31	5.62e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg07080220	chr10:102295463	HIF1AN	0.44	9.78	0.36	3.68e-21	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.53	12.07	0.43	2.21e-30	Colorectal cancer;
BRCA	trans	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg02030672	chr11:45687055	CHST1	-0.39	-8.9	-0.33	5.53e-18	Obesity-related traits;
BRCA	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg20891558	chr2:74357851	NA	-0.47	-10.28	-0.38	4.66e-23	Gestational age at birth (maternal effect);
BRCA	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg04166393	chr7:2884313	GNA12	0.42	8.72	0.33	2.46e-17	Height;
BRCA	cis	rs698833	0.926	rs1067367	chr2:44654905	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	10.02	0.37	4.87e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg08885076	chr2:99613938	TSGA10	-0.54	-12.53	-0.44	2.24e-32	Chronic sinus infection;
BRCA	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg04727924	chr7:799746	HEATR2	-0.54	-10.27	-0.38	5.12e-23	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg24562669	chr7:97807699	LMTK2	-0.39	-10.53	-0.38	5.33e-24	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg13660082	chr14:53194042	PSMC6	-0.57	-8.13	-0.31	2.15e-15	Alzheimer's disease (late onset);
BRCA	cis	rs16976116	0.901	rs28708989	chr15:55498934	C/T	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg04455712	chr21:45112962	RRP1B	0.4	10.47	0.38	8.8e-24	Mean corpuscular volume;
BRCA	cis	rs28830936	1.000	rs12441300	chr15:42102845	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.36	-9.67	-0.36	1e-20	Diastolic blood pressure;
BRCA	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.33	-10.56	-0.39	3.85e-24	Bipolar disorder;
BRCA	cis	rs13095912	0.962	rs34505819	chr3:185340721	C/T	cg11274856	chr3:185301563	NA	0.34	8.37	0.31	3.72e-16	Systolic blood pressure;
BRCA	cis	rs858239	0.899	rs28458177	chr7:23294872	G/A	cg23682824	chr7:23144976	KLHL7	0.32	8.18	0.31	1.54e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs117623576	0.941	rs16932939	chr10:32407862	T/C	cg03047570	chr10:32398778	NA	-0.59	-8.97	-0.33	3.31e-18	Anti-saccade response;
BRCA	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg24110177	chr3:50126178	RBM5	0.41	11.24	0.41	6.84e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg09307838	chr4:120376055	NA	0.69	14.02	0.49	3.82e-39	Corneal astigmatism;
BRCA	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg26597838	chr10:835615	NA	1.02	18.06	0.58	3.33e-59	Eosinophil percentage of granulocytes;
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07308232	chr7:1071921	C7orf50	-0.42	-8.55	-0.32	9.4e-17	Longevity;Endometriosis;
BRCA	cis	rs2859741	0.935	rs2782410	chr1:37509489	G/C	cg09363841	chr1:37513479	NA	-0.65	-16.02	-0.54	8e-49	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs9467773	0.595	rs3799379	chr6:26404694	C/T	cg09904177	chr6:26538194	HMGN4	-0.36	-9.5	-0.35	4.14e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03264133	chr6:25882463	NA	0.5	11.19	0.4	1.12e-26	Blood metabolite levels;
BRCA	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg23229984	chr5:148520753	ABLIM3	-0.35	-8.81	-0.33	1.2e-17	Breast cancer;
BRCA	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg17971929	chr21:40555470	PSMG1	0.79	18.79	0.6	4.9e-63	Cognitive function;
BRCA	cis	rs4742903	0.967	rs10125661	chr9:106868443	A/G	cg21169611	chr9:106856078	SMC2	0.36	9.35	0.35	1.44e-19	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg11833968	chr6:79620685	NA	-0.39	-8.72	-0.33	2.33e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs68170813	0.605	rs74632724	chr7:107136759	A/G	cg02696742	chr7:106810147	HBP1	-0.5	-7.91	-0.3	1.17e-14	Coronary artery disease;
BRCA	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg23711669	chr6:146136114	FBXO30	0.77	17.91	0.58	1.9e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7249921	0.833	rs7255878	chr19:35667192	C/T	cg15419183	chr19:35660584	FXYD5	0.45	10.17	0.37	1.22e-22	Platelet count;
BRCA	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg08000102	chr2:233561755	GIGYF2	-0.62	-13.55	-0.47	6.2e-37	Coronary artery disease;
BRCA	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg05340658	chr4:99064831	C4orf37	-0.45	-10.26	-0.38	5.51e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg05340658	chr4:99064831	C4orf37	0.49	10.75	0.39	6.87e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	11.62	0.42	1.86e-28	Mean platelet volume;
BRCA	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg20503657	chr10:835505	NA	1.02	15.54	0.52	1.96e-46	Eosinophil percentage of granulocytes;
BRCA	cis	rs6910061	0.956	rs61185321	chr6:11103103	T/G	cg27233058	chr6:11094804	LOC221710	0.53	9.36	0.35	1.3e-19	Diabetic kidney disease;
BRCA	cis	rs11229555	0.598	rs12276438	chr11:58185419	G/A	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg17063962	chr7:91808500	NA	0.52	12.33	0.44	1.72e-31	Breast cancer;
BRCA	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg17366294	chr4:99064904	C4orf37	0.41	9.22	0.34	4.31e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7707921	1.000	rs17245188	chr5:81469082	A/C	cg15871215	chr5:81402204	ATG10	0.4	8.35	0.31	4.21e-16	Breast cancer;
BRCA	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg06552810	chr11:31128660	NA	0.41	8.92	0.33	4.71e-18	Red blood cell count;
BRCA	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg23711669	chr6:146136114	FBXO30	0.63	14.52	0.5	1.67e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3772130	0.924	rs55643643	chr3:121440197	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	9.13	0.34	9.23e-19	Cognitive performance;
BRCA	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg20503657	chr10:835505	NA	1.04	17.4	0.57	8.52e-56	Eosinophil percentage of granulocytes;
BRCA	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg05457628	chr5:178986728	RUFY1	-0.5	-12.39	-0.44	9.85e-32	Lung cancer;
BRCA	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg01017244	chr2:74357527	NA	0.52	12.29	0.44	2.49e-31	Gestational age at birth (maternal effect);
BRCA	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg11663144	chr21:46675770	NA	-0.47	-11.05	-0.4	4.46e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6920965	0.545	rs614031	chr6:126165720	A/C	cg05901451	chr6:126070800	HEY2	-0.35	-8.62	-0.32	5.43e-17	High light scatter reticulocyte count;
BRCA	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg03342759	chr3:160939853	NMD3	-0.64	-14.76	-0.5	1.21e-42	Morning vs. evening chronotype;
BRCA	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg05555928	chr11:63887634	MACROD1	-0.44	-8.03	-0.3	4.61e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg14983838	chr19:29218262	NA	0.54	10.03	0.37	4.44e-22	Methadone dose in opioid dependence;
BRCA	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.43	-0.38	1.3e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg06784218	chr1:46089804	CCDC17	0.49	11.91	0.43	1.16e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.44	-0.52	6.07e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg24642439	chr20:33292090	TP53INP2	0.7	16.24	0.54	6.72e-50	Coronary artery disease;
BRCA	cis	rs758324	0.947	rs13154286	chr5:131160189	A/G	cg06307176	chr5:131281290	NA	0.52	10.16	0.37	1.42e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03264133	chr6:25882463	NA	-0.82	-19.86	-0.62	9.97e-69	Urate levels;
BRCA	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	11.73	0.42	6.62e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03517284	chr6:25882590	NA	0.43	8.89	0.33	6.13e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6901250	1.000	rs993394	chr6:117117143	G/A	cg12892004	chr6:117198278	RFX6	0.49	11.07	0.4	3.55e-26	C-reactive protein levels;
BRCA	cis	rs7633857	0.512	rs10936215	chr3:160652271	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-10.96	-0.4	9.53e-26	Educational attainment (years of education);
BRCA	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.45	-0.32	1.98e-16	Total body bone mineral density;
BRCA	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg17143192	chr8:8559678	CLDN23	0.55	10.43	0.38	1.27e-23	Obesity-related traits;
BRCA	cis	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg06521331	chr12:34319734	NA	-0.52	-10.27	-0.38	5.25e-23	Morning vs. evening chronotype;
BRCA	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg04362960	chr10:104952993	NT5C2	0.43	9.75	0.36	4.83e-21	Arsenic metabolism;
BRCA	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg24692254	chr21:30365293	RNF160	0.41	9.04	0.34	1.82e-18	Selective IgA deficiency;
BRCA	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg13397359	chr6:42928475	GNMT	0.67	16.1	0.54	3.13e-49	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1691799	0.867	rs1168332	chr12:66761548	C/T	cg16791601	chr12:66731901	HELB	-0.66	-17.99	-0.58	7.53e-59	White blood cell count (basophil);
BRCA	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-7.9	-0.3	1.22e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs10911251	0.546	rs3359	chr1:183112041	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	15.18	0.51	1.17e-44	Colorectal cancer;
BRCA	cis	rs6973256	0.897	rs17601462	chr7:133347066	A/G	cg07491979	chr7:133331646	EXOC4	-0.39	-8.94	-0.33	4.2e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11764359	chr7:65958608	NA	-0.8	-19.12	-0.6	8.59e-65	Aortic root size;
BRCA	cis	rs7072216	0.763	rs2274244	chr10:100175218	A/G	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.68	-0.36	8.8e-21	Metabolite levels;
BRCA	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg17330251	chr7:94953956	PON1	-0.42	-8.57	-0.32	7.92e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg01448562	chr3:133502909	NA	0.57	13.84	0.48	2.87e-38	Iron status biomarkers;
BRCA	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg05564831	chr3:52568323	NT5DC2	0.34	8.11	0.31	2.54e-15	Electroencephalogram traits;
BRCA	cis	rs2019216	0.500	rs6565385	chr17:21897646	C/A	cg22648282	chr17:21454238	C17orf51	-0.4	-9.27	-0.34	2.93e-19	Pelvic organ prolapse;
BRCA	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg24558204	chr6:135376177	HBS1L	0.45	12.29	0.44	2.63e-31	Red blood cell count;
BRCA	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	11.9	0.43	1.18e-29	Schizophrenia;
BRCA	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.61	9.94	0.37	9.84e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg12516959	chr21:47718080	NA	-0.35	-8.36	-0.31	3.99e-16	Testicular germ cell tumor;
BRCA	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	9.24	0.34	3.66e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-21.69	-0.65	1.36e-78	Heart rate;
BRCA	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg05347473	chr6:146136440	FBXO30	-0.42	-8.41	-0.32	2.75e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg14835575	chr10:16859367	RSU1	0.63	14.06	0.49	2.53e-39	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg05340658	chr4:99064831	C4orf37	-0.56	-11.42	-0.41	1.23e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.66	-0.53	4.96e-47	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	12.88	0.45	6.66e-34	Mean platelet volume;
BRCA	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg24675658	chr1:53192096	ZYG11B	-0.65	-14.33	-0.49	1.34e-40	Monocyte count;
BRCA	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg26384229	chr12:38710491	ALG10B	0.67	14.29	0.49	2.1e-40	Morning vs. evening chronotype;
BRCA	cis	rs11955398	0.501	rs10067618	chr5:60010995	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.41	-9.65	-0.36	1.2e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg24562669	chr7:97807699	LMTK2	0.47	12.58	0.45	1.38e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11764359	chr7:65958608	NA	0.77	17.42	0.57	6.69e-56	Aortic root size;
BRCA	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.37	0.38	2.23e-23	Motion sickness;
BRCA	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	10.5	0.38	6.63e-24	Iron status biomarkers;
BRCA	trans	rs8073060	0.586	rs4796100	chr17:33997657	G/T	cg19694781	chr19:47549865	TMEM160	1.01	20.07	0.62	7.78e-70	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.52	-10.97	-0.4	9.27e-26	Lymphocyte counts;
BRCA	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg03806693	chr22:41940476	POLR3H	0.97	18.76	0.6	6.57e-63	Vitiligo;
BRCA	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg26343298	chr8:95960752	TP53INP1	0.29	8.3	0.31	6.38e-16	Type 2 diabetes;
BRCA	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg08470875	chr2:26401718	FAM59B	-0.63	-9.41	-0.35	8.56e-20	Gut microbiome composition (summer);
BRCA	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg20587970	chr11:113659929	NA	-1.2	-22.13	-0.66	5.45e-81	Hip circumference adjusted for BMI;
BRCA	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg05340658	chr4:99064831	C4orf37	0.58	12.42	0.44	7.03e-32	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg15704280	chr7:45808275	SEPT13	-0.44	-8.14	-0.31	2.1e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.17	-0.31	1.66e-15	Aortic root size;
BRCA	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05731713	chr7:157510257	PTPRN2	0.39	10.12	0.37	1.94e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs7246657	0.722	rs1564208	chr19:38041221	A/G	cg18154014	chr19:37997991	ZNF793	0.48	9.1	0.34	1.1e-18	Coronary artery calcification;
BRCA	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg04166393	chr7:2884313	GNA12	0.42	9.09	0.34	1.21e-18	Height;
BRCA	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg11822812	chr5:140052017	DND1	-0.3	-8.1	-0.31	2.72e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg04025307	chr7:1156635	C7orf50	0.75	19.71	0.61	6.57e-68	Longevity;Endometriosis;
BRCA	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg11663144	chr21:46675770	NA	-0.6	-13.88	-0.48	1.75e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9469578	0.792	rs73743329	chr6:33713943	T/A	cg18708504	chr6:33715942	IP6K3	0.7	10.18	0.37	1.12e-22	Phosphorus levels;
BRCA	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg21535247	chr6:8435926	SLC35B3	0.42	9.42	0.35	7.86e-20	Motion sickness;
BRCA	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg25019033	chr10:957182	NA	-0.41	-7.89	-0.3	1.34e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg11752832	chr7:134001865	SLC35B4	0.53	13.72	0.48	9.45e-38	Mean platelet volume;
BRCA	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg12386194	chr3:101231763	SENP7	0.48	9.79	0.36	3.56e-21	Colorectal cancer;
BRCA	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg14019146	chr3:50243930	SLC38A3	-0.34	-8.16	-0.31	1.84e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg06636001	chr8:8085503	FLJ10661	0.53	10.04	0.37	3.92e-22	Retinal vascular caliber;
BRCA	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-13.34	-0.47	5.56e-36	Morning vs. evening chronotype;
BRCA	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	10.92	0.4	1.48e-25	Rheumatoid arthritis;
BRCA	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg21138405	chr5:131827807	IRF1	0.4	12.97	0.46	2.5e-34	Asthma (sex interaction);
BRCA	cis	rs7944584	0.632	rs11039159	chr11:47294021	G/T	cg03711944	chr11:47377212	SPI1	-0.35	-7.83	-0.3	1.98e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg05343316	chr1:45956843	TESK2	0.7	14.57	0.5	1.02e-41	Platelet count;
BRCA	cis	rs4919694	0.572	rs7080935	chr10:104929113	C/A	cg04362960	chr10:104952993	NT5C2	0.71	12.33	0.44	1.66e-31	Arsenic metabolism;
BRCA	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg20701182	chr2:24300061	SF3B14	0.63	8.97	0.33	3.35e-18	Lymphocyte counts;
BRCA	cis	rs757081	0.637	rs34941502	chr11:17155432	G/A	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.66	-0.32	3.73e-17	Systolic blood pressure;
BRCA	cis	rs9297145	0.585	rs10953283	chr7:98782750	A/G	cg05967295	chr7:98741636	SMURF1	0.61	13.2	0.46	2.47e-35	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.45	-0.32	1.93e-16	Total body bone mineral density;
BRCA	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.12	0.49	1.35e-39	Eye color traits;
BRCA	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.87	0.36	1.75e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9790314	0.659	rs13066683	chr3:160847410	A/G	cg03342759	chr3:160939853	NMD3	-0.5	-10.14	-0.37	1.7e-22	Morning vs. evening chronotype;
BRCA	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg20628663	chr10:43360327	NA	-0.69	-13.4	-0.47	2.99e-36	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.37e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2637266	0.935	rs12772269	chr10:78394292	C/A	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg04756594	chr16:24857601	SLC5A11	-0.34	-8.32	-0.31	5.29e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-9.07	-0.34	1.45e-18	Myopia (pathological);
BRCA	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg03929089	chr4:120376271	NA	-0.68	-13.52	-0.47	7.85e-37	Coronary artery disease;
BRCA	cis	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg06521331	chr12:34319734	NA	-0.58	-11.65	-0.42	1.47e-28	Morning vs. evening chronotype;
BRCA	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg26384229	chr12:38710491	ALG10B	0.54	11.51	0.41	5.36e-28	Morning vs. evening chronotype;
BRCA	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.38	-10.1	-0.37	2.35e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg14784868	chr12:69753453	YEATS4	0.45	11.64	0.42	1.48e-28	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7246657	0.722	rs954504	chr19:38045394	A/G	cg18154014	chr19:37997991	ZNF793	0.48	9.13	0.34	8.69e-19	Coronary artery calcification;
BRCA	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg21782813	chr7:2030301	MAD1L1	0.43	12.37	0.44	1.18e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg13385521	chr17:29058706	SUZ12P	0.62	8.49	0.32	1.49e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg26384229	chr12:38710491	ALG10B	0.75	16.51	0.55	2.8e-51	Morning vs. evening chronotype;
BRCA	cis	rs13046373	0.534	rs9305426	chr21:31964916	A/C	cg16431978	chr21:31797932	KRTAP13-3	0.38	9.42	0.35	8.21e-20	HDL cholesterol;
BRCA	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	22.76	0.67	2.09e-84	Platelet count;
BRCA	trans	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg21775007	chr8:11205619	TDH	0.4	8.63	0.32	4.81e-17	Mood instability;
BRCA	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg23711669	chr6:146136114	FBXO30	0.72	16.49	0.55	3.69e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg25838465	chr1:92012736	NA	-0.66	-19.85	-0.62	1.1e-68	Breast cancer;
BRCA	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg17691542	chr6:26056736	HIST1H1C	0.47	9.74	0.36	5.38e-21	Height;
BRCA	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg08888203	chr3:10149979	C3orf24	0.66	14.05	0.49	2.73e-39	Alzheimer's disease;
BRCA	cis	rs1499972	0.941	rs817508	chr3:117685576	T/C	cg07612923	chr3:117604196	NA	-0.6	-8.21	-0.31	1.19e-15	Schizophrenia;
BRCA	cis	rs6580649	0.883	rs7967762	chr12:48420214	C/T	cg05342945	chr12:48394962	COL2A1	0.44	8.57	0.32	7.75e-17	Lung cancer;
BRCA	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg17143192	chr8:8559678	CLDN23	0.55	10.46	0.38	9.4e-24	Obesity-related traits;
BRCA	trans	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-20.85	-0.64	4.92e-74	Exhaled nitric oxide output;
BRCA	trans	rs12517041	1.000	rs7734577	chr5:23290864	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05901451	chr6:126070800	HEY2	0.39	9.59	0.35	1.91e-20	Endometrial cancer;
BRCA	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg25174290	chr11:3078921	CARS	0.41	12.06	0.43	2.56e-30	Longevity;
BRCA	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg17425144	chr1:10567563	PEX14	0.55	14.03	0.49	3.39e-39	Breast cancer;
BRCA	cis	rs4566357	0.595	rs10201538	chr2:227914449	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-9.26	-0.34	3.12e-19	Coronary artery disease;
BRCA	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.38e-52	Colorectal cancer;
BRCA	cis	rs11785693	0.865	rs7815144	chr8:4970788	G/T	cg26367366	chr8:4980734	NA	-0.6	-10.77	-0.39	5.53e-25	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg18132916	chr6:79620363	NA	-0.45	-10.32	-0.38	3.31e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.13	0.34	8.92e-19	Tonsillectomy;
BRCA	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg04756594	chr16:24857601	SLC5A11	-0.46	-9.22	-0.34	4.1e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.51	11.22	0.41	8.73e-27	IgG glycosylation;
BRCA	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg08477640	chr19:41863820	B9D2	-0.39	-7.97	-0.3	7.17e-15	Migraine;Coronary artery disease;
BRCA	cis	rs61935443	0.832	rs11107768	chr12:95274182	A/T	cg21533806	chr12:95267307	NA	-0.44	-8.77	-0.33	1.65e-17	Schizophrenia;
BRCA	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg02176678	chr2:219576539	TTLL4	-0.47	-12.25	-0.44	4e-31	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg15556689	chr8:8085844	FLJ10661	0.37	8.72	0.33	2.37e-17	Retinal vascular caliber;
BRCA	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-8.05	-0.3	4.13e-15	Prostate cancer;
BRCA	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg17971929	chr21:40555470	PSMG1	0.8	19.47	0.61	1.2e-66	Cognitive function;
BRCA	cis	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg06521331	chr12:34319734	NA	-0.6	-11.88	-0.43	1.49e-29	Morning vs. evening chronotype;
BRCA	cis	rs4566357	0.615	rs10198406	chr2:227913539	A/G	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.12	-0.31	2.44e-15	Coronary artery disease;
BRCA	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg11584989	chr19:19387371	SF4	0.63	13.52	0.47	7.85e-37	Bipolar disorder;
BRCA	trans	rs75804782	0.515	rs75251934	chr2:239288387	A/C	cg01134436	chr17:81009848	B3GNTL1	0.74	7.95	0.3	8.38e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg26384229	chr12:38710491	ALG10B	0.54	13.78	0.48	5.34e-38	Morning vs. evening chronotype;
BRCA	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.49	10.34	0.38	2.89e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs10242455	0.702	rs59240302	chr7:99072991	C/G	cg18809830	chr7:99032528	PTCD1	-0.62	-8.83	-0.33	9.64e-18	Blood metabolite levels;
BRCA	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.54	13.44	0.47	1.96e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg26384229	chr12:38710491	ALG10B	-0.48	-11.1	-0.4	2.77e-26	Morning vs. evening chronotype;
BRCA	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg25173405	chr17:45401733	C17orf57	-0.54	-11.99	-0.43	5.22e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00149659	chr3:10157352	C3orf10	0.79	13.72	0.48	9.42e-38	Alzheimer's disease;
BRCA	trans	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	14.26	0.49	3.04e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs11958404	0.932	rs72816564	chr5:157427484	T/C	cg05962755	chr5:157440814	NA	0.58	10.55	0.39	4.36e-24	IgG glycosylation;
BRCA	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg13010199	chr12:38710504	ALG10B	0.5	10.03	0.37	4.54e-22	Bladder cancer;
BRCA	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21659725	chr3:3221576	CRBN	0.72	22.05	0.66	1.54e-80	Intelligence (multi-trait analysis);
BRCA	trans	rs1941687	0.563	rs2032189	chr18:31332200	T/A	cg15819921	chr19:927150	ARID3A	-0.43	-8.24	-0.31	9.75e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs897080	0.515	rs1065783	chr2:44660741	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	7.97	0.3	7.43e-15	Height;
BRCA	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg17063962	chr7:91808500	NA	0.53	12.45	0.44	5.16e-32	Breast cancer;
BRCA	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.81	-0.45	1.36e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg08885076	chr2:99613938	TSGA10	-0.59	-13.21	-0.46	2.12e-35	Chronic sinus infection;
BRCA	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg12373951	chr3:133503437	NA	0.45	10.74	0.39	7.77e-25	Iron status biomarkers;
BRCA	cis	rs1451375	0.617	rs1376524	chr7:50563582	G/A	cg18232548	chr7:50535776	DDC	-0.42	-9.09	-0.34	1.19e-18	Malaria;
BRCA	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-13.29	-0.47	9.55e-36	Platelet count;
BRCA	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg21475434	chr5:93447410	FAM172A	0.66	8.83	0.33	9.99e-18	Diabetic retinopathy;
BRCA	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.54	-13.35	-0.47	5.16e-36	Urate levels in overweight individuals;
BRCA	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.47	0.5	2.98e-41	Colorectal cancer;
BRCA	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.79	-0.53	1.19e-47	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg04455712	chr21:45112962	RRP1B	0.38	9.63	0.36	1.4e-20	Mean corpuscular volume;
BRCA	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.42	-0.41	1.23e-27	Personality dimensions;
BRCA	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg03342759	chr3:160939853	NMD3	-0.8	-18.81	-0.6	4.02e-63	Parkinson's disease;
BRCA	trans	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg25214090	chr10:38739885	LOC399744	0.45	10.4	0.38	1.72e-23	Corneal astigmatism;
BRCA	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg03060546	chr3:49711283	APEH	0.56	8.68	0.32	3.36e-17	Menarche (age at onset);
BRCA	cis	rs13046373	0.562	rs12627602	chr21:32022924	G/A	cg14062083	chr21:31802829	KRTAP13-4	0.34	9.46	0.35	5.73e-20	HDL cholesterol;
BRCA	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg03146154	chr1:46216737	IPP	-0.51	-11.33	-0.41	3.08e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.53	-0.35	3.33e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	14.92	0.51	2.14e-43	Mean corpuscular hemoglobin;
BRCA	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg19678392	chr7:94953810	PON1	-0.42	-8.67	-0.32	3.47e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs758324	0.891	rs635164	chr5:131312874	C/T	cg06307176	chr5:131281290	NA	-0.54	-10.55	-0.39	4.14e-24	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg19418458	chr7:158789849	NA	-0.43	-9.64	-0.36	1.22e-20	Facial morphology (factor 20);
BRCA	cis	rs73001065	0.591	rs57962361	chr19:19425025	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	12.84	0.45	1.03e-33	LDL cholesterol;
BRCA	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg24130564	chr14:104152367	KLC1	-0.35	-8.04	-0.3	4.23e-15	Body mass index;
BRCA	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg13319975	chr6:146136371	FBXO30	-0.62	-14.34	-0.49	1.2e-40	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg11879182	chr18:77439856	CTDP1	0.64	13.66	0.48	1.85e-37	Monocyte count;
BRCA	cis	rs11997175	0.716	rs7460818	chr8:33816362	A/G	ch.8.33884649F	chr8:33765107	NA	0.42	10.22	0.37	8.56e-23	Body mass index;
BRCA	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18876405	chr7:65276391	NA	-0.5	-11.18	-0.4	1.25e-26	Aortic root size;
BRCA	cis	rs10504073	0.584	rs55908480	chr8:49923431	G/A	cg00325661	chr8:49890786	NA	0.51	15.04	0.51	5.21e-44	Blood metabolite ratios;
BRCA	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg13628971	chr7:2884303	GNA12	0.38	8.76	0.33	1.73e-17	Height;
BRCA	cis	rs7677751	0.767	rs6831380	chr4:55076345	G/A	cg17187183	chr4:55093834	PDGFRA	0.4	8.11	0.31	2.69e-15	Corneal astigmatism;
BRCA	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.35	-9.33	-0.35	1.7e-19	Body mass index;
BRCA	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg02574844	chr11:5959923	NA	-0.4	-8.02	-0.3	5.18e-15	DNA methylation (variation);
BRCA	cis	rs559928	1.000	rs7105178	chr11:64145109	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.57	-8.75	-0.33	1.84e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26314531	chr2:26401878	FAM59B	-0.59	-10.14	-0.37	1.68e-22	Gut microbiome composition (summer);
BRCA	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.02	15.18	0.51	1.1e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg13944838	chr5:179740914	GFPT2	-0.71	-15.11	-0.51	2.51e-44	Height;
BRCA	trans	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg25214090	chr10:38739885	LOC399744	0.51	10.48	0.38	7.8e-24	Corneal astigmatism;
BRCA	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	9.9	0.36	1.35e-21	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs2204008	0.526	rs2320448	chr12:38224180	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.74	-0.36	5.26e-21	Bladder cancer;
BRCA	cis	rs490234	0.966	rs542974	chr9:128373218	G/A	cg14078157	chr9:128172775	NA	0.33	8.04	0.3	4.28e-15	Mean arterial pressure;
BRCA	cis	rs965469	1.000	rs1040726	chr20:3264267	C/T	cg25506879	chr20:3388711	C20orf194	-0.54	-10.44	-0.38	1.18e-23	IFN-related cytopenia;
BRCA	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.37	7.97	0.3	7.5e-15	Total cholesterol levels;
BRCA	cis	rs4728302	0.869	rs6954712	chr7:133618853	G/A	cg07491979	chr7:133331646	EXOC4	0.37	7.83	0.3	2.06e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg26116260	chr4:7069785	GRPEL1	-0.91	-19.01	-0.6	3.47e-64	Monocyte percentage of white cells;
BRCA	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg27129171	chr3:47204927	SETD2	0.63	13.41	0.47	2.49e-36	Birth weight;
BRCA	cis	rs72627509	0.767	rs6853156	chr4:57774843	C/T	cg26694713	chr4:57773883	REST	0.48	9.27	0.34	2.78e-19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.72	-11.88	-0.43	1.52e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7737355	0.947	rs17167760	chr5:130782699	A/G	cg06307176	chr5:131281290	NA	-0.55	-10.99	-0.4	7.66e-26	Life satisfaction;
BRCA	trans	rs11976180	1.000	rs7777389	chr7:143744802	T/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.24	-0.31	9.58e-16	Obesity-related traits;
BRCA	cis	rs858239	0.600	rs10256359	chr7:23123877	C/T	cg23682824	chr7:23144976	KLHL7	0.45	11.69	0.42	9.57e-29	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24549020	chr5:56110836	MAP3K1	-0.48	-8.58	-0.32	7.41e-17	Initial pursuit acceleration;
BRCA	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg26384229	chr12:38710491	ALG10B	0.7	16.39	0.54	1.2e-50	Bladder cancer;
BRCA	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg11584989	chr19:19387371	SF4	0.63	13.46	0.47	1.53e-36	Bipolar disorder;
BRCA	cis	rs6142102	0.961	rs6088355	chr20:32545887	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	8.03	0.3	4.57e-15	Skin pigmentation;
BRCA	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-14.53	-0.5	1.47e-41	Hemoglobin concentration;
BRCA	cis	rs738322	0.772	rs9619724	chr22:38517880	T/G	cg25457927	chr22:38595422	NA	-0.29	-10.25	-0.38	6.19e-23	Cutaneous nevi;
BRCA	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg23649088	chr2:200775458	C2orf69	0.61	9.06	0.34	1.54e-18	Schizophrenia;
BRCA	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg21475434	chr5:93447410	FAM172A	0.7	8.95	0.33	3.8e-18	Diabetic retinopathy;
BRCA	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	7.83	0.3	1.99e-14	Tonsillectomy;
BRCA	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg16339924	chr4:17578868	LAP3	0.56	13.82	0.48	3.26e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7617773	0.676	rs13060020	chr3:48372646	C/T	cg11946769	chr3:48343235	NME6	0.67	13.41	0.47	2.67e-36	Coronary artery disease;
BRCA	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg11266682	chr4:10021025	SLC2A9	0.49	12.86	0.45	8.33e-34	Bone mineral density;
BRCA	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg10523679	chr1:76189770	ACADM	-0.77	-15.98	-0.53	1.35e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.32	9.0	0.34	2.59e-18	Response to antipsychotic treatment;
BRCA	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.3	-0.31	6.38e-16	Bipolar disorder;
BRCA	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg23711669	chr6:146136114	FBXO30	-0.68	-16.34	-0.54	2.12e-50	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6763687	0.637	rs1875093	chr3:171807714	T/C	cg16233210	chr3:171778391	FNDC3B	0.39	9.39	0.35	1e-19	Red cell distribution width;
BRCA	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg06784218	chr1:46089804	CCDC17	-0.45	-10.79	-0.39	4.67e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7520050	0.966	rs946529	chr1:46485548	G/T	cg24296786	chr1:45957014	TESK2	0.43	9.78	0.36	3.74e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg23933602	chr10:16859644	RSU1	1.0	32.65	0.79	2.69e-138	Platelet distribution width;
BRCA	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg20607287	chr7:12443886	VWDE	-0.57	-8.39	-0.31	3.13e-16	Coronary artery disease;
BRCA	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05025164	chr4:1340916	KIAA1530	0.6	12.26	0.44	3.43e-31	Longevity;
BRCA	cis	rs1829883	0.729	rs714385	chr5:98887617	T/C	cg08333243	chr5:99726346	NA	-0.34	-8.0	-0.3	5.96e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg00105475	chr2:10696890	NA	0.43	9.83	0.36	2.47e-21	Prostate cancer;
BRCA	cis	rs4588572	0.688	rs11743511	chr5:77692819	C/T	cg11547950	chr5:77652471	NA	-0.43	-8.42	-0.32	2.54e-16	Triglycerides;
BRCA	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.51	-8.86	-0.33	8.07e-18	Body mass index (adult);
BRCA	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg08888203	chr3:10149979	C3orf24	0.56	10.24	0.38	7.16e-23	Alzheimer's disease;
BRCA	cis	rs2637266	1.000	rs7900616	chr10:78367075	C/T	cg18941641	chr10:78392320	NA	0.35	7.82	0.3	2.18e-14	Pulmonary function;
BRCA	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg02569458	chr12:86230093	RASSF9	0.33	8.14	0.31	2.08e-15	Major depressive disorder;
BRCA	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-12.32	-0.44	1.92e-31	Hemoglobin concentration;
BRCA	cis	rs71636778	0.543	rs17162330	chr1:27236212	A/G	cg12203394	chr1:27248618	NUDC	0.6	9.38	0.35	1.14e-19	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg08508325	chr11:3079039	CARS	0.28	8.45	0.32	2e-16	Calcium levels;
BRCA	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg23711669	chr6:146136114	FBXO30	-0.62	-13.95	-0.48	8.79e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg10523679	chr1:76189770	ACADM	-0.49	-9.52	-0.35	3.5e-20	Daytime sleep phenotypes;
BRCA	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2463822	1.000	rs2246920	chr11:62104937	T/G	cg06239285	chr11:62104954	ASRGL1	0.67	11.41	0.41	1.38e-27	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg02951883	chr7:2050386	MAD1L1	-0.61	-15.14	-0.51	1.76e-44	Bipolar disorder and schizophrenia;
BRCA	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg18230493	chr5:56204884	C5orf35	-0.75	-14.62	-0.5	6e-42	Initial pursuit acceleration;
BRCA	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg03954927	chr1:10346856	KIF1B	0.48	15.05	0.51	5.04e-44	Hepatocellular carcinoma;
BRCA	trans	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg17145862	chr1:211918768	LPGAT1	0.69	18.15	0.58	1.04e-59	Leprosy;
BRCA	cis	rs6942756	0.774	rs6946288	chr7:129004277	A/G	cg02491457	chr7:128862824	NA	-0.57	-11.97	-0.43	6.07e-30	White matter hyperintensity burden;
BRCA	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg12310025	chr6:25882481	NA	-0.53	-12.02	-0.43	3.91e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-10.81	-0.39	3.83e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg23933602	chr10:16859644	RSU1	0.56	9.1	0.34	1.15e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs4919694	0.572	rs12240508	chr10:104939232	G/A	cg04362960	chr10:104952993	NT5C2	0.71	12.36	0.44	1.32e-31	Arsenic metabolism;
BRCA	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg24060327	chr5:131705240	SLC22A5	-0.47	-9.58	-0.35	2.07e-20	Blood metabolite levels;
BRCA	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg12016809	chr21:47604291	C21orf56	0.4	8.39	0.32	3.04e-16	Testicular germ cell tumor;
BRCA	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg05729581	chr11:3078854	CARS	-0.35	-8.64	-0.32	4.64e-17	Longevity;
BRCA	cis	rs243505	1.000	rs243515	chr7:148426672	A/C	cg09806900	chr7:148480153	CUL1	-0.39	-8.12	-0.31	2.46e-15	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6429082	0.818	rs167092	chr1:235642359	A/G	cg26050004	chr1:235667680	B3GALNT2	0.57	14.13	0.49	1.15e-39	Adiposity;
BRCA	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-9.76	-0.36	4.36e-21	Bladder cancer;
BRCA	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	10.33	0.38	3.03e-23	Calcium levels;
BRCA	cis	rs6120849	0.901	rs6060278	chr20:33753262	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	8.93	0.33	4.66e-18	Protein C levels;
BRCA	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg16482183	chr6:26056742	HIST1H1C	0.74	12.96	0.46	2.9e-34	Iron status biomarkers;
BRCA	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg22920501	chr2:26401640	FAM59B	-0.81	-13.19	-0.46	2.66e-35	Gut microbiome composition (summer);
BRCA	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg18252515	chr7:66147081	NA	-0.82	-11.88	-0.43	1.52e-29	Diabetic kidney disease;
BRCA	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.54	-0.32	9.57e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs8017423	0.647	rs12590712	chr14:90822481	T/C	cg04374321	chr14:90722782	PSMC1	-0.49	-11.86	-0.42	1.75e-29	Mortality in heart failure;
BRCA	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg03433033	chr1:76189801	ACADM	0.75	16.85	0.55	5.63e-53	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06108461	chr20:60628389	TAF4	-0.78	-17.09	-0.56	3.18e-54	Body mass index;
BRCA	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	26.55	0.72	2.89e-105	Chronic sinus infection;
BRCA	cis	rs3768617	0.510	rs3768616	chr1:183103551	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.62	15.86	0.53	5.42e-48	Fuchs's corneal dystrophy;
BRCA	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.67	-0.61	9.89e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs701145	0.556	rs355751	chr3:153971602	T/C	cg16511985	chr3:153974050	SGEF	0.41	8.96	0.33	3.45e-18	Coronary artery disease;
BRCA	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg05234568	chr11:5960015	NA	-0.51	-9.93	-0.37	1.04e-21	DNA methylation (variation);
BRCA	cis	rs68170813	0.559	rs7981	chr7:106843133	G/C	cg02696742	chr7:106810147	HBP1	-0.52	-8.35	-0.31	4.12e-16	Coronary artery disease;
BRCA	cis	rs4285028	0.699	rs12637968	chr3:121599976	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.73	-13.2	-0.46	2.35e-35	Multiple sclerosis;
BRCA	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.17	0.46	3.12e-35	Bipolar disorder;
BRCA	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg17063962	chr7:91808500	NA	0.52	12.35	0.44	1.41e-31	Breast cancer;
BRCA	cis	rs34779708	0.931	rs1926556	chr10:35344907	T/C	cg03585969	chr10:35415529	CREM	0.55	11.41	0.41	1.41e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.73e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs3849570	0.615	rs35779564	chr3:81982771	G/A	cg07356753	chr3:81810745	GBE1	-0.34	-7.98	-0.3	6.63e-15	Waist circumference;Body mass index;
BRCA	cis	rs9467773	0.587	rs10946812	chr6:26344975	G/C	cg09904177	chr6:26538194	HMGN4	-0.29	-7.86	-0.3	1.63e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs778371	0.915	rs748002	chr2:233757679	G/A	cg08000102	chr2:233561755	GIGYF2	-0.75	-16.35	-0.54	1.91e-50	Schizophrenia;
BRCA	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.4	9.47	0.35	5.46e-20	Eosinophil percentage of white cells;
BRCA	cis	rs17095355	1.000	rs55728195	chr10:111715599	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.79	-0.36	3.57e-21	Biliary atresia;
BRCA	cis	rs17601876	0.623	rs1062033	chr15:51547938	C/G	cg19946085	chr15:51559439	CYP19A1	-0.34	-9.17	-0.34	6.31e-19	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs6546550	0.901	rs6546556	chr2:70139001	A/G	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.62	-0.42	1.94e-28	Prevalent atrial fibrillation;
BRCA	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.85	-0.33	8.4e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.06	0.49	2.68e-39	Motion sickness;
BRCA	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg08645402	chr16:4508243	NA	0.4	9.25	0.34	3.35e-19	Schizophrenia;
BRCA	trans	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.25	-0.34	3.26e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg00071950	chr4:10020882	SLC2A9	-0.43	-10.08	-0.37	2.75e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	8.36	0.31	4.06e-16	Rheumatoid arthritis;
BRCA	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.43	-8.93	-0.33	4.34e-18	Cognitive ability;
BRCA	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.94	0.3	8.88e-15	Depression;
BRCA	cis	rs1355223	0.525	rs55796371	chr11:34872769	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-9.48	-0.35	4.85e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs66887589	0.967	rs7678973	chr4:120511817	T/C	cg09307838	chr4:120376055	NA	-0.44	-9.22	-0.34	4.34e-19	Diastolic blood pressure;
BRCA	cis	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.08	-0.3	3.26e-15	Total body bone mineral density;
BRCA	cis	rs870825	0.616	rs4263438	chr4:185624238	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs7560272	0.502	rs13013228	chr2:73925216	G/A	cg20560298	chr2:73613845	ALMS1	0.35	9.13	0.34	8.74e-19	Schizophrenia;
BRCA	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg23231163	chr10:75533350	FUT11	-0.34	-8.83	-0.33	9.85e-18	Inflammatory bowel disease;
BRCA	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg24060327	chr5:131705240	SLC22A5	0.46	9.44	0.35	7.06e-20	Blood metabolite levels;
BRCA	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05025164	chr4:1340916	KIAA1530	-0.62	-12.63	-0.45	8.35e-33	Obesity-related traits;
BRCA	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg06046430	chr4:77819534	ANKRD56	0.61	13.63	0.47	2.57e-37	Emphysema distribution in smoking;
BRCA	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg24596788	chr1:163392923	NA	-0.4	-10.68	-0.39	1.28e-24	Motion sickness;
BRCA	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg22974920	chr21:40686053	BRWD1	-0.35	-7.91	-0.3	1.17e-14	Menarche (age at onset);
BRCA	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg24069376	chr3:38537580	EXOG	-0.41	-11.76	-0.42	4.65e-29	Electrocardiographic conduction measures;
BRCA	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg20607798	chr8:58055168	NA	0.48	8.43	0.32	2.29e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs17095355	1.000	rs12259261	chr10:111725145	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.8	-0.36	3.11e-21	Biliary atresia;
BRCA	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg00666640	chr1:248458726	OR2T12	0.35	8.97	0.33	3.21e-18	Common traits (Other);
BRCA	cis	rs7520050	0.931	rs6688365	chr1:46329884	G/C	cg24296786	chr1:45957014	TESK2	0.44	9.89	0.36	1.5e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	14.14	0.49	1.06e-39	Colorectal cancer;
BRCA	cis	rs61935443	0.778	rs78522691	chr12:95267340	G/T	cg21533806	chr12:95267307	NA	0.45	8.56	0.32	8.66e-17	Schizophrenia;
BRCA	cis	rs17095355	1.000	rs4565840	chr10:111717140	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.39	-10.06	-0.37	3.45e-22	Biliary atresia;
BRCA	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-11.48	-0.41	7.04e-28	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.92	-0.33	4.93e-18	Neuroticism;
BRCA	trans	rs61931739	0.635	rs1405024	chr12:33937939	A/T	cg26384229	chr12:38710491	ALG10B	-0.39	-8.95	-0.33	3.98e-18	Morning vs. evening chronotype;
BRCA	cis	rs3784262	0.669	rs4646594	chr15:58302386	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.23	-0.38	7.56e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.97	-0.3	7.41e-15	Depression;
BRCA	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg04989706	chr14:50066350	PPIL5	0.44	8.35	0.31	4.21e-16	Carotid intima media thickness;
BRCA	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg01262667	chr19:19385393	TM6SF2	0.4	10.33	0.38	3.12e-23	Tonsillectomy;
BRCA	trans	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg25214090	chr10:38739885	LOC399744	0.45	10.66	0.39	1.59e-24	Corneal astigmatism;
BRCA	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg18305652	chr10:134549665	INPP5A	0.49	12.03	0.43	3.31e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg26536863	chr7:158807979	LOC154822	-0.36	-8.62	-0.32	5.09e-17	Facial morphology (factor 20);
BRCA	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg13047869	chr3:10149882	C3orf24	0.57	11.77	0.42	4.49e-29	Alzheimer's disease;
BRCA	cis	rs30380	0.632	rs26489	chr5:96133427	C/T	cg16492584	chr5:96139282	ERAP1	-0.46	-11.09	-0.4	2.93e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	11.46	0.41	8.52e-28	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg04450456	chr4:17643702	FAM184B	0.35	9.6	0.36	1.76e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3771570	1.000	rs62193202	chr2:242303717	G/A	cg21155796	chr2:242212141	HDLBP	0.6	9.23	0.34	3.83e-19	Prostate cancer;
BRCA	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg02297831	chr4:17616191	MED28	0.36	7.89	0.3	1.32e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg16339924	chr4:17578868	LAP3	0.56	13.89	0.48	1.62e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-10.68	-0.39	1.25e-24	Hemoglobin concentration;
BRCA	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg11845111	chr2:191398756	TMEM194B	-0.79	-14.81	-0.51	6.99e-43	Diastolic blood pressure;
BRCA	cis	rs8028182	0.636	rs4322627	chr15:75810659	C/T	cg20655648	chr15:75932815	IMP3	0.42	8.01	0.3	5.34e-15	Sudden cardiac arrest;
BRCA	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18876405	chr7:65276391	NA	-0.5	-11.19	-0.4	1.18e-26	Aortic root size;
BRCA	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-12.19	-0.43	6.7e-31	Tonsillectomy;
BRCA	cis	rs11083475	0.714	rs7248584	chr19:39258110	C/T	cg07905965	chr19:39260460	NA	0.47	11.13	0.4	2.01e-26	Heart rate;
BRCA	trans	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg26043149	chr18:55253948	FECH	-0.4	-8.56	-0.32	8.69e-17	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs17023223	0.537	rs12064033	chr1:119709558	G/A	cg05756136	chr1:119680316	WARS2	-0.42	-8.05	-0.3	3.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.49e-52	Hypertriglyceridemia;
BRCA	cis	rs7246657	0.509	rs10426093	chr19:37615629	G/A	cg23950597	chr19:37808831	NA	-0.64	-9.52	-0.35	3.4e-20	Coronary artery calcification;
BRCA	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg04025307	chr7:1156635	C7orf50	0.47	9.11	0.34	1.03e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg00277334	chr10:82204260	NA	-0.43	-8.48	-0.32	1.53e-16	Post bronchodilator FEV1;
BRCA	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26314531	chr2:26401878	FAM59B	0.95	16.54	0.55	2.07e-51	Gut microbiome composition (summer);
BRCA	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg25237894	chr2:233734115	C2orf82	0.39	11.03	0.4	5.21e-26	Coronary artery disease;
BRCA	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg26608667	chr7:1196370	ZFAND2A	0.43	9.65	0.36	1.13e-20	Longevity;Endometriosis;
BRCA	cis	rs36051895	0.695	rs10120763	chr9:5002911	C/G	cg02405213	chr9:5042618	JAK2	-0.47	-8.49	-0.32	1.47e-16	Pediatric autoimmune diseases;
BRCA	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	6.82e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg17063962	chr7:91808500	NA	0.53	12.5	0.44	3.23e-32	Breast cancer;
BRCA	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg09904177	chr6:26538194	HMGN4	0.55	17.71	0.57	2.23e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs3820928	0.904	rs2894623	chr2:227766112	T/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.42	-0.32	2.58e-16	Pulmonary function;
BRCA	cis	rs11622475	1.000	rs11625697	chr14:104464800	C/T	cg12183467	chr14:104352244	NA	-0.49	-10.19	-0.37	1.09e-22	Bipolar disorder;
BRCA	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	12.23	0.44	4.6e-31	Mood instability;
BRCA	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg04518342	chr5:131593106	PDLIM4	0.37	9.31	0.35	2.02e-19	Breast cancer;
BRCA	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-11.58	-0.42	2.69e-28	Bipolar disorder;
BRCA	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg08847533	chr14:75593920	NEK9	0.69	15.01	0.51	7.51e-44	Coronary artery disease;
BRCA	cis	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg21775007	chr8:11205619	TDH	-0.46	-9.64	-0.36	1.27e-20	Retinal vascular caliber;
BRCA	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.66	10.4	0.38	1.6e-23	Schizophrenia;
BRCA	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-10.56	-0.39	3.96e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg03709012	chr19:19516395	GATAD2A	-0.75	-16.72	-0.55	2.46e-52	Tonsillectomy;
BRCA	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.77	12.85	0.45	8.99e-34	Schizophrenia;
BRCA	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg12395012	chr8:11607386	GATA4	-0.35	-8.15	-0.31	1.85e-15	Myopia (pathological);
BRCA	cis	rs3820928	0.934	rs1366756	chr2:227772038	G/A	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.31	-0.31	5.59e-16	Pulmonary function;
BRCA	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08564027	chr20:61660810	NA	0.85	21.89	0.65	1.06e-79	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg14926445	chr8:58193284	C8orf71	-0.44	-8.53	-0.32	1.06e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg23708337	chr7:1209742	NA	0.42	8.26	0.31	8.3e-16	Longevity;Endometriosis;
BRCA	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg12016809	chr21:47604291	C21orf56	0.4	8.42	0.32	2.57e-16	Testicular germ cell tumor;
BRCA	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg05863683	chr7:1912471	MAD1L1	0.4	8.57	0.32	7.59e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg18512352	chr11:47633146	NA	0.32	8.02	0.3	4.99e-15	Subjective well-being;
BRCA	cis	rs7766436	0.561	rs1342206	chr6:22593676	G/A	cg13666174	chr6:22585274	NA	-0.41	-10.21	-0.37	8.68e-23	Coronary artery disease;
BRCA	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08048268	chr3:133502702	NA	-0.32	-8.16	-0.31	1.81e-15	Iron status biomarkers;
BRCA	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg00106254	chr7:1943704	MAD1L1	-0.39	-10.05	-0.37	3.81e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg10523679	chr1:76189770	ACADM	-0.45	-8.05	-0.3	4.16e-15	Daytime sleep phenotypes;
BRCA	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg07828340	chr4:882639	GAK	0.86	10.53	0.38	4.92e-24	Parkinson's disease;
BRCA	cis	rs6499255	0.951	rs16959025	chr16:69695589	G/T	cg15192750	chr16:69999425	NA	-0.58	-8.94	-0.33	4.03e-18	IgE levels;
BRCA	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg20891283	chr12:69753455	YEATS4	0.73	21.66	0.65	1.94e-78	Blood protein levels;
BRCA	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg03877680	chr5:178157825	ZNF354A	0.82	16.29	0.54	3.56e-50	Neutrophil percentage of white cells;
BRCA	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg08601574	chr20:25228251	PYGB	0.35	8.22	0.31	1.14e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg19077165	chr18:44547161	KATNAL2	0.39	8.47	0.32	1.67e-16	Personality dimensions;
BRCA	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg03433313	chr16:819064	MIR662	-0.51	-10.48	-0.38	8.24e-24	Mean corpuscular volume;
BRCA	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg08975724	chr8:8085496	FLJ10661	0.43	8.03	0.3	4.59e-15	Retinal vascular caliber;
BRCA	cis	rs1997103	0.863	rs2140916	chr7:55403154	A/C	cg17469321	chr7:55412551	NA	0.51	9.72	0.36	6.37e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs16854884	0.657	rs13086088	chr3:143723942	G/A	cg06585982	chr3:143692056	C3orf58	0.43	9.04	0.34	1.92e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg09537434	chr19:41945824	ATP5SL	-0.63	-13.12	-0.46	5.22e-35	Migraine;Coronary artery disease;
BRCA	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.32	-10.2	-0.37	9.69e-23	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg24130564	chr14:104152367	KLC1	0.36	8.21	0.31	1.25e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg25517755	chr10:38738941	LOC399744	-0.4	-8.03	-0.3	4.59e-15	Corneal astigmatism;
BRCA	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	13.85	0.48	2.4e-38	Motion sickness;
BRCA	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.33	0.31	4.94e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg06212747	chr3:49208901	KLHDC8B	0.45	9.36	0.35	1.36e-19	Parkinson's disease;
BRCA	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg21782813	chr7:2030301	MAD1L1	-0.4	-11.8	-0.42	3.23e-29	Bipolar disorder and schizophrenia;
BRCA	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg26597838	chr10:835615	NA	0.73	10.7	0.39	1.11e-24	Eosinophil percentage of granulocytes;
BRCA	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg21475434	chr5:93447410	FAM172A	0.67	8.58	0.32	7.41e-17	Diabetic retinopathy;
BRCA	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-19.32	-0.61	8.01e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg08470875	chr2:26401718	FAM59B	-0.51	-8.22	-0.31	1.14e-15	Gut microbiome composition (summer);
BRCA	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11890956	chr21:40555474	PSMG1	1.07	31.04	0.78	1.05e-129	Cognitive function;
BRCA	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.49e-52	Colorectal cancer;
BRCA	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg21132104	chr15:45694354	SPATA5L1	0.67	14.03	0.49	3.66e-39	Homoarginine levels;
BRCA	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg11189052	chr15:85197271	WDR73	-0.36	-8.71	-0.33	2.66e-17	P wave terminal force;
BRCA	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg21918786	chr6:109611834	NA	-0.45	-12.1	-0.43	1.74e-30	Reticulocyte fraction of red cells;
BRCA	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08564027	chr20:61660810	NA	0.85	23.04	0.67	5.44e-86	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg01874867	chr7:94954059	PON1	-0.39	-8.02	-0.3	4.93e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg04518342	chr5:131593106	PDLIM4	0.36	9.03	0.34	1.99e-18	Breast cancer;
BRCA	cis	rs6545883	0.894	rs778148	chr2:61606866	G/A	cg15711740	chr2:61764176	XPO1	0.49	12.13	0.43	1.33e-30	Tuberculosis;
BRCA	cis	rs4975616	0.773	rs10078017	chr5:1314009	C/T	cg07493874	chr5:1342172	CLPTM1L	0.44	12.0	0.43	4.74e-30	Lung cancer;
BRCA	cis	rs4363385	0.667	rs399550	chr1:153049917	T/C	cg24667326	chr1:152973720	SPRR3	-0.3	-7.92	-0.3	1.07e-14	Inflammatory skin disease;
BRCA	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg17330251	chr7:94953956	PON1	-0.43	-9.06	-0.34	1.51e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs644148	0.803	rs2686771	chr19:44999494	T/C	cg15540054	chr19:45004280	ZNF180	-0.57	-12.28	-0.44	2.9e-31	Personality dimensions;
BRCA	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg00814883	chr7:100076585	TSC22D4	-0.47	-10.53	-0.38	5.1900000000000004e-24	Platelet count;
BRCA	trans	rs9944715	0.954	rs12457740	chr18:43741742	G/A	cg01718231	chr17:29326311	RNF135	0.44	8.95	0.33	3.74e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs7903847	0.620	rs17112676	chr10:99122288	G/A	cg20016023	chr10:99160130	RRP12	-0.26	-8.19	-0.31	1.46e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.41	0.35	8.46e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.38	-8.31	-0.31	5.7e-16	Educational attainment;
BRCA	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.22	-0.31	1.16e-15	Axial length;
BRCA	trans	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg13565492	chr6:43139072	SRF	-0.78	-10.67	-0.39	1.44e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg14196790	chr5:131705035	SLC22A5	0.33	8.66	0.32	3.85e-17	Breast cancer;
BRCA	cis	rs11997175	0.583	rs17780571	chr8:33817821	G/C	ch.8.33884649F	chr8:33765107	NA	0.37	8.52	0.32	1.14e-16	Body mass index;
BRCA	cis	rs7927771	0.507	rs7111606	chr11:47787538	G/A	cg20307385	chr11:47447363	PSMC3	0.42	9.56	0.35	2.48e-20	Subjective well-being;
BRCA	cis	rs2463822	0.858	rs2463836	chr11:62126494	A/G	cg06239285	chr11:62104954	ASRGL1	0.69	11.52	0.41	4.72e-28	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	14.5	0.5	2.09e-41	Alzheimer's disease;
BRCA	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.44	9.31	0.35	2.04e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6121246	0.512	rs45443696	chr20:30311396	A/C	cg21427119	chr20:30132790	HM13	-0.36	-8.09	-0.3	3.1e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs13064411	0.696	rs1486894	chr3:113211513	G/A	cg18753928	chr3:113234510	CCDC52	-0.59	-12.52	-0.44	2.53e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs12541635	0.639	rs10095827	chr8:106984403	A/G	cg10147462	chr8:107024639	NA	0.4	10.77	0.39	5.51e-25	Age of smoking initiation;
BRCA	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.68	-13.77	-0.48	5.85e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6120849	0.851	rs13040631	chr20:33747714	T/C	cg24642439	chr20:33292090	TP53INP2	0.48	8.61	0.32	5.91e-17	Protein C levels;
BRCA	cis	rs3087591	1.000	rs2525578	chr17:29711411	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.45	-9.44	-0.35	6.74e-20	Hip circumference;
BRCA	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg08859206	chr1:53392774	SCP2	0.49	10.84	0.39	2.91e-25	Monocyte count;
BRCA	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.81	13.47	0.47	1.45e-36	Schizophrenia;
BRCA	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg24829409	chr8:58192753	C8orf71	-0.57	-12.24	-0.44	4.41e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs701145	0.585	rs242577	chr3:153941208	G/A	cg17054900	chr3:154042577	DHX36	0.58	9.74	0.36	5.2e-21	Coronary artery disease;
BRCA	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03452623	chr4:187889614	NA	-0.35	-11.44	-0.41	1.08e-27	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg25427524	chr10:38739819	LOC399744	0.46	9.8	0.36	3.22e-21	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs870825	0.616	rs6834156	chr4:185639903	G/C	cg04058563	chr4:185651563	MLF1IP	0.77	17.21	0.56	7.75e-55	Blood protein levels;
BRCA	cis	rs4423214	0.592	rs11233933	chr11:71210070	C/T	cg05163923	chr11:71159392	DHCR7	-0.48	-8.43	-0.32	2.34e-16	Vitamin D levels;
BRCA	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg04455712	chr21:45112962	RRP1B	0.38	9.71	0.36	7.17e-21	Mean corpuscular volume;
BRCA	cis	rs7301826	0.610	rs7961690	chr12:131296880	G/T	cg11011512	chr12:131303247	STX2	-0.45	-11.17	-0.4	1.44e-26	Plasma plasminogen activator levels;
BRCA	cis	rs9296092	0.560	rs9469502	chr6:33526648	G/A	cg13560919	chr6:33536144	NA	-0.85	-18.69	-0.59	1.6e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs17641971	0.645	rs341806	chr8:50034028	A/C	cg00325661	chr8:49890786	NA	0.35	9.51	0.35	3.71e-20	Blood metabolite levels;
BRCA	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg23018236	chr17:30244563	NA	-0.63	-10.28	-0.38	4.91e-23	Hip circumference adjusted for BMI;
BRCA	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.59	-12.31	-0.44	2.07e-31	Lymphocyte counts;
BRCA	cis	rs365132	0.875	rs353476	chr5:176424035	A/G	cg16309518	chr5:176445507	NA	-0.4	-9.72	-0.36	6.41e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg11752832	chr7:134001865	SLC35B4	0.53	13.77	0.48	5.95e-38	Mean platelet volume;
BRCA	cis	rs2806561	0.606	rs218341	chr1:23294153	G/C	cg12483005	chr1:23474871	LUZP1	0.42	9.17	0.34	6.34e-19	Height;
BRCA	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg08470875	chr2:26401718	FAM59B	-0.71	-11.35	-0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23583168	chr7:148888333	NA	-0.85	-19.73	-0.62	4.99e-68	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg11673840	chr17:47092156	IGF2BP1	0.32	7.94	0.3	9.19e-15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
BRCA	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg23358479	chr7:1110784	C7orf50	-0.48	-8.17	-0.31	1.68e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg12292205	chr6:26970375	C6orf41	0.57	12.64	0.45	7.47e-33	Schizophrenia;
BRCA	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06028605	chr16:24865363	SLC5A11	0.45	9.93	0.37	1.05e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg02951883	chr7:2050386	MAD1L1	-0.48	-10.58	-0.39	3.35e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg21747090	chr2:27597821	SNX17	-0.43	-9.27	-0.34	2.87e-19	Total body bone mineral density;
BRCA	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg20587970	chr11:113659929	NA	-1.23	-22.07	-0.66	1.11e-80	Hip circumference adjusted for BMI;
BRCA	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	10.07	0.37	3.19e-22	Bipolar disorder;
BRCA	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.28	-0.61	1.29e-65	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.58	-0.61	3.27e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg01448562	chr3:133502909	NA	0.39	8.96	0.33	3.5e-18	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg08213375	chr14:104286397	PPP1R13B	0.64	18.47	0.59	2.2e-61	Schizophrenia;
BRCA	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg09877947	chr5:131593287	PDLIM4	0.37	7.93	0.3	1.01e-14	Breast cancer;
BRCA	cis	rs6890695	1	rs6890695	chr5:130888424	C/G	cg06307176	chr5:131281290	NA	0.53	10.64	0.39	1.96e-24	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18876405	chr7:65276391	NA	0.55	13.29	0.47	9.4e-36	Aortic root size;
BRCA	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	trans	rs7980799	0.649	rs2389218	chr12:33680929	C/A	cg26384229	chr12:38710491	ALG10B	0.52	10.95	0.4	1.09e-25	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg04025307	chr7:1156635	C7orf50	0.58	9.0	0.34	2.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-9.95	-0.37	8.79e-22	Alzheimer's disease (late onset);
BRCA	trans	rs877282	0.945	rs35342920	chr10:790484	T/C	cg22713356	chr15:30763199	NA	1.42	28.55	0.75	3.22e-116	Uric acid levels;
BRCA	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg26384229	chr12:38710491	ALG10B	0.74	17.77	0.58	1.03e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg12193833	chr17:30244370	NA	-0.56	-8.77	-0.33	1.63e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs738321	0.757	rs4821748	chr22:38541936	G/A	cg25457927	chr22:38595422	NA	-0.36	-12.61	-0.45	1.02e-32	Breast cancer;
BRCA	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg25173405	chr17:45401733	C17orf57	0.52	11.16	0.4	1.46e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.09	-0.34	1.19e-18	Menopause (age at onset);
BRCA	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg04166393	chr7:2884313	GNA12	0.48	9.16	0.34	7e-19	Height;
BRCA	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg08975724	chr8:8085496	FLJ10661	0.52	11.13	0.4	1.95e-26	Mood instability;
BRCA	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg04013093	chr6:42928303	GNMT	-0.27	-8.51	-0.32	1.23e-16	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.54	11.41	0.41	1.44e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg06064525	chr11:970664	AP2A2	-0.3	-8.7	-0.33	2.87e-17	Alzheimer's disease (late onset);
BRCA	cis	rs8014204	0.762	rs10148293	chr14:75296831	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.42	-8.76	-0.33	1.81e-17	Caffeine consumption;
BRCA	cis	rs72781680	0.756	rs2712059	chr2:24020539	T/C	cg08917208	chr2:24149416	ATAD2B	0.57	9.43	0.35	7.39e-20	Lymphocyte counts;
BRCA	trans	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg25214090	chr10:38739885	LOC399744	0.56	12.2	0.43	6.68e-31	Corneal astigmatism;
BRCA	cis	rs1020064	0.636	rs2679883	chr2:105949668	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.42	7.95	0.3	8.73e-15	AIDS;
BRCA	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-15.66	-0.53	5.1e-47	Extrinsic epigenetic age acceleration;
BRCA	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg26587870	chr6:27730563	NA	-0.53	-7.88	-0.3	1.42e-14	Depression;
BRCA	cis	rs631288	0.557	rs4534444	chr1:146679283	T/C	cg25205988	chr1:146714368	CHD1L	0.81	7.86	0.3	1.6e-14	PR interval in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg06115741	chr20:33292138	TP53INP2	0.39	8.58	0.32	7.19e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.56	9.0	0.34	2.59e-18	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11971779	0.752	rs4732371	chr7:139077317	T/A	cg07862535	chr7:139043722	LUC7L2	0.41	11.02	0.4	5.68e-26	Diisocyanate-induced asthma;
BRCA	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11764359	chr7:65958608	NA	-0.65	-14.23	-0.49	4.19e-40	Aortic root size;
BRCA	cis	rs6484504	0.512	rs2774402	chr11:31312897	G/C	cg14844989	chr11:31128820	NA	0.45	10.02	0.37	4.89e-22	Red blood cell count;
BRCA	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg13319975	chr6:146136371	FBXO30	0.35	8.07	0.3	3.42e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg24549020	chr5:56110836	MAP3K1	-0.39	-8.35	-0.31	4.14e-16	Coronary artery disease;
BRCA	trans	rs2018683	0.707	rs1021690	chr7:28974488	A/G	cg19402173	chr7:128379420	CALU	-0.42	-9.92	-0.37	1.1e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	12.09	0.43	1.94e-30	Attention deficit hyperactivity disorder;
BRCA	cis	rs4588572	0.643	rs6453391	chr5:77755035	T/C	cg11547950	chr5:77652471	NA	-0.47	-8.4	-0.32	2.81e-16	Triglycerides;
BRCA	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg14829155	chr15:31115871	NA	-0.41	-9.68	-0.36	8.8e-21	Huntington's disease progression;
BRCA	cis	rs6545883	0.524	rs778159	chr2:61556744	T/C	cg15711740	chr2:61764176	XPO1	0.32	7.86	0.3	1.62e-14	Tuberculosis;
BRCA	cis	rs12541635	0.967	rs11997513	chr8:107093325	C/T	cg10147462	chr8:107024639	NA	-0.29	-7.84	-0.3	1.84e-14	Age of smoking initiation;
BRCA	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg08807101	chr21:30365312	RNF160	0.75	19.73	0.62	5.14e-68	Dental caries;
BRCA	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg23602478	chr1:26503979	CNKSR1	0.23	7.95	0.3	8.44e-15	Height;
BRCA	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg10523679	chr1:76189770	ACADM	-0.59	-11.06	-0.4	4.06e-26	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.74e-18	Motion sickness;
BRCA	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg01689657	chr7:91764605	CYP51A1	0.22	8.05	0.3	3.98e-15	Breast cancer;
BRCA	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg22906224	chr7:99728672	NA	-0.43	-8.09	-0.3	2.95e-15	Coronary artery disease;
BRCA	cis	rs13272623	0.502	rs268594	chr8:71513130	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.43	8.91	0.33	5.17e-18	IgG glycosylation;
BRCA	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.56	-0.52	1.55e-46	Chronic sinus infection;
BRCA	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.46	8.02	0.3	4.98e-15	Mean platelet volume;
BRCA	cis	rs6142102	0.625	rs4012234	chr20:32553047	T/G	cg24642439	chr20:33292090	TP53INP2	0.39	7.82	0.3	2.17e-14	Skin pigmentation;
BRCA	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11890956	chr21:40555474	PSMG1	1.04	29.33	0.76	1.92e-120	Cognitive function;
BRCA	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	12.69	0.45	4.39e-33	Mean platelet volume;
BRCA	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg24060327	chr5:131705240	SLC22A5	-0.49	-10.22	-0.37	8.39e-23	Blood metabolite levels;
BRCA	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg27284194	chr4:1044797	NA	0.44	9.42	0.35	7.8500000000000006e-20	Recombination rate (males);
BRCA	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.3	0.49	1.92e-40	Motion sickness;
BRCA	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4302748	0.862	rs79729347	chr7:36184584	G/A	cg24442661	chr7:36192818	EEPD1	0.49	8.87	0.33	7.24e-18	Platelet count;
BRCA	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg00666640	chr1:248458726	OR2T12	0.33	9.04	0.34	1.9e-18	Common traits (Other);
BRCA	cis	rs4363385	0.747	rs4845508	chr1:152968421	G/C	cg21543102	chr1:152974771	SPRR3	-0.3	-8.3	-0.31	6.13e-16	Inflammatory skin disease;
BRCA	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-11.18	-0.4	1.22e-26	Neuroticism;
BRCA	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg18357645	chr12:58087776	OS9	0.48	13.61	0.47	3.19e-37	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7809950	0.731	rs2712196	chr7:107128797	G/T	cg23024343	chr7:107201750	COG5	-0.49	-10.34	-0.38	2.95e-23	Coronary artery disease;
BRCA	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg06808227	chr14:105710500	BRF1	-0.79	-16.08	-0.54	4.3e-49	Mean platelet volume;Platelet distribution width;
BRCA	trans	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.79	-0.33	1.39e-17	Bladder cancer;
BRCA	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg06640241	chr16:89574553	SPG7	-0.55	-12.33	-0.44	1.72e-31	Multiple myeloma (IgH translocation);
BRCA	trans	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.8	-25.29	-0.71	2.52e-98	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22029157	chr1:209979665	IRF6	0.53	12.09	0.43	1.83e-30	Cleft lip with or without cleft palate;
BRCA	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg03060546	chr3:49711283	APEH	0.6	9.83	0.36	2.5e-21	Menarche (age at onset);
BRCA	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg17063962	chr7:91808500	NA	-0.51	-11.89	-0.43	1.32e-29	Breast cancer;
BRCA	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-15.12	-0.51	2.36e-44	Bipolar disorder and schizophrenia;
BRCA	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg23289794	chr7:2394357	EIF3B	-0.64	-11.97	-0.43	6.36e-30	Multiple sclerosis;
BRCA	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg00106254	chr7:1943704	MAD1L1	-0.39	-9.6	-0.36	1.72e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-7.89	-0.3	1.27e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg12483005	chr1:23474871	LUZP1	0.44	9.81	0.36	2.88e-21	Height;
BRCA	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg15485101	chr11:133734466	NA	0.4	10.08	0.37	2.78e-22	Childhood ear infection;
BRCA	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg05793240	chr7:2802953	GNA12	-0.31	-7.81	-0.3	2.37e-14	Height;
BRCA	cis	rs7524258	0.868	rs2412153	chr1:7272412	C/T	cg07173049	chr1:7289937	CAMTA1	0.48	11.71	0.42	8.08e-29	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg18850127	chr7:39170497	POU6F2	0.49	10.42	0.38	1.36e-23	IgG glycosylation;
BRCA	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.87	-0.33	7.37e-18	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg03060546	chr3:49711283	APEH	0.6	10.31	0.38	3.56e-23	Menarche (age at onset);
BRCA	cis	rs911119	0.954	rs35966482	chr20:23620716	G/T	cg16589663	chr20:23618590	CST3	0.46	8.73	0.33	2.21e-17	Chronic kidney disease;
BRCA	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.85	-0.53	5.78e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9318086	0.663	rs2312295	chr13:24457744	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.3	8.4	0.32	2.79e-16	Myopia (pathological);
BRCA	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg21535247	chr6:8435926	SLC35B3	0.41	9.34	0.35	1.59e-19	Motion sickness;
BRCA	cis	rs1499972	0.887	rs1499970	chr3:117692767	G/A	cg07612923	chr3:117604196	NA	-0.6	-8.14	-0.31	2.14e-15	Schizophrenia;
BRCA	cis	rs3125734	0.633	rs6479791	chr10:63980341	T/C	cg19640130	chr10:64028056	RTKN2	-0.31	-9.07	-0.34	1.4e-18	Rheumatoid arthritis;
BRCA	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg20476274	chr7:133979776	SLC35B4	0.59	16.4	0.54	9.86e-51	Mean platelet volume;
BRCA	cis	rs6028335	0.674	rs57993460	chr20:37662068	C/A	cg16355469	chr20:37678765	NA	0.48	8.67	0.32	3.57e-17	Alcohol and nicotine co-dependence;
BRCA	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg22676075	chr6:135203613	NA	0.44	8.56	0.32	8.6e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg17971929	chr21:40555470	PSMG1	-0.47	-10.42	-0.38	1.38e-23	Menarche (age at onset);
BRCA	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.34	-9.04	-0.34	1.8e-18	Resting heart rate;
BRCA	cis	rs4919087	0.892	rs10882880	chr10:99008068	G/A	cg25902810	chr10:99078978	FRAT1	0.43	9.15	0.34	7.7e-19	Monocyte count;
BRCA	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg14683738	chr19:37701593	ZNF585B	0.45	8.02	0.3	4.94e-15	Coronary artery calcification;
BRCA	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.67	11.34	0.41	2.78e-27	Lung function (FEV1/FVC);
BRCA	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg12591125	chr7:1885375	MAD1L1	0.51	8.93	0.33	4.6e-18	Bipolar disorder;
BRCA	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-13.16	-0.46	3.62e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11644478	chr21:40555479	PSMG1	-0.55	-11.79	-0.42	3.59e-29	Menarche (age at onset);
BRCA	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.71	-0.42	7.78e-29	Gut microbiome composition (summer);
BRCA	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg08601574	chr20:25228251	PYGB	0.33	7.91	0.3	1.14e-14	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs11165623	0.543	rs6656866	chr1:97002238	T/C	cg10631902	chr5:14652156	NA	-0.43	-12.14	-0.43	1.18e-30	Hip circumference;Waist circumference;
BRCA	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg15556689	chr8:8085844	FLJ10661	-0.34	-8.45	-0.32	1.95e-16	Retinal vascular caliber;
BRCA	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg03146154	chr1:46216737	IPP	-0.44	-9.78	-0.36	3.68e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg08213375	chr14:104286397	PPP1R13B	0.63	18.0	0.58	6.9e-59	Schizophrenia;
BRCA	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg02175503	chr12:58329896	NA	0.43	8.48	0.32	1.58e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9473147	0.543	rs13211285	chr6:47479618	C/T	cg12968598	chr6:47444699	CD2AP	0.43	9.51	0.35	3.85e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg25251562	chr2:3704773	ALLC	-0.42	-7.98	-0.3	6.88e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs7572733	0.534	rs1607375	chr2:198800387	C/T	cg00792783	chr2:198669748	PLCL1	0.45	9.89	0.36	1.53e-21	Dermatomyositis;
BRCA	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg08601574	chr20:25228251	PYGB	0.35	8.23	0.31	1.02e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs16866061	1.000	rs10933068	chr2:225418360	G/A	cg12698349	chr2:225449008	CUL3	0.78	21.58	0.65	5.64e-78	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs2859741	0.967	rs494157	chr1:37512995	C/T	cg09363841	chr1:37513479	NA	0.68	17.65	0.57	4.49e-57	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs4845875	0.600	rs6696752	chr1:11835935	T/C	cg24844545	chr1:11908347	NPPA	0.38	8.75	0.33	1.82e-17	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg15395560	chr15:45543142	SLC28A2	-0.29	-7.83	-0.3	2.02e-14	Uric acid levels;
BRCA	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg07169764	chr2:136633963	MCM6	1.31	26.09	0.72	9.68e-103	Corneal structure;
BRCA	trans	rs4596713	0.538	rs7048094	chr9:71745660	G/C	cg16512924	chr15:28394682	HERC2	0.4	9.45	0.35	6.24e-20	Headache;
BRCA	cis	rs911119	1.000	rs5030707	chr20:23618656	C/G	cg16589663	chr20:23618590	CST3	0.47	8.84	0.33	9.27e-18	Chronic kidney disease;
BRCA	trans	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg06521331	chr12:34319734	NA	-0.46	-8.73	-0.33	2.23e-17	Bladder cancer;
BRCA	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg00071950	chr4:10020882	SLC2A9	0.54	13.35	0.47	4.83e-36	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.48	0.35	4.92e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08564027	chr20:61660810	NA	0.84	22.69	0.67	4.62e-84	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10819733	chr22:24237672	NA	-0.3	-8.44	-0.32	2.08e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg23711669	chr6:146136114	FBXO30	0.74	17.02	0.56	7.93e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.6	9.63	0.36	1.39e-20	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs490234	0.812	rs4329365	chr9:128445758	A/C	cg14078157	chr9:128172775	NA	-0.45	-10.03	-0.37	4.39e-22	Mean arterial pressure;
BRCA	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg07169764	chr2:136633963	MCM6	1.32	32.94	0.79	7.3e-140	Corneal structure;
BRCA	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.61	14.75	0.5	1.35e-42	Colorectal cancer;
BRCA	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg06453172	chr10:134556979	INPP5A	-0.58	-12.15	-0.43	1.04e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg26384229	chr12:38710491	ALG10B	-0.46	-10.53	-0.38	5.05e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.52	9.12	0.34	9.47e-19	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg17366294	chr4:99064904	C4orf37	0.41	9.7	0.36	7.41e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13102973	0.965	rs11099306	chr4:135895674	A/G	cg14419869	chr4:135874104	NA	0.52	10.97	0.4	9.3e-26	Subjective well-being;
BRCA	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg20933634	chr6:27740509	NA	-0.41	-7.85	-0.3	1.76e-14	Parkinson's disease;
BRCA	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg10932868	chr11:921992	NA	0.38	9.03	0.34	1.93e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.05	0.3	3.98e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg24006582	chr15:45444508	DUOX1	0.54	10.55	0.39	4.14e-24	Uric acid levels;
BRCA	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg17366294	chr4:99064904	C4orf37	0.52	11.54	0.42	4.23e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-13.52	-0.47	8.46e-37	Bipolar disorder and schizophrenia;
BRCA	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg11843238	chr5:131593191	PDLIM4	0.38	9.34	0.35	1.56e-19	Acylcarnitine levels;
BRCA	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	12.62	0.45	9.24e-33	Ileal carcinoids;
BRCA	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg18964960	chr10:1102726	WDR37	-0.58	-7.87	-0.3	1.5e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs250677	0.522	rs11954893	chr5:148392362	A/G	cg18129178	chr5:148520854	ABLIM3	-0.54	-10.53	-0.38	5.23e-24	Breast cancer;
BRCA	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg13334819	chr7:99746414	C7orf59	0.45	10.49	0.38	7.52e-24	Coronary artery disease;
BRCA	cis	rs877282	0.945	rs35342920	chr10:790484	T/C	cg17470449	chr10:769945	NA	0.51	8.62	0.32	5.29e-17	Uric acid levels;
BRCA	trans	rs6479891	1.000	rs7899715	chr10:65078455	T/C	cg14819942	chr15:35414228	NA	-0.34	-8.48	-0.32	1.62e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.4	0.5	6.27e-41	Motion sickness;
BRCA	cis	rs10751667	0.560	rs10902267	chr11:1007831	T/C	cg06064525	chr11:970664	AP2A2	-0.28	-8.22	-0.31	1.12e-15	Alzheimer's disease (late onset);
BRCA	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg23711669	chr6:146136114	FBXO30	0.71	17.15	0.56	1.55e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg09658497	chr7:2847517	GNA12	-0.4	-8.57	-0.32	8e-17	Height;
BRCA	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg08917208	chr2:24149416	ATAD2B	0.57	9.07	0.34	1.43e-18	Lymphocyte counts;
BRCA	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11644478	chr21:40555479	PSMG1	-0.66	-14.23	-0.49	3.94e-40	Cognitive function;
BRCA	cis	rs6484504	0.576	rs208067	chr11:31153578	C/T	cg06552810	chr11:31128660	NA	-0.38	-8.41	-0.32	2.64e-16	Red blood cell count;
BRCA	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.2	0.31	1.29e-15	Cognitive ability;
BRCA	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs939658	0.935	rs2204069	chr15:79449335	A/G	cg17916960	chr15:79447300	NA	0.43	10.72	0.39	9.4e-25	Refractive error;
BRCA	trans	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg26043149	chr18:55253948	FECH	0.39	8.44	0.32	2.2e-16	Bone mineral density;
BRCA	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.51e-36	High light scatter reticulocyte count;
BRCA	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.66e-18	Motion sickness;
BRCA	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg07395648	chr5:131743802	NA	-0.38	-8.27	-0.31	7.67e-16	Breast cancer;
BRCA	cis	rs12541635	1.000	rs2881037	chr8:107090901	C/T	cg10147462	chr8:107024639	NA	-0.3	-8.24	-0.31	9.5e-16	Age of smoking initiation;
BRCA	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg02176678	chr2:219576539	TTLL4	0.39	10.4	0.38	1.64e-23	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg27446573	chr6:127587934	RNF146	0.89	20.41	0.63	1.09e-71	Breast cancer;
BRCA	trans	rs57046232	0.552	rs6054166	chr20:6348251	A/C	cg21095983	chr6:86352623	SYNCRIP	0.38	7.98	0.3	6.64e-15	Colorectal cancer;
BRCA	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg24069376	chr3:38537580	EXOG	0.32	8.83	0.33	1e-17	Electrocardiographic conduction measures;
BRCA	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg11663144	chr21:46675770	NA	-0.61	-14.16	-0.49	8.39e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs6782228	0.651	rs9289332	chr3:128387884	C/G	cg16766828	chr3:128327626	NA	-0.43	-9.49	-0.35	4.68e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg03060546	chr3:49711283	APEH	-0.54	-10.99	-0.4	7.38e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg14789911	chr21:47582049	C21orf56	-0.36	-7.84	-0.3	1.83e-14	Testicular germ cell tumor;
BRCA	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg16109817	chr1:16162209	FLJ37453	0.3	8.31	0.31	5.64e-16	Systolic blood pressure;
BRCA	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24549020	chr5:56110836	MAP3K1	0.66	13.4	0.47	3.01e-36	Initial pursuit acceleration;
BRCA	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg06618935	chr21:46677482	NA	-0.38	-8.56	-0.32	8.68e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg06618935	chr21:46677482	NA	0.36	7.91	0.3	1.1e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10037055	1.000	rs6886255	chr5:176718361	A/G	cg06733329	chr5:176740039	MXD3	-0.41	-9.75	-0.36	4.78e-21	Migraine without aura;
BRCA	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg09184832	chr6:79620586	NA	-0.53	-11.52	-0.41	4.77e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs4908768	0.539	rs11121205	chr1:8658085	G/A	cg20416874	chr1:8611966	RERE	-0.28	-7.86	-0.3	1.64e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs1003719	0.743	rs2835615	chr21:38497303	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.25	-0.49	3.38e-40	Eye color traits;
BRCA	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg26608667	chr7:1196370	ZFAND2A	0.38	9.18	0.34	5.92e-19	Longevity;Endometriosis;
BRCA	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-15.96	-0.53	1.63e-48	Total cholesterol levels;
BRCA	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg26384229	chr12:38710491	ALG10B	-0.55	-13.14	-0.46	4.58e-35	Morning vs. evening chronotype;
BRCA	trans	rs7939886	0.764	rs11227350	chr11:55912289	T/C	cg15704280	chr7:45808275	SEPT13	0.63	7.84	0.3	1.88e-14	Myopia (pathological);
BRCA	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg24130564	chr14:104152367	KLC1	-0.41	-8.84	-0.33	9.14e-18	Reticulocyte count;
BRCA	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	13.38	0.47	3.61e-36	Height;
BRCA	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg07169764	chr2:136633963	MCM6	1.28	28.6	0.75	1.86e-116	Corneal structure;
BRCA	cis	rs2732480	0.538	rs2468943	chr12:48747249	G/T	cg04545296	chr12:48745243	ZNF641	-0.25	-8.4	-0.32	2.9e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg24675658	chr1:53192096	ZYG11B	0.83	18.75	0.6	7.51e-63	Monocyte count;
BRCA	cis	rs7254827	0.868	rs3745349	chr19:17212992	C/T	cg19418318	chr19:17219073	MYO9B	-0.51	-10.34	-0.38	2.79e-23	Mean platelet volume;
BRCA	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg11168104	chr5:1857477	NA	-0.33	-8.88	-0.33	6.46e-18	Cardiovascular disease risk factors;
BRCA	cis	rs9473147	0.516	rs9463342	chr6:47585106	A/T	cg12968598	chr6:47444699	CD2AP	0.44	9.58	0.35	2.15e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg25173405	chr17:45401733	C17orf57	0.48	9.81	0.36	2.87e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg26384229	chr12:38710491	ALG10B	-0.45	-10.73	-0.39	8.24e-25	Morning vs. evening chronotype;
BRCA	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg21226059	chr5:178986404	RUFY1	-0.53	-15.07	-0.51	3.79e-44	Lung cancer;
BRCA	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg22713356	chr15:30763199	NA	1.35	27.49	0.74	2.15e-110	Uric acid levels;
BRCA	cis	rs72928364	1.000	rs41273553	chr3:100617532	T/C	cg10123952	chr3:100791384	NA	0.54	7.95	0.3	8.19e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.46	0.38	9.2e-24	IgG glycosylation;
BRCA	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg08885076	chr2:99613938	TSGA10	0.53	11.78	0.42	3.88e-29	Chronic sinus infection;
BRCA	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg22117172	chr7:91764530	CYP51A1	-0.23	-7.87	-0.3	1.47e-14	Breast cancer;
BRCA	cis	rs17095355	1.000	rs17126890	chr10:111699169	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.39	-10.32	-0.38	3.24e-23	Biliary atresia;
BRCA	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg18230493	chr5:56204884	C5orf35	-0.72	-14.03	-0.49	3.47e-39	Initial pursuit acceleration;
BRCA	cis	rs9837602	0.688	rs793488	chr3:99495567	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-10.79	-0.39	4.67e-25	Breast cancer;
BRCA	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-10.06	-0.37	3.32e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg05535760	chr7:792225	HEATR2	0.71	13.04	0.46	1.21e-34	Cerebrospinal P-tau181p levels;
BRCA	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg19784903	chr17:45786737	TBKBP1	-0.34	-8.02	-0.3	4.92e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg23029597	chr12:123009494	RSRC2	-0.48	-9.56	-0.35	2.57e-20	Body mass index;
BRCA	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg24562669	chr7:97807699	LMTK2	0.45	11.96	0.43	6.76e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg23602478	chr1:26503979	CNKSR1	0.23	8.03	0.3	4.83e-15	Height;
BRCA	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg09467607	chr2:36825704	FEZ2	-0.55	-13.86	-0.48	2.09e-38	Height;
BRCA	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg06784218	chr1:46089804	CCDC17	-0.53	-12.92	-0.45	4.51e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg07460842	chr6:66804631	NA	0.77	14.02	0.48	4.08e-39	Exhaled nitric oxide levels;
BRCA	trans	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg26043149	chr18:55253948	FECH	1.09	23.48	0.68	2.32e-88	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00149659	chr3:10157352	C3orf10	0.77	13.14	0.46	4.31e-35	Alzheimer's disease;
BRCA	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg15605315	chr1:45957053	TESK2	0.49	10.21	0.37	8.77e-23	High light scatter reticulocyte count;
BRCA	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg21856205	chr7:94953877	PON1	-0.37	-7.89	-0.3	1.31e-14	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg08000102	chr2:233561755	GIGYF2	-0.47	-10.43	-0.38	1.26e-23	Coronary artery disease;
BRCA	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg03060546	chr3:49711283	APEH	0.6	10.21	0.37	8.9e-23	Menarche (age at onset);
BRCA	trans	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg26043149	chr18:55253948	FECH	-0.37	-8.21	-0.31	1.2e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg18132916	chr6:79620363	NA	-0.45	-9.96	-0.37	8.37e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05901451	chr6:126070800	HEY2	0.41	10.01	0.37	5.02e-22	Endometrial cancer;
BRCA	cis	rs3820928	0.839	rs13404750	chr2:227876129	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.79	-0.33	1.33e-17	Pulmonary function;
BRCA	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg07262247	chr5:131593730	PDLIM4	0.34	7.87	0.3	1.51e-14	Acylcarnitine levels;
BRCA	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg23505145	chr19:12996616	KLF1	0.54	12.33	0.44	1.69e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg19077165	chr18:44547161	KATNAL2	-0.58	-12.73	-0.45	2.98e-33	Personality dimensions;
BRCA	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-9.74	-0.36	5.49e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02353165	chr6:42928485	GNMT	0.78	18.84	0.6	2.77e-63	Plasma homocysteine levels (post-methionine load test);
BRCA	trans	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.5	-0.32	1.33e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg08999081	chr20:33150536	PIGU	0.5	14.01	0.48	4.45e-39	Coronary artery disease;
BRCA	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-9.46	-0.35	5.67e-20	Joint mobility (Beighton score);
BRCA	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.68	0.61	9.04e-68	Alzheimer's disease;
BRCA	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg08885076	chr2:99613938	TSGA10	-0.57	-12.88	-0.45	6.45e-34	Chronic sinus infection;
BRCA	cis	rs7572733	0.515	rs700675	chr2:198700216	G/A	cg00792783	chr2:198669748	PLCL1	0.47	10.17	0.37	1.28e-22	Dermatomyositis;
BRCA	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg04944784	chr2:26401820	FAM59B	-0.85	-13.27	-0.46	1.19e-35	Gut microbiome composition (summer);
BRCA	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg18132916	chr6:79620363	NA	-0.45	-10.16	-0.37	1.44e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg12310025	chr6:25882481	NA	-0.38	-8.79	-0.33	1.32e-17	Height;
BRCA	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg22903471	chr2:27725779	GCKR	-0.35	-8.51	-0.32	1.24e-16	Total body bone mineral density;
BRCA	cis	rs10463316	0.832	rs246486	chr5:150727880	C/T	cg03212797	chr5:150827313	SLC36A1	0.48	9.41	0.35	8.64e-20	Metabolite levels (Pyroglutamine);
BRCA	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg08755490	chr11:65554678	OVOL1	0.53	10.97	0.4	8.98e-26	Acne (severe);
BRCA	cis	rs34293785	1.000	rs34293785	chr1:66137192	T/C	cg04111102	chr1:66153794	NA	0.36	8.71	0.33	2.67e-17	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;
BRCA	cis	rs7091068	0.616	rs4322326	chr10:95483382	A/T	cg20715218	chr10:95462985	C10orf4	0.46	8.57	0.32	7.96e-17	Urinary tract infection frequency;
BRCA	cis	rs6032067	0.673	rs13042474	chr20:43893068	G/T	cg20256260	chr20:43936981	MATN4;RBPJL	0.34	8.19	0.31	1.47e-15	Blood protein levels;
BRCA	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg20219911	chr3:52813652	ITIH1	0.29	7.83	0.3	1.97e-14	Electroencephalogram traits;
BRCA	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg06115741	chr20:33292138	TP53INP2	0.38	8.46	0.32	1.86e-16	Glomerular filtration rate (creatinine);
BRCA	trans	rs61931739	0.927	rs12315970	chr12:34038535	A/G	cg26384229	chr12:38710491	ALG10B	-0.41	-9.33	-0.35	1.76e-19	Morning vs. evening chronotype;
BRCA	cis	rs9986765	1.000	rs73452570	chr7:142817482	T/A	cg22531018	chr7:142981779	TMEM139	0.58	9.61	0.36	1.58e-20	Cancer;Dermatomyositis;
BRCA	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	9.1e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.06e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	9.69	0.36	8.32e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs3771570	0.901	rs4075818	chr2:242432142	T/C	cg21155796	chr2:242212141	HDLBP	0.63	9.7	0.36	7.62e-21	Prostate cancer;
BRCA	cis	rs752010	0.714	rs7515948	chr1:42079046	T/G	cg06885757	chr1:42089581	HIVEP3	0.28	10.24	0.38	6.6e-23	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs30380	0.632	rs27434	chr5:96129512	A/G	cg16492584	chr5:96139282	ERAP1	-0.46	-10.95	-0.4	1.04e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs72772090	0.522	rs76961889	chr5:95987932	G/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-8.15	-0.31	1.91e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs919433	0.783	rs787979	chr2:198242868	A/T	cg00792783	chr2:198669748	PLCL1	0.35	7.92	0.3	1.09e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg17063962	chr7:91808500	NA	0.54	12.91	0.45	4.89e-34	Breast cancer;
BRCA	cis	rs2479724	0.818	rs9357369	chr6:41818202	A/C	cg17623882	chr6:41773611	USP49	-0.38	-10.33	-0.38	2.97e-23	Menarche (age at onset);
BRCA	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-13.35	-0.47	4.84e-36	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg22705602	chr4:152727874	NA	-0.38	-10.5	-0.38	6.91e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg21475434	chr5:93447410	FAM172A	-0.71	-8.9	-0.33	5.79e-18	Diabetic retinopathy;
BRCA	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg02951883	chr7:2050386	MAD1L1	-0.35	-8.04	-0.3	4.43e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs600806	0.745	rs4246517	chr1:110007636	G/C	cg20591472	chr1:110008990	SYPL2	0.33	8.38	0.31	3.29e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg13010199	chr12:38710504	ALG10B	0.5	10.4	0.38	1.68e-23	Bladder cancer;
BRCA	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg23505145	chr19:12996616	KLF1	0.53	11.99	0.43	5.27e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg13047869	chr3:10149882	C3orf24	0.6	12.76	0.45	2.33e-33	Alzheimer's disease;
BRCA	cis	rs9290065	0.519	rs1530636	chr3:160697442	A/G	cg03342759	chr3:160939853	NMD3	0.47	9.49	0.35	4.38e-20	Kawasaki disease;
BRCA	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg26597838	chr10:835615	NA	-1.0	-17.46	-0.57	3.92e-56	Eosinophil percentage of granulocytes;
BRCA	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-9.84	-0.36	2.22e-21	Schizophrenia;
BRCA	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg00677455	chr12:58241039	CTDSP2	0.63	15.54	0.52	1.94e-46	Multiple sclerosis;
BRCA	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg13628971	chr7:2884303	GNA12	0.39	8.47	0.32	1.72e-16	Height;
BRCA	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	12.01	0.43	4.17e-30	Tonsillectomy;
BRCA	cis	rs35661897	0.920	rs4490174	chr2:227325171	G/A	cg03426602	chr2:227312417	NA	-0.5	-8.09	-0.3	3.11e-15	Urinary tract infection frequency;
BRCA	cis	rs2294693	0.891	rs9369256	chr6:40998344	G/C	cg14418226	chr6:40996092	UNC5CL	0.47	8.57	0.32	7.82e-17	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs6834538	0.597	rs9991830	chr4:113485372	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.41	9.77	0.36	4.3e-21	Free thyroxine concentration;
BRCA	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-10.44	-0.38	1.16e-23	Mood instability;
BRCA	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.32	8.02	0.3	5.22e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg20701182	chr2:24300061	SF3B14	0.63	8.97	0.33	3.36e-18	Lymphocyte counts;
BRCA	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg25174290	chr11:3078921	CARS	-0.43	-12.78	-0.45	1.76e-33	Longevity;
BRCA	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.64	10.15	0.37	1.55e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs1997103	1.000	rs12532070	chr7:55407698	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-12.76	-0.45	2.2e-33	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	8.83	0.33	1.02e-17	Mean corpuscular volume;
BRCA	cis	rs10046574	0.831	rs77693675	chr7:135142402	T/C	cg27474649	chr7:135195673	CNOT4	0.61	8.71	0.33	2.65e-17	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.93	0.46	3.84e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg23649088	chr2:200775458	C2orf69	0.59	8.66	0.32	3.85e-17	Schizophrenia;
BRCA	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg03477792	chr4:77819574	ANKRD56	0.64	15.42	0.52	7.8e-46	Emphysema distribution in smoking;
BRCA	cis	rs7131987	0.683	rs7954278	chr12:29459290	G/A	cg09582351	chr12:29534625	ERGIC2	-0.44	-10.36	-0.38	2.36e-23	QT interval;
BRCA	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg03585969	chr10:35415529	CREM	-0.49	-10.26	-0.38	5.62e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.7	10.61	0.39	2.47e-24	Lung function (FEV1/FVC);
BRCA	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18876405	chr7:65276391	NA	0.5	11.1	0.4	2.63e-26	Aortic root size;
BRCA	cis	rs7395581	0.918	rs3847502	chr11:47333685	C/A	cg25783544	chr11:47291846	MADD	0.42	9.52	0.35	3.6e-20	HDL cholesterol;
BRCA	cis	rs13082711	0.554	rs35840701	chr3:27334231	A/C	cg02860705	chr3:27208620	NA	0.75	13.91	0.48	1.24e-38	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg09658497	chr7:2847517	GNA12	-0.48	-10.62	-0.39	2.21e-24	Plateletcrit;
BRCA	cis	rs11690935	0.851	rs7573003	chr2:172741415	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.81	-23.79	-0.69	4.31e-90	Schizophrenia;
BRCA	cis	rs870825	0.929	rs55746424	chr4:185589603	C/T	cg20176042	chr4:185552304	CASP3	-0.6	-8.12	-0.31	2.37e-15	Blood protein levels;
BRCA	cis	rs9649465	1.000	rs2896334	chr7:123367705	A/C	cg04330084	chr7:123175371	IQUB	-0.31	-8.54	-0.32	9.74e-17	Migraine;
BRCA	trans	rs3960554	0.808	rs11983987	chr7:75657850	A/G	cg19862616	chr7:65841803	NCRNA00174	0.58	12.21	0.43	5.66e-31	Eotaxin levels;
BRCA	trans	rs61931739	1.000	rs11052989	chr12:34057614	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-9.17	-0.34	6.25e-19	Morning vs. evening chronotype;
BRCA	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg12463550	chr7:65579703	CRCP	-0.37	-8.04	-0.3	4.23e-15	Aortic root size;
BRCA	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-14.17	-0.49	7.88e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.71	10.88	0.4	2.03e-25	Lung function (FEV1/FVC);
BRCA	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg22713356	chr15:30763199	NA	1.2	24.44	0.7	1.23e-93	Uric acid levels;
BRCA	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg10057126	chr4:77819792	ANKRD56	0.65	15.17	0.51	1.24e-44	Emphysema distribution in smoking;
BRCA	cis	rs3820928	0.874	rs4234066	chr2:227882180	G/A	cg11843606	chr2:227700838	RHBDD1	-0.36	-7.95	-0.3	8.19e-15	Pulmonary function;
BRCA	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.56	11.9	0.43	1.23e-29	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs11785693	0.862	rs6995565	chr8:4990461	C/T	cg26367366	chr8:4980734	NA	-0.57	-9.83	-0.36	2.56e-21	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg12573674	chr2:1569213	NA	-0.56	-12.3	-0.44	2.4e-31	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg23791538	chr6:167370224	RNASET2	-0.44	-11.01	-0.4	6.36e-26	Crohn's disease;
BRCA	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg21782813	chr7:2030301	MAD1L1	0.34	9.09	0.34	1.23e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg18512352	chr11:47633146	NA	-0.36	-8.99	-0.34	2.74e-18	Subjective well-being;
BRCA	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.46	10.19	0.37	1.08e-22	Cognitive ability;
BRCA	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg15501526	chr10:2543763	NA	0.56	13.79	0.48	4.55e-38	Age-related hearing impairment;
BRCA	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg08992911	chr2:238395768	MLPH	0.53	8.31	0.31	5.62e-16	Prostate cancer;
BRCA	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg26031613	chr14:104095156	KLC1	0.44	8.73	0.33	2.14e-17	Schizophrenia;
BRCA	trans	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg25214090	chr10:38739885	LOC399744	0.45	10.38	0.38	2.04e-23	Corneal astigmatism;
BRCA	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg08213375	chr14:104286397	PPP1R13B	0.63	18.06	0.58	3.25e-59	Schizophrenia;
BRCA	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg06636001	chr8:8085503	FLJ10661	0.47	10.27	0.38	5.37e-23	Joint mobility (Beighton score);
BRCA	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs427394	1.000	rs427394	chr5:6745875	A/G	cg10857441	chr5:6722123	POLS	-0.31	-10.29	-0.38	4.26e-23	Menopause (age at onset);
BRCA	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.66	-0.32	3.85e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.49	-0.32	1.4e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.55	-10.0	-0.37	5.66e-22	Renal function-related traits (BUN);
BRCA	cis	rs7191700	0.511	rs8043625	chr16:11361895	C/G	cg00044050	chr16:11439710	C16orf75	-0.42	-9.72	-0.36	6.13e-21	Multiple sclerosis;
BRCA	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg03709012	chr19:19516395	GATAD2A	-0.8	-18.43	-0.59	3.95e-61	Tonsillectomy;
BRCA	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg18446336	chr7:2847575	GNA12	-0.35	-8.31	-0.31	5.85e-16	Height;
BRCA	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg04362960	chr10:104952993	NT5C2	0.43	10.32	0.38	3.32e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs897080	0.515	rs1067319	chr2:44633458	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.41	0.35	8.74e-20	Height;
BRCA	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg16586182	chr3:47516702	SCAP	-0.56	-12.96	-0.46	2.81e-34	Colorectal cancer;
BRCA	cis	rs2108225	0.900	rs2051956	chr7:107441358	G/C	cg18560240	chr7:107437656	SLC26A3	-0.56	-11.72	-0.42	7.12e-29	Ulcerative colitis;
BRCA	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg27170947	chr2:26402098	FAM59B	-0.7	-11.81	-0.42	3.07e-29	Gut microbiome composition (summer);
BRCA	trans	rs12517041	1.000	rs2081950	chr5:23287505	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.36	-0.31	4.04e-16	Calcium levels;
BRCA	cis	rs10992471	0.528	rs7860786	chr9:95245473	C/T	cg14631576	chr9:95140430	CENPP	-0.33	-8.41	-0.32	2.68e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg19196401	chr6:110721138	DDO	-0.41	-10.23	-0.38	7.51e-23	Platelet distribution width;
BRCA	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08219700	chr8:58056026	NA	0.54	8.9	0.33	5.58e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9986765	0.867	rs1994498	chr7:142816448	C/T	cg15652212	chr7:142981776	TMEM139	0.57	9.4	0.35	9.23e-20	Cancer;Dermatomyositis;
BRCA	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg20503657	chr10:835505	NA	0.9	16.21	0.54	9.56e-50	Eosinophil percentage of granulocytes;
BRCA	cis	rs4466137	0.903	rs3734092	chr5:83016743	C/T	cg15083037	chr5:83017644	HAPLN1	-0.54	-10.92	-0.4	1.49e-25	Prostate cancer;
BRCA	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.85	0.33	8.55e-18	Motion sickness;
BRCA	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.71	0.55	2.93e-52	Hypertriglyceridemia;
BRCA	cis	rs34779708	0.702	rs7087150	chr10:35542138	A/T	cg03585969	chr10:35415529	CREM	0.45	9.23	0.34	3.93e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg24675658	chr1:53192096	ZYG11B	-0.69	-14.79	-0.5	9.16e-43	Monocyte count;
BRCA	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.32	-0.44	1.93e-31	Bipolar disorder;
BRCA	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24549020	chr5:56110836	MAP3K1	0.67	13.55	0.47	6.1e-37	Initial pursuit acceleration;
BRCA	cis	rs10782582	0.609	rs5745543	chr1:76365111	A/T	cg03433033	chr1:76189801	ACADM	-0.38	-7.97	-0.3	7.45e-15	Daytime sleep phenotypes;
BRCA	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg09307838	chr4:120376055	NA	0.61	12.31	0.44	2.23e-31	Corneal astigmatism;
BRCA	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg10057126	chr4:77819792	ANKRD56	0.65	14.76	0.5	1.2e-42	Emphysema distribution in smoking;
BRCA	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg22980127	chr19:33182716	NUDT19	0.9	18.16	0.58	9.86e-60	Red blood cell traits;
BRCA	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26314531	chr2:26401878	FAM59B	0.95	16.58	0.55	1.33e-51	Gut microbiome composition (summer);
BRCA	cis	rs7246657	0.653	rs10401525	chr19:37658979	C/G	cg18154014	chr19:37997991	ZNF793	0.54	8.99	0.34	2.81e-18	Coronary artery calcification;
BRCA	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg22980127	chr19:33182716	NUDT19	0.9	17.54	0.57	1.69e-56	Red blood cell traits;
BRCA	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg15017067	chr4:17643749	FAM184B	0.33	10.12	0.37	1.91e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03517284	chr6:25882590	NA	-0.46	-9.64	-0.36	1.27e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg11764359	chr7:65958608	NA	0.64	10.96	0.4	9.82e-26	Aortic root size;
BRCA	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg11707556	chr5:10655725	ANKRD33B	0.4	8.55	0.32	9.24e-17	Coronary artery disease;
BRCA	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg18402987	chr7:1209562	NA	0.67	11.68	0.42	1.07e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.5	0.32	1.34e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg08085267	chr17:45401833	C17orf57	-0.64	-13.91	-0.48	1.36e-38	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08219700	chr8:58056026	NA	0.44	8.0	0.3	5.75e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs11229555	0.645	rs12272911	chr11:58183839	G/C	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6782228	0.585	rs2811492	chr3:128356279	A/G	cg16766828	chr3:128327626	NA	-0.43	-9.68	-0.36	9.36e-21	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.99	21.22	0.64	4.87e-76	Gut microbiome composition (summer);
BRCA	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	18.33	0.59	1.3e-60	Hip circumference adjusted for BMI;
BRCA	cis	rs7553864	0.614	rs10493796	chr1:87614175	A/G	cg17420885	chr1:87600446	LOC339524	0.4	7.96	0.3	7.78e-15	Smoking behavior;
BRCA	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg10295955	chr4:187884368	NA	-0.9	-26.24	-0.72	1.48e-103	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.46e-34	Alzheimer's disease (late onset);
BRCA	cis	rs72781680	0.716	rs2712065	chr2:23973603	C/T	cg08917208	chr2:24149416	ATAD2B	-0.54	-9.18	-0.34	5.91e-19	Lymphocyte counts;
BRCA	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.49e-52	Hypertriglyceridemia;
BRCA	cis	rs1568889	1.000	rs78140392	chr11:28203231	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	13.3	0.47	8.19e-36	Bipolar disorder;
BRCA	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-12.7	-0.45	4.2e-33	Response to antipsychotic treatment;
BRCA	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.53	-11.02	-0.4	5.67e-26	Lymphocyte counts;
BRCA	cis	rs477692	0.549	rs7098548	chr10:131455028	A/G	cg05714579	chr10:131428358	MGMT	-0.45	-9.84	-0.36	2.27e-21	Response to temozolomide;
BRCA	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-8.96	-0.33	3.63e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	25.66	0.71	2.38e-100	Chronic sinus infection;
BRCA	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg09307838	chr4:120376055	NA	-0.68	-13.55	-0.47	6.02e-37	Corneal astigmatism;
BRCA	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18876405	chr7:65276391	NA	0.58	14.5	0.5	2.06e-41	Aortic root size;
BRCA	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg07080220	chr10:102295463	HIF1AN	0.65	12.92	0.46	4.1e-34	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs965469	0.779	rs6051683	chr20:3237822	G/C	cg25506879	chr20:3388711	C20orf194	-0.44	-8.73	-0.33	2.27e-17	IFN-related cytopenia;
BRCA	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-13.54	-0.47	6.62e-37	Bladder cancer;
BRCA	cis	rs6087771	0.926	rs6058431	chr20:30297133	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	18.56	0.59	7.93e-62	Subcortical brain region volumes;Putamen volume;
BRCA	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg21770322	chr7:97807741	LMTK2	0.42	11.1	0.4	2.55e-26	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg15819921	chr19:927150	ARID3A	-0.48	-9.17	-0.34	6.5e-19	Life satisfaction;
BRCA	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg09065629	chr16:1709722	CRAMP1L	0.36	8.37	0.31	3.59e-16	Coronary artery disease;
BRCA	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg24060327	chr5:131705240	SLC22A5	-0.63	-12.27	-0.44	3.2e-31	Breast cancer;
BRCA	cis	rs2274273	1.000	rs6573006	chr14:55610432	T/C	cg04306507	chr14:55594613	LGALS3	0.32	9.0	0.34	2.57e-18	Protein biomarker;
BRCA	cis	rs965469	1.000	rs2281497	chr20:3258874	G/A	cg25506879	chr20:3388711	C20orf194	-0.53	-10.56	-0.39	3.93e-24	IFN-related cytopenia;
BRCA	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg15698299	chr3:52233019	ALAS1	-0.4	-9.61	-0.36	1.58e-20	Electroencephalogram traits;
BRCA	cis	rs4478858	0.735	rs7556340	chr1:31788453	A/T	cg00250761	chr1:31883323	NA	-0.3	-7.93	-0.3	9.88e-15	Alcohol dependence;
BRCA	cis	rs870825	1.000	rs9995633	chr4:185584441	C/T	cg04058563	chr4:185651563	MLF1IP	0.69	12.56	0.45	1.65e-32	Blood protein levels;
BRCA	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	12.02	0.43	3.77e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2742234	0.955	rs2435385	chr10:43665750	A/G	cg02780029	chr10:43622663	RET	-0.39	-9.55	-0.35	2.82e-20	Hirschsprung disease;
BRCA	cis	rs11785693	0.862	rs17435605	chr8:4987302	A/G	cg26367366	chr8:4980734	NA	0.63	11.37	0.41	2.14e-27	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	trans	rs6600671	0.899	rs11249432	chr1:121283476	T/A	cg00646200	chr1:148855367	NA	0.32	8.13	0.31	2.2e-15	Hip geometry;
BRCA	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00166722	chr3:10149974	C3orf24	0.67	13.3	0.47	8.21e-36	Alzheimer's disease;
BRCA	cis	rs6120849	0.754	rs3746436	chr20:33586193	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	10.35	0.38	2.61e-23	Protein C levels;
BRCA	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg21518248	chr2:162101506	NA	-0.47	-10.13	-0.37	1.78e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs4891159	0.790	rs35516239	chr18:74129942	C/T	cg24786174	chr18:74118243	ZNF516	-0.76	-18.61	-0.59	4.07e-62	Longevity;
BRCA	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-11.07	-0.4	3.59e-26	IgG glycosylation;
BRCA	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg27170947	chr2:26402098	FAM59B	0.93	16.66	0.55	4.84e-52	Gut microbiome composition (summer);
BRCA	cis	rs9560113	1.000	rs9555810	chr13:112181437	C/G	cg10483660	chr13:112241077	NA	0.32	8.02	0.3	5.06e-15	Menarche (age at onset);
BRCA	cis	rs68170813	0.523	rs79619227	chr7:107025335	T/C	cg02696742	chr7:106810147	HBP1	-0.54	-8.6	-0.32	6.19e-17	Coronary artery disease;
BRCA	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg09469691	chr10:81107165	PPIF	0.5	10.5	0.38	6.62e-24	Height;
BRCA	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.27e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg25174290	chr11:3078921	CARS	0.44	13.35	0.47	5.15e-36	Longevity;
BRCA	cis	rs4561483	0.801	rs33637	chr16:11989875	A/T	cg08843971	chr16:11963173	GSPT1	-0.52	-11.97	-0.43	6.16e-30	Testicular germ cell tumor;
BRCA	trans	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.29	0.31	6.69e-16	Mean corpuscular volume;
BRCA	cis	rs9549260	0.753	rs9532563	chr13:41160270	T/C	cg21288729	chr13:41239152	FOXO1	0.55	9.18	0.34	5.85e-19	Red blood cell count;
BRCA	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	9.06	0.34	1.6e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08859206	chr1:53392774	SCP2	-0.59	-12.81	-0.45	1.39e-33	Monocyte count;
BRCA	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.94e-24	Motion sickness;
BRCA	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg01181863	chr3:195395398	SDHAP2	-0.46	-8.05	-0.3	4.19e-15	Pancreatic cancer;
BRCA	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg16586182	chr3:47516702	SCAP	0.51	11.42	0.41	1.27e-27	Colorectal cancer;
BRCA	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg08885076	chr2:99613938	TSGA10	0.46	10.73	0.39	8.53e-25	Chronic sinus infection;
BRCA	cis	rs13046373	0.535	rs7281489	chr21:31978125	C/T	cg22337977	chr21:31811175	KRTAP15-1	0.36	8.67	0.32	3.6e-17	HDL cholesterol;
BRCA	cis	rs870825	0.616	rs10428373	chr4:185639002	A/T	cg04058563	chr4:185651563	MLF1IP	0.77	17.27	0.56	4.14e-55	Blood protein levels;
BRCA	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg25036284	chr2:26402008	FAM59B	-0.66	-11.21	-0.41	9.28e-27	Gut microbiome composition (summer);
BRCA	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg00981070	chr1:2046702	PRKCZ	0.31	8.25	0.31	9.06e-16	Height;
BRCA	trans	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg17675199	chr6:35436792	RPL10A	0.3	8.12	0.31	2.32e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg09754948	chr16:28834200	ATXN2L	0.46	9.13	0.34	9.04e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11890956	chr21:40555474	PSMG1	-0.82	-19.54	-0.61	5.3800000000000003e-67	Cognitive function;
BRCA	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs34779708	0.733	rs3936503	chr10:35549257	A/G	cg03585969	chr10:35415529	CREM	-0.42	-8.73	-0.33	2.27e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs524281	0.861	rs918299	chr11:65927607	C/T	cg16950941	chr11:66035639	RAB1B	-0.37	-8.02	-0.3	4.9e-15	Electroencephalogram traits;
BRCA	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg09307838	chr4:120376055	NA	0.64	13.8	0.48	4.15e-38	Corneal astigmatism;
BRCA	cis	rs829883	0.616	rs249832	chr12:98832387	C/T	cg25150519	chr12:98850993	NA	0.66	16.05	0.54	5.72e-49	Colorectal adenoma (advanced);
BRCA	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.51	-0.32	1.21e-16	Colorectal cancer;
BRCA	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg07080220	chr10:102295463	HIF1AN	0.44	9.8	0.36	3.19e-21	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs208520	0.779	rs208446	chr6:66903515	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-15.98	-0.53	1.37e-48	Exhaled nitric oxide output;
BRCA	cis	rs10492096	0.947	rs10849482	chr12:6635274	G/A	cg13857086	chr12:6580257	VAMP1	0.43	8.26	0.31	8.61e-16	Hip geometry;
BRCA	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg06212747	chr3:49208901	KLHDC8B	0.47	9.67	0.36	9.85e-21	Parkinson's disease;
BRCA	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.0	-0.34	2.61e-18	Total body bone mineral density;
BRCA	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg06115741	chr20:33292138	TP53INP2	0.4	8.76	0.33	1.73e-17	Coronary artery disease;
BRCA	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.62	0.42	1.93e-28	Homoarginine levels;
BRCA	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg15133208	chr4:90757351	SNCA	0.4	7.9	0.3	1.2e-14	Neuroticism;
BRCA	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg22907277	chr7:1156413	C7orf50	0.62	11.87	0.43	1.61e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg21856205	chr7:94953877	PON1	-0.37	-8.17	-0.31	1.68e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.01	0.58	5.66e-59	Fuchs's corneal dystrophy;
BRCA	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.8	-0.36	3.25e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg12011299	chr4:100065546	ADH4	0.48	11.18	0.4	1.28e-26	Alcohol dependence;
BRCA	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-16.1	-0.54	3.4e-49	Chronic sinus infection;
BRCA	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg22834771	chr12:69754056	YEATS4	-0.39	-9.64	-0.36	1.29e-20	Blood protein levels;
BRCA	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-10.77	-0.39	5.79e-25	IgG glycosylation;
BRCA	cis	rs7020830	0.931	rs13293916	chr9:37136359	C/G	cg14294708	chr9:37120828	ZCCHC7	1.19	42.07	0.86	2.61e-186	Schizophrenia;
BRCA	cis	rs708547	0.647	rs781668	chr4:57825140	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.38	-9.56	-0.35	2.44e-20	Response to bleomycin (chromatid breaks);
BRCA	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg12292205	chr6:26970375	C6orf41	-0.43	-8.74	-0.33	2.1e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg13334819	chr7:99746414	C7orf59	-0.34	-7.9	-0.3	1.24e-14	Coronary artery disease;
BRCA	cis	rs3925075	1.000	rs4411512	chr16:31347445	C/T	cg02846316	chr16:31340340	ITGAM	0.54	13.29	0.47	9.24e-36	IgA nephropathy;
BRCA	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-10.91	-0.4	1.55e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs7953508	0.506	rs1316740	chr12:93968288	C/A	cg18151635	chr12:93972918	NA	-0.46	-9.19	-0.34	5.6e-19	Pubertal anthropometrics;
BRCA	cis	rs12922317	0.535	rs8051349	chr16:12105523	T/A	cg09319797	chr16:12061715	TNFRSF17	-0.34	-7.94	-0.3	9.01e-15	Schizophrenia;
BRCA	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg18404041	chr3:52824283	ITIH1	-0.31	-7.97	-0.3	7.1e-15	Schizophrenia;
BRCA	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.44	8.38	0.31	3.25e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg10876282	chr6:28092338	ZSCAN16	0.42	8.38	0.31	3.25e-16	Cardiac Troponin-T levels;
BRCA	trans	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	28.37	0.75	3.37e-115	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg02743256	chr7:2109353	MAD1L1	-0.45	-8.4	-0.32	2.8e-16	Bipolar disorder;
BRCA	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg12573674	chr2:1569213	NA	-0.58	-11.19	-0.4	1.14e-26	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs12618769	0.597	rs3754886	chr2:99107677	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg11845111	chr2:191398756	TMEM194B	0.4	9.29	0.35	2.32e-19	Pulse pressure;
BRCA	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.44	0.32	2.08e-16	Tonsillectomy;
BRCA	cis	rs6484504	0.576	rs208072	chr11:31141288	A/G	cg26647111	chr11:31128758	NA	0.41	8.76	0.33	1.79e-17	Red blood cell count;
BRCA	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg07148914	chr20:33460835	GGT7	0.42	9.26	0.34	3.04e-19	Height;
BRCA	trans	rs2562456	0.917	rs2650805	chr19:21687939	T/G	cg25042112	chr7:64838748	ZNF92	0.45	8.31	0.31	5.89e-16	Pain;
BRCA	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg02503808	chr4:7069936	GRPEL1	-0.8	-14.14	-0.49	1.11e-39	Monocyte percentage of white cells;
BRCA	cis	rs72772090	0.539	rs3334	chr5:96115085	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.16	-0.43	9.57e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg20503657	chr10:835505	NA	1.29	21.5	0.65	1.46e-77	Eosinophil percentage of granulocytes;
BRCA	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg11663144	chr21:46675770	NA	-0.6	-13.84	-0.48	2.6e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	14.56	0.5	1.15e-41	Ileal carcinoids;
BRCA	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg04455712	chr21:45112962	RRP1B	-0.39	-9.48	-0.35	5.07e-20	Mean corpuscular volume;
BRCA	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg03711944	chr11:47377212	SPI1	-0.47	-12.01	-0.43	4.14e-30	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-10.23	-0.38	7.41e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4423214	0.879	rs1790353	chr11:71136730	C/T	cg05163923	chr11:71159392	DHCR7	-0.56	-11.24	-0.41	7.37e-27	Vitamin D levels;
BRCA	trans	rs459571	0.959	rs392134	chr9:136909008	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.81	-15.44	-0.52	5.94e-46	Platelet distribution width;
BRCA	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg27489772	chr12:121021490	NA	0.46	8.15	0.31	1.98e-15	Type 1 diabetes nephropathy;
BRCA	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg27029518	chr18:72166324	CNDP2	-0.31	-8.68	-0.32	3.35e-17	Refractive error;
BRCA	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg06784218	chr1:46089804	CCDC17	0.5	12.1	0.43	1.78e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg16586182	chr3:47516702	SCAP	0.55	12.35	0.44	1.44e-31	Colorectal cancer;
BRCA	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg15017067	chr4:17643749	FAM184B	0.28	8.52	0.32	1.17e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.18e-17	Iron status biomarkers;
BRCA	cis	rs2108225	1.000	rs6466190	chr7:107451045	G/T	cg18560240	chr7:107437656	SLC26A3	0.5	10.13	0.37	1.88e-22	Ulcerative colitis;
BRCA	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg12483005	chr1:23474871	LUZP1	0.47	10.47	0.38	8.71e-24	Height;
BRCA	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg23505145	chr19:12996616	KLF1	0.54	12.43	0.44	6.62e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg06640241	chr16:89574553	SPG7	0.87	22.39	0.66	2.05e-82	Multiple myeloma (IgH translocation);
BRCA	cis	rs870825	1.000	rs870825	chr4:185588045	A/G	cg04058563	chr4:185651563	MLF1IP	0.78	13.36	0.47	4.56e-36	Blood protein levels;
BRCA	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.96	25.16	0.71	1.37e-97	Subjective well-being;
BRCA	cis	rs6087990	0.735	rs910083	chr20:31378690	A/C	cg13636640	chr20:31349939	DNMT3B	0.64	18.0	0.58	6.89e-59	Ulcerative colitis;
BRCA	cis	rs72772090	0.539	rs72773947	chr5:96125533	T/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.13	-0.43	1.28e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg26043149	chr18:55253948	FECH	0.38	8.63	0.32	4.97e-17	Bone mineral density;
BRCA	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg13010199	chr12:38710504	ALG10B	-0.37	-8.92	-0.33	4.97e-18	Morning vs. evening chronotype;
BRCA	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg02773041	chr1:40204384	PPIE	-0.44	-9.33	-0.35	1.68e-19	Blood protein levels;
BRCA	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg22800045	chr5:56110881	MAP3K1	-0.47	-9.31	-0.35	1.95e-19	Initial pursuit acceleration;
BRCA	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	16.69	0.55	3.7e-52	Alzheimer's disease;
BRCA	cis	rs11051970	0.661	rs188979	chr12:32569684	G/T	cg02745156	chr12:32552066	NA	0.25	8.27	0.31	7.85e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	8.18	0.31	1.48e-15	Menarche (age at onset);
BRCA	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs12367572	0.663	rs1118481	chr12:45354469	C/G	cg04608330	chr12:45269318	NELL2	-0.48	-10.26	-0.38	5.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg13319975	chr6:146136371	FBXO30	-0.35	-8.11	-0.31	2.52e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg08999081	chr20:33150536	PIGU	0.47	12.95	0.46	3.17e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.37	-7.93	-0.3	9.54e-15	Longevity;Endometriosis;
BRCA	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11764359	chr7:65958608	NA	-0.77	-17.63	-0.57	5.38e-57	Aortic root size;
BRCA	cis	rs1003719	0.715	rs7277820	chr21:38580309	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.45	-0.5	3.7e-41	Eye color traits;
BRCA	cis	rs55665837	1.000	rs4412729	chr11:14439000	A/G	cg19336497	chr11:14380999	RRAS2	-0.34	-8.18	-0.31	1.52e-15	Vitamin D levels;
BRCA	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	11.35	0.41	2.61e-27	Height;
BRCA	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg03954927	chr1:10346856	KIF1B	0.48	14.88	0.51	3.21e-43	Hepatocellular carcinoma;
BRCA	cis	rs67981189	0.537	rs917067	chr14:71371904	C/T	cg15816911	chr14:71606274	NA	-0.39	-8.92	-0.33	4.79e-18	Schizophrenia;
BRCA	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg08422745	chr4:174089978	GALNT7	-0.78	-15.97	-0.53	1.52e-48	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11764359	chr7:65958608	NA	-0.75	-16.53	-0.55	2.26e-51	Aortic root size;
BRCA	cis	rs6484504	0.576	rs158146	chr11:31210433	G/A	cg14844989	chr11:31128820	NA	-0.43	-9.56	-0.35	2.59e-20	Red blood cell count;
BRCA	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg08000102	chr2:233561755	GIGYF2	0.63	14.58	0.5	8.97e-42	Coronary artery disease;
BRCA	cis	rs7631605	0.935	rs6550448	chr3:37108896	T/A	cg15934958	chr3:37212084	LRRFIP2	0.41	9.51	0.35	3.86e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg20607798	chr8:58055168	NA	0.58	9.25	0.34	3.26e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg17330251	chr7:94953956	PON1	-0.41	-8.5	-0.32	1.35e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg00339695	chr16:24857497	SLC5A11	0.54	11.79	0.42	3.76e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.36	-8.31	-0.31	5.9e-16	Longevity;Endometriosis;
BRCA	cis	rs9462027	0.628	rs11759151	chr6:34747603	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.0	-0.3	5.77e-15	Systemic lupus erythematosus;
BRCA	cis	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg04990556	chr1:26633338	UBXN11	0.55	9.12	0.34	9.28e-19	Obesity-related traits;
BRCA	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg14019146	chr3:50243930	SLC38A3	0.37	9.03	0.34	2.09e-18	Menarche (age at onset);
BRCA	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07636037	chr3:49044803	WDR6	0.69	14.23	0.49	3.95e-40	Menarche (age at onset);
BRCA	cis	rs757081	0.636	rs214934	chr11:17193475	T/A	cg15432903	chr11:17409602	KCNJ11	-0.45	-8.5	-0.32	1.33e-16	Systolic blood pressure;
BRCA	cis	rs1882538	0.503	rs1345938	chr7:133137867	C/T	cg10665199	chr7:133106180	EXOC4	-0.48	-10.12	-0.37	1.99e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs12612619	0.732	rs13032100	chr2:27233859	T/C	cg00617064	chr2:27272375	NA	-0.3	-7.97	-0.3	7.44e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg11822812	chr5:140052017	DND1	-0.33	-8.96	-0.33	3.61e-18	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10504073	0.584	rs7820270	chr8:49971395	G/T	cg00325661	chr8:49890786	NA	0.42	12.27	0.44	3.32e-31	Blood metabolite ratios;
BRCA	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-13.33	-0.47	5.81e-36	Morning vs. evening chronotype;
BRCA	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.67	-11.22	-0.41	8.97e-27	Resting heart rate;
BRCA	cis	rs6545883	0.794	rs778152	chr2:61608540	C/A	cg15711740	chr2:61764176	XPO1	0.53	13.52	0.47	7.87e-37	Tuberculosis;
BRCA	cis	rs7640424	0.649	rs62262371	chr3:107896108	C/T	cg09227934	chr3:107805635	CD47	-0.38	-7.88	-0.3	1.39e-14	Body mass index;
BRCA	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22968622	chr17:43663579	NA	1.13	19.43	0.61	2.1e-66	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
BRCA	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg23711669	chr6:146136114	FBXO30	0.62	14.02	0.49	3.95e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg22800045	chr5:56110881	MAP3K1	-0.43	-8.44	-0.32	2.16e-16	Initial pursuit acceleration;
BRCA	cis	rs2904967	0.852	rs1858783	chr11:65042941	A/G	cg09225861	chr11:65069680	NA	0.39	8.07	0.3	3.62e-15	Mean corpuscular volume;
BRCA	cis	rs113835537	0.735	rs519380	chr11:66409409	G/A	cg24851651	chr11:66362959	CCS	0.49	8.13	0.31	2.2e-15	Airway imaging phenotypes;
BRCA	trans	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg18876405	chr7:65276391	NA	0.43	8.45	0.32	1.96e-16	Corneal structure;
BRCA	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg16325326	chr1:53192061	ZYG11B	-0.95	-25.95	-0.72	6.27e-102	Monocyte count;
BRCA	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg26536863	chr7:158807979	LOC154822	0.36	8.26	0.31	8.56e-16	Facial morphology (factor 20);
BRCA	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06636551	chr8:101224915	SPAG1	-0.38	-8.72	-0.33	2.39e-17	Atrioventricular conduction;
BRCA	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg08859206	chr1:53392774	SCP2	-0.4	-8.63	-0.32	5e-17	Monocyte count;
BRCA	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg21385522	chr1:16154831	NA	0.43	9.05	0.34	1.69e-18	Systolic blood pressure;
BRCA	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg19077165	chr18:44547161	KATNAL2	-0.6	-13.5	-0.47	1.01e-36	Personality dimensions;
BRCA	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg04944784	chr2:26401820	FAM59B	1.0	16.75	0.55	1.77e-52	Gut microbiome composition (summer);
BRCA	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg06115741	chr20:33292138	TP53INP2	-0.42	-9.35	-0.35	1.4e-19	Coronary artery disease;
BRCA	cis	rs701145	0.643	rs357488	chr3:153885006	A/G	cg17054900	chr3:154042577	DHX36	0.57	9.53	0.35	3.22e-20	Coronary artery disease;
BRCA	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg19338460	chr6:170058176	WDR27	-0.77	-11.01	-0.4	6.26e-26	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg24110177	chr3:50126178	RBM5	-0.45	-9.93	-0.37	1.07e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2742234	0.541	rs7073849	chr10:43740474	G/C	cg15436174	chr10:43711423	RASGEF1A	0.5	9.96	0.37	7.74e-22	Hirschsprung disease;
BRCA	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg04362960	chr10:104952993	NT5C2	0.42	10.18	0.37	1.22e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs7246657	0.663	rs4803287	chr19:38079435	A/G	cg14683738	chr19:37701593	ZNF585B	0.48	8.14	0.31	2.02e-15	Coronary artery calcification;
BRCA	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg20387954	chr3:183756860	HTR3D	0.45	10.12	0.37	1.93e-22	Anterior chamber depth;
BRCA	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.78	-0.42	4.09e-29	Bipolar disorder;
BRCA	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg05535760	chr7:792225	HEATR2	0.7	13.32	0.47	6.96e-36	Cerebrospinal P-tau181p levels;
BRCA	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.15	0.34	7.49e-19	Tonsillectomy;
BRCA	cis	rs965469	0.901	rs6037586	chr20:3368114	G/A	cg25506879	chr20:3388711	C20orf194	-0.52	-10.25	-0.38	6.11e-23	IFN-related cytopenia;
BRCA	cis	rs416603	0.901	rs149597	chr16:11343942	C/G	cg00044050	chr16:11439710	C16orf75	-0.41	-9.5	-0.35	4.08e-20	Type 1 diabetes;
BRCA	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg04553112	chr3:125709451	NA	-0.5	-8.11	-0.31	2.63e-15	Blood pressure (smoking interaction);
BRCA	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg08917208	chr2:24149416	ATAD2B	0.91	13.46	0.47	1.5e-36	Lymphocyte counts;
BRCA	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg07080220	chr10:102295463	HIF1AN	0.61	13.07	0.46	9.45e-35	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12310025	chr6:25882481	NA	0.55	12.07	0.43	2.38e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.44	-0.32	2.16e-16	Height;
BRCA	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg06627628	chr2:24431161	ITSN2	-0.63	-12.02	-0.43	3.88e-30	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg05775895	chr3:12838266	CAND2	0.35	7.84	0.3	1.84e-14	QRS complex (12-leadsum);
BRCA	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-10.69	-0.39	1.22e-24	IgG glycosylation;
BRCA	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.42	-8.4	-0.32	2.87e-16	Monocyte percentage of white cells;
BRCA	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	7.97	0.3	7.13e-15	Total cholesterol levels;
BRCA	cis	rs78707713	0.524	rs10823377	chr10:71213327	G/A	cg12610070	chr10:71211762	TSPAN15	-0.26	-10.03	-0.37	4.48e-22	Venous thromboembolism;
BRCA	cis	rs7249921	0.833	rs2285515	chr19:35660450	T/C	cg15419183	chr19:35660584	FXYD5	0.46	10.26	0.38	5.53e-23	Platelet count;
BRCA	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg23625390	chr15:77176239	SCAPER	-0.52	-12.1	-0.43	1.75e-30	Blood metabolite levels;
BRCA	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.49	0.57	2.75e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg04455712	chr21:45112962	RRP1B	0.46	12.18	0.43	7.92e-31	Mean corpuscular volume;
BRCA	cis	rs847577	0.677	rs951988	chr7:97762474	C/G	cg21770322	chr7:97807741	LMTK2	-0.46	-12.21	-0.44	5.54e-31	Breast cancer;
BRCA	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	11.38	0.41	1.81e-27	IgG glycosylation;
BRCA	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg12292205	chr6:26970375	C6orf41	-0.59	-11.05	-0.4	4.14e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9788682	0.747	rs12101809	chr15:78779801	C/T	cg24631222	chr15:78858424	CHRNA5	0.46	9.06	0.34	1.6e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg22963979	chr7:1858916	MAD1L1	-0.4	-8.46	-0.32	1.77e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg11764359	chr7:65958608	NA	-0.47	-9.11	-0.34	1.07e-18	Calcium levels;
BRCA	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg05347473	chr6:146136440	FBXO30	0.41	8.03	0.3	4.76e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2712184	0.935	rs2712169	chr2:217671349	G/A	cg05032264	chr2:217675019	NA	-0.4	-9.83	-0.36	2.56e-21	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs17401966	1.000	rs60743860	chr1:10442926	G/C	cg03954927	chr1:10346856	KIF1B	0.43	11.9	0.43	1.27e-29	Hepatocellular carcinoma;
BRCA	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.21	-0.46	2.18e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg26384229	chr12:38710491	ALG10B	0.75	17.25	0.56	4.78e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg22535103	chr8:58192502	C8orf71	-0.53	-9.09	-0.34	1.24e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg04455712	chr21:45112962	RRP1B	0.39	9.9	0.36	1.36e-21	Mean corpuscular volume;
BRCA	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg09307838	chr4:120376055	NA	0.76	16.36	0.54	1.61e-50	Corneal astigmatism;
BRCA	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.89	-0.33	6e-18	Total body bone mineral density;
BRCA	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg13047869	chr3:10149882	C3orf24	0.57	10.41	0.38	1.45e-23	Alzheimer's disease;
BRCA	cis	rs7172677	1.000	rs4886422	chr15:75426723	C/T	cg14664628	chr15:75095509	CSK	-0.39	-8.1	-0.31	2.8e-15	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.3	-0.35	2.22e-19	Bipolar disorder;
BRCA	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.21	-0.43	5.78e-31	Alzheimer's disease;
BRCA	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg24558204	chr6:135376177	HBS1L	0.45	12.26	0.44	3.46e-31	Red blood cell count;
BRCA	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg24812749	chr6:127587940	RNF146	0.89	20.97	0.64	1.08e-74	Breast cancer;
BRCA	cis	rs1476670	0.683	rs813642	chr1:44506420	A/C	cg09470012	chr1:44509516	NA	0.42	9.29	0.34	2.4e-19	Eotaxin levels;
BRCA	cis	rs3925075	0.531	rs4608351	chr16:31348848	T/C	cg02846316	chr16:31340340	ITGAM	0.42	8.65	0.32	4.12e-17	IgA nephropathy;
BRCA	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg10978503	chr1:24200527	CNR2	-0.42	-9.77	-0.36	4.13e-21	Immature fraction of reticulocytes;
BRCA	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-11.7	-0.42	8.41e-29	Lymphocyte counts;
BRCA	trans	rs2018683	0.649	rs221193	chr7:29015784	G/T	cg19402173	chr7:128379420	CALU	-0.37	-8.13	-0.31	2.29e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	trans	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg19862616	chr7:65841803	NCRNA00174	0.82	26.58	0.72	2.01e-105	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg16405210	chr4:1374714	KIAA1530	-0.49	-11.39	-0.41	1.71e-27	Longevity;
BRCA	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg09065629	chr16:1709722	CRAMP1L	0.36	8.4	0.32	2.83e-16	Coronary artery disease;
BRCA	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg22875332	chr1:76189707	ACADM	-0.69	-15.05	-0.51	4.97e-44	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17384381	0.861	rs2300640	chr1:85823795	C/G	cg16011679	chr1:85725395	C1orf52	0.53	8.12	0.31	2.34e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs12545109	0.800	rs2118261	chr8:57393286	A/G	cg09654669	chr8:57350985	NA	0.37	7.96	0.3	8.04e-15	Obesity-related traits;
BRCA	cis	rs4588572	0.570	rs2362832	chr5:77795843	A/G	cg11547950	chr5:77652471	NA	-0.49	-8.89	-0.33	6.42e-18	Triglycerides;
BRCA	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg26384229	chr12:38710491	ALG10B	-0.47	-10.87	-0.4	2.28e-25	Morning vs. evening chronotype;
BRCA	trans	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17712092	chr4:129076599	LARP1B	-0.67	-16.8	-0.55	9.9e-53	Eosinophil percentage of white cells;
BRCA	cis	rs71386921	1	rs71386921	chr10:27478698	AAT/A	cg14240646	chr10:27532245	ACBD5	-0.57	-9.61	-0.36	1.69e-20	Breast cancer;
BRCA	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg09137382	chr11:130731461	NA	0.34	8.21	0.31	1.25e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg24642439	chr20:33292090	TP53INP2	-0.44	-9.06	-0.34	1.63e-18	Glomerular filtration rate (creatinine);
BRCA	cis	rs9341808	0.718	rs10080237	chr6:80854470	T/C	cg08355045	chr6:80787529	NA	0.37	9.29	0.35	2.32e-19	Sitting height ratio;
BRCA	cis	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.2	-0.31	1.33e-15	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg04414720	chr1:150670196	GOLPH3L	0.35	7.87	0.3	1.55e-14	Tonsillectomy;
BRCA	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg22431228	chr1:16359049	CLCNKA	-0.49	-11.06	-0.4	3.96e-26	Systolic blood pressure;
BRCA	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg24069376	chr3:38537580	EXOG	0.41	11.82	0.42	2.77e-29	Electrocardiographic conduction measures;
BRCA	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg23711669	chr6:146136114	FBXO30	0.64	15.05	0.51	4.81e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg21951975	chr1:209979733	IRF6	0.39	8.18	0.31	1.57e-15	Cleft lip with or without cleft palate;
BRCA	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-16.7	-0.55	3.26e-52	Heart rate;
BRCA	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03264133	chr6:25882463	NA	-0.37	-8.31	-0.31	5.86e-16	Height;
BRCA	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.36	0.35	1.38e-19	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg25358565	chr5:93447407	FAM172A	1.14	18.27	0.59	2.57e-60	Diabetic retinopathy;
BRCA	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg16339924	chr4:17578868	LAP3	-0.59	-14.21	-0.49	4.84e-40	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2599510	0.811	rs2710615	chr2:32791222	A/T	cg02381751	chr2:32503542	YIPF4	0.42	8.39	0.31	3.17e-16	Interleukin-18 levels;
BRCA	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.38	8.11	0.31	2.66e-15	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.49	-8.91	-0.33	5.4e-18	Renal function-related traits (BUN);
BRCA	trans	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg06521331	chr12:34319734	NA	-0.47	-8.73	-0.33	2.14e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg06521331	chr12:34319734	NA	-0.62	-11.38	-0.41	1.88e-27	Morning vs. evening chronotype;
BRCA	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.33	0.31	4.75e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-12.95	-0.46	3.08e-34	Lymphocyte counts;
BRCA	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-8.59	-0.32	6.42e-17	Schizophrenia;
BRCA	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg01420254	chr6:26195488	NA	0.59	9.16	0.34	6.84e-19	Gout;Renal underexcretion gout;
BRCA	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg23533926	chr12:111358616	MYL2	-0.41	-8.57	-0.32	7.8e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-18.12	-0.58	1.59e-59	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg03060546	chr3:49711283	APEH	-0.53	-11.08	-0.4	3.1e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs12949688	0.967	rs12451753	chr17:55822214	T/A	cg12582317	chr17:55822272	NA	0.32	7.93	0.3	9.97e-15	Schizophrenia;
BRCA	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg18252515	chr7:66147081	NA	0.49	10.22	0.37	7.93e-23	Corneal structure;
BRCA	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.9	-29.55	-0.76	1.26e-121	Schizophrenia;
BRCA	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	18.83	0.6	3.08e-63	Tonsillectomy;
BRCA	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg13852791	chr20:30311386	BCL2L1	0.86	16.98	0.56	1.13e-53	Monocyte count;
BRCA	cis	rs13102973	0.965	rs6853276	chr4:135881445	A/T	cg14419869	chr4:135874104	NA	0.51	10.79	0.39	4.54e-25	Subjective well-being;
BRCA	cis	rs8038465	0.594	rs55816897	chr15:73869767	G/T	cg15420318	chr15:73925796	NPTN	0.46	10.57	0.39	3.71e-24	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg18196295	chr10:418757	DIP2C	0.49	11.74	0.42	5.86e-29	Psychosis in Alzheimer's disease;
BRCA	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24308560	chr3:49941425	MST1R	0.39	8.23	0.31	1.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg14458575	chr2:238380390	NA	-0.48	-11.05	-0.4	4.35e-26	Prostate cancer;
BRCA	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg13319975	chr6:146136371	FBXO30	0.42	9.57	0.35	2.3e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg22431228	chr1:16359049	CLCNKA	-0.44	-9.95	-0.37	9.16e-22	Dilated cardiomyopathy;
BRCA	cis	rs1868673	1.000	rs16862651	chr3:150157388	C/T	cg04908077	chr3:150187338	NA	-0.33	-9.0	-0.34	2.56e-18	Waist circumference;
BRCA	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg01475377	chr6:109611718	NA	-0.56	-15.22	-0.52	6.95e-45	Reticulocyte fraction of red cells;
BRCA	cis	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg16586182	chr3:47516702	SCAP	0.53	11.4	0.41	1.62e-27	Colorectal cancer;
BRCA	cis	rs10193935	1.000	rs12622910	chr2:42398918	C/A	cg27598129	chr2:42591480	NA	-0.92	-14.81	-0.51	7.13e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg01884057	chr2:25150051	NA	0.34	9.22	0.34	4.2e-19	Body mass index;
BRCA	cis	rs4363385	0.597	rs6679201	chr1:152976840	C/A	cg24667326	chr1:152973720	SPRR3	-0.35	-9.78	-0.36	3.71e-21	Inflammatory skin disease;
BRCA	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg26384229	chr12:38710491	ALG10B	0.75	17.51	0.57	2.3e-56	Bladder cancer;
BRCA	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.69	0.32	3.12e-17	Personality dimensions;
BRCA	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg00701064	chr4:6280414	WFS1	0.69	18.92	0.6	1.06e-63	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs34779708	0.931	rs12242882	chr10:35347860	G/C	cg03585969	chr10:35415529	CREM	0.46	9.52	0.35	3.37e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12210905	0.610	rs72845208	chr6:27395664	C/A	cg08851530	chr6:28072375	NA	0.81	7.95	0.3	8.51e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg00530320	chr1:46809349	NSUN4	0.48	9.6	0.35	1.83e-20	Menopause (age at onset);
BRCA	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg22431228	chr1:16359049	CLCNKA	-0.45	-9.3	-0.35	2.11e-19	Dilated cardiomyopathy;
BRCA	cis	rs17092148	1.000	rs6060047	chr20:33367400	G/T	cg16810054	chr20:33298113	TP53INP2	0.48	10.86	0.39	2.43e-25	Neuroticism;
BRCA	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg20637307	chr2:213403960	ERBB4	0.73	21.29	0.64	1.97e-76	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	12.14	0.43	1.12e-30	Coronary artery disease;
BRCA	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18404041	chr3:52824283	ITIH1	0.42	12.48	0.44	3.87e-32	Bipolar disorder;
BRCA	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg23711669	chr6:146136114	FBXO30	0.64	14.96	0.51	1.34e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-9.12	-0.34	9.9e-19	IgG glycosylation;
BRCA	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg11062466	chr8:58055876	NA	0.41	7.84	0.3	1.84e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.41	0.61	2.5e-66	Alzheimer's disease;
BRCA	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.51	11.13	0.4	2.05e-26	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-9.0	-0.34	2.61e-18	Aortic root size;
BRCA	cis	rs4588572	0.615	rs4143070	chr5:77769094	G/C	cg11547950	chr5:77652471	NA	-0.45	-8.63	-0.32	4.99e-17	Triglycerides;
BRCA	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg05340658	chr4:99064831	C4orf37	0.68	16.87	0.56	4.31e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg09436375	chr6:42928200	GNMT	-0.29	-10.78	-0.39	5.22e-25	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg25358565	chr5:93447407	FAM172A	1.17	18.34	0.59	1.17e-60	Diabetic retinopathy;
BRCA	cis	rs701145	0.938	rs165275	chr3:153991875	T/C	cg17054900	chr3:154042577	DHX36	0.68	11.76	0.42	4.97e-29	Coronary artery disease;
BRCA	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg02038168	chr22:39784481	NA	-0.43	-8.5	-0.32	1.31e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.08	-0.3	3.26e-15	Total body bone mineral density;
BRCA	cis	rs4363385	0.747	rs6689609	chr1:152967588	G/A	cg24667326	chr1:152973720	SPRR3	-0.35	-9.68	-0.36	9.02e-21	Inflammatory skin disease;
BRCA	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg00409905	chr10:38381863	ZNF37A	-0.48	-9.98	-0.37	6.6e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg24296786	chr1:45957014	TESK2	0.48	11.5	0.41	5.88e-28	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg20203395	chr5:56204925	C5orf35	0.41	9.14	0.34	8.1e-19	Initial pursuit acceleration;
BRCA	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.7	0.36	7.47e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6545883	0.965	rs1562308	chr2:61768421	A/C	cg15711740	chr2:61764176	XPO1	-0.56	-14.33	-0.49	1.35e-40	Tuberculosis;
BRCA	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-8.75	-0.33	1.94e-17	Morning vs. evening chronotype;
BRCA	cis	rs9463078	0.547	rs764396	chr6:44710691	C/G	cg25276700	chr6:44698697	NA	0.36	8.18	0.31	1.56e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	13.59	0.47	3.93e-37	Platelet count;
BRCA	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-12.59	-0.45	1.2e-32	Bone mineral density;
BRCA	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03517284	chr6:25882590	NA	-0.49	-10.29	-0.38	4.27e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg24450063	chr1:156163899	SLC25A44	1.08	32.41	0.79	5.16e-137	Testicular germ cell tumor;
BRCA	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg04586622	chr2:25135609	ADCY3	0.46	11.38	0.41	1.91e-27	Body mass index;
BRCA	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg09307838	chr4:120376055	NA	-0.7	-14.33	-0.49	1.3e-40	Corneal astigmatism;
BRCA	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.32	0.31	5.33e-16	Aortic root size;
BRCA	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	15.54	0.52	1.97e-46	Bone mineral density;
BRCA	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12516959	chr21:47718080	NA	0.33	7.84	0.3	1.94e-14	Testicular germ cell tumor;
BRCA	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.61	-13.93	-0.48	1.09e-38	Ulcerative colitis;
BRCA	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.05	0.34	1.7e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7572263	0.724	rs7579275	chr2:209053080	A/C	cg23998903	chr2:209048830	C2orf80	-0.42	-8.78	-0.33	1.52e-17	Glioma;Non-glioblastoma glioma;
BRCA	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	10.93	0.4	1.31e-25	Neuroticism;
BRCA	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.97	19.95	0.62	3.16e-69	Cognitive ability;
BRCA	cis	rs11229555	0.609	rs11229451	chr11:58201687	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg01884057	chr2:25150051	NA	0.34	9.22	0.34	4.2e-19	Body mass index;
BRCA	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg08888203	chr3:10149979	C3orf24	-0.66	-14.15	-0.49	9.55e-40	Alzheimer's disease;
BRCA	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg11887960	chr12:57824829	NA	-0.5	-8.19	-0.31	1.46e-15	Obesity-related traits;
BRCA	cis	rs2522056	0.935	rs1981524	chr5:131756506	C/T	cg24060327	chr5:131705240	SLC22A5	0.5	8.66	0.32	3.88e-17	Lymphocyte counts;Fibrinogen;
BRCA	cis	rs909002	0.789	rs3817398	chr1:32119431	C/T	cg13919466	chr1:32135498	COL16A1	0.25	8.35	0.31	4.4e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg23283495	chr1:209979779	IRF6	0.42	13.42	0.47	2.34e-36	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
BRCA	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.75	-0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg11812906	chr14:75593930	NEK9	-0.64	-14.79	-0.5	9.24e-43	Height;
BRCA	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg16230307	chr14:35515116	FAM177A1	0.75	15.49	0.52	3.35e-46	Psoriasis;
BRCA	trans	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg06521331	chr12:34319734	NA	0.45	8.89	0.33	6.03e-18	Morning vs. evening chronotype;
BRCA	cis	rs312274	0.532	rs312276	chr12:41243143	A/G	cg17827154	chr12:41323612	CNTN1	0.36	8.83	0.33	1.03e-17	Metabolite levels  (X-11787);
BRCA	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	8.62	0.32	5.33e-17	Educational attainment;
BRCA	trans	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg07211511	chr3:129823064	LOC729375	-0.63	-10.91	-0.4	1.51e-25	Blood pressure (smoking interaction);
BRCA	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6752107	0.935	rs11688431	chr2:234147175	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	10.61	0.39	2.4e-24	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg05340658	chr4:99064831	C4orf37	-0.49	-11.42	-0.41	1.32e-27	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1784581	0.894	rs1626020	chr6:162383379	G/A	cg17173639	chr6:162384350	PARK2	-0.45	-10.72	-0.39	9.15e-25	Itch intensity from mosquito bite;
BRCA	cis	rs12711979	0.509	rs12711972	chr2:3823786	T/C	cg17052675	chr2:3827356	NA	-0.7	-23.81	-0.69	3.44e-90	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg27432699	chr2:27873401	GPN1	-0.46	-9.75	-0.36	5.04e-21	Oral cavity cancer;
BRCA	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg07414643	chr4:187882934	NA	0.28	9.67	0.36	9.82e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg21782813	chr7:2030301	MAD1L1	0.35	9.24	0.34	3.66e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg15485101	chr11:133734466	NA	0.4	9.59	0.35	1.93e-20	Childhood ear infection;
BRCA	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08219700	chr8:58056026	NA	0.44	7.94	0.3	8.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.74	0.67	2.6e-84	Chronic sinus infection;
BRCA	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg23029597	chr12:123009494	RSRC2	-0.62	-12.72	-0.45	3.37e-33	Body mass index;
BRCA	cis	rs7617773	0.817	rs11130162	chr3:48297611	A/G	cg11946769	chr3:48343235	NME6	0.5	11.26	0.41	5.79e-27	Coronary artery disease;
BRCA	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg26384229	chr12:38710491	ALG10B	0.77	17.57	0.57	1.14e-56	Bladder cancer;
BRCA	trans	rs2270927	0.510	rs246813	chr5:75599605	G/T	cg13563193	chr19:33072644	PDCD5	0.84	10.05	0.37	3.68e-22	Mean corpuscular volume;
BRCA	trans	rs2797160	1.000	rs2747717	chr6:126008435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.06	0.3	3.87e-15	Endometrial cancer;
BRCA	cis	rs9937943	0.721	rs8059315	chr16:74506447	C/G	cg01733217	chr16:74700730	RFWD3	0.47	7.85	0.3	1.8e-14	Neutrophil percentage of white cells;
BRCA	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.7e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.06	-0.34	1.53e-18	Total body bone mineral density;
BRCA	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.28e-36	Developmental language disorder (linguistic errors);
BRCA	trans	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg06521331	chr12:34319734	NA	-0.46	-8.48	-0.32	1.58e-16	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs1997103	1.000	rs4948011	chr7:55403859	A/G	cg20935933	chr6:143382018	AIG1	0.59	11.37	0.41	2.04e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg11993925	chr19:44307056	LYPD5	0.38	8.91	0.33	5.4e-18	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs6542838	0.641	rs12478574	chr2:99476369	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.37	-8.34	-0.31	4.66e-16	Fear of minor pain;
BRCA	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg12620499	chr2:216877984	MREG	0.81	26.45	0.72	1.02e-104	Alcohol dependence;
BRCA	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg24642439	chr20:33292090	TP53INP2	0.52	11.42	0.41	1.23e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs74181299	0.684	rs6741255	chr2:65306905	C/T	cg05010058	chr2:65284262	CEP68	-0.3	-7.98	-0.3	6.57e-15	Pulse pressure;
BRCA	cis	rs2288073	0.801	rs6757275	chr2:24375230	A/G	cg06627628	chr2:24431161	ITSN2	-0.53	-10.35	-0.38	2.52e-23	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-9.23	-0.34	3.87e-19	Monocyte percentage of white cells;
BRCA	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.73	15.87	0.53	4.42e-48	Cognitive ability;
BRCA	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg15934090	chr1:100435551	SLC35A3	0.35	7.91	0.3	1.11e-14	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg11833968	chr6:79620685	NA	0.43	9.44	0.35	6.68e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg00074818	chr8:8560427	CLDN23	0.37	8.16	0.31	1.78e-15	Obesity-related traits;
BRCA	cis	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05901451	chr6:126070800	HEY2	-0.41	-10.08	-0.37	2.73e-22	Endometrial cancer;
BRCA	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg10560079	chr2:191398806	TMEM194B	-0.71	-12.48	-0.44	3.92e-32	Diastolic blood pressure;
BRCA	trans	rs1997103	1.000	rs6973450	chr7:55396537	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.52	0.41	4.77e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-9.62	-0.36	1.44e-20	Alzheimer's disease (late onset);
BRCA	cis	rs6893300	0.961	rs62406219	chr5:179211629	G/A	cg14593053	chr5:179126677	CANX	-0.37	-8.03	-0.3	4.61e-15	Resting heart rate;
BRCA	cis	rs16854884	0.657	rs6766685	chr3:143736916	C/T	cg06585982	chr3:143692056	C3orf58	0.43	8.99	0.33	2.87e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg12386194	chr3:101231763	SENP7	0.46	9.79	0.36	3.64e-21	Colorectal cancer;
BRCA	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg12292205	chr6:26970375	C6orf41	-0.58	-12.71	-0.45	3.79e-33	Schizophrenia;
BRCA	cis	rs7520050	0.966	rs6695809	chr1:46285461	T/C	cg24296786	chr1:45957014	TESK2	0.43	9.8	0.36	3.18e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2652834	0.950	rs2652815	chr15:63401345	T/C	cg05507819	chr15:63340323	TPM1	0.45	8.05	0.3	3.97e-15	HDL cholesterol;
BRCA	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.62	0.36	1.5e-20	Morning vs. evening chronotype;
BRCA	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg22907277	chr7:1156413	C7orf50	0.59	9.28	0.34	2.7e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg22535103	chr8:58192502	C8orf71	-0.49	-8.66	-0.32	3.91e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.58	-13.08	-0.46	8.49e-35	Platelet count;
BRCA	trans	rs12517041	1.000	rs2099090	chr5:23287823	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.36	-0.31	4.04e-16	Calcium levels;
BRCA	cis	rs7903847	0.642	rs1048442	chr10:99160152	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.5	-0.32	1.38e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.66	9.98	0.37	6.49e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	30.54	0.77	5.46e-127	Chronic sinus infection;
BRCA	cis	rs6433895	1.000	rs13025711	chr2:182019461	A/G	cg00481216	chr2:181971175	NA	0.39	9.15	0.34	7.59e-19	Lymphocyte counts;
BRCA	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06002616	chr8:101225028	SPAG1	-0.34	-8.3	-0.31	6.4e-16	Atrioventricular conduction;
BRCA	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg02880119	chr16:3481970	NA	0.54	9.64	0.36	1.21e-20	Body mass index (adult);
BRCA	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg19077165	chr18:44547161	KATNAL2	-0.52	-10.98	-0.4	7.85e-26	Personality dimensions;
BRCA	cis	rs8032158	1.000	rs11633263	chr15:56135559	A/C	cg02198044	chr15:56286336	NEDD4	-0.37	-8.9	-0.33	5.7e-18	Keloid;
BRCA	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11890956	chr21:40555474	PSMG1	-0.81	-19.34	-0.61	6.08e-66	Cognitive function;
BRCA	cis	rs36051895	0.530	rs4142064	chr9:5221818	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-8.37	-0.31	3.59e-16	Pediatric autoimmune diseases;
BRCA	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg07395648	chr5:131743802	NA	0.38	8.23	0.31	1.02e-15	Blood metabolite levels;
BRCA	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11644478	chr21:40555479	PSMG1	0.81	18.1	0.58	1.96e-59	Cognitive function;
BRCA	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg08917208	chr2:24149416	ATAD2B	0.51	8.06	0.3	3.73e-15	Asthma;
BRCA	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg01065977	chr19:18549689	ISYNA1	-0.3	-8.83	-0.33	9.65e-18	Breast cancer;
BRCA	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.31	-0.31	5.82e-16	Obesity-related traits;
BRCA	cis	rs2066819	1.000	rs74673257	chr12:56638077	T/C	cg26734620	chr12:56694298	CS	0.86	9.88	0.36	1.64e-21	Psoriasis vulgaris;
BRCA	trans	rs61931739	0.635	rs1486884	chr12:33908876	A/T	cg13010199	chr12:38710504	ALG10B	-0.36	-7.83	-0.3	2.05e-14	Morning vs. evening chronotype;
BRCA	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg06697600	chr4:7070879	GRPEL1	-0.53	-10.82	-0.39	3.57e-25	Monocyte percentage of white cells;
BRCA	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	11.35	0.41	2.57e-27	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11890956	chr21:40555474	PSMG1	-0.62	-13.7	-0.48	1.18e-37	Menarche (age at onset);
BRCA	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg21132104	chr15:45694354	SPATA5L1	0.74	16.46	0.55	5.36e-51	Homoarginine levels;
BRCA	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg21535247	chr6:8435926	SLC35B3	0.42	9.48	0.35	5.1e-20	Motion sickness;
BRCA	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg19274703	chr22:41806451	NA	0.36	8.99	0.34	2.76e-18	Vitiligo;
BRCA	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.55	-0.47	5.94e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs965469	0.779	rs6051693	chr20:3244449	T/G	cg25506879	chr20:3388711	C20orf194	-0.44	-8.73	-0.33	2.27e-17	IFN-related cytopenia;
BRCA	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg04851639	chr8:1020857	NA	-0.32	-8.82	-0.33	1.05e-17	Schizophrenia;
BRCA	cis	rs990171	0.607	rs3917246	chr2:102775164	T/C	cg22835712	chr2:102737379	NA	0.53	8.96	0.33	3.61e-18	Lymphocyte counts;
BRCA	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.2	-0.37	9.64e-23	IgG glycosylation;
BRCA	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg17971929	chr21:40555470	PSMG1	0.77	18.03	0.58	4.67e-59	Cognitive function;
BRCA	cis	rs6901250	0.632	rs339355	chr6:117196503	A/T	cg12892004	chr6:117198278	RFX6	-0.39	-9.62	-0.36	1.53e-20	C-reactive protein levels;
BRCA	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg21770322	chr7:97807741	LMTK2	0.42	11.18	0.4	1.21e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg16606324	chr3:10149918	C3orf24	0.56	11.01	0.4	5.91e-26	Alzheimer's disease;
BRCA	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21659725	chr3:3221576	CRBN	-0.47	-11.99	-0.43	5.23e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.57	-0.47	4.99e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07636037	chr3:49044803	WDR6	-0.73	-15.81	-0.53	9.22e-48	Menarche (age at onset);
BRCA	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.8	-0.36	3.31e-21	IgG glycosylation;
BRCA	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg08601574	chr20:25228251	PYGB	-0.38	-8.86	-0.33	7.62e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg01483505	chr11:975446	AP2A2	0.3	8.17	0.31	1.63e-15	Alzheimer's disease (late onset);
BRCA	cis	rs11112613	0.653	rs59504344	chr12:105950837	C/T	cg03607813	chr12:105948248	NA	0.58	11.02	0.4	5.68e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07636037	chr3:49044803	WDR6	-0.73	-15.84	-0.53	6.49e-48	Menarche (age at onset);
BRCA	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.24	8.3	0.31	6.32e-16	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs11165623	0.715	rs1980769	chr1:96888201	A/T	cg10631902	chr5:14652156	NA	-0.5	-16.09	-0.54	3.83e-49	Hip circumference;Waist circumference;
BRCA	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg05775895	chr3:12838266	CAND2	0.36	8.14	0.31	2.07e-15	QRS complex (12-leadsum);
BRCA	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg00717180	chr2:96193071	NA	0.31	8.66	0.32	3.73e-17	Coronary artery disease;
BRCA	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.58e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11644478	chr21:40555479	PSMG1	0.85	19.56	0.61	4.1e-67	Cognitive function;
BRCA	cis	rs7586879	0.765	rs6545758	chr2:25074874	C/T	cg04586622	chr2:25135609	ADCY3	-0.34	-8.19	-0.31	1.44e-15	Body mass index;
BRCA	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg23711669	chr6:146136114	FBXO30	0.72	17.24	0.56	5.44e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7149337	0.836	rs4901087	chr14:51668499	T/C	cg23942311	chr14:51606299	NA	0.43	12.12	0.43	1.37e-30	Cancer;
BRCA	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.27	8.14	0.31	2.06e-15	Parkinson's disease;
BRCA	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg04362960	chr10:104952993	NT5C2	0.42	10.05	0.37	3.54e-22	Arsenic metabolism;
BRCA	cis	rs6121246	0.559	rs6087782	chr20:30391580	C/T	cg21427119	chr20:30132790	HM13	-0.36	-8.13	-0.31	2.28e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-9.64	-0.36	1.26e-20	Tonsillectomy;
BRCA	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg08999081	chr20:33150536	PIGU	0.36	9.08	0.34	1.33e-18	Coronary artery disease;
BRCA	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg23358479	chr7:1110784	C7orf50	-0.48	-8.17	-0.31	1.68e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg12483005	chr1:23474871	LUZP1	0.44	9.89	0.36	1.43e-21	Height;
BRCA	cis	rs965469	0.652	rs6051837	chr20:3388994	G/T	cg25506879	chr20:3388711	C20orf194	-0.48	-9.9	-0.36	1.31e-21	IFN-related cytopenia;
BRCA	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg06064525	chr11:970664	AP2A2	-0.29	-8.7	-0.33	2.88e-17	Alzheimer's disease (late onset);
BRCA	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.06	-0.34	1.6e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	ch.11.42038R	chr11:967971	AP2A2	0.51	16.14	0.54	2.02e-49	Alzheimer's disease (late onset);
BRCA	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg03425785	chr20:62221387	GMEB2	0.51	8.25	0.31	9.21e-16	Glioblastoma;
BRCA	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg02734326	chr4:10020555	SLC2A9	0.39	8.46	0.32	1.78e-16	Bone mineral density;
BRCA	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg22764044	chr5:178986830	RUFY1	-0.49	-13.87	-0.48	2.03e-38	Lung cancer;
BRCA	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg05985134	chr18:33552581	C18orf21	0.71	13.62	0.47	2.99e-37	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs9811920	0.809	rs902159	chr3:99747445	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	12.96	0.46	2.99e-34	Axial length;
BRCA	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.6	9.54	0.35	2.89e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg26384229	chr12:38710491	ALG10B	-0.5	-13.14	-0.46	4.29e-35	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-9.73	-0.36	5.94e-21	Height;
BRCA	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg15103426	chr22:29168792	CCDC117	0.54	12.57	0.45	1.56e-32	Lymphocyte counts;
BRCA	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-14.95	-0.51	1.54e-43	Total cholesterol levels;
BRCA	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19748678	chr4:122722346	EXOSC9	0.71	15.2	0.52	9.39e-45	Type 2 diabetes;
BRCA	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg03684893	chr10:554711	DIP2C	0.41	9.99	0.37	6.23e-22	Psychosis in Alzheimer's disease;
BRCA	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg05340658	chr4:99064831	C4orf37	0.61	14.41	0.5	5.65e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-13.97	-0.48	6.67e-39	Bipolar disorder and schizophrenia;
BRCA	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.59	-8.32	-0.31	5.14e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg14728415	chr7:32535168	LSM5;AVL9	0.36	7.97	0.3	7.3e-15	Cognitive ability;
BRCA	cis	rs7246657	0.663	rs9304568	chr19:38054508	C/A	cg23950597	chr19:37808831	NA	-0.49	-8.52	-0.32	1.14e-16	Coronary artery calcification;
BRCA	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg26528668	chr16:1614120	IFT140	0.36	7.9	0.3	1.23e-14	Coronary artery disease;
BRCA	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg04756594	chr16:24857601	SLC5A11	0.5	11.57	0.42	3.07e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg14664628	chr15:75095509	CSK	-0.93	-27.07	-0.73	4.18e-108	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg20587970	chr11:113659929	NA	-1.12	-20.23	-0.62	1.11e-70	Hip circumference adjusted for BMI;
BRCA	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg24069376	chr3:38537580	EXOG	0.29	7.91	0.3	1.1e-14	Electrocardiographic conduction measures;
BRCA	cis	rs7766436	0.922	rs11753523	chr6:22602094	G/A	cg13666174	chr6:22585274	NA	-0.42	-9.16	-0.34	7.25e-19	Coronary artery disease;
BRCA	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.54	8.29	0.31	6.62e-16	HIV-1 control;
BRCA	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.83	-0.42	2.56e-29	Platelet count;
BRCA	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02176678	chr2:219576539	TTLL4	0.46	11.67	0.42	1.14e-28	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs68170813	0.641	rs12538848	chr7:106984569	G/T	cg02696742	chr7:106810147	HBP1	-0.5	-8.06	-0.3	3.74e-15	Coronary artery disease;
BRCA	cis	rs10193935	0.901	rs222471	chr2:42638057	C/T	cg27598129	chr2:42591480	NA	0.84	14.12	0.49	1.31e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg16576597	chr16:28551801	NUPR1	0.36	9.68	0.36	8.82e-21	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg08975724	chr8:8085496	FLJ10661	0.47	10.06	0.37	3.38e-22	Mood instability;
BRCA	trans	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.88	-0.3	1.41e-14	Corneal astigmatism;
BRCA	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg18758796	chr5:131593413	PDLIM4	0.35	9.28	0.34	2.52e-19	Breast cancer;
BRCA	cis	rs3849570	1.000	rs9818006	chr3:81828230	A/C	cg07356753	chr3:81810745	GBE1	-0.43	-10.28	-0.38	4.65e-23	Waist circumference;Body mass index;
BRCA	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg23033748	chr14:75592666	NEK9	-0.43	-10.61	-0.39	2.43e-24	Height;
BRCA	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg13770153	chr20:60521292	NA	-0.35	-8.1	-0.3	2.89e-15	Body mass index;
BRCA	cis	rs751728	0.664	rs943475	chr6:33749978	C/T	cg25922239	chr6:33757077	LEMD2	-0.5	-12.68	-0.45	4.83e-33	Crohn's disease;
BRCA	cis	rs2637030	0.559	rs549131	chr5:52902238	T/C	cg06476337	chr5:52856530	NDUFS4	0.37	8.53	0.32	1.09e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	trans	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg11693508	chr17:37793320	STARD3	0.38	7.87	0.3	1.47e-14	Bipolar disorder;
BRCA	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg08999081	chr20:33150536	PIGU	0.35	9.04	0.34	1.78e-18	Coronary artery disease;
BRCA	cis	rs1776421	0.760	rs61768412	chr1:53901450	C/G	cg10892335	chr1:53966318	NA	0.47	7.86	0.3	1.68e-14	PR interval in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.39	8.24	0.31	9.46e-16	Electroencephalogram traits;
BRCA	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.05	0.4	4.42e-26	Bipolar disorder;
BRCA	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg12292205	chr6:26970375	C6orf41	-0.81	-19.89	-0.62	7.21e-69	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7572733	0.534	rs770657	chr2:198674184	C/A	cg00792783	chr2:198669748	PLCL1	0.47	10.22	0.37	8.54e-23	Dermatomyositis;
BRCA	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg00701064	chr4:6280414	WFS1	0.71	19.23	0.61	2.26e-65	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	16.52	0.55	2.57e-51	Nonalcoholic fatty liver disease;
BRCA	cis	rs365132	0.875	rs353477	chr5:176418927	C/T	cg16309518	chr5:176445507	NA	-0.4	-9.73	-0.36	5.73e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	trans	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.28	0.31	7.37e-16	Mean corpuscular volume;
BRCA	cis	rs2425143	1.000	rs74785978	chr20:34373234	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.17	-0.34	6.32e-19	Blood protein levels;
BRCA	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg10932868	chr11:921992	NA	0.47	12.11	0.43	1.62e-30	Alzheimer's disease (late onset);
BRCA	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18876405	chr7:65276391	NA	-0.51	-11.43	-0.41	1.13e-27	Aortic root size;
BRCA	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg25174290	chr11:3078921	CARS	-0.3	-7.87	-0.3	1.54e-14	Calcium levels;
BRCA	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg20283391	chr11:68216788	NA	-0.45	-8.93	-0.33	4.39e-18	Total body bone mineral density;
BRCA	cis	rs6142102	0.961	rs1319363	chr20:32541876	T/A	cg24642439	chr20:33292090	TP53INP2	0.44	8.35	0.31	4.09e-16	Skin pigmentation;
BRCA	cis	rs1595825	0.891	rs74965164	chr2:198499162	C/T	cg19156104	chr2:198669113	PLCL1	-0.42	-8.14	-0.31	2.02e-15	Ulcerative colitis;
BRCA	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.36	-8.18	-0.31	1.59e-15	Colorectal cancer;
BRCA	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg07080220	chr10:102295463	HIF1AN	-0.5	-11.85	-0.42	1.95e-29	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg01262667	chr19:19385393	TM6SF2	0.38	9.71	0.36	6.68e-21	Tonsillectomy;
BRCA	cis	rs28735056	1.000	rs28735056	chr18:77622879	A/G	cg20368463	chr18:77673604	PQLC1	-0.33	-8.05	-0.3	4.18e-15	Schizophrenia;
BRCA	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg07080220	chr10:102295463	HIF1AN	0.6	14.17	0.49	7.71e-40	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	14.3	0.49	1.97e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg26116260	chr4:7069785	GRPEL1	-0.9	-19.55	-0.61	4.37e-67	Monocyte percentage of white cells;
BRCA	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.47	9.49	0.35	4.36e-20	Lymphocyte counts;
BRCA	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.21	0.37	9.15e-23	Aortic root size;
BRCA	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg25174290	chr11:3078921	CARS	-0.3	-7.87	-0.3	1.54e-14	Calcium levels;
BRCA	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg24675658	chr1:53192096	ZYG11B	-0.6	-13.8	-0.48	4.01e-38	Monocyte count;
BRCA	trans	rs61931739	0.635	rs1405025	chr12:33908491	C/T	cg26384229	chr12:38710491	ALG10B	0.41	9.24	0.34	3.74e-19	Morning vs. evening chronotype;
BRCA	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg27279351	chr12:120934652	DYNLL1	0.55	13.12	0.46	5.72e-35	High light scatter reticulocyte count;
BRCA	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg25767906	chr1:53392781	SCP2	0.37	8.6	0.32	5.92e-17	Monocyte count;
BRCA	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.29	-8.48	-0.32	1.57e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg07148914	chr20:33460835	GGT7	-0.37	-7.97	-0.3	7.47e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg04166393	chr7:2884313	GNA12	0.51	9.62	0.36	1.5e-20	Height;
BRCA	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg02176678	chr2:219576539	TTLL4	0.39	10.48	0.38	7.73e-24	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs701145	0.585	rs401162	chr3:153905988	T/A	cg17054900	chr3:154042577	DHX36	0.58	9.66	0.36	1.1e-20	Coronary artery disease;
BRCA	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02176678	chr2:219576539	TTLL4	-0.51	-12.82	-0.45	1.24e-33	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6977660	0.714	rs10249477	chr7:19805388	T/A	cg05791153	chr7:19748676	TWISTNB	0.59	10.83	0.39	3.39e-25	Thyroid stimulating hormone;
BRCA	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg00990874	chr7:1149470	C7orf50	-0.53	-9.83	-0.36	2.46e-21	Bronchopulmonary dysplasia;
BRCA	trans	rs783540	0.934	rs1594511	chr15:83307063	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.27	-8.23	-0.31	1.04e-15	Schizophrenia;
BRCA	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg00383909	chr3:49044727	WDR6	0.63	11.23	0.41	7.62e-27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg04476341	chr5:669733	TPPP	0.39	7.86	0.3	1.65e-14	Lung disease severity in cystic fibrosis;
BRCA	cis	rs897080	0.552	rs1067326	chr2:44628605	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	9.35	0.35	1.46e-19	Height;
BRCA	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg18402987	chr7:1209562	NA	0.4	8.18	0.31	1.53e-15	Longevity;Endometriosis;
BRCA	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.69	0.39	1.24e-24	IgG glycosylation;
BRCA	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	7.93	0.3	9.62e-15	Menarche (age at onset);
BRCA	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.5	-9.15	-0.34	7.65e-19	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs11971779	0.941	rs74299967	chr7:139043769	G/T	cg07862535	chr7:139043722	LUC7L2	0.53	12.98	0.46	2.21e-34	Diisocyanate-induced asthma;
BRCA	cis	rs3784262	0.669	rs7178598	chr15:58309016	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.03	-0.37	4.41e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7903847	0.667	rs11189181	chr10:99144154	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.01	-0.3	5.35e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg20933634	chr6:27740509	NA	0.43	8.5	0.32	1.35e-16	Parkinson's disease;
BRCA	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg06212747	chr3:49208901	KLHDC8B	0.46	9.56	0.35	2.45e-20	Parkinson's disease;
BRCA	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg00666640	chr1:248458726	OR2T12	0.32	8.59	0.32	6.44e-17	Common traits (Other);
BRCA	cis	rs7520050	0.966	rs4660898	chr1:46402171	A/G	cg24296786	chr1:45957014	TESK2	0.44	9.87	0.36	1.74e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7523050	0.643	rs36047249	chr1:109401499	T/C	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg13010199	chr12:38710504	ALG10B	0.42	9.0	0.34	2.64e-18	Morning vs. evening chronotype;
BRCA	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg08754654	chr5:154026448	NA	0.43	9.99	0.37	6.1e-22	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs17401966	0.931	rs12409754	chr1:10457540	T/C	cg19773385	chr1:10388646	KIF1B	-0.4	-8.53	-0.32	1.08e-16	Hepatocellular carcinoma;
BRCA	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg12935359	chr14:103987150	CKB	-0.59	-13.47	-0.47	1.42e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs690037	0.551	rs690522	chr3:16377067	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.39	-7.85	-0.3	1.75e-14	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
BRCA	cis	rs2463822	1.000	rs115395195	chr11:62100353	G/A	cg06239285	chr11:62104954	ASRGL1	-0.66	-8.94	-0.33	4.29e-18	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg03877680	chr5:178157825	ZNF354A	0.79	14.73	0.5	1.74e-42	Neutrophil percentage of white cells;
BRCA	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg04756594	chr16:24857601	SLC5A11	0.43	8.36	0.31	3.97e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg16486109	chr11:613632	IRF7	0.42	8.81	0.33	1.17e-17	Systemic lupus erythematosus;
BRCA	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg17470723	chr8:74884337	TCEB1	0.41	8.64	0.32	4.43e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg13334819	chr7:99746414	C7orf59	0.34	8.01	0.3	5.56e-15	Coronary artery disease;
BRCA	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg27170947	chr2:26402098	FAM59B	-0.65	-11.27	-0.41	5.26e-27	Gut microbiome composition (summer);
BRCA	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg13010199	chr12:38710504	ALG10B	0.41	8.42	0.32	2.42e-16	Bladder cancer;
BRCA	cis	rs4613509	1	rs4613509	chr3:160728059	T/C	cg03342759	chr3:160939853	NMD3	-0.46	-8.78	-0.33	1.53e-17	Morning vs. evening chronotype;
BRCA	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg13385521	chr17:29058706	SUZ12P	-0.61	-8.24	-0.31	1e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs6121246	0.559	rs6060962	chr20:30397847	A/G	cg21427119	chr20:30132790	HM13	-0.35	-7.95	-0.3	8.41e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs4285028	0.948	rs1920291	chr3:121672440	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.82	-0.39	3.64e-25	Multiple sclerosis;
BRCA	cis	rs13136331	0.680	rs2732171	chr4:88655984	A/G	cg12990093	chr4:88570587	DMP1	-0.4	-8.22	-0.31	1.14e-15	Sitting height ratio;
BRCA	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg14036092	chr11:66035641	RAB1B	0.39	10.23	0.38	7.55e-23	Gout;
BRCA	trans	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg15556689	chr8:8085844	FLJ10661	-0.32	-8.1	-0.31	2.85e-15	Triglycerides;
BRCA	cis	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05901451	chr6:126070800	HEY2	-0.42	-10.07	-0.37	3.05e-22	Endometrial cancer;
BRCA	cis	rs9341808	0.718	rs9352801	chr6:80817468	G/T	cg08355045	chr6:80787529	NA	0.37	9.36	0.35	1.39e-19	Sitting height ratio;
BRCA	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg00106254	chr7:1943704	MAD1L1	-0.44	-10.94	-0.4	1.13e-25	Bipolar disorder and schizophrenia;
BRCA	trans	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.58	-0.35	2.18e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg22705602	chr4:152727874	NA	-0.33	-8.18	-0.31	1.54e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10754283	0.934	rs10493829	chr1:90117833	T/C	cg21401794	chr1:90099060	LRRC8C	0.48	11.9	0.43	1.29e-29	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.88	0.64	3.29e-74	Chronic sinus infection;
BRCA	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg11366901	chr6:160182831	ACAT2	-0.65	-13.04	-0.46	1.24e-34	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.21	0.68	6.53e-87	Chronic sinus infection;
BRCA	trans	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg26384229	chr12:38710491	ALG10B	0.59	11.89	0.43	1.4e-29	Resting heart rate;
BRCA	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg21775007	chr8:11205619	TDH	0.45	9.01	0.34	2.37e-18	Triglycerides;
BRCA	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03452623	chr4:187889614	NA	-0.32	-10.37	-0.38	2.09e-23	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg20587970	chr11:113659929	NA	1.02	14.49	0.5	2.42e-41	Hip circumference adjusted for BMI;
BRCA	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg09307838	chr4:120376055	NA	0.73	15.95	0.53	1.9e-48	Corneal astigmatism;
BRCA	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg21138405	chr5:131827807	IRF1	0.39	12.9	0.45	5.51e-34	Asthma (sex interaction);
BRCA	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg24130564	chr14:104152367	KLC1	-0.41	-8.76	-0.33	1.75e-17	Reticulocyte count;
BRCA	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg16006841	chr5:176797999	RGS14	-0.58	-11.6	-0.42	2.22e-28	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.2	0.49	5.86e-40	Motion sickness;
BRCA	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg26384229	chr12:38710491	ALG10B	0.65	14.16	0.49	8.57e-40	Morning vs. evening chronotype;
BRCA	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg05283184	chr6:79620031	NA	-0.43	-11.03	-0.4	4.97e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg18479299	chr3:125709523	NA	-0.54	-8.36	-0.31	4.05e-16	Blood pressure (smoking interaction);
BRCA	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg07414643	chr4:187882934	NA	0.28	9.61	0.36	1.65e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg12483005	chr1:23474871	LUZP1	0.44	9.89	0.36	1.43e-21	Height;
BRCA	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg02659138	chr7:134003124	SLC35B4	0.36	10.41	0.38	1.49e-23	Mean platelet volume;
BRCA	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.1	-0.37	2.47e-22	IgG glycosylation;
BRCA	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.46	-11.03	-0.4	4.91e-26	IgG glycosylation;
BRCA	cis	rs2882667	0.690	rs10078079	chr5:138256139	C/T	cg04439458	chr5:138467593	SIL1	-0.37	-8.9	-0.33	5.53e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4074536	0.574	rs10923362	chr1:116292908	A/G	cg21648376	chr1:116311395	CASQ2	-0.49	-8.63	-0.32	5e-17	QRS duration;
BRCA	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg05507819	chr15:63340323	TPM1	-0.41	-9.01	-0.34	2.38e-18	Platelet count;
BRCA	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg00531865	chr16:30841666	NA	-0.49	-11.35	-0.41	2.57e-27	Multiple myeloma;
BRCA	cis	rs4363385	0.667	rs73014331	chr1:152964533	A/G	cg24667326	chr1:152973720	SPRR3	-0.33	-9.0	-0.34	2.53e-18	Inflammatory skin disease;
BRCA	cis	rs713587	0.520	rs1530016	chr2:25305756	C/T	cg01884057	chr2:25150051	NA	-0.32	-8.32	-0.31	5.2e-16	Body mass index in non-asthmatics;
BRCA	cis	rs4302748	0.862	rs11768269	chr7:36172741	A/G	cg24442661	chr7:36192818	EEPD1	0.41	7.9	0.3	1.22e-14	Platelet count;
BRCA	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg14530993	chr4:882597	GAK	0.51	8.69	0.33	2.99e-17	Parkinson's disease;
BRCA	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg00701064	chr4:6280414	WFS1	0.71	18.93	0.6	8.74e-64	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs897080	0.515	rs1145519	chr2:44708709	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	9.14	0.34	8.3e-19	Height;
BRCA	cis	rs7646881	0.812	rs73017540	chr3:158460788	T/A	cg19483011	chr3:158453295	NA	-0.46	-8.05	-0.3	4.08e-15	Tetralogy of Fallot;
BRCA	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg02951883	chr7:2050386	MAD1L1	-0.52	-11.56	-0.42	3.45e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.18	0.31	1.53e-15	Uric acid levels;
BRCA	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.72	9.71	0.36	6.7e-21	Initial pursuit acceleration;
BRCA	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg24562669	chr7:97807699	LMTK2	0.42	11.08	0.4	3.12e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg03342759	chr3:160939853	NMD3	-0.72	-18.01	-0.58	5.81e-59	Morning vs. evening chronotype;
BRCA	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg09455208	chr3:40491958	NA	0.53	11.94	0.43	8.23e-30	Renal cell carcinoma;
BRCA	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg01657329	chr11:68192670	LRP5	0.37	8.31	0.31	5.83e-16	Bone mineral density (spine);
BRCA	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg16482183	chr6:26056742	HIST1H1C	0.59	10.2	0.37	9.38e-23	Iron status biomarkers;
BRCA	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg04944784	chr2:26401820	FAM59B	-0.99	-16.67	-0.55	4.37e-52	Gut microbiome composition (summer);
BRCA	cis	rs68170813	0.559	rs3823960	chr7:107009349	T/C	cg02696742	chr7:106810147	HBP1	-0.54	-8.68	-0.32	3.23e-17	Coronary artery disease;
BRCA	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg21427119	chr20:30132790	HM13	-0.42	-8.79	-0.33	1.38e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-12.11	-0.43	1.51e-30	Chronic sinus infection;
BRCA	cis	rs600806	0.778	rs6693932	chr1:110003575	T/C	cg20591472	chr1:110008990	SYPL2	0.31	7.89	0.3	1.31e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg12935359	chr14:103987150	CKB	-0.46	-10.36	-0.38	2.25e-23	Body mass index;
BRCA	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg18230493	chr5:56204884	C5orf35	-0.41	-8.01	-0.3	5.54e-15	Coronary artery disease;
BRCA	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18876405	chr7:65276391	NA	-0.62	-15.37	-0.52	1.36e-45	Aortic root size;
BRCA	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg05283184	chr6:79620031	NA	-0.37	-8.28	-0.31	7.09e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs10129255	0.556	rs8010005	chr14:107186226	A/G	cg07958169	chr14:107095056	NA	-0.4	-8.48	-0.32	1.59e-16	Kawasaki disease;
BRCA	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg23711669	chr6:146136114	FBXO30	0.67	15.04	0.51	5.29e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7903847	0.642	rs11189200	chr10:99156273	C/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.53	-0.32	1.03e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg15112475	chr7:1198522	ZFAND2A	-0.44	-8.6	-0.32	6.01e-17	Bronchopulmonary dysplasia;
BRCA	cis	rs7640424	0.649	rs6795280	chr3:107876232	T/C	cg09227934	chr3:107805635	CD47	-0.37	-7.86	-0.3	1.62e-14	Body mass index;
BRCA	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-13.0	-0.46	1.84e-34	Longevity;Endometriosis;
BRCA	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26314531	chr2:26401878	FAM59B	0.6	10.04	0.37	3.98e-22	Gut microbiome composition (summer);
BRCA	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg06159980	chr1:16340746	HSPB7	-0.38	-8.84	-0.33	9.14e-18	Dilated cardiomyopathy;
BRCA	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-13.14	-0.46	4.59e-35	Lymphocyte counts;
BRCA	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.53	10.52	0.38	5.52e-24	Lymphocyte counts;
BRCA	cis	rs7572733	0.534	rs771009	chr2:198691082	A/G	cg00792783	chr2:198669748	PLCL1	0.47	10.17	0.37	1.3e-22	Dermatomyositis;
BRCA	cis	rs113835537	0.529	rs17580784	chr11:66214859	T/A	cg24851651	chr11:66362959	CCS	0.5	8.75	0.33	1.94e-17	Airway imaging phenotypes;
BRCA	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg13010199	chr12:38710504	ALG10B	0.43	9.14	0.34	7.95e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs754466	0.830	rs61854186	chr10:79703255	G/A	cg17075019	chr10:79541650	NA	-0.63	-11.83	-0.42	2.52e-29	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg08999081	chr20:33150536	PIGU	-0.44	-12.38	-0.44	1.01e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06028605	chr16:24865363	SLC5A11	0.43	9.53	0.35	3.1e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6782228	0.606	rs2811497	chr3:128363332	C/T	cg16766828	chr3:128327626	NA	-0.43	-9.64	-0.36	1.22e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.7	0.33	2.82e-17	Iron status biomarkers;
BRCA	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg01877450	chr7:97915802	BRI3	-0.39	-8.8	-0.33	1.25e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	8.52	0.32	1.12e-16	Electroencephalogram traits;
BRCA	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg23788917	chr6:8435910	SLC35B3	0.47	10.27	0.38	5.4e-23	Motion sickness;
BRCA	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg04166393	chr7:2884313	GNA12	0.5	9.59	0.35	1.96e-20	Height;
BRCA	trans	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg16141378	chr3:129829833	LOC729375	0.34	8.3	0.31	6.28e-16	Mood instability;
BRCA	cis	rs67981189	0.679	rs221901	chr14:71602226	C/T	cg15816911	chr14:71606274	NA	-0.38	-8.27	-0.31	7.72e-16	Schizophrenia;
BRCA	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg08470875	chr2:26401718	FAM59B	-0.51	-8.25	-0.31	9.29e-16	Gut microbiome composition (summer);
BRCA	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.17	-0.43	8.86e-31	Total cholesterol levels;
BRCA	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg02376097	chr19:46275166	DMPK	0.47	10.57	0.39	3.64e-24	Coronary artery disease;
BRCA	cis	rs7523050	0.730	rs12079547	chr1:109469314	A/C	cg08274380	chr1:109419600	GPSM2	0.98	14.31	0.49	1.79e-40	Fat distribution (HIV);
BRCA	cis	rs911119	1.000	rs6114206	chr20:23611789	A/G	cg16589663	chr20:23618590	CST3	0.46	8.68	0.32	3.24e-17	Chronic kidney disease;
BRCA	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg22676075	chr6:135203613	NA	0.45	8.79	0.33	1.38e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.18	-0.4	1.28e-26	Morning vs. evening chronotype;
BRCA	cis	rs6893300	0.857	rs6860716	chr5:179162840	T/C	cg14593053	chr5:179126677	CANX	-0.36	-8.06	-0.3	3.85e-15	Resting heart rate;
BRCA	cis	rs9341808	0.558	rs2322635	chr6:80897210	A/G	cg08355045	chr6:80787529	NA	0.32	7.81	0.3	2.37e-14	Sitting height ratio;
BRCA	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg11062466	chr8:58055876	NA	0.49	8.67	0.32	3.64e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11890956	chr21:40555474	PSMG1	1.04	28.18	0.74	3.6e-114	Cognitive function;
BRCA	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg06238570	chr21:40685208	BRWD1	-0.39	-8.09	-0.3	3.07e-15	Menarche (age at onset);
BRCA	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg08885076	chr2:99613938	TSGA10	-0.5	-9.22	-0.34	4.36e-19	Chronic sinus infection;
BRCA	cis	rs6840360	0.593	rs6847844	chr4:152693246	C/T	cg22705602	chr4:152727874	NA	-0.38	-10.58	-0.39	3.14e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg09021430	chr5:549028	NA	-0.68	-14.28	-0.49	2.5e-40	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2013441	1.000	rs2107566	chr17:20103252	C/T	cg13482628	chr17:19912719	NA	-0.4	-8.9	-0.33	5.77e-18	Obesity-related traits;
BRCA	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg11057378	chr10:81107060	PPIF	0.39	8.95	0.33	3.96e-18	Height;
BRCA	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg01483505	chr11:975446	AP2A2	0.34	9.14	0.34	7.89e-19	Alzheimer's disease (late onset);
BRCA	cis	rs10267417	0.603	rs6960607	chr7:19869407	A/G	cg07541023	chr7:19748670	TWISTNB	0.47	8.49	0.32	1.49e-16	Night sleep phenotypes;
BRCA	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg17063962	chr7:91808500	NA	0.53	12.5	0.44	3.23e-32	Breast cancer;
BRCA	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg16325326	chr1:53192061	ZYG11B	-0.66	-16.28	-0.54	4.2e-50	Monocyte count;
BRCA	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23583168	chr7:148888333	NA	-0.85	-19.85	-0.62	1.13e-68	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.78	-0.33	1.44e-17	Depression;
BRCA	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg08085267	chr17:45401833	C17orf57	-0.64	-13.75	-0.48	7.49e-38	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg24112000	chr20:60950667	NA	0.49	9.48	0.35	4.82e-20	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg12463550	chr7:65579703	CRCP	-0.37	-8.1	-0.31	2.84e-15	Aortic root size;
BRCA	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg08885076	chr2:99613938	TSGA10	0.41	9.62	0.36	1.45e-20	Chronic sinus infection;
BRCA	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg24578937	chr1:2090814	PRKCZ	0.58	17.89	0.58	2.47e-58	Height;
BRCA	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.74	16.29	0.54	3.92e-50	Cognitive ability;
BRCA	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg03929089	chr4:120376271	NA	0.57	9.27	0.34	2.8e-19	Axial length;
BRCA	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg19901468	chr14:105411992	AHNAK2	-0.51	-12.43	-0.44	6.12e-32	Rheumatoid arthritis;
BRCA	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.56	-9.87	-0.36	1.78e-21	Body mass index (adult);
BRCA	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg18850127	chr7:39170497	POU6F2	0.5	10.96	0.4	1.02e-25	IgG glycosylation;
BRCA	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08280861	chr8:58055591	NA	0.53	8.4	0.32	2.84e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg25206134	chr2:45395956	NA	0.51	8.68	0.32	3.31e-17	Bipolar disorder;
BRCA	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg08508325	chr11:3079039	CARS	-0.45	-16.17	-0.54	1.41e-49	Longevity;
BRCA	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg07741184	chr6:167504864	NA	0.28	7.99	0.3	6.14e-15	Crohn's disease;
BRCA	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg20387954	chr3:183756860	HTR3D	0.45	10.02	0.37	4.7e-22	Anterior chamber depth;
BRCA	cis	rs460214	0.576	rs2836604	chr21:40041295	A/C	cg21578987	chr21:40029669	ERG	0.34	8.21	0.31	1.2e-15	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg23442198	chr4:187126114	CYP4V2	0.66	8.98	0.33	3.13e-18	Blood protein levels;
BRCA	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg14844989	chr11:31128820	NA	0.47	9.96	0.37	7.98e-22	Bone mineral density (spine);
BRCA	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg09537434	chr19:41945824	ATP5SL	-0.99	-23.45	-0.68	3.09e-88	Height;
BRCA	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg03354898	chr7:1950403	MAD1L1	-0.49	-10.09	-0.37	2.57e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs28595532	0.546	rs36058627	chr4:119233201	G/T	cg21605333	chr4:119757512	SEC24D	0.83	8.78	0.33	1.46e-17	Cannabis dependence symptom count;
BRCA	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg17366294	chr4:99064904	C4orf37	0.44	10.31	0.38	3.67e-23	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg26043149	chr18:55253948	FECH	0.4	8.8	0.33	1.24e-17	Bone mineral density;
BRCA	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg24596788	chr1:163392923	NA	0.42	11.12	0.4	2.27e-26	Motion sickness;
BRCA	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.59	-0.32	6.69e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.51	-0.32	1.22e-16	Total body bone mineral density;
BRCA	cis	rs965469	0.779	rs6515791	chr20:3310443	C/G	cg25506879	chr20:3388711	C20orf194	-0.44	-8.87	-0.33	7.39e-18	IFN-related cytopenia;
BRCA	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.33	8.14	0.31	2.03e-15	Personality dimensions;
BRCA	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg15704280	chr7:45808275	SEPT13	0.64	11.28	0.41	4.86e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg01877450	chr7:97915802	BRI3	-0.37	-8.36	-0.31	3.93e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs58235267	0.543	rs2539990	chr2:63170185	C/T	cg17519650	chr2:63277830	OTX1	0.43	10.01	0.37	5.36e-22	Prostate-specific antigen levels (conditioned on lead SNPs);
BRCA	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg00814883	chr7:100076585	TSC22D4	-0.48	-10.01	-0.37	5.03e-22	Platelet count;
BRCA	cis	rs7246967	0.673	rs4933036	chr19:22963069	C/A	cg23217946	chr19:22817039	ZNF492	0.5	9.11	0.34	1.04e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg14019146	chr3:50243930	SLC38A3	-0.65	-15.89	-0.53	3.57e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg04756594	chr16:24857601	SLC5A11	-0.34	-8.89	-0.33	6.34e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg21659725	chr3:3221576	CRBN	-0.45	-9.87	-0.36	1.73e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg20476274	chr7:133979776	SLC35B4	0.51	11.82	0.42	2.71e-29	Mean platelet volume;
BRCA	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.05	-0.4	4.1e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	13.16	0.46	3.67e-35	Bone mineral density;
BRCA	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg24692254	chr21:30365293	RNF160	0.66	18.19	0.58	6.62e-60	Dental caries;
BRCA	trans	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04565464	chr8:145669602	NFKBIL2	0.34	8.17	0.31	1.59e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs877529	0.967	rs12158877	chr22:39549426	T/G	cg18708252	chr22:39545030	CBX7	-0.31	-8.14	-0.31	2.02e-15	Multiple myeloma;
BRCA	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg23109721	chr2:106886537	NA	0.55	10.83	0.39	3.36e-25	Facial morphology (factor 23);
BRCA	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.86	-0.33	7.99e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.66e-18	Motion sickness;
BRCA	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg11584989	chr19:19387371	SF4	-0.65	-14.21	-0.49	4.81e-40	Bipolar disorder;
BRCA	cis	rs350251	0.899	rs350275	chr16:12233099	G/C	cg06014057	chr16:12226852	SNX29	0.29	7.91	0.3	1.15e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg10932868	chr11:921992	NA	-0.5	-12.77	-0.45	2.09e-33	Alzheimer's disease (late onset);
BRCA	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	21.81	0.65	2.95e-79	Platelet count;
BRCA	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg12923728	chr3:195709715	SDHAP1	0.38	7.85	0.3	1.72e-14	Mean corpuscular volume;
BRCA	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg20991723	chr1:152506922	NA	0.37	8.32	0.31	5.36e-16	Hair morphology;
BRCA	trans	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg17145862	chr1:211918768	LPGAT1	-0.68	-17.82	-0.58	5.77e-58	Leprosy;
BRCA	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.38	-0.31	3.25e-16	Aortic root size;
BRCA	cis	rs9815354	1.000	rs9815354	chr3:41912651	G/A	cg03022575	chr3:42003672	ULK4	0.51	8.31	0.31	5.54e-16	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.56	-0.32	8.25e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9942416	0.660	rs193344	chr5:74977854	T/C	cg19683494	chr5:74908142	NA	-0.44	-8.66	-0.32	3.74e-17	Age-related disease endophenotypes;
BRCA	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	21.92	0.66	7.54e-80	Platelet count;
BRCA	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11644478	chr21:40555479	PSMG1	0.88	20.84	0.64	5.49e-74	Cognitive function;
BRCA	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg26384229	chr12:38710491	ALG10B	0.69	16.13	0.54	2.41e-49	Bladder cancer;
BRCA	trans	rs6964833	0.872	rs4717903	chr7:74068167	T/C	cg07504079	chr7:72649617	NCF1B	-0.47	-9.19	-0.34	5.46e-19	Menarche (age at onset);
BRCA	cis	rs72781680	0.716	rs72788206	chr2:24084989	T/C	cg08917208	chr2:24149416	ATAD2B	0.61	10.24	0.38	7.17e-23	Lymphocyte counts;
BRCA	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-9.24	-0.34	3.52e-19	Fear of minor pain;
BRCA	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-13.3	-0.47	8.04e-36	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg04058563	chr4:185651563	MLF1IP	0.36	9.0	0.34	2.47e-18	Kawasaki disease;
BRCA	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg01262667	chr19:19385393	TM6SF2	0.39	8.3	0.31	6.37e-16	Nonalcoholic fatty liver disease;
BRCA	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg23950597	chr19:37808831	NA	-0.67	-12.13	-0.43	1.28e-30	Coronary artery calcification;
BRCA	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-13.84	-0.48	2.81e-38	Migraine;Coronary artery disease;
BRCA	cis	rs7766436	0.848	rs13211568	chr6:22573180	A/T	cg13666174	chr6:22585274	NA	-0.45	-9.64	-0.36	1.21e-20	Coronary artery disease;
BRCA	cis	rs2279817	0.863	rs2354291	chr1:18027554	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-14.34	-0.49	1.21e-40	Neuroticism;
BRCA	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10463316	0.747	rs10077700	chr5:150768324	A/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.33	-0.31	4.92e-16	Metabolite levels (Pyroglutamine);
BRCA	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.31	8.55	0.32	8.8e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08564027	chr20:61660810	NA	0.69	14.23	0.49	4.26e-40	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2742234	0.590	rs2435338	chr10:43642115	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.54	-10.96	-0.4	1.02e-25	Hirschsprung disease;
BRCA	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.23	-0.31	1.06e-15	Depression;
BRCA	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg00383909	chr3:49044727	WDR6	0.71	12.7	0.45	4.18e-33	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs13102973	0.932	rs4130840	chr4:135869598	T/G	cg14419869	chr4:135874104	NA	-0.59	-13.06	-0.46	1.02e-34	Subjective well-being;
BRCA	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.41	-7.87	-0.3	1.48e-14	Bronchopulmonary dysplasia;
BRCA	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg17143192	chr8:8559678	CLDN23	0.57	11.1	0.4	2.61e-26	Obesity-related traits;
BRCA	cis	rs4363385	0.720	rs1984197	chr1:152962915	C/G	cg24667326	chr1:152973720	SPRR3	-0.33	-9.3	-0.35	2.13e-19	Inflammatory skin disease;
BRCA	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg10523679	chr1:76189770	ACADM	-0.47	-9.1	-0.34	1.17e-18	Daytime sleep phenotypes;
BRCA	cis	rs6120849	0.754	rs6120788	chr20:33583716	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	10.35	0.38	2.61e-23	Protein C levels;
BRCA	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg23533926	chr12:111358616	MYL2	-0.41	-8.5	-0.32	1.32e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs586533	0.881	rs674717	chr11:99506867	A/T	cg22878054	chr11:99397252	CNTN5	0.32	8.24	0.31	9.43e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.17	-0.31	1.66e-15	Aortic root size;
BRCA	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05890377	chr2:74357713	NA	0.5	12.27	0.44	3.24e-31	Gestational age at birth (maternal effect);
BRCA	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg22907277	chr7:1156413	C7orf50	0.6	11.44	0.41	1.04e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24531977	chr5:56204891	C5orf35	-0.87	-17.9	-0.58	2.27e-58	Initial pursuit acceleration;
BRCA	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg12641515	chr19:46296257	DMWD	0.71	17.75	0.57	1.37e-57	Coronary artery disease;
BRCA	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02018176	chr4:1364513	KIAA1530	0.4	8.21	0.31	1.2e-15	Longevity;
BRCA	cis	rs6772849	0.930	rs55987729	chr3:128340110	T/C	cg16766828	chr3:128327626	NA	-0.38	-8.48	-0.32	1.57e-16	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs4363385	0.818	rs441229	chr1:153015059	A/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.46	-0.32	1.88e-16	Inflammatory skin disease;
BRCA	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg04727924	chr7:799746	HEATR2	-0.57	-11.27	-0.41	5.25e-27	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg04362960	chr10:104952993	NT5C2	-0.33	-7.97	-0.3	7.18e-15	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18876405	chr7:65276391	NA	-0.5	-11.01	-0.4	6.44e-26	Aortic root size;
BRCA	cis	rs7523273	0.526	rs2724375	chr1:207997973	C/A	cg22525895	chr1:207977042	MIR29B2	-0.5	-12.75	-0.45	2.59e-33	Schizophrenia;
BRCA	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg18404041	chr3:52824283	ITIH1	-0.35	-9.31	-0.35	2.02e-19	Schizophrenia;
BRCA	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg18904891	chr8:8559673	CLDN23	-0.52	-9.63	-0.36	1.38e-20	Obesity-related traits;
BRCA	cis	rs829883	0.724	rs3168521	chr12:98908547	C/T	cg25150519	chr12:98850993	NA	-0.51	-9.34	-0.35	1.54e-19	Colorectal adenoma (advanced);
BRCA	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.5	0.5	2.04e-41	Colorectal cancer;
BRCA	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg10518572	chr11:65560635	OVOL1	0.28	8.15	0.31	1.99e-15	Acne (severe);
BRCA	cis	rs965469	1.000	rs6051718	chr20:3270370	C/T	cg25506879	chr20:3388711	C20orf194	-0.54	-10.51	-0.38	6.02e-24	IFN-related cytopenia;
BRCA	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3768617	0.811	rs12043805	chr1:183008150	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.89	0.36	1.46e-21	Fuchs's corneal dystrophy;
BRCA	cis	rs7072216	0.763	rs942804	chr10:100168499	C/A	cg26618903	chr10:100175079	PYROXD2	-0.31	-8.87	-0.33	7.47e-18	Metabolite levels;
BRCA	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg06671706	chr8:8559999	CLDN23	0.43	8.31	0.31	5.84e-16	Obesity-related traits;
BRCA	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg07148914	chr20:33460835	GGT7	0.38	8.63	0.32	4.77e-17	Height;
BRCA	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg07636037	chr3:49044803	WDR6	-0.58	-8.37	-0.31	3.57e-16	Cognitive function;
BRCA	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.62e-18	Alzheimer's disease (late onset);
BRCA	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-12.14	-0.43	1.13e-30	Tonsillectomy;
BRCA	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg01028140	chr2:1542097	TPO	-0.62	-12.85	-0.45	8.52e-34	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg12317470	chr15:67143691	NA	0.47	8.21	0.31	1.26e-15	Lung cancer (smoking interaction);
BRCA	cis	rs9296092	0.538	rs9469486	chr6:33516849	G/A	cg13560919	chr6:33536144	NA	-0.85	-18.39	-0.59	6.37e-61	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg02476566	chr12:106696527	TCP11L2	0.51	9.48	0.35	4.7e-20	Tourette syndrome;
BRCA	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg06026331	chr20:60912101	LAMA5	-0.48	-10.02	-0.37	4.8e-22	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.85	-0.3	1.76e-14	Colorectal cancer;
BRCA	cis	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg07460842	chr6:66804631	NA	-1.17	-37.04	-0.83	3.07e-161	Exhaled nitric oxide output;
BRCA	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg24558204	chr6:135376177	HBS1L	0.52	11.52	0.41	4.92e-28	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg03060546	chr3:49711283	APEH	-0.59	-8.48	-0.32	1.55e-16	Menarche (age at onset);
BRCA	cis	rs7147624	1.000	rs1009465	chr14:65970370	G/C	cg03016385	chr14:66212404	NA	-0.55	-8.3	-0.31	6.42e-16	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs9807989	0.507	rs6749014	chr2:103006448	C/T	cg03938978	chr2:103052716	IL18RAP	0.29	8.42	0.32	2.39e-16	Asthma;
BRCA	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg08000102	chr2:233561755	GIGYF2	0.61	13.0	0.46	1.96e-34	Coronary artery disease;
BRCA	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg19257562	chr1:2043853	PRKCZ	-0.35	-9.77	-0.36	4.21e-21	Height;
BRCA	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg18132916	chr6:79620363	NA	-0.49	-11.16	-0.4	1.53e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7818345	1.000	rs6981898	chr8:19305705	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.32	8.46	0.32	1.84e-16	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs36051895	0.659	rs59668095	chr9:5043688	C/G	cg02405213	chr9:5042618	JAK2	-0.51	-9.12	-0.34	9.89e-19	Pediatric autoimmune diseases;
BRCA	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg00631329	chr6:26305371	NA	-0.48	-13.62	-0.47	2.93e-37	Educational attainment;
BRCA	cis	rs2481665	0.772	rs6668600	chr1:62536683	C/G	cg18591186	chr1:62594603	INADL	0.54	12.42	0.44	7.37e-32	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.28e-23	Prostate cancer;
BRCA	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.66	12.38	0.44	1.06e-31	Alzheimer's disease;
BRCA	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg13010199	chr12:38710504	ALG10B	0.49	9.56	0.35	2.42e-20	Morning vs. evening chronotype;
BRCA	cis	rs4780401	0.703	rs3190321	chr16:11773662	C/G	cg01061890	chr16:11836724	TXNDC11	-0.42	-9.26	-0.34	3.1400000000000002e-19	Rheumatoid arthritis;
BRCA	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-9.73	-0.36	6e-21	Coronary artery disease;
BRCA	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg24397884	chr7:158709396	WDR60	0.63	13.19	0.46	2.63e-35	Height;
BRCA	cis	rs13064411	0.591	rs7628945	chr3:113201754	A/T	cg18753928	chr3:113234510	CCDC52	-0.46	-9.92	-0.37	1.14e-21	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg23505145	chr19:12996616	KLF1	0.54	12.28	0.44	2.95e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg03709012	chr19:19516395	GATAD2A	-0.5	-9.95	-0.37	8.69e-22	Tonsillectomy;
BRCA	trans	rs208520	0.661	rs207099	chr6:66796373	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.04	-0.64	4.67e-75	Exhaled nitric oxide output;
BRCA	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.84	0.33	9.42e-18	Motion sickness;
BRCA	cis	rs3743832	0.520	rs8045589	chr16:9210373	A/T	cg08831531	chr16:9218945	NA	0.38	7.99	0.3	6.21e-15	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
BRCA	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22307029	chr19:49891270	CCDC155	0.54	9.03	0.34	2.04e-18	Multiple sclerosis;
BRCA	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg23950597	chr19:37808831	NA	-0.72	-12.54	-0.44	2.15e-32	Coronary artery calcification;
BRCA	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg02574844	chr11:5959923	NA	-0.42	-8.16	-0.31	1.79e-15	DNA methylation (variation);
BRCA	cis	rs7651736	0.835	rs6439679	chr3:136757463	C/T	cg21827317	chr3:136751795	NA	-0.48	-10.49	-0.38	7.05e-24	Neuroticism;
BRCA	cis	rs2859741	0.967	rs534131	chr1:37484237	T/C	cg09363841	chr1:37513479	NA	-0.66	-16.63	-0.55	7.46e-52	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs6669384	0.547	rs2745979	chr1:208018219	G/C	cg22525895	chr1:207977042	MIR29B2	-0.41	-9.11	-0.34	1.08e-18	Immune response to measles vaccine (measles-specific neutralising antibody titre);
BRCA	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg09307838	chr4:120376055	NA	0.72	15.24	0.52	5.6e-45	Corneal astigmatism;
BRCA	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	21.62	0.65	3.42e-78	Platelet count;
BRCA	cis	rs754466	0.580	rs12356063	chr10:79558131	G/C	cg17075019	chr10:79541650	NA	-0.87	-23.79	-0.69	4.63e-90	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.43	-0.32	2.26e-16	Monocyte percentage of white cells;
BRCA	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.76	-0.33	1.81e-17	Breast cancer;
BRCA	cis	rs4742903	0.967	rs2417485	chr9:106867106	A/C	cg14250997	chr9:106856677	SMC2	0.35	11.18	0.4	1.21e-26	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg11663144	chr21:46675770	NA	-0.6	-13.84	-0.48	2.6e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg18512352	chr11:47633146	NA	0.35	8.68	0.32	3.31e-17	Subjective well-being;
BRCA	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg12386194	chr3:101231763	SENP7	0.67	13.0	0.46	1.96e-34	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg27446573	chr6:127587934	RNF146	0.84	18.9	0.6	1.34e-63	Breast cancer;
BRCA	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.23e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7100689	0.556	rs10788541	chr10:82016530	T/G	cg01528321	chr10:82214614	TSPAN14	0.71	15.83	0.53	7.55e-48	Post bronchodilator FEV1;
BRCA	cis	rs2415984	0.644	rs1669808	chr14:46930473	A/G	cg14871534	chr14:47121158	RPL10L	0.33	8.06	0.3	3.77e-15	Number of children ever born;
BRCA	cis	rs12618769	0.597	rs72819996	chr2:99059983	G/A	cg10123293	chr2:99228465	UNC50	0.41	8.14	0.31	2.05e-15	Bipolar disorder;
BRCA	cis	rs698833	0.788	rs1142523	chr2:44545576	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	10.65	0.39	1.78e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg18132916	chr6:79620363	NA	-0.5	-11.27	-0.41	5.13e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg21132104	chr15:45694354	SPATA5L1	0.73	16.14	0.54	2.01e-49	Homoarginine levels;
BRCA	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	16.56	0.55	1.64e-51	Intelligence (multi-trait analysis);
BRCA	cis	rs8038465	0.615	rs4075802	chr15:73963239	A/G	cg15420318	chr15:73925796	NPTN	0.41	9.12	0.34	9.27e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg06115741	chr20:33292138	TP53INP2	-0.38	-8.45	-0.32	1.97e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18918831	chr3:195489782	MUC4	0.56	9.0	0.34	2.56e-18	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6558530	0.932	rs6558531	chr8:1707566	A/G	cg19131313	chr8:1704013	NA	-0.37	-7.85	-0.3	1.77e-14	Systolic blood pressure;
BRCA	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg22875332	chr1:76189707	ACADM	0.62	11.91	0.43	1.17e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11608355	0.545	rs35018715	chr12:109893134	T/C	cg05360138	chr12:110035743	NA	0.71	13.18	0.46	2.85e-35	Neuroticism;
BRCA	cis	rs1829883	1.000	rs2461991	chr5:98793332	C/G	cg08333243	chr5:99726346	NA	-0.36	-8.81	-0.33	1.22e-17	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	8.89	0.33	5.97e-18	Educational attainment;
BRCA	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.32	8.99	0.34	2.74e-18	Response to antipsychotic treatment;
BRCA	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.7	-11.88	-0.43	1.57e-29	Platelet count;
BRCA	cis	rs35661897	0.920	rs62190909	chr2:227294858	C/G	cg03426602	chr2:227312417	NA	-0.52	-8.87	-0.33	7.55e-18	Urinary tract infection frequency;
BRCA	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.05	-0.34	1.65e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs312274	0.507	rs3816251	chr12:41318169	G/T	cg17827154	chr12:41323612	CNTN1	-0.43	-10.63	-0.39	2.05e-24	Metabolite levels  (X-11787);
BRCA	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg01819863	chr10:32635814	EPC1	1.17	20.75	0.63	1.69e-73	Sexual dysfunction (female);
BRCA	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg18252515	chr7:66147081	NA	-0.8	-11.18	-0.4	1.23e-26	Diabetic kidney disease;
BRCA	cis	rs8044868	0.530	rs8059437	chr16:72116467	A/G	cg16558253	chr16:72132732	DHX38	-0.48	-11.28	-0.41	5.08e-27	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	cis	rs10129255	0.518	rs11847766	chr14:107187425	T/C	cg07958169	chr14:107095056	NA	-0.39	-8.54	-0.32	9.72e-17	Kawasaki disease;
BRCA	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.93e-24	Motion sickness;
BRCA	cis	rs9325144	1.000	rs7963123	chr12:38976617	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-9.46	-0.35	5.66e-20	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.31	-7.83	-0.3	2.1e-14	Total body bone mineral density;
BRCA	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.39	9.02	0.34	2.2e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs11051970	0.704	rs2733694	chr12:32555230	A/G	cg24626660	chr12:32551988	NA	0.32	9.43	0.35	7.74e-20	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs754466	0.580	rs10824573	chr10:79540969	T/C	cg17075019	chr10:79541650	NA	-0.84	-20.61	-0.63	9.89e-73	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs6076960	0.846	rs6053962	chr20:6176915	A/G	cg21095983	chr6:86352623	SYNCRIP	0.41	9.7	0.36	7.65e-21	Smooth-surface caries;
BRCA	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11890956	chr21:40555474	PSMG1	0.82	20.69	0.63	3.72e-73	Cognitive function;
BRCA	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg25817165	chr18:72167213	CNDP2	-0.74	-14.1	-0.49	1.58e-39	Refractive error;
BRCA	cis	rs2116941	1.000	rs7250265	chr19:10339818	G/C	cg01850179	chr19:10340795	S1PR2	-0.64	-12.58	-0.45	1.41e-32	Pulse pressure;
BRCA	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.05	-0.56	5.13e-54	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.32	0.66	4.72e-82	Chronic sinus infection;
BRCA	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg10523679	chr1:76189770	ACADM	0.62	10.61	0.39	2.49e-24	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24549020	chr5:56110836	MAP3K1	0.58	11.73	0.42	6.76e-29	Initial pursuit acceleration;
BRCA	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg04362960	chr10:104952993	NT5C2	0.47	10.8	0.39	4.18e-25	Arsenic metabolism;
BRCA	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.26	-0.31	8.25e-16	Breast cancer;
BRCA	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg13902645	chr11:5959945	NA	-0.48	-10.42	-0.38	1.34e-23	DNA methylation (variation);
BRCA	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.02	15.09	0.51	3.01e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-16.27	-0.54	4.64e-50	Alzheimer's disease (late onset);
BRCA	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg06191203	chr2:152266755	RIF1	-0.34	-9.28	-0.34	2.67e-19	Lung cancer;
BRCA	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg24829409	chr8:58192753	C8orf71	-0.49	-9.25	-0.34	3.45e-19	Developmental language disorder (linguistic errors);
BRCA	trans	rs783540	0.967	rs17158390	chr15:83293028	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.27	-8.61	-0.32	5.71e-17	Schizophrenia;
BRCA	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.17	-0.34	6.4e-19	Total body bone mineral density;
BRCA	cis	rs16976116	0.901	rs28433503	chr15:55499857	T/C	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg12863693	chr15:85201151	NMB	0.45	8.22	0.31	1.16e-15	Schizophrenia;
BRCA	cis	rs11955398	0.585	rs12655977	chr5:60034475	A/G	cg02684056	chr5:59996105	DEPDC1B	0.38	8.99	0.34	2.82e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg11266682	chr4:10021025	SLC2A9	0.45	11.99	0.43	4.9e-30	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10045504	0.502	rs72746038	chr5:38753999	G/A	cg15396434	chr5:38725168	NA	-0.56	-10.55	-0.39	4.41e-24	Night sleep phenotypes;
BRCA	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12379764	chr21:47803548	PCNT	-0.38	-8.24	-0.31	9.57e-16	Testicular germ cell tumor;
BRCA	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg09555818	chr19:45449301	APOC2	0.48	12.7	0.45	4.25e-33	Blood protein levels;
BRCA	trans	rs11039798	0.844	rs41431447	chr11:48983199	A/G	cg15704280	chr7:45808275	SEPT13	0.66	7.89	0.3	1.27e-14	Axial length;
BRCA	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg22907277	chr7:1156413	C7orf50	0.65	12.23	0.44	4.83e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg01324343	chr3:183735012	ABCC5	0.83	20.91	0.64	2.19e-74	Anterior chamber depth;
BRCA	cis	rs4363385	0.693	rs76987906	chr1:152964530	A/G	cg21543102	chr1:152974771	SPRR3	-0.31	-8.92	-0.33	4.88e-18	Inflammatory skin disease;
BRCA	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-10.07	-0.37	3.07e-22	Tonsillectomy;
BRCA	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-15.88	-0.53	3.95e-48	Coronary artery disease;
BRCA	cis	rs17401966	0.838	rs10492971	chr1:10342975	G/A	cg03954927	chr1:10346856	KIF1B	0.43	13.78	0.48	5.32e-38	Hepatocellular carcinoma;
BRCA	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-16.45	-0.55	5.71e-51	Alzheimer's disease (late onset);
BRCA	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg23711669	chr6:146136114	FBXO30	0.72	16.38	0.54	1.28e-50	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg08601574	chr20:25228251	PYGB	0.36	8.58	0.32	7.39e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg17211192	chr8:82754475	SNX16	-0.62	-11.53	-0.42	4.32e-28	Diastolic blood pressure;
BRCA	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg18154014	chr19:37997991	ZNF793	0.62	11.63	0.42	1.7e-28	Coronary artery calcification;
BRCA	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07080220	chr10:102295463	HIF1AN	0.51	11.48	0.41	7.13e-28	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	18.13	0.58	1.36e-59	Alzheimer's disease;
BRCA	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg23033748	chr14:75592666	NEK9	-0.43	-10.49	-0.38	7.42e-24	Height;
BRCA	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg11843238	chr5:131593191	PDLIM4	0.36	7.88	0.3	1.39e-14	Breast cancer;
BRCA	cis	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg06521331	chr12:34319734	NA	-0.56	-10.19	-0.37	1.08e-22	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg14863265	chr7:2801509	GNA12	-0.4	-9.27	-0.34	2.81e-19	Height;
BRCA	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11764359	chr7:65958608	NA	-0.76	-16.98	-0.56	1.25e-53	Aortic root size;
BRCA	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg26384229	chr12:38710491	ALG10B	0.55	14.11	0.49	1.44e-39	Heart rate;
BRCA	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg02176678	chr2:219576539	TTLL4	0.47	9.52	0.35	3.39e-20	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg12165864	chr7:66369176	NA	-0.46	-10.34	-0.38	2.74e-23	Corneal structure;
BRCA	cis	rs312274	0.515	rs312273	chr12:41247742	A/G	cg17827154	chr12:41323612	CNTN1	0.41	9.92	0.37	1.1e-21	Metabolite levels  (X-11787);
BRCA	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6714710	0.603	rs58546246	chr2:98521823	C/A	cg26665480	chr2:98280029	ACTR1B	0.57	13.39	0.47	3.3e-36	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg26384229	chr12:38710491	ALG10B	0.7	15.83	0.53	7.18e-48	Bladder cancer;
BRCA	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	14.09	0.49	1.82e-39	Alzheimer's disease;
BRCA	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg00105475	chr2:10696890	NA	0.42	9.64	0.36	1.24e-20	Prostate cancer;
BRCA	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg10057126	chr4:77819792	ANKRD56	0.65	14.81	0.51	6.83e-43	Emphysema distribution in smoking;
BRCA	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg12863693	chr15:85201151	NMB	0.44	7.85	0.3	1.81e-14	Schizophrenia;
BRCA	cis	rs9309473	0.583	rs35885918	chr2:73612234	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-12.35	-0.44	1.4e-31	Metabolite levels;
BRCA	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg12501888	chr15:85177176	SCAND2	0.35	8.44	0.32	2.16e-16	P wave terminal force;
BRCA	cis	rs908922	0.676	rs2146120	chr1:152504200	A/T	cg20991723	chr1:152506922	NA	0.38	7.84	0.3	1.88e-14	Hair morphology;
BRCA	trans	rs1422110	0.616	rs6452689	chr5:85445059	A/T	cg01787110	chr1:109008453	NBPF6	0.4	8.65	0.32	4.21e-17	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18876405	chr7:65276391	NA	-0.5	-11.19	-0.4	1.18e-26	Aortic root size;
BRCA	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19346786	chr7:2764209	NA	-0.32	-9.6	-0.36	1.79e-20	Height;
BRCA	trans	rs2797160	1.000	rs983543	chr6:126005767	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.35	-7.83	-0.3	2.01e-14	Endometrial cancer;
BRCA	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.29	0.31	6.45e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs3740540	0.761	rs61870251	chr10:126284415	A/C	cg04949429	chr10:126290192	LHPP	-0.41	-8.96	-0.33	3.43e-18	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs3815308	0.530	rs2269880	chr19:2195611	T/C	cg09261902	chr19:2140048	AP3D1	0.34	8.43	0.32	2.23e-16	Breast cancer;
BRCA	cis	rs7520050	0.833	rs1085242	chr1:46544224	T/A	cg24296786	chr1:45957014	TESK2	0.41	9.19	0.34	5.42e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-11.39	-0.41	1.79e-27	Hemoglobin concentration;
BRCA	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-8.97	-0.33	3.15e-18	Educational attainment;
BRCA	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg17063962	chr7:91808500	NA	0.57	12.99	0.46	2.14e-34	Breast cancer;
BRCA	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-11.39	-0.41	1.76e-27	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg14004847	chr7:1930337	MAD1L1	-0.46	-8.85	-0.33	8.71e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg09307838	chr4:120376055	NA	0.75	16.17	0.54	1.48e-49	Corneal astigmatism;
BRCA	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.21	0.68	7.15e-87	Chronic sinus infection;
BRCA	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.8	-0.42	3.24e-29	Response to antipsychotic treatment;
BRCA	cis	rs3820068	0.603	rs2236215	chr1:15892415	A/C	cg17385448	chr1:15911702	AGMAT	0.4	8.6	0.32	6.09e-17	Systolic blood pressure;
BRCA	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.94e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.33	9.06	0.34	1.56e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg00409905	chr10:38381863	ZNF37A	-0.5	-10.45	-0.38	1.03e-23	Extrinsic epigenetic age acceleration;
BRCA	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg25482853	chr8:67687455	SGK3	1.01	17.39	0.57	1.01e-55	Lung disease severity in cystic fibrosis;
BRCA	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-7.92	-0.3	1.07e-14	Total body bone mineral density;
BRCA	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg11833968	chr6:79620685	NA	-0.41	-9.17	-0.34	6.16e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7523050	0.908	rs17621536	chr1:109396908	A/G	cg08274380	chr1:109419600	GPSM2	0.84	12.92	0.46	4.12e-34	Fat distribution (HIV);
BRCA	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg17691542	chr6:26056736	HIST1H1C	0.54	11.43	0.41	1.2100000000000001e-27	Height;
BRCA	trans	rs8073060	0.586	rs8064895	chr17:34001121	T/C	cg19694781	chr19:47549865	TMEM160	-1.04	-21.53	-0.65	9.91e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00166722	chr3:10149974	C3orf24	0.67	13.46	0.47	1.52e-36	Alzheimer's disease;
BRCA	trans	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04565464	chr8:145669602	NFKBIL2	0.38	8.92	0.33	5.04e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs1420338	0.933	rs6462533	chr7:34168028	G/A	cg01275685	chr7:34179230	BMPER	-0.51	-11.41	-0.41	1.37e-27	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg05283184	chr6:79620031	NA	-0.43	-11.22	-0.41	8.77e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg08470875	chr2:26401718	FAM59B	-0.52	-7.99	-0.3	6.24e-15	Gut microbiome composition (summer);
BRCA	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.1	0.46	6.97e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg18305652	chr10:134549665	INPP5A	0.49	11.17	0.4	1.39e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg03433033	chr1:76189801	ACADM	0.89	23.76	0.68	6.23e-90	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	12.04	0.43	2.97e-30	Personality dimensions;
BRCA	cis	rs11608355	0.515	rs2241204	chr12:109972037	G/A	cg05360138	chr12:110035743	NA	0.73	13.35	0.47	4.74e-36	Neuroticism;
BRCA	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg06766960	chr11:133703094	NA	-0.61	-12.51	-0.44	2.96e-32	Childhood ear infection;
BRCA	cis	rs13053817	0.898	rs16987627	chr22:29835060	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.49	-9.74	-0.36	5.54e-21	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs2354432	0.607	rs11587707	chr1:146707186	T/C	cg25205988	chr1:146714368	CHD1L	-0.91	-11.34	-0.41	2.84e-27	Mitochondrial DNA levels;
BRCA	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.37	-0.41	2.06e-27	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg19318889	chr4:1322082	MAEA	0.36	7.93	0.3	9.58e-15	Longevity;
BRCA	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg03425785	chr20:62221387	GMEB2	0.51	8.23	0.31	1.04e-15	Glioblastoma;
BRCA	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.32	-8.0	-0.3	5.96e-15	Personality dimensions;
BRCA	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	19.65	0.61	1.3e-67	Smoking behavior;
BRCA	cis	rs7818345	1.000	rs11780343	chr8:19290963	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.3	7.97	0.3	7.15e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg10932868	chr11:921992	NA	0.42	10.02	0.37	4.98e-22	Alzheimer's disease (late onset);
BRCA	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg09904177	chr6:26538194	HMGN4	0.57	18.43	0.59	3.7e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg02376097	chr19:46275166	DMPK	0.45	10.21	0.37	8.91e-23	Coronary artery disease;
BRCA	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.65	-15.08	-0.51	3.41e-44	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg20203395	chr5:56204925	C5orf35	-0.51	-10.03	-0.37	4.49e-22	Initial pursuit acceleration;
BRCA	cis	rs17253792	0.545	rs12879705	chr14:56017684	C/G	cg01858014	chr14:56050164	KTN1	-0.61	-7.99	-0.3	6.09e-15	Putamen volume;
BRCA	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.35	9.07	0.34	1.44e-18	Resting heart rate;
BRCA	cis	rs586533	0.801	rs651446	chr11:99496269	A/G	cg22878054	chr11:99397252	CNTN5	0.32	7.95	0.3	8.3e-15	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	10.53	0.38	5.02e-24	Brugada syndrome;
BRCA	cis	rs738322	0.805	rs2235344	chr22:38518083	G/A	cg20207973	chr22:38506712	BAIAP2L2	0.38	9.92	0.37	1.11e-21	Cutaneous nevi;
BRCA	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg27446573	chr6:127587934	RNF146	0.86	19.7	0.61	7.62e-68	Breast cancer;
BRCA	trans	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.71	0.33	2.63e-17	Mean corpuscular volume;
BRCA	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg26384229	chr12:38710491	ALG10B	0.41	9.21	0.34	4.52e-19	Morning vs. evening chronotype;
BRCA	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg11366901	chr6:160182831	ACAT2	0.78	15.08	0.51	3.42e-44	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs4363385	0.818	rs2339492	chr1:152985552	G/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.42	-0.32	2.39e-16	Inflammatory skin disease;
BRCA	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg03060546	chr3:49711283	APEH	0.6	10.4	0.38	1.61e-23	Menarche (age at onset);
BRCA	cis	rs4845875	0.514	rs198406	chr1:11897592	A/G	cg24844545	chr1:11908347	NPPA	-0.31	-8.08	-0.3	3.13e-15	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09263875	chr16:632152	PIGQ	0.74	21.36	0.65	7.95e-77	Height;
BRCA	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	17.7	0.57	2.51e-57	Platelet count;
BRCA	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg03146154	chr1:46216737	IPP	0.45	10.08	0.37	2.88e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7903847	0.596	rs7922512	chr10:99155685	C/A	cg08345082	chr10:99160200	RRP12	-0.3	-8.72	-0.33	2.41e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs858239	0.536	rs6956974	chr7:23252318	C/G	cg23682824	chr7:23144976	KLHL7	-0.32	-8.2	-0.31	1.27e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg11663144	chr21:46675770	NA	0.6	13.98	0.48	5.86e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg06623918	chr6:96969491	KIAA0776	-0.68	-12.16	-0.43	9.25e-31	Migraine;Coronary artery disease;
BRCA	cis	rs13082711	0.513	rs7612102	chr3:27372826	A/G	cg02860705	chr3:27208620	NA	-0.56	-10.69	-0.39	1.15e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg11766577	chr21:47581405	C21orf56	0.43	9.53	0.35	3.17e-20	Testicular germ cell tumor;
BRCA	cis	rs13046373	0.505	rs2832934	chr21:31899760	A/G	cg22337977	chr21:31811175	KRTAP15-1	0.35	8.06	0.3	3.82e-15	HDL cholesterol;
BRCA	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.28	-0.31	7.47e-16	Bipolar disorder;
BRCA	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.56	0.55	1.64e-51	Colorectal cancer;
BRCA	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	14.56	0.5	1.15e-41	Ileal carcinoids;
BRCA	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg08992911	chr2:238395768	MLPH	0.4	8.72	0.33	2.31e-17	Prostate cancer;
BRCA	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg02175503	chr12:58329896	NA	0.49	10.38	0.38	2.01e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg02493740	chr2:85810744	VAMP5	-0.54	-11.23	-0.41	8.17e-27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.61e-19	Morning vs. evening chronotype;
BRCA	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	12.23	0.44	4.85e-31	Platelet count;
BRCA	cis	rs13046373	0.535	rs1354866	chr21:31981559	A/T	cg06468780	chr21:31798236	KRTAP13-3	0.34	8.66	0.32	3.99e-17	HDL cholesterol;
BRCA	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg12863693	chr15:85201151	NMB	-0.54	-11.18	-0.4	1.31e-26	Schizophrenia;
BRCA	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg19920283	chr7:105172520	RINT1	0.58	9.24	0.34	3.49e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg16576597	chr16:28551801	NUPR1	0.3	8.48	0.32	1.6e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg06521331	chr12:34319734	NA	-0.52	-10.17	-0.37	1.27e-22	Morning vs. evening chronotype;
BRCA	trans	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg06521331	chr12:34319734	NA	-0.53	-9.53	-0.35	3.32e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4891159	0.757	rs11665518	chr18:74147054	C/T	cg24786174	chr18:74118243	ZNF516	-0.75	-18.0	-0.58	6.43e-59	Longevity;
BRCA	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.56	0.63	1.72e-72	Electrocardiographic conduction measures;
BRCA	trans	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	14.47	0.5	3.09e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg27170947	chr2:26402098	FAM59B	-0.67	-11.53	-0.42	4.46e-28	Gut microbiome composition (summer);
BRCA	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg04990556	chr1:26633338	UBXN11	-0.47	-9.27	-0.34	2.76e-19	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg15704280	chr7:45808275	SEPT13	0.62	10.34	0.38	2.9e-23	Axial length;
BRCA	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg23625390	chr15:77176239	SCAPER	0.52	12.95	0.46	3.33e-34	Blood metabolite levels;
BRCA	cis	rs58804349	0.685	rs11239855	chr10:43483879	A/G	cg15903213	chr10:43522190	NA	0.37	8.0	0.3	5.85e-15	Pediatric bone mineral content (radius);
BRCA	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg18351406	chr4:77819688	ANKRD56	0.62	14.04	0.49	3.05e-39	Emphysema distribution in smoking;
BRCA	cis	rs870825	0.616	rs7692367	chr4:185651056	T/C	cg04058563	chr4:185651563	MLF1IP	0.79	17.79	0.58	7.74e-58	Blood protein levels;
BRCA	trans	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg01620082	chr3:125678407	NA	-0.7	-8.64	-0.32	4.42e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs113835537	0.529	rs60358007	chr11:66222353	G/A	cg24851651	chr11:66362959	CCS	0.5	8.62	0.32	5.19e-17	Airway imaging phenotypes;
BRCA	cis	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg06521331	chr12:34319734	NA	-0.52	-10.25	-0.38	6.04e-23	Morning vs. evening chronotype;
BRCA	cis	rs4302748	0.862	rs59125899	chr7:36182857	G/A	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs798766	0.779	rs55895920	chr4:1735930	C/T	cg10756475	chr4:1757242	NA	0.38	8.58	0.32	7.19e-17	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-18.16	-0.58	1.03e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg24324837	chr19:49891574	CCDC155	0.54	9.6	0.36	1.75e-20	Multiple sclerosis;
BRCA	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-11.77	-0.42	4.46e-29	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg05340658	chr4:99064831	C4orf37	0.62	14.69	0.5	2.65e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg17971929	chr21:40555470	PSMG1	0.77	18.12	0.58	1.6e-59	Cognitive function;
BRCA	trans	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	20.73	0.63	2.22e-73	Exhaled nitric oxide output;
BRCA	cis	rs6684514	1.000	rs66965793	chr1:156285814	G/A	cg16558208	chr1:156270281	VHLL	0.36	8.36	0.31	4.06e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs7172677	0.737	rs7163083	chr15:75442337	A/C	cg14664628	chr15:75095509	CSK	-0.37	-7.88	-0.3	1.46e-14	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	trans	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg26043149	chr18:55253948	FECH	0.39	8.89	0.33	6.31e-18	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4728302	0.583	rs1424583	chr7:133159583	T/G	cg10665199	chr7:133106180	EXOC4	0.47	10.09	0.37	2.48e-22	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs12612619	0.732	rs11681562	chr2:27250603	A/G	cg00617064	chr2:27272375	NA	-0.32	-8.45	-0.32	1.91e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg06697600	chr4:7070879	GRPEL1	0.59	9.98	0.37	6.68e-22	Monocyte percentage of white cells;
BRCA	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg03474202	chr17:45855739	NA	-0.46	-12.35	-0.44	1.47e-31	IgG glycosylation;
BRCA	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.47	-0.47	1.33e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs9811920	0.660	rs11719468	chr3:99671848	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-11.15	-0.4	1.6e-26	Axial length;
BRCA	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.17	0.49	7.64e-40	Motion sickness;
BRCA	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	9.2e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24531977	chr5:56204891	C5orf35	-0.88	-17.68	-0.57	2.99e-57	Initial pursuit acceleration;
BRCA	cis	rs7617773	0.780	rs7653336	chr3:48369464	T/A	cg11946769	chr3:48343235	NME6	0.67	13.64	0.47	2.37e-37	Coronary artery disease;
BRCA	cis	rs6545883	0.929	rs1838978	chr2:61540923	T/C	cg15711740	chr2:61764176	XPO1	0.51	12.2	0.43	6.69e-31	Tuberculosis;
BRCA	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg18252515	chr7:66147081	NA	-1.0	-14.27	-0.49	2.76e-40	Diabetic kidney disease;
BRCA	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-16.53	-0.55	2.17e-51	Lymphocyte percentage of white cells;
BRCA	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.52	8.84	0.33	9.33e-18	Mean platelet volume;
BRCA	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg06060754	chr5:176797920	RGS14	0.59	11.18	0.4	1.31e-26	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg26384229	chr12:38710491	ALG10B	-0.51	-12.16	-0.43	9.46e-31	Morning vs. evening chronotype;
BRCA	trans	rs2840044	1.000	rs1671656	chr17:33939661	C/T	cg19694781	chr19:47549865	TMEM160	-0.44	-10.24	-0.38	6.94e-23	Response to radiotherapy in cancer (late toxicity);
BRCA	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg22713356	chr15:30763199	NA	1.31	26.42	0.72	1.54e-104	Uric acid levels;
BRCA	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.75	-12.66	-0.45	6.21e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs587242	1.000	rs12727152	chr1:96915548	G/A	cg10631902	chr5:14652156	NA	0.4	9.94	0.37	9.26e-22	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
BRCA	cis	rs12530845	0.623	rs77454235	chr7:135341862	T/C	cg23117316	chr7:135346802	PL-5283	-0.4	-8.2	-0.31	1.35e-15	Red blood cell traits;
BRCA	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg04317338	chr11:64019027	PLCB3	0.52	7.97	0.3	7.56e-15	Mean platelet volume;
BRCA	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg06360820	chr2:242988706	NA	0.74	13.73	0.48	8.56e-38	Obesity-related traits;
BRCA	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.5	-14.04	-0.49	3.14e-39	Lung cancer;
BRCA	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg00071950	chr4:10020882	SLC2A9	0.64	15.96	0.53	1.61e-48	Bone mineral density;
BRCA	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.43	9.7	0.36	7.47e-21	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19748678	chr4:122722346	EXOSC9	0.74	15.9	0.53	3.11e-48	Type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.94e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	20.08	0.62	6.67e-70	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7523273	0.606	rs2796263	chr1:207915978	T/C	cg22525895	chr1:207977042	MIR29B2	0.48	12.22	0.44	5.47e-31	Schizophrenia;
BRCA	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg11584989	chr19:19387371	SF4	0.61	13.9	0.48	1.5e-38	Bipolar disorder;
BRCA	cis	rs7945705	0.782	rs3763918	chr11:8819683	T/A	cg21881798	chr11:8931708	C11orf17;ST5	0.49	10.62	0.39	2.21e-24	Hemoglobin concentration;
BRCA	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg24692254	chr21:30365293	RNF160	-0.6	-15.11	-0.51	2.49e-44	Dental caries;
BRCA	cis	rs754466	0.561	rs11002344	chr10:79709725	A/T	cg17075019	chr10:79541650	NA	-0.5	-7.83	-0.3	1.98e-14	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg12062639	chr20:23401060	NAPB	0.94	13.03	0.46	1.46e-34	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.77	-0.42	4.5e-29	Response to antipsychotic treatment;
BRCA	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.64	-0.36	1.25e-20	Developmental language disorder (linguistic errors);
BRCA	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg26384229	chr12:38710491	ALG10B	0.68	14.09	0.49	1.77e-39	Morning vs. evening chronotype;
BRCA	cis	rs2882667	0.894	rs1433008	chr5:138333664	T/C	cg04439458	chr5:138467593	SIL1	-0.34	-9.47	-0.35	5.33e-20	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg00750074	chr16:89608354	SPG7	0.37	9.66	0.36	1.05e-20	Multiple myeloma (IgH translocation);
BRCA	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.22	-0.37	8.46e-23	Psoriasis;
BRCA	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg27661571	chr11:113659931	NA	-0.83	-12.11	-0.43	1.55e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs1868673	1.000	rs9784281	chr3:150159779	C/G	cg04908077	chr3:150187338	NA	-0.33	-8.82	-0.33	1.09e-17	Waist circumference;
BRCA	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg01777586	chr17:80163174	CCDC57	-0.41	-8.28	-0.31	7.21e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg00757033	chr12:89920650	WDR51B	0.54	10.87	0.39	2.32e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs9287719	0.601	rs6751436	chr2:10723862	C/T	cg00105475	chr2:10696890	NA	0.47	10.48	0.38	7.94e-24	Prostate cancer;
BRCA	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg23533926	chr12:111358616	MYL2	-0.44	-9.19	-0.34	5.59e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg13628971	chr7:2884303	GNA12	0.38	8.42	0.32	2.39e-16	Height;
BRCA	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg20573242	chr4:122745356	CCNA2	0.49	10.77	0.39	5.75e-25	Type 2 diabetes;
BRCA	trans	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg25214090	chr10:38739885	LOC399744	0.45	10.33	0.38	3.04e-23	Corneal astigmatism;
BRCA	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg18904891	chr8:8559673	CLDN23	0.64	12.57	0.45	1.54e-32	Obesity-related traits;
BRCA	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg23711669	chr6:146136114	FBXO30	-0.77	-18.56	-0.59	7.93e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs16867321	0.950	rs12472841	chr2:181491840	C/A	cg23363182	chr2:181467187	NA	-0.45	-8.58	-0.32	6.96e-17	Obesity;
BRCA	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07343612	chr16:622815	PIGQ	-0.68	-22.79	-0.67	1.27e-84	Height;
BRCA	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg09915433	chr19:53449742	NA	-0.81	-19.97	-0.62	2.5e-69	Psoriasis;
BRCA	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03264133	chr6:25882463	NA	0.72	16.63	0.55	7.45e-52	Blood metabolite levels;
BRCA	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg15839431	chr19:19639596	YJEFN3	-0.41	-9.13	-0.34	9.05e-19	Bipolar disorder;
BRCA	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg16606324	chr3:10149918	C3orf24	0.56	10.91	0.4	1.64e-25	Alzheimer's disease;
BRCA	trans	rs208520	0.661	rs207090	chr6:66783963	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.23	-0.64	4.44e-76	Exhaled nitric oxide output;
BRCA	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	cg06064525	chr11:970664	AP2A2	-0.29	-8.56	-0.32	8.47e-17	Alzheimer's disease (late onset);
BRCA	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg23895963	chr12:117471115	NA	0.5	9.47	0.35	5.37e-20	Subcortical brain region volumes;Hippocampal volume;
BRCA	trans	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg25214090	chr10:38739885	LOC399744	0.49	10.87	0.4	2.29e-25	Corneal astigmatism;
BRCA	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.31	-0.49	1.65e-40	Total cholesterol levels;
BRCA	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg21782813	chr7:2030301	MAD1L1	-0.33	-9.54	-0.35	3.06e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg07148914	chr20:33460835	GGT7	-0.42	-9.11	-0.34	1.09e-18	Height;
BRCA	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg20387954	chr3:183756860	HTR3D	0.44	10.0	0.37	5.71e-22	Anterior chamber depth;
BRCA	cis	rs1557765	0.527	rs10832782	chr11:17397273	G/C	cg04705435	chr11:17411270	KCNJ11	0.34	7.84	0.3	1.95e-14	Body mass index;Social communication problems;
BRCA	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg18402987	chr7:1209562	NA	0.43	8.08	0.3	3.13e-15	Longevity;Endometriosis;
BRCA	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg23711669	chr6:146136114	FBXO30	0.67	15.72	0.53	2.45e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6121246	0.559	rs1062794	chr20:30381758	G/C	cg13852791	chr20:30311386	BCL2L1	0.94	22.82	0.67	9.51e-85	Mean corpuscular hemoglobin;
BRCA	cis	rs1018836	0.923	rs12545279	chr8:91636373	C/G	cg16814680	chr8:91681699	NA	-0.51	-10.66	-0.39	1.53e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11764359	chr7:65958608	NA	0.75	16.82	0.55	8.27e-53	Aortic root size;
BRCA	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg12661370	chr5:149340060	SLC26A2	0.56	8.3	0.31	6.09e-16	HIV-1 control;
BRCA	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg12011299	chr4:100065546	ADH4	0.43	10.82	0.39	3.46e-25	Alcohol dependence;
BRCA	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg25173405	chr17:45401733	C17orf57	0.52	11.1	0.4	2.79e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg23711669	chr6:146136114	FBXO30	0.73	16.88	0.56	3.73e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10871290	0.551	rs3863435	chr16:74465396	C/G	cg01733217	chr16:74700730	RFWD3	-0.52	-13.09	-0.46	7.62e-35	Breast cancer;
BRCA	trans	rs11165623	0.792	rs1931180	chr1:96914049	C/T	cg10631902	chr5:14652156	NA	-0.52	-16.97	-0.56	1.36e-53	Hip circumference;Waist circumference;
BRCA	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg11062466	chr8:58055876	NA	0.4	7.85	0.3	1.74e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg12160578	chr15:63334699	TPM1	-0.42	-8.53	-0.32	1.04e-16	Platelet count;
BRCA	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg23229984	chr5:148520753	ABLIM3	0.35	8.69	0.33	3.04e-17	Breast cancer;
BRCA	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg06640241	chr16:89574553	SPG7	0.56	12.3	0.44	2.25e-31	Multiple myeloma (IgH translocation);
BRCA	cis	rs2559856	1.000	rs2695285	chr12:102089043	G/A	cg12924262	chr12:102091054	CHPT1	0.38	8.6	0.32	6.38e-17	Blood protein levels;
BRCA	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.78	-11.25	-0.41	6.26e-27	Schizophrenia;
BRCA	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg07414643	chr4:187882934	NA	-0.24	-8.04	-0.3	4.31e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs243505	1.000	rs243522	chr7:148420509	A/G	cg09806900	chr7:148480153	CUL1	-0.4	-8.37	-0.31	3.73e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.68	-0.32	3.18e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg15704280	chr7:45808275	SEPT13	0.5	9.26	0.34	3.15e-19	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7246967	0.673	rs8103012	chr19:22879285	C/T	cg23217946	chr19:22817039	ZNF492	0.46	8.46	0.32	1.87e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg12463550	chr7:65579703	CRCP	-0.38	-8.13	-0.31	2.28e-15	Aortic root size;
BRCA	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg01939980	chr4:1354348	KIAA1530	0.32	9.07	0.34	1.41e-18	Longevity;
BRCA	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.18	0.4	1.22e-26	Bipolar disorder;
BRCA	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg24747557	chr10:131355152	MGMT	-0.31	-7.89	-0.3	1.28e-14	Response to temozolomide;
BRCA	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg01262667	chr19:19385393	TM6SF2	-0.42	-10.68	-0.39	1.35e-24	Tonsillectomy;
BRCA	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-9.93	-0.37	1.03e-21	Gut microbiome composition (summer);
BRCA	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg22834771	chr12:69754056	YEATS4	-0.37	-9.05	-0.34	1.69e-18	Blood protein levels;
BRCA	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-14.85	-0.51	4.73e-43	Bipolar disorder and schizophrenia;
BRCA	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23248424	chr5:179741104	GFPT2	-0.67	-14.24	-0.49	3.72e-40	Height;
BRCA	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg04756594	chr16:24857601	SLC5A11	0.34	8.31	0.31	5.53e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.37	-7.91	-0.3	1.12e-14	IgG glycosylation;
BRCA	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg23711669	chr6:146136114	FBXO30	0.64	14.42	0.5	5.1e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg09060608	chr5:178986726	RUFY1	0.55	12.66	0.45	6.24e-33	Lung cancer;
BRCA	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg03477792	chr4:77819574	ANKRD56	0.62	14.81	0.51	6.91e-43	Emphysema distribution in smoking;
BRCA	cis	rs501916	0.833	rs11629796	chr15:48045248	A/G	cg16110827	chr15:48056943	SEMA6D	-0.44	-9.38	-0.35	1.14e-19	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs4423214	0.879	rs1792282	chr11:71135166	G/A	cg05163923	chr11:71159392	DHCR7	-0.51	-10.24	-0.38	6.61e-23	Vitamin D levels;
BRCA	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-9.26	-0.34	2.96e-19	Colorectal cancer;
BRCA	cis	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg00852783	chr1:26633632	UBXN11	-0.47	-8.4	-0.32	2.87e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg09462578	chr12:12878428	APOLD1	-0.69	-11.85	-0.42	2.08e-29	Systemic lupus erythematosus;
BRCA	cis	rs887829	0.641	rs10179094	chr2:234597825	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.35	-8.67	-0.32	3.66e-17	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs9790314	0.715	rs980976	chr3:160771668	T/G	cg03342759	chr3:160939853	NMD3	-0.51	-9.79	-0.36	3.62e-21	Morning vs. evening chronotype;
BRCA	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg24130564	chr14:104152367	KLC1	0.4	9.19	0.34	5.61e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs507080	0.845	rs509641	chr11:118558952	T/C	cg09144398	chr11:118550485	TREH	-0.37	-8.96	-0.33	3.5e-18	Serum metabolite levels;
BRCA	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg14092571	chr14:90743983	NA	-0.33	-7.87	-0.3	1.57e-14	Mortality in heart failure;
BRCA	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.62	-13.89	-0.48	1.63e-38	Multiple sclerosis;
BRCA	trans	rs8002861	0.935	rs4942256	chr13:44455920	A/T	cg17145862	chr1:211918768	LPGAT1	0.73	19.3	0.61	1.01e-65	Leprosy;
BRCA	cis	rs897080	0.552	rs1067377	chr2:44648239	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	9.56	0.35	2.59e-20	Height;
BRCA	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg22920501	chr2:26401640	FAM59B	-0.65	-11.29	-0.41	4.42e-27	Gut microbiome composition (summer);
BRCA	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg04450456	chr4:17643702	FAM184B	0.41	12.47	0.44	4.22e-32	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg01420254	chr6:26195488	NA	0.55	8.58	0.32	7.05e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs6704768	0.545	rs5004510	chr2:233679275	A/C	cg08000102	chr2:233561755	GIGYF2	-0.78	-17.16	-0.56	1.52e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg25208724	chr1:156163844	SLC25A44	0.59	11.95	0.43	7.53e-30	Testicular germ cell tumor;
BRCA	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.61	-12.72	-0.45	3.34e-33	Lymphocyte counts;
BRCA	cis	rs6484504	0.576	rs208083	chr11:31196880	C/T	cg26647111	chr11:31128758	NA	-0.44	-9.61	-0.36	1.61e-20	Red blood cell count;
BRCA	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg06532163	chr17:45867833	NA	0.39	8.08	0.3	3.17e-15	IgG glycosylation;
BRCA	trans	rs1493916	0.748	rs1941684	chr18:31304421	C/G	cg15819921	chr19:927150	ARID3A	-0.43	-8.32	-0.31	5.49e-16	Life satisfaction;
BRCA	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg05283184	chr6:79620031	NA	-0.43	-11.08	-0.4	3.33e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg05347473	chr6:146136440	FBXO30	-0.42	-7.92	-0.3	1.08e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2629540	0.824	rs1552345	chr10:126477406	A/G	cg08799069	chr10:126477246	METTL10	-0.54	-11.85	-0.42	1.97e-29	Cocaine dependence;
BRCA	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.57	0.39	3.5e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg08000102	chr2:233561755	GIGYF2	-0.64	-14.0	-0.48	5.16e-39	Coronary artery disease;
BRCA	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg07741184	chr6:167504864	NA	0.31	8.94	0.33	4.11e-18	Primary biliary cholangitis;
BRCA	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03264133	chr6:25882463	NA	0.73	16.65	0.55	5.4e-52	Blood metabolite levels;
BRCA	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.51e-36	High light scatter reticulocyte count;
BRCA	cis	rs2599510	0.811	rs2710628	chr2:32758353	A/C	cg02381751	chr2:32503542	YIPF4	0.41	8.29	0.31	6.85e-16	Interleukin-18 levels;
BRCA	cis	rs36051895	0.632	rs11793886	chr9:5125469	A/G	cg02405213	chr9:5042618	JAK2	-0.49	-8.9	-0.33	5.81e-18	Pediatric autoimmune diseases;
BRCA	trans	rs2262909	0.962	rs12609368	chr19:22263996	T/C	cg17074339	chr11:11642133	GALNTL4	0.42	8.15	0.31	1.93e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	trans	rs4714291	0.698	rs2983144	chr6:40046724	G/A	cg02267698	chr19:7991119	CTXN1	-0.44	-8.85	-0.33	8.61e-18	Strep throat;
BRCA	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg11584989	chr19:19387371	SF4	0.63	13.52	0.47	7.85e-37	Bipolar disorder;
BRCA	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg22638593	chr5:131593259	PDLIM4	0.32	7.86	0.3	1.7e-14	Acylcarnitine levels;
BRCA	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05535760	chr7:792225	HEATR2	0.87	14.93	0.51	1.94e-43	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.65	-10.28	-0.38	4.77e-23	Lung cancer in ever smokers;
BRCA	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.76	-12.68	-0.45	5.04e-33	Schizophrenia;
BRCA	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg10729496	chr3:10149963	C3orf24	0.46	8.61	0.32	5.75e-17	Alzheimer's disease;
BRCA	cis	rs877282	0.786	rs11253392	chr10:788768	G/A	cg17470449	chr10:769945	NA	0.51	8.62	0.32	5.29e-17	Uric acid levels;
BRCA	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.36	9.23	0.34	3.99e-19	Resting heart rate;
BRCA	cis	rs1421811	0.509	rs7733428	chr5:32689850	G/A	cg16267343	chr5:32710456	NPR3	0.63	11.96	0.43	7.05e-30	Blood pressure;
BRCA	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg05714579	chr10:131428358	MGMT	-0.56	-13.71	-0.48	1.07e-37	Response to temozolomide;
BRCA	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg09307838	chr4:120376055	NA	0.6	13.0	0.46	1.91e-34	Corneal astigmatism;
BRCA	trans	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.16	0.31	1.73e-15	Mean corpuscular volume;
BRCA	cis	rs9815354	0.723	rs77572508	chr3:41938044	C/A	cg03022575	chr3:42003672	ULK4	0.68	9.48	0.35	4.71e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg21535247	chr6:8435926	SLC35B3	0.42	9.42	0.35	7.86e-20	Motion sickness;
BRCA	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.37	-0.38	2.18e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	24.7	0.7	4.42e-95	Platelet count;
BRCA	cis	rs7020830	0.858	rs67036212	chr9:37133538	A/G	cg14294708	chr9:37120828	ZCCHC7	1.2	38.04	0.83	2.49e-166	Schizophrenia;
BRCA	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg21395723	chr22:39101663	GTPBP1	0.39	8.33	0.31	4.9e-16	Menopause (age at onset);
BRCA	cis	rs3892630	0.588	rs7245709	chr19:33242755	C/T	cg22980127	chr19:33182716	NUDT19	0.92	20.75	0.63	1.6e-73	Red blood cell traits;
BRCA	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.46	9.25	0.34	3.33e-19	Tonsillectomy;
BRCA	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg08000102	chr2:233561755	GIGYF2	-0.62	-13.31	-0.47	7.64e-36	Coronary artery disease;
BRCA	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg00990874	chr7:1149470	C7orf50	-0.52	-9.49	-0.35	4.61e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10802521	chr3:52805072	NEK4	-0.33	-9.13	-0.34	8.81e-19	Bipolar disorder;
BRCA	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg02176678	chr2:219576539	TTLL4	0.42	10.85	0.39	2.79e-25	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg03342759	chr3:160939853	NMD3	-0.78	-17.38	-0.57	1.13e-55	Morning vs. evening chronotype;
BRCA	cis	rs1997103	1.000	rs4947504	chr7:55409428	T/C	cg17469321	chr7:55412551	NA	0.5	9.55	0.35	2.71e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4953318	0.577	rs67087783	chr2:46363544	C/T	cg12428440	chr2:46370979	PRKCE	0.5	10.53	0.38	5.1900000000000004e-24	Red blood cell count;Hematocrit;Red blood cell traits;
BRCA	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-11.04	-0.4	4.7e-26	IgG glycosylation;
BRCA	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg16230307	chr14:35515116	FAM177A1	0.74	15.5	0.52	3.27e-46	Psoriasis;
BRCA	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg11879182	chr18:77439856	CTDP1	0.65	13.74	0.48	7.88e-38	Monocyte count;
BRCA	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg01420254	chr6:26195488	NA	0.53	8.54	0.32	9.95e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg12463550	chr7:65579703	CRCP	-0.37	-8.04	-0.3	4.31e-15	Aortic root size;
BRCA	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg11584989	chr19:19387371	SF4	0.63	13.46	0.47	1.53e-36	Bipolar disorder;
BRCA	cis	rs12711979	0.904	rs12329356	chr2:3868533	G/C	cg17052675	chr2:3827356	NA	-0.43	-11.52	-0.41	4.81e-28	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.51	0.35	3.85e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504073	0.647	rs10105794	chr8:50012793	G/C	cg00325661	chr8:49890786	NA	0.39	11.34	0.41	2.81e-27	Blood metabolite ratios;
BRCA	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg16482183	chr6:26056742	HIST1H1C	0.5	10.46	0.38	9.27e-24	Height;
BRCA	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-8.29	-0.31	6.81e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-16.55	-0.55	1.78e-51	Chronic sinus infection;
BRCA	trans	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg26384229	chr12:38710491	ALG10B	0.52	11.22	0.41	8.84e-27	Morning vs. evening chronotype;
BRCA	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg06238570	chr21:40685208	BRWD1	-0.46	-9.19	-0.34	5.6e-19	Cognitive function;
BRCA	cis	rs7633770	0.769	rs3796371	chr3:46667224	C/T	cg11219411	chr3:46661640	NA	0.7	19.14	0.6	6.79e-65	Coronary artery disease;
BRCA	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg14844989	chr11:31128820	NA	-0.45	-9.52	-0.35	3.53e-20	Red blood cell count;
BRCA	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg07148914	chr20:33460835	GGT7	0.46	9.9	0.36	1.35e-21	Height;
BRCA	cis	rs7617773	0.780	rs6442111	chr3:48312060	G/C	cg11946769	chr3:48343235	NME6	0.62	13.51	0.47	9.11e-37	Coronary artery disease;
BRCA	cis	rs6138458	0.828	rs6132785	chr20:24993414	T/C	cg26195577	chr20:24973756	C20orf3	0.71	17.49	0.57	2.8e-56	Blood protein levels;
BRCA	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.46	10.83	0.39	3.25e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs965469	0.947	rs7274193	chr20:3329750	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-10.7	-0.39	1.07e-24	IFN-related cytopenia;
BRCA	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg23711669	chr6:146136114	FBXO30	0.77	17.96	0.58	1.11e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.08	-0.4	3.36e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg00645731	chr22:42541494	CYP2D7P1	-0.5	-7.86	-0.3	1.66e-14	Birth weight;
BRCA	trans	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg26043149	chr18:55253948	FECH	1.09	23.3	0.68	2.09e-87	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs1691799	0.867	rs1495497	chr12:66770020	A/T	cg16791601	chr12:66731901	HELB	-0.63	-17.15	-0.56	1.68e-54	White blood cell count (basophil);
BRCA	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg10818794	chr15:86012489	AKAP13	-0.3	-8.45	-0.32	1.92e-16	Coronary artery disease;
BRCA	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.27	-0.41	5.58e-27	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg08470875	chr2:26401718	FAM59B	-0.76	-12.04	-0.43	3.12e-30	Gut microbiome composition (summer);
BRCA	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24110177	chr3:50126178	RBM5	-0.36	-9.59	-0.35	2e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg23711669	chr6:146136114	FBXO30	0.64	15.05	0.51	4.81e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.818	rs1334849	chr1:153004652	A/G	cg25856811	chr1:152973957	SPRR3	0.32	8.56	0.32	8.22e-17	Inflammatory skin disease;
BRCA	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg07636037	chr3:49044803	WDR6	-0.49	-8.1	-0.31	2.79e-15	Menarche (age at onset);
BRCA	cis	rs7560272	0.513	rs7558546	chr2:73937732	A/T	cg20560298	chr2:73613845	ALMS1	0.34	8.67	0.32	3.68e-17	Schizophrenia;
BRCA	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg24006582	chr15:45444508	DUOX1	-0.56	-11.54	-0.42	4.12e-28	Uric acid levels;
BRCA	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	15.77	0.53	1.5e-47	Electrocardiographic conduction measures;
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.47	-10.08	-0.37	2.72e-22	Longevity;Endometriosis;
BRCA	trans	rs57046232	0.552	rs6076987	chr20:6351417	A/C	cg21095983	chr6:86352623	SYNCRIP	0.4	8.29	0.31	6.64e-16	Colorectal cancer;
BRCA	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg20801007	chr11:830320	EFCAB4A	-0.49	-10.65	-0.39	1.72e-24	Mean platelet volume;
BRCA	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg05084668	chr3:125655381	ALG1L	-0.47	-8.1	-0.31	2.84e-15	Blood pressure (smoking interaction);
BRCA	cis	rs7512552	0.839	rs12042229	chr1:150447398	A/G	cg15654264	chr1:150340011	RPRD2	0.43	9.05	0.34	1.76e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-10.69	-0.39	1.2e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4908768	0.501	rs6577499	chr1:8612104	C/G	cg20416874	chr1:8611966	RERE	0.29	8.49	0.32	1.46e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg14582100	chr15:45693742	SPATA5L1	0.35	10.84	0.39	2.97e-25	Homoarginine levels;
BRCA	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg03929089	chr4:120376271	NA	-0.53	-8.82	-0.33	1.09e-17	Axial length;
BRCA	cis	rs208520	0.802	rs208496	chr6:66930786	G/C	cg07460842	chr6:66804631	NA	-0.89	-15.7	-0.53	3.24e-47	Exhaled nitric oxide output;
BRCA	cis	rs2997447	0.595	rs3008425	chr1:26385660	T/C	cg19633962	chr1:26362018	EXTL1	-0.5	-9.06	-0.34	1.59e-18	QRS complex (12-leadsum);
BRCA	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg02176678	chr2:219576539	TTLL4	0.39	10.4	0.38	1.6e-23	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg00738919	chr7:1100172	C7orf50	0.46	7.82	0.3	2.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg13047869	chr3:10149882	C3orf24	0.59	12.13	0.43	1.26e-30	Alzheimer's disease;
BRCA	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg13852791	chr20:30311386	BCL2L1	0.85	16.77	0.55	1.43e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg24324837	chr19:49891574	CCDC155	0.52	9.35	0.35	1.43e-19	Multiple sclerosis;
BRCA	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg14036092	chr11:66035641	RAB1B	-0.35	-9.58	-0.35	2.08e-20	Gout;
BRCA	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg08847533	chr14:75593920	NEK9	-0.84	-21.09	-0.64	2.39e-75	Height;
BRCA	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg15704280	chr7:45808275	SEPT13	-0.7	-14.16	-0.49	8.71e-40	Coronary artery disease;
BRCA	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg18806716	chr10:30721971	MAP3K8	0.58	13.56	0.47	5.49e-37	Inflammatory bowel disease;
BRCA	trans	rs4650994	0.525	rs4651000	chr1:178532223	A/G	cg05059571	chr16:84539110	KIAA1609	-0.56	-12.54	-0.44	2e-32	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg21395723	chr22:39101663	GTPBP1	0.4	8.72	0.33	2.42e-17	Menopause (age at onset);
BRCA	cis	rs7707921	0.881	rs2629744	chr5:81381997	A/T	cg15871215	chr5:81402204	ATG10	-0.37	-8.07	-0.3	3.37e-15	Breast cancer;
BRCA	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg05347473	chr6:146136440	FBXO30	0.39	7.93	0.3	9.59e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7737355	0.947	rs7724769	chr5:130954943	C/T	cg06307176	chr5:131281290	NA	0.53	10.27	0.38	5.2e-23	Life satisfaction;
BRCA	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg23018236	chr17:30244563	NA	-0.64	-10.28	-0.38	4.62e-23	Hip circumference adjusted for BMI;
BRCA	cis	rs13136331	0.680	rs2732206	chr4:88652504	T/A	cg22416721	chr4:88570574	DMP1	-0.57	-13.64	-0.47	2.43e-37	Sitting height ratio;
BRCA	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.35	-0.41	2.47e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17641971	0.662	rs1858312	chr8:49996521	G/A	cg00325661	chr8:49890786	NA	0.39	10.77	0.39	5.97e-25	Blood metabolite levels;
BRCA	cis	rs1011018	0.628	rs73158614	chr7:139436800	G/A	cg03224163	chr7:139420300	HIPK2	-0.54	-9.23	-0.34	3.9e-19	Systolic blood pressure;
BRCA	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg14415214	chr11:2950403	PHLDA2	0.35	7.87	0.3	1.54e-14	Mosquito bite size;
BRCA	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.87	0.56	4.48e-53	Hypertriglyceridemia;
BRCA	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg20307385	chr11:47447363	PSMC3	0.86	25.99	0.72	3.64e-102	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs1011018	0.628	rs17262390	chr7:139454209	T/C	cg03224163	chr7:139420300	HIPK2	-0.58	-8.8	-0.33	1.31e-17	Systolic blood pressure;
BRCA	cis	rs2387326	0.671	rs11016104	chr10:129946512	G/A	cg16087940	chr10:129947807	NA	-0.46	-8.25	-0.31	8.89e-16	Select biomarker traits;
BRCA	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	19.8	0.62	2.19e-68	Platelet count;
BRCA	cis	rs877282	0.898	rs11253346	chr10:765313	A/G	cg17470449	chr10:769945	NA	0.47	7.96	0.3	8.16e-15	Uric acid levels;
BRCA	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg19000871	chr14:103996768	TRMT61A	-0.35	-8.04	-0.3	4.21e-15	Coronary artery disease;
BRCA	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.43	0.55	7.1e-51	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08219700	chr8:58056026	NA	0.58	9.7	0.36	7.56e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg00666640	chr1:248458726	OR2T12	0.31	8.31	0.31	5.74e-16	Common traits (Other);
BRCA	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	10.13	0.37	1.84e-22	Lung cancer in ever smokers;
BRCA	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg22676075	chr6:135203613	NA	0.45	8.89	0.33	6.22e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs7178424	0.806	rs4775453	chr15:62217391	A/C	cg00456672	chr15:62358751	C2CD4A	0.38	9.26	0.34	2.98e-19	Height;
BRCA	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	8.79	0.33	1.4e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg13736514	chr6:26305472	NA	-0.35	-12.08	-0.43	2.04e-30	Educational attainment;
BRCA	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg11645453	chr3:52864694	ITIH4	-0.46	-11.6	-0.42	2.36e-28	Schizophrenia;
BRCA	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22857025	chr5:266934	NA	-1.03	-20.11	-0.62	4.43e-70	Breast cancer;
BRCA	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-12.28	-0.44	2.95e-31	Bipolar disorder;
BRCA	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	21.57	0.65	5.96e-78	Mean platelet volume;
BRCA	cis	rs6435161	0.959	rs72926966	chr2:203493293	C/A	cg18429434	chr2:203499731	FAM117B	-0.43	-8.47	-0.32	1.73e-16	Total cholesterol levels;
BRCA	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg06552810	chr11:31128660	NA	-0.4	-8.82	-0.33	1.09e-17	Red blood cell count;
BRCA	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg22800045	chr5:56110881	MAP3K1	0.69	11.06	0.4	3.72e-26	Type 2 diabetes;
BRCA	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg24829409	chr8:58192753	C8orf71	-0.48	-9.14	-0.34	7.94e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs66887589	1.000	rs66887589	chr4:120509279	T/C	cg09307838	chr4:120376055	NA	-0.44	-9.09	-0.34	1.18e-18	Diastolic blood pressure;
BRCA	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.54	11.02	0.4	5.73e-26	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs965469	0.779	rs6051746	chr20:3307290	C/G	cg25506879	chr20:3388711	C20orf194	-0.45	-8.97	-0.33	3.33e-18	IFN-related cytopenia;
BRCA	cis	rs2404602	0.575	rs11633309	chr15:76962349	C/A	cg23625390	chr15:77176239	SCAPER	-0.53	-11.31	-0.41	3.73e-27	Blood metabolite levels;
BRCA	cis	rs6066825	0.644	rs761271	chr20:47315637	A/G	cg18078177	chr20:47281410	PREX1	0.41	10.15	0.37	1.57e-22	Colorectal cancer;
BRCA	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg08917208	chr2:24149416	ATAD2B	1.05	14.38	0.49	7.78e-41	Lymphocyte counts;
BRCA	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23221052	chr5:179740743	GFPT2	-0.65	-13.28	-0.47	1.03e-35	Height;
BRCA	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg13770153	chr20:60521292	NA	-0.44	-9.84	-0.36	2.37e-21	Body mass index;
BRCA	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg09307838	chr4:120376055	NA	0.64	14.0	0.48	5.12e-39	Corneal astigmatism;
BRCA	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.6	9.91	0.37	1.21e-21	Lung function (FEV1/FVC);
BRCA	trans	rs2018683	0.707	rs4722877	chr7:28972906	A/G	cg19402173	chr7:128379420	CALU	-0.42	-9.85	-0.36	2.07e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg20933634	chr6:27740509	NA	0.44	8.45	0.32	2.04e-16	Parkinson's disease;
BRCA	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs68170813	0.559	rs2107318	chr7:106845969	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-8.46	-0.32	1.78e-16	Coronary artery disease;
BRCA	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.71	13.29	0.47	9.21e-36	Gut microbiome composition (summer);
BRCA	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg04511125	chr2:88470314	THNSL2	0.77	11.17	0.4	1.35e-26	Plasma clusterin levels;
BRCA	cis	rs142958719	1	rs142958719	chr5:131232959	G/A	cg06307176	chr5:131281290	NA	-0.53	-10.19	-0.37	1.06e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.04	-0.3	4.51e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs939658	1.000	rs34286854	chr15:79454374	C/T	cg17916960	chr15:79447300	NA	-0.43	-10.63	-0.39	2e-24	Refractive error;
BRCA	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg11663144	chr21:46675770	NA	-0.5	-9.89	-0.36	1.42e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4074536	0.574	rs6693356	chr1:116296510	T/A	cg21648376	chr1:116311395	CASQ2	-0.48	-8.48	-0.32	1.53e-16	QRS duration;
BRCA	trans	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg25214090	chr10:38739885	LOC399744	0.55	12.35	0.44	1.44e-31	Corneal astigmatism;
BRCA	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.74	16.09	0.54	3.59e-49	Cognitive ability;
BRCA	cis	rs13064411	0.660	rs1872747	chr3:113175785	T/A	cg18753928	chr3:113234510	CCDC52	-0.56	-10.15	-0.37	1.5e-22	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08704250	chr15:31115839	NA	-0.36	-8.92	-0.33	4.76e-18	Huntington's disease progression;
BRCA	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.56	8.2	0.31	1.3e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg15839431	chr19:19639596	YJEFN3	-0.43	-8.93	-0.33	4.53e-18	Bipolar disorder;
BRCA	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg12310025	chr6:25882481	NA	0.51	12.25	0.44	3.7e-31	Blood metabolite levels;
BRCA	cis	rs10788264	0.569	rs7089468	chr10:124019052	T/C	cg09507567	chr10:124027408	NA	0.39	8.36	0.31	3.87e-16	Total body bone mineral density;
BRCA	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	12.32	0.44	1.94e-31	Lung cancer in ever smokers;
BRCA	cis	rs7633857	0.595	rs7640874	chr3:160672617	T/A	cg03342759	chr3:160939853	NMD3	-0.51	-10.43	-0.38	1.31e-23	Educational attainment (years of education);
BRCA	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg05623727	chr3:50126028	RBM5	-0.38	-8.21	-0.31	1.2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg04374321	chr14:90722782	PSMC1	0.73	19.21	0.61	2.79e-65	Mortality in heart failure;
BRCA	cis	rs698833	0.692	rs786410	chr2:44731156	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	10.45	0.38	1.06e-23	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11644478	chr21:40555479	PSMG1	-0.82	-18.5	-0.59	1.61e-61	Cognitive function;
BRCA	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg08999081	chr20:33150536	PIGU	0.42	11.59	0.42	2.5e-28	Coronary artery disease;
BRCA	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg21385522	chr1:16154831	NA	0.46	8.38	0.31	3.46e-16	Dilated cardiomyopathy;
BRCA	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg12311346	chr5:56204834	C5orf35	-0.73	-14.47	-0.5	3.11e-41	Initial pursuit acceleration;
BRCA	cis	rs312273	0.631	rs1442189	chr12:41364503	A/T	cg17827154	chr12:41323612	CNTN1	-0.39	-10.09	-0.37	2.69e-22	Bipolar disorder;
BRCA	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg24812749	chr6:127587940	RNF146	-0.68	-15.39	-0.52	1.08e-45	Breast cancer;
BRCA	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs9296092	0.538	rs62405948	chr6:33522753	A/C	cg13560919	chr6:33536144	NA	-0.85	-18.66	-0.59	2.26e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	trans	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg13565492	chr6:43139072	SRF	-0.79	-11.12	-0.4	2.25e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg00071950	chr4:10020882	SLC2A9	0.54	13.11	0.46	5.88e-35	Bone mineral density;
BRCA	cis	rs1568889	1.000	rs12797155	chr11:28290866	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	13.94	0.48	9.54e-39	Bipolar disorder;
BRCA	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.34	9.43	0.35	7.46e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-9.82	-0.36	2.72e-21	Neuroticism;
BRCA	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg18404041	chr3:52824283	ITIH1	-0.29	-8.68	-0.32	3.31e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg13256891	chr4:100009986	ADH5	0.54	10.01	0.37	5.06e-22	Alcohol dependence;
BRCA	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.45	-7.99	-0.3	6.35e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6545883	0.826	rs2694651	chr2:61588642	T/C	cg15711740	chr2:61764176	XPO1	0.5	12.19	0.43	6.78e-31	Tuberculosis;
BRCA	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg13319975	chr6:146136371	FBXO30	0.35	8.07	0.3	3.44e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg10818794	chr15:86012489	AKAP13	-0.32	-8.95	-0.33	3.95e-18	Coronary artery disease;
BRCA	cis	rs10193935	0.901	rs2088281	chr2:42672731	A/G	cg27598129	chr2:42591480	NA	0.87	13.96	0.48	7.25e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs858239	0.539	rs10279194	chr7:23191083	T/C	cg23682824	chr7:23144976	KLHL7	0.41	10.94	0.4	1.21e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.89	-0.33	6e-18	Total body bone mineral density;
BRCA	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-13.95	-0.48	8.75e-39	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg20991723	chr1:152506922	NA	0.39	9.07	0.34	1.4e-18	Hair morphology;
BRCA	trans	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-15.22	-0.52	7.28e-45	Obesity-related traits;
BRCA	cis	rs9341808	0.718	rs9294171	chr6:80839815	C/T	cg08355045	chr6:80787529	NA	0.37	9.28	0.34	2.66e-19	Sitting height ratio;
BRCA	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg16325326	chr1:53192061	ZYG11B	-0.65	-16.18	-0.54	1.39e-49	Monocyte count;
BRCA	cis	rs7640424	0.652	rs12152307	chr3:107861766	T/C	cg09227934	chr3:107805635	CD47	-0.42	-8.63	-0.32	4.99e-17	Body mass index;
BRCA	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.09	16.64	0.55	6.15e-52	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7903847	0.642	rs11189172	chr10:99135215	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.28	-0.31	7.46e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg12193833	chr17:30244370	NA	-0.58	-8.78	-0.33	1.54e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs7539409	0.651	rs10747407	chr1:84314754	G/A	cg10977910	chr1:84465055	TTLL7	0.7	10.51	0.38	6.2e-24	Alzheimer's disease;
BRCA	trans	rs1997103	0.954	rs2177809	chr7:55378125	T/C	cg20935933	chr6:143382018	AIG1	0.6	11.43	0.41	1.15e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22307029	chr19:49891270	CCDC155	0.54	9.03	0.34	2.04e-18	Multiple sclerosis;
BRCA	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.85	0.3	1.76e-14	Depression;
BRCA	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg16576597	chr16:28551801	NUPR1	0.3	8.45	0.32	2.03e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg18016565	chr1:150552671	MCL1	0.35	8.23	0.31	1.05e-15	Melanoma;
BRCA	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg22307297	chr20:60903441	LAMA5	-0.35	-9.82	-0.36	2.65e-21	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg19773385	chr1:10388646	KIF1B	-0.36	-7.89	-0.3	1.27e-14	Hepatocellular carcinoma;
BRCA	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.14	0.31	2.12e-15	Tonsillectomy;
BRCA	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg27446573	chr6:127587934	RNF146	0.88	20.71	0.63	2.59e-73	Breast cancer;
BRCA	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg26384229	chr12:38710491	ALG10B	0.68	16.29	0.54	3.53e-50	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg21782813	chr7:2030301	MAD1L1	0.32	8.52	0.32	1.18e-16	Bipolar disorder and schizophrenia;
BRCA	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg11707556	chr5:10655725	ANKRD33B	0.42	9.35	0.35	1.46e-19	Coronary artery disease;
BRCA	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg18446336	chr7:2847575	GNA12	-0.41	-10.25	-0.38	6.39e-23	Height;
BRCA	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.45	10.34	0.38	2.9e-23	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs13082711	0.555	rs73149363	chr3:27265394	C/A	cg02860705	chr3:27208620	NA	0.56	10.64	0.39	1.93e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg02551604	chr5:131831745	NA	-0.4	-13.94	-0.48	9.43e-39	Asthma (sex interaction);
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.52	-11.02	-0.4	5.56e-26	Longevity;Endometriosis;
BRCA	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg23422044	chr7:1970798	MAD1L1	-0.56	-9.67	-0.36	9.51e-21	Neuroticism;
BRCA	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg12826209	chr6:26865740	GUSBL1	0.61	8.07	0.3	3.52e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7975161	0.572	rs4964226	chr12:104570489	A/G	cg25273343	chr12:104657179	TXNRD1	-0.52	-9.09	-0.34	1.24e-18	Toenail selenium levels;
BRCA	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	19.47	0.61	1.19e-66	Smoking behavior;
BRCA	trans	rs60843830	1.000	rs9213	chr2:218386	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	13.92	0.48	1.12e-38	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08219700	chr8:58056026	NA	-0.54	-8.89	-0.33	6.33e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6484504	0.652	rs494464	chr11:31386150	C/T	cg14844989	chr11:31128820	NA	0.44	9.65	0.36	1.14e-20	Red blood cell count;
BRCA	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg17366294	chr4:99064904	C4orf37	0.54	11.58	0.42	2.76e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9400271	0.632	rs9398191	chr6:109586561	C/T	cg01475377	chr6:109611718	NA	-0.43	-10.4	-0.38	1.58e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg09658497	chr7:2847517	GNA12	-0.42	-8.67	-0.32	3.68e-17	Height;
BRCA	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg22467129	chr15:76604101	ETFA	-0.41	-9.02	-0.34	2.13e-18	Blood metabolite levels;
BRCA	cis	rs72772090	0.710	rs11750399	chr5:96077940	A/G	cg24982541	chr5:96078678	CAST	-0.46	-8.07	-0.3	3.42e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.07e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14442939	chr10:27389572	ANKRD26	0.69	9.28	0.34	2.68e-19	Breast cancer;
BRCA	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg26384229	chr12:38710491	ALG10B	0.73	17.17	0.56	1.28e-54	Bladder cancer;
BRCA	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg04362960	chr10:104952993	NT5C2	0.43	10.54	0.38	4.81e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs1371614	0.545	rs3769136	chr2:27168743	C/T	cg00617064	chr2:27272375	NA	-0.32	-8.36	-0.31	3.84e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg25237894	chr2:233734115	C2orf82	0.4	11.45	0.41	1.01e-27	Coronary artery disease;
BRCA	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.18	-0.34	6e-19	Bipolar disorder;
BRCA	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg06212747	chr3:49208901	KLHDC8B	0.46	9.38	0.35	1.16e-19	Parkinson's disease;
BRCA	cis	rs1030877	1.000	rs1030877	chr2:105910513	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.72	17.38	0.57	1.07e-55	Obesity-related traits;
BRCA	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg08896387	chr1:24191740	FUCA1	-0.24	-7.93	-0.3	1e-14	Immature fraction of reticulocytes;
BRCA	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg25482853	chr8:67687455	SGK3	1.02	17.46	0.57	4.04e-56	Lung disease severity in cystic fibrosis;
BRCA	trans	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.14	0.31	2.04e-15	Corneal astigmatism;
BRCA	cis	rs4660306	0.961	rs7546268	chr1:45965340	T/C	cg24296786	chr1:45957014	TESK2	0.42	8.42	0.32	2.52e-16	Homocysteine levels;
BRCA	cis	rs1595825	0.891	rs74265511	chr2:198494782	C/T	cg19156104	chr2:198669113	PLCL1	-0.43	-8.23	-0.31	1.04e-15	Ulcerative colitis;
BRCA	cis	rs10267417	0.603	rs13241328	chr7:19939232	G/A	cg05791153	chr7:19748676	TWISTNB	0.43	7.98	0.3	6.59e-15	Night sleep phenotypes;
BRCA	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg26384229	chr12:38710491	ALG10B	0.54	11.26	0.41	5.69e-27	Morning vs. evening chronotype;
BRCA	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg06627628	chr2:24431161	ITSN2	-0.51	-8.2	-0.31	1.27e-15	Lymphocyte counts;
BRCA	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg14675211	chr2:100938903	LONRF2	0.45	10.28	0.38	4.83e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.818	rs10888526	chr1:153000311	G/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.34	-0.31	4.71e-16	Inflammatory skin disease;
BRCA	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02176678	chr2:219576539	TTLL4	0.46	11.88	0.43	1.57e-29	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg12219531	chr12:120966889	COQ5	0.54	11.37	0.41	2.15e-27	High light scatter reticulocyte count;
BRCA	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22857025	chr5:266934	NA	-1.03	-19.77	-0.62	3.13e-68	Breast cancer;
BRCA	cis	rs56399783	0.901	rs73047387	chr7:2774125	G/A	cg23627948	chr7:2760692	NA	0.5	7.84	0.3	1.85e-14	Childhood ear infection;
BRCA	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg02733842	chr7:1102375	C7orf50	-0.61	-11.53	-0.41	4.57e-28	Bronchopulmonary dysplasia;
BRCA	trans	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-20.54	-0.63	2.23e-72	Exhaled nitric oxide output;
BRCA	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03517284	chr6:25882590	NA	-0.45	-9.29	-0.34	2.45e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg23422044	chr7:1970798	MAD1L1	-0.44	-9.0	-0.34	2.54e-18	Neuroticism;
BRCA	trans	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg15556689	chr8:8085844	FLJ10661	-0.29	-7.83	-0.3	2.09e-14	Retinal vascular caliber;
BRCA	cis	rs28830936	0.510	rs11070349	chr15:42085017	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.51	-19.51	-0.61	7e-67	Diastolic blood pressure;
BRCA	cis	rs6714710	0.580	rs11680018	chr2:98479581	C/A	cg26665480	chr2:98280029	ACTR1B	0.59	13.54	0.47	6.4e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.86e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4285028	0.747	rs58367397	chr3:121451700	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-13.91	-0.48	1.25e-38	Multiple sclerosis;
BRCA	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg09998033	chr7:158218633	PTPRN2	-0.41	-9.49	-0.35	4.36e-20	Obesity-related traits;
BRCA	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg03585969	chr10:35415529	CREM	0.57	11.63	0.42	1.65e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs10267417	0.603	rs1557774	chr7:19908777	A/G	cg07541023	chr7:19748670	TWISTNB	0.45	8.2	0.31	1.3e-15	Night sleep phenotypes;
BRCA	cis	rs6910061	0.750	rs16870965	chr6:11123550	G/A	cg27233058	chr6:11094804	LOC221710	0.5	8.27	0.31	8e-16	Diabetic kidney disease;
BRCA	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.87e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg00800038	chr16:89945340	TCF25	-0.7	-10.64	-0.39	1.87e-24	Skin colour saturation;
BRCA	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.08	-0.4	3.36e-26	Extrinsic epigenetic age acceleration;
BRCA	trans	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg25214090	chr10:38739885	LOC399744	0.57	12.94	0.46	3.6e-34	Corneal astigmatism;
BRCA	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg00750074	chr16:89608354	SPG7	-0.33	-8.95	-0.33	3.68e-18	Multiple myeloma (IgH translocation);
BRCA	cis	rs36051895	0.632	rs12337481	chr9:5134599	T/G	cg02405213	chr9:5042618	JAK2	-0.46	-9.01	-0.34	2.43e-18	Pediatric autoimmune diseases;
BRCA	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg00666640	chr1:248458726	OR2T12	0.33	9.43	0.35	7.61e-20	Common traits (Other);
BRCA	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg02297831	chr4:17616191	MED28	0.36	8.33	0.31	4.84e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg00825309	chr19:58991885	ZNF446	-0.64	-14.27	-0.49	2.66e-40	Uric acid clearance;
BRCA	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02018176	chr4:1364513	KIAA1530	0.4	8.17	0.31	1.6e-15	Longevity;
BRCA	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.72	12.18	0.43	8.02e-31	Lung cancer in ever smokers;
BRCA	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.79	-0.42	3.45e-29	Mean corpuscular volume;
BRCA	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg00012203	chr2:219082015	ARPC2	-0.58	-12.23	-0.44	4.95e-31	Colorectal cancer;
BRCA	cis	rs6120849	0.754	rs13433216	chr20:33616301	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	10.29	0.38	4.57e-23	Protein C levels;
BRCA	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg10495392	chr1:46806563	NSUN4	-0.44	-8.22	-0.31	1.14e-15	Menopause (age at onset);
BRCA	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg05714579	chr10:131428358	MGMT	0.54	12.72	0.45	3.5e-33	Response to temozolomide;
BRCA	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg27170947	chr2:26402098	FAM59B	0.92	16.52	0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg16230307	chr14:35515116	FAM177A1	0.73	14.85	0.51	4.44e-43	Psoriasis;
BRCA	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.73	17.76	0.57	1.2e-57	Chronic sinus infection;
BRCA	cis	rs12618769	0.597	rs12617721	chr2:99083892	G/T	cg10123293	chr2:99228465	UNC50	-0.4	-8.12	-0.31	2.49e-15	Bipolar disorder;
BRCA	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03517284	chr6:25882590	NA	-0.39	-8.23	-0.31	1.08e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs1997103	1.000	rs2177804	chr7:55410302	G/A	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg04362960	chr10:104952993	NT5C2	0.45	10.28	0.38	4.8e-23	Arsenic metabolism;
BRCA	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg25554036	chr4:6271136	WFS1	0.43	9.62	0.36	1.48e-20	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg18301423	chr5:131593218	PDLIM4	0.32	8.42	0.32	2.42e-16	Breast cancer;
BRCA	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	15.63	0.53	7.54e-47	Smoking behavior;
BRCA	cis	rs7617773	0.743	rs6804986	chr3:48363595	A/G	cg11946769	chr3:48343235	NME6	0.63	13.47	0.47	1.45e-36	Coronary artery disease;
BRCA	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg07988820	chr12:82153109	PPFIA2	-0.59	-9.41	-0.35	8.79e-20	Resting heart rate;
BRCA	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg23033748	chr14:75592666	NEK9	-0.43	-10.11	-0.37	2.14e-22	Height;
BRCA	cis	rs36051895	0.659	rs1576271	chr9:5039652	A/C	cg02405213	chr9:5042618	JAK2	-0.48	-8.67	-0.32	3.42e-17	Pediatric autoimmune diseases;
BRCA	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg07395648	chr5:131743802	NA	-0.38	-8.29	-0.31	6.7e-16	Acylcarnitine levels;
BRCA	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.22	7.87	0.3	1.49e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg24296786	chr1:45957014	TESK2	0.5	11.85	0.42	2.05e-29	Red blood cell count;Reticulocyte count;
BRCA	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg19920283	chr7:105172520	RINT1	0.59	9.46	0.35	5.64e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs17767294	0.614	rs72850302	chr6:28241398	A/G	cg08851530	chr6:28072375	NA	1.14	10.35	0.38	2.5e-23	Parkinson's disease;
BRCA	cis	rs4363385	0.747	rs4478766	chr1:152984906	G/A	cg25856811	chr1:152973957	SPRR3	-0.34	-9.2	-0.34	5.11e-19	Inflammatory skin disease;
BRCA	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13012494	chr21:47604986	C21orf56	0.45	9.42	0.35	8.04e-20	Testicular germ cell tumor;
BRCA	cis	rs6545883	0.929	rs1186707	chr2:61673520	C/A	cg15711740	chr2:61764176	XPO1	-0.53	-13.33	-0.47	6.2e-36	Tuberculosis;
BRCA	cis	rs7523273	0.526	rs1204706	chr1:208021060	G/T	cg22525895	chr1:207977042	MIR29B2	-0.46	-11.43	-0.41	1.13e-27	Schizophrenia;
BRCA	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg02544614	chr20:61657117	NA	0.28	8.15	0.31	1.93e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs999943	0.846	rs9357162	chr6:33613344	G/A	cg14003231	chr6:33640908	ITPR3	0.64	14.26	0.49	2.91e-40	Obesity (extreme);
BRCA	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg26384229	chr12:38710491	ALG10B	0.72	17.02	0.56	7.11e-54	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg25358565	chr5:93447407	FAM172A	-0.51	-9.44	-0.35	6.68e-20	Diabetic retinopathy;
BRCA	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg10932868	chr11:921992	NA	0.47	12.09	0.43	1.93e-30	Alzheimer's disease (late onset);
BRCA	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	9.86	0.36	1.96e-21	Aortic root size;
BRCA	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg04267008	chr7:1944627	MAD1L1	-0.47	-9.77	-0.36	4.22e-21	Schizophrenia;
BRCA	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg17143192	chr8:8559678	CLDN23	0.5	9.72	0.36	6.54e-21	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.39	0.38	1.77e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg21280719	chr6:42927975	GNMT	-0.29	-12.11	-0.43	1.54e-30	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.66	-0.36	1.04e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs208520	0.690	rs207119	chr6:66786408	C/T	cg07460842	chr6:66804631	NA	-1.02	-20.41	-0.63	1.11e-71	Exhaled nitric oxide output;
BRCA	cis	rs11030122	0.702	rs12281293	chr11:3963814	C/T	cg18678763	chr11:4115507	RRM1	-0.36	-8.17	-0.31	1.6e-15	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg14675211	chr2:100938903	LONRF2	0.43	9.45	0.35	6.54e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg12310025	chr6:25882481	NA	-0.54	-13.09	-0.46	7.43e-35	Blood metabolite levels;
BRCA	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg26597838	chr10:835615	NA	0.89	13.86	0.48	2.29e-38	Eosinophil percentage of granulocytes;
BRCA	cis	rs13082711	0.689	rs34641383	chr3:27320210	G/A	cg02860705	chr3:27208620	NA	0.85	15.37	0.52	1.31e-45	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg01528321	chr10:82214614	TSPAN14	0.77	17.28	0.56	3.55e-55	Post bronchodilator FEV1;
BRCA	trans	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-7.86	-0.3	1.65e-14	Menarche (age at onset);
BRCA	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg23711669	chr6:146136114	FBXO30	0.72	17.44	0.57	5.49e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs926392	0.533	rs6129162	chr20:37683195	G/A	cg16355469	chr20:37678765	NA	0.49	11.07	0.4	3.57e-26	Dialysis-related mortality;
BRCA	trans	rs2562456	0.874	rs9304986	chr19:21682062	G/A	cg25042112	chr7:64838748	ZNF92	0.44	8.18	0.31	1.5e-15	Pain;
BRCA	cis	rs1975991	0.765	rs4381925	chr3:187952250	C/T	cg15417654	chr3:187959138	LPP	-0.34	-8.32	-0.31	5.18e-16	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg20503657	chr10:835505	NA	0.9	13.79	0.48	4.67e-38	Eosinophil percentage of granulocytes;
BRCA	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg05714579	chr10:131428358	MGMT	0.5	11.0	0.4	6.51e-26	Response to temozolomide;
BRCA	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18876405	chr7:65276391	NA	-0.62	-15.24	-0.52	5.51e-45	Aortic root size;
BRCA	cis	rs13136331	0.641	rs2732174	chr4:88682910	A/T	cg22416721	chr4:88570574	DMP1	-0.5	-11.44	-0.41	1.04e-27	Sitting height ratio;
BRCA	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg13271783	chr10:134563150	INPP5A	-0.51	-9.59	-0.35	1.99e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg03060546	chr3:49711283	APEH	0.56	9.84	0.36	2.26e-21	Menarche (age at onset);
BRCA	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14169450	chr9:139327907	INPP5E	-0.38	-8.92	-0.33	4.7e-18	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg24324837	chr19:49891574	CCDC155	0.47	7.94	0.3	9.35e-15	Multiple sclerosis;
BRCA	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.09	0.34	1.28e-18	Motion sickness;
BRCA	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg13397359	chr6:42928475	GNMT	0.75	19.35	0.61	5.1e-66	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs8054556	0.647	rs11649149	chr16:30008644	C/T	cg06326092	chr16:30034487	C16orf92	0.35	8.67	0.32	3.69e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11644478	chr21:40555479	PSMG1	-0.85	-19.93	-0.62	4.19e-69	Cognitive function;
BRCA	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.17	-0.43	8.86e-31	Total cholesterol levels;
BRCA	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg08917208	chr2:24149416	ATAD2B	1.05	14.25	0.49	3.4e-40	Lymphocyte counts;
BRCA	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg05347473	chr6:146136440	FBXO30	0.41	8.27	0.31	7.88e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg03354898	chr7:1950403	MAD1L1	0.46	9.12	0.34	9.29e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	15.49	0.52	3.59e-46	Coronary artery disease;
BRCA	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg18016565	chr1:150552671	MCL1	-0.46	-10.68	-0.39	1.28e-24	Tonsillectomy;
BRCA	cis	rs67460515	0.531	rs13315565	chr3:160754626	G/C	cg03342759	chr3:160939853	NMD3	-0.62	-12.67	-0.45	5.55e-33	Parkinson's disease;
BRCA	trans	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg06521331	chr12:34319734	NA	-0.5	-9.31	-0.35	1.97e-19	Bladder cancer;
BRCA	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	11.81	0.42	3.04e-29	Mood instability;
BRCA	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg15704280	chr7:45808275	SEPT13	0.7	13.95	0.48	8.34e-39	Coronary artery disease;
BRCA	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg06238570	chr21:40685208	BRWD1	-0.4	-8.11	-0.31	2.53e-15	Menarche (age at onset);
BRCA	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg25358565	chr5:93447407	FAM172A	1.14	18.67	0.59	2.14e-62	Diabetic retinopathy;
BRCA	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24531977	chr5:56204891	C5orf35	-0.87	-17.89	-0.58	2.43e-58	Type 2 diabetes;
BRCA	cis	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.33	-0.31	5.04e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg23533926	chr12:111358616	MYL2	-0.43	-8.97	-0.33	3.37e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg22705602	chr4:152727874	NA	-0.32	-8.03	-0.3	4.59e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6120849	0.901	rs6060273	chr20:33744323	G/C	cg24642439	chr20:33292090	TP53INP2	0.47	8.42	0.32	2.42e-16	Protein C levels;
BRCA	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg22535103	chr8:58192502	C8orf71	-0.61	-13.17	-0.46	3.08e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.08	-0.34	1.34e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg12310025	chr6:25882481	NA	-0.58	-12.87	-0.45	7.09e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg14343924	chr8:8086146	FLJ10661	-0.41	-8.73	-0.33	2.16e-17	Mood instability;
BRCA	cis	rs4285028	0.747	rs10049060	chr3:121358448	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	13.56	0.47	5.6e-37	Multiple sclerosis;
BRCA	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	7.83	0.3	1.99e-14	Tonsillectomy;
BRCA	cis	rs9309473	0.606	rs6759452	chr2:73878352	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-8.41	-0.32	2.76e-16	Metabolite levels;
BRCA	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg17063962	chr7:91808500	NA	-0.53	-12.21	-0.43	5.86e-31	Breast cancer;
BRCA	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg22903657	chr4:1355424	KIAA1530	-0.37	-7.99	-0.3	6.21e-15	Obesity-related traits;
BRCA	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg12483005	chr1:23474871	LUZP1	0.48	10.46	0.38	9.57e-24	Height;
BRCA	cis	rs12618769	0.652	rs17513468	chr2:99235169	T/G	cg10123293	chr2:99228465	UNC50	0.41	8.16	0.31	1.82e-15	Bipolar disorder;
BRCA	cis	rs9815354	0.904	rs9848992	chr3:41875297	C/T	cg03022575	chr3:42003672	ULK4	0.49	7.99	0.3	6.4e-15	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-13.32	-0.47	6.68e-36	Response to antipsychotic treatment;
BRCA	trans	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg16141378	chr3:129829833	LOC729375	-0.32	-7.84	-0.3	1.9e-14	Mood instability;
BRCA	cis	rs754466	0.580	rs2579176	chr10:79529350	A/G	cg17075019	chr10:79541650	NA	-0.81	-19.36	-0.61	4.53e-66	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9341808	0.718	rs12203867	chr6:80820833	G/T	cg08355045	chr6:80787529	NA	0.37	9.35	0.35	1.43e-19	Sitting height ratio;
BRCA	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21659725	chr3:3221576	CRBN	0.36	8.92	0.33	4.89e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg06784218	chr1:46089804	CCDC17	0.45	10.79	0.39	4.55e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs727479	0.502	rs4775932	chr15:51498539	A/G	cg19946085	chr15:51559439	CYP19A1	-0.3	-8.44	-0.32	2.08e-16	Estradiol levels;
BRCA	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-14.1	-0.49	1.71e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg01028140	chr2:1542097	TPO	-0.6	-12.64	-0.45	7.84e-33	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.46e-34	Alzheimer's disease (late onset);
BRCA	cis	rs17253792	0.822	rs17746033	chr14:56061837	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs73086581	1.000	rs17215340	chr20:3970173	C/G	cg02187196	chr20:3869020	PANK2	-0.47	-8.75	-0.33	1.86e-17	Response to antidepressants in depression;
BRCA	cis	rs7077164	1.000	rs7077164	chr10:71583198	C/T	cg07630274	chr10:71583235	COL13A1	0.26	8.25	0.31	8.93e-16	Non-alcoholic fatty liver disease histology (lobular);
BRCA	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.6	-0.42	2.21e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg23950597	chr19:37808831	NA	-0.72	-12.06	-0.43	2.65e-30	Coronary artery calcification;
BRCA	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg27502298	chr12:9555721	NA	0.81	17.27	0.56	3.88e-55	IgG glycosylation;
BRCA	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg24631222	chr15:78858424	CHRNA5	-0.48	-9.57	-0.35	2.37e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg14784868	chr12:69753453	YEATS4	0.53	13.73	0.48	8.56e-38	Blood protein levels;
BRCA	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg09307838	chr4:120376055	NA	0.58	11.73	0.42	6.56e-29	Corneal astigmatism;
BRCA	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.79	0.39	4.86e-25	Bipolar disorder;
BRCA	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.05	0.3	3.95e-15	Menarche (age at onset);
BRCA	cis	rs10992471	0.528	rs4744133	chr9:95226702	C/T	cg14631576	chr9:95140430	CENPP	-0.35	-8.82	-0.33	1.11e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12310025	chr6:25882481	NA	-0.54	-12.02	-0.43	3.8e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg22800045	chr5:56110881	MAP3K1	0.43	8.84	0.33	9.05e-18	Coronary artery disease;
BRCA	trans	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg26043149	chr18:55253948	FECH	0.38	8.3	0.31	6.27e-16	Bone mineral density;
BRCA	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg21535247	chr6:8435926	SLC35B3	0.42	9.42	0.35	7.86e-20	Motion sickness;
BRCA	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg07636037	chr3:49044803	WDR6	0.46	9.17	0.34	6.59e-19	Resting heart rate;
BRCA	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg14993813	chr1:46806288	NSUN4	-0.47	-8.86	-0.33	7.67e-18	Menopause (age at onset);
BRCA	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg22875332	chr1:76189707	ACADM	-0.79	-21.75	-0.65	6.71e-79	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-13.14	-0.46	4.44e-35	Gut microbiome composition (summer);
BRCA	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	22.2	0.66	2.32e-81	Platelet count;
BRCA	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.54	0.57	1.59e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	15.9	0.53	3.46e-48	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.86	-14.22	-0.49	4.72e-40	Platelet count;
BRCA	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.38	-8.3	-0.31	6.36e-16	Tonsillectomy;
BRCA	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg11645453	chr3:52864694	ITIH4	-0.44	-11.14	-0.4	1.8e-26	Schizophrenia;
BRCA	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg16482183	chr6:26056742	HIST1H1C	0.55	11.32	0.41	3.23e-27	Height;
BRCA	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg11584989	chr19:19387371	SF4	0.64	13.49	0.47	1.14e-36	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg23442198	chr4:187126114	CYP4V2	0.78	8.26	0.31	8.71e-16	Blood protein levels;
BRCA	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg20283391	chr11:68216788	NA	-0.46	-8.97	-0.33	3.25e-18	Total body bone mineral density;
BRCA	cis	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg06521331	chr12:34319734	NA	0.55	10.24	0.38	6.77e-23	Morning vs. evening chronotype;
BRCA	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg20887711	chr4:1340912	KIAA1530	0.6	13.23	0.46	1.8e-35	Longevity;
BRCA	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.46	-0.35	5.64e-20	Body mass index;
BRCA	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg21138405	chr5:131827807	IRF1	0.4	12.97	0.46	2.65e-34	Asthma (sex interaction);
BRCA	cis	rs72772090	0.710	rs11750399	chr5:96077940	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.8	-0.45	1.52e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg24812749	chr6:127587940	RNF146	0.86	20.26	0.63	7.08e-71	Breast cancer;
BRCA	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg23018236	chr17:30244563	NA	-0.61	-10.05	-0.37	3.63e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	16.03	0.54	7.54e-49	Smoking behavior;
BRCA	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.9	20.0	0.62	1.77e-69	Cognitive ability;
BRCA	cis	rs1635	0.655	rs10484542	chr6:28309753	C/T	cg15743358	chr6:28303923	ZNF323	-0.64	-7.92	-0.3	1.07e-14	Schizophrenia;
BRCA	cis	rs68170813	0.559	rs12536485	chr7:106978005	T/C	cg02696742	chr7:106810147	HBP1	-0.55	-8.79	-0.33	1.4e-17	Coronary artery disease;
BRCA	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg10932868	chr11:921992	NA	0.49	12.6	0.45	1.18e-32	Alzheimer's disease (late onset);
BRCA	cis	rs6840258	1.000	rs767315	chr4:87960435	C/T	cg08197287	chr4:87952173	AFF1	-0.45	-8.95	-0.33	3.72e-18	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.19e-40	Motion sickness;
BRCA	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.52	-11.04	-0.4	4.78e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg05340658	chr4:99064831	C4orf37	0.62	14.89	0.51	2.77e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	13.26	0.46	1.33e-35	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs13006833	0.668	rs291458	chr2:191181481	A/C	cg11845111	chr2:191398756	TMEM194B	0.34	7.81	0.3	2.37e-14	Urinary metabolites;
BRCA	cis	rs7727544	0.547	rs10076758	chr5:131524299	A/G	cg14196790	chr5:131705035	SLC22A5	0.37	9.05	0.34	1.72e-18	Blood metabolite levels;
BRCA	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg21045802	chr8:109455806	TTC35	0.35	7.95	0.3	8.59e-15	Dupuytren's disease;
BRCA	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg12935359	chr14:103987150	CKB	-0.46	-10.53	-0.38	4.9e-24	Body mass index;
BRCA	cis	rs11112613	0.713	rs17041546	chr12:105950801	G/T	cg03607813	chr12:105948248	NA	-0.55	-10.9	-0.4	1.74e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg09307838	chr4:120376055	NA	0.62	13.38	0.47	3.73e-36	Corneal astigmatism;
BRCA	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg07541023	chr7:19748670	TWISTNB	-0.64	-10.59	-0.39	3.04e-24	Thyroid stimulating hormone;
BRCA	cis	rs754466	0.606	rs3740250	chr10:79580101	C/T	cg17075019	chr10:79541650	NA	-0.86	-23.36	-0.68	1.01e-87	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg00814883	chr7:100076585	TSC22D4	-0.48	-10.59	-0.39	2.94e-24	Platelet count;
BRCA	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg11764359	chr7:65958608	NA	-0.63	-13.48	-0.47	1.2e-36	Aortic root size;
BRCA	cis	rs4919087	0.961	rs11189120	chr10:99069493	G/T	cg25902810	chr10:99078978	FRAT1	0.52	11.67	0.42	1.17e-28	Monocyte count;
BRCA	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg26384229	chr12:38710491	ALG10B	0.43	10.28	0.38	4.63e-23	Heart rate;
BRCA	cis	rs68170813	0.559	rs76646886	chr7:107034328	T/C	cg02696742	chr7:106810147	HBP1	-0.54	-8.3	-0.31	6.28e-16	Coronary artery disease;
BRCA	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.36	0.35	1.34e-19	Morning vs. evening chronotype;
BRCA	cis	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg24110177	chr3:50126178	RBM5	0.3	7.84	0.3	1.9e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.02	-0.3	5.01e-15	Aortic root size;
BRCA	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.58	12.19	0.43	6.92e-31	Lymphocyte counts;
BRCA	cis	rs1595825	0.891	rs7595819	chr2:198543156	A/C	cg19156104	chr2:198669113	PLCL1	0.43	7.95	0.3	8.55e-15	Ulcerative colitis;
BRCA	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg26597838	chr10:835615	NA	1.3	21.79	0.65	4.02e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg18357645	chr12:58087776	OS9	0.46	13.3	0.47	7.96e-36	Celiac disease or Rheumatoid arthritis;
BRCA	trans	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.01	0.3	5.51e-15	Corneal astigmatism;
BRCA	cis	rs3892630	0.588	rs7260037	chr19:33242701	G/A	cg22980127	chr19:33182716	NUDT19	0.92	20.75	0.63	1.6e-73	Red blood cell traits;
BRCA	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg26031613	chr14:104095156	KLC1	0.44	8.73	0.33	2.14e-17	Schizophrenia;
BRCA	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02176678	chr2:219576539	TTLL4	-0.51	-13.26	-0.46	1.28e-35	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg18230493	chr5:56204884	C5orf35	-0.73	-14.26	-0.49	3.1e-40	Initial pursuit acceleration;
BRCA	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg18964960	chr10:1102726	WDR37	0.61	8.12	0.31	2.48e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.72	16.09	0.54	3.82e-49	Lymphocyte percentage of white cells;
BRCA	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg27129171	chr3:47204927	SETD2	-0.62	-14.37	-0.49	8.49e-41	Colorectal cancer;
BRCA	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.95	0.56	1.78e-53	Hypertriglyceridemia;
BRCA	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg03433033	chr1:76189801	ACADM	0.73	16.14	0.54	2.07e-49	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17253792	0.822	rs10148122	chr14:56146694	G/T	cg01858014	chr14:56050164	KTN1	-0.75	-10.26	-0.38	5.89e-23	Putamen volume;
BRCA	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg13628971	chr7:2884303	GNA12	0.4	9.12	0.34	9.5e-19	Height;
BRCA	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.92	-0.33	5.05e-18	Monocyte percentage of white cells;
BRCA	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.48	-0.38	7.85e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg05863683	chr7:1912471	MAD1L1	0.37	8.28	0.31	7.31e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19626725	chr5:178986131	RUFY1	-0.32	-9.75	-0.36	4.76e-21	Lung cancer;
BRCA	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg25703541	chr22:24373054	LOC391322	-0.66	-15.08	-0.51	3.37e-44	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs919433	0.713	rs6719729	chr2:198480072	G/A	cg00792783	chr2:198669748	PLCL1	0.34	7.9	0.3	1.2e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs490234	0.616	rs2841325	chr9:128163620	C/G	cg14078157	chr9:128172775	NA	0.36	8.2	0.31	1.34e-15	Mean arterial pressure;
BRCA	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg26384229	chr12:38710491	ALG10B	0.66	15.1	0.51	2.91e-44	Bladder cancer;
BRCA	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18876405	chr7:65276391	NA	-0.5	-11.13	-0.4	1.96e-26	Aortic root size;
BRCA	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg08807101	chr21:30365312	RNF160	-0.57	-13.96	-0.48	7.81e-39	Dental caries;
BRCA	trans	rs11165623	0.543	rs60982887	chr1:96989155	T/G	cg10631902	chr5:14652156	NA	-0.43	-12.07	-0.43	2.24e-30	Hip circumference;Waist circumference;
BRCA	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg24531977	chr5:56204891	C5orf35	-0.42	-8.42	-0.32	2.43e-16	Coronary artery disease;
BRCA	cis	rs9815354	0.812	rs73081361	chr3:41912535	G/A	cg03022575	chr3:42003672	ULK4	0.71	9.74	0.36	5.4e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-10.57	-0.39	3.64e-24	Pancreatic cancer;
BRCA	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-10.58	-0.39	3.11e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg04166393	chr7:2884313	GNA12	-0.42	-9.1	-0.34	1.12e-18	Height;
BRCA	cis	rs36051895	0.659	rs12336577	chr9:5063690	T/A	cg02405213	chr9:5042618	JAK2	-0.53	-9.56	-0.35	2.39e-20	Pediatric autoimmune diseases;
BRCA	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg10636054	chr15:40330586	SRP14	-0.91	-13.26	-0.46	1.29e-35	Corneal curvature;
BRCA	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg11764359	chr7:65958608	NA	-0.61	-13.28	-0.47	9.82e-36	Aortic root size;
BRCA	trans	rs208520	0.874	rs208470	chr6:66916402	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.29	-0.54	3.62e-50	Exhaled nitric oxide output;
BRCA	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg17063962	chr7:91808500	NA	0.54	12.41	0.44	7.86e-32	Breast cancer;
BRCA	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	11.36	0.41	2.38e-27	Height;
BRCA	cis	rs887829	0.569	rs4294999	chr2:234635467	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-8.86	-0.33	8.03e-18	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg00409905	chr10:38381863	ZNF37A	-0.47	-10.18	-0.37	1.12e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg21573476	chr21:45109991	RRP1B	-0.34	-9.0	-0.34	2.61e-18	Mean corpuscular volume;
BRCA	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg09307838	chr4:120376055	NA	-0.53	-11.07	-0.4	3.59e-26	Corneal astigmatism;
BRCA	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-9.81	-0.36	3.08e-21	Alzheimer's disease (late onset);
BRCA	cis	rs1421811	0.532	rs72740626	chr5:32692220	G/C	cg16267343	chr5:32710456	NPR3	0.65	12.48	0.44	3.91e-32	Blood pressure;
BRCA	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg13256891	chr4:100009986	ADH5	-0.52	-9.64	-0.36	1.27e-20	Alcohol dependence;
BRCA	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.72	-0.33	2.47e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9309711	0.772	rs9309714	chr2:3491830	G/C	cg16153549	chr2:3496821	NA	-0.44	-9.98	-0.37	7.04e-22	Neurofibrillary tangles;
BRCA	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg21475434	chr5:93447410	FAM172A	0.66	9.05	0.34	1.75e-18	Diabetic retinopathy;
BRCA	trans	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg06521331	chr12:34319734	NA	-0.46	-8.57	-0.32	8.05e-17	Bladder cancer;
BRCA	cis	rs6087990	0.842	rs6119279	chr20:31330612	A/G	cg13636640	chr20:31349939	DNMT3B	0.7	21.1	0.64	2.05e-75	Ulcerative colitis;
BRCA	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12756686	chr19:29218302	NA	0.38	8.03	0.3	4.58e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg11645453	chr3:52864694	ITIH4	-0.4	-10.68	-0.39	1.26e-24	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs96067	0.805	rs7522400	chr1:36613380	A/G	cg24686825	chr1:36642396	MAP7D1	-0.45	-8.67	-0.32	3.61e-17	Corneal structure;
BRCA	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg14196790	chr5:131705035	SLC22A5	0.33	8.64	0.32	4.66e-17	Breast cancer;
BRCA	cis	rs4974559	0.739	rs28429103	chr4:1320023	G/A	cg02980000	chr4:1222292	CTBP1	0.81	13.19	0.46	2.75e-35	Systolic blood pressure;
BRCA	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg21226059	chr5:178986404	RUFY1	0.5	12.84	0.45	1.01e-33	Lung cancer;
BRCA	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-9.73	-0.36	5.87e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4988958	0.584	rs12712149	chr2:103045193	A/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.38	0.31	3.39e-16	Asthma (childhood onset);
BRCA	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg20887711	chr4:1340912	KIAA1530	0.59	13.07	0.46	9.07e-35	Longevity;
BRCA	cis	rs7818345	0.967	rs7006702	chr8:19272533	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.26	0.31	8.36e-16	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg00666640	chr1:248458726	OR2T12	0.29	8.29	0.31	6.55e-16	Common traits (Other);
BRCA	trans	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg06521331	chr12:34319734	NA	-0.49	-9.15	-0.34	7.35e-19	Bladder cancer;
BRCA	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg08514558	chr10:81106712	PPIF	0.39	8.99	0.33	2.88e-18	Height;
BRCA	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.1	0.31	2.71e-15	Uric acid levels;
BRCA	cis	rs7809950	0.678	rs62483641	chr7:106901741	T/C	cg23024343	chr7:107201750	COG5	-0.45	-8.95	-0.33	3.83e-18	Coronary artery disease;
BRCA	cis	rs11997175	0.624	rs67643247	chr8:33700790	G/A	ch.8.33884649F	chr8:33765107	NA	0.37	8.09	0.3	3.02e-15	Body mass index;
BRCA	cis	rs4660306	0.961	rs4660871	chr1:45995232	C/A	cg24296786	chr1:45957014	TESK2	0.45	9.5	0.35	4.12e-20	Homocysteine levels;
BRCA	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg20219911	chr3:52813652	ITIH1	0.3	8.21	0.31	1.18e-15	Bipolar disorder;
BRCA	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg20790798	chr5:1857306	NA	-0.39	-9.09	-0.34	1.2e-18	Cardiovascular disease risk factors;
BRCA	cis	rs7011049	0.908	rs72640866	chr8:53843014	C/T	cg26025543	chr8:53854495	NA	0.56	9.66	0.36	1.11e-20	Systolic blood pressure;
BRCA	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg04166393	chr7:2884313	GNA12	0.42	9.1	0.34	1.09e-18	Height;
BRCA	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg16482183	chr6:26056742	HIST1H1C	-0.45	-9.0	-0.34	2.65e-18	Iron status biomarkers;
BRCA	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg26617929	chr16:1858877	NA	-0.45	-7.94	-0.3	9.45e-15	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg03146154	chr1:46216737	IPP	-0.44	-9.74	-0.36	5.58e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg23625390	chr15:77176239	SCAPER	-0.54	-13.63	-0.47	2.7e-37	Blood metabolite levels;
BRCA	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	17.21	0.56	8.14e-55	Hip circumference adjusted for BMI;
BRCA	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg05347473	chr6:146136440	FBXO30	0.42	8.28	0.31	7.18e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs312273	0.806	rs1372538	chr12:41325578	C/T	cg17827154	chr12:41323612	CNTN1	-0.43	-11.27	-0.41	5.23e-27	Bipolar disorder;
BRCA	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg11764359	chr7:65958608	NA	-0.64	-14.51	-0.5	1.83e-41	Aortic root size;
BRCA	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.82	0.62	1.64e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.64	13.63	0.47	2.48e-37	Lymphocyte counts;
BRCA	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.73	0.42	6.43e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-13.52	-0.47	7.81e-37	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg16230307	chr14:35515116	FAM177A1	0.73	15.23	0.52	6.64e-45	Psoriasis;
BRCA	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.14	-0.43	1.14e-30	Alzheimer's disease;
BRCA	cis	rs6942756	1.000	rs67520056	chr7:128982075	A/G	cg02491457	chr7:128862824	NA	-0.72	-14.15	-0.49	9.48e-40	White matter hyperintensity burden;
BRCA	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg15556689	chr8:8085844	FLJ10661	0.35	8.61	0.32	5.82e-17	Neuroticism;
BRCA	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18876405	chr7:65276391	NA	0.62	15.48	0.52	4.02e-46	Aortic root size;
BRCA	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg03433033	chr1:76189801	ACADM	-0.42	-8.63	-0.32	4.85e-17	Daytime sleep phenotypes;
BRCA	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg10556349	chr10:835070	NA	0.64	9.31	0.35	1.97e-19	Eosinophil percentage of granulocytes;
BRCA	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg19346786	chr7:2764209	NA	-0.28	-8.85	-0.33	8.37e-18	Height;
BRCA	cis	rs9463078	0.845	rs2396425	chr6:45177025	A/G	cg25276700	chr6:44698697	NA	-0.35	-7.97	-0.3	7.51e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-15.22	-0.52	6.9e-45	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23708337	chr7:1209742	NA	0.52	10.22	0.37	8.38e-23	Longevity;Endometriosis;
BRCA	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.54	0.38	4.59e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg17425144	chr1:10567563	PEX14	0.55	13.77	0.48	6e-38	Prostate cancer;
BRCA	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08704250	chr15:31115839	NA	-0.34	-8.13	-0.31	2.31e-15	Huntington's disease progression;
BRCA	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs524281	0.861	rs2889313	chr11:65966066	G/C	cg16950941	chr11:66035639	RAB1B	-0.39	-8.06	-0.3	3.88e-15	Electroencephalogram traits;
BRCA	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg23505145	chr19:12996616	KLF1	0.56	12.75	0.45	2.49e-33	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg25482853	chr8:67687455	SGK3	0.78	12.93	0.46	3.98e-34	Obesity-related traits;
BRCA	cis	rs9942416	0.660	rs17649055	chr5:74984269	C/T	cg19683494	chr5:74908142	NA	0.48	9.06	0.34	1.57e-18	Age-related disease endophenotypes;
BRCA	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24549020	chr5:56110836	MAP3K1	0.66	13.54	0.47	6.71e-37	Initial pursuit acceleration;
BRCA	trans	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg06521331	chr12:34319734	NA	-0.49	-9.15	-0.34	7.35e-19	Bladder cancer;
BRCA	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg22920501	chr2:26401640	FAM59B	-0.64	-11.26	-0.41	6.05e-27	Gut microbiome composition (summer);
BRCA	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg05472934	chr7:22766657	IL6	-0.59	-14.41	-0.5	5.87e-41	Lung cancer;
BRCA	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg08888203	chr3:10149979	C3orf24	0.65	11.88	0.43	1.45e-29	Alzheimer's disease;
BRCA	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg02734326	chr4:10020555	SLC2A9	0.36	7.87	0.3	1.53e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9815354	0.812	rs59146151	chr3:41949301	T/C	cg03022575	chr3:42003672	ULK4	0.68	9.48	0.35	4.82e-20	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg15556689	chr8:8085844	FLJ10661	-0.35	-8.59	-0.32	6.47e-17	Retinal vascular caliber;
BRCA	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	14.13	0.49	1.25e-39	Lymphocyte counts;
BRCA	cis	rs4908768	0.539	rs2100888	chr1:8659282	T/A	cg20416874	chr1:8611966	RERE	-0.28	-7.94	-0.3	9.16e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	8.48	0.32	1.53e-16	Electroencephalogram traits;
BRCA	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.33	-0.31	5.01e-16	Total body bone mineral density;
BRCA	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg00071950	chr4:10020882	SLC2A9	0.66	16.76	0.55	1.61e-52	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.07	-0.3	3.4e-15	Prostate cancer;
BRCA	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg03433033	chr1:76189801	ACADM	-0.76	-17.43	-0.57	5.73e-56	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg08601574	chr20:25228251	PYGB	-0.37	-8.91	-0.33	5.15e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg03188948	chr7:1209495	NA	0.45	8.22	0.31	1.14e-15	Longevity;Endometriosis;
BRCA	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11890956	chr21:40555474	PSMG1	-0.84	-21.85	-0.65	1.78e-79	Cognitive function;
BRCA	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9649465	1.000	rs1506635	chr7:123317184	C/T	cg04330084	chr7:123175371	IQUB	-0.3	-8.38	-0.31	3.26e-16	Migraine;
BRCA	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.35	0.59	9.88e-61	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg24006582	chr15:45444508	DUOX1	0.54	10.71	0.39	9.67e-25	Uric acid levels;
BRCA	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.85	-0.53	5.78e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12711979	0.509	rs10195488	chr2:3824135	T/C	cg17052675	chr2:3827356	NA	-0.7	-23.65	-0.68	2.6e-89	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg23791538	chr6:167370224	RNASET2	0.43	10.61	0.39	2.57e-24	Crohn's disease;
BRCA	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg07741184	chr6:167504864	NA	0.28	8.18	0.31	1.58e-15	Crohn's disease;
BRCA	cis	rs3820928	1.000	rs7579961	chr2:227776976	T/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.46	-0.32	1.8e-16	Pulmonary function;
BRCA	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.48	-9.34	-0.35	1.55e-19	Chronic sinus infection;
BRCA	cis	rs586533	0.801	rs669596	chr11:99499507	G/C	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg06271696	chr7:157225062	NA	-0.37	-9.55	-0.35	2.72e-20	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg13319975	chr6:146136371	FBXO30	0.62	13.86	0.48	2.15e-38	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg21782813	chr7:2030301	MAD1L1	0.36	9.79	0.36	3.37e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg20933634	chr6:27740509	NA	0.44	8.43	0.32	2.27e-16	Parkinson's disease;
BRCA	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.08	0.62	6.44e-70	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg00105475	chr2:10696890	NA	0.44	10.3	0.38	4.11e-23	Prostate cancer;
BRCA	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg08917208	chr2:24149416	ATAD2B	0.88	12.68	0.45	5.05e-33	Lymphocyte counts;
BRCA	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg26384229	chr12:38710491	ALG10B	0.77	17.47	0.57	3.66e-56	Bladder cancer;
BRCA	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	12.24	0.44	4.39e-31	Monocyte percentage of white cells;
BRCA	cis	rs17818399	0.815	rs62136873	chr2:46861237	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.45	8.02	0.3	4.96e-15	Height;
BRCA	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.33	-0.41	3.01e-27	Personality dimensions;
BRCA	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.27	-0.41	5.18e-27	Colorectal cancer;
BRCA	cis	rs7178424	1.000	rs12442212	chr15:62380482	A/C	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.43	-0.32	2.35e-16	Height;
BRCA	cis	rs10638925	1	rs10638925	chr3:194119749	C/CCATAAA	cg00834899	chr3:194121120	GP5	0.45	9.22	0.34	4.11e-19	Platelet distribution width;
BRCA	cis	rs2712184	0.868	rs1548946	chr2:217665368	C/T	cg05032264	chr2:217675019	NA	-0.43	-10.63	-0.39	2.04e-24	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg14683738	chr19:37701593	ZNF585B	0.46	8.12	0.31	2.48e-15	Coronary artery calcification;
BRCA	trans	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg15704280	chr7:45808275	SEPT13	0.6	8.83	0.33	1.02e-17	Axial length;
BRCA	trans	rs6011368	0.765	rs7270745	chr20:62892756	C/G	cg13869341	chr1:15865	WASH5P	-0.35	-7.94	-0.3	9.44e-15	Clozapine-induced cytotoxicity;
BRCA	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg05793240	chr7:2802953	GNA12	-0.32	-7.82	-0.3	2.23e-14	Height;
BRCA	cis	rs4787491	0.729	rs11642399	chr16:30059593	T/G	cg06326092	chr16:30034487	C16orf92	0.37	9.48	0.35	4.82e-20	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg06521331	chr12:34319734	NA	-0.48	-8.9	-0.33	5.63e-18	Bladder cancer;
BRCA	cis	rs68170813	0.559	rs61406169	chr7:106903421	A/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.97	-0.33	3.36e-18	Coronary artery disease;
BRCA	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg08807892	chr2:162101083	NA	0.72	16.5	0.55	3.35e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15506890	chr2:3487001	NA	-0.57	-12.33	-0.44	1.67e-31	Neurofibrillary tangles;
BRCA	trans	rs1459104	1.000	rs34965777	chr11:55238748	G/A	cg15704280	chr7:45808275	SEPT13	0.67	8.35	0.31	4.13e-16	Body mass index;
BRCA	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	10.69	0.39	1.18e-24	Motion sickness;
BRCA	trans	rs8073060	0.586	rs72828038	chr17:33893908	C/A	cg19694781	chr19:47549865	TMEM160	1.03	21.28	0.64	2.24e-76	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs1506636	1.000	rs1506636	chr7:123317140	C/T	cg03229431	chr7:123269106	ASB15	0.59	13.19	0.46	2.59e-35	Plateletcrit;Platelet count;
BRCA	cis	rs68170813	0.559	rs6965001	chr7:106933196	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-8.7	-0.33	2.87e-17	Coronary artery disease;
BRCA	cis	rs2992756	0.663	rs2992757	chr1:18807137	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.4	-8.22	-0.31	1.1e-15	Breast cancer;
BRCA	cis	rs6446731	0.517	rs2071667	chr4:3269926	C/A	cg08886695	chr4:3369023	RGS12	0.37	9.87	0.36	1.82e-21	Mean platelet volume;
BRCA	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg08085267	chr17:45401833	C17orf57	-0.58	-11.98	-0.43	5.79e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9788721	0.836	rs17405217	chr15:78731149	C/T	cg18825076	chr15:78729989	IREB2	-0.44	-8.37	-0.31	3.56e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.24	-0.31	9.98e-16	Colorectal cancer;
BRCA	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	21.85	0.65	1.87e-79	Smoking behavior;
BRCA	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg02711726	chr17:80685570	FN3KRP	0.68	16.5	0.55	3.31e-51	Glycated hemoglobin levels;
BRCA	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg23533926	chr12:111358616	MYL2	-0.41	-8.49	-0.32	1.4e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	26.17	0.72	3.74e-103	Platelet count;
BRCA	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg10523679	chr1:76189770	ACADM	-0.55	-10.19	-0.37	1.04e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg15133208	chr4:90757351	SNCA	-0.39	-7.97	-0.3	7.23e-15	Neuroticism;
BRCA	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg05340658	chr4:99064831	C4orf37	0.62	14.99	0.51	1e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg13507429	chr1:18807550	KLHDC7A	-0.44	-10.96	-0.4	9.55e-26	Breast cancer;
BRCA	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.33	-8.28	-0.31	7.16e-16	Total body bone mineral density;
BRCA	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03517284	chr6:25882590	NA	0.47	10.45	0.38	1.05e-23	Blood metabolite levels;
BRCA	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	9.31	0.35	2.02e-19	Aortic root size;
BRCA	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg03929089	chr4:120376271	NA	0.6	9.82	0.36	2.78e-21	Axial length;
BRCA	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg11812906	chr14:75593930	NEK9	-0.63	-14.3	-0.49	1.84e-40	Height;
BRCA	cis	rs2882667	0.894	rs10054478	chr5:138354075	G/A	cg04439458	chr5:138467593	SIL1	-0.34	-9.23	-0.34	3.83e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18404041	chr3:52824283	ITIH1	-0.38	-11.74	-0.42	5.84e-29	Bipolar disorder;
BRCA	cis	rs7577696	0.597	rs212689	chr2:32437338	G/A	cg02381751	chr2:32503542	YIPF4	0.47	8.58	0.32	7.11e-17	Inflammatory biomarkers;
BRCA	cis	rs7607369	0.536	rs4646535	chr2:219664663	C/T	cg02176678	chr2:219576539	TTLL4	-0.4	-10.55	-0.39	4.18e-24	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg21226059	chr5:178986404	RUFY1	-0.36	-9.44	-0.35	6.86e-20	Lung cancer;
BRCA	trans	rs208520	0.837	rs208509	chr6:66941706	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-15.26	-0.52	4.4e-45	Exhaled nitric oxide output;
BRCA	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg03342759	chr3:160939853	NMD3	-0.81	-19.0	-0.6	3.77e-64	Parkinson's disease;
BRCA	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.3	9.6	0.36	1.75e-20	Bipolar disorder;
BRCA	cis	rs8005677	0.611	rs11624528	chr14:23459156	A/G	cg23176270	chr14:23476067	C14orf93	0.46	9.35	0.35	1.46e-19	Cognitive ability (multi-trait analysis);
BRCA	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.58	-0.35	2.17e-20	Tonsillectomy;
BRCA	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.46	7.85	0.3	1.79e-14	Height;
BRCA	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg14196790	chr5:131705035	SLC22A5	0.32	8.46	0.32	1.86e-16	Breast cancer;
BRCA	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg20476274	chr7:133979776	SLC35B4	0.67	19.69	0.61	8.42e-68	Mean platelet volume;
BRCA	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.74	0.39	7.72e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg20503657	chr10:835505	NA	1.04	17.17	0.56	1.32e-54	Eosinophil percentage of granulocytes;
BRCA	cis	rs7131987	0.903	rs7974221	chr12:29399448	A/G	cg09582351	chr12:29534625	ERGIC2	-0.39	-9.51	-0.35	3.89e-20	QT interval;
BRCA	cis	rs887829	0.570	rs13002774	chr2:234593706	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.32	-8.31	-0.31	5.65e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs1113500	0.730	rs1361829	chr1:108593895	A/G	cg06207961	chr1:108661230	NA	-0.33	-7.91	-0.3	1.12e-14	Growth-regulated protein alpha levels;
BRCA	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg07211511	chr3:129823064	LOC729375	-0.59	-10.63	-0.39	2.15e-24	Blood pressure (smoking interaction);
BRCA	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.4	0.38	1.71e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	10.85	0.39	2.75e-25	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs9649465	0.935	rs7780086	chr7:123378471	C/A	cg04330084	chr7:123175371	IQUB	-0.33	-8.88	-0.33	6.76e-18	Migraine;
BRCA	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07636037	chr3:49044803	WDR6	0.66	14.19	0.49	6.13e-40	Menarche (age at onset);
BRCA	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-11.23	-0.41	7.66e-27	Morning vs. evening chronotype;
BRCA	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg24060327	chr5:131705240	SLC22A5	-0.61	-11.54	-0.42	4.19e-28	Breast cancer;
BRCA	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.8e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs28374715	0.510	rs8034073	chr15:41545613	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.51	-11.28	-0.41	4.73e-27	Ulcerative colitis;
BRCA	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg00531865	chr16:30841666	NA	-0.5	-11.66	-0.42	1.28e-28	Multiple myeloma;
BRCA	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.48	0.5	2.79e-41	Motion sickness;
BRCA	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg05714579	chr10:131428358	MGMT	0.53	12.51	0.44	2.76e-32	Response to temozolomide;
BRCA	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-19.35	-0.61	5.45e-66	Electrocardiographic conduction measures;
BRCA	trans	rs8105895	0.825	rs62112369	chr19:22313901	C/T	cg05197062	chr11:11642011	GALNTL4	-0.51	-8.24	-0.31	9.86e-16	Body mass index (change over time);
BRCA	cis	rs11887277	0.507	rs6743539	chr2:27056239	A/G	cg12368169	chr2:27073192	DPYSL5	-0.27	-8.01	-0.3	5.28e-15	Obesity-related traits;
BRCA	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.53	15.38	0.52	1.25e-45	Total body bone mineral density;
BRCA	cis	rs11608355	0.545	rs11609019	chr12:109895958	G/A	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-10.97	-0.4	9.29e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg11050988	chr7:1952600	MAD1L1	-0.23	-7.82	-0.3	2.11e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs6545883	0.894	rs2177962	chr2:61588070	T/A	cg15711740	chr2:61764176	XPO1	0.5	12.29	0.44	2.54e-31	Tuberculosis;
BRCA	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg03060546	chr3:49711283	APEH	0.52	10.81	0.39	3.85e-25	Resting heart rate;
BRCA	cis	rs2594989	0.943	rs2594995	chr3:11369117	A/G	cg01796438	chr3:11312864	ATG7	0.53	8.22	0.31	1.15e-15	Circulating chemerin levels;
BRCA	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	10.3	0.38	4.05e-23	Aortic root size;
BRCA	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg18357645	chr12:58087776	OS9	0.36	9.98	0.37	6.69e-22	Multiple sclerosis;
BRCA	trans	rs6479891	1.000	rs12413029	chr10:65189126	T/C	cg14819942	chr15:35414228	NA	0.35	8.58	0.32	7.31e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs9815354	0.812	rs73077386	chr3:41857652	A/G	cg03022575	chr3:42003672	ULK4	0.68	9.45	0.35	6.07e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.18e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg00701064	chr4:6280414	WFS1	0.68	17.68	0.57	3.11e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24110177	chr3:50126178	RBM5	0.4	10.85	0.39	2.73e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs7809950	1.000	rs2520268	chr7:107191161	T/A	cg23024343	chr7:107201750	COG5	-0.41	-9.13	-0.34	8.66e-19	Coronary artery disease;
BRCA	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg06494592	chr3:125709126	NA	-0.53	-8.27	-0.31	7.78e-16	Blood pressure (smoking interaction);
BRCA	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg00012203	chr2:219082015	ARPC2	-0.57	-12.08	-0.43	2.08e-30	Colorectal cancer;
BRCA	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg06115741	chr20:33292138	TP53INP2	0.36	8.01	0.3	5.64e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg08045932	chr20:61659980	NA	0.5	11.02	0.4	5.42e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg03060546	chr3:49711283	APEH	-0.6	-10.47	-0.38	8.64e-24	Menarche (age at onset);
BRCA	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg12011299	chr4:100065546	ADH4	0.38	11.02	0.4	5.74e-26	Alcohol dependence;
BRCA	trans	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs1003719	0.591	rs9636914	chr21:38589732	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.55	11.69	0.42	9.14e-29	Eye color traits;
BRCA	cis	rs3845702	0.935	rs3845695	chr2:180796989	A/G	cg01881094	chr2:180872142	CWC22	-0.68	-13.59	-0.47	3.76e-37	Schizophrenia;
BRCA	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg25427524	chr10:38739819	LOC399744	-0.56	-9.54	-0.35	3.02e-20	Obesity (extreme);
BRCA	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg21433313	chr16:3507492	NAT15	0.61	9.58	0.35	2.07e-20	Tuberculosis;
BRCA	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg10523679	chr1:76189770	ACADM	-0.62	-11.68	-0.42	1.05e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg11845111	chr2:191398756	TMEM194B	-0.79	-14.92	-0.51	2.19e-43	Diastolic blood pressure;
BRCA	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	10.1	0.37	2.45e-22	Bipolar disorder;
BRCA	cis	rs57024841	0.500	rs6560652	chr9:139830940	C/T	cg00693599	chr9:139836323	FBXW5	-0.4	-9.94	-0.37	9.59e-22	Beta-trace protein levels;
BRCA	cis	rs17818399	0.533	rs4384837	chr2:46789514	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	9.97	0.37	7.59e-22	Height;
BRCA	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg05526886	chr2:227700861	RHBDD1	-0.4	-8.34	-0.31	4.49e-16	Pulmonary function;
BRCA	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg18129178	chr5:148520854	ABLIM3	-0.64	-12.5	-0.44	3.06e-32	Breast cancer;
BRCA	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg14835575	chr10:16859367	RSU1	0.41	10.04	0.37	3.95e-22	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg24558204	chr6:135376177	HBS1L	0.59	15.94	0.53	1.98e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg18132916	chr6:79620363	NA	-0.48	-10.78	-0.39	5.12e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs6484504	0.576	rs169623	chr11:31184157	T/C	cg14844989	chr11:31128820	NA	-0.44	-9.45	-0.35	6.13e-20	Red blood cell count;
BRCA	trans	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg25214090	chr10:38739885	LOC399744	0.52	11.58	0.42	2.68e-28	Corneal astigmatism;
BRCA	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg01475377	chr6:109611718	NA	-0.57	-15.31	-0.52	2.73e-45	Reticulocyte fraction of red cells;
BRCA	cis	rs1506636	1.000	rs2896332	chr7:123297223	A/T	cg03229431	chr7:123269106	ASB15	-0.64	-14.3	-0.49	1.95e-40	Plateletcrit;Platelet count;
BRCA	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg18132916	chr6:79620363	NA	-0.48	-10.85	-0.39	2.86e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg03433033	chr1:76189801	ACADM	0.68	13.8	0.48	4.24e-38	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg07741184	chr6:167504864	NA	0.3	8.84	0.33	9.56e-18	Primary biliary cholangitis;
BRCA	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg21782813	chr7:2030301	MAD1L1	-0.29	-8.25	-0.31	9.28e-16	Schizophrenia;
BRCA	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.56	14.74	0.5	1.57e-42	Schizophrenia;
BRCA	trans	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg26043149	chr18:55253948	FECH	-0.6	-13.0	-0.46	1.81e-34	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs17604090	0.938	rs28457783	chr7:29687058	T/G	cg19413766	chr7:29689036	LOC646762	-0.59	-8.17	-0.31	1.67e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg16414030	chr3:133502952	NA	-0.47	-11.0	-0.4	7.11e-26	Iron status biomarkers;
BRCA	trans	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-15.17	-0.51	1.22e-44	Obesity-related traits;
BRCA	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg20302533	chr7:39170763	POU6F2	0.37	7.83	0.3	2.08e-14	IgG glycosylation;
BRCA	cis	rs6543140	0.964	rs11886793	chr2:103072220	T/G	cg04239558	chr2:103089729	SLC9A4	0.34	9.56	0.35	2.4e-20	Blood protein levels;
BRCA	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg21045802	chr8:109455806	TTC35	0.34	7.87	0.3	1.52e-14	Dupuytren's disease;
BRCA	cis	rs9318086	0.624	rs9510909	chr13:24436760	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.33	9.43	0.35	7.59e-20	Myopia (pathological);
BRCA	cis	rs698833	0.828	rs2165421	chr2:44526010	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	10.29	0.38	4.31e-23	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.41	-9.19	-0.34	5.3e-19	Longevity;Endometriosis;
BRCA	cis	rs701145	0.537	rs377565	chr3:153921953	A/G	cg17054900	chr3:154042577	DHX36	0.42	8.05	0.3	3.99e-15	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg23788917	chr6:8435910	SLC35B3	-0.47	-10.25	-0.38	6.36e-23	Motion sickness;
BRCA	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg20701182	chr2:24300061	SF3B14	0.71	13.49	0.47	1.15e-36	Lymphocyte counts;
BRCA	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg17063962	chr7:91808500	NA	-0.54	-12.82	-0.45	1.26e-33	Breast cancer;
BRCA	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg01283332	chr5:1856932	NA	-0.33	-8.24	-0.31	1.01e-15	Cardiovascular disease risk factors;
BRCA	cis	rs3820928	0.967	rs16822905	chr2:227770727	G/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.46	-0.32	1.77e-16	Pulmonary function;
BRCA	cis	rs11969893	0.850	rs9791284	chr6:101353886	G/A	cg12253828	chr6:101329408	ASCC3	1.02	12.24	0.44	4.43e-31	Economic and political preferences (immigration/crime);
BRCA	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg04691961	chr3:161091175	C3orf57	-0.59	-14.04	-0.49	3.35e-39	Morning vs. evening chronotype;
BRCA	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg24675658	chr1:53192096	ZYG11B	0.63	15.25	0.52	5.13e-45	Monocyte count;
BRCA	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg04607235	chr12:12878440	APOLD1	-0.69	-10.73	-0.39	8.18e-25	Systemic lupus erythematosus;
BRCA	cis	rs61990749	0.597	rs176943	chr14:78175797	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	-0.62	-9.5	-0.35	4.3e-20	Fibroblast growth factor basic levels;
BRCA	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg09537434	chr19:41945824	ATP5SL	1.02	23.92	0.69	8.77e-91	Height;
BRCA	cis	rs4948102	0.690	rs35844144	chr7:56050525	C/T	cg09872392	chr7:56161020	PHKG1	-0.37	-8.75	-0.33	1.85e-17	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg23649088	chr2:200775458	C2orf69	0.49	9.98	0.37	7.05e-22	Osteoporosis;
BRCA	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	13.98	0.48	5.79e-39	Motion sickness;
BRCA	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-15.41	-0.52	9.02e-46	Systemic lupus erythematosus;
BRCA	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19626725	chr5:178986131	RUFY1	0.33	9.31	0.35	2.05e-19	Lung cancer;
BRCA	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg25019033	chr10:957182	NA	-0.42	-8.03	-0.3	4.66e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05025164	chr4:1340916	KIAA1530	-0.76	-15.52	-0.52	2.34e-46	Longevity;
BRCA	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.62	16.13	0.54	2.36e-49	Electrocardiographic conduction measures;
BRCA	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs3960554	1.000	rs2079477	chr7:75836549	C/G	cg19862616	chr7:65841803	NCRNA00174	0.57	12.26	0.44	3.4e-31	Eotaxin levels;
BRCA	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg05340658	chr4:99064831	C4orf37	0.55	10.76	0.39	6.32e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg06618935	chr21:46677482	NA	-0.36	-8.0	-0.3	5.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg08999081	chr20:33150536	PIGU	-0.3	-7.82	-0.3	2.25e-14	Height;
BRCA	cis	rs10046574	0.764	rs10269360	chr7:135147425	A/C	cg27474649	chr7:135195673	CNOT4	0.56	8.09	0.3	2.99e-15	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs6138458	0.962	rs6036976	chr20:24901567	T/G	cg26195577	chr20:24973756	C20orf3	-0.98	-24.76	-0.7	2.17e-95	Blood protein levels;
BRCA	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg08601574	chr20:25228251	PYGB	-0.33	-7.99	-0.3	6.45e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg06484146	chr7:12443880	VWDE	-0.76	-10.67	-0.39	1.43e-24	Coronary artery disease;
BRCA	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg17470723	chr8:74884337	TCEB1	0.4	8.67	0.32	3.48e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.6	-10.42	-0.38	1.37e-23	Body mass index (adult);
BRCA	cis	rs3820928	0.904	rs59135978	chr2:227857763	T/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.43	-0.32	2.35e-16	Pulmonary function;
BRCA	cis	rs2742234	0.504	rs10899780	chr10:43725796	T/C	cg15436174	chr10:43711423	RASGEF1A	0.54	10.68	0.39	1.35e-24	Hirschsprung disease;
BRCA	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg03585969	chr10:35415529	CREM	0.45	9.44	0.35	6.64e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03264133	chr6:25882463	NA	-0.49	-11.09	-0.4	3.07e-26	Blood metabolite levels;
BRCA	cis	rs909002	0.811	rs11575883	chr1:32085485	G/A	cg11573219	chr1:32083031	HCRTR1	0.26	8.25	0.31	9.21e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg05340658	chr4:99064831	C4orf37	0.69	17.28	0.56	3.38e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs831571	0.519	rs13059603	chr3:63827381	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.69	13.89	0.48	1.6e-38	Type 2 diabetes;
BRCA	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg07169764	chr2:136633963	MCM6	0.99	19.85	0.62	1.12e-68	Corneal structure;
BRCA	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	20.24	0.62	9.74e-71	Platelet count;
BRCA	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg22920501	chr2:26401640	FAM59B	-0.91	-16.27	-0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg14403583	chr14:105418241	AHNAK2	-0.4	-9.32	-0.35	1.86e-19	Rheumatoid arthritis;
BRCA	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.35	-0.41	2.51e-27	Gut microbiome composition (summer);
BRCA	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg23262073	chr20:60523788	NA	0.43	9.39	0.35	1.06e-19	Body mass index;
BRCA	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg04944784	chr2:26401820	FAM59B	0.95	16.64	0.55	6.56e-52	Gut microbiome composition (summer);
BRCA	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg27661571	chr11:113659931	NA	-0.81	-12.13	-0.43	1.25e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg12373951	chr3:133503437	NA	0.34	8.11	0.31	2.68e-15	Iron status biomarkers;
BRCA	cis	rs17253792	0.822	rs78429067	chr14:56092551	G/A	cg01858014	chr14:56050164	KTN1	-0.74	-9.19	-0.34	5.63e-19	Putamen volume;
BRCA	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10802521	chr3:52805072	NEK4	-0.34	-9.2	-0.34	5.17e-19	Bipolar disorder;
BRCA	cis	rs813218	0.523	rs1708167	chr3:99459236	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.4	-9.22	-0.34	4.26e-19	Orofacial clefts;
BRCA	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg11266682	chr4:10021025	SLC2A9	0.49	13.11	0.46	6.05e-35	Bone mineral density;
BRCA	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg09184832	chr6:79620586	NA	-0.51	-11.12	-0.4	2.32e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs4566357	0.576	rs10187255	chr2:227913442	T/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.44	-0.35	6.61e-20	Coronary artery disease;
BRCA	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg02196655	chr2:10830764	NOL10	0.29	7.82	0.3	2.13e-14	Prostate cancer;
BRCA	cis	rs3820928	1.000	rs11692572	chr2:227774503	C/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.87	-0.33	7.08e-18	Pulmonary function;
BRCA	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg16325326	chr1:53192061	ZYG11B	-0.56	-11.48	-0.41	7.53e-28	Monocyte count;
BRCA	cis	rs847649	0.731	rs10808120	chr7:102672234	A/G	cg18108683	chr7:102477205	FBXL13	-0.35	-7.81	-0.3	2.33e-14	Morning vs. evening chronotype;
BRCA	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg26384229	chr12:38710491	ALG10B	0.74	16.83	0.55	6.77e-53	Bladder cancer;
BRCA	cis	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg04990556	chr1:26633338	UBXN11	0.53	8.53	0.32	1.04e-16	Obesity-related traits;
BRCA	cis	rs11971779	0.616	rs2883772	chr7:139072756	T/C	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg10523679	chr1:76189770	ACADM	-0.47	-9.19	-0.34	5.54e-19	Daytime sleep phenotypes;
BRCA	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg03060546	chr3:49711283	APEH	-0.48	-9.56	-0.35	2.39e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7809615	0.901	rs17161761	chr7:99156934	C/T	cg12290671	chr7:99195819	NA	-0.5	-8.44	-0.32	2.2e-16	Blood metabolite ratios;
BRCA	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.16	-0.43	9.46e-31	Breast cancer;
BRCA	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg05347473	chr6:146136440	FBXO30	-0.44	-8.74	-0.33	2.08e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg05527609	chr1:210001259	C1orf107	-0.78	-16.55	-0.55	1.91e-51	Orofacial clefts;
BRCA	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg01028140	chr2:1542097	TPO	0.76	15.07	0.51	3.88e-44	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg20387954	chr3:183756860	HTR3D	0.45	10.16	0.37	1.44e-22	Anterior chamber depth;
BRCA	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.75	15.37	0.52	1.35e-45	Smoking behavior;
BRCA	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs4363385	0.654	rs1129654	chr1:152958238	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.31	-0.31	5.93e-16	Inflammatory skin disease;
BRCA	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	11.27	0.41	5.3e-27	Height;
BRCA	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	11.77	0.42	4.22e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg20701182	chr2:24300061	SF3B14	0.71	12.98	0.46	2.33e-34	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.52	10.26	0.38	5.84e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03264133	chr6:25882463	NA	-0.52	-11.75	-0.42	5.15e-29	Blood metabolite levels;
BRCA	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg06191203	chr2:152266755	RIF1	0.28	8.23	0.31	1.05e-15	Lung cancer;
BRCA	cis	rs34779708	0.931	rs12248333	chr10:35362977	A/G	cg03585969	chr10:35415529	CREM	0.46	9.56	0.35	2.43e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.42	8.52	0.32	1.17e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs17253792	0.822	rs111467375	chr14:56046159	T/G	cg01858014	chr14:56050164	KTN1	-0.73	-9.45	-0.35	6.29e-20	Putamen volume;
BRCA	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg02012338	chr4:187126139	CYP4V2	0.78	8.82	0.33	1.07e-17	Activated partial thromboplastin time;
BRCA	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg15934090	chr1:100435551	SLC35A3	0.36	8.33	0.31	4.87e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.7	-0.33	2.74e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg08601574	chr20:25228251	PYGB	0.35	8.48	0.32	1.52e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg21918786	chr6:109611834	NA	-0.44	-11.7	-0.42	8.55e-29	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
BRCA	cis	rs4727443	0.866	rs12531809	chr7:99620473	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.41	9.12	0.34	9.84e-19	Interstitial lung disease;
BRCA	trans	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.2	0.31	1.29e-15	Mean corpuscular volume;
BRCA	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg02951883	chr7:2050386	MAD1L1	0.45	10.54	0.38	4.67e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg02734326	chr4:10020555	SLC2A9	0.37	8.42	0.32	2.43e-16	Bone mineral density;
BRCA	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg09904177	chr6:26538194	HMGN4	0.47	14.7	0.5	2.27e-42	Intelligence (multi-trait analysis);
BRCA	trans	rs6560039	1	rs6560039	chr9:90474946	C/T	cg24436365	chr6:63940138	NA	0.66	17.05	0.56	5.3e-54	Gait variability;
BRCA	cis	rs4812048	0.649	rs6070702	chr20:57621562	G/C	cg14073986	chr20:57617431	SLMO2	0.78	12.14	0.43	1.17e-30	Mean platelet volume;
BRCA	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.49	0.65	1.55e-77	Lymphocyte percentage of white cells;
BRCA	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.67	0.42	1.12e-28	Metabolite levels (small molecules and protein measures);
BRCA	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg13010199	chr12:38710504	ALG10B	-0.39	-8.83	-0.33	1.04e-17	Morning vs. evening chronotype;
BRCA	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg03711944	chr11:47377212	SPI1	-0.39	-9.42	-0.35	7.84e-20	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg00105475	chr2:10696890	NA	0.44	10.3	0.38	4.08e-23	Prostate cancer;
BRCA	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg04756594	chr16:24857601	SLC5A11	0.45	9.52	0.35	3.53e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	8.12	0.31	2.36e-15	Monocyte percentage of white cells;
BRCA	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg25206134	chr2:45395956	NA	0.54	8.8	0.33	1.31e-17	Bipolar disorder;
BRCA	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg13010199	chr12:38710504	ALG10B	0.51	10.06	0.37	3.41e-22	Bladder cancer;
BRCA	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.74	-11.52	-0.41	4.85e-28	Mean platelet volume;
BRCA	cis	rs7524258	0.903	rs4908608	chr1:7292772	T/C	cg07173049	chr1:7289937	CAMTA1	0.55	13.39	0.47	3.18e-36	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.24	0.31	9.55e-16	Cognitive ability;
BRCA	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg00409905	chr10:38381863	ZNF37A	0.44	9.13	0.34	8.87e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.43	-8.29	-0.31	6.84e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs113835537	0.529	rs4542420	chr11:66277610	G/C	cg24851651	chr11:66362959	CCS	0.44	8.3	0.31	6.33e-16	Airway imaging phenotypes;
BRCA	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg14343924	chr8:8086146	FLJ10661	0.45	9.31	0.35	2e-19	Systolic blood pressure;
BRCA	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg15595755	chr5:1867978	NA	0.36	8.49	0.32	1.45e-16	Cardiovascular disease risk factors;
BRCA	cis	rs17641971	0.899	rs818557	chr8:49984515	G/C	cg00325661	chr8:49890786	NA	-0.31	-8.18	-0.31	1.52e-15	Blood metabolite levels;
BRCA	trans	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg06521331	chr12:34319734	NA	0.5	9.02	0.34	2.25e-18	Bladder cancer;
BRCA	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.69	-13.81	-0.48	3.74e-38	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg16606324	chr3:10149918	C3orf24	0.57	10.04	0.37	4e-22	Alzheimer's disease;
BRCA	cis	rs6942407	0.546	rs3789251	chr7:86793303	A/G	cg02420886	chr7:86849541	C7orf23	0.52	7.81	0.3	2.31e-14	Food allergy;
BRCA	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg15133208	chr4:90757351	SNCA	-0.39	-8.06	-0.3	3.72e-15	Neuroticism;
BRCA	trans	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.45	-0.35	6.17e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6545883	0.929	rs6545873	chr2:61733012	T/C	cg15711740	chr2:61764176	XPO1	-0.54	-14.02	-0.49	3.95e-39	Tuberculosis;
BRCA	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg17063962	chr7:91808500	NA	0.57	13.25	0.46	1.42e-35	Breast cancer;
BRCA	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	ch.11.42038R	chr11:967971	AP2A2	0.46	13.79	0.48	4.71e-38	Alzheimer's disease (late onset);
BRCA	trans	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg19862616	chr7:65841803	NCRNA00174	0.83	27.27	0.73	3.26e-109	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg23533926	chr12:111358616	MYL2	-0.44	-9.18	-0.34	5.78e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg20203395	chr5:56204925	C5orf35	-0.45	-8.73	-0.33	2.27e-17	Initial pursuit acceleration;
BRCA	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.32	-0.38	3.36e-23	Aortic root size;
BRCA	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.2	0.37	1.01e-22	Aortic root size;
BRCA	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg15704280	chr7:45808275	SEPT13	0.78	18.4	0.59	5.58e-61	Coronary artery disease;
BRCA	cis	rs701145	0.585	rs1358405	chr3:153810992	A/G	cg17054900	chr3:154042577	DHX36	0.53	8.92	0.33	4.83e-18	Coronary artery disease;
BRCA	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg20307385	chr11:47447363	PSMC3	-0.43	-9.03	-0.34	1.96e-18	Subjective well-being;
BRCA	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.63	11.49	0.41	6.86e-28	Height;
BRCA	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg24747557	chr10:131355152	MGMT	-0.36	-8.68	-0.32	3.27e-17	Response to temozolomide;
BRCA	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg09904177	chr6:26538194	HMGN4	0.47	15.01	0.51	7.99e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg08603382	chr10:743973	NA	-0.46	-8.78	-0.33	1.52e-17	Psychosis in Alzheimer's disease;
BRCA	cis	rs1018836	0.884	rs9643307	chr8:91625257	A/C	cg16814680	chr8:91681699	NA	-0.59	-12.7	-0.45	4.08e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg26384229	chr12:38710491	ALG10B	0.68	14.36	0.49	1.04e-40	Morning vs. evening chronotype;
BRCA	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg07741184	chr6:167504864	NA	0.27	7.94	0.3	9.36e-15	Crohn's disease;
BRCA	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg17127132	chr2:85788382	GGCX	0.35	7.97	0.3	7.48e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs68170813	0.559	rs10953534	chr7:106913718	A/G	cg02696742	chr7:106810147	HBP1	0.54	8.79	0.33	1.41e-17	Coronary artery disease;
BRCA	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18876405	chr7:65276391	NA	-0.63	-15.65	-0.53	5.63e-47	Aortic root size;
BRCA	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg18811423	chr2:55921094	PNPT1	0.71	23.03	0.67	6.31e-86	Metabolic syndrome;
BRCA	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-11.21	-0.41	9.48e-27	Gut microbiome composition (summer);
BRCA	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg11812906	chr14:75593930	NEK9	-0.64	-14.88	-0.51	3.09e-43	Height;
BRCA	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg09537434	chr19:41945824	ATP5SL	-1.01	-24.77	-0.7	1.88e-95	Height;
BRCA	cis	rs17401966	0.540	rs1467653	chr1:10413123	A/G	cg03954927	chr1:10346856	KIF1B	-0.33	-9.75	-0.36	4.74e-21	Hepatocellular carcinoma;
BRCA	cis	rs7523273	0.606	rs12401619	chr1:207976276	G/C	cg22525895	chr1:207977042	MIR29B2	-0.53	-13.56	-0.47	5.43e-37	Schizophrenia;
BRCA	cis	rs68170813	0.559	rs11769527	chr7:106912948	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.67	-0.32	3.43e-17	Coronary artery disease;
BRCA	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg00420348	chr11:830190	EFCAB4A	-0.5	-10.71	-0.39	1.01e-24	Mean platelet volume;
BRCA	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg23711669	chr6:146136114	FBXO30	0.72	16.79	0.55	1.07e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9462027	0.628	rs6906759	chr6:34742990	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.0	-0.3	5.77e-15	Systemic lupus erythematosus;
BRCA	cis	rs9308433	0.529	rs10465696	chr1:214499883	G/A	cg06198575	chr1:214491504	SMYD2	0.55	12.1	0.43	1.65e-30	IgG glycosylation;
BRCA	cis	rs243505	0.559	rs2072407	chr7:148508833	A/G	cg09806900	chr7:148480153	CUL1	0.52	10.73	0.39	7.94e-25	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg04117972	chr1:227635322	NA	-0.46	-8.39	-0.31	3.13e-16	Major depressive disorder;
BRCA	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs526821	0.595	rs532278	chr11:55344983	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-7.86	-0.3	1.64e-14	Pediatric bone mineral density (spine);
BRCA	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg02753203	chr1:228287806	NA	-0.55	-11.81	-0.42	3.02e-29	Diastolic blood pressure;
BRCA	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg21427119	chr20:30132790	HM13	-0.42	-8.88	-0.33	6.48e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs16958440	1.000	rs4609941	chr18:44645491	T/C	cg17192377	chr18:44677553	HDHD2	0.67	9.8	0.36	3.33e-21	Sitting height ratio;
BRCA	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg23625390	chr15:77176239	SCAPER	-0.54	-13.79	-0.48	4.61e-38	Blood metabolite levels;
BRCA	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg08888203	chr3:10149979	C3orf24	0.54	10.05	0.37	3.55e-22	Alzheimer's disease;
BRCA	cis	rs4561483	0.673	rs28279	chr16:11968555	A/C	cg08843971	chr16:11963173	GSPT1	0.49	11.07	0.4	3.43e-26	Testicular germ cell tumor;
BRCA	cis	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.72	-0.33	2.42e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs6479891	1.000	rs7916282	chr10:65031811	A/T	cg14819942	chr15:35414228	NA	-0.35	-8.57	-0.32	7.85e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs460214	0.576	rs28446127	chr21:40029568	C/A	cg21578987	chr21:40029669	ERG	0.38	8.78	0.33	1.53e-17	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	11.94	0.43	8.68e-30	Rheumatoid arthritis;
BRCA	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg16606324	chr3:10149918	C3orf24	0.56	11.15	0.4	1.74e-26	Alzheimer's disease;
BRCA	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg01206211	chr2:36825736	FEZ2	0.46	10.86	0.39	2.58e-25	Height;
BRCA	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg10523679	chr1:76189770	ACADM	0.68	12.55	0.44	1.96e-32	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.96	-0.3	7.72e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs17095355	1.000	rs12570423	chr10:111690942	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.38	-9.63	-0.36	1.35e-20	Biliary atresia;
BRCA	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.77	12.24	0.44	4.32e-31	Platelet count;
BRCA	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg23711669	chr6:146136114	FBXO30	0.74	17.77	0.58	1.06e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg10876282	chr6:28092338	ZSCAN16	0.41	8.16	0.31	1.79e-15	Cardiac Troponin-T levels;
BRCA	cis	rs7512552	0.839	rs1103115	chr1:150332304	G/A	cg15654264	chr1:150340011	RPRD2	0.38	8.4	0.32	2.81e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs427394	0.582	rs274665	chr5:6707981	C/T	cg10857441	chr5:6722123	POLS	-0.3	-9.47	-0.35	5.28e-20	Menopause (age at onset);
BRCA	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg08917208	chr2:24149416	ATAD2B	0.51	7.96	0.3	7.95e-15	Lymphocyte counts;
BRCA	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.87	0.51	3.77e-43	Colorectal cancer;
BRCA	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg08645402	chr16:4508243	NA	-0.41	-9.55	-0.35	2.69e-20	Schizophrenia;
BRCA	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg09359103	chr1:154839909	KCNN3	-0.58	-15.36	-0.52	1.47e-45	Prostate cancer;
BRCA	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg23649088	chr2:200775458	C2orf69	0.44	9.53	0.35	3.3e-20	Systolic blood pressure;
BRCA	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	12.25	0.44	3.94e-31	Mean corpuscular hemoglobin;
BRCA	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg01529538	chr14:23388837	RBM23	0.42	11.46	0.41	8.38e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg05793240	chr7:2802953	GNA12	-0.33	-8.45	-0.32	2.01e-16	Height;
BRCA	cis	rs34779708	0.931	rs2490663	chr10:35329735	A/G	cg03585969	chr10:35415529	CREM	-0.45	-9.53	-0.35	3.34e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs17092148	0.945	rs6058115	chr20:33358397	T/G	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.26	-0.41	5.82e-27	Neuroticism;
BRCA	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.6	0.39	2.74e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-14.01	-0.48	4.39e-39	Platelet count;
BRCA	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg04944784	chr2:26401820	FAM59B	-0.95	-16.58	-0.55	1.26e-51	Gut microbiome composition (summer);
BRCA	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	14.95	0.51	1.43e-43	Hip circumference adjusted for BMI;
BRCA	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg26384229	chr12:38710491	ALG10B	0.59	13.62	0.47	2.98e-37	Morning vs. evening chronotype;
BRCA	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg09904177	chr6:26538194	HMGN4	0.47	14.71	0.5	2.11e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg01324343	chr3:183735012	ABCC5	0.63	15.03	0.51	6.31e-44	Anterior chamber depth;
BRCA	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg04450456	chr4:17643702	FAM184B	0.38	11.29	0.41	4.51e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	23.44	0.68	3.67e-88	Platelet count;
BRCA	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06108461	chr20:60628389	TAF4	-1.01	-23.05	-0.67	5.07e-86	Body mass index;
BRCA	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg03342759	chr3:160939853	NMD3	-0.78	-18.39	-0.59	6.32e-61	Parkinson's disease;
BRCA	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.9	0.62	6.05e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10782582	0.609	rs5745545	chr1:76377356	A/G	cg03433033	chr1:76189801	ACADM	-0.39	-7.94	-0.3	8.9e-15	Daytime sleep phenotypes;
BRCA	cis	rs7851660	0.967	rs3758251	chr9:100613700	G/C	cg13688889	chr9:100608707	NA	-0.36	-8.71	-0.33	2.56e-17	Strep throat;
BRCA	cis	rs870825	0.616	rs12512839	chr4:185610347	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	16.13	0.54	2.46e-49	Blood protein levels;
BRCA	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg07636037	chr3:49044803	WDR6	0.98	29.34	0.76	1.7e-120	Parkinson's disease;
BRCA	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26314531	chr2:26401878	FAM59B	0.75	10.66	0.39	1.59e-24	Gut microbiome composition (summer);
BRCA	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg04851639	chr8:1020857	NA	-0.35	-10.33	-0.38	3.07e-23	Schizophrenia;
BRCA	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg26384229	chr12:38710491	ALG10B	0.67	18.57	0.59	6.75e-62	Morning vs. evening chronotype;
BRCA	cis	rs9473147	0.503	rs9473123	chr6:47475339	G/A	cg12968598	chr6:47444699	CD2AP	0.44	9.57	0.35	2.33e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg23719950	chr11:63933701	MACROD1	-0.52	-8.56	-0.32	8.52e-17	Mean platelet volume;
BRCA	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg26597838	chr10:835615	NA	0.66	11.09	0.4	3.02e-26	Eosinophil percentage of granulocytes;
BRCA	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg04450456	chr4:17643702	FAM184B	0.39	11.66	0.42	1.3e-28	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs829883	0.872	rs1641637	chr12:98890564	G/A	cg25150519	chr12:98850993	NA	0.59	11.88	0.43	1.52e-29	Colorectal adenoma (advanced);
BRCA	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg09654669	chr8:57350985	NA	-0.39	-8.74	-0.33	2.11e-17	Obesity-related traits;
BRCA	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg11833968	chr6:79620685	NA	-0.44	-9.81	-0.36	2.92e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg04842962	chr6:43655489	MRPS18A	-0.88	-14.68	-0.5	2.84e-42	IgG glycosylation;
BRCA	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg05527609	chr1:210001259	C1orf107	-0.7	-15.02	-0.51	6.67e-44	Orofacial clefts;
BRCA	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.74	-12.85	-0.45	9.13e-34	Platelet count;
BRCA	cis	rs6088813	1.000	rs6142369	chr20:33973315	T/G	cg14752227	chr20:34000481	UQCC	-0.43	-9.12	-0.34	9.99e-19	Height;
BRCA	trans	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.02	30.59	0.77	3.06e-127	Exhaled nitric oxide output;
BRCA	trans	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.93	0.3	9.71e-15	Corneal astigmatism;
BRCA	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-8.23	-0.31	1.08e-15	Total body bone mineral density;
BRCA	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg27129171	chr3:47204927	SETD2	-0.72	-17.49	-0.57	2.94e-56	Colorectal cancer;
BRCA	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg23625390	chr15:77176239	SCAPER	-0.53	-12.24	-0.44	4.09e-31	Blood metabolite levels;
BRCA	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg06092702	chr1:163392909	NA	-0.33	-8.71	-0.33	2.69e-17	Motion sickness;
BRCA	cis	rs534126	0.778	rs10256011	chr7:142936243	G/A	cg15652212	chr7:142981776	TMEM139	0.46	10.34	0.38	2.81e-23	Cancer;
BRCA	cis	rs36051895	0.695	rs7045000	chr9:5015143	G/A	cg02405213	chr9:5042618	JAK2	-0.45	-8.35	-0.31	4.21e-16	Pediatric autoimmune diseases;
BRCA	cis	rs6782228	0.606	rs7650156	chr3:128361555	T/A	cg16766828	chr3:128327626	NA	-0.43	-9.67	-0.36	9.7e-21	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg06784218	chr1:46089804	CCDC17	0.49	11.63	0.42	1.71e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3845702	0.736	rs3843323	chr2:180856459	T/C	cg01881094	chr2:180872142	CWC22	-1.01	-18.87	-0.6	1.89e-63	Schizophrenia;
BRCA	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg20991723	chr1:152506922	NA	0.39	8.95	0.33	3.87e-18	Hair morphology;
BRCA	cis	rs9287719	0.649	rs10929684	chr2:10732224	C/T	cg00105475	chr2:10696890	NA	-0.42	-9.43	-0.35	7.69e-20	Prostate cancer;
BRCA	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11644478	chr21:40555479	PSMG1	0.54	11.62	0.42	1.94e-28	Cognitive function;
BRCA	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg04691961	chr3:161091175	C3orf57	-0.52	-12.94	-0.46	3.68e-34	Morning vs. evening chronotype;
BRCA	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg26384229	chr12:38710491	ALG10B	0.87	23.95	0.69	5.8e-91	Heart rate;
BRCA	cis	rs4363385	0.818	rs382292	chr1:153006641	G/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.57	-0.32	7.61e-17	Inflammatory skin disease;
BRCA	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg20203395	chr5:56204925	C5orf35	-0.42	-9.33	-0.35	1.7e-19	Initial pursuit acceleration;
BRCA	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg14835575	chr10:16859367	RSU1	0.62	12.38	0.44	1.07e-31	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs4728302	0.869	rs11770927	chr7:133593126	G/A	cg07491979	chr7:133331646	EXOC4	0.36	7.89	0.3	1.31e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.41	0.57	7.61e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg06115741	chr20:33292138	TP53INP2	0.39	8.59	0.32	6.82e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg23711669	chr6:146136114	FBXO30	-0.69	-15.47	-0.52	4.38e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11718455	1.000	rs1524885	chr3:44031847	G/A	cg08738300	chr3:44038990	NA	0.47	8.94	0.33	4.09e-18	Coronary artery disease;
BRCA	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg09307838	chr4:120376055	NA	0.74	15.84	0.53	6.39e-48	Corneal astigmatism;
BRCA	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg16405210	chr4:1374714	KIAA1530	-0.37	-8.13	-0.31	2.24e-15	Obesity-related traits;
BRCA	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg09307838	chr4:120376055	NA	0.46	9.53	0.35	3.29e-20	Diastolic blood pressure;
BRCA	cis	rs1776421	0.760	rs78493155	chr1:53898195	G/A	cg10892335	chr1:53966318	NA	0.5	7.96	0.3	7.83e-15	PR interval in Tripanosoma cruzi seropositivity;
BRCA	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg23750338	chr8:142222470	SLC45A4	0.53	12.79	0.45	1.62e-33	Immature fraction of reticulocytes;
BRCA	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg07741184	chr6:167504864	NA	-0.3	-8.71	-0.33	2.63e-17	Primary biliary cholangitis;
BRCA	cis	rs6942407	0.546	rs3789252	chr7:86793362	G/C	cg02420886	chr7:86849541	C7orf23	0.52	7.81	0.3	2.31e-14	Food allergy;
BRCA	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg14863265	chr7:2801509	GNA12	0.39	8.76	0.33	1.74e-17	Height;
BRCA	cis	rs7177699	0.557	rs12442476	chr15:79117856	G/A	cg00540400	chr15:79124168	NA	0.27	7.81	0.3	2.44e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg08603382	chr10:743973	NA	-0.47	-9.92	-0.37	1.1e-21	Psychosis in Alzheimer's disease;
BRCA	cis	rs2281845	0.507	rs7547762	chr1:201088245	A/G	cg06714761	chr1:201096289	NA	0.57	14.78	0.5	9.32e-43	Permanent tooth development;
BRCA	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg22467129	chr15:76604101	ETFA	-0.42	-9.22	-0.34	4.26e-19	Blood metabolite levels;
BRCA	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18876405	chr7:65276391	NA	-0.55	-13.19	-0.46	2.51e-35	Aortic root size;
BRCA	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-9.97	-0.37	7.19e-22	Fear of minor pain;
BRCA	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.42	8.05	0.3	4e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg09184832	chr6:79620586	NA	-0.47	-10.26	-0.38	5.98e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02187348	chr16:89574699	SPG7	0.53	13.04	0.46	1.21e-34	Multiple myeloma (IgH translocation);
BRCA	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg16482183	chr6:26056742	HIST1H1C	0.41	8.78	0.33	1.49e-17	Iron status biomarkers;
BRCA	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg20701182	chr2:24300061	SF3B14	0.58	9.1	0.34	1.12e-18	Lymphocyte counts;
BRCA	cis	rs9296092	0.538	rs115770720	chr6:33517032	A/T	cg13560919	chr6:33536144	NA	-0.85	-18.39	-0.59	6.37e-61	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg11584989	chr19:19387371	SF4	0.34	8.94	0.33	4.28e-18	Tonsillectomy;
BRCA	cis	rs870825	0.746	rs1107908	chr4:185620113	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg25036284	chr2:26402008	FAM59B	0.95	16.08	0.54	4.12e-49	Gut microbiome composition (summer);
BRCA	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.6	12.56	0.45	1.65e-32	Personality dimensions;
BRCA	cis	rs4766646	0.619	rs4766637	chr12:110292155	A/C	cg01252219	chr12:110302105	GLTP	0.38	8.59	0.32	6.89e-17	Metabolite levels (MHPG);
BRCA	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg01420254	chr6:26195488	NA	0.55	8.52	0.32	1.1e-16	Gout;Renal underexcretion gout;
BRCA	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.71	0.39	1.01e-24	Cognitive ability;
BRCA	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-7.94	-0.3	9.04e-15	Ulcerative colitis;
BRCA	cis	rs4363385	0.818	rs2879487	chr1:152985360	C/A	cg24667326	chr1:152973720	SPRR3	-0.33	-9.25	-0.34	3.21e-19	Inflammatory skin disease;
BRCA	cis	rs735860	0.726	rs209490	chr6:53179047	C/T	cg10236188	chr6:53219634	NA	0.38	7.98	0.3	6.78e-15	Glaucoma;
BRCA	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg17063962	chr7:91808500	NA	0.53	12.45	0.44	5.32e-32	Breast cancer;
BRCA	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg03709012	chr19:19516395	GATAD2A	-0.75	-16.68	-0.55	3.8e-52	Tonsillectomy;
BRCA	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg00814883	chr7:100076585	TSC22D4	-0.51	-11.72	-0.42	7.39e-29	Platelet count;
BRCA	cis	rs4919087	0.923	rs12357266	chr10:98978045	G/A	cg25902810	chr10:99078978	FRAT1	0.41	8.59	0.32	6.62e-17	Monocyte count;
BRCA	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg23992470	chr4:843637	GAK	0.56	8.31	0.31	5.57e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg12935359	chr14:103987150	CKB	0.61	13.49	0.47	1.08e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg21747090	chr2:27597821	SNX17	-0.37	-8.08	-0.3	3.26e-15	Total body bone mineral density;
BRCA	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg21856205	chr7:94953877	PON1	-0.37	-8.17	-0.31	1.68e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.39	0.38	1.87e-23	Mean corpuscular volume;
BRCA	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.57	9.73	0.36	5.88e-21	Gut microbiome composition (summer);
BRCA	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg25486957	chr4:152246857	NA	-0.36	-7.9	-0.3	1.26e-14	Intelligence (multi-trait analysis);
BRCA	trans	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg21659725	chr3:3221576	CRBN	-0.34	-8.23	-0.31	1.07e-15	Menarche (age at onset);
BRCA	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.21	0.49	5.09e-40	Motion sickness;
BRCA	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg00012203	chr2:219082015	ARPC2	-0.47	-9.2	-0.34	4.93e-19	Colorectal cancer;
BRCA	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00166722	chr3:10149974	C3orf24	0.55	10.74	0.39	7.48e-25	Alzheimer's disease;
BRCA	trans	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg06521331	chr12:34319734	NA	-0.47	-8.55	-0.32	8.91e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg09877947	chr5:131593287	PDLIM4	0.42	9.88	0.36	1.55e-21	Acylcarnitine levels;
BRCA	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg26395211	chr5:140044315	WDR55	0.37	8.59	0.32	6.46e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg17507749	chr15:85114479	UBE2QP1	0.56	9.07	0.34	1.45e-18	Schizophrenia;
BRCA	cis	rs4363385	0.818	rs382653	chr1:153006761	G/A	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.08e-14	Inflammatory skin disease;
BRCA	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	13.55	0.47	6.2e-37	Mean platelet volume;
BRCA	trans	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg25206134	chr2:45395956	NA	0.53	8.97	0.33	3.15e-18	Bipolar disorder;
BRCA	cis	rs2019216	0.903	rs1817415	chr17:21893338	C/G	cg22648282	chr17:21454238	C17orf51	-0.35	-8.03	-0.3	4.85e-15	Pelvic organ prolapse;
BRCA	cis	rs11734570	0.581	rs79354477	chr4:38597448	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.53	9.92	0.37	1.11e-21	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03264133	chr6:25882463	NA	-0.76	-18.58	-0.59	6.39e-62	Uric acid levels;
BRCA	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg25427524	chr10:38739819	LOC399744	-0.55	-10.09	-0.37	2.52e-22	Obesity (extreme);
BRCA	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg26587870	chr6:27730563	NA	-0.54	-8.15	-0.31	1.9e-15	Depression;
BRCA	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.06	-18.86	-0.6	1.99e-63	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs113835537	0.597	rs3737525	chr11:66306355	A/G	cg24851651	chr11:66362959	CCS	0.53	9.23	0.34	3.81e-19	Airway imaging phenotypes;
BRCA	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg16482183	chr6:26056742	HIST1H1C	0.53	11.03	0.4	5.12e-26	Height;
BRCA	cis	rs1864400	0.696	rs2742239	chr10:43621712	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.53	-10.75	-0.39	6.99e-25	Hirschsprung disease;
BRCA	trans	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-16.17	-0.54	1.52e-49	Colorectal cancer;
BRCA	cis	rs864745	0.690	rs849140	chr7:28183702	T/C	cg22892036	chr7:28189139	JAZF1	0.48	10.61	0.39	2.56e-24	Crohn's disease;Type 2 diabetes;
BRCA	cis	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg07460842	chr6:66804631	NA	-0.95	-17.73	-0.57	1.73e-57	Exhaled nitric oxide output;
BRCA	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg17366294	chr4:99064904	C4orf37	-0.41	-9.7	-0.36	7.63e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-14.77	-0.5	1.12e-42	Bipolar disorder and schizophrenia;
BRCA	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-11.59	-0.42	2.62e-28	Platelet count;
BRCA	cis	rs3768617	0.811	rs10797828	chr1:183028430	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.72	0.36	6.38e-21	Fuchs's corneal dystrophy;
BRCA	cis	rs7523273	0.586	rs2796264	chr1:207919968	A/G	cg22525895	chr1:207977042	MIR29B2	0.47	12.1	0.43	1.74e-30	Schizophrenia;
BRCA	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.67	15.53	0.52	2.23e-46	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11764359	chr7:65958608	NA	0.77	17.35	0.57	1.46e-55	Aortic root size;
BRCA	trans	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	8.65	0.32	4e-17	Retinal vascular caliber;
BRCA	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg06640241	chr16:89574553	SPG7	0.87	22.48	0.66	6.59e-83	Multiple myeloma (IgH translocation);
BRCA	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25427524	chr10:38739819	LOC399744	0.68	16.57	0.55	1.48e-51	Extrinsic epigenetic age acceleration;
BRCA	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg25801113	chr15:45476975	SHF	-0.34	-8.33	-0.31	4.87e-16	Uric acid levels;
BRCA	cis	rs9341808	0.754	rs9294173	chr6:80991630	T/A	cg08355045	chr6:80787529	NA	0.35	9.11	0.34	1.03e-18	Sitting height ratio;
BRCA	cis	rs13046373	0.535	rs1395778	chr21:31985502	G/C	cg22337977	chr21:31811175	KRTAP15-1	0.34	8.01	0.3	5.5e-15	HDL cholesterol;
BRCA	cis	rs7586879	0.752	rs11683748	chr2:25130434	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.5	0.35	4.12e-20	Body mass index;
BRCA	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs2836633	0.895	rs61085980	chr21:40032140	C/T	cg05519781	chr21:40033154	ERG	0.37	8.0	0.3	5.68e-15	Coronary artery disease;
BRCA	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.42	0.35	8.21e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg22875332	chr1:76189707	ACADM	0.69	14.42	0.5	5.03e-41	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg08601574	chr20:25228251	PYGB	-0.35	-8.6	-0.32	6.2e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.74	16.09	0.54	3.59e-49	Cognitive ability;
BRCA	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.4	-7.91	-0.3	1.12e-14	Extrinsic epigenetic age acceleration;
BRCA	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-10.1	-0.37	2.41e-22	Schizophrenia;
BRCA	cis	rs7011049	1.000	rs11985687	chr8:53832602	G/A	cg26025543	chr8:53854495	NA	0.55	9.98	0.37	7e-22	Systolic blood pressure;
BRCA	cis	rs1784581	0.802	rs7768986	chr6:162427890	G/C	cg17173639	chr6:162384350	PARK2	0.39	9.15	0.34	7.26e-19	Itch intensity from mosquito bite;
BRCA	trans	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg25214090	chr10:38739885	LOC399744	0.52	11.58	0.42	2.83e-28	Corneal astigmatism;
BRCA	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg04691961	chr3:161091175	C3orf57	-0.42	-10.17	-0.37	1.23e-22	Morning vs. evening chronotype;
BRCA	trans	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg26043149	chr18:55253948	FECH	-0.37	-8.14	-0.31	2.06e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg12011299	chr4:100065546	ADH4	0.48	10.79	0.39	4.86e-25	Smoking initiation;
BRCA	cis	rs4077515	0.934	rs3829111	chr9:139269483	G/A	cg14019695	chr9:139328340	INPP5E	0.32	8.13	0.31	2.31e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg21775007	chr8:11205619	TDH	-0.42	-8.69	-0.33	2.94e-17	Triglycerides;
BRCA	cis	rs3916	0.911	rs12829722	chr12:121155622	C/T	cg21892295	chr12:121157589	UNC119B	-0.35	-8.45	-0.32	1.92e-16	Urinary metabolites (H-NMR features);
BRCA	cis	rs9811920	0.695	rs1287284	chr3:99516962	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.54	-12.87	-0.45	7.38e-34	Axial length;
BRCA	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.24	0.49	3.83e-40	Motion sickness;
BRCA	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg20476274	chr7:133979776	SLC35B4	0.7	21.43	0.65	3.4e-77	Mean platelet volume;
BRCA	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg24562669	chr7:97807699	LMTK2	0.45	12.04	0.43	3.16e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7572733	0.515	rs1518368	chr2:198839145	G/A	cg00792783	chr2:198669748	PLCL1	0.45	9.86	0.36	1.98e-21	Dermatomyositis;
BRCA	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg23711669	chr6:146136114	FBXO30	0.75	17.42	0.57	6.43e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.95	0.37	8.46e-22	Bipolar disorder;
BRCA	cis	rs858239	0.600	rs7456915	chr7:23143049	T/C	cg23682824	chr7:23144976	KLHL7	0.46	12.25	0.44	3.7e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg16322792	chr1:120165303	ZNF697	0.58	15.43	0.52	6.54e-46	Systemic lupus erythematosus;
BRCA	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.78	11.05	0.4	4.45e-26	Initial pursuit acceleration;
BRCA	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg20387954	chr3:183756860	HTR3D	0.37	8.6	0.32	5.95e-17	Anterior chamber depth;
BRCA	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg17691542	chr6:26056736	HIST1H1C	0.46	9.33	0.35	1.73e-19	Iron status biomarkers;
BRCA	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg17366294	chr4:99064904	C4orf37	0.41	9.64	0.36	1.28e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18876405	chr7:65276391	NA	0.56	13.33	0.47	6.11e-36	Aortic root size;
BRCA	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg08885076	chr2:99613938	TSGA10	0.46	10.82	0.39	3.68e-25	Chronic sinus infection;
BRCA	trans	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-8.6	-0.32	6.36e-17	Retinal vascular caliber;
BRCA	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg26384229	chr12:38710491	ALG10B	0.74	17.32	0.57	2.11e-55	Bladder cancer;
BRCA	cis	rs7809950	1.000	rs2894475	chr7:107262558	A/T	cg23024343	chr7:107201750	COG5	-0.35	-8.03	-0.3	4.74e-15	Coronary artery disease;
BRCA	trans	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	8.92e-15	Corneal astigmatism;
BRCA	cis	rs12431939	0.948	rs12436158	chr14:51669891	G/A	cg23942311	chr14:51606299	NA	-0.43	-8.02	-0.3	5.06e-15	Cancer;
BRCA	cis	rs12711979	0.729	rs6714956	chr2:3820454	T/C	cg17052675	chr2:3827356	NA	-0.48	-14.09	-0.49	1.93e-39	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg15112475	chr7:1198522	ZFAND2A	-0.58	-14.57	-0.5	9.62e-42	Longevity;Endometriosis;
BRCA	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg18105134	chr13:113819100	PROZ	-0.64	-14.55	-0.5	1.17e-41	Platelet distribution width;
BRCA	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18876405	chr7:65276391	NA	0.61	15.07	0.51	3.77e-44	Aortic root size;
BRCA	cis	rs1506403	0.685	rs1994497	chr7:142816927	A/G	cg21852589	chr7:142981689	TMEM139	0.4	7.89	0.3	1.28e-14	Cancer;
BRCA	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg14863265	chr7:2801509	GNA12	0.45	9.88	0.36	1.59e-21	Height;
BRCA	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg09307838	chr4:120376055	NA	0.76	17.1	0.56	2.9e-54	Corneal astigmatism;
BRCA	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.86	-0.48	2.11e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg16850897	chr7:100343110	ZAN	-0.57	-10.61	-0.39	2.54e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-8.71	-0.33	2.62e-17	Response to antipsychotic treatment;
BRCA	cis	rs9463078	0.764	rs9395051	chr6:44825715	C/A	cg25276700	chr6:44698697	NA	-0.36	-8.3	-0.31	6.41e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg04166393	chr7:2884313	GNA12	0.49	9.05	0.34	1.77e-18	Height;
BRCA	cis	rs10193935	0.901	rs10490552	chr2:42559947	C/T	cg27598129	chr2:42591480	NA	0.61	10.55	0.39	4.09e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg04989706	chr14:50066350	PPIL5	-0.5	-10.04	-0.37	3.96e-22	Carotid intima media thickness;
BRCA	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.58e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-16.72	-0.55	2.49e-52	Breast cancer;
BRCA	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.05	22.15	0.66	4.01e-81	Gut microbiome composition (summer);
BRCA	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg21573476	chr21:45109991	RRP1B	-0.36	-9.05	-0.34	1.76e-18	Mean corpuscular volume;
BRCA	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg05347473	chr6:146136440	FBXO30	0.4	7.94	0.3	9.04e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg18230493	chr5:56204884	C5orf35	-0.73	-14.18	-0.49	7.38e-40	Initial pursuit acceleration;
BRCA	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	17.69	0.57	2.6e-57	Alzheimer's disease;
BRCA	cis	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg06521331	chr12:34319734	NA	-0.62	-12.41	-0.44	8.14e-32	Morning vs. evening chronotype;
BRCA	cis	rs36051895	0.659	rs7045491	chr9:5045658	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-9.59	-0.35	1.9e-20	Pediatric autoimmune diseases;
BRCA	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg14092571	chr14:90743983	NA	-0.81	-21.02	-0.64	6.16e-75	Gut microbiota (bacterial taxa);
BRCA	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14019695	chr9:139328340	INPP5E	-0.4	-10.65	-0.39	1.69e-24	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg04989706	chr14:50066350	PPIL5	-0.47	-9.21	-0.34	4.76e-19	Carotid intima media thickness;
BRCA	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg18351406	chr4:77819688	ANKRD56	0.56	12.4	0.44	8.76e-32	Emphysema distribution in smoking;
BRCA	cis	rs6834538	1.000	rs6823117	chr4:113447354	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.41	9.15	0.34	7.29e-19	Free thyroxine concentration;
BRCA	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg22491629	chr6:157744540	C6orf35	-0.68	-12.22	-0.44	5.38e-31	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg06521331	chr12:34319734	NA	-0.62	-12.41	-0.44	8.14e-32	Morning vs. evening chronotype;
BRCA	cis	rs17401966	0.540	rs10864452	chr1:10395683	G/T	cg03954927	chr1:10346856	KIF1B	0.34	10.41	0.38	1.54e-23	Hepatocellular carcinoma;
BRCA	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg27433088	chr4:174089019	GALNT7	0.34	9.24	0.34	3.48e-19	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg10818794	chr15:86012489	AKAP13	-0.4	-10.79	-0.39	4.89e-25	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg08355456	chr11:67383691	NA	0.4	8.42	0.32	2.4e-16	Mean corpuscular volume;
BRCA	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg00012203	chr2:219082015	ARPC2	-0.49	-9.47	-0.35	5.19e-20	Colorectal cancer;
BRCA	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg08917208	chr2:24149416	ATAD2B	0.53	8.25	0.31	8.81e-16	Asthma;
BRCA	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-10.61	-0.39	2.57e-24	Gut microbiome composition (summer);
BRCA	cis	rs2290402	0.536	rs17165130	chr4:875339	A/C	cg08937613	chr4:881914	GAK	0.49	8.05	0.3	4.2e-15	Type 2 diabetes;
BRCA	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.96	-0.46	2.97e-34	Migraine;Coronary artery disease;
BRCA	cis	rs7264396	0.790	rs761825	chr20:34194054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-13.72	-0.48	1.03e-37	Total cholesterol levels;
BRCA	cis	rs3762637	1.000	rs11932	chr3:122141135	A/G	cg24169773	chr3:122142474	KPNA1	0.43	8.21	0.31	1.18e-15	LDL cholesterol levels;
BRCA	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg00631329	chr6:26305371	NA	-0.44	-13.13	-0.46	5.16e-35	Educational attainment;
BRCA	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg22920501	chr2:26401640	FAM59B	-0.89	-16.19	-0.54	1.2e-49	Gut microbiome composition (summer);
BRCA	cis	rs3772130	0.962	rs9812228	chr3:121495682	C/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.68	0.39	1.31e-24	Cognitive performance;
BRCA	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg00409905	chr10:38381863	ZNF37A	0.45	9.36	0.35	1.3e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-12.9	-0.45	5.31e-34	Response to antipsychotic treatment;
BRCA	cis	rs701145	0.585	rs6769099	chr3:153852442	T/C	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.22e-14	Coronary artery disease;
BRCA	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.31	-0.35	2.06e-19	Alzheimer's disease (late onset);
BRCA	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00149659	chr3:10157352	C3orf10	0.72	12.57	0.45	1.49e-32	Alzheimer's disease;
BRCA	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.73	0.42	6.45e-29	Tonsillectomy;
BRCA	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg27129171	chr3:47204927	SETD2	0.72	17.71	0.57	2.19e-57	Colorectal cancer;
BRCA	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg12564285	chr5:131593104	PDLIM4	0.37	9.95	0.37	8.59e-22	Breast cancer;
BRCA	cis	rs6745190	0.575	rs35049898	chr2:181982277	C/T	cg00481216	chr2:181971175	NA	0.4	9.38	0.35	1.09e-19	White blood cell count;
BRCA	cis	rs1163251	0.837	rs517533	chr1:120229170	T/G	cg19096424	chr1:120255104	PHGDH	0.45	10.28	0.38	4.69e-23	Blood metabolite levels;
BRCA	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-12.22	-0.44	4.98e-31	Personality dimensions;
BRCA	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg01191920	chr7:158217561	PTPRN2	-0.46	-11.01	-0.4	6.11e-26	Obesity-related traits;
BRCA	cis	rs3857536	0.642	rs7755840	chr6:66891913	A/G	cg07460842	chr6:66804631	NA	-0.46	-8.86	-0.33	8.14e-18	Blood trace element (Cu levels);
BRCA	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.57	0.39	3.43e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-11.06	-0.4	3.82e-26	Lymphocyte counts;
BRCA	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg18512352	chr11:47633146	NA	-0.34	-8.24	-0.31	9.79e-16	Subjective well-being;
BRCA	cis	rs4588572	0.601	rs10942855	chr5:77737529	G/A	cg11547950	chr5:77652471	NA	-0.45	-8.07	-0.3	3.57e-15	Triglycerides;
BRCA	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg24110177	chr3:50126178	RBM5	-0.5	-14.25	-0.49	3.44e-40	Body mass index;
BRCA	cis	rs6429082	0.689	rs10802803	chr1:235709610	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.54	-12.59	-0.45	1.31e-32	Adiposity;
BRCA	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg24642439	chr20:33292090	TP53INP2	0.59	10.26	0.38	5.53e-23	Protein C levels;
BRCA	cis	rs10267417	0.603	rs2892957	chr7:19952910	T/A	cg05791153	chr7:19748676	TWISTNB	0.42	7.9	0.3	1.2e-14	Night sleep phenotypes;
BRCA	trans	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg25214090	chr10:38739885	LOC399744	0.54	12.59	0.45	1.29e-32	Corneal astigmatism;
BRCA	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg10556349	chr10:835070	NA	0.73	9.85	0.36	2.01e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg01689657	chr7:91764605	CYP51A1	0.23	8.3	0.31	6.06e-16	Breast cancer;
BRCA	trans	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg13565492	chr6:43139072	SRF	-0.87	-15.93	-0.53	2.33e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10733682	0.524	rs10987419	chr9:129462594	T/C	cg00232160	chr9:129468157	NA	0.35	8.02	0.3	5.09e-15	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21659725	chr3:3221576	CRBN	0.48	12.2	0.43	6.63e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg22920501	chr2:26401640	FAM59B	0.9	16.44	0.55	6.44e-51	Gut microbiome composition (summer);
BRCA	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg22713356	chr15:30763199	NA	1.31	26.42	0.72	1.54e-104	Uric acid levels;
BRCA	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg04166393	chr7:2884313	GNA12	0.41	8.7	0.33	2.74e-17	Height;
BRCA	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg09307838	chr4:120376055	NA	0.73	15.87	0.53	4.5e-48	Corneal astigmatism;
BRCA	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg22153745	chr1:153894579	GATAD2B	-0.49	-9.7	-0.36	7.72e-21	Total cholesterol levels;
BRCA	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	17.21	0.56	8.31e-55	Colorectal cancer;
BRCA	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg08975724	chr8:8085496	FLJ10661	0.5	10.64	0.39	1.9e-24	Mood instability;
BRCA	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg15395560	chr15:45543142	SLC28A2	0.29	8.08	0.3	3.2e-15	Uric acid levels;
BRCA	cis	rs11971779	0.590	rs4732374	chr7:139091453	G/C	cg07862535	chr7:139043722	LUC7L2	0.38	10.36	0.38	2.36e-23	Diisocyanate-induced asthma;
BRCA	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg22491629	chr6:157744540	C6orf35	-0.6	-11.7	-0.42	8.34e-29	Hemostatic factors and hematological phenotypes;
BRCA	trans	rs8073060	0.586	rs7208672	chr17:33989759	G/A	cg19694781	chr19:47549865	TMEM160	-1.04	-21.1	-0.64	2.24e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-12.7	-0.45	3.91e-33	Platelet count;
BRCA	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg23895963	chr12:117471115	NA	0.51	9.18	0.34	6.12e-19	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	17.71	0.57	2.06e-57	Alzheimer's disease;
BRCA	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg23711669	chr6:146136114	FBXO30	-0.76	-17.44	-0.57	5.18e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7607369	0.574	rs12990478	chr2:219667463	T/A	cg02176678	chr2:219576539	TTLL4	-0.38	-10.17	-0.37	1.3e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs2880765	0.835	rs7161880	chr15:86018746	C/T	cg10818794	chr15:86012489	AKAP13	-0.31	-8.63	-0.32	4.91e-17	Coronary artery disease;
BRCA	cis	rs6684514	1.000	rs12038481	chr1:156284815	T/C	cg16558208	chr1:156270281	VHLL	0.36	8.47	0.32	1.73e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.72	0.36	6.47e-21	Bladder cancer;
BRCA	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18876405	chr7:65276391	NA	0.51	11.49	0.41	6.32e-28	Aortic root size;
BRCA	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg25174290	chr11:3078921	CARS	0.44	12.99	0.46	2.06e-34	Longevity;
BRCA	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg08000102	chr2:233561755	GIGYF2	-0.63	-14.74	-0.5	1.61e-42	Coronary artery disease;
BRCA	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg04691961	chr3:161091175	C3orf57	-0.41	-10.17	-0.37	1.33e-22	Morning vs. evening chronotype;
BRCA	cis	rs72772090	0.710	rs11750400	chr5:96077968	A/T	cg24982541	chr5:96078678	CAST	-0.46	-8.03	-0.3	4.58e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.33	-0.44	1.69e-31	Chronic sinus infection;
BRCA	cis	rs1891275	0.515	rs4244930	chr10:93466849	T/C	cg07889827	chr10:93443413	NA	-0.4	-10.95	-0.4	1.12e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg23791538	chr6:167370224	RNASET2	-0.46	-11.48	-0.41	7.26e-28	Crohn's disease;
BRCA	cis	rs495337	0.736	rs568124	chr20:48484125	C/T	cg17835207	chr20:48524531	SPATA2	-0.5	-10.58	-0.39	3.21e-24	Psoriasis;
BRCA	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11890956	chr21:40555474	PSMG1	1.06	31.2	0.78	1.58e-130	Cognitive function;
BRCA	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg12311346	chr5:56204834	C5orf35	-0.46	-9.23	-0.34	4.04e-19	Coronary artery disease;
BRCA	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg14458575	chr2:238380390	NA	0.5	11.48	0.41	7.3e-28	Prostate cancer;
BRCA	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg20503657	chr10:835505	NA	1.3	21.68	0.65	1.61e-78	Eosinophil percentage of granulocytes;
BRCA	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg23711669	chr6:146136114	FBXO30	0.64	15.08	0.51	3.35e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9462027	0.606	rs7341253	chr6:34726838	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.96	-0.3	7.76e-15	Systemic lupus erythematosus;
BRCA	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	10.25	0.38	6.32e-23	Height;
BRCA	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.07	-0.56	4.02e-54	Intelligence (multi-trait analysis);
BRCA	trans	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg26043149	chr18:55253948	FECH	0.42	9.08	0.34	1.33e-18	Bone mineral density;
BRCA	cis	rs13161895	1.000	rs4700853	chr5:179473328	G/A	cg02702477	chr5:179499311	RNF130	0.46	8.53	0.32	1.03e-16	LDL cholesterol;
BRCA	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg26384229	chr12:38710491	ALG10B	0.5	12.61	0.45	1.05e-32	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.3e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17092148	0.895	rs4417778	chr20:33350987	T/C	cg16810054	chr20:33298113	TP53INP2	-0.49	-11.19	-0.4	1.19e-26	Neuroticism;
BRCA	cis	rs13190036	1.000	rs3733875	chr5:176637240	G/T	cg06733329	chr5:176740039	MXD3	0.46	8.33	0.31	5.04e-16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs6032067	0.673	rs991048	chr20:43898227	C/T	cg06407657	chr20:43937138	MATN4;RBPJL	-0.3	-8.28	-0.31	7.18e-16	Blood protein levels;
BRCA	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg22974920	chr21:40686053	BRWD1	-0.39	-8.73	-0.33	2.15e-17	Cognitive function;
BRCA	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06022373	chr22:39101656	GTPBP1	0.74	18.2	0.58	5.93e-60	Menopause (age at onset);
BRCA	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg05863683	chr7:1912471	MAD1L1	0.42	8.94	0.33	4.25e-18	Schizophrenia;
BRCA	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg18016565	chr1:150552671	MCL1	-0.45	-10.16	-0.37	1.39e-22	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.63	0.55	7.2e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg17143192	chr8:8559678	CLDN23	-0.54	-10.32	-0.38	3.41e-23	Obesity-related traits;
BRCA	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg17691542	chr6:26056736	HIST1H1C	0.75	14.56	0.5	1.06e-41	Iron status biomarkers;
BRCA	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg18806716	chr10:30721971	MAP3K8	0.48	11.48	0.41	7.15e-28	Inflammatory bowel disease;
BRCA	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg27624424	chr6:160112604	SOD2	0.41	8.79	0.33	1.35e-17	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs3771570	0.901	rs55764424	chr2:242407467	C/T	cg21155796	chr2:242212141	HDLBP	0.55	9.29	0.34	2.4e-19	Prostate cancer;
BRCA	cis	rs4268898	0.552	rs11125444	chr2:24367205	G/T	cg26838691	chr2:24397539	C2orf84	0.39	7.96	0.3	8.05e-15	Asthma;
BRCA	cis	rs3087591	0.922	rs2953013	chr17:29496343	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.42	-8.27	-0.31	7.97e-16	Hip circumference;
BRCA	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12826209	chr6:26865740	GUSBL1	0.58	10.3	0.38	3.9699999999999997e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg26384229	chr12:38710491	ALG10B	0.69	16.21	0.54	9.67e-50	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	18.23	0.58	4.19e-60	Platelet count;
BRCA	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.24	-0.31	9.68e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-18.93	-0.6	8.44e-64	Chronic sinus infection;
BRCA	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.77	-0.42	4.23e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.45	10.65	0.39	1.66e-24	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg06885757	chr1:42089581	HIVEP3	0.31	11.08	0.4	3.24e-26	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs6750047	0.638	rs336031	chr2:38265130	C/A	cg07380506	chr2:38303506	CYP1B1	-0.44	-9.54	-0.35	3.02e-20	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-8.9	-0.33	5.71e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.19	-0.43	6.98e-31	Alzheimer's disease;
BRCA	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg08888203	chr3:10149979	C3orf24	-0.69	-14.67	-0.5	3.13e-42	Alzheimer's disease;
BRCA	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03264133	chr6:25882463	NA	-0.52	-10.92	-0.4	1.44e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg01528321	chr10:82214614	TSPAN14	0.78	16.58	0.55	1.23e-51	Post bronchodilator FEV1;
BRCA	trans	rs7786808	0.552	rs4909205	chr7:158185283	G/A	cg02030672	chr11:45687055	CHST1	0.46	9.78	0.36	3.82e-21	Obesity-related traits;
BRCA	trans	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg06521331	chr12:34319734	NA	-0.46	-8.45	-0.32	1.9e-16	Bladder cancer;
BRCA	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg24675658	chr1:53192096	ZYG11B	0.55	12.64	0.45	7.42e-33	Monocyte count;
BRCA	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg05347473	chr6:146136440	FBXO30	-0.43	-8.67	-0.32	3.5e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg05729581	chr11:3078854	CARS	-0.37	-9.15	-0.34	7.77e-19	Longevity;
BRCA	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg21475434	chr5:93447410	FAM172A	0.66	8.66	0.32	3.97e-17	Diabetic retinopathy;
BRCA	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg19318889	chr4:1322082	MAEA	0.54	11.25	0.41	6.56e-27	Longevity;
BRCA	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24110177	chr3:50126178	RBM5	0.37	9.93	0.37	1.07e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	0.649	rs2024432	chr2:10731474	C/T	cg00105475	chr2:10696890	NA	0.41	9.18	0.34	5.88e-19	Prostate cancer;
BRCA	trans	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg17063962	chr7:91808500	NA	0.54	12.82	0.45	1.26e-33	Breast cancer;
BRCA	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg24450063	chr1:156163899	SLC25A44	0.95	18.31	0.59	1.66e-60	Testicular germ cell tumor;
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg26608667	chr7:1196370	ZFAND2A	-0.39	-8.79	-0.33	1.43e-17	Longevity;Endometriosis;
BRCA	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.07	0.34	1.47e-18	Tonsillectomy;
BRCA	cis	rs838147	0.815	rs28400015	chr19:49250633	G/A	cg13540341	chr19:49222985	MAMSTR	0.32	8.38	0.31	3.35e-16	Dietary macronutrient intake;
BRCA	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.37	0.57	1.26e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg05283184	chr6:79620031	NA	-0.43	-10.88	-0.4	2.01e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs698833	0.548	rs1372079	chr2:44543317	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	8.13	0.31	2.2e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.01	-0.46	1.66e-34	Migraine;Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg13319975	chr6:146136371	FBXO30	0.43	9.8	0.36	3.22e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.2	0.34	5.09e-19	Tonsillectomy;
BRCA	trans	rs1941687	0.505	rs9956918	chr18:31315878	C/G	cg27147174	chr7:100797783	AP1S1	0.38	7.9	0.3	1.26e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg14835575	chr10:16859367	RSU1	0.62	12.96	0.46	2.76e-34	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs870825	0.616	rs28579226	chr4:185650458	A/C	cg04058563	chr4:185651563	MLF1IP	0.79	17.79	0.58	7.74e-58	Blood protein levels;
BRCA	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.54	10.95	0.4	1.05e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs912057	0.965	rs1294409	chr6:6738355	A/G	cg06612196	chr6:6737390	NA	-0.46	-10.16	-0.37	1.43e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs7903847	0.620	rs9787454	chr10:99155561	A/T	cg08345082	chr10:99160200	RRP12	-0.3	-8.72	-0.33	2.41e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	11.29	0.41	4.34e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.37	-0.31	3.5e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2832191	0.545	rs2251381	chr21:30530692	T/G	cg24692254	chr21:30365293	RNF160	0.45	10.48	0.38	7.87e-24	Dental caries;
BRCA	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.74	-0.39	7.43e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs72928364	1.000	rs41273557	chr3:100621683	T/A	cg10123952	chr3:100791384	NA	0.54	8.07	0.3	3.62e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7809950	1.000	rs10243340	chr7:107090955	A/G	cg23024343	chr7:107201750	COG5	-0.4	-9.3	-0.35	2.23e-19	Coronary artery disease;
BRCA	cis	rs6087990	0.735	rs6058892	chr20:31388461	C/T	cg13636640	chr20:31349939	DNMT3B	0.6	16.51	0.55	3.06e-51	Ulcerative colitis;
BRCA	cis	rs6066835	1.000	rs6066833	chr20:47354494	G/C	cg18078177	chr20:47281410	PREX1	0.69	8.6	0.32	6.2e-17	Multiple myeloma;
BRCA	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg25110126	chr1:46999211	NA	0.49	9.46	0.35	6.02e-20	Monobrow;
BRCA	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	20.01	0.62	1.58e-69	Platelet count;
BRCA	trans	rs1493916	0.777	rs1493910	chr18:31318376	A/G	cg27147174	chr7:100797783	AP1S1	-0.41	-8.04	-0.3	4.47e-15	Life satisfaction;
BRCA	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-12.84	-0.45	9.7e-34	Alzheimer's disease;
BRCA	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg08885076	chr2:99613938	TSGA10	-0.58	-12.89	-0.45	6.11e-34	Chronic sinus infection;
BRCA	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg23711669	chr6:146136114	FBXO30	-0.72	-17.12	-0.56	2.39e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-10.0	-0.37	5.62e-22	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg17470723	chr8:74884337	TCEB1	0.4	8.64	0.32	4.37e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg01191920	chr7:158217561	PTPRN2	-0.46	-11.01	-0.4	6.11e-26	Obesity-related traits;
BRCA	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	9.05	0.34	1.65e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs16958440	1.000	rs60228288	chr18:44640412	G/A	cg17192377	chr18:44677553	HDHD2	0.67	9.8	0.36	3.33e-21	Sitting height ratio;
BRCA	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg14061069	chr19:46274453	DMPK	-0.48	-12.08	-0.43	2.05e-30	Coronary artery disease;
BRCA	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.39	0.35	1.06e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg15556689	chr8:8085844	FLJ10661	-0.39	-9.35	-0.35	1.5e-19	Retinal vascular caliber;
BRCA	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00166722	chr3:10149974	C3orf24	0.66	13.26	0.46	1.33e-35	Alzheimer's disease;
BRCA	trans	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg21775007	chr8:11205619	TDH	0.45	9.23	0.34	3.93e-19	Mood instability;
BRCA	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg03433033	chr1:76189801	ACADM	-0.4	-8.46	-0.32	1.79e-16	Daytime sleep phenotypes;
BRCA	trans	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg01620082	chr3:125678407	NA	-0.92	-10.32	-0.38	3.23e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg16482183	chr6:26056742	HIST1H1C	0.47	9.01	0.34	2.39e-18	Iron status biomarkers;
BRCA	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.52	0.32	1.17e-16	Rheumatoid arthritis;
BRCA	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg14196790	chr5:131705035	SLC22A5	0.33	8.56	0.32	8.38e-17	Breast cancer;
BRCA	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg00631329	chr6:26305371	NA	-0.42	-12.52	-0.44	2.45e-32	Educational attainment;
BRCA	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.92	0.33	4.82e-18	Iron status biomarkers;
BRCA	trans	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04565464	chr8:145669602	NFKBIL2	0.35	8.47	0.32	1.74e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg22963979	chr7:1858916	MAD1L1	-0.4	-8.29	-0.31	6.76e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg16325326	chr1:53192061	ZYG11B	0.7	17.53	0.57	1.73e-56	Monocyte count;
BRCA	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg03605463	chr16:89740564	NA	0.57	9.63	0.36	1.35e-20	Vitiligo;
BRCA	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg20283391	chr11:68216788	NA	-0.46	-9.29	-0.34	2.45e-19	Total body bone mineral density;
BRCA	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg25204440	chr1:209979598	IRF6	0.42	8.39	0.31	3.21e-16	Cleft lip with or without cleft palate;
BRCA	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg27446573	chr6:127587934	RNF146	0.89	20.34	0.63	2.69e-71	Breast cancer;
BRCA	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg22920501	chr2:26401640	FAM59B	-0.81	-13.22	-0.46	1.9e-35	Gut microbiome composition (summer);
BRCA	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	5.1e-16	Tonsillectomy;
BRCA	cis	rs9341808	0.718	rs9343978	chr6:80971978	A/G	cg08355045	chr6:80787529	NA	0.37	9.56	0.35	2.56e-20	Sitting height ratio;
BRCA	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18404041	chr3:52824283	ITIH1	-0.39	-11.99	-0.43	5.22e-30	Bipolar disorder;
BRCA	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg01689657	chr7:91764605	CYP51A1	0.26	9.23	0.34	4.06e-19	Breast cancer;
BRCA	cis	rs3820928	1.000	rs10210763	chr2:227776029	G/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.42	-0.32	2.53e-16	Pulmonary function;
BRCA	cis	rs11229555	0.645	rs11229459	chr11:58208025	G/A	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs151349	1.000	rs151345	chr20:57586849	G/C	cg23907860	chr20:57583709	CTSZ	-0.44	-10.78	-0.39	5.17e-25	Platelet distribution width;
BRCA	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg25358565	chr5:93447407	FAM172A	1.21	18.49	0.59	1.84e-61	Diabetic retinopathy;
BRCA	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg27588902	chr6:42928151	GNMT	-0.31	-10.17	-0.37	1.28e-22	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg16405210	chr4:1374714	KIAA1530	-0.91	-22.75	-0.67	2.13e-84	Longevity;
BRCA	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg00701064	chr4:6280414	WFS1	0.68	18.54	0.59	1e-61	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs6484504	0.576	rs16922084	chr11:31371109	C/T	cg14844989	chr11:31128820	NA	0.46	9.59	0.35	1.88e-20	Red blood cell count;
BRCA	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg07080220	chr10:102295463	HIF1AN	-0.58	-13.0	-0.46	1.92e-34	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg00531865	chr16:30841666	NA	-0.44	-10.27	-0.38	5.14e-23	Multiple myeloma;
BRCA	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg26398791	chr1:38455867	SF3A3	-0.5	-11.93	-0.43	9.41e-30	Coronary artery disease;
BRCA	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	27.91	0.74	1.14e-112	Chronic sinus infection;
BRCA	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg12927641	chr6:109611667	NA	0.42	10.88	0.4	2.05e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg00147160	chr1:26503991	CNKSR1	0.3	9.8	0.36	3.21e-21	Height;
BRCA	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg18154014	chr19:37997991	ZNF793	0.61	11.38	0.41	1.85e-27	Coronary artery calcification;
BRCA	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg04944784	chr2:26401820	FAM59B	-0.87	-13.54	-0.47	6.71e-37	Gut microbiome composition (summer);
BRCA	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg03161606	chr19:29218774	NA	0.46	8.28	0.31	7.41e-16	Methadone dose in opioid dependence;
BRCA	cis	rs6540556	0.769	rs2272867	chr1:209929579	C/A	cg05527609	chr1:210001259	C1orf107	-0.44	-8.24	-0.31	9.62e-16	Red blood cell count;
BRCA	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.37	-0.38	2.18e-23	Psoriasis;
BRCA	cis	rs7149337	0.805	rs2999357	chr14:51606001	C/G	cg23942311	chr14:51606299	NA	0.45	13.35	0.47	4.76e-36	Cancer;
BRCA	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.71	-0.36	7.2e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs13136331	0.642	rs2869681	chr4:88620187	A/G	cg22416721	chr4:88570574	DMP1	-0.47	-11.44	-0.41	1.02e-27	Sitting height ratio;
BRCA	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg00012203	chr2:219082015	ARPC2	-0.57	-12.01	-0.43	4.3e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7246657	0.653	rs4805207	chr19:37673733	G/A	cg23950597	chr19:37808831	NA	-0.66	-10.28	-0.38	4.82e-23	Coronary artery calcification;
BRCA	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.43	-0.32	2.22e-16	Colorectal cancer;
BRCA	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	10.41	0.38	1.48e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08045932	chr20:61659980	NA	0.49	11.29	0.41	4.65e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg21017887	chr14:105400489	NA	0.65	17.45	0.57	4.43e-56	Rheumatoid arthritis;
BRCA	cis	rs7560272	0.501	rs6755500	chr2:73942233	C/T	cg20560298	chr2:73613845	ALMS1	0.35	8.93	0.33	4.32e-18	Schizophrenia;
BRCA	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	4.01e-15	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.01	-22.16	-0.66	3.76e-81	Gut microbiome composition (summer);
BRCA	cis	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.39	8.81	0.33	1.16e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg20887711	chr4:1340912	KIAA1530	0.42	10.16	0.37	1.4e-22	Longevity;
BRCA	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.74	-11.91	-0.43	1.11e-29	Red cell distribution width;
BRCA	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg25427524	chr10:38739819	LOC399744	-0.59	-10.18	-0.37	1.21e-22	Obesity (extreme);
BRCA	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.29	0.44	2.59e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg08822215	chr16:89438651	ANKRD11	-0.4	-8.32	-0.31	5.39e-16	Multiple myeloma (IgH translocation);
BRCA	cis	rs708547	0.578	rs781665	chr4:57831461	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-8.16	-0.31	1.73e-15	Response to bleomycin (chromatid breaks);
BRCA	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg07884673	chr3:53033167	SFMBT1	0.85	9.61	0.36	1.7e-20	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg24812749	chr6:127587940	RNF146	0.86	19.78	0.62	2.55e-68	Breast cancer;
BRCA	trans	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg26384229	chr12:38710491	ALG10B	0.52	10.93	0.4	1.33e-25	Resting heart rate;
BRCA	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg21918786	chr6:109611834	NA	-0.44	-11.83	-0.42	2.47e-29	Reticulocyte fraction of red cells;
BRCA	trans	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-8.14	-0.31	2.03e-15	Menarche (age at onset);
BRCA	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02475777	chr4:1388615	CRIPAK	0.67	12.68	0.45	5.08e-33	Longevity;
BRCA	cis	rs4285028	0.848	rs77630152	chr3:121681194	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.58	-10.72	-0.39	8.65e-25	Multiple sclerosis;
BRCA	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg13010199	chr12:38710504	ALG10B	0.43	9.22	0.34	4.33e-19	Morning vs. evening chronotype;
BRCA	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-13.14	-0.46	4.35e-35	Lymphocyte counts;
BRCA	cis	rs26949	0.511	rs11740327	chr5:59899413	G/A	cg02684056	chr5:59996105	DEPDC1B	0.39	9.47	0.35	5.42e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg22907277	chr7:1156413	C7orf50	0.58	8.91	0.33	5.37e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg11843238	chr5:131593191	PDLIM4	0.41	10.35	0.38	2.63e-23	Acylcarnitine levels;
BRCA	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.42	-10.79	-0.39	4.75e-25	Schizophrenia;
BRCA	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg10876282	chr6:28092338	ZSCAN16	0.4	7.89	0.3	1.29e-14	Parkinson's disease;
BRCA	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.96	-0.33	3.64e-18	Breast cancer;
BRCA	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00166722	chr3:10149974	C3orf24	0.58	10.03	0.37	4.48e-22	Alzheimer's disease;
BRCA	cis	rs1003719	0.553	rs1063948	chr21:38574674	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.73	-0.5	1.77e-42	Eye color traits;
BRCA	cis	rs17401966	0.838	rs11579365	chr1:10470846	G/T	cg03954927	chr1:10346856	KIF1B	0.43	13.08	0.46	8.43e-35	Hepatocellular carcinoma;
BRCA	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg14863265	chr7:2801509	GNA12	-0.43	-9.25	-0.34	3.26e-19	Height;
BRCA	cis	rs2425143	1.000	rs55761608	chr20:34344226	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.02	-0.34	2.18e-18	Blood protein levels;
BRCA	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg17971929	chr21:40555470	PSMG1	-0.62	-14.23	-0.49	4.23e-40	Cognitive function;
BRCA	cis	rs2012796	0.913	rs8010181	chr14:81820125	T/C	cg02996355	chr14:81879375	NA	0.43	8.61	0.32	5.54e-17	Night sleep phenotypes;
BRCA	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg00254258	chr1:3105189	PRDM16	-0.47	-11.11	-0.4	2.51e-26	Migraine;
BRCA	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-13.37	-0.47	3.85e-36	Morning vs. evening chronotype;
BRCA	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19626725	chr5:178986131	RUFY1	-0.34	-10.66	-0.39	1.61e-24	Lung cancer;
BRCA	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg23625390	chr15:77176239	SCAPER	-0.54	-13.38	-0.47	3.53e-36	Blood metabolite levels;
BRCA	cis	rs631288	0.557	rs2354434	chr1:146679428	A/G	cg25205988	chr1:146714368	CHD1L	0.82	8.01	0.3	5.33e-15	PR interval in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg03433033	chr1:76189801	ACADM	-0.88	-28.26	-0.75	1.36e-114	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg26043149	chr18:55253948	FECH	-0.38	-8.4	-0.32	2.97e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg21775007	chr8:11205619	TDH	0.63	14.5	0.5	2.03e-41	Retinal vascular caliber;
BRCA	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg23033748	chr14:75592666	NEK9	-0.34	-7.98	-0.3	6.93e-15	Height;
BRCA	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-8.76	-0.33	1.77e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg21535247	chr6:8435926	SLC35B3	0.42	9.52	0.35	3.41e-20	Motion sickness;
BRCA	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg26384229	chr12:38710491	ALG10B	0.48	12.36	0.44	1.28e-31	Morning vs. evening chronotype;
BRCA	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg22455342	chr2:225449267	CUL3	0.34	8.29	0.31	6.67e-16	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.6	-0.39	2.7e-24	Bipolar disorder;
BRCA	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.09	0.46	7.12e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg07395648	chr5:131743802	NA	-0.38	-8.3	-0.31	6.16e-16	Breast cancer;
BRCA	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03517284	chr6:25882590	NA	-0.5	-11.34	-0.41	2.87e-27	Blood metabolite levels;
BRCA	cis	rs220324	0.688	rs715744	chr21:43565503	G/C	cg09727148	chr21:43560719	UMODL1	0.44	7.87	0.3	1.5e-14	Idiopathic osteonecrosis of the femoral head;
BRCA	trans	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-15.92	-0.53	2.61e-48	Obesity-related traits;
BRCA	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg08000102	chr2:233561755	GIGYF2	0.63	13.95	0.48	8.3e-39	Coronary artery disease;
BRCA	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg05340658	chr4:99064831	C4orf37	0.61	14.56	0.5	1.14e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg18806716	chr10:30721971	MAP3K8	0.41	9.96	0.37	8.35e-22	Inflammatory bowel disease;
BRCA	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02176678	chr2:219576539	TTLL4	-0.5	-12.73	-0.45	3.13e-33	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs3087591	0.920	rs11080150	chr17:29629326	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.45	-8.98	-0.33	2.97e-18	Hip circumference;
BRCA	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg00684032	chr4:1343700	KIAA1530	0.31	7.98	0.3	6.79e-15	Obesity-related traits;
BRCA	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg23533926	chr12:111358616	MYL2	-0.44	-9.29	-0.34	2.36e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6558530	0.965	rs6558529	chr8:1706206	C/T	cg19131313	chr8:1704013	NA	-0.35	-7.86	-0.3	1.69e-14	Systolic blood pressure;
BRCA	cis	rs4285028	0.948	rs76593525	chr3:121690477	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.88	-0.4	2.15e-25	Multiple sclerosis;
BRCA	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9487051	0.703	rs351755	chr6:109538073	G/A	cg01475377	chr6:109611718	NA	0.45	11.23	0.41	7.99e-27	Reticulocyte fraction of red cells;
BRCA	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.35	0.49	1.11e-40	Motion sickness;
BRCA	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg26384229	chr12:38710491	ALG10B	0.72	16.78	0.55	1.2e-52	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4730250	0.708	rs4730242	chr7:107057373	G/C	cg02696742	chr7:106810147	HBP1	-0.54	-8.13	-0.31	2.17e-15	Osteoarthritis;
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg18402987	chr7:1209562	NA	-0.49	-9.4	-0.35	9.79e-20	Longevity;Endometriosis;
BRCA	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.74	16.2	0.54	1.04e-49	Cognitive ability;
BRCA	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg10223061	chr2:219282414	VIL1	0.3	8.55	0.32	9.43e-17	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6484504	0.652	rs578666	chr11:31404484	C/T	cg26647111	chr11:31128758	NA	0.45	9.73	0.36	6e-21	Red blood cell count;
BRCA	cis	rs17818399	0.620	rs1080871	chr2:46854708	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	8.0	0.3	5.75e-15	Height;
BRCA	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.58	-11.48	-0.41	7.39e-28	Lymphocyte counts;
BRCA	cis	rs490234	0.966	rs509753	chr9:128303518	G/A	cg14078157	chr9:128172775	NA	0.33	7.89	0.3	1.3e-14	Mean arterial pressure;
BRCA	trans	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg25214090	chr10:38739885	LOC399744	0.55	12.24	0.44	4.27e-31	Corneal astigmatism;
BRCA	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg20283391	chr11:68216788	NA	-0.45	-9.32	-0.35	1.81e-19	Total body bone mineral density;
BRCA	cis	rs9309473	0.687	rs11693531	chr2:73608614	C/G	cg20560298	chr2:73613845	ALMS1	-0.52	-14.21	-0.49	5.14e-40	Metabolite levels;
BRCA	cis	rs586533	0.846	rs593538	chr11:99498435	G/A	cg22878054	chr11:99397252	CNTN5	0.32	8.06	0.3	3.7e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs897984	0.520	rs4889536	chr16:30871755	G/T	cg02466173	chr16:30829666	NA	0.46	9.31	0.35	1.99e-19	Dementia with Lewy bodies;
BRCA	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg21573476	chr21:45109991	RRP1B	-0.49	-12.68	-0.45	5.06e-33	Mean corpuscular volume;
BRCA	cis	rs7760949	0.889	rs9396264	chr6:13930342	T/A	cg27413430	chr6:13925136	RNF182	0.46	9.3	0.35	2.2e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7577696	0.597	rs7556942	chr2:32295694	G/A	cg02381751	chr2:32503542	YIPF4	-0.42	-8.01	-0.3	5.47e-15	Inflammatory biomarkers;
BRCA	cis	rs1997103	0.863	rs4480062	chr7:55401299	T/C	cg17469321	chr7:55412551	NA	0.51	9.72	0.36	6.37e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.58	-0.32	7.19e-17	Total body bone mineral density;
BRCA	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg19678392	chr7:94953810	PON1	-0.42	-8.84	-0.33	9.34e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs2249625	0.523	rs2496501	chr6:72885364	A/G	cg18830697	chr6:72922368	RIMS1	-0.63	-14.36	-0.49	9.82e-41	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg06115741	chr20:33292138	TP53INP2	-0.37	-8.22	-0.31	1.17e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg13119609	chr19:45449297	APOC2	0.47	13.08	0.46	8.51e-35	Blood protein levels;
BRCA	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	7.81	0.3	2.43e-14	Menarche (age at onset);
BRCA	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg13770153	chr20:60521292	NA	-0.45	-10.87	-0.39	2.31e-25	Body mass index;
BRCA	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg16473166	chr22:50639996	SELO	-0.49	-11.07	-0.4	3.5e-26	Obesity-related traits;
BRCA	cis	rs6714710	0.603	rs11684749	chr2:98420142	G/C	cg26665480	chr2:98280029	ACTR1B	0.58	13.61	0.47	3.29e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg22713356	chr15:30763199	NA	1.09	21.7	0.65	1.18e-78	Uric acid levels;
BRCA	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg26384229	chr12:38710491	ALG10B	0.75	17.2	0.56	8.9e-55	Bladder cancer;
BRCA	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.49	-0.32	1.4e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.45	-10.74	-0.39	7.19e-25	IgG glycosylation;
BRCA	cis	rs727479	0.545	rs10851499	chr15:51537127	G/C	cg19946085	chr15:51559439	CYP19A1	-0.29	-7.84	-0.3	1.89e-14	Estradiol levels;
BRCA	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg14847009	chr1:175162515	KIAA0040	0.25	9.47	0.35	5.34e-20	Alcohol dependence;
BRCA	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg06115741	chr20:33292138	TP53INP2	0.39	8.55	0.32	8.93e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg12419862	chr22:24373484	LOC391322	-0.69	-15.85	-0.53	5.94e-48	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	8.03	0.3	4.83e-15	Diabetic retinopathy;
BRCA	cis	rs16854884	0.657	rs6769910	chr3:143737830	C/G	cg06585982	chr3:143692056	C3orf58	0.43	8.99	0.33	2.87e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs6977660	0.714	rs10155949	chr7:19834747	T/C	cg05791153	chr7:19748676	TWISTNB	0.58	10.74	0.39	7.76e-25	Thyroid stimulating hormone;
BRCA	cis	rs870825	0.616	rs6810600	chr4:185616814	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.17	0.56	1.32e-54	Blood protein levels;
BRCA	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.69	0.5	2.56e-42	Personality dimensions;
BRCA	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg06060754	chr5:176797920	RGS14	0.94	19.24	0.61	2.09e-65	Urinary electrolytes (magnesium/calcium ratio);
BRCA	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg08885076	chr2:99613938	TSGA10	0.41	9.63	0.36	1.4e-20	Chronic sinus infection;
BRCA	cis	rs4787491	0.729	rs11150584	chr16:30039678	C/A	cg06326092	chr16:30034487	C16orf92	0.37	9.46	0.35	5.69e-20	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3740540	0.530	rs2362507	chr10:126290820	A/G	cg04949429	chr10:126290192	LHPP	0.43	12.26	0.44	3.62e-31	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs524281	0.817	rs10791859	chr11:65978453	C/T	cg16950941	chr11:66035639	RAB1B	-0.38	-8.11	-0.31	2.58e-15	Electroencephalogram traits;
BRCA	trans	rs6479901	0.512	rs4439410	chr10:64998772	C/G	cg14819942	chr15:35414228	NA	-0.35	-8.65	-0.32	4.26e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs8002861	0.664	rs9525873	chr13:44482204	T/C	cg17145862	chr1:211918768	LPGAT1	0.51	11.61	0.42	2.13e-28	Leprosy;
BRCA	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg12193833	chr17:30244370	NA	-0.61	-9.26	-0.34	3.03e-19	Hip circumference adjusted for BMI;
BRCA	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.6	-12.48	-0.44	3.66e-32	Lymphocyte counts;
BRCA	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg27535305	chr1:53392650	SCP2	0.49	11.37	0.41	2.12e-27	Monocyte count;
BRCA	trans	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.01	0.3	5.51e-15	Corneal astigmatism;
BRCA	cis	rs6878727	0.850	rs10055879	chr5:123704258	G/A	cg01806427	chr5:123737813	NA	0.42	8.65	0.32	4.29e-17	Breast cancer;
BRCA	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.03	0.3	4.7e-15	Breast cancer;
BRCA	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg01939980	chr4:1354348	KIAA1530	0.38	9.05	0.34	1.73e-18	Obesity-related traits;
BRCA	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.08	0.3	3.34e-15	Tonsillectomy;
BRCA	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg01884057	chr2:25150051	NA	0.31	8.09	0.3	3.08e-15	Body mass index;
BRCA	cis	rs17604090	0.938	rs850029	chr7:29678087	A/G	cg19413766	chr7:29689036	LOC646762	-0.55	-7.96	-0.3	7.86e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12379764	chr21:47803548	PCNT	-0.38	-8.24	-0.31	9.57e-16	Testicular germ cell tumor;
BRCA	cis	rs6545883	0.783	rs7579651	chr2:61800279	C/G	cg15711740	chr2:61764176	XPO1	-0.57	-14.38	-0.49	8.14e-41	Tuberculosis;
BRCA	trans	rs9944715	0.954	rs7240354	chr18:43809614	G/A	cg01718231	chr17:29326311	RNF135	-0.4	-8.04	-0.3	4.47e-15	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg12310025	chr6:25882481	NA	-0.55	-13.62	-0.47	2.93e-37	Blood metabolite levels;
BRCA	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg27170947	chr2:26402098	FAM59B	-0.99	-17.47	-0.57	3.52e-56	Gut microbiome composition (summer);
BRCA	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg02544614	chr20:61657117	NA	0.28	8.15	0.31	1.93e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg07988820	chr12:82153109	PPFIA2	-0.61	-10.97	-0.4	8.61e-26	Resting heart rate;
BRCA	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg14675211	chr2:100938903	LONRF2	-0.52	-11.21	-0.41	9.33e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg18876405	chr7:65276391	NA	0.71	18.24	0.59	3.68e-60	Calcium levels;
BRCA	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg02734326	chr4:10020555	SLC2A9	0.39	8.47	0.32	1.68e-16	Bone mineral density;
BRCA	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.54	-10.39	-0.38	1.83e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs34779708	0.702	rs35969476	chr10:35544318	G/A	cg03585969	chr10:35415529	CREM	0.45	9.1	0.34	1.11e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg14784868	chr12:69753453	YEATS4	0.45	11.79	0.42	3.52e-29	Blood protein levels;
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg00024416	chr22:24240387	NA	0.32	8.04	0.3	4.22e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-12.44	-0.44	5.95e-32	Morning vs. evening chronotype;
BRCA	cis	rs4478858	0.735	rs68008576	chr1:31805905	T/C	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	trans	rs75804782	0.521	rs72993073	chr2:239412925	G/A	cg01134436	chr17:81009848	B3GNTL1	0.68	8.52	0.32	1.11e-16	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs6763687	0.964	rs16856859	chr3:171784736	A/G	cg16233210	chr3:171778391	FNDC3B	0.49	11.77	0.42	4.59e-29	Red cell distribution width;
BRCA	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg21017887	chr14:105400489	NA	0.66	17.48	0.57	3.47e-56	Rheumatoid arthritis;
BRCA	cis	rs1165668	0.755	rs10735390	chr12:104311731	A/G	cg21863207	chr12:104234989	NT5DC3	0.39	8.19	0.31	1.37e-15	Coronary heart disease (SNP X SNP interaction);
BRCA	cis	rs12541635	0.934	rs2115703	chr8:107045935	C/G	cg10147462	chr8:107024639	NA	0.37	9.62	0.36	1.46e-20	Age of smoking initiation;
BRCA	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg15145296	chr3:125709740	NA	-0.56	-8.92	-0.33	5.06e-18	Blood pressure (smoking interaction);
BRCA	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.89	19.33	0.61	7.04e-66	Cognitive ability;
BRCA	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18876405	chr7:65276391	NA	0.52	12.2	0.43	6.26e-31	Aortic root size;
BRCA	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg00677455	chr12:58241039	CTDSP2	-0.41	-9.31	-0.35	2.07e-19	Multiple sclerosis;
BRCA	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg03585969	chr10:35415529	CREM	0.56	11.38	0.41	1.82e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7927771	0.560	rs4752858	chr11:47685829	C/T	cg20307385	chr11:47447363	PSMC3	-0.39	-9.1	-0.34	1.13e-18	Subjective well-being;
BRCA	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg08992911	chr2:238395768	MLPH	0.38	8.38	0.31	3.37e-16	Prostate cancer;
BRCA	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.31	0.41	3.68e-27	Electroencephalogram traits;
BRCA	cis	rs7586879	1.000	rs11683212	chr2:25120196	T/C	cg01884057	chr2:25150051	NA	0.33	8.28	0.31	7.49e-16	Body mass index;
BRCA	cis	rs11229555	0.645	rs4517537	chr11:58213695	G/A	cg15696309	chr11:58395628	NA	-0.45	-9.64	-0.36	1.27e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7394190	0.748	rs4746147	chr10:75527708	A/G	cg07699608	chr10:75541558	CHCHD1	0.65	9.66	0.36	1.06e-20	Incident atrial fibrillation;
BRCA	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	17.21	0.56	7.93e-55	Intelligence (multi-trait analysis);
BRCA	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg00071950	chr4:10020882	SLC2A9	0.4	8.43	0.32	2.27e-16	Blood metabolite levels;
BRCA	cis	rs73001065	1.000	rs73001065	chr19:19460541	G/C	cg03709012	chr19:19516395	GATAD2A	0.88	7.89	0.3	1.36e-14	LDL cholesterol;
BRCA	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg02659138	chr7:134003124	SLC35B4	0.34	10.73	0.39	8.26e-25	Mean platelet volume;
BRCA	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	trans	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg17830980	chr10:43048298	ZNF37B	-0.45	-8.05	-0.3	4.16e-15	Obesity (extreme);
BRCA	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg08470875	chr2:26401718	FAM59B	-0.51	-8.29	-0.31	6.93e-16	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg17366294	chr4:99064904	C4orf37	0.41	9.37	0.35	1.21e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7246967	0.611	rs34806882	chr19:22880104	T/C	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs2859741	0.647	rs548661	chr1:37479392	T/G	cg09363841	chr1:37513479	NA	-0.56	-11.98	-0.43	5.48e-30	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs6546550	0.835	rs3755389	chr2:70119469	T/C	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.62	-0.42	1.94e-28	Prevalent atrial fibrillation;
BRCA	cis	rs17092148	0.616	rs1122174	chr20:33110846	T/C	cg16810054	chr20:33298113	TP53INP2	-0.43	-9.41	-0.35	9e-20	Neuroticism;
BRCA	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg10560079	chr2:191398806	TMEM194B	-0.71	-12.48	-0.44	3.92e-32	Diastolic blood pressure;
BRCA	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg13010199	chr12:38710504	ALG10B	0.54	11.51	0.41	5.6e-28	Heart rate;
BRCA	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.28	0.56	3.49e-55	Bladder cancer;
BRCA	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg10523679	chr1:76189770	ACADM	0.76	15.98	0.53	1.34e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg14829155	chr15:31115871	NA	-0.33	-8.01	-0.3	5.32e-15	Huntington's disease progression;
BRCA	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg09163369	chr1:210001066	C1orf107	0.51	9.44	0.35	6.65e-20	Orofacial clefts;
BRCA	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg08999081	chr20:33150536	PIGU	-0.47	-12.95	-0.46	3.13e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg09307838	chr4:120376055	NA	0.61	12.33	0.44	1.65e-31	Corneal astigmatism;
BRCA	cis	rs2882667	0.898	rs6882330	chr5:138382182	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-8.99	-0.33	2.85e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs495337	0.760	rs4810995	chr20:48571802	C/A	cg17835207	chr20:48524531	SPATA2	-0.69	-16.88	-0.56	3.73e-53	Psoriasis;
BRCA	cis	rs17401966	1.000	rs4846208	chr1:10313839	T/C	cg15208524	chr1:10270712	KIF1B	0.39	8.43	0.32	2.24e-16	Hepatocellular carcinoma;
BRCA	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18876405	chr7:65276391	NA	0.55	13.29	0.47	9.4e-36	Aortic root size;
BRCA	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11764359	chr7:65958608	NA	0.76	17.57	0.57	1.11e-56	Aortic root size;
BRCA	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	12.0	0.43	4.85e-30	Breast cancer;
BRCA	trans	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.92	-0.3	1.04e-14	Corneal astigmatism;
BRCA	cis	rs1891275	0.509	rs76313529	chr10:93443076	T/C	cg07889827	chr10:93443413	NA	-0.44	-12.54	-0.44	2.03e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg04455712	chr21:45112962	RRP1B	0.39	10.18	0.37	1.19e-22	Mean corpuscular volume;
BRCA	cis	rs2455799	0.634	rs13085226	chr3:15923750	C/T	cg16303742	chr3:15540471	COLQ	-0.33	-7.89	-0.3	1.34e-14	Mean platelet volume;
BRCA	cis	rs80130819	0.515	rs1635536	chr12:48385945	A/G	cg05342945	chr12:48394962	COL2A1	-0.5	-9.62	-0.36	1.45e-20	Prostate cancer;
BRCA	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg04756594	chr16:24857601	SLC5A11	-0.34	-8.62	-0.32	5.2e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	8.5	0.32	1.39e-16	Menarche (age at onset);
BRCA	cis	rs4948102	0.727	rs4948097	chr7:56056571	A/G	cg09872392	chr7:56161020	PHKG1	-0.4	-9.08	-0.34	1.39e-18	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs2742234	0.590	rs2075912	chr10:43622217	T/C	cg02780029	chr10:43622663	RET	-0.35	-7.86	-0.3	1.64e-14	Hirschsprung disease;
BRCA	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-8.75	-0.33	1.91e-17	Mean corpuscular volume;
BRCA	cis	rs654950	0.653	rs2810568	chr1:42054247	A/G	cg06885757	chr1:42089581	HIVEP3	-0.33	-10.94	-0.4	1.22e-25	Airway imaging phenotypes;
BRCA	trans	rs637571	0.584	rs659824	chr11:65636509	A/G	cg17712092	chr4:129076599	LARP1B	-0.57	-13.28	-0.47	1.07e-35	Eosinophil percentage of white cells;
BRCA	cis	rs9369695	0.883	rs9381581	chr6:47580695	G/A	cg12968598	chr6:47444699	CD2AP	0.44	9.58	0.35	2.15e-20	Reticulocyte count;
BRCA	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12756686	chr19:29218302	NA	0.55	10.85	0.39	2.75e-25	Methadone dose in opioid dependence;
BRCA	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg15395560	chr15:45543142	SLC28A2	-0.29	-7.84	-0.3	1.9e-14	Uric acid levels;
BRCA	trans	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg26043149	chr18:55253948	FECH	-0.36	-8.05	-0.3	3.98e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.94	-0.33	4e-18	Coronary artery disease;
BRCA	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-14.65	-0.5	4.27e-42	Chronic sinus infection;
BRCA	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg08514558	chr10:81106712	PPIF	0.36	8.72	0.33	2.34e-17	Height;
BRCA	trans	rs7395662	0.833	rs1963073	chr11:48975094	T/A	cg00717180	chr2:96193071	NA	-0.31	-8.61	-0.32	5.68e-17	HDL cholesterol;
BRCA	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg14343924	chr8:8086146	FLJ10661	0.42	8.51	0.32	1.23e-16	Neuroticism;
BRCA	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg06494592	chr3:125709126	NA	-0.53	-8.23	-0.31	1.05e-15	Blood pressure (smoking interaction);
BRCA	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg03954927	chr1:10346856	KIF1B	-0.47	-15.0	-0.51	8.74e-44	Hepatocellular carcinoma;
BRCA	cis	rs838147	0.844	rs12975033	chr19:49249443	A/T	cg13540341	chr19:49222985	MAMSTR	0.3	7.88	0.3	1.39e-14	Dietary macronutrient intake;
BRCA	cis	rs1865721	0.804	rs1319789	chr18:73161157	C/A	cg26385618	chr18:73139727	C18orf62	-0.41	-9.85	-0.36	2.02e-21	Intelligence;
BRCA	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg23018236	chr17:30244563	NA	-0.72	-12.04	-0.43	3.26e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg23625390	chr15:77176239	SCAPER	0.37	8.87	0.33	7.19e-18	Blood metabolite levels;
BRCA	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg25801113	chr15:45476975	SHF	-0.34	-8.39	-0.31	3.14e-16	Uric acid levels;
BRCA	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.86	0.39	2.45e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13315871	0.929	rs11706920	chr3:58279672	C/T	cg20936604	chr3:58311152	NA	-0.65	-8.19	-0.31	1.44e-15	Cholesterol, total;
BRCA	cis	rs977987	0.806	rs11862095	chr16:75385418	T/A	cg03315344	chr16:75512273	CHST6	0.52	12.29	0.44	2.58e-31	Dupuytren's disease;
BRCA	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.14	-0.31	2.08e-15	Total body bone mineral density;
BRCA	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18876405	chr7:65276391	NA	0.55	13.18	0.46	3.03e-35	Aortic root size;
BRCA	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.19e-40	Motion sickness;
BRCA	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg25019033	chr10:957182	NA	-0.41	-7.91	-0.3	1.11e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs6715284	1.000	rs13398075	chr2:202376269	A/T	cg08521270	chr2:202316462	TRAK2;STRADB	0.66	8.83	0.33	1.03e-17	Rheumatoid arthritis;
BRCA	trans	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg13565492	chr6:43139072	SRF	-0.79	-10.95	-0.4	1.07e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg25237894	chr2:233734115	C2orf82	-0.44	-13.82	-0.48	3.21e-38	Coronary artery disease;
BRCA	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg24692254	chr21:30365293	RNF160	0.79	22.05	0.66	1.52e-80	Dental caries;
BRCA	cis	rs7246657	0.722	rs10403173	chr19:38078680	G/A	cg23950597	chr19:37808831	NA	-0.5	-8.64	-0.32	4.63e-17	Coronary artery calcification;
BRCA	cis	rs1865721	0.804	rs72977818	chr18:73146852	T/C	cg26385618	chr18:73139727	C18orf62	-0.44	-10.79	-0.39	4.95e-25	Intelligence;
BRCA	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg11764359	chr7:65958608	NA	-0.74	-16.09	-0.54	3.77e-49	Aortic root size;
BRCA	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg24060327	chr5:131705240	SLC22A5	0.61	11.38	0.41	1.91e-27	Breast cancer;
BRCA	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg18402987	chr7:1209562	NA	0.85	12.22	0.44	5.38e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg27600084	chr12:12264075	NA	0.4	9.21	0.34	4.65e-19	Breast size;
BRCA	cis	rs13136331	0.642	rs1319917	chr4:88628808	G/C	cg22416721	chr4:88570574	DMP1	-0.47	-11.48	-0.41	6.94e-28	Sitting height ratio;
BRCA	cis	rs13046373	0.535	rs1961491	chr21:31973685	C/T	cg27071517	chr21:31768726	KRTAP13-1	0.29	7.92	0.3	1.08e-14	HDL cholesterol;
BRCA	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg12310025	chr6:25882481	NA	-0.55	-13.63	-0.47	2.52e-37	Blood metabolite levels;
BRCA	cis	rs9815354	0.812	rs73071212	chr3:41981856	C/A	cg03022575	chr3:42003672	ULK4	0.7	9.67	0.36	9.51e-21	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg27661571	chr11:113659931	NA	-0.73	-11.22	-0.41	8.26e-27	Hip circumference adjusted for BMI;
BRCA	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.65	-17.6	-0.57	8.16e-57	Longevity;Endometriosis;
BRCA	cis	rs965469	0.625	rs1043159	chr20:3232031	C/T	cg25506879	chr20:3388711	C20orf194	-0.46	-9.63	-0.36	1.35e-20	IFN-related cytopenia;
BRCA	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-10.12	-0.37	1.99e-22	Neuroticism;
BRCA	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg04691961	chr3:161091175	C3orf57	0.46	10.95	0.4	1.05e-25	Morning vs. evening chronotype;
BRCA	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg12193833	chr17:30244370	NA	-0.54	-8.72	-0.33	2.47e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg09307838	chr4:120376055	NA	0.76	17.1	0.56	2.87e-54	Corneal astigmatism;
BRCA	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg26031613	chr14:104095156	KLC1	0.73	15.91	0.53	2.85e-48	Bone mineral density;
BRCA	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg04398451	chr17:18023971	MYO15A	0.66	14.55	0.5	1.25e-41	Total body bone mineral density;
BRCA	cis	rs965469	1.000	rs6037535	chr20:3270621	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-10.19	-0.37	1.08e-22	IFN-related cytopenia;
BRCA	cis	rs68170813	0.559	rs6963917	chr7:106953427	T/G	cg02696742	chr7:106810147	HBP1	-0.54	-8.72	-0.33	2.46e-17	Coronary artery disease;
BRCA	trans	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.38	7.96	0.3	8.16e-15	Menarche (age at onset);
BRCA	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.74	0.65	7.41e-79	Lymphocyte percentage of white cells;
BRCA	cis	rs4363385	0.818	rs406350	chr1:153007492	C/T	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs4363385	0.747	rs1984198	chr1:152958584	T/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.31	-0.31	5.84e-16	Inflammatory skin disease;
BRCA	trans	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg12386194	chr3:101231763	SENP7	0.46	9.7	0.36	7.87e-21	Colorectal cancer;
BRCA	cis	rs7809950	0.862	rs62482502	chr7:106987810	A/C	cg23024343	chr7:107201750	COG5	-0.4	-9.13	-0.34	8.84e-19	Coronary artery disease;
BRCA	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.76	-0.5	1.19e-42	Chronic sinus infection;
BRCA	cis	rs6687430	0.526	rs6688558	chr1:10611403	A/G	cg17425144	chr1:10567563	PEX14	0.51	11.9	0.43	1.18e-29	Hand grip strength;
BRCA	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg03354898	chr7:1950403	MAD1L1	0.44	9.34	0.35	1.59e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-8.1	-0.31	2.84e-15	Blood pressure (smoking interaction);
BRCA	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	25.66	0.71	2.38e-100	Chronic sinus infection;
BRCA	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18876405	chr7:65276391	NA	-0.5	-11.01	-0.4	6.21e-26	Aortic root size;
BRCA	cis	rs7903847	0.642	rs4635018	chr10:99137839	C/G	cg20016023	chr10:99160130	RRP12	0.27	8.59	0.32	6.62e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg27432699	chr2:27873401	GPN1	-0.41	-8.83	-0.33	9.84e-18	Oral cavity cancer;
BRCA	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg22467129	chr15:76604101	ETFA	-0.49	-10.77	-0.39	5.61e-25	Blood metabolite levels;
BRCA	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.84	-0.33	9.56e-18	Total body bone mineral density;
BRCA	cis	rs4363385	0.747	rs4845506	chr1:152968407	G/A	cg25856811	chr1:152973957	SPRR3	-0.34	-9.08	-0.34	1.35e-18	Inflammatory skin disease;
BRCA	cis	rs965469	0.779	rs6037571	chr20:3334322	C/T	cg25506879	chr20:3388711	C20orf194	-0.43	-8.74	-0.33	2.11e-17	IFN-related cytopenia;
BRCA	cis	rs1868673	1.000	rs1868672	chr3:150175231	T/C	cg04908077	chr3:150187338	NA	-0.32	-8.62	-0.32	5.31e-17	Waist circumference;
BRCA	cis	rs9986765	0.881	rs73452602	chr7:142828331	A/T	cg22531018	chr7:142981779	TMEM139	0.58	9.69	0.36	7.99e-21	Cancer;Dermatomyositis;
BRCA	cis	rs4363385	0.818	rs406350	chr1:153007492	C/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg02297831	chr4:17616191	MED28	0.36	8.38	0.31	3.46e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg12564285	chr5:131593104	PDLIM4	-0.44	-11.7	-0.42	8.46e-29	Acylcarnitine levels;
BRCA	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg00106254	chr7:1943704	MAD1L1	-0.39	-9.65	-0.36	1.21e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg14835575	chr10:16859367	RSU1	0.31	7.81	0.3	2.29e-14	Platelet distribution width;
BRCA	cis	rs10267417	0.603	rs4543442	chr7:19911140	G/A	cg07541023	chr7:19748670	TWISTNB	0.45	8.01	0.3	5.54e-15	Night sleep phenotypes;
BRCA	cis	rs4719841	0.662	rs9639523	chr7:25991977	A/C	cg24254488	chr7:25991654	NA	0.29	8.88	0.33	6.46e-18	Triglyceride levels;
BRCA	cis	rs9309711	0.961	rs11890651	chr2:3482796	T/G	cg16153549	chr2:3496821	NA	-0.38	-9.02	-0.34	2.09e-18	Neurofibrillary tangles;
BRCA	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg13010199	chr12:38710504	ALG10B	0.52	9.89	0.36	1.5e-21	Morning vs. evening chronotype;
BRCA	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.73	-0.33	2.29e-17	Colorectal cancer;
BRCA	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg02466173	chr16:30829666	NA	-0.54	-11.73	-0.42	6.71e-29	Multiple myeloma;
BRCA	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg04450456	chr4:17643702	FAM184B	0.37	10.95	0.4	1.08e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.75	-0.33	1.83e-17	Depression;
BRCA	cis	rs3125734	0.633	rs1368157	chr10:64001114	T/C	cg09941381	chr10:64027924	RTKN2	-0.27	-7.92	-0.3	1.07e-14	Rheumatoid arthritis;
BRCA	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg24642844	chr7:1081250	C7orf50	-0.89	-16.33	-0.54	2.28e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs760805	1.000	rs4648884	chr1:25261386	C/T	cg22509179	chr1:25234806	RUNX3	0.56	14.34	0.49	1.17e-40	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg26043149	chr18:55253948	FECH	0.4	8.94	0.33	3.99e-18	Bone mineral density;
BRCA	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg27129171	chr3:47204927	SETD2	-0.66	-15.28	-0.52	3.55e-45	Colorectal cancer;
BRCA	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg07395648	chr5:131743802	NA	-0.36	-9.08	-0.34	1.32e-18	Blood metabolite levels;
BRCA	cis	rs17092148	0.945	rs6142237	chr20:33340993	C/T	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.31	-0.41	3.81e-27	Neuroticism;
BRCA	cis	rs2425143	1.000	rs10485510	chr20:34445164	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.54	-0.32	9.92e-17	Blood protein levels;
BRCA	cis	rs16866061	0.855	rs11687736	chr2:225405122	A/T	cg12698349	chr2:225449008	CUL3	0.78	21.23	0.64	4.04e-76	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg03605463	chr16:89740564	NA	0.41	8.65	0.32	4e-17	Vitiligo;
BRCA	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg26314531	chr2:26401878	FAM59B	-0.63	-10.48	-0.38	7.95e-24	Gut microbiome composition (summer);
BRCA	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg25301532	chr20:43378953	KCNK15	0.45	10.77	0.39	5.61e-25	Obesity-related traits;
BRCA	trans	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg25214090	chr10:38739885	LOC399744	-0.54	-11.96	-0.43	6.99e-30	Corneal astigmatism;
BRCA	cis	rs9296092	0.560	rs9469500	chr6:33526196	C/T	cg13560919	chr6:33536144	NA	-0.85	-17.98	-0.58	8.28e-59	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.56	0.5	1.11e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	10.48	0.38	7.92e-24	Height;
BRCA	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg24558204	chr6:135376177	HBS1L	0.46	12.42	0.44	7.32e-32	Red blood cell count;
BRCA	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg15395560	chr15:45543142	SLC28A2	-0.3	-7.85	-0.3	1.79e-14	Uric acid levels;
BRCA	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg17143192	chr8:8559678	CLDN23	-0.54	-10.32	-0.38	3.35e-23	Obesity-related traits;
BRCA	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg23711669	chr6:146136114	FBXO30	-0.8	-19.34	-0.61	5.67e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02475777	chr4:1388615	CRIPAK	0.67	12.98	0.46	2.34e-34	Longevity;
BRCA	trans	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg26043149	chr18:55253948	FECH	0.39	8.42	0.32	2.43e-16	Bone mineral density;
BRCA	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg09184832	chr6:79620586	NA	-0.48	-10.52	-0.38	5.72e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs10845606	0.781	rs7972866	chr12:12828320	C/T	cg09462578	chr12:12878428	APOLD1	-0.43	-8.66	-0.32	3.79e-17	Systemic lupus erythematosus;
BRCA	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg13010199	chr12:38710504	ALG10B	0.52	9.84	0.36	2.2e-21	Bladder cancer;
BRCA	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg25019033	chr10:957182	NA	-0.42	-8.03	-0.3	4.66e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs9309711	0.922	rs11679058	chr2:3483813	C/G	cg16153549	chr2:3496821	NA	-0.41	-9.47	-0.35	5.32e-20	Neurofibrillary tangles;
BRCA	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg24848339	chr3:12840334	CAND2	0.43	11.51	0.41	5.55e-28	QRS complex (12-leadsum);
BRCA	trans	rs587242	0.868	rs35869184	chr1:97027749	G/C	cg10631902	chr5:14652156	NA	0.35	8.11	0.31	2.63e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
BRCA	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg14631576	chr9:95140430	CENPP	-0.35	-8.43	-0.32	2.23e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs72772090	0.710	rs17400685	chr5:96066366	A/C	cg24982541	chr5:96078678	CAST	0.46	7.99	0.3	6.19e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg13010199	chr12:38710504	ALG10B	0.41	8.37	0.31	3.59e-16	Bladder cancer;
BRCA	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg11833968	chr6:79620685	NA	-0.43	-9.67	-0.36	9.64e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-22.15	-0.66	4.01e-81	Gut microbiome composition (summer);
BRCA	cis	rs12612619	0.732	rs11679681	chr2:27298479	C/A	cg00617064	chr2:27272375	NA	-0.32	-8.31	-0.31	5.86e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs16854884	0.632	rs62267390	chr3:143644067	A/T	cg06585982	chr3:143692056	C3orf58	0.43	8.63	0.32	4.74e-17	Economic and political preferences (feminism/equality);
BRCA	trans	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.48	11.18	0.4	1.26e-26	Brugada syndrome;
BRCA	cis	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-8.42	-0.32	2.52e-16	Cognitive test performance;
BRCA	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.76	12.67	0.45	5.84e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3125734	0.633	rs7100297	chr10:63985100	T/C	cg09941381	chr10:64027924	RTKN2	-0.27	-8.05	-0.3	4.11e-15	Rheumatoid arthritis;
BRCA	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg09184832	chr6:79620586	NA	-0.48	-10.71	-0.39	1.01e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-19.61	-0.61	2.23e-67	Electrocardiographic conduction measures;
BRCA	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg27170947	chr2:26402098	FAM59B	-0.91	-17.39	-0.57	9.91e-56	Gut microbiome composition (summer);
BRCA	trans	rs3857536	0.813	rs62415859	chr6:66934278	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.12	-0.31	2.43e-15	Blood trace element (Cu levels);
BRCA	cis	rs2422052	0.527	rs2276695	chr2:118814868	A/G	cg22545206	chr2:118617499	NA	0.33	7.99	0.3	6.24e-15	Mosquito bite size;
BRCA	trans	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-9.39	-0.35	1.04e-19	Retinal vascular caliber;
BRCA	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.35	-0.35	1.45e-19	Bipolar disorder;
BRCA	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg18016565	chr1:150552671	MCL1	0.34	8.01	0.3	5.32e-15	Tonsillectomy;
BRCA	trans	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg06521331	chr12:34319734	NA	0.45	8.96	0.33	3.57e-18	Bladder cancer;
BRCA	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg06623918	chr6:96969491	KIAA0776	0.9	25.35	0.71	1.22e-98	Headache;
BRCA	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.03	0.49	3.57e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4690686	0.509	rs11730559	chr4:177259257	A/T	cg17059388	chr4:177262070	NA	0.49	9.94	0.37	9.88e-22	Essential tremor;
BRCA	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg16339924	chr4:17578868	LAP3	0.61	14.95	0.51	1.49e-43	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10463316	0.894	rs13361298	chr5:150765549	T/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.29	-0.31	6.58e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg18154014	chr19:37997991	ZNF793	-0.53	-10.45	-0.38	1.03e-23	Coronary artery calcification;
BRCA	cis	rs7394190	0.748	rs4746146	chr10:75527197	C/T	cg07699608	chr10:75541558	CHCHD1	0.66	9.81	0.36	3.03e-21	Incident atrial fibrillation;
BRCA	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.98	14.38	0.49	8.11e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6429082	0.783	rs291364	chr1:235687179	A/G	cg26050004	chr1:235667680	B3GALNT2	0.55	14.41	0.5	5.73e-41	Adiposity;
BRCA	trans	rs877282	0.945	rs10904556	chr10:789429	A/G	cg22713356	chr15:30763199	NA	1.36	27.31	0.73	2.1e-109	Uric acid levels;
BRCA	cis	rs1003719	0.715	rs13046581	chr21:38551985	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.49	-0.5	2.46e-41	Eye color traits;
BRCA	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19346786	chr7:2764209	NA	0.38	11.37	0.41	2.1e-27	Height;
BRCA	cis	rs2016266	0.819	rs1976938	chr12:53661925	C/T	cg26875137	chr12:53738046	NA	0.38	9.73	0.36	5.87e-21	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs7301826	0.651	rs7132657	chr12:131285187	T/C	cg11011512	chr12:131303247	STX2	0.52	13.58	0.47	4.57e-37	Plasma plasminogen activator levels;
BRCA	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.32	7.86	0.3	1.59e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg01657329	chr11:68192670	LRP5	-0.34	-8.04	-0.3	4.43e-15	Total body bone mineral density;
BRCA	cis	rs13040088	0.935	rs3787513	chr20:61573736	G/A	cg23096297	chr20:61557774	DIDO1	0.9	17.35	0.57	1.54e-55	Menopause (age at onset);
BRCA	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg04362960	chr10:104952993	NT5C2	0.47	10.77	0.39	5.66e-25	Arsenic metabolism;
BRCA	trans	rs1962073	0.528	rs9329223	chr8:10331754	C/T	cg15556689	chr8:8085844	FLJ10661	-0.3	-7.85	-0.3	1.82e-14	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
BRCA	cis	rs9487051	0.735	rs351754	chr6:109537553	A/G	cg01475377	chr6:109611718	NA	0.47	11.78	0.42	3.95e-29	Reticulocyte fraction of red cells;
BRCA	cis	rs9503598	0.714	rs11242859	chr6:3454032	G/A	cg00476032	chr6:3446245	SLC22A23	0.42	10.75	0.39	7.03e-25	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	17.05	0.56	5.17e-54	Alzheimer's disease;
BRCA	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	8.98	0.33	2.9e-18	Tonsillectomy;
BRCA	trans	rs7181230	1.000	rs9972424	chr15:40365851	A/G	cg22705835	chr10:65332833	REEP3	-0.4	-9.69	-0.36	8.28e-21	Dehydroepiandrosterone sulphate levels;
BRCA	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg00339695	chr16:24857497	SLC5A11	0.52	11.45	0.41	9.89e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.3	-0.35	2.15e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg22563815	chr15:78856949	CHRNA5	-0.36	-8.62	-0.32	5.39e-17	Sudden cardiac arrest;
BRCA	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg14196790	chr5:131705035	SLC22A5	0.39	9.52	0.35	3.55e-20	Breast cancer;Mosquito bite size;
BRCA	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-12.91	-0.45	4.83e-34	Developmental language disorder (linguistic errors);
BRCA	cis	rs12530845	0.673	rs73721607	chr7:135335822	C/T	cg23117316	chr7:135346802	PL-5283	-0.39	-8.02	-0.3	5.07e-15	Red blood cell traits;
BRCA	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.4	9.43	0.35	7.36e-20	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg08975724	chr8:8085496	FLJ10661	0.43	8.08	0.3	3.26e-15	Retinal vascular caliber;
BRCA	cis	rs1953600	0.805	rs2819947	chr10:81947757	T/C	cg04850286	chr10:81895943	PLAC9	0.31	9.1	0.34	1.14e-18	Sarcoidosis;
BRCA	cis	rs12612619	0.704	rs2119026	chr2:27310393	A/G	cg00617064	chr2:27272375	NA	0.34	8.81	0.33	1.14e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg27279351	chr12:120934652	DYNLL1	0.56	13.32	0.47	7.04e-36	High light scatter reticulocyte count;
BRCA	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	13.94	0.48	9.16e-39	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg23018236	chr17:30244563	NA	-0.69	-10.65	-0.39	1.73e-24	Hip circumference adjusted for BMI;
BRCA	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg20628663	chr10:43360327	NA	0.68	13.71	0.48	1.12e-37	Blood protein levels;
BRCA	cis	rs2131877	0.529	rs3892194	chr3:194855675	C/T	cg13868855	chr3:194833887	C3orf21	-0.37	-8.62	-0.32	5.14e-17	Non-small cell lung cancer;
BRCA	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg25072359	chr17:41440525	NA	-0.43	-10.77	-0.39	5.84e-25	Menopause (age at onset);
BRCA	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg14664628	chr15:75095509	CSK	-0.52	-12.29	-0.44	2.54e-31	Breast cancer;
BRCA	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg06064525	chr11:970664	AP2A2	0.49	16.3	0.54	3.41e-50	Alzheimer's disease (late onset);
BRCA	cis	rs870825	0.616	rs57271221	chr4:185627198	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	16.4	0.54	1.05e-50	Blood protein levels;
BRCA	cis	rs11585357	0.947	rs2977303	chr1:17611548	A/T	cg08277548	chr1:17600880	PADI3	-0.54	-10.21	-0.37	9.36e-23	Hair shape;
BRCA	trans	rs66887589	0.934	rs56843000	chr4:120516597	T/C	cg25214090	chr10:38739885	LOC399744	-0.35	-8.02	-0.3	5.21e-15	Diastolic blood pressure;
BRCA	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.28	-8.16	-0.31	1.82e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.47	8.69	0.32	3.16e-17	Breast cancer;
BRCA	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg13902645	chr11:5959945	NA	-0.52	-10.63	-0.39	2.14e-24	DNA methylation (variation);
BRCA	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	19.78	0.62	2.7e-68	Platelet count;
BRCA	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg03433033	chr1:76189801	ACADM	0.85	21.95	0.66	5.26e-80	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg11693508	chr17:37793320	STARD3	0.68	12.45	0.44	5.1e-32	Bipolar disorder;
BRCA	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.32	10.12	0.37	2.06e-22	Bipolar disorder;
BRCA	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg11062466	chr8:58055876	NA	0.41	7.88	0.3	1.38e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-12.78	-0.45	1.75e-33	Hip circumference adjusted for BMI;
BRCA	cis	rs733175	0.855	rs9291641	chr4:10007259	C/T	cg00071950	chr4:10020882	SLC2A9	0.42	8.68	0.32	3.26e-17	Psychosis and Alzheimer's disease;
BRCA	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg10792982	chr14:105748885	BRF1	0.47	11.08	0.4	3.2e-26	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.31	0.41	3.75e-27	Rheumatoid arthritis;
BRCA	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.84	-14.16	-0.49	8.39e-40	Alzheimer's disease;
BRCA	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg08923669	chr16:420230	MRPL28	-0.39	-9.41	-0.35	8.82e-20	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	8.51	0.32	1.22e-16	Rheumatoid arthritis;
BRCA	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg00814883	chr7:100076585	TSC22D4	-0.51	-11.67	-0.42	1.12e-28	Platelet count;
BRCA	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg05347473	chr6:146136440	FBXO30	0.39	7.92	0.3	1.08e-14	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs1493916	0.837	rs4997493	chr18:31407302	C/T	cg27147174	chr7:100797783	AP1S1	-0.42	-8.48	-0.32	1.55e-16	Life satisfaction;
BRCA	trans	rs1459104	0.641	rs12790762	chr11:54933709	T/A	cg15704280	chr7:45808275	SEPT13	0.58	8.04	0.3	4.29e-15	Body mass index;
BRCA	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg21951975	chr1:209979733	IRF6	-0.4	-9.3	-0.35	2.28e-19	Cleft lip with or without cleft palate;
BRCA	cis	rs1691799	0.899	rs1168295	chr12:66734151	G/C	cg16791601	chr12:66731901	HELB	-0.65	-17.59	-0.57	9.35e-57	White blood cell count (basophil);
BRCA	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg05896524	chr21:47604654	C21orf56	-0.49	-9.66	-0.36	1.07e-20	Testicular germ cell tumor;
BRCA	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg03342759	chr3:160939853	NMD3	-0.69	-14.38	-0.49	8.11e-41	Parkinson's disease;
BRCA	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	14.07	0.49	2.2e-39	Lymphocyte counts;
BRCA	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg03808351	chr9:123631620	PHF19	0.4	7.85	0.3	1.7e-14	Rheumatoid arthritis;
BRCA	cis	rs6484504	0.512	rs2761594	chr11:31318244	A/G	cg14844989	chr11:31128820	NA	0.46	9.91	0.36	1.27e-21	Red blood cell count;
BRCA	cis	rs698833	0.886	rs2053455	chr2:44550233	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	10.88	0.4	2.12e-25	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.67	0.36	1.02e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8017423	0.647	rs11626821	chr14:90824945	A/G	cg04374321	chr14:90722782	PSMC1	-0.49	-11.75	-0.42	5.33e-29	Mortality in heart failure;
BRCA	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.33	7.97	0.3	7.23e-15	Personality dimensions;
BRCA	cis	rs11608355	0.545	rs35422737	chr12:109911456	A/G	cg05360138	chr12:110035743	NA	0.71	13.05	0.46	1.09e-34	Neuroticism;
BRCA	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.43	-0.41	1.22e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6740322	0.748	rs6755601	chr2:43483044	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-14.33	-0.49	1.43e-40	Coronary artery disease;
BRCA	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg14683738	chr19:37701593	ZNF585B	0.45	8.07	0.3	3.58e-15	Coronary artery calcification;
BRCA	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg21770322	chr7:97807741	LMTK2	0.41	11.08	0.4	3.09e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.51	-0.35	3.7799999999999997e-20	Total body bone mineral density;
BRCA	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-13.76	-0.48	6.27e-38	Hemoglobin concentration;
BRCA	cis	rs3784262	0.528	rs10518961	chr15:58334345	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-9.67	-0.36	9.65e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.91	0.33	5.1e-18	Platelet count;
BRCA	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg13397359	chr6:42928475	GNMT	0.76	19.39	0.61	3.43e-66	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg25214090	chr10:38739885	LOC399744	0.42	9.85	0.36	2.11e-21	Corneal astigmatism;
BRCA	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs867371	1.000	rs7173339	chr15:82467594	A/G	cg00614314	chr15:82944287	LOC80154	0.43	8.92	0.33	4.89e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	trans	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg19694781	chr19:47549865	TMEM160	-1.05	-22.03	-0.66	1.81e-80	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs1577917	0.958	rs1337843	chr6:86675545	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.26	-0.41	5.73e-27	Response to antipsychotic treatment;
BRCA	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg24060327	chr5:131705240	SLC22A5	-0.46	-9.15	-0.34	7.57e-19	Acylcarnitine levels;
BRCA	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg26031613	chr14:104095156	KLC1	0.99	26.2	0.72	2.57e-103	Body mass index;
BRCA	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11890956	chr21:40555474	PSMG1	-0.53	-10.92	-0.4	1.43e-25	Menarche (age at onset);
BRCA	cis	rs858239	0.539	rs6975852	chr7:23186654	T/C	cg23682824	chr7:23144976	KLHL7	0.37	9.5	0.35	4.11e-20	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs877282	0.891	rs11595385	chr10:800539	A/G	cg17470449	chr10:769945	NA	0.49	8.41	0.32	2.62e-16	Uric acid levels;
BRCA	cis	rs3845702	1.000	rs9989852	chr2:180839707	G/A	cg01881094	chr2:180872142	CWC22	-0.69	-13.7	-0.48	1.18e-37	Schizophrenia;
BRCA	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg07169764	chr2:136633963	MCM6	1.29	28.7	0.75	5.33e-117	Corneal structure;
BRCA	cis	rs9309711	0.737	rs9284795	chr2:3492065	G/A	cg10845886	chr2:3471009	TTC15	-0.69	-14.1	-0.49	1.7e-39	Neurofibrillary tangles;
BRCA	cis	rs1865721	0.755	rs3213875	chr18:73184048	C/T	cg26385618	chr18:73139727	C18orf62	-0.33	-8.57	-0.32	7.55e-17	Intelligence;
BRCA	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg06238570	chr21:40685208	BRWD1	-0.42	-8.65	-0.32	4.03e-17	Cognitive function;
BRCA	cis	rs3762637	0.943	rs72960447	chr3:122235105	G/A	cg24169773	chr3:122142474	KPNA1	-0.43	-8.01	-0.3	5.54e-15	LDL cholesterol levels;
BRCA	cis	rs7520050	0.743	rs61789988	chr1:46085242	G/C	cg24296786	chr1:45957014	TESK2	0.46	10.59	0.39	3.09e-24	Red blood cell count;Reticulocyte count;
BRCA	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	trans	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg07817883	chr1:32538562	TMEM39B	-0.44	-7.97	-0.3	7.27e-15	Monocyte percentage of white cells;
BRCA	cis	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg07460842	chr6:66804631	NA	0.87	15.52	0.52	2.4e-46	Exhaled nitric oxide levels;
BRCA	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg12444411	chr7:2802554	GNA12	-0.35	-8.66	-0.32	3.82e-17	Height;
BRCA	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg20290983	chr6:43655470	MRPS18A	-1.09	-38.37	-0.84	5.86e-168	IgG glycosylation;
BRCA	cis	rs6028335	0.674	rs66486072	chr20:37647882	G/A	cg16355469	chr20:37678765	NA	0.51	9.61	0.36	1.58e-20	Alcohol and nicotine co-dependence;
BRCA	cis	rs72781680	0.716	rs2551325	chr2:23979729	C/T	cg08917208	chr2:24149416	ATAD2B	0.64	10.14	0.37	1.68e-22	Lymphocyte counts;
BRCA	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg05025164	chr4:1340916	KIAA1530	0.48	10.6	0.39	2.8e-24	Longevity;
BRCA	cis	rs34779708	0.931	rs34815241	chr10:35296676	T/C	cg03585969	chr10:35415529	CREM	0.49	10.21	0.37	9.07e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg00484396	chr16:3507460	NAT15	-0.46	-9.79	-0.36	3.59e-21	Tuberculosis;
BRCA	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg04944784	chr2:26401820	FAM59B	-0.95	-16.46	-0.55	5.26e-51	Gut microbiome composition (summer);
BRCA	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg22875332	chr1:76189707	ACADM	0.62	11.48	0.41	7.45e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs13082711	0.595	rs34453788	chr3:27330153	T/C	cg02860705	chr3:27208620	NA	0.74	13.43	0.47	2.13e-36	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	13.95	0.48	8.22e-39	Alzheimer's disease;
BRCA	cis	rs3784262	0.669	rs7171261	chr15:58356855	C/G	cg12031962	chr15:58353849	ALDH1A2	0.37	10.03	0.37	4.3e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs1975991	0.538	rs12629150	chr3:187963329	C/A	cg15417654	chr3:187959138	LPP	0.35	8.94	0.33	4.12e-18	White matter integrity (bipolar disorder risk interaction);
BRCA	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg15704280	chr7:45808275	SEPT13	0.43	7.98	0.3	6.55e-15	Intraocular pressure;
BRCA	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	19.55	0.61	4.35e-67	Electrocardiographic conduction measures;
BRCA	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg13256891	chr4:100009986	ADH5	0.47	9.06	0.34	1.52e-18	Alcohol dependence;
BRCA	cis	rs312274	0.546	rs7295964	chr12:41272564	T/C	cg17827154	chr12:41323612	CNTN1	-0.36	-8.98	-0.33	3.03e-18	Metabolite levels  (X-11787);
BRCA	cis	rs6484504	0.576	rs208103	chr11:31167400	A/G	cg06552810	chr11:31128660	NA	-0.39	-8.76	-0.33	1.8e-17	Red blood cell count;
BRCA	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg18252515	chr7:66147081	NA	1.04	15.72	0.53	2.58e-47	Diabetic kidney disease;
BRCA	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-9.61	-0.36	1.61e-20	Response to bleomycin (chromatid breaks);
BRCA	cis	rs4588572	0.643	rs1019739	chr5:77770241	G/C	cg11547950	chr5:77652471	NA	-0.48	-8.53	-0.32	1.08e-16	Triglycerides;
BRCA	cis	rs7631605	0.905	rs6773752	chr3:37225837	C/T	cg15934958	chr3:37212084	LRRFIP2	0.42	9.85	0.36	2.03e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg20283391	chr11:68216788	NA	-0.45	-9.04	-0.34	1.81e-18	Total body bone mineral density;
BRCA	cis	rs13272623	0.502	rs268628	chr8:71560505	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.51	-10.91	-0.4	1.58e-25	IgG glycosylation;
BRCA	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg06108461	chr20:60628389	TAF4	-0.84	-17.72	-0.57	1.8e-57	Body mass index;
BRCA	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg26597838	chr10:835615	NA	1.01	15.56	0.52	1.59e-46	Eosinophil percentage of granulocytes;
BRCA	cis	rs7851660	0.967	rs4743135	chr9:100599493	C/T	cg13688889	chr9:100608707	NA	-0.36	-8.61	-0.32	5.84e-17	Strep throat;
BRCA	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24549020	chr5:56110836	MAP3K1	0.67	13.31	0.47	7.36e-36	Initial pursuit acceleration;
BRCA	cis	rs12541635	0.677	rs2029880	chr8:107024649	T/C	cg10147462	chr8:107024639	NA	0.39	10.73	0.39	8.37e-25	Age of smoking initiation;
BRCA	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.23	0.38	7.64e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg04374321	chr14:90722782	PSMC1	-0.76	-21.46	-0.65	2.43e-77	Mortality in heart failure;
BRCA	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg10253484	chr15:75165896	SCAMP2	0.47	8.53	0.32	1.02e-16	Systemic lupus erythematosus;
BRCA	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-13.71	-0.48	1.09e-37	Hemoglobin concentration;
BRCA	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg08975724	chr8:8085496	FLJ10661	0.44	8.11	0.31	2.58e-15	Retinal vascular caliber;
BRCA	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg14863265	chr7:2801509	GNA12	-0.51	-11.17	-0.4	1.34e-26	Height;
BRCA	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.71	11.13	0.4	2.01e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs597583	0.775	rs12806865	chr11:117404769	C/T	cg27161313	chr11:117392002	DSCAML1	0.37	7.86	0.3	1.7e-14	Putamen volume;
BRCA	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg23711669	chr6:146136114	FBXO30	-0.76	-17.6	-0.57	8.28e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2953145	0.568	rs1133354	chr2:241522450	A/G	cg07929629	chr2:241523174	NA	0.54	11.9	0.43	1.18e-29	Bipolar disorder;
BRCA	cis	rs829883	0.966	rs249818	chr12:98896994	A/C	cg25150519	chr12:98850993	NA	0.59	11.9	0.43	1.19e-29	Colorectal adenoma (advanced);
BRCA	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg17971929	chr21:40555470	PSMG1	0.76	16.59	0.55	1.12e-51	Cognitive function;
BRCA	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg13319975	chr6:146136371	FBXO30	-0.4	-9.16	-0.34	6.79e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg23131131	chr22:24373011	LOC391322	0.45	9.56	0.35	2.59e-20	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	cis	rs11585357	0.895	rs112208664	chr1:17632010	G/A	cg08277548	chr1:17600880	PADI3	-0.69	-11.78	-0.42	3.86e-29	Hair shape;
BRCA	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg25173405	chr17:45401733	C17orf57	-0.54	-11.7	-0.42	8.9e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg14675211	chr2:100938903	LONRF2	0.52	11.67	0.42	1.21e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs9309473	0.607	rs10198301	chr2:73581600	T/A	cg20560298	chr2:73613845	ALMS1	-0.42	-10.93	-0.4	1.31e-25	Metabolite levels;
BRCA	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg04455712	chr21:45112962	RRP1B	0.4	10.28	0.38	4.82e-23	Mean corpuscular volume;
BRCA	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg00071950	chr4:10020882	SLC2A9	-0.42	-9.81	-0.36	3.04e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg26769984	chr7:1090371	C7orf50	0.64	11.29	0.41	4.46e-27	Bronchopulmonary dysplasia;
BRCA	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg05896524	chr21:47604654	C21orf56	0.48	9.9	0.36	1.41e-21	Testicular germ cell tumor;
BRCA	cis	rs17641971	0.684	rs4873310	chr8:49990006	A/T	cg00325661	chr8:49890786	NA	0.39	10.81	0.39	4.14e-25	Blood metabolite levels;
BRCA	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg08917208	chr2:24149416	ATAD2B	0.52	8.0	0.3	5.99e-15	Lymphocyte counts;
BRCA	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg15934090	chr1:100435551	SLC35A3	0.36	8.43	0.32	2.38e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg12193833	chr17:30244370	NA	-0.54	-8.72	-0.33	2.35e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-17.25	-0.56	4.72e-55	Colorectal cancer;
BRCA	cis	rs10845606	1.000	rs10845606	chr12:12834894	G/T	cg04607235	chr12:12878440	APOLD1	-0.66	-10.54	-0.38	4.76e-24	Systemic lupus erythematosus;
BRCA	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg02659138	chr7:134003124	SLC35B4	0.31	9.56	0.35	2.49e-20	Mean platelet volume;
BRCA	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg08999081	chr20:33150536	PIGU	0.5	14.19	0.49	6.64e-40	Coronary artery disease;
BRCA	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg04455712	chr21:45112962	RRP1B	0.4	10.7	0.39	1.05e-24	Mean corpuscular volume;
BRCA	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg02493740	chr2:85810744	VAMP5	-0.51	-10.48	-0.38	7.97e-24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18876405	chr7:65276391	NA	0.56	13.5	0.47	1.02e-36	Aortic root size;
BRCA	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.64	-0.32	4.39e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs8005677	0.611	rs11624528	chr14:23459156	A/G	cg01529538	chr14:23388837	RBM23	0.37	9.03	0.34	1.99e-18	Cognitive ability (multi-trait analysis);
BRCA	cis	rs4409675	0.576	rs6703851	chr1:28237556	G/A	cg23691781	chr1:28212827	C1orf38	0.31	9.92	0.37	1.12e-21	Corneal astigmatism;
BRCA	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg03934865	chr2:198174659	NA	-0.39	-8.4	-0.32	2.96e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg09307838	chr4:120376055	NA	0.59	12.85	0.45	8.72e-34	Corneal astigmatism;
BRCA	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg22920501	chr2:26401640	FAM59B	-0.72	-12.4	-0.44	8.2e-32	Gut microbiome composition (summer);
BRCA	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg04727924	chr7:799746	HEATR2	-0.51	-8.86	-0.33	7.84e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg10523679	chr1:76189770	ACADM	-0.49	-9.58	-0.35	2.09e-20	Daytime sleep phenotypes;
BRCA	cis	rs1018836	0.884	rs7008765	chr8:91632589	C/T	cg16814680	chr8:91681699	NA	-0.61	-12.96	-0.46	2.82e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.39	9.42	0.35	7.89e-20	Alzheimer's disease (late onset);
BRCA	cis	rs999943	0.846	rs10947422	chr6:33611351	G/A	cg14003231	chr6:33640908	ITPR3	0.62	14.08	0.49	2.06e-39	Obesity (extreme);
BRCA	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg13010199	chr12:38710504	ALG10B	0.56	12.33	0.44	1.71e-31	Heart rate;
BRCA	cis	rs7520050	0.966	rs4134386	chr1:46395089	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.8	0.36	3.19e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg25427524	chr10:38739819	LOC399744	0.7	15.63	0.53	7.03e-47	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6546550	0.901	rs34586537	chr2:70163316	G/T	cg02498382	chr2:70120550	SNRNP27	0.52	11.18	0.4	1.21e-26	Prevalent atrial fibrillation;
BRCA	cis	rs666930	0.519	rs662602	chr1:120266903	C/G	cg19096424	chr1:120255104	PHGDH	0.63	13.7	0.48	1.16e-37	Breast cancer;
BRCA	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg26248373	chr2:1572462	NA	-0.54	-10.6	-0.39	2.6e-24	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg05347473	chr6:146136440	FBXO30	0.4	8.28	0.31	7.34e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7394190	0.748	rs11000766	chr10:75512952	C/T	cg07699608	chr10:75541558	CHCHD1	0.66	9.85	0.36	2.01e-21	Incident atrial fibrillation;
BRCA	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg09904177	chr6:26538194	HMGN4	0.47	14.88	0.51	3.21e-43	Intelligence (multi-trait analysis);
BRCA	cis	rs73086581	1.000	rs6107391	chr20:3983083	A/G	cg02187196	chr20:3869020	PANK2	0.5	9.1	0.34	1.11e-18	Response to antidepressants in depression;
BRCA	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.7	-11.51	-0.41	5.66e-28	Red cell distribution width;
BRCA	cis	rs2274273	0.840	rs66486619	chr14:55869555	T/G	cg04306507	chr14:55594613	LGALS3	0.31	8.65	0.32	4e-17	Protein biomarker;
BRCA	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.61	0.32	5.6e-17	Rheumatoid arthritis;
BRCA	cis	rs12348691	0.503	rs907576	chr9:100615359	C/T	cg13688889	chr9:100608707	NA	-0.49	-9.9	-0.36	1.32e-21	Alopecia areata;
BRCA	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	11.08	0.4	3.27e-26	Bipolar disorder;
BRCA	cis	rs9420	0.961	rs527528	chr11:57433327	C/T	cg19752551	chr11:57585705	CTNND1	-0.41	-10.51	-0.38	6.25e-24	Schizophrenia;
BRCA	cis	rs3772130	0.540	rs11717089	chr3:121563271	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	14.39	0.49	7.2e-41	Cognitive performance;
BRCA	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg23711669	chr6:146136114	FBXO30	0.64	15.12	0.51	2.12e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.01	0.34	2.27e-18	Motion sickness;
BRCA	cis	rs72634258	0.945	rs12745223	chr1:8094978	C/T	cg00042356	chr1:8021962	PARK7	0.77	11.81	0.42	2.89e-29	Inflammatory bowel disease;
BRCA	cis	rs9469890	0.604	rs11758471	chr6:34503517	A/C	cg14254433	chr6:34482411	PACSIN1	-0.44	-9.07	-0.34	1.44e-18	Pubertal anthropometrics;Coronary artery disease;
BRCA	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-9.38	-0.35	1.09e-19	Menopause (age at onset);
BRCA	cis	rs9341808	0.754	rs9343973	chr6:80913216	A/G	cg08355045	chr6:80787529	NA	0.39	9.95	0.37	8.62e-22	Sitting height ratio;
BRCA	cis	rs6121246	0.609	rs6060948	chr20:30376393	C/G	cg13852791	chr20:30311386	BCL2L1	0.84	18.15	0.58	1.15e-59	Mean corpuscular hemoglobin;
BRCA	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-9.11	-0.34	1.06e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg03060546	chr3:49711283	APEH	-0.54	-10.99	-0.4	7.38e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.92	-0.3	1.02e-14	Corneal astigmatism;
BRCA	cis	rs9649465	1.000	rs13225220	chr7:123371026	C/A	cg04330084	chr7:123175371	IQUB	-0.33	-8.98	-0.33	2.94e-18	Migraine;
BRCA	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-8.73	-0.33	2.24e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs870825	0.616	rs12512839	chr4:185610347	G/A	cg20176042	chr4:185552304	CASP3	-0.54	-8.18	-0.31	1.57e-15	Blood protein levels;
BRCA	trans	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg26384229	chr12:38710491	ALG10B	0.44	10.54	0.38	4.79e-24	Morning vs. evening chronotype;
BRCA	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg24130564	chr14:104152367	KLC1	-0.34	-7.92	-0.3	1.09e-14	Body mass index;
BRCA	cis	rs55883249	1.000	rs56372340	chr2:9741536	A/G	cg23886495	chr2:9695866	ADAM17	0.55	7.95	0.3	8.63e-15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
BRCA	cis	rs7523273	0.606	rs2488253	chr1:207938709	C/A	cg22525895	chr1:207977042	MIR29B2	0.48	12.16	0.43	9.54e-31	Schizophrenia;
BRCA	trans	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.16	0.31	1.73e-15	Corneal astigmatism;
BRCA	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	13.93	0.48	1.08e-38	Motion sickness;
BRCA	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg21854759	chr1:92012499	NA	-0.39	-9.36	-0.35	1.3e-19	Breast cancer;
BRCA	cis	rs11677370	0.561	rs12711973	chr2:3825339	C/G	cg17052675	chr2:3827356	NA	-0.61	-15.78	-0.53	1.31e-47	Type 2 diabetes;
BRCA	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg01324343	chr3:183735012	ABCC5	0.63	14.92	0.51	2e-43	Anterior chamber depth;
BRCA	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg15556689	chr8:8085844	FLJ10661	-0.36	-9.51	-0.35	3.95e-20	Triglycerides;
BRCA	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.57	12.78	0.45	1.81e-33	Eosinophil percentage of white cells;
BRCA	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-12.3	-0.44	2.39e-31	Personality dimensions;
BRCA	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.51	8.42	0.32	2.57e-16	Renal function-related traits (BUN);
BRCA	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg15556689	chr8:8085844	FLJ10661	0.36	9.92	0.37	1.11e-21	Mood instability;
BRCA	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-14.52	-0.5	1.73e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-11.75	-0.42	5.12e-29	Mood instability;
BRCA	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg06671706	chr8:8559999	CLDN23	-0.43	-8.28	-0.31	7.08e-16	Obesity-related traits;
BRCA	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg23711669	chr6:146136114	FBXO30	0.72	16.44	0.55	6.45e-51	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg26043149	chr18:55253948	FECH	0.42	9.14	0.34	8.24e-19	Bone mineral density;
BRCA	trans	rs9944715	0.954	rs62096526	chr18:43745639	G/A	cg01718231	chr17:29326311	RNF135	0.45	8.88	0.33	6.98e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs600806	0.888	rs3853501	chr1:109864374	G/A	cg20591472	chr1:110008990	SYPL2	0.32	8.12	0.31	2.5e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg17971929	chr21:40555470	PSMG1	0.82	19.79	0.62	2.45e-68	Cognitive function;
BRCA	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg03929089	chr4:120376271	NA	-0.53	-8.81	-0.33	1.21e-17	Axial length;
BRCA	cis	rs1468333	1.000	rs7729926	chr5:137514641	A/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.44	9.31	0.35	1.96e-19	Resting heart rate;
BRCA	trans	rs7178375	1.000	rs10163148	chr15:31212684	C/G	cg04373760	chr16:53404718	NA	0.46	8.7	0.33	2.77e-17	Hypertriglyceridemia;
BRCA	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg03954927	chr1:10346856	KIF1B	0.47	14.99	0.51	1e-43	Hepatocellular carcinoma;
BRCA	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg12756686	chr19:29218302	NA	0.46	8.09	0.3	3.07e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg25206134	chr2:45395956	NA	0.54	8.75	0.33	1.87e-17	Bipolar disorder;
BRCA	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg00105475	chr2:10696890	NA	0.41	9.53	0.35	3.17e-20	Prostate cancer;
BRCA	trans	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.53	-0.32	1.1e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.33	-0.31	5.11e-16	Bipolar disorder;
BRCA	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg22907277	chr7:1156413	C7orf50	0.44	10.08	0.37	2.94e-22	Longevity;Endometriosis;
BRCA	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.34	-0.38	2.73e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6942756	0.668	rs644723	chr7:129107881	C/T	cg02491457	chr7:128862824	NA	-0.56	-11.38	-0.41	1.9e-27	White matter hyperintensity burden;
BRCA	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg08470875	chr2:26401718	FAM59B	-0.66	-9.77	-0.36	4.27e-21	Gut microbiome composition (summer);
BRCA	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19723775	chr5:179050963	HNRNPH1	0.36	8.73	0.33	2.19e-17	Lung cancer;
BRCA	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00802000	chr16:706648	WDR90	-0.4	-9.36	-0.35	1.32e-19	Height;
BRCA	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg11279151	chr3:101281821	RG9MTD1	-0.49	-10.63	-0.39	2.15e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17712092	chr4:129076599	LARP1B	0.54	13.22	0.46	1.83e-35	Eosinophil percentage of white cells;
BRCA	cis	rs10504073	0.647	rs10435612	chr8:49993696	A/T	cg00325661	chr8:49890786	NA	0.44	12.51	0.44	2.87e-32	Blood metabolite ratios;
BRCA	cis	rs701145	0.585	rs7612886	chr3:153821176	T/A	cg12800244	chr3:153838788	SGEF	0.63	7.87	0.3	1.47e-14	Coronary artery disease;
BRCA	cis	rs13046373	0.505	rs2832934	chr21:31899760	A/G	cg06468780	chr21:31798236	KRTAP13-3	0.39	9.53	0.35	3.15e-20	HDL cholesterol;
BRCA	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.74	17.63	0.57	5.68e-57	Chronic sinus infection;
BRCA	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg25036284	chr2:26402008	FAM59B	-0.88	-15.93	-0.53	2.26e-48	Gut microbiome composition (summer);
BRCA	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg11168104	chr5:1857477	NA	-0.35	-9.34	-0.35	1.5700000000000001e-19	Cardiovascular disease risk factors;
BRCA	cis	rs1691799	0.867	rs1168342	chr12:66758734	A/T	cg16791601	chr12:66731901	HELB	-0.66	-18.01	-0.58	6.07e-59	White blood cell count (basophil);
BRCA	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg18512352	chr11:47633146	NA	0.32	7.93	0.3	1e-14	Subjective well-being;
BRCA	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.43	-9.6	-0.36	1.76e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg09035930	chr12:129282057	SLC15A4	0.5	14.0	0.48	5e-39	Systemic lupus erythematosus;
BRCA	cis	rs12618769	0.625	rs56232707	chr2:99032298	G/A	cg10123293	chr2:99228465	UNC50	0.4	7.97	0.3	7.08e-15	Bipolar disorder;
BRCA	cis	rs6545883	0.831	rs9309336	chr2:61763165	T/C	cg15711740	chr2:61764176	XPO1	-0.55	-14.15	-0.49	9.2e-40	Tuberculosis;
BRCA	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg06115741	chr20:33292138	TP53INP2	0.36	8.13	0.31	2.23e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.01	0.34	2.33e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg25214090	chr10:38739885	LOC399744	0.44	10.23	0.38	7.5e-23	Corneal astigmatism;
BRCA	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14019695	chr9:139328340	INPP5E	-0.41	-11.25	-0.41	6.75e-27	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg04691961	chr3:161091175	C3orf57	-0.37	-8.01	-0.3	5.35e-15	Morning vs. evening chronotype;
BRCA	cis	rs7707921	0.881	rs324914	chr5:81389950	C/T	cg15871215	chr5:81402204	ATG10	0.38	7.98	0.3	6.6e-15	Breast cancer;
BRCA	cis	rs7520050	0.966	rs11810993	chr1:46478793	A/G	cg24296786	chr1:45957014	TESK2	0.44	9.84	0.36	2.35e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2882667	0.690	rs11749163	chr5:138262670	A/G	cg04439458	chr5:138467593	SIL1	-0.32	-8.02	-0.3	4.96e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs16944613	0.541	rs6496690	chr15:91097401	T/C	cg26821196	chr15:91095069	CRTC3	0.47	8.12	0.31	2.46e-15	Colorectal cancer;
BRCA	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg19418458	chr7:158789849	NA	-0.42	-9.41	-0.35	8.77e-20	Facial morphology (factor 20);
BRCA	cis	rs2710642	0.888	rs2539985	chr2:63134507	T/A	cg17519650	chr2:63277830	OTX1	0.36	7.97	0.3	7.51e-15	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs13427251	0.692	rs17765112	chr2:100149336	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.34	-7.85	-0.3	1.7e-14	Chronic sinus infection;
BRCA	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-9.54	-0.35	2.88e-20	Height;
BRCA	cis	rs4787491	0.704	rs67218159	chr16:30050505	C/T	cg06326092	chr16:30034487	C16orf92	0.38	9.92	0.37	1.16e-21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg24558204	chr6:135376177	HBS1L	0.46	12.41	0.44	7.89e-32	Red blood cell count;
BRCA	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg20503657	chr10:835505	NA	1.04	17.39	0.57	9.44e-56	Eosinophil percentage of granulocytes;
BRCA	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Tonsillectomy;
BRCA	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg24531977	chr5:56204891	C5orf35	-0.42	-8.5	-0.32	1.35e-16	Coronary artery disease;
BRCA	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	12.05	0.43	2.77e-30	Monocyte percentage of white cells;
BRCA	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-16.76	-0.55	1.52e-52	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg26395211	chr5:140044315	WDR55	0.37	8.48	0.32	1.58e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs654950	0.783	rs639298	chr1:42001530	A/G	cg06885757	chr1:42089581	HIVEP3	-0.24	-8.8	-0.33	1.23e-17	Airway imaging phenotypes;
BRCA	cis	rs3750965	0.959	rs3376	chr11:68856680	G/A	cg06818126	chr11:68850279	TPCN2	-0.36	-8.41	-0.32	2.65e-16	Hair color;
BRCA	cis	rs2625529	0.818	rs2246225	chr15:72115230	C/T	cg16672083	chr15:72433130	SENP8	0.71	14.79	0.5	9.16e-43	Red blood cell count;
BRCA	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg08807101	chr21:30365312	RNF160	0.74	19.35	0.61	5.06e-66	Dental caries;
BRCA	cis	rs9649465	1.000	rs2109725	chr7:123325459	C/T	cg04330084	chr7:123175371	IQUB	-0.3	-8.38	-0.31	3.26e-16	Migraine;
BRCA	cis	rs1555322	0.530	rs2425047	chr20:33871675	G/T	cg03689076	chr20:33865952	NA	-0.43	-8.03	-0.3	4.63e-15	Attention deficit hyperactivity disorder;
BRCA	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg00383909	chr3:49044727	WDR6	0.5	9.67	0.36	9.49e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg10223061	chr2:219282414	VIL1	-0.27	-8.1	-0.31	2.77e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg00684032	chr4:1343700	KIAA1530	0.31	7.97	0.3	7.36e-15	Obesity-related traits;
BRCA	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg11764359	chr7:65958608	NA	-0.68	-15.19	-0.52	9.94e-45	Aortic root size;
BRCA	cis	rs2073300	1.000	rs79255223	chr20:23443559	G/T	cg12062639	chr20:23401060	NAPB	0.88	10.43	0.38	1.28e-23	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs4561483	0.734	rs33655	chr16:11970381	C/T	cg08843971	chr16:11963173	GSPT1	-0.53	-11.97	-0.43	5.94e-30	Testicular germ cell tumor;
BRCA	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg00666640	chr1:248458726	OR2T12	0.32	8.83	0.33	9.7e-18	Common traits (Other);
BRCA	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg15017067	chr4:17643749	FAM184B	0.28	8.53	0.32	1.04e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10838687	0.736	rs830083	chr11:47254051	G/C	cg25783544	chr11:47291846	MADD	-0.41	-7.89	-0.3	1.36e-14	Proinsulin levels;
BRCA	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.69	-15.54	-0.52	1.99e-46	Axial length;
BRCA	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	11.84	0.42	2.28e-29	Height;
BRCA	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.18	-0.49	7.04e-40	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08564027	chr20:61660810	NA	0.85	22.56	0.67	2.3e-83	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-9.23	-0.34	3.8e-19	Tonsillectomy;
BRCA	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg13010199	chr12:38710504	ALG10B	0.47	9.18	0.34	5.96e-19	Morning vs. evening chronotype;
BRCA	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg17691542	chr6:26056736	HIST1H1C	0.48	9.55	0.35	2.75e-20	Iron status biomarkers;
BRCA	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg04362960	chr10:104952993	NT5C2	0.44	10.8	0.39	4.26e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22307029	chr19:49891270	CCDC155	0.6	10.98	0.4	8.1e-26	Multiple sclerosis;
BRCA	cis	rs17092148	0.887	rs932542	chr20:33171368	G/C	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.28	-0.38	5e-23	Neuroticism;
BRCA	cis	rs4074536	0.574	rs10754347	chr1:116286818	C/A	cg21648376	chr1:116311395	CASQ2	-0.49	-8.51	-0.32	1.27e-16	QRS duration;
BRCA	cis	rs10782582	0.609	rs5745553	chr1:76379135	A/T	cg03433033	chr1:76189801	ACADM	-0.38	-7.92	-0.3	1.05e-14	Daytime sleep phenotypes;
BRCA	trans	rs629535	0.679	rs62511660	chr8:70157089	G/A	cg21567404	chr3:27674614	NA	-0.96	-17.52	-0.57	2.09e-56	Dupuytren's disease;
BRCA	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg06453172	chr10:134556979	INPP5A	-0.5	-10.75	-0.39	7.16e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9359856	0.564	rs34732313	chr6:90368380	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.64	-8.54	-0.32	9.91e-17	Bipolar disorder;
BRCA	cis	rs4588572	0.644	rs1428864	chr5:77780263	C/T	cg11547950	chr5:77652471	NA	-0.45	-8.64	-0.32	4.64e-17	Triglycerides;
BRCA	cis	rs4642101	0.561	rs7638333	chr3:12806142	T/C	cg24848339	chr3:12840334	CAND2	0.38	9.38	0.35	1.09e-19	QRS complex (12-leadsum);
BRCA	cis	rs9811920	0.535	rs793481	chr3:99488742	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-9.86	-0.36	1.97e-21	Axial length;
BRCA	cis	rs17818399	0.620	rs6739397	chr2:46858321	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.42	8.37	0.31	3.57e-16	Height;
BRCA	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-11.85	-0.42	2e-29	Tonsillectomy;
BRCA	cis	rs2455799	0.573	rs2455793	chr3:15743844	A/G	cg16303742	chr3:15540471	COLQ	-0.36	-8.68	-0.32	3.36e-17	Mean platelet volume;
BRCA	cis	rs4363385	0.720	rs6672735	chr1:152981086	A/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.83	-0.36	2.47e-21	Inflammatory skin disease;
BRCA	cis	rs7246657	0.653	rs10401525	chr19:37658979	C/G	cg23950597	chr19:37808831	NA	-0.64	-9.79	-0.36	3.55e-21	Coronary artery calcification;
BRCA	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	11.14	0.4	1.9e-26	IgG glycosylation;
BRCA	cis	rs13082711	0.871	rs35572617	chr3:27499247	A/T	cg02860705	chr3:27208620	NA	0.59	11.08	0.4	3.26e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs6545883	0.894	rs2593633	chr2:61571513	T/C	cg15711740	chr2:61764176	XPO1	0.53	13.48	0.47	1.25e-36	Tuberculosis;
BRCA	cis	rs943466	1.000	rs6930201	chr6:33738749	A/C	cg25922239	chr6:33757077	LEMD2	-0.38	-8.38	-0.31	3.31e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg04607235	chr12:12878440	APOLD1	-0.65	-10.33	-0.38	3.05e-23	Systemic lupus erythematosus;
BRCA	cis	rs760805	1.000	rs7517302	chr1:25254317	C/T	cg22509179	chr1:25234806	RUNX3	-0.58	-14.81	-0.51	7.17e-43	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs9942416	0.592	rs10462521	chr5:74985867	T/C	cg19683494	chr5:74908142	NA	0.48	9.0	0.34	2.58e-18	Age-related disease endophenotypes;
BRCA	cis	rs9473147	0.516	rs9349415	chr6:47551861	T/C	cg12968598	chr6:47444699	CD2AP	0.44	9.59	0.35	1.92e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg14983838	chr19:29218262	NA	-0.46	-7.81	-0.3	2.32e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg24110177	chr3:50126178	RBM5	0.52	14.7	0.5	2.43e-42	Body mass index;
BRCA	cis	rs4478858	0.735	rs6687819	chr1:31801112	G/A	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	trans	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg25214090	chr10:38739885	LOC399744	0.54	12.24	0.44	4.06e-31	Corneal astigmatism;
BRCA	cis	rs2882667	0.690	rs10155636	chr5:138261990	A/G	cg04439458	chr5:138467593	SIL1	-0.34	-8.22	-0.31	1.1e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg19077165	chr18:44547161	KATNAL2	0.39	8.45	0.32	1.95e-16	Personality dimensions;
BRCA	cis	rs6987853	0.761	rs2974356	chr8:42434633	C/T	cg09913449	chr8:42400586	C8orf40	0.42	9.29	0.35	2.33e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg23711669	chr6:146136114	FBXO30	0.79	18.81	0.6	3.83e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg01579765	chr21:45077557	HSF2BP	0.41	10.71	0.39	1.02e-24	Mean corpuscular volume;
BRCA	cis	rs17253792	0.822	rs78522049	chr14:56071203	A/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.6	8.13	0.31	2.23e-15	Putamen volume;
BRCA	cis	rs17253792	0.822	rs79873916	chr14:56172631	G/C	cg01858014	chr14:56050164	KTN1	-0.74	-9.27	-0.34	2.85e-19	Putamen volume;
BRCA	cis	rs703842	0.532	rs238516	chr12:58117355	T/C	cg18357645	chr12:58087776	OS9	0.37	10.28	0.38	4.74e-23	Multiple sclerosis;
BRCA	cis	rs11229555	0.874	rs11229519	chr11:58310587	C/T	cg15696309	chr11:58395628	NA	-0.53	-11.54	-0.42	4.18e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.55	0.39	4.3e-24	Motion sickness;
BRCA	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00149659	chr3:10157352	C3orf10	0.79	13.61	0.47	3.02e-37	Alzheimer's disease;
BRCA	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg10932868	chr11:921992	NA	0.49	12.4	0.44	8.43e-32	Alzheimer's disease (late onset);
BRCA	trans	rs208520	0.690	rs866452	chr6:66849936	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-21.31	-0.64	1.63e-76	Exhaled nitric oxide output;
BRCA	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.55	8.27	0.31	7.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-8.55	-0.32	9.43e-17	Response to bleomycin (chromatid breaks);
BRCA	cis	rs6598955	0.543	rs12122527	chr1:26549748	C/T	cg12744634	chr1:26560303	CCDC21	0.3	8.18	0.31	1.49e-15	Obesity-related traits;
BRCA	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-7.84	-0.3	1.85e-14	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9807989	0.507	rs7584093	chr2:102997721	C/T	cg03938978	chr2:103052716	IL18RAP	0.29	8.36	0.31	4.03e-16	Asthma;
BRCA	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg16339924	chr4:17578868	LAP3	0.62	15.42	0.52	7.48e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs17253792	0.822	rs28831725	chr14:56087569	C/T	cg01858014	chr14:56050164	KTN1	-0.76	-10.26	-0.38	5.65e-23	Putamen volume;
BRCA	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg05791153	chr7:19748676	TWISTNB	0.53	10.24	0.38	7.06e-23	Thyroid stimulating hormone;
BRCA	cis	rs7617773	0.780	rs35297486	chr3:48378147	T/A	cg11946769	chr3:48343235	NME6	0.67	13.37	0.47	3.99e-36	Coronary artery disease;
BRCA	cis	rs9790314	0.602	rs4679926	chr3:160677240	A/T	cg03342759	chr3:160939853	NMD3	0.46	8.87	0.33	7.57e-18	Morning vs. evening chronotype;
BRCA	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	10.6	0.39	2.66e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg03342759	chr3:160939853	NMD3	-0.8	-18.96	-0.6	5.94e-64	Parkinson's disease;
BRCA	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg15839431	chr19:19639596	YJEFN3	-0.4	-8.66	-0.32	3.9e-17	Bipolar disorder;
BRCA	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.45	-0.66	9.76e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg04450456	chr4:17643702	FAM184B	-0.34	-9.83	-0.36	2.41e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg08085267	chr17:45401833	C17orf57	-0.69	-15.23	-0.52	6.86e-45	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg16482183	chr6:26056742	HIST1H1C	0.41	8.27	0.31	7.69e-16	Iron status biomarkers;
BRCA	cis	rs9807989	0.507	rs10208196	chr2:102996345	G/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.41	0.32	2.59e-16	Asthma;
BRCA	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg02734326	chr4:10020555	SLC2A9	0.39	8.54	0.32	9.51e-17	Bone mineral density;
BRCA	cis	rs3772130	0.962	rs9883467	chr3:121517833	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.85	0.39	2.68e-25	Cognitive performance;
BRCA	trans	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-8.49	-0.32	1.4e-16	Menarche (age at onset);
BRCA	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.84	-0.36	2.22e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs9296092	0.538	rs35381461	chr6:33519751	T/C	cg13560919	chr6:33536144	NA	-0.85	-18.66	-0.59	2.26e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18876405	chr7:65276391	NA	-0.5	-10.98	-0.4	8.51e-26	Aortic root size;
BRCA	cis	rs61160187	0.510	rs4577661	chr5:60040467	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.33	-7.87	-0.3	1.56e-14	Educational attainment (years of education);Educational attainment (college completion);
BRCA	cis	rs4845875	0.602	rs4846043	chr1:11839966	G/A	cg24844545	chr1:11908347	NPPA	0.32	8.14	0.31	2.12e-15	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs7254114	0.645	rs61045132	chr19:11303068	C/T	cg02815516	chr19:11306319	KANK2	-0.33	-8.56	-0.32	8.42e-17	Immature fraction of reticulocytes;
BRCA	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00149659	chr3:10157352	C3orf10	0.79	13.66	0.48	1.77e-37	Alzheimer's disease;
BRCA	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg22467129	chr15:76604101	ETFA	-0.48	-10.35	-0.38	2.62e-23	Blood metabolite levels;
BRCA	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg09658497	chr7:2847517	GNA12	-0.41	-7.84	-0.3	1.87e-14	Height;
BRCA	cis	rs9560113	1.000	rs4773387	chr13:112180955	T/C	cg10483660	chr13:112241077	NA	0.32	7.98	0.3	6.88e-15	Menarche (age at onset);
BRCA	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.03	0.3	4.61e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	0.38	8.03	0.3	4.56e-15	Longevity;Endometriosis;
BRCA	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg11502198	chr6:26597334	ABT1	0.47	9.48	0.35	4.73e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg04586622	chr2:25135609	ADCY3	0.4	9.63	0.36	1.33e-20	Body mass index in non-asthmatics;
BRCA	trans	rs2980436	1	rs2980436	chr8:8092025	A/G	cg16141378	chr3:129829833	LOC729375	0.43	10.31	0.38	3.81e-23	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.11	0.49	1.43e-39	Motion sickness;
BRCA	cis	rs13136331	0.500	rs1462371	chr4:88576655	T/C	cg22416721	chr4:88570574	DMP1	-0.59	-14.33	-0.49	1.43e-40	Sitting height ratio;
BRCA	cis	rs220324	0.688	rs56184115	chr21:43560554	G/T	cg09727148	chr21:43560719	UMODL1	0.5	8.9	0.33	5.53e-18	Idiopathic osteonecrosis of the femoral head;
BRCA	cis	rs509477	1.000	rs11660848	chr18:32574010	T/C	cg00449728	chr18:32561817	MAPRE2	-0.35	-8.06	-0.3	3.72e-15	Cerebrospinal fluid AB1-42 levels;
BRCA	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs7178424	0.967	rs10468026	chr15:62343850	C/T	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.07	-0.3	3.61e-15	Height;
BRCA	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg17420585	chr12:42539391	GXYLT1	-0.39	-8.14	-0.31	2.05e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.85	0.45	8.83e-34	Bipolar disorder;
BRCA	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-11.51	-0.41	5.58e-28	Extrinsic epigenetic age acceleration;
BRCA	trans	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg13565492	chr6:43139072	SRF	-0.84	-13.17	-0.46	3.33e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg10932868	chr11:921992	NA	0.49	12.51	0.44	2.84e-32	Alzheimer's disease (late onset);
BRCA	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg08601574	chr20:25228251	PYGB	-0.38	-9.01	-0.34	2.4e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg06784218	chr1:46089804	CCDC17	0.45	10.79	0.39	4.55e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1788820	0.917	rs1788785	chr18:21142340	T/C	cg14672496	chr18:21087552	C18orf8	0.34	8.19	0.31	1.43e-15	Body mass index;
BRCA	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.24	0.34	3.64e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.17	-0.31	1.62e-15	Gut microbiome composition (summer);
BRCA	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg24642439	chr20:33292090	TP53INP2	0.41	8.13	0.31	2.17e-15	Height;
BRCA	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg12072164	chr19:44306565	LYPD5	0.36	8.7	0.33	2.75e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	12.77	0.45	1.99e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10802521	chr3:52805072	NEK4	-0.33	-8.48	-0.32	1.61e-16	Bipolar disorder;
BRCA	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23978390	chr7:1156363	C7orf50	0.38	9.21	0.34	4.45e-19	Longevity;Endometriosis;
BRCA	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg26384229	chr12:38710491	ALG10B	0.75	17.0	0.56	9.05e-54	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	14.55	0.5	1.26e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg13010199	chr12:38710504	ALG10B	0.53	10.82	0.39	3.59e-25	Heart rate;
BRCA	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.75	0.62	3.7e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg26528668	chr16:1614120	IFT140	0.39	9.0	0.34	2.47e-18	Coronary artery disease;
BRCA	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.07	-0.3	3.48e-15	Prostate cancer;
BRCA	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg00105475	chr2:10696890	NA	0.44	10.37	0.38	2.16e-23	Prostate cancer;
BRCA	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg12311346	chr5:56204834	C5orf35	-0.62	-13.03	-0.46	1.37e-34	Initial pursuit acceleration;
BRCA	cis	rs12950390	0.512	rs11651000	chr17:45835278	G/A	cg03474202	chr17:45855739	NA	-0.43	-7.83	-0.3	2.06e-14	IgG glycosylation;
BRCA	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg15556689	chr8:8085844	FLJ10661	0.37	9.6	0.36	1.82e-20	Neuroticism;
BRCA	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg05457628	chr5:178986728	RUFY1	0.58	14.36	0.49	1.02e-40	Lung cancer;
BRCA	cis	rs965469	0.671	rs6139076	chr20:3305210	T/C	cg25506879	chr20:3388711	C20orf194	-0.44	-8.86	-0.33	7.91e-18	IFN-related cytopenia;
BRCA	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg11645453	chr3:52864694	ITIH4	0.38	9.17	0.34	6.34e-19	Schizophrenia;
BRCA	trans	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	7.99e-21	Bladder cancer;
BRCA	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg10932868	chr11:921992	NA	0.48	12.2	0.43	6.15e-31	Alzheimer's disease (late onset);
BRCA	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg26031613	chr14:104095156	KLC1	0.73	15.83	0.53	7.18e-48	Body mass index;
BRCA	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg08859206	chr1:53392774	SCP2	-0.52	-11.18	-0.4	1.31e-26	Monocyte count;
BRCA	cis	rs10779751	0.770	rs11585553	chr1:11233814	G/A	cg08854313	chr1:11322531	MTOR	-0.83	-14.89	-0.51	2.83e-43	Body mass index;
BRCA	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg22705602	chr4:152727874	NA	-0.32	-8.18	-0.31	1.57e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg08888203	chr3:10149979	C3orf24	-0.65	-12.0	-0.43	4.53e-30	Alzheimer's disease;
BRCA	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg24812749	chr6:127587940	RNF146	0.88	20.63	0.63	7.68e-73	Breast cancer;
BRCA	cis	rs16910800	0.731	rs55908012	chr11:23191640	G/A	cg20040320	chr11:23191996	NA	-0.59	-10.23	-0.38	7.61e-23	Cancer;
BRCA	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg03433033	chr1:76189801	ACADM	0.7	13.81	0.48	3.94e-38	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2652834	1.000	rs2729784	chr15:63402735	T/C	cg05507819	chr15:63340323	TPM1	0.45	8.32	0.31	5.39e-16	HDL cholesterol;
BRCA	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg21138405	chr5:131827807	IRF1	0.39	12.9	0.45	5.51e-34	Asthma (sex interaction);
BRCA	cis	rs7737355	1.000	rs2551036	chr5:130648994	G/A	cg06307176	chr5:131281290	NA	0.45	8.81	0.33	1.15e-17	Life satisfaction;
BRCA	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg04455712	chr21:45112962	RRP1B	0.35	8.77	0.33	1.64e-17	Mean corpuscular volume;
BRCA	cis	rs7737355	0.947	rs2215190	chr5:130921666	C/T	cg06307176	chr5:131281290	NA	0.53	10.47	0.38	8.93e-24	Life satisfaction;
BRCA	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg13385794	chr1:248469461	NA	0.29	7.87	0.3	1.48e-14	Common traits (Other);
BRCA	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05901451	chr6:126070800	HEY2	-0.7	-20.37	-0.63	1.75e-71	Brugada syndrome;
BRCA	cis	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg06521331	chr12:34319734	NA	0.49	9.08	0.34	1.31e-18	Morning vs. evening chronotype;
BRCA	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.57	10.73	0.39	8.21e-25	Birth weight;
BRCA	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg18806716	chr10:30721971	MAP3K8	-0.6	-13.97	-0.48	6.51e-39	Inflammatory bowel disease;
BRCA	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg27446573	chr6:127587934	RNF146	0.68	15.5	0.52	3.24e-46	Breast cancer;
BRCA	cis	rs9807989	0.507	rs1420094	chr2:103015687	C/T	cg03938978	chr2:103052716	IL18RAP	0.29	8.49	0.32	1.46e-16	Asthma;
BRCA	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.46e-34	Alzheimer's disease (late onset);
BRCA	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11644478	chr21:40555479	PSMG1	-0.67	-15.12	-0.51	2.35e-44	Cognitive function;
BRCA	cis	rs7523273	0.606	rs2488255	chr1:207941741	C/T	cg22525895	chr1:207977042	MIR29B2	0.47	11.89	0.43	1.42e-29	Schizophrenia;
BRCA	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg05340658	chr4:99064831	C4orf37	0.56	11.03	0.4	5.06e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg24324837	chr19:49891574	CCDC155	0.53	9.67	0.36	9.98e-21	Multiple sclerosis;
BRCA	cis	rs644148	0.836	rs2686777	chr19:45000386	T/C	cg15540054	chr19:45004280	ZNF180	-0.57	-12.29	-0.44	2.67e-31	Personality dimensions;
BRCA	cis	rs4845875	0.559	rs4846047	chr1:11843632	C/G	cg24844545	chr1:11908347	NPPA	0.36	8.59	0.32	6.75e-17	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg16414030	chr3:133502952	NA	-0.4	-8.88	-0.33	6.61e-18	Iron status biomarkers;
BRCA	cis	rs208520	0.609	rs208436	chr6:66897470	G/A	cg07460842	chr6:66804631	NA	-0.6	-11.09	-0.4	2.89e-26	Exhaled nitric oxide output;
BRCA	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg04727924	chr7:799746	HEATR2	-0.53	-9.88	-0.36	1.63e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg08885076	chr2:99613938	TSGA10	-0.6	-13.45	-0.47	1.67e-36	Chronic sinus infection;
BRCA	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg00106254	chr7:1943704	MAD1L1	-0.37	-9.78	-0.36	3.74e-21	Schizophrenia;
BRCA	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg26408565	chr15:76604113	ETFA	-0.47	-10.0	-0.37	5.73e-22	Blood metabolite levels;
BRCA	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg01324343	chr3:183735012	ABCC5	0.83	20.96	0.64	1.25e-74	Anterior chamber depth;
BRCA	cis	rs1371614	0.611	rs4665922	chr2:27133934	G/T	cg12368169	chr2:27073192	DPYSL5	-0.29	-8.63	-0.32	4.84e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg18279126	chr7:2041391	MAD1L1	0.37	8.09	0.3	2.95e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08048268	chr3:133502702	NA	-0.41	-10.38	-0.38	1.94e-23	Iron status biomarkers;
BRCA	cis	rs600806	0.821	rs3879451	chr1:109909269	C/T	cg20591472	chr1:110008990	SYPL2	0.32	8.06	0.3	3.71e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg26384229	chr12:38710491	ALG10B	0.7	15.82	0.53	8.5e-48	Morning vs. evening chronotype;
BRCA	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.41	-8.54	-0.32	9.9e-17	Bipolar disorder;
BRCA	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.33	-0.35	1.68e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg11764359	chr7:65958608	NA	0.65	11.69	0.42	9.72e-29	Aortic root size;
BRCA	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg07636037	chr3:49044803	WDR6	0.97	29.03	0.75	8.1e-119	Parkinson's disease;
BRCA	cis	rs7607369	0.536	rs12623007	chr2:219665335	T/C	cg02176678	chr2:219576539	TTLL4	-0.38	-10.1	-0.37	2.41e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs2425143	1.000	rs12479473	chr20:34398628	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.53	-0.32	1.09e-16	Blood protein levels;
BRCA	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.03e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg17143192	chr8:8559678	CLDN23	0.57	11.1	0.4	2.61e-26	Obesity-related traits;
BRCA	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg14186256	chr22:23484241	RTDR1	0.76	22.93	0.67	2.17e-85	Bone mineral density;
BRCA	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.71	-16.21	-0.54	9.25e-50	Axial length;
BRCA	trans	rs3857536	0.704	rs4710570	chr6:66890244	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-9.49	-0.35	4.54e-20	Blood trace element (Cu levels);
BRCA	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg27170947	chr2:26402098	FAM59B	-0.64	-11.42	-0.41	1.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs16958440	0.867	rs75287977	chr18:44686823	G/A	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg00071950	chr4:10020882	SLC2A9	0.51	11.69	0.42	9.18e-29	Bone mineral density;
BRCA	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10802521	chr3:52805072	NEK4	-0.33	-8.65	-0.32	4.15e-17	Bipolar disorder;
BRCA	cis	rs2387326	0.717	rs12254442	chr10:129945793	C/T	cg16087940	chr10:129947807	NA	-0.45	-8.01	-0.3	5.38e-15	Select biomarker traits;
BRCA	cis	rs9341808	0.727	rs10943697	chr6:80931506	A/C	cg08355045	chr6:80787529	NA	0.39	9.98	0.37	6.98e-22	Sitting height ratio;
BRCA	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03264133	chr6:25882463	NA	-0.58	-11.98	-0.43	5.76e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs870825	0.616	rs1401359	chr4:185640216	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	16.91	0.56	2.85e-53	Blood protein levels;
BRCA	cis	rs9467773	0.550	rs9379874	chr6:26440429	A/T	cg09904177	chr6:26538194	HMGN4	-0.37	-9.8	-0.36	3.34e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4953318	0.619	rs10198247	chr2:46362677	C/T	cg12428440	chr2:46370979	PRKCE	-0.48	-10.59	-0.39	3.02e-24	Red blood cell count;Hematocrit;Red blood cell traits;
BRCA	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg25838465	chr1:92012736	NA	0.67	19.12	0.6	8.94e-65	Breast cancer;
BRCA	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg04455712	chr21:45112962	RRP1B	0.44	11.96	0.43	6.83e-30	Mean corpuscular volume;
BRCA	trans	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg26384229	chr12:38710491	ALG10B	0.5	10.79	0.39	4.61e-25	Morning vs. evening chronotype;
BRCA	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg03146154	chr1:46216737	IPP	-0.44	-9.9	-0.36	1.39e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9649213	0.555	rs6955259	chr7:97892356	T/A	cg21770322	chr7:97807741	LMTK2	0.45	11.33	0.41	3.01e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.42	8.73	0.33	2.19e-17	Cognitive ability;
BRCA	cis	rs3824867	0.920	rs7105907	chr11:47450318	A/T	cg20307385	chr11:47447363	PSMC3	-0.49	-10.94	-0.4	1.16e-25	Mean corpuscular hemoglobin;
BRCA	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.76	-0.42	5.03e-29	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12474201	0.963	rs11676737	chr2:46929873	T/C	cg06386533	chr2:46925753	SOCS5	0.87	18.81	0.6	3.9e-63	Height;
BRCA	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg25019033	chr10:957182	NA	-0.42	-8.07	-0.3	3.47e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg26384229	chr12:38710491	ALG10B	0.7	15.94	0.53	1.97e-48	Bladder cancer;
BRCA	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg01877450	chr7:97915802	BRI3	-0.39	-8.61	-0.32	5.49e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg15485101	chr11:133734466	NA	0.4	9.73	0.36	5.69e-21	Childhood ear infection;
BRCA	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg15595755	chr5:1867978	NA	0.34	8.29	0.31	6.9e-16	Cardiovascular disease risk factors;
BRCA	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.03	-0.43	3.42e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.87	-0.3	1.49e-14	Electroencephalogram traits;
BRCA	cis	rs2070997	0.607	rs2855190	chr9:133708361	C/T	cg11464064	chr9:133710261	ABL1	-0.52	-9.44	-0.35	6.63e-20	Response to amphetamines;
BRCA	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg05793240	chr7:2802953	GNA12	-0.32	-8.11	-0.31	2.54e-15	Height;
BRCA	cis	rs8114671	0.967	rs6088753	chr20:33768252	C/T	cg07148914	chr20:33460835	GGT7	0.38	7.99	0.3	6.35e-15	Height;
BRCA	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-45.45	-0.87	2.29e-202	Myeloid white cell count;
BRCA	cis	rs13046373	0.507	rs2832969	chr21:32019627	A/G	cg16812893	chr21:31813075	KRTAP15-1	0.38	9.41	0.35	8.66e-20	HDL cholesterol;
BRCA	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg02880119	chr16:3481970	NA	0.48	8.75	0.33	1.91e-17	Body mass index (adult);
BRCA	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg21535247	chr6:8435926	SLC35B3	0.41	9.27	0.34	2.9e-19	Motion sickness;
BRCA	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg26608667	chr7:1196370	ZFAND2A	0.42	10.27	0.38	5.12e-23	Longevity;Endometriosis;
BRCA	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg22920501	chr2:26401640	FAM59B	-0.96	-16.94	-0.56	2.01e-53	Gut microbiome composition (summer);
BRCA	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg08213375	chr14:104286397	PPP1R13B	0.43	9.25	0.34	3.19e-19	Reticulocyte count;
BRCA	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg06552810	chr11:31128660	NA	-0.39	-8.81	-0.33	1.18e-17	Red blood cell count;
BRCA	cis	rs7246657	0.525	rs10410594	chr19:37477758	C/T	cg23950597	chr19:37808831	NA	-0.6	-9.41	-0.35	8.83e-20	Coronary artery calcification;
BRCA	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg06627628	chr2:24431161	ITSN2	-0.66	-12.11	-0.43	1.48e-30	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs6594499	0.872	rs10060003	chr5:110449357	A/G	cg04022379	chr5:110408740	TSLP	0.35	7.93	0.3	1.02e-14	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg19628046	chr18:33552617	C18orf21	0.53	10.37	0.38	2.07e-23	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs9463078	0.801	rs9395079	chr6:45154433	C/T	cg25276700	chr6:44698697	NA	-0.36	-8.22	-0.31	1.17e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg06238570	chr21:40685208	BRWD1	-0.4	-8.21	-0.31	1.26e-15	Menarche (age at onset);
BRCA	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg26384229	chr12:38710491	ALG10B	0.42	9.42	0.35	8.25e-20	Morning vs. evening chronotype;
BRCA	cis	rs72792276	1.000	rs17164395	chr5:127395526	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	10.21	0.37	9.02e-23	Red cell distribution width;
BRCA	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	12.5	0.44	3.17e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg00981070	chr1:2046702	PRKCZ	0.26	7.88	0.3	1.4e-14	Height;
BRCA	cis	rs7551345	0.853	rs7517820	chr1:31760665	T/C	cg19084893	chr1:31688959	NA	-0.48	-7.85	-0.3	1.79e-14	Schizophrenia;
BRCA	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg15997130	chr1:24165203	NA	-0.45	-10.01	-0.37	5.43e-22	Immature fraction of reticulocytes;
BRCA	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03264133	chr6:25882463	NA	0.42	9.68	0.36	9.22e-21	Blood metabolite levels;
BRCA	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	21.47	0.65	2.12e-77	Mean platelet volume;
BRCA	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg26384229	chr12:38710491	ALG10B	0.69	16.21	0.54	9.67e-50	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg07169764	chr2:136633963	MCM6	-0.89	-17.95	-0.58	1.19e-58	Corneal structure;
BRCA	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg04455712	chr21:45112962	RRP1B	-0.35	-8.95	-0.33	3.68e-18	Mean corpuscular volume;
BRCA	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.29	-0.31	6.47e-16	Colorectal cancer;
BRCA	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg14019146	chr3:50243930	SLC38A3	-0.46	-11.2	-0.41	1e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg23033748	chr14:75592666	NEK9	-0.39	-9.36	-0.35	1.38e-19	Height;
BRCA	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg06115741	chr20:33292138	TP53INP2	0.39	8.61	0.32	5.6e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs6028335	0.674	rs66476511	chr20:37605303	T/A	cg16355469	chr20:37678765	NA	0.48	8.75	0.33	1.88e-17	Alcohol and nicotine co-dependence;
BRCA	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-12.34	-0.44	1.61e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg08213375	chr14:104286397	PPP1R13B	0.42	8.99	0.33	2.87e-18	Reticulocyte count;
BRCA	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-13.59	-0.47	4.07e-37	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9880211	0.948	rs9872178	chr3:135986438	T/G	cg21827317	chr3:136751795	NA	-0.43	-7.83	-0.3	2.09e-14	Body mass index;Height;
BRCA	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg18357645	chr12:58087776	OS9	0.43	11.88	0.43	1.52e-29	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7809950	1.000	rs4730245	chr7:107087294	C/T	cg23024343	chr7:107201750	COG5	-0.42	-9.6	-0.36	1.76e-20	Coronary artery disease;
BRCA	trans	rs6600671	0.934	rs67718113	chr1:121238910	C/T	cg17023122	chr1:144479586	NA	-0.35	-7.92	-0.3	1.09e-14	Hip geometry;
BRCA	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.22e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg08601574	chr20:25228251	PYGB	-0.35	-8.55	-0.32	9.18e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg05457628	chr5:178986728	RUFY1	0.41	8.57	0.32	7.48e-17	Lung cancer;
BRCA	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.86	-0.3	1.61e-14	Electroencephalogram traits;
BRCA	cis	rs2282802	0.685	rs7717576	chr5:139623591	G/A	cg26211634	chr5:139558579	C5orf32	0.37	8.53	0.32	1.03e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg14558114	chr2:88469736	THNSL2	0.63	9.18	0.34	6.08e-19	Plasma clusterin levels;
BRCA	cis	rs700651	0.789	rs6434949	chr2:198855510	T/A	cg00792783	chr2:198669748	PLCL1	0.44	9.68	0.36	9.05e-21	Intracranial aneurysm;
BRCA	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.57	-0.32	7.75e-17	Total body bone mineral density;
BRCA	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	11.46	0.41	9.15e-28	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg15704280	chr7:45808275	SEPT13	0.52	8.93	0.33	4.35e-18	Axial length;
BRCA	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg13010199	chr12:38710504	ALG10B	0.48	9.46	0.35	5.66e-20	Morning vs. evening chronotype;
BRCA	cis	rs7737355	0.947	rs31253	chr5:130833011	A/C	cg06307176	chr5:131281290	NA	0.53	10.56	0.39	4.02e-24	Life satisfaction;
BRCA	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg27129171	chr3:47204927	SETD2	-0.71	-16.79	-0.55	1.08e-52	Colorectal cancer;
BRCA	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-9.58	-0.35	2.04e-20	Mood instability;
BRCA	cis	rs12464559	0.522	rs6715027	chr2:152626657	T/C	cg01189475	chr2:152685088	ARL5A	0.64	9.47	0.35	5.36e-20	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.23	-19.5	-0.61	8.19e-67	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg13256891	chr4:100009986	ADH5	-0.53	-10.0	-0.37	5.45e-22	Alcohol dependence;
BRCA	cis	rs4722404	0.502	rs1872879	chr7:3109430	A/C	cg19214707	chr7:3157722	NA	-0.37	-8.03	-0.3	4.58e-15	Atopic dermatitis;
BRCA	trans	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	22.76	0.67	2.09e-84	Platelet count;
BRCA	cis	rs3771570	1.000	rs62190367	chr2:242376276	G/A	cg21155796	chr2:242212141	HDLBP	0.62	9.37	0.35	1.22e-19	Prostate cancer;
BRCA	cis	rs9487051	0.768	rs445796	chr6:109520145	T/C	cg01475377	chr6:109611718	NA	-0.44	-11.28	-0.41	4.89e-27	Reticulocyte fraction of red cells;
BRCA	cis	rs1595825	0.891	rs76637837	chr2:198529496	G/A	cg19156104	chr2:198669113	PLCL1	-0.42	-8.15	-0.31	1.91e-15	Ulcerative colitis;
BRCA	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg11502198	chr6:26597334	ABT1	0.49	9.73	0.36	5.93e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg08923669	chr16:420230	MRPL28	-0.46	-8.99	-0.34	2.74e-18	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg15790184	chr11:494944	RNH1	0.64	9.95	0.37	8.42e-22	Body mass index;
BRCA	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg19318889	chr4:1322082	MAEA	0.57	11.79	0.42	3.58e-29	Longevity;
BRCA	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg04586622	chr2:25135609	ADCY3	-0.45	-11.31	-0.41	3.71e-27	Body mass index;
BRCA	cis	rs6700896	0.931	rs12044840	chr1:66115213	C/G	cg04111102	chr1:66153794	NA	0.34	8.42	0.32	2.57e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs17818399	0.620	rs7598578	chr2:46857085	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	8.36	0.31	4e-16	Height;
BRCA	cis	rs17604090	0.793	rs10241305	chr7:29689929	T/C	cg19413766	chr7:29689036	LOC646762	-0.49	-8.01	-0.3	5.4e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg09307838	chr4:120376055	NA	0.64	14.08	0.49	1.96e-39	Corneal astigmatism;
BRCA	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg26597838	chr10:835615	NA	-0.52	-9.49	-0.35	4.61e-20	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs7715811	0.913	rs6869474	chr5:13768691	C/T	cg07548982	chr5:13769939	DNAH5	-0.38	-8.25	-0.31	9.13e-16	Subclinical atherosclerosis traits (other);
BRCA	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg13010199	chr12:38710504	ALG10B	0.41	8.36	0.31	3.98e-16	Bladder cancer;
BRCA	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2463822	1.000	rs12279819	chr11:62137245	G/A	cg06239285	chr11:62104954	ASRGL1	-0.65	-9.63	-0.36	1.43e-20	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg22535103	chr8:58192502	C8orf71	-0.57	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg06636001	chr8:8085503	FLJ10661	0.45	8.88	0.33	6.95e-18	Neuroticism;
BRCA	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08219700	chr8:58056026	NA	0.44	7.94	0.3	8.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs6087990	0.899	rs998382	chr20:31384136	C/T	cg13636640	chr20:31349939	DNMT3B	-0.69	-21.87	-0.65	1.39e-79	Ulcerative colitis;
BRCA	cis	rs7729447	0.776	rs58739438	chr5:32693994	G/C	cg16267343	chr5:32710456	NPR3	0.44	9.06	0.34	1.6e-18	Blood pressure;
BRCA	cis	rs72772090	0.539	rs10515250	chr5:96150193	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-11.94	-0.43	8.28e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg14993813	chr1:46806288	NSUN4	0.51	9.95	0.37	8.53e-22	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.31	0.38	3.57e-23	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs75804782	0.521	rs60779166	chr2:239433943	G/A	cg01134436	chr17:81009848	B3GNTL1	0.7	8.78	0.33	1.5e-17	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs7246760	0.867	rs1820114	chr19:9805692	G/A	cg16876255	chr19:9731953	ZNF561	0.63	7.86	0.3	1.61e-14	Pursuit maintenance gain;
BRCA	cis	rs4588572	0.644	rs891150	chr5:77761794	G/A	cg11547950	chr5:77652471	NA	-0.45	-8.6	-0.32	5.99e-17	Triglycerides;
BRCA	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg20991723	chr1:152506922	NA	0.38	8.75	0.33	1.89e-17	Hair morphology;
BRCA	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg08888203	chr3:10149979	C3orf24	0.54	9.93	0.37	1.07e-21	Alzheimer's disease;
BRCA	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg15448220	chr1:150897856	SETDB1	0.37	8.26	0.31	8.34e-16	Urate levels;
BRCA	cis	rs2387326	0.672	rs10829344	chr10:129944569	A/C	cg16087940	chr10:129947807	NA	-0.45	-8.01	-0.3	5.47e-15	Select biomarker traits;
BRCA	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg09904177	chr6:26538194	HMGN4	0.47	14.71	0.5	2.11e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg22920501	chr2:26401640	FAM59B	-0.66	-11.52	-0.41	4.74e-28	Gut microbiome composition (summer);
BRCA	trans	rs12188164	0.515	rs2672744	chr5:411047	A/G	cg15371732	chr17:78194151	SLC26A11;SGSH	-0.36	-9.21	-0.34	4.52e-19	Cystic fibrosis severity;
BRCA	cis	rs11920090	0.858	rs61595505	chr3:170693472	C/T	cg09710316	chr3:170744871	SLC2A2	0.51	8.09	0.3	2.95e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg03146154	chr1:46216737	IPP	0.46	10.02	0.37	4.61e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg10845886	chr2:3471009	TTC15	-0.54	-12.22	-0.44	5.48e-31	Neurofibrillary tangles;
BRCA	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg19729930	chr2:74357872	NA	0.7	14.6	0.5	7.34e-42	Gestational age at birth (maternal effect);
BRCA	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg22508957	chr16:3507546	NAT15	0.48	11.73	0.42	6.25e-29	Tuberculosis;
BRCA	trans	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg25214090	chr10:38739885	LOC399744	0.45	10.4	0.38	1.72e-23	Corneal astigmatism;
BRCA	cis	rs10789491	1.000	rs4660956	chr1:47158486	A/G	cg15501359	chr1:47185051	KIAA0494	0.63	15.68	0.53	3.88e-47	Response to hepatitis C treatment;
BRCA	cis	rs6546550	0.867	rs6738174	chr2:70150215	A/C	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.47	-0.41	7.98e-28	Prevalent atrial fibrillation;
BRCA	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.38	0.38	1.96e-23	Motion sickness;
BRCA	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg15432903	chr11:17409602	KCNJ11	0.71	15.76	0.53	1.64e-47	Type 2 diabetes;
BRCA	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs11055008	0.620	rs2111941	chr12:12829404	A/T	cg09462578	chr12:12878428	APOLD1	0.43	9.58	0.35	2.13e-20	Pulse pressure;
BRCA	cis	rs2882667	0.658	rs10076442	chr5:138276779	T/C	cg04439458	chr5:138467593	SIL1	-0.32	-8.31	-0.31	5.83e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11764359	chr7:65958608	NA	0.8	19.53	0.61	6.05e-67	Aortic root size;
BRCA	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg12292205	chr6:26970375	C6orf41	-0.56	-12.5	-0.44	3.17e-32	Schizophrenia;
BRCA	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg22491629	chr6:157744540	C6orf35	-0.65	-12.0	-0.43	4.59e-30	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg17063962	chr7:91808500	NA	0.51	11.17	0.4	1.4e-26	Breast cancer;
BRCA	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg17971929	chr21:40555470	PSMG1	-0.49	-10.91	-0.4	1.5e-25	Menarche (age at onset);
BRCA	cis	rs870825	0.698	rs66462315	chr4:185623917	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs9837602	1.000	rs34626154	chr3:99756312	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	10.22	0.37	8.31e-23	Breast cancer;
BRCA	cis	rs12760731	0.565	rs12028023	chr1:178087408	G/A	cg00404053	chr1:178313656	RASAL2	0.66	8.07	0.3	3.41e-15	Obesity-related traits;
BRCA	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg12310025	chr6:25882481	NA	0.35	8.26	0.31	8.53e-16	Height;
BRCA	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg22875332	chr1:76189707	ACADM	-0.69	-15.07	-0.51	4.06e-44	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.35	-0.31	4.19e-16	Breast cancer;
BRCA	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg12927641	chr6:109611667	NA	-0.42	-10.93	-0.4	1.33e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs2652822	0.525	rs12148434	chr15:63510114	A/G	cg02713581	chr15:63449717	RPS27L	0.41	8.3	0.31	6.28e-16	Metabolic traits;
BRCA	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.74	0.67	2.43e-84	Chronic sinus infection;
BRCA	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg02017074	chr12:117425053	FBXW8	0.56	10.74	0.39	7.6e-25	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.36	2.29e-21	Morning vs. evening chronotype;
BRCA	cis	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg07460842	chr6:66804631	NA	-0.59	-12.59	-0.45	1.33e-32	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs867371	0.826	rs2047678	chr15:82498198	G/A	cg00614314	chr15:82944287	LOC80154	0.38	7.88	0.3	1.47e-14	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs17604090	0.877	rs28516764	chr7:29685245	T/G	cg19413766	chr7:29689036	LOC646762	-0.51	-7.99	-0.3	6.22e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg09184832	chr6:79620586	NA	-0.44	-9.02	-0.34	2.23e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg24130564	chr14:104152367	KLC1	-0.34	-7.94	-0.3	8.91e-15	Body mass index;
BRCA	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg16506815	chr2:162101123	NA	0.51	11.12	0.4	2.15e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs939658	0.805	rs939661	chr15:79431063	A/G	cg17916960	chr15:79447300	NA	-0.45	-11.39	-0.41	1.75e-27	Refractive error;
BRCA	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg03342759	chr3:160939853	NMD3	-0.62	-13.02	-0.46	1.53e-34	Morning vs. evening chronotype;
BRCA	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg11833968	chr6:79620685	NA	-0.4	-8.78	-0.33	1.55e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg20090143	chr19:45452003	APOC2	0.27	7.89	0.3	1.31e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.9	0.3	1.22e-14	Corneal astigmatism;
BRCA	trans	rs7395662	0.864	rs10839201	chr11:48989417	A/G	cg00717180	chr2:96193071	NA	0.3	8.23	0.31	1.03e-15	HDL cholesterol;
BRCA	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.65	10.65	0.39	1.68e-24	Renal function-related traits (BUN);
BRCA	trans	rs7939886	0.920	rs17150102	chr11:55904382	A/C	cg15704280	chr7:45808275	SEPT13	0.63	7.84	0.3	1.88e-14	Myopia (pathological);
BRCA	cis	rs2953174	0.786	rs2953146	chr2:241515252	A/G	cg07929629	chr2:241523174	NA	-0.43	-8.22	-0.31	1.11e-15	Bipolar disorder;
BRCA	cis	rs4363385	0.747	rs6704105	chr1:152964397	C/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.59	-0.35	1.87e-20	Inflammatory skin disease;
BRCA	cis	rs870825	0.616	rs1401360	chr4:185643571	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	17.2	0.56	9.11e-55	Blood protein levels;
BRCA	cis	rs6878727	0.665	rs256853	chr5:123662595	C/T	cg01806427	chr5:123737813	NA	-0.36	-8.01	-0.3	5.53e-15	Breast cancer;
BRCA	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg17971929	chr21:40555470	PSMG1	0.52	11.7	0.42	8.67e-29	Cognitive function;
BRCA	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.58	-0.35	2.17e-20	Tonsillectomy;
BRCA	cis	rs7000551	0.606	rs7844699	chr8:22248920	G/T	cg23129673	chr8:22266227	SLC39A14	-0.39	-8.44	-0.32	2.13e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs3820928	0.874	rs10177995	chr2:227781600	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.84	-0.33	8.95e-18	Pulmonary function;
BRCA	cis	rs6546550	0.901	rs6741449	chr2:70156589	A/G	cg02498382	chr2:70120550	SNRNP27	-0.52	-11.35	-0.41	2.54e-27	Prevalent atrial fibrillation;
BRCA	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg14675211	chr2:100938903	LONRF2	0.52	11.48	0.41	7.01e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	14.89	0.51	2.88e-43	Mean corpuscular hemoglobin;
BRCA	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.56	8.42	0.32	2.44e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9837602	1.000	rs6790535	chr3:99807735	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	10.37	0.38	2.16e-23	Breast cancer;
BRCA	trans	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-7.87	-0.3	1.53e-14	Corneal astigmatism;
BRCA	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.7	-12.14	-0.43	1.1e-30	Platelet count;
BRCA	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg10169327	chr19:45448959	APOC2	0.31	7.83	0.3	2.05e-14	Blood protein levels;
BRCA	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg10523679	chr1:76189770	ACADM	-0.48	-9.01	-0.34	2.39e-18	Daytime sleep phenotypes;
BRCA	cis	rs698813	0.572	rs13424464	chr2:44482263	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	7.84	0.3	1.85e-14	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg18230493	chr5:56204884	C5orf35	-0.73	-15.09	-0.51	3.09e-44	Initial pursuit acceleration;
BRCA	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg04362960	chr10:104952993	NT5C2	0.44	10.81	0.39	4e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg06060754	chr5:176797920	RGS14	0.57	10.96	0.4	1.01e-25	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs3818285	0.959	rs492943	chr10:111629030	A/T	cg00817464	chr10:111662876	XPNPEP1	0.32	8.73	0.33	2.29e-17	Superior crus of antihelix expression;
BRCA	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.74	-22.42	-0.66	1.37e-82	Longevity;Endometriosis;
BRCA	cis	rs501916	0.634	rs1561479	chr15:48070157	C/G	cg16110827	chr15:48056943	SEMA6D	-0.41	-8.83	-0.33	9.88e-18	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg18252515	chr7:66147081	NA	-0.99	-14.71	-0.5	2.03e-42	Diabetic kidney disease;
BRCA	cis	rs66887589	0.967	rs56173225	chr4:120509972	G/A	cg09307838	chr4:120376055	NA	-0.44	-9.18	-0.34	5.86e-19	Diastolic blood pressure;
BRCA	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg02544614	chr20:61657117	NA	0.29	8.16	0.31	1.79e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg09307838	chr4:120376055	NA	0.66	14.2	0.49	5.52e-40	Corneal astigmatism;
BRCA	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg18225595	chr11:63971243	STIP1	0.53	9.58	0.35	2.09e-20	Mean platelet volume;
BRCA	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.65	-10.48	-0.38	7.7e-24	Resting heart rate;
BRCA	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg26408565	chr15:76604113	ETFA	-0.47	-10.0	-0.37	5.88e-22	Blood metabolite levels;
BRCA	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.65	-14.49	-0.5	2.33e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.6	-12.37	-0.44	1.18e-31	Lymphocyte counts;
BRCA	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03452623	chr4:187889614	NA	0.35	11.86	0.42	1.75e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg13010199	chr12:38710504	ALG10B	-0.39	-8.86	-0.33	7.85e-18	Morning vs. evening chronotype;
BRCA	cis	rs7639513	0.767	rs6784168	chr3:12702847	T/G	cg23032965	chr3:12705835	RAF1	0.69	15.12	0.51	2.25e-44	Itch intensity from mosquito bite;
BRCA	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg19773385	chr1:10388646	KIF1B	-0.39	-8.37	-0.31	3.72e-16	Hepatocellular carcinoma;
BRCA	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg09904177	chr6:26538194	HMGN4	0.5	14.26	0.49	2.89e-40	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26314531	chr2:26401878	FAM59B	-0.78	-14.37	-0.49	8.64e-41	Gut microbiome composition (summer);
BRCA	cis	rs12611088	0.571	rs2305375	chr19:44013260	C/T	cg13740135	chr19:44006432	PHLDB3	-0.3	-7.94	-0.3	9.41e-15	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.05e-20	Menopause (age at onset);
BRCA	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg19418458	chr7:158789849	NA	0.42	9.4	0.35	9.8e-20	Facial morphology (factor 20);
BRCA	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg24578937	chr1:2090814	PRKCZ	0.58	17.95	0.58	1.28e-58	Height;
BRCA	trans	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.25	0.31	9.3e-16	Corneal astigmatism;
BRCA	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.8	-0.42	3.24e-29	Response to antipsychotic treatment;
BRCA	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	10.43	0.38	1.29e-23	Height;
BRCA	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-17.66	-0.57	3.7e-57	Morning vs. evening chronotype;
BRCA	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg17691542	chr6:26056736	HIST1H1C	0.55	11.62	0.42	1.82e-28	Height;
BRCA	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.42	8.61	0.32	5.54e-17	Monocyte percentage of white cells;
BRCA	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg18446336	chr7:2847575	GNA12	-0.35	-8.25	-0.31	8.73e-16	Height;
BRCA	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg02297831	chr4:17616191	MED28	0.36	8.33	0.31	4.9e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs61931739	0.635	rs1486883	chr12:33908740	C/T	cg26384229	chr12:38710491	ALG10B	0.41	9.24	0.34	3.74e-19	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg05340658	chr4:99064831	C4orf37	0.66	16.19	0.54	1.17e-49	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05926928	chr17:57297772	GDPD1	1.2	16.07	0.54	4.68e-49	Opioid sensitivity;
BRCA	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg15557168	chr22:42548783	NA	0.33	8.68	0.32	3.41e-17	Cognitive function;
BRCA	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.61	7.81	0.3	2.34e-14	Yeast infection;
BRCA	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg22705602	chr4:152727874	NA	-0.38	-10.33	-0.38	3.1e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg09455208	chr3:40491958	NA	-0.5	-10.84	-0.39	3.12e-25	Renal cell carcinoma;
BRCA	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg23708337	chr7:1209742	NA	0.55	11.53	0.41	4.53e-28	Longevity;Endometriosis;
BRCA	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg21045802	chr8:109455806	TTC35	0.45	10.45	0.38	1.01e-23	Dupuytren's disease;
BRCA	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg20476274	chr7:133979776	SLC35B4	0.7	21.34	0.65	1.05e-76	Mean platelet volume;
BRCA	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg11301795	chr4:187892539	NA	-0.31	-10.26	-0.38	6.01e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7523273	0.606	rs2761433	chr1:207917361	G/A	cg22525895	chr1:207977042	MIR29B2	0.47	12.11	0.43	1.61e-30	Schizophrenia;
BRCA	cis	rs2835872	0.733	rs1787393	chr21:39035934	G/A	cg06728970	chr21:39037746	KCNJ6	0.45	12.85	0.45	9.07e-34	Electroencephalographic traits in alcoholism;
BRCA	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg07741184	chr6:167504864	NA	0.33	9.87	0.36	1.81e-21	Primary biliary cholangitis;
BRCA	cis	rs365132	0.875	rs2940521	chr5:176339209	A/C	cg16309518	chr5:176445507	NA	-0.39	-9.67	-0.36	9.47e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg20701182	chr2:24300061	SF3B14	0.64	9.03	0.34	2.01e-18	Lymphocyte counts;
BRCA	cis	rs778371	0.676	rs4973563	chr2:233716421	C/T	cg08000102	chr2:233561755	GIGYF2	-0.79	-16.99	-0.56	1.1e-53	Schizophrenia;
BRCA	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	13.05	0.46	1.08e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.37	-9.2	-0.34	5.08e-19	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg16339924	chr4:17578868	LAP3	0.58	13.38	0.47	3.5e-36	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3761847	0.500	rs7037673	chr9:123740484	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	8.42	0.32	2.46e-16	Rheumatoid arthritis;
BRCA	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.03	-0.3	4.72e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.19	0.37	1.12e-22	Aortic root size;
BRCA	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg07169764	chr2:136633963	MCM6	1.02	19.42	0.61	2.33e-66	Corneal structure;
BRCA	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg19784903	chr17:45786737	TBKBP1	-0.35	-8.21	-0.31	1.21e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs3771570	0.901	rs73006381	chr2:242406654	G/C	cg21155796	chr2:242212141	HDLBP	0.61	9.48	0.35	4.82e-20	Prostate cancer;
BRCA	cis	rs10484885	0.793	rs9359862	chr6:90474508	A/G	cg13799429	chr6:90582589	CASP8AP2	0.72	11.06	0.4	3.84e-26	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg18232548	chr7:50535776	DDC	-0.48	-11.73	-0.42	6.28e-29	Malaria;
BRCA	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg13334819	chr7:99746414	C7orf59	-0.34	-8.11	-0.31	2.52e-15	Coronary artery disease;
BRCA	cis	rs2882667	0.964	rs12719517	chr5:138305502	C/T	cg04439458	chr5:138467593	SIL1	-0.39	-9.87	-0.36	1.69e-21	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg05901451	chr6:126070800	HEY2	-0.42	-10.14	-0.37	1.66e-22	Endometrial cancer;
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg22907277	chr7:1156413	C7orf50	0.52	11.38	0.41	1.88e-27	Longevity;Endometriosis;
BRCA	cis	rs754466	0.651	rs11002317	chr10:79617648	G/A	cg17075019	chr10:79541650	NA	-0.73	-17.63	-0.57	5.75e-57	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9815354	0.812	rs111967505	chr3:41873157	C/T	cg03022575	chr3:42003672	ULK4	0.69	9.47	0.35	5.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs3849570	0.925	rs6765917	chr3:81891116	C/T	cg07356753	chr3:81810745	GBE1	-0.43	-10.23	-0.38	7.71e-23	Waist circumference;Body mass index;
BRCA	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg02931644	chr1:25747376	RHCE	0.42	11.51	0.41	5.25e-28	Plateletcrit;Mean corpuscular volume;
BRCA	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.02	0.49	3.85e-39	Motion sickness;
BRCA	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg02403541	chr12:121454288	C12orf43	0.72	15.68	0.53	4e-47	N-glycan levels;
BRCA	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	14.36	0.49	9.52e-41	Personality dimensions;
BRCA	cis	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg06521331	chr12:34319734	NA	-0.53	-10.66	-0.39	1.51e-24	Morning vs. evening chronotype;
BRCA	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg06115741	chr20:33292138	TP53INP2	0.4	8.99	0.34	2.78e-18	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17712092	chr4:129076599	LARP1B	0.53	12.98	0.46	2.26e-34	Eosinophil percentage of white cells;
BRCA	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg14784868	chr12:69753453	YEATS4	0.47	10.99	0.4	7.58e-26	Response to diuretic therapy;
BRCA	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg06784218	chr1:46089804	CCDC17	0.5	12.18	0.43	7.68e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg22535103	chr8:58192502	C8orf71	0.48	8.54	0.32	9.83e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	13.8	0.48	4.21e-38	Coronary artery disease;
BRCA	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-9.95	-0.37	8.64e-22	Tonsillectomy;
BRCA	cis	rs495337	0.677	rs6012750	chr20:48430680	A/G	cg17835207	chr20:48524531	SPATA2	0.49	11.07	0.4	3.65e-26	Psoriasis;
BRCA	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg26769984	chr7:1090371	C7orf50	0.5	9.58	0.35	2.16e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05901451	chr6:126070800	HEY2	0.68	19.5	0.61	8.29e-67	Brugada syndrome;
BRCA	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	7.96	0.3	8.05e-15	Uric acid levels;
BRCA	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg12011299	chr4:100065546	ADH4	0.48	10.81	0.39	4.06e-25	Smoking initiation;
BRCA	cis	rs9649465	1.000	rs2109724	chr7:123325391	C/T	cg04330084	chr7:123175371	IQUB	-0.3	-8.38	-0.31	3.26e-16	Migraine;
BRCA	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.96	0.33	3.4e-18	Tonsillectomy;
BRCA	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg23505145	chr19:12996616	KLF1	0.56	12.73	0.45	2.95e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7011049	1.000	rs72648407	chr8:53857144	C/T	cg26025543	chr8:53854495	NA	0.55	9.5	0.35	4.24e-20	Systolic blood pressure;
BRCA	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg23711669	chr6:146136114	FBXO30	-0.77	-18.59	-0.59	5.61e-62	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs7939886	0.920	rs11227158	chr11:55843795	A/G	cg15704280	chr7:45808275	SEPT13	0.6	7.84	0.3	1.92e-14	Myopia (pathological);
BRCA	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg21475434	chr5:93447410	FAM172A	0.69	9.18	0.34	5.83e-19	Diabetic retinopathy;
BRCA	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	22.88	0.67	4.42e-85	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	trans	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg19894588	chr14:64061835	NA	0.37	8.98	0.33	2.93e-18	Glioblastoma;Glioma;
BRCA	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg21475434	chr5:93447410	FAM172A	0.66	8.64	0.32	4.59e-17	Diabetic retinopathy;
BRCA	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.11	0.37	2.23e-22	Aortic root size;
BRCA	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.39	-10.15	-0.37	1.56e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg10820045	chr2:198174542	NA	-0.38	-7.91	-0.3	1.1e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs193541	0.555	rs2438151	chr5:122199197	A/G	cg19412675	chr5:122181750	SNX24	0.33	7.93	0.3	9.66e-15	Glucose homeostasis traits;
BRCA	trans	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17712092	chr4:129076599	LARP1B	-0.54	-12.91	-0.45	4.77e-34	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	trans	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	13.25	0.46	1.4e-35	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg00666640	chr1:248458726	OR2T12	-0.29	-7.84	-0.3	1.84e-14	Common traits (Other);
BRCA	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg20007245	chr22:24372913	LOC391322	-0.58	-12.9	-0.45	5.14e-34	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg04025307	chr7:1156635	C7orf50	0.59	9.45	0.35	6.35e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-10.88	-0.4	2.07e-25	Schizophrenia;
BRCA	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	trans	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.83	-0.3	2.02e-14	Corneal astigmatism;
BRCA	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg08847533	chr14:75593920	NEK9	-0.79	-18.55	-0.59	8.54e-62	Height;
BRCA	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg07169764	chr2:136633963	MCM6	1.22	23.88	0.69	1.36e-90	Corneal structure;
BRCA	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg03433033	chr1:76189801	ACADM	0.75	17.29	0.56	3.16e-55	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9790314	0.637	rs778654	chr3:160716078	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-8.91	-0.33	5.28e-18	Morning vs. evening chronotype;
BRCA	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg24130564	chr14:104152367	KLC1	0.39	8.57	0.32	8.03e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg14835575	chr10:16859367	RSU1	0.64	14.1	0.49	1.62e-39	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs6433895	1.000	rs7598960	chr2:182018382	T/G	cg00481216	chr2:181971175	NA	0.39	8.91	0.33	5.34e-18	Lymphocyte counts;
BRCA	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg22535103	chr8:58192502	C8orf71	-0.46	-8.13	-0.31	2.25e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	14.05	0.49	2.88e-39	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg26031613	chr14:104095156	KLC1	-0.43	-8.59	-0.32	6.54e-17	Schizophrenia;
BRCA	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg18446336	chr7:2847575	GNA12	-0.35	-8.32	-0.31	5.18e-16	Height;
BRCA	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.59	12.07	0.43	2.27e-30	Body mass index (adult);
BRCA	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg26408565	chr15:76604113	ETFA	-0.37	-8.11	-0.31	2.67e-15	Blood metabolite levels;
BRCA	cis	rs4728302	0.838	rs10225605	chr7:133591676	G/A	cg07491979	chr7:133331646	EXOC4	0.36	7.82	0.3	2.17e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg24006582	chr15:45444508	DUOX1	-0.53	-11.02	-0.4	5.69e-26	Uric acid levels;
BRCA	cis	rs6782228	0.628	rs7641584	chr3:128392630	G/C	cg16766828	chr3:128327626	NA	-0.42	-9.33	-0.35	1.7e-19	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg27170947	chr2:26402098	FAM59B	0.78	11.05	0.4	4.25e-26	Gut microbiome composition (summer);
BRCA	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-8.03	-0.3	4.72e-15	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs72781680	0.821	rs113014365	chr2:24159903	C/T	cg08917208	chr2:24149416	ATAD2B	0.64	10.71	0.39	9.64e-25	Lymphocyte counts;
BRCA	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg02997394	chr19:33096574	ANKRD27	0.69	11.34	0.41	2.72e-27	Eosinophilic esophagitis;
BRCA	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg21045802	chr8:109455806	TTC35	0.35	8.06	0.3	3.69e-15	Dupuytren's disease;
BRCA	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.68	0.39	1.32e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4594175	0.926	rs4901083	chr14:51604998	C/A	cg23942311	chr14:51606299	NA	0.34	8.47	0.32	1.72e-16	Cancer;
BRCA	trans	rs66887589	0.967	rs56173225	chr4:120509972	G/A	cg25214090	chr10:38739885	LOC399744	-0.35	-8.09	-0.3	3.03e-15	Diastolic blood pressure;
BRCA	cis	rs1538970	0.924	rs11211108	chr1:45891152	C/T	cg05343316	chr1:45956843	TESK2	0.62	12.48	0.44	3.73e-32	Platelet count;
BRCA	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg26384229	chr12:38710491	ALG10B	-0.62	-15.05	-0.51	4.91e-44	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg16339924	chr4:17578868	LAP3	-0.56	-13.13	-0.46	5.09e-35	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.33	-0.44	1.69e-31	Chronic sinus infection;
BRCA	cis	rs4566357	0.615	rs1800517	chr2:227915832	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-9.58	-0.35	2.16e-20	Coronary artery disease;
BRCA	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	8.4	0.32	2.8e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	10.75	0.39	6.69e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.71	-15.3	-0.52	2.96e-45	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	13.95	0.48	8.22e-39	Alzheimer's disease;
BRCA	cis	rs7945718	0.840	rs10741601	chr11:12735873	T/C	cg25843174	chr11:12811716	TEAD1	0.23	8.55	0.32	9.3e-17	Educational attainment (years of education);
BRCA	cis	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg19338460	chr6:170058176	WDR27	-0.44	-7.84	-0.3	1.9e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg04450456	chr4:17643702	FAM184B	0.35	9.83	0.36	2.48e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6545883	0.894	rs1186703	chr2:61672965	A/C	cg15711740	chr2:61764176	XPO1	-0.56	-14.29	-0.49	2.14e-40	Tuberculosis;
BRCA	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg17971929	chr21:40555470	PSMG1	-0.5	-11.24	-0.41	7.24e-27	Menarche (age at onset);
BRCA	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg04989706	chr14:50066350	PPIL5	-0.47	-9.21	-0.34	4.57e-19	Carotid intima media thickness;
BRCA	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg24006582	chr15:45444508	DUOX1	-0.56	-11.58	-0.42	2.68e-28	Uric acid levels;
BRCA	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg21248554	chr2:27665150	KRTCAP3	0.35	8.99	0.34	2.75e-18	Total body bone mineral density;
BRCA	cis	rs12618769	0.597	rs72821956	chr2:99159966	G/T	cg10123293	chr2:99228465	UNC50	0.43	8.47	0.32	1.65e-16	Bipolar disorder;
BRCA	cis	rs10044254	0.563	rs12153463	chr5:15693370	G/A	cg07238450	chr5:15720153	FBXL7	-0.38	-7.82	-0.3	2.13e-14	Asthma (corticosteroid response);
BRCA	cis	rs6750047	0.649	rs4670231	chr2:38267836	T/G	cg07380506	chr2:38303506	CYP1B1	0.43	9.51	0.35	3.94e-20	Cutaneous malignant melanoma;Melanoma;
BRCA	trans	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg26384229	chr12:38710491	ALG10B	0.46	10.5	0.38	6.62e-24	Morning vs. evening chronotype;
BRCA	cis	rs16854884	0.657	rs35309714	chr3:143735011	T/A	cg06585982	chr3:143692056	C3orf58	0.43	9.0	0.34	2.63e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg03934865	chr2:198174659	NA	-0.44	-9.67	-0.36	1e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.93	0.46	3.84e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg10578991	chr7:12443926	VWDE	-0.56	-7.92	-0.3	1.04e-14	Coronary artery disease;
BRCA	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-9.65	-0.36	1.17e-20	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg09658497	chr7:2847517	GNA12	-0.41	-8.31	-0.31	5.82e-16	Height;
BRCA	cis	rs858239	0.600	rs7787110	chr7:23138474	C/T	cg23682824	chr7:23144976	KLHL7	0.45	12.1	0.43	1.8e-30	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1003719	0.680	rs2257091	chr21:38522618	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.37	-0.49	9.12e-41	Eye color traits;
BRCA	cis	rs4746818	1.000	rs7893492	chr10:70960448	C/T	cg11621586	chr10:70884670	VPS26A	-0.74	-13.01	-0.46	1.74e-34	Left atrial antero-posterior diameter;
BRCA	cis	rs7903847	0.642	rs10786341	chr10:99158607	G/A	cg20016023	chr10:99160130	RRP12	-0.26	-8.34	-0.31	4.68e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg05347473	chr6:146136440	FBXO30	-0.45	-9.13	-0.34	8.82e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs897984	0.609	rs732172	chr16:31050033	C/T	cg00531865	chr16:30841666	NA	-0.36	-8.44	-0.32	2.18e-16	Dementia with Lewy bodies;
BRCA	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg08470875	chr2:26401718	FAM59B	-0.51	-8.59	-0.32	6.87e-17	Gut microbiome composition (summer);
BRCA	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg17830980	chr10:43048298	ZNF37B	0.43	10.12	0.37	1.94e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17095355	0.818	rs57239324	chr10:111770871	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.45	-9.74	-0.36	5.35e-21	Biliary atresia;
BRCA	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	22.3	0.66	6.23e-82	Platelet count;
BRCA	cis	rs7560272	0.502	rs4513320	chr2:73920741	T/C	cg20560298	chr2:73613845	ALMS1	0.36	9.47	0.35	5.37e-20	Schizophrenia;
BRCA	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg16576597	chr16:28551801	NUPR1	0.32	8.83	0.33	1.01e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg20891283	chr12:69753455	YEATS4	0.84	28.6	0.75	1.77e-116	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg18154014	chr19:37997991	ZNF793	0.48	9.41	0.35	8.49e-20	Coronary artery calcification;
BRCA	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18876405	chr7:65276391	NA	-0.56	-13.42	-0.47	2.28e-36	Aortic root size;
BRCA	cis	rs2304069	0.954	rs2340462	chr5:149415219	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.62	13.43	0.47	2.05e-36	HIV-1 control;
BRCA	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg07828340	chr4:882639	GAK	0.8	10.28	0.38	4.7e-23	Parkinson's disease;
BRCA	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	15.73	0.53	2.16e-47	Bone mineral density;
BRCA	cis	rs4566357	0.615	rs2272200	chr2:227912331	G/A	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.17	-0.31	1.69e-15	Coronary artery disease;
BRCA	trans	rs4596713	0.538	rs7030146	chr9:71756390	T/G	cg16512924	chr15:28394682	HERC2	0.42	10.07	0.37	3.07e-22	Headache;
BRCA	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg08085267	chr17:45401833	C17orf57	-0.69	-15.26	-0.52	4.69e-45	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs10504073	0.584	rs4873307	chr8:49950417	C/T	cg00325661	chr8:49890786	NA	0.49	14.39	0.49	7.32e-41	Blood metabolite ratios;
BRCA	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg13385521	chr17:29058706	SUZ12P	0.77	12.14	0.43	1.15e-30	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg04317338	chr11:64019027	PLCB3	0.54	9.47	0.35	5.33e-20	Mean platelet volume;
BRCA	cis	rs34779708	0.966	rs17591781	chr10:35498538	G/A	cg03585969	chr10:35415529	CREM	0.49	10.25	0.38	6.11e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9314323	0.524	rs7816609	chr8:26202482	A/C	cg13160058	chr8:26243215	BNIP3L	-0.34	-8.76	-0.33	1.68e-17	Red cell distribution width;
BRCA	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.83	-0.33	1.03e-17	Total body bone mineral density;
BRCA	trans	rs1997103	0.911	rs9642575	chr7:55399090	C/T	cg20935933	chr6:143382018	AIG1	0.6	11.52	0.41	4.77e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg06521331	chr12:34319734	NA	-0.52	-9.41	-0.35	8.45e-20	Bladder cancer;
BRCA	cis	rs12760731	0.720	rs35905053	chr1:178441618	A/T	cg00404053	chr1:178313656	RASAL2	0.61	8.08	0.3	3.13e-15	Obesity-related traits;
BRCA	trans	rs12310956	0.510	rs7965329	chr12:33868199	C/A	cg26384229	chr12:38710491	ALG10B	0.39	9.15	0.34	7.57e-19	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.569	rs1872746	chr12:33985843	T/C	cg26384229	chr12:38710491	ALG10B	0.43	9.96	0.37	7.77e-22	Morning vs. evening chronotype;
BRCA	cis	rs7011049	1.000	rs72643585	chr8:53847651	A/G	cg26025543	chr8:53854495	NA	0.55	9.49	0.35	4.41e-20	Systolic blood pressure;
BRCA	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.35	8.51	0.32	1.25e-16	Resting heart rate;
BRCA	cis	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.5	-0.32	1.31e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.54	0.44	2.18e-32	Bipolar disorder;
BRCA	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg04944784	chr2:26401820	FAM59B	0.95	16.58	0.55	1.27e-51	Gut microbiome composition (summer);
BRCA	cis	rs2041840	0.503	rs3770756	chr2:37573897	T/C	cg25727520	chr2:37576821	QPCT	-0.28	-7.81	-0.3	2.34e-14	Chronic lymphocytic leukemia;
BRCA	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.14e-19	Total body bone mineral density;
BRCA	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg23711669	chr6:146136114	FBXO30	-0.68	-15.64	-0.53	6.62e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg18357645	chr12:58087776	OS9	-0.47	-13.5	-0.47	9.71e-37	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg09065629	chr16:1709722	CRAMP1L	0.38	8.78	0.33	1.52e-17	Coronary artery disease;
BRCA	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg02951883	chr7:2050386	MAD1L1	-0.47	-11.63	-0.42	1.66e-28	Schizophrenia;
BRCA	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg08975724	chr8:8085496	FLJ10661	0.41	8.67	0.32	3.48e-17	Mood instability;
BRCA	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg14664628	chr15:75095509	CSK	0.39	8.99	0.33	2.86e-18	Systemic lupus erythematosus;
BRCA	cis	rs7727544	0.625	rs3091338	chr5:131402738	C/T	cg14196790	chr5:131705035	SLC22A5	0.38	9.25	0.34	3.22e-19	Blood metabolite levels;
BRCA	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg09904177	chr6:26538194	HMGN4	0.56	18.25	0.59	3.12e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04267008	chr7:1944627	MAD1L1	-0.51	-10.88	-0.4	2.06e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg05863683	chr7:1912471	MAD1L1	0.38	8.49	0.32	1.41e-16	Bipolar disorder and schizophrenia;
BRCA	trans	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg26043149	chr18:55253948	FECH	-0.37	-8.29	-0.31	6.69e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg06026331	chr20:60912101	LAMA5	0.44	8.16	0.31	1.75e-15	Colorectal cancer;
BRCA	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg13798912	chr7:905769	UNC84A	-0.5	-7.88	-0.3	1.42e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6120849	0.802	rs6087681	chr20:33752896	G/C	cg24642439	chr20:33292090	TP53INP2	0.48	8.56	0.32	8.7e-17	Protein C levels;
BRCA	trans	rs10411161	0.702	rs16983200	chr19:52386723	G/A	cg22319618	chr22:45562946	NUP50	-0.43	-8.04	-0.3	4.43e-15	Breast cancer;
BRCA	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg02551604	chr5:131831745	NA	0.38	13.75	0.48	6.78e-38	Asthma (sex interaction);
BRCA	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21659725	chr3:3221576	CRBN	0.7	20.95	0.64	1.37e-74	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24549020	chr5:56110836	MAP3K1	-0.39	-8.07	-0.3	3.48e-15	Initial pursuit acceleration;
BRCA	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07988820	chr12:82153109	PPFIA2	-0.58	-9.61	-0.36	1.62e-20	Resting heart rate;
BRCA	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.92	-0.3	1.02e-14	Retinal vascular caliber;
BRCA	cis	rs4671400	0.543	rs62152274	chr2:61499588	C/A	cg15711740	chr2:61764176	XPO1	0.4	7.92	0.3	1.09e-14	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg00024416	chr22:24240387	NA	0.38	9.78	0.36	3.69e-21	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-21.54	-0.65	8.57e-78	Gut microbiome composition (summer);
BRCA	cis	rs9473147	0.516	rs9369695	chr6:47440565	C/A	cg12968598	chr6:47444699	CD2AP	0.44	9.26	0.34	3.1400000000000002e-19	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.8	-0.62	2.12e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg27170947	chr2:26402098	FAM59B	-0.65	-11.21	-0.41	9.48e-27	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.4	-8.8	-0.33	1.24e-17	Aortic root size;
BRCA	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg13319975	chr6:146136371	FBXO30	-0.34	-8.05	-0.3	3.93e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg07080220	chr10:102295463	HIF1AN	0.57	13.41	0.47	2.65e-36	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs250677	0.524	rs40521	chr5:148439639	C/T	cg12140854	chr5:148520817	ABLIM3	0.37	8.51	0.32	1.2e-16	Breast cancer;
BRCA	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg01416388	chr22:39784598	NA	-0.39	-8.06	-0.3	3.67e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg06627628	chr2:24431161	ITSN2	0.47	9.97	0.37	7.1e-22	Asthma;
BRCA	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg25358565	chr5:93447407	FAM172A	-0.67	-11.67	-0.42	1.17e-28	Diabetic retinopathy;
BRCA	cis	rs4285028	0.948	rs34478505	chr3:121694071	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.88	-0.4	2.15e-25	Multiple sclerosis;
BRCA	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.5	-0.41	6.24e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.43	9.03	0.34	2e-18	Cognitive ability;
BRCA	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg02175503	chr12:58329896	NA	0.44	8.5	0.32	1.31e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03264133	chr6:25882463	NA	-0.54	-12.42	-0.44	7.33e-32	Blood metabolite levels;
BRCA	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg23649088	chr2:200775458	C2orf69	-0.62	-10.05	-0.37	3.77e-22	Schizophrenia;
BRCA	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg12591125	chr7:1885375	MAD1L1	0.51	8.93	0.33	4.6e-18	Bipolar disorder;
BRCA	cis	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg06521331	chr12:34319734	NA	0.56	9.73	0.36	6.07e-21	Morning vs. evening chronotype;
BRCA	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-9.4	-0.35	9.47e-20	Menopause (age at onset);
BRCA	cis	rs9790314	0.645	rs6778254	chr3:160892792	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-12.13	-0.43	1.22e-30	Morning vs. evening chronotype;
BRCA	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-14.37	-0.49	9.19e-41	Blood metabolite levels;
BRCA	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.56	8.85	0.33	8.42e-18	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs250677	0.524	rs417413	chr5:148452726	T/C	cg12140854	chr5:148520817	ABLIM3	-0.37	-8.3	-0.31	6.18e-16	Breast cancer;
BRCA	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg26384229	chr12:38710491	ALG10B	0.77	17.76	0.57	1.24e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg24069376	chr3:38537580	EXOG	-0.43	-12.28	-0.44	2.92e-31	Electrocardiographic conduction measures;
BRCA	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg11608241	chr8:8085544	FLJ10661	-0.29	-8.75	-0.33	1.87e-17	Mood instability;
BRCA	cis	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05901451	chr6:126070800	HEY2	0.4	9.7	0.36	7.3e-21	Endometrial cancer;
BRCA	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.73	16.36	0.54	1.75e-50	Hip circumference adjusted for BMI;
BRCA	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg20628663	chr10:43360327	NA	-0.7	-13.62	-0.47	2.75e-37	Blood protein levels;
BRCA	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	16.38	0.54	1.35e-50	Colorectal cancer;
BRCA	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24549020	chr5:56110836	MAP3K1	0.64	13.06	0.46	9.94e-35	Initial pursuit acceleration;
BRCA	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg04362960	chr10:104952993	NT5C2	-0.44	-9.99	-0.37	5.95e-22	Arsenic metabolism;
BRCA	cis	rs4679121	0.642	rs55708952	chr3:126188912	A/G	cg01106040	chr3:126194903	ZXDC	-0.67	-7.96	-0.3	7.83e-15	Pursuit maintenance gain;
BRCA	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg03709012	chr19:19516395	GATAD2A	1.05	20.42	0.63	9.41e-72	Nonalcoholic fatty liver disease;
BRCA	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.22	-0.31	1.15e-15	Depression;
BRCA	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg26384229	chr12:38710491	ALG10B	0.85	22.93	0.67	2.44e-85	Heart rate;
BRCA	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg26061582	chr7:22766209	IL6	0.35	8.31	0.31	5.56e-16	Lung cancer;
BRCA	cis	rs7633770	0.710	rs4683259	chr3:46698538	A/G	cg11219411	chr3:46661640	NA	-0.52	-12.16	-0.43	9.9e-31	Coronary artery disease;
BRCA	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg04691961	chr3:161091175	C3orf57	-0.41	-9.18	-0.34	5.99e-19	Parkinson's disease;
BRCA	cis	rs6882046	0.513	rs618298	chr5:88038390	A/G	cg22951263	chr5:87985283	NA	-0.34	-9.38	-0.35	1.09e-19	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.67	-0.32	3.46e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg10876282	chr6:28092338	ZSCAN16	0.4	7.84	0.3	1.9e-14	Parkinson's disease;
BRCA	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.45	-9.99	-0.37	6.1e-22	Coronary artery disease;
BRCA	trans	rs12439619	1.000	rs35152457	chr15:82546548	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.42	-10.44	-0.38	1.13e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs752010	0.571	rs10890135	chr1:42054084	G/A	cg06885757	chr1:42089581	HIVEP3	0.22	8.01	0.3	5.4e-15	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	14.22	0.49	4.5e-40	Colorectal cancer;
BRCA	cis	rs7631605	0.905	rs7634972	chr3:37205716	C/T	cg15934958	chr3:37212084	LRRFIP2	0.42	9.87	0.36	1.69e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.49	0.38	7.52e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7809950	0.598	rs2283038	chr7:106835410	C/T	cg23024343	chr7:107201750	COG5	-0.46	-9.1	-0.34	1.16e-18	Coronary artery disease;
BRCA	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-11.11	-0.4	2.32e-26	Gut microbiome composition (summer);
BRCA	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg15145296	chr3:125709740	NA	-0.55	-8.92	-0.33	5.02e-18	Blood pressure (smoking interaction);
BRCA	cis	rs2066819	0.892	rs17118431	chr12:56667100	A/G	cg26714650	chr12:56694279	CS	-1.16	-15.27	-0.52	3.93e-45	Psoriasis vulgaris;
BRCA	cis	rs10189230	0.967	rs13026659	chr2:222353014	C/T	cg14652038	chr2:222343519	EPHA4	0.47	13.14	0.46	4.22e-35	Urate levels in lean individuals;
BRCA	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg08085267	chr17:45401833	C17orf57	-0.62	-13.37	-0.47	4.19e-36	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg06917634	chr15:78832804	PSMA4	-0.6	-13.13	-0.46	5.15e-35	Sudden cardiac arrest;
BRCA	cis	rs66679842	1	rs66679842	chr6:88171407	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.38	-0.31	3.34e-16	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg26384229	chr12:38710491	ALG10B	0.43	9.52	0.35	3.41e-20	Morning vs. evening chronotype;
BRCA	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	7.86	0.3	1.66e-14	Menarche (age at onset);
BRCA	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-11.49	-0.41	6.5e-28	Morning vs. evening chronotype;
BRCA	cis	rs12760731	0.565	rs12030488	chr1:178094751	A/C	cg00404053	chr1:178313656	RASAL2	-0.62	-7.93	-0.3	1.01e-14	Obesity-related traits;
BRCA	cis	rs17270561	0.609	rs760698	chr6:25685889	A/G	cg16482183	chr6:26056742	HIST1H1C	0.42	8.14	0.31	2.15e-15	Iron status biomarkers;
BRCA	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.2	-0.41	1.01e-26	Schizophrenia;
BRCA	cis	rs2712184	0.756	rs2541393	chr2:217651230	G/C	cg05032264	chr2:217675019	NA	-0.38	-9.15	-0.34	7.75e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg08888203	chr3:10149979	C3orf24	0.65	13.74	0.48	7.58e-38	Alzheimer's disease;
BRCA	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg06484146	chr7:12443880	VWDE	-0.65	-10.12	-0.37	1.98e-22	Coronary artery disease;
BRCA	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg22153463	chr1:85462885	MCOLN2	-0.62	-12.23	-0.44	4.88e-31	Serum sulfate level;
BRCA	trans	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg25214090	chr10:38739885	LOC399744	0.52	10.74	0.39	7.27e-25	Corneal astigmatism;
BRCA	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg01475377	chr6:109611718	NA	-0.61	-16.82	-0.55	8.28e-53	Reticulocyte fraction of red cells;
BRCA	cis	rs1371614	0.635	rs12612520	chr2:27137307	C/T	cg12368169	chr2:27073192	DPYSL5	-0.3	-8.96	-0.33	3.45e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13046373	0.535	rs1961491	chr21:31973685	C/T	cg22337977	chr21:31811175	KRTAP15-1	0.35	8.31	0.31	5.84e-16	HDL cholesterol;
BRCA	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg01579765	chr21:45077557	HSF2BP	-0.45	-11.95	-0.43	7.37e-30	Mean corpuscular volume;
BRCA	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.32	-0.38	3.23e-23	Psoriasis;
BRCA	cis	rs4663866	0.901	rs76312449	chr2:239190906	A/G	cg16914508	chr2:239161102	PER2	0.69	9.38	0.35	1.09e-19	Irritable bowel syndrome;
BRCA	cis	rs9359856	0.510	rs17294495	chr6:90445753	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.71	-10.75	-0.39	7.08e-25	Bipolar disorder;
BRCA	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg03060546	chr3:49711283	APEH	0.56	10.99	0.4	7.41e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg05623727	chr3:50126028	RBM5	0.43	10.08	0.37	2.94e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03517284	chr6:25882590	NA	0.46	10.42	0.38	1.35e-23	Blood metabolite levels;
BRCA	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg09060608	chr5:178986726	RUFY1	0.54	12.71	0.45	3.73e-33	Lung cancer;
BRCA	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg10495392	chr1:46806563	NSUN4	0.45	8.49	0.32	1.42e-16	Menopause (age at onset);
BRCA	cis	rs11690935	0.569	rs62183770	chr2:172838117	C/G	cg13550731	chr2:172543902	DYNC1I2	0.5	12.07	0.43	2.43e-30	Schizophrenia;
BRCA	cis	rs858239	0.601	rs12539331	chr7:23151330	A/G	cg23682824	chr7:23144976	KLHL7	0.4	10.35	0.38	2.62e-23	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.32	-9.57	-0.35	2.22e-20	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4290604	0.748	rs6431514	chr2:238051064	T/C	cg23555395	chr2:238036564	NA	-0.5	-8.16	-0.31	1.72e-15	Asthma;
BRCA	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg23625390	chr15:77176239	SCAPER	0.38	9.13	0.34	8.91e-19	Blood metabolite levels;
BRCA	cis	rs7760949	0.889	rs9475806	chr6:13934527	A/G	cg27413430	chr6:13925136	RNF182	0.47	9.41	0.35	8.55e-20	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg05340658	chr4:99064831	C4orf37	0.62	14.89	0.51	2.78e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg18811423	chr2:55921094	PNPT1	-0.78	-28.11	-0.74	8.19e-114	Metabolic syndrome;
BRCA	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25427524	chr10:38739819	LOC399744	-0.74	-18.02	-0.58	5.19e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs28830936	1.000	rs28830936	chr15:41906408	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.33	-9.34	-0.35	1.61e-19	Diastolic blood pressure;
BRCA	cis	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg06521331	chr12:34319734	NA	-0.61	-11.21	-0.41	9.27e-27	Morning vs. evening chronotype;
BRCA	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12923728	chr3:195709715	SDHAP1	-0.61	-12.48	-0.44	3.79e-32	Pancreatic cancer;
BRCA	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12541635	0.966	rs34177605	chr8:107065105	G/A	cg10147462	chr8:107024639	NA	0.38	9.88	0.36	1.6e-21	Age of smoking initiation;
BRCA	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg21724239	chr8:58056113	NA	0.56	9.08	0.34	1.3e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg11366901	chr6:160182831	ACAT2	0.82	15.87	0.53	4.73e-48	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg09307838	chr4:120376055	NA	0.72	15.26	0.52	4.91e-45	Corneal astigmatism;
BRCA	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg22920501	chr2:26401640	FAM59B	0.95	16.32	0.54	2.51e-50	Gut microbiome composition (summer);
BRCA	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.32	-8.24	-0.31	9.49e-16	Total body bone mineral density;
BRCA	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg01877450	chr7:97915802	BRI3	-0.39	-8.9	-0.33	5.76e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8067545	0.611	rs12603372	chr17:20181566	C/T	cg13482628	chr17:19912719	NA	0.48	12.55	0.44	1.8e-32	Schizophrenia;
BRCA	cis	rs1499972	0.941	rs62263120	chr3:117630253	A/G	cg07612923	chr3:117604196	NA	0.6	8.15	0.31	1.97e-15	Schizophrenia;
BRCA	cis	rs7633770	0.769	rs2385858	chr3:46660436	T/C	cg11219411	chr3:46661640	NA	0.72	20.93	0.64	1.73e-74	Coronary artery disease;
BRCA	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.19	0.34	5.28e-19	Tonsillectomy;
BRCA	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg08738300	chr3:44038990	NA	0.44	8.56	0.32	8.6e-17	Coronary artery disease;
BRCA	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg25036284	chr2:26402008	FAM59B	0.63	10.38	0.38	2.01e-23	Gut microbiome composition (summer);
BRCA	cis	rs6738485	0.601	rs13011900	chr2:106845059	G/C	cg16099169	chr2:106886729	NA	-0.41	-8.76	-0.33	1.69e-17	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
BRCA	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.36e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13190036	1.000	rs4976682	chr5:176726002	A/G	cg06733329	chr5:176740039	MXD3	-0.45	-8.75	-0.33	1.85e-17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg18105134	chr13:113819100	PROZ	-0.62	-14.1	-0.49	1.64e-39	Platelet distribution width;
BRCA	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.54	11.88	0.43	1.45e-29	HDL cholesterol;
BRCA	cis	rs4588572	0.643	rs6874309	chr5:77774498	A/T	cg11547950	chr5:77652471	NA	0.47	8.51	0.32	1.26e-16	Triglycerides;
BRCA	cis	rs897984	0.542	rs7294	chr16:31102321	A/G	cg00531865	chr16:30841666	NA	0.38	9.05	0.34	1.74e-18	Dementia with Lewy bodies;
BRCA	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24110177	chr3:50126178	RBM5	0.38	10.35	0.38	2.65e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg10495392	chr1:46806563	NSUN4	0.45	8.12	0.31	2.49e-15	Menopause (age at onset);
BRCA	cis	rs7246657	0.551	rs11084873	chr19:37583910	A/G	cg18154014	chr19:37997991	ZNF793	0.53	8.68	0.32	3.16e-17	Coronary artery calcification;
BRCA	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07636037	chr3:49044803	WDR6	0.73	15.88	0.53	4.04e-48	Menarche (age at onset);
BRCA	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg04450456	chr4:17643702	FAM184B	0.37	10.98	0.4	8.29e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg06784218	chr1:46089804	CCDC17	-0.45	-10.8	-0.39	4.54e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2070433	0.556	rs8129460	chr21:47822544	C/T	cg05998816	chr21:47859926	PCNT	0.36	8.54	0.32	9.59e-17	Lymphocyte counts;
BRCA	cis	rs11229555	0.645	rs4506677	chr11:58213852	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.64	-0.36	1.27e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs35995292	0.534	rs13228087	chr7:38909204	A/C	cg19327137	chr7:38886074	VPS41	0.4	13.3	0.47	8.14e-36	Subjective well-being (multi-trait analysis);
BRCA	cis	rs7809950	0.817	rs3779495	chr7:107250260	G/A	cg23024343	chr7:107201750	COG5	0.51	10.48	0.38	7.77e-24	Coronary artery disease;
BRCA	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.1	0.56	2.86e-54	Bladder cancer;
BRCA	cis	rs16976116	0.901	rs28864456	chr15:55503092	T/C	cg11288833	chr15:55489084	RSL24D1	0.47	10.52	0.38	5.59e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg06618935	chr21:46677482	NA	-0.36	-7.98	-0.3	6.64e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2882667	0.893	rs10069961	chr5:138294568	A/G	cg04439458	chr5:138467593	SIL1	-0.32	-8.54	-0.32	1.01e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg26031613	chr14:104095156	KLC1	-0.43	-8.5	-0.32	1.29e-16	Schizophrenia;
BRCA	cis	rs9296092	0.517	rs56206922	chr6:33522567	C/T	cg13560919	chr6:33536144	NA	-0.85	-18.66	-0.59	2.26e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.2e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg07828340	chr4:882639	GAK	1.07	14.28	0.49	2.32e-40	Intelligence (multi-trait analysis);
BRCA	cis	rs2625529	0.526	rs11637611	chr15:72551712	C/T	cg16672083	chr15:72433130	SENP8	0.62	14.71	0.5	2.21e-42	Red blood cell count;
BRCA	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg23711669	chr6:146136114	FBXO30	0.75	17.25	0.56	4.93e-55	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg26043149	chr18:55253948	FECH	-0.4	-8.8	-0.33	1.28e-17	Bone mineral density;
BRCA	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg24829409	chr8:58192753	C8orf71	-0.47	-9.0	-0.34	2.61e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg01839639	chr16:202542	HBZ	0.35	7.89	0.3	1.32e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.8	11.49	0.41	6.35e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs495337	0.760	rs624115	chr20:48523628	C/T	cg17835207	chr20:48524531	SPATA2	-0.66	-15.85	-0.53	5.68e-48	Psoriasis;
BRCA	trans	rs629535	0.725	rs639127	chr8:70073251	A/G	cg21567404	chr3:27674614	NA	1.01	21.13	0.64	1.52e-75	Dupuytren's disease;
BRCA	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.27	0.34	2.71e-19	Tonsillectomy;
BRCA	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14169450	chr9:139327907	INPP5E	-0.46	-11.32	-0.41	3.25e-27	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg06784218	chr1:46089804	CCDC17	0.49	11.45	0.41	1e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2559856	1.000	rs2559856	chr12:102089561	A/G	cg12924262	chr12:102091054	CHPT1	0.39	8.67	0.32	3.54e-17	Blood protein levels;
BRCA	cis	rs1256061	0.654	rs1256031	chr14:64746179	C/T	cg23250157	chr14:64679961	SYNE2	0.3	8.09	0.3	3e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs9486719	1.000	rs11756315	chr6:97008678	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	13.79	0.48	4.53e-38	Migraine;Coronary artery disease;
BRCA	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg12386194	chr3:101231763	SENP7	0.4	8.62	0.32	5.29e-17	Colorectal cancer;
BRCA	trans	rs6479891	1.000	rs2893922	chr10:65247019	G/T	cg14819942	chr15:35414228	NA	-0.34	-8.51	-0.32	1.24e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	trans	rs12517041	1.000	rs12519798	chr5:23290006	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.36	-0.31	4.04e-16	Calcium levels;
BRCA	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.99	0.4	7.26e-26	Bipolar disorder;
BRCA	cis	rs679087	0.932	rs10843507	chr12:29931056	C/A	cg14258853	chr12:29935411	TMTC1	0.36	8.26	0.31	8.17e-16	Schizophrenia;
BRCA	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg23422044	chr7:1970798	MAD1L1	-0.41	-8.63	-0.32	4.79e-17	Neuroticism;
BRCA	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.19	-0.4	1.19e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.53	0.35	3.26e-20	Tonsillectomy;
BRCA	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.48	-8.32	-0.31	5.32e-16	Renal function-related traits (BUN);
BRCA	cis	rs11229555	0.645	rs10896775	chr11:58175989	A/T	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg05519781	chr21:40033154	ERG	0.44	9.34	0.35	1.61e-19	Coronary artery disease;
BRCA	cis	rs698813	0.572	rs4953076	chr2:44480950	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	8.27	0.31	7.55e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.46	-13.72	-0.48	9.78e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	4.01e-15	Alzheimer's disease (late onset);
BRCA	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs10992471	0.603	rs7045572	chr9:95137964	T/C	cg14631576	chr9:95140430	CENPP	-0.4	-9.68	-0.36	8.86e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg25358565	chr5:93447407	FAM172A	-0.64	-11.14	-0.4	1.88e-26	Diabetic retinopathy;
BRCA	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.54	-0.44	2.15e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18404041	chr3:52824283	ITIH1	-0.28	-8.26	-0.31	8.39e-16	Electroencephalogram traits;
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg22907277	chr7:1156413	C7orf50	0.41	8.73	0.33	2.28e-17	Longevity;Endometriosis;
BRCA	cis	rs9715521	0.589	rs11726451	chr4:59852381	A/C	cg11281224	chr4:60001000	NA	-0.38	-8.82	-0.33	1.12e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg12311346	chr5:56204834	C5orf35	-0.81	-16.08	-0.54	4.04e-49	Initial pursuit acceleration;
BRCA	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg17470723	chr8:74884337	TCEB1	0.39	8.52	0.32	1.17e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs858239	0.570	rs10242166	chr7:23162799	A/G	cg23682824	chr7:23144976	KLHL7	0.45	12.1	0.43	1.81e-30	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg08601574	chr20:25228251	PYGB	0.34	8.36	0.31	3.9e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.21	-0.34	4.57e-19	Alzheimer's disease (late onset);
BRCA	cis	rs62380364	0.602	rs610217	chr5:88065263	G/A	cg22951263	chr5:87985283	NA	-0.38	-10.39	-0.38	1.81e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-8.71	-0.33	2.57e-17	Pulmonary function;
BRCA	cis	rs11920090	0.860	rs35297160	chr3:170738981	C/G	cg09710316	chr3:170744871	SLC2A2	0.48	8.82	0.33	1.08e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-12.78	-0.45	1.88e-33	Bipolar disorder;
BRCA	trans	rs11976180	1.000	rs13243677	chr7:143746572	T/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.43	-8.0	-0.3	5.89e-15	Obesity-related traits;
BRCA	cis	rs1050631	0.564	rs1785905	chr18:33713287	T/A	cg19453250	chr18:33710783	SLC39A6;ELP2	-0.29	-7.99	-0.3	6.25e-15	Esophageal squamous cell cancer (length of survival);
BRCA	cis	rs7818345	0.935	rs4333618	chr8:19283442	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.22	0.31	1.12e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11764359	chr7:65958608	NA	0.77	17.66	0.57	3.66e-57	Aortic root size;
BRCA	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg11887960	chr12:57824829	NA	0.5	8.27	0.31	7.83e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg25554036	chr4:6271136	WFS1	0.37	9.07	0.34	1.45e-18	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg03146154	chr1:46216737	IPP	-0.44	-9.8	-0.36	3.14e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg26384229	chr12:38710491	ALG10B	0.75	16.93	0.56	2.16e-53	Bladder cancer;
BRCA	cis	rs13082711	0.911	rs2371065	chr3:27494589	A/C	cg02860705	chr3:27208620	NA	0.59	11.05	0.4	4.22e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs11608355	0.515	rs61941592	chr12:109930497	G/A	cg05360138	chr12:110035743	NA	0.73	13.43	0.47	2.08e-36	Neuroticism;
BRCA	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg13880726	chr7:1868755	MAD1L1	0.47	9.2	0.34	4.96e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs763121	0.524	rs760645	chr22:39032270	C/T	cg06544989	chr22:39130855	UNC84B	0.35	8.15	0.31	1.9e-15	Menopause (age at onset);
BRCA	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg04455712	chr21:45112962	RRP1B	-0.37	-8.46	-0.32	1.82e-16	Mean corpuscular hemoglobin;
BRCA	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg09654669	chr8:57350985	NA	-0.38	-8.24	-0.31	9.83e-16	Obesity-related traits;
BRCA	cis	rs10746514	0.841	rs9725652	chr1:232245997	T/A	cg09506761	chr1:232265262	NA	0.48	10.38	0.38	1.94e-23	Response to statin therapy;
BRCA	cis	rs6545883	0.931	rs12713437	chr2:61722904	C/T	cg15711740	chr2:61764176	XPO1	-0.55	-13.99	-0.48	5.71e-39	Tuberculosis;
BRCA	cis	rs1953600	0.837	rs2819946	chr10:81951635	G/A	cg04850286	chr10:81895943	PLAC9	0.31	8.94	0.33	4.08e-18	Sarcoidosis;
BRCA	cis	rs3772130	0.885	rs9816844	chr3:121496324	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.68	0.39	1.31e-24	Cognitive performance;
BRCA	cis	rs1635	0.655	rs60698636	chr6:28316045	A/G	cg15743358	chr6:28303923	ZNF323	-0.74	-8.61	-0.32	5.76e-17	Schizophrenia;
BRCA	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg23708337	chr7:1209742	NA	0.63	8.84	0.33	8.9e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	19.13	0.6	7.84e-65	Platelet count;
BRCA	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-10.9	-0.4	1.78e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs3862030	0.720	rs12569526	chr10:104237007	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-13.24	-0.46	1.56e-35	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.83	0.51	5.53e-43	Colorectal cancer;
BRCA	cis	rs12200560	0.505	rs211171	chr6:97070579	T/G	cg06623918	chr6:96969491	KIAA0776	0.52	12.25	0.44	3.94e-31	Coronary heart disease;
BRCA	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg04267008	chr7:1944627	MAD1L1	-0.54	-10.88	-0.4	2.05e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18876405	chr7:65276391	NA	-0.55	-12.62	-0.45	9.73e-33	Aortic root size;
BRCA	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-13.89	-0.48	1.61e-38	Blood metabolite levels;
BRCA	cis	rs12200560	0.505	rs1988040	chr6:97076271	G/A	cg06623918	chr6:96969491	KIAA0776	0.53	12.7	0.45	4.04e-33	Coronary heart disease;
BRCA	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg27129171	chr3:47204927	SETD2	0.74	18.78	0.6	5.59e-63	Colorectal cancer;
BRCA	trans	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04565464	chr8:145669602	NFKBIL2	0.37	8.75	0.33	1.96e-17	Bipolar disorder and schizophrenia;
BRCA	trans	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg17470723	chr8:74884337	TCEB1	0.44	9.13	0.34	8.75e-19	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	18.28	0.59	2.39e-60	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07308232	chr7:1071921	C7orf50	-0.39	-8.27	-0.31	7.49e-16	Longevity;Endometriosis;
BRCA	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02187348	chr16:89574699	SPG7	-0.45	-10.78	-0.39	5.3e-25	Multiple myeloma (IgH translocation);
BRCA	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg11843238	chr5:131593191	PDLIM4	0.34	8.8	0.33	1.3e-17	Breast cancer;
BRCA	cis	rs4363385	0.818	rs1415969	chr1:153006448	G/T	cg21543102	chr1:152974771	SPRR3	-0.28	-7.84	-0.3	1.86e-14	Inflammatory skin disease;
BRCA	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg19539972	chr4:7069911	GRPEL1	0.7	16.36	0.54	1.58e-50	Monocyte percentage of white cells;
BRCA	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.98	-0.48	6.13e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg22800045	chr5:56110881	MAP3K1	-0.64	-12.32	-0.44	1.88e-31	Initial pursuit acceleration;
BRCA	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg11657440	chr19:46296263	DMWD	-0.55	-13.09	-0.46	7.26e-35	Coronary artery disease;
BRCA	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg25358565	chr5:93447407	FAM172A	0.7	11.94	0.43	8.08e-30	Diabetic retinopathy;
BRCA	cis	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05901451	chr6:126070800	HEY2	0.4	9.72	0.36	6.35e-21	Endometrial cancer;
BRCA	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg08601574	chr20:25228251	PYGB	-0.35	-8.64	-0.32	4.54e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08045932	chr20:61659980	NA	0.5	11.43	0.41	1.2100000000000001e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	ch.11.42038R	chr11:967971	AP2A2	0.52	16.55	0.55	1.84e-51	Alzheimer's disease (late onset);
BRCA	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg06784218	chr1:46089804	CCDC17	-0.47	-10.55	-0.39	4.12e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs877282	1.000	rs10904552	chr10:774326	A/G	cg17470449	chr10:769945	NA	0.5	9.49	0.35	4.33e-20	Uric acid levels;
BRCA	cis	rs250677	0.524	rs40521	chr5:148439639	C/T	cg18129178	chr5:148520854	ABLIM3	0.48	10.39	0.38	1.85e-23	Breast cancer;
BRCA	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg26446133	chr18:72167187	CNDP2	-0.74	-12.91	-0.45	4.65e-34	Refractive error;
BRCA	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg26874164	chr19:58962979	ZNF324B	0.43	9.0	0.34	2.46e-18	Uric acid clearance;
BRCA	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg06064525	chr11:970664	AP2A2	0.3	8.76	0.33	1.71e-17	Alzheimer's disease (late onset);
BRCA	cis	rs7572733	0.534	rs6760891	chr2:198768166	T/G	cg00792783	chr2:198669748	PLCL1	0.49	10.43	0.38	1.31e-23	Dermatomyositis;
BRCA	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	15.26	0.52	4.65e-45	Platelet count;
BRCA	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg27170947	chr2:26402098	FAM59B	-0.81	-13.07	-0.46	9.07e-35	Gut microbiome composition (summer);
BRCA	cis	rs36051895	0.658	rs12346093	chr9:5021140	T/A	cg02405213	chr9:5042618	JAK2	-0.51	-8.94	-0.33	3.99e-18	Pediatric autoimmune diseases;
BRCA	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.25	-8.27	-0.31	7.58e-16	Schizophrenia;
BRCA	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg27147174	chr7:100797783	AP1S1	-0.54	-10.42	-0.38	1.42e-23	Life satisfaction;
BRCA	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg12310025	chr6:25882481	NA	0.5	11.94	0.43	8.64e-30	Blood metabolite levels;
BRCA	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.54	12.0	0.43	4.46e-30	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg11764359	chr7:65958608	NA	0.65	11.57	0.42	3.14e-28	Aortic root size;
BRCA	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg11764359	chr7:65958608	NA	0.66	12.08	0.43	2.07e-30	Aortic root size;
BRCA	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg19920283	chr7:105172520	RINT1	0.67	13.47	0.47	1.46e-36	Bipolar disorder (body mass index interaction);
BRCA	cis	rs9815354	0.767	rs73081335	chr3:41895177	A/G	cg03022575	chr3:42003672	ULK4	0.68	9.46	0.35	5.93e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-7.81	-0.3	2.39e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg00071950	chr4:10020882	SLC2A9	0.63	15.86	0.53	5.11e-48	Bone mineral density;
BRCA	cis	rs3820928	0.845	rs1917126	chr2:227840923	G/T	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.31	-0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg13010199	chr12:38710504	ALG10B	0.55	11.67	0.42	1.2e-28	Heart rate;
BRCA	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.2	0.41	1e-26	Bipolar disorder;
BRCA	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	19.17	0.6	5.03e-65	Alzheimer's disease (late onset);
BRCA	cis	rs72829446	0.530	rs4796421	chr17:7379650	C/T	cg02795151	chr17:7402630	POLR2A	0.65	11.49	0.41	6.64e-28	Androgen levels;
BRCA	cis	rs13046373	0.535	rs2832966	chr21:32017177	A/G	cg06468780	chr21:31798236	KRTAP13-3	0.34	8.56	0.32	8.15e-17	HDL cholesterol;
BRCA	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg24692254	chr21:30365293	RNF160	0.6	15.87	0.53	4.43e-48	Dental caries;
BRCA	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.66	-0.36	1.04e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08704250	chr15:31115839	NA	0.34	8.85	0.33	8.75e-18	Huntington's disease progression;
BRCA	trans	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg02030672	chr11:45687055	CHST1	-0.41	-9.15	-0.34	7.53e-19	Obesity-related traits;
BRCA	cis	rs2652834	1.000	rs2652816	chr15:63403368	C/T	cg05507819	chr15:63340323	TPM1	0.45	8.26	0.31	8.19e-16	HDL cholesterol;
BRCA	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs2235642	1.000	rs2235642	chr16:1584866	T/C	cg09065629	chr16:1709722	CRAMP1L	0.37	8.69	0.32	3.13e-17	Coronary artery disease;
BRCA	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg22535103	chr8:58192502	C8orf71	-0.47	-8.36	-0.31	3.92e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs16866061	0.962	rs16866045	chr2:225413020	G/A	cg12698349	chr2:225449008	CUL3	0.78	21.23	0.64	4.46e-76	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	25.18	0.71	9.98e-98	Platelet count;
BRCA	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.44	0.38	1.17e-23	Motion sickness;
BRCA	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg16482183	chr6:26056742	HIST1H1C	0.53	11.49	0.41	6.29e-28	Height;
BRCA	cis	rs5017598	1.000	rs5017598	chr6:169211494	A/G	cg05672967	chr6:169256475	NA	0.35	8.15	0.31	1.97e-15	Pediatric bone mineral density (femoral neck);Pediatric bone mineral density (hip);
BRCA	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg00666640	chr1:248458726	OR2T12	0.3	8.42	0.32	2.5e-16	Common traits (Other);
BRCA	trans	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg07211511	chr3:129823064	LOC729375	-1.05	-18.66	-0.59	2.48e-62	Blood pressure (smoking interaction);
BRCA	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg03929089	chr4:120376271	NA	0.54	9.15	0.34	7.6e-19	Axial length;
BRCA	cis	rs4908768	0.501	rs6677736	chr1:8552804	A/T	cg20416874	chr1:8611966	RERE	-0.29	-8.32	-0.31	5.4e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg17971929	chr21:40555470	PSMG1	0.79	18.92	0.6	1.04e-63	Cognitive function;
BRCA	cis	rs9462027	0.628	rs6899938	chr6:34749113	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.94	-0.3	9.2e-15	Systemic lupus erythematosus;
BRCA	cis	rs17401966	0.838	rs12132134	chr1:10378428	A/G	cg03954927	chr1:10346856	KIF1B	0.43	13.53	0.47	7.6e-37	Hepatocellular carcinoma;
BRCA	cis	rs7246967	0.673	rs35061555	chr19:22963766	T/C	cg23217946	chr19:22817039	ZNF492	0.5	9.11	0.34	1.04e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08280861	chr8:58055591	NA	0.61	9.32	0.35	1.81e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs28374715	0.662	rs13329579	chr15:41467435	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.85	-17.71	-0.57	2.15e-57	Ulcerative colitis;
BRCA	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.55	-9.24	-0.34	3.66e-19	Schizophrenia;
BRCA	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg11645453	chr3:52864694	ITIH4	-0.46	-11.38	-0.41	1.86e-27	Schizophrenia;
BRCA	cis	rs9796	0.558	rs8043253	chr15:41503730	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.37	-8.28	-0.31	7.26e-16	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.58e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9682041	0.696	rs16855034	chr3:170097842	C/G	cg11886554	chr3:170076028	SKIL	0.51	10.11	0.37	2.1e-22	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	11.96	0.43	6.74e-30	Multiple sclerosis;
BRCA	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg12826209	chr6:26865740	GUSBL1	0.67	9.74	0.36	5.19e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg17366294	chr4:99064904	C4orf37	0.43	9.89	0.36	1.45e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs698813	0.789	rs2592195	chr2:44607707	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	10.59	0.39	3.05e-24	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	trans	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg12292205	chr6:26970375	C6orf41	-0.64	-10.65	-0.39	1.66e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7809950	0.817	rs4727678	chr7:107083635	C/G	cg23024343	chr7:107201750	COG5	-0.5	-10.49	-0.38	7.39e-24	Coronary artery disease;
BRCA	cis	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg06521331	chr12:34319734	NA	-0.62	-11.25	-0.41	6.25e-27	Morning vs. evening chronotype;
BRCA	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg23029597	chr12:123009494	RSRC2	-0.57	-11.19	-0.4	1.14e-26	Body mass index;
BRCA	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-8.74	-0.33	2.05e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg21573476	chr21:45109991	RRP1B	-0.37	-9.61	-0.36	1.58e-20	Mean corpuscular volume;
BRCA	cis	rs858239	0.600	rs2014768	chr7:23122440	C/A	cg23682824	chr7:23144976	KLHL7	0.45	12.23	0.44	4.63e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg02574844	chr11:5959923	NA	-0.42	-8.04	-0.3	4.25e-15	DNA methylation (variation);
BRCA	cis	rs1832871	0.672	rs56115227	chr6:158773884	G/A	cg07165851	chr6:158734300	TULP4	0.64	12.76	0.45	2.27e-33	Height;
BRCA	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg03709012	chr19:19516395	GATAD2A	0.99	18.37	0.59	8.18e-61	Nonalcoholic fatty liver disease;
BRCA	trans	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg23762105	chr12:34175262	ALG10	-0.41	-10.06	-0.37	3.39e-22	Morning vs. evening chronotype;
BRCA	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.42	11.75	0.42	5.35e-29	Monocyte percentage of white cells;
BRCA	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg21475434	chr5:93447410	FAM172A	-0.63	-8.46	-0.32	1.82e-16	Diabetic retinopathy;
BRCA	trans	rs1997103	1.000	rs2331065	chr7:55408392	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.32	8.99	0.34	2.79e-18	Response to antipsychotic treatment;
BRCA	cis	rs9323205	0.861	rs55763867	chr14:51608567	G/A	cg23942311	chr14:51606299	NA	-0.44	-9.54	-0.35	2.89e-20	Cancer;
BRCA	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg24450063	chr1:156163899	SLC25A44	0.94	18.49	0.59	1.82e-61	Testicular germ cell tumor;
BRCA	cis	rs17401966	0.867	rs6696056	chr1:10305992	C/A	cg03954927	chr1:10346856	KIF1B	0.43	13.72	0.48	1.01e-37	Hepatocellular carcinoma;
BRCA	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg08885076	chr2:99613938	TSGA10	0.45	10.67	0.39	1.46e-24	Chronic sinus infection;
BRCA	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg04362960	chr10:104952993	NT5C2	0.43	10.31	0.38	3.72e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg12564285	chr5:131593104	PDLIM4	0.31	8.2	0.31	1.34e-15	Blood metabolite levels;
BRCA	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs12541635	0.966	rs12680670	chr8:107006811	T/G	cg10147462	chr8:107024639	NA	0.37	9.98	0.37	6.74e-22	Age of smoking initiation;
BRCA	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg09060608	chr5:178986726	RUFY1	0.45	9.44	0.35	7.1e-20	Lung cancer;
BRCA	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.97	-0.3	7.41e-15	Depression;
BRCA	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg04013093	chr6:42928303	GNMT	-0.28	-8.88	-0.33	6.98e-18	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg14004847	chr7:1930337	MAD1L1	-0.45	-9.58	-0.35	2.06e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg16339924	chr4:17578868	LAP3	0.57	13.78	0.48	5.21e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-15.45	-0.52	5.49e-46	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	11.32	0.41	3.49e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg24558204	chr6:135376177	HBS1L	-0.53	-14.48	-0.5	2.6e-41	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg18016565	chr1:150552671	MCL1	0.34	7.95	0.3	8.65e-15	Tonsillectomy;
BRCA	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg14844989	chr11:31128820	NA	0.44	9.62	0.36	1.47e-20	Red blood cell count;
BRCA	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg24101359	chr6:42928495	GNMT	-0.42	-9.97	-0.37	7.52e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.49	10.94	0.4	1.16e-25	Cognitive ability;
BRCA	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg21747090	chr2:27597821	SNX17	-0.43	-9.43	-0.35	7.24e-20	Total body bone mineral density;
BRCA	cis	rs1468333	0.930	rs2269954	chr5:137501003	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.44	8.66	0.32	3.92e-17	Resting heart rate;
BRCA	cis	rs754466	0.651	rs11818687	chr10:79637709	C/T	cg17075019	chr10:79541650	NA	-0.75	-18.04	-0.58	4.02e-59	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-10.36	-0.38	2.4e-23	Longevity;Endometriosis;
BRCA	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg03808351	chr9:123631620	PHF19	0.61	12.82	0.45	1.27e-33	Birth weight;
BRCA	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg15556689	chr8:8085844	FLJ10661	-0.34	-8.89	-0.33	6.04e-18	Mood instability;
BRCA	cis	rs4865169	0.783	rs7668814	chr4:57825190	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.31	8.14	0.31	2.09e-15	Breast cancer;
BRCA	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05901451	chr6:126070800	HEY2	-0.7	-20.28	-0.63	5.55e-71	Brugada syndrome;
BRCA	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg17366294	chr4:99064904	C4orf37	0.41	9.66	0.36	1.07e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs96067	0.772	rs6700737	chr1:36598214	A/G	cg24686825	chr1:36642396	MAP7D1	-0.46	-8.33	-0.31	4.99e-16	Corneal structure;
BRCA	cis	rs17095355	1.000	rs921348	chr10:111707498	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.86	-0.36	1.88e-21	Biliary atresia;
BRCA	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg02176678	chr2:219576539	TTLL4	0.39	10.54	0.38	4.57e-24	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs965469	0.779	rs6051770	chr20:3327014	A/G	cg25506879	chr20:3388711	C20orf194	-0.43	-8.74	-0.33	2.11e-17	IFN-related cytopenia;
BRCA	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg05283184	chr6:79620031	NA	0.43	11.05	0.4	4.31e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg04166393	chr7:2884313	GNA12	0.45	9.77	0.36	4.32e-21	Height;
BRCA	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg19628046	chr18:33552617	C18orf21	0.53	10.64	0.39	1.83e-24	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg04990556	chr1:26633338	UBXN11	0.78	17.1	0.56	2.79e-54	Obesity-related traits;
BRCA	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs738322	0.726	rs5750561	chr22:38595260	A/T	cg25457927	chr22:38595422	NA	0.51	21.86	0.65	1.55e-79	Cutaneous nevi;
BRCA	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg09877947	chr5:131593287	PDLIM4	0.36	7.81	0.3	2.32e-14	Breast cancer;
BRCA	cis	rs2742417	0.603	rs2064063	chr3:45759924	T/A	cg04837898	chr3:45731254	SACM1L	-0.4	-8.09	-0.3	3.07e-15	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs7178424	0.817	rs12916052	chr15:62329382	A/G	cg00456672	chr15:62358751	C2CD4A	-0.36	-8.12	-0.31	2.46e-15	Height;
BRCA	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg20283391	chr11:68216788	NA	-0.46	-9.05	-0.34	1.66e-18	Total body bone mineral density;
BRCA	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2742234	0.666	rs715106	chr10:43616751	C/A	cg15436174	chr10:43711423	RASGEF1A	-0.54	-10.63	-0.39	2.08e-24	Hirschsprung disease;
BRCA	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg06623918	chr6:96969491	KIAA0776	-0.77	-13.77	-0.48	5.7800000000000005e-38	Migraine;Coronary artery disease;
BRCA	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	14.68	0.5	2.94e-42	Motion sickness;
BRCA	cis	rs4566357	0.595	rs10201538	chr2:227914449	A/G	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.2	-0.31	1.32e-15	Coronary artery disease;
BRCA	cis	rs10044254	0.587	rs4568364	chr5:15732533	T/G	cg07238450	chr5:15720153	FBXL7	-0.38	-8.04	-0.3	4.25e-15	Asthma (corticosteroid response);
BRCA	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.78	-0.42	3.93e-29	Bipolar disorder;
BRCA	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg19678392	chr7:94953810	PON1	-0.43	-9.17	-0.34	6.48e-19	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-9.43	-0.35	7.35e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs208520	0.690	rs207108	chr6:66794096	T/C	cg07460842	chr6:66804631	NA	-1.02	-20.41	-0.63	1.11e-71	Exhaled nitric oxide output;
BRCA	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.77	-11.77	-0.42	4.39e-29	Platelet count;
BRCA	cis	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg00852783	chr1:26633632	UBXN11	-0.46	-8.09	-0.3	2.9e-15	Obesity-related traits;
BRCA	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg03146154	chr1:46216737	IPP	-0.44	-9.78	-0.36	3.68e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	15.11	0.51	2.44e-44	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg05283184	chr6:79620031	NA	-0.35	-8.5	-0.32	1.29e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg13298116	chr11:62369859	EML3;MTA2	-0.53	-10.72	-0.39	8.85e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg26248373	chr2:1572462	NA	-0.65	-15.46	-0.52	4.64e-46	IgG glycosylation;
BRCA	trans	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.87	0.33	7.46e-18	Mean corpuscular volume;
BRCA	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg13047869	chr3:10149882	C3orf24	0.52	10.86	0.39	2.54e-25	Alzheimer's disease;
BRCA	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg12826209	chr6:26865740	GUSBL1	0.56	9.23	0.34	3.9e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs250677	0.522	rs6872701	chr5:148359086	C/G	cg12140854	chr5:148520817	ABLIM3	0.42	8.56	0.32	8.45e-17	Breast cancer;
BRCA	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.8	0.39	4.53e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.38	-0.31	3.39e-16	Colorectal cancer;
BRCA	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg26384229	chr12:38710491	ALG10B	0.74	17.21	0.56	7.75e-55	Bladder cancer;
BRCA	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	10.58	0.39	3.33e-24	Platelet count;
BRCA	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg23711669	chr6:146136114	FBXO30	-0.75	-18.0	-0.58	6.95e-59	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg23711669	chr6:146136114	FBXO30	0.72	16.9	0.56	2.9e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	11.13	0.4	1.95e-26	Platelet count;
BRCA	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.37e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg00383909	chr3:49044727	WDR6	0.71	12.63	0.45	8.28e-33	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg04315214	chr1:2043799	PRKCZ	-0.48	-12.65	-0.45	6.69e-33	Height;
BRCA	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06108461	chr20:60628389	TAF4	-0.98	-22.16	-0.66	3.66e-81	Body mass index;
BRCA	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg11301795	chr4:187892539	NA	-0.27	-8.71	-0.33	2.5e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg21918786	chr6:109611834	NA	-0.44	-12.53	-0.44	2.34e-32	Reticulocyte fraction of red cells;
BRCA	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.58	0.55	1.25e-51	Hypertriglyceridemia;
BRCA	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg22920501	chr2:26401640	FAM59B	-0.9	-16.59	-0.55	1.12e-51	Gut microbiome composition (summer);
BRCA	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22338127	chr1:209979572	IRF6	0.54	13.88	0.48	1.74e-38	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
BRCA	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg02733842	chr7:1102375	C7orf50	-0.43	-8.64	-0.32	4.37e-17	Bronchopulmonary dysplasia;
BRCA	cis	rs7512552	0.839	rs834232	chr1:150354682	T/C	cg15654264	chr1:150340011	RPRD2	0.38	8.44	0.32	2.06e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-10.04	-0.37	3.85e-22	Mean corpuscular volume;
BRCA	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.97	14.47	0.5	2.86e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg04362960	chr10:104952993	NT5C2	0.44	10.61	0.39	2.52e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg12193833	chr17:30244370	NA	-0.61	-9.77	-0.36	4.27e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg13319975	chr6:146136371	FBXO30	-0.35	-8.11	-0.31	2.52e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs911119	1.000	rs13041070	chr20:23614261	G/A	cg16589663	chr20:23618590	CST3	0.46	8.64	0.32	4.47e-17	Chronic kidney disease;
BRCA	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg08885076	chr2:99613938	TSGA10	0.44	10.4	0.38	1.72e-23	Chronic sinus infection;
BRCA	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg05665937	chr4:1216051	CTBP1	0.44	8.71	0.33	2.52e-17	Obesity-related traits;
BRCA	cis	rs13095912	0.752	rs13092283	chr3:185338005	T/C	cg11274856	chr3:185301563	NA	0.53	12.85	0.45	9.14e-34	Systolic blood pressure;
BRCA	cis	rs36051895	0.632	rs12343038	chr9:5178579	A/G	cg02405213	chr9:5042618	JAK2	0.47	9.07	0.34	1.5e-18	Pediatric autoimmune diseases;
BRCA	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.57	-12.95	-0.46	3.27e-34	Longevity;Endometriosis;
BRCA	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07256732	chr16:621771	PIGQ	-0.34	-8.8	-0.33	1.3e-17	Height;
BRCA	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg15704280	chr7:45808275	SEPT13	-0.77	-17.34	-0.57	1.8e-55	Coronary artery disease;
BRCA	trans	rs11165623	0.564	rs11165658	chr1:96985670	A/G	cg10631902	chr5:14652156	NA	-0.46	-12.94	-0.46	3.67e-34	Hip circumference;Waist circumference;
BRCA	cis	rs738321	0.725	rs9622738	chr22:38542346	G/A	cg25457927	chr22:38595422	NA	-0.38	-13.01	-0.46	1.67e-34	Breast cancer;
BRCA	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg02403541	chr12:121454288	C12orf43	0.59	12.8	0.45	1.51e-33	Subjective well-being;Cardiovascular disease risk factors;
BRCA	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg14349672	chr11:133703707	NA	-0.34	-8.5	-0.32	1.34e-16	Childhood ear infection;
BRCA	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	9.95	0.37	8.73e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9443189	0.526	rs10943255	chr6:76225928	T/A	cg01950844	chr6:76311363	SENP6	0.85	13.6	0.47	3.36e-37	Prostate cancer;
BRCA	cis	rs3125734	0.633	rs4979772	chr10:63967600	C/T	cg09941381	chr10:64027924	RTKN2	0.29	8.73	0.33	2.23e-17	Rheumatoid arthritis;
BRCA	cis	rs4308124	0.708	rs61358692	chr2:111965159	T/C	cg04571233	chr2:111982156	NA	-0.45	-9.71	-0.36	7.15e-21	Vitiligo;
BRCA	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22590775	chr19:49891494	CCDC155	0.45	7.97	0.3	7.15e-15	Multiple sclerosis;
BRCA	cis	rs2880765	0.835	rs4360874	chr15:86040820	A/T	cg10818794	chr15:86012489	AKAP13	-0.31	-8.56	-0.32	8.11e-17	Coronary artery disease;
BRCA	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg25554036	chr4:6271136	WFS1	0.44	9.25	0.34	3.34e-19	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs6558174	0.965	rs7831119	chr8:22489678	C/T	cg03733263	chr8:22462867	KIAA1967	-0.42	-8.08	-0.3	3.2e-15	Breast cancer;
BRCA	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg06784218	chr1:46089804	CCDC17	-0.43	-9.95	-0.37	8.5e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg09877947	chr5:131593287	PDLIM4	0.46	11.17	0.4	1.37e-26	Acylcarnitine levels;
BRCA	cis	rs66530629	1.000	rs4601530	chr1:25044111	A/G	cg01905478	chr1:25040257	NA	-0.34	-7.97	-0.3	7.14e-15	Plateletcrit;
BRCA	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg13010199	chr12:38710504	ALG10B	0.43	9.17	0.34	6.24e-19	Morning vs. evening chronotype;
BRCA	cis	rs7246657	0.678	rs2972446	chr19:38129893	G/A	cg18154014	chr19:37997991	ZNF793	-0.49	-9.24	-0.34	3.51e-19	Coronary artery calcification;
BRCA	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg26536863	chr7:158807979	LOC154822	-0.34	-7.85	-0.3	1.77e-14	Facial morphology (factor 20);
BRCA	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.71	0.42	8.19e-29	Tonsillectomy;
BRCA	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg24069376	chr3:38537580	EXOG	-0.41	-11.81	-0.42	2.95e-29	Electrocardiographic conduction measures;
BRCA	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg11843238	chr5:131593191	PDLIM4	0.37	9.68	0.36	9.38e-21	Breast cancer;
BRCA	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Tonsillectomy;
BRCA	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg16606324	chr3:10149918	C3orf24	0.56	9.97	0.37	7.35e-22	Alzheimer's disease;
BRCA	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.46	8.6	0.32	5.96e-17	Multiple sclerosis;
BRCA	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.63	-15.78	-0.53	1.3e-47	Multiple sclerosis;
BRCA	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg00012203	chr2:219082015	ARPC2	-0.42	-8.11	-0.31	2.54e-15	Ulcerative colitis;
BRCA	trans	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17712092	chr4:129076599	LARP1B	0.54	13.03	0.46	1.34e-34	Eosinophil percentage of white cells;
BRCA	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg13256891	chr4:100009986	ADH5	0.37	8.05	0.3	4.05e-15	Alcohol dependence;
BRCA	cis	rs7590368	1.000	rs7590368	chr2:10961474	T/C	cg15705551	chr2:10952987	PDIA6	0.44	8.16	0.31	1.83e-15	Educational attainment (years of education);
BRCA	cis	rs250677	0.522	rs919730	chr5:148352401	T/C	cg12140854	chr5:148520817	ABLIM3	0.4	8.13	0.31	2.15e-15	Breast cancer;
BRCA	cis	rs7246657	0.653	rs10414983	chr19:37665732	T/C	cg18154014	chr19:37997991	ZNF793	0.55	9.25	0.34	3.46e-19	Coronary artery calcification;
BRCA	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24531977	chr5:56204891	C5orf35	-0.88	-19.02	-0.6	2.83e-64	Initial pursuit acceleration;
BRCA	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg11584989	chr19:19387371	SF4	0.67	14.73	0.5	1.78e-42	Bipolar disorder;
BRCA	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.05	29.63	0.76	4.78e-122	Cognitive ability;
BRCA	cis	rs6120849	0.754	rs752448	chr20:33592248	C/T	cg24642439	chr20:33292090	TP53INP2	0.58	10.12	0.37	1.91e-22	Protein C levels;
BRCA	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-1.04	-28.95	-0.75	2.23e-118	Cognitive ability;
BRCA	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg22920501	chr2:26401640	FAM59B	-0.66	-11.6	-0.42	2.35e-28	Gut microbiome composition (summer);
BRCA	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg03609598	chr5:56110824	MAP3K1	-0.46	-8.03	-0.3	4.6e-15	Initial pursuit acceleration;
BRCA	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg24558204	chr6:135376177	HBS1L	0.45	12.31	0.44	2.04e-31	Red blood cell count;
BRCA	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.39	-0.44	9.24e-32	Type 2 diabetes;
BRCA	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg24642844	chr7:1081250	C7orf50	-0.58	-12.04	-0.43	3.04e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7799006	0.593	rs12531150	chr7:2289888	C/T	cg08027265	chr7:2291960	NA	-0.48	-12.74	-0.45	2.65e-33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg05527609	chr1:210001259	C1orf107	0.67	14.23	0.49	3.95e-40	Orofacial clefts;
BRCA	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg07930552	chr6:133119739	C6orf192	-0.66	-10.4	-0.38	1.64e-23	Type 2 diabetes nephropathy;
BRCA	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-13.96	-0.48	7.69e-39	Morning vs. evening chronotype;
BRCA	cis	rs9462027	0.583	rs7755982	chr6:34715297	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.96	-0.3	8.03e-15	Systemic lupus erythematosus;
BRCA	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg12062639	chr20:23401060	NAPB	0.87	10.46	0.38	9.93e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9533799	1.000	rs7999059	chr13:44807194	C/A	cg19190762	chr13:44806055	NA	0.41	9.02	0.34	2.17e-18	Amyotrophic lateral sclerosis;
BRCA	cis	rs490234	0.841	rs548793	chr9:128301931	C/T	cg14078157	chr9:128172775	NA	0.34	8.11	0.31	2.63e-15	Mean arterial pressure;
BRCA	cis	rs10493773	0.775	rs6667672	chr1:86171072	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.43	-9.5	-0.35	4.05e-20	Urate levels in overweight individuals;
BRCA	cis	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg03476357	chr21:30257390	N6AMT1	0.53	8.37	0.31	3.53e-16	Cognitive test performance;
BRCA	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-10.3	-0.38	3.92e-23	Aortic root size;
BRCA	cis	rs7246657	0.765	rs4803262	chr19:38066760	G/A	cg23950597	chr19:37808831	NA	-0.5	-8.64	-0.32	4.63e-17	Coronary artery calcification;
BRCA	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	19.29	0.61	1.07e-65	Smoking behavior;
BRCA	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg17691542	chr6:26056736	HIST1H1C	0.63	11.04	0.4	4.86e-26	Iron status biomarkers;
BRCA	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg03342759	chr3:160939853	NMD3	0.67	14.57	0.5	1.02e-41	Morning vs. evening chronotype;
BRCA	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg00631329	chr6:26305371	NA	-0.43	-12.71	-0.45	3.53e-33	Educational attainment;
BRCA	cis	rs4853036	0.951	rs61422548	chr2:70110249	G/T	cg02498382	chr2:70120550	SNRNP27	-0.56	-10.14	-0.37	1.6e-22	Colorectal or endometrial cancer;
BRCA	cis	rs7617773	0.743	rs11716371	chr3:48362750	C/T	cg11946769	chr3:48343235	NME6	0.67	13.64	0.47	2.37e-37	Coronary artery disease;
BRCA	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	11.31	0.41	3.81e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg04546413	chr19:29218101	NA	0.63	12.77	0.45	1.98e-33	Methadone dose in opioid dependence;
BRCA	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg09307838	chr4:120376055	NA	0.64	13.09	0.46	7.25e-35	Corneal astigmatism;
BRCA	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg15133208	chr4:90757351	SNCA	-0.38	-7.93	-0.3	9.7e-15	Neuroticism;
BRCA	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	18.0	0.58	6.37e-59	Platelet count;
BRCA	trans	rs5756813	1.000	rs5756813	chr22:38175477	A/C	cg19894588	chr14:64061835	NA	-0.52	-13.63	-0.47	2.68e-37	Optic cup area;Vertical cup-disc ratio;
BRCA	trans	rs75804782	0.572	rs56330821	chr2:239273949	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	7.98	0.3	6.64e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-8.8	-0.33	1.26e-17	Longevity;Endometriosis;
BRCA	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	12.69	0.45	4.45e-33	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs12540874	0.507	rs4947644	chr7:50618876	C/T	cg18232548	chr7:50535776	DDC	0.36	8.7	0.33	2.9e-17	Systemic sclerosis;
BRCA	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg17063962	chr7:91808500	NA	0.54	12.71	0.45	3.83e-33	Breast cancer;
BRCA	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg09035930	chr12:129282057	SLC15A4	0.57	16.81	0.55	8.83e-53	Systemic lupus erythematosus;
BRCA	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg23018236	chr17:30244563	NA	-0.46	-8.29	-0.31	6.9e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg06115741	chr20:33292138	TP53INP2	0.51	11.12	0.4	2.13e-26	Coronary artery disease;
BRCA	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg27588902	chr6:42928151	GNMT	-0.3	-10.14	-0.37	1.7e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs758324	0.947	rs60847707	chr5:131252554	C/T	cg06307176	chr5:131281290	NA	-0.52	-10.15	-0.37	1.56e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg01483505	chr11:975446	AP2A2	0.33	9.14	0.34	7.87e-19	Alzheimer's disease (late onset);
BRCA	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg21535247	chr6:8435926	SLC35B3	0.41	9.38	0.35	1.09e-19	Motion sickness;
BRCA	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg13256891	chr4:100009986	ADH5	0.51	9.77	0.36	4.23e-21	Smoking initiation;
BRCA	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg20607287	chr7:12443886	VWDE	-0.58	-8.36	-0.31	4.04e-16	Coronary artery disease;
BRCA	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	cg06064525	chr11:970664	AP2A2	-0.29	-8.42	-0.32	2.43e-16	Alzheimer's disease (late onset);
BRCA	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg23533926	chr12:111358616	MYL2	-0.41	-8.57	-0.32	7.8e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.67	-0.32	3.43e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg08742575	chr21:47604166	C21orf56	0.41	8.23	0.31	1.02e-15	Testicular germ cell tumor;
BRCA	cis	rs758324	0.947	rs7734536	chr5:131162124	C/T	cg06307176	chr5:131281290	NA	0.52	10.16	0.37	1.42e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg21385522	chr1:16154831	NA	0.99	25.46	0.71	3.02e-99	Dilated cardiomyopathy;
BRCA	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.6	0.39	2.68e-24	Motion sickness;
BRCA	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.03	-18.48	-0.59	2e-61	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg22907277	chr7:1156413	C7orf50	0.45	10.27	0.38	5.21e-23	Longevity;Endometriosis;
BRCA	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg10223061	chr2:219282414	VIL1	-0.28	-8.32	-0.31	5.35e-16	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7246657	0.524	rs28542490	chr19:37456584	C/A	cg14683738	chr19:37701593	ZNF585B	0.5	7.88	0.3	1.43e-14	Coronary artery calcification;
BRCA	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg20503657	chr10:835505	NA	1.04	18.38	0.59	7.04e-61	Eosinophil percentage of granulocytes;
BRCA	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00149659	chr3:10157352	C3orf10	0.8	13.69	0.48	1.4e-37	Alzheimer's disease;
BRCA	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21659725	chr3:3221576	CRBN	0.34	8.26	0.31	8.32e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg11845111	chr2:191398756	TMEM194B	0.4	9.34	0.35	1.55e-19	Pulse pressure;
BRCA	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg25767906	chr1:53392781	SCP2	0.34	7.83	0.3	2.09e-14	Monocyte count;
BRCA	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg03954927	chr1:10346856	KIF1B	0.43	13.76	0.48	6.16e-38	Hepatocellular carcinoma;
BRCA	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-11.53	-0.41	4.63e-28	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs7200543	1.000	rs2740	chr16:15132108	A/G	cg24683922	chr1:11983373	KIAA2013	-0.38	-8.47	-0.32	1.65e-16	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg18230493	chr5:56204884	C5orf35	-0.74	-14.97	-0.51	1.18e-43	Initial pursuit acceleration;
BRCA	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.54	-9.79	-0.36	3.53e-21	Renal function-related traits (BUN);
BRCA	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg12311346	chr5:56204834	C5orf35	-0.49	-9.92	-0.37	1.14e-21	Coronary artery disease;
BRCA	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg17063962	chr7:91808500	NA	0.57	13.25	0.46	1.44e-35	Breast cancer;
BRCA	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg16405210	chr4:1374714	KIAA1530	-0.37	-7.83	-0.3	2e-14	Obesity-related traits;
BRCA	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg03351412	chr1:154909251	PMVK	0.62	14.22	0.49	4.73e-40	Prostate cancer;
BRCA	trans	rs629535	0.783	rs658407	chr8:70035247	T/C	cg21567404	chr3:27674614	NA	1.0	21.1	0.64	2.04e-75	Dupuytren's disease;
BRCA	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.63	0.61	1.63e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg23788917	chr6:8435910	SLC35B3	-0.49	-10.6	-0.39	2.78e-24	Motion sickness;
BRCA	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg18811423	chr2:55921094	PNPT1	0.73	23.39	0.68	7.41e-88	Metabolic syndrome;
BRCA	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg09436375	chr6:42928200	GNMT	0.28	10.85	0.39	2.63e-25	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	11.34	0.41	2.79e-27	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg15448220	chr1:150897856	SETDB1	0.35	7.92	0.3	1.08e-14	Melanoma;
BRCA	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs858239	0.601	rs987257	chr7:23147840	G/A	cg23682824	chr7:23144976	KLHL7	0.42	10.94	0.4	1.16e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg00531865	chr16:30841666	NA	-0.49	-11.56	-0.42	3.47e-28	Multiple myeloma;
BRCA	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26314531	chr2:26401878	FAM59B	-0.67	-11.99	-0.43	4.89e-30	Gut microbiome composition (summer);
BRCA	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg18512352	chr11:47633146	NA	-0.36	-8.86	-0.33	7.89e-18	Subjective well-being;
BRCA	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg05472934	chr7:22766657	IL6	0.49	12.69	0.45	4.44e-33	Lung cancer;
BRCA	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg17366294	chr4:99064904	C4orf37	0.42	9.73	0.36	5.8e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.52	-0.61	6.62e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.36	7.85	0.3	1.78e-14	Endometrial cancer;
BRCA	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.54	0.38	4.59e-24	IgG glycosylation;
BRCA	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.91	0.62	5.12e-69	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18876405	chr7:65276391	NA	0.62	15.37	0.52	1.29e-45	Aortic root size;
BRCA	trans	rs2262909	0.962	rs409835	chr19:22230671	T/C	cg17074339	chr11:11642133	GALNTL4	-0.41	-7.98	-0.3	6.96e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs775227	0.574	rs16860849	chr3:113049993	C/T	cg18753928	chr3:113234510	CCDC52	0.54	9.24	0.34	3.54e-19	Dental caries;
BRCA	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg06064525	chr11:970664	AP2A2	-0.34	-10.11	-0.37	2.16e-22	Alzheimer's disease (late onset);
BRCA	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg02503808	chr4:7069936	GRPEL1	-0.81	-15.52	-0.52	2.51e-46	Monocyte percentage of white cells;
BRCA	cis	rs1568889	1.000	rs12797712	chr11:28290890	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	12.84	0.45	1.03e-33	Bipolar disorder;
BRCA	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.64e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg11843238	chr5:131593191	PDLIM4	0.38	9.32	0.35	1.92e-19	Acylcarnitine levels;
BRCA	trans	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17712092	chr4:129076599	LARP1B	-0.59	-14.32	-0.49	1.5e-40	Eosinophil percentage of white cells;
BRCA	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	11.54	0.42	3.94e-28	Height;
BRCA	cis	rs13046373	0.505	rs2832934	chr21:31899760	A/G	cg27071517	chr21:31768726	KRTAP13-1	0.3	7.95	0.3	8.5e-15	HDL cholesterol;
BRCA	cis	rs877529	0.966	rs5995688	chr22:39548027	A/G	cg12193277	chr22:39547181	CBX7	0.45	12.31	0.44	2.14e-31	Multiple myeloma;
BRCA	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.32	-0.44	1.9e-31	Alzheimer's disease;
BRCA	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg13319975	chr6:146136371	FBXO30	-0.62	-14.5	-0.5	2.1e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg00684032	chr4:1343700	KIAA1530	0.53	12.44	0.44	5.63e-32	Obesity-related traits;
BRCA	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg04756594	chr16:24857601	SLC5A11	0.33	8.32	0.31	5.51e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg04025307	chr7:1156635	C7orf50	0.48	10.12	0.37	1.98e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg09307838	chr4:120376055	NA	0.64	14.08	0.49	1.96e-39	Corneal astigmatism;
BRCA	cis	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg18196295	chr10:418757	DIP2C	-0.61	-12.68	-0.45	4.9e-33	Psychosis in Alzheimer's disease;
BRCA	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	9.89	0.36	1.45e-21	Aortic root size;
BRCA	cis	rs10465746	0.775	rs4907186	chr1:84340753	G/T	cg10977910	chr1:84465055	TTLL7	0.63	13.33	0.47	6.17e-36	Obesity-related traits;
BRCA	cis	rs12612619	0.579	rs13029206	chr2:27077610	G/A	cg12368169	chr2:27073192	DPYSL5	-0.33	-10.04	-0.37	3.85e-22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs13315871	1.000	rs9860970	chr3:58353781	C/T	cg20936604	chr3:58311152	NA	-0.62	-7.96	-0.3	8.01e-15	Cholesterol, total;
BRCA	cis	rs62229266	0.804	rs2835263	chr21:37430245	A/G	cg12218747	chr21:37451666	NA	0.33	7.95	0.3	8.37e-15	Mitral valve prolapse;
BRCA	cis	rs897984	0.520	rs4889614	chr16:30862135	G/A	cg02466173	chr16:30829666	NA	0.47	9.42	0.35	8.31e-20	Dementia with Lewy bodies;
BRCA	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.4	9.28	0.34	2.64e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.02	15.04	0.51	5.48e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	10.76	0.39	6.33e-25	Rheumatoid arthritis;
BRCA	cis	rs1994135	0.594	rs10772096	chr12:33732869	A/G	cg06521331	chr12:34319734	NA	-0.39	-8.06	-0.3	3.7e-15	Resting heart rate;
BRCA	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-11.2	-0.41	1e-26	Alzheimer's disease;
BRCA	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg22907277	chr7:1156413	C7orf50	0.6	11.68	0.42	1.07e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	7.89	0.3	1.36e-14	Bipolar disorder;
BRCA	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.3	-0.31	6.42e-16	Bipolar disorder;
BRCA	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg12062639	chr20:23401060	NAPB	0.91	13.46	0.47	1.54e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg24692254	chr21:30365293	RNF160	-0.47	-9.83	-0.36	2.59e-21	Cognitive test performance;
BRCA	cis	rs752010	0.841	rs11210498	chr1:42077958	T/G	cg06885757	chr1:42089581	HIVEP3	0.23	8.49	0.32	1.43e-16	Lupus nephritis in systemic lupus erythematosus;
BRCA	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg17470723	chr8:74884337	TCEB1	0.4	8.72	0.33	2.46e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	11.52	0.41	4.72e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg23625390	chr15:77176239	SCAPER	0.57	14.55	0.5	1.2e-41	Blood metabolite levels;
BRCA	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg08917208	chr2:24149416	ATAD2B	1.1	15.43	0.52	6.58e-46	Mean corpuscular hemoglobin;
BRCA	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.35e-15	Prostate cancer;
BRCA	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.69	-0.39	1.18e-24	Bipolar disorder;
BRCA	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg07395648	chr5:131743802	NA	-0.36	-9.11	-0.34	1.03e-18	Blood metabolite levels;
BRCA	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg26031613	chr14:104095156	KLC1	-0.43	-8.53	-0.32	1.04e-16	Schizophrenia;
BRCA	cis	rs7408868	0.908	rs2074619	chr19:15276919	G/A	cg14696996	chr19:15285081	NOTCH3	0.99	14.49	0.5	2.35e-41	Pulse pressure;
BRCA	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.13	-0.4	2.05e-26	Morning vs. evening chronotype;
BRCA	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg24692254	chr21:30365293	RNF160	-0.62	-15.86	-0.53	5.18e-48	Dental caries;
BRCA	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg14004847	chr7:1930337	MAD1L1	-0.46	-8.87	-0.33	7.52e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg26384229	chr12:38710491	ALG10B	0.72	17.02	0.56	7.88e-54	Bladder cancer;
BRCA	cis	rs10080237	0.564	rs2490230	chr6:80812464	G/A	cg08355045	chr6:80787529	NA	0.42	10.96	0.4	9.49e-26	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
BRCA	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.46e-34	Alzheimer's disease (late onset);
BRCA	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg03894339	chr8:19674705	INTS10	0.44	8.62	0.32	5.34e-17	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs708547	0.647	rs1718839	chr4:57827206	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.41	-7.99	-0.3	6.34e-15	Response to bleomycin (chromatid breaks);
BRCA	cis	rs9560113	1.000	rs4771757	chr13:112176379	G/T	cg10483660	chr13:112241077	NA	0.32	7.93	0.3	9.77e-15	Menarche (age at onset);
BRCA	cis	rs6977660	0.714	rs4721827	chr7:19825655	A/G	cg05791153	chr7:19748676	TWISTNB	0.59	11.0	0.4	6.53e-26	Thyroid stimulating hormone;
BRCA	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg14664628	chr15:75095509	CSK	-0.74	-18.23	-0.58	4.43e-60	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg21699342	chr2:239360505	ASB1	-0.54	-14.56	-0.5	1.09e-41	Multiple system atrophy;
BRCA	cis	rs8010715	0.816	rs8015168	chr14:24599872	A/T	cg23112188	chr14:24563095	PCK2	-0.32	-8.11	-0.31	2.52e-15	IgG glycosylation;
BRCA	cis	rs7809950	0.648	rs114452520	chr7:107176780	C/T	cg23024343	chr7:107201750	COG5	-0.41	-9.36	-0.35	1.29e-19	Coronary artery disease;
BRCA	cis	rs9341808	0.621	rs2322627	chr6:80806341	T/A	cg08355045	chr6:80787529	NA	0.46	12.07	0.43	2.31e-30	Sitting height ratio;
BRCA	cis	rs2882667	0.690	rs288032	chr5:138215328	G/A	cg04439458	chr5:138467593	SIL1	-0.35	-8.56	-0.32	8.34e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs11088226	0.681	rs2833912	chr21:33949822	G/A	cg09050820	chr6:167586206	TCP10L2	0.85	15.88	0.53	4.06e-48	Gastritis;
BRCA	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10802521	chr3:52805072	NEK4	-0.34	-9.28	-0.34	2.61e-19	Bipolar disorder;
BRCA	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg02297831	chr4:17616191	MED28	0.36	8.43	0.32	2.25e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg05623727	chr3:50126028	RBM5	-0.43	-10.03	-0.37	4.47e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.6	-12.36	-0.44	1.25e-31	Lymphocyte counts;
BRCA	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg22705602	chr4:152727874	NA	-0.32	-8.24	-0.31	9.68e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.94	-0.37	9.47e-22	Mean corpuscular volume;
BRCA	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg12641515	chr19:46296257	DMWD	-0.53	-11.76	-0.42	5.01e-29	Coronary artery disease;
BRCA	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg04362960	chr10:104952993	NT5C2	0.42	10.1	0.37	2.41e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg12927641	chr6:109611667	NA	-0.41	-10.54	-0.38	4.76e-24	Reticulocyte fraction of red cells;
BRCA	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.36	0.35	1.33e-19	Menopause (age at onset);
BRCA	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg05896524	chr21:47604654	C21orf56	0.5	9.82	0.36	2.75e-21	Testicular germ cell tumor;
BRCA	cis	rs3125734	0.660	rs10733769	chr10:63974255	G/T	cg19640130	chr10:64028056	RTKN2	-0.31	-8.95	-0.33	3.93e-18	Rheumatoid arthritis;
BRCA	cis	rs9341808	0.754	rs9361591	chr6:80953255	C/A	cg08355045	chr6:80787529	NA	0.39	9.92	0.37	1.17e-21	Sitting height ratio;
BRCA	cis	rs2731664	0.792	rs2630764	chr5:176880085	C/T	cg23176889	chr5:176863531	GRK6	-0.62	-17.02	-0.56	7.68e-54	Intelligence (multi-trait analysis);
BRCA	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg23505145	chr19:12996616	KLF1	0.54	12.33	0.44	1.69e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg10578991	chr7:12443926	VWDE	-0.54	-8.1	-0.31	2.87e-15	Coronary artery disease;
BRCA	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg20742385	chr13:113633654	MCF2L	-0.37	-7.86	-0.3	1.6e-14	Systolic blood pressure;
BRCA	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg13010199	chr12:38710504	ALG10B	0.41	8.34	0.31	4.59e-16	Morning vs. evening chronotype;
BRCA	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg06627628	chr2:24431161	ITSN2	0.5	10.43	0.38	1.31e-23	Asthma;
BRCA	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg24642439	chr20:33292090	TP53INP2	0.56	12.3	0.44	2.43e-31	Coronary artery disease;
BRCA	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08859206	chr1:53392774	SCP2	-0.59	-12.81	-0.45	1.39e-33	Monocyte count;
BRCA	cis	rs3762637	0.941	rs7653592	chr3:122218371	G/A	cg24169773	chr3:122142474	KPNA1	-0.43	-8.04	-0.3	4.23e-15	LDL cholesterol levels;
BRCA	cis	rs2742234	0.541	rs11238483	chr10:43728780	A/G	cg02780029	chr10:43622663	RET	0.35	7.85	0.3	1.71e-14	Hirschsprung disease;
BRCA	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11644478	chr21:40555479	PSMG1	0.84	19.08	0.6	1.4e-64	Cognitive function;
BRCA	cis	rs27434	0.583	rs149544	chr5:96157854	C/G	cg16492584	chr5:96139282	ERAP1	-0.5	-12.76	-0.45	2.31e-33	Ankylosing spondylitis;
BRCA	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg16049864	chr8:95962084	TP53INP1	-0.49	-12.22	-0.44	5.1e-31	Type 2 diabetes;
BRCA	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg25036284	chr2:26402008	FAM59B	0.88	15.06	0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg20476274	chr7:133979776	SLC35B4	0.61	15.56	0.52	1.52e-46	Mean platelet volume;
BRCA	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.89	-0.33	6.27e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs1997103	1.000	rs9642578	chr7:55400320	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.38	0.41	1.95e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.4	8.09	0.3	3.04e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg00277334	chr10:82204260	NA	-0.48	-7.89	-0.3	1.27e-14	Post bronchodilator FEV1;
BRCA	trans	rs629535	0.814	rs545720	chr8:70063370	T/C	cg21567404	chr3:27674614	NA	1.01	20.66	0.63	4.98e-73	Dupuytren's disease;
BRCA	cis	rs11971779	0.680	rs28579232	chr7:139073116	C/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg21644426	chr2:191273491	MFSD6	-0.42	-10.56	-0.39	3.77e-24	Pulse pressure;
BRCA	cis	rs11785693	0.862	rs11778367	chr8:4988398	T/C	cg26367366	chr8:4980734	NA	0.61	10.99	0.4	7.38e-26	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg11266682	chr4:10021025	SLC2A9	0.47	12.52	0.44	2.61e-32	Bone mineral density;
BRCA	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.12	0.37	1.97e-22	Aortic root size;
BRCA	cis	rs7246657	0.722	rs35863684	chr19:38109777	C/T	cg23950597	chr19:37808831	NA	-0.49	-8.41	-0.32	2.74e-16	Coronary artery calcification;
BRCA	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg14784868	chr12:69753453	YEATS4	0.66	19.14	0.6	6.6e-65	Blood protein levels;
BRCA	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg06238570	chr21:40685208	BRWD1	-0.39	-7.98	-0.3	6.8e-15	Menarche (age at onset);
BRCA	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	17.21	0.56	7.98e-55	Intelligence (multi-trait analysis);
BRCA	cis	rs9473147	0.543	rs9296559	chr6:47452270	T/C	cg12968598	chr6:47444699	CD2AP	0.45	9.6	0.36	1.72e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs2282802	0.711	rs3777095	chr5:139660916	G/A	cg26211634	chr5:139558579	C5orf32	0.35	8.22	0.31	1.15e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.57	-10.72	-0.39	8.98e-25	Menarche (age at onset);
BRCA	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg08885076	chr2:99613938	TSGA10	-0.6	-13.13	-0.46	4.92e-35	Chronic sinus infection;
BRCA	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07930192	chr7:1003750	NA	0.4	8.69	0.33	3.03e-17	Longevity;Endometriosis;
BRCA	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg08999081	chr20:33150536	PIGU	-0.34	-8.23	-0.31	1.07e-15	Coronary artery disease;
BRCA	cis	rs1865721	1.000	rs62089507	chr18:73179019	C/T	cg26385618	chr18:73139727	C18orf62	-0.41	-9.23	-0.34	3.87e-19	Intelligence;
BRCA	cis	rs11229555	0.645	rs11229435	chr11:58185796	G/C	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11893307	0.566	rs10170782	chr2:191623236	G/A	cg05765582	chr2:191677683	NA	0.48	8.46	0.32	1.8e-16	Mean platelet volume;
BRCA	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.54	0.38	4.58e-24	Motion sickness;
BRCA	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.76	12.39	0.44	9.76e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.29	0.31	6.47e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg22705602	chr4:152727874	NA	-0.34	-8.38	-0.31	3.27e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1035144	0.510	rs12432357	chr14:81299468	A/G	cg06600135	chr14:81408086	NA	-0.51	-12.37	-0.44	1.11e-31	Male sexual orientation;
BRCA	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg26536863	chr7:158807979	LOC154822	0.37	8.59	0.32	6.8e-17	Facial morphology (factor 20);
BRCA	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	13.95	0.48	8.22e-39	Alzheimer's disease;
BRCA	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg05347473	chr6:146136440	FBXO30	0.42	8.37	0.31	3.6e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2625529	0.652	rs8036307	chr15:72175120	A/G	cg16672083	chr15:72433130	SENP8	0.66	15.83	0.53	7.13e-48	Red blood cell count;
BRCA	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg08085267	chr17:45401833	C17orf57	0.6	12.26	0.44	3.56e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7927771	0.524	rs10838771	chr11:47831332	A/G	cg20307385	chr11:47447363	PSMC3	-0.38	-8.84	-0.33	9.34e-18	Subjective well-being;
BRCA	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg07537917	chr2:241836409	C2orf54	-0.43	-10.41	-0.38	1.46e-23	Urinary metabolites;
BRCA	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg07395648	chr5:131743802	NA	-0.36	-7.99	-0.3	6.34e-15	Breast cancer;
BRCA	cis	rs858239	0.600	rs6461691	chr7:23139345	G/A	cg23682824	chr7:23144976	KLHL7	0.43	11.39	0.41	1.68e-27	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg26384229	chr12:38710491	ALG10B	0.67	14.35	0.49	1.15e-40	Morning vs. evening chronotype;
BRCA	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg08601574	chr20:25228251	PYGB	0.34	8.15	0.31	1.86e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg07741184	chr6:167504864	NA	-0.31	-9.03	-0.34	2.05e-18	Primary biliary cholangitis;
BRCA	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg13010199	chr12:38710504	ALG10B	0.35	8.5	0.32	1.35e-16	Morning vs. evening chronotype;
BRCA	trans	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg26043149	chr18:55253948	FECH	0.4	8.89	0.33	6.3e-18	Bone mineral density;
BRCA	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg25036284	chr2:26402008	FAM59B	-0.9	-15.25	-0.52	5.18e-45	Gut microbiome composition (summer);
BRCA	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg24006582	chr15:45444508	DUOX1	0.56	10.9	0.4	1.72e-25	Uric acid levels;
BRCA	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg24642439	chr20:33292090	TP53INP2	-0.52	-11.42	-0.41	1.3e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg06484146	chr7:12443880	VWDE	-0.63	-9.88	-0.36	1.66e-21	Coronary artery disease;
BRCA	trans	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	20.36	0.63	1.98e-71	Exhaled nitric oxide output;
BRCA	cis	rs10992471	0.528	rs3780347	chr9:95266812	A/G	cg14631576	chr9:95140430	CENPP	-0.34	-8.63	-0.32	5.02e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg03146154	chr1:46216737	IPP	-0.51	-11.26	-0.41	5.93e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.4	-0.32	2.86e-16	Total body bone mineral density;
BRCA	trans	rs1200821	0.738	rs1926128	chr10:37654620	C/T	cg25427524	chr10:38739819	LOC399744	0.38	8.02	0.3	4.91e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs17601876	0.651	rs12907866	chr15:51545454	A/G	cg19946085	chr15:51559439	CYP19A1	-0.33	-8.76	-0.33	1.72e-17	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg17724175	chr1:150552817	MCL1	0.26	8.54	0.32	9.54e-17	Tonsillectomy;
BRCA	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg26373071	chr5:1325741	CLPTM1L	0.46	10.98	0.4	8.49e-26	Lung cancer;
BRCA	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg11645453	chr3:52864694	ITIH4	0.42	10.33	0.38	2.99e-23	Bipolar disorder;
BRCA	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-9.68	-0.36	8.95e-21	Alzheimer's disease (late onset);
BRCA	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.52	-13.3	-0.47	7.98e-36	Longevity;Endometriosis;
BRCA	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg17971929	chr21:40555470	PSMG1	-0.46	-9.93	-0.37	1.06e-21	Menarche (age at onset);
BRCA	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg19628046	chr18:33552617	C18orf21	0.61	12.03	0.43	3.33e-30	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg22972055	chr7:872293	UNC84A	0.39	8.76	0.33	1.68e-17	Cerebrospinal P-tau181p levels;
BRCA	trans	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	8.55e-21	Bladder cancer;
BRCA	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.51	9.91	0.37	1.2e-21	Birth weight;
BRCA	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg05868516	chr6:26286170	HIST1H4H	0.51	11.15	0.4	1.6e-26	Educational attainment;
BRCA	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.83	-0.39	3.4e-25	Personality dimensions;
BRCA	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.85	-18.46	-0.59	2.55e-61	Ulcerative colitis;
BRCA	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.14	-0.31	2.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg25554036	chr4:6271136	WFS1	0.42	9.99	0.37	6.36e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg11941060	chr3:133502564	NA	-0.34	-8.13	-0.31	2.19e-15	Iron status biomarkers;
BRCA	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg06618935	chr21:46677482	NA	-0.37	-8.05	-0.3	4.1e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs68170813	0.523	rs7777976	chr7:106888594	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.44	-0.32	2.05e-16	Coronary artery disease;
BRCA	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg13770153	chr20:60521292	NA	-0.39	-9.14	-0.34	8.52e-19	Body mass index;
BRCA	cis	rs3824867	0.920	rs3740685	chr11:47468791	C/T	cg20307385	chr11:47447363	PSMC3	0.55	12.1	0.43	1.7e-30	Mean corpuscular hemoglobin;
BRCA	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg07636037	chr3:49044803	WDR6	0.98	28.75	0.75	2.78e-117	Parkinson's disease;
BRCA	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg20503657	chr10:835505	NA	0.67	10.78	0.39	5.07e-25	Eosinophil percentage of granulocytes;
BRCA	trans	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg26384229	chr12:38710491	ALG10B	0.52	11.18	0.4	1.28e-26	Morning vs. evening chronotype;
BRCA	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg00106254	chr7:1943704	MAD1L1	-0.45	-12.42	-0.44	6.93e-32	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6785206	0.667	rs2253125	chr3:128329793	T/C	cg16766828	chr3:128327626	NA	-0.68	-11.07	-0.4	3.42e-26	Lymphocyte percentage of white cells;
BRCA	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg05552183	chr6:42928497	GNMT	-0.63	-11.02	-0.4	5.71e-26	Blood protein levels;
BRCA	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-16.06	-0.54	5.07e-49	Colorectal cancer;
BRCA	trans	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	15.72	0.53	2.52e-47	Exhaled nitric oxide levels;
BRCA	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg26677194	chr12:130822605	PIWIL1	0.6	14.47	0.5	2.92e-41	Menopause (age at onset);
BRCA	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg21252483	chr19:49399788	TULP2	-0.52	-11.06	-0.4	4.04e-26	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.69	0.36	8.27e-21	Lung cancer in ever smokers;
BRCA	cis	rs250677	0.522	rs6580590	chr5:148360374	C/T	cg12140854	chr5:148520817	ABLIM3	0.41	8.32	0.31	5.16e-16	Breast cancer;
BRCA	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.43	12.63	0.45	8.24e-33	Response to antipsychotic treatment;
BRCA	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.78	-0.36	3.67e-21	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-9.64	-0.36	1.29e-20	HDL cholesterol;
BRCA	cis	rs7254827	0.784	rs8108205	chr19:17220341	G/A	cg19418318	chr19:17219073	MYO9B	-0.51	-10.32	-0.38	3.34e-23	Mean platelet volume;
BRCA	cis	rs758324	0.947	rs600661	chr5:131290894	T/C	cg06307176	chr5:131281290	NA	-0.53	-10.4	-0.38	1.68e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg22800045	chr5:56110881	MAP3K1	0.66	12.27	0.44	3.09e-31	Type 2 diabetes;
BRCA	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg05084668	chr3:125655381	ALG1L	-0.48	-8.33	-0.31	4.83e-16	Blood pressure (smoking interaction);
BRCA	cis	rs929596	0.785	rs17862875	chr2:234649302	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-12.17	-0.43	8.46e-31	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs7020830	0.571	rs3780335	chr9:37376587	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.86	-16.25	-0.54	6.09e-50	Schizophrenia;
BRCA	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg16339924	chr4:17578868	LAP3	0.63	15.92	0.53	2.55e-48	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs36051895	0.622	rs10974952	chr9:5079828	A/T	cg02405213	chr9:5042618	JAK2	-0.55	-9.59	-0.35	2e-20	Pediatric autoimmune diseases;
BRCA	cis	rs4321325	0.733	rs79208542	chr2:127935686	G/C	cg11380483	chr2:127933992	NA	0.44	8.48	0.32	1.56e-16	Protein C levels;
BRCA	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg26384229	chr12:38710491	ALG10B	0.66	15.56	0.52	1.65e-46	Bladder cancer;
BRCA	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg02466173	chr16:30829666	NA	-0.49	-10.08	-0.37	2.82e-22	Multiple myeloma;
BRCA	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg17691542	chr6:26056736	HIST1H1C	0.48	9.55	0.35	2.75e-20	Iron status biomarkers;
BRCA	cis	rs1891275	0.508	rs7099557	chr10:93445364	C/G	cg07889827	chr10:93443413	NA	-0.44	-12.37	-0.44	1.2e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg18904891	chr8:8559673	CLDN23	0.58	11.29	0.41	4.28e-27	Obesity-related traits;
BRCA	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg12011299	chr4:100065546	ADH4	0.42	10.42	0.38	1.34e-23	Alcohol dependence;
BRCA	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg08601574	chr20:25228251	PYGB	-0.34	-8.06	-0.3	3.77e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12611088	0.571	rs2599447	chr19:44007012	G/A	cg15012607	chr19:44012195	ETHE1	-0.35	-9.11	-0.34	1.08e-18	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.55	-12.08	-0.43	2.01e-30	Longevity;Endometriosis;
BRCA	cis	rs3784262	0.669	rs4646564	chr15:58351797	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-10.57	-0.39	3.66e-24	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs10181042	0.528	rs2564118	chr2:61233289	A/G	cg15711740	chr2:61764176	XPO1	-0.34	-8.08	-0.3	3.35e-15	Crohn's disease;
BRCA	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.81	0.39	3.91e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg05347473	chr6:146136440	FBXO30	0.39	7.93	0.3	9.72e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg02030672	chr11:45687055	CHST1	0.52	11.53	0.41	4.55e-28	Obesity-related traits;
BRCA	cis	rs11190604	0.767	rs10883485	chr10:102174805	G/C	cg07080220	chr10:102295463	HIF1AN	0.5	10.14	0.37	1.66e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg20476274	chr7:133979776	SLC35B4	0.6	14.85	0.51	4.41e-43	Mean platelet volume;
BRCA	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	11.91	0.43	1.13e-29	Height;
BRCA	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06481639	chr22:41940642	POLR3H	-0.53	-8.77	-0.33	1.64e-17	Vitiligo;
BRCA	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.35	7.84	0.3	1.83e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs3784262	0.771	rs4775005	chr15:58208165	C/T	cg12031962	chr15:58353849	ALDH1A2	0.42	11.0	0.4	6.62e-26	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.71e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg12310025	chr6:25882481	NA	-0.49	-10.82	-0.39	3.66e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg20290983	chr6:43655470	MRPS18A	1.1	41.39	0.85	5.5e-183	IgG glycosylation;
BRCA	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg20607798	chr8:58055168	NA	0.47	8.07	0.3	3.41e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg10523679	chr1:76189770	ACADM	0.88	20.8	0.64	8.8e-74	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg17366294	chr4:99064904	C4orf37	0.44	10.37	0.38	2.23e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg04450456	chr4:17643702	FAM184B	0.37	10.78	0.39	5.07e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs858239	0.601	rs3735228	chr7:23170427	T/G	cg23682824	chr7:23144976	KLHL7	0.44	11.56	0.42	3.27e-28	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs16958440	0.867	rs75934126	chr18:44679781	T/C	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	18.69	0.59	1.7e-62	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg22875332	chr1:76189707	ACADM	0.68	14.82	0.51	6.53e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg05535760	chr7:792225	HEATR2	0.72	13.08	0.46	8.63e-35	Cerebrospinal P-tau181p levels;
BRCA	trans	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg06521331	chr12:34319734	NA	-0.53	-9.51	-0.35	3.7e-20	Bladder cancer;
BRCA	cis	rs877529	0.967	rs139411	chr22:39552888	A/G	cg12193277	chr22:39547181	CBX7	0.47	12.81	0.45	1.27e-33	Multiple myeloma;
BRCA	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg20290983	chr6:43655470	MRPS18A	1.11	40.54	0.85	8.31e-179	IgG glycosylation;
BRCA	cis	rs9487051	0.660	rs2884036	chr6:109642916	A/G	cg21918786	chr6:109611834	NA	0.34	8.32	0.31	5.35e-16	Reticulocyte fraction of red cells;
BRCA	cis	rs17767294	0.708	rs72848791	chr6:27986199	C/T	cg08851530	chr6:28072375	NA	1.06	9.75	0.36	5.08e-21	Parkinson's disease;
BRCA	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.6	0.55	9.92e-52	Morning vs. evening chronotype;
BRCA	cis	rs965469	1.000	rs6037526	chr20:3251248	T/C	cg25506879	chr20:3388711	C20orf194	-0.56	-10.92	-0.4	1.46e-25	IFN-related cytopenia;
BRCA	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg02297831	chr4:17616191	MED28	0.36	8.42	0.32	2.43e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg16339924	chr4:17578868	LAP3	0.63	15.68	0.53	4.2e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg05623727	chr3:50126028	RBM5	-0.52	-12.31	-0.44	2.14e-31	Body mass index;
BRCA	cis	rs6435161	0.959	rs1544913	chr2:203484781	T/C	cg18429434	chr2:203499731	FAM117B	-0.43	-9.0	-0.34	2.46e-18	Total cholesterol levels;
BRCA	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg01028140	chr2:1542097	TPO	-0.61	-12.23	-0.44	4.72e-31	IgG glycosylation;
BRCA	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg08313168	chr12:7315531	NA	0.5	8.04	0.3	4.5e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-11.72	-0.42	7.42e-29	Mood instability;
BRCA	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg09754948	chr16:28834200	ATXN2L	0.46	8.97	0.33	3.27e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg04362960	chr10:104952993	NT5C2	0.48	10.54	0.38	4.79e-24	Arsenic metabolism;
BRCA	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg09307838	chr4:120376055	NA	0.76	17.16	0.56	1.42e-54	Corneal astigmatism;
BRCA	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg13770153	chr20:60521292	NA	-0.45	-10.67	-0.39	1.4e-24	Body mass index;
BRCA	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg20607798	chr8:58055168	NA	0.45	7.88	0.3	1.38e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg24558204	chr6:135376177	HBS1L	0.45	12.26	0.44	3.46e-31	Red blood cell count;
BRCA	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.55	12.07	0.43	2.3e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6700896	0.931	rs1938492	chr1:66117829	A/C	cg04111102	chr1:66153794	NA	0.34	8.42	0.32	2.57e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	trans	rs12517041	1.000	rs12520032	chr5:23285074	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.9	-0.3	1.19e-14	Calcium levels;
BRCA	cis	rs4948102	0.731	rs4543497	chr7:56047215	T/C	cg09872392	chr7:56161020	PHKG1	-0.4	-9.15	-0.34	7.4e-19	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-12.61	-0.45	1.06e-32	Chronic sinus infection;
BRCA	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg25237894	chr2:233734115	C2orf82	-0.43	-13.33	-0.47	6.08e-36	Coronary artery disease;
BRCA	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.89	-0.33	6.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11644478	chr21:40555479	PSMG1	-0.5	-10.69	-0.39	1.15e-24	Menarche (age at onset);
BRCA	cis	rs919433	0.680	rs12621129	chr2:198265350	T/C	cg00792783	chr2:198669748	PLCL1	-0.38	-8.15	-0.31	1.93e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	trans	rs1997103	1.000	rs6593233	chr7:55406200	C/T	cg20935933	chr6:143382018	AIG1	-0.6	-11.61	-0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23583168	chr7:148888333	NA	-0.79	-18.05	-0.58	3.66e-59	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg04981885	chr1:160991156	F11R	-0.63	-11.62	-0.42	1.94e-28	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg14675211	chr2:100938903	LONRF2	0.43	9.53	0.35	3.14e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg26597838	chr10:835615	NA	0.6	10.39	0.38	1.87e-23	Eosinophil percentage of granulocytes;
BRCA	cis	rs4780401	0.609	rs9923954	chr16:11816855	G/T	cg01061890	chr16:11836724	TXNDC11	-0.56	-13.21	-0.46	2.03e-35	Rheumatoid arthritis;
BRCA	cis	rs9463078	0.739	rs1041333	chr6:44945206	A/T	cg25276700	chr6:44698697	NA	-0.35	-8.18	-0.31	1.58e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg25801113	chr15:45476975	SHF	-0.34	-8.26	-0.31	8.22e-16	Uric acid levels;
BRCA	trans	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg16141378	chr3:129829833	LOC729375	-0.39	-9.57	-0.35	2.27e-20	Mood instability;
BRCA	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10802521	chr3:52805072	NEK4	-0.33	-9.13	-0.34	8.81e-19	Bipolar disorder;
BRCA	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg16384552	chr7:74938386	SPDYE8P	-0.47	-9.78	-0.36	3.97e-21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-9.9	-0.36	1.36e-21	Mean corpuscular volume;
BRCA	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg01283332	chr5:1856932	NA	-0.34	-8.44	-0.32	2.17e-16	Cardiovascular disease risk factors;
BRCA	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg20628663	chr10:43360327	NA	-0.71	-13.64	-0.47	2.25e-37	Blood protein levels;
BRCA	cis	rs57024841	0.562	rs7862602	chr9:139840471	G/T	cg00693599	chr9:139836323	FBXW5	0.45	10.96	0.4	9.85e-26	Beta-trace protein levels;
BRCA	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg20129853	chr10:51489980	NA	0.31	8.44	0.32	2.18e-16	Prostate-specific antigen levels;
BRCA	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg06212747	chr3:49208901	KLHDC8B	0.49	10.02	0.37	4.9e-22	Parkinson's disease;
BRCA	cis	rs2652834	0.861	rs4774472	chr15:63353760	C/A	cg05507819	chr15:63340323	TPM1	0.57	10.29	0.38	4.29e-23	HDL cholesterol;
BRCA	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg09184832	chr6:79620586	NA	-0.49	-11.02	-0.4	5.45e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9473147	0.516	rs9357546	chr6:47549495	C/T	cg12968598	chr6:47444699	CD2AP	0.44	9.59	0.35	1.92e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg00012203	chr2:219082015	ARPC2	0.52	10.49	0.38	7.6e-24	Colorectal cancer;
BRCA	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg08807101	chr21:30365312	RNF160	0.38	7.97	0.3	7.24e-15	Selective IgA deficiency;
BRCA	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18404041	chr3:52824283	ITIH1	-0.37	-11.33	-0.41	3.04e-27	Electroencephalogram traits;
BRCA	cis	rs7707921	0.690	rs6870335	chr5:81590070	A/T	cg15871215	chr5:81402204	ATG10	-0.35	-8.32	-0.31	5.42e-16	Breast cancer;
BRCA	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg08917208	chr2:24149416	ATAD2B	0.48	7.83	0.3	2.08e-14	Asthma;
BRCA	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.52	-0.32	1.16e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg20019720	chr6:154832845	CNKSR3	0.52	10.31	0.38	3.64e-23	Lipoprotein (a) levels;
BRCA	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21659725	chr3:3221576	CRBN	0.51	12.05	0.43	2.86e-30	Resting heart rate;
BRCA	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg12483005	chr1:23474871	LUZP1	0.37	8.12	0.31	2.36e-15	Height;
BRCA	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.53	-13.38	-0.47	3.49e-36	Urate levels in overweight individuals;
BRCA	cis	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg06521331	chr12:34319734	NA	-0.52	-10.21	-0.37	9.32e-23	Morning vs. evening chronotype;
BRCA	cis	rs17092148	0.887	rs2889849	chr20:33164277	A/G	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.63	-0.39	2e-24	Neuroticism;
BRCA	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.42e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg18876405	chr7:65276391	NA	0.47	9.67	0.36	9.81e-21	Calcium levels;
BRCA	cis	rs9463078	0.683	rs227855	chr6:44702352	T/C	cg25276700	chr6:44698697	NA	0.35	7.85	0.3	1.71e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg26384229	chr12:38710491	ALG10B	0.58	13.17	0.46	3.41e-35	Morning vs. evening chronotype;
BRCA	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.02	0.48	4.03e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg01305625	chr5:131593812	PDLIM4	0.34	8.07	0.3	3.4e-15	Acylcarnitine levels;
BRCA	cis	rs17092148	0.616	rs6059908	chr20:33132159	T/C	cg16810054	chr20:33298113	TP53INP2	-0.44	-9.47	-0.35	5.21e-20	Neuroticism;
BRCA	cis	rs11785693	0.862	rs73189843	chr8:5000915	C/T	cg26367366	chr8:4980734	NA	0.65	11.11	0.4	2.47e-26	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	trans	rs1997103	1.000	rs10252413	chr7:55396740	C/G	cg20935933	chr6:143382018	AIG1	0.6	11.29	0.41	4.64e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs12760731	0.565	rs11585355	chr1:178181219	T/G	cg00404053	chr1:178313656	RASAL2	0.65	7.82	0.3	2.27e-14	Obesity-related traits;
BRCA	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.71	-16.05	-0.54	6.14e-49	Axial length;
BRCA	cis	rs895636	0.749	rs748947	chr2:45192600	A/C	cg16198908	chr2:45192207	NA	0.49	9.26	0.34	3.05e-19	Metabolite levels;Fasting plasma glucose;
BRCA	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24549020	chr5:56110836	MAP3K1	-0.58	-10.63	-0.39	1.99e-24	Initial pursuit acceleration;
BRCA	cis	rs4478858	0.684	rs3766289	chr1:31760128	G/A	cg00250761	chr1:31883323	NA	-0.31	-8.17	-0.31	1.63e-15	Alcohol dependence;
BRCA	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg16230307	chr14:35515116	FAM177A1	0.74	15.02	0.51	7.09e-44	Psoriasis;
BRCA	cis	rs2625529	0.641	rs2035379	chr15:72293202	C/T	cg16672083	chr15:72433130	SENP8	-0.85	-17.5	-0.57	2.71e-56	Red blood cell count;
BRCA	cis	rs73072330	1.000	rs17729010	chr3:47912703	A/G	cg09665691	chr3:47563885	NA	-0.98	-9.04	-0.34	1.92e-18	Stem cell growth factor beta levels;
BRCA	trans	rs4650994	0.544	rs2476561	chr1:178619900	C/T	cg05059571	chr16:84539110	KIAA1609	-0.52	-11.67	-0.42	1.16e-28	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.31	0.35	1.94e-19	Tonsillectomy;
BRCA	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.2e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg13789015	chr9:136890014	NCRNA00094	0.57	12.09	0.43	1.93e-30	Platelet distribution width;
BRCA	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg13319975	chr6:146136371	FBXO30	-0.35	-8.11	-0.31	2.52e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7639513	0.767	rs3806661	chr3:12705855	A/G	cg23032965	chr3:12705835	RAF1	0.71	15.61	0.53	9.16e-47	Itch intensity from mosquito bite;
BRCA	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23583168	chr7:148888333	NA	-0.8	-19.27	-0.61	1.44e-65	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg05340658	chr4:99064831	C4orf37	0.62	14.89	0.51	2.77e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg26647111	chr11:31128758	NA	-0.45	-9.92	-0.37	1.15e-21	Red blood cell count;
BRCA	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.8	-0.42	3.24e-29	Response to antipsychotic treatment;
BRCA	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg00666640	chr1:248458726	OR2T12	0.33	8.66	0.32	3.96e-17	Common traits (Other);
BRCA	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg11822812	chr5:140052017	DND1	0.29	8.12	0.31	2.38e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg09904177	chr6:26538194	HMGN4	0.48	15.45	0.52	5.34e-46	Intelligence (multi-trait analysis);
BRCA	cis	rs3820928	0.845	rs10165767	chr2:227781863	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.12	-0.34	9.3e-19	Pulmonary function;
BRCA	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-10.43	-0.38	1.28e-23	Schizophrenia;
BRCA	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23583168	chr7:148888333	NA	-0.75	-16.77	-0.55	1.34e-52	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg22903471	chr2:27725779	GCKR	-0.38	-9.18	-0.34	5.87e-19	Total body bone mineral density;
BRCA	cis	rs10484885	0.824	rs72919982	chr6:90532600	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.64	-0.36	1.23e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18404041	chr3:52824283	ITIH1	-0.43	-12.72	-0.45	3.32e-33	Bipolar disorder;
BRCA	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	8.65e-21	Menopause (age at onset);
BRCA	cis	rs3099143	1.000	rs3099138	chr15:77115524	G/A	cg21673338	chr15:77095150	SCAPER	-0.54	-9.27	-0.34	2.82e-19	Recalcitrant atopic dermatitis;
BRCA	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg06115741	chr20:33292138	TP53INP2	0.39	8.73	0.33	2.16e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg12573674	chr2:1569213	NA	-0.59	-13.05	-0.46	1.14e-34	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6963495	0.556	rs818474	chr7:105155243	A/T	cg19920283	chr7:105172520	RINT1	0.44	9.02	0.34	2.21e-18	Bipolar disorder (body mass index interaction);
BRCA	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg17063962	chr7:91808500	NA	0.63	14.87	0.51	3.75e-43	Breast cancer;
BRCA	cis	rs6750795	0.870	rs6754952	chr2:232381245	G/T	cg19187155	chr2:232395269	NMUR1	-0.8	-21.22	-0.64	4.98e-76	Height;
BRCA	trans	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg06521331	chr12:34319734	NA	-0.46	-8.49	-0.32	1.46e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2742234	0.955	rs1272142	chr10:43695484	G/T	cg02780029	chr10:43622663	RET	-0.36	-8.88	-0.33	6.52e-18	Hirschsprung disease;
BRCA	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.47	0.35	5.28e-20	Menopause (age at onset);
BRCA	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs1371614	0.513	rs562311	chr2:27098086	G/A	cg12368169	chr2:27073192	DPYSL5	-0.3	-8.76	-0.33	1.78e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-12.61	-0.45	1.06e-32	Personality dimensions;
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18402987	chr7:1209562	NA	0.6	11.81	0.42	3.07e-29	Longevity;Endometriosis;
BRCA	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg13256891	chr4:100009986	ADH5	0.46	9.68	0.36	8.9e-21	Alcohol dependence;
BRCA	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.69	11.67	0.42	1.16e-28	Mean platelet volume;
BRCA	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.35	-8.1	-0.31	2.78e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.55	17.85	0.58	3.83e-58	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10733682	0.659	rs867560	chr9:129465233	C/G	cg00232160	chr9:129468157	NA	-0.35	-8.37	-0.31	3.75e-16	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg25036284	chr2:26402008	FAM59B	-0.83	-13.06	-0.46	1.05e-34	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13095912	0.785	rs6444076	chr3:185321405	T/C	cg11274856	chr3:185301563	NA	0.55	13.28	0.47	1.01e-35	Systolic blood pressure;
BRCA	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg12564285	chr5:131593104	PDLIM4	0.35	9.39	0.35	1.06e-19	Breast cancer;
BRCA	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg24596788	chr1:163392923	NA	-0.36	-9.54	-0.35	2.91e-20	Motion sickness;
BRCA	cis	rs9810890	0.850	rs73198858	chr3:128514061	T/G	cg15033153	chr3:128514015	RAB7A	0.7	8.08	0.3	3.34e-15	Dental caries;
BRCA	cis	rs7590368	1.000	rs13429247	chr2:10960529	A/G	cg15705551	chr2:10952987	PDIA6	0.44	8.14	0.31	2.02e-15	Educational attainment (years of education);
BRCA	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg04450456	chr4:17643702	FAM184B	0.42	12.53	0.44	2.21e-32	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6840258	0.660	rs74784659	chr4:87888929	G/A	cg08197287	chr4:87952173	AFF1	-0.46	-8.4	-0.32	2.8e-16	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	trans	rs877282	0.891	rs12767062	chr10:797961	C/T	cg22713356	chr15:30763199	NA	1.41	28.9	0.75	4.24e-118	Uric acid levels;
BRCA	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg24006582	chr15:45444508	DUOX1	-0.55	-11.31	-0.41	3.61e-27	Uric acid levels;
BRCA	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg06212747	chr3:49208901	KLHDC8B	0.68	15.13	0.51	2.1e-44	Subjective well-being (multi-trait analysis);Menarche (age at onset);
BRCA	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg15819921	chr19:927150	ARID3A	-0.48	-9.17	-0.34	6.67e-19	Life satisfaction;
BRCA	cis	rs8028182	0.666	rs4886708	chr15:75762608	C/T	cg20655648	chr15:75932815	IMP3	0.41	8.01	0.3	5.53e-15	Sudden cardiac arrest;
BRCA	cis	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.17	-0.37	1.3e-22	Morning vs. evening chronotype;
BRCA	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg08975724	chr8:8085496	FLJ10661	0.43	8.08	0.3	3.28e-15	Retinal vascular caliber;
BRCA	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.57	9.7	0.36	7.35e-21	Gut microbiome composition (summer);
BRCA	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg23649088	chr2:200775458	C2orf69	0.55	9.55	0.35	2.79e-20	Schizophrenia;
BRCA	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg08885076	chr2:99613938	TSGA10	-0.59	-13.24	-0.46	1.49e-35	Chronic sinus infection;
BRCA	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg04317338	chr11:64019027	PLCB3	0.58	9.81	0.36	2.87e-21	Mean platelet volume;
BRCA	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg12365402	chr11:9010492	NRIP3	-0.37	-8.55	-0.32	9.42e-17	Hemoglobin concentration;
BRCA	cis	rs365132	0.875	rs2962844	chr5:176333748	G/T	cg16309518	chr5:176445507	NA	-0.4	-9.75	-0.36	5e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg24069376	chr3:38537580	EXOG	0.4	11.54	0.42	4.09e-28	Electrocardiographic conduction measures;
BRCA	cis	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg19338460	chr6:170058176	WDR27	-0.45	-8.03	-0.3	4.53e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg06115741	chr20:33292138	TP53INP2	0.5	11.22	0.41	8.59e-27	Coronary artery disease;
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23978390	chr7:1156363	C7orf50	0.33	8.16	0.31	1.81e-15	Longevity;Endometriosis;
BRCA	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.36	-12.28	-0.44	2.86e-31	Bipolar disorder;
BRCA	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg23442198	chr4:187126114	CYP4V2	0.85	9.8	0.36	3.1e-21	Blood protein levels;
BRCA	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-10.04	-0.37	4.14e-22	Mean corpuscular volume;
BRCA	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg01262667	chr19:19385393	TM6SF2	0.43	11.03	0.4	5.36e-26	Tonsillectomy;
BRCA	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.75	16.83	0.55	7.34e-53	Lymphocyte counts;
BRCA	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg07395648	chr5:131743802	NA	0.37	7.99	0.3	6.21e-15	Breast cancer;
BRCA	trans	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg21659725	chr3:3221576	CRBN	0.47	8.66	0.32	3.71e-17	Menarche (age at onset);
BRCA	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg06484146	chr7:12443880	VWDE	-0.64	-8.81	-0.33	1.14e-17	Coronary artery disease;
BRCA	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.57	-0.32	7.75e-17	Total body bone mineral density;
BRCA	cis	rs1712517	0.873	rs7894240	chr10:105000369	T/C	cg05636881	chr10:105038444	INA	-0.35	-8.17	-0.31	1.68e-15	Migraine;
BRCA	cis	rs11690935	0.851	rs6433319	chr2:172830953	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.76	-22.54	-0.67	3.05e-83	Schizophrenia;
BRCA	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg23750338	chr8:142222470	SLC45A4	-0.5	-12.17	-0.43	8.25e-31	Immature fraction of reticulocytes;
BRCA	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg08601574	chr20:25228251	PYGB	0.33	7.82	0.3	2.23e-14	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-11.19	-0.4	1.16e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg22535103	chr8:58192502	C8orf71	-0.44	-8.85	-0.33	8.5e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg00530320	chr1:46809349	NSUN4	0.48	9.63	0.36	1.41e-20	Menopause (age at onset);
BRCA	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg03354898	chr7:1950403	MAD1L1	-0.48	-9.68	-0.36	9.37e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg23711669	chr6:146136114	FBXO30	0.71	14.67	0.5	3.38e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12618769	0.597	rs72819981	chr2:99040696	T/C	cg10123293	chr2:99228465	UNC50	0.41	8.14	0.31	2.05e-15	Bipolar disorder;
BRCA	cis	rs3917254	0.596	rs12618571	chr2:102767192	G/A	cg22835712	chr2:102737379	NA	-0.54	-8.78	-0.33	1.51e-17	Blood protein levels;
BRCA	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg16606324	chr3:10149918	C3orf24	-0.57	-10.15	-0.37	1.54e-22	Alzheimer's disease;
BRCA	cis	rs2066819	1.000	rs77131854	chr12:56664231	C/T	cg26734620	chr12:56694298	CS	0.92	10.64	0.39	1.83e-24	Psoriasis vulgaris;
BRCA	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.38	-7.88	-0.3	1.4e-14	Lymphocyte counts;
BRCA	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg04374321	chr14:90722782	PSMC1	0.74	20.13	0.62	3.8e-70	Mortality in heart failure;
BRCA	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg26395211	chr5:140044315	WDR55	0.37	8.61	0.32	5.85e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg20607798	chr8:58055168	NA	0.47	8.07	0.3	3.41e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs897984	0.542	rs11865038	chr16:31095171	C/T	cg00531865	chr16:30841666	NA	-0.38	-9.02	-0.34	2.25e-18	Dementia with Lewy bodies;
BRCA	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg25206134	chr2:45395956	NA	0.51	8.66	0.32	3.71e-17	Bipolar disorder;
BRCA	cis	rs870825	0.616	rs14969	chr4:185615764	C/A	cg04058563	chr4:185651563	MLF1IP	0.78	17.17	0.56	1.32e-54	Blood protein levels;
BRCA	cis	rs9309473	1.000	rs13398956	chr2:73720258	C/A	cg20560298	chr2:73613845	ALMS1	-0.44	-10.67	-0.39	1.46e-24	Metabolite levels;
BRCA	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg10729496	chr3:10149963	C3orf24	0.45	8.74	0.33	2.11e-17	Alzheimer's disease;
BRCA	cis	rs9487051	0.676	rs9386775	chr6:109561779	T/C	cg21918786	chr6:109611834	NA	-0.32	-8.25	-0.31	9.15e-16	Reticulocyte fraction of red cells;
BRCA	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.84	20.47	0.63	5.21e-72	Birth weight;
BRCA	cis	rs12711979	1.000	rs12711979	chr2:3869559	A/G	cg17052675	chr2:3827356	NA	-0.44	-11.91	-0.43	1.1e-29	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-18.07	-0.58	3e-59	Chronic sinus infection;
BRCA	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg03474202	chr17:45855739	NA	-0.47	-12.85	-0.45	9.12e-34	IgG glycosylation;
BRCA	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.08	-0.43	2.06e-30	Total cholesterol levels;
BRCA	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.33	-0.44	1.69e-31	Chronic sinus infection;
BRCA	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg04944784	chr2:26401820	FAM59B	1.0	16.48	0.55	4.02e-51	Gut microbiome composition (summer);
BRCA	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg19318889	chr4:1322082	MAEA	-0.45	-9.64	-0.36	1.28e-20	Obesity-related traits;
BRCA	cis	rs4845875	0.535	rs4846045	chr1:11840380	A/G	cg24844545	chr1:11908347	NPPA	0.33	8.22	0.31	1.17e-15	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg24747557	chr10:131355152	MGMT	0.37	9.19	0.34	5.34e-19	Response to temozolomide;
BRCA	cis	rs16944613	0.541	rs13313427	chr15:91090768	G/A	cg26821196	chr15:91095069	CRTC3	0.47	8.52	0.32	1.18e-16	Colorectal cancer;
BRCA	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg20891283	chr12:69753455	YEATS4	0.84	28.41	0.75	1.93e-115	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.9e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg00012203	chr2:219082015	ARPC2	0.64	14.22	0.49	4.53e-40	Colorectal cancer;
BRCA	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg04455712	chr21:45112962	RRP1B	0.38	9.74	0.36	5.49e-21	Mean corpuscular volume;
BRCA	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg16339924	chr4:17578868	LAP3	0.63	15.41	0.52	8.34e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00166722	chr3:10149974	C3orf24	0.65	13.07	0.46	8.76e-35	Alzheimer's disease;
BRCA	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg26384229	chr12:38710491	ALG10B	-0.62	-16.24	-0.54	6.8e-50	Heart rate;
BRCA	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg04851639	chr8:1020857	NA	-0.32	-8.82	-0.33	1.05e-17	Schizophrenia;
BRCA	cis	rs6893300	0.542	rs7736300	chr5:179196898	G/A	cg14593053	chr5:179126677	CANX	0.48	12.95	0.46	3.14e-34	Resting heart rate;
BRCA	cis	rs3099143	1.000	rs3102712	chr15:77058926	G/A	cg21673338	chr15:77095150	SCAPER	-0.53	-9.55	-0.35	2.71e-20	Recalcitrant atopic dermatitis;
BRCA	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg21770322	chr7:97807741	LMTK2	0.45	11.26	0.41	5.83e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg13010199	chr12:38710504	ALG10B	-0.37	-8.55	-0.32	9.27e-17	Morning vs. evening chronotype;
BRCA	cis	rs6484504	0.576	rs208067	chr11:31153578	C/T	cg14844989	chr11:31128820	NA	-0.44	-9.27	-0.34	2.83e-19	Red blood cell count;
BRCA	cis	rs698833	0.852	rs2582918	chr2:44582275	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.6	12.37	0.44	1.11e-31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg00012203	chr2:219082015	ARPC2	-0.47	-9.1	-0.34	1.15e-18	Ulcerative colitis;
BRCA	cis	rs10992471	0.603	rs7033979	chr9:95223980	A/G	cg14631576	chr9:95140430	CENPP	-0.39	-9.47	-0.35	5.52e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09263875	chr16:632152	PIGQ	0.72	21.51	0.65	1.22e-77	Height;
BRCA	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.27	-0.31	8e-16	Bipolar disorder;
BRCA	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg05925327	chr15:68127851	NA	-0.37	-7.82	-0.3	2.13e-14	Obesity;
BRCA	cis	rs9296092	0.521	rs56332659	chr6:33537887	T/C	cg13560919	chr6:33536144	NA	-0.87	-16.85	-0.55	5.31e-53	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg23285459	chr7:2802560	GNA12	-0.37	-9.39	-0.35	1.01e-19	Height;
BRCA	cis	rs13040088	1.000	rs2295000	chr20:61536938	A/G	cg23096297	chr20:61557774	DIDO1	-0.9	-17.81	-0.58	6.73e-58	Menopause (age at onset);
BRCA	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg15448220	chr1:150897856	SETDB1	0.35	7.81	0.3	2.32e-14	Melanoma;
BRCA	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.47	0.66	7.52e-83	Chronic sinus infection;
BRCA	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg25730555	chr22:47059586	GRAMD4	-0.47	-8.99	-0.33	2.83e-18	Urate levels in obese individuals;
BRCA	cis	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg08601574	chr20:25228251	PYGB	0.34	8.16	0.31	1.77e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg00495681	chr13:53174319	NA	0.43	9.03	0.34	2.03e-18	Lewy body disease;
BRCA	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg20387954	chr3:183756860	HTR3D	0.46	10.31	0.38	3.71e-23	Anterior chamber depth;
BRCA	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg03477792	chr4:77819574	ANKRD56	0.66	15.67	0.53	4.35e-47	Emphysema distribution in smoking;
BRCA	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg18105134	chr13:113819100	PROZ	-0.59	-13.75	-0.48	6.96e-38	Platelet distribution width;
BRCA	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg05985134	chr18:33552581	C18orf21	0.65	11.65	0.42	1.42e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg11822812	chr5:140052017	DND1	-0.32	-8.81	-0.33	1.15e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg13256891	chr4:100009986	ADH5	0.53	9.77	0.36	4.33e-21	Smoking initiation;
BRCA	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg04450456	chr4:17643702	FAM184B	-0.34	-9.89	-0.36	1.44e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg17675199	chr6:35436792	RPL10A	-0.3	-8.21	-0.31	1.2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg25173405	chr17:45401733	C17orf57	0.44	9.11	0.34	1.01e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.87	0.3	1.54e-14	Axial length;
BRCA	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg08601574	chr20:25228251	PYGB	-0.35	-8.51	-0.32	1.24e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	21.88	0.65	1.24e-79	Platelet count;
BRCA	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg18301423	chr5:131593218	PDLIM4	-0.33	-8.16	-0.31	1.82e-15	Acylcarnitine levels;
BRCA	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg26384229	chr12:38710491	ALG10B	0.71	16.45	0.55	5.52e-51	Bladder cancer;
BRCA	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg12386194	chr3:101231763	SENP7	0.45	9.56	0.35	2.58e-20	Colorectal cancer;
BRCA	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.25	0.63	8.21e-71	Electrocardiographic conduction measures;
BRCA	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg26608667	chr7:1196370	ZFAND2A	0.46	10.46	0.38	9.92e-24	Longevity;Endometriosis;
BRCA	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg16325326	chr1:53192061	ZYG11B	0.7	17.51	0.57	2.2e-56	Monocyte count;
BRCA	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg00757033	chr12:89920650	WDR51B	0.54	11.08	0.4	3.24e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs9427116	0.531	rs35504625	chr1:154599778	C/G	cg17218026	chr1:154582156	ADAR	0.28	8.16	0.31	1.81e-15	Blood protein levels;
BRCA	cis	rs1468333	0.691	rs35839251	chr5:137584080	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.4	8.44	0.32	2.06e-16	Resting heart rate;
BRCA	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg16230307	chr14:35515116	FAM177A1	0.77	15.6	0.53	9.97e-47	Psoriasis;
BRCA	cis	rs7587476	0.784	rs36086595	chr2:215680293	A/G	cg04004882	chr2:215674386	BARD1	0.65	12.22	0.44	5.09e-31	Neuroblastoma;
BRCA	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg08847533	chr14:75593920	NEK9	-0.83	-20.34	-0.63	2.66e-71	Height;
BRCA	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg03433033	chr1:76189801	ACADM	0.68	13.64	0.47	2.19e-37	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg26384229	chr12:38710491	ALG10B	0.7	15.94	0.53	1.97e-48	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10129255	0.518	rs8004895	chr14:107193377	T/C	cg07958169	chr14:107095056	NA	-0.4	-8.67	-0.32	3.69e-17	Kawasaki disease;
BRCA	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg09537434	chr19:41945824	ATP5SL	-1.0	-25.35	-0.71	1.18e-98	Height;
BRCA	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-14.61	-0.5	6.48e-42	Total cholesterol levels;
BRCA	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11890956	chr21:40555474	PSMG1	1.06	30.49	0.77	1.02e-126	Cognitive function;
BRCA	cis	rs7945718	0.905	rs7124484	chr11:12745271	G/A	cg25843174	chr11:12811716	TEAD1	0.23	8.69	0.33	2.97e-17	Educational attainment (years of education);
BRCA	cis	rs7631605	0.905	rs6808735	chr3:37104246	A/C	cg15934958	chr3:37212084	LRRFIP2	0.47	10.83	0.39	3.16e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg03585969	chr10:35415529	CREM	0.56	11.55	0.42	3.74e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs698833	0.886	rs698775	chr2:44588941	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.61	12.68	0.45	5.1e-33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.38e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs61990749	0.597	rs2267761	chr14:78147849	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.63	-9.68	-0.36	9.08e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg08888203	chr3:10149979	C3orf24	0.63	11.82	0.42	2.73e-29	Alzheimer's disease;
BRCA	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg06484146	chr7:12443880	VWDE	-0.74	-10.77	-0.39	5.91e-25	Coronary artery disease;
BRCA	cis	rs7192750	0.617	rs9929256	chr16:72040032	A/C	cg14768367	chr16:72042858	DHODH	0.59	9.52	0.35	3.6e-20	LDL cholesterol levels;Total cholesterol levels;
BRCA	cis	rs10267417	0.603	rs4721829	chr7:19873199	A/G	cg05791153	chr7:19748676	TWISTNB	0.48	9.14	0.34	8.22e-19	Night sleep phenotypes;
BRCA	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11890956	chr21:40555474	PSMG1	-1.04	-29.63	-0.76	4.49e-122	Cognitive function;
BRCA	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg21605333	chr4:119757512	SEC24D	1.14	12.65	0.45	6.54e-33	Cannabis dependence symptom count;
BRCA	cis	rs701145	0.585	rs6440935	chr3:153816976	A/T	cg12800244	chr3:153838788	SGEF	0.63	7.87	0.3	1.47e-14	Coronary artery disease;
BRCA	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg26528668	chr16:1614120	IFT140	0.37	8.33	0.31	4.79e-16	Coronary artery disease;
BRCA	cis	rs4588572	0.644	rs6882191	chr5:77743098	G/A	cg11547950	chr5:77652471	NA	-0.45	-8.58	-0.32	7.33e-17	Triglycerides;
BRCA	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg25358565	chr5:93447407	FAM172A	-1.18	-17.88	-0.58	2.9e-58	Diabetic retinopathy;
BRCA	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg03213289	chr20:61660250	NA	0.63	16.54	0.55	2.05e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9443189	0.570	rs72888705	chr6:76403114	A/G	cg01950844	chr6:76311363	SENP6	0.84	13.53	0.47	7.52e-37	Prostate cancer;
BRCA	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-10.05	-0.37	3.63e-22	Neuroticism;
BRCA	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08045932	chr20:61659980	NA	0.49	11.35	0.41	2.57e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11764359	chr7:65958608	NA	0.79	19.31	0.61	8.49e-66	Aortic root size;
BRCA	trans	rs6076960	0.652	rs3905171	chr20:6211177	T/C	cg21095983	chr6:86352623	SYNCRIP	0.37	8.22	0.31	1.18e-15	Smooth-surface caries;
BRCA	cis	rs1669338	0.588	rs3864049	chr3:3186719	T/G	cg16797762	chr3:3221439	CRBN	-0.69	-10.57	-0.39	3.55e-24	White matter integrity;
BRCA	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	13.82	0.48	3.34e-38	Lymphocyte counts;
BRCA	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg23505145	chr19:12996616	KLF1	0.56	12.69	0.45	4.46e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg26248373	chr2:1572462	NA	-0.61	-13.78	-0.48	5.39e-38	IgG glycosylation;
BRCA	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg12863693	chr15:85201151	NMB	-0.55	-12.08	-0.43	2.07e-30	Schizophrenia;
BRCA	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg02931644	chr1:25747376	RHCE	0.42	11.46	0.41	8.59e-28	Erythrocyte sedimentation rate;
BRCA	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.07	-0.3	3.57e-15	Depression;
BRCA	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.11	0.31	2.51e-15	Total cholesterol levels;
BRCA	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg13256891	chr4:100009986	ADH5	0.47	8.9	0.33	5.92e-18	Alcohol dependence;
BRCA	cis	rs3784262	0.669	rs3204690	chr15:58246768	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.87	-0.36	1.73e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs12464559	0.522	rs1916301	chr2:152640498	G/A	cg01189475	chr2:152685088	ARL5A	0.63	9.16	0.34	6.97e-19	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.4	9.14	0.34	8.25e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg11833968	chr6:79620685	NA	0.42	9.07	0.34	1.44e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg23762105	chr12:34175262	ALG10	-0.4	-9.81	-0.36	2.96e-21	Morning vs. evening chronotype;
BRCA	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg25019033	chr10:957182	NA	-0.41	-7.85	-0.3	1.73e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.41	-7.96	-0.3	7.83e-15	Longevity;Endometriosis;
BRCA	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.83	-0.3	2.04e-14	Aortic root size;
BRCA	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg21747090	chr2:27597821	SNX17	-0.41	-8.82	-0.33	1.09e-17	Total body bone mineral density;
BRCA	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.52	-0.5	1.79e-41	Chronic sinus infection;
BRCA	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg18351406	chr4:77819688	ANKRD56	0.46	9.7	0.36	7.85e-21	Emphysema distribution in smoking;
BRCA	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg10729496	chr3:10149963	C3orf24	0.49	9.41	0.35	8.99e-20	Alzheimer's disease;
BRCA	trans	rs8073060	0.544	rs225244	chr17:33946581	A/G	cg19694781	chr19:47549865	TMEM160	1.06	21.34	0.65	1.05e-76	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.54	-11.78	-0.42	4.08e-29	Longevity;Endometriosis;
BRCA	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg22906224	chr7:99728672	NA	0.44	8.23	0.31	1.06e-15	Coronary artery disease;
BRCA	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg23711669	chr6:146136114	FBXO30	0.74	16.82	0.55	7.41e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12135062	0.538	rs2651929	chr1:3101353	C/T	cg00254258	chr1:3105189	PRDM16	0.36	8.78	0.33	1.49e-17	Migraine;
BRCA	cis	rs12541635	0.966	rs2029881	chr8:107002226	A/G	cg10147462	chr8:107024639	NA	0.37	9.91	0.37	1.2e-21	Age of smoking initiation;
BRCA	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg10578991	chr7:12443926	VWDE	-0.52	-7.94	-0.3	9.11e-15	Coronary artery disease;
BRCA	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00149659	chr3:10157352	C3orf10	-0.72	-12.68	-0.45	4.89e-33	Alzheimer's disease;
BRCA	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg03146154	chr1:46216737	IPP	0.45	10.11	0.37	2.13e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg04990556	chr1:26633338	UBXN11	-0.47	-9.23	-0.34	3.82e-19	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg11764359	chr7:65958608	NA	0.6	13.57	0.47	4.95e-37	Aortic root size;
BRCA	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.34	-9.28	-0.34	2.55e-19	Intelligence (multi-trait analysis);
BRCA	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21659725	chr3:3221576	CRBN	-0.35	-8.7	-0.33	2.74e-17	Body mass index;
BRCA	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg06784218	chr1:46089804	CCDC17	0.45	10.79	0.39	4.84e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11025559	0.812	rs10766678	chr11:20507180	A/G	cg19653624	chr11:20408972	PRMT3	-0.45	-10.36	-0.38	2.36e-23	Pursuit maintenance gain;
BRCA	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg07748719	chr16:1272498	TPSG1	0.5	11.14	0.4	1.76e-26	Blood protein levels;
BRCA	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg21747090	chr2:27597821	SNX17	-0.4	-8.55	-0.32	9.09e-17	Total body bone mineral density;
BRCA	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg08601574	chr20:25228251	PYGB	-0.37	-8.81	-0.33	1.21e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.54	-12.19	-0.43	6.83e-31	Longevity;Endometriosis;
BRCA	cis	rs10795061	0.576	rs12219804	chr10:3710626	C/T	cg22632523	chr10:3711048	NA	0.43	10.93	0.4	1.25e-25	Subjective well-being;
BRCA	cis	rs7903847	0.642	rs10882922	chr10:99158537	C/T	cg20016023	chr10:99160130	RRP12	-0.26	-8.36	-0.31	3.83e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs3772130	0.962	rs6789736	chr3:121543084	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.95	0.4	1.08e-25	Cognitive performance;
BRCA	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.76	0.39	6.41e-25	Cognitive ability;
BRCA	cis	rs367943	0.730	rs2914174	chr5:112978531	C/T	cg12552261	chr5:112820674	MCC	-0.43	-8.93	-0.33	4.51e-18	Type 2 diabetes;
BRCA	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg00277334	chr10:82204260	NA	-0.85	-24.9	-0.7	3.41e-96	Post bronchodilator FEV1;
BRCA	cis	rs10193935	1.000	rs13424523	chr2:42413562	T/G	cg27598129	chr2:42591480	NA	-0.94	-15.03	-0.51	6.18e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	11.13	0.4	2.02e-26	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	8.2	0.31	1.34e-15	Mean platelet volume;
BRCA	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-8.99	-0.34	2.73e-18	Alzheimer's disease (late onset);
BRCA	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg14582100	chr15:45693742	SPATA5L1	0.36	11.53	0.41	4.48e-28	Homoarginine levels;
BRCA	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg23285459	chr7:2802560	GNA12	-0.36	-9.17	-0.34	6.39e-19	Height;
BRCA	cis	rs7089973	0.584	rs4752255	chr10:116576790	C/T	cg03647239	chr10:116582469	FAM160B1	0.38	7.96	0.3	7.7e-15	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs919433	0.963	rs7582736	chr2:198170342	A/G	cg10820045	chr2:198174542	NA	-0.39	-8.07	-0.3	3.47e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg20933634	chr6:27740509	NA	0.44	8.56	0.32	8.24e-17	Parkinson's disease;
BRCA	cis	rs897984	0.721	rs28360557	chr16:30983260	A/C	cg00531865	chr16:30841666	NA	0.39	9.25	0.34	3.21e-19	Dementia with Lewy bodies;
BRCA	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12923728	chr3:195709715	SDHAP1	-0.6	-12.93	-0.46	3.83e-34	Pancreatic cancer;
BRCA	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.71	0.55	2.71e-52	Morning vs. evening chronotype;
BRCA	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg07507251	chr3:52567010	NT5DC2	0.39	9.29	0.34	2.47e-19	Electroencephalogram traits;
BRCA	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg06484146	chr7:12443880	VWDE	-0.62	-8.6	-0.32	5.97e-17	Coronary artery disease;
BRCA	trans	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	7.99e-21	Bladder cancer;
BRCA	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg12935359	chr14:103987150	CKB	0.64	14.71	0.5	2.11e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.02	0.58	5.02e-59	Fuchs's corneal dystrophy;
BRCA	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-11.13	-0.4	1.96e-26	Lymphocyte counts;
BRCA	cis	rs877529	0.967	rs139385	chr22:39530132	C/A	cg12193277	chr22:39547181	CBX7	0.48	13.09	0.46	7.6e-35	Multiple myeloma;
BRCA	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg01528321	chr10:82214614	TSPAN14	1.05	20.63	0.63	7.39e-73	Post bronchodilator FEV1;
BRCA	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06028605	chr16:24865363	SLC5A11	0.39	8.05	0.3	3.98e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.54	-0.32	1e-16	Bipolar disorder;
BRCA	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg13010199	chr12:38710504	ALG10B	0.43	9.22	0.34	4.33e-19	Morning vs. evening chronotype;
BRCA	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-12.03	-0.43	3.51e-30	Alzheimer's disease;
BRCA	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.54	-8.01	-0.3	5.64e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg03146154	chr1:46216737	IPP	0.53	11.75	0.42	5.61e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.21e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg26384229	chr12:38710491	ALG10B	-0.42	-9.71	-0.36	7.22e-21	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.57	-0.39	3.71e-24	Intelligence (multi-trait analysis);
BRCA	trans	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg26043149	chr18:55253948	FECH	0.37	8.16	0.31	1.83e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11644478	chr21:40555479	PSMG1	0.85	19.44	0.61	1.75e-66	Cognitive function;
BRCA	cis	rs7903847	0.673	rs3818908	chr10:99132701	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.51	-0.32	1.27e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg20016023	chr10:99160130	RRP12	-0.26	-8.39	-0.31	3.16e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10046574	0.519	rs10250947	chr7:135211017	T/G	cg27474649	chr7:135195673	CNOT4	0.63	10.71	0.39	9.6e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg24060327	chr5:131705240	SLC22A5	-0.49	-10.38	-0.38	1.93e-23	Blood metabolite levels;
BRCA	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg18270830	chr10:32634957	EPC1	0.58	10.04	0.37	4.01e-22	Sexual dysfunction (female);
BRCA	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.06	-0.56	4.9e-54	Intelligence (multi-trait analysis);
BRCA	cis	rs3820928	0.874	rs10167086	chr2:227792729	A/T	cg11843606	chr2:227700838	RHBDD1	0.4	8.85	0.33	8.4e-18	Pulmonary function;
BRCA	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg03585969	chr10:35415529	CREM	0.55	11.17	0.4	1.33e-26	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg06627628	chr2:24431161	ITSN2	0.44	9.09	0.34	1.25e-18	Asthma;
BRCA	cis	rs1941023	0.584	rs2241920	chr11:60164204	A/G	cg08716584	chr11:60157161	MS4A7	0.41	9.82	0.36	2.7e-21	Congenital heart disease (maternal effect);
BRCA	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.55	12.08	0.43	2.18e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6028335	0.610	rs16987687	chr20:37566737	T/C	cg16355469	chr20:37678765	NA	0.44	7.94	0.3	9.2e-15	Alcohol and nicotine co-dependence;
BRCA	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.31	0.49	1.68e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.83	0.39	3.41e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg03877680	chr5:178157825	ZNF354A	0.79	14.52	0.5	1.76e-41	Neutrophil percentage of white cells;
BRCA	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg01874867	chr7:94954059	PON1	-0.4	-8.13	-0.31	2.25e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg18252515	chr7:66147081	NA	1.06	15.89	0.53	3.65e-48	Diabetic kidney disease;
BRCA	cis	rs7131987	0.903	rs2194520	chr12:29423712	C/T	cg09582351	chr12:29534625	ERGIC2	-0.43	-10.48	-0.38	7.76e-24	QT interval;
BRCA	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg09877947	chr5:131593287	PDLIM4	0.34	8.38	0.31	3.28e-16	Blood metabolite levels;
BRCA	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg09307838	chr4:120376055	NA	0.74	16.02	0.54	8.36e-49	Corneal astigmatism;
BRCA	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg06212747	chr3:49208901	KLHDC8B	0.53	8.17	0.31	1.65e-15	Menarche (age at onset);
BRCA	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.35	0.49	1.13e-40	Motion sickness;
BRCA	cis	rs2836633	0.859	rs8132069	chr21:40032611	T/C	cg05519781	chr21:40033154	ERG	0.38	8.29	0.31	6.89e-16	Coronary artery disease;
BRCA	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg08847533	chr14:75593920	NEK9	-0.8	-19.02	-0.6	3.1e-64	Height;
BRCA	cis	rs12474201	0.630	rs897529	chr2:46948175	T/C	cg06386533	chr2:46925753	SOCS5	0.58	12.54	0.44	2.06e-32	Height;
BRCA	trans	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-16.34	-0.54	2.04e-50	Colorectal cancer;
BRCA	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg03342759	chr3:160939853	NMD3	-0.69	-13.91	-0.48	1.32e-38	Parkinson's disease;
BRCA	cis	rs6728642	1.000	rs116171118	chr2:97695036	C/A	cg26665480	chr2:98280029	ACTR1B	-0.69	-8.34	-0.31	4.62e-16	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs9467160	0.532	rs2744565	chr6:24458461	G/T	cg20631270	chr6:24437470	GPLD1	-0.43	-8.55	-0.32	9.07e-17	Liver enzyme levels;
BRCA	cis	rs3820928	1.000	rs59904960	chr2:227761269	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.81	-0.33	1.18e-17	Pulmonary function;
BRCA	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg15448220	chr1:150897856	SETDB1	-0.35	-8.05	-0.3	4.17e-15	Melanoma;
BRCA	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg12160578	chr15:63334699	TPM1	-0.42	-8.55	-0.32	9.03e-17	Platelet count;
BRCA	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.22	-0.31	1.13e-15	Depression;
BRCA	trans	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.93	-0.3	9.81e-15	Corneal astigmatism;
BRCA	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg08085267	chr17:45401833	C17orf57	-0.56	-11.44	-0.41	1.1e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg23711669	chr6:146136114	FBXO30	0.65	15.23	0.52	6.75e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg11502198	chr6:26597334	ABT1	0.48	9.61	0.36	1.58e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg10495392	chr1:46806563	NSUN4	0.44	8.11	0.31	2.59e-15	Menopause (age at onset);
BRCA	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-16.87	-0.56	4.27e-53	Colorectal cancer;
BRCA	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg04450456	chr4:17643702	FAM184B	0.42	12.7	0.45	4.17e-33	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg16482183	chr6:26056742	HIST1H1C	0.56	11.91	0.43	1.15e-29	Height;
BRCA	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg23708337	chr7:1209742	NA	0.49	8.26	0.31	8.64e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	14.08	0.49	2.02e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.59	11.11	0.4	2.52e-26	Birth weight;
BRCA	trans	rs3858145	0.588	rs4142049	chr10:70044452	C/A	cg04882175	chr6:131122610	NA	-0.34	-7.83	-0.3	1.99e-14	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
BRCA	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03452623	chr4:187889614	NA	-0.3	-9.81	-0.36	2.83e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11971779	0.680	rs1862879	chr7:139019951	A/G	cg07862535	chr7:139043722	LUC7L2	0.39	10.3	0.38	3.91e-23	Diisocyanate-induced asthma;
BRCA	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	13.78	0.48	4.93e-38	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg05340658	chr4:99064831	C4orf37	0.68	16.9	0.56	3.04e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg16339924	chr4:17578868	LAP3	0.67	16.21	0.54	9.04e-50	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs700651	0.789	rs5007118	chr2:198909738	G/C	cg00792783	chr2:198669748	PLCL1	0.42	9.05	0.34	1.76e-18	Intracranial aneurysm;
BRCA	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.34	-8.76	-0.33	1.69e-17	Total body bone mineral density;
BRCA	cis	rs10484885	0.878	rs55750696	chr6:90552336	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.47	-0.35	5.23e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg21775007	chr8:11205619	TDH	-0.47	-9.38	-0.35	1.12e-19	Triglycerides;
BRCA	cis	rs7523050	0.643	rs7551313	chr1:109399881	G/A	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs11958404	0.932	rs7706111	chr5:157416053	C/T	cg05962755	chr5:157440814	NA	0.47	9.36	0.35	1.34e-19	IgG glycosylation;
BRCA	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg08999081	chr20:33150536	PIGU	-0.34	-8.7	-0.33	2.7e-17	Coronary artery disease;
BRCA	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-11.52	-0.41	4.96e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg09436375	chr6:42928200	GNMT	0.28	10.57	0.39	3.63e-24	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1215050	0.782	rs6853916	chr4:98653387	C/T	cg05340658	chr4:99064831	C4orf37	-0.44	-9.97	-0.37	7.4e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg14784868	chr12:69753453	YEATS4	0.48	9.56	0.35	2.41e-20	Response to diuretic therapy;
BRCA	cis	rs10876993	0.893	rs7979246	chr12:58092554	A/G	cg18357645	chr12:58087776	OS9	0.46	12.98	0.46	2.23e-34	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.3	-0.44	2.28e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08564027	chr20:61660810	NA	0.85	22.5	0.66	5.11e-83	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg11845111	chr2:191398756	TMEM194B	0.79	15.25	0.52	5.19e-45	Diastolic blood pressure;
BRCA	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	9.43e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg06937882	chr20:24974362	C20orf3	-0.48	-9.46	-0.35	5.84e-20	Blood protein levels;
BRCA	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg21395723	chr22:39101663	GTPBP1	0.39	8.39	0.31	3.17e-16	Menopause (age at onset);
BRCA	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg22705602	chr4:152727874	NA	-0.32	-8.36	-0.31	4e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.51	-0.47	9.38e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg03433033	chr1:76189801	ACADM	0.66	11.9	0.43	1.24e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6942756	0.806	rs6467237	chr7:128964831	A/G	cg02491457	chr7:128862824	NA	-0.57	-12.11	-0.43	1.53e-30	White matter hyperintensity burden;
BRCA	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.74	0.67	2.43e-84	Chronic sinus infection;
BRCA	cis	rs4363385	0.747	rs4240866	chr1:152954875	T/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.31	-0.31	5.96e-16	Inflammatory skin disease;
BRCA	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.55	-9.53	-0.35	3.31e-20	Body mass index (adult);
BRCA	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg21535247	chr6:8435926	SLC35B3	0.42	9.42	0.35	7.86e-20	Motion sickness;
BRCA	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.6	-14.33	-0.49	1.35e-40	Longevity;Endometriosis;
BRCA	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg14558114	chr2:88469736	THNSL2	-0.42	-9.08	-0.34	1.36e-18	Response to metformin (IC50);
BRCA	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg17063962	chr7:91808500	NA	0.52	12.38	0.44	1.01e-31	Breast cancer;
BRCA	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.64e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg01528321	chr10:82214614	TSPAN14	1.07	20.42	0.63	9.67e-72	Post bronchodilator FEV1;
BRCA	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	14.3	0.49	1.97e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3772130	0.527	rs2141614	chr3:121590173	G/A	cg20356878	chr3:121714668	ILDR1	0.44	10.09	0.37	2.67e-22	Cognitive performance;
BRCA	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg24675658	chr1:53192096	ZYG11B	-0.7	-16.25	-0.54	5.9e-50	Monocyte count;
BRCA	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg18230493	chr5:56204884	C5orf35	-0.87	-16.72	-0.55	2.41e-52	Initial pursuit acceleration;
BRCA	cis	rs10129255	0.500	rs6576232	chr14:107195328	A/G	cg07958169	chr14:107095056	NA	-0.39	-8.44	-0.32	2.05e-16	Kawasaki disease;
BRCA	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg06784218	chr1:46089804	CCDC17	0.51	12.17	0.43	8.34e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504073	0.584	rs10957356	chr8:49980634	G/A	cg00325661	chr8:49890786	NA	0.44	12.82	0.45	1.2e-33	Blood metabolite ratios;
BRCA	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg19847866	chr10:1019161	NA	0.55	12.0	0.43	4.51e-30	Response to angiotensin II receptor blocker therapy;
BRCA	trans	rs9944715	0.954	rs36191490	chr18:43839653	C/T	cg01718231	chr17:29326311	RNF135	-0.44	-9.01	-0.34	2.36e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs6120849	0.518	rs11696652	chr20:33637060	T/G	cg24642439	chr20:33292090	TP53INP2	0.6	10.36	0.38	2.45e-23	Protein C levels;
BRCA	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg10057126	chr4:77819792	ANKRD56	0.67	15.28	0.52	3.62e-45	Emphysema distribution in smoking;
BRCA	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg18351406	chr4:77819688	ANKRD56	0.58	12.68	0.45	5.27e-33	Emphysema distribution in smoking;
BRCA	cis	rs919433	0.783	rs787980	chr2:198239225	C/T	cg00792783	chr2:198669748	PLCL1	0.35	7.83	0.3	1.98e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg09307838	chr4:120376055	NA	0.64	14.09	0.49	1.94e-39	Corneal astigmatism;
BRCA	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg27129171	chr3:47204927	SETD2	-0.72	-17.52	-0.57	2.05e-56	Colorectal cancer;
BRCA	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24531977	chr5:56204891	C5orf35	-0.8	-16.79	-0.55	1.14e-52	Initial pursuit acceleration;
BRCA	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.39	-0.32	3e-16	Total body bone mineral density;
BRCA	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg26850624	chr5:429559	AHRR	0.33	7.83	0.3	2.06e-14	Cystic fibrosis severity;
BRCA	trans	rs12517041	1.000	rs13156787	chr5:23280382	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.45	-8.23	-0.31	1.09e-15	Calcium levels;
BRCA	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.83	0.39	3.24e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg06784218	chr1:46089804	CCDC17	0.45	10.79	0.39	4.84e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.19	-0.31	1.45e-15	Aortic root size;
BRCA	cis	rs56399783	0.901	rs73049341	chr7:2812255	G/C	cg19731401	chr7:2775893	GNA12	0.48	8.34	0.31	4.49e-16	Childhood ear infection;
BRCA	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg08508325	chr11:3079039	CARS	0.28	8.48	0.32	1.56e-16	Calcium levels;
BRCA	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg13010199	chr12:38710504	ALG10B	0.42	8.87	0.33	7.17e-18	Bladder cancer;
BRCA	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg08508325	chr11:3079039	CARS	0.28	8.49	0.32	1.5e-16	Calcium levels;
BRCA	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg07148914	chr20:33460835	GGT7	0.43	9.24	0.34	3.69e-19	Height;
BRCA	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg05340658	chr4:99064831	C4orf37	0.45	10.18	0.37	1.21e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg24848339	chr3:12840334	CAND2	0.44	11.59	0.42	2.62e-28	QRS complex (12-leadsum);
BRCA	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg15212455	chr7:39170539	POU6F2	0.4	9.1	0.34	1.1e-18	IgG glycosylation;
BRCA	cis	rs2625529	0.824	rs12917428	chr15:72221998	T/C	cg16672083	chr15:72433130	SENP8	-0.84	-17.34	-0.57	1.67e-55	Red blood cell count;
BRCA	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.1	0.34	1.12e-18	Tonsillectomy;
BRCA	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.86e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9811920	0.809	rs6806323	chr3:99722564	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.55	-13.16	-0.46	3.55e-35	Axial length;
BRCA	cis	rs586533	0.881	rs590634	chr11:99500333	A/C	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg23422044	chr7:1970798	MAD1L1	-0.41	-8.71	-0.33	2.68e-17	Neuroticism;
BRCA	cis	rs72928364	0.860	rs13085636	chr3:100797104	G/A	cg10123952	chr3:100791384	NA	0.58	8.36	0.31	3.8e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg27170947	chr2:26402098	FAM59B	-0.88	-16.75	-0.55	1.71e-52	Gut microbiome composition (summer);
BRCA	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg26116260	chr4:7069785	GRPEL1	-0.59	-8.93	-0.33	4.43e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.46	0.38	9.36e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.61	0.32	5.64e-17	Rheumatoid arthritis;
BRCA	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg09307838	chr4:120376055	NA	0.59	12.12	0.43	1.43e-30	Corneal astigmatism;
BRCA	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg24562669	chr7:97807699	LMTK2	0.47	12.22	0.44	5.45e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg05234568	chr11:5960015	NA	-0.44	-9.15	-0.34	7.49e-19	DNA methylation (variation);
BRCA	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg11502198	chr6:26597334	ABT1	0.56	12.0	0.43	4.68e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg06784218	chr1:46089804	CCDC17	0.44	10.65	0.39	1.79e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.5	-0.32	1.31e-16	Menopause (age at onset);
BRCA	trans	rs1422110	0.572	rs6884343	chr5:85444051	G/T	cg01787110	chr1:109008453	NBPF6	0.4	8.54	0.32	9.94e-17	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg24101359	chr6:42928495	GNMT	0.65	16.2	0.54	1.08e-49	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs870825	0.616	rs7680639	chr4:185652915	C/T	cg04058563	chr4:185651563	MLF1IP	-0.73	-15.84	-0.53	6.2e-48	Blood protein levels;
BRCA	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg13010199	chr12:38710504	ALG10B	0.49	9.51	0.35	3.76e-20	Morning vs. evening chronotype;
BRCA	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-12.39	-0.44	9.86e-32	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.59	-8.63	-0.32	4.76e-17	Schizophrenia;
BRCA	cis	rs701145	0.585	rs1713828	chr3:153838553	C/T	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.22e-14	Coronary artery disease;
BRCA	trans	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg06521331	chr12:34319734	NA	-0.46	-8.57	-0.32	7.48e-17	Bladder cancer;
BRCA	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg21280719	chr6:42927975	GNMT	-0.33	-14.2	-0.49	5.89e-40	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg12935359	chr14:103987150	CKB	0.61	14.06	0.49	2.58e-39	Intelligence (multi-trait analysis);
BRCA	cis	rs701145	0.556	rs355756	chr3:154021063	G/A	cg16511985	chr3:153974050	SGEF	0.46	10.61	0.39	2.52e-24	Coronary artery disease;
BRCA	cis	rs7715811	1.000	rs12153762	chr5:13778890	A/G	cg07548982	chr5:13769939	DNAH5	-0.41	-9.09	-0.34	1.19e-18	Subclinical atherosclerosis traits (other);
BRCA	cis	rs7607369	0.536	rs7600248	chr2:219665963	C/T	cg02176678	chr2:219576539	TTLL4	-0.37	-10.09	-0.37	2.49e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg15448220	chr1:150897856	SETDB1	0.35	7.9	0.3	1.19e-14	Melanoma;
BRCA	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg08885076	chr2:99613938	TSGA10	0.45	10.46	0.38	9.19e-24	Chronic sinus infection;
BRCA	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg20503657	chr10:835505	NA	1.32	21.46	0.65	2.31e-77	Eosinophil percentage of granulocytes;
BRCA	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-10.46	-0.38	9.67e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08859206	chr1:53392774	SCP2	0.59	12.95	0.46	3.02e-34	Monocyte count;
BRCA	cis	rs829883	0.738	rs249846	chr12:98868739	T/C	cg25150519	chr12:98850993	NA	0.69	16.75	0.55	1.68e-52	Colorectal adenoma (advanced);
BRCA	cis	rs34779708	0.931	rs7920095	chr10:35303334	G/A	cg03585969	chr10:35415529	CREM	0.56	11.59	0.42	2.64e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs12472274	0.646	rs35468889	chr2:239090959	G/A	cg17459225	chr2:239074497	NA	0.59	10.62	0.39	2.35e-24	Phospholipid levels (plasma);
BRCA	cis	rs593982	0.777	rs72941015	chr11:65457514	A/C	cg08755490	chr11:65554678	OVOL1	-1.23	-14.64	-0.5	4.77e-42	Atopic dermatitis;
BRCA	cis	rs7814319	0.838	rs10955067	chr8:97230982	C/T	cg20787634	chr8:97240163	UQCRB	-0.45	-10.48	-0.38	8.28e-24	Lung function (FVC);
BRCA	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03264133	chr6:25882463	NA	0.72	16.86	0.55	4.87e-53	Blood metabolite levels;
BRCA	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg14196790	chr5:131705035	SLC22A5	0.34	9.13	0.34	8.61e-19	Breast cancer;
BRCA	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03264133	chr6:25882463	NA	-0.53	-11.95	-0.43	7.44e-30	Blood metabolite levels;
BRCA	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg18154014	chr19:37997991	ZNF793	0.48	9.12	0.34	9.48e-19	Coronary artery calcification;
BRCA	cis	rs36051895	0.594	rs10115464	chr9:5144268	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-8.63	-0.32	4.8e-17	Pediatric autoimmune diseases;
BRCA	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg16339924	chr4:17578868	LAP3	0.55	13.7	0.48	1.24e-37	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4363385	0.747	rs946098	chr1:152975038	A/C	cg24667326	chr1:152973720	SPRR3	-0.34	-9.54	-0.35	2.94e-20	Inflammatory skin disease;
BRCA	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11764359	chr7:65958608	NA	-0.75	-16.87	-0.55	4.61e-53	Aortic root size;
BRCA	trans	rs4596713	0.508	rs7862404	chr9:71779903	G/A	cg16512924	chr15:28394682	HERC2	0.45	10.58	0.39	3.12e-24	Headache;
BRCA	cis	rs3106136	0.527	rs4693376	chr4:95157240	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-8.21	-0.31	1.21e-15	Capecitabine sensitivity;
BRCA	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	trans	rs4650994	0.525	rs2493865	chr1:178545016	G/A	cg05059571	chr16:84539110	KIAA1609	0.54	12.5	0.44	3.11e-32	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.87	0.36	1.75e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg24549020	chr5:56110836	MAP3K1	0.5	10.44	0.38	1.15e-23	Type 2 diabetes;
BRCA	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg00701064	chr4:6280414	WFS1	0.68	17.68	0.57	3.11e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg26384229	chr12:38710491	ALG10B	-0.51	-12.1	-0.43	1.7e-30	Morning vs. evening chronotype;
BRCA	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg02297831	chr4:17616191	MED28	0.38	8.85	0.33	8.39e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg11707556	chr5:10655725	ANKRD33B	0.43	9.63	0.36	1.4e-20	Coronary artery disease;
BRCA	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg14403583	chr14:105418241	AHNAK2	-0.38	-8.84	-0.33	8.9e-18	Rheumatoid arthritis;
BRCA	trans	rs7395662	0.571	rs1605358	chr11:48689318	T/A	cg00717180	chr2:96193071	NA	-0.32	-8.73	-0.33	2.2e-17	HDL cholesterol;
BRCA	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.55	10.88	0.4	1.99e-25	Tonsillectomy;
BRCA	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.81e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg00321850	chr1:175162397	KIAA0040	-0.41	-11.47	-0.41	8.16e-28	Alcohol dependence;
BRCA	trans	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg05926928	chr17:57297772	GDPD1	0.64	9.12	0.34	9.95e-19	Opioid sensitivity;
BRCA	cis	rs708547	0.581	rs6554400	chr4:57805306	A/C	cg25525207	chr4:57843836	C4orf14;POLR2B	0.44	8.57	0.32	7.56e-17	Response to bleomycin (chromatid breaks);
BRCA	cis	rs9649213	0.574	rs7789440	chr7:97888798	G/T	cg24562669	chr7:97807699	LMTK2	0.47	11.93	0.43	9.16e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	ch.11.42038R	chr11:967971	AP2A2	0.5	15.89	0.53	3.78e-48	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg17366294	chr4:99064904	C4orf37	-0.36	-7.81	-0.3	2.38e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	18.43	0.59	3.6e-61	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg18132916	chr6:79620363	NA	-0.49	-11.09	-0.4	3.06e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs4780401	0.728	rs8191335	chr16:11771353	C/A	cg01061890	chr16:11836724	TXNDC11	-0.39	-8.32	-0.31	5.44e-16	Rheumatoid arthritis;
BRCA	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02176678	chr2:219576539	TTLL4	0.46	11.97	0.43	6.17e-30	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs300703	0.935	rs417829	chr2:206851	A/G	cg21211680	chr2:198530	NA	0.46	7.92	0.3	1.05e-14	Blood protein levels;
BRCA	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	8.98	0.33	3.05e-18	Bipolar disorder;
BRCA	trans	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg01620082	chr3:125678407	NA	-0.84	-9.24	-0.34	3.71e-19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
BRCA	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg01324343	chr3:183735012	ABCC5	0.44	9.79	0.36	3.62e-21	Anterior chamber depth;
BRCA	trans	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg05868516	chr6:26286170	HIST1H4H	0.46	9.22	0.34	4.37e-19	Educational attainment;
BRCA	cis	rs4711336	0.967	rs4713658	chr6:33667117	C/G	cg14003231	chr6:33640908	ITPR3	0.33	8.02	0.3	5.01e-15	Height;
BRCA	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07636037	chr3:49044803	WDR6	-0.73	-15.52	-0.52	2.44e-46	Menarche (age at onset);
BRCA	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21582582	chr3:182698605	DCUN1D1	-0.39	-10.21	-0.37	8.6e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg11584989	chr19:19387371	SF4	-0.65	-14.15	-0.49	9.63e-40	Bipolar disorder;
BRCA	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg14863265	chr7:2801509	GNA12	-0.47	-10.14	-0.37	1.72e-22	Height;
BRCA	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-9.29	-0.34	2.44e-19	Eosinophil percentage of white cells;
BRCA	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg26384229	chr12:38710491	ALG10B	0.68	14.47	0.5	3.08e-41	Morning vs. evening chronotype;
BRCA	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg13010199	chr12:38710504	ALG10B	0.5	9.98	0.37	6.83e-22	Bladder cancer;
BRCA	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.62	16.06	0.54	5.55e-49	Fuchs's corneal dystrophy;
BRCA	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg12310025	chr6:25882481	NA	-0.54	-12.03	-0.43	3.44e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs1371614	0.632	rs6738528	chr2:27149258	T/A	cg00617064	chr2:27272375	NA	0.32	8.37	0.31	3.52e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs887829	0.570	rs10175809	chr2:234596865	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.36	-0.31	3.83e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-14.52	-0.5	1.71e-41	Monocyte count;
BRCA	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg10818794	chr15:86012489	AKAP13	0.42	11.31	0.41	3.58e-27	Coronary artery disease;
BRCA	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg16339924	chr4:17578868	LAP3	0.61	14.99	0.51	9.23e-44	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg11789530	chr4:8429930	ACOX3	0.6	14.93	0.51	1.83e-43	Response to antineoplastic agents;
BRCA	cis	rs59918340	1.000	rs59918340	chr8:142232256	A/G	cg23750338	chr8:142222470	SLC45A4	0.4	9.77	0.36	4.15e-21	Immature fraction of reticulocytes;
BRCA	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg01689657	chr7:91764605	CYP51A1	0.24	8.31	0.31	5.93e-16	Breast cancer;
BRCA	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03264133	chr6:25882463	NA	-0.4	-8.6	-0.32	5.97e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	11.31	0.41	3.82e-27	Height;
BRCA	cis	rs9837602	1.000	rs4075038	chr3:99680086	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.59	-11.28	-0.41	4.78e-27	Breast cancer;
BRCA	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-14.38	-0.49	7.92e-41	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg08999081	chr20:33150536	PIGU	0.36	9.32	0.35	1.81e-19	Coronary artery disease;
BRCA	cis	rs11920090	0.858	rs66674286	chr3:170679289	T/C	cg09710316	chr3:170744871	SLC2A2	0.51	8.2	0.31	1.35e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs2425143	1.000	rs7264414	chr20:34446826	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.54	-0.32	9.92e-17	Blood protein levels;
BRCA	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	17.25	0.56	5.13e-55	Electrocardiographic conduction measures;
BRCA	cis	rs1483121	0.808	rs11039482	chr11:48009074	C/T	cg20307385	chr11:47447363	PSMC3	0.56	7.92	0.3	1.07e-14	Fasting blood glucose (BMI interaction);Fasting blood glucose;
BRCA	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	11.18	0.4	1.24e-26	Birth weight;
BRCA	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.98	-0.48	6.13e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6700896	0.931	rs12021623	chr1:66153586	A/C	cg04111102	chr1:66153794	NA	0.41	9.87	0.36	1.83e-21	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg22705602	chr4:152727874	NA	-0.32	-8.26	-0.31	8.6e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs13046373	0.535	rs13051529	chr21:32029743	G/C	cg14062083	chr21:31802829	KRTAP13-4	0.33	8.72	0.33	2.45e-17	HDL cholesterol;
BRCA	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg06191203	chr2:152266755	RIF1	-0.31	-9.11	-0.34	1.08e-18	Lung cancer;
BRCA	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.3	8.37	0.31	3.74e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-8.8	-0.33	1.26e-17	Alzheimer's disease (late onset);
BRCA	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg26384229	chr12:38710491	ALG10B	0.7	15.92	0.53	2.66e-48	Bladder cancer;
BRCA	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg24675658	chr1:53192096	ZYG11B	0.56	12.75	0.45	2.42e-33	Monocyte count;
BRCA	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg17971929	chr21:40555470	PSMG1	-0.61	-13.72	-0.48	9.54e-38	Cognitive function;
BRCA	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg17691542	chr6:26056736	HIST1H1C	0.74	14.71	0.5	2.08e-42	Iron status biomarkers;
BRCA	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg16606324	chr3:10149918	C3orf24	0.55	10.86	0.39	2.38e-25	Alzheimer's disease;
BRCA	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg12140854	chr5:148520817	ABLIM3	0.43	9.16	0.34	6.77e-19	Breast cancer;
BRCA	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26314531	chr2:26401878	FAM59B	-0.79	-12.6	-0.45	1.18e-32	Gut microbiome composition (summer);
BRCA	cis	rs11971779	0.793	rs11764426	chr7:139024050	C/G	cg07862535	chr7:139043722	LUC7L2	0.45	11.78	0.42	4.19e-29	Diisocyanate-induced asthma;
BRCA	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11764359	chr7:65958608	NA	0.81	19.67	0.61	1.05e-67	Aortic root size;
BRCA	cis	rs9612	1.000	rs346524	chr19:44260572	T/C	cg08581076	chr19:44259116	C19orf61	0.53	9.72	0.36	6.46e-21	Exhaled nitric oxide output;
BRCA	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg04267008	chr7:1944627	MAD1L1	-0.45	-9.53	-0.35	3.12e-20	Schizophrenia;
BRCA	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg06092702	chr1:163392909	NA	0.37	9.86	0.36	1.88e-21	Motion sickness;
BRCA	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-7.83	-0.3	2.04e-14	Response to antipsychotic treatment;
BRCA	cis	rs7254114	0.578	rs35248735	chr19:11312238	G/A	cg02815516	chr19:11306319	KANK2	-0.35	-10.01	-0.37	5.37e-22	Immature fraction of reticulocytes;
BRCA	cis	rs13046373	0.535	rs1395775	chr21:32025065	G/A	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.54	0.35	2.85e-20	HDL cholesterol;
BRCA	cis	rs1003719	0.788	rs2835584	chr21:38460338	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.59	13.62	0.47	2.93e-37	Eye color traits;
BRCA	cis	rs2066819	1.000	rs11171806	chr12:56733531	A/G	cg26734620	chr12:56694298	CS	-0.89	-10.37	-0.38	2.07e-23	Psoriasis vulgaris;
BRCA	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg23229984	chr5:148520753	ABLIM3	-0.36	-9.04	-0.34	1.8e-18	Breast cancer;
BRCA	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg07828340	chr4:882639	GAK	0.99	13.58	0.47	4.13e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg25817165	chr18:72167213	CNDP2	-0.75	-14.82	-0.51	6.34e-43	Refractive error;
BRCA	cis	rs7766436	0.614	rs60412116	chr6:22563741	G/T	cg13666174	chr6:22585274	NA	-0.41	-8.63	-0.32	4.72e-17	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg08888203	chr3:10149979	C3orf24	-0.62	-13.57	-0.47	4.78e-37	Alzheimer's disease;
BRCA	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg12615879	chr12:58013172	SLC26A10	0.32	9.05	0.34	1.75e-18	Multiple sclerosis;
BRCA	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.55	-0.32	8.79e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs12579753	0.917	rs7306043	chr12:82191282	G/A	cg07988820	chr12:82153109	PPFIA2	-0.51	-8.83	-0.33	1.03e-17	Resting heart rate;
BRCA	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg18758796	chr5:131593413	PDLIM4	0.31	8.12	0.31	2.35e-15	Blood metabolite levels;
BRCA	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg22535103	chr8:58192502	C8orf71	-0.46	-9.06	-0.34	1.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs13102973	0.899	rs7438900	chr4:135909921	T/A	cg14419869	chr4:135874104	NA	0.46	8.99	0.34	2.81e-18	Subjective well-being;
BRCA	cis	rs3739998	0.509	rs61841115	chr10:30333025	C/T	cg00730780	chr10:30316187	KIAA1462	0.56	10.75	0.39	6.95e-25	Coronary heart disease;
BRCA	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.43	7.86	0.3	1.6e-14	Mean platelet volume;
BRCA	trans	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg13010199	chr12:38710504	ALG10B	0.41	8.22	0.31	1.1e-15	Morning vs. evening chronotype;
BRCA	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg12373951	chr3:133503437	NA	0.34	8.1	0.31	2.73e-15	Iron status biomarkers;
BRCA	cis	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg06521331	chr12:34319734	NA	-0.56	-10.14	-0.37	1.7e-22	Morning vs. evening chronotype;
BRCA	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg20487152	chr13:99095054	FARP1	-0.3	-7.89	-0.3	1.33e-14	Longevity;
BRCA	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-11.64	-0.42	1.62e-28	Alzheimer's disease;
BRCA	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg04166393	chr7:2884313	GNA12	0.43	9.26	0.34	2.95e-19	Height;
BRCA	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.88	-0.3	1.43e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg09367891	chr1:107599246	PRMT6	-0.55	-10.08	-0.37	2.94e-22	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg22903471	chr2:27725779	GCKR	0.35	8.45	0.32	1.94e-16	Total body bone mineral density;
BRCA	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg02753203	chr1:228287806	NA	-0.72	-15.73	-0.53	2.34e-47	Diastolic blood pressure;
BRCA	cis	rs4268898	0.529	rs4426488	chr2:24372815	A/G	cg06627628	chr2:24431161	ITSN2	0.42	8.68	0.32	3.17e-17	Asthma;
BRCA	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg08601574	chr20:25228251	PYGB	0.39	8.95	0.33	3.74e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11229555	0.609	rs4519113	chr11:58216825	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.6	-0.35	1.79e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.76	-0.39	6.05e-25	Mean corpuscular volume;
BRCA	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg21784768	chr11:537496	LRRC56	-0.64	-8.28	-0.31	7.08e-16	Body mass index;
BRCA	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg08807101	chr21:30365312	RNF160	0.62	13.46	0.47	1.59e-36	Selective IgA deficiency;
BRCA	cis	rs12541635	0.966	rs62525734	chr8:106984056	T/C	cg10147462	chr8:107024639	NA	0.38	10.07	0.37	3.14e-22	Age of smoking initiation;
BRCA	cis	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg06521331	chr12:34319734	NA	-0.53	-10.29	-0.38	4.23e-23	Morning vs. evening chronotype;
BRCA	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg11814155	chr7:99998594	ZCWPW1	0.57	9.77	0.36	4.13e-21	Platelet count;
BRCA	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg03433033	chr1:76189801	ACADM	-0.47	-9.84	-0.36	2.25e-21	Daytime sleep phenotypes;
BRCA	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg13010199	chr12:38710504	ALG10B	0.49	9.61	0.36	1.57e-20	Morning vs. evening chronotype;
BRCA	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg00383909	chr3:49044727	WDR6	0.98	15.72	0.53	2.59e-47	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs3845702	0.877	rs12693216	chr2:180839793	T/A	cg01881094	chr2:180872142	CWC22	-0.69	-13.7	-0.48	1.18e-37	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.38	0.49	8.21e-41	Motion sickness;
BRCA	trans	rs12517041	1.000	rs35411935	chr5:23282784	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.32	-0.31	5.27e-16	Calcium levels;
BRCA	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg00409905	chr10:38381863	ZNF37A	-0.5	-10.44	-0.38	1.18e-23	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7043114	0.525	rs6479419	chr9:95110002	T/C	cg14631576	chr9:95140430	CENPP	-0.34	-8.38	-0.31	3.29e-16	Height;
BRCA	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg18016565	chr1:150552671	MCL1	0.34	8.11	0.31	2.61e-15	Melanoma;
BRCA	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg08470875	chr2:26401718	FAM59B	0.72	11.89	0.43	1.31e-29	Gut microbiome composition (summer);
BRCA	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg02574844	chr11:5959923	NA	-0.4	-8.22	-0.31	1.11e-15	DNA methylation (variation);
BRCA	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg08917208	chr2:24149416	ATAD2B	0.92	13.6	0.47	3.66e-37	Lymphocyte counts;
BRCA	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg11530693	chr1:120165357	ZNF697	0.63	15.57	0.52	1.44e-46	Systemic lupus erythematosus;
BRCA	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	11.55	0.42	3.54e-28	Personality dimensions;
BRCA	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-18.66	-0.59	2.46e-62	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg18105134	chr13:113819100	PROZ	0.71	15.07	0.51	3.77e-44	Platelet distribution width;
BRCA	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg19920283	chr7:105172520	RINT1	0.59	9.54	0.35	2.83e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg13319975	chr6:146136371	FBXO30	-0.39	-8.61	-0.32	5.61e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg08017756	chr2:100939284	LONRF2	-0.31	-7.98	-0.3	6.56e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03923535	chr7:1197113	ZFAND2A	0.47	10.29	0.38	4.58e-23	Longevity;Endometriosis;
BRCA	cis	rs3784262	0.692	rs1822205	chr15:58284657	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-9.9	-0.36	1.32e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.7e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4423214	0.840	rs1792224	chr11:71176141	C/T	cg05163923	chr11:71159392	DHCR7	-0.57	-11.6	-0.42	2.31e-28	Vitamin D levels;
BRCA	cis	rs6484504	0.625	rs4922859	chr11:31382517	A/G	cg26647111	chr11:31128758	NA	0.42	9.34	0.35	1.5700000000000001e-19	Red blood cell count;
BRCA	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg22307297	chr20:60903441	LAMA5	-0.34	-9.33	-0.35	1.65e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs2073300	1.000	rs6137961	chr20:23443102	G/T	cg12062639	chr20:23401060	NAPB	0.88	10.43	0.38	1.28e-23	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs34779708	0.733	rs7914468	chr10:35548071	G/A	cg03585969	chr10:35415529	CREM	0.44	9.1	0.34	1.17e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	10.52	0.38	5.65e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg00666640	chr1:248458726	OR2T12	0.32	8.61	0.32	5.63e-17	Common traits (Other);
BRCA	trans	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg12856521	chr11:46389249	DGKZ	0.37	8.12	0.31	2.36e-15	Leprosy;
BRCA	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.65	16.69	0.55	3.62e-52	Colorectal cancer;
BRCA	trans	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg25214090	chr10:38739885	LOC399744	0.45	10.38	0.38	2.04e-23	Corneal astigmatism;
BRCA	cis	rs7809950	0.678	rs77395658	chr7:107000651	G/A	cg23024343	chr7:107201750	COG5	-0.48	-9.65	-0.36	1.17e-20	Coronary artery disease;
BRCA	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-11.97	-0.43	6.14e-30	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg21475434	chr5:93447410	FAM172A	0.71	8.82	0.33	1.05e-17	Diabetic retinopathy;
BRCA	cis	rs11031096	0.782	rs11031110	chr11:4162652	G/C	cg18678763	chr11:4115507	RRM1	-0.37	-8.35	-0.31	4.08e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.96	-0.37	7.88e-22	Alzheimer's disease;
BRCA	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	11.46	0.41	8.86e-28	Height;
BRCA	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg18404041	chr3:52824283	ITIH1	-0.35	-9.0	-0.34	2.6e-18	Schizophrenia;
BRCA	cis	rs4919694	1.000	rs17787717	chr10:104695699	T/G	cg04362960	chr10:104952993	NT5C2	0.99	13.51	0.47	9.53e-37	Arsenic metabolism;
BRCA	cis	rs724568	0.546	rs6717648	chr2:67939688	C/T	cg17945962	chr2:67939740	NA	-0.38	-10.19	-0.37	1.09e-22	Major depressive disorder (broad);
BRCA	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.5	11.15	0.4	1.69e-26	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg07741184	chr6:167504864	NA	0.33	9.8	0.36	3.25e-21	Crohn's disease;
BRCA	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	11.17	0.4	1.43e-26	Platelet count;
BRCA	cis	rs1997103	1.000	rs2331065	chr7:55408392	A/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg02551604	chr5:131831745	NA	0.4	15.16	0.51	1.43e-44	Asthma (sex interaction);
BRCA	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg04727924	chr7:799746	HEATR2	-0.55	-10.78	-0.39	5.25e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg15704280	chr7:45808275	SEPT13	-0.55	-10.73	-0.39	7.9e-25	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg25358565	chr5:93447407	FAM172A	0.69	11.87	0.42	1.73e-29	Diabetic retinopathy;
BRCA	trans	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.81	-0.33	1.14e-17	Neuroticism;
BRCA	cis	rs7903847	0.642	rs10882914	chr10:99142057	A/G	cg20016023	chr10:99160130	RRP12	-0.27	-8.62	-0.32	5.46e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg08601574	chr20:25228251	PYGB	0.41	9.62	0.36	1.49e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.59	9.33	0.35	1.67e-19	Renal function-related traits (BUN);
BRCA	cis	rs1997103	0.954	rs2030807	chr7:55378485	A/G	cg17469321	chr7:55412551	NA	0.51	9.52	0.35	3.5e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7572733	0.534	rs700678	chr2:198705820	T/C	cg00792783	chr2:198669748	PLCL1	0.47	10.15	0.37	1.55e-22	Dermatomyositis;
BRCA	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg21535247	chr6:8435926	SLC35B3	0.41	9.36	0.35	1.36e-19	Motion sickness;
BRCA	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.4	8.38	0.31	3.4e-16	Total cholesterol levels;
BRCA	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.92	-27.31	-0.73	1.98e-109	Headache;
BRCA	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	11.31	0.41	3.77e-27	Tonsillectomy;
BRCA	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg04450456	chr4:17643702	FAM184B	-0.33	-9.39	-0.35	1.04e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg05340658	chr4:99064831	C4orf37	0.61	14.6	0.5	7.16e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs778371	0.522	rs10205801	chr2:233597196	G/A	cg08000102	chr2:233561755	GIGYF2	0.7	17.06	0.56	4.79e-54	Schizophrenia;
BRCA	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg16325326	chr1:53192061	ZYG11B	0.6	13.11	0.46	6.12e-35	Monocyte count;
BRCA	cis	rs9287719	0.674	rs12620209	chr2:10720441	T/C	cg00105475	chr2:10696890	NA	0.41	9.19	0.34	5.52e-19	Prostate cancer;
BRCA	cis	rs877282	0.898	rs11253352	chr10:766598	C/A	cg17470449	chr10:769945	NA	0.47	8.08	0.3	3.26e-15	Uric acid levels;
BRCA	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21659725	chr3:3221576	CRBN	0.5	12.72	0.45	3.48e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00166722	chr3:10149974	C3orf24	0.65	11.23	0.41	7.83e-27	Alzheimer's disease;
BRCA	cis	rs999943	0.846	rs9348923	chr6:33617924	C/T	cg14003231	chr6:33640908	ITPR3	0.64	14.24	0.49	3.79e-40	Obesity (extreme);
BRCA	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.38	-0.35	1.16e-19	Joint mobility (Beighton score);
BRCA	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg27279351	chr12:120934652	DYNLL1	0.55	13.11	0.46	6.1e-35	High light scatter reticulocyte count;
BRCA	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg06191203	chr2:152266755	RIF1	-0.34	-9.05	-0.34	1.76e-18	Squamous cell lung carcinoma;
BRCA	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.42	8.95	0.33	3.79e-18	IgG glycosylation;
BRCA	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg03146154	chr1:46216737	IPP	-0.44	-9.62	-0.36	1.5e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg16414030	chr3:133502952	NA	-0.34	-8.08	-0.3	3.17e-15	Ankle injury;
BRCA	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-9.81	-0.36	2.98e-21	Alzheimer's disease (late onset);
BRCA	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg08000102	chr2:233561755	GIGYF2	0.62	13.68	0.48	1.47e-37	Coronary artery disease;
BRCA	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg11057378	chr10:81107060	PPIF	0.43	10.35	0.38	2.66e-23	Height;
BRCA	cis	rs12541635	0.966	rs4734895	chr8:107002604	A/G	cg10147462	chr8:107024639	NA	0.38	9.95	0.37	8.45e-22	Age of smoking initiation;
BRCA	cis	rs4924935	0.770	rs4924946	chr17:18846525	A/T	cg26378065	chr17:18585709	ZNF286B	-0.35	-8.22	-0.31	1.14e-15	Pancreatic cancer;
BRCA	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg01483505	chr11:975446	AP2A2	0.33	9.05	0.34	1.7e-18	Alzheimer's disease (late onset);
BRCA	cis	rs1355223	0.506	rs11032898	chr11:34870111	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-9.38	-0.35	1.1e-19	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.59	0.39	2.9e-24	IgG glycosylation;
BRCA	cis	rs2444217	0.872	rs2531977	chr16:4043701	C/G	cg09300795	chr16:4042428	ADCY9	0.49	11.6	0.42	2.34e-28	Body mass index;
BRCA	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg12560992	chr17:57184187	TRIM37	-0.67	-18.01	-0.58	6e-59	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg08859206	chr1:53392774	SCP2	0.44	9.39	0.35	1.07e-19	Monocyte count;
BRCA	cis	rs6910061	1.000	rs13214777	chr6:11103597	C/G	cg27233058	chr6:11094804	LOC221710	0.53	9.37	0.35	1.27e-19	Diabetic kidney disease;
BRCA	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg05775895	chr3:12838266	CAND2	0.35	7.97	0.3	7.39e-15	QRS complex (12-leadsum);
BRCA	trans	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg06521331	chr12:34319734	NA	-0.51	-9.34	-0.35	1.53e-19	Heart rate;
BRCA	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.61	-0.39	2.56e-24	Tonsillectomy;
BRCA	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	7.95	0.3	8.39e-15	Total cholesterol levels;
BRCA	cis	rs2882667	0.690	rs288013	chr5:138195817	A/G	cg04439458	chr5:138467593	SIL1	0.31	7.94	0.3	9.16e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg26384229	chr12:38710491	ALG10B	0.43	9.61	0.36	1.69e-20	Morning vs. evening chronotype;
BRCA	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg11502198	chr6:26597334	ABT1	-0.45	-9.13	-0.34	8.79e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	8.29	0.31	6.67e-16	Breast cancer;
BRCA	cis	rs6484504	0.532	rs1475558	chr11:31263428	A/G	cg06552810	chr11:31128660	NA	-0.37	-8.44	-0.32	2.12e-16	Red blood cell count;
BRCA	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg09467607	chr2:36825704	FEZ2	0.57	14.0	0.48	4.76e-39	Height;
BRCA	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18876405	chr7:65276391	NA	0.5	11.2	0.4	1.09e-26	Aortic root size;
BRCA	cis	rs9815354	0.812	rs60796012	chr3:41908668	T/C	cg03022575	chr3:42003672	ULK4	0.69	9.49	0.35	4.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg24011408	chr12:48396354	COL2A1	-0.39	-7.84	-0.3	1.86e-14	Glycated hemoglobin levels;
BRCA	cis	rs1035144	0.506	rs2371416	chr14:81275672	A/T	cg06600135	chr14:81408086	NA	-0.43	-10.08	-0.37	2.84e-22	Male sexual orientation;
BRCA	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg05347473	chr6:146136440	FBXO30	-0.43	-8.57	-0.32	7.58e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08045932	chr20:61659980	NA	0.5	11.21	0.41	9.24e-27	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg03929089	chr4:120376271	NA	0.57	9.28	0.34	2.5e-19	Axial length;
BRCA	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.55	11.9	0.43	1.25e-29	HDL cholesterol;
BRCA	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.78	0.33	1.48e-17	Motion sickness;
BRCA	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg03060546	chr3:49711283	APEH	-0.51	-10.51	-0.38	6.34e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg11057378	chr10:81107060	PPIF	0.43	10.3	0.38	4.18e-23	Height;
BRCA	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg10811474	chr19:8428787	ANGPTL4	-0.33	-8.35	-0.31	4.18e-16	HDL cholesterol;
BRCA	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg01475735	chr3:40494733	NA	-0.43	-7.96	-0.3	7.63e-15	Renal cell carcinoma;
BRCA	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg16606324	chr3:10149918	C3orf24	0.53	10.09	0.37	2.68e-22	Alzheimer's disease;
BRCA	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg11833968	chr6:79620685	NA	-0.43	-9.55	-0.35	2.75e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs10189230	0.674	rs2710506	chr2:222379489	A/C	cg14652038	chr2:222343519	EPHA4	0.33	8.03	0.3	4.64e-15	Urate levels in lean individuals;
BRCA	cis	rs7635838	0.596	rs347598	chr3:11258289	G/C	cg00170343	chr3:11313890	ATG7	0.42	8.53	0.32	1.03e-16	HDL cholesterol;
BRCA	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.6	13.27	0.46	1.15e-35	Hemoglobin concentration;
BRCA	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg16339924	chr4:17578868	LAP3	0.66	16.65	0.55	5.39e-52	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg13770153	chr20:60521292	NA	-0.43	-9.73	-0.36	6.07e-21	Body mass index;
BRCA	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14240646	chr10:27532245	ACBD5	-0.6	-9.93	-0.37	1.06e-21	Breast cancer;
BRCA	trans	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-14.12	-0.49	1.28e-39	Brugada syndrome;
BRCA	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg09904177	chr6:26538194	HMGN4	0.55	17.67	0.57	3.26e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg21252483	chr19:49399788	TULP2	-0.39	-8.62	-0.32	5.41e-17	Red cell distribution width;
BRCA	cis	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg05901451	chr6:126070800	HEY2	0.39	9.6	0.36	1.76e-20	Endometrial cancer;
BRCA	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg13010199	chr12:38710504	ALG10B	0.42	9.01	0.34	2.3e-18	Morning vs. evening chronotype;
BRCA	cis	rs72627509	0.951	rs6554401	chr4:57825336	C/G	cg26694713	chr4:57773883	REST	0.48	9.22	0.34	4.37e-19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg14186256	chr22:23484241	RTDR1	0.74	22.01	0.66	2.53e-80	Bone mineral density;
BRCA	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	16.21	0.54	9.37e-50	Lymphocyte counts;
BRCA	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg08888203	chr3:10149979	C3orf24	0.66	11.99	0.43	5.24e-30	Alzheimer's disease;
BRCA	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.86	-0.48	2.11e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg02773041	chr1:40204384	PPIE	0.43	9.25	0.34	3.34e-19	Blood protein levels;
BRCA	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.35	-0.31	4.35e-16	Breast cancer;
BRCA	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	10.09	0.37	2.67e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs868036	1.000	rs868036	chr15:68055013	T/A	cg05925327	chr15:68127851	NA	0.34	8.54	0.32	9.66e-17	Restless legs syndrome;
BRCA	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg17143192	chr8:8559678	CLDN23	0.52	10.03	0.37	4.5e-22	Obesity-related traits;
BRCA	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.71	-0.53	2.72e-47	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.74e-18	Motion sickness;
BRCA	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg08645402	chr16:4508243	NA	0.37	8.91	0.33	5.21e-18	Schizophrenia;
BRCA	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-9.4	-0.35	9.23e-20	Chronic sinus infection;
BRCA	cis	rs7903847	0.642	rs11189179	chr10:99143320	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.66	-0.32	3.88e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs752010	0.902	rs28635337	chr1:42101391	G/A	cg06885757	chr1:42089581	HIVEP3	0.23	8.19	0.31	1.46e-15	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg04990556	chr1:26633338	UBXN11	0.56	8.89	0.33	6.12e-18	Obesity-related traits;
BRCA	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.34	-0.31	4.67e-16	Bipolar disorder;
BRCA	trans	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg17145862	chr1:211918768	LPGAT1	0.69	18.17	0.58	8.7e-60	Leprosy;
BRCA	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg20908204	chr19:46285434	DMPK	-0.27	-8.01	-0.3	5.34e-15	Coronary artery disease;
BRCA	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.12	0.31	2.38e-15	Tonsillectomy;
BRCA	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.41	-0.32	2.67e-16	Colorectal cancer;
BRCA	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg10523679	chr1:76189770	ACADM	0.78	18.69	0.59	1.61e-62	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg24692254	chr21:30365293	RNF160	-0.46	-8.03	-0.3	4.54e-15	Cognitive test performance;
BRCA	cis	rs3892630	0.824	rs2287882	chr19:33332952	C/T	cg22980127	chr19:33182716	NUDT19	0.87	16.42	0.54	8.4e-51	Red blood cell traits;
BRCA	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	16.26	0.54	5.12e-50	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg19717773	chr7:2847554	GNA12	-0.42	-8.91	-0.33	5.1e-18	Height;
BRCA	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg18252515	chr7:66147081	NA	-0.8	-11.18	-0.4	1.23e-26	Diabetic kidney disease;
BRCA	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.9	0.3	1.19e-14	Axial length;
BRCA	cis	rs757081	0.667	rs60173525	chr11:17259967	A/G	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.68	-0.32	3.25e-17	Systolic blood pressure;
BRCA	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-11.44	-0.41	1.04e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg18279126	chr7:2041391	MAD1L1	0.36	7.82	0.3	2.13e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg05519781	chr21:40033154	ERG	-0.45	-9.56	-0.35	2.5e-20	Coronary artery disease;
BRCA	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg20295408	chr7:1910781	MAD1L1	-0.34	-7.84	-0.3	1.94e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg25036284	chr2:26402008	FAM59B	-0.8	-14.44	-0.5	4.05e-41	Gut microbiome composition (summer);
BRCA	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.69	13.9	0.48	1.38e-38	Lymphocyte counts;
BRCA	cis	rs2191566	1.000	rs2191566	chr19:44511389	A/C	cg20607764	chr19:44506953	ZNF230	0.41	9.2	0.34	5.2e-19	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg18811423	chr2:55921094	PNPT1	0.7	22.66	0.67	6.58e-84	Metabolic syndrome;
BRCA	cis	rs4631830	0.863	rs2611507	chr10:51518673	T/C	cg20129853	chr10:51489980	NA	-0.29	-7.93	-0.3	9.53e-15	Prostate-specific antigen levels;
BRCA	cis	rs1691799	0.867	rs1168316	chr12:66746239	A/G	cg16791601	chr12:66731901	HELB	-0.69	-19.67	-0.61	1.03e-67	White blood cell count (basophil);
BRCA	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg12292205	chr6:26970375	C6orf41	-0.69	-15.0	-0.51	8.97e-44	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7551345	0.687	rs881882	chr1:31697370	G/A	cg19084893	chr1:31688959	NA	-0.46	-10.04	-0.37	4.13e-22	Schizophrenia;
BRCA	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg22189786	chr22:42395067	WBP2NL	-0.41	-8.24	-0.31	9.99e-16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg13271783	chr10:134563150	INPP5A	-0.42	-9.02	-0.34	2.19e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6740322	0.895	rs10166994	chr2:43557977	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-12.14	-0.43	1.18e-30	Coronary artery disease;
BRCA	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg24112000	chr20:60950667	NA	-0.47	-9.26	-0.34	3.06e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg22903471	chr2:27725779	GCKR	-0.35	-8.58	-0.32	7.35e-17	Total body bone mineral density;
BRCA	cis	rs4664304	0.620	rs1397717	chr2:160720444	G/T	cg14819504	chr2:160761413	LY75	0.34	8.47	0.32	1.65e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg20503657	chr10:835505	NA	0.56	9.54	0.35	2.92e-20	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs1011018	0.628	rs17262676	chr7:139468828	C/T	cg03224163	chr7:139420300	HIPK2	-0.59	-8.94	-0.33	4.08e-18	Systolic blood pressure;
BRCA	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg17063962	chr7:91808500	NA	-0.51	-11.89	-0.43	1.36e-29	Breast cancer;
BRCA	cis	rs7246657	0.598	rs28660259	chr19:37658681	C/T	cg23950597	chr19:37808831	NA	-0.65	-9.89	-0.36	1.5e-21	Coronary artery calcification;
BRCA	cis	rs7927771	0.524	rs10838777	chr11:47860954	A/C	cg20307385	chr11:47447363	PSMC3	0.42	9.49	0.35	4.65e-20	Subjective well-being;
BRCA	cis	rs12579753	0.827	rs7958100	chr12:82200782	G/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-8.33	-0.31	4.79e-16	Resting heart rate;
BRCA	cis	rs4478858	0.684	rs1532861	chr1:31766491	T/C	cg00250761	chr1:31883323	NA	-0.32	-8.23	-0.31	1.09e-15	Alcohol dependence;
BRCA	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg23711669	chr6:146136114	FBXO30	0.78	18.44	0.59	3.27e-61	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6479901	0.512	rs7082090	chr10:64999012	C/T	cg14819942	chr15:35414228	NA	0.33	8.29	0.31	6.79e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg25036284	chr2:26402008	FAM59B	-0.67	-10.99	-0.4	7.66e-26	Gut microbiome composition (summer);
BRCA	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg03060546	chr3:49711283	APEH	0.58	10.19	0.37	1.08e-22	Menarche (age at onset);
BRCA	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg09754948	chr16:28834200	ATXN2L	0.46	9.19	0.34	5.45e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg08000102	chr2:233561755	GIGYF2	-0.46	-10.01	-0.37	5.41e-22	Coronary artery disease;
BRCA	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg26384229	chr12:38710491	ALG10B	0.48	12.29	0.44	2.61e-31	Morning vs. evening chronotype;
BRCA	cis	rs1832871	0.672	rs9457344	chr6:158742043	C/T	cg07165851	chr6:158734300	TULP4	0.63	12.61	0.45	9.95e-33	Height;
BRCA	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg00080972	chr5:178986291	RUFY1	0.52	14.39	0.49	7.48e-41	Lung cancer;
BRCA	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.54	0.35	3.01e-20	Morning vs. evening chronotype;
BRCA	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg06623918	chr6:96969491	KIAA0776	0.72	14.29	0.49	2.11e-40	Migraine;Coronary artery disease;
BRCA	trans	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.84	-27.06	-0.73	4.85e-108	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg08999081	chr20:33150536	PIGU	0.44	11.88	0.43	1.48e-29	Coronary artery disease;
BRCA	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg02544614	chr20:61657117	NA	0.29	8.11	0.31	2.66e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	8.58	0.32	7.08e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs887829	0.588	rs7556676	chr2:234658250	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-9.17	-0.34	6.59e-19	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg00012203	chr2:219082015	ARPC2	-0.46	-8.95	-0.33	3.91e-18	Colorectal cancer;
BRCA	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.45	-0.41	9.33e-28	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26314531	chr2:26401878	FAM59B	0.88	15.31	0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs586533	0.881	rs668173	chr11:99499834	G/A	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg08645402	chr16:4508243	NA	0.39	8.5	0.32	1.29e-16	Schizophrenia;
BRCA	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg15145296	chr3:125709740	NA	-0.55	-8.7	-0.33	2.73e-17	Blood pressure (smoking interaction);
BRCA	cis	rs9560113	1.000	rs9555804	chr13:112179751	T/C	cg10483660	chr13:112241077	NA	0.31	7.84	0.3	1.91e-14	Menarche (age at onset);
BRCA	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg23711669	chr6:146136114	FBXO30	0.74	17.43	0.57	5.6e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg13047869	chr3:10149882	C3orf24	0.54	11.55	0.42	3.64e-28	Alzheimer's disease;
BRCA	cis	rs60780116	1	rs60780116	chr4:185708807	T/C	cg04058563	chr4:185651563	MLF1IP	0.57	9.38	0.35	1.1e-19	Type 2 diabetes;
BRCA	cis	rs897984	0.542	rs7197717	chr16:31083075	A/C	cg02466173	chr16:30829666	NA	-0.42	-9.38	-0.35	1.13e-19	Dementia with Lewy bodies;
BRCA	cis	rs698833	0.962	rs1085447	chr2:44670996	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.44	-9.0	-0.34	2.63e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg18154014	chr19:37997991	ZNF793	0.49	9.58	0.35	2.05e-20	Coronary artery calcification;
BRCA	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg05340658	chr4:99064831	C4orf37	0.55	10.76	0.39	6.32e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg18964960	chr10:1102726	WDR37	0.6	8.05	0.3	4.2e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-9.26	-0.34	3.13e-19	Tonsillectomy;
BRCA	trans	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.37	-9.13	-0.34	9.04e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9831754	0.906	rs7611939	chr3:78392751	A/C	cg06138941	chr3:78371609	NA	-0.76	-16.59	-0.55	1.18e-51	Calcium levels;
BRCA	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	13.77	0.48	5.88e-38	Coronary artery disease;
BRCA	trans	rs4650994	1.000	rs10798619	chr1:178532517	A/G	cg05059571	chr16:84539110	KIAA1609	-0.38	-8.51	-0.32	1.22e-16	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg04025307	chr7:1156635	C7orf50	0.47	9.42	0.35	8.29e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg04315214	chr1:2043799	PRKCZ	0.54	16.38	0.54	1.34e-50	Height;
BRCA	cis	rs1865721	1.000	rs8094181	chr18:73193976	T/A	cg26385618	chr18:73139727	C18orf62	-0.39	-9.0	-0.34	2.66e-18	Intelligence;
BRCA	cis	rs1468333	1.000	rs10479179	chr5:137564115	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.43	8.51	0.32	1.21e-16	Resting heart rate;
BRCA	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg26384229	chr12:38710491	ALG10B	0.43	9.48	0.35	4.78e-20	Morning vs. evening chronotype;
BRCA	cis	rs1034435	0.755	rs5767172	chr22:48892314	A/C	cg05992904	chr22:48892994	FAM19A5	-0.81	-21.16	-0.64	1.03e-75	Late-onset Alzheimer's disease;
BRCA	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg03188948	chr7:1209495	NA	0.67	11.33	0.41	2.99e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg05623727	chr3:50126028	RBM5	0.49	12.1	0.43	1.66e-30	Body mass index;
BRCA	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg27170947	chr2:26402098	FAM59B	0.76	10.95	0.4	1.04e-25	Gut microbiome composition (summer);
BRCA	trans	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.92	0.3	1.05e-14	Endometrial cancer;
BRCA	cis	rs367943	1.000	rs168365	chr5:112817984	G/A	cg12552261	chr5:112820674	MCC	-0.55	-12.1	-0.43	1.7e-30	Type 2 diabetes;
BRCA	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg03609598	chr5:56110824	MAP3K1	-0.47	-8.22	-0.31	1.13e-15	Initial pursuit acceleration;
BRCA	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg09654669	chr8:57350985	NA	-0.42	-9.39	-0.35	1.04e-19	Obesity-related traits;
BRCA	cis	rs9837602	1.000	rs9833888	chr3:99723580	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	11.21	0.41	9.09e-27	Breast cancer;
BRCA	cis	rs7225537	0.559	rs7214429	chr17:17059872	A/G	cg26176665	chr17:16994978	MPRIP	-0.38	-8.49	-0.32	1.42e-16	Mean platelet volume;
BRCA	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.56	8.33	0.31	5.05e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23583168	chr7:148888333	NA	0.78	18.48	0.59	2.03e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg16405210	chr4:1374714	KIAA1530	-0.92	-20.74	-0.63	1.88e-73	Longevity;
BRCA	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg20887711	chr4:1340912	KIAA1530	0.36	8.66	0.32	4e-17	Longevity;
BRCA	cis	rs13223928	0.592	rs4722439	chr7:3155858	C/T	cg19214707	chr7:3157722	NA	0.44	10.98	0.4	8.4e-26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
BRCA	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg26597838	chr10:835615	NA	-0.51	-9.65	-0.36	1.14e-20	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg18252515	chr7:66147081	NA	-1.08	-15.14	-0.51	1.87e-44	Diabetic kidney disease;
BRCA	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg22974920	chr21:40686053	BRWD1	-0.38	-8.76	-0.33	1.71e-17	Cognitive function;
BRCA	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg04362960	chr10:104952993	NT5C2	0.47	10.12	0.37	1.91e-22	Arsenic metabolism;
BRCA	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.93	20.76	0.63	1.49e-73	Lymphocyte percentage of white cells;
BRCA	trans	rs800082	0.668	rs9821986	chr3:144292701	T/G	cg24215973	chr2:240111563	HDAC4	-0.43	-10.32	-0.38	3.26e-23	Smoking behavior;
BRCA	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg25427524	chr10:38739819	LOC399744	-0.59	-9.95	-0.37	8.54e-22	Obesity (extreme);
BRCA	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	5.1e-16	Tonsillectomy;
BRCA	cis	rs4363385	0.818	rs12085426	chr1:153003074	C/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.24	-0.31	9.85e-16	Inflammatory skin disease;
BRCA	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg07080220	chr10:102295463	HIF1AN	0.63	14.78	0.5	9.71e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17509989	chr5:176798049	RGS14	0.67	13.13	0.46	5.08e-35	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11764359	chr7:65958608	NA	0.76	17.46	0.57	4.2e-56	Aortic root size;
BRCA	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg00106254	chr7:1943704	MAD1L1	-0.33	-8.22	-0.31	1.12e-15	Schizophrenia;
BRCA	cis	rs7729447	0.804	rs4867471	chr5:32693456	A/T	cg16267343	chr5:32710456	NPR3	0.41	8.27	0.31	7.85e-16	Blood pressure;
BRCA	cis	rs9309473	0.950	rs11689588	chr2:73773691	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-11.71	-0.42	8.08e-29	Metabolite levels;
BRCA	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg01689657	chr7:91764605	CYP51A1	0.21	7.87	0.3	1.48e-14	Breast cancer;
BRCA	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg07636037	chr3:49044803	WDR6	0.98	29.34	0.76	1.6e-120	Parkinson's disease;
BRCA	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg16850897	chr7:100343110	ZAN	-0.6	-12.61	-0.45	9.91e-33	Other erythrocyte phenotypes;
BRCA	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11890956	chr21:40555474	PSMG1	-0.8	-18.89	-0.6	1.44e-63	Cognitive function;
BRCA	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg23033748	chr14:75592666	NEK9	-0.41	-9.86	-0.36	1.84e-21	Height;
BRCA	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg06784218	chr1:46089804	CCDC17	0.49	11.58	0.42	2.67e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	19.26	0.61	1.53e-65	Alzheimer's disease;
BRCA	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg14675211	chr2:100938903	LONRF2	-0.52	-11.96	-0.43	6.89e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.43	-10.06	-0.37	3.38e-22	Lymphocyte counts;
BRCA	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg18232548	chr7:50535776	DDC	-0.55	-14.1	-0.49	1.7e-39	Systemic sclerosis;
BRCA	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08564027	chr20:61660810	NA	0.84	22.84	0.67	7.41e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg17366294	chr4:99064904	C4orf37	0.44	10.39	0.38	1.77e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg15017067	chr4:17643749	FAM184B	0.32	9.95	0.37	8.95e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg13628971	chr7:2884303	GNA12	0.38	8.53	0.32	1.08e-16	Height;
BRCA	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg24112000	chr20:60950667	NA	-0.58	-12.74	-0.45	2.82e-33	Colorectal cancer;
BRCA	cis	rs34779708	0.741	rs34397613	chr10:35550313	A/G	cg03585969	chr10:35415529	CREM	0.41	8.3	0.31	6.18e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg23018236	chr17:30244563	NA	-0.63	-10.05	-0.37	3.77e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs11252926	0.605	rs10904075	chr10:425667	A/G	cg18196295	chr10:418757	DIP2C	-0.61	-12.98	-0.46	2.35e-34	Psychosis in Alzheimer's disease;
BRCA	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg21573476	chr21:45109991	RRP1B	-0.37	-9.49	-0.35	4.48e-20	Mean corpuscular volume;
BRCA	cis	rs2108225	0.872	rs2051954	chr7:107441097	G/C	cg18560240	chr7:107437656	SLC26A3	-0.55	-11.52	-0.41	5.01e-28	Ulcerative colitis;
BRCA	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg20290983	chr6:43655470	MRPS18A	1.12	41.82	0.86	4.22e-185	IgG glycosylation;
BRCA	cis	rs758324	0.947	rs72793241	chr5:131240885	C/T	cg06307176	chr5:131281290	NA	-0.57	-11.95	-0.43	7.26e-30	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14240646	chr10:27532245	ACBD5	-0.64	-9.4	-0.35	9.32e-20	Breast cancer;
BRCA	cis	rs10504073	0.631	rs341813	chr8:50039916	T/C	cg00325661	chr8:49890786	NA	0.38	10.85	0.39	2.85e-25	Blood metabolite ratios;
BRCA	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg04476341	chr5:669733	TPPP	0.39	7.83	0.3	2.02e-14	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg01819863	chr10:32635814	EPC1	1.17	20.75	0.63	1.69e-73	Sexual dysfunction (female);
BRCA	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-8.72	-0.33	2.32e-17	Renal function-related traits (BUN);
BRCA	trans	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg25214090	chr10:38739885	LOC399744	0.57	13.01	0.46	1.79e-34	Corneal astigmatism;
BRCA	cis	rs10046574	1.000	rs10046574	chr7:135170470	C/T	cg27474649	chr7:135195673	CNOT4	0.61	8.89	0.33	6.04e-18	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg17366294	chr4:99064904	C4orf37	0.43	10.02	0.37	4.67e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg27490568	chr2:178487706	NA	-0.42	-7.96	-0.3	7.89e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.16	-0.34	6.72e-19	Total body bone mineral density;
BRCA	trans	rs3857536	0.813	rs7771569	chr6:66946717	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	2.02e-14	Blood trace element (Cu levels);
BRCA	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24308560	chr3:49941425	MST1R	-0.4	-8.54	-0.32	9.6e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.31	0.31	5.53e-16	Corneal astigmatism;
BRCA	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg10932868	chr11:921992	NA	0.5	12.8	0.45	1.55e-33	Alzheimer's disease (late onset);
BRCA	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-14.7	-0.5	2.5e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg23711669	chr6:146136114	FBXO30	0.67	15.51	0.52	2.73e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2279817	0.743	rs3766309	chr1:17977378	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.34	-9.53	-0.35	3.3e-20	Neuroticism;
BRCA	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg17691542	chr6:26056736	HIST1H1C	0.47	9.54	0.35	2.86e-20	Height;
BRCA	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.48	0.5	2.79e-41	Motion sickness;
BRCA	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg24692254	chr21:30365293	RNF160	-0.47	-10.33	-0.38	3.11e-23	Dental caries;
BRCA	cis	rs6066835	0.850	rs3827042	chr20:47319307	G/A	cg18078177	chr20:47281410	PREX1	0.69	8.04	0.3	4.49e-15	Multiple myeloma;
BRCA	cis	rs9649465	1.000	rs7776792	chr7:123335350	C/T	cg04330084	chr7:123175371	IQUB	0.33	9.01	0.34	2.3e-18	Migraine;
BRCA	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-15.45	-0.52	5.35e-46	Total cholesterol levels;
BRCA	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg12310025	chr6:25882481	NA	-0.54	-12.83	-0.45	1.04e-33	Blood metabolite levels;
BRCA	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg11584989	chr19:19387371	SF4	0.63	13.46	0.47	1.53e-36	Bipolar disorder;
BRCA	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg08085267	chr17:45401833	C17orf57	0.59	12.38	0.44	1.07e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg17063962	chr7:91808500	NA	0.54	12.75	0.45	2.53e-33	Breast cancer;
BRCA	cis	rs9649213	0.593	rs6967576	chr7:98016373	A/G	cg24562669	chr7:97807699	LMTK2	-0.39	-10.4	-0.38	1.7e-23	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg26446133	chr18:72167187	CNDP2	-0.79	-19.95	-0.62	3.38e-69	Refractive error;
BRCA	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg12011299	chr4:100065546	ADH4	0.49	11.08	0.4	3.25e-26	Alcohol dependence;
BRCA	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg08085267	chr17:45401833	C17orf57	-0.7	-15.4	-0.52	9.67e-46	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2880765	0.710	rs11630457	chr15:86004801	T/C	cg10818794	chr15:86012489	AKAP13	-0.3	-8.14	-0.31	2.01e-15	Coronary artery disease;
BRCA	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg23750338	chr8:142222470	SLC45A4	-0.49	-11.17	-0.4	1.36e-26	Immature fraction of reticulocytes;
BRCA	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg12311346	chr5:56204834	C5orf35	-0.81	-16.16	-0.54	1.65e-49	Initial pursuit acceleration;
BRCA	cis	rs858239	0.539	rs6956828	chr7:23187347	A/G	cg23682824	chr7:23144976	KLHL7	0.41	10.64	0.39	1.8e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg06623918	chr6:96969491	KIAA0776	0.74	12.97	0.46	2.61e-34	Migraine;Coronary artery disease;
BRCA	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	ch.11.42038R	chr11:967971	AP2A2	0.52	16.65	0.55	5.42e-52	Alzheimer's disease (late onset);
BRCA	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27286337	chr10:134555280	INPP5A	0.64	10.75	0.39	6.79e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg25174290	chr11:3078921	CARS	-0.36	-10.69	-0.39	1.22e-24	Longevity;
BRCA	cis	rs250677	0.522	rs10042466	chr5:148393634	T/C	cg18129178	chr5:148520854	ABLIM3	-0.52	-10.13	-0.37	1.78e-22	Breast cancer;
BRCA	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg23719950	chr11:63933701	MACROD1	-0.58	-9.62	-0.36	1.48e-20	Mean platelet volume;
BRCA	cis	rs6121246	0.511	rs879982	chr20:30398510	A/G	cg13852791	chr20:30311386	BCL2L1	0.95	23.13	0.68	1.89e-86	Mean corpuscular hemoglobin;
BRCA	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13126279	chr21:47581558	C21orf56	-0.45	-10.17	-0.37	1.33e-22	Testicular germ cell tumor;
BRCA	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg08645402	chr16:4508243	NA	-0.4	-9.52	-0.35	3.49e-20	Schizophrenia;
BRCA	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg12386194	chr3:101231763	SENP7	0.46	9.65	0.36	1.12e-20	Colorectal cancer;
BRCA	cis	rs2625529	0.775	rs62023342	chr15:72161305	A/C	cg16672083	chr15:72433130	SENP8	-0.84	-17.51	-0.57	2.35e-56	Red blood cell count;
BRCA	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg17063962	chr7:91808500	NA	0.54	12.69	0.45	4.49e-33	Breast cancer;
BRCA	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg18279126	chr7:2041391	MAD1L1	0.37	7.96	0.3	7.67e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.64	-9.51	-0.35	3.81e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.56	8.33	0.31	4.93e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7178424	0.806	rs4587915	chr15:62241962	C/T	cg00456672	chr15:62358751	C2CD4A	0.36	8.93	0.33	4.46e-18	Height;
BRCA	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg03733263	chr8:22462867	KIAA1967	0.97	23.58	0.68	6.65e-89	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg18132916	chr6:79620363	NA	-0.46	-10.32	-0.38	3.24e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.83	0.36	2.44e-21	Lung cancer in ever smokers;
BRCA	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg09904177	chr6:26538194	HMGN4	0.51	14.83	0.51	5.59e-43	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.24	-0.41	7.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs2637266	1.000	rs12260379	chr10:78365036	C/T	cg18941641	chr10:78392320	NA	0.35	7.82	0.3	2.18e-14	Pulmonary function;
BRCA	cis	rs7766436	0.885	rs7773749	chr6:22587190	C/G	cg13666174	chr6:22585274	NA	-0.5	-11.89	-0.43	1.36e-29	Coronary artery disease;
BRCA	cis	rs4141404	0.923	rs2413035	chr22:31600460	A/G	cg02404636	chr22:31891804	SFI1	-0.41	-8.75	-0.33	1.93e-17	Paclitaxel-induced neuropathy;
BRCA	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg02734326	chr4:10020555	SLC2A9	0.36	7.98	0.3	6.97e-15	Bone mineral density;
BRCA	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10802521	chr3:52805072	NEK4	-0.34	-9.33	-0.35	1.73e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs9581857	0.685	rs9319373	chr13:28042835	A/G	cg22138327	chr13:27999177	GTF3A	0.62	9.55	0.35	2.66e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
BRCA	cis	rs7220401	0.789	rs4794859	chr17:27962393	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.5	-11.68	-0.42	1.07e-28	Coronary artery disease;
BRCA	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg08805041	chr16:621841	PIGQ	-0.3	-8.04	-0.3	4.5e-15	Height;
BRCA	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg15556689	chr8:8085844	FLJ10661	0.4	10.14	0.37	1.7e-22	Triglycerides;
BRCA	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg22705602	chr4:152727874	NA	-0.32	-8.27	-0.31	7.76e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-19.31	-0.61	8.57e-66	Electrocardiographic conduction measures;
BRCA	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg23711669	chr6:146136114	FBXO30	0.7	16.79	0.55	1.07e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg09307838	chr4:120376055	NA	0.63	13.48	0.47	1.22e-36	Corneal astigmatism;
BRCA	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11764359	chr7:65958608	NA	0.62	13.63	0.47	2.69e-37	Aortic root size;
BRCA	cis	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg07460842	chr6:66804631	NA	0.97	19.47	0.61	1.26e-66	Exhaled nitric oxide output;
BRCA	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg20933634	chr6:27740509	NA	0.48	9.61	0.36	1.64e-20	Parkinson's disease;
BRCA	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-11.63	-0.42	1.78e-28	Monocyte percentage of white cells;
BRCA	cis	rs61990749	0.597	rs1477262	chr14:78226653	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.64	9.82	0.36	2.75e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg23358479	chr7:1110784	C7orf50	-0.47	-7.94	-0.3	9.1e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9831754	0.526	rs11927217	chr3:78341723	A/G	cg06138941	chr3:78371609	NA	-0.41	-9.93	-0.37	1.03e-21	Calcium levels;
BRCA	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	8.0	0.3	6.07e-15	Diabetic retinopathy;
BRCA	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.29	0.31	6.9e-16	Parkinson's disease;
BRCA	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg08885076	chr2:99613938	TSGA10	0.44	10.29	0.38	4.46e-23	Chronic sinus infection;
BRCA	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg17077180	chr1:38461687	NA	0.51	11.99	0.43	5.18e-30	Coronary artery disease;
BRCA	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.4	7.82	0.3	2.22e-14	Lung disease severity in cystic fibrosis;
BRCA	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg20587970	chr11:113659929	NA	-1.2	-22.15	-0.66	4.31e-81	Hip circumference adjusted for BMI;
BRCA	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.46	-9.26	-0.34	3.06e-19	Blood metabolite levels;
BRCA	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg20933634	chr6:27740509	NA	0.47	9.3	0.35	2.17e-19	Parkinson's disease;
BRCA	cis	rs6121246	0.512	rs6058384	chr20:30276409	A/T	cg13852791	chr20:30311386	BCL2L1	0.96	23.31	0.68	2.03e-87	Mean corpuscular hemoglobin;
BRCA	cis	rs36051895	0.664	rs10115172	chr9:5098549	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-8.88	-0.33	6.46e-18	Pediatric autoimmune diseases;
BRCA	cis	rs652260	0.967	rs667295	chr19:7901634	G/A	cg26014689	chr19:7917955	EVI5L	-0.51	-11.68	-0.42	1.05e-28	Menarche (age at onset);
BRCA	cis	rs9811920	0.965	rs10222474	chr3:99862551	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	12.76	0.45	2.31e-33	Axial length;
BRCA	cis	rs7246657	0.722	rs16958861	chr19:38124179	G/A	cg14683738	chr19:37701593	ZNF585B	0.47	7.98	0.3	6.94e-15	Coronary artery calcification;
BRCA	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg06784218	chr1:46089804	CCDC17	0.47	11.27	0.41	5.43e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	16.32	0.54	2.57e-50	Smoking behavior;
BRCA	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg08807892	chr2:162101083	NA	0.45	8.7	0.33	2.86e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg18538332	chr22:24372958	LOC391322	-0.57	-14.53	-0.5	1.55e-41	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.47	10.45	0.38	1.09e-23	Hemoglobin concentration;
BRCA	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg04545296	chr12:48745243	ZNF641	0.25	8.3	0.31	6.07e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-9.65	-0.36	1.14e-20	Tonsillectomy;
BRCA	cis	rs7246657	0.551	rs10407224	chr19:37651470	G/T	cg23950597	chr19:37808831	NA	-0.65	-9.88	-0.36	1.67e-21	Coronary artery calcification;
BRCA	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg22800045	chr5:56110881	MAP3K1	0.4	8.05	0.3	4.05e-15	Coronary artery disease;
BRCA	cis	rs6546886	0.957	rs4416242	chr2:74259894	A/T	cg14702570	chr2:74259524	NA	-0.32	-8.21	-0.31	1.22e-15	Dialysis-related mortality;
BRCA	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg25214090	chr10:38739885	LOC399744	0.51	11.61	0.42	2.01e-28	Corneal astigmatism;
BRCA	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.81	-19.17	-0.6	4.77e-65	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg03929089	chr4:120376271	NA	0.58	9.41	0.35	8.64e-20	Axial length;
BRCA	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	9.2	0.34	4.89e-19	Height;
BRCA	cis	rs6782228	0.606	rs1127030	chr3:128338953	T/C	cg16766828	chr3:128327626	NA	-0.42	-9.53	-0.35	3.29e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg14675211	chr2:100938903	LONRF2	0.43	9.78	0.36	3.77e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg02659138	chr7:134003124	SLC35B4	0.33	10.5	0.38	6.78e-24	Mean platelet volume;
BRCA	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg24296786	chr1:45957014	TESK2	0.64	15.92	0.53	2.57e-48	High light scatter reticulocyte count;
BRCA	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg13256891	chr4:100009986	ADH5	0.51	10.67	0.39	1.41e-24	Alcohol dependence;
BRCA	cis	rs12541635	0.899	rs1429676	chr8:107065790	G/A	cg10147462	chr8:107024639	NA	-0.33	-8.82	-0.33	1.05e-17	Age of smoking initiation;
BRCA	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg04166393	chr7:2884313	GNA12	0.51	9.44	0.35	6.58e-20	Height;
BRCA	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg04545296	chr12:48745243	ZNF641	0.25	8.3	0.31	6.07e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg22676075	chr6:135203613	NA	0.44	8.66	0.32	3.73e-17	Red blood cell count;
BRCA	cis	rs10463316	0.894	rs7729438	chr5:150762197	G/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.22	-0.31	1.12e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs754466	0.606	rs7084705	chr10:79596675	A/G	cg17075019	chr10:79541650	NA	-0.77	-20.19	-0.62	1.67e-70	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs17401966	1.000	rs2275424	chr1:10356562	C/A	cg03954927	chr1:10346856	KIF1B	0.45	12.76	0.45	2.13e-33	Hepatocellular carcinoma;
BRCA	cis	rs586533	0.757	rs657362	chr11:99501878	T/G	cg22878054	chr11:99397252	CNTN5	0.32	8.11	0.31	2.53e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.08	-0.4	3.14e-26	Schizophrenia;
BRCA	cis	rs2282802	0.685	rs7737543	chr5:139646026	A/G	cg26211634	chr5:139558579	C5orf32	0.35	8.39	0.31	3.17e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg21775007	chr8:11205619	TDH	-0.46	-9.24	-0.34	3.63e-19	Retinal vascular caliber;
BRCA	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg11901034	chr3:128598214	ACAD9	0.37	9.01	0.34	2.43e-18	IgG glycosylation;
BRCA	cis	rs2964802	0.505	rs10513058	chr5:10804383	C/T	cg14521931	chr5:10832172	NA	-0.56	-12.5	-0.44	3e-32	Major depressive disorder;Recurrent major depressive disorder;
BRCA	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	11.43	0.41	1.2100000000000001e-27	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg20887711	chr4:1340912	KIAA1530	0.35	8.49	0.32	1.41e-16	Longevity;
BRCA	cis	rs897080	0.515	rs698815	chr2:44706974	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	9.21	0.34	4.44e-19	Height;
BRCA	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg26384229	chr12:38710491	ALG10B	-0.58	-13.58	-0.47	4.59e-37	Bladder cancer;
BRCA	cis	rs3813567	0.759	rs12594550	chr15:78959037	C/G	cg04896959	chr15:78267971	NA	0.44	8.27	0.31	7.62e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg23029597	chr12:123009494	RSRC2	-0.58	-11.56	-0.42	3.4e-28	Body mass index;
BRCA	cis	rs490234	0.783	rs4838278	chr9:128403509	T/C	cg14078157	chr9:128172775	NA	-0.45	-10.32	-0.38	3.45e-23	Mean arterial pressure;
BRCA	cis	rs2425143	1.000	rs7273815	chr20:34232415	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.7	-0.33	2.75e-17	Blood protein levels;
BRCA	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg03060546	chr3:49711283	APEH	-0.58	-11.74	-0.42	5.82e-29	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg20607798	chr8:58055168	NA	0.47	8.32	0.31	5.26e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg09184832	chr6:79620586	NA	-0.52	-11.4	-0.41	1.61e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg18351406	chr4:77819688	ANKRD56	0.61	13.39	0.47	3.13e-36	Emphysema distribution in smoking;
BRCA	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2066819	0.892	rs17118431	chr12:56667100	A/G	cg26734620	chr12:56694298	CS	0.91	10.64	0.39	1.85e-24	Psoriasis vulgaris;
BRCA	cis	rs9560113	0.843	rs9555808	chr13:112181284	A/T	cg10483660	chr13:112241077	NA	0.32	7.98	0.3	6.63e-15	Menarche (age at onset);
BRCA	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg03560586	chr2:239334908	ASB1	-0.51	-11.24	-0.41	6.92e-27	Multiple system atrophy;
BRCA	cis	rs9463078	0.764	rs494982	chr6:44937255	C/T	cg25276700	chr6:44698697	NA	-0.34	-7.95	-0.3	8.39e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	trans	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg25214090	chr10:38739885	LOC399744	0.45	10.38	0.38	2.04e-23	Corneal astigmatism;
BRCA	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg23173402	chr1:227635558	NA	-0.52	-9.51	-0.35	3.69e-20	Major depressive disorder;
BRCA	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg02175503	chr12:58329896	NA	0.42	8.07	0.3	3.55e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg05283184	chr6:79620031	NA	-0.43	-10.89	-0.4	1.97e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg02734326	chr4:10020555	SLC2A9	0.37	8.43	0.32	2.21e-16	Bone mineral density;
BRCA	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg18964960	chr10:1102726	WDR37	0.6	8.21	0.31	1.26e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23583168	chr7:148888333	NA	-0.74	-16.17	-0.54	1.55e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg22834771	chr12:69754056	YEATS4	-0.34	-7.92	-0.3	1.09e-14	Blood protein levels;
BRCA	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg03146154	chr1:46216737	IPP	-0.44	-9.62	-0.36	1.5e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-12.03	-0.43	3.51e-30	Alzheimer's disease;
BRCA	trans	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.41	-8.36	-0.31	4.06e-16	Mean corpuscular volume;
BRCA	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg00021532	chr16:4324280	TFAP4	0.59	16.29	0.54	3.71e-50	Prostate-specific antigen levels;
BRCA	cis	rs1983170	0.736	rs745731	chr1:92011467	G/T	cg25838465	chr1:92012736	NA	0.47	8.23	0.31	1.06e-15	Eosinophil percentage of white cells;
BRCA	cis	rs6120849	0.754	rs36003887	chr20:33589107	G/A	cg24642439	chr20:33292090	TP53INP2	0.58	10.12	0.37	2.05e-22	Protein C levels;
BRCA	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg04025307	chr7:1156635	C7orf50	0.58	9.08	0.34	1.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6032067	0.561	rs2743317	chr20:43936931	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	0.35	8.38	0.31	3.3e-16	Blood protein levels;
BRCA	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.4	9.58	0.35	2.04e-20	Alzheimer's disease (late onset);
BRCA	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg11644478	chr21:40555479	PSMG1	-0.51	-10.53	-0.38	5.03e-24	Menarche (age at onset);
BRCA	cis	rs4631830	0.720	rs12763717	chr10:51500874	C/G	cg20129853	chr10:51489980	NA	0.32	8.63	0.32	4.85e-17	Prostate-specific antigen levels;
BRCA	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg23649088	chr2:200775458	C2orf69	-0.61	-10.28	-0.38	5e-23	Schizophrenia;
BRCA	cis	rs918629	0.530	rs17085249	chr5:95236415	C/T	cg16656078	chr5:95278638	ELL2	-0.35	-8.34	-0.31	4.5e-16	IgG glycosylation;
BRCA	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.8	0.36	3.22e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17818399	0.645	rs35870739	chr2:46784231	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.42	-7.84	-0.3	1.96e-14	Height;
BRCA	trans	rs6479891	1.000	rs9414788	chr10:65056712	A/G	cg14819942	chr15:35414228	NA	-0.34	-8.45	-0.32	1.9e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs6542838	0.641	rs6760065	chr2:99486318	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.37	-8.24	-0.31	9.76e-16	Fear of minor pain;
BRCA	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26314531	chr2:26401878	FAM59B	-0.63	-10.83	-0.39	3.28e-25	Gut microbiome composition (summer);
BRCA	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.16	-49.86	-0.89	2.04e-222	Myeloid white cell count;
BRCA	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.66	-0.5	3.76e-42	Chronic sinus infection;
BRCA	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg04455712	chr21:45112962	RRP1B	0.41	10.6	0.39	2.59e-24	Mean corpuscular volume;
BRCA	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.55	-0.42	3.72e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs4908768	0.520	rs7520025	chr1:8698277	C/T	cg20416874	chr1:8611966	RERE	-0.3	-8.52	-0.32	1.13e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg12310025	chr6:25882481	NA	0.72	18.11	0.58	1.8e-59	Blood metabolite levels;
BRCA	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg21775007	chr8:11205619	TDH	0.62	12.28	0.44	2.79e-31	Retinal vascular caliber;
BRCA	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg15595755	chr5:1867978	NA	0.36	8.6	0.32	6.01e-17	Cardiovascular disease risk factors;
BRCA	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg23708337	chr7:1209742	NA	0.6	8.31	0.31	5.89e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg14582100	chr15:45693742	SPATA5L1	0.37	11.66	0.42	1.32e-28	Homoarginine levels;
BRCA	cis	rs243505	1.000	rs243521	chr7:148421571	T/C	cg09806900	chr7:148480153	CUL1	-0.43	-8.82	-0.33	1.1e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9400271	0.504	rs9784763	chr6:109624937	A/G	cg01475377	chr6:109611718	NA	0.41	9.89	0.36	1.53e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg08917208	chr2:24149416	ATAD2B	0.91	13.38	0.47	3.55e-36	Lymphocyte counts;
BRCA	cis	rs13046373	0.535	rs1354866	chr21:31981559	A/T	cg14062083	chr21:31802829	KRTAP13-4	0.34	9.25	0.34	3.44e-19	HDL cholesterol;
BRCA	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg24296786	chr1:45957014	TESK2	0.42	9.5	0.35	4.24e-20	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg14186256	chr22:23484241	RTDR1	0.78	23.94	0.69	6.75e-91	Bone mineral density;
BRCA	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03264133	chr6:25882463	NA	-0.54	-11.24	-0.41	6.83e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs11030122	0.702	rs10835407	chr11:3993231	C/T	cg18678763	chr11:4115507	RRM1	0.35	7.91	0.3	1.16e-14	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05901451	chr6:126070800	HEY2	0.45	11.47	0.41	8.05e-28	Endometrial cancer;
BRCA	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-9.03	-0.34	1.96e-18	Alzheimer's disease (late onset);
BRCA	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg04117972	chr1:227635322	NA	0.52	9.34	0.35	1.5700000000000001e-19	Major depressive disorder;
BRCA	cis	rs4243830	0.737	rs11122083	chr1:6593532	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.9	-15.38	-0.52	1.22e-45	Body mass index;
BRCA	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg06612196	chr6:6737390	NA	-0.54	-12.98	-0.46	2.26e-34	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs868036	0.522	rs3784711	chr15:68072527	C/T	cg05925327	chr15:68127851	NA	0.31	7.9	0.3	1.18e-14	Restless legs syndrome;
BRCA	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg00409905	chr10:38381863	ZNF37A	-0.49	-9.03	-0.34	1.99e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg18016565	chr1:150552671	MCL1	0.34	8.12	0.31	2.43e-15	Tonsillectomy;
BRCA	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg19717773	chr7:2847554	GNA12	0.46	10.55	0.39	4.38e-24	Height;
BRCA	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.79	-0.36	3.42e-21	Schizophrenia;
BRCA	cis	rs7267979	0.714	rs2474763	chr20:25241295	A/G	cg08601574	chr20:25228251	PYGB	0.34	8.01	0.3	5.55e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6446731	0.593	rs2157090	chr4:3273110	C/T	cg08886695	chr4:3369023	RGS12	-0.37	-9.7	-0.36	7.62e-21	Mean platelet volume;
BRCA	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.02	0.48	4.03e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs10805346	0.558	rs12506562	chr4:10106954	G/T	cg26043149	chr18:55253948	FECH	0.43	9.73	0.36	5.85e-21	Urate levels in overweight individuals;Urate levels in obese individuals;
BRCA	cis	rs7539409	0.604	rs910183	chr1:84297285	A/G	cg10977910	chr1:84465055	TTLL7	0.58	9.04	0.34	1.84e-18	Alzheimer's disease;
BRCA	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg24069376	chr3:38537580	EXOG	-0.42	-12.15	-0.43	1.01e-30	Electrocardiographic conduction measures;
BRCA	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg15556689	chr8:8085844	FLJ10661	-0.31	-8.11	-0.31	2.59e-15	Joint mobility (Beighton score);
BRCA	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.41	8.92	0.33	4.93e-18	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-10.57	-0.39	3.57e-24	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg03894339	chr8:19674705	INTS10	0.44	8.72	0.33	2.44e-17	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg17366294	chr4:99064904	C4orf37	0.52	11.13	0.4	1.97e-26	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.36	9.2	0.34	4.85e-19	Resting heart rate;
BRCA	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg01528321	chr10:82214614	TSPAN14	0.67	14.17	0.49	8.12e-40	Post bronchodilator FEV1;
BRCA	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg03342759	chr3:160939853	NMD3	-0.56	-11.93	-0.43	9.38e-30	Morning vs. evening chronotype;
BRCA	cis	rs895636	0.848	rs4953156	chr2:45189763	G/A	cg16198908	chr2:45192207	NA	0.48	8.89	0.33	6.13e-18	Metabolite levels;Fasting plasma glucose;
BRCA	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg27588902	chr6:42928151	GNMT	-0.3	-9.85	-0.36	2.14e-21	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg20991723	chr1:152506922	NA	0.38	8.82	0.33	1.05e-17	Hair morphology;
BRCA	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg22535103	chr8:58192502	C8orf71	-0.46	-9.06	-0.34	1.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg07460842	chr6:66804631	NA	-1.01	-19.78	-0.62	2.57e-68	Exhaled nitric oxide output;
BRCA	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18876405	chr7:65276391	NA	-0.66	-16.59	-0.55	1.09e-51	Aortic root size;
BRCA	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg24069376	chr3:38537580	EXOG	0.4	11.4	0.41	1.51e-27	Electrocardiographic conduction measures;
BRCA	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg14186256	chr22:23484241	RTDR1	0.79	24.78	0.7	1.59e-95	Bone mineral density;
BRCA	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.82	0.62	1.64e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg12011299	chr4:100065546	ADH4	0.51	11.66	0.42	1.33e-28	Alcohol dependence;
BRCA	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg10845886	chr2:3471009	TTC15	-0.54	-11.99	-0.43	4.9e-30	Neurofibrillary tangles;
BRCA	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg11266682	chr4:10021025	SLC2A9	0.47	12.35	0.44	1.48e-31	Bone mineral density;
BRCA	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	9.24	0.34	3.7e-19	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.37	-8.66	-0.32	3.84e-17	Longevity;Endometriosis;
BRCA	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg06784218	chr1:46089804	CCDC17	-0.53	-12.82	-0.45	1.16e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02353165	chr6:42928485	GNMT	0.88	23.77	0.69	5.73e-90	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg07148914	chr20:33460835	GGT7	-0.36	-7.93	-0.3	9.56e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg12311346	chr5:56204834	C5orf35	-0.81	-16.03	-0.54	7.58e-49	Initial pursuit acceleration;
BRCA	cis	rs6910061	1.000	rs6910061	chr6:11101918	A/T	cg27233058	chr6:11094804	LOC221710	-0.5	-8.95	-0.33	3.68e-18	Diabetic kidney disease;
BRCA	cis	rs4730250	0.670	rs9641380	chr7:106868151	C/G	cg02696742	chr7:106810147	HBP1	-0.51	-8.58	-0.32	7.04e-17	Osteoarthritis;
BRCA	cis	rs9649465	0.561	rs2429618	chr7:123421662	G/A	cg03229431	chr7:123269106	ASB15	0.44	10.17	0.37	1.25e-22	Migraine;
BRCA	cis	rs12618769	0.543	rs56357378	chr2:99032455	T/G	cg10123293	chr2:99228465	UNC50	0.41	8.14	0.31	2.01e-15	Bipolar disorder;
BRCA	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.14e-19	Total body bone mineral density;
BRCA	trans	rs1459104	1.000	rs35453180	chr11:55324915	G/A	cg15704280	chr7:45808275	SEPT13	0.64	8.04	0.3	4.25e-15	Body mass index;
BRCA	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg24130564	chr14:104152367	KLC1	0.39	8.48	0.32	1.55e-16	Reticulocyte count;
BRCA	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg04705435	chr11:17411270	KCNJ11	0.45	9.35	0.35	1.44e-19	Type 2 diabetes;
BRCA	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg09307838	chr4:120376055	NA	0.71	15.07	0.51	3.93e-44	Corneal astigmatism;
BRCA	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.97	21.49	0.65	1.62e-77	Lymphocyte percentage of white cells;
BRCA	cis	rs11874712	0.965	rs8083998	chr18:43673144	A/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.09	0.3	2.98e-15	Migraine - clinic-based;
BRCA	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg17366294	chr4:99064904	C4orf37	0.45	10.77	0.39	5.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs829883	0.646	rs4762494	chr12:98933834	T/G	cg25150519	chr12:98850993	NA	-0.5	-9.1	-0.34	1.1e-18	Colorectal adenoma (advanced);
BRCA	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg02503808	chr4:7069936	GRPEL1	0.8	18.6	0.59	4.57e-62	Monocyte percentage of white cells;
BRCA	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg26597838	chr10:835615	NA	1.02	17.86	0.58	3.47e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs3857067	0.776	rs6858265	chr4:95112565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.49	-0.35	4.67e-20	QT interval;
BRCA	cis	rs34779708	0.706	rs36027395	chr10:35550323	T/A	cg03585969	chr10:35415529	CREM	0.43	8.58	0.32	7e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg11693508	chr17:37793320	STARD3	0.42	8.87	0.33	7.07e-18	Neuroticism;
BRCA	trans	rs3857536	0.740	rs9360191	chr6:66942454	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs10788264	0.621	rs9633733	chr10:124056546	A/G	cg09507567	chr10:124027408	NA	-0.38	-8.03	-0.3	4.81e-15	Total body bone mineral density;
BRCA	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg24596788	chr1:163392923	NA	-0.4	-10.66	-0.39	1.53e-24	Motion sickness;
BRCA	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg09307838	chr4:120376055	NA	0.69	13.84	0.48	2.79e-38	Corneal astigmatism;
BRCA	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg27446573	chr6:127587934	RNF146	0.9	21.07	0.64	2.99e-75	Breast cancer;
BRCA	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.5	8.81	0.33	1.17e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
BRCA	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg18758796	chr5:131593413	PDLIM4	0.39	9.94	0.37	9.96e-22	Acylcarnitine levels;
BRCA	cis	rs9875589	0.509	rs2731337	chr3:14091440	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	9.04	0.34	1.83e-18	Ovarian reserve;
BRCA	cis	rs503734	0.502	rs571391	chr3:100963154	C/T	cg27318481	chr3:100970896	IMPG2	-0.39	-9.27	-0.34	2.9e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11890956	chr21:40555474	PSMG1	-0.84	-20.5	-0.63	3.55e-72	Cognitive function;
BRCA	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg27170947	chr2:26402098	FAM59B	-0.65	-11.16	-0.4	1.47e-26	Gut microbiome composition (summer);
BRCA	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg19077165	chr18:44547161	KATNAL2	-0.37	-7.83	-0.3	2.09e-14	Educational attainment;
BRCA	cis	rs753778	0.962	rs4961341	chr8:142235154	G/T	cg18755752	chr8:142205143	DENND3	-0.42	-9.3	-0.35	2.21e-19	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg01191920	chr7:158217561	PTPRN2	0.46	11.06	0.4	3.71e-26	Obesity-related traits;
BRCA	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-9.48	-0.35	4.99e-20	Height;
BRCA	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-14.07	-0.49	2.41e-39	Hemoglobin concentration;
BRCA	cis	rs2629540	0.765	rs11245387	chr10:126537825	C/T	cg08799069	chr10:126477246	METTL10	-0.35	-8.03	-0.3	4.78e-15	Cocaine dependence;
BRCA	cis	rs1832871	0.599	rs1754413	chr6:158764741	C/T	cg07215822	chr6:158701037	NA	0.47	9.64	0.36	1.29e-20	Height;
BRCA	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg21045802	chr8:109455806	TTC35	0.35	7.94	0.3	9.27e-15	Dupuytren's disease;
BRCA	cis	rs1451375	0.652	rs7803903	chr7:50625945	C/T	cg18232548	chr7:50535776	DDC	0.38	8.03	0.3	4.84e-15	Malaria;
BRCA	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-9.64	-0.36	1.29e-20	HDL cholesterol;
BRCA	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.55	-0.32	9.03e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs877282	1.000	rs12219807	chr10:772870	A/C	cg17470449	chr10:769945	NA	0.5	9.37	0.35	1.23e-19	Uric acid levels;
BRCA	cis	rs870825	0.929	rs1405940	chr4:185591481	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.48	0.5	2.52e-41	Blood protein levels;
BRCA	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-8.05	-0.3	4.13e-15	Prostate cancer;
BRCA	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.84	0.39	2.96e-25	Cognitive ability;
BRCA	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg17366294	chr4:99064904	C4orf37	0.42	9.84	0.36	2.29e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg13073564	chr4:8508604	NA	-0.38	-10.44	-0.38	1.11e-23	Response to antineoplastic agents;
BRCA	cis	rs67460515	0.500	rs9860537	chr3:160660500	G/T	cg03342759	chr3:160939853	NMD3	0.59	11.78	0.42	3.81e-29	Parkinson's disease;
BRCA	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg26384229	chr12:38710491	ALG10B	0.77	17.27	0.56	4.05e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.59e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg01689657	chr7:91764605	CYP51A1	0.22	8.05	0.3	4.08e-15	Breast cancer;
BRCA	cis	rs4965272	1.000	rs4965557	chr15:100583717	C/G	cg27344315	chr15:100560801	ADAMTS17	-0.41	-8.66	-0.32	3.95e-17	Gastroesophageal reflux disease;
BRCA	cis	rs6546550	0.901	rs897119	chr2:70160658	T/C	cg02498382	chr2:70120550	SNRNP27	-0.52	-11.35	-0.41	2.54e-27	Prevalent atrial fibrillation;
BRCA	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-16.2	-0.54	1.11e-49	Alzheimer's disease (late onset);
BRCA	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg02503808	chr4:7069936	GRPEL1	-0.79	-14.16	-0.49	8.68e-40	Monocyte percentage of white cells;
BRCA	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.37e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs11608355	0.545	rs4766474	chr12:109908084	G/C	cg05360138	chr12:110035743	NA	0.71	13.09	0.46	7.36e-35	Neuroticism;
BRCA	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg23711669	chr6:146136114	FBXO30	0.69	16.01	0.54	9.25e-49	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg10862848	chr6:42927986	GNMT	-0.35	-14.74	-0.5	1.59e-42	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.42	-8.01	-0.3	5.52e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg09307838	chr4:120376055	NA	-0.49	-9.27	-0.34	2.75e-19	Corneal astigmatism;
BRCA	cis	rs6066825	0.644	rs6066823	chr20:47338768	C/G	cg18078177	chr20:47281410	PREX1	0.39	9.51	0.35	3.76e-20	Colorectal cancer;
BRCA	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg24675658	chr1:53192096	ZYG11B	-0.66	-14.29	-0.49	2.2e-40	Monocyte count;
BRCA	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	13.97	0.48	7.08e-39	Colorectal cancer;
BRCA	cis	rs7301826	0.627	rs4325342	chr12:131312482	G/A	cg11011512	chr12:131303247	STX2	0.52	13.72	0.48	9.48e-38	Plasma plasminogen activator levels;
BRCA	cis	rs1400816	0.850	rs2292814	chr2:172586567	A/G	cg13550731	chr2:172543902	DYNC1I2	0.53	8.31	0.31	5.84e-16	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.67	11.13	0.4	1.93e-26	Schizophrenia;
BRCA	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.28	-0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs250677	0.522	rs10477400	chr5:148359598	T/C	cg12140854	chr5:148520817	ABLIM3	0.4	8.13	0.31	2.3e-15	Breast cancer;
BRCA	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.76	0.39	6.24e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg21775007	chr8:11205619	TDH	-0.43	-8.18	-0.31	1.57e-15	Neuroticism;
BRCA	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg25801113	chr15:45476975	SHF	0.31	8.05	0.3	4.02e-15	Uric acid levels;
BRCA	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.28	0.56	3.49e-55	Bladder cancer;
BRCA	cis	rs9318086	0.712	rs9318099	chr13:24442462	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.31	-8.79	-0.33	1.35e-17	Myopia (pathological);
BRCA	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.79	-18.71	-0.59	1.36e-62	Hip circumference adjusted for BMI;
BRCA	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.55e-18	Motion sickness;
BRCA	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.4	0.35	9.62e-20	Morning vs. evening chronotype;
BRCA	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.56	-0.52	1.55e-46	Chronic sinus infection;
BRCA	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.72	0.55	2.66e-52	Fuchs's corneal dystrophy;
BRCA	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg23285459	chr7:2802560	GNA12	-0.34	-8.62	-0.32	5.08e-17	Height;
BRCA	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg27170947	chr2:26402098	FAM59B	0.93	16.85	0.55	5.51e-53	Gut microbiome composition (summer);
BRCA	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-12.77	-0.45	2.07e-33	Bipolar disorder;
BRCA	cis	rs939658	0.805	rs35291410	chr15:79438660	C/T	cg17916960	chr15:79447300	NA	-0.46	-11.6	-0.42	2.39e-28	Refractive error;
BRCA	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-10.05	-0.37	3.76e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs3741798	1.000	rs17375328	chr12:12485292	T/C	cg08615371	chr12:12503544	MANSC1	1.07	15.32	0.52	2.35e-45	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg22963979	chr7:1858916	MAD1L1	0.4	8.72	0.33	2.39e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs7727544	0.557	rs2897096	chr5:131486284	A/G	cg14196790	chr5:131705035	SLC22A5	0.37	9.21	0.34	4.52e-19	Blood metabolite levels;
BRCA	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-9.54	-0.35	3.02e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	trans	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	14.62	0.5	5.57e-42	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg22920501	chr2:26401640	FAM59B	-0.91	-16.27	-0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.53	-11.03	-0.4	5.04e-26	Lymphocyte counts;
BRCA	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-12.75	-0.45	2.45e-33	Response to antipsychotic treatment;
BRCA	cis	rs868036	1.000	rs884202	chr15:68054388	G/A	cg05925327	chr15:68127851	NA	0.34	8.54	0.32	9.66e-17	Restless legs syndrome;
BRCA	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg24006582	chr15:45444508	DUOX1	-0.55	-11.42	-0.41	1.3e-27	Uric acid levels;
BRCA	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg23285459	chr7:2802560	GNA12	-0.38	-9.65	-0.36	1.16e-20	Height;
BRCA	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg12573674	chr2:1569213	NA	-0.48	-9.47	-0.35	5.36e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.46	7.85	0.3	1.78e-14	Mean platelet volume;
BRCA	cis	rs10189230	0.967	rs13026378	chr2:222352712	G/A	cg14652038	chr2:222343519	EPHA4	0.46	12.75	0.45	2.57e-33	Urate levels in lean individuals;
BRCA	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg00071950	chr4:10020882	SLC2A9	0.56	13.52	0.47	7.89e-37	Bone mineral density;
BRCA	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-19.6	-0.61	2.49e-67	Systemic lupus erythematosus;
BRCA	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg04455712	chr21:45112962	RRP1B	0.41	10.55	0.39	4.16e-24	Mean corpuscular volume;
BRCA	cis	rs16854884	0.741	rs55909524	chr3:143794734	T/C	cg06585982	chr3:143692056	C3orf58	0.39	7.81	0.3	2.33e-14	Economic and political preferences (feminism/equality);
BRCA	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg10426581	chr7:100472382	SRRT	0.63	9.79	0.36	3.4e-21	Resting heart rate;
BRCA	cis	rs35740288	0.929	rs11636821	chr15:86306005	T/G	cg20737812	chr15:86336631	KLHL25	-0.32	-7.95	-0.3	8.56e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg02389323	chr16:88786976	FAM38A	0.75	11.89	0.43	1.4e-29	Plateletcrit;
BRCA	cis	rs654950	0.901	rs594656	chr1:41999873	C/T	cg06885757	chr1:42089581	HIVEP3	-0.32	-10.47	-0.38	8.86e-24	Airway imaging phenotypes;
BRCA	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg25482853	chr8:67687455	SGK3	0.97	15.32	0.52	2.31e-45	Lung disease severity in cystic fibrosis;
BRCA	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.2	-0.49	5.76e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs1784581	1.000	rs1615717	chr6:162400612	C/T	cg17173639	chr6:162384350	PARK2	-0.44	-10.31	-0.38	3.6e-23	Itch intensity from mosquito bite;
BRCA	trans	rs8002861	0.935	rs7319725	chr13:44445421	T/C	cg17145862	chr1:211918768	LPGAT1	0.7	18.43	0.59	3.74e-61	Leprosy;
BRCA	cis	rs11955398	0.625	rs286153	chr5:59928948	A/G	cg02684056	chr5:59996105	DEPDC1B	0.35	8.3	0.31	6.11e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg18154014	chr19:37997991	ZNF793	0.64	12.26	0.44	3.56e-31	Coronary artery calcification;
BRCA	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg05234568	chr11:5960015	NA	0.37	7.9	0.3	1.22e-14	DNA methylation (variation);
BRCA	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg06484146	chr7:12443880	VWDE	-0.74	-10.73	-0.39	8.46e-25	Coronary artery disease;
BRCA	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.08	0.58	2.46e-59	Fuchs's corneal dystrophy;
BRCA	cis	rs4409675	0.576	rs2474470	chr1:28234999	C/T	cg23691781	chr1:28212827	C1orf38	0.32	10.61	0.39	2.47e-24	Corneal astigmatism;
BRCA	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg21747090	chr2:27597821	SNX17	-0.43	-9.43	-0.35	7.24e-20	Total body bone mineral density;
BRCA	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03576123	chr11:487126	PTDSS2	-1.23	-18.51	-0.59	1.39e-61	Body mass index;
BRCA	cis	rs6120849	0.754	rs1885116	chr20:33600560	A/G	cg24642439	chr20:33292090	TP53INP2	0.59	10.15	0.37	1.51e-22	Protein C levels;
BRCA	trans	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04565464	chr8:145669602	NFKBIL2	0.38	8.79	0.33	1.41e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs10501293	0.662	rs4755686	chr11:42999785	A/C	cg03447554	chr11:43094025	NA	0.42	8.02	0.3	4.97e-15	Cognitive performance;
BRCA	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.43	-0.32	2.33e-16	Bipolar disorder;
BRCA	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.42	-0.61	2.35e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg13628971	chr7:2884303	GNA12	0.46	9.21	0.34	4.79e-19	Height;
BRCA	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.52	-0.32	1.11e-16	Electroencephalogram traits;
BRCA	cis	rs16958440	0.867	rs12326465	chr18:44678645	A/G	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg23711669	chr6:146136114	FBXO30	0.72	16.54	0.55	2.16e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg00431813	chr7:1051703	C7orf50	-0.38	-11.32	-0.41	3.25e-27	Longevity;Endometriosis;
BRCA	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg13010199	chr12:38710504	ALG10B	0.5	10.43	0.38	1.31e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	11.14	0.4	1.8e-26	Platelet count;
BRCA	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-11.28	-0.41	5e-27	Alzheimer's disease;
BRCA	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg24101359	chr6:42928495	GNMT	0.52	11.73	0.42	6.37e-29	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6066835	1.000	rs6095247	chr20:47320835	T/C	cg18078177	chr20:47281410	PREX1	0.69	8.04	0.3	4.49e-15	Multiple myeloma;
BRCA	cis	rs8038465	0.592	rs899981	chr15:73935329	G/A	cg15420318	chr15:73925796	NPTN	0.45	9.57	0.35	2.32e-20	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.18	-0.31	1.57e-15	Depression;
BRCA	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg08493051	chr2:3487164	NA	-0.43	-9.21	-0.34	4.64e-19	Neurofibrillary tangles;
BRCA	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	15.51	0.52	2.82e-46	Bone mineral density;
BRCA	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Parkinson's disease;
BRCA	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg24812749	chr6:127587940	RNF146	-0.77	-15.28	-0.52	3.61e-45	Breast cancer;
BRCA	cis	rs929596	0.563	rs1105879	chr2:234602202	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.37	-9.01	-0.34	2.43e-18	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg24642439	chr20:33292090	TP53INP2	0.72	16.79	0.55	1.12e-52	Coronary artery disease;
BRCA	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg12564285	chr5:131593104	PDLIM4	0.32	8.19	0.31	1.38e-15	Blood metabolite levels;
BRCA	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg10792982	chr14:105748885	BRF1	0.48	11.26	0.41	5.66e-27	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs8017423	0.569	rs10141476	chr14:90823351	C/T	cg04374321	chr14:90722782	PSMC1	-0.49	-11.86	-0.42	1.75e-29	Mortality in heart failure;
BRCA	cis	rs6429082	0.818	rs704714	chr1:235632094	T/C	cg26050004	chr1:235667680	B3GALNT2	0.57	13.48	0.47	1.27e-36	Adiposity;
BRCA	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg20387954	chr3:183756860	HTR3D	0.37	8.27	0.31	7.95e-16	Anterior chamber depth;
BRCA	cis	rs2625529	0.668	rs12591313	chr15:72556746	T/C	cg16672083	chr15:72433130	SENP8	-0.81	-16.99	-0.56	1.09e-53	Red blood cell count;
BRCA	trans	rs4596713	0.538	rs7865373	chr9:71765105	T/C	cg16512924	chr15:28394682	HERC2	0.42	9.98	0.37	6.79e-22	Headache;
BRCA	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg22676075	chr6:135203613	NA	0.44	8.54	0.32	9.62e-17	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs4664304	0.620	rs4665125	chr2:160714314	C/G	cg01092293	chr2:160761427	LY75	0.36	8.43	0.32	2.22e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2014572	0.967	rs10426174	chr19:57756055	G/A	cg24459738	chr19:57751996	ZNF805	-0.33	-7.98	-0.3	6.73e-15	Hyperactive-impulsive symptoms;
BRCA	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg06115741	chr20:33292138	TP53INP2	0.49	11.03	0.4	5.21e-26	Coronary artery disease;
BRCA	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.66	-0.61	1.21e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03264133	chr6:25882463	NA	0.49	10.21	0.37	9.25e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs1568889	0.838	rs10835276	chr11:28167147	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.63	0.63	7.09e-73	Bipolar disorder;
BRCA	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-12.07	-0.43	2.24e-30	Response to antipsychotic treatment;
BRCA	cis	rs7246657	0.722	rs2075284	chr19:38189616	T/C	cg18154014	chr19:37997991	ZNF793	-0.5	-9.46	-0.35	5.78e-20	Coronary artery calcification;
BRCA	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.08	0.49	2.08e-39	Motion sickness;
BRCA	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg17830980	chr10:43048298	ZNF37B	-0.4	-9.14	-0.34	8.34e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4363385	0.720	rs1611755	chr1:152956420	T/C	cg24667326	chr1:152973720	SPRR3	-0.34	-9.49	-0.35	4.57e-20	Inflammatory skin disease;
BRCA	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg21280719	chr6:42927975	GNMT	-0.32	-13.42	-0.47	2.44e-36	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg01262667	chr19:19385393	TM6SF2	0.41	10.45	0.38	1.08e-23	Tonsillectomy;
BRCA	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg26769984	chr7:1090371	C7orf50	-0.46	-8.82	-0.33	1.1e-17	Bronchopulmonary dysplasia;
BRCA	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg09021430	chr5:549028	NA	-0.68	-14.24	-0.49	3.68e-40	Lung disease severity in cystic fibrosis;
BRCA	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06028605	chr16:24865363	SLC5A11	-0.43	-8.83	-0.33	9.71e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs9682041	0.696	rs13067560	chr3:170094190	G/A	cg11886554	chr3:170076028	SKIL	0.51	10.16	0.37	1.41e-22	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs754466	0.561	rs67332822	chr10:79706118	G/A	cg17075019	chr10:79541650	NA	-0.54	-7.96	-0.3	7.75e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.9	0.62	6.05e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	9.29	0.34	2.47e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg04990556	chr1:26633338	UBXN11	0.55	9.12	0.34	9.99e-19	Obesity-related traits;
BRCA	trans	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg26043149	chr18:55253948	FECH	-0.41	-9.11	-0.34	1.08e-18	Bone mineral density;
BRCA	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.72	0.42	6.85e-29	Tonsillectomy;
BRCA	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-11.93	-0.43	8.84e-30	Mood instability;
BRCA	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg19077165	chr18:44547161	KATNAL2	0.63	14.1	0.49	1.64e-39	Personality dimensions;
BRCA	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg26384229	chr12:38710491	ALG10B	0.85	22.84	0.67	7.26e-85	Heart rate;
BRCA	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg24812749	chr6:127587940	RNF146	0.87	20.52	0.63	2.92e-72	Breast cancer;
BRCA	cis	rs17604090	1.000	rs28420551	chr7:29685353	G/A	cg19413766	chr7:29689036	LOC646762	-0.51	-7.99	-0.3	6.22e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.68	-13.27	-0.46	1.14e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4588572	0.643	rs7700390	chr5:77789532	T/C	cg11547950	chr5:77652471	NA	-0.5	-8.93	-0.33	4.39e-18	Triglycerides;
BRCA	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	20.81	0.64	8.17e-74	Platelet count;
BRCA	cis	rs1568889	1.000	rs66702115	chr11:28181703	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.84	0.51	5.15e-43	Bipolar disorder;
BRCA	trans	rs208520	0.690	rs851468	chr6:66825875	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-20.46	-0.63	6.47e-72	Exhaled nitric oxide output;
BRCA	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg22491629	chr6:157744540	C6orf35	-0.65	-11.64	-0.42	1.62e-28	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.26	-0.31	8.61e-16	Bipolar disorder;
BRCA	cis	rs6977660	0.652	rs10267417	chr7:19843797	C/T	cg07541023	chr7:19748670	TWISTNB	0.55	9.19	0.34	5.31e-19	Thyroid stimulating hormone;
BRCA	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.41	-8.97	-0.33	3.31e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg12573674	chr2:1569213	NA	-0.58	-12.54	-0.44	2.11e-32	IgG glycosylation;
BRCA	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg08085267	chr17:45401833	C17orf57	-0.58	-11.98	-0.43	5.85e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9309473	0.687	rs7576824	chr2:73611281	C/T	cg20560298	chr2:73613845	ALMS1	0.51	13.99	0.48	5.68e-39	Metabolite levels;
BRCA	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg00071950	chr4:10020882	SLC2A9	0.62	14.77	0.5	1.08e-42	Bone mineral density;
BRCA	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg05340658	chr4:99064831	C4orf37	0.61	14.54	0.5	1.37e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6594499	0.872	rs10038177	chr5:110436450	C/T	cg04022379	chr5:110408740	TSLP	0.35	8.0	0.3	5.7e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg11814155	chr7:99998594	ZCWPW1	0.48	8.59	0.32	6.58e-17	Platelet count;
BRCA	trans	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg06521331	chr12:34319734	NA	-0.47	-8.79	-0.33	1.32e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10465746	0.967	rs12120160	chr1:84342835	T/G	cg10977910	chr1:84465055	TTLL7	0.51	10.28	0.38	4.89e-23	Obesity-related traits;
BRCA	trans	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg26384229	chr12:38710491	ALG10B	-0.49	-10.57	-0.39	3.57e-24	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg17971929	chr21:40555470	PSMG1	-0.47	-10.19	-0.37	1.03e-22	Menarche (age at onset);
BRCA	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg16325326	chr1:53192061	ZYG11B	0.7	16.94	0.56	1.91e-53	Monocyte count;
BRCA	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg03060546	chr3:49711283	APEH	0.58	9.49	0.35	4.62e-20	Menarche (age at onset);
BRCA	cis	rs965469	0.948	rs6051769	chr20:3326438	G/A	cg25506879	chr20:3388711	C20orf194	-0.53	-9.86	-0.36	1.86e-21	IFN-related cytopenia;
BRCA	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg26384229	chr12:38710491	ALG10B	0.74	17.6	0.57	7.83e-57	Bladder cancer;
BRCA	cis	rs6878727	0.665	rs256851	chr5:123662677	T/C	cg01806427	chr5:123737813	NA	-0.36	-8.07	-0.3	3.5e-15	Breast cancer;
BRCA	cis	rs9828933	0.577	rs704374	chr3:63865947	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.83	14.3	0.49	1.96e-40	Type 2 diabetes;
BRCA	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg08807101	chr21:30365312	RNF160	-0.4	-8.16	-0.31	1.79e-15	Cognitive test performance;
BRCA	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.47	-9.32	-0.35	1.93e-19	Body mass index;
BRCA	cis	rs12618769	0.597	rs72821908	chr2:99085359	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.37	0.31	3.7e-16	Bipolar disorder;
BRCA	cis	rs6120849	0.754	rs1885117	chr20:33600740	C/T	cg24642439	chr20:33292090	TP53INP2	0.59	10.15	0.37	1.51e-22	Protein C levels;
BRCA	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg06552810	chr11:31128660	NA	-0.39	-8.81	-0.33	1.18e-17	Red blood cell count;
BRCA	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg25173405	chr17:45401733	C17orf57	0.51	11.12	0.4	2.23e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7555523	0.830	rs6660601	chr1:165695855	C/T	cg24409356	chr1:165738333	TMCO1	0.5	7.93	0.3	9.48e-15	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	trans	rs9784649	0.760	rs72755820	chr5:25066181	G/A	cg11038491	chr20:34638489	LOC647979	-0.47	-8.73	-0.33	2.19e-17	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg13319975	chr6:146136371	FBXO30	0.42	9.84	0.36	2.32e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg06115741	chr20:33292138	TP53INP2	-0.37	-8.15	-0.31	1.9e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg02753203	chr1:228287806	NA	-0.6	-12.82	-0.45	1.18e-33	Diastolic blood pressure;
BRCA	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	14.17	0.49	7.92e-40	Colorectal cancer;
BRCA	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg09033563	chr22:24373618	LOC391322	-0.38	-7.84	-0.3	1.88e-14	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg25237894	chr2:233734115	C2orf82	-0.4	-11.7	-0.42	8.58e-29	Coronary artery disease;
BRCA	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.31	-7.85	-0.3	1.74e-14	Total body bone mineral density;
BRCA	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg12219531	chr12:120966889	COQ5	0.54	11.32	0.41	3.35e-27	High light scatter reticulocyte count;
BRCA	cis	rs4722585	0.533	rs757371	chr7:26199207	A/G	cg07876897	chr7:26191696	NFE2L3	0.41	8.94	0.33	4.1e-18	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
BRCA	trans	rs4819388	0.693	rs4818889	chr21:45645308	A/G	cg17383793	chr5:52405638	MOCS2	0.48	10.75	0.39	6.56e-25	Celiac disease;
BRCA	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg27170947	chr2:26402098	FAM59B	-0.79	-12.76	-0.45	2.12e-33	Gut microbiome composition (summer);
BRCA	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg25358565	chr5:93447407	FAM172A	1.23	19.31	0.61	9.12e-66	Diabetic retinopathy;
BRCA	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg00105475	chr2:10696890	NA	0.44	10.26	0.38	5.62e-23	Prostate cancer;
BRCA	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-12.0	-0.43	4.43e-30	Monocyte percentage of white cells;
BRCA	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4664304	1.000	rs55977890	chr2:160776866	C/T	cg18514922	chr2:160761262	LY75	-0.36	-8.45	-0.32	1.99e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9837602	1.000	rs9878931	chr3:99712634	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	11.28	0.41	4.85e-27	Breast cancer;
BRCA	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg15352829	chr14:105391018	PLD4	0.37	12.14	0.43	1.17e-30	Rheumatoid arthritis;
BRCA	cis	rs1506636	0.962	rs10273985	chr7:123309538	A/T	cg03229431	chr7:123269106	ASB15	-0.63	-14.15	-0.49	9.48e-40	Plateletcrit;Platelet count;
BRCA	trans	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg07817883	chr1:32538562	TMEM39B	-0.44	-8.08	-0.3	3.22e-15	Monocyte percentage of white cells;
BRCA	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg09537434	chr19:41945824	ATP5SL	-0.96	-23.36	-0.68	9.73e-88	Height;
BRCA	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg19717773	chr7:2847554	GNA12	-0.41	-9.34	-0.35	1.52e-19	Height;
BRCA	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg12927641	chr6:109611667	NA	-0.42	-11.0	-0.4	6.83e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg04450456	chr4:17643702	FAM184B	0.42	12.53	0.44	2.21e-32	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg20476274	chr7:133979776	SLC35B4	0.66	19.45	0.61	1.48e-66	Mean platelet volume;
BRCA	trans	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.25	0.31	9.3e-16	Corneal astigmatism;
BRCA	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg16102102	chr5:83017553	HAPLN1	-0.86	-16.29	-0.54	3.74e-50	Prostate cancer;
BRCA	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	8.82	0.33	1.11e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg22800045	chr5:56110881	MAP3K1	-0.51	-10.11	-0.37	2.2e-22	Type 2 diabetes;
BRCA	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11764359	chr7:65958608	NA	0.76	17.67	0.57	3.46e-57	Aortic root size;
BRCA	cis	rs35110281	0.667	rs4819293	chr21:45125863	A/G	cg21573476	chr21:45109991	RRP1B	-0.44	-10.87	-0.39	2.34e-25	Mean corpuscular volume;
BRCA	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.15	-17.53	-0.57	1.79e-56	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg19183879	chr15:85880815	NA	-0.33	-8.03	-0.3	4.84e-15	Coronary artery disease;
BRCA	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.46	0.55	5.2e-51	Colorectal cancer;
BRCA	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-20.21	-0.62	1.29e-70	Chronic sinus infection;
BRCA	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg08975724	chr8:8085496	FLJ10661	0.47	9.97	0.37	7.55e-22	Mood instability;
BRCA	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg23033748	chr14:75592666	NEK9	0.45	10.58	0.39	3.38e-24	Height;
BRCA	cis	rs6450176	0.951	rs255757	chr5:53309371	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-15.16	-0.51	1.42e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg01802117	chr1:53393560	SCP2	-0.42	-9.6	-0.36	1.73e-20	Monocyte count;
BRCA	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.39	-8.3	-0.31	5.98e-16	IgG glycosylation;
BRCA	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg22455342	chr2:225449267	CUL3	0.34	9.15	0.34	7.34e-19	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	trans	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg25214090	chr10:38739885	LOC399744	0.56	12.85	0.45	9.23e-34	Corneal astigmatism;
BRCA	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg27347728	chr4:17578864	LAP3	-0.45	-8.79	-0.33	1.38e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2387326	0.717	rs12266400	chr10:129944536	C/G	cg16087940	chr10:129947807	NA	0.46	8.35	0.31	4.12e-16	Select biomarker traits;
BRCA	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg23018236	chr17:30244563	NA	0.61	8.75	0.33	1.95e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg18016565	chr1:150552671	MCL1	0.35	8.36	0.31	3.93e-16	Tonsillectomy;
BRCA	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.48	10.49	0.38	7.63e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg11752832	chr7:134001865	SLC35B4	-0.44	-11.1	-0.4	2.59e-26	Mean platelet volume;
BRCA	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23583168	chr7:148888333	NA	-0.86	-20.09	-0.62	5.61e-70	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg18305652	chr10:134549665	INPP5A	0.49	11.02	0.4	5.83e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg26384229	chr12:38710491	ALG10B	0.48	10.64	0.39	1.96e-24	Morning vs. evening chronotype;
BRCA	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00166722	chr3:10149974	C3orf24	0.64	12.73	0.45	3.13e-33	Alzheimer's disease;
BRCA	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg14019146	chr3:50243930	SLC38A3	-0.4	-9.84	-0.36	2.21e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-8.96	-0.33	3.42e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4812048	0.649	rs3761258	chr20:57618596	C/G	cg14073986	chr20:57617431	SLMO2	-0.76	-11.59	-0.42	2.61e-28	Mean platelet volume;
BRCA	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg22920501	chr2:26401640	FAM59B	-0.67	-11.56	-0.42	3.5e-28	Gut microbiome composition (summer);
BRCA	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg02503808	chr4:7069936	GRPEL1	0.76	17.42	0.57	6.83e-56	Monocyte percentage of white cells;
BRCA	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg18230493	chr5:56204884	C5orf35	-0.39	-8.1	-0.31	2.76e-15	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg23029597	chr12:123009494	RSRC2	-0.57	-11.43	-0.41	1.16e-27	Body mass index;
BRCA	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg22920501	chr2:26401640	FAM59B	-0.63	-11.34	-0.41	2.85e-27	Gut microbiome composition (summer);
BRCA	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7301826	0.651	rs34749116	chr12:131280752	G/A	cg11011512	chr12:131303247	STX2	-0.46	-11.26	-0.41	5.78e-27	Plasma plasminogen activator levels;
BRCA	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg12826209	chr6:26865740	GUSBL1	0.63	8.27	0.31	7.95e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg06784218	chr1:46089804	CCDC17	0.44	10.63	0.39	2.06e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg19077165	chr18:44547161	KATNAL2	0.58	12.68	0.45	5.24e-33	Personality dimensions;
BRCA	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.58	-0.32	7.19e-17	Total body bone mineral density;
BRCA	cis	rs3771570	1.000	rs1984598	chr2:242284824	G/A	cg21155796	chr2:242212141	HDLBP	0.48	8.36	0.31	3.97e-16	Prostate cancer;
BRCA	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7301826	0.651	rs10744485	chr12:131298550	A/G	cg11011512	chr12:131303247	STX2	0.5	13.03	0.46	1.42e-34	Plasma plasminogen activator levels;
BRCA	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.02	-24.09	-0.69	1.01e-91	Primary sclerosing cholangitis;
BRCA	cis	rs2637030	0.559	rs923609	chr5:52912249	G/A	cg06476337	chr5:52856530	NDUFS4	0.38	8.55	0.32	9.09e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg15017067	chr4:17643749	FAM184B	-0.33	-10.18	-0.37	1.21e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.6	11.84	0.42	2.17e-29	Multiple sclerosis;
BRCA	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg05347473	chr6:146136440	FBXO30	0.41	8.21	0.31	1.26e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	12.04	0.43	3.05e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg24675658	chr1:53192096	ZYG11B	-0.71	-16.09	-0.54	3.88e-49	Monocyte count;
BRCA	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	8.84	0.33	8.93e-18	Bipolar disorder;
BRCA	cis	rs727479	0.543	rs8023263	chr15:51517597	G/T	cg19946085	chr15:51559439	CYP19A1	-0.28	-7.94	-0.3	8.94e-15	Estradiol levels;
BRCA	cis	rs7590720	1.000	rs6435930	chr2:216885852	A/G	cg12620499	chr2:216877984	MREG	0.8	22.15	0.66	4.35e-81	Alcohol dependence;
BRCA	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.38	-8.42	-0.32	2.47e-16	Cognitive ability;
BRCA	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg21573476	chr21:45109991	RRP1B	-0.33	-8.39	-0.31	3.21e-16	Mean corpuscular volume;
BRCA	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg24130564	chr14:104152367	KLC1	0.36	8.2	0.31	1.33e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg17757837	chr7:157058334	UBE3C	-0.71	-17.58	-0.57	9.48e-57	Body mass index;
BRCA	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.22	-0.31	1.13e-15	Depression;
BRCA	trans	rs526821	0.532	rs578067	chr11:55313690	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.36	-8.11	-0.31	2.54e-15	Pediatric bone mineral density (spine);
BRCA	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg00376283	chr12:123451042	ABCB9	0.51	11.15	0.4	1.63e-26	Neutrophil percentage of white cells;
BRCA	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg04362960	chr10:104952993	NT5C2	0.94	14.5	0.5	2.26e-41	Arsenic metabolism;
BRCA	cis	rs7677751	0.806	rs7673853	chr4:55096606	T/C	cg17187183	chr4:55093834	PDGFRA	0.44	9.27	0.34	2.73e-19	Corneal astigmatism;
BRCA	cis	rs939658	1.000	rs8031504	chr15:79458589	G/T	cg17916960	chr15:79447300	NA	0.39	9.85	0.36	2.09e-21	Refractive error;
BRCA	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg14019146	chr3:50243930	SLC38A3	-0.42	-10.11	-0.37	2.11e-22	Body mass index;
BRCA	cis	rs9329289	0.510	rs28579610	chr10:2546080	C/A	cg15501526	chr10:2543763	NA	0.46	10.73	0.39	8.45e-25	Age-related hearing impairment;
BRCA	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg25482853	chr8:67687455	SGK3	1.02	16.08	0.54	4.27e-49	Lung disease severity in cystic fibrosis;
BRCA	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg11645453	chr3:52864694	ITIH4	-0.37	-9.52	-0.35	3.58e-20	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs17092148	1.000	rs3787220	chr20:33337751	T/C	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.3	-0.41	3.92e-27	Neuroticism;
BRCA	cis	rs2625529	0.590	rs3803471	chr15:72500786	A/G	cg16672083	chr15:72433130	SENP8	-0.83	-17.39	-0.57	1.01e-55	Red blood cell count;
BRCA	cis	rs4478858	0.735	rs7547897	chr1:31797593	G/A	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg17892150	chr10:133769511	PPP2R2D	0.72	15.77	0.53	1.51e-47	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs9816226	1.000	rs61587156	chr3:185831583	T/G	cg00760338	chr3:185826511	ETV5	-0.52	-8.06	-0.3	3.64e-15	Obesity;Body mass index;
BRCA	cis	rs965469	0.817	rs6515806	chr20:3359138	A/G	cg25506879	chr20:3388711	C20orf194	-0.47	-9.42	-0.35	7.83e-20	IFN-related cytopenia;
BRCA	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg05283184	chr6:79620031	NA	-0.43	-11.41	-0.41	1.41e-27	Intelligence (multi-trait analysis);
BRCA	trans	rs9409565	0.826	rs639276	chr9:97206737	G/T	cg05679027	chr9:99775184	HIATL2	-0.43	-9.44	-0.35	6.67e-20	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	9.35	0.35	1.45e-19	Parkinson's disease;
BRCA	cis	rs9287719	0.649	rs10929685	chr2:10732799	T/C	cg00105475	chr2:10696890	NA	0.41	9.23	0.34	3.83e-19	Prostate cancer;
BRCA	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	12.09	0.43	1.99e-30	Personality dimensions;
BRCA	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.06	-23.43	-0.68	4.26e-88	Ulcerative colitis;
BRCA	cis	rs12210905	0.688	rs72839474	chr6:27324757	T/C	cg08851530	chr6:28072375	NA	0.91	8.7	0.33	2.7e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	17.01	0.56	8.37e-54	Electrocardiographic conduction measures;
BRCA	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	12.01	0.43	4.3e-30	Coronary artery disease;
BRCA	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg21395723	chr22:39101663	GTPBP1	0.4	8.65	0.32	4.14e-17	Menopause (age at onset);
BRCA	trans	rs3960554	0.808	rs79864016	chr7:75655838	A/G	cg19862616	chr7:65841803	NCRNA00174	0.6	12.48	0.44	3.72e-32	Eotaxin levels;
BRCA	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.4	-0.41	1.63e-27	Electroencephalogram traits;
BRCA	cis	rs12541635	0.902	rs59123253	chr8:107006365	C/T	cg10147462	chr8:107024639	NA	0.37	9.97	0.37	7.11e-22	Age of smoking initiation;
BRCA	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26314531	chr2:26401878	FAM59B	-0.78	-12.62	-0.45	8.84e-33	Gut microbiome composition (summer);
BRCA	cis	rs13046373	0.535	rs1395775	chr21:32025065	G/A	cg27071517	chr21:31768726	KRTAP13-1	0.29	7.86	0.3	1.66e-14	HDL cholesterol;
BRCA	cis	rs7945718	0.967	rs11022491	chr11:12777620	A/G	cg25843174	chr11:12811716	TEAD1	-0.23	-8.66	-0.32	3.77e-17	Educational attainment (years of education);
BRCA	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.35	-8.3	-0.31	6.01e-16	Electroencephalogram traits;
BRCA	cis	rs4363385	0.818	rs436621	chr1:153005492	A/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.26	-0.34	3.19e-19	Inflammatory skin disease;
BRCA	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg03060546	chr3:49711283	APEH	0.6	10.31	0.38	3.76e-23	Menarche (age at onset);
BRCA	trans	rs877282	0.898	rs11253338	chr10:759559	C/T	cg22713356	chr15:30763199	NA	1.2	21.44	0.65	3.04e-77	Uric acid levels;
BRCA	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-16.04	-0.54	6.86e-49	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg15208524	chr1:10270712	KIF1B	0.38	7.91	0.3	1.12e-14	Hepatocellular carcinoma;
BRCA	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg06784218	chr1:46089804	CCDC17	-0.54	-13.22	-0.46	1.85e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2415984	0.622	rs12435397	chr14:46940867	G/A	cg14871534	chr14:47121158	RPL10L	-0.32	-7.87	-0.3	1.54e-14	Number of children ever born;
BRCA	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg14820908	chr5:178986412	RUFY1	0.48	11.48	0.41	7.07e-28	Lung cancer;
BRCA	trans	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.15	0.31	1.94e-15	Corneal astigmatism;
BRCA	cis	rs2904967	0.810	rs507005	chr11:65045615	T/C	cg09225861	chr11:65069680	NA	0.39	8.07	0.3	3.62e-15	Mean corpuscular volume;
BRCA	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg21644426	chr2:191273491	MFSD6	0.44	11.23	0.41	7.76e-27	Pulse pressure;
BRCA	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg05714579	chr10:131428358	MGMT	-0.47	-10.43	-0.38	1.21e-23	Response to temozolomide;
BRCA	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.53	-10.04	-0.37	4.13e-22	Aortic root size;
BRCA	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg13010199	chr12:38710504	ALG10B	0.41	8.52	0.32	1.14e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg18016565	chr1:150552671	MCL1	-0.37	-8.61	-0.32	5.55e-17	Tonsillectomy;
BRCA	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22496380	chr5:211416	CCDC127	-1.01	-14.34	-0.49	1.21e-40	Breast cancer;
BRCA	cis	rs7729447	0.776	rs58529247	chr5:32693889	C/T	cg16267343	chr5:32710456	NPR3	0.41	8.27	0.31	7.85e-16	Blood pressure;
BRCA	cis	rs495337	0.735	rs2281217	chr20:48568055	C/G	cg17835207	chr20:48524531	SPATA2	-0.67	-16.31	-0.54	2.93e-50	Psoriasis;
BRCA	cis	rs17641971	0.684	rs4873095	chr8:49990166	A/T	cg00325661	chr8:49890786	NA	0.39	10.81	0.39	4.14e-25	Blood metabolite levels;
BRCA	cis	rs12413816	0.818	rs35567671	chr10:13769722	C/A	cg16485048	chr10:13749193	FRMD4A	0.57	12.73	0.45	2.92e-33	Red cell distribution width;
BRCA	cis	rs7267979	0.932	rs6115215	chr20:25562500	C/T	cg08601574	chr20:25228251	PYGB	0.36	8.43	0.32	2.21e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.18	0.49	7.18e-40	Motion sickness;
BRCA	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11764359	chr7:65958608	NA	0.73	16.22	0.54	8.75e-50	Aortic root size;
BRCA	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	15.48	0.52	3.93e-46	Colorectal cancer;
BRCA	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.4	-8.8	-0.33	1.24e-17	Aortic root size;
BRCA	cis	rs10899021	1.000	rs7102084	chr11:74358132	T/C	cg25880958	chr11:74394337	NA	-0.5	-7.89	-0.3	1.27e-14	Response to metformin (IC50);
BRCA	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg24579218	chr15:68104479	NA	-0.35	-7.82	-0.3	2.19e-14	Obesity;
BRCA	trans	rs12517041	1.000	rs1366454	chr5:23319172	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-8.11	-0.31	2.55e-15	Calcium levels;
BRCA	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg05340658	chr4:99064831	C4orf37	0.7	17.73	0.57	1.62e-57	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7633770	0.710	rs11710586	chr3:46693457	A/G	cg11219411	chr3:46661640	NA	-0.51	-12.19	-0.43	7.14e-31	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg26408565	chr15:76604113	ETFA	-0.47	-9.93	-0.37	1.05e-21	Blood metabolite levels;
BRCA	cis	rs3916	0.955	rs12828810	chr12:121152017	T/G	cg21892295	chr12:121157589	UNC119B	-0.38	-9.74	-0.36	5.55e-21	Urinary metabolites (H-NMR features);
BRCA	cis	rs2637266	0.935	rs12259550	chr10:78352843	A/G	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.29e-14	Pulmonary function;
BRCA	cis	rs7809950	0.815	rs62482495	chr7:106965009	A/G	cg23024343	chr7:107201750	COG5	-0.47	-9.55	-0.35	2.67e-20	Coronary artery disease;
BRCA	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg17802220	chr15:77601643	NA	-0.44	-10.26	-0.38	5.62e-23	Type 2 diabetes;
BRCA	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.04	-0.3	4.35e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2387326	0.717	rs11016102	chr10:129945154	A/G	cg16087940	chr10:129947807	NA	-0.45	-8.08	-0.3	3.15e-15	Select biomarker traits;
BRCA	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg09184832	chr6:79620586	NA	-0.52	-11.36	-0.41	2.21e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg22907277	chr7:1156413	C7orf50	0.5	11.01	0.4	6.34e-26	Longevity;Endometriosis;
BRCA	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg02297831	chr4:17616191	MED28	0.37	8.58	0.32	7.18e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17467752	chr17:38218738	THRA	0.44	10.08	0.37	2.91e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
BRCA	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg25358565	chr5:93447407	FAM172A	1.14	18.59	0.59	5.23e-62	Diabetic retinopathy;
BRCA	cis	rs698833	0.828	rs6745281	chr2:44534472	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	10.24	0.38	6.63e-23	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs9790314	0.663	rs12639128	chr3:160639645	A/G	cg03342759	chr3:160939853	NMD3	0.44	8.83	0.33	1.04e-17	Morning vs. evening chronotype;
BRCA	cis	rs7246657	0.653	rs10406612	chr19:37716611	C/T	cg18154014	chr19:37997991	ZNF793	0.56	9.22	0.34	4.37e-19	Coronary artery calcification;
BRCA	cis	rs490234	0.588	rs34983978	chr9:128169170	G/A	cg14078157	chr9:128172775	NA	-0.55	-12.03	-0.43	3.3e-30	Mean arterial pressure;
BRCA	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg26446133	chr18:72167187	CNDP2	-0.8	-20.6	-0.63	1.1e-72	Refractive error;
BRCA	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg11301795	chr4:187892539	NA	-0.3	-10.15	-0.37	1.54e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	13.32	0.47	6.5e-36	Lung cancer in ever smokers;
BRCA	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.34	-7.86	-0.3	1.68e-14	High light scatter reticulocyte count;
BRCA	cis	rs2882667	0.620	rs3789151	chr5:138145460	C/T	cg04439458	chr5:138467593	SIL1	0.31	7.86	0.3	1.62e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg20307385	chr11:47447363	PSMC3	0.8	19.14	0.6	6.89e-65	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs3125734	0.633	rs12217669	chr10:63988456	A/G	cg19640130	chr10:64028056	RTKN2	0.29	8.2	0.31	1.3e-15	Rheumatoid arthritis;
BRCA	cis	rs6542838	0.641	rs7565510	chr2:99494833	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.39	-8.84	-0.33	9.53e-18	Fear of minor pain;
BRCA	cis	rs1691799	0.867	rs1168338	chr12:66759369	T/C	cg16791601	chr12:66731901	HELB	-0.67	-18.36	-0.59	8.64e-61	White blood cell count (basophil);
BRCA	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-11.32	-0.41	3.34e-27	Mood instability;
BRCA	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg26384229	chr12:38710491	ALG10B	-0.62	-14.81	-0.51	7.42e-43	Bladder cancer;
BRCA	cis	rs738322	0.577	rs6001034	chr22:38558459	A/G	cg25457927	chr22:38595422	NA	-0.35	-12.63	-0.45	8.21e-33	Cutaneous nevi;
BRCA	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.12	-0.49	1.38e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg03433033	chr1:76189801	ACADM	0.7	12.91	0.45	4.96e-34	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg18200150	chr17:30822561	MYO1D	0.34	8.74	0.33	2.08e-17	Schizophrenia;
BRCA	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg05340658	chr4:99064831	C4orf37	0.45	10.64	0.39	1.9e-24	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-8.84	-0.33	9.42e-18	Alzheimer's disease (late onset);
BRCA	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.05	-0.37	3.53e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-11.23	-0.41	7.67e-27	Lymphocyte counts;
BRCA	cis	rs921968	0.565	rs7605055	chr2:219627050	G/C	cg02176678	chr2:219576539	TTLL4	-0.41	-11.01	-0.4	6.22e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6977660	1.000	rs12672557	chr7:19804237	G/A	cg05791153	chr7:19748676	TWISTNB	0.47	9.03	0.34	1.95e-18	Thyroid stimulating hormone;
BRCA	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg06115741	chr20:33292138	TP53INP2	0.39	8.55	0.32	9.35e-17	Coronary artery disease;
BRCA	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23583168	chr7:148888333	NA	-0.81	-18.33	-0.59	1.28e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg16482183	chr6:26056742	HIST1H1C	0.46	8.88	0.33	6.97e-18	Iron status biomarkers;
BRCA	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg16950941	chr11:66035639	RAB1B	0.42	11.26	0.41	6.05e-27	Gout;
BRCA	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.76	0.39	6.24e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg06115741	chr20:33292138	TP53INP2	0.38	8.46	0.32	1.86e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs858239	0.602	rs6953996	chr7:23175946	A/G	cg23682824	chr7:23144976	KLHL7	0.4	10.48	0.38	7.88e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.35	0.57	1.6e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9296092	0.538	rs9461882	chr6:33520221	A/C	cg13560919	chr6:33536144	NA	-0.85	-17.72	-0.57	1.88e-57	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs9467160	0.651	rs9393558	chr6:24454196	G/T	cg20631270	chr6:24437470	GPLD1	0.43	8.69	0.32	3.16e-17	Liver enzyme levels;
BRCA	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg20283391	chr11:68216788	NA	-0.46	-9.02	-0.34	2.24e-18	Total body bone mineral density;
BRCA	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-11.82	-0.42	2.58e-29	Bipolar disorder;
BRCA	cis	rs10740039	0.768	rs920646	chr10:62463525	C/T	cg02922035	chr10:62493342	NA	0.41	7.81	0.3	2.37e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg14983838	chr19:29218262	NA	0.54	10.09	0.37	2.65e-22	Methadone dose in opioid dependence;
BRCA	cis	rs12348691	0.503	rs7849497	chr9:100615660	G/C	cg13688889	chr9:100608707	NA	-0.49	-9.9	-0.36	1.32e-21	Alopecia areata;
BRCA	trans	rs208520	0.802	rs208496	chr6:66930786	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.36	-0.54	1.71e-50	Exhaled nitric oxide output;
BRCA	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg18132916	chr6:79620363	NA	-0.49	-11.19	-0.4	1.1e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9986765	0.867	rs1994498	chr7:142816448	C/T	cg21852589	chr7:142981689	TMEM139	0.57	9.72	0.36	6.17e-21	Cancer;Dermatomyositis;
BRCA	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg09469691	chr10:81107165	PPIF	0.42	9.29	0.34	2.42e-19	Height;
BRCA	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg16586182	chr3:47516702	SCAP	-0.55	-12.36	-0.44	1.3e-31	Colorectal cancer;
BRCA	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg08885076	chr2:99613938	TSGA10	-0.52	-10.28	-0.38	4.9e-23	Chronic sinus infection;
BRCA	cis	rs12210905	0.688	rs12196452	chr6:27344415	A/T	cg08851530	chr6:28072375	NA	0.91	8.7	0.33	2.7e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg11266682	chr4:10021025	SLC2A9	0.49	13.12	0.46	5.22e-35	Bone mineral density;
BRCA	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg16590910	chr6:42928470	GNMT	0.42	9.22	0.34	4.38e-19	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	19.57	0.61	3.41e-67	Electrocardiographic conduction measures;
BRCA	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-16.16	-0.54	1.65e-49	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11890956	chr21:40555474	PSMG1	-0.68	-16.65	-0.55	5.63e-52	Cognitive function;
BRCA	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg18446336	chr7:2847575	GNA12	-0.41	-10.28	-0.38	4.86e-23	Height;
BRCA	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.49	0.57	2.8e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg12751644	chr20:60527061	NA	-0.33	-7.87	-0.3	1.57e-14	Body mass index;
BRCA	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg01849466	chr14:104193079	ZFYVE21	0.46	10.54	0.38	4.59e-24	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.05	0.49	2.98e-39	Eye color traits;
BRCA	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg25358565	chr5:93447407	FAM172A	1.17	17.98	0.58	8.92e-59	Diabetic retinopathy;
BRCA	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.71	-0.33	2.59e-17	Breast cancer;
BRCA	trans	rs62103177	0.608	rs34383580	chr18:77833263	A/G	cg05926928	chr17:57297772	GDPD1	-0.76	-10.74	-0.39	7.22e-25	Opioid sensitivity;
BRCA	cis	rs3772130	0.583	rs4296627	chr3:121567684	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	14.27	0.49	2.71e-40	Cognitive performance;
BRCA	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg01877450	chr7:97915802	BRI3	-0.39	-8.87	-0.33	7.43e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg13010199	chr12:38710504	ALG10B	-0.4	-8.59	-0.32	6.42e-17	Bladder cancer;
BRCA	trans	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg06521331	chr12:34319734	NA	-0.47	-8.6	-0.32	6.19e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg13271783	chr10:134563150	INPP5A	-0.46	-9.59	-0.35	1.97e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.55	0.57	1.47e-56	Bladder cancer;
BRCA	cis	rs2425143	1.000	rs11696947	chr20:34312658	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.96	-0.33	3.53e-18	Blood protein levels;
BRCA	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.38	0.38	2.02e-23	Motion sickness;
BRCA	cis	rs2346177	0.875	rs12986585	chr2:46644121	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.41	8.49	0.32	1.49e-16	HDL cholesterol;
BRCA	cis	rs6545883	0.929	rs3732170	chr2:61749716	C/T	cg15711740	chr2:61764176	XPO1	-0.55	-14.18	-0.49	7.07e-40	Tuberculosis;
BRCA	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-7.92	-0.3	1.05e-14	Total body bone mineral density;
BRCA	cis	rs13136331	0.684	rs13123354	chr4:88729912	C/T	cg22416721	chr4:88570574	DMP1	0.38	8.08	0.3	3.28e-15	Sitting height ratio;
BRCA	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11644478	chr21:40555479	PSMG1	0.73	14.23	0.49	4.17e-40	Cognitive function;
BRCA	cis	rs6484504	0.625	rs7112412	chr11:31370271	T/C	cg14844989	chr11:31128820	NA	0.44	9.7	0.36	7.83e-21	Red blood cell count;
BRCA	cis	rs17401966	0.518	rs10864453	chr1:10407169	T/G	cg03954927	chr1:10346856	KIF1B	0.34	10.32	0.38	3.51e-23	Hepatocellular carcinoma;
BRCA	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg03954927	chr1:10346856	KIF1B	0.48	14.83	0.51	5.68e-43	Hepatocellular carcinoma;
BRCA	cis	rs10463316	0.894	rs4099169	chr5:150766526	C/T	cg03212797	chr5:150827313	SLC36A1	-0.41	-8.13	-0.31	2.23e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg11062466	chr8:58055876	NA	0.54	9.12	0.34	9.92e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.49	-10.06	-0.37	3.27e-22	Rheumatoid arthritis;
BRCA	trans	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg14791747	chr16:20752902	THUMPD1	-0.4	-9.82	-0.36	2.75e-21	Cognitive test performance;
BRCA	trans	rs6964833	1.000	rs36044436	chr7:74089819	G/C	cg07504079	chr7:72649617	NCF1B	-0.51	-9.89	-0.36	1.47e-21	Menarche (age at onset);
BRCA	cis	rs3849570	0.695	rs1851930	chr3:81895318	T/G	cg07356753	chr3:81810745	GBE1	-0.42	-10.11	-0.37	2.11e-22	Waist circumference;Body mass index;
BRCA	cis	rs6546550	0.900	rs2054047	chr2:70117421	A/C	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.6	-0.42	2.21e-28	Prevalent atrial fibrillation;
BRCA	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.38	-0.31	3.45e-16	Bipolar disorder;
BRCA	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg14963724	chr18:72166303	CNDP2	-0.34	-9.43	-0.35	7.58e-20	Refractive error;
BRCA	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg23711669	chr6:146136114	FBXO30	0.73	17.61	0.57	6.77e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7395581	0.918	rs1449627	chr11:47290984	T/G	cg25783544	chr11:47291846	MADD	0.43	9.78	0.36	3.68e-21	HDL cholesterol;
BRCA	cis	rs7246657	0.551	rs10404069	chr19:37638404	C/T	cg23950597	chr19:37808831	NA	-0.55	-8.41	-0.32	2.65e-16	Coronary artery calcification;
BRCA	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg04013093	chr6:42928303	GNMT	0.29	9.73	0.36	5.88e-21	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg06766960	chr11:133703094	NA	-0.62	-13.0	-0.46	1.8e-34	Childhood ear infection;
BRCA	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.29	9.35	0.35	1.43e-19	Systemic lupus erythematosus;
BRCA	trans	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg06521331	chr12:34319734	NA	-0.5	-9.1	-0.34	1.13e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-11.81	-0.42	3.02e-29	Gut microbiome composition (summer);
BRCA	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11644478	chr21:40555479	PSMG1	0.76	16.06	0.54	5.46e-49	Cognitive function;
BRCA	cis	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg07460842	chr6:66804631	NA	-0.87	-15.63	-0.53	7.24e-47	Exhaled nitric oxide levels;
BRCA	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.51	-0.52	2.66e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6782228	0.565	rs2811496	chr3:128359958	A/T	cg16766828	chr3:128327626	NA	-0.42	-9.51	-0.35	3.94e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg22906224	chr7:99728672	NA	-0.42	-7.87	-0.3	1.54e-14	Coronary artery disease;
BRCA	cis	rs12611088	0.571	rs7252955	chr19:44021766	A/T	cg13740135	chr19:44006432	PHLDB3	-0.3	-7.86	-0.3	1.69e-14	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25427524	chr10:38739819	LOC399744	-0.68	-16.55	-0.55	1.89e-51	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.83	-20.73	-0.63	2.24e-73	Birth weight;
BRCA	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg26384229	chr12:38710491	ALG10B	0.74	16.99	0.56	1.12e-53	Bladder cancer;
BRCA	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg24562669	chr7:97807699	LMTK2	0.66	19.74	0.62	4.64e-68	Breast cancer;
BRCA	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.91	-29.23	-0.76	6.7e-120	Schizophrenia;
BRCA	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg05714579	chr10:131428358	MGMT	-0.58	-14.22	-0.49	4.45e-40	Response to temozolomide;
BRCA	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.32	-9.64	-0.36	1.3e-20	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg15704280	chr7:45808275	SEPT13	0.74	17.45	0.57	4.8e-56	Coronary artery disease;
BRCA	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11890956	chr21:40555474	PSMG1	0.99	23.93	0.69	7.69e-91	Cognitive function;
BRCA	trans	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-12.43	-0.44	6.1e-32	Brugada syndrome;
BRCA	trans	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg26043149	chr18:55253948	FECH	0.38	8.46	0.32	1.89e-16	Bone mineral density;
BRCA	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg20991723	chr1:152506922	NA	0.36	8.13	0.31	2.24e-15	Hair morphology;
BRCA	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg11833968	chr6:79620685	NA	-0.44	-9.73	-0.36	5.88e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg00684032	chr4:1343700	KIAA1530	-0.34	-8.8	-0.33	1.25e-17	Obesity-related traits;
BRCA	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	9.3	0.35	2.25e-19	Rheumatoid arthritis;
BRCA	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18876405	chr7:65276391	NA	0.55	13.31	0.47	7.72e-36	Aortic root size;
BRCA	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.4	8.27	0.31	7.56e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg08999081	chr20:33150536	PIGU	-0.45	-12.27	-0.44	3.01e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-12.48	-0.44	3.65e-32	Total cholesterol levels;
BRCA	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg06060754	chr5:176797920	RGS14	-0.67	-10.3	-0.38	4.09e-23	Urate levels in lean individuals;
BRCA	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	10.33	0.38	2.98e-23	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg07741184	chr6:167504864	NA	0.33	9.82	0.36	2.83e-21	Primary biliary cholangitis;
BRCA	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg03433033	chr1:76189801	ACADM	0.73	18.87	0.6	1.74e-63	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg03585969	chr10:35415529	CREM	0.56	11.5	0.41	5.98e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12210905	0.688	rs12194842	chr6:27367978	A/C	cg08851530	chr6:28072375	NA	0.84	8.27	0.31	7.64e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.57	8.89	0.33	6.41e-18	HIV-1 control;
BRCA	trans	rs7980799	0.565	rs2200159	chr12:33648544	G/C	cg26384229	chr12:38710491	ALG10B	-0.45	-9.67	-0.36	9.67e-21	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.79	-0.42	3.6e-29	Alcohol dependence;
BRCA	cis	rs290268	0.874	rs772407	chr9:93560850	A/C	cg02608019	chr9:93564028	SYK	0.56	12.41	0.44	7.39e-32	Platelet count;
BRCA	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg20203395	chr5:56204925	C5orf35	-0.51	-10.45	-0.38	1.08e-23	Initial pursuit acceleration;
BRCA	cis	rs6138458	1.000	rs2387362	chr20:24899906	C/T	cg06937882	chr20:24974362	C20orf3	0.44	8.35	0.31	4.34e-16	Blood protein levels;
BRCA	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg20887711	chr4:1340912	KIAA1530	0.42	10.29	0.38	4.24e-23	Longevity;
BRCA	cis	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg06521331	chr12:34319734	NA	-0.52	-10.17	-0.37	1.26e-22	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg03676636	chr4:99064102	C4orf37	0.21	7.98	0.3	6.8e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg18154014	chr19:37997991	ZNF793	0.48	9.5	0.35	4.29e-20	Coronary artery calcification;
BRCA	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-10.19	-0.37	1.09e-22	Heart rate;
BRCA	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-7.98	-0.3	6.81e-15	Total body bone mineral density;
BRCA	cis	rs782590	0.607	rs2061032	chr2:55679490	T/C	cg18811423	chr2:55921094	PNPT1	0.46	11.9	0.43	1.29e-29	Metabolic syndrome;
BRCA	trans	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg06521331	chr12:34319734	NA	-0.48	-8.78	-0.33	1.47e-17	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg07817883	chr1:32538562	TMEM39B	-0.44	-8.55	-0.32	8.74e-17	Monocyte percentage of white cells;
BRCA	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-8.15	-0.31	1.95e-15	Obesity-related traits;
BRCA	cis	rs4478858	0.735	rs11583123	chr1:31751772	T/C	cg00250761	chr1:31883323	NA	-0.32	-8.33	-0.31	4.93e-16	Alcohol dependence;
BRCA	cis	rs10046574	0.519	rs10265128	chr7:135211446	A/G	cg27474649	chr7:135195673	CNOT4	0.64	10.75	0.39	6.98e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs1506636	1.000	rs2429616	chr7:123406034	C/T	cg03229431	chr7:123269106	ASB15	0.61	13.61	0.47	3.2e-37	Plateletcrit;Platelet count;
BRCA	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg24101359	chr6:42928495	GNMT	0.63	15.45	0.52	5.19e-46	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	21.27	0.64	2.47e-76	Lymphocyte percentage of white cells;
BRCA	cis	rs6842047	1.000	rs4862668	chr4:187136443	A/T	cg09526685	chr4:187126073	CYP4V2	0.72	9.93	0.37	1.03e-21	Blood protein levels;
BRCA	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg25019033	chr10:957182	NA	-0.42	-8.2	-0.31	1.32e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg07828340	chr4:882639	GAK	1.04	12.39	0.44	9.94e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs9467773	0.572	rs2076029	chr6:26390830	T/C	cg09904177	chr6:26538194	HMGN4	-0.34	-9.1	-0.34	1.1e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs34779708	0.931	rs10508815	chr10:35332621	A/C	cg03585969	chr10:35415529	CREM	0.45	9.48	0.35	4.91e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	ch.11.42038R	chr11:967971	AP2A2	-0.52	-16.84	-0.55	6.38e-53	Alzheimer's disease (late onset);
BRCA	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.02	-0.3	5.22e-15	Depression;
BRCA	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	20.64	0.63	6.21e-73	Platelet count;
BRCA	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg24130564	chr14:104152367	KLC1	0.35	7.96	0.3	7.84e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg23711669	chr6:146136114	FBXO30	0.63	14.68	0.5	3e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs858239	0.600	rs10488077	chr7:23144182	A/T	cg23682824	chr7:23144976	KLHL7	0.42	11.16	0.4	1.52e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg08213375	chr14:104286397	PPP1R13B	0.42	9.1	0.34	1.1e-18	Reticulocyte count;
BRCA	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg06627628	chr2:24431161	ITSN2	-0.8	-15.15	-0.51	1.59e-44	Venous thromboembolism (SNP x SNP interaction);
BRCA	trans	rs6600671	1.000	rs4844616	chr1:121171208	A/G	cg17023122	chr1:144479586	NA	0.33	8.02	0.3	4.99e-15	Hip geometry;
BRCA	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg22903471	chr2:27725779	GCKR	-0.34	-8.16	-0.31	1.72e-15	Total body bone mineral density;
BRCA	cis	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg04990556	chr1:26633338	UBXN11	0.54	8.86	0.33	8.17e-18	Obesity-related traits;
BRCA	trans	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg25214090	chr10:38739885	LOC399744	0.53	11.53	0.41	4.45e-28	Corneal astigmatism;
BRCA	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-13.82	-0.48	3.53e-38	Blood metabolite levels;
BRCA	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-9.38	-0.35	1.09e-19	Schizophrenia;
BRCA	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg23231163	chr10:75533350	FUT11	-0.33	-8.74	-0.33	2.12e-17	Inflammatory bowel disease;
BRCA	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	11.77	0.42	4.57e-29	Calcium levels;
BRCA	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.6	0.65	3.99e-78	Lymphocyte percentage of white cells;
BRCA	cis	rs10046574	0.831	rs56101588	chr7:135128106	A/C	cg27474649	chr7:135195673	CNOT4	0.62	8.62	0.32	5.34e-17	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03517284	chr6:25882590	NA	-0.49	-10.27	-0.38	5.31e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.44	0.38	1.1e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg20891283	chr12:69753455	YEATS4	0.72	21.68	0.65	1.6e-78	Blood protein levels;
BRCA	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.45	-10.31	-0.38	3.64e-23	Reticulocyte count;
BRCA	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg26031613	chr14:104095156	KLC1	-0.45	-8.92	-0.33	5.04e-18	Schizophrenia;
BRCA	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg03954927	chr1:10346856	KIF1B	0.43	13.72	0.48	9.36e-38	Hepatocellular carcinoma;
BRCA	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg14019146	chr3:50243930	SLC38A3	-0.34	-8.16	-0.31	1.73e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg05347473	chr6:146136440	FBXO30	-0.42	-8.4	-0.32	2.9e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg19847866	chr10:1019161	NA	0.51	10.43	0.38	1.3e-23	Response to angiotensin II receptor blocker therapy;
BRCA	trans	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.38	8.49	0.32	1.41e-16	Corneal astigmatism;
BRCA	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg08807101	chr21:30365312	RNF160	0.45	9.62	0.36	1.5e-20	Pancreatic cancer;
BRCA	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg03923535	chr7:1197113	ZFAND2A	0.5	10.06	0.37	3.5e-22	Longevity;Endometriosis;
BRCA	cis	rs17092148	1.000	rs2425003	chr20:33403584	G/T	cg16810054	chr20:33298113	TP53INP2	0.47	10.9	0.4	1.75e-25	Neuroticism;
BRCA	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.87	0.56	4.51e-53	Hypertriglyceridemia;
BRCA	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.63	0.61	1.63e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	9.19	0.34	5.41e-19	Mean platelet volume;
BRCA	cis	rs72772090	0.539	rs10515248	chr5:96112005	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.08	-0.43	2.05e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.81	0.39	3.79e-25	Bipolar disorder;
BRCA	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg12463550	chr7:65579703	CRCP	-0.36	-7.92	-0.3	1.06e-14	Aortic root size;
BRCA	trans	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg25517755	chr10:38738941	LOC399744	-0.37	-7.86	-0.3	1.66e-14	Corneal astigmatism;
BRCA	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg19336497	chr11:14380999	RRAS2	0.44	11.65	0.42	1.48e-28	Vitamin D levels;
BRCA	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-12.99	-0.46	2.17e-34	Gut microbiome composition (summer);
BRCA	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg12016809	chr21:47604291	C21orf56	0.41	8.49	0.32	1.44e-16	Testicular germ cell tumor;
BRCA	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18876405	chr7:65276391	NA	0.55	13.15	0.46	3.95e-35	Aortic root size;
BRCA	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg12463550	chr7:65579703	CRCP	-0.37	-7.88	-0.3	1.37e-14	Aortic root size;
BRCA	cis	rs7766436	0.614	rs12660580	chr6:22564428	C/G	cg13666174	chr6:22585274	NA	-0.41	-8.66	-0.32	3.86e-17	Coronary artery disease;
BRCA	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.15	-48.94	-0.89	2.43e-218	Myeloid white cell count;
BRCA	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg14582100	chr15:45693742	SPATA5L1	0.37	12.11	0.43	1.48e-30	Homoarginine levels;
BRCA	cis	rs3825199	0.515	rs2072593	chr12:93970026	T/C	cg18151635	chr12:93972918	NA	-0.46	-9.16	-0.34	6.91e-19	Height;
BRCA	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg18876405	chr7:65276391	NA	0.54	11.99	0.43	4.95e-30	Calcium levels;
BRCA	trans	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.96	0.3	8.02e-15	Corneal astigmatism;
BRCA	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg12386194	chr3:101231763	SENP7	0.61	12.35	0.44	1.36e-31	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg04450456	chr4:17643702	FAM184B	0.32	9.35	0.35	1.44e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg09537434	chr19:41945824	ATP5SL	-1.0	-23.66	-0.68	2.44e-89	Height;
BRCA	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg11247378	chr22:39784982	NA	-0.64	-15.57	-0.52	1.39e-46	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg03146154	chr1:46216737	IPP	0.45	10.04	0.37	4.15e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08645402	chr16:4508243	NA	0.42	9.32	0.35	1.89e-19	Schizophrenia;
BRCA	cis	rs17253792	0.822	rs75115817	chr14:56069537	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-10.5	-0.38	6.49e-24	Putamen volume;
BRCA	trans	rs629535	0.767	rs72654070	chr8:70079369	G/A	cg21567404	chr3:27674614	NA	-1.01	-21.77	-0.65	5.17e-79	Dupuytren's disease;
BRCA	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg13628971	chr7:2884303	GNA12	0.46	9.2	0.34	4.83e-19	Height;
BRCA	cis	rs4845875	0.626	rs4845882	chr1:11843167	A/G	cg24844545	chr1:11908347	NPPA	0.33	8.22	0.31	1.09e-15	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs1371614	0.610	rs3820822	chr2:27155862	G/A	cg00617064	chr2:27272375	NA	0.31	7.82	0.3	2.15e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs367943	0.799	rs10057321	chr5:112974729	A/G	cg12552261	chr5:112820674	MCC	0.5	9.9	0.36	1.3e-21	Type 2 diabetes;
BRCA	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-10.76	-0.39	6.03e-25	IgG glycosylation;
BRCA	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg16586182	chr3:47516702	SCAP	-0.51	-10.85	-0.39	2.76e-25	Colorectal cancer;
BRCA	trans	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.17	0.31	1.61e-15	Corneal astigmatism;
BRCA	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg20848291	chr7:100343083	ZAN	0.37	8.36	0.31	4.02e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs7116495	0.529	rs575871	chr11:71778822	A/G	cg10381502	chr11:71823885	C11orf51	-0.76	-8.93	-0.33	4.62e-18	Severe influenza A (H1N1) infection;
BRCA	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg19508488	chr2:152266495	RIF1	0.53	10.98	0.4	8.3e-26	Lung cancer;
BRCA	cis	rs9790314	0.613	rs6809177	chr3:160630477	G/T	cg03342759	chr3:160939853	NMD3	0.43	8.66	0.32	3.78e-17	Morning vs. evening chronotype;
BRCA	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11644478	chr21:40555479	PSMG1	0.76	15.58	0.52	1.28e-46	Cognitive function;
BRCA	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.69	-0.36	8.1e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7903847	0.642	rs11812223	chr10:99158455	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.78	-0.33	1.47e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg06784218	chr1:46089804	CCDC17	-0.45	-10.84	-0.39	2.92e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.21	-0.56	7.74e-55	Intelligence (multi-trait analysis);
BRCA	cis	rs7572733	0.534	rs1464211	chr2:198798630	G/A	cg00792783	chr2:198669748	PLCL1	0.45	9.93	0.37	1.02e-21	Dermatomyositis;
BRCA	cis	rs11025559	0.812	rs10833336	chr11:20514288	C/G	cg19653624	chr11:20408972	PRMT3	-0.41	-9.67	-0.36	9.89e-21	Pursuit maintenance gain;
BRCA	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg16339924	chr4:17578868	LAP3	-0.57	-13.46	-0.47	1.49e-36	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12612619	0.732	rs1053609	chr2:27293150	G/T	cg00617064	chr2:27272375	NA	-0.33	-8.61	-0.32	5.5e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg01689657	chr7:91764605	CYP51A1	0.25	8.65	0.32	4.11e-17	Breast cancer;
BRCA	trans	rs1459104	1.000	rs12797013	chr11:55318288	T/G	cg15704280	chr7:45808275	SEPT13	0.63	7.91	0.3	1.13e-14	Body mass index;
BRCA	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.21	-0.34	4.63e-19	Bipolar disorder;
BRCA	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg06212747	chr3:49208901	KLHDC8B	0.53	8.17	0.31	1.65e-15	Menarche (age at onset);
BRCA	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg07148914	chr20:33460835	GGT7	-0.43	-8.83	-0.33	1.01e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg13334819	chr7:99746414	C7orf59	0.37	9.1	0.34	1.12e-18	Coronary artery disease;
BRCA	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg27478167	chr7:817139	HEATR2	0.52	10.16	0.37	1.4e-22	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7191700	0.712	rs7187741	chr16:11433103	C/G	cg00044050	chr16:11439710	C16orf75	-0.4	-9.84	-0.36	2.25e-21	Multiple sclerosis;
BRCA	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg01877450	chr7:97915802	BRI3	-0.37	-8.57	-0.32	7.96e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.43	-0.44	6.2e-32	Chronic sinus infection;
BRCA	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.76	16.77	0.55	1.41e-52	Lymphocyte counts;
BRCA	cis	rs9359856	0.564	rs17584108	chr6:90458209	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.7	-8.44	-0.32	2.16e-16	Bipolar disorder;
BRCA	cis	rs367943	0.698	rs6594746	chr5:112995895	A/C	cg12552261	chr5:112820674	MCC	-0.4	-9.02	-0.34	2.21e-18	Type 2 diabetes;
BRCA	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-12.9	-0.45	5.47e-34	Morning vs. evening chronotype;
BRCA	cis	rs4280164	0.945	rs11158632	chr14:24769663	A/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.46	-7.81	-0.3	2.38e-14	Parent of origin effect on language impairment (paternal);
BRCA	cis	rs7561273	0.609	rs10189243	chr2:24293756	C/T	cg04809136	chr2:24300158	SF3B14	-0.4	-9.24	-0.34	3.57e-19	Quantitative traits;
BRCA	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.79	0.51	8.75e-43	Colorectal cancer;
BRCA	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.45	-9.25	-0.34	3.29e-19	Body mass index;
BRCA	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg09307838	chr4:120376055	NA	0.6	11.03	0.4	5.04e-26	Corneal astigmatism;
BRCA	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.43	-0.32	2.28e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26314531	chr2:26401878	FAM59B	-0.69	-11.56	-0.42	3.21e-28	Gut microbiome composition (summer);
BRCA	cis	rs11716531	0.504	rs648103	chr3:27550301	T/C	cg02860705	chr3:27208620	NA	-0.41	-8.3	-0.31	5.99e-16	Diastolic blood pressure;
BRCA	cis	rs9816226	0.793	rs869400	chr3:185826740	T/G	cg00760338	chr3:185826511	ETV5	0.55	9.2	0.34	5e-19	Obesity;Body mass index;
BRCA	trans	rs75804782	0.641	rs41264155	chr2:239342096	G/A	cg01134436	chr17:81009848	B3GNTL1	0.79	9.77	0.36	4.09e-21	Morning vs. evening chronotype;Chronotype;
BRCA	trans	rs75804782	0.630	rs75921156	chr2:239279633	C/T	cg01134436	chr17:81009848	B3GNTL1	0.76	8.01	0.3	5.58e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.09e-15	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.56	-0.32	8.14e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.43	8.26	0.31	8.1e-16	Resistin levels;
BRCA	cis	rs12618769	0.597	rs1587835	chr2:99041269	A/C	cg10123293	chr2:99228465	UNC50	0.41	8.14	0.31	2.05e-15	Bipolar disorder;
BRCA	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg24558204	chr6:135376177	HBS1L	-0.51	-13.8	-0.48	4.02e-38	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.1	31.43	0.78	8.72e-132	Cognitive ability;
BRCA	cis	rs2742417	0.603	rs2253979	chr3:45773320	A/G	cg04837898	chr3:45731254	SACM1L	-0.38	-7.86	-0.3	1.59e-14	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg05340658	chr4:99064831	C4orf37	0.56	10.8	0.39	4.33e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3862030	0.720	rs7081467	chr10:104231662	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.14	-0.43	1.11e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg12573674	chr2:1569213	NA	-0.58	-13.0	-0.46	1.87e-34	IgG glycosylation;
BRCA	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.22	0.56	7.24e-55	Bladder cancer;
BRCA	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg05340658	chr4:99064831	C4orf37	0.45	10.14	0.37	1.6400000000000001e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-11.13	-0.4	1.98e-26	Bone mineral density;
BRCA	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.01	0.3	5.45e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg18132916	chr6:79620363	NA	-0.46	-10.35	-0.38	2.5e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg27489772	chr12:121021490	NA	-0.43	-7.94	-0.3	9.1e-15	Type 1 diabetes nephropathy;
BRCA	cis	rs6834538	0.862	rs7659503	chr4:113425304	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	-0.36	-8.34	-0.31	4.51e-16	Free thyroxine concentration;
BRCA	trans	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg26043149	chr18:55253948	FECH	0.43	9.29	0.34	2.32e-19	Bone mineral density;
BRCA	cis	rs9837602	1.000	rs7610486	chr3:99732564	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.17	0.4	1.35e-26	Breast cancer;
BRCA	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	13.92	0.48	1.2e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg18016565	chr1:150552671	MCL1	0.36	8.19	0.31	1.43e-15	Melanoma;
BRCA	cis	rs701145	0.537	rs449361	chr3:153922410	T/C	cg17054900	chr3:154042577	DHX36	0.57	9.59	0.35	1.96e-20	Coronary artery disease;
BRCA	cis	rs17401966	0.540	rs6682868	chr1:10454773	C/T	cg03954927	chr1:10346856	KIF1B	-0.33	-10.14	-0.37	1.73e-22	Hepatocellular carcinoma;
BRCA	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-10.38	-0.38	2.04e-23	Colorectal cancer;
BRCA	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	12.37	0.44	1.22e-31	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg06671706	chr8:8559999	CLDN23	0.45	8.54	0.32	9.48e-17	Obesity-related traits;
BRCA	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg03585969	chr10:35415529	CREM	0.56	11.51	0.41	5.36e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg13010199	chr12:38710504	ALG10B	0.43	9.2	0.34	5.11e-19	Morning vs. evening chronotype;
BRCA	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg24692254	chr21:30365293	RNF160	-0.68	-18.85	-0.6	2.26e-63	Dental caries;
BRCA	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	16.73	0.55	2.15e-52	Platelet count;
BRCA	cis	rs698813	0.674	rs11678787	chr2:44496315	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	8.21	0.31	1.2e-15	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-8.9	-0.33	5.59e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg26373071	chr5:1325741	CLPTM1L	0.49	11.5	0.41	6.25e-28	Lung cancer;
BRCA	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	10.08	0.37	2.77e-22	Bipolar disorder;
BRCA	cis	rs13082711	0.595	rs17681498	chr3:27331258	T/C	cg02860705	chr3:27208620	NA	0.75	14.0	0.48	4.94e-39	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg06115741	chr20:33292138	TP53INP2	0.39	8.67	0.32	3.67e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg09436375	chr6:42928200	GNMT	-0.3	-11.04	-0.4	4.56e-26	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg23033748	chr14:75592666	NEK9	-0.38	-9.15	-0.34	7.77e-19	Height;
BRCA	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg12365402	chr11:9010492	NRIP3	0.35	7.95	0.3	8.31e-15	Hemoglobin concentration;
BRCA	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.24	0.34	3.54e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1113500	0.787	rs4571989	chr1:108631344	G/A	cg06207961	chr1:108661230	NA	0.36	8.83	0.33	1e-17	Growth-regulated protein alpha levels;
BRCA	trans	rs3960554	0.808	rs9801125	chr7:75792451	C/T	cg19862616	chr7:65841803	NCRNA00174	0.59	11.95	0.43	7.33e-30	Eotaxin levels;
BRCA	cis	rs17228212	1.000	rs35738694	chr15:67454235	C/G	cg26876701	chr15:67458665	SMAD3	-0.47	-9.18	-0.34	5.81e-19	Coronary heart disease;
BRCA	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg10932868	chr11:921992	NA	0.49	12.38	0.44	1.09e-31	Alzheimer's disease (late onset);
BRCA	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg10862848	chr6:42927986	GNMT	-0.35	-14.46	-0.5	3.2e-41	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg01028140	chr2:1542097	TPO	-0.58	-12.18	-0.43	8e-31	IgG glycosylation;
BRCA	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg23260525	chr10:116636907	FAM160B1	0.3	7.94	0.3	9.17e-15	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg16339924	chr4:17578868	LAP3	-0.71	-16.42	-0.54	8.69e-51	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs738321	0.757	rs4821748	chr22:38541936	G/A	cg20207973	chr22:38506712	BAIAP2L2	0.38	9.23	0.34	3.81e-19	Breast cancer;
BRCA	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11764359	chr7:65958608	NA	0.75	16.57	0.55	1.37e-51	Aortic root size;
BRCA	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.4	8.34	0.31	4.42e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg25036284	chr2:26402008	FAM59B	-0.63	-10.64	-0.39	1.93e-24	Gut microbiome composition (summer);
BRCA	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-11.21	-0.41	9.84e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2387326	0.671	rs10829346	chr10:129946104	C/T	cg16087940	chr10:129947807	NA	-0.46	-8.23	-0.31	1.05e-15	Select biomarker traits;
BRCA	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg11502198	chr6:26597334	ABT1	0.47	9.48	0.35	4.75e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg13628971	chr7:2884303	GNA12	0.38	8.52	0.32	1.18e-16	Height;
BRCA	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21385522	chr1:16154831	NA	-0.62	-11.61	-0.42	2.14e-28	Dilated cardiomyopathy;
BRCA	cis	rs4808199	0.895	rs2285628	chr19:19467996	T/A	cg03709012	chr19:19516395	GATAD2A	0.91	16.66	0.55	4.81e-52	Nonalcoholic fatty liver disease;
BRCA	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-16.88	-0.56	4.06e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7818345	0.967	rs4554480	chr8:19284072	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.22	0.31	1.12e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg22875332	chr1:76189707	ACADM	0.64	11.42	0.41	1.32e-27	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4561483	0.799	rs33635	chr16:11991944	C/T	cg08843971	chr16:11963173	GSPT1	-0.44	-9.21	-0.34	4.76e-19	Testicular germ cell tumor;
BRCA	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg09307838	chr4:120376055	NA	0.65	14.19	0.49	6.52e-40	Corneal astigmatism;
BRCA	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg13319975	chr6:146136371	FBXO30	0.45	10.38	0.38	1.98e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg06917634	chr15:78832804	PSMA4	-0.56	-11.9	-0.43	1.27e-29	Sudden cardiac arrest;
BRCA	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg26893861	chr17:41843967	DUSP3	0.78	13.72	0.48	9.49e-38	Triglycerides;
BRCA	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg21699342	chr2:239360505	ASB1	0.53	14.02	0.49	3.75e-39	Multiple system atrophy;
BRCA	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg18252515	chr7:66147081	NA	-0.82	-11.87	-0.42	1.69e-29	Diabetic kidney disease;
BRCA	cis	rs1941023	0.584	rs10897057	chr11:60172273	A/T	cg08716584	chr11:60157161	MS4A7	-0.42	-9.73	-0.36	5.75e-21	Congenital heart disease (maternal effect);
BRCA	trans	rs10411161	0.702	rs10423835	chr19:52387322	A/G	cg22319618	chr22:45562946	NUP50	-0.43	-8.01	-0.3	5.43e-15	Breast cancer;
BRCA	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.42	-0.32	2.48e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg03585969	chr10:35415529	CREM	0.56	11.58	0.42	2.9e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7254114	0.578	rs3745682	chr19:11313256	C/T	cg06870470	chr19:11315767	DOCK6	-0.36	-8.1	-0.31	2.85e-15	Immature fraction of reticulocytes;
BRCA	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg18402987	chr7:1209562	NA	0.85	12.22	0.44	5.38e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg08601574	chr20:25228251	PYGB	0.36	8.45	0.32	2.03e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg22467129	chr15:76604101	ETFA	-0.4	-8.98	-0.33	3.05e-18	Blood metabolite levels;
BRCA	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	19.86	0.62	9.76e-69	Smoking behavior;
BRCA	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg07952391	chr2:88470173	THNSL2	0.68	9.27	0.34	2.76e-19	Plasma clusterin levels;
BRCA	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg26384229	chr12:38710491	ALG10B	0.69	16.42	0.54	8.54e-51	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6121246	0.559	rs6060621	chr20:30261562	G/C	cg13852791	chr20:30311386	BCL2L1	0.95	23.01	0.67	8.32e-86	Mean corpuscular hemoglobin;
BRCA	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg15704280	chr7:45808275	SEPT13	-0.82	-20.37	-0.63	1.84e-71	Coronary artery disease;
BRCA	cis	rs17164103	0.505	rs10500136	chr7:143014244	C/T	cg15652212	chr7:142981776	TMEM139	-0.7	-13.9	-0.48	1.49e-38	Cancer;
BRCA	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	12.95	0.46	3.33e-34	Bipolar disorder;
BRCA	cis	rs12541635	0.677	rs12546875	chr8:107012915	C/T	cg10147462	chr8:107024639	NA	0.39	10.61	0.39	2.5e-24	Age of smoking initiation;
BRCA	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	11.6	0.42	2.37e-28	Personality dimensions;
BRCA	cis	rs4363385	0.747	rs4845334	chr1:152982998	T/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.36	-0.31	3.99e-16	Inflammatory skin disease;
BRCA	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-9.73	-0.36	5.87e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs858239	0.601	rs2141307	chr7:23191424	G/C	cg23682824	chr7:23144976	KLHL7	0.37	9.7	0.36	7.62e-21	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08045932	chr20:61659980	NA	0.5	11.54	0.42	4.11e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg08847533	chr14:75593920	NEK9	-0.86	-21.96	-0.66	4.46e-80	Height;
BRCA	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.83	-0.36	2.48e-21	Schizophrenia;
BRCA	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg27446573	chr6:127587934	RNF146	0.86	20.0	0.62	1.76e-69	Breast cancer;
BRCA	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.25	8.05	0.3	3.98e-15	Parkinson's disease;
BRCA	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg22535103	chr8:58192502	C8orf71	-0.46	-8.16	-0.31	1.74e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg04166393	chr7:2884313	GNA12	0.41	8.42	0.32	2.44e-16	Height;
BRCA	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.76	12.67	0.45	5.84e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg12193833	chr17:30244370	NA	-0.6	-9.02	-0.34	2.17e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg03146154	chr1:46216737	IPP	0.53	11.75	0.42	5.61e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1050631	0.592	rs1010955	chr18:33710610	T/C	cg19453250	chr18:33710783	SLC39A6;ELP2	-0.29	-7.9	-0.3	1.19e-14	Esophageal squamous cell cancer (length of survival);
BRCA	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg02734326	chr4:10020555	SLC2A9	0.39	8.34	0.31	4.75e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18876405	chr7:65276391	NA	-0.69	-17.9	-0.58	2.12e-58	Aortic root size;
BRCA	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg15485101	chr11:133734466	NA	0.41	9.96	0.37	8.41e-22	Childhood ear infection;
BRCA	cis	rs7737355	0.947	rs3776005	chr5:130879003	T/C	cg06307176	chr5:131281290	NA	0.53	11.11	0.4	2.37e-26	Life satisfaction;
BRCA	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg21609526	chr1:3105151	PRDM16	-0.37	-8.93	-0.33	4.46e-18	Migraine;
BRCA	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg15997130	chr1:24165203	NA	0.49	12.94	0.46	3.38e-34	Immature fraction of reticulocytes;
BRCA	cis	rs7833986	1.000	rs34516759	chr8:57097138	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.46	8.22	0.31	1.14e-15	Height;
BRCA	cis	rs6450176	0.909	rs3776720	chr5:53296158	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-14.41	-0.5	5.71e-41	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg13256891	chr4:100009986	ADH5	0.4	8.34	0.31	4.42e-16	Alcohol dependence;
BRCA	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	10.07	0.37	3.07e-22	Lymphocyte counts;
BRCA	cis	rs1344694	0.548	rs12468812	chr2:216905867	C/T	cg25588852	chr2:216877276	MREG	-0.29	-8.09	-0.3	2.98e-15	Alcohol dependence;
BRCA	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg23719950	chr11:63933701	MACROD1	-0.59	-10.07	-0.37	3.18e-22	Mean platelet volume;
BRCA	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg22713356	chr15:30763199	NA	1.3	24.75	0.7	2.51e-95	Uric acid levels;
BRCA	cis	rs11229555	0.609	rs12270515	chr11:58217945	G/A	cg15696309	chr11:58395628	NA	-0.44	-9.47	-0.35	5.21e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg13010199	chr12:38710504	ALG10B	0.43	9.22	0.34	4.33e-19	Morning vs. evening chronotype;
BRCA	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.47	8.36	0.31	4.07e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.35	-9.15	-0.34	7.27e-19	Total body bone mineral density;
BRCA	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-9.55	-0.35	2.72e-20	Monocyte percentage of white cells;
BRCA	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.9e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg06494592	chr3:125709126	NA	-0.53	-8.2	-0.31	1.32e-15	Blood pressure (smoking interaction);
BRCA	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.35e-15	Prostate cancer;
BRCA	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08109568	chr15:31115862	NA	0.42	10.22	0.37	8.26e-23	Huntington's disease progression;
BRCA	cis	rs17095355	1.000	rs12570820	chr10:111732507	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.84	-0.36	2.27e-21	Biliary atresia;
BRCA	cis	rs6460942	0.597	rs12699381	chr7:12527026	G/A	cg06484146	chr7:12443880	VWDE	-0.6	-7.85	-0.3	1.8e-14	Coronary artery disease;
BRCA	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg14458575	chr2:238380390	NA	0.72	15.55	0.52	1.86e-46	Prostate cancer;
BRCA	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg12444411	chr7:2802554	GNA12	0.34	8.64	0.32	4.41e-17	Height;
BRCA	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11890956	chr21:40555474	PSMG1	-1.03	-28.62	-0.75	1.41e-116	Cognitive function;
BRCA	cis	rs4280164	0.945	rs2281472	chr14:24775846	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	0.47	9.08	0.34	1.3e-18	Parent of origin effect on language impairment (paternal);
BRCA	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg11584989	chr19:19387371	SF4	0.62	13.0	0.46	1.89e-34	Bipolar disorder;
BRCA	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg15412446	chr2:106886593	NA	-0.5	-9.18	-0.34	5.69e-19	Facial morphology (factor 23);
BRCA	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg24060327	chr5:131705240	SLC22A5	-0.48	-10.02	-0.37	4.79e-22	Blood metabolite levels;
BRCA	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.13	0.46	5.01e-35	Electroencephalogram traits;
BRCA	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-16.65	-0.55	5.68e-52	Colorectal cancer;
BRCA	trans	rs9951602	0.512	rs8089108	chr18:76651361	C/T	cg02800362	chr5:177631904	HNRNPAB	0.77	18.01	0.58	5.8e-59	Obesity-related traits;
BRCA	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg21252483	chr19:49399788	TULP2	-0.4	-9.06	-0.34	1.52e-18	Red cell distribution width;
BRCA	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg17366294	chr4:99064904	C4orf37	0.41	9.22	0.34	4.31e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs897080	0.515	rs698818	chr2:44709769	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	9.22	0.34	4.11e-19	Height;
BRCA	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg04362960	chr10:104952993	NT5C2	0.52	10.91	0.4	1.51e-25	Arsenic metabolism;
BRCA	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05903289	chr2:130345205	NA	-0.34	-8.5	-0.32	1.3e-16	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.44	0.55	6.47e-51	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs2652822	0.525	rs58789072	chr15:63497553	G/A	cg02713581	chr15:63449717	RPS27L	0.41	8.26	0.31	8.09e-16	Metabolic traits;
BRCA	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg07645718	chr20:61493192	TCFL5	-0.59	-8.09	-0.3	3.03e-15	Obesity-related traits;
BRCA	cis	rs4423214	0.840	rs1792231	chr11:71182681	G/A	cg05163923	chr11:71159392	DHCR7	-0.56	-11.3	-0.41	4.03e-27	Vitamin D levels;
BRCA	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg27170947	chr2:26402098	FAM59B	-0.7	-11.79	-0.42	3.45e-29	Gut microbiome composition (summer);
BRCA	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg05279229	chr7:1896384	MAD1L1	-0.41	-7.81	-0.3	2.32e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg05347473	chr6:146136440	FBXO30	-0.46	-9.22	-0.34	4.21e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg06046430	chr4:77819534	ANKRD56	0.58	12.97	0.46	2.53e-34	Emphysema distribution in smoking;
BRCA	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg20476274	chr7:133979776	SLC35B4	0.58	14.41	0.5	5.64e-41	Mean platelet volume;
BRCA	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg25801113	chr15:45476975	SHF	0.31	7.84	0.3	1.93e-14	Uric acid levels;
BRCA	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.38	-0.31	3.25e-16	Aortic root size;
BRCA	cis	rs2880765	0.743	rs8039049	chr15:86007629	A/G	cg10818794	chr15:86012489	AKAP13	-0.31	-8.37	-0.31	3.57e-16	Coronary artery disease;
BRCA	cis	rs17401966	0.838	rs4846197	chr1:10282166	G/A	cg03954927	chr1:10346856	KIF1B	0.43	13.75	0.48	7.29e-38	Hepatocellular carcinoma;
BRCA	cis	rs2425143	1.000	rs78421482	chr20:34376486	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.17	-0.34	6.32e-19	Blood protein levels;
BRCA	cis	rs4363385	0.818	rs61811863	chr1:152995721	T/C	cg24667326	chr1:152973720	SPRR3	-0.32	-8.7	-0.33	2.7e-17	Inflammatory skin disease;
BRCA	cis	rs6750047	0.719	rs336035	chr2:38261467	A/G	cg07380506	chr2:38303506	CYP1B1	-0.47	-10.68	-0.39	1.32e-24	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg06784218	chr1:46089804	CCDC17	0.52	12.41	0.44	8.07e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	11.72	0.42	7.45e-29	Schizophrenia;
BRCA	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	11.88	0.43	1.5e-29	Tonsillectomy;
BRCA	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg16576597	chr16:28551801	NUPR1	0.3	8.42	0.32	2.52e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg00071950	chr4:10020882	SLC2A9	0.52	12.84	0.45	9.58e-34	Bone mineral density;
BRCA	cis	rs6834538	1.000	rs1486864	chr4:113465766	G/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.39	8.98	0.33	3.13e-18	Free thyroxine concentration;
BRCA	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg08847533	chr14:75593920	NEK9	0.81	19.0	0.6	3.87e-64	Height;
BRCA	cis	rs9309711	0.770	rs13409323	chr2:3488184	C/T	cg16153549	chr2:3496821	NA	-0.4	-9.12	-0.34	1e-18	Neurofibrillary tangles;
BRCA	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg00701064	chr4:6280414	WFS1	0.67	17.2	0.56	8.78e-55	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg10223061	chr2:219282414	VIL1	-0.27	-7.89	-0.3	1.36e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg07636037	chr3:49044803	WDR6	0.42	8.65	0.32	4.2e-17	Resting heart rate;
BRCA	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg05665937	chr4:1216051	CTBP1	0.44	8.76	0.33	1.78e-17	Obesity-related traits;
BRCA	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg07460842	chr6:66804631	NA	0.77	13.99	0.48	5.51e-39	Exhaled nitric oxide levels;
BRCA	cis	rs7737355	0.947	rs12659474	chr5:130801304	T/C	cg06307176	chr5:131281290	NA	-0.53	-10.47	-0.38	8.48e-24	Life satisfaction;
BRCA	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs10267417	0.603	rs10267511	chr7:19896924	A/G	cg05791153	chr7:19748676	TWISTNB	0.47	9.05	0.34	1.73e-18	Night sleep phenotypes;
BRCA	cis	rs17641971	0.708	rs1511363	chr8:49901023	C/T	cg00325661	chr8:49890786	NA	0.36	9.83	0.36	2.4e-21	Blood metabolite levels;
BRCA	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg08859206	chr1:53392774	SCP2	-0.48	-10.65	-0.39	1.77e-24	Monocyte count;
BRCA	cis	rs1891275	0.515	rs2153653	chr10:93495926	T/A	cg07889827	chr10:93443413	NA	-0.4	-10.8	-0.39	4.34e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs526821	0.595	rs2926309	chr11:55314219	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-8.11	-0.31	2.54e-15	Pediatric bone mineral density (spine);
BRCA	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg02196655	chr2:10830764	NOL10	-0.3	-8.06	-0.3	3.81e-15	Prostate cancer;
BRCA	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12379764	chr21:47803548	PCNT	-0.4	-8.72	-0.33	2.45e-17	Testicular germ cell tumor;
BRCA	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg17425144	chr1:10567563	PEX14	0.63	16.75	0.55	1.73e-52	Breast size;
BRCA	cis	rs27434	0.583	rs193482	chr5:96157846	A/G	cg16492584	chr5:96139282	ERAP1	-0.5	-12.76	-0.45	2.31e-33	Ankylosing spondylitis;
BRCA	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.27	0.34	2.84e-19	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-9.46	-0.35	5.8e-20	Aortic root size;
BRCA	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	12.3	0.44	2.29e-31	Multiple sclerosis;
BRCA	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg20607798	chr8:58055168	NA	0.47	8.11	0.31	2.6e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg13906792	chr15:75199810	C15orf17	-0.4	-9.48	-0.35	4.77e-20	Breast cancer;
BRCA	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg01483505	chr11:975446	AP2A2	0.33	9.01	0.34	2.38e-18	Alzheimer's disease (late onset);
BRCA	cis	rs2742234	0.541	rs61268333	chr10:43721370	G/A	cg15436174	chr10:43711423	RASGEF1A	0.53	10.6	0.39	2.8e-24	Hirschsprung disease;
BRCA	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg14582100	chr15:45693742	SPATA5L1	0.36	11.68	0.42	1.1e-28	Homoarginine levels;
BRCA	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg05793240	chr7:2802953	GNA12	-0.32	-8.25	-0.31	9.33e-16	Height;
BRCA	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.42	0.38	1.34e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs56399783	0.614	rs55776032	chr7:2762255	T/C	cg23627948	chr7:2760692	NA	0.54	8.72	0.33	2.34e-17	Childhood ear infection;
BRCA	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg00071950	chr4:10020882	SLC2A9	-0.43	-10.08	-0.37	2.91e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg06521331	chr12:34319734	NA	-0.49	-8.88	-0.33	6.67e-18	Bladder cancer;
BRCA	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg24296786	chr1:45957014	TESK2	0.45	9.52	0.35	3.51e-20	Homocysteine levels;
BRCA	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-8.61	-0.32	5.66e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2070997	0.607	rs72765060	chr9:133712404	T/C	cg11464064	chr9:133710261	ABL1	0.56	10.1	0.37	2.44e-22	Response to amphetamines;
BRCA	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg13010199	chr12:38710504	ALG10B	0.51	9.8	0.36	3.24e-21	Bladder cancer;
BRCA	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg10495392	chr1:46806563	NSUN4	0.44	8.11	0.31	2.59e-15	Menopause (age at onset);
BRCA	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg08085267	chr17:45401833	C17orf57	-0.62	-13.37	-0.47	4.19e-36	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1018836	0.923	rs4735256	chr8:91612145	C/G	cg16814680	chr8:91681699	NA	-0.59	-12.55	-0.44	1.91e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	trans	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg06521331	chr12:34319734	NA	-0.5	-9.29	-0.34	2.35e-19	Bladder cancer;
BRCA	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.64	-14.26	-0.49	2.8e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg02574844	chr11:5959923	NA	0.41	8.01	0.3	5.32e-15	DNA methylation (variation);
BRCA	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.43	-9.19	-0.34	5.58e-19	Longevity;Endometriosis;
BRCA	cis	rs2625529	0.824	rs4777475	chr15:72218206	C/T	cg16672083	chr15:72433130	SENP8	-0.83	-17.37	-0.57	1.16e-55	Red blood cell count;
BRCA	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg07211511	chr3:129823064	LOC729375	-0.58	-10.46	-0.38	9.92e-24	Blood pressure (smoking interaction);
BRCA	trans	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg25214090	chr10:38739885	LOC399744	0.55	12.37	0.44	1.2e-31	Corneal astigmatism;
BRCA	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg09754948	chr16:28834200	ATXN2L	0.46	9.13	0.34	9.04e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs8073060	0.544	rs225249	chr17:33942540	T/C	cg19694781	chr19:47549865	TMEM160	-1.04	-21.68	-0.65	1.59e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg02753203	chr1:228287806	NA	-0.58	-12.36	-0.44	1.24e-31	Diastolic blood pressure;
BRCA	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg17509989	chr5:176798049	RGS14	-0.73	-11.7	-0.42	8.8e-29	Urate levels in lean individuals;
BRCA	cis	rs12210905	0.688	rs12212348	chr6:27361242	T/C	cg08851530	chr6:28072375	NA	0.84	8.3	0.31	6.28e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg19622623	chr12:86230825	RASSF9	-0.33	-9.27	-0.34	2.83e-19	Major depressive disorder;
BRCA	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg10523679	chr1:76189770	ACADM	-0.47	-9.19	-0.34	5.31e-19	Daytime sleep phenotypes;
BRCA	cis	rs600231	0.577	rs35826299	chr11:65240964	T/C	cg01292856	chr11:65242576	NA	0.65	14.83	0.51	5.53e-43	Bone mineral density;
BRCA	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg02403541	chr12:121454288	C12orf43	0.63	11.94	0.43	8.23e-30	N-glycan levels;
BRCA	cis	rs1018836	0.892	rs10103198	chr8:91579436	A/T	cg16814680	chr8:91681699	NA	-0.46	-9.79	-0.36	3.6e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs870825	0.655	rs28661636	chr4:185634218	A/C	cg04058563	chr4:185651563	MLF1IP	0.77	17.4	0.57	8.32e-56	Blood protein levels;
BRCA	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg26031613	chr14:104095156	KLC1	0.7	15.04	0.51	5.51e-44	Body mass index;
BRCA	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.77e-18	Motion sickness;
BRCA	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg11812906	chr14:75593930	NEK9	-0.63	-14.62	-0.5	5.46e-42	Height;
BRCA	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-9.73	-0.36	6.09e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs7178424	1.000	rs4775457	chr15:62374915	T/C	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.3	-0.31	6.42e-16	Height;
BRCA	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02018176	chr4:1364513	KIAA1530	-0.41	-8.38	-0.31	3.41e-16	Longevity;
BRCA	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg03929089	chr4:120376271	NA	-0.69	-13.63	-0.47	2.6e-37	Coronary artery disease;
BRCA	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg15839431	chr19:19639596	YJEFN3	0.41	8.97	0.33	3.34e-18	Bipolar disorder;
BRCA	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg25019033	chr10:957182	NA	-0.42	-8.86	-0.33	7.61e-18	Eosinophil percentage of granulocytes;
BRCA	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03517284	chr6:25882590	NA	-0.53	-12.55	-0.44	1.87e-32	Blood metabolite levels;
BRCA	cis	rs3815700	1.000	rs10406750	chr19:33097144	C/T	cg02997394	chr19:33096574	ANKRD27	0.69	11.69	0.42	9.23e-29	Eosinophilic esophagitis;
BRCA	cis	rs11971779	0.680	rs6960876	chr7:139112176	C/T	cg07862535	chr7:139043722	LUC7L2	-0.4	-10.93	-0.4	1.27e-25	Diisocyanate-induced asthma;
BRCA	cis	rs7246657	0.598	rs10417545	chr19:37654263	C/G	cg23950597	chr19:37808831	NA	-0.65	-9.98	-0.37	6.76e-22	Coronary artery calcification;
BRCA	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg25173405	chr17:45401733	C17orf57	0.52	10.74	0.39	7.4e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs758324	0.947	rs4705835	chr5:131116899	T/C	cg06307176	chr5:131281290	NA	0.53	10.27	0.38	5.48e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg03146154	chr1:46216737	IPP	-0.45	-9.49	-0.35	4.35e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6450176	1.000	rs7707547	chr5:53295737	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-14.39	-0.49	7.26e-41	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg19418458	chr7:158789849	NA	-0.42	-9.43	-0.35	7.42e-20	Facial morphology (factor 20);
BRCA	cis	rs10465746	0.570	rs11163886	chr1:84473445	C/A	cg10977910	chr1:84465055	TTLL7	0.54	11.08	0.4	3.22e-26	Obesity-related traits;
BRCA	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.6	-0.36	1.78e-20	Total body bone mineral density;
BRCA	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg06636551	chr8:101224915	SPAG1	0.37	8.49	0.32	1.45e-16	Atrioventricular conduction;
BRCA	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg23950597	chr19:37808831	NA	-0.66	-11.66	-0.42	1.25e-28	Coronary artery calcification;
BRCA	cis	rs9596863	0.950	rs9563183	chr13:54396931	A/C	ch.13.53330881F	chr13:54432880	NA	0.49	8.22	0.31	1.16e-15	Epilepsy and lamotrigine-induced maculopapular eruptions;
BRCA	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg06784218	chr1:46089804	CCDC17	0.51	12.22	0.44	5.44e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg26597838	chr10:835615	NA	1.03	18.39	0.59	6.28e-61	Eosinophil percentage of granulocytes;
BRCA	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg16386425	chr10:429943	DIP2C	-0.39	-7.94	-0.3	9.39e-15	Psychosis in Alzheimer's disease;
BRCA	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg24531977	chr5:56204891	C5orf35	0.51	10.76	0.39	6.37e-25	Coronary artery disease;
BRCA	cis	rs17641971	0.599	rs818555	chr8:49999211	A/G	cg00325661	chr8:49890786	NA	-0.32	-9.04	-0.34	1.87e-18	Blood metabolite levels;
BRCA	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18876405	chr7:65276391	NA	0.54	12.77	0.45	2.1e-33	Aortic root size;
BRCA	cis	rs11051970	0.879	rs950080	chr12:32588503	G/A	cg24626660	chr12:32551988	NA	0.29	8.36	0.31	4e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.05	0.3	3.95e-15	Menarche (age at onset);
BRCA	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg20607287	chr7:12443886	VWDE	-0.54	-8.28	-0.31	7.46e-16	Coronary artery disease;
BRCA	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg24562669	chr7:97807699	LMTK2	0.71	22.11	0.66	7.41e-81	Breast cancer;
BRCA	cis	rs8028182	0.636	rs28610581	chr15:75812474	A/G	cg20655648	chr15:75932815	IMP3	0.41	7.82	0.3	2.13e-14	Sudden cardiac arrest;
BRCA	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.58	-0.61	3.27e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4363385	0.747	rs9919333	chr1:152968744	G/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.42	-0.35	8e-20	Inflammatory skin disease;
BRCA	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02353165	chr6:42928485	GNMT	0.87	23.47	0.68	2.46e-88	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg18479299	chr3:125709523	NA	-0.53	-8.28	-0.31	7.29e-16	Blood pressure (smoking interaction);
BRCA	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08048268	chr3:133502702	NA	0.34	8.61	0.32	5.56e-17	Iron status biomarkers;
BRCA	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-13.65	-0.48	2.11e-37	Hemoglobin concentration;
BRCA	cis	rs3106136	0.546	rs2664880	chr4:95144177	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.07	-0.37	2.97e-22	Capecitabine sensitivity;
BRCA	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg12011299	chr4:100065546	ADH4	0.42	11.11	0.4	2.52e-26	Alcohol dependence;
BRCA	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg23033748	chr14:75592666	NEK9	-0.37	-8.78	-0.33	1.46e-17	Height;
BRCA	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg18016565	chr1:150552671	MCL1	0.36	8.14	0.31	2.02e-15	Melanoma;
BRCA	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.77	-0.55	1.45e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg07988820	chr12:82153109	PPFIA2	-0.6	-9.6	-0.35	1.84e-20	Resting heart rate;
BRCA	trans	rs867371	0.502	rs8025964	chr15:82521770	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.34	-8.97	-0.33	3.38e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	trans	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.12	0.31	2.44e-15	Corneal astigmatism;
BRCA	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg12573674	chr2:1569213	NA	-0.51	-9.48	-0.35	4.98e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.39	0.41	1.73e-27	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg24692254	chr21:30365293	RNF160	-0.52	-11.85	-0.42	1.96e-29	Cognitive test performance;
BRCA	cis	rs1451375	0.794	rs11238133	chr7:50542914	A/C	cg18232548	chr7:50535776	DDC	-0.49	-12.05	-0.43	2.84e-30	Malaria;
BRCA	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.23	-0.34	3.89e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg06784218	chr1:46089804	CCDC17	0.5	12.3	0.44	2.39e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-7.86	-0.3	1.65e-14	Menarche (age at onset);
BRCA	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.47	-0.32	1.7e-16	Monocyte percentage of white cells;
BRCA	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg08805041	chr16:621841	PIGQ	-0.29	-7.87	-0.3	1.47e-14	Height;
BRCA	cis	rs4887140	0.867	rs12899897	chr15:74055191	A/C	cg11789681	chr15:74046708	NA	0.48	8.31	0.31	5.68e-16	Glucose homeostasis traits;
BRCA	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg03929089	chr4:120376271	NA	-0.67	-12.9	-0.45	5.55e-34	Coronary artery disease;
BRCA	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg18016565	chr1:150552671	MCL1	0.35	8.23	0.31	1.08e-15	Tonsillectomy;
BRCA	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18404041	chr3:52824283	ITIH1	-0.4	-12.16	-0.43	9.45e-31	Electroencephalogram traits;
BRCA	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg13770153	chr20:60521292	NA	-0.39	-8.94	-0.33	4.09e-18	Body mass index;
BRCA	cis	rs965469	1.000	rs6037533	chr20:3268817	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-10.23	-0.38	7.7e-23	IFN-related cytopenia;
BRCA	cis	rs12618769	0.597	rs72821951	chr2:99157009	A/C	cg10123293	chr2:99228465	UNC50	0.42	8.39	0.32	3.12e-16	Bipolar disorder;
BRCA	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg21475434	chr5:93447410	FAM172A	0.7	8.69	0.33	3.02e-17	Diabetic retinopathy;
BRCA	cis	rs332507	0.830	rs62265580	chr3:124359842	C/T	cg05980111	chr3:124395277	KALRN	0.36	8.28	0.31	7.09e-16	Plateletcrit;
BRCA	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.4	0.49	6.57e-41	Motion sickness;
BRCA	cis	rs2191566	1.000	rs384544	chr19:44505255	A/T	cg20607764	chr19:44506953	ZNF230	0.49	10.83	0.39	3.22e-25	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs113835537	0.559	rs11227498	chr11:66269714	A/G	cg24851651	chr11:66362959	CCS	0.44	8.27	0.31	7.55e-16	Airway imaging phenotypes;
BRCA	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg23719950	chr11:63933701	MACROD1	-0.59	-9.68	-0.36	9.39e-21	Mean platelet volume;
BRCA	cis	rs7520050	0.931	rs6697557	chr1:46307809	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.9	0.36	1.4e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.49	-0.38	7.35e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg19508488	chr2:152266495	RIF1	0.52	10.65	0.39	1.72e-24	Lung cancer;
BRCA	cis	rs877282	0.945	rs10904554	chr10:786768	T/C	cg17470449	chr10:769945	NA	0.47	8.16	0.31	1.81e-15	Uric acid levels;
BRCA	cis	rs6715284	1.000	rs13398075	chr2:202376269	A/T	cg27024860	chr2:202316456	TRAK2;STRADB	0.67	8.52	0.32	1.14e-16	Rheumatoid arthritis;
BRCA	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg16850897	chr7:100343110	ZAN	-0.6	-12.41	-0.44	7.65e-32	Other erythrocyte phenotypes;
BRCA	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg05340658	chr4:99064831	C4orf37	-0.47	-10.81	-0.39	3.81e-25	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6977660	0.943	rs10274447	chr7:19850640	C/T	cg05791153	chr7:19748676	TWISTNB	0.4	8.23	0.31	1.02e-15	Thyroid stimulating hormone;
BRCA	cis	rs708547	0.957	rs1623306	chr4:57773595	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.46	9.8	0.36	3.31e-21	Response to bleomycin (chromatid breaks);
BRCA	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg21573476	chr21:45109991	RRP1B	0.32	7.97	0.3	7.22e-15	Mean corpuscular volume;
BRCA	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg12160578	chr15:63334699	TPM1	0.41	8.27	0.31	7.75e-16	Platelet count;
BRCA	trans	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg25214090	chr10:38739885	LOC399744	-0.43	-10.13	-0.37	1.82e-22	Corneal astigmatism;
BRCA	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg27147174	chr7:100797783	AP1S1	-0.54	-10.77	-0.39	5.93e-25	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs4853036	0.951	rs7575302	chr2:70055236	T/C	cg02498382	chr2:70120550	SNRNP27	-0.5	-9.21	-0.34	4.49e-19	Colorectal or endometrial cancer;
BRCA	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg05340658	chr4:99064831	C4orf37	0.45	10.35	0.38	2.52e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg12615879	chr12:58013172	SLC26A10	0.34	9.54	0.35	2.98e-20	Multiple sclerosis;
BRCA	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg14675211	chr2:100938903	LONRF2	0.41	9.16	0.34	6.71e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg27279351	chr12:120934652	DYNLL1	0.57	13.32	0.47	7.06e-36	High light scatter reticulocyte count;
BRCA	cis	rs427394	0.632	rs377137	chr5:6740468	T/G	cg10857441	chr5:6722123	POLS	-0.32	-10.17	-0.37	1.32e-22	Menopause (age at onset);
BRCA	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg07080220	chr10:102295463	HIF1AN	0.59	14.06	0.49	2.5e-39	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-9.52	-0.35	3.49e-20	Longevity;Endometriosis;
BRCA	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.91	-28.38	-0.75	2.97e-115	Schizophrenia;
BRCA	cis	rs2191566	0.959	rs7255623	chr19:44510906	G/C	cg20607764	chr19:44506953	ZNF230	-0.44	-9.95	-0.37	8.47e-22	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs12210905	0.688	rs12202956	chr6:27356476	T/C	cg08851530	chr6:28072375	NA	0.84	8.3	0.31	6.28e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	22.17	0.66	3.36e-81	Platelet count;
BRCA	cis	rs10162002	0.872	rs3764067	chr13:24042897	T/C	cg00158254	chr13:24040743	NA	0.55	8.78	0.33	1.48e-17	Hypothyroidism;
BRCA	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg08847533	chr14:75593920	NEK9	-0.46	-9.22	-0.34	4.16e-19	Neuroticism;
BRCA	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.57e-23	Motion sickness;
BRCA	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg13852791	chr20:30311386	BCL2L1	0.85	16.48	0.55	4.17e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg08213375	chr14:104286397	PPP1R13B	0.64	18.21	0.58	5.17e-60	Schizophrenia;
BRCA	cis	rs3857536	0.740	rs7773577	chr6:66892124	G/A	cg07460842	chr6:66804631	NA	-0.46	-8.86	-0.33	8.14e-18	Blood trace element (Cu levels);
BRCA	cis	rs6594713	0.531	rs13362189	chr5:112940706	A/G	cg12552261	chr5:112820674	MCC	0.46	7.88	0.3	1.38e-14	Brain cytoarchitecture;
BRCA	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg03188948	chr7:1209495	NA	0.83	11.33	0.41	2.93e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06108461	chr20:60628389	TAF4	-0.99	-22.25	-0.66	1.19e-81	Body mass index;
BRCA	trans	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	8.92e-15	Corneal astigmatism;
BRCA	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg03929089	chr4:120376271	NA	-0.48	-9.04	-0.34	1.81e-18	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg00277334	chr10:82204260	NA	-0.85	-24.9	-0.7	3.41e-96	Post bronchodilator FEV1;
BRCA	cis	rs1003719	0.641	rs13046844	chr21:38517603	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.44	-0.5	4e-41	Eye color traits;
BRCA	cis	rs2637266	1.000	rs1077916	chr10:78381951	G/A	cg18941641	chr10:78392320	NA	0.35	7.9	0.3	1.21e-14	Pulmonary function;
BRCA	cis	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg09307838	chr4:120376055	NA	0.53	10.47	0.38	8.78e-24	Corneal astigmatism;
BRCA	trans	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg17675199	chr6:35436792	RPL10A	-0.31	-8.24	-0.31	9.94e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.635	rs2838808	chr21:46621106	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.39	8.23	0.31	1.03e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg11833968	chr6:79620685	NA	-0.44	-9.83	-0.36	2.43e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg00631329	chr6:26305371	NA	-0.55	-15.71	-0.53	2.77e-47	Educational attainment;
BRCA	cis	rs17042140	0.904	rs6540844	chr1:214680378	C/T	cg16144317	chr1:214725524	PTPN14	0.34	8.0	0.3	5.94e-15	Plasma thyroid-stimulating hormone levels;
BRCA	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07080220	chr10:102295463	HIF1AN	0.49	11.29	0.41	4.34e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg08807101	chr21:30365312	RNF160	0.77	20.12	0.62	4.19e-70	Dental caries;
BRCA	trans	rs800082	0.690	rs800081	chr3:144339980	C/T	cg24215973	chr2:240111563	HDAC4	0.41	10.11	0.37	2.15e-22	Smoking behavior;
BRCA	cis	rs11229555	0.645	rs10466659	chr11:58190112	A/G	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg18964960	chr10:1102726	WDR37	0.63	8.83	0.33	9.63e-18	Eosinophil percentage of granulocytes;
BRCA	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.5	-14.11	-0.49	1.57e-39	Lung cancer;
BRCA	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.39	-8.05	-0.3	4.1e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4363385	0.667	rs454186	chr1:153049149	C/T	cg24667326	chr1:152973720	SPRR3	-0.29	-7.87	-0.3	1.47e-14	Inflammatory skin disease;
BRCA	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg06970220	chr1:156163860	SLC25A44	0.38	9.7	0.36	7.46e-21	Testicular germ cell tumor;
BRCA	cis	rs17741873	0.836	rs57771499	chr10:75605492	T/C	cg07699608	chr10:75541558	CHCHD1	0.56	8.81	0.33	1.16e-17	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs9341808	0.754	rs1324121	chr6:80946077	A/G	cg08355045	chr6:80787529	NA	0.39	10.01	0.37	5.21e-22	Sitting height ratio;
BRCA	cis	rs9341808	0.718	rs910266	chr6:80921170	A/T	cg08355045	chr6:80787529	NA	0.39	9.98	0.37	6.89e-22	Sitting height ratio;
BRCA	cis	rs4478137	0.824	rs4691907	chr4:164223658	G/T	cg06758707	chr4:164254230	NPY1R	0.57	12.13	0.43	1.28e-30	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-7.93	-0.3	9.72e-15	Longevity;Endometriosis;
BRCA	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg15819921	chr19:927150	ARID3A	-0.47	-9.23	-0.34	4.01e-19	Life satisfaction;
BRCA	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg26031613	chr14:104095156	KLC1	0.75	16.61	0.55	8.76e-52	Body mass index;
BRCA	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00149659	chr3:10157352	C3orf10	1.04	17.91	0.58	1.94e-58	Alzheimer's disease;
BRCA	cis	rs7635838	0.718	rs2606736	chr3:11400249	C/T	cg00170343	chr3:11313890	ATG7	0.38	7.81	0.3	2.37e-14	HDL cholesterol;
BRCA	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	20.11	0.62	4.61e-70	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.56	-16.96	-0.56	1.46e-53	Total body bone mineral density;
BRCA	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg02734326	chr4:10020555	SLC2A9	0.42	9.07	0.34	1.43e-18	Bone mineral density;
BRCA	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg10845886	chr2:3471009	TTC15	0.46	9.87	0.36	1.83e-21	Neurofibrillary tangles;
BRCA	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg12386194	chr3:101231763	SENP7	0.62	12.07	0.43	2.38e-30	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-9.4	-0.35	9.25e-20	Bone mineral density;
BRCA	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.88	-0.36	1.58e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	11.07	0.4	3.55e-26	Rheumatoid arthritis;
BRCA	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-12.45	-0.44	5.07e-32	Response to antipsychotic treatment;
BRCA	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg16339924	chr4:17578868	LAP3	0.63	15.73	0.53	2.27e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4589502	1.000	rs75502100	chr15:67131417	T/C	cg09911534	chr15:67153556	NA	-0.82	-10.58	-0.39	3.1e-24	Lung cancer (smoking interaction);
BRCA	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg07395648	chr5:131743802	NA	-0.37	-9.17	-0.34	6.67e-19	Blood metabolite levels;
BRCA	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg21747090	chr2:27597821	SNX17	-0.43	-9.36	-0.35	1.35e-19	Total body bone mineral density;
BRCA	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg23950597	chr19:37808831	NA	-0.72	-12.58	-0.45	1.42e-32	Coronary artery calcification;
BRCA	trans	rs1493916	0.807	rs10775455	chr18:31310761	A/C	cg27147174	chr7:100797783	AP1S1	-0.38	-7.81	-0.3	2.3e-14	Life satisfaction;
BRCA	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg10253484	chr15:75165896	SCAMP2	-0.5	-9.52	-0.35	3.42e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg00852783	chr1:26633632	UBXN11	-0.49	-8.11	-0.31	2.57e-15	Obesity-related traits;
BRCA	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg06784218	chr1:46089804	CCDC17	0.5	12.17	0.43	8.36e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-9.2	-0.34	5.21e-19	Menopause (age at onset);
BRCA	cis	rs9790314	0.581	rs6772578	chr3:160760851	T/A	cg04691961	chr3:161091175	C3orf57	-0.41	-8.6	-0.32	6.21e-17	Morning vs. evening chronotype;
BRCA	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg15704280	chr7:45808275	SEPT13	-0.47	-9.03	-0.34	2.09e-18	Height;
BRCA	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg13010199	chr12:38710504	ALG10B	0.48	9.19	0.34	5.33e-19	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg05707623	chr12:122985044	ZCCHC8	0.52	9.23	0.34	3.91e-19	Body mass index;
BRCA	cis	rs1555322	0.530	rs6060341	chr20:33863633	C/T	cg03689076	chr20:33865952	NA	-0.53	-9.98	-0.37	6.98e-22	Attention deficit hyperactivity disorder;
BRCA	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg12311346	chr5:56204834	C5orf35	-0.48	-9.81	-0.36	2.97e-21	Coronary artery disease;
BRCA	cis	rs7523050	0.643	rs35526993	chr1:109405107	A/T	cg08274380	chr1:109419600	GPSM2	0.98	14.02	0.49	3.82e-39	Fat distribution (HIV);
BRCA	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg02951883	chr7:2050386	MAD1L1	0.49	12.33	0.44	1.82e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg04362960	chr10:104952993	NT5C2	0.43	10.38	0.38	1.93e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg18230493	chr5:56204884	C5orf35	0.92	17.78	0.58	9.32e-58	Initial pursuit acceleration;
BRCA	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg17691542	chr6:26056736	HIST1H1C	0.47	9.48	0.35	4.95e-20	Height;
BRCA	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	11.56	0.42	3.29e-28	Bipolar disorder;
BRCA	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg07870213	chr5:140052090	DND1	0.79	15.63	0.53	6.79e-47	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
BRCA	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg21905437	chr5:178450457	ZNF879	0.52	10.79	0.39	4.69e-25	Pubertal anthropometrics;
BRCA	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg13047869	chr3:10149882	C3orf24	0.52	11.01	0.4	6.24e-26	Alzheimer's disease;
BRCA	cis	rs701145	1.000	rs701145	chr3:154054799	T/C	cg17054900	chr3:154042577	DHX36	0.68	11.88	0.43	1.56e-29	Coronary artery disease;
BRCA	trans	rs9329221	0.509	rs3088186	chr8:10226355	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	8.37	0.31	3.76e-16	Neuroticism;
BRCA	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg03060546	chr3:49711283	APEH	0.47	9.89	0.36	1.54e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
BRCA	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg05340658	chr4:99064831	C4orf37	0.45	10.41	0.38	1.48e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg23950597	chr19:37808831	NA	-0.72	-12.58	-0.45	1.42e-32	Coronary artery calcification;
BRCA	trans	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg21659725	chr3:3221576	CRBN	-0.45	-9.86	-0.36	1.94e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7587476	0.626	rs7593780	chr2:215640396	C/T	cg04004882	chr2:215674386	BARD1	0.39	7.9	0.3	1.23e-14	Neuroblastoma;
BRCA	cis	rs7631605	0.935	rs2302503	chr3:37107470	G/A	cg15934958	chr3:37212084	LRRFIP2	0.4	9.05	0.34	1.65e-18	Cerebrospinal P-tau181p levels;
BRCA	trans	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg21659725	chr3:3221576	CRBN	-0.46	-9.91	-0.36	1.27e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs870825	0.616	rs7668009	chr4:185641998	A/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.63	0.57	5.85e-57	Blood protein levels;
BRCA	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg16325326	chr1:53192061	ZYG11B	0.69	17.45	0.57	4.78e-56	Monocyte count;
BRCA	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.64e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.31	8.46	0.32	1.8e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg07636037	chr3:49044803	WDR6	0.98	29.33	0.76	1.88e-120	Parkinson's disease;
BRCA	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg25237894	chr2:233734115	C2orf82	-0.45	-14.26	-0.49	2.93e-40	Coronary artery disease;
BRCA	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg04362960	chr10:104952993	NT5C2	-0.42	-9.74	-0.36	5.61e-21	Arsenic metabolism;
BRCA	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg14004847	chr7:1930337	MAD1L1	-0.44	-8.95	-0.33	3.78e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.23e-24	Motion sickness;
BRCA	cis	rs1691799	0.867	rs1168339	chr12:66759236	T/G	cg16791601	chr12:66731901	HELB	-0.66	-18.01	-0.58	6.07e-59	White blood cell count (basophil);
BRCA	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-12.21	-0.43	5.77e-31	Tonsillectomy;
BRCA	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg12011299	chr4:100065546	ADH4	0.44	11.31	0.41	3.53e-27	Alcohol dependence;
BRCA	cis	rs6723226	0.842	rs2754522	chr2:32801257	C/G	cg02381751	chr2:32503542	YIPF4	0.68	14.6	0.5	6.83e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg07636037	chr3:49044803	WDR6	0.97	28.41	0.75	1.86e-115	Parkinson's disease;
BRCA	trans	rs9944715	0.954	rs62096525	chr18:43743820	G/A	cg01718231	chr17:29326311	RNF135	0.44	8.97	0.33	3.32e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg27661571	chr11:113659931	NA	-0.73	-11.28	-0.41	4.82e-27	Hip circumference adjusted for BMI;
BRCA	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg19077165	chr18:44547161	KATNAL2	-0.58	-12.72	-0.45	3.23e-33	Personality dimensions;
BRCA	cis	rs887829	0.570	rs10203266	chr2:234596368	G/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.35	-0.31	4.16e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg05340658	chr4:99064831	C4orf37	0.67	16.8	0.55	9.98e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.48	0.41	7.51e-28	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg13319975	chr6:146136371	FBXO30	-0.36	-8.55	-0.32	8.92e-17	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs8105895	0.735	rs17554694	chr19:22317148	A/G	cg05197062	chr11:11642011	GALNTL4	0.53	8.76	0.33	1.71e-17	Body mass index (change over time);
BRCA	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg20090143	chr19:45452003	APOC2	0.26	7.96	0.3	7.86e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.56	8.96	0.33	3.41e-18	Mean platelet volume;
BRCA	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg16576597	chr16:28551801	NUPR1	0.35	9.62	0.36	1.5e-20	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg09359103	chr1:154839909	KCNN3	0.56	14.34	0.49	1.26e-40	Prostate cancer;
BRCA	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg23711669	chr6:146136114	FBXO30	-0.62	-14.13	-0.49	1.21e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg19338460	chr6:170058176	WDR27	-0.44	-7.89	-0.3	1.31e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg01324343	chr3:183735012	ABCC5	0.84	21.26	0.64	3.06e-76	Anterior chamber depth;
BRCA	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02176678	chr2:219576539	TTLL4	-0.51	-13.15	-0.46	3.95e-35	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg12062639	chr20:23401060	NAPB	0.94	13.41	0.47	2.59e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs929596	0.501	rs4530361	chr2:234590041	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-8.53	-0.32	1.09e-16	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.56	12.2	0.43	6.07e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4302748	0.862	rs57651006	chr7:36184211	T/C	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs11585357	0.895	rs72633812	chr1:17623140	T/C	cg19159961	chr1:17633534	PADI4	0.57	9.04	0.34	1.84e-18	Hair shape;
BRCA	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	17.74	0.57	1.58e-57	Platelet count;
BRCA	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11644478	chr21:40555479	PSMG1	0.83	18.93	0.6	9.26e-64	Cognitive function;
BRCA	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg25358565	chr5:93447407	FAM172A	-1.13	-17.38	-0.57	1.09e-55	Diabetic retinopathy;
BRCA	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-15.32	-0.52	2.32e-45	Chronic sinus infection;
BRCA	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg07148914	chr20:33460835	GGT7	0.38	8.57	0.32	7.57e-17	Height;
BRCA	cis	rs11690935	0.589	rs6729945	chr2:172864695	C/G	cg13550731	chr2:172543902	DYNC1I2	0.49	12.04	0.43	3.06e-30	Schizophrenia;
BRCA	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg04025307	chr7:1156635	C7orf50	0.55	13.02	0.46	1.51e-34	Longevity;Endometriosis;
BRCA	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11764359	chr7:65958608	NA	-0.75	-16.69	-0.55	3.53e-52	Aortic root size;
BRCA	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg23711669	chr6:146136114	FBXO30	0.73	17.3	0.56	2.77e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06022373	chr22:39101656	GTPBP1	0.74	18.2	0.58	5.93e-60	Menopause (age at onset);
BRCA	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg00990874	chr7:1149470	C7orf50	-0.57	-10.78	-0.39	5.24e-25	Bronchopulmonary dysplasia;
BRCA	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg26384229	chr12:38710491	ALG10B	0.65	15.52	0.52	2.53e-46	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.75	0.62	3.7e-68	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg03923535	chr7:1197113	ZFAND2A	-0.4	-7.88	-0.3	1.42e-14	Longevity;Endometriosis;
BRCA	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg03929089	chr4:120376271	NA	-0.65	-12.05	-0.43	2.71e-30	Coronary artery disease;
BRCA	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg10518543	chr12:38710700	ALG10B	0.36	7.88	0.3	1.43e-14	Heart rate;
BRCA	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg11941060	chr3:133502564	NA	-0.34	-7.81	-0.3	2.31e-14	Iron status biomarkers;
BRCA	cis	rs10193935	0.901	rs10169411	chr2:42637749	G/A	cg27598129	chr2:42591480	NA	-0.81	-13.69	-0.48	1.36e-37	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg01689657	chr7:91764605	CYP51A1	0.22	8.16	0.31	1.79e-15	Breast cancer;
BRCA	cis	rs11690935	0.550	rs62183785	chr2:172866976	G/A	cg13550731	chr2:172543902	DYNC1I2	0.49	12.11	0.43	1.55e-30	Schizophrenia;
BRCA	cis	rs4664304	0.620	rs10186586	chr2:160715334	T/C	cg01092293	chr2:160761427	LY75	0.36	8.52	0.32	1.19e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg11833968	chr6:79620685	NA	-0.44	-9.89	-0.36	1.53e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg03146154	chr1:46216737	IPP	0.53	11.92	0.43	9.92e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg20607798	chr8:58055168	NA	0.48	8.43	0.32	2.29e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.42	-8.55	-0.32	9.38e-17	Glomerular filtration rate;
BRCA	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-10.29	-0.38	4.53e-23	Alzheimer's disease (late onset);
BRCA	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.48	0.38	7.92e-24	Motion sickness;
BRCA	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg00149659	chr3:10157352	C3orf10	1.06	18.2	0.58	6.23e-60	Alzheimer's disease;
BRCA	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11644478	chr21:40555479	PSMG1	0.75	15.99	0.53	1.12e-48	Cognitive function;
BRCA	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg16576597	chr16:28551801	NUPR1	0.3	8.12	0.31	2.49e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg13271783	chr10:134563150	INPP5A	-0.51	-9.59	-0.35	1.99e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg13319975	chr6:146136371	FBXO30	-0.34	-8.03	-0.3	4.84e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-7.83	-0.3	2.05e-14	Corneal astigmatism;
BRCA	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08109568	chr15:31115862	NA	0.42	10.24	0.38	7.12e-23	Huntington's disease progression;
BRCA	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg08885076	chr2:99613938	TSGA10	-0.49	-11.08	-0.4	3.31e-26	Chronic sinus infection;
BRCA	cis	rs6545883	0.929	rs10173974	chr2:61748900	C/G	cg15711740	chr2:61764176	XPO1	-0.54	-13.84	-0.48	2.75e-38	Tuberculosis;
BRCA	cis	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg06521331	chr12:34319734	NA	-0.57	-11.43	-0.41	1.17e-27	Morning vs. evening chronotype;
BRCA	cis	rs3892630	0.878	rs8108621	chr19:33183291	G/A	cg22980127	chr19:33182716	NUDT19	0.91	18.49	0.59	1.84e-61	Red blood cell traits;
BRCA	cis	rs9463078	0.774	rs6935398	chr6:45262427	G/A	cg25276700	chr6:44698697	NA	-0.35	-7.95	-0.3	8.26e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	19.61	0.61	2.3e-67	Total body bone mineral density;
BRCA	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg13319975	chr6:146136371	FBXO30	0.4	9.35	0.35	1.45e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg08132940	chr7:1081526	C7orf50	-0.59	-8.84	-0.33	9.37e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-9.33	-0.35	1.67e-19	Educational attainment;
BRCA	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg13010199	chr12:38710504	ALG10B	0.5	10.17	0.37	1.23e-22	Bladder cancer;
BRCA	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11764359	chr7:65958608	NA	0.62	13.35	0.47	4.82e-36	Aortic root size;
BRCA	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.58	0.39	3.38e-24	Motion sickness;
BRCA	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-8.19	-0.31	1.37e-15	Response to antipsychotic treatment;
BRCA	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg20573242	chr4:122745356	CCNA2	0.49	10.9	0.4	1.66e-25	Type 2 diabetes;
BRCA	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg03146154	chr1:46216737	IPP	0.52	11.61	0.42	2.16e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg23625390	chr15:77176239	SCAPER	-0.57	-14.54	-0.5	1.39e-41	Blood metabolite levels;
BRCA	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg18828365	chr5:78281819	ARSB	0.38	7.86	0.3	1.64e-14	Blood and toenail selenium levels;Blood trace element (Se levels);
BRCA	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.58	-0.52	1.25e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6743226	0.901	rs7592138	chr2:242218915	G/A	cg10021735	chr2:242295487	FARP2	0.35	9.61	0.36	1.7e-20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg20848291	chr7:100343083	ZAN	-0.57	-10.65	-0.39	1.66e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg16586182	chr3:47516702	SCAP	0.56	12.57	0.45	1.49e-32	Colorectal cancer;
BRCA	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg06238570	chr21:40685208	BRWD1	-0.41	-8.4	-0.32	2.9e-16	Cognitive function;
BRCA	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg04362960	chr10:104952993	NT5C2	0.42	10.14	0.37	1.67e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg03585969	chr10:35415529	CREM	0.5	10.39	0.38	1.73e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg23649088	chr2:200775458	C2orf69	0.58	8.56	0.32	8.56e-17	Schizophrenia;
BRCA	cis	rs9831754	0.906	rs9840031	chr3:78396140	C/T	cg06138941	chr3:78371609	NA	0.75	16.52	0.55	2.61e-51	Calcium levels;
BRCA	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg06917634	chr15:78832804	PSMA4	0.8	18.45	0.59	2.97e-61	Sudden cardiac arrest;
BRCA	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg01884057	chr2:25150051	NA	0.35	9.22	0.34	4.12e-19	Body mass index;
BRCA	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg04545296	chr12:48745243	ZNF641	0.25	8.3	0.31	6.07e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg25237894	chr2:233734115	C2orf82	0.39	11.33	0.41	3.13e-27	Coronary artery disease;
BRCA	cis	rs2580764	0.540	rs10174838	chr2:55241216	A/T	cg09592903	chr2:55203963	RTN4	-0.41	-10.41	-0.38	1.55e-23	Mean platelet volume;
BRCA	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Tonsillectomy;
BRCA	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11764359	chr7:65958608	NA	-0.77	-18.82	-0.6	3.47e-63	Aortic root size;
BRCA	cis	rs3761847	0.593	rs1468673	chr9:123809890	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	8.07	0.3	3.46e-15	Rheumatoid arthritis;
BRCA	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg08000102	chr2:233561755	GIGYF2	0.62	13.54	0.47	6.92e-37	Coronary artery disease;
BRCA	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg12923728	chr3:195709715	SDHAP1	0.4	9.01	0.34	2.4e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs12367572	0.601	rs1495042	chr12:45434386	C/T	cg04608330	chr12:45269318	NELL2	-0.44	-8.93	-0.33	4.6e-18	Gut microbiome composition (summer);
BRCA	cis	rs12612619	0.557	rs1368888	chr2:27068577	G/C	cg12368169	chr2:27073192	DPYSL5	-0.33	-10.03	-0.37	4.4e-22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs701145	0.938	rs355768	chr3:154045001	A/G	cg17054900	chr3:154042577	DHX36	0.68	11.88	0.43	1.56e-29	Coronary artery disease;
BRCA	cis	rs7677751	0.806	rs890203	chr4:55097405	A/C	cg17187183	chr4:55093834	PDGFRA	0.44	9.06	0.34	1.53e-18	Corneal astigmatism;
BRCA	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-13.15	-0.46	4.15e-35	Morning vs. evening chronotype;
BRCA	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg04851639	chr8:1020857	NA	-0.34	-10.57	-0.39	3.53e-24	Schizophrenia;
BRCA	cis	rs6063312	1.000	rs11699576	chr20:47349878	A/C	cg18078177	chr20:47281410	PREX1	0.64	11.67	0.42	1.2e-28	Tonometry;
BRCA	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg20387954	chr3:183756860	HTR3D	0.39	8.84	0.33	9.13e-18	Anterior chamber depth;
BRCA	cis	rs7095944	0.584	rs4962691	chr10:126424137	C/T	cg08799069	chr10:126477246	METTL10	-0.36	-8.18	-0.31	1.58e-15	Asthma;
BRCA	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg21770322	chr7:97807741	LMTK2	0.42	11.04	0.4	4.89e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4919694	1.000	rs4917382	chr10:104838510	G/A	cg04362960	chr10:104952993	NT5C2	0.94	14.65	0.5	4.14e-42	Arsenic metabolism;
BRCA	trans	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg25214090	chr10:38739885	LOC399744	0.55	12.09	0.43	1.97e-30	Corneal astigmatism;
BRCA	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.62e-18	Alzheimer's disease (late onset);
BRCA	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg21475434	chr5:93447410	FAM172A	-0.71	-8.97	-0.33	3.15e-18	Diabetic retinopathy;
BRCA	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg11502198	chr6:26597334	ABT1	0.48	9.67	0.36	9.55e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.83	-0.39	3.42e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6714710	0.580	rs11690737	chr2:98461953	C/T	cg26665480	chr2:98280029	ACTR1B	0.57	13.28	0.47	1.05e-35	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs17095355	1.000	rs59804002	chr10:111692043	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.38	-9.14	-0.34	8.24e-19	Biliary atresia;
BRCA	cis	rs3845702	1.000	rs3738943	chr2:180846743	G/T	cg01881094	chr2:180872142	CWC22	-0.65	-12.68	-0.45	4.85e-33	Schizophrenia;
BRCA	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.49	0.38	7.22e-24	Motion sickness;
BRCA	trans	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg07461501	chr17:79650226	HGS;ARL16	0.4	10.21	0.37	9.22e-23	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg10560079	chr2:191398806	TMEM194B	0.73	13.08	0.46	8.16e-35	Diastolic blood pressure;
BRCA	trans	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg13565492	chr6:43139072	SRF	-0.79	-10.95	-0.4	1.07e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1973993	0.691	rs6658131	chr1:96889314	C/T	cg10631902	chr5:14652156	NA	0.58	20.44	0.63	7.64e-72	Weight;
BRCA	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg06671706	chr8:8559999	CLDN23	0.45	8.76	0.33	1.69e-17	Obesity-related traits;
BRCA	cis	rs9682041	0.932	rs6782252	chr3:170133639	C/T	cg11886554	chr3:170076028	SKIL	0.79	13.94	0.48	9.52e-39	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg24642844	chr7:1081250	C7orf50	-0.58	-12.1	-0.43	1.76e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.1	-0.31	2.84e-15	Depression;
BRCA	cis	rs9473147	0.516	rs9395279	chr6:47542864	C/T	cg12968598	chr6:47444699	CD2AP	0.44	9.69	0.36	8.01e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg19274703	chr22:41806451	NA	0.39	9.44	0.35	6.82e-20	Vitiligo;
BRCA	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-20.74	-0.63	1.86e-73	Chronic sinus infection;
BRCA	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.88	-0.36	1.58e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg08888203	chr3:10149979	C3orf24	0.56	10.24	0.38	7.16e-23	Alzheimer's disease;
BRCA	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg11845111	chr2:191398756	TMEM194B	0.43	9.7	0.36	7.73e-21	Pulse pressure;
BRCA	trans	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg25042112	chr7:64838748	ZNF92	0.46	8.47	0.32	1.75e-16	Pain;
BRCA	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06636551	chr8:101224915	SPAG1	-0.38	-8.52	-0.32	1.18e-16	Atrioventricular conduction;
BRCA	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg07636037	chr3:49044803	WDR6	0.98	28.68	0.75	6.29e-117	Parkinson's disease;
BRCA	cis	rs6543140	0.964	rs10193485	chr2:103089573	T/C	cg04239558	chr2:103089729	SLC9A4	0.36	9.99	0.37	6.11e-22	Blood protein levels;
BRCA	trans	rs9951602	0.512	rs8084836	chr18:76647841	A/G	cg02800362	chr5:177631904	HNRNPAB	0.75	17.5	0.57	2.7e-56	Obesity-related traits;
BRCA	cis	rs1577917	0.958	rs12195776	chr6:86488599	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.95	-0.43	7.7e-30	Response to antipsychotic treatment;
BRCA	cis	rs6901250	1.000	rs6901250	chr6:117114025	A/G	cg12892004	chr6:117198278	RFX6	-0.49	-11.61	-0.42	2.14e-28	C-reactive protein levels;
BRCA	cis	rs12413816	0.784	rs11258560	chr10:13770137	A/G	cg16485048	chr10:13749193	FRMD4A	0.56	12.58	0.45	1.45e-32	Red cell distribution width;
BRCA	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg07395648	chr5:131743802	NA	-0.36	-8.04	-0.3	4.33e-15	Breast cancer;
BRCA	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg04691961	chr3:161091175	C3orf57	-0.38	-7.99	-0.3	6.47e-15	Parkinson's disease;
BRCA	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg22834771	chr12:69754056	YEATS4	-0.37	-9.06	-0.34	1.6e-18	Blood protein levels;
BRCA	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg12386194	chr3:101231763	SENP7	0.62	12.61	0.45	1.05e-32	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg15839431	chr19:19639596	YJEFN3	-0.38	-8.43	-0.32	2.26e-16	Bipolar disorder;
BRCA	cis	rs7523050	0.643	rs12741359	chr1:109400489	T/C	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs501916	0.634	rs3743286	chr15:48065792	A/G	cg16110827	chr15:48056943	SEMA6D	-0.42	-8.78	-0.33	1.52e-17	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg15103426	chr22:29168792	CCDC117	0.52	12.24	0.44	4.34e-31	Lymphocyte counts;
BRCA	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg01819863	chr10:32635814	EPC1	1.21	20.9	0.64	2.66e-74	Sexual dysfunction (female);
BRCA	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10463316	0.894	rs11167542	chr5:150760282	A/G	cg03212797	chr5:150827313	SLC36A1	0.42	8.05	0.3	4.01e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs9875589	0.509	rs4047237	chr3:14012861	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.33	8.67	0.32	3.62e-17	Ovarian reserve;
BRCA	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.18e-17	Iron status biomarkers;
BRCA	trans	rs12517041	1.000	rs1560177	chr5:23322987	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.1	-0.31	2.73e-15	Calcium levels;
BRCA	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.89	13.05	0.46	1.07e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1505368	0.781	rs4673664	chr2:213277649	T/C	cg16329650	chr2:213403929	ERBB4	0.32	7.99	0.3	6.27e-15	Symmetrical dimethylarginine levels;
BRCA	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.16	0.4	1.58e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs75804782	0.641	rs60841092	chr2:239349640	G/A	cg01134436	chr17:81009848	B3GNTL1	0.77	9.76	0.36	4.38e-21	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs7809950	1.000	rs28714607	chr7:107106253	T/C	cg23024343	chr7:107201750	COG5	-0.42	-9.77	-0.36	4.28e-21	Coronary artery disease;
BRCA	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg22920501	chr2:26401640	FAM59B	-0.64	-11.3	-0.41	4.14e-27	Gut microbiome composition (summer);
BRCA	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg16325326	chr1:53192061	ZYG11B	0.69	16.99	0.56	1.11e-53	Monocyte count;
BRCA	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg05793240	chr7:2802953	GNA12	0.32	8.17	0.31	1.61e-15	Height;
BRCA	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg06115741	chr20:33292138	TP53INP2	0.38	8.2	0.31	1.27e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.49	-9.4	-0.35	9.23e-20	Body mass index;
BRCA	cis	rs1067327	1	rs1067327	chr2:44628529	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	9.93	0.37	1.08e-21	Anxiety disorder (factor score);
BRCA	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg10523679	chr1:76189770	ACADM	0.72	15.15	0.51	1.66e-44	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg18755752	chr8:142205143	DENND3	-0.63	-16.56	-0.55	1.66e-51	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg25767906	chr1:53392781	SCP2	-0.39	-8.68	-0.32	3.34e-17	Monocyte count;
BRCA	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg13010199	chr12:38710504	ALG10B	0.44	8.89	0.33	6.39e-18	Bladder cancer;
BRCA	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg03146154	chr1:46216737	IPP	-0.47	-10.35	-0.38	2.48e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg22875332	chr1:76189707	ACADM	0.66	11.81	0.42	2.97e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-9.26	-0.34	3.02e-19	Colorectal cancer;
BRCA	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4984778	0.717	rs2738892	chr16:1268758	A/G	cg07748719	chr16:1272498	TPSG1	0.48	9.73	0.36	5.77e-21	Blood protein levels;
BRCA	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24549020	chr5:56110836	MAP3K1	-0.39	-8.2	-0.31	1.28e-15	Initial pursuit acceleration;
BRCA	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg07741184	chr6:167504864	NA	0.32	9.21	0.34	4.6e-19	Primary biliary cholangitis;
BRCA	cis	rs9473147	0.543	rs9296558	chr6:47451883	C/T	cg12968598	chr6:47444699	CD2AP	0.44	9.53	0.35	3.2e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs10463316	0.894	rs6579865	chr5:150762335	A/C	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.22	-0.31	1.12e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg25036284	chr2:26402008	FAM59B	-0.64	-11.04	-0.4	4.7e-26	Gut microbiome composition (summer);
BRCA	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.49	-0.38	7.6e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-9.11	-0.34	1.05e-18	Height;
BRCA	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg08000102	chr2:233561755	GIGYF2	-0.63	-13.64	-0.47	2.42e-37	Coronary artery disease;
BRCA	cis	rs6920965	0.527	rs7763515	chr6:126174714	C/G	cg05901451	chr6:126070800	HEY2	-0.35	-8.46	-0.32	1.76e-16	High light scatter reticulocyte count;
BRCA	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg17691542	chr6:26056736	HIST1H1C	0.55	11.91	0.43	1.13e-29	Height;
BRCA	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.48	-12.5	-0.44	3.15e-32	Height;
BRCA	cis	rs9815354	0.761	rs57638657	chr3:41809238	G/C	cg03022575	chr3:42003672	ULK4	0.7	9.61	0.36	1.66e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg05347473	chr6:146136440	FBXO30	-0.42	-8.34	-0.31	4.51e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg10876282	chr6:28092338	ZSCAN16	0.41	7.9	0.3	1.18e-14	Parkinson's disease;
BRCA	cis	rs11249608	0.600	rs6859767	chr5:178451107	T/C	cg21905437	chr5:178450457	ZNF879	0.53	11.0	0.4	6.6e-26	Pubertal anthropometrics;
BRCA	cis	rs7607369	0.536	rs6436090	chr2:219669002	A/G	cg02176678	chr2:219576539	TTLL4	-0.38	-10.11	-0.37	2.18e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg07460842	chr6:66804631	NA	0.88	14.14	0.49	1.11e-39	Exhaled nitric oxide output;
BRCA	trans	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	9.49	0.35	4.67e-20	Mean corpuscular volume;
BRCA	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.57	0.39	3.5e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs11252926	0.770	rs4880736	chr10:680133	C/G	cg08603382	chr10:743973	NA	0.39	8.1	0.31	2.8e-15	Psychosis in Alzheimer's disease;
BRCA	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	7.82	0.3	2.15e-14	Diabetic retinopathy;
BRCA	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-12.9	-0.45	5.43e-34	Gut microbiome composition (summer);
BRCA	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs17641971	0.708	rs1567555	chr8:49900154	G/A	cg00325661	chr8:49890786	NA	0.35	9.52	0.35	3.37e-20	Blood metabolite levels;
BRCA	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.22	-0.31	1.17e-15	Depression;
BRCA	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg16414030	chr3:133502952	NA	-0.5	-11.61	-0.42	2.01e-28	Iron status biomarkers;
BRCA	trans	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg23762105	chr12:34175262	ALG10	0.35	7.93	0.3	9.86e-15	Morning vs. evening chronotype;
BRCA	cis	rs11191205	0.686	rs11191067	chr10:103379882	G/T	cg15320455	chr10:103880129	LDB1	0.46	7.85	0.3	1.82e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.94	0.3	8.88e-15	Depression;
BRCA	cis	rs9880211	0.948	rs9813691	chr3:136260722	T/G	cg21827317	chr3:136751795	NA	-0.45	-8.15	-0.31	1.89e-15	Body mass index;Height;
BRCA	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg26384229	chr12:38710491	ALG10B	0.76	17.28	0.56	3.49e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg05804949	chr7:23719620	C7orf46	0.38	8.11	0.31	2.69e-15	Schizophrenia;
BRCA	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg13902645	chr11:5959945	NA	-0.53	-11.38	-0.41	1.96e-27	DNA methylation (variation);
BRCA	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg11766577	chr21:47581405	C21orf56	-0.38	-8.3	-0.31	6.06e-16	Testicular germ cell tumor;
BRCA	cis	rs7561273	0.609	rs10197527	chr2:24352398	A/C	cg04809136	chr2:24300158	SF3B14	-0.4	-8.85	-0.33	8.44e-18	Quantitative traits;
BRCA	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg15934090	chr1:100435551	SLC35A3	0.35	8.15	0.31	1.91e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg25237894	chr2:233734115	C2orf82	-0.44	-13.54	-0.47	6.66e-37	Coronary artery disease;
BRCA	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	9.32	0.35	1.83e-19	Personality dimensions;
BRCA	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.27	0.49	2.73e-40	Motion sickness;
BRCA	trans	rs800082	0.690	rs2717392	chr3:144280080	T/C	cg24215973	chr2:240111563	HDAC4	0.4	10.4	0.38	1.58e-23	Smoking behavior;
BRCA	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.47	-8.56	-0.32	8.37e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.09	-0.43	1.81e-30	Breast cancer;
BRCA	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg09021430	chr5:549028	NA	-0.64	-16.44	-0.55	6.66e-51	Obesity-related traits;
BRCA	cis	rs67981189	0.896	rs4391999	chr14:71445413	A/G	cg15816911	chr14:71606274	NA	0.36	7.98	0.3	7.01e-15	Schizophrenia;
BRCA	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg05283184	chr6:79620031	NA	0.45	11.27	0.41	5.63e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs490234	0.841	rs10114882	chr9:128303425	T/C	cg14078157	chr9:128172775	NA	-0.48	-10.96	-0.4	9.73e-26	Mean arterial pressure;
BRCA	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-14.07	-0.49	2.31e-39	Migraine;Coronary artery disease;
BRCA	cis	rs631288	0.557	rs7546434	chr1:146676339	A/G	cg25205988	chr1:146714368	CHD1L	0.82	8.08	0.3	3.13e-15	PR interval in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg14675211	chr2:100938903	LONRF2	0.52	11.49	0.41	6.69e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg04450456	chr4:17643702	FAM184B	0.41	12.17	0.43	8.33e-31	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg23649088	chr2:200775458	C2orf69	0.62	10.62	0.39	2.34e-24	Schizophrenia;
BRCA	cis	rs6430585	0.702	rs3213890	chr2:136552188	G/A	cg07169764	chr2:136633963	MCM6	1.27	30.26	0.77	1.84e-125	Corneal structure;
BRCA	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06022373	chr22:39101656	GTPBP1	0.6	11.29	0.41	4.48e-27	Menopause (age at onset);
BRCA	cis	rs7582720	0.943	rs72934551	chr2:203984117	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	12.77	0.45	2.02e-33	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.33	-0.44	1.69e-31	Chronic sinus infection;
BRCA	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg16230307	chr14:35515116	FAM177A1	0.73	15.28	0.52	3.85e-45	Psoriasis;
BRCA	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg10556349	chr10:835070	NA	0.59	8.32	0.31	5.29e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs2299587	0.560	rs3913556	chr8:17781401	A/G	cg01800426	chr8:17659068	MTUS1	-0.35	-8.09	-0.3	3.02e-15	Economic and political preferences;
BRCA	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg17063962	chr7:91808500	NA	0.54	12.85	0.45	8.6e-34	Breast cancer;
BRCA	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg15448220	chr1:150897856	SETDB1	0.35	7.93	0.3	1e-14	Melanoma;
BRCA	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02176678	chr2:219576539	TTLL4	-0.51	-13.01	-0.46	1.63e-34	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2806561	0.734	rs2235548	chr1:23394062	G/A	cg19743168	chr1:23544995	NA	0.35	8.03	0.3	4.79e-15	Height;
BRCA	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg20607798	chr8:58055168	NA	0.49	8.61	0.32	5.61e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg12292205	chr6:26970375	C6orf41	0.74	17.19	0.56	1e-54	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03264133	chr6:25882463	NA	-0.53	-11.95	-0.43	7.44e-30	Blood metabolite levels;
BRCA	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg06671706	chr8:8559999	CLDN23	0.41	7.95	0.3	8.36e-15	Obesity-related traits;
BRCA	cis	rs7254827	0.655	rs115002674	chr19:17167717	T/G	cg19418318	chr19:17219073	MYO9B	-0.48	-10.12	-0.37	2.05e-22	Mean platelet volume;
BRCA	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg13334819	chr7:99746414	C7orf59	-0.43	-10.05	-0.37	3.76e-22	Coronary artery disease;
BRCA	cis	rs67460515	0.500	rs1345156	chr3:160649272	G/T	cg03342759	chr3:160939853	NMD3	0.59	11.81	0.42	2.99e-29	Parkinson's disease;
BRCA	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg02951883	chr7:2050386	MAD1L1	-0.39	-8.82	-0.33	1.09e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg23711669	chr6:146136114	FBXO30	0.73	17.53	0.57	1.82e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.97	0.33	3.17e-18	Tonsillectomy;
BRCA	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg25237894	chr2:233734115	C2orf82	0.39	11.25	0.41	6.72e-27	Coronary artery disease;
BRCA	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg00814883	chr7:100076585	TSC22D4	-0.53	-11.81	-0.42	3.06e-29	Platelet count;
BRCA	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg06618935	chr21:46677482	NA	-0.37	-8.33	-0.31	5e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg27572855	chr1:25598939	RHD	0.47	13.32	0.47	6.43e-36	Erythrocyte sedimentation rate;
BRCA	cis	rs6598955	0.543	rs60676610	chr1:26543421	G/C	cg12744634	chr1:26560303	CCDC21	0.31	8.28	0.31	7.39e-16	Obesity-related traits;
BRCA	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24531977	chr5:56204891	C5orf35	-0.88	-18.06	-0.58	3.1e-59	Initial pursuit acceleration;
BRCA	cis	rs6594499	0.872	rs6880351	chr5:110451664	C/G	cg04022379	chr5:110408740	TSLP	0.35	8.02	0.3	4.93e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg27490568	chr2:178487706	NA	0.55	8.7	0.33	2.75e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.17	0.31	1.68e-15	Parkinson's disease;
BRCA	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs9811920	0.809	rs7649349	chr3:99725629	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.56	-13.41	-0.47	2.75e-36	Axial length;
BRCA	cis	rs11958404	0.932	rs11950297	chr5:157419938	T/G	cg05962755	chr5:157440814	NA	0.54	10.17	0.37	1.28e-22	IgG glycosylation;
BRCA	cis	rs116139393	0.540	rs12539942	chr7:6776585	C/T	cg00318111	chr7:6010084	RSPH10B;RSPH10B2	-0.41	-9.23	-0.34	3.96e-19	Alzheimer's disease (APOE e4 interaction);
BRCA	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg12062639	chr20:23401060	NAPB	0.88	10.42	0.38	1.43e-23	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg13010199	chr12:38710504	ALG10B	0.45	9.28	0.34	2.5e-19	Bladder cancer;
BRCA	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-10.24	-0.38	7.16e-23	Mood instability;
BRCA	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg03864215	chr11:17408437	KCNJ11	-0.27	-7.93	-0.3	9.96e-15	Type 2 diabetes;
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.48	-11.51	-0.41	5.35e-28	Longevity;Endometriosis;
BRCA	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg26384229	chr12:38710491	ALG10B	0.77	16.43	0.54	7.53e-51	Bladder cancer;
BRCA	cis	rs10267417	0.603	rs10243346	chr7:19862365	G/A	cg05791153	chr7:19748676	TWISTNB	0.51	9.74	0.36	5.38e-21	Night sleep phenotypes;
BRCA	trans	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg08917208	chr2:24149416	ATAD2B	0.52	8.28	0.31	7.42e-16	Asthma;
BRCA	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg15556689	chr8:8085844	FLJ10661	0.37	9.91	0.36	1.19e-21	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg12373951	chr3:133503437	NA	0.42	10.17	0.37	1.26e-22	Iron status biomarkers;
BRCA	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg03146154	chr1:46216737	IPP	-0.49	-10.77	-0.39	5.84e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.38	-8.49	-0.32	1.45e-16	Tonsillectomy;
BRCA	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg09455208	chr3:40491958	NA	0.45	10.84	0.39	3.1e-25	Renal cell carcinoma;
BRCA	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	24.67	0.7	6.7e-95	Platelet count;
BRCA	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-13.06	-0.46	1.02e-34	Morning vs. evening chronotype;
BRCA	trans	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.53	-0.35	3.28e-20	Bladder cancer;
BRCA	cis	rs6598955	0.543	rs6690461	chr1:26543097	T/A	cg12744634	chr1:26560303	CCDC21	0.31	8.27	0.31	7.92e-16	Obesity-related traits;
BRCA	cis	rs10129255	0.500	rs2027902	chr14:107215393	T/C	cg07958169	chr14:107095056	NA	-0.36	-7.89	-0.3	1.28e-14	Kawasaki disease;
BRCA	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg26597838	chr10:835615	NA	-0.52	-9.61	-0.36	1.63e-20	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs113835537	0.529	rs11227511	chr11:66281244	A/C	cg24851651	chr11:66362959	CCS	0.43	8.26	0.31	8.52e-16	Airway imaging phenotypes;
BRCA	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg21226059	chr5:178986404	RUFY1	0.47	12.69	0.45	4.56e-33	Lung cancer;
BRCA	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-16.62	-0.55	8.18e-52	Axial length;
BRCA	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.37	10.21	0.37	9.26e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg26395211	chr5:140044315	WDR55	0.38	8.56	0.32	8.49e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg09455208	chr3:40491958	NA	0.51	10.84	0.39	3.02e-25	Renal cell carcinoma;
BRCA	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg07080220	chr10:102295463	HIF1AN	0.63	14.78	0.5	9.71e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1997103	1.000	rs6949244	chr7:55411301	C/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs11874712	1.000	rs28504655	chr18:43665348	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.18	0.31	1.57e-15	Migraine - clinic-based;
BRCA	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg13175981	chr1:150552382	MCL1	0.42	9.32	0.35	1.93e-19	Tonsillectomy;
BRCA	cis	rs7131987	0.617	rs3764953	chr12:29502236	T/C	cg09582351	chr12:29534625	ERGIC2	-0.48	-10.71	-0.39	9.62e-25	QT interval;
BRCA	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg16586182	chr3:47516702	SCAP	0.55	12.17	0.43	9e-31	Colorectal cancer;
BRCA	cis	rs13161895	1.000	rs34674199	chr5:179473900	G/A	cg02702477	chr5:179499311	RNF130	0.46	8.53	0.32	1.03e-16	LDL cholesterol;
BRCA	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg16506815	chr2:162101123	NA	0.45	9.47	0.35	5.34e-20	Intelligence (multi-trait analysis);
BRCA	trans	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg26043149	chr18:55253948	FECH	-0.4	-8.5	-0.32	1.37e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs775227	0.706	rs808951	chr3:113002150	A/G	cg18753928	chr3:113234510	CCDC52	0.38	7.96	0.3	7.85e-15	Dental caries;
BRCA	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg11663144	chr21:46675770	NA	-0.61	-14.22	-0.49	4.45e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2387326	0.717	rs11016101	chr10:129945003	C/T	cg16087940	chr10:129947807	NA	-0.44	-8.07	-0.3	3.6e-15	Select biomarker traits;
BRCA	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg08422745	chr4:174089978	GALNT7	-0.81	-17.99	-0.58	7.54e-59	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg17691542	chr6:26056736	HIST1H1C	0.43	9.29	0.35	2.29e-19	Iron status biomarkers;
BRCA	cis	rs11779988	0.545	rs438873	chr8:17786516	G/A	cg01800426	chr8:17659068	MTUS1	-0.4	-8.37	-0.31	3.65e-16	Breast cancer;
BRCA	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg26769984	chr7:1090371	C7orf50	0.39	7.93	0.3	9.86e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.77	0.55	1.38e-52	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg20573242	chr4:122745356	CCNA2	0.48	10.84	0.39	2.96e-25	Type 2 diabetes;
BRCA	cis	rs6545883	0.507	rs4672427	chr2:61469250	A/G	cg15711740	chr2:61764176	XPO1	0.32	8.01	0.3	5.53e-15	Tuberculosis;
BRCA	cis	rs7586879	1.000	rs12713419	chr2:25121853	G/A	cg04586622	chr2:25135609	ADCY3	0.36	8.71	0.33	2.66e-17	Body mass index;
BRCA	cis	rs7903847	0.642	rs10882911	chr10:99138064	A/C	cg08345082	chr10:99160200	RRP12	-0.29	-8.51	-0.32	1.24e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7254114	0.578	rs12980863	chr19:11309871	C/T	cg06870470	chr19:11315767	DOCK6	-0.36	-8.57	-0.32	7.98e-17	Immature fraction of reticulocytes;
BRCA	cis	rs3772130	1.000	rs33988592	chr3:121415610	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	9.58	0.35	2.07e-20	Cognitive performance;
BRCA	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg01475735	chr3:40494733	NA	0.49	10.27	0.38	5.16e-23	Renal cell carcinoma;
BRCA	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg16386425	chr10:429943	DIP2C	-0.42	-9.02	-0.34	2.17e-18	Psychosis in Alzheimer's disease;
BRCA	cis	rs4664304	1.000	rs6735923	chr2:160769588	A/G	cg01092293	chr2:160761427	LY75	-0.44	-10.46	-0.38	9.84e-24	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg20476274	chr7:133979776	SLC35B4	0.64	18.19	0.58	6.56e-60	Mean platelet volume;
BRCA	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg10845886	chr2:3471009	TTC15	-0.54	-12.15	-0.43	1.0500000000000001e-30	Neurofibrillary tangles;
BRCA	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg00321850	chr1:175162397	KIAA0040	0.43	12.38	0.44	1.05e-31	Alcohol dependence;
BRCA	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg24829409	chr8:58192753	C8orf71	-0.47	-9.12	-0.34	9.38e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg27572855	chr1:25598939	RHD	0.45	12.85	0.45	8.63e-34	Erythrocyte sedimentation rate;
BRCA	trans	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg06521331	chr12:34319734	NA	-0.44	-8.37	-0.31	3.68e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg12935359	chr14:103987150	CKB	0.61	14.13	0.49	1.22e-39	Intelligence (multi-trait analysis);
BRCA	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.52	-0.32	1.14e-16	Monocyte percentage of white cells;
BRCA	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg14683738	chr19:37701593	ZNF585B	0.5	8.57	0.32	7.72e-17	Coronary artery calcification;
BRCA	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg12311346	chr5:56204834	C5orf35	-0.73	-14.47	-0.5	3.11e-41	Initial pursuit acceleration;
BRCA	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg14186256	chr22:23484241	RTDR1	0.79	24.79	0.7	1.46e-95	Bone mineral density;
BRCA	trans	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg15556689	chr8:8085844	FLJ10661	0.32	8.21	0.31	1.23e-15	Neuroticism;
BRCA	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg25554036	chr4:6271136	WFS1	0.38	9.28	0.34	2.65e-19	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs13046373	0.508	rs2253516	chr21:31993317	C/T	cg22337977	chr21:31811175	KRTAP15-1	0.34	8.01	0.3	5.43e-15	HDL cholesterol;
BRCA	cis	rs4509693	0.941	rs7914169	chr10:102495725	A/G	cg24179445	chr10:102496915	NA	0.36	9.68	0.36	9.01e-21	Alzheimer's disease;
BRCA	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg13047869	chr3:10149882	C3orf24	0.53	11.33	0.41	2.9e-27	Alzheimer's disease;
BRCA	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26314531	chr2:26401878	FAM59B	-0.88	-15.31	-0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-14.61	-0.5	6.65e-42	Personality dimensions;
BRCA	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00149659	chr3:10157352	C3orf10	0.76	12.99	0.46	2.1e-34	Alzheimer's disease;
BRCA	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.37	8.25	0.31	9.33e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs508618	1.000	rs508618	chr1:231532312	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.46	-8.27	-0.31	8.01e-16	Red blood cell count;
BRCA	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24110177	chr3:50126178	RBM5	-0.37	-9.96	-0.37	7.85e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg16576597	chr16:28551801	NUPR1	0.3	8.41	0.32	2.72e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg12310025	chr6:25882481	NA	0.42	9.43	0.35	7.17e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.82	0.3	2.21e-14	Aortic root size;
BRCA	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg15212455	chr7:39170539	POU6F2	0.43	9.54	0.35	2.9e-20	IgG glycosylation;
BRCA	cis	rs250677	0.522	rs62378210	chr5:148384885	G/A	cg18129178	chr5:148520854	ABLIM3	-0.55	-10.58	-0.39	3.39e-24	Breast cancer;
BRCA	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg09307838	chr4:120376055	NA	0.75	16.34	0.54	2.01e-50	Corneal astigmatism;
BRCA	cis	rs1506636	0.886	rs4731112	chr7:123269118	C/G	cg03229431	chr7:123269106	ASB15	-0.68	-15.75	-0.53	1.83e-47	Plateletcrit;Platelet count;
BRCA	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg13319975	chr6:146136371	FBXO30	0.42	9.78	0.36	3.73e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.54	0.38	4.59e-24	IgG glycosylation;
BRCA	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg25554036	chr4:6271136	WFS1	0.42	9.99	0.37	6.36e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg16606324	chr3:10149918	C3orf24	0.57	10.04	0.37	3.95e-22	Alzheimer's disease;
BRCA	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg08601574	chr20:25228251	PYGB	-0.37	-8.8	-0.33	1.25e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.78	12.94	0.46	3.53e-34	Platelet count;
BRCA	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21659725	chr3:3221576	CRBN	-0.5	-12.97	-0.46	2.49e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs7631605	0.935	rs6786857	chr3:37205015	C/T	cg15934958	chr3:37212084	LRRFIP2	0.4	9.37	0.35	1.24e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg08508325	chr11:3079039	CARS	-0.45	-16.92	-0.56	2.35e-53	Longevity;
BRCA	cis	rs2268241	0.938	rs9978166	chr21:34770516	A/G	cg14850771	chr21:34775459	IFNGR2	0.85	17.34	0.57	1.81e-55	Obesity-related traits;
BRCA	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg14675211	chr2:100938903	LONRF2	0.52	11.73	0.42	6.61e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs367943	0.901	rs348951	chr5:112822017	G/C	cg12552261	chr5:112820674	MCC	-0.55	-12.05	-0.43	2.83e-30	Type 2 diabetes;
BRCA	cis	rs4780401	0.933	rs4584833	chr16:11798758	C/T	cg01061890	chr16:11836724	TXNDC11	-0.4	-8.73	-0.33	2.18e-17	Rheumatoid arthritis;
BRCA	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg20607798	chr8:58055168	NA	0.58	9.19	0.34	5.3e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22633769	chr20:60982531	CABLES2	-0.47	-9.37	-0.35	1.24e-19	Colorectal cancer;
BRCA	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg03877680	chr5:178157825	ZNF354A	0.79	14.61	0.5	6.19e-42	Neutrophil percentage of white cells;
BRCA	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg14675211	chr2:100938903	LONRF2	0.47	10.58	0.39	3.33e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg14675211	chr2:100938903	LONRF2	0.45	10.19	0.37	1.06e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs4074536	0.574	rs10754352	chr1:116292369	T/C	cg21648376	chr1:116311395	CASQ2	-0.49	-8.63	-0.32	4.94e-17	QRS duration;
BRCA	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-13.0	-0.46	1.84e-34	Morning vs. evening chronotype;
BRCA	trans	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg26043149	chr18:55253948	FECH	0.39	8.86	0.33	7.79e-18	Bone mineral density;
BRCA	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg25036284	chr2:26402008	FAM59B	-0.88	-15.06	-0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg03354898	chr7:1950403	MAD1L1	0.56	12.32	0.44	1.97e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs4237845	0.844	rs7306124	chr12:58303349	A/T	cg02175503	chr12:58329896	NA	0.64	15.2	0.52	8.8e-45	Intelligence (multi-trait analysis);
BRCA	cis	rs6763687	0.664	rs9824019	chr3:171806327	T/C	cg16233210	chr3:171778391	FNDC3B	0.39	9.19	0.34	5.41e-19	Red cell distribution width;
BRCA	trans	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg25214090	chr10:38739885	LOC399744	0.54	12.41	0.44	8.17e-32	Corneal astigmatism;
BRCA	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg26384229	chr12:38710491	ALG10B	0.66	15.61	0.53	8.91e-47	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg08508325	chr11:3079039	CARS	0.35	11.72	0.42	7.2e-29	Longevity;
BRCA	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21659725	chr3:3221576	CRBN	0.35	8.39	0.32	3.11e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7398996	1	rs7398996	chr12:53659448	C/T	cg26875137	chr12:53738046	NA	0.38	9.72	0.36	6.39e-21	Total body bone mineral density (age 45-60);
BRCA	cis	rs7737355	0.947	rs2108871	chr5:131089044	A/C	cg06307176	chr5:131281290	NA	0.53	10.18	0.37	1.16e-22	Life satisfaction;
BRCA	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg17971929	chr21:40555470	PSMG1	-0.47	-10.29	-0.38	4.45e-23	Menarche (age at onset);
BRCA	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-14.47	-0.5	2.82e-41	Parkinson's disease;
BRCA	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-14.89	-0.51	2.92e-43	Chronic sinus infection;
BRCA	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg07636037	chr3:49044803	WDR6	-0.77	-15.49	-0.52	3.56e-46	Menarche (age at onset);
BRCA	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg14675211	chr2:100938903	LONRF2	0.51	11.71	0.42	7.77e-29	Intelligence (multi-trait analysis);
BRCA	trans	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg17145862	chr1:211918768	LPGAT1	0.69	18.17	0.58	8.7e-60	Leprosy;
BRCA	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg00105475	chr2:10696890	NA	0.44	10.26	0.38	5.78e-23	Prostate cancer;
BRCA	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg06026331	chr20:60912101	LAMA5	0.7	13.26	0.46	1.26e-35	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs897080	0.515	rs1067359	chr2:44661997	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	8.35	0.31	4.38e-16	Height;
BRCA	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19748678	chr4:122722346	EXOSC9	0.74	16.19	0.54	1.24e-49	Type 2 diabetes;
BRCA	cis	rs8017423	0.647	rs12882575	chr14:90820454	C/G	cg04374321	chr14:90722782	PSMC1	-0.5	-11.92	-0.43	9.86e-30	Mortality in heart failure;
BRCA	cis	rs6546550	0.901	rs7573442	chr2:70154037	G/A	cg02498382	chr2:70120550	SNRNP27	-0.52	-11.34	-0.41	2.86e-27	Prevalent atrial fibrillation;
BRCA	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg23649088	chr2:200775458	C2orf69	0.6	8.85	0.33	8.7e-18	Schizophrenia;
BRCA	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg02734326	chr4:10020555	SLC2A9	0.41	8.99	0.34	2.74e-18	Bone mineral density;
BRCA	cis	rs10267417	0.603	rs10243346	chr7:19862365	G/A	cg07541023	chr7:19748670	TWISTNB	0.5	8.92	0.33	4.85e-18	Night sleep phenotypes;
BRCA	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg10295955	chr4:187884368	NA	-0.99	-31.94	-0.78	1.62e-134	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9309473	0.632	rs6546825	chr2:73592253	G/C	cg20560298	chr2:73613845	ALMS1	-0.43	-11.15	-0.4	1.72e-26	Metabolite levels;
BRCA	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-9.86	-0.36	1.87e-21	Vitiligo;
BRCA	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg24324837	chr19:49891574	CCDC155	0.46	8.54	0.32	9.65e-17	Multiple sclerosis;
BRCA	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg11764359	chr7:65958608	NA	0.46	9.02	0.34	2.09e-18	Calcium levels;
BRCA	cis	rs2742234	0.590	rs2505553	chr10:43681251	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.56	-11.41	-0.41	1.38e-27	Hirschsprung disease;
BRCA	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	4.98e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs8028182	0.636	rs4299117	chr15:75789444	C/T	cg20655648	chr15:75932815	IMP3	0.41	7.82	0.3	2.13e-14	Sudden cardiac arrest;
BRCA	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs1018836	0.923	rs9694450	chr8:91618292	G/A	cg16814680	chr8:91681699	NA	-0.58	-12.54	-0.44	2.15e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg24829409	chr8:58192753	C8orf71	-0.48	-9.14	-0.34	7.94e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs698833	1.000	rs698834	chr2:44736957	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	9.44	0.35	6.84e-20	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs11051970	0.659	rs2728674	chr12:32587465	C/T	cg02745156	chr12:32552066	NA	0.26	8.09	0.3	2.98e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	11.2	0.41	1.05e-26	Retinal vascular caliber;
BRCA	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	8.68	0.32	3.27e-17	Tonsillectomy;
BRCA	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg16606324	chr3:10149918	C3orf24	0.56	10.5	0.38	6.78e-24	Alzheimer's disease;
BRCA	cis	rs4074536	0.622	rs12123600	chr1:116319088	G/A	cg21648376	chr1:116311395	CASQ2	-0.55	-9.08	-0.34	1.35e-18	QRS duration;
BRCA	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg03213289	chr20:61660250	NA	0.63	16.37	0.54	1.53e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6977660	1.000	rs7812001	chr7:19803323	A/G	cg05791153	chr7:19748676	TWISTNB	-0.45	-8.83	-0.33	1.03e-17	Thyroid stimulating hormone;
BRCA	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg22676075	chr6:135203613	NA	0.44	8.6	0.32	6.06e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg00031303	chr3:195681400	NA	0.45	8.54	0.32	9.64e-17	Pancreatic cancer;
BRCA	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg24130564	chr14:104152367	KLC1	0.35	7.96	0.3	8.02e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg27165867	chr14:105738592	BRF1	-0.36	-8.31	-0.31	5.65e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg18016565	chr1:150552671	MCL1	-0.4	-9.19	-0.34	5.61e-19	Blood protein levels;
BRCA	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg13902645	chr11:5959945	NA	-0.55	-11.27	-0.41	5.3e-27	DNA methylation (variation);
BRCA	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg09307838	chr4:120376055	NA	0.71	15.14	0.51	1.85e-44	Corneal astigmatism;
BRCA	cis	rs2742234	0.541	rs7098236	chr10:43740508	T/C	cg02780029	chr10:43622663	RET	0.35	7.91	0.3	1.14e-14	Hirschsprung disease;
BRCA	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg05340658	chr4:99064831	C4orf37	0.62	14.74	0.5	1.55e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7809615	0.901	rs1581492	chr7:99186826	C/T	cg12290671	chr7:99195819	NA	-0.51	-8.72	-0.33	2.31e-17	Blood metabolite ratios;
BRCA	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg23711669	chr6:146136114	FBXO30	-0.78	-18.71	-0.59	1.35e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	12.66	0.45	6.38e-33	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg03433033	chr1:76189801	ACADM	0.75	16.68	0.55	4.04e-52	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg12615879	chr12:58013172	SLC26A10	0.35	9.78	0.36	3.73e-21	Multiple sclerosis;
BRCA	cis	rs16910800	0.731	rs16910738	chr11:23189455	C/T	cg20040320	chr11:23191996	NA	-0.58	-10.16	-0.37	1.44e-22	Cancer;
BRCA	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg03709012	chr19:19516395	GATAD2A	1.11	21.25	0.64	3.38e-76	Nonalcoholic fatty liver disease;
BRCA	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg20019720	chr6:154832845	CNKSR3	0.52	10.31	0.38	3.64e-23	Lipoprotein (a) levels;
BRCA	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg05283184	chr6:79620031	NA	-0.43	-10.75	-0.39	6.92e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg17691542	chr6:26056736	HIST1H1C	0.47	9.44	0.35	6.72e-20	Iron status biomarkers;
BRCA	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg02038168	chr22:39784481	NA	0.42	7.87	0.3	1.56e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs68170813	0.559	rs76307631	chr7:107058018	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.23	-0.31	1.03e-15	Coronary artery disease;
BRCA	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg11766577	chr21:47581405	C21orf56	-0.41	-8.97	-0.33	3.3e-18	Testicular germ cell tumor;
BRCA	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg13319975	chr6:146136371	FBXO30	0.61	13.87	0.48	1.96e-38	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs57590327	0.555	rs13062054	chr3:81833906	A/G	cg07356753	chr3:81810745	GBE1	-0.47	-11.02	-0.4	5.63e-26	Extraversion;
BRCA	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-16.07	-0.54	4.52e-49	Alzheimer's disease (late onset);
BRCA	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.61	0.36	1.62e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs783540	0.967	rs1145173	chr15:83223425	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.26	-8.13	-0.31	2.27e-15	Schizophrenia;
BRCA	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.37	7.89	0.3	1.31e-14	Osteoporosis;
BRCA	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg20007245	chr22:24372913	LOC391322	0.58	12.91	0.45	4.76e-34	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg09904177	chr6:26538194	HMGN4	0.57	18.47	0.59	2.35e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs943466	1.000	rs6933174	chr6:33751003	G/A	cg25922239	chr6:33757077	LEMD2	-0.38	-7.88	-0.3	1.38e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg08859206	chr1:53392774	SCP2	-0.44	-8.84	-0.33	8.97e-18	Monocyte count;
BRCA	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg16230307	chr14:35515116	FAM177A1	-0.73	-15.86	-0.53	5e-48	Psoriasis;
BRCA	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg10495392	chr1:46806563	NSUN4	0.44	8.2	0.31	1.37e-15	Menopause (age at onset);
BRCA	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg15782153	chr7:917662	C7orf20	-0.39	-9.32	-0.35	1.89e-19	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22509189	chr2:225307070	NA	-0.46	-9.95	-0.37	8.9e-22	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12756686	chr19:29218302	NA	0.38	8.06	0.3	3.63e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg26061582	chr7:22766209	IL6	0.39	9.32	0.35	1.83e-19	Lung cancer;
BRCA	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg05340658	chr4:99064831	C4orf37	-0.5	-10.82	-0.39	3.56e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg12591125	chr7:1885375	MAD1L1	0.5	8.88	0.33	6.9e-18	Bipolar disorder;
BRCA	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.54	-9.47	-0.35	5.34e-20	Renal function-related traits (BUN);
BRCA	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg17063962	chr7:91808500	NA	-0.51	-11.89	-0.43	1.36e-29	Breast cancer;
BRCA	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg24399712	chr22:39784796	NA	-0.57	-12.62	-0.45	8.9e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg00745463	chr17:30367425	LRRC37B	-0.6	-9.77	-0.36	4.04e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs11997175	0.766	rs4733176	chr8:33685334	A/T	ch.8.33884649F	chr8:33765107	NA	0.35	8.09	0.3	2.94e-15	Body mass index;
BRCA	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg24642439	chr20:33292090	TP53INP2	0.69	13.82	0.48	3.35e-38	Coronary artery disease;
BRCA	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg03342759	chr3:160939853	NMD3	-0.81	-19.0	-0.6	3.77e-64	Parkinson's disease;
BRCA	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-11.86	-0.42	1.74e-29	Mood instability;
BRCA	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	8.08	0.3	3.2e-15	Uric acid levels;
BRCA	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg18230493	chr5:56204884	C5orf35	-0.44	-8.83	-0.33	1.01e-17	Coronary artery disease;
BRCA	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg20701182	chr2:24300061	SF3B14	0.55	8.51	0.32	1.21e-16	Lymphocyte counts;
BRCA	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg13393036	chr8:95962371	TP53INP1	-0.34	-9.18	-0.34	5.75e-19	Type 2 diabetes;
BRCA	cis	rs919433	0.679	rs7564924	chr2:198513877	C/T	cg00792783	chr2:198669748	PLCL1	0.41	9.2	0.34	5.22e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg02773041	chr1:40204384	PPIE	0.43	9.25	0.34	3.34e-19	Blood protein levels;
BRCA	cis	rs6484504	0.576	rs208091	chr11:31190099	G/C	cg14844989	chr11:31128820	NA	-0.44	-9.52	-0.35	3.45e-20	Red blood cell count;
BRCA	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg20307385	chr11:47447363	PSMC3	0.79	18.79	0.6	4.84e-63	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.21	-0.37	8.71e-23	Psoriasis;
BRCA	cis	rs11696845	0.666	rs13042905	chr20:43379454	T/C	cg25301532	chr20:43378953	KCNK15	0.44	10.41	0.38	1.45e-23	Obesity-related traits;
BRCA	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg00106254	chr7:1943704	MAD1L1	-0.32	-8.5	-0.32	1.36e-16	Schizophrenia;
BRCA	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg21226059	chr5:178986404	RUFY1	0.38	9.25	0.34	3.2e-19	Lung cancer;
BRCA	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-8.19	-0.31	1.47e-15	Blood pressure (smoking interaction);
BRCA	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00149659	chr3:10157352	C3orf10	0.7	12.11	0.43	1.56e-30	Alzheimer's disease;
BRCA	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg15017067	chr4:17643749	FAM184B	-0.32	-9.41	-0.35	8.89e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg27446573	chr6:127587934	RNF146	0.9	21.0	0.64	7.01e-75	Breast cancer;
BRCA	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg02734326	chr4:10020555	SLC2A9	0.39	8.48	0.32	1.59e-16	Bone mineral density;
BRCA	trans	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg25214090	chr10:38739885	LOC399744	-0.51	-11.0	-0.4	6.75e-26	Corneal astigmatism;
BRCA	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg21918786	chr6:109611834	NA	-0.47	-13.26	-0.46	1.33e-35	Reticulocyte fraction of red cells;
BRCA	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg26513180	chr16:89883248	FANCA	0.78	19.78	0.62	2.62e-68	Vitiligo;
BRCA	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg20476274	chr7:133979776	SLC35B4	0.65	18.34	0.59	1.16e-60	Mean platelet volume;
BRCA	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.24	0.38	7e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg16482183	chr6:26056742	HIST1H1C	0.45	8.72	0.33	2.43e-17	Iron status biomarkers;
BRCA	cis	rs7590720	1.000	rs7592663	chr2:216894978	T/C	cg12620499	chr2:216877984	MREG	0.8	22.82	0.67	9.79e-85	Alcohol dependence;
BRCA	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg11822812	chr5:140052017	DND1	-0.3	-8.22	-0.31	1.14e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg20848291	chr7:100343083	ZAN	-0.58	-10.81	-0.39	4.13e-25	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs7520050	0.898	rs34175029	chr1:46483871	C/T	cg24296786	chr1:45957014	TESK2	0.44	9.84	0.36	2.35e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg04362960	chr10:104952993	NT5C2	0.41	9.63	0.36	1.38e-20	Arsenic metabolism;
BRCA	cis	rs17092148	1.000	rs1884431	chr20:33338585	G/A	cg16810054	chr20:33298113	TP53INP2	-0.49	-11.2	-0.41	1.04e-26	Neuroticism;
BRCA	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg16482183	chr6:26056742	HIST1H1C	0.56	11.79	0.42	3.48e-29	Height;
BRCA	cis	rs9790314	0.637	rs7628880	chr3:160743217	C/A	cg03342759	chr3:160939853	NMD3	-0.46	-8.88	-0.33	6.53e-18	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg19717773	chr7:2847554	GNA12	-0.41	-9.25	-0.34	3.26e-19	Height;
BRCA	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22455342	chr2:225449267	CUL3	0.67	17.24	0.56	5.48e-55	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg04414720	chr1:150670196	GOLPH3L	0.35	7.83	0.3	1.99e-14	Tonsillectomy;
BRCA	cis	rs243505	0.861	rs243525	chr7:148418140	G/A	cg09806900	chr7:148480153	CUL1	-0.4	-8.38	-0.31	3.29e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.37	-8.33	-0.31	4.81e-16	Endometrial cancer;
BRCA	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg04450456	chr4:17643702	FAM184B	0.38	11.37	0.41	1.99e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.86	-0.42	1.86e-29	Response to antipsychotic treatment;
BRCA	cis	rs9715521	0.557	rs13146381	chr4:59853842	T/C	cg11281224	chr4:60001000	NA	-0.38	-8.74	-0.33	2.04e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg18402987	chr7:1209562	NA	0.89	14.68	0.5	2.95e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9790314	0.812	rs7631479	chr3:161139566	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-11.38	-0.41	1.81e-27	Morning vs. evening chronotype;
BRCA	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg21252483	chr19:49399788	TULP2	-0.51	-10.75	-0.39	7e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	1.02e-40	Motion sickness;
BRCA	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.25	0.31	9.32e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	14.06	0.49	2.61e-39	Colorectal cancer;
BRCA	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg06238570	chr21:40685208	BRWD1	-0.4	-8.21	-0.31	1.18e-15	Menarche (age at onset);
BRCA	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg17063962	chr7:91808500	NA	0.5	11.56	0.42	3.37e-28	Breast cancer;
BRCA	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.33	-8.67	-0.32	3.52e-17	Crohn's disease;
BRCA	cis	rs13053817	1.000	rs13057382	chr22:29850334	A/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.49	-9.06	-0.34	1.62e-18	Carotid atherosclerosis in HIV infection;
BRCA	trans	rs1973993	0.691	rs4000303	chr1:96913765	A/G	cg10631902	chr5:14652156	NA	0.59	21.04	0.64	4.47e-75	Weight;
BRCA	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.46	9.46	0.35	5.75e-20	Systemic lupus erythematosus;
BRCA	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.44	-0.41	1.03e-27	Platelet count;
BRCA	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.89	14.34	0.49	1.28e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs11958404	0.789	rs7736318	chr5:157477593	A/G	cg05962755	chr5:157440814	NA	0.54	9.43	0.35	7.74e-20	IgG glycosylation;
BRCA	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21659725	chr3:3221576	CRBN	0.48	12.29	0.44	2.61e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18402987	chr7:1209562	NA	0.58	11.4	0.41	1.55e-27	Longevity;Endometriosis;
BRCA	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg15395560	chr15:45543142	SLC28A2	0.29	8.1	0.31	2.71e-15	Uric acid levels;
BRCA	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	19.16	0.6	5.23e-65	Platelet count;
BRCA	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.75	0.62	3.7e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg14664628	chr15:75095509	CSK	0.51	10.68	0.39	1.28e-24	Systemic lupus erythematosus;
BRCA	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg25664220	chr3:72788482	NA	-0.55	-11.8	-0.42	3.14e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg24069376	chr3:38537580	EXOG	0.4	11.43	0.41	1.16e-27	Electrocardiographic conduction measures;
BRCA	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg11764359	chr7:65958608	NA	-0.64	-11.42	-0.41	1.33e-27	Aortic root size;
BRCA	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg13902645	chr11:5959945	NA	-0.47	-10.45	-0.38	1.1e-23	DNA methylation (variation);
BRCA	cis	rs6763687	1.000	rs6763687	chr3:171777646	A/T	cg16233210	chr3:171778391	FNDC3B	0.44	10.54	0.38	4.47e-24	Red cell distribution width;
BRCA	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.15	0.34	7.78e-19	Platelet count;
BRCA	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg13256891	chr4:100009986	ADH5	0.52	9.67	0.36	9.98e-21	Alcohol dependence;
BRCA	cis	rs11249608	0.548	rs6860309	chr5:178451428	T/C	cg21905437	chr5:178450457	ZNF879	0.54	11.32	0.41	3.38e-27	Pubertal anthropometrics;
BRCA	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg27535305	chr1:53392650	SCP2	-0.49	-12.43	-0.44	6.1e-32	Monocyte count;
BRCA	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-18.07	-0.58	3e-59	Chronic sinus infection;
BRCA	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg04944784	chr2:26401820	FAM59B	0.99	16.67	0.55	4.37e-52	Gut microbiome composition (summer);
BRCA	cis	rs9612	1.000	rs8105041	chr19:44258458	A/G	cg08581076	chr19:44259116	C19orf61	0.53	9.7	0.36	7.35e-21	Exhaled nitric oxide output;
BRCA	cis	rs495337	0.736	rs595027	chr20:48465722	G/T	cg17835207	chr20:48524531	SPATA2	-0.5	-11.06	-0.4	4.03e-26	Psoriasis;
BRCA	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	11.23	0.41	7.96e-27	Cognitive ability;
BRCA	cis	rs1505368	0.817	rs1283310	chr2:213273891	A/G	cg16329650	chr2:213403929	ERBB4	0.34	8.24	0.31	9.53e-16	Symmetrical dimethylarginine levels;
BRCA	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg02297831	chr4:17616191	MED28	0.39	9.1	0.34	1.13e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	ch.11.42038R	chr11:967971	AP2A2	0.52	16.68	0.55	4.17e-52	Alzheimer's disease (late onset);
BRCA	cis	rs6545883	0.894	rs2694639	chr2:61595291	G/A	cg15711740	chr2:61764176	XPO1	0.5	12.34	0.44	1.58e-31	Tuberculosis;
BRCA	trans	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg04565464	chr8:145669602	NFKBIL2	0.37	8.79	0.33	1.32e-17	Schizophrenia;
BRCA	trans	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg13565492	chr6:43139072	SRF	-0.7	-10.11	-0.37	2.17e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg18016565	chr1:150552671	MCL1	-0.39	-9.09	-0.34	1.24e-18	Tonsillectomy;
BRCA	cis	rs2346177	0.777	rs7587138	chr2:46657089	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.42	-8.74	-0.33	2.05e-17	HDL cholesterol;
BRCA	cis	rs10267417	0.535	rs6956976	chr7:19869168	G/A	cg07541023	chr7:19748670	TWISTNB	0.5	8.95	0.33	3.78e-18	Night sleep phenotypes;
BRCA	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg00504896	chr12:9437009	LOC642846	-0.46	-10.05	-0.37	3.66e-22	Breast size;
BRCA	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg24558204	chr6:135376177	HBS1L	0.59	16.07	0.54	4.78e-49	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs6687430	0.526	rs12117392	chr1:10608583	T/C	cg17425144	chr1:10567563	PEX14	0.57	12.99	0.46	2.05e-34	Hand grip strength;
BRCA	cis	rs2742234	0.656	rs1864400	chr10:43610366	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.53	-10.68	-0.39	1.26e-24	Hirschsprung disease;
BRCA	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.4	8.73	0.33	2.14e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg24692254	chr21:30365293	RNF160	0.63	14.41	0.5	5.84e-41	Selective IgA deficiency;
BRCA	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg21724239	chr8:58056113	NA	0.62	9.71	0.36	6.96e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	14.57	0.5	1.04e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.4	-9.05	-0.34	1.74e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg20587970	chr11:113659929	NA	-1.24	-22.54	-0.67	3.14e-83	Hip circumference adjusted for BMI;
BRCA	trans	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	27.56	0.74	8.71e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-10.63	-0.39	2.11e-24	Gut microbiome composition (summer);
BRCA	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	16.01	0.54	9.5e-49	Platelet count;
BRCA	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.58	16.96	0.56	1.46e-53	Total body bone mineral density;
BRCA	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg03676636	chr4:99064102	C4orf37	0.24	8.35	0.31	4.34e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1997103	1.000	rs6951294	chr7:55400835	C/T	cg17469321	chr7:55412551	NA	0.51	9.72	0.36	6.37e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-11.47	-0.41	8.01e-28	Morning vs. evening chronotype;
BRCA	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg20307385	chr11:47447363	PSMC3	-0.43	-9.19	-0.34	5.38e-19	Subjective well-being;
BRCA	cis	rs12711979	0.509	rs10205540	chr2:3827839	A/G	cg17052675	chr2:3827356	NA	-0.71	-24.21	-0.69	2.14e-92	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs8028182	0.636	rs4886712	chr15:75812888	C/T	cg20655648	chr15:75932815	IMP3	0.42	8.06	0.3	3.87e-15	Sudden cardiac arrest;
BRCA	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg13010199	chr12:38710504	ALG10B	0.51	10.04	0.37	3.97e-22	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg25214090	chr10:38739885	LOC399744	0.53	12.03	0.43	3.51e-30	Corneal astigmatism;
BRCA	trans	rs9929218	1.000	rs13334471	chr16:68800452	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-13.93	-0.48	1.03e-38	Colorectal cancer;
BRCA	cis	rs6450176	1.000	rs6450176	chr5:53298025	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-15.08	-0.51	3.62e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	trans	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg21659725	chr3:3221576	CRBN	-0.45	-9.6	-0.36	1.79e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg26043149	chr18:55253948	FECH	0.42	8.98	0.33	3.05e-18	Bone mineral density;
BRCA	cis	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg05901451	chr6:126070800	HEY2	0.39	9.43	0.35	7.33e-20	Endometrial cancer;
BRCA	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg08601574	chr20:25228251	PYGB	0.41	9.61	0.36	1.64e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg25767906	chr1:53392781	SCP2	0.52	10.96	0.4	1.02e-25	Monocyte count;
BRCA	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg13880726	chr7:1868755	MAD1L1	0.51	9.84	0.36	2.24e-21	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg24130564	chr14:104152367	KLC1	-0.41	-8.79	-0.33	1.35e-17	Reticulocyte count;
BRCA	trans	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg25214090	chr10:38739885	LOC399744	0.54	12.24	0.44	4.06e-31	Corneal astigmatism;
BRCA	cis	rs818427	0.927	rs153546	chr5:112238039	A/C	cg07820702	chr5:112228657	REEP5	-0.35	-8.65	-0.32	4.19e-17	Total body bone mineral density;
BRCA	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg24060327	chr5:131705240	SLC22A5	0.5	10.36	0.38	2.34e-23	Blood metabolite levels;
BRCA	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg10169327	chr19:45448959	APOC2	0.31	7.83	0.3	2.05e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21659725	chr3:3221576	CRBN	-0.45	-10.01	-0.37	5.05e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-10.61	-0.39	2.57e-24	Gut microbiome composition (summer);
BRCA	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.89	-18.47	-0.59	2.37e-61	Alzheimer's disease;
BRCA	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg26597838	chr10:835615	NA	1.03	18.39	0.59	6.28e-61	Eosinophil percentage of granulocytes;
BRCA	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg13628971	chr7:2884303	GNA12	0.39	8.65	0.32	4.24e-17	Height;
BRCA	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg06064525	chr11:970664	AP2A2	-0.49	-16.22	-0.54	7.89e-50	Alzheimer's disease (late onset);
BRCA	cis	rs1577917	0.958	rs36042496	chr6:86524214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.54	-0.42	4.21e-28	Response to antipsychotic treatment;
BRCA	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.52	-0.61	6.57e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg16606324	chr3:10149918	C3orf24	0.56	10.96	0.4	9.85e-26	Alzheimer's disease;
BRCA	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18876405	chr7:65276391	NA	0.55	13.15	0.46	3.95e-35	Aortic root size;
BRCA	cis	rs427394	0.743	rs274716	chr5:6722289	T/C	cg10857441	chr5:6722123	POLS	-0.33	-10.71	-0.39	9.57e-25	Menopause (age at onset);
BRCA	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg08601574	chr20:25228251	PYGB	-0.35	-8.51	-0.32	1.24e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10465746	0.780	rs11163872	chr1:84421969	G/T	cg10977910	chr1:84465055	TTLL7	0.56	11.71	0.42	8.2e-29	Obesity-related traits;
BRCA	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.96	-0.3	7.97e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg18357645	chr12:58087776	OS9	0.43	11.98	0.43	5.86e-30	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg20019720	chr6:154832845	CNKSR3	0.52	10.44	0.38	1.18e-23	Lipoprotein (a) levels;
BRCA	cis	rs6426558	0.537	rs56219094	chr1:227340191	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.48	-9.48	-0.35	4.92e-20	Neutrophil percentage of white cells;
BRCA	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg04166393	chr7:2884313	GNA12	0.48	10.29	0.38	4.52e-23	Height;
BRCA	cis	rs6700896	0.900	rs4459081	chr1:66164327	G/C	cg04111102	chr1:66153794	NA	-0.36	-8.33	-0.31	5.08e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg09035930	chr12:129282057	SLC15A4	0.55	16.11	0.54	2.99e-49	Systemic lupus erythematosus;
BRCA	trans	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg26384229	chr12:38710491	ALG10B	0.61	12.25	0.44	3.92e-31	Resting heart rate;
BRCA	cis	rs2859741	0.967	rs507460	chr1:37493206	C/G	cg09363841	chr1:37513479	NA	0.64	16.03	0.54	7.36e-49	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs10267417	0.603	rs1557774	chr7:19908777	A/G	cg05791153	chr7:19748676	TWISTNB	0.47	9.05	0.34	1.69e-18	Night sleep phenotypes;
BRCA	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.56	-0.39	3.89e-24	Mean corpuscular volume;
BRCA	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg13010199	chr12:38710504	ALG10B	0.33	7.86	0.3	1.59e-14	Morning vs. evening chronotype;
BRCA	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.2	-0.31	1.33e-15	Bipolar disorder;
BRCA	cis	rs10992471	0.603	rs7850528	chr9:95208992	A/G	cg14631576	chr9:95140430	CENPP	-0.38	-9.02	-0.34	2.19e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg05791153	chr7:19748676	TWISTNB	0.58	10.58	0.39	3.27e-24	Thyroid stimulating hormone;
BRCA	cis	rs12493885	0.818	rs55681005	chr3:153759257	G/T	cg17054900	chr3:154042577	DHX36	-0.5	-8.55	-0.32	8.73e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08280861	chr8:58055591	NA	0.61	9.32	0.35	1.81e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg06521331	chr12:34319734	NA	-0.55	-9.69	-0.36	7.96e-21	Morning vs. evening chronotype;
BRCA	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg20469991	chr17:27169893	C17orf63	-0.45	-8.87	-0.33	7.23e-18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg02733842	chr7:1102375	C7orf50	0.69	12.88	0.45	6.39e-34	Bronchopulmonary dysplasia;
BRCA	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.63	-0.42	1.75e-28	Mean corpuscular volume;
BRCA	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.91	-0.33	5.36e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg11366901	chr6:160182831	ACAT2	0.81	15.79	0.53	1.1e-47	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg03609598	chr5:56110824	MAP3K1	-0.46	-8.07	-0.3	3.55e-15	Initial pursuit acceleration;
BRCA	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.22	-0.44	5.38e-31	Alzheimer's disease;
BRCA	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg11189052	chr15:85197271	WDR73	0.39	7.88	0.3	1.37e-14	Schizophrenia;
BRCA	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.2	-0.34	5.17e-19	Bipolar disorder;
BRCA	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg23711669	chr6:146136114	FBXO30	0.66	13.82	0.48	3.22e-38	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg11584989	chr19:19387371	SF4	0.63	13.46	0.47	1.53e-36	Bipolar disorder;
BRCA	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg03354898	chr7:1950403	MAD1L1	0.44	9.34	0.35	1.59e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs12367572	0.965	rs7979717	chr12:45242272	A/T	cg04608330	chr12:45269318	NELL2	-0.58	-12.62	-0.45	9.49e-33	Gut microbiome composition (summer);
BRCA	cis	rs11971779	0.666	rs7786851	chr7:139007020	C/G	cg07862535	chr7:139043722	LUC7L2	-0.4	-8.97	-0.33	3.25e-18	Diisocyanate-induced asthma;
BRCA	cis	rs7119038	0.509	rs11216961	chr11:118580338	C/G	cg19308663	chr11:118741387	NA	0.37	8.23	0.31	1.02e-15	Sjögren's syndrome;
BRCA	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg14683738	chr19:37701593	ZNF585B	-0.44	-7.97	-0.3	7.07e-15	Coronary artery calcification;
BRCA	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg04025307	chr7:1156635	C7orf50	0.59	9.31	0.35	2e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17712092	chr4:129076599	LARP1B	0.62	14.62	0.5	5.91e-42	Eosinophil percentage of white cells;
BRCA	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg09184832	chr6:79620586	NA	-0.52	-11.32	-0.41	3.45e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.53	10.49	0.38	7.1e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2637266	0.935	rs2583048	chr10:78404507	C/G	cg18941641	chr10:78392320	NA	0.35	7.98	0.3	6.89e-15	Pulmonary function;
BRCA	cis	rs61990749	0.597	rs7147516	chr14:78153980	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.63	-9.65	-0.36	1.13e-20	Fibroblast growth factor basic levels;
BRCA	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg27446573	chr6:127587934	RNF146	0.81	18.44	0.59	3.29e-61	Breast cancer;
BRCA	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.59	13.88	0.48	1.69e-38	Systemic lupus erythematosus;
BRCA	trans	rs783540	0.967	rs783529	chr15:83267981	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.27	-8.29	-0.31	6.65e-16	Schizophrenia;
BRCA	cis	rs2425143	0.822	rs6060677	chr20:34499368	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.58	7.91	0.3	1.16e-14	Blood protein levels;
BRCA	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	8.48	0.32	1.52e-16	Rheumatoid arthritis;
BRCA	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-12.26	-0.44	3.51e-31	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg09184832	chr6:79620586	NA	-0.41	-7.94	-0.3	9.17e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg06115741	chr20:33292138	TP53INP2	-0.38	-8.46	-0.32	1.78e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs4595586	0.756	rs7137139	chr12:39364013	C/T	cg26384229	chr12:38710491	ALG10B	0.38	8.43	0.32	2.3e-16	Morning vs. evening chronotype;
BRCA	cis	rs897984	0.609	rs57576577	chr16:31036367	G/A	cg02466173	chr16:30829666	NA	-0.44	-9.86	-0.36	1.9e-21	Dementia with Lewy bodies;
BRCA	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg07636037	chr3:49044803	WDR6	-0.51	-8.28	-0.31	7.43e-16	Menarche (age at onset);
BRCA	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg01689657	chr7:91764605	CYP51A1	0.22	8.15	0.31	1.88e-15	Breast cancer;
BRCA	cis	rs2288073	0.801	rs72797831	chr2:24366829	G/A	cg26838691	chr2:24397539	C2orf84	-0.45	-8.18	-0.31	1.59e-15	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg16230307	chr14:35515116	FAM177A1	0.74	15.5	0.52	3.27e-46	Psoriasis;
BRCA	cis	rs4363385	0.818	rs472076	chr1:153013742	G/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.19	-0.34	5.43e-19	Inflammatory skin disease;
BRCA	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-8.52	-0.32	1.18e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg03709012	chr19:19516395	GATAD2A	0.71	15.53	0.52	2.1e-46	Tonsillectomy;
BRCA	trans	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg25042112	chr7:64838748	ZNF92	0.46	8.63	0.32	4.86e-17	Pain;
BRCA	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg21770322	chr7:97807741	LMTK2	0.43	11.49	0.41	6.49e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12200560	0.505	rs211165	chr6:97068520	A/T	cg06623918	chr6:96969491	KIAA0776	0.51	11.93	0.43	9.45e-30	Coronary heart disease;
BRCA	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg20701182	chr2:24300061	SF3B14	0.7	10.31	0.38	3.56e-23	Lymphocyte counts;
BRCA	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12379764	chr21:47803548	PCNT	-0.55	-10.91	-0.4	1.5e-25	Testicular germ cell tumor;
BRCA	cis	rs7903847	0.642	rs11189172	chr10:99135215	T/C	cg20016023	chr10:99160130	RRP12	-0.26	-8.06	-0.3	3.86e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs897984	0.609	rs12445650	chr16:31044897	G/A	cg00531865	chr16:30841666	NA	-0.38	-9.05	-0.34	1.67e-18	Dementia with Lewy bodies;
BRCA	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg21918786	chr6:109611834	NA	-0.49	-14.14	-0.49	1.03e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs4363385	0.747	rs1415971	chr1:152965779	T/G	cg24667326	chr1:152973720	SPRR3	-0.33	-9.38	-0.35	1.14e-19	Inflammatory skin disease;
BRCA	cis	rs34779708	0.931	rs7908573	chr10:35309513	T/C	cg03585969	chr10:35415529	CREM	0.55	11.39	0.41	1.72e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7833986	0.501	rs2668007	chr8:56944111	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.51	8.47	0.32	1.74e-16	Height;
BRCA	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg20307385	chr11:47447363	PSMC3	-0.41	-8.68	-0.32	3.32e-17	Subjective well-being;
BRCA	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg26384229	chr12:38710491	ALG10B	0.67	15.29	0.52	3.21e-45	Bladder cancer;
BRCA	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.69e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg12564285	chr5:131593104	PDLIM4	0.34	7.86	0.3	1.7e-14	Acylcarnitine levels;
BRCA	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00166722	chr3:10149974	C3orf24	-0.63	-11.22	-0.41	8.43e-27	Alzheimer's disease;
BRCA	cis	rs2012796	0.743	rs8020575	chr14:81859521	G/A	cg02996355	chr14:81879375	NA	0.52	10.38	0.38	1.98e-23	Night sleep phenotypes;
BRCA	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg03676636	chr4:99064102	C4orf37	0.21	7.94	0.3	9.23e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg03894339	chr8:19674705	INTS10	-0.45	-8.89	-0.33	6.11e-18	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-14.69	-0.5	2.76e-42	Hemoglobin concentration;
BRCA	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg12935359	chr14:103987150	CKB	-0.59	-14.08	-0.49	2.02e-39	Body mass index;
BRCA	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	9.87	0.36	1.77e-21	Tonsillectomy;
BRCA	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-8.62	-0.32	5.23e-17	Schizophrenia;
BRCA	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg05347473	chr6:146136440	FBXO30	0.42	8.37	0.31	3.59e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9649465	0.905	rs3757504	chr7:123391750	C/T	cg04330084	chr7:123175371	IQUB	-0.3	-8.13	-0.31	2.21e-15	Migraine;
BRCA	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg27661571	chr11:113659931	NA	-0.8	-12.01	-0.43	4.07e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg26408565	chr15:76604113	ETFA	-0.47	-9.94	-0.37	9.32e-22	Blood metabolite levels;
BRCA	cis	rs897080	0.515	rs1067336	chr2:44625876	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.65	0.32	4.16e-17	Height;
BRCA	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg08807101	chr21:30365312	RNF160	0.74	19.4	0.61	3.03e-66	Dental caries;
BRCA	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.66	15.54	0.52	1.89e-46	Chronic sinus infection;
BRCA	cis	rs698813	0.642	rs1837702	chr2:44492444	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	8.44	0.32	2.05e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg23950597	chr19:37808831	NA	-0.62	-11.45	-0.41	9.99e-28	Coronary artery calcification;
BRCA	trans	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg07211511	chr3:129823064	LOC729375	-0.62	-10.82	-0.39	3.47e-25	Blood pressure (smoking interaction);
BRCA	cis	rs7833986	1.000	rs4263734	chr8:57099931	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.46	8.27	0.31	8.08e-16	Height;
BRCA	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	9.92	0.37	1.14e-21	Tonsillectomy;
BRCA	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-18.22	-0.58	4.79e-60	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2797160	1.000	rs1739377	chr6:126012236	T/C	cg05901451	chr6:126070800	HEY2	0.4	9.64	0.36	1.24e-20	Endometrial cancer;
BRCA	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg21132104	chr15:45694354	SPATA5L1	0.75	16.54	0.55	2.01e-51	Homoarginine levels;
BRCA	cis	rs763121	0.524	rs760645	chr22:39032270	C/T	cg06022373	chr22:39101656	GTPBP1	0.5	10.77	0.39	5.82e-25	Menopause (age at onset);
BRCA	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-10.14	-0.37	1.7e-22	Schizophrenia;
BRCA	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.53	-0.52	2.1e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg04944784	chr2:26401820	FAM59B	0.95	16.17	0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs13190036	0.551	rs4976639	chr5:176550301	A/C	cg06733329	chr5:176740039	MXD3	-0.4	-8.07	-0.3	3.56e-15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg18305652	chr10:134549665	INPP5A	0.49	12.04	0.43	3.15e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.32	0.61	7.31e-66	Alzheimer's disease;
BRCA	cis	rs6138458	0.717	rs2179732	chr20:25000446	A/T	cg26195577	chr20:24973756	C20orf3	0.7	17.7	0.57	2.38e-57	Blood protein levels;
BRCA	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-9.8	-0.36	3.36e-21	Mean corpuscular volume;
BRCA	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	8.3	0.31	6.38e-16	Schizophrenia;
BRCA	trans	rs1973993	0.561	rs61334931	chr1:96988776	T/A	cg10631902	chr5:14652156	NA	-0.41	-10.06	-0.37	3.36e-22	Weight;
BRCA	cis	rs7523050	0.643	rs34801874	chr1:109404382	C/T	cg08274380	chr1:109419600	GPSM2	0.98	14.02	0.49	3.82e-39	Fat distribution (HIV);
BRCA	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg23018236	chr17:30244563	NA	-0.61	-9.92	-0.37	1.12e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.42	8.81	0.33	1.13e-17	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11674184	0.714	rs16857668	chr2:11723110	G/A	cg07314298	chr2:11723111	GREB1	-0.83	-20.63	-0.63	6.98e-73	Endometriosis;
BRCA	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.35	-8.29	-0.31	6.74e-16	Bipolar disorder;
BRCA	trans	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	20.36	0.63	1.98e-71	Exhaled nitric oxide output;
BRCA	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs4742903	0.935	rs1507513	chr9:106973857	A/G	cg14250997	chr9:106856677	SMC2	0.3	9.3	0.35	2.15e-19	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs1355223	0.545	rs7106831	chr11:34879542	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-9.62	-0.36	1.54e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg25457927	chr22:38595422	NA	-0.32	-11.87	-0.43	1.63e-29	Cutaneous nevi;
BRCA	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.35	-0.41	2.58e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg06671706	chr8:8559999	CLDN23	0.45	8.77	0.33	1.57e-17	Obesity-related traits;
BRCA	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs11690935	0.851	rs6731562	chr2:172798262	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.75	-22.26	-0.66	1.02e-81	Schizophrenia;
BRCA	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	11.66	0.42	1.3e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.5	-10.99	-0.4	7.31e-26	IgG glycosylation;
BRCA	cis	rs11634851	0.844	rs12917526	chr15:81025457	G/C	cg03950166	chr15:80988613	FAM108C1	-0.33	-7.9	-0.3	1.25e-14	Systolic blood pressure;
BRCA	trans	rs2736345	0.755	rs2736340	chr8:11343973	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	7.88	0.3	1.43e-14	Sjögren's syndrome;Systemic lupus erythematosus;
BRCA	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg10011062	chr15:43941034	CATSPER2	-0.53	-7.98	-0.3	6.85e-15	Lung cancer in ever smokers;
BRCA	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg08997352	chr12:9597637	DDX12	-0.5	-9.91	-0.37	1.19e-21	Breast size;
BRCA	cis	rs9902453	0.780	rs3115093	chr17:28039755	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	14.26	0.49	3.02e-40	Coffee consumption (cups per day);
BRCA	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg11812906	chr14:75593930	NEK9	-0.6	-13.62	-0.47	2.82e-37	Height;
BRCA	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg09307838	chr4:120376055	NA	0.59	12.48	0.44	3.76e-32	Corneal astigmatism;
BRCA	cis	rs897984	0.542	rs6565217	chr16:31083324	C/T	cg00531865	chr16:30841666	NA	-0.4	-9.88	-0.36	1.62e-21	Dementia with Lewy bodies;
BRCA	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg06238570	chr21:40685208	BRWD1	-0.47	-9.26	-0.34	3.09e-19	Cognitive function;
BRCA	cis	rs13082711	0.595	rs1445114	chr3:27345489	C/A	cg02860705	chr3:27208620	NA	0.76	13.86	0.48	2.22e-38	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	trans	rs1973993	0.691	rs11165623	chr1:96893000	G/A	cg10631902	chr5:14652156	NA	0.55	18.31	0.59	1.66e-60	Weight;
BRCA	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg19052272	chr2:3704530	ALLC	0.41	9.89	0.36	1.53e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg18252515	chr7:66147081	NA	-1.06	-15.7	-0.53	3.07e-47	Gout;
BRCA	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg18230493	chr5:56204884	C5orf35	0.62	13.23	0.46	1.64e-35	Initial pursuit acceleration;
BRCA	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg11952622	chr19:58962976	ZNF324B	0.51	10.52	0.38	5.47e-24	Uric acid clearance;
BRCA	cis	rs7172677	0.737	rs6495154	chr15:75437262	G/C	cg10253484	chr15:75165896	SCAMP2	-0.45	-8.31	-0.31	5.6e-16	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.87e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs11976180	1.000	rs1919949	chr7:143767723	G/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.43	-7.95	-0.3	8.47e-15	Obesity-related traits;
BRCA	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-12.42	-0.44	7.37e-32	Alzheimer's disease;
BRCA	trans	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg14791747	chr16:20752902	THUMPD1	0.39	9.19	0.34	5.45e-19	Cognitive test performance;
BRCA	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg21475434	chr5:93447410	FAM172A	0.7	8.65	0.32	4.16e-17	Diabetic retinopathy;
BRCA	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg22601191	chr20:60968625	CABLES2	0.43	10.48	0.38	8.1e-24	Colorectal cancer;
BRCA	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg19508488	chr2:152266495	RIF1	0.51	10.48	0.38	7.94e-24	Lung cancer;
BRCA	cis	rs4566357	0.615	rs10178098	chr2:227914425	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-9.26	-0.34	3.12e-19	Coronary artery disease;
BRCA	trans	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg25214090	chr10:38739885	LOC399744	0.41	9.28	0.34	2.54e-19	Corneal astigmatism;
BRCA	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg03709012	chr19:19516395	GATAD2A	-0.76	-16.69	-0.55	3.68e-52	Tonsillectomy;
BRCA	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg13073564	chr4:8508604	NA	0.33	8.33	0.31	5.03e-16	Response to antineoplastic agents;
BRCA	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.64	-0.5	4.53e-42	Chronic sinus infection;
BRCA	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg27165867	chr14:105738592	BRF1	-0.36	-8.37	-0.31	3.53e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7707921	0.767	rs226196	chr5:81576965	C/A	cg15871215	chr5:81402204	ATG10	0.35	8.02	0.3	5.16e-15	Breast cancer;
BRCA	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg13010199	chr12:38710504	ALG10B	0.35	8.22	0.31	1.12e-15	Morning vs. evening chronotype;
BRCA	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-9.99	-0.37	6.44e-22	Aortic root size;
BRCA	cis	rs4363385	0.747	rs4845506	chr1:152968407	G/A	cg24667326	chr1:152973720	SPRR3	-0.36	-9.89	-0.36	1.54e-21	Inflammatory skin disease;
BRCA	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg11764359	chr7:65958608	NA	0.65	11.67	0.42	1.12e-28	Aortic root size;
BRCA	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg27432699	chr2:27873401	GPN1	0.45	9.66	0.36	1.06e-20	Oral cavity cancer;
BRCA	cis	rs6120849	0.754	rs6119560	chr20:33606977	G/C	cg24642439	chr20:33292090	TP53INP2	0.6	10.3	0.38	4.11e-23	Protein C levels;
BRCA	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg22105103	chr4:187893119	NA	0.37	11.37	0.41	2.09e-27	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg17143192	chr8:8559678	CLDN23	0.52	9.93	0.37	1.04e-21	Obesity-related traits;
BRCA	trans	rs6479891	1.000	rs9414786	chr10:65044322	T/A	cg14819942	chr15:35414228	NA	-0.35	-8.57	-0.32	7.85e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.62	10.3	0.38	4.09e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg16584290	chr5:462447	EXOC3	0.54	15.14	0.51	1.72e-44	Cystic fibrosis severity;
BRCA	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg27446573	chr6:127587934	RNF146	0.8	15.52	0.52	2.37e-46	Breast cancer;
BRCA	cis	rs2120243	0.874	rs9868133	chr3:157151461	G/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	9.49	0.35	4.32e-20	Hepatocellular carcinoma in hepatitis B infection;
BRCA	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg15934090	chr1:100435551	SLC35A3	0.35	8.06	0.3	3.67e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg24690094	chr11:67383802	NA	0.53	11.4	0.41	1.63e-27	Mean corpuscular volume;
BRCA	cis	rs698833	0.926	rs1067394	chr2:44638123	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	10.77	0.39	5.71e-25	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.18	-0.34	6e-19	Bipolar disorder;
BRCA	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.43e-36	High light scatter reticulocyte count;
BRCA	cis	rs9814567	0.964	rs6805388	chr3:134173534	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.36	-7.91	-0.3	1.1e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg13010199	chr12:38710504	ALG10B	0.39	7.87	0.3	1.47e-14	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg26384229	chr12:38710491	ALG10B	0.65	13.76	0.48	6.33e-38	Morning vs. evening chronotype;
BRCA	cis	rs701145	0.938	rs355752	chr3:153970796	A/G	cg17054900	chr3:154042577	DHX36	0.67	11.71	0.42	8.15e-29	Coronary artery disease;
BRCA	trans	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg07393940	chr7:158741817	NA	0.51	10.01	0.37	5.26e-22	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.79	18.96	0.6	6.08e-64	Multiple sclerosis;
BRCA	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg22535103	chr8:58192502	C8orf71	-0.52	-8.91	-0.33	5.21e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg20891283	chr12:69753455	YEATS4	0.84	28.1	0.74	9.91e-114	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs783540	0.500	rs783541	chr15:83255061	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.34	-8.67	-0.32	3.65e-17	Schizophrenia;
BRCA	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg02659138	chr7:134003124	SLC35B4	0.32	9.78	0.36	3.74e-21	Mean platelet volume;
BRCA	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg11752832	chr7:134001865	SLC35B4	0.52	13.55	0.47	6.19e-37	Mean platelet volume;
BRCA	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00152838	chr16:24741724	TNRC6A	-0.35	-7.97	-0.3	7.2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs11955398	0.585	rs9654363	chr5:60033232	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.38	-8.98	-0.33	3.11e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.1	0.46	6.97e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg15432903	chr11:17409602	KCNJ11	0.71	15.48	0.52	3.81e-46	Type 2 diabetes;
BRCA	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03264133	chr6:25882463	NA	-0.52	-11.03	-0.4	5.04e-26	Intelligence (multi-trait analysis);
BRCA	trans	rs629535	0.734	rs542288	chr8:70057149	G/T	cg21567404	chr3:27674614	NA	-0.98	-21.35	-0.65	9.76e-77	Dupuytren's disease;
BRCA	cis	rs13315871	1.000	rs9819072	chr3:58353647	A/C	cg20936604	chr3:58311152	NA	-0.62	-7.96	-0.3	8.01e-15	Cholesterol, total;
BRCA	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.42	-9.55	-0.35	2.83e-20	Personality dimensions;
BRCA	cis	rs9815354	0.855	rs73071261	chr3:42003369	C/A	cg03022575	chr3:42003672	ULK4	0.74	10.27	0.38	5.43e-23	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1003719	0.708	rs3787788	chr21:38502804	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.19	-0.49	6.29e-40	Eye color traits;
BRCA	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg10223061	chr2:219282414	VIL1	-0.27	-8.1	-0.31	2.71e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs11874712	1.000	rs1800640	chr18:43671400	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.1	0.31	2.72e-15	Migraine - clinic-based;
BRCA	cis	rs829883	0.724	rs11109507	chr12:98904160	C/T	cg25150519	chr12:98850993	NA	0.52	9.64	0.36	1.22e-20	Colorectal adenoma (advanced);
BRCA	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg12179176	chr11:130786555	SNX19	0.59	13.23	0.46	1.7000000000000001e-35	Schizophrenia;
BRCA	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.32	8.34	0.31	4.41e-16	IgG glycosylation;
BRCA	trans	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.51	12.04	0.43	3.26e-30	Brugada syndrome;
BRCA	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg24631222	chr15:78858424	CHRNA5	0.5	9.91	0.37	1.21e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs1832871	0.672	rs9457363	chr6:158777515	C/T	cg07215822	chr6:158701037	NA	-0.49	-7.87	-0.3	1.47e-14	Height;
BRCA	trans	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg26043149	chr18:55253948	FECH	0.41	8.91	0.33	5.1e-18	Bone mineral density;
BRCA	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	10.14	0.37	1.61e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs2841233	0.681	rs2582558	chr14:105347488	A/G	cg01147727	chr14:105363015	KIAA0284	0.32	7.9	0.3	1.22e-14	IgG glycosylation;
BRCA	cis	rs9420	0.961	rs71484461	chr11:57488890	G/A	cg19752551	chr11:57585705	CTNND1	-0.51	-12.43	-0.44	6.13e-32	Schizophrenia;
BRCA	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg22920501	chr2:26401640	FAM59B	-0.65	-11.32	-0.41	3.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11644478	chr21:40555479	PSMG1	-0.68	-15.33	-0.52	2.16e-45	Cognitive function;
BRCA	trans	rs4596713	0.538	rs1416738	chr9:71787927	C/T	cg16512924	chr15:28394682	HERC2	0.45	10.56	0.39	3.97e-24	Headache;
BRCA	cis	rs1538970	0.962	rs4660849	chr1:45819872	A/G	cg05343316	chr1:45956843	TESK2	-0.56	-11.61	-0.42	2.1e-28	Platelet count;
BRCA	cis	rs754466	0.580	rs10824571	chr10:79531931	G/A	cg17075019	chr10:79541650	NA	-0.83	-20.15	-0.62	2.91e-70	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg10560079	chr2:191398806	TMEM194B	0.39	8.42	0.32	2.39e-16	Pulse pressure;
BRCA	cis	rs11249608	0.744	rs4701025	chr5:178444474	G/A	cg21905437	chr5:178450457	ZNF879	-0.45	-9.27	-0.34	2.76e-19	Pubertal anthropometrics;
BRCA	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg08668359	chr10:1443807	ADARB2	0.46	8.97	0.33	3.27e-18	Radiation response;
BRCA	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg06970220	chr1:156163860	SLC25A44	0.38	9.4	0.35	9.68e-20	Testicular germ cell tumor;
BRCA	cis	rs1997103	0.911	rs6949931	chr7:55391081	T/C	cg17469321	chr7:55412551	NA	0.5	9.35	0.35	1.49e-19	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg07148914	chr20:33460835	GGT7	0.44	9.64	0.36	1.27e-20	Height;
BRCA	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg22875332	chr1:76189707	ACADM	0.69	14.93	0.51	1.77e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg00147160	chr1:26503991	CNKSR1	0.28	9.24	0.34	3.71e-19	Height;
BRCA	cis	rs6121246	0.559	rs6060922	chr20:30333909	C/T	cg21427119	chr20:30132790	HM13	-0.35	-8.04	-0.3	4.42e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs2066819	1.000	rs2306693	chr12:56680531	T/C	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg02659138	chr7:134003124	SLC35B4	0.36	10.0	0.37	5.73e-22	Mean platelet volume;
BRCA	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg09307838	chr4:120376055	NA	-0.6	-11.96	-0.43	7.06e-30	Corneal astigmatism;
BRCA	cis	rs400736	0.930	rs442862	chr1:8079494	T/C	cg25007680	chr1:8021821	PARK7	0.48	12.05	0.43	2.87e-30	Response to antidepressants and depression;
BRCA	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg04691961	chr3:161091175	C3orf57	-0.63	-16.31	-0.54	2.99e-50	Morning vs. evening chronotype;
BRCA	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg17063962	chr7:91808500	NA	-0.51	-11.93	-0.43	9.32e-30	Breast cancer;
BRCA	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg08885076	chr2:99613938	TSGA10	-0.6	-13.44	-0.47	1.88e-36	Chronic sinus infection;
BRCA	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg27170947	chr2:26402098	FAM59B	0.97	17.18	0.56	1.18e-54	Gut microbiome composition (summer);
BRCA	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg07423050	chr13:99094983	FARP1	-0.42	-10.01	-0.37	5.39e-22	Longevity;
BRCA	trans	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg25214090	chr10:38739885	LOC399744	0.54	11.89	0.43	1.43e-29	Corneal astigmatism;
BRCA	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	12.07	0.43	2.39e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7523050	0.730	rs11102650	chr1:109464228	C/G	cg08274380	chr1:109419600	GPSM2	0.97	14.17	0.49	8.24e-40	Fat distribution (HIV);
BRCA	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg22875332	chr1:76189707	ACADM	-0.47	-9.04	-0.34	1.86e-18	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4363385	0.747	rs1933383	chr1:152963468	C/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.27	-0.34	2.87e-19	Inflammatory skin disease;
BRCA	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg17470723	chr8:74884337	TCEB1	0.4	8.74	0.33	2.06e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs754466	0.651	rs10824583	chr10:79619402	C/T	cg17075019	chr10:79541650	NA	0.71	16.94	0.56	2.01e-53	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.13	0.31	2.29e-15	Corneal astigmatism;
BRCA	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.72	-15.93	-0.53	2.37e-48	Hip circumference adjusted for BMI;
BRCA	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg08916839	chr5:415575	AHRR	-0.51	-9.26	-0.34	3.06e-19	Fat distribution (HIV);
BRCA	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg02196655	chr2:10830764	NOL10	-0.3	-8.06	-0.3	3.81e-15	Prostate cancer;
BRCA	cis	rs4948102	0.691	rs4470984	chr7:56033558	A/G	cg09872392	chr7:56161020	PHKG1	-0.4	-9.0	-0.34	2.55e-18	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs11051970	0.636	rs2733705	chr12:32561564	T/C	cg24626660	chr12:32551988	NA	0.31	9.26	0.34	2.98e-19	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg10523679	chr1:76189770	ACADM	-0.46	-8.79	-0.33	1.39e-17	Daytime sleep phenotypes;
BRCA	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.34	-9.6	-0.35	1.84e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg04398451	chr17:18023971	MYO15A	-0.71	-15.42	-0.52	7.44e-46	Total body bone mineral density;
BRCA	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg24154853	chr7:158122151	PTPRN2	0.34	8.05	0.3	4.16e-15	Calcium levels;
BRCA	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg03342759	chr3:160939853	NMD3	-0.71	-14.47	-0.5	2.82e-41	Parkinson's disease;
BRCA	trans	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg16011800	chr17:1958478	HIC1	-0.55	-8.95	-0.33	3.76e-18	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg02079420	chr8:82753780	SNX16	-0.31	-8.46	-0.32	1.77e-16	Diastolic blood pressure;
BRCA	cis	rs3815700	1.000	rs7248845	chr19:33096718	T/C	cg02997394	chr19:33096574	ANKRD27	0.7	12.01	0.43	4.13e-30	Eosinophilic esophagitis;
BRCA	cis	rs16910800	0.731	rs1871953	chr11:23192677	G/A	cg20040320	chr11:23191996	NA	-0.59	-9.84	-0.36	2.34e-21	Cancer;
BRCA	trans	rs4596713	0.507	rs1339546	chr9:71790297	G/A	cg16512924	chr15:28394682	HERC2	0.45	10.73	0.39	7.99e-25	Headache;
BRCA	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.4	8.65	0.32	4.05e-17	Cognitive ability;
BRCA	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg13010199	chr12:38710504	ALG10B	0.44	8.95	0.33	3.88e-18	Bladder cancer;
BRCA	cis	rs8016982	0.963	rs2099108	chr14:81675420	C/G	cg01989461	chr14:81687754	GTF2A1	0.52	11.19	0.4	1.11e-26	Schizophrenia;
BRCA	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg18478394	chr8:109455254	TTC35	0.29	8.28	0.31	7.19e-16	Dupuytren's disease;
BRCA	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11764359	chr7:65958608	NA	0.62	13.46	0.47	1.5e-36	Aortic root size;
BRCA	cis	rs4664304	0.772	rs12692572	chr2:160743793	G/A	cg01092293	chr2:160761427	LY75	0.37	8.83	0.33	9.81e-18	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6815814	0.861	rs11936050	chr4:38789524	C/T	cg06935464	chr4:38784597	TLR10	0.5	9.97	0.37	7.37e-22	Breast cancer;
BRCA	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg26384229	chr12:38710491	ALG10B	0.77	17.86	0.58	3.6e-58	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00166722	chr3:10149974	C3orf24	0.65	11.23	0.41	7.83e-27	Alzheimer's disease;
BRCA	cis	rs11229555	0.645	rs10896785	chr11:58233395	G/A	cg15696309	chr11:58395628	NA	-0.52	-10.81	-0.39	4.11e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12986413	1.000	rs4807208	chr19:2170205	A/C	cg09261902	chr19:2140048	AP3D1	0.39	10.21	0.37	8.69e-23	Height;
BRCA	cis	rs6558530	0.653	rs6984632	chr8:1700434	G/A	cg19131313	chr8:1704013	NA	-0.41	-8.06	-0.3	3.84e-15	Systolic blood pressure;
BRCA	trans	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg26043149	chr18:55253948	FECH	0.39	8.44	0.32	2.08e-16	Bone mineral density;
BRCA	cis	rs6433895	0.883	rs4432412	chr2:182069079	C/G	cg00481216	chr2:181971175	NA	0.38	8.49	0.32	1.49e-16	Lymphocyte counts;
BRCA	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg16482183	chr6:26056742	HIST1H1C	0.55	11.32	0.41	3.23e-27	Height;
BRCA	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg03676636	chr4:99064102	C4orf37	0.24	8.27	0.31	7.91e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2070488	0.804	rs1870914	chr3:38494220	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.63	16.57	0.55	1.51e-51	Electrocardiographic conduction measures;
BRCA	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.33	-8.27	-0.31	7.81e-16	IgG glycosylation;
BRCA	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.09	0.37	2.6e-22	Calcium levels;
BRCA	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-13.6	-0.47	3.6e-37	Morning vs. evening chronotype;
BRCA	trans	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	29.32	0.76	2.17e-120	Colorectal cancer;
BRCA	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg03161606	chr19:29218774	NA	0.46	8.11	0.31	2.56e-15	Methadone dose in opioid dependence;
BRCA	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg22906224	chr7:99728672	NA	0.46	8.72	0.33	2.31e-17	Coronary artery disease;
BRCA	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg10523679	chr1:76189770	ACADM	-0.5	-9.61	-0.36	1.58e-20	Daytime sleep phenotypes;
BRCA	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg21427119	chr20:30132790	HM13	-0.42	-8.92	-0.33	4.92e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg02493740	chr2:85810744	VAMP5	-0.53	-11.07	-0.4	3.46e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs2637030	0.515	rs381374	chr5:52927813	A/G	cg06476337	chr5:52856530	NDUFS4	0.38	8.82	0.33	1.09e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg14086364	chr5:150678334	SLC36A3	0.53	14.54	0.5	1.34e-41	Skin aging (microtopography measurement);
BRCA	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26314531	chr2:26401878	FAM59B	-0.62	-10.9	-0.4	1.7e-25	Gut microbiome composition (summer);
BRCA	trans	rs4714291	0.832	rs761798	chr6:40087514	C/T	cg02267698	chr19:7991119	CTXN1	0.47	9.68	0.36	8.95e-21	Strep throat;
BRCA	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26314531	chr2:26401878	FAM59B	-0.63	-10.83	-0.39	3.28e-25	Gut microbiome composition (summer);
BRCA	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg17971929	chr21:40555470	PSMG1	0.74	15.95	0.53	1.78e-48	Cognitive function;
BRCA	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	10.82	0.39	3.72e-25	Bone mineral density;
BRCA	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg11502198	chr6:26597334	ABT1	0.49	9.73	0.36	6.01e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs2270927	0.510	rs246814	chr5:75599208	C/T	cg13563193	chr19:33072644	PDCD5	0.92	10.65	0.39	1.77e-24	Mean corpuscular volume;
BRCA	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg01689657	chr7:91764605	CYP51A1	0.23	8.16	0.31	1.72e-15	Breast cancer;
BRCA	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg23505145	chr19:12996616	KLF1	0.56	12.79	0.45	1.66e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg00105475	chr2:10696890	NA	0.44	10.41	0.38	1.56e-23	Prostate cancer;
BRCA	cis	rs57908212	1	rs57908212	chr19:2161321	T/C	cg09261902	chr19:2140048	AP3D1	0.41	10.62	0.39	2.28e-24	Red blood cell count;Hemoglobin concentration;Hematocrit;
BRCA	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.7	11.66	0.42	1.29e-28	Lung function (FEV1/FVC);
BRCA	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.29	0.31	6.66e-16	Cognitive ability;
BRCA	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg13319975	chr6:146136371	FBXO30	0.41	9.26	0.34	3.15e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg18876405	chr7:65276391	NA	0.44	8.91	0.33	5.4e-18	Corneal structure;
BRCA	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	8.07	0.3	3.54e-15	Aortic root size;
BRCA	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg03213289	chr20:61660250	NA	0.63	16.57	0.55	1.44e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1113500	0.933	rs11185256	chr1:108633957	C/T	cg06207961	chr1:108661230	NA	0.46	11.28	0.41	5.1e-27	Growth-regulated protein alpha levels;
BRCA	cis	rs4919087	1.000	rs10786327	chr10:99071408	C/T	cg25902810	chr10:99078978	FRAT1	0.52	11.67	0.42	1.17e-28	Monocyte count;
BRCA	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg09307838	chr4:120376055	NA	0.69	13.8	0.48	4.33e-38	Corneal astigmatism;
BRCA	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg13271783	chr10:134563150	INPP5A	-0.45	-9.56	-0.35	2.52e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs3772130	0.583	rs9819530	chr3:121387784	T/G	cg20356878	chr3:121714668	ILDR1	0.38	8.62	0.32	5.06e-17	Cognitive performance;
BRCA	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg13047869	chr3:10149882	C3orf24	0.57	10.42	0.38	1.43e-23	Alzheimer's disease;
BRCA	cis	rs6740322	0.895	rs9309098	chr2:43554972	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.67	12.31	0.44	2.12e-31	Coronary artery disease;
BRCA	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg26384229	chr12:38710491	ALG10B	-0.45	-10.15	-0.37	1.53e-22	Bladder cancer;
BRCA	cis	rs9309473	0.607	rs6546824	chr2:73587331	G/A	cg20560298	chr2:73613845	ALMS1	-0.42	-10.78	-0.39	5.45e-25	Metabolite levels;
BRCA	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg23950597	chr19:37808831	NA	-0.72	-11.47	-0.41	8.03e-28	Coronary artery calcification;
BRCA	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg07169764	chr2:136633963	MCM6	1.3	29.42	0.76	5.9e-121	Corneal structure;
BRCA	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	7.94	0.3	9.22e-15	Mean platelet volume;
BRCA	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg20283391	chr11:68216788	NA	-0.44	-8.97	-0.33	3.35e-18	Total body bone mineral density;
BRCA	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-9.73	-0.36	5.87e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.46	8.88	0.33	6.66e-18	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg18016565	chr1:150552671	MCL1	0.35	8.42	0.32	2.54e-16	Tonsillectomy;
BRCA	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg13770153	chr20:60521292	NA	-0.42	-9.43	-0.35	7.61e-20	Body mass index;
BRCA	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg24829409	chr8:58192753	C8orf71	-0.47	-9.04	-0.34	1.81e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.43e-28	Corneal astigmatism;
BRCA	cis	rs10752881	0.652	rs10911262	chr1:183114956	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.44	0.55	6.21e-51	Colorectal cancer;
BRCA	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.56	0.42	3.32e-28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg24747557	chr10:131355152	MGMT	0.36	8.98	0.33	2.89e-18	Response to temozolomide;
BRCA	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.13	-0.34	8.85e-19	Bipolar disorder;
BRCA	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg02403541	chr12:121454288	C12orf43	0.64	12.18	0.43	7.81e-31	N-glycan levels;
BRCA	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.41	0.59	4.72e-61	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg11584989	chr19:19387371	SF4	-0.66	-14.28	-0.49	2.4e-40	Bipolar disorder;
BRCA	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.47	-0.32	1.72e-16	Total body bone mineral density;
BRCA	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg08859206	chr1:53392774	SCP2	-0.41	-8.7	-0.33	2.7e-17	Monocyte count;
BRCA	trans	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg07817883	chr1:32538562	TMEM39B	0.5	8.17	0.31	1.62e-15	Monocyte percentage of white cells;
BRCA	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg20933634	chr6:27740509	NA	-0.45	-8.51	-0.32	1.27e-16	Parkinson's disease;
BRCA	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs2797160	1.000	rs1739371	chr6:126011291	G/A	cg05901451	chr6:126070800	HEY2	0.39	9.53	0.35	3.34e-20	Endometrial cancer;
BRCA	cis	rs3820928	0.967	rs4675113	chr2:227766339	G/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.63	-0.32	4.82e-17	Pulmonary function;
BRCA	cis	rs4919087	0.810	rs10736115	chr10:99031685	A/G	cg25902810	chr10:99078978	FRAT1	0.41	9.04	0.34	1.86e-18	Monocyte count;
BRCA	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.41	-0.44	8.14e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs4302748	0.862	rs73335286	chr7:36184728	C/T	cg24442661	chr7:36192818	EEPD1	0.48	8.81	0.33	1.2e-17	Platelet count;
BRCA	cis	rs1003719	0.679	rs2246285	chr21:38582431	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.41	-0.5	5.89e-41	Eye color traits;
BRCA	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg08470875	chr2:26401718	FAM59B	-0.53	-8.21	-0.31	1.24e-15	Gut microbiome composition (summer);
BRCA	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg20307385	chr11:47447363	PSMC3	0.41	8.7	0.33	2.87e-17	Subjective well-being;
BRCA	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg00757033	chr12:89920650	WDR51B	0.52	10.52	0.38	5.8e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs4363385	0.818	rs1890285	chr1:153015396	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.57	-0.32	7.58e-17	Inflammatory skin disease;
BRCA	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	16.69	0.55	3.7e-52	Alzheimer's disease;
BRCA	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	12.31	0.44	2.06e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs775227	0.574	rs35765657	chr3:113078384	C/T	cg18753928	chr3:113234510	CCDC52	-0.55	-9.19	-0.34	5.28e-19	Dental caries;
BRCA	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	10.59	0.39	3.07e-24	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg14675211	chr2:100938903	LONRF2	0.52	11.96	0.43	7.15e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg06212747	chr3:49208901	KLHDC8B	0.48	9.9	0.36	1.38e-21	Parkinson's disease;
BRCA	cis	rs9473147	0.543	rs9473126	chr6:47481833	C/G	cg12968598	chr6:47444699	CD2AP	0.46	9.86	0.36	1.85e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs9811920	0.683	rs10936003	chr3:99667565	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-11.16	-0.4	1.52e-26	Axial length;
BRCA	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg18230493	chr5:56204884	C5orf35	-0.43	-8.88	-0.33	6.55e-18	Coronary artery disease;
BRCA	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg00383909	chr3:49044727	WDR6	0.64	10.54	0.38	4.75e-24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11644478	chr21:40555479	PSMG1	-0.5	-10.67	-0.39	1.46e-24	Menarche (age at onset);
BRCA	cis	rs2637266	0.935	rs2583052	chr10:78403288	C/G	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg08045932	chr20:61659980	NA	0.5	10.99	0.4	7.5e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg24692254	chr21:30365293	RNF160	-0.45	-8.04	-0.3	4.47e-15	Cognitive test performance;
BRCA	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.3	-0.38	4.09e-23	Psoriasis;
BRCA	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07080220	chr10:102295463	HIF1AN	0.48	11.1	0.4	2.65e-26	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg17971929	chr21:40555470	PSMG1	-0.48	-10.57	-0.39	3.65e-24	Menarche (age at onset);
BRCA	trans	rs12517041	1.000	rs10052994	chr5:23292784	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.0	-0.3	5.78e-15	Calcium levels;
BRCA	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9420	0.528	rs34052104	chr11:57384519	A/C	cg19752551	chr11:57585705	CTNND1	-0.42	-9.63	-0.36	1.41e-20	Schizophrenia;
BRCA	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.33	-0.41	2.93e-27	Mean corpuscular volume;
BRCA	cis	rs12210905	0.688	rs114843651	chr6:27449611	A/G	cg08851530	chr6:28072375	NA	0.82	7.99	0.3	6.52e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg04756594	chr16:24857601	SLC5A11	0.54	12.16	0.43	9.53e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg08885076	chr2:99613938	TSGA10	0.42	9.81	0.36	3.08e-21	Chronic sinus infection;
BRCA	cis	rs4664304	0.739	rs2162500	chr2:160708645	C/G	cg14819504	chr2:160761413	LY75	0.34	8.43	0.32	2.35e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-14.76	-0.5	1.22e-42	Morning vs. evening chronotype;
BRCA	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg03060546	chr3:49711283	APEH	-0.6	-10.48	-0.38	7.88e-24	Menarche (age at onset);
BRCA	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-9.21	-0.34	4.7e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg01528321	chr10:82214614	TSPAN14	0.63	13.97	0.48	6.43e-39	Post bronchodilator FEV1;
BRCA	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11644478	chr21:40555479	PSMG1	-0.52	-10.93	-0.4	1.36e-25	Menarche (age at onset);
BRCA	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.76	-0.42	4.94e-29	Colorectal cancer;
BRCA	cis	rs34779708	0.733	rs60553075	chr10:35542462	T/A	cg03585969	chr10:35415529	CREM	0.45	9.18	0.34	6.03e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg00339695	chr16:24857497	SLC5A11	-0.52	-11.18	-0.4	1.24e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs1941023	0.503	rs10792269	chr11:60117126	C/T	cg08716584	chr11:60157161	MS4A7	-0.42	-9.82	-0.36	2.72e-21	Congenital heart disease (maternal effect);
BRCA	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg25767906	chr1:53392781	SCP2	-0.46	-10.28	-0.38	4.66e-23	Monocyte count;
BRCA	cis	rs490234	0.627	rs4838276	chr9:128364901	A/G	cg14078157	chr9:128172775	NA	0.44	9.84	0.36	2.25e-21	Mean arterial pressure;
BRCA	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	12.02	0.43	3.78e-30	Multiple sclerosis;
BRCA	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19748678	chr4:122722346	EXOSC9	0.74	15.96	0.53	1.71e-48	Type 2 diabetes;
BRCA	cis	rs3125734	0.633	rs6479804	chr10:64048327	T/C	cg19640130	chr10:64028056	RTKN2	-0.32	-8.91	-0.33	5.37e-18	Rheumatoid arthritis;
BRCA	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg22676075	chr6:135203613	NA	-0.6	-12.96	-0.46	2.74e-34	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs9880211	0.752	rs9881831	chr3:136389718	T/C	cg21827317	chr3:136751795	NA	-0.45	-7.97	-0.3	7.3e-15	Body mass index;Height;
BRCA	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.34	-9.72	-0.36	6.45e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs3799977	0.531	rs62436031	chr6:44722203	A/G	cg25276700	chr6:44698697	NA	0.36	8.29	0.31	6.81e-16	Attention deficit hyperactivity disorder;
BRCA	cis	rs7301826	1.000	rs4619189	chr12:131313797	A/G	cg11011512	chr12:131303247	STX2	0.42	10.4	0.38	1.62e-23	Plasma plasminogen activator levels;
BRCA	cis	rs13046373	0.508	rs1012969	chr21:31996108	G/A	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.47	0.35	5.23e-20	HDL cholesterol;
BRCA	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg18446336	chr7:2847575	GNA12	-0.34	-8.1	-0.31	2.74e-15	Height;
BRCA	cis	rs10044254	0.641	rs2937074	chr5:15751645	G/A	cg07238450	chr5:15720153	FBXL7	-0.38	-8.03	-0.3	4.54e-15	Asthma (corticosteroid response);
BRCA	cis	rs11051970	0.879	rs2651379	chr12:32581778	A/G	cg24626660	chr12:32551988	NA	0.28	7.98	0.3	7.03e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs3125734	0.633	rs10740068	chr10:63982254	A/C	cg19640130	chr10:64028056	RTKN2	-0.31	-9.05	-0.34	1.64e-18	Rheumatoid arthritis;
BRCA	cis	rs9287719	0.624	rs6740245	chr2:10760902	T/C	cg00105475	chr2:10696890	NA	0.41	8.99	0.33	2.85e-18	Prostate cancer;
BRCA	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg04034577	chr2:241836375	C2orf54	-0.57	-13.94	-0.48	9.76e-39	Urinary metabolites;
BRCA	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg15934090	chr1:100435551	SLC35A3	0.36	8.43	0.32	2.38e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11971779	0.680	rs1133067	chr7:139053069	G/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.24	0.38	6.65e-23	Diisocyanate-induced asthma;
BRCA	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg00339695	chr16:24857497	SLC5A11	0.51	11.09	0.4	2.88e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	13.76	0.48	6.43e-38	Mood instability;
BRCA	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg25358565	chr5:93447407	FAM172A	1.15	18.67	0.59	2.15e-62	Diabetic retinopathy;
BRCA	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.53	-14.16	-0.49	8.87e-40	Colorectal cancer;
BRCA	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg25767906	chr1:53392781	SCP2	-0.48	-10.67	-0.39	1.44e-24	Monocyte count;
BRCA	cis	rs897984	0.542	rs11864806	chr16:31095204	G/C	cg02466173	chr16:30829666	NA	-0.44	-9.79	-0.36	3.39e-21	Dementia with Lewy bodies;
BRCA	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08704250	chr15:31115839	NA	0.34	8.77	0.33	1.6e-17	Huntington's disease progression;
BRCA	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg23711669	chr6:146136114	FBXO30	0.73	16.88	0.56	3.75e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.54	-0.32	9.93e-17	Monocyte percentage of white cells;
BRCA	cis	rs6426558	0.502	rs2813965	chr1:227445733	A/G	cg10327440	chr1:227177885	CDC42BPA	0.52	10.31	0.38	3.75e-23	Neutrophil percentage of white cells;
BRCA	cis	rs2294693	0.945	rs9369255	chr6:40989503	T/C	cg14769373	chr6:40998127	UNC5CL	-0.39	-7.83	-0.3	2.06e-14	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs7011049	1.000	rs72648403	chr8:53854848	T/C	cg26025543	chr8:53854495	NA	0.55	9.49	0.35	4.66e-20	Systolic blood pressure;
BRCA	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg06784218	chr1:46089804	CCDC17	0.5	12.08	0.43	2.02e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.7	-0.33	2.83e-17	Total body bone mineral density;
BRCA	cis	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.24	-0.38	6.8e-23	Morning vs. evening chronotype;
BRCA	cis	rs1420338	0.967	rs4720151	chr7:34160523	G/A	cg01275685	chr7:34179230	BMPER	-0.45	-9.25	-0.34	3.36e-19	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg26384229	chr12:38710491	ALG10B	-0.51	-12.16	-0.43	9.46e-31	Morning vs. evening chronotype;
BRCA	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24549020	chr5:56110836	MAP3K1	-0.4	-8.36	-0.31	4.01e-16	Initial pursuit acceleration;
BRCA	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg21798802	chr22:38057573	PDXP	0.31	8.41	0.32	2.78e-16	Fat distribution (HIV);
BRCA	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.63	-0.42	1.77e-28	Platelet count;
BRCA	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg20307385	chr11:47447363	PSMC3	0.42	9.54	0.35	3e-20	Subjective well-being;
BRCA	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg01448562	chr3:133502909	NA	-0.39	-9.13	-0.34	8.62e-19	Iron status biomarkers;
BRCA	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg22920501	chr2:26401640	FAM59B	-0.87	-16.6	-0.55	9.68e-52	Gut microbiome composition (summer);
BRCA	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg08601574	chr20:25228251	PYGB	-0.34	-8.26	-0.31	8.25e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg10523679	chr1:76189770	ACADM	-0.49	-9.52	-0.35	3.41e-20	Daytime sleep phenotypes;
BRCA	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg13902645	chr11:5959945	NA	0.6	13.77	0.48	5.93e-38	DNA methylation (variation);
BRCA	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg16109817	chr1:16162209	FLJ37453	-0.29	-8.19	-0.31	1.46e-15	Systolic blood pressure;
BRCA	cis	rs6500395	1.000	rs9924078	chr16:48557918	A/C	cg04672837	chr16:48644449	N4BP1	-0.42	-9.55	-0.35	2.61e-20	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg11578532	chr1:161008127	TSTD1	0.3	9.49	0.35	4.66e-20	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9462846	1.000	rs56158882	chr6:42860740	T/G	cg02353165	chr6:42928485	GNMT	0.49	8.64	0.32	4.47e-17	Blood protein levels;
BRCA	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg24101359	chr6:42928495	GNMT	0.54	12.57	0.45	1.5e-32	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg23205692	chr1:25664452	TMEM50A	-0.41	-10.01	-0.37	5.24e-22	Erythrocyte sedimentation rate;
BRCA	cis	rs9318086	0.935	rs9652080	chr13:24435426	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.29	-8.31	-0.31	5.74e-16	Myopia (pathological);
BRCA	cis	rs17095355	1.000	rs752584	chr10:111682934	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.43	-9.1	-0.34	1.12e-18	Biliary atresia;
BRCA	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg03929089	chr4:120376271	NA	-0.65	-12.83	-0.45	1.06e-33	Coronary artery disease;
BRCA	trans	rs75804782	0.641	rs72983861	chr2:239326126	G/A	cg01134436	chr17:81009848	B3GNTL1	0.76	9.58	0.35	2.02e-20	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg10792982	chr14:105748885	BRF1	0.47	10.94	0.4	1.14e-25	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg18252515	chr7:66147081	NA	-0.84	-12.12	-0.43	1.34e-30	Diabetic kidney disease;
BRCA	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg11584989	chr19:19387371	SF4	-0.66	-14.28	-0.49	2.4e-40	Bipolar disorder;
BRCA	cis	rs12618769	0.656	rs3769735	chr2:99092302	C/T	cg10123293	chr2:99228465	UNC50	0.41	8.51	0.32	1.28e-16	Bipolar disorder;
BRCA	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg26061582	chr7:22766209	IL6	0.44	9.91	0.36	1.24e-21	Lung cancer;
BRCA	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg12219531	chr12:120966889	COQ5	0.53	11.63	0.42	1.71e-28	High light scatter reticulocyte count;
BRCA	cis	rs10431058	0.708	rs651300	chr11:107488577	A/G	cg18204760	chr11:107461044	ELMOD1;LOC643923	-0.38	-8.27	-0.31	7.68e-16	Common traits (Other);
BRCA	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg15017067	chr4:17643749	FAM184B	-0.29	-8.64	-0.32	4.35e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13095912	0.785	rs34619288	chr3:185331678	G/C	cg11274856	chr3:185301563	NA	0.52	12.4	0.44	8.66e-32	Systolic blood pressure;
BRCA	cis	rs2882667	0.690	rs10045605	chr5:138272147	T/C	cg04439458	chr5:138467593	SIL1	-0.35	-8.41	-0.32	2.62e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4919694	1.000	rs7099987	chr10:104807926	C/T	cg04362960	chr10:104952993	NT5C2	0.94	14.43	0.5	4.38e-41	Arsenic metabolism;
BRCA	cis	rs4730250	0.554	rs76257331	chr7:106916279	G/A	cg02696742	chr7:106810147	HBP1	-0.49	-8.01	-0.3	5.32e-15	Osteoarthritis;
BRCA	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg17747265	chr1:1875780	NA	0.37	9.24	0.34	3.68e-19	Body mass index;
BRCA	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg13319975	chr6:146136371	FBXO30	0.41	9.31	0.35	1.98e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg15557168	chr22:42548783	NA	-0.31	-8.47	-0.32	1.62e-16	Cognitive function;
BRCA	cis	rs9682041	0.696	rs10936626	chr3:170095019	G/A	cg11886554	chr3:170076028	SKIL	0.51	10.16	0.37	1.41e-22	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-14.08	-0.49	2.01e-39	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg05340658	chr4:99064831	C4orf37	0.49	10.75	0.39	6.87e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg08859206	chr1:53392774	SCP2	0.51	11.2	0.41	1.04e-26	Monocyte count;
BRCA	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg26031613	chr14:104095156	KLC1	-0.43	-8.61	-0.32	5.69e-17	Schizophrenia;
BRCA	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg21475434	chr5:93447410	FAM172A	0.7	8.86	0.33	7.58e-18	Diabetic retinopathy;
BRCA	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-8.05	-0.3	4.07e-15	Blood pressure (smoking interaction);
BRCA	cis	rs7809950	1.000	rs10234355	chr7:107086517	T/G	cg23024343	chr7:107201750	COG5	-0.4	-9.28	-0.34	2.65e-19	Coronary artery disease;
BRCA	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.29	0.31	6.45e-16	Parkinson's disease;
BRCA	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg21782813	chr7:2030301	MAD1L1	0.35	9.08	0.34	1.31e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg15133208	chr4:90757351	SNCA	-0.39	-7.83	-0.3	2.04e-14	Neuroticism;
BRCA	cis	rs9790314	0.718	rs1599383	chr3:160829820	T/C	cg03342759	chr3:160939853	NMD3	-0.5	-10.01	-0.37	5.24e-22	Morning vs. evening chronotype;
BRCA	cis	rs72781680	0.679	rs718138	chr2:23976324	G/A	cg08917208	chr2:24149416	ATAD2B	0.62	9.83	0.36	2.52e-21	Lymphocyte counts;
BRCA	cis	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg06521331	chr12:34319734	NA	-0.56	-10.14	-0.37	1.7e-22	Morning vs. evening chronotype;
BRCA	cis	rs8077889	0.672	rs3785810	chr17:41850689	C/G	cg26893861	chr17:41843967	DUSP3	0.91	23.25	0.68	3.97e-87	Triglycerides;
BRCA	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg17470723	chr8:74884337	TCEB1	0.41	8.63	0.32	4.74e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg21775007	chr8:11205619	TDH	-0.43	-8.93	-0.33	4.39e-18	Triglycerides;
BRCA	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg05283184	chr6:79620031	NA	-0.34	-7.9	-0.3	1.2e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs877282	1.000	rs71494928	chr10:769134	A/G	cg17470449	chr10:769945	NA	0.49	8.54	0.32	9.71e-17	Uric acid levels;
BRCA	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg03342759	chr3:160939853	NMD3	0.6	12.63	0.45	8.72e-33	Morning vs. evening chronotype;
BRCA	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg24558204	chr6:135376177	HBS1L	0.42	10.7	0.39	1.12e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg13256891	chr4:100009986	ADH5	0.54	10.16	0.37	1.43e-22	Smoking initiation;
BRCA	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg26384229	chr12:38710491	ALG10B	0.41	9.22	0.34	4.35e-19	Morning vs. evening chronotype;
BRCA	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg08645402	chr16:4508243	NA	-0.48	-12.81	-0.45	1.32e-33	Schizophrenia;
BRCA	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg20701182	chr2:24300061	SF3B14	0.58	9.0	0.34	2.55e-18	Lymphocyte counts;
BRCA	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15541040	chr2:3486749	NA	-0.46	-10.21	-0.37	8.86e-23	Neurofibrillary tangles;
BRCA	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg11814155	chr7:99998594	ZCWPW1	0.47	8.38	0.31	3.41e-16	Platelet count;
BRCA	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21518248	chr2:162101506	NA	0.71	17.53	0.57	1.77e-56	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg00383909	chr3:49044727	WDR6	0.74	12.9	0.45	5.43e-34	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.44	-9.07	-0.34	1.43e-18	Total body bone mineral density;
BRCA	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.11	0.31	2.59e-15	Menopause (age at onset);
BRCA	trans	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg17675199	chr6:35436792	RPL10A	-0.3	-8.03	-0.3	4.8e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6142102	0.961	rs6120519	chr20:32688113	A/G	cg24642439	chr20:33292090	TP53INP2	0.4	7.97	0.3	7.48e-15	Skin pigmentation;
BRCA	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg23625390	chr15:77176239	SCAPER	0.39	9.59	0.35	1.94e-20	Blood metabolite levels;
BRCA	cis	rs10924970	0.967	rs12739707	chr1:235466564	C/G	cg26050004	chr1:235667680	B3GALNT2	0.31	7.83	0.3	2.09e-14	Asthma;
BRCA	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg13319975	chr6:146136371	FBXO30	-0.55	-12.06	-0.43	2.47e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7020830	0.823	rs7019699	chr9:37125081	C/A	cg14294708	chr9:37120828	ZCCHC7	1.19	43.18	0.86	1.27e-191	Schizophrenia;
BRCA	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg22029157	chr1:209979665	IRF6	-0.43	-8.19	-0.31	1.42e-15	Cleft lip with or without cleft palate;
BRCA	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.66	14.28	0.49	2.28e-40	Lymphocyte counts;
BRCA	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23583168	chr7:148888333	NA	-0.84	-19.64	-0.61	1.44e-67	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs11608355	0.515	rs2287192	chr12:109931594	C/T	cg05360138	chr12:110035743	NA	0.73	13.41	0.47	2.64e-36	Neuroticism;
BRCA	cis	rs7561273	0.586	rs7580772	chr2:24357657	T/C	cg04809136	chr2:24300158	SF3B14	-0.4	-8.97	-0.33	3.37e-18	Quantitative traits;
BRCA	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	ch.11.42038R	chr11:967971	AP2A2	0.5	15.77	0.53	1.38e-47	Alzheimer's disease (late onset);
BRCA	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg14019146	chr3:50243930	SLC38A3	-0.66	-16.44	-0.55	6.59e-51	Intelligence (multi-trait analysis);
BRCA	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg10295955	chr4:187884368	NA	-0.99	-31.87	-0.78	3.73e-134	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg21573476	chr21:45109991	RRP1B	-0.43	-11.67	-0.42	1.13e-28	Mean corpuscular volume;
BRCA	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg13256891	chr4:100009986	ADH5	0.54	10.14	0.37	1.65e-22	Alcohol dependence;
BRCA	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21385522	chr1:16154831	NA	0.47	8.5	0.32	1.39e-16	Dilated cardiomyopathy;
BRCA	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.6	0.39	2.83e-24	Motion sickness;
BRCA	trans	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg23762105	chr12:34175262	ALG10	0.34	7.99	0.3	6.54e-15	Morning vs. evening chronotype;
BRCA	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg26384229	chr12:38710491	ALG10B	0.66	15.14	0.51	1.78e-44	Bladder cancer;
BRCA	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.78	0.62	2.8e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.29	-8.03	-0.3	4.68e-15	Monocyte percentage of white cells;
BRCA	cis	rs12347191	0.500	rs973473	chr9:100620730	T/G	cg13688889	chr9:100608707	NA	-0.49	-9.96	-0.37	8.33e-22	Orofacial clefts;
BRCA	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.34	-0.31	4.5e-16	Total body bone mineral density;
BRCA	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-11.39	-0.41	1.76e-27	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6121246	0.559	rs10439608	chr20:30258814	T/C	cg21427119	chr20:30132790	HM13	-0.35	-7.92	-0.3	1.06e-14	Mean corpuscular hemoglobin;
BRCA	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg17425144	chr1:10567563	PEX14	0.63	16.63	0.55	6.95e-52	Breast size;
BRCA	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg06970220	chr1:156163860	SLC25A44	0.4	9.71	0.36	7.2e-21	Testicular germ cell tumor;
BRCA	cis	rs2625529	0.652	rs2957740	chr15:72307691	A/G	cg16672083	chr15:72433130	SENP8	0.69	16.77	0.55	1.32e-52	Red blood cell count;
BRCA	cis	rs877282	0.945	rs17293517	chr10:778770	C/T	cg17470449	chr10:769945	NA	0.52	8.8	0.33	1.22e-17	Uric acid levels;
BRCA	cis	rs9790314	0.663	rs61105146	chr3:160651949	T/A	cg03342759	chr3:160939853	NMD3	0.44	8.52	0.32	1.18e-16	Morning vs. evening chronotype;
BRCA	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	13.73	0.48	8.52e-38	Hip circumference adjusted for BMI;
BRCA	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg13010199	chr12:38710504	ALG10B	0.48	9.53	0.35	3.25e-20	Morning vs. evening chronotype;
BRCA	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.55	0.42	3.81e-28	Tonsillectomy;
BRCA	cis	rs2742234	0.541	rs10899786	chr10:43744583	G/A	cg02780029	chr10:43622663	RET	0.36	7.98	0.3	6.56e-15	Hirschsprung disease;
BRCA	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg11822812	chr5:140052017	DND1	-0.32	-8.69	-0.33	3.01e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg26384229	chr12:38710491	ALG10B	-0.43	-9.87	-0.36	1.75e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg12463550	chr7:65579703	CRCP	0.38	8.21	0.31	1.23e-15	Aortic root size;
BRCA	cis	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg06521331	chr12:34319734	NA	-0.67	-14.69	-0.5	2.6e-42	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19346786	chr7:2764209	NA	-0.36	-10.56	-0.39	4e-24	Height;
BRCA	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg20887711	chr4:1340912	KIAA1530	0.36	8.55	0.32	9.29e-17	Longevity;
BRCA	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.98	-0.3	6.79e-15	Bipolar disorder;
BRCA	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.35	9.01	0.34	2.3e-18	Resting heart rate;
BRCA	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.03e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg07810366	chr2:100720526	AFF3	-0.31	-7.9	-0.3	1.2e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs6005807	0.719	rs73430118	chr22:28913950	C/T	cg12565055	chr22:29076175	TTC28	0.46	8.45	0.32	1.97e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg07460842	chr6:66804631	NA	0.69	11.58	0.42	2.68e-28	Exhaled nitric oxide output;
BRCA	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11644478	chr21:40555479	PSMG1	-0.68	-15.46	-0.52	4.87e-46	Cognitive function;
BRCA	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg10523679	chr1:76189770	ACADM	-0.47	-9.1	-0.34	1.12e-18	Daytime sleep phenotypes;
BRCA	cis	rs10743315	0.599	rs11044451	chr12:19365798	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.55	-9.08	-0.34	1.29e-18	Gut microbiota (bacterial taxa);
BRCA	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg22800045	chr5:56110881	MAP3K1	-0.58	-9.93	-0.37	1.04e-21	Initial pursuit acceleration;
BRCA	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg04248312	chr19:17393744	ANKLE1	0.93	21.55	0.65	7.33e-78	Systemic lupus erythematosus;
BRCA	cis	rs7246657	0.654	rs10407568	chr19:38123009	A/T	cg14683738	chr19:37701593	ZNF585B	0.47	8.12	0.31	2.4e-15	Coronary artery calcification;
BRCA	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.72	-11.68	-0.42	1.05e-28	Red cell distribution width;
BRCA	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg17425144	chr1:10567563	PEX14	0.62	16.4	0.54	1.02e-50	Breast size;
BRCA	cis	rs113835537	0.529	rs11227510	chr11:66281220	T/C	cg24851651	chr11:66362959	CCS	0.44	8.29	0.31	6.92e-16	Airway imaging phenotypes;
BRCA	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	9.97	0.37	7.22e-22	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg17366294	chr4:99064904	C4orf37	0.42	9.81	0.36	2.94e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg05283184	chr6:79620031	NA	-0.36	-8.78	-0.33	1.54e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12292205	chr6:26970375	C6orf41	0.48	8.03	0.3	4.67e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg26818010	chr10:134567672	INPP5A	-0.79	-15.89	-0.53	3.58e-48	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs3857536	0.842	rs2188591	chr6:66939511	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs10046574	0.561	rs10226494	chr7:135214412	C/G	cg27474649	chr7:135195673	CNOT4	0.61	10.42	0.38	1.35e-23	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg22676075	chr6:135203613	NA	0.44	8.6	0.32	6.06e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.25	7.91	0.3	1.15e-14	Parkinson's disease;
BRCA	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg25173405	chr17:45401733	C17orf57	-0.51	-10.8	-0.39	4.43e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg23791538	chr6:167370224	RNASET2	-0.42	-10.05	-0.37	3.79e-22	Crohn's disease;
BRCA	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	ch.11.42038R	chr11:967971	AP2A2	0.46	13.98	0.48	5.97e-39	Alzheimer's disease (late onset);
BRCA	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg16405210	chr4:1374714	KIAA1530	-0.36	-7.83	-0.3	2.02e-14	Obesity-related traits;
BRCA	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.19	0.4	1.17e-26	Bipolar disorder;
BRCA	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg26818010	chr10:134567672	INPP5A	-0.54	-12.47	-0.44	4.05e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg11584989	chr19:19387371	SF4	0.64	13.51	0.47	8.71e-37	Bipolar disorder;
BRCA	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg06494592	chr3:125709126	NA	-0.53	-8.25	-0.31	9.2e-16	Blood pressure (smoking interaction);
BRCA	trans	rs8073060	0.586	rs225296	chr17:33924847	C/G	cg19694781	chr19:47549865	TMEM160	-1.0	-21.66	-0.65	1.96e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs7520050	0.966	rs6429582	chr1:46321843	C/T	cg24296786	chr1:45957014	TESK2	-0.44	-9.75	-0.36	5.11e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9341808	0.754	rs9352808	chr6:80997342	G/T	cg08355045	chr6:80787529	NA	0.35	9.01	0.34	2.36e-18	Sitting height ratio;
BRCA	cis	rs2764208	0.599	rs9368828	chr6:34661449	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.26	7.94	0.3	9.21e-15	Systemic lupus erythematosus;
BRCA	cis	rs4891159	0.790	rs660029	chr18:74149668	A/G	cg24786174	chr18:74118243	ZNF516	0.8	22.99	0.67	1.06e-85	Longevity;
BRCA	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11644478	chr21:40555479	PSMG1	0.84	19.08	0.6	1.5e-64	Cognitive function;
BRCA	trans	rs4650994	0.525	rs2493858	chr1:178541210	A/G	cg05059571	chr16:84539110	KIAA1609	-0.57	-12.7	-0.45	4.24e-33	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	18.57	0.59	7.05e-62	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs877282	0.945	rs11253396	chr10:789754	C/T	cg22713356	chr15:30763199	NA	1.42	28.55	0.75	3.22e-116	Uric acid levels;
BRCA	cis	rs9487051	0.738	rs171272	chr6:109530094	T/C	cg21918786	chr6:109611834	NA	-0.33	-8.87	-0.33	7.57e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08109568	chr15:31115862	NA	-0.45	-10.37	-0.38	2.14e-23	Huntington's disease progression;
BRCA	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.52	-9.82	-0.36	2.72e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12997796	0.556	rs13004867	chr2:86982504	C/G	cg25203885	chr2:87302643	LOC285074	-0.6	-9.8	-0.36	3.16e-21	Schizophrenia;
BRCA	cis	rs3849570	1.000	rs3849570	chr3:81792112	C/A	cg07356753	chr3:81810745	GBE1	-0.47	-11.41	-0.41	1.35e-27	Waist circumference;Body mass index;
BRCA	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg07080220	chr10:102295463	HIF1AN	0.6	14.4	0.5	6.25e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.09	0.49	1.88e-39	Eye color traits;
BRCA	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg26248373	chr2:1572462	NA	-0.62	-14.47	-0.5	2.94e-41	IgG glycosylation;
BRCA	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs3815700	0.841	rs10410895	chr19:33093655	T/G	cg02997394	chr19:33096574	ANKRD27	0.69	11.52	0.41	4.75e-28	Eosinophilic esophagitis;
BRCA	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.43	-0.41	1.14e-27	Gut microbiome composition (summer);
BRCA	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	9.81	0.36	2.99e-21	Tonsillectomy;
BRCA	cis	rs10128251	0.650	rs4469789	chr10:5712366	A/G	cg24097872	chr10:5724021	NA	0.44	9.95	0.37	8.44e-22	Childhood ear infection;
BRCA	cis	rs12530845	0.673	rs4073627	chr7:135312572	A/G	cg23117316	chr7:135346802	PL-5283	0.36	7.85	0.3	1.78e-14	Red blood cell traits;
BRCA	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg08917208	chr2:24149416	ATAD2B	0.54	8.43	0.32	2.29e-16	Asthma;
BRCA	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg24558204	chr6:135376177	HBS1L	0.45	12.36	0.44	1.22e-31	Red blood cell count;
BRCA	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11644478	chr21:40555479	PSMG1	0.84	19.08	0.6	1.5e-64	Cognitive function;
BRCA	cis	rs3857067	0.806	rs4693374	chr4:95086164	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.15	-0.34	7.51e-19	QT interval;
BRCA	cis	rs1707322	1.000	rs1613296	chr1:46546852	A/C	cg03146154	chr1:46216737	IPP	-0.42	-9.15	-0.34	7.39e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07930192	chr7:1003750	NA	0.41	8.7	0.33	2.76e-17	Longevity;Endometriosis;
BRCA	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11890956	chr21:40555474	PSMG1	1.01	24.99	0.7	1.11e-96	Cognitive function;
BRCA	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-9.32	-0.35	1.82e-19	Colorectal cancer;
BRCA	cis	rs17021463	0.902	rs10516950	chr4:95254730	C/T	cg11021082	chr4:95130006	SMARCAD1	0.4	9.28	0.34	2.64e-19	Testicular germ cell tumor;
BRCA	cis	rs250677	1.000	rs36069	chr5:148417253	G/C	cg18129178	chr5:148520854	ABLIM3	-0.57	-11.69	-0.42	9.61e-29	Breast cancer;
BRCA	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg13770153	chr20:60521292	NA	-0.45	-10.79	-0.39	4.77e-25	Body mass index;
BRCA	cis	rs2710642	0.962	rs7557501	chr2:63086639	C/T	cg17519650	chr2:63277830	OTX1	0.37	8.14	0.31	2.04e-15	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg02297831	chr4:17616191	MED28	0.36	8.49	0.32	1.41e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg16606324	chr3:10149918	C3orf24	0.49	9.81	0.36	2.97e-21	Alzheimer's disease;
BRCA	cis	rs4290604	0.748	rs12692198	chr2:238057391	C/A	cg23555395	chr2:238036564	NA	-0.51	-8.36	-0.31	3.94e-16	Asthma;
BRCA	cis	rs2882667	0.690	rs700627	chr5:138119400	A/T	cg04439458	chr5:138467593	SIL1	0.31	7.87	0.3	1.47e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	14.54	0.5	1.32e-41	Exhaled nitric oxide levels;
BRCA	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg08470875	chr2:26401718	FAM59B	-0.5	-8.17	-0.31	1.65e-15	Gut microbiome composition (summer);
BRCA	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.57	-0.47	4.99e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg03188948	chr7:1209495	NA	0.86	11.78	0.42	3.91e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6545883	0.895	rs2421192	chr2:61643631	T/C	cg15711740	chr2:61764176	XPO1	0.53	13.48	0.47	1.19e-36	Tuberculosis;
BRCA	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg08885076	chr2:99613938	TSGA10	-0.59	-13.21	-0.46	2.12e-35	Chronic sinus infection;
BRCA	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.15	0.31	1.87e-15	Tonsillectomy;
BRCA	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg00383909	chr3:49044727	WDR6	0.73	12.12	0.43	1.36e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg26384229	chr12:38710491	ALG10B	0.85	22.52	0.67	3.94e-83	Heart rate;
BRCA	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.59	-0.35	1.96e-20	Tonsillectomy;
BRCA	cis	rs7715806	0.500	rs2291630	chr5:75013356	G/A	cg19683494	chr5:74908142	NA	0.53	8.58	0.32	7.25e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	11.34	0.41	2.9e-27	Platelet count;
BRCA	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	11.58	0.42	2.75e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9649465	1.000	rs12537287	chr7:123364747	G/A	cg04330084	chr7:123175371	IQUB	-0.34	-9.1	-0.34	1.14e-18	Migraine;
BRCA	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg16506815	chr2:162101123	NA	0.45	9.59	0.35	1.88e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.51	9.36	0.35	1.32e-19	Height;
BRCA	cis	rs3772130	0.923	rs3805127	chr3:121556751	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.05	0.37	3.52e-22	Cognitive performance;
BRCA	cis	rs1577917	0.816	rs9353349	chr6:86707725	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.44	11.69	0.42	9.61e-29	Response to antipsychotic treatment;
BRCA	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg00339695	chr16:24857497	SLC5A11	-0.34	-7.82	-0.3	2.15e-14	Intelligence (multi-trait analysis);
BRCA	trans	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.6	0.39	2.78e-24	Type 2 diabetes;
BRCA	cis	rs1403694	0.695	rs10439971	chr3:186434188	C/T	cg12454167	chr3:186435060	KNG1	0.29	7.92	0.3	1.04e-14	Blood protein levels;
BRCA	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.4	9.02	0.34	2.14e-18	Eosinophil percentage of white cells;
BRCA	cis	rs11229555	0.645	rs11229489	chr11:58244917	A/G	cg15696309	chr11:58395628	NA	-0.52	-10.72	-0.39	9.29e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs11671005	0.504	rs3794963	chr19:59071051	C/G	cg22037779	chr5:139682734	PFDN1	0.54	10.93	0.4	1.34e-25	Mean platelet volume;
BRCA	cis	rs1904096	0.506	rs7697827	chr4:95184748	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-8.21	-0.31	1.22e-15	Type 2 diabetes;
BRCA	cis	rs868036	1.000	rs4325504	chr15:68055570	A/G	cg08079166	chr15:68083412	MAP2K5	-0.33	-8.71	-0.33	2.52e-17	Restless legs syndrome;
BRCA	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg17724175	chr1:150552817	MCL1	0.24	7.8	0.3	2.45e-14	Melanoma;
BRCA	cis	rs1476679	1.000	rs1476679	chr7:100004446	C/T	cg19116668	chr7:99932089	PMS2L1	0.48	8.87	0.33	7.34e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7512552	0.809	rs698923	chr1:150379159	G/A	cg15654264	chr1:150340011	RPRD2	0.43	9.23	0.34	3.93e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg22307297	chr20:60903441	LAMA5	0.36	9.93	0.37	1.03e-21	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14240646	chr10:27532245	ACBD5	0.64	9.52	0.35	3.43e-20	Breast cancer;
BRCA	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.02	0.58	5.02e-59	Fuchs's corneal dystrophy;
BRCA	cis	rs919433	0.679	rs6708239	chr2:198525084	A/G	cg00792783	chr2:198669748	PLCL1	0.39	9.03	0.34	2.08e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg19743168	chr1:23544995	NA	-0.46	-11.52	-0.41	4.8e-28	Height;
BRCA	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg24060327	chr5:131705240	SLC22A5	-0.4	-7.85	-0.3	1.82e-14	Acylcarnitine levels;
BRCA	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg21782813	chr7:2030301	MAD1L1	0.32	8.57	0.32	7.59e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs2625529	0.730	rs2929527	chr15:72282270	T/G	cg16672083	chr15:72433130	SENP8	0.66	15.72	0.53	2.5e-47	Red blood cell count;
BRCA	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg15103426	chr22:29168792	CCDC117	0.54	12.78	0.45	1.76e-33	Lymphocyte counts;
BRCA	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg14664628	chr15:75095509	CSK	0.4	9.14	0.34	7.89e-19	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.85	-19.71	-0.61	6.75e-68	Myeloid white cell count;
BRCA	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11890956	chr21:40555474	PSMG1	0.81	13.24	0.46	1.52e-35	Cognitive function;
BRCA	cis	rs4363385	0.818	rs559236	chr1:153010510	T/C	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03264133	chr6:25882463	NA	0.54	11.23	0.41	7.69e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.67	-0.32	3.43e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg14092571	chr14:90743983	NA	-0.81	-21.7	-0.65	1.26e-78	Gut microbiota (bacterial taxa);
BRCA	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.95	0.33	3.85e-18	Ovarian reserve;
BRCA	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	17.75	0.57	1.36e-57	Alzheimer's disease;
BRCA	cis	rs7264396	0.887	rs224360	chr20:34059675	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.41	8.53	0.32	1.03e-16	Total cholesterol levels;
BRCA	trans	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.84	-28.07	-0.74	1.43e-113	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs68092024	0.731	rs793480	chr3:99488364	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-10.56	-0.39	3.85e-24	Cleft lip with or without cleft palate;
BRCA	trans	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg13565492	chr6:43139072	SRF	-0.79	-10.95	-0.4	1.07e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg05340658	chr4:99064831	C4orf37	0.49	10.77	0.39	5.83e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4363385	0.818	rs2070964	chr1:153004213	C/T	cg24667326	chr1:152973720	SPRR3	-0.31	-8.52	-0.32	1.16e-16	Inflammatory skin disease;
BRCA	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg08807101	chr21:30365312	RNF160	-0.6	-15.0	-0.51	8.49e-44	Dental caries;
BRCA	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-10.11	-0.37	2.21e-22	Body mass index;
BRCA	cis	rs2070433	0.948	rs2839304	chr21:47952650	C/G	cg05998816	chr21:47859926	PCNT	-0.37	-8.77	-0.33	1.64e-17	Lymphocyte counts;
BRCA	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg23796481	chr11:64053134	BAD;GPR137	0.5	10.53	0.38	5.17e-24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs921968	0.565	rs2059717	chr2:219600316	A/T	cg02176678	chr2:219576539	TTLL4	-0.41	-10.93	-0.4	1.35e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.4	0.47	2.88e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6931421	1.000	rs6931421	chr6:80880138	A/C	cg08355045	chr6:80787529	NA	0.41	9.15	0.34	7.83e-19	Sitting height ratio;
BRCA	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg21770322	chr7:97807741	LMTK2	0.44	11.72	0.42	7.34e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg11657440	chr19:46296263	DMWD	0.71	19.22	0.61	2.7e-65	Coronary artery disease;
BRCA	cis	rs4363385	0.647	rs1995308	chr1:153014082	A/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.38	-0.31	3.35e-16	Inflammatory skin disease;
BRCA	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg13319975	chr6:146136371	FBXO30	-0.41	-9.39	-0.35	1e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg03188948	chr7:1209495	NA	-0.52	-9.63	-0.36	1.34e-20	Longevity;Endometriosis;
BRCA	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg13628971	chr7:2884303	GNA12	0.38	8.57	0.32	7.68e-17	Height;
BRCA	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg04546413	chr19:29218101	NA	0.49	8.47	0.32	1.63e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.53	0.32	1.07e-16	Cognitive ability;
BRCA	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg23625390	chr15:77176239	SCAPER	0.54	13.74	0.48	8.09e-38	Blood metabolite levels;
BRCA	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	trans	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.89	0.3	1.35e-14	Endometrial cancer;
BRCA	cis	rs6120849	0.754	rs3746446	chr20:33574765	T/C	cg24642439	chr20:33292090	TP53INP2	0.59	10.18	0.37	1.16e-22	Protein C levels;
BRCA	cis	rs151349	1.000	rs108727	chr20:57584890	C/T	cg23907860	chr20:57583709	CTSZ	0.45	11.06	0.4	3.92e-26	Platelet distribution width;
BRCA	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg09754948	chr16:28834200	ATXN2L	0.45	8.9	0.33	5.77e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg05283184	chr6:79620031	NA	-0.43	-11.21	-0.41	9.28e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg06060754	chr5:176797920	RGS14	-0.67	-10.3	-0.38	4.09e-23	Urate levels in lean individuals;
BRCA	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	17.73	0.57	1.61e-57	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs77972916	0.505	rs6719754	chr2:43526386	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-11.05	-0.4	4.32e-26	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1451375	0.669	rs59086818	chr7:50653830	G/A	cg18232548	chr7:50535776	DDC	0.4	9.24	0.34	3.6e-19	Malaria;
BRCA	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.47	-0.32	1.74e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8028182	0.577	rs28693593	chr15:75849776	A/C	cg20655648	chr15:75932815	IMP3	0.44	8.7	0.33	2.74e-17	Sudden cardiac arrest;
BRCA	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-11.31	-0.41	3.55e-27	Morning vs. evening chronotype;
BRCA	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg08999081	chr20:33150536	PIGU	0.45	12.72	0.45	3.46e-33	Glomerular filtration rate (creatinine);
BRCA	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.71	-0.39	9.99e-25	Bone mineral density;
BRCA	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18876405	chr7:65276391	NA	-0.57	-13.43	-0.47	2.16e-36	Aortic root size;
BRCA	cis	rs10504073	0.584	rs11778863	chr8:49954893	C/T	cg00325661	chr8:49890786	NA	0.49	14.07	0.49	2.32e-39	Blood metabolite ratios;
BRCA	cis	rs9487051	0.834	rs351728	chr6:109549099	T/C	cg01475377	chr6:109611718	NA	-0.41	-9.76	-0.36	4.7e-21	Reticulocyte fraction of red cells;
BRCA	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg24879335	chr3:133465180	TF	0.32	10.89	0.4	1.97e-25	Iron status biomarkers (transferrin levels);
BRCA	cis	rs1371614	0.635	rs12618836	chr2:27137616	A/G	cg12368169	chr2:27073192	DPYSL5	0.29	8.55	0.32	9.18e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	14.46	0.5	3.41e-41	Personality dimensions;
BRCA	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg08422745	chr4:174089978	GALNT7	-0.81	-18.41	-0.59	4.71e-61	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg25036284	chr2:26402008	FAM59B	0.77	10.71	0.39	1.01e-24	Gut microbiome composition (summer);
BRCA	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11890956	chr21:40555474	PSMG1	-0.62	-13.9	-0.48	1.43e-38	Menarche (age at onset);
BRCA	trans	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg06521331	chr12:34319734	NA	-0.5	-9.26	-0.34	3.16e-19	Morning vs. evening chronotype;
BRCA	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg10729496	chr3:10149963	C3orf24	-0.49	-9.24	-0.34	3.62e-19	Alzheimer's disease;
BRCA	cis	rs10992471	0.528	rs1924243	chr9:95224847	C/T	cg14631576	chr9:95140430	CENPP	-0.35	-8.86	-0.33	8.14e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg24006582	chr15:45444508	DUOX1	-0.55	-11.45	-0.41	9.28e-28	Uric acid levels;
BRCA	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg08601574	chr20:25228251	PYGB	0.41	9.62	0.36	1.49e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg24006582	chr15:45444508	DUOX1	-0.55	-11.31	-0.41	3.61e-27	Uric acid levels;
BRCA	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg26384229	chr12:38710491	ALG10B	0.57	13.13	0.46	5.01e-35	Morning vs. evening chronotype;
BRCA	cis	rs10463316	0.817	rs6877498	chr5:150802876	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.59	-0.32	6.42e-17	Metabolite levels (Pyroglutamine);
BRCA	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg23791538	chr6:167370224	RNASET2	0.51	13.06	0.46	9.76e-35	Crohn's disease;
BRCA	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg02079420	chr8:82753780	SNX16	0.32	8.64	0.32	4.33e-17	Diastolic blood pressure;
BRCA	cis	rs4891159	0.790	rs77878087	chr18:74116337	G/A	cg24786174	chr18:74118243	ZNF516	-0.76	-18.62	-0.59	4e-62	Longevity;
BRCA	cis	rs9297145	0.678	rs62473007	chr7:98749598	G/C	cg05967295	chr7:98741636	SMURF1	0.86	16.26	0.54	5.17e-50	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	trans	rs61931739	0.612	rs1906137	chr12:33939676	T/A	cg26384229	chr12:38710491	ALG10B	0.39	8.8	0.33	1.27e-17	Morning vs. evening chronotype;
BRCA	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26314531	chr2:26401878	FAM59B	-0.66	-11.2	-0.4	1.08e-26	Gut microbiome composition (summer);
BRCA	cis	rs9296092	0.560	rs17627049	chr6:33537802	G/T	cg13560919	chr6:33536144	NA	-0.92	-19.27	-0.61	1.44e-65	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg19622623	chr12:86230825	RASSF9	-0.35	-9.57	-0.35	2.21e-20	Major depressive disorder;
BRCA	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg12179176	chr11:130786555	SNX19	0.71	16.4	0.54	1.04e-50	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-12.82	-0.45	1.26e-33	Myopia (pathological);
BRCA	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	11.61	0.42	1.98e-28	Rheumatoid arthritis;
BRCA	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg23029597	chr12:123009494	RSRC2	-0.62	-12.62	-0.45	9.4e-33	Body mass index;
BRCA	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg24006582	chr15:45444508	DUOX1	0.56	11.23	0.41	8.18e-27	Uric acid levels;
BRCA	cis	rs2580764	0.515	rs4672005	chr2:55246551	C/T	cg09592903	chr2:55203963	RTN4	-0.39	-9.87	-0.36	1.73e-21	Mean platelet volume;
BRCA	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg00321850	chr1:175162397	KIAA0040	-0.41	-11.37	-0.41	2.11e-27	Alcohol dependence;
BRCA	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.34	8.75	0.33	1.92e-17	IgG glycosylation;
BRCA	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg08213375	chr14:104286397	PPP1R13B	0.42	9.05	0.34	1.69e-18	Reticulocyte count;
BRCA	cis	rs4423214	0.840	rs1629220	chr11:71174553	C/T	cg05163923	chr11:71159392	DHCR7	-0.58	-11.63	-0.42	1.67e-28	Vitamin D levels;
BRCA	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-11.46	-0.41	9.02e-28	Hemoglobin concentration;
BRCA	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg16109817	chr1:16162209	FLJ37453	-0.29	-8.16	-0.31	1.84e-15	Systolic blood pressure;
BRCA	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg20283391	chr11:68216788	NA	-0.45	-9.3	-0.35	2.17e-19	Total body bone mineral density;
BRCA	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.48e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg05507819	chr15:63340323	TPM1	0.42	9.14	0.34	7.97e-19	Platelet count;
BRCA	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg15556689	chr8:8085844	FLJ10661	-0.35	-8.57	-0.32	8.04e-17	Neuroticism;
BRCA	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs4363385	0.818	rs10888525	chr1:153000215	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.38	-0.31	3.34e-16	Inflammatory skin disease;
BRCA	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg14004847	chr7:1930337	MAD1L1	-0.44	-8.84	-0.33	9.29e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-10.56	-0.39	3.73e-24	Bladder cancer;
BRCA	cis	rs36051895	0.623	rs2381215	chr9:5262607	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-8.37	-0.31	3.61e-16	Pediatric autoimmune diseases;
BRCA	cis	rs6456156	1.000	rs6456156	chr6:167522300	T/C	cg07741184	chr6:167504864	NA	0.28	8.39	0.32	3.08e-16	Primary biliary cholangitis;
BRCA	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg08514558	chr10:81106712	PPIF	0.36	8.78	0.33	1.55e-17	Height;
BRCA	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.23	0.31	1.06e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-13.78	-0.48	5.11e-38	Colorectal cancer;
BRCA	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	11.48	0.41	7.53e-28	Tonsillectomy;
BRCA	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg01262667	chr19:19385393	TM6SF2	-0.42	-10.79	-0.39	4.77e-25	Tonsillectomy;
BRCA	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.51	11.19	0.4	1.1e-26	Multiple sclerosis;
BRCA	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg08807892	chr2:162101083	NA	-0.47	-9.23	-0.34	3.98e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg22907277	chr7:1156413	C7orf50	0.6	9.01	0.34	2.28e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.37	7.85	0.3	1.73e-14	Total cholesterol levels;
BRCA	cis	rs1190552	0.739	rs1998421	chr14:102979644	C/T	cg18135206	chr14:102964638	TECPR2	0.43	8.34	0.31	4.66e-16	Blood protein levels;
BRCA	cis	rs6750795	0.569	rs1667308	chr2:232406344	T/C	cg19187155	chr2:232395269	NMUR1	0.69	17.51	0.57	2.19e-56	Height;
BRCA	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-9.66	-0.36	1.04e-20	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9297145	0.761	rs62473015	chr7:98763301	G/A	cg05967295	chr7:98741636	SMURF1	0.96	18.17	0.58	8.37e-60	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	trans	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg06784218	chr1:46089804	CCDC17	0.45	10.79	0.39	4.97e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg20307385	chr11:47447363	PSMC3	0.41	9.22	0.34	4.13e-19	Subjective well-being;
BRCA	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg17366294	chr4:99064904	C4orf37	0.43	9.94	0.37	9.98e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg03923535	chr7:1197113	ZFAND2A	0.46	9.31	0.35	2.04e-19	Longevity;Endometriosis;
BRCA	cis	rs877282	0.583	rs12356155	chr10:823940	C/T	cg15764593	chr10:829463	NA	-0.65	-10.71	-0.39	1.02e-24	Uric acid levels;
BRCA	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg03585969	chr10:35415529	CREM	0.55	11.15	0.4	1.65e-26	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg23762105	chr12:34175262	ALG10	0.37	9.58	0.35	2.16e-20	Morning vs. evening chronotype;
BRCA	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg17135325	chr3:160939158	NMD3	0.39	7.82	0.3	2.14e-14	Parkinson's disease;
BRCA	cis	rs7520050	0.966	rs6668284	chr1:46354510	G/A	cg24296786	chr1:45957014	TESK2	0.43	9.73	0.36	5.98e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4853036	1.000	rs3732269	chr2:70046255	G/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-8.86	-0.33	7.8e-18	Colorectal or endometrial cancer;
BRCA	cis	rs11984145	1.000	rs73121399	chr7:38870368	T/C	cg19327137	chr7:38886074	VPS41	0.5	7.91	0.3	1.15e-14	Cognitive performance;
BRCA	cis	rs73001065	0.551	rs10424702	chr19:19508013	A/G	cg03709012	chr19:19516395	GATAD2A	0.99	14.79	0.51	8.7e-43	LDL cholesterol;
BRCA	cis	rs17253792	0.822	rs17685102	chr14:56129214	A/G	cg01858014	chr14:56050164	KTN1	-0.74	-9.16	-0.34	7.15e-19	Putamen volume;
BRCA	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	12.41	0.44	8.15e-32	Platelet count;
BRCA	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg27535305	chr1:53392650	SCP2	-0.49	-12.27	-0.44	3.16e-31	Monocyte count;
BRCA	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg08888203	chr3:10149979	C3orf24	0.55	11.76	0.42	4.89e-29	Alzheimer's disease;
BRCA	cis	rs6450176	0.638	rs1542167	chr5:53305742	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-17.27	-0.56	4.13e-55	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg23719950	chr11:63933701	MACROD1	-0.52	-8.31	-0.31	5.61e-16	Mean platelet volume;
BRCA	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg17063962	chr7:91808500	NA	0.52	12.38	0.44	1.01e-31	Breast cancer;
BRCA	cis	rs778371	0.723	rs6710294	chr2:233579634	T/C	cg08000102	chr2:233561755	GIGYF2	0.85	21.05	0.64	3.79e-75	Schizophrenia;
BRCA	cis	rs870825	0.929	rs2310102	chr4:185595141	C/G	cg04058563	chr4:185651563	MLF1IP	-0.63	-11.33	-0.41	3.05e-27	Blood protein levels;
BRCA	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.64	0.39	1.83e-24	IgG glycosylation;
BRCA	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg09307838	chr4:120376055	NA	0.77	17.15	0.56	1.63e-54	Corneal astigmatism;
BRCA	cis	rs68170813	0.559	rs80307895	chr7:106907781	T/A	cg02696742	chr7:106810147	HBP1	-0.53	-8.63	-0.32	4.99e-17	Coronary artery disease;
BRCA	cis	rs7903847	0.620	rs11189165	chr10:99123457	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.34	-0.31	4.5e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg05340658	chr4:99064831	C4orf37	0.67	16.71	0.55	2.87e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg18898632	chr2:242989856	NA	-0.51	-8.56	-0.32	8.62e-17	Obesity-related traits;
BRCA	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg09021430	chr5:549028	NA	-0.65	-13.68	-0.48	1.54e-37	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg13877915	chr19:58951672	ZNF132	0.46	10.81	0.39	4.09e-25	Uric acid clearance;
BRCA	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg17211192	chr8:82754475	SNX16	-0.56	-11.54	-0.42	4.05e-28	Diastolic blood pressure;
BRCA	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg18252515	chr7:66147081	NA	-0.82	-11.88	-0.43	1.52e-29	Diabetic kidney disease;
BRCA	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg21433313	chr16:3507492	NAT15	0.45	10.04	0.37	4.18e-22	Tuberculosis;
BRCA	cis	rs6545883	0.862	rs11691734	chr2:61702466	C/T	cg15711740	chr2:61764176	XPO1	-0.52	-13.14	-0.46	4.63e-35	Tuberculosis;
BRCA	cis	rs2742234	0.541	rs7096500	chr10:43712095	C/T	cg15436174	chr10:43711423	RASGEF1A	0.53	10.6	0.39	2.76e-24	Hirschsprung disease;
BRCA	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg24069376	chr3:38537580	EXOG	-0.42	-11.94	-0.43	8.5e-30	Electrocardiographic conduction measures;
BRCA	cis	rs2171564	0.791	rs4682420	chr3:112440692	C/T	cg06685282	chr3:112453648	NA	-0.36	-8.73	-0.33	2.15e-17	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	12.68	0.45	5.22e-33	Hip circumference adjusted for BMI;
BRCA	cis	rs1420338	0.967	rs2192874	chr7:34144916	G/A	cg01275685	chr7:34179230	BMPER	-0.51	-11.46	-0.41	8.84e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24531977	chr5:56204891	C5orf35	-0.87	-19.03	-0.6	2.76e-64	Initial pursuit acceleration;
BRCA	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.03	-0.3	4.64e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg23649088	chr2:200775458	C2orf69	0.6	8.85	0.33	8.7e-18	Schizophrenia;
BRCA	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg08885076	chr2:99613938	TSGA10	0.58	13.1	0.46	6.64e-35	Chronic sinus infection;
BRCA	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg00106254	chr7:1943704	MAD1L1	-0.42	-10.14	-0.37	1.61e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.59	13.82	0.48	3.46e-38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg03060546	chr3:49711283	APEH	0.6	10.38	0.38	1.97e-23	Menarche (age at onset);
BRCA	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.32	8.64	0.32	4.53e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.45	7.95	0.3	8.75e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs27434	0.583	rs34764	chr5:96155229	A/G	cg16492584	chr5:96139282	ERAP1	-0.51	-12.82	-0.45	1.15e-33	Ankylosing spondylitis;
BRCA	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-17.01	-0.56	8.42e-54	Colorectal cancer;
BRCA	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.89	0.45	6.08e-34	Bipolar disorder;
BRCA	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg09904177	chr6:26538194	HMGN4	0.55	17.65	0.57	4.4e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg21132104	chr15:45694354	SPATA5L1	0.45	9.58	0.35	2.04e-20	Response to fenofibrate (adiponectin levels);
BRCA	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg26031613	chr14:104095156	KLC1	0.53	9.58	0.35	2.12e-20	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7523273	0.606	rs2761430	chr1:207912408	G/A	cg22525895	chr1:207977042	MIR29B2	0.48	12.21	0.43	5.66e-31	Schizophrenia;
BRCA	cis	rs11585357	0.895	rs112208664	chr1:17632010	G/A	cg19159961	chr1:17633534	PADI4	0.58	9.68	0.36	8.83e-21	Hair shape;
BRCA	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.71	15.34	0.52	1.87e-45	Total cholesterol levels;
BRCA	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg26384229	chr12:38710491	ALG10B	0.85	22.95	0.67	1.8e-85	Heart rate;
BRCA	cis	rs4908768	0.501	rs7527389	chr1:8556545	A/G	cg20416874	chr1:8611966	RERE	-0.29	-8.29	-0.31	6.52e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.07	0.62	7.44e-70	Electrocardiographic conduction measures;
BRCA	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.68	-0.32	3.39e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg09307838	chr4:120376055	NA	0.75	16.63	0.55	7.36e-52	Corneal astigmatism;
BRCA	trans	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg23762105	chr12:34175262	ALG10	0.37	8.55	0.32	9.33e-17	Morning vs. evening chronotype;
BRCA	cis	rs7095944	0.613	rs11245366	chr10:126482849	C/T	cg08799069	chr10:126477246	METTL10	-0.39	-9.29	-0.34	2.46e-19	Asthma;
BRCA	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.74	0.36	5.32e-21	Bipolar disorder;
BRCA	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg01939980	chr4:1354348	KIAA1530	0.36	10.26	0.38	5.74e-23	Longevity;
BRCA	cis	rs3741151	0.773	rs73542976	chr11:73127471	A/G	cg17517138	chr11:73019481	ARHGEF17	0.88	12.73	0.45	3.1e-33	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg16325326	chr1:53192061	ZYG11B	0.86	25.13	0.7	2.04e-97	Monocyte count;
BRCA	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg06618935	chr21:46677482	NA	-0.36	-7.93	-0.3	9.76e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.53	-0.35	3.1e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs701145	0.938	rs2971446	chr3:154073445	G/C	cg17054900	chr3:154042577	DHX36	0.66	11.59	0.42	2.54e-28	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs752010	0.644	rs6700390	chr1:42112554	A/G	cg06885757	chr1:42089581	HIVEP3	0.27	9.39	0.35	1.01e-19	Lupus nephritis in systemic lupus erythematosus;
BRCA	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.49	-0.47	1.09e-36	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.29	-0.31	6.57e-16	Bipolar disorder;
BRCA	cis	rs7646881	0.812	rs79303235	chr3:158444793	C/T	cg19483011	chr3:158453295	NA	-0.47	-8.18	-0.31	1.5e-15	Tetralogy of Fallot;
BRCA	cis	rs7737355	1.000	rs12521320	chr5:130755920	A/G	cg06307176	chr5:131281290	NA	-0.5	-9.74	-0.36	5.22e-21	Life satisfaction;
BRCA	cis	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg06521331	chr12:34319734	NA	-0.65	-11.93	-0.43	9.53e-30	Morning vs. evening chronotype;
BRCA	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg15395560	chr15:45543142	SLC28A2	0.29	7.85	0.3	1.74e-14	Glomerular filtration rate;
BRCA	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg07169764	chr2:136633963	MCM6	1.22	24.82	0.7	9.71e-96	Corneal structure;
BRCA	trans	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg25214090	chr10:38739885	LOC399744	0.53	11.86	0.42	1.81e-29	Corneal astigmatism;
BRCA	cis	rs10463316	0.817	rs10040628	chr5:150821027	T/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-8.66	-0.32	3.76e-17	Metabolite levels (Pyroglutamine);
BRCA	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg24562669	chr7:97807699	LMTK2	0.46	12.22	0.44	5e-31	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs2018683	0.624	rs2286220	chr7:28998699	G/C	cg19402173	chr7:128379420	CALU	-0.48	-11.73	-0.42	6.82e-29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs953387	1.000	rs2056297	chr2:136899116	G/T	cg05194412	chr2:137003533	NA	-0.37	-8.62	-0.32	5.45e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg06115741	chr20:33292138	TP53INP2	0.39	8.67	0.32	3.53e-17	Coronary artery disease;
BRCA	cis	rs9811920	0.715	rs6810262	chr3:99906342	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.39	8.94	0.33	4.13e-18	Axial length;
BRCA	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg01529538	chr14:23388837	RBM23	0.41	11.12	0.4	2.25e-26	Cognitive ability (multi-trait analysis);
BRCA	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg01420254	chr6:26195488	NA	0.55	8.56	0.32	8.23e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs6543140	0.855	rs4851591	chr2:103077423	T/C	cg04239558	chr2:103089729	SLC9A4	0.34	9.6	0.36	1.72e-20	Blood protein levels;
BRCA	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	12.93	0.46	3.8e-34	Lymphocyte counts;
BRCA	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg27588902	chr6:42928151	GNMT	-0.31	-10.15	-0.37	1.49e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg18230493	chr5:56204884	C5orf35	0.53	10.82	0.39	3.71e-25	Type 2 diabetes;
BRCA	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg13334819	chr7:99746414	C7orf59	0.34	8.05	0.3	4.16e-15	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg03676636	chr4:99064102	C4orf37	0.21	8.03	0.3	4.61e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7178424	0.875	rs2414753	chr15:62200974	T/C	cg00456672	chr15:62358751	C2CD4A	-0.42	-9.34	-0.35	1.5700000000000001e-19	Height;
BRCA	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	8.65e-21	Menopause (age at onset);
BRCA	cis	rs11779988	0.545	rs397096	chr8:17798848	C/G	cg01800426	chr8:17659068	MTUS1	0.43	8.99	0.33	2.84e-18	Breast cancer;
BRCA	cis	rs7520050	0.807	rs72688483	chr1:46149209	A/G	cg24296786	chr1:45957014	TESK2	-0.47	-10.87	-0.39	2.32e-25	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24549020	chr5:56110836	MAP3K1	-0.63	-12.48	-0.44	3.86e-32	Initial pursuit acceleration;
BRCA	cis	rs72781680	0.756	rs2551337	chr2:24006886	C/T	cg08917208	chr2:24149416	ATAD2B	0.6	9.72	0.36	6.17e-21	Lymphocyte counts;
BRCA	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.98	0.56	1.21e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.77	0.36	4.33e-21	Morning vs. evening chronotype;
BRCA	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg17971929	chr21:40555470	PSMG1	0.79	18.56	0.59	7.95e-62	Cognitive function;
BRCA	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08109568	chr15:31115862	NA	-0.45	-10.55	-0.39	4.37e-24	Huntington's disease progression;
BRCA	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.6	0.5	6.87e-42	Personality dimensions;
BRCA	cis	rs7264396	0.836	rs2010565	chr20:34182517	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-11.84	-0.42	2.21e-29	Total cholesterol levels;
BRCA	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	18.68	0.59	1.76e-62	Alzheimer's disease;
BRCA	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg23711669	chr6:146136114	FBXO30	0.74	15.75	0.53	1.89e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9815354	1.000	rs56207540	chr3:41976627	G/C	cg03022575	chr3:42003672	ULK4	0.7	9.67	0.36	9.51e-21	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg06521331	chr12:34319734	NA	-0.53	-10.02	-0.37	4.82e-22	Bladder cancer;
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg12419862	chr22:24373484	LOC391322	-0.92	-24.24	-0.69	1.53e-92	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs34779708	0.897	rs7900480	chr10:35338699	A/G	cg03585969	chr10:35415529	CREM	-0.42	-8.53	-0.32	1.05e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg23033748	chr14:75592666	NEK9	-0.34	-7.98	-0.3	6.71e-15	Height;
BRCA	cis	rs9837602	0.938	rs10511177	chr3:99724873	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.54	-10.56	-0.39	4.01e-24	Breast cancer;
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg26608667	chr7:1196370	ZFAND2A	0.4	9.03	0.34	1.93e-18	Longevity;Endometriosis;
BRCA	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg06636001	chr8:8085503	FLJ10661	0.54	10.92	0.4	1.37e-25	Retinal vascular caliber;
BRCA	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.61	0.36	1.65e-20	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.78	0.55	1.19e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg08847533	chr14:75593920	NEK9	-0.83	-20.34	-0.63	2.66e-71	Height;
BRCA	cis	rs34779708	0.733	rs16935948	chr10:35549748	C/G	cg03585969	chr10:35415529	CREM	0.41	8.41	0.32	2.77e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg24692254	chr21:30365293	RNF160	-0.46	-8.19	-0.31	1.45e-15	Cognitive test performance;
BRCA	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg18850127	chr7:39170497	POU6F2	0.39	8.24	0.31	1.01e-15	IgG glycosylation;
BRCA	trans	rs11088226	0.645	rs2409457	chr21:33929895	T/C	cg09050820	chr6:167586206	TCP10L2	0.76	13.66	0.48	1.9e-37	Gastritis;
BRCA	trans	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg19862616	chr7:65841803	NCRNA00174	0.79	24.71	0.7	3.87e-95	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs13046373	0.534	rs9305426	chr21:31964916	A/C	cg16812893	chr21:31813075	KRTAP15-1	0.4	9.67	0.36	9.39e-21	HDL cholesterol;
BRCA	trans	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg19694781	chr19:47549865	TMEM160	-0.32	-7.85	-0.3	1.78e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs12541635	0.934	rs10955407	chr8:107020648	G/A	cg10147462	chr8:107024639	NA	0.35	9.82	0.36	2.76e-21	Age of smoking initiation;
BRCA	cis	rs12618769	0.597	rs4851136	chr2:99060873	A/T	cg10123293	chr2:99228465	UNC50	0.41	8.14	0.31	2.05e-15	Bipolar disorder;
BRCA	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14240646	chr10:27532245	ACBD5	-0.62	-9.58	-0.35	2.13e-20	Breast cancer;
BRCA	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg16414030	chr3:133502952	NA	-0.47	-11.19	-0.4	1.11e-26	Iron status biomarkers;
BRCA	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg10756475	chr4:1757242	NA	-0.37	-8.6	-0.32	5.99e-17	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg16262614	chr3:133464971	TF	0.24	7.91	0.3	1.12e-14	Iron status biomarkers (transferrin levels);
BRCA	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg26384229	chr12:38710491	ALG10B	0.76	16.63	0.55	7.3e-52	Morning vs. evening chronotype;
BRCA	cis	rs67981189	0.634	rs221898	chr14:71605516	A/G	cg15816911	chr14:71606274	NA	0.4	8.89	0.33	6.42e-18	Schizophrenia;
BRCA	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.42	0.38	1.42e-23	Motion sickness;
BRCA	cis	rs4722585	0.533	rs2237335	chr7:26200213	A/G	cg07876897	chr7:26191696	NFE2L3	0.41	8.77	0.33	1.67e-17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
BRCA	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.72	9.81	0.36	3.06e-21	Initial pursuit acceleration;
BRCA	cis	rs4478858	0.647	rs12752761	chr1:31710888	T/C	cg00250761	chr1:31883323	NA	-0.32	-8.21	-0.31	1.19e-15	Alcohol dependence;
BRCA	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.49	8.68	0.32	3.34e-17	Body mass index (adult);
BRCA	cis	rs6429082	0.715	rs2131923	chr1:235580821	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.55	-13.78	-0.48	4.97e-38	Adiposity;
BRCA	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg13736514	chr6:26305472	NA	0.36	11.97	0.43	6.35e-30	Educational attainment;
BRCA	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.03e-57	Fuchs's corneal dystrophy;
BRCA	trans	rs208520	0.802	rs851600	chr6:66893754	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-17.6	-0.57	7.86e-57	Exhaled nitric oxide output;
BRCA	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg21045802	chr8:109455806	TTC35	0.34	7.82	0.3	2.18e-14	Dupuytren's disease;
BRCA	cis	rs13046373	0.507	rs2832959	chr21:31982934	C/T	cg16431978	chr21:31797932	KRTAP13-3	0.37	9.37	0.35	1.27e-19	HDL cholesterol;
BRCA	cis	rs10181042	0.535	rs2441465	chr2:61311187	C/T	cg15711740	chr2:61764176	XPO1	-0.38	-9.54	-0.35	2.85e-20	Crohn's disease;
BRCA	cis	rs35110281	0.600	rs914198	chr21:45117456	A/C	cg21573476	chr21:45109991	RRP1B	-0.39	-10.23	-0.38	7.64e-23	Mean corpuscular volume;
BRCA	cis	rs6901250	0.851	rs9374624	chr6:117145837	A/C	cg12892004	chr6:117198278	RFX6	0.47	10.97	0.4	9.06e-26	C-reactive protein levels;
BRCA	cis	rs4594175	0.926	rs60234748	chr14:51630102	T/C	cg23942311	chr14:51606299	NA	0.33	8.27	0.31	7.87e-16	Cancer;
BRCA	cis	rs1577917	0.958	rs12198971	chr6:86525445	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.54	-0.42	4.21e-28	Response to antipsychotic treatment;
BRCA	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.81	-0.33	1.17e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg02951883	chr7:2050386	MAD1L1	-0.53	-11.54	-0.42	4.17e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.96	0.3	7.63e-15	Depression;
BRCA	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg02734326	chr4:10020555	SLC2A9	0.4	8.72	0.33	2.46e-17	Bone mineral density;
BRCA	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg23358479	chr7:1110784	C7orf50	-0.47	-7.9	-0.3	1.26e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg16506815	chr2:162101123	NA	-0.45	-8.69	-0.32	3.15e-17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
BRCA	cis	rs11229555	0.609	rs34133416	chr11:58184720	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs2262909	0.962	rs73019842	chr19:22249909	T/G	cg17074339	chr11:11642133	GALNTL4	0.42	8.14	0.31	2.13e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg25174290	chr11:3078921	CARS	0.44	13.75	0.48	6.97e-38	Longevity;
BRCA	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg20203395	chr5:56204925	C5orf35	0.63	12.4	0.44	8.78e-32	Initial pursuit acceleration;
BRCA	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	9.72	0.36	6.5e-21	Personality dimensions;
BRCA	cis	rs332507	0.830	rs2242425	chr3:124398644	A/G	cg05980111	chr3:124395277	KALRN	0.37	8.41	0.32	2.73e-16	Plateletcrit;
BRCA	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7092929	0.831	rs667943	chr10:3575417	C/T	cg14308648	chr10:3568949	NA	0.45	8.02	0.3	4.92e-15	Coronary artery calcification;
BRCA	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg17691542	chr6:26056736	HIST1H1C	0.52	10.47	0.38	8.91e-24	Height;
BRCA	cis	rs12464559	0.522	rs12472627	chr2:152633114	C/T	cg01189475	chr2:152685088	ARL5A	0.56	8.32	0.31	5.3e-16	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg17971929	chr21:40555470	PSMG1	0.75	16.28	0.54	4.32e-50	Cognitive function;
BRCA	cis	rs921968	0.528	rs13022583	chr2:219589175	T/C	cg02176678	chr2:219576539	TTLL4	-0.4	-10.97	-0.4	8.94e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg02527881	chr3:46936655	PTH1R	-0.36	-8.37	-0.31	3.76e-16	Birth weight;
BRCA	cis	rs2336384	1.000	rs6672267	chr1:12054911	A/G	cg13216073	chr1:12042593	MFN2	0.46	9.92	0.37	1.18e-21	Platelet count;
BRCA	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs9309711	0.961	rs35067331	chr2:3474085	C/T	cg10845886	chr2:3471009	TTC15	-0.8	-16.67	-0.55	4.62e-52	Neurofibrillary tangles;
BRCA	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.05	-0.34	1.66e-18	Total body bone mineral density;
BRCA	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.29	-0.31	6.47e-16	Colorectal cancer;
BRCA	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg25237894	chr2:233734115	C2orf82	0.4	11.51	0.41	5.29e-28	Coronary artery disease;
BRCA	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.59	13.01	0.46	1.7e-34	Depressive symptoms;
BRCA	trans	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-8.04	-0.3	4.52e-15	Neuroticism;
BRCA	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg06627628	chr2:24431161	ITSN2	-0.81	-14.39	-0.49	7.5e-41	Asthma;
BRCA	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.57	12.04	0.43	3.08e-30	Lymphocyte counts;
BRCA	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg03929089	chr4:120376271	NA	-0.44	-8.32	-0.31	5.44e-16	Height;
BRCA	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	8.74	0.33	2.01e-17	Iron status biomarkers;
BRCA	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg04998671	chr14:104000505	TRMT61A	-0.43	-9.5	-0.35	4.27e-20	Coronary artery disease;
BRCA	trans	rs62103177	0.608	rs8088089	chr18:77832154	A/G	cg05926928	chr17:57297772	GDPD1	-0.77	-10.88	-0.4	2.12e-25	Opioid sensitivity;
BRCA	cis	rs7590368	0.926	rs12621237	chr2:10957538	T/C	cg15705551	chr2:10952987	PDIA6	0.46	8.75	0.33	1.86e-17	Educational attainment (years of education);
BRCA	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg21724239	chr8:58056113	NA	0.62	9.78	0.36	3.87e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.34	-7.97	-0.3	7.46e-15	Alzheimer's disease (late onset);
BRCA	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03452623	chr4:187889614	NA	-0.31	-10.06	-0.37	3.36e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.49	0.32	1.42e-16	Menopause (age at onset);
BRCA	cis	rs36051895	0.623	rs6476955	chr9:5256533	C/G	cg02405213	chr9:5042618	JAK2	-0.45	-8.58	-0.32	7.16e-17	Pediatric autoimmune diseases;
BRCA	cis	rs1371614	0.545	rs1057115	chr2:27172069	T/C	cg00617064	chr2:27272375	NA	0.31	8.0	0.3	5.86e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg03146154	chr1:46216737	IPP	0.47	10.23	0.38	7.6e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg23033748	chr14:75592666	NEK9	0.35	8.17	0.31	1.72e-15	Height;
BRCA	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.85e-29	Chronic sinus infection;
BRCA	cis	rs3784262	0.669	rs4646597	chr15:58300768	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.8	-0.36	3.14e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs2066819	1.000	rs77768890	chr12:56725121	A/G	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg22705602	chr4:152727874	NA	-0.32	-8.0	-0.3	6.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg08885076	chr2:99613938	TSGA10	-0.57	-12.71	-0.45	3.59e-33	Chronic sinus infection;
BRCA	cis	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg05901451	chr6:126070800	HEY2	-0.39	-9.41	-0.35	9.06e-20	Endometrial cancer;
BRCA	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg23711669	chr6:146136114	FBXO30	0.74	17.75	0.57	1.29e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-8.16	-0.31	1.81e-15	Tonsillectomy;
BRCA	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg25358565	chr5:93447407	FAM172A	1.16	17.91	0.58	1.93e-58	Diabetic retinopathy;
BRCA	cis	rs75229567	0.618	rs11177853	chr12:70184924	A/G	cg10114359	chr12:70132523	RAB3IP	1.17	13.1	0.46	6.84e-35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
BRCA	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg15605315	chr1:45957053	TESK2	0.46	9.37	0.35	1.19e-19	High light scatter reticulocyte count;
BRCA	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg06618935	chr21:46677482	NA	-0.37	-7.99	-0.3	6.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs524281	0.861	rs1862005	chr11:65863402	T/C	cg16950941	chr11:66035639	RAB1B	-0.38	-8.05	-0.3	4.15e-15	Electroencephalogram traits;
BRCA	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg13256891	chr4:100009986	ADH5	0.43	8.86	0.33	7.78e-18	Alcohol dependence;
BRCA	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg12011299	chr4:100065546	ADH4	0.42	11.1	0.4	2.67e-26	Alcohol dependence;
BRCA	trans	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs6543140	0.601	rs78178597	chr2:103023596	G/T	cg04239558	chr2:103089729	SLC9A4	0.32	7.84	0.3	1.95e-14	Blood protein levels;
BRCA	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg12444411	chr7:2802554	GNA12	0.34	8.64	0.32	4.6e-17	Height;
BRCA	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.27	-0.31	7.72e-16	Gut microbiome composition (summer);
BRCA	cis	rs6840360	0.593	rs11723227	chr4:152689717	G/A	cg22705602	chr4:152727874	NA	-0.38	-10.45	-0.38	1.08e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	19.72	0.62	5.57e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg08859206	chr1:53392774	SCP2	-0.61	-13.04	-0.46	1.29e-34	Monocyte count;
BRCA	cis	rs10129255	0.556	rs6576224	chr14:107186236	G/A	cg07958169	chr14:107095056	NA	-0.4	-8.48	-0.32	1.59e-16	Kawasaki disease;
BRCA	cis	rs6977660	0.714	rs10155949	chr7:19834747	T/C	cg07541023	chr7:19748670	TWISTNB	0.54	9.25	0.34	3.21e-19	Thyroid stimulating hormone;
BRCA	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg16606324	chr3:10149918	C3orf24	0.56	11.06	0.4	3.88e-26	Alzheimer's disease;
BRCA	cis	rs6433895	1.000	rs7558428	chr2:182018554	C/T	cg00481216	chr2:181971175	NA	-0.39	-9.12	-0.34	9.27e-19	Lymphocyte counts;
BRCA	cis	rs16854884	0.657	rs6778627	chr3:143720869	G/T	cg06585982	chr3:143692056	C3orf58	0.42	8.86	0.33	8.11e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.74	-0.42	5.84e-29	Bipolar disorder;
BRCA	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg24069376	chr3:38537580	EXOG	-0.42	-12.09	-0.43	1.88e-30	Electrocardiographic conduction measures;
BRCA	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg04166393	chr7:2884313	GNA12	0.4	8.39	0.31	3.23e-16	Height;
BRCA	cis	rs5771069	0.933	rs137848	chr22:50440296	A/G	cg03721641	chr22:50451245	IL17REL	0.3	8.83	0.33	1.02e-17	Ulcerative colitis;
BRCA	cis	rs6714710	0.603	rs6757357	chr2:98491750	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	13.5	0.47	9.75e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg26384229	chr12:38710491	ALG10B	0.85	22.64	0.67	8.85e-84	Heart rate;
BRCA	cis	rs9790314	0.747	rs9848239	chr3:160823488	A/C	cg03342759	chr3:160939853	NMD3	-0.54	-10.52	-0.38	5.41e-24	Morning vs. evening chronotype;
BRCA	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg26248373	chr2:1572462	NA	-0.65	-15.81	-0.53	9.41e-48	IgG glycosylation;
BRCA	cis	rs7677751	0.848	rs4635872	chr4:55099041	C/A	cg17187183	chr4:55093834	PDGFRA	0.44	9.07	0.34	1.44e-18	Corneal astigmatism;
BRCA	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg22903471	chr2:27725779	GCKR	-0.36	-8.83	-0.33	1.04e-17	Total body bone mineral density;
BRCA	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg24562669	chr7:97807699	LMTK2	0.47	12.39	0.44	9.53e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs13046373	0.535	rs2832966	chr21:32017177	A/G	cg27071517	chr21:31768726	KRTAP13-1	0.29	8.08	0.3	3.2e-15	HDL cholesterol;
BRCA	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg00074818	chr8:8560427	CLDN23	0.39	8.61	0.32	5.71e-17	Obesity-related traits;
BRCA	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg04455712	chr21:45112962	RRP1B	0.4	10.47	0.38	8.8e-24	Mean corpuscular volume;
BRCA	cis	rs7640424	0.659	rs7639774	chr3:107816216	T/G	cg09227934	chr3:107805635	CD47	-0.43	-8.19	-0.31	1.44e-15	Body mass index;
BRCA	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg00945666	chr1:160990265	F11R	-0.27	-8.0	-0.3	6.03e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.33	0.31	4.76e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03517284	chr6:25882590	NA	-0.44	-10.24	-0.38	6.87e-23	Blood metabolite levels;
BRCA	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.43	-0.41	1.14e-27	Colorectal cancer;
BRCA	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.21	0.34	4.65e-19	Tonsillectomy;
BRCA	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg04944784	chr2:26401820	FAM59B	-0.66	-11.17	-0.4	1.41e-26	Gut microbiome composition (summer);
BRCA	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.86	-0.3	1.64e-14	Colorectal cancer;
BRCA	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.08e-57	Fuchs's corneal dystrophy;
BRCA	trans	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.46	0.32	1.88e-16	Mean corpuscular volume;
BRCA	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg01262667	chr19:19385393	TM6SF2	0.41	10.51	0.38	6.09e-24	Tonsillectomy;
BRCA	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg06627628	chr2:24431161	ITSN2	-0.54	-8.81	-0.33	1.15e-17	Lymphocyte counts;
BRCA	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg20283391	chr11:68216788	NA	0.43	8.62	0.32	5.07e-17	Total body bone mineral density;
BRCA	cis	rs13082711	0.911	rs13077400	chr3:27473066	A/G	cg02860705	chr3:27208620	NA	0.54	10.59	0.39	2.91e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs6763687	0.828	rs2219263	chr3:171786974	A/C	cg16233210	chr3:171778391	FNDC3B	0.39	8.64	0.32	4.37e-17	Red cell distribution width;
BRCA	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.42	8.33	0.31	4.82e-16	Height;
BRCA	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg04518342	chr5:131593106	PDLIM4	0.36	9.09	0.34	1.25e-18	Breast cancer;
BRCA	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.46	0.35	5.93e-20	Tonsillectomy;
BRCA	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	11.63	0.42	1.66e-28	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.04	16.01	0.54	9.44e-49	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs68170813	0.559	rs2023892	chr7:106847686	C/T	cg02696742	chr7:106810147	HBP1	0.48	8.2	0.31	1.36e-15	Coronary artery disease;
BRCA	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg13073564	chr4:8508604	NA	-0.38	-10.36	-0.38	2.43e-23	Response to antineoplastic agents;
BRCA	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg04944784	chr2:26401820	FAM59B	-0.95	-16.17	-0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	11.32	0.41	3.22e-27	Multiple sclerosis;
BRCA	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg16482183	chr6:26056742	HIST1H1C	0.45	8.76	0.33	1.8e-17	Iron status biomarkers;
BRCA	cis	rs460214	0.528	rs6517474	chr21:40023133	G/A	cg21578987	chr21:40029669	ERG	0.35	8.27	0.31	7.79e-16	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.77e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg08564027	chr20:61660810	NA	0.85	22.71	0.67	3.5e-84	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4588572	0.644	rs7714871	chr5:77754268	G/T	cg11547950	chr5:77652471	NA	-0.45	-8.55	-0.32	9.09e-17	Triglycerides;
BRCA	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06108461	chr20:60628389	TAF4	-0.98	-22.1	-0.66	8.19e-81	Body mass index;
BRCA	cis	rs2797160	1.000	rs1777225	chr6:126018270	T/C	cg05901451	chr6:126070800	HEY2	0.4	9.62	0.36	1.48e-20	Endometrial cancer;
BRCA	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg21782813	chr7:2030301	MAD1L1	0.41	10.83	0.39	3.14e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-8.7	-0.33	2.91e-17	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg04545296	chr12:48745243	ZNF641	0.25	8.3	0.31	5.97e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs7586879	0.929	rs6545808	chr2:25124388	C/A	cg01884057	chr2:25150051	NA	0.34	8.49	0.32	1.4e-16	Body mass index;
BRCA	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.5	-9.88	-0.36	1.6e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg06970220	chr1:156163860	SLC25A44	0.39	9.45	0.35	6.4e-20	Testicular germ cell tumor;
BRCA	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18357526	chr6:26021779	HIST1H4A	0.5	9.13	0.34	8.8e-19	Intelligence (multi-trait analysis);
BRCA	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg15704280	chr7:45808275	SEPT13	0.62	10.23	0.38	7.37e-23	Axial length;
BRCA	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg05283184	chr6:79620031	NA	-0.43	-10.93	-0.4	1.28e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs10992471	0.603	rs10761155	chr9:95153729	C/G	cg14631576	chr9:95140430	CENPP	-0.39	-9.48	-0.35	5.08e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs13136331	0.532	rs2615477	chr4:88579803	T/C	cg22416721	chr4:88570574	DMP1	-0.6	-14.52	-0.5	1.71e-41	Sitting height ratio;
BRCA	cis	rs11690935	0.959	rs6724337	chr2:172735329	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.9	-29.48	-0.76	2.81e-121	Schizophrenia;
BRCA	cis	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg05901451	chr6:126070800	HEY2	0.4	9.73	0.36	6.12e-21	Endometrial cancer;
BRCA	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.7	-19.84	-0.62	1.23e-68	Longevity;Endometriosis;
BRCA	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.74	-0.42	5.64e-29	Bipolar disorder;
BRCA	cis	rs295140	0.507	rs13019821	chr2:201106815	C/G	cg23649088	chr2:200775458	C2orf69	-0.39	-8.11	-0.31	2.53e-15	QT interval;
BRCA	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg24296786	chr1:45957014	TESK2	-0.46	-10.54	-0.38	4.68e-24	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg08888203	chr3:10149979	C3orf24	0.65	11.93	0.43	8.91e-30	Alzheimer's disease;
BRCA	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg23229984	chr5:148520753	ABLIM3	0.36	8.74	0.33	2.06e-17	Breast cancer;
BRCA	trans	rs3857536	0.740	rs7769722	chr6:66891363	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-9.49	-0.35	4.6e-20	Blood trace element (Cu levels);
BRCA	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	14.98	0.51	1.08e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1874326	0.524	rs6968570	chr7:138110039	T/G	cg18008034	chr7:138118925	NA	-0.44	-9.2	-0.34	5.03e-19	Quantitative traits;
BRCA	cis	rs6435161	0.959	rs72926961	chr2:203489948	G/A	cg18429434	chr2:203499731	FAM117B	-0.43	-8.28	-0.31	7.37e-16	Total cholesterol levels;
BRCA	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg01262667	chr19:19385393	TM6SF2	0.43	11.19	0.4	1.14e-26	Tonsillectomy;
BRCA	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg24531977	chr5:56204891	C5orf35	-0.63	-13.94	-0.48	8.86e-39	Coronary artery disease;
BRCA	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	13.73	0.48	8.4e-38	Lymphocyte counts;
BRCA	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg24558204	chr6:135376177	HBS1L	0.44	12.2	0.43	6.19e-31	Red blood cell count;
BRCA	cis	rs7246657	0.524	rs28542490	chr19:37456584	C/A	cg18154014	chr19:37997991	ZNF793	0.52	8.94	0.33	4.31e-18	Coronary artery calcification;
BRCA	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	8.26	0.31	8.22e-16	Aortic root size;
BRCA	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.2e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs16958440	0.867	rs79285649	chr18:44699019	A/T	cg17192377	chr18:44677553	HDHD2	0.99	13.47	0.47	1.43e-36	Sitting height ratio;
BRCA	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg24829409	chr8:58192753	C8orf71	-0.47	-8.98	-0.33	2.97e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg24397884	chr7:158709396	WDR60	0.7	15.37	0.52	1.31e-45	Height;
BRCA	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg23708337	chr7:1209742	NA	0.47	7.84	0.3	1.92e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg06784218	chr1:46089804	CCDC17	0.5	12.08	0.43	2.02e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg25427524	chr10:38739819	LOC399744	-0.52	-9.65	-0.36	1.12e-20	Obesity (extreme);
BRCA	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.53	-0.35	3.34e-20	Metabolite levels;
BRCA	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.66	0.32	3.82e-17	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg25036284	chr2:26402008	FAM59B	-0.7	-11.49	-0.41	6.85e-28	Gut microbiome composition (summer);
BRCA	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	11.32	0.41	3.23e-27	Monocyte percentage of white cells;
BRCA	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg08000102	chr2:233561755	GIGYF2	-0.61	-13.43	-0.47	2.03e-36	Coronary artery disease;
BRCA	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	17.0	0.56	9.23e-54	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.88	-0.3	1.39e-14	Prostate cancer;
BRCA	cis	rs2016266	0.855	rs6580941	chr12:53662199	T/C	cg26875137	chr12:53738046	NA	0.39	9.41	0.35	8.82e-20	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg18357645	chr12:58087776	OS9	-0.33	-8.0	-0.3	5.66e-15	Multiple sclerosis;
BRCA	cis	rs939658	0.805	rs8036435	chr15:79420031	T/C	cg17916960	chr15:79447300	NA	-0.46	-11.49	-0.41	6.72e-28	Refractive error;
BRCA	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg00277334	chr10:82204260	NA	-0.85	-24.9	-0.7	3.41e-96	Post bronchodilator FEV1;
BRCA	cis	rs7131987	0.903	rs10843371	chr12:29414232	G/A	cg09582351	chr12:29534625	ERGIC2	-0.47	-11.56	-0.42	3.34e-28	QT interval;
BRCA	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg04013093	chr6:42928303	GNMT	-0.29	-8.93	-0.33	4.64e-18	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	12.69	0.45	4.45e-33	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg18230493	chr5:56204884	C5orf35	-0.72	-14.07	-0.49	2.32e-39	Initial pursuit acceleration;
BRCA	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg16743903	chr16:89593216	SPG7	0.31	7.81	0.3	2.41e-14	Multiple myeloma (IgH translocation);
BRCA	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg03161606	chr19:29218774	NA	0.46	8.11	0.31	2.56e-15	Methadone dose in opioid dependence;
BRCA	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-10.58	-0.39	3.11e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg06521331	chr12:34319734	NA	-0.54	-9.65	-0.36	1.13e-20	Bladder cancer;
BRCA	cis	rs1829883	0.775	rs7717158	chr5:98843529	C/T	cg08333243	chr5:99726346	NA	-0.36	-8.1	-0.3	2.9e-15	Hemostatic factors and hematological phenotypes;
BRCA	trans	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.66	-0.32	3.7e-17	Urinary tract infection frequency;
BRCA	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg04691961	chr3:161091175	C3orf57	-0.59	-14.13	-0.49	1.19e-39	Morning vs. evening chronotype;
BRCA	cis	rs2013441	1.000	rs11654025	chr17:20198160	A/T	cg13482628	chr17:19912719	NA	-0.37	-8.15	-0.31	1.9e-15	Obesity-related traits;
BRCA	cis	rs10504073	0.584	rs55838473	chr8:49948281	C/A	cg00325661	chr8:49890786	NA	0.49	14.23	0.49	4.24e-40	Blood metabolite ratios;
BRCA	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-9.21	-0.34	4.72e-19	Morning vs. evening chronotype;
BRCA	cis	rs6430585	0.527	rs7592050	chr2:136459227	C/T	cg07169764	chr2:136633963	MCM6	-1.02	-19.72	-0.62	5.72e-68	Corneal structure;
BRCA	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg08917208	chr2:24149416	ATAD2B	1.04	14.17	0.49	8.05e-40	Lymphocyte counts;
BRCA	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg10057126	chr4:77819792	ANKRD56	0.51	11.01	0.4	6.04e-26	Emphysema distribution in smoking;
BRCA	cis	rs2882667	0.858	rs11956159	chr5:138408568	T/C	cg04439458	chr5:138467593	SIL1	-0.43	-10.83	-0.39	3.31e-25	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4862307	0.836	rs6829678	chr4:185001631	C/T	cg06737308	chr4:185021514	ENPP6	-0.37	-8.23	-0.31	1.05e-15	Serum dimethylarginine levels (asymmetric/symetric ratio);
BRCA	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg18132916	chr6:79620363	NA	-0.44	-9.89	-0.36	1.47e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg24562669	chr7:97807699	LMTK2	0.44	11.84	0.42	2.12e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg01475377	chr6:109611718	NA	-0.6	-16.46	-0.55	5.32e-51	Reticulocyte fraction of red cells;
BRCA	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg23625390	chr15:77176239	SCAPER	-0.52	-12.24	-0.44	4.28e-31	Blood metabolite levels;
BRCA	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-12.94	-0.46	3.67e-34	Response to antipsychotic treatment;
BRCA	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.37e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs9790314	0.663	rs10513559	chr3:160667465	G/A	cg03342759	chr3:160939853	NMD3	0.46	8.72	0.33	2.47e-17	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.44	0.38	1.19e-23	Motion sickness;
BRCA	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.78	0.36	3.77e-21	Bipolar disorder;
BRCA	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg06970220	chr1:156163860	SLC25A44	0.39	9.47	0.35	5.38e-20	Testicular germ cell tumor;
BRCA	cis	rs858239	0.601	rs73272053	chr7:23155525	A/G	cg23682824	chr7:23144976	KLHL7	0.4	10.26	0.38	5.65e-23	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs8073060	0.504	rs225271	chr17:33969836	C/T	cg19694781	chr19:47549865	TMEM160	-1.05	-21.83	-0.65	2.3e-79	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs1577917	1.000	rs13199006	chr6:86608708	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-11.28	-0.41	5.11e-27	Response to antipsychotic treatment;
BRCA	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	19.61	0.61	2.24e-67	Platelet count;
BRCA	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg06064525	chr11:970664	AP2A2	-0.49	-16.41	-0.54	9.05e-51	Alzheimer's disease (late onset);
BRCA	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg27446573	chr6:127587934	RNF146	-0.69	-15.6	-0.53	1.01e-46	Breast cancer;
BRCA	cis	rs701145	0.640	rs896016	chr3:153929902	C/T	cg17054900	chr3:154042577	DHX36	0.43	8.18	0.31	1.59e-15	Coronary artery disease;
BRCA	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg21427119	chr20:30132790	HM13	-0.43	-8.99	-0.33	2.86e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs7903847	0.642	rs10786339	chr10:99153076	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.78	-0.33	1.53e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs72792276	1.000	rs17839658	chr5:127423013	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	10.32	0.38	3.32e-23	Red cell distribution width;
BRCA	cis	rs1678542	0.679	rs10783834	chr12:57975953	G/C	cg00677455	chr12:58241039	CTDSP2	0.38	7.81	0.3	2.34e-14	Rheumatoid arthritis;
BRCA	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6738485	0.589	rs13021716	chr2:106837931	A/C	cg16099169	chr2:106886729	NA	-0.37	-7.93	-0.3	9.83e-15	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
BRCA	trans	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.48	-10.17	-0.37	1.32e-22	Mean corpuscular volume;
BRCA	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg26116260	chr4:7069785	GRPEL1	0.88	22.52	0.67	3.79e-83	Monocyte percentage of white cells;
BRCA	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03517284	chr6:25882590	NA	-0.51	-11.52	-0.41	5.1e-28	Blood metabolite levels;
BRCA	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	8.6	0.32	6.27e-17	Height;
BRCA	cis	rs7607369	0.536	rs12694443	chr2:219664977	G/T	cg02176678	chr2:219576539	TTLL4	-0.38	-10.1	-0.37	2.3e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs11249608	0.548	rs35568336	chr5:178451854	A/G	cg21905437	chr5:178450457	ZNF879	0.55	11.3	0.41	3.89e-27	Pubertal anthropometrics;
BRCA	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-11.74	-0.42	6.17e-29	Chronic sinus infection;
BRCA	cis	rs7903847	0.642	rs11189204	chr10:99164394	C/T	cg08345082	chr10:99160200	RRP12	-0.3	-8.75	-0.33	1.95e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg08807101	chr21:30365312	RNF160	-0.44	-9.44	-0.35	7.1e-20	Dental caries;
BRCA	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg05340658	chr4:99064831	C4orf37	0.65	15.98	0.53	1.35e-48	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.99	-0.3	6.39e-15	Prostate cancer;
BRCA	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg11663144	chr21:46675770	NA	-0.6	-13.88	-0.48	1.88e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.23	-0.49	4.16e-40	Eye color traits;
BRCA	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg11584989	chr19:19387371	SF4	0.64	13.49	0.47	1.14e-36	Bipolar disorder;
BRCA	cis	rs9462027	0.628	rs7769961	chr6:34760162	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.88	-0.3	1.44e-14	Systemic lupus erythematosus;
BRCA	trans	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg07817883	chr1:32538562	TMEM39B	0.53	8.58	0.32	7.44e-17	Monocyte percentage of white cells;
BRCA	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.65	-14.26	-0.49	2.85e-40	Lung cancer;
BRCA	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.65	10.41	0.38	1.57e-23	Renal function-related traits (BUN);
BRCA	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg01181863	chr3:195395398	SDHAP2	-0.46	-8.01	-0.3	5.54e-15	Pancreatic cancer;
BRCA	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg12935359	chr14:103987150	CKB	-0.59	-13.99	-0.48	5.55e-39	Body mass index;
BRCA	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.05e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg26516362	chr5:178986906	RUFY1	0.44	12.39	0.44	9.58e-32	Lung cancer;
BRCA	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg26384229	chr12:38710491	ALG10B	0.84	22.26	0.66	1.06e-81	Heart rate;
BRCA	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg00677455	chr12:58241039	CTDSP2	0.64	15.95	0.53	1.79e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg03161606	chr19:29218774	NA	0.46	8.04	0.3	4.23e-15	Methadone dose in opioid dependence;
BRCA	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg13770153	chr20:60521292	NA	-0.39	-9.17	-0.34	6.67e-19	Body mass index;
BRCA	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg22920501	chr2:26401640	FAM59B	-0.9	-16.0	-0.53	1.07e-48	Gut microbiome composition (summer);
BRCA	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg20701182	chr2:24300061	SF3B14	0.66	9.65	0.36	1.17e-20	Lymphocyte counts;
BRCA	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13126279	chr21:47581558	C21orf56	-0.5	-10.68	-0.39	1.29e-24	Testicular germ cell tumor;
BRCA	cis	rs73086581	1.000	rs56324992	chr20:3978153	C/A	cg02187196	chr20:3869020	PANK2	0.43	7.83	0.3	2.07e-14	Response to antidepressants in depression;
BRCA	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg16339924	chr4:17578868	LAP3	0.6	14.62	0.5	5.9e-42	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg11764359	chr7:65958608	NA	-0.77	-18.03	-0.58	4.5e-59	Aortic root size;
BRCA	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg00757033	chr12:89920650	WDR51B	0.55	11.24	0.41	7.05e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs55882075	1.000	rs55882075	chr5:179210115	C/G	cg14593053	chr5:179126677	CANX	0.41	10.31	0.38	3.6e-23	Monocyte percentage of white cells;
BRCA	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg11502198	chr6:26597334	ABT1	0.48	9.69	0.36	8.28e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg06026331	chr20:60912101	LAMA5	0.61	12.03	0.43	3.57e-30	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.82	-0.33	1.07e-17	Alzheimer's disease (late onset);
BRCA	cis	rs3857067	0.836	rs12501138	chr4:95098444	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.33	-0.35	1.66e-19	QT interval;
BRCA	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg18964960	chr10:1102726	WDR37	0.53	9.03	0.34	1.97e-18	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23583168	chr7:148888333	NA	-0.79	-18.98	-0.6	4.88e-64	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2559856	1.000	rs2695284	chr12:102089318	A/G	cg12924262	chr12:102091054	CHPT1	-0.38	-8.57	-0.32	7.86e-17	Blood protein levels;
BRCA	cis	rs6088813	0.885	rs224331	chr20:34022387	A/C	cg14752227	chr20:34000481	UQCC	0.39	7.85	0.3	1.73e-14	Height;
BRCA	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11890956	chr21:40555474	PSMG1	1.05	30.01	0.76	3.89e-124	Cognitive function;
BRCA	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg03709012	chr19:19516395	GATAD2A	-0.75	-16.72	-0.55	2.46e-52	Tonsillectomy;
BRCA	cis	rs4423214	0.879	rs1792264	chr11:71150247	C/T	cg05163923	chr11:71159392	DHCR7	-0.57	-11.65	-0.42	1.42e-28	Vitamin D levels;
BRCA	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11764359	chr7:65958608	NA	-0.76	-16.79	-0.55	1.17e-52	Aortic root size;
BRCA	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg05283184	chr6:79620031	NA	-0.41	-10.63	-0.39	2.12e-24	Intelligence (multi-trait analysis);
BRCA	trans	rs1997103	1.000	rs12718956	chr7:55407763	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg12140854	chr5:148520817	ABLIM3	-0.43	-9.07	-0.34	1.41e-18	Breast cancer;
BRCA	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg01579765	chr21:45077557	HSF2BP	0.44	12.27	0.44	3.11e-31	Mean corpuscular volume;
BRCA	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg06671706	chr8:8559999	CLDN23	0.44	8.48	0.32	1.59e-16	Obesity-related traits;
BRCA	trans	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg21659725	chr3:3221576	CRBN	-0.45	-9.93	-0.37	1.03e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.48	0.5	2.81e-41	Motion sickness;
BRCA	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg12386194	chr3:101231763	SENP7	0.46	9.88	0.36	1.64e-21	Colorectal cancer;
BRCA	cis	rs68170813	0.559	rs79705824	chr7:106848325	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-8.44	-0.32	2.11e-16	Coronary artery disease;
BRCA	cis	rs6496044	0.568	rs11855789	chr15:86066403	G/A	cg10818794	chr15:86012489	AKAP13	-0.29	-7.91	-0.3	1.1e-14	Interstitial lung disease;
BRCA	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.35	-8.31	-0.31	5.84e-16	Electroencephalogram traits;
BRCA	cis	rs7903847	0.646	rs10882924	chr10:99159304	T/A	cg08345082	chr10:99160200	RRP12	-0.3	-8.86	-0.33	7.98e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6750047	0.781	rs4670809	chr2:38277364	A/C	cg07380506	chr2:38303506	CYP1B1	0.36	8.16	0.31	1.77e-15	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11890956	chr21:40555474	PSMG1	-0.84	-21.56	-0.65	6.65e-78	Cognitive function;
BRCA	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg01448562	chr3:133502909	NA	-0.38	-8.72	-0.33	2.36e-17	Ankle injury;
BRCA	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg27535305	chr1:53392650	SCP2	-0.37	-9.32	-0.35	1.85e-19	Monocyte count;
BRCA	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg16576597	chr16:28551801	NUPR1	0.3	8.32	0.31	5.25e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.57	-10.94	-0.4	1.16e-25	Iron status biomarkers;
BRCA	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.7	14.15	0.49	1.01e-39	Alzheimer's disease;
BRCA	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.17	-0.4	1.42e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.82	0.45	1.24e-33	Bipolar disorder;
BRCA	cis	rs6543140	0.964	rs6543144	chr2:103092575	A/G	cg04239558	chr2:103089729	SLC9A4	0.36	9.9	0.36	1.37e-21	Blood protein levels;
BRCA	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg21573476	chr21:45109991	RRP1B	0.31	7.99	0.3	6.39e-15	Mean corpuscular volume;
BRCA	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg23625390	chr15:77176239	SCAPER	0.46	11.53	0.42	4.4e-28	Blood metabolite levels;
BRCA	cis	rs2147904	0.934	rs2786487	chr1:42368339	C/G	cg16685388	chr1:42384056	HIVEP3	-0.36	-10.17	-0.37	1.33e-22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
BRCA	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg15782153	chr7:917662	C7orf20	0.39	9.42	0.35	8.39e-20	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg24531977	chr5:56204891	C5orf35	-0.54	-11.41	-0.41	1.4e-27	Coronary artery disease;
BRCA	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg17971929	chr21:40555470	PSMG1	0.8	18.71	0.59	1.3e-62	Cognitive function;
BRCA	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg05283184	chr6:79620031	NA	-0.39	-9.9	-0.36	1.4e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	18.13	0.58	1.36e-59	Alzheimer's disease;
BRCA	trans	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg26384229	chr12:38710491	ALG10B	0.48	10.3	0.38	4.15e-23	Resting heart rate;
BRCA	trans	rs4650994	0.625	rs6681354	chr1:178526279	A/G	cg05059571	chr16:84539110	KIAA1609	-0.42	-9.44	-0.35	7.1e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.02	26.51	0.72	4.86e-105	Cognitive ability;
BRCA	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg16339924	chr4:17578868	LAP3	0.66	16.9	0.56	3.1e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-12.44	-0.44	5.63e-32	Personality dimensions;
BRCA	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.45	-0.61	1.55e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg07741184	chr6:167504864	NA	0.31	8.96	0.33	3.51e-18	Primary biliary cholangitis;
BRCA	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-9.96	-0.37	7.87e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs3925075	0.531	rs4597342	chr16:31343769	T/C	cg02846316	chr16:31340340	ITGAM	0.43	8.73	0.33	2.22e-17	IgA nephropathy;
BRCA	cis	rs1209950	1.000	rs1013841	chr21:40173345	A/G	cg01359822	chr21:40176597	ETS2	0.34	8.52	0.32	1.17e-16	Non-small cell lung cancer (survival);
BRCA	cis	rs13046373	0.535	rs9977510	chr21:32027920	A/G	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.13	0.34	8.8e-19	HDL cholesterol;
BRCA	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.57	-15.0	-0.51	8.3e-44	Electrocardiographic conduction measures;
BRCA	trans	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg25214090	chr10:38739885	LOC399744	0.51	11.58	0.42	2.83e-28	Corneal astigmatism;
BRCA	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg11502198	chr6:26597334	ABT1	0.48	9.59	0.35	2.02e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.21	-0.31	1.18e-15	Breast cancer;
BRCA	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.43	8.3	0.31	6.18e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg25358565	chr5:93447407	FAM172A	-1.18	-17.53	-0.57	1.81e-56	Diabetic retinopathy;
BRCA	cis	rs332507	0.789	rs11928787	chr3:124408149	C/T	cg05980111	chr3:124395277	KALRN	0.38	8.7	0.33	2.89e-17	Plateletcrit;
BRCA	cis	rs36051895	0.664	rs28378223	chr9:5113087	C/G	cg02405213	chr9:5042618	JAK2	-0.48	-9.37	-0.35	1.2e-19	Pediatric autoimmune diseases;
BRCA	cis	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.49	-0.41	6.35e-28	Morning vs. evening chronotype;
BRCA	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.78	0.67	1.45e-84	Chronic sinus infection;
BRCA	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.01	15.68	0.53	4.08e-47	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4588572	0.570	rs2115433	chr5:77700363	C/T	cg11547950	chr5:77652471	NA	-0.44	-8.39	-0.32	3.07e-16	Triglycerides;
BRCA	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg22875332	chr1:76189707	ACADM	0.66	15.77	0.53	1.39e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg09307838	chr4:120376055	NA	0.64	13.93	0.48	1.02e-38	Corneal astigmatism;
BRCA	cis	rs9462027	0.651	rs9469885	chr6:34758716	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.99	-0.3	6.33e-15	Systemic lupus erythematosus;
BRCA	cis	rs28830936	0.967	rs9672671	chr15:41917075	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.33	-9.28	-0.34	2.54e-19	Diastolic blood pressure;
BRCA	cis	rs3740540	0.530	rs10751598	chr10:126290951	A/G	cg04949429	chr10:126290192	LHPP	-0.42	-12.07	-0.43	2.41e-30	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs4631830	0.896	rs7088225	chr10:51522120	T/C	cg20129853	chr10:51489980	NA	0.29	7.93	0.3	9.64e-15	Prostate-specific antigen levels;
BRCA	cis	rs4588572	0.688	rs1594055	chr5:77695088	G/A	cg11547950	chr5:77652471	NA	-0.43	-8.29	-0.31	6.51e-16	Triglycerides;
BRCA	trans	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg25214090	chr10:38739885	LOC399744	0.56	12.24	0.44	4.11e-31	Corneal astigmatism;
BRCA	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg07636037	chr3:49044803	WDR6	0.51	8.4	0.32	2.94e-16	Menarche (age at onset);
BRCA	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	14.72	0.5	1.84e-42	Ileal carcinoids;
BRCA	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg21770322	chr7:97807741	LMTK2	0.43	11.49	0.41	6.49e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg18305652	chr10:134549665	INPP5A	0.5	11.54	0.42	4.03e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg02297831	chr4:17616191	MED28	0.38	8.88	0.33	6.9e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.08	-25.41	-0.71	5.37e-99	Ulcerative colitis;
BRCA	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg07169764	chr2:136633963	MCM6	1.22	23.92	0.69	8.51e-91	Corneal structure;
BRCA	cis	rs6088813	1.000	rs6141549	chr20:33974051	T/C	cg14752227	chr20:34000481	UQCC	-0.41	-8.65	-0.32	4.1e-17	Height;
BRCA	cis	rs3960554	0.808	rs59882870	chr7:75638421	G/A	cg17325771	chr7:75508891	RHBDD2	-0.33	-8.0	-0.3	6.04e-15	Eotaxin levels;
BRCA	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg24578937	chr1:2090814	PRKCZ	0.35	10.77	0.39	5.97e-25	Height;
BRCA	cis	rs9359856	0.564	rs17584290	chr6:90467114	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.7	-8.55	-0.32	8.85e-17	Bipolar disorder;
BRCA	cis	rs72792276	1.000	rs10519971	chr5:127379216	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.62	-10.71	-0.39	1.03e-24	Red cell distribution width;
BRCA	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg08067268	chr2:26466485	HADHB;HADHA	0.58	10.33	0.38	3.14e-23	Gut microbiome composition (summer);
BRCA	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg22713356	chr15:30763199	NA	1.29	24.34	0.69	4.4e-93	Uric acid levels;
BRCA	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg11062466	chr8:58055876	NA	0.51	8.86	0.33	8.08e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg18357645	chr12:58087776	OS9	0.43	11.75	0.42	5.42e-29	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg06885757	chr1:42089581	HIVEP3	-0.27	-9.64	-0.36	1.32e-20	Lupus nephritis in systemic lupus erythematosus;
BRCA	trans	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg26384229	chr12:38710491	ALG10B	0.39	8.59	0.32	6.67e-17	Resting heart rate;
BRCA	cis	rs870825	0.860	rs72703527	chr4:185605997	C/A	cg04058563	chr4:185651563	MLF1IP	0.65	11.26	0.41	5.77e-27	Blood protein levels;
BRCA	cis	rs67981189	0.896	rs2158997	chr14:71497794	C/G	cg15816911	chr14:71606274	NA	-0.36	-8.23	-0.31	1.02e-15	Schizophrenia;
BRCA	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-11.12	-0.4	2.2e-26	Schizophrenia;
BRCA	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg04317338	chr11:64019027	PLCB3	0.57	9.68	0.36	9.03e-21	Mean platelet volume;
BRCA	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg14343924	chr8:8086146	FLJ10661	0.39	8.27	0.31	7.69e-16	Neuroticism;
BRCA	trans	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg25214090	chr10:38739885	LOC399744	0.53	11.98	0.43	5.63e-30	Corneal astigmatism;
BRCA	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg24101359	chr6:42928495	GNMT	0.61	14.92	0.51	2.02e-43	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6545883	0.929	rs55806663	chr2:61740487	G/T	cg15711740	chr2:61764176	XPO1	-0.55	-14.18	-0.49	6.89e-40	Tuberculosis;
BRCA	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg25036284	chr2:26402008	FAM59B	-0.8	-12.42	-0.44	7.32e-32	Gut microbiome composition (summer);
BRCA	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.1	0.37	2.28e-22	Bipolar disorder;
BRCA	cis	rs1451375	0.652	rs10249420	chr7:50623451	C/G	cg18232548	chr7:50535776	DDC	-0.38	-8.19	-0.31	1.38e-15	Malaria;
BRCA	cis	rs713587	0.520	rs530951	chr2:25307005	C/T	cg01884057	chr2:25150051	NA	-0.32	-8.26	-0.31	8.59e-16	Body mass index in non-asthmatics;
BRCA	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg23788917	chr6:8435910	SLC35B3	-0.44	-9.48	-0.35	4.73e-20	Motion sickness;
BRCA	cis	rs10752881	0.602	rs9425569	chr1:182942202	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.49	11.09	0.4	3.04e-26	Colorectal cancer;
BRCA	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg00106254	chr7:1943704	MAD1L1	0.36	10.07	0.37	3.15e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs2066819	1.000	rs79718165	chr12:56644251	C/T	cg26734620	chr12:56694298	CS	0.86	9.88	0.36	1.64e-21	Psoriasis vulgaris;
BRCA	cis	rs7683537	0.887	rs7678412	chr4:185648611	T/C	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Systemic lupus erythematosus;
BRCA	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11764359	chr7:65958608	NA	0.79	19.19	0.6	3.68e-65	Aortic root size;
BRCA	cis	rs6543140	0.964	rs918000	chr2:103067862	C/T	cg04239558	chr2:103089729	SLC9A4	0.34	9.55	0.35	2.73e-20	Blood protein levels;
BRCA	cis	rs6445967	0.832	rs1055973	chr3:58308960	T/C	cg23715586	chr3:58305044	RPP14	0.35	8.73	0.33	2.25e-17	Platelet count;
BRCA	cis	rs1003719	0.667	rs28666643	chr21:38455999	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.53	11.28	0.41	4.7e-27	Eye color traits;
BRCA	cis	rs11229555	0.609	rs34782543	chr11:58187398	G/A	cg15696309	chr11:58395628	NA	-0.45	-9.71	-0.36	7.05e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs698833	0.859	rs1067360	chr2:44661817	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	9.43	0.35	7.46e-20	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg04455712	chr21:45112962	RRP1B	0.46	11.72	0.42	6.9e-29	Mean corpuscular volume;
BRCA	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18402987	chr7:1209562	NA	0.61	12.94	0.46	3.62e-34	Longevity;Endometriosis;
BRCA	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg16262614	chr3:133464971	TF	0.24	7.82	0.3	2.18e-14	Iron status biomarkers;
BRCA	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg19784903	chr17:45786737	TBKBP1	-0.46	-11.13	-0.4	1.96e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg21659725	chr3:3221576	CRBN	-0.45	-9.86	-0.36	1.94e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.67	0.42	1.12e-28	Homoarginine levels;
BRCA	cis	rs9297145	0.565	rs56132062	chr7:98778198	C/T	cg05967295	chr7:98741636	SMURF1	-0.62	-13.76	-0.48	6.7e-38	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.6	0.39	2.68e-24	Motion sickness;
BRCA	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.97	-0.3	7.41e-15	Depression;
BRCA	trans	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.8	-0.33	1.28e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	8.02	0.3	5.23e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg18252515	chr7:66147081	NA	-0.84	-12.14	-0.43	1.2e-30	Diabetic kidney disease;
BRCA	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-11.84	-0.42	2.16e-29	Gut microbiome composition (summer);
BRCA	trans	rs8002861	0.870	rs4942251	chr13:44440048	G/T	cg17145862	chr1:211918768	LPGAT1	0.63	16.12	0.54	2.56e-49	Leprosy;
BRCA	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg20019720	chr6:154832845	CNKSR3	0.52	10.35	0.38	2.56e-23	Lipoprotein (a) levels;
BRCA	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg01579765	chr21:45077557	HSF2BP	0.4	10.25	0.38	6.52e-23	Mean corpuscular volume;
BRCA	trans	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	13.54	0.47	6.44e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.54	-13.87	-0.48	1.9e-38	Longevity;Endometriosis;
BRCA	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg26248373	chr2:1572462	NA	-0.62	-14.37	-0.49	8.48e-41	IgG glycosylation;
BRCA	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg07169764	chr2:136633963	MCM6	1.23	23.98	0.69	4.14e-91	Corneal structure;
BRCA	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg14530993	chr4:882597	GAK	0.56	9.29	0.35	2.32e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg03806693	chr22:41940476	POLR3H	-0.56	-9.86	-0.36	1.84e-21	Neuroticism;
BRCA	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg23625390	chr15:77176239	SCAPER	-0.54	-13.71	-0.48	1.09e-37	Blood metabolite levels;
BRCA	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg01475377	chr6:109611718	NA	-0.6	-16.64	-0.55	6.47e-52	Reticulocyte fraction of red cells;
BRCA	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.54	11.58	0.42	2.75e-28	HDL cholesterol;
BRCA	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05890377	chr2:74357713	NA	0.51	11.74	0.42	5.98e-29	Gestational age at birth (maternal effect);
BRCA	cis	rs6723226	0.598	rs2710629	chr2:32765844	C/T	cg02381751	chr2:32503542	YIPF4	0.47	10.27	0.38	5.14e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs290268	1.000	rs290274	chr9:93546913	C/T	cg02608019	chr9:93564028	SYK	0.54	12.02	0.43	3.72e-30	Platelet count;
BRCA	cis	rs586533	0.881	rs5006806	chr11:99506226	C/A	cg22878054	chr11:99397252	CNTN5	0.32	8.12	0.31	2.44e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg00277334	chr10:82204260	NA	-0.82	-23.14	-0.68	1.58e-86	Post bronchodilator FEV1;
BRCA	cis	rs965469	0.895	rs6139124	chr20:3398144	C/T	cg25506879	chr20:3388711	C20orf194	-0.52	-10.21	-0.37	8.88e-23	IFN-related cytopenia;
BRCA	cis	rs7729447	0.813	rs7715279	chr5:32689875	T/A	cg16267343	chr5:32710456	NPR3	0.44	8.94	0.33	4.27e-18	Blood pressure;
BRCA	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	10.83	0.39	3.4e-25	Personality dimensions;
BRCA	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.98	0.37	6.57e-22	Bladder cancer;
BRCA	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.01	0.3	5.45e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9469578	1.000	rs16869464	chr6:33715127	A/G	cg18708504	chr6:33715942	IP6K3	0.7	10.19	0.37	1.09e-22	Phosphorus levels;
BRCA	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19346786	chr7:2764209	NA	-0.34	-10.62	-0.39	2.17e-24	Height;
BRCA	trans	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg26384229	chr12:38710491	ALG10B	0.48	10.61	0.39	2.41e-24	Morning vs. evening chronotype;
BRCA	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg00106254	chr7:1943704	MAD1L1	-0.35	-8.74	-0.33	2.04e-17	Schizophrenia;
BRCA	cis	rs9341808	0.650	rs6909546	chr6:80869923	C/G	cg08355045	chr6:80787529	NA	0.37	9.24	0.34	3.63e-19	Sitting height ratio;
BRCA	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg20007245	chr22:24372913	LOC391322	-0.57	-12.81	-0.45	1.34e-33	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg27446573	chr6:127587934	RNF146	0.68	15.48	0.52	3.72e-46	Breast cancer;
BRCA	cis	rs11676348	0.776	rs11690316	chr2:219017462	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-8.9	-0.33	5.54e-18	Ulcerative colitis;
BRCA	cis	rs1832871	0.711	rs9459826	chr6:158680396	C/G	cg07215822	chr6:158701037	NA	0.51	8.31	0.31	5.94e-16	Height;
BRCA	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.63	-0.42	1.77e-28	Platelet count;
BRCA	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg25110126	chr1:46999211	NA	0.74	13.81	0.48	3.64e-38	Monobrow;
BRCA	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg20607798	chr8:58055168	NA	0.54	8.39	0.31	3.17e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs3960554	0.808	rs868555	chr7:75697418	G/A	cg19862616	chr7:65841803	NCRNA00174	0.59	12.55	0.44	1.93e-32	Eotaxin levels;
BRCA	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg16606324	chr3:10149918	C3orf24	0.57	9.94	0.37	1e-21	Alzheimer's disease;
BRCA	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg10556349	chr10:835070	NA	0.73	9.88	0.36	1.6e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs9815354	0.812	rs73073230	chr3:42008263	G/A	cg03022575	chr3:42003672	ULK4	0.74	10.29	0.38	4.49e-23	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg04545296	chr12:48745243	ZNF641	0.25	8.18	0.31	1.52e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs754466	0.651	rs10762767	chr10:79645070	C/A	cg17075019	chr10:79541650	NA	-0.73	-17.54	-0.57	1.53e-56	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-15.79	-0.53	1.16e-47	Obesity-related traits;
BRCA	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.34	-8.44	-0.32	2.15e-16	Personality dimensions;
BRCA	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.52	-0.41	4.82e-28	Mean corpuscular volume;
BRCA	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg01939980	chr4:1354348	KIAA1530	0.38	9.05	0.34	1.7e-18	Obesity-related traits;
BRCA	cis	rs4074536	0.574	rs10801969	chr1:116287634	A/G	cg21648376	chr1:116311395	CASQ2	-0.48	-8.43	-0.32	2.24e-16	QRS duration;
BRCA	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-11.28	-0.41	4.93e-27	Schizophrenia;
BRCA	cis	rs13082711	0.595	rs7615321	chr3:27368010	A/G	cg02860705	chr3:27208620	NA	0.71	13.12	0.46	5.32e-35	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	13.32	0.47	6.57e-36	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.34	9.44	0.35	6.58e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg18016565	chr1:150552671	MCL1	0.34	7.81	0.3	2.33e-14	Melanoma;
BRCA	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg14675211	chr2:100938903	LONRF2	0.43	9.69	0.36	8.25e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs965469	1.000	rs6051716	chr20:3267736	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-9.49	-0.35	4.55e-20	IFN-related cytopenia;
BRCA	cis	rs4423214	0.559	rs10898203	chr11:71203436	C/T	cg05163923	chr11:71159392	DHCR7	-0.51	-8.73	-0.33	2.16e-17	Vitamin D levels;
BRCA	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08704250	chr15:31115839	NA	-0.48	-12.23	-0.44	4.9e-31	Huntington's disease progression;
BRCA	trans	rs877282	0.520	rs12360072	chr10:813082	C/T	cg22713356	chr15:30763199	NA	0.53	9.91	0.36	1.27e-21	Uric acid levels;
BRCA	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg03877680	chr5:178157825	ZNF354A	0.79	14.65	0.5	4.19e-42	Neutrophil percentage of white cells;
BRCA	cis	rs6820391	0.816	rs7681869	chr4:54447773	G/A	cg04173182	chr4:54446035	LNX1	0.53	11.85	0.42	1.98e-29	Cervical artery dissection;
BRCA	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-8.05	-0.3	4.1e-15	Prostate cancer;
BRCA	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	0.36	9.13	0.34	8.63e-19	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg20469991	chr17:27169893	C17orf63	-0.45	-8.8	-0.33	1.25e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg22705602	chr4:152727874	NA	-0.31	-7.83	-0.3	2.09e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2120243	1.000	rs9289982	chr3:157144444	G/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	8.91	0.33	5.35e-18	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs36051895	0.586	rs12342421	chr9:5065750	G/C	cg02405213	chr9:5042618	JAK2	-0.53	-9.25	-0.34	3.21e-19	Pediatric autoimmune diseases;
BRCA	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg17063962	chr7:91808500	NA	-0.55	-12.68	-0.45	5.13e-33	Breast cancer;
BRCA	cis	rs4728302	0.869	rs10224575	chr7:133590875	G/A	cg07491979	chr7:133331646	EXOC4	0.36	7.81	0.3	2.32e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs7903847	0.642	rs10786341	chr10:99158607	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-8.73	-0.33	2.16e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg16586182	chr3:47516702	SCAP	-0.57	-13.11	-0.46	6.28e-35	Colorectal cancer;
BRCA	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg13902645	chr11:5959945	NA	0.53	11.08	0.4	3.36e-26	DNA methylation (variation);
BRCA	trans	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg25042112	chr7:64838748	ZNF92	-0.44	-8.61	-0.32	5.47e-17	Pain;
BRCA	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg11833968	chr6:79620685	NA	-0.43	-9.51	-0.35	3.74e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs12612619	0.732	rs920433	chr2:27212526	A/C	cg00617064	chr2:27272375	NA	-0.31	-8.16	-0.31	1.72e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs68170813	0.562	rs78181351	chr7:106999301	A/G	cg02696742	chr7:106810147	HBP1	-0.55	-8.61	-0.32	5.89e-17	Coronary artery disease;
BRCA	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg01689657	chr7:91764605	CYP51A1	0.22	8.14	0.31	2.13e-15	Breast cancer;
BRCA	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg25110126	chr1:46999211	NA	0.74	13.93	0.48	1.1e-38	Monobrow;
BRCA	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg19628046	chr18:33552617	C18orf21	0.54	10.95	0.4	1.12e-25	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg24675658	chr1:53192096	ZYG11B	0.66	14.41	0.5	5.75e-41	Monocyte count;
BRCA	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	20.02	0.62	1.47e-69	Chronic sinus infection;
BRCA	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11890956	chr21:40555474	PSMG1	1.0	26.11	0.72	7.56e-103	Cognitive function;
BRCA	cis	rs3820928	0.904	rs10188570	chr2:227792540	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-8.24	-0.31	9.57e-16	Pulmonary function;
BRCA	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg06064525	chr11:970664	AP2A2	-0.49	-16.41	-0.54	9.05e-51	Alzheimer's disease (late onset);
BRCA	trans	rs3857536	0.813	rs6455083	chr6:66935406	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-10.4	-0.38	1.59e-23	Triglycerides;
BRCA	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg22535103	chr8:58192502	C8orf71	-0.46	-9.07	-0.34	1.5e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs11229555	1.000	rs10896795	chr11:58366561	A/G	cg15696309	chr11:58395628	NA	-0.52	-11.32	-0.41	3.39e-27	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg12373951	chr3:133503437	NA	-0.54	-13.11	-0.46	5.94e-35	Iron status biomarkers;
BRCA	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg10932868	chr11:921992	NA	-0.49	-12.5	-0.44	3.23e-32	Alzheimer's disease (late onset);
BRCA	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg23711669	chr6:146136114	FBXO30	0.72	16.53	0.55	2.2e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg26384229	chr12:38710491	ALG10B	-0.58	-13.43	-0.47	2.13e-36	Morning vs. evening chronotype;
BRCA	cis	rs7178424	1.000	rs1436964	chr15:62374487	A/G	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.3	-0.31	6.42e-16	Height;
BRCA	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg27535305	chr1:53392650	SCP2	-0.38	-9.28	-0.34	2.59e-19	Monocyte count;
BRCA	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-18.01	-0.58	5.81e-59	Morning vs. evening chronotype;
BRCA	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg19784903	chr17:45786737	TBKBP1	0.34	8.25	0.31	8.93e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2376015	1	rs2376015	chr1:66123774	A/G	cg04111102	chr1:66153794	NA	0.36	8.86	0.33	7.84e-18	Fibrinogen levels;
BRCA	cis	rs10193935	0.901	rs7605782	chr2:42502332	C/T	cg27598129	chr2:42591480	NA	-0.95	-14.52	-0.5	1.78e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2764980	1.000	rs2764980	chr10:3284007	C/T	cg11630169	chr10:3283847	NA	0.41	9.25	0.34	3.27e-19	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg06627628	chr2:24431161	ITSN2	-0.66	-12.11	-0.43	1.48e-30	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg27398817	chr8:82754497	SNX16	-0.37	-8.57	-0.32	7.68e-17	Diastolic blood pressure;
BRCA	trans	rs877282	0.755	rs11253399	chr10:790030	T/A	cg22713356	chr15:30763199	NA	1.14	22.57	0.67	2.18e-83	Uric acid levels;
BRCA	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg18252515	chr7:66147081	NA	1.0	15.17	0.51	1.35e-44	Diabetic kidney disease;
BRCA	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg22601191	chr20:60968625	CABLES2	0.46	10.78	0.39	4.99e-25	Colorectal cancer;
BRCA	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-12.21	-0.43	5.68e-31	Gut microbiome composition (summer);
BRCA	cis	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg07460842	chr6:66804631	NA	0.69	11.58	0.42	2.68e-28	Exhaled nitric oxide output;
BRCA	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg04025307	chr7:1156635	C7orf50	0.55	13.71	0.48	1.06e-37	Longevity;Endometriosis;
BRCA	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11890956	chr21:40555474	PSMG1	0.99	24.13	0.69	5.74e-92	Cognitive function;
BRCA	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	13.86	0.48	2.32e-38	Hip circumference adjusted for BMI;
BRCA	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.48	0.38	8.25e-24	Motion sickness;
BRCA	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg01448562	chr3:133502909	NA	-0.39	-8.93	-0.33	4.53e-18	Iron status biomarkers;
BRCA	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg00990874	chr7:1149470	C7orf50	-0.49	-10.87	-0.4	2.25e-25	Bronchopulmonary dysplasia;
BRCA	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20887711	chr4:1340912	KIAA1530	0.49	11.1	0.4	2.69e-26	Longevity;
BRCA	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg20607287	chr7:12443886	VWDE	-0.57	-8.09	-0.3	3.08e-15	Coronary artery disease;
BRCA	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg19346786	chr7:2764209	NA	-0.26	-8.54	-0.32	1.01e-16	Height;
BRCA	cis	rs367943	1.000	rs367943	chr5:112809728	C/T	cg12552261	chr5:112820674	MCC	0.55	12.25	0.44	3.85e-31	Type 2 diabetes;
BRCA	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.1	0.46	6.54e-35	Electroencephalogram traits;
BRCA	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg03560586	chr2:239334908	ASB1	-0.41	-7.87	-0.3	1.55e-14	Multiple system atrophy;
BRCA	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg03188948	chr7:1209495	NA	0.82	11.39	0.41	1.8e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.39	-0.32	3.05e-16	Schizophrenia;
BRCA	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg15704280	chr7:45808275	SEPT13	0.65	11.44	0.41	1.06e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs698833	0.548	rs6721421	chr2:44535686	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.47	0.32	1.65e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	16.92	0.56	2.33e-53	Platelet count;
BRCA	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-10.35	-0.38	2.55e-23	Heart rate;
BRCA	cis	rs12618769	0.543	rs6753380	chr2:99129040	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.26	0.31	8.44e-16	Bipolar disorder;
BRCA	cis	rs600806	0.778	rs11101961	chr1:110008813	T/C	cg20591472	chr1:110008990	SYPL2	0.31	7.98	0.3	6.74e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg16606324	chr3:10149918	C3orf24	0.48	9.47	0.35	5.5e-20	Alzheimer's disease;
BRCA	cis	rs796364	0.616	rs769956	chr2:200693720	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.5	-7.95	-0.3	8.6e-15	Schizophrenia;
BRCA	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg13880726	chr7:1868755	MAD1L1	0.52	10.54	0.38	4.87e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg24692254	chr21:30365293	RNF160	0.37	8.39	0.31	3.19e-16	Selective IgA deficiency;
BRCA	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.06	-0.34	1.62e-18	Menopause (age at onset);
BRCA	cis	rs6745190	0.575	rs55664819	chr2:181980069	T/G	cg00481216	chr2:181971175	NA	0.4	9.45	0.35	6.15e-20	White blood cell count;
BRCA	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg18016565	chr1:150552671	MCL1	0.36	8.41	0.32	2.75e-16	Tonsillectomy;
BRCA	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg05457628	chr5:178986728	RUFY1	0.5	12.08	0.43	2.14e-30	Lung cancer;
BRCA	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg13047869	chr3:10149882	C3orf24	0.59	12.55	0.44	1.94e-32	Alzheimer's disease;
BRCA	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg26408565	chr15:76604113	ETFA	-0.51	-11.6	-0.42	2.19e-28	Blood metabolite levels;
BRCA	cis	rs9487051	0.698	rs35757653	chr6:109644599	A/C	cg21918786	chr6:109611834	NA	-0.38	-8.31	-0.31	5.63e-16	Reticulocyte fraction of red cells;
BRCA	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg04709771	chr16:646395	RAB40C	0.42	10.47	0.38	8.88e-24	Height;
BRCA	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg13319975	chr6:146136371	FBXO30	0.62	14.44	0.5	4.22e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	12.41	0.44	8.15e-32	Platelet count;
BRCA	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg03609598	chr5:56110824	MAP3K1	-0.47	-8.01	-0.3	5.6e-15	Initial pursuit acceleration;
BRCA	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg00631329	chr6:26305371	NA	-0.42	-12.68	-0.45	5.25e-33	Educational attainment;
BRCA	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg20908204	chr19:46285434	DMPK	-0.28	-8.13	-0.31	2.18e-15	Coronary artery disease;
BRCA	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg08219700	chr8:58056026	NA	0.45	7.87	0.3	1.57e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg22907277	chr7:1156413	C7orf50	0.46	10.7	0.39	1.08e-24	Longevity;Endometriosis;
BRCA	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg04586622	chr2:25135609	ADCY3	0.46	11.66	0.42	1.26e-28	Body mass index;
BRCA	trans	rs10057188	0.742	rs9293756	chr5:77918136	A/C	cg11941228	chr5:65891968	MAST4	0.34	8.26	0.31	8.43e-16	Pulse pressure;
BRCA	cis	rs10504073	0.584	rs62507182	chr8:49942500	C/A	cg00325661	chr8:49890786	NA	0.49	14.23	0.49	3.9e-40	Blood metabolite ratios;
BRCA	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg27478167	chr7:817139	HEATR2	0.49	9.41	0.35	9.07e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1568889	1.000	rs12287732	chr11:28120845	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	13.96	0.48	7.91e-39	Bipolar disorder;
BRCA	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg04989706	chr14:50066350	PPIL5	-0.5	-9.99	-0.37	6.46e-22	Carotid intima media thickness;
BRCA	cis	rs1215050	0.791	rs684210	chr4:98678740	G/C	cg05340658	chr4:99064831	C4orf37	0.44	10.07	0.37	3.12e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-11.05	-0.4	4.42e-26	Neuroticism;
BRCA	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg09184832	chr6:79620586	NA	-0.52	-11.45	-0.41	9.86e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs250677	0.522	rs55732303	chr5:148392538	C/T	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.43	-0.32	2.22e-16	Breast cancer;
BRCA	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg09455208	chr3:40491958	NA	0.35	8.59	0.32	6.75e-17	Renal cell carcinoma;
BRCA	cis	rs11718455	0.960	rs11921995	chr3:44017301	C/A	cg08738300	chr3:44038990	NA	0.47	8.86	0.33	8e-18	Coronary artery disease;
BRCA	cis	rs490234	0.746	rs1266009	chr9:128192316	A/G	cg14078157	chr9:128172775	NA	-0.34	-7.89	-0.3	1.3e-14	Mean arterial pressure;
BRCA	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.53	0.5	1.53e-41	Motion sickness;
BRCA	trans	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	trans	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	8.66	0.32	3.77e-17	Mean corpuscular volume;
BRCA	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg07080220	chr10:102295463	HIF1AN	0.51	11.73	0.42	6.43e-29	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg26384229	chr12:38710491	ALG10B	0.67	14.33	0.49	1.43e-40	Morning vs. evening chronotype;
BRCA	cis	rs56399783	0.901	rs73047393	chr7:2775879	C/T	cg19731401	chr7:2775893	GNA12	0.52	8.24	0.31	9.73e-16	Childhood ear infection;
BRCA	cis	rs743757	1.000	rs2282754	chr3:50436827	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.45	8.14	0.31	2.12e-15	Diastolic blood pressure;
BRCA	trans	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg11663144	chr21:46675770	NA	-0.61	-14.22	-0.49	4.45e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs637571	0.510	rs3892696	chr11:65582341	G/C	cg17712092	chr4:129076599	LARP1B	-0.52	-11.66	-0.42	1.26e-28	Eosinophil percentage of white cells;
BRCA	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs9796	0.558	rs7166205	chr15:41514733	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.36	-7.85	-0.3	1.76e-14	Menopause (age at onset);
BRCA	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg27398817	chr8:82754497	SNX16	0.44	8.66	0.32	3.76e-17	Diastolic blood pressure;
BRCA	trans	rs12517041	1.000	rs7723641	chr5:23298305	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.44	-8.07	-0.3	3.61e-15	Calcium levels;
BRCA	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06022373	chr22:39101656	GTPBP1	-0.73	-15.82	-0.53	7.82e-48	Menopause (age at onset);
BRCA	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg00383909	chr3:49044727	WDR6	0.96	14.94	0.51	1.61e-43	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs12618769	0.597	rs4850879	chr2:99113082	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.51	-10.64	-0.39	1.79e-24	Caffeine consumption;
BRCA	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg00990874	chr7:1149470	C7orf50	-0.51	-9.93	-0.37	1.08e-21	Bronchopulmonary dysplasia;
BRCA	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg08645402	chr16:4508243	NA	0.39	8.4	0.32	2.8e-16	Schizophrenia;
BRCA	cis	rs838147	0.760	rs281408	chr19:49233406	A/C	cg12258179	chr19:49232187	RASIP1	-0.32	-8.02	-0.3	4.9e-15	Dietary macronutrient intake;
BRCA	cis	rs9942416	0.660	rs41534344	chr5:74997832	T/C	cg19683494	chr5:74908142	NA	0.48	8.93	0.33	4.33e-18	Age-related disease endophenotypes;
BRCA	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg24812749	chr6:127587940	RNF146	0.69	15.72	0.53	2.58e-47	Breast cancer;
BRCA	cis	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.18	-0.4	1.22e-26	Morning vs. evening chronotype;
BRCA	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg01448562	chr3:133502909	NA	-0.61	-14.38	-0.49	7.95e-41	Iron status biomarkers;
BRCA	cis	rs7246657	0.722	rs10417576	chr19:38119212	A/C	cg14683738	chr19:37701593	ZNF585B	0.47	8.11	0.31	2.51e-15	Coronary artery calcification;
BRCA	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.37	10.28	0.38	4.82e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg04117972	chr1:227635322	NA	0.52	9.28	0.34	2.55e-19	Major depressive disorder;
BRCA	cis	rs6910061	1.000	rs36067344	chr6:11094764	C/T	cg27233058	chr6:11094804	LOC221710	0.53	9.39	0.35	1.01e-19	Diabetic kidney disease;
BRCA	cis	rs6546550	0.868	rs12713682	chr2:70154134	G/A	cg02498382	chr2:70120550	SNRNP27	-0.52	-11.34	-0.41	2.86e-27	Prevalent atrial fibrillation;
BRCA	cis	rs1712517	0.873	rs7903004	chr10:105004101	G/A	cg05636881	chr10:105038444	INA	-0.35	-7.94	-0.3	9.06e-15	Migraine;
BRCA	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg11845111	chr2:191398756	TMEM194B	-0.82	-14.72	-0.5	1.92e-42	Diastolic blood pressure;
BRCA	cis	rs57590327	0.503	rs6802480	chr3:81906671	G/A	cg07356753	chr3:81810745	GBE1	-0.44	-10.06	-0.37	3.41e-22	Extraversion;
BRCA	cis	rs10504073	0.647	rs59064792	chr8:50018337	A/C	cg00325661	chr8:49890786	NA	0.38	11.26	0.41	5.95e-27	Blood metabolite ratios;
BRCA	trans	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg04565464	chr8:145669602	NFKBIL2	0.36	7.91	0.3	1.13e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs9487051	0.768	rs371960	chr6:109525082	A/G	cg21918786	chr6:109611834	NA	-0.36	-9.71	-0.36	7.07e-21	Reticulocyte fraction of red cells;
BRCA	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg26395211	chr5:140044315	WDR55	-0.37	-8.32	-0.31	5.39e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg03354898	chr7:1950403	MAD1L1	-0.37	-7.9	-0.3	1.23e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg12311346	chr5:56204834	C5orf35	-0.73	-14.47	-0.5	3.11e-41	Initial pursuit acceleration;
BRCA	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg26597838	chr10:835615	NA	0.97	17.04	0.56	6.2e-54	Eosinophil percentage of granulocytes;
BRCA	cis	rs7523050	0.643	rs34920128	chr1:109400889	C/T	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-18.66	-0.59	2.46e-62	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.59	0.55	1.2e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.8	0.51	7.85e-43	Colorectal cancer;
BRCA	cis	rs9649465	0.561	rs2429621	chr7:123430316	A/G	cg03229431	chr7:123269106	ASB15	0.41	9.47	0.35	5.49e-20	Migraine;
BRCA	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg25237894	chr2:233734115	C2orf82	0.38	11.12	0.4	2.2e-26	Coronary artery disease;
BRCA	trans	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.43	0.32	2.32e-16	Corneal astigmatism;
BRCA	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg20503657	chr10:835505	NA	0.68	10.8	0.39	4.43e-25	Eosinophil percentage of granulocytes;
BRCA	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg15934090	chr1:100435551	SLC35A3	0.37	8.27	0.31	7.71e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.1	-0.31	2.84e-15	Depression;
BRCA	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg06064525	chr11:970664	AP2A2	-0.47	-15.53	-0.52	2.32e-46	Alzheimer's disease (late onset);
BRCA	cis	rs2425143	1.000	rs1056196	chr20:34327159	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.96	-0.33	3.53e-18	Blood protein levels;
BRCA	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg03433033	chr1:76189801	ACADM	0.76	17.39	0.57	9.52e-56	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg08601574	chr20:25228251	PYGB	0.35	8.48	0.32	1.61e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7737355	1.000	rs257390	chr5:130740617	C/T	cg06307176	chr5:131281290	NA	-0.48	-9.38	-0.35	1.1e-19	Life satisfaction;
BRCA	cis	rs2637266	1.000	rs7477433	chr10:78358116	C/T	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg21573476	chr21:45109991	RRP1B	-0.37	-9.6	-0.35	1.83e-20	Mean corpuscular volume;
BRCA	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-9.73	-0.36	5.87e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs66887589	0.967	rs13104219	chr4:120438174	G/T	cg09307838	chr4:120376055	NA	0.46	9.56	0.35	2.53e-20	Diastolic blood pressure;
BRCA	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg01475377	chr6:109611718	NA	-0.56	-15.06	-0.51	4.35e-44	Reticulocyte fraction of red cells;
BRCA	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.34	-0.31	4.42e-16	Total body bone mineral density;
BRCA	cis	rs9649465	0.935	rs3815458	chr7:123304323	A/T	cg04330084	chr7:123175371	IQUB	-0.3	-8.34	-0.31	4.66e-16	Migraine;
BRCA	trans	rs11039798	0.841	rs11039760	chr11:48479009	C/T	cg15704280	chr7:45808275	SEPT13	0.69	8.22	0.31	1.16e-15	Axial length;
BRCA	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.68	0.57	3.2e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg17385448	chr1:15911702	AGMAT	0.35	7.95	0.3	8.17e-15	Systolic blood pressure;
BRCA	cis	rs701145	0.585	rs62276840	chr3:153783622	G/C	cg17054900	chr3:154042577	DHX36	-0.54	-9.14	-0.34	7.93e-19	Coronary artery disease;
BRCA	cis	rs7809950	1.000	rs12667527	chr7:107086969	T/C	cg23024343	chr7:107201750	COG5	-0.42	-9.67	-0.36	1.02e-20	Coronary artery disease;
BRCA	trans	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-7.86	-0.3	1.65e-14	Menarche (age at onset);
BRCA	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg25208724	chr1:156163844	SLC25A44	1.05	33.53	0.8	5.46e-143	Testicular germ cell tumor;
BRCA	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg16590910	chr6:42928470	GNMT	0.36	7.87	0.3	1.54e-14	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg04450456	chr4:17643702	FAM184B	0.35	9.42	0.35	8.36e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg08999081	chr20:33150536	PIGU	0.47	12.95	0.46	3.15e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs6121246	0.512	rs6060941	chr20:30367383	C/T	cg21427119	chr20:30132790	HM13	-0.36	-8.12	-0.31	2.35e-15	Mean corpuscular hemoglobin;
BRCA	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg25482853	chr8:67687455	SGK3	1.05	16.94	0.56	1.94e-53	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg26384229	chr12:38710491	ALG10B	-0.43	-10.11	-0.37	2.08e-22	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.4	8.13	0.31	2.22e-15	Menarche (age at onset);
BRCA	cis	rs68170813	0.559	rs7800443	chr7:106910723	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-8.61	-0.32	5.62e-17	Coronary artery disease;
BRCA	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg13010199	chr12:38710504	ALG10B	0.44	8.97	0.33	3.33e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.51	12.17	0.43	8.78e-31	Electrocardiographic conduction measures;
BRCA	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg24642439	chr20:33292090	TP53INP2	0.61	13.43	0.47	2.21e-36	Coronary artery disease;
BRCA	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg04944784	chr2:26401820	FAM59B	-0.84	-13.23	-0.46	1.74e-35	Gut microbiome composition (summer);
BRCA	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg26587870	chr6:27730563	NA	-0.44	-7.84	-0.3	1.84e-14	Lung cancer in ever smokers;
BRCA	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12923728	chr3:195709715	SDHAP1	-0.58	-12.41	-0.44	7.61e-32	Pancreatic cancer;
BRCA	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg23229984	chr5:148520753	ABLIM3	0.35	8.64	0.32	4.48e-17	Breast cancer;
BRCA	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg16606324	chr3:10149918	C3orf24	0.51	10.15	0.37	1.52e-22	Alzheimer's disease;
BRCA	trans	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.12	0.31	2.33e-15	Corneal astigmatism;
BRCA	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg03954927	chr1:10346856	KIF1B	0.47	13.17	0.46	3.22e-35	Hepatocellular carcinoma;
BRCA	cis	rs6942407	0.546	rs2074757	chr7:86794121	G/A	cg02420886	chr7:86849541	C7orf23	0.54	8.1	0.31	2.73e-15	Food allergy;
BRCA	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg08508325	chr11:3079039	CARS	-0.42	-14.39	-0.49	7.51e-41	Longevity;
BRCA	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14442939	chr10:27389572	ANKRD26	0.69	11.53	0.42	4.38e-28	Breast cancer;
BRCA	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg15605315	chr1:45957053	TESK2	-0.44	-8.88	-0.33	6.59e-18	High light scatter reticulocyte count;
BRCA	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg08885076	chr2:99613938	TSGA10	-0.6	-13.6	-0.47	3.48e-37	Chronic sinus infection;
BRCA	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00149659	chr3:10157352	C3orf10	1.08	18.1	0.58	1.93e-59	Alzheimer's disease;
BRCA	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg20307385	chr11:47447363	PSMC3	-0.43	-9.14	-0.34	8.4e-19	Subjective well-being;
BRCA	cis	rs7178572	0.743	rs62009090	chr15:77837055	T/G	cg22256960	chr15:77711686	NA	-0.38	-8.26	-0.31	8.65e-16	Type 2 diabetes;
BRCA	cis	rs9790314	0.589	rs4679662	chr3:160603024	T/C	cg03342759	chr3:160939853	NMD3	0.41	8.17	0.31	1.69e-15	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg23711669	chr6:146136114	FBXO30	-0.69	-15.97	-0.53	1.4e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg07541023	chr7:19748670	TWISTNB	0.57	9.79	0.36	3.53e-21	Thyroid stimulating hormone;
BRCA	cis	rs12989701	0.825	rs4663096	chr2:127861766	T/A	cg08168897	chr2:127865431	BIN1	0.6	10.95	0.4	1.1e-25	Alzheimer's disease (late onset);
BRCA	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg14844989	chr11:31128820	NA	0.44	9.82	0.36	2.67e-21	Red blood cell count;
BRCA	cis	rs7727544	0.582	rs3792894	chr5:131547271	C/T	cg14196790	chr5:131705035	SLC22A5	0.34	8.89	0.33	5.99e-18	Blood metabolite levels;
BRCA	cis	rs6901250	0.655	rs636252	chr6:117157774	A/G	cg12892004	chr6:117198278	RFX6	-0.38	-9.4	-0.35	9.27e-20	C-reactive protein levels;
BRCA	cis	rs17818399	0.597	rs13385693	chr2:46867158	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.41	7.99	0.3	6.3e-15	Height;
BRCA	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg14789911	chr21:47582049	C21orf56	-0.36	-7.92	-0.3	1.04e-14	Testicular germ cell tumor;
BRCA	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg16606324	chr3:10149918	C3orf24	0.56	11.2	0.41	1.01e-26	Alzheimer's disease;
BRCA	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg14784868	chr12:69753453	YEATS4	0.78	25.12	0.7	2.27e-97	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg01620082	chr3:125678407	NA	-0.71	-8.39	-0.32	3.09e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6740322	0.948	rs6722694	chr2:43569798	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-12.78	-0.45	1.85e-33	Coronary artery disease;
BRCA	cis	rs4891159	0.790	rs10514217	chr18:74144939	A/G	cg24786174	chr18:74118243	ZNF516	-0.69	-16.61	-0.55	8.92e-52	Longevity;
BRCA	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11890956	chr21:40555474	PSMG1	0.82	20.46	0.63	6.03e-72	Cognitive function;
BRCA	trans	rs9944715	0.954	rs6507676	chr18:43739730	T/C	cg01718231	chr17:29326311	RNF135	0.44	8.92	0.33	5.02e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs1113500	0.814	rs893983	chr1:108630338	C/T	cg06207961	chr1:108661230	NA	-0.35	-8.65	-0.32	4.06e-17	Growth-regulated protein alpha levels;
BRCA	cis	rs1468333	0.964	rs2967786	chr5:137547675	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.42	8.58	0.32	7.31e-17	Resting heart rate;
BRCA	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg10932868	chr11:921992	NA	0.49	12.66	0.45	5.96e-33	Alzheimer's disease (late onset);
BRCA	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18404041	chr3:52824283	ITIH1	-0.39	-11.57	-0.42	3.19e-28	Bipolar disorder;
BRCA	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg18154014	chr19:37997991	ZNF793	0.65	11.84	0.42	2.15e-29	Coronary artery calcification;
BRCA	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg15083037	chr5:83017644	HAPLN1	-0.52	-10.1	-0.37	2.31e-22	Prostate cancer;
BRCA	cis	rs4478858	0.735	rs4622114	chr1:31772571	A/G	cg00250761	chr1:31883323	NA	-0.32	-8.25	-0.31	9.14e-16	Alcohol dependence;
BRCA	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25427524	chr10:38739819	LOC399744	-0.64	-15.4	-0.52	9.88e-46	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4285028	0.747	rs1127412	chr3:121414061	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.69	-13.75	-0.48	7.15e-38	Multiple sclerosis;
BRCA	cis	rs9796	0.621	rs7170049	chr15:41484287	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.37	-7.83	-0.3	2.04e-14	Menopause (age at onset);
BRCA	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg14664628	chr15:75095509	CSK	0.72	17.95	0.58	1.16e-58	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.37e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.46	-10.47	-0.38	8.44e-24	Urate levels in overweight individuals;
BRCA	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg17211192	chr8:82754475	SNX16	0.52	11.9	0.43	1.23e-29	Diastolic blood pressure;
BRCA	cis	rs7565124	0.909	rs6747472	chr2:20252007	C/T	cg23821541	chr2:20251993	LAPTM4A	0.39	8.23	0.31	1.02e-15	Major depressive disorder;
BRCA	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00166722	chr3:10149974	C3orf24	0.67	13.44	0.47	1.83e-36	Alzheimer's disease;
BRCA	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg08501292	chr6:25962987	TRIM38	0.59	8.02	0.3	4.97e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg23649088	chr2:200775458	C2orf69	-0.41	-8.76	-0.33	1.81e-17	QT interval;
BRCA	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.5	0.5	2.04e-41	Colorectal cancer;
BRCA	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.31	-0.38	3.54e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg14863265	chr7:2801509	GNA12	-0.39	-8.97	-0.33	3.21e-18	Height;
BRCA	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg08888203	chr3:10149979	C3orf24	0.67	14.48	0.5	2.56e-41	Alzheimer's disease;
BRCA	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg05552183	chr6:42928497	GNMT	0.79	19.21	0.6	3.07e-65	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.27	-0.38	5.11e-23	Mean corpuscular volume;
BRCA	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg22920501	chr2:26401640	FAM59B	-0.8	-13.18	-0.46	3e-35	Gut microbiome composition (summer);
BRCA	cis	rs250677	0.522	rs7702695	chr5:148402550	T/A	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.52	-0.32	1.12e-16	Breast cancer;
BRCA	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg22800045	chr5:56110881	MAP3K1	-0.4	-8.25	-0.31	9.3e-16	Coronary artery disease;
BRCA	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.69	-0.5	2.63e-42	Total cholesterol levels;
BRCA	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg04691961	chr3:161091175	C3orf57	-0.59	-14.92	-0.51	2.15e-43	Morning vs. evening chronotype;
BRCA	cis	rs3820928	0.904	rs2396431	chr2:227765488	G/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.46	-0.32	1.77e-16	Pulmonary function;
BRCA	cis	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg07460842	chr6:66804631	NA	1.15	37.82	0.83	3.38e-165	Exhaled nitric oxide output;
BRCA	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-12.67	-0.45	5.66e-33	Bipolar disorder;
BRCA	cis	rs2415984	0.622	rs61993303	chr14:46949716	G/C	cg14871534	chr14:47121158	RPL10L	-0.33	-8.2	-0.31	1.35e-15	Number of children ever born;
BRCA	cis	rs4423214	0.840	rs2017686	chr11:71187061	C/G	cg05163923	chr11:71159392	DHCR7	-0.56	-11.35	-0.41	2.58e-27	Vitamin D levels;
BRCA	cis	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg05901451	chr6:126070800	HEY2	0.4	9.7	0.36	7.76e-21	Endometrial cancer;
BRCA	cis	rs6545883	0.507	rs2123111	chr2:61450454	A/G	cg15711740	chr2:61764176	XPO1	0.32	8.04	0.3	4.39e-15	Tuberculosis;
BRCA	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26314531	chr2:26401878	FAM59B	-0.97	-16.81	-0.55	9.01e-53	Gut microbiome composition (summer);
BRCA	trans	rs8002861	0.664	rs9533662	chr13:44435988	T/A	cg17145862	chr1:211918768	LPGAT1	0.47	10.77	0.39	5.47e-25	Leprosy;
BRCA	trans	rs8002861	0.664	rs1808097	chr13:44424766	A/G	cg17145862	chr1:211918768	LPGAT1	0.47	10.77	0.39	5.77e-25	Leprosy;
BRCA	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg21138405	chr5:131827807	IRF1	0.4	13.0	0.46	1.85e-34	Asthma (sex interaction);
BRCA	cis	rs243505	1.000	rs1019058	chr7:148424243	A/G	cg09806900	chr7:148480153	CUL1	-0.43	-8.81	-0.33	1.15e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg06108461	chr20:60628389	TAF4	-0.69	-14.42	-0.5	5.25e-41	Body mass index;
BRCA	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.35	0.54	1.78e-50	Hypertriglyceridemia;
BRCA	cis	rs2859741	1.000	rs2795009	chr1:37509494	C/T	cg09363841	chr1:37513479	NA	-0.67	-16.68	-0.55	4.16e-52	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg24642439	chr20:33292090	TP53INP2	-0.52	-11.5	-0.41	6.15e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg05313129	chr8:58192883	C8orf71	-0.46	-9.46	-0.35	5.73e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs6138458	1.000	rs227618	chr20:24909472	T/C	cg26195577	chr20:24973756	C20orf3	0.99	24.7	0.7	4.74e-95	Blood protein levels;
BRCA	cis	rs13046373	0.505	rs2832934	chr21:31899760	A/G	cg14062083	chr21:31802829	KRTAP13-4	0.33	8.78	0.33	1.46e-17	HDL cholesterol;
BRCA	cis	rs116979167	0.545	rs1706914	chr7:105196445	A/T	cg19920283	chr7:105172520	RINT1	0.44	8.95	0.33	3.92e-18	Bipolar disorder (body mass index interaction);
BRCA	trans	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg06521331	chr12:34319734	NA	-0.51	-9.27	-0.34	2.72e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg06784218	chr1:46089804	CCDC17	0.51	12.22	0.44	5.44e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg17691542	chr6:26056736	HIST1H1C	0.51	10.41	0.38	1.49e-23	Height;
BRCA	trans	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg25214090	chr10:38739885	LOC399744	0.42	9.45	0.35	6.21e-20	Educational attainment;
BRCA	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11644478	chr21:40555479	PSMG1	0.86	19.84	0.62	1.25e-68	Cognitive function;
BRCA	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg12379764	chr21:47803548	PCNT	-0.37	-7.86	-0.3	1.61e-14	Testicular germ cell tumor;
BRCA	cis	rs2797160	0.874	rs58305111	chr6:126008386	G/T	cg05901451	chr6:126070800	HEY2	0.4	9.65	0.36	1.19e-20	Endometrial cancer;
BRCA	cis	rs6987853	0.787	rs2974346	chr8:42401205	T/C	cg09913449	chr8:42400586	C8orf40	0.41	9.08	0.34	1.35e-18	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg06784218	chr1:46089804	CCDC17	-0.53	-12.92	-0.45	4.51e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg05347473	chr6:146136440	FBXO30	0.42	8.46	0.32	1.78e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11785693	0.862	rs10503292	chr8:4992275	A/G	cg26367366	chr8:4980734	NA	0.47	8.11	0.31	2.6e-15	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg27478167	chr7:817139	HEATR2	-0.48	-9.89	-0.36	1.52e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-10.89	-0.4	1.85e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	8.0	0.3	5.9e-15	Retinal vascular caliber;
BRCA	trans	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	14.8	0.51	8.09e-43	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6942756	1.000	rs66970518	chr7:128871006	G/A	cg02491457	chr7:128862824	NA	-0.71	-14.34	-0.49	1.22e-40	White matter hyperintensity burden;
BRCA	cis	rs7178424	0.742	rs7170293	chr15:62236373	A/T	cg00456672	chr15:62358751	C2CD4A	0.41	9.93	0.37	1.02e-21	Height;
BRCA	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24308560	chr3:49941425	MST1R	0.39	8.3	0.31	6.01e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.13	-0.49	1.2e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	trans	rs459571	0.959	rs416390	chr9:136908549	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.81	15.71	0.53	2.85e-47	Platelet distribution width;
BRCA	cis	rs34779708	0.898	rs11595898	chr10:35326263	T/C	cg03585969	chr10:35415529	CREM	0.55	11.39	0.41	1.72e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.38	-8.33	-0.31	4.87e-16	Longevity;Endometriosis;
BRCA	cis	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg06521331	chr12:34319734	NA	-0.6	-11.02	-0.4	5.61e-26	Morning vs. evening chronotype;
BRCA	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg26395211	chr5:140044315	WDR55	0.34	7.84	0.3	1.84e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg23711669	chr6:146136114	FBXO30	-0.76	-17.46	-0.57	4.11e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.42	-9.31	-0.35	2.01e-19	Personality dimensions;
BRCA	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11764359	chr7:65958608	NA	-0.73	-16.08	-0.54	3.99e-49	Aortic root size;
BRCA	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	8.15	0.31	1.97e-15	Educational attainment;
BRCA	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg26384229	chr12:38710491	ALG10B	0.77	17.64	0.57	4.77e-57	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg26384229	chr12:38710491	ALG10B	0.59	13.53	0.47	7.42e-37	Morning vs. evening chronotype;
BRCA	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.16	0.34	7.11e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs939658	0.683	rs8041222	chr15:79465549	A/G	cg17916960	chr15:79447300	NA	-0.36	-8.71	-0.33	2.69e-17	Refractive error;
BRCA	cis	rs1003719	0.715	rs6517405	chr21:38560334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.49	-0.5	2.46e-41	Eye color traits;
BRCA	trans	rs984440	0.524	rs10111139	chr8:139084283	C/T	cg03334052	chr1:168888044	NA	-0.37	-8.53	-0.32	1.1e-16	Obesity-related traits;
BRCA	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.33	0.41	2.94e-27	Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs8002861	0.840	rs7989353	chr13:44438957	T/C	cg17145862	chr1:211918768	LPGAT1	0.63	16.18	0.54	1.31e-49	Leprosy;
BRCA	cis	rs701145	0.585	rs1470662	chr3:153870997	T/G	cg17054900	chr3:154042577	DHX36	0.55	9.29	0.35	2.32e-19	Coronary artery disease;
BRCA	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg23992470	chr4:843637	GAK	0.56	8.34	0.31	4.4e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg03929089	chr4:120376271	NA	-0.71	-14.17	-0.49	7.75e-40	Height;
BRCA	cis	rs10046574	0.831	rs10251162	chr7:135190264	C/T	cg27474649	chr7:135195673	CNOT4	0.64	9.17	0.34	6.38e-19	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg11608241	chr8:8085544	FLJ10661	0.3	8.12	0.31	2.38e-15	Mood instability;
BRCA	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-10.81	-0.39	3.96e-25	Monocyte percentage of white cells;
BRCA	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg08917208	chr2:24149416	ATAD2B	0.51	8.16	0.31	1.81e-15	Asthma;
BRCA	cis	rs9487051	0.773	rs421790	chr6:109543428	T/A	cg21918786	chr6:109611834	NA	-0.35	-8.61	-0.32	5.78e-17	Reticulocyte fraction of red cells;
BRCA	cis	rs7582720	0.943	rs72934550	chr2:203983940	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	12.77	0.45	2.02e-33	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg18758796	chr5:131593413	PDLIM4	-0.41	-10.83	-0.39	3.32e-25	Acylcarnitine levels;
BRCA	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg21535247	chr6:8435926	SLC35B3	0.38	8.39	0.32	3.1e-16	Motion sickness;
BRCA	cis	rs10504073	0.584	rs55795863	chr8:49898055	A/G	cg00325661	chr8:49890786	NA	0.52	15.1	0.51	2.79e-44	Blood metabolite ratios;
BRCA	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg08999081	chr20:33150536	PIGU	0.35	9.04	0.34	1.86e-18	Coronary artery disease;
BRCA	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg07423050	chr13:99094983	FARP1	-0.49	-10.83	-0.39	3.37e-25	Longevity;
BRCA	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg24692254	chr21:30365293	RNF160	-0.45	-9.98	-0.37	6.8e-22	Pancreatic cancer;
BRCA	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg01283332	chr5:1856932	NA	-0.33	-8.01	-0.3	5.39e-15	Cardiovascular disease risk factors;
BRCA	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg26384229	chr12:38710491	ALG10B	0.7	15.94	0.53	1.97e-48	Bladder cancer;
BRCA	trans	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-10.97	-0.4	8.96e-26	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs7809950	1.000	rs10273733	chr7:107258121	A/G	cg23024343	chr7:107201750	COG5	0.39	8.38	0.31	3.36e-16	Coronary artery disease;
BRCA	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.61	12.97	0.46	2.54e-34	Eosinophil percentage of white cells;
BRCA	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.03	0.56	6.82e-54	Bladder cancer;
BRCA	cis	rs13136331	0.721	rs2732175	chr4:88682574	C/G	cg22416721	chr4:88570574	DMP1	-0.52	-12.29	-0.44	2.52e-31	Sitting height ratio;
BRCA	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg23358479	chr7:1110784	C7orf50	-0.48	-8.17	-0.31	1.68e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6835174	0.881	rs4516655	chr4:5975378	G/A	cg08509927	chr4:5976063	C4orf50	-0.52	-8.56	-0.32	8.23e-17	Cannabis use (initiation);
BRCA	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg16325326	chr1:53192061	ZYG11B	-0.66	-16.28	-0.54	4.37e-50	Monocyte count;
BRCA	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg18016565	chr1:150552671	MCL1	-0.34	-8.11	-0.31	2.5e-15	Tonsillectomy;
BRCA	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg25358565	chr5:93447407	FAM172A	0.69	11.97	0.43	6.3e-30	Diabetic retinopathy;
BRCA	cis	rs12949688	0.967	rs9910446	chr17:55821485	G/C	cg12582317	chr17:55822272	NA	0.32	7.93	0.3	9.68e-15	Schizophrenia;
BRCA	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-16.93	-0.56	2.1e-53	Chronic sinus infection;
BRCA	cis	rs73198271	0.562	rs17154743	chr8:8650787	A/G	cg01851573	chr8:8652454	MFHAS1	0.49	9.3	0.35	2.21e-19	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Tonsillectomy;
BRCA	cis	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg07460842	chr6:66804631	NA	-1.02	-20.26	-0.63	7.39e-71	Exhaled nitric oxide output;
BRCA	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg24399712	chr22:39784796	NA	0.54	12.36	0.44	1.34e-31	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs12618769	0.597	rs4851138	chr2:99065464	A/C	cg10123293	chr2:99228465	UNC50	0.4	8.17	0.31	1.71e-15	Bipolar disorder;
BRCA	cis	rs30380	0.666	rs26512	chr5:96128400	G/T	cg16492584	chr5:96139282	ERAP1	-0.46	-10.93	-0.4	1.25e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4285028	0.747	rs6791882	chr3:121373058	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.82	-15.88	-0.53	4.21e-48	Multiple sclerosis;
BRCA	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-9.5	-0.35	4.26e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg10862848	chr6:42927986	GNMT	-0.35	-14.62	-0.5	5.61e-42	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg19346786	chr7:2764209	NA	-0.33	-9.84	-0.36	2.22e-21	Height;
BRCA	trans	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg13565492	chr6:43139072	SRF	-0.79	-10.84	-0.39	2.99e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12541635	0.639	rs6469030	chr8:107030321	C/T	cg10147462	chr8:107024639	NA	0.38	9.97	0.37	7.2e-22	Age of smoking initiation;
BRCA	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27286337	chr10:134555280	INPP5A	0.8	12.94	0.46	3.49e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9815354	0.680	rs73073263	chr3:42018666	C/A	cg03022575	chr3:42003672	ULK4	0.77	9.77	0.36	4e-21	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-15.46	-0.52	5.17e-46	Obesity-related traits;
BRCA	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-9.38	-0.35	1.12e-19	Retinal vascular caliber;
BRCA	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg16606324	chr3:10149918	C3orf24	0.55	10.84	0.39	2.97e-25	Alzheimer's disease;
BRCA	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg19743168	chr1:23544995	NA	0.4	9.6	0.36	1.72e-20	Height;
BRCA	trans	rs783540	0.609	rs803686	chr15:83219340	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.32	-8.5	-0.32	1.31e-16	Schizophrenia;
BRCA	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.05	0.3	4.15e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.12	-0.37	1.97e-22	IgG glycosylation;
BRCA	cis	rs13095912	0.597	rs112800013	chr3:185313807	A/G	cg11274856	chr3:185301563	NA	0.52	12.35	0.44	1.46e-31	Systolic blood pressure;
BRCA	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg05793240	chr7:2802953	GNA12	0.31	7.99	0.3	6.14e-15	Height;
BRCA	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.54	11.43	0.41	1.18e-27	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg12463550	chr7:65579703	CRCP	0.38	8.09	0.3	2.99e-15	Aortic root size;
BRCA	trans	rs7939886	0.920	rs12223014	chr11:55878290	G/A	cg15704280	chr7:45808275	SEPT13	0.61	7.98	0.3	6.74e-15	Myopia (pathological);
BRCA	trans	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg25214090	chr10:38739885	LOC399744	-0.48	-10.23	-0.38	7.19e-23	Corneal astigmatism;
BRCA	trans	rs11039798	0.920	rs11039848	chr11:48598243	C/T	cg15704280	chr7:45808275	SEPT13	0.64	7.82	0.3	2.12e-14	Axial length;
BRCA	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.37	0.38	2.25e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2274471	0.645	rs73395330	chr9:5082839	C/T	cg03390472	chr9:5043263	JAK2	-0.49	-8.86	-0.33	7.63e-18	Crohn's disease;
BRCA	cis	rs738322	0.804	rs4821742	chr22:38514839	T/C	cg20207973	chr22:38506712	BAIAP2L2	0.39	9.82	0.36	2.79e-21	Cutaneous nevi;
BRCA	cis	rs1003719	0.646	rs2835671	chr21:38581125	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.51	-0.5	1.83e-41	Eye color traits;
BRCA	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-13.58	-0.47	4.27e-37	Morning vs. evening chronotype;
BRCA	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-9.88	-0.36	1.68e-21	Heart rate;
BRCA	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg06640241	chr16:89574553	SPG7	0.84	20.91	0.64	2.41e-74	Multiple myeloma (IgH translocation);
BRCA	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03264133	chr6:25882463	NA	-0.61	-12.65	-0.45	6.79e-33	Intelligence (multi-trait analysis);
BRCA	trans	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.4	-0.35	9.2e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-9.75	-0.36	5.15e-21	Joint mobility (Beighton score);
BRCA	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg01420254	chr6:26195488	NA	0.55	8.49	0.32	1.49e-16	Gout;Renal underexcretion gout;
BRCA	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-8.06	-0.3	3.78e-15	Bipolar disorder;
BRCA	cis	rs12618769	0.652	rs3754878	chr2:99179384	G/A	cg10123293	chr2:99228465	UNC50	0.44	8.67	0.32	3.42e-17	Bipolar disorder;
BRCA	cis	rs965469	0.779	rs6037528	chr20:3260978	A/G	cg25506879	chr20:3388711	C20orf194	-0.44	-8.72	-0.33	2.31e-17	IFN-related cytopenia;
BRCA	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.13	-0.43	1.26e-30	Total cholesterol levels;
BRCA	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg26373071	chr5:1325741	CLPTM1L	0.5	12.26	0.44	3.6e-31	Lung cancer;
BRCA	cis	rs208520	0.690	rs207077	chr6:66769855	A/C	cg07460842	chr6:66804631	NA	-1.01	-19.86	-0.62	9.57e-69	Exhaled nitric oxide output;
BRCA	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg18301423	chr5:131593218	PDLIM4	0.38	9.57	0.35	2.32e-20	Acylcarnitine levels;
BRCA	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.03	-0.37	4.35e-22	Bladder cancer;
BRCA	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.35	0.38	2.64e-23	Motion sickness;
BRCA	cis	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs495337	0.736	rs686996	chr20:48476266	C/G	cg17835207	chr20:48524531	SPATA2	-0.5	-11.06	-0.4	3.87e-26	Psoriasis;
BRCA	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg04691961	chr3:161091175	C3orf57	-0.59	-13.97	-0.48	7.07e-39	Morning vs. evening chronotype;
BRCA	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg21252483	chr19:49399788	TULP2	-0.46	-8.94	-0.33	4.3e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs2505998	0.957	rs1864408	chr10:43575883	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.43	-8.43	-0.32	2.25e-16	Hirschsprung disease;
BRCA	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.43	12.45	0.44	5.29e-32	Response to antipsychotic treatment;
BRCA	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	13.86	0.48	2.21e-38	Lymphocyte counts;
BRCA	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg23950597	chr19:37808831	NA	-0.75	-13.12	-0.46	5.71e-35	Coronary artery calcification;
BRCA	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19346786	chr7:2764209	NA	-0.33	-9.79	-0.36	3.5e-21	Height;
BRCA	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg15556689	chr8:8085844	FLJ10661	0.33	8.93	0.33	4.4e-18	Myopia (pathological);
BRCA	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg13319975	chr6:146136371	FBXO30	-0.37	-8.56	-0.32	8.47e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg01939980	chr4:1354348	KIAA1530	0.37	10.57	0.39	3.69e-24	Longevity;
BRCA	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg12011299	chr4:100065546	ADH4	0.5	11.72	0.42	7.29e-29	Alcohol dependence;
BRCA	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-15.69	-0.53	3.55e-47	Chronic sinus infection;
BRCA	cis	rs36051895	0.623	rs3780383	chr9:5232409	G/C	cg02405213	chr9:5042618	JAK2	-0.48	-8.21	-0.31	1.22e-15	Pediatric autoimmune diseases;
BRCA	trans	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.37	0.49	9.11e-41	Exhaled nitric oxide output;
BRCA	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg08738300	chr3:44038990	NA	-0.46	-9.06	-0.34	1.64e-18	Coronary artery disease;
BRCA	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	8.2	0.31	1.31e-15	Mean platelet volume;
BRCA	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg13256891	chr4:100009986	ADH5	0.53	9.88	0.36	1.64e-21	Alcohol dependence;
BRCA	cis	rs9790314	0.750	rs6765270	chr3:160899974	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-10.91	-0.4	1.57e-25	Morning vs. evening chronotype;
BRCA	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg03146154	chr1:46216737	IPP	0.45	9.84	0.36	2.28e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	19.95	0.62	3.51e-69	Platelet count;
BRCA	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg18402987	chr7:1209562	NA	0.82	11.85	0.42	1.95e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg23711669	chr6:146136114	FBXO30	0.79	18.86	0.6	2.06e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg08601574	chr20:25228251	PYGB	0.35	8.4	0.32	2.92e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg05491587	chr18:77659695	KCNG2	-0.32	-8.1	-0.31	2.86e-15	Schizophrenia;
BRCA	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.33	11.18	0.4	1.28e-26	Systemic lupus erythematosus;
BRCA	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg08085267	chr17:45401833	C17orf57	0.59	12.26	0.44	3.67e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg18154014	chr19:37997991	ZNF793	0.62	11.63	0.42	1.7e-28	Coronary artery calcification;
BRCA	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03517284	chr6:25882590	NA	-0.5	-11.34	-0.41	2.87e-27	Blood metabolite levels;
BRCA	cis	rs2066819	1.000	rs744051	chr12:56667298	C/T	cg26734620	chr12:56694298	CS	-0.91	-10.64	-0.39	1.85e-24	Psoriasis vulgaris;
BRCA	cis	rs1568889	0.592	rs7110074	chr11:28469325	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	8.76	0.33	1.75e-17	Bipolar disorder;
BRCA	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	19.59	0.61	2.82e-67	Electrocardiographic conduction measures;
BRCA	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg12386194	chr3:101231763	SENP7	-0.45	-9.82	-0.36	2.78e-21	Colorectal cancer;
BRCA	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg26769984	chr7:1090371	C7orf50	0.68	12.78	0.45	1.76e-33	Bronchopulmonary dysplasia;
BRCA	cis	rs700651	0.821	rs700690	chr2:198727626	A/G	cg00792783	chr2:198669748	PLCL1	0.47	10.18	0.37	1.21e-22	Intracranial aneurysm;
BRCA	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg26384229	chr12:38710491	ALG10B	0.76	16.91	0.56	2.6e-53	Bladder cancer;
BRCA	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg23711669	chr6:146136114	FBXO30	0.64	14.85	0.51	4.51e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg12311346	chr5:56204834	C5orf35	0.61	12.73	0.45	3.11e-33	Initial pursuit acceleration;
BRCA	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg21747090	chr2:27597821	SNX17	-0.39	-8.47	-0.32	1.75e-16	Total body bone mineral density;
BRCA	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00149659	chr3:10157352	C3orf10	0.76	12.99	0.46	2.1e-34	Alzheimer's disease;
BRCA	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12893428	chr3:195717962	SDHAP1	0.32	7.88	0.3	1.43e-14	Pancreatic cancer;
BRCA	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg21775007	chr8:11205619	TDH	-0.39	-7.95	-0.3	8.33e-15	Neuroticism;
BRCA	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.36	-0.41	2.22e-27	Gut microbiome composition (summer);
BRCA	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg26384229	chr12:38710491	ALG10B	0.69	16.25	0.54	6.19e-50	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg20503657	chr10:835505	NA	0.67	10.55	0.39	4.26e-24	Eosinophil percentage of granulocytes;
BRCA	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-10.01	-0.37	5.17e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg06784218	chr1:46089804	CCDC17	0.45	10.79	0.39	4.84e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs965469	0.779	rs6515810	chr20:3370861	T/C	cg25506879	chr20:3388711	C20orf194	-0.46	-9.05	-0.34	1.71e-18	IFN-related cytopenia;
BRCA	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.03	-0.56	6.83e-54	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg16339924	chr4:17578868	LAP3	0.63	15.59	0.52	1.11e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.19e-40	Motion sickness;
BRCA	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg03676636	chr4:99064102	C4orf37	0.22	8.04	0.3	4.36e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2108225	0.900	rs4518594	chr7:107451060	G/C	cg18560240	chr7:107437656	SLC26A3	-0.49	-9.86	-0.36	1.9e-21	Ulcerative colitis;
BRCA	trans	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs867371	0.820	rs7164362	chr15:82486742	C/G	cg00614314	chr15:82944287	LOC80154	0.39	7.93	0.3	1.01e-14	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg22834771	chr12:69754056	YEATS4	-0.4	-10.02	-0.37	4.59e-22	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24531977	chr5:56204891	C5orf35	-0.78	-12.9	-0.45	5.38e-34	Type 2 diabetes;
BRCA	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.45	-0.38	1.04e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg13047869	chr3:10149882	C3orf24	0.53	11.33	0.41	3.18e-27	Alzheimer's disease;
BRCA	cis	rs897984	0.572	rs112906665	chr16:31040139	T/C	cg00531865	chr16:30841666	NA	-0.38	-9.06	-0.34	1.6e-18	Dementia with Lewy bodies;
BRCA	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs4268898	0.760	rs11676939	chr2:24479057	C/T	cg06627628	chr2:24431161	ITSN2	0.41	8.75	0.33	1.83e-17	Asthma;
BRCA	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23583168	chr7:148888333	NA	-0.99	-26.11	-0.72	8.01e-103	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs11051970	0.636	rs325424	chr12:32570193	C/T	cg24626660	chr12:32551988	NA	0.31	9.03	0.34	1.99e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.02	15.53	0.52	2.22e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg00701064	chr4:6280414	WFS1	-0.62	-14.81	-0.51	7.02e-43	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs10044254	0.587	rs4484432	chr5:15739776	T/G	cg07238450	chr5:15720153	FBXL7	-0.38	-7.9	-0.3	1.19e-14	Asthma (corticosteroid response);
BRCA	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg20290983	chr6:43655470	MRPS18A	-0.95	-22.17	-0.66	3.18e-81	IgG glycosylation;
BRCA	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08219700	chr8:58056026	NA	0.54	8.93	0.33	4.66e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4742903	0.904	rs10114234	chr9:107003646	C/T	cg14250997	chr9:106856677	SMC2	-0.3	-9.45	-0.35	6.56e-20	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23708337	chr7:1209742	NA	0.49	9.56	0.35	2.52e-20	Longevity;Endometriosis;
BRCA	cis	rs858239	0.899	rs7794684	chr7:23310805	A/G	cg23682824	chr7:23144976	KLHL7	0.36	9.09	0.34	1.24e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg17063962	chr7:91808500	NA	-0.53	-12.46	-0.44	4.56e-32	Breast cancer;
BRCA	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg04166393	chr7:2884313	GNA12	0.52	10.0	0.37	5.74e-22	Height;
BRCA	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03517284	chr6:25882590	NA	0.39	9.04	0.34	1.8e-18	Blood metabolite levels;
BRCA	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg20387954	chr3:183756860	HTR3D	0.46	10.54	0.38	4.64e-24	Anterior chamber depth;
BRCA	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg22705602	chr4:152727874	NA	-0.33	-8.02	-0.3	5.22e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.13	-0.31	2.31e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs912057	0.841	rs1294423	chr6:6743795	C/T	cg06612196	chr6:6737390	NA	0.4	8.86	0.33	7.98e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg20469991	chr17:27169893	C17orf63	-0.45	-8.88	-0.33	6.75e-18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg14675211	chr2:100938903	LONRF2	0.44	9.94	0.37	9.24e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg23422044	chr7:1970798	MAD1L1	0.59	10.72	0.39	9.27e-25	Bipolar disorder;
BRCA	trans	rs11976180	1.000	rs11976037	chr7:143741024	A/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.48	-8.72	-0.33	2.47e-17	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg03609598	chr5:56110824	MAP3K1	-0.47	-8.24	-0.31	9.74e-16	Initial pursuit acceleration;
BRCA	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg17063962	chr7:91808500	NA	0.57	13.02	0.46	1.56e-34	Breast cancer;
BRCA	cis	rs10992471	0.603	rs11794346	chr9:95247288	C/T	cg14631576	chr9:95140430	CENPP	-0.38	-9.37	-0.35	1.25e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg24596788	chr1:163392923	NA	-0.38	-9.9	-0.36	1.37e-21	Motion sickness;
BRCA	cis	rs6484504	0.600	rs10835763	chr11:31345574	G/A	cg26647111	chr11:31128758	NA	0.45	9.71	0.36	7.27e-21	Red blood cell count;
BRCA	cis	rs13315871	0.929	rs11130627	chr3:58315749	G/A	cg20936604	chr3:58311152	NA	-0.65	-8.24	-0.31	9.48e-16	Cholesterol, total;
BRCA	cis	rs6813479	0.523	rs2926565	chr4:137744017	C/T	cg16185213	chr4:137733633	NA	0.33	7.98	0.3	6.83e-15	Longevity;
BRCA	cis	rs11112613	0.713	rs12296355	chr12:105953321	C/A	cg03607813	chr12:105948248	NA	0.55	10.4	0.38	1.6e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-15.61	-0.53	8.97e-47	Extrinsic epigenetic age acceleration;
BRCA	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.25	7.98	0.3	6.85e-15	Cardiac Troponin-T levels;
BRCA	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg01657329	chr11:68192670	LRP5	-0.39	-9.72	-0.36	6.62e-21	Total body bone mineral density;
BRCA	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.4	-0.32	2.84e-16	Total body bone mineral density;
BRCA	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg08508325	chr11:3079039	CARS	-0.39	-13.31	-0.47	7.71e-36	Longevity;
BRCA	cis	rs858239	0.539	rs4294098	chr7:23185995	G/A	cg23682824	chr7:23144976	KLHL7	0.41	10.63	0.39	1.99e-24	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs12517041	1.000	rs10520889	chr5:23280920	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.33	-0.31	4.92e-16	Calcium levels;
BRCA	trans	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg25214090	chr10:38739885	LOC399744	0.52	11.71	0.42	7.85e-29	Corneal astigmatism;
BRCA	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg00666640	chr1:248458726	OR2T12	0.32	8.77	0.33	1.63e-17	Common traits (Other);
BRCA	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg27279351	chr12:120934652	DYNLL1	0.56	13.32	0.47	6.68e-36	High light scatter reticulocyte count;
BRCA	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-12.59	-0.45	1.2e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs6087990	0.735	rs6087420	chr20:31359391	G/A	cg13636640	chr20:31349939	DNMT3B	0.67	20.46	0.63	5.89e-72	Ulcerative colitis;
BRCA	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg05863683	chr7:1912471	MAD1L1	0.41	8.63	0.32	4.79e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg08885076	chr2:99613938	TSGA10	-0.52	-11.73	-0.42	6.2e-29	Chronic sinus infection;
BRCA	trans	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.47	0.32	1.73e-16	Corneal astigmatism;
BRCA	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7131987	0.868	rs7958210	chr12:29395181	G/C	cg09582351	chr12:29534625	ERGIC2	-0.4	-9.6	-0.36	1.73e-20	QT interval;
BRCA	cis	rs1003719	0.788	rs1543750	chr21:38446918	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.19	0.49	6.57e-40	Eye color traits;
BRCA	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.81	-0.3	2.3e-14	Electroencephalogram traits;
BRCA	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.92	0.4	1.43e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-13.47	-0.47	1.4e-36	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg18446336	chr7:2847575	GNA12	-0.34	-8.23	-0.31	1.03e-15	Height;
BRCA	cis	rs921968	0.565	rs12612395	chr2:219621642	G/C	cg02176678	chr2:219576539	TTLL4	-0.42	-11.25	-0.41	6.19e-27	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg03060546	chr3:49711283	APEH	-0.51	-10.03	-0.37	4.39e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs17209837	0.607	rs1473154	chr7:87082042	A/G	cg00919237	chr7:87102261	ABCB4	-0.52	-10.19	-0.37	1.05e-22	Gallbladder cancer;
BRCA	cis	rs1691799	0.777	rs11176145	chr12:66719795	A/G	cg16791601	chr12:66731901	HELB	0.49	12.73	0.45	2.92e-33	White blood cell count (basophil);
BRCA	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg05340658	chr4:99064831	C4orf37	0.45	10.19	0.37	1.12e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg26384229	chr12:38710491	ALG10B	0.52	13.86	0.48	2.26e-38	Morning vs. evening chronotype;
BRCA	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18252515	chr7:66147081	NA	-0.65	-10.89	-0.4	1.92e-25	Diabetic kidney disease;
BRCA	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg13010199	chr12:38710504	ALG10B	0.52	10.81	0.39	3.81e-25	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg26384229	chr12:38710491	ALG10B	0.74	17.6	0.57	7.83e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs35123781	1.000	rs601336	chr5:139057167	T/C	cg05227215	chr5:139057496	CXXC5	0.33	7.94	0.3	9.35e-15	Schizophrenia;
BRCA	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg27170947	chr2:26402098	FAM59B	0.59	9.9	0.36	1.39e-21	Gut microbiome composition (summer);
BRCA	cis	rs4363385	0.765	rs11205165	chr1:152986928	G/T	cg24667326	chr1:152973720	SPRR3	-0.31	-8.4	-0.32	2.78e-16	Inflammatory skin disease;
BRCA	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg03929089	chr4:120376271	NA	0.64	11.72	0.42	7.04e-29	Coronary artery disease;
BRCA	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg01689657	chr7:91764605	CYP51A1	0.23	7.87	0.3	1.54e-14	Breast cancer;
BRCA	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.67e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.49	10.92	0.4	1.39e-25	Cognitive ability;
BRCA	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-7.96	-0.3	8.11e-15	Axial length;
BRCA	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg11663144	chr21:46675770	NA	-0.6	-13.87	-0.48	2.05e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg12373951	chr3:133503437	NA	0.34	8.05	0.3	3.95e-15	Iron status biomarkers;
BRCA	trans	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg06521331	chr12:34319734	NA	-0.47	-8.68	-0.32	3.32e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg08470875	chr2:26401718	FAM59B	0.76	11.92	0.43	1.02e-29	Gut microbiome composition (summer);
BRCA	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.05	29.57	0.76	9.6e-122	Cognitive ability;
BRCA	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg07636037	chr3:49044803	WDR6	0.97	29.49	0.76	2.61e-121	Parkinson's disease;
BRCA	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg05555928	chr11:63887634	MACROD1	-0.44	-7.99	-0.3	6.39e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs4780401	0.933	rs12926451	chr16:11819569	A/C	cg01061890	chr16:11836724	TXNDC11	0.36	7.89	0.3	1.35e-14	Rheumatoid arthritis;
BRCA	trans	rs8073060	0.559	rs10438814	chr17:34007065	A/G	cg19694781	chr19:47549865	TMEM160	-1.03	-21.09	-0.64	2.33e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg19920283	chr7:105172520	RINT1	0.61	9.53	0.35	3.16e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg23422044	chr7:1970798	MAD1L1	-0.56	-9.55	-0.35	2.6e-20	Neuroticism;
BRCA	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg04709771	chr16:646395	RAB40C	0.45	11.25	0.41	6.33e-27	Height;
BRCA	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	7.15e-19	Alzheimer's disease (late onset);
BRCA	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg20701182	chr2:24300061	SF3B14	0.58	9.05	0.34	1.68e-18	Lymphocyte counts;
BRCA	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg26384229	chr12:38710491	ALG10B	0.82	21.7	0.65	1.25e-78	Heart rate;
BRCA	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg01262667	chr19:19385393	TM6SF2	0.41	10.58	0.39	3.35e-24	Tonsillectomy;
BRCA	cis	rs11231017	0.507	rs10897266	chr11:62155112	A/T	cg23876832	chr11:62092739	NA	0.33	8.47	0.32	1.64e-16	HIV-1 viral setpoint;
BRCA	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg26587870	chr6:27730563	NA	-0.52	-8.02	-0.3	5.04e-15	Breast cancer;
BRCA	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg00012203	chr2:219082015	ARPC2	0.49	9.76	0.36	4.64e-21	Colorectal cancer;
BRCA	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg23950597	chr19:37808831	NA	-0.61	-11.22	-0.41	8.27e-27	Coronary artery calcification;
BRCA	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06636551	chr8:101224915	SPAG1	-0.38	-8.58	-0.32	7.08e-17	Atrioventricular conduction;
BRCA	cis	rs10504073	0.609	rs17644494	chr8:50019679	T/C	cg00325661	chr8:49890786	NA	0.38	11.15	0.4	1.65e-26	Blood metabolite ratios;
BRCA	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18357526	chr6:26021779	HIST1H4A	0.51	9.48	0.35	4.82e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.5	10.98	0.4	8.36e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.68	-0.39	1.31e-24	Tonsillectomy;
BRCA	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.85	-0.33	8.29e-18	Alzheimer's disease (late onset);
BRCA	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs17384381	0.859	rs28529751	chr1:85910951	G/A	cg16011679	chr1:85725395	C1orf52	0.51	7.97	0.3	7.29e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3784262	0.565	rs34676542	chr15:58318716	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.46	-0.35	5.84e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg17366294	chr4:99064904	C4orf37	0.42	9.71	0.36	6.85e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg06115741	chr20:33292138	TP53INP2	0.51	11.53	0.42	4.35e-28	Coronary artery disease;
BRCA	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00802000	chr16:706648	WDR90	-0.39	-9.18	-0.34	5.86e-19	Height;
BRCA	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg17063962	chr7:91808500	NA	-0.54	-12.92	-0.46	4.26e-34	Breast cancer;
BRCA	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg25036284	chr2:26402008	FAM59B	-0.88	-15.06	-0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Tonsillectomy;
BRCA	cis	rs68170813	0.559	rs58663672	chr7:106949444	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-9.02	-0.34	2.2e-18	Coronary artery disease;
BRCA	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg05340658	chr4:99064831	C4orf37	0.59	12.66	0.45	6.47e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg12011299	chr4:100065546	ADH4	0.53	12.95	0.46	3.03e-34	Alcohol dependence;
BRCA	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg05283184	chr6:79620031	NA	-0.42	-10.85	-0.39	2.79e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs1040555	0.516	rs242547	chr20:31418581	T/C	cg13636640	chr20:31349939	DNMT3B	0.46	10.83	0.39	3.32e-25	Lymphocyte percentage of white cells;
BRCA	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.43	-0.38	1.21e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10267417	0.603	rs28819981	chr7:19933631	A/G	cg05791153	chr7:19748676	TWISTNB	0.42	7.91	0.3	1.11e-14	Night sleep phenotypes;
BRCA	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.3	0.31	6.36e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg05340658	chr4:99064831	C4orf37	0.7	17.35	0.57	1.57e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg14863265	chr7:2801509	GNA12	-0.45	-9.48	-0.35	4.9e-20	Height;
BRCA	cis	rs6942756	0.956	rs13235668	chr7:128879710	A/G	cg02491457	chr7:128862824	NA	-0.73	-14.9	-0.51	2.65e-43	White matter hyperintensity burden;
BRCA	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg13628971	chr7:2884303	GNA12	0.44	8.72	0.33	2.44e-17	Height;
BRCA	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg18402987	chr7:1209562	NA	0.66	11.51	0.41	5.35e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg02820040	chr2:241836501	C2orf54	-0.53	-10.22	-0.37	8.42e-23	Urinary metabolites;
BRCA	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg01448562	chr3:133502909	NA	-0.43	-9.43	-0.35	7.36e-20	Iron status biomarkers;
BRCA	cis	rs654950	0.806	rs941971	chr1:42040893	T/C	cg06885757	chr1:42089581	HIVEP3	-0.31	-10.45	-0.38	1.03e-23	Airway imaging phenotypes;
BRCA	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.29	-0.31	6.59e-16	Breast cancer;
BRCA	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg23711669	chr6:146136114	FBXO30	0.64	15.0	0.51	8.96e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.45	8.43	0.32	2.25e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6763687	0.637	rs7636026	chr3:171814021	A/T	cg16233210	chr3:171778391	FNDC3B	0.4	9.38	0.35	1.16e-19	Red cell distribution width;
BRCA	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	11.17	0.4	1.4e-26	Rheumatoid arthritis;
BRCA	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg07952391	chr2:88470173	THNSL2	0.64	8.95	0.33	3.77e-18	Plasma clusterin levels;
BRCA	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg12310025	chr6:25882481	NA	0.5	12.16	0.43	9.55e-31	Blood metabolite levels;
BRCA	cis	rs6083	0.549	rs11858020	chr15:58852422	A/T	cg05156742	chr15:59063176	FAM63B	0.44	9.35	0.35	1.43e-19	Schizophrenia;
BRCA	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg02038168	chr22:39784481	NA	0.42	8.02	0.3	5.17e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4566357	0.615	rs2272202	chr2:227914625	C/T	cg05526886	chr2:227700861	RHBDD1	0.4	8.37	0.31	3.56e-16	Coronary artery disease;
BRCA	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.83e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg06784218	chr1:46089804	CCDC17	-0.52	-12.76	-0.45	2.29e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg18357645	chr12:58087776	OS9	0.44	12.49	0.44	3.55e-32	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg03354898	chr7:1950403	MAD1L1	-0.6	-14.56	-0.5	1.1e-41	Bipolar disorder and schizophrenia;
BRCA	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08564027	chr20:61660810	NA	-0.9	-23.39	-0.68	6.98e-88	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs13102973	0.899	rs7442212	chr4:135899800	A/G	cg14419869	chr4:135874104	NA	-0.53	-10.84	-0.39	2.93e-25	Subjective well-being;
BRCA	cis	rs2625529	0.730	rs12908882	chr15:72437572	G/A	cg16672083	chr15:72433130	SENP8	-0.85	-17.86	-0.58	3.75e-58	Red blood cell count;
BRCA	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.43	0.41	1.22e-27	Electroencephalogram traits;
BRCA	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg05283184	chr6:79620031	NA	-0.42	-10.88	-0.4	2.13e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.69e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.22e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg09307838	chr4:120376055	NA	0.67	12.32	0.44	1.99e-31	Corneal astigmatism;
BRCA	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.65	-0.32	4.07e-17	Monocyte percentage of white cells;
BRCA	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg08470875	chr2:26401718	FAM59B	0.72	11.93	0.43	8.78e-30	Gut microbiome composition (summer);
BRCA	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.89	0.33	5.97e-18	Tonsillectomy;
BRCA	cis	rs62380364	0.602	rs665324	chr5:88055517	T/C	cg22951263	chr5:87985283	NA	-0.38	-10.65	-0.39	1.69e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.44	0.35	6.85e-20	Tonsillectomy;
BRCA	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.94	0.3	8.88e-15	Depression;
BRCA	cis	rs9400271	0.632	rs34981677	chr6:109590920	T/C	cg01475377	chr6:109611718	NA	-0.43	-10.27	-0.38	5.06e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs672059	0.812	rs61418038	chr1:183155717	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.38	8.83	0.33	9.91e-18	Hypertriglyceridemia;
BRCA	trans	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg26384229	chr12:38710491	ALG10B	0.52	11.13	0.4	2.02e-26	Morning vs. evening chronotype;
BRCA	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg02297831	chr4:17616191	MED28	0.36	8.24	0.31	9.75e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22590775	chr19:49891494	CCDC155	0.46	8.03	0.3	4.84e-15	Multiple sclerosis;
BRCA	cis	rs2742234	0.614	rs3026750	chr10:43607756	G/A	cg02780029	chr10:43622663	RET	-0.4	-9.97	-0.37	7.55e-22	Hirschsprung disease;
BRCA	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg12062639	chr20:23401060	NAPB	0.95	13.22	0.46	1.89e-35	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg23978390	chr7:1156363	C7orf50	0.41	9.33	0.35	1.73e-19	Longevity;Endometriosis;
BRCA	cis	rs13046373	0.535	rs2832970	chr21:32020767	T/C	cg14062083	chr21:31802829	KRTAP13-4	0.34	9.46	0.35	5.95e-20	HDL cholesterol;
BRCA	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.36	9.23	0.34	3.88e-19	IgG glycosylation;
BRCA	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg08514558	chr10:81106712	PPIF	0.38	8.66	0.32	3.9e-17	Height;
BRCA	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg23649088	chr2:200775458	C2orf69	-0.57	-8.58	-0.32	7.26e-17	Schizophrenia;
BRCA	cis	rs61990749	0.597	rs2267768	chr14:78216014	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.66	10.57	0.39	3.61e-24	Fibroblast growth factor basic levels;
BRCA	cis	rs4900538	0.819	rs72698591	chr14:102838896	G/A	cg18135206	chr14:102964638	TECPR2	-0.96	-22.29	-0.66	7.07e-82	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-11.64	-0.42	1.58e-28	Alzheimer's disease;
BRCA	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.18	0.4	1.23e-26	Bipolar disorder;
BRCA	cis	rs1538970	0.962	rs9429077	chr1:45820667	C/A	cg05343316	chr1:45956843	TESK2	0.56	11.34	0.41	2.74e-27	Platelet count;
BRCA	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.46	-9.1	-0.34	1.1e-18	Parkinson's disease;
BRCA	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg20573242	chr4:122745356	CCNA2	0.48	10.87	0.4	2.23e-25	Type 2 diabetes;
BRCA	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-10.0	-0.37	5.53e-22	Alzheimer's disease (late onset);
BRCA	cis	rs2882667	0.659	rs288037	chr5:138208441	A/G	cg04439458	chr5:138467593	SIL1	-0.35	-8.55	-0.32	9.12e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4742903	0.967	rs10512325	chr9:106861191	C/T	cg21169611	chr9:106856078	SMC2	0.35	9.25	0.34	3.19e-19	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg26874164	chr19:58962979	ZNF324B	0.42	9.05	0.34	1.72e-18	Uric acid clearance;
BRCA	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg04756594	chr16:24857601	SLC5A11	0.5	11.51	0.41	5.37e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs41005	0.597	rs34452414	chr2:8101593	C/T	cg03155496	chr2:8117019	LOC339788	-0.49	-11.12	-0.4	2.28e-26	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-18.97	-0.6	5.62e-64	Chronic sinus infection;
BRCA	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg00757033	chr12:89920650	WDR51B	0.54	10.82	0.39	3.61e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	13.23	0.46	1.7000000000000001e-35	Lymphocyte percentage of white cells;
BRCA	cis	rs1050631	0.564	rs1625385	chr18:33717364	C/A	cg19453250	chr18:33710783	SLC39A6;ELP2	-0.29	-7.99	-0.3	6.25e-15	Esophageal squamous cell cancer (length of survival);
BRCA	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.01	-20.8	-0.64	8.85e-74	Gut microbiome composition (summer);
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg03923535	chr7:1197113	ZFAND2A	0.44	8.7	0.33	2.73e-17	Longevity;Endometriosis;
BRCA	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.74	0.67	2.6e-84	Chronic sinus infection;
BRCA	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.35	-9.87	-0.36	1.79e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.77	0.33	1.65e-17	Motion sickness;
BRCA	cis	rs507080	0.885	rs693037	chr11:118553326	C/T	cg09144398	chr11:118550485	TREH	-0.37	-8.9	-0.33	5.82e-18	Serum metabolite levels;
BRCA	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg07080220	chr10:102295463	HIF1AN	0.56	12.4	0.44	8.77e-32	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1018836	0.923	rs12680211	chr8:91633434	C/T	cg16814680	chr8:91681699	NA	-0.53	-11.37	-0.41	2.04e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs62158211	1.000	rs62158211	chr2:114106139	G/T	cg17784749	chr2:114082611	LOC440839	0.49	8.5	0.32	1.35e-16	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
BRCA	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg09904177	chr6:26538194	HMGN4	0.46	14.64	0.5	4.66e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg17135325	chr3:160939158	NMD3	0.39	7.82	0.3	2.14e-14	Morning vs. evening chronotype;
BRCA	cis	rs7528419	0.617	rs4970834	chr1:109814880	C/T	cg00908766	chr1:109817496	CELSR2	-0.35	-8.99	-0.34	2.8e-18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
BRCA	cis	rs7264396	0.832	rs224349	chr20:34045392	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-8.31	-0.31	5.81e-16	Total cholesterol levels;
BRCA	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.11	-0.34	1.09e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.03	-0.4	5.15e-26	Morning vs. evening chronotype;
BRCA	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg23505145	chr19:12996616	KLF1	0.53	12.03	0.43	3.3e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg18811423	chr2:55921094	PNPT1	0.73	23.54	0.68	1.07e-88	Metabolic syndrome;
BRCA	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg09307838	chr4:120376055	NA	0.46	9.64	0.36	1.24e-20	Diastolic blood pressure;
BRCA	cis	rs6087990	0.806	rs1474738	chr20:31380309	G/A	cg13636640	chr20:31349939	DNMT3B	0.62	18.64	0.59	3.06e-62	Ulcerative colitis;
BRCA	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg26031613	chr14:104095156	KLC1	0.7	14.77	0.5	1.15e-42	Body mass index;
BRCA	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.77	12.85	0.45	8.99e-34	Schizophrenia;
BRCA	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg07371521	chr5:154026371	NA	0.41	8.1	0.31	2.79e-15	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg14500267	chr11:67383377	NA	-0.4	-8.41	-0.32	2.73e-16	Mean corpuscular volume;
BRCA	cis	rs58785573	0.504	rs9522	chr4:38666972	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.56	11.88	0.43	1.55e-29	Lymphocyte percentage of white cells;
BRCA	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg14784868	chr12:69753453	YEATS4	-0.76	-24.83	-0.7	9.17e-96	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs10504073	0.584	rs56078938	chr8:49940342	A/C	cg00325661	chr8:49890786	NA	0.51	14.6	0.5	6.96e-42	Blood metabolite ratios;
BRCA	cis	rs7246657	0.722	rs958305	chr19:38189440	A/G	cg18154014	chr19:37997991	ZNF793	-0.42	-8.05	-0.3	3.96e-15	Coronary artery calcification;
BRCA	cis	rs2882667	0.898	rs6862393	chr5:138364698	T/C	cg04439458	chr5:138467593	SIL1	-0.33	-8.93	-0.33	4.46e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	30.52	0.77	6.7e-127	Chronic sinus infection;
BRCA	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24549020	chr5:56110836	MAP3K1	0.62	12.39	0.44	9.7e-32	Initial pursuit acceleration;
BRCA	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11644478	chr21:40555479	PSMG1	0.71	13.93	0.48	1.01e-38	Cognitive function;
BRCA	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	12.5	0.44	3.17e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.9	0.51	2.56e-43	Colorectal cancer;
BRCA	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.29	0.31	6.9e-16	Parkinson's disease;
BRCA	cis	rs6484504	0.532	rs2616799	chr11:31319044	T/C	cg26647111	chr11:31128758	NA	0.45	9.79	0.36	3.41e-21	Red blood cell count;
BRCA	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg18538332	chr22:24372958	LOC391322	-0.49	-11.56	-0.42	3.36e-28	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-11.92	-0.43	9.74e-30	Tonsillectomy;
BRCA	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg09035930	chr12:129282057	SLC15A4	0.58	17.51	0.57	2.2e-56	Systemic lupus erythematosus;
BRCA	cis	rs3862030	0.720	rs11593971	chr10:104234090	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-13.2	-0.46	2.44e-35	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	trans	rs8002861	0.664	rs895266	chr13:44461179	T/C	cg17145862	chr1:211918768	LPGAT1	0.52	11.55	0.42	3.62e-28	Leprosy;
BRCA	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg01256987	chr12:42539512	GXYLT1	-0.42	-8.32	-0.31	5.3e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.45	9.81	0.36	2.89e-21	IgG glycosylation;
BRCA	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg09654669	chr8:57350985	NA	-0.39	-8.36	-0.31	4.02e-16	Obesity-related traits;
BRCA	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-11.51	-0.41	5.7e-28	Electroencephalogram traits;
BRCA	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.81	-0.3	2.42e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.1	0.31	2.71e-15	Total cholesterol levels;
BRCA	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13012494	chr21:47604986	C21orf56	-0.45	-9.06	-0.34	1.6e-18	Testicular germ cell tumor;
BRCA	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg05901451	chr6:126070800	HEY2	-0.39	-9.41	-0.35	9.06e-20	Endometrial cancer;
BRCA	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg14789911	chr21:47582049	C21orf56	0.36	7.86	0.3	1.63e-14	Testicular germ cell tumor;
BRCA	cis	rs169738	1	rs169738	chr6:33537546	A/G	cg13560919	chr6:33536144	NA	-0.38	-8.08	-0.3	3.32e-15	Platelet count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.78	0.36	3.76e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs400736	0.562	rs7551900	chr1:8178526	A/C	cg25007680	chr1:8021821	PARK7	-0.36	-8.82	-0.33	1.05e-17	Response to antidepressants and depression;
BRCA	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg21775007	chr8:11205619	TDH	0.62	12.04	0.43	3.02e-30	Retinal vascular caliber;
BRCA	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.97	14.79	0.51	8.69e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg04691961	chr3:161091175	C3orf57	-0.59	-14.34	-0.49	1.2e-40	Morning vs. evening chronotype;
BRCA	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg26373071	chr5:1325741	CLPTM1L	0.51	12.36	0.44	1.32e-31	Lung cancer;
BRCA	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg00105475	chr2:10696890	NA	0.44	10.15	0.37	1.46e-22	Prostate cancer;
BRCA	cis	rs858239	0.601	rs1034963	chr7:23148473	T/C	cg23682824	chr7:23144976	KLHL7	0.45	12.17	0.43	8.16e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg09555818	chr19:45449301	APOC2	0.47	12.21	0.43	5.83e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9503598	0.783	rs9503599	chr6:3451048	T/C	cg00476032	chr6:3446245	SLC22A23	0.43	10.79	0.39	4.67e-25	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.85e-29	Chronic sinus infection;
BRCA	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26314531	chr2:26401878	FAM59B	0.9	16.15	0.54	1.92e-49	Gut microbiome composition (summer);
BRCA	cis	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.17	-0.37	1.26e-22	Morning vs. evening chronotype;
BRCA	cis	rs6546550	0.901	rs6546553	chr2:70111711	C/A	cg02498382	chr2:70120550	SNRNP27	-0.5	-10.98	-0.4	7.86e-26	Prevalent atrial fibrillation;
BRCA	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg04362960	chr10:104952993	NT5C2	0.46	10.41	0.38	1.55e-23	Arsenic metabolism;
BRCA	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg13902645	chr11:5959945	NA	-0.53	-11.37	-0.41	2.02e-27	DNA methylation (variation);
BRCA	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.68	0.61	9.04e-68	Alzheimer's disease;
BRCA	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg22105103	chr4:187893119	NA	-0.37	-11.65	-0.42	1.35e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg23711669	chr6:146136114	FBXO30	-0.66	-15.34	-0.52	1.85e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1865721	0.656	rs724765	chr18:73139794	A/G	cg26385618	chr18:73139727	C18orf62	-0.37	-9.3	-0.35	2.2e-19	Intelligence;
BRCA	cis	rs74181299	0.750	rs12472718	chr2:65327620	G/A	cg05010058	chr2:65284262	CEP68	-0.3	-8.43	-0.32	2.21e-16	Pulse pressure;
BRCA	cis	rs6120849	0.754	rs6088667	chr20:33566722	A/C	cg24642439	chr20:33292090	TP53INP2	0.57	9.91	0.37	1.21e-21	Protein C levels;
BRCA	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg22920501	chr2:26401640	FAM59B	0.94	16.57	0.55	1.46e-51	Gut microbiome composition (summer);
BRCA	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.92	-0.3	1.09e-14	Retinal vascular caliber;
BRCA	cis	rs1971762	0.561	rs4759288	chr12:54084006	T/A	cg23533419	chr12:54090519	NA	-0.32	-7.97	-0.3	7.44e-15	Height;
BRCA	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg09462578	chr12:12878428	APOLD1	-0.68	-11.7	-0.42	8.62e-29	Systemic lupus erythematosus;
BRCA	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg03060546	chr3:49711283	APEH	0.6	9.83	0.36	2.5e-21	Menarche (age at onset);
BRCA	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg20203395	chr5:56204925	C5orf35	-0.52	-10.96	-0.4	9.63e-26	Initial pursuit acceleration;
BRCA	cis	rs6545883	0.894	rs778144	chr2:61583128	A/C	cg15711740	chr2:61764176	XPO1	0.52	13.45	0.47	1.73e-36	Tuberculosis;
BRCA	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg03146154	chr1:46216737	IPP	0.46	10.22	0.37	8.35e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs939658	0.805	rs4778924	chr15:79443363	T/C	cg17916960	chr15:79447300	NA	-0.44	-11.05	-0.4	4.3e-26	Refractive error;
BRCA	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg00684032	chr4:1343700	KIAA1530	0.36	8.65	0.32	4.05e-17	Obesity-related traits;
BRCA	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	11.3	0.41	4.15e-27	Platelet count;
BRCA	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.34	-9.47	-0.35	5.34e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.6	-0.32	6.27e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.85	0.33	8.79e-18	Motion sickness;
BRCA	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-11.01	-0.4	5.91e-26	C-reactive protein levels or triglyceride levels (pleiotropy);
BRCA	cis	rs9487051	0.768	rs371960	chr6:109525082	A/G	cg01475377	chr6:109611718	NA	-0.45	-11.51	-0.41	5.67e-28	Reticulocyte fraction of red cells;
BRCA	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg21770322	chr7:97807741	LMTK2	0.44	11.72	0.42	7.34e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg13010199	chr12:38710504	ALG10B	0.5	10.43	0.38	1.31e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg16482183	chr6:26056742	HIST1H1C	0.74	14.73	0.5	1.78e-42	Iron status biomarkers;
BRCA	cis	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg07460842	chr6:66804631	NA	-0.98	-18.46	-0.59	2.69e-61	Exhaled nitric oxide output;
BRCA	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.02	15.49	0.52	3.3e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9287719	0.649	rs2160258	chr2:10717221	T/A	cg00105475	chr2:10696890	NA	0.41	9.23	0.34	4.02e-19	Prostate cancer;
BRCA	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12826209	chr6:26865740	GUSBL1	0.58	10.45	0.38	1.03e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4679121	0.642	rs16837507	chr3:126189395	A/G	cg05485589	chr3:126194908	ZXDC	-0.74	-8.36	-0.31	3.92e-16	Pursuit maintenance gain;
BRCA	cis	rs2806561	1.000	rs1208932	chr1:23429122	T/G	cg19743168	chr1:23544995	NA	-0.41	-9.91	-0.37	1.21e-21	Height;
BRCA	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg02196655	chr2:10830764	NOL10	-0.31	-8.27	-0.31	8.07e-16	Prostate cancer;
BRCA	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg27478167	chr7:817139	HEATR2	-0.55	-11.3	-0.41	3.89e-27	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg26769984	chr7:1090371	C7orf50	0.65	11.47	0.41	8.13e-28	Bronchopulmonary dysplasia;
BRCA	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg08213375	chr14:104286397	PPP1R13B	0.63	17.6	0.57	7.78e-57	Schizophrenia;
BRCA	cis	rs17092148	1.000	rs1884432	chr20:33342439	A/G	cg16810054	chr20:33298113	TP53INP2	-0.51	-11.45	-0.41	9.76e-28	Neuroticism;
BRCA	trans	rs208520	0.874	rs208491	chr6:66928459	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.36	-0.54	1.72e-50	Exhaled nitric oxide output;
BRCA	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg15448220	chr1:150897856	SETDB1	-0.34	-8.01	-0.3	5.42e-15	Melanoma;
BRCA	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg06935464	chr4:38784597	TLR10	0.51	8.2	0.31	1.31e-15	Breast cancer;
BRCA	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02018176	chr4:1364513	KIAA1530	0.4	8.17	0.31	1.67e-15	Longevity;
BRCA	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg20203395	chr5:56204925	C5orf35	-0.52	-10.57	-0.39	3.58e-24	Initial pursuit acceleration;
BRCA	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg06917634	chr15:78832804	PSMA4	-0.55	-11.98	-0.43	5.61e-30	Sudden cardiac arrest;
BRCA	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.71	-0.42	7.78e-29	Alcohol dependence;
BRCA	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.57	13.7	0.48	1.23e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.42	0.38	1.42e-23	Mean corpuscular volume;
BRCA	cis	rs3771570	1.000	rs17386695	chr2:242379751	A/G	cg21155796	chr2:242212141	HDLBP	-0.61	-9.65	-0.36	1.18e-20	Prostate cancer;
BRCA	cis	rs6446731	0.517	rs2157093	chr4:3270913	C/G	cg08886695	chr4:3369023	RGS12	0.38	10.0	0.37	5.47e-22	Mean platelet volume;
BRCA	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg24812749	chr6:127587940	RNF146	0.88	20.78	0.63	1.21e-73	Breast cancer;
BRCA	cis	rs6901250	0.655	rs1398404	chr6:117126345	A/C	cg12892004	chr6:117198278	RFX6	0.38	9.21	0.34	4.57e-19	C-reactive protein levels;
BRCA	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg20203395	chr5:56204925	C5orf35	0.4	8.91	0.33	5.1e-18	Initial pursuit acceleration;
BRCA	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.5	7.89	0.3	1.35e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg05754148	chr16:3507555	NAT15	0.39	8.15	0.31	1.86e-15	Tuberculosis;
BRCA	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.29	0.31	6.59e-16	Aortic root size;
BRCA	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	11.39	0.41	1.76e-27	Height;
BRCA	trans	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg07211511	chr3:129823064	LOC729375	-0.62	-10.82	-0.39	3.47e-25	Blood pressure (smoking interaction);
BRCA	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg08470875	chr2:26401718	FAM59B	-0.51	-8.11	-0.31	2.61e-15	Gut microbiome composition (summer);
BRCA	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg22875332	chr1:76189707	ACADM	0.8	19.35	0.61	5.36e-66	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1468333	1.000	rs2906127	chr5:137539466	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.43	8.56	0.32	8.09e-17	Resting heart rate;
BRCA	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg12564285	chr5:131593104	PDLIM4	0.37	9.87	0.36	1.77e-21	Breast cancer;
BRCA	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg12386194	chr3:101231763	SENP7	0.39	8.45	0.32	1.98e-16	Colorectal cancer;
BRCA	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg16558253	chr16:72132732	DHX38	-0.5	-10.83	-0.39	3.24e-25	Blood protein levels;
BRCA	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-9.51	-0.35	3.69e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg08601574	chr20:25228251	PYGB	-0.34	-8.25	-0.31	9.18e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.91	18.16	0.58	9.24e-60	Body mass index;
BRCA	cis	rs7178424	0.934	rs4143843	chr15:62373121	C/T	cg00456672	chr15:62358751	C2CD4A	-0.36	-8.26	-0.31	8.6e-16	Height;
BRCA	cis	rs7975161	0.630	rs4964260	chr12:104634270	A/G	cg25273343	chr12:104657179	TXNRD1	-0.61	-9.53	-0.35	3.31e-20	Toenail selenium levels;
BRCA	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg26597838	chr10:835615	NA	1.02	18.05	0.58	3.47e-59	Eosinophil percentage of granulocytes;
BRCA	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg05340658	chr4:99064831	C4orf37	0.59	12.05	0.43	2.85e-30	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg25042112	chr7:64838748	ZNF92	0.46	8.51	0.32	1.27e-16	Pain;
BRCA	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg23358479	chr7:1110784	C7orf50	-0.49	-8.2	-0.31	1.27e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26314531	chr2:26401878	FAM59B	0.92	13.82	0.48	3.35e-38	Gut microbiome composition (summer);
BRCA	trans	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg04565464	chr8:145669602	NFKBIL2	0.44	10.39	0.38	1.79e-23	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg05340658	chr4:99064831	C4orf37	-0.69	-17.38	-0.57	1.07e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg08859206	chr1:53392774	SCP2	0.43	8.57	0.32	8.01e-17	Monocyte count;
BRCA	cis	rs2014572	0.967	rs4801452	chr19:57768066	A/G	cg24459738	chr19:57751996	ZNF805	-0.36	-8.4	-0.32	2.85e-16	Hyperactive-impulsive symptoms;
BRCA	trans	rs783540	0.967	rs4779044	chr15:83339353	A/C	cg18393722	chr15:85113863	UBE2QP1	0.26	8.03	0.3	4.65e-15	Schizophrenia;
BRCA	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg13902645	chr11:5959945	NA	-0.49	-10.45	-0.38	1.08e-23	DNA methylation (variation);
BRCA	cis	rs12618769	0.652	rs2230388	chr2:99193496	C/T	cg10123293	chr2:99228465	UNC50	0.43	8.56	0.32	8.35e-17	Bipolar disorder;
BRCA	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg12379764	chr21:47803548	PCNT	-0.37	-7.83	-0.3	2.1e-14	Testicular germ cell tumor;
BRCA	trans	rs75804782	0.521	rs1123472	chr2:239414355	C/T	cg01134436	chr17:81009848	B3GNTL1	-0.68	-9.04	-0.34	1.92e-18	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg19336497	chr11:14380999	RRAS2	-0.48	-11.98	-0.43	5.81e-30	Sense of smell;
BRCA	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg11845111	chr2:191398756	TMEM194B	-0.69	-13.57	-0.47	4.89e-37	Diastolic blood pressure;
BRCA	cis	rs17092148	0.790	rs6087602	chr20:33170689	G/A	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.74	-0.39	7.59e-25	Neuroticism;
BRCA	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg22834771	chr12:69754056	YEATS4	-0.34	-8.33	-0.31	5.11e-16	Blood protein levels;
BRCA	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg06085985	chr11:830527	EFCAB4A	-0.41	-8.94	-0.33	4.15e-18	Mean platelet volume;
BRCA	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg00666640	chr1:248458726	OR2T12	0.3	8.45	0.32	2e-16	Common traits (Other);
BRCA	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.52	8.41	0.32	2.67e-16	Gut microbiome composition (summer);
BRCA	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg06917634	chr15:78832804	PSMA4	-0.57	-11.66	-0.42	1.23e-28	Sudden cardiac arrest;
BRCA	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg03711944	chr11:47377212	SPI1	0.4	9.77	0.36	4.21e-21	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs2014572	0.967	rs8111977	chr19:57759158	T/A	cg24459738	chr19:57751996	ZNF805	-0.36	-8.53	-0.32	1.03e-16	Hyperactive-impulsive symptoms;
BRCA	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg26384229	chr12:38710491	ALG10B	0.74	17.03	0.56	6.82e-54	Bladder cancer;
BRCA	cis	rs6545883	0.894	rs6545867	chr2:61651027	C/T	cg15711740	chr2:61764176	XPO1	0.54	13.6	0.47	3.52e-37	Tuberculosis;
BRCA	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg26384229	chr12:38710491	ALG10B	0.76	16.91	0.56	2.6e-53	Bladder cancer;
BRCA	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg22681709	chr2:178499509	PDE11A	-0.41	-8.91	-0.33	5.31e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs17741873	0.779	rs58125091	chr10:75605420	A/T	cg07699608	chr10:75541558	CHCHD1	0.49	7.91	0.3	1.11e-14	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs870825	0.616	rs28649620	chr4:185648997	G/A	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.88	-16.07	-0.54	4.79e-49	Body mass index;
BRCA	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg02574844	chr11:5959923	NA	0.5	11.0	0.4	7.03e-26	DNA methylation (variation);
BRCA	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs2840044	1.000	rs11080357	chr17:33898933	G/A	cg19694781	chr19:47549865	TMEM160	0.46	10.92	0.4	1.37e-25	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs12431939	0.947	rs56026555	chr14:51649066	G/T	cg23942311	chr14:51606299	NA	-0.44	-8.17	-0.31	1.67e-15	Cancer;
BRCA	cis	rs6138458	1.000	rs6138458	chr20:24973769	C/T	cg26195577	chr20:24973756	C20orf3	1.04	29.29	0.76	3.11e-120	Blood protein levels;
BRCA	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08280861	chr8:58055591	NA	0.6	9.42	0.35	7.86e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.21	-0.34	4.63e-19	Bipolar disorder;
BRCA	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg27129171	chr3:47204927	SETD2	-0.71	-16.97	-0.56	1.35e-53	Colorectal cancer;
BRCA	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.91	13.65	0.48	2.03e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg04450456	chr4:17643702	FAM184B	0.33	9.64	0.36	1.27e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs4596713	0.508	rs4745656	chr9:71782556	A/G	cg16512924	chr15:28394682	HERC2	0.46	10.95	0.4	1.07e-25	Headache;
BRCA	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.47	9.53	0.35	3.29e-20	Height;
BRCA	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg19683494	chr5:74908142	NA	-0.66	-10.2	-0.37	9.64e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg08917208	chr2:24149416	ATAD2B	1.12	16.1	0.54	3.21e-49	Lymphocyte counts;
BRCA	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.77	-0.36	4.2e-21	IgG glycosylation;
BRCA	trans	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg25214090	chr10:38739885	LOC399744	0.53	12.31	0.44	2.2e-31	Corneal astigmatism;
BRCA	cis	rs12541635	0.677	rs62527405	chr8:107058109	G/C	cg10147462	chr8:107024639	NA	0.39	10.31	0.38	3.63e-23	Age of smoking initiation;
BRCA	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg02297831	chr4:17616191	MED28	0.36	8.31	0.31	5.8e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg08470875	chr2:26401718	FAM59B	0.56	8.81	0.33	1.15e-17	Gut microbiome composition (summer);
BRCA	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg26446133	chr18:72167187	CNDP2	-0.73	-12.72	-0.45	3.22e-33	Refractive error;
BRCA	trans	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg07211511	chr3:129823064	LOC729375	-0.62	-10.94	-0.4	1.23e-25	Blood pressure (smoking interaction);
BRCA	cis	rs6570726	0.516	rs10484700	chr6:145728933	C/T	cg23711669	chr6:146136114	FBXO30	0.5	10.4	0.38	1.66e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs644148	1.000	rs644148	chr19:44970935	T/G	cg15540054	chr19:45004280	ZNF180	-0.58	-12.16	-0.43	9.82e-31	Personality dimensions;
BRCA	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg15242686	chr22:24348715	GSTTP1	-0.43	-10.63	-0.39	2.06e-24	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg09719594	chr16:21412588	NA	-0.34	-8.18	-0.31	1.51e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs17601876	0.520	rs28757201	chr15:51503897	G/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-9.02	-0.34	2.12e-18	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs10463316	0.894	rs10476769	chr5:150763970	A/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.4	-0.32	2.96e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg20701182	chr2:24300061	SF3B14	0.6	9.39	0.35	1.02e-19	Lymphocyte counts;
BRCA	cis	rs72928364	0.929	rs62275826	chr3:100762644	G/A	cg10123952	chr3:100791384	NA	0.59	8.6	0.32	6.1e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.62	0.32	5.33e-17	Rheumatoid arthritis;
BRCA	cis	rs13095912	0.889	rs35917986	chr3:185310041	G/A	cg11274856	chr3:185301563	NA	0.34	8.53	0.32	1.1e-16	Systolic blood pressure;
BRCA	cis	rs2637266	0.935	rs2583050	chr10:78403615	C/T	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	11.07	0.4	3.39e-26	Rheumatoid arthritis;
BRCA	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-12.19	-0.43	7.39e-31	Tonsillectomy;
BRCA	cis	rs507080	0.885	rs7926959	chr11:118559866	T/C	cg09144398	chr11:118550485	TREH	-0.38	-8.96	-0.33	3.57e-18	Serum metabolite levels;
BRCA	cis	rs2777491	1.000	rs11631770	chr15:41737059	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.67	-16.15	-0.54	1.95e-49	Ulcerative colitis;
BRCA	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.57	0.32	7.83e-17	Cognitive ability;
BRCA	cis	rs12612619	0.579	rs6756245	chr2:27083489	C/T	cg08802533	chr2:27073253	DPYSL5	0.29	7.91	0.3	1.14e-14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg10011062	chr15:43941034	CATSPER2	-0.54	-7.93	-0.3	9.54e-15	Lung cancer in ever smokers;
BRCA	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg05234568	chr11:5960015	NA	-0.48	-9.59	-0.35	1.97e-20	DNA methylation (variation);
BRCA	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-11.39	-0.41	1.74e-27	Morning vs. evening chronotype;
BRCA	trans	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04565464	chr8:145669602	NFKBIL2	0.37	8.72	0.33	2.49e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg14784868	chr12:69753453	YEATS4	0.53	13.35	0.47	5.08e-36	Blood protein levels;
BRCA	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg19336497	chr11:14380999	RRAS2	0.45	11.25	0.41	6.24e-27	Sense of smell;
BRCA	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02176678	chr2:219576539	TTLL4	-0.51	-12.86	-0.45	7.96e-34	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.58	13.56	0.47	5.14e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs877282	0.838	rs11253373	chr10:774857	A/G	cg22713356	chr15:30763199	NA	1.36	26.59	0.72	1.81e-105	Uric acid levels;
BRCA	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-8.51	-0.32	1.21e-16	Bladder cancer;
BRCA	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg21143896	chr7:2802374	GNA12	-0.34	-8.55	-0.32	9.15e-17	Height;
BRCA	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg13010199	chr12:38710504	ALG10B	0.55	11.99	0.43	5.04e-30	Heart rate;
BRCA	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02176678	chr2:219576539	TTLL4	0.46	12.19	0.43	6.78e-31	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1577917	0.958	rs7739241	chr6:86575796	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.29	-0.41	4.61e-27	Response to antipsychotic treatment;
BRCA	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-14.94	-0.51	1.71e-43	Parkinson's disease;
BRCA	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg19622623	chr12:86230825	RASSF9	-0.33	-9.32	-0.35	1.83e-19	Major depressive disorder;
BRCA	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	11.65	0.42	1.35e-28	Personality dimensions;
BRCA	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg03585969	chr10:35415529	CREM	-0.55	-11.38	-0.41	1.84e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg26031613	chr14:104095156	KLC1	-0.42	-8.45	-0.32	1.94e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg00495681	chr13:53174319	NA	-0.38	-8.12	-0.31	2.49e-15	Lewy body disease;
BRCA	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.5	0.38	6.5e-24	Tonsillectomy;
BRCA	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24549020	chr5:56110836	MAP3K1	0.55	10.98	0.4	7.84e-26	Initial pursuit acceleration;
BRCA	cis	rs11585357	1.000	rs11203346	chr1:17600822	A/G	cg08277548	chr1:17600880	PADI3	-0.74	-12.93	-0.46	3.83e-34	Hair shape;
BRCA	cis	rs7635838	0.718	rs2594981	chr3:11380638	C/G	cg00170343	chr3:11313890	ATG7	0.42	8.65	0.32	4.15e-17	HDL cholesterol;
BRCA	cis	rs700651	0.685	rs976180	chr2:198880443	C/T	cg00792783	chr2:198669748	PLCL1	-0.4	-8.95	-0.33	3.73e-18	Intracranial aneurysm;
BRCA	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg03433033	chr1:76189801	ACADM	0.76	17.55	0.57	1.4e-56	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.79	-0.42	3.6e-29	Bipolar disorder;
BRCA	cis	rs17253792	0.822	rs112374071	chr14:56061919	C/T	cg01858014	chr14:56050164	KTN1	-0.74	-10.1	-0.37	2.31e-22	Putamen volume;
BRCA	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg13119609	chr19:45449297	APOC2	0.48	13.29	0.47	9.51e-36	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg06521331	chr12:34319734	NA	-0.48	-9.28	-0.34	2.57e-19	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs9409565	0.826	rs9409564	chr9:97248166	C/T	cg05679027	chr9:99775184	HIATL2	-0.42	-9.23	-0.34	3.78e-19	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	12.18	0.43	7.6e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06028605	chr16:24865363	SLC5A11	-0.46	-10.29	-0.38	4.27e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg15395560	chr15:45543142	SLC28A2	-0.32	-8.64	-0.32	4.65e-17	Uric acid levels;
BRCA	cis	rs7555523	0.887	rs4657476	chr1:165732661	A/G	cg24409356	chr1:165738333	TMCO1	-0.51	-8.58	-0.32	7.08e-17	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	10.88	0.4	2.14e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg12311346	chr5:56204834	C5orf35	0.9	16.95	0.56	1.67e-53	Initial pursuit acceleration;
BRCA	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-11.31	-0.41	3.73e-27	Gut microbiome composition (summer);
BRCA	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg27446573	chr6:127587934	RNF146	0.89	20.42	0.63	1e-71	Breast cancer;
BRCA	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	16.99	0.56	1.1e-53	Platelet count;
BRCA	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	19.61	0.61	2.16e-67	Electrocardiographic conduction measures;
BRCA	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.46	0.38	9.18e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg06521331	chr12:34319734	NA	-0.48	-8.85	-0.33	8.59e-18	Bladder cancer;
BRCA	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg00012203	chr2:219082015	ARPC2	0.48	9.22	0.34	4.08e-19	Colorectal cancer;
BRCA	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg04362960	chr10:104952993	NT5C2	0.43	10.44	0.38	1.2e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg04990556	chr1:26633338	UBXN11	0.54	8.86	0.33	8.17e-18	Obesity-related traits;
BRCA	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg13877915	chr19:58951672	ZNF132	0.47	11.09	0.4	2.96e-26	Uric acid clearance;
BRCA	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg08999081	chr20:33150536	PIGU	0.45	12.1	0.43	1.76e-30	Glomerular filtration rate (creatinine);
BRCA	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.36	-8.38	-0.31	3.41e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg03709012	chr19:19516395	GATAD2A	0.74	16.06	0.54	5.26e-49	Tonsillectomy;
BRCA	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg24006582	chr15:45444508	DUOX1	-0.56	-11.54	-0.42	4.12e-28	Uric acid levels;
BRCA	trans	rs78049276	0.512	rs6855875	chr4:148402737	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.51	-10.53	-0.38	4.95e-24	Pulse pressure;
BRCA	cis	rs1710278	0.935	rs1278270	chr10:127747785	G/A	cg22975853	chr10:127789788	ADAM12	0.31	7.96	0.3	8.07e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
BRCA	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg08917208	chr2:24149416	ATAD2B	0.58	9.13	0.34	8.87e-19	Lymphocyte counts;
BRCA	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg10523679	chr1:76189770	ACADM	0.69	11.95	0.43	7.32e-30	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg07636037	chr3:49044803	WDR6	0.97	28.46	0.75	1.02e-115	Parkinson's disease;
BRCA	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.32	-0.38	3.3e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4589502	0.614	rs17273637	chr15:67193084	C/T	cg09911534	chr15:67153556	NA	-0.69	-8.23	-0.31	1.05e-15	Lung cancer (smoking interaction);
BRCA	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-9.56	-0.35	2.59e-20	Blood metabolite levels;
BRCA	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg17971929	chr21:40555470	PSMG1	0.76	16.57	0.55	1.43e-51	Cognitive function;
BRCA	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg06484146	chr7:12443880	VWDE	-0.6	-8.66	-0.32	3.91e-17	Coronary artery disease;
BRCA	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.01	0.4	6.14e-26	Electroencephalogram traits;
BRCA	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-13.49	-0.47	1.16e-36	Chronic sinus infection;
BRCA	trans	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	27.75	0.74	7.88e-112	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg19920283	chr7:105172520	RINT1	0.65	12.93	0.46	3.95e-34	Bipolar disorder (body mass index interaction);
BRCA	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg13010199	chr12:38710504	ALG10B	0.42	10.06	0.37	3.25e-22	Heart rate;
BRCA	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg03474202	chr17:45855739	NA	-0.45	-12.42	-0.44	7.08e-32	IgG glycosylation;
BRCA	cis	rs867371	0.929	rs7176075	chr15:82471339	C/G	cg00614314	chr15:82944287	LOC80154	0.44	9.3	0.35	2.27e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.95	0.37	8.91e-22	Bladder cancer;
BRCA	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.42	-8.31	-0.31	5.69e-16	Monocyte percentage of white cells;
BRCA	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.32	8.08	0.3	3.24e-15	IgG glycosylation;
BRCA	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11890956	chr21:40555474	PSMG1	1.05	29.72	0.76	1.54e-122	Cognitive function;
BRCA	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg23992470	chr4:843637	GAK	0.56	8.25	0.31	9e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	0.611	rs74661620	chr2:24365260	C/A	cg06627628	chr2:24431161	ITSN2	-0.53	-8.35	-0.31	4.24e-16	Lymphocyte counts;
BRCA	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-14.14	-0.49	1.05e-39	Hemoglobin concentration;
BRCA	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg24130564	chr14:104152367	KLC1	-0.34	-7.89	-0.3	1.33e-14	Body mass index;
BRCA	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg27661571	chr11:113659931	NA	-0.72	-11.08	-0.4	3.21e-26	Hip circumference adjusted for BMI;
BRCA	cis	rs11679564	0.714	rs10490657	chr2:37178255	C/T	cg14987922	chr2:37194071	STRN	0.4	8.42	0.32	2.45e-16	Immature fraction of reticulocytes;
BRCA	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.87	-0.36	1.72e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg11764359	chr7:65958608	NA	0.62	13.31	0.47	7.5e-36	Aortic root size;
BRCA	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg14675211	chr2:100938903	LONRF2	0.38	8.34	0.31	4.63e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.8	-0.33	1.28e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg14019146	chr3:50243930	SLC38A3	0.42	10.09	0.37	2.48e-22	Body mass index;
BRCA	cis	rs6733011	0.578	rs1878585	chr2:99501698	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.36	-8.5	-0.32	1.31e-16	Bipolar disorder;
BRCA	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg05347473	chr6:146136440	FBXO30	0.43	8.48	0.32	1.56e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg02733842	chr7:1102375	C7orf50	-0.71	-12.99	-0.46	2.07e-34	Bronchopulmonary dysplasia;
BRCA	trans	rs61931739	0.513	rs10844698	chr12:33890158	C/T	cg26384229	chr12:38710491	ALG10B	0.41	9.44	0.35	6.6e-20	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg25214090	chr10:38739885	LOC399744	0.55	12.2	0.43	6.37e-31	Corneal astigmatism;
BRCA	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	11.58	0.42	2.78e-28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs7677751	0.806	rs7698425	chr4:55090656	C/T	cg17187183	chr4:55093834	PDGFRA	0.44	9.17	0.34	6.18e-19	Corneal astigmatism;
BRCA	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	18.52	0.59	1.25e-61	Alzheimer's disease;
BRCA	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg07211511	chr3:129823064	LOC729375	-0.58	-10.71	-0.39	1.02e-24	Blood pressure (smoking interaction);
BRCA	cis	rs3767633	0.858	rs2341468	chr1:161862312	G/A	cg09175582	chr1:161736000	ATF6	0.53	8.71	0.33	2.49e-17	IgG glycosylation;
BRCA	trans	rs12517041	1.000	rs995216	chr5:23285541	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.32	-0.31	5.27e-16	Calcium levels;
BRCA	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs9837602	0.938	rs9823908	chr3:99795507	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.24	0.41	7.33e-27	Breast cancer;
BRCA	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg01028140	chr2:1542097	TPO	-0.61	-11.85	-0.42	2.04e-29	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7809950	1.000	rs2253146	chr7:107200319	A/G	cg23024343	chr7:107201750	COG5	-0.39	-8.94	-0.33	4.32e-18	Coronary artery disease;
BRCA	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg07741184	chr6:167504864	NA	-0.29	-8.47	-0.32	1.7e-16	Crohn's disease;
BRCA	cis	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg05901451	chr6:126070800	HEY2	0.4	9.7	0.36	7.76e-21	Endometrial cancer;
BRCA	cis	rs909002	0.886	rs11807225	chr1:32083193	G/C	cg13919466	chr1:32135498	COL16A1	-0.27	-9.1	-0.34	1.16e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.01	-0.34	2.42e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2559856	1.000	rs10745921	chr12:102087193	A/G	cg12924262	chr12:102091054	CHPT1	0.38	8.56	0.32	8.5e-17	Blood protein levels;
BRCA	cis	rs2797160	1.000	rs1739378	chr6:126012262	C/A	cg05901451	chr6:126070800	HEY2	0.39	9.58	0.35	2.2e-20	Endometrial cancer;
BRCA	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg26343298	chr8:95960752	TP53INP1	0.29	8.41	0.32	2.78e-16	Type 2 diabetes;
BRCA	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08109568	chr15:31115862	NA	-0.54	-13.02	-0.46	1.59e-34	Huntington's disease progression;
BRCA	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg15557168	chr22:42548783	NA	-0.31	-8.58	-0.32	7.07e-17	Schizophrenia;
BRCA	trans	rs6076960	0.681	rs4487157	chr20:6249581	G/A	cg17788362	chr6:86352627	SYNCRIP	0.4	7.85	0.3	1.82e-14	Smooth-surface caries;
BRCA	trans	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg23762105	chr12:34175262	ALG10	-0.41	-10.14	-0.37	1.7e-22	Morning vs. evening chronotype;
BRCA	cis	rs6580649	0.943	rs3803183	chr12:48398080	T/A	cg05342945	chr12:48394962	COL2A1	-0.47	-9.55	-0.35	2.64e-20	Lung cancer;
BRCA	cis	rs778371	0.723	rs1973675	chr2:233636450	C/T	cg08000102	chr2:233561755	GIGYF2	-0.85	-21.32	-0.64	1.37e-76	Schizophrenia;
BRCA	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.93	-0.33	4.63e-18	Alzheimer's disease (late onset);
BRCA	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg09184832	chr6:79620586	NA	0.51	10.83	0.39	3.33e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg04362960	chr10:104952993	NT5C2	0.42	10.18	0.37	1.22e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg24578937	chr1:2090814	PRKCZ	0.58	17.92	0.58	1.69e-58	Height;
BRCA	cis	rs10465746	0.780	rs10874423	chr1:84374071	C/T	cg10977910	chr1:84465055	TTLL7	0.55	11.46	0.41	8.86e-28	Obesity-related traits;
BRCA	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.06	0.34	1.53e-18	Platelet count;
BRCA	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.22e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg14349672	chr11:133703707	NA	-0.41	-9.12	-0.34	9.54e-19	Childhood ear infection;
BRCA	cis	rs708547	0.874	rs781551	chr4:57718406	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.47	-10.42	-0.38	1.43e-23	Response to bleomycin (chromatid breaks);
BRCA	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg14784868	chr12:69753453	YEATS4	0.78	24.97	0.7	1.46e-96	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs926392	0.547	rs6129161	chr20:37678327	T/G	cg16355469	chr20:37678765	NA	0.51	11.58	0.42	2.72e-28	Dialysis-related mortality;
BRCA	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg09455208	chr3:40491958	NA	-0.43	-10.77	-0.39	5.69e-25	Renal cell carcinoma;
BRCA	cis	rs9649465	0.935	rs1605285	chr7:123374412	A/G	cg04330084	chr7:123175371	IQUB	-0.31	-8.39	-0.31	3.23e-16	Migraine;
BRCA	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.07	23.75	0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs495337	0.735	rs636987	chr20:48524288	A/C	cg17835207	chr20:48524531	SPATA2	-0.68	-16.8	-0.55	9.77e-53	Psoriasis;
BRCA	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	22.34	0.66	4e-82	Platelet count;
BRCA	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	12.56	0.44	1.71e-32	Bone mineral density;
BRCA	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg05535760	chr7:792225	HEATR2	0.83	14.24	0.49	3.57e-40	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	14.7	0.5	2.41e-42	Motion sickness;
BRCA	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg21475434	chr5:93447410	FAM172A	0.65	9.0	0.34	2.59e-18	Diabetic retinopathy;
BRCA	cis	rs73198271	0.562	rs79296712	chr8:8659978	G/A	cg01851573	chr8:8652454	MFHAS1	0.49	7.94	0.3	8.88e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.54	-0.77	5.19e-127	Schizophrenia;
BRCA	trans	rs7241530	0.623	rs6506772	chr18:75918499	T/C	cg25697769	chr22:39097335	JOSD1	0.38	8.26	0.31	8.47e-16	Educational attainment (years of education);
BRCA	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-8.71	-0.33	2.63e-17	Bladder cancer;
BRCA	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg19077165	chr18:44547161	KATNAL2	-0.59	-13.49	-0.47	1.11e-36	Personality dimensions;
BRCA	cis	rs9837602	1.000	rs7616988	chr3:99701134	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.55	-10.68	-0.39	1.29e-24	Breast cancer;
BRCA	cis	rs6088813	1.000	rs6142379	chr20:33999267	A/G	cg14752227	chr20:34000481	UQCC	-0.43	-9.15	-0.34	7.31e-19	Height;
BRCA	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg20203395	chr5:56204925	C5orf35	0.52	10.69	0.39	1.14e-24	Initial pursuit acceleration;
BRCA	cis	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.14	-0.4	1.81e-26	Morning vs. evening chronotype;
BRCA	cis	rs460214	0.539	rs28718905	chr21:40032244	C/A	cg21578987	chr21:40029669	ERG	0.38	8.73	0.33	2.22e-17	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg01877450	chr7:97915802	BRI3	-0.37	-8.45	-0.32	2.02e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg21045802	chr8:109455806	TTC35	0.35	7.88	0.3	1.37e-14	Dupuytren's disease;
BRCA	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg26838691	chr2:24397539	C2orf84	-0.46	-8.49	-0.32	1.44e-16	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg15556689	chr8:8085844	FLJ10661	-0.37	-9.48	-0.35	4.7e-20	Joint mobility (Beighton score);
BRCA	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg10253484	chr15:75165896	SCAMP2	-0.51	-9.61	-0.36	1.68e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg14926445	chr8:58193284	C8orf71	-0.44	-8.41	-0.32	2.72e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg05347473	chr6:146136440	FBXO30	0.41	8.07	0.3	3.41e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg05868516	chr6:26286170	HIST1H4H	0.5	11.25	0.41	6.6e-27	Educational attainment;
BRCA	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg03354898	chr7:1950403	MAD1L1	-0.4	-8.34	-0.31	4.42e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg04553112	chr3:125709451	NA	-0.55	-8.27	-0.31	7.6e-16	Blood pressure (smoking interaction);
BRCA	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg25208724	chr1:156163844	SLC25A44	1.07	35.23	0.81	7.01e-152	Testicular germ cell tumor;
BRCA	cis	rs4363385	0.818	rs2787629	chr1:153011966	A/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.22	-0.34	4.12e-19	Inflammatory skin disease;
BRCA	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg19508488	chr2:152266495	RIF1	0.44	9.35	0.35	1.46e-19	Lung cancer;
BRCA	cis	rs6426558	0.502	rs2813970	chr1:227410637	C/T	cg10327440	chr1:227177885	CDC42BPA	0.45	8.73	0.33	2.14e-17	Neutrophil percentage of white cells;
BRCA	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.61	-0.39	2.39e-24	Personality dimensions;
BRCA	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05962382	chr2:130345044	NA	-0.34	-8.02	-0.3	5.05e-15	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg18230493	chr5:56204884	C5orf35	-0.72	-14.12	-0.49	1.36e-39	Initial pursuit acceleration;
BRCA	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg22676075	chr6:135203613	NA	0.44	8.67	0.32	3.67e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg21132104	chr15:45694354	SPATA5L1	0.7	15.25	0.52	5.07e-45	Homoarginine levels;
BRCA	cis	rs708547	0.874	rs1315006	chr4:57858193	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-8.8	-0.33	1.26e-17	Response to bleomycin (chromatid breaks);
BRCA	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg11502198	chr6:26597334	ABT1	0.52	10.06	0.37	3.5e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg26384229	chr12:38710491	ALG10B	0.69	16.16	0.54	1.62e-49	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg18357645	chr12:58087776	OS9	-0.34	-8.36	-0.31	4.07e-16	Multiple sclerosis;
BRCA	trans	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.52	0.38	5.4e-24	Mean corpuscular volume;
BRCA	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.81	13.51	0.47	8.98e-37	Schizophrenia;
BRCA	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg09307838	chr4:120376055	NA	0.76	17.1	0.56	2.9e-54	Corneal astigmatism;
BRCA	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg24642439	chr20:33292090	TP53INP2	0.53	11.6	0.42	2.23e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg04546413	chr19:29218101	NA	0.64	12.28	0.44	2.81e-31	Methadone dose in opioid dependence;
BRCA	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.32	0.31	5.43e-16	Axial length;
BRCA	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg15556689	chr8:8085844	FLJ10661	-0.38	-9.81	-0.36	3.08e-21	Triglycerides;
BRCA	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg06784218	chr1:46089804	CCDC17	0.5	12.3	0.44	2.39e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg16049864	chr8:95962084	TP53INP1	-0.49	-12.03	-0.43	3.51e-30	Type 2 diabetes;
BRCA	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg20283391	chr11:68216788	NA	-0.45	-8.92	-0.33	4.96e-18	Total body bone mineral density;
BRCA	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21545522	chr1:205238299	TMCC2	0.38	8.41	0.32	2.68e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg05340658	chr4:99064831	C4orf37	0.49	10.75	0.39	7.12e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg23018236	chr17:30244563	NA	-0.63	-10.19	-0.37	1.06e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs9341808	0.628	rs2490245	chr6:80892427	A/G	cg08355045	chr6:80787529	NA	0.33	8.1	0.31	2.8e-15	Sitting height ratio;
BRCA	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18876405	chr7:65276391	NA	-0.51	-11.49	-0.41	6.61e-28	Aortic root size;
BRCA	cis	rs7927771	0.542	rs6485775	chr11:47773518	A/G	cg20307385	chr11:47447363	PSMC3	-0.39	-9.12	-0.34	9.9e-19	Subjective well-being;
BRCA	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.96	0.3	7.63e-15	Depression;
BRCA	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg17366294	chr4:99064904	C4orf37	0.45	10.78	0.39	5.29e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg18402987	chr7:1209562	NA	0.43	8.13	0.31	2.2e-15	Longevity;Endometriosis;
BRCA	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg24558204	chr6:135376177	HBS1L	0.56	15.27	0.52	4.2e-45	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg15556689	chr8:8085844	FLJ10661	0.32	8.31	0.31	5.78e-16	Morning vs. evening chronotype;
BRCA	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg26384229	chr12:38710491	ALG10B	0.66	15.49	0.52	3.57e-46	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs939658	0.805	rs11630571	chr15:79432992	C/A	cg17916960	chr15:79447300	NA	-0.44	-10.78	-0.39	5.09e-25	Refractive error;
BRCA	cis	rs11955398	0.647	rs6449483	chr5:59995393	C/T	cg02684056	chr5:59996105	DEPDC1B	0.39	8.99	0.33	2.83e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-12.31	-0.44	2.1e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs13095912	1.000	rs17523471	chr3:185304018	T/C	cg11274856	chr3:185301563	NA	0.36	8.89	0.33	6.05e-18	Systolic blood pressure;
BRCA	cis	rs28830936	1.000	rs11632424	chr15:42095351	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.37	-10.06	-0.37	3.35e-22	Diastolic blood pressure;
BRCA	cis	rs4363385	0.818	rs4845335	chr1:152993955	G/A	cg25856811	chr1:152973957	SPRR3	-0.31	-8.1	-0.31	2.71e-15	Inflammatory skin disease;
BRCA	cis	rs12348691	0.503	rs894672	chr9:100612185	C/T	cg13688889	chr9:100608707	NA	-0.49	-9.9	-0.36	1.35e-21	Alopecia areata;
BRCA	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-12.45	-0.44	5.07e-32	Response to antipsychotic treatment;
BRCA	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg23933602	chr10:16859644	RSU1	0.56	8.75	0.33	1.83e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	14.44	0.5	4.01e-41	Personality dimensions;
BRCA	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.31	-0.31	5.73e-16	Retinal vascular caliber;
BRCA	cis	rs7395581	0.918	rs4752825	chr11:47352409	G/A	cg25783544	chr11:47291846	MADD	0.41	9.27	0.34	2.76e-19	HDL cholesterol;
BRCA	cis	rs4965272	0.830	rs990422	chr15:100559768	T/C	cg27344315	chr15:100560801	ADAMTS17	0.43	8.33	0.31	4.79e-16	Gastroesophageal reflux disease;
BRCA	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-16.33	-0.54	2.24e-50	Heart rate;
BRCA	cis	rs9810890	1.000	rs73196989	chr3:128454638	G/A	cg15033153	chr3:128514015	RAB7A	0.7	8.08	0.3	3.34e-15	Dental caries;
BRCA	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg25358565	chr5:93447407	FAM172A	1.2	19.89	0.62	7.04e-69	Diabetic retinopathy;
BRCA	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.95	0.4	1.12e-25	Rheumatoid arthritis;
BRCA	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.41	-8.28	-0.31	7.16e-16	Rheumatoid arthritis;
BRCA	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.8	11.85	0.42	2.07e-29	Platelet count;
BRCA	cis	rs61990749	0.597	rs10142722	chr14:78275549	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	9.55	0.35	2.66e-20	Fibroblast growth factor basic levels;
BRCA	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg00012203	chr2:219082015	ARPC2	0.47	9.08	0.34	1.38e-18	Ulcerative colitis;
BRCA	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg21770322	chr7:97807741	LMTK2	0.55	15.72	0.53	2.69e-47	Breast cancer;
BRCA	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg19901468	chr14:105411992	AHNAK2	-0.51	-12.43	-0.44	6.12e-32	Rheumatoid arthritis;
BRCA	cis	rs7631605	0.905	rs4647269	chr3:37057591	C/T	cg15934958	chr3:37212084	LRRFIP2	0.47	10.76	0.39	6.54e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg02544614	chr20:61657117	NA	0.29	8.15	0.31	1.9e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg14349672	chr11:133703707	NA	-0.41	-9.15	-0.34	7.43e-19	Childhood ear infection;
BRCA	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg16099169	chr2:106886729	NA	-0.59	-10.7	-0.39	1.12e-24	Facial morphology (factor 23);
BRCA	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg24692254	chr21:30365293	RNF160	0.79	21.45	0.65	2.71e-77	Dental caries;
BRCA	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs30380	1.000	rs30380	chr5:96122281	A/C	cg16492584	chr5:96139282	ERAP1	-0.31	-7.95	-0.3	8.49e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg20891283	chr12:69753455	YEATS4	0.73	21.96	0.66	4.86e-80	Blood protein levels;
BRCA	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.56	-0.32	8.25e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	15.42	0.52	8.02e-46	Platelet count;
BRCA	trans	rs78049276	0.651	rs59415853	chr4:148378225	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.45	-8.35	-0.31	4.21e-16	Pulse pressure;
BRCA	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg27170947	chr2:26402098	FAM59B	-0.92	-16.52	-0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs6882046	0.513	rs187270	chr5:88026870	C/T	cg22951263	chr5:87985283	NA	-0.38	-10.68	-0.39	1.27e-24	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.85	0.36	2.07e-21	Bipolar disorder;
BRCA	cis	rs9381107	0.932	rs2223603	chr6:9487956	C/T	cg14735645	chr6:9486422	NA	0.45	8.12	0.31	2.36e-15	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs3845702	0.736	rs6733426	chr2:180830958	A/G	cg01881094	chr2:180872142	CWC22	-1.0	-18.07	-0.58	2.91e-59	Schizophrenia;
BRCA	trans	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.93	0.3	1.01e-14	Corneal astigmatism;
BRCA	trans	rs7395662	0.929	rs10838982	chr11:48640168	C/T	cg00717180	chr2:96193071	NA	-0.32	-8.69	-0.33	3.07e-17	HDL cholesterol;
BRCA	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg21770322	chr7:97807741	LMTK2	0.42	11.28	0.41	4.79e-27	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	16.05	0.54	5.96e-49	Intelligence (multi-trait analysis);
BRCA	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg18016565	chr1:150552671	MCL1	0.34	8.05	0.3	4.08e-15	Tonsillectomy;
BRCA	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg06115741	chr20:33292138	TP53INP2	-0.37	-8.02	-0.3	5.14e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg14092571	chr14:90743983	NA	-0.34	-8.03	-0.3	4.54e-15	Mortality in heart failure;
BRCA	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg08213375	chr14:104286397	PPP1R13B	0.65	18.22	0.58	4.99e-60	Schizophrenia;
BRCA	cis	rs724568	0.546	rs724567	chr2:67942439	T/C	cg14046302	chr2:67939758	NA	-0.4	-10.22	-0.37	8.53e-23	Major depressive disorder (broad);
BRCA	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg19913688	chr11:428466	ANO9	-0.67	-9.76	-0.36	4.67e-21	Body mass index;
BRCA	cis	rs9341808	0.718	rs9448893	chr6:80837239	A/G	cg08355045	chr6:80787529	NA	0.37	9.33	0.35	1.74e-19	Sitting height ratio;
BRCA	cis	rs7092929	0.941	rs668923	chr10:3575664	G/T	cg14308648	chr10:3568949	NA	0.44	8.01	0.3	5.54e-15	Coronary artery calcification;
BRCA	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg06623918	chr6:96969491	KIAA0776	0.86	24.01	0.69	2.59e-91	Headache;
BRCA	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg03433033	chr1:76189801	ACADM	0.67	13.55	0.47	5.82e-37	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg12483005	chr1:23474871	LUZP1	0.44	9.81	0.36	2.88e-21	Height;
BRCA	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg26384229	chr12:38710491	ALG10B	0.77	17.85	0.58	4.14e-58	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1003719	0.591	rs2835618	chr21:38503126	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.57	-13.21	-0.46	2.12e-35	Eye color traits;
BRCA	cis	rs507080	0.922	rs514143	chr11:118558449	G/A	cg08498647	chr11:118550644	TREH	-0.37	-8.12	-0.31	2.48e-15	Serum metabolite levels;
BRCA	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg17366294	chr4:99064904	C4orf37	0.42	9.87	0.36	1.78e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.57	12.14	0.43	1.14e-30	Lymphocyte counts;
BRCA	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg15819921	chr19:927150	ARID3A	-0.52	-9.67	-0.36	1.01e-20	Life satisfaction;
BRCA	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg22467129	chr15:76604101	ETFA	-0.5	-10.9	-0.4	1.7e-25	Blood metabolite levels;
BRCA	cis	rs10754283	0.967	rs10801759	chr1:90113745	A/G	cg21401794	chr1:90099060	LRRC8C	0.46	11.06	0.4	4.04e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg08917208	chr2:24149416	ATAD2B	0.57	9.07	0.34	1.43e-18	Lymphocyte counts;
BRCA	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg13880726	chr7:1868755	MAD1L1	0.52	9.81	0.36	2.84e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs3809566	0.526	rs35829897	chr15:63334688	G/C	cg05507819	chr15:63340323	TPM1	-0.83	-15.26	-0.52	4.77e-45	Platelet count;
BRCA	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18876405	chr7:65276391	NA	0.48	10.83	0.39	3.43e-25	Aortic root size;
BRCA	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg22713356	chr15:30763199	NA	1.3	24.75	0.7	2.51e-95	Uric acid levels;
BRCA	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg08470875	chr2:26401718	FAM59B	0.71	11.35	0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg16386425	chr10:429943	DIP2C	-0.4	-8.4	-0.32	2.8e-16	Psychosis in Alzheimer's disease;
BRCA	cis	rs9875589	0.957	rs13077668	chr3:13929756	A/G	cg19554555	chr3:13937349	NA	-0.43	-9.13	-0.34	8.92e-19	Ovarian reserve;
BRCA	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.67	0.57	3.59e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg23018236	chr17:30244563	NA	-0.6	-9.9	-0.36	1.39e-21	Hip circumference adjusted for BMI;
BRCA	trans	rs747782	0.527	rs2270993	chr11:48145166	G/A	cg15704280	chr7:45808275	SEPT13	0.58	8.13	0.31	2.23e-15	Intraocular pressure;
BRCA	cis	rs7408868	1.000	rs7247835	chr19:15262844	A/G	cg14696996	chr19:15285081	NOTCH3	0.98	14.7	0.5	2.37e-42	Pulse pressure;
BRCA	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg17063962	chr7:91808500	NA	0.53	12.53	0.44	2.32e-32	Breast cancer;
BRCA	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.6	12.03	0.43	3.35e-30	Multiple sclerosis;
BRCA	cis	rs1451375	0.617	rs10271341	chr7:50591583	A/C	cg18232548	chr7:50535776	DDC	0.43	9.22	0.34	4.17e-19	Malaria;
BRCA	cis	rs1506636	1.000	rs2259457	chr7:123424350	A/G	cg03229431	chr7:123269106	ASB15	0.61	13.54	0.47	6.54e-37	Plateletcrit;Platelet count;
BRCA	trans	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs9682041	0.597	rs13076319	chr3:170104630	T/G	cg11886554	chr3:170076028	SKIL	0.48	9.83	0.36	2.46e-21	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg07395648	chr5:131743802	NA	-0.36	-7.99	-0.3	6.34e-15	Breast cancer;
BRCA	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg08807101	chr21:30365312	RNF160	-0.59	-14.68	-0.5	3.1e-42	Dental caries;
BRCA	cis	rs56399783	0.901	rs17241904	chr7:2875574	C/T	cg19731401	chr7:2775893	GNA12	0.54	8.25	0.31	9.25e-16	Childhood ear infection;
BRCA	cis	rs1784581	0.674	rs1789990	chr6:162406957	G/T	cg17173639	chr6:162384350	PARK2	-0.33	-7.82	-0.3	2.24e-14	Itch intensity from mosquito bite;
BRCA	cis	rs4880487	0.888	rs4880789	chr10:1254393	G/T	cg03183215	chr10:1252341	ADARB2	-0.38	-8.33	-0.31	4.9e-16	Migraine;
BRCA	cis	rs13136331	0.532	rs1462366	chr4:88570492	G/A	cg22416721	chr4:88570574	DMP1	-0.6	-14.99	-0.51	9.39e-44	Sitting height ratio;
BRCA	cis	rs6088813	1.000	rs6088821	chr20:33987576	G/A	cg14752227	chr20:34000481	UQCC	-0.43	-9.14	-0.34	8.09e-19	Height;
BRCA	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.39	8.29	0.31	6.67e-16	Multiple sclerosis;
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg22907277	chr7:1156413	C7orf50	0.52	11.51	0.41	5.37e-28	Longevity;Endometriosis;
BRCA	cis	rs1593	0.734	rs6815076	chr4:187224558	G/C	cg14349977	chr4:187219430	NA	0.57	10.37	0.38	2.1e-23	Activated partial thromboplastin time;
BRCA	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-12.41	-0.44	7.93e-32	Response to antipsychotic treatment;
BRCA	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06028605	chr16:24865363	SLC5A11	0.45	9.78	0.36	3.88e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.5	0.57	2.46e-56	Fuchs's corneal dystrophy;
BRCA	trans	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.84	-27.72	-0.74	1.21e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs965469	1.000	rs6051779	chr20:3333449	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-10.5	-0.38	6.58e-24	IFN-related cytopenia;
BRCA	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.48	-0.77	1.09e-126	Schizophrenia;
BRCA	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg03213289	chr20:61660250	NA	0.63	16.54	0.55	2.05e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6723226	0.881	rs10181198	chr2:32686582	A/G	cg02381751	chr2:32503542	YIPF4	0.64	13.76	0.48	6.15e-38	Intelligence (multi-trait analysis);
BRCA	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg14036092	chr11:66035641	RAB1B	0.39	10.23	0.38	7.55e-23	Gout;
BRCA	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.57	-13.6	-0.47	3.5e-37	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08219700	chr8:58056026	NA	0.44	7.91	0.3	1.12e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg21475434	chr5:93447410	FAM172A	0.65	8.28	0.31	6.96e-16	Diabetic retinopathy;
BRCA	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg13010199	chr12:38710504	ALG10B	-0.44	-9.5	-0.35	4.29e-20	Morning vs. evening chronotype;
BRCA	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg15145296	chr3:125709740	NA	-0.57	-9.39	-0.35	1.07e-19	Blood pressure (smoking interaction);
BRCA	trans	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04565464	chr8:145669602	NFKBIL2	-0.34	-8.41	-0.32	2.61e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-10.31	-0.38	3.65e-23	Reticulocyte count;
BRCA	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.56	0.42	3.32e-28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.22e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs3820928	0.845	rs13384342	chr2:227805010	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.68	-0.32	3.4e-17	Pulmonary function;
BRCA	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.47	10.98	0.4	8e-26	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.67	-0.32	3.58e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg00106254	chr7:1943704	MAD1L1	-0.32	-7.97	-0.3	7.18e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg07395648	chr5:131743802	NA	0.4	10.04	0.37	4.13e-22	Blood metabolite levels;
BRCA	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg11645453	chr3:52864694	ITIH4	0.48	11.63	0.42	1.73e-28	Schizophrenia;
BRCA	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg00383909	chr3:49044727	WDR6	-0.43	-8.17	-0.31	1.65e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.48	-0.35	4.76e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.73	-0.36	5.85e-21	Alcohol dependence;
BRCA	cis	rs11585357	1.000	rs11585357	chr1:17601165	C/T	cg19159961	chr1:17633534	PADI4	0.55	8.57	0.32	7.5e-17	Hair shape;
BRCA	cis	rs11945232	1.000	rs11945232	chr4:88342369	A/G	cg23841344	chr4:88312519	HSD17B11	-0.39	-8.2	-0.31	1.3e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg07988820	chr12:82153109	PPFIA2	-0.67	-10.76	-0.39	6.11e-25	Resting heart rate;
BRCA	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-23.05	-0.67	4.91e-86	Height;
BRCA	cis	rs2425143	1.000	rs7267759	chr20:34257284	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.82	-0.33	1.07e-17	Blood protein levels;
BRCA	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1371614	0.635	rs9309558	chr2:27141504	C/T	cg12368169	chr2:27073192	DPYSL5	-0.3	-8.85	-0.33	8.83e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg09537434	chr19:41945824	ATP5SL	-0.98	-23.22	-0.68	6.18e-87	Height;
BRCA	cis	rs944722	0.839	rs8073631	chr17:26104547	C/T	cg07704981	chr17:26127537	NOS2	-0.38	-8.01	-0.3	5.6e-15	Fractional exhaled nitric oxide (childhood);
BRCA	cis	rs12348691	0.503	rs7024345	chr9:100595238	A/G	cg13688889	chr9:100608707	NA	-0.48	-9.85	-0.36	2.06e-21	Alopecia areata;
BRCA	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg21395723	chr22:39101663	GTPBP1	0.39	8.39	0.31	3.17e-16	Menopause (age at onset);
BRCA	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-9.82	-0.36	2.68e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg11789530	chr4:8429930	ACOX3	0.59	14.57	0.5	9.58e-42	Response to antineoplastic agents;
BRCA	cis	rs9790314	0.645	rs9879687	chr3:160874938	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-13.75	-0.48	6.93e-38	Morning vs. evening chronotype;
BRCA	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg05623727	chr3:50126028	RBM5	0.43	10.08	0.37	2.74e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2282802	0.651	rs6863474	chr5:139630862	C/T	cg26211634	chr5:139558579	C5orf32	0.34	8.22	0.31	1.11e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.47	-10.22	-0.37	7.99e-23	Multiple sclerosis;
BRCA	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	15.63	0.53	7.54e-47	Colorectal cancer;
BRCA	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.65	-0.45	6.63e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs312274	0.588	rs4768312	chr12:41236642	T/C	cg17827154	chr12:41323612	CNTN1	0.4	9.9	0.36	1.39e-21	Metabolite levels  (X-11787);
BRCA	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg18200150	chr17:30822561	MYO1D	0.33	8.27	0.31	8.05e-16	Schizophrenia;
BRCA	trans	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg21659725	chr3:3221576	CRBN	-0.47	-8.44	-0.32	2.17e-16	Menarche (age at onset);
BRCA	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.83	-0.33	1e-17	Total body bone mineral density;
BRCA	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg03060546	chr3:49711283	APEH	-0.52	-10.88	-0.4	2.06e-25	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.62	0.5	5.74e-42	Personality dimensions;
BRCA	cis	rs4664304	0.620	rs2136977	chr2:160722850	C/T	cg18514922	chr2:160761262	LY75	0.34	7.92	0.3	1.05e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs6479891	0.818	rs59215788	chr10:65233834	A/G	cg14819942	chr15:35414228	NA	0.35	8.69	0.33	3.04e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07080220	chr10:102295463	HIF1AN	0.49	11.34	0.41	2.78e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg18230493	chr5:56204884	C5orf35	-0.73	-15.09	-0.51	3.04e-44	Initial pursuit acceleration;
BRCA	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg13175981	chr1:150552382	MCL1	0.48	10.61	0.39	2.57e-24	Tonsillectomy;
BRCA	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-8.31	-0.31	5.77e-16	Total body bone mineral density;
BRCA	cis	rs7602441	0.521	rs77940955	chr2:14767411	T/C	cg06545361	chr2:14773388	FAM84A	0.61	8.06	0.3	3.88e-15	Visceral adipose tissue adjusted for BMI;
BRCA	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg24812749	chr6:127587940	RNF146	0.66	14.91	0.51	2.21e-43	Breast cancer;
BRCA	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	15.54	0.52	1.9e-46	Lymphocyte counts;
BRCA	cis	rs6700896	0.931	rs4655574	chr1:66135328	T/A	cg04111102	chr1:66153794	NA	0.36	8.72	0.33	2.37e-17	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg08999081	chr20:33150536	PIGU	-0.46	-12.5	-0.44	3.12e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.27	8.91	0.33	5.33e-18	Bipolar disorder;
BRCA	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg26893861	chr17:41843967	DUSP3	0.89	22.52	0.67	3.85e-83	Triglycerides;
BRCA	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-7.98	-0.3	6.73e-15	Total body bone mineral density;
BRCA	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg11764359	chr7:65958608	NA	-0.66	-12.14	-0.43	1.21e-30	Aortic root size;
BRCA	cis	rs7247513	0.790	rs17476839	chr19:12762783	C/T	cg01871581	chr19:12707946	ZNF490	0.61	13.07	0.46	9.15e-35	Bipolar disorder;
BRCA	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg13010199	chr12:38710504	ALG10B	0.54	11.77	0.42	4.49e-29	Heart rate;
BRCA	trans	rs9951602	0.512	rs1903722	chr18:76646539	G/A	cg02800362	chr5:177631904	HNRNPAB	0.77	17.94	0.58	1.43e-58	Obesity-related traits;
BRCA	cis	rs9463078	0.845	rs1329713	chr6:45004028	A/C	cg25276700	chr6:44698697	NA	-0.35	-7.97	-0.3	7.38e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.07	15.94	0.53	2.05e-48	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	10.09	0.37	2.5e-22	Neuroticism;
BRCA	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg08992911	chr2:238395768	MLPH	0.53	8.36	0.31	3.84e-16	Prostate cancer;
BRCA	trans	rs877282	0.583	rs12356155	chr10:823940	C/T	cg22713356	chr15:30763199	NA	0.95	15.33	0.52	2.01e-45	Uric acid levels;
BRCA	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg06623918	chr6:96969491	KIAA0776	0.7	12.83	0.45	1.05e-33	Migraine;Coronary artery disease;
BRCA	cis	rs868036	1.000	rs868037	chr15:68054996	A/G	cg05925327	chr15:68127851	NA	0.34	8.64	0.32	4.62e-17	Restless legs syndrome;
BRCA	cis	rs9790314	0.750	rs6765270	chr3:160899974	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-9.36	-0.35	1.29e-19	Morning vs. evening chronotype;
BRCA	trans	rs75804782	0.566	rs56314406	chr2:239280377	A/G	cg01134436	chr17:81009848	B3GNTL1	0.76	8.01	0.3	5.58e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.92	-0.3	1.08e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1003719	0.707	rs9976360	chr21:38587860	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.51	-0.5	1.83e-41	Eye color traits;
BRCA	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg19773385	chr1:10388646	KIF1B	-0.38	-8.28	-0.31	6.99e-16	Hepatocellular carcinoma;
BRCA	cis	rs870825	0.550	rs28525282	chr4:185631468	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	17.14	0.56	1.85e-54	Blood protein levels;
BRCA	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg20891283	chr12:69753455	YEATS4	0.71	20.3	0.63	4.25e-71	Blood protein levels;
BRCA	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.47	8.65	0.32	4.02e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08219700	chr8:58056026	NA	-0.44	-7.98	-0.3	6.8e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs78707713	0.592	rs3829182	chr10:71251384	A/G	cg12610070	chr10:71211762	TSPAN15	-0.32	-10.13	-0.37	1.76e-22	Venous thromboembolism;
BRCA	cis	rs12973672	1.000	rs12973672	chr19:35767866	A/G	cg12095397	chr19:35769544	USF2	0.38	8.56	0.32	8.4e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg14983838	chr19:29218262	NA	0.54	10.08	0.37	2.78e-22	Methadone dose in opioid dependence;
BRCA	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.8	-0.42	3.24e-29	Response to antipsychotic treatment;
BRCA	trans	rs4714291	0.963	rs847743	chr6:40087154	C/G	cg02267698	chr19:7991119	CTXN1	0.42	8.26	0.31	8.69e-16	Strep throat;
BRCA	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg18252515	chr7:66147081	NA	-0.9	-12.9	-0.45	5.33e-34	Diabetic kidney disease;
BRCA	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-8.61	-0.32	5.69e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg22875332	chr1:76189707	ACADM	0.5	9.85	0.36	2.01e-21	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs3743102	0.591	rs78104714	chr15:83381199	C/G	cg00614314	chr15:82944287	LOC80154	-0.58	-8.37	-0.31	3.66e-16	Colorectal adenoma (advanced);
BRCA	cis	rs2011503	0.782	rs8113006	chr19:19669441	C/G	cg15839431	chr19:19639596	YJEFN3	0.38	8.32	0.31	5.13e-16	Bipolar disorder;
BRCA	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg24675658	chr1:53192096	ZYG11B	0.63	14.09	0.49	1.87e-39	Monocyte count;
BRCA	cis	rs9420	0.884	rs673344	chr11:57657141	G/A	cg19752551	chr11:57585705	CTNND1	0.48	12.06	0.43	2.65e-30	Schizophrenia;
BRCA	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs11051970	0.879	rs950080	chr12:32588503	G/A	cg02745156	chr12:32552066	NA	0.27	8.87	0.33	7.25e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18876405	chr7:65276391	NA	0.48	10.71	0.39	1.01e-24	Aortic root size;
BRCA	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg00666640	chr1:248458726	OR2T12	0.35	9.27	0.34	2.76e-19	Common traits (Other);
BRCA	cis	rs9868809	0.772	rs13070798	chr3:48705934	C/T	cg00383909	chr3:49044727	WDR6	-0.48	-9.55	-0.35	2.65e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg26597838	chr10:835615	NA	0.69	11.12	0.4	2.3e-26	Eosinophil percentage of granulocytes;
BRCA	cis	rs6088813	0.857	rs6142378	chr20:33997291	T/A	cg14752227	chr20:34000481	UQCC	-0.43	-9.14	-0.34	8.11e-19	Height;
BRCA	cis	rs4363385	0.679	rs6686285	chr1:152984561	T/G	cg24667326	chr1:152973720	SPRR3	-0.32	-8.81	-0.33	1.22e-17	Inflammatory skin disease;
BRCA	cis	rs4642101	0.534	rs13316229	chr3:12807371	C/T	cg24848339	chr3:12840334	CAND2	0.38	9.24	0.34	3.49e-19	QRS complex (12-leadsum);
BRCA	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg21747090	chr2:27597821	SNX17	-0.43	-9.47	-0.35	5.14e-20	Total body bone mineral density;
BRCA	cis	rs7646881	0.812	rs73015665	chr3:158453934	A/T	cg19483011	chr3:158453295	NA	-0.46	-8.02	-0.3	4.95e-15	Tetralogy of Fallot;
BRCA	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.41	0.35	8.46e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg04025307	chr7:1156635	C7orf50	0.42	7.9	0.3	1.19e-14	Bronchopulmonary dysplasia;
BRCA	cis	rs4948102	0.595	rs10255049	chr7:56121304	G/A	cg09872392	chr7:56161020	PHKG1	-0.44	-11.09	-0.4	2.95e-26	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg19077165	chr18:44547161	KATNAL2	0.37	8.06	0.3	3.88e-15	Personality dimensions;
BRCA	cis	rs56399783	0.901	rs73049362	chr7:2826822	G/A	cg19731401	chr7:2775893	GNA12	0.52	8.44	0.32	2.17e-16	Childhood ear infection;
BRCA	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg24130564	chr14:104152367	KLC1	0.34	7.81	0.3	2.35e-14	Intelligence (multi-trait analysis);
BRCA	trans	rs1459104	0.925	rs67465952	chr11:55194045	T/A	cg15704280	chr7:45808275	SEPT13	0.66	8.17	0.31	1.62e-15	Body mass index;
BRCA	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-14.38	-0.49	7.74e-41	Morning vs. evening chronotype;
BRCA	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg21905437	chr5:178450457	ZNF879	0.51	10.64	0.39	1.95e-24	Pubertal anthropometrics;
BRCA	cis	rs754466	0.580	rs2289308	chr10:79579251	G/A	cg17075019	chr10:79541650	NA	-0.82	-19.74	-0.62	4.32e-68	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs812925	0.502	rs2053750	chr2:61656273	T/A	cg15711740	chr2:61764176	XPO1	0.32	7.9	0.3	1.23e-14	Immature fraction of reticulocytes;
BRCA	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg25036284	chr2:26402008	FAM59B	-0.64	-10.71	-0.39	1e-24	Gut microbiome composition (summer);
BRCA	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.52	-0.32	1.15e-16	Monocyte percentage of white cells;
BRCA	cis	rs4766646	0.619	rs7966820	chr12:110302270	A/G	cg01252219	chr12:110302105	GLTP	-0.38	-8.71	-0.33	2.49e-17	Metabolite levels (MHPG);
BRCA	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	11.08	0.4	3.27e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2882667	0.824	rs12173085	chr5:138480025	A/G	cg04439458	chr5:138467593	SIL1	-0.44	-11.13	-0.4	2e-26	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3917254	0.596	rs6754776	chr2:102764778	C/G	cg22835712	chr2:102737379	NA	-0.53	-8.89	-0.33	6.21e-18	Blood protein levels;
BRCA	trans	rs11976180	1.000	rs1533266	chr7:143766714	G/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.43	-8.05	-0.3	4.02e-15	Obesity-related traits;
BRCA	cis	rs6782228	0.606	rs2811488	chr3:128336517	C/T	cg16766828	chr3:128327626	NA	-0.42	-9.28	-0.34	2.57e-19	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg16482183	chr6:26056742	HIST1H1C	0.49	9.66	0.36	1.1e-20	Iron status biomarkers;
BRCA	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg17971929	chr21:40555470	PSMG1	0.61	14.16	0.49	8.34e-40	Cognitive function;
BRCA	cis	rs9400271	0.632	rs6930698	chr6:109590304	A/G	cg01475377	chr6:109611718	NA	-0.43	-10.27	-0.38	5.06e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg06521331	chr12:34319734	NA	-0.52	-10.24	-0.38	6.62e-23	Morning vs. evening chronotype;
BRCA	cis	rs2625529	0.824	rs4131630	chr15:72355398	C/T	cg16672083	chr15:72433130	SENP8	-0.84	-17.45	-0.57	4.66e-56	Red blood cell count;
BRCA	trans	rs9951602	0.512	rs9304070	chr18:76654890	A/C	cg02800362	chr5:177631904	HNRNPAB	0.74	17.67	0.57	3.54e-57	Obesity-related traits;
BRCA	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11890956	chr21:40555474	PSMG1	1.06	31.86	0.78	4.18e-134	Cognitive function;
BRCA	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	ch.11.42038R	chr11:967971	AP2A2	0.52	16.68	0.55	4.17e-52	Alzheimer's disease (late onset);
BRCA	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.88	0.64	3.29e-74	Chronic sinus infection;
BRCA	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg21724239	chr8:58056113	NA	0.61	9.64	0.36	1.23e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs7246760	0.867	rs8102257	chr19:9830795	C/T	cg16876255	chr19:9731953	ZNF561	0.62	7.91	0.3	1.14e-14	Pursuit maintenance gain;
BRCA	trans	rs1459104	1.000	rs12789360	chr11:55289751	C/T	cg15704280	chr7:45808275	SEPT13	0.64	8.1	0.31	2.84e-15	Body mass index;
BRCA	trans	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg21775007	chr8:11205619	TDH	-0.4	-8.37	-0.31	3.58e-16	Joint mobility (Beighton score);
BRCA	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.63	-0.61	1.65e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg18129178	chr5:148520854	ABLIM3	-0.59	-11.98	-0.43	5.71e-30	Breast cancer;
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.41	-8.02	-0.3	5.05e-15	Longevity;Endometriosis;
BRCA	cis	rs77972916	0.536	rs59362315	chr2:43594931	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-10.43	-0.38	1.23e-23	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6546550	0.658	rs10186725	chr2:70015491	A/G	cg02498382	chr2:70120550	SNRNP27	-0.4	-8.55	-0.32	9.1e-17	Prevalent atrial fibrillation;
BRCA	trans	rs931812	1.000	rs931812	chr8:101919321	A/G	cg20993868	chr7:22813445	NA	-0.49	-13.65	-0.48	2.13e-37	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs965469	0.947	rs965468	chr20:3381443	C/T	cg25506879	chr20:3388711	C20orf194	-0.54	-10.46	-0.38	9.8e-24	IFN-related cytopenia;
BRCA	cis	rs7523050	0.730	rs72984612	chr1:109434826	T/C	cg08274380	chr1:109419600	GPSM2	1.18	16.83	0.55	6.67e-53	Fat distribution (HIV);
BRCA	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg26597838	chr10:835615	NA	0.91	14.21	0.49	4.98e-40	Eosinophil percentage of granulocytes;
BRCA	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg17211192	chr8:82754475	SNX16	-0.49	-11.13	-0.4	1.94e-26	Diastolic blood pressure;
BRCA	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg20203395	chr5:56204925	C5orf35	-0.5	-10.56	-0.39	4.06e-24	Initial pursuit acceleration;
BRCA	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg16339924	chr4:17578868	LAP3	0.57	13.96	0.48	7.72e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg24060327	chr5:131705240	SLC22A5	-0.48	-9.67	-0.36	1.02e-20	Blood metabolite levels;
BRCA	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg15556689	chr8:8085844	FLJ10661	0.38	10.52	0.38	5.69e-24	Neuroticism;
BRCA	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg12310025	chr6:25882481	NA	0.33	7.87	0.3	1.51e-14	Blood metabolite levels;
BRCA	cis	rs7683537	0.725	rs28837443	chr4:185641497	G/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.18	0.56	1.08e-54	Systemic lupus erythematosus;
BRCA	cis	rs7246657	0.722	rs2909105	chr19:38167906	A/G	cg18154014	chr19:37997991	ZNF793	-0.5	-9.49	-0.35	4.36e-20	Coronary artery calcification;
BRCA	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg21475434	chr5:93447410	FAM172A	0.68	8.69	0.33	3.1e-17	Diabetic retinopathy;
BRCA	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg21951975	chr1:209979733	IRF6	0.4	9.26	0.34	2.98e-19	Cleft lip with or without cleft palate;
BRCA	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.56	8.3	0.31	6.22e-16	Cerebrospinal P-tau181p levels;
BRCA	trans	rs7746199	0.736	rs34038546	chr6:27607660	C/A	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.5	-0.32	1.31e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7394190	0.630	rs78845904	chr10:75517249	C/A	cg07699608	chr10:75541558	CHCHD1	0.66	9.89	0.36	1.44e-21	Incident atrial fibrillation;
BRCA	cis	rs7524258	0.517	rs6577430	chr1:7324468	C/T	cg08033730	chr1:7319125	CAMTA1	0.33	7.82	0.3	2.24e-14	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs16867321	0.639	rs12466770	chr2:181441312	C/G	cg23363182	chr2:181467187	NA	0.47	10.24	0.38	6.67e-23	Obesity;
BRCA	cis	rs12474201	0.862	rs13025595	chr2:46977893	A/G	cg06386533	chr2:46925753	SOCS5	0.82	17.82	0.58	5.78e-58	Height;
BRCA	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02176678	chr2:219576539	TTLL4	0.45	11.62	0.42	1.97e-28	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg18225595	chr11:63971243	STIP1	0.56	13.54	0.47	6.93e-37	Platelet count;
BRCA	cis	rs7944584	1.000	rs7944584	chr11:47336320	A/T	cg03711944	chr11:47377212	SPI1	-0.36	-7.9	-0.3	1.24e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs812925	0.537	rs778139	chr2:61684564	A/G	cg15711740	chr2:61764176	XPO1	0.32	7.82	0.3	2.13e-14	Immature fraction of reticulocytes;
BRCA	cis	rs7903847	0.642	rs9888026	chr10:99159869	G/T	cg08345082	chr10:99160200	RRP12	0.3	8.74	0.33	2.11e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg00071950	chr4:10020882	SLC2A9	0.5	11.87	0.42	1.72e-29	Bone mineral density;
BRCA	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg05347473	chr6:146136440	FBXO30	0.43	8.53	0.32	1.07e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg20503657	chr10:835505	NA	0.86	15.72	0.53	2.53e-47	Eosinophil percentage of granulocytes;
BRCA	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24838063	chr12:130822603	PIWIL1	0.69	16.92	0.56	2.48e-53	Menopause (age at onset);
BRCA	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg13334819	chr7:99746414	C7orf59	-0.42	-10.0	-0.37	5.87e-22	Coronary artery disease;
BRCA	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg16006841	chr5:176797999	RGS14	-0.69	-11.26	-0.41	5.79e-27	Urate levels in lean individuals;
BRCA	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg11822372	chr1:151115635	SEMA6C	0.51	8.07	0.3	3.43e-15	Blood trace element (Cu levels);
BRCA	cis	rs12532878	0.652	rs11768465	chr7:100198386	C/T	cg20848291	chr7:100343083	ZAN	-0.38	-8.06	-0.3	3.87e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.68	14.36	0.49	9.62e-41	Lymphocyte counts;
BRCA	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg05347473	chr6:146136440	FBXO30	0.39	7.81	0.3	2.36e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg05340658	chr4:99064831	C4orf37	0.56	11.14	0.4	1.86e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.6	9.36	0.35	1.32e-19	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	10.09	0.37	2.62e-22	Neuroticism;
BRCA	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.55	-0.32	9.43e-17	Total body bone mineral density;
BRCA	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg01181863	chr3:195395398	SDHAP2	-0.57	-10.35	-0.38	2.69e-23	Pancreatic cancer;
BRCA	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.77	12.85	0.45	8.99e-34	Schizophrenia;
BRCA	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg26677194	chr12:130822605	PIWIL1	0.6	14.41	0.5	5.64e-41	Menopause (age at onset);
BRCA	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg26647111	chr11:31128758	NA	-0.44	-9.68	-0.36	9.03e-21	Red blood cell count;
BRCA	cis	rs9341808	0.655	rs9350846	chr6:80865481	T/A	cg08355045	chr6:80787529	NA	0.37	9.34	0.35	1.63e-19	Sitting height ratio;
BRCA	cis	rs10754283	0.967	rs7523518	chr1:90110010	G/A	cg21401794	chr1:90099060	LRRC8C	0.49	11.63	0.42	1.69e-28	Amyotrophic lateral sclerosis (sporadic);
BRCA	trans	rs4650994	0.525	rs17361286	chr1:178521916	C/G	cg05059571	chr16:84539110	KIAA1609	-0.58	-12.86	-0.45	7.99e-34	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg18132916	chr6:79620363	NA	-0.46	-10.43	-0.38	1.23e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg05340658	chr4:99064831	C4orf37	0.67	16.63	0.55	7.2e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg23262073	chr20:60523788	NA	-0.39	-8.67	-0.32	3.63e-17	Body mass index;
BRCA	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg24803719	chr17:45855879	NA	-0.31	-7.99	-0.3	6.54e-15	IgG glycosylation;
BRCA	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.54	-9.6	-0.36	1.78e-20	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg13647721	chr17:30228624	UTP6	0.56	8.05	0.3	4.16e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-10.25	-0.38	6.05e-23	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26314531	chr2:26401878	FAM59B	-0.89	-16.14	-0.54	2.19e-49	Gut microbiome composition (summer);
BRCA	cis	rs6545977	0.531	rs2539982	chr2:63111004	G/A	cg17519650	chr2:63277830	OTX1	0.43	10.11	0.37	2.22e-22	Prostate cancer;
BRCA	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg26769984	chr7:1090371	C7orf50	0.48	8.72	0.33	2.45e-17	Bronchopulmonary dysplasia;
BRCA	cis	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg07460842	chr6:66804631	NA	0.85	15.31	0.52	2.76e-45	Exhaled nitric oxide levels;
BRCA	cis	rs909002	0.745	rs4949458	chr1:32142332	G/T	cg13919466	chr1:32135498	COL16A1	0.23	7.88	0.3	1.37e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7560272	0.538	rs12053242	chr2:73937168	G/A	cg20560298	chr2:73613845	ALMS1	0.34	8.96	0.33	3.56e-18	Schizophrenia;
BRCA	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg05340658	chr4:99064831	C4orf37	0.45	10.39	0.38	1.79e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6484504	0.600	rs366758	chr11:31222499	A/C	cg14844989	chr11:31128820	NA	-0.45	-9.62	-0.36	1.51e-20	Red blood cell count;
BRCA	cis	rs12973672	1.000	rs10421768	chr19:35772899	A/G	cg12095397	chr19:35769544	USF2	0.38	8.35	0.31	4.36e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg04727924	chr7:799746	HEATR2	-0.52	-10.14	-0.37	1.7e-22	Cerebrospinal P-tau181p levels;
BRCA	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg27478167	chr7:817139	HEATR2	0.54	10.48	0.38	7.72e-24	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-12.27	-0.44	3.16e-31	Personality dimensions;
BRCA	cis	rs6750047	0.605	rs1374191	chr2:38265420	T/G	cg07380506	chr2:38303506	CYP1B1	-0.47	-10.26	-0.38	5.66e-23	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs7408868	0.908	rs4809028	chr19:15273231	A/G	cg14696996	chr19:15285081	NOTCH3	0.99	14.46	0.5	3.39e-41	Pulse pressure;
BRCA	cis	rs2859741	0.546	rs10489413	chr1:37513906	C/T	cg09363841	chr1:37513479	NA	-0.54	-12.49	-0.44	3.46e-32	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.41	-0.44	8.14e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg23649088	chr2:200775458	C2orf69	0.6	8.83	0.33	1e-17	Schizophrenia;
BRCA	cis	rs9394841	0.667	rs3827633	chr6:41759846	A/C	cg08135965	chr6:41755394	TOMM6	0.5	8.13	0.31	2.18e-15	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs3771570	0.892	rs59715783	chr2:242366262	C/T	cg21155796	chr2:242212141	HDLBP	0.61	9.27	0.34	2.73e-19	Prostate cancer;
BRCA	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg27170947	chr2:26402098	FAM59B	-0.96	-15.4	-0.52	9.17e-46	Gut microbiome composition (summer);
BRCA	trans	rs12517041	1.000	rs6874000	chr5:23304235	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	0.48	8.58	0.32	7.38e-17	Calcium levels;
BRCA	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg25036284	chr2:26402008	FAM59B	-0.96	-16.35	-0.54	1.76e-50	Gut microbiome composition (summer);
BRCA	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.05	-0.3	4.14e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	10.03	0.37	4.23e-22	Bipolar disorder;
BRCA	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.33	0.49	1.37e-40	Personality dimensions;
BRCA	cis	rs4908768	0.539	rs1934138	chr1:8645816	G/A	cg20416874	chr1:8611966	RERE	-0.3	-8.35	-0.31	4.15e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.4	-7.95	-0.3	8.78e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg18154014	chr19:37997991	ZNF793	0.61	11.48	0.41	7.17e-28	Coronary artery calcification;
BRCA	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00149659	chr3:10157352	C3orf10	0.72	12.57	0.45	1.49e-32	Alzheimer's disease;
BRCA	cis	rs10465746	0.967	rs5028806	chr1:84329295	G/A	cg10977910	chr1:84465055	TTLL7	0.51	10.3	0.38	4.19e-23	Obesity-related traits;
BRCA	cis	rs10046574	0.519	rs7810403	chr7:135216172	G/A	cg27474649	chr7:135195673	CNOT4	0.64	10.73	0.39	7.98e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-13.19	-0.46	2.64e-35	Bipolar disorder and schizophrenia;
BRCA	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg04455712	chr21:45112962	RRP1B	0.39	10.19	0.37	1.05e-22	Mean corpuscular volume;
BRCA	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg02403541	chr12:121454288	C12orf43	0.53	10.1	0.37	2.36e-22	N-glycan levels;
BRCA	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-8.98	-0.33	3e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg09555818	chr19:45449301	APOC2	0.47	12.21	0.43	5.72e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg16339924	chr4:17578868	LAP3	0.55	12.82	0.45	1.27e-33	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg03585969	chr10:35415529	CREM	0.49	10.31	0.38	3.76e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08704250	chr15:31115839	NA	-0.35	-8.77	-0.33	1.64e-17	Huntington's disease progression;
BRCA	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.59	12.27	0.44	3.12e-31	Lymphocyte counts;
BRCA	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg24578937	chr1:2090814	PRKCZ	0.38	11.53	0.41	4.59e-28	Height;
BRCA	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg20203395	chr5:56204925	C5orf35	0.49	9.82	0.36	2.66e-21	Initial pursuit acceleration;
BRCA	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	17.04	0.56	5.91e-54	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08564027	chr20:61660810	NA	0.84	22.5	0.66	5.42e-83	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs921968	0.565	rs2272189	chr2:219610322	G/A	cg02176678	chr2:219576539	TTLL4	-0.42	-11.21	-0.41	9.84e-27	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs600806	0.778	rs10745357	chr1:110001876	G/C	cg20591472	chr1:110008990	SYPL2	0.33	8.42	0.32	2.39e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.04	21.58	0.65	5.52e-78	Gut microbiome composition (summer);
BRCA	trans	rs12310956	0.510	rs10844693	chr12:33865197	A/G	cg26384229	chr12:38710491	ALG10B	-0.38	-9.0	-0.34	2.55e-18	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg21535247	chr6:8435926	SLC35B3	0.4	9.09	0.34	1.28e-18	Motion sickness;
BRCA	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.81	0.3	2.32e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.46	-9.23	-0.34	3.84e-19	Body mass index;
BRCA	cis	rs7264396	0.887	rs224347	chr20:34037523	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-8.37	-0.31	3.77e-16	Total cholesterol levels;
BRCA	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.9	-0.33	5.82e-18	Mood instability;
BRCA	cis	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg06521331	chr12:34319734	NA	-0.52	-10.24	-0.38	6.63e-23	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg13010199	chr12:38710504	ALG10B	0.48	9.48	0.35	5.09e-20	Morning vs. evening chronotype;
BRCA	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg23649088	chr2:200775458	C2orf69	0.64	13.28	0.47	1.05e-35	Osteoporosis;
BRCA	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	20.1	0.62	4.94e-70	Platelet count;
BRCA	cis	rs2742417	0.603	rs2742374	chr3:45784082	T/C	cg04837898	chr3:45731254	SACM1L	-0.38	-7.81	-0.3	2.31e-14	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.48	-9.9	-0.36	1.33e-21	Tonsillectomy;
BRCA	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg04414720	chr1:150670196	GOLPH3L	0.35	8.06	0.3	3.82e-15	Tonsillectomy;
BRCA	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg04691961	chr3:161091175	C3orf57	-0.6	-15.14	-0.51	1.7e-44	Morning vs. evening chronotype;
BRCA	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg06115741	chr20:33292138	TP53INP2	0.48	10.72	0.39	8.71e-25	Coronary artery disease;
BRCA	cis	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg24692254	chr21:30365293	RNF160	-0.46	-7.96	-0.3	7.6e-15	Cognitive test performance;
BRCA	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07256732	chr16:621771	PIGQ	-0.35	-9.12	-0.34	9.72e-19	Height;
BRCA	cis	rs66530629	1.000	rs66530629	chr1:25032168	G/A	cg01905478	chr1:25040257	NA	0.38	8.86	0.33	8.15e-18	Plateletcrit;
BRCA	cis	rs708547	0.647	rs1718831	chr4:57886946	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.38	9.79	0.36	3.44e-21	Response to bleomycin (chromatid breaks);
BRCA	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg24130564	chr14:104152367	KLC1	0.35	7.98	0.3	6.97e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg11764359	chr7:65958608	NA	0.68	15.1	0.51	2.81e-44	Aortic root size;
BRCA	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.46	-8.1	-0.31	2.72e-15	Body mass index (adult);
BRCA	trans	rs75804782	0.630	rs56108200	chr2:239276888	C/T	cg01134436	chr17:81009848	B3GNTL1	0.74	7.95	0.3	8.38e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg13628971	chr7:2884303	GNA12	0.46	9.25	0.34	3.2e-19	Height;
BRCA	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg06108461	chr20:60628389	TAF4	0.49	8.37	0.31	3.75e-16	Obesity-related traits;
BRCA	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg00701064	chr4:6280414	WFS1	-0.71	-17.38	-0.57	1.1e-55	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	trans	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg14791747	chr16:20752902	THUMPD1	0.4	9.35	0.35	1.51e-19	Cognitive test performance;
BRCA	cis	rs9807989	0.507	rs6710034	chr2:103023678	G/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.51	0.32	1.25e-16	Asthma;
BRCA	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg00383909	chr3:49044727	WDR6	0.52	10.27	0.38	5.2e-23	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
BRCA	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg07636037	chr3:49044803	WDR6	-0.49	-8.27	-0.31	7.57e-16	Menarche (age at onset);
BRCA	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg26587870	chr6:27730563	NA	-0.45	-8.03	-0.3	4.73e-15	Lung cancer in ever smokers;
BRCA	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg19418458	chr7:158789849	NA	-0.43	-9.62	-0.36	1.52e-20	Facial morphology (factor 20);
BRCA	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.67	-0.57	3.38e-57	Chronic sinus infection;
BRCA	cis	rs1568889	1.000	rs12797689	chr11:28076042	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	13.48	0.47	1.2e-36	Bipolar disorder;
BRCA	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-16.77	-0.55	1.35e-52	Intelligence (multi-trait analysis);
BRCA	trans	rs10242455	0.557	rs77997620	chr7:99070415	G/T	cg09045935	chr12:6379348	NA	0.88	8.55	0.32	9.14e-17	Blood metabolite levels;
BRCA	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg17063962	chr7:91808500	NA	-0.53	-12.62	-0.45	9.64e-33	Breast cancer;
BRCA	cis	rs6700896	0.931	rs10789192	chr1:66125770	G/A	cg04111102	chr1:66153794	NA	0.36	8.82	0.33	1.08e-17	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg05714579	chr10:131428358	MGMT	0.48	10.17	0.37	1.24e-22	Response to temozolomide;
BRCA	cis	rs12711979	0.584	rs11694096	chr2:3868113	G/A	cg17052675	chr2:3827356	NA	-0.53	-15.54	-0.52	2e-46	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg14863265	chr7:2801509	GNA12	-0.5	-10.99	-0.4	7.8e-26	Height;
BRCA	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21582582	chr3:182698605	DCUN1D1	0.39	10.14	0.37	1.61e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg20283391	chr11:68216788	NA	-0.46	-8.98	-0.33	3.03e-18	Total body bone mineral density;
BRCA	cis	rs9682041	0.660	rs34158232	chr3:170115360	T/C	cg11886554	chr3:170076028	SKIL	0.51	10.15	0.37	1.49e-22	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.37	-0.44	1.11e-31	Type 2 diabetes;
BRCA	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg11764359	chr7:65958608	NA	-0.64	-11.15	-0.4	1.64e-26	Aortic root size;
BRCA	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.22	0.31	1.12e-15	Menopause (age at onset);
BRCA	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg00277334	chr10:82204260	NA	-0.43	-8.48	-0.32	1.53e-16	Post bronchodilator FEV1;
BRCA	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg08885076	chr2:99613938	TSGA10	-0.59	-13.08	-0.46	8.32e-35	Chronic sinus infection;
BRCA	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg14926445	chr8:58193284	C8orf71	-0.46	-8.69	-0.33	2.95e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg02376097	chr19:46275166	DMPK	0.43	9.7	0.36	7.64e-21	Coronary artery disease;
BRCA	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	11.42	0.41	1.26e-27	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs8002861	0.619	rs1337203	chr13:44423621	T/G	cg12856521	chr11:46389249	DGKZ	0.37	8.13	0.31	2.15e-15	Leprosy;
BRCA	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg01819863	chr10:32635814	EPC1	1.17	20.84	0.64	5.16e-74	Sexual dysfunction (female);
BRCA	cis	rs13315871	0.929	rs71311853	chr3:58319152	C/T	cg20936604	chr3:58311152	NA	-0.66	-8.42	-0.32	2.54e-16	Cholesterol, total;
BRCA	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg01874867	chr7:94954059	PON1	-0.4	-8.26	-0.31	8.66e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18404041	chr3:52824283	ITIH1	-0.37	-11.21	-0.41	9.26e-27	Electroencephalogram traits;
BRCA	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg00666640	chr1:248458726	OR2T12	0.31	8.73	0.33	2.19e-17	Common traits (Other);
BRCA	trans	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg06521331	chr12:34319734	NA	-0.46	-8.53	-0.32	1.08e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.73	10.2	0.37	9.6e-23	Initial pursuit acceleration;
BRCA	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14442939	chr10:27389572	ANKRD26	0.64	10.74	0.39	7.61e-25	Breast cancer;
BRCA	cis	rs9837602	1.000	rs6806178	chr3:99780393	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	10.56	0.39	3.77e-24	Breast cancer;
BRCA	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg07395648	chr5:131743802	NA	0.4	9.96	0.37	7.84e-22	Blood metabolite levels;
BRCA	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg07169764	chr2:136633963	MCM6	1.28	28.75	0.75	2.6e-117	Corneal structure;
BRCA	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg16606324	chr3:10149918	C3orf24	0.57	11.38	0.41	1.87e-27	Alzheimer's disease;
BRCA	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg02503808	chr4:7069936	GRPEL1	-0.79	-14.52	-0.5	1.79e-41	Monocyte percentage of white cells;
BRCA	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg16576597	chr16:28551801	NUPR1	-0.29	-8.05	-0.3	3.95e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg07395648	chr5:131743802	NA	0.37	8.02	0.3	4.93e-15	Breast cancer;
BRCA	cis	rs4243830	1.000	rs58415361	chr1:6592377	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.92	13.91	0.48	1.3e-38	Body mass index;
BRCA	cis	rs4363385	0.747	rs6668696	chr1:152964910	A/G	cg21543102	chr1:152974771	SPRR3	-0.3	-8.52	-0.32	1.18e-16	Inflammatory skin disease;
BRCA	cis	rs1555322	0.530	rs7004	chr20:33866753	G/C	cg17927777	chr20:33865990	NA	0.47	8.71	0.33	2.67e-17	Attention deficit hyperactivity disorder;
BRCA	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.08	0.4	3.31e-26	Bipolar disorder;
BRCA	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18876405	chr7:65276391	NA	-0.51	-12.02	-0.43	3.98e-30	Aortic root size;
BRCA	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg16339924	chr4:17578868	LAP3	0.63	15.85	0.53	5.85e-48	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2637266	0.905	rs2579772	chr10:78406555	A/G	cg18941641	chr10:78392320	NA	0.36	8.3	0.31	6.03e-16	Pulmonary function;
BRCA	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg20848291	chr7:100343083	ZAN	-0.6	-12.59	-0.45	1.23e-32	Other erythrocyte phenotypes;
BRCA	trans	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	20.36	0.63	1.98e-71	Exhaled nitric oxide output;
BRCA	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg09184832	chr6:79620586	NA	-0.44	-8.52	-0.32	1.12e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9612	1.000	rs28373139	chr19:44246706	A/G	cg08581076	chr19:44259116	C19orf61	0.52	9.02	0.34	2.17e-18	Exhaled nitric oxide output;
BRCA	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg21427119	chr20:30132790	HM13	-0.44	-9.29	-0.35	2.34e-19	Mean corpuscular hemoglobin;
BRCA	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg04362960	chr10:104952993	NT5C2	0.41	9.73	0.36	5.65e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs9487051	0.703	rs351755	chr6:109538073	G/A	cg21918786	chr6:109611834	NA	0.36	9.6	0.35	1.81e-20	Reticulocyte fraction of red cells;
BRCA	cis	rs16866061	1.000	rs72974238	chr2:225432470	C/A	cg12698349	chr2:225449008	CUL3	0.79	20.49	0.63	4.1e-72	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.24	0.49	3.5e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-11.85	-0.42	2.1e-29	Gut microbiome composition (summer);
BRCA	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06028605	chr16:24865363	SLC5A11	0.45	9.74	0.36	5.58e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs17601876	0.814	rs34784350	chr15:51559552	C/T	cg19946085	chr15:51559439	CYP19A1	-0.36	-10.19	-0.37	1.08e-22	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	trans	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.46	0.5	3.3e-41	Exhaled nitric oxide output;
BRCA	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.57	-0.47	4.99e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.1	0.31	2.7e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12923728	chr3:195709715	SDHAP1	-0.58	-12.58	-0.45	1.45e-32	Pancreatic cancer;
BRCA	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.4	9.7	0.36	7.73e-21	Eosinophil percentage of white cells;
BRCA	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00166722	chr3:10149974	C3orf24	0.55	10.74	0.39	7.48e-25	Alzheimer's disease;
BRCA	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.2	0.56	9.34e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-8.96	-0.33	3.67e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg14926445	chr8:58193284	C8orf71	-0.47	-8.92	-0.33	4.83e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg06521331	chr12:34319734	NA	-0.51	-9.15	-0.34	7.41e-19	Bladder cancer;
BRCA	cis	rs835154	0.817	rs835157	chr5:14874533	T/C	cg18064842	chr5:14874549	NA	-0.51	-13.61	-0.47	3.01e-37	Blood metabolite levels;
BRCA	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg01304814	chr3:48885189	PRKAR2A	0.63	7.84	0.3	1.91e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg13010199	chr12:38710504	ALG10B	0.54	11.48	0.41	7.08e-28	Heart rate;
BRCA	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.45	-0.38	1.04e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg15704280	chr7:45808275	SEPT13	-0.46	-7.94	-0.3	9.25e-15	Axial length;
BRCA	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg20503657	chr10:835505	NA	1.33	22.05	0.66	1.42e-80	Eosinophil percentage of granulocytes;
BRCA	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.7	14.26	0.49	2.95e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs977987	0.843	rs11860231	chr16:75385159	A/G	cg03315344	chr16:75512273	CHST6	0.52	12.04	0.43	2.97e-30	Dupuytren's disease;
BRCA	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg01420254	chr6:26195488	NA	0.59	9.16	0.34	6.84e-19	Gout;Renal underexcretion gout;
BRCA	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg10932868	chr11:921992	NA	0.5	13.0	0.46	1.88e-34	Alzheimer's disease (late onset);
BRCA	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg24851651	chr11:66362959	CCS	-0.45	-9.08	-0.34	1.37e-18	Bipolar disorder;
BRCA	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg03929089	chr4:120376271	NA	0.49	8.17	0.31	1.7e-15	Axial length;
BRCA	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg12935359	chr14:103987150	CKB	-0.6	-13.61	-0.47	3.28e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg20203395	chr5:56204925	C5orf35	-0.5	-10.39	-0.38	1.72e-23	Initial pursuit acceleration;
BRCA	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg06640241	chr16:89574553	SPG7	0.77	18.48	0.59	2.18e-61	Multiple myeloma (IgH translocation);
BRCA	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg26528668	chr16:1614120	IFT140	0.34	7.93	0.3	9.75e-15	Coronary artery disease;
BRCA	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg24110177	chr3:50126178	RBM5	-0.51	-14.48	-0.5	2.58e-41	Body mass index;
BRCA	cis	rs507080	0.883	rs563549	chr11:118558953	G/A	cg09144398	chr11:118550485	TREH	-0.37	-8.96	-0.33	3.5e-18	Serum metabolite levels;
BRCA	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.42	9.8	0.36	3.12e-21	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg06521331	chr12:34319734	NA	0.45	8.78	0.33	1.47e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg01528321	chr10:82214614	TSPAN14	0.77	17.31	0.57	2.34e-55	Post bronchodilator FEV1;
BRCA	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg04414720	chr1:150670196	GOLPH3L	0.35	7.83	0.3	2.05e-14	Tonsillectomy;
BRCA	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-11.54	-0.42	4.21e-28	Tonsillectomy;
BRCA	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg20701182	chr2:24300061	SF3B14	0.57	9.01	0.34	2.39e-18	Lymphocyte counts;
BRCA	cis	rs9296092	0.538	rs62405941	chr6:33517297	G/A	cg13560919	chr6:33536144	NA	-0.85	-17.41	-0.57	7.54e-56	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg08470875	chr2:26401718	FAM59B	-0.63	-9.49	-0.35	4.62e-20	Gut microbiome composition (summer);
BRCA	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg16950941	chr11:66035639	RAB1B	0.44	11.97	0.43	6.29e-30	Gout;
BRCA	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg05347473	chr6:146136440	FBXO30	0.41	8.07	0.3	3.41e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-8.18	-0.31	1.57e-15	Longevity;Endometriosis;
BRCA	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03517284	chr6:25882590	NA	0.7	15.67	0.53	4.46e-47	Blood metabolite levels;
BRCA	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.62	-14.12	-0.49	1.38e-39	Ulcerative colitis;
BRCA	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg13628971	chr7:2884303	GNA12	0.39	8.63	0.32	4.98e-17	Height;
BRCA	cis	rs12530845	0.623	rs73721662	chr7:135341314	G/A	cg23117316	chr7:135346802	PL-5283	-0.4	-8.2	-0.31	1.35e-15	Red blood cell traits;
BRCA	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg18129178	chr5:148520854	ABLIM3	-0.58	-11.93	-0.43	9.28e-30	Breast cancer;
BRCA	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg05623727	chr3:50126028	RBM5	-0.49	-12.3	-0.44	2.32e-31	Body mass index;
BRCA	cis	rs12530845	0.887	rs79100776	chr7:135315817	G/A	cg23117316	chr7:135346802	PL-5283	-0.34	-8.15	-0.31	1.89e-15	Red blood cell traits;
BRCA	trans	rs3857536	0.741	rs4710582	chr6:66939984	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg06885757	chr1:42089581	HIVEP3	0.27	9.72	0.36	6.56e-21	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg03342759	chr3:160939853	NMD3	-0.75	-15.82	-0.53	8.19e-48	Parkinson's disease;
BRCA	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg10818794	chr15:86012489	AKAP13	-0.31	-8.68	-0.32	3.27e-17	Coronary artery disease;
BRCA	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-13.93	-0.48	1.04e-38	Mood instability;
BRCA	cis	rs13053817	0.950	rs13056528	chr22:29829333	C/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	0.49	9.66	0.36	1.02e-20	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.42	-8.2	-0.31	1.37e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06108461	chr20:60628389	TAF4	-0.99	-22.33	-0.66	4.6e-82	Body mass index;
BRCA	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg12573674	chr2:1569213	NA	-0.43	-8.0	-0.3	6.04e-15	Placebo response in major depressive disorder (% change in symptom score);
BRCA	trans	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg07211511	chr3:129823064	LOC729375	-0.59	-11.17	-0.4	1.34e-26	Blood pressure (smoking interaction);
BRCA	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg03929089	chr4:120376271	NA	0.57	9.25	0.34	3.26e-19	Axial length;
BRCA	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg15242686	chr22:24348715	GSTTP1	-0.36	-8.8	-0.33	1.26e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg20019720	chr6:154832845	CNKSR3	0.52	10.31	0.38	3.64e-23	Lipoprotein (a) levels;
BRCA	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03526776	chr6:41159608	TREML2	0.39	8.32	0.31	5.46e-16	Alzheimer's disease (late onset);
BRCA	cis	rs7565124	1.000	rs12471796	chr2:20256192	G/A	cg23821541	chr2:20251993	LAPTM4A	0.39	8.05	0.3	4.15e-15	Major depressive disorder;
BRCA	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg09184832	chr6:79620586	NA	-0.41	-8.18	-0.31	1.52e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	12.14	0.43	1.18e-30	Lung cancer in ever smokers;
BRCA	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg08822215	chr16:89438651	ANKRD11	0.38	8.43	0.32	2.32e-16	Multiple myeloma (IgH translocation);
BRCA	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg08885076	chr2:99613938	TSGA10	0.44	10.29	0.38	4.34e-23	Chronic sinus infection;
BRCA	cis	rs72772090	0.710	rs17479052	chr5:96065636	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.59	-0.45	1.28e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs1505368	0.505	rs1394781	chr2:213248822	C/T	cg16329650	chr2:213403929	ERBB4	-0.33	-8.05	-0.3	4.04e-15	Symmetrical dimethylarginine levels;
BRCA	trans	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.83	0.3	2.02e-14	Corneal astigmatism;
BRCA	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11764359	chr7:65958608	NA	0.8	19.31	0.61	8.41e-66	Aortic root size;
BRCA	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg15395560	chr15:45543142	SLC28A2	0.3	8.32	0.31	5.52e-16	Uric acid levels;
BRCA	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg05283184	chr6:79620031	NA	-0.45	-11.47	-0.41	8.17e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs1882538	0.569	rs11562037	chr7:133076885	A/G	cg10665199	chr7:133106180	EXOC4	0.46	9.99	0.37	6.16e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs12760731	0.720	rs12048834	chr1:178353998	A/G	cg00404053	chr1:178313656	RASAL2	0.69	8.26	0.31	8.46e-16	Obesity-related traits;
BRCA	cis	rs11051970	0.877	rs2728671	chr12:32589715	T/A	cg24626660	chr12:32551988	NA	0.29	8.36	0.31	4e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg20908204	chr19:46285434	DMPK	-0.28	-8.15	-0.31	1.87e-15	Coronary artery disease;
BRCA	cis	rs7560272	0.723	rs780391	chr2:73703904	C/T	cg20560298	chr2:73613845	ALMS1	0.43	11.65	0.42	1.47e-28	Schizophrenia;
BRCA	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg26373071	chr5:1325741	CLPTM1L	0.45	10.63	0.39	2.12e-24	Lung cancer;
BRCA	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/T	cg03929089	chr4:120376271	NA	0.59	8.14	0.31	2.02e-15	Height;
BRCA	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg12193833	chr17:30244370	NA	-0.61	-9.25	-0.34	3.32e-19	Hip circumference adjusted for BMI;
BRCA	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg24006582	chr15:45444508	DUOX1	-0.56	-11.58	-0.42	2.68e-28	Uric acid levels;
BRCA	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11764359	chr7:65958608	NA	-0.79	-19.17	-0.6	4.65e-65	Aortic root size;
BRCA	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg00599163	chr2:162100495	NA	0.27	8.86	0.33	7.95e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	8.99	0.34	2.67e-18	Tonsillectomy;
BRCA	cis	rs6750795	0.569	rs1797387	chr2:232414692	A/G	cg19187155	chr2:232395269	NMUR1	0.69	17.55	0.57	1.41e-56	Height;
BRCA	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg10932868	chr11:921992	NA	0.38	9.27	0.34	2.72e-19	Alzheimer's disease (late onset);
BRCA	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg11645453	chr3:52864694	ITIH4	0.45	11.15	0.4	1.71e-26	Schizophrenia;
BRCA	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg21433313	chr16:3507492	NAT15	0.45	10.04	0.37	4.04e-22	Tuberculosis;
BRCA	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg25767906	chr1:53392781	SCP2	0.38	8.71	0.33	2.67e-17	Monocyte count;
BRCA	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11764359	chr7:65958608	NA	0.78	18.53	0.59	1.17e-61	Aortic root size;
BRCA	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg04518342	chr5:131593106	PDLIM4	0.42	10.3	0.38	3.93e-23	Acylcarnitine levels;
BRCA	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg04267008	chr7:1944627	MAD1L1	-0.46	-9.61	-0.36	1.63e-20	Schizophrenia;
BRCA	cis	rs68170813	0.559	rs17427849	chr7:106864237	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.69	-0.33	2.97e-17	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.85e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03923535	chr7:1197113	ZFAND2A	0.51	10.95	0.4	1.13e-25	Longevity;Endometriosis;
BRCA	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.34	-9.64	-0.36	1.23e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6942756	0.715	rs6467242	chr7:129001173	T/A	cg02491457	chr7:128862824	NA	-0.58	-11.97	-0.43	6.09e-30	White matter hyperintensity burden;
BRCA	cis	rs2066819	1.000	rs17118403	chr12:56630067	C/T	cg26714650	chr12:56694279	CS	-1.18	-15.33	-0.52	2.13e-45	Psoriasis vulgaris;
BRCA	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-7.98	-0.3	6.55e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2147904	0.934	rs783622	chr1:42366988	C/T	cg16685388	chr1:42384056	HIVEP3	-0.31	-8.58	-0.32	7e-17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
BRCA	cis	rs4363385	0.747	rs1577965	chr1:152968294	T/C	cg25856811	chr1:152973957	SPRR3	-0.35	-9.22	-0.34	4.35e-19	Inflammatory skin disease;
BRCA	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg05552183	chr6:42928497	GNMT	0.81	19.52	0.61	6.5e-67	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-8.03	-0.3	4.72e-15	Response to antipsychotic treatment;
BRCA	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-13.56	-0.47	5.25e-37	Gut microbiome composition (summer);
BRCA	cis	rs10046574	0.831	rs10261625	chr7:135173544	C/T	cg27474649	chr7:135195673	CNOT4	0.6	8.96	0.33	3.59e-18	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg05896524	chr21:47604654	C21orf56	-0.47	-9.57	-0.35	2.35e-20	Testicular germ cell tumor;
BRCA	trans	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	20.26	0.63	7.44e-71	Exhaled nitric oxide output;
BRCA	cis	rs7072216	0.763	rs9787550	chr10:100169051	C/T	cg26618903	chr10:100175079	PYROXD2	-0.32	-9.16	-0.34	6.79e-19	Metabolite levels;
BRCA	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-11.36	-0.41	2.25e-27	Gut microbiome composition (summer);
BRCA	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	11.66	0.42	1.3e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4690686	0.538	rs13120287	chr4:177260184	T/C	cg17059388	chr4:177262070	NA	0.49	10.02	0.37	4.99e-22	Essential tremor;
BRCA	trans	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-14.65	-0.5	4.29e-42	Obesity-related traits;
BRCA	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	11.59	0.42	2.63e-28	Hip circumference adjusted for BMI;
BRCA	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg16586182	chr3:47516702	SCAP	0.62	14.39	0.49	7.23e-41	Colorectal cancer;
BRCA	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.89	14.34	0.49	1.28e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg03433033	chr1:76189801	ACADM	-0.48	-9.11	-0.34	1.04e-18	Daytime sleep phenotypes;
BRCA	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg00012203	chr2:219082015	ARPC2	0.49	9.59	0.35	1.91e-20	Colorectal cancer;
BRCA	trans	rs877282	0.898	rs12359731	chr10:759497	A/G	cg22713356	chr15:30763199	NA	1.26	24.29	0.69	8.32e-93	Uric acid levels;
BRCA	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg00666640	chr1:248458726	OR2T12	0.3	8.42	0.32	2.5e-16	Common traits (Other);
BRCA	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg12927641	chr6:109611667	NA	-0.37	-9.17	-0.34	6.27e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg01884057	chr2:25150051	NA	0.35	9.25	0.34	3.24e-19	Body mass index;
BRCA	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg05347473	chr6:146136440	FBXO30	0.41	8.25	0.31	9.15e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs858239	0.537	rs10279691	chr7:23228387	A/G	cg23682824	chr7:23144976	KLHL7	0.35	8.9	0.33	5.77e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	8.34	0.31	4.51e-16	Schizophrenia;
BRCA	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.92	-31.13	-0.78	3.51e-130	Schizophrenia;
BRCA	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg24060327	chr5:131705240	SLC22A5	-0.47	-9.46	-0.35	5.92e-20	Blood metabolite levels;
BRCA	cis	rs2625529	0.586	rs7170456	chr15:72469946	G/C	cg16672083	chr15:72433130	SENP8	0.67	16.12	0.54	2.52e-49	Red blood cell count;
BRCA	cis	rs9810890	1.000	rs73196996	chr3:128458416	G/A	cg15033153	chr3:128514015	RAB7A	0.7	8.08	0.3	3.34e-15	Dental caries;
BRCA	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.93	-0.37	1.05e-21	Mean corpuscular volume;
BRCA	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	15.54	0.52	2.06e-46	Hip circumference adjusted for BMI;
BRCA	trans	rs783540	0.500	rs1313494	chr15:83274279	C/T	cg16105309	chr15:79090380	ADAMTS7	0.3	7.83	0.3	2.01e-14	Schizophrenia;
BRCA	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg22676075	chr6:135203613	NA	0.41	8.28	0.31	7.41e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs10463316	0.709	rs3857426	chr5:150789831	C/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.21	-0.31	1.25e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs3784262	0.669	rs4646642	chr15:58246916	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.76	-0.36	4.45e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg09307838	chr4:120376055	NA	0.69	14.89	0.51	2.79e-43	Corneal astigmatism;
BRCA	cis	rs7586879	0.789	rs36029941	chr2:25127801	C/T	cg01884057	chr2:25150051	NA	0.31	7.84	0.3	1.83e-14	Body mass index;
BRCA	cis	rs7178424	0.805	rs5006593	chr15:62250008	T/C	cg00456672	chr15:62358751	C2CD4A	0.43	9.9	0.36	1.41e-21	Height;
BRCA	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.55	11.76	0.42	4.97e-29	Monocyte percentage of white cells;
BRCA	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg12573674	chr2:1569213	NA	-0.64	-14.46	-0.5	3.35e-41	IgG glycosylation;
BRCA	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.56	-0.52	1.55e-46	Chronic sinus infection;
BRCA	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06221963	chr1:154839813	KCNN3	-0.58	-16.31	-0.54	3.02e-50	Prostate cancer;
BRCA	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg11833968	chr6:79620685	NA	-0.44	-9.81	-0.36	2.92e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.64	-0.55	6.39e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg11952622	chr19:58962976	ZNF324B	0.43	8.81	0.33	1.13e-17	Uric acid clearance;
BRCA	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg12310025	chr6:25882481	NA	-0.42	-9.55	-0.35	2.8e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03264133	chr6:25882463	NA	-0.53	-11.96	-0.43	7.1e-30	Blood metabolite levels;
BRCA	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08280861	chr8:58055591	NA	0.57	8.91	0.33	5.15e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2806561	0.929	rs2867315	chr1:23541286	C/T	cg12483005	chr1:23474871	LUZP1	-0.37	-8.06	-0.3	3.8e-15	Height;
BRCA	cis	rs10992471	0.528	rs10820975	chr9:95211922	T/G	cg14631576	chr9:95140430	CENPP	-0.35	-8.73	-0.33	2.23e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg09307838	chr4:120376055	NA	0.65	14.06	0.49	2.52e-39	Corneal astigmatism;
BRCA	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22455342	chr2:225449267	CUL3	0.67	17.22	0.56	7.49e-55	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs3820928	1.000	rs3820928	chr2:227773466	A/G	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.42	-0.32	2.51e-16	Pulmonary function;
BRCA	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg12011299	chr4:100065546	ADH4	0.49	10.95	0.4	1.12e-25	Smoking initiation;
BRCA	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg06784218	chr1:46089804	CCDC17	0.52	12.34	0.44	1.51e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg25208724	chr1:156163844	SLC25A44	1.07	35.26	0.81	4.84e-152	Testicular germ cell tumor;
BRCA	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg17366294	chr4:99064904	C4orf37	0.51	11.24	0.41	7.08e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg13944838	chr5:179740914	GFPT2	0.68	14.67	0.5	3.46e-42	Height;
BRCA	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg02734326	chr4:10020555	SLC2A9	-0.35	-7.88	-0.3	1.41e-14	Bone mineral density;
BRCA	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg13319975	chr6:146136371	FBXO30	-0.37	-8.56	-0.32	8.47e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg01420254	chr6:26195488	NA	0.59	9.16	0.34	6.84e-19	Gout;Renal underexcretion gout;
BRCA	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg11266682	chr4:10021025	SLC2A9	0.48	12.67	0.45	5.57e-33	Bone mineral density;
BRCA	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg01324343	chr3:183735012	ABCC5	0.83	21.18	0.64	8.22e-76	Anterior chamber depth;
BRCA	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-13.29	-0.47	9.55e-36	Platelet count;
BRCA	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg05347473	chr6:146136440	FBXO30	0.62	12.15	0.43	1.07e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7617773	0.780	rs7632297	chr3:48348163	A/C	cg11946769	chr3:48343235	NME6	0.69	13.89	0.48	1.67e-38	Coronary artery disease;
BRCA	cis	rs9308433	0.529	rs4655332	chr1:214490756	G/A	cg06198575	chr1:214491504	SMYD2	0.58	12.69	0.45	4.46e-33	IgG glycosylation;
BRCA	cis	rs3892630	0.878	rs7246451	chr19:33209614	C/G	cg22980127	chr19:33182716	NUDT19	0.89	17.2	0.56	9.34e-55	Red blood cell traits;
BRCA	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg09074113	chr2:20870087	GDF7	-0.34	-8.39	-0.32	3.05e-16	Abdominal aortic aneurysm;
BRCA	trans	rs8073060	0.586	rs9303690	chr17:34005513	C/T	cg19694781	chr19:47549865	TMEM160	-1.03	-21.74	-0.65	7.58e-79	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg17366294	chr4:99064904	C4orf37	0.45	10.78	0.39	5.41e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg19622623	chr12:86230825	RASSF9	-0.28	-7.99	-0.3	6.42e-15	Major depressive disorder;
BRCA	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg13852791	chr20:30311386	BCL2L1	0.84	16.5	0.55	3.24e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs9296092	0.517	rs113111213	chr6:33520790	A/G	cg13560919	chr6:33536144	NA	-0.85	-18.66	-0.59	2.26e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.32	0.38	3.41e-23	Motion sickness;
BRCA	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg13902645	chr11:5959945	NA	-0.47	-10.09	-0.37	2.5e-22	DNA methylation (variation);
BRCA	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-12.26	-0.44	3.45e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11955398	0.665	rs11948543	chr5:59918937	T/C	cg02684056	chr5:59996105	DEPDC1B	0.39	9.38	0.35	1.13e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg24596788	chr1:163392923	NA	-0.37	-9.76	-0.36	4.49e-21	Motion sickness;
BRCA	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg23711669	chr6:146136114	FBXO30	-0.73	-15.46	-0.52	5.03e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg10253484	chr15:75165896	SCAMP2	-0.54	-10.05	-0.37	3.67e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs4319547	0.737	rs11058226	chr12:122938958	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.41	-8.51	-0.32	1.26e-16	Body mass index;
BRCA	cis	rs7301016	1.000	rs11174518	chr12:62902550	T/C	cg01804193	chr12:63026212	NA	0.46	7.93	0.3	1.01e-14	IgG glycosylation;
BRCA	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.75	-12.95	-0.46	3.01e-34	Platelet count;
BRCA	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg24110177	chr3:50126178	RBM5	0.39	10.49	0.38	7.16e-24	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg25214090	chr10:38739885	LOC399744	0.54	12.48	0.44	3.81e-32	Corneal astigmatism;
BRCA	cis	rs9816226	1.000	rs55835921	chr3:185831474	T/C	cg00760338	chr3:185826511	ETV5	-0.52	-8.82	-0.33	1.1e-17	Obesity;Body mass index;
BRCA	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg21856205	chr7:94953877	PON1	-0.38	-8.05	-0.3	3.96e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs9287719	0.649	rs10182589	chr2:10720664	C/T	cg00105475	chr2:10696890	NA	0.41	9.19	0.34	5.52e-19	Prostate cancer;
BRCA	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.58	-0.39	3.1e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg04450456	chr4:17643702	FAM184B	0.38	11.15	0.4	1.66e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11764359	chr7:65958608	NA	0.77	17.25	0.56	5.26e-55	Aortic root size;
BRCA	cis	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.17	-0.4	1.35e-26	Morning vs. evening chronotype;
BRCA	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg00686598	chr14:53173677	PSMC6	1.25	16.56	0.55	1.56e-51	Alzheimer's disease (late onset);
BRCA	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	8.88	0.33	6.81e-18	Iron status biomarkers;
BRCA	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg13175981	chr1:150552382	MCL1	0.47	10.51	0.38	5.93e-24	Tonsillectomy;
BRCA	cis	rs6687430	0.562	rs6676491	chr1:10633421	A/C	cg17425144	chr1:10567563	PEX14	0.54	12.4	0.44	8.67e-32	Hand grip strength;
BRCA	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg02551604	chr5:131831745	NA	-0.4	-14.94	-0.51	1.73e-43	Asthma (sex interaction);
BRCA	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg24879335	chr3:133465180	TF	0.32	10.83	0.39	3.36e-25	Iron status biomarkers (transferrin levels);
BRCA	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.16	-50.17	-0.89	8.1e-224	Myeloid white cell count;
BRCA	cis	rs2882667	0.898	rs2882792	chr5:138380480	G/T	cg04439458	chr5:138467593	SIL1	-0.33	-8.98	-0.33	3.06e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.97	21.23	0.64	4.1e-76	Lymphocyte percentage of white cells;
BRCA	cis	rs13095912	1.000	rs6762208	chr3:185331165	A/C	cg11274856	chr3:185301563	NA	-0.34	-8.5	-0.32	1.34e-16	Systolic blood pressure;
BRCA	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg04705435	chr11:17411270	KCNJ11	0.42	9.1	0.34	1.18e-18	Type 2 diabetes;
BRCA	cis	rs10501293	0.529	rs2902301	chr11:43093159	A/T	cg03447554	chr11:43094025	NA	-0.56	-12.94	-0.46	3.58e-34	Cognitive performance;
BRCA	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg22972055	chr7:872293	UNC84A	0.39	8.68	0.32	3.38e-17	Cerebrospinal P-tau181p levels;
BRCA	trans	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg06636001	chr8:8085503	FLJ10661	0.45	8.48	0.32	1.55e-16	Triglycerides;
BRCA	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.08	0.37	2.72e-22	Calcium levels;
BRCA	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg26384229	chr12:38710491	ALG10B	0.76	16.99	0.56	1.04e-53	Morning vs. evening chronotype;
BRCA	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.9	19.33	0.61	7.02e-66	Lymphocyte percentage of white cells;
BRCA	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.43	0.35	7.76e-20	Tonsillectomy;
BRCA	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-15.85	-0.53	5.65e-48	Heart rate;
BRCA	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-11.91	-0.43	1.09e-29	Mood instability;
BRCA	cis	rs758324	0.947	rs6886188	chr5:131178252	C/T	cg06307176	chr5:131281290	NA	0.53	10.25	0.38	6.22e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs7072216	0.763	rs3750601	chr10:100174561	C/A	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.64	-0.36	1.31e-20	Metabolite levels;
BRCA	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	19.65	0.61	1.3e-67	Smoking behavior;
BRCA	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg19156104	chr2:198669113	PLCL1	-0.44	-8.13	-0.31	2.26e-15	Ulcerative colitis;
BRCA	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg03188948	chr7:1209495	NA	0.59	11.13	0.4	1.99e-26	Longevity;Endometriosis;
BRCA	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.53	10.72	0.39	8.76e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.84	0.42	2.32e-29	Tonsillectomy;
BRCA	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18876405	chr7:65276391	NA	-0.63	-15.57	-0.52	1.4300000000000001e-46	Aortic root size;
BRCA	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg14530993	chr4:882597	GAK	0.58	9.57	0.35	2.28e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.19	0.4	1.17e-26	Bipolar disorder;
BRCA	cis	rs7677751	0.806	rs7678144	chr4:55102425	T/C	cg17187183	chr4:55093834	PDGFRA	0.45	9.22	0.34	4.11e-19	Corneal astigmatism;
BRCA	cis	rs2066819	1.000	rs77853814	chr12:56687572	G/T	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs870825	0.587	rs35845099	chr4:185639762	A/G	cg04058563	chr4:185651563	MLF1IP	0.78	17.43	0.57	5.93e-56	Blood protein levels;
BRCA	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.75	0.6	7.86e-63	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg18225595	chr11:63971243	STIP1	0.4	9.79	0.36	3.38e-21	Platelet count;
BRCA	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03452623	chr4:187889614	NA	-0.31	-10.06	-0.37	3.36e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3772130	0.545	rs7340674	chr3:121574215	T/C	cg20356878	chr3:121714668	ILDR1	0.43	9.82	0.36	2.65e-21	Cognitive performance;
BRCA	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg06115741	chr20:33292138	TP53INP2	0.42	9.48	0.35	4.91e-20	Coronary artery disease;
BRCA	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.85	-0.48	2.38e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg14019146	chr3:50243930	SLC38A3	0.38	9.35	0.35	1.45e-19	Body mass index;
BRCA	trans	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg26043149	chr18:55253948	FECH	0.4	8.96	0.33	3.48e-18	Bone mineral density;
BRCA	cis	rs7395581	0.959	rs2279239	chr11:47281780	T/C	cg25783544	chr11:47291846	MADD	0.43	9.45	0.35	6.2e-20	HDL cholesterol;
BRCA	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-13.47	-0.47	1.45e-36	Chronic sinus infection;
BRCA	cis	rs3849570	0.925	rs2873054	chr3:81888255	A/C	cg07356753	chr3:81810745	GBE1	-0.43	-10.19	-0.37	1.04e-22	Waist circumference;Body mass index;
BRCA	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg13628971	chr7:2884303	GNA12	0.46	9.09	0.34	1.2e-18	Height;
BRCA	cis	rs2882667	0.931	rs7720150	chr5:138334069	C/A	cg04439458	chr5:138467593	SIL1	-0.35	-9.85	-0.36	2.16e-21	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-10.43	-0.38	1.25e-23	Neuroticism;
BRCA	cis	rs4629710	0.545	rs11755717	chr6:131547028	A/T	cg12606694	chr6:131520996	AKAP7	-0.4	-8.43	-0.32	2.37e-16	Multiple myeloma (IgH translocation);
BRCA	trans	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg01620082	chr3:125678407	NA	-0.69	-8.51	-0.32	1.23e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1020064	0.636	rs2576750	chr2:105916635	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.41	7.96	0.3	7.75e-15	AIDS;
BRCA	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg18964960	chr10:1102726	WDR37	0.66	9.22	0.34	4.25e-19	Eosinophil percentage of granulocytes;
BRCA	cis	rs7408868	0.908	rs757474	chr19:15273624	T/C	cg14696996	chr19:15285081	NOTCH3	0.99	14.46	0.5	3.39e-41	Pulse pressure;
BRCA	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg05714579	chr10:131428358	MGMT	-0.57	-13.54	-0.47	6.91e-37	Response to temozolomide;
BRCA	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg05340658	chr4:99064831	C4orf37	-0.48	-10.94	-0.4	1.24e-25	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs74181299	0.684	rs6736728	chr2:65305499	A/G	cg05010058	chr2:65284262	CEP68	0.3	7.97	0.3	7.45e-15	Pulse pressure;
BRCA	cis	rs4363385	0.747	rs9919227	chr1:152970867	A/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.42	-0.35	8e-20	Inflammatory skin disease;
BRCA	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.84	0.39	3.02e-25	Bipolar disorder;
BRCA	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.55	8.35	0.31	4.22e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7737355	0.947	rs193458	chr5:130816284	G/C	cg06307176	chr5:131281290	NA	0.54	11.38	0.41	1.86e-27	Life satisfaction;
BRCA	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.16	-0.49	8.76e-40	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg06064525	chr11:970664	AP2A2	-0.48	-15.6	-0.53	1.04e-46	Alzheimer's disease (late onset);
BRCA	cis	rs17092148	0.836	rs4322911	chr20:33182577	G/A	cg16810054	chr20:33298113	TP53INP2	-0.44	-10.1	-0.37	2.3e-22	Neuroticism;
BRCA	trans	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg25214090	chr10:38739885	LOC399744	0.35	8.01	0.3	5.35e-15	Diastolic blood pressure;
BRCA	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg15605315	chr1:45957053	TESK2	-0.47	-9.21	-0.34	4.52e-19	High light scatter reticulocyte count;
BRCA	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg21573476	chr21:45109991	RRP1B	-0.39	-10.44	-0.38	1.14e-23	Mean corpuscular volume;
BRCA	cis	rs2858942	0.602	rs1211375	chr16:240280	G/T	cg08400316	chr16:204221	HBZ	-0.37	-8.08	-0.3	3.32e-15	Mean corpuscular hemoglobin;
BRCA	trans	rs5756813	1.000	rs1129448	chr22:38170026	G/A	cg19894588	chr14:64061835	NA	0.54	13.82	0.48	3.47e-38	Optic cup area;Vertical cup-disc ratio;
BRCA	cis	rs12368653	0.544	rs11172304	chr12:58097862	T/C	cg18357645	chr12:58087776	OS9	0.41	11.96	0.43	6.59e-30	Multiple sclerosis;
BRCA	trans	rs35110281	0.667	rs4818859	chr21:45117120	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	8.76	0.33	1.77e-17	Mean corpuscular volume;
BRCA	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg05665937	chr4:1216051	CTBP1	0.43	8.62	0.32	5.41e-17	Obesity-related traits;
BRCA	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	16.85	0.55	5.43e-53	Alzheimer's disease;
BRCA	trans	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg07211511	chr3:129823064	LOC729375	0.99	13.89	0.48	1.6e-38	Blood pressure (smoking interaction);
BRCA	cis	rs775227	0.574	rs13064411	chr3:113046640	A/G	cg18753928	chr3:113234510	CCDC52	-0.59	-9.24	-0.34	3.54e-19	Dental caries;
BRCA	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg07211511	chr3:129823064	LOC729375	-1.01	-19.21	-0.61	3.06e-65	Blood pressure (smoking interaction);
BRCA	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg24130564	chr14:104152367	KLC1	-0.39	-8.91	-0.33	5.2e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg05623727	chr3:50126028	RBM5	-0.49	-11.69	-0.42	9.64e-29	Body mass index;
BRCA	cis	rs10754283	0.967	rs4658130	chr1:90113447	G/C	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.31e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg07169764	chr2:136633963	MCM6	0.99	19.92	0.62	4.78e-69	Mosquito bite size;
BRCA	cis	rs73198271	0.740	rs10105690	chr8:8649232	G/T	cg15556689	chr8:8085844	FLJ10661	-0.32	-7.85	-0.3	1.81e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27286337	chr10:134555280	INPP5A	0.6	10.15	0.37	1.51e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg08885076	chr2:99613938	TSGA10	-0.48	-9.26	-0.34	3.18e-19	Chronic sinus infection;
BRCA	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg11941060	chr3:133502564	NA	-0.5	-11.87	-0.43	1.61e-29	Iron status biomarkers;
BRCA	cis	rs35740288	1.000	rs35740288	chr15:86297085	T/A	cg20737812	chr15:86336631	KLHL25	-0.33	-8.82	-0.33	1.07e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-14.89	-0.51	2.92e-43	Chronic sinus infection;
BRCA	cis	rs9462027	0.628	rs2764206	chr6:34712900	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.87	-0.3	1.54e-14	Systemic lupus erythematosus;
BRCA	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.46	0.35	5.72e-20	Morning vs. evening chronotype;
BRCA	cis	rs9309711	0.922	rs13431788	chr2:3482912	G/A	cg16153549	chr2:3496821	NA	-0.41	-9.38	-0.35	1.13e-19	Neurofibrillary tangles;
BRCA	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.07	-30.59	-0.77	2.77e-127	Cognitive ability;
BRCA	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg08807101	chr21:30365312	RNF160	0.59	15.17	0.51	1.26e-44	Dental caries;
BRCA	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.48	9.72	0.36	6.51e-21	Height;
BRCA	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg01528321	chr10:82214614	TSPAN14	0.91	19.98	0.62	2.21e-69	Post bronchodilator FEV1;
BRCA	trans	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg25214090	chr10:38739885	LOC399744	0.43	10.0	0.37	5.45e-22	Corneal astigmatism;
BRCA	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg10223061	chr2:219282414	VIL1	0.27	7.96	0.3	7.8e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg03060546	chr3:49711283	APEH	-0.51	-10.42	-0.38	1.34e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.35	-8.1	-0.31	2.72e-15	Bipolar disorder;
BRCA	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg26769984	chr7:1090371	C7orf50	0.44	9.47	0.35	5.3e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg00852783	chr1:26633632	UBXN11	-0.5	-8.26	-0.31	8.7e-16	Obesity-related traits;
BRCA	cis	rs7737355	0.947	rs31587	chr5:131000711	A/T	cg06307176	chr5:131281290	NA	0.53	10.41	0.38	1.51e-23	Life satisfaction;
BRCA	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	13.8	0.48	4.37e-38	Response to bleomycin (chromatid breaks);
BRCA	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.22	0.34	4.35e-19	Tonsillectomy;
BRCA	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg23950597	chr19:37808831	NA	-0.62	-11.37	-0.41	2.02e-27	Coronary artery calcification;
BRCA	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-26.1	-0.72	9.5e-103	Chronic sinus infection;
BRCA	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	18.12	0.58	1.51e-59	Hip circumference adjusted for BMI;
BRCA	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg03477792	chr4:77819574	ANKRD56	0.52	11.69	0.42	9.73e-29	Emphysema distribution in smoking;
BRCA	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg13319975	chr6:146136371	FBXO30	-0.37	-8.56	-0.32	8.47e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17818399	0.735	rs11894342	chr2:46836439	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.42	8.62	0.32	5.28e-17	Height;
BRCA	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08704250	chr15:31115839	NA	-0.36	-9.07	-0.34	1.43e-18	Huntington's disease progression;
BRCA	cis	rs782590	0.875	rs62165175	chr2:55745810	T/A	cg18811423	chr2:55921094	PNPT1	0.67	19.88	0.62	7.72e-69	Metabolic syndrome;
BRCA	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg22875332	chr1:76189707	ACADM	-0.54	-10.34	-0.38	2.74e-23	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.47	-10.66	-0.39	1.63e-24	Longevity;Endometriosis;
BRCA	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.31	-0.38	3.63e-23	Gut microbiome composition (summer);
BRCA	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-11.13	-0.4	1.96e-26	Lymphocyte counts;
BRCA	trans	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg26043149	chr18:55253948	FECH	-0.37	-8.13	-0.31	2.18e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg12935359	chr14:103987150	CKB	0.64	14.67	0.5	3.48e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg04990556	chr1:26633338	UBXN11	0.54	8.86	0.33	8.17e-18	Obesity-related traits;
BRCA	cis	rs9394841	0.692	rs56215622	chr6:41892457	G/A	cg08135965	chr6:41755394	TOMM6	0.51	8.44	0.32	2.17e-16	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.29	-0.38	4.31e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg01256987	chr12:42539512	GXYLT1	-0.56	-11.49	-0.41	6.43e-28	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg10224037	chr5:178157518	ZNF354A	0.79	17.9	0.58	2.18e-58	Neutrophil percentage of white cells;
BRCA	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg26384229	chr12:38710491	ALG10B	0.69	16.21	0.54	9.67e-50	Bladder cancer;
BRCA	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-9.83	-0.36	2.39e-21	Schizophrenia;
BRCA	cis	rs9649213	0.614	rs1006169	chr7:97938443	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.58	15.4	0.52	9.2e-46	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9400271	0.609	rs9386782	chr6:109588643	G/T	cg01475377	chr6:109611718	NA	-0.44	-10.41	-0.38	1.56e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg11502198	chr6:26597334	ABT1	0.48	9.54	0.35	3.06e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg17211192	chr8:82754475	SNX16	-0.51	-11.71	-0.42	7.97e-29	Diastolic blood pressure;
BRCA	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg16586182	chr3:47516702	SCAP	0.62	14.49	0.5	2.41e-41	Colorectal cancer;
BRCA	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg02012338	chr4:187126139	CYP4V2	0.85	9.6	0.35	1.82e-20	Blood protein levels;
BRCA	cis	rs2731664	0.792	rs2544809	chr5:176885499	T/C	cg23176889	chr5:176863531	GRK6	-0.64	-17.72	-0.57	1.82e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg06713675	chr4:122721982	EXOSC9	-0.53	-12.44	-0.44	5.58e-32	Type 2 diabetes;
BRCA	trans	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	10.06	0.37	3.27e-22	Mean corpuscular volume;
BRCA	cis	rs7737355	0.947	rs1422081	chr5:130776053	A/C	cg06307176	chr5:131281290	NA	0.5	9.92	0.37	1.12e-21	Life satisfaction;
BRCA	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.06	0.34	1.52e-18	Tonsillectomy;
BRCA	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26168224	chr5:2018326	NA	-0.64	-18.47	-0.59	2.39e-61	Gut microbiome composition (winter);
BRCA	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.11	-18.14	-0.58	1.28e-59	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg12386194	chr3:101231763	SENP7	0.46	9.91	0.36	1.29e-21	Colorectal cancer;
BRCA	trans	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg25042112	chr7:64838748	ZNF92	0.46	8.63	0.32	4.86e-17	Pain;
BRCA	cis	rs2625529	0.530	rs2959930	chr15:72598614	A/G	cg16672083	chr15:72433130	SENP8	-0.71	-15.2	-0.52	9.33e-45	Red blood cell count;
BRCA	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg24112000	chr20:60950667	NA	-0.5	-9.67	-0.36	1.01e-20	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs10411936	0.692	rs10413787	chr19:16594967	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.47	9.72	0.36	6.35e-21	White blood cell count;Multiple sclerosis;
BRCA	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg01420254	chr6:26195488	NA	0.6	9.24	0.34	3.6e-19	Gout;Renal underexcretion gout;
BRCA	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11890956	chr21:40555474	PSMG1	1.03	27.92	0.74	9.19e-113	Cognitive function;
BRCA	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg11843238	chr5:131593191	PDLIM4	0.44	11.34	0.41	2.81e-27	Acylcarnitine levels;
BRCA	cis	rs4474465	1.000	rs6592779	chr11:78197283	G/C	cg27205649	chr11:78285834	NARS2	-0.32	-8.83	-0.33	9.82e-18	Alzheimer's disease (survival time);
BRCA	cis	rs4908760	0.899	rs61783642	chr1:8591397	T/C	cg20416874	chr1:8611966	RERE	-0.28	-8.02	-0.3	5.12e-15	Vitiligo;
BRCA	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg25833597	chr17:30823145	MYO1D	0.34	8.34	0.31	4.72e-16	Schizophrenia;
BRCA	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg00383909	chr3:49044727	WDR6	0.59	11.07	0.4	3.56e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs12474201	0.928	rs13025984	chr2:46938789	T/C	cg06386533	chr2:46925753	SOCS5	0.87	18.93	0.6	8.6e-64	Height;
BRCA	cis	rs3925075	1.000	rs3925075	chr16:31347748	C/T	cg02846316	chr16:31340340	ITGAM	-0.54	-13.45	-0.47	1.8e-36	IgA nephropathy;
BRCA	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg15145296	chr3:125709740	NA	-0.57	-9.37	-0.35	1.19e-19	Blood pressure (smoking interaction);
BRCA	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg05707623	chr12:122985044	ZCCHC8	0.44	8.77	0.33	1.67e-17	Body mass index;
BRCA	cis	rs1451375	1.000	rs4452748	chr7:50625056	A/C	cg18232548	chr7:50535776	DDC	-0.43	-10.12	-0.37	2.02e-22	Malaria;
BRCA	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg20587970	chr11:113659929	NA	-1.2	-22.13	-0.66	5.45e-81	Hip circumference adjusted for BMI;
BRCA	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg20503657	chr10:835505	NA	0.93	14.38	0.49	8.36e-41	Eosinophil percentage of granulocytes;
BRCA	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.42	0.32	2.42e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	26.21	0.72	2.25e-103	Chronic sinus infection;
BRCA	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg18811423	chr2:55921094	PNPT1	0.77	26.87	0.73	5.06e-107	Metabolic syndrome;
BRCA	cis	rs887829	0.569	rs7574296	chr2:234638249	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-8.99	-0.34	2.76e-18	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs56399783	0.901	rs73047393	chr7:2775879	C/T	cg23627948	chr7:2760692	NA	0.49	8.04	0.3	4.21e-15	Childhood ear infection;
BRCA	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg09654669	chr8:57350985	NA	-0.39	-8.59	-0.32	6.42e-17	Obesity-related traits;
BRCA	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg03060546	chr3:49711283	APEH	-0.59	-10.21	-0.37	9.07e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-10.02	-0.37	4.61e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6973256	0.828	rs4731974	chr7:133344010	C/T	cg07491979	chr7:133331646	EXOC4	-0.39	-9.05	-0.34	1.69e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.03e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.62	-16.35	-0.54	1.96e-50	Longevity;Endometriosis;
BRCA	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02353165	chr6:42928485	GNMT	0.89	23.98	0.69	3.97e-91	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg03806693	chr22:41940476	POLR3H	-1.15	-22.86	-0.67	5.77e-85	Vitiligo;
BRCA	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-10.2	-0.37	9.61e-23	IgG glycosylation;
BRCA	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs36051895	0.559	rs10815172	chr9:5212254	T/A	cg02405213	chr9:5042618	JAK2	-0.45	-8.61	-0.32	5.59e-17	Pediatric autoimmune diseases;
BRCA	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg26597838	chr10:835615	NA	0.68	10.89	0.4	1.82e-25	Eosinophil percentage of granulocytes;
BRCA	cis	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.36	-0.35	1.39e-19	Morning vs. evening chronotype;
BRCA	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg24558204	chr6:135376177	HBS1L	0.44	12.2	0.43	6.19e-31	Red blood cell count;
BRCA	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs8054556	0.669	rs9972866	chr16:30018982	C/G	cg06326092	chr16:30034487	C16orf92	0.35	8.76	0.33	1.8e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.64	9.94	0.37	9.42e-22	Lung function (FEV1/FVC);
BRCA	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg02640540	chr1:67518911	SLC35D1	0.51	11.18	0.4	1.27e-26	Lymphocyte percentage of white cells;
BRCA	cis	rs2882667	0.690	rs176381	chr5:138196731	C/T	cg04439458	chr5:138467593	SIL1	0.31	7.97	0.3	7.43e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg01819759	chr13:79234251	RNF219	0.66	11.7	0.42	8.78e-29	Large artery stroke;
BRCA	cis	rs2882667	0.690	rs288017	chr5:138193515	A/T	cg04439458	chr5:138467593	SIL1	0.35	8.57	0.32	7.79e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4891159	0.756	rs8084155	chr18:74134952	A/G	cg24786174	chr18:74118243	ZNF516	-0.81	-22.62	-0.67	1.08e-83	Longevity;
BRCA	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-9.44	-0.35	6.86e-20	Personality dimensions;
BRCA	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg11663144	chr21:46675770	NA	-0.49	-9.54	-0.35	2.92e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg13010199	chr12:38710504	ALG10B	0.48	9.29	0.34	2.41e-19	Morning vs. evening chronotype;
BRCA	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg13334819	chr7:99746414	C7orf59	-0.36	-8.1	-0.31	2.73e-15	Coronary artery disease;
BRCA	cis	rs1997103	1.000	rs6973337	chr7:55411534	T/C	cg17469321	chr7:55412551	NA	0.51	9.68	0.36	8.77e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-14.98	-0.51	1.04e-43	Obesity-related traits;
BRCA	cis	rs7512552	0.839	rs2264418	chr1:150368579	G/A	cg15654264	chr1:150340011	RPRD2	0.38	8.4	0.32	2.96e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg11845111	chr2:191398756	TMEM194B	-0.75	-13.49	-0.47	1.17e-36	Diastolic blood pressure;
BRCA	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg08917208	chr2:24149416	ATAD2B	0.9	13.2	0.46	2.27e-35	Lymphocyte counts;
BRCA	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24531977	chr5:56204891	C5orf35	-1.0	-20.39	-0.63	1.43e-71	Initial pursuit acceleration;
BRCA	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg08470875	chr2:26401718	FAM59B	-0.68	-11.68	-0.42	1.05e-28	Gut microbiome composition (summer);
BRCA	cis	rs2745967	0.715	rs2724367	chr1:208067329	C/T	cg09788693	chr1:208063733	CD34	0.37	7.84	0.3	1.86e-14	Resting heart rate;
BRCA	trans	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg06521331	chr12:34319734	NA	-0.51	-9.27	-0.34	2.75e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg21782813	chr7:2030301	MAD1L1	0.29	7.94	0.3	9.15e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.37	9.67	0.36	1.02e-20	IgG glycosylation;
BRCA	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg20476274	chr7:133979776	SLC35B4	0.7	21.25	0.64	3.26e-76	Mean platelet volume;
BRCA	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg24558204	chr6:135376177	HBS1L	0.45	12.33	0.44	1.74e-31	Red blood cell count;
BRCA	cis	rs9837602	0.938	rs34922392	chr3:99794730	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	10.46	0.38	9.25e-24	Breast cancer;
BRCA	cis	rs9463078	0.683	rs227851	chr6:44699209	A/C	cg25276700	chr6:44698697	NA	0.35	7.81	0.3	2.39e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs312274	0.515	rs2583992	chr12:41241863	C/T	cg17827154	chr12:41323612	CNTN1	0.36	8.84	0.33	9.34e-18	Metabolite levels  (X-11787);
BRCA	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16024904	chr19:17905718	B3GNT3	0.37	7.81	0.3	2.38e-14	Tumor biomarkers;
BRCA	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg01871581	chr19:12707946	ZNF490	-0.64	-14.39	-0.49	6.83e-41	Bipolar disorder;
BRCA	cis	rs922182	0.617	rs17777266	chr15:64241242	A/G	cg24729988	chr15:64271149	DAPK2	0.49	10.87	0.39	2.34e-25	Blood protein levels;
BRCA	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg21770322	chr7:97807741	LMTK2	0.41	11.02	0.4	5.9e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9341808	0.718	rs2322636	chr6:80897436	C/T	cg08355045	chr6:80787529	NA	0.39	9.91	0.36	1.26e-21	Sitting height ratio;
BRCA	cis	rs2019216	0.835	rs402052	chr17:21908388	G/C	cg22648282	chr17:21454238	C17orf51	-0.36	-8.07	-0.3	3.6e-15	Pelvic organ prolapse;
BRCA	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg18230493	chr5:56204884	C5orf35	-0.73	-14.31	-0.49	1.77e-40	Initial pursuit acceleration;
BRCA	cis	rs61935443	0.666	rs11107780	chr12:95299142	G/A	cg21533806	chr12:95267307	NA	0.47	8.16	0.31	1.77e-15	Schizophrenia;
BRCA	cis	rs753274	0.650	rs72998945	chr19:14418441	C/A	cg25450033	chr19:14444658	NA	0.33	7.82	0.3	2.23e-14	Tumor necrosis factor beta levels;
BRCA	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg26373071	chr5:1325741	CLPTM1L	0.49	11.78	0.42	4.06e-29	Lung cancer;
BRCA	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg27529037	chr20:44575021	PCIF1	0.32	7.84	0.3	1.96e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg17330251	chr7:94953956	PON1	-0.43	-8.6	-0.32	5.91e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg14847009	chr1:175162515	KIAA0040	0.25	9.65	0.36	1.14e-20	Alcohol dependence;
BRCA	cis	rs72772090	0.539	rs72775807	chr5:96179761	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-11.31	-0.41	3.56e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg00701064	chr4:6280414	WFS1	0.65	16.41	0.54	8.8e-51	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg13319975	chr6:146136371	FBXO30	0.34	7.94	0.3	9.3e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17253792	0.822	rs17253716	chr14:56153661	G/C	cg01858014	chr14:56050164	KTN1	-0.76	-9.53	-0.35	3.34e-20	Putamen volume;
BRCA	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-12.51	-0.44	2.77e-32	Hemoglobin concentration;
BRCA	cis	rs757081	0.667	rs17641418	chr11:17161341	T/C	cg15432903	chr11:17409602	KCNJ11	-0.47	-8.81	-0.33	1.17e-17	Systolic blood pressure;
BRCA	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg03433033	chr1:76189801	ACADM	0.75	17.08	0.56	3.59e-54	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg01475377	chr6:109611718	NA	-0.51	-12.99	-0.46	2.1e-34	Reticulocyte fraction of red cells;
BRCA	cis	rs4891159	0.790	rs1056714	chr18:74149526	A/G	cg24786174	chr18:74118243	ZNF516	-0.74	-18.11	-0.58	1.84e-59	Longevity;
BRCA	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg08601574	chr20:25228251	PYGB	-0.36	-8.53	-0.32	1.03e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.24	0.38	6.64e-23	Aortic root size;
BRCA	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.57	9.81	0.36	3e-21	Gut microbiome composition (summer);
BRCA	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg14863265	chr7:2801509	GNA12	-0.42	-9.64	-0.36	1.21e-20	Height;
BRCA	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.42	0.32	2.49e-16	Tonsillectomy;
BRCA	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	13.29	0.47	9e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-9.39	-0.35	1.07e-19	Colorectal cancer;
BRCA	cis	rs4809760	0.692	rs8118160	chr20:48434636	A/G	cg17835207	chr20:48524531	SPATA2	0.38	8.3	0.31	6.18e-16	Gut microbiota (beta diversity);
BRCA	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg06115741	chr20:33292138	TP53INP2	0.41	8.94	0.33	4e-18	Coronary artery disease;
BRCA	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg04287289	chr16:89883240	FANCA	-0.61	-13.94	-0.48	9.47e-39	Vitiligo;
BRCA	cis	rs7258465	0.965	rs10408290	chr19:18542701	C/T	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.76	-0.33	1.76e-17	Breast cancer;
BRCA	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.66	-0.61	1.21e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.34	-0.38	2.72e-23	Schizophrenia;
BRCA	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg18252515	chr7:66147081	NA	-1.0	-11.23	-0.41	7.95e-27	Diabetic kidney disease;
BRCA	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg06484146	chr7:12443880	VWDE	-0.76	-10.77	-0.39	5.66e-25	Coronary artery disease;
BRCA	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg05340658	chr4:99064831	C4orf37	0.69	17.38	0.57	1.11e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2354432	1.000	rs10900325	chr1:146692174	C/T	cg25205988	chr1:146714368	CHD1L	-0.93	-15.28	-0.52	3.67e-45	Mitochondrial DNA levels;
BRCA	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-16.23	-0.54	7.7e-50	Alzheimer's disease (late onset);
BRCA	cis	rs72772090	0.634	rs17401901	chr5:96091925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-13.46	-0.47	1.57e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg01529538	chr14:23388837	RBM23	0.42	11.48	0.41	7.01e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs10046574	0.831	rs10276768	chr7:135064346	A/G	cg27474649	chr7:135195673	CNOT4	0.58	8.3	0.31	6.41e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs11030122	0.632	rs4910596	chr11:4084604	A/G	cg18678763	chr11:4115507	RRM1	-0.35	-7.88	-0.3	1.37e-14	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg14440974	chr22:39074834	NA	-0.38	-9.14	-0.34	8.06e-19	Menopause (age at onset);
BRCA	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg24006582	chr15:45444508	DUOX1	-0.56	-11.55	-0.42	3.82e-28	Uric acid levels;
BRCA	cis	rs929596	0.614	rs10929302	chr2:234665782	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-12.03	-0.43	3.53e-30	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs490234	0.702	rs2416964	chr9:128360413	C/T	cg14078157	chr9:128172775	NA	-0.48	-10.75	-0.39	7.08e-25	Mean arterial pressure;
BRCA	cis	rs10465746	0.780	rs12139191	chr1:84387871	A/C	cg10977910	chr1:84465055	TTLL7	0.58	12.06	0.43	2.57e-30	Obesity-related traits;
BRCA	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-12.29	-0.44	2.72e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg11952622	chr19:58962976	ZNF324B	-0.5	-10.71	-0.39	9.77e-25	Uric acid clearance;
BRCA	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg08601574	chr20:25228251	PYGB	0.33	8.2	0.31	1.3e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18876405	chr7:65276391	NA	0.52	11.74	0.42	5.66e-29	Aortic root size;
BRCA	trans	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg15017067	chr4:17643749	FAM184B	-0.28	-7.83	-0.3	1.99e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg23950597	chr19:37808831	NA	-0.62	-11.59	-0.42	2.48e-28	Coronary artery calcification;
BRCA	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	0.35	8.45	0.32	2.04e-16	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs3849570	1.000	rs3772882	chr3:81808602	C/A	cg07356753	chr3:81810745	GBE1	-0.45	-10.63	-0.39	2.14e-24	Waist circumference;Body mass index;
BRCA	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg23978390	chr7:1156363	C7orf50	0.38	9.12	0.34	9.98e-19	Longevity;Endometriosis;
BRCA	cis	rs72772090	0.522	rs76590269	chr5:95996410	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-8.5	-0.32	1.3e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.86	0.45	7.85e-34	Bipolar disorder;
BRCA	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg10523679	chr1:76189770	ACADM	0.78	18.71	0.59	1.25e-62	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg15485101	chr11:133734466	NA	-0.42	-10.48	-0.38	8.34e-24	Childhood ear infection;
BRCA	trans	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.51	0.5	1.93e-41	Exhaled nitric oxide output;
BRCA	cis	rs12579753	0.917	rs7138895	chr12:82203280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.48	-8.4	-0.32	2.96e-16	Resting heart rate;
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.53	-11.52	-0.41	4.96e-28	Longevity;Endometriosis;
BRCA	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg06547715	chr2:218990976	CXCR2	0.32	7.89	0.3	1.3e-14	Ulcerative colitis;
BRCA	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.73	-0.5	1.74e-42	Total cholesterol levels;
BRCA	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18876405	chr7:65276391	NA	0.71	18.61	0.59	4.39e-62	Calcium levels;
BRCA	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-16.18	-0.54	1.39e-49	Heart rate;
BRCA	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.76	0.36	4.62e-21	Bipolar disorder;
BRCA	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg18016565	chr1:150552671	MCL1	0.35	8.43	0.32	2.25e-16	Tonsillectomy;
BRCA	cis	rs701145	0.585	rs1727953	chr3:153871392	G/T	cg17054900	chr3:154042577	DHX36	0.55	9.34	0.35	1.58e-19	Coronary artery disease;
BRCA	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg16339924	chr4:17578868	LAP3	0.58	13.97	0.48	6.48e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.58	0.55	1.3e-51	Colorectal cancer;
BRCA	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.14	0.46	4.34e-35	Bipolar disorder;
BRCA	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.56	-0.32	8.45e-17	Menopause (age at onset);
BRCA	cis	rs701145	0.556	rs355771	chr3:154039385	G/C	cg12800244	chr3:153838788	SGEF	0.44	8.66	0.32	3.98e-17	Coronary artery disease;
BRCA	cis	rs7011049	1.000	rs72643577	chr8:53846358	A/T	cg26025543	chr8:53854495	NA	0.55	9.57	0.35	2.31e-20	Systolic blood pressure;
BRCA	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg24642844	chr7:1081250	C7orf50	-0.74	-13.87	-0.48	1.88e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4363385	0.818	rs1048296	chr1:153012240	A/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.82	-13.66	-0.48	1.78e-37	Platelet count;
BRCA	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg23708337	chr7:1209742	NA	0.64	8.74	0.33	2.05e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg15133208	chr4:90757351	SNCA	-0.38	-7.82	-0.3	2.14e-14	Neuroticism;
BRCA	cis	rs7833986	0.501	rs72653978	chr8:57018393	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	12.93	0.46	3.74e-34	Height;
BRCA	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.6	-12.55	-0.44	1.86e-32	Lymphocyte counts;
BRCA	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.29	-0.31	6.69e-16	Gut microbiome composition (summer);
BRCA	cis	rs290268	0.838	rs1333635	chr9:93566406	A/G	cg02608019	chr9:93564028	SYK	0.56	12.4	0.44	8.82e-32	Platelet count;
BRCA	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg18301423	chr5:131593218	PDLIM4	0.35	8.75	0.33	1.93e-17	Acylcarnitine levels;
BRCA	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg10223061	chr2:219282414	VIL1	0.28	7.94	0.3	8.93e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.41	-0.47	2.55e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg04705435	chr11:17411270	KCNJ11	0.44	9.4	0.35	9.82e-20	Type 2 diabetes;
BRCA	cis	rs1691799	0.836	rs1184552	chr12:66756215	A/G	cg16791601	chr12:66731901	HELB	-0.66	-18.01	-0.58	6.19e-59	White blood cell count (basophil);
BRCA	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg27432699	chr2:27873401	GPN1	0.45	9.3	0.35	2.19e-19	Oral cavity cancer;
BRCA	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg06360820	chr2:242988706	NA	-0.85	-15.11	-0.51	2.45e-44	Obesity-related traits;
BRCA	cis	rs7267979	0.844	rs2257649	chr20:25263457	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.28	7.85	0.3	1.74e-14	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.41	0.35	8.46e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4363385	0.693	rs608509	chr1:153034650	G/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.3	-0.31	6.2e-16	Inflammatory skin disease;
BRCA	cis	rs6901250	0.851	rs339362	chr6:117165370	A/C	cg12892004	chr6:117198278	RFX6	-0.5	-11.43	-0.41	1.15e-27	C-reactive protein levels;
BRCA	trans	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg07461501	chr17:79650226	HGS;ARL16	0.4	10.09	0.37	2.53e-22	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg02951883	chr7:2050386	MAD1L1	-0.57	-13.19	-0.46	2.53e-35	Bipolar disorder and schizophrenia;
BRCA	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg09754948	chr16:28834200	ATXN2L	0.46	8.59	0.32	6.53e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7560272	0.723	rs7566315	chr2:73791808	C/T	cg20560298	chr2:73613845	ALMS1	-0.41	-11.52	-0.41	5.08e-28	Schizophrenia;
BRCA	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg03146154	chr1:46216737	IPP	0.45	10.04	0.37	4.15e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4660306	0.884	rs7543076	chr1:45964238	T/C	cg24296786	chr1:45957014	TESK2	0.42	8.42	0.32	2.52e-16	Homocysteine levels;
BRCA	cis	rs7833986	0.501	rs2719258	chr8:56941389	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.67	13.11	0.46	5.97e-35	Height;
BRCA	trans	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg06521331	chr12:34319734	NA	-0.52	-9.35	-0.35	1.41e-19	Bladder cancer;
BRCA	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg25237894	chr2:233734115	C2orf82	-0.41	-11.81	-0.42	3.04e-29	Coronary artery disease;
BRCA	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.29	-0.38	4.31e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg04450456	chr4:17643702	FAM184B	-0.34	-9.9	-0.36	1.4e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.95	14.43	0.5	4.75e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg08847533	chr14:75593920	NEK9	-0.84	-21.75	-0.65	6.46e-79	Height;
BRCA	trans	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg25206134	chr2:45395956	NA	0.53	8.94	0.33	4.23e-18	Bipolar disorder;
BRCA	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg22705602	chr4:152727874	NA	-0.33	-8.26	-0.31	8.67e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg24562669	chr7:97807699	LMTK2	0.45	12.08	0.43	2.16e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg15485101	chr11:133734466	NA	-0.39	-9.87	-0.36	1.81e-21	Childhood ear infection;
BRCA	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	15.6	0.53	9.49e-47	Coronary artery disease;
BRCA	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg16576597	chr16:28551801	NUPR1	0.35	8.8	0.33	1.32e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6121246	0.559	rs6121172	chr20:30296095	A/C	cg21427119	chr20:30132790	HM13	-0.35	-7.9	-0.3	1.18e-14	Mean corpuscular hemoglobin;
BRCA	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg15448220	chr1:150897856	SETDB1	0.35	7.9	0.3	1.22e-14	Melanoma;
BRCA	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg15212455	chr7:39170539	POU6F2	0.39	8.31	0.31	5.54e-16	IgG glycosylation;
BRCA	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	7.94	0.3	9.05e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3784262	0.904	rs3784260	chr15:58253269	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.44	-11.8	-0.42	3.28e-29	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg26384229	chr12:38710491	ALG10B	0.64	14.93	0.51	1.8e-43	Bladder cancer;
BRCA	cis	rs8022179	0.566	rs62006258	chr14:103838909	A/C	cg12935359	chr14:103987150	CKB	0.45	8.59	0.32	6.69e-17	Monocyte count;
BRCA	cis	rs6815814	0.950	rs5743563	chr4:38806019	A/G	cg02016764	chr4:38805732	TLR1	-0.61	-9.73	-0.36	5.9e-21	Breast cancer;
BRCA	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	4.08e-15	Alzheimer's disease (late onset);
BRCA	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg21724239	chr8:58056113	NA	0.59	9.5	0.35	4.25e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs12760731	0.565	rs7541122	chr1:178199214	G/C	cg00404053	chr1:178313656	RASAL2	0.64	7.9	0.3	1.2e-14	Obesity-related traits;
BRCA	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.46	13.56	0.47	5.41e-37	Response to antipsychotic treatment;
BRCA	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg09021430	chr5:549028	NA	-0.65	-13.67	-0.48	1.7e-37	Lung disease severity in cystic fibrosis;
BRCA	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg22920501	chr2:26401640	FAM59B	0.94	16.22	0.54	8.59e-50	Gut microbiome composition (summer);
BRCA	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00166722	chr3:10149974	C3orf24	0.63	11.14	0.4	1.77e-26	Alzheimer's disease;
BRCA	cis	rs7590720	0.840	rs705648	chr2:216933792	C/T	cg12620499	chr2:216877984	MREG	0.71	17.4	0.57	8.81e-56	Alcohol dependence;
BRCA	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11644478	chr21:40555479	PSMG1	0.85	19.32	0.61	7.99e-66	Cognitive function;
BRCA	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg10729496	chr3:10149963	C3orf24	0.47	7.83	0.3	2.04e-14	Alzheimer's disease;
BRCA	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	13.47	0.47	1.43e-36	Mean platelet volume;
BRCA	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg13010199	chr12:38710504	ALG10B	0.44	9.01	0.34	2.44e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg24642439	chr20:33292090	TP53INP2	-0.44	-9.12	-0.34	1e-18	Glomerular filtration rate (creatinine);
BRCA	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg06784218	chr1:46089804	CCDC17	0.51	12.23	0.44	4.9e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03452623	chr4:187889614	NA	-0.31	-10.11	-0.37	2.26e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg14675211	chr2:100938903	LONRF2	0.38	8.34	0.31	4.63e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-11.1	-0.4	2.77e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12541635	0.934	rs1353450	chr8:107035120	A/G	cg10147462	chr8:107024639	NA	-0.38	-10.43	-0.38	1.28e-23	Age of smoking initiation;
BRCA	cis	rs897080	0.552	rs1085442	chr2:44635454	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	8.89	0.33	6.35e-18	Height;
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-10.89	-0.4	1.96e-25	Longevity;Endometriosis;
BRCA	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg23711669	chr6:146136114	FBXO30	0.72	16.15	0.54	1.91e-49	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg19346786	chr7:2764209	NA	-0.3	-9.43	-0.35	7.72e-20	Height;
BRCA	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-20.02	-0.62	1.4e-69	Systemic lupus erythematosus;
BRCA	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11890956	chr21:40555474	PSMG1	-0.82	-19.6	-0.61	2.48e-67	Cognitive function;
BRCA	cis	rs10503871	0.625	rs13275869	chr8:30310335	T/C	cg26383811	chr8:30366931	RBPMS	0.31	8.17	0.31	1.66e-15	Metabolite levels  (X-11787);
BRCA	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg20891283	chr12:69753455	YEATS4	0.56	11.31	0.41	3.83e-27	Response to diuretic therapy;
BRCA	cis	rs6138458	1.000	rs4273288	chr20:24900873	G/A	cg06937882	chr20:24974362	C20orf3	0.44	8.38	0.31	3.34e-16	Blood protein levels;
BRCA	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg27129171	chr3:47204927	SETD2	-0.69	-16.29	-0.54	3.8e-50	Colorectal cancer;
BRCA	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg14582100	chr15:45693742	SPATA5L1	0.35	11.34	0.41	2.68e-27	Homoarginine levels;
BRCA	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg03188948	chr7:1209495	NA	0.84	11.6	0.42	2.4e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs35995292	0.500	rs1019065	chr7:38939775	C/T	cg19327137	chr7:38886074	VPS41	0.39	12.81	0.45	1.3e-33	Subjective well-being (multi-trait analysis);
BRCA	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg23711669	chr6:146136114	FBXO30	-0.71	-17.03	-0.56	6.36e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03517284	chr6:25882590	NA	-0.45	-10.37	-0.38	2.07e-23	Blood metabolite levels;
BRCA	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg27147174	chr7:100797783	AP1S1	-0.56	-10.86	-0.39	2.57e-25	Life satisfaction;
BRCA	cis	rs3771570	1.000	rs62193256	chr2:242362168	C/T	cg21155796	chr2:242212141	HDLBP	0.61	9.27	0.34	2.73e-19	Prostate cancer;
BRCA	cis	rs727479	0.543	rs6493488	chr15:51513922	G/C	cg19946085	chr15:51559439	CYP19A1	-0.3	-8.3	-0.31	5.99e-16	Estradiol levels;
BRCA	cis	rs758324	0.947	rs1500114	chr5:131138120	C/A	cg06307176	chr5:131281290	NA	0.53	10.27	0.38	5.48e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs4074536	0.796	rs10801990	chr1:116309183	G/A	cg21648376	chr1:116311395	CASQ2	-0.5	-8.79	-0.33	1.36e-17	QRS duration;
BRCA	cis	rs858239	0.539	rs2141306	chr7:23191664	G/A	cg23682824	chr7:23144976	KLHL7	0.41	10.94	0.4	1.21e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	8.62	0.32	5.44e-17	Schizophrenia;
BRCA	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg14019146	chr3:50243930	SLC38A3	0.37	9.02	0.34	2.15e-18	Menarche (age at onset);
BRCA	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg24578937	chr1:2090814	PRKCZ	0.58	17.85	0.58	3.97e-58	Height;
BRCA	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg06238570	chr21:40685208	BRWD1	0.41	8.36	0.31	3.97e-16	Cognitive function;
BRCA	cis	rs815815	0.608	rs815808	chr2:47381097	C/T	cg27223769	chr2:47403360	CALM2	0.44	9.7	0.36	7.58e-21	Dialysis-related mortality;
BRCA	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs67981189	0.896	rs17108804	chr14:71441524	A/G	cg15816911	chr14:71606274	NA	-0.36	-8.14	-0.31	2.09e-15	Schizophrenia;
BRCA	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg24562669	chr7:97807699	LMTK2	0.45	12.14	0.43	1.12e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7147624	1.000	rs2411354	chr14:66062132	T/C	cg03016385	chr14:66212404	NA	-0.57	-8.58	-0.32	7.08e-17	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg09184832	chr6:79620586	NA	-0.53	-11.72	-0.42	7.38e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg26597838	chr10:835615	NA	1.3	21.91	0.65	8.86e-80	Eosinophil percentage of granulocytes;
BRCA	cis	rs2625529	1.000	rs2625529	chr15:72118777	C/G	cg16672083	chr15:72433130	SENP8	0.67	14.42	0.5	5.4e-41	Red blood cell count;
BRCA	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg06636001	chr8:8085503	FLJ10661	0.54	10.13	0.37	1.79e-22	Retinal vascular caliber;
BRCA	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg26384229	chr12:38710491	ALG10B	0.55	11.69	0.42	9.73e-29	Morning vs. evening chronotype;
BRCA	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23583168	chr7:148888333	NA	-0.79	-18.42	-0.59	4.27e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg02951883	chr7:2050386	MAD1L1	-0.6	-14.79	-0.5	8.99e-43	Bipolar disorder and schizophrenia;
BRCA	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18876405	chr7:65276391	NA	0.58	13.82	0.48	3.53e-38	Aortic root size;
BRCA	cis	rs870825	0.616	rs4437295	chr4:185643336	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	17.2	0.56	9.11e-55	Blood protein levels;
BRCA	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg07917127	chr4:99064746	C4orf37	0.43	8.0	0.3	5.74e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00166722	chr3:10149974	C3orf24	0.64	11.21	0.41	9.9e-27	Alzheimer's disease;
BRCA	cis	rs7246967	0.673	rs4932782	chr19:22812801	A/G	cg23217946	chr19:22817039	ZNF492	0.47	8.43	0.32	2.22e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg09307838	chr4:120376055	NA	0.72	15.35	0.52	1.79e-45	Corneal astigmatism;
BRCA	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg24112000	chr20:60950667	NA	-0.54	-10.49	-0.38	7.11e-24	Colorectal cancer;
BRCA	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg10523679	chr1:76189770	ACADM	-0.48	-9.37	-0.35	1.2e-19	Daytime sleep phenotypes;
BRCA	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	16.34	0.54	2.16e-50	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.56	-0.52	1.55e-46	Chronic sinus infection;
BRCA	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg12483005	chr1:23474871	LUZP1	0.48	10.46	0.38	9.57e-24	Height;
BRCA	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg14196790	chr5:131705035	SLC22A5	0.44	11.23	0.41	7.91e-27	Blood metabolite levels;
BRCA	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg01304814	chr3:48885189	PRKAR2A	0.62	7.84	0.3	1.9e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.59	-0.42	2.63e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.39	0.49	7.17e-41	Motion sickness;
BRCA	cis	rs9815354	0.812	rs17214945	chr3:41808660	A/C	cg03022575	chr3:42003672	ULK4	0.71	9.78	0.36	3.77e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.19	0.46	2.76e-35	Electroencephalogram traits;
BRCA	cis	rs13053817	1.000	rs73405097	chr22:29855836	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.48	-9.24	-0.34	3.69e-19	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06108461	chr20:60628389	TAF4	-0.83	-18.02	-0.58	5.48e-59	Body mass index;
BRCA	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg02196655	chr2:10830764	NOL10	-0.3	-8.16	-0.31	1.79e-15	Prostate cancer;
BRCA	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.27e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs312273	0.774	rs10879421	chr12:41350775	T/A	cg17827154	chr12:41323612	CNTN1	-0.42	-11.08	-0.4	3.3e-26	Bipolar disorder;
BRCA	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18404041	chr3:52824283	ITIH1	-0.28	-8.15	-0.31	1.95e-15	Electroencephalogram traits;
BRCA	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.33	12.21	0.44	5.52e-31	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs6076960	0.629	rs6054024	chr20:6229282	A/C	cg21095983	chr6:86352623	SYNCRIP	0.42	9.28	0.34	2.53e-19	Smooth-surface caries;
BRCA	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg23029597	chr12:123009494	RSRC2	-0.54	-11.27	-0.41	5.32e-27	Body mass index;
BRCA	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg12935359	chr14:103987150	CKB	-0.59	-13.89	-0.48	1.67e-38	Body mass index;
BRCA	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24110177	chr3:50126178	RBM5	0.41	11.23	0.41	8.18e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg00981070	chr1:2046702	PRKCZ	0.31	8.16	0.31	1.75e-15	Height;
BRCA	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg01733217	chr16:74700730	RFWD3	-0.77	-19.49	-0.61	9.95e-67	Testicular germ cell tumor;
BRCA	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg05623727	chr3:50126028	RBM5	0.48	11.82	0.42	2.58e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-10.63	-0.39	2.01e-24	Myopia (pathological);
BRCA	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg16586182	chr3:47516702	SCAP	0.65	15.07	0.51	3.86e-44	Colorectal cancer;
BRCA	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg03060546	chr3:49711283	APEH	-0.51	-10.27	-0.38	5.2e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg27661571	chr11:113659931	NA	-0.8	-12.01	-0.43	4.07e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs13082711	0.834	rs2172297	chr3:27428423	C/T	cg02860705	chr3:27208620	NA	0.54	10.23	0.38	7.78e-23	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs2797160	1.000	rs1739362	chr6:126020703	A/T	cg05901451	chr6:126070800	HEY2	0.39	9.44	0.35	7.03e-20	Endometrial cancer;
BRCA	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	11.14	0.4	1.78e-26	Schizophrenia;
BRCA	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.35	-9.19	-0.34	5.55e-19	Total body bone mineral density;
BRCA	cis	rs17253792	0.822	rs77315200	chr14:56072643	C/A	cg01858014	chr14:56050164	KTN1	-0.76	-10.52	-0.38	5.5e-24	Putamen volume;
BRCA	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg06159980	chr1:16340746	HSPB7	-0.37	-7.87	-0.3	1.53e-14	Dilated cardiomyopathy;
BRCA	cis	rs36051895	0.632	rs57698263	chr9:5143262	G/A	cg02405213	chr9:5042618	JAK2	-0.45	-8.65	-0.32	4.04e-17	Pediatric autoimmune diseases;
BRCA	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg24069376	chr3:38537580	EXOG	-0.42	-12.16	-0.43	9.9e-31	Electrocardiographic conduction measures;
BRCA	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg18252515	chr7:66147081	NA	-0.55	-11.18	-0.4	1.24e-26	Corneal structure;
BRCA	cis	rs10746514	0.833	rs2356925	chr1:232261769	G/A	cg09506761	chr1:232265262	NA	-0.42	-8.54	-0.32	9.77e-17	Response to statin therapy;
BRCA	cis	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg07460842	chr6:66804631	NA	-1.02	-20.08	-0.62	6.71e-70	Exhaled nitric oxide output;
BRCA	cis	rs701145	0.585	rs1727919	chr3:153788757	G/A	cg17054900	chr3:154042577	DHX36	0.53	9.19	0.34	5.62e-19	Coronary artery disease;
BRCA	trans	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.76	0.39	6.29e-25	Type 2 diabetes;
BRCA	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	29.81	0.76	4.96e-123	Chronic sinus infection;
BRCA	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.11	-0.43	1.53e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg13319975	chr6:146136371	FBXO30	0.35	8.09	0.3	3.08e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg24812749	chr6:127587940	RNF146	0.86	19.78	0.62	2.55e-68	Breast cancer;
BRCA	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg22713356	chr15:30763199	NA	1.17	23.7	0.68	1.43e-89	Uric acid levels;
BRCA	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg20283391	chr11:68216788	NA	-0.45	-8.98	-0.33	3.1e-18	Total body bone mineral density;
BRCA	cis	rs10090774	0.710	rs11166992	chr8:141677470	C/T	cg18440839	chr8:141609380	EIF2C2	-0.25	-8.29	-0.31	6.6e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-14.76	-0.5	1.17e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2304069	1.000	rs216126	chr5:149428424	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.57	12.06	0.43	2.64e-30	HIV-1 control;
BRCA	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg27170947	chr2:26402098	FAM59B	0.92	16.52	0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg04546413	chr19:29218101	NA	0.64	12.33	0.44	1.75e-31	Methadone dose in opioid dependence;
BRCA	cis	rs71636778	0.584	rs17162316	chr1:27177907	C/G	cg12203394	chr1:27248618	NUDC	0.5	7.92	0.3	1.06e-14	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg21475434	chr5:93447410	FAM172A	0.66	9.02	0.34	2.24e-18	Diabetic retinopathy;
BRCA	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.37	-7.85	-0.3	1.76e-14	Longevity;Endometriosis;
BRCA	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg20476274	chr7:133979776	SLC35B4	0.66	19.45	0.61	1.48e-66	Mean platelet volume;
BRCA	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg13256891	chr4:100009986	ADH5	0.53	9.87	0.36	1.75e-21	Smoking initiation;
BRCA	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg05925327	chr15:68127851	NA	0.34	8.34	0.31	4.45e-16	Restless legs syndrome;
BRCA	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg11062466	chr8:58055876	NA	0.41	7.84	0.3	1.84e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs6088813	0.922	rs6088800	chr20:33934437	T/A	cg14752227	chr20:34000481	UQCC	-0.39	-8.43	-0.32	2.34e-16	Height;
BRCA	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.96	0.58	1.14e-58	Fuchs's corneal dystrophy;
BRCA	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg01802117	chr1:53393560	SCP2	-0.35	-8.03	-0.3	4.71e-15	Monocyte count;
BRCA	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg06212747	chr3:49208901	KLHDC8B	0.41	7.84	0.3	1.9e-14	Menarche (age at onset);
BRCA	cis	rs1865760	0.541	rs1436309	chr6:25970109	T/A	cg16482183	chr6:26056742	HIST1H1C	0.53	10.94	0.4	1.18e-25	Height;
BRCA	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg19257562	chr1:2043853	PRKCZ	-0.32	-8.83	-0.33	9.99e-18	Height;
BRCA	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg05340658	chr4:99064831	C4orf37	0.69	17.37	0.57	1.25e-55	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg06521331	chr12:34319734	NA	-0.46	-8.44	-0.32	2.08e-16	Bladder cancer;
BRCA	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg16339924	chr4:17578868	LAP3	-0.56	-13.35	-0.47	4.83e-36	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.66e-15	Menopause (age at onset);
BRCA	cis	rs1568889	0.838	rs6484359	chr11:28262328	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.59	0.63	1.17e-72	Bipolar disorder;
BRCA	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg22535103	chr8:58192502	C8orf71	-0.46	-8.24	-0.31	9.84e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg23625390	chr15:77176239	SCAPER	0.39	9.61	0.36	1.62e-20	Blood metabolite levels;
BRCA	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg23711669	chr6:146136114	FBXO30	-0.71	-16.78	-0.55	1.24e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg07169764	chr2:136633963	MCM6	1.23	26.49	0.72	6.67e-105	Corneal structure;
BRCA	cis	rs3820928	0.874	rs4675134	chr2:227843489	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.21	-0.31	1.19e-15	Pulmonary function;
BRCA	cis	rs11874712	0.965	rs28694780	chr18:43665338	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.18	0.31	1.57e-15	Migraine - clinic-based;
BRCA	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg22920501	chr2:26401640	FAM59B	-0.81	-13.19	-0.46	2.66e-35	Gut microbiome composition (summer);
BRCA	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg09307838	chr4:120376055	NA	0.76	17.1	0.56	2.9e-54	Corneal astigmatism;
BRCA	cis	rs394563	0.601	rs439495	chr6:149793224	A/G	cg07828024	chr6:149772892	ZC3H12D	0.3	8.46	0.32	1.83e-16	Dupuytren's disease;
BRCA	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg07606381	chr6:8435919	SLC35B3	-0.64	-14.12	-0.49	1.31e-39	Motion sickness;
BRCA	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg24558204	chr6:135376177	HBS1L	-0.47	-12.99	-0.46	2.15e-34	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg11764359	chr7:65958608	NA	0.65	11.55	0.42	3.6e-28	Aortic root size;
BRCA	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.61	-15.19	-0.51	1.07e-44	Longevity;Endometriosis;
BRCA	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.51	-0.32	1.19e-16	Monocyte percentage of white cells;
BRCA	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.34	-9.29	-0.34	2.45e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.55	0.57	1.5e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.3	0.41	3.86e-27	Electroencephalogram traits;
BRCA	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.66	-0.53	4.96e-47	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg09307838	chr4:120376055	NA	0.64	13.91	0.48	1.32e-38	Corneal astigmatism;
BRCA	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg10253484	chr15:75165896	SCAMP2	-0.51	-9.84	-0.36	2.38e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg27446573	chr6:127587934	RNF146	0.9	21.24	0.64	3.9e-76	Breast cancer;
BRCA	cis	rs4975616	0.807	rs28379291	chr5:1313701	A/G	cg07493874	chr5:1342172	CLPTM1L	0.45	12.15	0.43	1.09e-30	Lung cancer;
BRCA	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg11301795	chr4:187892539	NA	-0.31	-9.97	-0.37	7.56e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13126279	chr21:47581558	C21orf56	-0.45	-9.9	-0.36	1.4e-21	Testicular germ cell tumor;
BRCA	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg22713356	chr15:30763199	NA	1.3	24.75	0.7	2.51e-95	Uric acid levels;
BRCA	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg22467129	chr15:76604101	ETFA	-0.41	-9.14	-0.34	8.13e-19	Blood metabolite levels;
BRCA	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg10295955	chr4:187884368	NA	0.73	18.09	0.58	2.35e-59	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg12751644	chr20:60527061	NA	-0.33	-7.95	-0.3	8.44e-15	Body mass index;
BRCA	cis	rs17253792	0.822	rs17683728	chr14:56060389	C/T	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs312274	0.508	rs11178858	chr12:41267529	A/G	cg17827154	chr12:41323612	CNTN1	-0.36	-8.8	-0.33	1.3e-17	Metabolite levels  (X-11787);
BRCA	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.09	0.51	2.99e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.89	-0.36	1.49e-21	IgG glycosylation;
BRCA	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg22307297	chr20:60903441	LAMA5	0.34	9.35	0.35	1.47e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs4588572	0.601	rs10070202	chr5:77792462	A/C	cg11547950	chr5:77652471	NA	-0.5	-8.95	-0.33	3.93e-18	Triglycerides;
BRCA	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08280861	chr8:58055591	NA	0.54	8.82	0.33	1.12e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4409675	0.576	rs7520860	chr1:28232952	C/A	cg23691781	chr1:28212827	C1orf38	0.33	10.95	0.4	1.06e-25	Corneal astigmatism;
BRCA	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg20503657	chr10:835505	NA	1.3	21.68	0.65	1.61e-78	Eosinophil percentage of granulocytes;
BRCA	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg18402987	chr7:1209562	NA	0.82	11.83	0.42	2.38e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.63	-0.32	4.88e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs8028182	0.636	rs4545784	chr15:75755651	A/G	cg20655648	chr15:75932815	IMP3	0.41	8.01	0.3	5.5e-15	Sudden cardiac arrest;
BRCA	cis	rs332507	0.830	rs10804562	chr3:124377196	C/T	cg05980111	chr3:124395277	KALRN	0.34	8.14	0.31	2.09e-15	Plateletcrit;
BRCA	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg16576597	chr16:28551801	NUPR1	0.33	8.83	0.33	9.92e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs754466	0.580	rs2289309	chr10:79571108	C/T	cg17075019	chr10:79541650	NA	-0.86	-23.42	-0.68	4.49e-88	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18357526	chr6:26021779	HIST1H4A	0.51	9.48	0.35	4.78e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg25801113	chr15:45476975	SHF	0.31	7.83	0.3	2e-14	Uric acid levels;
BRCA	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg08859206	chr1:53392774	SCP2	-0.42	-8.46	-0.32	1.85e-16	Monocyte count;
BRCA	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg10932868	chr11:921992	NA	0.35	8.03	0.3	4.74e-15	Alzheimer's disease (late onset);
BRCA	trans	rs57046232	0.552	rs6038449	chr20:6337980	C/T	cg21095983	chr6:86352623	SYNCRIP	0.38	8.06	0.3	3.86e-15	Colorectal cancer;
BRCA	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12292205	chr6:26970375	C6orf41	-0.49	-8.3	-0.31	6.14e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs997295	0.520	rs4776971	chr15:68081097	C/A	cg08079166	chr15:68083412	MAP2K5	0.31	8.29	0.31	6.61e-16	Motion sickness;
BRCA	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg22972055	chr7:872293	UNC84A	0.38	8.34	0.31	4.73e-16	Cerebrospinal P-tau181p levels;
BRCA	trans	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.0	0.3	5.96e-15	Corneal astigmatism;
BRCA	cis	rs36051895	0.664	rs3780374	chr9:5099677	G/A	cg02405213	chr9:5042618	JAK2	-0.48	-8.59	-0.32	6.75e-17	Pediatric autoimmune diseases;
BRCA	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg05340658	chr4:99064831	C4orf37	-0.48	-10.94	-0.4	1.22e-25	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	13.19	0.46	2.72e-35	Bone mineral density;
BRCA	cis	rs6543140	0.964	rs13383602	chr2:103085962	C/T	cg04239558	chr2:103089729	SLC9A4	0.35	9.9	0.36	1.39e-21	Blood protein levels;
BRCA	trans	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg21659725	chr3:3221576	CRBN	-0.46	-9.92	-0.37	1.15e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02176678	chr2:219576539	TTLL4	-0.48	-12.13	-0.43	1.3e-30	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg21775007	chr8:11205619	TDH	0.61	11.78	0.42	3.94e-29	Retinal vascular caliber;
BRCA	trans	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	10.33	0.38	3.1e-23	Type 2 diabetes;
BRCA	cis	rs10789491	0.953	rs11211337	chr1:47133811	T/C	cg15501359	chr1:47185051	KIAA0494	0.66	18.07	0.58	2.88e-59	Response to hepatitis C treatment;
BRCA	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg27170947	chr2:26402098	FAM59B	-0.95	-16.91	-0.56	2.58e-53	Gut microbiome composition (summer);
BRCA	cis	rs7781557	1.000	rs11496066	chr7:102486254	T/C	cg18108683	chr7:102477205	FBXL13	-0.43	-7.81	-0.3	2.44e-14	Colorectal adenoma (advanced);
BRCA	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.74e-16	Menopause (age at onset);
BRCA	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg26168224	chr5:2018326	NA	0.63	17.47	0.57	3.54e-56	Gut microbiome composition (winter);
BRCA	cis	rs1003719	0.586	rs2298685	chr21:38533390	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.54	-0.5	1.43e-41	Eye color traits;
BRCA	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg22467129	chr15:76604101	ETFA	0.53	12.41	0.44	7.84e-32	Blood metabolite levels;
BRCA	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	16.0	0.53	1.06e-48	Bone mineral density;
BRCA	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg26384229	chr12:38710491	ALG10B	0.56	11.64	0.42	1.58e-28	Morning vs. evening chronotype;
BRCA	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg04267008	chr7:1944627	MAD1L1	-0.38	-8.34	-0.31	4.53e-16	Schizophrenia;
BRCA	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg11266682	chr4:10021025	SLC2A9	0.48	12.5	0.44	3.17e-32	Bone mineral density;
BRCA	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.41	-0.32	2.67e-16	Schizophrenia;
BRCA	trans	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg25214090	chr10:38739885	LOC399744	0.56	12.45	0.44	5.14e-32	Corneal astigmatism;
BRCA	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg07817648	chr10:79422355	NA	-0.66	-12.38	-0.44	1.09e-31	Bone mineral density;
BRCA	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg03425785	chr20:62221387	GMEB2	0.51	8.27	0.31	7.88e-16	Glioblastoma;
BRCA	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg04267008	chr7:1944627	MAD1L1	-0.55	-10.97	-0.4	8.66e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs3960554	0.673	rs112680895	chr7:75623520	G/A	cg17325771	chr7:75508891	RHBDD2	-0.32	-7.87	-0.3	1.48e-14	Eotaxin levels;
BRCA	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg19539972	chr4:7069911	GRPEL1	0.7	17.16	0.56	1.42e-54	Monocyte percentage of white cells;
BRCA	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.51	-0.47	9.34e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg05373962	chr22:49881684	NA	-0.31	-8.5	-0.32	1.38e-16	Monocyte count;Monocyte percentage of white cells;
BRCA	cis	rs775227	0.574	rs55693215	chr3:113064094	T/C	cg18753928	chr3:113234510	CCDC52	-0.58	-9.44	-0.35	6.65e-20	Dental caries;
BRCA	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg02951883	chr7:2050386	MAD1L1	-0.55	-12.43	-0.44	6.65e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg01448562	chr3:133502909	NA	-0.65	-15.37	-0.52	1.4e-45	Iron status biomarkers;
BRCA	cis	rs9420	0.528	rs73480556	chr11:57400462	G/C	cg19752551	chr11:57585705	CTNND1	-0.38	-9.61	-0.36	1.69e-20	Schizophrenia;
BRCA	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg23033748	chr14:75592666	NEK9	-0.44	-10.37	-0.38	2.06e-23	Height;
BRCA	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	8.65	0.32	4e-17	Multiple sclerosis;
BRCA	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg07741184	chr6:167504864	NA	0.33	9.87	0.36	1.8e-21	Primary biliary cholangitis;
BRCA	cis	rs701145	0.938	rs355769	chr3:154042550	T/C	cg17054900	chr3:154042577	DHX36	0.68	11.88	0.43	1.56e-29	Coronary artery disease;
BRCA	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg05234568	chr11:5960015	NA	-0.47	-9.75	-0.36	4.86e-21	DNA methylation (variation);
BRCA	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg19678392	chr7:94953810	PON1	-0.41	-8.77	-0.33	1.66e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg21573476	chr21:45109991	RRP1B	-0.37	-9.64	-0.36	1.32e-20	Mean corpuscular volume;
BRCA	cis	rs17401966	0.838	rs12125535	chr1:10350849	T/A	cg03954927	chr1:10346856	KIF1B	0.44	13.78	0.48	5.15e-38	Hepatocellular carcinoma;
BRCA	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg12311346	chr5:56204834	C5orf35	0.41	8.4	0.32	2.82e-16	Coronary artery disease;
BRCA	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg24642439	chr20:33292090	TP53INP2	0.47	10.44	0.38	1.19e-23	Glomerular filtration rate (creatinine);
BRCA	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg02951883	chr7:2050386	MAD1L1	-0.6	-15.49	-0.52	3.48e-46	Bipolar disorder and schizophrenia;
BRCA	cis	rs4285028	0.747	rs3732410	chr3:121415720	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-16.36	-0.54	1.66e-50	Multiple sclerosis;
BRCA	cis	rs12618769	0.597	rs3754891	chr2:99088018	T/C	cg10123293	chr2:99228465	UNC50	0.41	8.52	0.32	1.14e-16	Bipolar disorder;
BRCA	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg14675211	chr2:100938903	LONRF2	0.52	11.47	0.41	8.1e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs752010	0.808	rs7529858	chr1:42086606	G/C	cg06885757	chr1:42089581	HIVEP3	0.3	10.72	0.39	8.97e-25	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg04362960	chr10:104952993	NT5C2	0.4	9.64	0.36	1.23e-20	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	16.39	0.54	1.2e-50	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg06521331	chr12:34319734	NA	-0.65	-11.93	-0.43	9.53e-30	Morning vs. evening chronotype;
BRCA	trans	rs4596713	0.568	rs7038833	chr9:71748097	C/T	cg16512924	chr15:28394682	HERC2	0.4	9.65	0.36	1.13e-20	Headache;
BRCA	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg03808351	chr9:123631620	PHF19	-0.6	-12.8	-0.45	1.48e-33	Birth weight;
BRCA	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.87	0.56	4.53e-53	Colorectal cancer;
BRCA	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg06115741	chr20:33292138	TP53INP2	-0.4	-8.8	-0.33	1.25e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	12.11	0.43	1.58e-30	Tonsillectomy;
BRCA	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg03452623	chr4:187889614	NA	-0.35	-11.63	-0.42	1.71e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.747	rs2339496	chr1:152970719	C/T	cg24667326	chr1:152973720	SPRR3	-0.35	-9.85	-0.36	2.13e-21	Inflammatory skin disease;
BRCA	cis	rs1882538	0.569	rs11562036	chr7:133076862	T/C	cg10665199	chr7:133106180	EXOC4	0.44	9.21	0.34	4.69e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs2354432	0.607	rs6703847	chr1:146669444	G/A	cg25205988	chr1:146714368	CHD1L	0.86	10.6	0.39	2.66e-24	Mitochondrial DNA levels;
BRCA	cis	rs11971779	0.941	rs28395455	chr7:139035986	A/G	cg07862535	chr7:139043722	LUC7L2	0.4	9.56	0.35	2.41e-20	Diisocyanate-induced asthma;
BRCA	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.3e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg17971929	chr21:40555470	PSMG1	-0.47	-10.26	-0.38	5.66e-23	Menarche (age at onset);
BRCA	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg24069376	chr3:38537580	EXOG	0.31	8.69	0.32	3.12e-17	Electrocardiographic conduction measures;
BRCA	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg19418458	chr7:158789849	NA	-0.41	-9.07	-0.34	1.46e-18	Facial morphology (factor 20);
BRCA	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg23649088	chr2:200775458	C2orf69	-0.62	-10.36	-0.38	2.39e-23	Schizophrenia;
BRCA	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg04450456	chr4:17643702	FAM184B	0.32	9.36	0.35	1.33e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs1941687	0.563	rs2032189	chr18:31332200	T/A	cg27147174	chr7:100797783	AP1S1	-0.44	-8.6	-0.32	6.24e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.22	-0.37	8.01e-23	Schizophrenia;
BRCA	cis	rs752010	0.806	rs1109255	chr1:42091708	C/T	cg06885757	chr1:42089581	HIVEP3	0.28	10.15	0.37	1.57e-22	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg16230307	chr14:35515116	FAM177A1	0.75	15.43	0.52	6.65e-46	Psoriasis;
BRCA	cis	rs10193935	0.901	rs871045	chr2:42609431	G/C	cg27598129	chr2:42591480	NA	-0.84	-14.07	-0.49	2.42e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.78	-0.42	4.09e-29	Bipolar disorder;
BRCA	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg21951975	chr1:209979733	IRF6	0.4	9.3	0.35	2.28e-19	Cleft lip with or without cleft palate;
BRCA	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11890956	chr21:40555474	PSMG1	0.94	23.2	0.68	7.77e-87	Cognitive function;
BRCA	cis	rs965469	0.947	rs6051692	chr20:3244098	T/C	cg25506879	chr20:3388711	C20orf194	-0.55	-10.54	-0.38	4.7e-24	IFN-related cytopenia;
BRCA	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg24562669	chr7:97807699	LMTK2	0.63	18.75	0.6	7.64e-63	Breast cancer;
BRCA	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-20.03	-0.62	1.28e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.09	0.34	1.28e-18	Tonsillectomy;
BRCA	cis	rs11997175	0.766	rs4273817	chr8:33702686	C/T	ch.8.33884649F	chr8:33765107	NA	0.35	8.32	0.31	5.3e-16	Body mass index;
BRCA	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg26031613	chr14:104095156	KLC1	0.75	16.48	0.55	4.1e-51	Body mass index;
BRCA	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg12463550	chr7:65579703	CRCP	-0.37	-7.95	-0.3	8.25e-15	Aortic root size;
BRCA	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg20628663	chr10:43360327	NA	-0.71	-13.64	-0.47	2.25e-37	Blood protein levels;
BRCA	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg24296786	chr1:45957014	TESK2	-0.47	-10.67	-0.39	1.44e-24	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg14789911	chr21:47582049	C21orf56	0.38	7.98	0.3	6.75e-15	Testicular germ cell tumor;
BRCA	cis	rs3820928	0.967	rs4675118	chr2:227773157	C/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.45	-0.32	1.9e-16	Pulmonary function;
BRCA	trans	rs1459104	1.000	rs12788969	chr11:55253357	G/T	cg15704280	chr7:45808275	SEPT13	0.65	8.15	0.31	1.85e-15	Body mass index;
BRCA	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00166722	chr3:10149974	C3orf24	0.56	10.98	0.4	7.86e-26	Alzheimer's disease;
BRCA	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.57	8.93	0.33	4.48e-18	Lung function (FEV1/FVC);
BRCA	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg10792982	chr14:105748885	BRF1	0.5	11.4	0.41	1.55e-27	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.84	0.55	5.87e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg12373951	chr3:133503437	NA	0.53	12.58	0.45	1.41e-32	Iron status biomarkers;
BRCA	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-12.69	-0.45	4.41e-33	Response to antipsychotic treatment;
BRCA	cis	rs4363385	0.818	rs57311099	chr1:153005597	A/C	cg24667326	chr1:152973720	SPRR3	-0.34	-9.26	-0.34	3.19e-19	Inflammatory skin disease;
BRCA	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24110177	chr3:50126178	RBM5	-0.36	-9.59	-0.35	1.96e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs295140	0.605	rs10931893	chr2:201114652	A/G	cg23649088	chr2:200775458	C2orf69	-0.39	-8.15	-0.31	1.93e-15	QT interval;
BRCA	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.35	0.38	2.53e-23	Motion sickness;
BRCA	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg13010199	chr12:38710504	ALG10B	0.51	10.13	0.37	1.85e-22	Bladder cancer;
BRCA	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg04166393	chr7:2884313	GNA12	0.46	8.72	0.33	2.42e-17	Height;
BRCA	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg12927641	chr6:109611667	NA	-0.36	-8.96	-0.33	3.66e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-8.14	-0.31	2.06e-15	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg04851639	chr8:1020857	NA	-0.32	-8.82	-0.33	1.05e-17	Schizophrenia;
BRCA	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg00958927	chr1:175162553	KIAA0040	0.21	7.92	0.3	1.03e-14	Alcohol dependence;
BRCA	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.03	-0.34	1.97e-18	Mood instability;
BRCA	cis	rs1568889	0.938	rs7128045	chr11:28190180	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.76	0.5	1.17e-42	Bipolar disorder;
BRCA	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg08847533	chr14:75593920	NEK9	-0.88	-21.91	-0.65	8.97e-80	Height;
BRCA	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	21.71	0.65	1.08e-78	Platelet count;
BRCA	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg25036284	chr2:26402008	FAM59B	0.88	15.16	0.51	1.48e-44	Gut microbiome composition (summer);
BRCA	cis	rs4363385	0.791	rs489323	chr1:153006047	G/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.26	-0.34	3.19e-19	Inflammatory skin disease;
BRCA	cis	rs2404602	0.552	rs11072613	chr15:76961526	A/C	cg23625390	chr15:77176239	SCAPER	-0.52	-11.15	-0.4	1.71e-26	Blood metabolite levels;
BRCA	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg10664184	chr19:17420304	DDA1	-0.36	-10.11	-0.37	2.24e-22	Systemic lupus erythematosus;
BRCA	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-9.04	-0.34	1.88e-18	Tonsillectomy;
BRCA	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg23029597	chr12:123009494	RSRC2	-0.61	-11.79	-0.42	3.46e-29	Body mass index;
BRCA	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg01448562	chr3:133502909	NA	-0.59	-14.23	-0.49	4.11e-40	Iron status biomarkers;
BRCA	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.45	-11.1	-0.4	2.76e-26	Height;
BRCA	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg16405210	chr4:1374714	KIAA1530	-0.43	-9.67	-0.36	9.69e-21	Longevity;
BRCA	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg12310025	chr6:25882481	NA	-0.5	-12.06	-0.43	2.52e-30	Blood metabolite levels;
BRCA	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.57	-0.35	2.21e-20	Hip circumference adjusted for BMI;
BRCA	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg19622623	chr12:86230825	RASSF9	-0.33	-8.84	-0.33	9.37e-18	Major depressive disorder;
BRCA	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg04374321	chr14:90722782	PSMC1	0.43	9.26	0.34	3.06e-19	Gut microbiota (bacterial taxa);
BRCA	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	13.92	0.48	1.2e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg05343316	chr1:45956843	TESK2	0.69	13.83	0.48	3.08e-38	Platelet count;
BRCA	cis	rs3925075	0.553	rs3087796	chr16:31343653	A/G	cg02846316	chr16:31340340	ITGAM	0.43	8.73	0.33	2.22e-17	IgA nephropathy;
BRCA	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.35e-15	Prostate cancer;
BRCA	cis	rs113835537	0.529	rs75685325	chr11:66235242	A/G	cg24851651	chr11:66362959	CCS	0.51	8.79	0.33	1.32e-17	Airway imaging phenotypes;
BRCA	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg03585969	chr10:35415529	CREM	0.55	11.37	0.41	2.17e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg04586622	chr2:25135609	ADCY3	0.46	11.61	0.42	2.11e-28	Body mass index;
BRCA	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg23173402	chr1:227635558	NA	0.5	9.12	0.34	9.47e-19	Major depressive disorder;
BRCA	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg13010199	chr12:38710504	ALG10B	-0.4	-8.58	-0.32	6.91e-17	Bladder cancer;
BRCA	cis	rs41005	0.967	rs41006	chr2:8109348	A/G	cg03155496	chr2:8117019	LOC339788	0.56	14.96	0.51	1.26e-43	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg13385521	chr17:29058706	SUZ12P	-0.67	-9.39	-0.35	1.05e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg08514558	chr10:81106712	PPIF	0.35	8.42	0.32	2.43e-16	Height;
BRCA	cis	rs6594499	0.872	rs10043631	chr5:110443228	C/T	cg04022379	chr5:110408740	TSLP	0.35	8.1	0.31	2.81e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs6987853	0.787	rs2923437	chr8:42425399	A/C	cg09913449	chr8:42400586	C8orf40	0.4	8.89	0.33	6.02e-18	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg15605315	chr1:45957053	TESK2	0.5	9.99	0.37	6.14e-22	High light scatter reticulocyte count;
BRCA	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg27129171	chr3:47204927	SETD2	0.73	17.76	0.57	1.15e-57	Colorectal cancer;
BRCA	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg12311346	chr5:56204834	C5orf35	-0.46	-9.15	-0.34	7.58e-19	Coronary artery disease;
BRCA	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg07138768	chr7:917805	C7orf20	0.28	8.09	0.3	3.09e-15	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg10729496	chr3:10149963	C3orf24	0.49	9.14	0.34	8.16e-19	Alzheimer's disease;
BRCA	trans	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg11693508	chr17:37793320	STARD3	0.48	10.28	0.38	4.99e-23	Bipolar disorder;
BRCA	cis	rs13082711	0.863	rs34611823	chr3:27500344	A/G	cg02860705	chr3:27208620	NA	0.53	10.58	0.39	3.1e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.12	-0.31	2.44e-15	Bipolar disorder;
BRCA	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg06618935	chr21:46677482	NA	-0.38	-8.6	-0.32	6.24e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg06484146	chr7:12443880	VWDE	-0.75	-10.68	-0.39	1.29e-24	Coronary artery disease;
BRCA	cis	rs250677	0.522	rs2895837	chr5:148357535	C/T	cg18129178	chr5:148520854	ABLIM3	0.54	10.4	0.38	1.58e-23	Breast cancer;
BRCA	cis	rs9462027	0.628	rs2814961	chr6:34706951	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.87	-0.3	1.55e-14	Systemic lupus erythematosus;
BRCA	trans	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg26043149	chr18:55253948	FECH	0.39	8.38	0.31	3.34e-16	Bone mineral density;
BRCA	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg15705551	chr2:10952987	PDIA6	0.53	9.52	0.35	3.45e-20	Cardiac Troponin-T levels;
BRCA	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	10.5	0.38	6.54e-24	Bone mineral density;
BRCA	cis	rs7789940	0.809	rs12533836	chr7:75935622	G/T	cg10167463	chr7:75959203	YWHAG	-0.42	-8.33	-0.31	5.07e-16	Multiple sclerosis;
BRCA	cis	rs897080	0.552	rs1067405	chr2:44674861	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.62	0.36	1.5e-20	Height;
BRCA	cis	rs2580764	0.565	rs2919129	chr2:55216545	G/T	cg09592903	chr2:55203963	RTN4	0.39	9.93	0.37	1.02e-21	Mean platelet volume;
BRCA	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg12219531	chr12:120966889	COQ5	0.53	11.53	0.41	4.63e-28	High light scatter reticulocyte count;
BRCA	cis	rs2645424	0.530	rs1293303	chr8:11720227	C/G	cg21281001	chr8:11725306	CTSB	-0.39	-8.04	-0.3	4.52e-15	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
BRCA	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg18811423	chr2:55921094	PNPT1	0.74	24.19	0.69	2.83e-92	Metabolic syndrome;
BRCA	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg17971929	chr21:40555470	PSMG1	0.6	13.68	0.48	1.55e-37	Cognitive function;
BRCA	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.28	-0.31	7.1e-16	Bipolar disorder;
BRCA	cis	rs9463078	0.845	rs6458419	chr6:45085038	T/C	cg25276700	chr6:44698697	NA	-0.36	-8.19	-0.31	1.38e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs9290065	0.686	rs1839021	chr3:160623669	T/G	cg03342759	chr3:160939853	NMD3	0.43	8.67	0.32	3.42e-17	Kawasaki disease;
BRCA	cis	rs870825	0.616	rs7692104	chr4:185650895	T/G	cg04058563	chr4:185651563	MLF1IP	0.79	17.79	0.58	7.74e-58	Blood protein levels;
BRCA	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg19183879	chr15:85880815	NA	-0.32	-7.89	-0.3	1.29e-14	Coronary artery disease;
BRCA	cis	rs17253792	0.822	rs78988988	chr14:56152404	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-9.53	-0.35	3.34e-20	Putamen volume;
BRCA	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg07080220	chr10:102295463	HIF1AN	0.64	14.77	0.5	1.06e-42	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9308731	0.644	rs3789068	chr2:111909247	A/G	cg04780086	chr2:111875790	ACOXL	0.27	7.81	0.3	2.44e-14	Chronic lymphocytic leukemia;
BRCA	cis	rs12367572	0.796	rs7979141	chr12:45282630	A/T	cg04608330	chr12:45269318	NELL2	-0.62	-13.68	-0.48	1.43e-37	Gut microbiome composition (summer);
BRCA	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg25208724	chr1:156163844	SLC25A44	1.07	35.1	0.81	3.35e-151	Testicular germ cell tumor;
BRCA	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-7.98	-0.3	6.99e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg14582100	chr15:45693742	SPATA5L1	0.29	8.61	0.32	5.82e-17	Homoarginine levels;
BRCA	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg12923728	chr3:195709715	SDHAP1	0.38	7.92	0.3	1.09e-14	Mean corpuscular volume;
BRCA	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21659725	chr3:3221576	CRBN	0.47	11.96	0.43	6.65e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.6	13.8	0.48	4.39e-38	Colorectal cancer;
BRCA	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg05973401	chr12:123451056	ABCB9	0.42	9.25	0.34	3.25e-19	Platelet count;
BRCA	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg20476274	chr7:133979776	SLC35B4	0.7	21.47	0.65	2.12e-77	Mean platelet volume;
BRCA	cis	rs12760731	0.720	rs3791023	chr1:178398092	A/C	cg00404053	chr1:178313656	RASAL2	0.6	7.86	0.3	1.58e-14	Obesity-related traits;
BRCA	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.36	-0.35	1.33e-19	Bipolar disorder;
BRCA	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg08975724	chr8:8085496	FLJ10661	0.5	11.01	0.4	6.27e-26	Mood instability;
BRCA	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg03433033	chr1:76189801	ACADM	0.76	17.06	0.56	4.94e-54	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg17330251	chr7:94953956	PON1	-0.42	-8.87	-0.33	7.37e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs2637266	1.000	rs2395388	chr10:78357203	C/T	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg13114125	chr14:105738426	BRF1	-0.53	-11.02	-0.4	5.39e-26	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	9.02	0.34	2.13e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs629535	0.862	rs2178955	chr8:70045303	C/T	cg21567404	chr3:27674614	NA	1.0	21.1	0.64	2.04e-75	Dupuytren's disease;
BRCA	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg09184832	chr6:79620586	NA	-0.41	-8.24	-0.31	1.01e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg20818283	chr2:191399100	TMEM194B	0.38	8.87	0.33	7.24e-18	Pulse pressure;
BRCA	cis	rs9549260	0.755	rs2721066	chr13:41156188	C/T	cg21288729	chr13:41239152	FOXO1	-0.67	-14.93	-0.51	1.81e-43	Red blood cell count;
BRCA	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg27129171	chr3:47204927	SETD2	-0.7	-16.91	-0.56	2.66e-53	Colorectal cancer;
BRCA	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg05340658	chr4:99064831	C4orf37	0.67	16.75	0.55	1.82e-52	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.35	-7.98	-0.3	6.56e-15	Endometrial cancer;
BRCA	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.3	0.38	4.03e-23	Aortic root size;
BRCA	cis	rs6032067	0.673	rs4522674	chr20:43893276	T/C	cg06407657	chr20:43937138	MATN4;RBPJL	0.3	8.13	0.31	2.3e-15	Blood protein levels;
BRCA	cis	rs7617773	0.780	rs13066044	chr3:48377276	C/T	cg11946769	chr3:48343235	NME6	0.67	13.48	0.47	1.23e-36	Coronary artery disease;
BRCA	cis	rs654950	0.901	rs1885654	chr1:42007188	C/A	cg06885757	chr1:42089581	HIVEP3	-0.33	-10.88	-0.4	1.98e-25	Airway imaging phenotypes;
BRCA	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg12219531	chr12:120966889	COQ5	0.55	11.43	0.41	1.17e-27	High light scatter reticulocyte count;
BRCA	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24549020	chr5:56110836	MAP3K1	0.63	12.79	0.45	1.71e-33	Initial pursuit acceleration;
BRCA	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg13699009	chr12:122356056	WDR66	0.35	7.99	0.3	6.12e-15	Mean platelet volume;
BRCA	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg13047869	chr3:10149882	C3orf24	0.53	9.72	0.36	6.19e-21	Alzheimer's disease;
BRCA	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08219700	chr8:58056026	NA	0.58	9.7	0.36	7.56e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11890956	chr21:40555474	PSMG1	0.83	13.8	0.48	3.98e-38	Cognitive function;
BRCA	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg20891283	chr12:69753455	YEATS4	0.56	14.26	0.49	2.96e-40	Blood protein levels;
BRCA	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	11.02	0.4	5.84e-26	Monocyte percentage of white cells;
BRCA	cis	rs3820928	0.935	rs113195824	chr2:227769139	A/G	cg05526886	chr2:227700861	RHBDD1	-0.38	-7.83	-0.3	2.03e-14	Pulmonary function;
BRCA	cis	rs4363385	0.747	rs1055935	chr1:152975941	C/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.24	-0.31	1.01e-15	Inflammatory skin disease;
BRCA	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.58	12.24	0.44	4.16e-31	Lymphocyte percentage of white cells;
BRCA	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg13010199	chr12:38710504	ALG10B	-0.42	-9.78	-0.36	3.79e-21	Heart rate;
BRCA	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	7.97	0.3	7.54e-15	Menarche (age at onset);
BRCA	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.54	-10.17	-0.37	1.24e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg07636037	chr3:49044803	WDR6	0.55	8.7	0.33	2.75e-17	Menarche (age at onset);
BRCA	cis	rs1476670	0.710	rs753637	chr1:44508927	A/G	cg09470012	chr1:44509516	NA	0.45	9.49	0.35	4.33e-20	Eotaxin levels;
BRCA	cis	rs698833	0.509	rs6715202	chr2:44516282	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.34	0.31	4.66e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg24006582	chr15:45444508	DUOX1	-0.56	-11.54	-0.42	4.12e-28	Uric acid levels;
BRCA	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13012494	chr21:47604986	C21orf56	0.44	8.92	0.33	5.06e-18	Testicular germ cell tumor;
BRCA	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg22920501	chr2:26401640	FAM59B	0.94	16.38	0.54	1.37e-50	Gut microbiome composition (summer);
BRCA	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg07636037	chr3:49044803	WDR6	0.98	28.62	0.75	1.36e-116	Parkinson's disease;
BRCA	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs3857067	0.806	rs12505596	chr4:95109600	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-9.35	-0.35	1.5e-19	QT interval;
BRCA	cis	rs10181042	0.514	rs1177288	chr2:61352985	A/G	cg15711740	chr2:61764176	XPO1	-0.37	-8.6	-0.32	6e-17	Crohn's disease;
BRCA	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-10.61	-0.39	2.52e-24	Mean corpuscular volume;
BRCA	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg11632617	chr15:75315747	PPCDC	-0.35	-7.98	-0.3	6.9e-15	Blood trace element (Zn levels);
BRCA	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg04990556	chr1:26633338	UBXN11	-0.47	-9.3	-0.35	2.25e-19	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg04025307	chr7:1156635	C7orf50	0.58	9.0	0.34	2.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.86	0.3	1.64e-14	Corneal astigmatism;
BRCA	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg27129171	chr3:47204927	SETD2	0.67	15.63	0.53	7.35e-47	Colorectal cancer;
BRCA	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg12193833	chr17:30244370	NA	-0.54	-8.66	-0.32	3.95e-17	Hip circumference adjusted for BMI;
BRCA	trans	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg01620082	chr3:125678407	NA	-0.69	-8.52	-0.32	1.12e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs312274	0.674	rs11178540	chr12:41213695	T/C	cg17827154	chr12:41323612	CNTN1	0.36	8.84	0.33	8.92e-18	Metabolite levels  (X-11787);
BRCA	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.15e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg07423050	chr13:99094983	FARP1	-0.63	-16.07	-0.54	4.67e-49	Neuroticism;
BRCA	cis	rs67072384	0.818	rs12287481	chr11:72472336	A/C	cg04827223	chr11:72435913	ARAP1	0.56	9.38	0.35	1.13e-19	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
BRCA	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg06627628	chr2:24431161	ITSN2	-0.84	-15.52	-0.52	2.6e-46	Asthma;
BRCA	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg24642844	chr7:1081250	C7orf50	-0.58	-11.88	-0.43	1.53e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg10495392	chr1:46806563	NSUN4	0.44	8.11	0.31	2.59e-15	Menopause (age at onset);
BRCA	cis	rs11971779	0.680	rs7779900	chr7:139082987	G/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs4363385	0.818	rs653332	chr1:153010481	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.62	-0.32	5.39e-17	Inflammatory skin disease;
BRCA	cis	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg06521331	chr12:34319734	NA	-0.44	-8.18	-0.31	1.54e-15	Resting heart rate;
BRCA	cis	rs7586879	0.929	rs6545808	chr2:25124388	C/A	cg04586622	chr2:25135609	ADCY3	0.4	9.23	0.34	3.91e-19	Body mass index;
BRCA	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg27129171	chr3:47204927	SETD2	0.67	15.64	0.53	6.56e-47	Colorectal cancer;
BRCA	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg00750074	chr16:89608354	SPG7	-0.39	-10.48	-0.38	7.9e-24	Multiple myeloma (IgH translocation);
BRCA	trans	rs4714291	0.832	rs9471244	chr6:40092331	A/G	cg02267698	chr19:7991119	CTXN1	0.44	9.23	0.34	3.92e-19	Strep throat;
BRCA	cis	rs6005807	0.668	rs9620808	chr22:28993331	A/C	cg12565055	chr22:29076175	TTC28	0.5	9.38	0.35	1.17e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.35	-0.31	4.32e-16	Colorectal cancer;
BRCA	cis	rs490234	0.841	rs497531	chr9:128314664	C/T	cg14078157	chr9:128172775	NA	0.34	8.07	0.3	3.42e-15	Mean arterial pressure;
BRCA	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg06064525	chr11:970664	AP2A2	-0.48	-15.94	-0.53	2.15e-48	Alzheimer's disease (late onset);
BRCA	cis	rs2742234	0.590	rs741968	chr10:43611708	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.54	-10.84	-0.39	2.99e-25	Hirschsprung disease;
BRCA	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg24558204	chr6:135376177	HBS1L	0.44	12.22	0.44	5.38e-31	Red blood cell count;
BRCA	cis	rs10992471	0.528	rs3739606	chr9:95237222	G/T	cg14631576	chr9:95140430	CENPP	-0.34	-8.69	-0.33	3.01e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs2425143	1.000	rs11700256	chr20:34372941	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.17	-0.34	6.32e-19	Blood protein levels;
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg04025307	chr7:1156635	C7orf50	0.62	14.72	0.5	2.01e-42	Longevity;Endometriosis;
BRCA	trans	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg25214090	chr10:38739885	LOC399744	-0.4	-9.14	-0.34	8.21e-19	Corneal astigmatism;
BRCA	cis	rs9649465	0.967	rs12538876	chr7:123296320	C/A	cg04330084	chr7:123175371	IQUB	-0.32	-8.87	-0.33	7.15e-18	Migraine;
BRCA	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg27170947	chr2:26402098	FAM59B	-0.92	-16.52	-0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg17986701	chr20:44574422	PCIF1	-0.4	-9.35	-0.35	1.41e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.98	0.66	3.63e-80	Lymphocyte percentage of white cells;
BRCA	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.23	-0.61	2.35e-65	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11229555	0.645	rs12283414	chr11:58176920	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.77	-0.36	4.3e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-7.91	-0.3	1.16e-14	Axial length;
BRCA	cis	rs13095912	1.000	rs1823238	chr3:185341970	G/A	cg11274856	chr3:185301563	NA	0.35	8.84	0.33	9.08e-18	Systolic blood pressure;
BRCA	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg14019146	chr3:50243930	SLC38A3	-0.43	-10.37	-0.38	2.13e-23	Body mass index;
BRCA	cis	rs2880765	0.835	rs4360875	chr15:86040394	A/G	cg10818794	chr15:86012489	AKAP13	-0.29	-8.19	-0.31	1.37e-15	Coronary artery disease;
BRCA	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg06453172	chr10:134556979	INPP5A	-0.47	-11.06	-0.4	4e-26	Migraine;
BRCA	cis	rs6700896	0.931	rs11809906	chr1:66115064	C/T	cg04111102	chr1:66153794	NA	0.34	8.42	0.32	2.57e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg23711669	chr6:146136114	FBXO30	0.78	18.68	0.59	1.85e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8028182	0.636	rs8030802	chr15:75813153	A/G	cg20655648	chr15:75932815	IMP3	0.42	8.06	0.3	3.87e-15	Sudden cardiac arrest;
BRCA	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg18154014	chr19:37997991	ZNF793	-0.62	-12.13	-0.43	1.31e-30	Coronary artery calcification;
BRCA	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg27432699	chr2:27873401	GPN1	0.49	10.25	0.38	6.18e-23	Oral cavity cancer;
BRCA	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	12.95	0.46	3.2e-34	Lymphocyte counts;
BRCA	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.18e-17	Iron status biomarkers;
BRCA	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg17143192	chr8:8559678	CLDN23	-0.58	-11.81	-0.42	3.01e-29	Obesity-related traits;
BRCA	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-9.59	-0.35	1.94e-20	Fear of minor pain;
BRCA	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.81	0.55	8.35e-53	Axial length;
BRCA	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg03146154	chr1:46216737	IPP	-0.44	-9.72	-0.36	6.67e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg24812749	chr6:127587940	RNF146	0.66	14.91	0.51	2.21e-43	Breast cancer;
BRCA	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg02659138	chr7:134003124	SLC35B4	0.35	10.85	0.39	2.84e-25	Mean platelet volume;
BRCA	cis	rs1863824	0.625	rs7091192	chr10:88167456	A/G	cg07322936	chr10:88137208	NA	-0.45	-8.87	-0.33	7.29e-18	Schizophrenia;
BRCA	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg08601574	chr20:25228251	PYGB	0.34	8.07	0.3	3.54e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg00677455	chr12:58241039	CTDSP2	0.63	14.33	0.49	1.39e-40	Multiple sclerosis;
BRCA	cis	rs12101261	0.560	rs1035144	chr14:81445121	C/T	cg06600135	chr14:81408086	NA	0.34	8.33	0.31	4.94e-16	Graves' disease;
BRCA	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg06618935	chr21:46677482	NA	-0.36	-8.0	-0.3	5.85e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1341267	0.529	rs6492721	chr13:95258944	A/G	cg18412871	chr13:95254051	GPR180	-0.37	-9.0	-0.34	2.54e-18	Triglyceride levels;
BRCA	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg03929089	chr4:120376271	NA	0.65	12.61	0.45	1.01e-32	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg16606324	chr3:10149918	C3orf24	0.5	10.02	0.37	4.84e-22	Alzheimer's disease;
BRCA	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg13256891	chr4:100009986	ADH5	0.5	9.53	0.35	3.08e-20	Alcohol dependence;
BRCA	cis	rs12711979	0.509	rs13005405	chr2:3826324	C/T	cg17052675	chr2:3827356	NA	-0.69	-23.52	-0.68	1.37e-88	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg03709012	chr19:19516395	GATAD2A	0.73	16.16	0.54	1.74e-49	Tonsillectomy;
BRCA	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg14664628	chr15:75095509	CSK	-0.95	-29.41	-0.76	6.68e-121	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs6495367	1.000	rs13380109	chr15:79378775	G/A	cg17916960	chr15:79447300	NA	0.32	8.1	0.31	2.85e-15	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg05234568	chr11:5960015	NA	-0.44	-9.26	-0.34	2.98e-19	DNA methylation (variation);
BRCA	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg23711669	chr6:146136114	FBXO30	0.77	17.98	0.58	8.97e-59	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	1.92e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg18357645	chr12:58087776	OS9	0.46	13.48	0.47	1.26e-36	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.98	0.4	7.99e-26	Height;
BRCA	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.57	11.35	0.41	2.54e-27	Monocyte percentage of white cells;
BRCA	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg23018236	chr17:30244563	NA	-0.64	-10.28	-0.38	4.62e-23	Hip circumference adjusted for BMI;
BRCA	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg13010199	chr12:38710504	ALG10B	0.51	10.22	0.37	8.24e-23	Bladder cancer;
BRCA	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg23711669	chr6:146136114	FBXO30	0.72	17.41	0.57	7.59e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-11.89	-0.43	1.31e-29	Mood instability;
BRCA	cis	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg08807101	chr21:30365312	RNF160	-0.46	-7.93	-0.3	9.9e-15	Cognitive test performance;
BRCA	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-12.15	-0.43	1.01e-30	Morning vs. evening chronotype;
BRCA	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.43	-0.32	2.26e-16	Monocyte percentage of white cells;
BRCA	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg10495392	chr1:46806563	NSUN4	0.45	8.49	0.32	1.42e-16	Menopause (age at onset);
BRCA	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg24006582	chr15:45444508	DUOX1	-0.56	-11.55	-0.42	3.82e-28	Uric acid levels;
BRCA	cis	rs897080	0.552	rs1067374	chr2:44650250	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.48	-8.83	-0.33	9.84e-18	Height;
BRCA	trans	rs629535	0.814	rs62513373	chr8:70080753	C/T	cg21567404	chr3:27674614	NA	-1.01	-21.8	-0.65	3.47e-79	Dupuytren's disease;
BRCA	trans	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg15556689	chr8:8085844	FLJ10661	0.34	9.37	0.35	1.25e-19	Retinal vascular caliber;
BRCA	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg08132940	chr7:1081526	C7orf50	-0.61	-9.05	-0.34	1.74e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs17253792	0.822	rs28392709	chr14:56093685	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-10.14	-0.37	1.7e-22	Schizophrenia;
BRCA	trans	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg26043149	chr18:55253948	FECH	0.39	8.46	0.32	1.78e-16	Bone mineral density;
BRCA	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18876405	chr7:65276391	NA	0.45	8.72	0.33	2.46e-17	Corneal structure;
BRCA	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.52	-11.38	-0.41	1.82e-27	Longevity;Endometriosis;
BRCA	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg04025307	chr7:1156635	C7orf50	0.6	15.26	0.52	4.76e-45	Longevity;Endometriosis;
BRCA	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg17135325	chr3:160939158	NMD3	0.41	7.91	0.3	1.11e-14	Morning vs. evening chronotype;
BRCA	cis	rs3784262	0.607	rs4646576	chr15:58338998	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.54	-13.8	-0.48	4.4e-38	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs16958440	0.867	rs80006910	chr18:44696382	C/G	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg12573674	chr2:1569213	NA	-0.48	-9.25	-0.34	3.41e-19	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg11584989	chr19:19387371	SF4	0.64	12.57	0.45	1.49e-32	Bipolar disorder;
BRCA	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24110177	chr3:50126178	RBM5	-0.37	-9.86	-0.36	1.89e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1499972	0.941	rs73183041	chr3:117610500	C/A	cg07612923	chr3:117604196	NA	0.59	7.91	0.3	1.11e-14	Schizophrenia;
BRCA	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg03354898	chr7:1950403	MAD1L1	-0.4	-8.34	-0.31	4.42e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg08999081	chr20:33150536	PIGU	0.47	12.97	0.46	2.57e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-12.21	-0.43	5.77e-31	Tonsillectomy;
BRCA	cis	rs2415984	0.622	rs1761027	chr14:46929611	G/A	cg14871534	chr14:47121158	RPL10L	0.33	8.1	0.31	2.77e-15	Number of children ever born;
BRCA	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg17971929	chr21:40555470	PSMG1	0.79	18.43	0.59	3.92e-61	Cognitive function;
BRCA	cis	rs4660306	1.000	rs10736426	chr1:45984353	A/G	cg24296786	chr1:45957014	TESK2	-0.44	-9.32	-0.35	1.84e-19	Homocysteine levels;
BRCA	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg04025307	chr7:1156635	C7orf50	0.57	13.38	0.47	3.7e-36	Longevity;Endometriosis;
BRCA	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.28e-23	Prostate cancer;
BRCA	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg13385794	chr1:248469461	NA	0.27	7.89	0.3	1.32e-14	Common traits (Other);
BRCA	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg08470875	chr2:26401718	FAM59B	-0.5	-8.11	-0.31	2.69e-15	Gut microbiome composition (summer);
BRCA	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg07080220	chr10:102295463	HIF1AN	0.61	14.49	0.5	2.37e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg02016764	chr4:38805732	TLR1	-0.54	-8.84	-0.33	9.38e-18	Breast cancer;
BRCA	cis	rs3799379	0.530	rs10456045	chr6:26404958	A/G	cg12826209	chr6:26865740	GUSBL1	-0.44	-8.03	-0.3	4.68e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg11764359	chr7:65958608	NA	-0.62	-13.69	-0.48	1.34e-37	Aortic root size;
BRCA	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg16141378	chr3:129829833	LOC729375	-0.34	-7.88	-0.3	1.41e-14	Neuroticism;
BRCA	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg22705602	chr4:152727874	NA	0.36	9.95	0.37	8.71e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	13.29	0.47	9.28e-36	Response to antipsychotic treatment;
BRCA	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06558623	chr16:89946397	TCF25	0.65	11.89	0.43	1.36e-29	Skin colour saturation;
BRCA	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00149659	chr3:10157352	C3orf10	0.79	13.72	0.48	9.42e-38	Alzheimer's disease;
BRCA	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg27490568	chr2:178487706	NA	0.59	10.28	0.38	4.95e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.3	0.38	4.03e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs72772090	0.522	rs75553638	chr5:95992460	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-8.42	-0.32	2.4e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg17971929	chr21:40555470	PSMG1	0.79	18.87	0.6	1.9e-63	Cognitive function;
BRCA	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.58	9.12	0.34	9.64e-19	Lung function (FEV1/FVC);
BRCA	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-16.89	-0.56	3.51e-53	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg06618935	chr21:46677482	NA	-0.35	-8.01	-0.3	5.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs751728	0.605	rs1535950	chr6:33785827	A/G	cg15252951	chr6:33757062	LEMD2	0.36	8.65	0.32	4.29e-17	Crohn's disease;
BRCA	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg12193833	chr17:30244370	NA	-0.54	-8.66	-0.32	3.95e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg27129171	chr3:47204927	SETD2	-0.68	-15.69	-0.53	3.44e-47	Colorectal cancer;
BRCA	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.76	0.62	3.43e-68	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg05340658	chr4:99064831	C4orf37	0.68	16.86	0.55	5.15e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg25237894	chr2:233734115	C2orf82	-0.4	-11.34	-0.41	2.66e-27	Coronary artery disease;
BRCA	trans	rs11976180	1.000	rs2371248	chr7:143764189	C/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.26	-0.31	8.66e-16	Obesity-related traits;
BRCA	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg11764359	chr7:65958608	NA	0.65	11.88	0.43	1.52e-29	Aortic root size;
BRCA	trans	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg25214090	chr10:38739885	LOC399744	0.51	11.54	0.42	4.01e-28	Corneal astigmatism;
BRCA	cis	rs2742417	0.603	rs9826208	chr3:45773991	C/T	cg04837898	chr3:45731254	SACM1L	-0.38	-7.82	-0.3	2.24e-14	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg25237894	chr2:233734115	C2orf82	-0.38	-11.09	-0.4	2.95e-26	Coronary artery disease;
BRCA	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	16.64	0.55	6.55e-52	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg23711669	chr6:146136114	FBXO30	0.83	20.04	0.62	1.16e-69	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg20362242	chr5:692897	TPPP	0.56	8.74	0.33	2.03e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs701145	0.585	rs9839821	chr3:153796323	G/A	cg17054900	chr3:154042577	DHX36	0.54	9.14	0.34	8.17e-19	Coronary artery disease;
BRCA	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg11279151	chr3:101281821	RG9MTD1	0.35	8.06	0.3	3.77e-15	Colorectal cancer;
BRCA	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg18402987	chr7:1209562	NA	0.84	11.92	0.43	9.85e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4280164	0.945	rs3181384	chr14:24786976	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.45	-7.87	-0.3	1.49e-14	Parent of origin effect on language impairment (paternal);
BRCA	cis	rs3125734	0.633	rs10740068	chr10:63982254	A/C	cg09941381	chr10:64027924	RTKN2	-0.29	-8.73	-0.33	2.29e-17	Rheumatoid arthritis;
BRCA	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	7.92	0.3	1.05e-14	Educational attainment;
BRCA	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg06623918	chr6:96969491	KIAA0776	0.76	16.01	0.54	8.84e-49	Migraine;Coronary artery disease;
BRCA	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg03560586	chr2:239334908	ASB1	-0.5	-11.2	-0.41	9.95e-27	Multiple system atrophy;
BRCA	cis	rs1595825	0.891	rs75946628	chr2:198546239	C/T	cg19156104	chr2:198669113	PLCL1	-0.43	-7.97	-0.3	7.09e-15	Ulcerative colitis;
BRCA	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg11271282	chr2:238384023	NA	0.43	8.21	0.31	1.2e-15	Prostate cancer;
BRCA	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg16329650	chr2:213403929	ERBB4	-0.39	-9.45	-0.35	6.16e-20	Symmetrical dimethylarginine levels;
BRCA	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.08	-0.3	3.16e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03713592	chr11:72463424	ARAP1	0.77	11.59	0.42	2.41e-28	Type 2 diabetes;
BRCA	cis	rs4478858	0.684	rs7544946	chr1:31749736	T/C	cg00250761	chr1:31883323	NA	-0.31	-8.17	-0.31	1.63e-15	Alcohol dependence;
BRCA	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg10729496	chr3:10149963	C3orf24	0.41	7.85	0.3	1.75e-14	Alzheimer's disease;
BRCA	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg06238570	chr21:40685208	BRWD1	-0.41	-8.21	-0.31	1.26e-15	Menarche (age at onset);
BRCA	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.05	0.3	3.98e-15	Breast cancer;
BRCA	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg24829409	chr8:58192753	C8orf71	-0.59	-12.3	-0.44	2.45e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg26373071	chr5:1325741	CLPTM1L	0.5	12.32	0.44	1.92e-31	Lung cancer;
BRCA	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11644478	chr21:40555479	PSMG1	0.85	19.43	0.61	2.08e-66	Cognitive function;
BRCA	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg18850127	chr7:39170497	POU6F2	0.55	11.95	0.43	7.19e-30	IgG glycosylation;
BRCA	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg20848291	chr7:100343083	ZAN	-0.51	-11.56	-0.42	3.37e-28	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg27490568	chr2:178487706	NA	0.51	8.58	0.32	7.29e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg20701182	chr2:24300061	SF3B14	0.59	9.19	0.34	5.66e-19	Lymphocyte counts;
BRCA	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg23711669	chr6:146136114	FBXO30	0.71	17.04	0.56	6.19e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg11645453	chr3:52864694	ITIH4	-0.46	-11.38	-0.41	1.86e-27	Schizophrenia;
BRCA	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21659725	chr3:3221576	CRBN	-0.45	-11.4	-0.41	1.54e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.58	-0.52	1.25e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7607369	0.536	rs13032993	chr2:219666377	T/C	cg02176678	chr2:219576539	TTLL4	-0.38	-10.11	-0.37	2.09e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.62	0.42	1.93e-28	Homoarginine levels;
BRCA	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg17063962	chr7:91808500	NA	0.57	13.54	0.47	6.61e-37	Breast cancer;
BRCA	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg15832292	chr6:96025679	MANEA	0.55	8.32	0.31	5.14e-16	Behavioural disinhibition (generation interaction);
BRCA	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg18806716	chr10:30721971	MAP3K8	-0.42	-10.05	-0.37	3.58e-22	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs17401966	0.558	rs17402762	chr1:10414470	T/C	cg03954927	chr1:10346856	KIF1B	0.34	10.2	0.37	1.02e-22	Hepatocellular carcinoma;
BRCA	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	11.06	0.4	3.96e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg13010199	chr12:38710504	ALG10B	0.45	9.34	0.35	1.53e-19	Bladder cancer;
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg12419862	chr22:24373484	LOC391322	0.86	21.98	0.66	3.4e-80	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11764359	chr7:65958608	NA	-0.65	-14.24	-0.49	3.73e-40	Aortic root size;
BRCA	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg17830980	chr10:43048298	ZNF37B	0.56	13.91	0.48	1.31e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12973672	0.855	rs7256866	chr19:35771257	A/G	cg12095397	chr19:35769544	USF2	0.37	8.33	0.31	5.05e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs12618769	0.597	rs17505326	chr2:99156807	T/A	cg10123293	chr2:99228465	UNC50	0.43	8.32	0.31	5.53e-16	Bipolar disorder;
BRCA	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg07741184	chr6:167504864	NA	0.36	10.44	0.38	1.19e-23	Crohn's disease;
BRCA	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg00717180	chr2:96193071	NA	-0.31	-8.54	-0.32	9.83e-17	Coronary artery disease;
BRCA	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21659725	chr3:3221576	CRBN	-0.47	-11.88	-0.43	1.56e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.747	rs6668215	chr1:152964498	A/G	cg21543102	chr1:152974771	SPRR3	-0.3	-8.62	-0.32	5.33e-17	Inflammatory skin disease;
BRCA	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg06784218	chr1:46089804	CCDC17	0.45	10.79	0.39	4.75e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg26395211	chr5:140044315	WDR55	0.35	7.98	0.3	6.55e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs68170813	0.559	rs2249043	chr7:106960515	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.76	-0.33	1.77e-17	Coronary artery disease;
BRCA	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg18758796	chr5:131593413	PDLIM4	0.39	9.94	0.37	9.96e-22	Acylcarnitine levels;
BRCA	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg21475434	chr5:93447410	FAM172A	0.66	8.71	0.33	2.68e-17	Diabetic retinopathy;
BRCA	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg15103426	chr22:29168792	CCDC117	0.49	9.79	0.36	3.45e-21	Lymphocyte counts;
BRCA	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg06627628	chr2:24431161	ITSN2	-0.84	-15.29	-0.52	3.32e-45	Asthma;
BRCA	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.1	0.49	1.71e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs17253792	0.822	rs10083303	chr14:56068521	T/C	cg01858014	chr14:56050164	KTN1	-0.76	-10.5	-0.38	6.49e-24	Putamen volume;
BRCA	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg07952391	chr2:88470173	THNSL2	0.57	8.09	0.3	3.05e-15	Plasma clusterin levels;
BRCA	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-11.2	-0.41	9.98e-27	Response to bleomycin (chromatid breaks);
BRCA	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg10224037	chr5:178157518	ZNF354A	0.8	18.29	0.59	1.93e-60	Neutrophil percentage of white cells;
BRCA	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg21143896	chr7:2802374	GNA12	-0.35	-8.88	-0.33	6.96e-18	Height;
BRCA	trans	rs7181230	0.961	rs7183977	chr15:40377092	C/T	cg22705835	chr10:65332833	REEP3	0.44	9.85	0.36	2.06e-21	Dehydroepiandrosterone sulphate levels;
BRCA	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg05340658	chr4:99064831	C4orf37	0.56	11.11	0.4	2.53e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg07988820	chr12:82153109	PPFIA2	-0.63	-10.44	-0.38	1.19e-23	Resting heart rate;
BRCA	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.41	-0.41	1.44e-27	Mean corpuscular volume;
BRCA	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-11.37	-0.41	2.12e-27	Morning vs. evening chronotype;
BRCA	cis	rs1865760	0.688	rs9379814	chr6:25979869	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	10.27	0.38	5.38e-23	Height;
BRCA	cis	rs9462846	0.919	rs9462844	chr6:42856502	T/G	cg02353165	chr6:42928485	GNMT	0.44	8.19	0.31	1.44e-15	Blood protein levels;
BRCA	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg21573476	chr21:45109991	RRP1B	-0.32	-8.29	-0.31	6.57e-16	Mean corpuscular volume;
BRCA	cis	rs3740540	0.530	rs4297414	chr10:126292116	T/G	cg04949429	chr10:126290192	LHPP	0.43	11.96	0.43	6.87e-30	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg27170947	chr2:26402098	FAM59B	-0.79	-12.58	-0.45	1.34e-32	Gut microbiome composition (summer);
BRCA	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg13628971	chr7:2884303	GNA12	0.51	9.88	0.36	1.61e-21	Height;
BRCA	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-11.15	-0.4	1.63e-26	Calcium levels;
BRCA	cis	rs34779708	0.733	rs12240638	chr10:35542610	G/T	cg03585969	chr10:35415529	CREM	0.45	9.18	0.34	6.03e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg09658497	chr7:2847517	GNA12	-0.39	-8.0	-0.3	5.75e-15	Height;
BRCA	cis	rs72781680	0.716	rs2712050	chr2:24059408	A/C	cg08917208	chr2:24149416	ATAD2B	0.6	10.25	0.38	6.06e-23	Lymphocyte counts;
BRCA	cis	rs6484504	0.625	rs1535741	chr11:31375072	T/C	cg14844989	chr11:31128820	NA	0.44	9.67	0.36	9.56e-21	Red blood cell count;
BRCA	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg18270830	chr10:32634957	EPC1	0.6	10.44	0.38	1.1e-23	Sexual dysfunction (female);
BRCA	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg24006582	chr15:45444508	DUOX1	0.55	10.72	0.39	9.44e-25	Uric acid levels;
BRCA	trans	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg25214090	chr10:38739885	LOC399744	0.57	12.97	0.46	2.58e-34	Corneal astigmatism;
BRCA	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg06552810	chr11:31128660	NA	-0.39	-8.71	-0.33	2.51e-17	Red blood cell count;
BRCA	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.28	-0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg00339695	chr16:24857497	SLC5A11	0.49	9.71	0.36	6.87e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg11879182	chr18:77439856	CTDP1	0.64	13.99	0.48	5.41e-39	Monocyte count;
BRCA	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.14	0.31	2.09e-15	Breast cancer;
BRCA	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg13902645	chr11:5959945	NA	-0.49	-10.0	-0.37	5.84e-22	DNA methylation (variation);
BRCA	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.83e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12826209	chr6:26865740	GUSBL1	0.58	10.3	0.38	3.9699999999999997e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg06115741	chr20:33292138	TP53INP2	0.37	8.27	0.31	8.07e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	11.68	0.42	1.08e-28	Neuroticism;
BRCA	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.83	-0.58	5.25e-58	Chronic sinus infection;
BRCA	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg21573476	chr21:45109991	RRP1B	-0.37	-9.65	-0.36	1.19e-20	Mean corpuscular volume;
BRCA	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.85	-0.53	5.78e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg08807101	chr21:30365312	RNF160	-0.43	-9.14	-0.34	8.02e-19	Pancreatic cancer;
BRCA	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg00383909	chr3:49044727	WDR6	0.92	13.81	0.48	3.6e-38	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg20387954	chr3:183756860	HTR3D	0.45	10.16	0.37	1.4e-22	Anterior chamber depth;
BRCA	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg21132104	chr15:45694354	SPATA5L1	0.75	16.9	0.56	3.2e-53	Homoarginine levels;
BRCA	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13732083	chr21:47605072	C21orf56	-0.38	-7.88	-0.3	1.42e-14	Testicular germ cell tumor;
BRCA	cis	rs6545883	0.783	rs6545888	chr2:61845215	T/G	cg15711740	chr2:61764176	XPO1	-0.48	-11.7	-0.42	8.37e-29	Tuberculosis;
BRCA	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg24675658	chr1:53192096	ZYG11B	-0.52	-11.61	-0.42	2.03e-28	Monocyte count;
BRCA	cis	rs6745190	0.557	rs34504038	chr2:181992954	T/G	cg00481216	chr2:181971175	NA	0.47	8.89	0.33	6.33e-18	White blood cell count;
BRCA	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg02175503	chr12:58329896	NA	0.45	8.58	0.32	7.21e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg20283391	chr11:68216788	NA	0.45	9.3	0.35	2.13e-19	Total body bone mineral density;
BRCA	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg12292205	chr6:26970375	C6orf41	-0.65	-10.03	-0.37	4.55e-22	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg15242686	chr22:24348715	GSTTP1	0.33	7.86	0.3	1.62e-14	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.35	0.31	4.08e-16	Aortic root size;
BRCA	cis	rs6840258	1.000	rs72667759	chr4:87952199	C/G	cg08197287	chr4:87952173	AFF1	-0.45	-8.81	-0.33	1.13e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26314531	chr2:26401878	FAM59B	-0.66	-11.25	-0.41	6.5e-27	Gut microbiome composition (summer);
BRCA	cis	rs34779708	0.931	rs4007289	chr10:35269790	G/A	cg03585969	chr10:35415529	CREM	0.49	10.1	0.37	2.44e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg05868516	chr6:26286170	HIST1H4H	0.49	10.97	0.4	8.67e-26	Educational attainment;
BRCA	cis	rs3087591	0.922	rs2905801	chr17:29524974	C/T	cg24425628	chr17:29625626	OMG;NF1	0.41	7.97	0.3	7.44e-15	Hip circumference;
BRCA	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg02659138	chr7:134003124	SLC35B4	0.33	10.38	0.38	1.94e-23	Mean platelet volume;
BRCA	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg00750074	chr16:89608354	SPG7	-0.37	-9.78	-0.36	3.68e-21	Multiple myeloma (IgH translocation);
BRCA	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg03864215	chr11:17408437	KCNJ11	-0.27	-8.18	-0.31	1.48e-15	Type 2 diabetes;
BRCA	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-10.77	-0.39	5.57e-25	Type 2 diabetes;
BRCA	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg19628046	chr18:33552617	C18orf21	0.54	11.15	0.4	1.69e-26	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.82	0.58	5.95e-58	Fuchs's corneal dystrophy;
BRCA	trans	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg06521331	chr12:34319734	NA	0.45	8.87	0.33	7.15e-18	Bladder cancer;
BRCA	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg14675211	chr2:100938903	LONRF2	0.52	11.52	0.41	4.71e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg20476274	chr7:133979776	SLC35B4	0.6	15.08	0.51	3.63e-44	Mean platelet volume;
BRCA	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg08888203	chr3:10149979	C3orf24	0.65	13.7	0.48	1.19e-37	Alzheimer's disease;
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11141652	chr22:24348549	GSTTP1	0.43	8.72	0.33	2.4e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.53	-0.35	3.1e-20	Total body bone mineral density;
BRCA	cis	rs6901250	0.632	rs688961	chr6:117089080	A/T	cg12892004	chr6:117198278	RFX6	0.35	8.65	0.32	4.23e-17	C-reactive protein levels;
BRCA	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg11764359	chr7:65958608	NA	-0.62	-13.14	-0.46	4.35e-35	Aortic root size;
BRCA	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg14784868	chr12:69753453	YEATS4	0.45	9.03	0.34	1.95e-18	Response to diuretic therapy;
BRCA	cis	rs73086581	0.947	rs17287577	chr20:3966254	C/T	cg02187196	chr20:3869020	PANK2	0.54	9.56	0.35	2.59e-20	Response to antidepressants in depression;
BRCA	cis	rs6032067	0.673	rs36019441	chr20:43892401	G/A	cg06407657	chr20:43937138	MATN4;RBPJL	0.31	8.18	0.31	1.54e-15	Blood protein levels;
BRCA	cis	rs3820928	0.874	rs7605032	chr2:227847630	T/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.39	-0.32	3.08e-16	Pulmonary function;
BRCA	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.58	10.28	0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.17	-0.31	1.6e-15	Aortic root size;
BRCA	trans	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.77	-0.36	4.1e-21	Bladder cancer;
BRCA	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg06046430	chr4:77819534	ANKRD56	0.58	12.8	0.45	1.42e-33	Emphysema distribution in smoking;
BRCA	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg04455712	chr21:45112962	RRP1B	-0.43	-11.56	-0.42	3.29e-28	Mean corpuscular volume;
BRCA	cis	rs6598955	0.543	rs12122527	chr1:26549748	C/T	cg04990556	chr1:26633338	UBXN11	0.7	12.25	0.44	3.77e-31	Obesity-related traits;
BRCA	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg23422044	chr7:1970798	MAD1L1	-0.44	-9.4	-0.35	9.71e-20	Neuroticism;
BRCA	cis	rs3771570	1.000	rs62193210	chr2:242323616	G/A	cg21155796	chr2:242212141	HDLBP	0.6	9.18	0.34	5.69e-19	Prostate cancer;
BRCA	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg00383909	chr3:49044727	WDR6	0.77	12.81	0.45	1.35e-33	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg01528321	chr10:82214614	TSPAN14	0.71	15.97	0.53	1.47e-48	Post bronchodilator FEV1;
BRCA	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.84	16.95	0.56	1.78e-53	HIV-1 control;
BRCA	cis	rs722599	0.683	rs8011071	chr14:75286705	T/C	cg08847533	chr14:75593920	NEK9	0.43	8.02	0.3	5.18e-15	IgG glycosylation;
BRCA	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg00071950	chr4:10020882	SLC2A9	0.67	16.82	0.55	7.99e-53	Bone mineral density;
BRCA	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.63	-0.42	1.68e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg18016565	chr1:150552671	MCL1	0.34	8.01	0.3	5.63e-15	Tonsillectomy;
BRCA	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg27129171	chr3:47204927	SETD2	-0.59	-13.57	-0.47	4.98e-37	Colorectal cancer;
BRCA	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	8.03	0.3	4.62e-15	Tonsillectomy;
BRCA	cis	rs2120243	0.845	rs2305619	chr3:157154861	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	8.76	0.33	1.81e-17	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg03433033	chr1:76189801	ACADM	0.64	11.41	0.41	1.39e-27	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-12.57	-0.45	1.62e-32	Response to antipsychotic treatment;
BRCA	cis	rs72781680	0.716	rs6718631	chr2:24036086	A/G	cg08917208	chr2:24149416	ATAD2B	-0.59	-10.15	-0.37	1.53e-22	Lymphocyte counts;
BRCA	cis	rs2070488	0.662	rs6599202	chr3:38480651	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	12.92	0.46	4.38e-34	Electrocardiographic conduction measures;
BRCA	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg03146154	chr1:46216737	IPP	0.52	11.61	0.42	2.16e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg03433033	chr1:76189801	ACADM	-0.76	-17.35	-0.57	1.57e-55	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-10.94	-0.4	1.13e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7715806	0.500	rs17563589	chr5:74980019	A/G	cg19683494	chr5:74908142	NA	0.53	8.58	0.32	7.02e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg25554036	chr4:6271136	WFS1	0.44	10.48	0.38	7.8e-24	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg23711669	chr6:146136114	FBXO30	0.78	18.79	0.6	4.89e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	8.05	0.3	4.15e-15	Diabetic retinopathy;
BRCA	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	25.89	0.72	1.21e-101	Chronic sinus infection;
BRCA	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg21535247	chr6:8435926	SLC35B3	0.41	9.24	0.34	3.57e-19	Motion sickness;
BRCA	cis	rs72634258	0.554	rs13306061	chr1:7913445	C/T	cg26816564	chr1:7831052	VAMP3	0.54	10.4	0.38	1.68e-23	Inflammatory bowel disease;
BRCA	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg08999081	chr20:33150536	PIGU	-0.44	-12.15	-0.43	1.01e-30	Glomerular filtration rate (creatinine);
BRCA	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24229701	chr12:130821962	PIWIL1	0.39	8.89	0.33	6.08e-18	Menopause (age at onset);
BRCA	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg25208724	chr1:156163844	SLC25A44	-1.06	-35.94	-0.82	1.46e-155	Testicular germ cell tumor;
BRCA	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg06238570	chr21:40685208	BRWD1	0.4	8.04	0.3	4.48e-15	Cognitive function;
BRCA	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.82	-0.33	1.08e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-10.66	-0.39	1.56e-24	Mood instability;
BRCA	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg10729496	chr3:10149963	C3orf24	0.48	8.98	0.33	2.93e-18	Alzheimer's disease;
BRCA	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.46	-0.61	1.35e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg02175503	chr12:58329896	NA	0.56	13.34	0.47	5.6e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs11030122	0.702	rs12286710	chr11:3967171	T/G	cg18678763	chr11:4115507	RRM1	-0.37	-8.67	-0.32	3.44e-17	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.37	-8.13	-0.31	2.23e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	trans	rs526821	0.595	rs485555	chr11:55323570	A/G	cg15704280	chr7:45808275	SEPT13	0.41	7.87	0.3	1.56e-14	Pediatric bone mineral density (spine);
BRCA	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg22974920	chr21:40686053	BRWD1	-0.4	-8.74	-0.33	2.01e-17	Cognitive function;
BRCA	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg20703242	chr1:230279135	GALNT2	0.42	8.3	0.31	6.04e-16	Coronary artery disease;
BRCA	cis	rs4953318	0.619	rs13406773	chr2:46362868	T/C	cg12428440	chr2:46370979	PRKCE	0.49	10.76	0.39	6.19e-25	Red blood cell count;Hematocrit;Red blood cell traits;
BRCA	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg12310025	chr6:25882481	NA	-0.5	-12.1	-0.43	1.71e-30	Blood metabolite levels;
BRCA	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg21399703	chr1:247681439	NA	0.49	10.5	0.38	6.53e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg24642439	chr20:33292090	TP53INP2	0.61	13.6	0.47	3.42e-37	Coronary artery disease;
BRCA	cis	rs7336332	0.598	rs7669	chr13:28009851	C/T	cg22138327	chr13:27999177	GTF3A	0.65	11.57	0.42	2.92e-28	Weight;
BRCA	cis	rs3772130	0.603	rs10470410	chr3:121434977	G/T	cg20356878	chr3:121714668	ILDR1	0.37	8.27	0.31	7.51e-16	Cognitive performance;
BRCA	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.46	-0.32	1.83e-16	Monocyte percentage of white cells;
BRCA	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg01689657	chr7:91764605	CYP51A1	0.22	8.02	0.3	5.14e-15	Breast cancer;
BRCA	cis	rs490234	0.702	rs35237975	chr9:128313867	A/G	cg14078157	chr9:128172775	NA	-0.53	-11.58	-0.42	2.68e-28	Mean arterial pressure;
BRCA	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-12.61	-0.45	1.07e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	12.15	0.43	9.98e-31	Platelet count;
BRCA	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21582582	chr3:182698605	DCUN1D1	0.4	10.41	0.38	1.49e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg00105475	chr2:10696890	NA	0.43	9.83	0.36	2.47e-21	Prostate cancer;
BRCA	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.55	-0.35	2.64e-20	Tonsillectomy;
BRCA	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg17971929	chr21:40555470	PSMG1	-0.62	-14.48	-0.5	2.58e-41	Cognitive function;
BRCA	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg02951883	chr7:2050386	MAD1L1	-0.37	-8.24	-0.31	9.67e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.59	-11.17	-0.4	1.4e-26	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg24578937	chr1:2090814	PRKCZ	0.57	17.81	0.58	6.82e-58	Height;
BRCA	trans	rs3857536	0.740	rs9354390	chr6:66890162	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.46	9.12	0.34	1e-18	Blood trace element (Cu levels);
BRCA	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg24011408	chr12:48396354	COL2A1	-0.45	-9.98	-0.37	6.85e-22	Plateletcrit;
BRCA	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg26384229	chr12:38710491	ALG10B	0.68	14.54	0.5	1.35e-41	Morning vs. evening chronotype;
BRCA	cis	rs72781680	0.768	rs56339558	chr2:24125234	G/A	cg08917208	chr2:24149416	ATAD2B	0.62	10.54	0.38	4.72e-24	Lymphocyte counts;
BRCA	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	22.56	0.67	2.43e-83	Chronic sinus infection;
BRCA	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21518248	chr2:162101506	NA	0.71	17.54	0.57	1.55e-56	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	trans	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg06521331	chr12:34319734	NA	-0.46	-8.83	-0.33	1.01e-17	Bladder cancer;
BRCA	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	22.15	0.66	4.42e-81	Chronic sinus infection;
BRCA	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg11833968	chr6:79620685	NA	-0.39	-8.47	-0.32	1.72e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg21573476	chr21:45109991	RRP1B	0.34	9.03	0.34	2.06e-18	Mean corpuscular volume;
BRCA	cis	rs4363385	0.597	rs6679201	chr1:152976840	C/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.31	-0.31	5.57e-16	Inflammatory skin disease;
BRCA	cis	rs10046574	0.519	rs9656456	chr7:135202208	G/A	cg27474649	chr7:135195673	CNOT4	0.67	11.09	0.4	3.01e-26	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.44	0.35	6.82e-20	Morning vs. evening chronotype;
BRCA	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	17.69	0.57	2.73e-57	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs8038465	0.622	rs710086	chr15:73877001	C/T	cg15420318	chr15:73925796	NPTN	0.48	10.05	0.37	3.73e-22	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg11764359	chr7:65958608	NA	-0.62	-13.27	-0.46	1.09e-35	Aortic root size;
BRCA	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.9	0.4	1.73e-25	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.48	-0.35	4.87e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
BRCA	cis	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.22	-0.31	1.14e-15	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg24829409	chr8:58192753	C8orf71	-0.47	-9.08	-0.34	1.35e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-23.4	-0.68	6.38e-88	Height;
BRCA	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg21782813	chr7:2030301	MAD1L1	0.35	9.36	0.35	1.35e-19	Schizophrenia;
BRCA	cis	rs911119	0.913	rs6036461	chr20:23576754	C/G	cg16589663	chr20:23618590	CST3	0.4	7.99	0.3	6.34e-15	Chronic kidney disease;
BRCA	cis	rs9925964	0.748	rs4889603	chr16:30982225	C/T	cg02466173	chr16:30829666	NA	-0.45	-9.09	-0.34	1.19e-18	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs2018683	1.000	rs4719963	chr7:29011064	A/G	cg19402173	chr7:128379420	CALU	0.56	14.04	0.49	3.25e-39	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs2120243	1.000	rs10936090	chr3:157142754	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	9.09	0.34	1.28e-18	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs1152591	0.643	rs3020449	chr14:64773392	C/T	cg21174375	chr14:64681225	SYNE2	-0.36	-8.15	-0.31	1.86e-15	Atrial fibrillation;
BRCA	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18876405	chr7:65276391	NA	-0.49	-10.84	-0.39	3.06e-25	Aortic root size;
BRCA	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg08885076	chr2:99613938	TSGA10	-0.45	-10.53	-0.38	5.11e-24	Chronic sinus infection;
BRCA	cis	rs13040088	1.000	rs10854167	chr20:61533039	G/C	cg23096297	chr20:61557774	DIDO1	0.88	17.77	0.58	1.07e-57	Menopause (age at onset);
BRCA	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg03709012	chr19:19516395	GATAD2A	-0.75	-16.77	-0.55	1.34e-52	Tonsillectomy;
BRCA	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	10.84	0.39	3.02e-25	Height;
BRCA	cis	rs9341808	0.754	rs9352817	chr6:81025879	T/G	cg08355045	chr6:80787529	NA	0.35	9.23	0.34	3.85e-19	Sitting height ratio;
BRCA	cis	rs2554380	0.943	rs2585040	chr15:84340468	G/C	cg14598478	chr15:84363061	ADAMTSL3	-0.32	-7.96	-0.3	7.7e-15	Height;
BRCA	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg09526685	chr4:187126073	CYP4V2	1.01	12.05	0.43	2.91e-30	Blood protein levels;
BRCA	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg06784218	chr1:46089804	CCDC17	0.48	11.63	0.42	1.68e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg03146154	chr1:46216737	IPP	0.45	10.03	0.37	4.49e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg12365402	chr11:9010492	NRIP3	-0.37	-8.35	-0.31	4.12e-16	Hemoglobin concentration;
BRCA	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg24829409	chr8:58192753	C8orf71	-0.49	-8.44	-0.32	2.19e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.4	-10.71	-0.39	9.95e-25	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg13660082	chr14:53194042	PSMC6	-0.57	-8.12	-0.31	2.41e-15	Alzheimer's disease (late onset);
BRCA	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg15934090	chr1:100435551	SLC35A3	0.36	8.22	0.31	1.11e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7809799	1.000	rs6975245	chr7:98755272	G/T	cg05967295	chr7:98741636	SMURF1	-0.81	-8.11	-0.31	2.68e-15	Ulcerative colitis;
BRCA	trans	rs6479891	1.000	rs10761745	chr10:65101071	C/G	cg14819942	chr15:35414228	NA	-0.33	-8.21	-0.31	1.24e-15	Arthritis (juvenile idiopathic);
BRCA	cis	rs4818225	0.793	rs960231	chr21:42622657	C/G	cg21268422	chr21:42620091	BACE2	0.46	8.6	0.32	6.19e-17	Educational attainment;
BRCA	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg07423050	chr13:99094983	FARP1	-0.51	-11.28	-0.41	4.85e-27	Longevity;
BRCA	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg02196655	chr2:10830764	NOL10	0.29	7.81	0.3	2.35e-14	Prostate cancer;
BRCA	trans	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg02030672	chr11:45687055	CHST1	-0.43	-9.67	-0.36	9.51e-21	Obesity-related traits;
BRCA	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	8.65e-21	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1975974	0.872	rs17052352	chr17:21721972	A/G	cg18423549	chr17:21743878	NA	-0.52	-11.44	-0.41	1.08e-27	Psoriasis;
BRCA	trans	rs7939886	0.920	rs11227222	chr11:55876393	G/T	cg15704280	chr7:45808275	SEPT13	-0.62	-8.09	-0.3	2.93e-15	Myopia (pathological);
BRCA	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg02403541	chr12:121454288	C12orf43	0.54	10.3	0.38	3.9699999999999997e-23	N-glycan levels;
BRCA	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg26874164	chr19:58962979	ZNF324B	0.44	9.39	0.35	1.08e-19	Uric acid clearance;
BRCA	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.75	-13.9	-0.48	1.48e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg02773041	chr1:40204384	PPIE	0.43	9.25	0.34	3.34e-19	Blood protein levels;
BRCA	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.87	0.33	7.22e-18	Motion sickness;
BRCA	cis	rs3818285	0.556	rs2084607	chr10:111681411	C/T	cg00817464	chr10:111662876	XPNPEP1	0.35	9.69	0.36	8.44e-21	Superior crus of antihelix expression;
BRCA	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg09467607	chr2:36825704	FEZ2	0.62	15.32	0.52	2.25e-45	Height;
BRCA	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg27129171	chr3:47204927	SETD2	-0.64	-14.43	-0.5	4.62e-41	Colorectal cancer;
BRCA	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15506890	chr2:3487001	NA	-0.58	-13.14	-0.46	4.26e-35	Neurofibrillary tangles;
BRCA	cis	rs13136331	0.721	rs2732186	chr4:88673987	T/C	cg22416721	chr4:88570574	DMP1	-0.51	-11.61	-0.42	2.04e-28	Sitting height ratio;
BRCA	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg02079420	chr8:82753780	SNX16	0.31	7.94	0.3	9.08e-15	Diastolic blood pressure;
BRCA	trans	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg13010199	chr12:38710504	ALG10B	0.4	8.0	0.3	5.92e-15	Morning vs. evening chronotype;
BRCA	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg25358565	chr5:93447407	FAM172A	1.2	18.58	0.59	6.04e-62	Diabetic retinopathy;
BRCA	cis	rs3820928	0.934	rs60141402	chr2:227761445	A/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.36	-0.31	3.79e-16	Pulmonary function;
BRCA	trans	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg06636001	chr8:8085503	FLJ10661	0.4	8.24	0.31	9.56e-16	Retinal vascular caliber;
BRCA	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg14675211	chr2:100938903	LONRF2	0.4	8.99	0.34	2.77e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg19920283	chr7:105172520	RINT1	-0.64	-13.08	-0.46	7.89e-35	Bipolar disorder (body mass index interaction);
BRCA	cis	rs1865721	1.000	rs62089509	chr18:73194519	G/A	cg26385618	chr18:73139727	C18orf62	-0.39	-9.03	-0.34	2.07e-18	Intelligence;
BRCA	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg08085267	chr17:45401833	C17orf57	-0.59	-12.06	-0.43	2.63e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.08e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg21782813	chr7:2030301	MAD1L1	0.43	12.34	0.44	1.53e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11764359	chr7:65958608	NA	0.8	19.49	0.61	9.4e-67	Aortic root size;
BRCA	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg13175981	chr1:150552382	MCL1	0.47	10.54	0.38	4.68e-24	Lymphocyte counts;
BRCA	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-10.0	-0.37	5.64e-22	Joint mobility (Beighton score);
BRCA	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.64	-0.42	1.5e-28	Mean corpuscular volume;
BRCA	cis	rs3743102	0.527	rs117959961	chr15:83339895	C/T	cg00614314	chr15:82944287	LOC80154	-0.59	-8.18	-0.31	1.54e-15	Colorectal adenoma (advanced);
BRCA	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.11	0.43	1.51e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	17.14	0.56	1.93e-54	Smoking behavior;
BRCA	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21659725	chr3:3221576	CRBN	-0.46	-9.71	-0.36	7.18e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs12431939	1.000	rs4567626	chr14:51647640	A/T	cg23942311	chr14:51606299	NA	0.41	8.01	0.3	5.46e-15	Cancer;
BRCA	cis	rs9875589	0.509	rs2733556	chr3:14100172	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.33	8.72	0.33	2.41e-17	Ovarian reserve;
BRCA	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg09658497	chr7:2847517	GNA12	-0.39	-7.97	-0.3	7.12e-15	Height;
BRCA	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-13.97	-0.48	6.65e-39	Platelet count;
BRCA	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg06092702	chr1:163392909	NA	-0.36	-9.6	-0.35	1.85e-20	Motion sickness;
BRCA	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.99	0.3	6.4e-15	Depression;
BRCA	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg26769984	chr7:1090371	C7orf50	0.49	9.17	0.34	6.59e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg02175503	chr12:58329896	NA	0.56	13.26	0.46	1.23e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs3740540	0.507	rs942015	chr10:126289932	G/T	cg04949429	chr10:126290192	LHPP	0.44	12.33	0.44	1.73e-31	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.45	-0.38	1.07e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25427524	chr10:38739819	LOC399744	0.66	16.21	0.54	9.7e-50	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg23788917	chr6:8435910	SLC35B3	-0.47	-10.22	-0.37	8.45e-23	Motion sickness;
BRCA	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.22	0.37	7.92e-23	Aortic root size;
BRCA	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.46	-9.29	-0.35	2.34e-19	Tonsillectomy;
BRCA	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.45	10.72	0.39	9.38e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs752010	0.684	rs10789402	chr1:42084649	A/G	cg06885757	chr1:42089581	HIVEP3	0.3	10.74	0.39	7.23e-25	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs11679564	0.714	rs4016031	chr2:37184754	C/T	cg14987922	chr2:37194071	STRN	0.4	8.24	0.31	1e-15	Immature fraction of reticulocytes;
BRCA	cis	rs243505	1.000	rs243511	chr7:148430148	A/C	cg09806900	chr7:148480153	CUL1	-0.44	-8.9	-0.33	5.96e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg06784218	chr1:46089804	CCDC17	-0.44	-10.53	-0.38	5.14e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg24112000	chr20:60950667	NA	0.53	11.37	0.41	2.04e-27	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.39	-9.19	-0.34	5.6e-19	Tonsillectomy;
BRCA	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg03146154	chr1:46216737	IPP	0.53	11.98	0.43	5.79e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg06627628	chr2:24431161	ITSN2	-0.64	-12.47	-0.44	4.44e-32	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs3849570	0.961	rs13340130	chr3:81790970	A/T	cg07356753	chr3:81810745	GBE1	-0.47	-11.41	-0.41	1.35e-27	Waist circumference;Body mass index;
BRCA	trans	rs8073060	0.586	rs225305	chr17:33921160	C/T	cg19694781	chr19:47549865	TMEM160	-1.02	-21.11	-0.64	1.88e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-11.27	-0.41	5.34e-27	Triglycerides;
BRCA	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	15.55	0.52	1.78e-46	Response to antipsychotic treatment;
BRCA	cis	rs10193935	0.786	rs10178087	chr2:42409631	C/A	cg27598129	chr2:42591480	NA	-0.91	-14.5	-0.5	2.15e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.31	-0.31	5.73e-16	Colorectal cancer;
BRCA	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg25457927	chr22:38595422	NA	-0.32	-11.89	-0.43	1.34e-29	Cutaneous nevi;
BRCA	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg13393036	chr8:95962371	TP53INP1	-0.34	-9.12	-0.34	1.01e-18	Type 2 diabetes;
BRCA	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg09184832	chr6:79620586	NA	-0.47	-10.07	-0.37	3.08e-22	Intelligence (multi-trait analysis);
BRCA	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg27661571	chr11:113659931	NA	-0.83	-12.29	-0.44	2.55e-31	Hip circumference adjusted for BMI;
BRCA	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg08847533	chr14:75593920	NEK9	-0.94	-24.86	-0.7	5.75e-96	Height;
BRCA	cis	rs2066819	1.000	rs59811639	chr12:56695954	C/T	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg13010199	chr12:38710504	ALG10B	0.49	10.12	0.37	1.96e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg16576597	chr16:28551801	NUPR1	0.3	8.42	0.32	2.52e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg08807101	chr21:30365312	RNF160	0.74	19.48	0.61	1.12e-66	Dental caries;
BRCA	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.94e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00339695	chr16:24857497	SLC5A11	0.34	7.92	0.3	1.03e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg24829409	chr8:58192753	C8orf71	-0.49	-9.25	-0.34	3.45e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs12997796	0.503	rs34492196	chr2:87021758	T/C	cg25203885	chr2:87302643	LOC285074	-0.52	-8.49	-0.32	1.4e-16	Schizophrenia;
BRCA	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg22907277	chr7:1156413	C7orf50	0.58	8.91	0.33	5.37e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg11764359	chr7:65958608	NA	-0.64	-11.24	-0.41	6.96e-27	Aortic root size;
BRCA	cis	rs2677744	0.626	rs11207	chr15:91497239	C/T	cg23684204	chr15:91497937	RCCD1	0.46	9.52	0.35	3.4e-20	Attention deficit hyperactivity disorder;
BRCA	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg09307838	chr4:120376055	NA	0.7	14.3	0.49	1.96e-40	Corneal astigmatism;
BRCA	cis	rs3820928	0.874	rs3752896	chr2:227886925	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.42	-0.32	2.44e-16	Pulmonary function;
BRCA	cis	rs6740322	1.000	rs6756736	chr2:43558743	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-12.0	-0.43	4.47e-30	Coronary artery disease;
BRCA	cis	rs6723226	0.767	rs10172308	chr2:32555760	G/A	cg02381751	chr2:32503542	YIPF4	-0.72	-16.17	-0.54	1.45e-49	Intelligence (multi-trait analysis);
BRCA	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg09035930	chr12:129282057	SLC15A4	0.51	14.64	0.5	4.86e-42	Systemic lupus erythematosus;
BRCA	cis	rs9790314	0.690	rs6441354	chr3:160826404	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-10.51	-0.38	6.04e-24	Morning vs. evening chronotype;
BRCA	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.77	-0.42	4.31e-29	Mean corpuscular volume;
BRCA	cis	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg04990556	chr1:26633338	UBXN11	0.54	9.0	0.34	2.58e-18	Obesity-related traits;
BRCA	trans	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17712092	chr4:129076599	LARP1B	0.5	12.07	0.43	2.21e-30	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.75	16.35	0.54	1.84e-50	Cognitive ability;
BRCA	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg19318889	chr4:1322082	MAEA	-0.59	-12.12	-0.43	1.43e-30	Longevity;
BRCA	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg07549590	chr16:15018862	NA	-0.36	-9.15	-0.34	7.32e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.35	-9.78	-0.36	3.84e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg20607798	chr8:58055168	NA	0.47	8.09	0.3	3.07e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.38	9.13	0.34	8.57e-19	Platelet count;
BRCA	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	8.54	0.32	9.95e-17	Electroencephalogram traits;
BRCA	cis	rs7646881	0.812	rs73017539	chr3:158460743	A/G	cg19483011	chr3:158453295	NA	-0.45	-7.97	-0.3	7.19e-15	Tetralogy of Fallot;
BRCA	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg13010199	chr12:38710504	ALG10B	0.41	8.09	0.3	3.03e-15	Bladder cancer;
BRCA	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19346786	chr7:2764209	NA	-0.31	-8.95	-0.33	3.7e-18	Height;
BRCA	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08859206	chr1:53392774	SCP2	-0.62	-13.31	-0.47	7.72e-36	Monocyte count;
BRCA	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24308560	chr3:49941425	MST1R	0.39	8.43	0.32	2.37e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.04e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6025261	0.761	rs6099360	chr20:55511902	C/T	cg04763273	chr20:55502381	NA	-0.33	-7.99	-0.3	6.45e-15	Verbal memory performance (delayed recall level);
BRCA	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg21064579	chr19:49206444	FUT2	0.32	8.02	0.3	4.92e-15	Dietary macronutrient intake;
BRCA	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.59	11.03	0.4	5.16e-26	Birth weight;
BRCA	cis	rs1003719	0.715	rs9974494	chr21:38566566	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.47	-0.5	2.85e-41	Eye color traits;
BRCA	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg12011299	chr4:100065546	ADH4	0.53	12.95	0.46	3.03e-34	Alcohol dependence;
BRCA	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg15704280	chr7:45808275	SEPT13	0.76	16.12	0.54	2.56e-49	Coronary artery disease;
BRCA	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg04586622	chr2:25135609	ADCY3	-0.45	-11.45	-0.41	9.4e-28	Body mass index;
BRCA	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg10518543	chr12:38710700	ALG10B	0.36	7.93	0.3	1.01e-14	Morning vs. evening chronotype;
BRCA	cis	rs312274	0.505	rs17622354	chr12:41323480	C/T	cg17827154	chr12:41323612	CNTN1	-0.42	-11.3	-0.41	4.06e-27	Metabolite levels  (X-11787);
BRCA	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	15.03	0.51	6.36e-44	Parkinson's disease;
BRCA	cis	rs1691799	0.899	rs1168327	chr12:66728842	G/A	cg16791601	chr12:66731901	HELB	-0.65	-17.46	-0.57	4.06e-56	White blood cell count (basophil);
BRCA	cis	rs1003719	0.646	rs9985082	chr21:38501021	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.24	-0.49	3.73e-40	Eye color traits;
BRCA	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.15	-0.31	1.89e-15	Total body bone mineral density;
BRCA	cis	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg06521331	chr12:34319734	NA	-0.61	-11.11	-0.4	2.37e-26	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.8	0.33	1.28e-17	Motion sickness;
BRCA	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg20701182	chr2:24300061	SF3B14	0.68	9.83	0.36	2.55e-21	Lymphocyte counts;
BRCA	cis	rs1829883	0.835	rs2511977	chr5:98819617	A/G	cg08333243	chr5:99726346	NA	0.35	7.91	0.3	1.1e-14	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24531977	chr5:56204891	C5orf35	-0.66	-14.55	-0.5	1.18e-41	Coronary artery disease;
BRCA	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.6	-0.67	1.57e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs34779708	0.931	rs12261654	chr10:35322024	G/A	cg03585969	chr10:35415529	CREM	0.47	10.02	0.37	4.7e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	17.73	0.57	1.65e-57	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6815814	0.861	rs6531663	chr4:38792340	T/C	cg06935464	chr4:38784597	TLR10	0.49	9.7	0.36	7.89e-21	Breast cancer;
BRCA	trans	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.13	0.31	2.16e-15	Corneal astigmatism;
BRCA	cis	rs10929956	0.760	rs2729704	chr2:160707866	T/A	cg18514922	chr2:160761262	LY75	-0.34	-7.97	-0.3	7.27e-15	Crohn's disease-related phenotypes;
BRCA	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg03474202	chr17:45855739	NA	-0.46	-12.57	-0.45	1.56e-32	IgG glycosylation;
BRCA	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08219700	chr8:58056026	NA	0.6	9.6	0.35	1.81e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs9463078	0.739	rs1293467	chr6:44769204	C/G	cg25276700	chr6:44698697	NA	0.4	9.18	0.34	5.91e-19	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06636551	chr8:101224915	SPAG1	-0.35	-7.84	-0.3	1.84e-14	Atrioventricular conduction;
BRCA	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	17.72	0.57	2e-57	Alzheimer's disease (late onset);
BRCA	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg08999081	chr20:33150536	PIGU	0.36	9.27	0.34	2.78e-19	Coronary artery disease;
BRCA	trans	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg15556689	chr8:8085844	FLJ10661	-0.34	-8.09	-0.3	3e-15	Neuroticism;
BRCA	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.8	17.4	0.57	8.4e-56	IgG glycosylation;
BRCA	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00166722	chr3:10149974	C3orf24	0.65	11.23	0.41	7.83e-27	Alzheimer's disease;
BRCA	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg16482183	chr6:26056742	HIST1H1C	0.54	11.24	0.41	7.04e-27	Height;
BRCA	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg26248373	chr2:1572462	NA	-0.51	-10.03	-0.37	4.22e-22	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg14019146	chr3:50243930	SLC38A3	-0.43	-10.43	-0.38	1.24e-23	Body mass index;
BRCA	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.71	0.55	2.93e-52	Colorectal cancer;
BRCA	cis	rs6723226	0.803	rs387780	chr2:32502495	T/C	cg02381751	chr2:32503542	YIPF4	0.67	13.85	0.48	2.45e-38	Intelligence (multi-trait analysis);
BRCA	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06022373	chr22:39101656	GTPBP1	0.74	17.69	0.57	2.79e-57	Menopause (age at onset);
BRCA	cis	rs7394190	0.748	rs79936644	chr10:75545117	C/T	cg07699608	chr10:75541558	CHCHD1	0.66	10.0	0.37	5.62e-22	Incident atrial fibrillation;
BRCA	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg22467129	chr15:76604101	ETFA	-0.49	-10.77	-0.39	5.82e-25	Blood metabolite levels;
BRCA	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg26597838	chr10:835615	NA	0.98	15.02	0.51	6.75e-44	Eosinophil percentage of granulocytes;
BRCA	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18876405	chr7:65276391	NA	-0.62	-15.42	-0.52	7.35e-46	Aortic root size;
BRCA	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg11301795	chr4:187892539	NA	-0.28	-9.06	-0.34	1.61e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg18252515	chr7:66147081	NA	-0.8	-11.18	-0.4	1.23e-26	Diabetic kidney disease;
BRCA	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.74	0.36	5.26e-21	Morning vs. evening chronotype;
BRCA	cis	rs7927771	0.524	rs1056387	chr11:47681370	A/C	cg20307385	chr11:47447363	PSMC3	0.4	9.04	0.34	1.83e-18	Subjective well-being;
BRCA	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg01256987	chr12:42539512	GXYLT1	-0.41	-7.93	-0.3	9.88e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg21747090	chr2:27597821	SNX17	-0.43	-9.36	-0.35	1.29e-19	Total body bone mineral density;
BRCA	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23583168	chr7:148888333	NA	-0.83	-18.56	-0.59	7.99e-62	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.47	-9.57	-0.35	2.24e-20	Body mass index;
BRCA	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg10818794	chr15:86012489	AKAP13	-0.42	-11.41	-0.41	1.46e-27	Coronary artery disease;
BRCA	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-10.05	-0.37	3.8e-22	Eosinophil percentage of white cells;
BRCA	cis	rs7833986	0.534	rs72653928	chr8:56907735	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	12.71	0.45	3.73e-33	Height;
BRCA	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-9.63	-0.36	1.38e-20	Monocyte percentage of white cells;
BRCA	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00149659	chr3:10157352	C3orf10	0.8	13.67	0.48	1.69e-37	Alzheimer's disease;
BRCA	trans	rs800082	0.501	rs9844730	chr3:144216886	T/G	cg24215973	chr2:240111563	HDAC4	0.35	8.31	0.31	5.64e-16	Smoking behavior;
BRCA	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg12140854	chr5:148520817	ABLIM3	0.41	8.85	0.33	8.72e-18	Breast cancer;
BRCA	cis	rs9463078	0.774	rs7451423	chr6:45241343	C/T	cg25276700	chr6:44698697	NA	-0.35	-7.85	-0.3	1.77e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	trans	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.87	0.3	1.51e-14	Corneal astigmatism;
BRCA	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg11279151	chr3:101281821	RG9MTD1	-0.49	-10.04	-0.37	3.92e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg11952622	chr19:58962976	ZNF324B	0.43	8.75	0.33	1.95e-17	Uric acid clearance;
BRCA	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg23649088	chr2:200775458	C2orf69	0.6	8.92	0.33	4.8e-18	Schizophrenia;
BRCA	cis	rs2731664	0.792	rs385981	chr5:176886539	C/T	cg23176889	chr5:176863531	GRK6	-0.61	-16.71	-0.55	2.98e-52	Intelligence (multi-trait analysis);
BRCA	cis	rs7572733	0.555	rs700671	chr2:198690001	T/C	cg00792783	chr2:198669748	PLCL1	0.47	10.16	0.37	1.44e-22	Dermatomyositis;
BRCA	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	17.27	0.56	4.14e-55	Alzheimer's disease;
BRCA	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg05340658	chr4:99064831	C4orf37	0.66	16.1	0.54	3.26e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.43	0.32	2.29e-16	Rheumatoid arthritis;
BRCA	cis	rs7737355	0.947	rs244739	chr5:130806874	A/C	cg06307176	chr5:131281290	NA	-0.53	-10.48	-0.38	8.24e-24	Life satisfaction;
BRCA	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg18811423	chr2:55921094	PNPT1	0.78	26.62	0.73	1.31e-105	Metabolic syndrome;
BRCA	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg16606324	chr3:10149918	C3orf24	0.57	11.38	0.41	1.87e-27	Alzheimer's disease;
BRCA	trans	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg06521331	chr12:34319734	NA	-0.54	-10.31	-0.38	3.53e-23	Bladder cancer;
BRCA	cis	rs11191270	0.590	rs12569901	chr10:104025410	C/G	cg15320455	chr10:103880129	LDB1	0.75	11.22	0.41	8.29e-27	Intelligence (multi-trait analysis);
BRCA	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg03929089	chr4:120376271	NA	-0.43	-8.17	-0.31	1.7e-15	HDL cholesterol;
BRCA	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg00677455	chr12:58241039	CTDSP2	0.39	8.65	0.32	4.32e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs1371614	0.513	rs13010712	chr2:27087709	T/A	cg12368169	chr2:27073192	DPYSL5	-0.35	-10.26	-0.38	5.74e-23	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg14403583	chr14:105418241	AHNAK2	0.37	8.51	0.32	1.27e-16	Rheumatoid arthritis;
BRCA	cis	rs10754283	0.935	rs1934046	chr1:90119290	A/T	cg21401794	chr1:90099060	LRRC8C	-0.48	-11.0	-0.4	7.01e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs2425143	1.000	rs7261284	chr20:34244104	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.97	-0.33	3.3e-18	Blood protein levels;
BRCA	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg18446336	chr7:2847575	GNA12	-0.37	-8.66	-0.32	3.72e-17	Height;
BRCA	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg22920501	chr2:26401640	FAM59B	-0.59	-10.73	-0.39	8.42e-25	Gut microbiome composition (summer);
BRCA	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg23711669	chr6:146136114	FBXO30	0.71	14.34	0.49	1.26e-40	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg25767906	chr1:53392781	SCP2	-0.38	-8.7	-0.33	2.75e-17	Monocyte count;
BRCA	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg18404041	chr3:52824283	ITIH1	-0.34	-9.3	-0.35	2.27e-19	Bipolar disorder;
BRCA	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.35	-9.78	-0.36	3.81e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2882667	0.931	rs10075951	chr5:138355963	G/T	cg04439458	chr5:138467593	SIL1	-0.33	-9.02	-0.34	2.2e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg08885076	chr2:99613938	TSGA10	-0.58	-12.99	-0.46	2.01e-34	Chronic sinus infection;
BRCA	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.75	16.25	0.54	5.61e-50	Lymphocyte counts;
BRCA	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-7.92	-0.3	1.05e-14	Total body bone mineral density;
BRCA	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg09307838	chr4:120376055	NA	0.72	15.33	0.52	2.08e-45	Corneal astigmatism;
BRCA	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg09307838	chr4:120376055	NA	0.61	12.35	0.44	1.42e-31	Corneal astigmatism;
BRCA	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.68	15.83	0.53	7.51e-48	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.78	-12.47	-0.44	4.35e-32	Platelet count;
BRCA	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg02176678	chr2:219576539	TTLL4	0.46	12.44	0.44	5.57e-32	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg00173435	chr12:106696525	TCP11L2	0.57	10.06	0.37	3.42e-22	Tourette syndrome;
BRCA	trans	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs1829883	1.000	rs2511973	chr5:98807871	T/A	cg08333243	chr5:99726346	NA	-0.36	-8.59	-0.32	6.81e-17	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.5	-12.0	-0.43	4.82e-30	Longevity;Endometriosis;
BRCA	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-9.59	-0.35	2e-20	Heart rate;
BRCA	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	8.92	0.33	4.8e-18	Personality dimensions;
BRCA	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00149659	chr3:10157352	C3orf10	1.08	18.29	0.59	1.95e-60	Alzheimer's disease;
BRCA	cis	rs9790314	0.663	rs4557202	chr3:160820524	G/C	cg03342759	chr3:160939853	NMD3	-0.53	-11.46	-0.41	8.46e-28	Morning vs. evening chronotype;
BRCA	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg08601574	chr20:25228251	PYGB	-0.34	-8.25	-0.31	9.18e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg00106254	chr7:1943704	MAD1L1	-0.42	-10.15	-0.37	1.56e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs1865721	0.771	rs4410169	chr18:73138840	A/G	cg26385618	chr18:73139727	C18orf62	-0.44	-10.78	-0.39	5.22e-25	Intelligence;
BRCA	cis	rs367943	1.000	rs348929	chr5:112814883	T/A	cg12552261	chr5:112820674	MCC	-0.56	-12.28	-0.44	2.97e-31	Type 2 diabetes;
BRCA	cis	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.54	-0.32	9.97e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg24069376	chr3:38537580	EXOG	0.32	9.08	0.34	1.36e-18	Electrocardiographic conduction measures;
BRCA	cis	rs7737355	0.947	rs58895212	chr5:130797057	C/A	cg06307176	chr5:131281290	NA	-0.51	-10.26	-0.38	5.92e-23	Life satisfaction;
BRCA	trans	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg25214090	chr10:38739885	LOC399744	0.54	12.46	0.44	4.58e-32	Corneal astigmatism;
BRCA	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg20503657	chr10:835505	NA	1.0	15.57	0.52	1.4e-46	Eosinophil percentage of granulocytes;
BRCA	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg01448562	chr3:133502909	NA	-0.41	-9.41	-0.35	8.84e-20	Iron status biomarkers;
BRCA	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg05340658	chr4:99064831	C4orf37	0.59	12.67	0.45	5.43e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg22906224	chr7:99728672	NA	0.4	7.99	0.3	6.09e-15	Coronary artery disease;
BRCA	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg17063962	chr7:91808500	NA	0.53	12.5	0.44	3.23e-32	Breast cancer;
BRCA	cis	rs2354432	0.556	rs12568866	chr1:146718430	A/C	cg25205988	chr1:146714368	CHD1L	-0.94	-13.46	-0.47	1.53e-36	Mitochondrial DNA levels;
BRCA	cis	rs11677370	0.603	rs11696104	chr2:3849512	C/G	cg17052675	chr2:3827356	NA	-0.5	-12.25	-0.44	3.74e-31	Type 2 diabetes;
BRCA	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg25173405	chr17:45401733	C17orf57	-0.5	-10.52	-0.38	5.55e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.36	9.13	0.34	9.24e-19	Resting heart rate;
BRCA	cis	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg06521331	chr12:34319734	NA	-0.62	-11.21	-0.41	9.26e-27	Morning vs. evening chronotype;
BRCA	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-9.03	-0.34	1.95e-18	Alzheimer's disease (late onset);
BRCA	trans	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg26043149	chr18:55253948	FECH	1.09	23.21	0.68	7.07e-87	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg06521331	chr12:34319734	NA	-0.65	-12.08	-0.43	2.1000000000000002e-30	Morning vs. evening chronotype;
BRCA	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg08422745	chr4:174089978	GALNT7	-0.78	-16.06	-0.54	5.51e-49	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg23625390	chr15:77176239	SCAPER	-0.51	-11.96	-0.43	7.15e-30	Blood metabolite levels;
BRCA	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg09904177	chr6:26538194	HMGN4	0.47	15.0	0.51	8.32e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg01444801	chr10:135216882	MTG1	-0.46	-10.37	-0.38	2.07e-23	Systemic lupus erythematosus;
BRCA	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg03433033	chr1:76189801	ACADM	-0.4	-8.08	-0.3	3.16e-15	Daytime sleep phenotypes;
BRCA	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg24250549	chr1:154909240	PMVK	0.65	16.88	0.56	3.74e-53	Prostate cancer;
BRCA	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg04267008	chr7:1944627	MAD1L1	0.52	11.47	0.41	7.72e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11644478	chr21:40555479	PSMG1	0.85	19.82	0.62	1.71e-68	Cognitive function;
BRCA	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg25208724	chr1:156163844	SLC25A44	0.85	23.37	0.68	9.52e-88	Testicular germ cell tumor;
BRCA	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg16339924	chr4:17578868	LAP3	0.66	16.9	0.56	3.1e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7523050	0.643	rs35662800	chr1:109400816	C/A	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg20908204	chr19:46285434	DMPK	-0.29	-8.6	-0.32	6.32e-17	Coronary artery disease;
BRCA	cis	rs999943	0.774	rs12205634	chr6:33611667	C/G	cg14003231	chr6:33640908	ITPR3	0.74	16.8	0.55	9.37e-53	Obesity (extreme);
BRCA	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.33	-0.44	1.71e-31	Response to antipsychotic treatment;
BRCA	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg04944784	chr2:26401820	FAM59B	0.73	11.93	0.43	8.96e-30	Gut microbiome composition (summer);
BRCA	cis	rs7607369	0.559	rs13027908	chr2:219660374	T/C	cg02176678	chr2:219576539	TTLL4	-0.39	-10.33	-0.38	3.02e-23	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	trans	rs75804782	0.641	rs11885523	chr2:239344263	G/A	cg01134436	chr17:81009848	B3GNTL1	0.72	9.3	0.35	2.26e-19	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg07169764	chr2:136633963	MCM6	1.21	26.37	0.72	2.96e-104	Corneal structure;
BRCA	cis	rs999943	0.846	rs9366826	chr6:33619184	C/G	cg14003231	chr6:33640908	ITPR3	0.6	13.42	0.47	2.41e-36	Obesity (extreme);
BRCA	trans	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg05039488	chr6:79577232	IRAK1BP1	0.36	7.95	0.3	8.19e-15	Endometrial cancer;
BRCA	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg26384229	chr12:38710491	ALG10B	0.4	9.62	0.36	1.46e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg06108461	chr20:60628389	TAF4	-0.82	-17.52	-0.57	2.13e-56	Body mass index;
BRCA	cis	rs12612619	0.542	rs6710065	chr2:27076557	C/T	cg12368169	chr2:27073192	DPYSL5	-0.34	-10.24	-0.38	6.78e-23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg23625390	chr15:77176239	SCAPER	0.54	13.99	0.48	5.71e-39	Blood metabolite levels;
BRCA	cis	rs7520050	0.966	rs6680380	chr1:46300189	T/G	cg24296786	chr1:45957014	TESK2	0.44	9.89	0.36	1.43e-21	Red blood cell count;Reticulocyte count;
BRCA	trans	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg14791747	chr16:20752902	THUMPD1	0.4	9.51	0.35	3.8e-20	Cognitive test performance;
BRCA	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg21252483	chr19:49399788	TULP2	-0.51	-10.75	-0.39	7e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs6752107	0.935	rs10929326	chr2:234151045	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	10.9	0.4	1.74e-25	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg20628663	chr10:43360327	NA	0.7	13.53	0.47	7.1e-37	Blood protein levels;
BRCA	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg03711944	chr11:47377212	SPI1	-0.42	-11.53	-0.41	4.54e-28	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg03433033	chr1:76189801	ACADM	-0.49	-10.43	-0.38	1.28e-23	Daytime sleep phenotypes;
BRCA	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg04545296	chr12:48745243	ZNF641	0.25	8.21	0.31	1.25e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs2712184	0.721	rs2541401	chr2:217641006	T/C	cg05032264	chr2:217675019	NA	-0.38	-9.13	-0.34	9.04e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg04691961	chr3:161091175	C3orf57	-0.46	-10.85	-0.39	2.66e-25	Morning vs. evening chronotype;
BRCA	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.62	-13.5	-0.47	9.64e-37	Lymphocyte percentage of white cells;
BRCA	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18402987	chr7:1209562	NA	0.47	9.9	0.36	1.4e-21	Longevity;Endometriosis;
BRCA	cis	rs6088813	0.885	rs6142353	chr20:33942685	G/A	cg14752227	chr20:34000481	UQCC	-0.43	-9.16	-0.34	6.86e-19	Height;
BRCA	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.33	-0.31	4.93e-16	Bipolar disorder;
BRCA	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.47	-0.35	5.41e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg14784868	chr12:69753453	YEATS4	-0.55	-13.91	-0.48	1.25e-38	Blood protein levels;
BRCA	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.64e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs478222	1.000	rs551573	chr2:25305504	A/G	cg01884057	chr2:25150051	NA	0.31	8.17	0.31	1.7e-15	Type 1 diabetes;
BRCA	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg03433033	chr1:76189801	ACADM	0.86	22.28	0.66	8.17e-82	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg13010199	chr12:38710504	ALG10B	-0.38	-8.75	-0.33	1.88e-17	Morning vs. evening chronotype;
BRCA	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg24692254	chr21:30365293	RNF160	0.45	9.53	0.35	3.17e-20	Cognitive test performance;
BRCA	cis	rs698833	0.506	rs4952705	chr2:44499867	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	8.73	0.33	2.26e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	trans	rs10242455	0.557	rs2404487	chr7:99038057	G/A	cg09045935	chr12:6379348	NA	0.84	8.26	0.31	8.16e-16	Blood metabolite levels;
BRCA	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	15.43	0.52	6.55e-46	Hypertriglyceridemia;
BRCA	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg00666640	chr1:248458726	OR2T12	0.33	8.55	0.32	9.4e-17	Common traits (Other);
BRCA	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg20701182	chr2:24300061	SF3B14	0.66	9.09	0.34	1.18e-18	Lymphocyte counts;
BRCA	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg01324343	chr3:183735012	ABCC5	0.85	21.59	0.65	4.58e-78	Anterior chamber depth;
BRCA	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg24110177	chr3:50126178	RBM5	0.51	14.4	0.5	6.06e-41	Body mass index;
BRCA	cis	rs1371614	0.632	rs4665363	chr2:27156416	T/G	cg00617064	chr2:27272375	NA	0.31	8.02	0.3	5.14e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.48	-10.95	-0.4	1.08e-25	Bipolar disorder;
BRCA	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg12437481	chr16:420112	MRPL28	-0.39	-8.63	-0.32	5.01e-17	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs8016982	0.674	rs8004096	chr14:81701082	T/G	cg01989461	chr14:81687754	GTF2A1	0.62	14.47	0.5	2.86e-41	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg05340658	chr4:99064831	C4orf37	0.61	14.11	0.49	1.47e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg25767906	chr1:53392781	SCP2	0.37	8.6	0.32	6.07e-17	Monocyte count;
BRCA	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg09307838	chr4:120376055	NA	0.64	14.0	0.48	5.12e-39	Corneal astigmatism;
BRCA	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-10.24	-0.38	7.06e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2481665	0.617	rs12732781	chr1:62518459	T/C	cg18591186	chr1:62594603	INADL	-0.39	-8.47	-0.32	1.74e-16	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg09904177	chr6:26538194	HMGN4	0.47	14.7	0.5	2.27e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.34	-0.61	6.06e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg20307385	chr11:47447363	PSMC3	0.57	14.09	0.49	1.86e-39	Neuroticism;
BRCA	cis	rs2070433	0.539	rs1008549	chr21:47959698	C/T	cg12379764	chr21:47803548	PCNT	0.56	11.82	0.42	2.83e-29	Lymphocyte counts;
BRCA	cis	rs1555322	0.505	rs639763	chr20:33861904	C/T	cg17927777	chr20:33865990	NA	0.46	8.41	0.32	2.71e-16	Attention deficit hyperactivity disorder;
BRCA	cis	rs7766436	0.648	rs7757111	chr6:22591154	C/A	cg13666174	chr6:22585274	NA	-0.43	-10.77	-0.39	5.81e-25	Coronary artery disease;
BRCA	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.59e-23	Motion sickness;
BRCA	cis	rs490234	0.841	rs13285366	chr9:128375047	G/A	cg14078157	chr9:128172775	NA	-0.47	-10.7	-0.39	1.05e-24	Mean arterial pressure;
BRCA	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00149659	chr3:10157352	C3orf10	1.07	18.1	0.58	2.08e-59	Alzheimer's disease;
BRCA	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.79	-12.89	-0.45	5.78e-34	Platelet count;
BRCA	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg26343298	chr8:95960752	TP53INP1	0.3	8.74	0.33	2.07e-17	Type 2 diabetes;
BRCA	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg23711669	chr6:146136114	FBXO30	0.66	15.51	0.52	2.73e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg06060754	chr5:176797920	RGS14	-0.67	-10.85	-0.39	2.65e-25	Urate levels in lean individuals;
BRCA	cis	rs6484504	0.652	rs494464	chr11:31386150	C/T	cg26647111	chr11:31128758	NA	0.43	9.53	0.35	3.18e-20	Red blood cell count;
BRCA	cis	rs6878727	0.665	rs698179	chr5:123668072	C/A	cg01806427	chr5:123737813	NA	-0.36	-8.21	-0.31	1.24e-15	Breast cancer;
BRCA	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg12011299	chr4:100065546	ADH4	0.39	9.37	0.35	1.26e-19	Alcohol dependence;
BRCA	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.5	9.7	0.36	7.59e-21	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6433895	0.677	rs11688120	chr2:181997950	T/C	cg00481216	chr2:181971175	NA	0.46	8.68	0.32	3.35e-17	Lymphocyte counts;
BRCA	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg23708337	chr7:1209742	NA	0.64	8.93	0.33	4.47e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7582720	1.000	rs72934563	chr2:203995405	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	12.75	0.45	2.48e-33	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-8.44	-0.32	2.12e-16	Gut microbiome composition (summer);
BRCA	trans	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.91	-0.3	1.14e-14	Corneal astigmatism;
BRCA	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg12219531	chr12:120966889	COQ5	0.53	11.26	0.41	5.91e-27	High light scatter reticulocyte count;
BRCA	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg24846343	chr22:24311635	DDTL	0.56	14.54	0.5	1.34e-41	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	12.07	0.43	2.33e-30	Tonsillectomy;
BRCA	cis	rs10496034	1.000	rs77602473	chr2:55184781	A/C	cg16098955	chr2:55172992	EML6	0.52	9.2	0.34	5.07e-19	Refractive astigmatism;
BRCA	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg04450456	chr4:17643702	FAM184B	0.35	9.6	0.35	1.82e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6446731	0.517	rs2858086	chr4:3270611	A/G	cg08886695	chr4:3369023	RGS12	0.37	9.87	0.36	1.82e-21	Mean platelet volume;
BRCA	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.73	-0.33	2.23e-17	Breast cancer;
BRCA	cis	rs1468333	1.000	rs62381795	chr5:137577870	G/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.44	9.22	0.34	4.3e-19	Resting heart rate;
BRCA	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-18.46	-0.59	2.61e-61	Morning vs. evening chronotype;
BRCA	cis	rs17095355	1.000	rs7080576	chr10:111710817	C/T	cg00817464	chr10:111662876	XPNPEP1	0.37	9.71	0.36	6.89e-21	Biliary atresia;
BRCA	cis	rs9392556	0.829	rs633290	chr6:4114788	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	0.37	8.19	0.31	1.4e-15	Blood metabolite levels;
BRCA	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg09035930	chr12:129282057	SLC15A4	-0.52	-15.8	-0.53	9.91e-48	Systemic lupus erythematosus;
BRCA	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-12.28	-0.44	2.89e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg13010199	chr12:38710504	ALG10B	0.51	9.97	0.37	7.62e-22	Bladder cancer;
BRCA	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.82	-0.55	7.94e-53	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.6	-14.29	-0.49	2.04e-40	Hemoglobin concentration;
BRCA	cis	rs7789940	0.951	rs73140055	chr7:75975777	A/T	cg10167463	chr7:75959203	YWHAG	-0.44	-8.72	-0.33	2.34e-17	Multiple sclerosis;
BRCA	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg23285459	chr7:2802560	GNA12	-0.34	-8.34	-0.31	4.73e-16	Height;
BRCA	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07636037	chr3:49044803	WDR6	-0.73	-15.9	-0.53	3.45e-48	Menarche (age at onset);
BRCA	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08564027	chr20:61660810	NA	0.85	22.97	0.67	1.42e-85	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs1459104	1.000	rs66654577	chr11:55168539	G/A	cg15704280	chr7:45808275	SEPT13	0.63	8.0	0.3	5.74e-15	Body mass index;
BRCA	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18876405	chr7:65276391	NA	-0.5	-11.07	-0.4	3.5e-26	Aortic root size;
BRCA	cis	rs4889855	0.530	rs8079792	chr17:78609394	A/G	cg16591659	chr17:78472290	NA	-0.31	-8.0	-0.3	6.06e-15	Fractional excretion of uric acid;
BRCA	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10802521	chr3:52805072	NEK4	0.32	8.34	0.31	4.52e-16	Bipolar disorder;
BRCA	cis	rs751728	0.626	rs6457741	chr6:33756026	C/T	cg25922239	chr6:33757077	LEMD2	0.49	12.55	0.44	1.92e-32	Crohn's disease;
BRCA	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg14196790	chr5:131705035	SLC22A5	0.32	8.49	0.32	1.46e-16	Breast cancer;
BRCA	cis	rs870825	0.550	rs10000507	chr4:185619281	C/T	cg04058563	chr4:185651563	MLF1IP	0.76	17.0	0.56	1e-53	Blood protein levels;
BRCA	cis	rs9403521	1.000	rs116980222	chr6:143998987	C/T	cg18240653	chr6:144019428	PHACTR2	-0.41	-8.18	-0.31	1.5e-15	Obesity-related traits;
BRCA	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg23029597	chr12:123009494	RSRC2	0.62	11.99	0.43	4.88e-30	Body mass index;
BRCA	cis	rs4363385	0.747	rs946099	chr1:152971618	A/G	cg25856811	chr1:152973957	SPRR3	-0.35	-9.35	-0.35	1.47e-19	Inflammatory skin disease;
BRCA	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg19539972	chr4:7069911	GRPEL1	0.69	16.89	0.56	3.38e-53	Monocyte percentage of white cells;
BRCA	cis	rs2806561	0.964	rs1757041	chr1:23506063	G/A	cg19743168	chr1:23544995	NA	0.41	9.92	0.37	1.14e-21	Height;
BRCA	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.5	-10.94	-0.4	1.21e-25	Longevity;Endometriosis;
BRCA	trans	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg26384229	chr12:38710491	ALG10B	0.47	10.39	0.38	1.73e-23	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.83	0.36	2.48e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.39	2.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8028182	0.636	rs10152155	chr15:75701554	A/T	cg20655648	chr15:75932815	IMP3	0.42	8.27	0.31	7.82e-16	Sudden cardiac arrest;
BRCA	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg16590910	chr6:42928470	GNMT	0.41	9.17	0.34	6.58e-19	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg14820908	chr5:178986412	RUFY1	0.49	12.99	0.46	2.11e-34	Lung cancer;
BRCA	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg05340658	chr4:99064831	C4orf37	0.66	15.53	0.52	2.29e-46	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.74	0.39	7.59e-25	Cognitive ability;
BRCA	trans	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg26043149	chr18:55253948	FECH	1.05	22.5	0.66	5.15e-83	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg06108461	chr20:60628389	TAF4	-0.72	-15.04	-0.51	5.71e-44	Body mass index;
BRCA	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg24692254	chr21:30365293	RNF160	-0.79	-21.88	-0.65	1.3e-79	Dental caries;
BRCA	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.81	13.5	0.47	9.75e-37	Schizophrenia;
BRCA	cis	rs524281	0.648	rs10896089	chr11:65936292	A/G	cg16950941	chr11:66035639	RAB1B	-0.37	-7.83	-0.3	2e-14	Electroencephalogram traits;
BRCA	cis	rs12618769	0.597	rs3754885	chr2:99121708	G/T	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	21.99	0.66	3.34e-80	Chronic sinus infection;
BRCA	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.08	-0.3	3.26e-15	Bipolar disorder;
BRCA	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg00071950	chr4:10020882	SLC2A9	0.66	16.62	0.55	7.62e-52	Bone mineral density;
BRCA	cis	rs4853036	1.000	rs28362672	chr2:70056866	A/G	cg02498382	chr2:70120550	SNRNP27	-0.51	-9.27	-0.34	2.72e-19	Colorectal or endometrial cancer;
BRCA	cis	rs7178424	0.875	rs8029942	chr15:62353458	G/A	cg00456672	chr15:62358751	C2CD4A	-0.36	-8.58	-0.32	7.3e-17	Height;
BRCA	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.66	-0.32	3.7e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6910061	0.830	rs9468435	chr6:11112486	G/A	cg27233058	chr6:11094804	LOC221710	0.5	8.51	0.32	1.21e-16	Diabetic kidney disease;
BRCA	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg23285459	chr7:2802560	GNA12	0.35	8.95	0.33	3.85e-18	Height;
BRCA	cis	rs4141404	0.561	rs5994376	chr22:31563555	A/C	cg02404636	chr22:31891804	SFI1	-0.35	-8.42	-0.32	2.46e-16	Paclitaxel-induced neuropathy;
BRCA	cis	rs7408868	1.000	rs10406754	chr19:15274201	T/A	cg14696996	chr19:15285081	NOTCH3	0.99	14.46	0.5	3.39e-41	Pulse pressure;
BRCA	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg25237894	chr2:233734115	C2orf82	0.38	10.98	0.4	7.87e-26	Coronary artery disease;
BRCA	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg27624424	chr6:160112604	SOD2	0.39	8.23	0.31	1.02e-15	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.38	-7.95	-0.3	8.41e-15	Homocysteine levels;
BRCA	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg19257562	chr1:2043853	PRKCZ	-0.32	-8.86	-0.33	7.62e-18	Height;
BRCA	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg11814155	chr7:99998594	ZCWPW1	0.57	9.69	0.36	7.98e-21	Platelet count;
BRCA	cis	rs7246657	0.722	rs2972437	chr19:38210511	G/T	cg14683738	chr19:37701593	ZNF585B	0.46	7.82	0.3	2.11e-14	Coronary artery calcification;
BRCA	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg11752832	chr7:134001865	SLC35B4	0.39	9.65	0.36	1.21e-20	Mean platelet volume;
BRCA	cis	rs2953174	0.507	rs2953172	chr2:241525316	C/T	cg07929629	chr2:241523174	NA	0.57	10.92	0.4	1.43e-25	Bipolar disorder;
BRCA	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg01802117	chr1:53393560	SCP2	-0.42	-9.43	-0.35	7.5599999999999994e-20	Monocyte count;
BRCA	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11764359	chr7:65958608	NA	-0.76	-17.18	-0.56	1.11e-54	Aortic root size;
BRCA	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-7.89	-0.3	1.36e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg13628971	chr7:2884303	GNA12	0.6	13.49	0.47	1.16e-36	Height;
BRCA	cis	rs7927771	0.524	rs6485773	chr11:47763509	A/G	cg20307385	chr11:47447363	PSMC3	0.42	9.56	0.35	2.48e-20	Subjective well-being;
BRCA	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg19622623	chr12:86230825	RASSF9	-0.33	-9.22	-0.34	4.11e-19	Major depressive disorder;
BRCA	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.41	-10.09	-0.37	2.59e-22	Longevity;Endometriosis;
BRCA	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24531977	chr5:56204891	C5orf35	-0.88	-18.15	-0.58	1.15e-59	Initial pursuit acceleration;
BRCA	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.03	0.49	3.57e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg04944784	chr2:26401820	FAM59B	-0.9	-16.49	-0.55	3.51e-51	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.47	0.38	9.14e-24	Motion sickness;
BRCA	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg13010199	chr12:38710504	ALG10B	0.43	9.09	0.34	1.28e-18	Morning vs. evening chronotype;
BRCA	cis	rs4660306	1.000	rs2356561	chr1:45980862	T/G	cg24296786	chr1:45957014	TESK2	0.43	9.08	0.34	1.33e-18	Homocysteine levels;
BRCA	cis	rs867371	0.929	rs7173852	chr15:82461853	A/G	cg00614314	chr15:82944287	LOC80154	0.42	8.88	0.33	6.72e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg26384229	chr12:38710491	ALG10B	0.74	17.21	0.56	7.75e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg20701182	chr2:24300061	SF3B14	0.66	9.65	0.36	1.15e-20	Lymphocyte counts;
BRCA	cis	rs6973256	0.865	rs11771373	chr7:133334842	A/G	cg07491979	chr7:133331646	EXOC4	-0.39	-8.91	-0.33	5.11e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg13010199	chr12:38710504	ALG10B	0.49	9.48	0.35	4.85e-20	Morning vs. evening chronotype;
BRCA	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg12927641	chr6:109611667	NA	-0.36	-8.97	-0.33	3.21e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.03	-0.3	4.72e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg17063962	chr7:91808500	NA	0.54	12.26	0.44	3.63e-31	Breast cancer;
BRCA	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg03954927	chr1:10346856	KIF1B	0.47	14.9	0.51	2.49e-43	Hepatocellular carcinoma;
BRCA	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06634786	chr22:41940651	POLR3H	0.5	9.13	0.34	9.23e-19	Vitiligo;
BRCA	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg23029597	chr12:123009494	RSRC2	-0.63	-11.3	-0.41	3.87e-27	Body mass index;
BRCA	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.9e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg14664628	chr15:75095509	CSK	0.84	22.56	0.67	2.58e-83	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg01579765	chr21:45077557	HSF2BP	-0.44	-11.84	-0.42	2.26e-29	Mean corpuscular volume;
BRCA	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.41	-0.35	8.6e-20	Total body bone mineral density;
BRCA	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg11812906	chr14:75593930	NEK9	-0.56	-12.63	-0.45	8.23e-33	Height;
BRCA	cis	rs67981189	0.892	rs221899	chr14:71605268	C/T	cg15816911	chr14:71606274	NA	0.36	8.13	0.31	2.19e-15	Schizophrenia;
BRCA	cis	rs9487051	0.676	rs11964178	chr6:109562035	A/G	cg21918786	chr6:109611834	NA	-0.31	-8.07	-0.3	3.38e-15	Reticulocyte fraction of red cells;
BRCA	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg01483505	chr11:975446	AP2A2	0.34	9.21	0.34	4.73e-19	Alzheimer's disease (late onset);
BRCA	cis	rs9473147	0.543	rs9369716	chr6:47552180	A/T	cg12968598	chr6:47444699	CD2AP	0.46	9.84	0.36	2.34e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg08885076	chr2:99613938	TSGA10	0.45	10.6	0.39	2.62e-24	Chronic sinus infection;
BRCA	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.45	-0.32	1.93e-16	Total body bone mineral density;
BRCA	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg08085267	chr17:45401833	C17orf57	-0.64	-13.75	-0.48	7.46e-38	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7131987	0.675	rs2194515	chr12:29550383	T/C	cg09582351	chr12:29534625	ERGIC2	0.4	9.52	0.35	3.5e-20	QT interval;
BRCA	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35995292	0.534	rs10274968	chr7:38939254	C/T	cg19327137	chr7:38886074	VPS41	0.41	13.47	0.47	1.37e-36	Subjective well-being (multi-trait analysis);
BRCA	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.72	-15.56	-0.52	1.5e-46	Lymphocyte counts;
BRCA	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.64	-11.83	-0.42	2.49e-29	IgG glycosylation;
BRCA	cis	rs12050794	0.671	rs7179427	chr15:72516821	G/A	cg16672083	chr15:72433130	SENP8	0.63	14.81	0.51	6.89e-43	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs12618769	0.597	rs3769738	chr2:99078367	T/C	cg10123293	chr2:99228465	UNC50	0.41	8.27	0.31	8.05e-16	Bipolar disorder;
BRCA	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.55	8.58	0.32	7.26e-17	Renal function-related traits (BUN);
BRCA	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.55	11.56	0.42	3.47e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25427524	chr10:38739819	LOC399744	-0.71	-17.44	-0.57	5.3e-56	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7633857	0.512	rs2376477	chr3:160700699	G/T	cg03342759	chr3:160939853	NMD3	-0.55	-11.66	-0.42	1.32e-28	Educational attainment (years of education);
BRCA	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg06627628	chr2:24431161	ITSN2	-0.57	-8.99	-0.34	2.78e-18	Lymphocyte counts;
BRCA	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg17691542	chr6:26056736	HIST1H1C	0.52	11.23	0.41	7.91e-27	Height;
BRCA	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg18230493	chr5:56204884	C5orf35	-0.72	-14.34	-0.49	1.18e-40	Initial pursuit acceleration;
BRCA	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.77	-0.42	4.37e-29	Electroencephalogram traits;
BRCA	cis	rs27434	0.583	rs151909	chr5:96156888	T/C	cg16492584	chr5:96139282	ERAP1	-0.51	-12.73	-0.45	3.03e-33	Ankylosing spondylitis;
BRCA	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.37	-0.31	3.51e-16	Total body bone mineral density;
BRCA	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg06623918	chr6:96969491	KIAA0776	0.74	15.48	0.52	3.88e-46	Migraine;Coronary artery disease;
BRCA	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	19.29	0.61	1.09e-65	Tonsillectomy;
BRCA	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg00074818	chr8:8560427	CLDN23	0.37	8.16	0.31	1.73e-15	Obesity-related traits;
BRCA	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg00666640	chr1:248458726	OR2T12	0.35	9.27	0.34	2.87e-19	Common traits (Other);
BRCA	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg05025164	chr4:1340916	KIAA1530	0.36	7.93	0.3	9.59e-15	Longevity;
BRCA	trans	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg26043149	chr18:55253948	FECH	-0.37	-8.25	-0.31	9.34e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs11249608	0.636	rs13361077	chr5:178449174	G/C	cg21905437	chr5:178450457	ZNF879	0.5	10.61	0.39	2.55e-24	Pubertal anthropometrics;
BRCA	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg02951883	chr7:2050386	MAD1L1	0.47	11.86	0.42	1.87e-29	Bipolar disorder and schizophrenia;
BRCA	trans	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.38	7.82	0.3	2.2e-14	Menarche (age at onset);
BRCA	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg13010199	chr12:38710504	ALG10B	-0.49	-10.69	-0.39	1.22e-24	Heart rate;
BRCA	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg24596788	chr1:163392923	NA	0.3	8.04	0.3	4.46e-15	Motion sickness;
BRCA	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-15.71	-0.53	2.76e-47	Electrocardiographic conduction measures;
BRCA	cis	rs4478858	0.647	rs6425720	chr1:31709555	A/G	cg00250761	chr1:31883323	NA	-0.31	-8.17	-0.31	1.71e-15	Alcohol dependence;
BRCA	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.56	13.22	0.46	1.93e-35	Eye color traits;
BRCA	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg26384229	chr12:38710491	ALG10B	-0.64	-16.83	-0.55	7.02e-53	Heart rate;
BRCA	cis	rs17228212	1.000	rs17227883	chr15:67443078	C/T	cg26876701	chr15:67458665	SMAD3	-0.47	-9.1	-0.34	1.16e-18	Coronary heart disease;
BRCA	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg14863265	chr7:2801509	GNA12	-0.45	-10.0	-0.37	5.64e-22	Height;
BRCA	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg13256891	chr4:100009986	ADH5	0.45	8.03	0.3	4.7e-15	Alcohol dependence;
BRCA	cis	rs6546550	0.901	rs13028508	chr2:70118427	A/T	cg02498382	chr2:70120550	SNRNP27	0.52	11.54	0.42	3.9e-28	Prevalent atrial fibrillation;
BRCA	cis	rs1198430	1.000	rs1198431	chr1:23755716	C/T	cg19827787	chr1:23763612	ASAP3	-0.36	-9.7	-0.36	7.37e-21	Total cholesterol levels;
BRCA	cis	rs2742234	0.910	rs2503866	chr10:43646261	T/A	cg02780029	chr10:43622663	RET	-0.4	-10.03	-0.37	4.25e-22	Hirschsprung disease;
BRCA	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-12.02	-0.43	3.77e-30	Bipolar disorder;
BRCA	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg04455712	chr21:45112962	RRP1B	0.42	10.41	0.38	1.5e-23	Mean corpuscular volume;
BRCA	cis	rs2276314	0.553	rs4799842	chr18:33627968	C/A	cg05985134	chr18:33552581	C18orf21	0.42	8.14	0.31	2.09e-15	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs13053817	1.000	rs34305567	chr22:29853562	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.49	-8.89	-0.33	6.29e-18	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.48	10.82	0.39	3.69e-25	Response to bleomycin (chromatid breaks);
BRCA	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.82e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.63	13.67	0.48	1.62e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg26116260	chr4:7069785	GRPEL1	-0.86	-17.83	-0.58	5.1e-58	Monocyte percentage of white cells;
BRCA	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg24690094	chr11:67383802	NA	0.49	10.57	0.39	3.65e-24	Mean corpuscular volume;
BRCA	cis	rs2011503	0.509	rs11668721	chr19:19760916	G/A	cg11584989	chr19:19387371	SF4	0.44	8.5	0.32	1.35e-16	Bipolar disorder;
BRCA	cis	rs7246657	0.722	rs8103647	chr19:38100452	C/A	cg23950597	chr19:37808831	NA	-0.49	-8.49	-0.32	1.46e-16	Coronary artery calcification;
BRCA	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.22	0.34	4.35e-19	Tonsillectomy;
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg22907277	chr7:1156413	C7orf50	0.4	8.56	0.32	8.34e-17	Longevity;Endometriosis;
BRCA	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg10729496	chr3:10149963	C3orf24	0.48	8.97	0.33	3.2e-18	Alzheimer's disease;
BRCA	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg13319975	chr6:146136371	FBXO30	0.43	10.04	0.37	4.06e-22	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg26043149	chr18:55253948	FECH	-0.4	-8.51	-0.32	1.21e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg07169764	chr2:136633963	MCM6	1.0	19.2	0.6	3.34e-65	Corneal structure;
BRCA	cis	rs13102973	0.829	rs55951114	chr4:135897925	T/C	cg14419869	chr4:135874104	NA	0.48	9.61	0.36	1.69e-20	Subjective well-being;
BRCA	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg24642439	chr20:33292090	TP53INP2	0.73	16.99	0.56	1.02e-53	Coronary artery disease;
BRCA	cis	rs11997175	0.819	rs6415400	chr8:33783714	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	11.41	0.41	1.46e-27	Body mass index;
BRCA	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.87	-0.3	1.52e-14	Prostate cancer;
BRCA	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg00277334	chr10:82204260	NA	-0.44	-8.59	-0.32	6.6e-17	Post bronchodilator FEV1;
BRCA	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg14664628	chr15:75095509	CSK	-0.9	-24.51	-0.7	4.95e-94	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs7020830	0.898	rs2790063	chr9:37287405	G/A	cg14294708	chr9:37120828	ZCCHC7	1.05	30.81	0.77	1.85e-128	Schizophrenia;
BRCA	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	7.89	0.3	1.31e-14	Menarche (age at onset);
BRCA	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	11.85	0.42	2.03e-29	Lung cancer in ever smokers;
BRCA	cis	rs10465746	0.780	rs1324486	chr1:84384825	A/G	cg10977910	chr1:84465055	TTLL7	-0.56	-11.42	-0.41	1.3e-27	Obesity-related traits;
BRCA	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg27490568	chr2:178487706	NA	0.42	7.87	0.3	1.47e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	9.85	0.36	2.18e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg26043149	chr18:55253948	FECH	-0.37	-8.24	-0.31	9.84e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs6479891	1.000	rs10761730	chr10:65017053	C/T	cg14819942	chr15:35414228	NA	-0.35	-8.57	-0.32	7.85e-17	Arthritis (juvenile idiopathic);
BRCA	trans	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.85	-27.43	-0.74	4.31e-110	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg22906224	chr7:99728672	NA	-0.42	-7.82	-0.3	2.27e-14	Coronary artery disease;
BRCA	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg26408565	chr15:76604113	ETFA	-0.48	-10.23	-0.38	7.71e-23	Blood metabolite levels;
BRCA	cis	rs911119	0.913	rs13043266	chr20:23588127	C/T	cg16589663	chr20:23618590	CST3	0.44	8.14	0.31	2.09e-15	Chronic kidney disease;
BRCA	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.0	0.51	8.96e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs877282	0.628	rs11253435	chr10:824169	T/C	cg15764593	chr10:829463	NA	-0.65	-10.7	-0.39	1.04e-24	Uric acid levels;
BRCA	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg05279229	chr7:1896384	MAD1L1	-0.39	-8.02	-0.3	5.08e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg18758796	chr5:131593413	PDLIM4	-0.39	-9.49	-0.35	4.59e-20	Acylcarnitine levels;
BRCA	cis	rs887829	0.570	rs4261716	chr2:234593117	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.32	-8.31	-0.31	5.65e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03452623	chr4:187889614	NA	-0.31	-10.14	-0.37	1.7e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.7	0.39	1.11e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg12573674	chr2:1569213	NA	-0.57	-12.43	-0.44	6.56e-32	Placebo response in major depressive disorder (% change in symptom score);
BRCA	trans	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-8.11	-0.31	2.53e-15	Menarche (age at onset);
BRCA	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg02751453	chr18:77725136	HSBP1L1	0.38	9.19	0.34	5.6e-19	Opioid sensitivity;
BRCA	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.66	-14.4	-0.49	6.67e-41	Lung cancer;
BRCA	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg17143192	chr8:8559678	CLDN23	0.54	10.49	0.38	7.14e-24	Obesity-related traits;
BRCA	cis	rs365132	0.875	rs691141	chr5:176323298	A/G	cg16309518	chr5:176445507	NA	0.39	9.51	0.35	3.91e-20	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg09537434	chr19:41945824	ATP5SL	-0.95	-23.17	-0.68	1.15e-86	Height;
BRCA	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg04166393	chr7:2884313	GNA12	0.4	8.27	0.31	7.54e-16	Height;
BRCA	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg10482532	chr10:96946522	NA	-0.55	-13.66	-0.48	1.96e-37	Immune response to smallpox vaccine (IL-6);
BRCA	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg22705602	chr4:152727874	NA	-0.32	-8.06	-0.3	3.79e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg09658497	chr7:2847517	GNA12	-0.43	-8.54	-0.32	9.92e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
BRCA	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22307029	chr19:49891270	CCDC155	0.54	9.07	0.34	1.4e-18	Multiple sclerosis;
BRCA	cis	rs7147624	1.000	rs11848209	chr14:66022832	T/A	cg03016385	chr14:66212404	NA	-0.59	-8.96	-0.33	3.61e-18	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs724568	0.546	rs1367458	chr2:67946328	C/T	cg17945962	chr2:67939740	NA	-0.37	-10.2	-0.37	9.64e-23	Major depressive disorder (broad);
BRCA	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg20307385	chr11:47447363	PSMC3	0.89	27.06	0.73	4.95e-108	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg21143896	chr7:2802374	GNA12	-0.33	-8.18	-0.31	1.53e-15	Height;
BRCA	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg01028140	chr2:1542097	TPO	-0.77	-15.42	-0.52	8.12e-46	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4478858	0.684	rs7549343	chr1:31752260	A/G	cg00250761	chr1:31883323	NA	-0.32	-8.33	-0.31	4.93e-16	Alcohol dependence;
BRCA	cis	rs11887277	0.507	rs1821410	chr2:27058507	T/C	cg12368169	chr2:27073192	DPYSL5	-0.27	-8.0	-0.3	5.94e-15	Obesity-related traits;
BRCA	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg13010199	chr12:38710504	ALG10B	0.54	11.5	0.41	6.2e-28	Heart rate;
BRCA	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.62	-13.14	-0.46	4.52e-35	Lymphocyte counts;
BRCA	cis	rs877529	1.000	rs139413	chr22:39553772	C/T	cg12193277	chr22:39547181	CBX7	-0.42	-11.35	-0.41	2.47e-27	Multiple myeloma;
BRCA	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg10523679	chr1:76189770	ACADM	0.66	13.76	0.48	6.31e-38	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs290268	0.838	rs290993	chr9:93559572	G/A	cg02608019	chr9:93564028	SYK	0.56	12.32	0.44	1.91e-31	Platelet count;
BRCA	cis	rs7975161	0.630	rs4246264	chr12:104637743	C/G	cg25273343	chr12:104657179	TXNRD1	-0.61	-9.53	-0.35	3.31e-20	Toenail selenium levels;
BRCA	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13732083	chr21:47605072	C21orf56	0.38	8.01	0.3	5.6e-15	Testicular germ cell tumor;
BRCA	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg08847533	chr14:75593920	NEK9	-0.45	-8.09	-0.3	3.03e-15	IgG glycosylation;
BRCA	trans	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg20993868	chr7:22813445	NA	0.58	16.18	0.54	1.26e-49	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg21747090	chr2:27597821	SNX17	-0.4	-8.67	-0.32	3.42e-17	Total body bone mineral density;
BRCA	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg24977027	chr2:88469347	THNSL2	-0.45	-10.69	-0.39	1.23e-24	Response to metformin (IC50);
BRCA	cis	rs3820928	0.874	rs10182307	chr2:227875360	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.48	-0.32	1.57e-16	Pulmonary function;
BRCA	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.49	-0.32	1.4e-16	Colorectal cancer;
BRCA	trans	rs3857536	0.813	rs2040591	chr6:66945915	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	2.02e-14	Blood trace element (Cu levels);
BRCA	trans	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg07211511	chr3:129823064	LOC729375	-0.78	-15.04	-0.51	5.2e-44	Blood pressure (smoking interaction);
BRCA	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg03213289	chr20:61660250	NA	0.63	16.54	0.55	2.05e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg26384229	chr12:38710491	ALG10B	0.86	23.3	0.68	2.11e-87	Heart rate;
BRCA	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05025164	chr4:1340916	KIAA1530	0.76	15.7	0.53	3.33e-47	Longevity;
BRCA	cis	rs6138458	1.000	rs227624	chr20:24911562	T/C	cg26195577	chr20:24973756	C20orf3	0.98	24.76	0.7	2.17e-95	Blood protein levels;
BRCA	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg22920501	chr2:26401640	FAM59B	-0.7	-11.81	-0.42	3.01e-29	Gut microbiome composition (summer);
BRCA	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg04414720	chr1:150670196	GOLPH3L	0.34	7.82	0.3	2.13e-14	Tonsillectomy;
BRCA	cis	rs11231017	0.507	rs11231058	chr11:62138890	C/T	cg23876832	chr11:62092739	NA	0.33	8.23	0.31	1.04e-15	HIV-1 viral setpoint;
BRCA	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.45	10.7	0.39	1.13e-24	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg27129171	chr3:47204927	SETD2	0.76	19.64	0.61	1.58e-67	Colorectal cancer;
BRCA	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg09537434	chr19:41945824	ATP5SL	-0.99	-24.68	-0.7	5.87e-95	Height;
BRCA	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12292205	chr6:26970375	C6orf41	-0.47	-7.97	-0.3	7.21e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7193541	0.859	rs12598791	chr16:74500745	A/C	cg01733217	chr16:74700730	RFWD3	0.63	16.32	0.54	2.76e-50	Multiple myeloma;
BRCA	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg07636037	chr3:49044803	WDR6	0.97	29.29	0.76	3.21e-120	Parkinson's disease;
BRCA	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg06784218	chr1:46089804	CCDC17	-0.47	-11.08	-0.4	3.29e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg06623918	chr6:96969491	KIAA0776	0.92	27.08	0.73	3.74e-108	Headache;
BRCA	cis	rs738322	0.640	rs738321	chr22:38568833	C/G	cg25457927	chr22:38595422	NA	-0.33	-12.24	-0.44	4.42e-31	Cutaneous nevi;
BRCA	cis	rs701145	0.586	rs181443	chr3:153959028	G/T	cg12800244	chr3:153838788	SGEF	0.45	8.92	0.33	4.82e-18	Coronary artery disease;
BRCA	cis	rs3125734	0.633	rs6479792	chr10:63983264	T/G	cg09941381	chr10:64027924	RTKN2	-0.27	-8.09	-0.3	3.02e-15	Rheumatoid arthritis;
BRCA	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	4.76e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg15819921	chr19:927150	ARID3A	-0.47	-9.01	-0.34	2.3e-18	Life satisfaction;
BRCA	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg17971929	chr21:40555470	PSMG1	-0.62	-14.4	-0.49	6.73e-41	Cognitive function;
BRCA	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg00666640	chr1:248458726	OR2T12	0.3	8.58	0.32	7.32e-17	Common traits (Other);
BRCA	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg22875332	chr1:76189707	ACADM	-0.5	-9.51	-0.35	3.72e-20	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs225245	0.782	rs321599	chr17:33905745	C/T	cg19694781	chr19:47549865	TMEM160	-0.32	-7.81	-0.3	2.31e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs1712517	0.873	rs1163083	chr10:105038455	T/A	cg05636881	chr10:105038444	INA	0.4	9.06	0.34	1.53e-18	Migraine;
BRCA	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg16590910	chr6:42928470	GNMT	0.42	9.24	0.34	3.62e-19	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00166722	chr3:10149974	C3orf24	0.65	12.95	0.46	3.08e-34	Alzheimer's disease;
BRCA	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg14196790	chr5:131705035	SLC22A5	0.45	11.57	0.42	3.01e-28	Blood metabolite levels;
BRCA	cis	rs490234	0.812	rs7875713	chr9:128268903	G/T	cg14078157	chr9:128172775	NA	-0.34	-8.02	-0.3	4.94e-15	Mean arterial pressure;
BRCA	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.36	-8.4	-0.32	2.92e-16	Longevity;Endometriosis;
BRCA	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg26597838	chr10:835615	NA	0.82	14.82	0.51	6.49e-43	Eosinophil percentage of granulocytes;
BRCA	trans	rs1973993	0.603	rs1925833	chr1:97023641	C/A	cg10631902	chr5:14652156	NA	-0.39	-9.99	-0.37	6.45e-22	Weight;
BRCA	cis	rs4363385	0.818	rs2070963	chr1:153004004	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.56	-0.32	8.65e-17	Inflammatory skin disease;
BRCA	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg01579765	chr21:45077557	HSF2BP	0.31	8.14	0.31	2.14e-15	Mean corpuscular volume;
BRCA	trans	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg21659725	chr3:3221576	CRBN	-0.47	-9.99	-0.37	6.33e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6714710	0.580	rs6711101	chr2:98379813	G/A	cg26665480	chr2:98280029	ACTR1B	0.56	13.05	0.46	1.11e-34	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg25173405	chr17:45401733	C17orf57	-0.44	-8.97	-0.33	3.18e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-11.37	-0.41	2.11e-27	Bipolar disorder;
BRCA	cis	rs2859741	0.565	rs12031540	chr1:37513757	C/T	cg09363841	chr1:37513479	NA	-0.51	-11.75	-0.42	5.41e-29	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg20607798	chr8:58055168	NA	0.47	8.07	0.3	3.41e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs11083475	0.681	rs62121377	chr19:39257296	G/A	cg07403899	chr19:39283540	NA	-0.24	-7.89	-0.3	1.33e-14	Heart rate;
BRCA	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg05283184	chr6:79620031	NA	-0.41	-10.47	-0.38	8.84e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg24069376	chr3:38537580	EXOG	0.43	12.26	0.44	3.42e-31	Electrocardiographic conduction measures;
BRCA	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg05623727	chr3:50126028	RBM5	0.42	10.01	0.37	5.4e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7707921	0.522	rs10065463	chr5:81500280	A/G	cg15871215	chr5:81402204	ATG10	-0.37	-9.41	-0.35	8.93e-20	Breast cancer;
BRCA	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg04166393	chr7:2884313	GNA12	0.44	9.6	0.35	1.83e-20	Height;
BRCA	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg02734326	chr4:10020555	SLC2A9	0.39	8.51	0.32	1.21e-16	Bone mineral density;
BRCA	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg19920283	chr7:105172520	RINT1	0.59	9.4	0.35	9.51e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7851660	0.935	rs10818124	chr9:100603008	C/T	cg13688889	chr9:100608707	NA	-0.36	-8.61	-0.32	5.84e-17	Strep throat;
BRCA	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	8.22	0.31	1.16e-15	Retinal vascular caliber;
BRCA	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg14863265	chr7:2801509	GNA12	-0.42	-8.78	-0.33	1.45e-17	Height;
BRCA	cis	rs965469	1.000	rs8123289	chr20:3253831	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-9.93	-0.37	1e-21	IFN-related cytopenia;
BRCA	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg23711669	chr6:146136114	FBXO30	0.8	18.91	0.6	1.06e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg02659138	chr7:134003124	SLC35B4	-0.34	-9.64	-0.36	1.22e-20	Mean platelet volume;
BRCA	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg12549451	chr6:135224345	NA	-0.36	-8.19	-0.31	1.47e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	trans	rs2736345	0.516	rs7844858	chr8:11392659	T/A	cg15556689	chr8:8085844	FLJ10661	0.34	9.01	0.34	2.28e-18	Sjögren's syndrome;Systemic lupus erythematosus;
BRCA	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	21.43	0.65	3.4e-77	Mean platelet volume;
BRCA	cis	rs17095355	1.000	rs12242642	chr10:111724213	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.82	-0.36	2.61e-21	Biliary atresia;
BRCA	trans	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg25214090	chr10:38739885	LOC399744	0.46	10.34	0.38	2.86e-23	Corneal astigmatism;
BRCA	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg00166722	chr3:10149974	C3orf24	0.64	11.27	0.41	5.44e-27	Alzheimer's disease;
BRCA	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg12463550	chr7:65579703	CRCP	0.37	7.9	0.3	1.23e-14	Aortic root size;
BRCA	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg00409905	chr10:38381863	ZNF37A	0.52	11.24	0.41	7.39e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg01448562	chr3:133502909	NA	-0.43	-9.46	-0.35	5.59e-20	Iron status biomarkers;
BRCA	trans	rs35847492	1.000	rs17730481	chr8:9276163	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.75	-0.36	4.92e-21	Neuroticism;
BRCA	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-15.36	-0.52	1.57e-45	Systemic lupus erythematosus;
BRCA	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03452623	chr4:187889614	NA	-0.35	-11.45	-0.41	9.92e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27286337	chr10:134555280	INPP5A	0.63	10.7	0.39	1.08e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg19622623	chr12:86230825	RASSF9	-0.28	-8.12	-0.31	2.41e-15	Major depressive disorder;
BRCA	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg09177884	chr7:1199841	ZFAND2A	0.43	9.12	0.34	9.78e-19	Longevity;Endometriosis;
BRCA	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg05234568	chr11:5960015	NA	-0.44	-9.54	-0.35	2.85e-20	DNA methylation (variation);
BRCA	trans	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg27600084	chr12:12264075	NA	0.37	8.66	0.32	3.82e-17	Breast size;
BRCA	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-15.85	-0.53	6.05e-48	Chronic sinus infection;
BRCA	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg14500267	chr11:67383377	NA	0.4	8.5	0.32	1.33e-16	Mean corpuscular volume;
BRCA	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs919433	0.617	rs34632716	chr2:198542619	C/T	cg00792783	chr2:198669748	PLCL1	-0.44	-9.64	-0.36	1.24e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg22713356	chr15:30763199	NA	1.31	26.42	0.72	1.6e-104	Uric acid levels;
BRCA	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.34	-9.56	-0.35	2.51e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg04248312	chr19:17393744	ANKLE1	-0.93	-21.69	-0.65	1.32e-78	Systemic lupus erythematosus;
BRCA	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg03161606	chr19:29218774	NA	0.47	8.24	0.31	9.51e-16	Methadone dose in opioid dependence;
BRCA	trans	rs4714291	0.802	rs1923465	chr6:39971376	A/T	cg02267698	chr19:7991119	CTXN1	-0.45	-9.41	-0.35	8.5e-20	Strep throat;
BRCA	cis	rs10465746	0.967	rs11163861	chr1:84354282	T/C	cg10977910	chr1:84465055	TTLL7	0.51	10.2	0.37	9.92e-23	Obesity-related traits;
BRCA	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-12.7	-0.45	4.28e-33	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg21143896	chr7:2802374	GNA12	-0.37	-9.38	-0.35	1.15e-19	Height;
BRCA	cis	rs9807989	0.507	rs4479442	chr2:103054074	A/T	cg03938978	chr2:103052716	IL18RAP	0.29	8.5	0.32	1.34e-16	Asthma;
BRCA	cis	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg07460842	chr6:66804631	NA	0.87	15.64	0.53	6.69e-47	Exhaled nitric oxide levels;
BRCA	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg18016565	chr1:150552671	MCL1	-0.41	-9.43	-0.35	7.2e-20	Tonsillectomy;
BRCA	cis	rs6910061	0.512	rs67794216	chr6:11114209	G/T	cg27233058	chr6:11094804	LOC221710	0.54	9.54	0.35	2.87e-20	Diabetic kidney disease;
BRCA	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg06115741	chr20:33292138	TP53INP2	0.38	8.47	0.32	1.7e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.72e-18	Alzheimer's disease (late onset);
BRCA	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg10011062	chr15:43941034	CATSPER2	-0.53	-7.81	-0.3	2.27e-14	Lung cancer in ever smokers;
BRCA	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg00757033	chr12:89920650	WDR51B	0.53	10.71	0.39	1.02e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg19257562	chr1:2043853	PRKCZ	0.36	10.5	0.38	6.7e-24	Height;
BRCA	cis	rs4285028	0.948	rs13083557	chr3:121687613	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.88	-0.4	2.15e-25	Multiple sclerosis;
BRCA	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-8.86	-0.33	7.77e-18	Alzheimer's disease (late onset);
BRCA	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs16958440	0.867	rs12326221	chr18:44682893	G/T	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg24296786	chr1:45957014	TESK2	0.64	15.96	0.53	1.75e-48	High light scatter reticulocyte count;
BRCA	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.52	-0.61	6.85e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg10560079	chr2:191398806	TMEM194B	-0.74	-13.38	-0.47	3.5e-36	Diastolic blood pressure;
BRCA	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg04025307	chr7:1156635	C7orf50	0.53	10.45	0.38	1.07e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg06623918	chr6:96969491	KIAA0776	0.77	13.47	0.47	1.43e-36	Migraine;Coronary artery disease;
BRCA	cis	rs1005224	0.853	rs6574251	chr14:76136883	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.35	-8.19	-0.31	1.42e-15	Large artery stroke;
BRCA	cis	rs9287719	0.601	rs12995465	chr2:10716828	G/A	cg00105475	chr2:10696890	NA	0.47	10.46	0.38	9.8e-24	Prostate cancer;
BRCA	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-12.05	-0.43	2.69e-30	Total cholesterol levels;
BRCA	cis	rs68170813	0.605	rs4730227	chr7:106904031	G/C	cg02696742	chr7:106810147	HBP1	-0.52	-9.03	-0.34	1.96e-18	Coronary artery disease;
BRCA	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	13.13	0.46	4.75e-35	Ileal carcinoids;
BRCA	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg12311346	chr5:56204834	C5orf35	-0.79	-16.01	-0.53	9.84e-49	Initial pursuit acceleration;
BRCA	trans	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg26384229	chr12:38710491	ALG10B	0.6	12.16	0.43	9.04e-31	Resting heart rate;
BRCA	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg03433033	chr1:76189801	ACADM	0.86	22.18	0.66	2.75e-81	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4891159	0.724	rs690401	chr18:74108576	C/T	cg24786174	chr18:74118243	ZNF516	0.73	17.99	0.58	7.89e-59	Longevity;
BRCA	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.92	0.4	1.43e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg09307838	chr4:120376055	NA	0.72	15.33	0.52	2.08e-45	Corneal astigmatism;
BRCA	cis	rs2880765	0.835	rs7178991	chr15:86050944	G/C	cg10818794	chr15:86012489	AKAP13	-0.31	-8.85	-0.33	8.84e-18	Coronary artery disease;
BRCA	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg02544614	chr20:61657117	NA	0.28	7.93	0.3	1.01e-14	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg11764359	chr7:65958608	NA	-0.64	-11.38	-0.41	1.97e-27	Aortic root size;
BRCA	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.51	-10.58	-0.39	3.13e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg12751644	chr20:60527061	NA	0.4	8.81	0.33	1.16e-17	Obesity-related traits;
BRCA	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7777754	0.512	rs11238131	chr7:50538589	T/C	cg18232548	chr7:50535776	DDC	-0.54	-13.02	-0.46	1.55e-34	Response to zileuton treatment in asthma (FEV1 change interaction);
BRCA	trans	rs1941687	0.527	rs12608181	chr18:31339351	T/G	cg27147174	chr7:100797783	AP1S1	-0.4	-8.19	-0.31	1.43e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg19717773	chr7:2847554	GNA12	-0.48	-11.35	-0.41	2.63e-27	Height;
BRCA	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg02574844	chr11:5959923	NA	-0.4	-7.81	-0.3	2.43e-14	DNA methylation (variation);
BRCA	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg23533926	chr12:111358616	MYL2	-0.42	-8.66	-0.32	3.88e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg23711669	chr6:146136114	FBXO30	0.79	18.96	0.6	5.82e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9463078	0.739	rs6910749	chr6:44773892	A/G	cg25276700	chr6:44698697	NA	-0.39	-8.99	-0.33	2.87e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02353165	chr6:42928485	GNMT	0.88	23.62	0.68	3.77e-89	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	19.55	0.61	4.35e-67	Electrocardiographic conduction measures;
BRCA	cis	rs9287719	0.649	rs10929677	chr2:10717548	A/G	cg00105475	chr2:10696890	NA	0.41	9.23	0.34	3.91e-19	Prostate cancer;
BRCA	cis	rs7617773	0.817	rs9819094	chr3:48319558	C/T	cg11946769	chr3:48343235	NME6	0.56	12.02	0.43	3.85e-30	Coronary artery disease;
BRCA	cis	rs10754283	0.967	rs1934044	chr1:90107501	C/T	cg21401794	chr1:90099060	LRRC8C	-0.48	-11.61	-0.42	2.05e-28	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg20387954	chr3:183756860	HTR3D	0.46	10.59	0.39	2.89e-24	Anterior chamber depth;
BRCA	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg10523679	chr1:76189770	ACADM	-0.75	-15.69	-0.53	3.66e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4663969	0.873	rs759174	chr2:234668245	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.32	-8.53	-0.32	1.04e-16	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg14675211	chr2:100938903	LONRF2	0.43	10.0	0.37	5.89e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg21724239	chr8:58056113	NA	0.64	9.9	0.36	1.34e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg13319975	chr6:146136371	FBXO30	-0.4	-9.14	-0.34	8.3e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg13010199	chr12:38710504	ALG10B	0.35	8.22	0.31	1.1e-15	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg10518543	chr12:38710700	ALG10B	0.36	8.0	0.3	5.92e-15	Morning vs. evening chronotype;
BRCA	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg23887609	chr12:130822674	PIWIL1	0.43	9.33	0.35	1.71e-19	Menopause (age at onset);
BRCA	cis	rs12612619	0.732	rs714513	chr2:27206474	T/C	cg00617064	chr2:27272375	NA	-0.33	-8.63	-0.32	5.03e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg08885076	chr2:99613938	TSGA10	0.51	9.22	0.34	4.18e-19	Chronic sinus infection;
BRCA	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg06784218	chr1:46089804	CCDC17	0.51	12.23	0.44	4.9e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1451375	0.698	rs1839740	chr7:50646280	C/T	cg18232548	chr7:50535776	DDC	0.39	9.19	0.34	5.5e-19	Malaria;
BRCA	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg02734326	chr4:10020555	SLC2A9	0.41	8.92	0.33	4.74e-18	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg19717773	chr7:2847554	GNA12	-0.41	-8.85	-0.33	8.32e-18	Height;
BRCA	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg12011299	chr4:100065546	ADH4	0.48	10.81	0.39	4.06e-25	Smoking initiation;
BRCA	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg06238570	chr21:40685208	BRWD1	-0.4	-8.06	-0.3	3.89e-15	Menarche (age at onset);
BRCA	cis	rs7766436	0.848	rs66989470	chr6:22598707	G/C	cg13666174	chr6:22585274	NA	-0.44	-9.56	-0.35	2.43e-20	Coronary artery disease;
BRCA	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	8.0	0.3	6.07e-15	Diabetic retinopathy;
BRCA	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg23711669	chr6:146136114	FBXO30	0.69	15.96	0.53	1.73e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg24642439	chr20:33292090	TP53INP2	0.54	11.63	0.42	1.67e-28	Coronary artery disease;
BRCA	cis	rs3781663	0.526	rs7936612	chr11:70019182	A/G	cg06393558	chr11:69982916	ANO1	-0.35	-8.13	-0.31	2.23e-15	Survival in rectal cancer;
BRCA	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg06784218	chr1:46089804	CCDC17	0.52	12.34	0.44	1.51e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg09877947	chr5:131593287	PDLIM4	0.4	9.44	0.35	6.61e-20	Acylcarnitine levels;
BRCA	cis	rs1691799	0.899	rs1168303	chr12:66738586	A/G	cg16791601	chr12:66731901	HELB	-0.64	-17.29	-0.56	3.01e-55	White blood cell count (basophil);
BRCA	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg04842962	chr6:43655489	MRPS18A	-1.1	-36.42	-0.82	4.74e-158	IgG glycosylation;
BRCA	cis	rs72634258	0.554	rs13306061	chr1:7913445	C/T	cg00042356	chr1:8021962	PARK7	0.53	8.18	0.31	1.51e-15	Inflammatory bowel disease;
BRCA	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg18232548	chr7:50535776	DDC	-0.53	-13.45	-0.47	1.7e-36	Systemic sclerosis;
BRCA	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.01	0.37	5.24e-22	Morning vs. evening chronotype;
BRCA	cis	rs7809950	0.798	rs10281535	chr7:107229618	T/G	cg23024343	chr7:107201750	COG5	0.39	8.87	0.33	7.04e-18	Coronary artery disease;
BRCA	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg05623727	chr3:50126028	RBM5	-0.43	-10.3	-0.38	3.88e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg11663144	chr21:46675770	NA	-0.6	-13.81	-0.48	3.78e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg14019146	chr3:50243930	SLC38A3	0.41	10.05	0.37	3.63e-22	Body mass index;
BRCA	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.27	-0.31	8e-16	Bipolar disorder;
BRCA	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg27170947	chr2:26402098	FAM59B	-0.79	-12.79	-0.45	1.7e-33	Gut microbiome composition (summer);
BRCA	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg18446336	chr7:2847575	GNA12	-0.34	-8.09	-0.3	3.07e-15	Height;
BRCA	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg27446573	chr6:127587934	RNF146	0.91	21.01	0.64	6.71e-75	Breast cancer;
BRCA	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg20362242	chr5:692897	TPPP	-0.49	-7.85	-0.3	1.72e-14	Obesity-related traits;
BRCA	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02176678	chr2:219576539	TTLL4	0.45	11.73	0.42	6.24e-29	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg15145296	chr3:125709740	NA	-0.55	-8.65	-0.32	4.23e-17	Blood pressure (smoking interaction);
BRCA	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg26384229	chr12:38710491	ALG10B	0.67	15.47	0.52	4.55e-46	Bladder cancer;
BRCA	cis	rs7520050	0.966	rs4660321	chr1:46366760	A/G	cg24296786	chr1:45957014	TESK2	0.43	9.85	0.36	2.18e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1451375	0.617	rs7790758	chr7:50561544	G/A	cg18232548	chr7:50535776	DDC	-0.42	-9.07	-0.34	1.51e-18	Malaria;
BRCA	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg22963979	chr7:1858916	MAD1L1	0.4	8.72	0.33	2.39e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-8.15	-0.31	1.86e-15	Schizophrenia;
BRCA	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	trans	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17712092	chr4:129076599	LARP1B	0.53	12.7	0.45	4.22e-33	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg23442198	chr4:187126114	CYP4V2	0.62	8.49	0.32	1.42e-16	Blood protein levels;
BRCA	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg06484146	chr7:12443880	VWDE	-0.6	-8.77	-0.33	1.57e-17	Coronary artery disease;
BRCA	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	14.13	0.49	1.18e-39	Lymphocyte percentage of white cells;
BRCA	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg21143896	chr7:2802374	GNA12	-0.32	-8.08	-0.3	3.22e-15	Height;
BRCA	cis	rs483180	0.512	rs866321	chr1:120224469	T/C	cg19096424	chr1:120255104	PHGDH	0.45	10.01	0.37	5.27e-22	Macular telangiectasia type 2;
BRCA	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-10.23	-0.38	7.58e-23	Morning vs. evening chronotype;
BRCA	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg08601574	chr20:25228251	PYGB	-0.34	-8.07	-0.3	3.52e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17253792	0.822	rs17253730	chr14:56157911	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-9.54	-0.35	3.02e-20	Putamen volume;
BRCA	cis	rs58785573	0.504	rs62294474	chr4:38628725	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.49	10.39	0.38	1.75e-23	Lymphocyte percentage of white cells;
BRCA	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg02527881	chr3:46936655	PTH1R	0.35	8.23	0.31	1.09e-15	Birth weight;
BRCA	cis	rs10504073	0.584	rs1511365	chr8:49975321	A/T	cg00325661	chr8:49890786	NA	0.48	13.76	0.48	6.64e-38	Blood metabolite ratios;
BRCA	cis	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg07460842	chr6:66804631	NA	0.93	18.53	0.59	1.17e-61	Exhaled nitric oxide output;
BRCA	cis	rs2625529	0.526	rs11634622	chr15:72562327	G/A	cg16672083	chr15:72433130	SENP8	0.61	14.64	0.5	4.47e-42	Red blood cell count;
BRCA	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg06627628	chr2:24431161	ITSN2	-0.51	-10.37	-0.38	2.19e-23	Asthma;
BRCA	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg21573476	chr21:45109991	RRP1B	-0.34	-8.72	-0.33	2.34e-17	Mean corpuscular volume;
BRCA	cis	rs7512552	0.839	rs11577600	chr1:150407443	G/A	cg15654264	chr1:150340011	RPRD2	0.41	8.87	0.33	7.38e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg10578991	chr7:12443926	VWDE	-0.54	-7.96	-0.3	7.88e-15	Coronary artery disease;
BRCA	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg04455712	chr21:45112962	RRP1B	0.42	10.54	0.38	4.45e-24	Mean corpuscular volume;
BRCA	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02353165	chr6:42928485	GNMT	-0.89	-23.18	-0.68	1e-86	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg08085267	chr17:45401833	C17orf57	0.67	15.0	0.51	8.13e-44	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg19920283	chr7:105172520	RINT1	0.59	9.4	0.35	9.51e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10819733	chr22:24237672	NA	0.34	9.26	0.34	3.16e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg17063962	chr7:91808500	NA	0.61	14.54	0.5	1.46e-41	Breast cancer;
BRCA	cis	rs9308433	0.529	rs4655336	chr1:214499667	A/C	cg06198575	chr1:214491504	SMYD2	0.56	12.32	0.44	2e-31	IgG glycosylation;
BRCA	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg23422044	chr7:1970798	MAD1L1	-0.45	-9.53	-0.35	3.34e-20	Neuroticism;
BRCA	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg26384229	chr12:38710491	ALG10B	0.75	17.2	0.56	8.96e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg11764359	chr7:65958608	NA	-0.74	-16.09	-0.54	3.77e-49	Aortic root size;
BRCA	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	27.92	0.74	9.27e-113	Chronic sinus infection;
BRCA	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg06552810	chr11:31128660	NA	0.37	8.58	0.32	7.41e-17	Red blood cell count;
BRCA	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg20534287	chr10:135191450	PAOX	0.58	9.75	0.36	5.13e-21	Lifespan;
BRCA	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-9.64	-0.36	1.29e-20	HDL cholesterol;
BRCA	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg04102894	chr7:1000210	NA	-0.36	-8.56	-0.32	8.32e-17	Bronchopulmonary dysplasia;
BRCA	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg08999081	chr20:33150536	PIGU	0.46	12.96	0.46	2.82e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg20307385	chr11:47447363	PSMC3	-0.42	-8.61	-0.32	5.68e-17	Subjective well-being;
BRCA	cis	rs1971762	0.563	rs3897117	chr12:54077407	T/G	cg23533419	chr12:54090519	NA	-0.33	-8.3	-0.31	6.23e-16	Height;
BRCA	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18876405	chr7:65276391	NA	-0.5	-11.04	-0.4	4.74e-26	Aortic root size;
BRCA	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg08847533	chr14:75593920	NEK9	-0.47	-9.39	-0.35	1.01e-19	Neuroticism;
BRCA	cis	rs2882667	0.654	rs4835704	chr5:138151325	G/A	cg04439458	chr5:138467593	SIL1	0.35	8.47	0.32	1.63e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs490234	0.702	rs13287071	chr9:128268224	T/C	cg14078157	chr9:128172775	NA	-0.55	-11.96	-0.43	6.65e-30	Mean arterial pressure;
BRCA	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg25173405	chr17:45401733	C17orf57	-0.53	-11.25	-0.41	6.7e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg18904891	chr8:8559673	CLDN23	0.54	10.46	0.38	9.81e-24	Obesity-related traits;
BRCA	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.85	0.42	1.99e-29	Homoarginine levels;
BRCA	cis	rs7598759	0.548	rs6750795	chr2:232378231	T/C	cg19187155	chr2:232395269	NMUR1	0.73	17.19	0.56	1.05e-54	Noise-induced hearing loss;
BRCA	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg18850127	chr7:39170497	POU6F2	-0.48	-10.79	-0.39	4.63e-25	IgG glycosylation;
BRCA	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.13	-0.34	8.78e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg03929089	chr4:120376271	NA	0.49	8.21	0.31	1.24e-15	Axial length;
BRCA	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	14.73	0.5	1.72e-42	Platelet count;
BRCA	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.05	-0.51	4.84e-44	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	8.02e-19	Lymphocyte counts;
BRCA	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg02503808	chr4:7069936	GRPEL1	-0.8	-17.93	-0.58	1.55e-58	Monocyte percentage of white cells;
BRCA	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg08917208	chr2:24149416	ATAD2B	1.06	14.37	0.49	8.94e-41	Lymphocyte counts;
BRCA	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg06026331	chr20:60912101	LAMA5	0.39	7.82	0.3	2.25e-14	Colorectal cancer;
BRCA	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg17063962	chr7:91808500	NA	-0.51	-11.93	-0.43	9.13e-30	Breast cancer;
BRCA	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg04518342	chr5:131593106	PDLIM4	0.42	10.1	0.37	2.41e-22	Acylcarnitine levels;
BRCA	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg13770153	chr20:60521292	NA	-0.43	-9.51	-0.35	3.76e-20	Body mass index;
BRCA	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg19678392	chr7:94953810	PON1	-0.41	-8.88	-0.33	6.78e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs858239	0.600	rs6978827	chr7:23125544	A/T	cg23682824	chr7:23144976	KLHL7	0.45	12.23	0.44	4.63e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.24	-0.31	1.01e-15	Axial length;
BRCA	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg21782813	chr7:2030301	MAD1L1	0.33	8.8	0.33	1.31e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs56399783	0.901	rs17132744	chr7:2874982	T/C	cg19731401	chr7:2775893	GNA12	0.52	8.47	0.32	1.63e-16	Childhood ear infection;
BRCA	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg20701182	chr2:24300061	SF3B14	0.57	8.67	0.32	3.66e-17	Lymphocyte counts;
BRCA	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg16482183	chr6:26056742	HIST1H1C	0.46	9.34	0.35	1.53e-19	Iron status biomarkers;
BRCA	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg18225595	chr11:63971243	STIP1	0.53	9.82	0.36	2.77e-21	Mean platelet volume;
BRCA	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg00277334	chr10:82204260	NA	-0.85	-25.05	-0.7	5.02e-97	Post bronchodilator FEV1;
BRCA	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.41	-8.18	-0.31	1.5e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs7677751	0.806	rs4864861	chr4:55097685	C/T	cg17187183	chr4:55093834	PDGFRA	0.45	8.9	0.33	5.87e-18	Corneal astigmatism;
BRCA	trans	rs7178375	1.000	rs35162264	chr15:31200683	T/A	cg04373760	chr16:53404718	NA	0.47	8.81	0.33	1.21e-17	Hypertriglyceridemia;
BRCA	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg16482183	chr6:26056742	HIST1H1C	0.51	9.91	0.36	1.27e-21	Iron status biomarkers;
BRCA	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg15605315	chr1:45957053	TESK2	0.47	9.77	0.36	4.19e-21	High light scatter reticulocyte count;
BRCA	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg23711669	chr6:146136114	FBXO30	0.77	17.73	0.57	1.74e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11608355	0.515	rs11611011	chr12:109936948	C/T	cg05360138	chr12:110035743	NA	0.74	13.68	0.48	1.56e-37	Neuroticism;
BRCA	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	7.97	0.3	7.41e-15	Menarche (age at onset);
BRCA	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg18479299	chr3:125709523	NA	-0.52	-8.63	-0.32	4.83e-17	Blood pressure (smoking interaction);
BRCA	cis	rs9880211	0.800	rs34324561	chr3:136101242	T/G	cg21827317	chr3:136751795	NA	-0.44	-7.98	-0.3	6.98e-15	Body mass index;Height;
BRCA	cis	rs56399783	0.901	rs73047387	chr7:2774125	G/A	cg19731401	chr7:2775893	GNA12	0.56	8.63	0.32	4.69e-17	Childhood ear infection;
BRCA	trans	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg23762105	chr12:34175262	ALG10	-0.38	-9.61	-0.36	1.62e-20	Heart rate;
BRCA	cis	rs6723226	0.572	rs176411	chr2:32643528	A/G	cg02381751	chr2:32503542	YIPF4	0.44	9.46	0.35	5.68e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs3820928	0.967	rs720501	chr2:227778445	C/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.65	-0.32	4.08e-17	Pulmonary function;
BRCA	trans	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg26043149	chr18:55253948	FECH	-0.37	-8.3	-0.31	6.41e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg06521331	chr12:34319734	NA	-0.54	-9.78	-0.36	3.7e-21	Bladder cancer;
BRCA	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.3	8.23	0.31	1.05e-15	Response to antipsychotic treatment;
BRCA	trans	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg06521331	chr12:34319734	NA	-0.46	-8.38	-0.31	3.31e-16	Bladder cancer;
BRCA	cis	rs6882046	0.533	rs599402	chr5:88043656	G/C	cg22951263	chr5:87985283	NA	-0.39	-10.87	-0.4	2.19e-25	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg26695010	chr11:65641043	EFEMP2	-0.34	-7.98	-0.3	6.64e-15	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg06521331	chr12:34319734	NA	-0.56	-9.94	-0.37	9.53e-22	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg22920501	chr2:26401640	FAM59B	-0.9	-16.71	-0.55	2.92e-52	Gut microbiome composition (summer);
BRCA	cis	rs897080	0.589	rs1067380	chr2:44646834	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	9.61	0.36	1.64e-20	Height;
BRCA	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg11764359	chr7:65958608	NA	0.59	10.36	0.38	2.3e-23	Aortic root size;
BRCA	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg00106254	chr7:1943704	MAD1L1	-0.44	-11.89	-0.43	1.31e-29	Bipolar disorder and schizophrenia;
BRCA	cis	rs7617773	0.694	rs13099560	chr3:48204768	C/T	cg11946769	chr3:48343235	NME6	-0.5	-11.14	-0.4	1.86e-26	Coronary artery disease;
BRCA	cis	rs2629540	0.766	rs10794177	chr10:126407409	G/C	cg08799069	chr10:126477246	METTL10	0.46	9.35	0.35	1.4e-19	Cocaine dependence;
BRCA	cis	rs2430307	0.556	rs3905501	chr7:76542080	C/T	cg05843312	chr7:76586131	NA	-0.48	-8.55	-0.32	8.97e-17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg23711669	chr6:146136114	FBXO30	0.84	20.17	0.62	2.1e-70	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg07507251	chr3:52567010	NT5DC2	0.35	7.95	0.3	8.35e-15	Electroencephalogram traits;
BRCA	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg19743168	chr1:23544995	NA	0.35	8.15	0.31	1.89e-15	Height;
BRCA	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg00852783	chr1:26633632	UBXN11	-0.46	-8.09	-0.3	3.08e-15	Obesity-related traits;
BRCA	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg06115741	chr20:33292138	TP53INP2	0.5	11.11	0.4	2.49e-26	Coronary artery disease;
BRCA	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg09367891	chr1:107599246	PRMT6	-0.43	-8.46	-0.32	1.84e-16	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs6977660	0.714	rs10252965	chr7:19822385	A/C	cg07541023	chr7:19748670	TWISTNB	0.53	9.27	0.34	2.77e-19	Thyroid stimulating hormone;
BRCA	cis	rs2479724	0.846	rs2251084	chr6:41838119	T/C	cg17623882	chr6:41773611	USP49	-0.34	-9.13	-0.34	8.98e-19	Menarche (age at onset);
BRCA	cis	rs7246657	0.722	rs2075284	chr19:38189616	T/C	cg23950597	chr19:37808831	NA	0.51	8.56	0.32	8.59e-17	Coronary artery calcification;
BRCA	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.37	-0.41	1.98e-27	Platelet count;
BRCA	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg26031613	chr14:104095156	KLC1	0.72	15.64	0.53	6.49e-47	Body mass index;
BRCA	trans	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.17	-0.34	6.34e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg24450063	chr1:156163899	SLC25A44	0.91	17.64	0.57	5.11e-57	Testicular germ cell tumor;
BRCA	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.2	-0.4	1.08e-26	Colorectal cancer;
BRCA	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg09658497	chr7:2847517	GNA12	0.51	10.34	0.38	2.7e-23	Loneliness (linear analysis);
BRCA	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg06627628	chr2:24431161	ITSN2	-0.82	-14.82	-0.51	6.31e-43	Asthma;
BRCA	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg20701182	chr2:24300061	SF3B14	0.55	8.51	0.32	1.21e-16	Lymphocyte counts;
BRCA	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg05863683	chr7:1912471	MAD1L1	0.38	7.82	0.3	2.21e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11644478	chr21:40555479	PSMG1	0.85	19.63	0.61	1.6e-67	Cognitive function;
BRCA	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg20587970	chr11:113659929	NA	-0.89	-16.5	-0.55	3.42e-51	Hip circumference adjusted for BMI;
BRCA	cis	rs13102973	0.899	rs4546304	chr4:135902382	G/A	cg14419869	chr4:135874104	NA	0.46	9.22	0.34	4.42e-19	Subjective well-being;
BRCA	cis	rs7635838	0.596	rs13353463	chr3:11260221	T/C	cg00170343	chr3:11313890	ATG7	0.4	8.17	0.31	1.61e-15	HDL cholesterol;
BRCA	cis	rs9487051	0.737	rs1260593	chr6:109521400	C/T	cg21918786	chr6:109611834	NA	-0.35	-9.24	-0.34	3.73e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs4930561	0.714	rs7126326	chr11:67947275	T/G	cg04465784	chr11:67976953	SUV420H1	-0.27	-8.82	-0.33	1.1e-17	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg23711669	chr6:146136114	FBXO30	0.74	16.82	0.55	7.41e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.43	-0.32	2.23e-16	Total body bone mineral density;
BRCA	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.66	-15.96	-0.53	1.59e-48	Ulcerative colitis;
BRCA	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg17971929	chr21:40555470	PSMG1	0.78	18.39	0.59	6.48e-61	Cognitive function;
BRCA	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg27170947	chr2:26402098	FAM59B	-0.92	-16.52	-0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08045932	chr20:61659980	NA	0.48	10.67	0.39	1.47e-24	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03264133	chr6:25882463	NA	0.52	10.8	0.39	4.52e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg10295955	chr4:187884368	NA	-0.93	-26.99	-0.73	1.23e-107	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg20991723	chr1:152506922	NA	0.39	9.07	0.34	1.4e-18	Hair morphology;
BRCA	cis	rs3771570	0.681	rs12151655	chr2:242281438	T/A	cg21155796	chr2:242212141	HDLBP	0.6	9.3	0.35	2.25e-19	Prostate cancer;
BRCA	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg22980127	chr19:33182716	NUDT19	0.9	17.6	0.57	7.68e-57	Red blood cell traits;
BRCA	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg08859206	chr1:53392774	SCP2	0.45	9.94	0.37	9.63e-22	Monocyte count;
BRCA	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg24450063	chr1:156163899	SLC25A44	1.08	33.86	0.8	9.84e-145	Testicular germ cell tumor;
BRCA	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.07e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.03	0.34	1.96e-18	Motion sickness;
BRCA	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.89	0.51	2.93e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg23231163	chr10:75533350	FUT11	-0.33	-8.78	-0.33	1.48e-17	Inflammatory bowel disease;
BRCA	cis	rs877282	0.583	rs112372193	chr10:826602	A/G	cg15764593	chr10:829463	NA	-0.65	-10.71	-0.39	1.02e-24	Uric acid levels;
BRCA	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	19.25	0.61	1.83e-65	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg20891283	chr12:69753455	YEATS4	0.83	28.58	0.75	2.23e-116	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	13.0	0.46	1.99e-34	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9815354	0.812	rs73830532	chr3:41898814	T/C	cg03022575	chr3:42003672	ULK4	0.71	9.71	0.36	7.25e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg16414030	chr3:133502952	NA	-0.47	-11.22	-0.41	8.72e-27	Iron status biomarkers;
BRCA	cis	rs7123876	0.504	rs1157343	chr11:72429141	A/G	cg04827223	chr11:72435913	ARAP1	0.51	13.23	0.46	1.66e-35	Body mass index;
BRCA	cis	rs2625529	0.730	rs1481861	chr15:72240129	A/G	cg16672083	chr15:72433130	SENP8	0.71	16.5	0.55	3.25e-51	Red blood cell count;
BRCA	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18876405	chr7:65276391	NA	-0.55	-13.42	-0.47	2.26e-36	Aortic root size;
BRCA	cis	rs34779708	0.931	rs72789609	chr10:35306206	C/T	cg03585969	chr10:35415529	CREM	0.55	11.4	0.41	1.62e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs56399783	0.901	rs7803944	chr7:2809087	G/A	cg19731401	chr7:2775893	GNA12	0.47	8.13	0.31	2.26e-15	Childhood ear infection;
BRCA	cis	rs4690686	0.500	rs12498564	chr4:177264827	T/C	cg17059388	chr4:177262070	NA	0.51	10.75	0.39	6.89e-25	Essential tremor;
BRCA	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.98	-0.3	6.79e-15	Bipolar disorder;
BRCA	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg04362960	chr10:104952993	NT5C2	-0.44	-10.05	-0.37	3.68e-22	Arsenic metabolism;
BRCA	cis	rs9309473	0.948	rs10183818	chr2:73714556	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-12.11	-0.43	1.57e-30	Metabolite levels;
BRCA	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-14.52	-0.5	1.76e-41	Monocyte count;
BRCA	cis	rs41005	1.000	rs41004	chr2:8111580	C/T	cg03155496	chr2:8117019	LOC339788	0.57	15.32	0.52	2.26e-45	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs2249625	0.523	rs2496554	chr6:72855840	A/T	cg18830697	chr6:72922368	RIMS1	-0.51	-11.54	-0.42	4.16e-28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs10254118	0.757	rs13241123	chr7:133135507	A/T	cg10665199	chr7:133106180	EXOC4	0.47	9.53	0.35	3.15e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs3784262	1.000	rs12903474	chr15:58276747	A/C	cg12031962	chr15:58353849	ALDH1A2	0.48	12.69	0.45	4.49e-33	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	trans	rs75804782	0.630	rs74404946	chr2:239300772	C/G	cg01134436	chr17:81009848	B3GNTL1	0.76	8.18	0.31	1.48e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg13628971	chr7:2884303	GNA12	0.37	7.97	0.3	7.3e-15	Height;
BRCA	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07080220	chr10:102295463	HIF1AN	0.51	11.37	0.41	2.08e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.4	9.5	0.35	4.06e-20	Eosinophil percentage of white cells;
BRCA	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg04362960	chr10:104952993	NT5C2	0.46	10.56	0.39	3.89e-24	Arsenic metabolism;
BRCA	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg26898376	chr11:64110657	CCDC88B	0.36	7.86	0.3	1.69e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg06671706	chr8:8559999	CLDN23	0.46	8.83	0.33	1.02e-17	Obesity-related traits;
BRCA	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg20887711	chr4:1340912	KIAA1530	0.36	8.66	0.32	3.8e-17	Longevity;
BRCA	cis	rs12134245	0.527	rs6681073	chr1:92022597	A/C	cg25838465	chr1:92012736	NA	-0.38	-8.54	-0.32	9.54e-17	Breast cancer;
BRCA	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg11764359	chr7:65958608	NA	-0.77	-17.76	-0.57	1.21e-57	Aortic root size;
BRCA	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg13395646	chr4:1353034	KIAA1530	-0.52	-9.3	-0.35	2.25e-19	Obesity-related traits;
BRCA	cis	rs10754283	0.967	rs10801763	chr1:90120822	C/T	cg21401794	chr1:90099060	LRRC8C	0.47	11.61	0.42	2.01e-28	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.34	0.38	2.79e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg18252515	chr7:66147081	NA	-0.87	-12.08	-0.43	2.13e-30	Diabetic kidney disease;
BRCA	cis	rs17641971	0.708	rs4873303	chr8:49922675	G/A	cg00325661	chr8:49890786	NA	0.35	9.59	0.35	1.98e-20	Blood metabolite levels;
BRCA	cis	rs7598759	0.548	rs11693738	chr2:232360484	C/T	cg19187155	chr2:232395269	NMUR1	0.7	16.94	0.56	1.96e-53	Noise-induced hearing loss;
BRCA	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg26446133	chr18:72167187	CNDP2	-0.78	-14.37	-0.49	8.43e-41	Refractive error;
BRCA	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg26818010	chr10:134567672	INPP5A	-0.78	-15.17	-0.51	1.27e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9649213	0.593	rs6967576	chr7:98016373	A/G	cg21770322	chr7:97807741	LMTK2	-0.37	-9.79	-0.36	3.62e-21	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg26043149	chr18:55253948	FECH	0.43	9.17	0.34	6.33e-19	Bone mineral density;
BRCA	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg22974920	chr21:40686053	BRWD1	-0.34	-7.86	-0.3	1.59e-14	Menarche (age at onset);
BRCA	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19748678	chr4:122722346	EXOSC9	0.74	16.02	0.54	8.68e-49	Type 2 diabetes;
BRCA	cis	rs1003719	0.788	rs61701101	chr21:38450317	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.25	0.49	3.24e-40	Eye color traits;
BRCA	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg25664220	chr3:72788482	NA	-0.54	-11.66	-0.42	1.28e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg14019146	chr3:50243930	SLC38A3	0.4	9.71	0.36	7.01e-21	Body mass index;
BRCA	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.58	0.39	3.15e-24	Motion sickness;
BRCA	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg18154014	chr19:37997991	ZNF793	0.48	9.41	0.35	8.49e-20	Coronary artery calcification;
BRCA	trans	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg25214090	chr10:38739885	LOC399744	0.45	10.1	0.37	2.44e-22	Corneal astigmatism;
BRCA	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg03264133	chr6:25882463	NA	-0.37	-8.0	-0.3	5.94e-15	Height;
BRCA	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11890956	chr21:40555474	PSMG1	-0.84	-21.73	-0.65	8.47e-79	Cognitive function;
BRCA	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg25767906	chr1:53392781	SCP2	0.35	7.92	0.3	1.06e-14	Monocyte count;
BRCA	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.21	-0.34	4.59e-19	Menopause (age at onset);
BRCA	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg21782813	chr7:2030301	MAD1L1	0.37	10.34	0.38	2.84e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg13047869	chr3:10149882	C3orf24	0.53	9.73	0.36	5.63e-21	Alzheimer's disease;
BRCA	cis	rs34779708	0.931	rs1926554	chr10:35344969	C/T	cg03585969	chr10:35415529	CREM	0.55	11.41	0.41	1.41e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2066819	1.000	rs78121408	chr12:56684798	C/T	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03264133	chr6:25882463	NA	-0.52	-11.75	-0.42	5.15e-29	Blood metabolite levels;
BRCA	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg11366901	chr6:160182831	ACAT2	0.78	15.03	0.51	5.93e-44	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-18.07	-0.58	3e-59	Chronic sinus infection;
BRCA	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg12373951	chr3:133503437	NA	0.34	8.11	0.31	2.68e-15	Iron status biomarkers;
BRCA	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg16606324	chr3:10149918	C3orf24	0.46	7.95	0.3	8.24e-15	Alzheimer's disease;
BRCA	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg03433033	chr1:76189801	ACADM	-0.47	-9.57	-0.35	2.33e-20	Daytime sleep phenotypes;
BRCA	cis	rs4363385	0.818	rs532773	chr1:153011750	T/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.56	-0.32	8.51e-17	Inflammatory skin disease;
BRCA	trans	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg26043149	chr18:55253948	FECH	0.4	8.78	0.33	1.48e-17	Bone mineral density;
BRCA	cis	rs3741151	0.773	rs57354084	chr11:73139376	A/T	cg17517138	chr11:73019481	ARHGEF17	0.89	12.84	0.45	9.44e-34	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg09307838	chr4:120376055	NA	0.64	13.92	0.48	1.13e-38	Corneal astigmatism;
BRCA	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08280861	chr8:58055591	NA	0.58	8.99	0.33	2.88e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg26384229	chr12:38710491	ALG10B	0.8	20.24	0.62	9.55e-71	Heart rate;
BRCA	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	16.42	0.54	7.84e-51	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.42	7.96	0.3	8.08e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg21143896	chr7:2802374	GNA12	-0.38	-9.65	-0.36	1.14e-20	Height;
BRCA	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	14.54	0.5	1.34e-41	Platelet count;
BRCA	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg19622623	chr12:86230825	RASSF9	0.33	9.41	0.35	8.68e-20	Major depressive disorder;
BRCA	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.59	-12.29	-0.44	2.48e-31	Lymphocyte counts;
BRCA	cis	rs476633	0.573	rs6492995	chr15:41529712	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-11.36	-0.41	2.34e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs708547	0.541	rs6554392	chr4:57739948	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.33	-7.98	-0.3	6.86e-15	Response to bleomycin (chromatid breaks);
BRCA	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg08313168	chr12:7315531	NA	0.5	8.09	0.3	2.95e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg06484146	chr7:12443880	VWDE	-0.55	-8.69	-0.33	2.94e-17	Coronary artery disease;
BRCA	cis	rs36051895	0.659	rs4495487	chr9:5072798	T/C	cg02405213	chr9:5042618	JAK2	-0.54	-9.64	-0.36	1.3e-20	Pediatric autoimmune diseases;
BRCA	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.54	-13.52	-0.47	8.39e-37	Urate levels in overweight individuals;
BRCA	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg02038168	chr22:39784481	NA	-0.42	-8.8	-0.33	1.3e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs4566357	0.615	rs12328878	chr2:227918962	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-9.69	-0.36	8.15e-21	Coronary artery disease;
BRCA	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg15145296	chr3:125709740	NA	-0.55	-8.7	-0.33	2.73e-17	Blood pressure (smoking interaction);
BRCA	cis	rs9682041	0.561	rs6444928	chr3:170147875	A/G	cg11886554	chr3:170076028	SKIL	0.46	8.41	0.32	2.76e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	trans	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.16	0.37	1.37e-22	Mean corpuscular volume;
BRCA	trans	rs78049276	0.688	rs61075980	chr4:148374767	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.47	-8.01	-0.3	5.47e-15	Pulse pressure;
BRCA	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07256732	chr16:621771	PIGQ	-0.33	-8.86	-0.33	8e-18	Height;
BRCA	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg11833968	chr6:79620685	NA	-0.43	-9.55	-0.35	2.75e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg14784868	chr12:69753453	YEATS4	0.78	24.97	0.7	1.45e-96	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg07395648	chr5:131743802	NA	-0.41	-10.15	-0.37	1.57e-22	Blood metabolite levels;
BRCA	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg20607798	chr8:58055168	NA	0.5	8.58	0.32	7.03e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs11249608	0.548	rs6875622	chr5:178451397	C/T	cg21905437	chr5:178450457	ZNF879	0.54	11.32	0.41	3.38e-27	Pubertal anthropometrics;
BRCA	cis	rs919433	0.963	rs10153881	chr2:198171098	T/C	cg10820045	chr2:198174542	NA	-0.4	-8.65	-0.32	4.06e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6546886	0.912	rs7560668	chr2:74300717	A/G	cg14702570	chr2:74259524	NA	-0.32	-8.2	-0.31	1.33e-15	Dialysis-related mortality;
BRCA	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg15556689	chr8:8085844	FLJ10661	0.35	8.75	0.33	1.87e-17	Neuroticism;
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.63	-15.13	-0.51	1.98e-44	Longevity;Endometriosis;
BRCA	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg00383909	chr3:49044727	WDR6	0.5	9.77	0.36	4.23e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs17818399	0.510	rs12105801	chr2:46799343	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.53	11.05	0.4	4.09e-26	Height;
BRCA	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg19920283	chr7:105172520	RINT1	0.58	9.39	0.35	1.07e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.11	0.4	2.44e-26	Bipolar disorder;
BRCA	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12667521	chr19:29218732	NA	0.47	8.68	0.32	3.4e-17	Methadone dose in opioid dependence;
BRCA	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.74	11.71	0.42	7.68e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg11941060	chr3:133502564	NA	-0.6	-14.9	-0.51	2.59e-43	Iron status biomarkers;
BRCA	trans	rs9944715	0.954	rs4890317	chr18:43770510	A/G	cg01718231	chr17:29326311	RNF135	-0.45	-8.73	-0.33	2.18e-17	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg18225595	chr11:63971243	STIP1	-0.4	-9.96	-0.37	7.81e-22	Platelet count;
BRCA	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08280861	chr8:58055591	NA	0.56	8.78	0.33	1.49e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs17209837	0.607	rs12539936	chr7:87110017	A/G	cg00919237	chr7:87102261	ABCB4	0.51	9.87	0.36	1.7e-21	Gallbladder cancer;
BRCA	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg08917208	chr2:24149416	ATAD2B	0.92	13.6	0.47	3.66e-37	Lymphocyte counts;
BRCA	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg11764359	chr7:65958608	NA	-0.69	-13.28	-0.47	1.04e-35	Aortic root size;
BRCA	cis	rs10924970	0.601	rs2803847	chr1:235503611	C/G	cg26050004	chr1:235667680	B3GALNT2	0.36	8.48	0.32	1.58e-16	Asthma;
BRCA	cis	rs12474201	0.928	rs12998762	chr2:46938393	A/C	cg06386533	chr2:46925753	SOCS5	0.91	19.84	0.62	1.33e-68	Height;
BRCA	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.87	-0.33	7.27e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg10792982	chr14:105748885	BRF1	0.44	10.38	0.38	2.03e-23	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg08601574	chr20:25228251	PYGB	0.36	8.58	0.32	7.39e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg21951975	chr1:209979733	IRF6	0.39	8.21	0.31	1.19e-15	Cleft lip with or without cleft palate;
BRCA	cis	rs6910061	0.913	rs28712814	chr6:11108745	T/G	cg27233058	chr6:11094804	LOC221710	0.53	9.36	0.35	1.31e-19	Diabetic kidney disease;
BRCA	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg23029597	chr12:123009494	RSRC2	-0.6	-11.85	-0.42	1.96e-29	Body mass index;
BRCA	trans	rs867371	0.502	rs3759800	chr15:82532963	A/C	cg04831495	chr15:85060580	GOLGA6L5	0.3	8.17	0.31	1.67e-15	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg04362960	chr10:104952993	NT5C2	0.43	10.54	0.38	4.54e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs9296092	0.500	rs9469503	chr6:33527234	G/T	cg13560919	chr6:33536144	NA	-0.85	-18.69	-0.59	1.6e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.67	-16.97	-0.56	1.31e-53	Multiple sclerosis;
BRCA	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg05340658	chr4:99064831	C4orf37	0.67	16.75	0.55	1.82e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg05623727	chr3:50126028	RBM5	-0.5	-12.14	-0.43	1.17e-30	Body mass index;
BRCA	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg07138768	chr7:917805	C7orf20	-0.28	-8.09	-0.3	3.02e-15	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs11608355	0.545	rs4766473	chr12:109900596	C/T	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg18876405	chr7:65276391	NA	0.71	18.44	0.59	3.4800000000000003e-61	Aortic root size;
BRCA	cis	rs7301016	0.793	rs11174557	chr12:62979216	C/T	cg11441379	chr12:63026424	NA	0.46	8.73	0.33	2.19e-17	IgG glycosylation;
BRCA	cis	rs6840360	0.571	rs718800	chr4:152549307	A/T	cg22705602	chr4:152727874	NA	0.32	8.08	0.3	3.2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4285028	0.948	rs13089878	chr3:121703895	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.85	-0.39	2.68e-25	Multiple sclerosis;
BRCA	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	9.1e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg04455712	chr21:45112962	RRP1B	-0.47	-12.92	-0.46	4.4e-34	Mean corpuscular volume;
BRCA	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg18357645	chr12:58087776	OS9	0.44	12.52	0.44	2.63e-32	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs5771069	0.897	rs137858	chr22:50445601	T/C	cg03721641	chr22:50451245	IL17REL	0.32	9.93	0.37	1.05e-21	Ulcerative colitis;
BRCA	cis	rs6942756	1.000	rs2012919	chr7:128890812	C/T	cg02491457	chr7:128862824	NA	-0.7	-13.77	-0.48	5.71e-38	White matter hyperintensity burden;
BRCA	cis	rs36051895	0.659	rs12337134	chr9:5061578	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-8.91	-0.33	5.44e-18	Pediatric autoimmune diseases;
BRCA	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg16482183	chr6:26056742	HIST1H1C	0.51	10.58	0.39	3.17e-24	Height;
BRCA	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-9.06	-0.34	1.57e-18	Schizophrenia;
BRCA	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg04362960	chr10:104952993	NT5C2	0.39	9.07	0.34	1.45e-18	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.6	9.31	0.35	2e-19	Lung function (FEV1/FVC);
BRCA	cis	rs9611519	0.580	rs7286603	chr22:41440061	T/C	cg03806693	chr22:41940476	POLR3H	-0.41	-7.81	-0.3	2.29e-14	Neuroticism;
BRCA	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.33	8.6	0.32	6.08e-17	IgG glycosylation;
BRCA	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg25036284	chr2:26402008	FAM59B	-0.77	-13.87	-0.48	1.96e-38	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg08470875	chr2:26401718	FAM59B	0.58	7.87	0.3	1.5e-14	Gut microbiome composition (summer);
BRCA	cis	rs858239	1.000	rs858240	chr7:23284237	A/G	cg23682824	chr7:23144976	KLHL7	0.37	9.14	0.34	8.34e-19	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg17971929	chr21:40555470	PSMG1	0.8	18.85	0.6	2.22e-63	Cognitive function;
BRCA	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg19318889	chr4:1322082	MAEA	-0.59	-11.92	-0.43	1e-29	Longevity;
BRCA	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.92	0.37	1.13e-21	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg02030672	chr11:45687055	CHST1	0.52	11.47	0.41	8.1e-28	Obesity-related traits;
BRCA	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-10.41	-0.38	1.5e-23	Schizophrenia;
BRCA	cis	rs12618769	0.625	rs61180742	chr2:99148078	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.15	0.31	1.92e-15	Bipolar disorder;
BRCA	trans	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg06521331	chr12:34319734	NA	-0.44	-8.35	-0.31	4.37e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg09035930	chr12:129282057	SLC15A4	0.49	13.79	0.48	4.53e-38	Systemic lupus erythematosus;
BRCA	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19346786	chr7:2764209	NA	-0.31	-9.1	-0.34	1.12e-18	Height;
BRCA	cis	rs870825	0.616	rs12502860	chr4:185636105	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	17.32	0.57	2.07e-55	Blood protein levels;
BRCA	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg24803719	chr17:45855879	NA	-0.32	-8.47	-0.32	1.75e-16	IgG glycosylation;
BRCA	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg23708337	chr7:1209742	NA	0.37	7.85	0.3	1.74e-14	Longevity;Endometriosis;
BRCA	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.19e-40	Motion sickness;
BRCA	trans	rs1997103	1.000	rs2331067	chr7:55408232	A/T	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.64	-0.32	4.45e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2882667	0.587	rs825674	chr5:138102720	A/G	cg04439458	chr5:138467593	SIL1	0.37	8.78	0.33	1.5e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	17.25	0.56	4.82e-55	Platelet count;
BRCA	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg27170947	chr2:26402098	FAM59B	-0.65	-11.15	-0.4	1.68e-26	Gut microbiome composition (summer);
BRCA	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg24692254	chr21:30365293	RNF160	-0.64	-16.6	-0.55	9.92e-52	Dental caries;
BRCA	cis	rs6433895	0.961	rs6746347	chr2:182017374	T/G	cg00481216	chr2:181971175	NA	0.39	8.91	0.33	5.34e-18	Lymphocyte counts;
BRCA	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg05234568	chr11:5960015	NA	-0.49	-9.69	-0.36	7.99e-21	DNA methylation (variation);
BRCA	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.58	-0.35	2.17e-20	Tonsillectomy;
BRCA	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18876405	chr7:65276391	NA	-0.51	-11.68	-0.42	1.02e-28	Aortic root size;
BRCA	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.97	-0.33	3.22e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg19628046	chr18:33552617	C18orf21	0.54	11.0	0.4	6.54e-26	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg13175981	chr1:150552382	MCL1	-0.35	-8.28	-0.31	6.97e-16	Tonsillectomy;
BRCA	trans	rs4714291	0.862	rs2984433	chr6:39973445	T/G	cg02267698	chr19:7991119	CTXN1	-0.47	-9.69	-0.36	8.07e-21	Strep throat;
BRCA	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-8.75	-0.33	1.88e-17	Bone mineral density;
BRCA	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg23029597	chr12:123009494	RSRC2	-0.65	-12.41	-0.44	7.73e-32	Body mass index;
BRCA	trans	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.87	0.3	1.55e-14	Corneal astigmatism;
BRCA	cis	rs9309473	0.607	rs2421488	chr2:73590625	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-12.75	-0.45	2.55e-33	Metabolite levels;
BRCA	cis	rs9815354	0.669	rs113059632	chr3:41932858	G/A	cg03022575	chr3:42003672	ULK4	0.68	9.48	0.35	4.71e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2115536	0.606	rs8024713	chr15:80206958	C/G	cg00225070	chr15:80189496	MTHFS	0.48	11.5	0.41	5.92e-28	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
BRCA	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg03433033	chr1:76189801	ACADM	-0.4	-8.18	-0.31	1.52e-15	Daytime sleep phenotypes;
BRCA	cis	rs6138458	1.000	rs6138458	chr20:24973769	C/T	cg06937882	chr20:24974362	C20orf3	-0.48	-9.45	-0.35	6.15e-20	Blood protein levels;
BRCA	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg03146154	chr1:46216737	IPP	-0.45	-9.48	-0.35	4.71e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs28595532	0.623	rs34531766	chr4:119230339	T/C	cg21605333	chr4:119757512	SEC24D	0.83	8.78	0.33	1.46e-17	Cannabis dependence symptom count;
BRCA	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg04450456	chr4:17643702	FAM184B	0.32	9.41	0.35	8.79e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1538970	0.962	rs2487442	chr1:45857176	C/G	cg05343316	chr1:45956843	TESK2	-0.53	-10.98	-0.4	8.58e-26	Platelet count;
BRCA	cis	rs7903847	0.642	rs7092350	chr10:99140218	A/T	cg08345082	chr10:99160200	RRP12	-0.29	-8.5	-0.32	1.31e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg12310025	chr6:25882481	NA	0.73	17.74	0.57	1.54e-57	Blood metabolite levels;
BRCA	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs9309473	1.000	rs7572722	chr2:73724675	T/C	cg20560298	chr2:73613845	ALMS1	-0.44	-10.68	-0.39	1.33e-24	Metabolite levels;
BRCA	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg06092702	chr1:163392909	NA	-0.34	-8.81	-0.33	1.21e-17	Motion sickness;
BRCA	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg09455208	chr3:40491958	NA	-0.39	-9.29	-0.35	2.3e-19	Renal cell carcinoma;
BRCA	cis	rs858239	0.508	rs7805085	chr7:23190243	C/T	cg23682824	chr7:23144976	KLHL7	0.37	9.65	0.36	1.12e-20	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs10242455	0.702	rs6974831	chr7:99131605	A/G	cg18809830	chr7:99032528	PTCD1	-0.62	-8.73	-0.33	2.23e-17	Blood metabolite levels;
BRCA	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg03146154	chr1:46216737	IPP	0.45	9.98	0.37	6.77e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11890956	chr21:40555474	PSMG1	0.68	15.76	0.53	1.67e-47	Cognitive function;
BRCA	cis	rs870825	0.616	rs7667409	chr4:185650941	C/T	cg04058563	chr4:185651563	MLF1IP	-0.78	-17.85	-0.58	4.14e-58	Blood protein levels;
BRCA	trans	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg26043149	chr18:55253948	FECH	-0.37	-8.27	-0.31	7.64e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs738322	0.600	rs5995542	chr22:38558141	C/T	cg25457927	chr22:38595422	NA	-0.35	-12.8	-0.45	1.49e-33	Cutaneous nevi;
BRCA	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg22920501	chr2:26401640	FAM59B	0.91	16.27	0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	12.86	0.45	8.23e-34	Lymphocyte counts;
BRCA	cis	rs4363385	0.747	rs6678107	chr1:152966818	T/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.6	-0.35	1.81e-20	Inflammatory skin disease;
BRCA	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs4321325	0.733	rs4284778	chr2:127946326	A/G	cg11380483	chr2:127933992	NA	0.42	8.16	0.31	1.83e-15	Protein C levels;
BRCA	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg13010199	chr12:38710504	ALG10B	0.44	9.57	0.35	2.34e-20	Bladder cancer;
BRCA	trans	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg06521331	chr12:34319734	NA	-0.47	-8.69	-0.33	2.99e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs367943	0.608	rs2972662	chr5:112990330	C/T	cg12552261	chr5:112820674	MCC	-0.37	-8.14	-0.31	2.07e-15	Type 2 diabetes;
BRCA	cis	rs735860	0.726	rs209519	chr6:53208680	G/A	cg10236188	chr6:53219634	NA	0.38	7.89	0.3	1.31e-14	Glaucoma;
BRCA	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.56	-11.06	-0.4	3.73e-26	Tonsillectomy;
BRCA	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.68	0.57	3.2e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg18016565	chr1:150552671	MCL1	0.35	8.17	0.31	1.62e-15	Tonsillectomy;
BRCA	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.4	-0.32	2.98e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg25554036	chr4:6271136	WFS1	-0.36	-8.79	-0.33	1.35e-17	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25427524	chr10:38739819	LOC399744	-0.64	-14.77	-0.5	1.08e-42	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg23711669	chr6:146136114	FBXO30	0.71	16.76	0.55	1.52e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg12062639	chr20:23401060	NAPB	-0.88	-12.34	-0.44	1.5e-31	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2066819	1.000	rs41423244	chr12:56693520	A/C	cg26714650	chr12:56694279	CS	1.19	15.73	0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg13385794	chr1:248469461	NA	0.29	7.89	0.3	1.34e-14	Common traits (Other);
BRCA	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg08645402	chr16:4508243	NA	0.37	7.89	0.3	1.36e-14	Schizophrenia;
BRCA	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg15485101	chr11:133734466	NA	0.41	9.89	0.36	1.51e-21	Childhood ear infection;
BRCA	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg21518248	chr2:162101506	NA	0.46	9.59	0.35	1.9e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg20701182	chr2:24300061	SF3B14	0.67	9.75	0.36	4.9e-21	Lymphocyte counts;
BRCA	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-14.26	-0.49	2.82e-40	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg14863265	chr7:2801509	GNA12	-0.46	-10.11	-0.37	2.19e-22	Height;
BRCA	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg08917208	chr2:24149416	ATAD2B	1.07	14.82	0.51	5.99e-43	Lymphocyte counts;
BRCA	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg24812749	chr6:127587940	RNF146	0.88	20.66	0.63	4.91e-73	Breast cancer;
BRCA	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg18811423	chr2:55921094	PNPT1	-0.69	-22.38	-0.66	2.21e-82	Metabolic syndrome;
BRCA	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.38	-0.44	1.03e-31	Type 2 diabetes;
BRCA	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.56	-0.68	8.48e-89	Gut microbiome composition (summer);
BRCA	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg15145296	chr3:125709740	NA	-0.55	-8.65	-0.32	4.23e-17	Blood pressure (smoking interaction);
BRCA	trans	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.58	-0.35	2.18e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4363385	0.818	rs407103	chr1:153007106	C/T	cg24667326	chr1:152973720	SPRR3	0.33	9.19	0.34	5.28e-19	Inflammatory skin disease;
BRCA	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg16339924	chr4:17578868	LAP3	0.63	15.65	0.53	5.38e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4389656	0.857	rs274709	chr5:6726464	T/C	cg10857441	chr5:6722123	POLS	-0.25	-7.82	-0.3	2.21e-14	Coronary artery disease;
BRCA	cis	rs7766436	0.813	rs7773580	chr6:22587114	C/T	cg13666174	chr6:22585274	NA	-0.49	-11.6	-0.42	2.25e-28	Coronary artery disease;
BRCA	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg11584989	chr19:19387371	SF4	0.49	11.05	0.4	4.14e-26	Bipolar disorder;
BRCA	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg07169764	chr2:136633963	MCM6	1.23	25.96	0.72	5.36e-102	Corneal structure;
BRCA	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg17410650	chr12:54324560	NA	-0.43	-10.69	-0.39	1.18e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
BRCA	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.65	-11.53	-0.41	4.61e-28	Lung cancer in ever smokers;
BRCA	cis	rs3772130	0.560	rs7649585	chr3:121562300	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	14.39	0.49	7.26e-41	Cognitive performance;
BRCA	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg24562669	chr7:97807699	LMTK2	0.47	11.96	0.43	7.09e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg27211696	chr2:191398769	TMEM194B	0.5	11.59	0.42	2.53e-28	Pulse pressure;
BRCA	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg07402062	chr16:89894098	SPIRE2	0.26	9.17	0.34	6.54e-19	Vitiligo;
BRCA	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg13047869	chr3:10149882	C3orf24	0.6	12.76	0.45	2.33e-33	Alzheimer's disease;
BRCA	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.46	-8.59	-0.32	6.75e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs68170813	0.559	rs7779062	chr7:106880195	T/A	cg02696742	chr7:106810147	HBP1	-0.47	-8.15	-0.31	1.94e-15	Coronary artery disease;
BRCA	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg12193833	chr17:30244370	NA	-0.54	-8.6	-0.32	5.98e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	14.3	0.49	1.97e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12760731	0.565	rs11583144	chr1:178222070	C/G	cg00404053	chr1:178313656	RASAL2	0.64	7.83	0.3	2.01e-14	Obesity-related traits;
BRCA	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg27170947	chr2:26402098	FAM59B	-0.81	-13.05	-0.46	1.1e-34	Gut microbiome composition (summer);
BRCA	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	9.18	0.34	6e-19	Platelet count;
BRCA	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg07636037	chr3:49044803	WDR6	0.55	8.7	0.33	2.75e-17	Menarche (age at onset);
BRCA	cis	rs7593730	0.636	rs6743795	chr2:161122134	A/G	cg22609984	chr2:161126801	NA	0.43	9.24	0.34	3.68e-19	Type 2 diabetes;
BRCA	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.26	8.68	0.32	3.23e-17	Electroencephalogram traits;
BRCA	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03517284	chr6:25882590	NA	0.68	15.76	0.53	1.56e-47	Blood metabolite levels;
BRCA	cis	rs12618769	0.571	rs72821939	chr2:99138872	T/C	cg10123293	chr2:99228465	UNC50	0.42	8.1	0.31	2.81e-15	Bipolar disorder;
BRCA	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	9.82	0.36	2.67e-21	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	17.25	0.56	5.04e-55	Hip circumference adjusted for BMI;
BRCA	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg09184832	chr6:79620586	NA	-0.51	-11.2	-0.41	1e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9462027	0.628	rs9462006	chr6:34710327	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.87	-0.3	1.55e-14	Systemic lupus erythematosus;
BRCA	cis	rs4908768	0.501	rs12046643	chr1:8547866	A/C	cg20416874	chr1:8611966	RERE	-0.29	-8.31	-0.31	5.62e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs965469	1.000	rs6051808	chr20:3350697	A/T	cg25506879	chr20:3388711	C20orf194	-0.53	-10.45	-0.38	1.06e-23	IFN-related cytopenia;
BRCA	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11644478	chr21:40555479	PSMG1	0.73	14.82	0.51	6.06e-43	Cognitive function;
BRCA	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg00530320	chr1:46809349	NSUN4	-0.48	-9.75	-0.36	5.01e-21	Menopause (age at onset);
BRCA	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg27102117	chr16:15229624	NA	0.33	7.93	0.3	1.02e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs9308433	0.529	rs6660335	chr1:214501855	C/T	cg06198575	chr1:214491504	SMYD2	0.52	11.76	0.42	4.86e-29	IgG glycosylation;
BRCA	cis	rs701145	0.585	rs454837	chr3:153915417	T/C	cg17054900	chr3:154042577	DHX36	0.57	9.57	0.35	2.21e-20	Coronary artery disease;
BRCA	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg04450456	chr4:17643702	FAM184B	0.37	10.68	0.39	1.3e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg09537434	chr19:41945824	ATP5SL	0.98	24.78	0.7	1.67e-95	Height;
BRCA	cis	rs6973256	0.865	rs763646	chr7:133343353	C/T	cg07491979	chr7:133331646	EXOC4	-0.39	-9.03	-0.34	2.04e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.02	0.58	5.02e-59	Fuchs's corneal dystrophy;
BRCA	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.29	-0.35	2.32e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.54	-0.32	9.87e-17	Bipolar disorder;
BRCA	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg00074818	chr8:8560427	CLDN23	0.38	8.4	0.32	2.82e-16	Obesity-related traits;
BRCA	cis	rs1635	0.655	rs58019071	chr6:28304016	T/C	cg15743358	chr6:28303923	ZNF323	-0.75	-8.56	-0.32	8.52e-17	Schizophrenia;
BRCA	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg02734326	chr4:10020555	SLC2A9	0.39	8.44	0.32	2.17e-16	Bone mineral density;
BRCA	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg27661571	chr11:113659931	NA	-0.81	-12.17	-0.43	8.64e-31	Hip circumference adjusted for BMI;
BRCA	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg26384229	chr12:38710491	ALG10B	0.76	17.13	0.56	2.04e-54	Bladder cancer;
BRCA	cis	rs3892630	0.878	rs1061686	chr19:33204544	C/T	cg22980127	chr19:33182716	NUDT19	-0.9	-17.14	-0.56	1.85e-54	Red blood cell traits;
BRCA	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg23711669	chr6:146136114	FBXO30	0.77	17.96	0.58	1.11e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg01657329	chr11:68192670	LRP5	0.36	8.08	0.3	3.22e-15	Bone mineral density (spine);
BRCA	trans	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg25214090	chr10:38739885	LOC399744	0.45	10.36	0.38	2.36e-23	Corneal astigmatism;
BRCA	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11764359	chr7:65958608	NA	0.62	13.51	0.47	8.75e-37	Calcium levels;
BRCA	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.23e-40	Motion sickness;
BRCA	cis	rs7246967	0.551	rs7249473	chr19:22906694	T/C	cg23217946	chr19:22817039	ZNF492	0.51	9.31	0.35	1.99e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs6942756	1.000	rs7806089	chr7:128972215	C/G	cg02491457	chr7:128862824	NA	-0.71	-14.04	-0.49	3.12e-39	White matter hyperintensity burden;
BRCA	cis	rs7523050	0.643	rs34114412	chr1:109402866	C/T	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg00666640	chr1:248458726	OR2T12	0.33	9.04	0.34	1.9e-18	Common traits (Other);
BRCA	cis	rs7715806	0.500	rs4703676	chr5:74979866	G/C	cg19683494	chr5:74908142	NA	0.53	8.6	0.32	6.36e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg09537434	chr19:41945824	ATP5SL	-0.99	-23.54	-0.68	1.1e-88	Height;
BRCA	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.72	11.47	0.41	7.81e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs77633900	0.614	rs280033	chr15:77023099	G/A	cg21673338	chr15:77095150	SCAPER	-0.53	-9.72	-0.36	6.2e-21	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs4363385	0.714	rs4845329	chr1:152974454	G/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.33	-0.31	4.93e-16	Inflammatory skin disease;
BRCA	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg10820045	chr2:198174542	NA	-0.41	-9.36	-0.35	1.28e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs17401966	0.838	rs912963	chr1:10348042	C/T	cg03954927	chr1:10346856	KIF1B	0.4	12.65	0.45	7.17e-33	Hepatocellular carcinoma;
BRCA	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg04450456	chr4:17643702	FAM184B	0.32	9.32	0.35	1.79e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg07080220	chr10:102295463	HIF1AN	0.61	14.38	0.49	7.97e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg08213375	chr14:104286397	PPP1R13B	0.63	17.16	0.56	1.37e-54	Schizophrenia;
BRCA	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg27535305	chr1:53392650	SCP2	0.33	8.11	0.31	2.53e-15	Monocyte count;
BRCA	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.66	13.47	0.47	1.37e-36	Lymphocyte counts;
BRCA	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg13256891	chr4:100009986	ADH5	0.53	9.79	0.36	3.62e-21	Alcohol dependence;
BRCA	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.2	-0.31	1.3e-15	Bipolar disorder;
BRCA	cis	rs919433	0.648	rs787975	chr2:198248128	C/T	cg00792783	chr2:198669748	PLCL1	0.37	8.36	0.31	4.04e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg03433033	chr1:76189801	ACADM	-0.59	-11.68	-0.42	1.1e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.89	-0.33	6.03e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4268898	1.000	rs4268898	chr2:24490413	C/T	cg06627628	chr2:24431161	ITSN2	0.49	10.19	0.37	1.1e-22	Asthma;
BRCA	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg26384229	chr12:38710491	ALG10B	0.76	17.14	0.56	1.82e-54	Morning vs. evening chronotype;
BRCA	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg06108461	chr20:60628389	TAF4	-1.02	-23.08	-0.67	3.38e-86	Body mass index;
BRCA	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg02659138	chr7:134003124	SLC35B4	0.32	9.73	0.36	5.95e-21	Mean platelet volume;
BRCA	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg18252515	chr7:66147081	NA	-0.97	-13.78	-0.48	5.15e-38	Diabetic kidney disease;
BRCA	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg21747090	chr2:27597821	SNX17	-0.43	-9.44	-0.35	7.04e-20	Total body bone mineral density;
BRCA	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg24060327	chr5:131705240	SLC22A5	0.5	10.38	0.38	1.97e-23	Blood metabolite levels;
BRCA	cis	rs1371614	0.611	rs877272	chr2:27139888	C/T	cg00617064	chr2:27272375	NA	-0.3	-7.93	-0.3	9.74e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg11707556	chr5:10655725	ANKRD33B	0.43	9.58	0.35	2.19e-20	Coronary artery disease;
BRCA	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg23711669	chr6:146136114	FBXO30	0.77	17.49	0.57	2.75e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg27279351	chr12:120934652	DYNLL1	0.56	13.31	0.47	7.75e-36	High light scatter reticulocyte count;
BRCA	cis	rs6460942	0.915	rs10488158	chr7:12508894	C/T	cg20607287	chr7:12443886	VWDE	-0.57	-8.03	-0.3	4.78e-15	Coronary artery disease;
BRCA	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.46	-13.73	-0.48	8.75e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2637266	1.000	rs2579747	chr10:78327759	C/T	cg18941641	chr10:78392320	NA	0.36	7.93	0.3	9.78e-15	Pulmonary function;
BRCA	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24110177	chr3:50126178	RBM5	-0.36	-9.71	-0.36	6.98e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.82	0.62	1.64e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.41	8.61	0.32	5.62e-17	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs644148	0.836	rs2571111	chr19:45000581	C/A	cg15540054	chr19:45004280	ZNF180	-0.59	-12.57	-0.45	1.53e-32	Personality dimensions;
BRCA	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg20290983	chr6:43655470	MRPS18A	1.11	40.87	0.85	1.95e-180	IgG glycosylation;
BRCA	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg08755490	chr11:65554678	OVOL1	0.53	10.96	0.4	9.69e-26	Acne (severe);
BRCA	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg07169764	chr2:136633963	MCM6	1.22	23.75	0.68	7.81e-90	Corneal structure;
BRCA	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg08132940	chr7:1081526	C7orf50	-0.48	-7.85	-0.3	1.78e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg23289794	chr7:2394357	EIF3B	-0.64	-12.22	-0.44	4.99e-31	Multiple sclerosis;
BRCA	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.38e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs34779708	0.733	rs12777960	chr10:35541026	C/A	cg03585969	chr10:35415529	CREM	0.45	9.19	0.34	5.29e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg20887711	chr4:1340912	KIAA1530	0.74	15.79	0.53	1.18e-47	Longevity;
BRCA	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-9.12	-0.34	1e-18	Psoriasis;
BRCA	cis	rs7593730	0.551	rs6706685	chr2:161151559	T/C	cg22609984	chr2:161126801	NA	0.38	8.25	0.31	8.91e-16	Type 2 diabetes;
BRCA	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg24879335	chr3:133465180	TF	0.32	10.94	0.4	1.14e-25	Iron status biomarkers (transferrin levels);
BRCA	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.25	0.38	6.1e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4974559	0.947	rs10000797	chr4:1345647	G/A	cg02980000	chr4:1222292	CTBP1	0.76	12.91	0.45	4.7e-34	Systolic blood pressure;
BRCA	cis	rs8028182	0.636	rs8034317	chr15:75764343	G/A	cg20655648	chr15:75932815	IMP3	0.41	8.1	0.31	2.81e-15	Sudden cardiac arrest;
BRCA	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg13010199	chr12:38710504	ALG10B	0.51	10.05	0.37	3.59e-22	Bladder cancer;
BRCA	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg20607798	chr8:58055168	NA	-0.52	-8.13	-0.31	2.28e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg13854012	chr2:162103682	NA	-0.39	-8.72	-0.33	2.43e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs10501293	1.000	rs10838010	chr11:43122962	T/C	cg03447554	chr11:43094025	NA	-0.47	-8.57	-0.32	7.95e-17	Cognitive performance;
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg04234412	chr22:24373322	LOC391322	-0.82	-23.08	-0.67	3.58e-86	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg25703541	chr22:24373054	LOC391322	0.7	15.83	0.53	7.15e-48	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1595825	0.891	rs16825917	chr2:198805185	C/T	cg19156104	chr2:198669113	PLCL1	-0.46	-8.12	-0.31	2.38e-15	Ulcerative colitis;
BRCA	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.95	0.3	8.23e-15	Parkinson's disease;
BRCA	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg05340658	chr4:99064831	C4orf37	0.61	14.29	0.49	2.23e-40	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18876405	chr7:65276391	NA	0.53	8.49	0.32	1.42e-16	Diabetic kidney disease;
BRCA	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06002616	chr8:101225028	SPAG1	0.42	10.54	0.38	4.73e-24	Atrioventricular conduction;
BRCA	cis	rs3772130	1.000	rs17691170	chr3:121357626	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	9.5	0.35	4.22e-20	Cognitive performance;
BRCA	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.17	0.31	1.68e-15	Axial length;
BRCA	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg26384229	chr12:38710491	ALG10B	0.72	16.21	0.54	9e-50	Morning vs. evening chronotype;
BRCA	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07930192	chr7:1003750	NA	0.48	10.7	0.39	1.04e-24	Longevity;Endometriosis;
BRCA	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg22189786	chr22:42395067	WBP2NL	0.41	8.05	0.3	3.94e-15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg05340658	chr4:99064831	C4orf37	0.68	17.28	0.56	3.44e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.14	0.49	1.04e-39	Eye color traits;
BRCA	cis	rs9369695	0.881	rs9349409	chr6:47463126	G/T	cg12968598	chr6:47444699	CD2AP	0.44	9.7	0.36	7.62e-21	Reticulocyte count;
BRCA	cis	rs4588572	0.644	rs2241566	chr5:77784738	C/T	cg11547950	chr5:77652471	NA	0.44	8.34	0.31	4.53e-16	Triglycerides;
BRCA	cis	rs1371614	0.588	rs10181727	chr2:27171245	C/T	cg00617064	chr2:27272375	NA	0.31	8.0	0.3	5.86e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg13010199	chr12:38710504	ALG10B	0.35	8.24	0.31	9.47e-16	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg23711669	chr6:146136114	FBXO30	0.67	15.44	0.52	6.1e-46	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs2018683	1.000	rs4719962	chr7:28999237	G/A	cg19402173	chr7:128379420	CALU	-0.6	-15.0	-0.51	8.08e-44	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10150615	chr22:24372951	LOC391322	0.43	9.4	0.35	9.9e-20	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg11645453	chr3:52864694	ITIH4	-0.45	-11.08	-0.4	3.29e-26	Schizophrenia;
BRCA	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg07606381	chr6:8435919	SLC35B3	0.66	14.55	0.5	1.27e-41	Motion sickness;
BRCA	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg11764359	chr7:65958608	NA	-0.68	-15.1	-0.51	2.75e-44	Aortic root size;
BRCA	cis	rs6545883	0.811	rs2921718	chr2:61795267	C/A	cg15711740	chr2:61764176	XPO1	-0.56	-14.33	-0.49	1.33e-40	Tuberculosis;
BRCA	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg15556689	chr8:8085844	FLJ10661	-0.33	-9.02	-0.34	2.15e-18	Neuroticism;
BRCA	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg08999081	chr20:33150536	PIGU	-0.43	-12.03	-0.43	3.34e-30	Glomerular filtration rate (creatinine);
BRCA	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24531977	chr5:56204891	C5orf35	0.66	14.48	0.5	2.59e-41	Initial pursuit acceleration;
BRCA	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-16.2	-0.54	1.01e-49	Alzheimer's disease (late onset);
BRCA	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg04673462	chr1:38461896	NA	0.39	7.9	0.3	1.2e-14	Coronary artery disease;
BRCA	trans	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg06521331	chr12:34319734	NA	0.46	9.02	0.34	2.17e-18	Morning vs. evening chronotype;
BRCA	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23583168	chr7:148888333	NA	-0.85	-20.03	-0.62	1.24e-69	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg22974920	chr21:40686053	BRWD1	0.39	8.83	0.33	9.89e-18	Cognitive function;
BRCA	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	8.78	0.33	1.45e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.78	-0.33	1.52e-17	Mood instability;
BRCA	trans	rs3857536	0.740	rs4710572	chr6:66890361	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-9.48	-0.35	4.88e-20	Blood trace element (Cu levels);
BRCA	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg19920283	chr7:105172520	RINT1	0.58	9.39	0.35	1.07e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs9287719	0.649	rs12618726	chr2:10728375	C/G	cg00105475	chr2:10696890	NA	0.41	9.18	0.34	5.88e-19	Prostate cancer;
BRCA	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg02733842	chr7:1102375	C7orf50	-0.45	-8.53	-0.32	1.06e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg26384229	chr12:38710491	ALG10B	0.65	15.35	0.52	1.64e-45	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7927771	0.524	rs10838746	chr11:47706291	A/G	cg20307385	chr11:47447363	PSMC3	0.42	9.52	0.35	3.42e-20	Subjective well-being;
BRCA	cis	rs76419734	0.510	rs2553461	chr4:106731410	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.43	-9.39	-0.35	1.01e-19	Post bronchodilator FEV1;
BRCA	cis	rs7246967	0.673	rs16994997	chr19:22879610	T/G	cg23217946	chr19:22817039	ZNF492	0.48	8.92	0.33	4.93e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11764359	chr7:65958608	NA	0.78	18.5	0.59	1.63e-61	Aortic root size;
BRCA	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg13880726	chr7:1868755	MAD1L1	0.52	10.45	0.38	1.04e-23	Bipolar disorder and schizophrenia;
BRCA	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg21775007	chr8:11205619	TDH	-0.41	-8.66	-0.32	3.76e-17	Neuroticism;
BRCA	cis	rs2249625	0.523	rs1969530	chr6:72861276	A/C	cg18830697	chr6:72922368	RIMS1	-0.51	-11.46	-0.41	8.64e-28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg22713356	chr15:30763199	NA	1.31	26.42	0.72	1.54e-104	Uric acid levels;
BRCA	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg08917208	chr2:24149416	ATAD2B	0.9	12.93	0.46	3.8e-34	Lymphocyte counts;
BRCA	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg23711669	chr6:146136114	FBXO30	0.74	17.76	0.57	1.14e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1509123	0.609	rs17804635	chr17:6703985	A/G	cg12642237	chr17:6703447	TEKT1	0.76	10.52	0.38	5.45e-24	Blood metabolite levels;
BRCA	cis	rs7077164	1.000	rs1227776	chr10:71580893	G/A	cg07630274	chr10:71583235	COL13A1	-0.24	-7.92	-0.3	1.05e-14	Non-alcoholic fatty liver disease histology (lobular);
BRCA	cis	rs2742234	0.955	rs1272142	chr10:43695484	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.4	-8.27	-0.31	7.89e-16	Hirschsprung disease;
BRCA	cis	rs7918232	0.567	rs4749215	chr10:27312005	T/C	cg14240646	chr10:27532245	ACBD5	-0.47	-8.18	-0.31	1.55e-15	Breast cancer;
BRCA	cis	rs2072438	0.505	rs7034074	chr9:123923029	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	8.99	0.33	2.86e-18	Rheumatoid arthritis;
BRCA	cis	rs9487051	0.766	rs351748	chr6:109532296	C/T	cg01475377	chr6:109611718	NA	0.47	11.78	0.42	3.96e-29	Reticulocyte fraction of red cells;
BRCA	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	12.34	0.44	1.55e-31	Platelet count;
BRCA	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.4	8.01	0.3	5.58e-15	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg26587870	chr6:27730563	NA	-0.39	-8.33	-0.31	5.11e-16	Parkinson's disease;
BRCA	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg27478167	chr7:817139	HEATR2	-0.43	-9.13	-0.34	8.64e-19	Cerebrospinal P-tau181p levels;
BRCA	trans	rs1994135	0.715	rs10506110	chr12:33708552	A/C	cg26384229	chr12:38710491	ALG10B	0.53	10.79	0.39	4.9e-25	Resting heart rate;
BRCA	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg05347473	chr6:146136440	FBXO30	-0.6	-11.36	-0.41	2.22e-27	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs490234	0.676	rs1129	chr9:128199873	A/G	cg14078157	chr9:128172775	NA	0.53	11.41	0.41	1.42e-27	Mean arterial pressure;
BRCA	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg12011299	chr4:100065546	ADH4	0.5	13.37	0.47	4.02e-36	Alcohol dependence;
BRCA	cis	rs6424115	0.618	rs10917420	chr1:24062987	C/T	cg15997130	chr1:24165203	NA	0.32	7.89	0.3	1.27e-14	Immature fraction of reticulocytes;
BRCA	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg25036284	chr2:26402008	FAM59B	-0.63	-10.46	-0.38	9.54e-24	Gut microbiome composition (summer);
BRCA	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg23711669	chr6:146136114	FBXO30	0.71	16.52	0.55	2.73e-51	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg04565464	chr8:145669602	NFKBIL2	0.38	8.21	0.31	1.19e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg16405210	chr4:1374714	KIAA1530	0.36	8.01	0.3	5.53e-15	Obesity-related traits;
BRCA	trans	rs8073060	0.505	rs225276	chr17:33973034	T/C	cg19694781	chr19:47549865	TMEM160	-1.05	-20.96	-0.64	1.16e-74	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg21385522	chr1:16154831	NA	-0.48	-10.25	-0.38	6.51e-23	Systolic blood pressure;
BRCA	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg00376283	chr12:123451042	ABCB9	0.5	11.45	0.41	9.91e-28	Height;Educational attainment;Head circumference (infant);
BRCA	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.15	-0.31	1.87e-15	Total body bone mineral density;
BRCA	cis	rs6763687	1.000	rs4894796	chr3:171780763	A/G	cg16233210	chr3:171778391	FNDC3B	0.45	10.66	0.39	1.63e-24	Red cell distribution width;
BRCA	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg09307838	chr4:120376055	NA	0.61	11.16	0.4	1.57e-26	Corneal astigmatism;
BRCA	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg04546413	chr19:29218101	NA	0.64	12.28	0.44	2.81e-31	Methadone dose in opioid dependence;
BRCA	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg00981070	chr1:2046702	PRKCZ	0.31	8.24	0.31	9.76e-16	Height;
BRCA	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg06026331	chr20:60912101	LAMA5	0.44	8.29	0.31	6.94e-16	Colorectal cancer;
BRCA	cis	rs4660306	0.961	rs937290	chr1:45961955	A/G	cg24296786	chr1:45957014	TESK2	0.42	8.4	0.32	2.93e-16	Homocysteine levels;
BRCA	cis	rs4862307	0.733	rs28631204	chr4:184996363	T/G	cg06737308	chr4:185021514	ENPP6	0.4	8.99	0.34	2.69e-18	Serum dimethylarginine levels (asymmetric/symetric ratio);
BRCA	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg15790184	chr11:494944	RNH1	0.6	9.53	0.35	3.09e-20	Body mass index;
BRCA	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg05863683	chr7:1912471	MAD1L1	0.45	9.98	0.37	7.04e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs4566357	0.615	rs10177528	chr2:227913706	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-9.0	-0.34	2.51e-18	Coronary artery disease;
BRCA	trans	rs1200821	0.671	rs2226276	chr10:37673052	A/T	cg25427524	chr10:38739819	LOC399744	0.38	8.16	0.31	1.81e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12292205	chr6:26970375	C6orf41	-0.47	-8.0	-0.3	5.77e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg02175503	chr12:58329896	NA	0.42	8.12	0.31	2.38e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg14675211	chr2:100938903	LONRF2	0.52	11.97	0.43	6.22e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg03433033	chr1:76189801	ACADM	-0.48	-9.89	-0.36	1.45e-21	Daytime sleep phenotypes;
BRCA	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07930192	chr7:1003750	NA	0.48	10.75	0.39	6.59e-25	Longevity;Endometriosis;
BRCA	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.97	0.33	3.34e-18	Platelet count;
BRCA	cis	rs586533	0.881	rs2458167	chr11:99500748	A/C	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg22903471	chr2:27725779	GCKR	-0.38	-9.15	-0.34	7.38e-19	Total body bone mineral density;
BRCA	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg15704280	chr7:45808275	SEPT13	-0.53	-10.28	-0.38	4.75e-23	Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs4596713	0.538	rs10869961	chr9:71787071	C/T	cg16512924	chr15:28394682	HERC2	0.45	10.86	0.39	2.46e-25	Headache;
BRCA	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	12.72	0.45	3.4e-33	Bone mineral density;
BRCA	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg21361702	chr7:150065534	REPIN1	0.54	9.8	0.36	3.17e-21	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	10.77	0.39	5.5e-25	Mean corpuscular hemoglobin;
BRCA	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg06494592	chr3:125709126	NA	-0.54	-8.44	-0.32	2.09e-16	Blood pressure (smoking interaction);
BRCA	cis	rs6942756	0.806	rs2566886	chr7:128917866	G/A	cg02491457	chr7:128862824	NA	0.56	11.97	0.43	6.22e-30	White matter hyperintensity burden;
BRCA	cis	rs36051895	0.632	rs12684720	chr9:5150800	T/C	cg02405213	chr9:5042618	JAK2	-0.44	-8.59	-0.32	6.71e-17	Pediatric autoimmune diseases;
BRCA	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg15556689	chr8:8085844	FLJ10661	0.33	9.13	0.34	8.76e-19	Retinal vascular caliber;
BRCA	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg08514558	chr10:81106712	PPIF	0.4	9.23	0.34	4e-19	Height;
BRCA	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.64e-24	Motion sickness;
BRCA	cis	rs698761	0.519	rs2005202	chr2:44541706	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	7.84	0.3	1.91e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	10.08	0.37	2.77e-22	Bipolar disorder;
BRCA	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg25173405	chr17:45401733	C17orf57	0.54	11.59	0.42	2.41e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs12612619	0.732	rs2053385	chr2:27231145	G/A	cg00617064	chr2:27272375	NA	-0.32	-8.46	-0.32	1.77e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.4	0.47	2.88e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg23711669	chr6:146136114	FBXO30	-0.66	-15.16	-0.51	1.45e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg22920501	chr2:26401640	FAM59B	-0.9	-16.0	-0.53	1.07e-48	Gut microbiome composition (summer);
BRCA	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg00717180	chr2:96193071	NA	-0.38	-10.16	-0.37	1.38e-22	HDL cholesterol;
BRCA	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-9.79	-0.36	3.47e-21	Monocyte percentage of white cells;
BRCA	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-13.01	-0.46	1.76e-34	Developmental language disorder (linguistic errors);
BRCA	cis	rs7095944	0.585	rs11245357	chr10:126452042	A/G	cg08799069	chr10:126477246	METTL10	-0.4	-10.16	-0.37	1.43e-22	Asthma;
BRCA	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-11.12	-0.4	2.2e-26	Schizophrenia;
BRCA	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11905131	chr22:24372483	LOC391322	-0.53	-11.75	-0.42	5.27e-29	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs28830936	1.000	rs9672360	chr15:41912411	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.31	-9.02	-0.34	2.24e-18	Diastolic blood pressure;
BRCA	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11764359	chr7:65958608	NA	-0.75	-18.0	-0.58	6.97e-59	Aortic root size;
BRCA	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg07080220	chr10:102295463	HIF1AN	0.63	14.78	0.5	9.71e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg26043149	chr18:55253948	FECH	0.43	9.17	0.34	6.33e-19	Bone mineral density;
BRCA	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.88	0.56	3.66e-53	Hypertriglyceridemia;
BRCA	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	9.93	0.37	1.03e-21	Tonsillectomy;
BRCA	cis	rs6714710	0.580	rs13032265	chr2:98409565	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	13.65	0.48	2.04e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs6542838	0.698	rs7565736	chr2:99464952	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.36	-7.97	-0.3	7.42e-15	Fear of minor pain;
BRCA	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-10.72	-0.39	8.84e-25	Triglycerides;
BRCA	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg22535103	chr8:58192502	C8orf71	-0.6	-13.09	-0.46	7.81e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	13.61	0.47	3.12e-37	Lymphocyte counts;
BRCA	cis	rs12431939	1.000	rs55851845	chr14:51645583	A/T	cg23942311	chr14:51606299	NA	-0.44	-8.34	-0.31	4.53e-16	Cancer;
BRCA	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg22875332	chr1:76189707	ACADM	0.81	19.76	0.62	3.25e-68	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2731664	0.792	rs2630765	chr5:176876825	T/C	cg23176889	chr5:176863531	GRK6	-0.64	-17.66	-0.57	3.86e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Educational attainment;
BRCA	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.33	-0.38	3.17e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	11.46	0.41	8.48e-28	Personality dimensions;
BRCA	cis	rs10789491	1.000	rs601060	chr1:47139580	C/G	cg15501359	chr1:47185051	KIAA0494	-0.65	-18.42	-0.59	4.22e-61	Response to hepatitis C treatment;
BRCA	cis	rs6882046	0.513	rs454214	chr5:88003403	A/G	cg22951263	chr5:87985283	NA	0.41	11.14	0.4	1.91e-26	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg01939980	chr4:1354348	KIAA1530	0.38	8.8	0.33	1.24e-17	Obesity-related traits;
BRCA	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg27478167	chr7:817139	HEATR2	-0.56	-11.13	-0.4	2.03e-26	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.6	0.42	2.29e-28	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg22117172	chr7:91764530	CYP51A1	0.24	8.03	0.3	4.81e-15	Breast cancer;
BRCA	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg05623727	chr3:50126028	RBM5	0.5	12.45	0.44	5.4e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs501916	0.634	rs8037600	chr15:48060331	A/G	cg16110827	chr15:48056943	SEMA6D	-0.43	-9.05	-0.34	1.73e-18	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs3820928	0.874	rs2396452	chr2:227838040	T/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.22	-0.31	1.12e-15	Pulmonary function;
BRCA	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg08999081	chr20:33150536	PIGU	0.36	9.28	0.34	2.53e-19	Coronary artery disease;
BRCA	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.89	-0.33	6.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg03146154	chr1:46216737	IPP	0.53	11.57	0.42	2.94e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg24069376	chr3:38537580	EXOG	0.41	11.92	0.43	9.9e-30	Electrocardiographic conduction measures;
BRCA	trans	rs61931739	1.000	rs12424741	chr12:34022771	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-9.44	-0.35	7e-20	Morning vs. evening chronotype;
BRCA	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg03146154	chr1:46216737	IPP	-0.47	-10.34	-0.38	2.71e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg26597838	chr10:835615	NA	1.3	21.87	0.65	1.45e-79	Eosinophil percentage of granulocytes;
BRCA	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg25482853	chr8:67687455	SGK3	1.06	17.17	0.56	1.31e-54	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	11.87	0.43	1.6800000000000001e-29	Mean platelet volume;
BRCA	trans	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-16.05	-0.54	5.92e-49	Exhaled nitric oxide levels;
BRCA	cis	rs4742903	1.000	rs7854630	chr9:106875277	A/C	cg14250997	chr9:106856677	SMC2	-0.34	-10.77	-0.39	5.73e-25	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs11191205	0.644	rs7899178	chr10:103359285	G/A	cg15320455	chr10:103880129	LDB1	0.46	7.91	0.3	1.1e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg04691961	chr3:161091175	C3orf57	-0.38	-8.28	-0.31	7.19e-16	Morning vs. evening chronotype;
BRCA	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg13906792	chr15:75199810	C15orf17	-0.39	-9.23	-0.34	3.96e-19	Breast cancer;
BRCA	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg18404041	chr3:52824283	ITIH1	-0.49	-15.25	-0.52	4.96e-45	Bipolar disorder;
BRCA	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg09754948	chr16:28834200	ATXN2L	0.46	8.45	0.32	2.02e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg03060546	chr3:49711283	APEH	-0.54	-10.77	-0.39	5.96e-25	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22857025	chr5:266934	NA	-1.04	-19.68	-0.61	9.4e-68	Breast cancer;
BRCA	cis	rs9473147	0.543	rs9473122	chr6:47474962	C/T	cg12968598	chr6:47444699	CD2AP	0.44	9.59	0.35	1.93e-20	Platelet distribution width;Mean platelet volume;
BRCA	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg13010199	chr12:38710504	ALG10B	0.48	9.21	0.34	4.58e-19	Morning vs. evening chronotype;
BRCA	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg19318889	chr4:1322082	MAEA	0.58	12.01	0.43	4.2000000000000004e-30	Longevity;
BRCA	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg13073564	chr4:8508604	NA	0.44	11.91	0.43	1.11e-29	Response to antineoplastic agents;
BRCA	cis	rs9649213	0.614	rs2240348	chr7:97984077	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.59	-16.01	-0.54	9.43e-49	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6840258	1.000	rs75550773	chr4:87955423	G/T	cg08197287	chr4:87952173	AFF1	-0.44	-8.78	-0.33	1.48e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.58	-0.32	7.07e-17	Neuroticism;
BRCA	cis	rs72928364	1.000	rs62275200	chr3:100696631	C/T	cg10123952	chr3:100791384	NA	0.53	7.85	0.3	1.71e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg17971929	chr21:40555470	PSMG1	-0.77	-18.21	-0.58	5.54e-60	Cognitive function;
BRCA	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg10556349	chr10:835070	NA	0.59	8.25	0.31	8.76e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg04990556	chr1:26633338	UBXN11	0.68	11.87	0.42	1.7e-29	Obesity-related traits;
BRCA	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.73	-16.68	-0.55	4.09e-52	Homoarginine levels;
BRCA	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.45	-0.61	1.55e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	0.4	9.03	0.34	2e-18	Alzheimer's disease (late onset);
BRCA	cis	rs11785693	0.862	rs73183618	chr8:4988340	T/C	cg26367366	chr8:4980734	NA	0.6	10.92	0.4	1.48e-25	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg08213375	chr14:104286397	PPP1R13B	-0.53	-12.39	-0.44	9.14e-32	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.35	0.59	9.88e-61	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg04166393	chr7:2884313	GNA12	-0.51	-10.12	-0.37	1.97e-22	Height;
BRCA	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg05347473	chr6:146136440	FBXO30	0.41	8.07	0.3	3.41e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4594175	0.926	rs66625118	chr14:51631062	T/C	cg23942311	chr14:51606299	NA	0.33	8.3	0.31	6.24e-16	Cancer;
BRCA	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg11764359	chr7:65958608	NA	0.63	11.52	0.41	4.94e-28	Aortic root size;
BRCA	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.38	-7.85	-0.3	1.81e-14	Alzheimer's disease (late onset);
BRCA	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	13.86	0.48	2.19e-38	Coronary artery disease;
BRCA	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg22491629	chr6:157744540	C6orf35	-0.66	-11.63	-0.42	1.64e-28	Hemostatic factors and hematological phenotypes;
BRCA	trans	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg25214090	chr10:38739885	LOC399744	0.56	12.45	0.44	5.14e-32	Corneal astigmatism;
BRCA	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg00857998	chr1:205179979	DSTYK	0.41	8.2	0.31	1.28e-15	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs7715806	0.500	rs17649248	chr5:74998426	C/T	cg19683494	chr5:74908142	NA	0.53	8.77	0.33	1.61e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg05347473	chr6:146136440	FBXO30	0.42	8.39	0.32	3.1e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs16958440	0.867	rs78547658	chr18:44669852	C/T	cg17192377	chr18:44677553	HDHD2	0.99	13.87	0.48	1.94e-38	Sitting height ratio;
BRCA	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg03929089	chr4:120376271	NA	0.46	7.87	0.3	1.53e-14	Axial length;
BRCA	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08045932	chr20:61659980	NA	0.5	11.43	0.41	1.2100000000000001e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg24397884	chr7:158709396	WDR60	0.85	14.32	0.49	1.58e-40	Height;
BRCA	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	16.69	0.55	3.7e-52	Alzheimer's disease;
BRCA	trans	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg23762105	chr12:34175262	ALG10	0.38	9.4	0.35	9.38e-20	Morning vs. evening chronotype;
BRCA	cis	rs7560272	0.538	rs12233115	chr2:73931891	G/A	cg20560298	chr2:73613845	ALMS1	0.34	8.71	0.33	2.6e-17	Schizophrenia;
BRCA	cis	rs6484504	0.600	rs208063	chr11:31159777	C/T	cg14844989	chr11:31128820	NA	-0.44	-9.49	-0.35	4.33e-20	Red blood cell count;
BRCA	cis	rs4363385	0.782	rs1933381	chr1:153003255	C/G	cg24667326	chr1:152973720	SPRR3	-0.33	-9.12	-0.34	9.92e-19	Inflammatory skin disease;
BRCA	cis	rs990171	0.571	rs3771202	chr2:102772669	C/G	cg22835712	chr2:102737379	NA	0.54	9.43	0.35	7.18e-20	Lymphocyte counts;
BRCA	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg11952622	chr19:58962976	ZNF324B	0.51	10.59	0.39	2.91e-24	Uric acid clearance;
BRCA	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.1	-0.43	1.73e-30	Response to antipsychotic treatment;
BRCA	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	28.21	0.74	2.43e-114	Chronic sinus infection;
BRCA	trans	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg19862616	chr7:65841803	NCRNA00174	0.8	24.55	0.7	2.9e-94	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg11789530	chr4:8429930	ACOX3	-0.62	-16.31	-0.54	2.93e-50	Response to antineoplastic agents;
BRCA	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg16049864	chr8:95962084	TP53INP1	-0.42	-10.09	-0.37	2.69e-22	Type 2 diabetes;
BRCA	cis	rs16958440	1.000	rs60854219	chr18:44646664	G/A	cg17192377	chr18:44677553	HDHD2	0.67	9.8	0.36	3.33e-21	Sitting height ratio;
BRCA	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg11764359	chr7:65958608	NA	-0.67	-14.9	-0.51	2.48e-43	Aortic root size;
BRCA	cis	rs2637266	0.902	rs2583056	chr10:78399498	A/G	cg18941641	chr10:78392320	NA	0.35	7.98	0.3	6.89e-15	Pulmonary function;
BRCA	cis	rs9837602	0.938	rs9828079	chr3:99806645	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.18	0.4	1.3e-26	Breast cancer;
BRCA	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.02e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.38	8.57	0.32	8e-17	Corneal astigmatism;
BRCA	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11764359	chr7:65958608	NA	0.81	19.52	0.61	6.65e-67	Aortic root size;
BRCA	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.81e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs892961	0.931	rs2411110	chr17:75400143	A/C	cg05865280	chr17:75406074	SEPT9	0.36	9.76	0.36	4.64e-21	Airflow obstruction;
BRCA	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg18404041	chr3:52824283	ITIH1	-0.35	-9.31	-0.35	2.02e-19	Schizophrenia;
BRCA	cis	rs2898681	0.874	rs59649036	chr4:53741175	T/C	cg00338735	chr4:53728038	RASL11B	0.41	7.82	0.3	2.15e-14	Optic nerve measurement (cup area);
BRCA	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg20307385	chr11:47447363	PSMC3	-0.41	-8.68	-0.32	3.23e-17	Subjective well-being;
BRCA	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	ch.11.42038R	chr11:967971	AP2A2	0.47	14.22	0.49	4.33e-40	Alzheimer's disease (late onset);
BRCA	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg02659138	chr7:134003124	SLC35B4	0.32	9.76	0.36	4.42e-21	Mean platelet volume;
BRCA	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg10876282	chr6:28092338	ZSCAN16	0.41	7.96	0.3	7.79e-15	Parkinson's disease;
BRCA	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	17.65	0.57	4.17e-57	Platelet count;
BRCA	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg20283391	chr11:68216788	NA	-0.4	-8.09	-0.3	3.05e-15	Total body bone mineral density;
BRCA	cis	rs7833986	0.501	rs2668007	chr8:56944111	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	10.55	0.39	4.31e-24	Height;
BRCA	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08704250	chr15:31115839	NA	-0.36	-8.7	-0.33	2.83e-17	Huntington's disease progression;
BRCA	cis	rs68170813	0.559	rs78267892	chr7:106823734	C/T	cg02696742	chr7:106810147	HBP1	-0.54	-8.83	-0.33	1e-17	Coronary artery disease;
BRCA	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg08470875	chr2:26401718	FAM59B	0.65	8.47	0.32	1.65e-16	Gut microbiome composition (summer);
BRCA	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.7	-14.38	-0.49	7.87e-41	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg07636037	chr3:49044803	WDR6	0.96	28.39	0.75	2.58e-115	Parkinson's disease;
BRCA	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24549020	chr5:56110836	MAP3K1	0.6	12.36	0.44	1.29e-31	Initial pursuit acceleration;
BRCA	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg23029597	chr12:123009494	RSRC2	0.57	11.12	0.4	2.18e-26	Body mass index;
BRCA	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg05340658	chr4:99064831	C4orf37	0.67	16.58	0.55	1.29e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg01475377	chr6:109611718	NA	-0.59	-16.37	-0.54	1.4e-50	Reticulocyte fraction of red cells;
BRCA	trans	rs66887589	0.967	rs7678973	chr4:120511817	T/C	cg25214090	chr10:38739885	LOC399744	-0.35	-8.11	-0.31	2.54e-15	Diastolic blood pressure;
BRCA	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15664640	chr17:80829946	TBCD	-0.38	-10.18	-0.37	1.18e-22	Breast cancer;
BRCA	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.72	0.39	9.15e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.37	-0.31	3.51e-16	Monocyte percentage of white cells;
BRCA	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22307029	chr19:49891270	CCDC155	-0.52	-8.74	-0.33	2.1e-17	Multiple sclerosis;
BRCA	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg13271783	chr10:134563150	INPP5A	-0.49	-9.95	-0.37	8.44e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.06	-0.34	1.53e-18	Total body bone mineral density;
BRCA	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg17971929	chr21:40555470	PSMG1	0.79	18.34	0.59	1.08e-60	Cognitive function;
BRCA	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.6	8.59	0.32	6.55e-17	Schizophrenia;
BRCA	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg25251562	chr2:3704773	ALLC	-0.41	-7.9	-0.3	1.21e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg21132104	chr15:45694354	SPATA5L1	0.6	11.9	0.43	1.22e-29	Homoarginine levels;
BRCA	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg24692254	chr21:30365293	RNF160	-0.52	-12.05	-0.43	2.7e-30	Cognitive test performance;
BRCA	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.26	-0.31	8.38e-16	Gut microbiome composition (summer);
BRCA	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg04450456	chr4:17643702	FAM184B	0.37	10.91	0.4	1.54e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg05623727	chr3:50126028	RBM5	0.5	12.0	0.43	4.84e-30	Body mass index;
BRCA	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg17366294	chr4:99064904	C4orf37	0.42	8.34	0.31	4.7e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg06618935	chr21:46677482	NA	-0.37	-8.04	-0.3	4.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg23711669	chr6:146136114	FBXO30	0.67	15.65	0.53	5.42e-47	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs8073060	0.544	rs225283	chr17:33934912	A/G	cg19694781	chr19:47549865	TMEM160	-1.06	-21.34	-0.65	1.09e-76	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg17971929	chr21:40555470	PSMG1	-0.61	-13.49	-0.47	1.18e-36	Cognitive function;
BRCA	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.31	-0.38	3.74e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg13175981	chr1:150552382	MCL1	0.54	11.79	0.42	3.59e-29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg15934090	chr1:100435551	SLC35A3	0.36	8.43	0.32	2.38e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg05340658	chr4:99064831	C4orf37	0.56	11.09	0.4	3.06e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg21132104	chr15:45694354	SPATA5L1	0.7	15.43	0.52	6.64e-46	Homoarginine levels;
BRCA	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	13.77	0.48	5.64e-38	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6429082	0.875	rs2291688	chr1:235594250	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.35	-8.18	-0.31	1.54e-15	Adiposity;
BRCA	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg16325326	chr1:53192061	ZYG11B	0.69	17.16	0.56	1.36e-54	Monocyte count;
BRCA	trans	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg26043149	chr18:55253948	FECH	-0.38	-8.34	-0.31	4.43e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs919433	0.510	rs34631382	chr2:198390009	C/T	cg00792783	chr2:198669748	PLCL1	0.36	8.31	0.31	5.72e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg03929089	chr4:120376271	NA	-0.53	-8.67	-0.32	3.67e-17	Axial length;
BRCA	cis	rs7586879	0.796	rs916484	chr2:25082588	A/C	cg04586622	chr2:25135609	ADCY3	0.37	9.01	0.34	2.34e-18	Body mass index;
BRCA	cis	rs9807989	0.524	rs7594402	chr2:103021267	A/T	cg03938978	chr2:103052716	IL18RAP	0.29	8.51	0.32	1.25e-16	Asthma;
BRCA	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg02659138	chr7:134003124	SLC35B4	0.31	9.79	0.36	3.38e-21	Mean platelet volume;
BRCA	cis	rs9341808	0.935	rs2322633	chr6:80845989	C/T	cg08355045	chr6:80787529	NA	-0.31	-8.07	-0.3	3.5e-15	Sitting height ratio;
BRCA	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.46	-10.56	-0.39	3.9e-24	Longevity;Endometriosis;
BRCA	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg01483505	chr11:975446	AP2A2	0.31	8.48	0.32	1.53e-16	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg00339695	chr16:24857497	SLC5A11	0.49	9.92	0.37	1.18e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7799006	0.782	rs2159044	chr7:2262941	C/A	cg08027265	chr7:2291960	NA	-0.34	-8.89	-0.33	6.43e-18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg05729581	chr11:3078854	CARS	-0.34	-8.49	-0.32	1.43e-16	Longevity;
BRCA	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg04896959	chr15:78267971	NA	-0.45	-10.52	-0.38	5.69e-24	Coronary artery disease or large artery stroke;
BRCA	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg04414720	chr1:150670196	GOLPH3L	0.36	8.34	0.31	4.72e-16	Tonsillectomy;
BRCA	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg14582100	chr15:45693742	SPATA5L1	0.37	11.83	0.42	2.38e-29	Homoarginine levels;
BRCA	cis	rs11229555	0.645	rs12801475	chr11:58189034	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg21143896	chr7:2802374	GNA12	-0.34	-8.44	-0.32	2.12e-16	Height;
BRCA	cis	rs4423214	0.840	rs1792234	chr11:71182018	T/C	cg05163923	chr11:71159392	DHCR7	-0.57	-11.46	-0.41	9.02e-28	Vitamin D levels;
BRCA	cis	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg26168224	chr5:2018326	NA	0.64	17.71	0.57	2.02e-57	Gut microbiome composition (winter);
BRCA	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11890956	chr21:40555474	PSMG1	1.04	29.22	0.76	7.53e-120	Cognitive function;
BRCA	cis	rs11920090	0.720	rs58284370	chr3:170738849	G/A	cg09710316	chr3:170744871	SLC2A2	0.64	10.28	0.38	4.89e-23	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg05340658	chr4:99064831	C4orf37	0.63	15.15	0.51	1.51e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg10253484	chr15:75165896	SCAMP2	-0.51	-9.8	-0.36	3.29e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs4851870	0.514	rs4851840	chr2:106369253	G/C	cg15488963	chr2:106262226	NA	0.39	8.2	0.31	1.28e-15	Addiction;
BRCA	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg11645453	chr3:52864694	ITIH4	-0.35	-9.42	-0.35	8.1e-20	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg23533926	chr12:111358616	MYL2	0.41	8.61	0.32	5.64e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg22920501	chr2:26401640	FAM59B	-0.64	-11.15	-0.4	1.61e-26	Gut microbiome composition (summer);
BRCA	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg19077165	chr18:44547161	KATNAL2	-0.39	-8.27	-0.31	7.79e-16	Educational attainment;
BRCA	cis	rs9790314	0.632	rs62280333	chr3:160689060	G/A	cg03342759	chr3:160939853	NMD3	0.47	9.14	0.34	8.53e-19	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg05340658	chr4:99064831	C4orf37	0.61	14.5	0.5	2.05e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg25554036	chr4:6271136	WFS1	-0.36	-8.04	-0.3	4.31e-15	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg21782813	chr7:2030301	MAD1L1	0.37	10.79	0.39	4.62e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg27170947	chr2:26402098	FAM59B	-0.93	-16.88	-0.56	4.1e-53	Gut microbiome composition (summer);
BRCA	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg19628046	chr18:33552617	C18orf21	0.54	10.62	0.39	2.2e-24	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg07506560	chr2:240697449	NA	0.49	10.87	0.39	2.35e-25	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11890956	chr21:40555474	PSMG1	0.98	23.88	0.69	1.43e-90	Cognitive function;
BRCA	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg13010199	chr12:38710504	ALG10B	0.5	9.74	0.36	5.54e-21	Morning vs. evening chronotype;
BRCA	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg21475434	chr5:93447410	FAM172A	0.66	8.7	0.33	2.8e-17	Diabetic retinopathy;
BRCA	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg20607287	chr7:12443886	VWDE	-0.58	-8.32	-0.31	5.34e-16	Coronary artery disease;
BRCA	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	27.88	0.74	1.6e-112	Chronic sinus infection;
BRCA	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.79	-0.42	3.6e-29	Alcohol dependence;
BRCA	cis	rs4363385	0.747	rs1577964	chr1:152961784	C/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.3e-17	Inflammatory skin disease;
BRCA	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.13	-0.4	1.98e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg02896835	chr1:92012615	NA	0.44	8.32	0.31	5.16e-16	Eosinophil percentage of white cells;
BRCA	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg18446336	chr7:2847575	GNA12	-0.34	-8.19	-0.31	1.4e-15	Height;
BRCA	cis	rs4566357	0.576	rs3769644	chr2:227917240	C/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-9.55	-0.35	2.65e-20	Coronary artery disease;
BRCA	cis	rs710865	0.519	rs3748759	chr1:19487656	C/T	cg13387374	chr1:19411106	UBR4	-0.42	-9.24	-0.34	3.66e-19	Brain structure;
BRCA	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg04455712	chr21:45112962	RRP1B	0.41	10.93	0.4	1.29e-25	Mean corpuscular volume;
BRCA	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	16.67	0.55	4.51e-52	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs4690686	0.538	rs4690687	chr4:177259635	A/G	cg17059388	chr4:177262070	NA	-0.5	-10.39	-0.38	1.82e-23	Essential tremor;
BRCA	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg07138768	chr7:917805	C7orf20	0.28	7.92	0.3	1.02e-14	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18357526	chr6:26021779	HIST1H4A	0.46	8.51	0.32	1.21e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs12579753	0.917	rs7313521	chr12:82205656	G/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-8.42	-0.32	2.41e-16	Resting heart rate;
BRCA	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03452623	chr4:187889614	NA	-0.35	-11.19	-0.4	1.19e-26	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg05283184	chr6:79620031	NA	0.36	8.99	0.34	2.67e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg19683494	chr5:74908142	NA	-0.63	-10.28	-0.38	4.77e-23	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
BRCA	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg06212747	chr3:49208901	KLHDC8B	0.47	9.66	0.36	1.09e-20	Parkinson's disease;
BRCA	cis	rs1568889	1.000	rs7937778	chr11:28104605	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	14.54	0.5	1.37e-41	Bipolar disorder;
BRCA	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08219700	chr8:58056026	NA	0.44	8.0	0.3	5.75e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs17092148	1.000	rs62211617	chr20:33400355	C/G	cg16810054	chr20:33298113	TP53INP2	0.5	11.25	0.41	6.79e-27	Neuroticism;
BRCA	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg08603382	chr10:743973	NA	-0.46	-8.64	-0.32	4.44e-17	Psychosis in Alzheimer's disease;
BRCA	cis	rs7178424	1.000	rs12438803	chr15:62374942	T/A	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.3	-0.31	6.42e-16	Height;
BRCA	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.68	-0.42	1.02e-28	Mean corpuscular volume;
BRCA	cis	rs3820928	0.874	rs55743026	chr2:227802813	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.72	-0.33	2.42e-17	Pulmonary function;
BRCA	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg22875332	chr1:76189707	ACADM	0.69	14.91	0.51	2.21e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4566357	0.615	rs3769642	chr2:227917323	T/C	cg05526886	chr2:227700861	RHBDD1	-0.4	-8.31	-0.31	5.82e-16	Coronary artery disease;
BRCA	cis	rs13064411	0.518	rs2669909	chr3:113265727	A/G	cg18753928	chr3:113234510	CCDC52	0.4	9.13	0.34	8.98e-19	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.73	-0.33	2.15e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.72e-22	Bladder cancer;
BRCA	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg08999081	chr20:33150536	PIGU	-0.45	-12.15	-0.43	1.03e-30	Glomerular filtration rate (creatinine);
BRCA	cis	rs870825	0.860	rs72689295	chr4:185600930	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	13.82	0.48	3.56e-38	Blood protein levels;
BRCA	cis	rs6546550	0.867	rs1551374	chr2:70079633	C/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-10.21	-0.37	8.82e-23	Prevalent atrial fibrillation;
BRCA	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg22535103	chr8:58192502	C8orf71	-0.49	-8.6	-0.32	5.95e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg21918786	chr6:109611834	NA	-0.49	-14.15	-0.49	1.02e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs7565124	1.000	rs7568106	chr2:20261969	G/A	cg23821541	chr2:20251993	LAPTM4A	0.37	7.83	0.3	2.07e-14	Major depressive disorder;
BRCA	cis	rs10465746	0.780	rs11163862	chr1:84355418	A/T	cg10977910	chr1:84465055	TTLL7	-0.56	-11.78	-0.42	3.89e-29	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.2e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs743757	1.000	rs2236955	chr3:50429876	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.45	7.92	0.3	1.08e-14	Diastolic blood pressure;
BRCA	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg15997130	chr1:24165203	NA	-0.45	-10.18	-0.37	1.12e-22	Immature fraction of reticulocytes;
BRCA	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.84	0.39	3.02e-25	Bipolar disorder;
BRCA	cis	rs2274471	0.591	rs7034539	chr9:5081585	C/T	cg03390472	chr9:5043263	JAK2	0.48	8.6	0.32	6.33e-17	Crohn's disease;
BRCA	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg17971929	chr21:40555470	PSMG1	-0.62	-14.46	-0.5	3.37e-41	Cognitive function;
BRCA	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg04267008	chr7:1944627	MAD1L1	-0.46	-9.81	-0.36	3.08e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg16262614	chr3:133464971	TF	-0.25	-8.12	-0.31	2.41e-15	Iron status biomarkers (transferrin levels);
BRCA	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg20887711	chr4:1340912	KIAA1530	0.42	10.2	0.37	1.02e-22	Longevity;
BRCA	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs2412459	1.000	rs2279581	chr15:40300092	A/G	cg10636054	chr15:40330586	SRP14	0.5	8.41	0.32	2.67e-16	Response to haloperidol in psychosis;
BRCA	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.44	-0.32	2.08e-16	Monocyte percentage of white cells;
BRCA	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg22491629	chr6:157744540	C6orf35	-0.66	-11.63	-0.42	1.64e-28	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg13010199	chr12:38710504	ALG10B	0.52	10.19	0.37	1.05e-22	Bladder cancer;
BRCA	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg24101359	chr6:42928495	GNMT	0.55	12.98	0.46	2.32e-34	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08219700	chr8:58056026	NA	0.54	8.98	0.33	2.94e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg22875332	chr1:76189707	ACADM	-0.53	-10.27	-0.38	5.49e-23	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10504073	0.647	rs62507246	chr8:50013449	G/A	cg00325661	chr8:49890786	NA	0.44	12.52	0.44	2.54e-32	Blood metabolite ratios;
BRCA	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-10.38	-0.38	2e-23	Morning vs. evening chronotype;
BRCA	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05025164	chr4:1340916	KIAA1530	0.59	12.33	0.44	1.66e-31	Longevity;
BRCA	cis	rs16854884	0.802	rs6783329	chr3:143798454	T/G	cg06585982	chr3:143692056	C3orf58	0.44	8.88	0.33	6.67e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-10.34	-0.38	2.73e-23	Heart rate;
BRCA	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg09998033	chr7:158218633	PTPRN2	0.4	9.52	0.35	3.46e-20	Obesity-related traits;
BRCA	cis	rs10733682	0.524	rs10987422	chr9:129462687	C/A	cg00232160	chr9:129468157	NA	0.35	8.09	0.3	3.1e-15	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg21143896	chr7:2802374	GNA12	-0.38	-9.53	-0.35	3.1e-20	Height;
BRCA	cis	rs6088813	1.000	rs6142370	chr20:33973378	G/A	cg14752227	chr20:34000481	UQCC	-0.41	-8.65	-0.32	4.1e-17	Height;
BRCA	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg06552810	chr11:31128660	NA	-0.39	-8.77	-0.33	1.59e-17	Red blood cell count;
BRCA	cis	rs3820928	0.874	rs10202239	chr2:227901819	C/T	cg11843606	chr2:227700838	RHBDD1	-0.36	-7.91	-0.3	1.16e-14	Pulmonary function;
BRCA	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg04450456	chr4:17643702	FAM184B	-0.33	-9.4	-0.35	9.83e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1190552	0.846	rs3783381	chr14:102965435	A/G	cg18135206	chr14:102964638	TECPR2	0.46	8.9	0.33	5.89e-18	Blood protein levels;
BRCA	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.81	0.55	8.35e-53	Axial length;
BRCA	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg23533926	chr12:111358616	MYL2	-0.43	-9.14	-0.34	8.32e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10150615	chr22:24372951	LOC391322	-0.44	-9.88	-0.36	1.66e-21	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg21475434	chr5:93447410	FAM172A	0.7	8.93	0.33	4.37e-18	Diabetic retinopathy;
BRCA	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg23033748	chr14:75592666	NEK9	-0.41	-9.93	-0.37	1e-21	Height;
BRCA	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg11812906	chr14:75593930	NEK9	-0.61	-13.88	-0.48	1.76e-38	Height;
BRCA	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg19622623	chr12:86230825	RASSF9	-0.33	-9.31	-0.35	2.09e-19	Major depressive disorder;
BRCA	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg08805041	chr16:621841	PIGQ	-0.33	-8.99	-0.34	2.82e-18	Height;
BRCA	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.49	-11.01	-0.4	6.23e-26	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11112613	0.713	rs12580741	chr12:105941328	A/G	cg03607813	chr12:105948248	NA	-0.53	-9.66	-0.36	1.04e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg23029597	chr12:123009494	RSRC2	-0.61	-11.79	-0.42	3.46e-29	Body mass index;
BRCA	cis	rs3772130	0.962	rs6768621	chr3:121530274	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.91	0.4	1.63e-25	Cognitive performance;
BRCA	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.54	11.6	0.42	2.32e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	8.36	0.31	3.97e-16	Schizophrenia;
BRCA	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03264133	chr6:25882463	NA	0.71	16.19	0.54	1.12e-49	Blood metabolite levels;
BRCA	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg15819921	chr19:927150	ARID3A	-0.51	-9.69	-0.36	8.22e-21	Life satisfaction;
BRCA	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.47	8.16	0.31	1.73e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs1030877	0.515	rs2679895	chr2:105906480	C/G	cg02079111	chr2:105885981	TGFBRAP1	0.62	12.04	0.43	3.19e-30	Obesity-related traits;
BRCA	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg14289826	chr9:140003911	NA	0.52	13.8	0.48	4.25e-38	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg12564285	chr5:131593104	PDLIM4	0.43	11.04	0.4	4.77e-26	Acylcarnitine levels;
BRCA	cis	rs2637266	0.935	rs12414653	chr10:78394071	C/G	cg18941641	chr10:78392320	NA	0.36	8.28	0.31	7.41e-16	Pulmonary function;
BRCA	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg22907277	chr7:1156413	C7orf50	0.5	11.14	0.4	1.84e-26	Longevity;Endometriosis;
BRCA	trans	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07923666	chr12:49932857	KCNH3	0.4	7.82	0.3	2.25e-14	Resting heart rate;
BRCA	trans	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg25214090	chr10:38739885	LOC399744	0.45	10.2	0.37	9.49e-23	Corneal astigmatism;
BRCA	cis	rs9790314	0.718	rs9847866	chr3:160758275	A/G	cg03342759	chr3:160939853	NMD3	-0.49	-9.25	-0.34	3.39e-19	Morning vs. evening chronotype;
BRCA	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg13628971	chr7:2884303	GNA12	0.47	9.13	0.34	8.69e-19	Height;
BRCA	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg13047869	chr3:10149882	C3orf24	0.51	9.51	0.35	3.77e-20	Alzheimer's disease;
BRCA	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg12564285	chr5:131593104	PDLIM4	0.36	9.55	0.35	2.64e-20	Breast cancer;
BRCA	cis	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.4	1.52e-26	Morning vs. evening chronotype;
BRCA	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg08754654	chr5:154026448	NA	0.43	10.11	0.37	2.11e-22	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03576123	chr11:487126	PTDSS2	-1.2	-18.77	-0.6	6.11e-63	Body mass index;
BRCA	trans	rs12439619	0.883	rs62012045	chr15:82521707	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.46	-11.24	-0.41	6.94e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.22	-0.31	1.17e-15	Depression;
BRCA	trans	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg06521331	chr12:34319734	NA	0.45	8.9	0.33	5.72e-18	Morning vs. evening chronotype;
BRCA	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg00757033	chr12:89920650	WDR51B	0.55	11.24	0.41	7.05e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg27398817	chr8:82754497	SNX16	-0.38	-8.13	-0.31	2.16e-15	Diastolic blood pressure;
BRCA	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-10.81	-0.39	4.09e-25	IgG glycosylation;
BRCA	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21545522	chr1:205238299	TMCC2	0.37	8.19	0.31	1.43e-15	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg08470875	chr2:26401718	FAM59B	-0.51	-8.24	-0.31	9.64e-16	Gut microbiome composition (summer);
BRCA	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg10495392	chr1:46806563	NSUN4	0.45	8.32	0.31	5.33e-16	Menopause (age at onset);
BRCA	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.73	0.65	7.9e-79	Lymphocyte percentage of white cells;
BRCA	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg01256987	chr12:42539512	GXYLT1	-0.4	-7.82	-0.3	2.21e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs8017423	0.605	rs4904676	chr14:90819220	G/A	cg04374321	chr14:90722782	PSMC1	-0.5	-11.92	-0.43	9.86e-30	Mortality in heart failure;
BRCA	cis	rs10193935	1.000	rs4048	chr2:42424595	A/C	cg27598129	chr2:42591480	NA	-0.99	-14.71	-0.5	2.03e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2282802	0.617	rs10477348	chr5:139666906	A/T	cg26211634	chr5:139558579	C5orf32	0.35	8.21	0.31	1.19e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg13047869	chr3:10149882	C3orf24	0.59	12.55	0.44	1.94e-32	Alzheimer's disease;
BRCA	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.5	12.01	0.43	4.15e-30	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2859741	0.565	rs11263962	chr1:37509239	C/T	cg09363841	chr1:37513479	NA	-0.54	-11.71	-0.42	8.16e-29	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg24060327	chr5:131705240	SLC22A5	-0.46	-9.16	-0.34	7.14e-19	Acylcarnitine levels;
BRCA	cis	rs2806561	0.754	rs10917337	chr1:23300723	G/A	cg19743168	chr1:23544995	NA	-0.41	-9.78	-0.36	3.68e-21	Height;
BRCA	cis	rs897080	0.515	rs1067351	chr2:44669907	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	9.19	0.34	5.54e-19	Height;
BRCA	cis	rs7586879	0.789	rs13428763	chr2:25132855	T/G	cg04586622	chr2:25135609	ADCY3	0.4	9.44	0.35	7.05e-20	Body mass index;
BRCA	cis	rs13082711	0.871	rs7624790	chr3:27468601	C/A	cg02860705	chr3:27208620	NA	0.53	10.65	0.39	1.65e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg02493740	chr2:85810744	VAMP5	-0.51	-10.58	-0.39	3.16e-24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.42	-0.38	1.37e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.54	11.9	0.43	1.18e-29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg14186256	chr22:23484241	RTDR1	0.77	22.44	0.66	1.1e-82	Bone mineral density;
BRCA	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg13010199	chr12:38710504	ALG10B	0.51	10.42	0.38	1.41e-23	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21659725	chr3:3221576	CRBN	-0.49	-12.55	-0.44	1.8e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.49	-12.07	-0.43	2.24e-30	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg05874882	chr4:1763078	NA	-0.46	-8.42	-0.32	2.43e-16	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg23708337	chr7:1209742	NA	0.44	8.36	0.31	4.01e-16	Longevity;Endometriosis;
BRCA	cis	rs9420	0.796	rs685149	chr11:57657413	A/G	cg19752551	chr11:57585705	CTNND1	0.42	10.74	0.39	7.41e-25	Schizophrenia;
BRCA	cis	rs921968	0.565	rs6723334	chr2:219629303	C/T	cg02176678	chr2:219576539	TTLL4	0.4	10.88	0.4	1.98e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7100689	0.524	rs7902460	chr10:82199263	T/A	cg00277334	chr10:82204260	NA	-0.61	-14.02	-0.49	3.75e-39	Post bronchodilator FEV1;
BRCA	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg10523679	chr1:76189770	ACADM	-0.52	-9.64	-0.36	1.23e-20	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg18016565	chr1:150552671	MCL1	-0.39	-9.5	-0.35	4.1e-20	Urate levels;
BRCA	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg21252483	chr19:49399788	TULP2	-0.51	-10.75	-0.39	7e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg00814883	chr7:100076585	TSC22D4	0.55	11.69	0.42	9.37e-29	Platelet count;
BRCA	cis	rs1865760	0.688	rs1436310	chr6:25969958	G/C	cg17691542	chr6:26056736	HIST1H1C	0.48	9.98	0.37	6.82e-22	Height;
BRCA	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg06360820	chr2:242988706	NA	-0.86	-14.92	-0.51	2.11e-43	Obesity-related traits;
BRCA	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg00277334	chr10:82204260	NA	0.49	8.14	0.31	2.15e-15	Post bronchodilator FEV1;
BRCA	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg06494592	chr3:125709126	NA	-0.54	-8.36	-0.31	4.06e-16	Blood pressure (smoking interaction);
BRCA	cis	rs870825	0.616	rs72703531	chr4:185611092	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	16.21	0.54	8.96e-50	Blood protein levels;
BRCA	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19626725	chr5:178986131	RUFY1	0.36	11.3	0.41	3.99e-27	Lung cancer;
BRCA	cis	rs6942756	0.876	rs822040	chr7:129065922	C/G	cg02491457	chr7:128862824	NA	0.6	12.57	0.45	1.49e-32	White matter hyperintensity burden;
BRCA	cis	rs9658691	0.607	rs9658757	chr10:90769455	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.55	-8.01	-0.3	5.57e-15	Mosquito bite size;
BRCA	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg15352829	chr14:105391018	PLD4	-0.38	-12.39	-0.44	9.37e-32	Rheumatoid arthritis;
BRCA	cis	rs6977660	0.943	rs10270447	chr7:19849823	C/G	cg05791153	chr7:19748676	TWISTNB	-0.41	-8.57	-0.32	8.02e-17	Thyroid stimulating hormone;
BRCA	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg13010199	chr12:38710504	ALG10B	0.5	10.38	0.38	2.04e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg12564285	chr5:131593104	PDLIM4	0.37	10.06	0.37	3.39e-22	Breast cancer;
BRCA	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg09555818	chr19:45449301	APOC2	-0.55	-14.48	-0.5	2.6e-41	Blood protein levels;
BRCA	cis	rs847577	0.715	rs4729402	chr7:97707731	A/G	cg24562669	chr7:97807699	LMTK2	0.48	13.34	0.47	5.69e-36	Breast cancer;
BRCA	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs9880211	1.000	rs67949818	chr3:136212978	G/A	cg21827317	chr3:136751795	NA	-0.45	-8.22	-0.31	1.12e-15	Body mass index;Height;
BRCA	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg09537434	chr19:41945824	ATP5SL	-0.99	-23.95	-0.69	5.75e-91	Height;
BRCA	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg12826209	chr6:26865740	GUSBL1	0.56	9.17	0.34	6.68e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg15737290	chr11:93063684	CCDC67	0.54	10.29	0.38	4.6e-23	Pulmonary function decline;
BRCA	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.05	0.3	3.93e-15	Tonsillectomy;
BRCA	cis	rs6005807	0.545	rs134488	chr22:28728344	G/A	cg12565055	chr22:29076175	TTC28	-0.44	-7.83	-0.3	1.98e-14	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.02e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7707921	0.767	rs226199	chr5:81572464	G/C	cg15871215	chr5:81402204	ATG10	0.36	8.32	0.31	5.15e-16	Breast cancer;
BRCA	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg06623918	chr6:96969491	KIAA0776	0.89	25.14	0.71	1.8e-97	Headache;
BRCA	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg27129171	chr3:47204927	SETD2	-0.67	-14.87	-0.51	3.74e-43	Colorectal cancer;
BRCA	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg25554036	chr4:6271136	WFS1	0.41	9.58	0.35	2.18e-20	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs9300255	0.739	rs1879380	chr12:123739111	G/A	cg00376283	chr12:123451042	ABCB9	-0.57	-10.9	-0.4	1.65e-25	Neutrophil percentage of white cells;
BRCA	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg00814883	chr7:100076585	TSC22D4	-0.54	-10.68	-0.39	1.27e-24	Platelet count;
BRCA	cis	rs13046373	0.535	rs1911571	chr21:32031538	A/C	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.42	0.32	2.39e-16	HDL cholesterol;
BRCA	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg08807101	chr21:30365312	RNF160	-0.76	-20.05	-0.62	1e-69	Dental caries;
BRCA	cis	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg21775007	chr8:11205619	TDH	-0.38	-8.06	-0.3	3.68e-15	Retinal vascular caliber;
BRCA	trans	rs11088226	0.681	rs2833891	chr21:33928821	A/G	cg09050820	chr6:167586206	TCP10L2	0.79	14.32	0.49	1.59e-40	Gastritis;
BRCA	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg16006841	chr5:176797999	RGS14	0.78	14.28	0.49	2.28e-40	Urinary electrolytes (magnesium/calcium ratio);
BRCA	cis	rs16976116	0.901	rs28564077	chr15:55495151	G/A	cg11288833	chr15:55489084	RSL24D1	0.48	10.68	0.39	1.25e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg14926445	chr8:58193284	C8orf71	-0.47	-8.92	-0.33	4.83e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs12439619	0.921	rs4778672	chr15:82537354	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.45	11.0	0.4	6.93e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg18904891	chr8:8559673	CLDN23	0.64	12.48	0.44	3.89e-32	Obesity-related traits;
BRCA	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	18.99	0.6	4.41e-64	Platelet count;
BRCA	trans	rs61931739	0.635	rs7138254	chr12:33914422	G/T	cg26384229	chr12:38710491	ALG10B	0.4	8.98	0.33	3.05e-18	Morning vs. evening chronotype;
BRCA	trans	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg26043149	chr18:55253948	FECH	0.4	8.73	0.33	2.17e-17	Bone mineral density;
BRCA	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg14675211	chr2:100938903	LONRF2	0.48	11.08	0.4	3.09e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.14	0.37	1.62e-22	Bladder cancer;
BRCA	cis	rs6783573	0.965	rs7650998	chr3:46607255	C/T	cg16875182	chr3:46619291	LRRC2;TDGF1	0.41	8.31	0.31	5.75e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs113835537	0.559	rs57045447	chr11:66339683	A/G	cg24851651	chr11:66362959	CCS	0.45	8.59	0.32	6.55e-17	Airway imaging phenotypes;
BRCA	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02475777	chr4:1388615	CRIPAK	0.66	12.77	0.45	1.98e-33	Longevity;
BRCA	cis	rs3820928	0.874	rs4675132	chr2:227841792	A/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.27	-0.31	7.92e-16	Pulmonary function;
BRCA	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg00383909	chr3:49044727	WDR6	0.56	9.78	0.36	3.97e-21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.46e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg06640241	chr16:89574553	SPG7	0.56	11.95	0.43	7.93e-30	Multiple myeloma (IgH translocation);
BRCA	trans	rs4714291	0.832	rs7764688	chr6:40115442	G/T	cg02267698	chr19:7991119	CTXN1	-0.46	-9.49	-0.35	4.57e-20	Strep throat;
BRCA	cis	rs7246657	0.550	rs10411176	chr19:37686953	G/T	cg14683738	chr19:37701593	ZNF585B	0.52	7.81	0.3	2.32e-14	Coronary artery calcification;
BRCA	cis	rs12541635	0.677	rs34872724	chr8:107033071	C/T	cg10147462	chr8:107024639	NA	-0.39	-10.57	-0.39	3.46e-24	Age of smoking initiation;
BRCA	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.42	9.71	0.36	6.95e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg10845886	chr2:3471009	TTC15	-0.5	-10.71	-0.39	9.6e-25	Neurofibrillary tangles;
BRCA	cis	rs4853036	1.000	rs56223710	chr2:70049715	C/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-8.9	-0.33	5.59e-18	Colorectal or endometrial cancer;
BRCA	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs8114671	0.647	rs945959	chr20:33734905	G/C	cg24642439	chr20:33292090	TP53INP2	0.4	8.58	0.32	7.04e-17	Height;
BRCA	cis	rs2731664	0.792	rs335467	chr5:176890642	A/G	cg23176889	chr5:176863531	GRK6	-0.6	-16.42	-0.54	8.15e-51	Intelligence (multi-trait analysis);
BRCA	cis	rs17092148	0.836	rs4911157	chr20:33167075	T/C	cg16810054	chr20:33298113	TP53INP2	-0.48	-10.45	-0.38	1.06e-23	Neuroticism;
BRCA	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg04691961	chr3:161091175	C3orf57	-0.6	-15.12	-0.51	2.13e-44	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg07606381	chr6:8435919	SLC35B3	-0.66	-14.37	-0.49	8.75e-41	Motion sickness;
BRCA	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg23505145	chr19:12996616	KLF1	0.54	12.33	0.44	1.69e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.56	8.54	0.32	9.87e-17	Gut microbiome composition (summer);
BRCA	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg19717773	chr7:2847554	GNA12	-0.43	-9.45	-0.35	6.5e-20	Height;
BRCA	trans	rs4714291	0.963	rs9369159	chr6:39998853	T/C	cg02267698	chr19:7991119	CTXN1	0.4	7.92	0.3	1.08e-14	Strep throat;
BRCA	trans	rs6479891	0.908	rs11819167	chr10:64976169	G/A	cg14819942	chr15:35414228	NA	0.34	8.48	0.32	1.58e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08704250	chr15:31115839	NA	0.34	8.81	0.33	1.19e-17	Huntington's disease progression;
BRCA	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08045932	chr20:61659980	NA	0.5	11.55	0.42	3.63e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3845702	0.935	rs6433822	chr2:180840422	G/C	cg01881094	chr2:180872142	CWC22	-0.66	-12.58	-0.45	1.43e-32	Schizophrenia;
BRCA	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06544989	chr22:39130855	UNC84B	0.34	7.94	0.3	9.19e-15	Menopause (age at onset);
BRCA	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg14829155	chr15:31115871	NA	-0.42	-9.7	-0.36	7.72e-21	Huntington's disease progression;
BRCA	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg06453172	chr10:134556979	INPP5A	-0.6	-11.88	-0.43	1.45e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs147120681	1	rs147120681	chr1:101239293	CT/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.41	-10.36	-0.38	2.29e-23	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg20307385	chr11:47447363	PSMC3	0.72	15.82	0.53	8.23e-48	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg08917208	chr2:24149416	ATAD2B	0.54	8.23	0.31	1.06e-15	Lymphocyte counts;
BRCA	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg24130564	chr14:104152367	KLC1	-0.41	-10.02	-0.37	4.85e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.75	16.53	0.55	2.32e-51	Lymphocyte counts;
BRCA	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg22834771	chr12:69754056	YEATS4	-0.39	-9.64	-0.36	1.29e-20	Blood protein levels;
BRCA	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg03342759	chr3:160939853	NMD3	-0.72	-16.33	-0.54	2.28e-50	Parkinson's disease;
BRCA	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.8	-0.48	4.14e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11644478	chr21:40555479	PSMG1	0.84	19.32	0.61	7.72e-66	Cognitive function;
BRCA	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg27170947	chr2:26402098	FAM59B	-0.65	-11.21	-0.41	9.48e-27	Gut microbiome composition (summer);
BRCA	cis	rs1506636	0.924	rs4370458	chr7:123260968	G/A	cg03229431	chr7:123269106	ASB15	-0.66	-15.28	-0.52	3.91e-45	Plateletcrit;Platelet count;
BRCA	cis	rs4302748	0.862	rs11980735	chr7:36183683	C/T	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.5	-0.32	1.35e-16	Monocyte percentage of white cells;
BRCA	cis	rs11690935	0.550	rs4280427	chr2:172813218	G/A	cg13550731	chr2:172543902	DYNC1I2	0.54	13.01	0.46	1.62e-34	Schizophrenia;
BRCA	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg18230493	chr5:56204884	C5orf35	-0.68	-13.75	-0.48	7.51e-38	Initial pursuit acceleration;
BRCA	cis	rs2882667	0.654	rs288019	chr5:138191393	A/G	cg04439458	chr5:138467593	SIL1	0.31	7.94	0.3	9.37e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs1459104	1.000	rs12795435	chr11:55047287	C/T	cg15704280	chr7:45808275	SEPT13	0.64	8.36	0.31	3.82e-16	Body mass index;
BRCA	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.37	8.56	0.32	8.64e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07308232	chr7:1071921	C7orf50	-0.41	-8.2	-0.31	1.33e-15	Longevity;Endometriosis;
BRCA	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg15934090	chr1:100435551	SLC35A3	0.36	8.43	0.32	2.38e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24531977	chr5:56204891	C5orf35	0.71	15.72	0.53	2.7e-47	Initial pursuit acceleration;
BRCA	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg26384229	chr12:38710491	ALG10B	0.44	10.7	0.39	1.08e-24	Morning vs. evening chronotype;
BRCA	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg26384229	chr12:38710491	ALG10B	-0.42	-9.61	-0.36	1.6e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10503871	0.967	rs2294085	chr8:30436779	C/T	cg26383811	chr8:30366931	RBPMS	0.31	8.41	0.32	2.74e-16	Metabolite levels  (X-11787);
BRCA	cis	rs3772130	0.962	rs13065245	chr3:121566729	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	9.94	0.37	9.38e-22	Cognitive performance;
BRCA	cis	rs6942756	0.806	rs1880854	chr7:128949748	G/T	cg02491457	chr7:128862824	NA	0.56	12.02	0.43	3.83e-30	White matter hyperintensity burden;
BRCA	trans	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	10.35	0.38	2.56e-23	Retinal vascular caliber;
BRCA	cis	rs1784581	0.894	rs1784594	chr6:162382734	A/G	cg17173639	chr6:162384350	PARK2	-0.43	-10.48	-0.38	8.03e-24	Itch intensity from mosquito bite;
BRCA	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	11.9	0.43	1.2e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs10838687	0.736	rs7120158	chr11:47265194	G/C	cg25783544	chr11:47291846	MADD	0.42	7.87	0.3	1.57e-14	Proinsulin levels;
BRCA	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg05025164	chr4:1340916	KIAA1530	0.41	9.27	0.34	2.75e-19	Longevity;
BRCA	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg01181863	chr3:195395398	SDHAP2	-0.46	-8.01	-0.3	5.54e-15	Pancreatic cancer;
BRCA	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	10.23	0.38	7.31e-23	Iron status biomarkers;
BRCA	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg12379764	chr21:47803548	PCNT	-0.37	-7.91	-0.3	1.11e-14	Testicular germ cell tumor;
BRCA	cis	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg06521331	chr12:34319734	NA	-0.65	-11.95	-0.43	7.75e-30	Morning vs. evening chronotype;
BRCA	cis	rs2455799	0.613	rs6802048	chr3:15883933	A/G	cg16303742	chr3:15540471	COLQ	-0.38	-9.27	-0.34	2.85e-19	Mean platelet volume;
BRCA	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg21573476	chr21:45109991	RRP1B	-0.47	-11.63	-0.42	1.74e-28	Mean corpuscular volume;
BRCA	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-15.83	-0.53	7.73e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg22920501	chr2:26401640	FAM59B	0.63	10.89	0.4	1.81e-25	Gut microbiome composition (summer);
BRCA	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08859206	chr1:53392774	SCP2	-0.59	-12.76	-0.45	2.13e-33	Monocyte count;
BRCA	cis	rs2279817	1.000	rs905389	chr1:18021406	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.54	16.44	0.55	6.25e-51	Neuroticism;
BRCA	cis	rs1011018	0.628	rs10230692	chr7:139421180	A/G	cg03224163	chr7:139420300	HIPK2	-0.54	-9.18	-0.34	5.9e-19	Systolic blood pressure;
BRCA	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.24	8.29	0.31	6.5e-16	Schizophrenia;
BRCA	cis	rs4930561	0.690	rs6591334	chr11:67924559	A/G	cg04465784	chr11:67976953	SUV420H1	-0.27	-8.71	-0.33	2.62e-17	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg14196790	chr5:131705035	SLC22A5	0.35	9.27	0.34	2.93e-19	Breast cancer;
BRCA	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.47	10.35	0.38	2.49e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.51	-0.35	3.95e-20	Total body bone mineral density;
BRCA	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg04025307	chr7:1156635	C7orf50	0.57	13.32	0.47	6.41e-36	Longevity;Endometriosis;
BRCA	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg05283184	chr6:79620031	NA	-0.43	-11.05	-0.4	4.25e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.2e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg05775895	chr3:12838266	CAND2	0.38	8.37	0.31	3.64e-16	QRS complex (12-leadsum);
BRCA	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg07395648	chr5:131743802	NA	-0.36	-9.09	-0.34	1.25e-18	Blood metabolite levels;
BRCA	cis	rs16976116	0.901	rs1061873	chr15:55496756	T/C	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg11502198	chr6:26597334	ABT1	0.48	9.62	0.36	1.45e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg24692254	chr21:30365293	RNF160	-0.47	-10.25	-0.38	6.31e-23	Dental caries;
BRCA	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg08807892	chr2:162101083	NA	0.72	16.41	0.54	9.16e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs1018836	0.923	rs11784529	chr8:91640956	C/A	cg16814680	chr8:91681699	NA	-0.57	-12.24	-0.44	4.44e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.69	14.03	0.49	3.53e-39	Lymphocyte counts;
BRCA	trans	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg25214090	chr10:38739885	LOC399744	0.52	11.67	0.42	1.18e-28	Corneal astigmatism;
BRCA	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg01483505	chr11:975446	AP2A2	0.35	9.39	0.35	1.06e-19	Alzheimer's disease (late onset);
BRCA	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg24060327	chr5:131705240	SLC22A5	0.46	9.41	0.35	9e-20	Blood metabolite levels;
BRCA	cis	rs2304069	0.601	rs216143	chr5:149444147	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.61	12.83	0.45	1.13e-33	HIV-1 control;
BRCA	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.49	-9.9	-0.36	1.32e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1003719	0.708	rs8126491	chr21:38551219	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.49	-0.5	2.46e-41	Eye color traits;
BRCA	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg01884057	chr2:25150051	NA	-0.32	-8.57	-0.32	7.51e-17	Body mass index;
BRCA	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg06671706	chr8:8559999	CLDN23	0.45	8.63	0.32	4.94e-17	Obesity-related traits;
BRCA	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	25.73	0.71	9.83e-101	Chronic sinus infection;
BRCA	cis	rs17401966	0.838	rs7553228	chr1:10350438	G/C	cg03954927	chr1:10346856	KIF1B	0.44	13.78	0.48	5.15e-38	Hepatocellular carcinoma;
BRCA	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg03188948	chr7:1209495	NA	0.45	8.62	0.32	5.4e-17	Longevity;Endometriosis;
BRCA	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg09307838	chr4:120376055	NA	0.64	14.09	0.49	1.94e-39	Corneal astigmatism;
BRCA	cis	rs27434	0.583	rs151911	chr5:96157084	A/G	cg16492584	chr5:96139282	ERAP1	-0.51	-12.8	-0.45	1.52e-33	Ankylosing spondylitis;
BRCA	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	14.67	0.5	3.48e-42	Eye color traits;
BRCA	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg22920501	chr2:26401640	FAM59B	-0.65	-11.32	-0.41	3.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg00106254	chr7:1943704	MAD1L1	0.45	12.55	0.44	1.85e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-15.1	-0.51	2.86e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg22705602	chr4:152727874	NA	-0.33	-8.22	-0.31	1.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg06521331	chr12:34319734	NA	-0.62	-11.28	-0.41	5.11e-27	Morning vs. evening chronotype;
BRCA	cis	rs708547	0.647	rs1718878	chr4:57876955	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.38	9.87	0.36	1.76e-21	Response to bleomycin (chromatid breaks);
BRCA	cis	rs8016982	0.662	rs7148100	chr14:81678096	A/G	cg01989461	chr14:81687754	GTF2A1	0.47	8.58	0.32	6.97e-17	Schizophrenia;
BRCA	cis	rs911119	1.000	rs3787498	chr20:23616781	C/T	cg16589663	chr20:23618590	CST3	0.46	8.66	0.32	3.93e-17	Chronic kidney disease;
BRCA	cis	rs6545883	0.894	rs9677047	chr2:61585295	C/G	cg15711740	chr2:61764176	XPO1	0.51	12.45	0.44	5.07e-32	Tuberculosis;
BRCA	cis	rs7677751	0.806	rs1800813	chr4:55094467	G/A	cg17187183	chr4:55093834	PDGFRA	0.45	8.63	0.32	4.93e-17	Corneal astigmatism;
BRCA	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg24692254	chr21:30365293	RNF160	-0.79	-22.61	-0.67	1.3e-83	Dental caries;
BRCA	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg24562669	chr7:97807699	LMTK2	0.45	12.09	0.43	1.83e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7903847	0.642	rs9888026	chr10:99159869	G/T	cg20016023	chr10:99160130	RRP12	0.26	8.36	0.31	3.99e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2880765	0.743	rs8039631	chr15:86007931	A/G	cg10818794	chr15:86012489	AKAP13	-0.31	-8.37	-0.31	3.57e-16	Coronary artery disease;
BRCA	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg12927641	chr6:109611667	NA	-0.42	-10.87	-0.4	2.22e-25	Reticulocyte fraction of red cells;
BRCA	trans	rs2018683	0.707	rs1021691	chr7:28974496	C/T	cg19402173	chr7:128379420	CALU	-0.42	-9.92	-0.37	1.1e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.24	-0.31	9.74e-16	Axial length;
BRCA	cis	rs208520	0.874	rs208473	chr6:66917265	G/C	cg07460842	chr6:66804631	NA	-0.89	-15.64	-0.53	6.62e-47	Exhaled nitric oxide output;
BRCA	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11141652	chr22:24348549	GSTTP1	-0.38	-7.81	-0.3	2.41e-14	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7677751	0.806	rs6554163	chr4:55102559	A/T	cg17187183	chr4:55093834	PDGFRA	0.45	9.5	0.35	4.01e-20	Corneal astigmatism;
BRCA	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-11.71	-0.42	8.23e-29	Lymphocyte counts;
BRCA	cis	rs7575217	0.682	rs4851401	chr2:101700518	T/C	cg23907051	chr2:101730305	TBC1D8	0.2	7.92	0.3	1.08e-14	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs2742234	0.910	rs2505511	chr10:43641029	T/A	cg15436174	chr10:43711423	RASGEF1A	-0.43	-9.0	-0.34	2.49e-18	Hirschsprung disease;
BRCA	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg04362960	chr10:104952993	NT5C2	0.45	10.34	0.38	2.75e-23	Arsenic metabolism;
BRCA	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg11783602	chr8:55087084	NA	-0.33	-9.98	-0.37	7e-22	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs7524258	0.868	rs7538921	chr1:7267007	T/C	cg07173049	chr1:7289937	CAMTA1	0.54	13.01	0.46	1.63e-34	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg21545522	chr1:205238299	TMCC2	0.39	8.25	0.31	9.23e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	trans	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.61	13.71	0.48	1.05e-37	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs672059	0.934	rs6703054	chr1:183155778	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.38	8.64	0.32	4.44e-17	Hypertriglyceridemia;
BRCA	cis	rs4363385	0.782	rs4845515	chr1:153003871	G/T	cg25856811	chr1:152973957	SPRR3	-0.31	-8.34	-0.31	4.49e-16	Inflammatory skin disease;
BRCA	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg23649088	chr2:200775458	C2orf69	-0.47	-9.6	-0.35	1.83e-20	Osteoporosis;
BRCA	trans	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	20.27	0.63	6.67e-71	Exhaled nitric oxide output;
BRCA	cis	rs698833	0.886	rs2241871	chr2:44548613	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	10.1	0.37	2.4e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.11	0.31	2.51e-15	Tonsillectomy;
BRCA	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21659725	chr3:3221576	CRBN	-0.36	-8.54	-0.32	9.92e-17	Body mass index;
BRCA	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03517284	chr6:25882590	NA	-0.48	-10.3	-0.38	3.96e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs236352	0.576	rs2116447	chr6:36837364	T/C	cg10099585	chr6:36853529	C6orf89	-0.34	-7.87	-0.3	1.49e-14	Heart rate;
BRCA	cis	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg07460842	chr6:66804631	NA	-1.18	-38.99	-0.84	3.98e-171	Exhaled nitric oxide output;
BRCA	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg24558204	chr6:135376177	HBS1L	0.59	15.99	0.53	1.14e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg24558204	chr6:135376177	HBS1L	0.46	12.61	0.45	9.93e-33	Red blood cell count;
BRCA	cis	rs16958440	0.867	rs57744138	chr18:44700482	A/C	cg17192377	chr18:44677553	HDHD2	0.99	13.47	0.47	1.43e-36	Sitting height ratio;
BRCA	cis	rs10754283	0.967	rs10737707	chr1:90119304	A/G	cg21401794	chr1:90099060	LRRC8C	0.48	11.68	0.42	1.04e-28	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg08601574	chr20:25228251	PYGB	0.37	8.8	0.33	1.23e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg03474202	chr17:45855739	NA	0.45	11.88	0.43	1.56e-29	IgG glycosylation;
BRCA	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.54	8.51	0.32	1.25e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs490234	0.812	rs4838284	chr9:128446365	G/T	cg14078157	chr9:128172775	NA	-0.42	-9.51	-0.35	3.9e-20	Mean arterial pressure;
BRCA	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.92	0.4	1.43e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13102973	0.965	rs4629509	chr4:135872410	C/T	cg14419869	chr4:135874104	NA	-0.59	-12.98	-0.46	2.36e-34	Subjective well-being;
BRCA	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg11843238	chr5:131593191	PDLIM4	0.35	7.86	0.3	1.62e-14	Breast cancer;
BRCA	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg16586182	chr3:47516702	SCAP	-0.56	-12.49	-0.44	3.39e-32	Colorectal cancer;
BRCA	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg04450456	chr4:17643702	FAM184B	0.32	9.35	0.35	1.41e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg21252483	chr19:49399788	TULP2	-0.51	-10.86	-0.39	2.53e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg09021430	chr5:549028	NA	-0.68	-14.27	-0.49	2.58e-40	Lung disease severity in cystic fibrosis;
BRCA	cis	rs877282	0.700	rs816311	chr10:796490	C/A	cg17470449	chr10:769945	NA	0.41	7.83	0.3	2.04e-14	Uric acid levels;
BRCA	cis	rs10193935	0.901	rs13426988	chr2:42604081	G/A	cg27598129	chr2:42591480	NA	-1.0	-14.8	-0.51	7.67e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg20701182	chr2:24300061	SF3B14	0.55	8.2	0.31	1.35e-15	Lymphocyte counts;
BRCA	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg01483505	chr11:975446	AP2A2	0.33	9.02	0.34	2.22e-18	Alzheimer's disease (late onset);
BRCA	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg10802521	chr3:52805072	NEK4	-0.3	-7.82	-0.3	2.16e-14	Electroencephalogram traits;
BRCA	trans	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17712092	chr4:129076599	LARP1B	0.51	12.34	0.44	1.51e-31	Eosinophil percentage of white cells;
BRCA	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg10729496	chr3:10149963	C3orf24	0.48	9.0	0.34	2.49e-18	Alzheimer's disease;
BRCA	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-13.66	-0.48	1.94e-37	Platelet count;
BRCA	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg25237894	chr2:233734115	C2orf82	0.4	11.36	0.41	2.22e-27	Coronary artery disease;
BRCA	cis	rs10924970	0.870	rs12095886	chr1:235432249	A/G	cg26050004	chr1:235667680	B3GALNT2	0.34	8.52	0.32	1.16e-16	Asthma;
BRCA	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg10193763	chr2:225306901	NA	0.3	7.81	0.3	2.28e-14	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs11051970	0.545	rs2728681	chr12:32582977	T/C	cg24626660	chr12:32551988	NA	0.3	8.78	0.33	1.45e-17	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg18252515	chr7:66147081	NA	-0.54	-11.01	-0.4	6.36e-26	Corneal structure;
BRCA	cis	rs16976116	0.901	rs62020114	chr15:55501116	T/C	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/T	cg15704280	chr7:45808275	SEPT13	0.62	8.68	0.32	3.19e-17	Height;
BRCA	cis	rs9790314	0.613	rs11716265	chr3:160602111	A/G	cg03342759	chr3:160939853	NMD3	-0.42	-7.92	-0.3	1.04e-14	Morning vs. evening chronotype;
BRCA	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.61	-0.32	5.63e-17	Colorectal cancer;
BRCA	cis	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg24110177	chr3:50126178	RBM5	-0.37	-9.91	-0.36	1.26e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.17	0.56	1.31e-54	Bladder cancer;
BRCA	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	18.87	0.6	1.93e-63	Alzheimer's disease;
BRCA	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.42	8.59	0.32	6.9e-17	Lymphocyte counts;
BRCA	trans	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg15704280	chr7:45808275	SEPT13	0.6	8.88	0.33	6.87e-18	Axial length;
BRCA	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	17.69	0.57	2.73e-57	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg25457927	chr22:38595422	NA	-0.31	-11.65	-0.42	1.41e-28	Cutaneous nevi;
BRCA	trans	rs1997103	0.911	rs11238361	chr7:55395981	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.52	0.41	4.77e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2274273	0.837	rs7146748	chr14:55747086	G/A	cg04306507	chr14:55594613	LGALS3	0.33	9.13	0.34	8.8e-19	Protein biomarker;
BRCA	cis	rs6545883	0.524	rs2593631	chr2:61572286	A/G	cg15711740	chr2:61764176	XPO1	0.32	7.81	0.3	2.29e-14	Tuberculosis;
BRCA	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg16339924	chr4:17578868	LAP3	0.63	15.82	0.53	8.4e-48	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg05985134	chr18:33552581	C18orf21	-0.68	-12.63	-0.45	8.42e-33	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg17971929	chr21:40555470	PSMG1	-0.62	-14.48	-0.5	2.58e-41	Cognitive function;
BRCA	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.53	-0.32	1.1e-16	Monocyte percentage of white cells;
BRCA	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.04	21.37	0.65	7.12e-77	Gut microbiome composition (summer);
BRCA	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg04553112	chr3:125709451	NA	-0.55	-8.44	-0.32	2.1e-16	Blood pressure (smoking interaction);
BRCA	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg06808227	chr14:105710500	BRF1	-0.79	-15.91	-0.53	2.86e-48	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs2070433	0.752	rs11701058	chr21:47776382	T/C	cg05998816	chr21:47859926	PCNT	0.36	8.17	0.31	1.65e-15	Lymphocyte counts;
BRCA	cis	rs919433	0.679	rs10931787	chr2:198520615	A/G	cg00792783	chr2:198669748	PLCL1	0.39	9.02	0.34	2.24e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg22834771	chr12:69754056	YEATS4	-0.36	-9.03	-0.34	2.08e-18	Blood protein levels;
BRCA	cis	rs9290065	0.519	rs10513560	chr3:160710798	C/T	cg03342759	chr3:160939853	NMD3	-0.47	-9.64	-0.36	1.24e-20	Kawasaki disease;
BRCA	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21659725	chr3:3221576	CRBN	0.53	13.7	0.48	1.25e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg26384229	chr12:38710491	ALG10B	0.66	15.27	0.52	4.12e-45	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg05340658	chr4:99064831	C4orf37	0.69	17.29	0.56	3.24e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg10253484	chr15:75165896	SCAMP2	0.52	10.01	0.37	5.4e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg11502198	chr6:26597334	ABT1	-0.49	-10.35	-0.38	2.66e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.59	13.3	0.47	8.2e-36	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg23978390	chr7:1156363	C7orf50	0.4	7.93	0.3	9.97e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg09307838	chr4:120376055	NA	0.71	15.07	0.51	3.93e-44	Corneal astigmatism;
BRCA	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg21573476	chr21:45109991	RRP1B	-0.47	-12.13	-0.43	1.22e-30	Mean corpuscular volume;
BRCA	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	11.15	0.4	1.7e-26	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg04944784	chr2:26401820	FAM59B	0.96	16.57	0.55	1.43e-51	Gut microbiome composition (summer);
BRCA	trans	rs66887589	0.967	rs2892869	chr4:120521297	T/C	cg25214090	chr10:38739885	LOC399744	-0.35	-7.92	-0.3	1.08e-14	Diastolic blood pressure;
BRCA	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg01283332	chr5:1856932	NA	-0.35	-8.6	-0.32	6.29e-17	Cardiovascular disease risk factors;
BRCA	trans	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg19862616	chr7:65841803	NCRNA00174	0.85	28.13	0.74	6.66e-114	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14240646	chr10:27532245	ACBD5	0.64	9.43	0.35	7.69e-20	Breast cancer;
BRCA	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg04691961	chr3:161091175	C3orf57	-0.38	-8.05	-0.3	4.06e-15	Parkinson's disease;
BRCA	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg10862848	chr6:42927986	GNMT	-0.36	-15.1	-0.51	2.83e-44	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1538970	1.000	rs4520450	chr1:45834773	A/G	cg05343316	chr1:45956843	TESK2	0.56	11.47	0.41	7.95e-28	Platelet count;
BRCA	cis	rs11971779	0.680	rs7788777	chr7:139055193	G/C	cg07862535	chr7:139043722	LUC7L2	0.38	10.24	0.38	6.65e-23	Diisocyanate-induced asthma;
BRCA	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg26031613	chr14:104095156	KLC1	0.73	15.88	0.53	3.91e-48	Body mass index;
BRCA	cis	rs1568889	0.838	rs11030265	chr11:28296168	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	19.44	0.61	1.67e-66	Bipolar disorder;
BRCA	cis	rs7707921	0.522	rs9293290	chr5:81474225	A/T	cg15871215	chr5:81402204	ATG10	-0.36	-9.14	-0.34	8.47e-19	Breast cancer;
BRCA	cis	rs6138458	1.000	rs7268095	chr20:24972333	C/T	cg06937882	chr20:24974362	C20orf3	-0.46	-9.02	-0.34	2.15e-18	Blood protein levels;
BRCA	cis	rs10754283	0.967	rs6657988	chr1:90106745	G/C	cg21401794	chr1:90099060	LRRC8C	0.46	11.13	0.4	2e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs6987853	0.736	rs35295075	chr8:42428852	A/G	cg09913449	chr8:42400586	C8orf40	0.41	9.2	0.34	5.12e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	11.94	0.43	8.34e-30	Tonsillectomy;
BRCA	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7727544	0.647	rs7721882	chr5:131418948	A/G	cg14196790	chr5:131705035	SLC22A5	0.37	9.07	0.34	1.46e-18	Blood metabolite levels;
BRCA	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	10.91	0.4	1.52e-25	Menarche (age at onset);
BRCA	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg05084668	chr3:125655381	ALG1L	0.46	7.83	0.3	2.01e-14	Blood pressure (smoking interaction);
BRCA	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg12935359	chr14:103987150	CKB	-0.59	-14.22	-0.49	4.73e-40	Bone mineral density;
BRCA	cis	rs10129255	0.500	rs8022547	chr14:107190222	A/T	cg07958169	chr14:107095056	NA	-0.39	-8.46	-0.32	1.84e-16	Kawasaki disease;
BRCA	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg11814155	chr7:99998594	ZCWPW1	0.45	7.89	0.3	1.36e-14	Platelet count;
BRCA	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	8.05	0.3	4.09e-15	Aortic root size;
BRCA	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg17135325	chr3:160939158	NMD3	0.39	7.93	0.3	9.79e-15	Parkinson's disease;
BRCA	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg04450456	chr4:17643702	FAM184B	-0.31	-8.64	-0.32	4.65e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg06784218	chr1:46089804	CCDC17	-0.42	-9.58	-0.35	2.19e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg04727924	chr7:799746	HEATR2	-0.52	-9.9	-0.36	1.39e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7587476	0.862	rs13001462	chr2:215678346	G/A	cg04004882	chr2:215674386	BARD1	0.65	12.12	0.43	1.41e-30	Neuroblastoma;
BRCA	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.07	0.37	2.99e-22	Bladder cancer;
BRCA	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg11833968	chr6:79620685	NA	-0.44	-9.88	-0.36	1.67e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs6066835	1.000	rs6125446	chr20:47348161	C/G	cg18078177	chr20:47281410	PREX1	0.69	8.61	0.32	5.58e-17	Multiple myeloma;
BRCA	trans	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	10.06	0.37	3.5e-22	Mean corpuscular volume;
BRCA	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-11.66	-0.42	1.23e-28	Schizophrenia;
BRCA	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg04234412	chr22:24373322	LOC391322	-0.62	-15.57	-0.52	1.38e-46	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7123876	0.553	rs12099027	chr11:72433920	A/G	cg04827223	chr11:72435913	ARAP1	-0.57	-14.8	-0.51	7.67e-43	Body mass index;
BRCA	trans	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg11693508	chr17:37793320	STARD3	0.57	10.87	0.4	2.23e-25	Neuroticism;
BRCA	cis	rs56804039	1.000	rs56804039	chr8:8381029	C/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-9.32	-0.35	1.91e-19	Cervical cancer;
BRCA	cis	rs758324	0.853	rs6882899	chr5:131172467	G/C	cg06307176	chr5:131281290	NA	0.52	10.15	0.37	1.55e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs73242632	0.881	rs55734441	chr4:57833717	G/A	cg20415529	chr4:57845134	POLR2B;C4orf14	0.7	8.62	0.32	5.37e-17	Congenital heart disease (maternal effect);
BRCA	cis	rs912057	0.833	rs1294421	chr6:6743149	A/C	cg06612196	chr6:6737390	NA	0.39	8.82	0.33	1.05e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs911119	1.000	rs3827143	chr20:23619617	A/G	cg16589663	chr20:23618590	CST3	0.47	8.81	0.33	1.2e-17	Chronic kidney disease;
BRCA	cis	rs4730250	0.707	rs257378	chr7:106801395	C/G	cg02696742	chr7:106810147	HBP1	-0.62	-9.76	-0.36	4.45e-21	Osteoarthritis;
BRCA	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg11764359	chr7:65958608	NA	0.63	10.79	0.39	4.96e-25	Aortic root size;
BRCA	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg16482183	chr6:26056742	HIST1H1C	0.56	11.8	0.42	3.38e-29	Height;
BRCA	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg07080220	chr10:102295463	HIF1AN	0.61	14.51	0.5	1.97e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg03146154	chr1:46216737	IPP	0.52	11.6	0.42	2.36e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg08660285	chr1:67390436	MIER1;WDR78	-0.98	-21.6	-0.65	3.93e-78	Lymphocyte percentage of white cells;
BRCA	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.79	-0.42	3.6e-29	Alcohol dependence;
BRCA	cis	rs73036520	0.846	rs17356664	chr19:45740771	C/T	cg01416317	chr19:45737208	EXOC3L2	0.39	8.08	0.3	3.35e-15	Monocyte percentage of white cells;
BRCA	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg14530993	chr4:882597	GAK	0.55	9.95	0.37	8.79e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg02951883	chr7:2050386	MAD1L1	-0.49	-11.19	-0.4	1.1e-26	Schizophrenia;
BRCA	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg26384229	chr12:38710491	ALG10B	0.54	11.47	0.41	7.77e-28	Morning vs. evening chronotype;
BRCA	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.4	10.87	0.4	2.2e-25	Total body bone mineral density;
BRCA	cis	rs73198271	0.563	rs3748143	chr8:8655237	A/G	cg01851573	chr8:8652454	MFHAS1	-0.42	-7.83	-0.3	2.09e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.77	-0.42	4.23e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs1451375	0.642	rs6963996	chr7:50559300	T/C	cg18232548	chr7:50535776	DDC	-0.42	-8.87	-0.33	7.06e-18	Malaria;
BRCA	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg08085267	chr17:45401833	C17orf57	-0.58	-12.13	-0.43	1.27e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg01236616	chr12:121019343	POP5	1.2	25.9	0.72	1.14e-101	Type 1 diabetes nephropathy;
BRCA	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.65	-10.48	-0.38	7.7e-24	Resting heart rate;
BRCA	cis	rs208520	0.690	rs207081	chr6:66773742	A/G	cg07460842	chr6:66804631	NA	-1.03	-20.44	-0.63	7.46e-72	Exhaled nitric oxide output;
BRCA	cis	rs1595825	0.891	rs1030796	chr2:198674673	A/G	cg19156104	chr2:198669113	PLCL1	-0.44	-8.33	-0.31	4.87e-16	Ulcerative colitis;
BRCA	trans	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.45	-0.35	6.17e-20	Bladder cancer;
BRCA	cis	rs600626	0.636	rs10899109	chr11:75451201	G/A	cg24262691	chr11:75473276	NA	0.47	7.85	0.3	1.75e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
BRCA	cis	rs3857067	0.806	rs28408270	chr4:95114572	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-9.74	-0.36	5.47e-21	QT interval;
BRCA	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg10818794	chr15:86012489	AKAP13	-0.42	-11.41	-0.41	1.46e-27	Coronary artery disease;
BRCA	cis	rs13082711	0.911	rs2131205	chr3:27428501	A/G	cg02860705	chr3:27208620	NA	0.53	10.32	0.38	3.48e-23	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg06521331	chr12:34319734	NA	-0.63	-12.47	-0.44	4.13e-32	Morning vs. evening chronotype;
BRCA	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg07080220	chr10:102295463	HIF1AN	0.53	12.26	0.44	3.67e-31	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.26	-0.34	3.12e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-11.79	-0.42	3.7e-29	Alzheimer's disease;
BRCA	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg17691542	chr6:26056736	HIST1H1C	0.49	10.3	0.38	3.94e-23	Height;
BRCA	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg14983838	chr19:29218262	NA	0.54	10.09	0.37	2.65e-22	Methadone dose in opioid dependence;
BRCA	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg03161606	chr19:29218774	NA	0.44	7.89	0.3	1.33e-14	Methadone dose in opioid dependence;
BRCA	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg12463550	chr7:65579703	CRCP	-0.37	-7.96	-0.3	8.11e-15	Aortic root size;
BRCA	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.43	8.8	0.33	1.25e-17	Cognitive ability;
BRCA	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg01884057	chr2:25150051	NA	0.31	8.1	0.31	2.84e-15	Body mass index;
BRCA	trans	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg11693508	chr17:37793320	STARD3	0.52	9.19	0.34	5.36e-19	Neuroticism;
BRCA	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.53	-15.14	-0.51	1.73e-44	Lung cancer;
BRCA	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg08213375	chr14:104286397	PPP1R13B	0.63	18.11	0.58	1.69e-59	Schizophrenia;
BRCA	cis	rs495337	0.760	rs2745078	chr20:48525460	C/T	cg17835207	chr20:48524531	SPATA2	-0.68	-16.82	-0.55	8.02e-53	Psoriasis;
BRCA	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11644478	chr21:40555479	PSMG1	-0.67	-15.11	-0.51	2.41e-44	Cognitive function;
BRCA	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg24642844	chr7:1081250	C7orf50	-0.92	-12.25	-0.44	3.88e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg06784218	chr1:46089804	CCDC17	0.52	12.72	0.45	3.23e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg04565464	chr8:145669602	NFKBIL2	0.4	8.75	0.33	1.85e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg08888203	chr3:10149979	C3orf24	0.65	11.93	0.43	8.91e-30	Alzheimer's disease;
BRCA	cis	rs2286885	1.000	rs741025	chr9:129251792	C/T	cg15282417	chr9:129245246	FAM125B	0.3	7.81	0.3	2.28e-14	Intraocular pressure;
BRCA	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-11.76	-0.42	4.68e-29	Homoarginine levels;
BRCA	cis	rs7131987	0.903	rs10843367	chr12:29408380	G/A	cg09582351	chr12:29534625	ERGIC2	-0.49	-11.77	-0.42	4.32e-29	QT interval;
BRCA	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg27170947	chr2:26402098	FAM59B	-0.66	-11.43	-0.41	1.22e-27	Gut microbiome composition (summer);
BRCA	trans	rs6076960	0.629	rs6054024	chr20:6229282	A/C	cg17788362	chr6:86352627	SYNCRIP	0.4	8.08	0.3	3.17e-15	Smooth-surface caries;
BRCA	cis	rs7737355	0.738	rs3776016	chr5:130855352	C/T	cg06307176	chr5:131281290	NA	0.45	9.86	0.36	1.88e-21	Life satisfaction;
BRCA	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg12373951	chr3:133503437	NA	0.53	12.5	0.44	3.06e-32	Iron status biomarkers;
BRCA	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22307029	chr19:49891270	CCDC155	0.68	12.44	0.44	5.71e-32	Multiple sclerosis;
BRCA	cis	rs6121246	0.559	rs6060919	chr20:30331922	A/T	cg21427119	chr20:30132790	HM13	-0.35	-8.04	-0.3	4.42e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg08501292	chr6:25962987	TRIM38	0.58	7.87	0.3	1.52e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg24642439	chr20:33292090	TP53INP2	-0.7	-16.31	-0.54	2.91e-50	Coronary artery disease;
BRCA	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg08564027	chr20:61660810	NA	0.9	23.51	0.68	1.56e-88	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12620038	0.525	rs7598661	chr2:47468955	C/T	cg13204236	chr2:47476732	NA	0.36	9.9	0.36	1.38e-21	Survival in pancreatic cancer;
BRCA	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.62	10.26	0.38	5.56e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.46	10.01	0.37	5.06e-22	Cognitive ability;
BRCA	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg11062466	chr8:58055876	NA	0.41	8.0	0.3	5.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7246657	0.712	rs4803263	chr19:38066782	G/A	cg18154014	chr19:37997991	ZNF793	0.48	9.16	0.34	7.24e-19	Coronary artery calcification;
BRCA	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg08645402	chr16:4508243	NA	0.39	8.42	0.32	2.56e-16	Schizophrenia;
BRCA	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-12.61	-0.45	9.81e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg22907277	chr7:1156413	C7orf50	0.59	9.1	0.34	1.11e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs26949	0.511	rs2898287	chr5:59884233	C/G	cg02684056	chr5:59996105	DEPDC1B	-0.4	-9.77	-0.36	4.03e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7617773	0.851	rs7647817	chr3:48236507	G/A	cg11946769	chr3:48343235	NME6	0.67	13.96	0.48	7.95e-39	Coronary artery disease;
BRCA	cis	rs250677	0.522	rs10038913	chr5:148354224	A/G	cg12140854	chr5:148520817	ABLIM3	0.41	8.24	0.31	9.73e-16	Breast cancer;
BRCA	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.35	-0.35	1.46e-19	Bipolar disorder;
BRCA	cis	rs7639513	0.737	rs13070228	chr3:12706914	G/A	cg23032965	chr3:12705835	RAF1	0.71	15.83	0.53	7.73e-48	Itch intensity from mosquito bite;
BRCA	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg21535247	chr6:8435926	SLC35B3	0.42	9.51	0.35	3.89e-20	Motion sickness;
BRCA	cis	rs3784262	0.869	rs4646628	chr15:58255282	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.44	-11.91	-0.43	1.12e-29	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-8.25	-0.31	9.4e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00684032	chr4:1343700	KIAA1530	0.52	12.41	0.44	8.07e-32	Obesity-related traits;
BRCA	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	10.66	0.39	1.55e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg10523679	chr1:76189770	ACADM	-0.47	-8.98	-0.33	3.02e-18	Daytime sleep phenotypes;
BRCA	cis	rs1569175	0.522	rs2202923	chr2:200879804	C/T	cg23649088	chr2:200775458	C2orf69	-0.55	-8.23	-0.31	1.09e-15	Response to treatment for acute lymphoblastic leukemia;
BRCA	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg05283184	chr6:79620031	NA	-0.41	-10.47	-0.38	8.51e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.47	-10.79	-0.39	4.77e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg20203395	chr5:56204925	C5orf35	-0.5	-10.12	-0.37	1.97e-22	Initial pursuit acceleration;
BRCA	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg15017067	chr4:17643749	FAM184B	0.32	10.2	0.37	1.01e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg17971929	chr21:40555470	PSMG1	-0.61	-13.27	-0.46	1.17e-35	Cognitive function;
BRCA	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-15.35	-0.52	1.74e-45	Total cholesterol levels;
BRCA	cis	rs10189230	0.935	rs6731133	chr2:222359155	C/T	cg14652038	chr2:222343519	EPHA4	0.49	13.66	0.48	1.9e-37	Urate levels in lean individuals;
BRCA	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg21395723	chr22:39101663	GTPBP1	0.38	8.32	0.31	5.17e-16	Menopause (age at onset);
BRCA	cis	rs34779708	0.733	rs3936502	chr10:35549218	C/T	cg03585969	chr10:35415529	CREM	0.44	9.1	0.34	1.17e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg11266682	chr4:10021025	SLC2A9	0.4	10.78	0.39	4.99e-25	Bone mineral density;
BRCA	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg03709012	chr19:19516395	GATAD2A	-0.75	-16.73	-0.55	2.17e-52	Tonsillectomy;
BRCA	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg08085267	chr17:45401833	C17orf57	-0.69	-15.12	-0.51	2.12e-44	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg25036284	chr2:26402008	FAM59B	0.96	15.95	0.53	1.78e-48	Gut microbiome composition (summer);
BRCA	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.51	8.43	0.32	2.21e-16	Lung function (FEV1/FVC);
BRCA	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.06	-25.06	-0.7	4.57e-97	Ulcerative colitis;
BRCA	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg20887711	chr4:1340912	KIAA1530	0.74	15.79	0.53	1.18e-47	Longevity;
BRCA	cis	rs2860975	0.905	rs10882516	chr10:96791217	A/C	cg09036531	chr10:96991505	NA	-0.39	-8.3	-0.31	6.26e-16	Immune response to smallpox vaccine (IL-6);
BRCA	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg00012203	chr2:219082015	ARPC2	-0.59	-12.24	-0.44	4.06e-31	Colorectal cancer;
BRCA	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.97	21.6	0.65	4.26e-78	Lymphocyte percentage of white cells;
BRCA	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg23711669	chr6:146136114	FBXO30	0.72	17.32	0.57	2.26e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6450176	1.000	rs58369491	chr5:53297295	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-15.07	-0.51	3.76e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs17741873	0.779	rs4746153	chr10:75598282	G/C	cg07699608	chr10:75541558	CHCHD1	0.5	8.21	0.31	1.27e-15	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.16	0.4	1.54e-26	Electroencephalogram traits;
BRCA	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg07817648	chr10:79422355	NA	0.64	12.44	0.44	5.5e-32	Bone mineral density;
BRCA	cis	rs9831754	0.906	rs7621811	chr3:78388816	G/A	cg06138941	chr3:78371609	NA	-0.76	-16.59	-0.55	1.18e-51	Calcium levels;
BRCA	cis	rs8016982	0.962	rs8007841	chr14:81647878	C/T	cg01989461	chr14:81687754	GTF2A1	-0.47	-9.65	-0.36	1.12e-20	Schizophrenia;
BRCA	cis	rs12617721	0.574	rs6542754	chr2:99025400	C/T	cg10123293	chr2:99228465	UNC50	0.43	8.46	0.32	1.88e-16	Bipolar disorder with mood-incongruent psychosis;
BRCA	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg08847533	chr14:75593920	NEK9	0.95	24.95	0.7	1.99e-96	Height;
BRCA	cis	rs17384381	1.000	rs12128907	chr1:85891385	A/G	cg16011679	chr1:85725395	C1orf52	0.52	8.07	0.3	3.49e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3760982	0.585	rs1386502	chr19:44293356	T/C	cg11993925	chr19:44307056	LYPD5	0.37	8.78	0.33	1.54e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs3741151	0.773	rs73544729	chr11:73183418	G/T	cg17517138	chr11:73019481	ARHGEF17	0.88	12.43	0.44	6.17e-32	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg18279126	chr7:2041391	MAD1L1	0.39	8.94	0.33	4.18e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg12935359	chr14:103987150	CKB	0.64	15.0	0.51	8.63e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg22875332	chr1:76189707	ACADM	0.57	10.03	0.37	4.2e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg01689657	chr7:91764605	CYP51A1	0.23	8.39	0.32	3.08e-16	Breast cancer;
BRCA	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg01420254	chr6:26195488	NA	0.55	8.64	0.32	4.59e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg10518543	chr12:38710700	ALG10B	0.36	7.94	0.3	9.4e-15	Morning vs. evening chronotype;
BRCA	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg12483005	chr1:23474871	LUZP1	0.44	9.81	0.36	2.84e-21	Height;
BRCA	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.43	0.54	7.51e-51	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg21479132	chr6:26055353	NA	0.57	7.97	0.3	7.48e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg04025307	chr7:1156635	C7orf50	0.59	9.46	0.35	5.6e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.56	15.64	0.53	6.57e-47	Response to bleomycin (chromatid breaks);
BRCA	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.7	0.33	2.92e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg13393036	chr8:95962371	TP53INP1	-0.34	-9.29	-0.35	2.32e-19	Type 2 diabetes;
BRCA	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg22920501	chr2:26401640	FAM59B	0.91	13.72	0.48	9.56e-38	Gut microbiome composition (summer);
BRCA	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg26384229	chr12:38710491	ALG10B	0.75	17.26	0.56	4.56e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg15017067	chr4:17643749	FAM184B	0.34	10.78	0.39	5.23e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg18850127	chr7:39170497	POU6F2	0.59	12.81	0.45	1.33e-33	IgG glycosylation;
BRCA	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg13047869	chr3:10149882	C3orf24	0.52	11.01	0.4	6.24e-26	Alzheimer's disease;
BRCA	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg09184832	chr6:79620586	NA	-0.51	-11.21	-0.41	9.87e-27	Intelligence (multi-trait analysis);
BRCA	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg15556689	chr8:8085844	FLJ10661	0.33	8.74	0.33	2.06e-17	Triglycerides;
BRCA	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg06484146	chr7:12443880	VWDE	-0.78	-11.09	-0.4	3.03e-26	Coronary artery disease;
BRCA	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg06697600	chr4:7070879	GRPEL1	-0.52	-10.61	-0.39	2.42e-24	Monocyte percentage of white cells;
BRCA	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg09469691	chr10:81107165	PPIF	0.45	9.72	0.36	6.56e-21	Height;
BRCA	cis	rs9788682	0.747	rs7174190	chr15:78763617	C/T	cg24631222	chr15:78858424	CHRNA5	0.47	9.32	0.35	1.86e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg05347473	chr6:146136440	FBXO30	0.4	8.03	0.3	4.72e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg01529538	chr14:23388837	RBM23	0.42	11.48	0.41	7.01e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs10465746	0.809	rs2389617	chr1:84437652	A/T	cg10977910	chr1:84465055	TTLL7	0.57	11.92	0.43	1.01e-29	Obesity-related traits;
BRCA	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg03585969	chr10:35415529	CREM	0.48	10.22	0.37	8.56e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg24450063	chr1:156163899	SLC25A44	1.04	33.59	0.8	2.68e-143	Testicular germ cell tumor;
BRCA	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg26818010	chr10:134567672	INPP5A	0.39	9.21	0.34	4.44e-19	Migraine;
BRCA	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg00376283	chr12:123451042	ABCB9	0.46	11.23	0.41	7.82e-27	Neutrophil percentage of white cells;
BRCA	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg03060546	chr3:49711283	APEH	-0.61	-14.18	-0.49	7.36e-40	Resting heart rate;
BRCA	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg27398817	chr8:82754497	SNX16	-0.37	-8.55	-0.32	8.8e-17	Diastolic blood pressure;
BRCA	cis	rs28830936	0.966	rs890498	chr15:42111298	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.37	-10.22	-0.37	8.41e-23	Diastolic blood pressure;
BRCA	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg20476274	chr7:133979776	SLC35B4	0.5	11.79	0.42	3.72e-29	Mean platelet volume;
BRCA	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-8.59	-0.32	6.86e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7833986	1.000	rs66553445	chr8:57096781	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.46	8.27	0.31	8.08e-16	Height;
BRCA	trans	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.03	0.3	4.84e-15	Mean corpuscular volume;
BRCA	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg06623918	chr6:96969491	KIAA0776	0.87	24.24	0.69	1.48e-92	Headache;
BRCA	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg13047869	chr3:10149882	C3orf24	0.52	11.1	0.4	2.76e-26	Alzheimer's disease;
BRCA	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg03060546	chr3:49711283	APEH	0.6	10.38	0.38	1.97e-23	Menarche (age at onset);
BRCA	trans	rs17685	0.884	rs8565	chr7:75630274	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.65	-17.59	-0.57	8.92e-57	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg25237894	chr2:233734115	C2orf82	-0.41	-11.81	-0.42	3.12e-29	Coronary artery disease;
BRCA	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg20283391	chr11:68216788	NA	-0.42	-8.49	-0.32	1.44e-16	Total body bone mineral density;
BRCA	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	8.4	0.32	3e-16	Breast cancer;
BRCA	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.59	-12.3	-0.44	2.25e-31	Lymphocyte counts;
BRCA	trans	rs8002861	0.935	rs1811464	chr13:44469290	T/G	cg17145862	chr1:211918768	LPGAT1	0.73	19.55	0.61	4.54e-67	Leprosy;
BRCA	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg20587970	chr11:113659929	NA	-1.13	-20.42	-0.63	1.05e-71	Hip circumference adjusted for BMI;
BRCA	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-9.73	-0.36	5.71e-21	IgG glycosylation;
BRCA	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.56	8.35	0.31	4.2e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4653767	1.000	rs708774	chr1:226921530	C/G	cg05049329	chr1:226924846	ITPKB	0.34	9.71	0.36	7.15e-21	Parkinson's disease;
BRCA	cis	rs4363385	0.818	rs1334848	chr1:153004721	A/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.59	-0.32	6.68e-17	Inflammatory skin disease;
BRCA	cis	rs208520	0.690	rs207096	chr6:66797287	T/C	cg07460842	chr6:66804631	NA	-1.0	-20.02	-0.62	1.44e-69	Exhaled nitric oxide output;
BRCA	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg25237894	chr2:233734115	C2orf82	-0.36	-10.21	-0.37	8.64e-23	Coronary artery disease;
BRCA	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg21433313	chr16:3507492	NAT15	-0.46	-9.8	-0.36	3.23e-21	Tuberculosis;
BRCA	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-11.87	-0.42	1.72e-29	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg18252515	chr7:66147081	NA	-0.89	-12.28	-0.44	2.95e-31	Diabetic kidney disease;
BRCA	cis	rs3768617	0.811	rs10911205	chr1:183009277	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.89	0.36	1.46e-21	Fuchs's corneal dystrophy;
BRCA	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg26384229	chr12:38710491	ALG10B	0.59	13.54	0.47	6.37e-37	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.42	0.35	7.88e-20	Morning vs. evening chronotype;
BRCA	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-10.53	-0.38	5.05e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg26587870	chr6:27730563	NA	-0.55	-8.23	-0.31	1.08e-15	Depression;
BRCA	cis	rs10504073	0.647	rs1511359	chr8:50006448	T/A	cg00325661	chr8:49890786	NA	0.45	12.82	0.45	1.19e-33	Blood metabolite ratios;
BRCA	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.35	-8.32	-0.31	5.42e-16	Electroencephalogram traits;
BRCA	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg08885076	chr2:99613938	TSGA10	-0.52	-11.68	-0.42	1.08e-28	Chronic sinus infection;
BRCA	cis	rs9583531	0.509	rs12184676	chr13:111396484	A/G	cg24331049	chr13:111365604	ING1	-0.65	-12.99	-0.46	2.16e-34	Coronary artery disease;
BRCA	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg02659138	chr7:134003124	SLC35B4	0.33	10.62	0.39	2.18e-24	Mean platelet volume;
BRCA	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.54	-0.32	9.68e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg24112000	chr20:60950667	NA	-0.47	-8.75	-0.33	1.94e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg04709771	chr16:646395	RAB40C	0.43	10.63	0.39	1.97e-24	Height;
BRCA	cis	rs7617773	0.817	rs6806112	chr3:48276077	A/T	cg11946769	chr3:48343235	NME6	0.5	11.47	0.41	7.68e-28	Coronary artery disease;
BRCA	cis	rs6815814	0.950	rs73236617	chr4:38793860	C/G	cg02016764	chr4:38805732	TLR1	-0.64	-9.96	-0.37	7.93e-22	Breast cancer;
BRCA	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.69	0.5	2.56e-42	Colorectal cancer;
BRCA	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg13319975	chr6:146136371	FBXO30	-0.36	-8.08	-0.3	3.18e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-9.04	-0.34	1.8e-18	Schizophrenia;
BRCA	cis	rs7124681	0.584	rs10769285	chr11:47709212	C/T	cg20307385	chr11:47447363	PSMC3	0.42	9.52	0.35	3.42e-20	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08045932	chr20:61659980	NA	0.49	11.48	0.41	7.01e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg04455712	chr21:45112962	RRP1B	0.46	11.68	0.42	1.07e-28	Coronary artery disease;
BRCA	cis	rs751728	0.689	rs3763257	chr6:33773696	T/A	cg15252951	chr6:33757062	LEMD2	0.38	8.67	0.32	3.45e-17	Crohn's disease;
BRCA	cis	rs9394152	0.845	rs9380367	chr6:33474975	G/A	cg13560919	chr6:33536144	NA	0.62	12.76	0.45	2.34e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.25	0.34	3.34e-19	Tonsillectomy;
BRCA	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg06697600	chr4:7070879	GRPEL1	-0.53	-10.82	-0.39	3.53e-25	Monocyte percentage of white cells;
BRCA	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg16325326	chr1:53192061	ZYG11B	0.52	11.72	0.42	7.31e-29	Monocyte count;
BRCA	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg00530320	chr1:46809349	NSUN4	0.48	9.74	0.36	5.54e-21	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.52e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg03929089	chr4:120376271	NA	-0.47	-9.04	-0.34	1.9e-18	HDL cholesterol;
BRCA	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	12.96	0.46	2.93e-34	Lymphocyte percentage of white cells;
BRCA	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-12.13	-0.43	1.24e-30	Personality dimensions;
BRCA	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg05340658	chr4:99064831	C4orf37	0.65	16.2	0.54	1.04e-49	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.65	-0.45	6.63e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.6	12.59	0.45	1.25e-32	Personality dimensions;
BRCA	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg27284194	chr4:1044797	NA	-0.69	-16.07	-0.54	4.63e-49	Recombination rate (males);
BRCA	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	14.61	0.5	6.71e-42	Total cholesterol levels;
BRCA	cis	rs6723226	0.679	rs116617324	chr2:32622709	C/T	cg02381751	chr2:32503542	YIPF4	-0.48	-10.29	-0.38	4.51e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg23260525	chr10:116636907	FAM160B1	0.32	8.45	0.32	1.9e-16	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.47	0.38	8.7e-24	Cognitive ability;
BRCA	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	14.11	0.49	1.5e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs757278	0.608	rs4500028	chr7:117342315	T/A	cg10524701	chr7:117356490	CTTNBP2	0.43	7.9	0.3	1.23e-14	Response to methotrexate in juvenile idiopathic arthritis;
BRCA	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg12564285	chr5:131593104	PDLIM4	0.38	9.5	0.35	4.17e-20	Acylcarnitine levels;
BRCA	cis	rs9443189	0.570	rs775072	chr6:76377998	G/A	cg01950844	chr6:76311363	SENP6	-0.84	-13.48	-0.47	1.32e-36	Prostate cancer;
BRCA	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg05868516	chr6:26286170	HIST1H4H	0.51	11.33	0.41	3.05e-27	Educational attainment;
BRCA	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg25036284	chr2:26402008	FAM59B	0.95	16.07	0.54	4.82e-49	Gut microbiome composition (summer);
BRCA	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.12	-0.31	2.39e-15	Total body bone mineral density;
BRCA	cis	rs11051970	0.879	rs2728680	chr12:32583512	T/C	cg02745156	chr12:32552066	NA	0.27	8.89	0.33	6.35e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03452623	chr4:187889614	NA	-0.31	-10.06	-0.37	3.36e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg04362960	chr10:104952993	NT5C2	0.45	10.19	0.37	1.09e-22	Arsenic metabolism;
BRCA	cis	rs2559856	1.000	rs10860771	chr12:102087242	A/G	cg12924262	chr12:102091054	CHPT1	0.38	8.56	0.32	8.5e-17	Blood protein levels;
BRCA	cis	rs7095944	0.584	rs4962692	chr10:126424823	G/A	cg08799069	chr10:126477246	METTL10	-0.38	-8.85	-0.33	8.32e-18	Asthma;
BRCA	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg00983440	chr10:79422392	NA	-0.54	-10.21	-0.37	8.98e-23	Bone mineral density;
BRCA	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-10.85	-0.39	2.62e-25	Neuroticism;
BRCA	trans	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.34	0.31	4.72e-16	Corneal astigmatism;
BRCA	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.68	0.42	1.01e-28	Homoarginine levels;
BRCA	cis	rs1050631	0.564	rs1785929	chr18:33725165	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.39	7.93	0.3	1.01e-14	Esophageal squamous cell cancer (length of survival);
BRCA	cis	rs4363385	0.782	rs310105	chr1:153022253	A/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.51	-0.32	1.27e-16	Inflammatory skin disease;
BRCA	cis	rs312273	0.967	rs312269	chr12:41249381	T/G	cg17827154	chr12:41323612	CNTN1	-0.41	-9.88	-0.36	1.63e-21	Bipolar disorder;
BRCA	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg12310025	chr6:25882481	NA	-0.56	-13.43	-0.47	2.13e-36	Blood metabolite levels;
BRCA	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18404041	chr3:52824283	ITIH1	-0.43	-12.75	-0.45	2.44e-33	Bipolar disorder;
BRCA	trans	rs9944715	1.000	rs718514	chr18:43856354	A/C	cg01718231	chr17:29326311	RNF135	-0.43	-8.56	-0.32	8.57e-17	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg16325326	chr1:53192061	ZYG11B	0.86	25.26	0.71	3.84e-98	Monocyte count;
BRCA	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	11.05	0.4	4.12e-26	Monocyte percentage of white cells;
BRCA	cis	rs7851660	0.967	rs1443435	chr9:100617583	T/C	cg13688889	chr9:100608707	NA	-0.36	-8.7	-0.33	2.78e-17	Strep throat;
BRCA	cis	rs2710642	0.927	rs1468748	chr2:63204611	C/T	cg17519650	chr2:63277830	OTX1	0.37	8.3	0.31	6.24e-16	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs4074536	0.740	rs6659025	chr1:116301019	A/G	cg21648376	chr1:116311395	CASQ2	-0.48	-8.54	-0.32	9.76e-17	QRS duration;
BRCA	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.58	-12.15	-0.43	1.04e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs1568889	0.838	rs6484347	chr11:28040969	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.77	-19.92	-0.62	4.9e-69	Bipolar disorder;
BRCA	cis	rs4766646	0.619	rs7397059	chr12:110310916	C/T	cg01252219	chr12:110302105	GLTP	0.36	8.15	0.31	1.92e-15	Metabolite levels (MHPG);
BRCA	cis	rs34779708	0.966	rs12762493	chr10:35471873	G/A	cg03585969	chr10:35415529	CREM	0.45	9.44	0.35	7.02e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg23978390	chr7:1156363	C7orf50	0.4	9.11	0.34	1.08e-18	Longevity;Endometriosis;
BRCA	cis	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg02751453	chr18:77725136	HSBP1L1	0.37	9.06	0.34	1.54e-18	Opioid sensitivity;
BRCA	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg18154014	chr19:37997991	ZNF793	0.49	9.68	0.36	9.12e-21	Coronary artery calcification;
BRCA	cis	rs7572733	0.534	rs4850813	chr2:198775982	C/T	cg00792783	chr2:198669748	PLCL1	-0.48	-10.32	-0.38	3.35e-23	Dermatomyositis;
BRCA	cis	rs1712517	0.844	rs4918003	chr10:105044157	C/T	cg05636881	chr10:105038444	INA	0.4	9.02	0.34	2.24e-18	Migraine;
BRCA	cis	rs6545883	0.894	rs10177303	chr2:61594459	G/A	cg15711740	chr2:61764176	XPO1	0.5	12.35	0.44	1.39e-31	Tuberculosis;
BRCA	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg11833968	chr6:79620685	NA	-0.44	-9.81	-0.36	2.92e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.45	-8.21	-0.31	1.23e-15	Menarche (age at onset);
BRCA	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg11301795	chr4:187892539	NA	-0.31	-10.26	-0.38	5.62e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs16976116	0.901	rs7172108	chr15:55501551	C/G	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg06060754	chr5:176797920	RGS14	0.59	11.18	0.4	1.31e-26	Hemoglobin concentration;Hematocrit;
BRCA	trans	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg06521331	chr12:34319734	NA	0.44	8.48	0.32	1.57e-16	Morning vs. evening chronotype;
BRCA	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-9.35	-0.35	1.51e-19	Fear of minor pain;
BRCA	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg08999081	chr20:33150536	PIGU	0.36	9.31	0.35	2.01e-19	Coronary artery disease;
BRCA	cis	rs11083475	0.686	rs73040728	chr19:39257601	C/G	cg07403899	chr19:39283540	NA	-0.24	-8.02	-0.3	5.02e-15	Heart rate;
BRCA	cis	rs12973672	1.000	rs1051995	chr19:35770292	C/T	cg12095397	chr19:35769544	USF2	0.38	8.38	0.31	3.28e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg25173405	chr17:45401733	C17orf57	0.54	11.18	0.4	1.3e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg17830980	chr10:43048298	ZNF37B	-0.43	-9.98	-0.37	6.54e-22	Extrinsic epigenetic age acceleration;
BRCA	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg03929089	chr4:120376271	NA	-0.66	-13.2	-0.46	2.35e-35	Height;
BRCA	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg23029597	chr12:123009494	RSRC2	-0.48	-10.09	-0.37	2.62e-22	Body mass index;
BRCA	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08859206	chr1:53392774	SCP2	-0.56	-12.3	-0.44	2.27e-31	Monocyte count;
BRCA	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6484504	0.600	rs208063	chr11:31159777	C/T	cg26647111	chr11:31128758	NA	-0.43	-9.41	-0.35	8.91e-20	Red blood cell count;
BRCA	cis	rs1029738	0.659	rs1608553	chr7:22896231	G/C	cg22407942	chr7:22894828	SNORD93	-0.3	-8.45	-0.32	1.9e-16	Fibrinogen levels;
BRCA	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.32	-8.23	-0.31	1.05e-15	Total body bone mineral density;
BRCA	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg01884057	chr2:25150051	NA	0.32	8.52	0.32	1.19e-16	Body mass index in non-asthmatics;
BRCA	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg07080220	chr10:102295463	HIF1AN	0.49	10.17	0.37	1.33e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs672059	0.967	rs514183	chr1:183163174	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.38	8.61	0.32	5.48e-17	Hypertriglyceridemia;
BRCA	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-14.79	-0.51	8.4e-43	Personality dimensions;
BRCA	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.78	0.55	1.27e-52	Axial length;
BRCA	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg27170947	chr2:26402098	FAM59B	-0.98	-17.28	-0.56	3.42e-55	Gut microbiome composition (summer);
BRCA	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg17830980	chr10:43048298	ZNF37B	-0.55	-13.32	-0.47	6.81e-36	Extrinsic epigenetic age acceleration;
BRCA	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.36	12.5	0.44	3.3e-32	Bipolar disorder;
BRCA	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg00677455	chr12:58241039	CTDSP2	0.39	8.99	0.34	2.79e-18	Multiple sclerosis;
BRCA	cis	rs6460942	0.915	rs7803056	chr7:12306913	A/C	cg10578991	chr7:12443926	VWDE	-0.44	-8.08	-0.3	3.35e-15	Coronary artery disease;
BRCA	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg04025307	chr7:1156635	C7orf50	0.38	9.14	0.34	8.2e-19	Longevity;Endometriosis;
BRCA	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg12923728	chr3:195709715	SDHAP1	0.38	7.92	0.3	1.09e-14	Mean corpuscular volume;
BRCA	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg24101359	chr6:42928495	GNMT	0.54	12.75	0.45	2.43e-33	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg18811423	chr2:55921094	PNPT1	0.72	22.7	0.67	4.07e-84	Metabolic syndrome;
BRCA	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.17	-0.31	1.66e-15	Aortic root size;
BRCA	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg05868516	chr6:26286170	HIST1H4H	0.41	8.1	0.31	2.8e-15	Educational attainment;
BRCA	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg02574844	chr11:5959923	NA	-0.4	-8.5	-0.32	1.33e-16	DNA methylation (variation);
BRCA	cis	rs1018836	0.923	rs4734269	chr8:91635474	G/C	cg16814680	chr8:91681699	NA	-0.51	-10.67	-0.39	1.45e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21659725	chr3:3221576	CRBN	-0.34	-8.03	-0.3	4.75e-15	Body mass index;
BRCA	cis	rs1165668	0.785	rs2583223	chr12:104316841	G/A	cg21863207	chr12:104234989	NT5DC3	0.39	8.02	0.3	5.08e-15	Coronary heart disease (SNP X SNP interaction);
BRCA	cis	rs11711311	0.712	rs2271498	chr3:113334752	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-8.3	-0.31	6.1e-16	IgG glycosylation;
BRCA	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg11789530	chr4:8429930	ACOX3	-0.53	-12.19	-0.43	6.87e-31	Response to antineoplastic agents;
BRCA	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg14728415	chr7:32535168	LSM5;AVL9	0.38	8.19	0.31	1.46e-15	Cognitive ability;
BRCA	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg20573242	chr4:122745356	CCNA2	0.49	11.28	0.41	4.91e-27	Type 2 diabetes;
BRCA	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg11814155	chr7:99998594	ZCWPW1	0.43	8.19	0.31	1.38e-15	Platelet count;
BRCA	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg20476274	chr7:133979776	SLC35B4	0.7	21.43	0.65	3.5e-77	Mean platelet volume;
BRCA	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.95	0.3	8.6e-15	Depression;
BRCA	cis	rs6785206	0.892	rs6793907	chr3:128391626	A/G	cg16766828	chr3:128327626	NA	0.73	11.48	0.41	7.28e-28	Lymphocyte percentage of white cells;
BRCA	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg14675211	chr2:100938903	LONRF2	0.51	11.53	0.41	4.71e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg11645453	chr3:52864694	ITIH4	0.48	11.55	0.42	3.69e-28	Schizophrenia;
BRCA	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg19077165	chr18:44547161	KATNAL2	-0.39	-8.25	-0.31	9.35e-16	Educational attainment;
BRCA	cis	rs9309711	0.736	rs13412581	chr2:3497187	G/A	cg10845886	chr2:3471009	TTC15	-0.66	-12.92	-0.45	4.53e-34	Neurofibrillary tangles;
BRCA	trans	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg13565492	chr6:43139072	SRF	-0.79	-10.98	-0.4	8.18e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg04455712	chr21:45112962	RRP1B	0.41	11.34	0.41	2.8e-27	Mean corpuscular volume;
BRCA	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-13.55	-0.47	5.83e-37	Bipolar disorder and schizophrenia;
BRCA	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg09184832	chr6:79620586	NA	-0.42	-8.19	-0.31	1.39e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg04989706	chr14:50066350	PPIL5	-0.48	-9.17	-0.34	6.6e-19	Carotid intima media thickness;
BRCA	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg18016565	chr1:150552671	MCL1	-0.42	-9.66	-0.36	1.06e-20	Tonsillectomy;
BRCA	trans	rs6479891	1.000	rs9414800	chr10:65131282	T/A	cg14819942	chr15:35414228	NA	0.35	8.6	0.32	6.08e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.84	12.63	0.45	7.99e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg14689365	chr7:158441557	NCAPG2	-0.42	-8.59	-0.32	6.72e-17	Height;
BRCA	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg03213289	chr20:61660250	NA	0.61	16.24	0.54	6.55e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06028605	chr16:24865363	SLC5A11	0.43	9.75	0.36	4.94e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.18	-0.34	6e-19	Bipolar disorder;
BRCA	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg12560992	chr17:57184187	TRIM37	0.39	8.77	0.33	1.57e-17	Primary tooth development (time to first tooth eruption);
BRCA	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg11789530	chr4:8429930	ACOX3	-0.55	-12.61	-0.45	1.05e-32	Response to antineoplastic agents;
BRCA	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	12.96	0.46	2.79e-34	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg14835575	chr10:16859367	RSU1	0.64	13.91	0.48	1.25e-38	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11644478	chr21:40555479	PSMG1	0.85	19.35	0.61	5.38e-66	Cognitive function;
BRCA	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg17330251	chr7:94953956	PON1	-0.41	-8.7	-0.33	2.84e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg02734326	chr4:10020555	SLC2A9	0.38	8.22	0.31	1.17e-15	Bone mineral density;
BRCA	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg19622623	chr12:86230825	RASSF9	-0.29	-8.26	-0.31	8.66e-16	Major depressive disorder;
BRCA	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg23422044	chr7:1970798	MAD1L1	-0.46	-9.74	-0.36	5.34e-21	Neuroticism;
BRCA	cis	rs1865721	1.000	rs7236756	chr18:73175689	T/C	cg26385618	chr18:73139727	C18orf62	-0.4	-9.05	-0.34	1.67e-18	Intelligence;
BRCA	cis	rs2016266	0.819	rs7398228	chr12:53660285	T/C	cg26875137	chr12:53738046	NA	0.38	9.73	0.36	5.87e-21	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg05872129	chr22:39784769	NA	-0.51	-11.12	-0.4	2.23e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg24642844	chr7:1081250	C7orf50	-0.89	-16.22	-0.54	8.17e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.58	0.55	1.29e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.29	0.41	4.47e-27	Bipolar disorder;
BRCA	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg01324343	chr3:183735012	ABCC5	0.85	21.76	0.65	5.82e-79	Anterior chamber depth;
BRCA	cis	rs701145	0.585	rs1534386	chr3:153819035	C/G	cg12800244	chr3:153838788	SGEF	0.63	7.87	0.3	1.47e-14	Coronary artery disease;
BRCA	cis	rs56399783	0.614	rs73047368	chr7:2766396	G/T	cg19731401	chr7:2775893	GNA12	0.54	8.53	0.32	1.06e-16	Childhood ear infection;
BRCA	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg04414720	chr1:150670196	GOLPH3L	0.35	8.02	0.3	5.16e-15	Tonsillectomy;
BRCA	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg16339924	chr4:17578868	LAP3	0.54	13.31	0.47	7.37e-36	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg03354898	chr7:1950403	MAD1L1	-0.48	-10.07	-0.37	2.99e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs4908768	0.501	rs1922983	chr1:8531326	A/G	cg20416874	chr1:8611966	RERE	-0.28	-8.06	-0.3	3.84e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg20307385	chr11:47447363	PSMC3	0.37	8.01	0.3	5.56e-15	Subjective well-being;
BRCA	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg20476274	chr7:133979776	SLC35B4	0.6	16.15	0.54	1.82e-49	Mean platelet volume;
BRCA	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05903289	chr2:130345205	NA	-0.33	-8.06	-0.3	3.75e-15	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs34779708	0.733	rs7083266	chr10:35541632	C/A	cg03585969	chr10:35415529	CREM	0.45	9.16	0.34	6.91e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg12756686	chr19:29218302	NA	0.46	8.07	0.3	3.39e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg14820908	chr5:178986412	RUFY1	0.44	11.2	0.41	1.01e-26	Lung cancer;
BRCA	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg13852791	chr20:30311386	BCL2L1	0.89	20.17	0.62	2.15e-70	Mean corpuscular hemoglobin;
BRCA	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.3	-0.31	6.02e-16	Aortic root size;
BRCA	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg03929089	chr4:120376271	NA	-0.69	-14.66	-0.5	3.76e-42	Coronary artery disease;
BRCA	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg00757033	chr12:89920650	WDR51B	0.54	10.82	0.39	3.61e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs6138458	0.626	rs6050261	chr20:25014206	C/T	cg26195577	chr20:24973756	C20orf3	0.64	15.67	0.53	4.41e-47	Blood protein levels;
BRCA	cis	rs17604090	0.529	rs10239226	chr7:29716312	C/G	cg19413766	chr7:29689036	LOC646762	-0.56	-9.01	-0.34	2.35e-18	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs4728302	0.838	rs10224828	chr7:133591071	G/A	cg07491979	chr7:133331646	EXOC4	0.36	7.81	0.3	2.32e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg22906224	chr7:99728672	NA	0.44	8.4	0.32	2.92e-16	Coronary artery disease;
BRCA	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg11657440	chr19:46296263	DMWD	-0.45	-10.25	-0.38	6.31e-23	Coronary artery disease;
BRCA	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27286337	chr10:134555280	INPP5A	0.8	13.17	0.46	3.32e-35	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6882046	0.513	rs601942	chr5:88031820	T/C	cg22951263	chr5:87985283	NA	-0.38	-10.65	-0.39	1.72e-24	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.73	-15.0	-0.51	8.14e-44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.25	-0.31	9.02e-16	Depression;
BRCA	cis	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg06521331	chr12:34319734	NA	-0.56	-10.84	-0.39	2.95e-25	Morning vs. evening chronotype;
BRCA	cis	rs868036	0.957	rs9920662	chr15:68104297	G/A	cg05925327	chr15:68127851	NA	-0.31	-7.9	-0.3	1.23e-14	Restless legs syndrome;
BRCA	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg05340658	chr4:99064831	C4orf37	0.59	14.46	0.5	3.43e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06028605	chr16:24865363	SLC5A11	0.43	9.65	0.36	1.17e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg07636037	chr3:49044803	WDR6	0.98	29.45	0.76	4.2e-121	Parkinson's disease;
BRCA	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg07080220	chr10:102295463	HIF1AN	0.47	10.63	0.39	2.03e-24	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg07061783	chr6:25882402	NA	-0.45	-9.04	-0.34	1.8e-18	Urate levels;
BRCA	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg00981070	chr1:2046702	PRKCZ	0.31	8.25	0.31	9.06e-16	Height;
BRCA	cis	rs1829883	0.729	rs2682142	chr5:98899578	T/C	cg08333243	chr5:99726346	NA	-0.34	-8.19	-0.31	1.42e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs16854884	0.683	rs6766544	chr3:143736659	G/T	cg06585982	chr3:143692056	C3orf58	0.43	8.99	0.33	2.87e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs1506636	1.000	rs2429619	chr7:123425599	C/G	cg03229431	chr7:123269106	ASB15	0.61	13.53	0.47	7.36e-37	Plateletcrit;Platelet count;
BRCA	trans	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg25214090	chr10:38739885	LOC399744	0.5	11.02	0.4	5.79e-26	Corneal astigmatism;
BRCA	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg08601574	chr20:25228251	PYGB	-0.35	-8.4	-0.32	2.82e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg14530993	chr4:882597	GAK	0.6	9.75	0.36	4.99e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg20476274	chr7:133979776	SLC35B4	0.62	18.04	0.58	4.19e-59	Mean platelet volume;
BRCA	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg20283391	chr11:68216788	NA	-0.43	-8.56	-0.32	8.2e-17	Total body bone mineral density;
BRCA	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg16586182	chr3:47516702	SCAP	0.63	14.55	0.5	1.18e-41	Colorectal cancer;
BRCA	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg23711669	chr6:146136114	FBXO30	-0.79	-18.4	-0.59	5.66e-61	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.49	9.27	0.34	2.83e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg02551604	chr5:131831745	NA	-0.39	-14.1	-0.49	1.7e-39	Asthma (sex interaction);
BRCA	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	11.13	0.4	1.99e-26	Height;
BRCA	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg24642439	chr20:33292090	TP53INP2	0.45	9.86	0.36	1.96e-21	Height;
BRCA	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.74	16.0	0.53	1.1e-48	Lymphocyte counts;
BRCA	trans	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.4	0.49	6.56e-41	Exhaled nitric oxide output;
BRCA	cis	rs73001065	0.818	rs12610191	chr19:19721976	C/T	cg03709012	chr19:19516395	GATAD2A	0.76	9.18	0.34	5.84e-19	LDL cholesterol;
BRCA	cis	rs2066819	1.000	rs80317430	chr12:56727705	G/A	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs1403694	0.695	rs3774292	chr3:186433574	A/T	cg12454167	chr3:186435060	KNG1	0.29	7.92	0.3	1.04e-14	Blood protein levels;
BRCA	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg26384229	chr12:38710491	ALG10B	-0.62	-16.08	-0.54	4.35e-49	Heart rate;
BRCA	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg18132916	chr6:79620363	NA	-0.4	-8.15	-0.31	1.87e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9487051	0.735	rs396000	chr6:109519611	A/G	cg01475377	chr6:109611718	NA	0.47	12.04	0.43	2.98e-30	Reticulocyte fraction of red cells;
BRCA	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-7.96	-0.3	8.12e-15	Homocysteine levels;
BRCA	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12311346	chr5:56204834	C5orf35	-0.94	-18.23	-0.58	4.4e-60	Initial pursuit acceleration;
BRCA	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg02176678	chr2:219576539	TTLL4	0.43	11.56	0.42	3.34e-28	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2386661	0.522	rs11258044	chr10:5644392	C/T	cg17085576	chr10:5658249	NA	-0.32	-8.18	-0.31	1.58e-15	Breast cancer;
BRCA	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18876405	chr7:65276391	NA	0.71	18.63	0.59	3.17e-62	Calcium levels;
BRCA	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	10.41	0.38	1.49e-23	Height;
BRCA	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18876405	chr7:65276391	NA	0.7	18.38	0.59	7.02e-61	Aortic root size;
BRCA	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.87	0.33	7.22e-18	Motion sickness;
BRCA	cis	rs6500395	0.962	rs9937623	chr16:48571590	A/T	cg04672837	chr16:48644449	N4BP1	-0.43	-10.12	-0.37	1.93e-22	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.61	12.97	0.46	2.62e-34	Personality dimensions;
BRCA	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg13010199	chr12:38710504	ALG10B	0.43	9.03	0.34	2e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9658691	0.607	rs12416581	chr10:90780440	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.52	-8.02	-0.3	4.91e-15	Mosquito bite size;
BRCA	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg04709771	chr16:646395	RAB40C	0.44	10.84	0.39	2.93e-25	Height;
BRCA	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg13319975	chr6:146136371	FBXO30	0.42	9.7	0.36	7.66e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg26031613	chr14:104095156	KLC1	0.74	15.96	0.53	1.67e-48	Body mass index;
BRCA	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg18351406	chr4:77819688	ANKRD56	0.54	11.96	0.43	6.86e-30	Emphysema distribution in smoking;
BRCA	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg23978390	chr7:1156363	C7orf50	0.48	11.33	0.41	2.99e-27	Longevity;Endometriosis;
BRCA	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg20503657	chr10:835505	NA	0.68	10.88	0.4	2.13e-25	Eosinophil percentage of granulocytes;
BRCA	cis	rs2066819	1.000	rs118130855	chr12:56677979	T/A	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg00321850	chr1:175162397	KIAA0040	0.44	12.4	0.44	9.02e-32	Alcohol dependence;
BRCA	cis	rs6484504	0.625	rs6484501	chr11:31373100	G/T	cg06552810	chr11:31128660	NA	0.4	8.73	0.33	2.16e-17	Red blood cell count;
BRCA	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg00383909	chr3:49044727	WDR6	0.52	10.13	0.37	1.85e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	18.26	0.59	2.84e-60	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg20476274	chr7:133979776	SLC35B4	0.7	21.43	0.65	3.4e-77	Mean platelet volume;
BRCA	cis	rs7617773	0.817	rs13068265	chr3:48301614	A/C	cg11946769	chr3:48343235	NME6	0.67	13.98	0.48	5.92e-39	Coronary artery disease;
BRCA	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg20587970	chr11:113659929	NA	1.02	14.49	0.5	2.42e-41	Hip circumference adjusted for BMI;
BRCA	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg10495392	chr1:46806563	NSUN4	0.47	8.73	0.33	2.19e-17	Menopause (age at onset);
BRCA	cis	rs11191270	0.554	rs11191275	chr10:104142800	C/T	cg12477931	chr10:104193363	CUEDC2	-0.5	-7.81	-0.3	2.35e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg27478167	chr7:817139	HEATR2	0.45	9.01	0.34	2.31e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg24692254	chr21:30365293	RNF160	-0.47	-10.62	-0.39	2.34e-24	Pancreatic cancer;
BRCA	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg03146154	chr1:46216737	IPP	0.52	11.59	0.42	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg00677455	chr12:58241039	CTDSP2	0.68	15.19	0.52	9.85e-45	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-8.83	-0.33	9.73e-18	Longevity;Endometriosis;
BRCA	cis	rs754466	0.606	rs11002309	chr10:79594931	C/T	cg17075019	chr10:79541650	NA	-0.81	-20.56	-0.63	1.81e-72	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg12140854	chr5:148520817	ABLIM3	-0.42	-9.02	-0.34	2.18e-18	Breast cancer;
BRCA	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg22467129	chr15:76604101	ETFA	0.39	8.6	0.32	6.39e-17	Blood metabolite levels;
BRCA	trans	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-20.46	-0.63	5.77e-72	Exhaled nitric oxide output;
BRCA	cis	rs6700896	0.931	rs4655582	chr1:66153363	C/G	cg04111102	chr1:66153794	NA	0.42	9.97	0.37	7.42e-22	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.64	11.93	0.43	9.57e-30	Total cholesterol levels;
BRCA	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg04586622	chr2:25135609	ADCY3	0.46	11.76	0.42	4.91e-29	Body mass index;
BRCA	cis	rs7617773	0.780	rs4511915	chr3:48343858	G/A	cg11946769	chr3:48343235	NME6	0.69	13.87	0.48	2.01e-38	Coronary artery disease;
BRCA	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg08610935	chr16:1836813	NUBP2	-0.43	-11.19	-0.4	1.12e-26	Insulin-like growth factors;
BRCA	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg25358565	chr5:93447407	FAM172A	-1.16	-18.35	-0.59	9.85e-61	Diabetic retinopathy;
BRCA	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg26384229	chr12:38710491	ALG10B	0.69	14.65	0.5	4.12e-42	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8170	0.603	rs971693	chr19:17422649	G/C	cg02455703	chr19:17412272	ABHD8	-0.34	-7.84	-0.3	1.87e-14	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
BRCA	cis	rs4713675	0.584	rs9394163	chr6:33682414	A/G	cg14003231	chr6:33640908	ITPR3	0.33	8.41	0.32	2.6e-16	Plateletcrit;
BRCA	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.54	-0.44	2.15e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg09307838	chr4:120376055	NA	0.69	14.02	0.49	3.82e-39	Corneal astigmatism;
BRCA	cis	rs1451375	1.000	rs921451	chr7:50623285	A/G	cg18232548	chr7:50535776	DDC	0.43	10.12	0.37	1.99e-22	Malaria;
BRCA	cis	rs2425143	1.000	rs17093026	chr20:34318911	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.57	8.38	0.31	3.36e-16	Blood protein levels;
BRCA	cis	rs4363385	0.747	rs3964619	chr1:152972811	A/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.22	-0.31	1.13e-15	Inflammatory skin disease;
BRCA	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg11663144	chr21:46675770	NA	-0.62	-14.66	-0.5	3.53e-42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg03254818	chr6:169586852	NA	-0.41	-8.67	-0.32	3.55e-17	Pulse pressure;
BRCA	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg06627628	chr2:24431161	ITSN2	0.6	11.51	0.41	5.31e-28	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26913058	chr16:419975	MRPL28	-0.37	-8.78	-0.33	1.52e-17	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg19622623	chr12:86230825	RASSF9	-0.33	-9.32	-0.35	1.83e-19	Major depressive disorder;
BRCA	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg01819863	chr10:32635814	EPC1	1.14	19.89	0.62	7.38e-69	Sexual dysfunction (female);
BRCA	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23583168	chr7:148888333	NA	-0.85	-22.35	-0.66	3.26e-82	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-10.68	-0.39	1.3e-24	Systemic lupus erythematosus;
BRCA	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg00277334	chr10:82204260	NA	-0.48	-10.26	-0.38	5.96e-23	Post bronchodilator FEV1;
BRCA	cis	rs858239	0.699	rs858260	chr7:23212934	G/T	cg23682824	chr7:23144976	KLHL7	0.35	9.08	0.34	1.3e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7178424	0.967	rs17271403	chr15:62375389	C/T	cg00456672	chr15:62358751	C2CD4A	-0.36	-8.41	-0.32	2.77e-16	Height;
BRCA	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10802521	chr3:52805072	NEK4	-0.33	-8.49	-0.32	1.45e-16	Bipolar disorder;
BRCA	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.22	-0.31	1.15e-15	Depression;
BRCA	cis	rs7520050	0.966	rs12049588	chr1:46472422	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.84	0.36	2.33e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg05535760	chr7:792225	HEATR2	0.73	13.46	0.47	1.52e-36	Cerebrospinal P-tau181p levels;
BRCA	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.46	-9.44	-0.35	6.84e-20	Eosinophil percentage of white cells;
BRCA	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg26116260	chr4:7069785	GRPEL1	0.93	27.24	0.73	4.83e-109	Monocyte percentage of white cells;
BRCA	trans	rs61931739	0.513	rs10772116	chr12:33897795	G/C	cg26384229	chr12:38710491	ALG10B	0.46	10.77	0.39	5.91e-25	Morning vs. evening chronotype;
BRCA	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.18	-0.31	1.57e-15	Depression;
BRCA	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg11266682	chr4:10021025	SLC2A9	0.48	12.8	0.45	1.51e-33	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.04	0.4	4.78e-26	Rheumatoid arthritis;
BRCA	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg00012203	chr2:219082015	ARPC2	0.48	9.22	0.34	4.08e-19	Colorectal cancer;
BRCA	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	14.13	0.49	1.18e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.37	8.27	0.31	7.98e-16	Endometrial cancer;
BRCA	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg08807101	chr21:30365312	RNF160	-0.45	-7.89	-0.3	1.35e-14	Cognitive test performance;
BRCA	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs586533	0.881	rs638740	chr11:99504483	A/T	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.31	2.78e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg25809561	chr17:30822961	MYO1D	0.4	9.52	0.35	3.4e-20	Schizophrenia;
BRCA	trans	rs877282	0.947	rs7475589	chr10:767479	C/G	cg22713356	chr15:30763199	NA	1.35	26.98	0.73	1.41e-107	Uric acid levels;
BRCA	cis	rs7640424	0.620	rs71321252	chr3:107813107	A/C	cg09227934	chr3:107805635	CD47	-0.43	-8.2	-0.31	1.32e-15	Body mass index;
BRCA	cis	rs9469890	0.604	rs11758420	chr6:34503279	A/C	cg17674042	chr6:34482479	PACSIN1	-0.33	-8.56	-0.32	8.1e-17	Pubertal anthropometrics;Coronary artery disease;
BRCA	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg06623918	chr6:96969491	KIAA0776	-0.77	-13.77	-0.48	5.7800000000000005e-38	Migraine;Coronary artery disease;
BRCA	cis	rs8038465	0.622	rs7182124	chr15:73915254	C/T	cg15420318	chr15:73925796	NPTN	0.48	10.33	0.38	3.08e-23	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.39	9.36	0.35	1.35e-19	Alzheimer's disease (late onset);
BRCA	cis	rs6426558	0.537	rs6662583	chr1:227383889	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.48	-9.8	-0.36	3.26e-21	Neutrophil percentage of white cells;
BRCA	cis	rs6973256	0.568	rs7783019	chr7:133347347	A/G	cg07491979	chr7:133331646	EXOC4	-0.35	-8.1	-0.31	2.73e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs11971779	0.938	rs28477480	chr7:139036058	C/T	cg07862535	chr7:139043722	LUC7L2	-0.4	-9.81	-0.36	2.85e-21	Diisocyanate-induced asthma;
BRCA	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg09307838	chr4:120376055	NA	0.59	12.23	0.44	4.56e-31	Corneal astigmatism;
BRCA	cis	rs6066835	1.000	rs6066828	chr20:47344233	C/T	cg18078177	chr20:47281410	PREX1	0.69	8.65	0.32	4.17e-17	Multiple myeloma;
BRCA	trans	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.29	0.31	6.82e-16	Corneal astigmatism;
BRCA	cis	rs870825	0.549	rs7699919	chr4:185648610	A/C	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs6484504	0.512	rs7940020	chr11:31366453	T/G	cg06552810	chr11:31128660	NA	0.39	8.58	0.32	7.02e-17	Red blood cell count;
BRCA	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg07169764	chr2:136633963	MCM6	1.28	28.78	0.75	1.99e-117	Corneal structure;
BRCA	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg03923535	chr7:1197113	ZFAND2A	0.4	7.83	0.3	1.97e-14	Longevity;Endometriosis;
BRCA	trans	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg25214090	chr10:38739885	LOC399744	-0.4	-9.48	-0.35	5.09e-20	Corneal astigmatism;
BRCA	cis	rs698833	0.758	rs7586188	chr2:44544955	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	10.5	0.38	6.73e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.17e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4499344	0.768	rs10411319	chr19:33102805	C/A	cg22980127	chr19:33182716	NUDT19	-0.37	-7.85	-0.3	1.8e-14	Mean platelet volume;
BRCA	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg21775979	chr11:780331	NA	0.36	7.8	0.3	2.45e-14	Breast cancer;
BRCA	cis	rs1997103	0.906	rs6593232	chr7:55402916	C/T	cg17469321	chr7:55412551	NA	0.51	9.72	0.36	6.37e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg03146154	chr1:46216737	IPP	0.49	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg04362960	chr10:104952993	NT5C2	0.44	10.02	0.37	4.77e-22	Arsenic metabolism;
BRCA	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-9.21	-0.34	4.54e-19	Aortic root size;
BRCA	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg17691542	chr6:26056736	HIST1H1C	0.54	11.58	0.42	2.67e-28	Height;
BRCA	trans	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.58	-0.35	2.16e-20	Morning vs. evening chronotype;
BRCA	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg01292856	chr11:65242576	NA	0.33	8.26	0.31	8.51e-16	Bone mineral density;
BRCA	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.77	16.11	0.54	2.93e-49	HIV-1 control;
BRCA	cis	rs6429082	0.608	rs903348	chr1:235571343	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.53	-12.09	-0.43	1.89e-30	Adiposity;
BRCA	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-13.56	-0.47	5.52e-37	Bipolar disorder and schizophrenia;
BRCA	cis	rs1568889	1.000	rs12803655	chr11:28060785	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	14.71	0.5	2.14e-42	Bipolar disorder;
BRCA	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg04691961	chr3:161091175	C3orf57	-0.46	-10.84	-0.39	2.87e-25	Morning vs. evening chronotype;
BRCA	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg23711669	chr6:146136114	FBXO30	0.71	17.19	0.56	1.05e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7551222	0.749	rs4951409	chr1:204560990	A/T	cg20240347	chr1:204465584	NA	-0.28	-8.73	-0.33	2.23e-17	Schizophrenia;
BRCA	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	17.96	0.58	1.11e-58	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg18357645	chr12:58087776	OS9	0.44	12.46	0.44	4.7e-32	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs965469	0.708	rs80050989	chr20:3297881	A/G	cg25506879	chr20:3388711	C20orf194	-0.43	-8.73	-0.33	2.23e-17	IFN-related cytopenia;
BRCA	cis	rs754466	0.580	rs17516020	chr10:79538734	C/T	cg17075019	chr10:79541650	NA	-0.74	-14.89	-0.51	2.8e-43	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg08975724	chr8:8085496	FLJ10661	0.41	7.9	0.3	1.23e-14	Retinal vascular caliber;
BRCA	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg26384229	chr12:38710491	ALG10B	0.67	14.23	0.49	4.21e-40	Morning vs. evening chronotype;
BRCA	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg10578991	chr7:12443926	VWDE	-0.55	-7.9	-0.3	1.2e-14	Coronary artery disease;
BRCA	trans	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs701145	0.585	rs1470664	chr3:153865193	C/T	cg17054900	chr3:154042577	DHX36	0.43	8.07	0.3	3.55e-15	Coronary artery disease;
BRCA	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg24562669	chr7:97807699	LMTK2	0.45	11.74	0.42	5.89e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11958404	0.719	rs72818153	chr5:157487035	T/C	cg05962755	chr5:157440814	NA	0.56	9.36	0.35	1.31e-19	IgG glycosylation;
BRCA	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg14675211	chr2:100938903	LONRF2	0.52	11.54	0.42	3.94e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.84	-0.3	1.83e-14	Total body bone mineral density;
BRCA	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg14675211	chr2:100938903	LONRF2	0.48	11.13	0.4	2.07e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg05665937	chr4:1216051	CTBP1	0.39	8.21	0.31	1.27e-15	Obesity-related traits;
BRCA	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg13319975	chr6:146136371	FBXO30	0.41	9.44	0.35	7.04e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	20.17	0.62	2.23e-70	Chronic sinus infection;
BRCA	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg26597838	chr10:835615	NA	1.32	22.11	0.66	7.25e-81	Eosinophil percentage of granulocytes;
BRCA	cis	rs7944584	0.588	rs2697923	chr11:47363215	G/T	cg20307385	chr11:47447363	PSMC3	-0.51	-11.58	-0.42	2.83e-28	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg04362960	chr10:104952993	NT5C2	0.43	9.66	0.36	1.11e-20	Arsenic metabolism;
BRCA	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg16339924	chr4:17578868	LAP3	-0.59	-14.11	-0.49	1.54e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04565464	chr8:145669602	NFKBIL2	0.42	9.47	0.35	5.25e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs6545883	0.825	rs4672426	chr2:61457148	G/A	cg15711740	chr2:61764176	XPO1	0.51	13.06	0.46	1.06e-34	Tuberculosis;
BRCA	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg00684032	chr4:1343700	KIAA1530	0.34	8.49	0.32	1.47e-16	Obesity-related traits;
BRCA	cis	rs6910061	0.913	rs35199324	chr6:11112863	C/T	cg27233058	chr6:11094804	LOC221710	0.53	9.43	0.35	7.64e-20	Diabetic kidney disease;
BRCA	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	19.2	0.6	3.34e-65	Smoking behavior;
BRCA	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-9.88	-0.36	1.64e-21	Corneal structure;
BRCA	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21659725	chr3:3221576	CRBN	-0.38	-9.18	-0.34	5.82e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs9487051	0.768	rs1766814	chr6:109526696	G/A	cg21918786	chr6:109611834	NA	-0.33	-8.96	-0.33	3.5e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg16006841	chr5:176797999	RGS14	0.59	11.76	0.42	4.93e-29	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.8	-0.36	3.32e-21	Bladder cancer;
BRCA	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	13.88	0.48	1.79e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg04362960	chr10:104952993	NT5C2	0.46	10.7	0.39	1.08e-24	Arsenic metabolism;
BRCA	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg18357645	chr12:58087776	OS9	-0.41	-10.96	-0.4	9.6e-26	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.47	10.73	0.39	7.92e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.79	11.11	0.4	2.5e-26	Initial pursuit acceleration;
BRCA	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg17971929	chr21:40555470	PSMG1	-0.62	-13.63	-0.47	2.5e-37	Cognitive function;
BRCA	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg18252515	chr7:66147081	NA	-0.9	-12.89	-0.45	6.08e-34	Diabetic kidney disease;
BRCA	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg15017067	chr4:17643749	FAM184B	0.26	8.04	0.3	4.24e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3857067	0.806	rs72665627	chr4:95111824	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.49	-0.35	4.67e-20	QT interval;
BRCA	cis	rs6942756	0.747	rs692697	chr7:129112576	C/T	cg02491457	chr7:128862824	NA	0.52	10.68	0.39	1.3e-24	White matter hyperintensity burden;
BRCA	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg18404041	chr3:52824283	ITIH1	-0.35	-9.31	-0.35	2.02e-19	Schizophrenia;
BRCA	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.44	-9.76	-0.36	4.37e-21	Bipolar disorder;
BRCA	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.52	8.35	0.31	4.13e-16	Renal function-related traits (BUN);
BRCA	cis	rs250677	0.958	rs17109282	chr5:148416677	A/G	cg12140854	chr5:148520817	ABLIM3	0.41	8.8	0.33	1.22e-17	Breast cancer;
BRCA	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg25062951	chr7:817576	HEATR2	-0.38	-7.82	-0.3	2.19e-14	Cerebrospinal P-tau181p levels;
BRCA	trans	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg26043149	chr18:55253948	FECH	-0.37	-8.12	-0.31	2.34e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs11690935	0.879	rs908671	chr2:172690265	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.89	-27.51	-0.74	1.68e-110	Schizophrenia;
BRCA	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg11584989	chr19:19387371	SF4	0.64	13.49	0.47	1.14e-36	Bipolar disorder;
BRCA	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg12193833	chr17:30244370	NA	-0.62	-9.85	-0.36	2e-21	Hip circumference adjusted for BMI;
BRCA	trans	rs10411161	0.702	rs7251689	chr19:52389117	A/T	cg22319618	chr22:45562946	NUP50	-0.42	-8.02	-0.3	4.89e-15	Breast cancer;
BRCA	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg01420254	chr6:26195488	NA	0.55	8.52	0.32	1.1e-16	Gout;Renal underexcretion gout;
BRCA	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg05340658	chr4:99064831	C4orf37	0.69	17.49	0.57	2.77e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg14835575	chr10:16859367	RSU1	0.65	14.32	0.49	1.58e-40	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs1451375	0.729	rs6593017	chr7:50644812	G/A	cg18232548	chr7:50535776	DDC	0.39	9.19	0.34	5.5e-19	Malaria;
BRCA	cis	rs11605275	1.000	rs16937347	chr11:20026717	A/G	cg14835545	chr11:20032148	NAV2	-0.54	-9.58	-0.35	2.13e-20	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-12.23	-0.44	4.57e-31	Personality dimensions;
BRCA	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	9.86	0.36	2e-21	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg10523679	chr1:76189770	ACADM	0.77	15.5	0.52	3.17e-46	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs752010	0.967	rs10890153	chr1:42102060	C/A	cg06885757	chr1:42089581	HIVEP3	0.25	8.88	0.33	6.96e-18	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg03474202	chr17:45855739	NA	-0.46	-12.39	-0.44	9.18e-32	IgG glycosylation;
BRCA	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg27129171	chr3:47204927	SETD2	0.77	19.97	0.62	2.64e-69	Colorectal cancer;
BRCA	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.26	7.81	0.3	2.28e-14	Parkinson's disease;
BRCA	cis	rs4363385	0.747	rs946097	chr1:152974732	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.07	-0.34	1.48e-18	Inflammatory skin disease;
BRCA	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11764359	chr7:65958608	NA	-0.75	-16.8	-0.55	9.56e-53	Aortic root size;
BRCA	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-9.87	-0.36	1.72e-21	Mood instability;
BRCA	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg11663144	chr21:46675770	NA	-0.6	-13.84	-0.48	2.6e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg19678392	chr7:94953810	PON1	-0.43	-9.19	-0.34	5.6e-19	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-10.23	-0.38	7.34e-23	Eosinophil percentage of white cells;
BRCA	trans	rs629535	0.773	rs72654090	chr8:70118666	G/A	cg21567404	chr3:27674614	NA	-0.97	-20.42	-0.63	9.69e-72	Dupuytren's disease;
BRCA	cis	rs2742234	0.656	rs1864400	chr10:43610366	G/A	cg02780029	chr10:43622663	RET	-0.37	-8.41	-0.32	2.69e-16	Hirschsprung disease;
BRCA	cis	rs9470366	0.772	rs9918353	chr6:36622677	A/C	cg08179530	chr6:36648295	CDKN1A	0.51	10.21	0.37	9.18e-23	QRS duration;
BRCA	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08859206	chr1:53392774	SCP2	-0.6	-13.35	-0.47	4.76e-36	Monocyte count;
BRCA	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg18811423	chr2:55921094	PNPT1	0.68	20.77	0.63	1.27e-73	Metabolic syndrome;
BRCA	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg08885076	chr2:99613938	TSGA10	-0.59	-13.08	-0.46	8e-35	Chronic sinus infection;
BRCA	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg03676636	chr4:99064102	C4orf37	0.21	7.94	0.3	9.23e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg19318889	chr4:1322082	MAEA	-0.48	-10.01	-0.37	5.14e-22	Obesity-related traits;
BRCA	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg20307385	chr11:47447363	PSMC3	0.42	9.29	0.35	2.34e-19	Subjective well-being;
BRCA	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg23711669	chr6:146136114	FBXO30	0.74	17.76	0.57	1.14e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7408868	0.764	rs45504393	chr19:15277010	A/G	cg14696996	chr19:15285081	NOTCH3	0.99	14.49	0.5	2.35e-41	Pulse pressure;
BRCA	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg24558204	chr6:135376177	HBS1L	0.54	14.87	0.51	3.45e-43	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg21747090	chr2:27597821	SNX17	0.4	8.57	0.32	7.86e-17	Total body bone mineral density;
BRCA	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.74	11.76	0.42	4.72e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg00852783	chr1:26633632	UBXN11	-0.51	-12.21	-0.43	5.82e-31	Obesity-related traits;
BRCA	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg22713356	chr15:30763199	NA	1.32	25.69	0.71	1.56e-100	Uric acid levels;
BRCA	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.85	-0.53	5.78e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg16482183	chr6:26056742	HIST1H1C	0.45	8.76	0.33	1.8e-17	Iron status biomarkers;
BRCA	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-9.07	-0.34	1.41e-18	Educational attainment;
BRCA	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg24060327	chr5:131705240	SLC22A5	0.47	9.48	0.35	4.75e-20	Blood metabolite levels;
BRCA	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg12082025	chr19:1064218	ABCA7	-0.44	-9.41	-0.35	8.61e-20	Alzheimer's disease (late onset);
BRCA	cis	rs4766646	0.640	rs4766488	chr12:110296095	G/C	cg01252219	chr12:110302105	GLTP	0.36	7.83	0.3	1.98e-14	Metabolite levels (MHPG);
BRCA	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg22987457	chr7:157211561	NA	0.33	7.97	0.3	7.1e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	cis	rs9400271	0.527	rs9386798	chr6:109639971	T/C	cg01475377	chr6:109611718	NA	0.36	7.96	0.3	7.82e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs7178424	1.000	rs17205463	chr15:62381413	C/T	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.19	-0.31	1.44e-15	Height;
BRCA	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg24101359	chr6:42928495	GNMT	0.55	12.61	0.45	1.01e-32	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18876405	chr7:65276391	NA	-0.56	-13.4	-0.47	3.02e-36	Aortic root size;
BRCA	cis	rs9290065	0.519	rs7613316	chr3:160674533	A/G	cg03342759	chr3:160939853	NMD3	-0.46	-9.46	-0.35	5.94e-20	Kawasaki disease;
BRCA	cis	rs2882667	0.858	rs35812969	chr5:138377550	G/C	cg04439458	chr5:138467593	SIL1	-0.43	-10.72	-0.39	8.66e-25	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-11.28	-0.41	5e-27	Alzheimer's disease;
BRCA	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg11764359	chr7:65958608	NA	-0.66	-13.1	-0.46	6.86e-35	Aortic root size;
BRCA	cis	rs4423214	0.840	rs3794057	chr11:71186744	G/A	cg05163923	chr11:71159392	DHCR7	-0.56	-11.35	-0.41	2.58e-27	Vitamin D levels;
BRCA	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg17330251	chr7:94953956	PON1	-0.43	-8.9	-0.33	5.89e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6430585	0.527	rs62168836	chr2:136463117	G/A	cg07169764	chr2:136633963	MCM6	1.01	19.31	0.61	9.06e-66	Corneal structure;
BRCA	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg17366294	chr4:99064904	C4orf37	0.42	9.75	0.36	5.01e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg03934865	chr2:198174659	NA	-0.41	-8.86	-0.33	7.61e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	trans	rs526821	0.595	rs608964	chr11:55339266	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-8.02	-0.3	5.15e-15	Pediatric bone mineral density (spine);
BRCA	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	16.23	0.54	7.75e-50	Intelligence (multi-trait analysis);
BRCA	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.6	9.05	0.34	1.69e-18	Lung function (FEV1/FVC);
BRCA	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg06238570	chr21:40685208	BRWD1	-0.41	-8.3	-0.31	6.11e-16	Cognitive function;
BRCA	trans	rs2235573	0.625	rs139905	chr22:38409596	C/T	cg19894588	chr14:64061835	NA	-0.32	-8.02	-0.3	5.09e-15	Glioblastoma;Glioma;
BRCA	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg13010199	chr12:38710504	ALG10B	0.49	9.61	0.36	1.61e-20	Morning vs. evening chronotype;
BRCA	trans	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg05926928	chr17:57297772	GDPD1	-0.43	-7.82	-0.3	2.15e-14	Schizophrenia;
BRCA	cis	rs16958440	0.867	rs12326412	chr18:44683594	A/C	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg08807892	chr2:162101083	NA	-0.46	-8.18	-0.31	1.51e-15	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
BRCA	cis	rs3925075	0.966	rs7195945	chr16:31344309	T/C	cg02846316	chr16:31340340	ITGAM	0.54	13.33	0.47	5.89e-36	IgA nephropathy;
BRCA	cis	rs6450176	0.625	rs16881958	chr5:53288201	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-15.2	-0.52	9.03e-45	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs73086581	1.000	rs17214949	chr20:3940952	T/C	cg02187196	chr20:3869020	PANK2	0.54	9.62	0.36	1.48e-20	Response to antidepressants in depression;
BRCA	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg24642439	chr20:33292090	TP53INP2	0.42	8.73	0.33	2.15e-17	Height;
BRCA	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-11.29	-0.41	4.39e-27	IgG glycosylation;
BRCA	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.36	8.34	0.31	4.41e-16	Insulin-like growth factors;
BRCA	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg09998033	chr7:158218633	PTPRN2	-0.4	-9.1	-0.34	1.1e-18	Obesity-related traits;
BRCA	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg09307838	chr4:120376055	NA	0.73	15.81	0.53	9.12e-48	Corneal astigmatism;
BRCA	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg03060546	chr3:49711283	APEH	0.6	9.83	0.36	2.5e-21	Menarche (age at onset);
BRCA	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.24	8.31	0.31	5.96e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg01324343	chr3:183735012	ABCC5	0.63	15.0	0.51	8.8e-44	Anterior chamber depth;
BRCA	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg08601574	chr20:25228251	PYGB	-0.38	-9.09	-0.34	1.28e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.03	-0.54	7.47e-49	Alzheimer's disease (late onset);
BRCA	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg26384229	chr12:38710491	ALG10B	-0.46	-10.54	-0.38	4.58e-24	Bladder cancer;
BRCA	cis	rs9420	0.925	rs78587207	chr11:57654991	T/G	cg19752551	chr11:57585705	CTNND1	-0.53	-12.84	-0.45	9.43e-34	Schizophrenia;
BRCA	cis	rs1595825	0.891	rs1851779	chr2:198647108	C/T	cg19156104	chr2:198669113	PLCL1	-0.42	-7.97	-0.3	7.13e-15	Ulcerative colitis;
BRCA	trans	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg15704280	chr7:45808275	SEPT13	-0.48	-8.17	-0.31	1.66e-15	Axial length;
BRCA	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg02551604	chr5:131831745	NA	-0.4	-14.98	-0.51	1.03e-43	Asthma (sex interaction);
BRCA	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	7e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg11843238	chr5:131593191	PDLIM4	0.34	8.92	0.33	4.82e-18	Breast cancer;
BRCA	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg12444411	chr7:2802554	GNA12	-0.36	-8.98	-0.33	3.1e-18	Height;
BRCA	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.2	0.49	5.58e-40	Motion sickness;
BRCA	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg06115741	chr20:33292138	TP53INP2	0.39	8.64	0.32	4.33e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.22	-0.31	1.13e-15	Parkinson's disease;
BRCA	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10802521	chr3:52805072	NEK4	-0.34	-9.32	-0.35	1.84e-19	Bipolar disorder;
BRCA	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg18132916	chr6:79620363	NA	-0.47	-10.45	-0.38	1.06e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg01181863	chr3:195395398	SDHAP2	-0.46	-8.07	-0.3	3.56e-15	Pancreatic cancer;
BRCA	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg00383909	chr3:49044727	WDR6	0.75	12.18	0.43	7.55e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs9309473	1.000	rs6755241	chr2:73641364	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-11.14	-0.4	1.88e-26	Metabolite levels;
BRCA	cis	rs13040088	1.000	rs12480117	chr20:61558274	G/A	cg23096297	chr20:61557774	DIDO1	0.93	19.15	0.6	6.41e-65	Menopause (age at onset);
BRCA	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg04374321	chr14:90722782	PSMC1	0.71	18.43	0.59	3.71e-61	Mortality in heart failure;
BRCA	cis	rs11971779	0.793	rs4728464	chr7:139017670	C/T	cg07862535	chr7:139043722	LUC7L2	-0.42	-11.51	-0.41	5.66e-28	Diisocyanate-induced asthma;
BRCA	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg01119278	chr6:110721349	DDO	0.39	9.56	0.35	2.5e-20	Platelet distribution width;
BRCA	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg12935359	chr14:103987150	CKB	-0.58	-13.84	-0.48	2.86e-38	Body mass index;
BRCA	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg26384229	chr12:38710491	ALG10B	0.42	9.33	0.35	1.68e-19	Morning vs. evening chronotype;
BRCA	cis	rs698813	0.555	rs7605771	chr2:44479778	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	8.16	0.31	1.79e-15	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg21770322	chr7:97807741	LMTK2	0.43	10.98	0.4	7.84e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs490234	0.812	rs4838286	chr9:128460057	G/A	cg14078157	chr9:128172775	NA	-0.43	-9.72	-0.36	6.54e-21	Mean arterial pressure;
BRCA	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg06212747	chr3:49208901	KLHDC8B	0.46	9.56	0.35	2.45e-20	Parkinson's disease;
BRCA	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg25301532	chr20:43378953	KCNK15	-0.45	-10.89	-0.4	1.89e-25	Obesity-related traits;
BRCA	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25427524	chr10:38739819	LOC399744	-0.55	-12.48	-0.44	3.85e-32	Extrinsic epigenetic age acceleration;
BRCA	trans	rs9409565	0.826	rs9409550	chr9:97223294	C/G	cg05679027	chr9:99775184	HIATL2	-0.43	-9.4	-0.35	9.82e-20	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25427524	chr10:38739819	LOC399744	0.66	16.21	0.54	9.22e-50	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg18876405	chr7:65276391	NA	0.47	9.96	0.37	8.3e-22	Calcium levels;
BRCA	cis	rs7572733	0.515	rs6724526	chr2:198858401	A/G	cg00792783	chr2:198669748	PLCL1	0.44	9.68	0.36	9.05e-21	Dermatomyositis;
BRCA	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg24578937	chr1:2090814	PRKCZ	0.38	11.65	0.42	1.42e-28	Height;
BRCA	cis	rs2637266	1.000	rs7082587	chr10:78386328	C/T	cg18941641	chr10:78392320	NA	0.34	7.88	0.3	1.46e-14	Pulmonary function;
BRCA	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg05863683	chr7:1912471	MAD1L1	0.38	8.41	0.32	2.77e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07636037	chr3:49044803	WDR6	0.71	15.39	0.52	1.02e-45	Menarche (age at onset);
BRCA	cis	rs4566357	0.615	rs6436644	chr2:227914275	T/A	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.14	-0.31	2.13e-15	Coronary artery disease;
BRCA	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg00666640	chr1:248458726	OR2T12	0.33	8.82	0.33	1.11e-17	Common traits (Other);
BRCA	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg27446573	chr6:127587934	RNF146	0.9	21.24	0.64	3.9e-76	Breast cancer;
BRCA	cis	rs2171564	0.791	rs9852197	chr3:112442538	T/A	cg06685282	chr3:112453648	NA	0.36	8.65	0.32	4.23e-17	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg16325326	chr1:53192061	ZYG11B	0.69	17.55	0.57	1.44e-56	Monocyte count;
BRCA	trans	rs8073060	0.586	rs7212488	chr17:33993476	A/T	cg19694781	chr19:47549865	TMEM160	-1.05	-22.33	-0.66	4.41e-82	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	trans	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg07461501	chr17:79650226	HGS;ARL16	0.4	9.92	0.37	1.18e-21	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.46e-34	Alzheimer's disease (late onset);
BRCA	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg00701064	chr4:6280414	WFS1	-0.62	-15.9	-0.53	3.18e-48	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs4891159	0.584	rs690397	chr18:74117767	C/T	cg24786174	chr18:74118243	ZNF516	0.84	26.04	0.72	1.91e-102	Longevity;
BRCA	cis	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg21775007	chr8:11205619	TDH	-0.51	-10.14	-0.37	1.71e-22	Triglycerides;
BRCA	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg20607798	chr8:58055168	NA	0.53	8.34	0.31	4.56e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg02297831	chr4:17616191	MED28	0.36	7.88	0.3	1.43e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23248424	chr5:179741104	GFPT2	-0.65	-13.59	-0.47	3.92e-37	Height;
BRCA	cis	rs1712517	0.873	rs1712516	chr10:105033628	G/A	cg05636881	chr10:105038444	INA	0.36	7.91	0.3	1.17e-14	Migraine;
BRCA	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg05863683	chr7:1912471	MAD1L1	0.4	8.44	0.32	2.17e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg14186256	chr22:23484241	RTDR1	0.81	25.53	0.71	1.17e-99	Bone mineral density;
BRCA	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg11752832	chr7:134001865	SLC35B4	0.55	14.41	0.5	6.01e-41	Mean platelet volume;
BRCA	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg21475434	chr5:93447410	FAM172A	0.69	9.03	0.34	1.97e-18	Diabetic retinopathy;
BRCA	cis	rs11958404	0.932	rs72816556	chr5:157424412	C/G	cg05962755	chr5:157440814	NA	0.49	9.61	0.36	1.64e-20	IgG glycosylation;
BRCA	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg12179176	chr11:130786555	SNX19	0.61	13.63	0.47	2.56e-37	Schizophrenia;
BRCA	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-10.06	-0.37	3.32e-22	Joint mobility (Beighton score);
BRCA	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg27170947	chr2:26402098	FAM59B	0.97	17.16	0.56	1.38e-54	Gut microbiome composition (summer);
BRCA	cis	rs10465746	0.780	rs11163866	chr1:84367123	A/G	cg10977910	chr1:84465055	TTLL7	0.56	11.7	0.42	8.62e-29	Obesity-related traits;
BRCA	cis	rs6450176	0.909	rs6884936	chr5:53293198	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.59	-13.85	-0.48	2.33e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.69	0.39	1.24e-24	IgG glycosylation;
BRCA	cis	rs6878727	0.665	rs173958	chr5:123675242	G/T	cg01806427	chr5:123737813	NA	-0.36	-8.07	-0.3	3.41e-15	Breast cancer;
BRCA	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.6	-0.67	1.57e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs705471	0.966	rs12573508	chr10:3656268	C/T	cg14308648	chr10:3568949	NA	0.35	7.88	0.3	1.38e-14	Capecitabine sensitivity;
BRCA	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg05791153	chr7:19748676	TWISTNB	0.67	11.97	0.43	5.91e-30	Thyroid stimulating hormone;
BRCA	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg24803719	chr17:45855879	NA	-0.33	-8.59	-0.32	6.46e-17	IgG glycosylation;
BRCA	cis	rs7560272	0.538	rs13000788	chr2:73918312	C/T	cg20560298	chr2:73613845	ALMS1	0.35	9.06	0.34	1.53e-18	Schizophrenia;
BRCA	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg11062466	chr8:58055876	NA	0.5	8.88	0.33	6.54e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs12711979	0.692	rs6751947	chr2:3820739	G/A	cg17052675	chr2:3827356	NA	-0.48	-14.26	-0.49	2.93e-40	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	8.95	0.33	3.75e-18	Tonsillectomy;
BRCA	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg15934090	chr1:100435551	SLC35A3	0.36	8.53	0.32	1.08e-16	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg25214090	chr10:38739885	LOC399744	-0.53	-11.74	-0.42	6.17e-29	Corneal astigmatism;
BRCA	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg15103426	chr22:29168792	CCDC117	0.52	12.2	0.43	6.37e-31	Lymphocyte counts;
BRCA	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.39	-8.84	-0.33	9.31e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg26031613	chr14:104095156	KLC1	-0.42	-8.46	-0.32	1.86e-16	Schizophrenia;
BRCA	cis	rs11984145	1.000	rs68175808	chr7:38832209	G/A	cg19327137	chr7:38886074	VPS41	0.46	7.83	0.3	2.07e-14	Cognitive performance;
BRCA	cis	rs919433	0.680	rs788017	chr2:198265173	T/A	cg00792783	chr2:198669748	PLCL1	0.38	8.55	0.32	9.31e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg20607798	chr8:58055168	NA	0.61	9.75	0.36	4.75e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg01579765	chr21:45077557	HSF2BP	0.4	10.57	0.39	3.62e-24	Mean corpuscular volume;
BRCA	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19346786	chr7:2764209	NA	-0.26	-8.0	-0.3	5.86e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
BRCA	trans	rs11039798	0.925	rs10769373	chr11:48531980	T/A	cg15704280	chr7:45808275	SEPT13	0.56	8.34	0.31	4.74e-16	Axial length;
BRCA	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg17366294	chr4:99064904	C4orf37	0.42	9.67	0.36	9.72e-21	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg07211511	chr3:129823064	LOC729375	-0.63	-11.17	-0.4	1.39e-26	Blood pressure (smoking interaction);
BRCA	cis	rs7818345	1.000	rs4430112	chr8:19293365	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.3	7.95	0.3	8.41e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs897984	0.806	rs1458202	chr16:30953202	A/G	cg02466173	chr16:30829666	NA	-0.49	-11.22	-0.41	8.58e-27	Dementia with Lewy bodies;
BRCA	cis	rs1832871	0.672	rs56075516	chr6:158745752	G/A	cg07165851	chr6:158734300	TULP4	0.63	12.61	0.45	9.79e-33	Height;
BRCA	cis	rs61990749	0.597	rs8003691	chr14:78211225	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.44	7.88	0.3	1.38e-14	Fibroblast growth factor basic levels;
BRCA	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11764359	chr7:65958608	NA	0.74	16.66	0.55	4.99e-52	Aortic root size;
BRCA	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.12	-0.34	1e-18	Bipolar disorder;
BRCA	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg10523679	chr1:76189770	ACADM	0.76	15.88	0.53	4.12e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg10011062	chr15:43941034	CATSPER2	0.51	8.25	0.31	8.83e-16	Lung cancer in ever smokers;
BRCA	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	14.13	0.49	1.22e-39	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs965469	1.000	rs2236122	chr20:3305240	C/T	cg25506879	chr20:3388711	C20orf194	-0.52	-10.26	-0.38	5.74e-23	IFN-related cytopenia;
BRCA	cis	rs11690935	0.527	rs7586556	chr2:172901887	G/C	cg13550731	chr2:172543902	DYNC1I2	0.58	14.43	0.5	4.74e-41	Schizophrenia;
BRCA	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-10.56	-0.39	3.98e-24	Lymphocyte counts;
BRCA	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg03146154	chr1:46216737	IPP	0.44	9.72	0.36	6.39e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg13319975	chr6:146136371	FBXO30	-0.35	-8.25	-0.31	9.4e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.22	-0.31	1.17e-15	Depression;
BRCA	trans	rs12439619	1.000	rs12439619	chr15:82546946	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.42	-10.72	-0.39	9.14e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg00701064	chr4:6280414	WFS1	0.68	17.03	0.56	6.41e-54	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	trans	rs12310956	0.531	rs10772110	chr12:33841755	A/G	cg26384229	chr12:38710491	ALG10B	0.39	8.72	0.33	2.45e-17	Morning vs. evening chronotype;
BRCA	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg03864215	chr11:17408437	KCNJ11	-0.27	-8.01	-0.3	5.41e-15	Type 2 diabetes;
BRCA	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg18016565	chr1:150552671	MCL1	0.35	8.23	0.31	1.08e-15	Tonsillectomy;
BRCA	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg12311346	chr5:56204834	C5orf35	-0.81	-16.16	-0.54	1.65e-49	Initial pursuit acceleration;
BRCA	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.9	22.74	0.67	2.56e-84	Body mass index (adult);
BRCA	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg26384229	chr12:38710491	ALG10B	0.42	9.33	0.35	1.73e-19	Morning vs. evening chronotype;
BRCA	cis	rs12472274	0.941	rs6748440	chr2:239100375	C/T	cg17459225	chr2:239074497	NA	0.63	12.87	0.45	7.58e-34	Phospholipid levels (plasma);
BRCA	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg21399703	chr1:247681439	NA	0.42	9.37	0.35	1.22e-19	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9814567	0.806	rs4074521	chr3:134325536	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	16.56	0.55	1.58e-51	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9400271	0.527	rs9400274	chr6:109639876	G/A	cg01475377	chr6:109611718	NA	0.36	7.96	0.3	7.82e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs3818285	1.000	rs3740138	chr10:111630931	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.36	-8.94	-0.33	4.19e-18	Superior crus of antihelix expression;
BRCA	cis	rs1420338	0.933	rs731844	chr7:34150264	C/T	cg01275685	chr7:34179230	BMPER	-0.52	-11.7	-0.42	8.48e-29	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08564027	chr20:61660810	NA	0.85	22.97	0.67	1.42e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04155289	chr7:94953770	PON1	-0.53	-11.44	-0.41	1.05e-27	Paraoxonase activity;
BRCA	trans	rs9951602	0.512	rs73494176	chr18:76644895	T/C	cg02800362	chr5:177631904	HNRNPAB	0.76	17.68	0.57	3.16e-57	Obesity-related traits;
BRCA	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-11.89	-0.43	1.33e-29	Mood instability;
BRCA	trans	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	16.01	0.54	9.02e-49	Exhaled nitric oxide levels;
BRCA	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg02743256	chr7:2109353	MAD1L1	-0.45	-7.98	-0.3	6.75e-15	Neuroticism;
BRCA	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg19508488	chr2:152266495	RIF1	0.37	7.93	0.3	9.6e-15	Lung cancer;
BRCA	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg13319975	chr6:146136371	FBXO30	0.41	9.35	0.35	1.51e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg06627628	chr2:24431161	ITSN2	-0.78	-14.72	-0.5	1.86e-42	Asthma;
BRCA	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.57	11.98	0.43	5.64e-30	Lymphocyte counts;
BRCA	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg03060546	chr3:49711283	APEH	-0.54	-10.91	-0.4	1.61e-25	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg05527609	chr1:210001259	C1orf107	0.68	14.53	0.5	1.54e-41	Orofacial clefts;
BRCA	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg22974920	chr21:40686053	BRWD1	-0.38	-8.62	-0.32	5.12e-17	Cognitive function;
BRCA	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg11189052	chr15:85197271	WDR73	0.44	8.93	0.33	4.54e-18	Schizophrenia;
BRCA	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18876405	chr7:65276391	NA	0.7	18.65	0.59	2.72e-62	Aortic root size;
BRCA	cis	rs6743226	0.901	rs12478458	chr2:242237856	A/G	cg10021735	chr2:242295487	FARP2	0.37	10.12	0.37	1.95e-22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg20573242	chr4:122745356	CCNA2	0.46	9.82	0.36	2.76e-21	Type 2 diabetes;
BRCA	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg16230307	chr14:35515116	FAM177A1	0.74	15.31	0.52	2.58e-45	Psoriasis;
BRCA	cis	rs7586879	0.929	rs6545807	chr2:25124358	C/T	cg01884057	chr2:25150051	NA	0.34	8.49	0.32	1.43e-16	Body mass index;
BRCA	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg04362960	chr10:104952993	NT5C2	0.46	10.7	0.39	1.13e-24	Arsenic metabolism;
BRCA	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg26031613	chr14:104095156	KLC1	0.73	15.88	0.53	3.91e-48	Body mass index;
BRCA	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.08	-0.49	2.11e-39	Eye color traits;
BRCA	cis	rs4629180	1.000	rs59246268	chr2:102089021	G/A	cg04415270	chr2:102091202	RFX8	-0.33	-8.32	-0.31	5.14e-16	Chronic rhinosinusitis with nasal polyps;
BRCA	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.71	15.55	0.52	1.74e-46	Lymphocyte counts;
BRCA	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-8.99	-0.34	2.69e-18	IgG glycosylation;
BRCA	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.6	12.3	0.44	2.41e-31	Monocyte percentage of white cells;
BRCA	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg26597838	chr10:835615	NA	0.9	13.67	0.48	1.64e-37	Eosinophil percentage of granulocytes;
BRCA	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg19773385	chr1:10388646	KIF1B	-0.35	-7.81	-0.3	2.31e-14	Hepatocellular carcinoma;
BRCA	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg00409905	chr10:38381863	ZNF37A	-0.43	-8.99	-0.34	2.67e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs701145	0.585	rs1727945	chr3:153882865	G/A	cg17054900	chr3:154042577	DHX36	0.56	9.46	0.35	5.73e-20	Coronary artery disease;
BRCA	cis	rs870825	0.860	rs60523653	chr4:185604676	T/C	cg04058563	chr4:185651563	MLF1IP	0.65	11.26	0.41	5.77e-27	Blood protein levels;
BRCA	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg25838465	chr1:92012736	NA	0.47	9.24	0.34	3.51e-19	Eosinophil percentage of white cells;
BRCA	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg21747090	chr2:27597821	SNX17	-0.39	-8.55	-0.32	9.37e-17	Total body bone mineral density;
BRCA	cis	rs921968	0.565	rs6745700	chr2:219639862	T/C	cg02176678	chr2:219576539	TTLL4	-0.41	-11.02	-0.4	5.7e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg24812749	chr6:127587940	RNF146	0.88	20.06	0.62	9.03e-70	Breast cancer;
BRCA	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg16950941	chr11:66035639	RAB1B	0.43	11.85	0.42	1.99e-29	Gout;
BRCA	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02018176	chr4:1364513	KIAA1530	-0.39	-8.23	-0.31	1.07e-15	Longevity;
BRCA	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg14844989	chr11:31128820	NA	-0.45	-9.77	-0.36	4.21e-21	Red blood cell count;
BRCA	trans	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.22	0.31	1.11e-15	Mean corpuscular volume;
BRCA	cis	rs17253792	0.545	rs12894613	chr14:56016221	T/C	cg01858014	chr14:56050164	KTN1	-0.61	-7.99	-0.3	6.09e-15	Putamen volume;
BRCA	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg08493051	chr2:3487164	NA	-0.43	-9.25	-0.34	3.33e-19	Neurofibrillary tangles;
BRCA	cis	rs4363385	0.747	rs1129655	chr1:152958267	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.72	-0.33	2.43e-17	Inflammatory skin disease;
BRCA	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.34	-0.31	4.7e-16	Retinal vascular caliber;
BRCA	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg01528321	chr10:82214614	TSPAN14	0.78	17.03	0.56	6.88e-54	Post bronchodilator FEV1;
BRCA	cis	rs600806	0.850	rs1465607	chr1:109958035	T/C	cg20591472	chr1:110008990	SYPL2	0.32	7.91	0.3	1.12e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg04374321	chr14:90722782	PSMC1	0.42	8.24	0.31	9.48e-16	Gut microbiota (bacterial taxa);
BRCA	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg22676075	chr6:135203613	NA	0.45	8.89	0.33	6.22e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs61931739	0.613	rs1525898	chr12:33904445	G/T	cg06521331	chr12:34319734	NA	-0.39	-7.85	-0.3	1.71e-14	Morning vs. evening chronotype;
BRCA	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg08601574	chr20:25228251	PYGB	0.35	8.36	0.31	3.92e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg05834845	chr3:195489306	MUC4	-0.56	-8.51	-0.32	1.22e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	11.65	0.42	1.48e-28	Schizophrenia;
BRCA	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.67	-9.72	-0.36	6.19e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg20607798	chr8:58055168	NA	0.47	8.07	0.3	3.41e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg03711944	chr11:47377212	SPI1	-0.41	-11.06	-0.4	3.75e-26	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	10.34	0.38	2.83e-23	Aortic root size;
BRCA	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg01939980	chr4:1354348	KIAA1530	0.38	9.11	0.34	1.02e-18	Obesity-related traits;
BRCA	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg21535247	chr6:8435926	SLC35B3	0.4	9.09	0.34	1.25e-18	Motion sickness;
BRCA	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg13010199	chr12:38710504	ALG10B	0.47	8.99	0.34	2.82e-18	Morning vs. evening chronotype;
BRCA	cis	rs6740322	0.895	rs6544643	chr2:43560072	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-12.59	-0.45	1.23e-32	Coronary artery disease;
BRCA	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg21427119	chr20:30132790	HM13	-0.41	-8.78	-0.33	1.53e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg24069376	chr3:38537580	EXOG	0.32	8.97	0.33	3.13e-18	Electrocardiographic conduction measures;
BRCA	cis	rs807669	0.586	rs5746671	chr22:19160899	A/G	cg02655711	chr22:19163373	SLC25A1	0.48	11.16	0.4	1.48e-26	Metabolite levels;
BRCA	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24531977	chr5:56204891	C5orf35	-0.89	-19.09	-0.6	1.23e-64	Initial pursuit acceleration;
BRCA	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg00149659	chr3:10157352	C3orf10	1.06	18.2	0.58	6.23e-60	Alzheimer's disease;
BRCA	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-11.75	-0.42	5.31e-29	Personality dimensions;
BRCA	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg23229984	chr5:148520753	ABLIM3	0.31	7.81	0.3	2.36e-14	Breast cancer;
BRCA	cis	rs11677370	0.603	rs10164826	chr2:3849951	G/C	cg17052675	chr2:3827356	NA	-0.54	-12.99	-0.46	2.01e-34	Type 2 diabetes;
BRCA	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg11062466	chr8:58055876	NA	0.49	8.67	0.32	3.64e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7572733	0.555	rs6434954	chr2:198929716	T/C	cg00792783	chr2:198669748	PLCL1	0.36	7.99	0.3	6.43e-15	Dermatomyositis;
BRCA	cis	rs7512552	0.839	rs1260405	chr1:150304781	A/G	cg15654264	chr1:150340011	RPRD2	0.41	9.05	0.34	1.73e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-19.9	-0.62	6.31e-69	Headache;
BRCA	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg03060546	chr3:49711283	APEH	0.6	10.31	0.38	3.56e-23	Menarche (age at onset);
BRCA	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	trans	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg25214090	chr10:38739885	LOC399744	0.48	10.58	0.39	3.28e-24	Corneal astigmatism;
BRCA	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg03433033	chr1:76189801	ACADM	-0.6	-11.84	-0.42	2.22e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg23505145	chr19:12996616	KLF1	0.56	12.64	0.45	7.94e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg05283184	chr6:79620031	NA	-0.44	-11.31	-0.41	3.85e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	10.7	0.39	1.11e-24	IgG glycosylation;
BRCA	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	13.81	0.48	3.96e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg00677455	chr12:58241039	CTDSP2	0.47	11.52	0.41	5.01e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg23711669	chr6:146136114	FBXO30	-0.7	-16.49	-0.55	3.76e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg26408565	chr15:76604113	ETFA	-0.47	-10.06	-0.37	3.32e-22	Blood metabolite levels;
BRCA	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.6	12.04	0.43	3.05e-30	Multiple sclerosis;
BRCA	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg25358565	chr5:93447407	FAM172A	1.21	18.85	0.6	2.32e-63	Diabetic retinopathy;
BRCA	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg21475434	chr5:93447410	FAM172A	0.67	8.72	0.33	2.36e-17	Diabetic retinopathy;
BRCA	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03517284	chr6:25882590	NA	-0.47	-10.55	-0.39	4.14e-24	Blood metabolite levels;
BRCA	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	9.05	0.34	1.65e-18	Educational attainment;
BRCA	cis	rs912057	0.932	rs1294406	chr6:6737737	A/G	cg06612196	chr6:6737390	NA	0.46	10.49	0.38	7.19e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	trans	rs1973993	0.669	rs510552	chr1:96891671	A/G	cg10631902	chr5:14652156	NA	0.59	21.2	0.64	6.24e-76	Weight;
BRCA	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg00990874	chr7:1149470	C7orf50	-0.62	-13.13	-0.46	5.1e-35	Bronchopulmonary dysplasia;
BRCA	trans	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.37	8.33	0.31	4.98e-16	Endometrial cancer;
BRCA	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg21775007	chr8:11205619	TDH	0.61	11.98	0.43	5.7e-30	Retinal vascular caliber;
BRCA	trans	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04565464	chr8:145669602	NFKBIL2	0.44	9.86	0.36	1.89e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg14675211	chr2:100938903	LONRF2	0.47	10.19	0.37	1.09e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7927771	0.524	rs7929725	chr11:47881740	A/G	cg20307385	chr11:47447363	PSMC3	0.42	9.53	0.35	3.18e-20	Subjective well-being;
BRCA	trans	rs7746199	0.736	rs56405707	chr6:27640246	G/A	cg01620082	chr3:125678407	NA	-0.91	-10.26	-0.38	5.96e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg21475434	chr5:93447410	FAM172A	0.69	9.37	0.35	1.21e-19	Diabetic retinopathy;
BRCA	cis	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg21775007	chr8:11205619	TDH	-0.6	-11.74	-0.42	5.93e-29	Retinal vascular caliber;
BRCA	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11764359	chr7:65958608	NA	0.78	18.59	0.59	5.33e-62	Aortic root size;
BRCA	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg03929089	chr4:120376271	NA	0.71	16.15	0.54	1.82e-49	Coronary artery disease;
BRCA	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg17971929	chr21:40555470	PSMG1	-0.61	-13.39	-0.47	3.24e-36	Cognitive function;
BRCA	cis	rs17604090	0.877	rs57253003	chr7:29686556	T/C	cg19413766	chr7:29689036	LOC646762	-0.51	-7.98	-0.3	6.76e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs12530845	0.887	rs78641973	chr7:135324311	C/T	cg23117316	chr7:135346802	PL-5283	-0.35	-8.26	-0.31	8.45e-16	Red blood cell traits;
BRCA	cis	rs870825	0.616	rs7683537	chr4:185631998	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	17.4	0.57	8.32e-56	Blood protein levels;
BRCA	cis	rs3820928	1.000	rs4675116	chr2:227769607	A/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.56	-0.32	8.49e-17	Pulmonary function;
BRCA	cis	rs11997175	0.583	rs17780153	chr8:33789161	A/G	ch.8.33884649F	chr8:33765107	NA	0.37	8.3	0.31	6.26e-16	Body mass index;
BRCA	cis	rs17384381	0.953	rs12122816	chr1:85792384	C/T	cg16011679	chr1:85725395	C1orf52	0.54	8.17	0.31	1.69e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.7	-0.48	1.21e-37	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1020064	0.945	rs1030878	chr2:105910598	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.63	11.86	0.42	1.76e-29	AIDS;
BRCA	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.05	15.19	0.52	9.72e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg25214090	chr10:38739885	LOC399744	0.48	10.66	0.39	1.53e-24	Corneal astigmatism;
BRCA	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg01262667	chr19:19385393	TM6SF2	0.41	10.54	0.38	4.75e-24	Tonsillectomy;
BRCA	cis	rs897080	0.515	rs698791	chr2:44683168	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	9.43	0.35	7.39e-20	Height;
BRCA	trans	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg13010199	chr12:38710504	ALG10B	0.43	7.99	0.3	6.18e-15	Resting heart rate;
BRCA	cis	rs7945718	0.806	rs7927346	chr11:12835835	C/T	cg25843174	chr11:12811716	TEAD1	0.21	8.34	0.31	4.6e-16	Educational attainment (years of education);
BRCA	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-13.08	-0.46	8.41e-35	Migraine;Coronary artery disease;
BRCA	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg15501526	chr10:2543763	NA	-0.57	-13.99	-0.48	5.6e-39	Age-related hearing impairment;
BRCA	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg20801007	chr11:830320	EFCAB4A	-0.49	-10.72	-0.39	9.01e-25	Mean platelet volume;
BRCA	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg14186256	chr22:23484241	RTDR1	0.82	25.75	0.71	7.97e-101	Bone mineral density;
BRCA	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.46	0.35	5.61e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7809799	1.000	rs6969313	chr7:98754007	G/A	cg05967295	chr7:98741636	SMURF1	-0.81	-8.04	-0.3	4.24e-15	Ulcerative colitis;
BRCA	cis	rs3125734	0.633	rs7100297	chr10:63985100	T/C	cg19640130	chr10:64028056	RTKN2	-0.29	-8.38	-0.31	3.27e-16	Rheumatoid arthritis;
BRCA	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.72	11.11	0.4	2.34e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	11.08	0.4	3.19e-26	Personality dimensions;
BRCA	cis	rs965469	0.857	rs1922990	chr20:3252348	G/A	cg25506879	chr20:3388711	C20orf194	-0.45	-9.1	-0.34	1.12e-18	IFN-related cytopenia;
BRCA	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg18154014	chr19:37997991	ZNF793	0.49	9.72	0.36	6.14e-21	Coronary artery calcification;
BRCA	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18876405	chr7:65276391	NA	-0.51	-11.75	-0.42	5.48e-29	Aortic root size;
BRCA	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.83	0.65	2.21e-79	Lymphocyte percentage of white cells;
BRCA	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg25358565	chr5:93447407	FAM172A	-0.67	-11.7	-0.42	8.73e-29	Diabetic retinopathy;
BRCA	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg06784218	chr1:46089804	CCDC17	-0.54	-13.14	-0.46	4.5e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.9	-0.3	1.26e-14	Corneal astigmatism;
BRCA	cis	rs12541635	0.966	rs12681183	chr8:107007156	T/A	cg10147462	chr8:107024639	NA	0.37	9.98	0.37	6.74e-22	Age of smoking initiation;
BRCA	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg24558204	chr6:135376177	HBS1L	0.45	12.29	0.44	2.61e-31	Red blood cell count;
BRCA	trans	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-20.2	-0.62	1.49e-70	Exhaled nitric oxide output;
BRCA	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg00814883	chr7:100076585	TSC22D4	-0.47	-10.45	-0.38	1.06e-23	Platelet count;
BRCA	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg10223061	chr2:219282414	VIL1	0.3	8.68	0.32	3.39e-17	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg25214090	chr10:38739885	LOC399744	0.54	12.24	0.44	4.06e-31	Corneal astigmatism;
BRCA	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg00631329	chr6:26305371	NA	-0.44	-13.0	-0.46	1.8e-34	Educational attainment;
BRCA	cis	rs6545883	0.929	rs1186700	chr2:61663372	A/C	cg15711740	chr2:61764176	XPO1	-0.51	-12.33	-0.44	1.81e-31	Tuberculosis;
BRCA	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg04691961	chr3:161091175	C3orf57	-0.38	-8.91	-0.33	5.14e-18	Morning vs. evening chronotype;
BRCA	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg24562669	chr7:97807699	LMTK2	0.45	11.98	0.43	5.55e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03452623	chr4:187889614	NA	-0.34	-11.62	-0.42	1.81e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9400271	0.632	rs9374071	chr6:109588681	T/C	cg21918786	chr6:109611834	NA	-0.32	-8.09	-0.3	3.08e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs2516839	0.517	rs1556257	chr1:161051134	A/G	cg23055938	chr1:160991191	F11R	-0.44	-8.44	-0.32	2.19e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.29	-0.35	2.32e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg24558204	chr6:135376177	HBS1L	0.44	11.85	0.42	2.03e-29	Red blood cell count;
BRCA	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg18479299	chr3:125709523	NA	-0.53	-8.18	-0.31	1.53e-15	Blood pressure (smoking interaction);
BRCA	cis	rs3892630	0.588	rs28787932	chr19:33226229	T/C	cg22980127	chr19:33182716	NUDT19	0.92	20.5	0.63	3.92e-72	Red blood cell traits;
BRCA	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg04414720	chr1:150670196	GOLPH3L	0.35	8.06	0.3	3.82e-15	Tonsillectomy;
BRCA	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.06	0.37	3.41e-22	Bladder cancer;
BRCA	cis	rs929596	0.785	rs6747843	chr2:234664354	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-12.05	-0.43	2.92e-30	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg19678392	chr7:94953810	PON1	-0.43	-9.08	-0.34	1.38e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.02	0.3	4.91e-15	Corneal astigmatism;
BRCA	cis	rs6060717	0.536	rs11699815	chr20:34543125	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.0	-0.3	5.95e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.9	-29.81	-0.76	4.77e-123	Schizophrenia;
BRCA	cis	rs1003719	0.788	rs2835576	chr21:38457393	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.18	0.49	7.11e-40	Eye color traits;
BRCA	cis	rs3916	0.911	rs2239758	chr12:121162637	A/G	cg21892295	chr12:121157589	UNC119B	-0.38	-9.95	-0.37	8.62e-22	Urinary metabolites (H-NMR features);
BRCA	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg10729496	chr3:10149963	C3orf24	0.51	9.1	0.34	1.17e-18	Alzheimer's disease;
BRCA	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg21573476	chr21:45109991	RRP1B	-0.33	-8.68	-0.32	3.25e-17	Mean corpuscular volume;
BRCA	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-8.06	-0.3	3.78e-15	Bipolar disorder;
BRCA	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg27170947	chr2:26402098	FAM59B	0.84	12.18	0.43	8.02e-31	Gut microbiome composition (summer);
BRCA	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.53	-0.32	1.05e-16	Gut microbiome composition (summer);
BRCA	trans	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg26043149	chr18:55253948	FECH	0.6	13.51	0.47	9.41e-37	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs12348691	0.503	rs7046645	chr9:100617375	T/C	cg13688889	chr9:100608707	NA	-0.49	-9.9	-0.36	1.32e-21	Alopecia areata;
BRCA	cis	rs3815700	1.000	rs8100168	chr19:33093084	G/A	cg02997394	chr19:33096574	ANKRD27	0.61	8.67	0.32	3.58e-17	Eosinophilic esophagitis;
BRCA	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg27478167	chr7:817139	HEATR2	0.53	10.41	0.38	1.46e-23	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg15448220	chr1:150897856	SETDB1	0.36	8.02	0.3	5.06e-15	Melanoma;
BRCA	trans	rs7395662	0.818	rs2200181	chr11:48413175	C/G	cg00717180	chr2:96193071	NA	-0.29	-7.93	-0.3	9.78e-15	HDL cholesterol;
BRCA	cis	rs939658	0.683	rs8024572	chr15:79465600	A/G	cg17916960	chr15:79447300	NA	0.36	8.61	0.32	5.55e-17	Refractive error;
BRCA	cis	rs3857067	0.806	rs2171384	chr4:95103545	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.34	-0.35	1.56e-19	QT interval;
BRCA	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	8.09	0.3	2.97e-15	Diabetic retinopathy;
BRCA	cis	rs9302690	0.557	rs223875	chr16:57506915	C/T	cg16753122	chr16:57506917	DOK4	0.47	7.86	0.3	1.58e-14	Blood protein levels;
BRCA	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	10.81	0.39	3.99e-25	Rheumatoid arthritis;
BRCA	cis	rs9369695	0.842	rs9395262	chr6:47465267	T/C	cg12968598	chr6:47444699	CD2AP	0.44	9.68	0.36	9.34e-21	Reticulocyte count;
BRCA	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg24450063	chr1:156163899	SLC25A44	1.11	36.3	0.82	2.03e-157	Testicular germ cell tumor;
BRCA	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	5.1e-16	Tonsillectomy;
BRCA	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg02951883	chr7:2050386	MAD1L1	-0.45	-10.04	-0.37	4.19e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg20701182	chr2:24300061	SF3B14	0.58	9.01	0.34	2.37e-18	Lymphocyte counts;
BRCA	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg26587870	chr6:27730563	NA	-0.52	-8.05	-0.3	4.11e-15	Breast cancer;
BRCA	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg10523679	chr1:76189770	ACADM	0.76	15.89	0.53	3.87e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7766436	0.885	rs7742025	chr6:22575798	A/T	cg13666174	chr6:22585274	NA	-0.45	-9.76	-0.36	4.67e-21	Coronary artery disease;
BRCA	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg03684893	chr10:554711	DIP2C	-0.4	-9.6	-0.36	1.71e-20	Psychosis in Alzheimer's disease;
BRCA	cis	rs13064411	0.501	rs13092925	chr3:113209375	C/G	cg18753928	chr3:113234510	CCDC52	-0.46	-9.92	-0.37	1.14e-21	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	14.21	0.49	4.93e-40	Colorectal cancer;
BRCA	trans	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg15704280	chr7:45808275	SEPT13	0.56	8.77	0.33	1.67e-17	Intraocular pressure;
BRCA	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg11498726	chr8:26250323	BNIP3L	0.59	14.82	0.51	6.01e-43	Red cell distribution width;
BRCA	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg04025307	chr7:1156635	C7orf50	0.57	9.96	0.37	8.36e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.99	0.33	2.85e-18	Tonsillectomy;
BRCA	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg26838691	chr2:24397539	C2orf84	-0.44	-8.3	-0.31	6.21e-16	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs1669338	0.588	rs73005226	chr3:3195369	A/G	cg16797762	chr3:3221439	CRBN	-0.58	-9.11	-0.34	1.06e-18	White matter integrity;
BRCA	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg19920283	chr7:105172520	RINT1	0.58	9.39	0.35	1.07e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs6714710	0.603	rs11680321	chr2:98379267	C/T	cg26665480	chr2:98280029	ACTR1B	0.56	13.05	0.46	1.11e-34	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg10556349	chr10:835070	NA	0.75	10.06	0.37	3.24e-22	Eosinophil percentage of granulocytes;
BRCA	cis	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg06521331	chr12:34319734	NA	-0.62	-12.2	-0.43	6.08e-31	Morning vs. evening chronotype;
BRCA	trans	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg06521331	chr12:34319734	NA	-0.51	-9.28	-0.34	2.52e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12826209	chr6:26865740	GUSBL1	0.58	10.3	0.38	3.9699999999999997e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	11.21	0.41	9.38e-27	Longevity;
BRCA	cis	rs3768617	0.811	rs4366285	chr1:183013672	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.46	9.97	0.37	7.54e-22	Fuchs's corneal dystrophy;
BRCA	cis	rs4561483	0.798	rs33629	chr16:11997490	G/A	cg08843971	chr16:11963173	GSPT1	-0.45	-9.45	-0.35	6.4e-20	Testicular germ cell tumor;
BRCA	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.31	0.49	1.68e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	14.34	0.49	1.3e-40	Alzheimer's disease;
BRCA	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg12386194	chr3:101231763	SENP7	-0.43	-8.56	-0.32	8.35e-17	Colorectal cancer;
BRCA	cis	rs11955398	0.716	rs56191602	chr5:59954444	T/A	cg02684056	chr5:59996105	DEPDC1B	0.39	9.35	0.35	1.46e-19	Intelligence (multi-trait analysis);
BRCA	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg13010199	chr12:38710504	ALG10B	0.44	9.31	0.35	1.98e-19	Morning vs. evening chronotype;
BRCA	cis	rs10411936	0.712	rs8100755	chr19:16593415	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.47	9.74	0.36	5.51e-21	White blood cell count;Multiple sclerosis;
BRCA	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.54	-13.36	-0.47	4.41e-36	Urate levels in overweight individuals;
BRCA	cis	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg04990556	chr1:26633338	UBXN11	0.54	8.9	0.33	5.55e-18	Obesity-related traits;
BRCA	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg17063962	chr7:91808500	NA	-0.55	-12.71	-0.45	3.76e-33	Breast cancer;
BRCA	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg12310025	chr6:25882481	NA	0.42	9.45	0.35	6.29e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.4	9.26	0.34	3.15e-19	Multiple sclerosis;
BRCA	cis	rs16854884	0.657	rs16854816	chr3:143734147	A/G	cg06585982	chr3:143692056	C3orf58	0.43	9.0	0.34	2.63e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg18854424	chr1:2615690	NA	0.31	8.22	0.31	1.12e-15	Ulcerative colitis;
BRCA	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg00277334	chr10:82204260	NA	-0.44	-9.25	-0.34	3.42e-19	Post bronchodilator FEV1;
BRCA	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg24631222	chr15:78858424	CHRNA5	0.5	9.77	0.36	4.31e-21	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg11502198	chr6:26597334	ABT1	0.47	9.39	0.35	9.98e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03517284	chr6:25882590	NA	0.38	8.22	0.31	1.1e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18876405	chr7:65276391	NA	-0.58	-13.71	-0.48	1.06e-37	Aortic root size;
BRCA	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg21918786	chr6:109611834	NA	-0.48	-13.79	-0.48	4.72e-38	Reticulocyte fraction of red cells;
BRCA	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.85	-0.3	1.79e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.54	9.49	0.35	4.59e-20	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg20573242	chr4:122745356	CCNA2	0.49	11.15	0.4	1.62e-26	Type 2 diabetes;
BRCA	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg05347473	chr6:146136440	FBXO30	0.55	10.26	0.38	5.59e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg17971929	chr21:40555470	PSMG1	-0.48	-10.57	-0.39	3.68e-24	Menarche (age at onset);
BRCA	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg12386194	chr3:101231763	SENP7	0.65	12.82	0.45	1.23e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg26395211	chr5:140044315	WDR55	0.38	8.65	0.32	4.25e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-13.7	-0.48	1.18e-37	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg13902645	chr11:5959945	NA	-0.45	-8.8	-0.33	1.24e-17	DNA methylation (variation);
BRCA	cis	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg07460842	chr6:66804631	NA	0.88	14.29	0.49	2.04e-40	Exhaled nitric oxide output;
BRCA	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg14196790	chr5:131705035	SLC22A5	0.5	13.08	0.46	8.41e-35	Blood metabolite levels;
BRCA	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg15704280	chr7:45808275	SEPT13	0.43	8.13	0.31	2.23e-15	Intraocular pressure;
BRCA	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg12591125	chr7:1885375	MAD1L1	0.51	8.92	0.33	5.05e-18	Bipolar disorder;
BRCA	cis	rs9986765	1.000	rs73452567	chr7:142816043	T/G	cg15652212	chr7:142981776	TMEM139	0.64	10.06	0.37	3.47e-22	Cancer;Dermatomyositis;
BRCA	trans	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.38	7.9	0.3	1.18e-14	Menarche (age at onset);
BRCA	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-13.08	-0.46	8.23e-35	Bipolar disorder;
BRCA	cis	rs9443189	0.570	rs659807	chr6:76293435	C/A	cg01950844	chr6:76311363	SENP6	0.85	14.09	0.49	1.77e-39	Prostate cancer;
BRCA	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-13.99	-0.48	5.29e-39	Morning vs. evening chronotype;
BRCA	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg06060754	chr5:176797920	RGS14	-0.79	-15.44	-0.52	6.19e-46	Urinary electrolytes (magnesium/calcium ratio);
BRCA	cis	rs7408868	1.000	rs7245814	chr19:15274503	A/G	cg14696996	chr19:15285081	NOTCH3	0.99	14.46	0.5	3.39e-41	Pulse pressure;
BRCA	cis	rs68170813	0.522	rs12531187	chr7:106963650	C/G	cg02696742	chr7:106810147	HBP1	-0.53	-8.47	-0.32	1.7e-16	Coronary artery disease;
BRCA	cis	rs6005807	0.719	rs9625513	chr22:29022172	C/T	cg12565055	chr22:29076175	TTC28	0.49	9.36	0.35	1.35e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	trans	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17712092	chr4:129076599	LARP1B	0.51	12.04	0.43	3.15e-30	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs9309473	0.607	rs7560272	chr2:73561485	A/T	cg20560298	chr2:73613845	ALMS1	-0.44	-11.65	-0.42	1.39e-28	Metabolite levels;
BRCA	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg17063962	chr7:91808500	NA	0.53	11.71	0.42	7.83e-29	Breast cancer;
BRCA	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08280861	chr8:58055591	NA	0.53	8.59	0.32	6.53e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9462027	0.628	rs9296127	chr6:34719628	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.99	-0.3	6.39e-15	Systemic lupus erythematosus;
BRCA	trans	rs3741489	1.000	rs4758915	chr12:133477147	A/G	cg24132527	chr5:140019269	TMCO6	0.97	10.3	0.38	3.94e-23	Cognitive function;
BRCA	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg02574844	chr11:5959923	NA	-0.41	-8.2	-0.31	1.36e-15	DNA methylation (variation);
BRCA	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.28	-0.31	7.1e-16	Bipolar disorder;
BRCA	cis	rs7565124	0.909	rs6747473	chr2:20252008	C/G	cg23821541	chr2:20251993	LAPTM4A	0.39	8.23	0.31	1.02e-15	Major depressive disorder;
BRCA	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.6	-0.67	1.57e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs1568889	0.838	rs10835283	chr11:28214985	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.57	0.63	1.62e-72	Bipolar disorder;
BRCA	cis	rs9790314	0.589	rs13097130	chr3:160669279	G/A	cg03342759	chr3:160939853	NMD3	0.46	8.72	0.33	2.47e-17	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg22920501	chr2:26401640	FAM59B	0.9	16.59	0.55	1.12e-51	Gut microbiome composition (summer);
BRCA	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg02493740	chr2:85810744	VAMP5	0.55	11.44	0.41	1.06e-27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11644478	chr21:40555479	PSMG1	-0.69	-15.64	-0.53	6.64e-47	Cognitive function;
BRCA	trans	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg01620082	chr3:125678407	NA	-0.7	-8.74	-0.33	2e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg11584989	chr19:19387371	SF4	0.63	13.4	0.47	2.87e-36	Bipolar disorder;
BRCA	cis	rs7560272	0.501	rs2421676	chr2:73966087	G/A	cg20560298	chr2:73613845	ALMS1	0.34	8.58	0.32	6.99e-17	Schizophrenia;
BRCA	cis	rs7586879	0.964	rs4077679	chr2:25122852	T/C	cg01884057	chr2:25150051	NA	0.34	8.49	0.32	1.4e-16	Body mass index;
BRCA	cis	rs36051895	0.658	rs11999928	chr9:5006743	T/G	cg02405213	chr9:5042618	JAK2	-0.47	-8.78	-0.33	1.49e-17	Pediatric autoimmune diseases;
BRCA	cis	rs10463316	0.894	rs7712569	chr5:150766089	A/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.29	-0.31	6.58e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg27170947	chr2:26402098	FAM59B	-0.66	-11.62	-0.42	1.91e-28	Gut microbiome composition (summer);
BRCA	cis	rs757278	0.608	rs11767185	chr7:117345652	G/A	cg10524701	chr7:117356490	CTTNBP2	0.43	7.81	0.3	2.42e-14	Response to methotrexate in juvenile idiopathic arthritis;
BRCA	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.2e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19346786	chr7:2764209	NA	-0.28	-8.71	-0.33	2.66e-17	Height;
BRCA	cis	rs701145	0.585	rs1713822	chr3:153863505	A/G	cg17054900	chr3:154042577	DHX36	0.55	9.23	0.34	3.79e-19	Coronary artery disease;
BRCA	cis	rs2637266	0.967	rs12254242	chr10:78352934	T/C	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.29e-14	Pulmonary function;
BRCA	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg04727924	chr7:799746	HEATR2	-0.56	-11.14	-0.4	1.83e-26	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg17366294	chr4:99064904	C4orf37	0.45	10.81	0.39	3.9e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg21535247	chr6:8435926	SLC35B3	0.42	9.42	0.35	7.86e-20	Motion sickness;
BRCA	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.77	12.34	0.44	1.64e-31	Platelet count;
BRCA	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg22638593	chr5:131593259	PDLIM4	0.32	7.86	0.3	1.7e-14	Acylcarnitine levels;
BRCA	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg17366294	chr4:99064904	C4orf37	0.45	10.74	0.39	7.86e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg03560586	chr2:239334908	ASB1	0.49	10.97	0.4	9.14e-26	Multiple system atrophy;
BRCA	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg04709771	chr16:646395	RAB40C	0.44	11.32	0.41	3.33e-27	Height;
BRCA	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg08807101	chr21:30365312	RNF160	0.72	18.73	0.6	9.67e-63	Dental caries;
BRCA	cis	rs870825	0.616	rs7654208	chr4:185648877	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	11.25	0.41	6.6e-27	Personality dimensions;
BRCA	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg01689657	chr7:91764605	CYP51A1	0.23	8.32	0.31	5.27e-16	Breast cancer;
BRCA	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.81	0.3	2.43e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9831754	0.856	rs9824624	chr3:78407182	G/A	cg06138941	chr3:78371609	NA	-0.74	-15.99	-0.53	1.21e-48	Calcium levels;
BRCA	cis	rs7246657	0.551	rs10419174	chr19:37605341	A/G	cg18154014	chr19:37997991	ZNF793	0.52	8.38	0.31	3.49e-16	Coronary artery calcification;
BRCA	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg04455712	chr21:45112962	RRP1B	0.41	10.46	0.38	9.44e-24	Mean corpuscular volume;
BRCA	trans	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg21659725	chr3:3221576	CRBN	-0.45	-9.59	-0.35	1.86e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg08999081	chr20:33150536	PIGU	0.47	13.11	0.46	6.3e-35	Glomerular filtration rate (creatinine);
BRCA	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg26343298	chr8:95960752	TP53INP1	0.29	8.22	0.31	1.17e-15	Type 2 diabetes;
BRCA	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04267008	chr7:1944627	MAD1L1	0.68	15.16	0.51	1.39e-44	Bipolar disorder and schizophrenia;
BRCA	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg24977027	chr2:88469347	THNSL2	0.53	9.0	0.34	2.63e-18	Plasma clusterin levels;
BRCA	trans	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg26043149	chr18:55253948	FECH	0.36	8.0	0.3	5.96e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg03676636	chr4:99064102	C4orf37	0.22	8.04	0.3	4.24e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.58	0.32	7.01e-17	Rheumatoid arthritis;
BRCA	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-13.2	-0.46	2.48e-35	Bipolar disorder and schizophrenia;
BRCA	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg03954927	chr1:10346856	KIF1B	0.43	13.86	0.48	2.33e-38	Hepatocellular carcinoma;
BRCA	cis	rs2191566	0.614	rs396497	chr19:44494430	A/T	cg20607764	chr19:44506953	ZNF230	-0.39	-8.05	-0.3	3.99e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg08601574	chr20:25228251	PYGB	-0.35	-8.35	-0.31	4.24e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08564027	chr20:61660810	NA	0.85	22.97	0.67	1.42e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg00814883	chr7:100076585	TSC22D4	-0.48	-10.01	-0.37	5.03e-22	Platelet count;
BRCA	cis	rs17092148	0.945	rs17092080	chr20:33335657	A/G	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.31	-0.41	3.74e-27	Neuroticism;
BRCA	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg27535305	chr1:53392650	SCP2	0.32	8.07	0.3	3.4e-15	Monocyte count;
BRCA	cis	rs2464469	0.631	rs2704218	chr15:58345001	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-8.26	-0.31	8.53e-16	Barrett's esophagus  or Esophageal adenocarcinoma;
BRCA	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.41	-9.09	-0.34	1.2e-18	Personality dimensions;
BRCA	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22509189	chr2:225307070	NA	-0.43	-9.14	-0.34	8.36e-19	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.85	-0.53	5.78e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs877282	1.000	rs12775643	chr10:773242	G/A	cg17470449	chr10:769945	NA	0.49	9.32	0.35	1.83e-19	Uric acid levels;
BRCA	cis	rs6815814	0.950	rs5743566	chr4:38805942	G/C	cg02016764	chr4:38805732	TLR1	-0.61	-9.73	-0.36	5.9e-21	Breast cancer;
BRCA	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	14.7	0.5	2.49e-42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg10523679	chr1:76189770	ACADM	0.69	12.71	0.45	3.59e-33	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg15017067	chr4:17643749	FAM184B	-0.3	-8.4	-0.32	2.86e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs34779708	0.931	rs11010067	chr10:35295431	C/G	cg03585969	chr10:35415529	CREM	-0.44	-9.13	-0.34	8.67e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs1493916	0.748	rs7230463	chr18:31309133	G/C	cg15819921	chr19:927150	ARID3A	-0.41	-8.24	-0.31	9.8e-16	Life satisfaction;
BRCA	cis	rs2580764	0.678	rs2580765	chr2:55204028	A/C	cg09592903	chr2:55203963	RTN4	0.43	10.95	0.4	1.08e-25	Mean platelet volume;
BRCA	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg15017067	chr4:17643749	FAM184B	0.32	9.94	0.37	9.73e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg17063962	chr7:91808500	NA	0.57	13.5	0.47	1.01e-36	Breast cancer;
BRCA	cis	rs30380	0.587	rs469674	chr5:96130015	G/C	cg16492584	chr5:96139282	ERAP1	-0.45	-10.49	-0.38	7.32e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.91	-20.39	-0.63	1.51e-71	Lymphocyte percentage of white cells;
BRCA	cis	rs4730250	0.707	rs1981696	chr7:106794100	C/T	cg02696742	chr7:106810147	HBP1	0.51	8.41	0.32	2.68e-16	Osteoarthritis;
BRCA	trans	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg06636001	chr8:8085503	FLJ10661	0.67	15.33	0.52	2.16e-45	Mood instability;
BRCA	cis	rs7072216	0.763	rs10883092	chr10:100167276	A/C	cg26618903	chr10:100175079	PYROXD2	-0.3	-8.86	-0.33	7.61e-18	Metabolite levels;
BRCA	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg13256891	chr4:100009986	ADH5	0.54	10.01	0.37	5.06e-22	Smoking initiation;
BRCA	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg12179176	chr11:130786555	SNX19	-0.69	-17.38	-0.57	1.07e-55	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg13902645	chr11:5959945	NA	0.46	10.15	0.37	1.48e-22	DNA methylation (variation);
BRCA	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg23018236	chr17:30244563	NA	-0.66	-10.02	-0.37	4.74e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg13010199	chr12:38710504	ALG10B	0.36	8.62	0.32	5.15e-17	Morning vs. evening chronotype;
BRCA	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg15112475	chr7:1198522	ZFAND2A	-0.42	-8.18	-0.31	1.58e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg06521331	chr12:34319734	NA	-0.53	-10.6	-0.39	2.71e-24	Morning vs. evening chronotype;
BRCA	cis	rs751728	0.571	rs4713691	chr6:33790415	A/G	cg25922239	chr6:33757077	LEMD2	-0.39	-8.43	-0.32	2.21e-16	Crohn's disease;
BRCA	cis	rs12711979	0.509	rs1031478	chr2:3827425	G/A	cg17052675	chr2:3827356	NA	-0.71	-24.21	-0.69	2.14e-92	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	11.19	0.4	1.15e-26	Mean platelet volume;
BRCA	cis	rs2742234	0.590	rs2115817	chr10:43686552	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.55	-11.25	-0.41	6.37e-27	Hirschsprung disease;
BRCA	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11644478	chr21:40555479	PSMG1	0.61	9.37	0.35	1.18e-19	Cognitive function;
BRCA	cis	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.77	-0.33	1.58e-17	Resting heart rate;
BRCA	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg18252515	chr7:66147081	NA	-1.07	-15.54	-0.52	2.03e-46	Diabetic kidney disease;
BRCA	trans	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg13010199	chr12:38710504	ALG10B	0.38	8.38	0.31	3.45e-16	Morning vs. evening chronotype;
BRCA	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.57	0.39	3.57e-24	Tonsillectomy;
BRCA	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg03433033	chr1:76189801	ACADM	-0.59	-11.68	-0.42	1.1e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg00105475	chr2:10696890	NA	0.44	10.41	0.38	1.56e-23	Prostate cancer;
BRCA	cis	rs4268898	0.552	rs7560342	chr2:24371691	T/C	cg26838691	chr2:24397539	C2orf84	0.4	8.1	0.31	2.86e-15	Asthma;
BRCA	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg11822812	chr5:140052017	DND1	-0.31	-8.58	-0.32	7.38e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7520050	0.931	rs1707333	chr1:46547035	C/G	cg24296786	chr1:45957014	TESK2	0.41	9.19	0.34	5.42e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg11608241	chr8:8085544	FLJ10661	0.34	9.46	0.35	6.01e-20	Mood instability;
BRCA	cis	rs495337	0.760	rs6125830	chr20:48571662	G/A	cg17835207	chr20:48524531	SPATA2	-0.68	-16.82	-0.55	7.73e-53	Psoriasis;
BRCA	cis	rs757081	0.643	rs665311	chr11:17206740	A/T	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.58	-0.32	7.23e-17	Systolic blood pressure;
BRCA	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg24642439	chr20:33292090	TP53INP2	0.72	16.53	0.55	2.25e-51	Coronary artery disease;
BRCA	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg01884057	chr2:25150051	NA	0.34	9.22	0.34	4.2e-19	Body mass index;
BRCA	cis	rs701145	0.878	rs355753	chr3:153968846	T/C	cg17054900	chr3:154042577	DHX36	0.67	11.71	0.42	8.15e-29	Coronary artery disease;
BRCA	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg00376283	chr12:123451042	ABCB9	-0.49	-11.21	-0.41	9.52e-27	Neutrophil percentage of white cells;
BRCA	cis	rs11690935	0.550	rs62183801	chr2:172867475	G/A	cg13550731	chr2:172543902	DYNC1I2	0.49	12.11	0.43	1.55e-30	Schizophrenia;
BRCA	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg17063962	chr7:91808500	NA	0.58	13.45	0.47	1.7e-36	Breast cancer;
BRCA	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg15595755	chr5:1867978	NA	0.36	8.61	0.32	5.48e-17	Cardiovascular disease risk factors;
BRCA	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.46	0.35	5.66e-20	Morning vs. evening chronotype;
BRCA	cis	rs7246967	0.551	rs6511367	chr19:22821270	G/A	cg23217946	chr19:22817039	ZNF492	0.47	8.48	0.32	1.56e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs17604090	0.775	rs10225523	chr7:29689735	C/A	cg19413766	chr7:29689036	LOC646762	-0.51	-8.22	-0.31	1.11e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	trans	rs877282	0.583	rs11595057	chr10:819203	A/C	cg22713356	chr15:30763199	NA	0.91	14.96	0.51	1.31e-43	Uric acid levels;
BRCA	cis	rs738322	0.511	rs2267371	chr22:38577119	T/G	cg25457927	chr22:38595422	NA	-0.36	-12.04	-0.43	3.1e-30	Cutaneous nevi;
BRCA	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.12	-0.4	2.28e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg15395560	chr15:45543142	SLC28A2	0.3	8.3	0.31	6.2e-16	Uric acid levels;
BRCA	cis	rs7590368	1.000	rs17456225	chr2:10963238	C/G	cg15705551	chr2:10952987	PDIA6	0.43	8.06	0.3	3.89e-15	Educational attainment (years of education);
BRCA	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg05294307	chr14:35346193	BAZ1A	-0.6	-10.42	-0.38	1.37e-23	Psoriasis;
BRCA	cis	rs705471	0.725	rs705465	chr10:3645633	G/A	cg14308648	chr10:3568949	NA	0.4	10.26	0.38	5.85e-23	Capecitabine sensitivity;
BRCA	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-16.97	-0.56	1.31e-53	Chronic sinus infection;
BRCA	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12826209	chr6:26865740	GUSBL1	0.54	9.51	0.35	3.8e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24531977	chr5:56204891	C5orf35	-0.87	-18.47	-0.59	2.34e-61	Initial pursuit acceleration;
BRCA	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.83	0.51	5.53e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg15017067	chr4:17643749	FAM184B	0.29	8.4	0.32	2.81e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs68170813	0.559	rs3801959	chr7:106955666	A/G	cg02696742	chr7:106810147	HBP1	-0.54	-8.67	-0.32	3.66e-17	Coronary artery disease;
BRCA	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19723775	chr5:179050963	HNRNPH1	0.45	10.66	0.39	1.6e-24	Lung cancer;
BRCA	cis	rs9875589	0.957	rs1108341	chr3:13937328	T/A	cg19554555	chr3:13937349	NA	0.42	8.68	0.32	3.4e-17	Ovarian reserve;
BRCA	cis	rs16976116	0.901	rs28526269	chr15:55499190	A/G	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1975974	0.574	rs17052370	chr17:21736353	A/G	cg18423549	chr17:21743878	NA	0.65	14.33	0.49	1.43e-40	Psoriasis;
BRCA	cis	rs7640424	0.589	rs78673584	chr3:107813133	A/G	cg09227934	chr3:107805635	CD47	-0.44	-8.28	-0.31	7.14e-16	Body mass index;
BRCA	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.66	-0.32	3.86e-17	Alzheimer's disease (late onset);
BRCA	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg21770322	chr7:97807741	LMTK2	0.56	16.02	0.54	7.92e-49	Breast cancer;
BRCA	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg07148914	chr20:33460835	GGT7	0.37	8.33	0.31	5.11e-16	Height;
BRCA	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg17845761	chr1:175162550	KIAA0040	0.25	9.6	0.36	1.76e-20	Alcohol dependence;
BRCA	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.59	11.79	0.42	3.55e-29	Body mass index (adult);
BRCA	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg02153584	chr22:29168773	CCDC117	0.57	11.92	0.43	1.06e-29	Lymphocyte counts;
BRCA	cis	rs6867913	0.709	rs891987	chr5:141467196	A/T	cg08523384	chr5:141488047	NDFIP1	0.35	8.64	0.32	4.55e-17	Asthma;
BRCA	cis	rs919433	0.617	rs4850809	chr2:198583403	C/T	cg00792783	chr2:198669748	PLCL1	-0.44	-9.73	-0.36	6.06e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg13010199	chr12:38710504	ALG10B	0.44	9.28	0.34	2.55e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6543140	0.964	rs6543138	chr2:103066132	G/A	cg04239558	chr2:103089729	SLC9A4	0.34	9.58	0.35	2.16e-20	Blood protein levels;
BRCA	cis	rs7766436	0.845	rs1342207	chr6:22587762	G/A	cg13666174	chr6:22585274	NA	-0.49	-11.6	-0.42	2.25e-28	Coronary artery disease;
BRCA	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg00277334	chr10:82204260	NA	-0.85	-24.69	-0.7	5.01e-95	Post bronchodilator FEV1;
BRCA	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg09307838	chr4:120376055	NA	-0.7	-14.15	-0.49	9.19e-40	Corneal astigmatism;
BRCA	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00166722	chr3:10149974	C3orf24	0.63	13.07	0.46	9.55e-35	Alzheimer's disease;
BRCA	cis	rs7520050	0.966	rs4376778	chr1:46288846	C/G	cg24296786	chr1:45957014	TESK2	0.44	9.9	0.36	1.38e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.47	8.0	0.3	5.89e-15	HIV-1 control;
BRCA	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg11663144	chr21:46675770	NA	-0.62	-14.66	-0.5	3.53e-42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg08213375	chr14:104286397	PPP1R13B	0.4	8.68	0.32	3.17e-17	Reticulocyte count;
BRCA	cis	rs7809950	1.000	rs2520249	chr7:107146748	A/G	cg23024343	chr7:107201750	COG5	-0.39	-9.09	-0.34	1.25e-18	Coronary artery disease;
BRCA	cis	rs4920343	0.890	rs4920531	chr1:19095746	A/G	cg26220594	chr1:19110978	NA	-0.37	-7.95	-0.3	8.58e-15	Knee osteoarthritis;
BRCA	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg17063962	chr7:91808500	NA	0.52	11.82	0.42	2.65e-29	Breast cancer;
BRCA	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg15934090	chr1:100435551	SLC35A3	0.35	8.15	0.31	1.91e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg05623727	chr3:50126028	RBM5	0.43	10.1	0.37	2.4e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg02951883	chr7:2050386	MAD1L1	-0.53	-11.59	-0.42	2.6e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs3106136	0.546	rs2664881	chr4:95143484	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.07	-0.37	2.97e-22	Capecitabine sensitivity;
BRCA	trans	rs3134353	0.704	rs2386922	chr8:101975479	A/C	cg20993868	chr7:22813445	NA	-0.27	-8.22	-0.31	1.1e-15	Body mass index;
BRCA	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg15704280	chr7:45808275	SEPT13	0.63	11.25	0.41	6.26e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24531977	chr5:56204891	C5orf35	-0.86	-18.56	-0.59	8.34e-62	Initial pursuit acceleration;
BRCA	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.55	-0.35	2.8e-20	Tonsillectomy;
BRCA	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.07	0.37	3.07e-22	Bipolar disorder;
BRCA	cis	rs8114671	0.933	rs6087683	chr20:33774444	C/T	cg07148914	chr20:33460835	GGT7	0.37	7.92	0.3	1.08e-14	Height;
BRCA	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-10.57	-0.39	3.71e-24	Bladder cancer;
BRCA	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg13902645	chr11:5959945	NA	-0.56	-11.45	-0.41	9.81e-28	DNA methylation (variation);
BRCA	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg16850897	chr7:100343110	ZAN	-0.57	-10.63	-0.39	2.09e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs3824344	0.507	rs2297105	chr9:37020622	A/C	cg14294708	chr9:37120828	ZCCHC7	-0.42	-8.41	-0.32	2.7e-16	Intelligence;
BRCA	cis	rs13053817	1.000	rs13340033	chr22:29846339	A/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.48	-10.06	-0.37	3.34e-22	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	13.2	0.46	2.36e-35	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs3857536	0.813	rs7757118	chr6:66946661	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	2.02e-14	Blood trace element (Cu levels);
BRCA	cis	rs11603020	0.950	rs3824988	chr11:57377968	C/T	cg19752551	chr11:57585705	CTNND1	0.42	9.86	0.36	1.89e-21	Blood protein levels;
BRCA	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg23029597	chr12:123009494	RSRC2	-0.6	-12.45	-0.44	5.12e-32	Body mass index;
BRCA	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg09035930	chr12:129282057	SLC15A4	0.53	15.21	0.52	8.15e-45	Systemic lupus erythematosus;
BRCA	cis	rs11997175	0.545	rs66783231	chr8:33811467	A/T	ch.8.33884649F	chr8:33765107	NA	0.36	8.52	0.32	1.15e-16	Body mass index;
BRCA	cis	rs10242455	0.702	rs73403290	chr7:99157828	C/T	cg18809830	chr7:99032528	PTCD1	-0.61	-8.49	-0.32	1.42e-16	Blood metabolite levels;
BRCA	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24308560	chr3:49941425	MST1R	0.4	8.43	0.32	2.33e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19346786	chr7:2764209	NA	-0.33	-9.67	-0.36	9.83e-21	Height;
BRCA	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18876405	chr7:65276391	NA	-0.56	-13.35	-0.47	5.16e-36	Aortic root size;
BRCA	cis	rs835154	1.000	rs835154	chr5:14876569	A/G	cg18064842	chr5:14874549	NA	0.4	10.3	0.38	4e-23	Blood metabolite levels;
BRCA	cis	rs3784262	0.528	rs8027964	chr15:58335272	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-9.89	-0.36	1.54e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg16103275	chr6:290800	DUSP22	-0.46	-10.13	-0.37	1.78e-22	Menopause (age at onset);
BRCA	cis	rs78487399	0.908	rs57066469	chr2:43843813	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-7.95	-0.3	8.73e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg05347473	chr6:146136440	FBXO30	0.6	11.7	0.42	8.29e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg24130564	chr14:104152367	KLC1	0.35	7.98	0.3	6.97e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg24642439	chr20:33292090	TP53INP2	0.54	11.61	0.42	2e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg08601574	chr20:25228251	PYGB	0.32	7.83	0.3	2.11e-14	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg17691542	chr6:26056736	HIST1H1C	0.47	9.74	0.36	5.38e-21	Height;
BRCA	cis	rs9473147	0.571	rs9395285	chr6:47554177	G/A	cg12968598	chr6:47444699	CD2AP	0.46	9.88	0.36	1.62e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.56	-0.32	8.13e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs965469	1.000	rs6051745	chr20:3307243	T/G	cg25506879	chr20:3388711	C20orf194	-0.54	-10.53	-0.38	4.92e-24	IFN-related cytopenia;
BRCA	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	ch.11.42038R	chr11:967971	AP2A2	0.57	18.41	0.59	4.76e-61	Alzheimer's disease (late onset);
BRCA	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg27535305	chr1:53392650	SCP2	0.46	11.22	0.41	8.44e-27	Monocyte count;
BRCA	cis	rs7264396	0.563	rs7264869	chr20:34346502	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.66	-0.42	1.25e-28	Total cholesterol levels;
BRCA	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg18154014	chr19:37997991	ZNF793	0.49	9.56	0.35	2.42e-20	Coronary artery calcification;
BRCA	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg17507749	chr15:85114479	UBE2QP1	0.5	8.44	0.32	2.09e-16	Schizophrenia;
BRCA	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.46	-0.38	9.46e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg11764359	chr7:65958608	NA	-0.64	-11.27	-0.41	5.23e-27	Aortic root size;
BRCA	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25427524	chr10:38739819	LOC399744	-0.69	-16.72	-0.55	2.55e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2637030	0.533	rs7731940	chr5:52863638	A/T	cg06476337	chr5:52856530	NDUFS4	0.35	7.92	0.3	1.05e-14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg14926445	chr8:58193284	C8orf71	-0.46	-8.88	-0.33	6.81e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg07803811	chr1:43423981	SLC2A1	0.42	8.98	0.33	3.1e-18	Red cell distribution width;
BRCA	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg27490568	chr2:178487706	NA	-0.54	-7.89	-0.3	1.3e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs17023223	0.537	rs12083510	chr1:119746620	T/G	cg05756136	chr1:119680316	WARS2	-0.41	-7.87	-0.3	1.51e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs12200560	0.505	rs211167	chr6:97069087	T/A	cg06623918	chr6:96969491	KIAA0776	0.51	12.12	0.43	1.44e-30	Coronary heart disease;
BRCA	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg23711669	chr6:146136114	FBXO30	0.77	17.59	0.57	8.37e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12545109	0.879	rs2670015	chr8:57376607	T/A	cg09654669	chr8:57350985	NA	-0.46	-8.69	-0.33	3.08e-17	Obesity-related traits;
BRCA	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg11663144	chr21:46675770	NA	-0.53	-12.53	-0.44	2.4e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg23762105	chr12:34175262	ALG10	0.35	8.3	0.31	6.43e-16	Morning vs. evening chronotype;
BRCA	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg27478167	chr7:817139	HEATR2	-0.42	-9.01	-0.34	2.28e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.16	-0.4	1.55e-26	Schizophrenia;
BRCA	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg08999081	chr20:33150536	PIGU	0.34	8.66	0.32	3.71e-17	Coronary artery disease;
BRCA	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-11.01	-0.4	6.33e-26	Monocyte percentage of white cells;
BRCA	cis	rs3845702	0.736	rs72960664	chr2:180832672	C/T	cg01881094	chr2:180872142	CWC22	1.01	16.69	0.55	3.51e-52	Schizophrenia;
BRCA	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg22467129	chr15:76604101	ETFA	-0.47	-10.15	-0.37	1.57e-22	Blood metabolite levels;
BRCA	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg27433088	chr4:174089019	GALNT7	-0.33	-8.3	-0.31	6.34e-16	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24110177	chr3:50126178	RBM5	-0.4	-10.91	-0.4	1.54e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg12573674	chr2:1569213	NA	-0.58	-12.23	-0.44	4.78e-31	IgG glycosylation;
BRCA	cis	rs870825	0.616	rs6814278	chr4:185644417	G/C	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.54	10.46	0.38	9.97e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1557765	0.527	rs2018218	chr11:17390855	A/G	cg15432903	chr11:17409602	KCNJ11	0.4	8.7	0.33	2.72e-17	Body mass index;Social communication problems;
BRCA	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg08917208	chr2:24149416	ATAD2B	0.52	8.07	0.3	3.37e-15	Lymphocyte counts;
BRCA	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg06627628	chr2:24431161	ITSN2	-0.54	-8.89	-0.33	6.17e-18	Lymphocyte counts;
BRCA	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.34	-0.44	1.64e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg12927641	chr6:109611667	NA	-0.39	-9.78	-0.36	3.85e-21	Reticulocyte fraction of red cells;
BRCA	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg07080220	chr10:102295463	HIF1AN	0.63	13.39	0.47	3.18e-36	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg06212747	chr3:49208901	KLHDC8B	0.48	9.61	0.36	1.57e-20	Parkinson's disease;
BRCA	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg25237894	chr2:233734115	C2orf82	0.4	11.52	0.41	4.8e-28	Coronary artery disease;
BRCA	cis	rs9790314	0.663	rs6804650	chr3:160648953	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-8.27	-0.31	8.02e-16	Morning vs. evening chronotype;
BRCA	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.06	-0.34	1.62e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg05347473	chr6:146136440	FBXO30	0.61	12.02	0.43	3.84e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg04455712	chr21:45112962	RRP1B	0.41	10.45	0.38	1.05e-23	Mean corpuscular volume;
BRCA	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg10495392	chr1:46806563	NSUN4	0.45	8.34	0.31	4.65e-16	Menopause (age at onset);
BRCA	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg22875332	chr1:76189707	ACADM	0.68	14.74	0.5	1.52e-42	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg03060546	chr3:49711283	APEH	0.6	10.31	0.38	3.56e-23	Menarche (age at onset);
BRCA	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg04492858	chr10:133558786	NA	-0.34	-8.02	-0.3	5.17e-15	Survival in rectal cancer;
BRCA	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg03676636	chr4:99064102	C4orf37	0.2	7.87	0.3	1.47e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24308560	chr3:49941425	MST1R	-0.39	-8.1	-0.31	2.85e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6545883	0.859	rs2600661	chr2:61543081	T/C	cg15711740	chr2:61764176	XPO1	0.52	13.19	0.46	2.62e-35	Tuberculosis;
BRCA	cis	rs9290065	0.538	rs9860182	chr3:160768962	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-10.61	-0.39	2.51e-24	Kawasaki disease;
BRCA	trans	rs8002861	0.902	rs1445557	chr13:44464827	C/T	cg17145862	chr1:211918768	LPGAT1	0.73	19.6	0.61	2.35e-67	Leprosy;
BRCA	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg06115741	chr20:33292138	TP53INP2	-0.37	-8.23	-0.31	1.04e-15	Glomerular filtration rate (creatinine);
BRCA	trans	rs6479891	1.000	rs63749191	chr10:65119887	T/C	cg14819942	chr15:35414228	NA	0.34	8.27	0.31	7.58e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg25237894	chr2:233734115	C2orf82	0.39	11.23	0.41	8.1e-27	Coronary artery disease;
BRCA	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg24069376	chr3:38537580	EXOG	-0.33	-9.43	-0.35	7.59e-20	Electrocardiographic conduction measures;
BRCA	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg13047869	chr3:10149882	C3orf24	0.59	12.55	0.44	1.94e-32	Alzheimer's disease;
BRCA	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg12927641	chr6:109611667	NA	-0.42	-10.97	-0.4	8.93e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	12.23	0.44	4.9e-31	Monocyte percentage of white cells;
BRCA	cis	rs7091068	0.518	rs9633674	chr10:95455431	C/T	cg20715218	chr10:95462985	C10orf4	0.47	9.86	0.36	1.88e-21	Urinary tract infection frequency;
BRCA	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg18154014	chr19:37997991	ZNF793	0.62	11.63	0.42	1.7e-28	Coronary artery calcification;
BRCA	cis	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg07460842	chr6:66804631	NA	0.64	13.82	0.48	3.46e-38	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg05313129	chr8:58192883	C8orf71	-0.44	-9.5	-0.35	4.13e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg06064525	chr11:970664	AP2A2	-0.48	-16.02	-0.54	7.9e-49	Alzheimer's disease (late onset);
BRCA	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	17.08	0.56	3.87e-54	Colorectal cancer;
BRCA	cis	rs36051895	0.659	rs7025540	chr9:5043152	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-9.18	-0.34	5.99e-19	Pediatric autoimmune diseases;
BRCA	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-11.47	-0.41	8.32e-28	Total cholesterol levels;
BRCA	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg22491629	chr6:157744540	C6orf35	-0.64	-11.71	-0.42	7.75e-29	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.59	0.35	1.97e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.35	7.86	0.3	1.68e-14	Platelet count;
BRCA	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg13010199	chr12:38710504	ALG10B	0.51	10.06	0.37	3.42e-22	Morning vs. evening chronotype;
BRCA	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs7301826	0.627	rs61937256	chr12:131302645	G/A	cg11011512	chr12:131303247	STX2	-0.45	-11.23	-0.41	8.14e-27	Plasma plasminogen activator levels;
BRCA	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg23711669	chr6:146136114	FBXO30	0.77	17.96	0.58	1.11e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg23602478	chr1:26503979	CNKSR1	-0.23	-8.06	-0.3	3.85e-15	Height;
BRCA	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg05896524	chr21:47604654	C21orf56	0.47	9.53	0.35	3.26e-20	Testicular germ cell tumor;
BRCA	trans	rs6600671	1.000	rs4844381	chr1:121184898	C/T	cg17023122	chr1:144479586	NA	0.33	7.97	0.3	7.25e-15	Hip geometry;
BRCA	cis	rs2645424	0.666	rs2272767	chr8:11711059	C/T	cg21281001	chr8:11725306	CTSB	0.4	8.0	0.3	5.85e-15	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
BRCA	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg08859206	chr1:53392774	SCP2	-0.39	-8.19	-0.31	1.43e-15	Monocyte count;
BRCA	trans	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.45	-8.37	-0.31	3.62e-16	Monocyte count;
BRCA	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg08422745	chr4:174089978	GALNT7	-0.8	-18.39	-0.59	6.03e-61	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg17507749	chr15:85114479	UBE2QP1	0.55	8.93	0.33	4.42e-18	Schizophrenia;
BRCA	cis	rs7524258	0.868	rs4908448	chr1:7269283	A/G	cg07173049	chr1:7289937	CAMTA1	-0.37	-9.12	-0.34	9.56e-19	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs367615	0.918	rs17161895	chr5:108855831	T/G	cg17395555	chr5:108820864	NA	0.36	9.48	0.35	5.09e-20	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs12545109	0.842	rs2670050	chr8:57402914	T/G	cg09654669	chr8:57350985	NA	-0.38	-7.87	-0.3	1.47e-14	Obesity-related traits;
BRCA	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg03342759	chr3:160939853	NMD3	0.63	14.1	0.49	1.66e-39	Morning vs. evening chronotype;
BRCA	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-9.61	-0.36	1.64e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.48	-10.28	-0.38	4.77e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg24558204	chr6:135376177	HBS1L	0.59	16.22	0.54	8.81e-50	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs208520	0.874	rs208491	chr6:66928459	C/G	cg07460842	chr6:66804631	NA	-0.9	-15.72	-0.53	2.51e-47	Exhaled nitric oxide output;
BRCA	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg22963979	chr7:1858916	MAD1L1	-0.47	-9.46	-0.35	5.78e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs10193935	0.901	rs13429697	chr2:42529818	C/T	cg27598129	chr2:42591480	NA	-0.95	-14.96	-0.51	1.33e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2882667	0.690	rs825677	chr5:138104770	T/C	cg04439458	chr5:138467593	SIL1	0.34	8.47	0.32	1.74e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg05347473	chr6:146136440	FBXO30	0.41	8.16	0.31	1.82e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg21017887	chr14:105400489	NA	0.65	17.16	0.56	1.41e-54	Rheumatoid arthritis;
BRCA	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg07741184	chr6:167504864	NA	0.36	10.4	0.38	1.6e-23	Crohn's disease;
BRCA	trans	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg06521331	chr12:34319734	NA	-0.47	-8.88	-0.33	6.98e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg24069376	chr3:38537580	EXOG	0.42	12.07	0.43	2.24e-30	Electrocardiographic conduction measures;
BRCA	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg02574844	chr11:5959923	NA	-0.43	-8.48	-0.32	1.58e-16	DNA methylation (variation);
BRCA	cis	rs17253792	0.822	rs76555508	chr14:56071868	A/G	cg01858014	chr14:56050164	KTN1	-0.78	-11.08	-0.4	3.12e-26	Putamen volume;
BRCA	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg11502198	chr6:26597334	ABT1	0.57	12.14	0.43	1.21e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg20701182	chr2:24300061	SF3B14	0.59	9.19	0.34	5.66e-19	Lymphocyte counts;
BRCA	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.15	-48.94	-0.89	2.43e-218	Myeloid white cell count;
BRCA	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg11845111	chr2:191398756	TMEM194B	-0.79	-15.17	-0.51	1.28e-44	Diastolic blood pressure;
BRCA	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg22920501	chr2:26401640	FAM59B	-0.61	-10.7	-0.39	1.04e-24	Gut microbiome composition (summer);
BRCA	cis	rs13095912	1.000	rs10937226	chr3:185302885	G/A	cg11274856	chr3:185301563	NA	0.35	8.76	0.33	1.71e-17	Systolic blood pressure;
BRCA	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg15212455	chr7:39170539	POU6F2	0.43	9.59	0.35	1.87e-20	IgG glycosylation;
BRCA	cis	rs6835098	0.887	rs12644699	chr4:174142874	A/G	cg08422745	chr4:174089978	GALNT7	0.71	13.03	0.46	1.45e-34	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg08470875	chr2:26401718	FAM59B	-0.54	-8.24	-0.31	9.97e-16	Gut microbiome composition (summer);
BRCA	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg04691961	chr3:161091175	C3orf57	-0.58	-15.09	-0.51	3.29e-44	Morning vs. evening chronotype;
BRCA	trans	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg19862616	chr7:65841803	NCRNA00174	0.77	23.53	0.68	1.2e-88	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs73086581	1.000	rs6052196	chr20:3945824	T/C	cg02187196	chr20:3869020	PANK2	0.51	9.28	0.34	2.51e-19	Response to antidepressants in depression;
BRCA	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26314531	chr2:26401878	FAM59B	-0.66	-11.29	-0.41	4.42e-27	Gut microbiome composition (summer);
BRCA	trans	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.94	0.3	9.3e-15	Corneal astigmatism;
BRCA	cis	rs758324	0.947	rs72793242	chr5:131242506	A/T	cg06307176	chr5:131281290	NA	-0.53	-10.34	-0.38	2.79e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs7020830	0.858	rs1492714	chr9:37141259	T/C	cg14294708	chr9:37120828	ZCCHC7	1.18	42.51	0.86	1.97e-188	Schizophrenia;
BRCA	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg03342759	chr3:160939853	NMD3	-0.69	-13.47	-0.47	1.4e-36	Parkinson's disease;
BRCA	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg14683738	chr19:37701593	ZNF585B	0.46	8.12	0.31	2.48e-15	Coronary artery calcification;
BRCA	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.33	-8.44	-0.32	2.09e-16	Total body bone mineral density;
BRCA	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg13397359	chr6:42928475	GNMT	0.68	16.37	0.54	1.42e-50	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6496044	0.568	rs1982743	chr15:86068759	A/T	cg10818794	chr15:86012489	AKAP13	-0.29	-8.05	-0.3	4.19e-15	Interstitial lung disease;
BRCA	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-9.11	-0.34	1.03e-18	Joint mobility (Beighton score);
BRCA	cis	rs7124681	0.565	rs2904127	chr11:47817290	A/G	cg20307385	chr11:47447363	PSMC3	0.41	9.4	0.35	9.67e-20	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs7246967	0.604	rs58653025	chr19:22941617	T/C	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg05340658	chr4:99064831	C4orf37	0.69	17.54	0.57	1.68e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg06484146	chr7:12443880	VWDE	-0.75	-10.82	-0.39	3.54e-25	Coronary artery disease;
BRCA	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.15	-0.34	7.46e-19	Electroencephalogram traits;
BRCA	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-13.56	-0.47	5.62e-37	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.89	-0.33	6.26e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9329289	0.510	rs35854428	chr10:2554280	T/C	cg15501526	chr10:2543763	NA	0.42	9.82	0.36	2.64e-21	Age-related hearing impairment;
BRCA	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-13.69	-0.48	1.38e-37	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs11971779	0.648	rs66463279	chr7:139118661	A/G	cg07862535	chr7:139043722	LUC7L2	0.39	10.38	0.38	2.02e-23	Diisocyanate-induced asthma;
BRCA	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg16141378	chr3:129829833	LOC729375	-0.33	-8.3	-0.31	6.01e-16	Mood instability;
BRCA	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg05665937	chr4:1216051	CTBP1	0.42	8.22	0.31	1.12e-15	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg12193833	chr17:30244370	NA	-0.61	-10.08	-0.37	2.9e-22	Hip circumference adjusted for BMI;
BRCA	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg26384229	chr12:38710491	ALG10B	0.67	14.13	0.49	1.25e-39	Morning vs. evening chronotype;
BRCA	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg15556689	chr8:8085844	FLJ10661	-0.34	-8.76	-0.33	1.73e-17	Triglycerides;
BRCA	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg14019146	chr3:50243930	SLC38A3	-0.45	-10.94	-0.4	1.24e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.53	0.57	1.71e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	13.75	0.48	7.49e-38	Personality dimensions;
BRCA	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.53	-0.61	5.8e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg12000995	chr2:27665139	KRTCAP3	-0.31	-7.81	-0.3	2.35e-14	Total body bone mineral density;
BRCA	cis	rs7520050	0.933	rs6694340	chr1:46289416	C/T	cg24296786	chr1:45957014	TESK2	0.41	9.34	0.35	1.55e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg05283184	chr6:79620031	NA	-0.42	-10.82	-0.39	3.57e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18876405	chr7:65276391	NA	-0.51	-11.65	-0.42	1.36e-28	Aortic root size;
BRCA	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg02297831	chr4:17616191	MED28	0.37	8.61	0.32	5.47e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg17063962	chr7:91808500	NA	0.55	12.6	0.45	1.13e-32	Breast cancer;
BRCA	cis	rs13394619	0.744	rs10929759	chr2:11722012	C/G	cg07314298	chr2:11723111	GREB1	0.56	13.31	0.47	7.12e-36	Endometriosis;
BRCA	cis	rs6878727	0.850	rs12658088	chr5:123719448	T/C	cg01806427	chr5:123737813	NA	0.41	9.52	0.35	3.36e-20	Breast cancer;
BRCA	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg12473912	chr3:136751656	NA	0.51	12.1	0.43	1.74e-30	Schizophrenia;
BRCA	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06022373	chr22:39101656	GTPBP1	-0.62	-15.23	-0.52	6.37e-45	Menopause (age at onset);
BRCA	cis	rs858239	0.806	rs10268610	chr7:23274764	A/G	cg23682824	chr7:23144976	KLHL7	0.36	9.06	0.34	1.62e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg09537434	chr19:41945824	ATP5SL	-1.01	-25.27	-0.71	3.37e-98	Height;
BRCA	cis	rs1499972	0.941	rs2860308	chr3:117690309	T/G	cg07612923	chr3:117604196	NA	-0.6	-8.14	-0.31	2.14e-15	Schizophrenia;
BRCA	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg20587970	chr11:113659929	NA	-0.96	-18.65	-0.59	2.81e-62	Hip circumference adjusted for BMI;
BRCA	cis	rs921968	0.565	rs35189512	chr2:219628759	T/C	cg02176678	chr2:219576539	TTLL4	-0.42	-11.2	-0.41	1e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08109568	chr15:31115862	NA	-0.42	-10.33	-0.38	3.13e-23	Huntington's disease progression;
BRCA	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg02153584	chr22:29168773	CCDC117	0.52	10.8	0.39	4.39e-25	Lymphocyte counts;
BRCA	cis	rs2839186	0.565	rs2839183	chr21:47687144	G/A	cg12379764	chr21:47803548	PCNT	0.58	13.39	0.47	3.15e-36	Testicular germ cell tumor;
BRCA	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg16482183	chr6:26056742	HIST1H1C	0.44	9.2	0.34	4.91e-19	Iron status biomarkers;
BRCA	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.59	-0.32	6.57e-17	Monocyte percentage of white cells;
BRCA	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.75	-0.53	1.83e-47	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg18811423	chr2:55921094	PNPT1	0.72	23.04	0.67	5.41e-86	Metabolic syndrome;
BRCA	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg04025307	chr7:1156635	C7orf50	0.59	9.36	0.35	1.38e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg11266682	chr4:10021025	SLC2A9	0.45	11.98	0.43	5.43e-30	Bone mineral density;
BRCA	cis	rs12950390	1.000	rs8068453	chr17:45852354	A/G	cg03474202	chr17:45855739	NA	0.42	9.86	0.36	1.94e-21	IgG glycosylation;
BRCA	cis	rs34779708	0.966	rs12257770	chr10:35517234	A/G	cg03585969	chr10:35415529	CREM	0.45	9.47	0.35	5.2e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.5	-11.81	-0.42	3e-29	Breast cancer;
BRCA	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg15819921	chr19:927150	ARID3A	-0.51	-9.72	-0.36	6.6e-21	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg20387954	chr3:183756860	HTR3D	0.45	10.19	0.37	1.04e-22	Anterior chamber depth;
BRCA	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	9.92	0.37	1.18e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg21545522	chr1:205238299	TMCC2	0.4	8.3	0.31	6.2e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg22920501	chr2:26401640	FAM59B	-0.65	-11.32	-0.41	3.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg20307385	chr11:47447363	PSMC3	-0.42	-8.93	-0.33	4.38e-18	Subjective well-being;
BRCA	cis	rs3820928	0.839	rs12151848	chr2:227859326	G/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.3	-0.31	6e-16	Pulmonary function;
BRCA	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg07537917	chr2:241836409	C2orf54	-0.55	-13.81	-0.48	3.78e-38	Urinary metabolites;
BRCA	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg23708337	chr7:1209742	NA	0.51	8.73	0.33	2.26e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs2018683	0.707	rs4719961	chr7:28969513	C/T	cg19402173	chr7:128379420	CALU	-0.44	-10.5	-0.38	6.62e-24	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26314531	chr2:26401878	FAM59B	-0.66	-11.25	-0.41	6.5e-27	Gut microbiome composition (summer);
BRCA	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg22713356	chr15:30763199	NA	1.31	24.8	0.7	1.26e-95	Uric acid levels;
BRCA	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg22903471	chr2:27725779	GCKR	-0.36	-8.65	-0.32	4e-17	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.59	9.31	0.35	2.05e-19	Renal function-related traits (BUN);
BRCA	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg14820908	chr5:178986412	RUFY1	0.46	11.99	0.43	5.14e-30	Lung cancer;
BRCA	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg13010199	chr12:38710504	ALG10B	0.43	9.11	0.34	1.03e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4975616	0.773	rs10078017	chr5:1314009	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.44	-10.27	-0.38	5.38e-23	Lung cancer;
BRCA	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg14530993	chr4:882597	GAK	0.51	8.72	0.33	2.44e-17	Parkinson's disease;
BRCA	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg25801113	chr15:45476975	SHF	0.31	7.83	0.3	2e-14	Uric acid levels;
BRCA	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.72	-16.56	-0.55	1.54e-51	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg23649088	chr2:200775458	C2orf69	0.58	8.56	0.32	8.56e-17	Schizophrenia;
BRCA	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.0	-0.46	1.92e-34	Migraine;Coronary artery disease;
BRCA	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.38	-0.31	3.39e-16	Colorectal cancer;
BRCA	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg14019146	chr3:50243930	SLC38A3	0.43	10.41	0.38	1.54e-23	Body mass index;
BRCA	cis	rs7715811	1.000	rs6554814	chr5:13774231	T/A	cg07548982	chr5:13769939	DNAH5	-0.4	-9.03	-0.34	2.02e-18	Subclinical atherosclerosis traits (other);
BRCA	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg12219531	chr12:120966889	COQ5	0.54	11.19	0.4	1.16e-26	High light scatter reticulocyte count;
BRCA	cis	rs6893300	0.785	rs17617710	chr5:179206107	G/A	cg14593053	chr5:179126677	CANX	-0.36	-8.02	-0.3	4.9e-15	Resting heart rate;
BRCA	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg11062466	chr8:58055876	NA	0.52	8.74	0.33	2.01e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs12612619	0.732	rs1866655	chr2:27208867	A/T	cg00617064	chr2:27272375	NA	0.3	7.83	0.3	1.99e-14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg05985134	chr18:33552581	C18orf21	0.67	12.83	0.45	1.1e-33	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg14926445	chr8:58193284	C8orf71	-0.46	-8.83	-0.33	1.01e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6430549	0.518	rs41521049	chr2:135693069	G/A	cg15893373	chr2:135677154	CCNT2	-0.29	-7.85	-0.3	1.78e-14	Hematocrit;
BRCA	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg02659138	chr7:134003124	SLC35B4	0.4	11.65	0.42	1.45e-28	Mean platelet volume;
BRCA	trans	rs783540	0.967	rs783526	chr15:83285795	C/A	cg18393722	chr15:85113863	UBE2QP1	-0.27	-8.36	-0.31	4.05e-16	Schizophrenia;
BRCA	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.6	-0.42	2.3e-28	Mean corpuscular volume;
BRCA	cis	rs11971779	0.715	rs11772771	chr7:139058803	T/C	cg07862535	chr7:139043722	LUC7L2	0.4	10.97	0.4	9e-26	Diisocyanate-induced asthma;
BRCA	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg22705602	chr4:152727874	NA	-0.31	-8.06	-0.3	3.68e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.73	-0.33	2.15e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg04517722	chr19:17905589	B3GNT3	0.43	8.46	0.32	1.85e-16	Tumor biomarkers;
BRCA	cis	rs36051895	0.695	rs10815147	chr9:5016145	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-8.33	-0.31	4.8e-16	Pediatric autoimmune diseases;
BRCA	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg01579765	chr21:45077557	HSF2BP	-0.45	-12.77	-0.45	2.01e-33	Mean corpuscular volume;
BRCA	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg24450063	chr1:156163899	SLC25A44	0.93	18.27	0.59	2.48e-60	Testicular germ cell tumor;
BRCA	trans	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg25214090	chr10:38739885	LOC399744	-0.53	-11.23	-0.41	7.74e-27	Corneal astigmatism;
BRCA	trans	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg25214090	chr10:38739885	LOC399744	0.36	8.37	0.31	3.73e-16	Diastolic blood pressure;
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg20007245	chr22:24372913	LOC391322	-0.8	-19.94	-0.62	3.72e-69	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg23711669	chr6:146136114	FBXO30	-0.75	-17.43	-0.57	5.61e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24229701	chr12:130821962	PIWIL1	0.39	8.89	0.33	6.08e-18	Menopause (age at onset);
BRCA	cis	rs26949	0.511	rs1562235	chr5:59877538	T/G	cg02684056	chr5:59996105	DEPDC1B	0.4	9.57	0.35	2.34e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg23719950	chr11:63933701	MACROD1	-0.58	-9.62	-0.36	1.48e-20	Mean platelet volume;
BRCA	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.12	-0.43	1.38e-30	Total cholesterol levels;
BRCA	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg12193833	chr17:30244370	NA	-0.55	-8.62	-0.32	5.43e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.81	0.33	1.2e-17	Iron status biomarkers;
BRCA	cis	rs2279817	0.863	rs12749985	chr1:18026004	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.49	-15.59	-0.52	1.13e-46	Neuroticism;
BRCA	cis	rs6120849	0.754	rs8501	chr20:33590584	T/C	cg24642439	chr20:33292090	TP53INP2	0.58	10.12	0.37	1.91e-22	Protein C levels;
BRCA	cis	rs7590720	0.531	rs6435932	chr2:216906030	T/C	cg12620499	chr2:216877984	MREG	0.51	12.56	0.44	1.72e-32	Alcohol dependence;
BRCA	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg16586182	chr3:47516702	SCAP	0.53	11.54	0.42	3.94e-28	Colorectal cancer;
BRCA	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg00321850	chr1:175162397	KIAA0040	0.43	12.3	0.44	2.24e-31	Alcohol dependence;
BRCA	cis	rs9290065	0.622	rs11705811	chr3:160643787	C/T	cg03342759	chr3:160939853	NMD3	-0.38	-7.97	-0.3	7.16e-15	Kawasaki disease;
BRCA	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg20203395	chr5:56204925	C5orf35	0.38	8.67	0.32	3.6e-17	Initial pursuit acceleration;
BRCA	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.38	7.82	0.3	2.19e-14	Alzheimer's disease (late onset);
BRCA	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg03684893	chr10:554711	DIP2C	0.39	9.14	0.34	8.08e-19	Psychosis in Alzheimer's disease;
BRCA	cis	rs7903847	0.642	rs10882914	chr10:99142057	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.66	-0.32	3.88e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.58	13.44	0.47	1.88e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2625529	0.590	rs12442886	chr15:72473611	T/C	cg16672083	chr15:72433130	SENP8	0.67	15.2	0.52	9e-45	Red blood cell count;
BRCA	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg09165964	chr15:75287851	SCAMP5	-0.85	-20.27	-0.63	6.12e-71	Blood trace element (Zn levels);
BRCA	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg26384229	chr12:38710491	ALG10B	0.76	17.04	0.56	6.16e-54	Morning vs. evening chronotype;
BRCA	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg27398817	chr8:82754497	SNX16	-0.35	-8.05	-0.3	4.1e-15	Diastolic blood pressure;
BRCA	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg02527881	chr3:46936655	PTH1R	-0.36	-8.35	-0.31	4.17e-16	Birth weight;
BRCA	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg06115741	chr20:33292138	TP53INP2	-0.37	-8.15	-0.31	1.9e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg11901034	chr3:128598214	ACAD9	-0.36	-8.83	-0.33	9.67e-18	IgG glycosylation;
BRCA	cis	rs698833	0.501	rs35347977	chr2:44506921	C/T	cg04920474	chr2:44395004	PPM1B	0.38	8.89	0.33	5.99e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs360798	0.512	rs2710640	chr2:63144305	A/G	cg17519650	chr2:63277830	OTX1	0.37	8.28	0.31	7.2e-16	Coronary artery disease;
BRCA	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg24549020	chr5:56110836	MAP3K1	0.52	10.66	0.39	1.55e-24	Type 2 diabetes;
BRCA	cis	rs911119	1.000	rs34374560	chr20:23609462	C/T	cg16589663	chr20:23618590	CST3	0.45	8.5	0.32	1.35e-16	Chronic kidney disease;
BRCA	cis	rs11229555	0.645	rs11229549	chr11:58395914	T/C	cg15696309	chr11:58395628	NA	-0.49	-9.65	-0.36	1.15e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg12591125	chr7:1885375	MAD1L1	-0.48	-8.67	-0.32	3.42e-17	Bipolar disorder;
BRCA	cis	rs4321325	0.546	rs11886766	chr2:127948621	G/A	cg11380483	chr2:127933992	NA	0.43	8.81	0.33	1.14e-17	Protein C levels;
BRCA	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.67	14.68	0.5	2.88e-42	Chronic sinus infection;
BRCA	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg09640425	chr7:158790006	NA	-0.37	-7.89	-0.3	1.35e-14	Facial morphology (factor 20);
BRCA	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.57	9.77	0.36	4.08e-21	Mean corpuscular hemoglobin;
BRCA	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg08888203	chr3:10149979	C3orf24	0.67	14.48	0.5	2.56e-41	Alzheimer's disease;
BRCA	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg23711669	chr6:146136114	FBXO30	0.79	18.99	0.6	4.44e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.36e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg22491629	chr6:157744540	C6orf35	-0.65	-11.64	-0.42	1.62e-28	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg02659138	chr7:134003124	SLC35B4	0.34	10.72	0.39	9.27e-25	Mean platelet volume;
BRCA	cis	rs72634258	0.554	rs12745962	chr1:7919825	C/T	cg26816564	chr1:7831052	VAMP3	0.54	10.53	0.38	5.3e-24	Inflammatory bowel disease;
BRCA	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg05340658	chr4:99064831	C4orf37	0.49	10.82	0.39	3.73e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18876405	chr7:65276391	NA	0.44	8.6	0.32	6.13e-17	Corneal structure;
BRCA	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22455342	chr2:225449267	CUL3	0.68	16.82	0.55	7.71e-53	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs7809950	0.954	rs2520245	chr7:107137428	G/C	cg23024343	chr7:107201750	COG5	-0.42	-9.55	-0.35	2.73e-20	Coronary artery disease;
BRCA	cis	rs887829	0.694	rs6749496	chr2:234624286	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.38	-9.63	-0.36	1.4e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg14582100	chr15:45693742	SPATA5L1	0.38	11.8	0.42	3.22e-29	Homoarginine levels;
BRCA	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg25457927	chr22:38595422	NA	-0.31	-11.81	-0.42	3.02e-29	Cutaneous nevi;
BRCA	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg11663144	chr21:46675770	NA	-0.6	-13.81	-0.48	3.58e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4664304	0.620	rs10929956	chr2:160714615	C/T	cg18514922	chr2:160761262	LY75	0.34	7.97	0.3	7.35e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.62	-16.51	-0.55	2.75e-51	Colorectal cancer;
BRCA	cis	rs4285028	0.747	rs1463736	chr3:121400725	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-13.85	-0.48	2.53e-38	Multiple sclerosis;
BRCA	cis	rs7927771	0.524	rs754434	chr11:47814280	A/G	cg20307385	chr11:47447363	PSMC3	0.41	9.34	0.35	1.54e-19	Subjective well-being;
BRCA	cis	rs4919694	0.901	rs113541728	chr10:104716771	A/T	cg04362960	chr10:104952993	NT5C2	0.97	15.09	0.51	3.25e-44	Arsenic metabolism;
BRCA	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.2	-0.31	1.37e-15	Total body bone mineral density;
BRCA	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-8.88	-0.33	6.98e-18	Longevity;Endometriosis;
BRCA	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.68	16.03	0.54	7.64e-49	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-9.61	-0.36	1.69e-20	Menopause (age at onset);
BRCA	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg18904891	chr8:8559673	CLDN23	0.64	12.57	0.45	1.54e-32	Obesity-related traits;
BRCA	trans	rs629535	0.814	rs506931	chr8:70068129	T/G	cg21567404	chr3:27674614	NA	1.01	20.74	0.63	1.84e-73	Dupuytren's disease;
BRCA	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.34	-7.96	-0.3	7.65e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs870825	0.616	rs10022834	chr4:185649431	A/G	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg10932868	chr11:921992	NA	0.49	12.53	0.44	2.39e-32	Alzheimer's disease (late onset);
BRCA	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg06145435	chr7:1022769	CYP2W1	0.5	9.25	0.34	3.29e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg17063962	chr7:91808500	NA	-0.51	-11.82	-0.42	2.74e-29	Breast cancer;
BRCA	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg18016565	chr1:150552671	MCL1	-0.45	-9.97	-0.37	7.34e-22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg11502198	chr6:26597334	ABT1	0.57	12.14	0.43	1.21e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg13902645	chr11:5959945	NA	-0.55	-11.1	-0.4	2.73e-26	DNA methylation (variation);
BRCA	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg01475377	chr6:109611718	NA	-0.59	-16.37	-0.54	1.4e-50	Reticulocyte fraction of red cells;
BRCA	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg23625390	chr15:77176239	SCAPER	0.55	13.96	0.48	7.5e-39	Blood metabolite levels;
BRCA	cis	rs9837602	1.000	rs10049383	chr3:99748548	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.22	0.41	8.3e-27	Breast cancer;
BRCA	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg22681709	chr2:178499509	PDE11A	-0.38	-8.22	-0.31	1.15e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg09367891	chr1:107599246	PRMT6	0.56	10.32	0.38	3.37e-23	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-8.55	-0.32	8.9e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs72848980	0.512	rs3781362	chr10:105375601	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.45	8.76	0.33	1.72e-17	White matter hyperintensity burden;
BRCA	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg11812906	chr14:75593930	NEK9	0.68	15.27	0.52	4.2e-45	Height;
BRCA	cis	rs208520	0.690	rs207102	chr6:66795671	G/A	cg07460842	chr6:66804631	NA	-1.02	-20.41	-0.63	1.11e-71	Exhaled nitric oxide output;
BRCA	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg07169764	chr2:136633963	MCM6	1.23	26.55	0.72	2.93e-105	Corneal structure;
BRCA	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	9.32	0.35	1.83e-19	Personality dimensions;
BRCA	trans	rs66887589	0.934	rs7672519	chr4:120544112	C/T	cg25214090	chr10:38739885	LOC399744	-0.34	-7.85	-0.3	1.72e-14	Diastolic blood pressure;
BRCA	cis	rs10465746	0.935	rs35946036	chr1:84438991	A/G	cg10977910	chr1:84465055	TTLL7	0.51	10.36	0.38	2.4e-23	Obesity-related traits;
BRCA	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg17747265	chr1:1875780	NA	-0.46	-13.24	-0.46	1.5e-35	Body mass index;
BRCA	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg09509183	chr1:209979624	IRF6	0.34	8.21	0.31	1.25e-15	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
BRCA	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12756686	chr19:29218302	NA	0.57	11.02	0.4	5.79e-26	Methadone dose in opioid dependence;
BRCA	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg00277334	chr10:82204260	NA	-0.45	-9.52	-0.35	3.44e-20	Post bronchodilator FEV1;
BRCA	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg25554036	chr4:6271136	WFS1	0.42	9.8	0.36	3.2e-21	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg23625390	chr15:77176239	SCAPER	-0.55	-13.79	-0.48	4.74e-38	Blood metabolite levels;
BRCA	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg01475377	chr6:109611718	NA	-0.6	-16.77	-0.55	1.45e-52	Reticulocyte fraction of red cells;
BRCA	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-12.28	-0.44	2.79e-31	Monocyte percentage of white cells;
BRCA	cis	rs6594713	0.717	rs13436825	chr5:112817687	T/A	cg12552261	chr5:112820674	MCC	0.49	8.47	0.32	1.64e-16	Brain cytoarchitecture;
BRCA	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg02951883	chr7:2050386	MAD1L1	0.39	8.47	0.32	1.71e-16	Neuroticism;
BRCA	cis	rs7580658	0.963	rs12622436	chr2:128081682	C/A	cg09760422	chr2:128146352	NA	-0.35	-7.88	-0.3	1.38e-14	Protein C levels;
BRCA	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg14440974	chr22:39074834	NA	0.35	8.11	0.31	2.65e-15	Menopause (age at onset);
BRCA	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg18252515	chr7:66147081	NA	-1.05	-15.74	-0.53	2.14e-47	Diabetic kidney disease;
BRCA	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg21573476	chr21:45109991	RRP1B	-0.37	-9.4	-0.35	9.62e-20	Mean corpuscular volume;
BRCA	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg24060327	chr5:131705240	SLC22A5	-0.64	-12.41	-0.44	7.93e-32	Breast cancer;
BRCA	trans	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.4	-0.35	9.41e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	11.62	0.42	1.82e-28	Height;
BRCA	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-9.85	-0.36	2.18e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg21045802	chr8:109455806	TTC35	0.35	8.02	0.3	5.19e-15	Dupuytren's disease;
BRCA	cis	rs919433	0.713	rs6719483	chr2:198472886	A/G	cg00792783	chr2:198669748	PLCL1	0.35	7.9	0.3	1.18e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.49	-10.05	-0.37	3.53e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.05	-0.3	4.13e-15	Prostate cancer;
BRCA	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg24060327	chr5:131705240	SLC22A5	-0.46	-9.15	-0.34	7.57e-19	Acylcarnitine levels;
BRCA	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18876405	chr7:65276391	NA	-0.55	-12.97	-0.46	2.65e-34	Aortic root size;
BRCA	cis	rs7301016	0.846	rs73124315	chr12:62970437	C/T	cg11441379	chr12:63026424	NA	0.46	8.69	0.32	3.13e-17	IgG glycosylation;
BRCA	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg18132916	chr6:79620363	NA	-0.48	-10.94	-0.4	1.21e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg11663144	chr21:46675770	NA	-0.6	-13.87	-0.48	2.05e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1003719	0.788	rs2835579	chr21:38457965	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.18	0.49	7.11e-40	Eye color traits;
BRCA	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg22153463	chr1:85462885	MCOLN2	-0.57	-10.21	-0.37	9.06e-23	Serum sulfate level;
BRCA	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg21535247	chr6:8435926	SLC35B3	0.42	9.57	0.35	2.35e-20	Motion sickness;
BRCA	cis	rs4478858	0.735	rs4949205	chr1:31800579	A/G	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs6840258	1.000	rs72667765	chr4:87965942	G/A	cg08197287	chr4:87952173	AFF1	-0.45	-8.95	-0.33	3.78e-18	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg04025307	chr7:1156635	C7orf50	0.44	9.78	0.36	3.7e-21	Bronchopulmonary dysplasia;
BRCA	trans	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg26384229	chr12:38710491	ALG10B	0.53	11.32	0.41	3.38e-27	Morning vs. evening chronotype;
BRCA	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg15997130	chr1:24165203	NA	-0.45	-11.33	-0.41	3.15e-27	Immature fraction of reticulocytes;
BRCA	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg05868516	chr6:26286170	HIST1H4H	0.45	9.95	0.37	8.61e-22	Educational attainment;
BRCA	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg19622623	chr12:86230825	RASSF9	-0.33	-9.22	-0.34	4.11e-19	Major depressive disorder;
BRCA	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg09307838	chr4:120376055	NA	0.69	14.08	0.49	2.13e-39	Corneal astigmatism;
BRCA	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg08645402	chr16:4508243	NA	0.4	9.28	0.34	2.65e-19	Schizophrenia;
BRCA	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09256448	chr16:638327	NA	0.32	8.6	0.32	6.25e-17	Height;
BRCA	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.24	-0.41	7.07e-27	Schizophrenia;
BRCA	cis	rs7809950	0.954	rs11977187	chr7:107210383	C/T	cg23024343	chr7:107201750	COG5	0.39	8.5	0.32	1.38e-16	Coronary artery disease;
BRCA	cis	rs2016266	0.785	rs10747660	chr12:53649874	C/G	cg26875137	chr12:53738046	NA	0.31	8.09	0.3	2.91e-15	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg25319279	chr11:5960081	NA	-0.38	-8.11	-0.31	2.6e-15	DNA methylation (variation);
BRCA	cis	rs10845606	1.000	rs11055013	chr12:12829037	T/C	cg09462578	chr12:12878428	APOLD1	-0.61	-10.85	-0.39	2.84e-25	Systemic lupus erythematosus;
BRCA	cis	rs6448317	0.954	rs7666033	chr4:24925272	A/G	cg21108841	chr4:24914750	CCDC149	-0.39	-8.65	-0.32	4.21e-17	Heschl's gyrus morphology;
BRCA	trans	rs4714291	0.832	rs2984431	chr6:39980900	T/A	cg02267698	chr19:7991119	CTXN1	-0.43	-8.79	-0.33	1.34e-17	Strep throat;
BRCA	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	8.5	0.32	1.38e-16	Birth weight;
BRCA	cis	rs939658	1.000	rs8033963	chr15:79455350	C/T	cg17916960	chr15:79447300	NA	0.38	9.76	0.36	4.44e-21	Refractive error;
BRCA	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.45	10.36	0.38	2.27e-23	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg03146154	chr1:46216737	IPP	-0.5	-10.92	-0.4	1.47e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg22907277	chr7:1156413	C7orf50	0.55	8.87	0.33	7.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs853679	0.546	rs2232429	chr6:28359632	T/G	cg06606381	chr12:133084897	FBRSL1	-0.9	-8.84	-0.33	9.38e-18	Depression;
BRCA	cis	rs10046574	0.634	rs10266715	chr7:135155366	C/T	cg27474649	chr7:135195673	CNOT4	-0.53	-8.15	-0.31	1.92e-15	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7512552	0.839	rs834231	chr1:150389392	A/T	cg15654264	chr1:150340011	RPRD2	-0.37	-8.19	-0.31	1.44e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs9487051	0.646	rs55677234	chr6:109621974	G/A	cg01475377	chr6:109611718	NA	-0.4	-8.73	-0.33	2.27e-17	Reticulocyte fraction of red cells;
BRCA	trans	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs7524258	0.835	rs2412150	chr1:7303343	A/C	cg07173049	chr1:7289937	CAMTA1	0.54	13.02	0.46	1.57e-34	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg07755735	chr2:20870362	GDF7	0.32	8.33	0.31	5.08e-16	Abdominal aortic aneurysm;
BRCA	cis	rs3820928	0.874	rs4675138	chr2:227884118	G/A	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.23	-0.31	1.03e-15	Pulmonary function;
BRCA	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.49	0.57	2.8e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06636551	chr8:101224915	SPAG1	-0.38	-8.72	-0.33	2.39e-17	Atrioventricular conduction;
BRCA	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg21385522	chr1:16154831	NA	0.54	10.01	0.37	5.17e-22	Dilated cardiomyopathy;
BRCA	cis	rs311392	0.902	rs419813	chr8:55092385	A/T	cg11783602	chr8:55087084	NA	-0.31	-9.07	-0.34	1.49e-18	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg18252515	chr7:66147081	NA	1.04	15.68	0.53	4.14e-47	Diabetic kidney disease;
BRCA	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg21905437	chr5:178450457	ZNF879	0.51	10.78	0.39	5.29e-25	Pubertal anthropometrics;
BRCA	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg13047869	chr3:10149882	C3orf24	0.58	12.1	0.43	1.7e-30	Alzheimer's disease;
BRCA	cis	rs3760982	0.585	rs68073292	chr19:44291401	T/C	cg11993925	chr19:44307056	LYPD5	0.38	8.89	0.33	6e-18	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs10504073	0.584	rs11784268	chr8:49956339	T/G	cg00325661	chr8:49890786	NA	0.49	14.07	0.49	2.32e-39	Blood metabolite ratios;
BRCA	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.27	8.43	0.32	2.24e-16	Prostate cancer;
BRCA	cis	rs7188861	0.724	rs1794019	chr16:11379775	T/C	cg01510278	chr16:11456238	NA	0.42	8.29	0.31	6.46e-16	HDL cholesterol;
BRCA	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.41	-0.38	1.53e-23	Aortic root size;
BRCA	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-8.82	-0.33	1.1e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs911119	1.000	rs1010117	chr20:23608421	G/C	cg16589663	chr20:23618590	CST3	0.45	8.56	0.32	8.21e-17	Chronic kidney disease;
BRCA	cis	rs716316	0.590	rs6135309	chr20:14902522	C/T	cg04470754	chr20:14904432	MACROD2	-0.36	-8.05	-0.3	4.2e-15	Advanced glycation end-product levels;
BRCA	cis	rs4722585	0.764	rs4259314	chr7:26182214	A/G	cg07876897	chr7:26191696	NFE2L3	-0.4	-8.46	-0.32	1.84e-16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
BRCA	trans	rs1997103	0.954	rs1917769	chr7:55392325	T/A	cg20935933	chr6:143382018	AIG1	0.61	11.61	0.42	2.03e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg13565492	chr6:43139072	SRF	-0.84	-11.44	-0.41	1.02e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08219700	chr8:58056026	NA	0.63	10.0	0.37	5.69e-22	Developmental language disorder (linguistic errors);
BRCA	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg08742575	chr21:47604166	C21orf56	0.41	8.01	0.3	5.51e-15	Testicular germ cell tumor;
BRCA	cis	rs7737355	0.898	rs26007	chr5:131006356	T/A	cg06307176	chr5:131281290	NA	0.52	10.24	0.38	6.86e-23	Life satisfaction;
BRCA	cis	rs7975161	0.640	rs4477504	chr12:104710465	T/C	cg25273343	chr12:104657179	TXNRD1	-0.49	-9.76	-0.36	4.49e-21	Toenail selenium levels;
BRCA	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg10862848	chr6:42927986	GNMT	-0.36	-14.93	-0.51	1.89e-43	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg27432699	chr2:27873401	GPN1	0.43	9.0	0.34	2.57e-18	Oral cavity cancer;
BRCA	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg06453172	chr10:134556979	INPP5A	-0.53	-11.12	-0.4	2.14e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg26384229	chr12:38710491	ALG10B	-0.5	-12.1	-0.43	1.65e-30	Morning vs. evening chronotype;
BRCA	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg13770153	chr20:60521292	NA	-0.37	-8.46	-0.32	1.8e-16	Body mass index;
BRCA	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg22800045	chr5:56110881	MAP3K1	0.65	12.34	0.44	1.62e-31	Initial pursuit acceleration;
BRCA	cis	rs17345786	0.520	rs1476123	chr3:101313413	C/G	cg12386194	chr3:101231763	SENP7	0.43	9.55	0.35	2.73e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg05896524	chr21:47604654	C21orf56	-0.51	-9.92	-0.37	1.18e-21	Testicular germ cell tumor;
BRCA	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.44	-10.23	-0.38	7.3e-23	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.77e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg10523679	chr1:76189770	ACADM	0.77	15.83	0.53	7.1e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs877282	0.583	rs11253441	chr10:828288	C/T	cg15764593	chr10:829463	NA	0.64	10.34	0.38	2.8e-23	Uric acid levels;
BRCA	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs6424115	0.546	rs35993651	chr1:24180613	C/G	cg15997130	chr1:24165203	NA	-0.51	-13.39	-0.47	3.11e-36	Immature fraction of reticulocytes;
BRCA	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg26384229	chr12:38710491	ALG10B	0.66	13.95	0.48	8.57e-39	Morning vs. evening chronotype;
BRCA	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.67	-0.32	3.56e-17	Breast cancer;
BRCA	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg17724175	chr1:150552817	MCL1	-0.34	-10.88	-0.4	2.05e-25	Blood protein levels;
BRCA	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg23625390	chr15:77176239	SCAPER	-0.53	-12.87	-0.45	7.31e-34	Blood metabolite levels;
BRCA	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg01528321	chr10:82214614	TSPAN14	0.67	14.46	0.5	3.38e-41	Post bronchodilator FEV1;
BRCA	trans	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg26043149	chr18:55253948	FECH	0.36	7.81	0.3	2.29e-14	Bone mineral density;
BRCA	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg09307838	chr4:120376055	NA	-0.74	-15.9	-0.53	3.32e-48	Corneal astigmatism;
BRCA	cis	rs1800682	0.528	rs11202918	chr10:90742008	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.53	12.52	0.44	2.54e-32	Chronic lymphocytic leukemia;
BRCA	cis	rs9463078	0.809	rs9357469	chr6:45049811	C/T	cg25276700	chr6:44698697	NA	-0.36	-8.19	-0.31	1.4e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg06766960	chr11:133703094	NA	-0.62	-13.29	-0.47	9.43e-36	Childhood ear infection;
BRCA	cis	rs10089	0.552	rs56718459	chr5:127546214	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	11.73	0.42	6.7200000000000006e-29	Ileal carcinoids;
BRCA	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg11941060	chr3:133502564	NA	-0.35	-8.01	-0.3	5.36e-15	Iron status biomarkers;
BRCA	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08219700	chr8:58056026	NA	0.44	7.91	0.3	1.12e-14	Developmental language disorder (linguistic errors);
BRCA	trans	rs7200543	1.000	rs72774845	chr16:15147954	A/C	cg24683922	chr1:11983373	KIAA2013	-0.37	-8.48	-0.32	1.59e-16	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	trans	rs2018683	0.707	rs917218	chr7:28975122	A/C	cg19402173	chr7:128379420	CALU	-0.39	-9.38	-0.35	1.13e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg04518342	chr5:131593106	PDLIM4	0.36	9.03	0.34	1.99e-18	Breast cancer;
BRCA	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg08754478	chr10:133766260	PPP2R2D	0.57	11.78	0.42	3.87e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg06212747	chr3:49208901	KLHDC8B	0.54	11.82	0.42	2.74e-29	Menarche (age at onset);
BRCA	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00166722	chr3:10149974	C3orf24	0.67	13.49	0.47	1.13e-36	Alzheimer's disease;
BRCA	cis	rs9296092	0.538	rs3916674	chr6:33522975	C/T	cg13560919	chr6:33536144	NA	-0.85	-17.72	-0.57	1.88e-57	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.6	-13.23	-0.46	1.81e-35	IgG glycosylation;
BRCA	cis	rs11690935	0.686	rs10165126	chr2:172820315	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.7	-18.9	-0.6	1.34e-63	Schizophrenia;
BRCA	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg18357645	chr12:58087776	OS9	0.3	7.87	0.3	1.56e-14	Multiple sclerosis;
BRCA	cis	rs877282	0.583	rs10904564	chr10:819459	C/G	cg15764593	chr10:829463	NA	-0.65	-10.53	-0.38	5.14e-24	Uric acid levels;
BRCA	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21659725	chr3:3221576	CRBN	-0.5	-12.88	-0.45	6.45e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.65	10.54	0.38	4.62e-24	Renal function-related traits (BUN);
BRCA	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg04833646	chr19:10679720	CDKN2D	0.72	13.42	0.47	2.43e-36	Red cell distribution width;
BRCA	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg26384229	chr12:38710491	ALG10B	0.76	17.13	0.56	1.94e-54	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg00012203	chr2:219082015	ARPC2	-0.47	-9.1	-0.34	1.09e-18	Colorectal cancer;
BRCA	cis	rs10193935	0.901	rs2118889	chr2:42451683	G/T	cg27598129	chr2:42591480	NA	-0.8	-13.48	-0.47	1.3e-36	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs672059	1.000	rs544352	chr1:183157546	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.56	0.32	8.08e-17	Hypertriglyceridemia;
BRCA	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg06238570	chr21:40685208	BRWD1	-0.43	-8.77	-0.33	1.61e-17	Cognitive function;
BRCA	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg06238570	chr21:40685208	BRWD1	-0.41	-8.37	-0.31	3.65e-16	Menarche (age at onset);
BRCA	cis	rs7809950	1.000	rs2520264	chr7:107179344	T/C	cg23024343	chr7:107201750	COG5	-0.39	-8.99	-0.33	2.87e-18	Coronary artery disease;
BRCA	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg04944784	chr2:26401820	FAM59B	-0.74	-12.06	-0.43	2.62e-30	Gut microbiome composition (summer);
BRCA	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.51	0.55	2.97e-51	Colorectal cancer;
BRCA	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg09537434	chr19:41945824	ATP5SL	-1.01	-22.91	-0.67	2.9e-85	Height;
BRCA	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.5	-10.65	-0.39	1.65e-24	Longevity;Endometriosis;
BRCA	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.94	-0.33	3.99e-18	Monocyte percentage of white cells;
BRCA	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg06784218	chr1:46089804	CCDC17	-0.43	-10.2	-0.37	9.99e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1538970	0.962	rs4660301	chr1:45820149	T/A	cg05343316	chr1:45956843	TESK2	0.58	11.74	0.42	5.64e-29	Platelet count;
BRCA	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg20607287	chr7:12443886	VWDE	-0.56	-7.85	-0.3	1.77e-14	Coronary artery disease;
BRCA	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23583168	chr7:148888333	NA	-0.79	-18.98	-0.6	4.88e-64	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2425143	1.000	rs45595739	chr20:34320759	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.96	-0.33	3.53e-18	Blood protein levels;
BRCA	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg03929089	chr4:120376271	NA	-0.48	-9.04	-0.34	1.81e-18	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02018176	chr4:1364513	KIAA1530	0.38	7.92	0.3	1.05e-14	Longevity;
BRCA	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.56	-0.47	5.53e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-8.57	-0.32	8.03e-17	IgG glycosylation;
BRCA	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg11608241	chr8:8085544	FLJ10661	0.31	8.56	0.32	8.24e-17	Systolic blood pressure;
BRCA	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.36	-8.17	-0.31	1.64e-15	Colorectal cancer;
BRCA	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg23033748	chr14:75592666	NEK9	-0.34	-8.06	-0.3	3.8e-15	Height;
BRCA	cis	rs72772090	0.710	rs1559085	chr5:96078702	A/G	cg24982541	chr5:96078678	CAST	-0.46	-8.03	-0.3	4.58e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg06671706	chr8:8559999	CLDN23	0.45	8.59	0.32	6.51e-17	Obesity-related traits;
BRCA	cis	rs10751667	0.600	rs11246377	chr11:999796	G/T	cg01483505	chr11:975446	AP2A2	0.33	9.05	0.34	1.66e-18	Alzheimer's disease (late onset);
BRCA	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg18252515	chr7:66147081	NA	-0.8	-11.18	-0.4	1.23e-26	Diabetic kidney disease;
BRCA	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	11.92	0.43	1.01e-29	Coronary artery disease;
BRCA	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg13175981	chr1:150552382	MCL1	0.43	9.54	0.35	2.86e-20	Tonsillectomy;
BRCA	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	trans	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg14791747	chr16:20752902	THUMPD1	0.45	14.25	0.49	3.24e-40	Cognitive test performance;
BRCA	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg08859206	chr1:53392774	SCP2	-0.43	-8.62	-0.32	5.43e-17	Monocyte count;
BRCA	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	8.8	0.33	1.24e-17	Platelet count;
BRCA	cis	rs6684514	1.000	rs12134983	chr1:156290409	T/C	cg16558208	chr1:156270281	VHLL	0.36	8.28	0.31	6.96e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	10.58	0.39	3.1e-24	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs7631605	0.905	rs4678943	chr3:37197355	T/C	cg15934958	chr3:37212084	LRRFIP2	0.42	9.87	0.36	1.83e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12756686	chr19:29218302	NA	0.57	10.99	0.4	7.43e-26	Methadone dose in opioid dependence;
BRCA	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg00666640	chr1:248458726	OR2T12	0.32	8.77	0.33	1.6e-17	Common traits (Other);
BRCA	cis	rs6772849	0.930	rs7639400	chr3:128323356	T/C	cg16766828	chr3:128327626	NA	-0.41	-9.06	-0.34	1.6e-18	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs2992756	0.625	rs2992752	chr1:18808526	A/C	cg14356550	chr1:18808102	KLHDC7A	-0.4	-8.29	-0.31	6.67e-16	Breast cancer;
BRCA	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24531977	chr5:56204891	C5orf35	-0.88	-18.18	-0.58	7.95e-60	Initial pursuit acceleration;
BRCA	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	13.36	0.47	4.56e-36	Height;
BRCA	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg09654669	chr8:57350985	NA	-0.41	-9.04	-0.34	1.85e-18	Obesity-related traits;
BRCA	cis	rs1874326	0.545	rs4626544	chr7:138110301	C/G	cg18008034	chr7:138118925	NA	-0.45	-9.28	-0.34	2.54e-19	Quantitative traits;
BRCA	cis	rs1113500	0.933	rs1419003	chr1:108616955	A/C	cg06207961	chr1:108661230	NA	0.45	11.09	0.4	2.99e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg11502198	chr6:26597334	ABT1	0.56	11.95	0.43	7.23e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs4423214	0.798	rs12224205	chr11:71180992	A/G	cg05163923	chr11:71159392	DHCR7	-0.58	-11.81	-0.42	2.95e-29	Vitamin D levels;
BRCA	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.42	-9.42	-0.35	8.03e-20	Personality dimensions;
BRCA	trans	rs12517041	1.000	rs16892316	chr5:23282819	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.29	-0.31	6.76e-16	Calcium levels;
BRCA	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.3	-0.31	6.42e-16	Bipolar disorder;
BRCA	cis	rs4664304	0.620	rs55664214	chr2:160708059	C/T	cg01092293	chr2:160761427	LY75	-0.33	-7.95	-0.3	8.65e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs4662945	0.504	rs35568023	chr2:130251812	A/T	cg05903289	chr2:130345205	NA	-0.32	-8.08	-0.3	3.22e-15	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11644478	chr21:40555479	PSMG1	0.89	21.0	0.64	7.43e-75	Cognitive function;
BRCA	cis	rs4900538	0.855	rs12586378	chr14:102853150	T/C	cg18135206	chr14:102964638	TECPR2	-0.91	-21.1	-0.64	2.26e-75	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg22834771	chr12:69754056	YEATS4	-0.43	-10.64	-0.39	1.85e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg27478167	chr7:817139	HEATR2	-0.48	-9.96	-0.37	7.97e-22	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.2e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg08601574	chr20:25228251	PYGB	-0.39	-8.93	-0.33	4.57e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12516959	chr21:47718080	NA	0.33	7.86	0.3	1.59e-14	Testicular germ cell tumor;
BRCA	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg06970220	chr1:156163860	SLC25A44	0.39	9.52	0.35	3.51e-20	Testicular germ cell tumor;
BRCA	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.57	0.57	1.12e-56	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs8170	0.603	rs10259	chr19:17430915	G/A	cg04749549	chr19:17459798	NA	-0.37	-9.76	-0.36	4.38e-21	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
BRCA	cis	rs12618769	0.625	rs12618524	chr2:99064029	T/A	cg10123293	chr2:99228465	UNC50	0.41	8.14	0.31	2.05e-15	Bipolar disorder;
BRCA	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	13.34	0.47	5.6e-36	Mean platelet volume;
BRCA	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.72	11.54	0.42	3.99e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	11.66	0.42	1.24e-28	Schizophrenia;
BRCA	cis	rs870825	0.616	rs28500698	chr4:185627746	A/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg11845111	chr2:191398756	TMEM194B	-0.77	-14.86	-0.51	3.91e-43	Diastolic blood pressure;
BRCA	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg01448562	chr3:133502909	NA	-0.74	-17.48	-0.57	3.2e-56	Iron status biomarkers;
BRCA	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg15549821	chr19:49342101	PLEKHA4	-1.06	-16.49	-0.55	3.59e-51	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs9296095	0.656	rs547391	chr6:33563913	T/A	cg14003231	chr6:33640908	ITPR3	0.36	8.18	0.31	1.56e-15	Platelet count;
BRCA	cis	rs6450176	1.000	rs3776706	chr5:53304933	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-15.55	-0.52	1.79e-46	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs6594499	0.872	rs13178997	chr5:110444249	G/T	cg04022379	chr5:110408740	TSLP	0.35	7.97	0.3	7.58e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs4714291	0.963	rs1721409	chr6:40112439	A/T	cg02267698	chr19:7991119	CTXN1	0.42	8.21	0.31	1.27e-15	Strep throat;
BRCA	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg11752832	chr7:134001865	SLC35B4	-0.44	-9.69	-0.36	8.15e-21	Mean platelet volume;
BRCA	cis	rs57590327	0.503	rs1524557	chr3:81892031	A/G	cg07356753	chr3:81810745	GBE1	-0.44	-10.41	-0.38	1.44e-23	Extraversion;
BRCA	cis	rs68170813	0.559	rs17427123	chr7:106823661	G/A	cg02696742	chr7:106810147	HBP1	-0.54	-8.83	-0.33	1e-17	Coronary artery disease;
BRCA	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24308560	chr3:49941425	MST1R	-0.4	-8.55	-0.32	9.36e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7246967	0.673	rs8106215	chr19:22879446	G/A	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg08645402	chr16:4508243	NA	0.42	9.74	0.36	5.44e-21	Schizophrenia;
BRCA	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg12444411	chr7:2802554	GNA12	0.35	8.54	0.32	9.49e-17	Height;
BRCA	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06108461	chr20:60628389	TAF4	-0.99	-21.96	-0.66	4.49e-80	Body mass index;
BRCA	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg25319279	chr11:5960081	NA	-0.43	-8.4	-0.32	3e-16	DNA methylation (variation);
BRCA	cis	rs7246657	0.722	rs10410588	chr19:38042410	C/G	cg14683738	chr19:37701593	ZNF585B	0.46	7.92	0.3	1.02e-14	Coronary artery calcification;
BRCA	cis	rs2050392	0.858	rs306583	chr10:30710057	C/T	cg18806716	chr10:30721971	MAP3K8	0.34	7.98	0.3	6.83e-15	Inflammatory bowel disease;
BRCA	cis	rs4594175	0.926	rs10138269	chr14:51615360	T/C	cg23942311	chr14:51606299	NA	0.34	8.49	0.32	1.44e-16	Cancer;
BRCA	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg16482183	chr6:26056742	HIST1H1C	0.52	11.24	0.41	6.95e-27	Height;
BRCA	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg10862848	chr6:42927986	GNMT	-0.36	-15.23	-0.52	6.63e-45	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00149659	chr3:10157352	C3orf10	0.77	12.6	0.45	1.1e-32	Alzheimer's disease;
BRCA	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg20701182	chr2:24300061	SF3B14	0.58	9.01	0.34	2.37e-18	Lymphocyte counts;
BRCA	cis	rs9309711	0.922	rs13399524	chr2:3480206	C/G	cg16153549	chr2:3496821	NA	-0.37	-8.63	-0.32	4.72e-17	Neurofibrillary tangles;
BRCA	cis	rs4302748	0.909	rs11763993	chr7:36172486	G/A	cg24442661	chr7:36192818	EEPD1	0.43	8.13	0.31	2.29e-15	Platelet count;
BRCA	trans	rs208520	0.874	rs208473	chr6:66917265	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.3	-0.54	3.22e-50	Exhaled nitric oxide output;
BRCA	trans	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg25214090	chr10:38739885	LOC399744	0.55	12.09	0.43	1.97e-30	Corneal astigmatism;
BRCA	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.03	-0.3	4.61e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg18446336	chr7:2847575	GNA12	0.35	8.36	0.31	3.98e-16	Height;
BRCA	cis	rs13102973	0.899	rs13127569	chr4:135900762	C/A	cg14419869	chr4:135874104	NA	0.46	9.37	0.35	1.18e-19	Subjective well-being;
BRCA	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg04025307	chr7:1156635	C7orf50	0.57	13.46	0.47	1.61e-36	Longevity;Endometriosis;
BRCA	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.42	-8.67	-0.32	3.53e-17	Eosinophil percentage of white cells;
BRCA	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg06212747	chr3:49208901	KLHDC8B	0.47	9.64	0.36	1.23e-20	Parkinson's disease;
BRCA	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg10729496	chr3:10149963	C3orf24	0.49	9.3	0.35	2.22e-19	Alzheimer's disease;
BRCA	cis	rs6137287	0.722	rs1007226	chr20:21103987	A/G	cg04219410	chr20:21106687	PLK1S1	0.36	8.34	0.31	4.59e-16	Height;
BRCA	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg14926445	chr8:58193284	C8orf71	-0.43	-8.57	-0.32	7.61e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.15e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg13047869	chr3:10149882	C3orf24	-0.55	-12.13	-0.43	1.3e-30	Alzheimer's disease;
BRCA	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg18876405	chr7:65276391	NA	-0.52	-11.7	-0.42	8.87e-29	Aortic root size;
BRCA	cis	rs4908768	0.501	rs6577494	chr1:8576925	C/T	cg20416874	chr1:8611966	RERE	-0.28	-8.2	-0.31	1.29e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg16049864	chr8:95962084	TP53INP1	0.48	10.62	0.39	2.17e-24	Type 2 diabetes;
BRCA	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.4	-8.38	-0.31	3.37e-16	Ulcerative colitis;
BRCA	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg26647111	chr11:31128758	NA	0.44	9.74	0.36	5.46e-21	Red blood cell count;
BRCA	cis	rs10924970	0.967	rs10754588	chr1:235438205	C/T	cg26050004	chr1:235667680	B3GALNT2	0.35	8.69	0.33	3.01e-17	Asthma;
BRCA	cis	rs2066819	1.000	rs59626664	chr12:56636975	C/G	cg26734620	chr12:56694298	CS	0.86	9.88	0.36	1.64e-21	Psoriasis vulgaris;
BRCA	cis	rs7572733	0.534	rs1518363	chr2:198810131	C/T	cg00792783	chr2:198669748	PLCL1	0.45	9.94	0.37	9.5e-22	Dermatomyositis;
BRCA	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.46	-0.32	1.8e-16	Monocyte percentage of white cells;
BRCA	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	16.03	0.54	7.54e-49	Smoking behavior;
BRCA	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg02196655	chr2:10830764	NOL10	0.3	7.92	0.3	1.05e-14	Prostate cancer;
BRCA	cis	rs1997103	0.871	rs6956733	chr7:55393032	A/C	cg17469321	chr7:55412551	NA	0.49	8.63	0.32	4.88e-17	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg20935933	chr6:143382018	AIG1	0.61	11.59	0.42	2.5e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.74	0.33	2.06e-17	Motion sickness;
BRCA	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.3	8.18	0.31	1.55e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg17691542	chr6:26056736	HIST1H1C	0.51	10.53	0.38	5.05e-24	Height;
BRCA	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg00666640	chr1:248458726	OR2T12	0.31	8.48	0.32	1.57e-16	Common traits (Other);
BRCA	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	19.24	0.61	2.09e-65	Alzheimer's disease;
BRCA	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg03526776	chr6:41159608	TREML2	0.43	8.0	0.3	5.81e-15	Alzheimer's disease (late onset);
BRCA	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.48	-10.25	-0.38	6.49e-23	Bipolar disorder;
BRCA	trans	rs8002861	0.619	rs1337203	chr13:44423621	T/G	cg17145862	chr1:211918768	LPGAT1	0.47	10.76	0.39	6.31e-25	Leprosy;
BRCA	cis	rs9290065	0.519	rs7644586	chr3:160674133	T/C	cg03342759	chr3:160939853	NMD3	-0.5	-10.16	-0.37	1.34e-22	Kawasaki disease;
BRCA	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg17691542	chr6:26056736	HIST1H1C	0.37	8.08	0.3	3.28e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg03709012	chr19:19516395	GATAD2A	-0.5	-9.91	-0.36	1.26e-21	Tonsillectomy;
BRCA	cis	rs2882667	0.690	rs995177	chr5:138169563	G/A	cg04439458	chr5:138467593	SIL1	0.34	8.47	0.32	1.73e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg23649088	chr2:200775458	C2orf69	-0.63	-8.11	-0.31	2.61e-15	Schizophrenia;
BRCA	cis	rs3750965	0.959	rs4930264	chr11:68852181	C/T	cg06818126	chr11:68850279	TPCN2	-0.34	-8.14	-0.31	2.02e-15	Hair color;
BRCA	cis	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg06521331	chr12:34319734	NA	-0.68	-14.68	-0.5	3.01e-42	Morning vs. evening chronotype;
BRCA	cis	rs17604090	0.887	rs850013	chr7:29666530	T/C	cg19413766	chr7:29689036	LOC646762	-0.49	-7.82	-0.3	2.2e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg24642439	chr20:33292090	TP53INP2	0.62	13.99	0.48	5.7e-39	Coronary artery disease;
BRCA	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg06618935	chr21:46677482	NA	-0.37	-8.04	-0.3	4.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg01262667	chr19:19385393	TM6SF2	-0.42	-10.79	-0.39	4.77e-25	Tonsillectomy;
BRCA	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg09184832	chr6:79620586	NA	-0.5	-11.19	-0.4	1.16e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2806561	1.000	rs2806561	chr1:23504795	C/T	cg19743168	chr1:23544995	NA	-0.4	-9.53	-0.35	3.2e-20	Height;
BRCA	trans	rs11088226	1.000	rs2833890	chr21:33927886	A/G	cg09050820	chr6:167586206	TCP10L2	-0.49	-8.71	-0.33	2.5e-17	Gastritis;
BRCA	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg19773385	chr1:10388646	KIF1B	-0.38	-8.15	-0.31	1.93e-15	Hepatocellular carcinoma;
BRCA	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg14789911	chr21:47582049	C21orf56	-0.36	-7.99	-0.3	6.11e-15	Testicular germ cell tumor;
BRCA	cis	rs3768617	0.811	rs11590958	chr1:183023636	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	9.7	0.36	7.76e-21	Fuchs's corneal dystrophy;
BRCA	cis	rs4953076	0.533	rs10173126	chr2:44446492	T/C	cg04920474	chr2:44395004	PPM1B	0.51	9.92	0.37	1.16e-21	Height;
BRCA	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg26408565	chr15:76604113	ETFA	-0.36	-7.87	-0.3	1.52e-14	Blood metabolite levels;
BRCA	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg04450456	chr4:17643702	FAM184B	0.37	10.94	0.4	1.2e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs912057	1.000	rs912057	chr6:6736931	C/T	cg06612196	chr6:6737390	NA	-0.45	-10.29	-0.38	4.46e-23	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs13315871	1.000	rs9862969	chr3:58341917	A/G	cg20936604	chr3:58311152	NA	-0.63	-8.07	-0.3	3.42e-15	Cholesterol, total;
BRCA	trans	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	12.18	0.43	8.13e-31	Exhaled nitric oxide output;
BRCA	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg24562669	chr7:97807699	LMTK2	0.44	11.78	0.42	4.07e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6450176	1.000	rs3776707	chr5:53304873	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-15.55	-0.52	1.79e-46	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg06238570	chr21:40685208	BRWD1	-0.4	-8.22	-0.31	1.16e-15	Menarche (age at onset);
BRCA	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.54	-9.73	-0.36	5.69e-21	Renal function-related traits (BUN);
BRCA	cis	rs6120849	0.901	rs6058193	chr20:33734464	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	8.52	0.32	1.18e-16	Protein C levels;
BRCA	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	13.92	0.48	1.2e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg22764044	chr5:178986830	RUFY1	0.44	10.77	0.39	5.57e-25	Lung cancer;
BRCA	cis	rs73086581	1.000	rs73086549	chr20:3954662	C/A	cg02187196	chr20:3869020	PANK2	0.54	9.62	0.36	1.48e-20	Response to antidepressants in depression;
BRCA	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.96e-21	Total body bone mineral density;
BRCA	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-10.25	-0.38	6.36e-23	Mean corpuscular volume;
BRCA	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg26031613	chr14:104095156	KLC1	-0.43	-8.55	-0.32	9.31e-17	Schizophrenia;
BRCA	cis	rs9837602	1.000	rs1038294	chr3:99503728	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.59	-10.83	-0.39	3.42e-25	Breast cancer;
BRCA	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg09035930	chr12:129282057	SLC15A4	0.5	13.98	0.48	6.25e-39	Systemic lupus erythematosus;
BRCA	cis	rs2070997	0.667	rs2260323	chr9:133700786	C/T	cg11464064	chr9:133710261	ABL1	-0.5	-9.15	-0.34	7.56e-19	Response to amphetamines;
BRCA	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg03733263	chr8:22462867	KIAA1967	0.73	16.73	0.55	2.12e-52	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	trans	rs1459104	0.925	rs35019440	chr11:55218270	C/G	cg15704280	chr7:45808275	SEPT13	0.64	8.15	0.31	1.95e-15	Body mass index;
BRCA	cis	rs698833	0.828	rs6706053	chr2:44517662	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.44	-8.84	-0.33	9.1e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg20848291	chr7:100343083	ZAN	0.36	8.04	0.3	4.39e-15	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.34	-0.31	4.67e-16	Bipolar disorder;
BRCA	cis	rs7512552	0.839	rs1260386	chr1:150369622	G/T	cg15654264	chr1:150340011	RPRD2	0.38	8.4	0.32	2.96e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg13736514	chr6:26305472	NA	-0.35	-12.04	-0.43	3.2e-30	Educational attainment;
BRCA	cis	rs2354432	0.607	rs12404113	chr1:146750343	C/A	cg25205988	chr1:146714368	CHD1L	-0.93	-12.28	-0.44	2.77e-31	Mitochondrial DNA levels;
BRCA	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg03954927	chr1:10346856	KIF1B	0.44	13.77	0.48	6.06e-38	Hepatocellular carcinoma;
BRCA	cis	rs4363385	0.818	rs3820141	chr1:153004778	C/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.59	-0.32	6.68e-17	Inflammatory skin disease;
BRCA	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.02	-0.34	2.13e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	19.97	0.62	2.45e-69	Platelet count;
BRCA	trans	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg23762105	chr12:34175262	ALG10	0.36	8.27	0.31	7.73e-16	Morning vs. evening chronotype;
BRCA	cis	rs4566357	0.595	rs2272203	chr2:227914655	C/G	cg05526886	chr2:227700861	RHBDD1	-0.41	-8.57	-0.32	7.98e-17	Coronary artery disease;
BRCA	cis	rs6942756	1.000	rs17168512	chr7:128955033	A/G	cg02491457	chr7:128862824	NA	-0.71	-14.0	-0.48	5.08e-39	White matter hyperintensity burden;
BRCA	cis	rs9811920	0.893	rs6798114	chr3:99892825	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.51	11.68	0.42	1.06e-28	Axial length;
BRCA	cis	rs6901250	0.851	rs339322	chr6:117193356	T/C	cg12892004	chr6:117198278	RFX6	-0.49	-11.24	-0.41	6.81e-27	C-reactive protein levels;
BRCA	cis	rs922182	0.547	rs6494458	chr15:64271095	A/C	cg24729988	chr15:64271149	DAPK2	-0.71	-19.4	-0.61	2.91e-66	Blood protein levels;
BRCA	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg08999081	chr20:33150536	PIGU	-0.34	-8.69	-0.33	2.93e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs17345786	0.520	rs1476123	chr3:101313413	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.39	9.11	0.34	1.05e-18	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg09307838	chr4:120376055	NA	0.6	12.21	0.44	5.54e-31	Corneal astigmatism;
BRCA	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg10523679	chr1:76189770	ACADM	-0.47	-9.0	-0.34	2.55e-18	Daytime sleep phenotypes;
BRCA	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg07395648	chr5:131743802	NA	0.38	8.19	0.31	1.38e-15	Breast cancer;
BRCA	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.3e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg15017067	chr4:17643749	FAM184B	0.35	10.83	0.39	3.2e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg21770322	chr7:97807741	LMTK2	0.45	11.84	0.42	2.23e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg21138405	chr5:131827807	IRF1	0.4	12.97	0.46	2.5e-34	Asthma (sex interaction);
BRCA	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg25214090	chr10:38739885	LOC399744	0.49	11.41	0.41	1.47e-27	Corneal astigmatism;
BRCA	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg18512352	chr11:47633146	NA	-0.38	-9.1	-0.34	1.11e-18	Subjective well-being;
BRCA	cis	rs1691799	0.899	rs1168294	chr12:66733988	T/C	cg16791601	chr12:66731901	HELB	-0.64	-17.13	-0.56	1.98e-54	White blood cell count (basophil);
BRCA	cis	rs919433	0.680	rs67580728	chr2:198431258	C/T	cg00792783	chr2:198669748	PLCL1	0.34	7.91	0.3	1.15e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg27170947	chr2:26402098	FAM59B	-0.95	-17.03	-0.56	7.03e-54	Gut microbiome composition (summer);
BRCA	cis	rs838147	0.760	rs412712	chr19:49234299	A/T	cg13540341	chr19:49222985	MAMSTR	0.34	9.42	0.35	8.11e-20	Dietary macronutrient intake;
BRCA	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg15832292	chr6:96025679	MANEA	0.52	8.58	0.32	7.34e-17	Behavioural disinhibition (generation interaction);
BRCA	cis	rs4302748	0.862	rs4720196	chr7:36183300	C/T	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg08645402	chr16:4508243	NA	-0.37	-9.11	-0.34	1.06e-18	Schizophrenia;
BRCA	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg20503657	chr10:835505	NA	0.98	14.92	0.51	2.13e-43	Eosinophil percentage of granulocytes;
BRCA	cis	rs4363385	0.667	rs73014331	chr1:152964533	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-8.94	-0.33	4e-18	Inflammatory skin disease;
BRCA	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg14019146	chr3:50243930	SLC38A3	0.64	16.15	0.54	1.88e-49	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-12.21	-0.43	5.77e-31	Tonsillectomy;
BRCA	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg18129178	chr5:148520854	ABLIM3	-0.59	-11.98	-0.43	5.71e-30	Breast cancer;
BRCA	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg10223061	chr2:219282414	VIL1	-0.27	-7.82	-0.3	2.2e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg26168224	chr5:2018326	NA	0.64	17.64	0.57	5.07e-57	Gut microbiome composition (winter);
BRCA	cis	rs16866061	1.000	rs11681451	chr2:225334104	T/C	cg12698349	chr2:225449008	CUL3	0.77	21.36	0.65	8.52e-77	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19346786	chr7:2764209	NA	-0.37	-10.8	-0.39	4.4e-25	Height;
BRCA	cis	rs12711979	0.765	rs13030772	chr2:3821280	T/C	cg17052675	chr2:3827356	NA	-0.48	-14.31	-0.49	1.8e-40	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg20503657	chr10:835505	NA	-1.01	-18.63	-0.59	3.45e-62	Eosinophil percentage of granulocytes;
BRCA	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11764359	chr7:65958608	NA	0.81	19.65	0.61	1.26e-67	Aortic root size;
BRCA	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg05084668	chr3:125655381	ALG1L	-0.5	-9.51	-0.35	3.87e-20	Blood pressure (smoking interaction);
BRCA	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg01819863	chr10:32635814	EPC1	-1.07	-18.93	-0.6	8.73e-64	Sexual dysfunction (female);
BRCA	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg26248373	chr2:1572462	NA	-0.54	-11.33	-0.41	3.17e-27	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg22467129	chr15:76604101	ETFA	-0.5	-10.9	-0.4	1.7e-25	Blood metabolite levels;
BRCA	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg13010199	chr12:38710504	ALG10B	0.5	10.44	0.38	1.18e-23	Bladder cancer;
BRCA	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	23.75	0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg21138405	chr5:131827807	IRF1	-0.37	-11.65	-0.42	1.39e-28	Asthma (sex interaction);
BRCA	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg16482183	chr6:26056742	HIST1H1C	0.51	10.32	0.38	3.34e-23	Iron status biomarkers;
BRCA	cis	rs72781680	0.821	rs72790329	chr2:24129277	A/G	cg08917208	chr2:24149416	ATAD2B	0.62	10.58	0.39	3.35e-24	Lymphocyte counts;
BRCA	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg09184832	chr6:79620586	NA	-0.47	-9.17	-0.34	6.22e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.82	0.3	2.21e-14	Aortic root size;
BRCA	cis	rs2304069	0.909	rs30831	chr5:149359053	C/T	cg12661370	chr5:149340060	SLC26A2	-0.56	-8.23	-0.31	1.07e-15	HIV-1 control;
BRCA	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg20203395	chr5:56204925	C5orf35	-0.37	-8.39	-0.32	3.01e-16	Coronary artery disease;
BRCA	cis	rs9394841	0.667	rs10807268	chr6:41777591	A/T	cg08135965	chr6:41755394	TOMM6	0.5	8.21	0.31	1.19e-15	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg08885076	chr2:99613938	TSGA10	-0.47	-8.99	-0.33	2.88e-18	Chronic sinus infection;
BRCA	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-9.98	-0.37	6.92e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.74	0.42	6.16e-29	Tonsillectomy;
BRCA	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	11.24	0.41	6.92e-27	Platelet count;
BRCA	cis	rs1163251	0.869	rs629735	chr1:120206932	G/T	cg19096424	chr1:120255104	PHGDH	-0.42	-9.34	-0.35	1.62e-19	Blood metabolite levels;
BRCA	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg06784218	chr1:46089804	CCDC17	-0.52	-12.63	-0.45	8.19e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg04166393	chr7:2884313	GNA12	0.4	8.47	0.32	1.74e-16	Height;
BRCA	cis	rs4631830	0.720	rs11599333	chr10:51499655	A/C	cg20129853	chr10:51489980	NA	0.32	8.65	0.32	4e-17	Prostate-specific antigen levels;
BRCA	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg08470875	chr2:26401718	FAM59B	-0.51	-8.36	-0.31	3.88e-16	Gut microbiome composition (summer);
BRCA	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg03462622	chr3:195777018	TFRC	-0.38	-8.63	-0.32	4.86e-17	Mean corpuscular volume;
BRCA	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	12.47	0.44	4.31e-32	Multiple sclerosis;
BRCA	cis	rs6484504	0.625	rs7940420	chr11:31366700	T/A	cg06552810	chr11:31128660	NA	0.39	8.61	0.32	5.84e-17	Red blood cell count;
BRCA	cis	rs1593	0.565	rs10025152	chr4:187225304	C/T	cg14349977	chr4:187219430	NA	0.53	10.04	0.37	3.95e-22	Activated partial thromboplastin time;
BRCA	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg13877915	chr19:58951672	ZNF132	0.46	10.72	0.39	9.33e-25	Uric acid clearance;
BRCA	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg18811423	chr2:55921094	PNPT1	0.67	20.31	0.63	3.82e-71	Metabolic syndrome;
BRCA	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg25427524	chr10:38739819	LOC399744	-0.52	-9.24	-0.34	3.56e-19	Obesity (extreme);
BRCA	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-8.86	-0.33	8.09e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg10495392	chr1:46806563	NSUN4	0.44	8.0	0.3	5.92e-15	Menopause (age at onset);
BRCA	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg01262667	chr19:19385393	TM6SF2	0.41	10.58	0.39	3.35e-24	Tonsillectomy;
BRCA	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.05e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg21518248	chr2:162101506	NA	0.49	10.24	0.38	6.77e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs68170813	0.559	rs10487271	chr7:106898458	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.65	-0.32	4.02e-17	Coronary artery disease;
BRCA	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg09904177	chr6:26538194	HMGN4	0.56	18.25	0.59	3.28e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg24006582	chr15:45444508	DUOX1	-0.56	-11.41	-0.41	1.37e-27	Uric acid levels;
BRCA	cis	rs911119	1.000	rs6515375	chr20:23610841	G/A	cg16589663	chr20:23618590	CST3	0.45	8.54	0.32	9.77e-17	Chronic kidney disease;
BRCA	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.49	-9.88	-0.36	1.55e-21	Body mass index;
BRCA	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg17691542	chr6:26056736	HIST1H1C	0.48	9.79	0.36	3.64e-21	Height;
BRCA	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.7	10.84	0.39	3.06e-25	Lung function (FEV1/FVC);
BRCA	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.81	0.39	3.9e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg10560079	chr2:191398806	TMEM194B	-0.74	-13.7	-0.48	1.19e-37	Diastolic blood pressure;
BRCA	cis	rs7617773	0.817	rs6800492	chr3:48323890	G/A	cg11946769	chr3:48343235	NME6	0.63	13.42	0.47	2.33e-36	Coronary artery disease;
BRCA	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg05340658	chr4:99064831	C4orf37	0.68	16.67	0.55	4.69e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg27432699	chr2:27873401	GPN1	0.47	9.83	0.36	2.56e-21	Oral cavity cancer;
BRCA	cis	rs2073300	1.000	rs79169006	chr20:23443535	A/T	cg12062639	chr20:23401060	NAPB	0.88	10.43	0.38	1.28e-23	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs701145	0.537	rs1727952	chr3:153871565	C/T	cg17054900	chr3:154042577	DHX36	0.55	9.29	0.35	2.32e-19	Coronary artery disease;
BRCA	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg08975724	chr8:8085496	FLJ10661	0.48	10.29	0.38	4.42e-23	Mood instability;
BRCA	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg11941060	chr3:133502564	NA	-0.5	-11.89	-0.43	1.35e-29	Iron status biomarkers;
BRCA	cis	rs3917254	0.509	rs13035227	chr2:102763837	T/C	cg22835712	chr2:102737379	NA	-0.52	-8.79	-0.33	1.33e-17	Blood protein levels;
BRCA	trans	rs12517041	0.872	rs67191421	chr5:23281046	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.27	-0.31	7.73e-16	Calcium levels;
BRCA	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg24812749	chr6:127587940	RNF146	0.88	20.25	0.63	8.34e-71	Breast cancer;
BRCA	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.21	-0.34	4.59e-19	Menopause (age at onset);
BRCA	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg05234568	chr11:5960015	NA	-0.48	-9.58	-0.35	2.14e-20	DNA methylation (variation);
BRCA	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg05340658	chr4:99064831	C4orf37	0.62	14.74	0.5	1.55e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg15737290	chr11:93063684	CCDC67	-0.49	-9.75	-0.36	4.95e-21	Pulmonary function decline;
BRCA	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg06784218	chr1:46089804	CCDC17	0.49	11.52	0.41	4.73e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.98	0.37	6.83e-22	Bladder cancer;
BRCA	cis	rs9324022	0.858	rs1004572	chr14:101178330	G/A	cg18089426	chr14:101175970	NA	0.59	11.28	0.41	4.7e-27	Plateletcrit;
BRCA	cis	rs57590327	0.504	rs11712243	chr3:81840674	T/G	cg07356753	chr3:81810745	GBE1	-0.47	-11.07	-0.4	3.54e-26	Extraversion;
BRCA	cis	rs1003719	0.667	rs8127148	chr21:38481292	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.57	13.21	0.46	2.11e-35	Eye color traits;
BRCA	cis	rs13190036	1.000	rs13177748	chr5:176643954	T/G	cg06733329	chr5:176740039	MXD3	0.45	8.21	0.31	1.2e-15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg08132940	chr7:1081526	C7orf50	-0.46	-8.39	-0.32	3.02e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11051970	0.661	rs188979	chr12:32569684	G/T	cg24626660	chr12:32551988	NA	0.31	9.03	0.34	2.04e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg02297831	chr4:17616191	MED28	0.36	8.47	0.32	1.67e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg01689657	chr7:91764605	CYP51A1	0.22	8.05	0.3	3.98e-15	Breast cancer;
BRCA	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg20701182	chr2:24300061	SF3B14	0.65	9.37	0.35	1.2e-19	Lymphocyte counts;
BRCA	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg20469991	chr17:27169893	C17orf63	-0.44	-8.66	-0.32	3.88e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg03146154	chr1:46216737	IPP	0.52	11.59	0.42	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11764359	chr7:65958608	NA	-0.75	-17.64	-0.57	4.71e-57	Aortic root size;
BRCA	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg25457927	chr22:38595422	NA	-0.32	-11.87	-0.43	1.63e-29	Cutaneous nevi;
BRCA	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg00321850	chr1:175162397	KIAA0040	0.44	12.39	0.44	9.15e-32	Diastolic blood pressure;
BRCA	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg04414720	chr1:150670196	GOLPH3L	0.35	7.84	0.3	1.88e-14	Tonsillectomy;
BRCA	trans	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg11663144	chr21:46675770	NA	-0.55	-12.75	-0.45	2.41e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg17366294	chr4:99064904	C4orf37	0.43	9.67	0.36	9.64e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11764359	chr7:65958608	NA	0.78	18.57	0.59	7.06e-62	Aortic root size;
BRCA	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg06623918	chr6:96969491	KIAA0776	0.9	25.45	0.71	3.19e-99	Headache;
BRCA	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.89	-0.33	6e-18	Total body bone mineral density;
BRCA	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.18	-0.4	1.27e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg20019720	chr6:154832845	CNKSR3	0.5	11.78	0.42	4.1e-29	Lipoprotein (a) levels;
BRCA	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg25554036	chr4:6271136	WFS1	0.42	9.99	0.37	6.36e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	trans	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg26043149	chr18:55253948	FECH	1.03	21.7	0.65	1.15e-78	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg21747090	chr2:27597821	SNX17	-0.43	-9.4	-0.35	9.66e-20	Total body bone mineral density;
BRCA	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.41	-9.63	-0.36	1.43e-20	Tonsillectomy;
BRCA	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-11.1	-0.4	2.74e-26	Renal function-related traits (BUN);
BRCA	cis	rs7301016	0.901	rs12369961	chr12:62966584	C/T	cg01804193	chr12:63026212	NA	0.47	8.56	0.32	8.12e-17	IgG glycosylation;
BRCA	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.32	-10.29	-0.38	4.29e-23	Bipolar disorder;
BRCA	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg25237894	chr2:233734115	C2orf82	0.39	11.36	0.41	2.39e-27	Coronary artery disease;
BRCA	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs6545883	0.525	rs1177274	chr2:61368532	T/G	cg15711740	chr2:61764176	XPO1	-0.47	-11.87	-0.43	1.66e-29	Tuberculosis;
BRCA	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.59	13.47	0.47	1.38e-36	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs7020830	0.931	rs13288178	chr9:37107799	A/G	cg14294708	chr9:37120828	ZCCHC7	1.17	36.62	0.82	4.66e-159	Schizophrenia;
BRCA	cis	rs701145	0.537	rs1713831	chr3:153836299	T/C	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.2e-14	Coronary artery disease;
BRCA	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.76	-0.39	6.3e-25	Personality dimensions;
BRCA	cis	rs1997103	0.871	rs1997101	chr7:55399652	A/T	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.72e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg07988820	chr12:82153109	PPFIA2	-0.63	-10.3	-0.38	3.95e-23	Resting heart rate;
BRCA	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.85e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg03934865	chr2:198174659	NA	-0.38	-8.29	-0.31	6.5e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	trans	rs1997103	1.000	rs2331063	chr7:55408914	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs13046373	0.535	rs7276743	chr21:31984545	C/T	cg14062083	chr21:31802829	KRTAP13-4	0.32	8.42	0.32	2.44e-16	HDL cholesterol;
BRCA	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg15485101	chr11:133734466	NA	0.4	10.14	0.37	1.73e-22	Childhood ear infection;
BRCA	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg03585969	chr10:35415529	CREM	0.56	11.6	0.42	2.21e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7520050	0.931	rs11211198	chr1:46282673	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.85	0.36	2.07e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.5	-0.44	2.98e-32	Bipolar disorder;
BRCA	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	11.48	0.41	7.34e-28	Height;
BRCA	cis	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-8.29	-0.31	6.54e-16	Obesity-related traits;
BRCA	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg26248373	chr2:1572462	NA	-0.5	-9.65	-0.36	1.16e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs3784262	0.565	rs9635346	chr15:58298118	C/G	cg12031962	chr15:58353849	ALDH1A2	0.33	8.57	0.32	7.64e-17	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10802521	chr3:52805072	NEK4	-0.31	-8.08	-0.3	3.18e-15	Bipolar disorder;
BRCA	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg13319975	chr6:146136371	FBXO30	0.45	10.42	0.38	1.41e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-9.87	-0.36	1.8e-21	Mean corpuscular volume;
BRCA	trans	rs10411161	0.702	rs8110461	chr19:52383569	A/C	cg22319618	chr22:45562946	NUP50	-0.41	-7.84	-0.3	1.95e-14	Breast cancer;
BRCA	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.4	-0.35	9.22e-20	Body mass index;
BRCA	cis	rs4722166	1.000	rs4722166	chr7:22738762	G/T	cg05472934	chr7:22766657	IL6	0.49	10.79	0.39	4.78e-25	Lung cancer;
BRCA	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03517284	chr6:25882590	NA	-0.46	-10.44	-0.38	1.11e-23	Blood metabolite levels;
BRCA	cis	rs4363385	0.747	rs1015995	chr1:152976114	G/C	cg24667326	chr1:152973720	SPRR3	-0.35	-9.82	-0.36	2.63e-21	Inflammatory skin disease;
BRCA	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg22467129	chr15:76604101	ETFA	-0.39	-8.67	-0.32	3.66e-17	Blood metabolite levels;
BRCA	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg05868516	chr6:26286170	HIST1H4H	0.43	8.39	0.32	3.1e-16	Educational attainment;
BRCA	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg08885076	chr2:99613938	TSGA10	0.45	10.46	0.38	9.8599999999999993e-24	Chronic sinus infection;
BRCA	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg07080220	chr10:102295463	HIF1AN	0.44	9.7	0.36	7.66e-21	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	9.87	0.36	1.72e-21	Mean corpuscular volume;
BRCA	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg11993925	chr19:44307056	LYPD5	0.37	8.89	0.33	6.39e-18	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.46	-10.42	-0.38	1.41e-23	Longevity;Endometriosis;
BRCA	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg20283391	chr11:68216788	NA	-0.46	-9.05	-0.34	1.66e-18	Total body bone mineral density;
BRCA	trans	rs7939886	0.920	rs12226441	chr11:55867822	G/A	cg15704280	chr7:45808275	SEPT13	0.61	7.93	0.3	1.01e-14	Myopia (pathological);
BRCA	cis	rs2070997	0.667	rs13295907	chr9:133718242	G/T	cg11464064	chr9:133710261	ABL1	0.53	9.6	0.35	1.84e-20	Response to amphetamines;
BRCA	cis	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg04990556	chr1:26633338	UBXN11	0.54	9.01	0.34	2.4e-18	Obesity-related traits;
BRCA	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.49	-11.16	-0.4	1.45e-26	Pulmonary function;
BRCA	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg16606324	chr3:10149918	C3orf24	0.57	10.02	0.37	4.74e-22	Alzheimer's disease;
BRCA	trans	rs3960554	0.932	rs11971220	chr7:75842792	C/T	cg19862616	chr7:65841803	NCRNA00174	0.6	11.68	0.42	1.08e-28	Eotaxin levels;
BRCA	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.27	0.41	5.55e-27	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00149659	chr3:10157352	C3orf10	0.81	14.21	0.49	5.29e-40	Alzheimer's disease;
BRCA	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.31	0.38	3.78e-23	Motion sickness;
BRCA	trans	rs11088226	0.681	rs1134747	chr21:33939011	T/A	cg09050820	chr6:167586206	TCP10L2	0.77	13.24	0.46	1.49e-35	Gastritis;
BRCA	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	13.28	0.46	1.07e-35	Schizophrenia;
BRCA	cis	rs2625529	0.652	rs12148078	chr15:72300471	G/C	cg16672083	chr15:72433130	SENP8	0.7	16.85	0.55	5.43e-53	Red blood cell count;
BRCA	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg18129178	chr5:148520854	ABLIM3	0.58	11.62	0.42	1.88e-28	Breast cancer;
BRCA	cis	rs7172677	0.737	rs7178625	chr15:75441017	A/G	cg10253484	chr15:75165896	SCAMP2	-0.45	-8.46	-0.32	1.8e-16	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg21775007	chr8:11205619	TDH	-0.47	-9.7	-0.36	7.84e-21	Triglycerides;
BRCA	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg00677455	chr12:58241039	CTDSP2	0.69	15.97	0.53	1.46e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.5	0.63	3.81e-72	Chronic sinus infection;
BRCA	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-13.59	-0.47	3.78e-37	Gut microbiome composition (summer);
BRCA	cis	rs2294693	0.947	rs9349176	chr6:40989525	C/T	cg14418226	chr6:40996092	UNC5CL	0.45	8.28	0.31	7.4e-16	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-12.96	-0.46	2.73e-34	Morning vs. evening chronotype;
BRCA	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg01304814	chr3:48885189	PRKAR2A	0.79	8.09	0.3	3.07e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg24829409	chr8:58192753	C8orf71	-0.49	-9.45	-0.35	6.51e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11644478	chr21:40555479	PSMG1	0.75	15.36	0.52	1.5e-45	Cognitive function;
BRCA	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00149659	chr3:10157352	C3orf10	0.79	13.66	0.48	1.77e-37	Alzheimer's disease;
BRCA	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.77	-21.18	-0.64	8.35e-76	Multiple sclerosis;
BRCA	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg06238570	chr21:40685208	BRWD1	-0.47	-9.26	-0.34	3.16e-19	Cognitive function;
BRCA	trans	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg06521331	chr12:34319734	NA	-0.51	-9.16	-0.34	7.04e-19	Bladder cancer;
BRCA	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg01529538	chr14:23388837	RBM23	0.42	11.48	0.41	7.35e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs10463316	0.862	rs59390562	chr5:150776092	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.32	-0.31	5.34e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs10838687	1.000	rs6485751	chr11:47336442	G/C	cg25783544	chr11:47291846	MADD	0.42	8.45	0.32	2.04e-16	Proinsulin levels;
BRCA	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg20090143	chr19:45452003	APOC2	0.27	7.89	0.3	1.31e-14	Blood protein levels;
BRCA	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-10.38	-0.38	1.96e-23	Personality dimensions;
BRCA	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-8.05	-0.3	4.13e-15	Bipolar disorder;
BRCA	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg04450456	chr4:17643702	FAM184B	0.39	11.6	0.42	2.34e-28	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg09021430	chr5:549028	NA	0.43	12.33	0.44	1.66e-31	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
BRCA	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg21132104	chr15:45694354	SPATA5L1	0.7	15.6	0.53	9.98e-47	Homoarginine levels;
BRCA	cis	rs4742903	0.509	rs7020317	chr9:106872682	T/A	cg14250997	chr9:106856677	SMC2	0.27	8.03	0.3	4.71e-15	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg12193833	chr17:30244370	NA	-0.6	-9.35	-0.35	1.42e-19	Hip circumference adjusted for BMI;
BRCA	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.42	11.86	0.42	1.84e-29	Monocyte percentage of white cells;
BRCA	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg20302533	chr7:39170763	POU6F2	0.37	7.96	0.3	8.05e-15	IgG glycosylation;
BRCA	cis	rs7172677	0.737	rs7179426	chr15:75441488	A/G	cg14664628	chr15:75095509	CSK	-0.36	-7.81	-0.3	2.3e-14	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg26408565	chr15:76604113	ETFA	-0.39	-8.43	-0.32	2.33e-16	Blood metabolite levels;
BRCA	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg02527881	chr3:46936655	PTH1R	0.35	8.9	0.33	5.55e-18	Colorectal cancer;
BRCA	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg21699342	chr2:239360505	ASB1	0.53	14.05	0.49	2.92e-39	Multiple system atrophy;
BRCA	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg05340658	chr4:99064831	C4orf37	0.66	16.08	0.54	4.09e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.57	9.73	0.36	5.88e-21	Gut microbiome composition (summer);
BRCA	cis	rs3820928	0.874	rs2228557	chr2:227872182	G/A	cg11843606	chr2:227700838	RHBDD1	-0.36	-7.99	-0.3	6.28e-15	Pulmonary function;
BRCA	trans	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg05926928	chr17:57297772	GDPD1	-0.8	-11.81	-0.42	3.04e-29	Opioid sensitivity;
BRCA	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg22800045	chr5:56110881	MAP3K1	0.42	8.6	0.32	6.21e-17	Coronary artery disease;
BRCA	cis	rs1163251	0.902	rs640195	chr1:120217650	T/A	cg19096424	chr1:120255104	PHGDH	0.44	9.73	0.36	5.98e-21	Blood metabolite levels;
BRCA	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.73	11.73	0.42	6.69e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg08885076	chr2:99613938	TSGA10	0.43	10.31	0.38	3.72e-23	Chronic sinus infection;
BRCA	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg14582100	chr15:45693742	SPATA5L1	0.37	11.87	0.42	1.71e-29	Homoarginine levels;
BRCA	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg01528321	chr10:82214614	TSPAN14	0.64	14.52	0.5	1.65e-41	Post bronchodilator FEV1;
BRCA	trans	rs12439619	0.846	rs62010071	chr15:82581783	G/C	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-7.81	-0.3	2.38e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs56399783	0.708	rs56208415	chr7:2813806	G/A	cg19731401	chr7:2775893	GNA12	0.48	8.35	0.31	4.14e-16	Childhood ear infection;
BRCA	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg03060546	chr3:49711283	APEH	0.5	10.76	0.39	6.45e-25	Resting heart rate;
BRCA	cis	rs12714314	0.830	rs12612812	chr2:1962131	A/C	cg22511877	chr2:1942942	MYT1L	0.38	8.15	0.31	1.98e-15	Type 2 diabetes (age of onset);
BRCA	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg24112000	chr20:60950667	NA	-0.6	-13.49	-0.47	1.17e-36	Colorectal cancer;
BRCA	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg27661571	chr11:113659931	NA	-0.7	-10.86	-0.39	2.59e-25	Hip circumference adjusted for BMI;
BRCA	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.4	-0.47	3.01e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg00757033	chr12:89920650	WDR51B	0.54	11.15	0.4	1.63e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs12612619	0.579	rs41448746	chr2:27080706	A/G	cg12368169	chr2:27073192	DPYSL5	-0.33	-10.0	-0.37	5.87e-22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg11663144	chr21:46675770	NA	-0.6	-13.82	-0.48	3.24e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04565464	chr8:145669602	NFKBIL2	0.38	8.74	0.33	2.05e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.4	8.85	0.33	8.71e-18	Aortic root size;
BRCA	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg11366901	chr6:160182831	ACAT2	0.82	15.87	0.53	4.47e-48	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	9.91	0.37	1.19e-21	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs3125734	0.633	rs4561099	chr10:64041163	T/C	cg09941381	chr10:64027924	RTKN2	-0.28	-8.19	-0.31	1.44e-15	Rheumatoid arthritis;
BRCA	cis	rs1595825	0.838	rs80172713	chr2:198508044	T/C	cg19156104	chr2:198669113	PLCL1	-0.46	-8.59	-0.32	6.53e-17	Ulcerative colitis;
BRCA	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	9.47	0.35	5.24e-20	Electroencephalogram traits;
BRCA	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.35	0.38	2.69e-23	Motion sickness;
BRCA	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg03709012	chr19:19516395	GATAD2A	0.75	17.06	0.56	4.72e-54	Tonsillectomy;
BRCA	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg04756594	chr16:24857601	SLC5A11	0.34	8.38	0.31	3.46e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg03929089	chr4:120376271	NA	0.72	14.73	0.5	1.63e-42	Coronary artery disease;
BRCA	trans	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.63	-0.36	1.33e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg17219203	chr10:38645113	HSD17B7P2	-0.43	-8.27	-0.31	7.86e-16	Breast cancer;
BRCA	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg08470875	chr2:26401718	FAM59B	-0.71	-11.35	-0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg25173405	chr17:45401733	C17orf57	-0.5	-9.87	-0.36	1.73e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-10.02	-0.37	4.67e-22	Alzheimer's disease (late onset);
BRCA	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg25281562	chr12:121454272	C12orf43	0.35	9.15	0.34	7.6e-19	N-glycan levels;
BRCA	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg12386194	chr3:101231763	SENP7	0.46	9.84	0.36	2.37e-21	Colorectal cancer;
BRCA	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg20607287	chr7:12443886	VWDE	-0.6	-8.53	-0.32	1.08e-16	Coronary artery disease;
BRCA	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.29	-0.35	2.32e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg23719950	chr11:63933701	MACROD1	-0.54	-8.79	-0.33	1.36e-17	Mean platelet volume;
BRCA	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg10932868	chr11:921992	NA	0.47	11.85	0.42	1.99e-29	Alzheimer's disease (late onset);
BRCA	trans	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg21659725	chr3:3221576	CRBN	-0.47	-8.64	-0.32	4.67e-17	Menarche (age at onset);
BRCA	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg22535103	chr8:58192502	C8orf71	-0.44	-8.87	-0.33	7.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg04166393	chr7:2884313	GNA12	0.4	8.54	0.32	9.97e-17	Height;
BRCA	cis	rs495337	0.760	rs6067282	chr20:48569278	T/C	cg17835207	chr20:48524531	SPATA2	-0.69	-16.72	-0.55	2.51e-52	Psoriasis;
BRCA	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg18811423	chr2:55921094	PNPT1	0.68	20.87	0.64	3.62e-74	Metabolic syndrome;
BRCA	cis	rs17023223	0.537	rs66715579	chr1:119725432	G/A	cg05756136	chr1:119680316	WARS2	-0.42	-8.05	-0.3	3.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs7809950	0.834	rs3801946	chr7:107242995	T/A	cg23024343	chr7:107201750	COG5	0.42	9.18	0.34	5.8e-19	Coronary artery disease;
BRCA	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.75	12.07	0.43	2.39e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg13010199	chr12:38710504	ALG10B	0.5	9.87	0.36	1.74e-21	Bladder cancer;
BRCA	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg24069376	chr3:38537580	EXOG	0.32	9.08	0.34	1.35e-18	Electrocardiographic conduction measures;
BRCA	cis	rs9611198	0.765	rs5757721	chr22:39947574	A/G	cg03390717	chr22:39966585	CACNA1I	0.28	8.51	0.32	1.26e-16	Schizophrenia;
BRCA	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg02176678	chr2:219576539	TTLL4	0.39	10.47	0.38	8.73e-24	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg16339924	chr4:17578868	LAP3	0.63	15.65	0.53	5.75e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg17712092	chr4:129076599	LARP1B	-0.38	-8.28	-0.31	6.99e-16	DNA methylation (variation);
BRCA	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	12.92	0.46	4.27e-34	Lymphocyte counts;
BRCA	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg16482183	chr6:26056742	HIST1H1C	0.5	10.69	0.39	1.16e-24	Height;
BRCA	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08564027	chr20:61660810	NA	0.84	22.49	0.66	5.99e-83	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg04944784	chr2:26401820	FAM59B	-0.84	-12.93	-0.46	3.78e-34	Gut microbiome composition (summer);
BRCA	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.34	-0.49	1.29e-40	Chronic sinus infection;
BRCA	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02176678	chr2:219576539	TTLL4	-0.5	-12.84	-0.45	9.49e-34	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-10.77	-0.39	5.98e-25	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg24069376	chr3:38537580	EXOG	0.41	11.68	0.42	1.01e-28	Electrocardiographic conduction measures;
BRCA	cis	rs11231017	0.507	rs10792346	chr11:62140069	A/C	cg23876832	chr11:62092739	NA	-0.33	-8.31	-0.31	5.62e-16	HIV-1 viral setpoint;
BRCA	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.57	13.86	0.48	2.2e-38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg10978503	chr1:24200527	CNR2	-0.45	-10.33	-0.38	3.01e-23	Immature fraction of reticulocytes;
BRCA	trans	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg06521331	chr12:34319734	NA	-0.47	-8.66	-0.32	3.96e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg15556689	chr8:8085844	FLJ10661	0.46	12.83	0.45	1.13e-33	Mood instability;
BRCA	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.26	0.38	5.81e-23	Bipolar disorder;
BRCA	cis	rs10463316	0.862	rs7720582	chr5:150776502	C/T	cg03212797	chr5:150827313	SLC36A1	0.44	8.72	0.33	2.44e-17	Metabolite levels (Pyroglutamine);
BRCA	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg15017067	chr4:17643749	FAM184B	-0.28	-8.51	-0.32	1.2e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg08508325	chr11:3079039	CARS	-0.41	-14.63	-0.5	5.31e-42	Longevity;
BRCA	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18404041	chr3:52824283	ITIH1	0.35	10.79	0.39	4.74e-25	Electroencephalogram traits;
BRCA	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg26031613	chr14:104095156	KLC1	-0.43	-8.48	-0.32	1.57e-16	Schizophrenia;
BRCA	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg03806693	chr22:41940476	POLR3H	-0.9	-17.54	-0.57	1.65e-56	Vitiligo;
BRCA	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg16482183	chr6:26056742	HIST1H1C	0.44	8.66	0.32	3.97e-17	Iron status biomarkers;
BRCA	cis	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg11548914	chr2:179343871	FKBP7;PLEKHA3;MIR548N	0.53	8.96	0.33	3.55e-18	Atrial fibrillation;
BRCA	cis	rs965469	0.779	rs6037541	chr20:3287704	G/C	cg25506879	chr20:3388711	C20orf194	-0.44	-8.8	-0.33	1.22e-17	IFN-related cytopenia;
BRCA	cis	rs10504073	0.565	rs12056536	chr8:49890132	C/T	cg00325661	chr8:49890786	NA	-0.49	-14.43	-0.5	4.68e-41	Blood metabolite ratios;
BRCA	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg15557168	chr22:42548783	NA	0.31	8.67	0.32	3.48e-17	Cognitive function;
BRCA	cis	rs9308433	0.643	rs955920	chr1:214464309	G/A	cg06198575	chr1:214491504	SMYD2	0.52	10.92	0.4	1.44e-25	IgG glycosylation;
BRCA	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg13770153	chr20:60521292	NA	-0.45	-10.81	-0.39	4.09e-25	Body mass index;
BRCA	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.69	12.47	0.44	4.06e-32	IgG glycosylation;
BRCA	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24308560	chr3:49941425	MST1R	-0.41	-8.57	-0.32	7.77e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg23711669	chr6:146136114	FBXO30	0.64	15.13	0.51	1.91e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg14343924	chr8:8086146	FLJ10661	0.42	8.81	0.33	1.13e-17	Mood instability;
BRCA	cis	rs3771570	1.000	rs62193204	chr2:242315443	A/G	cg21155796	chr2:242212141	HDLBP	0.6	9.21	0.34	4.8e-19	Prostate cancer;
BRCA	trans	rs8073060	0.614	rs225275	chr17:33972567	G/C	cg19694781	chr19:47549865	TMEM160	-1.05	-21.76	-0.65	5.94e-79	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg13047869	chr3:10149882	C3orf24	0.53	10.94	0.4	1.14e-25	Alzheimer's disease;
BRCA	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg03929089	chr4:120376271	NA	0.48	8.12	0.31	2.36e-15	Axial length;
BRCA	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-8.88	-0.33	6.5e-18	Pulmonary function;
BRCA	cis	rs8010715	0.804	rs1134334	chr14:24594114	A/G	cg23112188	chr14:24563095	PCK2	-0.33	-8.28	-0.31	7.35e-16	IgG glycosylation;
BRCA	cis	rs7809950	0.817	rs17154091	chr7:107084790	T/C	cg23024343	chr7:107201750	COG5	-0.52	-10.58	-0.39	3.39e-24	Coronary artery disease;
BRCA	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.33	-7.83	-0.3	1.98e-14	Bipolar disorder;
BRCA	cis	rs6740322	0.895	rs6744746	chr2:43555805	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.65	11.98	0.43	5.45e-30	Coronary artery disease;
BRCA	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg14019146	chr3:50243930	SLC38A3	0.42	10.14	0.37	1.61e-22	Body mass index;
BRCA	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg08999081	chr20:33150536	PIGU	0.36	9.27	0.34	2.9e-19	Coronary artery disease;
BRCA	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs7587476	0.822	rs6726763	chr2:215681580	T/G	cg04004882	chr2:215674386	BARD1	0.67	12.41	0.44	8.16e-32	Neuroblastoma;
BRCA	cis	rs7072216	0.655	rs3830024	chr10:100176106	G/A	cg26618903	chr10:100175079	PYROXD2	-0.32	-8.93	-0.33	4.6e-18	Metabolite levels;
BRCA	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg11941060	chr3:133502564	NA	-0.51	-12.42	-0.44	6.79e-32	Iron status biomarkers;
BRCA	cis	rs727479	0.502	rs1065779	chr15:51504811	A/C	cg19946085	chr15:51559439	CYP19A1	-0.31	-8.72	-0.33	2.44e-17	Estradiol levels;
BRCA	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg00012203	chr2:219082015	ARPC2	0.49	9.72	0.36	6.57e-21	Colorectal cancer;
BRCA	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg21960279	chr19:17905606	B3GNT3	0.48	10.85	0.39	2.78e-25	Tumor biomarkers;
BRCA	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg13010199	chr12:38710504	ALG10B	0.52	10.48	0.38	8.03e-24	Bladder cancer;
BRCA	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg07741184	chr6:167504864	NA	0.27	7.83	0.3	1.98e-14	Crohn's disease;
BRCA	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg25110126	chr1:46999211	NA	-0.72	-12.53	-0.44	2.23e-32	Monobrow;
BRCA	cis	rs12348691	0.503	rs7847259	chr9:100600712	A/G	cg13688889	chr9:100608707	NA	-0.49	-9.94	-0.37	9.46e-22	Alopecia areata;
BRCA	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg23887609	chr12:130822674	PIWIL1	0.43	9.35	0.35	1.47e-19	Menopause (age at onset);
BRCA	cis	rs2882667	0.690	rs825758	chr5:138126977	G/A	cg04439458	chr5:138467593	SIL1	0.31	7.87	0.3	1.47e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg11764359	chr7:65958608	NA	0.78	18.66	0.59	2.47e-62	Aortic root size;
BRCA	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg19077165	chr18:44547161	KATNAL2	0.37	7.97	0.3	7.15e-15	Personality dimensions;
BRCA	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg04362960	chr10:104952993	NT5C2	0.43	10.09	0.37	2.49e-22	Arsenic metabolism;
BRCA	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg20891283	chr12:69753455	YEATS4	0.42	8.29	0.31	6.76e-16	Response to diuretic therapy;
BRCA	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.71	10.85	0.39	2.72e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg03929089	chr4:120376271	NA	0.63	12.47	0.44	4.07e-32	Coronary artery disease;
BRCA	trans	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.58	-0.35	2.16e-20	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.57	9.7	0.36	7.35e-21	Gut microbiome composition (summer);
BRCA	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.56	-0.32	8.61e-17	Height;
BRCA	cis	rs8067545	0.750	rs4925077	chr17:19982276	C/T	cg13482628	chr17:19912719	NA	0.54	14.89	0.51	2.99e-43	Schizophrenia;
BRCA	cis	rs2481665	0.739	rs6674622	chr1:62534938	A/G	cg18591186	chr1:62594603	INADL	-0.46	-10.46	-0.38	1e-23	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg16482183	chr6:26056742	HIST1H1C	0.56	11.87	0.42	1.69e-29	Height;
BRCA	cis	rs1163251	0.837	rs611365	chr1:120242571	C/T	cg19096424	chr1:120255104	PHGDH	0.45	10.3	0.38	4.15e-23	Blood metabolite levels;
BRCA	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg18132916	chr6:79620363	NA	-0.42	-8.47	-0.32	1.65e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.53	-0.32	1.09e-16	Electroencephalogram traits;
BRCA	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg23625390	chr15:77176239	SCAPER	0.39	9.11	0.34	1.09e-18	Blood metabolite levels;
BRCA	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg01802117	chr1:53393560	SCP2	0.34	7.86	0.3	1.68e-14	Monocyte count;
BRCA	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.92	-0.3	1.08e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg27279351	chr12:120934652	DYNLL1	0.56	13.17	0.46	3.14e-35	High light scatter reticulocyte count;
BRCA	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg13047869	chr3:10149882	C3orf24	0.53	11.43	0.41	1.22e-27	Alzheimer's disease;
BRCA	cis	rs1011018	0.628	rs61054086	chr7:139452190	A/C	cg03224163	chr7:139420300	HIPK2	-0.59	-8.89	-0.33	6.11e-18	Systolic blood pressure;
BRCA	cis	rs7246657	0.722	rs10412510	chr19:38075944	A/G	cg18154014	chr19:37997991	ZNF793	0.48	9.16	0.34	7.24e-19	Coronary artery calcification;
BRCA	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg03929089	chr4:120376271	NA	-0.74	-15.94	-0.53	2.09e-48	Coronary artery disease;
BRCA	cis	rs6546550	0.900	rs897122	chr2:70140271	C/T	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.62	-0.42	1.93e-28	Prevalent atrial fibrillation;
BRCA	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg09998033	chr7:158218633	PTPRN2	-0.41	-9.67	-0.36	9.9e-21	Obesity-related traits;
BRCA	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg08422745	chr4:174089978	GALNT7	-0.75	-15.36	-0.52	1.46e-45	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg07810366	chr2:100720526	AFF3	-0.32	-8.08	-0.3	3.33e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg13256891	chr4:100009986	ADH5	0.52	9.56	0.35	2.54e-20	Smoking initiation;
BRCA	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26314531	chr2:26401878	FAM59B	0.88	15.31	0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg15704280	chr7:45808275	SEPT13	-0.74	-15.05	-0.51	5.06e-44	Coronary artery disease;
BRCA	cis	rs6545883	0.501	rs935860	chr2:61406561	G/C	cg15711740	chr2:61764176	XPO1	-0.33	-8.25	-0.31	8.76e-16	Tuberculosis;
BRCA	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg06671706	chr8:8559999	CLDN23	0.46	8.77	0.33	1.61e-17	Obesity-related traits;
BRCA	cis	rs4423214	0.802	rs4616066	chr11:71183846	G/A	cg05163923	chr11:71159392	DHCR7	-0.56	-11.35	-0.41	2.58e-27	Vitamin D levels;
BRCA	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.68	-14.83	-0.51	5.53e-43	Homoarginine levels;
BRCA	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	23.35	0.68	1.22e-87	Chronic sinus infection;
BRCA	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg11645453	chr3:52864694	ITIH4	0.39	9.28	0.34	2.68e-19	Schizophrenia;
BRCA	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg14863265	chr7:2801509	GNA12	-0.44	-9.36	-0.35	1.32e-19	Height;
BRCA	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.43	9.76	0.36	4.7e-21	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs1499972	0.941	rs62264819	chr3:117671941	T/C	cg07612923	chr3:117604196	NA	0.6	8.2	0.31	1.35e-15	Schizophrenia;
BRCA	cis	rs7617773	0.780	rs11710257	chr3:48373214	T/G	cg11946769	chr3:48343235	NME6	0.67	13.41	0.47	2.67e-36	Coronary artery disease;
BRCA	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs1997103	1.000	rs6968966	chr7:55411356	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7617773	0.817	rs3731497	chr3:48226553	T/G	cg11946769	chr3:48343235	NME6	0.65	13.59	0.47	3.98e-37	Coronary artery disease;
BRCA	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg22491629	chr6:157744540	C6orf35	-0.67	-12.46	-0.44	4.53e-32	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs11608355	0.545	rs12822891	chr12:109896002	A/G	cg05360138	chr12:110035743	NA	0.69	12.74	0.45	2.67e-33	Neuroticism;
BRCA	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg22875332	chr1:76189707	ACADM	-0.48	-9.19	-0.34	5.58e-19	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1883415	0.553	rs760907	chr6:24479873	T/C	cg20631270	chr6:24437470	GPLD1	0.4	8.16	0.31	1.78e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-12.56	-0.44	1.72e-32	Personality dimensions;
BRCA	cis	rs6901250	0.851	rs339307	chr6:117177340	A/G	cg12892004	chr6:117198278	RFX6	-0.49	-11.41	-0.41	1.38e-27	C-reactive protein levels;
BRCA	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg15352829	chr14:105391018	PLD4	-0.38	-12.42	-0.44	7.38e-32	Rheumatoid arthritis;
BRCA	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg22681709	chr2:178499509	PDE11A	-0.38	-8.29	-0.31	6.71e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-10.56	-0.39	3.95e-24	Pancreatic cancer;
BRCA	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg09658497	chr7:2847517	GNA12	-0.47	-10.49	-0.38	7.66e-24	Height;
BRCA	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg20891283	chr12:69753455	YEATS4	0.57	11.52	0.41	5.1e-28	Response to diuretic therapy;
BRCA	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	10.01	0.37	5.17e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2130392	1.000	rs3796689	chr4:185649866	C/A	cg21366198	chr4:185655624	MLF1IP	-0.39	-9.19	-0.34	5.6e-19	Kawasaki disease;
BRCA	cis	rs1538970	0.962	rs2153609	chr1:45814058	A/G	cg05343316	chr1:45956843	TESK2	0.5	10.3	0.38	3.9699999999999997e-23	Platelet count;
BRCA	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11764359	chr7:65958608	NA	0.79	19.17	0.6	4.63e-65	Aortic root size;
BRCA	cis	rs17401966	1.000	rs12402052	chr1:10318652	C/G	cg03954927	chr1:10346856	KIF1B	0.45	12.8	0.45	1.41e-33	Hepatocellular carcinoma;
BRCA	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.44	0.35	6.84e-20	Tonsillectomy;
BRCA	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg22920501	chr2:26401640	FAM59B	0.96	16.92	0.56	2.42e-53	Gut microbiome composition (summer);
BRCA	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11644478	chr21:40555479	PSMG1	-0.68	-14.8	-0.51	8.2e-43	Cognitive function;
BRCA	trans	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg25214090	chr10:38739885	LOC399744	0.46	10.62	0.39	2.31e-24	Corneal astigmatism;
BRCA	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	12.82	0.45	1.26e-33	Bone mineral density;
BRCA	cis	rs68170813	0.559	rs113422695	chr7:107070208	T/A	cg02696742	chr7:106810147	HBP1	-0.51	-7.97	-0.3	7.42e-15	Coronary artery disease;
BRCA	cis	rs6546886	0.957	rs11885172	chr2:74257094	T/C	cg14702570	chr2:74259524	NA	-0.3	-7.82	-0.3	2.22e-14	Dialysis-related mortality;
BRCA	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg20891283	chr12:69753455	YEATS4	0.47	12.36	0.44	1.32e-31	Blood protein levels;
BRCA	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.27	-0.34	2.9e-19	Alzheimer's disease (late onset);
BRCA	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg08085267	chr17:45401833	C17orf57	0.6	12.3	0.44	2.38e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs58785573	0.504	rs11947292	chr4:38634749	A/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.56	12.2	0.43	6.43e-31	Lymphocyte percentage of white cells;
BRCA	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg05294307	chr14:35346193	BAZ1A	-0.58	-9.98	-0.37	7.07e-22	Psoriasis;
BRCA	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg05714579	chr10:131428358	MGMT	0.59	14.57	0.5	9.89e-42	Response to temozolomide;
BRCA	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.49	12.3	0.44	2.45e-31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23708337	chr7:1209742	NA	0.59	12.86	0.45	8.27e-34	Longevity;Endometriosis;
BRCA	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.53	-0.32	1.03e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11958404	0.932	rs72816541	chr5:157414686	G/A	cg05962755	chr5:157440814	NA	0.48	9.46	0.35	5.98e-20	IgG glycosylation;
BRCA	cis	rs1891275	0.515	rs7092745	chr10:93483820	C/T	cg07889827	chr10:93443413	NA	-0.4	-10.83	-0.39	3.36e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs9426691	1	rs9426691	chr1:23484904	A/G	cg12483005	chr1:23474871	LUZP1	0.6	12.58	0.45	1.4e-32	Coenzyme Q10 levels;
BRCA	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg06917634	chr15:78832804	PSMA4	0.58	12.5	0.44	3.04e-32	Sudden cardiac arrest;
BRCA	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg00383909	chr3:49044727	WDR6	0.74	12.43	0.44	6.64e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg20607287	chr7:12443886	VWDE	-0.56	-8.48	-0.32	1.55e-16	Coronary artery disease;
BRCA	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg11663144	chr21:46675770	NA	-0.61	-14.22	-0.49	4.32e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15541040	chr2:3486749	NA	-0.45	-9.58	-0.35	2.06e-20	Neurofibrillary tangles;
BRCA	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg05313129	chr8:58192883	C8orf71	-0.46	-9.36	-0.35	1.36e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg00750074	chr16:89608354	SPG7	0.34	9.11	0.34	1.02e-18	Multiple myeloma (IgH translocation);
BRCA	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.36	8.77	0.33	1.63e-17	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg24531977	chr5:56204891	C5orf35	0.66	13.98	0.48	5.77e-39	Initial pursuit acceleration;
BRCA	cis	rs6426558	0.537	rs2492630	chr1:227286931	A/G	cg10327440	chr1:227177885	CDC42BPA	0.48	9.44	0.35	6.63e-20	Neutrophil percentage of white cells;
BRCA	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg04546413	chr19:29218101	NA	0.43	8.02	0.3	5.23e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.72	0.42	7.23e-29	Tonsillectomy;
BRCA	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.47	-7.99	-0.3	6.39e-15	Mean platelet volume;
BRCA	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg12463550	chr7:65579703	CRCP	-0.39	-8.36	-0.31	3.99e-16	Aortic root size;
BRCA	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.35	-0.41	2.4200000000000002e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.43	-9.55	-0.35	2.74e-20	Personality dimensions;
BRCA	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.68	-0.32	3.26e-17	Colorectal cancer;
BRCA	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg13010199	chr12:38710504	ALG10B	0.48	9.62	0.36	1.51e-20	Morning vs. evening chronotype;
BRCA	cis	rs10193935	0.901	rs10196091	chr2:42541591	T/C	cg27598129	chr2:42591480	NA	-0.81	-13.14	-0.46	4.31e-35	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4423214	0.840	rs1790341	chr11:71177578	T/C	cg05163923	chr11:71159392	DHCR7	-0.57	-11.6	-0.42	2.31e-28	Vitamin D levels;
BRCA	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00166722	chr3:10149974	C3orf24	0.66	13.19	0.46	2.55e-35	Alzheimer's disease;
BRCA	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg06238570	chr21:40685208	BRWD1	-0.45	-8.89	-0.33	6.42e-18	Cognitive function;
BRCA	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg15556689	chr8:8085844	FLJ10661	0.36	8.68	0.32	3.33e-17	Retinal vascular caliber;
BRCA	cis	rs9341808	0.718	rs9443735	chr6:80820474	G/T	cg08355045	chr6:80787529	NA	0.37	9.38	0.35	1.13e-19	Sitting height ratio;
BRCA	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg06636001	chr8:8085503	FLJ10661	0.47	9.65	0.36	1.15e-20	Neuroticism;
BRCA	cis	rs10501293	1.000	rs1425850	chr11:43109833	T/C	cg03447554	chr11:43094025	NA	-0.48	-8.88	-0.33	6.85e-18	Cognitive performance;
BRCA	cis	rs1344694	0.566	rs4672790	chr2:216892446	C/T	cg12620499	chr2:216877984	MREG	0.57	14.91	0.51	2.45e-43	Alcohol dependence;
BRCA	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.72	-0.36	6.22e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.25	0.31	9.3e-16	Corneal astigmatism;
BRCA	trans	rs3857536	0.740	rs4710571	chr6:66890250	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-9.49	-0.35	4.54e-20	Blood trace element (Cu levels);
BRCA	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18876405	chr7:65276391	NA	-0.62	-15.42	-0.52	7.35e-46	Aortic root size;
BRCA	cis	rs490234	0.934	rs10119068	chr9:128424508	A/G	cg14078157	chr9:128172775	NA	-0.4	-9.2	-0.34	5.03e-19	Mean arterial pressure;
BRCA	cis	rs9986765	0.881	rs73452602	chr7:142828331	A/T	cg15652212	chr7:142981776	TMEM139	0.55	9.25	0.34	3.23e-19	Cancer;Dermatomyositis;
BRCA	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg03060546	chr3:49711283	APEH	0.5	10.7	0.39	1.08e-24	Resting heart rate;
BRCA	trans	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg26384229	chr12:38710491	ALG10B	0.49	10.53	0.38	5.18e-24	Resting heart rate;
BRCA	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	trans	rs12517041	0.786	rs7715927	chr5:23247790	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.4	-7.89	-0.3	1.36e-14	Calcium levels;
BRCA	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg18016565	chr1:150552671	MCL1	-0.43	-10.26	-0.38	5.81e-23	Tonsillectomy;
BRCA	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02176678	chr2:219576539	TTLL4	0.48	12.44	0.44	5.54e-32	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg01939980	chr4:1354348	KIAA1530	0.37	10.48	0.38	8.34e-24	Longevity;
BRCA	trans	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg21659725	chr3:3221576	CRBN	-0.48	-8.73	-0.33	2.22e-17	Menarche (age at onset);
BRCA	cis	rs751728	0.664	rs9394167	chr6:33754396	A/G	cg25922239	chr6:33757077	LEMD2	0.49	12.55	0.44	1.92e-32	Crohn's disease;
BRCA	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg21252483	chr19:49399788	TULP2	-0.43	-9.4	-0.35	9.68e-20	Red cell distribution width;
BRCA	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg12219531	chr12:120966889	COQ5	0.54	11.42	0.41	1.31e-27	High light scatter reticulocyte count;
BRCA	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg10253484	chr15:75165896	SCAMP2	-0.59	-11.45	-0.41	9.57e-28	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg24558204	chr6:135376177	HBS1L	0.45	12.41	0.44	8.13e-32	Red blood cell count;
BRCA	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg26384229	chr12:38710491	ALG10B	-0.65	-14.07	-0.49	2.3e-39	Heart rate;
BRCA	cis	rs7766436	0.648	rs2876643	chr6:22591525	C/A	cg13666174	chr6:22585274	NA	-0.43	-10.77	-0.39	5.81e-25	Coronary artery disease;
BRCA	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg26384229	chr12:38710491	ALG10B	0.81	20.23	0.62	1.02e-70	Heart rate;
BRCA	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	12.26	0.44	3.57e-31	Neuroticism;
BRCA	trans	rs931812	0.895	rs965625	chr8:101909749	T/C	cg20993868	chr7:22813445	NA	0.56	15.96	0.53	1.59e-48	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg18351406	chr4:77819688	ANKRD56	0.61	13.39	0.47	3.13e-36	Emphysema distribution in smoking;
BRCA	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg03709012	chr19:19516395	GATAD2A	0.81	19.12	0.6	8.79e-65	Tonsillectomy;
BRCA	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg05347473	chr6:146136440	FBXO30	0.41	8.05	0.3	4.05e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-9.87	-0.36	1.74e-21	Gut microbiome composition (summer);
BRCA	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg07636037	chr3:49044803	WDR6	0.82	21.76	0.65	5.6e-79	Menarche (age at onset);
BRCA	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg18402987	chr7:1209562	NA	0.84	12.05	0.43	2.8e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg08755490	chr11:65554678	OVOL1	0.53	10.96	0.4	9.69e-26	Acne (severe);
BRCA	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg03929089	chr4:120376271	NA	0.5	8.3	0.31	6.17e-16	Axial length;
BRCA	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg21770322	chr7:97807741	LMTK2	0.58	16.99	0.56	1.12e-53	Breast cancer;
BRCA	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg10560079	chr2:191398806	TMEM194B	-0.69	-12.97	-0.46	2.47e-34	Diastolic blood pressure;
BRCA	trans	rs9393777	0.920	rs13196692	chr6:27379119	C/T	cg01620082	chr3:125678407	NA	-0.85	-10.28	-0.38	4.85e-23	Intelligence (multi-trait analysis);
BRCA	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	8.11	0.31	2.53e-15	Retinal vascular caliber;
BRCA	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg24634471	chr8:143751801	JRK	0.42	8.83	0.33	9.89e-18	Schizophrenia;
BRCA	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg09307838	chr4:120376055	NA	0.63	13.65	0.48	2.17e-37	Corneal astigmatism;
BRCA	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg10932868	chr11:921992	NA	0.39	9.55	0.35	2.82e-20	Alzheimer's disease (late onset);
BRCA	cis	rs2130392	0.926	rs4610379	chr4:185624388	A/G	cg04058563	chr4:185651563	MLF1IP	0.32	7.94	0.3	8.9e-15	Kawasaki disease;
BRCA	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg20701182	chr2:24300061	SF3B14	0.66	9.46	0.35	5.67e-20	Birth weight;
BRCA	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	3.94e-15	Alzheimer's disease (late onset);
BRCA	cis	rs3820928	0.874	rs13423046	chr2:227901805	G/T	cg11843606	chr2:227700838	RHBDD1	-0.36	-7.91	-0.3	1.16e-14	Pulmonary function;
BRCA	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg21770322	chr7:97807741	LMTK2	0.41	10.95	0.4	1.04e-25	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs11976180	1.000	rs1919948	chr7:143762843	T/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.26	-0.31	8.66e-16	Obesity-related traits;
BRCA	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	18.8	0.6	4.08e-63	Hip circumference adjusted for BMI;
BRCA	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08280861	chr8:58055591	NA	0.53	8.52	0.32	1.16e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg04455712	chr21:45112962	RRP1B	-0.42	-10.8	-0.39	4.19e-25	Mean corpuscular volume;
BRCA	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg24812749	chr6:127587940	RNF146	0.69	15.11	0.51	2.58e-44	Breast cancer;
BRCA	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg06026331	chr20:60912101	LAMA5	-0.64	-13.04	-0.46	1.31e-34	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs7589728	1.000	rs6722069	chr2:88533151	C/T	cg04511125	chr2:88470314	THNSL2	0.69	10.2	0.37	1.01e-22	Plasma clusterin levels;
BRCA	cis	rs7527798	0.592	rs11118345	chr1:207854827	A/T	cg21110645	chr1:207815933	NA	-0.28	-7.84	-0.3	1.92e-14	Erythrocyte sedimentation rate;
BRCA	cis	rs9463078	0.547	rs4449629	chr6:44717808	T/C	cg25276700	chr6:44698697	NA	0.37	8.57	0.32	7.53e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08564027	chr20:61660810	NA	0.84	22.78	0.67	1.49e-84	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg23533926	chr12:111358616	MYL2	-0.43	-8.97	-0.33	3.19e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.7	-15.41	-0.52	8.32e-46	Homoarginine levels;
BRCA	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2425143	0.730	rs7263640	chr20:34314725	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.96	-0.33	3.53e-18	Blood protein levels;
BRCA	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08109568	chr15:31115862	NA	-0.45	-10.64	-0.39	1.84e-24	Huntington's disease progression;
BRCA	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg00666640	chr1:248458726	OR2T12	0.33	8.99	0.34	2.75e-18	Common traits (Other);
BRCA	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg11502198	chr6:26597334	ABT1	0.48	9.45	0.35	6.1e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg09904177	chr6:26538194	HMGN4	0.57	18.5	0.59	1.62e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg26031613	chr14:104095156	KLC1	-0.45	-8.62	-0.32	5.24e-17	Schizophrenia;
BRCA	cis	rs1003719	0.667	rs73201942	chr21:38475164	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	10.89	0.4	1.92e-25	Eye color traits;
BRCA	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11764359	chr7:65958608	NA	0.71	16.0	0.53	1e-48	Aortic root size;
BRCA	cis	rs17023223	0.537	rs10923766	chr1:119726932	G/A	cg05756136	chr1:119680316	WARS2	-0.42	-8.05	-0.3	3.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs3784262	0.669	rs34226780	chr15:58280168	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.04	-0.37	3.94e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs2046867	0.818	rs6808341	chr3:72914847	A/G	cg25664220	chr3:72788482	NA	-0.4	-9.29	-0.35	2.3e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11764359	chr7:65958608	NA	-0.79	-19.23	-0.61	2.32e-65	Aortic root size;
BRCA	cis	rs1865721	0.958	rs11663060	chr18:73172806	T/C	cg26385618	chr18:73139727	C18orf62	-0.39	-9.0	-0.34	2.6e-18	Intelligence;
BRCA	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg24324837	chr19:49891574	CCDC155	0.48	8.23	0.31	1.03e-15	Multiple sclerosis;
BRCA	cis	rs7707921	0.705	rs226194	chr5:81585026	G/T	cg15871215	chr5:81402204	ATG10	0.35	8.25	0.31	8.86e-16	Breast cancer;
BRCA	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18252515	chr7:66147081	NA	-0.56	-11.25	-0.41	6.39e-27	Corneal structure;
BRCA	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg24558204	chr6:135376177	HBS1L	-0.45	-11.86	-0.42	1.78e-29	Red blood cell count;
BRCA	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg11584989	chr19:19387371	SF4	0.5	11.16	0.4	1.47e-26	Bipolar disorder;
BRCA	cis	rs6138458	0.743	rs3746330	chr20:24999795	A/G	cg26195577	chr20:24973756	C20orf3	0.64	15.71	0.53	2.74e-47	Blood protein levels;
BRCA	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.37	-8.12	-0.31	2.41e-15	Mean platelet volume;
BRCA	cis	rs9790314	0.613	rs1447620	chr3:160616211	T/C	cg03342759	chr3:160939853	NMD3	0.43	8.56	0.32	8.3e-17	Morning vs. evening chronotype;
BRCA	cis	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg09307838	chr4:120376055	NA	0.48	9.96	0.37	8.35e-22	Diastolic blood pressure;
BRCA	cis	rs7520050	0.966	rs785481	chr1:46554518	G/A	cg24296786	chr1:45957014	TESK2	0.41	9.21	0.34	4.54e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg11584989	chr19:19387371	SF4	0.6	13.67	0.48	1.66e-37	Bipolar disorder;
BRCA	cis	rs7246657	0.525	rs1667359	chr19:37486172	G/A	cg23950597	chr19:37808831	NA	-0.52	-8.28	-0.31	7.37e-16	Coronary artery calcification;
BRCA	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg24879335	chr3:133465180	TF	0.33	11.11	0.4	2.36e-26	Iron status biomarkers (transferrin levels);
BRCA	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg26384229	chr12:38710491	ALG10B	0.75	17.0	0.56	9.05e-54	Bladder cancer;
BRCA	cis	rs2859741	0.565	rs12023397	chr1:37507739	G/A	cg09363841	chr1:37513479	NA	-0.54	-11.77	-0.42	4.55e-29	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.53	11.72	0.42	7.16e-29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg26031613	chr14:104095156	KLC1	0.77	16.65	0.55	5.89e-52	Body mass index;
BRCA	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg04374321	chr14:90722782	PSMC1	-0.5	-11.99	-0.43	5.23e-30	Mortality in heart failure;
BRCA	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.24	-0.31	9.74e-16	Axial length;
BRCA	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02176678	chr2:219576539	TTLL4	-0.54	-13.52	-0.47	8.18e-37	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg25427524	chr10:38739819	LOC399744	-0.42	-8.89	-0.33	6.26e-18	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg12373951	chr3:133503437	NA	0.33	7.97	0.3	7.11e-15	Iron status biomarkers;
BRCA	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg01620082	chr3:125678407	NA	-0.74	-9.14	-0.34	8.09e-19	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.56	-0.32	8.45e-17	Menopause (age at onset);
BRCA	cis	rs13095912	1.000	rs6784842	chr3:185342723	C/T	cg11274856	chr3:185301563	NA	0.33	8.26	0.31	8.26e-16	Systolic blood pressure;
BRCA	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.38	8.27	0.31	7.81e-16	Alzheimer's disease (late onset);
BRCA	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg02951883	chr7:2050386	MAD1L1	-0.38	-9.02	-0.34	2.26e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg01689657	chr7:91764605	CYP51A1	0.23	8.31	0.31	5.54e-16	Breast cancer;
BRCA	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg23131131	chr22:24373011	LOC391322	-0.46	-11.02	-0.4	5.69e-26	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg08885076	chr2:99613938	TSGA10	-0.52	-11.73	-0.42	6.2e-29	Chronic sinus infection;
BRCA	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg04518342	chr5:131593106	PDLIM4	0.42	10.1	0.37	2.41e-22	Acylcarnitine levels;
BRCA	trans	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg09719594	chr16:21412588	NA	-0.35	-8.36	-0.31	3.87e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs72960926	0.744	rs2351778	chr6:74866814	T/G	cg03266952	chr6:74778945	NA	-0.67	-8.02	-0.3	5.06e-15	Metabolite levels (MHPG);
BRCA	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg13319975	chr6:146136371	FBXO30	-0.42	-9.71	-0.36	7.12e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg26750617	chr12:132293702	NA	-0.43	-9.61	-0.36	1.69e-20	Migraine;
BRCA	cis	rs965469	1.000	rs6051810	chr20:3355384	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-10.49	-0.38	7.39e-24	IFN-related cytopenia;
BRCA	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg18402987	chr7:1209562	NA	0.9	14.51	0.5	1.95e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11677370	0.574	rs12329183	chr2:3866943	G/A	cg17052675	chr2:3827356	NA	-0.51	-11.38	-0.41	1.86e-27	Type 2 diabetes;
BRCA	cis	rs6750047	0.605	rs2121260	chr2:38268763	T/G	cg07380506	chr2:38303506	CYP1B1	0.47	10.11	0.37	2.22e-22	Cutaneous malignant melanoma;Melanoma;
BRCA	trans	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg25214090	chr10:38739885	LOC399744	0.46	10.53	0.38	4.92e-24	Corneal astigmatism;
BRCA	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg00376283	chr12:123451042	ABCB9	0.51	11.15	0.4	1.63e-26	Neutrophil percentage of white cells;
BRCA	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.23	0.31	1.06e-15	Cognitive ability;
BRCA	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.11	-0.43	1.57e-30	Alzheimer's disease;
BRCA	cis	rs61990749	0.597	rs1008988	chr14:78260795	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.66	10.25	0.38	6.39e-23	Fibroblast growth factor basic levels;
BRCA	cis	rs6973256	0.605	rs13237435	chr7:133347570	C/T	cg07491979	chr7:133331646	EXOC4	-0.34	-7.82	-0.3	2.17e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.44	8.6	0.32	6.03e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.2	-0.31	1.37e-15	Menopause (age at onset);
BRCA	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.28	-0.44	2.79e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	14.28	0.49	2.44e-40	Alzheimer's disease;
BRCA	cis	rs10056811	0.538	rs4632781	chr5:74376658	G/C	cg19683494	chr5:74908142	NA	0.56	8.32	0.31	5.39e-16	Coronary artery disease;
BRCA	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg00530320	chr1:46809349	NSUN4	0.49	9.7	0.36	7.91e-21	Menopause (age at onset);
BRCA	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg06623918	chr6:96969491	KIAA0776	0.86	23.87	0.69	1.55e-90	Headache;
BRCA	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.53	12.1	0.43	1.79e-30	Colorectal cancer;
BRCA	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg08873628	chr1:175162347	KIAA0040	-0.34	-8.13	-0.31	2.3e-15	Diastolic blood pressure;
BRCA	cis	rs9807989	0.507	rs7605284	chr2:103044175	T/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.38	0.31	3.39e-16	Asthma;
BRCA	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	ch.11.42038R	chr11:967971	AP2A2	0.49	15.53	0.52	2.31e-46	Alzheimer's disease (late onset);
BRCA	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg17724175	chr1:150552817	MCL1	-0.24	-8.05	-0.3	3.99e-15	Tonsillectomy;
BRCA	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21659725	chr3:3221576	CRBN	-0.46	-10.22	-0.37	8.57e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg11843238	chr5:131593191	PDLIM4	0.35	9.03	0.34	1.93e-18	Breast cancer;
BRCA	trans	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.92	0.3	1.05e-14	Endometrial cancer;
BRCA	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg11812906	chr14:75593930	NEK9	-0.59	-13.06	-0.46	9.96e-35	Height;
BRCA	cis	rs965469	0.895	rs6037592	chr20:3392950	T/G	cg25506879	chr20:3388711	C20orf194	-0.51	-10.0	-0.37	5.6e-22	IFN-related cytopenia;
BRCA	cis	rs4919694	1.000	rs11191445	chr10:104651055	C/T	cg04362960	chr10:104952993	NT5C2	0.95	14.86	0.51	4.07e-43	Arsenic metabolism;
BRCA	cis	rs6545883	0.929	rs6707830	chr2:61749472	G/A	cg15711740	chr2:61764176	XPO1	-0.52	-13.17	-0.46	3.39e-35	Tuberculosis;
BRCA	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-13.45	-0.47	1.81e-36	Bone mineral density;
BRCA	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg20307385	chr11:47447363	PSMC3	0.44	10.09	0.37	2.65e-22	Subjective well-being;
BRCA	cis	rs4974559	0.947	rs12639938	chr4:1343135	G/C	cg02980000	chr4:1222292	CTBP1	0.76	12.89	0.45	5.61e-34	Systolic blood pressure;
BRCA	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg24642439	chr20:33292090	TP53INP2	0.56	12.22	0.44	5.09e-31	Coronary artery disease;
BRCA	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg18446336	chr7:2847575	GNA12	0.36	8.57	0.32	7.8e-17	Loneliness (linear analysis);
BRCA	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	21.17	0.64	8.76e-76	Smoking behavior;
BRCA	cis	rs73001065	0.636	rs10415849	chr19:19505087	C/T	cg03709012	chr19:19516395	GATAD2A	1.0	14.91	0.51	2.29e-43	LDL cholesterol;
BRCA	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg22431228	chr1:16359049	CLCNKA	-0.43	-9.71	-0.36	6.72e-21	Dilated cardiomyopathy;
BRCA	cis	rs965469	1.000	rs6133036	chr20:3349682	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-10.54	-0.38	4.61e-24	IFN-related cytopenia;
BRCA	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg00677455	chr12:58241039	CTDSP2	-0.35	-7.88	-0.3	1.46e-14	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg21573476	chr21:45109991	RRP1B	-0.33	-8.55	-0.32	8.92e-17	Mean corpuscular volume;
BRCA	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg24562669	chr7:97807699	LMTK2	0.46	12.25	0.44	3.74e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	9.14	0.34	8.5e-19	Systemic lupus erythematosus;
BRCA	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg25358565	chr5:93447407	FAM172A	1.17	18.44	0.59	3.18e-61	Diabetic retinopathy;
BRCA	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg07395648	chr5:131743802	NA	-0.35	-7.86	-0.3	1.58e-14	Blood metabolite levels;
BRCA	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg16931447	chr4:875861	GAK	-0.37	-8.45	-0.32	2e-16	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
BRCA	cis	rs912057	0.833	rs1294424	chr6:6744135	G/A	cg06612196	chr6:6737390	NA	0.39	8.72	0.33	2.31e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.36	9.33	0.35	1.72e-19	IgG glycosylation;
BRCA	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg11843238	chr5:131593191	PDLIM4	0.32	7.81	0.3	2.29e-14	Blood metabolite levels;
BRCA	cis	rs4900538	0.963	rs1885708	chr14:102960164	A/G	cg18135206	chr14:102964638	TECPR2	1.05	29.55	0.76	1.18e-121	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg24558204	chr6:135376177	HBS1L	0.59	15.99	0.53	1.14e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg02659138	chr7:134003124	SLC35B4	0.32	9.8	0.36	3.24e-21	Mean platelet volume;
BRCA	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.73	-15.81	-0.53	9.55e-48	Lymphocyte counts;
BRCA	cis	rs7481584	0.564	rs432585	chr11:3084903	G/A	cg08508325	chr11:3079039	CARS	0.3	8.89	0.33	6.18e-18	Calcium levels;
BRCA	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg12310025	chr6:25882481	NA	-0.52	-11.54	-0.42	4.14e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.69	0.33	2.92e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg14926445	chr8:58193284	C8orf71	-0.47	-8.83	-0.33	9.87e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	13.21	0.46	2.03e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10465746	0.780	rs4907190	chr1:84409168	T/C	cg10977910	chr1:84465055	TTLL7	0.56	11.77	0.42	4.52e-29	Obesity-related traits;
BRCA	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg11502198	chr6:26597334	ABT1	0.5	9.91	0.36	1.29e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg10495392	chr1:46806563	NSUN4	0.45	8.23	0.31	1.09e-15	Menopause (age at onset);
BRCA	cis	rs999943	0.846	rs2274200	chr6:33625696	T/C	cg14003231	chr6:33640908	ITPR3	0.68	15.46	0.52	4.92e-46	Obesity (extreme);
BRCA	cis	rs4891159	0.548	rs654754	chr18:74143695	T/C	cg24786174	chr18:74118243	ZNF516	0.8	23.43	0.68	4.11e-88	Longevity;
BRCA	cis	rs7264396	0.561	rs2064725	chr20:34569142	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-9.73	-0.36	6.04e-21	Total cholesterol levels;
BRCA	cis	rs10193935	0.901	rs10171643	chr2:42532912	C/T	cg27598129	chr2:42591480	NA	-0.8	-12.32	-0.44	1.98e-31	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4478858	0.806	rs6686845	chr1:31708796	A/T	cg00250761	chr1:31883323	NA	-0.33	-8.56	-0.32	8.52e-17	Alcohol dependence;
BRCA	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg26395211	chr5:140044315	WDR55	-0.38	-8.77	-0.33	1.62e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-8.57	-0.32	7.47e-17	Total body bone mineral density;
BRCA	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg12444411	chr7:2802554	GNA12	-0.38	-9.5	-0.35	4.01e-20	Height;
BRCA	cis	rs3125734	0.608	rs7094950	chr10:64019744	T/C	cg09941381	chr10:64027924	RTKN2	-0.28	-8.12	-0.31	2.33e-15	Rheumatoid arthritis;
BRCA	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.3e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg23649088	chr2:200775458	C2orf69	0.61	11.87	0.43	1.63e-29	Schizophrenia;
BRCA	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg10818794	chr15:86012489	AKAP13	-0.31	-8.68	-0.32	3.27e-17	Coronary artery disease;
BRCA	cis	rs17253792	0.545	rs34446601	chr14:56010586	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-7.83	-0.3	1.99e-14	Putamen volume;
BRCA	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg10560079	chr2:191398806	TMEM194B	0.36	8.2	0.31	1.31e-15	Pulse pressure;
BRCA	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg11502198	chr6:26597334	ABT1	0.56	12.0	0.43	4.68e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg04025307	chr7:1156635	C7orf50	0.72	17.91	0.58	1.88e-58	Longevity;Endometriosis;
BRCA	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg01877450	chr7:97915802	BRI3	-0.37	-8.33	-0.31	4.82e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8014204	0.762	rs8016389	chr14:75287554	T/C	cg06637938	chr14:75390232	RPS6KL1	0.44	9.06	0.34	1.62e-18	Caffeine consumption;
BRCA	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg04998671	chr14:104000505	TRMT61A	0.43	9.4	0.35	9.86e-20	Coronary artery disease;
BRCA	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg24558204	chr6:135376177	HBS1L	0.45	12.29	0.44	2.57e-31	Red blood cell count;
BRCA	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg17211192	chr8:82754475	SNX16	0.61	11.71	0.42	7.86e-29	Diastolic blood pressure;
BRCA	cis	rs10227331	0.846	rs12673606	chr7:157297518	C/G	cg04156418	chr7:157293606	NA	0.38	10.78	0.39	5.21e-25	Inattentive symptoms;
BRCA	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18404041	chr3:52824283	ITIH1	-0.42	-12.32	-0.44	1.93e-31	Bipolar disorder;
BRCA	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.2	-0.31	1.31e-15	Depression;
BRCA	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg09555818	chr19:45449301	APOC2	0.47	12.21	0.43	5.83e-31	Blood protein levels;
BRCA	cis	rs2882667	0.690	rs288036	chr5:138210895	C/A	cg04439458	chr5:138467593	SIL1	-0.35	-8.55	-0.32	9.12e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9296092	0.560	rs62407561	chr6:33528103	T/C	cg13560919	chr6:33536144	NA	-0.85	-18.69	-0.59	1.6e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg25482853	chr8:67687455	SGK3	1.03	17.7	0.57	2.42e-57	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg14683738	chr19:37701593	ZNF585B	0.45	8.02	0.3	4.94e-15	Coronary artery calcification;
BRCA	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg04691961	chr3:161091175	C3orf57	-0.59	-14.13	-0.49	1.19e-39	Morning vs. evening chronotype;
BRCA	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg21017887	chr14:105400489	NA	0.66	17.5	0.57	2.47e-56	Rheumatoid arthritis;
BRCA	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg27121462	chr16:89883253	FANCA	-0.58	-13.63	-0.47	2.47e-37	Vitiligo;
BRCA	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.41	0.54	8.87e-51	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg25036284	chr2:26402008	FAM59B	-0.9	-15.25	-0.52	5.07e-45	Gut microbiome composition (summer);
BRCA	cis	rs1538970	0.962	rs9429076	chr1:45819489	A/G	cg05343316	chr1:45956843	TESK2	0.41	7.85	0.3	1.7e-14	Platelet count;
BRCA	cis	rs7617773	0.539	rs13087050	chr3:48392800	C/T	cg11946769	chr3:48343235	NME6	0.45	9.69	0.36	8.34e-21	Coronary artery disease;
BRCA	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg05347473	chr6:146136440	FBXO30	-0.42	-8.53	-0.32	1.03e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg00531865	chr16:30841666	NA	-0.5	-11.54	-0.42	4.12e-28	Multiple myeloma;
BRCA	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	9.7	0.36	7.89e-21	Aortic root size;
BRCA	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg02820040	chr2:241836501	C2orf54	-0.47	-9.15	-0.34	7.58e-19	Urinary metabolites;
BRCA	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg05283184	chr6:79620031	NA	-0.43	-10.94	-0.4	1.23e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs701145	0.585	rs1727880	chr3:153835972	G/A	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.89e-18	Coronary artery disease;
BRCA	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg08085267	chr17:45401833	C17orf57	-0.67	-14.76	-0.5	1.29e-42	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs12618769	0.570	rs116051325	chr2:99056836	G/A	cg10123293	chr2:99228465	UNC50	0.41	8.14	0.31	2.05e-15	Bipolar disorder;
BRCA	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg06618935	chr21:46677482	NA	-0.38	-8.39	-0.32	3.11e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg25237894	chr2:233734115	C2orf82	0.4	11.42	0.41	1.32e-27	Coronary artery disease;
BRCA	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg19743168	chr1:23544995	NA	0.47	11.77	0.42	4.24e-29	Height;
BRCA	cis	rs7737355	0.947	rs7725220	chr5:130877001	C/G	cg06307176	chr5:131281290	NA	0.54	10.68	0.39	1.3e-24	Life satisfaction;
BRCA	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.39	-0.38	1.8e-23	Aortic root size;
BRCA	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg15448220	chr1:150897856	SETDB1	0.35	7.83	0.3	2.11e-14	Melanoma;
BRCA	cis	rs2637030	0.559	rs256110	chr5:52879803	A/G	cg06476337	chr5:52856530	NDUFS4	0.36	8.13	0.31	2.23e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg00071950	chr4:10020882	SLC2A9	0.55	13.57	0.47	4.91e-37	Bone mineral density;
BRCA	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg15212455	chr7:39170539	POU6F2	0.39	8.77	0.33	1.66e-17	IgG glycosylation;
BRCA	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg06623918	chr6:96969491	KIAA0776	0.74	12.81	0.45	1.39e-33	Migraine;Coronary artery disease;
BRCA	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg04450456	chr4:17643702	FAM184B	0.38	11.11	0.4	2.49e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg14349672	chr11:133703707	NA	-0.42	-9.53	-0.35	3.35e-20	Childhood ear infection;
BRCA	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg08999081	chr20:33150536	PIGU	0.36	9.21	0.34	4.44e-19	Coronary artery disease;
BRCA	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18876405	chr7:65276391	NA	0.47	10.6	0.39	2.68e-24	Aortic root size;
BRCA	cis	rs11229555	0.645	rs12785578	chr11:58206432	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg15145296	chr3:125709740	NA	-0.55	-8.65	-0.32	4.23e-17	Blood pressure (smoking interaction);
BRCA	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg17971929	chr21:40555470	PSMG1	-0.78	-18.15	-0.58	1.04e-59	Cognitive function;
BRCA	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg23708337	chr7:1209742	NA	0.63	8.84	0.33	9.2e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg15704280	chr7:45808275	SEPT13	0.51	8.72	0.33	2.4e-17	Axial length;
BRCA	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	8.39	0.32	3.01e-16	Mean platelet volume;
BRCA	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9811920	0.809	rs4928153	chr3:99808445	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.53	-12.87	-0.45	7.45e-34	Axial length;
BRCA	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11890956	chr21:40555474	PSMG1	1.04	28.62	0.75	1.45e-116	Cognitive function;
BRCA	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg26816564	chr1:7831052	VAMP3	0.67	12.44	0.44	5.76e-32	Inflammatory bowel disease;
BRCA	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg17366294	chr4:99064904	C4orf37	0.43	9.78	0.36	3.98e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs367943	0.966	rs364738	chr5:112808329	A/G	cg12552261	chr5:112820674	MCC	-0.55	-12.22	-0.44	4.98e-31	Type 2 diabetes;
BRCA	cis	rs10754283	0.967	rs10801761	chr1:90115269	C/T	cg21401794	chr1:90099060	LRRC8C	0.45	10.94	0.4	1.2e-25	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg15212455	chr7:39170539	POU6F2	0.39	8.65	0.32	4.22e-17	IgG glycosylation;
BRCA	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	10.17	0.37	1.31e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs4664304	0.620	rs2048437	chr2:160712065	C/T	cg01092293	chr2:160761427	LY75	0.36	8.52	0.32	1.14e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg09877947	chr5:131593287	PDLIM4	0.38	9.54	0.35	2.98e-20	Breast cancer;
BRCA	cis	rs644148	0.902	rs12982159	chr19:44964300	C/T	cg15540054	chr19:45004280	ZNF180	-0.56	-11.68	-0.42	1.05e-28	Personality dimensions;
BRCA	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	18.91	0.6	1.2e-63	Tonsillectomy;
BRCA	cis	rs6901250	0.744	rs636872	chr6:117087944	C/T	cg12892004	chr6:117198278	RFX6	0.45	10.54	0.38	4.53e-24	C-reactive protein levels;
BRCA	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg05623727	chr3:50126028	RBM5	0.5	12.37	0.44	1.16e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg06494592	chr3:125709126	NA	-0.53	-8.22	-0.31	1.17e-15	Blood pressure (smoking interaction);
BRCA	cis	rs9318086	0.753	rs9553094	chr13:24474613	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.31	-8.77	-0.33	1.66e-17	Myopia (pathological);
BRCA	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.42e-34	Alzheimer's disease (late onset);
BRCA	cis	rs6546537	0.562	rs1985342	chr2:69758927	C/T	cg10773587	chr2:69614142	GFPT1	-0.37	-8.34	-0.31	4.45e-16	Serum thyroid-stimulating hormone levels;
BRCA	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg17294928	chr15:75287854	SCAMP5	0.75	15.93	0.53	2.42e-48	Blood trace element (Zn levels);
BRCA	cis	rs7586879	0.789	rs17046737	chr2:25127835	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.48	0.35	4.99e-20	Body mass index;
BRCA	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg23711669	chr6:146136114	FBXO30	0.72	17.08	0.56	3.73e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6087990	0.735	rs1040555	chr20:31380201	A/T	cg13636640	chr20:31349939	DNMT3B	-0.61	-17.72	-0.57	1.91e-57	Ulcerative colitis;
BRCA	trans	rs9393777	0.920	rs13196692	chr6:27379119	C/T	cg06606381	chr12:133084897	FBRSL1	-0.77	-8.15	-0.31	1.98e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs3925075	0.531	rs4594268	chr16:31343243	T/C	cg02846316	chr16:31340340	ITGAM	0.43	8.73	0.33	2.22e-17	IgA nephropathy;
BRCA	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	12.07	0.43	2.33e-30	Tonsillectomy;
BRCA	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.31	8.61	0.32	5.48e-17	Response to antipsychotic treatment;
BRCA	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg21782813	chr7:2030301	MAD1L1	0.4	10.77	0.39	5.85e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg20307385	chr11:47447363	PSMC3	-0.39	-9.08	-0.34	1.32e-18	Subjective well-being;
BRCA	cis	rs332507	0.830	rs2173852	chr3:124420102	C/G	cg05980111	chr3:124395277	KALRN	-0.33	-7.85	-0.3	1.7e-14	Plateletcrit;
BRCA	cis	rs870825	0.929	rs55635512	chr4:185589982	G/T	cg04058563	chr4:185651563	MLF1IP	0.69	11.73	0.42	6.4e-29	Blood protein levels;
BRCA	cis	rs11690935	0.595	rs788166	chr2:172915489	G/C	cg13550731	chr2:172543902	DYNC1I2	0.56	14.24	0.49	3.61e-40	Schizophrenia;
BRCA	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg00701064	chr4:6280414	WFS1	0.68	17.62	0.57	5.86e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg00677455	chr12:58241039	CTDSP2	0.63	14.53	0.5	1.61e-41	Multiple sclerosis;
BRCA	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg25173405	chr17:45401733	C17orf57	-0.51	-10.59	-0.39	2.89e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg14675211	chr2:100938903	LONRF2	0.52	11.65	0.42	1.41e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg20307385	chr11:47447363	PSMC3	0.87	26.56	0.72	2.59e-105	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg06623918	chr6:96969491	KIAA0776	-0.71	-12.76	-0.45	2.19e-33	Migraine;Coronary artery disease;
BRCA	trans	rs1973993	0.662	rs2057427	chr1:96888897	C/G	cg10631902	chr5:14652156	NA	-0.45	-12.41	-0.44	7.5e-32	Weight;
BRCA	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.15	0.31	1.97e-15	Breast cancer;
BRCA	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.21	0.68	6.53e-87	Chronic sinus infection;
BRCA	cis	rs13064411	0.696	rs2129434	chr3:113138763	A/C	cg18753928	chr3:113234510	CCDC52	-0.49	-9.38	-0.35	1.1e-19	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21659725	chr3:3221576	CRBN	0.51	13.15	0.46	3.86e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs9807989	0.524	rs4851576	chr2:103028895	C/T	cg03938978	chr2:103052716	IL18RAP	0.29	8.37	0.31	3.62e-16	Asthma;
BRCA	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg23711669	chr6:146136114	FBXO30	0.74	17.75	0.57	1.29e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs490234	0.902	rs12351538	chr9:128281503	A/G	cg14078157	chr9:128172775	NA	-0.33	-7.83	-0.3	1.96e-14	Mean arterial pressure;
BRCA	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg18404041	chr3:52824283	ITIH1	0.32	8.51	0.32	1.26e-16	Schizophrenia;
BRCA	cis	rs11958404	0.789	rs72818150	chr5:157484121	A/G	cg05962755	chr5:157440814	NA	0.55	9.68	0.36	8.67e-21	IgG glycosylation;
BRCA	cis	rs7809615	0.901	rs6947941	chr7:99156446	G/T	cg12290671	chr7:99195819	NA	-0.5	-8.44	-0.32	2.2e-16	Blood metabolite ratios;
BRCA	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg02773041	chr1:40204384	PPIE	0.45	9.68	0.36	8.97e-21	Blood protein levels;
BRCA	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	8.55	0.32	9.33e-17	Electroencephalogram traits;
BRCA	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg04851639	chr8:1020857	NA	0.33	10.29	0.38	4.36e-23	Schizophrenia;
BRCA	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg00012203	chr2:219082015	ARPC2	-0.5	-10.2	-0.37	9.7e-23	Colorectal cancer;
BRCA	trans	rs7746199	0.736	rs56405707	chr6:27640246	G/A	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.5	-0.32	1.31e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg03188948	chr7:1209495	NA	0.61	11.6	0.42	2.3e-28	Longevity;Endometriosis;
BRCA	cis	rs6496044	0.568	rs7176291	chr15:86067398	T/C	cg10818794	chr15:86012489	AKAP13	-0.29	-7.91	-0.3	1.18e-14	Interstitial lung disease;
BRCA	cis	rs4664304	0.772	rs12692572	chr2:160743793	G/A	cg02280532	chr2:160761244	LY75	0.36	7.98	0.3	6.9e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg13010199	chr12:38710504	ALG10B	0.51	10.25	0.38	6.57e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg12386194	chr3:101231763	SENP7	0.47	9.83	0.36	2.59e-21	Colorectal cancer;
BRCA	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg18404041	chr3:52824283	ITIH1	-0.31	-7.83	-0.3	2.02e-14	Schizophrenia;
BRCA	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.72	-0.39	9.09e-25	Mean corpuscular volume;
BRCA	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.31	-8.08	-0.3	3.15e-15	Response to antipsychotic treatment;
BRCA	cis	rs698813	0.674	rs713447	chr2:44505185	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	9.27	0.34	2.85e-19	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg02551604	chr5:131831745	NA	-0.4	-14.07	-0.49	2.23e-39	Asthma (sex interaction);
BRCA	trans	rs877282	1.000	rs11253369	chr10:773610	C/G	cg22713356	chr15:30763199	NA	1.03	19.89	0.62	7.27e-69	Uric acid levels;
BRCA	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg12311346	chr5:56204834	C5orf35	-0.73	-11.77	-0.42	4.34e-29	Type 2 diabetes;
BRCA	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	12.14	0.43	1.1e-30	Tonsillectomy;
BRCA	cis	rs6543140	0.601	rs6543135	chr2:103062406	C/T	cg04239558	chr2:103089729	SLC9A4	0.34	8.1	0.31	2.71e-15	Blood protein levels;
BRCA	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.67	14.34	0.49	1.18e-40	Lymphocyte counts;
BRCA	cis	rs3768617	0.811	rs12120747	chr1:183042531	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.63	0.36	1.34e-20	Fuchs's corneal dystrophy;
BRCA	cis	rs13046373	0.535	rs1961167	chr21:32030310	T/C	cg06468780	chr21:31798236	KRTAP13-3	0.35	8.45	0.32	1.96e-16	HDL cholesterol;
BRCA	cis	rs6987853	0.712	rs2974343	chr8:42400679	G/A	cg09913449	chr8:42400586	C8orf40	0.41	9.08	0.34	1.35e-18	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.03	-18.48	-0.59	2.01e-61	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg11814155	chr7:99998594	ZCWPW1	0.49	8.91	0.33	5.41e-18	Platelet count;
BRCA	cis	rs11958404	0.932	rs72816552	chr5:157422376	G/A	cg05962755	chr5:157440814	NA	0.52	9.89	0.36	1.52e-21	IgG glycosylation;
BRCA	cis	rs870825	0.616	rs7694899	chr4:185625390	C/T	cg04058563	chr4:185651563	MLF1IP	0.74	16.53	0.55	2.4e-51	Blood protein levels;
BRCA	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg18850127	chr7:39170497	POU6F2	0.53	11.92	0.43	1.04e-29	IgG glycosylation;
BRCA	cis	rs858239	1.000	rs858239	chr7:23286315	G/A	cg23682824	chr7:23144976	KLHL7	0.36	8.95	0.33	3.75e-18	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg06521331	chr12:34319734	NA	-0.54	-10.37	-0.38	2.16e-23	Bladder cancer;
BRCA	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg12419862	chr22:24373484	LOC391322	-0.64	-14.69	-0.5	2.79e-42	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2880765	0.743	rs6497191	chr15:86011501	T/C	cg10818794	chr15:86012489	AKAP13	-0.31	-8.51	-0.32	1.2e-16	Coronary artery disease;
BRCA	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg07952391	chr2:88470173	THNSL2	0.6	9.29	0.34	2.39e-19	Plasma clusterin levels;
BRCA	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21659725	chr3:3221576	CRBN	0.49	11.34	0.41	2.88e-27	Resting heart rate;
BRCA	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-9.03	-0.34	1.99e-18	Alzheimer's disease (late onset);
BRCA	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg08603382	chr10:743973	NA	-0.46	-8.67	-0.32	3.64e-17	Psychosis in Alzheimer's disease;
BRCA	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18876405	chr7:65276391	NA	-0.51	-11.36	-0.41	2.28e-27	Aortic root size;
BRCA	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg24130564	chr14:104152367	KLC1	-0.41	-8.79	-0.33	1.35e-17	Reticulocyte count;
BRCA	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-11.4	-0.41	1.56e-27	Gut microbiome composition (summer);
BRCA	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg06494592	chr3:125709126	NA	-0.53	-8.5	-0.32	1.29e-16	Blood pressure (smoking interaction);
BRCA	cis	rs701145	0.585	rs1629659	chr3:153798731	C/T	cg17054900	chr3:154042577	DHX36	0.54	9.14	0.34	8.17e-19	Coronary artery disease;
BRCA	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg01324343	chr3:183735012	ABCC5	0.84	21.26	0.64	2.76e-76	Anterior chamber depth;
BRCA	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg08645402	chr16:4508243	NA	-0.37	-8.81	-0.33	1.22e-17	Schizophrenia;
BRCA	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg13397359	chr6:42928475	GNMT	0.76	19.42	0.61	2.14e-66	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2882667	0.690	rs288026	chr5:138222594	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-8.21	-0.31	1.19e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg02574844	chr11:5959923	NA	-0.41	-8.5	-0.32	1.38e-16	DNA methylation (variation);
BRCA	trans	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg25214090	chr10:38739885	LOC399744	0.52	11.63	0.42	1.64e-28	Corneal astigmatism;
BRCA	cis	rs6543140	0.964	rs10169192	chr2:103072211	A/G	cg04239558	chr2:103089729	SLC9A4	0.34	9.56	0.35	2.4e-20	Blood protein levels;
BRCA	cis	rs1003719	0.646	rs7276711	chr21:38578189	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.73	-0.5	1.77e-42	Eye color traits;
BRCA	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg18154014	chr19:37997991	ZNF793	0.61	11.38	0.41	1.85e-27	Coronary artery calcification;
BRCA	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg11584989	chr19:19387371	SF4	0.63	13.4	0.47	2.84e-36	Bipolar disorder;
BRCA	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-12.89	-0.45	6.01e-34	Response to antipsychotic treatment;
BRCA	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.89	0.33	6.22e-18	Tonsillectomy;
BRCA	cis	rs9560113	1.000	rs61967684	chr13:112178026	G/C	cg10483660	chr13:112241077	NA	0.32	7.86	0.3	1.65e-14	Menarche (age at onset);
BRCA	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.04	-0.34	1.81e-18	Total body bone mineral density;
BRCA	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg01884057	chr2:25150051	NA	0.33	8.68	0.32	3.24e-17	Body mass index in non-asthmatics;
BRCA	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.37	0.35	1.19e-19	Morning vs. evening chronotype;
BRCA	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg11764359	chr7:65958608	NA	0.63	10.74	0.39	7.39e-25	Aortic root size;
BRCA	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg12927641	chr6:109611667	NA	-0.41	-10.59	-0.39	3.05e-24	Reticulocyte fraction of red cells;
BRCA	cis	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.22	-0.31	1.14e-15	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg00750074	chr16:89608354	SPG7	0.38	10.33	0.38	3.05e-23	Multiple myeloma (IgH translocation);
BRCA	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg24296786	chr1:45957014	TESK2	-0.54	-12.73	-0.45	2.96e-33	High light scatter reticulocyte count;
BRCA	cis	rs11718455	0.921	rs1404482	chr3:43997282	A/G	cg08738300	chr3:44038990	NA	0.44	8.57	0.32	8.06e-17	Coronary artery disease;
BRCA	cis	rs6772849	0.930	rs6768344	chr3:128373556	G/A	cg16766828	chr3:128327626	NA	-0.39	-8.64	-0.32	4.64e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-12.28	-0.44	2.95e-31	Tonsillectomy;
BRCA	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg20503657	chr10:835505	NA	0.95	17.83	0.58	5.12e-58	Eosinophil percentage of granulocytes;
BRCA	trans	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg25214090	chr10:38739885	LOC399744	0.37	8.61	0.32	5.53e-17	Diastolic blood pressure;
BRCA	cis	rs922182	0.556	rs12443020	chr15:64215823	G/T	cg24729988	chr15:64271149	DAPK2	0.46	9.49	0.35	4.5e-20	Blood protein levels;
BRCA	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.99	0.43	5.31e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg21427119	chr20:30132790	HM13	-0.43	-9.28	-0.34	2.51e-19	Mean corpuscular volume;
BRCA	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg12011299	chr4:100065546	ADH4	0.37	9.28	0.34	2.56e-19	Alcohol dependence;
BRCA	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg06238570	chr21:40685208	BRWD1	-0.41	-8.32	-0.31	5.28e-16	Cognitive function;
BRCA	cis	rs17401966	0.800	rs12725210	chr1:10416993	G/A	cg03954927	chr1:10346856	KIF1B	0.43	13.57	0.47	4.97e-37	Hepatocellular carcinoma;
BRCA	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg20307385	chr11:47447363	PSMC3	0.74	17.0	0.56	9.98e-54	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06002616	chr8:101225028	SPAG1	-0.34	-8.34	-0.31	4.47e-16	Atrioventricular conduction;
BRCA	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg13319975	chr6:146136371	FBXO30	0.42	9.28	0.34	2.62e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg16606324	chr3:10149918	C3orf24	0.55	10.84	0.39	2.97e-25	Alzheimer's disease;
BRCA	cis	rs738322	0.804	rs2076116	chr22:38517405	A/G	cg25457927	chr22:38595422	NA	-0.29	-10.45	-0.38	1.04e-23	Cutaneous nevi;
BRCA	trans	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg07211511	chr3:129823064	LOC729375	-0.63	-11.59	-0.42	2.56e-28	Blood pressure (smoking interaction);
BRCA	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2882667	0.690	rs7722965	chr5:138100455	T/C	cg04439458	chr5:138467593	SIL1	0.34	8.41	0.32	2.59e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg04025307	chr7:1156635	C7orf50	0.54	13.6	0.47	3.58e-37	Longevity;Endometriosis;
BRCA	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03264133	chr6:25882463	NA	0.7	16.09	0.54	3.68e-49	Blood metabolite levels;
BRCA	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg19784903	chr17:45786737	TBKBP1	0.34	8.06	0.3	3.76e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23583168	chr7:148888333	NA	-0.79	-18.48	-0.59	2.1e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	ch.11.42038R	chr11:967971	AP2A2	0.47	14.22	0.49	4.33e-40	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg24812749	chr6:127587940	RNF146	0.84	19.32	0.61	7.62e-66	Breast cancer;
BRCA	cis	rs16867321	0.588	rs1919156	chr2:181456978	C/T	cg23363182	chr2:181467187	NA	-0.49	-10.85	-0.39	2.72e-25	Obesity;
BRCA	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.91	0.62	5.12e-69	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs11605924	0.692	rs877412	chr11:45897651	A/C	ch.11.939596F	chr11:45881766	CRY2	0.57	14.12	0.49	1.3e-39	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg01181863	chr3:195395398	SDHAP2	0.49	8.63	0.32	5.03e-17	Pancreatic cancer;
BRCA	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg08738300	chr3:44038990	NA	-0.45	-8.81	-0.33	1.18e-17	Coronary artery disease;
BRCA	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg06618935	chr21:46677482	NA	-0.37	-8.1	-0.31	2.87e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1691799	0.899	rs1168307	chr12:66739539	A/G	cg16791601	chr12:66731901	HELB	-0.7	-19.78	-0.62	2.81e-68	White blood cell count (basophil);
BRCA	cis	rs6450176	0.597	rs1541682	chr5:53304401	C/T	cg22592108	chr5:53304441	ARL15	0.34	8.1	0.31	2.81e-15	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg00277334	chr10:82204260	NA	-0.49	-10.57	-0.39	3.61e-24	Post bronchodilator FEV1;
BRCA	cis	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg08807101	chr21:30365312	RNF160	-0.47	-7.97	-0.3	7.37e-15	Cognitive test performance;
BRCA	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg27446573	chr6:127587934	RNF146	0.89	20.5	0.63	3.86e-72	Breast cancer;
BRCA	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg07741184	chr6:167504864	NA	0.27	8.1	0.31	2.78e-15	Crohn's disease;
BRCA	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg13010199	chr12:38710504	ALG10B	0.43	9.19	0.34	5.3e-19	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.63	0.32	4.71e-17	Motion sickness;
BRCA	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.21	0.68	6.53e-87	Chronic sinus infection;
BRCA	cis	rs477692	0.517	rs871026	chr10:131293145	A/G	cg05714579	chr10:131428358	MGMT	-0.48	-10.62	-0.39	2.21e-24	Response to temozolomide;
BRCA	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg24154853	chr7:158122151	PTPRN2	0.38	8.26	0.31	8.35e-16	Calcium levels;
BRCA	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	25.61	0.71	4.28e-100	Platelet count;
BRCA	cis	rs61990749	0.597	rs9323650	chr14:78150336	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.63	10.12	0.37	1.97e-22	Fibroblast growth factor basic levels;
BRCA	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg24631222	chr15:78858424	CHRNA5	-0.5	-9.95	-0.37	8.52e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs9400271	0.632	rs9400262	chr6:109591433	T/C	cg21918786	chr6:109611834	NA	-0.32	-8.1	-0.31	2.78e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	trans	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg25214090	chr10:38739885	LOC399744	0.56	12.85	0.45	9.31e-34	Corneal astigmatism;
BRCA	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg22508957	chr16:3507546	NAT15	0.47	11.67	0.42	1.18e-28	Tuberculosis;
BRCA	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26314531	chr2:26401878	FAM59B	-0.88	-15.45	-0.52	5.59e-46	Gut microbiome composition (summer);
BRCA	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00908189	chr16:619842	PIGQ	0.68	17.0	0.56	9.38e-54	Height;
BRCA	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.8	-0.36	3.27e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs367615	0.918	rs4576198	chr5:108867350	T/G	cg17395555	chr5:108820864	NA	0.38	9.67	0.36	1e-20	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs7301826	0.627	rs10773823	chr12:131294501	C/T	cg11011512	chr12:131303247	STX2	0.51	13.62	0.47	3e-37	Plasma plasminogen activator levels;
BRCA	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	10.45	0.38	1.08e-23	Aortic root size;
BRCA	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg27147174	chr7:100797783	AP1S1	-0.54	-10.89	-0.4	1.83e-25	Life satisfaction;
BRCA	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11764359	chr7:65958608	NA	0.8	19.51	0.61	7.33e-67	Aortic root size;
BRCA	cis	rs2835872	0.733	rs1709822	chr21:39035485	A/G	cg06728970	chr21:39037746	KCNJ6	0.45	12.83	0.45	1.12e-33	Electroencephalographic traits in alcoholism;
BRCA	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg15208524	chr1:10270712	KIF1B	0.36	8.19	0.31	1.42e-15	Hepatocellular carcinoma;
BRCA	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg14675211	chr2:100938903	LONRF2	0.41	9.29	0.35	2.31e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11644478	chr21:40555479	PSMG1	0.84	19.21	0.61	2.91e-65	Cognitive function;
BRCA	cis	rs12210905	0.688	rs12215289	chr6:27468705	T/C	cg08851530	chr6:28072375	NA	0.82	8.04	0.3	4.42e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18876405	chr7:65276391	NA	0.55	13.09	0.46	7.42e-35	Aortic root size;
BRCA	cis	rs7011049	0.673	rs72640835	chr8:53828012	T/C	cg26025543	chr8:53854495	NA	0.43	7.85	0.3	1.8e-14	Systolic blood pressure;
BRCA	cis	rs16858210	0.657	rs73177515	chr3:183566825	T/A	cg25686905	chr3:183603175	PARL	-0.39	-8.35	-0.31	4.4e-16	Menopause (age at onset);
BRCA	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.0	0.48	4.7e-39	Motion sickness;
BRCA	cis	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg06521331	chr12:34319734	NA	-0.44	-8.06	-0.3	3.7e-15	Resting heart rate;
BRCA	cis	rs2073300	1.000	rs6137976	chr20:23463241	C/T	cg12062639	chr20:23401060	NAPB	0.83	9.87	0.36	1.77e-21	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg00012203	chr2:219082015	ARPC2	-0.47	-9.22	-0.34	4.42e-19	Colorectal cancer;
BRCA	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg13010199	chr12:38710504	ALG10B	0.41	8.47	0.32	1.64e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10193935	0.792	rs13423729	chr2:42492874	C/T	cg27598129	chr2:42591480	NA	-0.58	-9.68	-0.36	9.27e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.38	-0.38	1.89e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg04034577	chr2:241836375	C2orf54	-0.57	-14.0	-0.48	4.96e-39	Urinary metabolites;
BRCA	cis	rs4363385	0.818	rs3795381	chr1:153004848	T/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.21	-0.34	4.44e-19	Inflammatory skin disease;
BRCA	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg26384229	chr12:38710491	ALG10B	0.67	14.24	0.49	3.81e-40	Morning vs. evening chronotype;
BRCA	cis	rs3862030	0.694	rs41306870	chr10:104229785	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.14	-0.43	1.12e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg12373951	chr3:133503437	NA	0.34	8.03	0.3	4.6e-15	Iron status biomarkers;
BRCA	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg04709771	chr16:646395	RAB40C	0.45	11.23	0.41	8.1e-27	Height;
BRCA	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-13.18	-0.46	3.02e-35	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs7903847	0.642	rs7896100	chr10:99156994	C/T	cg08345082	chr10:99160200	RRP12	-0.3	-8.83	-0.33	9.93e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2425143	1.000	rs2425143	chr20:34350666	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.14	-0.37	1.61e-22	Blood protein levels;
BRCA	cis	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.42	-0.32	2.51e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs311392	0.902	rs438437	chr8:55094187	G/C	cg11783602	chr8:55087084	NA	-0.32	-9.36	-0.35	1.36e-19	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.81	12.49	0.44	3.53e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6604026	0.740	rs6604031	chr1:93400766	T/G	cg17283838	chr1:93427260	FAM69A	-0.39	-8.09	-0.3	2.99e-15	Multiple sclerosis;
BRCA	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg23950597	chr19:37808831	NA	-0.75	-13.02	-0.46	1.52e-34	Coronary artery calcification;
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg18765753	chr7:1198926	ZFAND2A	0.46	10.56	0.39	3.82e-24	Longevity;Endometriosis;
BRCA	trans	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg23762105	chr12:34175262	ALG10	-0.39	-9.58	-0.35	2.07e-20	Morning vs. evening chronotype;
BRCA	cis	rs3771570	0.901	rs35496488	chr2:242434316	G/A	cg21155796	chr2:242212141	HDLBP	0.63	9.7	0.36	7.62e-21	Prostate cancer;
BRCA	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg20503657	chr10:835505	NA	0.9	13.78	0.48	5.04e-38	Eosinophil percentage of granulocytes;
BRCA	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-11.21	-0.41	9.48e-27	Gut microbiome composition (summer);
BRCA	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg15017067	chr4:17643749	FAM184B	0.31	8.6	0.32	5.99e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs17270561	0.636	rs9379779	chr6:25695441	G/T	cg17691542	chr6:26056736	HIST1H1C	0.48	9.1	0.34	1.12e-18	Iron status biomarkers;
BRCA	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg16576597	chr16:28551801	NUPR1	-0.28	-8.01	-0.3	5.42e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs1451375	0.617	rs2329371	chr7:50615440	G/A	cg18232548	chr7:50535776	DDC	0.43	9.17	0.34	6.45e-19	Malaria;
BRCA	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.48	-9.38	-0.35	1.11e-19	Chronic sinus infection;
BRCA	cis	rs897080	0.552	rs1067397	chr2:44679285	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	9.31	0.35	1.98e-19	Height;
BRCA	cis	rs11585357	0.895	rs4625336	chr1:17630964	G/T	cg08277548	chr1:17600880	PADI3	-0.62	-10.65	-0.39	1.77e-24	Hair shape;
BRCA	cis	rs17095355	0.901	rs12240333	chr10:111743972	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.38	-9.64	-0.36	1.26e-20	Biliary atresia;
BRCA	cis	rs9400271	0.632	rs6930844	chr6:109590286	C/A	cg21918786	chr6:109611834	NA	-0.32	-8.02	-0.3	4.96e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg11843238	chr5:131593191	PDLIM4	-0.37	-7.89	-0.3	1.36e-14	Breast cancer;
BRCA	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.48	0.32	1.51e-16	Cognitive ability;
BRCA	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg15704280	chr7:45808275	SEPT13	0.7	14.14	0.49	1.11e-39	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg05340658	chr4:99064831	C4orf37	0.68	16.98	0.56	1.21e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.68	0.61	9.04e-68	Alzheimer's disease;
BRCA	cis	rs1865721	0.917	rs62089506	chr18:73178913	A/G	cg26385618	chr18:73139727	C18orf62	-0.41	-9.23	-0.34	3.87e-19	Intelligence;
BRCA	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg00106254	chr7:1943704	MAD1L1	-0.42	-11.46	-0.41	8.67e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.28	-0.41	5.11e-27	Morning vs. evening chronotype;
BRCA	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg22307297	chr20:60903441	LAMA5	-0.34	-9.44	-0.35	6.97e-20	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs7301016	0.846	rs11174569	chr12:63021161	A/C	cg01804193	chr12:63026212	NA	0.47	8.41	0.32	2.73e-16	IgG glycosylation;
BRCA	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg03146154	chr1:46216737	IPP	0.46	10.21	0.37	8.87e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg26043149	chr18:55253948	FECH	-0.36	-7.89	-0.3	1.34e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg01528321	chr10:82214614	TSPAN14	0.62	14.12	0.49	1.3e-39	Post bronchodilator FEV1;
BRCA	trans	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.85	19.38	0.61	3.79e-66	Cognitive ability;
BRCA	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg23202291	chr11:1979235	NA	0.4	9.06	0.34	1.61e-18	DNA methylation (parent-of-origin);DNA methylation (variation);
BRCA	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00339695	chr16:24857497	SLC5A11	-0.34	-8.25	-0.31	8.84e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg04025307	chr7:1156635	C7orf50	0.58	14.65	0.5	4.28e-42	Longevity;Endometriosis;
BRCA	cis	rs12200560	0.505	rs211163	chr6:97067654	A/G	cg06623918	chr6:96969491	KIAA0776	0.51	12.06	0.43	2.45e-30	Coronary heart disease;
BRCA	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19346786	chr7:2764209	NA	-0.37	-11.15	-0.4	1.64e-26	Height;
BRCA	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg03585969	chr10:35415529	CREM	0.48	10.19	0.37	1.07e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.89	0.3	1.33e-14	Corneal astigmatism;
BRCA	cis	rs250677	0.522	rs4431331	chr5:148353574	A/C	cg18129178	chr5:148520854	ABLIM3	-0.5	-9.64	-0.36	1.24e-20	Breast cancer;
BRCA	cis	rs7827545	0.545	rs6988000	chr8:135559534	C/T	cg17885191	chr8:135476712	NA	0.58	9.99	0.37	6.27e-22	Hypertension (SNP x SNP interaction);
BRCA	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg13010199	chr12:38710504	ALG10B	0.5	10.12	0.37	1.91e-22	Bladder cancer;
BRCA	cis	rs9296092	0.500	rs35150558	chr6:33519612	T/A	cg13560919	chr6:33536144	NA	-0.85	-18.66	-0.59	2.26e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg04920474	chr2:44395004	PPM1B	0.48	10.07	0.37	3.18e-22	Height;
BRCA	cis	rs7119	1.000	rs7119	chr15:77777632	C/T	cg17802220	chr15:77601643	NA	-0.33	-8.11	-0.31	2.57e-15	Type 2 diabetes;
BRCA	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg11584989	chr19:19387371	SF4	0.63	13.56	0.47	5.66e-37	Bipolar disorder;
BRCA	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg18811423	chr2:55921094	PNPT1	0.73	23.61	0.68	4.33e-89	Metabolic syndrome;
BRCA	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.54	8.41	0.32	2.77e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg13319975	chr6:146136371	FBXO30	-0.54	-12.08	-0.43	2.01e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs754466	0.561	rs72806025	chr10:79707026	C/T	cg17075019	chr10:79541650	NA	-0.54	-8.13	-0.31	2.21e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg23625390	chr15:77176239	SCAPER	0.52	12.36	0.44	1.31e-31	Blood metabolite levels;
BRCA	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg24558204	chr6:135376177	HBS1L	0.46	12.62	0.45	8.89e-33	Reticulocyte count;High light scatter reticulocyte count;
BRCA	cis	rs4363385	0.818	rs10788853	chr1:153002231	C/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.42	-0.32	2.38e-16	Inflammatory skin disease;
BRCA	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-14.12	-0.49	1.31e-39	Monocyte count;
BRCA	cis	rs16958440	1.000	rs61316646	chr18:44610670	G/C	cg17192377	chr18:44677553	HDHD2	0.67	9.76	0.36	4.65e-21	Sitting height ratio;
BRCA	cis	rs13136331	0.721	rs2627717	chr4:88684745	C/T	cg22416721	chr4:88570574	DMP1	-0.52	-12.29	-0.44	2.52e-31	Sitting height ratio;
BRCA	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg24579218	chr15:68104479	NA	-0.36	-7.83	-0.3	1.97e-14	Restless legs syndrome;
BRCA	cis	rs524281	0.861	rs10896081	chr11:65880354	A/T	cg16950941	chr11:66035639	RAB1B	-0.39	-8.56	-0.32	8.12e-17	Electroencephalogram traits;
BRCA	cis	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg07460842	chr6:66804631	NA	0.88	14.29	0.49	2.04e-40	Exhaled nitric oxide output;
BRCA	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg02820040	chr2:241836501	C2orf54	-0.47	-9.16	-0.34	6.78e-19	Urinary metabolites;
BRCA	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg11789530	chr4:8429930	ACOX3	-0.55	-12.79	-0.45	1.7e-33	Response to antineoplastic agents;
BRCA	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg00383909	chr3:49044727	WDR6	0.58	10.53	0.38	4.88e-24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg17330251	chr7:94953956	PON1	-0.42	-8.78	-0.33	1.52e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08564027	chr20:61660810	NA	0.85	22.12	0.66	6.49e-81	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11958404	0.860	rs11135023	chr5:157420082	G/T	cg05962755	chr5:157440814	NA	0.45	9.44	0.35	6.92e-20	IgG glycosylation;
BRCA	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg07537917	chr2:241836409	C2orf54	-0.49	-11.68	-0.42	1.08e-28	Urinary metabolites;
BRCA	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-11.74	-0.42	5.88e-29	Chronic sinus infection;
BRCA	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.21	0.34	4.65e-19	Tonsillectomy;
BRCA	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg03676636	chr4:99064102	C4orf37	0.22	8.07	0.3	3.51e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg16339924	chr4:17578868	LAP3	0.67	17.11	0.56	2.65e-54	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12516959	chr21:47718080	NA	-0.34	-8.29	-0.31	6.75e-16	Testicular germ cell tumor;
BRCA	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.4	-8.38	-0.31	3.27e-16	Aortic root size;
BRCA	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-12.45	-0.44	5.45e-32	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs1891275	0.515	rs1361552	chr10:93534624	T/C	cg07889827	chr10:93443413	NA	-0.41	-11.27	-0.41	5.27e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	18.11	0.58	1.89e-59	Menopause (age at onset);
BRCA	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg27661571	chr11:113659931	NA	-0.73	-11.22	-0.41	8.28e-27	Hip circumference adjusted for BMI;
BRCA	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg05621596	chr22:47072043	GRAMD4	0.65	14.23	0.49	3.92e-40	Urate levels in obese individuals;
BRCA	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24531977	chr5:56204891	C5orf35	-0.88	-18.17	-0.58	8.2e-60	Initial pursuit acceleration;
BRCA	cis	rs13394619	1.000	rs2884374	chr2:11731846	C/T	cg07314298	chr2:11723111	GREB1	0.52	11.89	0.43	1.37e-29	Endometriosis;
BRCA	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg15352829	chr14:105391018	PLD4	0.38	12.12	0.43	1.41e-30	Rheumatoid arthritis;
BRCA	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg27129171	chr3:47204927	SETD2	-0.68	-16.12	-0.54	2.59e-49	Colorectal cancer;
BRCA	cis	rs870825	0.616	rs3184982	chr4:185615768	T/G	cg04058563	chr4:185651563	MLF1IP	0.78	17.17	0.56	1.32e-54	Blood protein levels;
BRCA	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg05340658	chr4:99064831	C4orf37	0.58	11.85	0.42	1.93e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg21280719	chr6:42927975	GNMT	0.29	12.71	0.45	3.64e-33	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs3857536	0.813	rs4710581	chr6:66939954	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs7572733	0.534	rs10931794	chr2:198776140	C/T	cg00792783	chr2:198669748	PLCL1	-0.48	-10.32	-0.38	3.35e-23	Dermatomyositis;
BRCA	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg20607798	chr8:58055168	NA	0.6	9.24	0.34	3.61e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg13010199	chr12:38710504	ALG10B	0.41	8.5	0.32	1.35e-16	Bladder cancer;
BRCA	cis	rs96067	0.711	rs272811	chr1:36634414	G/A	cg24686825	chr1:36642396	MAP7D1	-0.57	-11.56	-0.42	3.44e-28	Corneal structure;
BRCA	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-9.64	-0.36	1.26e-20	Mean corpuscular volume;
BRCA	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg17063962	chr7:91808500	NA	0.55	12.63	0.45	8.24e-33	Breast cancer;
BRCA	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	19.52	0.61	6.5e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg04025307	chr7:1156635	C7orf50	0.47	9.14	0.34	8.42e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs9976767	0.608	rs9784208	chr21:43824986	A/G	cg23042151	chr21:43824109	UBASH3A	-0.27	-8.48	-0.32	1.57e-16	Type 1 diabetes;
BRCA	cis	rs6684514	1.000	rs10908500	chr1:156280671	A/T	cg16558208	chr1:156270281	VHLL	0.35	8.07	0.3	3.53e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.65	-14.03	-0.49	3.54e-39	Lung cancer;
BRCA	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.78	-17.87	-0.58	3.18e-58	Schizophrenia;
BRCA	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg13789015	chr9:136890014	NCRNA00094	0.55	11.43	0.41	1.14e-27	Platelet distribution width;
BRCA	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg25358565	chr5:93447407	FAM172A	1.21	18.85	0.6	2.32e-63	Diabetic retinopathy;
BRCA	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.81	-0.36	2.86e-21	IgG glycosylation;
BRCA	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg02659138	chr7:134003124	SLC35B4	0.34	10.47	0.38	8.67e-24	Mean platelet volume;
BRCA	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg11584989	chr19:19387371	SF4	0.55	12.35	0.44	1.43e-31	Bipolar disorder;
BRCA	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg21395723	chr22:39101663	GTPBP1	0.39	8.28	0.31	7.23e-16	Menopause (age at onset);
BRCA	cis	rs2625529	0.713	rs16956634	chr15:72552243	C/G	cg16672083	chr15:72433130	SENP8	0.77	15.77	0.53	1.49e-47	Red blood cell count;
BRCA	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg22920501	chr2:26401640	FAM59B	-0.91	-16.27	-0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.72	15.73	0.53	2.39e-47	Lymphocyte counts;
BRCA	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg14558114	chr2:88469736	THNSL2	0.63	9.17	0.34	6.56e-19	Plasma clusterin levels;
BRCA	cis	rs7851660	0.527	rs7870795	chr9:100574120	A/G	cg13688889	chr9:100608707	NA	-0.51	-11.92	-0.43	1.03e-29	Strep throat;
BRCA	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg22834771	chr12:69754056	YEATS4	-0.37	-9.05	-0.34	1.68e-18	Blood protein levels;
BRCA	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg13902645	chr11:5959945	NA	-0.48	-9.8	-0.36	3.33e-21	DNA methylation (variation);
BRCA	cis	rs758324	0.947	rs4493667	chr5:131247218	G/T	cg06307176	chr5:131281290	NA	-0.52	-10.16	-0.37	1.38e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg17691542	chr6:26056736	HIST1H1C	0.43	9.27	0.34	2.89e-19	Iron status biomarkers;
BRCA	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg05313129	chr8:58192883	C8orf71	-0.46	-9.63	-0.36	1.33e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11890956	chr21:40555474	PSMG1	-0.62	-13.74	-0.48	7.58e-38	Menarche (age at onset);
BRCA	cis	rs7577696	0.597	rs17011801	chr2:32298072	A/T	cg02381751	chr2:32503542	YIPF4	-0.42	-7.99	-0.3	6.45e-15	Inflammatory biomarkers;
BRCA	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg17063962	chr7:91808500	NA	-0.52	-12.15	-0.43	1e-30	Breast cancer;
BRCA	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg09307838	chr4:120376055	NA	0.71	14.86	0.51	4.18e-43	Corneal astigmatism;
BRCA	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.18	0.46	2.94e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg06917634	chr15:78832804	PSMA4	-0.56	-11.65	-0.42	1.44e-28	Sudden cardiac arrest;
BRCA	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg13319975	chr6:146136371	FBXO30	0.62	14.55	0.5	1.28e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg18876405	chr7:65276391	NA	0.58	13.94	0.48	9.77e-39	Aortic root size;
BRCA	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24308560	chr3:49941425	MST1R	-0.39	-8.23	-0.31	1.08e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	8.78	0.33	1.45e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs67981189	0.593	rs2526871	chr14:71385113	G/A	cg15816911	chr14:71606274	NA	-0.37	-8.45	-0.32	2e-16	Schizophrenia;
BRCA	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg04025307	chr7:1156635	C7orf50	-0.43	-9.64	-0.36	1.22e-20	Longevity;Endometriosis;
BRCA	cis	rs72627509	0.904	rs56281640	chr4:57765816	G/A	cg26694713	chr4:57773883	REST	0.52	10.24	0.38	6.91e-23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg08754654	chr5:154026448	NA	0.43	10.07	0.37	3.12e-22	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6545883	0.895	rs2256617	chr2:61679924	A/G	cg15711740	chr2:61764176	XPO1	-0.53	-13.28	-0.47	1.02e-35	Tuberculosis;
BRCA	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg09184832	chr6:79620586	NA	-0.49	-10.63	-0.39	2.06e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg02175503	chr12:58329896	NA	0.4	7.98	0.3	6.88e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	9.79	0.36	3.65e-21	Bipolar disorder;
BRCA	cis	rs3772130	0.962	rs11707518	chr3:121496568	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.56	9.87	0.36	1.78e-21	Cognitive performance;
BRCA	cis	rs490234	0.841	rs1755936	chr9:128388991	C/G	cg14078157	chr9:128172775	NA	-0.35	-8.29	-0.31	6.88e-16	Mean arterial pressure;
BRCA	cis	rs9837602	1.000	rs1688772	chr3:99503366	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.59	-10.77	-0.39	5.51e-25	Breast cancer;
BRCA	cis	rs17401966	0.540	rs6541094	chr1:10467074	G/A	cg03954927	chr1:10346856	KIF1B	0.34	10.08	0.37	2.78e-22	Hepatocellular carcinoma;
BRCA	cis	rs66569888	0.581	rs17271098	chr2:106692818	A/G	cg16099169	chr2:106886729	NA	0.54	9.83	0.36	2.59e-21	Facial morphology (factor 23);
BRCA	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg00717180	chr2:96193071	NA	-0.36	-9.93	-0.37	1.06e-21	Height;
BRCA	cis	rs3760982	0.585	rs4803659	chr19:44290235	C/T	cg12072164	chr19:44306565	LYPD5	0.36	8.62	0.32	5.08e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg12432903	chr7:1882776	MAD1L1	0.46	8.15	0.31	1.96e-15	Bipolar disorder;
BRCA	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg08000102	chr2:233561755	GIGYF2	-0.61	-13.6	-0.47	3.61e-37	Coronary artery disease;
BRCA	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-12.33	-0.44	1.73e-31	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2177596	0.549	rs4592846	chr2:227948866	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.12	-0.34	9.83e-19	Body mass index;
BRCA	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg10932868	chr11:921992	NA	0.49	12.66	0.45	6.42e-33	Alzheimer's disease (late onset);
BRCA	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg08992911	chr2:238395768	MLPH	0.4	7.91	0.3	1.14e-14	Prostate cancer;
BRCA	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22455342	chr2:225449267	CUL3	0.66	17.05	0.56	5.19e-54	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.38	-0.35	1.11e-19	Resting heart rate;
BRCA	trans	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.1	0.31	2.79e-15	Corneal astigmatism;
BRCA	trans	rs6600671	1.000	rs4844380	chr1:121193620	A/T	cg17023122	chr1:144479586	NA	0.34	7.94	0.3	9.34e-15	Hip geometry;
BRCA	cis	rs2625529	0.652	rs2929532	chr15:72345110	C/T	cg16672083	chr15:72433130	SENP8	0.67	16.17	0.54	1.53e-49	Red blood cell count;
BRCA	cis	rs2421770	0.504	rs4756213	chr11:35363566	T/C	cg13971030	chr11:35366721	SLC1A2	-0.44	-9.73	-0.36	5.79e-21	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg05340658	chr4:99064831	C4orf37	0.55	10.59	0.39	2.88e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg18806716	chr10:30721971	MAP3K8	-0.42	-10.05	-0.37	3.56e-22	Itch intensity from mosquito bite;
BRCA	cis	rs2594714	0.538	rs895819	chr19:13947292	A/G	cg17299615	chr19:13944571	NA	0.39	8.28	0.31	6.95e-16	Breast cancer;
BRCA	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg07262247	chr5:131593730	PDLIM4	0.37	8.76	0.33	1.71e-17	Acylcarnitine levels;
BRCA	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg18446336	chr7:2847575	GNA12	-0.35	-8.25	-0.31	8.73e-16	Height;
BRCA	cis	rs701145	0.585	rs6789213	chr3:153792795	T/C	cg12800244	chr3:153838788	SGEF	0.62	7.82	0.3	2.21e-14	Coronary artery disease;
BRCA	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg23033748	chr14:75592666	NEK9	-0.42	-10.2	-0.37	1.02e-22	Height;
BRCA	cis	rs2985684	0.740	rs2883438	chr14:50044392	T/C	cg04989706	chr14:50066350	PPIL5	-0.48	-9.26	-0.34	3e-19	Carotid intima media thickness;
BRCA	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg01324343	chr3:183735012	ABCC5	0.48	11.04	0.4	4.52e-26	Anterior chamber depth;
BRCA	cis	rs6809651	0.524	rs6444106	chr3:185811495	C/T	cg00760338	chr3:185826511	ETV5	-0.47	-9.39	-0.35	1.07e-19	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
BRCA	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.81	-18.58	-0.59	6.55e-62	Body mass index (adult);
BRCA	trans	rs8073060	0.544	rs9912939	chr17:34005264	T/G	cg19694781	chr19:47549865	TMEM160	-1.05	-21.46	-0.65	2.49e-77	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs9469578	1.000	rs16869458	chr6:33714639	C/T	cg18708504	chr6:33715942	IP6K3	0.7	10.19	0.37	1.09e-22	Phosphorus levels;
BRCA	cis	rs9341808	0.690	rs3805926	chr6:80879280	C/G	cg08355045	chr6:80787529	NA	0.39	9.8	0.36	3.31e-21	Sitting height ratio;
BRCA	cis	rs6546550	0.901	rs6729760	chr2:70161032	C/T	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.57	-0.42	3.16e-28	Prevalent atrial fibrillation;
BRCA	cis	rs7319311	1.000	rs7320755	chr13:111031092	C/G	cg05272587	chr13:111038400	COL4A2	-0.44	-10.48	-0.38	8.32e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg17330251	chr7:94953956	PON1	0.42	9.04	0.34	1.82e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg19077165	chr18:44547161	KATNAL2	-0.59	-12.98	-0.46	2.37e-34	Personality dimensions;
BRCA	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.17	0.31	1.61e-15	Tonsillectomy;
BRCA	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg21427119	chr20:30132790	HM13	-0.44	-9.3	-0.35	2.16e-19	Mean corpuscular hemoglobin;
BRCA	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg21644426	chr2:191273491	MFSD6	-0.42	-10.63	-0.39	2.14e-24	Pulse pressure;
BRCA	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	8.44	0.32	2.11e-16	Educational attainment;
BRCA	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg20203395	chr5:56204925	C5orf35	-0.5	-10.18	-0.37	1.14e-22	Initial pursuit acceleration;
BRCA	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg18196295	chr10:418757	DIP2C	0.46	10.99	0.4	7.25e-26	Psychosis in Alzheimer's disease;
BRCA	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07636037	chr3:49044803	WDR6	0.89	20.86	0.64	4.14e-74	Subjective well-being (multi-trait analysis);Menarche (age at onset);
BRCA	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg06623918	chr6:96969491	KIAA0776	-0.92	-26.51	-0.72	5.11e-105	Headache;
BRCA	cis	rs9649465	1.000	rs2109723	chr7:123325339	A/G	cg04330084	chr7:123175371	IQUB	-0.3	-8.38	-0.31	3.26e-16	Migraine;
BRCA	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg11189052	chr15:85197271	WDR73	-0.33	-7.81	-0.3	2.38e-14	P wave terminal force;
BRCA	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg26597838	chr10:835615	NA	1.3	21.81	0.65	2.87e-79	Eosinophil percentage of granulocytes;
BRCA	trans	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg22105103	chr4:187893119	NA	0.36	11.7	0.42	8.8e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg16325326	chr1:53192061	ZYG11B	-0.65	-16.14	-0.54	2.19e-49	Monocyte count;
BRCA	cis	rs724568	0.546	rs1367458	chr2:67946328	C/T	cg14046302	chr2:67939758	NA	-0.38	-10.55	-0.39	4.12e-24	Major depressive disorder (broad);
BRCA	cis	rs367943	0.966	rs348945	chr5:112822889	C/T	cg12552261	chr5:112820674	MCC	-0.55	-12.07	-0.43	2.28e-30	Type 2 diabetes;
BRCA	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.56e-18	Motion sickness;
BRCA	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.89e-29	Chronic sinus infection;
BRCA	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.29	0.38	4.41e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg23887609	chr12:130822674	PIWIL1	0.41	9.03	0.34	2.05e-18	Menopause (age at onset);
BRCA	cis	rs151349	0.714	rs6026647	chr20:57606791	C/T	cg23907860	chr20:57583709	CTSZ	-0.36	-8.46	-0.32	1.76e-16	Platelet distribution width;
BRCA	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.31	-8.63	-0.32	4.95e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.2	-0.34	5.17e-19	Bipolar disorder;
BRCA	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg20307385	chr11:47447363	PSMC3	-0.42	-8.36	-0.31	3.86e-16	Subjective well-being;
BRCA	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-17.75	-0.57	1.29e-57	Morning vs. evening chronotype;
BRCA	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg05340658	chr4:99064831	C4orf37	0.58	11.85	0.42	1.93e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg16482183	chr6:26056742	HIST1H1C	0.53	11.36	0.41	2.21e-27	Height;
BRCA	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg22903657	chr4:1355424	KIAA1530	-0.37	-7.94	-0.3	9.11e-15	Obesity-related traits;
BRCA	cis	rs10208940	0.777	rs4513330	chr2:68850921	C/T	cg12452813	chr2:68675892	NA	-0.48	-8.64	-0.32	4.47e-17	Urate levels in lean individuals;
BRCA	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg06046430	chr4:77819534	ANKRD56	0.58	12.69	0.45	4.58e-33	Emphysema distribution in smoking;
BRCA	cis	rs7246657	0.722	rs2909100	chr19:38212680	C/T	cg14683738	chr19:37701593	ZNF585B	-0.47	-8.02	-0.3	5.04e-15	Coronary artery calcification;
BRCA	cis	rs6426558	0.537	rs4653813	chr1:227461510	G/C	cg10327440	chr1:227177885	CDC42BPA	0.48	9.57	0.35	2.21e-20	Neutrophil percentage of white cells;
BRCA	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg14926445	chr8:58193284	C8orf71	-0.47	-9.0	-0.34	2.48e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg06784218	chr1:46089804	CCDC17	-0.49	-11.41	-0.41	1.48e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg24060327	chr5:131705240	SLC22A5	-0.49	-10.38	-0.38	1.93e-23	Blood metabolite levels;
BRCA	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.23	8.04	0.3	4.4e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs17401966	0.931	rs4240911	chr1:10307453	A/G	cg03954927	chr1:10346856	KIF1B	0.44	14.7	0.5	2.45e-42	Hepatocellular carcinoma;
BRCA	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg23173402	chr1:227635558	NA	0.48	8.89	0.33	6.09e-18	Major depressive disorder;
BRCA	cis	rs6496044	0.568	rs6496049	chr15:86069205	C/G	cg10818794	chr15:86012489	AKAP13	-0.29	-8.0	-0.3	5.67e-15	Interstitial lung disease;
BRCA	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.92	-0.43	9.92e-30	Total cholesterol levels;
BRCA	cis	rs8016982	0.674	rs6574631	chr14:81675772	C/T	cg01989461	chr14:81687754	GTF2A1	0.72	16.81	0.55	9.26e-53	Schizophrenia;
BRCA	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.15	-0.31	1.9e-15	Depression;
BRCA	cis	rs385076	0.503	rs212702	chr2:32444250	A/G	cg02381751	chr2:32503542	YIPF4	0.45	7.92	0.3	1.09e-14	Interleukin-18 levels;
BRCA	cis	rs7254827	0.737	rs35557167	chr19:17171887	G/C	cg19418318	chr19:17219073	MYO9B	-0.48	-10.07	-0.37	3.1e-22	Mean platelet volume;
BRCA	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg17848003	chr1:3704513	LRRC47	0.25	8.56	0.32	8.47e-17	Red cell distribution width;
BRCA	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	9.31	0.35	2.09e-19	Iron status biomarkers;
BRCA	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg18479299	chr3:125709523	NA	-0.52	-8.77	-0.33	1.68e-17	Blood pressure (smoking interaction);
BRCA	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg20891558	chr2:74357851	NA	0.51	12.19	0.43	7.01e-31	Gestational age at birth (maternal effect);
BRCA	cis	rs1003719	0.788	rs9977602	chr21:38450650	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.25	0.49	3.24e-40	Eye color traits;
BRCA	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21659725	chr3:3221576	CRBN	-0.47	-12.06	-0.43	2.45e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg10978503	chr1:24200527	CNR2	0.52	13.93	0.48	9.94e-39	Immature fraction of reticulocytes;
BRCA	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg08999081	chr20:33150536	PIGU	-0.44	-12.35	-0.44	1.48e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg06550200	chr5:1325588	CLPTM1L	0.56	11.54	0.42	4.1e-28	Lung cancer;
BRCA	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg09904177	chr6:26538194	HMGN4	0.47	14.71	0.5	2.02e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg27121462	chr16:89883253	FANCA	-0.53	-11.46	-0.41	8.68e-28	Vitiligo;
BRCA	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg12219531	chr12:120966889	COQ5	0.55	11.43	0.41	1.22e-27	High light scatter reticulocyte count;
BRCA	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.56	-0.32	8.57e-17	Total body bone mineral density;
BRCA	cis	rs332507	0.830	rs11718359	chr3:124395987	G/A	cg05980111	chr3:124395277	KALRN	0.36	8.4	0.32	2.92e-16	Plateletcrit;
BRCA	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.5	-0.38	6.78e-24	Mean corpuscular volume;
BRCA	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg03146154	chr1:46216737	IPP	-0.44	-9.6	-0.35	1.84e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg24558204	chr6:135376177	HBS1L	0.45	12.41	0.44	8.13e-32	Red blood cell count;
BRCA	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg00666640	chr1:248458726	OR2T12	0.32	8.77	0.33	1.63e-17	Common traits (Other);
BRCA	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg20607798	chr8:58055168	NA	-0.62	-9.66	-0.36	1.06e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs795484	0.633	rs904661	chr12:118581860	C/T	cg16572268	chr12:118583242	PEBP1	0.3	7.93	0.3	9.64e-15	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
BRCA	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.53	-9.23	-0.34	4.03e-19	Schizophrenia;
BRCA	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.1	0.46	6.97e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg08847533	chr14:75593920	NEK9	0.91	23.19	0.68	8.49e-87	Height;
BRCA	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg11502198	chr6:26597334	ABT1	0.48	9.53	0.35	3.23e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs3768617	0.706	rs4129858	chr1:183004334	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.49	11.22	0.41	8.44e-27	Fuchs's corneal dystrophy;
BRCA	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	10.85	0.39	2.86e-25	Rheumatoid arthritis;
BRCA	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg11941060	chr3:133502564	NA	-0.58	-13.65	-0.48	2.05e-37	Iron status biomarkers;
BRCA	trans	rs2262909	0.962	rs73019889	chr19:22277826	C/G	cg17074339	chr11:11642133	GALNTL4	0.44	8.48	0.32	1.5e-16	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg16386425	chr10:429943	DIP2C	-0.39	-8.09	-0.3	3e-15	Psychosis in Alzheimer's disease;
BRCA	cis	rs2629540	0.889	rs7090422	chr10:126439361	T/A	cg08799069	chr10:126477246	METTL10	-0.54	-11.73	-0.42	6.57e-29	Cocaine dependence;
BRCA	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg18252515	chr7:66147081	NA	-0.81	-11.34	-0.41	2.84e-27	Diabetic kidney disease;
BRCA	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-16.41	-0.54	9.05e-51	Alzheimer's disease (late onset);
BRCA	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg06115741	chr20:33292138	TP53INP2	0.45	10.03	0.37	4.49e-22	Coronary artery disease;
BRCA	cis	rs7191700	0.511	rs12923756	chr16:11359675	C/T	cg00044050	chr16:11439710	C16orf75	-0.4	-9.24	-0.34	3.58e-19	Multiple sclerosis;
BRCA	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg25554036	chr4:6271136	WFS1	0.42	9.98	0.37	6.91e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	trans	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.98	0.3	6.79e-15	Corneal astigmatism;
BRCA	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg13852791	chr20:30311386	BCL2L1	0.84	16.41	0.54	9.67e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg13628971	chr7:2884303	GNA12	0.38	8.54	0.32	1e-16	Height;
BRCA	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg09184832	chr6:79620586	NA	-0.51	-11.33	-0.41	3.1e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.71	-0.33	2.64e-17	Mood instability;
BRCA	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg24692254	chr21:30365293	RNF160	-0.52	-11.83	-0.42	2.44e-29	Cognitive test performance;
BRCA	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.38	0.38	2.02e-23	Motion sickness;
BRCA	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.51	-0.32	1.21e-16	Colorectal cancer;
BRCA	cis	rs9487051	0.768	rs398944	chr6:109523444	T/G	cg21918786	chr6:109611834	NA	-0.35	-9.24	-0.34	3.73e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg10932868	chr11:921992	NA	-0.38	-9.05	-0.34	1.72e-18	Alzheimer's disease (late onset);
BRCA	trans	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg19894588	chr14:64061835	NA	0.37	8.93	0.33	4.48e-18	Glioblastoma;Glioma;
BRCA	cis	rs1506636	1.000	rs600774	chr7:123397831	C/T	cg03229431	chr7:123269106	ASB15	0.61	13.56	0.47	5.64e-37	Plateletcrit;Platelet count;
BRCA	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg26850624	chr5:429559	AHRR	0.33	7.9	0.3	1.22e-14	Cystic fibrosis severity;
BRCA	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg24154853	chr7:158122151	PTPRN2	0.35	8.16	0.31	1.73e-15	Calcium levels;
BRCA	cis	rs4561483	0.801	rs4511557	chr16:11949458	T/C	cg08843971	chr16:11963173	GSPT1	0.51	11.43	0.41	1.16e-27	Testicular germ cell tumor;
BRCA	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg04362960	chr10:104952993	NT5C2	0.46	10.8	0.39	4.25e-25	Arsenic metabolism;
BRCA	trans	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg15704280	chr7:45808275	SEPT13	-0.52	-8.0	-0.3	5.75e-15	Intraocular pressure;
BRCA	cis	rs17401966	1.000	rs12402052	chr1:10318652	C/G	cg15208524	chr1:10270712	KIF1B	0.39	8.43	0.32	2.24e-16	Hepatocellular carcinoma;
BRCA	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	10.07	0.37	3.05e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.68	14.53	0.5	1.51e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg02734326	chr4:10020555	SLC2A9	0.36	7.92	0.3	1.04e-14	Bone mineral density;
BRCA	cis	rs10504073	0.647	rs4493918	chr8:50015937	C/G	cg00325661	chr8:49890786	NA	0.44	12.52	0.44	2.54e-32	Blood metabolite ratios;
BRCA	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-11.01	-0.4	5.99e-26	Bone mineral density;
BRCA	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-9.14	-0.34	8.3e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7178424	0.742	rs12915825	chr15:62175636	A/G	cg00456672	chr15:62358751	C2CD4A	-0.37	-8.95	-0.33	3.74e-18	Height;
BRCA	cis	rs7737355	0.853	rs6873582	chr5:130892741	A/G	cg06307176	chr5:131281290	NA	0.53	10.53	0.38	5.24e-24	Life satisfaction;
BRCA	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg24692254	chr21:30365293	RNF160	0.61	15.44	0.52	6.14e-46	Dental caries;
BRCA	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg16586182	chr3:47516702	SCAP	-0.56	-12.91	-0.45	5.02e-34	Colorectal cancer;
BRCA	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg17143192	chr8:8559678	CLDN23	0.53	10.23	0.38	7.52e-23	Obesity-related traits;
BRCA	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg24642439	chr20:33292090	TP53INP2	0.42	8.83	0.33	9.85e-18	Height;
BRCA	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.77	0.6	6.25e-63	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg07169764	chr2:136633963	MCM6	1.25	30.25	0.77	1.89e-125	Corneal structure;
BRCA	cis	rs1499972	0.941	rs62264782	chr3:117655445	C/A	cg07612923	chr3:117604196	NA	0.6	8.11	0.31	2.61e-15	Schizophrenia;
BRCA	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg27129171	chr3:47204927	SETD2	0.57	11.88	0.43	1.48e-29	Birth weight;
BRCA	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	9.96	0.37	8.28e-22	Retinal vascular caliber;
BRCA	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.76	0.36	4.41e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.14	0.56	1.9e-54	Bladder cancer;
BRCA	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg00800038	chr16:89945340	TCF25	-0.57	-9.34	-0.35	1.59e-19	Skin colour saturation;
BRCA	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg01262667	chr19:19385393	TM6SF2	0.41	10.73	0.39	8.34e-25	Tonsillectomy;
BRCA	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg23711669	chr6:146136114	FBXO30	-0.79	-19.25	-0.61	1.82e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2979489	0.891	rs7822839	chr8:30354453	A/G	cg26383811	chr8:30366931	RBPMS	0.52	12.49	0.44	3.44e-32	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
BRCA	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg12573674	chr2:1569213	NA	-0.63	-14.26	-0.49	3.01e-40	IgG glycosylation;
BRCA	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg20991723	chr1:152506922	NA	0.39	9.07	0.34	1.4e-18	Hair morphology;
BRCA	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg24209194	chr3:40518798	ZNF619	-0.38	-7.9	-0.3	1.21e-14	Renal cell carcinoma;
BRCA	trans	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.61	-0.36	1.57e-20	Bladder cancer;
BRCA	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg17724175	chr1:150552817	MCL1	-0.33	-10.91	-0.4	1.53e-25	Urate levels;
BRCA	cis	rs4409675	0.556	rs2064710	chr1:28231154	G/A	cg23691781	chr1:28212827	C1orf38	0.32	10.56	0.39	3.89e-24	Corneal astigmatism;
BRCA	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg18904891	chr8:8559673	CLDN23	0.65	12.95	0.46	3.24e-34	Obesity-related traits;
BRCA	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.55	9.12	0.34	9.71e-19	Renal function-related traits (BUN);
BRCA	cis	rs6964587	0.621	rs38798	chr7:92044539	C/A	cg17063962	chr7:91808500	NA	-0.49	-10.75	-0.39	6.99e-25	Breast cancer;
BRCA	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg14558114	chr2:88469736	THNSL2	0.63	9.11	0.34	1.06e-18	Plasma clusterin levels;
BRCA	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg17143192	chr8:8559678	CLDN23	0.54	10.34	0.38	2.71e-23	Obesity-related traits;
BRCA	cis	rs10484885	0.878	rs72921934	chr6:90579464	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.46	-0.35	5.86e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs698833	0.852	rs2241870	chr2:44549204	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	10.2	0.37	9.79e-23	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg19773385	chr1:10388646	KIF1B	-0.39	-8.37	-0.31	3.72e-16	Hepatocellular carcinoma;
BRCA	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg26384229	chr12:38710491	ALG10B	-0.5	-12.11	-0.43	1.56e-30	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg05340658	chr4:99064831	C4orf37	0.69	17.39	0.57	9.59e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.89	19.5	0.61	8.03e-67	Cognitive ability;
BRCA	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg23719950	chr11:63933701	MACROD1	-0.57	-9.53	-0.35	3.2e-20	Mean platelet volume;
BRCA	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg07395648	chr5:131743802	NA	0.4	9.98	0.37	6.8e-22	Blood metabolite levels;
BRCA	cis	rs17384381	0.953	rs2284797	chr1:85792383	C/T	cg16011679	chr1:85725395	C1orf52	0.54	8.17	0.31	1.69e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg26384229	chr12:38710491	ALG10B	0.77	17.24	0.56	5.75e-55	Bladder cancer;
BRCA	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg23602478	chr1:26503979	CNKSR1	0.23	8.03	0.3	4.83e-15	Height;
BRCA	trans	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-15.54	-0.52	2.08e-46	Obesity-related traits;
BRCA	cis	rs36051895	0.623	rs7023639	chr9:5244058	A/C	cg02405213	chr9:5042618	JAK2	-0.42	-8.06	-0.3	3.73e-15	Pediatric autoimmune diseases;
BRCA	cis	rs7246657	0.722	rs2909105	chr19:38167906	A/G	cg14683738	chr19:37701593	ZNF585B	-0.48	-8.23	-0.31	1.04e-15	Coronary artery calcification;
BRCA	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg17063962	chr7:91808500	NA	0.6	14.13	0.49	1.22e-39	Breast cancer;
BRCA	cis	rs737337	0.623	rs4804155	chr19:11334295	C/G	cg00586551	chr19:11347513	LOC55908;DOCK6	0.53	10.54	0.38	4.84e-24	HDL cholesterol;HDL cholesterol levels;
BRCA	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg05347473	chr6:146136440	FBXO30	0.39	8.06	0.3	3.81e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg06521331	chr12:34319734	NA	-0.6	-11.91	-0.43	1.17e-29	Morning vs. evening chronotype;
BRCA	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg11814155	chr7:99998594	ZCWPW1	0.58	9.8	0.36	3.16e-21	Platelet count;
BRCA	cis	rs4679121	0.642	rs16837507	chr3:126189395	A/G	cg01106040	chr3:126194903	ZXDC	-0.66	-7.85	-0.3	1.72e-14	Pursuit maintenance gain;
BRCA	cis	rs6973256	0.795	rs763643	chr7:133343243	T/A	cg07491979	chr7:133331646	EXOC4	-0.39	-9.05	-0.34	1.69e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg07148914	chr20:33460835	GGT7	0.38	8.32	0.31	5.29e-16	Height;
BRCA	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.64	0.55	6.41e-52	Bladder cancer;
BRCA	cis	rs724568	0.546	rs724567	chr2:67942439	T/C	cg17945962	chr2:67939740	NA	-0.39	-9.87	-0.36	1.8e-21	Major depressive disorder (broad);
BRCA	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg01283332	chr5:1856932	NA	-0.36	-8.87	-0.33	7.31e-18	Cardiovascular disease risk factors;
BRCA	cis	rs735860	0.763	rs2817111	chr6:53125700	G/C	cg10236188	chr6:53219634	NA	-0.38	-8.19	-0.31	1.41e-15	Glaucoma;
BRCA	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	11.28	0.41	4.76e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg07460842	chr6:66804631	NA	-0.94	-17.3	-0.56	2.69e-55	Exhaled nitric oxide output;
BRCA	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.01	-21.02	-0.64	5.52e-75	Gut microbiome composition (summer);
BRCA	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.93	-31.0	-0.78	1.68e-129	Schizophrenia;
BRCA	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26314531	chr2:26401878	FAM59B	0.97	16.5	0.55	3.27e-51	Gut microbiome composition (summer);
BRCA	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg20587970	chr11:113659929	NA	-1.21	-22.23	-0.66	1.6e-81	Hip circumference adjusted for BMI;
BRCA	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg23018236	chr17:30244563	NA	-0.64	-10.28	-0.38	4.62e-23	Hip circumference adjusted for BMI;
BRCA	cis	rs2637266	1.000	rs7081214	chr10:78361134	G/A	cg18941641	chr10:78392320	NA	0.35	7.84	0.3	1.83e-14	Pulmonary function;
BRCA	cis	rs75229567	0.618	rs1599745	chr12:70186029	A/G	cg10114359	chr12:70132523	RAB3IP	0.64	9.84	0.36	2.31e-21	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
BRCA	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg22920501	chr2:26401640	FAM59B	0.94	16.25	0.54	5.88e-50	Gut microbiome composition (summer);
BRCA	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg12011299	chr4:100065546	ADH4	0.48	13.63	0.47	2.69e-37	Alcohol dependence;
BRCA	trans	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-11.89	-0.43	1.41e-29	Brugada syndrome;
BRCA	cis	rs2629540	0.793	rs10794180	chr10:126449306	T/A	cg08799069	chr10:126477246	METTL10	-0.54	-11.73	-0.42	6.57e-29	Cocaine dependence;
BRCA	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.72	-0.39	9.03e-25	Tonsillectomy;
BRCA	trans	rs1493916	0.837	rs1027332	chr18:31410097	A/C	cg15819921	chr19:927150	ARID3A	-0.41	-8.07	-0.3	3.37e-15	Life satisfaction;
BRCA	cis	rs4423214	0.879	rs1792281	chr11:71135496	G/A	cg05163923	chr11:71159392	DHCR7	-0.54	-10.94	-0.4	1.17e-25	Vitamin D levels;
BRCA	trans	rs6479891	1.000	rs9415705	chr10:65161550	A/C	cg14819942	chr15:35414228	NA	0.34	8.61	0.32	5.87e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-12.97	-0.46	2.5e-34	Lymphocyte counts;
BRCA	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg26384229	chr12:38710491	ALG10B	-0.77	-19.82	-0.62	1.61e-68	Heart rate;
BRCA	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg22431228	chr1:16359049	CLCNKA	-0.43	-9.5	-0.35	4.02e-20	Dilated cardiomyopathy;
BRCA	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg25036284	chr2:26402008	FAM59B	0.95	15.91	0.53	2.86e-48	Gut microbiome composition (summer);
BRCA	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21659725	chr3:3221576	CRBN	-0.49	-10.27	-0.38	5.09e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4664304	0.620	rs10929957	chr2:160716508	A/G	cg02280532	chr2:160761244	LY75	0.35	7.81	0.3	2.28e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs6479891	0.818	rs2393976	chr10:65253439	G/C	cg14819942	chr15:35414228	NA	0.35	8.59	0.32	6.62e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs829880	0.858	rs733180	chr12:98842588	C/T	cg25150519	chr12:98850993	NA	0.62	13.79	0.48	4.51e-38	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg24675658	chr1:53192096	ZYG11B	-0.67	-15.42	-0.52	7.61e-46	Monocyte count;
BRCA	cis	rs6087990	0.735	rs6119946	chr20:31329704	A/G	cg13636640	chr20:31349939	DNMT3B	-0.63	-17.66	-0.57	3.92e-57	Ulcerative colitis;
BRCA	trans	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.15	0.31	1.9e-15	Endometrial cancer;
BRCA	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	14.49	0.5	2.52e-41	Motion sickness;
BRCA	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg20307385	chr11:47447363	PSMC3	0.39	8.38	0.31	3.42e-16	Subjective well-being;
BRCA	cis	rs3892630	0.878	rs11878394	chr19:33205844	G/C	cg22980127	chr19:33182716	NUDT19	0.89	17.45	0.57	4.94e-56	Red blood cell traits;
BRCA	cis	rs2882667	0.822	rs13187096	chr5:138404088	C/A	cg04439458	chr5:138467593	SIL1	-0.42	-10.62	-0.39	2.33e-24	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg20891283	chr12:69753455	YEATS4	0.56	11.36	0.41	2.22e-27	Response to diuretic therapy;
BRCA	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg10295955	chr4:187884368	NA	0.99	28.93	0.75	3.04e-118	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11679564	0.714	rs4389320	chr2:37172531	T/C	cg14987922	chr2:37194071	STRN	0.43	9.33	0.35	1.73e-19	Immature fraction of reticulocytes;
BRCA	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg15448220	chr1:150897856	SETDB1	0.37	8.31	0.31	5.9e-16	Melanoma;
BRCA	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-9.91	-0.36	1.28e-21	Joint mobility (Beighton score);
BRCA	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19346786	chr7:2764209	NA	-0.31	-8.71	-0.33	2.58e-17	Height;
BRCA	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg11941060	chr3:133502564	NA	-0.33	-7.84	-0.3	1.83e-14	Iron status biomarkers;
BRCA	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg11366901	chr6:160182831	ACAT2	0.83	16.25	0.54	5.81e-50	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs12579753	0.872	rs11519752	chr12:82207300	A/G	cg07988820	chr12:82153109	PPFIA2	-0.48	-8.29	-0.31	6.82e-16	Resting heart rate;
BRCA	trans	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.53	0.32	1.05e-16	Corneal astigmatism;
BRCA	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg05347473	chr6:146136440	FBXO30	0.39	7.91	0.3	1.1e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6546550	0.901	rs10205487	chr2:70151471	C/T	cg02498382	chr2:70120550	SNRNP27	0.5	10.81	0.39	3.84e-25	Prevalent atrial fibrillation;
BRCA	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg23602478	chr1:26503979	CNKSR1	0.23	7.84	0.3	1.95e-14	Height;
BRCA	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06028605	chr16:24865363	SLC5A11	0.43	9.78	0.36	3.96e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.2	-0.37	9.98e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg18512352	chr11:47633146	NA	-0.34	-8.24	-0.31	9.79e-16	Subjective well-being;
BRCA	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg04025307	chr7:1156635	C7orf50	0.71	17.89	0.58	2.56e-58	Longevity;Endometriosis;
BRCA	cis	rs67981189	0.896	rs2526890	chr14:71430127	A/T	cg15816911	chr14:71606274	NA	-0.35	-7.93	-0.3	9.74e-15	Schizophrenia;
BRCA	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.81	-0.51	7.14e-43	Chronic sinus infection;
BRCA	trans	rs1941687	0.563	rs7232237	chr18:31324934	C/T	cg27147174	chr7:100797783	AP1S1	0.42	8.03	0.3	4.54e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs870825	0.616	rs4623061	chr4:185643161	A/C	cg04058563	chr4:185651563	MLF1IP	0.77	17.2	0.56	9.11e-55	Blood protein levels;
BRCA	trans	rs877282	0.945	rs12776447	chr10:790625	A/G	cg22713356	chr15:30763199	NA	1.42	28.55	0.75	3.22e-116	Uric acid levels;
BRCA	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	9.08	0.34	1.34e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18404041	chr3:52824283	ITIH1	0.43	12.56	0.44	1.76e-32	Bipolar disorder;
BRCA	cis	rs3771570	1.000	rs62193175	chr2:242284405	G/A	cg21155796	chr2:242212141	HDLBP	0.6	9.3	0.35	2.25e-19	Prostate cancer;
BRCA	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg11502198	chr6:26597334	ABT1	0.57	12.09	0.43	1.82e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg00757033	chr12:89920650	WDR51B	-0.54	-11.37	-0.41	2.03e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs2066819	1.000	rs57279772	chr12:56698960	G/A	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg09307838	chr4:120376055	NA	0.69	14.55	0.5	1.24e-41	Corneal astigmatism;
BRCA	cis	rs7264396	0.561	rs6142474	chr20:34574914	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.5	8.92	0.33	4.68e-18	Total cholesterol levels;
BRCA	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.74	0.5	1.48e-42	Colorectal cancer;
BRCA	cis	rs12541635	0.902	rs62525696	chr8:106968703	C/T	cg10147462	chr8:107024639	NA	0.37	9.71	0.36	6.9e-21	Age of smoking initiation;
BRCA	cis	rs870825	0.932	rs28594349	chr4:185574415	G/A	cg04058563	chr4:185651563	MLF1IP	0.64	10.71	0.39	1e-24	Blood protein levels;
BRCA	cis	rs4722166	0.704	rs4321884	chr7:22741459	A/T	cg05472934	chr7:22766657	IL6	0.36	8.69	0.33	3.09e-17	Lung cancer;
BRCA	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg03146154	chr1:46216737	IPP	0.45	10.08	0.37	2.88e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg24692254	chr21:30365293	RNF160	0.38	8.51	0.32	1.19e-16	Pancreatic cancer;
BRCA	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.6	-0.32	6.34e-17	Monocyte percentage of white cells;
BRCA	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg17691542	chr6:26056736	HIST1H1C	-0.52	-10.63	-0.39	1.98e-24	Height;
BRCA	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg01420254	chr6:26195488	NA	0.59	9.22	0.34	4.15e-19	Gout;Renal underexcretion gout;
BRCA	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg22920501	chr2:26401640	FAM59B	0.91	14.2	0.49	5.51e-40	Gut microbiome composition (summer);
BRCA	cis	rs3818285	0.515	rs12258440	chr10:111676799	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.36	-9.73	-0.36	5.66e-21	Superior crus of antihelix expression;
BRCA	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg00080972	chr5:178986291	RUFY1	-0.5	-14.28	-0.49	2.47e-40	Lung cancer;
BRCA	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.76	0.39	6.26e-25	Bipolar disorder;
BRCA	cis	rs4285028	0.948	rs73855480	chr3:121676646	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.82	-0.39	3.64e-25	Multiple sclerosis;
BRCA	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	22.22	0.66	1.73e-81	Platelet count;
BRCA	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg17425144	chr1:10567563	PEX14	0.64	16.77	0.55	1.46e-52	Breast size;
BRCA	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.06	-0.4	4.01e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg20007245	chr22:24372913	LOC391322	-0.55	-12.08	-0.43	2.12e-30	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs13095912	0.719	rs7625483	chr3:185297113	T/C	cg11274856	chr3:185301563	NA	0.53	12.68	0.45	5.11e-33	Systolic blood pressure;
BRCA	cis	rs870825	0.929	rs1405941	chr4:185591518	A/C	cg04058563	chr4:185651563	MLF1IP	-0.64	-11.42	-0.41	1.23e-27	Blood protein levels;
BRCA	cis	rs4566357	0.615	rs3769643	chr2:227917270	T/C	cg05526886	chr2:227700861	RHBDD1	-0.4	-8.23	-0.31	1.06e-15	Coronary artery disease;
BRCA	cis	rs9443189	0.526	rs775060	chr6:76373567	G/A	cg01950844	chr6:76311363	SENP6	-0.84	-13.4	-0.47	2.89e-36	Prostate cancer;
BRCA	cis	rs6840258	1.000	rs10516788	chr4:87960857	A/G	cg08197287	chr4:87952173	AFF1	-0.46	-9.19	-0.34	5.23e-19	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs312274	0.802	rs12371725	chr12:41235555	A/G	cg17827154	chr12:41323612	CNTN1	-0.36	-7.9	-0.3	1.23e-14	Metabolite levels  (X-11787);
BRCA	cis	rs12949688	0.967	rs8064970	chr17:55824687	T/C	cg12582317	chr17:55822272	NA	0.33	7.98	0.3	6.77e-15	Schizophrenia;
BRCA	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg22705602	chr4:152727874	NA	-0.33	-8.02	-0.3	5.22e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg25358565	chr5:93447407	FAM172A	0.7	12.23	0.44	4.77e-31	Diabetic retinopathy;
BRCA	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg03146154	chr1:46216737	IPP	0.54	12.02	0.43	3.92e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.07	-0.3	3.54e-15	Aortic root size;
BRCA	cis	rs13046373	0.508	rs1911572	chr21:32031648	A/G	cg27071517	chr21:31768726	KRTAP13-1	-0.3	-8.27	-0.31	7.72e-16	HDL cholesterol;
BRCA	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg12311346	chr5:56204834	C5orf35	-0.81	-16.16	-0.54	1.7e-49	Initial pursuit acceleration;
BRCA	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.3	-7.81	-0.3	2.34e-14	Total body bone mineral density;
BRCA	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg08807101	chr21:30365312	RNF160	-0.59	-14.68	-0.5	3.08e-42	Dental caries;
BRCA	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg11843606	chr2:227700838	RHBDD1	-0.73	-14.73	-0.5	1.72e-42	Coronary artery disease;
BRCA	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg24675658	chr1:53192096	ZYG11B	-0.52	-11.62	-0.42	1.91e-28	Monocyte count;
BRCA	cis	rs9796	0.621	rs691702	chr15:41474399	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.37	-7.91	-0.3	1.13e-14	Menopause (age at onset);
BRCA	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg14500267	chr11:67383377	NA	-0.39	-8.08	-0.3	3.24e-15	Mean corpuscular volume;
BRCA	cis	rs7408868	0.908	rs45591935	chr19:15277006	T/C	cg14696996	chr19:15285081	NOTCH3	0.99	14.48	0.5	2.74e-41	Pulse pressure;
BRCA	cis	rs6005807	0.545	rs12169120	chr22:29005302	A/C	cg12565055	chr22:29076175	TTC28	0.48	8.79	0.33	1.41e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs9815354	0.767	rs79323474	chr3:42000973	C/T	cg03022575	chr3:42003672	ULK4	0.73	10.08	0.37	2.94e-22	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg06784218	chr1:46089804	CCDC17	0.5	12.02	0.43	3.67e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg16482183	chr6:26056742	HIST1H1C	0.49	9.66	0.36	1.1e-20	Iron status biomarkers;
BRCA	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg09904177	chr6:26538194	HMGN4	-0.54	-17.53	-0.57	1.9e-56	Intelligence (multi-trait analysis);
BRCA	cis	rs1451375	0.698	rs7797131	chr7:50647934	A/G	cg18232548	chr7:50535776	DDC	0.39	9.19	0.34	5.5e-19	Malaria;
BRCA	cis	rs13064411	0.542	rs1463643	chr3:113215447	A/G	cg18753928	chr3:113234510	CCDC52	-0.46	-9.92	-0.37	1.14e-21	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg23791538	chr6:167370224	RNASET2	-0.33	-8.02	-0.3	4.98e-15	Crohn's disease;
BRCA	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.93	0.3	9.65e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10771511	1	rs10771511	chr12:29437217	T/C	cg09582351	chr12:29534625	ERGIC2	-0.34	-8.33	-0.31	4.78e-16	Platelet distribution width;
BRCA	trans	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg21659725	chr3:3221576	CRBN	-0.46	-9.91	-0.36	1.27e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4478858	0.709	rs3766296	chr1:31820223	G/A	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg18811423	chr2:55921094	PNPT1	-0.78	-26.64	-0.73	1.02e-105	Metabolic syndrome;
BRCA	cis	rs4253311	0.544	rs4253256	chr4:187159282	G/C	cg24794857	chr4:187113578	CYP4V2	0.4	8.16	0.31	1.82e-15	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
BRCA	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg15395560	chr15:45543142	SLC28A2	0.3	8.29	0.31	6.44e-16	Uric acid levels;
BRCA	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg22834771	chr12:69754056	YEATS4	-0.43	-10.63	-0.39	2.04e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7408868	1.000	rs10410514	chr19:15277610	C/T	cg14696996	chr19:15285081	NOTCH3	0.99	14.48	0.5	2.63e-41	Pulse pressure;
BRCA	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg27347728	chr4:17578864	LAP3	0.43	7.94	0.3	9.17e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6545883	0.718	rs6715259	chr2:61851845	G/T	cg15711740	chr2:61764176	XPO1	-0.46	-11.27	-0.41	5.55e-27	Tuberculosis;
BRCA	cis	rs68170813	0.559	rs12536491	chr7:106978024	T/G	cg02696742	chr7:106810147	HBP1	-0.55	-8.79	-0.33	1.4e-17	Coronary artery disease;
BRCA	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg09754948	chr16:28834200	ATXN2L	0.46	9.12	0.34	9.55e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2625529	0.652	rs2930069	chr15:72226977	G/A	cg16672083	chr15:72433130	SENP8	0.65	15.64	0.53	6.25e-47	Red blood cell count;
BRCA	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs11229555	1.000	rs11603890	chr11:58402251	T/C	cg15696309	chr11:58395628	NA	-0.52	-11.48	-0.41	6.93e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg09060608	chr5:178986726	RUFY1	0.45	9.44	0.35	7.1e-20	Lung cancer;
BRCA	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg00530320	chr1:46809349	NSUN4	0.48	9.42	0.35	8.15e-20	Menopause (age at onset);
BRCA	cis	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg06521331	chr12:34319734	NA	-0.65	-11.99	-0.43	5.16e-30	Morning vs. evening chronotype;
BRCA	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg20891283	chr12:69753455	YEATS4	-0.51	-10.12	-0.37	1.9e-22	Response to diuretic therapy;
BRCA	cis	rs10193935	0.901	rs6720837	chr2:42463173	A/T	cg27598129	chr2:42591480	NA	-0.6	-9.96	-0.37	7.74e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9309473	1.000	rs56154726	chr2:73721767	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-10.74	-0.39	7.36e-25	Metabolite levels;
BRCA	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg25019033	chr10:957182	NA	-0.41	-7.85	-0.3	1.75e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg04362960	chr10:104952993	NT5C2	0.44	10.09	0.37	2.57e-22	Arsenic metabolism;
BRCA	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-9.65	-0.36	1.2e-20	Menopause (age at onset);
BRCA	cis	rs2797160	1.000	rs9321050	chr6:126001568	A/G	cg05901451	chr6:126070800	HEY2	-0.39	-9.42	-0.35	8.36e-20	Endometrial cancer;
BRCA	cis	rs78366141	0.649	rs7666372	chr4:89687531	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.78	7.9	0.3	1.23e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg03711944	chr11:47377212	SPI1	-0.39	-9.25	-0.34	3.28e-19	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.28	-0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.66	-0.32	3.86e-17	Alzheimer's disease (late onset);
BRCA	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	9.57	0.35	2.22e-20	Systolic blood pressure;
BRCA	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg11663144	chr21:46675770	NA	0.45	10.78	0.39	5.31e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg04944784	chr2:26401820	FAM59B	0.99	16.67	0.55	4.32e-52	Gut microbiome composition (summer);
BRCA	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg20224285	chr3:52813920	ITIH1	0.32	8.0	0.3	5.68e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11890956	chr21:40555474	PSMG1	-0.83	-19.97	-0.62	2.55e-69	Cognitive function;
BRCA	cis	rs2016266	0.964	rs2272313	chr12:53671549	A/G	cg26875137	chr12:53738046	NA	0.36	9.59	0.35	2e-20	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs3772130	0.540	rs57791671	chr3:121608433	T/A	cg20356878	chr3:121714668	ILDR1	0.42	9.55	0.35	2.81e-20	Cognitive performance;
BRCA	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg15448220	chr1:150897856	SETDB1	0.35	7.99	0.3	6.1e-15	Melanoma;
BRCA	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.85	-0.33	8.7e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg05347473	chr6:146136440	FBXO30	0.44	8.66	0.32	3.75e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg14829155	chr15:31115871	NA	-0.43	-9.9	-0.36	1.4e-21	Huntington's disease progression;
BRCA	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.45	0.35	6.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.52	-0.32	1.14e-16	Total body bone mineral density;
BRCA	cis	rs868036	0.522	rs3784711	chr15:68072527	C/T	cg08079166	chr15:68083412	MAP2K5	-0.32	-8.57	-0.32	7.75e-17	Restless legs syndrome;
BRCA	cis	rs503734	0.521	rs546105	chr3:100967920	A/G	cg27318481	chr3:100970896	IMPG2	-0.34	-8.19	-0.31	1.41e-15	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06028605	chr16:24865363	SLC5A11	0.39	8.15	0.31	1.96e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg13073564	chr4:8508604	NA	0.43	11.8	0.42	3.31e-29	Response to antineoplastic agents;
BRCA	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg25019033	chr10:957182	NA	-0.41	-7.86	-0.3	1.63e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.62	-15.03	-0.51	6.11e-44	Hemoglobin concentration;
BRCA	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg08132940	chr7:1081526	C7orf50	-0.59	-8.77	-0.33	1.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg06115741	chr20:33292138	TP53INP2	0.47	10.63	0.39	2.05e-24	Coronary artery disease;
BRCA	cis	rs11608355	0.515	rs12579916	chr12:109924528	T/G	cg05360138	chr12:110035743	NA	0.72	13.17	0.46	3.38e-35	Neuroticism;
BRCA	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.62	0.42	1.89e-28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg24296786	chr1:45957014	TESK2	-0.45	-9.07	-0.34	1.43e-18	Homocysteine levels;
BRCA	cis	rs965469	0.779	rs6139092	chr20:3334651	T/C	cg25506879	chr20:3388711	C20orf194	-0.42	-8.1	-0.31	2.81e-15	IFN-related cytopenia;
BRCA	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg07636037	chr3:49044803	WDR6	0.97	29.12	0.76	2.84e-119	Parkinson's disease;
BRCA	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg03929089	chr4:120376271	NA	0.57	9.25	0.34	3.26e-19	Axial length;
BRCA	cis	rs7677751	0.806	rs67432867	chr4:55104454	A/T	cg17187183	chr4:55093834	PDGFRA	0.44	9.1	0.34	1.14e-18	Corneal astigmatism;
BRCA	cis	rs6121246	0.559	rs1484994	chr20:30305975	A/G	cg21427119	chr20:30132790	HM13	-0.36	-8.1	-0.31	2.87e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.27e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1400816	0.850	rs59414074	chr2:172535198	C/T	cg13550731	chr2:172543902	DYNC1I2	0.5	8.55	0.32	9.26e-17	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.34	-0.31	4.64e-16	Total body bone mineral density;
BRCA	cis	rs751728	0.664	rs2395402	chr6:33753673	G/A	cg25922239	chr6:33757077	LEMD2	0.5	12.67	0.45	5.49e-33	Crohn's disease;
BRCA	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg22491629	chr6:157744540	C6orf35	-0.67	-12.32	-0.44	1.87e-31	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6901250	1.000	rs6924002	chr6:117114223	A/T	cg12892004	chr6:117198278	RFX6	0.48	10.7	0.39	1.1e-24	C-reactive protein levels;
BRCA	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg11266682	chr4:10021025	SLC2A9	-0.34	-8.39	-0.32	3.1e-16	Bone mineral density;
BRCA	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg00071950	chr4:10020882	SLC2A9	0.64	15.64	0.53	6.38e-47	Bone mineral density;
BRCA	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg01579765	chr21:45077557	HSF2BP	0.42	11.76	0.42	5.09e-29	Mean corpuscular volume;
BRCA	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg07148914	chr20:33460835	GGT7	-0.43	-9.18	-0.34	5.73e-19	Height;
BRCA	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	20.6	0.63	1.04e-72	Lymphocyte percentage of white cells;
BRCA	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00149659	chr3:10157352	C3orf10	-0.64	-11.21	-0.41	9.21e-27	Alzheimer's disease;
BRCA	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.02	-0.3	5.2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9649465	0.967	rs6944031	chr7:123299304	T/C	cg04330084	chr7:123175371	IQUB	-0.31	-8.64	-0.32	4.54e-17	Migraine;
BRCA	cis	rs12611088	0.571	rs8110232	chr19:44027390	T/C	cg13740135	chr19:44006432	PHLDB3	-0.3	-7.84	-0.3	1.83e-14	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	trans	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg04565464	chr8:145669602	NFKBIL2	0.46	10.91	0.4	1.51e-25	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.57e-23	Motion sickness;
BRCA	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg00031303	chr3:195681400	NA	0.46	8.6	0.32	6.13e-17	Pancreatic cancer;
BRCA	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs6011368	0.740	rs6062357	chr20:62892739	C/T	cg13869341	chr1:15865	WASH5P	0.37	8.38	0.31	3.31e-16	Clozapine-induced cytotoxicity;
BRCA	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	9.82	0.36	2.68e-21	Glomerular filtration rate (creatinine);
BRCA	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg08601574	chr20:25228251	PYGB	-0.33	-7.83	-0.3	1.99e-14	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg23711669	chr6:146136114	FBXO30	0.8	19.0	0.6	3.7e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg20503657	chr10:835505	NA	0.61	10.44	0.38	1.14e-23	Eosinophil percentage of granulocytes;
BRCA	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-8.21	-0.31	1.2e-15	Tonsillectomy;
BRCA	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg21747090	chr2:27597821	SNX17	-0.37	-7.89	-0.3	1.33e-14	Total body bone mineral density;
BRCA	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg26893861	chr17:41843967	DUSP3	0.78	15.54	0.52	2.02e-46	Triglycerides;
BRCA	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.2	0.34	5.09e-19	Tonsillectomy;
BRCA	cis	rs12618769	0.597	rs12622341	chr2:99074680	A/T	cg10123293	chr2:99228465	UNC50	0.41	7.9	0.3	1.21e-14	Bipolar disorder;
BRCA	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg21475434	chr5:93447410	FAM172A	0.69	8.58	0.32	6.97e-17	Diabetic retinopathy;
BRCA	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg06026331	chr20:60912101	LAMA5	-0.58	-11.49	-0.41	6.83e-28	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg07460842	chr6:66804631	NA	-1.0	-19.6	-0.61	2.47e-67	Exhaled nitric oxide output;
BRCA	cis	rs6840258	0.660	rs17012213	chr4:87889167	G/T	cg08197287	chr4:87952173	AFF1	-0.46	-8.4	-0.32	2.8e-16	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg02733842	chr7:1102375	C7orf50	-0.61	-11.38	-0.41	1.83e-27	Bronchopulmonary dysplasia;
BRCA	cis	rs7975161	0.753	rs7972034	chr12:104640881	G/T	cg25273343	chr12:104657179	TXNRD1	-0.6	-9.31	-0.35	2.1e-19	Toenail selenium levels;
BRCA	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.02	0.48	4.01e-39	Motion sickness;
BRCA	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg04034577	chr2:241836375	C2orf54	-0.56	-13.8	-0.48	3.98e-38	Urinary metabolites;
BRCA	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg18132916	chr6:79620363	NA	-0.5	-11.42	-0.41	1.29e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.64	10.41	0.38	1.47e-23	Renal function-related traits (BUN);
BRCA	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg05347473	chr6:146136440	FBXO30	0.6	11.55	0.42	3.69e-28	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg19894588	chr14:64061835	NA	0.35	8.55	0.32	9.11e-17	Glioblastoma;Glioma;
BRCA	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg05340658	chr4:99064831	C4orf37	0.69	17.11	0.56	2.48e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg18154014	chr19:37997991	ZNF793	0.62	11.75	0.42	5.29e-29	Coronary artery calcification;
BRCA	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg13906792	chr15:75199810	C15orf17	-0.4	-9.28	-0.34	2.59e-19	Breast cancer;
BRCA	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.8	-0.33	1.23e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs870825	1.000	rs870823	chr4:185588195	G/A	cg20176042	chr4:185552304	CASP3	-0.58	-7.9	-0.3	1.24e-14	Blood protein levels;
BRCA	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg00278107	chr5:1061253	SLC12A7	-0.72	-14.48	-0.5	2.62e-41	QT interval;
BRCA	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.41	-0.32	2.58e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6424115	0.644	rs2267960	chr1:24068544	T/C	cg10978503	chr1:24200527	CNR2	0.34	8.0	0.3	5.73e-15	Immature fraction of reticulocytes;
BRCA	cis	rs4919694	1.000	rs12261040	chr10:104665397	T/C	cg04362960	chr10:104952993	NT5C2	0.93	14.99	0.51	9.22e-44	Arsenic metabolism;
BRCA	cis	rs4363385	0.617	rs5010885	chr1:152973141	C/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.26	-0.31	8.37e-16	Inflammatory skin disease;
BRCA	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg13073564	chr4:8508604	NA	0.31	8.03	0.3	4.8e-15	Response to antineoplastic agents;
BRCA	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg20701182	chr2:24300061	SF3B14	0.57	8.69	0.33	3.09e-17	Lymphocyte counts;
BRCA	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-14.26	-0.49	3e-40	Platelet count;
BRCA	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08280861	chr8:58055591	NA	0.45	8.03	0.3	4.83e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	19.33	0.61	6.33e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg08470875	chr2:26401718	FAM59B	0.77	11.95	0.43	7.7e-30	Gut microbiome composition (summer);
BRCA	cis	rs6028335	0.674	rs16987712	chr20:37601243	A/G	cg16355469	chr20:37678765	NA	0.44	8.01	0.3	5.34e-15	Alcohol and nicotine co-dependence;
BRCA	cis	rs3820928	0.874	rs6728239	chr2:227856552	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.42	-0.32	2.46e-16	Pulmonary function;
BRCA	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg15128208	chr22:42549153	NA	0.32	8.24	0.31	1.01e-15	Cognitive function;
BRCA	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.48	-9.83	-0.36	2.49e-21	Tonsillectomy;
BRCA	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg06636001	chr8:8085503	FLJ10661	0.56	11.53	0.42	4.34e-28	Mood instability;
BRCA	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.36	-0.31	3.99e-16	Bipolar disorder;
BRCA	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26314531	chr2:26401878	FAM59B	-0.88	-15.31	-0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg20203395	chr5:56204925	C5orf35	-0.41	-9.25	-0.34	3.32e-19	Initial pursuit acceleration;
BRCA	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg08885076	chr2:99613938	TSGA10	0.43	10.22	0.37	8.29e-23	Chronic sinus infection;
BRCA	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg09658497	chr7:2847517	GNA12	-0.42	-8.01	-0.3	5.43e-15	Height;
BRCA	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg04362960	chr10:104952993	NT5C2	0.43	9.57	0.35	2.35e-20	Arsenic metabolism;
BRCA	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2594714	0.538	rs895819	chr19:13947292	A/G	cg18576835	chr19:13944261	NA	-0.41	-11.58	-0.42	2.81e-28	Breast cancer;
BRCA	cis	rs600806	0.850	rs115935180	chr1:109976775	C/G	cg20591472	chr1:110008990	SYPL2	0.33	8.38	0.31	3.37e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.64	-0.36	1.23e-20	Alcohol dependence;
BRCA	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg10295955	chr4:187884368	NA	-0.97	-28.47	-0.75	9.28e-116	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.72	0.36	6.56e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.74	-0.39	7.53e-25	Mean corpuscular volume;
BRCA	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg21132104	chr15:45694354	SPATA5L1	0.75	16.48	0.55	4.24e-51	Homoarginine levels;
BRCA	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg12573674	chr2:1569213	NA	-0.51	-9.54	-0.35	2.88e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg08000102	chr2:233561755	GIGYF2	0.63	13.89	0.48	1.61e-38	Coronary artery disease;
BRCA	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-8.95	-0.33	3.96e-18	IgG glycosylation;
BRCA	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg11789530	chr4:8429930	ACOX3	-0.56	-13.3	-0.47	7.97e-36	Response to antineoplastic agents;
BRCA	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11764359	chr7:65958608	NA	-0.78	-17.83	-0.58	5.07e-58	Aortic root size;
BRCA	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg26898376	chr11:64110657	CCDC88B	0.36	7.88	0.3	1.44e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg10523679	chr1:76189770	ACADM	0.68	13.47	0.47	1.37e-36	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.42	9.15	0.34	7.46e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.3	-0.31	6.43e-16	Total body bone mineral density;
BRCA	cis	rs3087591	1.000	rs7226006	chr17:29650656	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.44	-9.05	-0.34	1.69e-18	Hip circumference;
BRCA	cis	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg20368463	chr18:77673604	PQLC1	0.46	11.73	0.42	6.66e-29	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
BRCA	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.36	-0.38	2.35e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg07211511	chr3:129823064	LOC729375	-0.63	-11.09	-0.4	2.86e-26	Blood pressure (smoking interaction);
BRCA	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg12863693	chr15:85201151	NMB	-0.36	-8.55	-0.32	9.38e-17	P wave terminal force;
BRCA	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg14683738	chr19:37701593	ZNF585B	0.54	8.42	0.32	2.48e-16	Coronary artery calcification;
BRCA	cis	rs11250464	0.794	rs11250487	chr10:1434168	C/A	cg08668359	chr10:1443807	ADARB2	0.5	9.56	0.35	2.51e-20	Radiation response;
BRCA	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg27446573	chr6:127587934	RNF146	0.8	15.56	0.52	1.5e-46	Breast cancer;
BRCA	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg18225595	chr11:63971243	STIP1	0.54	9.66	0.36	1.07e-20	Mean platelet volume;
BRCA	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg19784903	chr17:45786737	TBKBP1	0.34	8.3	0.31	6.1e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg11584989	chr19:19387371	SF4	0.63	12.67	0.45	5.37e-33	Bipolar disorder;
BRCA	cis	rs208515	0.560	rs207084	chr6:66776966	T/C	cg07460842	chr6:66804631	NA	-1.09	-31.58	-0.78	1.37e-132	Exhaled nitric oxide levels;
BRCA	cis	rs4953076	0.573	rs6734443	chr2:44408282	G/C	cg04920474	chr2:44395004	PPM1B	0.51	10.4	0.38	1.66e-23	Height;
BRCA	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg12072164	chr19:44306565	LYPD5	0.44	9.76	0.36	4.68e-21	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.81	12.49	0.44	3.53e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg14847009	chr1:175162515	KIAA0040	0.24	9.05	0.34	1.72e-18	Alcohol dependence;
BRCA	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg03146154	chr1:46216737	IPP	0.52	11.27	0.41	5.52e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg18252515	chr7:66147081	NA	-1.07	-15.88	-0.53	3.98e-48	Diabetic kidney disease;
BRCA	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg03433033	chr1:76189801	ACADM	0.68	13.08	0.46	8.56e-35	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg00701064	chr4:6280414	WFS1	0.7	19.38	0.61	3.64e-66	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg25427524	chr10:38739819	LOC399744	-0.54	-9.5	-0.35	3.97e-20	Obesity (extreme);
BRCA	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg11879182	chr18:77439856	CTDP1	0.62	12.85	0.45	8.51e-34	Monocyte count;
BRCA	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg00757033	chr12:89920650	WDR51B	0.53	10.7	0.39	1.13e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg18402987	chr7:1209562	NA	0.43	8.72	0.33	2.37e-17	Longevity;Endometriosis;
BRCA	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg11789530	chr4:8429930	ACOX3	0.59	14.72	0.5	1.85e-42	Response to antineoplastic agents;
BRCA	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg18305652	chr10:134549665	INPP5A	0.49	11.17	0.4	1.39e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.62	12.9	0.45	5.52e-34	Monocyte percentage of white cells;
BRCA	trans	rs6479891	1.000	rs12415038	chr10:65160858	A/G	cg14819942	chr15:35414228	NA	0.35	8.67	0.32	3.63e-17	Arthritis (juvenile idiopathic);
BRCA	trans	rs629535	0.911	rs490165	chr8:70014976	A/G	cg21567404	chr3:27674614	NA	-0.93	-19.74	-0.62	4.33e-68	Dupuytren's disease;
BRCA	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.85	-0.3	1.81e-14	Aortic root size;
BRCA	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg05863683	chr7:1912471	MAD1L1	-0.41	-9.7	-0.36	7.6e-21	Bipolar disorder and schizophrenia;
BRCA	trans	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.81	0.3	2.3e-14	Corneal astigmatism;
BRCA	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg18252515	chr7:66147081	NA	-0.57	-11.42	-0.41	1.27e-27	Corneal structure;
BRCA	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	17.7	0.57	2.51e-57	Platelet count;
BRCA	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-10.3	-0.38	4.02e-23	Aortic root size;
BRCA	cis	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg06521331	chr12:34319734	NA	-0.57	-11.13	-0.4	1.93e-26	Morning vs. evening chronotype;
BRCA	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg11843238	chr5:131593191	PDLIM4	0.41	10.35	0.38	2.63e-23	Acylcarnitine levels;
BRCA	cis	rs909002	0.789	rs3817398	chr1:32119431	C/T	cg11573219	chr1:32083031	HCRTR1	-0.29	-9.26	-0.34	3.05e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	8.13	0.31	2.25e-15	Educational attainment;
BRCA	cis	rs7635838	0.654	rs346086	chr3:11272932	G/T	cg00170343	chr3:11313890	ATG7	0.43	8.37	0.31	3.53e-16	HDL cholesterol;
BRCA	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg11845111	chr2:191398756	TMEM194B	-0.69	-13.52	-0.47	8.46e-37	Diastolic blood pressure;
BRCA	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-12.53	-0.44	2.41e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg13114125	chr14:105738426	BRF1	-0.48	-10.26	-0.38	5.53e-23	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs10911251	0.508	rs2296297	chr1:183105324	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.88	0.56	3.96e-53	Colorectal cancer;
BRCA	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg19418458	chr7:158789849	NA	0.41	9.39	0.35	1e-19	Facial morphology (factor 20);
BRCA	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.55	-10.96	-0.4	9.86e-26	Lymphocyte counts;
BRCA	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg07741184	chr6:167504864	NA	0.33	9.87	0.36	1.8e-21	Primary biliary cholangitis;
BRCA	cis	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg04990556	chr1:26633338	UBXN11	0.54	9.04	0.34	1.84e-18	Obesity-related traits;
BRCA	cis	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.17	-0.4	1.44e-26	Morning vs. evening chronotype;
BRCA	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24549020	chr5:56110836	MAP3K1	-0.39	-8.19	-0.31	1.48e-15	Initial pursuit acceleration;
BRCA	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg23950597	chr19:37808831	NA	-0.72	-12.58	-0.45	1.42e-32	Coronary artery calcification;
BRCA	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg22974920	chr21:40686053	BRWD1	-0.37	-8.35	-0.31	4.26e-16	Cognitive function;
BRCA	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.41	-0.41	1.37e-27	Gut microbiome composition (summer);
BRCA	cis	rs9658691	0.607	rs9658750	chr10:90766596	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.55	-8.01	-0.3	5.34e-15	Mosquito bite size;
BRCA	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.29	0.31	6.9e-16	Parkinson's disease;
BRCA	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.88	22.77	0.67	1.65e-84	Body mass index (adult);
BRCA	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg11843238	chr5:131593191	PDLIM4	0.35	7.85	0.3	1.77e-14	Acylcarnitine levels;
BRCA	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg14926445	chr8:58193284	C8orf71	-0.47	-8.92	-0.33	4.83e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.58	-0.32	7.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs495337	0.736	rs596195	chr20:48474768	T/C	cg17835207	chr20:48524531	SPATA2	-0.5	-10.94	-0.4	1.24e-25	Psoriasis;
BRCA	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.53	-10.17	-0.37	1.32e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.99	14.82	0.51	6.43e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.23	0.34	3.94e-19	Morning vs. evening chronotype;
BRCA	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.29	-0.41	4.58e-27	Schizophrenia;
BRCA	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg16141378	chr3:129829833	LOC729375	0.32	7.9	0.3	1.21e-14	Neuroticism;
BRCA	cis	rs10193935	1.000	rs10185742	chr2:42429666	A/G	cg27598129	chr2:42591480	NA	-0.96	-15.3	-0.52	2.9e-45	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg13010199	chr12:38710504	ALG10B	0.42	7.89	0.3	1.33e-14	Resting heart rate;
BRCA	cis	rs6963495	0.556	rs711433	chr7:105153191	A/G	cg19920283	chr7:105172520	RINT1	-0.43	-8.89	-0.33	6e-18	Bipolar disorder (body mass index interaction);
BRCA	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg10729496	chr3:10149963	C3orf24	0.48	8.93	0.33	4.51e-18	Alzheimer's disease;
BRCA	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg06808227	chr14:105710500	BRF1	-0.79	-16.08	-0.54	4.34e-49	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08219700	chr8:58056026	NA	0.47	8.51	0.32	1.22e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7395581	0.918	rs4752824	chr11:47324666	A/T	cg25783544	chr11:47291846	MADD	0.43	9.71	0.36	6.74e-21	HDL cholesterol;
BRCA	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg21132104	chr15:45694354	SPATA5L1	0.76	17.06	0.56	4.53e-54	Homoarginine levels;
BRCA	trans	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg07211511	chr3:129823064	LOC729375	0.55	9.49	0.35	4.63e-20	Blood pressure (smoking interaction);
BRCA	cis	rs243505	1.000	rs243520	chr7:148423560	C/T	cg09806900	chr7:148480153	CUL1	-0.43	-8.68	-0.32	3.19e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	12.74	0.45	2.81e-33	Mean platelet volume;
BRCA	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg02659138	chr7:134003124	SLC35B4	0.34	10.72	0.39	9.27e-25	Mean platelet volume;
BRCA	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg21143896	chr7:2802374	GNA12	-0.38	-9.55	-0.35	2.69e-20	Height;
BRCA	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.91	0.4	1.6e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg03342759	chr3:160939853	NMD3	-0.64	-13.47	-0.47	1.34e-36	Morning vs. evening chronotype;
BRCA	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg11887960	chr12:57824829	NA	0.49	8.21	0.31	1.22e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg12437481	chr16:420112	MRPL28	-0.6	-15.24	-0.52	6.05e-45	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg11879182	chr18:77439856	CTDP1	0.64	13.91	0.48	1.33e-38	Monocyte count;
BRCA	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11764359	chr7:65958608	NA	-0.77	-17.55	-0.57	1.38e-56	Aortic root size;
BRCA	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg13319975	chr6:146136371	FBXO30	-0.38	-8.37	-0.31	3.51e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs586533	0.813	rs642881	chr11:99502807	A/G	cg22878054	chr11:99397252	CNTN5	0.32	8.12	0.31	2.45e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg18758796	chr5:131593413	PDLIM4	0.39	9.94	0.37	9.96e-22	Acylcarnitine levels;
BRCA	cis	rs10193935	1.000	rs10180528	chr2:42436723	T/A	cg27598129	chr2:42591480	NA	-0.92	-15.03	-0.51	5.82e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11634851	1.000	rs4630510	chr15:81032822	C/T	cg03950166	chr15:80988613	FAM108C1	-0.35	-7.93	-0.3	9.69e-15	Systolic blood pressure;
BRCA	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg10523679	chr1:76189770	ACADM	-0.73	-14.94	-0.51	1.75e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg15557168	chr22:42548783	NA	-0.31	-8.66	-0.32	3.9e-17	Cognitive function;
BRCA	cis	rs6723226	0.650	rs6729952	chr2:32764922	T/C	cg02381751	chr2:32503542	YIPF4	0.55	12.04	0.43	3.12e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs7715811	0.913	rs73749952	chr5:13762518	T/C	cg07548982	chr5:13769939	DNAH5	-0.37	-7.99	-0.3	6.24e-15	Subclinical atherosclerosis traits (other);
BRCA	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.41	-0.41	1.37e-27	Gut microbiome composition (summer);
BRCA	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-12.01	-0.43	4.18e-30	Chronic sinus infection;
BRCA	cis	rs12612619	0.732	rs2304681	chr2:27315252	G/A	cg00617064	chr2:27272375	NA	0.34	8.39	0.32	3.02e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg01849466	chr14:104193079	ZFYVE21	0.46	10.87	0.39	2.31e-25	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.79	-0.77	2.53e-128	Schizophrenia;
BRCA	cis	rs1113500	0.580	rs1781058	chr1:108564059	C/G	cg06207961	chr1:108661230	NA	0.35	8.14	0.31	2.09e-15	Growth-regulated protein alpha levels;
BRCA	cis	rs897984	0.542	rs11864839	chr16:31095251	G/C	cg00531865	chr16:30841666	NA	-0.41	-9.87	-0.36	1.69e-21	Dementia with Lewy bodies;
BRCA	cis	rs68170813	0.596	rs76888321	chr7:106945926	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-8.88	-0.33	6.49e-18	Coronary artery disease;
BRCA	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg13010199	chr12:38710504	ALG10B	0.45	9.38	0.35	1.16e-19	Bladder cancer;
BRCA	cis	rs7586879	0.828	rs7597157	chr2:25089166	C/T	cg04586622	chr2:25135609	ADCY3	0.38	9.16	0.34	7.06e-19	Body mass index;
BRCA	cis	rs1003719	0.715	rs4261789	chr21:38503762	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.15	-0.49	9.86e-40	Eye color traits;
BRCA	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg09307838	chr4:120376055	NA	0.69	14.08	0.49	2.13e-39	Corneal astigmatism;
BRCA	cis	rs4363385	0.818	rs12085426	chr1:153003074	C/A	cg24667326	chr1:152973720	SPRR3	-0.32	-8.44	-0.32	2.11e-16	Inflammatory skin disease;
BRCA	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg19743168	chr1:23544995	NA	0.68	16.93	0.56	2.04e-53	Height;
BRCA	cis	rs11955398	0.716	rs10939860	chr5:59999360	C/T	cg02684056	chr5:59996105	DEPDC1B	0.39	9.35	0.35	1.42e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg12483005	chr1:23474871	LUZP1	0.44	9.89	0.36	1.43e-21	Height;
BRCA	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg25554036	chr4:6271136	WFS1	0.41	10.06	0.37	3.45e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs4363385	0.747	rs4845334	chr1:152982998	T/A	cg25856811	chr1:152973957	SPRR3	-0.34	-9.15	-0.34	7.34e-19	Inflammatory skin disease;
BRCA	cis	rs1163251	0.902	rs639761	chr1:120217558	G/A	cg19096424	chr1:120255104	PHGDH	0.44	9.73	0.36	5.98e-21	Blood metabolite levels;
BRCA	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.43	-0.35	7.6e-20	Bipolar disorder;
BRCA	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg22535103	chr8:58192502	C8orf71	-0.46	-8.16	-0.31	1.74e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21659725	chr3:3221576	CRBN	0.69	20.42	0.63	9.85e-72	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg24110177	chr3:50126178	RBM5	0.37	10.1	0.37	2.45e-22	Menarche (age at onset);
BRCA	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg17971929	chr21:40555470	PSMG1	-0.6	-13.26	-0.46	1.25e-35	Cognitive function;
BRCA	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg17691542	chr6:26056736	HIST1H1C	0.43	9.27	0.34	2.89e-19	Iron status biomarkers;
BRCA	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	11.98	0.43	5.44e-30	Bipolar disorder and schizophrenia;
BRCA	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg07636037	chr3:49044803	WDR6	0.98	28.99	0.75	1.42e-118	Parkinson's disease;
BRCA	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg18357645	chr12:58087776	OS9	-0.39	-11.25	-0.41	6.53e-27	Multiple sclerosis;
BRCA	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg01483505	chr11:975446	AP2A2	0.3	7.99	0.3	6.46e-15	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg05340658	chr4:99064831	C4orf37	-0.68	-16.95	-0.56	1.75e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg15105969	chr2:36825350	FEZ2	-0.4	-7.85	-0.3	1.72e-14	Height;
BRCA	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2041840	0.538	rs2372998	chr2:37573556	G/A	cg25727520	chr2:37576821	QPCT	-0.29	-8.13	-0.31	2.23e-15	Chronic lymphocytic leukemia;
BRCA	cis	rs700651	0.786	rs58224025	chr2:198821988	G/A	cg00792783	chr2:198669748	PLCL1	0.45	9.89	0.36	1.47e-21	Intracranial aneurysm;
BRCA	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg05340658	chr4:99064831	C4orf37	0.68	16.9	0.56	2.97e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg25358565	chr5:93447407	FAM172A	1.21	18.79	0.6	5.1e-63	Diabetic retinopathy;
BRCA	trans	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-20.69	-0.63	3.65e-73	Exhaled nitric oxide output;
BRCA	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg23283495	chr1:209979779	IRF6	-0.38	-9.07	-0.34	1.46e-18	Cleft lip with or without cleft palate;
BRCA	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg16339924	chr4:17578868	LAP3	0.71	16.78	0.55	1.18e-52	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg16506815	chr2:162101123	NA	0.72	18.09	0.58	2.31e-59	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.16	0.34	7.11e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg12011299	chr4:100065546	ADH4	0.41	10.23	0.38	7.27e-23	Alcohol dependence;
BRCA	trans	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.95	-0.3	8.63e-15	Corneal astigmatism;
BRCA	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.59	-0.42	2.56e-28	Platelet count;
BRCA	cis	rs6433895	0.677	rs34825850	chr2:182005326	C/A	cg00481216	chr2:181971175	NA	0.46	8.68	0.32	3.35e-17	Lymphocyte counts;
BRCA	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06022373	chr22:39101656	GTPBP1	0.71	17.15	0.56	1.56e-54	Menopause (age at onset);
BRCA	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg06064525	chr11:970664	AP2A2	-0.28	-8.21	-0.31	1.24e-15	Alzheimer's disease (late onset);
BRCA	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg11812906	chr14:75593930	NEK9	-0.61	-13.89	-0.48	1.55e-38	Height;
BRCA	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-12.3	-0.44	2.45e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs36051895	0.522	rs12341844	chr9:5177872	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-9.15	-0.34	7.86e-19	Pediatric autoimmune diseases;
BRCA	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg13319975	chr6:146136371	FBXO30	0.41	8.99	0.34	2.67e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg21433313	chr16:3507492	NAT15	-0.6	-8.35	-0.31	4.14e-16	Tuberculosis;
BRCA	cis	rs4363385	0.720	rs6680624	chr1:152983872	A/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.89	-0.36	1.52e-21	Inflammatory skin disease;
BRCA	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg08470875	chr2:26401718	FAM59B	0.72	11.93	0.43	8.78e-30	Gut microbiome composition (summer);
BRCA	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.05	-0.3	4.13e-15	Prostate cancer;
BRCA	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg09904177	chr6:26538194	HMGN4	0.47	14.69	0.5	2.58e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg02176678	chr2:219576539	TTLL4	-0.47	-12.22	-0.44	5.27e-31	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg24977027	chr2:88469347	THNSL2	0.46	7.99	0.3	6.1e-15	Plasma clusterin levels;
BRCA	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg00745463	chr17:30367425	LRRC37B	-0.57	-9.35	-0.35	1.42e-19	Hip circumference adjusted for BMI;
BRCA	cis	rs858239	0.632	rs6952947	chr7:23121042	C/G	cg23682824	chr7:23144976	KLHL7	-0.44	-11.65	-0.42	1.44e-28	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11764359	chr7:65958608	NA	0.77	17.59	0.57	9.21e-57	Aortic root size;
BRCA	cis	rs9308433	0.529	rs59864830	chr1:214474889	A/G	cg06198575	chr1:214491504	SMYD2	0.58	11.77	0.42	4.48e-29	IgG glycosylation;
BRCA	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg19077165	chr18:44547161	KATNAL2	-0.59	-13.29	-0.47	9.5e-36	Personality dimensions;
BRCA	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.48	-10.85	-0.39	2.65e-25	Bipolar disorder and schizophrenia;
BRCA	trans	rs4650994	1.000	rs4077194	chr1:178533832	A/C	cg05059571	chr16:84539110	KIAA1609	0.36	8.31	0.31	5.97e-16	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08564027	chr20:61660810	NA	0.84	22.49	0.66	5.99e-83	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-8.61	-0.32	5.88e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11997175	0.784	rs36083407	chr8:33812930	G/T	ch.8.33884649F	chr8:33765107	NA	0.43	10.39	0.38	1.74e-23	Body mass index;
BRCA	cis	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg01251360	chr16:68772225	CDH1	-0.2	-7.95	-0.3	8.57e-15	Colorectal cancer;
BRCA	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg08000102	chr2:233561755	GIGYF2	0.64	13.84	0.48	2.76e-38	Coronary artery disease;
BRCA	cis	rs10789491	1.000	rs10749863	chr1:47174328	C/T	cg15501359	chr1:47185051	KIAA0494	0.66	18.1	0.58	1.96e-59	Response to hepatitis C treatment;
BRCA	cis	rs698813	0.774	rs2304769	chr2:44569474	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	11.47	0.41	7.78e-28	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg11062466	chr8:58055876	NA	0.42	8.0	0.3	6.04e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg19508488	chr2:152266495	RIF1	0.39	8.4	0.32	2.83e-16	Lung cancer;
BRCA	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg20587970	chr11:113659929	NA	-1.24	-22.64	-0.67	8.57e-84	Hip circumference adjusted for BMI;
BRCA	cis	rs738321	0.757	rs2284062	chr22:38544221	A/G	cg25457927	chr22:38595422	NA	-0.36	-12.81	-0.45	1.31e-33	Breast cancer;
BRCA	cis	rs870825	0.616	rs28442259	chr4:185646962	T/G	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.94e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2010099	0.941	rs73191621	chr3:124303090	T/C	cg14688451	chr3:124303035	KALRN	0.55	9.08	0.34	1.38e-18	Thyroid peroxidase antibody levels;
BRCA	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg25703541	chr22:24373054	LOC391322	-0.66	-15.05	-0.51	4.73e-44	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05901451	chr6:126070800	HEY2	-0.71	-20.6	-0.63	1.08e-72	Brugada syndrome;
BRCA	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg26384229	chr12:38710491	ALG10B	0.54	11.37	0.41	2.1e-27	Morning vs. evening chronotype;
BRCA	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg01324343	chr3:183735012	ABCC5	0.83	20.85	0.64	4.81e-74	Anterior chamber depth;
BRCA	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg01475377	chr6:109611718	NA	-0.59	-16.37	-0.54	1.4e-50	Reticulocyte fraction of red cells;
BRCA	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg03351412	chr1:154909251	PMVK	0.59	13.6	0.47	3.55e-37	Prostate cancer;
BRCA	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg09307838	chr4:120376055	NA	-0.68	-13.66	-0.48	1.94e-37	Corneal astigmatism;
BRCA	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg20108693	chr8:143823809	SLURP1	0.41	11.68	0.42	1.07e-28	Urinary tract infection frequency;
BRCA	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg00666640	chr1:248458726	OR2T12	0.32	8.67	0.32	3.56e-17	Common traits (Other);
BRCA	cis	rs68170813	0.559	rs77013162	chr7:107071674	A/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.24	-0.31	9.54e-16	Coronary artery disease;
BRCA	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.72e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg12564285	chr5:131593104	PDLIM4	0.35	9.4	0.35	9.49e-20	Blood metabolite levels;
BRCA	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg04455712	chr21:45112962	RRP1B	0.4	10.68	0.39	1.29e-24	Mean corpuscular volume;
BRCA	cis	rs651907	1.000	rs662792	chr3:101599608	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.34	8.88	0.33	6.56e-18	Colorectal cancer;
BRCA	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.82	-0.36	2.72e-21	Bladder cancer;
BRCA	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg10556349	chr10:835070	NA	0.75	9.92	0.37	1.09e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg21132104	chr15:45694354	SPATA5L1	0.73	16.29	0.54	3.75e-50	Homoarginine levels;
BRCA	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	8.35	0.31	4.26e-16	Gout;Urate levels;Serum uric acid levels;
BRCA	trans	rs11088226	0.681	rs2833895	chr21:33929802	G/A	cg09050820	chr6:167586206	TCP10L2	0.76	13.66	0.48	1.9e-37	Gastritis;
BRCA	trans	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg06521331	chr12:34319734	NA	0.43	8.47	0.32	1.7e-16	Bladder cancer;
BRCA	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg15448220	chr1:150897856	SETDB1	0.35	7.99	0.3	6.16e-15	Melanoma;
BRCA	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg23018236	chr17:30244563	NA	-0.64	-10.28	-0.38	4.62e-23	Hip circumference adjusted for BMI;
BRCA	cis	rs4595586	0.679	rs11169992	chr12:39317207	C/T	cg26384229	chr12:38710491	ALG10B	0.36	7.85	0.3	1.75e-14	Morning vs. evening chronotype;
BRCA	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg07741184	chr6:167504864	NA	0.27	8.1	0.31	2.78e-15	Crohn's disease;
BRCA	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg11833968	chr6:79620685	NA	0.41	9.43	0.35	7.26e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg11301795	chr4:187892539	NA	-0.3	-10.15	-0.37	1.55e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.01	-0.3	5.37e-15	Total body bone mineral density;
BRCA	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02353165	chr6:42928485	GNMT	0.76	18.64	0.59	2.94e-62	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4243830	1.000	rs12027598	chr1:6600804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.92	12.84	0.45	9.64e-34	Body mass index;
BRCA	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg02659138	chr7:134003124	SLC35B4	0.35	9.96	0.37	8.04e-22	Mean platelet volume;
BRCA	cis	rs754466	0.580	rs11002301	chr10:79574078	G/A	cg17075019	chr10:79541650	NA	-0.86	-23.5	-0.68	1.74e-88	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg04025307	chr7:1156635	C7orf50	0.52	10.06	0.37	3.2800000000000002e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2835872	0.758	rs1709835	chr21:39037636	A/G	cg06728970	chr21:39037746	KCNJ6	0.45	12.93	0.46	3.9e-34	Electroencephalographic traits in alcoholism;
BRCA	cis	rs30380	0.587	rs30185	chr5:96125465	G/A	cg16492584	chr5:96139282	ERAP1	-0.46	-10.84	-0.39	3.03e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg18230493	chr5:56204884	C5orf35	-0.68	-13.41	-0.47	2.57e-36	Initial pursuit acceleration;
BRCA	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.52	8.96	0.33	3.55e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg10223061	chr2:219282414	VIL1	-0.27	-7.95	-0.3	8.39e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2882667	0.589	rs825770	chr5:138115219	T/G	cg04439458	chr5:138467593	SIL1	0.31	7.87	0.3	1.47e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg01939980	chr4:1354348	KIAA1530	0.4	9.86	0.36	2e-21	Obesity-related traits;
BRCA	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg00012203	chr2:219082015	ARPC2	-0.4	-7.85	-0.3	1.82e-14	Ulcerative colitis;
BRCA	cis	rs6087990	0.899	rs6087999	chr20:31363774	A/G	cg13636640	chr20:31349939	DNMT3B	0.76	25.07	0.7	4.15e-97	Ulcerative colitis;
BRCA	cis	rs3849570	1.000	rs11915016	chr3:81833966	G/A	cg07356753	chr3:81810745	GBE1	-0.47	-11.33	-0.41	3.13e-27	Waist circumference;Body mass index;
BRCA	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg13010199	chr12:38710504	ALG10B	0.5	10.53	0.38	4.99e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4363385	0.747	rs6587716	chr1:152966705	C/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.39	-0.35	1.01e-19	Inflammatory skin disease;
BRCA	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg23708337	chr7:1209742	NA	0.61	8.87	0.33	7.38e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs34779708	0.801	rs12255409	chr10:35535425	G/A	cg03585969	chr10:35415529	CREM	0.46	9.27	0.34	2.77e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs8018808	0.935	rs8018513	chr14:77928288	T/C	cg20045696	chr14:77926864	AHSA1	0.37	8.47	0.32	1.72e-16	Myeloid white cell count;
BRCA	cis	rs2625529	0.652	rs3759820	chr15:72300031	A/C	cg16672083	chr15:72433130	SENP8	0.68	16.39	0.54	1.14e-50	Red blood cell count;
BRCA	cis	rs7520050	0.966	rs11579634	chr1:46466391	A/G	cg24296786	chr1:45957014	TESK2	-0.42	-9.42	-0.35	8.1e-20	Red blood cell count;Reticulocyte count;
BRCA	trans	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg13010199	chr12:38710504	ALG10B	0.39	8.1	0.31	2.69e-15	Morning vs. evening chronotype;
BRCA	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg04362960	chr10:104952993	NT5C2	0.45	10.26	0.38	5.92e-23	Arsenic metabolism;
BRCA	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg09904177	chr6:26538194	HMGN4	0.55	17.59	0.57	9.06e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg05340658	chr4:99064831	C4orf37	0.68	16.98	0.56	1.21e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03923535	chr7:1197113	ZFAND2A	0.5	10.95	0.4	1.1e-25	Longevity;Endometriosis;
BRCA	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.84	12.53	0.44	2.21e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg17971929	chr21:40555470	PSMG1	-0.47	-10.36	-0.38	2.31e-23	Menarche (age at onset);
BRCA	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.59e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg01206211	chr2:36825736	FEZ2	0.49	12.3	0.44	2.33e-31	Height;
BRCA	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.67	0.55	4.49e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6450176	1.000	rs9687611	chr5:53300288	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.62	-15.07	-0.51	3.71e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs2066819	1.000	rs41363748	chr12:56696056	C/T	cg26734620	chr12:56694298	CS	-0.75	-9.3	-0.35	2.25e-19	Psoriasis vulgaris;
BRCA	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg10729496	chr3:10149963	C3orf24	0.49	9.01	0.34	2.35e-18	Alzheimer's disease;
BRCA	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg11941060	chr3:133502564	NA	0.47	11.43	0.41	1.16e-27	Iron status biomarkers;
BRCA	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg12386194	chr3:101231763	SENP7	0.67	13.23	0.46	1.71e-35	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.48	-0.32	1.59e-16	Monocyte percentage of white cells;
BRCA	cis	rs9815354	0.680	rs114478966	chr3:42007050	T/C	cg03022575	chr3:42003672	ULK4	0.65	9.49	0.35	4.62e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg03354898	chr7:1950403	MAD1L1	-0.39	-8.18	-0.31	1.57e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg23950597	chr19:37808831	NA	-0.72	-12.58	-0.45	1.42e-32	Coronary artery calcification;
BRCA	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg20933634	chr6:27740509	NA	0.43	8.21	0.31	1.22e-15	Parkinson's disease;
BRCA	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg08645402	chr16:4508243	NA	0.37	8.03	0.3	4.78e-15	Schizophrenia;
BRCA	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg03213289	chr20:61660250	NA	0.63	16.01	0.53	9.62e-49	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03517284	chr6:25882590	NA	-0.46	-10.45	-0.38	1.07e-23	Blood metabolite levels;
BRCA	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg22117172	chr7:91764530	CYP51A1	-0.26	-8.78	-0.33	1.54e-17	Breast cancer;
BRCA	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg12062639	chr20:23401060	NAPB	0.91	12.79	0.45	1.65e-33	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg05535760	chr7:792225	HEATR2	0.71	12.93	0.46	3.86e-34	Cerebrospinal P-tau181p levels;
BRCA	cis	rs3857067	0.806	rs6858342	chr4:95112318	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.49	-0.35	4.67e-20	QT interval;
BRCA	cis	rs2562152	0.744	rs1045001	chr16:107275	G/T	cg02949481	chr16:131562	MPG	-0.54	-9.16	-0.34	7.02e-19	Glioblastoma;
BRCA	cis	rs919433	0.713	rs1455653	chr2:198478320	G/A	cg00792783	chr2:198669748	PLCL1	0.35	8.13	0.31	2.16e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg27490568	chr2:178487706	NA	0.52	8.92	0.33	4.76e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg25809561	chr17:30822961	MYO1D	0.59	15.93	0.53	2.21e-48	Schizophrenia;
BRCA	cis	rs9296092	0.538	rs75652975	chr6:33516251	C/T	cg13560919	chr6:33536144	NA	-0.85	-17.45	-0.57	4.51e-56	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-13.38	-0.47	3.56e-36	Morning vs. evening chronotype;
BRCA	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg17971929	chr21:40555470	PSMG1	-0.48	-10.82	-0.39	3.7e-25	Menarche (age at onset);
BRCA	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg00071950	chr4:10020882	SLC2A9	0.37	8.36	0.31	3.84e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1198430	0.929	rs1210852	chr1:23753533	T/C	cg19827787	chr1:23763612	ASAP3	0.37	9.85	0.36	2.14e-21	Total cholesterol levels;
BRCA	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg02574844	chr11:5959923	NA	-0.42	-8.26	-0.31	8.54e-16	DNA methylation (variation);
BRCA	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg06917634	chr15:78832804	PSMA4	-0.78	-17.95	-0.58	1.18e-58	Sudden cardiac arrest;
BRCA	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg08917208	chr2:24149416	ATAD2B	0.9	12.95	0.46	3.2e-34	Lymphocyte counts;
BRCA	cis	rs2304069	0.909	rs2544931	chr5:149367837	C/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.59	-8.69	-0.32	3.13e-17	HIV-1 control;
BRCA	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg22676075	chr6:135203613	NA	0.4	8.15	0.31	1.97e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg11764359	chr7:65958608	NA	-0.64	-11.24	-0.41	7.01e-27	Aortic root size;
BRCA	cis	rs7903847	0.667	rs3818787	chr10:99145179	T/C	cg20016023	chr10:99160130	RRP12	-0.25	-8.1	-0.3	2.89e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08219700	chr8:58056026	NA	0.46	8.42	0.32	2.4e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.6	0.36	1.72e-20	Menopause (age at onset);
BRCA	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	18.19	0.58	7e-60	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg05623727	chr3:50126028	RBM5	-0.43	-10.52	-0.38	5.82e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7523273	0.606	rs1474742	chr1:207976666	A/C	cg22525895	chr1:207977042	MIR29B2	0.46	11.97	0.43	6.04e-30	Schizophrenia;
BRCA	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg03462622	chr3:195777018	TFRC	-0.38	-8.61	-0.32	5.5e-17	Mean corpuscular volume;
BRCA	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg04450456	chr4:17643702	FAM184B	0.41	12.15	0.43	1.06e-30	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg04450456	chr4:17643702	FAM184B	0.33	9.45	0.35	6.04e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9649465	1.000	rs2299982	chr7:123356511	A/C	cg04330084	chr7:123175371	IQUB	-0.33	-9.01	-0.34	2.32e-18	Migraine;
BRCA	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg00814883	chr7:100076585	TSC22D4	-0.52	-11.77	-0.42	4.38e-29	Platelet count;
BRCA	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg07211511	chr3:129823064	LOC729375	1.05	21.59	0.65	4.62e-78	Blood pressure (smoking interaction);
BRCA	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg13010199	chr12:38710504	ALG10B	-0.47	-9.11	-0.34	1.01e-18	Morning vs. evening chronotype;
BRCA	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg16339924	chr4:17578868	LAP3	-0.58	-13.98	-0.48	5.94e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs858239	0.539	rs4559148	chr7:23185967	G/A	cg23682824	chr7:23144976	KLHL7	0.37	9.62	0.36	1.54e-20	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg01262667	chr19:19385393	TM6SF2	0.38	8.23	0.31	1.09e-15	Nonalcoholic fatty liver disease;
BRCA	cis	rs11055008	0.620	rs10845608	chr12:12836088	C/T	cg09462578	chr12:12878428	APOLD1	0.43	9.68	0.36	9.28e-21	Pulse pressure;
BRCA	trans	rs208520	0.754	rs851593	chr6:66875783	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	19.63	0.61	1.64e-67	Exhaled nitric oxide output;
BRCA	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg13397359	chr6:42928475	GNMT	0.66	16.05	0.54	6.04e-49	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg05457628	chr5:178986728	RUFY1	0.4	9.52	0.35	3.59e-20	Lung cancer;
BRCA	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-13.44	-0.47	1.88e-36	Migraine;Coronary artery disease;
BRCA	cis	rs6009527	0.752	rs7286232	chr22:49568490	A/G	cg12746016	chr22:49560550	NA	0.39	9.13	0.34	9.05e-19	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
BRCA	cis	rs887829	0.570	rs6736508	chr2:234595747	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.32	-8.22	-0.31	1.15e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg15704280	chr7:45808275	SEPT13	0.62	10.25	0.38	6.54e-23	Axial length;
BRCA	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg26695010	chr11:65641043	EFEMP2	0.38	8.41	0.32	2.62e-16	Eosinophil percentage of white cells;
BRCA	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg17366294	chr4:99064904	C4orf37	0.46	10.83	0.39	3.22e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg25214090	chr10:38739885	LOC399744	0.45	10.36	0.38	2.38e-23	Corneal astigmatism;
BRCA	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg06271696	chr7:157225062	NA	-0.37	-9.71	-0.36	7.04e-21	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	cis	rs2742234	0.578	rs2435354	chr10:43652445	C/T	cg02780029	chr10:43622663	RET	-0.35	-7.81	-0.3	2.4e-14	Hirschsprung disease;
BRCA	cis	rs4631830	0.737	rs7071471	chr10:51503335	C/T	cg20129853	chr10:51489980	NA	0.29	7.91	0.3	1.12e-14	Prostate-specific antigen levels;
BRCA	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg04362960	chr10:104952993	NT5C2	0.46	10.74	0.39	7.57e-25	Arsenic metabolism;
BRCA	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg03929089	chr4:120376271	NA	-0.98	-29.5	-0.76	2.38e-121	Height;
BRCA	trans	rs9944715	1.000	rs9959813	chr18:43841082	C/T	cg01718231	chr17:29326311	RNF135	0.45	8.99	0.34	2.82e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg25358565	chr5:93447407	FAM172A	1.25	18.29	0.59	2.09e-60	Diabetic retinopathy;
BRCA	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg06784218	chr1:46089804	CCDC17	0.45	10.91	0.4	1.54e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs965469	1.000	rs2236117	chr20:3302021	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-10.14	-0.37	1.68e-22	IFN-related cytopenia;
BRCA	cis	rs11971779	0.680	rs4732370	chr7:139077240	A/C	cg07862535	chr7:139043722	LUC7L2	-0.39	-10.66	-0.39	1.52e-24	Diisocyanate-induced asthma;
BRCA	trans	rs1997103	0.906	rs2177806	chr7:55402609	A/T	cg20935933	chr6:143382018	AIG1	0.6	11.42	0.41	1.32e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg21951975	chr1:209979733	IRF6	0.39	8.39	0.31	3.18e-16	Cleft lip with or without cleft palate;
BRCA	cis	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg05901451	chr6:126070800	HEY2	0.39	9.55	0.35	2.8e-20	Endometrial cancer;
BRCA	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.35	-0.41	2.51e-27	Gut microbiome composition (summer);
BRCA	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg16482183	chr6:26056742	HIST1H1C	0.53	11.4	0.41	1.56e-27	Height;
BRCA	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.61	-13.84	-0.48	2.86e-38	Platelet count;
BRCA	cis	rs2637030	0.559	rs256083	chr5:52893681	G/A	cg06476337	chr5:52856530	NDUFS4	0.38	8.62	0.32	5.24e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.08	0.4	3.31e-26	Bipolar disorder;
BRCA	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg22491629	chr6:157744540	C6orf35	-0.65	-11.65	-0.42	1.47e-28	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg03213289	chr20:61660250	NA	0.61	16.07	0.54	4.85e-49	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg04944784	chr2:26401820	FAM59B	-0.66	-11.2	-0.41	1.06e-26	Gut microbiome composition (summer);
BRCA	cis	rs7246657	0.722	rs2909102	chr19:38167364	C/T	cg18154014	chr19:37997991	ZNF793	-0.51	-9.56	-0.35	2.58e-20	Coronary artery calcification;
BRCA	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg19077165	chr18:44547161	KATNAL2	-0.64	-14.56	-0.5	1.14e-41	Personality dimensions;
BRCA	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg08847533	chr14:75593920	NEK9	-0.83	-20.94	-0.64	1.66e-74	Height;
BRCA	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg09307838	chr4:120376055	NA	0.65	13.17	0.46	3.31e-35	Corneal astigmatism;
BRCA	cis	rs2422052	0.654	rs1433530	chr2:118649083	G/A	cg22545206	chr2:118617499	NA	0.4	9.84	0.36	2.24e-21	Mosquito bite size;
BRCA	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg06212747	chr3:49208901	KLHDC8B	0.45	9.37	0.35	1.26e-19	Parkinson's disease;
BRCA	trans	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg26043149	chr18:55253948	FECH	-0.37	-8.21	-0.31	1.2e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4363385	0.818	rs4845514	chr1:153000820	T/C	cg24667326	chr1:152973720	SPRR3	-0.32	-8.74	-0.33	2.11e-17	Inflammatory skin disease;
BRCA	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.62	-13.15	-0.46	3.85e-35	Lymphocyte percentage of white cells;
BRCA	cis	rs870825	0.655	rs72703561	chr4:185630890	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	17.14	0.56	1.9e-54	Blood protein levels;
BRCA	cis	rs698833	0.886	rs2053454	chr2:44550290	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	10.0	0.37	5.74e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg12310025	chr6:25882481	NA	-0.5	-11.01	-0.4	6.42e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.43	0.57	6.11e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg26384229	chr12:38710491	ALG10B	0.43	10.26	0.38	5.72e-23	Heart rate;
BRCA	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg26677194	chr12:130822605	PIWIL1	0.6	14.33	0.49	1.31e-40	Menopause (age at onset);
BRCA	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07636037	chr3:49044803	WDR6	0.73	15.92	0.53	2.73e-48	Menarche (age at onset);
BRCA	trans	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg08999081	chr20:33150536	PIGU	0.36	9.03	0.34	2.01e-18	Coronary artery disease;
BRCA	trans	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.37	8.13	0.31	2.16e-15	Mean corpuscular volume;
BRCA	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10802521	chr3:52805072	NEK4	-0.33	-8.37	-0.31	3.7e-16	Bipolar disorder;
BRCA	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg03425785	chr20:62221387	GMEB2	0.51	8.26	0.31	8.42e-16	Glioblastoma;
BRCA	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08564027	chr20:61660810	NA	0.85	22.97	0.67	1.42e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg19784903	chr17:45786737	TBKBP1	-0.45	-10.72	-0.39	9.07e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7635838	0.596	rs443503	chr3:11261912	A/T	cg00170343	chr3:11313890	ATG7	-0.39	-8.08	-0.3	3.13e-15	HDL cholesterol;
BRCA	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg03453431	chr7:157225567	NA	-0.45	-8.97	-0.33	3.2e-18	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg14019146	chr3:50243930	SLC38A3	-0.45	-10.92	-0.4	1.4e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs931812	0.964	rs2102290	chr8:101919844	G/C	cg20993868	chr7:22813445	NA	0.49	13.56	0.47	5.25e-37	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.47	-14.47	-0.5	2.87e-41	Alzheimer's disease (late onset);
BRCA	cis	rs2710642	0.888	rs13418889	chr2:63079775	T/C	cg17519650	chr2:63277830	OTX1	0.38	8.43	0.32	2.36e-16	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs9790314	0.582	rs6796201	chr3:160634313	A/G	cg03342759	chr3:160939853	NMD3	0.43	8.63	0.32	4.82e-17	Morning vs. evening chronotype;
BRCA	cis	rs2882667	0.754	rs11746434	chr5:138435303	A/G	cg04439458	chr5:138467593	SIL1	-0.43	-10.74	-0.39	7.24e-25	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs193541	0.632	rs154512	chr5:122195040	T/C	cg19412675	chr5:122181750	SNX24	0.32	7.85	0.3	1.79e-14	Glucose homeostasis traits;
BRCA	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg19622623	chr12:86230825	RASSF9	-0.33	-9.39	-0.35	1.02e-19	Major depressive disorder;
BRCA	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.79e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg06917634	chr15:78832804	PSMA4	-0.78	-17.48	-0.57	3.41e-56	Sudden cardiac arrest;
BRCA	cis	rs2742234	0.541	rs11238481	chr10:43719286	A/G	cg02780029	chr10:43622663	RET	0.35	7.86	0.3	1.69e-14	Hirschsprung disease;
BRCA	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.22	0.49	4.42e-40	Motion sickness;
BRCA	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg11608241	chr8:8085544	FLJ10661	-0.35	-9.73	-0.36	5.76e-21	Schizophrenia;
BRCA	trans	rs629535	0.814	rs674429	chr8:70069942	G/A	cg21567404	chr3:27674614	NA	1.01	20.96	0.64	1.2e-74	Dupuytren's disease;
BRCA	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg01262667	chr19:19385393	TM6SF2	0.41	10.52	0.38	5.77e-24	Tonsillectomy;
BRCA	cis	rs72627509	0.638	rs7658601	chr4:57781347	C/T	cg26694713	chr4:57773883	REST	0.46	8.55	0.32	8.93e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs12618769	0.652	rs1139829	chr2:99225168	C/T	cg10123293	chr2:99228465	UNC50	0.44	8.64	0.32	4.34e-17	Bipolar disorder;
BRCA	cis	rs4800452	0.745	rs8093542	chr18:20709123	A/C	cg26136497	chr18:20735537	CABLES1	-0.4	-9.08	-0.34	1.33e-18	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg21775007	chr8:11205619	TDH	-0.37	-7.86	-0.3	1.6e-14	Systolic blood pressure;
BRCA	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg17724175	chr1:150552817	MCL1	0.25	8.17	0.31	1.6e-15	Tonsillectomy;
BRCA	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg16850897	chr7:100343110	ZAN	0.35	8.08	0.3	3.16e-15	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.0	15.21	0.52	8.07e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14240646	chr10:27532245	ACBD5	-0.62	-9.58	-0.35	2.13e-20	Breast cancer;
BRCA	cis	rs10504073	0.669	rs62507251	chr8:50028524	T/G	cg00325661	chr8:49890786	NA	0.44	12.16	0.43	9.27e-31	Blood metabolite ratios;
BRCA	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg22705602	chr4:152727874	NA	-0.31	-8.05	-0.3	4.03e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10504073	0.584	rs62507178	chr8:49938572	A/C	cg00325661	chr8:49890786	NA	0.52	14.71	0.5	2.04e-42	Blood metabolite ratios;
BRCA	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.49	-10.5	-0.38	6.64e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg07537917	chr2:241836409	C2orf54	-0.49	-11.74	-0.42	5.86e-29	Urinary metabolites;
BRCA	cis	rs3824867	0.920	rs9734013	chr11:47451517	G/T	cg20307385	chr11:47447363	PSMC3	-0.49	-10.94	-0.4	1.16e-25	Mean corpuscular hemoglobin;
BRCA	cis	rs507080	0.922	rs638805	chr11:118558889	G/T	cg08498647	chr11:118550644	TREH	-0.38	-8.26	-0.31	8.53e-16	Serum metabolite levels;
BRCA	cis	rs7818345	0.967	rs6992893	chr8:19287504	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.3	7.97	0.3	7.11e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs559928	1.000	rs641168	chr11:64146289	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.54	-8.08	-0.3	3.17e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg25173405	chr17:45401733	C17orf57	0.47	9.82	0.36	2.7e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7927771	0.524	rs3816605	chr11:47857253	T/C	cg20307385	chr11:47447363	PSMC3	0.42	9.62	0.36	1.56e-20	Subjective well-being;
BRCA	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	16.51	0.55	2.77e-51	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg09021430	chr5:549028	NA	-0.69	-14.43	-0.5	4.56e-41	Lung disease severity in cystic fibrosis;
BRCA	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg02187348	chr16:89574699	SPG7	0.51	12.23	0.44	4.91e-31	Multiple myeloma (IgH translocation);
BRCA	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg07952391	chr2:88470173	THNSL2	-0.4	-8.01	-0.3	5.51e-15	Response to metformin (IC50);
BRCA	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg18478394	chr8:109455254	TTC35	0.29	8.56	0.32	8.59e-17	Dupuytren's disease;
BRCA	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-15.84	-0.53	6.63e-48	Systemic lupus erythematosus;
BRCA	cis	rs11249608	0.789	rs7704963	chr5:178436854	A/G	cg21905437	chr5:178450457	ZNF879	0.44	9.0	0.34	2.46e-18	Pubertal anthropometrics;
BRCA	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg20469991	chr17:27169893	C17orf63	0.45	8.82	0.33	1.12e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.72	-0.33	2.47e-17	Mood instability;
BRCA	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg27432699	chr2:27873401	GPN1	0.46	9.69	0.36	8.42e-21	Oral cavity cancer;
BRCA	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	14.49	0.5	2.52e-41	Motion sickness;
BRCA	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg17063962	chr7:91808500	NA	0.53	12.49	0.44	3.57e-32	Breast cancer;
BRCA	trans	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg25214090	chr10:38739885	LOC399744	0.45	10.38	0.38	2.04e-23	Corneal astigmatism;
BRCA	trans	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg06521331	chr12:34319734	NA	-0.49	-8.94	-0.33	4.09e-18	Bladder cancer;
BRCA	cis	rs12541635	0.966	rs7819327	chr8:106986003	A/C	cg10147462	chr8:107024639	NA	0.39	10.31	0.38	3.69e-23	Age of smoking initiation;
BRCA	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg15704280	chr7:45808275	SEPT13	-0.55	-10.6	-0.39	2.7e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg13770153	chr20:60521292	NA	-0.54	-11.45	-0.41	9.39e-28	Body mass index;
BRCA	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-14.27	-0.49	2.56e-40	Parkinson's disease;
BRCA	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg07080220	chr10:102295463	HIF1AN	0.61	14.45	0.5	3.82e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9287719	0.601	rs1861300	chr2:10763961	A/G	cg00105475	chr2:10696890	NA	0.47	10.32	0.38	3.26e-23	Prostate cancer;
BRCA	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg17063962	chr7:91808500	NA	0.57	13.51	0.47	8.97e-37	Breast cancer;
BRCA	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg22676075	chr6:135203613	NA	-0.46	-9.64	-0.36	1.25e-20	High light scatter reticulocyte percentage of red cells;
BRCA	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg20587970	chr11:113659929	NA	-1.34	-24.21	-0.69	2.24e-92	Hip circumference adjusted for BMI;
BRCA	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg26384229	chr12:38710491	ALG10B	0.59	13.61	0.47	3.04e-37	Morning vs. evening chronotype;
BRCA	cis	rs9811920	0.683	rs4928230	chr3:99661963	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-11.18	-0.4	1.29e-26	Axial length;
BRCA	trans	rs4650994	0.967	rs4650992	chr1:178515135	A/T	cg05059571	chr16:84539110	KIAA1609	-0.42	-9.6	-0.36	1.71e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.43	-0.44	6.2e-32	Chronic sinus infection;
BRCA	cis	rs7043114	0.525	rs1053446	chr9:95146761	T/A	cg14631576	chr9:95140430	CENPP	-0.33	-8.33	-0.31	4.77e-16	Height;
BRCA	cis	rs2016266	0.859	rs10876433	chr12:53734114	G/A	cg26875137	chr12:53738046	NA	-0.44	-9.74	-0.36	5.43e-21	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg05340658	chr4:99064831	C4orf37	0.7	17.39	0.57	9.76e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg05283184	chr6:79620031	NA	-0.41	-10.37	-0.38	2.09e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.51	-10.17	-0.37	1.33e-22	Body mass index;
BRCA	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg05294307	chr14:35346193	BAZ1A	-0.57	-9.99	-0.37	5.97e-22	Psoriasis;
BRCA	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.33	8.07	0.3	3.41e-15	IgG glycosylation;
BRCA	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4594175	0.926	rs9323206	chr14:51621800	C/T	cg23942311	chr14:51606299	NA	0.33	8.36	0.31	4.05e-16	Cancer;
BRCA	cis	rs10267417	0.603	rs13307910	chr7:19858392	C/T	cg07541023	chr7:19748670	TWISTNB	0.48	8.85	0.33	8.88e-18	Night sleep phenotypes;
BRCA	cis	rs2279817	0.735	rs12067869	chr1:17989765	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.45	-11.57	-0.42	2.92e-28	Neuroticism;
BRCA	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg11266682	chr4:10021025	SLC2A9	0.49	13.12	0.46	5.22e-35	Bone mineral density;
BRCA	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg13010199	chr12:38710504	ALG10B	-0.35	-8.54	-0.32	9.47e-17	Morning vs. evening chronotype;
BRCA	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22307029	chr19:49891270	CCDC155	0.54	9.03	0.34	2.04e-18	Multiple sclerosis;
BRCA	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg08888203	chr3:10149979	C3orf24	0.65	11.91	0.43	1.07e-29	Alzheimer's disease;
BRCA	cis	rs758324	0.812	rs477086	chr5:131284610	C/T	cg06307176	chr5:131281290	NA	-0.47	-10.21	-0.37	8.96e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg04756594	chr16:24857601	SLC5A11	0.36	8.78	0.33	1.43e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.747	rs1129655	chr1:152958267	T/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.12	-0.31	2.37e-15	Inflammatory skin disease;
BRCA	cis	rs2274471	0.699	rs10974985	chr9:5156061	C/T	cg03390472	chr9:5043263	JAK2	0.44	8.08	0.3	3.25e-15	Crohn's disease;
BRCA	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg18479299	chr3:125709523	NA	-0.53	-8.18	-0.31	1.53e-15	Blood pressure (smoking interaction);
BRCA	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.51	-0.35	3.69e-20	Hip circumference adjusted for BMI;
BRCA	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00684032	chr4:1343700	KIAA1530	0.52	12.28	0.44	2.85e-31	Obesity-related traits;
BRCA	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.84	-17.06	-0.56	4.66e-54	HIV-1 control;
BRCA	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg14004847	chr7:1930337	MAD1L1	0.43	8.86	0.33	8.06e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg24562669	chr7:97807699	LMTK2	0.46	11.8	0.42	3.21e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg10223061	chr2:219282414	VIL1	0.3	8.47	0.32	1.72e-16	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg21475434	chr5:93447410	FAM172A	0.67	8.97	0.33	3.29e-18	Diabetic retinopathy;
BRCA	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg17366294	chr4:99064904	C4orf37	0.41	9.27	0.34	2.92e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18404041	chr3:52824283	ITIH1	0.43	13.51	0.47	9.39e-37	Bipolar disorder;
BRCA	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg26384229	chr12:38710491	ALG10B	0.85	22.95	0.67	1.8e-85	Heart rate;
BRCA	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18404041	chr3:52824283	ITIH1	-0.32	-9.54	-0.35	2.84e-20	Cognitive function;
BRCA	cis	rs7617773	0.780	rs3197223	chr3:48335857	C/T	cg11946769	chr3:48343235	NME6	0.68	14.05	0.49	2.93e-39	Coronary artery disease;
BRCA	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg11764359	chr7:65958608	NA	-0.67	-14.95	-0.51	1.53e-43	Aortic root size;
BRCA	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.88	-0.3	1.43e-14	Bipolar disorder;
BRCA	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg23018236	chr17:30244563	NA	-0.64	-10.28	-0.38	4.62e-23	Hip circumference adjusted for BMI;
BRCA	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg03146154	chr1:46216737	IPP	-0.5	-11.16	-0.4	1.54e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.35	0.57	1.6e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.36	-8.19	-0.31	1.45e-15	Colorectal cancer;
BRCA	cis	rs870825	0.616	rs67409049	chr4:185623989	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg23109721	chr2:106886537	NA	-0.46	-8.34	-0.31	4.6e-16	Facial morphology (factor 23);
BRCA	cis	rs3845702	0.736	rs6433818	chr2:180810264	A/T	cg01881094	chr2:180872142	CWC22	-1.03	-17.25	-0.56	5.06e-55	Schizophrenia;
BRCA	cis	rs6484504	0.532	rs11031342	chr11:31309818	G/A	cg14844989	chr11:31128820	NA	-0.46	-9.91	-0.36	1.27e-21	Red blood cell count;
BRCA	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg10327440	chr1:227177885	CDC42BPA	-1.09	-38.38	-0.84	4.95e-168	Myeloid white cell count;
BRCA	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21659725	chr3:3221576	CRBN	0.52	13.59	0.47	3.75e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg24829409	chr8:58192753	C8orf71	-0.49	-9.25	-0.34	3.45e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg07636037	chr3:49044803	WDR6	0.52	8.46	0.32	1.81e-16	Menarche (age at onset);
BRCA	cis	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg18898632	chr2:242989856	NA	-0.5	-8.54	-0.32	9.65e-17	Obesity-related traits;
BRCA	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg27535305	chr1:53392650	SCP2	-0.37	-9.32	-0.35	1.85e-19	Monocyte count;
BRCA	cis	rs16866061	0.926	rs17479770	chr2:225335814	A/G	cg12698349	chr2:225449008	CUL3	0.74	17.78	0.58	9.15e-58	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs4389656	0.740	rs412643	chr5:6720715	A/G	cg10857441	chr5:6722123	POLS	-0.25	-7.82	-0.3	2.22e-14	Coronary artery disease;
BRCA	cis	rs2073300	1.000	rs12625999	chr20:23442085	A/G	cg12062639	chr20:23401060	NAPB	-0.88	-10.65	-0.39	1.65e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2505998	0.843	rs2506004	chr10:43582273	A/C	cg15436174	chr10:43711423	RASGEF1A	-0.4	-7.97	-0.3	7.42e-15	Hirschsprung disease;
BRCA	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg02880119	chr16:3481970	NA	0.44	8.16	0.31	1.77e-15	Body mass index (adult);
BRCA	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.18	-0.31	1.57e-15	Depression;
BRCA	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg10876282	chr6:28092338	ZSCAN16	0.42	8.41	0.32	2.74e-16	Cardiac Troponin-T levels;
BRCA	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg18225595	chr11:63971243	STIP1	0.4	9.91	0.37	1.2e-21	Platelet count;
BRCA	cis	rs17095355	1.000	rs12570607	chr10:111696704	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.39	-10.05	-0.37	3.83e-22	Biliary atresia;
BRCA	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.8	16.01	0.54	9.17e-49	Body mass index;
BRCA	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg04990556	chr1:26633338	UBXN11	0.7	11.98	0.43	5.53e-30	Obesity-related traits;
BRCA	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg07636037	chr3:49044803	WDR6	0.81	20.97	0.64	1.15e-74	Menarche (age at onset);
BRCA	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg00277334	chr10:82204260	NA	-0.44	-8.62	-0.32	5.31e-17	Post bronchodilator FEV1;
BRCA	cis	rs1941023	0.503	rs4939348	chr11:60135871	A/C	cg08716584	chr11:60157161	MS4A7	-0.42	-9.79	-0.36	3.45e-21	Congenital heart disease (maternal effect);
BRCA	cis	rs74181299	0.684	rs1420184	chr2:65315880	G/C	cg05010058	chr2:65284262	CEP68	-0.29	-7.93	-0.3	9.96e-15	Pulse pressure;
BRCA	cis	rs4671400	0.571	rs4672429	chr2:61495469	G/C	cg15711740	chr2:61764176	XPO1	0.39	7.96	0.3	7.63e-15	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs10501293	1.000	rs1559762	chr11:43128541	C/T	cg03447554	chr11:43094025	NA	0.49	9.0	0.34	2.47e-18	Cognitive performance;
BRCA	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg05535760	chr7:792225	HEATR2	0.78	13.66	0.48	1.8e-37	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1971762	0.583	rs3852561	chr12:54085842	C/T	cg23533419	chr12:54090519	NA	-0.33	-8.39	-0.32	3.12e-16	Height;
BRCA	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18876405	chr7:65276391	NA	0.5	11.04	0.4	4.57e-26	Aortic root size;
BRCA	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	16.54	0.55	2.16e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs798766	1.000	rs3752749	chr4:1737262	T/C	cg05874882	chr4:1763078	NA	-0.47	-8.46	-0.32	1.79e-16	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs2742234	0.590	rs2435383	chr10:43675671	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.54	-10.87	-0.4	2.23e-25	Hirschsprung disease;
BRCA	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg04607235	chr12:12878440	APOLD1	-0.63	-10.14	-0.37	1.65e-22	Systemic lupus erythematosus;
BRCA	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg03676636	chr4:99064102	C4orf37	0.21	7.98	0.3	6.94e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.94	0.3	8.91e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg18252515	chr7:66147081	NA	1.02	15.22	0.52	7.34e-45	Diabetic kidney disease;
BRCA	cis	rs858239	0.539	rs2390757	chr7:23191492	A/G	cg23682824	chr7:23144976	KLHL7	0.36	9.47	0.35	5.44e-20	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6446731	0.517	rs2858087	chr4:3268892	A/T	cg08886695	chr4:3369023	RGS12	0.38	10.09	0.37	2.57e-22	Mean platelet volume;
BRCA	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.85e-29	Chronic sinus infection;
BRCA	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	ch.11.42038R	chr11:967971	AP2A2	0.52	16.59	0.55	1.19e-51	Alzheimer's disease (late onset);
BRCA	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg20503657	chr10:835505	NA	1.05	18.47	0.59	2.42e-61	Eosinophil percentage of granulocytes;
BRCA	cis	rs4974559	0.739	rs10032327	chr4:1323537	C/T	cg02980000	chr4:1222292	CTBP1	0.81	12.97	0.46	2.66e-34	Systolic blood pressure;
BRCA	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.4	0.47	2.88e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	19.33	0.61	6.67e-66	Smoking behavior;
BRCA	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg10523679	chr1:76189770	ACADM	-0.63	-11.74	-0.42	6.16e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04267008	chr7:1944627	MAD1L1	-0.6	-12.6	-0.45	1.13e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	9.01	0.34	2.41e-18	Iron status biomarkers;
BRCA	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg08601574	chr20:25228251	PYGB	-0.34	-8.25	-0.31	9.06e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs877282	0.898	rs11253340	chr10:764786	G/T	cg17470449	chr10:769945	NA	0.47	7.96	0.3	8.16e-15	Uric acid levels;
BRCA	trans	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg25214090	chr10:38739885	LOC399744	0.43	9.99	0.37	6.03e-22	Corneal astigmatism;
BRCA	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg03709012	chr19:19516395	GATAD2A	0.91	17.82	0.58	5.64e-58	Nonalcoholic fatty liver disease;
BRCA	cis	rs672059	1.000	rs480132	chr1:183161779	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.38	8.71	0.33	2.52e-17	Hypertriglyceridemia;
BRCA	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg06494592	chr3:125709126	NA	-0.53	-8.18	-0.31	1.53e-15	Blood pressure (smoking interaction);
BRCA	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg11502198	chr6:26597334	ABT1	0.47	9.47	0.35	5.19e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg23711669	chr6:146136114	FBXO30	0.71	17.0	0.56	8.98e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-14.27	-0.49	2.71e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg05340658	chr4:99064831	C4orf37	0.44	10.13	0.37	1.74e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg26031613	chr14:104095156	KLC1	0.44	7.92	0.3	1.09e-14	Coronary artery disease;
BRCA	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.56	-9.01	-0.34	2.44e-18	Body mass index (adult);
BRCA	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.8	0.39	4.53e-25	Rheumatoid arthritis;
BRCA	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg10862848	chr6:42927986	GNMT	-0.36	-15.1	-0.51	2.68e-44	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg06484146	chr7:12443880	VWDE	0.62	9.81	0.36	3e-21	Coronary artery disease;
BRCA	cis	rs11971779	0.618	rs10085814	chr7:139064089	A/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.27	0.38	5.48e-23	Diisocyanate-induced asthma;
BRCA	cis	rs7092929	0.824	rs11251951	chr10:3622867	C/T	cg14308648	chr10:3568949	NA	-0.46	-8.2	-0.31	1.34e-15	Coronary artery calcification;
BRCA	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11764359	chr7:65958608	NA	0.8	19.53	0.61	6.05e-67	Aortic root size;
BRCA	cis	rs4363385	0.791	rs11205177	chr1:153002502	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.37	-0.31	3.55e-16	Inflammatory skin disease;
BRCA	trans	rs853679	0.599	rs188015	chr6:27877446	T/A	cg01620082	chr3:125678407	NA	-0.53	-7.84	-0.3	1.86e-14	Depression;
BRCA	cis	rs7520050	0.966	rs785479	chr1:46492144	C/T	cg24296786	chr1:45957014	TESK2	0.43	9.64	0.36	1.3e-20	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9463078	0.683	rs1342640	chr6:44743516	T/C	cg25276700	chr6:44698697	NA	0.36	8.06	0.3	3.89e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	trans	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg26043149	chr18:55253948	FECH	-0.37	-8.3	-0.31	6.41e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2479724	0.905	rs2149274	chr6:41839092	T/C	cg17623882	chr6:41773611	USP49	-0.38	-10.28	-0.38	4.85e-23	Menarche (age at onset);
BRCA	cis	rs829883	0.664	rs249833	chr12:98832189	T/C	cg25150519	chr12:98850993	NA	0.66	16.05	0.54	5.72e-49	Colorectal adenoma (advanced);
BRCA	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg02734326	chr4:10020555	SLC2A9	0.4	8.7	0.33	2.7e-17	Bone mineral density;
BRCA	cis	rs1113500	0.836	rs1122158	chr1:108588668	G/T	cg06207961	chr1:108661230	NA	0.4	9.58	0.35	2.03e-20	Growth-regulated protein alpha levels;
BRCA	cis	rs2070997	0.667	rs13287613	chr9:133715291	T/C	cg11464064	chr9:133710261	ABL1	0.53	9.6	0.35	1.81e-20	Response to amphetamines;
BRCA	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg04944784	chr2:26401820	FAM59B	-0.95	-16.17	-0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg04362960	chr10:104952993	NT5C2	0.46	10.7	0.39	1.05e-24	Arsenic metabolism;
BRCA	cis	rs6942756	1.000	rs11769045	chr7:128895335	A/G	cg02491457	chr7:128862824	NA	-0.7	-14.04	-0.49	3.02e-39	White matter hyperintensity burden;
BRCA	cis	rs6433857	0.627	rs6741769	chr2:181500545	G/A	cg23363182	chr2:181467187	NA	-0.45	-9.73	-0.36	5.81e-21	Body mass index;
BRCA	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07636037	chr3:49044803	WDR6	0.87	20.79	0.64	9.85e-74	Menarche (age at onset);
BRCA	cis	rs910873	0.505	rs6058099	chr20:33249134	C/T	cg16810054	chr20:33298113	TP53INP2	-0.48	-10.44	-0.38	1.17e-23	Melanoma;
BRCA	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-11.17	-0.4	1.4e-26	Gut microbiome composition (summer);
BRCA	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg08917208	chr2:24149416	ATAD2B	0.53	8.25	0.31	8.81e-16	Asthma;
BRCA	cis	rs903263	0.601	rs34179759	chr1:84533842	G/T	cg10977910	chr1:84465055	TTLL7	0.44	8.5	0.32	1.3e-16	Breast cancer (male);
BRCA	trans	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg25214090	chr10:38739885	LOC399744	0.47	10.74	0.39	7.86e-25	Corneal astigmatism;
BRCA	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg09307838	chr4:120376055	NA	0.63	13.64	0.47	2.32e-37	Corneal astigmatism;
BRCA	cis	rs4363385	0.818	rs561143	chr1:153010734	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg20307385	chr11:47447363	PSMC3	0.86	26.42	0.72	1.55e-104	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.55	-0.35	2.64e-20	Tonsillectomy;
BRCA	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg19784903	chr17:45786737	TBKBP1	0.36	8.48	0.32	1.56e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7818345	0.845	rs7821446	chr8:19268822	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.35	-9.15	-0.34	7.31e-19	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.55	0.32	9.16e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg22875332	chr1:76189707	ACADM	0.66	15.64	0.53	6.25e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.43	8.99	0.34	2.69e-18	Cognitive ability;
BRCA	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.42	0.38	1.4e-23	IgG glycosylation;
BRCA	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	ch.11.42038R	chr11:967971	AP2A2	0.52	16.55	0.55	1.84e-51	Alzheimer's disease (late onset);
BRCA	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg22029157	chr1:209979665	IRF6	0.44	8.33	0.31	4.95e-16	Cleft lip with or without cleft palate;
BRCA	cis	rs7011049	1.000	rs72640850	chr8:53836681	A/C	cg26025543	chr8:53854495	NA	0.55	9.59	0.35	1.92e-20	Systolic blood pressure;
BRCA	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg00383909	chr3:49044727	WDR6	0.74	12.51	0.44	2.83e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg08213375	chr14:104286397	PPP1R13B	0.63	17.61	0.57	7.19e-57	Schizophrenia;
BRCA	cis	rs10992471	0.580	rs1535756	chr9:95202032	G/A	cg14631576	chr9:95140430	CENPP	-0.39	-9.31	-0.35	2.09e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg12365402	chr11:9010492	NRIP3	-0.42	-9.95	-0.37	9.05e-22	Hemoglobin concentration;
BRCA	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg04414720	chr1:150670196	GOLPH3L	0.35	8.06	0.3	3.82e-15	Tonsillectomy;
BRCA	cis	rs7809950	0.954	rs2189839	chr7:107230026	A/G	cg23024343	chr7:107201750	COG5	0.39	8.87	0.33	7.04e-18	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.33	-0.31	4.94e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg21770322	chr7:97807741	LMTK2	0.39	10.38	0.38	1.95e-23	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg01262667	chr19:19385393	TM6SF2	0.42	10.91	0.4	1.59e-25	Tonsillectomy;
BRCA	cis	rs3925075	1.000	rs9674009	chr16:31347541	C/A	cg02846316	chr16:31340340	ITGAM	0.53	13.04	0.46	1.2e-34	IgA nephropathy;
BRCA	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.63	13.81	0.48	3.77e-38	Lymphocyte percentage of white cells;
BRCA	trans	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg26043149	chr18:55253948	FECH	1.0	22.05	0.66	1.39e-80	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs7178424	1.000	rs7178424	chr15:62380259	C/T	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.23	-0.31	1.06e-15	Height;
BRCA	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg00012203	chr2:219082015	ARPC2	-0.46	-8.77	-0.33	1.58e-17	Colorectal cancer;
BRCA	cis	rs4718428	0.705	rs13227468	chr7:66433563	T/C	cg18252515	chr7:66147081	NA	-0.54	-10.76	-0.39	6.5e-25	Corneal structure;
BRCA	cis	rs2637030	0.515	rs439552	chr5:52978517	G/A	cg06476337	chr5:52856530	NDUFS4	0.36	8.28	0.31	7.15e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs28830936	1.000	rs11070343	chr15:41940146	T/A	cg17847044	chr15:42102381	MAPKBP1	-0.34	-9.56	-0.35	2.4e-20	Diastolic blood pressure;
BRCA	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg06935464	chr4:38784597	TLR10	0.51	8.96	0.33	3.43e-18	Breast cancer;
BRCA	cis	rs778371	0.788	rs778355	chr2:233784749	T/G	cg08000102	chr2:233561755	GIGYF2	-0.51	-9.7	-0.36	7.71e-21	Schizophrenia;
BRCA	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.58	8.94	0.33	4.26e-18	HIV-1 control;
BRCA	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-23.38	-0.68	8.2e-88	Chronic sinus infection;
BRCA	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	8.43	0.32	2.28e-16	Schizophrenia;
BRCA	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg24060327	chr5:131705240	SLC22A5	0.64	12.42	0.44	7.04e-32	Breast cancer;
BRCA	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.42	-11.03	-0.4	4.99e-26	Schizophrenia;
BRCA	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg02659138	chr7:134003124	SLC35B4	0.34	10.79	0.39	4.94e-25	Mean platelet volume;
BRCA	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg24633833	chr3:10029261	TMEM111	0.41	8.02	0.3	5.1e-15	Alzheimer's disease;
BRCA	trans	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg06521331	chr12:34319734	NA	-0.47	-8.73	-0.33	2.28e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6545883	0.524	rs4599092	chr2:61498968	T/G	cg15711740	chr2:61764176	XPO1	0.33	8.11	0.31	2.67e-15	Tuberculosis;
BRCA	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg05872129	chr22:39784769	NA	0.58	13.27	0.46	1.16e-35	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg20203395	chr5:56204925	C5orf35	0.41	9.22	0.34	4.12e-19	Initial pursuit acceleration;
BRCA	cis	rs10746514	0.833	rs10864720	chr1:232271232	C/T	cg09506761	chr1:232265262	NA	-0.42	-8.24	-0.31	9.78e-16	Response to statin therapy;
BRCA	cis	rs11051970	0.704	rs7312698	chr12:32554695	G/T	cg24626660	chr12:32551988	NA	0.32	9.4	0.35	9.38e-20	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-11.8	-0.42	3.43e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg04691961	chr3:161091175	C3orf57	-0.41	-9.66	-0.36	1.06e-20	Morning vs. evening chronotype;
BRCA	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11644478	chr21:40555479	PSMG1	-0.5	-10.23	-0.38	7.72e-23	Menarche (age at onset);
BRCA	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18876405	chr7:65276391	NA	0.52	11.63	0.42	1.7e-28	Aortic root size;
BRCA	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg13256891	chr4:100009986	ADH5	0.42	9.57	0.35	2.29e-20	Alcohol dependence;
BRCA	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08045932	chr20:61659980	NA	-0.42	-9.8	-0.36	3.11e-21	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg03146154	chr1:46216737	IPP	0.53	11.81	0.42	2.91e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2742234	0.590	rs2435376	chr10:43684963	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.54	-11.11	-0.4	2.36e-26	Hirschsprung disease;
BRCA	trans	rs1459104	1.000	rs12576386	chr11:55252365	T/G	cg15704280	chr7:45808275	SEPT13	0.65	8.15	0.31	1.85e-15	Body mass index;
BRCA	cis	rs360798	0.553	rs7562734	chr2:63047973	G/C	cg17519650	chr2:63277830	OTX1	-0.38	-8.19	-0.31	1.39e-15	Coronary artery disease;
BRCA	cis	rs12368653	0.840	rs10877020	chr12:58188014	G/A	cg00677455	chr12:58241039	CTDSP2	-0.41	-9.37	-0.35	1.19e-19	Multiple sclerosis;
BRCA	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	17.01	0.56	8.21e-54	Electrocardiographic conduction measures;
BRCA	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg14343924	chr8:8086146	FLJ10661	0.41	8.55	0.32	9.27e-17	Mood instability;
BRCA	cis	rs6121246	0.559	rs6058352	chr20:30269179	T/C	cg21427119	chr20:30132790	HM13	-0.35	-7.89	-0.3	1.35e-14	Mean corpuscular hemoglobin;
BRCA	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.91	-0.33	5.1e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1832871	0.579	rs828006	chr6:158775014	T/C	cg07215822	chr6:158701037	NA	0.47	9.53	0.35	3.16e-20	Height;
BRCA	cis	rs1144713	0.600	rs2683489	chr12:32251181	A/G	cg01321189	chr12:32259338	BICD1	0.32	8.16	0.31	1.8e-15	Obesity-related traits;
BRCA	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11890956	chr21:40555474	PSMG1	1.0	24.45	0.7	1.04e-93	Cognitive function;
BRCA	cis	rs9420	0.961	rs11604333	chr11:57467035	C/G	cg19752551	chr11:57585705	CTNND1	-0.51	-12.51	-0.44	2.91e-32	Schizophrenia;
BRCA	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.13	0.62	3.46e-70	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs12950390	1.000	rs8068453	chr17:45852354	A/G	cg24803719	chr17:45855879	NA	0.33	7.94	0.3	8.85e-15	IgG glycosylation;
BRCA	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg26384229	chr12:38710491	ALG10B	0.74	17.1	0.56	3.05e-54	Bladder cancer;
BRCA	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg27129171	chr3:47204927	SETD2	-0.69	-16.58	-0.55	1.33e-51	Colorectal cancer;
BRCA	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg14349672	chr11:133703707	NA	-0.4	-8.99	-0.33	2.84e-18	Childhood ear infection;
BRCA	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg12463550	chr7:65579703	CRCP	-0.36	-7.82	-0.3	2.2e-14	Aortic root size;
BRCA	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08045932	chr20:61659980	NA	0.49	11.32	0.41	3.36e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg23978390	chr7:1156363	C7orf50	0.42	9.62	0.36	1.44e-20	Longevity;Endometriosis;
BRCA	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.4	-8.53	-0.32	1.05e-16	Body mass index;
BRCA	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg06766960	chr11:133703094	NA	0.59	13.01	0.46	1.77e-34	Childhood ear infection;
BRCA	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg11608241	chr8:8085544	FLJ10661	0.31	8.53	0.32	1.07e-16	Mood instability;
BRCA	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg01528321	chr10:82214614	TSPAN14	0.91	19.96	0.62	2.86e-69	Post bronchodilator FEV1;
BRCA	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.63	10.09	0.37	2.52e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9457247	0.534	rs2345568	chr6:167381804	A/G	cg23791538	chr6:167370224	RNASET2	0.52	13.11	0.46	5.8e-35	Crohn's disease;
BRCA	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg03923535	chr7:1197113	ZFAND2A	0.51	10.98	0.4	8.26e-26	Longevity;Endometriosis;
BRCA	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg05340658	chr4:99064831	C4orf37	0.57	11.05	0.4	4.39e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg19847866	chr10:1019161	NA	0.56	12.04	0.43	2.97e-30	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs1050631	0.623	rs7242481	chr18:33709217	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.4	7.87	0.3	1.48e-14	Esophageal squamous cell cancer (length of survival);
BRCA	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg07395648	chr5:131743802	NA	-0.36	-7.99	-0.3	6.39e-15	Breast cancer;
BRCA	cis	rs870825	0.655	rs28451943	chr4:185645572	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	trans	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg26043149	chr18:55253948	FECH	-0.37	-8.14	-0.31	2.06e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7512552	0.724	rs7002	chr1:150445819	A/G	cg15654264	chr1:150340011	RPRD2	0.43	9.14	0.34	8.09e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs1215050	0.791	rs165244	chr4:98687889	C/T	cg05340658	chr4:99064831	C4orf37	0.44	10.01	0.37	5.1e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	7.89	0.3	1.34e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.36	-0.38	2.27e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg18446336	chr7:2847575	GNA12	-0.35	-8.37	-0.31	3.75e-16	Height;
BRCA	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg23719950	chr11:63933701	MACROD1	-0.56	-9.33	-0.35	1.65e-19	Mean platelet volume;
BRCA	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg26384229	chr12:38710491	ALG10B	0.67	14.25	0.49	3.21e-40	Morning vs. evening chronotype;
BRCA	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.57	-12.01	-0.43	3.98e-30	Schizophrenia;
BRCA	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-13.27	-0.46	1.09e-35	Response to antipsychotic treatment;
BRCA	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-7.97	-0.3	7.5e-15	Hematocrit;
BRCA	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.7	-0.36	7.54e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg13010199	chr12:38710504	ALG10B	-0.38	-8.18	-0.31	1.55e-15	Bladder cancer;
BRCA	cis	rs4363385	0.693	rs4845331	chr1:152982623	A/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.87	-0.36	1.81e-21	Inflammatory skin disease;
BRCA	cis	rs6901250	0.632	rs1853080	chr6:117196157	T/C	cg12892004	chr6:117198278	RFX6	-0.37	-9.06	-0.34	1.57e-18	C-reactive protein levels;
BRCA	cis	rs897984	0.542	rs73530203	chr16:31099859	G/A	cg00531865	chr16:30841666	NA	-0.38	-8.78	-0.33	1.49e-17	Dementia with Lewy bodies;
BRCA	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-11.07	-0.4	3.42e-26	Uric acid levels;
BRCA	trans	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.82	0.39	3.75e-25	Type 2 diabetes;
BRCA	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	12.73	0.45	3.03e-33	Bone mineral density;
BRCA	cis	rs1568889	0.730	rs6484350	chr11:28113658	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.79	-20.33	-0.63	2.93e-71	Bipolar disorder;
BRCA	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg06784218	chr1:46089804	CCDC17	0.46	10.8	0.39	4.41e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.36	7.87	0.3	1.55e-14	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs460214	0.528	rs4817954	chr21:40023857	C/T	cg21578987	chr21:40029669	ERG	0.37	8.63	0.32	4.83e-17	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.94	0.4	1.2e-25	Rheumatoid arthritis;
BRCA	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg24562669	chr7:97807699	LMTK2	0.62	18.7	0.59	1.41e-62	Breast cancer;
BRCA	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg05347473	chr6:146136440	FBXO30	-0.43	-8.53	-0.32	1.04e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6942756	0.876	rs57263220	chr7:129010858	C/A	cg02491457	chr7:128862824	NA	-0.63	-12.86	-0.45	7.93e-34	White matter hyperintensity burden;
BRCA	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.82	-18.42	-0.59	4.46e-61	Cognitive ability;
BRCA	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	11.97	0.43	5.92e-30	Lung cancer in ever smokers;
BRCA	cis	rs7617773	0.817	rs11710861	chr3:48297560	C/T	cg11946769	chr3:48343235	NME6	0.61	13.54	0.47	6.65e-37	Coronary artery disease;
BRCA	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg06092702	chr1:163392909	NA	-0.35	-9.57	-0.35	2.39e-20	Motion sickness;
BRCA	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg11645453	chr3:52864694	ITIH4	-0.38	-9.94	-0.37	9.24e-22	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs757278	0.646	rs17140352	chr7:117344368	G/C	cg10524701	chr7:117356490	CTTNBP2	0.42	7.85	0.3	1.81e-14	Response to methotrexate in juvenile idiopathic arthritis;
BRCA	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.11	0.4	2.33e-26	Bipolar disorder;
BRCA	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg17366294	chr4:99064904	C4orf37	0.44	10.25	0.38	6.04e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs922182	0.579	rs11856257	chr15:64239941	T/C	cg24729988	chr15:64271149	DAPK2	0.49	10.74	0.39	7.31e-25	Blood protein levels;
BRCA	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00166722	chr3:10149974	C3orf24	0.65	13.07	0.46	8.76e-35	Alzheimer's disease;
BRCA	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg26031613	chr14:104095156	KLC1	-0.44	-8.0	-0.3	6.01e-15	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg20607798	chr8:58055168	NA	0.48	8.33	0.31	4.87e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4660306	0.848	rs1088099	chr1:45946654	T/C	cg24296786	chr1:45957014	TESK2	-0.41	-8.02	-0.3	4.93e-15	Homocysteine levels;
BRCA	cis	rs4664304	0.620	rs11675085	chr2:160713352	C/G	cg01092293	chr2:160761427	LY75	0.36	8.52	0.32	1.14e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg26597838	chr10:835615	NA	0.89	13.86	0.48	2.29e-38	Eosinophil percentage of granulocytes;
BRCA	cis	rs965469	1.000	rs1331215	chr20:3376565	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-10.44	-0.38	1.19e-23	IFN-related cytopenia;
BRCA	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg20476274	chr7:133979776	SLC35B4	0.6	15.08	0.51	3.63e-44	Mean platelet volume;
BRCA	cis	rs3771570	1.000	rs62193171	chr2:242276523	C/A	cg21155796	chr2:242212141	HDLBP	0.6	9.3	0.35	2.25e-19	Prostate cancer;
BRCA	cis	rs12431939	1.000	rs7148508	chr14:51635137	G/A	cg23942311	chr14:51606299	NA	-0.43	-8.29	-0.31	6.89e-16	Cancer;
BRCA	cis	rs365132	0.846	rs184784	chr5:176440229	G/T	cg16309518	chr5:176445507	NA	-0.4	-9.72	-0.36	6.35e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg09307838	chr4:120376055	NA	0.43	8.62	0.32	5.33e-17	Diastolic blood pressure;
BRCA	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26314531	chr2:26401878	FAM59B	0.82	11.34	0.41	2.76e-27	Gut microbiome composition (summer);
BRCA	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg27129171	chr3:47204927	SETD2	-0.67	-14.82	-0.51	6.36e-43	Colorectal cancer;
BRCA	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg20891283	chr12:69753455	YEATS4	-0.82	-27.81	-0.74	3.94e-112	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs3771570	0.901	rs3771587	chr2:242409701	A/G	cg21155796	chr2:242212141	HDLBP	0.62	9.56	0.35	2.44e-20	Prostate cancer;
BRCA	cis	rs7631605	0.905	rs9755599	chr3:37208192	T/C	cg15934958	chr3:37212084	LRRFIP2	0.42	9.87	0.36	1.69e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg13877915	chr19:58951672	ZNF132	0.46	10.88	0.4	2.09e-25	Uric acid clearance;
BRCA	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg26384229	chr12:38710491	ALG10B	0.7	15.83	0.53	7.18e-48	Bladder cancer;
BRCA	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg20476274	chr7:133979776	SLC35B4	0.7	21.47	0.65	2.06e-77	Mean platelet volume;
BRCA	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg16989086	chr20:62203971	PRIC285	0.52	8.77	0.33	1.63e-17	Glioblastoma;
BRCA	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg10636054	chr15:40330586	SRP14	0.6	9.3	0.35	2.24e-19	Response to haloperidol in psychosis;
BRCA	cis	rs2652822	0.525	rs8037296	chr15:63516759	A/G	cg02713581	chr15:63449717	RPS27L	0.41	8.29	0.31	6.45e-16	Metabolic traits;
BRCA	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg04455712	chr21:45112962	RRP1B	0.4	10.36	0.38	2.28e-23	Mean corpuscular volume;
BRCA	cis	rs290268	1.000	rs188313	chr9:93548302	C/T	cg02608019	chr9:93564028	SYK	0.54	11.8	0.42	3.37e-29	Platelet count;
BRCA	cis	rs13046373	0.535	rs2832966	chr21:32017177	A/G	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.63	0.36	1.37e-20	HDL cholesterol;
BRCA	cis	rs10992471	0.580	rs12341093	chr9:95234182	G/T	cg14631576	chr9:95140430	CENPP	-0.38	-9.31	-0.35	2.01e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg03929089	chr4:120376271	NA	-0.68	-13.25	-0.46	1.36e-35	Coronary artery disease;
BRCA	cis	rs10779751	0.770	rs11121696	chr1:11238063	A/G	cg08854313	chr1:11322531	MTOR	-0.64	-12.49	-0.44	3.44e-32	Body mass index;
BRCA	cis	rs73242632	1.000	rs10026915	chr4:57857771	G/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.68	8.26	0.31	8.42e-16	Congenital heart disease (maternal effect);
BRCA	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.09	0.34	1.24e-18	Tonsillectomy;
BRCA	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg20573242	chr4:122745356	CCNA2	0.48	10.84	0.39	2.96e-25	Type 2 diabetes;
BRCA	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg20387954	chr3:183756860	HTR3D	0.44	9.81	0.36	3e-21	Anterior chamber depth;
BRCA	cis	rs11051970	0.879	rs1500874	chr12:32589407	G/A	cg24626660	chr12:32551988	NA	0.29	8.36	0.31	3.94e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg23978390	chr7:1156363	C7orf50	0.42	10.04	0.37	3.95e-22	Longevity;Endometriosis;
BRCA	cis	rs1832871	0.672	rs6899322	chr6:158753669	G/T	cg07165851	chr6:158734300	TULP4	0.63	12.57	0.45	1.62e-32	Height;
BRCA	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.48	8.58	0.32	7.11e-17	Schizophrenia;
BRCA	cis	rs7520050	0.808	rs11211196	chr1:46282296	A/T	cg24296786	chr1:45957014	TESK2	0.44	9.83	0.36	2.51e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4285028	0.948	rs35902163	chr3:121649526	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.61	-10.76	-0.39	6.05e-25	Multiple sclerosis;
BRCA	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg03929089	chr4:120376271	NA	-0.6	-10.39	-0.38	1.85e-23	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9596863	1.000	rs9568939	chr13:54411497	A/C	ch.13.53330881F	chr13:54432880	NA	0.49	8.09	0.3	3.04e-15	Epilepsy and lamotrigine-induced maculopapular eruptions;
BRCA	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg16950941	chr11:66035639	RAB1B	0.46	12.3	0.44	2.24e-31	Gout;
BRCA	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg07741184	chr6:167504864	NA	0.38	11.06	0.4	3.78e-26	Crohn's disease;
BRCA	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg00152838	chr16:24741724	TNRC6A	-0.35	-7.9	-0.3	1.2e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12292205	chr6:26970375	C6orf41	-0.49	-8.27	-0.31	7.96e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg16584290	chr5:462447	EXOC3	0.52	14.7	0.5	2.36e-42	Cystic fibrosis severity;
BRCA	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg06618935	chr21:46677482	NA	-0.37	-8.04	-0.3	4.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg14664628	chr15:75095509	CSK	-0.52	-12.17	-0.43	8.64e-31	Breast cancer;
BRCA	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.93	-0.37	1.07e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg24558204	chr6:135376177	HBS1L	0.45	12.42	0.44	7.31e-32	Red blood cell count;
BRCA	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg24558204	chr6:135376177	HBS1L	0.45	12.32	0.44	1.99e-31	Red blood cell count;
BRCA	cis	rs7903847	0.544	rs61861865	chr10:99144867	C/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.68	-0.32	3.31e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.88	-15.5	-0.52	3.25e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg04362960	chr10:104952993	NT5C2	0.42	10.02	0.37	4.67e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs1034435	0.755	rs5767173	chr22:48892473	T/C	cg05992904	chr22:48892994	FAM19A5	-0.8	-20.86	-0.64	3.99e-74	Late-onset Alzheimer's disease;
BRCA	trans	rs7980799	0.682	rs10844612	chr12:33603676	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-10.99	-0.4	7.56e-26	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg06521331	chr12:34319734	NA	-0.52	-10.29	-0.38	4.53e-23	Morning vs. evening chronotype;
BRCA	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg21475434	chr5:93447410	FAM172A	0.68	9.19	0.34	5.41e-19	Diabetic retinopathy;
BRCA	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg16950941	chr11:66035639	RAB1B	0.46	12.3	0.44	2.24e-31	Gout;
BRCA	cis	rs7590368	0.926	rs12623588	chr2:10957612	C/G	cg15705551	chr2:10952987	PDIA6	-0.45	-8.36	-0.31	4.04e-16	Educational attainment (years of education);
BRCA	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg13319975	chr6:146136371	FBXO30	-0.37	-8.44	-0.32	2.09e-16	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs8073060	0.963	rs4795082	chr17:33873501	C/T	cg19694781	chr19:47549865	TMEM160	0.57	12.09	0.43	1.81e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg11366901	chr6:160182831	ACAT2	0.81	15.73	0.53	2.29e-47	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	10.04	0.37	4.02e-22	Height;
BRCA	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg08917208	chr2:24149416	ATAD2B	0.87	12.43	0.44	6.24e-32	Lymphocyte counts;
BRCA	cis	rs6433857	0.536	rs1542035	chr2:181351114	T/C	cg23363182	chr2:181467187	NA	-0.38	-7.93	-0.3	9.89e-15	Body mass index;
BRCA	cis	rs6782228	0.606	rs7627549	chr3:128353079	G/A	cg16766828	chr3:128327626	NA	-0.43	-9.7	-0.36	7.92e-21	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs56399783	0.901	rs73049380	chr7:2832845	C/T	cg19731401	chr7:2775893	GNA12	0.49	8.15	0.31	1.9e-15	Childhood ear infection;
BRCA	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.89	-0.33	6.32e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs2742234	0.590	rs2435337	chr10:43661836	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.54	-11.03	-0.4	5.02e-26	Hirschsprung disease;
BRCA	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg00080972	chr5:178986291	RUFY1	0.47	12.39	0.44	9.93e-32	Lung cancer;
BRCA	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-9.42	-0.35	8.08e-20	Reticulocyte count;
BRCA	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg05347473	chr6:146136440	FBXO30	0.43	8.67	0.32	3.67e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg09163369	chr1:210001066	C1orf107	-0.49	-9.76	-0.36	4.49e-21	Orofacial clefts;
BRCA	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg26384229	chr12:38710491	ALG10B	0.76	17.17	0.56	1.31e-54	Bladder cancer;
BRCA	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.19	-0.34	5.64e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg23708337	chr7:1209742	NA	0.49	8.13	0.31	2.17e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4466137	0.953	rs1585153	chr5:83000385	A/T	cg15083037	chr5:83017644	HAPLN1	-0.53	-10.68	-0.39	1.28e-24	Prostate cancer;
BRCA	cis	rs12760731	0.565	rs2095133	chr1:178198612	C/G	cg00404053	chr1:178313656	RASAL2	0.64	7.9	0.3	1.2e-14	Obesity-related traits;
BRCA	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg04450456	chr4:17643702	FAM184B	0.38	11.26	0.41	5.95e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg24006582	chr15:45444508	DUOX1	-0.55	-11.32	-0.41	3.43e-27	Uric acid levels;
BRCA	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg26031613	chr14:104095156	KLC1	-0.43	-8.48	-0.32	1.58e-16	Schizophrenia;
BRCA	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg07169764	chr2:136633963	MCM6	1.24	27.67	0.74	2.32e-111	Corneal structure;
BRCA	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg18252515	chr7:66147081	NA	-1.07	-15.54	-0.52	2.03e-46	Diabetic kidney disease;
BRCA	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg16482183	chr6:26056742	HIST1H1C	0.51	10.37	0.38	2.12e-23	Height;
BRCA	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg16049864	chr8:95962084	TP53INP1	0.4	9.58	0.35	2.14e-20	Type 2 diabetes;
BRCA	cis	rs61990749	0.597	rs8016416	chr14:78213100	T/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.64	9.76	0.36	4.52e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg13877915	chr19:58951672	ZNF132	0.46	10.67	0.39	1.46e-24	Uric acid clearance;
BRCA	cis	rs8114671	0.967	rs2065979	chr20:33767690	T/C	cg07148914	chr20:33460835	GGT7	0.39	8.28	0.31	7.4e-16	Height;
BRCA	trans	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg26043149	chr18:55253948	FECH	-0.38	-8.09	-0.3	2.96e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9837602	1.000	rs793472	chr3:99546110	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.59	-10.76	-0.39	6e-25	Breast cancer;
BRCA	cis	rs501916	0.575	rs56345741	chr15:48065010	A/C	cg16110827	chr15:48056943	SEMA6D	-0.42	-8.88	-0.33	6.88e-18	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.3	-0.38	4.09e-23	Psoriasis;
BRCA	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	8.81	0.33	1.19e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg03146154	chr1:46216737	IPP	0.46	10.15	0.37	1.56e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4690686	0.538	rs6855882	chr4:177261061	T/G	cg17059388	chr4:177262070	NA	0.49	9.92	0.37	1.18e-21	Essential tremor;
BRCA	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg13770153	chr20:60521292	NA	-0.4	-8.92	-0.33	4.74e-18	Body mass index;
BRCA	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg04450456	chr4:17643702	FAM184B	0.33	9.6	0.35	1.8e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg17077180	chr1:38461687	NA	0.41	8.42	0.32	2.45e-16	Coronary artery disease;
BRCA	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg12219531	chr12:120966889	COQ5	0.55	11.42	0.41	1.25e-27	High light scatter reticulocyte count;
BRCA	trans	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg06521331	chr12:34319734	NA	-0.46	-8.6	-0.32	6.31e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg07148914	chr20:33460835	GGT7	0.47	10.01	0.37	5.42e-22	Height;
BRCA	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.29	0.38	4.23e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg03146154	chr1:46216737	IPP	0.49	10.54	0.38	4.8e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17401966	1.000	rs12407992	chr1:10311983	A/C	cg03954927	chr1:10346856	KIF1B	0.43	12.33	0.44	1.82e-31	Hepatocellular carcinoma;
BRCA	trans	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.92	0.3	1.09e-14	Corneal astigmatism;
BRCA	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg07741184	chr6:167504864	NA	0.33	9.87	0.36	1.8e-21	Primary biliary cholangitis;
BRCA	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-12.55	-0.44	1.94e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs10499694	0.933	rs11575352	chr7:50594982	A/G	cg18232548	chr7:50535776	DDC	-0.39	-9.4	-0.35	9.8e-20	Body mass index;
BRCA	trans	rs11165623	0.585	rs6698447	chr1:96999473	C/T	cg10631902	chr5:14652156	NA	-0.43	-12.14	-0.43	1.15e-30	Hip circumference;Waist circumference;
BRCA	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-11.86	-0.42	1.8e-29	Joint mobility (Beighton score);
BRCA	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13126279	chr21:47581558	C21orf56	0.5	10.8	0.39	4.4e-25	Testicular germ cell tumor;
BRCA	trans	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg15934090	chr1:100435551	SLC35A3	0.36	8.4	0.32	2.92e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg17366294	chr4:99064904	C4orf37	0.46	10.81	0.39	3.82e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	13.02	0.46	1.48e-34	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.32	-0.44	1.93e-31	Bipolar disorder;
BRCA	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08219700	chr8:58056026	NA	0.44	7.91	0.3	1.12e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg00339695	chr16:24857497	SLC5A11	-0.48	-9.28	-0.34	2.66e-19	Intelligence (multi-trait analysis);
BRCA	trans	rs7395662	0.853	rs4882054	chr11:48399899	A/G	cg00717180	chr2:96193071	NA	-0.28	-7.82	-0.3	2.16e-14	HDL cholesterol;
BRCA	cis	rs4919087	1.000	rs3740512	chr10:99078745	C/T	cg25902810	chr10:99078978	FRAT1	0.52	11.44	0.41	1.09e-27	Monocyte count;
BRCA	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.61	-12.94	-0.46	3.38e-34	Lymphocyte counts;
BRCA	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg23711669	chr6:146136114	FBXO30	0.72	17.23	0.56	6.09e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg25344623	chr2:136566232	LCT	-0.32	-8.09	-0.3	3.1e-15	Mosquito bite size;
BRCA	cis	rs27434	0.583	rs34759	chr5:96153133	T/C	cg16492584	chr5:96139282	ERAP1	-0.51	-12.82	-0.45	1.2e-33	Ankylosing spondylitis;
BRCA	cis	rs2415984	0.622	rs73245837	chr14:46947914	A/G	cg14871534	chr14:47121158	RPL10L	-0.32	-7.96	-0.3	7.98e-15	Number of children ever born;
BRCA	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11890956	chr21:40555474	PSMG1	1.06	30.33	0.77	7.59e-126	Cognitive function;
BRCA	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg12292205	chr6:26970375	C6orf41	0.58	12.99	0.46	2.15e-34	Schizophrenia;
BRCA	cis	rs6854137	0.967	rs10033898	chr4:169734457	A/G	cg20607169	chr4:169750834	PALLD	-0.34	-8.1	-0.31	2.8e-15	Vein graft stenosis in coronary artery bypass grafting;
BRCA	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-10.19	-0.37	1.04e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg18351406	chr4:77819688	ANKRD56	0.57	12.65	0.45	6.54e-33	Emphysema distribution in smoking;
BRCA	cis	rs9359856	0.564	rs17506403	chr6:90499059	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.67	-8.81	-0.33	1.13e-17	Bipolar disorder;
BRCA	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg06092702	chr1:163392909	NA	-0.36	-9.71	-0.36	6.9e-21	Motion sickness;
BRCA	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.55	11.01	0.4	5.93e-26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg09307838	chr4:120376055	NA	0.6	11.15	0.4	1.72e-26	Corneal astigmatism;
BRCA	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg24848339	chr3:12840334	CAND2	0.43	11.36	0.41	2.39e-27	QRS complex (12-leadsum);
BRCA	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg13256891	chr4:100009986	ADH5	0.54	9.99	0.37	6.11e-22	Smoking initiation;
BRCA	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	ch.11.42038R	chr11:967971	AP2A2	0.56	17.96	0.58	1.12e-58	Alzheimer's disease (late onset);
BRCA	cis	rs2191566	0.576	rs414402	chr19:44492568	A/G	cg20607764	chr19:44506953	ZNF230	0.37	7.89	0.3	1.29e-14	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02475777	chr4:1388615	CRIPAK	0.38	7.82	0.3	2.27e-14	Longevity;
BRCA	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg15934090	chr1:100435551	SLC35A3	0.36	8.23	0.31	1.02e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg08999081	chr20:33150536	PIGU	-0.34	-8.71	-0.33	2.59e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs2463822	1.000	rs2463820	chr11:62112290	A/T	cg06239285	chr11:62104954	ASRGL1	0.63	9.24	0.34	3.67e-19	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs7927771	0.524	rs7123952	chr11:47852057	T/C	cg20307385	chr11:47447363	PSMC3	0.41	9.38	0.35	1.11e-19	Subjective well-being;
BRCA	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.58	-0.32	7.07e-17	Aortic root size;
BRCA	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg13047869	chr3:10149882	C3orf24	0.6	12.76	0.45	2.33e-33	Alzheimer's disease;
BRCA	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg13010199	chr12:38710504	ALG10B	0.44	9.22	0.34	4.31e-19	Morning vs. evening chronotype;
BRCA	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg21280719	chr6:42927975	GNMT	-0.33	-13.86	-0.48	2.21e-38	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-14.38	-0.49	7.89e-41	Blood metabolite levels;
BRCA	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.55	-0.32	8.86e-17	Total body bone mineral density;
BRCA	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg10223061	chr2:219282414	VIL1	-0.27	-8.09	-0.3	2.96e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.56	0.39	3.95e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9487051	0.768	rs442405	chr6:109526980	T/G	cg21918786	chr6:109611834	NA	-0.34	-8.97	-0.33	3.22e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.53	-11.09	-0.4	2.8e-26	Lymphocyte counts;
BRCA	cis	rs10193935	0.901	rs13384323	chr2:42631346	C/T	cg27598129	chr2:42591480	NA	-0.72	-12.48	-0.44	3.68e-32	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7586879	0.663	rs6760328	chr2:25077991	T/C	cg04586622	chr2:25135609	ADCY3	0.37	8.54	0.32	9.82e-17	Body mass index;
BRCA	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.53	-16.8	-0.55	9.57e-53	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	19.42	0.61	2.35e-66	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs754466	0.651	rs7895188	chr10:79623378	C/G	cg17075019	chr10:79541650	NA	0.71	17.28	0.56	3.56e-55	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs2562456	0.876	rs7252585	chr19:21657943	C/T	cg25042112	chr7:64838748	ZNF92	0.42	8.5	0.32	1.33e-16	Pain;
BRCA	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg14196790	chr5:131705035	SLC22A5	-0.38	-9.73	-0.36	5.85e-21	Blood metabolite levels;
BRCA	trans	rs2270927	0.510	rs10942765	chr5:75591324	G/A	cg13563193	chr19:33072644	PDCD5	0.91	10.44	0.38	1.14e-23	Mean corpuscular volume;
BRCA	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg18867708	chr6:26865862	GUSBL1	0.42	8.27	0.31	7.7e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg03146154	chr1:46216737	IPP	-0.47	-10.38	-0.38	1.99e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg12826209	chr6:26865740	GUSBL1	0.56	9.17	0.34	6.34e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg23711669	chr6:146136114	FBXO30	-0.7	-16.89	-0.56	3.45e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg18252515	chr7:66147081	NA	1.06	16.03	0.54	7.81e-49	Diabetic kidney disease;
BRCA	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg09065629	chr16:1709722	CRAMP1L	0.37	8.65	0.32	4.27e-17	Coronary artery disease;
BRCA	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg00684032	chr4:1343700	KIAA1530	0.31	8.01	0.3	5.45e-15	Obesity-related traits;
BRCA	cis	rs68092024	0.731	rs792840	chr3:99471251	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	10.74	0.39	7.81e-25	Cleft lip with or without cleft palate;
BRCA	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07636037	chr3:49044803	WDR6	0.74	16.35	0.54	1.9e-50	Menarche (age at onset);
BRCA	cis	rs9309711	0.922	rs11679058	chr2:3483813	C/G	cg10845886	chr2:3471009	TTC15	-0.82	-18.37	-0.59	7.92e-61	Neurofibrillary tangles;
BRCA	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9811920	0.770	rs4928237	chr3:99731330	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.56	-13.37	-0.47	4.18e-36	Axial length;
BRCA	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg09065629	chr16:1709722	CRAMP1L	0.37	8.69	0.33	3.08e-17	Coronary artery disease;
BRCA	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg04166393	chr7:2884313	GNA12	-0.62	-12.87	-0.45	7.17e-34	Height;
BRCA	cis	rs4891159	0.548	rs690423	chr18:74117984	G/A	cg24786174	chr18:74118243	ZNF516	0.84	25.71	0.71	1.21e-100	Longevity;
BRCA	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg16590910	chr6:42928470	GNMT	0.42	9.25	0.34	3.23e-19	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-9.61	-0.36	1.69e-20	Menopause (age at onset);
BRCA	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg08470875	chr2:26401718	FAM59B	0.71	11.35	0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10802521	chr3:52805072	NEK4	-0.34	-9.25	-0.34	3.35e-19	Bipolar disorder;
BRCA	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg09915433	chr19:53449742	NA	-0.74	-17.02	-0.56	7.39e-54	Psoriasis;
BRCA	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg23711669	chr6:146136114	FBXO30	0.8	19.26	0.61	1.59e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg21132104	chr15:45694354	SPATA5L1	0.69	13.91	0.48	1.23e-38	Homoarginine levels;
BRCA	cis	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg04374321	chr14:90722782	PSMC1	0.73	19.34	0.61	5.61e-66	Mortality in heart failure;
BRCA	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg01579765	chr21:45077557	HSF2BP	-0.44	-11.62	-0.42	1.92e-28	Mean corpuscular volume;
BRCA	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg18252515	chr7:66147081	NA	0.52	10.32	0.38	3.33e-23	Corneal structure;
BRCA	cis	rs919433	0.679	rs1598469	chr2:198515658	T/C	cg00792783	chr2:198669748	PLCL1	0.4	9.0	0.34	2.59e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg15556689	chr8:8085844	FLJ10661	0.41	11.2	0.41	9.96e-27	Neuroticism;
BRCA	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg08742575	chr21:47604166	C21orf56	0.42	8.4	0.32	2.92e-16	Testicular germ cell tumor;
BRCA	cis	rs6545883	0.894	rs12997538	chr2:61564249	A/C	cg15711740	chr2:61764176	XPO1	0.52	12.49	0.44	3.62e-32	Tuberculosis;
BRCA	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg16482183	chr6:26056742	HIST1H1C	0.5	10.19	0.37	1.1e-22	Height;
BRCA	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg16482183	chr6:26056742	HIST1H1C	0.58	11.22	0.41	8.4e-27	Height;
BRCA	cis	rs6121246	0.583	rs28815498	chr20:30351560	T/C	cg21427119	chr20:30132790	HM13	-0.36	-8.12	-0.31	2.35e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	13.33	0.47	5.94e-36	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg10818794	chr15:86012489	AKAP13	-0.42	-11.14	-0.4	1.76e-26	Coronary artery disease;
BRCA	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg13319975	chr6:146136371	FBXO30	-0.46	-10.47	-0.38	9.11e-24	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg17830980	chr10:43048298	ZNF37B	0.42	9.5	0.35	4.05e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs13053817	0.948	rs7287166	chr22:29843932	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.49	-9.75	-0.36	4.83e-21	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs7395581	0.918	rs1052373	chr11:47354787	A/G	cg25783544	chr11:47291846	MADD	-0.41	-9.28	-0.34	2.59e-19	HDL cholesterol;
BRCA	trans	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg25517755	chr10:38738941	LOC399744	-0.37	-7.87	-0.3	1.53e-14	Corneal astigmatism;
BRCA	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg12386194	chr3:101231763	SENP7	0.46	9.79	0.36	3.64e-21	Colorectal cancer;
BRCA	cis	rs6426558	0.537	rs6699828	chr1:227274591	T/C	cg10327440	chr1:227177885	CDC42BPA	0.48	9.41	0.35	9.14e-20	Neutrophil percentage of white cells;
BRCA	cis	rs68170813	0.559	rs77641084	chr7:106970522	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-8.79	-0.33	1.41e-17	Coronary artery disease;
BRCA	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg17971929	chr21:40555470	PSMG1	0.78	18.14	0.58	1.25e-59	Cognitive function;
BRCA	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg14675211	chr2:100938903	LONRF2	0.43	9.57	0.35	2.26e-20	Intelligence (multi-trait analysis);
BRCA	trans	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg26384229	chr12:38710491	ALG10B	0.6	12.16	0.43	9.39e-31	Resting heart rate;
BRCA	cis	rs17401966	0.522	rs6541085	chr1:10285709	A/G	cg03954927	chr1:10346856	KIF1B	0.35	10.61	0.39	2.38e-24	Hepatocellular carcinoma;
BRCA	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.14e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg01689657	chr7:91764605	CYP51A1	-0.22	-7.83	-0.3	2e-14	Breast cancer;
BRCA	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg17063962	chr7:91808500	NA	0.5	11.28	0.41	5.07e-27	Breast cancer;
BRCA	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg10224037	chr5:178157518	ZNF354A	0.63	12.02	0.43	3.73e-30	Neutrophil percentage of white cells;
BRCA	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg05340658	chr4:99064831	C4orf37	0.59	12.81	0.45	1.29e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.38	-0.31	3.39e-16	Colorectal cancer;
BRCA	trans	rs11976180	1.000	rs1919951	chr7:143768891	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.21	-0.31	1.22e-15	Obesity-related traits;
BRCA	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg23950597	chr19:37808831	NA	-0.63	-10.93	-0.4	1.3e-25	Coronary artery calcification;
BRCA	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg06784218	chr1:46089804	CCDC17	0.47	11.25	0.41	6.68e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.58e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg13010199	chr12:38710504	ALG10B	0.41	8.5	0.32	1.31e-16	Bladder cancer;
BRCA	cis	rs7940866	0.845	rs1433976	chr11:130875123	C/T	cg12179176	chr11:130786555	SNX19	-0.57	-12.42	-0.44	6.82e-32	Schizophrenia;
BRCA	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg10523679	chr1:76189770	ACADM	-0.76	-16.11	-0.54	2.86e-49	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg04998671	chr14:104000505	TRMT61A	-0.41	-8.92	-0.33	4.71e-18	Coronary artery disease;
BRCA	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13126279	chr21:47581558	C21orf56	-0.48	-10.75	-0.39	6.88e-25	Testicular germ cell tumor;
BRCA	cis	rs796364	0.616	rs6718118	chr2:200691852	G/T	cg23649088	chr2:200775458	C2orf69	-0.51	-7.83	-0.3	2e-14	Schizophrenia;
BRCA	trans	rs208520	0.874	rs208515	chr6:66945749	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.45	-0.55	5.68e-51	Exhaled nitric oxide output;
BRCA	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg09658497	chr7:2847517	GNA12	-0.41	-8.59	-0.32	6.86e-17	Height;
BRCA	trans	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg16011800	chr17:1958478	HIC1	0.5	8.11	0.31	2.56e-15	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg25554036	chr4:6271136	WFS1	0.43	10.46	0.38	9.97e-24	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg16339924	chr4:17578868	LAP3	0.56	13.35	0.47	4.69e-36	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.4	8.97	0.33	3.33e-18	Endometrial cancer;
BRCA	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg04450456	chr4:17643702	FAM184B	0.35	9.74	0.36	5.26e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-10.0	-0.37	5.91e-22	Height;
BRCA	cis	rs847577	0.508	rs12538837	chr7:97684468	C/T	cg18676790	chr7:97680731	NA	0.35	7.91	0.3	1.15e-14	Breast cancer;
BRCA	cis	rs897080	0.552	rs1067320	chr2:44633122	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.39	0.35	1.04e-19	Height;
BRCA	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22509189	chr2:225307070	NA	-0.47	-9.67	-0.36	9.53e-21	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18357526	chr6:26021779	HIST1H4A	0.48	8.82	0.33	1.1e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-9.91	-0.36	1.26e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4363385	0.818	rs3181787	chr1:153004809	T/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.59	-0.32	6.67e-17	Inflammatory skin disease;
BRCA	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg20283391	chr11:68216788	NA	0.45	8.96	0.33	3.67e-18	Total body bone mineral density;
BRCA	cis	rs4363385	0.818	rs532773	chr1:153011750	T/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.27	-0.34	2.84e-19	Inflammatory skin disease;
BRCA	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	14.31	0.49	1.69e-40	Platelet count;
BRCA	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	14.17	0.49	7.83e-40	Electrocardiographic conduction measures;
BRCA	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg27129171	chr3:47204927	SETD2	0.75	19.16	0.6	5.43e-65	Colorectal cancer;
BRCA	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.71	-0.53	2.9e-47	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7394190	0.748	rs11000764	chr10:75506864	A/G	cg07699608	chr10:75541558	CHCHD1	0.6	8.87	0.33	7.03e-18	Incident atrial fibrillation;
BRCA	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg22431228	chr1:16359049	CLCNKA	-0.41	-8.24	-0.31	1.01e-15	Dilated cardiomyopathy;
BRCA	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21582582	chr3:182698605	DCUN1D1	0.39	10.11	0.37	2.08e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg15352829	chr14:105391018	PLD4	-0.38	-12.39	-0.44	9.37e-32	Rheumatoid arthritis;
BRCA	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1971762	0.583	rs2365345	chr12:54086820	C/T	cg23533419	chr12:54090519	NA	-0.33	-8.35	-0.31	4.36e-16	Height;
BRCA	cis	rs6545883	0.965	rs7591345	chr2:61729641	T/A	cg15711740	chr2:61764176	XPO1	-0.55	-14.03	-0.49	3.74e-39	Tuberculosis;
BRCA	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7122539	0.768	rs7931485	chr11:66578635	G/A	cg24851651	chr11:66362959	CCS	0.39	8.45	0.32	2.04e-16	HIV-1 susceptibility;
BRCA	cis	rs4948102	0.731	rs4948099	chr7:56072250	A/C	cg09872392	chr7:56161020	PHKG1	0.37	8.75	0.33	1.86e-17	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg04455712	chr21:45112962	RRP1B	0.35	8.2	0.31	1.36e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs2599510	0.783	rs62136349	chr2:32827504	G/A	cg02381751	chr2:32503542	YIPF4	0.43	8.21	0.31	1.19e-15	Interleukin-18 levels;
BRCA	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg11814155	chr7:99998594	ZCWPW1	-0.49	-8.77	-0.33	1.58e-17	Platelet count;
BRCA	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.35	-0.47	4.79e-36	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	10.99	0.4	7.67e-26	Monocyte percentage of white cells;
BRCA	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg04851639	chr8:1020857	NA	-0.38	-10.88	-0.4	1.99e-25	Schizophrenia;
BRCA	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg00701064	chr4:6280414	WFS1	-0.67	-18.3	-0.59	1.76e-60	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs2070997	0.607	rs2314342	chr9:133707362	A/G	cg11464064	chr9:133710261	ABL1	0.53	9.65	0.36	1.14e-20	Response to amphetamines;
BRCA	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg23018236	chr17:30244563	NA	-0.68	-10.6	-0.39	2.7e-24	Hip circumference adjusted for BMI;
BRCA	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.58	-0.32	7.15e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.73e-18	Motion sickness;
BRCA	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg22834771	chr12:69754056	YEATS4	-0.37	-9.08	-0.34	1.31e-18	Blood protein levels;
BRCA	cis	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg09307838	chr4:120376055	NA	0.45	9.3	0.35	2.14e-19	Diastolic blood pressure;
BRCA	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg17691542	chr6:26056736	HIST1H1C	0.52	10.56	0.39	3.87e-24	Height;
BRCA	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	17.89	0.58	2.44e-58	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs11025559	0.631	rs11025571	chr11:20482801	C/G	cg19653624	chr11:20408972	PRMT3	0.43	8.4	0.32	2.79e-16	Pursuit maintenance gain;
BRCA	trans	rs11165623	0.792	rs2104236	chr1:96908690	C/T	cg10631902	chr5:14652156	NA	-0.5	-16.03	-0.54	7.01e-49	Hip circumference;Waist circumference;
BRCA	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg23533926	chr12:111358616	MYL2	-0.41	-8.61	-0.32	5.77e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg03474202	chr17:45855739	NA	-0.48	-12.66	-0.45	6.03e-33	IgG glycosylation;
BRCA	trans	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg06521331	chr12:34319734	NA	0.46	9.31	0.35	2.03e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.78	-0.36	3.67e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg26384229	chr12:38710491	ALG10B	0.7	15.71	0.53	2.79e-47	Bladder cancer;
BRCA	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg18512352	chr11:47633146	NA	-0.35	-8.52	-0.32	1.15e-16	Subjective well-being;
BRCA	trans	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg19894588	chr14:64061835	NA	0.35	8.75	0.33	1.96e-17	Glioblastoma;Glioma;
BRCA	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg13770153	chr20:60521292	NA	-0.45	-10.79	-0.39	4.77e-25	Body mass index;
BRCA	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	8.73	0.33	2.24e-17	Tonsillectomy;
BRCA	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg21856205	chr7:94953877	PON1	-0.37	-8.03	-0.3	4.74e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	28.19	0.74	2.98e-114	Chronic sinus infection;
BRCA	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg15549821	chr19:49342101	PLEKHA4	0.99	20.26	0.63	7.26e-71	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs2120243	1.000	rs2120243	chr3:157147568	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.35	7.84	0.3	1.91e-14	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs796364	0.715	rs77089299	chr2:201116853	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-7.9	-0.3	1.18e-14	Schizophrenia;
BRCA	cis	rs2979489	0.891	rs17627965	chr8:30354376	C/T	cg26383811	chr8:30366931	RBPMS	0.41	9.66	0.36	1.1e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
BRCA	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg11266682	chr4:10021025	SLC2A9	0.45	11.94	0.43	7.98e-30	Bone mineral density;
BRCA	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg09998033	chr7:158218633	PTPRN2	-0.41	-9.6	-0.35	1.81e-20	Obesity-related traits;
BRCA	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-10.86	-0.39	2.6e-25	Mean corpuscular volume;
BRCA	cis	rs9283706	0.608	rs10060497	chr5:66332406	A/G	cg11590213	chr5:66331682	MAST4	0.37	7.9	0.3	1.23e-14	Coronary artery disease;
BRCA	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg23625390	chr15:77176239	SCAPER	-0.43	-10.58	-0.39	3.34e-24	Blood metabolite levels;
BRCA	cis	rs7818345	0.874	rs56298301	chr8:19305937	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.33	8.54	0.32	9.69e-17	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs17401966	0.867	rs7546364	chr1:10418815	G/A	cg03954927	chr1:10346856	KIF1B	0.43	13.57	0.47	4.97e-37	Hepatocellular carcinoma;
BRCA	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.69	-13.87	-0.48	1.98e-38	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2806561	0.729	rs35919647	chr1:23326072	C/T	cg19743168	chr1:23544995	NA	-0.4	-9.09	-0.34	1.25e-18	Height;
BRCA	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg24829409	chr8:58192753	C8orf71	-0.47	-9.01	-0.34	2.38e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg10433463	chr1:1889099	KIAA1751	0.35	9.1	0.34	1.16e-18	Body mass index;
BRCA	cis	rs6580649	0.771	rs1034762	chr12:48389643	G/T	cg05342945	chr12:48394962	COL2A1	0.46	9.1	0.34	1.11e-18	Lung cancer;
BRCA	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg18196295	chr10:418757	DIP2C	0.48	10.87	0.4	2.24e-25	Psychosis in Alzheimer's disease;
BRCA	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.59	-12.34	-0.44	1.56e-31	Lymphocyte counts;
BRCA	trans	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg21659725	chr3:3221576	CRBN	-0.53	-9.35	-0.35	1.44e-19	Menarche (age at onset);
BRCA	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg25405998	chr7:65216604	CCT6P1	0.43	8.92	0.33	4.79e-18	Calcium levels;
BRCA	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg21782813	chr7:2030301	MAD1L1	-0.32	-9.49	-0.35	4.61e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.83	0.6	2.85e-63	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-9.18	-0.34	5.93e-19	Joint mobility (Beighton score);
BRCA	cis	rs13136331	0.532	rs2615479	chr4:88578310	C/T	cg22416721	chr4:88570574	DMP1	0.58	13.97	0.48	7.11e-39	Sitting height ratio;
BRCA	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg20701182	chr2:24300061	SF3B14	0.67	9.78	0.36	3.86e-21	Mean corpuscular hemoglobin;
BRCA	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg14530993	chr4:882597	GAK	0.55	9.95	0.37	8.79e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs1499972	0.941	rs7631320	chr3:117650116	T/C	cg07612923	chr3:117604196	NA	0.6	8.11	0.31	2.57e-15	Schizophrenia;
BRCA	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	11.38	0.41	1.83e-27	Tonsillectomy;
BRCA	cis	rs977987	0.806	rs4888404	chr16:75428097	G/A	cg03315344	chr16:75512273	CHST6	0.53	12.55	0.44	1.91e-32	Dupuytren's disease;
BRCA	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg12379764	chr21:47803548	PCNT	-0.39	-8.31	-0.31	5.63e-16	Testicular germ cell tumor;
BRCA	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg26168224	chr5:2018326	NA	-0.51	-10.43	-0.38	1.31e-23	Gut microbiome composition (winter);
BRCA	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg12444411	chr7:2802554	GNA12	-0.37	-9.3	-0.35	2.27e-19	Height;
BRCA	trans	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	27.75	0.74	7.88e-112	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg09307838	chr4:120376055	NA	0.68	14.12	0.49	1.28e-39	Corneal astigmatism;
BRCA	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg12311346	chr5:56204834	C5orf35	0.9	17.1	0.56	3.04e-54	Initial pursuit acceleration;
BRCA	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.59	-0.32	6.69e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4409675	0.576	rs2749119	chr1:28236248	G/A	cg23691781	chr1:28212827	C1orf38	0.33	10.96	0.4	9.57e-26	Corneal astigmatism;
BRCA	cis	rs7043114	0.525	rs7023004	chr9:95098712	A/G	cg14631576	chr9:95140430	CENPP	-0.34	-8.38	-0.31	3.3e-16	Height;
BRCA	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg22920501	chr2:26401640	FAM59B	-0.7	-11.53	-0.42	4.32e-28	Gut microbiome composition (summer);
BRCA	cis	rs6545883	0.825	rs7578139	chr2:61564121	G/A	cg15711740	chr2:61764176	XPO1	0.53	13.39	0.47	3.37e-36	Tuberculosis;
BRCA	cis	rs573521	0.967	rs639752	chr11:102707339	G/T	cg15619439	chr11:102700944	NA	0.29	8.4	0.32	2.82e-16	Cerebrospinal fluid levels of Alzheimer's disease-related proteins;
BRCA	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg10792982	chr14:105748885	BRF1	0.48	11.25	0.41	6.68e-27	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg20503657	chr10:835505	NA	0.66	11.02	0.4	5.59e-26	Eosinophil percentage of granulocytes;
BRCA	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.04	-0.54	6.86e-49	Alzheimer's disease (late onset);
BRCA	cis	rs7945718	0.967	rs11022490	chr11:12773526	C/G	cg25843174	chr11:12811716	TEAD1	-0.23	-8.93	-0.33	4.62e-18	Educational attainment (years of education);
BRCA	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg17143192	chr8:8559678	CLDN23	0.55	10.63	0.39	2.04e-24	Obesity-related traits;
BRCA	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg26769984	chr7:1090371	C7orf50	0.49	9.09	0.34	1.21e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs4948102	0.824	rs11238389	chr7:56079744	A/G	cg09872392	chr7:56161020	PHKG1	-0.41	-9.39	-0.35	1.03e-19	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.64	10.09	0.37	2.64e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.07	0.34	1.49e-18	Motion sickness;
BRCA	cis	rs7903847	0.642	rs7084654	chr10:99135262	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-8.63	-0.32	4.7e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.14	0.31	2.09e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg15704280	chr7:45808275	SEPT13	0.76	16.16	0.54	1.72e-49	Coronary artery disease;
BRCA	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg16230307	chr14:35515116	FAM177A1	0.73	15.12	0.51	2.22e-44	Psoriasis;
BRCA	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07930192	chr7:1003750	NA	0.39	8.35	0.31	4.34e-16	Longevity;Endometriosis;
BRCA	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg23289794	chr7:2394357	EIF3B	-0.61	-11.34	-0.41	2.89e-27	Multiple sclerosis;
BRCA	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23248424	chr5:179741104	GFPT2	-0.67	-14.18	-0.49	6.94e-40	Height;
BRCA	cis	rs6430585	0.527	rs57530667	chr2:136444338	A/G	cg07169764	chr2:136633963	MCM6	1.0	19.33	0.61	6.52e-66	Corneal structure;
BRCA	trans	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg06521331	chr12:34319734	NA	-0.45	-8.4	-0.32	2.92e-16	Bladder cancer;
BRCA	cis	rs11997175	0.624	rs4733175	chr8:33679744	T/A	ch.8.33884649F	chr8:33765107	NA	0.4	9.19	0.34	5.56e-19	Body mass index;
BRCA	cis	rs17001868	0.568	rs17001846	chr22:40744053	A/G	cg07138101	chr22:40742427	ADSL	0.59	11.25	0.41	6.55e-27	Mammographic density (dense area);
BRCA	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg09904177	chr6:26538194	HMGN4	0.47	15.03	0.51	6.02e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-13.23	-0.46	1.7000000000000001e-35	Platelet count;
BRCA	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.14	-0.4	1.77e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg19773385	chr1:10388646	KIF1B	-0.38	-8.12	-0.31	2.34e-15	Hepatocellular carcinoma;
BRCA	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-8.73	-0.33	2.24e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03517284	chr6:25882590	NA	-0.35	-7.92	-0.3	1.05e-14	Height;
BRCA	cis	rs6772849	0.830	rs7633674	chr3:128355026	G/A	cg16766828	chr3:128327626	NA	-0.39	-8.63	-0.32	4.9e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.58	-11.81	-0.42	2.84e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg18132916	chr6:79620363	NA	-0.39	-7.99	-0.3	6.22e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg04025307	chr7:1156635	C7orf50	0.56	13.93	0.48	1.03e-38	Longevity;Endometriosis;
BRCA	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg15242686	chr22:24348715	GSTTP1	0.36	8.93	0.33	4.35e-18	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg25358565	chr5:93447407	FAM172A	1.23	19.7	0.61	7.39e-68	Diabetic retinopathy;
BRCA	cis	rs17401966	0.964	rs17400510	chr1:10290421	T/C	cg15208524	chr1:10270712	KIF1B	0.37	8.21	0.31	1.26e-15	Hepatocellular carcinoma;
BRCA	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg00106254	chr7:1943704	MAD1L1	-0.4	-10.96	-0.4	1.01e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.45	8.51	0.32	1.24e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7617773	0.779	rs11718329	chr3:48309828	C/G	cg11946769	chr3:48343235	NME6	0.58	12.64	0.45	7.76e-33	Coronary artery disease;
BRCA	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.9	-0.51	2.56e-43	Total cholesterol levels;
BRCA	cis	rs10267417	0.603	rs4721836	chr7:19910497	A/G	cg07541023	chr7:19748670	TWISTNB	0.45	8.21	0.31	1.25e-15	Night sleep phenotypes;
BRCA	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	25.68	0.71	1.87e-100	Platelet count;
BRCA	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg13010199	chr12:38710504	ALG10B	0.35	8.59	0.32	6.53e-17	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg26384229	chr12:38710491	ALG10B	0.71	15.79	0.53	1.15e-47	Morning vs. evening chronotype;
BRCA	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg03929089	chr4:120376271	NA	0.55	9.14	0.34	8.16e-19	Axial length;
BRCA	cis	rs10504073	0.647	rs4873098	chr8:50021041	T/C	cg00325661	chr8:49890786	NA	0.39	11.35	0.41	2.6e-27	Blood metabolite ratios;
BRCA	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg13319975	chr6:146136371	FBXO30	-0.38	-8.76	-0.33	1.81e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg18351406	chr4:77819688	ANKRD56	0.61	13.51	0.47	9.23e-37	Emphysema distribution in smoking;
BRCA	cis	rs11997175	0.624	rs7464055	chr8:33679382	G/A	ch.8.33884649F	chr8:33765107	NA	0.4	9.19	0.34	5.56e-19	Body mass index;
BRCA	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.56	-14.6	-0.5	7.2e-42	Electrocardiographic conduction measures;
BRCA	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg09307838	chr4:120376055	NA	0.74	16.03	0.54	7.46e-49	Corneal astigmatism;
BRCA	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.54	8.76	0.33	1.77e-17	Renal function-related traits (BUN);
BRCA	cis	rs698813	0.703	rs2053457	chr2:44572164	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.61	11.66	0.42	1.31e-28	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg07636037	chr3:49044803	WDR6	0.52	8.72	0.33	2.42e-17	Menarche (age at onset);
BRCA	cis	rs13046373	0.535	rs9980934	chr21:31982988	C/T	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.41	0.32	2.63e-16	HDL cholesterol;
BRCA	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg08859206	chr1:53392774	SCP2	-0.42	-8.47	-0.32	1.72e-16	Monocyte count;
BRCA	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg05347473	chr6:146136440	FBXO30	0.41	8.07	0.3	3.41e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg04727924	chr7:799746	HEATR2	0.55	10.22	0.37	7.9399999999999994e-23	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg16339924	chr4:17578868	LAP3	-0.58	-13.82	-0.48	3.49e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12618769	0.597	rs17031146	chr2:99036683	A/G	cg10123293	chr2:99228465	UNC50	0.43	8.73	0.33	2.24e-17	Bipolar disorder;
BRCA	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg19508488	chr2:152266495	RIF1	-0.43	-9.34	-0.35	1.63e-19	Lung cancer;
BRCA	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg14582100	chr15:45693742	SPATA5L1	0.37	11.87	0.42	1.69e-29	Homoarginine levels;
BRCA	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg12140854	chr5:148520817	ABLIM3	-0.4	-8.47	-0.32	1.71e-16	Breast cancer;
BRCA	cis	rs151349	0.714	rs6123845	chr20:57607668	C/T	cg23907860	chr20:57583709	CTSZ	-0.37	-8.54	-0.32	9.56e-17	Platelet distribution width;
BRCA	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg20307385	chr11:47447363	PSMC3	-0.43	-8.93	-0.33	4.63e-18	Subjective well-being;
BRCA	cis	rs6545883	0.894	rs6760075	chr2:61612881	C/A	cg15711740	chr2:61764176	XPO1	0.55	14.22	0.49	4.43e-40	Tuberculosis;
BRCA	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg14683738	chr19:37701593	ZNF585B	0.5	8.57	0.32	7.72e-17	Coronary artery calcification;
BRCA	cis	rs6142102	0.625	rs1883705	chr20:32552878	C/T	cg24642439	chr20:33292090	TP53INP2	0.39	7.82	0.3	2.17e-14	Skin pigmentation;
BRCA	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg03146154	chr1:46216737	IPP	0.45	10.04	0.37	4.15e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.1	0.46	6.97e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg13319975	chr6:146136371	FBXO30	-0.39	-8.79	-0.33	1.36e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7395581	0.959	rs35879051	chr11:47275882	C/G	cg25783544	chr11:47291846	MADD	0.43	9.49	0.35	4.43e-20	HDL cholesterol;
BRCA	cis	rs1451375	0.583	rs7776816	chr7:50583534	G/A	cg18232548	chr7:50535776	DDC	0.44	9.33	0.35	1.65e-19	Malaria;
BRCA	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	11.79	0.42	3.77e-29	Mean platelet volume;
BRCA	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg04727924	chr7:799746	HEATR2	-0.54	-10.52	-0.38	5.8e-24	Cerebrospinal P-tau181p levels;
BRCA	cis	rs4919087	1.000	rs4919091	chr10:99088682	A/T	cg25902810	chr10:99078978	FRAT1	-0.44	-9.25	-0.34	3.35e-19	Monocyte count;
BRCA	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg22974920	chr21:40686053	BRWD1	-0.38	-8.63	-0.32	4.86e-17	Cognitive function;
BRCA	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-16.29	-0.54	3.61e-50	Mean platelet volume;
BRCA	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.89	0.43	1.31e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs912057	0.601	rs1294411	chr6:6739034	T/C	cg06612196	chr6:6737390	NA	0.57	14.04	0.49	3.04e-39	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs6691722	0.506	rs11587667	chr1:24715435	C/G	cg18323236	chr1:24743029	NIPAL3	0.37	10.24	0.38	6.71e-23	Response to interferon beta in multiple sclerosis;
BRCA	cis	rs2070997	0.607	rs2772028	chr9:133707940	C/T	cg11464064	chr9:133710261	ABL1	0.55	10.1	0.37	2.3e-22	Response to amphetamines;
BRCA	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg13010199	chr12:38710504	ALG10B	-0.35	-8.55	-0.32	9.32e-17	Morning vs. evening chronotype;
BRCA	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg04362960	chr10:104952993	NT5C2	0.38	9.19	0.34	5.52e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10802521	chr3:52805072	NEK4	0.32	8.92	0.33	4.89e-18	Electroencephalogram traits;
BRCA	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-9.55	-0.35	2.81e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.3	-8.38	-0.31	3.32e-16	Lymphocyte counts;
BRCA	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg26597838	chr10:835615	NA	-0.52	-9.61	-0.36	1.63e-20	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	11.07	0.4	3.38e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg07169764	chr2:136633963	MCM6	1.28	28.44	0.75	1.36e-115	Corneal structure;
BRCA	trans	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg21167628	chr1:45308625	PTCH2	-0.32	-8.22	-0.31	1.16e-15	Facial morphology (factor 20);
BRCA	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg26384229	chr12:38710491	ALG10B	0.59	15.09	0.51	3.02e-44	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.48	0.38	8.25e-24	Motion sickness;
BRCA	cis	rs912057	0.632	rs1294432	chr6:6745027	C/T	cg06612196	chr6:6737390	NA	0.46	10.79	0.39	4.81e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.45	0.55	5.92e-51	Colorectal cancer;
BRCA	cis	rs929596	0.785	rs17864701	chr2:234652717	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-12.28	-0.44	2.92e-31	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs7020830	0.823	rs13285624	chr9:37129496	T/G	cg14294708	chr9:37120828	ZCCHC7	1.17	40.58	0.85	5.34e-179	Schizophrenia;
BRCA	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg24531977	chr5:56204891	C5orf35	0.62	12.63	0.45	8.75e-33	Coronary artery disease;
BRCA	cis	rs9649465	1.000	rs2052128	chr7:123380405	T/A	cg04330084	chr7:123175371	IQUB	-0.3	-8.27	-0.31	7.73e-16	Migraine;
BRCA	cis	rs701145	0.585	rs896013	chr3:153863873	A/G	cg17054900	chr3:154042577	DHX36	0.44	8.09	0.3	2.93e-15	Coronary artery disease;
BRCA	cis	rs2882667	0.898	rs2116789	chr5:138394262	G/T	cg04439458	chr5:138467593	SIL1	-0.35	-9.55	-0.35	2.78e-20	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs754466	0.874	rs61855849	chr10:79659934	G/A	cg17075019	chr10:79541650	NA	-0.69	-13.09	-0.46	7.46e-35	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg06697600	chr4:7070879	GRPEL1	0.61	10.23	0.37	7.83e-23	Monocyte percentage of white cells;
BRCA	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg12311346	chr5:56204834	C5orf35	-0.62	-12.19	-0.43	7.35e-31	Type 2 diabetes;
BRCA	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Urate levels;
BRCA	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg23358479	chr7:1110784	C7orf50	-0.47	-7.94	-0.3	9.1e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs16910800	0.689	rs7101737	chr11:23165031	C/T	cg20040320	chr11:23191996	NA	-0.55	-9.43	-0.35	7.19e-20	Cancer;
BRCA	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.95	0.3	8.67e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11690935	0.550	rs62183784	chr2:172866696	A/G	cg13550731	chr2:172543902	DYNC1I2	0.49	12.11	0.43	1.56e-30	Schizophrenia;
BRCA	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg06618935	chr21:46677482	NA	-0.37	-8.07	-0.3	3.41e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.42	-9.04	-0.34	1.92e-18	Longevity;Endometriosis;
BRCA	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg15934090	chr1:100435551	SLC35A3	0.35	8.18	0.31	1.48e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4363385	0.791	rs372490	chr1:153008971	A/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs4363385	0.747	rs946100	chr1:152971663	C/T	cg24667326	chr1:152973720	SPRR3	0.33	9.19	0.34	5.25e-19	Inflammatory skin disease;
BRCA	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.9	0.36	1.34e-21	Bladder cancer;
BRCA	cis	rs9790314	0.663	rs778648	chr3:160708943	A/G	cg03342759	chr3:160939853	NMD3	-0.46	-8.84	-0.33	9.06e-18	Morning vs. evening chronotype;
BRCA	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg24642439	chr20:33292090	TP53INP2	0.41	8.13	0.31	2.24e-15	Height;
BRCA	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.37	-8.07	-0.3	3.49e-15	Alzheimer's disease (late onset);
BRCA	cis	rs6484504	0.576	rs158139	chr11:31216076	C/T	cg06552810	chr11:31128660	NA	-0.39	-8.69	-0.33	3.06e-17	Red blood cell count;
BRCA	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg20307385	chr11:47447363	PSMC3	0.41	8.8	0.33	1.24e-17	Subjective well-being;
BRCA	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.85	-0.33	8.27e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg23625390	chr15:77176239	SCAPER	0.4	9.38	0.35	1.12e-19	Blood metabolite levels;
BRCA	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03517284	chr6:25882590	NA	0.67	15.17	0.51	1.32e-44	Blood metabolite levels;
BRCA	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.88	0.33	6.95e-18	Tonsillectomy;
BRCA	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg04607235	chr12:12878440	APOLD1	-0.65	-10.34	-0.38	2.88e-23	Systemic lupus erythematosus;
BRCA	cis	rs4908768	0.539	rs6666191	chr1:8658442	C/T	cg20416874	chr1:8611966	RERE	-0.28	-7.88	-0.3	1.43e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.48	8.78	0.33	1.52e-17	Breast cancer;
BRCA	cis	rs929596	0.755	rs4148324	chr2:234672722	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-10.88	-0.4	2.09e-25	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg12062639	chr20:23401060	NAPB	0.96	13.42	0.47	2.36e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs10899021	0.512	rs10219168	chr11:74374453	A/T	cg25880958	chr11:74394337	NA	0.37	8.11	0.31	2.5e-15	Response to metformin (IC50);
BRCA	cis	rs6714710	0.603	rs11123974	chr2:98605982	A/G	cg26665480	chr2:98280029	ACTR1B	0.58	13.38	0.47	3.69e-36	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg12310025	chr6:25882481	NA	-1.0	-29.75	-0.76	1.03e-122	Urate levels;
BRCA	cis	rs6714710	0.603	rs11679828	chr2:98517626	G/A	cg26665480	chr2:98280029	ACTR1B	0.59	13.64	0.47	2.36e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg18305652	chr10:134549665	INPP5A	0.49	12.92	0.46	4.39e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.9	0.4	1.8e-25	Rheumatoid arthritis;
BRCA	cis	rs6060717	0.536	rs6060670	chr20:34481143	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.08	-0.3	3.21e-15	Hip circumference adjusted for BMI;
BRCA	trans	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.15	0.31	1.87e-15	Corneal astigmatism;
BRCA	cis	rs1635	0.655	rs723475	chr6:28304841	G/T	cg15743358	chr6:28303923	ZNF323	0.75	8.66	0.32	3.77e-17	Schizophrenia;
BRCA	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	30.52	0.77	6.7e-127	Chronic sinus infection;
BRCA	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg10223061	chr2:219282414	VIL1	0.3	8.73	0.33	2.25e-17	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs4237845	0.611	rs7298370	chr12:58318897	C/T	cg00677455	chr12:58241039	CTDSP2	0.43	9.46	0.35	5.69e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-11.11	-0.4	2.48e-26	Morning vs. evening chronotype;
BRCA	cis	rs11955398	0.692	rs897672	chr5:59996101	C/G	cg02684056	chr5:59996105	DEPDC1B	0.41	9.55	0.35	2.7e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6435161	0.959	rs72926952	chr2:203485086	G/T	cg18429434	chr2:203499731	FAM117B	-0.43	-9.0	-0.34	2.46e-18	Total cholesterol levels;
BRCA	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.85	-0.33	8.64e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs7560272	0.723	rs12995433	chr2:73641326	C/T	cg20560298	chr2:73613845	ALMS1	0.42	11.33	0.41	2.96e-27	Schizophrenia;
BRCA	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg18016565	chr1:150552671	MCL1	0.34	8.05	0.3	4.08e-15	Tonsillectomy;
BRCA	cis	rs919433	0.927	rs1429418	chr2:198158151	G/C	cg00792783	chr2:198669748	PLCL1	-0.37	-7.9	-0.3	1.22e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11764359	chr7:65958608	NA	0.74	16.46	0.55	4.94e-51	Aortic root size;
BRCA	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg17691542	chr6:26056736	HIST1H1C	0.5	10.55	0.39	4.14e-24	Height;
BRCA	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08859206	chr1:53392774	SCP2	-0.66	-14.58	-0.5	9.07e-42	Monocyte count;
BRCA	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	16.85	0.55	5.55e-53	Electrocardiographic conduction measures;
BRCA	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	9.04	0.34	1.82e-18	Platelet count;
BRCA	cis	rs4671400	0.571	rs62152275	chr2:61502238	C/A	cg15711740	chr2:61764176	XPO1	0.4	7.92	0.3	1.02e-14	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg08999081	chr20:33150536	PIGU	-0.45	-12.14	-0.43	1.13e-30	Glomerular filtration rate (creatinine);
BRCA	cis	rs13082711	0.554	rs73055750	chr3:27401505	C/G	cg02860705	chr3:27208620	NA	0.65	11.42	0.41	1.24e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs7474896	0.515	rs2738203	chr10:38277596	G/A	cg25427524	chr10:38739819	LOC399744	0.58	10.0	0.37	5.69e-22	Obesity (extreme);
BRCA	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg21770322	chr7:97807741	LMTK2	0.44	11.74	0.42	6.15e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg06698575	chr12:117470875	NA	0.45	7.97	0.3	7.32e-15	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg06550200	chr5:1325588	CLPTM1L	0.65	14.03	0.49	3.66e-39	Lung cancer;
BRCA	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg23033748	chr14:75592666	NEK9	-0.44	-10.66	-0.39	1.59e-24	Height;
BRCA	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.94	0.3	8.91e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2979489	0.786	rs2915595	chr8:30402817	A/G	cg26383811	chr8:30366931	RBPMS	0.5	11.73	0.42	6.39e-29	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
BRCA	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07636037	chr3:49044803	WDR6	-0.71	-15.29	-0.52	3.47e-45	Menarche (age at onset);
BRCA	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	9.24	0.34	3.63e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg21856205	chr7:94953877	PON1	-0.37	-7.89	-0.3	1.36e-14	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.42	-8.34	-0.31	4.63e-16	Monocyte percentage of white cells;
BRCA	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg11812906	chr14:75593930	NEK9	0.62	13.78	0.48	5.25e-38	Height;
BRCA	trans	rs1991651	0.578	rs11778453	chr8:10489836	C/G	cg15556689	chr8:8085844	FLJ10661	-0.37	-9.33	-0.35	1.69e-19	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
BRCA	cis	rs68170813	0.559	rs76299183	chr7:106904859	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-9.03	-0.34	1.96e-18	Coronary artery disease;
BRCA	trans	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg21659725	chr3:3221576	CRBN	-0.48	-8.65	-0.32	4.23e-17	Menarche (age at onset);
BRCA	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24531977	chr5:56204891	C5orf35	-0.88	-18.12	-0.58	1.51e-59	Initial pursuit acceleration;
BRCA	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg06453172	chr10:134556979	INPP5A	-0.62	-12.15	-0.43	1.03e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg01483505	chr11:975446	AP2A2	0.3	7.9	0.3	1.27e-14	Alzheimer's disease (late onset);
BRCA	cis	rs1538970	0.847	rs781230	chr1:45880751	C/T	cg05343316	chr1:45956843	TESK2	-0.54	-11.17	-0.4	1.34e-26	Platelet count;
BRCA	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg27279351	chr12:120934652	DYNLL1	0.57	13.35	0.47	4.69e-36	High light scatter reticulocyte count;
BRCA	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg25237894	chr2:233734115	C2orf82	-0.4	-11.66	-0.42	1.25e-28	Coronary artery disease;
BRCA	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.77	10.99	0.4	7.18e-26	Initial pursuit acceleration;
BRCA	cis	rs9549260	0.755	rs2297627	chr13:41233931	A/G	cg21288729	chr13:41239152	FOXO1	0.67	14.97	0.51	1.23e-43	Red blood cell count;
BRCA	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg05347473	chr6:146136440	FBXO30	0.39	7.94	0.3	9e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs965469	1.000	rs6037567	chr20:3332160	C/A	cg25506879	chr20:3388711	C20orf194	-0.55	-10.77	-0.39	5.7e-25	IFN-related cytopenia;
BRCA	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg08888203	chr3:10149979	C3orf24	0.63	11.75	0.42	5.1e-29	Alzheimer's disease;
BRCA	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg05283184	chr6:79620031	NA	-0.43	-10.75	-0.39	7.01e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs4588572	0.643	rs6861678	chr5:77764613	G/C	cg11547950	chr5:77652471	NA	-0.49	-8.54	-0.32	9.64e-17	Triglycerides;
BRCA	cis	rs17095355	1.000	rs17095355	chr10:111735750	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.82	-0.36	2.66e-21	Biliary atresia;
BRCA	cis	rs7577696	0.597	rs34197800	chr2:32389646	C/A	cg02381751	chr2:32503542	YIPF4	-0.42	-7.91	-0.3	1.17e-14	Inflammatory biomarkers;
BRCA	cis	rs4253772	0.550	rs9615347	chr22:46728153	A/G	cg00784671	chr22:46762841	CELSR1	-0.63	-9.32	-0.35	1.85e-19	LDL cholesterol;Cholesterol, total;
BRCA	cis	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg20368463	chr18:77673604	PQLC1	0.47	11.6	0.42	2.24e-28	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
BRCA	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg04362960	chr10:104952993	NT5C2	0.94	14.64	0.5	4.47e-42	Arsenic metabolism;
BRCA	cis	rs6973256	0.897	rs4728296	chr7:133344566	C/T	cg07491979	chr7:133331646	EXOC4	-0.39	-9.05	-0.34	1.69e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs912057	0.833	rs1294418	chr6:6742185	A/G	cg06612196	chr6:6737390	NA	0.41	9.08	0.34	1.36e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg18806716	chr10:30721971	MAP3K8	-0.34	-7.9	-0.3	1.25e-14	Inflammatory bowel disease;
BRCA	cis	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg04990556	chr1:26633338	UBXN11	0.54	8.86	0.33	8.17e-18	Obesity-related traits;
BRCA	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	9.31	0.35	2.07e-19	Lung cancer in ever smokers;
BRCA	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg24069376	chr3:38537580	EXOG	-0.31	-8.53	-0.32	1.04e-16	Electrocardiographic conduction measures;
BRCA	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08704250	chr15:31115839	NA	-0.36	-8.71	-0.33	2.56e-17	Huntington's disease progression;
BRCA	cis	rs12200560	0.505	rs1334321	chr6:97079571	C/T	cg06623918	chr6:96969491	KIAA0776	-0.46	-10.61	-0.39	2.51e-24	Coronary heart disease;
BRCA	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg08601574	chr20:25228251	PYGB	0.36	8.34	0.31	4.67e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg15704280	chr7:45808275	SEPT13	0.55	8.22	0.31	1.18e-15	Intraocular pressure;
BRCA	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg10792982	chr14:105748885	BRF1	0.44	10.39	0.38	1.72e-23	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs593982	0.719	rs11606668	chr11:65472758	A/G	cg08755490	chr11:65554678	OVOL1	-1.0	-15.28	-0.52	3.55e-45	Atopic dermatitis;
BRCA	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg17691542	chr6:26056736	HIST1H1C	0.51	10.44	0.38	1.11e-23	Height;
BRCA	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg10495392	chr1:46806563	NSUN4	0.45	8.49	0.32	1.42e-16	Menopause (age at onset);
BRCA	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg17063962	chr7:91808500	NA	0.55	12.97	0.46	2.58e-34	Breast cancer;
BRCA	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	9.72	0.36	6.46e-21	Mood instability;
BRCA	cis	rs3936840	0.647	rs942024	chr14:102979463	C/T	cg18135206	chr14:102964638	TECPR2	0.5	10.75	0.39	6.66e-25	Plateletcrit;
BRCA	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg13010199	chr12:38710504	ALG10B	0.56	12.22	0.44	5.11e-31	Heart rate;
BRCA	trans	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg13565492	chr6:43139072	SRF	-0.79	-10.95	-0.4	1.07e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11229555	0.574	rs11603800	chr11:58202085	A/G	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg25214090	chr10:38739885	LOC399744	0.44	10.27	0.38	5.09e-23	Corneal astigmatism;
BRCA	cis	rs36051895	0.623	rs1830610	chr9:5260079	C/T	cg02405213	chr9:5042618	JAK2	-0.43	-8.15	-0.31	1.97e-15	Pediatric autoimmune diseases;
BRCA	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00908189	chr16:619842	PIGQ	0.69	17.19	0.56	1.03e-54	Height;
BRCA	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg24397884	chr7:158709396	WDR60	-0.99	-25.51	-0.71	1.62e-99	Height;
BRCA	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg05340658	chr4:99064831	C4orf37	0.68	16.86	0.55	4.66e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1878931	0.559	rs11643501	chr16:3392752	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.64	13.7	0.48	1.19e-37	Body mass index (adult);
BRCA	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.22	-0.34	4.3e-19	Total body bone mineral density;
BRCA	cis	rs8017423	0.647	rs4904680	chr14:90822075	C/T	cg04374321	chr14:90722782	PSMC1	-0.47	-11.51	-0.41	5.2e-28	Mortality in heart failure;
BRCA	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09256448	chr16:638327	NA	0.3	7.89	0.3	1.28e-14	Height;
BRCA	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg10556349	chr10:835070	NA	0.64	8.79	0.33	1.4e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg07148914	chr20:33460835	GGT7	0.38	8.55	0.32	8.77e-17	Height;
BRCA	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	12.95	0.46	3.16e-34	Migraine;Coronary artery disease;
BRCA	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs35740288	0.787	rs2291047	chr15:86225805	A/G	cg20737812	chr15:86336631	KLHL25	-0.32	-7.86	-0.3	1.68e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	trans	rs12517041	1.000	rs74322845	chr5:23293404	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	trans	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg04565464	chr8:145669602	NFKBIL2	-0.34	-8.18	-0.31	1.58e-15	Schizophrenia;
BRCA	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11764359	chr7:65958608	NA	0.76	16.74	0.55	1.98e-52	Aortic root size;
BRCA	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg05347473	chr6:146136440	FBXO30	-0.43	-8.5	-0.32	1.29e-16	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-8.03	-0.3	4.53e-15	Corneal astigmatism;
BRCA	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-9.98	-0.37	7.05e-22	Alzheimer's disease (late onset);
BRCA	cis	rs1568889	1.000	rs61889046	chr11:28297024	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	14.44	0.5	3.97e-41	Bipolar disorder;
BRCA	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	11.13	0.4	2.02e-26	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	trans	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg01620082	chr3:125678407	NA	-0.91	-10.26	-0.38	5.88e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg08807101	chr21:30365312	RNF160	0.77	20.27	0.63	6.04e-71	Dental caries;
BRCA	cis	rs11718455	0.960	rs3843372	chr3:43997666	C/T	cg08738300	chr3:44038990	NA	0.44	8.49	0.32	1.42e-16	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.39	0.57	9.59e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg15664640	chr17:80829946	TBCD	-0.4	-10.83	-0.39	3.22e-25	Breast cancer;
BRCA	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg22713356	chr15:30763199	NA	1.19	23.81	0.69	3.46e-90	Uric acid levels;
BRCA	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg18305652	chr10:134549665	INPP5A	0.49	11.17	0.4	1.39e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1568889	1.000	rs16917687	chr11:28062614	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	14.62	0.5	5.52e-42	Bipolar disorder;
BRCA	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg11663144	chr21:46675770	NA	-0.6	-13.81	-0.48	3.87e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg12444411	chr7:2802554	GNA12	-0.36	-8.76	-0.33	1.76e-17	Height;
BRCA	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg23992470	chr4:843637	GAK	0.49	8.16	0.31	1.72e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs912330	0.529	rs4772100	chr13:99196573	G/T	cg07423050	chr13:99094983	FARP1	-0.31	-7.91	-0.3	1.13e-14	Alzheimer's disease;
BRCA	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg11366901	chr6:160182831	ACAT2	0.82	15.87	0.53	4.47e-48	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	7.87	0.3	1.5e-14	Educational attainment;
BRCA	cis	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05901451	chr6:126070800	HEY2	-0.39	-9.53	-0.35	3.35e-20	Endometrial cancer;
BRCA	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg07636037	chr3:49044803	WDR6	-0.49	-8.29	-0.31	6.85e-16	Menarche (age at onset);
BRCA	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg03425785	chr20:62221387	GMEB2	0.52	8.47	0.32	1.7e-16	Glioblastoma;
BRCA	cis	rs17092148	0.652	rs2281695	chr20:33129164	T/C	cg16810054	chr20:33298113	TP53INP2	-0.45	-10.09	-0.37	2.51e-22	Neuroticism;
BRCA	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.47	-10.54	-0.38	4.87e-24	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs12612619	0.732	rs4665366	chr2:27212596	G/A	cg00617064	chr2:27272375	NA	0.32	8.25	0.31	8.72e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.44	0.57	5.31e-56	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg04944784	chr2:26401820	FAM59B	0.95	16.17	0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-13.95	-0.48	8.27e-39	Coronary artery disease;
BRCA	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg12193833	chr17:30244370	NA	-0.56	-8.77	-0.33	1.58e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.54	-0.32	9.72e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-9.39	-0.35	1.08e-19	Monocyte percentage of white cells;
BRCA	cis	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg13789015	chr9:136890014	NCRNA00094	0.55	11.5	0.41	6.01e-28	Platelet distribution width;
BRCA	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.08	-0.37	2.83e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2652834	1.000	rs2652832	chr15:63396928	T/C	cg05507819	chr15:63340323	TPM1	0.44	7.92	0.3	1.09e-14	HDL cholesterol;
BRCA	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10484885	0.824	rs11967579	chr6:90540008	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-9.84	-0.36	2.24e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg04455712	chr21:45112962	RRP1B	0.4	10.45	0.38	1.1e-23	Mean corpuscular volume;
BRCA	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-20.98	-0.64	9.21e-75	Lymphocyte percentage of white cells;
BRCA	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	11.81	0.42	2.86e-29	Neuroticism;
BRCA	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg24130564	chr14:104152367	KLC1	0.35	7.91	0.3	1.12e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.28	0.56	3.49e-55	Bladder cancer;
BRCA	trans	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.25	-0.34	3.26e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg06970220	chr1:156163860	SLC25A44	-0.36	-9.11	-0.34	1.04e-18	Testicular germ cell tumor;
BRCA	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	12.61	0.45	1e-32	Menarche (age at onset);
BRCA	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg21856205	chr7:94953877	PON1	0.37	8.17	0.31	1.6e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11764359	chr7:65958608	NA	0.62	13.51	0.47	9.34e-37	Calcium levels;
BRCA	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg01483505	chr11:975446	AP2A2	0.33	9.04	0.34	1.84e-18	Alzheimer's disease (late onset);
BRCA	cis	rs3925075	0.531	rs4075052	chr16:31348233	G/T	cg02846316	chr16:31340340	ITGAM	-0.41	-8.4	-0.32	2.98e-16	IgA nephropathy;
BRCA	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg00071950	chr4:10020882	SLC2A9	-0.49	-11.23	-0.41	7.93e-27	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	8.28	0.31	7.32e-16	Bipolar disorder;
BRCA	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg07148914	chr20:33460835	GGT7	-0.43	-9.33	-0.35	1.76e-19	Height;
BRCA	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.56	11.81	0.42	3.03e-29	Monocyte percentage of white cells;
BRCA	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg10057126	chr4:77819792	ANKRD56	0.66	15.36	0.52	1.54e-45	Emphysema distribution in smoking;
BRCA	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-7.86	-0.3	1.65e-14	Axial length;
BRCA	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg15212455	chr7:39170539	POU6F2	0.35	8.05	0.3	4.13e-15	IgG glycosylation;
BRCA	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg26384229	chr12:38710491	ALG10B	0.82	21.94	0.66	5.8e-80	Heart rate;
BRCA	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-9.71	-0.36	6.8e-21	Tonsillectomy;
BRCA	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg08917208	chr2:24149416	ATAD2B	1.05	14.21	0.49	5.26e-40	Lymphocyte counts;
BRCA	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg23711669	chr6:146136114	FBXO30	-0.78	-19.02	-0.6	2.88e-64	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg01620082	chr3:125678407	NA	-0.71	-8.8	-0.33	1.28e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.66	-0.32	3.99e-17	Monocyte percentage of white cells;
BRCA	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.1e-32	Developmental language disorder (linguistic errors);
BRCA	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.33	9.48	0.35	4.73e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs1190552	0.894	rs2236349	chr14:102963640	G/A	cg18135206	chr14:102964638	TECPR2	0.45	8.23	0.31	1.08e-15	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs62380364	0.602	rs588282	chr5:88032651	G/T	cg22951263	chr5:87985283	NA	-0.38	-10.66	-0.39	1.58e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg25237894	chr2:233734115	C2orf82	0.39	11.27	0.41	5.52e-27	Coronary artery disease;
BRCA	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-12.66	-0.45	5.95e-33	Platelet count;
BRCA	cis	rs7927771	0.524	rs10769299	chr11:47865160	G/T	cg20307385	chr11:47447363	PSMC3	0.41	9.47	0.35	5.45e-20	Subjective well-being;
BRCA	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25427524	chr10:38739819	LOC399744	0.65	15.6	0.53	9.72e-47	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.47	-10.66	-0.39	1.63e-24	Longevity;Endometriosis;
BRCA	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg00106254	chr7:1943704	MAD1L1	-0.46	-12.38	-0.44	1.03e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg03709012	chr19:19516395	GATAD2A	0.81	18.81	0.6	3.97e-63	Tonsillectomy;
BRCA	cis	rs4664304	0.620	rs1828480	chr2:160720384	G/A	cg14819504	chr2:160761413	LY75	0.34	8.47	0.32	1.65e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs13046373	0.508	rs1012969	chr21:31996108	G/A	cg16431978	chr21:31797932	KRTAP13-3	0.35	9.01	0.34	2.42e-18	HDL cholesterol;
BRCA	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg24692254	chr21:30365293	RNF160	0.62	14.25	0.49	3.16e-40	Selective IgA deficiency;
BRCA	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg18230493	chr5:56204884	C5orf35	-0.62	-11.24	-0.41	7.4e-27	Initial pursuit acceleration;
BRCA	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg06766960	chr11:133703094	NA	0.53	11.58	0.42	2.85e-28	Childhood ear infection;
BRCA	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg24642844	chr7:1081250	C7orf50	-0.56	-11.4	-0.41	1.57e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.07	0.4	3.52e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg13256891	chr4:100009986	ADH5	0.46	8.29	0.31	6.45e-16	Alcohol dependence;
BRCA	cis	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.42	-0.32	2.51e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	7.81	0.3	2.43e-14	Menarche (age at onset);
BRCA	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg26343298	chr8:95960752	TP53INP1	0.3	8.74	0.33	2.07e-17	Type 2 diabetes;
BRCA	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg04362960	chr10:104952993	NT5C2	0.44	10.8	0.39	4.26e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.04	-0.3	4.35e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg22903471	chr2:27725779	GCKR	-0.35	-8.52	-0.32	1.12e-16	Total body bone mineral density;
BRCA	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg07930192	chr7:1003750	NA	0.35	7.92	0.3	1.02e-14	Longevity;Endometriosis;
BRCA	cis	rs778371	0.788	rs4973569	chr2:233767037	A/G	cg08000102	chr2:233561755	GIGYF2	-0.64	-12.25	-0.44	3.76e-31	Schizophrenia;
BRCA	cis	rs6878727	0.665	rs161015	chr5:123653814	G/A	cg01806427	chr5:123737813	NA	-0.36	-8.05	-0.3	4.17e-15	Breast cancer;
BRCA	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg06064525	chr11:970664	AP2A2	-0.34	-9.9	-0.36	1.41e-21	Alzheimer's disease (late onset);
BRCA	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg01877450	chr7:97915802	BRI3	-0.38	-8.56	-0.32	8.45e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.63	-9.88	-0.36	1.59e-21	Body mass index (adult);
BRCA	cis	rs6484504	0.625	rs7112412	chr11:31370271	T/C	cg26647111	chr11:31128758	NA	0.42	9.38	0.35	1.09e-19	Red blood cell count;
BRCA	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.43	-0.38	1.21e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg11941060	chr3:133502564	NA	-0.51	-12.11	-0.43	1.5e-30	Iron status biomarkers;
BRCA	cis	rs2302729	0.578	rs11062299	chr12:2771738	T/C	cg19945202	chr12:2788847	CACNA1C	-0.44	-9.79	-0.36	3.54e-21	Sleep quality;
BRCA	cis	rs17270561	0.609	rs4711094	chr6:25706174	T/A	cg16482183	chr6:26056742	HIST1H1C	0.42	8.19	0.31	1.44e-15	Iron status biomarkers;
BRCA	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.86	-0.3	1.68e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg14019146	chr3:50243930	SLC38A3	0.37	8.99	0.34	2.73e-18	Body mass index;
BRCA	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11764359	chr7:65958608	NA	-0.79	-18.98	-0.6	5.11e-64	Aortic root size;
BRCA	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg11663144	chr21:46675770	NA	-0.6	-13.84	-0.48	2.6e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs6479891	1.000	rs7070052	chr10:64903814	A/G	cg14819942	chr15:35414228	NA	-0.33	-8.37	-0.31	3.55e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg24812749	chr6:127587940	RNF146	0.84	18.89	0.6	1.45e-63	Breast cancer;
BRCA	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg11189052	chr15:85197271	WDR73	-0.37	-8.93	-0.33	4.57e-18	P wave terminal force;
BRCA	cis	rs887829	0.570	rs10171367	chr2:234597667	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.29	-0.31	6.48e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	trans	rs9951602	0.573	rs78623099	chr18:76646228	G/T	cg02800362	chr5:177631904	HNRNPAB	0.77	17.87	0.58	3.31e-58	Obesity-related traits;
BRCA	cis	rs9463078	0.683	rs227841	chr6:44690309	A/T	cg25276700	chr6:44698697	NA	0.38	8.31	0.31	5.74e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs7766436	0.848	rs13200143	chr6:22586212	T/G	cg13666174	chr6:22585274	NA	-0.44	-9.52	-0.35	3.43e-20	Coronary artery disease;
BRCA	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg00666640	chr1:248458726	OR2T12	0.33	9.04	0.34	1.9e-18	Common traits (Other);
BRCA	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.05	0.4	4.35e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs870825	0.929	rs72689263	chr4:185590961	C/T	cg04058563	chr4:185651563	MLF1IP	0.69	11.83	0.42	2.39e-29	Blood protein levels;
BRCA	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg24829409	chr8:58192753	C8orf71	-0.61	-12.57	-0.45	1.5e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg04004882	chr2:215674386	BARD1	0.67	12.38	0.44	1.05e-31	Neuroblastoma;
BRCA	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg26384229	chr12:38710491	ALG10B	0.67	15.12	0.51	2.21e-44	Morning vs. evening chronotype;
BRCA	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.28	-0.34	2.64e-19	Electroencephalogram traits;
BRCA	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg15704280	chr7:45808275	SEPT13	0.62	10.28	0.38	4.74e-23	Axial length;
BRCA	cis	rs6450176	0.909	rs6866586	chr5:53295568	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-14.33	-0.49	1.33e-40	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg21770322	chr7:97807741	LMTK2	0.44	11.76	0.42	4.65e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2191566	0.576	rs402785	chr19:44492236	T/G	cg20607764	chr19:44506953	ZNF230	0.37	7.98	0.3	6.59e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6594713	0.642	rs6867579	chr5:112899573	T/C	cg12552261	chr5:112820674	MCC	0.5	7.91	0.3	1.13e-14	Brain cytoarchitecture;
BRCA	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg08085267	chr17:45401833	C17orf57	-0.69	-15.18	-0.51	1.18e-44	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs62229266	0.804	rs62230822	chr21:37429945	T/C	cg12218747	chr21:37451666	NA	-0.35	-8.17	-0.31	1.68e-15	Mitral valve prolapse;
BRCA	cis	rs8114671	0.967	rs6058202	chr20:33777983	A/G	cg07148914	chr20:33460835	GGT7	0.37	7.87	0.3	1.51e-14	Height;
BRCA	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11890956	chr21:40555474	PSMG1	1.06	30.2	0.77	3.72e-125	Cognitive function;
BRCA	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg10223061	chr2:219282414	VIL1	-0.27	-8.1	-0.31	2.71e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.53	11.92	0.43	1e-29	Colorectal cancer;
BRCA	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-11.79	-0.42	3.7e-29	Alzheimer's disease;
BRCA	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-14.39	-0.49	6.79e-41	Chronic sinus infection;
BRCA	cis	rs2066819	1.000	rs74496027	chr12:56726340	C/T	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg23711669	chr6:146136114	FBXO30	-0.7	-16.57	-0.55	1.5e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03264133	chr6:25882463	NA	-0.52	-11.75	-0.42	5.15e-29	Blood metabolite levels;
BRCA	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg20933634	chr6:27740509	NA	0.46	9.22	0.34	4.15e-19	Parkinson's disease;
BRCA	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg11584989	chr19:19387371	SF4	0.63	13.46	0.47	1.53e-36	Bipolar disorder;
BRCA	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg24562669	chr7:97807699	LMTK2	0.45	12.28	0.44	2.88e-31	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.07	0.3	3.37e-15	Mean corpuscular volume;
BRCA	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.35	-0.31	4.24e-16	Total body bone mineral density;
BRCA	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.4	-8.75	-0.33	1.84e-17	Aortic root size;
BRCA	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg12193833	chr17:30244370	NA	-0.54	-8.57	-0.32	7.97e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs7640424	0.649	rs11917909	chr3:107864673	G/A	cg09227934	chr3:107805635	CD47	-0.37	-8.03	-0.3	4.6e-15	Body mass index;
BRCA	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg15395560	chr15:45543142	SLC28A2	0.28	7.87	0.3	1.5e-14	Uric acid levels;
BRCA	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03264133	chr6:25882463	NA	0.42	9.21	0.34	4.68e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg08917208	chr2:24149416	ATAD2B	0.94	14.13	0.49	1.25e-39	Lymphocyte counts;
BRCA	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg12432903	chr7:1882776	MAD1L1	-0.45	-8.42	-0.32	2.51e-16	Bipolar disorder;
BRCA	cis	rs9463078	0.764	rs3799968	chr6:44805377	C/T	cg25276700	chr6:44698697	NA	-0.36	-8.24	-0.31	9.88e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs12545109	0.765	rs2438063	chr8:57384360	A/G	cg09654669	chr8:57350985	NA	0.47	9.72	0.36	6.43e-21	Obesity-related traits;
BRCA	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg00325661	chr8:49890786	NA	0.33	8.57	0.32	7.8e-17	Sudden cardiac arrest;
BRCA	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg13010199	chr12:38710504	ALG10B	-0.39	-8.36	-0.31	3.85e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg17724175	chr1:150552817	MCL1	0.26	8.72	0.33	2.42e-17	Tonsillectomy;
BRCA	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg03146154	chr1:46216737	IPP	-0.47	-9.99	-0.37	6.14e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18876405	chr7:65276391	NA	-0.64	-15.91	-0.53	2.83e-48	Aortic root size;
BRCA	trans	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg02002194	chr4:3960332	NA	0.32	8.18	0.31	1.57e-15	Mood instability;
BRCA	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg02017074	chr12:117425053	FBXW8	-0.58	-10.79	-0.39	4.54e-25	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg00684032	chr4:1343700	KIAA1530	-0.37	-9.49	-0.35	4.38e-20	Obesity-related traits;
BRCA	cis	rs1843834	0.716	rs6716600	chr2:225481991	A/T	cg22455342	chr2:225449267	CUL3	0.38	9.4	0.35	9.63e-20	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs73086581	1.000	rs73086544	chr20:3950928	C/A	cg02187196	chr20:3869020	PANK2	0.54	9.62	0.36	1.48e-20	Response to antidepressants in depression;
BRCA	cis	rs10193935	0.901	rs222486	chr2:42649664	C/T	cg27598129	chr2:42591480	NA	-0.81	-13.49	-0.47	1.14e-36	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9682041	0.627	rs34392658	chr3:170091584	C/T	cg11886554	chr3:170076028	SKIL	0.49	9.93	0.37	1e-21	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs72781680	0.678	rs11125293	chr2:24102423	A/G	cg08917208	chr2:24149416	ATAD2B	0.61	10.39	0.38	1.77e-23	Lymphocyte counts;
BRCA	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.34e-24	Motion sickness;
BRCA	cis	rs912057	0.632	rs1294429	chr6:6744652	G/A	cg06612196	chr6:6737390	NA	0.46	10.85	0.39	2.81e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg01420254	chr6:26195488	NA	0.56	8.61	0.32	5.67e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04267008	chr7:1944627	MAD1L1	-0.58	-12.14	-0.43	1.11e-30	Bipolar disorder and schizophrenia;
BRCA	cis	rs30380	1.000	rs27529	chr5:96126308	A/G	cg16492584	chr5:96139282	ERAP1	-0.31	-8.06	-0.3	3.69e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7124681	0.565	rs2203712	chr11:47534964	T/C	cg20307385	chr11:47447363	PSMC3	0.45	10.37	0.38	2.16e-23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs1975991	0.765	rs4686941	chr3:187958554	G/A	cg15417654	chr3:187959138	LPP	0.36	9.26	0.34	3.17e-19	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs312273	0.719	rs4767995	chr12:41361851	C/T	cg17827154	chr12:41323612	CNTN1	-0.39	-10.05	-0.37	3.56e-22	Bipolar disorder;
BRCA	cis	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg06521331	chr12:34319734	NA	-0.61	-12.02	-0.43	3.63e-30	Morning vs. evening chronotype;
BRCA	cis	rs6066825	0.568	rs6095245	chr20:47320770	G/C	cg18078177	chr20:47281410	PREX1	0.41	10.26	0.38	5.71e-23	Colorectal cancer;
BRCA	cis	rs796364	0.616	rs7589545	chr2:200676102	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	8.33	0.31	4.96e-16	Schizophrenia;
BRCA	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg04842962	chr6:43655489	MRPS18A	1.12	38.92	0.84	9.6e-171	IgG glycosylation;
BRCA	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg18357645	chr12:58087776	OS9	-0.42	-11.41	-0.41	1.38e-27	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg08888203	chr3:10149979	C3orf24	0.65	11.93	0.43	8.91e-30	Alzheimer's disease;
BRCA	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg08807101	chr21:30365312	RNF160	-0.57	-13.89	-0.48	1.67e-38	Dental caries;
BRCA	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.07	23.87	0.69	1.58e-90	Gut microbiome composition (summer);
BRCA	cis	rs10465746	0.905	rs34274953	chr1:84415011	G/A	cg10977910	chr1:84465055	TTLL7	0.49	9.94	0.37	9.67e-22	Obesity-related traits;
BRCA	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg13047869	chr3:10149882	C3orf24	0.6	12.62	0.45	9.38e-33	Alzheimer's disease;
BRCA	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg00825309	chr19:58991885	ZNF446	-0.83	-19.72	-0.62	5.84e-68	Mean platelet volume;
BRCA	cis	rs4919694	0.901	rs12251035	chr10:104671459	A/C	cg04362960	chr10:104952993	NT5C2	0.98	15.23	0.52	6.73e-45	Arsenic metabolism;
BRCA	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18876405	chr7:65276391	NA	-0.5	-11.21	-0.41	9.49e-27	Aortic root size;
BRCA	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.58	0.42	2.8e-28	Homoarginine levels;
BRCA	cis	rs495337	0.965	rs4809768	chr20:48576312	T/A	cg17835207	chr20:48524531	SPATA2	-0.58	-13.29	-0.47	9.43e-36	Psoriasis;
BRCA	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg13877915	chr19:58951672	ZNF132	0.46	10.83	0.39	3.32e-25	Uric acid clearance;
BRCA	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg27541892	chr1:1571801	CDK11B	-0.58	-13.2	-0.46	2.37e-35	Body mass index;
BRCA	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.71	0.39	9.66e-25	Cognitive ability;
BRCA	trans	rs12543645	0.598	rs35338507	chr8:10277982	G/A	cg06636001	chr8:8085503	FLJ10661	0.47	8.63	0.32	5e-17	Schizophrenia;
BRCA	cis	rs3784262	0.904	rs4646616	chr15:58261349	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.46	-12.35	-0.44	1.42e-31	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs11971779	0.700	rs11763942	chr7:139005795	A/T	cg07862535	chr7:139043722	LUC7L2	0.4	8.63	0.32	4.95e-17	Diisocyanate-induced asthma;
BRCA	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg24060327	chr5:131705240	SLC22A5	-0.46	-9.15	-0.34	7.57e-19	Acylcarnitine levels;
BRCA	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-12.21	-0.43	5.9e-31	Total cholesterol levels;
BRCA	cis	rs72627509	0.904	rs3796529	chr4:57797414	C/T	cg26694713	chr4:57773883	REST	0.49	9.64	0.36	1.28e-20	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03517284	chr6:25882590	NA	-0.47	-10.66	-0.39	1.51e-24	Blood metabolite levels;
BRCA	cis	rs4780401	0.527	rs4780402	chr16:11839809	C/T	cg01061890	chr16:11836724	TXNDC11	-0.46	-9.74	-0.36	5.47e-21	Rheumatoid arthritis;
BRCA	cis	rs35306767	0.668	rs35657988	chr10:1103590	A/G	cg26597838	chr10:835615	NA	0.6	10.04	0.37	4.02e-22	Eosinophil percentage of granulocytes;
BRCA	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg27170947	chr2:26402098	FAM59B	0.92	16.52	0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs6450176	0.909	rs80213371	chr5:53300874	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-14.52	-0.5	1.65e-41	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.43	9.88	0.36	1.6e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg06026331	chr20:60912101	LAMA5	-0.49	-10.18	-0.37	1.19e-22	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-8.1	-0.31	2.8e-15	Alzheimer's disease (late onset);
BRCA	cis	rs897080	0.515	rs698792	chr2:44683219	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.47	-8.6	-0.32	6.09e-17	Height;
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg03923535	chr7:1197113	ZFAND2A	0.5	10.17	0.37	1.31e-22	Longevity;Endometriosis;
BRCA	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg07262247	chr5:131593730	PDLIM4	0.36	8.58	0.32	7.25e-17	Acylcarnitine levels;
BRCA	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg23711669	chr6:146136114	FBXO30	0.63	14.71	0.5	2.07e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg17644776	chr2:200775616	C2orf69	0.45	9.35	0.35	1.51e-19	Osteoporosis;
BRCA	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg26384229	chr12:38710491	ALG10B	0.74	17.18	0.56	1.19e-54	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17767294	0.614	rs72845068	chr6:27668147	A/C	cg08851530	chr6:28072375	NA	1.11	10.02	0.37	4.78e-22	Parkinson's disease;
BRCA	trans	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.77	0.39	5.51e-25	Type 2 diabetes;
BRCA	cis	rs58785573	1.000	rs58785573	chr4:38653773	A/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.47	9.89	0.36	1.53e-21	Lymphocyte percentage of white cells;
BRCA	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg05863683	chr7:1912471	MAD1L1	0.36	8.38	0.31	3.28e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs17818399	0.926	rs35350086	chr2:46834036	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.56	10.24	0.38	6.6e-23	Height;
BRCA	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-12.3	-0.44	2.39e-31	Personality dimensions;
BRCA	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg13119609	chr19:45449297	APOC2	0.48	13.24	0.46	1.5e-35	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	11.04	0.4	4.76e-26	Monocyte percentage of white cells;
BRCA	cis	rs4891159	0.790	rs56077581	chr18:74116865	T/G	cg24786174	chr18:74118243	ZNF516	-0.76	-18.69	-0.59	1.55e-62	Longevity;
BRCA	cis	rs2625529	0.730	rs2957725	chr15:72248205	C/A	cg16672083	chr15:72433130	SENP8	0.73	17.35	0.57	1.55e-55	Red blood cell count;
BRCA	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg13271783	chr10:134563150	INPP5A	-0.44	-8.93	-0.33	4.51e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	14.16	0.49	8.32e-40	Platelet count;
BRCA	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg00149659	chr3:10157352	C3orf10	1.06	18.2	0.58	6.23e-60	Alzheimer's disease;
BRCA	cis	rs3741151	0.773	rs73543000	chr11:73151774	T/C	cg17517138	chr11:73019481	ARHGEF17	0.87	12.41	0.44	7.71e-32	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg17971929	chr21:40555470	PSMG1	0.7	15.48	0.52	3.79e-46	Cognitive function;
BRCA	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2637266	1.000	rs2395386	chr10:78341623	C/T	cg18941641	chr10:78392320	NA	0.34	7.91	0.3	1.14e-14	Pulmonary function;
BRCA	cis	rs68170813	0.559	rs10953531	chr7:106827867	A/G	cg02696742	chr7:106810147	HBP1	0.51	8.46	0.32	1.87e-16	Coronary artery disease;
BRCA	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg05973401	chr12:123451056	ABCB9	-0.41	-8.88	-0.33	6.9e-18	Height;Educational attainment;Head circumference (infant);
BRCA	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.35	-0.44	1.36e-31	Bipolar disorder;
BRCA	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.03	22.71	0.67	3.92e-84	Gut microbiome composition (summer);
BRCA	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg01689657	chr7:91764605	CYP51A1	0.22	8.17	0.31	1.63e-15	Breast cancer;
BRCA	cis	rs758324	0.947	rs2896961	chr5:131165006	C/T	cg06307176	chr5:131281290	NA	0.55	11.75	0.42	5.19e-29	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg01483505	chr11:975446	AP2A2	0.34	9.32	0.35	1.9e-19	Alzheimer's disease (late onset);
BRCA	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg12444411	chr7:2802554	GNA12	-0.32	-8.27	-0.31	7.86e-16	Height;
BRCA	trans	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg21659725	chr3:3221576	CRBN	-0.46	-10.04	-0.37	4.1e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.83	0.45	1.13e-33	Bipolar disorder;
BRCA	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg02297831	chr4:17616191	MED28	0.36	8.34	0.31	4.43e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg13010199	chr12:38710504	ALG10B	-0.35	-8.54	-0.32	9.47e-17	Morning vs. evening chronotype;
BRCA	cis	rs9467160	0.734	rs9467170	chr6:24452754	G/A	cg20631270	chr6:24437470	GPLD1	0.43	7.81	0.3	2.41e-14	Liver enzyme levels;
BRCA	cis	rs2599510	0.783	rs13399071	chr2:32793783	C/T	cg02381751	chr2:32503542	YIPF4	0.43	8.53	0.32	1.07e-16	Interleukin-18 levels;
BRCA	cis	rs3772130	0.962	rs11721291	chr3:121563285	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.82	0.39	3.58e-25	Cognitive performance;
BRCA	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg13047869	chr3:10149882	C3orf24	-0.53	-9.97	-0.37	7.63e-22	Alzheimer's disease;
BRCA	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg04756594	chr16:24857601	SLC5A11	-0.36	-8.54	-0.32	1.01e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.39	0.49	7.17e-41	Motion sickness;
BRCA	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.51	8.06	0.3	3.82e-15	Renal function-related traits (BUN);
BRCA	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg06636001	chr8:8085503	FLJ10661	0.45	9.63	0.36	1.38e-20	Neuroticism;
BRCA	cis	rs9341808	0.617	rs9294170	chr6:80814080	A/G	cg08355045	chr6:80787529	NA	0.44	11.51	0.41	5.62e-28	Sitting height ratio;
BRCA	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18876405	chr7:65276391	NA	-0.55	-13.02	-0.46	1.6e-34	Aortic root size;
BRCA	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	11.38	0.41	1.82e-27	Platelet count;
BRCA	cis	rs2979489	0.891	rs6982511	chr8:30355513	G/T	cg26383811	chr8:30366931	RBPMS	-0.56	-13.55	-0.47	6.16e-37	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
BRCA	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg24069376	chr3:38537580	EXOG	0.4	11.31	0.41	3.69e-27	Electrocardiographic conduction measures;
BRCA	cis	rs1344694	0.548	rs12468812	chr2:216905867	C/T	cg12620499	chr2:216877984	MREG	0.53	13.17	0.46	3.35e-35	Alcohol dependence;
BRCA	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg08847533	chr14:75593920	NEK9	-0.85	-21.51	-0.65	1.33e-77	Height;
BRCA	cis	rs72772090	0.539	rs72773942	chr5:96123366	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.13	-0.43	1.28e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	12.74	0.45	2.61e-33	Mood instability;
BRCA	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-10.27	-0.38	5.26e-23	Heart rate;
BRCA	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg08807101	chr21:30365312	RNF160	0.59	15.15	0.51	1.55e-44	Dental caries;
BRCA	cis	rs7598759	1.000	rs7598759	chr2:232321956	C/T	cg19187155	chr2:232395269	NMUR1	0.39	8.68	0.32	3.31e-17	Noise-induced hearing loss;
BRCA	cis	rs7020830	0.830	rs13296413	chr9:37258105	C/T	cg14294708	chr9:37120828	ZCCHC7	1.13	35.72	0.82	1.95e-154	Schizophrenia;
BRCA	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg18478394	chr8:109455254	TTC35	0.32	9.42	0.35	8.22e-20	Dupuytren's disease;
BRCA	cis	rs11585357	0.895	rs72633808	chr1:17618665	A/G	cg19159961	chr1:17633534	PADI4	0.55	8.72	0.33	2.44e-17	Hair shape;
BRCA	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.03	0.56	6.3e-54	Bladder cancer;
BRCA	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg18252515	chr7:66147081	NA	1.07	15.89	0.53	3.53e-48	Diabetic kidney disease;
BRCA	cis	rs11688816	0.569	rs7591708	chr2:63022050	T/C	cg17519650	chr2:63277830	OTX1	-0.4	-8.64	-0.32	4.64e-17	Body mass index;
BRCA	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg18301423	chr5:131593218	PDLIM4	0.33	8.57	0.32	7.71e-17	Breast cancer;
BRCA	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg05623727	chr3:50126028	RBM5	0.41	9.68	0.36	8.68e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1595825	0.786	rs75619425	chr2:198537281	A/G	cg19156104	chr2:198669113	PLCL1	-0.44	-8.08	-0.3	3.13e-15	Ulcerative colitis;
BRCA	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg12310025	chr6:25882481	NA	-0.54	-12.83	-0.45	1.04e-33	Blood metabolite levels;
BRCA	cis	rs2625529	0.667	rs16956381	chr15:72193237	A/C	cg16672083	chr15:72433130	SENP8	-0.82	-17.02	-0.56	7.35e-54	Red blood cell count;
BRCA	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg26587870	chr6:27730563	NA	-0.39	-8.29	-0.31	6.75e-16	Parkinson's disease;
BRCA	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg24562669	chr7:97807699	LMTK2	0.47	12.54	0.44	2.15e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3820928	0.874	rs2276593	chr2:227898434	A/G	cg11843606	chr2:227700838	RHBDD1	0.37	8.17	0.31	1.65e-15	Pulmonary function;
BRCA	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg20573242	chr4:122745356	CCNA2	0.49	10.92	0.4	1.45e-25	Type 2 diabetes;
BRCA	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19748678	chr4:122722346	EXOSC9	0.73	16.0	0.53	1.09e-48	Type 2 diabetes;
BRCA	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg06115741	chr20:33292138	TP53INP2	-0.37	-8.32	-0.31	5.5e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg12310025	chr6:25882481	NA	0.43	10.58	0.39	3.21e-24	Blood metabolite levels;
BRCA	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg20307385	chr11:47447363	PSMC3	0.38	8.22	0.31	1.12e-15	Subjective well-being;
BRCA	cis	rs724568	0.546	rs10191089	chr2:67941210	C/T	cg17945962	chr2:67939740	NA	-0.39	-10.56	-0.39	3.92e-24	Major depressive disorder (broad);
BRCA	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg08999081	chr20:33150536	PIGU	0.37	9.4	0.35	9.56e-20	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg11057378	chr10:81107060	PPIF	0.36	8.88	0.33	6.98e-18	Height;
BRCA	cis	rs4713675	0.565	rs4713670	chr6:33699882	C/T	cg14003231	chr6:33640908	ITPR3	-0.34	-8.37	-0.31	3.65e-16	Plateletcrit;
BRCA	cis	rs6594713	0.648	rs36023163	chr5:112891009	A/G	cg12552261	chr5:112820674	MCC	0.5	7.91	0.3	1.13e-14	Brain cytoarchitecture;
BRCA	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.29	0.31	6.59e-16	Aortic root size;
BRCA	cis	rs9790314	0.638	rs6764019	chr3:160638851	A/C	cg03342759	chr3:160939853	NMD3	0.45	8.73	0.33	2.3e-17	Morning vs. evening chronotype;
BRCA	trans	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	14.16	0.49	9.06e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.75	-0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs11984145	1.000	rs713243	chr7:38871105	T/C	cg19327137	chr7:38886074	VPS41	0.5	7.91	0.3	1.15e-14	Cognitive performance;
BRCA	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg17105886	chr17:28927953	LRRC37B2	0.62	8.17	0.31	1.67e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs12986413	0.935	rs36065733	chr19:2163771	T/G	cg09261902	chr19:2140048	AP3D1	0.4	10.47	0.38	9.01e-24	Height;
BRCA	cis	rs1865721	0.682	rs1561080	chr18:73145847	A/G	cg26385618	chr18:73139727	C18orf62	-0.37	-9.31	-0.35	1.94e-19	Intelligence;
BRCA	cis	rs10924970	1.000	rs2382567	chr1:235349803	A/G	cg26050004	chr1:235667680	B3GALNT2	0.34	8.51	0.32	1.23e-16	Asthma;
BRCA	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg07148914	chr20:33460835	GGT7	0.41	8.72	0.33	2.47e-17	Height;
BRCA	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg17366294	chr4:99064904	C4orf37	0.41	9.39	0.35	1.01e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4919694	1.000	rs12257935	chr10:104803062	C/A	cg04362960	chr10:104952993	NT5C2	0.94	14.5	0.5	2.26e-41	Arsenic metabolism;
BRCA	cis	rs7246657	0.639	rs12459015	chr19:38083189	T/A	cg18154014	chr19:37997991	ZNF793	0.48	9.16	0.34	7.24e-19	Coronary artery calcification;
BRCA	trans	rs4714291	0.832	rs9471247	chr6:40105318	A/G	cg02267698	chr19:7991119	CTXN1	-0.48	-9.7	-0.36	7.32e-21	Strep throat;
BRCA	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.26e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg08601574	chr20:25228251	PYGB	0.35	8.43	0.32	2.33e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg06521331	chr12:34319734	NA	-0.62	-11.22	-0.41	8.98e-27	Morning vs. evening chronotype;
BRCA	cis	rs2415984	0.622	rs11846013	chr14:46932291	A/C	cg14871534	chr14:47121158	RPL10L	0.37	8.92	0.33	4.89e-18	Number of children ever born;
BRCA	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg02297831	chr4:17616191	MED28	0.37	8.55	0.32	9.34e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7249921	0.802	rs1046345	chr19:35660752	C/T	cg15419183	chr19:35660584	FXYD5	0.45	10.04	0.37	3.97e-22	Platelet count;
BRCA	cis	rs672059	1.000	rs660602	chr1:183162774	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.38	8.68	0.32	3.3e-17	Hypertriglyceridemia;
BRCA	cis	rs7247513	0.964	rs4804202	chr19:12718619	T/C	cg01871581	chr19:12707946	ZNF490	-0.69	-16.39	-0.54	1.22e-50	Bipolar disorder;
BRCA	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg23711669	chr6:146136114	FBXO30	-0.66	-15.66	-0.53	4.98e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg24006582	chr15:45444508	DUOX1	-0.56	-11.57	-0.42	2.96e-28	Uric acid levels;
BRCA	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg24130564	chr14:104152367	KLC1	-0.34	-7.84	-0.3	1.83e-14	Body mass index;
BRCA	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg08345082	chr10:99160200	RRP12	-0.3	-8.89	-0.33	6.14e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg18252515	chr7:66147081	NA	-1.06	-15.58	-0.52	1.26e-46	Diabetic kidney disease;
BRCA	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg08601574	chr20:25228251	PYGB	-0.33	-7.97	-0.3	7.24e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11690935	0.885	rs6752812	chr2:172851502	C/A	cg13550731	chr2:172543902	DYNC1I2	-0.8	-23.43	-0.68	4.13e-88	Schizophrenia;
BRCA	cis	rs2882667	0.556	rs6873733	chr5:138403317	G/T	cg04439458	chr5:138467593	SIL1	-0.29	-7.91	-0.3	1.12e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg23000734	chr10:126850823	CTBP2	-0.45	-11.95	-0.43	7.88e-30	Menarche (age at onset);
BRCA	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.94	-0.51	1.6e-43	Total cholesterol levels;
BRCA	cis	rs1538970	0.924	rs6657284	chr1:45879088	T/C	cg05343316	chr1:45956843	TESK2	0.62	12.49	0.44	3.3e-32	Platelet count;
BRCA	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-7.92	-0.3	1.05e-14	Total body bone mineral density;
BRCA	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7809950	0.678	rs12672451	chr7:106853817	C/G	cg23024343	chr7:107201750	COG5	-0.45	-9.09	-0.34	1.26e-18	Coronary artery disease;
BRCA	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg20701182	chr2:24300061	SF3B14	-0.7	-13.34	-0.47	5.59e-36	Lymphocyte counts;
BRCA	cis	rs1355223	0.506	rs6484738	chr11:34860858	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-8.98	-0.33	3.04e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg09184832	chr6:79620586	NA	-0.42	-8.23	-0.31	1.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2274471	0.645	rs3780376	chr9:5109485	G/T	cg03390472	chr9:5043263	JAK2	-0.43	-8.07	-0.3	3.57e-15	Crohn's disease;
BRCA	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg12365402	chr11:9010492	NRIP3	-0.44	-10.3	-0.38	4.05e-23	Hemoglobin concentration;
BRCA	cis	rs17253792	0.822	rs80174205	chr14:56058694	T/C	cg01858014	chr14:56050164	KTN1	-0.73	-9.19	-0.34	5.56e-19	Putamen volume;
BRCA	cis	rs2625529	0.824	rs4238449	chr15:72421603	G/A	cg16672083	chr15:72433130	SENP8	-0.84	-17.67	-0.57	3.54e-57	Red blood cell count;
BRCA	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg08885076	chr2:99613938	TSGA10	0.45	10.69	0.39	1.17e-24	Chronic sinus infection;
BRCA	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg23422044	chr7:1970798	MAD1L1	-0.56	-9.62	-0.36	1.5e-20	Neuroticism;
BRCA	cis	rs9837602	1.000	rs13064704	chr3:99767541	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.18	0.4	1.29e-26	Breast cancer;
BRCA	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6580649	0.941	rs1635529	chr12:48395102	T/G	cg24011408	chr12:48396354	COL2A1	0.57	9.48	0.35	4.93e-20	Lung cancer;
BRCA	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg14983838	chr19:29218262	NA	0.5	9.86	0.36	1.91e-21	Methadone dose in opioid dependence;
BRCA	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg26043149	chr18:55253948	FECH	1.14	27.84	0.74	2.65e-112	Gout;Urate levels;Serum uric acid levels;
BRCA	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg15556689	chr8:8085844	FLJ10661	0.34	9.1	0.34	1.14e-18	Retinal vascular caliber;
BRCA	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg17724175	chr1:150552817	MCL1	0.25	8.37	0.31	3.7e-16	Urate levels;
BRCA	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.43	12.11	0.43	1.57e-30	Monocyte percentage of white cells;
BRCA	trans	rs1493916	0.748	rs1389535	chr18:31310416	A/G	cg15819921	chr19:927150	ARID3A	0.43	8.35	0.31	4.08e-16	Life satisfaction;
BRCA	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.33	0.49	1.33e-40	Motion sickness;
BRCA	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg04691961	chr3:161091175	C3orf57	-0.54	-12.48	-0.44	3.96e-32	Morning vs. evening chronotype;
BRCA	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.67	-0.61	9.89e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg26384229	chr12:38710491	ALG10B	0.71	16.15	0.54	1.87e-49	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg13319975	chr6:146136371	FBXO30	0.34	7.82	0.3	2.21e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg03433033	chr1:76189801	ACADM	0.39	8.22	0.31	1.11e-15	Daytime sleep phenotypes;
BRCA	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08859206	chr1:53392774	SCP2	-0.51	-11.23	-0.41	7.76e-27	Monocyte count;
BRCA	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11644478	chr21:40555479	PSMG1	0.83	18.81	0.6	3.63e-63	Cognitive function;
BRCA	trans	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.81	0.33	1.18e-17	Mean corpuscular volume;
BRCA	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.87	-0.3	1.48e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.93	0.56	2.16e-53	Bladder cancer;
BRCA	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs1568889	1.000	rs11603799	chr11:28196488	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.8	0.51	8.3e-43	Bipolar disorder;
BRCA	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.57	-11.52	-0.41	4.97e-28	Tonsillectomy;
BRCA	trans	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-18.58	-0.59	6.47e-62	Exhaled nitric oxide output;
BRCA	cis	rs10838687	0.736	rs4647726	chr11:47245494	A/T	cg25783544	chr11:47291846	MADD	0.43	7.86	0.3	1.63e-14	Proinsulin levels;
BRCA	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg05347473	chr6:146136440	FBXO30	0.6	11.44	0.41	1.1e-27	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15541040	chr2:3486749	NA	-0.47	-10.42	-0.38	1.39e-23	Neurofibrillary tangles;
BRCA	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.33	-0.44	1.69e-31	Chronic sinus infection;
BRCA	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg08754478	chr10:133766260	PPP2R2D	0.68	14.1	0.49	1.64e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg11657440	chr19:46296263	DMWD	0.7	18.48	0.59	2e-61	Coronary artery disease;
BRCA	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg18806716	chr10:30721971	MAP3K8	-0.6	-13.97	-0.48	6.51e-39	Inflammatory bowel disease;
BRCA	trans	rs2262909	1.000	rs436039	chr19:22214873	T/C	cg17074339	chr11:11642133	GALNTL4	-0.41	-7.81	-0.3	2.39e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	26.53	0.72	4.11e-105	Body mass index (adult);
BRCA	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18876405	chr7:65276391	NA	0.62	15.37	0.52	1.28e-45	Aortic root size;
BRCA	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11764359	chr7:65958608	NA	0.76	17.07	0.56	4.29e-54	Aortic root size;
BRCA	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg05714579	chr10:131428358	MGMT	0.55	13.01	0.46	1.78e-34	Response to temozolomide;
BRCA	cis	rs9341808	0.667	rs3805913	chr6:80927322	A/G	cg08355045	chr6:80787529	NA	0.32	7.86	0.3	1.64e-14	Sitting height ratio;
BRCA	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19748678	chr4:122722346	EXOSC9	0.74	15.96	0.53	1.71e-48	Type 2 diabetes;
BRCA	cis	rs7119038	0.818	rs6589684	chr11:118610957	A/G	cg19308663	chr11:118741387	NA	-0.4	-9.37	-0.35	1.21e-19	Sjögren's syndrome;
BRCA	trans	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg19894588	chr14:64061835	NA	0.36	8.68	0.32	3.34e-17	Glioblastoma;Glioma;
BRCA	cis	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg06521331	chr12:34319734	NA	-0.62	-11.18	-0.4	1.22e-26	Morning vs. evening chronotype;
BRCA	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	14.19	0.49	6.03e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg12011299	chr4:100065546	ADH4	0.42	10.56	0.39	3.95e-24	Alcohol dependence;
BRCA	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg06484146	chr7:12443880	VWDE	-0.63	-9.49	-0.35	4.59e-20	Coronary artery disease;
BRCA	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg02524346	chr8:600233	NA	-0.74	-9.11	-0.34	1.08e-18	IgG glycosylation;
BRCA	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.75	0.62	3.7e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg00825309	chr19:58991885	ZNF446	-0.59	-12.88	-0.45	6.82e-34	Uric acid clearance;
BRCA	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-8.01	-0.3	5.43e-15	Platelet count;
BRCA	cis	rs11229555	0.574	rs66573492	chr11:58183797	G/A	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg10792982	chr14:105748885	BRF1	0.4	9.76	0.36	4.58e-21	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs1109501	1.000	rs1109501	chr4:71329490	G/A	cg22786090	chr4:71381880	NA	0.37	7.85	0.3	1.77e-14	Alcoholism (heaviness of drinking);
BRCA	cis	rs698833	0.852	rs4953092	chr2:44565293	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	11.25	0.41	6.6e-27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg10792982	chr14:105748885	BRF1	0.5	11.25	0.41	6.71e-27	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs6450176	1.000	rs60492935	chr5:53306240	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-15.32	-0.52	2.36e-45	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11644478	chr21:40555479	PSMG1	-0.7	-16.04	-0.54	6.27e-49	Cognitive function;
BRCA	cis	rs13046373	0.508	rs1507393	chr21:31992779	A/G	cg22337977	chr21:31811175	KRTAP15-1	0.33	7.92	0.3	1.05e-14	HDL cholesterol;
BRCA	cis	rs9815354	0.812	rs74947509	chr3:42006323	T/C	cg03022575	chr3:42003672	ULK4	0.65	9.49	0.35	4.62e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-10.7	-0.39	1.09e-24	IgG glycosylation;
BRCA	cis	rs28374715	0.662	rs28827035	chr15:41492290	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.87	-18.09	-0.58	2.39e-59	Ulcerative colitis;
BRCA	cis	rs4566357	0.557	rs2272201	chr2:227912551	T/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.44	-0.35	6.61e-20	Coronary artery disease;
BRCA	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.44	0.41	1.07e-27	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg22467129	chr15:76604101	ETFA	-0.49	-10.82	-0.39	3.71e-25	Blood metabolite levels;
BRCA	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg23711669	chr6:146136114	FBXO30	0.75	17.43	0.57	6.04e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg16586182	chr3:47516702	SCAP	-0.43	-8.84	-0.33	9.49e-18	Birth weight;
BRCA	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	11.49	0.41	6.29e-28	Height;
BRCA	cis	rs7953508	0.659	rs1316739	chr12:93968256	G/A	cg18151635	chr12:93972918	NA	-0.43	-9.09	-0.34	1.21e-18	Pubertal anthropometrics;
BRCA	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg12463550	chr7:65579703	CRCP	-0.37	-7.89	-0.3	1.33e-14	Aortic root size;
BRCA	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.57	0.45	1.51e-32	Electroencephalogram traits;
BRCA	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg24768116	chr2:27665128	KRTCAP3	-0.33	-8.27	-0.31	7.74e-16	Total body bone mineral density;
BRCA	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg01448562	chr3:133502909	NA	0.73	17.48	0.57	3.26e-56	Iron status biomarkers;
BRCA	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-14.67	-0.5	3.19e-42	Chronic sinus infection;
BRCA	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg13319975	chr6:146136371	FBXO30	0.4	9.32	0.35	1.81e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6940638	0.662	rs6915678	chr6:27235866	T/G	cg12292205	chr6:26970375	C6orf41	-0.44	-9.06	-0.34	1.55e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	15.89	0.53	3.85e-48	Exhaled nitric oxide levels;
BRCA	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg23711669	chr6:146136114	FBXO30	0.73	15.2	0.52	8.77e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs243505	1.000	rs243514	chr7:148427873	A/G	cg09806900	chr7:148480153	CUL1	0.4	8.32	0.31	5.43e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.64	0.36	1.22e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg13319975	chr6:146136371	FBXO30	-0.34	-7.91	-0.3	1.1e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg20307385	chr11:47447363	PSMC3	0.67	14.35	0.49	1.15e-40	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11890956	chr21:40555474	PSMG1	1.04	29.72	0.76	1.44e-122	Cognitive function;
BRCA	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg04362960	chr10:104952993	NT5C2	0.44	8.81	0.33	1.14e-17	Arsenic metabolism;
BRCA	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.63	10.06	0.37	3.3e-22	Renal function-related traits (BUN);
BRCA	cis	rs2294693	0.891	rs9369256	chr6:40998344	G/C	cg14769373	chr6:40998127	UNC5CL	-0.38	-7.93	-0.3	1e-14	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg17691542	chr6:26056736	HIST1H1C	0.47	9.55	0.35	2.61e-20	Height;
BRCA	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	8.54	0.32	9.73e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg24848339	chr3:12840334	CAND2	0.5	13.19	0.46	2.64e-35	QRS complex (12-leadsum);
BRCA	cis	rs11608355	0.545	rs9943724	chr12:109902903	G/A	cg05360138	chr12:110035743	NA	0.71	13.15	0.46	3.98e-35	Neuroticism;
BRCA	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	14.16	0.49	8.38e-40	Lymphocyte percentage of white cells;
BRCA	cis	rs4302748	1.000	rs4302748	chr7:36191699	C/T	cg24442661	chr7:36192818	EEPD1	0.51	9.61	0.36	1.68e-20	Platelet count;
BRCA	cis	rs6930083	0.605	rs3829964	chr6:36644498	T/C	cg08179530	chr6:36648295	CDKN1A	0.74	17.69	0.57	2.66e-57	Coronary artery disease;
BRCA	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg01448562	chr3:133502909	NA	-0.41	-9.41	-0.35	9.13e-20	Iron status biomarkers;
BRCA	cis	rs2425143	0.730	rs6060626	chr20:34415073	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.33	-0.31	5.07e-16	Blood protein levels;
BRCA	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg00495681	chr13:53174319	NA	0.41	8.73	0.33	2.15e-17	Lewy body disease;
BRCA	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.85	17.04	0.56	6.18e-54	Smoking behavior;
BRCA	cis	rs6121246	0.559	rs10439608	chr20:30258814	T/C	cg13852791	chr20:30311386	BCL2L1	0.95	23.24	0.68	4.65e-87	Mean corpuscular hemoglobin;
BRCA	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg05340658	chr4:99064831	C4orf37	0.56	10.76	0.39	6.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4891159	0.790	rs8087557	chr18:74116848	G/C	cg24786174	chr18:74118243	ZNF516	-0.75	-20.02	-0.62	1.36e-69	Longevity;
BRCA	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg13736514	chr6:26305472	NA	-0.4	-12.7	-0.45	4.06e-33	Educational attainment;
BRCA	trans	rs9951602	0.512	rs12455566	chr18:76655926	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	18.07	0.58	3.01e-59	Obesity-related traits;
BRCA	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg01483505	chr11:975446	AP2A2	0.33	9.07	0.34	1.44e-18	Alzheimer's disease (late onset);
BRCA	cis	rs12220238	1.000	rs7076721	chr10:75996682	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.49	7.99	0.3	6.44e-15	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg16339924	chr4:17578868	LAP3	0.66	16.87	0.56	4.19e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10193935	0.901	rs2286701	chr2:42555636	T/C	cg27598129	chr2:42591480	NA	-0.95	-14.8	-0.51	7.85e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg27433088	chr4:174089019	GALNT7	-0.33	-8.14	-0.31	2.11e-15	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg05283184	chr6:79620031	NA	0.41	10.99	0.4	7.36e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg17135325	chr3:160939158	NMD3	0.39	7.82	0.3	2.14e-14	Parkinson's disease;
BRCA	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg19077165	chr18:44547161	KATNAL2	0.53	11.76	0.42	4.93e-29	Personality dimensions;
BRCA	cis	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg06521331	chr12:34319734	NA	-0.65	-11.92	-0.43	1.01e-29	Morning vs. evening chronotype;
BRCA	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg13256891	chr4:100009986	ADH5	0.39	7.98	0.3	6.99e-15	Alcohol dependence;
BRCA	cis	rs7092929	0.941	rs705477	chr10:3582161	A/G	cg14308648	chr10:3568949	NA	0.45	8.04	0.3	4.3e-15	Coronary artery calcification;
BRCA	cis	rs6546550	0.935	rs13017134	chr2:70090579	C/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-9.39	-0.35	9.99e-20	Prevalent atrial fibrillation;
BRCA	cis	rs7254827	0.955	rs12977269	chr19:17215648	G/T	cg19418318	chr19:17219073	MYO9B	-0.5	-10.18	-0.37	1.17e-22	Mean platelet volume;
BRCA	cis	rs7408868	1.000	rs7254269	chr19:15277429	A/T	cg14696996	chr19:15285081	NOTCH3	-1.01	-14.98	-0.51	1.08e-43	Pulse pressure;
BRCA	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg26587870	chr6:27730563	NA	-0.41	-8.58	-0.32	6.99e-17	Parkinson's disease;
BRCA	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg14349672	chr11:133703707	NA	-0.39	-8.77	-0.33	1.58e-17	Childhood ear infection;
BRCA	cis	rs9287719	0.601	rs10084172	chr2:10771228	A/C	cg00105475	chr2:10696890	NA	0.46	10.25	0.38	6.48e-23	Prostate cancer;
BRCA	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg21699342	chr2:239360505	ASB1	0.5	11.52	0.41	5.08e-28	Multiple system atrophy;
BRCA	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg24642439	chr20:33292090	TP53INP2	-0.6	-12.98	-0.46	2.39e-34	Coronary artery disease;
BRCA	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.95	-0.3	8.21e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs11229555	0.645	rs7931394	chr11:58212617	T/A	cg15696309	chr11:58395628	NA	-0.45	-9.64	-0.36	1.27e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1997103	1.000	rs2331067	chr7:55408232	A/T	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.53	10.31	0.38	3.77e-23	Birth weight;
BRCA	cis	rs6740322	0.895	rs11684601	chr2:43574242	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-12.13	-0.43	1.24e-30	Coronary artery disease;
BRCA	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.4	-8.41	-0.32	2.7e-16	Ulcerative colitis;
BRCA	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg23422044	chr7:1970798	MAD1L1	-0.45	-9.44	-0.35	6.86e-20	Neuroticism;
BRCA	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg23711669	chr6:146136114	FBXO30	0.72	16.16	0.54	1.62e-49	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg02466173	chr16:30829666	NA	-0.51	-11.02	-0.4	5.43e-26	Multiple myeloma;
BRCA	cis	rs758324	0.947	rs6861174	chr5:131156129	A/G	cg06307176	chr5:131281290	NA	0.52	10.15	0.37	1.55e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-13.43	-0.47	2.03e-36	Morning vs. evening chronotype;
BRCA	cis	rs9463078	0.746	rs9395095	chr6:45273877	C/A	cg25276700	chr6:44698697	NA	-0.36	-8.14	-0.31	2.01e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.1	-40.33	-0.85	8.61e-178	Myeloid white cell count;
BRCA	cis	rs9443645	0.527	rs7756996	chr6:79509367	A/C	cg09184832	chr6:79620586	NA	-0.4	-7.83	-0.3	2.1e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg17063962	chr7:91808500	NA	0.52	12.35	0.44	1.39e-31	Breast cancer;
BRCA	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg14784868	chr12:69753453	YEATS4	0.79	25.2	0.71	7.93e-98	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.28	-0.34	2.69e-19	Morning vs. evening chronotype;
BRCA	cis	rs57024841	0.562	rs2071006	chr9:139839904	G/T	cg00693599	chr9:139836323	FBXW5	-0.46	-11.51	-0.41	5.39e-28	Beta-trace protein levels;
BRCA	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg07636037	chr3:49044803	WDR6	0.7	15.0	0.51	8.93e-44	Menarche (age at onset);
BRCA	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg21545522	chr1:205238299	TMCC2	0.4	8.36	0.31	3.9e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.7	-16.94	-0.56	1.86e-53	Ileal carcinoids;
BRCA	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	9.12	0.34	9.75e-19	Height;
BRCA	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	11.87	0.42	1.69e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13064411	0.518	rs2399480	chr3:113228599	T/C	cg18753928	chr3:113234510	CCDC52	-0.45	-9.68	-0.36	8.97e-21	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs11674184	0.743	rs12470971	chr2:11725241	A/G	cg07314298	chr2:11723111	GREB1	0.8	19.82	0.62	1.7e-68	Endometriosis;
BRCA	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-7.84	-0.3	1.84e-14	Breast cancer;
BRCA	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg08061076	chr7:1943177	MAD1L1	-0.34	-7.84	-0.3	1.93e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs2274273	0.840	rs11547116	chr14:55738165	T/C	cg04306507	chr14:55594613	LGALS3	0.31	8.61	0.32	5.51e-17	Protein biomarker;
BRCA	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	9.57	0.35	2.35e-20	Lung cancer in ever smokers;
BRCA	cis	rs652260	0.967	rs569175	chr19:7901160	T/G	cg26014689	chr19:7917955	EVI5L	-0.52	-11.77	-0.42	4.49e-29	Menarche (age at onset);
BRCA	cis	rs7147624	0.938	rs7151148	chr14:65936665	G/C	cg03016385	chr14:66212404	NA	-0.55	-8.38	-0.31	3.32e-16	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg21747090	chr2:27597821	SNX17	-0.37	-8.0	-0.3	5.8e-15	Total body bone mineral density;
BRCA	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg01579765	chr21:45077557	HSF2BP	-0.45	-12.17	-0.43	8.31e-31	Mean corpuscular volume;
BRCA	cis	rs921968	0.565	rs1541777	chr2:219587291	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-10.97	-0.4	8.94e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg26446133	chr18:72167187	CNDP2	-0.75	-14.34	-0.49	1.23e-40	Refractive error;
BRCA	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	8.0	0.3	5.67e-15	Diabetic retinopathy;
BRCA	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11764359	chr7:65958608	NA	-0.75	-16.69	-0.55	3.49e-52	Aortic root size;
BRCA	trans	rs75804782	0.521	rs56387296	chr2:239426298	A/G	cg01134436	chr17:81009848	B3GNTL1	0.69	8.83	0.33	1.03e-17	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg04944784	chr2:26401820	FAM59B	-0.95	-16.58	-0.55	1.26e-51	Gut microbiome composition (summer);
BRCA	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg05665937	chr4:1216051	CTBP1	0.39	8.23	0.31	1.09e-15	Obesity-related traits;
BRCA	cis	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg21775007	chr8:11205619	TDH	-0.43	-8.88	-0.33	6.77e-18	Triglycerides;
BRCA	trans	rs111612372	1	rs111612372	chr2:20433218	T/C	cg27368651	chr22:31829985	DRG1	-0.38	-9.01	-0.34	2.39e-18	Body mass index;
BRCA	cis	rs12618769	0.597	rs3769741	chr2:99068204	G/T	cg10123293	chr2:99228465	UNC50	0.4	8.12	0.31	2.46e-15	Bipolar disorder;
BRCA	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg01689657	chr7:91764605	CYP51A1	0.22	8.03	0.3	4.73e-15	Breast cancer;
BRCA	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg10523679	chr1:76189770	ACADM	0.76	15.68	0.53	4.21e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7572733	0.555	rs6434953	chr2:198929693	A/G	cg00792783	chr2:198669748	PLCL1	0.39	8.38	0.31	3.32e-16	Dermatomyositis;
BRCA	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg24466277	chr1:23519622	HTR1D	0.39	8.74	0.33	2.08e-17	Height;
BRCA	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg03806693	chr22:41940476	POLR3H	0.74	13.84	0.48	2.88e-38	Vitiligo;
BRCA	cis	rs9470366	0.545	rs6930083	chr6:36634156	A/G	cg08179530	chr6:36648295	CDKN1A	-0.51	-11.31	-0.41	3.77e-27	QRS duration;
BRCA	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg04455712	chr21:45112962	RRP1B	0.46	11.72	0.42	6.9e-29	Mean corpuscular volume;
BRCA	cis	rs877282	1.000	rs11253369	chr10:773610	C/G	cg17470449	chr10:769945	NA	0.43	8.27	0.31	7.55e-16	Uric acid levels;
BRCA	cis	rs9324022	0.929	rs17099617	chr14:101170488	A/G	cg18089426	chr14:101175970	NA	0.64	12.56	0.45	1.65e-32	Plateletcrit;
BRCA	cis	rs501916	0.605	rs8031169	chr15:48080330	G/C	cg16110827	chr15:48056943	SEMA6D	-0.39	-8.27	-0.31	7.67e-16	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs1451375	0.698	rs11238214	chr7:50636018	A/G	cg18232548	chr7:50535776	DDC	0.4	9.29	0.34	2.47e-19	Malaria;
BRCA	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg18898632	chr2:242989856	NA	-0.53	-8.84	-0.33	9.49e-18	Obesity-related traits;
BRCA	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg03146154	chr1:46216737	IPP	0.54	12.03	0.43	3.34e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.15	0.37	1.57e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg06598544	chr20:61472147	COL9A3	-0.76	-10.64	-0.39	1.87e-24	Obesity-related traits;
BRCA	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg04476341	chr5:669733	TPPP	-0.38	-10.56	-0.39	3.77e-24	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
BRCA	trans	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.02	0.3	4.93e-15	Corneal astigmatism;
BRCA	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.66	-0.32	3.86e-17	Alzheimer's disease (late onset);
BRCA	cis	rs4588572	0.644	rs11742212	chr5:77779033	G/A	cg11547950	chr5:77652471	NA	-0.44	-8.45	-0.32	1.95e-16	Triglycerides;
BRCA	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	14.87	0.51	3.82e-43	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg04455712	chr21:45112962	RRP1B	0.44	12.15	0.43	1.07e-30	Mean corpuscular volume;
BRCA	cis	rs1997103	0.954	rs2177809	chr7:55378125	T/C	cg17469321	chr7:55412551	NA	0.51	9.66	0.36	1.06e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs1215050	0.669	rs783962	chr4:98884473	G/A	cg05340658	chr4:99064831	C4orf37	-0.41	-9.18	-0.34	6.12e-19	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1113500	0.933	rs61797345	chr1:108623728	G/A	cg06207961	chr1:108661230	NA	0.45	11.11	0.4	2.48e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg23711669	chr6:146136114	FBXO30	-0.82	-20.11	-0.62	4.6e-70	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.02	0.48	4.03e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg00666640	chr1:248458726	OR2T12	0.31	8.02	0.3	4.91e-15	Common traits (Other);
BRCA	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg17691542	chr6:26056736	HIST1H1C	0.55	11.54	0.42	3.94e-28	Height;
BRCA	cis	rs7851660	0.967	rs6478437	chr9:100607497	A/G	cg13688889	chr9:100608707	NA	-0.35	-8.56	-0.32	8.52e-17	Strep throat;
BRCA	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg24692254	chr21:30365293	RNF160	-0.63	-16.57	-0.55	1.49e-51	Dental caries;
BRCA	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.4	0.47	2.88e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4308124	0.708	rs67816163	chr2:111963310	A/G	cg04571233	chr2:111982156	NA	-0.45	-9.69	-0.36	8.37e-21	Vitiligo;
BRCA	cis	rs2625529	0.652	rs2899776	chr15:72268365	A/T	cg16672083	chr15:72433130	SENP8	0.68	16.28	0.54	4.22e-50	Red blood cell count;
BRCA	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg25036284	chr2:26402008	FAM59B	-0.64	-10.61	-0.39	2.5e-24	Gut microbiome composition (summer);
BRCA	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	9.09	0.34	1.22e-18	Personality dimensions;
BRCA	trans	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg21659725	chr3:3221576	CRBN	-0.48	-8.8	-0.33	1.32e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg23711669	chr6:146136114	FBXO30	0.63	14.68	0.5	2.85e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs28830936	1.000	rs11629678	chr15:41932530	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.33	-9.2	-0.34	4.83e-19	Diastolic blood pressure;
BRCA	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg05340658	chr4:99064831	C4orf37	0.67	16.82	0.55	7.42e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs113835537	0.529	rs11227512	chr11:66281291	T/C	cg24851651	chr11:66362959	CCS	0.44	8.29	0.31	6.92e-16	Airway imaging phenotypes;
BRCA	cis	rs16976116	0.901	rs113679855	chr15:55502428	C/T	cg11288833	chr15:55489084	RSL24D1	0.47	10.57	0.39	3.56e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.9	0.3	1.22e-14	Corneal astigmatism;
BRCA	trans	rs9951602	0.512	rs6506874	chr18:76653467	G/T	cg02800362	chr5:177631904	HNRNPAB	0.77	18.23	0.58	4.25e-60	Obesity-related traits;
BRCA	cis	rs17095355	1.000	rs17126883	chr10:111694696	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.4	-9.08	-0.34	1.35e-18	Biliary atresia;
BRCA	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.26	0.38	5.81e-23	Bipolar disorder;
BRCA	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg06598544	chr20:61472147	COL9A3	0.66	9.54	0.35	2.95e-20	Obesity-related traits;
BRCA	cis	rs7561273	0.561	rs35268318	chr2:24352824	A/T	cg04809136	chr2:24300158	SF3B14	-0.4	-8.94	-0.33	4.13e-18	Quantitative traits;
BRCA	cis	rs6565180	1.000	rs12930787	chr16:30381303	C/G	cg17640201	chr16:30407289	ZNF48	-0.72	-16.6	-0.55	1.07e-51	Tonsillectomy;
BRCA	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg08997352	chr12:9597637	DDX12	-0.5	-9.84	-0.36	2.24e-21	Breast size;
BRCA	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg09307838	chr4:120376055	NA	-0.77	-16.63	-0.55	6.84e-52	Corneal astigmatism;
BRCA	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg21017887	chr14:105400489	NA	0.66	17.47	0.57	3.64e-56	Rheumatoid arthritis;
BRCA	cis	rs6684514	0.961	rs12029695	chr1:156299847	C/T	cg16558208	chr1:156270281	VHLL	0.35	8.08	0.3	3.34e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg21475434	chr5:93447410	FAM172A	0.67	8.58	0.32	7.41e-17	Diabetic retinopathy;
BRCA	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg05623727	chr3:50126028	RBM5	-0.42	-10.2	-0.37	1.02e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg17063962	chr7:91808500	NA	0.56	12.95	0.46	3.21e-34	Breast cancer;
BRCA	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.66	-0.42	1.31e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs7572733	0.514	rs770659	chr2:198669754	G/C	cg00792783	chr2:198669748	PLCL1	0.47	10.27	0.38	5.27e-23	Dermatomyositis;
BRCA	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg05340658	chr4:99064831	C4orf37	0.59	12.38	0.44	1.07e-31	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00166722	chr3:10149974	C3orf24	0.65	12.8	0.45	1.54e-33	Alzheimer's disease;
BRCA	cis	rs965469	0.817	rs16988490	chr20:3335431	C/T	cg25506879	chr20:3388711	C20orf194	0.46	8.91	0.33	5.25e-18	IFN-related cytopenia;
BRCA	cis	rs11030122	0.702	rs12223176	chr11:3982537	T/G	cg18678763	chr11:4115507	RRM1	-0.35	-7.87	-0.3	1.53e-14	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg15556689	chr8:8085844	FLJ10661	0.49	13.87	0.48	2.09e-38	Mood instability;
BRCA	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg01483505	chr11:975446	AP2A2	0.33	9.01	0.34	2.38e-18	Alzheimer's disease (late onset);
BRCA	cis	rs897984	0.609	rs57576577	chr16:31036367	G/A	cg00531865	chr16:30841666	NA	-0.41	-10.08	-0.37	2.92e-22	Dementia with Lewy bodies;
BRCA	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg10253484	chr15:75165896	SCAMP2	-0.55	-11.3	-0.41	4.2e-27	Breast cancer;
BRCA	cis	rs3106136	0.527	rs2883	chr4:95158610	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.14	-0.37	1.7e-22	Capecitabine sensitivity;
BRCA	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg08000102	chr2:233561755	GIGYF2	-0.62	-13.46	-0.47	1.55e-36	Coronary artery disease;
BRCA	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.31	10.05	0.37	3.54e-22	Electroencephalogram traits;
BRCA	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.33	-7.87	-0.3	1.53e-14	Personality dimensions;
BRCA	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg07636037	chr3:49044803	WDR6	-0.6	-8.74	-0.33	2.01e-17	Cognitive function;
BRCA	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg18230493	chr5:56204884	C5orf35	0.58	12.17	0.43	8.57e-31	Initial pursuit acceleration;
BRCA	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg05347473	chr6:146136440	FBXO30	0.41	8.02	0.3	5.01e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.34	-7.86	-0.3	1.66e-14	High light scatter reticulocyte count;
BRCA	cis	rs3820928	0.874	rs10210963	chr2:227821845	A/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.66	-0.32	3.71e-17	Pulmonary function;
BRCA	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg03188948	chr7:1209495	NA	0.86	11.78	0.42	3.91e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4363385	0.818	rs3806222	chr1:153002606	C/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.36	-0.31	3.83e-16	Inflammatory skin disease;
BRCA	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg18876405	chr7:65276391	NA	-0.58	-14.46	-0.5	3.27e-41	Aortic root size;
BRCA	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.08	0.58	2.69e-59	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	8.78	0.33	1.53e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs35995292	0.500	rs7776996	chr7:38919762	G/C	cg19327137	chr7:38886074	VPS41	0.38	12.68	0.45	4.91e-33	Subjective well-being (multi-trait analysis);
BRCA	cis	rs1003719	0.612	rs2835652	chr21:38557408	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.36	-0.49	1e-40	Eye color traits;
BRCA	cis	rs9815354	0.812	rs73071328	chr3:41810055	A/C	cg03022575	chr3:42003672	ULK4	0.7	9.61	0.36	1.66e-20	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg01620082	chr3:125678407	NA	-0.58	-8.22	-0.31	1.11e-15	Depression;
BRCA	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	13.6	0.47	3.45e-37	Colorectal cancer;
BRCA	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg20991723	chr1:152506922	NA	0.37	8.29	0.31	6.61e-16	Hair morphology;
BRCA	cis	rs12493885	0.769	rs11718319	chr3:153776944	G/A	cg17054900	chr3:154042577	DHX36	-0.5	-8.64	-0.32	4.44e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg26384229	chr12:38710491	ALG10B	0.68	14.28	0.49	2.34e-40	Morning vs. evening chronotype;
BRCA	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg12373951	chr3:133503437	NA	0.45	10.48	0.38	8.02e-24	Iron status biomarkers;
BRCA	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg21132104	chr15:45694354	SPATA5L1	0.75	16.99	0.56	1.07e-53	Homoarginine levels;
BRCA	cis	rs7474896	0.583	rs1208770	chr10:38044683	C/T	cg25427524	chr10:38739819	LOC399744	-0.54	-9.73	-0.36	6.02e-21	Obesity (extreme);
BRCA	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg21573476	chr21:45109991	RRP1B	-0.4	-10.6	-0.39	2.81e-24	Mean corpuscular volume;
BRCA	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26314531	chr2:26401878	FAM59B	-0.63	-10.93	-0.4	1.27e-25	Gut microbiome composition (summer);
BRCA	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.64	-16.35	-0.54	1.94e-50	Colorectal cancer;
BRCA	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg26850624	chr5:429559	AHRR	-0.34	-8.29	-0.31	6.85e-16	Cystic fibrosis severity;
BRCA	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg08888203	chr3:10149979	C3orf24	0.66	14.05	0.49	2.73e-39	Alzheimer's disease;
BRCA	cis	rs11718455	1.000	rs4682928	chr3:44037192	T/C	cg08738300	chr3:44038990	NA	0.47	9.0	0.34	2.63e-18	Coronary artery disease;
BRCA	cis	rs10411936	0.720	rs2885706	chr19:16582937	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.46	9.65	0.36	1.19e-20	White blood cell count;Multiple sclerosis;
BRCA	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg22601191	chr20:60968625	CABLES2	0.42	9.74	0.36	5.35e-21	Colorectal cancer;
BRCA	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg14196790	chr5:131705035	SLC22A5	0.42	10.05	0.37	3.72e-22	Breast cancer;Mosquito bite size;
BRCA	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg20701182	chr2:24300061	SF3B14	0.67	9.77	0.36	4.1e-21	Lymphocyte counts;
BRCA	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg23708337	chr7:1209742	NA	0.64	8.93	0.33	4.47e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2816062	0.786	rs2816055	chr1:18898248	A/G	cg18795169	chr1:18902165	NA	-0.98	-29.37	-0.76	1.19e-120	Urate levels in lean individuals;
BRCA	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg07606381	chr6:8435919	SLC35B3	-0.92	-18.13	-0.58	1.39e-59	Motion sickness;
BRCA	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-11.32	-0.41	3.19e-27	Neuroticism;
BRCA	trans	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	14.54	0.5	1.32e-41	Exhaled nitric oxide levels;
BRCA	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg21775007	chr8:11205619	TDH	-0.44	-9.32	-0.35	1.84e-19	Neuroticism;
BRCA	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.03	0.37	4.22e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9462027	0.628	rs9469887	chr6:34758940	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.99	-0.3	6.33e-15	Systemic lupus erythematosus;
BRCA	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.31	-0.35	2.07e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg11266682	chr4:10021025	SLC2A9	0.48	12.56	0.44	1.71e-32	Bone mineral density;
BRCA	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg16482183	chr6:26056742	HIST1H1C	0.53	11.49	0.41	6.29e-28	Height;
BRCA	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.7	15.23	0.52	6.47e-45	HIV-1 control;
BRCA	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg25174290	chr11:3078921	CARS	0.45	13.71	0.48	1.08e-37	Longevity;
BRCA	trans	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg06521331	chr12:34319734	NA	-0.47	-8.77	-0.33	1.59e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs11585357	0.947	rs11585118	chr1:17605774	C/A	cg19159961	chr1:17633534	PADI4	0.57	8.9	0.33	5.53e-18	Hair shape;
BRCA	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.97	-0.3	7.41e-15	Depression;
BRCA	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg20933634	chr6:27740509	NA	0.44	8.34	0.31	4.63e-16	Parkinson's disease;
BRCA	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg23505145	chr19:12996616	KLF1	0.54	12.39	0.44	9.54e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg20891558	chr2:74357851	NA	0.53	12.34	0.44	1.61e-31	Gestational age at birth (maternal effect);
BRCA	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg12140854	chr5:148520817	ABLIM3	-0.45	-9.39	-0.35	1.07e-19	Breast cancer;
BRCA	cis	rs78761021	0.720	rs874174	chr17:9798619	C/T	cg26853458	chr17:9805074	RCVRN	-0.44	-8.88	-0.33	6.52e-18	Type 2 diabetes;
BRCA	cis	rs6942756	0.876	rs1559486	chr7:129015894	C/T	cg02491457	chr7:128862824	NA	-0.6	-12.43	-0.44	6.14e-32	White matter hyperintensity burden;
BRCA	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg11833968	chr6:79620685	NA	-0.42	-9.37	-0.35	1.24e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11890956	chr21:40555474	PSMG1	-0.61	-13.71	-0.48	1.1e-37	Menarche (age at onset);
BRCA	cis	rs16976116	0.851	rs28393427	chr15:55490981	A/G	cg11288833	chr15:55489084	RSL24D1	0.47	10.61	0.39	2.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg11833968	chr6:79620685	NA	-0.43	-9.58	-0.35	2.18e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg00086871	chr4:6988644	TBC1D14	0.77	11.86	0.42	1.9e-29	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6028335	0.674	rs66647661	chr20:37671577	C/T	cg16355469	chr20:37678765	NA	0.51	9.08	0.34	1.37e-18	Alcohol and nicotine co-dependence;
BRCA	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg12365402	chr11:9010492	NRIP3	-0.37	-8.44	-0.32	2.14e-16	Hemoglobin concentration;
BRCA	cis	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.33	-0.31	5.04e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.51	0.55	2.86e-51	Alzheimer's disease (late onset);
BRCA	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg17372223	chr3:52568218	NT5DC2	0.34	7.91	0.3	1.11e-14	Electroencephalogram traits;
BRCA	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg00383909	chr3:49044727	WDR6	0.6	10.99	0.4	7.27e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7249921	0.833	rs1046294	chr19:35660546	T/C	cg15419183	chr19:35660584	FXYD5	0.45	10.15	0.37	1.46e-22	Platelet count;
BRCA	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-9.64	-0.36	1.26e-20	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg03060546	chr3:49711283	APEH	-0.57	-7.88	-0.3	1.41e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs4766646	0.619	rs4766639	chr12:110298925	A/G	cg01252219	chr12:110302105	GLTP	0.36	8.11	0.31	2.6e-15	Metabolite levels (MHPG);
BRCA	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.46	9.98	0.37	6.74e-22	Cognitive ability;
BRCA	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg24296786	chr1:45957014	TESK2	-0.52	-12.02	-0.43	3.96e-30	High light scatter reticulocyte count;
BRCA	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg03954927	chr1:10346856	KIF1B	0.44	12.42	0.44	7.37e-32	Hepatocellular carcinoma;
BRCA	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg23708337	chr7:1209742	NA	0.64	8.74	0.33	2.05e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg00530320	chr1:46809349	NSUN4	-0.47	-9.6	-0.35	1.84e-20	Menopause (age at onset);
BRCA	cis	rs7520050	0.966	rs1085244	chr1:46563680	C/A	cg24296786	chr1:45957014	TESK2	0.43	9.71	0.36	6.81e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7572733	0.534	rs10211202	chr2:198771941	A/G	cg00792783	chr2:198669748	PLCL1	0.48	10.36	0.38	2.27e-23	Dermatomyositis;
BRCA	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg08807101	chr21:30365312	RNF160	0.4	8.53	0.32	1.08e-16	Pancreatic cancer;
BRCA	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.6	-0.32	5.96e-17	Total body bone mineral density;
BRCA	cis	rs9427116	0.502	rs9427100	chr1:154583762	G/A	cg17218026	chr1:154582156	ADAR	0.28	8.36	0.31	4.03e-16	Blood protein levels;
BRCA	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg15704280	chr7:45808275	SEPT13	0.65	11.44	0.41	1.06e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg09877947	chr5:131593287	PDLIM4	0.36	7.81	0.3	2.32e-14	Breast cancer;
BRCA	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg13256891	chr4:100009986	ADH5	0.54	10.01	0.37	5.06e-22	Smoking initiation;
BRCA	cis	rs1113500	0.897	rs55980437	chr1:108639498	G/A	cg06207961	chr1:108661230	NA	0.45	10.95	0.4	1.11e-25	Growth-regulated protein alpha levels;
BRCA	cis	rs7975161	0.938	rs10400561	chr12:104640920	A/G	cg25273343	chr12:104657179	TXNRD1	-0.54	-11.36	-0.41	2.25e-27	Toenail selenium levels;
BRCA	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg08917208	chr2:24149416	ATAD2B	0.87	12.44	0.44	5.65e-32	Lymphocyte counts;
BRCA	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.17	0.31	1.61e-15	Tonsillectomy;
BRCA	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-14.17	-0.49	8.17e-40	Chronic sinus infection;
BRCA	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11890956	chr21:40555474	PSMG1	1.05	30.23	0.77	2.39e-125	Cognitive function;
BRCA	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg20573242	chr4:122745356	CCNA2	0.46	10.24	0.38	7.15e-23	Type 2 diabetes;
BRCA	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg04013093	chr6:42928303	GNMT	0.28	8.9	0.33	5.53e-18	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9790314	0.905	rs7632797	chr3:161002694	C/T	cg03342759	chr3:160939853	NMD3	0.65	14.31	0.49	1.73e-40	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg21747090	chr2:27597821	SNX17	-0.41	-8.86	-0.33	7.64e-18	Total body bone mineral density;
BRCA	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg09904177	chr6:26538194	HMGN4	0.55	17.62	0.57	6.29e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs9487051	0.735	rs459956	chr6:109524760	A/G	cg21918786	chr6:109611834	NA	-0.34	-9.12	-0.34	9.73e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-10.68	-0.39	1.28e-24	Blood metabolite levels;
BRCA	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg03146154	chr1:46216737	IPP	-0.51	-11.29	-0.41	4.29e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.01	-0.48	4.52e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg04117972	chr1:227635322	NA	0.49	8.91	0.33	5.22e-18	Major depressive disorder;
BRCA	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg23285459	chr7:2802560	GNA12	-0.34	-8.67	-0.32	3.57e-17	Height;
BRCA	cis	rs700651	0.821	rs771005	chr2:198675948	C/T	cg00792783	chr2:198669748	PLCL1	0.47	10.22	0.37	8.54e-23	Intracranial aneurysm;
BRCA	cis	rs201673768	1	rs201673768	chr12:48699606	TGTTTTGTTTTG/T	cg24011408	chr12:48396354	COL2A1	0.43	8.65	0.32	4.24e-17	Platelet count;
BRCA	cis	rs4237845	0.611	rs7298370	chr12:58318897	C/T	cg02175503	chr12:58329896	NA	0.77	18.75	0.6	7.52e-63	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.720	rs1611754	chr1:152956415	A/T	cg21543102	chr1:152974771	SPRR3	-0.3	-8.65	-0.32	4.25e-17	Inflammatory skin disease;
BRCA	cis	rs7756236	0.521	rs6930671	chr6:36625272	T/C	cg08179530	chr6:36648295	CDKN1A	0.38	8.19	0.31	1.47e-15	QRS duration;
BRCA	cis	rs6580649	0.941	rs72644847	chr12:48516093	C/A	cg05342945	chr12:48394962	COL2A1	0.44	8.34	0.31	4.73e-16	Lung cancer;
BRCA	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.35	-8.77	-0.33	1.64e-17	Total body bone mineral density;
BRCA	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.96	-0.46	2.7200000000000002e-34	Migraine;Coronary artery disease;
BRCA	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg04518342	chr5:131593106	PDLIM4	0.35	8.99	0.34	2.75e-18	Breast cancer;
BRCA	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg25208724	chr1:156163844	SLC25A44	1.07	35.1	0.81	3.35e-151	Testicular germ cell tumor;
BRCA	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs7975161	0.882	rs4406890	chr12:104638773	A/C	cg25273343	chr12:104657179	TXNRD1	-0.49	-10.83	-0.39	3.23e-25	Toenail selenium levels;
BRCA	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.94	-0.37	9.36e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18876405	chr7:65276391	NA	-0.5	-11.04	-0.4	4.59e-26	Aortic root size;
BRCA	cis	rs7833986	0.501	rs17814658	chr8:56989130	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	13.18	0.46	3.04e-35	Height;
BRCA	cis	rs7188861	0.768	rs12922733	chr16:11380670	C/G	cg01510278	chr16:11456238	NA	0.42	8.27	0.31	7.61e-16	HDL cholesterol;
BRCA	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg15556689	chr8:8085844	FLJ10661	0.41	10.11	0.37	2.15e-22	Retinal vascular caliber;
BRCA	cis	rs12431939	1.000	rs7160729	chr14:51637241	C/T	cg23942311	chr14:51606299	NA	-0.42	-8.2	-0.31	1.27e-15	Cancer;
BRCA	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg00031303	chr3:195681400	NA	0.72	12.11	0.43	1.57e-30	Pancreatic cancer;
BRCA	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg08738300	chr3:44038990	NA	0.42	8.25	0.31	9.2e-16	Coronary artery disease;
BRCA	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg10978503	chr1:24200527	CNR2	0.48	12.76	0.45	2.31e-33	Immature fraction of reticulocytes;
BRCA	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	9.24	0.34	3.68e-19	Systemic lupus erythematosus;
BRCA	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg04455712	chr21:45112962	RRP1B	0.38	9.8	0.36	3.13e-21	Mean corpuscular volume;
BRCA	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg20283391	chr11:68216788	NA	-0.42	-8.28	-0.31	7.03e-16	Total body bone mineral density;
BRCA	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg06212747	chr3:49208901	KLHDC8B	0.47	9.46	0.35	5.57e-20	Parkinson's disease;
BRCA	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg17366294	chr4:99064904	C4orf37	0.46	10.78	0.39	5.16e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7939886	0.841	rs11231800	chr11:55770930	A/G	cg15704280	chr7:45808275	SEPT13	0.72	8.55	0.32	8.79e-17	Myopia (pathological);
BRCA	trans	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.3	-0.35	2.25e-19	Bladder cancer;
BRCA	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21582582	chr3:182698605	DCUN1D1	0.37	9.86	0.36	1.95e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg25214090	chr10:38739885	LOC399744	0.54	12.24	0.44	4.48e-31	Corneal astigmatism;
BRCA	cis	rs738321	0.757	rs6001020	chr22:38538246	C/G	cg20207973	chr22:38506712	BAIAP2L2	0.43	10.23	0.38	7.42e-23	Breast cancer;
BRCA	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.02	28.55	0.75	3.43e-116	Body mass index (adult);
BRCA	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg27661571	chr11:113659931	NA	-0.49	-8.68	-0.32	3.31e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs3936840	0.752	rs2181343	chr14:102993303	A/C	cg18135206	chr14:102964638	TECPR2	-0.52	-11.16	-0.4	1.54e-26	Plateletcrit;
BRCA	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg22535103	chr8:58192502	C8orf71	-0.6	-13.25	-0.46	1.4e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg22467129	chr15:76604101	ETFA	-0.49	-10.63	-0.39	2.11e-24	Blood metabolite levels;
BRCA	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg05623727	chr3:50126028	RBM5	0.49	11.79	0.42	3.54e-29	Body mass index;
BRCA	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.38	0.54	1.32e-50	Alzheimer's disease (late onset);
BRCA	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg11812906	chr14:75593930	NEK9	-0.7	-16.24	-0.54	6.29e-50	Height;
BRCA	cis	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg07460842	chr6:66804631	NA	0.61	10.47	0.38	8.69e-24	Type 2 diabetes;
BRCA	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg16586182	chr3:47516702	SCAP	0.56	12.87	0.45	7.33e-34	Colorectal cancer;
BRCA	cis	rs2430307	0.556	rs3930019	chr7:76541610	C/T	cg05843312	chr7:76586131	NA	0.48	8.32	0.31	5.13e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	trans	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg26384229	chr12:38710491	ALG10B	0.42	10.01	0.37	5.35e-22	Morning vs. evening chronotype;
BRCA	cis	rs858239	0.632	rs13438452	chr7:23174182	A/G	cg23682824	chr7:23144976	KLHL7	0.44	11.85	0.42	2.01e-29	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03517284	chr6:25882590	NA	0.48	10.84	0.39	3.09e-25	Blood metabolite levels;
BRCA	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg23033748	chr14:75592666	NEK9	0.4	9.79	0.36	3.45e-21	Height;
BRCA	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg03060546	chr3:49711283	APEH	0.49	10.39	0.38	1.76e-23	Resting heart rate;
BRCA	cis	rs10193935	0.901	rs6733464	chr2:42563597	A/G	cg27598129	chr2:42591480	NA	-0.91	-14.73	-0.5	1.78e-42	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9951602	0.512	rs8085719	chr18:76649111	A/G	cg02800362	chr5:177631904	HNRNPAB	0.77	18.06	0.58	3.43e-59	Obesity-related traits;
BRCA	cis	rs911186	0.812	rs35454259	chr6:27254475	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.34	-0.31	4.56e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg00666640	chr1:248458726	OR2T12	0.3	8.23	0.31	1.03e-15	Common traits (Other);
BRCA	trans	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg25214090	chr10:38739885	LOC399744	0.56	12.85	0.45	9.31e-34	Corneal astigmatism;
BRCA	trans	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg25214090	chr10:38739885	LOC399744	0.57	13.01	0.46	1.79e-34	Corneal astigmatism;
BRCA	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg04553112	chr3:125709451	NA	0.56	8.5	0.32	1.37e-16	Blood pressure (smoking interaction);
BRCA	cis	rs4853036	0.638	rs55723319	chr2:70118385	C/T	cg02498382	chr2:70120550	SNRNP27	-0.59	-8.72	-0.33	2.43e-17	Colorectal or endometrial cancer;
BRCA	cis	rs7523273	0.927	rs1891423	chr1:207931913	G/A	cg22525895	chr1:207977042	MIR29B2	0.47	11.2	0.4	1.08e-26	Schizophrenia;
BRCA	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.44	-8.43	-0.32	2.29e-16	Tonsillectomy;
BRCA	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg27170947	chr2:26402098	FAM59B	-0.66	-11.39	-0.41	1.75e-27	Gut microbiome composition (summer);
BRCA	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg25319279	chr11:5960081	NA	-0.4	-8.68	-0.32	3.36e-17	DNA methylation (variation);
BRCA	cis	rs1595825	0.891	rs16825188	chr2:198741134	G/C	cg19156104	chr2:198669113	PLCL1	-0.46	-8.25	-0.31	8.76e-16	Ulcerative colitis;
BRCA	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs6450176	1.000	rs4334836	chr5:53300835	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.62	-15.07	-0.51	3.83e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-18.07	-0.58	3e-59	Chronic sinus infection;
BRCA	cis	rs6987853	0.787	rs2974351	chr8:42407047	A/T	cg09913449	chr8:42400586	C8orf40	0.42	9.39	0.35	1.07e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27286337	chr10:134555280	INPP5A	0.63	11.17	0.4	1.42e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg18252515	chr7:66147081	NA	-0.89	-12.82	-0.45	1.17e-33	Diabetic kidney disease;
BRCA	trans	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	15.96	0.53	1.74e-48	Exhaled nitric oxide levels;
BRCA	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	8.6	0.32	6.24e-17	Platelet count;
BRCA	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg17971929	chr21:40555470	PSMG1	-0.62	-14.65	-0.5	3.97e-42	Cognitive function;
BRCA	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg04450456	chr4:17643702	FAM184B	0.35	9.83	0.36	2.48e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg11833968	chr6:79620685	NA	0.44	10.0	0.37	5.91e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg00576331	chr11:65640516	EFEMP2	0.42	9.48	0.35	4.85e-20	DNA methylation (variation);
BRCA	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.55	9.15	0.34	7.4e-19	Renal function-related traits (BUN);
BRCA	cis	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg14683738	chr19:37701593	ZNF585B	-0.45	-7.97	-0.3	7.48e-15	Coronary artery calcification;
BRCA	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg02376097	chr19:46275166	DMPK	0.45	10.08	0.37	2.72e-22	Coronary artery disease;
BRCA	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg08885076	chr2:99613938	TSGA10	0.45	10.46	0.38	9.19e-24	Chronic sinus infection;
BRCA	cis	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg14019146	chr3:50243930	SLC38A3	-0.68	-16.59	-0.55	1.11e-51	Intelligence (multi-trait analysis);
BRCA	cis	rs12618769	0.597	rs3769734	chr2:99096149	A/T	cg10123293	chr2:99228465	UNC50	0.42	8.18	0.31	1.53e-15	Bipolar disorder;
BRCA	cis	rs2882667	0.931	rs10044736	chr5:138320809	A/G	cg04439458	chr5:138467593	SIL1	0.34	9.38	0.35	1.16e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg19077165	chr18:44547161	KATNAL2	0.42	8.95	0.33	3.85e-18	Educational attainment;
BRCA	cis	rs11608355	0.515	rs3742018	chr12:109949134	C/T	cg05360138	chr12:110035743	NA	0.74	13.64	0.47	2.36e-37	Neuroticism;
BRCA	trans	rs9951602	0.512	rs7237214	chr18:76657394	C/G	cg02800362	chr5:177631904	HNRNPAB	0.78	17.72	0.57	1.79e-57	Obesity-related traits;
BRCA	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg12011299	chr4:100065546	ADH4	0.5	11.72	0.42	7.29e-29	Alcohol dependence;
BRCA	cis	rs9807989	0.507	rs6734762	chr2:103062926	C/T	cg03938978	chr2:103052716	IL18RAP	0.28	8.17	0.31	1.62e-15	Asthma;
BRCA	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18876405	chr7:65276391	NA	-0.63	-15.47	-0.52	4.35e-46	Aortic root size;
BRCA	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg24642439	chr20:33292090	TP53INP2	-0.43	-8.61	-0.32	5.56e-17	Height;
BRCA	cis	rs36051895	0.664	rs10117565	chr9:5094461	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-8.97	-0.33	3.16e-18	Pediatric autoimmune diseases;
BRCA	cis	rs7474896	0.515	rs2505233	chr10:38340265	C/T	cg25427524	chr10:38739819	LOC399744	-0.51	-9.68	-0.36	8.7e-21	Obesity (extreme);
BRCA	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg13319975	chr6:146136371	FBXO30	0.41	9.29	0.34	2.42e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-8.2	-0.31	1.35e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg20019365	chr2:219134978	PNKD;AAMP	0.52	11.78	0.42	4.16e-29	Colorectal cancer;
BRCA	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.78	-0.42	4.09e-29	Bipolar disorder;
BRCA	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-13.43	-0.47	2.23e-36	Bladder cancer;
BRCA	cis	rs7715806	0.500	rs58968428	chr5:75004107	A/G	cg19683494	chr5:74908142	NA	0.5	8.1	0.31	2.81e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11874712	0.931	rs8095031	chr18:43666861	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.18	0.31	1.57e-15	Migraine - clinic-based;
BRCA	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg04705435	chr11:17411270	KCNJ11	0.42	9.03	0.34	2.06e-18	Type 2 diabetes;
BRCA	cis	rs2505998	0.833	rs1864405	chr10:43604148	A/C	cg15436174	chr10:43711423	RASGEF1A	-0.43	-8.33	-0.31	4.83e-16	Hirschsprung disease;
BRCA	cis	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg07460842	chr6:66804631	NA	0.81	15.13	0.51	2.08e-44	Exhaled nitric oxide levels;
BRCA	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08219700	chr8:58056026	NA	0.57	9.56	0.35	2.56e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg11502198	chr6:26597334	ABT1	0.47	9.4	0.35	9.69e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6450176	1.000	rs6876198	chr5:53303595	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.65	-15.91	-0.53	2.82e-48	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs965469	0.762	rs6515783	chr20:3245006	T/C	cg25506879	chr20:3388711	C20orf194	-0.43	-8.68	-0.32	3.38e-17	IFN-related cytopenia;
BRCA	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg20203395	chr5:56204925	C5orf35	-0.49	-10.06	-0.37	3.27e-22	Initial pursuit acceleration;
BRCA	cis	rs1474256	0.630	rs79015977	chr15:79450147	G/A	cg17916960	chr15:79447300	NA	0.38	8.42	0.32	2.43e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs7512552	0.839	rs17596326	chr1:150433819	A/G	cg15654264	chr1:150340011	RPRD2	0.4	8.56	0.32	8.26e-17	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs17604090	1.000	rs28591682	chr7:29690811	T/C	cg19413766	chr7:29689036	LOC646762	-0.57	-7.83	-0.3	2.1e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	trans	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg25214090	chr10:38739885	LOC399744	0.5	11.02	0.4	5.85e-26	Corneal astigmatism;
BRCA	cis	rs4285028	0.948	rs1920290	chr3:121672305	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.82	-0.39	3.64e-25	Multiple sclerosis;
BRCA	cis	rs965469	1.000	rs6037562	chr20:3326141	A/C	cg25506879	chr20:3388711	C20orf194	-0.55	-10.7	-0.39	1.07e-24	IFN-related cytopenia;
BRCA	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs10267417	0.603	rs10224041	chr7:19903837	T/C	cg05791153	chr7:19748676	TWISTNB	0.47	9.1	0.34	1.13e-18	Night sleep phenotypes;
BRCA	cis	rs2880765	0.835	rs11856869	chr15:86029097	C/G	cg10818794	chr15:86012489	AKAP13	-0.31	-8.62	-0.32	5.2e-17	Coronary artery disease;
BRCA	cis	rs9400271	0.632	rs9398192	chr6:109587236	C/T	cg01475377	chr6:109611718	NA	-0.44	-10.49	-0.38	7.17e-24	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs7091068	0.518	rs4144098	chr10:95432600	C/T	cg20715218	chr10:95462985	C10orf4	0.48	10.3	0.38	4.04e-23	Urinary tract infection frequency;
BRCA	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg06484146	chr7:12443880	VWDE	-0.63	-8.62	-0.32	5.11e-17	Coronary artery disease;
BRCA	cis	rs72781680	0.716	rs2712061	chr2:24026411	G/A	cg08917208	chr2:24149416	ATAD2B	0.57	9.46	0.35	5.72e-20	Lymphocyte counts;
BRCA	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg10862848	chr6:42927986	GNMT	0.35	14.93	0.51	1.83e-43	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-9.88	-0.36	1.66e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6446731	0.593	rs7674472	chr4:3273538	C/G	cg08886695	chr4:3369023	RGS12	-0.38	-9.89	-0.36	1.49e-21	Mean platelet volume;
BRCA	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08645402	chr16:4508243	NA	0.45	10.16	0.37	1.41e-22	Schizophrenia;
BRCA	cis	rs11249608	0.636	rs6888539	chr5:178449010	T/A	cg21905437	chr5:178450457	ZNF879	0.51	10.7	0.39	1.12e-24	Pubertal anthropometrics;
BRCA	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.69	-0.53	3.49e-47	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs7523273	0.606	rs2724388	chr1:207933577	T/G	cg22525895	chr1:207977042	MIR29B2	0.47	12.07	0.43	2.39e-30	Schizophrenia;
BRCA	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg18196295	chr10:418757	DIP2C	-0.59	-13.79	-0.48	4.68e-38	Psychosis in Alzheimer's disease;
BRCA	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg05040210	chr1:18807594	KLHDC7A	-0.56	-13.51	-0.47	9.17e-37	Breast cancer;
BRCA	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg15208524	chr1:10270712	KIF1B	0.37	7.95	0.3	8.69e-15	Hepatocellular carcinoma;
BRCA	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg03709012	chr19:19516395	GATAD2A	-0.46	-9.03	-0.34	2e-18	Tonsillectomy;
BRCA	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg11502198	chr6:26597334	ABT1	0.56	12.0	0.43	4.68e-30	Intelligence (multi-trait analysis);
BRCA	trans	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.33	8.17	0.31	1.62e-15	Resting heart rate;
BRCA	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg23711669	chr6:146136114	FBXO30	0.74	17.75	0.57	1.27e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26168224	chr5:2018326	NA	0.63	18.24	0.59	3.85e-60	Gut microbiome composition (winter);
BRCA	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-11.11	-0.4	2.4e-26	Glomerular filtration rate (creatinine);
BRCA	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.57	-9.59	-0.35	1.91e-20	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs11608355	0.545	rs11615336	chr12:109914802	C/A	cg05360138	chr12:110035743	NA	0.71	13.05	0.46	1.09e-34	Neuroticism;
BRCA	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg18252515	chr7:66147081	NA	-0.88	-12.21	-0.43	5.75e-31	Diabetic kidney disease;
BRCA	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.67e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg08422745	chr4:174089978	GALNT7	-0.79	-16.5	-0.55	3.13e-51	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.25	8.12	0.31	2.41e-15	Cardiac Troponin-T levels;
BRCA	cis	rs250677	1.000	rs36079	chr5:148430504	G/A	cg12140854	chr5:148520817	ABLIM3	-0.4	-8.52	-0.32	1.18e-16	Breast cancer;
BRCA	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.66	10.4	0.38	1.6e-23	Schizophrenia;
BRCA	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg06640241	chr16:89574553	SPG7	0.84	21.15	0.64	1.14e-75	Multiple myeloma (IgH translocation);
BRCA	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-10.41	-0.38	1.45e-23	Blood metabolite levels;
BRCA	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg06917634	chr15:78832804	PSMA4	0.58	11.74	0.42	5.77e-29	Sudden cardiac arrest;
BRCA	cis	rs12618769	0.543	rs58778964	chr2:99110599	G/C	cg10123293	chr2:99228465	UNC50	0.42	8.37	0.31	3.7e-16	Bipolar disorder;
BRCA	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg07211511	chr3:129823064	LOC729375	-0.57	-10.48	-0.38	8.33e-24	Blood pressure (smoking interaction);
BRCA	cis	rs16910800	0.689	rs7128636	chr11:23164689	C/T	cg20040320	chr11:23191996	NA	-0.56	-9.28	-0.34	2.49e-19	Cancer;
BRCA	cis	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg06521331	chr12:34319734	NA	-0.5	-9.31	-0.35	1.94e-19	Resting heart rate;
BRCA	cis	rs312274	0.515	rs1928558	chr12:41253042	T/C	cg17827154	chr12:41323612	CNTN1	-0.41	-10.02	-0.37	4.83e-22	Metabolite levels  (X-11787);
BRCA	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg13256891	chr4:100009986	ADH5	0.49	10.3	0.38	3.9699999999999997e-23	Alcohol dependence;
BRCA	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg24812749	chr6:127587940	RNF146	0.62	13.6	0.47	3.34e-37	Breast cancer;
BRCA	cis	rs4285028	0.747	rs9850439	chr3:121393075	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-13.85	-0.48	2.53e-38	Multiple sclerosis;
BRCA	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-15.36	-0.52	1.46e-45	Bipolar disorder;
BRCA	trans	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	11.68	0.42	1.01e-28	Exhaled nitric oxide output;
BRCA	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.26e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg18016565	chr1:150552671	MCL1	0.34	8.04	0.3	4.38e-15	Tonsillectomy;
BRCA	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03264133	chr6:25882463	NA	0.49	10.96	0.4	1.01e-25	Blood metabolite levels;
BRCA	cis	rs10782582	0.609	rs10873797	chr1:76377191	G/T	cg03433033	chr1:76189801	ACADM	-0.39	-7.96	-0.3	8.16e-15	Daytime sleep phenotypes;
BRCA	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg12432903	chr7:1882776	MAD1L1	0.45	8.07	0.3	3.4e-15	Bipolar disorder;
BRCA	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg12386194	chr3:101231763	SENP7	0.46	9.67	0.36	9.52e-21	Colorectal cancer;
BRCA	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg22676075	chr6:135203613	NA	0.44	8.54	0.32	9.62e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs6714710	0.535	rs13033383	chr2:98339513	C/T	cg26665480	chr2:98280029	ACTR1B	0.62	13.78	0.48	5.07e-38	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs897080	0.515	rs698767	chr2:44576417	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.62	11.82	0.42	2.77e-29	Height;
BRCA	trans	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg25214090	chr10:38739885	LOC399744	0.45	10.29	0.38	4.57e-23	Corneal astigmatism;
BRCA	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg05665937	chr4:1216051	CTBP1	0.43	8.62	0.32	5.41e-17	Obesity-related traits;
BRCA	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg22974920	chr21:40686053	BRWD1	-0.38	-8.76	-0.33	1.73e-17	Cognitive function;
BRCA	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg06627628	chr2:24431161	ITSN2	-0.52	-10.38	-0.38	1.9e-23	Asthma;
BRCA	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.35	-0.44	1.36e-31	Bipolar disorder;
BRCA	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg11764359	chr7:65958608	NA	0.67	14.96	0.51	1.27e-43	Aortic root size;
BRCA	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-9.46	-0.35	5.8e-20	Tonsillectomy;
BRCA	cis	rs9308433	0.529	rs9430133	chr1:214496313	C/T	cg06198575	chr1:214491504	SMYD2	0.56	12.24	0.44	4.43e-31	IgG glycosylation;
BRCA	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18876405	chr7:65276391	NA	0.48	10.79	0.39	4.64e-25	Aortic root size;
BRCA	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg07080220	chr10:102295463	HIF1AN	0.51	11.68	0.42	1.02e-28	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	9.08	0.34	1.29e-18	Renal function-related traits (BUN);
BRCA	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-16.77	-0.55	1.37e-52	Colorectal cancer;
BRCA	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg17366294	chr4:99064904	C4orf37	0.45	10.76	0.39	6.24e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs360798	0.532	rs360799	chr2:62953166	G/A	cg17519650	chr2:63277830	OTX1	-0.36	-7.87	-0.3	1.52e-14	Coronary artery disease;
BRCA	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.65	-0.32	4.19e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg00666640	chr1:248458726	OR2T12	0.32	8.61	0.32	5.63e-17	Common traits (Other);
BRCA	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg21747090	chr2:27597821	SNX17	-0.45	-9.65	-0.36	1.2e-20	Menopause (age at onset);
BRCA	cis	rs77972916	0.611	rs61552842	chr2:43584036	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-10.13	-0.37	1.8e-22	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9682041	0.627	rs11924474	chr3:170091333	T/G	cg11886554	chr3:170076028	SKIL	0.49	9.93	0.37	1e-21	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg23096020	chr7:158799433	NA	-0.37	-8.76	-0.33	1.69e-17	Facial morphology (factor 20);
BRCA	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg04414720	chr1:150670196	GOLPH3L	0.36	8.12	0.31	2.4e-15	Tonsillectomy;
BRCA	cis	rs6545883	0.965	rs766447	chr2:61735569	C/T	cg15711740	chr2:61764176	XPO1	-0.55	-14.12	-0.49	1.34e-39	Tuberculosis;
BRCA	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg18200150	chr17:30822561	MYO1D	0.35	8.91	0.33	5.17e-18	Schizophrenia;
BRCA	trans	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg25214090	chr10:38739885	LOC399744	0.57	13.01	0.46	1.79e-34	Corneal astigmatism;
BRCA	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg01802117	chr1:53393560	SCP2	0.4	8.6	0.32	6e-17	Monocyte count;
BRCA	cis	rs1829883	0.739	rs2461969	chr5:98728440	G/A	cg08333243	chr5:99726346	NA	0.34	8.45	0.32	1.98e-16	Hemostatic factors and hematological phenotypes;
BRCA	trans	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-8.57	-0.32	7.75e-17	Monocyte count;
BRCA	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg07952391	chr2:88470173	THNSL2	0.58	8.19	0.31	1.41e-15	Plasma clusterin levels;
BRCA	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18876405	chr7:65276391	NA	-0.49	-11.0	-0.4	6.88e-26	Aortic root size;
BRCA	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.05	-19.05	-0.6	1.99e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg04586622	chr2:25135609	ADCY3	0.39	9.54	0.35	3.04e-20	Body mass index in non-asthmatics;
BRCA	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg27170947	chr2:26402098	FAM59B	-0.66	-11.32	-0.41	3.45e-27	Gut microbiome composition (summer);
BRCA	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg13010199	chr12:38710504	ALG10B	0.42	9.01	0.34	2.3e-18	Morning vs. evening chronotype;
BRCA	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	8.72	0.33	2.37e-17	Height;
BRCA	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg11812906	chr14:75593930	NEK9	0.65	15.01	0.51	7.86e-44	Height;
BRCA	cis	rs9462027	0.628	rs9462020	chr6:34751265	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.99	-0.3	6.33e-15	Systemic lupus erythematosus;
BRCA	cis	rs11984145	1.000	rs79643038	chr7:38880129	T/A	cg19327137	chr7:38886074	VPS41	0.5	8.65	0.32	4.09e-17	Cognitive performance;
BRCA	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg26248373	chr2:1572462	NA	-0.5	-9.76	-0.36	4.55e-21	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg10223061	chr2:219282414	VIL1	0.29	8.39	0.32	3.07e-16	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg06064525	chr11:970664	AP2A2	-0.49	-16.18	-0.54	1.25e-49	Alzheimer's disease (late onset);
BRCA	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg03188948	chr7:1209495	NA	0.75	10.95	0.4	1.07e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg26384229	chr12:38710491	ALG10B	0.67	13.91	0.48	1.34e-38	Morning vs. evening chronotype;
BRCA	cis	rs10789491	1.000	rs1371834	chr1:47176894	G/A	cg15501359	chr1:47185051	KIAA0494	0.66	18.26	0.59	3.04e-60	Response to hepatitis C treatment;
BRCA	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg21573476	chr21:45109991	RRP1B	0.44	12.01	0.43	4.15e-30	Mean corpuscular volume;
BRCA	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg06092702	chr1:163392909	NA	-0.33	-8.87	-0.33	7.5e-18	Motion sickness;
BRCA	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.67	0.5	3.17e-42	Personality dimensions;
BRCA	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg07917127	chr4:99064746	C4orf37	0.44	8.16	0.31	1.84e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg08888203	chr3:10149979	C3orf24	0.68	14.18	0.49	7.04e-40	Alzheimer's disease;
BRCA	cis	rs495337	0.760	rs2254930	chr20:48527107	T/A	cg17835207	chr20:48524531	SPATA2	-0.68	-16.81	-0.55	9.28e-53	Psoriasis;
BRCA	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg00277334	chr10:82204260	NA	-0.49	-10.27	-0.38	5.4e-23	Post bronchodilator FEV1;
BRCA	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08109568	chr15:31115862	NA	0.42	10.18	0.37	1.19e-22	Huntington's disease progression;
BRCA	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.64	-0.32	4.44e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs953387	0.910	rs13415439	chr2:136930232	C/A	cg05194412	chr2:137003533	NA	-0.35	-8.01	-0.3	5.37e-15	Arthritis (juvenile idiopathic);
BRCA	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	14.78	0.5	9.71e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg06115741	chr20:33292138	TP53INP2	0.51	11.3	0.41	3.92e-27	Coronary artery disease;
BRCA	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12379764	chr21:47803548	PCNT	-0.41	-8.54	-0.32	9.84e-17	Testicular germ cell tumor;
BRCA	cis	rs7903847	0.692	rs7900255	chr10:99157575	G/A	cg20016023	chr10:99160130	RRP12	-0.26	-8.43	-0.32	2.25e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-17.83	-0.58	5.39e-58	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.15	-0.34	7.38e-19	Menopause (age at onset);
BRCA	cis	rs34779708	0.931	rs4934709	chr10:35339324	A/C	cg03585969	chr10:35415529	CREM	-0.47	-9.84	-0.36	2.19e-21	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg16339924	chr4:17578868	LAP3	0.66	16.9	0.56	3.1e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg14036092	chr11:66035641	RAB1B	0.39	10.23	0.38	7.55e-23	Gout;
BRCA	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	19.75	0.62	3.8e-68	Smoking behavior;
BRCA	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg04756594	chr16:24857601	SLC5A11	0.5	11.61	0.42	2.12e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6977660	0.652	rs10249291	chr7:19844448	C/G	cg05791153	chr7:19748676	TWISTNB	0.77	12.98	0.46	2.22e-34	Thyroid stimulating hormone;
BRCA	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08280861	chr8:58055591	NA	0.56	9.1	0.34	1.17e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg17971929	chr21:40555470	PSMG1	-0.47	-10.51	-0.38	6.25e-24	Menarche (age at onset);
BRCA	trans	rs783540	0.656	rs783538	chr15:83253143	C/G	cg16105309	chr15:79090380	ADAMTS7	0.33	9.14	0.34	8.11e-19	Schizophrenia;
BRCA	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg21782813	chr7:2030301	MAD1L1	0.33	9.29	0.35	2.31e-19	Schizophrenia;
BRCA	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg15448220	chr1:150897856	SETDB1	0.35	7.94	0.3	9.2e-15	Melanoma;
BRCA	cis	rs1568889	0.838	rs10458896	chr11:28057957	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	20.22	0.62	1.19e-70	Bipolar disorder;
BRCA	cis	rs10489202	0.608	rs7533646	chr1:168077593	A/C	cg24449463	chr1:168025552	DCAF6	-0.47	-14.7	-0.5	2.37e-42	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs9395066	0.620	rs227831	chr6:44680808	A/G	cg25276700	chr6:44698697	NA	0.39	8.27	0.31	7.68e-16	Height;
BRCA	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg21798802	chr22:38057573	PDXP	0.3	8.2	0.31	1.35e-15	Fat distribution (HIV);
BRCA	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg14784868	chr12:69753453	YEATS4	0.37	8.96	0.33	3.45e-18	Blood protein levels;
BRCA	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.52	9.91	0.36	1.25e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs17641971	0.645	rs4873099	chr8:50025683	G/T	cg00325661	chr8:49890786	NA	0.35	9.89	0.36	1.45e-21	Blood metabolite levels;
BRCA	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg24692254	chr21:30365293	RNF160	0.63	13.89	0.48	1.56e-38	Selective IgA deficiency;
BRCA	cis	rs6060717	0.529	rs6060535	chr20:34235522	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.0	-0.34	2.49e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs7523050	0.643	rs12752417	chr1:109400639	A/C	cg08274380	chr1:109419600	GPSM2	-0.97	-12.89	-0.45	5.72e-34	Fat distribution (HIV);
BRCA	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg23711669	chr6:146136114	FBXO30	0.78	18.79	0.6	4.89e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-16.21	-0.54	9.22e-50	Extrinsic epigenetic age acceleration;
BRCA	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg17143192	chr8:8559678	CLDN23	0.54	10.72	0.39	8.93e-25	Obesity-related traits;
BRCA	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg14728415	chr7:32535168	LSM5;AVL9	0.4	8.92	0.33	4.75e-18	Cognitive ability;
BRCA	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	8.39	0.31	3.18e-16	Schizophrenia;
BRCA	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg23229984	chr5:148520753	ABLIM3	0.36	8.74	0.33	2.06e-17	Breast cancer;
BRCA	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg13010199	chr12:38710504	ALG10B	0.43	9.16	0.34	6.77e-19	Morning vs. evening chronotype;
BRCA	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15541040	chr2:3486749	NA	-0.46	-10.11	-0.37	2.2e-22	Neurofibrillary tangles;
BRCA	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg04691961	chr3:161091175	C3orf57	-0.52	-12.87	-0.45	6.99e-34	Morning vs. evening chronotype;
BRCA	cis	rs16867321	0.853	rs73023563	chr2:181502830	C/T	cg23363182	chr2:181467187	NA	-0.44	-8.26	-0.31	8.11e-16	Obesity;
BRCA	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg01475377	chr6:109611718	NA	0.59	16.4	0.54	1.1e-50	Reticulocyte fraction of red cells;
BRCA	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg06784218	chr1:46089804	CCDC17	-0.53	-12.8	-0.45	1.42e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg18230493	chr5:56204884	C5orf35	-0.74	-14.85	-0.51	4.45e-43	Initial pursuit acceleration;
BRCA	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg25237894	chr2:233734115	C2orf82	-0.41	-11.81	-0.42	3.12e-29	Coronary artery disease;
BRCA	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg09035930	chr12:129282057	SLC15A4	0.58	17.51	0.57	2.2e-56	Systemic lupus erythematosus;
BRCA	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg23711669	chr6:146136114	FBXO30	-0.77	-17.44	-0.57	5.43e-56	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs1011018	0.628	rs6967634	chr7:139448455	C/T	cg03224163	chr7:139420300	HIPK2	-0.6	-9.01	-0.34	2.35e-18	Systolic blood pressure;
BRCA	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24549020	chr5:56110836	MAP3K1	0.65	13.24	0.46	1.51e-35	Initial pursuit acceleration;
BRCA	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.64	0.55	6.17e-52	Colorectal cancer;
BRCA	cis	rs4363385	0.747	rs4845509	chr1:152981900	T/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.13	-0.34	9.03e-19	Inflammatory skin disease;
BRCA	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.7	-0.42	8.74e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03517284	chr6:25882590	NA	0.69	16.02	0.54	8.07e-49	Blood metabolite levels;
BRCA	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs10242455	0.571	rs11734	chr7:99229768	C/G	cg18809830	chr7:99032528	PTCD1	0.58	8.46	0.32	1.84e-16	Blood metabolite levels;
BRCA	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.29	-0.34	2.43e-19	Alzheimer's disease (late onset);
BRCA	cis	rs1863824	0.625	rs11202023	chr10:88165453	C/T	cg07322936	chr10:88137208	NA	-0.47	-9.41	-0.35	8.52e-20	Schizophrenia;
BRCA	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg00651523	chr6:28411279	ZSCAN23	-0.36	-7.81	-0.3	2.28e-14	Pubertal anthropometrics;
BRCA	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.33	-9.26	-0.34	3.03e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs28374715	0.532	rs28477406	chr15:41642036	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.07	-23.57	-0.68	7.36e-89	Ulcerative colitis;
BRCA	trans	rs1941687	0.527	rs6507059	chr18:31303643	A/G	cg15819921	chr19:927150	ARID3A	-0.44	-8.32	-0.31	5.43e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	trans	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg23762105	chr12:34175262	ALG10	-0.4	-9.73	-0.36	5.98e-21	Morning vs. evening chronotype;
BRCA	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg04004882	chr2:215674386	BARD1	0.67	12.46	0.44	4.77e-32	Neuroblastoma;
BRCA	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg13010199	chr12:38710504	ALG10B	0.45	9.47	0.35	5.17e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg23711669	chr6:146136114	FBXO30	0.67	15.74	0.53	2.07e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg18446336	chr7:2847575	GNA12	0.34	8.03	0.3	4.64e-15	Height;
BRCA	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-11.93	-0.43	9.38e-30	Morning vs. evening chronotype;
BRCA	cis	rs11601602	0.576	rs12576396	chr11:28555952	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	9.39	0.35	1e-19	Obesity-related traits;
BRCA	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.84	0.36	2.26e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05901451	chr6:126070800	HEY2	0.4	9.72	0.36	6.35e-21	Endometrial cancer;
BRCA	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg15662616	chr7:148823355	ZNF425;ZNF398	-0.41	-9.16	-0.34	6.79e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.47	-0.32	1.73e-16	Total body bone mineral density;
BRCA	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg15395560	chr15:45543142	SLC28A2	0.29	8.17	0.31	1.67e-15	Uric acid levels;
BRCA	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.58	13.44	0.47	1.88e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.48	8.51	0.32	1.21e-16	Body mass index (adult);
BRCA	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	0.39	8.36	0.31	3.95e-16	Alzheimer's disease (late onset);
BRCA	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.65e-15	Prostate cancer;
BRCA	cis	rs10484885	0.793	rs1465954	chr6:90475013	G/A	cg13799429	chr6:90582589	CASP8AP2	0.71	11.03	0.4	5.34e-26	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg26408565	chr15:76604113	ETFA	-0.41	-8.76	-0.33	1.77e-17	Blood metabolite levels;
BRCA	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12667521	chr19:29218732	NA	0.47	8.75	0.33	1.93e-17	Methadone dose in opioid dependence;
BRCA	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.18	-0.31	1.57e-15	Depression;
BRCA	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg01483505	chr11:975446	AP2A2	0.34	9.11	0.34	1.05e-18	Alzheimer's disease (late onset);
BRCA	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg21535247	chr6:8435926	SLC35B3	0.42	9.64	0.36	1.24e-20	Motion sickness;
BRCA	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg20587970	chr11:113659929	NA	0.91	13.51	0.47	9.08e-37	Hip circumference adjusted for BMI;
BRCA	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-19.25	-0.61	1.69e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg11833968	chr6:79620685	NA	-0.45	-10.1	-0.37	2.37e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg05082376	chr22:42548792	NA	-0.31	-7.85	-0.3	1.71e-14	Cognitive function;
BRCA	cis	rs36051895	0.623	rs10975023	chr9:5239549	A/G	cg02405213	chr9:5042618	JAK2	0.46	8.44	0.32	2.06e-16	Pediatric autoimmune diseases;
BRCA	cis	rs6546550	0.901	rs897120	chr2:70160982	C/T	cg02498382	chr2:70120550	SNRNP27	0.49	10.72	0.39	8.9e-25	Prevalent atrial fibrillation;
BRCA	cis	rs4363385	0.747	rs1577963	chr1:152961882	T/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.3	-0.35	2.14e-19	Inflammatory skin disease;
BRCA	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg21535247	chr6:8435926	SLC35B3	0.42	9.49	0.35	4.51e-20	Motion sickness;
BRCA	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg07817648	chr10:79422355	NA	0.7	12.83	0.45	1.04e-33	Bone mineral density;
BRCA	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg06238570	chr21:40685208	BRWD1	-0.43	-8.5	-0.32	1.33e-16	Cognitive function;
BRCA	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg05313129	chr8:58192883	C8orf71	-0.48	-9.84	-0.36	2.23e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.39	-9.23	-0.34	3.95e-19	Tonsillectomy;
BRCA	trans	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg26043149	chr18:55253948	FECH	0.39	8.38	0.31	3.34e-16	Bone mineral density;
BRCA	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg06623918	chr6:96969491	KIAA0776	0.89	25.79	0.71	4.53e-101	Headache;
BRCA	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg05347473	chr6:146136440	FBXO30	0.39	8.0	0.3	5.85e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs312274	0.569	rs11178878	chr12:41273551	C/T	cg17827154	chr12:41323612	CNTN1	0.36	8.98	0.33	3.02e-18	Metabolite levels  (X-11787);
BRCA	cis	rs2882667	0.931	rs10070021	chr5:138324706	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-9.11	-0.34	1.03e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7301826	0.651	rs10773825	chr12:131298913	G/A	cg11011512	chr12:131303247	STX2	0.51	13.57	0.47	4.71e-37	Plasma plasminogen activator levels;
BRCA	cis	rs28374715	0.662	rs522063	chr15:41476209	A/G	cg18705301	chr15:41695430	NDUFAF1	0.79	17.01	0.56	8.18e-54	Ulcerative colitis;
BRCA	cis	rs1371614	0.545	rs3769137	chr2:27169490	C/T	cg00617064	chr2:27272375	NA	0.31	8.03	0.3	4.65e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs9447004	0.584	rs56093139	chr6:74432923	C/T	cg03006477	chr6:74432658	CD109	0.33	9.24	0.34	3.55e-19	Blood protein levels;Calcium levels;
BRCA	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.55	8.15	0.31	1.92e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.6	-0.67	1.57e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg10932868	chr11:921992	NA	0.49	12.59	0.45	1.21e-32	Alzheimer's disease (late onset);
BRCA	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg11752832	chr7:134001865	SLC35B4	-0.43	-9.53	-0.35	3.1e-20	Mean platelet volume;
BRCA	cis	rs6580649	1.000	rs3825404	chr12:48399931	A/G	cg05342945	chr12:48394962	COL2A1	-0.46	-9.29	-0.34	2.47e-19	Lung cancer;
BRCA	cis	rs7512552	0.809	rs2794679	chr1:150324857	G/A	cg15654264	chr1:150340011	RPRD2	0.38	8.4	0.32	2.81e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs55882075	0.690	rs12374485	chr5:179131395	G/C	cg14593053	chr5:179126677	CANX	0.48	12.65	0.45	7.01e-33	Monocyte percentage of white cells;
BRCA	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-11.43	-0.41	1.15e-27	Putamen volume;
BRCA	cis	rs6714710	0.603	rs12988571	chr2:98405695	C/T	cg26665480	chr2:98280029	ACTR1B	0.59	13.44	0.47	1.83e-36	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg15017067	chr4:17643749	FAM184B	0.34	10.55	0.39	4.43e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg11752832	chr7:134001865	SLC35B4	0.53	13.75	0.48	7.37e-38	Mean platelet volume;
BRCA	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.83	-0.3	1.98e-14	Aortic root size;
BRCA	cis	rs412050	0.502	rs17759796	chr22:22190163	A/C	cg17089214	chr22:22089827	YPEL1	-0.55	-7.91	-0.3	1.14e-14	Attention deficit hyperactivity disorder;
BRCA	cis	rs6910061	1.000	rs73445479	chr6:11114770	T/C	cg27233058	chr6:11094804	LOC221710	0.53	9.43	0.35	7.64e-20	Diabetic kidney disease;
BRCA	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg22920501	chr2:26401640	FAM59B	-0.9	-16.59	-0.55	1.12e-51	Gut microbiome composition (summer);
BRCA	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg00012203	chr2:219082015	ARPC2	-0.52	-10.53	-0.38	5.23e-24	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs2481665	0.806	rs55725347	chr1:62538252	G/A	cg18591186	chr1:62594603	INADL	-0.57	-12.2	-0.43	6.21e-31	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs13046373	0.535	rs2832957	chr21:31973140	C/T	cg16431978	chr21:31797932	KRTAP13-3	0.36	9.16	0.34	6.97e-19	HDL cholesterol;
BRCA	cis	rs6450176	0.909	rs1541681	chr5:53304620	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.61	-14.78	-0.5	9.62e-43	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs7561273	0.586	rs11900665	chr2:24298198	T/C	cg04809136	chr2:24300158	SF3B14	-0.4	-9.27	-0.34	2.74e-19	Quantitative traits;
BRCA	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg12072164	chr19:44306565	LYPD5	0.36	8.75	0.33	1.97e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs943466	0.513	rs755497	chr6:33734419	C/T	cg25922239	chr6:33757077	LEMD2	-0.33	-8.11	-0.31	2.62e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.65	10.59	0.39	2.9e-24	Renal function-related traits (BUN);
BRCA	cis	rs4908760	0.868	rs12131864	chr1:8591162	A/G	cg20416874	chr1:8611966	RERE	-0.29	-8.2	-0.31	1.28e-15	Vitiligo;
BRCA	cis	rs6942756	0.774	rs2566876	chr7:128890055	A/G	cg02491457	chr7:128862824	NA	0.58	12.53	0.44	2.36e-32	White matter hyperintensity burden;
BRCA	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.79	18.93	0.6	8.87e-64	Multiple sclerosis;
BRCA	cis	rs9394841	0.646	rs9369313	chr6:41847065	C/T	cg08135965	chr6:41755394	TOMM6	0.51	8.29	0.31	6.88e-16	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg26384229	chr12:38710491	ALG10B	-0.51	-12.16	-0.43	9.48e-31	Morning vs. evening chronotype;
BRCA	cis	rs738322	0.577	rs4820320	chr22:38572977	G/A	cg25457927	chr22:38595422	NA	-0.25	-8.68	-0.32	3.41e-17	Cutaneous nevi;
BRCA	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-11.43	-0.41	1.15e-27	Bone mineral density;
BRCA	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	9.91	0.37	1.23e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14829155	chr15:31115871	NA	-0.43	-9.97	-0.37	7.15e-22	Huntington's disease progression;
BRCA	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.54	-0.32	9.58e-17	Glomerular filtration rate (creatinine);
BRCA	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-9.22	-0.34	4.3e-19	Neuroticism;
BRCA	cis	rs6545883	0.894	rs7566035	chr2:61520815	C/T	cg15711740	chr2:61764176	XPO1	0.5	12.24	0.44	4.38e-31	Tuberculosis;
BRCA	cis	rs10838687	0.736	rs4647725	chr11:47245389	T/C	cg25783544	chr11:47291846	MADD	0.43	7.86	0.3	1.63e-14	Proinsulin levels;
BRCA	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg21095983	chr6:86352623	SYNCRIP	0.42	9.51	0.35	3.75e-20	Smooth-surface caries;
BRCA	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	19.46	0.61	1.38e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg13256891	chr4:100009986	ADH5	0.54	10.01	0.37	5.06e-22	Smoking initiation;
BRCA	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg01483505	chr11:975446	AP2A2	0.34	9.22	0.34	4.38e-19	Alzheimer's disease (late onset);
BRCA	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg06212747	chr3:49208901	KLHDC8B	0.46	9.35	0.35	1.48e-19	Parkinson's disease;
BRCA	cis	rs6901250	0.807	rs339303	chr6:117176691	C/T	cg12892004	chr6:117198278	RFX6	-0.5	-11.41	-0.41	1.44e-27	C-reactive protein levels;
BRCA	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg01028140	chr2:1542097	TPO	-0.69	-13.84	-0.48	2.68e-38	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4409675	0.576	rs6700473	chr1:28236682	C/T	cg23691781	chr1:28212827	C1orf38	0.33	9.98	0.37	6.92e-22	Corneal astigmatism;
BRCA	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg11168104	chr5:1857477	NA	-0.33	-8.78	-0.33	1.45e-17	Cardiovascular disease risk factors;
BRCA	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg08798685	chr6:27730294	NA	-0.72	-8.91	-0.33	5.23e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg23649088	chr2:200775458	C2orf69	-0.53	-8.69	-0.33	3.04e-17	Schizophrenia;
BRCA	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.91	-0.3	1.14e-14	Aortic root size;
BRCA	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg19336497	chr11:14380999	RRAS2	-0.46	-11.54	-0.42	4.11e-28	Sense of smell;
BRCA	cis	rs78487399	0.808	rs6705351	chr2:43843137	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-8.16	-0.31	1.74e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.55	8.27	0.31	7.9e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.81	-0.3	2.42e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9649213	0.533	rs1541409	chr7:98027580	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.59	-15.82	-0.53	7.81e-48	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs367615	0.918	rs17161889	chr5:108855251	A/G	cg17395555	chr5:108820864	NA	-0.37	-9.99	-0.37	6.39e-22	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg26384229	chr12:38710491	ALG10B	-0.44	-10.4	-0.38	1.62e-23	Bladder cancer;
BRCA	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg27279351	chr12:120934652	DYNLL1	0.57	13.34	0.47	5.7e-36	High light scatter reticulocyte count;
BRCA	cis	rs9469578	1.000	rs73743328	chr6:33713550	G/A	cg18708504	chr6:33715942	IP6K3	0.7	10.18	0.37	1.12e-22	Phosphorus levels;
BRCA	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg14675211	chr2:100938903	LONRF2	-0.42	-8.99	-0.33	2.87e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg27129171	chr3:47204927	SETD2	0.77	19.91	0.62	5.34e-69	Colorectal cancer;
BRCA	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg04362960	chr10:104952993	NT5C2	0.44	9.92	0.37	1.15e-21	Arsenic metabolism;
BRCA	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg06627628	chr2:24431161	ITSN2	-0.57	-9.16	-0.34	7.23e-19	Lymphocyte counts;
BRCA	cis	rs10492096	0.947	rs10849484	chr12:6637941	C/T	cg13857086	chr12:6580257	VAMP1	0.43	8.13	0.31	2.29e-15	Hip geometry;
BRCA	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg10523679	chr1:76189770	ACADM	0.78	18.69	0.59	1.61e-62	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.85e-29	Chronic sinus infection;
BRCA	cis	rs7945705	0.846	rs4929911	chr11:8816495	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.49	10.36	0.38	2.37e-23	Hemoglobin concentration;
BRCA	cis	rs7617773	0.780	rs4130522	chr3:48352313	G/A	cg11946769	chr3:48343235	NME6	0.69	14.01	0.48	4.54e-39	Coronary artery disease;
BRCA	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg03354898	chr7:1950403	MAD1L1	-0.4	-8.34	-0.31	4.42e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs8010715	0.848	rs2277483	chr14:24591892	A/G	cg23112188	chr14:24563095	PCK2	-0.33	-8.34	-0.31	4.74e-16	IgG glycosylation;
BRCA	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg01305625	chr5:131593812	PDLIM4	0.35	8.28	0.31	7.06e-16	Acylcarnitine levels;
BRCA	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.3	8.93	0.33	4.33e-18	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.35	-0.35	1.46e-19	Bipolar disorder;
BRCA	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg11822812	chr5:140052017	DND1	-0.3	-8.2	-0.31	1.37e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.87	-0.3	1.49e-14	Electroencephalogram traits;
BRCA	trans	rs877282	0.583	rs10904562	chr10:819058	T/C	cg22713356	chr15:30763199	NA	1.03	16.89	0.56	3.36e-53	Uric acid levels;
BRCA	trans	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	11.2	0.41	1.01e-26	Type 2 diabetes;
BRCA	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg10223061	chr2:219282414	VIL1	-0.27	-7.83	-0.3	2.02e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs912057	0.582	rs1294412	chr6:6739854	A/G	cg06612196	chr6:6737390	NA	0.58	14.29	0.49	2.23e-40	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg01528321	chr10:82214614	TSPAN14	-0.82	-17.44	-0.57	5.45e-56	Post bronchodilator FEV1;
BRCA	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.98	0.56	1.21e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.79	-0.42	3.6e-29	Bipolar disorder;
BRCA	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg01475377	chr6:109611718	NA	-0.59	-16.46	-0.55	5.05e-51	Reticulocyte fraction of red cells;
BRCA	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg01324343	chr3:183735012	ABCC5	0.48	10.69	0.39	1.18e-24	Anterior chamber depth;
BRCA	cis	rs6087990	0.806	rs4911108	chr20:31375311	A/G	cg13636640	chr20:31349939	DNMT3B	0.62	19.22	0.61	2.63e-65	Ulcerative colitis;
BRCA	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.88	-17.72	-0.57	1.8e-57	Body mass index;
BRCA	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.05e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7789940	0.904	rs6953281	chr7:75946943	C/T	cg10167463	chr7:75959203	YWHAG	-0.45	-8.82	-0.33	1.06e-17	Multiple sclerosis;
BRCA	cis	rs9649465	0.967	rs2402666	chr7:123285478	A/T	cg04330084	chr7:123175371	IQUB	-0.31	-8.6	-0.32	6.13e-17	Migraine;
BRCA	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg26343298	chr8:95960752	TP53INP1	0.28	7.95	0.3	8.76e-15	Type 2 diabetes;
BRCA	cis	rs2120243	0.874	rs2316706	chr3:157160061	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.44	9.81	0.36	2.85e-21	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs9487051	0.766	rs351748	chr6:109532296	C/T	cg21918786	chr6:109611834	NA	0.36	9.61	0.36	1.67e-20	Reticulocyte fraction of red cells;
BRCA	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg13798780	chr7:105162888	PUS7	0.45	7.95	0.3	8.55e-15	Bipolar disorder (body mass index interaction);
BRCA	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg00012203	chr2:219082015	ARPC2	-0.57	-11.98	-0.43	5.8e-30	Colorectal cancer;
BRCA	cis	rs735860	0.763	rs1346603	chr6:53149262	C/T	cg10236188	chr6:53219634	NA	0.39	8.35	0.31	4.28e-16	Glaucoma;
BRCA	cis	rs6433895	1.000	rs11893821	chr2:182017148	A/G	cg00481216	chr2:181971175	NA	0.39	9.11	0.34	1.09e-18	Lymphocyte counts;
BRCA	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.01	-0.34	2.44e-18	Recombination measurement;
BRCA	cis	rs6426558	0.537	rs488104	chr1:227300277	G/A	cg10327440	chr1:227177885	CDC42BPA	0.47	9.34	0.35	1.64e-19	Neutrophil percentage of white cells;
BRCA	cis	rs7572733	0.534	rs696817	chr2:198722225	A/G	cg00792783	chr2:198669748	PLCL1	0.47	10.12	0.37	1.95e-22	Dermatomyositis;
BRCA	cis	rs938554	0.542	rs7678287	chr4:10000501	A/G	cg00071950	chr4:10020882	SLC2A9	0.42	7.95	0.3	8.23e-15	Blood metabolite levels;
BRCA	cis	rs501916	0.796	rs55961203	chr15:48050518	G/T	cg16110827	chr15:48056943	SEMA6D	-0.4	-8.51	-0.32	1.27e-16	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs117623576	0.680	rs211415	chr10:32397358	C/T	cg03047570	chr10:32398778	NA	0.55	8.47	0.32	1.7e-16	Anti-saccade response;
BRCA	cis	rs6580649	0.943	rs9651993	chr12:48404692	G/A	cg05342945	chr12:48394962	COL2A1	-0.52	-10.2	-0.37	9.38e-23	Lung cancer;
BRCA	trans	rs877282	0.628	rs11253435	chr10:824169	T/C	cg22713356	chr15:30763199	NA	0.95	15.31	0.52	2.57e-45	Uric acid levels;
BRCA	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12310025	chr6:25882481	NA	-0.5	-11.24	-0.41	7.23e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs7737355	0.947	rs6596009	chr5:130608093	C/A	cg06307176	chr5:131281290	NA	0.48	8.14	0.31	2.08e-15	Life satisfaction;
BRCA	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg05347473	chr6:146136440	FBXO30	-0.43	-8.51	-0.32	1.27e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	19.12	0.6	8.79e-65	Tonsillectomy;
BRCA	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg24531977	chr5:56204891	C5orf35	-0.41	-8.22	-0.31	1.15e-15	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg14926445	chr8:58193284	C8orf71	-0.46	-8.83	-0.33	1.01e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg04545296	chr12:48745243	ZNF641	0.25	8.31	0.31	5.74e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg04034577	chr2:241836375	C2orf54	-0.57	-14.01	-0.48	4.62e-39	Urinary metabolites;
BRCA	cis	rs2658782	0.724	rs1869914	chr11:93112492	C/G	cg15737290	chr11:93063684	CCDC67	0.47	9.51	0.35	3.87e-20	Pulmonary function decline;
BRCA	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg12573674	chr2:1569213	NA	-0.51	-9.72	-0.36	6.58e-21	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7395581	0.918	rs61896050	chr11:47309063	T/C	cg25783544	chr11:47291846	MADD	0.43	9.76	0.36	4.41e-21	HDL cholesterol;
BRCA	cis	rs1355223	0.506	rs7131229	chr11:34869328	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.49	9.65	0.36	1.16e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg23708337	chr7:1209742	NA	0.6	8.31	0.31	5.89e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg06521331	chr12:34319734	NA	-0.53	-10.6	-0.39	2.71e-24	Morning vs. evening chronotype;
BRCA	cis	rs6973256	0.897	rs12333918	chr7:133330374	T/G	cg07491979	chr7:133331646	EXOC4	-0.39	-8.8	-0.33	1.22e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg05234568	chr11:5960015	NA	-0.41	-7.95	-0.3	8.48e-15	DNA methylation (variation);
BRCA	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.69	-0.33	3.04e-17	Breast cancer;
BRCA	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	18.4	0.59	5.27e-61	Platelet count;
BRCA	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg22189786	chr22:42395067	WBP2NL	0.41	8.32	0.31	5.29e-16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs2742234	0.541	rs1879310	chr10:43734775	A/G	cg02780029	chr10:43622663	RET	0.36	8.12	0.31	2.43e-15	Hirschsprung disease;
BRCA	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.81	0.36	2.99e-21	Morning vs. evening chronotype;
BRCA	cis	rs1451375	0.698	rs11489736	chr7:50645372	G/A	cg18232548	chr7:50535776	DDC	0.39	9.19	0.34	5.5e-19	Malaria;
BRCA	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.99	14.79	0.51	8.45e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.03	-22.71	-0.67	3.62e-84	Lymphocyte percentage of white cells;
BRCA	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12532878	0.652	rs11768465	chr7:100198386	C/T	cg16850897	chr7:100343110	ZAN	-0.39	-8.27	-0.31	7.99e-16	Mean corpuscular hemoglobin;
BRCA	cis	rs1941023	0.584	rs2014121	chr11:60156297	T/C	cg08716584	chr11:60157161	MS4A7	-0.43	-10.46	-0.38	9.49e-24	Congenital heart disease (maternal effect);
BRCA	trans	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg15556689	chr8:8085844	FLJ10661	-0.33	-7.96	-0.3	7.93e-15	Triglycerides;
BRCA	cis	rs3820928	0.874	rs13385711	chr2:227830414	G/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.46	-0.32	1.81e-16	Pulmonary function;
BRCA	cis	rs1190552	0.639	rs3742446	chr14:102975572	C/T	cg18135206	chr14:102964638	TECPR2	0.43	7.87	0.3	1.48e-14	Blood protein levels;
BRCA	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg16262614	chr3:133464971	TF	0.24	7.88	0.3	1.45e-14	Iron status biomarkers (transferrin levels);
BRCA	cis	rs68170813	0.559	rs76020313	chr7:106877468	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-8.43	-0.32	2.25e-16	Coronary artery disease;
BRCA	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.13	0.31	2.28e-15	Total cholesterol levels;
BRCA	cis	rs6942756	0.737	rs61570833	chr7:128933492	C/A	cg02491457	chr7:128862824	NA	-0.71	-13.84	-0.48	2.81e-38	White matter hyperintensity burden;
BRCA	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg22508957	chr16:3507546	NAT15	0.64	8.33	0.31	4.87e-16	Tuberculosis;
BRCA	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg23950597	chr19:37808831	NA	-0.72	-12.52	-0.44	2.54e-32	Coronary artery calcification;
BRCA	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg19628046	chr18:33552617	C18orf21	0.52	10.77	0.39	5.52e-25	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs4389656	0.826	rs192443	chr5:6733664	G/T	cg10857441	chr5:6722123	POLS	-0.25	-7.83	-0.3	2.08e-14	Coronary artery disease;
BRCA	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg18230493	chr5:56204884	C5orf35	-0.72	-14.12	-0.49	1.37e-39	Initial pursuit acceleration;
BRCA	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.69	0.33	3.03e-17	Platelet count;
BRCA	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	17.47	0.57	3.62e-56	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14026747	chr4:135865398	NA	0.46	8.96	0.33	3.42e-18	Menarche (age at onset);
BRCA	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg26384229	chr12:38710491	ALG10B	0.7	15.88	0.53	4.21e-48	Bladder cancer;
BRCA	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.5	-10.71	-0.39	9.57e-25	Longevity;Endometriosis;
BRCA	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs13102973	0.640	rs6833827	chr4:135839731	T/C	cg14419869	chr4:135874104	NA	0.45	9.09	0.34	1.24e-18	Subjective well-being;
BRCA	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.88	-17.81	-0.58	6.35e-58	Body mass index;
BRCA	trans	rs2736340	0.539	rs11250138	chr8:11323312	C/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-8.69	-0.33	3.12e-17	Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;Systemic lupus erythematosus;Kawasaki disease;Systemic lupus erythematosus or rheumatoid arthritis;
BRCA	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg24154853	chr7:158122151	PTPRN2	0.35	7.98	0.3	6.82e-15	Calcium levels;
BRCA	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-16.13	-0.54	2.33e-49	Colorectal cancer;
BRCA	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00166722	chr3:10149974	C3orf24	-0.65	-13.08	-0.46	7.93e-35	Alzheimer's disease;
BRCA	cis	rs6546550	0.935	rs2872075	chr2:70068635	G/T	cg02498382	chr2:70120550	SNRNP27	-0.52	-10.84	-0.39	3.05e-25	Prevalent atrial fibrillation;
BRCA	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg20701182	chr2:24300061	SF3B14	0.58	9.05	0.34	1.68e-18	Lymphocyte counts;
BRCA	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg04944784	chr2:26401820	FAM59B	-0.97	-16.58	-0.55	1.35e-51	Gut microbiome composition (summer);
BRCA	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg12219531	chr12:120966889	COQ5	0.53	11.64	0.42	1.58e-28	High light scatter reticulocyte count;
BRCA	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.58	-0.32	7.39e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg26168224	chr5:2018326	NA	0.63	17.6	0.57	7.82e-57	Gut microbiome composition (winter);
BRCA	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg24531977	chr5:56204891	C5orf35	-0.4	-8.07	-0.3	3.5e-15	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg08807101	chr21:30365312	RNF160	-0.44	-9.34	-0.35	1.51e-19	Dental caries;
BRCA	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-11.27	-0.41	5.2e-27	Colorectal cancer;
BRCA	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg24006582	chr15:45444508	DUOX1	0.55	10.8	0.39	4.45e-25	Uric acid levels;
BRCA	cis	rs698813	0.851	rs698804	chr2:44699720	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	8.81	0.33	1.18e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11141652	chr22:24348549	GSTTP1	-0.39	-7.94	-0.3	8.8e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs509477	1.000	rs7245165	chr18:32567007	C/A	cg23791764	chr18:32556832	MAPRE2	0.35	8.33	0.31	5.03e-16	Cerebrospinal fluid AB1-42 levels;
BRCA	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-9.79	-0.36	3.59e-21	Gut microbiome composition (summer);
BRCA	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13732083	chr21:47605072	C21orf56	0.38	7.81	0.3	2.29e-14	Testicular germ cell tumor;
BRCA	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg12011299	chr4:100065546	ADH4	0.42	10.52	0.38	5.44e-24	Alcohol dependence;
BRCA	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg08564027	chr20:61660810	NA	0.9	23.66	0.68	2.44e-89	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs897080	0.552	rs1067383	chr2:44645911	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	9.42	0.35	7.79e-20	Height;
BRCA	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg23131131	chr22:24373011	LOC391322	0.43	9.9	0.36	1.35e-21	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10227331	0.692	rs34036749	chr7:157298870	T/C	cg04156418	chr7:157293606	NA	0.35	10.05	0.37	3.51e-22	Inattentive symptoms;
BRCA	cis	rs4908760	0.864	rs6674832	chr1:8691879	T/C	cg20416874	chr1:8611966	RERE	-0.28	-8.11	-0.31	2.66e-15	Vitiligo;
BRCA	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23583168	chr7:148888333	NA	-0.78	-18.85	-0.6	2.33e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg18850127	chr7:39170497	POU6F2	0.39	8.31	0.31	5.58e-16	IgG glycosylation;
BRCA	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.68	15.79	0.53	1.18e-47	Axial length;
BRCA	trans	rs61931739	0.635	rs1486884	chr12:33908876	A/T	cg26384229	chr12:38710491	ALG10B	-0.43	-9.84	-0.36	2.2e-21	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08219700	chr8:58056026	NA	0.47	8.51	0.32	1.21e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs9951602	0.512	rs9958497	chr18:76655296	G/C	cg02800362	chr5:177631904	HNRNPAB	0.78	18.16	0.58	1.01e-59	Obesity-related traits;
BRCA	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-12.56	-0.44	1.73e-32	Platelet count;
BRCA	cis	rs6977660	0.660	rs10253753	chr7:19823032	A/G	cg05791153	chr7:19748676	TWISTNB	0.57	10.8	0.39	4.43e-25	Thyroid stimulating hormone;
BRCA	cis	rs919433	0.679	rs13000656	chr2:198522126	T/C	cg00792783	chr2:198669748	PLCL1	-0.44	-9.38	-0.35	1.12e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs2806561	0.734	rs2143156	chr1:23374629	T/G	cg19743168	chr1:23544995	NA	0.36	8.38	0.31	3.28e-16	Height;
BRCA	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg00376283	chr12:123451042	ABCB9	0.47	10.81	0.39	4.12e-25	Neutrophil percentage of white cells;
BRCA	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg10932868	chr11:921992	NA	0.47	12.11	0.43	1.62e-30	Alzheimer's disease (late onset);
BRCA	cis	rs9341808	0.667	rs2490244	chr6:80891112	A/T	cg08355045	chr6:80787529	NA	0.33	8.09	0.3	3.07e-15	Sitting height ratio;
BRCA	cis	rs10089	0.552	rs11955148	chr5:127557814	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.5	10.04	0.37	4.17e-22	Ileal carcinoids;
BRCA	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg24692254	chr21:30365293	RNF160	-0.35	-8.06	-0.3	3.7e-15	Pancreatic cancer;
BRCA	cis	rs9462027	0.675	rs7755926	chr6:34722574	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.27	-8.25	-0.31	9.32e-16	Systemic lupus erythematosus;
BRCA	cis	rs55665837	1.000	rs12792120	chr11:14469443	G/T	cg19336497	chr11:14380999	RRAS2	-0.37	-9.66	-0.36	1.04e-20	Vitamin D levels;
BRCA	cis	rs6763687	0.964	rs16856838	chr3:171775451	G/A	cg16233210	chr3:171778391	FNDC3B	0.48	11.34	0.41	2.88e-27	Red cell distribution width;
BRCA	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12379764	chr21:47803548	PCNT	0.39	8.44	0.32	2.07e-16	Testicular germ cell tumor;
BRCA	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	9.9	0.36	1.32e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg04450456	chr4:17643702	FAM184B	0.38	11.21	0.41	9.12e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2652834	1.000	rs2652835	chr15:63396408	T/C	cg05507819	chr15:63340323	TPM1	0.47	8.65	0.32	4.18e-17	HDL cholesterol;
BRCA	cis	rs13046373	0.535	rs1961167	chr21:32030310	T/C	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.21	0.31	1.26e-15	HDL cholesterol;
BRCA	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg06623918	chr6:96969491	KIAA0776	-0.77	-13.62	-0.47	2.78e-37	Migraine;Coronary artery disease;
BRCA	trans	rs3960554	0.808	rs59882870	chr7:75638421	G/A	cg19862616	chr7:65841803	NCRNA00174	0.52	10.0	0.37	5.67e-22	Eotaxin levels;
BRCA	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg02574844	chr11:5959923	NA	-0.45	-9.02	-0.34	2.22e-18	DNA methylation (variation);
BRCA	cis	rs7523050	0.643	rs34572569	chr1:109401856	A/T	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12756686	chr19:29218302	NA	0.57	10.97	0.4	9.04e-26	Methadone dose in opioid dependence;
BRCA	trans	rs8073060	0.586	rs6505487	chr17:33996850	A/G	cg19694781	chr19:47549865	TMEM160	-1.02	-20.87	-0.64	3.87e-74	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg08213375	chr14:104286397	PPP1R13B	0.41	8.82	0.33	1.09e-17	Reticulocyte count;
BRCA	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg22800045	chr5:56110881	MAP3K1	-0.45	-9.04	-0.34	1.84e-18	Initial pursuit acceleration;
BRCA	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg01877450	chr7:97915802	BRI3	-0.38	-8.56	-0.32	8.45e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg25237894	chr2:233734115	C2orf82	0.4	11.51	0.41	5.56e-28	Coronary artery disease;
BRCA	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24531977	chr5:56204891	C5orf35	-0.79	-15.1	-0.51	2.72e-44	Initial pursuit acceleration;
BRCA	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg20387954	chr3:183756860	HTR3D	0.46	10.31	0.38	3.71e-23	Anterior chamber depth;
BRCA	cis	rs6433895	0.736	rs13012524	chr2:181985834	G/A	cg00481216	chr2:181971175	NA	0.41	8.74	0.33	2.02e-17	Lymphocyte counts;
BRCA	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg17063962	chr7:91808500	NA	-0.52	-12.17	-0.43	8.52e-31	Breast cancer;
BRCA	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg19761014	chr17:28927070	LRRC37B2	0.58	8.24	0.31	1.01e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg05707623	chr12:122985044	ZCCHC8	0.5	9.68	0.36	8.65e-21	Body mass index;
BRCA	trans	rs75804782	0.521	rs56121087	chr2:239435766	A/G	cg01134436	chr17:81009848	B3GNTL1	0.69	8.81	0.33	1.17e-17	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.1	-0.37	2.47e-22	IgG glycosylation;
BRCA	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg00631329	chr6:26305371	NA	0.44	13.17	0.46	3.2e-35	Educational attainment;
BRCA	cis	rs593982	0.920	rs4930298	chr11:65448108	T/A	cg08755490	chr11:65554678	OVOL1	-1.23	-14.75	-0.5	1.37e-42	Atopic dermatitis;
BRCA	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-10.7	-0.39	1.08e-24	Alzheimer's disease;
BRCA	trans	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg25214090	chr10:38739885	LOC399744	0.54	12.08	0.43	2.12e-30	Corneal astigmatism;
BRCA	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.3	10.11	0.37	2.19e-22	Bipolar disorder;
BRCA	cis	rs6088813	1.000	rs6579234	chr20:33983485	A/G	cg14752227	chr20:34000481	UQCC	-0.39	-8.33	-0.31	4.79e-16	Height;
BRCA	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11644478	chr21:40555479	PSMG1	0.75	15.22	0.52	6.94e-45	Cognitive function;
BRCA	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg05340658	chr4:99064831	C4orf37	-0.47	-10.92	-0.4	1.41e-25	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.09	-0.37	2.62e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg08422745	chr4:174089978	GALNT7	-0.78	-15.87	-0.53	4.43e-48	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg16327482	chr19:10226339	EIF3G	0.39	10.08	0.37	2.88e-22	Narcolepsy;
BRCA	cis	rs3771570	0.901	rs10190033	chr2:242412358	A/C	cg21155796	chr2:242212141	HDLBP	0.47	8.3	0.31	6.11e-16	Prostate cancer;
BRCA	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.69	0.42	9.8e-29	Homoarginine levels;
BRCA	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg14061069	chr19:46274453	DMPK	0.65	18.52	0.59	1.33e-61	Coronary artery disease;
BRCA	trans	rs1493916	0.967	rs34341086	chr18:31400141	C/T	cg27147174	chr7:100797783	AP1S1	-0.52	-10.24	-0.38	7.01e-23	Life satisfaction;
BRCA	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg01420254	chr6:26195488	NA	0.55	8.64	0.32	4.59e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg24296786	chr1:45957014	TESK2	0.62	15.49	0.52	3.59e-46	High light scatter reticulocyte count;
BRCA	cis	rs10782582	0.668	rs7516477	chr1:76204502	C/G	cg03433033	chr1:76189801	ACADM	-0.37	-8.0	-0.3	6.02e-15	Daytime sleep phenotypes;
BRCA	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg12863693	chr15:85201151	NMB	-0.35	-8.44	-0.32	2.1e-16	P wave terminal force;
BRCA	cis	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg07460842	chr6:66804631	NA	-1.18	-38.66	-0.84	2e-169	Exhaled nitric oxide output;
BRCA	cis	rs9815354	0.812	rs57162396	chr3:41896031	G/A	cg03022575	chr3:42003672	ULK4	0.68	9.46	0.35	5.93e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg00666640	chr1:248458726	OR2T12	-0.3	-8.59	-0.32	6.89e-17	Common traits (Other);
BRCA	cis	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg07460842	chr6:66804631	NA	-0.69	-14.83	-0.51	5.63e-43	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs4478137	0.931	rs7665672	chr4:164236875	G/A	cg06758707	chr4:164254230	NPY1R	0.57	12.52	0.44	2.5e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg16744531	chr19:17905626	B3GNT3	0.55	11.9	0.43	1.22e-29	Tumor biomarkers;
BRCA	trans	rs7980799	1.000	rs7980799	chr12:33576990	A/C	cg26384229	chr12:38710491	ALG10B	-0.42	-8.63	-0.32	4.89e-17	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg18225595	chr11:63971243	STIP1	0.53	9.6	0.35	1.82e-20	Mean platelet volume;
BRCA	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg27129171	chr3:47204927	SETD2	0.7	16.5	0.55	3.23e-51	Colorectal cancer;
BRCA	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.13	-18.59	-0.59	5.48e-62	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg18402987	chr7:1209562	NA	0.85	12.22	0.44	5.38e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg12034118	chr1:209979487	IRF6	0.63	16.3	0.54	3.38e-50	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
BRCA	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg15395560	chr15:45543142	SLC28A2	0.29	7.95	0.3	8.67e-15	Glomerular filtration rate;
BRCA	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg24692254	chr21:30365293	RNF160	-0.66	-17.95	-0.58	1.26e-58	Dental caries;
BRCA	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg07988820	chr12:82153109	PPFIA2	-0.63	-10.13	-0.37	1.78e-22	Resting heart rate;
BRCA	cis	rs17253792	0.822	rs8013714	chr14:56172286	T/C	cg01858014	chr14:56050164	KTN1	-0.58	-9.01	-0.34	2.31e-18	Putamen volume;
BRCA	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.23e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.16e-47	Alzheimer's disease (late onset);
BRCA	cis	rs965469	0.843	rs6139122	chr20:3395871	T/G	cg25506879	chr20:3388711	C20orf194	-0.57	-10.96	-0.4	9.79e-26	IFN-related cytopenia;
BRCA	cis	rs6484504	0.576	rs208066	chr11:31156206	C/G	cg26647111	chr11:31128758	NA	-0.42	-8.88	-0.33	6.94e-18	Red blood cell count;
BRCA	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	ch.11.42038R	chr11:967971	AP2A2	0.52	16.51	0.55	2.86e-51	Alzheimer's disease (late onset);
BRCA	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg22431228	chr1:16359049	CLCNKA	-0.49	-11.0	-0.4	6.86e-26	Systolic blood pressure;
BRCA	cis	rs6740322	0.793	rs9808360	chr2:43546835	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-12.12	-0.43	1.42e-30	Coronary artery disease;
BRCA	cis	rs2120243	0.791	rs7615621	chr3:157152600	A/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	9.59	0.35	1.95e-20	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25427524	chr10:38739819	LOC399744	-0.72	-17.76	-0.57	1.13e-57	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg16606324	chr3:10149918	C3orf24	0.56	9.78	0.36	3.7e-21	Alzheimer's disease;
BRCA	cis	rs7092929	0.883	rs705458	chr10:3611415	C/T	cg14308648	chr10:3568949	NA	-0.46	-8.37	-0.31	3.52e-16	Coronary artery calcification;
BRCA	cis	rs3772130	0.962	rs28660600	chr3:121482637	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.89	0.4	1.96e-25	Cognitive performance;
BRCA	cis	rs12638540	0.543	rs12487678	chr3:32603358	A/C	cg11605617	chr3:32612461	DYNC1LI1	0.77	11.54	0.42	3.91e-28	Mortality in heart failure;
BRCA	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg05340658	chr4:99064831	C4orf37	0.7	16.97	0.56	1.42e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg00080972	chr5:178986291	RUFY1	0.47	12.46	0.44	4.79e-32	Lung cancer;
BRCA	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg22875332	chr1:76189707	ACADM	0.69	14.94	0.51	1.65e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.52	-11.21	-0.41	9.63e-27	Longevity;Endometriosis;
BRCA	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg08859206	chr1:53392774	SCP2	-0.41	-8.17	-0.31	1.6e-15	Monocyte count;
BRCA	cis	rs16854884	0.657	rs7610378	chr3:143711298	G/A	cg06585982	chr3:143692056	C3orf58	0.41	8.49	0.32	1.45e-16	Economic and political preferences (feminism/equality);
BRCA	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg02297831	chr4:17616191	MED28	0.35	8.07	0.3	3.52e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg24531977	chr5:56204891	C5orf35	-0.39	-8.03	-0.3	4.67e-15	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg18252515	chr7:66147081	NA	-1.04	-15.46	-0.52	5.05e-46	Diabetic kidney disease;
BRCA	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.41	8.46	0.32	1.86e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs35740288	0.822	rs17574774	chr15:86233370	C/T	cg20737812	chr15:86336631	KLHL25	0.32	7.82	0.3	2.12e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg18016565	chr1:150552671	MCL1	0.35	8.26	0.31	8.2e-16	Tonsillectomy;
BRCA	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg13628971	chr7:2884303	GNA12	0.46	10.24	0.38	6.9e-23	Height;
BRCA	cis	rs10493773	1.000	rs12754358	chr1:86248431	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.46	-9.47	-0.35	5.53e-20	Urate levels in overweight individuals;
BRCA	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg21280719	chr6:42927975	GNMT	-0.33	-13.91	-0.48	1.34e-38	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs3820928	0.874	rs10178731	chr2:227874232	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.27	-0.31	7.98e-16	Pulmonary function;
BRCA	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.88	0.51	3.12e-43	Colorectal cancer;
BRCA	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg21475434	chr5:93447410	FAM172A	-0.69	-8.61	-0.32	5.74e-17	Diabetic retinopathy;
BRCA	cis	rs13136331	0.680	rs2732169	chr4:88656433	C/T	cg12990093	chr4:88570587	DMP1	-0.4	-8.22	-0.31	1.14e-15	Sitting height ratio;
BRCA	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg15704280	chr7:45808275	SEPT13	0.62	10.32	0.38	3.42e-23	Axial length;
BRCA	cis	rs11971779	0.680	rs6963867	chr7:139059964	T/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.24	0.38	6.65e-23	Diisocyanate-induced asthma;
BRCA	cis	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg06521331	chr12:34319734	NA	-0.65	-11.93	-0.43	9.53e-30	Morning vs. evening chronotype;
BRCA	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	14.07	0.49	2.2e-39	Lymphocyte counts;
BRCA	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg21475434	chr5:93447410	FAM172A	0.71	8.97	0.33	3.15e-18	Diabetic retinopathy;
BRCA	cis	rs758324	0.947	rs804059	chr5:131270136	T/C	cg06307176	chr5:131281290	NA	-0.53	-10.15	-0.37	1.49e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg04450456	chr4:17643702	FAM184B	0.33	9.57	0.35	2.35e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg17675199	chr6:35436792	RPL10A	-0.3	-8.14	-0.31	2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg18755752	chr8:142205143	DENND3	-0.63	-16.36	-0.54	1.71e-50	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg23950597	chr19:37808831	NA	-0.71	-12.02	-0.43	3.68e-30	Coronary artery calcification;
BRCA	cis	rs7395581	0.918	rs10501321	chr11:47294626	A/G	cg25783544	chr11:47291846	MADD	0.39	8.92	0.33	4.83e-18	HDL cholesterol;
BRCA	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg08807101	chr21:30365312	RNF160	0.68	17.5	0.57	2.59e-56	Dental caries;
BRCA	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg04025307	chr7:1156635	C7orf50	0.54	10.61	0.39	2.52e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	-0.34	-8.07	-0.3	3.56e-15	Corneal astigmatism;
BRCA	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.34	-9.28	-0.34	2.63e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.17	-0.4	1.39e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12200560	0.505	rs4839849	chr6:97076673	T/C	cg06623918	chr6:96969491	KIAA0776	0.53	12.7	0.45	4.04e-33	Coronary heart disease;
BRCA	cis	rs9811920	0.809	rs923472	chr3:99758029	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.57	-13.61	-0.47	3.16e-37	Axial length;
BRCA	cis	rs4908760	0.864	rs6701331	chr1:8670206	A/C	cg20416874	chr1:8611966	RERE	-0.28	-7.97	-0.3	7.38e-15	Vitiligo;
BRCA	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg08807101	chr21:30365312	RNF160	-0.53	-13.16	-0.46	3.57e-35	Dental caries;
BRCA	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg26384229	chr12:38710491	ALG10B	0.42	9.35	0.35	1.44e-19	Morning vs. evening chronotype;
BRCA	cis	rs1538970	0.924	rs10890327	chr1:45891458	C/T	cg05343316	chr1:45956843	TESK2	0.62	12.48	0.44	3.73e-32	Platelet count;
BRCA	cis	rs1568889	1.000	rs12808162	chr11:28067027	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	14.61	0.5	6.1e-42	Bipolar disorder;
BRCA	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00149659	chr3:10157352	C3orf10	0.79	13.72	0.48	9.42e-38	Alzheimer's disease;
BRCA	cis	rs7599312	0.963	rs10184221	chr2:213409014	G/A	cg16329650	chr2:213403929	ERBB4	0.45	9.59	0.35	1.96e-20	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg21573476	chr21:45109991	RRP1B	-0.46	-12.06	-0.43	2.61e-30	Mean corpuscular volume;
BRCA	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.36	-0.35	1.31e-19	Tonsillectomy;
BRCA	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg24324837	chr19:49891574	CCDC155	0.43	7.99	0.3	6.13e-15	Multiple sclerosis;
BRCA	cis	rs760805	1.000	rs4649037	chr1:25258301	G/T	cg22509179	chr1:25234806	RUNX3	-0.57	-14.67	-0.5	3.23e-42	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.6	9.68	0.36	9.22e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg04025307	chr7:1156635	C7orf50	0.51	9.82	0.36	2.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg11663144	chr21:46675770	NA	-0.61	-14.26	-0.49	3.01e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7715811	1.000	rs7715552	chr5:13769959	A/T	cg07548982	chr5:13769939	DNAH5	-0.38	-8.56	-0.32	8.25e-17	Subclinical atherosclerosis traits (other);
BRCA	cis	rs701145	0.586	rs355785	chr3:153990251	T/G	cg17054900	chr3:154042577	DHX36	0.68	11.76	0.42	4.97e-29	Coronary artery disease;
BRCA	cis	rs2816062	0.813	rs6698315	chr1:18895806	A/G	cg18795169	chr1:18902165	NA	-0.94	-27.92	-0.74	9.25e-113	Urate levels in lean individuals;
BRCA	cis	rs793571	0.523	rs7163162	chr15:58983588	T/A	cg05156742	chr15:59063176	FAM63B	0.56	11.58	0.42	2.84e-28	Schizophrenia;
BRCA	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.46	-0.35	6.03e-20	Total body bone mineral density;
BRCA	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg04362960	chr10:104952993	NT5C2	0.43	9.72	0.36	6.14e-21	Arsenic metabolism;
BRCA	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg04362960	chr10:104952993	NT5C2	0.43	9.77	0.36	4.15e-21	Arsenic metabolism;
BRCA	trans	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg25214090	chr10:38739885	LOC399744	0.42	9.67	0.36	9.88e-21	Corneal astigmatism;
BRCA	cis	rs4363385	0.747	rs6665575	chr1:152960506	G/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.16	-0.31	1.74e-15	Inflammatory skin disease;
BRCA	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	13.98	0.48	5.96e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg03676636	chr4:99064102	C4orf37	0.23	8.04	0.3	4.26e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg06026331	chr20:60912101	LAMA5	0.49	10.22	0.37	8.21e-23	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	8.46	0.32	1.84e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	9.83	0.36	2.59e-21	Aortic root size;
BRCA	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg22705602	chr4:152727874	NA	-0.33	-8.02	-0.3	5.22e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs68170813	0.559	rs1018946	chr7:106851754	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-8.47	-0.32	1.72e-16	Coronary artery disease;
BRCA	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg26395211	chr5:140044315	WDR55	0.38	8.65	0.32	4.31e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg26874164	chr19:58962979	ZNF324B	-0.51	-11.24	-0.41	7.44e-27	Uric acid clearance;
BRCA	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-8.13	-0.31	2.3e-15	Bladder cancer;
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.54	-12.05	-0.43	2.71e-30	Longevity;Endometriosis;
BRCA	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg00277334	chr10:82204260	NA	-0.42	-8.07	-0.3	3.42e-15	Post bronchodilator FEV1;
BRCA	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg19628046	chr18:33552617	C18orf21	0.55	10.58	0.39	3.18e-24	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg11764359	chr7:65958608	NA	0.68	15.2	0.52	8.76e-45	Aortic root size;
BRCA	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg05985134	chr18:33552581	C18orf21	-0.64	-12.37	-0.44	1.15e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs7395581	0.918	rs12575456	chr11:47326073	G/A	cg25783544	chr11:47291846	MADD	0.43	9.64	0.36	1.23e-20	HDL cholesterol;
BRCA	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg02176678	chr2:219576539	TTLL4	0.38	10.2	0.37	9.8e-23	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg02951883	chr7:2050386	MAD1L1	-0.5	-11.5	-0.41	5.78e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.62	-14.14	-0.49	1.13e-39	Ulcerative colitis;
BRCA	cis	rs10851411	0.688	rs17709596	chr15:42767981	C/T	cg21293051	chr15:42870591	STARD9	0.51	8.4	0.32	2.94e-16	Glucose homeostasis traits;
BRCA	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11905131	chr22:24372483	LOC391322	-0.53	-12.2	-0.43	6.53e-31	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg21573476	chr21:45109991	RRP1B	-0.39	-10.46	-0.38	1e-23	Mean corpuscular volume;
BRCA	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	12.11	0.43	1.56e-30	Rheumatoid arthritis;
BRCA	cis	rs17021463	0.902	rs2865352	chr4:95253263	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.38	-0.38	2.0500000000000001e-23	Testicular germ cell tumor;
BRCA	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg04756594	chr16:24857601	SLC5A11	0.49	9.46	0.35	5.59e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg18351406	chr4:77819688	ANKRD56	0.56	12.57	0.45	1.47e-32	Emphysema distribution in smoking;
BRCA	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg23649088	chr2:200775458	C2orf69	-0.61	-7.95	-0.3	8.5e-15	Schizophrenia;
BRCA	cis	rs7301826	0.585	rs6486600	chr12:131292977	C/T	cg11011512	chr12:131303247	STX2	0.47	12.11	0.43	1.56e-30	Plasma plasminogen activator levels;
BRCA	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg01689657	chr7:91764605	CYP51A1	-0.24	-8.41	-0.32	2.62e-16	Breast cancer;
BRCA	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.31	8.4	0.32	2.97e-16	Birth weight;
BRCA	cis	rs9308433	0.529	rs11120298	chr1:214500620	A/G	cg06198575	chr1:214491504	SMYD2	0.57	12.44	0.44	5.68e-32	IgG glycosylation;
BRCA	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-16.0	-0.53	1.08e-48	Total cholesterol levels;
BRCA	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg08888203	chr3:10149979	C3orf24	0.56	11.44	0.41	1.05e-27	Alzheimer's disease;
BRCA	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg06784218	chr1:46089804	CCDC17	-0.5	-11.84	-0.42	2.31e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg04944784	chr2:26401820	FAM59B	0.95	16.17	0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg00383909	chr3:49044727	WDR6	0.97	15.45	0.52	5.37e-46	Cognitive function;
BRCA	trans	rs12517041	1.000	rs1366452	chr5:23279222	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.9	-0.3	1.19e-14	Calcium levels;
BRCA	cis	rs6772849	0.931	rs60825080	chr3:128384834	G/T	cg16766828	chr3:128327626	NA	-0.41	-8.9	-0.33	5.75e-18	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	11.96	0.43	6.77e-30	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg03433033	chr1:76189801	ACADM	0.73	18.51	0.59	1.47e-61	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs909002	0.849	rs2271933	chr1:32092525	C/T	cg11573219	chr1:32083031	HCRTR1	-0.26	-8.2	-0.31	1.36e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs365132	0.967	rs58279426	chr5:176448139	T/C	cg16309518	chr5:176445507	NA	-0.51	-12.94	-0.46	3.54e-34	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs11051970	0.879	rs2651378	chr12:32581794	A/G	cg02745156	chr12:32552066	NA	0.27	8.93	0.33	4.43e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg06521331	chr12:34319734	NA	-0.58	-11.65	-0.42	1.47e-28	Morning vs. evening chronotype;
BRCA	cis	rs17095355	1.000	rs55781439	chr10:111670220	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.39	-10.0	-0.37	5.84e-22	Biliary atresia;
BRCA	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.39	-8.4	-0.32	3e-16	IgG glycosylation;
BRCA	cis	rs4409675	0.576	rs6598912	chr1:28233289	C/T	cg23691781	chr1:28212827	C1orf38	0.32	10.43	0.38	1.29e-23	Corneal astigmatism;
BRCA	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg07395648	chr5:131743802	NA	-0.37	-9.14	-0.34	7.96e-19	Blood metabolite levels;
BRCA	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg04267008	chr7:1944627	MAD1L1	-0.49	-10.79	-0.39	4.6e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.43e-36	High light scatter reticulocyte count;
BRCA	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg18305652	chr10:134549665	INPP5A	-0.5	-12.66	-0.45	6.37e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg18132916	chr6:79620363	NA	-0.48	-10.82	-0.39	3.65e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	20.09	0.62	5.9e-70	Platelet count;
BRCA	cis	rs2625529	0.824	rs16956452	chr15:72284092	T/C	cg16672083	chr15:72433130	SENP8	-0.85	-17.66	-0.57	4.05e-57	Red blood cell count;
BRCA	trans	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.38	-9.24	-0.34	3.51e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Tonsillectomy;
BRCA	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg10295955	chr4:187884368	NA	-1.0	-31.58	-0.78	1.35e-132	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg17971929	chr21:40555470	PSMG1	0.77	18.12	0.58	1.53e-59	Cognitive function;
BRCA	cis	rs9420	0.961	rs11229131	chr11:57562525	G/A	cg19752551	chr11:57585705	CTNND1	-0.51	-12.55	-0.44	1.96e-32	Schizophrenia;
BRCA	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg16586182	chr3:47516702	SCAP	-0.57	-13.01	-0.46	1.66e-34	Colorectal cancer;
BRCA	cis	rs34779708	0.931	rs2384289	chr10:35343525	G/A	cg03585969	chr10:35415529	CREM	0.45	9.51	0.35	3.94e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg18129178	chr5:148520854	ABLIM3	-0.59	-12.03	-0.43	3.56e-30	Breast cancer;
BRCA	cis	rs4478858	0.735	rs1566964	chr1:31792794	C/A	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.1e-16	Alcohol dependence;
BRCA	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg04013093	chr6:42928303	GNMT	-0.27	-8.54	-0.32	9.68e-17	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg26384229	chr12:38710491	ALG10B	0.77	17.62	0.57	6.36e-57	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.7	0.33	2.81e-17	Mean corpuscular volume;
BRCA	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg03213289	chr20:61660250	NA	0.63	16.54	0.55	2.05e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7011049	1.000	rs11997775	chr8:53833571	C/T	cg26025543	chr8:53854495	NA	-0.49	-9.46	-0.35	6.03e-20	Systolic blood pressure;
BRCA	trans	rs61332075	0.518	rs112649209	chr2:239422814	C/G	cg01134436	chr17:81009848	B3GNTL1	0.69	8.91	0.33	5.13e-18	Lung function (FEV1/FVC);
BRCA	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg11584989	chr19:19387371	SF4	0.63	13.46	0.47	1.53e-36	Bipolar disorder;
BRCA	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	12.02	0.43	3.77e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10949834	0.730	rs2237503	chr7:73509326	G/C	cg07137043	chr7:73588983	EIF4H	-0.51	-7.92	-0.3	1.06e-14	Verbal memory performance (residualized delayed recall change);
BRCA	cis	rs12369635	1.000	rs12369635	chr12:129561356	C/T	cg01909103	chr12:129572610	TMEM132D	-0.69	-7.85	-0.3	1.73e-14	Schizophrenia (inflammation and infection response interaction);
BRCA	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg03433033	chr1:76189801	ACADM	-0.59	-11.68	-0.42	1.03e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.6	-0.32	6.33e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs3771570	1.000	rs4675811	chr2:242402062	A/T	cg21155796	chr2:242212141	HDLBP	0.51	8.86	0.33	8.03e-18	Prostate cancer;
BRCA	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg27170947	chr2:26402098	FAM59B	0.77	11.03	0.4	5.15e-26	Gut microbiome composition (summer);
BRCA	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.66	11.74	0.42	6.17e-29	Total cholesterol levels;
BRCA	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.38	-9.16	-0.34	7.13e-19	Bipolar disorder;
BRCA	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg19622623	chr12:86230825	RASSF9	-0.33	-9.28	-0.34	2.49e-19	Major depressive disorder;
BRCA	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg07741184	chr6:167504864	NA	0.37	10.82	0.39	3.6e-25	Crohn's disease;
BRCA	cis	rs41005	0.967	rs6752776	chr2:8104594	A/G	cg03155496	chr2:8117019	LOC339788	0.54	14.32	0.49	1.58e-40	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.35	-0.41	2.48e-27	Personality dimensions;
BRCA	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.22	-0.31	1.15e-15	Depression;
BRCA	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg20701182	chr2:24300061	SF3B14	0.66	9.7	0.36	7.36e-21	Lymphocyte counts;
BRCA	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg14458575	chr2:238380390	NA	0.53	8.5	0.32	1.31e-16	Prostate cancer;
BRCA	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg11645453	chr3:52864694	ITIH4	0.32	8.28	0.31	7.28e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs12472274	0.648	rs67102443	chr2:239084602	A/G	cg17459225	chr2:239074497	NA	0.42	9.07	0.34	1.43e-18	Phospholipid levels (plasma);
BRCA	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.72	0.36	6.47e-21	Bladder cancer;
BRCA	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06636551	chr8:101224915	SPAG1	-0.38	-8.62	-0.32	5.27e-17	Atrioventricular conduction;
BRCA	cis	rs6752107	0.967	rs11694081	chr2:234148586	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	10.65	0.39	1.78e-24	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg26446133	chr18:72167187	CNDP2	-0.79	-19.95	-0.62	3.38e-69	Refractive error;
BRCA	cis	rs13046373	0.508	rs1507393	chr21:31992779	A/G	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.25	0.34	3.32e-19	HDL cholesterol;
BRCA	cis	rs10181042	0.565	rs1177233	chr2:61262134	C/T	cg15711740	chr2:61764176	XPO1	0.37	8.57	0.32	7.92e-17	Crohn's disease;
BRCA	cis	rs4363385	0.818	rs454993	chr1:153008992	C/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.14	0.46	4.34e-35	Bipolar disorder;
BRCA	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg09654669	chr8:57350985	NA	-0.39	-8.4	-0.32	2.82e-16	Obesity-related traits;
BRCA	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg18200150	chr17:30822561	MYO1D	-0.37	-9.19	-0.34	5.26e-19	Schizophrenia;
BRCA	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg15595755	chr5:1867978	NA	0.36	8.46	0.32	1.81e-16	Cardiovascular disease risk factors;
BRCA	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10802521	chr3:52805072	NEK4	-0.33	-8.53	-0.32	1.04e-16	Bipolar disorder;
BRCA	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-11.54	-0.42	3.92e-28	Menarche (age at onset);
BRCA	cis	rs9790314	0.696	rs9290069	chr3:160890946	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-11.6	-0.42	2.33e-28	Morning vs. evening chronotype;
BRCA	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	13.59	0.47	3.9e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11644478	chr21:40555479	PSMG1	0.65	14.61	0.5	6.15e-42	Cognitive function;
BRCA	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.01	0.34	2.33e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs698833	0.926	rs786407	chr2:44735865	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	10.04	0.37	4.11e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs965469	1.000	rs6037551	chr20:3306690	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-10.68	-0.39	1.32e-24	IFN-related cytopenia;
BRCA	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg12373951	chr3:133503437	NA	0.53	12.48	0.44	3.98e-32	Iron status biomarkers;
BRCA	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg26769984	chr7:1090371	C7orf50	0.69	13.39	0.47	3.22e-36	Bronchopulmonary dysplasia;
BRCA	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg20701182	chr2:24300061	SF3B14	0.71	13.2	0.46	2.33e-35	Lymphocyte counts;
BRCA	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg26597838	chr10:835615	NA	0.95	14.42	0.5	5.19e-41	Eosinophil percentage of granulocytes;
BRCA	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.36	0.38	2.26e-23	Motion sickness;
BRCA	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg13047869	chr3:10149882	C3orf24	0.6	12.74	0.45	2.67e-33	Alzheimer's disease;
BRCA	trans	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs2766692	0.956	rs35696661	chr14:100742355	G/C	cg14866419	chr14:100704911	YY1	0.44	9.31	0.35	1.99e-19	Electroencephalographic traits in alcoholism;
BRCA	cis	rs9427116	0.677	rs9426831	chr1:154609657	A/T	cg17218026	chr1:154582156	ADAR	-0.28	-7.9	-0.3	1.18e-14	Blood protein levels;
BRCA	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg12751644	chr20:60527061	NA	-0.33	-7.95	-0.3	8.44e-15	Body mass index;
BRCA	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg23711669	chr6:146136114	FBXO30	0.8	18.81	0.6	3.7e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg06935464	chr4:38784597	TLR10	0.51	8.96	0.33	3.43e-18	Breast cancer;
BRCA	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg23711669	chr6:146136114	FBXO30	0.74	16.82	0.55	7.41e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9316337	1.000	rs9316337	chr13:21962207	C/T	cg21011702	chr13:21951294	ZDHHC20	-0.32	-8.2	-0.31	1.31e-15	Schizophrenia;
BRCA	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg06115741	chr20:33292138	TP53INP2	0.49	11.08	0.4	3.37e-26	Coronary artery disease;
BRCA	trans	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.09	0.3	3.09e-15	Corneal astigmatism;
BRCA	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.51	0.32	1.21e-16	Rheumatoid arthritis;
BRCA	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg21775007	chr8:11205619	TDH	-0.46	-8.86	-0.33	7.62e-18	Triglycerides;
BRCA	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg26384229	chr12:38710491	ALG10B	0.55	11.69	0.42	9.73e-29	Morning vs. evening chronotype;
BRCA	cis	rs96067	0.805	rs6425966	chr1:36611287	C/T	cg24686825	chr1:36642396	MAP7D1	0.5	9.17	0.34	6.64e-19	Corneal structure;
BRCA	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg23649088	chr2:200775458	C2orf69	0.57	9.53	0.35	3.32e-20	Schizophrenia;
BRCA	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	8.4	0.32	2.94e-16	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg23229984	chr5:148520753	ABLIM3	0.36	8.89	0.33	6.37e-18	Breast cancer;
BRCA	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.63	-0.42	1.74e-28	Gut microbiome composition (summer);
BRCA	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.62	0.39	2.33e-24	Bipolar disorder;
BRCA	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg11752832	chr7:134001865	SLC35B4	0.5	12.74	0.45	2.81e-33	Mean platelet volume;
BRCA	cis	rs72627509	0.904	rs17081933	chr4:57822869	T/A	cg26694713	chr4:57773883	REST	0.48	9.05	0.34	1.69e-18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-13.15	-0.46	3.89e-35	Migraine;Coronary artery disease;
BRCA	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07080220	chr10:102295463	HIF1AN	0.49	11.33	0.41	2.98e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9359856	0.623	rs1179906	chr6:90323624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.53	-8.66	-0.32	3.9e-17	Bipolar disorder;
BRCA	cis	rs9807989	0.507	rs4851571	chr2:103019000	C/T	cg03938978	chr2:103052716	IL18RAP	0.29	8.49	0.32	1.49e-16	Asthma;
BRCA	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11764359	chr7:65958608	NA	-0.74	-16.31	-0.54	3.11e-50	Aortic root size;
BRCA	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg02574844	chr11:5959923	NA	-0.42	-8.76	-0.33	1.79e-17	DNA methylation (variation);
BRCA	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg27432699	chr2:27873401	GPN1	0.47	9.83	0.36	2.46e-21	Oral cavity cancer;
BRCA	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00908189	chr16:619842	PIGQ	0.7	18.32	0.59	1.5e-60	Height;
BRCA	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg08999081	chr20:33150536	PIGU	0.47	12.95	0.46	3.17e-34	Glomerular filtration rate (creatinine);
BRCA	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg11693508	chr17:37793320	STARD3	0.58	10.72	0.39	9.07e-25	Bipolar disorder;
BRCA	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg08885076	chr2:99613938	TSGA10	-0.59	-13.21	-0.46	2.12e-35	Chronic sinus infection;
BRCA	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.16	-49.12	-0.89	3.85e-219	Myeloid white cell count;
BRCA	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg18154014	chr19:37997991	ZNF793	0.53	9.99	0.37	6.38e-22	Coronary artery calcification;
BRCA	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg22713356	chr15:30763199	NA	1.25	20.77	0.63	1.25e-73	Uric acid levels;
BRCA	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.34	-0.41	2.79e-27	Personality dimensions;
BRCA	cis	rs7617773	0.815	rs6793150	chr3:48351560	G/A	cg11946769	chr3:48343235	NME6	0.69	14.01	0.48	4.54e-39	Coronary artery disease;
BRCA	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.41	-9.22	-0.34	4.33e-19	Personality dimensions;
BRCA	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg13736514	chr6:26305472	NA	-0.35	-11.82	-0.42	2.62e-29	Educational attainment;
BRCA	cis	rs754466	0.914	rs12219971	chr10:79701526	T/C	cg17075019	chr10:79541650	NA	-0.64	-12.18	-0.43	7.91e-31	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg16479474	chr6:28041457	NA	0.42	7.82	0.3	2.18e-14	Parkinson's disease;
BRCA	cis	rs919433	0.680	rs2564389	chr2:198260098	A/T	cg00792783	chr2:198669748	PLCL1	0.38	8.66	0.32	3.94e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11890956	chr21:40555474	PSMG1	-0.82	-20.51	-0.63	3.3e-72	Cognitive function;
BRCA	cis	rs1691799	0.899	rs903587	chr12:66746061	C/A	cg16791601	chr12:66731901	HELB	-0.69	-19.55	-0.61	4.29e-67	White blood cell count (basophil);
BRCA	cis	rs6599636	1	rs6599636	chr10:124677899	T/G	cg05252487	chr10:124670562	FAM24A	-0.32	-8.08	-0.3	3.28e-15	Red cell distribution width;
BRCA	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg00376283	chr12:123451042	ABCB9	0.58	15.19	0.51	1.07e-44	Platelet count;
BRCA	cis	rs72799341	1.000	rs7200879	chr16:30947572	A/G	cg02466173	chr16:30829666	NA	-0.47	-8.56	-0.32	8.2e-17	Diastolic blood pressure;
BRCA	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg03709012	chr19:19516395	GATAD2A	0.72	15.81	0.53	9.57e-48	Tonsillectomy;
BRCA	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.41	-9.32	-0.35	1.86e-19	Longevity;Endometriosis;
BRCA	cis	rs13046373	0.535	rs1605428	chr21:32028976	T/C	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.29	0.34	2.47e-19	HDL cholesterol;
BRCA	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	18.05	0.58	3.74e-59	Platelet count;
BRCA	cis	rs2282802	0.685	rs35214989	chr5:139636127	T/C	cg26211634	chr5:139558579	C5orf32	0.35	8.18	0.31	1.51e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.28	0.34	2.56e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg11645453	chr3:52864694	ITIH4	0.38	10.07	0.37	3.03e-22	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.85	-0.33	8.44e-18	Mood instability;
BRCA	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg23533926	chr12:111358616	MYL2	-0.43	-9.14	-0.34	8.32e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-7.92	-0.3	1.06e-14	Response to antipsychotic treatment;
BRCA	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg21782813	chr7:2030301	MAD1L1	0.33	9.05	0.34	1.76e-18	Schizophrenia;
BRCA	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	11.65	0.42	1.45e-28	Mean platelet volume;
BRCA	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg04691961	chr3:161091175	C3orf57	-0.45	-10.81	-0.39	4.13e-25	Morning vs. evening chronotype;
BRCA	cis	rs870825	0.616	rs7660939	chr4:185640792	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	17.18	0.56	1.08e-54	Blood protein levels;
BRCA	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg17691542	chr6:26056736	HIST1H1C	0.51	10.59	0.39	2.96e-24	Height;
BRCA	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg08975724	chr8:8085496	FLJ10661	0.43	8.0	0.3	5.82e-15	Retinal vascular caliber;
BRCA	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg00701064	chr4:6280414	WFS1	0.68	17.7	0.57	2.54e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg19622623	chr12:86230825	RASSF9	-0.28	-8.08	-0.3	3.17e-15	Major depressive disorder;
BRCA	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg08917208	chr2:24149416	ATAD2B	1.1	15.63	0.53	7.08e-47	Lymphocyte counts;
BRCA	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg03433033	chr1:76189801	ACADM	-0.46	-9.42	-0.35	8.36e-20	Daytime sleep phenotypes;
BRCA	cis	rs950776	0.720	rs11637890	chr15:78935419	C/G	cg06917634	chr15:78832804	PSMA4	-0.52	-10.19	-0.37	1.03e-22	Sudden cardiac arrest;
BRCA	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg05729581	chr11:3078854	CARS	-0.36	-8.86	-0.33	7.97e-18	Longevity;
BRCA	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg05527609	chr1:210001259	C1orf107	0.69	15.0	0.51	8.45e-44	Orofacial clefts;
BRCA	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	7.9e-19	Lymphocyte counts;
BRCA	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg07988820	chr12:82153109	PPFIA2	0.59	9.64	0.36	1.26e-20	Resting heart rate;
BRCA	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg02734326	chr4:10020555	SLC2A9	0.41	8.92	0.33	4.81e-18	Bone mineral density;
BRCA	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.38	0.49	7.88e-41	Motion sickness;
BRCA	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.63	13.58	0.47	4.23e-37	Lymphocyte percentage of white cells;
BRCA	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11644478	chr21:40555479	PSMG1	-0.66	-14.65	-0.5	4.24e-42	Cognitive function;
BRCA	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.48	0.38	8.25e-24	Motion sickness;
BRCA	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg23711669	chr6:146136114	FBXO30	0.74	16.99	0.56	1.09e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6901250	0.851	rs339360	chr6:117160872	G/T	cg12892004	chr6:117198278	RFX6	-0.5	-11.55	-0.42	3.85e-28	C-reactive protein levels;
BRCA	trans	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg25214090	chr10:38739885	LOC399744	0.52	11.9	0.43	1.24e-29	Corneal astigmatism;
BRCA	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.61	8.47	0.32	1.68e-16	Putamen volume;
BRCA	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg10978503	chr1:24200527	CNR2	0.47	12.16	0.43	9.86e-31	Immature fraction of reticulocytes;
BRCA	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg07080220	chr10:102295463	HIF1AN	0.65	15.11	0.51	2.53e-44	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg12311346	chr5:56204834	C5orf35	-0.8	-16.01	-0.54	9.43e-49	Initial pursuit acceleration;
BRCA	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg20019365	chr2:219134978	PNKD;AAMP	0.6	13.38	0.47	3.74e-36	High light scatter reticulocyte percentage of red cells;Plateletcrit;
BRCA	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.89	-0.33	6.07e-18	Total body bone mineral density;
BRCA	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08704250	chr15:31115839	NA	0.34	8.81	0.33	1.22e-17	Huntington's disease progression;
BRCA	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-9.73	-0.36	5.71e-21	IgG glycosylation;
BRCA	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	9.17	0.34	6.48e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg05901451	chr6:126070800	HEY2	-0.39	-9.41	-0.35	9.06e-20	Endometrial cancer;
BRCA	cis	rs7927771	0.524	rs4752796	chr11:47841862	A/G	cg20307385	chr11:47447363	PSMC3	-0.4	-9.5	-0.35	4.26e-20	Subjective well-being;
BRCA	cis	rs698833	0.886	rs4953087	chr2:44561627	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	10.11	0.37	2.15e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs701145	0.585	rs1713798	chr3:153807407	G/A	cg17054900	chr3:154042577	DHX36	0.54	9.14	0.34	8.17e-19	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg24829409	chr8:58192753	C8orf71	-0.47	-9.08	-0.34	1.32e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.44	10.25	0.38	6.04e-23	Lymphocyte counts;
BRCA	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg10174797	chr19:8464628	RAB11B	0.35	9.01	0.34	2.41e-18	HDL cholesterol;
BRCA	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg13736514	chr6:26305472	NA	-0.35	-11.82	-0.42	2.62e-29	Educational attainment;
BRCA	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg08213375	chr14:104286397	PPP1R13B	0.41	8.83	0.33	1.02e-17	Reticulocyte count;
BRCA	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg25817165	chr18:72167213	CNDP2	-0.5	-10.9	-0.4	1.7e-25	Mononucleosis;
BRCA	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg23285459	chr7:2802560	GNA12	-0.39	-9.86	-0.36	1.97e-21	Height;
BRCA	cis	rs2882667	0.898	rs11956089	chr5:138394604	G/T	cg04439458	chr5:138467593	SIL1	0.33	8.96	0.33	3.66e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs350251	0.934	rs350210	chr16:12212689	T/G	cg06014057	chr16:12226852	SNX29	0.3	7.87	0.3	1.48e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg26898376	chr11:64110657	CCDC88B	-0.39	-8.36	-0.31	3.92e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg11822812	chr5:140052017	DND1	-0.3	-8.27	-0.31	8e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs17021463	0.902	rs13102926	chr4:95245527	C/T	cg11021082	chr4:95130006	SMARCAD1	0.38	8.03	0.3	4.72e-15	Testicular germ cell tumor;
BRCA	cis	rs7474896	0.559	rs1024202	chr10:38278977	A/C	cg25427524	chr10:38739819	LOC399744	0.54	9.63	0.36	1.4e-20	Obesity (extreme);
BRCA	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.39	8.69	0.32	3.15e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg08000102	chr2:233561755	GIGYF2	0.62	13.68	0.48	1.58e-37	Coronary artery disease;
BRCA	cis	rs8017423	0.647	rs12883844	chr14:90820519	T/C	cg04374321	chr14:90722782	PSMC1	-0.5	-11.92	-0.43	9.86e-30	Mortality in heart failure;
BRCA	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg27489772	chr12:121021490	NA	0.44	7.95	0.3	8.41e-15	Type 1 diabetes nephropathy;
BRCA	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.69	0.36	8.18e-21	Bipolar disorder;
BRCA	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg01262667	chr19:19385393	TM6SF2	0.38	8.23	0.31	1.09e-15	Nonalcoholic fatty liver disease;
BRCA	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg00701064	chr4:6280414	WFS1	0.68	17.68	0.57	3.11e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs11723261	0.621	rs7440274	chr4:155713	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	-0.36	-7.86	-0.3	1.59e-14	Immune response to smallpox vaccine (IL-6);
BRCA	cis	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.59	-11.19	-0.4	1.15e-26	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs10242455	0.702	rs45448997	chr7:99041598	G/C	cg18809830	chr7:99032528	PTCD1	-0.63	-8.98	-0.33	3.13e-18	Blood metabolite levels;
BRCA	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-11.98	-0.43	5.7e-30	Chronic sinus infection;
BRCA	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-13.52	-0.47	7.81e-37	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg22980127	chr19:33182716	NUDT19	-0.9	-18.46	-0.59	2.68e-61	Red blood cell traits;
BRCA	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg21724239	chr8:58056113	NA	0.63	9.8	0.36	3.32e-21	Developmental language disorder (linguistic errors);
BRCA	trans	rs66887589	0.934	rs6817317	chr4:120542827	A/G	cg25214090	chr10:38739885	LOC399744	-0.34	-7.85	-0.3	1.72e-14	Diastolic blood pressure;
BRCA	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg20203395	chr5:56204925	C5orf35	-0.5	-10.12	-0.37	1.97e-22	Initial pursuit acceleration;
BRCA	cis	rs12210905	0.688	rs12374649	chr6:27343726	C/T	cg08851530	chr6:28072375	NA	0.84	8.07	0.3	3.48e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs4845875	0.626	rs10779764	chr1:11832311	G/C	cg24844545	chr1:11908347	NPPA	0.31	7.85	0.3	1.78e-14	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.37	-7.99	-0.3	6.32e-15	Longevity;Endometriosis;
BRCA	cis	rs679087	0.932	rs721617	chr12:29934586	C/T	cg14258853	chr12:29935411	TMTC1	0.4	8.92	0.33	4.99e-18	Schizophrenia;
BRCA	trans	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg17712092	chr4:129076599	LARP1B	-0.54	-12.43	-0.44	6.53e-32	Eosinophil percentage of white cells;
BRCA	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-8.91	-0.33	5.22e-18	Alzheimer's disease (late onset);
BRCA	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.16e-47	Alzheimer's disease (late onset);
BRCA	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.01	-0.43	4.17e-30	Alzheimer's disease;
BRCA	cis	rs17253792	0.822	rs17683656	chr14:56053361	C/T	cg01858014	chr14:56050164	KTN1	0.77	10.98	0.4	8.52e-26	Putamen volume;
BRCA	cis	rs2806561	0.754	rs648322	chr1:23294839	C/T	cg19743168	chr1:23544995	NA	0.38	9.29	0.34	2.47e-19	Height;
BRCA	cis	rs250677	0.522	rs10045726	chr5:148352990	C/T	cg12140854	chr5:148520817	ABLIM3	0.41	8.46	0.32	1.83e-16	Breast cancer;
BRCA	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg03585969	chr10:35415529	CREM	0.47	10.03	0.37	4.46e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg21782813	chr7:2030301	MAD1L1	0.38	10.19	0.37	1.07e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-11.5	-0.41	5.94e-28	Gut microbiome composition (summer);
BRCA	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg12373951	chr3:133503437	NA	0.45	10.61	0.39	2.43e-24	Iron status biomarkers;
BRCA	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21659725	chr3:3221576	CRBN	-0.49	-12.59	-0.45	1.28e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11764359	chr7:65958608	NA	0.76	16.6	0.55	1.05e-51	Aortic root size;
BRCA	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg07828340	chr4:882639	GAK	0.96	11.41	0.41	1.46e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs3768617	0.782	rs12143211	chr1:182990172	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.47	10.17	0.37	1.31e-22	Fuchs's corneal dystrophy;
BRCA	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg02544614	chr20:61657117	NA	0.29	8.19	0.31	1.44e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg05347473	chr6:146136440	FBXO30	0.4	7.93	0.3	9.88e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg02574844	chr11:5959923	NA	-0.4	-8.22	-0.31	1.11e-15	DNA methylation (variation);
BRCA	cis	rs13401104	0.587	rs6431443	chr2:237150311	T/C	cg19324714	chr2:237145437	ASB18	0.38	7.86	0.3	1.65e-14	Educational attainment;
BRCA	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	8.0	0.3	6.07e-15	Diabetic retinopathy;
BRCA	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg04455712	chr21:45112962	RRP1B	0.4	10.5	0.38	6.75e-24	Mean corpuscular volume;
BRCA	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.46	-10.87	-0.39	2.32e-25	IgG glycosylation;
BRCA	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg04553112	chr3:125709451	NA	-0.55	-8.77	-0.33	1.57e-17	Blood pressure (smoking interaction);
BRCA	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg18512352	chr11:47633146	NA	-0.37	-8.84	-0.33	9.5e-18	Subjective well-being;
BRCA	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg24296786	chr1:45957014	TESK2	0.62	15.49	0.52	3.48e-46	High light scatter reticulocyte count;
BRCA	cis	rs28669119	0.841	rs10044342	chr5:88178683	C/T	cg18498987	chr5:88179539	MEF2C	-0.42	-8.08	-0.3	3.13e-15	Schizophrenia;
BRCA	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg13010199	chr12:38710504	ALG10B	0.55	12.21	0.43	5.87e-31	Heart rate;
BRCA	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg10876282	chr6:28092338	ZSCAN16	0.42	8.39	0.32	3.09e-16	Cardiac Troponin-T levels;
BRCA	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg24692254	chr21:30365293	RNF160	-0.46	-9.93	-0.37	1.02e-21	Cognitive test performance;
BRCA	cis	rs17253792	0.822	rs77033617	chr14:56129746	T/A	cg01858014	chr14:56050164	KTN1	-0.74	-9.16	-0.34	7.15e-19	Putamen volume;
BRCA	cis	rs7572263	0.959	rs7583625	chr2:209048739	A/G	cg23998903	chr2:209048830	C2orf80	-0.32	-8.11	-0.31	2.63e-15	Glioma;Non-glioblastoma glioma;
BRCA	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18402987	chr7:1209562	NA	0.61	13.06	0.46	1.05e-34	Longevity;Endometriosis;
BRCA	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg00012203	chr2:219082015	ARPC2	-0.42	-8.14	-0.31	2.12e-15	Ulcerative colitis;
BRCA	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg16606324	chr3:10149918	C3orf24	0.46	7.95	0.3	8.24e-15	Alzheimer's disease;
BRCA	cis	rs9880211	1.000	rs9826454	chr3:135953220	A/G	cg21827317	chr3:136751795	NA	-0.43	-7.87	-0.3	1.55e-14	Body mass index;Height;
BRCA	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg00152838	chr16:24741724	TNRC6A	-0.35	-7.98	-0.3	7.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg07741184	chr6:167504864	NA	0.34	10.11	0.37	2.23e-22	Primary biliary cholangitis;
BRCA	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	13.42	0.47	2.29e-36	Mean platelet volume;
BRCA	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg23029597	chr12:123009494	RSRC2	-0.6	-12.31	-0.44	2.21e-31	Body mass index;
BRCA	cis	rs2652834	0.808	rs11071723	chr15:63355275	A/T	cg05507819	chr15:63340323	TPM1	0.53	9.25	0.34	3.23e-19	HDL cholesterol;
BRCA	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg22974920	chr21:40686053	BRWD1	-0.39	-8.79	-0.33	1.34e-17	Cognitive function;
BRCA	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.01	15.23	0.52	6.41e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg25356066	chr3:128598488	ACAD9	0.36	8.39	0.32	3.1e-16	IgG glycosylation;
BRCA	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg03453431	chr7:157225567	NA	-0.48	-9.78	-0.36	3.94e-21	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	trans	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg25214090	chr10:38739885	LOC399744	0.35	7.98	0.3	6.75e-15	Diastolic blood pressure;
BRCA	trans	rs1459104	0.929	rs2017467	chr11:55234605	G/A	cg15704280	chr7:45808275	SEPT13	0.67	8.35	0.31	4.13e-16	Body mass index;
BRCA	cis	rs7677751	0.708	rs2052699	chr4:55063994	C/T	cg17187183	chr4:55093834	PDGFRA	0.4	8.14	0.31	2.01e-15	Corneal astigmatism;
BRCA	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.03	0.34	2.08e-18	Motion sickness;
BRCA	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg24088639	chr11:34937564	PDHX;APIP	-0.4	-9.04	-0.34	1.8e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg22713356	chr15:30763199	NA	1.3	26.04	0.72	1.81e-102	Uric acid levels;
BRCA	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg22800045	chr5:56110881	MAP3K1	0.61	11.5	0.41	6.04e-28	Initial pursuit acceleration;
BRCA	cis	rs7246657	0.653	rs10402050	chr19:37688958	A/T	cg14683738	chr19:37701593	ZNF585B	0.54	8.19	0.31	1.4e-15	Coronary artery calcification;
BRCA	cis	rs6446731	0.734	rs10937921	chr4:3276491	C/T	cg08886695	chr4:3369023	RGS12	-0.34	-8.63	-0.32	5.01e-17	Mean platelet volume;
BRCA	trans	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg06521331	chr12:34319734	NA	-0.45	-8.34	-0.31	4.44e-16	Bladder cancer;
BRCA	cis	rs3771570	0.901	rs4675963	chr2:242324763	G/A	cg21155796	chr2:242212141	HDLBP	0.47	8.22	0.31	1.1e-15	Prostate cancer;
BRCA	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.43	-0.32	2.27e-16	Monocyte percentage of white cells;
BRCA	cis	rs6142102	0.923	rs4911383	chr20:32555779	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	7.97	0.3	7.52e-15	Skin pigmentation;
BRCA	cis	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg07460842	chr6:66804631	NA	0.98	19.6	0.61	2.42e-67	Exhaled nitric oxide output;
BRCA	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-12.95	-0.46	3.16e-34	Migraine;Coronary artery disease;
BRCA	cis	rs7766436	0.885	rs13198323	chr6:22577065	C/T	cg13666174	chr6:22585274	NA	-0.48	-11.17	-0.4	1.34e-26	Coronary artery disease;
BRCA	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg12062639	chr20:23401060	NAPB	-0.88	-12.83	-0.45	1.08e-33	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg20887711	chr4:1340912	KIAA1530	0.43	10.48	0.38	7.81e-24	Longevity;
BRCA	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg13010199	chr12:38710504	ALG10B	0.45	9.59	0.35	1.8899999999999998e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.59	7.98	0.3	6.61e-15	Diabetic retinopathy;
BRCA	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg20203395	chr5:56204925	C5orf35	-0.5	-10.02	-0.37	4.88e-22	Initial pursuit acceleration;
BRCA	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg01475377	chr6:109611718	NA	-0.6	-16.59	-0.55	1.15e-51	Reticulocyte fraction of red cells;
BRCA	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.23e-24	Motion sickness;
BRCA	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg19717773	chr7:2847554	GNA12	-0.42	-9.37	-0.35	1.18e-19	Height;
BRCA	cis	rs2066819	1.000	rs79718165	chr12:56644251	C/T	cg26714650	chr12:56694279	CS	-1.18	-15.33	-0.52	2.13e-45	Psoriasis vulgaris;
BRCA	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg09904177	chr6:26538194	HMGN4	0.43	12.65	0.45	6.53e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg10223061	chr2:219282414	VIL1	-0.27	-8.03	-0.3	4.76e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7254827	0.868	rs71338610	chr19:17210041	G/A	cg19418318	chr19:17219073	MYO9B	-0.51	-10.4	-0.38	1.69e-23	Mean platelet volume;
BRCA	trans	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg06521331	chr12:34319734	NA	-0.49	-9.11	-0.34	1.06e-18	Bladder cancer;
BRCA	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07080220	chr10:102295463	HIF1AN	0.52	12.36	0.44	1.28e-31	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	7e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg20587970	chr11:113659929	NA	-1.24	-22.64	-0.67	8.57e-84	Hip circumference adjusted for BMI;
BRCA	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg23711669	chr6:146136114	FBXO30	0.67	15.72	0.53	2.45e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8017423	0.626	rs8003363	chr14:90826840	T/C	cg04374321	chr14:90722782	PSMC1	-0.49	-11.68	-0.42	1.02e-28	Mortality in heart failure;
BRCA	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg03433033	chr1:76189801	ACADM	0.73	18.86	0.6	2.17e-63	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg09455208	chr3:40491958	NA	-0.49	-10.91	-0.4	1.62e-25	Renal cell carcinoma;
BRCA	cis	rs12618769	0.543	rs2278211	chr2:99149946	G/A	cg10123293	chr2:99228465	UNC50	0.43	7.98	0.3	7.01e-15	Bipolar disorder;
BRCA	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg16325326	chr1:53192061	ZYG11B	-0.79	-22.16	-0.66	3.5e-81	Monocyte count;
BRCA	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2430386	1.000	rs2430386	chr2:63178111	C/T	cg17519650	chr2:63277830	OTX1	0.42	9.92	0.37	1.17e-21	Prostate cancer;
BRCA	cis	rs13136331	0.641	rs2627685	chr4:88657792	T/C	cg22416721	chr4:88570574	DMP1	-0.56	-13.49	-0.47	1.15e-36	Sitting height ratio;
BRCA	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg21770322	chr7:97807741	LMTK2	0.42	11.3	0.41	4e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6087771	0.890	rs6089056	chr20:30325773	A/G	cg21427119	chr20:30132790	HM13	-0.35	-8.04	-0.3	4.42e-15	Subcortical brain region volumes;Putamen volume;
BRCA	cis	rs11971779	0.680	rs6962637	chr7:139051350	G/A	cg07862535	chr7:139043722	LUC7L2	0.38	10.31	0.38	3.76e-23	Diisocyanate-induced asthma;
BRCA	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-15.94	-0.53	2.15e-48	Alzheimer's disease (late onset);
BRCA	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg22508957	chr16:3507546	NAT15	-0.46	-11.32	-0.41	3.21e-27	Tuberculosis;
BRCA	trans	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-21.02	-0.64	5.66e-75	Exhaled nitric oxide output;
BRCA	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg20387954	chr3:183756860	HTR3D	0.45	10.11	0.37	2.13e-22	Anterior chamber depth;
BRCA	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg24812749	chr6:127587940	RNF146	0.85	19.76	0.62	3.28e-68	Breast cancer;
BRCA	cis	rs9341808	0.718	rs9443734	chr6:80820293	C/T	cg08355045	chr6:80787529	NA	0.37	9.38	0.35	1.13e-19	Sitting height ratio;
BRCA	trans	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg01620082	chr3:125678407	NA	-0.88	-10.15	-0.37	1.5e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg10950924	chr17:47092072	IGF2BP1	0.36	9.37	0.35	1.25e-19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
BRCA	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg24692254	chr21:30365293	RNF160	0.5	11.32	0.41	3.3e-27	Cognitive test performance;
BRCA	cis	rs8028182	0.609	rs10220738	chr15:75666546	A/T	cg20655648	chr15:75932815	IMP3	-0.4	-7.83	-0.3	2.03e-14	Sudden cardiac arrest;
BRCA	cis	rs218264	0.592	rs6840845	chr4:55366235	A/G	cg17105814	chr4:55365203	NA	0.38	7.82	0.3	2.12e-14	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.29	0.31	6.69e-16	Axial length;
BRCA	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.84	18.62	0.59	3.9e-62	Smoking behavior;
BRCA	cis	rs9290065	0.622	rs6797798	chr3:160646598	G/A	cg03342759	chr3:160939853	NMD3	0.41	8.49	0.32	1.4e-16	Kawasaki disease;
BRCA	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.43	-0.44	6.2e-32	Chronic sinus infection;
BRCA	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-12.81	-0.45	1.34e-33	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg08601574	chr20:25228251	PYGB	0.4	9.36	0.35	1.35e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg06521331	chr12:34319734	NA	-0.61	-11.18	-0.4	1.2e-26	Morning vs. evening chronotype;
BRCA	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg14664628	chr15:75095509	CSK	-0.86	-22.99	-0.67	1.13e-85	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg22431228	chr1:16359049	CLCNKA	0.45	9.42	0.35	8.08e-20	Dilated cardiomyopathy;
BRCA	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg19678392	chr7:94953810	PON1	-0.39	-8.05	-0.3	4.05e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs208515	0.560	rs207084	chr6:66776966	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-32.55	-0.79	9.22e-138	Exhaled nitric oxide levels;
BRCA	cis	rs4730250	0.634	rs257371	chr7:106795043	C/A	cg02696742	chr7:106810147	HBP1	-0.58	-9.53	-0.35	3.32e-20	Osteoarthritis;
BRCA	trans	rs8073060	0.586	rs2011897	chr17:34054408	A/T	cg19694781	chr19:47549865	TMEM160	1.06	21.21	0.64	5.22e-76	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21659725	chr3:3221576	CRBN	-0.48	-10.32	-0.38	3.26e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4919694	0.611	rs76695159	chr10:105070837	C/T	cg04362960	chr10:104952993	NT5C2	0.72	11.29	0.41	4.47e-27	Arsenic metabolism;
BRCA	cis	rs897080	0.515	rs1067409	chr2:44673057	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	9.17	0.34	6.53e-19	Height;
BRCA	cis	rs7394190	0.748	rs2292307	chr10:75549916	C/A	cg07699608	chr10:75541558	CHCHD1	0.71	10.36	0.38	2.41e-23	Incident atrial fibrillation;
BRCA	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg19920283	chr7:105172520	RINT1	0.59	9.53	0.35	3.29e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg06115741	chr20:33292138	TP53INP2	0.5	11.31	0.41	3.64e-27	Coronary artery disease;
BRCA	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg25703541	chr22:24373054	LOC391322	-0.49	-9.04	-0.34	1.92e-18	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-10.14	-0.37	1.7e-22	Personality dimensions;
BRCA	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	10.01	0.37	5.23e-22	Tonsillectomy;
BRCA	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	9.84	0.36	2.37e-21	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg27446573	chr6:127587934	RNF146	-0.78	-15.52	-0.52	2.38e-46	Breast cancer;
BRCA	cis	rs524281	0.861	rs10791855	chr11:65963737	A/G	cg16950941	chr11:66035639	RAB1B	-0.39	-8.37	-0.31	3.77e-16	Electroencephalogram traits;
BRCA	cis	rs28830936	0.510	rs11858843	chr15:42092915	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.51	-19.45	-0.61	1.53e-66	Diastolic blood pressure;
BRCA	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.53	-0.5	1.55e-41	Eye color traits;
BRCA	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.39	0.57	9.59e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg08470875	chr2:26401718	FAM59B	-0.75	-12.08	-0.43	2.14e-30	Gut microbiome composition (summer);
BRCA	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg16049864	chr8:95962084	TP53INP1	-0.44	-10.83	-0.39	3.3e-25	Type 2 diabetes;
BRCA	cis	rs7577696	0.597	rs2280968	chr2:32290040	G/T	cg02381751	chr2:32503542	YIPF4	-0.42	-8.01	-0.3	5.47e-15	Inflammatory biomarkers;
BRCA	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	9.26	0.34	3.02e-19	Height;
BRCA	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg06885757	chr1:42089581	HIVEP3	-0.28	-10.32	-0.38	3.37e-23	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs6484504	0.625	rs4922859	chr11:31382517	A/G	cg14844989	chr11:31128820	NA	0.44	9.6	0.35	1.85e-20	Red blood cell count;
BRCA	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg08085267	chr17:45401833	C17orf57	-0.59	-12.15	-0.43	1.07e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9811920	0.665	rs1872609	chr3:99906579	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.4	-9.22	-0.34	4.35e-19	Axial length;
BRCA	cis	rs10838687	0.736	rs1449626	chr11:47290759	A/C	cg25783544	chr11:47291846	MADD	0.41	7.84	0.3	1.92e-14	Proinsulin levels;
BRCA	cis	rs701145	0.585	rs1727882	chr3:153837246	C/T	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.22e-14	Coronary artery disease;
BRCA	cis	rs13315871	0.929	rs77487951	chr3:58290892	G/A	cg20936604	chr3:58311152	NA	-0.67	-8.64	-0.32	4.35e-17	Cholesterol, total;
BRCA	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg18132916	chr6:79620363	NA	-0.48	-10.88	-0.4	2.14e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs1403694	0.695	rs13317089	chr3:186436217	G/C	cg12454167	chr3:186435060	KNG1	0.29	7.94	0.3	9.4e-15	Blood protein levels;
BRCA	cis	rs12611088	0.600	rs2355994	chr19:44005107	T/C	cg15012607	chr19:44012195	ETHE1	-0.33	-7.98	-0.3	6.9e-15	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs6426558	0.537	rs694740	chr1:227293451	A/G	cg10327440	chr1:227177885	CDC42BPA	0.47	9.32	0.35	1.81e-19	Neutrophil percentage of white cells;
BRCA	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg21132104	chr15:45694354	SPATA5L1	0.76	17.26	0.56	4.5e-55	Homoarginine levels;
BRCA	cis	rs6545883	0.965	rs1992765	chr2:61751333	A/G	cg15711740	chr2:61764176	XPO1	-0.54	-14.03	-0.49	3.53e-39	Tuberculosis;
BRCA	cis	rs2415984	0.600	rs61993299	chr14:46944880	A/C	cg14871534	chr14:47121158	RPL10L	-0.32	-7.92	-0.3	1.09e-14	Number of children ever born;
BRCA	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg08132940	chr7:1081526	C7orf50	-0.47	-8.34	-0.31	4.69e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-11.27	-0.41	5.36e-27	IgG glycosylation;
BRCA	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	8.11	0.31	2.67e-15	Schizophrenia;
BRCA	trans	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.9	0.3	1.22e-14	Corneal astigmatism;
BRCA	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg01256987	chr12:42539512	GXYLT1	-0.46	-9.14	-0.34	7.98e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg04025307	chr7:1156635	C7orf50	0.5	8.33	0.31	4.97e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg04450456	chr4:17643702	FAM184B	-0.36	-10.39	-0.38	1.79e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg17691542	chr6:26056736	HIST1H1C	0.53	11.39	0.41	1.7e-27	Height;
BRCA	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg19729930	chr2:74357872	NA	0.58	14.23	0.49	4.2e-40	Gestational age at birth (maternal effect);
BRCA	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25427524	chr10:38739819	LOC399744	-0.59	-13.57	-0.47	4.76e-37	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg14019146	chr3:50243930	SLC38A3	-0.38	-9.2	-0.34	5.22e-19	Body mass index;
BRCA	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg08213375	chr14:104286397	PPP1R13B	0.66	18.75	0.6	7.68e-63	Schizophrenia;
BRCA	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg09307838	chr4:120376055	NA	0.69	13.95	0.48	8.36e-39	Corneal astigmatism;
BRCA	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.11	0.34	1.06e-18	Platelet count;
BRCA	trans	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-18.32	-0.59	1.38e-60	Exhaled nitric oxide output;
BRCA	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg22139774	chr2:100720529	AFF3	-0.31	-8.73	-0.33	2.26e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg00277334	chr10:82204260	NA	-0.85	-25.05	-0.7	5.02e-97	Post bronchodilator FEV1;
BRCA	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg27572855	chr1:25598939	RHD	-0.47	-13.55	-0.47	6.06e-37	Erythrocyte sedimentation rate;
BRCA	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.89	16.26	0.54	5.05e-50	Lymphocyte percentage of white cells;
BRCA	cis	rs4948102	0.595	rs7793921	chr7:56120881	G/A	cg09872392	chr7:56161020	PHKG1	-0.44	-11.11	-0.4	2.47e-26	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg11168104	chr5:1857477	NA	-0.32	-8.43	-0.32	2.35e-16	Cardiovascular disease risk factors;
BRCA	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg07537917	chr2:241836409	C2orf54	-0.43	-10.42	-0.38	1.38e-23	Urinary metabolites;
BRCA	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg13119609	chr19:45449297	APOC2	0.48	13.24	0.46	1.64e-35	Blood protein levels;
BRCA	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg18252515	chr7:66147081	NA	-1.08	-15.16	-0.51	1.51e-44	Diabetic kidney disease;
BRCA	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg05707623	chr12:122985044	ZCCHC8	0.41	8.5	0.32	1.36e-16	Body mass index;
BRCA	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg16405210	chr4:1374714	KIAA1530	-0.36	-7.87	-0.3	1.58e-14	Obesity-related traits;
BRCA	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-13.45	-0.47	1.71e-36	Total cholesterol levels;
BRCA	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg08470875	chr2:26401718	FAM59B	-0.51	-8.17	-0.31	1.62e-15	Gut microbiome composition (summer);
BRCA	cis	rs12612619	0.667	rs11126871	chr2:27344457	T/A	cg00617064	chr2:27272375	NA	0.32	8.01	0.3	5.6e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs7582720	1.000	rs72936304	chr2:204036357	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	12.25	0.44	3.99e-31	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs9815354	0.812	rs111277902	chr3:41950312	C/T	cg03022575	chr3:42003672	ULK4	0.69	9.62	0.36	1.44e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs113835537	0.529	rs3819247	chr11:66293779	T/C	cg24851651	chr11:66362959	CCS	0.47	8.81	0.33	1.22e-17	Airway imaging phenotypes;
BRCA	cis	rs7631605	0.905	rs4678940	chr3:37187513	G/A	cg15934958	chr3:37212084	LRRFIP2	0.43	9.97	0.37	7.56e-22	Cerebrospinal P-tau181p levels;
BRCA	cis	rs4965272	1.000	rs1480955	chr15:100581989	T/A	cg27344315	chr15:100560801	ADAMTS17	0.39	8.1	0.31	2.78e-15	Gastroesophageal reflux disease;
BRCA	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.17	-0.43	8.62e-31	Alzheimer's disease;
BRCA	trans	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.42	-0.35	7.92e-20	Neuroticism;
BRCA	cis	rs6882046	0.513	rs587490	chr5:88032522	C/T	cg22951263	chr5:87985283	NA	-0.38	-10.66	-0.39	1.58e-24	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg00383909	chr3:49044727	WDR6	0.98	15.72	0.53	2.59e-47	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs1691799	0.899	rs1168292	chr12:66732660	C/T	cg16791601	chr12:66731901	HELB	-0.65	-17.6	-0.57	7.75e-57	White blood cell count (basophil);
BRCA	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg09904177	chr6:26538194	HMGN4	0.55	17.68	0.57	3.11e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg00105475	chr2:10696890	NA	0.44	10.25	0.38	6.46e-23	Prostate cancer;
BRCA	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	14.77	0.5	1.09e-42	Platelet count;
BRCA	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg26384229	chr12:38710491	ALG10B	0.54	11.47	0.41	7.77e-28	Morning vs. evening chronotype;
BRCA	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg12373951	chr3:133503437	NA	0.46	10.82	0.39	3.66e-25	Iron status biomarkers;
BRCA	cis	rs312273	0.748	rs10879450	chr12:41367808	T/C	cg17827154	chr12:41323612	CNTN1	-0.39	-10.12	-0.37	2.01e-22	Bipolar disorder;
BRCA	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg23358479	chr7:1110784	C7orf50	-0.47	-7.95	-0.3	8.75e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11764359	chr7:65958608	NA	-0.78	-17.82	-0.58	5.88e-58	Aortic root size;
BRCA	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.34	-0.31	4.55e-16	Total body bone mineral density;
BRCA	cis	rs6435161	1.000	rs72926976	chr2:203512138	C/A	cg18429434	chr2:203499731	FAM117B	-0.45	-8.83	-0.33	9.7e-18	Total cholesterol levels;
BRCA	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg24642439	chr20:33292090	TP53INP2	-0.64	-13.18	-0.46	2.8e-35	Coronary artery disease;
BRCA	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg22800045	chr5:56110881	MAP3K1	0.55	10.24	0.38	6.72e-23	Initial pursuit acceleration;
BRCA	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.36	-0.38	2.35e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg00376283	chr12:123451042	ABCB9	0.51	11.53	0.41	4.56e-28	Neutrophil percentage of white cells;
BRCA	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg24154853	chr7:158122151	PTPRN2	0.34	7.85	0.3	1.81e-14	Calcium levels;
BRCA	cis	rs7246967	0.551	rs16998998	chr19:22911116	T/C	cg23217946	chr19:22817039	ZNF492	0.5	9.16	0.34	6.71e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg08885076	chr2:99613938	TSGA10	-0.59	-13.21	-0.46	2.12e-35	Chronic sinus infection;
BRCA	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	8.75	0.33	1.89e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg17211192	chr8:82754475	SNX16	-0.49	-11.16	-0.4	1.5e-26	Diastolic blood pressure;
BRCA	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.44	9.08	0.34	1.3e-18	Eosinophil percentage of white cells;
BRCA	cis	rs1865721	0.656	rs727894	chr18:73137117	C/T	cg26385618	chr18:73139727	C18orf62	-0.36	-9.03	-0.34	2.08e-18	Intelligence;
BRCA	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg20891283	chr12:69753455	YEATS4	0.84	28.41	0.75	1.93e-115	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-10.88	-0.4	2.03e-25	Personality dimensions;
BRCA	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg08508325	chr11:3079039	CARS	-0.43	-15.37	-0.52	1.38e-45	Longevity;
BRCA	cis	rs13046373	0.535	rs2832970	chr21:32020767	T/C	cg22337977	chr21:31811175	KRTAP15-1	0.33	7.86	0.3	1.6e-14	HDL cholesterol;
BRCA	cis	rs6580649	0.783	rs1635526	chr12:48396785	C/T	cg24011408	chr12:48396354	COL2A1	0.54	9.14	0.34	8.5e-19	Lung cancer;
BRCA	trans	rs9409565	1.000	rs9409565	chr9:97251034	C/T	cg05679027	chr9:99775184	HIATL2	-0.36	-7.85	-0.3	1.75e-14	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs7737355	0.947	rs10478980	chr5:130618247	C/T	cg06307176	chr5:131281290	NA	0.46	8.91	0.33	5.14e-18	Life satisfaction;
BRCA	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg00101154	chr16:420108	MRPL28	0.46	10.64	0.39	1.87e-24	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs6446731	0.614	rs6446727	chr4:3274488	T/A	cg08886695	chr4:3369023	RGS12	-0.38	-10.01	-0.37	5.02e-22	Mean platelet volume;
BRCA	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg26754761	chr2:177040938	NA	-0.45	-8.78	-0.33	1.43e-17	Obstructive sleep apnea trait (apnea hypopnea index);
BRCA	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg21479132	chr6:26055353	NA	0.56	8.03	0.3	4.84e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg20848291	chr7:100343083	ZAN	0.36	8.13	0.31	2.17e-15	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg00852783	chr1:26633632	UBXN11	-0.46	-8.09	-0.3	2.9e-15	Obesity-related traits;
BRCA	cis	rs829883	1.000	rs829883	chr12:98879606	G/A	cg25150519	chr12:98850993	NA	0.58	11.77	0.42	4.21e-29	Colorectal adenoma (advanced);
BRCA	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-16.76	-0.55	1.62e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.03	-0.43	3.53e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg00717180	chr2:96193071	NA	-0.37	-10.23	-0.38	7.69e-23	Height;
BRCA	cis	rs13102973	0.899	rs4479760	chr4:135867474	T/C	cg14419869	chr4:135874104	NA	0.51	10.89	0.4	1.89e-25	Subjective well-being;
BRCA	cis	rs1355223	0.507	rs11032903	chr11:34876176	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-9.48	-0.35	4.85e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg15605315	chr1:45957053	TESK2	0.49	9.83	0.36	2.41e-21	High light scatter reticulocyte count;
BRCA	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	12.32	0.44	1.93e-31	Monocyte percentage of white cells;
BRCA	cis	rs6893300	0.524	rs12522926	chr5:179214818	G/A	cg14593053	chr5:179126677	CANX	0.48	13.17	0.46	3.21e-35	Resting heart rate;
BRCA	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg00814883	chr7:100076585	TSC22D4	0.5	10.27	0.38	5.29e-23	Platelet count;
BRCA	cis	rs1420338	0.933	rs12540602	chr7:34174056	G/A	cg01275685	chr7:34179230	BMPER	-0.51	-11.27	-0.41	5.39e-27	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg11764359	chr7:65958608	NA	-0.64	-11.36	-0.41	2.28e-27	Aortic root size;
BRCA	cis	rs4919694	0.572	rs4917995	chr10:104845443	A/T	cg04362960	chr10:104952993	NT5C2	-0.72	-12.66	-0.45	6.06e-33	Arsenic metabolism;
BRCA	cis	rs7945718	0.935	rs4757059	chr11:12812356	G/A	cg25843174	chr11:12811716	TEAD1	-0.23	-8.67	-0.32	3.64e-17	Educational attainment (years of education);
BRCA	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg05863683	chr7:1912471	MAD1L1	-0.35	-8.21	-0.31	1.21e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg22535103	chr8:58192502	C8orf71	-0.44	-8.85	-0.33	8.47e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.46	0.38	9.36e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs34779708	0.931	rs2384283	chr10:35326789	G/A	cg03585969	chr10:35415529	CREM	0.56	11.56	0.42	3.36e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	18.56	0.59	7.92e-62	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg03213289	chr20:61660250	NA	0.61	16.23	0.54	7.73e-50	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21659725	chr3:3221576	CRBN	-0.5	-12.78	-0.45	1.75e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg11663144	chr21:46675770	NA	-0.62	-14.15	-0.49	9.92e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg25427524	chr10:38739819	LOC399744	0.43	8.97	0.33	3.29e-18	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs12474201	0.894	rs34401107	chr2:46972768	A/C	cg06386533	chr2:46925753	SOCS5	0.83	18.7	0.59	1.4e-62	Height;
BRCA	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg21143896	chr7:2802374	GNA12	-0.34	-8.39	-0.32	3.09e-16	Height;
BRCA	cis	rs11229555	0.609	rs12289198	chr11:58175057	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.77	-0.36	4.3e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg03433033	chr1:76189801	ACADM	0.62	13.83	0.48	3.11e-38	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.52	-0.32	1.11e-16	Monocyte percentage of white cells;
BRCA	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg23711669	chr6:146136114	FBXO30	0.64	14.61	0.5	6.74e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11229555	1.000	rs11229555	chr11:58408687	G/T	cg15696309	chr11:58395628	NA	-0.52	-11.61	-0.42	2.13e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3770081	1.000	rs2303339	chr2:86346180	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.67	8.86	0.33	8.1e-18	Facial emotion recognition (sad faces);
BRCA	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg06552810	chr11:31128660	NA	-0.4	-8.82	-0.33	1.09e-17	Red blood cell count;
BRCA	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg09307838	chr4:120376055	NA	0.6	11.15	0.4	1.72e-26	Corneal astigmatism;
BRCA	trans	rs8002861	0.901	rs9525867	chr13:44463557	G/A	cg17145862	chr1:211918768	LPGAT1	0.74	19.7	0.61	7.66e-68	Leprosy;
BRCA	trans	rs225245	0.782	rs225293	chr17:33925906	A/G	cg19694781	chr19:47549865	TMEM160	-0.32	-7.85	-0.3	1.8e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.31	-7.85	-0.3	1.74e-14	Total body bone mineral density;
BRCA	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg07636037	chr3:49044803	WDR6	-0.49	-8.13	-0.31	2.23e-15	Menarche (age at onset);
BRCA	trans	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg19894588	chr14:64061835	NA	0.34	8.43	0.32	2.32e-16	Glioblastoma;Glioma;
BRCA	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	11.49	0.41	6.29e-28	Height;
BRCA	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg26384229	chr12:38710491	ALG10B	0.66	15.05	0.51	4.81e-44	Bladder cancer;
BRCA	cis	rs757081	0.667	rs12577418	chr11:17101554	C/G	cg15432903	chr11:17409602	KCNJ11	-0.47	-8.59	-0.32	6.48e-17	Systolic blood pressure;
BRCA	cis	rs6545883	0.929	rs2694625	chr2:61616055	G/A	cg15711740	chr2:61764176	XPO1	0.52	12.75	0.45	2.4e-33	Tuberculosis;
BRCA	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-13.35	-0.47	4.93e-36	Morning vs. evening chronotype;
BRCA	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg27129171	chr3:47204927	SETD2	0.7	16.95	0.56	1.76e-53	Colorectal cancer;
BRCA	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg08807101	chr21:30365312	RNF160	-0.73	-19.02	-0.6	3e-64	Dental caries;
BRCA	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg04586622	chr2:25135609	ADCY3	0.46	11.53	0.42	4.28e-28	Body mass index;
BRCA	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg24060327	chr5:131705240	SLC22A5	-0.63	-12.05	-0.43	2.95e-30	Breast cancer;
BRCA	cis	rs4787491	0.729	rs4788215	chr16:30047930	G/A	cg06326092	chr16:30034487	C16orf92	0.38	9.9	0.36	1.38e-21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs4596713	0.568	rs6560585	chr9:71747395	A/G	cg16512924	chr15:28394682	HERC2	0.39	9.47	0.35	5.51e-20	Headache;
BRCA	trans	rs6076960	0.598	rs3905168	chr20:6226752	C/T	cg21095983	chr6:86352623	SYNCRIP	0.42	9.2	0.34	4.84e-19	Smooth-surface caries;
BRCA	cis	rs672059	1.000	rs551569	chr1:183158293	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.56	0.32	8.26e-17	Hypertriglyceridemia;
BRCA	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.18	0.4	1.24e-26	Bipolar disorder;
BRCA	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg06092702	chr1:163392909	NA	-0.33	-8.68	-0.32	3.17e-17	Motion sickness;
BRCA	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg02544614	chr20:61657117	NA	0.29	8.19	0.31	1.45e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg25237894	chr2:233734115	C2orf82	0.4	11.48	0.41	7.43e-28	Coronary artery disease;
BRCA	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg24675658	chr1:53192096	ZYG11B	-0.65	-14.34	-0.49	1.24e-40	Monocyte count;
BRCA	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg01528321	chr10:82214614	TSPAN14	0.64	14.64	0.5	4.66e-42	Post bronchodilator FEV1;
BRCA	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg23708337	chr7:1209742	NA	0.49	8.4	0.32	2.81e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7246967	0.551	rs8103204	chr19:22936517	T/A	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg22920501	chr2:26401640	FAM59B	0.9	16.59	0.55	1.12e-51	Gut microbiome composition (summer);
BRCA	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg16405210	chr4:1374714	KIAA1530	0.69	14.29	0.49	2.13e-40	Obesity-related traits;
BRCA	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg25124228	chr12:125621409	AACS	0.45	9.44	0.35	6.77e-20	Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs9462846	0.959	rs9471954	chr6:42880326	C/A	cg05552183	chr6:42928497	GNMT	0.45	7.93	0.3	1.01e-14	Blood protein levels;
BRCA	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	18.14	0.58	1.22e-59	Platelet count;
BRCA	cis	rs9337951	0.596	rs3739998	chr10:30316072	C/G	cg00730780	chr10:30316187	KIAA1462	0.48	10.09	0.37	2.7e-22	Pulse pressure;Coronary artery disease;
BRCA	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-12.59	-0.45	1.26e-32	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg20573242	chr4:122745356	CCNA2	0.49	10.93	0.4	1.25e-25	Type 2 diabetes;
BRCA	cis	rs17092148	0.887	rs6059915	chr20:33147737	C/G	cg16810054	chr20:33298113	TP53INP2	-0.46	-10.35	-0.38	2.59e-23	Neuroticism;
BRCA	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg04362960	chr10:104952993	NT5C2	0.45	10.42	0.38	1.39e-23	Arsenic metabolism;
BRCA	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.38e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg02297831	chr4:17616191	MED28	0.36	8.47	0.32	1.67e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg23711669	chr6:146136114	FBXO30	0.72	16.75	0.55	1.67e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg14008862	chr17:28927542	LRRC37B2	0.58	8.08	0.3	3.28e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.71	11.94	0.43	8.59e-30	Schizophrenia;
BRCA	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg12365402	chr11:9010492	NRIP3	-0.36	-7.86	-0.3	1.58e-14	Hematocrit;
BRCA	cis	rs528301	0.868	rs570305	chr2:45142726	C/G	cg02372786	chr2:45167549	SIX3	-0.49	-11.37	-0.41	2.1e-27	Alcohol and nicotine co-dependence;
BRCA	cis	rs921968	0.541	rs933995	chr2:219650718	G/A	cg02176678	chr2:219576539	TTLL4	-0.41	-11.05	-0.4	4.09e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg16325326	chr1:53192061	ZYG11B	-0.95	-26.1	-0.72	8.67e-103	Monocyte count;
BRCA	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.6	8.29	0.31	6.94e-16	Putamen volume;
BRCA	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg04248312	chr19:17393744	ANKLE1	-0.87	-19.22	-0.61	2.5e-65	Systemic lupus erythematosus;
BRCA	cis	rs708547	0.581	rs13121027	chr4:57813369	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.35	-8.65	-0.32	4.28e-17	Response to bleomycin (chromatid breaks);
BRCA	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg22105103	chr4:187893119	NA	0.41	13.27	0.46	1.16e-35	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3820928	0.874	rs4144328	chr2:227790187	A/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.74	-0.33	1.99e-17	Pulmonary function;
BRCA	trans	rs208520	0.874	rs208518	chr6:66948501	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	16.37	0.54	1.39e-50	Exhaled nitric oxide output;
BRCA	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg03733263	chr8:22462867	KIAA1967	-0.95	-21.25	-0.64	3.18e-76	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg04455712	chr21:45112962	RRP1B	-0.4	-10.07	-0.37	3.04e-22	Mean corpuscular volume;
BRCA	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06108461	chr20:60628389	TAF4	-0.97	-21.29	-0.64	2.06e-76	Body mass index;
BRCA	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg11645453	chr3:52864694	ITIH4	0.49	11.85	0.42	1.94e-29	Schizophrenia;
BRCA	cis	rs12530845	0.887	rs4492299	chr7:135315690	T/G	cg23117316	chr7:135346802	PL-5283	-0.35	-8.17	-0.31	1.62e-15	Red blood cell traits;
BRCA	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.57	11.12	0.4	2.31e-26	HDL cholesterol;
BRCA	cis	rs2625529	0.712	rs2054601	chr15:72184968	T/C	cg16672083	chr15:72433130	SENP8	-0.82	-17.19	-0.56	1.07e-54	Red blood cell count;
BRCA	cis	rs7267979	1.000	rs2500424	chr20:25391969	C/T	cg08601574	chr20:25228251	PYGB	-0.39	-9.04	-0.34	1.84e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg22903471	chr2:27725779	GCKR	-0.38	-9.15	-0.34	7.38e-19	Total body bone mineral density;
BRCA	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg17845761	chr1:175162550	KIAA0040	0.25	9.7	0.36	7.43e-21	Alcohol dependence;
BRCA	cis	rs10751667	0.600	rs11246380	chr11:1009890	T/C	ch.11.42038R	chr11:967971	AP2A2	0.45	13.45	0.47	1.77e-36	Alzheimer's disease (late onset);
BRCA	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg10523679	chr1:76189770	ACADM	-0.73	-14.64	-0.5	4.56e-42	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7520050	0.966	rs9429183	chr1:46524582	G/A	cg24296786	chr1:45957014	TESK2	0.41	9.12	0.34	9.33e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.18	-0.31	1.57e-15	Depression;
BRCA	trans	rs8073060	0.592	rs225306	chr17:33920036	A/C	cg19694781	chr19:47549865	TMEM160	0.56	12.9	0.45	5.11e-34	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs10227331	0.632	rs10215531	chr7:157301180	A/G	cg04156418	chr7:157293606	NA	0.33	9.21	0.34	4.74e-19	Inattentive symptoms;
BRCA	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg19683494	chr5:74908142	NA	-0.57	-8.72	-0.33	2.45e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg01028140	chr2:1542097	TPO	-0.58	-12.18	-0.43	8e-31	IgG glycosylation;
BRCA	trans	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04565464	chr8:145669602	NFKBIL2	0.4	9.85	0.36	2.1e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs6080550	1.000	rs73606110	chr20:1759957	G/A	cg03128590	chr20:1760507	NA	-0.54	-9.09	-0.34	1.22e-18	Non-obstructive azoospermia;
BRCA	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg05623727	chr3:50126028	RBM5	0.42	9.73	0.36	5.68e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs2018683	0.600	rs6948880	chr7:29003478	C/T	cg19402173	chr7:128379420	CALU	-0.48	-11.61	-0.42	2.05e-28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08859206	chr1:53392774	SCP2	0.67	13.78	0.48	5.27e-38	Monocyte count;
BRCA	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.64	-0.36	1.27e-20	Alcohol dependence;
BRCA	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg01689657	chr7:91764605	CYP51A1	0.23	8.37	0.31	3.68e-16	Breast cancer;
BRCA	trans	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg07817883	chr1:32538562	TMEM39B	0.49	8.1	0.31	2.72e-15	Monocyte percentage of white cells;
BRCA	cis	rs4853036	0.857	rs12613717	chr2:70039263	T/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-8.86	-0.33	7.63e-18	Colorectal or endometrial cancer;
BRCA	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07636037	chr3:49044803	WDR6	-0.59	-12.38	-0.44	1e-31	Menarche (age at onset);
BRCA	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg06627628	chr2:24431161	ITSN2	-0.82	-14.8	-0.51	8.19e-43	Asthma;
BRCA	cis	rs9880211	0.948	rs34913797	chr3:136127570	G/A	cg21827317	chr3:136751795	NA	-0.47	-8.32	-0.31	5.34e-16	Body mass index;Height;
BRCA	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00166722	chr3:10149974	C3orf24	0.64	12.62	0.45	9.76e-33	Alzheimer's disease;
BRCA	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg23173402	chr1:227635558	NA	0.53	9.62	0.36	1.46e-20	Major depressive disorder;
BRCA	trans	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg25482853	chr8:67687455	SGK3	0.78	13.92	0.48	1.13e-38	Ulcerative colitis;
BRCA	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg04025307	chr7:1156635	C7orf50	0.47	9.32	0.35	1.86e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg13393036	chr8:95962371	TP53INP1	-0.34	-9.13	-0.34	8.57e-19	Type 2 diabetes;
BRCA	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.52	-0.52	2.52e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs990171	0.506	rs9284725	chr2:102744854	C/A	cg22835712	chr2:102737379	NA	0.6	11.32	0.41	3.42e-27	Lymphocyte counts;
BRCA	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg06552810	chr11:31128660	NA	-0.39	-8.81	-0.33	1.21e-17	Red blood cell count;
BRCA	cis	rs4389656	0.857	rs274699	chr5:6730332	A/C	cg10857441	chr5:6722123	POLS	-0.25	-7.82	-0.3	2.21e-14	Coronary artery disease;
BRCA	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18713687	chr3:195489789	MUC4	-0.56	-8.91	-0.33	5.22e-18	Lung disease severity in cystic fibrosis;
BRCA	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg20387954	chr3:183756860	HTR3D	0.41	9.22	0.34	4.23e-19	Anterior chamber depth;
BRCA	cis	rs10992471	0.729	rs6479418	chr9:95064762	G/A	cg14631576	chr9:95140430	CENPP	-0.36	-8.65	-0.32	4.12e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	trans	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg06521331	chr12:34319734	NA	-0.5	-9.31	-0.35	1.97e-19	Bladder cancer;
BRCA	cis	rs6433857	0.657	rs6756509	chr2:181500273	T/C	cg23363182	chr2:181467187	NA	-0.45	-9.73	-0.36	5.81e-21	Body mass index;
BRCA	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.24	-0.31	9.83e-16	Total body bone mineral density;
BRCA	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg02753203	chr1:228287806	NA	-0.58	-12.16	-0.43	9.57e-31	Diastolic blood pressure;
BRCA	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.02	-0.49	3.77e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-12.92	-0.46	4.11e-34	Chronic sinus infection;
BRCA	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	14.09	0.49	1.81e-39	Lymphocyte percentage of white cells;
BRCA	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	19.25	0.61	1.87e-65	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg08888203	chr3:10149979	C3orf24	0.63	11.48	0.41	7.36e-28	Alzheimer's disease;
BRCA	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	11.53	0.41	4.65e-28	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23583168	chr7:148888333	NA	-0.79	-18.42	-0.59	4.27e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg10729496	chr3:10149963	C3orf24	0.44	8.13	0.31	2.21e-15	Alzheimer's disease;
BRCA	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg24011408	chr12:48396354	COL2A1	-0.44	-9.85	-0.36	2.05e-21	Plateletcrit;
BRCA	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg13256891	chr4:100009986	ADH5	0.52	9.56	0.35	2.54e-20	Smoking initiation;
BRCA	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.4	0.41	1.52e-27	Homoarginine levels;
BRCA	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg19156104	chr2:198669113	PLCL1	-0.44	-8.18	-0.31	1.48e-15	Ulcerative colitis;
BRCA	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.32	0.38	3.52e-23	Bladder cancer;
BRCA	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg20908204	chr19:46285434	DMPK	-0.29	-8.55	-0.32	8.79e-17	Coronary artery disease;
BRCA	cis	rs1511802	0.625	rs7667777	chr4:187126077	C/G	cg24794857	chr4:187113578	CYP4V2	0.37	7.81	0.3	2.39e-14	Blood protein levels;
BRCA	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg17420585	chr12:42539391	GXYLT1	-0.38	-8.08	-0.3	3.27e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg05527609	chr1:210001259	C1orf107	-0.77	-15.96	-0.53	1.72e-48	Orofacial clefts;
BRCA	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg04450456	chr4:17643702	FAM184B	0.33	9.43	0.35	7.14e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1499972	0.817	rs62263118	chr3:117629053	C/T	cg07612923	chr3:117604196	NA	0.6	8.15	0.31	1.97e-15	Schizophrenia;
BRCA	cis	rs7127900	0.583	rs11043142	chr11:2234042	A/G	cg12428727	chr11:2234665	NA	0.54	13.21	0.46	2.08e-35	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
BRCA	trans	rs12439619	0.846	rs62012004	chr15:82476265	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.4	-7.92	-0.3	1.02e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs6545883	0.894	rs7602859	chr2:61458206	A/T	cg15711740	chr2:61764176	XPO1	0.48	11.91	0.43	1.13e-29	Tuberculosis;
BRCA	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.66	-0.39	1.62e-24	Personality dimensions;
BRCA	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg21427119	chr20:30132790	HM13	-0.42	-8.74	-0.33	1.98e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.72	9.91	0.37	1.19e-21	Initial pursuit acceleration;
BRCA	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	8.64	0.32	4.5e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-8.93	-0.33	4.47e-18	Longevity;Endometriosis;
BRCA	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.26	0.38	5.81e-23	Bipolar disorder;
BRCA	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg02176678	chr2:219576539	TTLL4	-0.51	-12.15	-0.43	1.03e-30	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg17971929	chr21:40555470	PSMG1	-0.64	-14.93	-0.51	1.84e-43	Cognitive function;
BRCA	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg05472934	chr7:22766657	IL6	0.49	12.55	0.44	1.88e-32	Lung cancer;
BRCA	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.97	0.6	5.18e-64	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-11.09	-0.4	2.84e-26	Lymphocyte counts;
BRCA	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg01324343	chr3:183735012	ABCC5	0.7	16.55	0.55	1.92e-51	Anterior chamber depth;
BRCA	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg04267008	chr7:1944627	MAD1L1	-0.43	-8.5	-0.32	1.32e-16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs6684514	1.000	rs12130361	chr1:156260301	C/T	cg16558208	chr1:156270281	VHLL	0.35	7.95	0.3	8.56e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs10189230	0.967	rs1864460	chr2:222347655	A/C	cg14652038	chr2:222343519	EPHA4	0.48	13.27	0.46	1.11e-35	Urate levels in lean individuals;
BRCA	cis	rs6450176	0.953	rs3776724	chr5:53292270	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-14.11	-0.49	1.51e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg14664628	chr15:75095509	CSK	-0.59	-14.42	-0.5	4.92e-41	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg03342759	chr3:160939853	NMD3	-0.62	-14.03	-0.49	3.69e-39	Morning vs. evening chronotype;
BRCA	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-11.19	-0.4	1.19e-26	Gut microbiome composition (summer);
BRCA	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-11.2	-0.41	1e-26	Alzheimer's disease;
BRCA	cis	rs9463078	0.764	rs2396370	chr6:44946472	A/G	cg25276700	chr6:44698697	NA	-0.36	-8.32	-0.31	5.2e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg20573242	chr4:122745356	CCNA2	0.44	9.94	0.37	9.4e-22	Type 2 diabetes;
BRCA	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg06191203	chr2:152266755	RIF1	-0.42	-12.21	-0.43	6.03e-31	Lung cancer;
BRCA	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.67	0.32	3.69e-17	Personality dimensions;
BRCA	trans	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.28	0.38	4.78e-23	Mean corpuscular volume;
BRCA	cis	rs943466	0.513	rs943467	chr6:33731811	A/T	cg25922239	chr6:33757077	LEMD2	0.33	8.19	0.31	1.39e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg26384229	chr12:38710491	ALG10B	0.73	17.0	0.56	9.24e-54	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs672059	1.000	rs563026	chr1:183161037	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.38	-8.72	-0.33	2.32e-17	Hypertriglyceridemia;
BRCA	cis	rs9403521	1.000	rs6901659	chr6:143985106	T/C	cg18240653	chr6:144019428	PHACTR2	-0.4	-7.9	-0.3	1.21e-14	Obesity-related traits;
BRCA	cis	rs312273	0.846	rs312264	chr12:41251889	T/C	cg17827154	chr12:41323612	CNTN1	-0.37	-8.85	-0.33	8.29e-18	Bipolar disorder;
BRCA	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg19622623	chr12:86230825	RASSF9	-0.34	-9.52	-0.35	3.39e-20	Major depressive disorder;
BRCA	cis	rs701145	1.000	rs355784	chr3:153986371	A/C	cg17054900	chr3:154042577	DHX36	0.67	11.49	0.41	6.85e-28	Coronary artery disease;
BRCA	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg04450456	chr4:17643702	FAM184B	0.38	11.48	0.41	7.03e-28	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg20848291	chr7:100343083	ZAN	0.37	8.26	0.31	8.54e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg18154014	chr19:37997991	ZNF793	0.49	9.58	0.35	2.05e-20	Coronary artery calcification;
BRCA	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg27432699	chr2:27873401	GPN1	-0.52	-10.97	-0.4	9.23e-26	Oral cavity cancer;
BRCA	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg17691542	chr6:26056736	HIST1H1C	0.48	9.18	0.34	6.14e-19	Iron status biomarkers;
BRCA	cis	rs250677	0.522	rs2217638	chr5:148364355	A/G	cg18129178	chr5:148520854	ABLIM3	0.56	10.77	0.39	5.93e-25	Breast cancer;
BRCA	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.47	9.2	0.34	5.02e-19	Lung cancer in ever smokers;
BRCA	cis	rs4953076	0.573	rs2054005	chr2:44401843	C/T	cg04920474	chr2:44395004	PPM1B	0.5	10.31	0.38	3.66e-23	Height;
BRCA	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg09021430	chr5:549028	NA	-0.64	-15.32	-0.52	2.49e-45	Obesity-related traits;
BRCA	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12667521	chr19:29218732	NA	0.49	8.83	0.33	9.71e-18	Methadone dose in opioid dependence;
BRCA	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg19784903	chr17:45786737	TBKBP1	-0.33	-7.83	-0.3	2.11e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg09307838	chr4:120376055	NA	0.7	14.09	0.49	1.96e-39	Corneal astigmatism;
BRCA	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.28	-0.31	7.41e-16	Bipolar disorder;
BRCA	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg16070123	chr10:51489643	NA	0.38	8.69	0.32	3.11e-17	Prostate-specific antigen levels;
BRCA	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg11266682	chr4:10021025	SLC2A9	0.49	12.82	0.45	1.23e-33	Bone mineral density;
BRCA	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-8.08	-0.3	3.32e-15	Response to antipsychotic treatment;
BRCA	cis	rs6684514	1.000	rs12122180	chr1:156244559	G/A	cg16558208	chr1:156270281	VHLL	0.35	7.96	0.3	8.05e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs7707921	0.881	rs73134709	chr5:81268499	G/A	cg15871215	chr5:81402204	ATG10	-0.4	-8.22	-0.31	1.16e-15	Breast cancer;
BRCA	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg18252515	chr7:66147081	NA	-0.84	-12.26	-0.44	3.6e-31	Diabetic kidney disease;
BRCA	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg04025307	chr7:1156635	C7orf50	0.58	9.08	0.34	1.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg08999081	chr20:33150536	PIGU	0.47	12.92	0.46	4.13e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	9.62	0.36	1.52e-20	Tonsillectomy;
BRCA	cis	rs754466	0.874	rs10430531	chr10:79660125	T/C	cg17075019	chr10:79541650	NA	-0.69	-13.06	-0.46	9.9e-35	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg19862616	chr7:65841803	NCRNA00174	0.85	27.84	0.74	2.67e-112	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg03146154	chr1:46216737	IPP	-0.51	-11.19	-0.4	1.11e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg25482853	chr8:67687455	SGK3	1.02	16.08	0.54	4.27e-49	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg02734326	chr4:10020555	SLC2A9	0.37	8.02	0.3	5.08e-15	Bone mineral density;
BRCA	cis	rs921968	0.565	rs4674328	chr2:219593203	T/C	cg02176678	chr2:219576539	TTLL4	-0.42	-11.18	-0.4	1.22e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg24642844	chr7:1081250	C7orf50	-0.88	-16.21	-0.54	9.48e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg04691961	chr3:161091175	C3orf57	-0.39	-8.72	-0.33	2.46e-17	Parkinson's disease;
BRCA	cis	rs4664304	1.000	rs55977890	chr2:160776866	C/T	cg14819504	chr2:160761413	LY75	-0.38	-9.34	-0.35	1.52e-19	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg15556689	chr8:8085844	FLJ10661	0.41	10.2	0.37	9.85e-23	Neuroticism;
BRCA	cis	rs6495367	0.803	rs2870111	chr15:79403585	C/T	cg17916960	chr15:79447300	NA	0.39	9.24	0.34	3.51e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg18538332	chr22:24372958	LOC391322	-0.55	-13.57	-0.47	4.72e-37	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.93	0.33	4.51e-18	Motion sickness;
BRCA	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-16.08	-0.54	4.01e-49	Alzheimer's disease (late onset);
BRCA	cis	rs7512552	0.780	rs55823828	chr1:150467296	G/C	cg15654264	chr1:150340011	RPRD2	0.39	8.35	0.31	4.36e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs6479891	1.000	rs72829170	chr10:64940289	A/G	cg14819942	chr15:35414228	NA	0.35	8.52	0.32	1.13e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs10129255	0.500	rs7161740	chr14:107184358	G/T	cg07958169	chr14:107095056	NA	-0.39	-8.3	-0.31	6.3e-16	Kawasaki disease;
BRCA	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	trans	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.53	-0.35	3.16e-20	Bladder cancer;
BRCA	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg24675658	chr1:53192096	ZYG11B	0.67	14.68	0.5	3.02e-42	Monocyte count;
BRCA	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg00277334	chr10:82204260	NA	-0.85	-24.9	-0.7	3.41e-96	Post bronchodilator FEV1;
BRCA	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg19628046	chr18:33552617	C18orf21	0.63	12.99	0.46	2.07e-34	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00166722	chr3:10149974	C3orf24	0.61	11.95	0.43	7.46e-30	Alzheimer's disease;
BRCA	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg01528321	chr10:82214614	TSPAN14	0.63	14.24	0.49	3.47e-40	Post bronchodilator FEV1;
BRCA	cis	rs1595825	0.891	rs73056811	chr2:198766642	T/C	cg19156104	chr2:198669113	PLCL1	-0.41	-7.82	-0.3	2.17e-14	Ulcerative colitis;
BRCA	cis	rs2836633	0.895	rs62217513	chr21:40024416	A/T	cg05519781	chr21:40033154	ERG	0.46	9.78	0.36	3.72e-21	Coronary artery disease;
BRCA	cis	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg07460842	chr6:66804631	NA	-0.83	-13.54	-0.47	6.61e-37	Exhaled nitric oxide output;
BRCA	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	8.67	0.32	3.59e-17	Schizophrenia;
BRCA	cis	rs13223928	0.631	rs12531881	chr7:3156842	C/T	cg19214707	chr7:3157722	NA	-0.42	-9.42	-0.35	8.11e-20	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
BRCA	cis	rs698833	0.852	rs698774	chr2:44584314	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	11.6	0.42	2.18e-28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.2	-0.34	5.17e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg23711669	chr6:146136114	FBXO30	0.74	17.76	0.57	1.14e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg03433033	chr1:76189801	ACADM	-0.47	-9.81	-0.36	2.98e-21	Daytime sleep phenotypes;
BRCA	cis	rs870825	0.932	rs28702958	chr4:185575562	C/T	cg04058563	chr4:185651563	MLF1IP	0.64	10.71	0.39	1e-24	Blood protein levels;
BRCA	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg17971929	chr21:40555470	PSMG1	0.74	16.43	0.54	7.65e-51	Cognitive function;
BRCA	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg01579765	chr21:45077557	HSF2BP	0.41	11.28	0.41	4.91e-27	Mean corpuscular volume;
BRCA	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg12863693	chr15:85201151	NMB	-0.34	-7.99	-0.3	6.16e-15	P wave terminal force;
BRCA	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg08975724	chr8:8085496	FLJ10661	-0.4	-8.29	-0.31	6.86e-16	Neuroticism;
BRCA	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.41	-8.76	-0.33	1.79e-17	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg05926928	chr17:57297772	GDPD1	0.46	9.03	0.34	2.02e-18	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
BRCA	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs7927771	0.524	rs2170815	chr11:47875910	T/C	cg20307385	chr11:47447363	PSMC3	0.41	9.43	0.35	7.15e-20	Subjective well-being;
BRCA	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg24642439	chr20:33292090	TP53INP2	0.54	11.77	0.42	4.49e-29	Glomerular filtration rate (creatinine);
BRCA	trans	rs8073060	0.586	rs225307	chr17:33918311	A/G	cg19694781	chr19:47549865	TMEM160	1.01	21.02	0.64	6.02e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs13046373	0.535	rs9980934	chr21:31982988	C/T	cg14062083	chr21:31802829	KRTAP13-4	0.33	9.22	0.34	4.33e-19	HDL cholesterol;
BRCA	cis	rs17253792	0.545	rs12893061	chr14:56016097	A/T	cg01858014	chr14:56050164	KTN1	-0.61	-7.99	-0.3	6.09e-15	Putamen volume;
BRCA	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg11941060	chr3:133502564	NA	0.51	12.39	0.44	9.65e-32	Iron status biomarkers;
BRCA	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg26695010	chr11:65641043	EFEMP2	-0.35	-7.99	-0.3	6.34e-15	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs2274273	0.967	rs2094102	chr14:55591098	T/C	cg04306507	chr14:55594613	LGALS3	0.32	8.86	0.33	7.64e-18	Protein biomarker;
BRCA	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg06671706	chr8:8559999	CLDN23	-0.42	-8.01	-0.3	5.31e-15	Obesity-related traits;
BRCA	cis	rs6815814	0.950	rs45588337	chr4:38807328	A/G	cg02016764	chr4:38805732	TLR1	-0.6	-9.56	-0.35	2.42e-20	Breast cancer;
BRCA	cis	rs6684428	1.000	rs58538058	chr1:56370474	G/A	cg11651538	chr1:56320950	NA	-0.46	-7.81	-0.3	2.32e-14	Airflow obstruction;
BRCA	trans	rs12517041	1.000	rs1366453	chr5:23283409	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.32	-0.31	5.27e-16	Calcium levels;
BRCA	cis	rs870825	0.616	rs28636679	chr4:185627481	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	16.89	0.56	3.35e-53	Blood protein levels;
BRCA	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg02403541	chr12:121454288	C12orf43	0.7	15.05	0.51	4.82e-44	N-glycan levels;
BRCA	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg13877915	chr19:58951672	ZNF132	0.45	10.66	0.39	1.54e-24	Uric acid clearance;
BRCA	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg06784218	chr1:46089804	CCDC17	0.5	12.01	0.43	4.08e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6750047	0.585	rs4670808	chr2:38267794	A/G	cg07380506	chr2:38303506	CYP1B1	0.45	9.76	0.36	4.56e-21	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg01181863	chr3:195395398	SDHAP2	-0.46	-8.18	-0.31	1.52e-15	Pancreatic cancer;
BRCA	cis	rs7633857	0.532	rs9858335	chr3:160760146	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-11.83	-0.42	2.53e-29	Educational attainment (years of education);
BRCA	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg23711669	chr6:146136114	FBXO30	0.65	13.34	0.47	5.52e-36	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs72928364	1.000	rs62275198	chr3:100687973	A/G	cg10123952	chr3:100791384	NA	0.53	7.89	0.3	1.3e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-10.56	-0.39	3.72e-24	Gut microbiome composition (summer);
BRCA	cis	rs926392	1.000	rs926391	chr20:37690485	A/G	cg16355469	chr20:37678765	NA	0.32	7.84	0.3	1.85e-14	Dialysis-related mortality;
BRCA	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg06627628	chr2:24431161	ITSN2	-0.51	-10.39	-0.38	1.87e-23	Asthma;
BRCA	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg24768116	chr2:27665128	KRTCAP3	-0.31	-7.88	-0.3	1.46e-14	Total body bone mineral density;
BRCA	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg07636037	chr3:49044803	WDR6	0.48	7.99	0.3	6.28e-15	Menarche (age at onset);
BRCA	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg15017067	chr4:17643749	FAM184B	0.27	8.04	0.3	4.24e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08045932	chr20:61659980	NA	0.49	11.35	0.41	2.57e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg02734326	chr4:10020555	SLC2A9	-0.35	-7.81	-0.3	2.38e-14	Bone mineral density;
BRCA	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg09654669	chr8:57350985	NA	-0.39	-8.4	-0.32	2.82e-16	Obesity-related traits;
BRCA	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-11.13	-0.4	1.99e-26	Mean corpuscular volume;
BRCA	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08219700	chr8:58056026	NA	0.44	8.0	0.3	5.7e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg11502198	chr6:26597334	ABT1	-0.48	-9.54	-0.35	3.04e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg22139774	chr2:100720529	AFF3	-0.29	-8.15	-0.31	1.97e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg25036284	chr2:26402008	FAM59B	-0.59	-10.23	-0.38	7.44e-23	Gut microbiome composition (summer);
BRCA	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg08859206	chr1:53392774	SCP2	0.48	10.51	0.38	6.29e-24	Monocyte count;
BRCA	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18876405	chr7:65276391	NA	0.63	15.8	0.53	1.05e-47	Aortic root size;
BRCA	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg01528321	chr10:82214614	TSPAN14	0.67	14.46	0.5	3.38e-41	Post bronchodilator FEV1;
BRCA	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg04553112	chr3:125709451	NA	-0.57	-8.7	-0.33	2.72e-17	Blood pressure (smoking interaction);
BRCA	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg15839431	chr19:19639596	YJEFN3	0.42	9.24	0.34	3.72e-19	Bipolar disorder;
BRCA	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	13.81	0.48	3.93e-38	Platelet count;
BRCA	trans	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg26043149	chr18:55253948	FECH	0.42	9.08	0.34	1.35e-18	Bone mineral density;
BRCA	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg24011408	chr12:48396354	COL2A1	-0.39	-7.9	-0.3	1.24e-14	Glycated hemoglobin levels;
BRCA	cis	rs698833	0.886	rs698802	chr2:44697624	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	9.96	0.37	7.96e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.07	-0.3	3.54e-15	Aortic root size;
BRCA	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.84	0.42	2.32e-29	Tonsillectomy;
BRCA	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg05340658	chr4:99064831	C4orf37	0.45	10.39	0.38	1.79e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg22535103	chr8:58192502	C8orf71	-0.42	-8.34	-0.31	4.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg03806693	chr22:41940476	POLR3H	-1.15	-22.86	-0.67	5.77e-85	Vitiligo;
BRCA	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg08470875	chr2:26401718	FAM59B	-0.71	-11.35	-0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	trans	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg25214090	chr10:38739885	LOC399744	0.57	13.01	0.46	1.79e-34	Corneal astigmatism;
BRCA	cis	rs4853036	1.000	rs1454499	chr2:70062939	T/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-8.87	-0.33	7.4e-18	Colorectal or endometrial cancer;
BRCA	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg23229984	chr5:148520753	ABLIM3	0.35	8.38	0.31	3.26e-16	Breast cancer;
BRCA	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg00666640	chr1:248458726	OR2T12	0.33	9.04	0.34	1.79e-18	Common traits (Other);
BRCA	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg14993813	chr1:46806288	NSUN4	-0.51	-9.73	-0.36	5.66e-21	Menopause (age at onset);
BRCA	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.38	-0.41	1.92e-27	Platelet count;
BRCA	cis	rs7020830	0.898	rs308492	chr9:37298020	C/T	cg14294708	chr9:37120828	ZCCHC7	1.09	33.67	0.8	1.09e-143	Schizophrenia;
BRCA	cis	rs858239	0.601	rs10224327	chr7:23161820	T/C	cg23682824	chr7:23144976	KLHL7	0.41	10.82	0.39	3.69e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs311392	0.867	rs364484	chr8:55093492	G/T	cg11783602	chr8:55087084	NA	-0.31	-9.12	-0.34	9.47e-19	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs739496	0.542	rs7312913	chr12:111793552	A/G	cg10833066	chr12:111807467	FAM109A	0.35	8.1	0.31	2.77e-15	Platelet count;
BRCA	cis	rs9308433	0.529	rs4655333	chr1:214493549	A/G	cg06198575	chr1:214491504	SMYD2	0.53	11.84	0.42	2.32e-29	IgG glycosylation;
BRCA	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-12.61	-0.45	1e-32	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs7539409	0.651	rs6576953	chr1:84316946	A/G	cg10977910	chr1:84465055	TTLL7	0.71	10.71	0.39	1.01e-24	Alzheimer's disease;
BRCA	cis	rs754466	0.580	rs1058198	chr10:79566632	G/A	cg17075019	chr10:79541650	NA	-0.76	-18.91	-0.6	1.19e-63	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg10932868	chr11:921992	NA	0.47	12.11	0.43	1.62e-30	Alzheimer's disease (late onset);
BRCA	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26913058	chr16:419975	MRPL28	0.37	8.68	0.32	3.32e-17	Bone mineral density (spine);Bone mineral density;
BRCA	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21659725	chr3:3221576	CRBN	0.5	11.93	0.43	9.4e-30	Resting heart rate;
BRCA	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15664640	chr17:80829946	TBCD	-0.67	-17.54	-0.57	1.53e-56	Breast cancer;
BRCA	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg13010199	chr12:38710504	ALG10B	0.45	9.38	0.35	1.16e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9837602	1.000	rs62285462	chr3:99769834	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.18	0.4	1.31e-26	Breast cancer;
BRCA	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg22681709	chr2:178499509	PDE11A	-0.41	-9.1	-0.34	1.17e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	14.13	0.49	1.22e-39	Platelet count;
BRCA	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs7246657	0.722	rs2927747	chr19:38159530	C/T	cg18154014	chr19:37997991	ZNF793	-0.49	-9.2	-0.34	4.98e-19	Coronary artery calcification;
BRCA	cis	rs919433	0.679	rs10497806	chr2:198508951	G/A	cg00792783	chr2:198669748	PLCL1	0.41	9.06	0.34	1.52e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.98	-19.75	-0.62	4.07e-68	Gut microbiome composition (summer);
BRCA	cis	rs10754283	0.967	rs7515375	chr1:90109854	T/C	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.31e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	trans	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg06521331	chr12:34319734	NA	-0.54	-10.21	-0.37	8.63e-23	Bladder cancer;
BRCA	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg04166393	chr7:2884313	GNA12	0.4	8.53	0.32	1.07e-16	Height;
BRCA	cis	rs72799341	1.000	rs35675346	chr16:30936081	G/A	cg02466173	chr16:30829666	NA	-0.41	-8.0	-0.3	5.86e-15	Diastolic blood pressure;
BRCA	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg27535305	chr1:53392650	SCP2	-0.39	-9.35	-0.35	1.5e-19	Monocyte count;
BRCA	cis	rs7809950	0.678	rs12670688	chr7:106821016	A/G	cg23024343	chr7:107201750	COG5	0.45	8.82	0.33	1.06e-17	Coronary artery disease;
BRCA	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg13852791	chr20:30311386	BCL2L1	0.74	12.21	0.43	5.76e-31	Mean corpuscular hemoglobin;
BRCA	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	8.84	0.33	9.01e-18	Mood instability;
BRCA	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg07148914	chr20:33460835	GGT7	-0.36	-8.24	-0.31	9.7e-16	Height;
BRCA	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.51	-11.06	-0.4	3.71e-26	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg12310025	chr6:25882481	NA	-0.54	-13.07	-0.46	9.5e-35	Blood metabolite levels;
BRCA	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.1	0.31	2.78e-15	Uric acid levels;
BRCA	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg21770322	chr7:97807741	LMTK2	0.45	11.72	0.42	7.41e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	13.42	0.47	2.48e-36	Lymphocyte counts;
BRCA	cis	rs9790314	0.812	rs7631479	chr3:161139566	C/T	cg04691961	chr3:161091175	C3orf57	-0.48	-11.6	-0.42	2.23e-28	Morning vs. evening chronotype;
BRCA	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg00409905	chr10:38381863	ZNF37A	-0.5	-10.51	-0.38	6.31e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.74	0.39	7.86e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2191566	0.576	rs393536	chr19:44493018	T/C	cg20607764	chr19:44506953	ZNF230	0.4	8.63	0.32	4.71e-17	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6772849	0.830	rs4857917	chr3:128376178	C/T	cg16766828	chr3:128327626	NA	-0.4	-8.85	-0.33	8.76e-18	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg04944784	chr2:26401820	FAM59B	0.95	16.17	0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.65	17.08	0.56	3.87e-54	Hypertriglyceridemia;
BRCA	cis	rs4919087	0.892	rs10882881	chr10:99010067	T/A	cg25902810	chr10:99078978	FRAT1	0.37	8.08	0.3	3.21e-15	Monocyte count;
BRCA	cis	rs9381107	0.860	rs9369385	chr6:9477277	A/G	cg14735645	chr6:9486422	NA	-0.46	-8.11	-0.31	2.53e-15	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg27541892	chr1:1571801	CDK11B	-0.58	-12.99	-0.46	2.2e-34	Body mass index;
BRCA	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg05347473	chr6:146136440	FBXO30	0.41	8.07	0.3	3.54e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg04756594	chr16:24857601	SLC5A11	0.52	11.8	0.42	3.19e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg00990874	chr7:1149470	C7orf50	-0.59	-11.99	-0.43	4.88e-30	Bronchopulmonary dysplasia;
BRCA	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs68170813	0.559	rs76933738	chr7:106814574	T/C	cg02696742	chr7:106810147	HBP1	-0.55	-9.03	-0.34	2.07e-18	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7572733	0.576	rs1865586	chr2:198758868	C/T	cg00792783	chr2:198669748	PLCL1	-0.45	-9.9	-0.36	1.35e-21	Dermatomyositis;
BRCA	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg13047869	chr3:10149882	C3orf24	0.52	11.01	0.4	6.24e-26	Alzheimer's disease;
BRCA	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg08885076	chr2:99613938	TSGA10	-0.53	-12.25	-0.44	3.9e-31	Chronic sinus infection;
BRCA	cis	rs9427116	0.532	rs9426828	chr1:154591489	G/A	cg17218026	chr1:154582156	ADAR	0.27	8.23	0.31	1.07e-15	Blood protein levels;
BRCA	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg06238570	chr21:40685208	BRWD1	0.41	8.32	0.31	5.3e-16	Cognitive function;
BRCA	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.66	-0.57	3.68e-57	Chronic sinus infection;
BRCA	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	-0.37	-8.22	-0.31	1.16e-15	Menopause (age at onset);
BRCA	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.62	-0.32	5.25e-17	Total body bone mineral density;
BRCA	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg06115741	chr20:33292138	TP53INP2	0.38	8.37	0.31	3.61e-16	Coronary artery disease;
BRCA	cis	rs10193935	1.000	rs13411405	chr2:42413811	C/A	cg27598129	chr2:42591480	NA	-0.95	-15.02	-0.51	6.54e-44	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg01620082	chr3:125678407	NA	-0.83	-9.94	-0.37	9.21e-22	Depression;
BRCA	cis	rs4363385	0.818	rs3795382	chr1:153004853	C/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.21	-0.34	4.44e-19	Inflammatory skin disease;
BRCA	cis	rs12618769	0.625	rs3820945	chr2:99105156	G/A	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-10.96	-0.4	9.67e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.24	0.49	3.5e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg23708337	chr7:1209742	NA	0.53	11.08	0.4	3.34e-26	Longevity;Endometriosis;
BRCA	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg04842962	chr6:43655489	MRPS18A	1.12	37.36	0.83	7.55e-163	IgG glycosylation;
BRCA	cis	rs870825	0.616	rs7674952	chr4:185622327	A/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.35	0.57	1.49e-55	Blood protein levels;
BRCA	cis	rs4919694	1.000	rs112809537	chr10:104670346	C/T	cg04362960	chr10:104952993	NT5C2	0.98	15.23	0.52	6.73e-45	Arsenic metabolism;
BRCA	cis	rs11112613	0.775	rs10507194	chr12:105959488	G/A	cg03607813	chr12:105948248	NA	0.59	10.33	0.38	3.13e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg26818010	chr10:134567672	INPP5A	-0.78	-15.61	-0.53	8.91e-47	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg16482183	chr6:26056742	HIST1H1C	0.49	9.66	0.36	1.1e-20	Iron status biomarkers;
BRCA	cis	rs490234	0.616	rs2648318	chr9:128163447	T/C	cg14078157	chr9:128172775	NA	-0.38	-9.04	-0.34	1.9e-18	Mean arterial pressure;
BRCA	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.31	-7.83	-0.3	1.98e-14	Response to antipsychotic treatment;
BRCA	cis	rs67072384	1.000	rs55957377	chr11:72445476	A/G	cg04827223	chr11:72435913	ARAP1	-0.68	-11.14	-0.4	1.91e-26	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
BRCA	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-11.09	-0.4	3.03e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg06212747	chr3:49208901	KLHDC8B	0.46	9.26	0.34	3.12e-19	Parkinson's disease;
BRCA	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg08470875	chr2:26401718	FAM59B	0.58	9.2	0.34	4.99e-19	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.31	-0.31	5.55e-16	Aortic root size;
BRCA	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg17845761	chr1:175162550	KIAA0040	-0.25	-9.29	-0.35	2.29e-19	Alcohol dependence;
BRCA	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg23625390	chr15:77176239	SCAPER	0.4	9.25	0.34	3.36e-19	Blood metabolite levels;
BRCA	cis	rs12478296	0.591	rs4973646	chr2:243001373	C/T	cg06360820	chr2:242988706	NA	0.62	12.04	0.43	3.16e-30	Obesity-related traits;
BRCA	trans	rs4650994	0.525	rs4076563	chr1:178516901	C/T	cg05059571	chr16:84539110	KIAA1609	-0.58	-12.94	-0.46	3.37e-34	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg12564285	chr5:131593104	PDLIM4	0.37	9.83	0.36	2.41e-21	Breast cancer;
BRCA	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg22903471	chr2:27725779	GCKR	-0.35	-8.52	-0.32	1.16e-16	Total body bone mineral density;
BRCA	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg23229984	chr5:148520753	ABLIM3	0.35	8.64	0.32	4.48e-17	Breast cancer;
BRCA	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg18252515	chr7:66147081	NA	-1.08	-16.09	-0.54	3.78e-49	Diabetic kidney disease;
BRCA	trans	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg06521331	chr12:34319734	NA	-0.52	-9.45	-0.35	6.17e-20	Bladder cancer;
BRCA	cis	rs7975161	1.000	rs4964728	chr12:104649733	G/A	cg25273343	chr12:104657179	TXNRD1	-0.51	-11.06	-0.4	3.93e-26	Toenail selenium levels;
BRCA	cis	rs34526934	0.566	rs1374325	chr2:177043971	G/A	cg26754761	chr2:177040938	NA	-0.46	-9.0	-0.34	2.53e-18	Obstructive sleep apnea trait (apnea hypopnea index);
BRCA	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.37	-0.41	2.08e-27	Gut microbiome composition (summer);
BRCA	trans	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	13.94	0.48	8.87e-39	Exhaled nitric oxide output;
BRCA	cis	rs858239	0.539	rs6955969	chr7:23186699	C/T	cg23682824	chr7:23144976	KLHL7	0.4	10.56	0.39	4e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg07741184	chr6:167504864	NA	0.33	9.88	0.36	1.68e-21	Primary biliary cholangitis;
BRCA	cis	rs1832871	0.711	rs76962726	chr6:158674041	C/T	cg07165851	chr6:158734300	TULP4	0.62	12.8	0.45	1.55e-33	Height;
BRCA	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-12.57	-0.45	1.61e-32	Hemoglobin concentration;
BRCA	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg04944784	chr2:26401820	FAM59B	-0.93	-16.97	-0.56	1.34e-53	Gut microbiome composition (summer);
BRCA	cis	rs757081	0.667	rs17560341	chr11:17107163	C/T	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.62	-0.32	5.14e-17	Systolic blood pressure;
BRCA	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg13319975	chr6:146136371	FBXO30	-0.4	-9.17	-0.34	6.56e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg26408565	chr15:76604113	ETFA	-0.4	-8.62	-0.32	5.37e-17	Blood metabolite levels;
BRCA	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-14.7	-0.5	2.33e-42	Hemoglobin concentration;
BRCA	cis	rs6700896	0.931	rs10749755	chr1:66129530	C/T	cg04111102	chr1:66153794	NA	0.36	8.82	0.33	1.08e-17	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs3857067	0.806	rs12507575	chr4:95114920	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.49	-0.35	4.67e-20	QT interval;
BRCA	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg00701064	chr4:6280414	WFS1	0.68	17.57	0.57	1.15e-56	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs1499972	0.941	rs73168388	chr3:117645824	C/T	cg07612923	chr3:117604196	NA	0.6	8.11	0.31	2.61e-15	Schizophrenia;
BRCA	cis	rs4499344	0.693	rs8106944	chr19:33097783	A/C	cg22980127	chr19:33182716	NUDT19	-0.38	-7.91	-0.3	1.11e-14	Mean platelet volume;
BRCA	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg26343298	chr8:95960752	TP53INP1	0.3	8.74	0.33	2.12e-17	Type 2 diabetes;
BRCA	cis	rs600806	0.778	rs4970767	chr1:110015183	G/A	cg20591472	chr1:110008990	SYPL2	0.31	7.9	0.3	1.25e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg07460842	chr6:66804631	NA	-1.02	-20.1	-0.62	5.5e-70	Exhaled nitric oxide output;
BRCA	trans	rs11165623	0.792	rs1125358	chr1:96971800	T/C	cg10631902	chr5:14652156	NA	-0.5	-15.88	-0.53	3.91e-48	Hip circumference;Waist circumference;
BRCA	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg26408565	chr15:76604113	ETFA	0.49	10.76	0.39	6.29e-25	Blood metabolite levels;
BRCA	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg24642844	chr7:1081250	C7orf50	-0.89	-16.21	-0.54	9.83e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg24069376	chr3:38537580	EXOG	0.32	8.83	0.33	9.97e-18	Electrocardiographic conduction measures;
BRCA	cis	rs1355223	0.525	rs7129533	chr11:34872292	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-9.48	-0.35	4.85e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg18016565	chr1:150552671	MCL1	-0.42	-9.67	-0.36	9.71e-21	Tonsillectomy;
BRCA	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-16.58	-0.55	1.24e-51	Colorectal cancer;
BRCA	cis	rs9880211	1.000	rs28811905	chr3:136252052	T/C	cg21827317	chr3:136751795	NA	-0.43	-7.86	-0.3	1.7e-14	Body mass index;Height;
BRCA	cis	rs6815814	0.950	rs5743565	chr4:38805983	T/C	cg06935464	chr4:38784597	TLR10	0.51	8.49	0.32	1.46e-16	Breast cancer;
BRCA	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg08493051	chr2:3487164	NA	-0.44	-9.28	-0.34	2.7e-19	Neurofibrillary tangles;
BRCA	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-11.22	-0.41	8.4e-27	Gut microbiome composition (summer);
BRCA	trans	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg26043149	chr18:55253948	FECH	0.39	8.42	0.32	2.47e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.35	-8.52	-0.32	1.11e-16	Type 2 diabetes;
BRCA	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg17971929	chr21:40555470	PSMG1	-0.49	-10.82	-0.39	3.54e-25	Menarche (age at onset);
BRCA	cis	rs9296092	0.517	rs56043172	chr6:33522363	T/G	cg13560919	chr6:33536144	NA	-0.85	-18.66	-0.59	2.26e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.39	8.62	0.32	5.37e-17	Multiple sclerosis;
BRCA	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21659725	chr3:3221576	CRBN	-0.35	-8.07	-0.3	3.61e-15	Body mass index;
BRCA	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg26248373	chr2:1572462	NA	-0.66	-15.34	-0.52	1.9e-45	IgG glycosylation;
BRCA	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.42	-7.91	-0.3	1.17e-14	Colorectal cancer;
BRCA	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg00814883	chr7:100076585	TSC22D4	-0.49	-10.48	-0.38	8.35e-24	Platelet count;
BRCA	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12756686	chr19:29218302	NA	0.57	10.98	0.4	8.46e-26	Methadone dose in opioid dependence;
BRCA	cis	rs849141	0.925	rs1029534	chr7:28189083	T/G	cg22892036	chr7:28189139	JAZF1	0.46	8.28	0.31	7.31e-16	Height;Hip circumference adjusted for BMI;
BRCA	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23583168	chr7:148888333	NA	-0.96	-25.09	-0.7	3.35e-97	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs13046373	0.562	rs12627602	chr21:32022924	G/A	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.29	0.34	2.49e-19	HDL cholesterol;
BRCA	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg21361702	chr7:150065534	REPIN1	0.42	7.81	0.3	2.28e-14	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg05234568	chr11:5960015	NA	-0.47	-9.45	-0.35	6.04e-20	DNA methylation (variation);
BRCA	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg03146154	chr1:46216737	IPP	0.45	10.07	0.37	2.99e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg10224037	chr5:178157518	ZNF354A	0.76	16.01	0.53	9.84e-49	Neutrophil percentage of white cells;
BRCA	cis	rs312274	0.515	rs1822598	chr12:41231443	A/G	cg17827154	chr12:41323612	CNTN1	0.36	9.03	0.34	2.09e-18	Metabolite levels  (X-11787);
BRCA	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-13.22	-0.46	1.88e-35	Bladder cancer;
BRCA	cis	rs10739663	0.520	rs2819624	chr9:128156519	A/G	cg14078157	chr9:128172775	NA	-0.43	-10.25	-0.38	6.5e-23	Resting heart rate;
BRCA	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00149659	chr3:10157352	C3orf10	0.78	13.55	0.47	5.8e-37	Alzheimer's disease;
BRCA	cis	rs9816226	0.590	rs869401	chr3:185826546	G/A	cg00760338	chr3:185826511	ETV5	0.57	12.4	0.44	8.35e-32	Obesity;Body mass index;
BRCA	cis	rs1669338	0.588	rs7629889	chr3:3187643	C/T	cg16797762	chr3:3221439	CRBN	-0.58	-9.07	-0.34	1.46e-18	White matter integrity;
BRCA	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg11621586	chr10:70884670	VPS26A	-0.62	-12.03	-0.43	3.36e-30	Left atrial antero-posterior diameter;
BRCA	cis	rs6973256	0.897	rs2911495	chr7:133331405	T/C	cg07491979	chr7:133331646	EXOC4	-0.38	-8.77	-0.33	1.67e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	20.04	0.62	1.11e-69	Platelet count;
BRCA	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg02551604	chr5:131831745	NA	-0.4	-14.94	-0.51	1.73e-43	Asthma (sex interaction);
BRCA	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.36	-8.83	-0.33	1.04e-17	Personality dimensions;
BRCA	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg05347473	chr6:146136440	FBXO30	-0.39	-7.9	-0.3	1.18e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg27432699	chr2:27873401	GPN1	0.42	8.93	0.33	4.62e-18	Oral cavity cancer;
BRCA	trans	rs3857536	0.674	rs9345798	chr6:66951331	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.95	-0.3	8.27e-15	Blood trace element (Cu levels);
BRCA	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.23	-0.41	7.77e-27	Schizophrenia;
BRCA	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg13319975	chr6:146136371	FBXO30	-0.37	-8.54	-0.32	9.47e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6426558	0.537	rs2102634	chr1:227324308	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.47	-9.3	-0.35	2.13e-19	Neutrophil percentage of white cells;
BRCA	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg16230307	chr14:35515116	FAM177A1	0.73	15.06	0.51	4.55e-44	Psoriasis;
BRCA	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg04374321	chr14:90722782	PSMC1	0.71	18.51	0.59	1.5e-61	Mortality in heart failure;
BRCA	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-17.01	-0.56	7.96e-54	Schizophrenia;
BRCA	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg15819921	chr19:927150	ARID3A	-0.47	-8.98	-0.33	2.89e-18	Life satisfaction;
BRCA	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg03709012	chr19:19516395	GATAD2A	0.98	18.55	0.59	8.85e-62	Nonalcoholic fatty liver disease;
BRCA	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	15.83	0.53	7.6e-48	Lymphocyte counts;
BRCA	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg05804949	chr7:23719620	C7orf46	0.38	7.88	0.3	1.39e-14	Schizophrenia;
BRCA	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11764359	chr7:65958608	NA	0.79	19.35	0.61	5.48e-66	Aortic root size;
BRCA	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18357526	chr6:26021779	HIST1H4A	0.51	9.39	0.35	1.02e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-24.01	-0.69	2.89e-91	Height;
BRCA	cis	rs10489202	0.608	rs10918827	chr1:168077044	A/G	cg24449463	chr1:168025552	DCAF6	0.46	15.34	0.52	1.96e-45	Schizophrenia;
BRCA	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg26695010	chr11:65641043	EFEMP2	0.45	9.79	0.36	3.63e-21	Eosinophil percentage of white cells;
BRCA	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg26528668	chr16:1614120	IFT140	0.35	7.88	0.3	1.4e-14	Coronary artery disease;
BRCA	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg04691961	chr3:161091175	C3orf57	-0.46	-10.85	-0.39	2.66e-25	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26314531	chr2:26401878	FAM59B	-0.63	-10.77	-0.39	5.55e-25	Gut microbiome composition (summer);
BRCA	cis	rs1003719	0.715	rs2835644	chr21:38545610	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.36	-0.49	1e-40	Eye color traits;
BRCA	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg09469691	chr10:81107165	PPIF	0.44	9.5	0.35	4.16e-20	Height;
BRCA	cis	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg07460842	chr6:66804631	NA	0.98	19.59	0.61	2.75e-67	Exhaled nitric oxide output;
BRCA	cis	rs4308124	0.708	rs6749633	chr2:111988016	A/G	cg04571233	chr2:111982156	NA	0.44	9.49	0.35	4.55e-20	Vitiligo;
BRCA	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.81e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11890956	chr21:40555474	PSMG1	0.99	22.83	0.67	8.23e-85	Cognitive function;
BRCA	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.28	0.56	3.49e-55	Bladder cancer;
BRCA	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg15212455	chr7:39170539	POU6F2	0.35	7.81	0.3	2.41e-14	IgG glycosylation;
BRCA	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg21280719	chr6:42927975	GNMT	-0.33	-13.93	-0.48	1.01e-38	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11644478	chr21:40555479	PSMG1	-0.44	-8.49	-0.32	1.48e-16	Menarche (age at onset);
BRCA	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg03433033	chr1:76189801	ACADM	-0.38	-7.83	-0.3	2.1e-14	Daytime sleep phenotypes;
BRCA	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg12193833	chr17:30244370	NA	-0.54	-8.72	-0.33	2.47e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg23933602	chr10:16859644	RSU1	0.57	9.12	0.34	9.77e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.58	0.39	3.22e-24	IgG glycosylation;
BRCA	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.91	14.15	0.49	1.02e-39	Body mass index;
BRCA	cis	rs11608355	0.545	rs61941585	chr12:109905222	C/T	cg05360138	chr12:110035743	NA	0.65	10.77	0.39	5.72e-25	Neuroticism;
BRCA	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg26647111	chr11:31128758	NA	-0.42	-9.48	-0.35	4.94e-20	Red blood cell count;
BRCA	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg12573674	chr2:1569213	NA	-0.55	-12.15	-0.43	1.01e-30	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg06627628	chr2:24431161	ITSN2	-0.69	-13.03	-0.46	1.34e-34	Asthma;
BRCA	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06002616	chr8:101225028	SPAG1	-0.34	-8.34	-0.31	4.47e-16	Atrioventricular conduction;
BRCA	cis	rs8044868	0.586	rs2070937	chr16:72089740	A/G	cg16558253	chr16:72132732	DHX38	-0.45	-10.74	-0.39	7.78e-25	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11764359	chr7:65958608	NA	-0.76	-16.74	-0.55	1.98e-52	Aortic root size;
BRCA	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.41	-10.86	-0.39	2.41e-25	IgG glycosylation;
BRCA	cis	rs724568	0.509	rs10179159	chr2:67923516	T/C	cg14046302	chr2:67939758	NA	-0.37	-9.45	-0.35	6.37e-20	Major depressive disorder (broad);
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg26608667	chr7:1196370	ZFAND2A	0.37	8.3	0.31	6.03e-16	Longevity;Endometriosis;
BRCA	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg23711669	chr6:146136114	FBXO30	-0.64	-14.56	-0.5	1.16e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6546550	0.935	rs1531025	chr2:70055505	G/T	cg02498382	chr2:70120550	SNRNP27	-0.51	-10.58	-0.39	3.1e-24	Prevalent atrial fibrillation;
BRCA	cis	rs3820928	0.904	rs2217359	chr2:227759892	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.29	-0.31	6.84e-16	Pulmonary function;
BRCA	cis	rs7737355	0.898	rs4706025	chr5:130913788	T/A	cg06307176	chr5:131281290	NA	0.52	10.43	0.38	1.27e-23	Life satisfaction;
BRCA	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	3.94e-15	Alzheimer's disease (late onset);
BRCA	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg12165864	chr7:66369176	NA	-0.45	-10.26	-0.38	5.58e-23	Corneal structure;
BRCA	cis	rs13082711	0.911	rs34307140	chr3:27467875	A/C	cg02860705	chr3:27208620	NA	0.53	10.65	0.39	1.65e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs6138458	0.828	rs6138466	chr20:24997137	A/G	cg26195577	chr20:24973756	C20orf3	0.71	17.45	0.57	4.57e-56	Blood protein levels;
BRCA	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.37	-0.38	2.13e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg18446336	chr7:2847575	GNA12	-0.34	-7.9	-0.3	1.19e-14	Height;
BRCA	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg02175503	chr12:58329896	NA	0.41	7.87	0.3	1.47e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.66	-15.18	-0.51	1.19e-44	Systemic lupus erythematosus;
BRCA	trans	rs2736337	0.532	rs6998387	chr8:11293458	C/T	cg15556689	chr8:8085844	FLJ10661	0.34	8.56	0.32	8.58e-17	Rheumatoid arthritis;
BRCA	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg20891283	chr12:69753455	YEATS4	0.57	14.78	0.5	1.01e-42	Blood protein levels;
BRCA	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-10.55	-0.39	4.11e-24	Blood metabolite levels;
BRCA	cis	rs2288327	0.643	rs1559908	chr2:179336347	C/T	cg11548914	chr2:179343871	FKBP7;PLEKHA3;MIR548N	-0.5	-8.68	-0.32	3.23e-17	Atrial fibrillation;
BRCA	cis	rs2294693	0.685	rs67525613	chr6:41008956	G/T	cg14769373	chr6:40998127	UNC5CL	-0.43	-8.04	-0.3	4.37e-15	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs586533	0.881	rs669212	chr11:99502265	G/A	cg22878054	chr11:99397252	CNTN5	0.32	8.06	0.3	3.65e-15	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg25214090	chr10:38739885	LOC399744	0.45	10.32	0.38	3.27e-23	Corneal astigmatism;
BRCA	cis	rs6987853	0.712	rs56220385	chr8:42428862	A/T	cg09913449	chr8:42400586	C8orf40	0.41	9.22	0.34	4.19e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg19077165	chr18:44547161	KATNAL2	-0.52	-11.28	-0.41	4.75e-27	Personality dimensions;
BRCA	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.86	0.45	7.85e-34	Bipolar disorder;
BRCA	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.89	-0.33	6e-18	Total body bone mineral density;
BRCA	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg23711669	chr6:146136114	FBXO30	0.8	19.33	0.61	6.42e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6495367	1.000	rs1007365	chr15:79379492	T/G	cg17916960	chr15:79447300	NA	0.36	8.66	0.32	3.7e-17	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg21747090	chr2:27597821	SNX17	-0.4	-8.76	-0.33	1.72e-17	Total body bone mineral density;
BRCA	cis	rs73001065	0.636	rs28720066	chr19:19572220	G/T	cg03709012	chr19:19516395	GATAD2A	1.01	15.28	0.52	3.85e-45	LDL cholesterol;
BRCA	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg09654669	chr8:57350985	NA	-0.38	-8.4	-0.32	2.9e-16	Obesity-related traits;
BRCA	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-13.38	-0.47	3.56e-36	Morning vs. evening chronotype;
BRCA	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg08601574	chr20:25228251	PYGB	-0.38	-8.86	-0.33	7.62e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2625529	0.607	rs2912231	chr15:72567957	G/T	cg16672083	chr15:72433130	SENP8	-0.76	-16.42	-0.54	7.84e-51	Red blood cell count;
BRCA	cis	rs9790314	0.690	rs1599390	chr3:160833246	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-11.33	-0.41	3.02e-27	Morning vs. evening chronotype;
BRCA	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	18.92	0.6	1.05e-63	Alzheimer's disease;
BRCA	cis	rs6429082	0.783	rs291385	chr1:235646613	T/C	cg26050004	chr1:235667680	B3GALNT2	0.57	13.53	0.47	7.03e-37	Adiposity;
BRCA	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg14993813	chr1:46806288	NSUN4	-0.5	-9.69	-0.36	8.4e-21	Menopause (age at onset);
BRCA	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.79	-0.77	2.53e-128	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.38	0.57	1.03e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg23711669	chr6:146136114	FBXO30	0.8	19.39	0.61	3.15e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg11764359	chr7:65958608	NA	-0.67	-14.9	-0.51	2.62e-43	Aortic root size;
BRCA	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg06618935	chr21:46677482	NA	-0.37	-8.12	-0.31	2.41e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg21782813	chr7:2030301	MAD1L1	0.43	12.38	0.44	1.09e-31	Bipolar disorder and schizophrenia;
BRCA	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg08470875	chr2:26401718	FAM59B	-0.5	-8.17	-0.31	1.65e-15	Gut microbiome composition (summer);
BRCA	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg02951883	chr7:2050386	MAD1L1	0.38	7.81	0.3	2.28e-14	Neuroticism;
BRCA	cis	rs10193935	0.605	rs10169492	chr2:42401961	G/T	cg27598129	chr2:42591480	NA	-0.94	-14.86	-0.51	4.13e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg12573674	chr2:1569213	NA	-0.62	-14.09	-0.49	1.83e-39	IgG glycosylation;
BRCA	cis	rs2806561	0.578	rs6702719	chr1:23302576	T/C	cg19743168	chr1:23544995	NA	0.35	8.09	0.3	3.03e-15	Height;
BRCA	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	13.73	0.48	8.4e-38	Lymphocyte counts;
BRCA	cis	rs3771570	0.901	rs35256094	chr2:242439938	A/C	cg21155796	chr2:242212141	HDLBP	0.63	9.72	0.36	6.29e-21	Prostate cancer;
BRCA	cis	rs16854884	0.789	rs34096668	chr3:143794483	C/T	cg06585982	chr3:143692056	C3orf58	0.39	7.88	0.3	1.38e-14	Economic and political preferences (feminism/equality);
BRCA	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg09537434	chr19:41945824	ATP5SL	-0.98	-23.56	-0.68	8.11e-89	Height;
BRCA	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg14530993	chr4:882597	GAK	0.59	9.66	0.36	1.04e-20	Intelligence (multi-trait analysis);
BRCA	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	17.21	0.56	8.02e-55	Intelligence (multi-trait analysis);
BRCA	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg07169764	chr2:136633963	MCM6	0.73	14.58	0.5	8.62e-42	Mosquito bite size;
BRCA	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	17.29	0.56	3.05e-55	Hip circumference adjusted for BMI;
BRCA	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg14784868	chr12:69753453	YEATS4	0.78	25.03	0.7	6.84e-97	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg13319975	chr6:146136371	FBXO30	-0.62	-13.66	-0.48	1.86e-37	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504073	0.584	rs11786103	chr8:49904077	A/G	cg00325661	chr8:49890786	NA	0.47	13.98	0.48	5.83e-39	Blood metabolite ratios;
BRCA	cis	rs858239	0.601	rs764534	chr7:23153935	C/T	cg23682824	chr7:23144976	KLHL7	0.4	10.42	0.38	1.42e-23	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.09	0.4	2.94e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs4596713	0.508	rs35490502	chr9:71747895	T/A	cg16512924	chr15:28394682	HERC2	0.4	9.73	0.36	5.9e-21	Headache;
BRCA	cis	rs6942756	1.000	rs2141075	chr7:128877305	C/T	cg02491457	chr7:128862824	NA	0.72	14.77	0.5	1.08e-42	White matter hyperintensity burden;
BRCA	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26314531	chr2:26401878	FAM59B	-0.63	-10.82	-0.39	3.45e-25	Gut microbiome composition (summer);
BRCA	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	17.65	0.57	4.28e-57	Electrocardiographic conduction measures;
BRCA	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg26384229	chr12:38710491	ALG10B	0.76	16.99	0.56	1.04e-53	Morning vs. evening chronotype;
BRCA	cis	rs6750795	0.518	rs1434519	chr2:232433761	A/G	cg19187155	chr2:232395269	NMUR1	0.62	11.56	0.42	3.44e-28	Height;
BRCA	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg00990874	chr7:1149470	C7orf50	-0.53	-9.51	-0.35	3.86e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg01483505	chr11:975446	AP2A2	0.33	9.01	0.34	2.32e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.39	0.57	9.41e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1420338	0.837	rs17753041	chr7:34176925	G/A	cg01275685	chr7:34179230	BMPER	-0.51	-11.34	-0.41	2.66e-27	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg15704280	chr7:45808275	SEPT13	0.81	19.61	0.61	2.25e-67	Coronary artery disease;
BRCA	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg08601574	chr20:25228251	PYGB	0.36	8.58	0.32	7.39e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg26043149	chr18:55253948	FECH	-0.37	-8.14	-0.31	2e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7572733	0.515	rs893808	chr2:198860837	C/G	cg00792783	chr2:198669748	PLCL1	0.44	9.68	0.36	9.05e-21	Dermatomyositis;
BRCA	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11764359	chr7:65958608	NA	-0.75	-16.65	-0.55	5.39e-52	Aortic root size;
BRCA	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	16.17	0.54	1.47e-49	Electrocardiographic conduction measures;
BRCA	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.5	7.93	0.3	9.47e-15	Renal function-related traits (BUN);
BRCA	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.45	-10.59	-0.39	2.92e-24	IgG glycosylation;
BRCA	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg25801113	chr15:45476975	SHF	-0.34	-8.33	-0.31	4.87e-16	Uric acid levels;
BRCA	cis	rs1371614	0.632	rs3769134	chr2:27150891	A/G	cg00617064	chr2:27272375	NA	-0.3	-8.04	-0.3	4.24e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.63	-0.39	1.98e-24	Bone mineral density;
BRCA	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.84	-0.36	2.26e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg26384229	chr12:38710491	ALG10B	0.41	9.29	0.34	2.48e-19	Morning vs. evening chronotype;
BRCA	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg13271783	chr10:134563150	INPP5A	0.53	10.23	0.38	7.52e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	8.79	0.33	1.35e-17	Iron status biomarkers;
BRCA	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg08601574	chr20:25228251	PYGB	0.36	8.72	0.33	2.4e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg14791747	chr16:20752902	THUMPD1	0.4	9.41	0.35	8.7e-20	Cognitive test performance;
BRCA	cis	rs1595825	0.891	rs57990618	chr2:198660838	C/T	cg19156104	chr2:198669113	PLCL1	-0.48	-8.54	-0.32	9.79e-17	Ulcerative colitis;
BRCA	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.7	0.36	7.74e-21	Menopause (age at onset);
BRCA	cis	rs3796352	0.571	rs11713926	chr3:53155072	C/T	cg07884673	chr3:53033167	SFMBT1	0.69	8.49	0.32	1.46e-16	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg03354898	chr7:1950403	MAD1L1	0.38	8.55	0.32	9.37e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg02297831	chr4:17616191	MED28	0.38	8.88	0.33	6.9e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7607369	0.500	rs6712856	chr2:219658617	A/T	cg02176678	chr2:219576539	TTLL4	-0.43	-11.41	-0.41	1.4e-27	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg27129171	chr3:47204927	SETD2	-0.69	-16.1	-0.54	3.34e-49	Colorectal cancer;
BRCA	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg14820908	chr5:178986412	RUFY1	0.5	13.02	0.46	1.61e-34	Lung cancer;
BRCA	trans	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.84	-27.81	-0.74	3.6e-112	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg06784218	chr1:46089804	CCDC17	0.47	11.09	0.4	3e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg03433033	chr1:76189801	ACADM	0.58	11.49	0.41	6.74e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.55	-0.42	3.75e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs12541635	0.677	rs61002083	chr8:106982132	A/G	cg10147462	chr8:107024639	NA	0.41	10.96	0.4	1.01e-25	Age of smoking initiation;
BRCA	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg08888203	chr3:10149979	C3orf24	0.67	14.13	0.49	1.27e-39	Alzheimer's disease;
BRCA	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg16989086	chr20:62203971	PRIC285	0.52	8.77	0.33	1.63e-17	Glioblastoma;
BRCA	cis	rs4363385	0.818	rs2711	chr1:153005156	C/T	cg21543102	chr1:152974771	SPRR3	-0.28	-7.81	-0.3	2.39e-14	Inflammatory skin disease;
BRCA	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.5	-10.44	-0.38	1.14e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg27170947	chr2:26402098	FAM59B	-0.94	-16.9	-0.56	3.15e-53	Gut microbiome composition (summer);
BRCA	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg23711669	chr6:146136114	FBXO30	0.63	14.75	0.5	1.31e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	7.87	0.3	1.53e-14	Total cholesterol levels;
BRCA	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.19	0.56	1.07e-54	Bladder cancer;
BRCA	cis	rs6733011	0.578	rs12712039	chr2:99497980	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.36	-8.31	-0.31	5.94e-16	Bipolar disorder;
BRCA	trans	rs75804782	0.691	rs55886641	chr2:239319185	T/C	cg01134436	chr17:81009848	B3GNTL1	0.77	9.69	0.36	8.3e-21	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs6028335	0.610	rs67743908	chr20:37572643	G/A	cg16355469	chr20:37678765	NA	0.44	8.07	0.3	3.62e-15	Alcohol and nicotine co-dependence;
BRCA	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg09307838	chr4:120376055	NA	0.72	15.37	0.52	1.39e-45	Corneal astigmatism;
BRCA	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg02951883	chr7:2050386	MAD1L1	-0.54	-13.61	-0.47	3.15e-37	Bipolar disorder and schizophrenia;
BRCA	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.76	-18.71	-0.59	1.35e-62	Systemic lupus erythematosus;
BRCA	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg24069376	chr3:38537580	EXOG	0.3	8.24	0.31	9.84e-16	Electrocardiographic conduction measures;
BRCA	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.19	-0.43	6.84e-31	Breast cancer;
BRCA	cis	rs9296092	0.560	rs3846854	chr6:33528466	T/C	cg13560919	chr6:33536144	NA	-0.85	-18.69	-0.59	1.6e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg12310025	chr6:25882481	NA	-0.54	-12.83	-0.45	1.04e-33	Blood metabolite levels;
BRCA	cis	rs6087990	0.806	rs875041	chr20:31383530	C/T	cg13636640	chr20:31349939	DNMT3B	0.64	19.49	0.61	9.05e-67	Ulcerative colitis;
BRCA	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg22713356	chr15:30763199	NA	1.28	23.73	0.68	9.93e-90	Uric acid levels;
BRCA	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11890956	chr21:40555474	PSMG1	-0.65	-14.64	-0.5	4.52e-42	Menarche (age at onset);
BRCA	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	13.68	0.48	1.44e-37	Personality dimensions;
BRCA	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg25237894	chr2:233734115	C2orf82	0.4	11.45	0.41	9.38e-28	Coronary artery disease;
BRCA	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg17971929	chr21:40555470	PSMG1	0.79	18.36	0.59	9.14e-61	Cognitive function;
BRCA	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg20283391	chr11:68216788	NA	-0.46	-9.05	-0.34	1.68e-18	Total body bone mineral density;
BRCA	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg23711669	chr6:146136114	FBXO30	0.73	16.47	0.55	4.82e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg14847009	chr1:175162515	KIAA0040	-0.24	-8.87	-0.33	7.24e-18	Alcohol dependence;
BRCA	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12667521	chr19:29218732	NA	0.49	9.51	0.35	3.69e-20	Methadone dose in opioid dependence;
BRCA	cis	rs36051895	0.664	rs4593605	chr9:5107278	C/A	cg02405213	chr9:5042618	JAK2	-0.49	-8.81	-0.33	1.14e-17	Pediatric autoimmune diseases;
BRCA	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg05863683	chr7:1912471	MAD1L1	0.4	8.38	0.31	3.27e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs919433	0.680	rs788021	chr2:198293691	T/C	cg00792783	chr2:198669748	PLCL1	0.38	8.44	0.32	2.18e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs10267417	0.603	rs10271293	chr7:19932427	A/G	cg05791153	chr7:19748676	TWISTNB	0.42	7.91	0.3	1.11e-14	Night sleep phenotypes;
BRCA	cis	rs12618769	0.625	rs78518453	chr2:99213899	T/C	cg10123293	chr2:99228465	UNC50	0.44	8.69	0.32	3.15e-17	Bipolar disorder;
BRCA	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg16339924	chr4:17578868	LAP3	-0.76	-19.16	-0.6	5.53e-65	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7944584	0.611	rs10838696	chr11:47363285	A/G	cg03711944	chr11:47377212	SPI1	0.34	7.93	0.3	9.91e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg16576597	chr16:28551801	NUPR1	-0.34	-9.31	-0.35	2.05e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs10129255	0.500	rs8011115	chr14:107194530	T/C	cg07958169	chr14:107095056	NA	-0.37	-7.96	-0.3	7.64e-15	Kawasaki disease;
BRCA	cis	rs870825	0.698	rs2696046	chr4:185599972	G/A	cg04058563	chr4:185651563	MLF1IP	-0.66	-11.83	-0.42	2.55e-29	Blood protein levels;
BRCA	trans	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.78	-0.33	1.44e-17	Depression;
BRCA	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg17063962	chr7:91808500	NA	0.57	13.55	0.47	5.69e-37	Breast cancer;
BRCA	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg16325326	chr1:53192061	ZYG11B	-0.65	-16.18	-0.54	1.39e-49	Monocyte count;
BRCA	trans	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	17.37	0.57	1.26e-55	Exhaled nitric oxide output;
BRCA	cis	rs4280164	0.943	rs2516564	chr14:24778643	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.46	-7.89	-0.3	1.31e-14	Parent of origin effect on language impairment (paternal);
BRCA	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg03188948	chr7:1209495	NA	0.68	11.32	0.41	3.3699999999999996e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7131987	0.622	rs7294598	chr12:29531989	A/C	cg09582351	chr12:29534625	ERGIC2	0.48	10.77	0.39	5.87e-25	QT interval;
BRCA	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21659725	chr3:3221576	CRBN	-0.48	-10.29	-0.38	4.33e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg11301795	chr4:187892539	NA	-0.29	-9.86	-0.36	1.99e-21	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg26384229	chr12:38710491	ALG10B	0.58	13.18	0.46	2.81e-35	Morning vs. evening chronotype;
BRCA	trans	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg18876405	chr7:65276391	NA	0.44	8.51	0.32	1.21e-16	Corneal structure;
BRCA	cis	rs2835872	0.758	rs1787401	chr21:39038893	C/T	cg06728970	chr21:39037746	KCNJ6	0.44	12.57	0.45	1.51e-32	Electroencephalographic traits in alcoholism;
BRCA	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg12419862	chr22:24373484	LOC391322	-0.69	-15.93	-0.53	2.38e-48	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg24642439	chr20:33292090	TP53INP2	0.41	7.98	0.3	6.92e-15	Height;
BRCA	trans	rs4596713	0.508	rs13289984	chr9:71775047	A/C	cg16512924	chr15:28394682	HERC2	0.45	10.58	0.39	3.12e-24	Headache;
BRCA	trans	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg26043149	chr18:55253948	FECH	-0.37	-8.22	-0.31	1.12e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg13073564	chr4:8508604	NA	-0.43	-11.88	-0.43	1.57e-29	Response to antineoplastic agents;
BRCA	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg09307838	chr4:120376055	NA	0.72	15.19	0.52	9.94e-45	Corneal astigmatism;
BRCA	cis	rs1003719	0.715	rs7280251	chr21:38567911	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.5	-0.5	2.11e-41	Eye color traits;
BRCA	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-12.66	-0.45	6.23e-33	Developmental language disorder (linguistic errors);
BRCA	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg18402987	chr7:1209562	NA	0.66	11.17	0.4	1.4e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.34	-9.31	-0.35	2.08e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.28	0.38	4.9e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6772849	0.805	rs13325747	chr3:128336023	G/A	cg16766828	chr3:128327626	NA	-0.37	-8.57	-0.32	7.67e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg20701182	chr2:24300061	SF3B14	0.58	9.04	0.34	1.86e-18	Lymphocyte counts;
BRCA	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg24848339	chr3:12840334	CAND2	0.49	13.14	0.46	4.54e-35	QRS complex (12-leadsum);
BRCA	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	11.51	0.41	5.53e-28	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg04691961	chr3:161091175	C3orf57	-0.46	-10.84	-0.39	2.87e-25	Morning vs. evening chronotype;
BRCA	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg06618935	chr21:46677482	NA	-0.36	-7.98	-0.3	6.64e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs138549714	1	rs138549714	chr18:3220755	G/GT	cg14944538	chr18:3220532	MYOM1	-0.66	-9.68	-0.36	9.35e-21	Brain volume in infants (white matter);
BRCA	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg06623918	chr6:96969491	KIAA0776	0.9	25.81	0.71	3.73e-101	Headache;
BRCA	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg06453172	chr10:134556979	INPP5A	-0.49	-10.41	-0.38	1.49e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	8.32	0.31	5.23e-16	Axial length;
BRCA	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg02466173	chr16:30829666	NA	-0.49	-11.18	-0.4	1.21e-26	Dementia with Lewy bodies;
BRCA	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg00290607	chr11:67383545	NA	0.52	11.71	0.42	7.67e-29	Mean corpuscular volume;
BRCA	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg05283184	chr6:79620031	NA	-0.43	-11.36	-0.41	2.37e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg24060327	chr5:131705240	SLC22A5	-0.48	-9.87	-0.36	1.81e-21	Blood metabolite levels;
BRCA	cis	rs55986470	0.670	rs56313033	chr2:239346202	C/T	cg18131467	chr2:239335373	ASB1	-0.62	-8.08	-0.3	3.22e-15	Chronotype;
BRCA	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg06115741	chr20:33292138	TP53INP2	-0.38	-8.39	-0.31	3.15e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs751728	0.717	rs3763260	chr6:33774070	C/T	cg15252951	chr6:33757062	LEMD2	0.38	8.67	0.32	3.45e-17	Crohn's disease;
BRCA	cis	rs1113500	0.862	rs2336129	chr1:108640669	A/G	cg06207961	chr1:108661230	NA	-0.44	-10.69	-0.39	1.24e-24	Growth-regulated protein alpha levels;
BRCA	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11764359	chr7:65958608	NA	0.8	19.51	0.61	7.33e-67	Aortic root size;
BRCA	cis	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg07460842	chr6:66804631	NA	0.6	10.31	0.38	3.59e-23	Type 2 diabetes;
BRCA	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.25	8.04	0.3	4.45e-15	Cardiac Troponin-T levels;
BRCA	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.6	0.39	2.68e-24	Motion sickness;
BRCA	cis	rs3862030	0.720	rs1056744	chr10:104236687	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-13.23	-0.46	1.65e-35	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg24675658	chr1:53192096	ZYG11B	0.66	14.55	0.5	1.3e-41	Monocyte count;
BRCA	cis	rs7246657	0.678	rs2927740	chr19:38140966	A/G	cg23950597	chr19:37808831	NA	0.5	8.72	0.33	2.37e-17	Coronary artery calcification;
BRCA	cis	rs59698941	0.550	rs11748063	chr5:132200943	C/T	cg14825688	chr5:132208181	LEAP2	-0.38	-8.82	-0.33	1.09e-17	Apolipoprotein A-IV levels;
BRCA	cis	rs10789491	0.767	rs1595898	chr1:47193577	G/A	cg15501359	chr1:47185051	KIAA0494	0.69	17.11	0.56	2.66e-54	Response to hepatitis C treatment;
BRCA	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-11.32	-0.41	3.36e-27	Systolic blood pressure;
BRCA	cis	rs6598955	0.543	rs12125620	chr1:26552238	G/A	cg12744634	chr1:26560303	CCDC21	0.3	7.86	0.3	1.58e-14	Obesity-related traits;
BRCA	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg26597838	chr10:835615	NA	1.01	17.8	0.58	7.47e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-8.79	-0.33	1.37e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg09436375	chr6:42928200	GNMT	-0.27	-10.09	-0.37	2.6e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	9.49	0.35	4.61e-20	Rheumatoid arthritis;
BRCA	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg18016565	chr1:150552671	MCL1	0.34	8.01	0.3	5.52e-15	Tonsillectomy;
BRCA	trans	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg26043149	chr18:55253948	FECH	1.17	28.24	0.75	1.75e-114	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg04450456	chr4:17643702	FAM184B	-0.33	-9.4	-0.35	9.83e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg05347473	chr6:146136440	FBXO30	0.43	8.56	0.32	8.72e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25427524	chr10:38739819	LOC399744	-0.68	-16.56	-0.55	1.72e-51	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg02753203	chr1:228287806	NA	-0.58	-12.36	-0.44	1.24e-31	Diastolic blood pressure;
BRCA	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg12219531	chr12:120966889	COQ5	0.55	11.6	0.42	2.28e-28	High light scatter reticulocyte count;
BRCA	cis	rs6977660	0.660	rs10253753	chr7:19823032	A/G	cg07541023	chr7:19748670	TWISTNB	0.53	9.27	0.34	2.77e-19	Thyroid stimulating hormone;
BRCA	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.7e-23	Prostate cancer;
BRCA	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg21775007	chr8:11205619	TDH	0.61	11.82	0.42	2.7e-29	Retinal vascular caliber;
BRCA	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06634786	chr22:41940651	POLR3H	-0.67	-11.79	-0.42	3.69e-29	Vitiligo;
BRCA	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg18196295	chr10:418757	DIP2C	0.49	11.74	0.42	5.63e-29	Psychosis in Alzheimer's disease;
BRCA	cis	rs2964802	0.505	rs6872243	chr5:10818337	C/T	cg14521931	chr5:10832172	NA	-0.58	-12.75	-0.45	2.56e-33	Major depressive disorder;Recurrent major depressive disorder;
BRCA	cis	rs4812048	1.000	rs6070696	chr20:57597645	A/G	cg14073986	chr20:57617431	SLMO2	0.47	8.04	0.3	4.28e-15	Mean platelet volume;
BRCA	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg04398451	chr17:18023971	MYO15A	-0.69	-14.93	-0.51	1.79e-43	Total body bone mineral density;
BRCA	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.59	-13.71	-0.48	1.05e-37	Ulcerative colitis;
BRCA	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg19628046	chr18:33552617	C18orf21	0.52	9.9	0.36	1.35e-21	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs4363385	0.818	rs1415965	chr1:153002750	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.36	-0.31	3.83e-16	Inflammatory skin disease;
BRCA	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg00857998	chr1:205179979	DSTYK	0.4	7.91	0.3	1.13e-14	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs9796	0.621	rs58109657	chr15:41471750	A/G	cg18705301	chr15:41695430	NDUFAF1	0.37	8.1	0.31	2.85e-15	Menopause (age at onset);
BRCA	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.0	22.82	0.67	8.71e-85	Lymphocyte percentage of white cells;
BRCA	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg11168104	chr5:1857477	NA	-0.32	-8.44	-0.32	2.21e-16	Cardiovascular disease risk factors;
BRCA	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg13628971	chr7:2884303	GNA12	0.46	9.18	0.34	5.82e-19	Height;
BRCA	cis	rs6840258	1.000	rs72667752	chr4:87939531	G/A	cg08197287	chr4:87952173	AFF1	-0.44	-8.56	-0.32	8.22e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg26528668	chr16:1614120	IFT140	0.36	7.97	0.3	7.48e-15	Coronary artery disease;
BRCA	trans	rs783540	0.967	rs34186444	chr15:83287500	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.27	-8.43	-0.32	2.33e-16	Schizophrenia;
BRCA	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg23625390	chr15:77176239	SCAPER	0.39	9.06	0.34	1.52e-18	Blood metabolite levels;
BRCA	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg05283184	chr6:79620031	NA	-0.37	-9.14	-0.34	8.13e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs12760731	0.720	rs12035174	chr1:178314311	A/T	cg00404053	chr1:178313656	RASAL2	0.62	8.66	0.32	3.71e-17	Obesity-related traits;
BRCA	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-11.76	-0.42	4.8e-29	Gut microbiome composition (summer);
BRCA	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg26384229	chr12:38710491	ALG10B	0.74	17.53	0.57	1.85e-56	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	20.56	0.63	1.85e-72	Platelet count;
BRCA	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg17366294	chr4:99064904	C4orf37	0.54	11.56	0.42	3.22e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.36	8.98	0.33	3.05e-18	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.21	-0.31	1.2e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg23711669	chr6:146136114	FBXO30	-0.62	-14.3	-0.49	1.86e-40	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-10.85	-0.39	2.82e-25	IgG glycosylation;
BRCA	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg05519781	chr21:40033154	ERG	-0.42	-8.95	-0.33	3.93e-18	Coronary artery disease;
BRCA	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15664640	chr17:80829946	TBCD	-0.59	-10.71	-0.39	9.54e-25	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
BRCA	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11764359	chr7:65958608	NA	-0.76	-16.74	-0.55	1.98e-52	Aortic root size;
BRCA	trans	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg13565492	chr6:43139072	SRF	-0.79	-11.0	-0.4	6.8e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4308124	0.708	rs28871990	chr2:111962441	G/A	cg04571233	chr2:111982156	NA	-0.45	-9.65	-0.36	1.2e-20	Vitiligo;
BRCA	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-11.88	-0.43	1.48e-29	Mood instability;
BRCA	cis	rs7945705	0.791	rs7944560	chr11:8817276	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.44	9.36	0.35	1.37e-19	Hemoglobin concentration;
BRCA	cis	rs6815814	0.699	rs11730390	chr4:38881414	T/C	cg02016764	chr4:38805732	TLR1	-0.51	-7.97	-0.3	7.2e-15	Breast cancer;
BRCA	trans	rs9944715	0.911	rs8090542	chr18:43771364	G/A	cg01718231	chr17:29326311	RNF135	-0.41	-8.39	-0.32	3.19e-16	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg01874867	chr7:94954059	PON1	-0.4	-8.17	-0.31	1.6e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs13136331	0.680	rs4440183	chr4:88653805	C/T	cg12990093	chr4:88570587	DMP1	-0.4	-8.19	-0.31	1.38e-15	Sitting height ratio;
BRCA	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg14675211	chr2:100938903	LONRF2	0.45	10.38	0.38	2.02e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg20503657	chr10:835505	NA	1.33	21.49	0.65	1.64e-77	Eosinophil percentage of granulocytes;
BRCA	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg00383909	chr3:49044727	WDR6	0.98	15.26	0.52	4.45e-45	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg12615879	chr12:58013172	SLC26A10	-0.33	-9.04	-0.34	1.8e-18	Multiple sclerosis;
BRCA	cis	rs17253792	0.908	rs9972177	chr14:56073206	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.87	0.3	1.48e-14	Putamen volume;
BRCA	cis	rs68170813	0.559	rs75672288	chr7:107031549	G/C	cg02696742	chr7:106810147	HBP1	-0.54	-8.73	-0.33	2.21e-17	Coronary artery disease;
BRCA	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg03929089	chr4:120376271	NA	-0.51	-9.91	-0.36	1.28e-21	HDL cholesterol;
BRCA	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.28	-8.03	-0.3	4.78e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg22875332	chr1:76189707	ACADM	0.78	18.62	0.59	3.68e-62	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg15017067	chr4:17643749	FAM184B	0.33	10.21	0.37	8.99e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg18357645	chr12:58087776	OS9	0.43	11.52	0.41	4.9e-28	Celiac disease or Rheumatoid arthritis;
BRCA	trans	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-18.36	-0.59	9.01e-61	Exhaled nitric oxide output;
BRCA	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg18357645	chr12:58087776	OS9	0.34	8.22	0.31	1.11e-15	Multiple sclerosis;
BRCA	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg07828340	chr4:882639	GAK	1.06	14.13	0.49	1.18e-39	Intelligence (multi-trait analysis);
BRCA	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg13902645	chr11:5959945	NA	-0.44	-8.74	-0.33	2.05e-17	DNA methylation (variation);
BRCA	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg06917634	chr15:78832804	PSMA4	-0.6	-13.52	-0.47	8.59e-37	Sudden cardiac arrest;
BRCA	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg24130564	chr14:104152367	KLC1	0.36	8.1	0.31	2.84e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg16325326	chr1:53192061	ZYG11B	0.66	16.4	0.54	1.06e-50	Monocyte count;
BRCA	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.52	-0.32	1.15e-16	Neuroticism;
BRCA	trans	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg22153745	chr1:153894579	GATAD2B	-0.48	-9.28	-0.34	2.49e-19	Total cholesterol levels;
BRCA	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg04691961	chr3:161091175	C3orf57	-0.58	-13.52	-0.47	8.2e-37	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.59	9.98	0.37	6.53e-22	Gut microbiome composition (summer);
BRCA	trans	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg26043149	chr18:55253948	FECH	0.4	8.61	0.32	5.71e-17	Bone mineral density;
BRCA	cis	rs6138458	0.847	rs56312312	chr20:24959386	C/A	cg06937882	chr20:24974362	C20orf3	-0.46	-7.99	-0.3	6.28e-15	Blood protein levels;
BRCA	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg12011299	chr4:100065546	ADH4	0.48	10.86	0.39	2.48e-25	Smoking initiation;
BRCA	cis	rs7737355	0.947	rs31585	chr5:130999082	A/G	cg06307176	chr5:131281290	NA	0.53	10.4	0.38	1.68e-23	Life satisfaction;
BRCA	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg09307838	chr4:120376055	NA	0.74	15.96	0.53	1.74e-48	Corneal astigmatism;
BRCA	trans	rs2018683	0.677	rs55718000	chr7:28975625	T/C	cg19402173	chr7:128379420	CALU	-0.42	-10.01	-0.37	5.3e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs6750795	0.765	rs6742387	chr2:232354832	G/T	cg19187155	chr2:232395269	NMUR1	0.7	16.77	0.55	1.42e-52	Height;
BRCA	cis	rs6060717	0.536	rs3787173	chr20:34472105	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.08	-0.3	3.21e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs7523050	0.643	rs17621922	chr1:109404454	C/T	cg08274380	chr1:109419600	GPSM2	0.94	13.57	0.47	4.9e-37	Fat distribution (HIV);
BRCA	trans	rs4650994	0.905	rs12753251	chr1:178529898	G/A	cg05059571	chr16:84539110	KIAA1609	-0.41	-9.43	-0.35	7.71e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs4363385	0.818	rs11205166	chr1:152988627	C/G	cg24667326	chr1:152973720	SPRR3	-0.33	-9.03	-0.34	1.95e-18	Inflammatory skin disease;
BRCA	cis	rs752010	0.631	rs7515066	chr1:42076915	A/G	cg06885757	chr1:42089581	HIVEP3	-0.39	-12.61	-0.45	9.83e-33	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs11690935	0.549	rs2129475	chr2:172916772	A/G	cg13550731	chr2:172543902	DYNC1I2	0.54	13.6	0.47	3.6e-37	Schizophrenia;
BRCA	cis	rs12545109	0.642	rs2055984	chr8:57418332	A/G	cg09654669	chr8:57350985	NA	-0.45	-8.31	-0.31	5.58e-16	Obesity-related traits;
BRCA	cis	rs68170813	0.521	rs75035695	chr7:106818731	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.49	-0.32	1.47e-16	Coronary artery disease;
BRCA	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg12698349	chr2:225449008	CUL3	-0.59	-13.02	-0.46	1.49e-34	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.56	8.44	0.32	2.13e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg25482853	chr8:67687455	SGK3	1.02	16.08	0.54	4.27e-49	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg20891283	chr12:69753455	YEATS4	0.71	20.79	0.64	1e-73	Blood protein levels;
BRCA	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg20587970	chr11:113659929	NA	-0.89	-16.5	-0.55	3.42e-51	Hip circumference adjusted for BMI;
BRCA	cis	rs17601876	0.814	rs28520437	chr15:51553277	C/T	cg19946085	chr15:51559439	CYP19A1	-0.38	-11.0	-0.4	6.61e-26	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs870825	0.616	rs7678900	chr4:185635249	A/G	cg04058563	chr4:185651563	MLF1IP	0.74	16.78	0.55	1.27e-52	Blood protein levels;
BRCA	trans	rs9951602	0.541	rs12454297	chr18:76654445	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	18.3	0.59	1.73e-60	Obesity-related traits;
BRCA	cis	rs1865721	1.000	rs17283692	chr18:73193911	T/C	cg26385618	chr18:73139727	C18orf62	-0.39	-9.0	-0.34	2.66e-18	Intelligence;
BRCA	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg09307838	chr4:120376055	NA	0.64	14.09	0.49	1.94e-39	Corneal astigmatism;
BRCA	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.2	0.41	1.03e-26	Bipolar disorder;
BRCA	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-12.65	-0.45	6.8e-33	Bipolar disorder;
BRCA	cis	rs7903847	0.642	rs10882923	chr10:99159018	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-8.86	-0.33	7.98e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg01939980	chr4:1354348	KIAA1530	0.29	7.96	0.3	7.95e-15	Obesity-related traits;
BRCA	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg27170947	chr2:26402098	FAM59B	0.92	16.89	0.56	3.63e-53	Gut microbiome composition (summer);
BRCA	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg13456504	chr1:91191583	NA	0.54	10.0	0.37	5.55e-22	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs911119	1.000	rs3827142	chr20:23617007	G/A	cg16589663	chr20:23618590	CST3	0.47	8.72	0.33	2.36e-17	Chronic kidney disease;
BRCA	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg24692254	chr21:30365293	RNF160	-0.37	-8.23	-0.31	1.05e-15	Selective IgA deficiency;
BRCA	cis	rs912057	0.671	rs1294427	chr6:6744546	T/G	cg06612196	chr6:6737390	NA	0.46	10.85	0.39	2.81e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	14.15	0.49	9.42e-40	Alzheimer's disease;
BRCA	trans	rs7939886	0.920	rs11227212	chr11:55873334	A/G	cg15704280	chr7:45808275	SEPT13	0.61	7.93	0.3	1.01e-14	Myopia (pathological);
BRCA	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg03060546	chr3:49711283	APEH	0.6	9.96	0.37	8.39e-22	Menarche (age at onset);
BRCA	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg06784218	chr1:46089804	CCDC17	0.51	12.48	0.44	4.02e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg12419862	chr22:24373484	LOC391322	-0.69	-15.73	-0.53	2.35e-47	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1577917	0.545	rs9294338	chr6:86474368	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.34	9.22	0.34	4.23e-19	Response to antipsychotic treatment;
BRCA	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	trans	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg26384229	chr12:38710491	ALG10B	0.39	8.59	0.32	6.67e-17	Resting heart rate;
BRCA	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg16850897	chr7:100343110	ZAN	-0.57	-10.63	-0.39	2.09e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg17691542	chr6:26056736	HIST1H1C	0.53	11.28	0.41	4.82e-27	Height;
BRCA	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg11843238	chr5:131593191	PDLIM4	0.36	9.24	0.34	3.66e-19	Breast cancer;
BRCA	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg08470875	chr2:26401718	FAM59B	-0.51	-8.53	-0.32	1.06e-16	Gut microbiome composition (summer);
BRCA	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg20294984	chr1:43412752	SLC2A1	-0.5	-8.03	-0.3	4.8e-15	Monocyte count;
BRCA	cis	rs733592	0.931	rs765260	chr12:48431936	C/T	cg24011408	chr12:48396354	COL2A1	-0.44	-9.42	-0.35	7.98e-20	Plateletcrit;
BRCA	cis	rs1595825	0.786	rs73054839	chr2:198671665	C/A	cg19156104	chr2:198669113	PLCL1	-0.44	-8.27	-0.31	7.86e-16	Ulcerative colitis;
BRCA	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg11752832	chr7:134001865	SLC35B4	0.51	11.84	0.42	2.27e-29	Mean platelet volume;
BRCA	cis	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg06521331	chr12:34319734	NA	0.62	11.88	0.43	1.47e-29	Morning vs. evening chronotype;
BRCA	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg03560586	chr2:239334908	ASB1	-0.5	-10.92	-0.4	1.43e-25	Multiple system atrophy;
BRCA	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.59	-10.38	-0.38	1.89e-23	Gut microbiome composition (summer);
BRCA	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg27535305	chr1:53392650	SCP2	-0.38	-8.41	-0.32	2.68e-16	Monocyte count;
BRCA	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg08213375	chr14:104286397	PPP1R13B	-0.64	-17.83	-0.58	5.23e-58	Schizophrenia;
BRCA	trans	rs526821	0.553	rs519637	chr11:55295935	A/T	cg15704280	chr7:45808275	SEPT13	-0.42	-7.91	-0.3	1.15e-14	Pediatric bone mineral density (spine);
BRCA	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.11	-0.34	1.01e-18	Joint mobility (Beighton score);
BRCA	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg27432699	chr2:27873401	GPN1	0.48	10.32	0.38	3.39e-23	Oral cavity cancer;
BRCA	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Colorectal cancer;
BRCA	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.5	11.15	0.4	1.67e-26	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	8.03	0.3	4.62e-15	Tonsillectomy;
BRCA	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg21017887	chr14:105400489	NA	0.66	17.41	0.57	7.56e-56	Rheumatoid arthritis;
BRCA	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg13256891	chr4:100009986	ADH5	0.4	8.34	0.31	4.42e-16	Alcohol dependence;
BRCA	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.89	-0.33	6e-18	Total body bone mineral density;
BRCA	cis	rs2901460	0.509	rs11677509	chr2:62045191	T/G	cg02183531	chr2:62113199	CCT4	-0.45	-8.43	-0.32	2.38e-16	Mean corpuscular volume;
BRCA	trans	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg25214090	chr10:38739885	LOC399744	0.54	11.8	0.42	3.21e-29	Corneal astigmatism;
BRCA	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg08807101	chr21:30365312	RNF160	0.43	8.92	0.33	4.92e-18	Pancreatic cancer;
BRCA	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg05234568	chr11:5960015	NA	-0.52	-10.35	-0.38	2.52e-23	DNA methylation (variation);
BRCA	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg12379764	chr21:47803548	PCNT	-0.39	-8.36	-0.31	3.9e-16	Testicular germ cell tumor;
BRCA	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg22800045	chr5:56110881	MAP3K1	0.65	12.51	0.44	2.71e-32	Initial pursuit acceleration;
BRCA	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg10295955	chr4:187884368	NA	0.95	28.22	0.74	2.28e-114	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg21475434	chr5:93447410	FAM172A	0.67	8.73	0.33	2.19e-17	Diabetic retinopathy;
BRCA	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.42	0.54	8.67e-51	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.19	-0.4	1.19e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-13.41	-0.47	2.75e-36	Bipolar disorder and schizophrenia;
BRCA	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg26384229	chr12:38710491	ALG10B	-0.54	-14.15	-0.49	9.26e-40	Heart rate;
BRCA	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg01262667	chr19:19385393	TM6SF2	0.34	8.76	0.33	1.71e-17	Tonsillectomy;
BRCA	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg12311346	chr5:56204834	C5orf35	-0.82	-16.7	-0.55	3.35e-52	Initial pursuit acceleration;
BRCA	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg04025307	chr7:1156635	C7orf50	0.38	8.87	0.33	7.51e-18	Longevity;Endometriosis;
BRCA	cis	rs701145	0.556	rs357502	chr3:153955950	C/T	cg12800244	chr3:153838788	SGEF	0.44	8.79	0.33	1.36e-17	Coronary artery disease;
BRCA	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-13.19	-0.46	2.51e-35	Response to antipsychotic treatment;
BRCA	trans	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg25214090	chr10:38739885	LOC399744	-0.4	-9.08	-0.34	1.37e-18	Corneal astigmatism;
BRCA	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03264133	chr6:25882463	NA	-0.52	-11.75	-0.42	5.15e-29	Blood metabolite levels;
BRCA	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg00631329	chr6:26305371	NA	-0.44	-13.0	-0.46	1.8e-34	Educational attainment;
BRCA	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg21143896	chr7:2802374	GNA12	-0.38	-9.49	-0.35	4.44e-20	Height;
BRCA	cis	rs11190604	1.000	rs28522614	chr10:102323141	T/A	cg07080220	chr10:102295463	HIF1AN	0.6	13.77	0.48	5.6e-38	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2637030	0.559	rs2607497	chr5:52995482	A/G	cg06476337	chr5:52856530	NDUFS4	0.35	7.99	0.3	6.23e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs3849570	0.925	rs9841087	chr3:81907949	A/G	cg07356753	chr3:81810745	GBE1	-0.43	-10.11	-0.37	2.25e-22	Waist circumference;Body mass index;
BRCA	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg04455712	chr21:45112962	RRP1B	0.4	10.54	0.38	4.6e-24	Mean corpuscular volume;
BRCA	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg24692254	chr21:30365293	RNF160	-0.6	-15.07	-0.51	3.75e-44	Dental caries;
BRCA	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg20387954	chr3:183756860	HTR3D	0.46	10.31	0.38	3.78e-23	Anterior chamber depth;
BRCA	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg11189052	chr15:85197271	WDR73	-0.34	-8.01	-0.3	5.36e-15	P wave terminal force;
BRCA	cis	rs2637266	1.000	rs10219023	chr10:78364537	G/A	cg18941641	chr10:78392320	NA	0.35	7.83	0.3	1.97e-14	Pulmonary function;
BRCA	cis	rs6750047	0.585	rs4670235	chr2:38272528	C/T	cg07380506	chr2:38303506	CYP1B1	0.47	10.39	0.38	1.76e-23	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs416603	0.967	rs11644184	chr16:11365104	G/A	cg00044050	chr16:11439710	C16orf75	-0.44	-10.22	-0.37	8.5e-23	Type 1 diabetes;
BRCA	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg02297831	chr4:17616191	MED28	0.39	8.51	0.32	1.22e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg16586182	chr3:47516702	SCAP	-0.63	-14.73	-0.5	1.79e-42	Colorectal cancer;
BRCA	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg02574844	chr11:5959923	NA	-0.43	-8.42	-0.32	2.55e-16	DNA methylation (variation);
BRCA	cis	rs4965272	1.000	rs1585933	chr15:100585715	A/G	cg27344315	chr15:100560801	ADAMTS17	-0.38	-7.85	-0.3	1.73e-14	Gastroesophageal reflux disease;
BRCA	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg04450456	chr4:17643702	FAM184B	0.36	10.45	0.38	1.05e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg14784868	chr12:69753453	YEATS4	0.78	25.0	0.7	9.83e-97	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-15.49	-0.52	3.38e-46	Obesity-related traits;
BRCA	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg24642439	chr20:33292090	TP53INP2	0.55	12.25	0.44	3.96e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.2e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg18351406	chr4:77819688	ANKRD56	0.58	12.6	0.45	1.14e-32	Emphysema distribution in smoking;
BRCA	cis	rs11634851	0.844	rs4778849	chr15:81026226	C/T	cg03950166	chr15:80988613	FAM108C1	-0.33	-8.0	-0.3	5.99e-15	Systolic blood pressure;
BRCA	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	12.95	0.46	3.16e-34	Migraine;Coronary artery disease;
BRCA	cis	rs568617	0.626	rs10896050	chr11:65577516	G/T	cg04055107	chr11:65626734	MUS81;CFL1	0.57	9.26	0.34	2.97e-19	Crohn's disease;
BRCA	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg11125805	chr5:150678162	SLC36A3	0.73	19.48	0.61	1.03e-66	Skin aging (microtopography measurement);
BRCA	cis	rs6743226	0.934	rs6705421	chr2:242212672	A/G	cg10021735	chr2:242295487	FARP2	0.37	10.02	0.37	4.92e-22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg13010199	chr12:38710504	ALG10B	0.55	12.23	0.44	4.72e-31	Heart rate;
BRCA	cis	rs3820928	0.874	rs3752895	chr2:227886773	A/G	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.28	-0.31	6.97e-16	Pulmonary function;
BRCA	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.6	0.36	1.8e-20	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg18446336	chr7:2847575	GNA12	-0.35	-8.11	-0.31	2.61e-15	Height;
BRCA	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg24562669	chr7:97807699	LMTK2	0.43	11.46	0.41	8.48e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7191700	0.509	rs415595	chr16:11363692	A/G	cg00044050	chr16:11439710	C16orf75	0.35	8.11	0.31	2.5e-15	Multiple sclerosis;
BRCA	cis	rs4588572	0.643	rs1864172	chr5:77690945	T/C	cg11547950	chr5:77652471	NA	0.44	7.82	0.3	2.21e-14	Triglycerides;
BRCA	cis	rs56399783	0.901	rs73049327	chr7:2795544	T/G	cg19731401	chr7:2775893	GNA12	0.52	8.19	0.31	1.45e-15	Childhood ear infection;
BRCA	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg19678392	chr7:94953810	PON1	-0.41	-8.73	-0.33	2.17e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg21659725	chr3:3221576	CRBN	-0.47	-8.46	-0.32	1.86e-16	Menarche (age at onset);
BRCA	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg17063962	chr7:91808500	NA	0.52	11.37	0.41	2.03e-27	Breast cancer;
BRCA	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg13852791	chr20:30311386	BCL2L1	0.84	16.5	0.55	3.24e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-13.78	-0.48	5.26e-38	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg05234568	chr11:5960015	NA	-0.46	-9.25	-0.34	3.2e-19	DNA methylation (variation);
BRCA	cis	rs9309711	0.961	rs35067331	chr2:3474085	C/T	cg16153549	chr2:3496821	NA	-0.37	-8.2	-0.31	1.34e-15	Neurofibrillary tangles;
BRCA	cis	rs1997103	1.000	rs2177805	chr7:55404381	T/A	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg21724239	chr8:58056113	NA	0.56	9.08	0.34	1.3e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg14784868	chr12:69753453	YEATS4	0.68	19.81	0.62	1.97e-68	Blood protein levels;
BRCA	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18876405	chr7:65276391	NA	-0.51	-11.62	-0.42	1.85e-28	Aortic root size;
BRCA	cis	rs600806	0.813	rs4970759	chr1:109982213	C/A	cg20591472	chr1:110008990	SYPL2	0.32	7.85	0.3	1.8e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22455342	chr2:225449267	CUL3	0.68	17.33	0.57	1.97e-55	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg11789530	chr4:8429930	ACOX3	-0.55	-12.62	-0.45	8.99e-33	Response to antineoplastic agents;
BRCA	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg22705602	chr4:152727874	NA	-0.37	-10.01	-0.37	5.1e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg06623918	chr6:96969491	KIAA0776	-0.93	-27.35	-0.73	1.21e-109	Headache;
BRCA	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg04546413	chr19:29218101	NA	0.49	8.44	0.32	2.17e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.85	0.33	8.73e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs921968	0.565	rs12694439	chr2:219590871	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-10.97	-0.4	8.94e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2882667	0.690	rs851278	chr5:138103266	A/G	cg04439458	chr5:138467593	SIL1	0.31	7.87	0.3	1.47e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg17971929	chr21:40555470	PSMG1	0.77	18.09	0.58	2.17e-59	Cognitive function;
BRCA	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs4596713	0.507	rs10115134	chr9:71800562	T/C	cg16512924	chr15:28394682	HERC2	0.45	10.67	0.39	1.44e-24	Headache;
BRCA	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg09307838	chr4:120376055	NA	0.71	14.74	0.5	1.46e-42	Corneal astigmatism;
BRCA	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11764359	chr7:65958608	NA	0.8	19.2	0.6	3.43e-65	Aortic root size;
BRCA	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg05340658	chr4:99064831	C4orf37	0.44	10.2	0.37	1e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.51	12.23	0.44	4.75e-31	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06108461	chr20:60628389	TAF4	-0.99	-22.27	-0.66	9.76e-82	Body mass index;
BRCA	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18876405	chr7:65276391	NA	0.55	12.97	0.46	2.45e-34	Aortic root size;
BRCA	cis	rs4631830	0.863	rs2611489	chr10:51524889	C/T	cg20129853	chr10:51489980	NA	-0.29	-7.94	-0.3	9.36e-15	Prostate-specific antigen levels;
BRCA	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg04546413	chr19:29218101	NA	0.64	12.26	0.44	3.55e-31	Methadone dose in opioid dependence;
BRCA	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg26384229	chr12:38710491	ALG10B	0.74	17.32	0.57	2.11e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg08885076	chr2:99613938	TSGA10	0.45	10.6	0.39	2.78e-24	Chronic sinus infection;
BRCA	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg05754148	chr16:3507555	NAT15	0.37	7.84	0.3	1.86e-14	Tuberculosis;
BRCA	cis	rs12760731	0.565	rs10913519	chr1:178196094	A/T	cg00404053	chr1:178313656	RASAL2	0.65	7.85	0.3	1.82e-14	Obesity-related traits;
BRCA	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg08000102	chr2:233561755	GIGYF2	0.61	13.08	0.46	8.04e-35	Coronary artery disease;
BRCA	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg19678392	chr7:94953810	PON1	-0.41	-8.45	-0.32	2.04e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs11603020	0.950	rs11229066	chr11:57374871	C/G	cg19752551	chr11:57585705	CTNND1	-0.41	-9.63	-0.36	1.41e-20	Blood protein levels;
BRCA	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg25427524	chr10:38739819	LOC399744	0.59	11.08	0.4	3.27e-26	Obesity (extreme);
BRCA	cis	rs77861329	1.000	rs9847073	chr3:52144947	C/T	cg08692210	chr3:52188851	WDR51A	-0.71	-10.62	-0.39	2.33e-24	Macrophage inflammatory protein 1b levels;
BRCA	trans	rs11165623	0.792	rs13375510	chr1:96920723	A/G	cg10631902	chr5:14652156	NA	-0.5	-16.07	-0.54	4.66e-49	Hip circumference;Waist circumference;
BRCA	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg08885076	chr2:99613938	TSGA10	-0.59	-13.08	-0.46	8e-35	Chronic sinus infection;
BRCA	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.09e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg20503657	chr10:835505	NA	1.03	17.95	0.58	1.18e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs7766436	0.885	rs6935379	chr6:22581462	A/G	cg13666174	chr6:22585274	NA	-0.49	-11.6	-0.42	2.25e-28	Coronary artery disease;
BRCA	cis	rs965469	0.843	rs6037580	chr20:3351374	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-10.54	-0.38	4.61e-24	IFN-related cytopenia;
BRCA	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg24505687	chr6:33548425	BAK1	0.57	12.15	0.43	1e-30	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
BRCA	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	13.34	0.47	5.43e-36	Mean platelet volume;
BRCA	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-12.92	-0.46	4.26e-34	Blood metabolite levels;
BRCA	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg22563815	chr15:78856949	CHRNA5	0.36	8.39	0.31	3.14e-16	Sudden cardiac arrest;
BRCA	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-13.56	-0.47	5.14e-37	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg04166393	chr7:2884313	GNA12	0.54	10.1	0.37	2.32e-22	Height;
BRCA	cis	rs17209837	0.607	rs2072384	chr7:87082868	A/T	cg00919237	chr7:87102261	ABCB4	-0.53	-10.24	-0.38	6.94e-23	Gallbladder cancer;
BRCA	trans	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg21659725	chr3:3221576	CRBN	-0.47	-8.33	-0.31	5.12e-16	Menarche (age at onset);
BRCA	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg22875332	chr1:76189707	ACADM	-0.54	-10.3	-0.38	4.18e-23	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs870825	0.860	rs34985821	chr4:185599489	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	14.24	0.49	3.6e-40	Blood protein levels;
BRCA	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg11663144	chr21:46675770	NA	0.58	13.66	0.48	1.93e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg03585969	chr10:35415529	CREM	0.56	11.51	0.41	5.36e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.46	0.38	9.2e-24	IgG glycosylation;
BRCA	cis	rs3087591	0.879	rs59015798	chr17:29580882	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.4	-7.81	-0.3	2.42e-14	Hip circumference;
BRCA	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg24692254	chr21:30365293	RNF160	0.63	14.48	0.5	2.76e-41	Selective IgA deficiency;
BRCA	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24549020	chr5:56110836	MAP3K1	-0.62	-12.69	-0.45	4.57e-33	Initial pursuit acceleration;
BRCA	cis	rs778371	0.697	rs11893358	chr2:233636922	T/C	cg08000102	chr2:233561755	GIGYF2	0.82	19.37	0.61	4.01e-66	Schizophrenia;
BRCA	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg22875332	chr1:76189707	ACADM	-0.66	-13.89	-0.48	1.68e-38	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg07741184	chr6:167504864	NA	0.33	9.88	0.36	1.68e-21	Primary biliary cholangitis;
BRCA	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.8	-0.33	1.23e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg15819921	chr19:927150	ARID3A	-0.51	-9.68	-0.36	9.27e-21	Life satisfaction;
BRCA	cis	rs6973256	0.865	rs2991230	chr7:133332086	A/C	cg07491979	chr7:133331646	EXOC4	-0.38	-8.71	-0.33	2.51e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs1691799	0.899	rs1060724	chr12:66740444	T/C	cg16791601	chr12:66731901	HELB	-0.65	-17.57	-0.57	1.16e-56	White blood cell count (basophil);
BRCA	cis	rs2108225	0.967	rs6466189	chr7:107448516	C/T	cg18560240	chr7:107437656	SLC26A3	-0.5	-10.35	-0.38	2.54e-23	Ulcerative colitis;
BRCA	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg12483005	chr1:23474871	LUZP1	-0.46	-10.4	-0.38	1.61e-23	Height;
BRCA	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg23711669	chr6:146136114	FBXO30	0.73	17.52	0.57	2.06e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.39	8.54	0.32	1.01e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1451375	0.741	rs55738142	chr7:50632326	T/C	cg18232548	chr7:50535776	DDC	0.4	9.43	0.35	7.21e-20	Malaria;
BRCA	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-7.82	-0.3	2.13e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03576123	chr11:487126	PTDSS2	-1.2	-18.77	-0.6	6.11e-63	Body mass index;
BRCA	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg05775895	chr3:12838266	CAND2	0.38	8.49	0.32	1.44e-16	QRS complex (12-leadsum);
BRCA	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06028605	chr16:24865363	SLC5A11	-0.46	-10.11	-0.37	2.19e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg24829409	chr8:58192753	C8orf71	-0.47	-9.12	-0.34	9.38e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg08000102	chr2:233561755	GIGYF2	0.65	14.11	0.49	1.47e-39	Coronary artery disease;
BRCA	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.21	-0.34	4.59e-19	Menopause (age at onset);
BRCA	cis	rs7598759	0.675	rs6727530	chr2:232332058	T/C	cg19187155	chr2:232395269	NMUR1	0.37	7.83	0.3	2.1e-14	Noise-induced hearing loss;
BRCA	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg10556349	chr10:835070	NA	0.59	8.35	0.31	4.35e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg26384229	chr12:38710491	ALG10B	0.74	17.23	0.56	6.19e-55	Bladder cancer;
BRCA	cis	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg04990556	chr1:26633338	UBXN11	0.54	8.86	0.33	8.17e-18	Obesity-related traits;
BRCA	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg10556349	chr10:835070	NA	0.73	9.71	0.36	6.8e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg00105475	chr2:10696890	NA	0.44	10.25	0.38	6.03e-23	Prostate cancer;
BRCA	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg11663144	chr21:46675770	NA	-0.64	-15.38	-0.52	1.24e-45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg12165864	chr7:66369176	NA	-0.46	-10.44	-0.38	1.13e-23	Corneal structure;
BRCA	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23583168	chr7:148888333	NA	-0.92	-24.01	-0.69	2.79e-91	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2625529	0.730	rs8182011	chr15:72389948	C/T	cg16672083	chr15:72433130	SENP8	0.74	16.86	0.55	4.69e-53	Red blood cell count;
BRCA	cis	rs7523050	0.643	rs34367763	chr1:109400805	C/T	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg03146154	chr1:46216737	IPP	-0.47	-10.33	-0.38	3.19e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12711979	0.509	rs10191674	chr2:3827891	C/T	cg17052675	chr2:3827356	NA	-0.69	-23.74	-0.68	8.1e-90	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg27170947	chr2:26402098	FAM59B	-0.92	-16.52	-0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	28.21	0.74	2.43e-114	Chronic sinus infection;
BRCA	cis	rs6813479	0.524	rs2612113	chr4:137745583	C/G	cg16185213	chr4:137733633	NA	0.34	8.19	0.31	1.37e-15	Longevity;
BRCA	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7301826	0.651	rs7971046	chr12:131286807	G/A	cg11011512	chr12:131303247	STX2	0.51	13.49	0.47	1.11e-36	Plasma plasminogen activator levels;
BRCA	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg21775007	chr8:11205619	TDH	0.7	17.09	0.56	3.4e-54	Retinal vascular caliber;
BRCA	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg13271783	chr10:134563150	INPP5A	-0.51	-9.59	-0.35	1.99e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	trans	rs3960554	1.000	rs2097947	chr7:75836382	A/T	cg19862616	chr7:65841803	NCRNA00174	0.58	12.54	0.44	2.01e-32	Eotaxin levels;
BRCA	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg08992911	chr2:238395768	MLPH	0.4	7.96	0.3	7.81e-15	Prostate cancer;
BRCA	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg11663144	chr21:46675770	NA	-0.53	-12.98	-0.46	2.31e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs61990749	0.597	rs2299930	chr14:78163722	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.58	-9.05	-0.34	1.65e-18	Fibroblast growth factor basic levels;
BRCA	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg05340658	chr4:99064831	C4orf37	0.63	14.98	0.51	1.1e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.38	-7.87	-0.3	1.47e-14	Alzheimer's disease (late onset);
BRCA	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg11247378	chr22:39784982	NA	0.61	14.49	0.5	2.5e-41	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs1003719	0.680	rs767998	chr21:38525652	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.43	-0.5	4.74e-41	Eye color traits;
BRCA	cis	rs36051895	0.632	rs62541959	chr9:5175687	G/C	cg02405213	chr9:5042618	JAK2	-0.48	-8.72	-0.33	2.39e-17	Pediatric autoimmune diseases;
BRCA	cis	rs9463078	0.764	rs7754698	chr6:44782717	A/G	cg25276700	chr6:44698697	NA	-0.36	-8.3	-0.31	6.05e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs10992471	0.528	rs7022562	chr9:95216340	A/G	cg14631576	chr9:95140430	CENPP	-0.35	-8.7	-0.33	2.83e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs829883	0.622	rs4762498	chr12:98964737	A/G	cg25150519	chr12:98850993	NA	-0.48	-8.65	-0.32	4.25e-17	Colorectal adenoma (advanced);
BRCA	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06022373	chr22:39101656	GTPBP1	0.67	16.95	0.56	1.69e-53	Menopause (age at onset);
BRCA	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg23533926	chr12:111358616	MYL2	-0.43	-8.89	-0.33	6.43e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2115536	0.704	rs2163005	chr15:80194480	A/G	cg00225070	chr15:80189496	MTHFS	0.45	10.31	0.38	3.81e-23	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
BRCA	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg16482183	chr6:26056742	HIST1H1C	0.41	8.78	0.33	1.49e-17	Iron status biomarkers;
BRCA	cis	rs12413816	0.824	rs1571008	chr10:13760776	T/C	cg16485048	chr10:13749193	FRMD4A	0.58	14.08	0.49	1.96e-39	Red cell distribution width;
BRCA	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.6	-0.32	6.2e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg08807101	chr21:30365312	RNF160	-0.57	-13.96	-0.48	7.55e-39	Dental caries;
BRCA	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg24250549	chr1:154909240	PMVK	0.69	18.17	0.58	8.55e-60	Prostate cancer;
BRCA	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.76	0.39	6.24e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.45	-0.47	1.72e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg09877947	chr5:131593287	PDLIM4	0.41	9.69	0.36	8.24e-21	Acylcarnitine levels;
BRCA	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg24848339	chr3:12840334	CAND2	0.47	12.77	0.45	2e-33	QRS complex (12-leadsum);
BRCA	cis	rs829883	0.763	rs249843	chr12:98870987	G/A	cg25150519	chr12:98850993	NA	0.67	16.5	0.55	3.36e-51	Colorectal adenoma (advanced);
BRCA	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg17063962	chr7:91808500	NA	0.53	12.48	0.44	3.69e-32	Breast cancer;
BRCA	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.43	-9.02	-0.34	2.23e-18	Body mass index;
BRCA	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.38	8.41	0.32	2.58e-16	Cognitive ability;
BRCA	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg03929089	chr4:120376271	NA	0.61	10.56	0.39	3.97e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.93	0.33	4.45e-18	Tonsillectomy;
BRCA	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.91	-0.33	5.1e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg16586182	chr3:47516702	SCAP	0.55	12.2	0.43	6.14e-31	Colorectal cancer;
BRCA	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.08	16.37	0.54	1.44e-50	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7523273	0.606	rs2281289	chr1:207978916	C/T	cg22525895	chr1:207977042	MIR29B2	-0.5	-12.84	-0.45	1.02e-33	Schizophrenia;
BRCA	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg18252515	chr7:66147081	NA	-0.86	-12.34	-0.44	1.53e-31	Diabetic kidney disease;
BRCA	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.85	-0.3	1.77e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg11663144	chr21:46675770	NA	-0.49	-10.15	-0.37	1.55e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.29	0.31	6.9e-16	Parkinson's disease;
BRCA	cis	rs26949	0.526	rs3899221	chr5:60036377	A/G	cg02684056	chr5:59996105	DEPDC1B	-0.34	-7.89	-0.3	1.32e-14	Intelligence (multi-trait analysis);
BRCA	trans	rs2262909	0.962	rs12610034	chr19:22314528	G/A	cg17074339	chr11:11642133	GALNTL4	0.45	8.88	0.33	6.73e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.35	9.03	0.34	1.98e-18	IgG glycosylation;
BRCA	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg08999081	chr20:33150536	PIGU	0.44	12.36	0.44	1.32e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg00686598	chr14:53173677	PSMC6	1.26	16.57	0.55	1.38e-51	Alzheimer's disease (late onset);
BRCA	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg21132104	chr15:45694354	SPATA5L1	0.7	15.4	0.52	1.01e-45	Homoarginine levels;
BRCA	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg21782813	chr7:2030301	MAD1L1	0.4	10.7	0.39	1.08e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg04455712	chr21:45112962	RRP1B	0.41	10.92	0.4	1.4e-25	Mean corpuscular volume;
BRCA	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg24562669	chr7:97807699	LMTK2	0.47	12.39	0.44	9.53e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	14.97	0.51	1.26e-43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.68	-0.42	1.03e-28	Mean corpuscular volume;
BRCA	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg08888203	chr3:10149979	C3orf24	0.66	14.08	0.49	2.03e-39	Alzheimer's disease;
BRCA	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-16.21	-0.54	9.23e-50	Heart rate;
BRCA	cis	rs4363385	0.818	rs11205174	chr1:153001230	C/T	cg24667326	chr1:152973720	SPRR3	0.32	8.71	0.33	2.67e-17	Inflammatory skin disease;
BRCA	cis	rs3106136	0.527	rs2664872	chr4:95146952	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.07	-0.37	2.97e-22	Capecitabine sensitivity;
BRCA	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg03929089	chr4:120376271	NA	0.56	9.08	0.34	1.31e-18	Axial length;
BRCA	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg22907277	chr7:1156413	C7orf50	0.59	9.18	0.34	5.82e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs2834485	1.000	rs5010906	chr21:35818590	G/C	cg07474852	chr4:123073612	NA	0.48	10.27	0.38	5.44e-23	Cancer;
BRCA	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-10.01	-0.37	5.32e-22	Heart rate;
BRCA	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg17420585	chr12:42539391	GXYLT1	-0.47	-9.97	-0.37	7.33e-22	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	trans	rs1325195	1.000	rs1325195	chr1:179071756	G/A	cg11624085	chr17:8464688	MYH10	-0.27	-8.52	-0.32	1.16e-16	IgE grass sensitization;
BRCA	trans	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg26043149	chr18:55253948	FECH	-0.41	-9.16	-0.34	7.11e-19	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4965272	0.953	rs12441162	chr15:100592818	C/T	cg27344315	chr15:100560801	ADAMTS17	-0.43	-8.36	-0.31	4.03e-16	Gastroesophageal reflux disease;
BRCA	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg00071950	chr4:10020882	SLC2A9	0.54	13.4	0.47	3.05e-36	Bone mineral density;
BRCA	cis	rs11608355	0.545	rs2302708	chr12:109893726	A/C	cg05360138	chr12:110035743	NA	0.71	13.18	0.46	2.85e-35	Neuroticism;
BRCA	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg09184832	chr6:79620586	NA	-0.55	-12.1	-0.43	1.76e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg20476274	chr7:133979776	SLC35B4	0.66	19.46	0.61	1.39e-66	Mean platelet volume;
BRCA	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg00105475	chr2:10696890	NA	0.44	10.1	0.37	2.43e-22	Prostate cancer;
BRCA	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.37e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg19678392	chr7:94953810	PON1	-0.44	-10.28	-0.38	4.72e-23	Paraoxonase activity;
BRCA	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.23	0.31	1.07e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs4650994	1.000	rs10913570	chr1:178523126	A/C	cg05059571	chr16:84539110	KIAA1609	-0.42	-9.51	-0.35	3.7e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs2204008	0.776	rs3861074	chr12:38483021	C/T	cg26384229	chr12:38710491	ALG10B	0.74	15.92	0.53	2.63e-48	Bladder cancer;
BRCA	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg01877450	chr7:97915802	BRI3	-0.38	-8.62	-0.32	5.12e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6484504	0.576	rs2756191	chr11:31135882	A/T	cg26647111	chr11:31128758	NA	0.4	8.73	0.33	2.26e-17	Red blood cell count;
BRCA	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg00684032	chr4:1343700	KIAA1530	-0.35	-8.92	-0.33	4.97e-18	Obesity-related traits;
BRCA	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00149659	chr3:10157352	C3orf10	0.72	12.57	0.45	1.49e-32	Alzheimer's disease;
BRCA	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.61	-13.1	-0.46	6.7e-35	Lymphocyte counts;
BRCA	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg26384229	chr12:38710491	ALG10B	0.75	17.0	0.56	9.05e-54	Bladder cancer;
BRCA	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg03342759	chr3:160939853	NMD3	-0.54	-11.63	-0.42	1.75e-28	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.635	rs1601627	chr12:33962420	G/A	cg26384229	chr12:38710491	ALG10B	0.39	8.87	0.33	7e-18	Morning vs. evening chronotype;
BRCA	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg24596788	chr1:163392923	NA	0.36	9.67	0.36	9.65e-21	Motion sickness;
BRCA	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.03	0.49	3.57e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7737355	0.947	rs3776027	chr5:130802970	T/C	cg06307176	chr5:131281290	NA	-0.52	-10.51	-0.38	6e-24	Life satisfaction;
BRCA	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg24692254	chr21:30365293	RNF160	0.79	21.84	0.65	2.02e-79	Dental caries;
BRCA	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg07606381	chr6:8435919	SLC35B3	-0.63	-13.9	-0.48	1.5e-38	Motion sickness;
BRCA	cis	rs922182	0.617	rs2899697	chr15:64240436	T/C	cg24729988	chr15:64271149	DAPK2	0.49	10.73	0.39	8.62e-25	Blood protein levels;
BRCA	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg20476274	chr7:133979776	SLC35B4	0.65	19.39	0.61	3.04e-66	Mean platelet volume;
BRCA	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg08847533	chr14:75593920	NEK9	-0.86	-21.61	-0.65	3.52e-78	Height;
BRCA	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23583168	chr7:148888333	NA	-0.85	-19.4	-0.61	2.91e-66	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg26384229	chr12:38710491	ALG10B	0.5	12.47	0.44	4.1e-32	Morning vs. evening chronotype;
BRCA	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg01304814	chr3:48885189	PRKAR2A	0.71	8.01	0.3	5.28e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs8022179	0.580	rs58153827	chr14:103844630	G/A	cg12935359	chr14:103987150	CKB	0.52	9.98	0.37	6.95e-22	Monocyte count;
BRCA	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg05313129	chr8:58192883	C8orf71	-0.46	-9.59	-0.35	2.01e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg04546413	chr19:29218101	NA	0.66	13.28	0.46	1.08e-35	Methadone dose in opioid dependence;
BRCA	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg10950524	chr7:2139216	MAD1L1	0.27	7.84	0.3	1.88e-14	Schizophrenia;
BRCA	cis	rs7639513	0.767	rs13060705	chr3:12710016	C/A	cg23032965	chr3:12705835	RAF1	0.69	15.37	0.52	1.28e-45	Itch intensity from mosquito bite;
BRCA	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg12386194	chr3:101231763	SENP7	0.6	12.21	0.43	5.79e-31	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7927771	0.524	rs11039415	chr11:47845814	A/G	cg20307385	chr11:47447363	PSMC3	0.41	9.4	0.35	9.67e-20	Subjective well-being;
BRCA	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg03060546	chr3:49711283	APEH	-0.61	-12.33	-0.44	1.69e-31	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4409675	0.576	rs6679432	chr1:28227665	T/C	cg23691781	chr1:28212827	C1orf38	0.32	10.66	0.39	1.5e-24	Corneal astigmatism;
BRCA	cis	rs4363385	0.818	rs10788856	chr1:153011517	G/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs708547	0.647	rs1403233	chr4:57885053	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.37	-9.42	-0.35	7.95e-20	Response to bleomycin (chromatid breaks);
BRCA	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.79	0.36	3.52e-21	Bipolar disorder;
BRCA	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg18402987	chr7:1209562	NA	0.84	11.92	0.43	9.85e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1635	0.655	rs16893973	chr6:28302113	C/T	cg15743358	chr6:28303923	ZNF323	-0.75	-8.7	-0.33	2.85e-17	Schizophrenia;
BRCA	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg20307385	chr11:47447363	PSMC3	-0.43	-9.03	-0.34	1.96e-18	Subjective well-being;
BRCA	cis	rs9394841	0.667	rs1891453	chr6:41765265	T/C	cg08135965	chr6:41755394	TOMM6	0.5	8.13	0.31	2.18e-15	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg05234568	chr11:5960015	NA	-0.47	-10.75	-0.39	6.82e-25	DNA methylation (variation);
BRCA	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg11584989	chr19:19387371	SF4	-0.62	-13.16	-0.46	3.66e-35	Bipolar disorder;
BRCA	cis	rs13046373	0.535	rs1911571	chr21:32031538	A/C	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.3	0.35	2.17e-19	HDL cholesterol;
BRCA	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.37	0.35	1.18e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9790314	0.723	rs1026572	chr3:160887654	A/G	cg04691961	chr3:161091175	C3orf57	-0.35	-8.02	-0.3	4.95e-15	Morning vs. evening chronotype;
BRCA	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg16049864	chr8:95962084	TP53INP1	-0.44	-10.78	-0.39	5.31e-25	Type 2 diabetes;
BRCA	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.33	7.95	0.3	8.77e-15	Personality dimensions;
BRCA	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg08807101	chr21:30365312	RNF160	0.62	13.46	0.47	1.59e-36	Selective IgA deficiency;
BRCA	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.66	-0.32	3.86e-17	Alzheimer's disease (late onset);
BRCA	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg02196655	chr2:10830764	NOL10	0.29	7.81	0.3	2.27e-14	Prostate cancer;
BRCA	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.11	0.31	2.59e-15	Menopause (age at onset);
BRCA	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg13010199	chr12:38710504	ALG10B	0.51	10.69	0.39	1.24e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1003719	0.715	rs2835675	chr21:38582815	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.45	-0.5	3.7e-41	Eye color traits;
BRCA	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg05729581	chr11:3078854	CARS	-0.36	-8.84	-0.33	9.48e-18	Longevity;
BRCA	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg05234568	chr11:5960015	NA	0.53	12.04	0.43	3.16e-30	DNA methylation (variation);
BRCA	cis	rs9341808	0.791	rs1324122	chr6:80946061	G/A	cg08355045	chr6:80787529	NA	0.39	9.95	0.37	8.77e-22	Sitting height ratio;
BRCA	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg03711944	chr11:47377212	SPI1	-0.38	-9.11	-0.34	1.02e-18	Diastolic blood pressure;Systolic blood pressure;
BRCA	trans	rs208520	1.000	rs208527	chr6:66957209	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-14.55	-0.5	1.17e-41	Exhaled nitric oxide output;
BRCA	cis	rs13046373	0.535	rs7276743	chr21:31984545	C/T	cg06468780	chr21:31798236	KRTAP13-3	0.34	8.34	0.31	4.45e-16	HDL cholesterol;
BRCA	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.53	8.89	0.33	6.37e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4363385	0.693	rs310102	chr1:153042423	T/C	cg25856811	chr1:152973957	SPRR3	-0.31	-8.01	-0.3	5.53e-15	Inflammatory skin disease;
BRCA	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg25358565	chr5:93447407	FAM172A	1.24	18.91	0.6	1.1e-63	Diabetic retinopathy;
BRCA	cis	rs4363385	0.693	rs440598	chr1:153044733	T/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.04	-0.3	4.26e-15	Inflammatory skin disease;
BRCA	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.58	-11.04	-0.4	4.82e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-12.87	-0.45	7.39e-34	Monocyte percentage of white cells;
BRCA	cis	rs4566357	0.521	rs78411533	chr2:227910807	G/A	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.12	-0.31	2.34e-15	Coronary artery disease;
BRCA	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg11266682	chr4:10021025	SLC2A9	0.45	11.9	0.43	1.26e-29	Bone mineral density;
BRCA	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg12310025	chr6:25882481	NA	-0.54	-12.83	-0.45	1.04e-33	Blood metabolite levels;
BRCA	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg27170947	chr2:26402098	FAM59B	-0.99	-17.06	-0.56	4.44e-54	Gut microbiome composition (summer);
BRCA	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg05714579	chr10:131428358	MGMT	0.59	14.65	0.5	3.99e-42	Response to temozolomide;
BRCA	cis	rs2625529	0.824	rs10518979	chr15:72268986	A/G	cg16672083	chr15:72433130	SENP8	-0.86	-17.76	-0.57	1.11e-57	Red blood cell count;
BRCA	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14442939	chr10:27389572	ANKRD26	0.7	11.0	0.4	6.54e-26	Breast cancer;
BRCA	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.54	-9.75	-0.36	4.93e-21	Response to bleomycin (chromatid breaks);
BRCA	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.72	0.39	9.35e-25	Cognitive ability;
BRCA	cis	rs919433	0.680	rs2565161	chr2:198285554	C/G	cg00792783	chr2:198669748	PLCL1	0.38	8.39	0.32	3.12e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg12193833	chr17:30244370	NA	-0.55	-8.62	-0.32	5.36e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg11247378	chr22:39784982	NA	-0.64	-15.78	-0.53	1.31e-47	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs1371614	0.635	rs10196691	chr2:27141359	T/A	cg12368169	chr2:27073192	DPYSL5	-0.29	-8.54	-0.32	9.6e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs12711979	0.765	rs6705742	chr2:3820672	C/T	cg17052675	chr2:3827356	NA	-0.48	-14.21	-0.49	5.12e-40	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg15128208	chr22:42549153	NA	0.32	8.25	0.31	8.99e-16	Cognitive function;
BRCA	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.24	-0.38	6.57e-23	Mean corpuscular volume;
BRCA	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg13319975	chr6:146136371	FBXO30	0.35	8.07	0.3	3.44e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg24642439	chr20:33292090	TP53INP2	0.43	9.19	0.34	5.32e-19	Height;
BRCA	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg06627628	chr2:24431161	ITSN2	0.55	11.2	0.4	1.07e-26	Asthma;
BRCA	cis	rs7945705	0.875	rs10769947	chr11:8758114	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.48	10.23	0.38	7.6e-23	Hemoglobin concentration;
BRCA	trans	rs8002861	0.869	rs7989857	chr13:44464090	C/T	cg17145862	chr1:211918768	LPGAT1	0.73	19.6	0.61	2.43e-67	Leprosy;
BRCA	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg24531977	chr5:56204891	C5orf35	-0.4	-8.07	-0.3	3.39e-15	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg11833968	chr6:79620685	NA	-0.45	-9.84	-0.36	2.37e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg18512352	chr11:47633146	NA	-0.34	-8.31	-0.31	5.91e-16	Subjective well-being;
BRCA	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg24250549	chr1:154909240	PMVK	0.67	17.32	0.57	2.16e-55	Prostate cancer;
BRCA	cis	rs910873	0.505	rs7261964	chr20:33205011	C/T	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.01	-0.37	5.2e-22	Melanoma;
BRCA	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg21775007	chr8:11205619	TDH	0.42	8.5	0.32	1.36e-16	Neuroticism;
BRCA	cis	rs9434723	0.920	rs2239560	chr1:9304731	C/T	cg04199779	chr1:9294473	H6PD	0.48	8.53	0.32	1.02e-16	Height;
BRCA	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg02733842	chr7:1102375	C7orf50	-0.64	-11.68	-0.42	1.09e-28	Bronchopulmonary dysplasia;
BRCA	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg23711669	chr6:146136114	FBXO30	0.73	17.53	0.57	1.75e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg20701182	chr2:24300061	SF3B14	0.55	8.51	0.32	1.21e-16	Lymphocyte counts;
BRCA	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg18252515	chr7:66147081	NA	-0.81	-11.24	-0.41	6.88e-27	Diabetic kidney disease;
BRCA	cis	rs965469	1.000	rs6037556	chr20:3317890	G/C	cg25506879	chr20:3388711	C20orf194	-0.53	-10.56	-0.39	3.9e-24	IFN-related cytopenia;
BRCA	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.93	-0.3	9.7e-15	Bipolar disorder;
BRCA	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg15145296	chr3:125709740	NA	-0.55	-8.7	-0.33	2.7e-17	Blood pressure (smoking interaction);
BRCA	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg25427524	chr10:38739819	LOC399744	-0.53	-9.27	-0.34	2.88e-19	Obesity (extreme);
BRCA	cis	rs2882667	0.858	rs13170388	chr5:138436865	A/G	cg04439458	chr5:138467593	SIL1	-0.41	-10.37	-0.38	2.07e-23	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4891159	0.527	rs689642	chr18:74119120	A/C	cg24786174	chr18:74118243	ZNF516	0.84	25.82	0.71	3.3e-101	Longevity;
BRCA	cis	rs4478137	0.931	rs11100488	chr4:164237660	C/A	cg06758707	chr4:164254230	NPY1R	0.59	12.99	0.46	2.04e-34	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg02079420	chr8:82753780	SNX16	0.31	8.43	0.32	2.27e-16	Diastolic blood pressure;
BRCA	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21659725	chr3:3221576	CRBN	0.38	8.84	0.33	8.91e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg08470875	chr2:26401718	FAM59B	-0.7	-11.27	-0.41	5.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg01483505	chr11:975446	AP2A2	0.35	9.37	0.35	1.27e-19	Alzheimer's disease (late onset);
BRCA	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.03	-18.48	-0.59	2e-61	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	20.34	0.63	2.67e-71	Electrocardiographic conduction measures;
BRCA	cis	rs9341808	0.718	rs7740627	chr6:80916347	A/G	cg08355045	chr6:80787529	NA	0.39	10.0	0.37	5.65e-22	Sitting height ratio;
BRCA	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	16.16	0.54	1.74e-49	Tonsillectomy;
BRCA	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.31	8.09	0.3	2.93e-15	Ovarian reserve;
BRCA	cis	rs4746818	0.711	rs4745976	chr10:70845181	A/G	cg11621586	chr10:70884670	VPS26A	0.45	8.12	0.31	2.41e-15	Left atrial antero-posterior diameter;
BRCA	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg00684032	chr4:1343700	KIAA1530	0.53	12.47	0.44	4.28e-32	Obesity-related traits;
BRCA	cis	rs4662945	0.525	rs28625431	chr2:130303333	A/G	cg05903289	chr2:130345205	NA	-0.33	-8.3	-0.31	6.35e-16	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs7577696	0.512	rs212691	chr2:32438075	G/A	cg02381751	chr2:32503542	YIPF4	0.46	8.44	0.32	2.12e-16	Inflammatory biomarkers;
BRCA	cis	rs1568889	1.000	rs16917735	chr11:28119980	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.58	-12.5	-0.44	3.21e-32	Bipolar disorder;
BRCA	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.33	-8.08	-0.3	3.16e-15	Total body bone mineral density;
BRCA	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg26384229	chr12:38710491	ALG10B	0.85	22.84	0.67	7.26e-85	Heart rate;
BRCA	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	8.08	0.3	3.34e-15	Aortic root size;
BRCA	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02018176	chr4:1364513	KIAA1530	0.4	7.96	0.3	8.12e-15	Longevity;
BRCA	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.1	15.83	0.53	7.44e-48	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg12292205	chr6:26970375	C6orf41	0.73	16.65	0.55	5.71e-52	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.81	0.3	2.3e-14	Corneal astigmatism;
BRCA	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg06552810	chr11:31128660	NA	-0.4	-8.88	-0.33	6.88e-18	Red blood cell count;
BRCA	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg08999081	chr20:33150536	PIGU	0.37	9.59	0.35	2e-20	Coronary artery disease;
BRCA	trans	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg25214090	chr10:38739885	LOC399744	0.56	12.85	0.45	9.31e-34	Corneal astigmatism;
BRCA	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	17.54	0.57	1.64e-56	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6977660	0.714	rs17141945	chr7:19805056	T/A	cg05791153	chr7:19748676	TWISTNB	0.59	10.83	0.39	3.39e-25	Thyroid stimulating hormone;
BRCA	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.35e-15	Prostate cancer;
BRCA	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg06970220	chr1:156163860	SLC25A44	0.39	7.88	0.3	1.39e-14	Testicular germ cell tumor;
BRCA	cis	rs2904967	1.000	rs630055	chr11:65087533	G/T	cg09225861	chr11:65069680	NA	-0.38	-7.95	-0.3	8.73e-15	Mean corpuscular volume;
BRCA	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-8.11	-0.31	2.6e-15	Obesity-related traits;
BRCA	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg09035930	chr12:129282057	SLC15A4	-0.56	-16.6	-0.55	9.65e-52	Systemic lupus erythematosus;
BRCA	trans	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-7.87	-0.3	1.53e-14	Corneal astigmatism;
BRCA	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg02574844	chr11:5959923	NA	-0.4	-8.33	-0.31	4.96e-16	DNA methylation (variation);
BRCA	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.8	0.36	3.22e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg13334819	chr7:99746414	C7orf59	-0.35	-7.93	-0.3	9.57e-15	Coronary artery disease;
BRCA	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.06	0.74	1.6e-113	Chronic sinus infection;
BRCA	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.65	13.39	0.47	3.29e-36	Lymphocyte counts;
BRCA	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg23533926	chr12:111358616	MYL2	0.39	8.26	0.31	8.23e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg21775007	chr8:11205619	TDH	0.47	9.93	0.37	1.02e-21	Triglycerides;
BRCA	cis	rs68170813	0.559	rs997311	chr7:106953033	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-8.53	-0.32	1.02e-16	Coronary artery disease;
BRCA	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.41	0.38	1.57e-23	Bladder cancer;
BRCA	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3849570	0.961	rs3849571	chr3:81777716	A/C	cg07356753	chr3:81810745	GBE1	-0.47	-11.41	-0.41	1.35e-27	Waist circumference;Body mass index;
BRCA	cis	rs6691722	0.506	rs1016209	chr1:24745615	A/G	cg18323236	chr1:24743029	NIPAL3	-0.36	-10.17	-0.37	1.27e-22	Response to interferon beta in multiple sclerosis;
BRCA	cis	rs2249625	0.523	rs2463707	chr6:72861732	G/A	cg18830697	chr6:72922368	RIMS1	-0.51	-11.49	-0.41	6.66e-28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg01256987	chr12:42539512	GXYLT1	-0.57	-11.64	-0.42	1.49e-28	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs12348691	0.503	rs7048394	chr9:100605433	T/C	cg13688889	chr9:100608707	NA	-0.49	-10.0	-0.37	5.81e-22	Alopecia areata;
BRCA	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-13.14	-0.46	4.29e-35	Morning vs. evening chronotype;
BRCA	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg11833968	chr6:79620685	NA	-0.43	-9.4	-0.35	9.24e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.63	-12.17	-0.43	8.36e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1691799	0.899	rs1168320	chr12:66744849	C/T	cg16791601	chr12:66731901	HELB	-0.69	-19.67	-0.61	1.03e-67	White blood cell count (basophil);
BRCA	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg16339924	chr4:17578868	LAP3	0.67	16.95	0.56	1.68e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg13852791	chr20:30311386	BCL2L1	0.86	16.75	0.55	1.82e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg11608241	chr8:8085544	FLJ10661	-0.28	-8.03	-0.3	4.69e-15	Mood instability;
BRCA	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg11812906	chr14:75593930	NEK9	0.57	12.37	0.44	1.19e-31	Coronary artery disease;
BRCA	cis	rs4742903	0.527	rs10820607	chr9:106888750	A/C	cg14250997	chr9:106856677	SMC2	0.29	8.53	0.32	1.05e-16	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-12.54	-0.44	2.05e-32	Alzheimer's disease;
BRCA	cis	rs977987	0.806	rs4888383	chr16:75386349	C/T	cg03315344	chr16:75512273	CHST6	0.5	11.79	0.42	3.75e-29	Dupuytren's disease;
BRCA	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg22713356	chr15:30763199	NA	1.26	22.09	0.66	8.41e-81	Uric acid levels;
BRCA	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg04450456	chr4:17643702	FAM184B	0.41	12.15	0.43	1.06e-30	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23248424	chr5:179741104	GFPT2	-0.64	-13.5	-0.47	9.64e-37	Height;
BRCA	cis	rs701145	0.938	rs2596630	chr3:153992586	A/G	cg17054900	chr3:154042577	DHX36	0.68	11.79	0.42	3.71e-29	Coronary artery disease;
BRCA	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	18.26	0.59	2.84e-60	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg06784218	chr1:46089804	CCDC17	0.45	10.85	0.39	2.66e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7131987	0.868	rs737160	chr12:29429012	T/C	cg09582351	chr12:29534625	ERGIC2	-0.42	-10.05	-0.37	3.53e-22	QT interval;
BRCA	cis	rs12760731	0.565	rs11585236	chr1:178108441	G/A	cg00404053	chr1:178313656	RASAL2	0.65	8.14	0.31	2.04e-15	Obesity-related traits;
BRCA	cis	rs9914988	0.943	rs2043032	chr17:27136692	A/G	cg20469991	chr17:27169893	C17orf63	-0.48	-8.95	-0.33	3.81e-18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	trans	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg25214090	chr10:38739885	LOC399744	0.56	12.85	0.45	9.31e-34	Corneal astigmatism;
BRCA	cis	rs4363385	0.818	rs10788852	chr1:153000491	C/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.41	-0.32	2.58e-16	Inflammatory skin disease;
BRCA	cis	rs2742234	0.590	rs2742237	chr10:43621323	C/G	cg15436174	chr10:43711423	RASGEF1A	-0.56	-11.16	-0.4	1.46e-26	Hirschsprung disease;
BRCA	cis	rs2505998	1.000	rs2505998	chr10:43570925	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.44	-8.62	-0.32	5.06e-17	Hirschsprung disease;
BRCA	cis	rs10267417	0.603	rs10263094	chr7:19872801	C/T	cg05791153	chr7:19748676	TWISTNB	0.49	9.27	0.34	2.88e-19	Night sleep phenotypes;
BRCA	cis	rs12541635	0.677	rs6469026	chr8:107006356	T/C	cg10147462	chr8:107024639	NA	0.4	10.53	0.38	5.13e-24	Age of smoking initiation;
BRCA	cis	rs1018836	0.923	rs13267989	chr8:91581648	C/T	cg16814680	chr8:91681699	NA	-0.58	-12.32	-0.44	2e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs365132	0.934	rs149307	chr5:176471591	C/T	cg16309518	chr5:176445507	NA	-0.52	-13.02	-0.46	1.59e-34	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs416603	0.967	rs7191538	chr16:11363389	C/G	cg00044050	chr16:11439710	C16orf75	-0.43	-10.09	-0.37	2.48e-22	Type 1 diabetes;
BRCA	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00290607	chr11:67383545	NA	-0.54	-12.59	-0.45	1.28e-32	Mean corpuscular volume;
BRCA	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11764359	chr7:65958608	NA	0.8	19.51	0.61	7.85e-67	Aortic root size;
BRCA	cis	rs62229266	0.740	rs2835233	chr21:37393582	A/G	cg12218747	chr21:37451666	NA	-0.34	-8.08	-0.3	3.16e-15	Mitral valve prolapse;
BRCA	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26314531	chr2:26401878	FAM59B	-0.78	-12.5	-0.44	3.19e-32	Gut microbiome composition (summer);
BRCA	cis	rs9788721	0.802	rs56219465	chr15:78742579	A/G	cg18825076	chr15:78729989	IREB2	-0.39	-8.23	-0.31	1.08e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg00277334	chr10:82204260	NA	-0.5	-10.73	-0.39	7.97e-25	Post bronchodilator FEV1;
BRCA	cis	rs2816062	0.786	rs2745316	chr1:18896830	G/A	cg18795169	chr1:18902165	NA	-0.97	-29.22	-0.76	7.6e-120	Urate levels in lean individuals;
BRCA	cis	rs3857536	0.706	rs1418854	chr6:66893284	C/T	cg07460842	chr6:66804631	NA	-0.46	-8.83	-0.33	1.02e-17	Blood trace element (Cu levels);
BRCA	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg12419862	chr22:24373484	LOC391322	-0.66	-14.99	-0.51	9.83e-44	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-16.41	-0.54	9.05e-51	Alzheimer's disease (late onset);
BRCA	cis	rs593982	1.000	rs1941746	chr11:65502413	A/G	cg08755490	chr11:65554678	OVOL1	1.27	29.33	0.76	1.95e-120	Atopic dermatitis;
BRCA	cis	rs9649465	0.967	rs6950373	chr7:123361773	C/T	cg04330084	chr7:123175371	IQUB	-0.33	-9.0	-0.34	2.51e-18	Migraine;
BRCA	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg08999081	chr20:33150536	PIGU	-0.34	-8.77	-0.33	1.56e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	8.24	0.31	9.59e-16	Tonsillectomy;
BRCA	cis	rs68170813	0.559	rs74745121	chr7:106958037	T/C	cg02696742	chr7:106810147	HBP1	-0.54	-8.72	-0.33	2.46e-17	Coronary artery disease;
BRCA	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg11502198	chr6:26597334	ABT1	0.43	8.13	0.31	2.18e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg25214090	chr10:38739885	LOC399744	0.44	10.1	0.37	2.4e-22	Corneal astigmatism;
BRCA	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg25206134	chr2:45395956	NA	0.49	8.54	0.32	9.79e-17	Bipolar disorder;
BRCA	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg20891283	chr12:69753455	YEATS4	0.83	28.18	0.74	3.43e-114	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg11266682	chr4:10021025	SLC2A9	0.45	11.99	0.43	4.9e-30	Bone mineral density;
BRCA	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25427524	chr10:38739819	LOC399744	-0.73	-18.04	-0.58	4.15e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.2e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05901451	chr6:126070800	HEY2	0.44	10.98	0.4	8.35e-26	Endometrial cancer;
BRCA	trans	rs9784649	0.760	rs17343923	chr5:25052414	G/A	cg11038491	chr20:34638489	LOC647979	-0.5	-9.13	-0.34	8.87e-19	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs11674184	0.632	rs17529680	chr2:11727087	A/C	cg07314298	chr2:11723111	GREB1	0.7	14.37	0.49	8.87e-41	Endometriosis;
BRCA	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg20290983	chr6:43655470	MRPS18A	-0.85	-14.42	-0.5	5.23e-41	IgG glycosylation;
BRCA	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg12179176	chr11:130786555	SNX19	0.5	10.78	0.39	5.21e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.21	0.37	8.65e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg11645453	chr3:52864694	ITIH4	-0.37	-9.69	-0.36	8.24e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg06484146	chr7:12443880	VWDE	-0.62	-8.57	-0.32	7.55e-17	Coronary artery disease;
BRCA	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.64	-16.76	-0.55	1.55e-52	Colorectal cancer;
BRCA	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg22105103	chr4:187893119	NA	0.37	11.92	0.43	1.05e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg13047869	chr3:10149882	C3orf24	0.53	11.33	0.41	2.9e-27	Alzheimer's disease;
BRCA	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg08470875	chr2:26401718	FAM59B	-0.58	-9.2	-0.34	4.82e-19	Gut microbiome composition (summer);
BRCA	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.84	-17.11	-0.56	2.54e-54	HIV-1 control;
BRCA	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24531977	chr5:56204891	C5orf35	-0.87	-18.04	-0.58	4.2e-59	Initial pursuit acceleration;
BRCA	trans	rs4650994	0.544	rs2761469	chr1:178590638	A/C	cg05059571	chr16:84539110	KIAA1609	0.52	11.63	0.42	1.78e-28	HDL cholesterol levels;HDL cholesterol;
BRCA	trans	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg25214090	chr10:38739885	LOC399744	0.55	12.18	0.43	7.52e-31	Corneal astigmatism;
BRCA	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg00105475	chr2:10696890	NA	0.44	10.27	0.38	5.08e-23	Prostate cancer;
BRCA	cis	rs1595825	0.838	rs60079260	chr2:198673636	G/A	cg19156104	chr2:198669113	PLCL1	-0.48	-8.58	-0.32	7.39e-17	Ulcerative colitis;
BRCA	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg09307838	chr4:120376055	NA	0.6	13.0	0.46	1.91e-34	Corneal astigmatism;
BRCA	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-16.69	-0.55	3.62e-52	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.34	-10.7	-0.39	1.05e-24	Bipolar disorder;
BRCA	cis	rs17818399	0.926	rs1824050	chr2:46839477	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.55	9.92	0.37	1.13e-21	Height;
BRCA	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.3	7.85	0.3	1.73e-14	Monocyte percentage of white cells;
BRCA	cis	rs713587	0.563	rs10865315	chr2:25100738	C/A	cg04586622	chr2:25135609	ADCY3	0.44	11.23	0.41	8.19e-27	Body mass index in non-asthmatics;
BRCA	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24531977	chr5:56204891	C5orf35	-0.86	-18.47	-0.59	2.37e-61	Initial pursuit acceleration;
BRCA	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08219700	chr8:58056026	NA	0.63	10.0	0.37	5.69e-22	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.47	-11.16	-0.4	1.51e-26	Longevity;Endometriosis;
BRCA	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg26597838	chr10:835615	NA	0.64	11.12	0.4	2.17e-26	Eosinophil percentage of granulocytes;
BRCA	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg06640241	chr16:89574553	SPG7	-0.58	-11.67	-0.42	1.11e-28	Multiple myeloma (IgH translocation);
BRCA	cis	rs9325144	0.957	rs1995419	chr12:38950726	C/G	cg26384229	chr12:38710491	ALG10B	0.45	8.97	0.33	3.2e-18	Morning vs. evening chronotype;
BRCA	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg21132104	chr15:45694354	SPATA5L1	0.7	15.45	0.52	5.52e-46	Homoarginine levels;
BRCA	trans	rs6076960	0.681	rs4487157	chr20:6249581	G/A	cg21095983	chr6:86352623	SYNCRIP	0.42	9.06	0.34	1.53e-18	Smooth-surface caries;
BRCA	trans	rs1459104	0.571	rs10459012	chr11:55091574	C/A	cg03929089	chr4:120376271	NA	0.54	9.63	0.36	1.38e-20	Body mass index;
BRCA	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg06484146	chr7:12443880	VWDE	-0.7	-9.7	-0.36	7.38e-21	Coronary artery disease;
BRCA	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg15556689	chr8:8085844	FLJ10661	0.42	11.72	0.42	6.93e-29	Mood instability;
BRCA	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25427524	chr10:38739819	LOC399744	0.69	16.61	0.55	8.83e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg05234568	chr11:5960015	NA	-0.4	-8.33	-0.31	4.75e-16	DNA methylation (variation);
BRCA	cis	rs897080	0.552	rs1085443	chr2:44635015	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.48	0.35	5.06e-20	Height;
BRCA	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg17724175	chr1:150552817	MCL1	-0.3	-10.03	-0.37	4.42e-22	Blood protein levels;
BRCA	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.32	-0.41	3.4e-27	Mean corpuscular volume;
BRCA	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg22431228	chr1:16359049	CLCNKA	-0.47	-9.7	-0.36	7.58e-21	Dilated cardiomyopathy;
BRCA	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25427524	chr10:38739819	LOC399744	-0.79	-20.45	-0.63	6.97e-72	Breast cancer;
BRCA	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg00631329	chr6:26305371	NA	-0.55	-15.65	-0.53	5.64e-47	Educational attainment;
BRCA	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg17063962	chr7:91808500	NA	0.53	12.43	0.44	6.26e-32	Breast cancer;
BRCA	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12893428	chr3:195717962	SDHAP1	0.35	8.18	0.31	1.53e-15	Pancreatic cancer;
BRCA	cis	rs4363385	0.747	rs6670614	chr1:152964338	A/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.93	-0.37	1.04e-21	Inflammatory skin disease;
BRCA	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg13010199	chr12:38710504	ALG10B	0.47	9.0	0.34	2.52e-18	Morning vs. evening chronotype;
BRCA	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg06784218	chr1:46089804	CCDC17	-0.44	-10.47	-0.38	8.95e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg03146154	chr1:46216737	IPP	0.53	11.89	0.43	1.37e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11229555	0.645	rs61889554	chr11:58424081	C/A	cg15696309	chr11:58395628	NA	-0.43	-8.95	-0.33	3.87e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9814567	0.727	rs4437193	chr3:134352344	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-16.05	-0.54	6.21e-49	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg23711669	chr6:146136114	FBXO30	0.72	17.08	0.56	3.59e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1941023	0.568	rs1373064	chr11:60168200	C/T	cg08716584	chr11:60157161	MS4A7	-0.42	-9.73	-0.36	5.83e-21	Congenital heart disease (maternal effect);
BRCA	cis	rs2455601	0.766	rs1109304	chr11:8955455	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-8.78	-0.33	1.52e-17	Schizophrenia;
BRCA	cis	rs600806	0.713	rs12140694	chr1:109998386	C/T	cg20591472	chr1:110008990	SYPL2	0.33	8.3	0.31	6.14e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg27170947	chr2:26402098	FAM59B	0.85	14.09	0.49	1.92e-39	Gut microbiome composition (summer);
BRCA	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg01181863	chr3:195395398	SDHAP2	-0.69	-10.69	-0.39	1.16e-24	Pancreatic cancer;
BRCA	cis	rs929596	0.755	rs6742078	chr2:234672639	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.44	11.16	0.4	1.57e-26	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg06618935	chr21:46677482	NA	-0.37	-8.11	-0.31	2.52e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg23743428	chr13:21893420	NA	-0.38	-8.52	-0.32	1.16e-16	White matter hyperintensity burden;
BRCA	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-21.97	-0.66	3.93e-80	Headache;
BRCA	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-8.76	-0.33	1.81e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4919087	1.000	rs10786326	chr10:99070377	G/A	cg25902810	chr10:99078978	FRAT1	0.52	11.67	0.42	1.17e-28	Monocyte count;
BRCA	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03264133	chr6:25882463	NA	-0.52	-11.75	-0.42	5.15e-29	Blood metabolite levels;
BRCA	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg08885076	chr2:99613938	TSGA10	-0.59	-13.07	-0.46	9.29e-35	Chronic sinus infection;
BRCA	cis	rs11051970	0.655	rs10771942	chr12:32528488	G/A	cg24626660	chr12:32551988	NA	0.28	8.12	0.31	2.35e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs74181299	0.750	rs1420185	chr2:65315903	A/G	cg05010058	chr2:65284262	CEP68	0.31	8.39	0.32	3.1e-16	Pulse pressure;
BRCA	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg14582100	chr15:45693742	SPATA5L1	0.37	11.84	0.42	2.32e-29	Homoarginine levels;
BRCA	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.26e-14	Depression;
BRCA	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg11584989	chr19:19387371	SF4	0.6	12.28	0.44	2.87e-31	Bipolar disorder;
BRCA	cis	rs939658	0.567	rs11631829	chr15:79446529	C/T	cg17916960	chr15:79447300	NA	-0.4	-10.44	-0.38	1.19e-23	Refractive error;
BRCA	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.72	-0.33	2.38e-17	Total body bone mineral density;
BRCA	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.83	0.39	3.19e-25	Bipolar disorder;
BRCA	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.12	0.31	2.38e-15	Breast cancer;
BRCA	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08219700	chr8:58056026	NA	0.45	8.08	0.3	3.2e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg14791747	chr16:20752902	THUMPD1	-0.4	-12.33	-0.44	1.74e-31	Cognitive test performance;
BRCA	cis	rs11971779	0.646	rs58682779	chr7:139084712	C/T	cg07862535	chr7:139043722	LUC7L2	0.53	12.86	0.45	8.01e-34	Diisocyanate-induced asthma;
BRCA	cis	rs2425143	0.818	rs7272684	chr20:34424692	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.12	-0.31	2.49e-15	Blood protein levels;
BRCA	trans	rs11976180	1.000	rs2371247	chr7:143764179	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.39	-0.32	3.16e-16	Obesity-related traits;
BRCA	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.68	-0.42	1.08e-28	Gut microbiome composition (summer);
BRCA	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg26031613	chr14:104095156	KLC1	-0.44	-8.73	-0.33	2.22e-17	Schizophrenia;
BRCA	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg17971929	chr21:40555470	PSMG1	-0.63	-14.21	-0.49	4.99e-40	Cognitive function;
BRCA	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.38	0.63	1.62e-71	Electrocardiographic conduction measures;
BRCA	cis	rs7828089	0.934	rs12544427	chr8:22263115	C/T	cg12081754	chr8:22256438	SLC39A14	-0.39	-8.04	-0.3	4.41e-15	Verbal declarative memory;
BRCA	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg02353165	chr6:42928485	GNMT	0.92	26.29	0.72	7.98e-104	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg04450456	chr4:17643702	FAM184B	0.37	10.9	0.4	1.68e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10267417	0.589	rs6960989	chr7:19869349	G/A	cg07541023	chr7:19748670	TWISTNB	0.51	9.17	0.34	6.47e-19	Night sleep phenotypes;
BRCA	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg08888203	chr3:10149979	C3orf24	0.64	11.9	0.43	1.24e-29	Alzheimer's disease;
BRCA	cis	rs7524258	0.903	rs4908609	chr1:7292910	G/A	cg07173049	chr1:7289937	CAMTA1	0.55	13.54	0.47	6.48e-37	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs11971779	0.680	rs3924445	chr7:139044172	C/A	cg07862535	chr7:139043722	LUC7L2	0.38	10.37	0.38	2.13e-23	Diisocyanate-induced asthma;
BRCA	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	12.11	0.43	1.62e-30	Lung cancer in ever smokers;
BRCA	cis	rs10924970	0.934	rs56681442	chr1:235466800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.33	8.22	0.31	1.14e-15	Asthma;
BRCA	cis	rs10046574	0.561	rs6966294	chr7:135196479	G/A	cg27474649	chr7:135195673	CNOT4	0.66	10.84	0.39	3.11e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs858239	0.669	rs12539467	chr7:23115859	A/G	cg23682824	chr7:23144976	KLHL7	0.42	10.8	0.39	4.53e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.8	-0.62	2.12e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg17470723	chr8:74884337	TCEB1	0.4	8.62	0.32	5.44e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.55	0.39	4.26e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2933343	0.533	rs11915889	chr3:128700866	A/C	cg11901034	chr3:128598214	ACAD9	-0.34	-8.08	-0.3	3.31e-15	IgG glycosylation;
BRCA	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg21280719	chr6:42927975	GNMT	-0.33	-13.94	-0.48	9.74e-39	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00149659	chr3:10157352	C3orf10	0.8	13.78	0.48	5.12e-38	Alzheimer's disease;
BRCA	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg08213375	chr14:104286397	PPP1R13B	0.63	17.1	0.56	2.85e-54	Schizophrenia;
BRCA	cis	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg07988820	chr12:82153109	PPFIA2	-0.6	-9.7	-0.36	7.72e-21	Resting heart rate;
BRCA	cis	rs4363385	0.720	rs6680624	chr1:152983872	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.14	-0.34	8.11e-19	Inflammatory skin disease;
BRCA	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg18252515	chr7:66147081	NA	-0.82	-11.87	-0.42	1.69e-29	Diabetic kidney disease;
BRCA	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25427524	chr10:38739819	LOC399744	-0.7	-16.88	-0.56	4.06e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4891159	0.790	rs690619	chr18:74108744	A/G	cg24786174	chr18:74118243	ZNF516	0.73	17.99	0.58	7.89e-59	Longevity;
BRCA	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-12.84	-0.45	1.03e-33	Bipolar disorder;
BRCA	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg24692254	chr21:30365293	RNF160	-0.46	-10.19	-0.37	1.11e-22	Dental caries;
BRCA	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.38	-8.17	-0.31	1.67e-15	IgG glycosylation;
BRCA	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg20387954	chr3:183756860	HTR3D	-0.5	-10.61	-0.39	2.52e-24	Anterior chamber depth;
BRCA	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25427524	chr10:38739819	LOC399744	-0.69	-16.69	-0.55	3.49e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg08805041	chr16:621841	PIGQ	-0.29	-7.92	-0.3	1.05e-14	Height;
BRCA	trans	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.9	-0.3	1.26e-14	Corneal astigmatism;
BRCA	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25427524	chr10:38739819	LOC399744	-0.64	-14.77	-0.5	1.08e-42	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.83	-0.58	5.25e-58	Chronic sinus infection;
BRCA	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22307029	chr19:49891270	CCDC155	0.63	11.57	0.42	3.05e-28	Multiple sclerosis;
BRCA	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg11822812	chr5:140052017	DND1	-0.32	-8.92	-0.33	4.91e-18	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7560272	0.723	rs4852927	chr2:73641557	C/T	cg20560298	chr2:73613845	ALMS1	0.42	11.33	0.41	3.06e-27	Schizophrenia;
BRCA	cis	rs17209837	0.607	rs4148816	chr7:87087731	G/A	cg00919237	chr7:87102261	ABCB4	-0.53	-10.2	-0.37	9.44e-23	Gallbladder cancer;
BRCA	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18876405	chr7:65276391	NA	0.51	11.4	0.41	1.57e-27	Aortic root size;
BRCA	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	13.97	0.48	7.06e-39	Platelet count;
BRCA	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg22920501	chr2:26401640	FAM59B	-0.9	-16.59	-0.55	1.12e-51	Gut microbiome composition (summer);
BRCA	cis	rs7020830	0.825	rs66684257	chr9:37199087	G/T	cg14294708	chr9:37120828	ZCCHC7	1.05	31.55	0.78	1.91e-132	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.59	0.55	1.12e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs722599	0.748	rs20578	chr14:75367807	C/T	cg08847533	chr14:75593920	NEK9	-0.44	-8.0	-0.3	6.06e-15	IgG glycosylation;
BRCA	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg16586182	chr3:47516702	SCAP	-0.56	-12.34	-0.44	1.52e-31	Colorectal cancer;
BRCA	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg19901468	chr14:105411992	AHNAK2	-0.51	-12.37	-0.44	1.15e-31	Rheumatoid arthritis;
BRCA	cis	rs11605924	0.901	rs11038672	chr11:45846498	C/G	ch.11.939596F	chr11:45881766	CRY2	-0.43	-9.54	-0.35	3.08e-20	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.48e-23	Motion sickness;
BRCA	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg14829155	chr15:31115871	NA	-0.43	-9.79	-0.36	3.66e-21	Huntington's disease progression;
BRCA	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.03	-18.48	-0.59	1.95e-61	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.37e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08109568	chr15:31115862	NA	0.42	10.14	0.37	1.63e-22	Huntington's disease progression;
BRCA	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-12.58	-0.45	1.38e-32	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.12	0.4	2.2e-26	Bipolar disorder;
BRCA	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg22189786	chr22:42395067	WBP2NL	0.4	8.06	0.3	3.69e-15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs6120849	0.754	rs6120804	chr20:33623701	C/A	cg24642439	chr20:33292090	TP53INP2	0.6	10.31	0.38	3.78e-23	Protein C levels;
BRCA	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg24531977	chr5:56204891	C5orf35	0.4	8.16	0.31	1.84e-15	Coronary artery disease;
BRCA	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg15017067	chr4:17643749	FAM184B	0.32	9.36	0.35	1.28e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg26384229	chr12:38710491	ALG10B	-0.48	-11.25	-0.41	6.27e-27	Morning vs. evening chronotype;
BRCA	trans	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg06521331	chr12:34319734	NA	-0.47	-9.18	-0.34	6.09e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg04851639	chr8:1020857	NA	0.36	10.09	0.37	2.58e-22	Schizophrenia;
BRCA	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg13010199	chr12:38710504	ALG10B	0.5	9.98	0.37	6.74e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs13394619	0.775	rs10165819	chr2:11722102	A/T	cg07314298	chr2:11723111	GREB1	-0.56	-12.46	-0.44	4.86e-32	Endometriosis;
BRCA	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg10523679	chr1:76189770	ACADM	0.77	15.55	0.52	1.8e-46	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg20368463	chr18:77673604	PQLC1	0.4	10.18	0.37	1.18e-22	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.44	0.38	1.15e-23	Motion sickness;
BRCA	cis	rs16867321	0.694	rs721301	chr2:181387265	A/G	cg23363182	chr2:181467187	NA	0.39	8.16	0.31	1.81e-15	Obesity;
BRCA	cis	rs12493885	0.818	rs61791545	chr3:153768888	G/A	cg17054900	chr3:154042577	DHX36	-0.49	-8.56	-0.32	8.68e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg16606324	chr3:10149918	C3orf24	0.48	9.47	0.35	5.5e-20	Alzheimer's disease;
BRCA	trans	rs12517041	1.000	rs6890216	chr5:23299559	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg22117172	chr7:91764530	CYP51A1	0.24	8.35	0.31	4.19e-16	Breast cancer;
BRCA	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.57	0.39	3.58e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.54	8.27	0.31	8e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.67	-0.42	1.15e-28	Response to antipsychotic treatment;
BRCA	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg03954927	chr1:10346856	KIF1B	0.47	14.12	0.49	1.34e-39	Hepatocellular carcinoma;
BRCA	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg02493740	chr2:85810744	VAMP5	-0.39	-8.43	-0.32	2.34e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs7474896	0.515	rs688608	chr10:38331624	G/A	cg25427524	chr10:38739819	LOC399744	0.58	9.92	0.37	1.14e-21	Obesity (extreme);
BRCA	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg23711669	chr6:146136114	FBXO30	0.64	15.15	0.51	1.6e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg05340658	chr4:99064831	C4orf37	-0.65	-16.01	-0.54	9.04e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.74	-0.36	5.24e-21	IgG glycosylation;
BRCA	cis	rs2882667	0.858	rs11750382	chr5:138456994	A/G	cg04439458	chr5:138467593	SIL1	0.43	11.08	0.4	3.24e-26	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg01324343	chr3:183735012	ABCC5	0.48	10.83	0.39	3.2e-25	Anterior chamber depth;
BRCA	cis	rs9341808	0.527	rs2505946	chr6:80810683	A/G	cg08355045	chr6:80787529	NA	0.49	13.59	0.47	4.1e-37	Sitting height ratio;
BRCA	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.45e-35	Aortic root size;
BRCA	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg08975724	chr8:8085496	FLJ10661	0.41	8.35	0.31	4.27e-16	Triglycerides;
BRCA	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg25174290	chr11:3078921	CARS	0.46	14.01	0.48	4.32e-39	Longevity;
BRCA	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg17971929	chr21:40555470	PSMG1	0.79	18.92	0.6	1.04e-63	Cognitive function;
BRCA	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11890956	chr21:40555474	PSMG1	1.05	29.82	0.76	4.41e-123	Cognitive function;
BRCA	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.41	-8.85	-0.33	8.65e-18	Longevity;Endometriosis;
BRCA	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg11062466	chr8:58055876	NA	0.42	8.02	0.3	5.19e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs2262909	0.962	rs73019844	chr19:22249925	T/C	cg17074339	chr11:11642133	GALNTL4	0.42	8.14	0.31	2.13e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg15839431	chr19:19639596	YJEFN3	-0.41	-9.15	-0.34	7.53e-19	Bipolar disorder;
BRCA	cis	rs208520	1.000	rs208536	chr6:66963440	T/C	cg07460842	chr6:66804631	NA	-0.86	-14.3	-0.49	1.93e-40	Exhaled nitric oxide output;
BRCA	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.4e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.46	-8.97	-0.33	3.28e-18	Lung cancer in ever smokers;
BRCA	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11644478	chr21:40555479	PSMG1	-0.65	-13.86	-0.48	2.21e-38	Cognitive function;
BRCA	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg08470875	chr2:26401718	FAM59B	-0.51	-8.56	-0.32	8.5e-17	Gut microbiome composition (summer);
BRCA	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg24920358	chr1:40204285	PPIE	0.34	7.89	0.3	1.32e-14	Blood protein levels;
BRCA	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.72	-0.39	9.03e-25	Tonsillectomy;
BRCA	cis	rs11920090	0.720	rs5394	chr3:170744893	G/A	cg09710316	chr3:170744871	SLC2A2	0.64	10.46	0.38	1e-23	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs2425143	1.000	rs13038622	chr20:34319343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.96	-0.33	3.53e-18	Blood protein levels;
BRCA	cis	rs11051970	0.879	rs950079	chr12:32588620	A/G	cg02745156	chr12:32552066	NA	0.27	8.87	0.33	7.25e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg05507819	chr15:63340323	TPM1	0.43	9.15	0.34	7.29e-19	Platelet count;
BRCA	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.77	0.36	4.11e-21	Bipolar disorder;
BRCA	cis	rs113835537	0.529	rs61561111	chr11:66275923	T/C	cg24851651	chr11:66362959	CCS	0.43	8.24	0.31	9.69e-16	Airway imaging phenotypes;
BRCA	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	16.03	0.54	7.54e-49	Smoking behavior;
BRCA	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg24642844	chr7:1081250	C7orf50	-0.89	-16.21	-0.54	9.83e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06108461	chr20:60628389	TAF4	-0.74	-15.69	-0.53	3.54e-47	Body mass index;
BRCA	cis	rs1538970	0.810	rs12067642	chr1:45927517	G/T	cg05343316	chr1:45956843	TESK2	0.62	12.57	0.45	1.58e-32	Platelet count;
BRCA	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22307029	chr19:49891270	CCDC155	0.58	9.97	0.37	7.39e-22	Multiple sclerosis;
BRCA	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg25482853	chr8:67687455	SGK3	1.05	16.94	0.56	1.94e-53	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg06115741	chr20:33292138	TP53INP2	0.47	10.54	0.38	4.69e-24	Coronary artery disease;
BRCA	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg24578937	chr1:2090814	PRKCZ	0.57	17.86	0.58	3.77e-58	Height;
BRCA	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	cis	rs11971779	0.590	rs59602547	chr7:139117023	G/A	cg07862535	chr7:139043722	LUC7L2	0.39	10.58	0.39	3.14e-24	Diisocyanate-induced asthma;
BRCA	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.25	-0.34	3.32e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg12658694	chr1:38397304	INPP5B	0.47	11.37	0.41	1.99e-27	Coronary artery disease;
BRCA	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04267008	chr7:1944627	MAD1L1	-0.57	-12.88	-0.45	6.28e-34	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs17604090	0.793	rs17136535	chr7:29689158	C/T	cg19413766	chr7:29689036	LOC646762	-0.51	-8.3	-0.31	6.09e-16	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs17253792	0.822	rs10137340	chr14:56050989	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-11.33	-0.41	2.96e-27	Putamen volume;
BRCA	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg11814155	chr7:99998594	ZCWPW1	0.49	8.77	0.33	1.57e-17	Platelet count;
BRCA	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg21573476	chr21:45109991	RRP1B	-0.34	-9.12	-0.34	9.35e-19	Mean corpuscular volume;
BRCA	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22857025	chr5:266934	NA	-1.05	-20.18	-0.62	1.99e-70	Breast cancer;
BRCA	cis	rs11971779	0.680	rs2355783	chr7:139075879	C/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg10223061	chr2:219282414	VIL1	-0.27	-8.14	-0.31	2.13e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	15.24	0.52	5.94e-45	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	21.69	0.65	1.35e-78	Smoking behavior;
BRCA	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg03146154	chr1:46216737	IPP	0.45	10.04	0.37	4.15e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-11.33	-0.41	3.04e-27	Neuroticism;
BRCA	cis	rs7587476	0.906	rs17487827	chr2:215644335	C/G	cg04004882	chr2:215674386	BARD1	0.57	10.35	0.38	2.5e-23	Neuroblastoma;
BRCA	trans	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg14791747	chr16:20752902	THUMPD1	-0.33	-9.12	-0.34	9.35e-19	Cognitive test performance;
BRCA	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg10729496	chr3:10149963	C3orf24	0.49	9.03	0.34	1.99e-18	Alzheimer's disease;
BRCA	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg25036284	chr2:26402008	FAM59B	-0.89	-15.1	-0.51	2.72e-44	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.82	-0.3	2.16e-14	Aortic root size;
BRCA	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg26384229	chr12:38710491	ALG10B	0.76	17.1	0.56	2.86e-54	Bladder cancer;
BRCA	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg09184832	chr6:79620586	NA	-0.41	-8.16	-0.31	1.77e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12826209	chr6:26865740	GUSBL1	0.59	10.31	0.38	3.81e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg00757033	chr12:89920650	WDR51B	0.54	10.79	0.39	4.93e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs8077889	0.672	rs1230400	chr17:41845451	G/A	cg26893861	chr17:41843967	DUSP3	-0.95	-24.78	-0.7	1.65e-95	Triglycerides;
BRCA	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.77	0.33	1.65e-17	Motion sickness;
BRCA	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg25036284	chr2:26402008	FAM59B	0.88	15.06	0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	10.61	0.39	2.46e-24	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg11062466	chr8:58055876	NA	0.41	7.84	0.3	1.84e-14	Developmental language disorder (linguistic errors);
BRCA	trans	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.49	-0.35	4.44e-20	Morning vs. evening chronotype;
BRCA	cis	rs2559856	0.903	rs10128996	chr12:102081498	G/A	cg12924262	chr12:102091054	CHPT1	0.36	8.12	0.31	2.42e-15	Blood protein levels;
BRCA	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg05340658	chr4:99064831	C4orf37	0.55	10.68	0.39	1.26e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg04450456	chr4:17643702	FAM184B	0.41	11.91	0.43	1.14e-29	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg20476274	chr7:133979776	SLC35B4	0.7	21.43	0.65	3.4e-77	Mean platelet volume;
BRCA	cis	rs113835537	0.529	rs11227500	chr11:66273233	T/C	cg24851651	chr11:66362959	CCS	0.44	8.36	0.31	3.81e-16	Airway imaging phenotypes;
BRCA	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg21775007	chr8:11205619	TDH	0.73	16.3	0.54	3.22e-50	Retinal vascular caliber;
BRCA	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg21573476	chr21:45109991	RRP1B	-0.35	-9.28	-0.34	2.66e-19	Mean corpuscular volume;
BRCA	cis	rs113835537	0.597	rs10896129	chr11:66338300	T/C	cg24851651	chr11:66362959	CCS	0.45	8.59	0.32	6.55e-17	Airway imaging phenotypes;
BRCA	trans	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg26043149	chr18:55253948	FECH	0.4	8.53	0.32	1.06e-16	Bone mineral density;
BRCA	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.06	-0.34	1.53e-18	Total body bone mineral density;
BRCA	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg16482183	chr6:26056742	HIST1H1C	0.56	11.91	0.43	1.15e-29	Height;
BRCA	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12756686	chr19:29218302	NA	0.62	12.75	0.45	2.4e-33	Methadone dose in opioid dependence;
BRCA	trans	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg06521331	chr12:34319734	NA	-0.47	-8.83	-0.33	1.02e-17	Bladder cancer;
BRCA	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg16586182	chr3:47516702	SCAP	-0.46	-9.22	-0.34	4.37e-19	Birth weight;
BRCA	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg08085267	chr17:45401833	C17orf57	0.69	15.43	0.52	7.08e-46	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg24846343	chr22:24311635	DDTL	0.57	14.85	0.51	4.6e-43	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18876405	chr7:65276391	NA	-0.64	-15.59	-0.52	1.12e-46	Aortic root size;
BRCA	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg08601574	chr20:25228251	PYGB	-0.35	-8.51	-0.32	1.24e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9815354	0.812	rs73081372	chr3:41917993	C/T	cg03022575	chr3:42003672	ULK4	0.69	9.49	0.35	4.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs400736	0.930	rs226249	chr1:8021778	A/G	cg25007680	chr1:8021821	PARK7	0.5	12.75	0.45	2.57e-33	Response to antidepressants and depression;
BRCA	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg01262667	chr19:19385393	TM6SF2	-0.42	-10.69	-0.39	1.23e-24	Tonsillectomy;
BRCA	cis	rs2797160	1.000	rs1777226	chr6:126017691	C/A	cg05901451	chr6:126070800	HEY2	0.4	9.62	0.36	1.48e-20	Endometrial cancer;
BRCA	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg05234568	chr11:5960015	NA	-0.49	-10.28	-0.38	4.69e-23	DNA methylation (variation);
BRCA	cis	rs1784581	0.802	rs6455787	chr6:162411378	G/A	cg17173639	chr6:162384350	PARK2	0.39	9.11	0.34	1.08e-18	Itch intensity from mosquito bite;
BRCA	trans	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.95	0.3	8.6e-15	Corneal astigmatism;
BRCA	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg05347473	chr6:146136440	FBXO30	-0.4	-7.9	-0.3	1.2e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3916	1.000	rs2014355	chr12:121175524	A/G	cg21892295	chr12:121157589	UNC119B	-0.33	-7.99	-0.3	6.12e-15	Urinary metabolites (H-NMR features);
BRCA	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.93	0.33	4.43e-18	Motion sickness;
BRCA	cis	rs701145	0.585	rs1727880	chr3:153835972	G/A	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.2e-14	Coronary artery disease;
BRCA	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg22906224	chr7:99728672	NA	-0.42	-7.97	-0.3	7.32e-15	Coronary artery disease;
BRCA	cis	rs2191566	0.540	rs436739	chr19:44495553	A/G	cg20607764	chr19:44506953	ZNF230	0.4	8.68	0.32	3.21e-17	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7833986	0.941	rs13278255	chr8:57067975	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.46	8.41	0.32	2.66e-16	Height;
BRCA	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.93	-0.33	4.55e-18	Breast cancer;
BRCA	cis	rs10193935	0.792	rs6735571	chr2:42491951	C/T	cg27598129	chr2:42591480	NA	-0.58	-9.81	-0.36	2.94e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.65	13.88	0.48	1.78e-38	Lymphocyte counts;
BRCA	cis	rs701145	0.585	rs1727940	chr3:153827257	C/G	cg17054900	chr3:154042577	DHX36	0.5	8.6	0.32	6.24e-17	Coronary artery disease;
BRCA	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg23711669	chr6:146136114	FBXO30	0.73	16.94	0.56	1.97e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	15.05	0.51	5.12e-44	Hip circumference adjusted for BMI;
BRCA	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.76	16.96	0.56	1.54e-53	Lymphocyte counts;
BRCA	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg03585969	chr10:35415529	CREM	0.48	10.06	0.37	3.33e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.74	0.39	7.82e-25	Tonsillectomy;
BRCA	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg26647111	chr11:31128758	NA	-0.43	-9.68	-0.36	8.93e-21	Red blood cell count;
BRCA	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg14784868	chr12:69753453	YEATS4	0.51	12.54	0.44	2.18e-32	Blood protein levels;
BRCA	cis	rs17270561	0.636	rs10946793	chr6:25699999	A/G	cg16482183	chr6:26056742	HIST1H1C	0.45	8.51	0.32	1.23e-16	Iron status biomarkers;
BRCA	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg02743256	chr7:2109353	MAD1L1	-0.44	-8.31	-0.31	5.69e-16	Bipolar disorder;
BRCA	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg12311346	chr5:56204834	C5orf35	-0.8	-15.68	-0.53	4.12e-47	Initial pursuit acceleration;
BRCA	cis	rs6138458	0.626	rs6132789	chr20:25012809	C/T	cg26195577	chr20:24973756	C20orf3	-0.61	-14.73	-0.5	1.62e-42	Blood protein levels;
BRCA	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11764359	chr7:65958608	NA	-0.75	-16.84	-0.55	6.4e-53	Aortic root size;
BRCA	trans	rs75804782	0.521	rs55915157	chr2:239424273	T/C	cg01134436	chr17:81009848	B3GNTL1	0.57	8.13	0.31	2.19e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.46	0.41	9.01e-28	Bipolar disorder;
BRCA	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg23711669	chr6:146136114	FBXO30	0.64	15.05	0.51	4.81e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg04374321	chr14:90722782	PSMC1	0.72	18.83	0.6	2.97e-63	Mortality in heart failure;
BRCA	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg26893861	chr17:41843967	DUSP3	0.67	12.74	0.45	2.86e-33	Triglycerides;
BRCA	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg24558204	chr6:135376177	HBS1L	0.6	15.96	0.53	1.59e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs208520	0.690	rs207091	chr6:66799847	G/T	cg07460842	chr6:66804631	NA	-1.0	-20.02	-0.62	1.44e-69	Exhaled nitric oxide output;
BRCA	trans	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.4	0.38	1.64e-23	Mean corpuscular volume;
BRCA	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.89	-0.33	6.27e-18	Alzheimer's disease (late onset);
BRCA	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	8.7	0.33	2.73e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs2262909	0.962	rs55735642	chr19:22241176	C/T	cg17074339	chr11:11642133	GALNTL4	0.42	8.11	0.31	2.68e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg17971929	chr21:40555470	PSMG1	-0.63	-14.04	-0.49	3.05e-39	Cognitive function;
BRCA	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg03433033	chr1:76189801	ACADM	-0.59	-11.81	-0.42	2.98e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg06606381	chr12:133084897	FBRSL1	-0.78	-8.32	-0.31	5.37e-16	Depression;
BRCA	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg11663144	chr21:46675770	NA	0.56	12.96	0.46	2.76e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg03585969	chr10:35415529	CREM	0.55	11.23	0.41	7.64e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg04013166	chr16:89971882	TCF25	0.52	9.52	0.35	3.4e-20	Skin colour saturation;
BRCA	cis	rs7149337	0.804	rs4131981	chr14:51667504	A/T	cg23942311	chr14:51606299	NA	-0.4	-11.38	-0.41	1.81e-27	Cancer;
BRCA	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg09307838	chr4:120376055	NA	-0.49	-9.27	-0.34	2.75e-19	Corneal astigmatism;
BRCA	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg00074818	chr8:8560427	CLDN23	0.38	8.44	0.32	2.08e-16	Obesity-related traits;
BRCA	trans	rs9944715	0.911	rs7230995	chr18:43786822	G/A	cg01718231	chr17:29326311	RNF135	-0.46	-9.05	-0.34	1.76e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg22713356	chr15:30763199	NA	1.16	23.63	0.68	3.16e-89	Uric acid levels;
BRCA	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07343612	chr16:622815	PIGQ	-0.66	-21.57	-0.65	5.92e-78	Height;
BRCA	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg08807101	chr21:30365312	RNF160	0.39	8.39	0.32	3.1e-16	Pancreatic cancer;
BRCA	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg19773385	chr1:10388646	KIF1B	-0.35	-7.86	-0.3	1.66e-14	Hepatocellular carcinoma;
BRCA	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg18198730	chr1:247681584	NA	0.49	11.23	0.41	8.03e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg20573242	chr4:122745356	CCNA2	0.44	9.58	0.35	2.06e-20	Type 2 diabetes;
BRCA	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg20219911	chr3:52813652	ITIH1	0.29	8.0	0.3	5.99e-15	Electroencephalogram traits;
BRCA	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg16989086	chr20:62203971	PRIC285	0.52	8.77	0.33	1.63e-17	Glioblastoma;
BRCA	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg10370574	chr19:1840461	REXO1	-0.38	-8.51	-0.32	1.27e-16	Bipolar disorder;
BRCA	cis	rs77861329	1.000	rs9868101	chr3:52138377	T/C	cg08692210	chr3:52188851	WDR51A	0.69	10.67	0.39	1.49e-24	Macrophage inflammatory protein 1b levels;
BRCA	trans	rs1493916	0.837	rs9949631	chr18:31410567	G/A	cg15819921	chr19:927150	ARID3A	-0.41	-8.07	-0.3	3.37e-15	Life satisfaction;
BRCA	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg13010199	chr12:38710504	ALG10B	0.59	13.03	0.46	1.44e-34	Heart rate;
BRCA	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.54	-13.39	-0.47	3.18e-36	Urate levels in overweight individuals;
BRCA	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00166722	chr3:10149974	C3orf24	0.66	13.26	0.46	1.29e-35	Alzheimer's disease;
BRCA	cis	rs17092148	0.848	rs6060030	chr20:33340313	C/T	cg16810054	chr20:33298113	TP53INP2	-0.41	-9.57	-0.35	2.27e-20	Neuroticism;
BRCA	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg12292205	chr6:26970375	C6orf41	0.73	16.79	0.55	1.14e-52	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg10729496	chr3:10149963	C3orf24	0.49	9.06	0.34	1.51e-18	Alzheimer's disease;
BRCA	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg03929089	chr4:120376271	NA	-0.73	-15.85	-0.53	5.5e-48	Coronary artery disease;
BRCA	cis	rs7598759	0.966	rs6754426	chr2:232322779	G/A	cg19187155	chr2:232395269	NMUR1	0.41	8.9	0.33	5.62e-18	Noise-induced hearing loss;
BRCA	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.42	8.43	0.32	2.29e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg24558204	chr6:135376177	HBS1L	0.46	12.61	0.45	9.93e-33	Red blood cell count;
BRCA	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21659725	chr3:3221576	CRBN	-0.49	-10.29	-0.38	4.43e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.7	-0.33	2.8e-17	Total body bone mineral density;
BRCA	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-12.06	-0.43	2.59e-30	Tonsillectomy;
BRCA	cis	rs9837602	1.000	rs10212525	chr3:99713377	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	11.28	0.41	4.85e-27	Breast cancer;
BRCA	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg19622623	chr12:86230825	RASSF9	-0.29	-8.2	-0.31	1.37e-15	Major depressive disorder;
BRCA	cis	rs4845875	0.600	rs4846041	chr1:11837051	C/T	cg24844545	chr1:11908347	NPPA	0.37	8.68	0.32	3.35e-17	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg11645453	chr3:52864694	ITIH4	0.42	10.38	0.38	1.9e-23	Bipolar disorder;
BRCA	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08048268	chr3:133502702	NA	-0.34	-8.29	-0.31	6.85e-16	Iron status biomarkers;
BRCA	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg03676636	chr4:99064102	C4orf37	0.2	7.87	0.3	1.5e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg14186256	chr22:23484241	RTDR1	-0.72	-20.91	-0.64	2.19e-74	Bone mineral density;
BRCA	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.25	0.31	9.38e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6433895	0.961	rs7566434	chr2:182013615	C/T	cg00481216	chr2:181971175	NA	0.37	8.72	0.33	2.49e-17	Lymphocyte counts;
BRCA	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg23422044	chr7:1970798	MAD1L1	-0.44	-9.41	-0.35	9.01e-20	Neuroticism;
BRCA	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg13073564	chr4:8508604	NA	0.45	12.51	0.44	2.82e-32	Response to antineoplastic agents;
BRCA	trans	rs6600671	1.000	rs7532615	chr1:121172840	G/T	cg17023122	chr1:144479586	NA	-0.32	-7.82	-0.3	2.14e-14	Hip geometry;
BRCA	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg16606324	chr3:10149918	C3orf24	0.49	9.81	0.36	2.97e-21	Alzheimer's disease;
BRCA	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-12.32	-0.44	1.92e-31	Hemoglobin concentration;
BRCA	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg20387954	chr3:183756860	HTR3D	0.36	8.34	0.31	4.46e-16	Anterior chamber depth;
BRCA	cis	rs4800452	0.871	rs9961220	chr18:20733201	G/T	cg26136497	chr18:20735537	CABLES1	-0.48	-11.58	-0.42	2.88e-28	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-18.03	-0.58	4.7e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg09754948	chr16:28834200	ATXN2L	0.47	8.77	0.33	1.56e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg24069376	chr3:38537580	EXOG	-0.3	-8.31	-0.31	5.87e-16	Electrocardiographic conduction measures;
BRCA	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.79	-0.33	1.32e-17	Breast cancer;
BRCA	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg20476274	chr7:133979776	SLC35B4	0.58	14.36	0.49	9.7e-41	Mean platelet volume;
BRCA	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg06640241	chr16:89574553	SPG7	0.75	17.73	0.57	1.71e-57	Multiple myeloma (IgH translocation);
BRCA	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg24642439	chr20:33292090	TP53INP2	0.7	16.05	0.54	6.09e-49	Coronary artery disease;
BRCA	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg15556689	chr8:8085844	FLJ10661	-0.36	-9.63	-0.36	1.34e-20	Triglycerides;
BRCA	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	10.82	0.39	3.49e-25	Platelet count;
BRCA	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg19156104	chr2:198669113	PLCL1	-0.44	-8.22	-0.31	1.13e-15	Ulcerative colitis;
BRCA	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg00071950	chr4:10020882	SLC2A9	0.67	16.82	0.55	7.99e-53	Bone mineral density;
BRCA	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.13	-0.34	8.85e-19	Bipolar disorder;
BRCA	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-11.19	-0.4	1.19e-26	Gut microbiome composition (summer);
BRCA	cis	rs1371614	0.632	rs12615423	chr2:27158623	G/T	cg00617064	chr2:27272375	NA	0.32	8.37	0.31	3.65e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg01884057	chr2:25150051	NA	0.34	8.98	0.33	3.1e-18	Body mass index;
BRCA	trans	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg02030672	chr11:45687055	CHST1	0.39	8.89	0.33	6e-18	Obesity-related traits;
BRCA	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18876405	chr7:65276391	NA	0.51	11.76	0.42	4.79e-29	Aortic root size;
BRCA	cis	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-8.85	-0.33	8.3e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs501916	0.634	rs531596	chr15:48058214	C/T	cg16110827	chr15:48056943	SEMA6D	-0.42	-9.2	-0.34	5.1e-19	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs6942756	1.000	rs11763056	chr7:128960871	C/A	cg02491457	chr7:128862824	NA	-0.71	-14.04	-0.49	3.18e-39	White matter hyperintensity burden;
BRCA	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg16325326	chr1:53192061	ZYG11B	-0.65	-16.18	-0.54	1.29e-49	Monocyte count;
BRCA	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg10556349	chr10:835070	NA	0.73	9.85	0.36	2.13e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.52	12.65	0.45	6.79e-33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.15	0.31	1.92e-15	Tonsillectomy;
BRCA	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg19336497	chr11:14380999	RRAS2	-0.48	-11.83	-0.42	2.43e-29	Sense of smell;
BRCA	cis	rs4363385	0.693	rs581447	chr1:153033269	A/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.34	-0.31	4.7e-16	Inflammatory skin disease;
BRCA	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg08917208	chr2:24149416	ATAD2B	0.54	8.23	0.31	1.06e-15	Lymphocyte counts;
BRCA	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg15103426	chr22:29168792	CCDC117	-0.52	-12.21	-0.43	6e-31	Lymphocyte counts;
BRCA	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg01304814	chr3:48885189	PRKAR2A	0.63	7.91	0.3	1.17e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs9970334	0.596	rs709209	chr1:6278414	A/G	cg02892189	chr1:6321676	GPR153	-0.37	-8.06	-0.3	3.83e-15	Resting heart rate;
BRCA	cis	rs9815354	0.716	rs73087368	chr3:41930379	A/G	cg03022575	chr3:42003672	ULK4	0.69	9.5	0.35	4.17e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg20019720	chr6:154832845	CNKSR3	0.58	13.36	0.47	4.57e-36	Lipoprotein (a) levels;
BRCA	cis	rs9790314	0.715	rs980975	chr3:160771410	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-9.79	-0.36	3.62e-21	Morning vs. evening chronotype;
BRCA	cis	rs3820928	1.000	rs10204368	chr2:227774244	G/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.42	-0.32	2.53e-16	Pulmonary function;
BRCA	cis	rs2629540	0.889	rs7476729	chr10:126428174	C/G	cg08799069	chr10:126477246	METTL10	-0.52	-11.25	-0.41	6.77e-27	Cocaine dependence;
BRCA	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-12.08	-0.43	2.1000000000000002e-30	Chronic sinus infection;
BRCA	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.5	-0.38	6.41e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg22906224	chr7:99728672	NA	-0.43	-8.04	-0.3	4.29e-15	Coronary artery disease;
BRCA	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg03676636	chr4:99064102	C4orf37	0.21	8.03	0.3	4.61e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	8.0	0.3	6.06e-15	Tonsillectomy;
BRCA	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg03146154	chr1:46216737	IPP	0.45	10.06	0.37	3.5e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg05313129	chr8:58192883	C8orf71	-0.45	-9.46	-0.35	5.64e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg09537434	chr19:41945824	ATP5SL	-1.0	-23.23	-0.68	5.32e-87	Height;
BRCA	trans	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg00938859	chr5:1591904	SDHAP3	0.65	8.91	0.33	5.42e-18	Breast cancer;
BRCA	cis	rs8067545	0.641	rs119672	chr17:19818601	A/G	cg04132472	chr17:19861366	AKAP10	0.38	8.85	0.33	8.6e-18	Schizophrenia;
BRCA	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.58	9.31	0.35	1.98e-19	Alzheimer's disease;
BRCA	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg13852791	chr20:30311386	BCL2L1	0.84	16.5	0.55	3.24e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs4363385	0.747	rs12048412	chr1:152977092	A/T	cg25856811	chr1:152973957	SPRR3	-0.34	-8.98	-0.33	2.95e-18	Inflammatory skin disease;
BRCA	cis	rs220324	0.688	rs9979344	chr21:43559926	C/T	cg09727148	chr21:43560719	UMODL1	0.5	8.88	0.33	6.65e-18	Idiopathic osteonecrosis of the femoral head;
BRCA	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg17063962	chr7:91808500	NA	0.61	14.32	0.49	1.53e-40	Breast cancer;
BRCA	cis	rs68170813	0.559	rs6951639	chr7:106817639	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-8.49	-0.32	1.47e-16	Coronary artery disease;
BRCA	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg18252515	chr7:66147081	NA	-0.51	-9.91	-0.36	1.28e-21	Corneal structure;
BRCA	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.53	0.55	2.33e-51	Hypertriglyceridemia;
BRCA	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-11.75	-0.42	5.3e-29	Colorectal cancer;
BRCA	cis	rs10129255	0.500	rs10143242	chr14:107137831	C/T	cg07958169	chr14:107095056	NA	-0.38	-8.23	-0.31	1.08e-15	Kawasaki disease;
BRCA	cis	rs1371614	0.632	rs7589627	chr2:27159786	C/T	cg00617064	chr2:27272375	NA	-0.3	-7.93	-0.3	1.02e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs600806	0.778	rs10494040	chr1:110015732	C/T	cg20591472	chr1:110008990	SYPL2	0.31	7.9	0.3	1.25e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg05084668	chr3:125655381	ALG1L	-0.5	-9.49	-0.35	4.69e-20	Blood pressure (smoking interaction);
BRCA	cis	rs11030122	0.702	rs2898947	chr11:3977572	G/A	cg18678763	chr11:4115507	RRM1	-0.35	-7.97	-0.3	7.29e-15	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg23982607	chr1:1823379	GNB1	0.33	8.05	0.3	4e-15	Body mass index;
BRCA	cis	rs12541635	0.966	rs114386112	chr8:107036340	G/A	cg10147462	chr8:107024639	NA	0.37	9.72	0.36	6.56e-21	Age of smoking initiation;
BRCA	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg18357645	chr12:58087776	OS9	-0.33	-8.1	-0.31	2.79e-15	Multiple sclerosis;
BRCA	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	10.63	0.39	1.98e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.51	-0.35	3.7e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg11789530	chr4:8429930	ACOX3	-0.46	-10.97	-0.4	9.39e-26	Response to antineoplastic agents;
BRCA	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.54	-0.52	1.93e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9929218	0.954	rs12599393	chr16:68829021	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.6	-11.91	-0.43	1.09e-29	Colorectal cancer;
BRCA	cis	rs13082711	0.554	rs73055724	chr3:27380397	T/G	cg02860705	chr3:27208620	NA	0.66	11.58	0.42	2.68e-28	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs600806	0.821	rs10127790	chr1:109891133	C/T	cg20591472	chr1:110008990	SYPL2	0.33	8.17	0.31	1.64e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg21226059	chr5:178986404	RUFY1	0.47	12.61	0.45	1e-32	Lung cancer;
BRCA	cis	rs9790314	0.747	rs1599386	chr3:160856314	C/T	cg03342759	chr3:160939853	NMD3	0.54	10.82	0.39	3.46e-25	Morning vs. evening chronotype;
BRCA	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg03433033	chr1:76189801	ACADM	-0.4	-8.42	-0.32	2.57e-16	Daytime sleep phenotypes;
BRCA	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.48	-0.32	1.53e-16	Aortic root size;
BRCA	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg01304814	chr3:48885189	PRKAR2A	0.71	7.9	0.3	1.26e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.43	9.22	0.34	4.27e-19	Colorectal cancer;
BRCA	cis	rs870825	0.616	rs56844261	chr4:185632478	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	17.4	0.57	8.32e-56	Blood protein levels;
BRCA	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg02734326	chr4:10020555	SLC2A9	0.39	8.48	0.32	1.61e-16	Bone mineral density;
BRCA	cis	rs12210905	0.688	rs12213533	chr6:27346021	C/T	cg08851530	chr6:28072375	NA	0.91	8.7	0.33	2.7e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs312274	0.550	rs11179042	chr12:41311466	C/T	cg17827154	chr12:41323612	CNTN1	-0.42	-10.51	-0.38	6.29e-24	Metabolite levels  (X-11787);
BRCA	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-19.7	-0.61	7.49e-68	Electrocardiographic conduction measures;
BRCA	cis	rs9503598	0.662	rs2326232	chr6:3451953	A/G	cg00476032	chr6:3446245	SLC22A23	0.36	8.99	0.33	2.83e-18	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.65	-0.61	1.27e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg03477792	chr4:77819574	ANKRD56	0.66	15.57	0.52	1.47e-46	Emphysema distribution in smoking;
BRCA	cis	rs6598955	0.671	rs12354062	chr1:26608761	C/T	cg00852783	chr1:26633632	UBXN11	-0.47	-7.83	-0.3	1.99e-14	Obesity-related traits;
BRCA	cis	rs117623576	0.680	rs72777120	chr10:32367608	A/G	cg03047570	chr10:32398778	NA	-0.5	-7.9	-0.3	1.25e-14	Anti-saccade response;
BRCA	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.29	-0.31	6.52e-16	Bipolar disorder;
BRCA	trans	rs637571	0.510	rs3903072	chr11:65583066	G/T	cg17712092	chr4:129076599	LARP1B	-0.33	-7.9	-0.3	1.27e-14	Eosinophil percentage of white cells;
BRCA	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-9.05	-0.34	1.66e-18	Longevity;Endometriosis;
BRCA	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.24	-0.31	9.74e-16	Axial length;
BRCA	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg21775007	chr8:11205619	TDH	0.64	13.88	0.48	1.76e-38	Retinal vascular caliber;
BRCA	cis	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg06521331	chr12:34319734	NA	-0.54	-10.88	-0.4	2.15e-25	Morning vs. evening chronotype;
BRCA	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg03954927	chr1:10346856	KIF1B	0.47	14.55	0.5	1.26e-41	Hepatocellular carcinoma;
BRCA	cis	rs2637266	0.846	rs2583045	chr10:78412385	C/G	cg18941641	chr10:78392320	NA	-0.33	-7.87	-0.3	1.57e-14	Pulmonary function;
BRCA	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	11.57	0.42	3.01e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs1355223	0.506	rs7130774	chr11:34869267	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-9.4	-0.35	9.82e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.54	-11.39	-0.41	1.71e-27	Height;
BRCA	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg09085632	chr11:111637200	PPP2R1B	1.01	23.7	0.68	1.34e-89	Primary sclerosing cholangitis;
BRCA	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg27165867	chr14:105738592	BRF1	-0.35	-8.35	-0.31	4.17e-16	Mean platelet volume;Platelet distribution width;
BRCA	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg11693508	chr17:37793320	STARD3	0.68	12.43	0.44	6.04e-32	Bipolar disorder;
BRCA	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13732083	chr21:47605072	C21orf56	0.39	7.98	0.3	6.74e-15	Testicular germ cell tumor;
BRCA	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-9.74	-0.36	5.2e-21	Body mass index;
BRCA	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-11.27	-0.41	5.2e-27	Colorectal cancer;
BRCA	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.72	-0.33	2.44e-17	Total body bone mineral density;
BRCA	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg13119609	chr19:45449297	APOC2	0.47	13.08	0.46	8.22e-35	Blood protein levels;
BRCA	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg18132916	chr6:79620363	NA	-0.49	-11.14	-0.4	1.87e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.04	-0.3	4.35e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.52	-14.99	-0.51	9.47e-44	Lung cancer;
BRCA	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg16586182	chr3:47516702	SCAP	0.61	14.06	0.49	2.58e-39	Colorectal cancer;
BRCA	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg06627628	chr2:24431161	ITSN2	-0.79	-15.05	-0.51	5.04e-44	Asthma;
BRCA	trans	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg25214090	chr10:38739885	LOC399744	0.47	10.3	0.38	4.03e-23	Corneal astigmatism;
BRCA	cis	rs4660306	0.961	rs4660860	chr1:45946233	T/A	cg24296786	chr1:45957014	TESK2	0.42	8.39	0.32	3.08e-16	Homocysteine levels;
BRCA	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.01	-0.46	1.66e-34	Migraine;Coronary artery disease;
BRCA	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg20307385	chr11:47447363	PSMC3	0.73	16.79	0.55	1.06e-52	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg04362960	chr10:104952993	NT5C2	0.42	10.11	0.37	2.18e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg18811423	chr2:55921094	PNPT1	0.71	22.76	0.67	1.91e-84	Metabolic syndrome;
BRCA	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg00277334	chr10:82204260	NA	0.42	8.22	0.31	1.17e-15	Post bronchodilator FEV1;
BRCA	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-16.76	-0.55	1.62e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg08917208	chr2:24149416	ATAD2B	1.05	14.38	0.49	7.78e-41	Lymphocyte counts;
BRCA	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg11764359	chr7:65958608	NA	0.67	15.15	0.51	1.68e-44	Aortic root size;
BRCA	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-10.69	-0.39	1.23e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs587242	0.955	rs4949996	chr1:96965124	A/T	cg10631902	chr5:14652156	NA	0.43	10.61	0.39	2.5300000000000002e-24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
BRCA	cis	rs2625529	0.652	rs2957724	chr15:72248474	A/C	cg16672083	chr15:72433130	SENP8	0.67	15.9	0.53	3.39e-48	Red blood cell count;
BRCA	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-11.32	-0.41	3.25e-27	Gut microbiome composition (summer);
BRCA	cis	rs7131987	0.675	rs3847678	chr12:29551560	A/C	cg09582351	chr12:29534625	ERGIC2	0.38	9.2	0.34	5.04e-19	QT interval;
BRCA	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg08992911	chr2:238395768	MLPH	0.53	8.67	0.32	3.49e-17	Prostate cancer;
BRCA	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg27433088	chr4:174089019	GALNT7	0.28	7.95	0.3	8.32e-15	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.91	-0.43	1.07e-29	Response to antipsychotic treatment;
BRCA	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.72	-0.33	2.46e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7833986	0.534	rs10504198	chr8:57006254	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	12.99	0.46	2.13e-34	Height;
BRCA	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg05283184	chr6:79620031	NA	-0.43	-11.22	-0.41	8.77e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg03709012	chr19:19516395	GATAD2A	0.99	19.28	0.61	1.26e-65	Nonalcoholic fatty liver disease;
BRCA	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg21280719	chr6:42927975	GNMT	-0.33	-14.16	-0.49	8.78e-40	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg12483005	chr1:23474871	LUZP1	-0.45	-10.1	-0.37	2.37e-22	Height;
BRCA	cis	rs911119	1.000	rs67567111	chr20:23619075	G/T	cg16589663	chr20:23618590	CST3	0.47	8.94	0.33	4.25e-18	Chronic kidney disease;
BRCA	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-14.03	-0.49	3.36e-39	Morning vs. evening chronotype;
BRCA	trans	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	20.27	0.63	6.67e-71	Exhaled nitric oxide output;
BRCA	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg13047869	chr3:10149882	C3orf24	0.53	11.33	0.41	2.9e-27	Alzheimer's disease;
BRCA	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg26061582	chr7:22766209	IL6	-0.42	-9.16	-0.34	6.98e-19	Lung cancer;
BRCA	cis	rs1843834	1.000	rs1843834	chr2:225558042	A/G	cg22455342	chr2:225449267	CUL3	0.36	8.56	0.32	8.65e-17	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg01528321	chr10:82214614	TSPAN14	0.64	14.52	0.5	1.65e-41	Post bronchodilator FEV1;
BRCA	cis	rs1829883	0.931	rs7713876	chr5:98878187	C/G	cg08333243	chr5:99726346	NA	-0.36	-8.85	-0.33	8.53e-18	Hemostatic factors and hematological phenotypes;
BRCA	trans	rs7939886	0.844	rs17150088	chr11:55894862	T/G	cg15704280	chr7:45808275	SEPT13	0.61	7.9	0.3	1.21e-14	Myopia (pathological);
BRCA	trans	rs11165623	0.792	rs12123543	chr1:96964549	T/C	cg10631902	chr5:14652156	NA	-0.5	-15.88	-0.53	3.94e-48	Hip circumference;Waist circumference;
BRCA	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.51	-10.48	-0.38	7.77e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.67	-9.72	-0.36	6.19e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg25358565	chr5:93447407	FAM172A	1.14	18.13	0.58	1.46e-59	Diabetic retinopathy;
BRCA	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg17366294	chr4:99064904	C4orf37	0.43	8.42	0.32	2.42e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg21143896	chr7:2802374	GNA12	-0.36	-9.18	-0.34	5.97e-19	Height;
BRCA	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18876405	chr7:65276391	NA	-0.49	-10.8	-0.39	4.16e-25	Aortic root size;
BRCA	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.8	0.39	4.48e-25	Bipolar disorder;
BRCA	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg13047869	chr3:10149882	C3orf24	0.52	11.01	0.4	6.24e-26	Alzheimer's disease;
BRCA	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg02297831	chr4:17616191	MED28	-0.37	-8.42	-0.32	2.54e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs12517041	1.000	rs4547895	chr5:23323269	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.05	-0.3	3.91e-15	Calcium levels;
BRCA	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg23888215	chr10:79422304	NA	-0.55	-10.55	-0.39	4.12e-24	Bone mineral density;
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23978390	chr7:1156363	C7orf50	0.5	11.7	0.42	8.98e-29	Longevity;Endometriosis;
BRCA	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.67	-16.03	-0.54	7.19e-49	Ulcerative colitis;
BRCA	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-16.27	-0.54	4.72e-50	Alzheimer's disease (late onset);
BRCA	cis	rs11734570	0.581	rs76682731	chr4:38586045	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.48	8.74	0.33	2.12e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg07080220	chr10:102295463	HIF1AN	0.57	13.9	0.48	1.43e-38	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	9.92	0.37	1.16e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg26587870	chr6:27730563	NA	-0.4	-8.59	-0.32	6.5e-17	Parkinson's disease;
BRCA	cis	rs3772130	0.564	rs35178434	chr3:121595936	G/A	cg20356878	chr3:121714668	ILDR1	0.44	10.07	0.37	3.16e-22	Cognitive performance;
BRCA	trans	rs1941687	0.509	rs7230319	chr18:31321289	A/T	cg15819921	chr19:927150	ARID3A	-0.43	-8.12	-0.31	2.5e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	trans	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.73	-0.36	5.73e-21	Morning vs. evening chronotype;
BRCA	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg11764359	chr7:65958608	NA	0.67	15.02	0.51	6.93e-44	Aortic root size;
BRCA	cis	rs10046574	0.831	rs7797208	chr7:135137729	C/T	cg27474649	chr7:135195673	CNOT4	0.61	8.64	0.32	4.59e-17	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs11603020	0.950	rs11229067	chr11:57374946	A/C	cg19752551	chr11:57585705	CTNND1	0.43	9.83	0.36	2.53e-21	Blood protein levels;
BRCA	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.77	-0.39	5.61e-25	Mean corpuscular volume;
BRCA	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00149659	chr3:10157352	C3orf10	0.79	13.72	0.48	9.42e-38	Alzheimer's disease;
BRCA	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.22	-0.31	1.14e-15	Menopause (age at onset);
BRCA	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg18904891	chr8:8559673	CLDN23	0.65	12.97	0.46	2.56e-34	Obesity-related traits;
BRCA	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg17691542	chr6:26056736	HIST1H1C	0.51	10.55	0.39	4.23e-24	Height;
BRCA	cis	rs360798	0.512	rs2430388	chr2:63106784	T/C	cg17519650	chr2:63277830	OTX1	0.38	8.13	0.31	2.19e-15	Coronary artery disease;
BRCA	cis	rs6882046	0.513	rs625970	chr5:88042296	A/G	cg22951263	chr5:87985283	NA	-0.39	-10.85	-0.39	2.7e-25	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg26384229	chr12:38710491	ALG10B	0.74	17.6	0.57	7.83e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg04362960	chr10:104952993	NT5C2	0.46	10.64	0.39	1.87e-24	Arsenic metabolism;
BRCA	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg19318889	chr4:1322082	MAEA	0.58	11.55	0.42	3.77e-28	Longevity;
BRCA	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.44	0.38	1.15e-23	Motion sickness;
BRCA	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg25358565	chr5:93447407	FAM172A	1.18	19.89	0.62	6.63e-69	Diabetic retinopathy;
BRCA	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg24069376	chr3:38537580	EXOG	0.42	11.96	0.43	7.14e-30	Electrocardiographic conduction measures;
BRCA	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg12483005	chr1:23474871	LUZP1	0.48	10.49	0.38	7.26e-24	Height;
BRCA	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg21770322	chr7:97807741	LMTK2	0.43	11.28	0.41	4.71e-27	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg19862616	chr7:65841803	NCRNA00174	0.84	27.31	0.73	1.94e-109	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22455342	chr2:225449267	CUL3	-0.66	-17.09	-0.56	3.37e-54	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs754466	0.606	rs11002306	chr10:79591519	A/T	cg17075019	chr10:79541650	NA	-0.81	-21.35	-0.65	1e-76	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg07262247	chr5:131593730	PDLIM4	0.36	8.06	0.3	3.68e-15	Acylcarnitine levels;
BRCA	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.1	-0.31	2.84e-15	Depression;
BRCA	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.82	-12.38	-0.44	1.05e-31	Platelet count;
BRCA	cis	rs10871290	1.000	rs11149710	chr16:74472546	G/T	cg01733217	chr16:74700730	RFWD3	-0.49	-11.64	-0.42	1.55e-28	Breast cancer;
BRCA	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	12.91	0.45	4.81e-34	Lung cancer in ever smokers;
BRCA	cis	rs4285028	0.948	rs73855481	chr3:121676951	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.82	-0.39	3.64e-25	Multiple sclerosis;
BRCA	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg03453431	chr7:157225567	NA	-0.45	-9.07	-0.34	1.41e-18	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg00990874	chr7:1149470	C7orf50	-0.49	-9.47	-0.35	5.36e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18876405	chr7:65276391	NA	-0.51	-11.29	-0.41	4.34e-27	Aortic root size;
BRCA	cis	rs11229555	0.574	rs72919749	chr11:58323467	T/C	cg15696309	chr11:58395628	NA	-0.5	-9.59	-0.35	2.01e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg05025164	chr4:1340916	KIAA1530	0.36	7.97	0.3	7.26e-15	Longevity;
BRCA	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg24675658	chr1:53192096	ZYG11B	-0.54	-12.27	-0.44	3.21e-31	Monocyte count;
BRCA	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.22	7.87	0.3	1.49e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9473147	0.602	rs9296567	chr6:47553402	G/A	cg12968598	chr6:47444699	CD2AP	0.46	9.88	0.36	1.62e-21	Platelet distribution width;Mean platelet volume;
BRCA	trans	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg26384229	chr12:38710491	ALG10B	0.53	11.52	0.41	4.72e-28	Morning vs. evening chronotype;
BRCA	cis	rs7809950	1.000	rs2237673	chr7:107131580	T/C	cg23024343	chr7:107201750	COG5	-0.41	-9.64	-0.36	1.22e-20	Coronary artery disease;
BRCA	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg05347473	chr6:146136440	FBXO30	-0.41	-8.19	-0.31	1.38e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.36	-0.38	2.35e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.17	-0.31	1.66e-15	Aortic root size;
BRCA	trans	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg04565464	chr8:145669602	NFKBIL2	-0.37	-8.72	-0.33	2.36e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-10.49	-0.38	7.35e-24	Schizophrenia;
BRCA	cis	rs3768617	0.782	rs10752893	chr1:183046261	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.46	9.97	0.37	7.35e-22	Fuchs's corneal dystrophy;
BRCA	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	8.65e-21	Menopause (age at onset);
BRCA	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg18252515	chr7:66147081	NA	-1.06	-15.81	-0.53	9.02e-48	Diabetic kidney disease;
BRCA	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.61	9.59	0.35	2.01e-20	Lung function (FEV1/FVC);
BRCA	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-12.93	-0.46	3.78e-34	Bipolar disorder and schizophrenia;
BRCA	cis	rs8038465	0.615	rs11637315	chr15:73944068	G/C	cg15420318	chr15:73925796	NPTN	0.4	8.79	0.33	1.38e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9790314	0.747	rs7650703	chr3:160851639	T/C	cg04691961	chr3:161091175	C3orf57	-0.46	-9.95	-0.37	8.93e-22	Morning vs. evening chronotype;
BRCA	cis	rs4499344	0.693	rs8106502	chr19:33097796	C/T	cg22980127	chr19:33182716	NUDT19	-0.38	-7.91	-0.3	1.11e-14	Mean platelet volume;
BRCA	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26168224	chr5:2018326	NA	0.6	15.13	0.51	2.08e-44	Gut microbiome composition (winter);
BRCA	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.39	0.41	1.73e-27	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	13.87	0.48	1.91e-38	Lymphocyte counts;
BRCA	cis	rs3784262	0.528	rs4144005	chr15:58330094	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-10.43	-0.38	1.26e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs28374715	0.662	rs72737792	chr15:41515589	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.83	-17.2	-0.56	8.72e-55	Ulcerative colitis;
BRCA	cis	rs78487399	0.908	rs75597324	chr2:43811239	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-7.89	-0.3	1.33e-14	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg03433033	chr1:76189801	ACADM	-0.4	-8.15	-0.31	1.91e-15	Daytime sleep phenotypes;
BRCA	cis	rs2625529	0.652	rs28650442	chr15:72155445	A/T	cg16672083	chr15:72433130	SENP8	-0.69	-16.56	-0.55	1.69e-51	Red blood cell count;
BRCA	cis	rs4722404	0.592	rs13221367	chr7:3119823	C/T	cg19214707	chr7:3157722	NA	-0.37	-8.06	-0.3	3.75e-15	Atopic dermatitis;
BRCA	cis	rs2302729	0.578	rs10848682	chr12:2771756	C/G	cg19945202	chr12:2788847	CACNA1C	-0.44	-9.79	-0.36	3.54e-21	Sleep quality;
BRCA	cis	rs7131987	0.834	rs12228468	chr12:29453610	A/C	cg09582351	chr12:29534625	ERGIC2	0.49	11.93	0.43	9.59e-30	QT interval;
BRCA	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg27433088	chr4:174089019	GALNT7	-0.33	-8.15	-0.31	1.86e-15	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14442939	chr10:27389572	ANKRD26	0.68	11.27	0.41	5.47e-27	Breast cancer;
BRCA	cis	rs34779708	0.733	rs4007271	chr10:35546611	C/T	cg03585969	chr10:35415529	CREM	0.44	9.1	0.34	1.17e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs367943	1.000	rs348941	chr5:112824166	G/C	cg12552261	chr5:112820674	MCC	-0.57	-12.37	-0.44	1.18e-31	Type 2 diabetes;
BRCA	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.99	14.76	0.5	1.17e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	13.95	0.48	8.51e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg05340658	chr4:99064831	C4orf37	0.65	15.98	0.53	1.27e-48	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg00383909	chr3:49044727	WDR6	-0.71	-11.36	-0.41	2.22e-27	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs524281	0.861	rs3953856	chr11:65965908	T/A	cg16950941	chr11:66035639	RAB1B	-0.39	-8.06	-0.3	3.88e-15	Electroencephalogram traits;
BRCA	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg13770153	chr20:60521292	NA	-0.41	-9.1	-0.34	1.17e-18	Body mass index;
BRCA	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.46e-23	Motion sickness;
BRCA	cis	rs600806	0.850	rs1343465	chr1:109937426	T/C	cg20591472	chr1:110008990	SYPL2	0.33	8.22	0.31	1.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg01028140	chr2:1542097	TPO	-0.71	-14.29	-0.49	2.2e-40	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.97	21.54	0.65	8.37e-78	Lymphocyte percentage of white cells;
BRCA	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg05283184	chr6:79620031	NA	-0.42	-10.83	-0.39	3.42e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs17092148	0.887	rs6120684	chr20:33179788	A/G	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.67	-0.39	1.38e-24	Neuroticism;
BRCA	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	8.27	0.31	7.97e-16	Educational attainment;
BRCA	cis	rs7903847	0.642	rs7896100	chr10:99156994	C/T	cg20016023	chr10:99160130	RRP12	-0.26	-8.47	-0.32	1.68e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs3770081	1.000	rs56104203	chr2:86336256	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.63	-8.62	-0.32	5.42e-17	Facial emotion recognition (sad faces);
BRCA	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.81	-14.42	-0.5	5.27e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg25174290	chr11:3078921	CARS	0.37	11.25	0.41	6.29e-27	Longevity;
BRCA	cis	rs895636	0.716	rs873745	chr2:45193173	C/G	cg16198908	chr2:45192207	NA	0.44	8.6	0.32	6.23e-17	Metabolite levels;Fasting plasma glucose;
BRCA	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.44	-9.58	-0.35	2.07e-20	Multiple sclerosis;
BRCA	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg02503808	chr4:7069936	GRPEL1	-0.8	-14.52	-0.5	1.72e-41	Monocyte percentage of white cells;
BRCA	trans	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.81	-0.3	2.33e-14	Corneal astigmatism;
BRCA	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg24060327	chr5:131705240	SLC22A5	-0.64	-12.53	-0.44	2.43e-32	Blood metabolite levels;
BRCA	cis	rs9868809	0.881	rs57334642	chr3:48666795	C/T	cg00383909	chr3:49044727	WDR6	0.54	8.08	0.3	3.27e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	10.87	0.39	2.35e-25	Iron status biomarkers;
BRCA	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg10560079	chr2:191398806	TMEM194B	-0.68	-12.78	-0.45	1.86e-33	Diastolic blood pressure;
BRCA	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	23.32	0.68	1.65e-87	Platelet count;
BRCA	trans	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg19694781	chr19:47549865	TMEM160	-0.81	-16.93	-0.56	2.26e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	ch.11.42038R	chr11:967971	AP2A2	0.52	16.57	0.55	1.53e-51	Alzheimer's disease (late onset);
BRCA	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg11266682	chr4:10021025	SLC2A9	0.41	10.86	0.39	2.57e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg23505145	chr19:12996616	KLF1	0.56	12.12	0.43	1.35e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs713587	0.521	rs35177510	chr2:25089594	C/A	cg04586622	chr2:25135609	ADCY3	0.42	10.83	0.39	3.33e-25	Body mass index in non-asthmatics;
BRCA	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.32	-9.01	-0.34	2.31e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs11165623	0.740	rs12126692	chr1:96889258	C/G	cg10631902	chr5:14652156	NA	0.47	14.57	0.5	1.02e-41	Hip circumference;Waist circumference;
BRCA	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg23711669	chr6:146136114	FBXO30	-0.63	-12.41	-0.44	7.42e-32	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg14675211	chr2:100938903	LONRF2	0.51	11.53	0.41	4.71e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs11191270	0.554	rs10444022	chr10:104084889	A/G	cg15320455	chr10:103880129	LDB1	0.73	10.72	0.39	9.39e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.2	-18.94	-0.6	8.26e-64	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg07988820	chr12:82153109	PPFIA2	-0.66	-10.53	-0.38	4.99e-24	Resting heart rate;
BRCA	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg12160578	chr15:63334699	TPM1	-0.41	-8.31	-0.31	5.66e-16	Platelet count;
BRCA	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18876405	chr7:65276391	NA	0.62	15.36	0.52	1.54e-45	Aortic root size;
BRCA	cis	rs1865721	1.000	rs1865721	chr18:73192446	C/T	cg26385618	chr18:73139727	C18orf62	-0.39	-8.98	-0.33	3.1e-18	Intelligence;
BRCA	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg21905437	chr5:178450457	ZNF879	0.51	10.41	0.38	1.48e-23	Pubertal anthropometrics;
BRCA	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg18479299	chr3:125709523	NA	-0.56	-9.05	-0.34	1.75e-18	Blood pressure (smoking interaction);
BRCA	cis	rs4077515	0.934	rs78428995	chr9:139281847	T/C	cg14019695	chr9:139328340	INPP5E	0.31	7.86	0.3	1.6e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03452623	chr4:187889614	NA	-0.34	-11.62	-0.42	1.81e-28	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11976180	0.569	rs12703565	chr7:143754401	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.93	-13.93	-0.48	1.08e-38	Obesity-related traits;
BRCA	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18876405	chr7:65276391	NA	-0.5	-10.94	-0.4	1.15e-25	Aortic root size;
BRCA	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg13114125	chr14:105738426	BRF1	-0.49	-10.52	-0.38	5.82e-24	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg04586622	chr2:25135609	ADCY3	0.46	11.58	0.42	2.64e-28	Body mass index;
BRCA	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg04691961	chr3:161091175	C3orf57	-0.59	-14.0	-0.48	4.87e-39	Morning vs. evening chronotype;
BRCA	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg04944784	chr2:26401820	FAM59B	-0.66	-11.24	-0.41	6.93e-27	Gut microbiome composition (summer);
BRCA	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg27170947	chr2:26402098	FAM59B	-0.81	-13.05	-0.46	1.1e-34	Gut microbiome composition (summer);
BRCA	cis	rs3099143	1.000	rs7178759	chr15:77143513	A/G	cg21673338	chr15:77095150	SCAPER	0.46	8.64	0.32	4.5e-17	Recalcitrant atopic dermatitis;
BRCA	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg00339695	chr16:24857497	SLC5A11	-0.54	-11.49	-0.41	6.59e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.54	0.32	9.54e-17	Rheumatoid arthritis;
BRCA	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg13010199	chr12:38710504	ALG10B	0.44	8.48	0.32	1.53e-16	Heart rate;
BRCA	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg14844989	chr11:31128820	NA	-0.45	-9.56	-0.35	2.44e-20	Red blood cell count;
BRCA	cis	rs3784262	0.669	rs4646603	chr15:58290024	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.87	-0.36	1.75e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs4363385	0.597	rs6679201	chr1:152976840	C/A	cg25856811	chr1:152973957	SPRR3	-0.34	-9.08	-0.34	1.31e-18	Inflammatory skin disease;
BRCA	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04871131	chr7:94954202	PON1	-0.46	-9.91	-0.36	1.27e-21	Paraoxonase activity;
BRCA	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	18.49	0.59	1.93e-61	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs586533	0.801	rs637387	chr11:99495489	T/C	cg22878054	chr11:99397252	CNTN5	0.32	8.03	0.3	4.8e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.49e-23	Motion sickness;
BRCA	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12826209	chr6:26865740	GUSBL1	0.59	10.31	0.38	3.81e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg12386194	chr3:101231763	SENP7	0.6	12.41	0.44	7.93e-32	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	14.13	0.49	1.18e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg07636037	chr3:49044803	WDR6	0.98	28.9	0.75	4.43e-118	Parkinson's disease;
BRCA	cis	rs12618769	0.570	rs17444095	chr2:99075817	C/G	cg10123293	chr2:99228465	UNC50	0.4	7.95	0.3	8.23e-15	Bipolar disorder;
BRCA	cis	rs4845875	0.626	rs6697244	chr1:11838848	G/T	cg24844545	chr1:11908347	NPPA	0.32	8.09	0.3	2.93e-15	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg17845761	chr1:175162550	KIAA0040	0.26	9.9	0.36	1.35e-21	Alcohol dependence;
BRCA	cis	rs6714710	0.603	rs10432626	chr2:98561153	C/A	cg26665480	chr2:98280029	ACTR1B	0.57	13.39	0.47	3.18e-36	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs3772130	0.926	rs13072767	chr3:121504098	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.68	0.39	1.31e-24	Cognitive performance;
BRCA	cis	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg07460842	chr6:66804631	NA	-0.99	-19.46	-0.61	1.38e-66	Exhaled nitric oxide output;
BRCA	trans	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.38	-7.91	-0.3	1.14e-14	Menarche (age at onset);
BRCA	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg17845761	chr1:175162550	KIAA0040	0.26	9.91	0.37	1.19e-21	Alcohol dependence;
BRCA	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18876405	chr7:65276391	NA	0.55	13.22	0.46	1.89e-35	Aortic root size;
BRCA	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	11.07	0.4	3.42e-26	Rheumatoid arthritis;
BRCA	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.79	0.33	1.42e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg23625390	chr15:77176239	SCAPER	0.35	7.97	0.3	7.23e-15	Blood metabolite levels;
BRCA	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg26248373	chr2:1572462	NA	-0.47	-9.1	-0.34	1.16e-18	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	20.09	0.62	5.99e-70	Platelet count;
BRCA	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg19901468	chr14:105411992	AHNAK2	-0.48	-11.21	-0.41	9.51e-27	Rheumatoid arthritis;
BRCA	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg08923669	chr16:420230	MRPL28	0.37	9.03	0.34	2.05e-18	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.4e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg24642439	chr20:33292090	TP53INP2	0.51	11.35	0.41	2.46e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg23711669	chr6:146136114	FBXO30	0.64	15.05	0.51	4.81e-44	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6479891	1.000	rs9415697	chr10:65135137	T/C	cg14819942	chr15:35414228	NA	0.35	8.65	0.32	4.02e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg16606324	chr3:10149918	C3orf24	0.56	11.15	0.4	1.74e-26	Alzheimer's disease;
BRCA	trans	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg26043149	chr18:55253948	FECH	-0.37	-8.25	-0.31	9.34e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg24130564	chr14:104152367	KLC1	-0.34	-7.86	-0.3	1.63e-14	Body mass index;
BRCA	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg11189052	chr15:85197271	WDR73	0.57	14.3	0.49	1.81e-40	P wave terminal force;
BRCA	cis	rs10463316	0.894	rs7723016	chr5:150764828	T/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.4	-0.32	2.96e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs7631605	0.586	rs6550466	chr3:37305480	T/C	cg15934958	chr3:37212084	LRRFIP2	0.38	8.1	0.31	2.84e-15	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg02079420	chr8:82753780	SNX16	-0.3	-8.22	-0.31	1.12e-15	Diastolic blood pressure;
BRCA	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-11.19	-0.4	1.19e-26	Gut microbiome composition (summer);
BRCA	trans	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg26384229	chr12:38710491	ALG10B	0.5	11.1	0.4	2.64e-26	Morning vs. evening chronotype;
BRCA	cis	rs3845702	0.736	rs6727890	chr2:180832675	T/C	cg01881094	chr2:180872142	CWC22	-1.01	-18.23	-0.58	4.24e-60	Schizophrenia;
BRCA	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg20790798	chr5:1857306	NA	-0.38	-8.79	-0.33	1.38e-17	Cardiovascular disease risk factors;
BRCA	cis	rs7267979	0.844	rs6107027	chr20:25288632	A/G	cg08601574	chr20:25228251	PYGB	0.33	7.84	0.3	1.85e-14	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg14186256	chr22:23484241	RTDR1	0.76	22.93	0.67	2.18e-85	Bone mineral density;
BRCA	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	11.36	0.41	2.34e-27	Height;
BRCA	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg03877680	chr5:178157825	ZNF354A	0.83	16.47	0.55	4.74e-51	Neutrophil percentage of white cells;
BRCA	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg06212747	chr3:49208901	KLHDC8B	0.47	9.39	0.35	1e-19	Parkinson's disease;
BRCA	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08045932	chr20:61659980	NA	0.5	11.21	0.41	9.54e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-12.2	-0.43	6.36e-31	Personality dimensions;
BRCA	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg01292856	chr11:65242576	NA	-0.31	-7.94	-0.3	8.93e-15	Bone mineral density;
BRCA	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.38	-8.2	-0.31	1.28e-15	Osteoporosis;
BRCA	cis	rs877282	0.733	rs11253342	chr10:765072	A/G	cg17470449	chr10:769945	NA	0.47	7.96	0.3	8.16e-15	Uric acid levels;
BRCA	cis	rs9649465	0.967	rs2286831	chr7:123303477	A/G	cg04330084	chr7:123175371	IQUB	-0.3	-8.34	-0.31	4.66e-16	Migraine;
BRCA	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg22105103	chr4:187893119	NA	0.37	11.92	0.43	1.04e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	12.02	0.43	3.78e-30	Multiple sclerosis;
BRCA	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26314531	chr2:26401878	FAM59B	-0.78	-12.51	-0.44	2.79e-32	Gut microbiome composition (summer);
BRCA	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg00666640	chr1:248458726	OR2T12	0.33	8.54	0.32	9.9e-17	Common traits (Other);
BRCA	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18876405	chr7:65276391	NA	-0.5	-11.2	-0.41	1.06e-26	Aortic root size;
BRCA	cis	rs812925	0.515	rs1177308	chr2:61387254	C/G	cg15711740	chr2:61764176	XPO1	-0.32	-7.98	-0.3	6.66e-15	Immature fraction of reticulocytes;
BRCA	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11905131	chr22:24372483	LOC391322	-0.53	-12.18	-0.43	7.97e-31	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg06521331	chr12:34319734	NA	-0.46	-8.54	-0.32	9.43e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg06808227	chr14:105710500	BRF1	-0.8	-15.93	-0.53	2.39e-48	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg22535103	chr8:58192502	C8orf71	0.47	8.22	0.31	1.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.4	8.48	0.32	1.61e-16	Total cholesterol levels;
BRCA	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	26.42	0.72	1.58e-104	Chronic sinus infection;
BRCA	cis	rs4566357	0.615	rs10174591	chr2:227913140	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.44	-0.35	6.61e-20	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg20607798	chr8:58055168	NA	0.47	8.09	0.3	2.96e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg09359103	chr1:154839909	KCNN3	-0.57	-14.8	-0.51	7.83e-43	Prostate cancer;
BRCA	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg10556349	chr10:835070	NA	0.73	9.88	0.36	1.6e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg12292205	chr6:26970375	C6orf41	0.56	12.36	0.44	1.23e-31	Schizophrenia;
BRCA	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg22713356	chr15:30763199	NA	1.3	24.75	0.7	2.51e-95	Uric acid levels;
BRCA	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg02655711	chr22:19163373	SLC25A1	0.54	12.91	0.45	4.97e-34	Metabolite levels;
BRCA	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.36e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg15448220	chr1:150897856	SETDB1	0.35	7.9	0.3	1.24e-14	Melanoma;
BRCA	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg08470875	chr2:26401718	FAM59B	0.59	7.9	0.3	1.22e-14	Gut microbiome composition (summer);
BRCA	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	4.04e-15	Alzheimer's disease (late onset);
BRCA	cis	rs7011049	1.000	rs113124539	chr8:53854321	G/A	cg26025543	chr8:53854495	NA	0.54	9.41	0.35	8.91e-20	Systolic blood pressure;
BRCA	cis	rs13046373	0.535	rs9636840	chr21:32029979	A/G	cg16431978	chr21:31797932	KRTAP13-3	-0.32	-8.03	-0.3	4.74e-15	HDL cholesterol;
BRCA	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.68	11.24	0.41	7.45e-27	Lung function (FEV1/FVC);
BRCA	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg23649088	chr2:200775458	C2orf69	0.49	10.1	0.37	2.45e-22	Osteoporosis;
BRCA	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg15485101	chr11:133734466	NA	-0.39	-10.87	-0.39	2.32e-25	Childhood ear infection;
BRCA	cis	rs4742903	0.904	rs10991167	chr9:106974382	C/T	cg21169611	chr9:106856078	SMC2	-0.32	-8.4	-0.32	2.98e-16	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg23649088	chr2:200775458	C2orf69	0.59	8.81	0.33	1.18e-17	Schizophrenia;
BRCA	cis	rs6142102	0.625	rs1883706	chr20:32552877	G/A	cg24642439	chr20:33292090	TP53INP2	0.39	7.82	0.3	2.17e-14	Skin pigmentation;
BRCA	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg08859206	chr1:53392774	SCP2	0.48	10.79	0.39	4.83e-25	Monocyte count;
BRCA	cis	rs6835174	1.000	rs6835174	chr4:5976104	C/T	cg08509927	chr4:5976063	C4orf50	-0.55	-9.41	-0.35	8.6e-20	Cannabis use (initiation);
BRCA	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg15839431	chr19:19639596	YJEFN3	-0.39	-8.51	-0.32	1.22e-16	Bipolar disorder;
BRCA	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11644478	chr21:40555479	PSMG1	0.71	13.92	0.48	1.11e-38	Cognitive function;
BRCA	cis	rs7809950	0.954	rs62482543	chr7:107080656	G/A	cg23024343	chr7:107201750	COG5	-0.44	-10.09	-0.37	2.64e-22	Coronary artery disease;
BRCA	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg21280719	chr6:42927975	GNMT	-0.32	-13.75	-0.48	7.35e-38	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg04166393	chr7:2884313	GNA12	0.48	9.04	0.34	1.82e-18	Height;
BRCA	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18876405	chr7:65276391	NA	0.5	11.04	0.4	4.57e-26	Aortic root size;
BRCA	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg26031613	chr14:104095156	KLC1	0.75	16.33	0.54	2.24e-50	Body mass index;
BRCA	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg04553112	chr3:125709451	NA	-0.55	-8.29	-0.31	6.59e-16	Blood pressure (smoking interaction);
BRCA	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg22907277	chr7:1156413	C7orf50	0.59	9.17	0.34	6.51e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg20203395	chr5:56204925	C5orf35	-0.49	-10.25	-0.38	6.14e-23	Initial pursuit acceleration;
BRCA	cis	rs3849570	1.000	rs6548773	chr3:81840222	C/T	cg07356753	chr3:81810745	GBE1	0.47	11.38	0.41	1.92e-27	Waist circumference;Body mass index;
BRCA	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.87e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg06636001	chr8:8085503	FLJ10661	0.5	10.68	0.39	1.27e-24	Retinal vascular caliber;
BRCA	cis	rs6005807	0.719	rs12165893	chr22:29033545	T/C	cg12565055	chr22:29076175	TTC28	0.49	9.36	0.35	1.35e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg24531977	chr5:56204891	C5orf35	-0.55	-11.34	-0.41	2.7e-27	Coronary artery disease;
BRCA	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27286337	chr10:134555280	INPP5A	0.6	10.15	0.37	1.51e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg07636037	chr3:49044803	WDR6	0.42	8.51	0.32	1.22e-16	Resting heart rate;
BRCA	trans	rs1973993	0.544	rs2800427	chr1:97002766	A/C	cg10631902	chr5:14652156	NA	0.48	14.84	0.51	5.25e-43	Weight;
BRCA	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg22491629	chr6:157744540	C6orf35	-0.67	-12.44	-0.44	5.53e-32	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg25930673	chr12:123319894	HIP1R	0.52	7.92	0.3	1.08e-14	Schizophrenia;
BRCA	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg21475434	chr5:93447410	FAM172A	0.67	8.44	0.32	2.09e-16	Diabetic retinopathy;
BRCA	cis	rs4787491	0.729	rs3814878	chr16:30041966	A/G	cg06326092	chr16:30034487	C16orf92	0.35	8.65	0.32	4.13e-17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.89	21.69	0.65	1.39e-78	Colorectal cancer;
BRCA	cis	rs2387326	0.672	rs10829347	chr10:129947386	T/C	cg16087940	chr10:129947807	NA	-0.45	-7.94	-0.3	9.32e-15	Select biomarker traits;
BRCA	cis	rs36051895	0.632	rs10974979	chr9:5131731	C/A	cg02405213	chr9:5042618	JAK2	-0.48	-8.64	-0.32	4.37e-17	Pediatric autoimmune diseases;
BRCA	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg08917208	chr2:24149416	ATAD2B	0.89	12.44	0.44	5.85e-32	Lymphocyte counts;
BRCA	cis	rs11112613	0.762	rs17037308	chr12:105949847	T/G	cg03607813	chr12:105948248	NA	0.6	11.21	0.41	9.41e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs829883	0.966	rs249853	chr12:98864908	A/C	cg25150519	chr12:98850993	NA	0.45	8.6	0.32	6.18e-17	Colorectal adenoma (advanced);
BRCA	cis	rs7255436	0.965	rs7249624	chr19:8446135	G/A	cg10811474	chr19:8428787	ANGPTL4	-0.32	-8.05	-0.3	4.15e-15	HDL cholesterol;
BRCA	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg06494592	chr3:125709126	NA	-0.54	-8.5	-0.32	1.33e-16	Blood pressure (smoking interaction);
BRCA	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.59	12.25	0.44	4.02e-31	Lymphocyte counts;
BRCA	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.47	8.07	0.3	3.44e-15	HIV-1 control;
BRCA	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.23	-0.31	1.07e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.22	-0.31	1.13e-15	Parkinson's disease;
BRCA	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg01939980	chr4:1354348	KIAA1530	0.38	10.72	0.39	9.05e-25	Longevity;
BRCA	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg05340658	chr4:99064831	C4orf37	0.59	11.9	0.43	1.29e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg25358565	chr5:93447407	FAM172A	1.18	19.96	0.62	2.78e-69	Diabetic retinopathy;
BRCA	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.01	0.34	2.33e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.72e-18	Alzheimer's disease (late onset);
BRCA	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-7.97	-0.3	7.48e-15	Alzheimer's disease (late onset);
BRCA	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.13	-0.43	1.33e-30	Total cholesterol levels;
BRCA	trans	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04565464	chr8:145669602	NFKBIL2	0.42	9.51	0.35	3.7e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26314531	chr2:26401878	FAM59B	-0.95	-16.58	-0.55	1.33e-51	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg07606381	chr6:8435919	SLC35B3	0.63	13.66	0.48	1.79e-37	Motion sickness;
BRCA	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg10523679	chr1:76189770	ACADM	0.75	15.74	0.53	2.06e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg04517722	chr19:17905589	B3GNT3	0.42	8.17	0.31	1.71e-15	Tumor biomarkers;
BRCA	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg22920501	chr2:26401640	FAM59B	-0.63	-11.27	-0.41	5.37e-27	Gut microbiome composition (summer);
BRCA	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg11598736	chr3:195384522	SDHAP2	0.58	10.42	0.38	1.33e-23	Lung disease severity in cystic fibrosis;
BRCA	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05890377	chr2:74357713	NA	0.47	11.72	0.42	7.25e-29	Gestational age at birth (maternal effect);
BRCA	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg10876282	chr6:28092338	ZSCAN16	0.42	8.38	0.31	3.4e-16	Cardiac Troponin-T levels;
BRCA	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg05340658	chr4:99064831	C4orf37	0.56	10.98	0.4	8.17e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg05283184	chr6:79620031	NA	-0.39	-9.9	-0.36	1.35e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg11366901	chr6:160182831	ACAT2	0.78	15.21	0.52	8.47e-45	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.3	-0.38	4.09e-23	Psoriasis;
BRCA	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg27211696	chr2:191398769	TMEM194B	0.53	11.9	0.43	1.28e-29	Pulse pressure;
BRCA	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg16325326	chr1:53192061	ZYG11B	0.57	12.77	0.45	2.08e-33	Monocyte count;
BRCA	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.81	-18.94	-0.6	7.61e-64	Ulcerative colitis;
BRCA	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg10621924	chr7:39171070	POU6F2	0.41	8.48	0.32	1.61e-16	IgG glycosylation;
BRCA	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg12573674	chr2:1569213	NA	-0.55	-11.95	-0.43	7.83e-30	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-9.78	-0.36	3.77e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22496380	chr5:211416	CCDC127	-1.0	-14.19	-0.49	6.2e-40	Breast cancer;
BRCA	cis	rs936229	0.768	rs12442901	chr15:75083912	A/G	cg14664628	chr15:75095509	CSK	-0.93	-27.01	-0.73	9.35e-108	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg17063962	chr7:91808500	NA	-0.55	-12.75	-0.45	2.49e-33	Breast cancer;
BRCA	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg22431228	chr1:16359049	CLCNKA	0.4	8.97	0.33	3.28e-18	Dilated cardiomyopathy;
BRCA	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg06623918	chr6:96969491	KIAA0776	-0.91	-25.51	-0.71	1.54e-99	Headache;
BRCA	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg21475434	chr5:93447410	FAM172A	0.68	8.72	0.33	2.43e-17	Diabetic retinopathy;
BRCA	trans	rs6479891	0.915	rs7896677	chr10:65065305	T/G	cg14819942	chr15:35414228	NA	-0.35	-8.56	-0.32	8.37e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg18446336	chr7:2847575	GNA12	-0.41	-10.3	-0.38	4.01e-23	Height;
BRCA	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg25427524	chr10:38739819	LOC399744	0.55	10.07	0.37	3.12e-22	Obesity (extreme);
BRCA	cis	rs812925	0.511	rs11886950	chr2:61399317	A/C	cg15711740	chr2:61764176	XPO1	-0.33	-8.16	-0.31	1.77e-15	Immature fraction of reticulocytes;
BRCA	cis	rs887829	0.570	rs4553819	chr2:234594083	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.38	-0.31	3.32e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs58235267	0.656	rs12713469	chr2:63059927	C/T	cg17519650	chr2:63277830	OTX1	-0.43	-9.4	-0.35	9.93e-20	Prostate-specific antigen levels (conditioned on lead SNPs);
BRCA	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-16.74	-0.55	1.93e-52	Axial length;
BRCA	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs250677	0.522	rs998304	chr5:148382365	C/A	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.36	-0.31	3.82e-16	Breast cancer;
BRCA	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg14983838	chr19:29218262	NA	0.59	11.86	0.42	1.8e-29	Methadone dose in opioid dependence;
BRCA	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-8.26	-0.31	8.65e-16	Schizophrenia;
BRCA	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg00677455	chr12:58241039	CTDSP2	0.6	13.43	0.47	2.03e-36	Multiple sclerosis;
BRCA	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg10327440	chr1:227177885	CDC42BPA	0.84	18.09	0.58	2.29e-59	Myeloid white cell count;
BRCA	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg08999081	chr20:33150536	PIGU	0.38	10.06	0.37	3.31e-22	Coronary artery disease;
BRCA	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.09e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg11952622	chr19:58962976	ZNF324B	0.7	15.17	0.51	1.27e-44	Mean platelet volume;
BRCA	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.48	0.32	1.51e-16	Cognitive ability;
BRCA	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg06784218	chr1:46089804	CCDC17	0.51	12.22	0.44	5.44e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3768617	0.754	rs6673768	chr1:182983396	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.8	0.36	3.28e-21	Fuchs's corneal dystrophy;
BRCA	trans	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg25214090	chr10:38739885	LOC399744	0.46	10.61	0.39	2.52e-24	Corneal astigmatism;
BRCA	cis	rs7119038	0.818	rs7942535	chr11:118681464	C/T	cg19308663	chr11:118741387	NA	-0.37	-9.02	-0.34	2.1e-18	Sjögren's syndrome;
BRCA	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.11	0.4	2.44e-26	Bipolar disorder;
BRCA	cis	rs5167	0.504	rs3760628	chr19:45457225	G/A	cg20090143	chr19:45452003	APOC2	0.27	8.11	0.31	2.59e-15	Blood protein levels;
BRCA	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg12927641	chr6:109611667	NA	-0.42	-10.89	-0.4	1.93e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs4566357	0.576	rs6750845	chr2:227911037	T/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.48	-0.35	4.75e-20	Coronary artery disease;
BRCA	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg15395560	chr15:45543142	SLC28A2	0.29	8.07	0.3	3.4e-15	Uric acid levels;
BRCA	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg09307838	chr4:120376055	NA	0.69	14.25	0.49	3.17e-40	Corneal astigmatism;
BRCA	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	8.46	0.32	1.89e-16	Iron status biomarkers;
BRCA	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	9.24	0.34	3.68e-19	Systemic lupus erythematosus;
BRCA	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.33	-0.44	1.69e-31	Chronic sinus infection;
BRCA	trans	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg06521331	chr12:34319734	NA	-0.53	-10.04	-0.37	4.03e-22	Bladder cancer;
BRCA	trans	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.37	-9.07	-0.34	1.44e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs4650994	0.507	rs2811312	chr1:178617603	A/G	cg05059571	chr16:84539110	KIAA1609	0.54	11.95	0.43	7.58e-30	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.49	-0.32	1.45e-16	Bipolar disorder;
BRCA	trans	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg25214090	chr10:38739885	LOC399744	0.54	12.25	0.44	3.83e-31	Corneal astigmatism;
BRCA	cis	rs7607369	0.559	rs4674340	chr2:219659799	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-10.42	-0.38	1.35e-23	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18876405	chr7:65276391	NA	0.51	11.55	0.42	3.6e-28	Aortic root size;
BRCA	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.97	-0.3	7.18e-15	Aortic root size;
BRCA	cis	rs11605924	0.967	rs6485646	chr11:45865764	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.46	-10.16	-0.37	1.38e-22	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-12.32	-0.44	1.96e-31	Gut microbiome composition (summer);
BRCA	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg12292205	chr6:26970375	C6orf41	-0.65	-10.23	-0.38	7.54e-23	Intelligence (multi-trait analysis);
BRCA	trans	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg21659725	chr3:3221576	CRBN	-0.48	-8.4	-0.32	2.91e-16	Menarche (age at onset);
BRCA	cis	rs7555523	0.887	rs4657477	chr1:165736175	C/T	cg24409356	chr1:165738333	TMCO1	0.49	8.76	0.33	1.8e-17	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	cis	rs3845702	0.866	rs818659	chr2:180870893	G/A	cg01881094	chr2:180872142	CWC22	0.66	13.28	0.47	9.88e-36	Schizophrenia;
BRCA	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.18	-0.31	1.49e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-13.11	-0.46	5.75e-35	Platelet count;
BRCA	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg11645453	chr3:52864694	ITIH4	0.41	9.95	0.37	9.1e-22	Schizophrenia;
BRCA	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.42	-0.32	2.53e-16	Aortic root size;
BRCA	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00802000	chr16:706648	WDR90	-0.39	-9.18	-0.34	5.85e-19	Height;
BRCA	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg09307838	chr4:120376055	NA	0.57	10.62	0.39	2.16e-24	Corneal astigmatism;
BRCA	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08109568	chr15:31115862	NA	0.41	10.11	0.37	2.16e-22	Huntington's disease progression;
BRCA	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg15790184	chr11:494944	RNH1	0.64	9.62	0.36	1.54e-20	Body mass index;
BRCA	cis	rs7617773	0.707	rs13061269	chr3:48373343	C/T	cg11946769	chr3:48343235	NME6	0.67	13.39	0.47	3.13e-36	Coronary artery disease;
BRCA	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg10820045	chr2:198174542	NA	-0.41	-9.36	-0.35	1.29e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs2072438	0.503	rs1323474	chr9:123852859	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	8.26	0.31	8.23e-16	Rheumatoid arthritis;
BRCA	cis	rs3784262	0.904	rs4646620	chr15:58258241	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.43	-11.82	-0.42	2.59e-29	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs2882667	0.964	rs11958050	chr5:138301828	A/G	cg04439458	chr5:138467593	SIL1	-0.29	-8.1	-0.31	2.72e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg18904891	chr8:8559673	CLDN23	0.65	12.69	0.45	4.54e-33	Obesity-related traits;
BRCA	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg20476274	chr7:133979776	SLC35B4	0.7	21.42	0.65	4.15e-77	Mean platelet volume;
BRCA	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg15934090	chr1:100435551	SLC35A3	0.35	7.92	0.3	1.09e-14	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.36	9.28	0.34	2.7e-19	IgG glycosylation;
BRCA	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.39	-8.4	-0.32	2.81e-16	IgG glycosylation;
BRCA	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg24130564	chr14:104152367	KLC1	-0.38	-9.09	-0.34	1.19e-18	Body mass index;
BRCA	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg16586182	chr3:47516702	SCAP	0.63	13.66	0.48	1.8e-37	Colorectal cancer;
BRCA	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg21782813	chr7:2030301	MAD1L1	0.34	9.07	0.34	1.46e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg15017067	chr4:17643749	FAM184B	0.35	10.83	0.39	3.2e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs113835537	0.529	rs57724777	chr11:66236431	G/A	cg24851651	chr11:66362959	CCS	0.51	8.76	0.33	1.71e-17	Airway imaging phenotypes;
BRCA	cis	rs3767633	0.858	rs7532448	chr1:161862745	C/T	cg09175582	chr1:161736000	ATF6	0.53	8.75	0.33	1.93e-17	IgG glycosylation;
BRCA	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg14061069	chr19:46274453	DMPK	-0.48	-11.95	-0.43	7.69e-30	Coronary artery disease;
BRCA	cis	rs10751667	0.621	rs7396049	chr11:1001561	G/A	cg01483505	chr11:975446	AP2A2	0.34	9.19	0.34	5.61e-19	Alzheimer's disease (late onset);
BRCA	cis	rs2882667	0.898	rs4380651	chr5:138391072	A/G	cg04439458	chr5:138467593	SIL1	-0.31	-8.36	-0.31	3.79e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.67	-0.32	3.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03264133	chr6:25882463	NA	-0.41	-9.19	-0.34	5.63e-19	Height;
BRCA	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg24829409	chr8:58192753	C8orf71	-0.44	-8.51	-0.32	1.28e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-9.88	-0.36	1.6e-21	Alzheimer's disease (late onset);
BRCA	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg20891283	chr12:69753455	YEATS4	0.73	21.96	0.66	4.86e-80	Blood protein levels;
BRCA	trans	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg06521331	chr12:34319734	NA	0.46	9.15	0.34	7.82e-19	Bladder cancer;
BRCA	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg04362960	chr10:104952993	NT5C2	0.46	10.7	0.39	1.08e-24	Arsenic metabolism;
BRCA	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg13319975	chr6:146136371	FBXO30	0.34	8.04	0.3	4.24e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.45	9.98	0.37	7.02e-22	Alzheimer's disease (late onset);
BRCA	cis	rs1003719	0.667	rs6517404	chr21:38494918	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.57	13.35	0.47	4.87e-36	Eye color traits;
BRCA	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg16576597	chr16:28551801	NUPR1	0.29	8.27	0.31	7.65e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.29	0.31	6.9e-16	Parkinson's disease;
BRCA	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.82	20.2	0.62	1.55e-70	Body mass index (adult);
BRCA	cis	rs6835174	1.000	rs16837971	chr4:5977133	G/T	cg08509927	chr4:5976063	C4orf50	0.51	8.83	0.33	9.7e-18	Cannabis use (initiation);
BRCA	cis	rs7766436	0.885	rs12524244	chr6:22585287	T/C	cg13666174	chr6:22585274	NA	-0.49	-11.6	-0.42	2.25e-28	Coronary artery disease;
BRCA	cis	rs9309473	1.000	rs7598396	chr2:73652628	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-10.97	-0.4	8.59e-26	Metabolite levels;
BRCA	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-18.15	-0.58	1.17e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg08645402	chr16:4508243	NA	0.4	8.8	0.33	1.32e-17	Schizophrenia;
BRCA	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg12935359	chr14:103987150	CKB	-0.59	-14.06	-0.49	2.51e-39	Body mass index;
BRCA	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.69	0.32	3.12e-17	Personality dimensions;
BRCA	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg18578876	chr12:123200353	GPR109B	-0.53	-8.26	-0.31	8.3e-16	Body mass index;
BRCA	cis	rs10504073	0.669	rs818558	chr8:50030855	A/G	cg00325661	chr8:49890786	NA	0.38	10.87	0.39	2.38e-25	Blood metabolite ratios;
BRCA	cis	rs2354432	0.607	rs66486822	chr1:146802653	T/A	cg25205988	chr1:146714368	CHD1L	-0.91	-13.1	-0.46	6.75e-35	Mitochondrial DNA levels;
BRCA	cis	rs849141	0.961	rs506154	chr7:28202079	T/C	cg22892036	chr7:28189139	JAZF1	0.46	8.28	0.31	7.17e-16	Height;Hip circumference adjusted for BMI;
BRCA	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg25358565	chr5:93447407	FAM172A	1.19	18.3	0.59	1.86e-60	Diabetic retinopathy;
BRCA	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg18305652	chr10:134549665	INPP5A	0.5	11.37	0.41	2.14e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg20469991	chr17:27169893	C17orf63	-0.45	-8.82	-0.33	1.08e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg04362960	chr10:104952993	NT5C2	0.42	10.19	0.37	1.04e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.04	-0.54	6.73e-49	Alzheimer's disease (late onset);
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg15242686	chr22:24348715	GSTTP1	-0.48	-12.18	-0.43	8.1e-31	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.19	-0.31	1.47e-15	Total body bone mineral density;
BRCA	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg11062466	chr8:58055876	NA	0.51	8.95	0.33	3.73e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg12193833	chr17:30244370	NA	-0.56	-8.77	-0.33	1.58e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs1712517	0.838	rs6584543	chr10:104997014	G/A	cg05636881	chr10:105038444	INA	-0.4	-9.22	-0.34	4.3e-19	Migraine;
BRCA	cis	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.8	-0.36	3.17e-21	Morning vs. evening chronotype;
BRCA	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-10.75	-0.39	7.18e-25	Mood instability;
BRCA	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg01689657	chr7:91764605	CYP51A1	0.22	8.13	0.31	2.24e-15	Breast cancer;
BRCA	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg26384229	chr12:38710491	ALG10B	0.77	17.59	0.57	8.61e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg05025164	chr4:1340916	KIAA1530	0.64	12.84	0.45	9.4e-34	Longevity;
BRCA	cis	rs701145	0.643	rs453699	chr3:153924784	A/G	cg17054900	chr3:154042577	DHX36	0.57	9.59	0.35	1.96e-20	Coronary artery disease;
BRCA	cis	rs113835537	0.529	rs7943327	chr11:66256581	G/C	cg24851651	chr11:66362959	CCS	0.44	8.34	0.31	4.58e-16	Airway imaging phenotypes;
BRCA	cis	rs243505	0.898	rs243539	chr7:148403917	T/C	cg09806900	chr7:148480153	CUL1	-0.4	-8.38	-0.31	3.31e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs13136331	0.721	rs2627721	chr4:88683429	G/A	cg22416721	chr4:88570574	DMP1	-0.52	-12.29	-0.44	2.52e-31	Sitting height ratio;
BRCA	trans	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg25214090	chr10:38739885	LOC399744	0.46	10.45	0.38	1.05e-23	Corneal astigmatism;
BRCA	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10819733	chr22:24237672	NA	-0.31	-8.74	-0.33	2.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg04944784	chr2:26401820	FAM59B	-0.85	-13.19	-0.46	2.64e-35	Gut microbiome composition (summer);
BRCA	cis	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg06521331	chr12:34319734	NA	-0.63	-11.57	-0.42	3.12e-28	Morning vs. evening chronotype;
BRCA	cis	rs7249921	0.802	rs62111399	chr19:35668771	C/T	cg15419183	chr19:35660584	FXYD5	0.46	10.41	0.38	1.46e-23	Platelet count;
BRCA	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg21724239	chr8:58056113	NA	0.56	9.11	0.34	1.02e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg07460842	chr6:66804631	NA	-0.99	-19.46	-0.61	1.38e-66	Exhaled nitric oxide output;
BRCA	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	11.03	0.4	4.97e-26	Glomerular filtration rate (creatinine);
BRCA	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg01420254	chr6:26195488	NA	0.58	8.99	0.34	2.78e-18	Gout;Renal underexcretion gout;
BRCA	cis	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg05084668	chr3:125655381	ALG1L	-0.73	-12.97	-0.46	2.52e-34	Blood pressure (smoking interaction);
BRCA	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg00409905	chr10:38381863	ZNF37A	0.49	9.85	0.36	2.05e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg07460842	chr6:66804631	NA	0.89	14.32	0.49	1.58e-40	Exhaled nitric oxide output;
BRCA	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.42	-8.72	-0.33	2.4e-17	Longevity;Endometriosis;
BRCA	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg20129853	chr10:51489980	NA	-0.32	-8.4	-0.32	2.99e-16	Prostate-specific antigen levels;
BRCA	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg17507749	chr15:85114479	UBE2QP1	0.55	10.42	0.38	1.34e-23	Schizophrenia;
BRCA	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05890377	chr2:74357713	NA	0.48	11.55	0.42	3.63e-28	Gestational age at birth (maternal effect);
BRCA	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg06212747	chr3:49208901	KLHDC8B	0.52	10.89	0.4	1.81e-25	Parkinson's disease;
BRCA	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg09307838	chr4:120376055	NA	0.63	13.65	0.48	2.17e-37	Corneal astigmatism;
BRCA	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg11266682	chr4:10021025	SLC2A9	-0.42	-11.02	-0.4	5.48e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7520050	0.966	rs11589562	chr1:46466721	C/T	cg24296786	chr1:45957014	TESK2	-0.45	-9.62	-0.36	1.47e-20	Red blood cell count;Reticulocyte count;
BRCA	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg27535305	chr1:53392650	SCP2	0.49	11.38	0.41	1.82e-27	Monocyte count;
BRCA	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	18.59	0.59	5.39e-62	Smoking behavior;
BRCA	trans	rs6479891	1.000	rs4133250	chr10:65092405	G/A	cg14819942	chr15:35414228	NA	-0.34	-8.48	-0.32	1.54e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs9463078	0.683	rs12215252	chr6:44736265	C/T	cg25276700	chr6:44698697	NA	0.37	8.04	0.3	4.37e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.91	-0.33	5.1e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg08601574	chr20:25228251	PYGB	0.33	8.05	0.3	4.14e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	10.62	0.39	2.28e-24	Neuroticism;
BRCA	cis	rs36051895	0.559	rs7868706	chr9:5210936	T/G	cg02405213	chr9:5042618	JAK2	-0.45	-8.66	-0.32	3.94e-17	Pediatric autoimmune diseases;
BRCA	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-8.17	-0.31	1.61e-15	Bipolar disorder and schizophrenia;
BRCA	trans	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg21659725	chr3:3221576	CRBN	0.47	8.62	0.32	5.23e-17	Menarche (age at onset);
BRCA	trans	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg06521331	chr12:34319734	NA	-0.45	-8.33	-0.31	4.76e-16	Bladder cancer;
BRCA	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg14008862	chr17:28927542	LRRC37B2	0.57	8.09	0.3	2.93e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	trans	rs4714291	0.802	rs2983143	chr6:40044850	G/T	cg02267698	chr19:7991119	CTXN1	-0.44	-8.89	-0.33	6.16e-18	Strep throat;
BRCA	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg12219531	chr12:120966889	COQ5	0.52	11.28	0.41	4.97e-27	High light scatter reticulocyte count;
BRCA	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg08601574	chr20:25228251	PYGB	0.4	9.23	0.34	3.88e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg06145435	chr7:1022769	CYP2W1	0.42	8.31	0.31	5.79e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.77	12.19	0.43	7.2e-31	Platelet count;
BRCA	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg07395648	chr5:131743802	NA	-0.36	-8.7	-0.33	2.86e-17	Blood metabolite levels;
BRCA	trans	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.61	13.83	0.48	3e-38	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6580649	0.943	rs9651993	chr12:48404692	G/A	cg24011408	chr12:48396354	COL2A1	0.56	9.31	0.35	1.95e-19	Lung cancer;
BRCA	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.34	0.35	1.52e-19	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs34779708	0.750	rs35032841	chr10:35312687	G/A	cg03585969	chr10:35415529	CREM	0.49	10.25	0.38	6.46e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.48e-23	Motion sickness;
BRCA	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg17330251	chr7:94953956	PON1	-0.42	-8.48	-0.32	1.52e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6546550	0.933	rs57278310	chr2:70093647	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-9.27	-0.34	2.74e-19	Prevalent atrial fibrillation;
BRCA	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg09184832	chr6:79620586	NA	-0.41	-8.16	-0.31	1.82e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs929596	0.785	rs34352510	chr2:234650562	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-12.13	-0.43	1.22e-30	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs2286885	1.000	rs2286886	chr9:129246177	T/C	cg15282417	chr9:129245246	FAM125B	0.31	7.9	0.3	1.24e-14	Intraocular pressure;
BRCA	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18876405	chr7:65276391	NA	0.55	13.01	0.46	1.64e-34	Aortic root size;
BRCA	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.12	0.43	1.37e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg00814883	chr7:100076585	TSC22D4	-0.54	-10.74	-0.39	7.64e-25	Platelet count;
BRCA	cis	rs7617773	0.817	rs79310258	chr3:48259667	C/G	cg11946769	chr3:48343235	NME6	0.68	13.84	0.48	2.69e-38	Coronary artery disease;
BRCA	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-13.88	-0.48	1.75e-38	Morning vs. evening chronotype;
BRCA	cis	rs10089	0.552	rs17607942	chr5:127555435	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.52	9.87	0.36	1.81e-21	Ileal carcinoids;
BRCA	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.33	-9.02	-0.34	2.13e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	0.718	rs9847866	chr3:160758275	A/G	cg04691961	chr3:161091175	C3orf57	-0.39	-8.2	-0.31	1.34e-15	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.747	rs4478766	chr1:152984906	G/A	cg24667326	chr1:152973720	SPRR3	-0.36	-10.03	-0.37	4.19e-22	Inflammatory skin disease;
BRCA	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg04362960	chr10:104952993	NT5C2	-0.44	-9.76	-0.36	4.45e-21	Arsenic metabolism;
BRCA	cis	rs7523050	0.730	rs72984614	chr1:109435848	T/C	cg08274380	chr1:109419600	GPSM2	1.18	16.83	0.55	6.67e-53	Fat distribution (HIV);
BRCA	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22509189	chr2:225307070	NA	-0.47	-9.98	-0.37	6.87e-22	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg03351412	chr1:154909251	PMVK	0.58	13.76	0.48	6.23e-38	Prostate cancer;
BRCA	cis	rs10267417	0.535	rs6960731	chr7:19869379	C/G	cg07541023	chr7:19748670	TWISTNB	-0.5	-8.99	-0.34	2.67e-18	Night sleep phenotypes;
BRCA	cis	rs7131987	0.565	rs7976667	chr12:29426031	A/C	cg09582351	chr12:29534625	ERGIC2	-0.37	-9.06	-0.34	1.53e-18	QT interval;
BRCA	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg26031613	chr14:104095156	KLC1	-0.4	-8.07	-0.3	3.37e-15	Schizophrenia;
BRCA	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg18446336	chr7:2847575	GNA12	-0.37	-8.5	-0.32	1.39e-16	Height;
BRCA	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg17063962	chr7:91808500	NA	-0.56	-12.09	-0.43	1.87e-30	Breast cancer;
BRCA	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg22875332	chr1:76189707	ACADM	0.62	12.84	0.45	9.36e-34	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg26043149	chr18:55253948	FECH	1.08	23.35	0.68	1.17e-87	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs11051970	0.636	rs1045751	chr12:32569496	T/C	cg02745156	chr12:32552066	NA	0.25	8.4	0.32	2.92e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg13319975	chr6:146136371	FBXO30	-0.34	-8.07	-0.3	3.49e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1953600	0.818	rs2152546	chr10:81906384	G/T	cg04850286	chr10:81895943	PLAC9	-0.35	-10.22	-0.37	8.47e-23	Sarcoidosis;
BRCA	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg01858014	chr14:56050164	KTN1	-0.73	-10.81	-0.39	3.79e-25	Putamen volume;
BRCA	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12311346	chr5:56204834	C5orf35	-0.99	-20.02	-0.62	1.45e-69	Initial pursuit acceleration;
BRCA	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.67e-23	Motion sickness;
BRCA	cis	rs10227331	0.846	rs10237006	chr7:157298250	A/G	cg04156418	chr7:157293606	NA	0.33	9.45	0.35	6.12e-20	Inattentive symptoms;
BRCA	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.1	0.4	2.69e-26	Electroencephalogram traits;
BRCA	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.61	-0.32	5.81e-17	Total body bone mineral density;
BRCA	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg09021430	chr5:549028	NA	-0.69	-15.85	-0.53	5.74e-48	Lung disease severity in cystic fibrosis;
BRCA	cis	rs701145	0.640	rs357506	chr3:153932403	A/C	cg17054900	chr3:154042577	DHX36	0.57	9.59	0.35	1.96e-20	Coronary artery disease;
BRCA	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.15	-0.4	1.74e-26	Schizophrenia;
BRCA	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	14.03	0.49	3.44e-39	Lymphocyte counts;
BRCA	trans	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg01620082	chr3:125678407	NA	-0.84	-9.64	-0.36	1.27e-20	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg22907277	chr7:1156413	C7orf50	0.46	10.57	0.39	3.44e-24	Longevity;Endometriosis;
BRCA	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg03711944	chr11:47377212	SPI1	-0.44	-10.37	-0.38	2.11e-23	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs7715811	0.912	rs1502049	chr5:13779935	T/C	cg07548982	chr5:13769939	DNAH5	-0.41	-9.37	-0.35	1.18e-19	Subclinical atherosclerosis traits (other);
BRCA	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg02527881	chr3:46936655	PTH1R	0.35	8.23	0.31	1.09e-15	Birth weight;
BRCA	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg11764359	chr7:65958608	NA	-0.59	-12.54	-0.44	2.17e-32	Aortic root size;
BRCA	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs919433	0.713	rs11900232	chr2:198466273	T/C	cg00792783	chr2:198669748	PLCL1	0.36	8.21	0.31	1.2e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg19318889	chr4:1322082	MAEA	-0.47	-9.81	-0.36	2.89e-21	Obesity-related traits;
BRCA	cis	rs3771570	0.792	rs4675970	chr2:242200406	G/A	cg21155796	chr2:242212141	HDLBP	0.49	8.49	0.32	1.43e-16	Prostate cancer;
BRCA	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg05507819	chr15:63340323	TPM1	0.43	9.24	0.34	3.7e-19	Platelet count;
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18402987	chr7:1209562	NA	0.58	11.41	0.41	1.49e-27	Longevity;Endometriosis;
BRCA	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.58	10.28	0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs11955398	0.585	rs1117675	chr5:60034886	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.38	-9.06	-0.34	1.6e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg25036284	chr2:26402008	FAM59B	-0.64	-10.65	-0.39	1.75e-24	Gut microbiome composition (summer);
BRCA	cis	rs7301826	0.651	rs4759521	chr12:131297313	C/T	cg11011512	chr12:131303247	STX2	0.51	13.62	0.47	3e-37	Plasma plasminogen activator levels;
BRCA	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg10523679	chr1:76189770	ACADM	-0.77	-16.23	-0.54	7.59e-50	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg16606324	chr3:10149918	C3orf24	0.53	10.45	0.38	1.04e-23	Alzheimer's disease;
BRCA	cis	rs56804039	1.000	rs17616779	chr8:8382374	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	8.8	0.33	1.29e-17	Cervical cancer;
BRCA	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.35	-8.35	-0.31	4.31e-16	Electroencephalogram traits;
BRCA	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg13010199	chr12:38710504	ALG10B	0.4	8.24	0.31	1e-15	Bladder cancer;
BRCA	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.33	-0.44	1.66e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs758324	0.898	rs6877358	chr5:131111360	G/A	cg06307176	chr5:131281290	NA	0.53	10.26	0.38	5.65e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg08000102	chr2:233561755	GIGYF2	0.63	13.95	0.48	8.42e-39	Coronary artery disease;
BRCA	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg27170947	chr2:26402098	FAM59B	0.7	11.76	0.42	4.93e-29	Gut microbiome composition (summer);
BRCA	cis	rs12042938	0.600	rs823163	chr1:231771108	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.4	8.92	0.33	5.07e-18	Neuranatomic and neurocognitive phenotypes;
BRCA	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg04362960	chr10:104952993	NT5C2	-0.33	-7.95	-0.3	8.46e-15	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.65	17.11	0.56	2.53e-54	Electrocardiographic conduction measures;
BRCA	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg16006841	chr5:176797999	RGS14	-0.69	-10.95	-0.4	1.08e-25	Urate levels in lean individuals;
BRCA	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg26384229	chr12:38710491	ALG10B	0.4	9.14	0.34	8.43e-19	Morning vs. evening chronotype;
BRCA	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.99	-0.4	7.22e-26	Mean corpuscular volume;
BRCA	trans	rs1997103	0.765	rs55686950	chr7:55396552	A/C	cg20935933	chr6:143382018	AIG1	0.6	11.52	0.41	4.77e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.33	-9.06	-0.34	1.55e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.36	-8.45	-0.32	1.94e-16	Menarche (age at onset);
BRCA	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.33	9.21	0.34	4.71e-19	Response to antipsychotic treatment;
BRCA	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	13.87	0.48	1.91e-38	Lymphocyte counts;
BRCA	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26314531	chr2:26401878	FAM59B	0.88	15.31	0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg16584290	chr5:462447	EXOC3	0.51	14.17	0.49	7.4e-40	Cystic fibrosis severity;
BRCA	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.39	-0.35	1.06e-19	Alzheimer's disease (late onset);
BRCA	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg11812906	chr14:75593930	NEK9	0.7	16.13	0.54	2.24e-49	Height;
BRCA	trans	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg06521331	chr12:34319734	NA	-0.54	-9.58	-0.35	2.14e-20	Bladder cancer;
BRCA	cis	rs61990749	0.597	rs12887606	chr14:78200620	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.66	10.59	0.39	2.86e-24	Fibroblast growth factor basic levels;
BRCA	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg24558204	chr6:135376177	HBS1L	0.58	15.52	0.52	2.57e-46	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs66530629	1.000	rs7520844	chr1:25054223	C/G	cg01905478	chr1:25040257	NA	-0.35	-7.93	-0.3	9.55e-15	Plateletcrit;
BRCA	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.6	10.19	0.37	1.04e-22	Renal function-related traits (BUN);
BRCA	cis	rs12541635	0.934	rs60482457	chr8:106970504	A/G	cg10147462	chr8:107024639	NA	0.35	9.59	0.35	1.94e-20	Age of smoking initiation;
BRCA	cis	rs6750047	0.719	rs100489	chr2:38266478	T/C	cg07380506	chr2:38303506	CYP1B1	-0.43	-9.58	-0.35	2.05e-20	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs11608355	0.515	rs11614551	chr12:109931630	G/A	cg05360138	chr12:110035743	NA	0.72	13.3	0.47	8.56e-36	Neuroticism;
BRCA	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05535760	chr7:792225	HEATR2	0.86	14.44	0.5	4.06e-41	Cerebrospinal P-tau181p levels;
BRCA	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18876405	chr7:65276391	NA	-0.56	-13.35	-0.47	4.89e-36	Aortic root size;
BRCA	cis	rs2479724	0.776	rs2250428	chr6:41832772	T/A	cg17623882	chr6:41773611	USP49	-0.34	-9.02	-0.34	2.17e-18	Menarche (age at onset);
BRCA	cis	rs758324	0.947	rs4705900	chr5:131140241	G/A	cg06307176	chr5:131281290	NA	0.53	10.22	0.37	8.32e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg13010199	chr12:38710504	ALG10B	0.49	9.48	0.35	4.87e-20	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg11062466	chr8:58055876	NA	0.42	7.92	0.3	1.03e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	11.95	0.43	7.75e-30	Personality dimensions;
BRCA	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	18.55	0.59	8.71e-62	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg07148914	chr20:33460835	GGT7	-0.43	-9.41	-0.35	8.86e-20	Height;
BRCA	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25427524	chr10:38739819	LOC399744	0.67	16.32	0.54	2.5e-50	Extrinsic epigenetic age acceleration;
BRCA	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-9.17	-0.34	6.55e-19	Neuroticism;
BRCA	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg23625390	chr15:77176239	SCAPER	0.5	11.77	0.42	4.33e-29	Blood metabolite levels;
BRCA	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg02734326	chr4:10020555	SLC2A9	0.4	8.55	0.32	9.11e-17	Bone mineral density;
BRCA	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg07148914	chr20:33460835	GGT7	-0.36	-7.85	-0.3	1.73e-14	Glomerular filtration rate (creatinine);
BRCA	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	11.29	0.41	4.64e-27	Platelet count;
BRCA	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg00757033	chr12:89920650	WDR51B	0.54	10.82	0.39	3.61e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg04455712	chr21:45112962	RRP1B	-0.38	-9.86	-0.36	1.91e-21	Mean corpuscular volume;
BRCA	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-15.45	-0.52	5.35e-46	Total cholesterol levels;
BRCA	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg23711669	chr6:146136114	FBXO30	0.64	14.92	0.51	2e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00149659	chr3:10157352	C3orf10	0.71	12.54	0.44	2.2e-32	Alzheimer's disease;
BRCA	cis	rs7903847	0.620	rs11189168	chr10:99125769	T/C	cg08345082	chr10:99160200	RRP12	-0.28	-7.95	-0.3	8.45e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.31	-0.31	5.71e-16	Total body bone mineral density;
BRCA	cis	rs78456975	0.739	rs28913003	chr2:1519620	A/T	cg01028140	chr2:1542097	TPO	-0.69	-13.79	-0.48	4.63e-38	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.94e-24	Motion sickness;
BRCA	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg06784218	chr1:46089804	CCDC17	0.46	10.9	0.4	1.78e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9467160	0.520	rs2753910	chr6:24442473	C/T	cg20631270	chr6:24437470	GPLD1	-0.55	-11.53	-0.41	4.63e-28	Liver enzyme levels;
BRCA	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.78	17.16	0.56	1.41e-54	Smoking behavior;
BRCA	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg18404041	chr3:52824283	ITIH1	-0.38	-10.39	-0.38	1.85e-23	Bipolar disorder;
BRCA	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg23950597	chr19:37808831	NA	-0.6	-10.61	-0.39	2.51e-24	Coronary artery calcification;
BRCA	cis	rs6598955	0.543	rs61608823	chr1:26555090	G/A	cg04990556	chr1:26633338	UBXN11	0.71	11.94	0.43	8.06e-30	Obesity-related traits;
BRCA	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.6	9.13	0.34	8.93e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6785206	0.772	rs2811493	chr3:128357299	C/G	cg16766828	chr3:128327626	NA	-0.79	-11.37	-0.41	1.98e-27	Lymphocyte percentage of white cells;
BRCA	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	9.1e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg25214090	chr10:38739885	LOC399744	0.51	10.48	0.38	7.8e-24	Corneal astigmatism;
BRCA	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg24466277	chr1:23519622	HTR1D	-0.4	-8.58	-0.32	7.38e-17	Height;
BRCA	cis	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg14019146	chr3:50243930	SLC38A3	0.46	11.44	0.41	1.05e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs9341808	0.618	rs6916507	chr6:80862265	T/C	cg08355045	chr6:80787529	NA	0.37	9.33	0.35	1.78e-19	Sitting height ratio;
BRCA	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg12365402	chr11:9010492	NRIP3	-0.41	-9.58	-0.35	2.08e-20	Hemoglobin concentration;
BRCA	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg13256891	chr4:100009986	ADH5	0.54	9.93	0.37	1.04e-21	Smoking initiation;
BRCA	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg15133208	chr4:90757351	SNCA	-0.43	-8.62	-0.32	5.06e-17	Neuroticism;
BRCA	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.53	-11.54	-0.42	3.94e-28	IgG glycosylation;
BRCA	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.56	12.31	0.44	2.21e-31	HIV-1 control;
BRCA	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.95	26.07	0.72	1.32e-102	Birth weight;
BRCA	trans	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg18876405	chr7:65276391	NA	0.44	8.43	0.32	2.3e-16	Corneal structure;
BRCA	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11644478	chr21:40555479	PSMG1	0.84	19.3	0.61	9.57e-66	Cognitive function;
BRCA	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.53	-0.32	1.09e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg13319975	chr6:146136371	FBXO30	-0.36	-8.3	-0.31	6.19e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg23260525	chr10:116636907	FAM160B1	0.3	7.98	0.3	7.04e-15	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-7.85	-0.3	1.72e-14	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg17063962	chr7:91808500	NA	0.56	12.65	0.45	7.2e-33	Breast cancer;
BRCA	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.52	0.5	1.78e-41	Motion sickness;
BRCA	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg13319975	chr6:146136371	FBXO30	0.41	9.22	0.34	4.41e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.23e-24	Motion sickness;
BRCA	cis	rs7590720	1.000	rs7590720	chr2:216898658	A/G	cg12620499	chr2:216877984	MREG	-0.8	-22.36	-0.66	3.02e-82	Alcohol dependence;
BRCA	cis	rs13046373	0.507	rs8133828	chr21:32033046	C/G	cg16431978	chr21:31797932	KRTAP13-3	0.37	8.85	0.33	8.33e-18	HDL cholesterol;
BRCA	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg04166393	chr7:2884313	GNA12	0.5	9.17	0.34	6.41e-19	Height;
BRCA	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg04455712	chr21:45112962	RRP1B	-0.34	-8.5	-0.32	1.31e-16	Mean corpuscular volume;
BRCA	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg03060546	chr3:49711283	APEH	0.58	8.42	0.32	2.57e-16	Menarche (age at onset);
BRCA	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg18252515	chr7:66147081	NA	-1.05	-15.69	-0.53	3.48e-47	Diabetic kidney disease;
BRCA	cis	rs4690686	0.769	rs11133146	chr4:177278878	C/T	cg17059388	chr4:177262070	NA	-0.37	-8.19	-0.31	1.37e-15	Essential tremor;
BRCA	cis	rs1865721	0.682	rs35282535	chr18:73141206	G/A	cg26385618	chr18:73139727	C18orf62	-0.37	-9.4	-0.35	9.95e-20	Intelligence;
BRCA	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg07636037	chr3:49044803	WDR6	-0.5	-8.25	-0.31	9.35e-16	Menarche (age at onset);
BRCA	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.01	0.37	5e-22	Morning vs. evening chronotype;
BRCA	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.37	-0.38	2.18e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6433895	1.000	rs6433895	chr2:182012014	A/C	cg00481216	chr2:181971175	NA	0.37	8.54	0.32	9.6e-17	Lymphocyte counts;
BRCA	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.02e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10267417	0.603	rs12333603	chr7:19907821	C/G	cg07541023	chr7:19748670	TWISTNB	-0.46	-8.53	-0.32	1.09e-16	Night sleep phenotypes;
BRCA	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg14844989	chr11:31128820	NA	-0.44	-9.89	-0.36	1.49e-21	Red blood cell count;
BRCA	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-9.03	-0.34	1.96e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg14675211	chr2:100938903	LONRF2	0.47	10.81	0.39	3.93e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg08508325	chr11:3079039	CARS	-0.45	-16.31	-0.54	3.01e-50	Longevity;
BRCA	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg13010199	chr12:38710504	ALG10B	0.42	9.0	0.34	2.56e-18	Morning vs. evening chronotype;
BRCA	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg03709012	chr19:19516395	GATAD2A	0.96	16.98	0.56	1.2e-53	Nonalcoholic fatty liver disease;
BRCA	cis	rs2012796	1.000	rs10450894	chr14:81825172	T/A	cg02996355	chr14:81879375	NA	0.5	9.79	0.36	3.63e-21	Night sleep phenotypes;
BRCA	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg09184832	chr6:79620586	NA	-0.48	-10.46	-0.38	9.77e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg18132916	chr6:79620363	NA	-0.49	-11.02	-0.4	5.71e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.59	-12.31	-0.44	2.1e-31	Lymphocyte counts;
BRCA	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08219700	chr8:58056026	NA	0.45	8.14	0.31	2.05e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg13010199	chr12:38710504	ALG10B	-0.41	-8.75	-0.33	1.91e-17	Morning vs. evening chronotype;
BRCA	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg12365402	chr11:9010492	NRIP3	0.43	9.39	0.35	1.01e-19	Hemoglobin concentration;
BRCA	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg23109721	chr2:106886537	NA	-0.49	-8.36	-0.31	3.79e-16	Facial morphology (factor 23);
BRCA	trans	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	7.81	0.3	2.31e-14	Aortic root size;
BRCA	cis	rs7707921	0.767	rs862241	chr5:81588011	G/A	cg15871215	chr5:81402204	ATG10	0.35	8.32	0.31	5.42e-16	Breast cancer;
BRCA	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg11993925	chr19:44307056	LYPD5	0.38	8.96	0.33	3.64e-18	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.42	-8.61	-0.32	5.71e-17	Body mass index;
BRCA	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg13880726	chr7:1868755	MAD1L1	0.52	9.81	0.36	2.84e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg08885076	chr2:99613938	TSGA10	0.45	10.61	0.39	2.51e-24	Chronic sinus infection;
BRCA	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07308232	chr7:1071921	C7orf50	-0.42	-8.67	-0.32	3.65e-17	Longevity;Endometriosis;
BRCA	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-13.19	-0.46	2.53e-35	Bone mineral density;
BRCA	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg00106254	chr7:1943704	MAD1L1	-0.43	-10.97	-0.4	8.65e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-8.67	-0.32	3.48e-17	Personality dimensions;
BRCA	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg15017067	chr4:17643749	FAM184B	0.26	7.81	0.3	2.31e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02176678	chr2:219576539	TTLL4	0.39	10.48	0.38	8.11e-24	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs950173	1.000	rs13000153	chr2:172586067	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.73	-10.94	-0.4	1.21e-25	Hippocampal volume;
BRCA	cis	rs868036	0.560	rs12443086	chr15:68080454	C/A	cg08079166	chr15:68083412	MAP2K5	0.31	8.26	0.31	8.51e-16	Restless legs syndrome;
BRCA	cis	rs7707921	0.881	rs73136777	chr5:81434479	T/A	cg15871215	chr5:81402204	ATG10	-0.41	-8.55	-0.32	9.04e-17	Breast cancer;
BRCA	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg11584989	chr19:19387371	SF4	0.31	7.89	0.3	1.33e-14	Tonsillectomy;
BRCA	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg25486957	chr4:152246857	NA	-0.34	-8.18	-0.31	1.59e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10129255	0.500	rs8006888	chr14:107190456	A/C	cg07958169	chr14:107095056	NA	-0.4	-8.71	-0.33	2.69e-17	Kawasaki disease;
BRCA	cis	rs6820391	0.663	rs17083088	chr4:54448574	C/T	cg04173182	chr4:54446035	LNX1	0.47	10.75	0.39	6.93e-25	Cervical artery dissection;
BRCA	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg08668359	chr10:1443807	ADARB2	0.47	9.31	0.35	2.01e-19	Radiation response;
BRCA	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.97	0.58	9.15e-59	Colorectal cancer;
BRCA	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg09184832	chr6:79620586	NA	-0.51	-10.98	-0.4	8.19e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg18154014	chr19:37997991	ZNF793	0.55	10.28	0.38	4.63e-23	Coronary artery calcification;
BRCA	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg09904177	chr6:26538194	HMGN4	0.4	9.25	0.34	3.46e-19	Small cell lung carcinoma;
BRCA	cis	rs870825	0.549	rs28579266	chr4:185627262	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg24110177	chr3:50126178	RBM5	0.37	10.09	0.37	2.49e-22	Menarche (age at onset);
BRCA	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.09	0.4	2.83e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg02017074	chr12:117425053	FBXW8	-0.57	-10.36	-0.38	2.3e-23	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.94	0.33	4.11e-18	Tonsillectomy;
BRCA	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.7	-0.33	2.85e-17	Total body bone mineral density;
BRCA	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00166722	chr3:10149974	C3orf24	0.6	10.69	0.39	1.19e-24	Alzheimer's disease;
BRCA	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.78e-21	Total body bone mineral density;
BRCA	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg06784218	chr1:46089804	CCDC17	0.45	10.8	0.39	4.37e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg17145862	chr1:211918768	LPGAT1	0.69	18.15	0.58	1.04e-59	Leprosy;
BRCA	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.23	0.41	7.6e-27	Bipolar disorder;
BRCA	trans	rs3857536	0.813	rs7769683	chr6:66946256	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	2.02e-14	Blood trace element (Cu levels);
BRCA	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg26384229	chr12:38710491	ALG10B	0.55	11.72	0.42	6.9e-29	Morning vs. evening chronotype;
BRCA	trans	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.37	-9.05	-0.34	1.73e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00149659	chr3:10157352	C3orf10	0.8	13.73	0.48	9.11e-38	Alzheimer's disease;
BRCA	cis	rs68170813	0.559	rs7807648	chr7:106965091	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.22	-0.31	1.17e-15	Coronary artery disease;
BRCA	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg04362960	chr10:104952993	NT5C2	0.43	10.38	0.38	2.03e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	trans	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	9.1e-15	Corneal astigmatism;
BRCA	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg05234568	chr11:5960015	NA	0.49	9.99	0.37	6.13e-22	DNA methylation (variation);
BRCA	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg26395211	chr5:140044315	WDR55	0.38	8.62	0.32	5.29e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg13877915	chr19:58951672	ZNF132	0.46	10.8	0.39	4.43e-25	Uric acid clearance;
BRCA	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.91	0.3	1.16e-14	Axial length;
BRCA	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg14993813	chr1:46806288	NSUN4	-0.47	-9.07	-0.34	1.48e-18	Menopause (age at onset);
BRCA	cis	rs113835537	0.529	rs116867234	chr11:66209024	C/T	cg24851651	chr11:66362959	CCS	0.5	8.71	0.33	2.51e-17	Airway imaging phenotypes;
BRCA	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg22980127	chr19:33182716	NUDT19	0.9	18.18	0.58	7.62e-60	Red blood cell traits;
BRCA	cis	rs34779708	0.931	rs58159560	chr10:35351249	C/T	cg03585969	chr10:35415529	CREM	0.56	11.49	0.41	6.91e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg22875332	chr1:76189707	ACADM	0.64	11.9	0.43	1.18e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs2262909	0.962	rs1526884	chr19:22303651	A/G	cg17074339	chr11:11642133	GALNTL4	0.45	8.89	0.33	6.2e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg13852791	chr20:30311386	BCL2L1	0.77	11.3	0.41	4.02e-27	Mean corpuscular hemoglobin;
BRCA	trans	rs11088226	1.000	rs2833889	chr21:33927768	G/T	cg09050820	chr6:167586206	TCP10L2	-0.5	-8.71	-0.33	2.6e-17	Gastritis;
BRCA	cis	rs6942756	0.713	rs691158	chr7:129129982	G/T	cg02491457	chr7:128862824	NA	-0.55	-11.17	-0.4	1.34e-26	White matter hyperintensity burden;
BRCA	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.55	0.35	2.81e-20	Morning vs. evening chronotype;
BRCA	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12516959	chr21:47718080	NA	0.41	9.43	0.35	7.23e-20	Testicular germ cell tumor;
BRCA	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg11279151	chr3:101281821	RG9MTD1	0.38	8.67	0.32	3.47e-17	Colorectal cancer;
BRCA	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg15448220	chr1:150897856	SETDB1	0.35	7.9	0.3	1.19e-14	Melanoma;
BRCA	trans	rs11039798	0.925	rs7929225	chr11:48931739	G/C	cg15704280	chr7:45808275	SEPT13	0.6	8.93	0.33	4.6e-18	Axial length;
BRCA	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg08603382	chr10:743973	NA	-0.46	-8.51	-0.32	1.25e-16	Psychosis in Alzheimer's disease;
BRCA	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg00666640	chr1:248458726	OR2T12	0.3	8.42	0.32	2.46e-16	Common traits (Other);
BRCA	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg04990556	chr1:26633338	UBXN11	0.53	8.77	0.33	1.55e-17	Obesity-related traits;
BRCA	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg05234568	chr11:5960015	NA	-0.52	-10.27	-0.38	5.4e-23	DNA methylation (variation);
BRCA	cis	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg07460842	chr6:66804631	NA	-0.93	-18.93	-0.6	8.65e-64	Exhaled nitric oxide output;
BRCA	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	7.91	0.3	1.16e-14	Educational attainment;
BRCA	cis	rs427394	0.659	rs274717	chr5:6721067	C/T	cg10857441	chr5:6722123	POLS	0.3	9.64	0.36	1.29e-20	Menopause (age at onset);
BRCA	cis	rs12210905	0.688	rs12212389	chr6:27326397	T/C	cg08851530	chr6:28072375	NA	0.91	8.7	0.33	2.7e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs9359856	0.623	rs7742602	chr6:90327385	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.5	-8.2	-0.31	1.35e-15	Bipolar disorder;
BRCA	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg15595755	chr5:1867978	NA	0.36	8.55	0.32	8.94e-17	Cardiovascular disease risk factors;
BRCA	cis	rs6893300	0.776	rs56396231	chr5:179157298	T/G	cg14593053	chr5:179126677	CANX	-0.35	-7.9	-0.3	1.19e-14	Resting heart rate;
BRCA	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-18.1	-0.58	2.13e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs921968	0.565	rs7580147	chr2:219643036	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-10.82	-0.39	3.47e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7975161	0.572	rs10861163	chr12:104568613	C/A	cg25273343	chr12:104657179	TXNRD1	-0.5	-8.63	-0.32	4.99e-17	Toenail selenium levels;
BRCA	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.49	0.38	7.52e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs877529	0.967	rs139406	chr22:39551798	T/C	cg12193277	chr22:39547181	CBX7	0.46	12.54	0.44	1.99e-32	Multiple myeloma;
BRCA	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg18270830	chr10:32634957	EPC1	0.61	10.27	0.38	5.45e-23	Sexual dysfunction (female);
BRCA	cis	rs7809950	0.678	rs4730235	chr7:107022506	T/C	cg23024343	chr7:107201750	COG5	-0.47	-9.81	-0.36	3.03e-21	Coronary artery disease;
BRCA	cis	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg20368463	chr18:77673604	PQLC1	-0.33	-8.39	-0.31	3.22e-16	Schizophrenia;
BRCA	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg18964960	chr10:1102726	WDR37	0.53	9.2	0.34	5.2e-19	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs34891900	0.507	rs2535707	chr22:18181869	C/T	cg19898043	chr22:18121309	BCL2L13	-0.46	-9.8	-0.36	3.2e-21	Sum neutrophil eosinophil counts;
BRCA	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg18305652	chr10:134549665	INPP5A	0.5	11.49	0.41	6.68e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg19729930	chr2:74357872	NA	0.54	13.99	0.48	5.62e-39	Gestational age at birth (maternal effect);
BRCA	cis	rs6815814	0.898	rs73236646	chr4:38871385	T/C	cg02016764	chr4:38805732	TLR1	-0.52	-8.12	-0.31	2.47e-15	Breast cancer;
BRCA	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06002616	chr8:101225028	SPAG1	-0.34	-8.34	-0.31	4.47e-16	Atrioventricular conduction;
BRCA	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	10.54	0.38	4.74e-24	Aortic root size;
BRCA	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.43	-9.5	-0.35	4.28e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	8.96	0.33	3.49e-18	Motion sickness;
BRCA	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.55	0.32	9.24e-17	Cognitive ability;
BRCA	cis	rs7586879	0.964	rs13412941	chr2:25102709	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.48	0.35	4.77e-20	Body mass index;
BRCA	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg20703242	chr1:230279135	GALNT2	0.46	9.36	0.35	1.34e-19	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg11062466	chr8:58055876	NA	0.52	9.13	0.34	8.75e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs4077515	0.967	rs4567159	chr9:139277059	G/A	cg14019695	chr9:139328340	INPP5E	0.32	8.06	0.3	3.81e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs586533	0.846	rs609750	chr11:99497099	G/T	cg22878054	chr11:99397252	CNTN5	0.32	8.02	0.3	5.08e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg09021430	chr5:549028	NA	-0.64	-15.19	-0.52	1.04e-44	Obesity-related traits;
BRCA	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.54	11.39	0.41	1.76e-27	Height;
BRCA	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg03342759	chr3:160939853	NMD3	0.63	13.52	0.47	8.35e-37	Morning vs. evening chronotype;
BRCA	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg24675658	chr1:53192096	ZYG11B	0.63	15.2	0.52	8.74e-45	Monocyte count;
BRCA	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg25838465	chr1:92012736	NA	-0.64	-19.04	-0.6	2.27e-64	Breast cancer;
BRCA	cis	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg06521331	chr12:34319734	NA	-0.62	-12.24	-0.44	4.36e-31	Morning vs. evening chronotype;
BRCA	cis	rs4660306	0.961	rs3748643	chr1:45965703	G/T	cg24296786	chr1:45957014	TESK2	0.42	8.42	0.32	2.52e-16	Homocysteine levels;
BRCA	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	13.18	0.46	3.04e-35	Bone mineral density;
BRCA	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-8.72	-0.33	2.47e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08704250	chr15:31115839	NA	-0.36	-8.89	-0.33	6.4e-18	Huntington's disease progression;
BRCA	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg25554036	chr4:6271136	WFS1	0.41	9.72	0.36	6.5e-21	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7567389	0.740	rs1604817	chr2:127999921	C/T	cg09760422	chr2:128146352	NA	-0.41	-8.76	-0.33	1.78e-17	Self-rated health;
BRCA	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg21132104	chr15:45694354	SPATA5L1	0.62	12.26	0.44	3.56e-31	Homoarginine levels;
BRCA	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	8.87	0.33	7.48e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18876405	chr7:65276391	NA	0.59	14.59	0.5	7.67e-42	Aortic root size;
BRCA	cis	rs2836633	1.000	rs11088437	chr21:40053372	A/G	cg05519781	chr21:40033154	ERG	0.41	8.42	0.32	2.55e-16	Coronary artery disease;
BRCA	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.43	-0.32	2.23e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.67e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg26384229	chr12:38710491	ALG10B	0.66	13.86	0.48	2.1e-38	Morning vs. evening chronotype;
BRCA	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg23029597	chr12:123009494	RSRC2	-0.47	-9.63	-0.36	1.34e-20	Body mass index;
BRCA	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg18252515	chr7:66147081	NA	0.9	12.95	0.46	3.18e-34	Diabetic kidney disease;
BRCA	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg06064525	chr11:970664	AP2A2	-0.3	-8.9	-0.33	5.84e-18	Alzheimer's disease (late onset);
BRCA	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg20290983	chr6:43655470	MRPS18A	1.11	40.51	0.85	1.2e-178	IgG glycosylation;
BRCA	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg17845761	chr1:175162550	KIAA0040	0.26	9.92	0.37	1.17e-21	Alcohol dependence;
BRCA	cis	rs7011049	1.000	rs78200075	chr8:53845907	G/A	cg26025543	chr8:53854495	NA	0.53	9.06	0.34	1.59e-18	Systolic blood pressure;
BRCA	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11890956	chr21:40555474	PSMG1	1.01	24.77	0.7	1.94e-95	Cognitive function;
BRCA	cis	rs4722404	0.502	rs13234017	chr7:3110587	C/A	cg19214707	chr7:3157722	NA	-0.37	-7.84	-0.3	1.89e-14	Atopic dermatitis;
BRCA	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg13010199	chr12:38710504	ALG10B	-0.41	-9.6	-0.35	1.85e-20	Heart rate;
BRCA	cis	rs7011049	0.673	rs72640836	chr8:53828023	G/T	cg26025543	chr8:53854495	NA	0.43	7.85	0.3	1.8e-14	Systolic blood pressure;
BRCA	cis	rs61990749	0.544	rs12435761	chr14:78246077	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.57	9.27	0.34	2.92e-19	Fibroblast growth factor basic levels;
BRCA	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg26384229	chr12:38710491	ALG10B	0.7	15.94	0.53	1.97e-48	Bladder cancer;
BRCA	cis	rs56804039	1.000	rs11780966	chr8:8383396	T/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-8.78	-0.33	1.47e-17	Cervical cancer;
BRCA	cis	rs1577917	1.000	rs4706254	chr6:86602813	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-11.02	-0.4	5.9e-26	Response to antipsychotic treatment;
BRCA	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg27446573	chr6:127587934	RNF146	0.89	20.34	0.63	2.6e-71	Breast cancer;
BRCA	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg19052272	chr2:3704530	ALLC	0.44	9.43	0.35	7.36e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg24812749	chr6:127587940	RNF146	0.66	14.74	0.5	1.56e-42	Breast cancer;
BRCA	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg14675211	chr2:100938903	LONRF2	0.52	11.65	0.42	1.37e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg09307838	chr4:120376055	NA	0.63	13.63	0.47	2.45e-37	Corneal astigmatism;
BRCA	cis	rs36051895	0.695	rs62541534	chr9:5028921	C/G	cg02405213	chr9:5042618	JAK2	-0.51	-9.05	-0.34	1.74e-18	Pediatric autoimmune diseases;
BRCA	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg18402987	chr7:1209562	NA	0.84	12.05	0.43	2.8e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg14863265	chr7:2801509	GNA12	-0.42	-9.03	-0.34	1.93e-18	Height;
BRCA	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.7	-20.51	-0.63	3.32e-72	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12292205	chr6:26970375	C6orf41	-0.62	-10.66	-0.39	1.63e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs9462027	0.606	rs7756009	chr6:34715395	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.96	-0.3	8.03e-15	Systemic lupus erythematosus;
BRCA	trans	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.74	0.67	2.6e-84	Chronic sinus infection;
BRCA	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg24011408	chr12:48396354	COL2A1	-0.44	-9.85	-0.36	2.05e-21	Plateletcrit;
BRCA	cis	rs9462027	0.606	rs7759227	chr6:34728230	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.01	-0.3	5.4e-15	Systemic lupus erythematosus;
BRCA	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.4	-8.58	-0.32	7.43e-17	Alzheimer's disease (late onset);
BRCA	cis	rs738322	0.600	rs4821751	chr22:38564457	T/C	cg25457927	chr22:38595422	NA	-0.35	-12.97	-0.46	2.48e-34	Cutaneous nevi;
BRCA	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg14019695	chr9:139328340	INPP5E	0.39	8.32	0.31	5.16e-16	White blood cell count;
BRCA	cis	rs6138458	1.000	rs227629	chr20:24913551	G/T	cg06937882	chr20:24974362	C20orf3	-0.44	-8.41	-0.32	2.76e-16	Blood protein levels;
BRCA	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.35	0.38	2.48e-23	Motion sickness;
BRCA	trans	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg25214090	chr10:38739885	LOC399744	-0.46	-9.84	-0.36	2.35e-21	Corneal astigmatism;
BRCA	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs929596	0.785	rs11695484	chr2:234654449	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-12.06	-0.43	2.45e-30	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg07636037	chr3:49044803	WDR6	-0.81	-21.08	-0.64	2.61e-75	Menarche (age at onset);
BRCA	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg19784903	chr17:45786737	TBKBP1	-0.35	-8.43	-0.32	2.31e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs586533	0.846	rs602800	chr11:99499947	A/T	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4363385	0.693	rs76987906	chr1:152964530	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.07	-0.34	1.44e-18	Inflammatory skin disease;
BRCA	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg19622623	chr12:86230825	RASSF9	-0.32	-8.68	-0.32	3.37e-17	Major depressive disorder;
BRCA	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-13.66	-0.48	1.81e-37	Morning vs. evening chronotype;
BRCA	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-14.61	-0.5	6.32e-42	Coronary artery disease;
BRCA	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.72	-0.42	7.09e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg13047869	chr3:10149882	C3orf24	0.55	10.3	0.38	4.02e-23	Alzheimer's disease;
BRCA	cis	rs1691799	0.899	rs1168308	chr12:66742183	A/G	cg16791601	chr12:66731901	HELB	-0.65	-17.6	-0.57	7.75e-57	White blood cell count (basophil);
BRCA	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.48e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9649465	0.967	rs10487806	chr7:123314446	C/T	cg04330084	chr7:123175371	IQUB	0.31	8.33	0.31	4.93e-16	Migraine;
BRCA	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.64	0.55	6.78e-52	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg26384229	chr12:38710491	ALG10B	0.52	13.6	0.47	3.6e-37	Morning vs. evening chronotype;
BRCA	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	8.42	0.32	2.5e-16	Rheumatoid arthritis;
BRCA	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11890956	chr21:40555474	PSMG1	-0.63	-14.12	-0.49	1.33e-39	Menarche (age at onset);
BRCA	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg05347473	chr6:146136440	FBXO30	-0.42	-8.19	-0.31	1.39e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg14004847	chr7:1930337	MAD1L1	-0.47	-8.87	-0.33	7.53e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs6545883	0.894	rs6739427	chr2:61452879	T/C	cg15711740	chr2:61764176	XPO1	0.51	13.01	0.46	1.71e-34	Tuberculosis;
BRCA	cis	rs6740322	0.748	rs6544636	chr2:43487486	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.8	-15.38	-0.52	1.18e-45	Coronary artery disease;
BRCA	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg26384229	chr12:38710491	ALG10B	0.76	17.07	0.56	4.41e-54	Morning vs. evening chronotype;
BRCA	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg11941060	chr3:133502564	NA	-0.47	-11.47	-0.41	8.18e-28	Iron status biomarkers;
BRCA	cis	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05901451	chr6:126070800	HEY2	-0.42	-10.1	-0.37	2.39e-22	Endometrial cancer;
BRCA	cis	rs8017423	0.647	rs1958345	chr14:90823770	T/C	cg04374321	chr14:90722782	PSMC1	-0.49	-11.86	-0.42	1.75e-29	Mortality in heart failure;
BRCA	cis	rs4891159	0.790	rs17059325	chr18:74119567	A/C	cg24786174	chr18:74118243	ZNF516	-0.73	-17.79	-0.58	8.28e-58	Longevity;
BRCA	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg23649088	chr2:200775458	C2orf69	-0.39	-8.37	-0.31	3.65e-16	QT interval;
BRCA	trans	rs1941687	0.563	rs1565784	chr18:31358491	G/T	cg27147174	chr7:100797783	AP1S1	0.39	7.93	0.3	9.56e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.75	-0.5	1.31e-42	Total cholesterol levels;
BRCA	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg05552183	chr6:42928497	GNMT	0.8	19.33	0.61	6.54e-66	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.29	0.31	6.59e-16	Aortic root size;
BRCA	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg11663144	chr21:46675770	NA	-0.61	-14.31	-0.49	1.63e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg18154014	chr19:37997991	ZNF793	0.62	11.64	0.42	1.49e-28	Coronary artery calcification;
BRCA	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg20701182	chr2:24300061	SF3B14	0.66	9.66	0.36	1.04e-20	Lymphocyte counts;
BRCA	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg19539972	chr4:7069911	GRPEL1	0.69	16.87	0.56	4.3e-53	Monocyte percentage of white cells;
BRCA	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.55	8.47	0.32	1.64e-16	Platelet count;
BRCA	trans	rs1459104	0.925	rs35535067	chr11:54995548	G/T	cg15704280	chr7:45808275	SEPT13	0.59	7.81	0.3	2.27e-14	Body mass index;
BRCA	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg05283184	chr6:79620031	NA	-0.43	-11.04	-0.4	4.58e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.22	-0.37	8.46e-23	Psoriasis;
BRCA	trans	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.13	0.31	2.2e-15	Corneal astigmatism;
BRCA	cis	rs752010	0.967	rs752011	chr1:42092929	C/T	cg06885757	chr1:42089581	HIVEP3	0.27	9.5	0.35	4.05e-20	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg13319975	chr6:146136371	FBXO30	-0.61	-13.71	-0.48	1.09e-37	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg16362232	chr11:430036	ANO9	0.5	8.03	0.3	4.82e-15	Body mass index;
BRCA	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-9.55	-0.35	2.75e-20	Bone mineral density;
BRCA	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	14.22	0.49	4.48e-40	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg05665937	chr4:1216051	CTBP1	-0.43	-8.59	-0.32	6.41e-17	Obesity-related traits;
BRCA	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg03146154	chr1:46216737	IPP	0.5	10.59	0.39	2.87e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-9.52	-0.35	3.58e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg17420585	chr12:42539391	GXYLT1	-0.41	-8.54	-0.32	9.52e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.59	0.39	3.01e-24	Motion sickness;
BRCA	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.3	-0.31	6.27e-16	Total body bone mineral density;
BRCA	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg04450456	chr4:17643702	FAM184B	0.41	12.33	0.44	1.67e-31	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg21724239	chr8:58056113	NA	0.59	9.54	0.35	2.88e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs9462846	0.881	rs34498470	chr6:42879551	C/T	cg02353165	chr6:42928485	GNMT	0.5	9.17	0.34	6.2800000000000005e-19	Blood protein levels;
BRCA	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg05025164	chr4:1340916	KIAA1530	0.39	8.66	0.32	3.81e-17	Longevity;
BRCA	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg18402987	chr7:1209562	NA	0.61	12.76	0.45	2.24e-33	Longevity;Endometriosis;
BRCA	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg13047869	chr3:10149882	C3orf24	0.55	10.19	0.37	1.03e-22	Alzheimer's disease;
BRCA	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.07e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg24642439	chr20:33292090	TP53INP2	0.71	16.27	0.54	4.9e-50	Coronary artery disease;
BRCA	cis	rs867371	1.000	rs8041924	chr15:82473661	A/T	cg00614314	chr15:82944287	LOC80154	0.43	9.09	0.34	1.19e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg04518342	chr5:131593106	PDLIM4	-0.43	-10.86	-0.39	2.46e-25	Acylcarnitine levels;
BRCA	cis	rs877282	0.891	rs12357999	chr10:796468	A/C	cg17470449	chr10:769945	NA	0.51	8.71	0.33	2.54e-17	Uric acid levels;
BRCA	trans	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg25214090	chr10:38739885	LOC399744	0.52	11.94	0.43	8.18e-30	Corneal astigmatism;
BRCA	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg08999081	chr20:33150536	PIGU	-0.33	-8.54	-0.32	9.89e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs9811920	0.535	rs704574	chr3:99483773	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.41	9.67	0.36	1e-20	Axial length;
BRCA	cis	rs1568889	0.838	rs3812738	chr11:28129982	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	20.7	0.63	3.05e-73	Bipolar disorder;
BRCA	cis	rs9649465	0.967	rs13244694	chr7:123329879	T/C	cg04330084	chr7:123175371	IQUB	-0.31	-8.39	-0.32	3.01e-16	Migraine;
BRCA	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-16.08	-0.54	4.3e-49	Intelligence (multi-trait analysis);
BRCA	cis	rs12474201	0.928	rs13429704	chr2:46960329	G/T	cg06386533	chr2:46925753	SOCS5	0.75	16.45	0.55	6.13e-51	Height;
BRCA	cis	rs2637030	0.559	rs31303	chr5:52942197	C/T	cg06476337	chr5:52856530	NDUFS4	-0.37	-8.55	-0.32	9.11e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.8	0.33	1.28e-17	Iron status biomarkers;
BRCA	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg22117172	chr7:91764530	CYP51A1	0.24	7.99	0.3	6.32e-15	Breast cancer;
BRCA	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg08975724	chr8:8085496	FLJ10661	0.43	8.5	0.32	1.38e-16	Retinal vascular caliber;
BRCA	cis	rs4363385	0.655	rs11205163	chr1:152983677	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-8.98	-0.33	3.08e-18	Inflammatory skin disease;
BRCA	cis	rs175714	0.845	rs175702	chr14:75971133	G/T	cg01624173	chr14:75981868	NA	-0.34	-9.26	-0.34	3.02e-19	Lymphocyte counts;
BRCA	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Colorectal cancer;
BRCA	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg05552183	chr6:42928497	GNMT	-0.52	-11.78	-0.42	4.02e-29	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg17135325	chr3:160939158	NMD3	0.42	7.97	0.3	7.24e-15	Parkinson's disease;
BRCA	cis	rs2625529	0.824	rs7172309	chr15:72384483	C/T	cg16672083	chr15:72433130	SENP8	-0.84	-17.46	-0.57	4.05e-56	Red blood cell count;
BRCA	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03517284	chr6:25882590	NA	-0.54	-10.98	-0.4	8.43e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg21475434	chr5:93447410	FAM172A	0.67	8.72	0.33	2.48e-17	Diabetic retinopathy;
BRCA	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg05347473	chr6:146136440	FBXO30	-0.43	-8.53	-0.32	1.09e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg13114125	chr14:105738426	BRF1	-0.49	-10.27	-0.38	5.04e-23	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg14675211	chr2:100938903	LONRF2	0.52	11.7	0.42	8.61e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs16854884	0.609	rs9872126	chr3:143683851	G/A	cg06585982	chr3:143692056	C3orf58	0.49	10.55	0.39	4.44e-24	Economic and political preferences (feminism/equality);
BRCA	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06108461	chr20:60628389	TAF4	-0.99	-22.15	-0.66	4.18e-81	Body mass index;
BRCA	cis	rs311392	0.554	rs311387	chr8:55101623	A/G	cg11783602	chr8:55087084	NA	0.28	8.04	0.3	4.44e-15	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.58	-0.42	2.83e-28	Mean corpuscular volume;
BRCA	cis	rs701145	0.585	rs1713810	chr3:153876826	C/T	cg17054900	chr3:154042577	DHX36	-0.44	-8.28	-0.31	7.39e-16	Coronary artery disease;
BRCA	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg19847866	chr10:1019161	NA	0.42	9.23	0.34	3.91e-19	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg09184832	chr6:79620586	NA	-0.5	-10.89	-0.4	1.9e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs3739998	0.686	rs2505084	chr10:30335520	C/T	cg12786570	chr10:30316432	KIAA1462	-0.37	-8.32	-0.31	5.48e-16	Coronary heart disease;
BRCA	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	21.16	0.64	9.69e-76	Lymphocyte percentage of white cells;
BRCA	cis	rs1018836	0.923	rs34126139	chr8:91572045	T/G	cg16814680	chr8:91681699	NA	-0.59	-12.56	-0.44	1.77e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18110333	chr6:292329	DUSP22	0.59	12.52	0.44	2.63e-32	Menopause (age at onset);
BRCA	cis	rs6546550	0.901	rs6725425	chr2:70150674	T/C	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.47	-0.41	7.84e-28	Prevalent atrial fibrillation;
BRCA	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.72	0.39	9.23e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg26384229	chr12:38710491	ALG10B	0.76	17.17	0.56	1.31e-54	Bladder cancer;
BRCA	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg04691961	chr3:161091175	C3orf57	-0.59	-14.04	-0.49	3.32e-39	Morning vs. evening chronotype;
BRCA	cis	rs1593	0.641	rs28690003	chr4:187224562	G/A	cg14349977	chr4:187219430	NA	0.64	11.05	0.4	4.41e-26	Activated partial thromboplastin time;
BRCA	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg09184832	chr6:79620586	NA	-0.51	-11.17	-0.4	1.43e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03352830	chr11:487213	PTDSS2	0.87	13.62	0.47	2.74e-37	Body mass index;
BRCA	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.46	-0.61	1.35e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2070997	0.607	rs7856783	chr9:133713507	T/C	cg11464064	chr9:133710261	ABL1	0.55	10.12	0.37	2e-22	Response to amphetamines;
BRCA	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.9	0.43	1.19e-29	Homoarginine levels;
BRCA	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-10.97	-0.4	9.11e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.33	9.06	0.34	1.56e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg03060546	chr3:49711283	APEH	-0.53	-10.62	-0.39	2.21e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11764359	chr7:65958608	NA	0.8	19.37	0.61	4.34e-66	Aortic root size;
BRCA	cis	rs113835537	0.529	rs17496250	chr11:66270774	C/G	cg24851651	chr11:66362959	CCS	0.51	8.83	0.33	9.85e-18	Airway imaging phenotypes;
BRCA	cis	rs6763687	0.893	rs12633493	chr3:171778354	C/T	cg16233210	chr3:171778391	FNDC3B	0.5	12.04	0.43	3.18e-30	Red cell distribution width;
BRCA	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg16325326	chr1:53192061	ZYG11B	-0.57	-12.02	-0.43	3.81e-30	Monocyte count;
BRCA	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-13.15	-0.46	3.89e-35	Migraine;Coronary artery disease;
BRCA	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-11.19	-0.4	1.11e-26	Colorectal cancer;
BRCA	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg24977027	chr2:88469347	THNSL2	0.56	9.54	0.35	3.01e-20	Plasma clusterin levels;
BRCA	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg13770153	chr20:60521292	NA	-0.44	-10.72	-0.39	9.44e-25	Body mass index;
BRCA	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26314531	chr2:26401878	FAM59B	0.75	10.57	0.39	3.45e-24	Gut microbiome composition (summer);
BRCA	cis	rs965469	0.817	rs6037582	chr20:3351696	C/T	cg25506879	chr20:3388711	C20orf194	-0.44	-8.86	-0.33	7.9e-18	IFN-related cytopenia;
BRCA	cis	rs4363385	0.740	rs4845518	chr1:153003903	A/G	cg24667326	chr1:152973720	SPRR3	-0.31	-8.36	-0.31	3.86e-16	Inflammatory skin disease;
BRCA	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg23422044	chr7:1970798	MAD1L1	-0.56	-9.55	-0.35	2.7e-20	Neuroticism;
BRCA	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg14558114	chr2:88469736	THNSL2	-0.59	-8.39	-0.31	3.17e-16	Plasma clusterin levels;
BRCA	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg01475735	chr3:40494733	NA	-0.47	-9.68	-0.36	8.79e-21	Renal cell carcinoma;
BRCA	cis	rs1044826	0.518	rs295488	chr3:139239323	C/T	cg15131784	chr3:139108705	COPB2	0.36	8.99	0.34	2.68e-18	Obesity-related traits;
BRCA	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg06484146	chr7:12443880	VWDE	-0.64	-9.95	-0.37	8.95e-22	Coronary artery disease;
BRCA	cis	rs56399783	0.901	rs757788	chr7:2836433	A/G	cg19731401	chr7:2775893	GNA12	0.49	8.14	0.31	2.1e-15	Childhood ear infection;
BRCA	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg14863265	chr7:2801509	GNA12	-0.43	-9.8	-0.36	3.25e-21	Height;
BRCA	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.24	0.49	3.5e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg22875332	chr1:76189707	ACADM	0.66	15.64	0.53	6.25e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	14.7	0.5	2.41e-42	Motion sickness;
BRCA	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg09307838	chr4:120376055	NA	0.64	13.93	0.48	1.02e-38	Corneal astigmatism;
BRCA	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg26874164	chr19:58962979	ZNF324B	0.44	9.39	0.35	1.08e-19	Uric acid clearance;
BRCA	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg26597838	chr10:835615	NA	0.97	17.04	0.56	6.2e-54	Eosinophil percentage of granulocytes;
BRCA	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg18131467	chr2:239335373	ASB1	-0.8	-15.79	-0.53	1.17e-47	Multiple system atrophy;
BRCA	cis	rs7172677	0.737	rs12442410	chr15:75437510	G/A	cg14664628	chr15:75095509	CSK	-0.39	-8.05	-0.3	3.93e-15	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg04518342	chr5:131593106	PDLIM4	0.37	9.26	0.34	2.98e-19	Breast cancer;
BRCA	cis	rs7172677	0.737	rs12442410	chr15:75437510	G/A	cg10253484	chr15:75165896	SCAMP2	-0.45	-8.31	-0.31	5.6e-16	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-13.15	-0.46	4.08e-35	Lymphocyte counts;
BRCA	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.94	0.4	1.2e-25	Rheumatoid arthritis;
BRCA	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg14820908	chr5:178986412	RUFY1	0.36	9.01	0.34	2.36e-18	Lung cancer;
BRCA	cis	rs7851660	0.967	rs3758248	chr9:100614601	G/A	cg13688889	chr9:100608707	NA	-0.36	-8.72	-0.33	2.42e-17	Strep throat;
BRCA	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg04317338	chr11:64019027	PLCB3	0.54	9.41	0.35	8.75e-20	Mean platelet volume;
BRCA	cis	rs870825	0.616	rs7660064	chr4:185617529	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.18e-56	Blood protein levels;
BRCA	cis	rs2637266	0.935	rs2583055	chr10:78400029	C/T	cg18941641	chr10:78392320	NA	0.36	8.27	0.31	7.61e-16	Pulmonary function;
BRCA	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg08601574	chr20:25228251	PYGB	0.4	9.61	0.36	1.62e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg00677455	chr12:58241039	CTDSP2	-0.35	-7.89	-0.3	1.34e-14	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg03060546	chr3:49711283	APEH	-0.57	-8.51	-0.32	1.25e-16	Menarche (age at onset);
BRCA	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg18753928	chr3:113234510	CCDC52	-0.5	-9.42	-0.35	8.42e-20	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs10504073	0.584	rs4873092	chr8:49974053	T/C	cg00325661	chr8:49890786	NA	0.44	12.86	0.45	8.36e-34	Blood metabolite ratios;
BRCA	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11890956	chr21:40555474	PSMG1	1.04	29.21	0.76	9.04e-120	Cognitive function;
BRCA	cis	rs13190036	0.551	rs7710269	chr5:176614529	G/A	cg06733329	chr5:176740039	MXD3	0.37	8.02	0.3	5.22e-15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs9296092	0.538	rs78061112	chr6:33526587	T/G	cg13560919	chr6:33536144	NA	-0.85	-18.69	-0.59	1.6e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	11.91	0.43	1.13e-29	Height;
BRCA	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	11.65	0.42	1.47e-28	Mean platelet volume;
BRCA	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08219700	chr8:58056026	NA	0.44	7.94	0.3	8.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg21798802	chr22:38057573	PDXP	0.3	8.39	0.31	3.13e-16	Fat distribution (HIV);
BRCA	cis	rs57590327	0.555	rs3755713	chr3:81811224	A/G	cg07356753	chr3:81810745	GBE1	-0.46	-10.61	-0.39	2.42e-24	Extraversion;
BRCA	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg06092702	chr1:163392909	NA	0.33	8.8	0.33	1.27e-17	Motion sickness;
BRCA	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg07384165	chr1:10488281	NA	0.4	8.51	0.32	1.2e-16	Prostate cancer;
BRCA	trans	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg18876405	chr7:65276391	NA	0.44	8.51	0.32	1.19e-16	Corneal structure;
BRCA	cis	rs1568889	1.000	rs12804198	chr11:28143114	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	13.49	0.47	1.18e-36	Bipolar disorder;
BRCA	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.38	-9.24	-0.34	3.63e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4363385	0.818	rs368912	chr1:153016204	C/G	cg24667326	chr1:152973720	SPRR3	-0.32	-8.83	-0.33	1.04e-17	Inflammatory skin disease;
BRCA	cis	rs72792276	1.000	rs72794361	chr5:127435188	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	10.68	0.39	1.35e-24	Red cell distribution width;
BRCA	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.74	0.36	5.53e-21	Morning vs. evening chronotype;
BRCA	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg03433033	chr1:76189801	ACADM	0.88	23.77	0.68	5.96e-90	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg21132104	chr15:45694354	SPATA5L1	0.72	16.11	0.54	3.11e-49	Homoarginine levels;
BRCA	cis	rs7246657	0.722	rs2909102	chr19:38167364	C/T	cg23950597	chr19:37808831	NA	0.51	8.7	0.33	2.71e-17	Coronary artery calcification;
BRCA	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg14926445	chr8:58193284	C8orf71	-0.46	-8.73	-0.33	2.2e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg25042112	chr7:64838748	ZNF92	-0.45	-8.52	-0.32	1.18e-16	Pain;
BRCA	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg12573674	chr2:1569213	NA	-0.49	-9.34	-0.35	1.58e-19	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg08132940	chr7:1081526	C7orf50	-0.46	-8.33	-0.31	5e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg17330251	chr7:94953956	PON1	-0.42	-8.58	-0.32	7.32e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg25214090	chr10:38739885	LOC399744	0.53	10.87	0.4	2.23e-25	Corneal astigmatism;
BRCA	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg05340658	chr4:99064831	C4orf37	0.69	17.33	0.57	1.83e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.54	11.44	0.41	1.03e-27	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	1.01e-40	Motion sickness;
BRCA	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg22974920	chr21:40686053	BRWD1	-0.4	-8.95	-0.33	3.84e-18	Cognitive function;
BRCA	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.52	-0.32	1.17e-16	Monocyte percentage of white cells;
BRCA	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg23285459	chr7:2802560	GNA12	-0.32	-8.34	-0.31	4.68e-16	Height;
BRCA	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11764359	chr7:65958608	NA	0.74	16.57	0.55	1.44e-51	Aortic root size;
BRCA	trans	rs10880689	1	rs10880689	chr12:37930102	A/G	cg06521331	chr12:34319734	NA	-0.54	-10.29	-0.38	4.42e-23	Resting heart rate;
BRCA	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg23029597	chr12:123009494	RSRC2	-0.61	-11.81	-0.42	3e-29	Body mass index;
BRCA	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg00530320	chr1:46809349	NSUN4	-0.48	-9.68	-0.36	9.08e-21	Menopause (age at onset);
BRCA	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg01448562	chr3:133502909	NA	-0.39	-8.93	-0.33	4.53e-18	Iron status biomarkers;
BRCA	cis	rs11955398	0.585	rs1816861	chr5:60011676	T/A	cg02684056	chr5:59996105	DEPDC1B	-0.37	-9.04	-0.34	1.9e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7178424	0.935	rs17271438	chr15:62381065	C/A	cg00456672	chr15:62358751	C2CD4A	-0.34	-8.05	-0.3	4.14e-15	Height;
BRCA	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03517284	chr6:25882590	NA	-0.5	-11.34	-0.41	2.87e-27	Blood metabolite levels;
BRCA	cis	rs290268	0.669	rs10448310	chr9:93556174	A/G	cg02608019	chr9:93564028	SYK	0.49	10.99	0.4	7.69e-26	Platelet count;
BRCA	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.75	15.47	0.52	4.41e-46	Smoking behavior;
BRCA	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg03188948	chr7:1209495	NA	0.45	8.39	0.31	3.17e-16	Longevity;Endometriosis;
BRCA	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg04553112	chr3:125709451	NA	-0.56	-8.5	-0.32	1.34e-16	Blood pressure (smoking interaction);
BRCA	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.51	0.55	2.99e-51	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-10.11	-0.37	2.17e-22	Gut microbiome composition (summer);
BRCA	cis	rs2731664	0.792	rs335435	chr5:176867943	A/G	cg23176889	chr5:176863531	GRK6	-0.61	-16.35	-0.54	1.95e-50	Intelligence (multi-trait analysis);
BRCA	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg07636037	chr3:49044803	WDR6	0.51	8.57	0.32	7.96e-17	Menarche (age at onset);
BRCA	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg11502198	chr6:26597334	ABT1	0.56	12.0	0.43	4.5e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs4891159	0.790	rs1787448	chr18:74113179	T/C	cg24786174	chr18:74118243	ZNF516	0.74	18.65	0.59	2.67e-62	Longevity;
BRCA	cis	rs3772130	0.962	rs1318472	chr3:121556899	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.72	0.39	8.89e-25	Cognitive performance;
BRCA	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg16339924	chr4:17578868	LAP3	0.66	16.9	0.56	3.1e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15541040	chr2:3486749	NA	-0.42	-8.88	-0.33	6.58e-18	Neurofibrillary tangles;
BRCA	cis	rs7833986	1.000	rs34037954	chr8:57096841	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.46	8.19	0.31	1.46e-15	Height;
BRCA	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg17366294	chr4:99064904	C4orf37	0.53	11.6	0.42	2.24e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg09455208	chr3:40491958	NA	0.47	11.63	0.42	1.73e-28	Renal cell carcinoma;
BRCA	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg24450063	chr1:156163899	SLC25A44	1.11	35.2	0.81	9.83e-152	Testicular germ cell tumor;
BRCA	cis	rs3125734	0.633	rs1368157	chr10:64001114	T/C	cg19640130	chr10:64028056	RTKN2	-0.31	-8.68	-0.32	3.26e-17	Rheumatoid arthritis;
BRCA	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg26384229	chr12:38710491	ALG10B	0.78	18.29	0.59	2.17e-60	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg12573674	chr2:1569213	NA	0.47	9.1	0.34	1.14e-18	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg07148914	chr20:33460835	GGT7	0.38	8.62	0.32	5.1e-17	Height;
BRCA	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg14983838	chr19:29218262	NA	0.54	10.08	0.37	2.78e-22	Methadone dose in opioid dependence;
BRCA	cis	rs13190036	1.000	rs34446750	chr5:176595080	A/G	cg06733329	chr5:176740039	MXD3	0.46	8.3	0.31	6.01e-16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg01420254	chr6:26195488	NA	0.53	8.54	0.32	9.95e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs1371614	0.592	rs12613534	chr2:27138594	C/A	cg12368169	chr2:27073192	DPYSL5	-0.29	-8.74	-0.33	2.03e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg10876282	chr6:28092338	ZSCAN16	0.4	7.84	0.3	1.9e-14	Cardiac Troponin-T levels;
BRCA	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg23029597	chr12:123009494	RSRC2	-0.48	-9.57	-0.35	2.28e-20	Body mass index;
BRCA	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.65	-0.32	4.25e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg11789530	chr4:8429930	ACOX3	-0.68	-17.62	-0.57	6.51e-57	Response to antineoplastic agents;
BRCA	cis	rs11231017	0.507	rs2178260	chr11:62069365	C/T	cg23876832	chr11:62092739	NA	0.33	8.44	0.32	2.19e-16	HIV-1 viral setpoint;
BRCA	cis	rs2625529	0.652	rs2957736	chr15:72265344	A/G	cg16672083	chr15:72433130	SENP8	0.68	16.19	0.54	1.2e-49	Red blood cell count;
BRCA	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-10.42	-0.38	1.4e-23	Personality dimensions;
BRCA	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg18904891	chr8:8559673	CLDN23	0.61	12.07	0.43	2.36e-30	Obesity-related traits;
BRCA	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg25019033	chr10:957182	NA	-0.42	-8.05	-0.3	4.04e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg00540400	chr15:79124168	NA	-0.28	-7.88	-0.3	1.39e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs12347191	0.500	rs925486	chr9:100619733	C/T	cg13688889	chr9:100608707	NA	-0.49	-9.92	-0.37	1.19e-21	Orofacial clefts;
BRCA	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.77	-0.36	4.17e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs858239	0.932	rs199355	chr7:23296533	C/T	cg23682824	chr7:23144976	KLHL7	0.32	8.25	0.31	8.72e-16	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.56	0.39	3.82e-24	Mean corpuscular volume;
BRCA	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.58	11.16	0.4	1.52e-26	HDL cholesterol;
BRCA	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg21775007	chr8:11205619	TDH	0.62	11.99	0.43	5.15e-30	Retinal vascular caliber;
BRCA	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.52	-11.59	-0.42	2.51e-28	Personality dimensions;
BRCA	cis	rs6496044	0.526	rs4291869	chr15:86054523	G/A	cg10818794	chr15:86012489	AKAP13	-0.32	-8.69	-0.33	3.05e-17	Interstitial lung disease;
BRCA	cis	rs9463078	0.753	rs1980265	chr6:44928868	C/A	cg25276700	chr6:44698697	NA	-0.37	-8.56	-0.32	8.58e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs7737355	0.947	rs3776028	chr5:130789750	G/A	cg06307176	chr5:131281290	NA	-0.53	-10.58	-0.39	3.37e-24	Life satisfaction;
BRCA	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.22	0.37	8.56e-23	Calcium levels;
BRCA	cis	rs7903847	0.620	rs11189168	chr10:99125769	T/C	cg20016023	chr10:99160130	RRP12	-0.26	-8.26	-0.31	8.57e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg05343316	chr1:45956843	TESK2	0.62	12.58	0.45	1.39e-32	Platelet count;
BRCA	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.66	-0.61	1.19e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-9.67	-0.36	9.89e-21	Total body bone mineral density;
BRCA	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	12.97	0.46	2.61e-34	Migraine;Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg25319279	chr11:5960081	NA	-0.4	-7.9	-0.3	1.24e-14	DNA methylation (variation);
BRCA	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg11663144	chr21:46675770	NA	-0.6	-13.84	-0.48	2.6e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg00105475	chr2:10696890	NA	0.44	10.41	0.38	1.56e-23	Prostate cancer;
BRCA	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.65	-9.79	-0.36	3.38e-21	Schizophrenia;
BRCA	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg27490568	chr2:178487706	NA	0.42	7.85	0.3	1.74e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs1788820	0.917	rs4800489	chr18:21125942	A/G	cg14672496	chr18:21087552	C18orf8	0.34	8.34	0.31	4.72e-16	Body mass index;
BRCA	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg01262667	chr19:19385393	TM6SF2	0.38	7.98	0.3	6.56e-15	Nonalcoholic fatty liver disease;
BRCA	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg11663144	chr21:46675770	NA	-0.62	-14.32	-0.49	1.53e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs870825	0.655	rs28726376	chr4:185638954	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	17.27	0.56	3.85e-55	Blood protein levels;
BRCA	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg22963979	chr7:1858916	MAD1L1	-0.37	-7.82	-0.3	2.23e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.55	8.16	0.31	1.79e-15	Platelet count;
BRCA	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg17063962	chr7:91808500	NA	-0.55	-12.65	-0.45	6.88e-33	Breast cancer;
BRCA	cis	rs6546550	0.869	rs6720498	chr2:70124805	T/C	cg02498382	chr2:70120550	SNRNP27	-0.54	-11.63	-0.42	1.76e-28	Prevalent atrial fibrillation;
BRCA	cis	rs68170813	0.559	rs78610616	chr7:106951369	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.52	-0.32	1.16e-16	Coronary artery disease;
BRCA	cis	rs2249625	0.523	rs2463702	chr6:72853778	A/G	cg18830697	chr6:72922368	RIMS1	0.5	11.29	0.41	4.52e-27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24549020	chr5:56110836	MAP3K1	0.64	12.87	0.45	7.13e-34	Initial pursuit acceleration;
BRCA	cis	rs3857536	0.740	rs6455080	chr6:66887413	T/A	cg07460842	chr6:66804631	NA	-0.48	-9.27	-0.34	2.78e-19	Blood trace element (Cu levels);
BRCA	cis	rs11677370	0.561	rs12986995	chr2:3826965	G/A	cg17052675	chr2:3827356	NA	-0.6	-15.32	-0.52	2.33e-45	Type 2 diabetes;
BRCA	cis	rs11229555	0.645	rs56228632	chr11:58187444	A/G	cg15696309	chr11:58395628	NA	-0.45	-9.71	-0.36	7.05e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.45	-8.44	-0.32	2.15e-16	Menarche (age at onset);
BRCA	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00149659	chr3:10157352	C3orf10	0.77	13.29	0.47	9.06e-36	Alzheimer's disease;
BRCA	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg05791153	chr7:19748676	TWISTNB	0.58	10.55	0.39	4.25e-24	Thyroid stimulating hormone;
BRCA	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg05472934	chr7:22766657	IL6	0.59	15.1	0.51	2.92e-44	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
BRCA	cis	rs16854884	0.657	rs12107291	chr3:143739547	T/C	cg06585982	chr3:143692056	C3orf58	0.42	8.93	0.33	4.41e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg16576597	chr16:28551801	NUPR1	0.33	9.2	0.34	4.87e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.05	-0.37	3.72e-22	IgG glycosylation;
BRCA	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.49	8.62	0.32	5.17e-17	Mean platelet volume;
BRCA	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg23788917	chr6:8435910	SLC35B3	0.49	10.69	0.39	1.17e-24	Motion sickness;
BRCA	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.36	8.03	0.3	4.73e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs3768617	0.811	rs4350171	chr1:182982148	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.81	0.36	2.84e-21	Fuchs's corneal dystrophy;
BRCA	cis	rs6546550	0.935	rs1377995	chr2:70064155	C/G	cg02498382	chr2:70120550	SNRNP27	-0.5	-10.48	-0.38	7.82e-24	Prevalent atrial fibrillation;
BRCA	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg07884673	chr3:53033167	SFMBT1	0.86	9.98	0.37	6.83e-22	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg16414030	chr3:133502952	NA	-0.47	-11.11	-0.4	2.44e-26	Iron status biomarkers;
BRCA	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg05347473	chr6:146136440	FBXO30	0.41	7.97	0.3	7.08e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.59	13.92	0.48	1.17e-38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg22834771	chr12:69754056	YEATS4	-0.43	-10.63	-0.39	2.04e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs977987	0.806	rs1109342	chr16:75445675	A/G	cg03315344	chr16:75512273	CHST6	-0.51	-11.95	-0.43	7.88e-30	Dupuytren's disease;
BRCA	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg27490568	chr2:178487706	NA	0.49	8.21	0.31	1.26e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6545883	0.860	rs13023037	chr2:61620989	C/T	cg15711740	chr2:61764176	XPO1	0.56	14.42	0.5	5.05e-41	Tuberculosis;
BRCA	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg21918786	chr6:109611834	NA	0.48	14.01	0.48	4.6e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg03711944	chr11:47377212	SPI1	-0.42	-11.54	-0.42	3.99e-28	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs4363385	0.747	rs10399896	chr1:152975083	T/A	cg21543102	chr1:152974771	SPRR3	-0.3	-8.31	-0.31	5.88e-16	Inflammatory skin disease;
BRCA	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.97	0.33	3.29e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs72781680	0.716	rs2551334	chr2:24000396	G/A	cg08917208	chr2:24149416	ATAD2B	0.58	9.63	0.36	1.43e-20	Lymphocyte counts;
BRCA	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg13866156	chr1:1669148	SLC35E2	0.4	8.71	0.33	2.52e-17	Body mass index;
BRCA	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.19	-0.34	5.64e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.99	22.65	0.67	8.12e-84	Lymphocyte percentage of white cells;
BRCA	cis	rs6586163	0.546	rs12359362	chr10:90753145	G/C	cg03111039	chr10:90751583	FAS;ACTA2	0.57	13.21	0.46	2.16e-35	Chronic lymphocytic leukemia;
BRCA	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg08000102	chr2:233561755	GIGYF2	0.62	13.52	0.47	8.41e-37	Coronary artery disease;
BRCA	cis	rs7149337	0.805	rs3007069	chr14:51597392	G/A	cg23942311	chr14:51606299	NA	0.45	12.86	0.45	8.31e-34	Cancer;
BRCA	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg00999904	chr2:3704751	ALLC	0.39	7.85	0.3	1.72e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg17971929	chr21:40555470	PSMG1	0.78	17.91	0.58	2.02e-58	Cognitive function;
BRCA	cis	rs1691799	0.899	rs1168293	chr12:66733904	G/A	cg16791601	chr12:66731901	HELB	-0.62	-16.43	-0.55	6.98e-51	White blood cell count (basophil);
BRCA	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg09469691	chr10:81107165	PPIF	0.45	9.75	0.36	4.76e-21	Height;
BRCA	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.52	-0.35	3.37e-20	Morning vs. evening chronotype;
BRCA	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg24558204	chr6:135376177	HBS1L	0.45	12.26	0.44	3.46e-31	Red blood cell count;
BRCA	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg25767906	chr1:53392781	SCP2	-0.39	-8.79	-0.33	1.4e-17	Monocyte count;
BRCA	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg01864069	chr14:103024347	NA	-0.42	-8.18	-0.31	1.59e-15	Platelet count;
BRCA	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24110177	chr3:50126178	RBM5	0.52	14.76	0.5	1.21e-42	Body mass index;
BRCA	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg12483005	chr1:23474871	LUZP1	0.48	10.46	0.38	9.57e-24	Height;
BRCA	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg00083206	chr6:110721305	DDO	-0.4	-9.77	-0.36	4.22e-21	Platelet distribution width;
BRCA	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg24562669	chr7:97807699	LMTK2	0.44	11.52	0.41	4.96e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg20933634	chr6:27740509	NA	0.45	9.11	0.34	1.07e-18	Parkinson's disease;
BRCA	cis	rs11971779	0.680	rs6962186	chr7:139034806	T/C	cg07862535	chr7:139043722	LUC7L2	0.39	10.42	0.38	1.32e-23	Diisocyanate-induced asthma;
BRCA	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg26384229	chr12:38710491	ALG10B	0.74	17.29	0.56	3.29e-55	Bladder cancer;
BRCA	cis	rs7809950	1.000	rs2057837	chr7:107222725	C/G	cg23024343	chr7:107201750	COG5	0.4	9.1	0.34	1.1e-18	Coronary artery disease;
BRCA	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg20607798	chr8:58055168	NA	0.6	9.1	0.34	1.1e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg00666640	chr1:248458726	OR2T12	0.31	8.64	0.32	4.64e-17	Common traits (Other);
BRCA	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.66	-0.32	3.7e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7539409	0.651	rs910182	chr1:84297117	A/G	cg10977910	chr1:84465055	TTLL7	0.67	10.29	0.38	4.55e-23	Alzheimer's disease;
BRCA	trans	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.15	0.31	1.92e-15	Mean corpuscular volume;
BRCA	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.49	-10.07	-0.37	3.1e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.71	0.39	1.02e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9463078	0.774	rs4446571	chr6:45257662	T/C	cg25276700	chr6:44698697	NA	-0.35	-7.9	-0.3	1.25e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs877529	0.967	rs139400	chr22:39545396	C/T	cg12193277	chr22:39547181	CBX7	0.48	13.26	0.46	1.29e-35	Multiple myeloma;
BRCA	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg03342759	chr3:160939853	NMD3	0.63	13.78	0.48	5.16e-38	Morning vs. evening chronotype;
BRCA	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.43	-0.32	2.32e-16	Monocyte percentage of white cells;
BRCA	trans	rs1829883	0.685	rs7448995	chr5:98709481	C/T	cg08333243	chr5:99726346	NA	0.34	8.24	0.31	9.73e-16	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6710529	1	rs6710529	chr2:219645553	G/A	cg02176678	chr2:219576539	TTLL4	-0.41	-10.86	-0.39	2.58e-25	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg04944784	chr2:26401820	FAM59B	-0.62	-10.76	-0.39	6.13e-25	Gut microbiome composition (summer);
BRCA	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg20848291	chr7:100343083	ZAN	-0.61	-11.72	-0.42	7.38e-29	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs919433	0.679	rs10166328	chr2:198511917	A/G	cg00792783	chr2:198669748	PLCL1	0.41	9.06	0.34	1.52e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7149337	0.717	rs4309324	chr14:51606336	A/T	cg23942311	chr14:51606299	NA	-0.54	-16.15	-0.54	1.91e-49	Cancer;
BRCA	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg23950597	chr19:37808831	NA	-0.62	-11.39	-0.41	1.64e-27	Coronary artery calcification;
BRCA	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg24562669	chr7:97807699	LMTK2	0.43	11.34	0.41	2.65e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06544989	chr22:39130855	UNC84B	0.4	8.81	0.33	1.21e-17	Menopause (age at onset);
BRCA	cis	rs6840360	0.571	rs11736116	chr4:152531816	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.28	-0.31	7.42e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7903847	0.642	rs3814553	chr10:99155984	G/A	cg20016023	chr10:99160130	RRP12	-0.26	-8.53	-0.32	1.03e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.35	-0.38	2.57e-23	Schizophrenia;
BRCA	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.36	-0.61	4.51e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	10.15	0.37	1.49e-22	Retinal vascular caliber;
BRCA	cis	rs7582720	1.000	rs72934714	chr2:203711581	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	12.51	0.44	2.8e-32	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs2882667	0.931	rs10075039	chr5:138337854	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-9.1	-0.34	1.16e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg05340658	chr4:99064831	C4orf37	0.44	10.13	0.37	1.74e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.49	-8.66	-0.32	3.93e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg24562669	chr7:97807699	LMTK2	0.7	21.93	0.66	6.42e-80	Breast cancer;
BRCA	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg06671706	chr8:8559999	CLDN23	0.44	8.62	0.32	5.07e-17	Obesity-related traits;
BRCA	cis	rs2997447	0.655	rs2275949	chr1:26385150	C/G	cg19633962	chr1:26362018	EXTL1	-0.58	-10.26	-0.38	5.73e-23	QRS complex (12-leadsum);
BRCA	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg00383909	chr3:49044727	WDR6	0.73	12.97	0.46	2.53e-34	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs7091068	0.550	rs7901909	chr10:95492508	C/T	cg20715218	chr10:95462985	C10orf4	0.53	10.6	0.39	2.76e-24	Urinary tract infection frequency;
BRCA	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg08508325	chr11:3079039	CARS	0.28	8.52	0.32	1.17e-16	Calcium levels;
BRCA	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg17724175	chr1:150552817	MCL1	0.25	8.34	0.31	4.62e-16	Tonsillectomy;
BRCA	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg08422745	chr4:174089978	GALNT7	-0.81	-18.47	-0.59	2.37e-61	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg24250549	chr1:154909240	PMVK	0.66	17.58	0.57	1.04e-56	Prostate cancer;
BRCA	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05731713	chr7:157510257	PTPRN2	0.4	10.38	0.38	2.06e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs7555523	0.887	rs10800155	chr1:165723770	A/G	cg24409356	chr1:165738333	TMCO1	0.46	8.32	0.31	5.31e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.52	10.93	0.4	1.35e-25	Lymphocyte counts;
BRCA	trans	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-39.06	-0.84	1.79e-171	Exhaled nitric oxide output;
BRCA	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg10978503	chr1:24200527	CNR2	-0.42	-10.51	-0.38	5.86e-24	Immature fraction of reticulocytes;
BRCA	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.21	-0.31	1.25e-15	Schizophrenia;
BRCA	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18876405	chr7:65276391	NA	0.61	15.04	0.51	5.24e-44	Aortic root size;
BRCA	cis	rs11024102	0.830	rs11024110	chr11:17028390	T/A	cg15378786	chr11:17036137	PLEKHA7	0.47	8.62	0.32	5.16e-17	Glaucoma (primary angle closure);
BRCA	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg11843238	chr5:131593191	PDLIM4	0.35	7.93	0.3	1.01e-14	Breast cancer;
BRCA	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11644478	chr21:40555479	PSMG1	-0.52	-10.93	-0.4	1.36e-25	Menarche (age at onset);
BRCA	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg09307838	chr4:120376055	NA	0.73	15.4	0.52	9.48e-46	Corneal astigmatism;
BRCA	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg08742575	chr21:47604166	C21orf56	-0.41	-7.97	-0.3	7.33e-15	Testicular germ cell tumor;
BRCA	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg23029597	chr12:123009494	RSRC2	0.63	12.29	0.44	2.49e-31	Body mass index;
BRCA	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg21427119	chr20:30132790	HM13	0.41	8.81	0.33	1.14e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg05791153	chr7:19748676	TWISTNB	1.07	28.14	0.74	5.82e-114	Night sleep phenotypes;
BRCA	cis	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg06521331	chr12:34319734	NA	-0.61	-11.17	-0.4	1.36e-26	Morning vs. evening chronotype;
BRCA	trans	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	8.31e-21	Bladder cancer;
BRCA	cis	rs10504073	0.647	rs12156111	chr8:50017328	G/C	cg00325661	chr8:49890786	NA	0.38	11.19	0.4	1.12e-26	Blood metabolite ratios;
BRCA	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg01689657	chr7:91764605	CYP51A1	0.22	8.13	0.31	2.19e-15	Breast cancer;
BRCA	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs41005	1.000	rs35398717	chr2:8115041	A/T	cg03155496	chr2:8117019	LOC339788	-0.58	-15.78	-0.53	1.35e-47	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-9.4	-0.35	9.49e-20	Myopia;Myopia (pathological);
BRCA	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg18252515	chr7:66147081	NA	-0.56	-11.34	-0.41	2.84e-27	Corneal structure;
BRCA	trans	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.37	0.38	2.16e-23	Mean corpuscular volume;
BRCA	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-16.32	-0.54	2.48e-50	Chronic sinus infection;
BRCA	cis	rs7586879	0.789	rs11688754	chr2:25133885	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.56	0.35	2.55e-20	Body mass index;
BRCA	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.39	0.57	9.59e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4478858	0.684	rs10798837	chr1:31719340	C/T	cg00250761	chr1:31883323	NA	-0.31	-8.0	-0.3	6.03e-15	Alcohol dependence;
BRCA	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg09307838	chr4:120376055	NA	0.73	15.95	0.53	1.9e-48	Corneal astigmatism;
BRCA	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.59	12.41	0.44	7.44e-32	Lymphocyte percentage of white cells;
BRCA	cis	rs1904096	0.506	rs2865350	chr4:95212813	A/T	cg11021082	chr4:95130006	SMARCAD1	0.4	8.42	0.32	2.41e-16	Type 2 diabetes;
BRCA	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14442939	chr10:27389572	ANKRD26	0.79	19.8	0.62	2.09e-68	Breast cancer;
BRCA	cis	rs7178424	1.000	rs12439356	chr15:62380595	A/G	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.3	-0.31	6.17e-16	Height;
BRCA	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg10729496	chr3:10149963	C3orf24	0.48	9.03	0.34	1.93e-18	Alzheimer's disease;
BRCA	trans	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg25206134	chr2:45395956	NA	0.53	8.98	0.33	3.03e-18	Bipolar disorder;
BRCA	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.89	-0.33	6.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg02659138	chr7:134003124	SLC35B4	-0.34	-10.63	-0.39	2e-24	Mean platelet volume;
BRCA	cis	rs3849570	0.696	rs13092157	chr3:81875332	T/A	cg07356753	chr3:81810745	GBE1	-0.43	-9.95	-0.37	8.89e-22	Waist circumference;Body mass index;
BRCA	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg07148914	chr20:33460835	GGT7	0.38	8.62	0.32	5.21e-17	Height;
BRCA	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg00074818	chr8:8560427	CLDN23	0.4	8.63	0.32	4.93e-17	Obesity-related traits;
BRCA	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg10253484	chr15:75165896	SCAMP2	0.57	11.87	0.42	1.7e-29	Breast cancer;
BRCA	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg03934865	chr2:198174659	NA	-0.4	-9.05	-0.34	1.71e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	trans	rs2736345	0.788	rs998683	chr8:11353000	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.66	-0.32	3.86e-17	Sjögren's syndrome;Systemic lupus erythematosus;
BRCA	cis	rs2882667	0.627	rs1549203	chr5:138468344	A/G	cg04439458	chr5:138467593	SIL1	0.35	9.75	0.36	5.02e-21	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg18876405	chr7:65276391	NA	-0.52	-11.65	-0.42	1.39e-28	Aortic root size;
BRCA	cis	rs2712184	0.729	rs4674115	chr2:217659628	C/G	cg05032264	chr2:217675019	NA	-0.35	-8.37	-0.31	3.58e-16	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.47	-10.27	-0.38	5.43e-23	Cognitive ability;
BRCA	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg24642439	chr20:33292090	TP53INP2	-0.4	-8.36	-0.31	3.96e-16	Height;
BRCA	cis	rs1505368	0.781	rs10197836	chr2:213274278	T/C	cg16329650	chr2:213403929	ERBB4	0.32	8.01	0.3	5.5e-15	Symmetrical dimethylarginine levels;
BRCA	cis	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg07460842	chr6:66804631	NA	-1.19	-38.95	-0.84	6.75e-171	Exhaled nitric oxide output;
BRCA	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg04166393	chr7:2884313	GNA12	0.47	9.42	0.35	7.99e-20	Height;
BRCA	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24110177	chr3:50126178	RBM5	0.38	10.57	0.39	3.58e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg09904177	chr6:26538194	HMGN4	0.43	12.21	0.43	5.66e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	15.42	0.52	7.63e-46	Colorectal cancer;
BRCA	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.38	-0.31	3.25e-16	Aortic root size;
BRCA	cis	rs10733682	0.659	rs3906146	chr9:129463613	C/T	cg00232160	chr9:129468157	NA	0.36	8.41	0.32	2.67e-16	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg11062466	chr8:58055876	NA	0.5	8.8	0.33	1.28e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg08917208	chr2:24149416	ATAD2B	0.96	14.26	0.49	2.85e-40	Lymphocyte counts;
BRCA	cis	rs708547	0.957	rs2458552	chr4:57773442	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.47	-8.17	-0.31	1.63e-15	Response to bleomycin (chromatid breaks);
BRCA	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.76	12.43	0.44	6.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg24531977	chr5:56204891	C5orf35	-0.54	-11.41	-0.41	1.38e-27	Coronary artery disease;
BRCA	cis	rs9815354	0.680	rs17218936	chr3:42019392	C/T	cg03022575	chr3:42003672	ULK4	0.77	9.77	0.36	4e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg16262614	chr3:133464971	TF	0.24	7.88	0.3	1.45e-14	Iron status biomarkers (transferrin levels);
BRCA	cis	rs3106136	0.546	rs183993	chr4:95130025	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-9.96	-0.37	8.4e-22	Capecitabine sensitivity;
BRCA	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.88	-0.33	6.48e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.45	-0.41	1e-27	Mean corpuscular volume;
BRCA	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg11266682	chr4:10021025	SLC2A9	0.5	13.24	0.46	1.63e-35	Bone mineral density;
BRCA	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg05340658	chr4:99064831	C4orf37	-0.69	-17.44	-0.57	5.08e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg08601574	chr20:25228251	PYGB	-0.34	-8.26	-0.31	8.65e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg05347473	chr6:146136440	FBXO30	-0.39	-7.87	-0.3	1.5e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg03146154	chr1:46216737	IPP	0.53	11.92	0.43	1e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg04362960	chr10:104952993	NT5C2	0.43	10.26	0.38	5.93e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs17384381	1.000	rs17388521	chr1:85897904	A/G	cg16011679	chr1:85725395	C1orf52	-0.53	-8.26	-0.31	8.7e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11971779	0.680	rs7804388	chr7:139086413	A/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.0	-0.56	9.9e-54	Intelligence (multi-trait analysis);
BRCA	cis	rs701145	0.824	rs355767	chr3:154045895	G/A	cg17054900	chr3:154042577	DHX36	0.68	11.88	0.43	1.56e-29	Coronary artery disease;
BRCA	cis	rs9815354	0.680	rs115754309	chr3:42017246	A/G	cg03022575	chr3:42003672	ULK4	0.75	9.65	0.36	1.17e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg21573476	chr21:45109991	RRP1B	-0.39	-10.38	-0.38	1.94e-23	Mean corpuscular volume;
BRCA	cis	rs6820391	0.816	rs7683461	chr4:54447863	C/T	cg04173182	chr4:54446035	LNX1	0.53	11.9	0.43	1.27e-29	Cervical artery dissection;
BRCA	trans	rs2736345	0.788	rs2618476	chr8:11352541	A/G	cg06636001	chr8:8085503	FLJ10661	0.43	7.94	0.3	8.95e-15	Sjögren's syndrome;Systemic lupus erythematosus;
BRCA	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg13456504	chr1:91191583	NA	0.54	9.95	0.37	9.1e-22	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg12310025	chr6:25882481	NA	0.72	17.89	0.58	2.43e-58	Blood metabolite levels;
BRCA	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg11645453	chr3:52864694	ITIH4	0.48	11.63	0.42	1.73e-28	Schizophrenia;
BRCA	cis	rs9300255	0.620	rs1727311	chr12:123660716	T/G	cg00376283	chr12:123451042	ABCB9	0.51	9.74	0.36	5.37e-21	Neutrophil percentage of white cells;
BRCA	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg19784903	chr17:45786737	TBKBP1	-0.42	-9.93	-0.37	1.09e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg06627628	chr2:24431161	ITSN2	-0.54	-8.91	-0.33	5.27e-18	Lymphocyte counts;
BRCA	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg20701182	chr2:24300061	SF3B14	0.7	13.41	0.47	2.62e-36	Lymphocyte counts;
BRCA	cis	rs9296092	0.538	rs9461881	chr6:33520041	C/T	cg13560919	chr6:33536144	NA	-0.85	-18.66	-0.59	2.26e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg22713356	chr15:30763199	NA	1.25	20.77	0.63	1.25e-73	Uric acid levels;
BRCA	cis	rs782590	0.574	rs12991445	chr2:55675939	C/T	cg18811423	chr2:55921094	PNPT1	0.46	12.06	0.43	2.6e-30	Metabolic syndrome;
BRCA	cis	rs3768617	1.000	rs3820697	chr1:183100226	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	10.13	0.37	1.84e-22	Fuchs's corneal dystrophy;
BRCA	cis	rs9309473	0.718	rs10175529	chr2:73606093	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-12.64	-0.45	7.81e-33	Metabolite levels;
BRCA	cis	rs10267417	0.603	rs10281428	chr7:19857374	G/A	cg05791153	chr7:19748676	TWISTNB	0.51	9.71	0.36	6.75e-21	Night sleep phenotypes;
BRCA	cis	rs4660306	1.000	rs6429567	chr1:45956700	C/A	cg24296786	chr1:45957014	TESK2	0.42	8.38	0.31	3.31e-16	Homocysteine levels;
BRCA	cis	rs11625487	0.957	rs28820314	chr14:77963272	A/C	cg20045696	chr14:77926864	AHSA1	-0.43	-8.01	-0.3	5.47e-15	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
BRCA	cis	rs72772090	0.539	rs111886458	chr5:96125047	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.13	-0.43	1.28e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7729447	0.776	rs7738037	chr5:32696549	C/T	cg16267343	chr5:32710456	NPR3	0.47	9.82	0.36	2.65e-21	Blood pressure;
BRCA	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg14926445	chr8:58193284	C8orf71	-0.38	-7.82	-0.3	2.2e-14	Developmental language disorder (linguistic errors);
BRCA	trans	rs12517041	1.000	rs34157151	chr5:23289755	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs6772849	0.930	rs68090762	chr3:128343907	C/T	cg16766828	chr3:128327626	NA	-0.41	-8.94	-0.33	4.03e-18	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg12011299	chr4:100065546	ADH4	0.48	10.87	0.4	2.26e-25	Smoking initiation;
BRCA	cis	rs9649465	0.967	rs12537072	chr7:123377213	A/G	cg04330084	chr7:123175371	IQUB	-0.33	-8.98	-0.33	2.94e-18	Migraine;
BRCA	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg02996355	chr14:81879375	NA	0.57	11.59	0.42	2.53e-28	Night sleep phenotypes;
BRCA	cis	rs13053817	1.000	rs13053817	chr22:29847722	A/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	0.47	9.29	0.34	2.43e-19	Carotid atherosclerosis in HIV infection;
BRCA	trans	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.23	0.31	1.08e-15	Mean corpuscular volume;
BRCA	trans	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.65	-0.36	1.18e-20	Bladder cancer;
BRCA	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14442939	chr10:27389572	ANKRD26	0.65	10.87	0.39	2.37e-25	Breast cancer;
BRCA	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.33	8.32	0.31	5.32e-16	Resting heart rate;
BRCA	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg00071950	chr4:10020882	SLC2A9	0.55	13.19	0.46	2.62e-35	Bone mineral density;
BRCA	cis	rs10504073	0.584	rs10504070	chr8:49978554	A/G	cg00325661	chr8:49890786	NA	-0.44	-12.83	-0.45	1.07e-33	Blood metabolite ratios;
BRCA	cis	rs965469	1.000	rs2092990	chr20:3346338	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-10.54	-0.38	4.61e-24	IFN-related cytopenia;
BRCA	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-11.85	-0.42	2.06e-29	Tonsillectomy;
BRCA	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg24579218	chr15:68104479	NA	-0.36	-7.88	-0.3	1.38e-14	Restless legs syndrome;
BRCA	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21659725	chr3:3221576	CRBN	0.71	21.89	0.65	1.09e-79	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.66	-17.91	-0.58	1.86e-58	Longevity;Endometriosis;
BRCA	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.86	0.33	7.82e-18	Motion sickness;
BRCA	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-9.78	-0.36	3.91e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs6546537	0.562	rs7565783	chr2:69750113	C/T	cg10773587	chr2:69614142	GFPT1	-0.38	-8.58	-0.32	7.45e-17	Serum thyroid-stimulating hormone levels;
BRCA	cis	rs6723226	0.750	rs10182170	chr2:32704186	G/A	cg02381751	chr2:32503542	YIPF4	0.67	14.7	0.5	2.31e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg26384229	chr12:38710491	ALG10B	-0.49	-11.33	-0.41	2.91e-27	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg23649088	chr2:200775458	C2orf69	-0.55	-7.86	-0.3	1.68e-14	Schizophrenia;
BRCA	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg26384229	chr12:38710491	ALG10B	0.76	17.1	0.56	2.83e-54	Bladder cancer;
BRCA	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg06115741	chr20:33292138	TP53INP2	0.47	10.71	0.39	1.02e-24	Coronary artery disease;
BRCA	cis	rs4853036	0.586	rs6546546	chr2:70009035	A/C	cg02498382	chr2:70120550	SNRNP27	0.44	8.33	0.31	4.95e-16	Colorectal or endometrial cancer;
BRCA	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg26384229	chr12:38710491	ALG10B	0.74	17.29	0.56	3.29e-55	Bladder cancer;
BRCA	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	10.69	0.39	1.16e-24	Retinal vascular caliber;
BRCA	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg11645453	chr3:52864694	ITIH4	0.47	11.31	0.41	3.56e-27	Schizophrenia;
BRCA	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg19077165	chr18:44547161	KATNAL2	0.65	14.94	0.51	1.71e-43	Personality dimensions;
BRCA	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg13114125	chr14:105738426	BRF1	-0.5	-10.41	-0.38	1.44e-23	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs17401966	0.867	rs12403443	chr1:10423988	A/G	cg03954927	chr1:10346856	KIF1B	0.45	12.39	0.44	9.86e-32	Hepatocellular carcinoma;
BRCA	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.14e-19	Total body bone mineral density;
BRCA	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2455799	0.574	rs2455801	chr3:15701857	C/T	cg16303742	chr3:15540471	COLQ	-0.37	-9.01	-0.34	2.31e-18	Mean platelet volume;
BRCA	cis	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg24692254	chr21:30365293	RNF160	-0.46	-8.03	-0.3	4.54e-15	Cognitive test performance;
BRCA	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg15352829	chr14:105391018	PLD4	-0.38	-12.3	-0.44	2.41e-31	Rheumatoid arthritis;
BRCA	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg23625390	chr15:77176239	SCAPER	0.4	9.37	0.35	1.23e-19	Blood metabolite levels;
BRCA	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg15395560	chr15:45543142	SLC28A2	0.3	8.3	0.31	6.2e-16	Uric acid levels;
BRCA	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg17143192	chr8:8559678	CLDN23	0.55	10.38	0.38	2.04e-23	Obesity-related traits;
BRCA	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.36	8.18	0.31	1.53e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	9.76	0.36	4.54e-21	Morning vs. evening chronotype;
BRCA	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg13393036	chr8:95962371	TP53INP1	0.34	8.35	0.31	4.26e-16	Type 2 diabetes;
BRCA	cis	rs7631605	0.905	rs3774338	chr3:37062959	G/T	cg15934958	chr3:37212084	LRRFIP2	0.44	10.18	0.37	1.2e-22	Cerebrospinal P-tau181p levels;
BRCA	cis	rs4730250	0.707	rs6946931	chr7:106788621	G/T	cg02696742	chr7:106810147	HBP1	-0.57	-9.14	-0.34	8.52e-19	Osteoarthritis;
BRCA	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg13047869	chr3:10149882	C3orf24	0.59	12.21	0.44	5.53e-31	Alzheimer's disease;
BRCA	cis	rs4363385	0.747	rs946101	chr1:152972032	C/T	cg21543102	chr1:152974771	SPRR3	0.28	8.32	0.31	5.45e-16	Inflammatory skin disease;
BRCA	cis	rs4363385	0.818	rs4284210	chr1:152985711	G/A	cg24667326	chr1:152973720	SPRR3	-0.33	-9.02	-0.34	2.09e-18	Inflammatory skin disease;
BRCA	cis	rs11971779	0.878	rs4732378	chr7:139120395	C/T	cg07862535	chr7:139043722	LUC7L2	0.51	12.17	0.43	8.39e-31	Diisocyanate-induced asthma;
BRCA	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg11814155	chr7:99998594	ZCWPW1	0.54	9.32	0.35	1.81e-19	Platelet count;
BRCA	cis	rs9443645	0.527	rs9343870	chr6:79789473	T/G	cg09184832	chr6:79620586	NA	-0.42	-8.14	-0.31	2.06e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg01256987	chr12:42539512	GXYLT1	-0.48	-9.27	-0.34	2.77e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs3818285	0.556	rs944966	chr10:111658334	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.37	-9.93	-0.37	1.05e-21	Superior crus of antihelix expression;
BRCA	trans	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg25214090	chr10:38739885	LOC399744	-0.46	-9.84	-0.36	2.35e-21	Corneal astigmatism;
BRCA	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg24450063	chr1:156163899	SLC25A44	-1.04	-32.92	-0.79	9.46e-140	Testicular germ cell tumor;
BRCA	cis	rs858239	0.600	rs10256361	chr7:23123885	C/T	cg23682824	chr7:23144976	KLHL7	0.45	12.09	0.43	1.9e-30	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	14.79	0.5	8.48e-43	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg17366294	chr4:99064904	C4orf37	0.43	10.23	0.38	7.52e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg11845111	chr2:191398756	TMEM194B	-0.37	-8.49	-0.32	1.43e-16	Pulse pressure;
BRCA	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg09307838	chr4:120376055	NA	0.75	16.17	0.54	1.48e-49	Corneal astigmatism;
BRCA	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.32	0.31	5.39e-16	Aortic root size;
BRCA	cis	rs6580649	0.941	rs7310579	chr12:48427523	G/A	cg24011408	chr12:48396354	COL2A1	-0.47	-7.83	-0.3	2.06e-14	Lung cancer;
BRCA	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	16.24	0.54	6.9e-50	Neuroticism;
BRCA	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg04851639	chr8:1020857	NA	-0.32	-8.82	-0.33	1.05e-17	Schizophrenia;
BRCA	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg06159980	chr1:16340746	HSPB7	0.36	8.36	0.31	3.78e-16	Dilated cardiomyopathy;
BRCA	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg24011408	chr12:48396354	COL2A1	0.42	9.36	0.35	1.38e-19	Plateletcrit;
BRCA	cis	rs757081	0.667	rs12420958	chr11:17100432	G/T	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.59	-0.32	6.62e-17	Systolic blood pressure;
BRCA	cis	rs17641971	0.899	rs341804	chr8:49991553	G/C	cg00325661	chr8:49890786	NA	-0.31	-8.16	-0.31	1.76e-15	Blood metabolite levels;
BRCA	cis	rs2625529	0.730	rs982752	chr15:72145937	C/T	cg16672083	chr15:72433130	SENP8	-0.69	-16.38	-0.54	1.37e-50	Red blood cell count;
BRCA	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.75e-16	Menopause (age at onset);
BRCA	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21659725	chr3:3221576	CRBN	-0.46	-10.09	-0.37	2.62e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg23033748	chr14:75592666	NEK9	-0.42	-10.39	-0.38	1.86e-23	Height;
BRCA	cis	rs6882046	0.513	rs446219	chr5:88005827	T/C	cg22951263	chr5:87985283	NA	-0.39	-10.8	-0.39	4.41e-25	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.96	0.3	7.77e-15	Depression;
BRCA	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg19743168	chr1:23544995	NA	0.46	11.18	0.4	1.21e-26	Height;
BRCA	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg18209359	chr17:80159595	CCDC57	-0.4	-7.9	-0.3	1.22e-14	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.96	0.3	7.63e-15	Depression;
BRCA	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24531977	chr5:56204891	C5orf35	-0.86	-17.89	-0.58	2.57e-58	Initial pursuit acceleration;
BRCA	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg12311346	chr5:56204834	C5orf35	0.8	15.66	0.53	5.31e-47	Initial pursuit acceleration;
BRCA	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.84	0.36	2.34e-21	Bipolar disorder;
BRCA	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg18252515	chr7:66147081	NA	-0.82	-11.95	-0.43	7.52e-30	Diabetic kidney disease;
BRCA	cis	rs483180	0.512	rs597308	chr1:120214953	G/A	cg19096424	chr1:120255104	PHGDH	0.44	9.59	0.35	1.93e-20	Macular telangiectasia type 2;
BRCA	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg11663144	chr21:46675770	NA	-0.61	-14.1	-0.49	1.67e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg06238570	chr21:40685208	BRWD1	-0.43	-8.51	-0.32	1.25e-16	Cognitive function;
BRCA	cis	rs6882046	0.513	rs185291	chr5:88006764	T/C	cg22951263	chr5:87985283	NA	-0.39	-10.75	-0.39	6.62e-25	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs7737355	0.947	rs10463887	chr5:130776854	C/G	cg06307176	chr5:131281290	NA	-0.54	-10.76	-0.39	6.02e-25	Life satisfaction;
BRCA	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg19784903	chr17:45786737	TBKBP1	0.34	8.03	0.3	4.66e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.51	-0.38	5.96e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs1451375	0.652	rs7803440	chr7:50625632	C/T	cg18232548	chr7:50535776	DDC	0.38	8.03	0.3	4.84e-15	Malaria;
BRCA	cis	rs57590327	0.555	rs6767749	chr3:81725513	G/A	cg07356753	chr3:81810745	GBE1	-0.46	-10.98	-0.4	7.87e-26	Extraversion;
BRCA	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg25036284	chr2:26402008	FAM59B	0.73	12.02	0.43	3.63e-30	Gut microbiome composition (summer);
BRCA	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg11663144	chr21:46675770	NA	-0.6	-13.84	-0.48	2.6e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-13.92	-0.48	1.17e-38	Bipolar disorder and schizophrenia;
BRCA	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg22139774	chr2:100720529	AFF3	-0.29	-8.18	-0.31	1.5e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg15934090	chr1:100435551	SLC35A3	0.35	8.05	0.3	3.94e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg26384229	chr12:38710491	ALG10B	0.41	8.97	0.33	3.36e-18	Morning vs. evening chronotype;
BRCA	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg16482183	chr6:26056742	HIST1H1C	0.46	8.86	0.33	8.17e-18	Iron status biomarkers;
BRCA	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg26677194	chr12:130822605	PIWIL1	0.6	14.39	0.49	7.41e-41	Menopause (age at onset);
BRCA	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg13789015	chr9:136890014	NCRNA00094	0.57	11.94	0.43	8.55e-30	Platelet distribution width;
BRCA	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg17971929	chr21:40555470	PSMG1	0.76	16.65	0.55	5.41e-52	Cognitive function;
BRCA	cis	rs490234	0.966	rs631287	chr9:128412676	G/A	cg14078157	chr9:128172775	NA	0.33	8.13	0.31	2.31e-15	Mean arterial pressure;
BRCA	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg06623918	chr6:96969491	KIAA0776	0.74	12.19	0.43	6.85e-31	Migraine;Coronary artery disease;
BRCA	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	ch.11.42038R	chr11:967971	AP2A2	0.5	15.7	0.53	3.1e-47	Alzheimer's disease (late onset);
BRCA	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg06212747	chr3:49208901	KLHDC8B	0.47	9.67	0.36	9.4499999999999992e-21	Parkinson's disease;
BRCA	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg11663144	chr21:46675770	NA	-0.47	-11.21	-0.41	9.07e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs12517041	1.000	rs1428623	chr5:23286659	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.35	-0.31	4.37e-16	Calcium levels;
BRCA	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg06360820	chr2:242988706	NA	-0.83	-14.87	-0.51	3.68e-43	Obesity-related traits;
BRCA	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg02016764	chr4:38805732	TLR1	-0.59	-9.67	-0.36	9.75e-21	Breast cancer;
BRCA	cis	rs919433	0.619	rs699318	chr2:198281743	T/C	cg00792783	chr2:198669748	PLCL1	0.39	8.74	0.33	2e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg02743256	chr7:2109353	MAD1L1	-0.46	-8.17	-0.31	1.59e-15	Neuroticism;
BRCA	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs6973256	0.897	rs10231828	chr7:133348337	T/G	cg07491979	chr7:133331646	EXOC4	-0.39	-9.04	-0.34	1.92e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg13902645	chr11:5959945	NA	-0.53	-10.98	-0.4	8.22e-26	DNA methylation (variation);
BRCA	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg03929089	chr4:120376271	NA	0.65	12.85	0.45	8.83e-34	Coronary artery disease;
BRCA	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg26898376	chr11:64110657	CCDC88B	0.37	7.86	0.3	1.69e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs858239	0.539	rs6976957	chr7:23187333	T/A	cg23682824	chr7:23144976	KLHL7	0.41	10.65	0.39	1.74e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg21226059	chr5:178986404	RUFY1	0.4	10.44	0.38	1.13e-23	Lung cancer;
BRCA	cis	rs77633900	0.614	rs280001	chr15:77003566	C/A	cg21673338	chr15:77095150	SCAPER	-0.54	-9.56	-0.35	2.39e-20	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs587080	0.559	rs12364730	chr11:65228278	C/T	cg01292856	chr11:65242576	NA	0.66	14.6	0.5	7.11e-42	Plateletcrit;
BRCA	trans	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs9296092	0.517	rs11752179	chr6:33534713	G/T	cg13560919	chr6:33536144	NA	-0.91	-19.42	-0.61	2.12e-66	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg18225595	chr11:63971243	STIP1	0.53	9.59	0.35	1.8899999999999998e-20	Mean platelet volume;
BRCA	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02475777	chr4:1388615	CRIPAK	-0.67	-12.53	-0.44	2.24e-32	Longevity;
BRCA	cis	rs503734	0.502	rs1994201	chr3:100970062	C/T	cg27318481	chr3:100970896	IMPG2	0.39	9.56	0.35	2.51e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.59	0.63	1.23e-72	Electrocardiographic conduction measures;
BRCA	cis	rs250677	0.522	rs3763022	chr5:148381078	A/G	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.86	-0.33	8.15e-18	Breast cancer;
BRCA	cis	rs1997103	1.000	rs10263552	chr7:55404747	C/T	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.92e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg01529538	chr14:23388837	RBM23	0.42	11.56	0.42	3.3e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs858239	0.665	rs6964665	chr7:23211352	G/A	cg23682824	chr7:23144976	KLHL7	0.36	9.29	0.35	2.34e-19	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg08601574	chr20:25228251	PYGB	0.41	9.69	0.36	7.97e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg19628046	chr18:33552617	C18orf21	0.56	11.5	0.41	6.2e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs12541635	0.677	rs1603357	chr8:107000565	G/C	cg10147462	chr8:107024639	NA	0.39	10.51	0.38	5.98e-24	Age of smoking initiation;
BRCA	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.51	0.32	1.26e-16	Cognitive ability;
BRCA	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg22535103	chr8:58192502	C8orf71	-0.46	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00166722	chr3:10149974	C3orf24	0.61	11.95	0.43	7.46e-30	Alzheimer's disease;
BRCA	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg21395723	chr22:39101663	GTPBP1	0.38	8.32	0.31	5.17e-16	Menopause (age at onset);
BRCA	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg00105475	chr2:10696890	NA	0.44	10.41	0.38	1.56e-23	Prostate cancer;
BRCA	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.49e-52	Hypertriglyceridemia;
BRCA	cis	rs3820928	0.874	rs10194663	chr2:227875369	T/A	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.16	-0.31	1.77e-15	Pulmonary function;
BRCA	cis	rs7520050	0.902	rs4638056	chr1:46458153	T/G	cg24296786	chr1:45957014	TESK2	0.44	9.81	0.36	2.95e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs698833	0.926	rs1067339	chr2:44624448	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	10.8	0.39	4.44e-25	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-8.17	-0.31	1.64e-15	Longevity;Endometriosis;
BRCA	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-17.03	-0.56	6.87e-54	Chronic sinus infection;
BRCA	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg13010199	chr12:38710504	ALG10B	0.51	10.44	0.38	1.15e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg12062639	chr20:23401060	NAPB	0.96	13.42	0.47	2.43e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.27	0.31	7.79e-16	Aortic root size;
BRCA	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	8.17	0.31	1.63e-15	Diabetic retinopathy;
BRCA	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg26031613	chr14:104095156	KLC1	-0.53	-9.46	-0.35	5.92e-20	Reticulocyte count;
BRCA	cis	rs7973719	0.833	rs3825405	chr12:7360143	G/T	cg07052231	chr12:7363540	PEX5	0.34	7.88	0.3	1.44e-14	IgG glycosylation;
BRCA	trans	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.15	0.37	1.51e-22	Mean corpuscular volume;
BRCA	cis	rs13053817	0.950	rs12484045	chr22:29828751	A/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.45	-8.95	-0.33	3.76e-18	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg05084668	chr3:125655381	ALG1L	-0.47	-7.98	-0.3	6.69e-15	Blood pressure (smoking interaction);
BRCA	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg06212747	chr3:49208901	KLHDC8B	0.53	11.06	0.4	3.79e-26	Parkinson's disease;
BRCA	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.22	0.31	1.17e-15	Tonsillectomy;
BRCA	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg04727924	chr7:799746	HEATR2	-0.5	-8.93	-0.33	4.51e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	22.45	0.66	9.38e-83	Platelet count;
BRCA	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg03585969	chr10:35415529	CREM	0.56	11.5	0.41	5.98e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs1997103	0.906	rs6593232	chr7:55402916	C/T	cg20935933	chr6:143382018	AIG1	0.6	11.42	0.41	1.32e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs698813	0.674	rs6759891	chr2:44496005	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	8.88	0.33	6.56e-18	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg25237894	chr2:233734115	C2orf82	-0.43	-13.56	-0.47	5.32e-37	Coronary artery disease;
BRCA	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg18479299	chr3:125709523	NA	-0.57	-9.13	-0.34	9.11e-19	Blood pressure (smoking interaction);
BRCA	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18404041	chr3:52824283	ITIH1	-0.38	-11.8	-0.42	3.22e-29	Intelligence (multi-trait analysis);
BRCA	trans	rs7395662	0.819	rs1473579	chr11:48901553	A/G	cg00717180	chr2:96193071	NA	-0.31	-8.66	-0.32	3.9e-17	HDL cholesterol;
BRCA	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg03709012	chr19:19516395	GATAD2A	0.78	17.26	0.56	4.62e-55	Tonsillectomy;
BRCA	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg11845111	chr2:191398756	TMEM194B	-0.81	-14.34	-0.49	1.21e-40	Diastolic blood pressure;
BRCA	cis	rs9381107	0.932	rs16892279	chr6:9483186	A/G	cg14735645	chr6:9486422	NA	-0.46	-8.13	-0.31	2.29e-15	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg23719950	chr11:63933701	MACROD1	-0.58	-9.68	-0.36	9.11e-21	Mean platelet volume;
BRCA	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg24675658	chr1:53192096	ZYG11B	-0.68	-15.38	-0.52	1.18e-45	Monocyte count;
BRCA	cis	rs6545977	0.531	rs2539981	chr2:63104904	T/C	cg17519650	chr2:63277830	OTX1	0.45	10.22	0.37	7.9e-23	Prostate cancer;
BRCA	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.19	0.31	1.46e-15	Menarche (age at onset);
BRCA	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg01874867	chr7:94954059	PON1	0.39	8.15	0.31	1.89e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6545883	0.558	rs7587389	chr2:61649791	A/G	cg15711740	chr2:61764176	XPO1	0.32	7.88	0.3	1.44e-14	Tuberculosis;
BRCA	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-14.71	-0.5	2.2e-42	Menarche (age at onset);
BRCA	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03264133	chr6:25882463	NA	-0.45	-9.6	-0.36	1.71e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs41005	0.967	rs13430914	chr2:8114648	A/G	cg03155496	chr2:8117019	LOC339788	0.58	15.69	0.53	3.57e-47	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-9.93	-0.37	1.07e-21	Tonsillectomy;
BRCA	trans	rs3858145	0.588	rs55888445	chr10:70036456	C/T	cg04882175	chr6:131122610	NA	-0.35	-8.35	-0.31	4.33e-16	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
BRCA	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg24163568	chr5:669837	TPPP	-0.35	-9.38	-0.35	1.17e-19	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
BRCA	cis	rs12618769	0.652	rs1062847	chr2:99226173	T/A	cg10123293	chr2:99228465	UNC50	0.42	8.42	0.32	2.56e-16	Bipolar disorder;
BRCA	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-13.38	-0.47	3.57e-36	Morning vs. evening chronotype;
BRCA	cis	rs7523050	0.730	rs77425121	chr1:109417677	C/A	cg08274380	chr1:109419600	GPSM2	1.18	16.65	0.55	5.73e-52	Fat distribution (HIV);
BRCA	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg00666640	chr1:248458726	OR2T12	0.34	9.07	0.34	1.39e-18	Common traits (Other);
BRCA	cis	rs7809950	0.678	rs17154040	chr7:107005246	C/T	cg23024343	chr7:107201750	COG5	0.46	9.5	0.35	3.98e-20	Coronary artery disease;
BRCA	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg20848291	chr7:100343083	ZAN	-0.63	-13.31	-0.47	7.55e-36	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs9633740	0.685	rs4934284	chr10:82277297	C/G	cg01528321	chr10:82214614	TSPAN14	-0.94	-12.03	-0.43	3.43e-30	Post bronchodilator FEV1;
BRCA	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-8.29	-0.31	6.81e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg19156104	chr2:198669113	PLCL1	-0.41	-7.87	-0.3	1.53e-14	Ulcerative colitis;
BRCA	cis	rs877529	0.967	rs6001455	chr22:39547962	C/T	cg18708252	chr22:39545030	CBX7	-0.31	-8.17	-0.31	1.63e-15	Multiple myeloma;
BRCA	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs965469	0.779	rs6051752	chr20:3310452	C/T	cg25506879	chr20:3388711	C20orf194	-0.44	-8.87	-0.33	7.39e-18	IFN-related cytopenia;
BRCA	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg12011299	chr4:100065546	ADH4	0.52	12.53	0.44	2.37e-32	Alcohol dependence;
BRCA	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg08999081	chr20:33150536	PIGU	0.37	9.4	0.35	9.65e-20	Coronary artery disease;
BRCA	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg21573476	chr21:45109991	RRP1B	-0.36	-9.15	-0.34	7.52e-19	Mean corpuscular volume;
BRCA	cis	rs6594499	0.872	rs2112541	chr5:110449346	T/C	cg04022379	chr5:110408740	TSLP	0.35	7.93	0.3	1.02e-14	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.45	-8.53	-0.32	1.05e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.31	-8.08	-0.3	3.15e-15	Response to antipsychotic treatment;
BRCA	trans	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.61	-0.36	1.57e-20	Bladder cancer;
BRCA	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg16099169	chr2:106886729	NA	-0.69	-12.12	-0.43	1.44e-30	Facial morphology (factor 23);
BRCA	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg15395560	chr15:45543142	SLC28A2	-0.29	-7.81	-0.3	2.33e-14	Uric acid levels;
BRCA	cis	rs701145	0.556	rs355764	chr3:154013480	A/T	cg12800244	chr3:153838788	SGEF	0.43	8.5	0.32	1.31e-16	Coronary artery disease;
BRCA	cis	rs11031096	0.711	rs4910890	chr11:4153407	C/T	cg18678763	chr11:4115507	RRM1	-0.38	-8.58	-0.32	7.01e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.34	-0.41	2.88e-27	Electroencephalogram traits;
BRCA	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg01528321	chr10:82214614	TSPAN14	0.84	18.47	0.59	2.32e-61	Post bronchodilator FEV1;
BRCA	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg20203395	chr5:56204925	C5orf35	-0.5	-10.59	-0.39	3.03e-24	Initial pursuit acceleration;
BRCA	trans	rs9650657	0.771	rs6601513	chr8:10594843	A/G	cg15556689	chr8:8085844	FLJ10661	-0.3	-7.91	-0.3	1.17e-14	Neuroticism;
BRCA	cis	rs10911251	0.528	rs10911265	chr1:183115071	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	15.76	0.53	1.6e-47	Colorectal cancer;
BRCA	cis	rs2637266	1.000	rs12262400	chr10:78386862	T/C	cg18941641	chr10:78392320	NA	0.34	7.88	0.3	1.46e-14	Pulmonary function;
BRCA	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg19077165	chr18:44547161	KATNAL2	-0.58	-13.0	-0.46	1.81e-34	Personality dimensions;
BRCA	cis	rs2066819	1.000	rs11171803	chr12:56718422	T/C	cg26714650	chr12:56694279	CS	-1.19	-15.59	-0.52	1.14e-46	Psoriasis vulgaris;
BRCA	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg06917634	chr15:78832804	PSMA4	-0.61	-13.08	-0.46	8.34e-35	Sudden cardiac arrest;
BRCA	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg05535760	chr7:792225	HEATR2	0.7	12.65	0.45	6.83e-33	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7523273	0.925	rs10863593	chr1:208018074	C/T	cg22525895	chr1:207977042	MIR29B2	0.47	11.54	0.42	4.23e-28	Schizophrenia;
BRCA	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg25801113	chr15:45476975	SHF	0.31	8.06	0.3	3.9e-15	Uric acid levels;
BRCA	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.09	-0.3	2.95e-15	Depression;
BRCA	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg06064525	chr11:970664	AP2A2	-0.49	-16.53	-0.55	2.35e-51	Alzheimer's disease (late onset);
BRCA	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.66	-0.39	1.54e-24	Bipolar disorder;
BRCA	trans	rs9784649	1.000	rs11738315	chr5:24967891	T/C	cg08600765	chr20:34638493	LOC647979	-0.51	-8.4	-0.32	2.79e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg19508488	chr2:152266495	RIF1	0.46	8.97	0.33	3.28e-18	Squamous cell lung carcinoma;
BRCA	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	19.8	0.62	2.22e-68	Lymphocyte percentage of white cells;
BRCA	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg08601574	chr20:25228251	PYGB	0.38	9.19	0.34	5.5e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs921968	0.565	rs7599365	chr2:219620566	G/A	cg02176678	chr2:219576539	TTLL4	-0.41	-11.03	-0.4	5.37e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg08888203	chr3:10149979	C3orf24	0.57	12.11	0.43	1.62e-30	Alzheimer's disease;
BRCA	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.78	-0.36	3.92e-21	IgG glycosylation;
BRCA	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.47	-8.37	-0.31	3.78e-16	Schizophrenia;
BRCA	cis	rs3772130	0.923	rs4298081	chr3:121526037	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.91	0.4	1.63e-25	Cognitive performance;
BRCA	cis	rs6484504	0.576	rs2447671	chr11:31334323	A/G	cg06552810	chr11:31128660	NA	-0.37	-8.41	-0.32	2.64e-16	Red blood cell count;
BRCA	cis	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg06521331	chr12:34319734	NA	-0.66	-12.09	-0.43	1.83e-30	Morning vs. evening chronotype;
BRCA	cis	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg06521331	chr12:34319734	NA	-0.52	-10.3	-0.38	4.16e-23	Morning vs. evening chronotype;
BRCA	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24531977	chr5:56204891	C5orf35	-0.85	-17.66	-0.57	4.01e-57	Initial pursuit acceleration;
BRCA	cis	rs6901250	0.655	rs1398403	chr6:117122646	T/C	cg12892004	chr6:117198278	RFX6	0.38	9.27	0.34	2.76e-19	C-reactive protein levels;
BRCA	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.17	0.31	1.68e-15	Depression;
BRCA	cis	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg05084668	chr3:125655381	ALG1L	-0.82	-11.52	-0.41	4.73e-28	Blood pressure (smoking interaction);
BRCA	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg19678392	chr7:94953810	PON1	-0.43	-9.01	-0.34	2.41e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6120849	0.754	rs6120797	chr20:33606002	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	10.3	0.38	4.11e-23	Protein C levels;
BRCA	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg11301795	chr4:187892539	NA	0.31	10.28	0.38	4.82e-23	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg07211511	chr3:129823064	LOC729375	-0.58	-10.71	-0.39	1.02e-24	Blood pressure (smoking interaction);
BRCA	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg15605315	chr1:45957053	TESK2	0.49	10.13	0.37	1.81e-22	High light scatter reticulocyte count;
BRCA	cis	rs13315871	0.929	rs9837903	chr3:58301906	A/T	cg20936604	chr3:58311152	NA	-0.67	-8.65	-0.32	4.09e-17	Cholesterol, total;
BRCA	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg07828340	chr4:882639	GAK	1.03	12.36	0.44	1.34e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs2346177	0.875	rs6726089	chr2:46645480	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.4	8.22	0.31	1.11e-15	HDL cholesterol;
BRCA	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg05868516	chr6:26286170	HIST1H4H	0.39	8.4	0.32	2.91e-16	Educational attainment;
BRCA	cis	rs9633740	0.578	rs11185982	chr10:82305627	C/T	cg01528321	chr10:82214614	TSPAN14	0.75	12.25	0.44	3.78e-31	Post bronchodilator FEV1;
BRCA	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.59	8.98	0.33	3.06e-18	Renal function-related traits (BUN);
BRCA	cis	rs4742903	0.967	rs6479215	chr9:106885243	A/G	cg14250997	chr9:106856677	SMC2	-0.37	-11.82	-0.42	2.78e-29	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	9.25	0.34	3.44e-19	Platelet count;
BRCA	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg18196295	chr10:418757	DIP2C	0.46	10.96	0.4	9.86e-26	Psychosis in Alzheimer's disease;
BRCA	cis	rs654351	0.572	rs556578	chr6:10388755	T/C	cg04978078	chr6:10383147	NA	-0.43	-8.33	-0.31	4.83e-16	Squamous cell lung carcinoma;
BRCA	cis	rs977987	0.806	rs6564252	chr16:75388940	C/T	cg03315344	chr16:75512273	CHST6	0.51	11.9	0.43	1.21e-29	Dupuytren's disease;
BRCA	cis	rs4566357	0.595	rs2272203	chr2:227914655	C/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-9.15	-0.34	7.51e-19	Coronary artery disease;
BRCA	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.82	0.36	2.73e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg27211696	chr2:191398769	TMEM194B	-0.47	-10.73	-0.39	8.03e-25	Pulse pressure;
BRCA	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg03146154	chr1:46216737	IPP	0.52	11.54	0.42	3.9e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg01262667	chr19:19385393	TM6SF2	0.39	9.83	0.36	2.47e-21	Tonsillectomy;
BRCA	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06481639	chr22:41940642	POLR3H	-0.53	-8.72	-0.33	2.42e-17	Vitiligo;
BRCA	cis	rs870825	0.616	rs4610378	chr4:185624220	C/T	cg04058563	chr4:185651563	MLF1IP	-0.74	-16.9	-0.56	3.17e-53	Blood protein levels;
BRCA	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg21361702	chr7:150065534	REPIN1	0.55	9.96	0.37	7.73e-22	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs35995292	0.534	rs7793692	chr7:38940580	G/C	cg19327137	chr7:38886074	VPS41	0.38	12.61	0.45	1.02e-32	Subjective well-being (multi-trait analysis);
BRCA	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11644478	chr21:40555479	PSMG1	0.54	11.57	0.42	3.2e-28	Menarche (age at onset);
BRCA	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg20701182	chr2:24300061	SF3B14	0.55	8.53	0.32	1.09e-16	Lymphocyte counts;
BRCA	cis	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg06521331	chr12:34319734	NA	0.66	12.31	0.44	2.08e-31	Morning vs. evening chronotype;
BRCA	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg00071950	chr4:10020882	SLC2A9	0.53	12.54	0.44	2e-32	Bone mineral density;
BRCA	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.1	-0.43	1.73e-30	Response to antipsychotic treatment;
BRCA	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-9.29	-0.34	2.38e-19	Fear of minor pain;
BRCA	cis	rs1568889	1.000	rs2354427	chr11:28049623	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	14.76	0.5	1.21e-42	Bipolar disorder;
BRCA	cis	rs11585357	0.895	rs72633808	chr1:17618665	A/G	cg08277548	chr1:17600880	PADI3	-0.75	-12.48	-0.44	4.02e-32	Hair shape;
BRCA	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.76	0.39	6.17e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg00666640	chr1:248458726	OR2T12	0.34	9.11	0.34	1.03e-18	Common traits (Other);
BRCA	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg05340658	chr4:99064831	C4orf37	0.61	14.6	0.5	6.82e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs36051895	0.623	rs10975033	chr9:5262567	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-9.01	-0.34	2.44e-18	Pediatric autoimmune diseases;
BRCA	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-12.07	-0.43	2.4e-30	Gut microbiome composition (summer);
BRCA	cis	rs3750965	0.959	rs11228490	chr11:68860872	C/G	cg06818126	chr11:68850279	TPCN2	0.34	8.25	0.31	9.27e-16	Hair color;
BRCA	cis	rs11608355	0.515	rs7976796	chr12:109928013	C/T	cg05360138	chr12:110035743	NA	0.74	13.54	0.47	6.41e-37	Neuroticism;
BRCA	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg21252483	chr19:49399788	TULP2	-0.51	-10.86	-0.39	2.46e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.9	-0.51	2.56e-43	Total cholesterol levels;
BRCA	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.61	9.97	0.37	7.53e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg03954927	chr1:10346856	KIF1B	0.44	13.05	0.46	1.08e-34	Hepatocellular carcinoma;
BRCA	cis	rs6539267	0.748	rs1921953	chr12:106721012	C/T	cg02476566	chr12:106696527	TCP11L2	0.43	8.03	0.3	4.6e-15	Tourette syndrome;
BRCA	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-10.83	-0.39	3.37e-25	Chronic sinus infection;
BRCA	cis	rs858239	0.699	rs1881201	chr7:23194013	C/T	cg23682824	chr7:23144976	KLHL7	-0.32	-8.46	-0.32	1.81e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg08132940	chr7:1081526	C7orf50	-0.6	-8.99	-0.34	2.69e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7092929	0.574	rs10795050	chr10:3538655	C/G	cg14308648	chr10:3568949	NA	0.44	9.97	0.37	7.59e-22	Coronary artery calcification;
BRCA	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12826209	chr6:26865740	GUSBL1	0.59	10.4	0.38	1.65e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-9.11	-0.34	1.07e-18	Renal function-related traits (BUN);
BRCA	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg17971929	chr21:40555470	PSMG1	0.6	14.01	0.48	4.36e-39	Cognitive function;
BRCA	cis	rs870825	0.929	rs55746424	chr4:185589603	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	14.4	0.49	6.56e-41	Blood protein levels;
BRCA	cis	rs7766436	0.848	rs2294828	chr6:22598018	G/A	cg13666174	chr6:22585274	NA	-0.48	-11.32	-0.41	3.22e-27	Coronary artery disease;
BRCA	cis	rs708547	0.647	rs6843644	chr4:57891239	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.41	10.6	0.39	2.66e-24	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2430307	0.556	rs3930019	chr7:76541610	C/T	cg15770687	chr7:76625569	PMS2L11	0.53	9.14	0.34	8.51e-19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs13046373	0.562	rs12627602	chr21:32022924	G/A	cg16431978	chr21:31797932	KRTAP13-3	0.35	8.98	0.33	2.89e-18	HDL cholesterol;
BRCA	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg18270830	chr10:32634957	EPC1	0.58	9.98	0.37	6.64e-22	Sexual dysfunction (female);
BRCA	cis	rs6435161	0.919	rs7566220	chr2:203594559	A/G	cg18429434	chr2:203499731	FAM117B	-0.46	-9.03	-0.34	1.95e-18	Total cholesterol levels;
BRCA	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg11764359	chr7:65958608	NA	0.64	14.21	0.49	5.32e-40	Aortic root size;
BRCA	cis	rs1568889	1.000	rs9783281	chr11:28033786	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	14.35	0.49	1.07e-40	Bipolar disorder;
BRCA	trans	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.73	-0.36	5.73e-21	Morning vs. evening chronotype;
BRCA	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg08645402	chr16:4508243	NA	0.4	9.47	0.35	5.3e-20	Schizophrenia;
BRCA	cis	rs10046574	0.656	rs17403326	chr7:135194440	T/G	cg27474649	chr7:135195673	CNOT4	0.66	10.84	0.39	2.93e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs4839827	1	rs4839827	chr6:96853967	C/T	cg06623918	chr6:96969491	KIAA0776	0.6	13.7	0.48	1.2e-37	Migraine;
BRCA	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg02574844	chr11:5959923	NA	-0.43	-9.68	-0.36	8.71e-21	DNA methylation (variation);
BRCA	trans	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg06521331	chr12:34319734	NA	-0.5	-9.12	-0.34	9.82e-19	Bladder cancer;
BRCA	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-7.94	-0.3	8.8e-15	Ulcerative colitis;
BRCA	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg22903471	chr2:27725779	GCKR	-0.35	-8.61	-0.32	5.83e-17	Total body bone mineral density;
BRCA	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg00071950	chr4:10020882	SLC2A9	0.42	9.69	0.36	8.06e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	17.01	0.56	8.73e-54	Colorectal cancer;
BRCA	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg04362960	chr10:104952993	NT5C2	0.39	9.27	0.34	2.72e-19	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg03433033	chr1:76189801	ACADM	-0.51	-10.11	-0.37	2.11e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg26384229	chr12:38710491	ALG10B	0.55	12.04	0.43	3.26e-30	Morning vs. evening chronotype;
BRCA	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg08085267	chr17:45401833	C17orf57	0.67	14.9	0.51	2.68e-43	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs11051970	0.679	rs2651366	chr12:32560431	T/C	cg24626660	chr12:32551988	NA	0.31	9.18	0.34	5.82e-19	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs11229555	0.874	rs11601687	chr11:58338628	T/C	cg15696309	chr11:58395628	NA	-0.54	-11.75	-0.42	5.45e-29	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.51	-9.02	-0.34	2.22e-18	Schizophrenia;
BRCA	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg23029597	chr12:123009494	RSRC2	-0.6	-11.78	-0.42	3.83e-29	Body mass index;
BRCA	cis	rs7927771	0.524	rs2242081	chr11:47500267	T/C	cg20307385	chr11:47447363	PSMC3	0.45	10.08	0.37	2.85e-22	Subjective well-being;
BRCA	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08109568	chr15:31115862	NA	-0.44	-10.26	-0.38	5.56e-23	Huntington's disease progression;
BRCA	trans	rs11039798	0.844	rs11040177	chr11:48976211	G/C	cg15704280	chr7:45808275	SEPT13	0.6	8.89	0.33	6.42e-18	Axial length;
BRCA	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07080220	chr10:102295463	HIF1AN	0.48	10.76	0.39	6.5e-25	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.33	-8.51	-0.32	1.21e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg19156104	chr2:198669113	PLCL1	-0.44	-8.13	-0.31	2.19e-15	Ulcerative colitis;
BRCA	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg18252515	chr7:66147081	NA	-0.97	-13.78	-0.48	5.15e-38	Diabetic kidney disease;
BRCA	cis	rs600231	0.508	rs11227202	chr11:65242717	G/A	cg01292856	chr11:65242576	NA	0.66	14.88	0.51	3.36e-43	Bone mineral density;
BRCA	cis	rs17604090	0.775	rs73090343	chr7:29688768	T/C	cg19413766	chr7:29689036	LOC646762	-0.61	-8.71	-0.33	2.53e-17	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg07395648	chr5:131743802	NA	-0.38	-8.58	-0.32	6.98e-17	Breast cancer;Mosquito bite size;
BRCA	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg12386194	chr3:101231763	SENP7	0.46	9.91	0.37	1.21e-21	Colorectal cancer;
BRCA	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	trans	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.41	0.5	5.6e-41	Exhaled nitric oxide output;
BRCA	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg24803719	chr17:45855879	NA	-0.32	-8.35	-0.31	4.14e-16	IgG glycosylation;
BRCA	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg01877450	chr7:97915802	BRI3	-0.37	-8.51	-0.32	1.24e-16	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-15.49	-0.52	3.38e-46	Obesity-related traits;
BRCA	cis	rs2629540	0.847	rs10901807	chr10:126384610	G/A	cg08799069	chr10:126477246	METTL10	0.47	9.46	0.35	5.57e-20	Cocaine dependence;
BRCA	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg23708337	chr7:1209742	NA	0.6	8.31	0.31	5.89e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12541635	0.677	rs7846149	chr8:107053417	T/C	cg10147462	chr8:107024639	NA	0.4	10.83	0.39	3.22e-25	Age of smoking initiation;
BRCA	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg19318889	chr4:1322082	MAEA	0.57	11.47	0.41	7.96e-28	Longevity;
BRCA	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg27170947	chr2:26402098	FAM59B	-0.97	-17.16	-0.56	1.38e-54	Gut microbiome composition (summer);
BRCA	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg22189786	chr22:42395067	WBP2NL	0.43	8.68	0.32	3.29e-17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.81e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg03929089	chr4:120376271	NA	0.69	13.7	0.48	1.17e-37	Height;
BRCA	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg11843238	chr5:131593191	PDLIM4	0.42	10.58	0.39	3.1e-24	Acylcarnitine levels;
BRCA	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	8.65e-21	Menopause (age at onset);
BRCA	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24549020	chr5:56110836	MAP3K1	0.68	13.71	0.48	1.08e-37	Initial pursuit acceleration;
BRCA	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg24642844	chr7:1081250	C7orf50	-0.89	-16.0	-0.53	1.07e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg25517755	chr10:38738941	LOC399744	-0.37	-7.85	-0.3	1.73e-14	Corneal astigmatism;
BRCA	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg19622623	chr12:86230825	RASSF9	-0.33	-9.09	-0.34	1.19e-18	Major depressive disorder;
BRCA	cis	rs870825	0.929	rs10015218	chr4:185589789	T/C	cg04058563	chr4:185651563	MLF1IP	0.68	11.52	0.41	4.92e-28	Blood protein levels;
BRCA	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg01448562	chr3:133502909	NA	0.4	9.05	0.34	1.66e-18	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs2554380	0.943	rs2401128	chr15:84347178	C/A	cg14598478	chr15:84363061	ADAMTSL3	-0.32	-7.95	-0.3	8.2e-15	Height;
BRCA	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg01819863	chr10:32635814	EPC1	1.16	20.46	0.63	6.39e-72	Sexual dysfunction (female);
BRCA	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06544989	chr22:39130855	UNC84B	-0.35	-8.22	-0.31	1.13e-15	Menopause (age at onset);
BRCA	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23583168	chr7:148888333	NA	-0.72	-15.66	-0.53	5.3e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.02	0.3	4.91e-15	Corneal astigmatism;
BRCA	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg20476274	chr7:133979776	SLC35B4	0.7	21.43	0.65	3.5e-77	Mean platelet volume;
BRCA	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.07	16.15	0.54	1.85e-49	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.23	-0.31	1.03e-15	Breast cancer;
BRCA	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.49	-10.68	-0.39	1.27e-24	Longevity;Endometriosis;
BRCA	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg13010199	chr12:38710504	ALG10B	0.52	10.93	0.4	1.28e-25	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2282802	0.685	rs1529693	chr5:139678213	A/G	cg26211634	chr5:139558579	C5orf32	0.32	7.81	0.3	2.36e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs3892630	0.588	rs12610342	chr19:33250690	C/T	cg22980127	chr19:33182716	NUDT19	0.9	19.76	0.62	3.56e-68	Red blood cell traits;
BRCA	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg00717180	chr2:96193071	NA	-0.38	-10.34	-0.38	2.9e-23	HDL cholesterol;
BRCA	cis	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg07460842	chr6:66804631	NA	0.88	14.18	0.49	7.35e-40	Exhaled nitric oxide output;
BRCA	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs4730250	0.707	rs80095766	chr7:106901394	G/T	cg02696742	chr7:106810147	HBP1	-0.47	-8.34	-0.31	4.62e-16	Osteoarthritis;
BRCA	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg26587870	chr6:27730563	NA	-0.44	-7.91	-0.3	1.17e-14	Lung cancer in ever smokers;
BRCA	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg00717180	chr2:96193071	NA	-0.38	-10.34	-0.38	2.9e-23	HDL cholesterol;
BRCA	cis	rs2992756	0.663	rs2992753	chr1:18808292	A/C	cg14356550	chr1:18808102	KLHDC7A	0.41	8.55	0.32	9.35e-17	Breast cancer;
BRCA	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg13319975	chr6:146136371	FBXO30	-0.36	-8.28	-0.31	7.48e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg20503657	chr10:835505	NA	-0.92	-15.58	-0.52	1.21e-46	Eosinophil percentage of granulocytes;
BRCA	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg15017067	chr4:17643749	FAM184B	0.35	10.83	0.39	3.2e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-8.66	-0.32	3.97e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs999943	0.810	rs57088429	chr6:33644189	G/A	cg14003231	chr6:33640908	ITPR3	0.68	14.92	0.51	1.99e-43	Obesity (extreme);
BRCA	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.78	19.37	0.61	4.37e-66	Systemic lupus erythematosus;
BRCA	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	8.98	0.33	3.02e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg07988820	chr12:82153109	PPFIA2	-0.68	-11.44	-0.41	1.05e-27	Resting heart rate;
BRCA	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg10223061	chr2:219282414	VIL1	0.3	8.55	0.32	8.83e-17	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg12463550	chr7:65579703	CRCP	0.38	8.02	0.3	5.21e-15	Aortic root size;
BRCA	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg25554036	chr4:6271136	WFS1	0.42	9.99	0.37	6.36e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.52e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg01939980	chr4:1354348	KIAA1530	0.31	8.27	0.31	7.87e-16	Obesity-related traits;
BRCA	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg00071950	chr4:10020882	SLC2A9	-0.43	-9.95	-0.37	8.55e-22	Bone mineral density;
BRCA	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg15133208	chr4:90757351	SNCA	-0.41	-8.58	-0.32	7.38e-17	Neuroticism;
BRCA	cis	rs3820928	0.904	rs4414671	chr2:227816200	T/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.7	-0.33	2.7e-17	Pulmonary function;
BRCA	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg12193833	chr17:30244370	NA	-0.56	-8.77	-0.33	1.58e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg21770322	chr7:97807741	LMTK2	0.41	10.94	0.4	1.14e-25	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs36051895	0.659	rs62541556	chr9:5049092	G/T	cg02405213	chr9:5042618	JAK2	-0.51	-9.11	-0.34	1.02e-18	Pediatric autoimmune diseases;
BRCA	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-12.8	-0.45	1.41e-33	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.720	rs1611755	chr1:152956420	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.99	-0.33	2.87e-18	Inflammatory skin disease;
BRCA	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.47	9.68	0.36	8.89e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg06552810	chr11:31128660	NA	-0.4	-8.82	-0.33	1.09e-17	Red blood cell count;
BRCA	cis	rs6867032	1.000	rs4975796	chr5:2015520	A/T	cg26168224	chr5:2018326	NA	-0.63	-16.69	-0.55	3.66e-52	Gut microbiome composition (winter);
BRCA	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs62229266	0.804	rs2835241	chr21:37411380	G/T	cg12218747	chr21:37451666	NA	0.33	7.88	0.3	1.42e-14	Mitral valve prolapse;
BRCA	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg07640336	chr12:132677496	NA	0.49	11.27	0.41	5.13e-27	Anti-saccade response;
BRCA	cis	rs870825	0.587	rs7682995	chr4:185640684	G/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.18	0.56	1.08e-54	Blood protein levels;
BRCA	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg26373071	chr5:1325741	CLPTM1L	0.46	11.11	0.4	2.44e-26	Lung cancer;
BRCA	cis	rs3784262	0.935	rs4646636	chr15:58251034	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-11.61	-0.42	2.06e-28	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-7.96	-0.3	8.12e-15	Homocysteine levels;
BRCA	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg18129178	chr5:148520854	ABLIM3	0.58	11.94	0.43	8.25e-30	Breast cancer;
BRCA	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg24562669	chr7:97807699	LMTK2	0.44	11.74	0.42	5.96e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4662945	0.603	rs10168574	chr2:130267823	C/T	cg05903289	chr2:130345205	NA	-0.34	-8.29	-0.31	6.57e-16	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg04362960	chr10:104952993	NT5C2	0.39	9.37	0.35	1.18e-19	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs2625529	0.590	rs12904652	chr15:72548765	T/C	cg16672083	chr15:72433130	SENP8	-0.66	-14.5	-0.5	2.04e-41	Red blood cell count;
BRCA	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg25427524	chr10:38739819	LOC399744	-0.44	-9.28	-0.34	2.68e-19	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg04166393	chr7:2884313	GNA12	0.49	9.86	0.36	1.97e-21	Height;
BRCA	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg02659138	chr7:134003124	SLC35B4	0.35	10.01	0.37	5.01e-22	Mean platelet volume;
BRCA	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.94e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg25664220	chr3:72788482	NA	-0.55	-11.73	-0.42	6.4e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.49	11.31	0.41	3.65e-27	Chronic sinus infection;
BRCA	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg23791538	chr6:167370224	RNASET2	-0.35	-8.24	-0.31	9.57e-16	Crohn's disease;
BRCA	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.8	0.36	3.11e-21	Bipolar disorder;
BRCA	trans	rs8002861	0.870	rs2875541	chr13:44417441	G/T	cg17145862	chr1:211918768	LPGAT1	0.62	15.9	0.53	3.33e-48	Leprosy;
BRCA	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg00631329	chr6:26305371	NA	-0.45	-13.04	-0.46	1.23e-34	Educational attainment;
BRCA	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg18964960	chr10:1102726	WDR37	0.65	8.71	0.33	2.69e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs501916	0.634	rs1561480	chr15:48070050	C/G	cg16110827	chr15:48056943	SEMA6D	-0.41	-8.71	-0.33	2.68e-17	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.57	7.98	0.3	6.98e-15	Putamen volume;
BRCA	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg10932868	chr11:921992	NA	0.49	12.57	0.45	1.54e-32	Alzheimer's disease (late onset);
BRCA	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg15839431	chr19:19639596	YJEFN3	-0.4	-8.6	-0.32	6.25e-17	Bipolar disorder;
BRCA	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg14675211	chr2:100938903	LONRF2	0.52	11.56	0.42	3.53e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	15.51	0.52	2.68e-46	Colorectal cancer;
BRCA	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg16576597	chr16:28551801	NUPR1	0.3	8.32	0.31	5.25e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs10501293	1.000	rs4495880	chr11:43133626	A/C	cg03447554	chr11:43094025	NA	-0.47	-8.66	-0.32	3.84e-17	Cognitive performance;
BRCA	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg18016565	chr1:150552671	MCL1	0.35	8.36	0.31	3.9e-16	Tonsillectomy;
BRCA	cis	rs654128	0.590	rs339346	chr6:117218693	T/G	cg12892004	chr6:117198278	RFX6	-0.42	-7.82	-0.3	2.2e-14	Telomere length;
BRCA	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.3	8.23	0.31	1.08e-15	Birth weight;
BRCA	cis	rs2279817	0.863	rs12023877	chr1:18025633	A/C	cg21791023	chr1:18019539	ARHGEF10L	0.51	15.94	0.53	2.01e-48	Neuroticism;
BRCA	trans	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	27.58	0.74	6.51e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.44	-9.05	-0.34	1.67e-18	Body mass index;
BRCA	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg03146154	chr1:46216737	IPP	0.53	11.8	0.42	3.38e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg16339924	chr4:17578868	LAP3	0.62	15.6	0.53	9.9e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs61935443	0.720	rs10859780	chr12:95282601	T/C	cg21533806	chr12:95267307	NA	0.45	8.65	0.32	4.09e-17	Schizophrenia;
BRCA	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08704250	chr15:31115839	NA	-0.36	-9.07	-0.34	1.42e-18	Huntington's disease progression;
BRCA	trans	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg02030672	chr11:45687055	CHST1	0.42	8.72	0.33	2.47e-17	Obesity-related traits;
BRCA	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.6	-0.77	2.62e-127	Schizophrenia;
BRCA	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.84	-17.06	-0.56	4.79e-54	HIV-1 control;
BRCA	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg12140854	chr5:148520817	ABLIM3	-0.42	-9.09	-0.34	1.21e-18	Breast cancer;
BRCA	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg05457628	chr5:178986728	RUFY1	-0.54	-13.42	-0.47	2.27e-36	Lung cancer;
BRCA	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg12165864	chr7:66369176	NA	-0.43	-9.22	-0.34	4.39e-19	Corneal structure;
BRCA	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23583168	chr7:148888333	NA	-0.86	-20.09	-0.62	5.61e-70	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.25	7.84	0.3	1.96e-14	Electroencephalogram traits;
BRCA	cis	rs7149337	0.805	rs2999361	chr14:51605358	G/A	cg23942311	chr14:51606299	NA	0.45	13.26	0.46	1.21e-35	Cancer;
BRCA	cis	rs2742234	0.541	rs10793424	chr10:43717116	G/T	cg15436174	chr10:43711423	RASGEF1A	0.53	10.6	0.39	2.8e-24	Hirschsprung disease;
BRCA	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg17143192	chr8:8559678	CLDN23	0.5	9.7	0.36	7.32e-21	Obesity-related traits;
BRCA	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg12311346	chr5:56204834	C5orf35	-0.62	-13.08	-0.46	7.94e-35	Initial pursuit acceleration;
BRCA	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg05340658	chr4:99064831	C4orf37	0.66	16.19	0.54	1.17e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg26384229	chr12:38710491	ALG10B	0.42	9.44	0.35	6.82e-20	Morning vs. evening chronotype;
BRCA	cis	rs2652822	0.525	rs2053633	chr15:63505649	G/A	cg02713581	chr15:63449717	RPS27L	0.41	8.3	0.31	6.15e-16	Metabolic traits;
BRCA	cis	rs7903847	0.667	rs10882931	chr10:99165794	C/A	cg08345082	chr10:99160200	RRP12	-0.3	-8.78	-0.33	1.44e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.4	8.92	0.33	4.92e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.19	-0.43	6.84e-31	Breast cancer;
BRCA	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg00666640	chr1:248458726	OR2T12	-0.32	-8.6	-0.32	6.37e-17	Common traits (Other);
BRCA	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg11887960	chr12:57824829	NA	0.56	8.66	0.32	3.7e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs4808199	0.649	rs17216693	chr19:19666574	T/C	cg03709012	chr19:19516395	GATAD2A	0.76	12.43	0.44	6.66e-32	Nonalcoholic fatty liver disease;
BRCA	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-9.27	-0.34	2.76e-19	Monocyte percentage of white cells;
BRCA	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg02951883	chr7:2050386	MAD1L1	-0.41	-9.58	-0.35	2.07e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-12.23	-0.44	4.82e-31	Electroencephalogram traits;
BRCA	cis	rs17384381	1.000	rs12118950	chr1:85864519	T/C	cg16011679	chr1:85725395	C1orf52	0.53	8.15	0.31	1.86e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg02734326	chr4:10020555	SLC2A9	0.37	8.32	0.31	5.16e-16	Bone mineral density;
BRCA	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg27170947	chr2:26402098	FAM59B	0.99	15.28	0.52	3.79e-45	Gut microbiome composition (summer);
BRCA	cis	rs6088813	0.961	rs745931	chr20:33956004	A/T	cg14752227	chr20:34000481	UQCC	-0.39	-8.4	-0.32	2.82e-16	Height;
BRCA	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg14343924	chr8:8086146	FLJ10661	-0.47	-9.45	-0.35	6.39e-20	Neuroticism;
BRCA	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg03609598	chr5:56110824	MAP3K1	-0.47	-8.01	-0.3	5.6e-15	Initial pursuit acceleration;
BRCA	cis	rs10189230	0.868	rs1367242	chr2:222353441	A/G	cg14652038	chr2:222343519	EPHA4	0.47	13.02	0.46	1.53e-34	Urate levels in lean individuals;
BRCA	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-9.0	-0.34	2.62e-18	Aortic root size;
BRCA	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg04944784	chr2:26401820	FAM59B	-0.64	-10.66	-0.39	1.61e-24	Gut microbiome composition (summer);
BRCA	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	30.52	0.77	6.7e-127	Chronic sinus infection;
BRCA	cis	rs9467773	0.626	rs9379860	chr6:26370605	T/C	cg09904177	chr6:26538194	HMGN4	-0.32	-8.74	-0.33	2.11e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.07	0.3	3.49e-15	Endometrial cancer;
BRCA	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg26597838	chr10:835615	NA	-0.5	-9.42	-0.35	7.83e-20	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg11752832	chr7:134001865	SLC35B4	0.53	13.77	0.48	5.95e-38	Mean platelet volume;
BRCA	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg06159980	chr1:16340746	HSPB7	-0.36	-8.29	-0.31	6.63e-16	Dilated cardiomyopathy;
BRCA	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg05340658	chr4:99064831	C4orf37	0.45	10.41	0.38	1.48e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.56	-0.32	8.5e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03713592	chr11:72463424	ARAP1	1.15	16.93	0.56	2.09e-53	Type 2 diabetes;
BRCA	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg25036284	chr2:26402008	FAM59B	0.96	15.93	0.53	2.36e-48	Gut microbiome composition (summer);
BRCA	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg00745463	chr17:30367425	LRRC37B	-0.55	-9.24	-0.34	3.7e-19	Hip circumference adjusted for BMI;
BRCA	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-12.74	-0.45	2.61e-33	Bipolar disorder;
BRCA	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	10.8	0.39	4.34e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9309473	0.687	rs12465867	chr2:73612102	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-12.35	-0.44	1.4e-31	Metabolite levels;
BRCA	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg09307838	chr4:120376055	NA	0.75	16.17	0.54	1.48e-49	Corneal astigmatism;
BRCA	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-11.16	-0.4	1.56e-26	Mood instability;
BRCA	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg17063962	chr7:91808500	NA	0.57	13.08	0.46	8.24e-35	Breast cancer;
BRCA	cis	rs7582720	0.945	rs72934601	chr2:204031137	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	12.25	0.44	3.99e-31	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.48	11.0	0.4	7.07e-26	Colorectal cancer;
BRCA	cis	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg04990556	chr1:26633338	UBXN11	-0.51	-8.39	-0.31	3.18e-16	Obesity-related traits;
BRCA	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.53	8.33	0.31	4.76e-16	Birth weight;
BRCA	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.55	8.74	0.33	2.07e-17	Platelet count;
BRCA	trans	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.4	-8.7	-0.33	2.8e-17	Brugada syndrome;
BRCA	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.96	-0.46	2.7200000000000002e-34	Migraine;Coronary artery disease;
BRCA	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.36	7.9	0.3	1.25e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	18.26	0.59	2.77e-60	Platelet count;
BRCA	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg24112000	chr20:60950667	NA	0.48	9.37	0.35	1.22e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg05340658	chr4:99064831	C4orf37	0.62	14.72	0.5	1.88e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg00071950	chr4:10020882	SLC2A9	0.4	8.52	0.32	1.19e-16	Blood metabolite levels;
BRCA	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.39	-0.44	9.32e-32	Chronic sinus infection;
BRCA	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg01939980	chr4:1354348	KIAA1530	0.31	8.66	0.32	3.72e-17	Longevity;
BRCA	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19346786	chr7:2764209	NA	-0.26	-8.01	-0.3	5.46e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
BRCA	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-14.06	-0.49	2.65e-39	Monocyte count;
BRCA	cis	rs600806	0.815	rs4970730	chr1:109979526	T/C	cg20591472	chr1:110008990	SYPL2	0.32	7.89	0.3	1.34e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg07460842	chr6:66804631	NA	1.0	20.0	0.62	1.76e-69	Exhaled nitric oxide output;
BRCA	cis	rs36052053	0.908	rs13220206	chr6:109624481	G/T	cg12927641	chr6:109611667	NA	-0.51	-7.96	-0.3	7.92e-15	Red cell distribution width;
BRCA	cis	rs10992471	0.603	rs12336884	chr9:95234183	A/C	cg14631576	chr9:95140430	CENPP	-0.38	-9.31	-0.35	2.01e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs698833	0.561	rs696597	chr2:44722553	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	8.02	0.3	5.16e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26314531	chr2:26401878	FAM59B	0.89	15.87	0.53	4.58e-48	Gut microbiome composition (summer);
BRCA	cis	rs8141797	0.901	rs5751804	chr22:24490105	A/C	cg00411358	chr22:24577142	SUSD2	0.63	7.9	0.3	1.21e-14	Amyotrophic lateral sclerosis;Coronary artery disease;
BRCA	trans	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg11693508	chr17:37793320	STARD3	0.59	11.0	0.4	6.74e-26	Bipolar disorder;
BRCA	cis	rs4363385	0.747	rs1338180	chr1:152981404	A/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.86	-0.36	1.92e-21	Inflammatory skin disease;
BRCA	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg25382214	chr1:3105252	PRDM16	-0.34	-8.03	-0.3	4.54e-15	Migraine;
BRCA	cis	rs365132	0.934	rs251844	chr5:176476605	T/A	cg16309518	chr5:176445507	NA	-0.51	-13.0	-0.46	1.86e-34	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs6700896	0.931	rs4655764	chr1:66126159	C/T	cg04111102	chr1:66153794	NA	0.34	8.46	0.32	1.88e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg21475434	chr5:93447410	FAM172A	0.61	8.26	0.31	8.26e-16	Diabetic retinopathy;
BRCA	cis	rs7255436	0.931	rs7249520	chr19:8446056	G/A	cg10174797	chr19:8464628	RAB11B	0.35	8.91	0.33	5.31e-18	HDL cholesterol;
BRCA	trans	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg21659725	chr3:3221576	CRBN	0.48	8.84	0.33	9.32e-18	Menarche (age at onset);
BRCA	cis	rs10193935	0.901	rs7601905	chr2:42494144	A/G	cg27598129	chr2:42591480	NA	-0.55	-9.31	-0.35	2.08e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs698813	0.763	rs786614	chr2:44590567	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	11.02	0.4	5.64e-26	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00149659	chr3:10157352	C3orf10	0.81	14.21	0.49	5.29e-40	Alzheimer's disease;
BRCA	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg11766577	chr21:47581405	C21orf56	-0.48	-10.88	-0.4	2.15e-25	Testicular germ cell tumor;
BRCA	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg26031613	chr14:104095156	KLC1	0.65	14.23	0.49	3.94e-40	Body mass index;
BRCA	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg23711669	chr6:146136114	FBXO30	-0.78	-18.28	-0.59	2.24e-60	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg01097406	chr16:89675127	NA	-0.46	-8.56	-0.32	8.6e-17	Vitiligo;
BRCA	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.22	-0.37	8.51e-23	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg19077165	chr18:44547161	KATNAL2	-0.56	-12.25	-0.44	3.83e-31	Personality dimensions;
BRCA	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg02187348	chr16:89574699	SPG7	0.37	8.67	0.32	3.42e-17	Multiple myeloma (IgH translocation);
BRCA	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg21770322	chr7:97807741	LMTK2	0.44	11.74	0.42	6.15e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg16339924	chr4:17578868	LAP3	0.68	16.62	0.55	8.17e-52	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7020830	0.898	rs2047010	chr9:37077947	A/G	cg14294708	chr9:37120828	ZCCHC7	1.16	40.09	0.85	1.44e-176	Schizophrenia;
BRCA	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.75	-0.55	1.78e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs13102973	0.867	rs4521398	chr4:135906934	T/G	cg14419869	chr4:135874104	NA	0.45	8.99	0.34	2.75e-18	Subjective well-being;
BRCA	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	10.57	0.39	3.58e-24	Neuroticism;
BRCA	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-8.67	-0.32	3.64e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6121246	0.609	rs6089054	chr20:30323141	A/G	cg13852791	chr20:30311386	BCL2L1	0.84	18.23	0.58	4.23e-60	Mean corpuscular hemoglobin;
BRCA	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	19.68	0.61	9.03e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7301826	0.627	rs4334059	chr12:131314214	T/C	cg11011512	chr12:131303247	STX2	0.46	11.63	0.42	1.75e-28	Plasma plasminogen activator levels;
BRCA	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg22467129	chr15:76604101	ETFA	-0.48	-10.55	-0.39	4.25e-24	Blood metabolite levels;
BRCA	cis	rs10465746	0.752	rs10874426	chr1:84451820	A/G	cg10977910	chr1:84465055	TTLL7	0.62	13.37	0.47	4.14e-36	Obesity-related traits;
BRCA	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg21535247	chr6:8435926	SLC35B3	0.42	9.42	0.35	7.86e-20	Motion sickness;
BRCA	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg24562669	chr7:97807699	LMTK2	-0.5	-13.87	-0.48	2.09e-38	Breast cancer;
BRCA	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg03161606	chr19:29218774	NA	0.46	8.04	0.3	4.23e-15	Methadone dose in opioid dependence;
BRCA	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg05340658	chr4:99064831	C4orf37	0.66	16.1	0.54	3.26e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6545883	0.862	rs778141	chr2:61682178	A/G	cg15711740	chr2:61764176	XPO1	-0.52	-12.47	-0.44	4.25e-32	Tuberculosis;
BRCA	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg22903471	chr2:27725779	GCKR	-0.36	-8.43	-0.32	2.35e-16	Total body bone mineral density;
BRCA	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg24642439	chr20:33292090	TP53INP2	-0.52	-11.42	-0.41	1.3e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg08645402	chr16:4508243	NA	0.43	9.87	0.36	1.8e-21	Schizophrenia;
BRCA	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg17971929	chr21:40555470	PSMG1	-0.63	-14.03	-0.49	3.54e-39	Cognitive function;
BRCA	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg22907277	chr7:1156413	C7orf50	0.46	10.79	0.39	4.75e-25	Longevity;Endometriosis;
BRCA	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.1	0.31	2.83e-15	Parkinson's disease;
BRCA	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg11062466	chr8:58055876	NA	0.51	12.34	0.44	1.54e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	17.15	0.56	1.55e-54	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg11822812	chr5:140052017	DND1	-0.32	-9.02	-0.34	2.19e-18	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.65	0.55	5.42e-52	Alzheimer's disease (late onset);
BRCA	trans	rs11165623	0.564	rs6593611	chr1:97001996	T/C	cg10631902	chr5:14652156	NA	-0.43	-12.14	-0.43	1.18e-30	Hip circumference;Waist circumference;
BRCA	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-13.72	-0.48	9.53e-38	Morning vs. evening chronotype;
BRCA	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg20090143	chr19:45452003	APOC2	0.27	7.89	0.3	1.31e-14	Blood protein levels;
BRCA	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.46	-8.33	-0.31	5.03e-16	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.64	0.32	4.61e-17	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg04166393	chr7:2884313	GNA12	0.42	9.03	0.34	2.02e-18	Height;
BRCA	cis	rs68170813	0.559	rs80212020	chr7:106957596	C/T	cg02696742	chr7:106810147	HBP1	-0.54	-8.67	-0.32	3.66e-17	Coronary artery disease;
BRCA	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg08601574	chr20:25228251	PYGB	0.35	8.47	0.32	1.63e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg06766960	chr11:133703094	NA	-0.61	-12.64	-0.45	7.67e-33	Childhood ear infection;
BRCA	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-13.71	-0.48	1.08e-37	Morning vs. evening chronotype;
BRCA	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.42	-0.38	1.38e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs4650994	0.507	rs12405456	chr1:178512331	T/G	cg05059571	chr16:84539110	KIAA1609	-0.57	-13.03	-0.46	1.41e-34	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs2882667	0.690	rs13181762	chr5:138250106	G/A	cg04439458	chr5:138467593	SIL1	-0.32	-8.03	-0.3	4.61e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg17063962	chr7:91808500	NA	0.52	12.33	0.44	1.72e-31	Breast cancer;
BRCA	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg13902645	chr11:5959945	NA	-0.57	-11.47	-0.41	8.11e-28	DNA methylation (variation);
BRCA	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	27.2	0.73	7.83e-109	Chronic sinus infection;
BRCA	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg14196790	chr5:131705035	SLC22A5	0.44	11.54	0.42	4.09e-28	Blood metabolite levels;
BRCA	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg14675211	chr2:100938903	LONRF2	0.44	10.04	0.37	3.87e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.694	rs11179394	chr12:38210389	A/G	cg26384229	chr12:38710491	ALG10B	-0.45	-10.21	-0.37	8.93e-23	Bladder cancer;
BRCA	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg11764359	chr7:65958608	NA	0.45	8.66	0.32	3.7e-17	Calcium levels;
BRCA	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18876405	chr7:65276391	NA	0.5	11.38	0.41	1.89e-27	Aortic root size;
BRCA	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg00814883	chr7:100076585	TSC22D4	-0.51	-11.67	-0.42	1.17e-28	Platelet count;
BRCA	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg21475434	chr5:93447410	FAM172A	0.66	8.71	0.33	2.68e-17	Diabetic retinopathy;
BRCA	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg13047869	chr3:10149882	C3orf24	0.55	11.42	0.41	1.25e-27	Alzheimer's disease;
BRCA	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.94	0.3	8.88e-15	Depression;
BRCA	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg03146154	chr1:46216737	IPP	0.52	11.61	0.42	2e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.36	0.35	1.39e-19	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08280861	chr8:58055591	NA	0.57	8.82	0.33	1.11e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs11112613	0.775	rs7959699	chr12:105959848	C/A	cg03607813	chr12:105948248	NA	0.53	9.93	0.37	1.01e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs312274	0.588	rs11178530	chr12:41211874	G/C	cg17827154	chr12:41323612	CNTN1	0.32	7.9	0.3	1.2e-14	Metabolite levels  (X-11787);
BRCA	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10802521	chr3:52805072	NEK4	-0.33	-8.91	-0.33	5.38e-18	Bipolar disorder;
BRCA	cis	rs9815354	0.638	rs73073258	chr3:42017894	G/A	cg03022575	chr3:42003672	ULK4	0.75	9.65	0.36	1.17e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7520050	0.966	rs4660317	chr1:46326226	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.89	0.36	1.5e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs6088813	1.000	rs6060401	chr20:34005214	C/T	cg14752227	chr20:34000481	UQCC	-0.37	-7.85	-0.3	1.81e-14	Height;
BRCA	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	ch.11.42038R	chr11:967971	AP2A2	0.45	13.68	0.48	1.47e-37	Alzheimer's disease (late onset);
BRCA	cis	rs57920188	0.537	rs4440829	chr1:4080780	A/G	cg10510935	chr1:4059661	NA	-0.38	-8.08	-0.3	3.15e-15	Interleukin-17 levels;
BRCA	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg08085267	chr17:45401833	C17orf57	0.68	14.87	0.51	3.69e-43	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-8.11	-0.31	2.66e-15	Menarche (age at onset);
BRCA	cis	rs151349	0.743	rs151353	chr20:57604343	A/C	cg23907860	chr20:57583709	CTSZ	-0.37	-8.71	-0.33	2.67e-17	Platelet distribution width;
BRCA	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg21427119	chr20:30132790	HM13	-0.42	-8.83	-0.33	9.87e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs495337	0.965	rs12151879	chr20:48549242	C/T	cg17835207	chr20:48524531	SPATA2	-0.65	-15.14	-0.51	1.87e-44	Psoriasis;
BRCA	cis	rs2415984	0.622	rs28487986	chr14:46924435	T/G	cg14871534	chr14:47121158	RPL10L	-0.35	-8.3	-0.31	6.1e-16	Number of children ever born;
BRCA	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg19156104	chr2:198669113	PLCL1	-0.44	-8.15	-0.31	1.99e-15	Ulcerative colitis;
BRCA	cis	rs867371	0.722	rs8033050	chr15:82561989	G/A	cg00614314	chr15:82944287	LOC80154	0.47	9.63	0.36	1.42e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg26384229	chr12:38710491	ALG10B	0.54	13.71	0.48	1.05e-37	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	8.32	0.31	5.24e-16	Schizophrenia;
BRCA	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11644478	chr21:40555479	PSMG1	0.81	18.1	0.58	1.96e-59	Cognitive function;
BRCA	cis	rs2637266	0.935	rs4520537	chr10:78392978	C/T	cg18941641	chr10:78392320	NA	0.37	8.38	0.31	3.39e-16	Pulmonary function;
BRCA	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg22974920	chr21:40686053	BRWD1	-0.39	-8.71	-0.33	2.52e-17	Cognitive function;
BRCA	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg12483005	chr1:23474871	LUZP1	0.47	10.17	0.37	1.33e-22	Height;
BRCA	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.65	-15.6	-0.53	1e-46	Ulcerative colitis;
BRCA	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg08213375	chr14:104286397	PPP1R13B	0.64	18.05	0.58	3.45e-59	Schizophrenia;
BRCA	cis	rs2764980	1.000	rs2814925	chr10:3284061	A/G	cg11630169	chr10:3283847	NA	-0.42	-9.53	-0.35	3.13e-20	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs2882667	0.690	rs10054682	chr5:138259443	C/T	cg04439458	chr5:138467593	SIL1	-0.35	-8.61	-0.32	5.84e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10503871	0.905	rs6993952	chr8:30440564	T/C	cg26383811	chr8:30366931	RBPMS	0.33	8.91	0.33	5.21e-18	Metabolite levels  (X-11787);
BRCA	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.53	-0.38	4.9299999999999996e-24	Mean corpuscular volume;
BRCA	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg08000102	chr2:233561755	GIGYF2	-0.61	-13.56	-0.47	5.62e-37	Coronary artery disease;
BRCA	cis	rs9420	0.961	rs11607056	chr11:57496820	C/T	cg19752551	chr11:57585705	CTNND1	-0.51	-12.43	-0.44	6.59e-32	Schizophrenia;
BRCA	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg18402987	chr7:1209562	NA	0.88	14.46	0.5	3.45e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg06552810	chr11:31128660	NA	-0.39	-8.73	-0.33	2.2e-17	Red blood cell count;
BRCA	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg06623918	chr6:96969491	KIAA0776	0.73	13.06	0.46	9.81e-35	Migraine;Coronary artery disease;
BRCA	trans	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	9.29	0.34	2.37e-19	Mean corpuscular volume;
BRCA	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg21427119	chr20:30132790	HM13	-0.43	-9.01	-0.34	2.42e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg27170947	chr2:26402098	FAM59B	-0.7	-11.79	-0.42	3.45e-29	Gut microbiome composition (summer);
BRCA	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg25457927	chr22:38595422	NA	-0.36	-13.23	-0.46	1.68e-35	Cutaneous nevi;
BRCA	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg03929089	chr4:120376271	NA	0.48	8.1	0.31	2.74e-15	Axial length;
BRCA	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7072216	0.763	rs6584198	chr10:100169906	G/C	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.71	-0.36	7.24e-21	Metabolite levels;
BRCA	cis	rs4930561	0.739	rs7118045	chr11:67978734	C/G	cg04465784	chr11:67976953	SUV420H1	-0.26	-8.25	-0.31	8.8e-16	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg00106254	chr7:1943704	MAD1L1	0.37	10.32	0.38	3.25e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg16606324	chr3:10149918	C3orf24	0.55	10.84	0.39	2.97e-25	Alzheimer's disease;
BRCA	cis	rs2282802	0.685	rs11748023	chr5:139558584	C/T	cg26211634	chr5:139558579	C5orf32	-0.34	-8.11	-0.31	2.56e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg02574844	chr11:5959923	NA	-0.4	-8.28	-0.31	7.31e-16	DNA methylation (variation);
BRCA	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg20701182	chr2:24300061	SF3B14	0.57	8.67	0.32	3.66e-17	Lymphocyte counts;
BRCA	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg17063962	chr7:91808500	NA	0.54	12.69	0.45	4.49e-33	Breast cancer;
BRCA	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg25817165	chr18:72167213	CNDP2	-0.75	-14.54	-0.5	1.43e-41	Refractive error;
BRCA	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	16.14	0.54	2.01e-49	Homoarginine levels;
BRCA	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.37	7.86	0.3	1.62e-14	Total cholesterol levels;
BRCA	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg01579765	chr21:45077557	HSF2BP	0.4	9.47	0.35	5.52e-20	Mean corpuscular volume;
BRCA	cis	rs312274	0.515	rs7300719	chr12:41239198	A/T	cg17827154	chr12:41323612	CNTN1	0.36	8.89	0.33	5.99e-18	Metabolite levels  (X-11787);
BRCA	cis	rs9834373	0.553	rs9818134	chr3:78495979	A/C	cg06138941	chr3:78371609	NA	0.36	8.67	0.32	3.51e-17	Protein quantitative trait loci;
BRCA	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg15934090	chr1:100435551	SLC35A3	0.36	8.39	0.32	3.06e-16	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg25206134	chr2:45395956	NA	0.49	7.86	0.3	1.69e-14	Neuroticism;
BRCA	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg05868516	chr6:26286170	HIST1H4H	0.49	11.03	0.4	4.95e-26	Educational attainment;
BRCA	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg13334819	chr7:99746414	C7orf59	-0.45	-10.5	-0.38	6.77e-24	Coronary artery disease;
BRCA	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg24692254	chr21:30365293	RNF160	0.64	14.3	0.49	1.98e-40	Selective IgA deficiency;
BRCA	cis	rs897984	0.571	rs7184567	chr16:31021078	C/T	cg00531865	chr16:30841666	NA	-0.38	-9.07	-0.34	1.49e-18	Dementia with Lewy bodies;
BRCA	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	12.29	0.44	2.59e-31	Hip circumference adjusted for BMI;
BRCA	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg06636001	chr8:8085503	FLJ10661	0.63	12.12	0.43	1.48e-30	Red cell distribution width;
BRCA	cis	rs68170813	0.559	rs12536603	chr7:107002573	T/C	cg02696742	chr7:106810147	HBP1	-0.55	-8.81	-0.33	1.16e-17	Coronary artery disease;
BRCA	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07636037	chr3:49044803	WDR6	0.75	16.43	0.54	7.51e-51	Menarche (age at onset);
BRCA	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.61	9.65	0.36	1.2e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.51	0.35	3.94e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg06521331	chr12:34319734	NA	-0.65	-14.13	-0.49	1.21e-39	Morning vs. evening chronotype;
BRCA	cis	rs847577	0.677	rs1495525	chr7:97826232	G/A	cg21770322	chr7:97807741	LMTK2	-0.46	-11.93	-0.43	9.57e-30	Breast cancer;
BRCA	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg19622623	chr12:86230825	RASSF9	-0.31	-8.38	-0.31	3.35e-16	Major depressive disorder;
BRCA	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg23711669	chr6:146136114	FBXO30	-0.68	-15.88	-0.53	4.29e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1904096	0.506	rs4693381	chr4:95206855	A/T	cg11021082	chr4:95130006	SMARCAD1	0.45	10.46	0.38	9.26e-24	Type 2 diabetes;
BRCA	trans	rs35847492	1.000	rs35847492	chr8:9276025	G/C	cg15556689	chr8:8085844	FLJ10661	0.34	8.11	0.31	2.62e-15	Neuroticism;
BRCA	cis	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg07460842	chr6:66804631	NA	-1.16	-37.83	-0.83	2.9e-165	Exhaled nitric oxide output;
BRCA	trans	rs12517041	1.000	rs1428629	chr5:23311989	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-8.27	-0.31	7.52e-16	Calcium levels;
BRCA	cis	rs7264396	0.887	rs224344	chr20:34036865	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-8.3	-0.31	6.1e-16	Total cholesterol levels;
BRCA	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg26384229	chr12:38710491	ALG10B	0.52	11.42	0.41	1.25e-27	Morning vs. evening chronotype;
BRCA	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg19628046	chr18:33552617	C18orf21	0.56	11.59	0.42	2.47e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs367943	0.712	rs7731465	chr5:112687385	A/G	cg12552261	chr5:112820674	MCC	-0.39	-8.55	-0.32	8.73e-17	Type 2 diabetes;
BRCA	cis	rs17601876	0.814	rs28637352	chr15:51559666	C/A	cg19946085	chr15:51559439	CYP19A1	-0.39	-11.66	-0.42	1.27e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00166722	chr3:10149974	C3orf24	0.65	11.23	0.41	7.83e-27	Alzheimer's disease;
BRCA	cis	rs117623576	0.941	rs211423	chr10:32398777	A/G	cg03047570	chr10:32398778	NA	0.64	9.55	0.35	2.67e-20	Anti-saccade response;
BRCA	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg05340658	chr4:99064831	C4orf37	0.7	17.48	0.57	3.14e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3925075	1.000	rs9673404	chr16:31347592	A/T	cg02846316	chr16:31340340	ITGAM	0.53	13.04	0.46	1.2e-34	IgA nephropathy;
BRCA	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.63	0.36	1.36e-20	Lung cancer in ever smokers;
BRCA	cis	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg06521331	chr12:34319734	NA	-0.55	-9.88	-0.36	1.55e-21	Morning vs. evening chronotype;
BRCA	trans	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg01620082	chr3:125678407	NA	-0.71	-8.8	-0.33	1.28e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11229555	0.874	rs10896794	chr11:58339124	T/C	cg15696309	chr11:58395628	NA	-0.54	-11.83	-0.42	2.46e-29	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2066819	1.000	rs58852079	chr12:56706922	A/C	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.68	0.36	9.18e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg05340658	chr4:99064831	C4orf37	0.57	11.15	0.4	1.7e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6910061	1.000	rs2327335	chr6:11119047	A/G	cg27233058	chr6:11094804	LOC221710	-0.54	-9.73	-0.36	5.64e-21	Diabetic kidney disease;
BRCA	cis	rs7193541	0.640	rs4072222	chr16:74706736	A/C	cg01733217	chr16:74700730	RFWD3	0.87	30.35	0.77	5.56e-126	Multiple myeloma;
BRCA	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03526776	chr6:41159608	TREML2	-0.41	-8.27	-0.31	7.67e-16	Alzheimer's disease (late onset);
BRCA	cis	rs977987	0.778	rs2113232	chr16:75391185	T/C	cg03315344	chr16:75512273	CHST6	0.53	12.66	0.45	5.93e-33	Dupuytren's disease;
BRCA	cis	rs17741873	0.779	rs12572101	chr10:75600651	A/G	cg07699608	chr10:75541558	CHCHD1	0.48	7.81	0.3	2.38e-14	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg05025164	chr4:1340916	KIAA1530	0.66	13.38	0.47	3.53e-36	Longevity;
BRCA	trans	rs629535	0.862	rs655028	chr8:70049047	T/C	cg21567404	chr3:27674614	NA	1.0	21.1	0.64	2.04e-75	Dupuytren's disease;
BRCA	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg06064525	chr11:970664	AP2A2	-0.33	-9.82	-0.36	2.81e-21	Alzheimer's disease (late onset);
BRCA	trans	rs6479891	1.000	rs12414159	chr10:65238777	A/T	cg14819942	chr15:35414228	NA	0.35	8.51	0.32	1.23e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg22903471	chr2:27725779	GCKR	0.38	9.3	0.35	2.29e-19	Total body bone mineral density;
BRCA	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.39	-0.41	1.67e-27	Glomerular filtration rate (creatinine);
BRCA	trans	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg26043149	chr18:55253948	FECH	0.36	7.91	0.3	1.12e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.43	-8.36	-0.31	3.79e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs586533	0.813	rs636504	chr11:99495693	G/A	cg22878054	chr11:99397252	CNTN5	0.31	7.81	0.3	2.39e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs78456975	0.739	rs11896906	chr2:1519550	A/G	cg01028140	chr2:1542097	TPO	-0.69	-13.79	-0.48	4.63e-38	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.52	7.99	0.3	6.55e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg27490568	chr2:178487706	NA	-0.47	-8.21	-0.31	1.25e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg09307838	chr4:120376055	NA	0.63	13.36	0.47	4.56e-36	Corneal astigmatism;
BRCA	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg23625390	chr15:77176239	SCAPER	-0.55	-13.68	-0.48	1.56e-37	Blood metabolite levels;
BRCA	cis	rs3849570	1.000	rs78242412	chr3:81747219	A/G	cg07356753	chr3:81810745	GBE1	-0.46	-11.15	-0.4	1.71e-26	Waist circumference;Body mass index;
BRCA	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-8.74	-0.33	2.01e-17	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg13319975	chr6:146136371	FBXO30	-0.37	-8.54	-0.32	9.45e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg11843238	chr5:131593191	PDLIM4	0.37	9.67	0.36	9.4499999999999992e-21	Breast cancer;
BRCA	cis	rs921968	0.540	rs7582329	chr2:219620909	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-11.06	-0.4	3.87e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg04546413	chr19:29218101	NA	0.65	12.46	0.44	4.94e-32	Methadone dose in opioid dependence;
BRCA	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg03585969	chr10:35415529	CREM	0.49	10.38	0.38	1.94e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs1493916	0.905	rs34165207	chr18:31400153	G/A	cg15819921	chr19:927150	ARID3A	-0.45	-8.54	-0.32	9.84e-17	Life satisfaction;
BRCA	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg12483005	chr1:23474871	LUZP1	0.45	9.97	0.37	7.71e-22	Height;
BRCA	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg21724239	chr8:58056113	NA	0.62	9.69	0.36	8.16e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.81	-0.33	1.22e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9296092	0.538	rs9469488	chr6:33517117	G/T	cg13560919	chr6:33536144	NA	-0.85	-17.45	-0.57	4.51e-56	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg22907277	chr7:1156413	C7orf50	0.46	10.79	0.39	4.62e-25	Longevity;Endometriosis;
BRCA	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg15103426	chr22:29168792	CCDC117	0.45	10.8	0.39	4.41e-25	Red cell distribution width;
BRCA	cis	rs6750047	0.566	rs1157184	chr2:38285774	C/G	cg07380506	chr2:38303506	CYP1B1	0.49	11.63	0.42	1.72e-28	Cutaneous malignant melanoma;Melanoma;
BRCA	trans	rs1325195	0.920	rs4651013	chr1:179072966	C/T	cg11624085	chr17:8464688	MYH10	-0.26	-8.15	-0.31	1.93e-15	IgE grass sensitization;
BRCA	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg03929089	chr4:120376271	NA	-0.9	-24.17	-0.69	3.67e-92	Height;
BRCA	cis	rs1577917	0.655	rs1059307	chr6:86387888	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.37	10.13	0.37	1.85e-22	Response to antipsychotic treatment;
BRCA	cis	rs34779708	0.931	rs11597392	chr10:35288575	T/C	cg03585969	chr10:35415529	CREM	0.55	11.28	0.41	4.72e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	13.87	0.48	2.07e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg15017067	chr4:17643749	FAM184B	0.29	8.74	0.33	1.99e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4478858	0.735	rs6679365	chr1:31787866	A/C	cg00250761	chr1:31883323	NA	0.31	8.11	0.31	2.56e-15	Alcohol dependence;
BRCA	cis	rs7523273	0.606	rs2796283	chr1:207978732	C/T	cg22525895	chr1:207977042	MIR29B2	-0.48	-12.49	-0.44	3.59e-32	Schizophrenia;
BRCA	cis	rs208520	0.837	rs208486	chr6:66926255	A/T	cg07460842	chr6:66804631	NA	-0.89	-15.7	-0.53	3.28e-47	Exhaled nitric oxide output;
BRCA	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg20307385	chr11:47447363	PSMC3	-0.41	-8.24	-0.31	9.74e-16	Subjective well-being;
BRCA	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12923728	chr3:195709715	SDHAP1	-0.58	-12.45	-0.44	5.43e-32	Pancreatic cancer;
BRCA	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg09904177	chr6:26538194	HMGN4	0.47	14.71	0.5	2.02e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs11229555	1.000	rs12787765	chr11:58400686	G/A	cg15696309	chr11:58395628	NA	-0.52	-11.48	-0.41	6.93e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	30.54	0.77	5.46e-127	Chronic sinus infection;
BRCA	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg08601574	chr20:25228251	PYGB	0.35	8.39	0.31	3.21e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg13047869	chr3:10149882	C3orf24	0.59	12.27	0.44	3.13e-31	Alzheimer's disease;
BRCA	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.48e-23	Motion sickness;
BRCA	cis	rs752010	0.619	rs7539238	chr1:42113572	A/C	cg06885757	chr1:42089581	HIVEP3	0.29	9.95	0.37	9.07e-22	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.83	-0.33	1.03e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs77633900	0.614	rs280008	chr15:77011815	T/C	cg21673338	chr15:77095150	SCAPER	-0.53	-9.77	-0.36	4.33e-21	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.96	15.04	0.51	5.21e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.67	0.39	1.39e-24	Tonsillectomy;
BRCA	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg18252515	chr7:66147081	NA	-1.05	-14.44	-0.5	4.29e-41	Diabetic kidney disease;
BRCA	cis	rs6740322	0.841	rs10211126	chr2:43551416	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-11.77	-0.42	4.52e-29	Coronary artery disease;
BRCA	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg20607287	chr7:12443886	VWDE	-0.58	-8.32	-0.31	5.31e-16	Coronary artery disease;
BRCA	cis	rs72772090	0.539	rs72773922	chr5:96116660	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.19	-0.43	7.23e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg20290983	chr6:43655470	MRPS18A	1.11	40.93	0.85	1.03e-180	IgG glycosylation;
BRCA	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg07262247	chr5:131593730	PDLIM4	0.34	7.82	0.3	2.19e-14	Acylcarnitine levels;
BRCA	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg18252515	chr7:66147081	NA	-0.91	-12.95	-0.46	3.02e-34	Diabetic kidney disease;
BRCA	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg05347473	chr6:146136440	FBXO30	0.39	8.1	0.31	2.73e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg22907277	chr7:1156413	C7orf50	0.52	11.41	0.41	1.44e-27	Longevity;Endometriosis;
BRCA	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg20283391	chr11:68216788	NA	-0.43	-9.1	-0.34	1.14e-18	Total body bone mineral density;
BRCA	cis	rs9420	0.884	rs589914	chr11:57661032	A/G	cg19752551	chr11:57585705	CTNND1	0.5	12.07	0.43	2.32e-30	Schizophrenia;
BRCA	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg14196790	chr5:131705035	SLC22A5	0.5	13.99	0.48	5.41e-39	Blood metabolite levels;
BRCA	cis	rs2882667	0.505	rs7721110	chr5:138482506	G/T	cg04439458	chr5:138467593	SIL1	-0.31	-8.34	-0.31	4.57e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs77633900	0.614	rs2585730	chr15:76989344	A/G	cg21673338	chr15:77095150	SCAPER	-0.53	-9.54	-0.35	3.05e-20	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg13319975	chr6:146136371	FBXO30	-0.36	-8.34	-0.31	4.54e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.667	rs914197	chr21:45117439	A/G	cg01579765	chr21:45077557	HSF2BP	-0.44	-11.72	-0.42	6.85e-29	Mean corpuscular volume;
BRCA	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg05343316	chr1:45956843	TESK2	0.62	12.46	0.44	4.58e-32	Platelet count;
BRCA	trans	rs11295209	1	rs11295209	chr4:120480233	TA/T	cg25214090	chr10:38739885	LOC399744	-0.34	-7.96	-0.3	7.6e-15	Plateletcrit;
BRCA	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg24920358	chr1:40204285	PPIE	0.35	8.02	0.3	5.03e-15	Blood protein levels;
BRCA	trans	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	20.89	0.64	3.01e-74	Exhaled nitric oxide output;
BRCA	cis	rs911119	1.000	rs911119	chr20:23612737	C/T	cg16589663	chr20:23618590	CST3	-0.41	-7.92	-0.3	1.08e-14	Chronic kidney disease;
BRCA	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg21782813	chr7:2030301	MAD1L1	0.4	11.33	0.41	3.03e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.91	-13.26	-0.46	1.3e-35	Lung cancer in ever smokers;
BRCA	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg27433088	chr4:174089019	GALNT7	-0.33	-8.5	-0.32	1.3e-16	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg07460842	chr6:66804631	NA	0.6	10.31	0.38	3.59e-23	Type 2 diabetes;
BRCA	cis	rs3824867	0.920	rs7101772	chr11:47449378	A/G	cg20307385	chr11:47447363	PSMC3	-0.49	-10.98	-0.4	8.18e-26	Mean corpuscular hemoglobin;
BRCA	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg26384229	chr12:38710491	ALG10B	0.66	15.4	0.52	9.23e-46	Bladder cancer;
BRCA	cis	rs7684253	0.565	rs6830774	chr4:57816306	T/C	cg11939399	chr4:57773300	REST	0.29	7.97	0.3	7.32e-15	Migraine;
BRCA	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg10729496	chr3:10149963	C3orf24	0.42	8.08	0.3	3.25e-15	Alzheimer's disease;
BRCA	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.81	0.55	8.35e-53	Axial length;
BRCA	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg01939980	chr4:1354348	KIAA1530	0.3	8.06	0.3	3.67e-15	Longevity;
BRCA	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg27121462	chr16:89883253	FANCA	-0.51	-11.44	-0.41	1.02e-27	Vitiligo;
BRCA	cis	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg07460842	chr6:66804631	NA	0.89	17.13	0.56	1.98e-54	Exhaled nitric oxide output;
BRCA	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.77	-0.33	1.64e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg06623918	chr6:96969491	KIAA0776	0.9	25.54	0.71	1.14e-99	Headache;
BRCA	cis	rs8038465	0.516	rs8037836	chr15:73859855	G/A	cg15420318	chr15:73925796	NPTN	0.49	11.3	0.41	4.1e-27	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg20701182	chr2:24300061	SF3B14	0.7	13.37	0.47	4.01e-36	Lymphocyte counts;
BRCA	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg04944784	chr2:26401820	FAM59B	-0.66	-10.76	-0.39	6.37e-25	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg05340658	chr4:99064831	C4orf37	0.62	14.72	0.5	1.94e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg08213375	chr14:104286397	PPP1R13B	0.65	18.58	0.59	5.9e-62	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg02476566	chr12:106696527	TCP11L2	-0.52	-8.31	-0.31	5.94e-16	Tourette syndrome;
BRCA	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg08601574	chr20:25228251	PYGB	0.37	8.62	0.32	5.22e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	13.91	0.48	1.24e-38	Type 2 diabetes;
BRCA	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02475777	chr4:1388615	CRIPAK	-0.63	-12.5	-0.44	3.23e-32	Longevity;
BRCA	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg07080220	chr10:102295463	HIF1AN	-0.44	-10.06	-0.37	3.37e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs3857536	0.611	rs7748258	chr6:66932840	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.11	-0.31	2.53e-15	Blood trace element (Cu levels);
BRCA	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg25319279	chr11:5960081	NA	-0.42	-8.15	-0.31	1.95e-15	DNA methylation (variation);
BRCA	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg26384229	chr12:38710491	ALG10B	0.74	17.66	0.57	3.84e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	12.31	0.44	2.21e-31	Obesity-related traits;
BRCA	cis	rs4891159	0.513	rs35534021	chr18:74130523	G/A	cg24786174	chr18:74118243	ZNF516	0.82	24.48	0.7	6.91e-94	Longevity;
BRCA	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg27147174	chr7:100797783	AP1S1	-0.56	-10.9	-0.4	1.69e-25	Life satisfaction;
BRCA	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg25358565	chr5:93447407	FAM172A	1.18	19.6	0.61	2.41e-67	Diabetic retinopathy;
BRCA	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	11.54	0.42	3.92e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs1555322	0.505	rs639763	chr20:33861904	C/T	cg03689076	chr20:33865952	NA	0.47	8.29	0.31	6.86e-16	Attention deficit hyperactivity disorder;
BRCA	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.62	11.63	0.42	1.75e-28	Gut microbiome composition (summer);
BRCA	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12826209	chr6:26865740	GUSBL1	0.59	10.29	0.38	4.46e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg18301423	chr5:131593218	PDLIM4	0.33	8.48	0.32	1.53e-16	Breast cancer;
BRCA	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24308560	chr3:49941425	MST1R	-0.4	-8.57	-0.32	7.64e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg08999081	chr20:33150536	PIGU	0.34	8.66	0.32	3.7e-17	Coronary artery disease;
BRCA	cis	rs2882667	1.000	rs10064130	chr5:138309307	C/T	cg04439458	chr5:138467593	SIL1	-0.38	-9.86	-0.36	1.84e-21	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg05340658	chr4:99064831	C4orf37	0.67	16.52	0.55	2.45e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg05872129	chr22:39784769	NA	0.55	11.7	0.42	8.5e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs7553864	0.614	rs4559475	chr1:87614236	T/C	cg17420885	chr1:87600446	LOC339524	-0.41	-8.0	-0.3	6.02e-15	Smoking behavior;
BRCA	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg05343316	chr1:45956843	TESK2	0.66	13.3	0.47	7.95e-36	Platelet distribution width;
BRCA	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg05343316	chr1:45956843	TESK2	-0.6	-11.79	-0.42	3.51e-29	Platelet count;
BRCA	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg21475434	chr5:93447410	FAM172A	0.66	8.91	0.33	5.22e-18	Diabetic retinopathy;
BRCA	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg23711669	chr6:146136114	FBXO30	0.63	14.22	0.49	4.66e-40	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.21	-0.34	4.63e-19	Bipolar disorder;
BRCA	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg14440974	chr22:39074834	NA	-0.39	-9.16	-0.34	6.75e-19	Menopause (age at onset);
BRCA	cis	rs4642101	0.824	rs9852222	chr3:12848491	G/T	cg24848339	chr3:12840334	CAND2	0.41	10.56	0.39	4.02e-24	QRS complex (12-leadsum);
BRCA	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.32	-0.31	5.2e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg22800045	chr5:56110881	MAP3K1	0.61	11.45	0.41	9.32e-28	Initial pursuit acceleration;
BRCA	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg15698299	chr3:52233019	ALAS1	-0.38	-8.95	-0.33	3.9e-18	Electroencephalogram traits;
BRCA	cis	rs17767294	0.708	rs9380018	chr6:27740646	A/G	cg08851530	chr6:28072375	NA	0.74	7.89	0.3	1.29e-14	Parkinson's disease;
BRCA	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg06627628	chr2:24431161	ITSN2	0.49	10.23	0.38	7.72e-23	Asthma;
BRCA	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg13010199	chr12:38710504	ALG10B	0.52	10.96	0.4	9.82e-26	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg15737290	chr11:93063684	CCDC67	0.58	13.96	0.48	7.76e-39	Pulmonary function decline;
BRCA	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg08514558	chr10:81106712	PPIF	-0.39	-9.04	-0.34	1.84e-18	Height;
BRCA	cis	rs3820928	0.874	rs7582251	chr2:227791703	G/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.72	-0.33	2.46e-17	Pulmonary function;
BRCA	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg23711669	chr6:146136114	FBXO30	0.65	14.69	0.5	2.59e-42	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.15	-17.53	-0.57	1.79e-56	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg23625390	chr15:77176239	SCAPER	-0.55	-13.89	-0.48	1.61e-38	Blood metabolite levels;
BRCA	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg10978503	chr1:24200527	CNR2	-0.43	-9.41	-0.35	8.82e-20	Immature fraction of reticulocytes;
BRCA	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.46e-23	Motion sickness;
BRCA	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg16482183	chr6:26056742	HIST1H1C	0.44	9.15	0.34	7.27e-19	Iron status biomarkers;
BRCA	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	9.91	0.37	1.21e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3820928	0.874	rs10174073	chr2:227794944	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.78	-0.33	1.46e-17	Pulmonary function;
BRCA	cis	rs586533	0.881	rs624620	chr11:99505353	C/T	cg22878054	chr11:99397252	CNTN5	0.32	8.12	0.31	2.44e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9811920	0.809	rs6440967	chr3:99722396	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.57	13.83	0.48	2.97e-38	Axial length;
BRCA	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg22467129	chr15:76604101	ETFA	-0.4	-8.99	-0.34	2.75e-18	Blood metabolite levels;
BRCA	cis	rs6545883	0.895	rs2442029	chr2:61679552	G/T	cg15711740	chr2:61764176	XPO1	-0.53	-12.64	-0.45	7.37e-33	Tuberculosis;
BRCA	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg23950597	chr19:37808831	NA	-0.63	-10.93	-0.4	1.3e-25	Coronary artery calcification;
BRCA	cis	rs17381785	0.531	rs34479500	chr4:14939389	G/A	cg12377275	chr4:15005593	CPEB2	0.46	8.15	0.31	1.87e-15	Urate levels in overweight individuals;
BRCA	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg07169764	chr2:136633963	MCM6	1.0	20.31	0.63	4.04e-71	Corneal structure;
BRCA	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg19678392	chr7:94953810	PON1	-0.42	-8.58	-0.32	7.05e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs10189230	0.967	rs13002861	chr2:222352859	T/G	cg14652038	chr2:222343519	EPHA4	0.46	12.75	0.45	2.51e-33	Urate levels in lean individuals;
BRCA	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg04511125	chr2:88470314	THNSL2	0.8	11.59	0.42	2.46e-28	Plasma clusterin levels;
BRCA	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22857025	chr5:266934	NA	-1.04	-19.68	-0.61	9.4e-68	Breast cancer;
BRCA	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg02951883	chr7:2050386	MAD1L1	-0.55	-12.34	-0.44	1.63e-31	Schizophrenia;
BRCA	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg26528668	chr16:1614120	IFT140	0.37	8.33	0.31	4.87e-16	Coronary artery disease;
BRCA	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg18705301	chr15:41695430	NDUFAF1	0.49	10.72	0.39	8.97e-25	Ulcerative colitis;
BRCA	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg12935359	chr14:103987150	CKB	-0.6	-14.09	-0.49	1.78e-39	Body mass index;
BRCA	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg09021430	chr5:549028	NA	-0.68	-14.24	-0.49	3.68e-40	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7640424	0.819	rs162070	chr3:107835448	G/A	cg09227934	chr3:107805635	CD47	0.41	8.63	0.32	4.76e-17	Body mass index;
BRCA	cis	rs1799922	0.693	rs339086	chr7:128423617	T/C	cg02354431	chr7:128423266	NA	0.36	9.22	0.34	4.19e-19	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
BRCA	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg13319975	chr6:146136371	FBXO30	0.44	10.03	0.37	4.55e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg20701182	chr2:24300061	SF3B14	0.68	12.9	0.45	5.2e-34	Lymphocyte counts;
BRCA	cis	rs7617773	0.780	rs79089926	chr3:48348564	A/C	cg11946769	chr3:48343235	NME6	0.68	13.86	0.48	2.24e-38	Coronary artery disease;
BRCA	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg16743903	chr16:89593216	SPG7	0.31	8.16	0.31	1.73e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg16339924	chr4:17578868	LAP3	0.76	17.93	0.58	1.6e-58	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg01977079	chr11:17036644	PLEKHA7	-0.33	-8.55	-0.32	9.34e-17	Coronary artery disease;
BRCA	cis	rs1829883	0.651	rs2460653	chr5:98825627	A/G	cg08333243	chr5:99726346	NA	-0.36	-7.81	-0.3	2.41e-14	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg26195577	chr20:24973756	C20orf3	-0.97	-27.09	-0.73	3.13e-108	Blood protein levels;
BRCA	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.06	0.34	1.61e-18	Platelet count;
BRCA	cis	rs9283706	0.608	rs13189948	chr5:66355306	A/G	cg11590213	chr5:66331682	MAST4	0.4	8.03	0.3	4.72e-15	Coronary artery disease;
BRCA	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08045932	chr20:61659980	NA	0.5	11.4	0.41	1.63e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg03354898	chr7:1950403	MAD1L1	-0.39	-8.61	-0.32	5.63e-17	Schizophrenia;
BRCA	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.53	0.42	4.43e-28	Homoarginine levels;
BRCA	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg05340658	chr4:99064831	C4orf37	-0.68	-16.97	-0.56	1.4e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6684514	0.961	rs10908501	chr1:156285513	G/T	cg16558208	chr1:156270281	VHLL	0.36	8.36	0.31	4.06e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.43	8.22	0.31	1.11e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-39.11	-0.84	1.1e-171	Exhaled nitric oxide output;
BRCA	cis	rs1788820	0.917	rs1624695	chr18:21142992	A/T	cg14672496	chr18:21087552	C18orf8	0.35	8.53	0.32	1.06e-16	Body mass index;
BRCA	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg19539972	chr4:7069911	GRPEL1	0.68	17.0	0.56	9.84e-54	Monocyte percentage of white cells;
BRCA	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg09555818	chr19:45449301	APOC2	0.45	11.76	0.42	4.78e-29	Blood protein levels;
BRCA	cis	rs3925075	0.903	rs36100148	chr16:31345023	C/T	cg02846316	chr16:31340340	ITGAM	0.54	13.33	0.47	5.89e-36	IgA nephropathy;
BRCA	cis	rs12541635	0.677	rs1496183	chr8:107024445	C/T	cg10147462	chr8:107024639	NA	0.4	10.98	0.4	7.87e-26	Age of smoking initiation;
BRCA	cis	rs10779751	0.770	rs11121691	chr1:11181327	C/T	cg08854313	chr1:11322531	MTOR	-0.73	-14.45	-0.5	3.64e-41	Body mass index;
BRCA	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg12219531	chr12:120966889	COQ5	0.56	11.7	0.42	8.42e-29	High light scatter reticulocyte count;
BRCA	trans	rs877282	0.891	rs11595385	chr10:800539	A/G	cg22713356	chr15:30763199	NA	1.4	28.4	0.75	2.36e-115	Uric acid levels;
BRCA	cis	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg07460842	chr6:66804631	NA	0.87	15.6	0.53	1.03e-46	Exhaled nitric oxide levels;
BRCA	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg05793240	chr7:2802953	GNA12	-0.32	-8.23	-0.31	1.03e-15	Height;
BRCA	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg03709012	chr19:19516395	GATAD2A	0.81	19.22	0.61	2.61e-65	Tonsillectomy;
BRCA	cis	rs7631605	0.845	rs9311149	chr3:37030175	G/T	cg15934958	chr3:37212084	LRRFIP2	0.34	7.9	0.3	1.2e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs11112613	0.713	rs10507192	chr12:105948247	A/G	cg03607813	chr12:105948248	NA	0.66	13.07	0.46	9.2e-35	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg25036284	chr2:26402008	FAM59B	-0.89	-15.63	-0.53	7.3e-47	Gut microbiome composition (summer);
BRCA	cis	rs965469	0.779	rs2236121	chr20:3304320	A/G	cg25506879	chr20:3388711	C20orf194	-0.45	-8.77	-0.33	1.61e-17	IFN-related cytopenia;
BRCA	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg19678392	chr7:94953810	PON1	0.42	9.09	0.34	1.2e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg20290983	chr6:43655470	MRPS18A	1.11	41.43	0.85	3.52e-183	IgG glycosylation;
BRCA	cis	rs9341808	0.718	rs2874829	chr6:80856097	A/G	cg08355045	chr6:80787529	NA	0.37	9.29	0.35	2.32e-19	Sitting height ratio;
BRCA	cis	rs10739663	0.520	rs1566362	chr9:128163132	C/T	cg14078157	chr9:128172775	NA	0.46	10.54	0.38	4.54e-24	Resting heart rate;
BRCA	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg06618935	chr21:46677482	NA	-0.36	-7.96	-0.3	8.16e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg13385794	chr1:248469461	NA	0.28	8.11	0.31	2.62e-15	Common traits (Other);
BRCA	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg24692254	chr21:30365293	RNF160	0.64	14.3	0.49	1.98e-40	Selective IgA deficiency;
BRCA	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.57	-0.47	4.99e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg12365402	chr11:9010492	NRIP3	-0.42	-9.02	-0.34	2.24e-18	Hemoglobin concentration;
BRCA	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.21	-0.34	4.59e-19	Menopause (age at onset);
BRCA	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12379764	chr21:47803548	PCNT	0.61	12.32	0.44	1.92e-31	Testicular germ cell tumor;
BRCA	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.01	0.58	5.98e-59	Fuchs's corneal dystrophy;
BRCA	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg00938859	chr5:1591904	SDHAP3	0.69	9.4	0.35	9.53e-20	Breast cancer;
BRCA	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg06766960	chr11:133703094	NA	-0.63	-13.77	-0.48	5.89e-38	Childhood ear infection;
BRCA	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.01	0.4	6.48e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4908768	0.501	rs12061328	chr1:8531963	C/T	cg20416874	chr1:8611966	RERE	-0.28	-8.19	-0.31	1.43e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs6430585	0.527	rs12467569	chr2:136413847	T/C	cg07169764	chr2:136633963	MCM6	1.0	19.49	0.61	9.16e-67	Corneal structure;
BRCA	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg11764359	chr7:65958608	NA	-0.64	-13.92	-0.48	1.22e-38	Aortic root size;
BRCA	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-8.04	-0.3	4.25e-15	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs897984	0.542	rs750952	chr16:31093954	C/T	cg00531865	chr16:30841666	NA	-0.35	-8.36	-0.31	3.89e-16	Dementia with Lewy bodies;
BRCA	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg23939001	chr4:940644	TMEM175	0.4	9.98	0.37	6.88e-22	Sjögren's syndrome;
BRCA	cis	rs7809950	1.000	rs2520277	chr7:107130234	C/T	cg23024343	chr7:107201750	COG5	-0.41	-9.54	-0.35	2.86e-20	Coronary artery disease;
BRCA	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg05665937	chr4:1216051	CTBP1	0.39	8.3	0.31	6.21e-16	Obesity-related traits;
BRCA	cis	rs9467711	0.591	rs56294283	chr6:25976099	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.58	9.13	0.34	9e-19	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg06521331	chr12:34319734	NA	-0.47	-8.99	-0.34	2.75e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-14.89	-0.51	2.95e-43	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4074536	0.574	rs4472757	chr1:116293897	A/G	cg21648376	chr1:116311395	CASQ2	-0.48	-8.48	-0.32	1.61e-16	QRS duration;
BRCA	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg17691542	chr6:26056736	HIST1H1C	0.55	11.96	0.43	7.13e-30	Height;
BRCA	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19748678	chr4:122722346	EXOSC9	0.74	16.01	0.54	9.39e-49	Type 2 diabetes;
BRCA	cis	rs501916	0.833	rs59184310	chr15:48050205	A/T	cg16110827	chr15:48056943	SEMA6D	-0.43	-9.15	-0.34	7.52e-19	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.78	0.67	1.54e-84	Chronic sinus infection;
BRCA	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07636037	chr3:49044803	WDR6	0.72	15.86	0.53	5.2e-48	Menarche (age at onset);
BRCA	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg04944784	chr2:26401820	FAM59B	1.0	16.52	0.55	2.51e-51	Gut microbiome composition (summer);
BRCA	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg24562669	chr7:97807699	LMTK2	0.46	12.25	0.44	4e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3768617	1.000	rs1360704	chr1:183099380	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.47	-10.25	-0.38	6.4e-23	Fuchs's corneal dystrophy;
BRCA	cis	rs4588572	0.643	rs10474555	chr5:77799193	A/G	cg11547950	chr5:77652471	NA	0.48	8.54	0.32	9.86e-17	Triglycerides;
BRCA	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg24812749	chr6:127587940	RNF146	0.8	15.48	0.52	4.05e-46	Breast cancer;
BRCA	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg03188948	chr7:1209495	NA	0.92	13.73	0.48	8.92e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7944584	0.655	rs11039183	chr11:47346940	G/A	cg03711944	chr11:47377212	SPI1	-0.34	-7.99	-0.3	6.11e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	trans	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg25214090	chr10:38739885	LOC399744	0.51	10.78	0.39	5.13e-25	Corneal astigmatism;
BRCA	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg24562669	chr7:97807699	LMTK2	0.45	12.23	0.44	4.67e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg15997130	chr1:24165203	NA	0.44	11.49	0.41	6.91e-28	Immature fraction of reticulocytes;
BRCA	cis	rs28735056	0.967	rs8091497	chr18:77632565	G/A	cg20368463	chr18:77673604	PQLC1	-0.34	-8.0	-0.3	5.95e-15	Schizophrenia;
BRCA	cis	rs11920090	0.858	rs55692900	chr3:170701587	T/G	cg09710316	chr3:170744871	SLC2A2	0.5	8.01	0.3	5.52e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg27129171	chr3:47204927	SETD2	-0.67	-15.31	-0.52	2.71e-45	Colorectal cancer;
BRCA	cis	rs17095355	1.000	rs12570612	chr10:111717685	C/T	cg00817464	chr10:111662876	XPNPEP1	0.34	9.0	0.34	2.64e-18	Biliary atresia;
BRCA	cis	rs911119	0.955	rs4815224	chr20:23594112	C/G	cg16589663	chr20:23618590	CST3	0.45	8.41	0.32	2.61e-16	Chronic kidney disease;
BRCA	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	20.16	0.62	2.63e-70	Chronic sinus infection;
BRCA	cis	rs6088813	0.961	rs1886691	chr20:33986271	T/C	cg14752227	chr20:34000481	UQCC	-0.42	-8.92	-0.33	4.83e-18	Height;
BRCA	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg00898013	chr13:113819073	PROZ	-0.36	-8.61	-0.32	5.52e-17	Platelet distribution width;
BRCA	cis	rs7809950	0.678	rs2395868	chr7:106897500	C/T	cg23024343	chr7:107201750	COG5	0.42	8.59	0.32	6.8e-17	Coronary artery disease;
BRCA	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg10932868	chr11:921992	NA	0.51	13.27	0.46	1.11e-35	Alzheimer's disease (late onset);
BRCA	cis	rs71636778	0.543	rs17162333	chr1:27236757	C/G	cg12203394	chr1:27248618	NUDC	0.6	9.46	0.35	5.7e-20	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24549020	chr5:56110836	MAP3K1	0.66	13.44	0.47	1.98e-36	Initial pursuit acceleration;
BRCA	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.25	-0.44	3.78e-31	Response to antipsychotic treatment;
BRCA	cis	rs250677	0.522	rs919730	chr5:148352401	T/C	cg18129178	chr5:148520854	ABLIM3	0.55	10.49	0.38	7.11e-24	Breast cancer;
BRCA	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.48	0.5	2.79e-41	Motion sickness;
BRCA	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg16339924	chr4:17578868	LAP3	0.64	15.89	0.53	3.68e-48	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg06637938	chr14:75390232	RPS6KL1	0.4	7.95	0.3	8.45e-15	Coronary artery disease;
BRCA	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg10223061	chr2:219282414	VIL1	-0.27	-8.16	-0.31	1.76e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg10494973	chr17:80897199	TBCD	0.36	8.15	0.31	1.95e-15	Breast cancer;
BRCA	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg25174290	chr11:3078921	CARS	0.43	12.74	0.45	2.85e-33	Longevity;
BRCA	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg06784218	chr1:46089804	CCDC17	-0.52	-12.42	-0.44	7.05e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.57	-0.32	7.75e-17	Total body bone mineral density;
BRCA	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg18154014	chr19:37997991	ZNF793	0.47	9.36	0.35	1.33e-19	Coronary artery calcification;
BRCA	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg19622623	chr12:86230825	RASSF9	-0.34	-9.58	-0.35	2.05e-20	Major depressive disorder;
BRCA	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.87	-0.36	1.77e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg25767906	chr1:53392781	SCP2	-0.47	-10.2	-0.37	9.75e-23	Monocyte count;
BRCA	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg02176678	chr2:219576539	TTLL4	0.4	10.96	0.4	9.73e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg01028140	chr2:1542097	TPO	-0.62	-11.76	-0.42	4.75e-29	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6120849	0.707	rs6088694	chr20:33652371	G/A	cg24642439	chr20:33292090	TP53INP2	0.59	10.18	0.37	1.16e-22	Protein C levels;
BRCA	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg08917208	chr2:24149416	ATAD2B	1.12	15.98	0.53	1.31e-48	Lymphocyte counts;
BRCA	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.49	-0.32	1.48e-16	Monocyte percentage of white cells;
BRCA	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg24101359	chr6:42928495	GNMT	0.55	12.58	0.45	1.45e-32	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs7903847	0.642	rs11189182	chr10:99144186	A/G	cg20016023	chr10:99160130	RRP12	-0.27	-8.62	-0.32	5.46e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg27541892	chr1:1571801	CDK11B	-0.35	-7.82	-0.3	2.12e-14	Body mass index;
BRCA	cis	rs6545883	0.507	rs4411680	chr2:61584105	A/C	cg15711740	chr2:61764176	XPO1	0.32	7.82	0.3	2.24e-14	Tuberculosis;
BRCA	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14442939	chr10:27389572	ANKRD26	0.69	11.4	0.41	1.61e-27	Breast cancer;
BRCA	cis	rs2425143	0.818	rs73902932	chr20:34489009	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.25	-0.31	8.87e-16	Blood protein levels;
BRCA	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg13010199	chr12:38710504	ALG10B	0.4	9.07	0.34	1.47e-18	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg20607798	chr8:58055168	NA	0.49	8.52	0.32	1.19e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.3	0.31	6.43e-16	Uric acid levels;
BRCA	cis	rs7524258	0.835	rs75096060	chr1:7270248	G/C	cg07173049	chr1:7289937	CAMTA1	0.45	11.12	0.4	2.16e-26	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs34779708	0.966	rs12775548	chr10:35479504	G/T	cg03585969	chr10:35415529	CREM	0.54	11.18	0.4	1.28e-26	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.83	-0.51	5.41e-43	Chronic sinus infection;
BRCA	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg05340658	chr4:99064831	C4orf37	0.65	16.1	0.54	3.24e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2625529	0.668	rs34487006	chr15:72462350	G/T	cg16672083	chr15:72433130	SENP8	-0.84	-17.82	-0.58	5.65e-58	Red blood cell count;
BRCA	cis	rs7737355	0.947	rs4996522	chr5:130761470	G/A	cg06307176	chr5:131281290	NA	-0.51	-9.8	-0.36	3.09e-21	Life satisfaction;
BRCA	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg04586622	chr2:25135609	ADCY3	0.44	11.05	0.4	4.45e-26	Body mass index;
BRCA	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg03146154	chr1:46216737	IPP	-0.48	-10.5	-0.38	6.87e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg21395723	chr22:39101663	GTPBP1	0.41	8.57	0.32	7.56e-17	Menopause (age at onset);
BRCA	cis	rs3125734	0.633	rs3902162	chr10:64041817	C/T	cg19640130	chr10:64028056	RTKN2	-0.32	-8.96	-0.33	3.6e-18	Rheumatoid arthritis;
BRCA	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg21535247	chr6:8435926	SLC35B3	0.43	9.7	0.36	7.5e-21	Motion sickness;
BRCA	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg05283184	chr6:79620031	NA	-0.34	-7.99	-0.3	6.15e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg00825309	chr19:58991885	ZNF446	-0.57	-12.49	-0.44	3.44e-32	Uric acid clearance;
BRCA	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.11e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg20307385	chr11:47447363	PSMC3	0.89	27.06	0.73	4.95e-108	Diastolic blood pressure;Systolic blood pressure;
BRCA	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg26384229	chr12:38710491	ALG10B	0.63	13.28	0.47	9.95e-36	Morning vs. evening chronotype;
BRCA	cis	rs1371614	0.611	rs4665920	chr2:27128834	G/A	cg12368169	chr2:27073192	DPYSL5	-0.3	-8.74	-0.33	2.01e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg24848339	chr3:12840334	CAND2	0.43	11.47	0.41	8.05e-28	QRS complex (12-leadsum);
BRCA	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.51	-0.44	2.87e-32	Type 2 diabetes;
BRCA	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	8.51	0.32	1.22e-16	Rheumatoid arthritis;
BRCA	cis	rs72781680	0.716	rs2551343	chr2:24027002	C/G	cg08917208	chr2:24149416	ATAD2B	0.57	9.45	0.35	6.06e-20	Lymphocyte counts;
BRCA	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg02951883	chr7:2050386	MAD1L1	-0.54	-12.29	-0.44	2.69e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg08514558	chr10:81106712	PPIF	0.35	8.51	0.32	1.24e-16	Height;
BRCA	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg03342759	chr3:160939853	NMD3	-0.79	-18.75	-0.6	7.85e-63	Parkinson's disease;
BRCA	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg08807101	chr21:30365312	RNF160	-0.59	-14.28	-0.49	2.39e-40	Dental caries;
BRCA	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg04362960	chr10:104952993	NT5C2	0.44	10.71	0.39	1.02e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	13.42	0.47	2.36e-36	Mean platelet volume;
BRCA	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.13	0.56	1.99e-54	Fuchs's corneal dystrophy;
BRCA	cis	rs7737355	0.504	rs31256	chr5:130828749	T/C	cg06307176	chr5:131281290	NA	0.52	10.35	0.38	2.56e-23	Life satisfaction;
BRCA	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg27147174	chr7:100797783	AP1S1	-0.56	-10.9	-0.4	1.69e-25	Life satisfaction;
BRCA	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg07988820	chr12:82153109	PPFIA2	-0.63	-10.13	-0.37	1.78e-22	Resting heart rate;
BRCA	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.42	0.32	2.56e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg08917208	chr2:24149416	ATAD2B	1.1	15.47	0.52	4.15e-46	Lymphocyte counts;
BRCA	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg18154014	chr19:37997991	ZNF793	0.48	9.65	0.36	1.2e-20	Coronary artery calcification;
BRCA	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg04034577	chr2:241836375	C2orf54	-0.57	-14.0	-0.48	4.88e-39	Urinary metabolites;
BRCA	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	16.29	0.54	3.75e-50	Homoarginine levels;
BRCA	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg19748678	chr4:122722346	EXOSC9	0.44	9.22	0.34	4.32e-19	Type 2 diabetes;
BRCA	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.83	-0.42	2.53e-29	Alcohol dependence;
BRCA	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg22705602	chr4:152727874	NA	-0.32	-8.0	-0.3	6.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg04362960	chr10:104952993	NT5C2	0.4	9.55	0.35	2.75e-20	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg06115741	chr20:33292138	TP53INP2	0.36	8.01	0.3	5.64e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13012494	chr21:47604986	C21orf56	0.46	9.52	0.35	3.47e-20	Testicular germ cell tumor;
BRCA	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.76	-0.33	1.69e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.4	-8.33	-0.31	4.95e-16	Body mass index;
BRCA	cis	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.97	-0.37	7.13e-22	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.02	0.3	4.99e-15	Corneal astigmatism;
BRCA	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.56	11.86	0.42	1.79e-29	Height;
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg26608667	chr7:1196370	ZFAND2A	0.42	9.47	0.35	5.12e-20	Longevity;Endometriosis;
BRCA	cis	rs10463316	0.894	rs7710277	chr5:150767405	T/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.32	-0.31	5.17e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs11958404	0.932	rs11949394	chr5:157425198	A/G	cg05962755	chr5:157440814	NA	0.52	9.99	0.37	6.23e-22	IgG glycosylation;
BRCA	trans	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-39.43	-0.84	2.74e-173	Exhaled nitric oxide output;
BRCA	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg23602478	chr1:26503979	CNKSR1	0.24	8.16	0.31	1.73e-15	Height;
BRCA	trans	rs1493916	0.967	rs34341086	chr18:31400141	C/T	cg15819921	chr19:927150	ARID3A	-0.45	-8.48	-0.32	1.57e-16	Life satisfaction;
BRCA	cis	rs17490626	0.512	rs12241097	chr10:71216678	T/G	cg12610070	chr10:71211762	TSPAN15	-0.33	-11.47	-0.41	7.83e-28	Thrombosis;
BRCA	cis	rs68170813	0.559	rs4730223	chr7:106814234	A/T	cg02696742	chr7:106810147	HBP1	0.51	8.73	0.33	2.15e-17	Coronary artery disease;
BRCA	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg27147174	chr7:100797783	AP1S1	-0.58	-11.87	-0.43	1.7e-29	Life satisfaction;
BRCA	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24549020	chr5:56110836	MAP3K1	0.64	12.87	0.45	7.13e-34	Initial pursuit acceleration;
BRCA	cis	rs2481665	0.772	rs6668421	chr1:62536619	C/G	cg18591186	chr1:62594603	INADL	-0.56	-12.17	-0.43	8.89e-31	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg08000102	chr2:233561755	GIGYF2	0.45	9.72	0.36	6.19e-21	Coronary artery disease;
BRCA	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.52	11.56	0.42	3.39e-28	Colorectal cancer;
BRCA	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg27129171	chr3:47204927	SETD2	-0.49	-10.54	-0.38	4.65e-24	Birth weight;
BRCA	cis	rs941764	0.965	rs747159	chr14:91841030	A/C	cg10511902	chr14:91842949	CCDC88C	-0.54	-14.2	-0.49	5.87e-40	Breast cancer;
BRCA	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg06494592	chr3:125709126	NA	-0.53	-8.25	-0.31	9.2e-16	Blood pressure (smoking interaction);
BRCA	cis	rs877529	1.000	rs139401	chr22:39546074	C/G	cg12193277	chr22:39547181	CBX7	0.46	12.72	0.45	3.21e-33	Multiple myeloma;
BRCA	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg27129171	chr3:47204927	SETD2	-0.71	-17.57	-0.57	1.12e-56	Colorectal cancer;
BRCA	cis	rs10504073	0.647	rs12549138	chr8:50007203	C/T	cg00325661	chr8:49890786	NA	0.44	12.45	0.44	4.95e-32	Blood metabolite ratios;
BRCA	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg23711669	chr6:146136114	FBXO30	-0.78	-18.09	-0.58	2.33e-59	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg06521331	chr12:34319734	NA	0.52	9.43	0.35	7.17e-20	Bladder cancer;
BRCA	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg23711669	chr6:146136114	FBXO30	0.64	15.06	0.51	4.43e-44	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.0	0.3	6.04e-15	Mean corpuscular volume;
BRCA	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg08000102	chr2:233561755	GIGYF2	0.62	13.53	0.47	7.54e-37	Coronary artery disease;
BRCA	cis	rs4285028	0.847	rs1986712	chr3:121710986	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.6	-10.5	-0.38	6.83e-24	Multiple sclerosis;
BRCA	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg19508488	chr2:152266495	RIF1	0.43	9.34	0.35	1.63e-19	Lung cancer;
BRCA	cis	rs7617773	0.780	rs11130164	chr3:48369034	G/A	cg11946769	chr3:48343235	NME6	0.67	13.61	0.47	3.13e-37	Coronary artery disease;
BRCA	cis	rs9359856	0.623	rs1179903	chr6:90321736	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.55	-9.34	-0.35	1.58e-19	Bipolar disorder;
BRCA	cis	rs13046373	0.535	rs2226377	chr21:32031915	T/C	cg16812893	chr21:31813075	KRTAP15-1	0.37	8.99	0.34	2.78e-18	HDL cholesterol;
BRCA	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-8.03	-0.3	4.72e-15	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg07148914	chr20:33460835	GGT7	-0.41	-8.91	-0.33	5.12e-18	Height;
BRCA	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg13010199	chr12:38710504	ALG10B	0.56	12.22	0.44	5.11e-31	Heart rate;
BRCA	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg24562669	chr7:97807699	LMTK2	0.45	12.01	0.43	4.07e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg07148914	chr20:33460835	GGT7	0.38	8.63	0.32	4.83e-17	Height;
BRCA	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.36	-7.96	-0.3	8.13e-15	Educational attainment;
BRCA	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.86	-0.33	7.71e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs10992471	0.528	rs2296666	chr9:95274261	C/T	cg14631576	chr9:95140430	CENPP	0.33	8.23	0.31	1.04e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg03433033	chr1:76189801	ACADM	0.65	13.93	0.48	1.04e-38	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg09307838	chr4:120376055	NA	0.7	14.28	0.49	2.45e-40	Corneal astigmatism;
BRCA	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-9.39	-0.35	1.01e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6060717	0.536	rs6060676	chr20:34498551	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.24	-0.31	1e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg06064525	chr11:970664	AP2A2	-0.29	-8.51	-0.32	1.24e-16	Alzheimer's disease (late onset);
BRCA	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg10523679	chr1:76189770	ACADM	-0.53	-9.82	-0.36	2.67e-21	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg01620082	chr3:125678407	NA	-0.83	-9.04	-0.34	1.78e-18	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1577917	0.771	rs3812133	chr6:86354411	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-12.99	-0.46	2.19e-34	Response to antipsychotic treatment;
BRCA	cis	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg06521331	chr12:34319734	NA	-0.62	-11.23	-0.41	7.8e-27	Morning vs. evening chronotype;
BRCA	cis	rs495337	0.730	rs648095	chr20:48494178	G/A	cg17835207	chr20:48524531	SPATA2	-0.5	-10.5	-0.38	6.42e-24	Psoriasis;
BRCA	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg08000102	chr2:233561755	GIGYF2	-0.47	-10.24	-0.38	6.78e-23	Coronary artery disease;
BRCA	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-11.78	-0.42	4.01e-29	Bipolar disorder;
BRCA	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.67	-0.39	1.44e-24	Mean corpuscular volume;
BRCA	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02475777	chr4:1388615	CRIPAK	0.67	12.68	0.45	5.08e-33	Longevity;
BRCA	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.16	-0.34	6.89e-19	Neuroticism;
BRCA	cis	rs7635838	0.617	rs2606731	chr3:11291615	A/C	cg00170343	chr3:11313890	ATG7	0.42	8.22	0.31	1.11e-15	HDL cholesterol;
BRCA	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg24060327	chr5:131705240	SLC22A5	0.62	12.02	0.43	3.72e-30	Breast cancer;
BRCA	cis	rs4853036	1.000	rs34587942	chr2:70081501	G/A	cg02498382	chr2:70120550	SNRNP27	-0.49	-8.99	-0.34	2.74e-18	Colorectal or endometrial cancer;
BRCA	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.6	0.57	7.83e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.06	0.37	3.23e-22	Bladder cancer;
BRCA	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg06784218	chr1:46089804	CCDC17	0.52	12.53	0.44	2.24e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg00409905	chr10:38381863	ZNF37A	-0.56	-12.31	-0.44	2.08e-31	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9469578	1.000	rs73743336	chr6:33715391	G/A	cg18708504	chr6:33715942	IP6K3	0.7	10.19	0.37	1.09e-22	Phosphorus levels;
BRCA	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	9.82	0.36	2.71e-21	Tonsillectomy;
BRCA	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg18230493	chr5:56204884	C5orf35	-0.72	-13.87	-0.48	1.95e-38	Initial pursuit acceleration;
BRCA	cis	rs4363385	0.747	rs4845330	chr1:152981505	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.36	-0.31	3.82e-16	Inflammatory skin disease;
BRCA	cis	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg19338460	chr6:170058176	WDR27	-0.44	-7.83	-0.3	2.04e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs4363385	0.747	rs11205151	chr1:152961496	G/A	cg24667326	chr1:152973720	SPRR3	-0.33	-9.34	-0.35	1.55e-19	Inflammatory skin disease;
BRCA	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg00071950	chr4:10020882	SLC2A9	0.43	10.12	0.37	2.07e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12667521	chr19:29218732	NA	0.45	8.41	0.32	2.77e-16	Methadone dose in opioid dependence;
BRCA	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg08601574	chr20:25228251	PYGB	-0.35	-8.64	-0.32	4.54e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-16.57	-0.55	1.37e-51	Migraine;Coronary artery disease;
BRCA	cis	rs16867321	0.639	rs12466864	chr2:181441417	C/G	cg23363182	chr2:181467187	NA	0.47	10.3	0.38	4.2e-23	Obesity;
BRCA	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg03585969	chr10:35415529	CREM	0.5	10.43	0.38	1.26e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg10729496	chr3:10149963	C3orf24	0.49	9.17	0.34	6.54e-19	Alzheimer's disease;
BRCA	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.28	8.75	0.33	1.85e-17	Electroencephalogram traits;
BRCA	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg10932868	chr11:921992	NA	0.41	9.81	0.36	2.99e-21	Alzheimer's disease (late onset);
BRCA	trans	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg07211511	chr3:129823064	LOC729375	0.75	14.65	0.5	3.9e-42	Blood pressure (smoking interaction);
BRCA	cis	rs858239	0.539	rs1358442	chr7:23189739	C/T	cg23682824	chr7:23144976	KLHL7	0.42	10.96	0.4	1e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1506636	1.000	rs2215553	chr7:123318478	G/T	cg03229431	chr7:123269106	ASB15	-0.63	-14.19	-0.49	6.18e-40	Plateletcrit;Platelet count;
BRCA	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg23625390	chr15:77176239	SCAPER	-0.54	-12.48	-0.44	3.92e-32	Blood metabolite levels;
BRCA	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24110177	chr3:50126178	RBM5	0.51	14.42	0.5	4.95e-41	Body mass index;
BRCA	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-16.18	-0.54	1.39e-49	Heart rate;
BRCA	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.23	0.31	1.03e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.66	-0.61	1.21e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg01256987	chr12:42539512	GXYLT1	-0.41	-8.11	-0.31	2.66e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs6484504	0.652	rs674035	chr11:31399014	G/A	cg06552810	chr11:31128660	NA	0.39	8.5	0.32	1.38e-16	Red blood cell count;
BRCA	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.42	-0.32	2.5e-16	Bipolar disorder;
BRCA	cis	rs3857067	0.806	rs4693002	chr4:95115302	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.46	-0.35	5.77e-20	QT interval;
BRCA	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.65	0.55	5.99e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	19.65	0.61	1.42e-67	Platelet count;
BRCA	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg06064525	chr11:970664	AP2A2	-0.34	-10.35	-0.38	2.52e-23	Alzheimer's disease (late onset);
BRCA	trans	rs7980799	0.591	rs10844614	chr12:33605702	A/C	cg26384229	chr12:38710491	ALG10B	-0.51	-10.65	-0.39	1.78e-24	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs9612	1.000	rs12669	chr19:44235535	G/A	cg08581076	chr19:44259116	C19orf61	0.62	10.93	0.4	1.3e-25	Exhaled nitric oxide output;
BRCA	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.37	-8.12	-0.31	2.36e-15	Alzheimer's disease (late onset);
BRCA	cis	rs10267417	0.603	rs1557773	chr7:19908586	A/G	cg05791153	chr7:19748676	TWISTNB	-0.46	-9.03	-0.34	1.96e-18	Night sleep phenotypes;
BRCA	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg18132916	chr6:79620363	NA	-0.48	-10.89	-0.4	1.89e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	0.718	rs1599383	chr3:160829820	T/C	cg04691961	chr3:161091175	C3orf57	-0.37	-8.15	-0.31	1.89e-15	Morning vs. evening chronotype;
BRCA	cis	rs4690686	0.500	rs12498752	chr4:177265451	T/C	cg17059388	chr4:177262070	NA	0.51	10.68	0.39	1.34e-24	Essential tremor;
BRCA	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.32	0.49	1.55e-40	Motion sickness;
BRCA	cis	rs77972916	0.505	rs3851318	chr2:43532808	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-10.71	-0.39	1.01e-24	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg08888203	chr3:10149979	C3orf24	0.68	14.5	0.5	2.22e-41	Alzheimer's disease;
BRCA	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg24076588	chr1:18808559	KLHDC7A	-0.45	-10.5	-0.38	6.61e-24	Breast cancer;
BRCA	cis	rs3772130	0.775	rs6781857	chr3:121560721	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.74	0.39	7.27e-25	Cognitive performance;
BRCA	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07636037	chr3:49044803	WDR6	-0.77	-15.58	-0.52	1.28e-46	Menarche (age at onset);
BRCA	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg06046430	chr4:77819534	ANKRD56	0.51	11.08	0.4	3.12e-26	Emphysema distribution in smoking;
BRCA	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-14.0	-0.48	4.85e-39	Chronic sinus infection;
BRCA	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg05535760	chr7:792225	HEATR2	0.72	13.05	0.46	1.09e-34	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg05623727	chr3:50126028	RBM5	-0.43	-10.25	-0.38	6.46e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs3739998	0.647	rs7920682	chr10:30317826	C/T	cg00730780	chr10:30316187	KIAA1462	-0.55	-11.79	-0.42	3.68e-29	Coronary heart disease;
BRCA	cis	rs17209837	0.607	rs2888611	chr7:87103670	C/G	cg00919237	chr7:87102261	ABCB4	0.54	10.53	0.38	5.29e-24	Gallbladder cancer;
BRCA	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg11752832	chr7:134001865	SLC35B4	0.53	13.75	0.48	7.41e-38	Mean platelet volume;
BRCA	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11764359	chr7:65958608	NA	-0.79	-18.91	-0.6	1.14e-63	Aortic root size;
BRCA	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg21475434	chr5:93447410	FAM172A	0.66	8.55	0.32	8.79e-17	Diabetic retinopathy;
BRCA	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg25237894	chr2:233734115	C2orf82	-0.38	-11.01	-0.4	6.31e-26	Coronary artery disease;
BRCA	cis	rs4363385	0.818	rs11205175	chr1:153001296	A/C	cg24667326	chr1:152973720	SPRR3	-0.33	-8.77	-0.33	1.55e-17	Inflammatory skin disease;
BRCA	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	9.15	0.34	7.34e-19	Personality dimensions;
BRCA	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg14061069	chr19:46274453	DMPK	-0.48	-11.94	-0.43	8.25e-30	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg05340658	chr4:99064831	C4orf37	0.68	16.98	0.56	1.21e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs701145	0.585	rs447429	chr3:153909946	T/C	cg17054900	chr3:154042577	DHX36	0.57	9.59	0.35	1.96e-20	Coronary artery disease;
BRCA	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18876405	chr7:65276391	NA	0.52	11.63	0.42	1.7e-28	Aortic root size;
BRCA	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02187348	chr16:89574699	SPG7	0.51	12.04	0.43	3.2e-30	Multiple myeloma (IgH translocation);
BRCA	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg03433033	chr1:76189801	ACADM	0.76	17.39	0.57	9.02e-56	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08704250	chr15:31115839	NA	-0.38	-9.28	-0.34	2.59e-19	Huntington's disease progression;
BRCA	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg02574844	chr11:5959923	NA	-0.39	-8.06	-0.3	3.7e-15	DNA methylation (variation);
BRCA	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.63	-0.36	1.37e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg03711944	chr11:47377212	SPI1	-0.41	-9.76	-0.36	4.58e-21	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.67	0.32	3.43e-17	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg27398817	chr8:82754497	SNX16	0.35	8.05	0.3	4.1e-15	Diastolic blood pressure;
BRCA	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg05623727	chr3:50126028	RBM5	-0.43	-10.39	-0.38	1.82e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.747	rs1577965	chr1:152968294	T/C	cg21543102	chr1:152974771	SPRR3	-0.3	-8.36	-0.31	3.79e-16	Inflammatory skin disease;
BRCA	cis	rs6435161	0.959	rs1971740	chr2:203484736	G/A	cg18429434	chr2:203499731	FAM117B	-0.43	-9.0	-0.34	2.46e-18	Total cholesterol levels;
BRCA	cis	rs60843830	0.661	rs11674477	chr2:105822	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.49	9.31	0.35	2.01e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs897984	0.762	rs897986	chr16:30980902	T/C	cg02466173	chr16:30829666	NA	0.49	11.14	0.4	1.89e-26	Dementia with Lewy bodies;
BRCA	cis	rs1113500	0.836	rs2801220	chr1:108584649	A/G	cg06207961	chr1:108661230	NA	-0.4	-9.72	-0.36	6.31e-21	Growth-regulated protein alpha levels;
BRCA	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg24642844	chr7:1081250	C7orf50	-0.57	-11.6	-0.42	2.36e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg07080220	chr10:102295463	HIF1AN	0.61	14.33	0.49	1.36e-40	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg22535103	chr8:58192502	C8orf71	0.46	9.19	0.34	5.29e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.59	9.27	0.34	2.74e-19	Renal function-related traits (BUN);
BRCA	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg24110177	chr3:50126178	RBM5	-0.44	-9.69	-0.36	8.62e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7580658	0.963	rs12052483	chr2:128136820	T/G	cg09760422	chr2:128146352	NA	-0.35	-7.84	-0.3	1.83e-14	Protein C levels;
BRCA	cis	rs4423214	0.879	rs736894	chr11:71152258	A/G	cg05163923	chr11:71159392	DHCR7	0.58	12.02	0.43	3.88e-30	Vitamin D levels;
BRCA	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	9.03	0.34	2.05e-18	Personality dimensions;
BRCA	cis	rs733175	0.855	rs10023068	chr4:10004832	C/T	cg00071950	chr4:10020882	SLC2A9	-0.41	-8.69	-0.33	3.06e-17	Psychosis and Alzheimer's disease;
BRCA	trans	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg05926928	chr17:57297772	GDPD1	-0.59	-9.1	-0.34	1.13e-18	Opioid sensitivity;
BRCA	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-12.16	-0.43	9.45e-31	Electroencephalogram traits;
BRCA	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg25427524	chr10:38739819	LOC399744	-0.53	-9.45	-0.35	6.42e-20	Obesity (extreme);
BRCA	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg23711669	chr6:146136114	FBXO30	0.74	17.75	0.57	1.29e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-7.92	-0.3	1.06e-14	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17253792	0.915	rs78498383	chr14:56177585	C/T	cg01858014	chr14:56050164	KTN1	-0.67	-8.52	-0.32	1.13e-16	Putamen volume;
BRCA	trans	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	9.5	0.35	3.97e-20	Mean corpuscular volume;
BRCA	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-11.75	-0.42	5.1e-29	Chronic sinus infection;
BRCA	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.62	12.72	0.45	3.23e-33	Lymphocyte counts;
BRCA	cis	rs35740288	0.545	rs12916187	chr15:86326124	A/C	cg20737812	chr15:86336631	KLHL25	-0.38	-8.21	-0.31	1.27e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.93e-24	Motion sickness;
BRCA	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg05340658	chr4:99064831	C4orf37	-0.53	-12.42	-0.44	6.89e-32	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg07636037	chr3:49044803	WDR6	0.97	28.32	0.75	6.46e-115	Parkinson's disease;
BRCA	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	12.98	0.46	2.36e-34	Lymphocyte percentage of white cells;
BRCA	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg19920283	chr7:105172520	RINT1	0.59	9.53	0.35	3.29e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.7	-16.18	-0.54	1.39e-49	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.53	11.74	0.42	6.18e-29	Multiple sclerosis;
BRCA	cis	rs778371	0.958	rs778341	chr2:233728801	C/A	cg08000102	chr2:233561755	GIGYF2	-0.74	-15.68	-0.53	4.11e-47	Schizophrenia;
BRCA	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg00999904	chr2:3704751	ALLC	0.38	7.95	0.3	8.44e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs6963495	0.585	rs1706923	chr7:105221097	A/G	cg19920283	chr7:105172520	RINT1	0.43	8.89	0.33	6.34e-18	Bipolar disorder (body mass index interaction);
BRCA	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.59	-16.35	-0.54	1.85e-50	Colorectal cancer;
BRCA	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg16482183	chr6:26056742	HIST1H1C	0.46	8.85	0.33	8.66e-18	Iron status biomarkers;
BRCA	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg06547715	chr2:218990976	CXCR2	0.32	8.03	0.3	4.54e-15	Ulcerative colitis;
BRCA	cis	rs7953508	0.506	rs3869308	chr12:93959918	A/G	cg18151635	chr12:93972918	NA	-0.48	-9.71	-0.36	7.02e-21	Pubertal anthropometrics;
BRCA	cis	rs250677	0.522	rs4562031	chr5:148368451	A/G	cg18129178	chr5:148520854	ABLIM3	0.55	10.53	0.38	5.11e-24	Breast cancer;
BRCA	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg04362960	chr10:104952993	NT5C2	0.44	10.11	0.37	2.26e-22	Arsenic metabolism;
BRCA	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg09021430	chr5:549028	NA	-0.61	-15.75	-0.53	1.83e-47	Obesity-related traits;
BRCA	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-8.08	-0.3	3.23e-15	Blood pressure (smoking interaction);
BRCA	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg16339924	chr4:17578868	LAP3	0.64	16.14	0.54	2.19e-49	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.8	-0.33	1.3e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs9837602	0.683	rs9825882	chr3:99906250	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.52	-8.39	-0.32	3.01e-16	Breast cancer;
BRCA	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg09184832	chr6:79620586	NA	-0.52	-11.41	-0.41	1.44e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs6840258	0.660	rs72667741	chr4:87892075	T/C	cg08197287	chr4:87952173	AFF1	-0.46	-8.39	-0.31	3.18e-16	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg14926445	chr8:58193284	C8orf71	-0.44	-8.07	-0.3	3.57e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10465746	0.725	rs2024591	chr1:84329235	C/T	cg10977910	chr1:84465055	TTLL7	0.59	12.02	0.43	3.67e-30	Obesity-related traits;
BRCA	cis	rs16854884	0.770	rs1530478	chr3:143819553	C/T	cg06585982	chr3:143692056	C3orf58	0.42	8.34	0.31	4.56e-16	Economic and political preferences (feminism/equality);
BRCA	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg14349672	chr11:133703707	NA	-0.42	-9.17	-0.34	6.16e-19	Childhood ear infection;
BRCA	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	10.75	0.39	7.06e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs9443189	1.000	rs3822957	chr6:76607280	A/G	cg01950844	chr6:76311363	SENP6	-0.59	-9.3	-0.35	2.29e-19	Prostate cancer;
BRCA	cis	rs10992471	0.603	rs10820968	chr9:95106443	A/G	cg14631576	chr9:95140430	CENPP	-0.39	-9.58	-0.35	2.04e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg00757033	chr12:89920650	WDR51B	0.51	10.75	0.39	6.81e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.12	-39.61	-0.84	3.43e-174	Myeloid white cell count;
BRCA	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.6	9.47	0.35	5.18e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4812048	0.649	rs116580814	chr20:57618141	G/T	cg14073986	chr20:57617431	SLMO2	0.81	11.24	0.41	7.36e-27	Mean platelet volume;
BRCA	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg22907277	chr7:1156413	C7orf50	0.63	10.98	0.4	8.4e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	11.6	0.42	2.2e-28	Neuroticism;
BRCA	cis	rs9462027	0.628	rs2764198	chr6:34706128	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.87	-0.3	1.55e-14	Systemic lupus erythematosus;
BRCA	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg07080220	chr10:102295463	HIF1AN	0.59	13.77	0.48	5.59e-38	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg09184832	chr6:79620586	NA	-0.52	-11.41	-0.41	1.44e-27	Intelligence (multi-trait analysis);
BRCA	trans	rs72766638	0.848	rs11789898	chr9:136925663	A/C	cg09836344	chr4:1243392	C4orf42;CTBP1	0.66	9.84	0.36	2.34e-21	Mosquito bite size;
BRCA	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.27	0.31	7.75e-16	Melanoma;
BRCA	cis	rs7127900	0.583	rs11043147	chr11:2234169	C/G	cg25635251	chr11:2234043	NA	0.46	13.12	0.46	5.55e-35	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
BRCA	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg06784218	chr1:46089804	CCDC17	0.46	10.91	0.4	1.58e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs587242	0.955	rs35251373	chr1:96970538	C/T	cg10631902	chr5:14652156	NA	0.43	10.63	0.39	2.1e-24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
BRCA	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg06640241	chr16:89574553	SPG7	-0.77	-19.19	-0.6	3.66e-65	Multiple myeloma (IgH translocation);
BRCA	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-8.99	-0.33	2.87e-18	Alzheimer's disease (late onset);
BRCA	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7246657	0.550	rs10411176	chr19:37686953	G/T	cg18154014	chr19:37997991	ZNF793	0.56	9.33	0.35	1.69e-19	Coronary artery calcification;
BRCA	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg07080220	chr10:102295463	HIF1AN	-0.46	-10.37	-0.38	2.16e-23	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs3857536	0.813	rs9360189	chr6:66933424	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.11	-0.31	2.53e-15	Blood trace element (Cu levels);
BRCA	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.33	-8.06	-0.3	3.77e-15	Longevity;Endometriosis;
BRCA	cis	rs9633740	0.578	rs7084416	chr10:82304297	G/A	cg01528321	chr10:82214614	TSPAN14	-0.66	-11.07	-0.4	3.41e-26	Post bronchodilator FEV1;
BRCA	cis	rs2282802	0.685	rs6893253	chr5:139661279	T/C	cg26211634	chr5:139558579	C5orf32	0.35	8.22	0.31	1.15e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08045932	chr20:61659980	NA	0.5	11.43	0.41	1.2100000000000001e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg16102102	chr5:83017553	HAPLN1	-0.88	-17.61	-0.57	7.01e-57	Prostate cancer;
BRCA	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11764359	chr7:65958608	NA	0.76	16.82	0.55	7.85e-53	Aortic root size;
BRCA	cis	rs1215050	0.743	rs6532692	chr4:98648005	C/A	cg05340658	chr4:99064831	C4orf37	-0.41	-8.82	-0.33	1.05e-17	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs11229555	0.645	rs11601296	chr11:58423297	A/G	cg15696309	chr11:58395628	NA	-0.49	-9.73	-0.36	5.67e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19346786	chr7:2764209	NA	-0.31	-9.14	-0.34	8.22e-19	Height;
BRCA	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg24110177	chr3:50126178	RBM5	-0.48	-12.21	-0.43	5.96e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg06484146	chr7:12443880	VWDE	-0.6	-10.3	-0.38	4.07e-23	Coronary artery disease;
BRCA	cis	rs2625529	0.668	rs8192431	chr15:72492352	G/A	cg16672083	chr15:72433130	SENP8	-0.85	-17.4	-0.57	8.61e-56	Red blood cell count;
BRCA	trans	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs7809950	0.834	rs2712199	chr7:107140239	A/G	cg23024343	chr7:107201750	COG5	-0.4	-9.09	-0.34	1.21e-18	Coronary artery disease;
BRCA	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg16479474	chr6:28041457	NA	0.42	7.81	0.3	2.41e-14	Parkinson's disease;
BRCA	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg08888203	chr3:10149979	C3orf24	0.53	9.89	0.36	1.44e-21	Alzheimer's disease;
BRCA	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg17063962	chr7:91808500	NA	0.53	12.48	0.44	3.92e-32	Breast cancer;
BRCA	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg04013093	chr6:42928303	GNMT	-0.29	-8.9	-0.33	5.73e-18	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	5.1e-16	Tonsillectomy;
BRCA	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg13010199	chr12:38710504	ALG10B	0.5	9.66	0.36	1.03e-20	Morning vs. evening chronotype;
BRCA	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg15556689	chr8:8085844	FLJ10661	0.39	9.2	0.34	4.92e-19	Retinal vascular caliber;
BRCA	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg01689657	chr7:91764605	CYP51A1	0.22	8.16	0.31	1.78e-15	Breast cancer;
BRCA	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg24558204	chr6:135376177	HBS1L	0.45	12.41	0.44	8.13e-32	Red blood cell count;
BRCA	cis	rs2806561	0.606	rs10917335	chr1:23294136	A/G	cg19743168	chr1:23544995	NA	0.34	7.83	0.3	2.05e-14	Height;
BRCA	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg08470875	chr2:26401718	FAM59B	0.64	8.65	0.32	4.04e-17	Gut microbiome composition (summer);
BRCA	cis	rs1568889	0.938	rs6484358	chr11:28260364	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.71	0.5	2.04e-42	Bipolar disorder;
BRCA	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	18.25	0.59	3.13e-60	Alzheimer's disease;
BRCA	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg01236616	chr12:121019343	POP5	-1.22	-23.09	-0.67	3e-86	Type 1 diabetes nephropathy;
BRCA	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg04756594	chr16:24857601	SLC5A11	-0.55	-12.24	-0.44	4.24e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg21427119	chr20:30132790	HM13	-0.42	-8.85	-0.33	8.22e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.63	9.43	0.35	7.29e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg12935359	chr14:103987150	CKB	-0.59	-14.08	-0.49	1.99e-39	Body mass index;
BRCA	cis	rs1577917	0.545	rs1832070	chr6:86483172	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.34	9.19	0.34	5.44e-19	Response to antipsychotic treatment;
BRCA	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg26384229	chr12:38710491	ALG10B	0.75	17.2	0.56	8.96e-55	Bladder cancer;
BRCA	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.93	-0.33	4.44e-18	Breast cancer;
BRCA	cis	rs6594499	0.872	rs10055177	chr5:110450584	T/G	cg04022379	chr5:110408740	TSLP	0.35	7.95	0.3	8.57e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg21045802	chr8:109455806	TTC35	0.35	8.35	0.31	4.22e-16	Dupuytren's disease;
BRCA	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	13.29	0.47	9.61e-36	Mood instability;
BRCA	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03517284	chr6:25882590	NA	-0.44	-9.25	-0.34	3.24e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs34779708	0.931	rs2505631	chr10:35368385	A/T	cg03585969	chr10:35415529	CREM	-0.45	-9.65	-0.36	1.15e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	19.97	0.62	2.63e-69	Platelet count;
BRCA	cis	rs897984	0.609	rs1108431	chr16:31054607	C/T	cg00531865	chr16:30841666	NA	-0.4	-9.41	-0.35	9.14e-20	Dementia with Lewy bodies;
BRCA	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg23625390	chr15:77176239	SCAPER	0.39	9.14	0.34	8.44e-19	Blood metabolite levels;
BRCA	cis	rs877282	0.891	rs11599917	chr10:762288	G/A	cg17470449	chr10:769945	NA	0.47	8.12	0.31	2.39e-15	Uric acid levels;
BRCA	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	12.17	0.43	8.41e-31	Coronary artery disease;
BRCA	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg12573674	chr2:1569213	NA	-0.56	-12.3	-0.44	2.4e-31	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs953387	1.000	rs953387	chr2:136907170	A/C	cg05194412	chr2:137003533	NA	-0.37	-8.5	-0.32	1.31e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg08000102	chr2:233561755	GIGYF2	-0.45	-9.67	-0.36	9.49e-21	Coronary artery disease;
BRCA	cis	rs12911832	1.000	rs4774310	chr15:58985164	T/G	cg05156742	chr15:59063176	FAM63B	0.5	9.94	0.37	9.34e-22	Schizophrenia;
BRCA	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg04586622	chr2:25135609	ADCY3	0.46	11.59	0.42	2.61e-28	Body mass index;
BRCA	cis	rs10754283	0.905	rs7519969	chr1:90108721	G/C	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.31e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg09307838	chr4:120376055	NA	0.69	14.88	0.51	3.23e-43	Corneal astigmatism;
BRCA	trans	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.39	9.05	0.34	1.77e-18	Endometrial cancer;
BRCA	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.34	-9.6	-0.36	1.75e-20	Response to antipsychotic treatment;
BRCA	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg03808351	chr9:123631620	PHF19	-0.6	-10.12	-0.37	2.04e-22	Birth weight;
BRCA	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05535760	chr7:792225	HEATR2	0.85	14.21	0.49	4.98e-40	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2795502	0.564	rs72777187	chr10:43432224	C/T	cg08461752	chr10:43522343	NA	-0.48	-8.63	-0.32	4.91e-17	Blood protein levels;
BRCA	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	14.97	0.51	1.2e-43	Hip circumference adjusted for BMI;
BRCA	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg11645453	chr3:52864694	ITIH4	-0.37	-9.92	-0.37	1.17e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg24829409	chr8:58192753	C8orf71	-0.5	-11.06	-0.4	3.77e-26	Developmental language disorder (linguistic errors);
BRCA	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg13010199	chr12:38710504	ALG10B	0.44	8.64	0.32	4.6e-17	Morning vs. evening chronotype;
BRCA	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg09537434	chr19:41945824	ATP5SL	-0.98	-24.68	-0.7	5.66e-95	Height;
BRCA	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg17158414	chr2:27665306	KRTCAP3	0.35	9.23	0.34	3.84e-19	Total body bone mineral density;
BRCA	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-15.54	-0.52	1.92e-46	Systemic lupus erythematosus;
BRCA	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg11266682	chr4:10021025	SLC2A9	-0.42	-11.06	-0.4	4.01e-26	Bone mineral density;
BRCA	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg24209194	chr3:40518798	ZNF619	-0.4	-8.3	-0.31	6.37e-16	Renal cell carcinoma;
BRCA	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg18876405	chr7:65276391	NA	-0.52	-11.7	-0.42	8.87e-29	Aortic root size;
BRCA	cis	rs9649465	0.967	rs768680	chr7:123364127	T/C	cg04330084	chr7:123175371	IQUB	-0.31	-8.54	-0.32	9.74e-17	Migraine;
BRCA	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.82	0.62	1.64e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg04362960	chr10:104952993	NT5C2	0.43	10.54	0.38	4.65e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg03354898	chr7:1950403	MAD1L1	-0.5	-11.06	-0.4	3.79e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	5.1e-16	Tonsillectomy;
BRCA	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg27211696	chr2:191398769	TMEM194B	0.52	11.89	0.43	1.36e-29	Pulse pressure;
BRCA	cis	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg20368463	chr18:77673604	PQLC1	0.47	11.6	0.42	2.24e-28	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
BRCA	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-13.25	-0.46	1.46e-35	Bipolar disorder and schizophrenia;
BRCA	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg11822812	chr5:140052017	DND1	-0.31	-8.4	-0.32	2.86e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs701145	0.938	rs357504	chr3:153956857	A/C	cg17054900	chr3:154042577	DHX36	0.67	11.86	0.42	1.91e-29	Coronary artery disease;
BRCA	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg23285459	chr7:2802560	GNA12	-0.31	-8.11	-0.31	2.54e-15	Height;
BRCA	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg22376730	chr1:1715039	NA	0.34	8.88	0.33	6.81e-18	Body mass index;
BRCA	trans	rs6833159	0.527	rs10939231	chr4:28829372	A/T	cg25803693	chr12:82752707	CCDC59;C12orf26	0.37	8.43	0.32	2.21e-16	Underweight status;
BRCA	cis	rs12579753	1.000	rs12821073	chr12:82183260	G/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-8.46	-0.32	1.8e-16	Resting heart rate;
BRCA	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-10.85	-0.39	2.75e-25	Triglycerides;
BRCA	cis	rs9880211	0.948	rs6806123	chr3:136305476	C/G	cg21827317	chr3:136751795	NA	-0.45	-8.03	-0.3	4.53e-15	Body mass index;Height;
BRCA	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg03146154	chr1:46216737	IPP	-0.5	-11.11	-0.4	2.44e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs36051895	0.558	rs7038687	chr9:5134065	C/T	cg02405213	chr9:5042618	JAK2	0.46	9.09	0.34	1.19e-18	Pediatric autoimmune diseases;
BRCA	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg18196295	chr10:418757	DIP2C	0.49	11.86	0.42	1.87e-29	Psychosis in Alzheimer's disease;
BRCA	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg24110177	chr3:50126178	RBM5	0.55	16.08	0.54	3.99e-49	Body mass index;
BRCA	cis	rs778371	0.752	rs283487	chr2:233644011	A/G	cg08000102	chr2:233561755	GIGYF2	0.78	16.91	0.56	2.66e-53	Schizophrenia;
BRCA	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg18512352	chr11:47633146	NA	-0.38	-9.26	-0.34	3.02e-19	Subjective well-being;
BRCA	cis	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg08601574	chr20:25228251	PYGB	0.35	8.4	0.32	2.92e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-7.84	-0.3	1.86e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7254114	0.578	rs6511727	chr19:11315817	G/T	cg02815516	chr19:11306319	KANK2	-0.33	-9.41	-0.35	8.95e-20	Immature fraction of reticulocytes;
BRCA	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg04315214	chr1:2043799	PRKCZ	-0.45	-12.63	-0.45	8.29e-33	Height;
BRCA	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg17366294	chr4:99064904	C4orf37	0.44	10.31	0.38	3.67e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.6	-0.32	6e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2880765	0.743	rs16940052	chr15:86006674	G/A	cg10818794	chr15:86012489	AKAP13	-0.3	-8.27	-0.31	7.69e-16	Coronary artery disease;
BRCA	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.79	11.43	0.41	1.13e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg18252515	chr7:66147081	NA	-0.94	-10.68	-0.39	1.25e-24	Diabetic kidney disease;
BRCA	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg06092702	chr1:163392909	NA	-0.37	-9.8	-0.36	3.11e-21	Motion sickness;
BRCA	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg08470875	chr2:26401718	FAM59B	-0.64	-9.54	-0.35	2.95e-20	Gut microbiome composition (summer);
BRCA	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg03342759	chr3:160939853	NMD3	-0.64	-13.56	-0.47	5.21e-37	Morning vs. evening chronotype;
BRCA	cis	rs8014204	0.836	rs7154256	chr14:75252587	A/G	cg06637938	chr14:75390232	RPS6KL1	0.55	11.14	0.4	1.89e-26	Caffeine consumption;
BRCA	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.31	-0.38	3.71e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10504073	0.647	rs4348510	chr8:50016027	C/A	cg00325661	chr8:49890786	NA	0.38	11.24	0.41	7.42e-27	Blood metabolite ratios;
BRCA	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14240646	chr10:27532245	ACBD5	0.64	9.52	0.35	3.43e-20	Breast cancer;
BRCA	cis	rs2806561	0.780	rs12135629	chr1:23338899	A/G	cg19743168	chr1:23544995	NA	-0.42	-10.03	-0.37	4.2e-22	Height;
BRCA	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.75	-0.42	5.1e-29	Alcohol dependence;
BRCA	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg21573476	chr21:45109991	RRP1B	-0.33	-8.47	-0.32	1.73e-16	Mean corpuscular volume;
BRCA	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	11.34	0.41	2.88e-27	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.74	0.55	2.09e-52	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg25358565	chr5:93447407	FAM172A	1.16	18.33	0.59	1.33e-60	Diabetic retinopathy;
BRCA	cis	rs68092024	0.704	rs792832	chr3:99474862	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-10.53	-0.38	5.22e-24	Cleft lip with or without cleft palate;
BRCA	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg19773385	chr1:10388646	KIF1B	-0.39	-8.31	-0.31	5.63e-16	Hepatocellular carcinoma;
BRCA	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	18.31	0.59	1.69e-60	Platelet count;
BRCA	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.4	9.08	0.34	1.35e-18	Alzheimer's disease (late onset);
BRCA	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg04317338	chr11:64019027	PLCB3	0.55	9.48	0.35	4.9e-20	Mean platelet volume;
BRCA	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg27170947	chr2:26402098	FAM59B	0.97	15.4	0.52	9.96e-46	Gut microbiome composition (summer);
BRCA	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg10932868	chr11:921992	NA	0.49	12.62	0.45	9.59e-33	Alzheimer's disease (late onset);
BRCA	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg12463550	chr7:65579703	CRCP	0.37	7.85	0.3	1.75e-14	Aortic root size;
BRCA	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg09035930	chr12:129282057	SLC15A4	0.55	16.19	0.54	1.17e-49	Systemic lupus erythematosus;
BRCA	cis	rs3815700	1.000	rs8113165	chr19:33096316	C/T	cg02997394	chr19:33096574	ANKRD27	0.71	12.28	0.44	2.75e-31	Eosinophilic esophagitis;
BRCA	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg05084668	chr3:125655381	ALG1L	-0.44	-7.81	-0.3	2.4e-14	Blood pressure (smoking interaction);
BRCA	cis	rs4730250	0.655	rs75243311	chr7:106890791	C/T	cg02696742	chr7:106810147	HBP1	-0.47	-7.92	-0.3	1.08e-14	Osteoarthritis;
BRCA	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg21770322	chr7:97807741	LMTK2	0.44	11.72	0.42	7.34e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26314531	chr2:26401878	FAM59B	-0.66	-11.29	-0.41	4.42e-27	Gut microbiome composition (summer);
BRCA	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg06784218	chr1:46089804	CCDC17	-0.53	-13.0	-0.46	1.81e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10242455	0.557	rs73401516	chr7:99068351	C/A	cg18809830	chr7:99032528	PTCD1	-0.58	-8.33	-0.31	4.76e-16	Blood metabolite levels;
BRCA	cis	rs738322	0.555	rs5750547	chr22:38546700	A/G	cg20207973	chr22:38506712	BAIAP2L2	-0.32	-8.1	-0.31	2.87e-15	Cutaneous nevi;
BRCA	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg20503657	chr10:835505	NA	-0.45	-8.89	-0.33	6.05e-18	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs6700896	0.931	rs12042779	chr1:66133950	T/C	cg04111102	chr1:66153794	NA	0.35	8.55	0.32	8.78e-17	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg01579765	chr21:45077557	HSF2BP	0.38	10.14	0.37	1.71e-22	Mean corpuscular volume;
BRCA	cis	rs11585357	1.000	rs72646785	chr1:17603472	G/T	cg08277548	chr1:17600880	PADI3	-0.74	-12.07	-0.43	2.35e-30	Hair shape;
BRCA	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg20387954	chr3:183756860	HTR3D	0.45	10.05	0.37	3.66e-22	Anterior chamber depth;
BRCA	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg25036284	chr2:26402008	FAM59B	0.88	15.06	0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	18.62	0.59	3.63e-62	Alzheimer's disease;
BRCA	cis	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg07460842	chr6:66804631	NA	0.59	10.46	0.38	9.37e-24	Type 2 diabetes;
BRCA	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg22907277	chr7:1156413	C7orf50	0.59	9.19	0.34	5.33e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	11.34	0.41	2.69e-27	Birth weight;
BRCA	cis	rs858239	0.600	rs13438179	chr7:23143851	T/C	cg23682824	chr7:23144976	KLHL7	0.45	12.23	0.44	4.53e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs5751614	0.517	rs928780	chr22:23599869	G/A	cg25410636	chr22:23605411	BCR	-0.35	-8.01	-0.3	5.57e-15	Height;
BRCA	cis	rs11585357	0.557	rs17378462	chr1:17595702	C/T	cg08277548	chr1:17600880	PADI3	-0.53	-8.28	-0.31	7.04e-16	Hair shape;
BRCA	cis	rs6484504	0.576	rs208066	chr11:31156206	C/G	cg06552810	chr11:31128660	NA	-0.37	-8.1	-0.31	2.87e-15	Red blood cell count;
BRCA	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg17063962	chr7:91808500	NA	0.54	12.26	0.44	3.49e-31	Breast cancer;
BRCA	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.82	0.36	2.79e-21	Bipolar disorder;
BRCA	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.52	-9.55	-0.35	2.66e-20	Body mass index;
BRCA	cis	rs1050631	0.657	rs1789551	chr18:33716092	G/A	cg19453250	chr18:33710783	SLC39A6;ELP2	-0.29	-7.99	-0.3	6.25e-15	Esophageal squamous cell cancer (length of survival);
BRCA	cis	rs10504073	0.584	rs62507210	chr8:49946601	C/T	cg00325661	chr8:49890786	NA	0.47	13.71	0.48	1.04e-37	Blood metabolite ratios;
BRCA	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-10.54	-0.38	4.65e-24	Mood instability;
BRCA	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg21132104	chr15:45694354	SPATA5L1	0.74	16.82	0.55	7.77e-53	Homoarginine levels;
BRCA	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg25237894	chr2:233734115	C2orf82	0.4	11.39	0.41	1.76e-27	Coronary artery disease;
BRCA	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg00409905	chr10:38381863	ZNF37A	-0.51	-10.84	-0.39	3.13e-25	Extrinsic epigenetic age acceleration;
BRCA	trans	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg17675199	chr6:35436792	RPL10A	-0.3	-7.88	-0.3	1.42e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24110177	chr3:50126178	RBM5	-0.33	-8.93	-0.33	4.41e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs11997175	0.603	rs7464072	chr8:33776973	G/A	ch.8.33884649F	chr8:33765107	NA	0.38	9.01	0.34	2.29e-18	Body mass index;
BRCA	cis	rs1003719	0.688	rs2000413	chr21:38539718	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-13.71	-0.48	1.05e-37	Eye color traits;
BRCA	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg17971929	chr21:40555470	PSMG1	0.8	18.56	0.59	8.04e-62	Cognitive function;
BRCA	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	21.33	0.64	1.22e-76	Mean platelet volume;
BRCA	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg16339924	chr4:17578868	LAP3	0.62	15.46	0.52	4.66e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.68	-12.98	-0.46	2.35e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg21573476	chr21:45109991	RRP1B	-0.49	-13.01	-0.46	1.65e-34	Mean corpuscular volume;
BRCA	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg15145296	chr3:125709740	NA	-0.54	-8.64	-0.32	4.6e-17	Blood pressure (smoking interaction);
BRCA	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09263875	chr16:632152	PIGQ	0.71	20.83	0.64	6.33e-74	Height;
BRCA	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.15	-0.31	1.9e-15	Aortic root size;
BRCA	cis	rs7572263	0.724	rs67989853	chr2:209055164	T/C	cg23998903	chr2:209048830	C2orf80	-0.41	-8.37	-0.31	3.51e-16	Glioma;Non-glioblastoma glioma;
BRCA	trans	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg26043149	chr18:55253948	FECH	1.08	23.3	0.68	2.28e-87	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg10729496	chr3:10149963	C3orf24	0.48	9.02	0.34	2.09e-18	Alzheimer's disease;
BRCA	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-14.44	-0.5	4.31e-41	Eye color traits;
BRCA	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.46	0.38	9.29e-24	Bladder cancer;
BRCA	cis	rs1113500	0.814	rs12039712	chr1:108641199	A/G	cg06207961	chr1:108661230	NA	0.36	8.92	0.33	4.92e-18	Growth-regulated protein alpha levels;
BRCA	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg17063962	chr7:91808500	NA	-0.53	-12.19	-0.43	7.23e-31	Breast cancer;
BRCA	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.5	-0.44	3.15e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs7560272	0.538	rs35767294	chr2:73922834	A/G	cg20560298	chr2:73613845	ALMS1	0.35	9.01	0.34	2.41e-18	Schizophrenia;
BRCA	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg02221750	chr19:17393354	ANKLE1	-0.65	-12.55	-0.44	1.91e-32	Systemic lupus erythematosus;
BRCA	cis	rs2386661	0.637	rs7099771	chr10:5654742	A/G	cg17085576	chr10:5658249	NA	-0.32	-7.91	-0.3	1.16e-14	Breast cancer;
BRCA	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.41	9.24	0.34	3.61e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3772130	0.649	rs57636696	chr3:121619464	A/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	9.2	0.34	4.82e-19	Cognitive performance;
BRCA	cis	rs72781680	0.678	rs2551341	chr2:24014778	G/T	cg08917208	chr2:24149416	ATAD2B	0.57	9.52	0.35	3.38e-20	Lymphocyte counts;
BRCA	cis	rs9487051	0.768	rs386696	chr6:109520166	G/A	cg21918786	chr6:109611834	NA	-0.34	-9.15	-0.34	7.85e-19	Reticulocyte fraction of red cells;
BRCA	trans	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg23762105	chr12:34175262	ALG10	0.37	8.54	0.32	1.01e-16	Morning vs. evening chronotype;
BRCA	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24110177	chr3:50126178	RBM5	-0.39	-10.68	-0.39	1.28e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.71	-15.94	-0.53	2.04e-48	Hip circumference adjusted for BMI;
BRCA	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg18252515	chr7:66147081	NA	-0.99	-13.91	-0.48	1.31e-38	Diabetic kidney disease;
BRCA	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg20701182	chr2:24300061	SF3B14	0.67	9.8	0.36	3.18e-21	Lymphocyte counts;
BRCA	trans	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg25214090	chr10:38739885	LOC399744	0.56	12.86	0.45	7.72e-34	Corneal astigmatism;
BRCA	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg05347473	chr6:146136440	FBXO30	-0.43	-8.45	-0.32	1.92e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-13.34	-0.47	5.56e-36	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.54	-13.34	-0.47	5.37e-36	Urate levels in overweight individuals;
BRCA	cis	rs6543140	0.964	rs6734203	chr2:103080066	G/C	cg04239558	chr2:103089729	SLC9A4	0.35	9.74	0.36	5.21e-21	Blood protein levels;
BRCA	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg13770153	chr20:60521292	NA	-0.44	-9.76	-0.36	4.63e-21	Body mass index;
BRCA	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg07148914	chr20:33460835	GGT7	0.37	8.31	0.31	5.55e-16	Height;
BRCA	cis	rs1904096	0.506	rs17021463	chr4:95224812	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-9.92	-0.37	1.1e-21	Type 2 diabetes;
BRCA	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg07741184	chr6:167504864	NA	0.33	9.87	0.36	1.8e-21	Primary biliary cholangitis;
BRCA	cis	rs1371614	0.632	rs6718978	chr2:27161591	G/A	cg12368169	chr2:27073192	DPYSL5	0.27	7.92	0.3	1.09e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs4363385	0.669	rs4845519	chr1:153003916	G/T	cg25856811	chr1:152973957	SPRR3	0.3	8.23	0.31	1.05e-15	Inflammatory skin disease;
BRCA	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg26116260	chr4:7069785	GRPEL1	0.95	27.93	0.74	8.26e-113	Monocyte percentage of white cells;
BRCA	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg13902645	chr11:5959945	NA	-0.54	-11.02	-0.4	5.67e-26	DNA methylation (variation);
BRCA	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.07	0.34	1.47e-18	Tonsillectomy;
BRCA	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.0	-0.3	5.7e-15	Menopause (age at onset);
BRCA	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg05234568	chr11:5960015	NA	-0.41	-7.92	-0.3	1.07e-14	DNA methylation (variation);
BRCA	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg02891314	chr5:179741120	GFPT2	0.66	13.57	0.47	4.72e-37	Height;
BRCA	cis	rs7523273	0.606	rs2724382	chr1:207928635	G/C	cg22525895	chr1:207977042	MIR29B2	0.48	12.17	0.43	8.51e-31	Schizophrenia;
BRCA	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.37	8.8	0.33	1.22e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg24450063	chr1:156163899	SLC25A44	0.94	18.49	0.59	1.82e-61	Testicular germ cell tumor;
BRCA	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg14847009	chr1:175162515	KIAA0040	-0.25	-9.1	-0.34	1.12e-18	Alcohol dependence;
BRCA	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg19622623	chr12:86230825	RASSF9	-0.34	-9.47	-0.35	5.17e-20	Major depressive disorder;
BRCA	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg14963724	chr18:72166303	CNDP2	-0.34	-9.44	-0.35	6.73e-20	Refractive error;
BRCA	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg16590910	chr6:42928470	GNMT	0.41	9.2	0.34	4.85e-19	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs11955398	0.529	rs62373032	chr5:59956159	G/C	cg02684056	chr5:59996105	DEPDC1B	0.39	9.35	0.35	1.47e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg06159980	chr1:16340746	HSPB7	-0.38	-8.84	-0.33	9.14e-18	Dilated cardiomyopathy;
BRCA	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.39	-8.81	-0.33	1.15e-17	Colorectal cancer;
BRCA	cis	rs6450176	0.904	rs6889847	chr5:53303452	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-15.66	-0.53	5.04e-47	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	11.22	0.41	8.98e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10242455	0.702	rs57832867	chr7:98966396	C/T	cg18809830	chr7:99032528	PTCD1	-0.65	-8.65	-0.32	4.13e-17	Blood metabolite levels;
BRCA	cis	rs12618769	0.597	rs3754881	chr2:99132093	G/A	cg10123293	chr2:99228465	UNC50	0.41	8.24	0.31	9.45e-16	Bipolar disorder;
BRCA	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg10223061	chr2:219282414	VIL1	-0.27	-7.83	-0.3	2.02e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs672059	1.000	rs479994	chr1:183161729	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.38	8.71	0.33	2.52e-17	Hypertriglyceridemia;
BRCA	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	13.89	0.48	1.54e-38	Motion sickness;
BRCA	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26818010	chr10:134567672	INPP5A	-0.53	-12.19	-0.43	6.88e-31	Migraine;
BRCA	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg09654669	chr8:57350985	NA	-0.39	-8.54	-0.32	9.82e-17	Obesity-related traits;
BRCA	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg20283391	chr11:68216788	NA	-0.46	-9.22	-0.34	4.1e-19	Total body bone mineral density;
BRCA	trans	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.82	-26.73	-0.73	3.26e-106	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs929596	0.556	rs4477910	chr2:234643737	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-9.88	-0.36	1.66e-21	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.4	9.81	0.36	2.84e-21	Eosinophil percentage of white cells;
BRCA	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.03	0.3	4.61e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg06046430	chr4:77819534	ANKRD56	0.61	13.63	0.47	2.57e-37	Emphysema distribution in smoking;
BRCA	cis	rs6429082	0.905	rs12405889	chr1:235597252	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.35	-8.66	-0.32	3.9e-17	Adiposity;
BRCA	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg17063962	chr7:91808500	NA	0.5	11.45	0.41	9.91e-28	Breast cancer;
BRCA	trans	rs6600671	0.899	rs11249432	chr1:121283476	T/A	cg17023122	chr1:144479586	NA	0.34	7.91	0.3	1.11e-14	Hip geometry;
BRCA	cis	rs701145	0.585	rs1727923	chr3:153786303	C/T	cg17054900	chr3:154042577	DHX36	-0.54	-9.14	-0.34	7.93e-19	Coronary artery disease;
BRCA	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg03146154	chr1:46216737	IPP	0.46	10.17	0.37	1.24e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg13736514	chr6:26305472	NA	-0.35	-11.99	-0.43	4.93e-30	Educational attainment;
BRCA	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg17420585	chr12:42539391	GXYLT1	-0.39	-8.04	-0.3	4.39e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs12472274	0.618	rs12477307	chr2:239110514	G/T	cg17459225	chr2:239074497	NA	0.47	9.76	0.36	4.42e-21	Phospholipid levels (plasma);
BRCA	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg20503657	chr10:835505	NA	0.95	14.77	0.5	1.14e-42	Eosinophil percentage of granulocytes;
BRCA	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg02896835	chr1:92012615	NA	-0.64	-16.63	-0.55	6.99e-52	Breast cancer;
BRCA	cis	rs16958440	0.867	rs77149690	chr18:44697143	T/C	cg17192377	chr18:44677553	HDHD2	0.99	13.47	0.47	1.43e-36	Sitting height ratio;
BRCA	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg15595755	chr5:1867978	NA	0.37	8.87	0.33	7.31e-18	Cardiovascular disease risk factors;
BRCA	cis	rs8017423	0.934	rs2401874	chr14:90682467	C/T	cg04374321	chr14:90722782	PSMC1	0.73	19.29	0.61	1.04e-65	Mortality in heart failure;
BRCA	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-9.06	-0.34	1.53e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4930561	0.714	rs7950451	chr11:67962406	C/A	cg16338278	chr11:67432957	ALDH3B2	0.44	8.97	0.33	3.37e-18	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.38	8.19	0.31	1.46e-15	Cognitive ability;
BRCA	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg21064579	chr19:49206444	FUT2	0.32	8.15	0.31	1.87e-15	Dietary macronutrient intake;
BRCA	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg21775007	chr8:11205619	TDH	-0.4	-8.17	-0.31	1.63e-15	Neuroticism;
BRCA	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg11502198	chr6:26597334	ABT1	0.49	9.73	0.36	5.8e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg15737290	chr11:93063684	CCDC67	0.6	13.95	0.48	8e-39	Pulmonary function decline;
BRCA	cis	rs11696845	0.666	rs6073533	chr20:43361082	G/T	cg25301532	chr20:43378953	KCNK15	-0.38	-9.21	-0.34	4.48e-19	Obesity-related traits;
BRCA	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg05340658	chr4:99064831	C4orf37	-0.45	-10.5	-0.38	6.58e-24	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.78e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs36051895	0.603	rs10123980	chr9:5130363	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-8.87	-0.33	7.38e-18	Pediatric autoimmune diseases;
BRCA	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg22467129	chr15:76604101	ETFA	-0.39	-8.67	-0.32	3.66e-17	Blood metabolite levels;
BRCA	cis	rs965469	0.779	rs6051717	chr20:3270242	C/T	cg25506879	chr20:3388711	C20orf194	-0.44	-8.81	-0.33	1.17e-17	IFN-related cytopenia;
BRCA	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11764359	chr7:65958608	NA	0.74	16.46	0.55	4.94e-51	Aortic root size;
BRCA	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg06191203	chr2:152266755	RIF1	-0.36	-10.77	-0.39	5.98e-25	Lung cancer;
BRCA	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.52	-0.32	1.18e-16	Monocyte percentage of white cells;
BRCA	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg22713356	chr15:30763199	NA	1.28	24.19	0.69	2.78e-92	Uric acid levels;
BRCA	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg03433033	chr1:76189801	ACADM	-0.44	-8.89	-0.33	6.21e-18	Daytime sleep phenotypes;
BRCA	cis	rs9443189	0.570	rs6903124	chr6:76290079	A/C	cg01950844	chr6:76311363	SENP6	0.84	13.79	0.48	4.58e-38	Prostate cancer;
BRCA	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.35	-0.35	1.45e-19	Bipolar disorder;
BRCA	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg08888203	chr3:10149979	C3orf24	0.65	11.89	0.43	1.4e-29	Alzheimer's disease;
BRCA	cis	rs312274	0.632	rs10879339	chr12:41295119	T/C	cg17827154	chr12:41323612	CNTN1	-0.44	-10.92	-0.4	1.46e-25	Metabolite levels  (X-11787);
BRCA	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg19622623	chr12:86230825	RASSF9	-0.33	-9.32	-0.35	1.81e-19	Major depressive disorder;
BRCA	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg25817165	chr18:72167213	CNDP2	-0.72	-12.7	-0.45	4.06e-33	Refractive error;
BRCA	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg05313129	chr8:58192883	C8orf71	-0.48	-9.84	-0.36	2.23e-21	Developmental language disorder (linguistic errors);
BRCA	trans	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04565464	chr8:145669602	NFKBIL2	0.37	8.86	0.33	8.17e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg26384229	chr12:38710491	ALG10B	-0.63	-16.43	-0.55	6.93e-51	Heart rate;
BRCA	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg26597838	chr10:835615	NA	1.01	18.07	0.58	2.9e-59	Eosinophil percentage of granulocytes;
BRCA	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23583168	chr7:148888333	NA	-0.78	-18.9	-0.6	1.28e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg09877947	chr5:131593287	PDLIM4	0.41	10.35	0.38	2.52e-23	Breast cancer;
BRCA	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg26031613	chr14:104095156	KLC1	-0.45	-8.86	-0.33	7.62e-18	Schizophrenia;
BRCA	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.39	7.84	0.3	1.87e-14	Menarche (age at onset);
BRCA	cis	rs7131987	0.903	rs11050161	chr12:29420049	A/G	cg09582351	chr12:29534625	ERGIC2	-0.48	-11.73	-0.42	6.3e-29	QT interval;
BRCA	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-10.39	-0.38	1.87e-23	Resting heart rate;
BRCA	cis	rs1506636	0.927	rs6959270	chr7:123310628	G/A	cg03229431	chr7:123269106	ASB15	-0.63	-14.15	-0.49	9.48e-40	Plateletcrit;Platelet count;
BRCA	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-10.36	-0.38	2.4e-23	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.45	-9.21	-0.34	4.6e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg22431228	chr1:16359049	CLCNKA	-0.43	-9.71	-0.36	6.72e-21	Dilated cardiomyopathy;
BRCA	cis	rs7264396	0.887	rs224419	chr20:34143092	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-10.02	-0.37	4.91e-22	Total cholesterol levels;
BRCA	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg22764044	chr5:178986830	RUFY1	0.39	10.17	0.37	1.24e-22	Lung cancer;
BRCA	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.49e-52	Hypertriglyceridemia;
BRCA	cis	rs7246657	0.598	rs10405372	chr19:37668775	A/C	cg23950597	chr19:37808831	NA	-0.66	-10.28	-0.38	4.82e-23	Coronary artery calcification;
BRCA	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.68	-16.13	-0.54	2.43e-49	Mean platelet volume;
BRCA	cis	rs586533	0.846	rs636073	chr11:99495789	C/T	cg22878054	chr11:99397252	CNTN5	0.31	7.81	0.3	2.39e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg22920501	chr2:26401640	FAM59B	0.9	16.28	0.54	3.94e-50	Gut microbiome composition (summer);
BRCA	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.48	-8.21	-0.31	1.19e-15	Schizophrenia;
BRCA	cis	rs12541635	0.677	rs1496180	chr8:106973877	T/G	cg10147462	chr8:107024639	NA	0.39	10.49	0.38	7.38e-24	Age of smoking initiation;
BRCA	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg25482853	chr8:67687455	SGK3	1.02	16.08	0.54	4.27e-49	Lung disease severity in cystic fibrosis;
BRCA	trans	rs4650994	1.000	rs17361251	chr1:178520577	C/A	cg05059571	chr16:84539110	KIAA1609	-0.42	-9.64	-0.36	1.22e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-10.86	-0.39	2.54e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg13010199	chr12:38710504	ALG10B	0.39	8.89	0.33	6.14e-18	Morning vs. evening chronotype;
BRCA	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg15242686	chr22:24348715	GSTTP1	0.33	8.19	0.31	1.46e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	19.46	0.61	1.35e-66	Smoking behavior;
BRCA	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg04691961	chr3:161091175	C3orf57	-0.59	-14.35	-0.49	1.14e-40	Morning vs. evening chronotype;
BRCA	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg26597838	chr10:835615	NA	0.85	15.48	0.52	3.68e-46	Eosinophil percentage of granulocytes;
BRCA	trans	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg26043149	chr18:55253948	FECH	-0.39	-8.5	-0.32	1.29e-16	Bone mineral density;
BRCA	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-12.5	-0.44	3.27e-32	Response to antipsychotic treatment;
BRCA	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg16482183	chr6:26056742	HIST1H1C	0.5	10.51	0.38	6.27e-24	Height;
BRCA	cis	rs9815354	0.767	rs6805140	chr3:41995791	A/G	cg03022575	chr3:42003672	ULK4	0.62	9.06	0.34	1.62e-18	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18876405	chr7:65276391	NA	-0.51	-11.62	-0.42	1.94e-28	Aortic root size;
BRCA	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg04450456	chr4:17643702	FAM184B	0.38	10.42	0.38	1.35e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.89	-0.3	1.29e-14	Colorectal cancer;
BRCA	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.07	-0.3	3.56e-15	Aortic root size;
BRCA	cis	rs10740039	0.804	rs894384	chr10:62452293	C/G	cg02922035	chr10:62493342	NA	0.42	8.01	0.3	5.4e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8114671	0.967	rs2069945	chr20:33761837	C/G	cg24642439	chr20:33292090	TP53INP2	0.42	8.64	0.32	4.52e-17	Height;
BRCA	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11764359	chr7:65958608	NA	-0.75	-16.59	-0.55	1.12e-51	Aortic root size;
BRCA	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.88	-0.56	3.92e-53	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs672059	1.000	rs674343	chr1:183162052	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.38	8.71	0.33	2.56e-17	Hypertriglyceridemia;
BRCA	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg10523679	chr1:76189770	ACADM	0.71	12.78	0.45	1.85e-33	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg21609526	chr1:3105151	PRDM16	-0.38	-8.93	-0.33	4.57e-18	Migraine;
BRCA	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	16.69	0.55	3.7e-52	Alzheimer's disease;
BRCA	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	18.6	0.59	4.85e-62	Platelet count;
BRCA	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg13010199	chr12:38710504	ALG10B	0.45	9.42	0.35	8.38e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-20.85	-0.64	4.98e-74	Gut microbiome composition (summer);
BRCA	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18404041	chr3:52824283	ITIH1	-0.41	-12.03	-0.43	3.44e-30	Bipolar disorder;
BRCA	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.42	9.04	0.34	1.89e-18	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.32	0.49	1.48e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.86	0.45	7.85e-34	Bipolar disorder;
BRCA	cis	rs9815354	0.812	rs73071208	chr3:41978738	A/T	cg03022575	chr3:42003672	ULK4	0.7	9.69	0.36	8.3e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs11190604	0.767	rs10883483	chr10:102174244	T/C	cg07080220	chr10:102295463	HIF1AN	0.49	10.12	0.37	2.03e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7246657	0.722	rs6508736	chr19:38061757	A/G	cg23950597	chr19:37808831	NA	-0.5	-8.62	-0.32	5.36e-17	Coronary artery calcification;
BRCA	cis	rs7561273	0.609	rs2080727	chr2:24350907	A/G	cg04809136	chr2:24300158	SF3B14	-0.4	-8.84	-0.33	9.44e-18	Quantitative traits;
BRCA	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg18132916	chr6:79620363	NA	-0.47	-10.74	-0.39	7.41e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg22307297	chr20:60903441	LAMA5	0.34	8.58	0.32	7.39e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs4988958	0.565	rs1420100	chr2:103037002	C/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.35	0.31	4.32e-16	Asthma (childhood onset);
BRCA	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.54	8.37	0.31	3.68e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.69	14.31	0.49	1.72e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.43	-8.27	-0.31	7.67e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg26818010	chr10:134567672	INPP5A	-0.36	-8.62	-0.32	5.07e-17	Migraine;
BRCA	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg05279229	chr7:1896384	MAD1L1	-0.4	-7.95	-0.3	8.37e-15	Bipolar disorder and schizophrenia;
BRCA	trans	rs526821	0.595	rs551665	chr11:55343268	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-8.21	-0.31	1.19e-15	Pediatric bone mineral density (spine);
BRCA	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg04025307	chr7:1156635	C7orf50	0.37	8.45	0.32	2.02e-16	Longevity;Endometriosis;
BRCA	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24531977	chr5:56204891	C5orf35	-0.86	-17.89	-0.58	2.57e-58	Initial pursuit acceleration;
BRCA	cis	rs7020830	0.867	rs13301916	chr9:37361455	A/C	cg14294708	chr9:37120828	ZCCHC7	1.07	32.46	0.79	2.77e-137	Schizophrenia;
BRCA	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg25208724	chr1:156163844	SLC25A44	0.87	17.55	0.57	1.46e-56	Testicular germ cell tumor;
BRCA	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-12.5	-0.44	2.98e-32	Bipolar disorder;
BRCA	cis	rs4664304	0.620	rs2136977	chr2:160722850	C/T	cg01092293	chr2:160761427	LY75	0.35	8.45	0.32	1.91e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-9.65	-0.36	1.14e-20	Axial length;
BRCA	cis	rs1018836	0.923	rs2105967	chr8:91587522	A/G	cg16814680	chr8:91681699	NA	-0.59	-12.52	-0.44	2.63e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7301826	0.651	rs6486601	chr12:131301237	A/T	cg11011512	chr12:131303247	STX2	-0.44	-11.11	-0.4	2.5e-26	Plasma plasminogen activator levels;
BRCA	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11764359	chr7:65958608	NA	0.79	19.25	0.61	1.83e-65	Aortic root size;
BRCA	cis	rs16910800	0.689	rs56101126	chr11:23188861	T/A	cg20040320	chr11:23191996	NA	-0.59	-10.23	-0.38	7.61e-23	Cancer;
BRCA	trans	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg06521331	chr12:34319734	NA	-0.49	-9.74	-0.36	5.28e-21	Bladder cancer;
BRCA	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.81	-14.32	-0.49	1.58e-40	Gut microbiome composition (summer);
BRCA	cis	rs6977940	0.512	rs11765726	chr7:2850878	A/G	cg19731401	chr7:2775893	GNA12	0.48	7.96	0.3	7.68e-15	White matter integrity;
BRCA	cis	rs68170813	0.559	rs77829121	chr7:106968470	A/G	cg02696742	chr7:106810147	HBP1	-0.54	-8.87	-0.33	7.01e-18	Coronary artery disease;
BRCA	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg19077165	chr18:44547161	KATNAL2	-0.58	-12.99	-0.46	2.16e-34	Personality dimensions;
BRCA	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.53	0.32	1.09e-16	Rheumatoid arthritis;
BRCA	cis	rs698833	0.501	rs12473699	chr2:44507673	G/A	cg04920474	chr2:44395004	PPM1B	0.39	9.16	0.34	7.2e-19	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	10.78	0.39	5.33e-25	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs4787491	0.704	rs35605010	chr16:30033428	A/G	cg06326092	chr16:30034487	C16orf92	0.37	9.48	0.35	4.76e-20	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg08000102	chr2:233561755	GIGYF2	0.62	13.46	0.47	1.49e-36	Coronary artery disease;
BRCA	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg03342759	chr3:160939853	NMD3	-0.67	-13.16	-0.46	3.56e-35	Parkinson's disease;
BRCA	cis	rs1691799	0.899	rs1168299	chr12:66736074	C/G	cg16791601	chr12:66731901	HELB	-0.69	-19.26	-0.61	1.56e-65	White blood cell count (basophil);
BRCA	cis	rs4363385	0.747	rs11205149	chr1:152958840	C/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.69	-0.32	3.15e-17	Inflammatory skin disease;
BRCA	trans	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	10.01	0.37	5.06e-22	Mean corpuscular volume;
BRCA	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg24558204	chr6:135376177	HBS1L	0.6	16.25	0.54	5.98e-50	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs6066835	1.000	rs6063314	chr20:47353106	T/C	cg18078177	chr20:47281410	PREX1	0.69	8.6	0.32	6.2e-17	Multiple myeloma;
BRCA	cis	rs11112613	0.762	rs17037312	chr12:105950085	C/T	cg03607813	chr12:105948248	NA	0.6	11.16	0.4	1.57e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	trans	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	37.73	0.83	9.26e-165	Exhaled nitric oxide output;
BRCA	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg18132916	chr6:79620363	NA	-0.38	-7.82	-0.3	2.2e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-17.23	-0.56	6.2e-55	Colorectal cancer;
BRCA	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	17.01	0.56	8.71e-54	Hypertriglyceridemia;
BRCA	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg26446133	chr18:72167187	CNDP2	-0.75	-14.47	-0.5	2.9e-41	Refractive error;
BRCA	cis	rs829883	0.659	rs11109524	chr12:98939172	G/A	cg25150519	chr12:98850993	NA	-0.5	-9.04	-0.34	1.91e-18	Colorectal adenoma (advanced);
BRCA	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	12.89	0.45	5.95e-34	Ileal carcinoids;
BRCA	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg16606324	chr3:10149918	C3orf24	0.45	8.07	0.3	3.62e-15	Alzheimer's disease;
BRCA	cis	rs6546550	0.901	rs4144081	chr2:70155482	G/A	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.43	-0.41	1.2e-27	Prevalent atrial fibrillation;
BRCA	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg21782813	chr7:2030301	MAD1L1	0.4	10.63	0.39	2.08e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg12373951	chr3:133503437	NA	-0.43	-10.37	-0.38	2.12e-23	Iron status biomarkers;
BRCA	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.36	-7.86	-0.3	1.67e-14	Tonsillectomy;
BRCA	cis	rs9341808	0.727	rs9361599	chr6:81025242	C/G	cg08355045	chr6:80787529	NA	0.35	9.23	0.34	3.85e-19	Sitting height ratio;
BRCA	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.27	-0.41	5.59e-27	Schizophrenia;
BRCA	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg09035930	chr12:129282057	SLC15A4	0.49	13.82	0.48	3.51e-38	Systemic lupus erythematosus;
BRCA	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.58	11.75	0.42	5.34e-29	Body mass index (adult);
BRCA	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.48	-9.34	-0.35	1.55e-19	Chronic sinus infection;
BRCA	cis	rs4363385	0.720	rs1970328	chr1:152975829	A/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.82	-0.36	2.63e-21	Inflammatory skin disease;
BRCA	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	11.49	0.41	6.87e-28	Monocyte percentage of white cells;
BRCA	trans	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg26384229	chr12:38710491	ALG10B	0.44	10.57	0.39	3.4e-24	Morning vs. evening chronotype;
BRCA	cis	rs7809950	0.678	rs62482499	chr7:106975059	C/G	cg23024343	chr7:107201750	COG5	-0.43	-9.42	-0.35	8.36e-20	Coronary artery disease;
BRCA	cis	rs67981189	0.865	rs2526876	chr14:71378188	T/C	cg15816911	chr14:71606274	NA	-0.37	-8.23	-0.31	1.09e-15	Schizophrenia;
BRCA	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg06784218	chr1:46089804	CCDC17	0.45	10.79	0.39	4.84e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs8054556	0.647	rs4788211	chr16:30015565	C/T	cg06326092	chr16:30034487	C16orf92	0.35	8.82	0.33	1.06e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg08917208	chr2:24149416	ATAD2B	0.93	13.87	0.48	1.91e-38	Lymphocyte counts;
BRCA	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg05791153	chr7:19748676	TWISTNB	-0.57	-10.34	-0.38	2.73e-23	Thyroid stimulating hormone;
BRCA	cis	rs1568889	0.838	rs7127069	chr11:28325412	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	19.84	0.62	1.36e-68	Bipolar disorder;
BRCA	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg13319975	chr6:146136371	FBXO30	0.41	9.22	0.34	4.41e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11764359	chr7:65958608	NA	-0.62	-13.63	-0.47	2.45e-37	Calcium levels;
BRCA	cis	rs6032067	0.598	rs2741500	chr20:43944958	G/T	cg20256260	chr20:43936981	MATN4;RBPJL	0.34	8.08	0.3	3.31e-15	Blood protein levels;
BRCA	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg19913688	chr11:428466	ANO9	-0.65	-9.69	-0.36	7.98e-21	Body mass index;
BRCA	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg09307838	chr4:120376055	NA	0.64	14.0	0.48	5.12e-39	Corneal astigmatism;
BRCA	cis	rs4908768	0.501	rs1463050	chr1:8597042	G/A	cg20416874	chr1:8611966	RERE	-0.29	-8.35	-0.31	4.23e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg26248373	chr2:1572462	NA	-0.45	-9.03	-0.34	2.01e-18	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02018176	chr4:1364513	KIAA1530	0.39	8.13	0.31	2.22e-15	Longevity;
BRCA	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg24060327	chr5:131705240	SLC22A5	0.61	11.35	0.41	2.4200000000000002e-27	Breast cancer;
BRCA	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg03342759	chr3:160939853	NMD3	-0.81	-18.13	-0.58	1.44e-59	Parkinson's disease;
BRCA	cis	rs7737355	0.947	rs2191001	chr5:131096677	C/G	cg06307176	chr5:131281290	NA	0.53	10.2	0.37	9.89e-23	Life satisfaction;
BRCA	cis	rs654950	0.806	rs10749832	chr1:42041806	C/T	cg06885757	chr1:42089581	HIVEP3	0.3	10.25	0.38	6.54e-23	Airway imaging phenotypes;
BRCA	cis	rs6005807	0.719	rs9625523	chr22:29045745	T/C	cg12565055	chr22:29076175	TTC28	0.49	9.28	0.34	2.68e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg09184832	chr6:79620586	NA	-0.53	-11.56	-0.42	3.34e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs28830936	1.000	rs11629485	chr15:41904569	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.33	-9.13	-0.34	9.23e-19	Diastolic blood pressure;
BRCA	cis	rs1829883	1.000	rs1829883	chr5:98781103	C/T	cg08333243	chr5:99726346	NA	-0.37	-8.96	-0.33	3.5e-18	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg09537434	chr19:41945824	ATP5SL	-0.62	-12.85	-0.45	9.12e-34	Migraine;Coronary artery disease;
BRCA	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.58	-12.75	-0.45	2.47e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs427394	0.802	rs274718	chr5:6720988	G/T	cg10857441	chr5:6722123	POLS	-0.33	-11.06	-0.4	3.92e-26	Menopause (age at onset);
BRCA	cis	rs1865721	0.771	rs724764	chr18:73139742	C/T	cg26385618	chr18:73139727	C18orf62	-0.43	-10.63	-0.39	2.03e-24	Intelligence;
BRCA	cis	rs2479724	0.901	rs2185798	chr6:41773576	G/C	cg17623882	chr6:41773611	USP49	0.38	10.31	0.38	3.59e-23	Menarche (age at onset);
BRCA	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg22705602	chr4:152727874	NA	-0.32	-8.0	-0.3	6.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6733011	0.578	rs10181972	chr2:99497284	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.36	-8.43	-0.32	2.29e-16	Bipolar disorder;
BRCA	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg14993813	chr1:46806288	NSUN4	-0.47	-9.07	-0.34	1.48e-18	Menopause (age at onset);
BRCA	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg27129171	chr3:47204927	SETD2	0.71	16.89	0.56	3.29e-53	Colorectal cancer;
BRCA	trans	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.61	-12.77	-0.45	2.03e-33	Lymphocyte counts;
BRCA	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg20129853	chr10:51489980	NA	0.3	8.26	0.31	8.09e-16	Prostate-specific antigen levels;
BRCA	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg05552183	chr6:42928497	GNMT	0.7	15.76	0.53	1.61e-47	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg26043149	chr18:55253948	FECH	0.4	8.85	0.33	8.23e-18	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg01119278	chr6:110721349	DDO	-0.43	-10.54	-0.38	4.72e-24	Platelet distribution width;
BRCA	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.84	0.36	2.19e-21	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg27170947	chr2:26402098	FAM59B	-0.72	-13.08	-0.46	8.28e-35	Gut microbiome composition (summer);
BRCA	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg12935359	chr14:103987150	CKB	0.58	14.23	0.49	4.1e-40	Body mass index;
BRCA	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.73	15.93	0.53	2.46e-48	Lymphocyte counts;
BRCA	cis	rs9549260	0.709	rs4943795	chr13:41173433	C/T	cg21288729	chr13:41239152	FOXO1	-0.6	-12.35	-0.44	1.42e-31	Red blood cell count;
BRCA	trans	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg13010199	chr12:38710504	ALG10B	0.42	7.92	0.3	1.05e-14	Resting heart rate;
BRCA	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg15017067	chr4:17643749	FAM184B	-0.28	-8.59	-0.32	6.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9811920	0.660	rs7619512	chr3:99729132	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-10.45	-0.38	1.08e-23	Axial length;
BRCA	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg15556689	chr8:8085844	FLJ10661	0.4	9.3	0.35	2.2e-19	Retinal vascular caliber;
BRCA	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg20219911	chr3:52813652	ITIH1	0.29	8.05	0.3	3.93e-15	Bipolar disorder;
BRCA	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.89	-0.33	6.41e-18	Height;
BRCA	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-11.61	-0.42	2.01e-28	Pulmonary function;
BRCA	cis	rs4965272	1.000	rs4965273	chr15:100584818	C/T	cg27344315	chr15:100560801	ADAMTS17	0.38	8.51	0.32	1.25e-16	Gastroesophageal reflux disease;
BRCA	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg03388025	chr16:89894329	SPIRE2	0.29	9.12	0.34	9.29e-19	Vitiligo;
BRCA	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg05279229	chr7:1896384	MAD1L1	-0.4	-7.87	-0.3	1.47e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg26408565	chr15:76604113	ETFA	-0.48	-10.08	-0.37	2.78e-22	Blood metabolite levels;
BRCA	cis	rs2274273	1.000	rs61508494	chr14:55587297	T/C	cg04306507	chr14:55594613	LGALS3	0.32	9.0	0.34	2.52e-18	Protein biomarker;
BRCA	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg17971929	chr21:40555470	PSMG1	0.6	13.74	0.48	7.58e-38	Cognitive function;
BRCA	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg17644776	chr2:200775616	C2orf69	-0.42	-8.6	-0.32	6.19e-17	Osteoporosis;
BRCA	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03264133	chr6:25882463	NA	0.5	11.23	0.41	7.65e-27	Blood metabolite levels;
BRCA	cis	rs36051895	0.589	rs6476947	chr9:5204279	A/G	cg02405213	chr9:5042618	JAK2	-0.44	-8.26	-0.31	8.59e-16	Pediatric autoimmune diseases;
BRCA	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg18196295	chr10:418757	DIP2C	0.45	10.13	0.37	1.77e-22	Psychosis in Alzheimer's disease;
BRCA	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg21747090	chr2:27597821	SNX17	-0.43	-9.43	-0.35	7.24e-20	Total body bone mineral density;
BRCA	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg26597838	chr10:835615	NA	0.97	14.93	0.51	1.76e-43	Eosinophil percentage of granulocytes;
BRCA	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg17063962	chr7:91808500	NA	-0.55	-12.71	-0.45	3.57e-33	Breast cancer;
BRCA	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg09307838	chr4:120376055	NA	0.69	14.05	0.49	2.92e-39	Corneal astigmatism;
BRCA	cis	rs9400271	0.632	rs34981677	chr6:109590920	T/C	cg21918786	chr6:109611834	NA	-0.32	-8.05	-0.3	4.14e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg06108461	chr20:60628389	TAF4	-0.7	-14.5	-0.5	2.21e-41	Body mass index;
BRCA	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	17.73	0.57	1.64e-57	Platelet count;
BRCA	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg25319279	chr11:5960081	NA	-0.4	-7.92	-0.3	1.03e-14	DNA methylation (variation);
BRCA	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg03354898	chr7:1950403	MAD1L1	-0.45	-9.41	-0.35	8.94e-20	Bipolar disorder and schizophrenia;
BRCA	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.87	-0.4	2.22e-25	Retinal vascular caliber;
BRCA	cis	rs17001868	0.568	rs12484697	chr22:40736472	A/G	cg07138101	chr22:40742427	ADSL	-0.57	-10.59	-0.39	3.02e-24	Mammographic density (dense area);
BRCA	cis	rs9487051	0.738	rs449850	chr6:109525045	A/G	cg21918786	chr6:109611834	NA	-0.34	-9.11	-0.34	1.09e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs2769264	1.000	rs6684085	chr1:151357333	C/T	cg18801370	chr1:151430492	POGZ	-0.52	-12.26	-0.44	3.45e-31	Blood trace element (Cu levels);
BRCA	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	14.31	0.49	1.72e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14829155	chr15:31115871	NA	-0.43	-10.14	-0.37	1.74e-22	Huntington's disease progression;
BRCA	cis	rs17092148	0.597	rs57495888	chr20:33092724	T/C	cg16810054	chr20:33298113	TP53INP2	0.43	9.41	0.35	8.59e-20	Neuroticism;
BRCA	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	4.98e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3820928	0.874	rs10183633	chr2:227887828	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.42	-0.32	2.44e-16	Pulmonary function;
BRCA	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg21427119	chr20:30132790	HM13	-0.41	-8.64	-0.32	4.67e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.43	-0.44	6.18e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg10978503	chr1:24200527	CNR2	0.47	12.59	0.45	1.23e-32	Immature fraction of reticulocytes;
BRCA	cis	rs7178424	0.742	rs12906423	chr15:62203884	T/A	cg00456672	chr15:62358751	C2CD4A	-0.38	-9.29	-0.34	2.43e-19	Height;
BRCA	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg00383909	chr3:49044727	WDR6	0.74	12.69	0.45	4.57e-33	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg26446133	chr18:72167187	CNDP2	-0.75	-14.8	-0.51	7.75e-43	Refractive error;
BRCA	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg09184832	chr6:79620586	NA	-0.52	-11.63	-0.42	1.64e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs1595825	0.891	rs73054827	chr2:198649905	G/A	cg19156104	chr2:198669113	PLCL1	-0.42	-8.01	-0.3	5.33e-15	Ulcerative colitis;
BRCA	cis	rs7945718	0.967	rs10831904	chr11:12760937	A/G	cg25843174	chr11:12811716	TEAD1	0.23	8.8	0.33	1.25e-17	Educational attainment (years of education);
BRCA	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg23711669	chr6:146136114	FBXO30	0.7	16.7	0.55	3.23e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11718455	0.767	rs6782500	chr3:43990260	A/G	cg08738300	chr3:44038990	NA	-0.47	-8.8	-0.33	1.22e-17	Coronary artery disease;
BRCA	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg24006582	chr15:45444508	DUOX1	0.54	10.51	0.38	6.04e-24	Uric acid levels;
BRCA	cis	rs12617721	0.756	rs3754889	chr2:99088633	T/G	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder with mood-incongruent psychosis;
BRCA	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg14530993	chr4:882597	GAK	0.59	9.54	0.35	2.98e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26314531	chr2:26401878	FAM59B	-0.66	-11.25	-0.41	6.63e-27	Gut microbiome composition (summer);
BRCA	cis	rs7945705	0.776	rs11042069	chr11:8817315	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.5	10.39	0.38	1.84e-23	Hemoglobin concentration;
BRCA	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg20701182	chr2:24300061	SF3B14	0.65	9.37	0.35	1.2e-19	Lymphocyte counts;
BRCA	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10150615	chr22:24372951	LOC391322	0.47	10.46	0.38	9.73e-24	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs733592	0.965	rs1978161	chr12:48467721	A/G	cg24011408	chr12:48396354	COL2A1	-0.46	-9.79	-0.36	3.39e-21	Plateletcrit;
BRCA	cis	rs11249608	0.789	rs903989	chr5:178434434	C/T	cg21905437	chr5:178450457	ZNF879	0.48	9.75	0.36	4.85e-21	Pubertal anthropometrics;
BRCA	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.22	-19.87	-0.62	8.44e-69	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.45	0.38	1.08e-23	Motion sickness;
BRCA	trans	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg06521331	chr12:34319734	NA	-0.45	-8.49	-0.32	1.5e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.01	0.34	2.27e-18	Motion sickness;
BRCA	trans	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg26043149	chr18:55253948	FECH	0.43	9.22	0.34	4.29e-19	Bone mineral density;
BRCA	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.5	0.44	3.09e-32	Electroencephalogram traits;
BRCA	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg03146154	chr1:46216737	IPP	-0.44	-9.85	-0.36	2.04e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.43	10.12	0.37	2.05e-22	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg26384229	chr12:38710491	ALG10B	0.51	12.79	0.45	1.61e-33	Morning vs. evening chronotype;
BRCA	cis	rs1691799	0.867	rs1168347	chr12:66757303	T/C	cg16791601	chr12:66731901	HELB	-0.6	-16.06	-0.54	4.96e-49	White blood cell count (basophil);
BRCA	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7131987	0.903	rs10843373	chr12:29420608	A/T	cg09582351	chr12:29534625	ERGIC2	-0.39	-9.35	-0.35	1.48e-19	QT interval;
BRCA	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg12386194	chr3:101231763	SENP7	-0.6	-12.38	-0.44	1.09e-31	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.69	0.33	3.02e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.08	0.4	3.31e-26	Bipolar disorder;
BRCA	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg20307385	chr11:47447363	PSMC3	-0.4	-8.92	-0.33	4.96e-18	Subjective well-being;
BRCA	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.33	9.11	0.34	1.01e-18	Response to antipsychotic treatment;
BRCA	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg00071950	chr4:10020882	SLC2A9	0.43	10.01	0.37	5.27e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs17401966	0.867	rs61775872	chr1:10279308	T/C	cg03954927	chr1:10346856	KIF1B	0.44	13.75	0.48	7.09e-38	Hepatocellular carcinoma;
BRCA	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg26384229	chr12:38710491	ALG10B	0.43	10.32	0.38	3.28e-23	Heart rate;
BRCA	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg18225595	chr11:63971243	STIP1	0.39	9.68	0.36	8.78e-21	Platelet count;
BRCA	cis	rs2637266	0.935	rs7918777	chr10:78394375	A/G	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg17366294	chr4:99064904	C4orf37	0.43	10.02	0.37	4.91e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.4	8.97	0.33	3.13e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg02659138	chr7:134003124	SLC35B4	0.34	10.69	0.39	1.14e-24	Mean platelet volume;
BRCA	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg15557168	chr22:42548783	NA	-0.31	-8.64	-0.32	4.39e-17	Cognitive function;
BRCA	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	12.37	0.44	1.11e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	11.95	0.43	7.58e-30	Personality dimensions;
BRCA	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg15485101	chr11:133734466	NA	0.39	9.42	0.35	8.19e-20	Childhood ear infection;
BRCA	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.96	-0.4	1.03e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs208520	0.706	rs851601	chr6:66893853	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-17.6	-0.57	7.86e-57	Exhaled nitric oxide output;
BRCA	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg23587288	chr2:27483067	SLC30A3	-0.38	-8.9	-0.33	5.91e-18	Blood metabolite levels;
BRCA	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg21573476	chr21:45109991	RRP1B	-0.32	-7.99	-0.3	6.09e-15	Mean corpuscular volume;
BRCA	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg03060546	chr3:49711283	APEH	-0.61	-12.3	-0.44	2.28e-31	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-9.68	-0.36	9.05e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg18154014	chr19:37997991	ZNF793	0.6	10.34	0.38	2.87e-23	Coronary artery calcification;
BRCA	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg21385522	chr1:16154831	NA	0.46	9.97	0.37	7.08e-22	Systolic blood pressure;
BRCA	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg05863683	chr7:1912471	MAD1L1	0.38	7.82	0.3	2.21e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs6973256	0.897	rs17659708	chr7:133355098	A/G	cg07491979	chr7:133331646	EXOC4	-0.4	-9.21	-0.34	4.77e-19	Intelligence (multi-trait analysis);
BRCA	trans	rs783540	0.934	rs4779053	chr15:83371598	T/C	cg18393722	chr15:85113863	UBE2QP1	0.27	8.19	0.31	1.4e-15	Schizophrenia;
BRCA	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.45	10.44	0.38	1.14e-23	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg25358565	chr5:93447407	FAM172A	-1.21	-18.19	-0.58	6.75e-60	Diabetic retinopathy;
BRCA	cis	rs4409675	0.576	rs1474908	chr1:28213213	C/T	cg23691781	chr1:28212827	C1orf38	-0.31	-9.96	-0.37	7.97e-22	Corneal astigmatism;
BRCA	cis	rs79518236	1	rs79518236	chr7:98026554	ACT/A	cg09267113	chr7:98030324	BAIAP2L1	-0.59	-15.82	-0.53	7.81e-48	Breast cancer;
BRCA	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg11812906	chr14:75593930	NEK9	-0.68	-15.59	-0.52	1.17e-46	Height;
BRCA	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00166722	chr3:10149974	C3orf24	-0.66	-13.15	-0.46	4.12e-35	Alzheimer's disease;
BRCA	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg22535103	chr8:58192502	C8orf71	-0.57	-12.38	-0.44	1.01e-31	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg25214090	chr10:38739885	LOC399744	0.44	10.01	0.37	5.38e-22	Corneal astigmatism;
BRCA	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	trans	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg09719594	chr16:21412588	NA	-0.35	-7.99	-0.3	6.09e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06634786	chr22:41940651	POLR3H	-0.45	-8.52	-0.32	1.11e-16	Vitiligo;
BRCA	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg12483005	chr1:23474871	LUZP1	0.38	8.34	0.31	4.51e-16	Height;
BRCA	trans	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg21659725	chr3:3221576	CRBN	0.48	9.13	0.34	9.02e-19	Menarche (age at onset);
BRCA	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg21427119	chr20:30132790	HM13	-0.42	-8.92	-0.33	4.92e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg08975724	chr8:8085496	FLJ10661	-0.4	-8.69	-0.33	3.08e-17	Mood instability;
BRCA	cis	rs74181299	0.684	rs6713746	chr2:65324492	G/C	cg05010058	chr2:65284262	CEP68	-0.29	-7.86	-0.3	1.61e-14	Pulse pressure;
BRCA	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg20933634	chr6:27740509	NA	0.46	9.05	0.34	1.71e-18	Parkinson's disease;
BRCA	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.06	-27.14	-0.73	1.75e-108	Ulcerative colitis;
BRCA	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.04	-0.3	4.35e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2742234	0.590	rs2435339	chr10:43642173	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.54	-10.96	-0.4	1.02e-25	Hirschsprung disease;
BRCA	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.37	-0.41	1.99e-27	Schizophrenia;
BRCA	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-11.02	-0.4	5.82e-26	Neuroticism;
BRCA	cis	rs2904967	0.929	rs2904986	chr11:65031221	A/C	cg09225861	chr11:65069680	NA	0.39	8.07	0.3	3.62e-15	Mean corpuscular volume;
BRCA	cis	rs4706831	0.647	rs9350847	chr6:80889017	C/T	cg08355045	chr6:80787529	NA	0.31	7.83	0.3	2.04e-14	Joint mobility (Beighton score);
BRCA	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg04455712	chr21:45112962	RRP1B	0.47	12.63	0.45	8.79e-33	Mean corpuscular volume;
BRCA	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.54	-11.36	-0.41	2.39e-27	Lymphocyte counts;
BRCA	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg26031613	chr14:104095156	KLC1	0.74	15.86	0.53	5.21e-48	Body mass index;
BRCA	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg06636001	chr8:8085503	FLJ10661	0.43	7.92	0.3	1.03e-14	Obesity-related traits;
BRCA	cis	rs17655565	0.533	rs12301094	chr12:52707610	A/G	cg08257133	chr12:52711352	KRT83	0.38	11.29	0.41	4.43e-27	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg00981070	chr1:2046702	PRKCZ	0.31	8.23	0.31	1.07e-15	Height;
BRCA	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg15605315	chr1:45957053	TESK2	0.49	10.0	0.37	5.63e-22	High light scatter reticulocyte count;
BRCA	cis	rs16866061	0.962	rs72972361	chr2:225341550	G/A	cg12698349	chr2:225449008	CUL3	0.77	21.11	0.64	1.92e-75	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg07080220	chr10:102295463	HIF1AN	0.65	15.35	0.52	1.65e-45	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14240646	chr10:27532245	ACBD5	-0.64	-9.36	-0.35	1.38e-19	Breast cancer;
BRCA	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg07636037	chr3:49044803	WDR6	0.98	29.32	0.76	2.17e-120	Parkinson's disease;
BRCA	cis	rs96067	0.711	rs272827	chr1:36627191	C/T	cg24686825	chr1:36642396	MAP7D1	0.56	11.44	0.41	1.05e-27	Corneal structure;
BRCA	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg21017887	chr14:105400489	NA	0.66	17.54	0.57	1.6e-56	Rheumatoid arthritis;
BRCA	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg00686598	chr14:53173677	PSMC6	1.16	15.76	0.53	1.68e-47	Alzheimer's disease (late onset);
BRCA	cis	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg07988820	chr12:82153109	PPFIA2	-0.66	-10.65	-0.39	1.77e-24	Resting heart rate;
BRCA	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg12935359	chr14:103987150	CKB	0.6	13.69	0.48	1.35e-37	Intelligence (multi-trait analysis);
BRCA	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg15556689	chr8:8085844	FLJ10661	0.41	10.36	0.38	2.4e-23	Neuroticism;
BRCA	cis	rs7520050	0.966	rs7556436	chr1:46363880	C/T	cg24296786	chr1:45957014	TESK2	-0.41	-9.38	-0.35	1.16e-19	Red blood cell count;Reticulocyte count;
BRCA	trans	rs629535	0.773	rs569064	chr8:70065967	A/G	cg21567404	chr3:27674614	NA	1.01	20.67	0.63	4.59e-73	Dupuytren's disease;
BRCA	cis	rs12612619	0.732	rs722911	chr2:27211212	A/G	cg00617064	chr2:27272375	NA	-0.31	-8.03	-0.3	4.8e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg25208724	chr1:156163844	SLC25A44	0.88	17.63	0.57	5.29e-57	Testicular germ cell tumor;
BRCA	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg23229984	chr5:148520753	ABLIM3	-0.36	-9.13	-0.34	8.68e-19	Breast cancer;
BRCA	cis	rs11229555	0.609	rs12575080	chr11:58224917	A/G	cg15696309	chr11:58395628	NA	-0.53	-10.93	-0.4	1.29e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12220238	0.730	rs4746177	chr10:75913033	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.49	8.04	0.3	4.22e-15	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg06026331	chr20:60912101	LAMA5	0.46	8.55	0.32	9.35e-17	Colorectal cancer;
BRCA	cis	rs632111	0.519	rs281380	chr19:49214470	A/G	cg13540341	chr19:49222985	MAMSTR	0.33	8.57	0.32	7.76e-17	Serum lipase activity;
BRCA	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11644478	chr21:40555479	PSMG1	-0.66	-14.24	-0.49	3.59e-40	Cognitive function;
BRCA	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg23625390	chr15:77176239	SCAPER	-0.57	-13.21	-0.46	2.03e-35	Blood metabolite levels;
BRCA	cis	rs1506636	0.962	rs2896335	chr7:123376855	A/T	cg03229431	chr7:123269106	ASB15	-0.61	-13.88	-0.48	1.77e-38	Plateletcrit;Platelet count;
BRCA	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg13770153	chr20:60521292	NA	-0.38	-9.1	-0.34	1.18e-18	Body mass index;
BRCA	cis	rs700590	0.532	rs17558396	chr5:88102281	T/G	cg22951263	chr5:87985283	NA	-0.35	-8.89	-0.33	6.33e-18	Educational attainment (years of education);
BRCA	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg03060546	chr3:49711283	APEH	-0.56	-9.96	-0.37	7.79e-22	Menarche (age at onset);
BRCA	cis	rs926392	0.572	rs6129159	chr20:37675011	A/T	cg16355469	chr20:37678765	NA	0.5	11.73	0.42	6.74e-29	Dialysis-related mortality;
BRCA	trans	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg01620082	chr3:125678407	NA	-0.92	-10.33	-0.38	2.97e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs698833	0.892	rs698801	chr2:44691662	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	10.32	0.38	3.3e-23	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg05025164	chr4:1340916	KIAA1530	0.43	9.66	0.36	1.08e-20	Longevity;
BRCA	cis	rs16958440	1.000	rs62096469	chr18:44638298	A/G	cg17192377	chr18:44677553	HDHD2	0.67	9.8	0.36	3.33e-21	Sitting height ratio;
BRCA	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07256732	chr16:621771	PIGQ	-0.35	-9.26	-0.34	3.04e-19	Height;
BRCA	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg06484146	chr7:12443880	VWDE	-0.76	-10.59	-0.39	2.94e-24	Coronary artery disease;
BRCA	cis	rs13102973	0.965	rs28826933	chr4:135876644	T/A	cg14419869	chr4:135874104	NA	-0.59	-13.0	-0.46	1.93e-34	Subjective well-being;
BRCA	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg26168224	chr5:2018326	NA	0.63	17.39	0.57	9.07e-56	Gut microbiome composition (winter);
BRCA	cis	rs6580649	1.000	rs7305954	chr12:48403530	C/T	cg24011408	chr12:48396354	COL2A1	0.53	9.56	0.35	2.49e-20	Lung cancer;
BRCA	cis	rs2559856	1.000	rs10778139	chr12:102083202	C/T	cg12213457	chr12:102090980	CHPT1	0.36	8.04	0.3	4.25e-15	Blood protein levels;
BRCA	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg13010199	chr12:38710504	ALG10B	0.42	8.97	0.33	3.36e-18	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg05347473	chr6:146136440	FBXO30	0.39	7.98	0.3	6.65e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2463822	0.844	rs2513737	chr11:62119495	G/C	cg06239285	chr11:62104954	ASRGL1	0.69	11.52	0.41	4.72e-28	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg09307838	chr4:120376055	NA	0.61	11.94	0.43	8.48e-30	Corneal astigmatism;
BRCA	cis	rs6450176	0.638	rs56220547	chr5:53287952	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.9	-17.78	-0.58	9.16e-58	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg11845111	chr2:191398756	TMEM194B	-0.73	-14.25	-0.49	3.37e-40	Diastolic blood pressure;
BRCA	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg02569458	chr12:86230093	RASSF9	0.32	8.01	0.3	5.6e-15	Major depressive disorder;
BRCA	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg18357645	chr12:58087776	OS9	0.43	11.99	0.43	4.94e-30	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.37	-8.78	-0.33	1.53e-17	Longevity;Endometriosis;
BRCA	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg09462578	chr12:12878428	APOLD1	0.5	11.88	0.43	1.51e-29	Birth weight;
BRCA	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg16339924	chr4:17578868	LAP3	-0.55	-13.28	-0.47	9.99e-36	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.61e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg01448562	chr3:133502909	NA	-0.48	-10.48	-0.38	8.26e-24	Iron status biomarkers;
BRCA	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg04287289	chr16:89883240	FANCA	0.81	20.35	0.63	2.51e-71	Vitiligo;
BRCA	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18876405	chr7:65276391	NA	-0.51	-11.54	-0.42	3.95e-28	Aortic root size;
BRCA	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.14	-0.4	1.77e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-9.96	-0.37	8.18e-22	Mean corpuscular volume;
BRCA	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11890956	chr21:40555474	PSMG1	-0.65	-14.71	-0.5	2.19e-42	Menarche (age at onset);
BRCA	trans	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg07211511	chr3:129823064	LOC729375	-0.6	-11.36	-0.41	2.27e-27	Blood pressure (smoking interaction);
BRCA	cis	rs365132	0.517	rs6881002	chr5:176336755	T/C	cg16309518	chr5:176445507	NA	0.44	10.32	0.38	3.4e-23	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.19	-0.43	6.89e-31	Breast cancer;
BRCA	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg23711669	chr6:146136114	FBXO30	0.64	14.94	0.51	1.74e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg26838691	chr2:24397539	C2orf84	0.39	7.93	0.3	9.84e-15	Asthma;
BRCA	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	6.95e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs8073060	0.544	rs1080352	chr17:34002362	A/G	cg19694781	chr19:47549865	TMEM160	-1.03	-21.11	-0.64	1.9e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg13628971	chr7:2884303	GNA12	0.47	9.02	0.34	2.13e-18	Height;
BRCA	cis	rs6138458	1.000	rs227624	chr20:24911562	T/C	cg06937882	chr20:24974362	C20orf3	-0.44	-8.38	-0.31	3.34e-16	Blood protein levels;
BRCA	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06481639	chr22:41940642	POLR3H	0.52	8.08	0.3	3.3e-15	Vitiligo;
BRCA	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg03808351	chr9:123631620	PHF19	0.61	12.76	0.45	2.26e-33	Birth weight;
BRCA	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.01	0.4	6.14e-26	Electroencephalogram traits;
BRCA	cis	rs290268	0.838	rs290987	chr9:93563267	T/A	cg02608019	chr9:93564028	SYK	0.55	12.23	0.44	4.54e-31	Platelet count;
BRCA	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg12311346	chr5:56204834	C5orf35	-0.81	-16.67	-0.55	4.73e-52	Initial pursuit acceleration;
BRCA	cis	rs12541635	0.966	rs4734894	chr8:106995313	G/A	cg10147462	chr8:107024639	NA	0.38	9.94	0.37	9.45e-22	Age of smoking initiation;
BRCA	cis	rs2882667	0.893	rs10054796	chr5:138294344	G/A	cg04439458	chr5:138467593	SIL1	-0.32	-8.54	-0.32	1.01e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg27129171	chr3:47204927	SETD2	-0.66	-15.06	-0.51	4.17e-44	Colorectal cancer;
BRCA	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg27478167	chr7:817139	HEATR2	-0.48	-9.31	-0.35	1.99e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg05347473	chr6:146136440	FBXO30	0.58	11.2	0.41	1.05e-26	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg15017067	chr4:17643749	FAM184B	0.31	9.52	0.35	3.61e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12618769	0.652	rs4851144	chr2:99220707	T/C	cg10123293	chr2:99228465	UNC50	0.44	8.66	0.32	3.93e-17	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg17366294	chr4:99064904	C4orf37	0.45	10.6	0.39	2.78e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24110177	chr3:50126178	RBM5	0.4	11.28	0.41	4.87e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	8.34	0.31	4.51e-16	Schizophrenia;
BRCA	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-10.95	-0.4	1.1e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11764359	chr7:65958608	NA	0.78	18.57	0.59	6.75e-62	Aortic root size;
BRCA	cis	rs9400271	0.632	rs9384706	chr6:109601504	C/T	cg21918786	chr6:109611834	NA	-0.32	-8.01	-0.3	5.44e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12923728	chr3:195709715	SDHAP1	-0.58	-12.41	-0.44	7.61e-32	Pancreatic cancer;
BRCA	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg26384229	chr12:38710491	ALG10B	0.54	13.7	0.48	1.18e-37	Morning vs. evening chronotype;
BRCA	cis	rs4074536	0.622	rs12741300	chr1:116319761	C/T	cg21648376	chr1:116311395	CASQ2	-0.55	-9.15	-0.34	7.82e-19	QRS duration;
BRCA	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg24558204	chr6:135376177	HBS1L	0.45	12.24	0.44	4.37e-31	Red blood cell count;
BRCA	cis	rs921968	0.565	rs6704575	chr2:219589594	C/T	cg02176678	chr2:219576539	TTLL4	0.4	11.02	0.4	5.46e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg13010199	chr12:38710504	ALG10B	-0.39	-8.83	-0.33	1.04e-17	Morning vs. evening chronotype;
BRCA	cis	rs8050907	0.744	rs8044698	chr16:4577069	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.56	-8.22	-0.31	1.15e-15	Obesity-related traits;
BRCA	cis	rs10754283	0.967	rs7523046	chr1:90109499	G/A	cg21401794	chr1:90099060	LRRC8C	0.49	11.63	0.42	1.69e-28	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg18357645	chr12:58087776	OS9	0.48	13.8	0.48	4.14e-38	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7737355	0.947	rs6875058	chr5:130882702	C/G	cg06307176	chr5:131281290	NA	0.54	10.68	0.39	1.3e-24	Life satisfaction;
BRCA	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg14582100	chr15:45693742	SPATA5L1	0.37	11.87	0.42	1.69e-29	Homoarginine levels;
BRCA	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg19077165	chr18:44547161	KATNAL2	-0.55	-12.55	-0.44	1.8e-32	Personality dimensions;
BRCA	cis	rs3845702	0.736	rs72960660	chr2:180832482	A/G	cg01881094	chr2:180872142	CWC22	1.03	16.85	0.55	5.75e-53	Schizophrenia;
BRCA	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg02297831	chr4:17616191	MED28	0.36	8.51	0.32	1.21e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6543140	0.964	rs6543142	chr2:103082006	T/C	cg04239558	chr2:103089729	SLC9A4	0.35	9.74	0.36	5.21e-21	Blood protein levels;
BRCA	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg11502198	chr6:26597334	ABT1	0.56	12.0	0.43	4.76e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-11.85	-0.42	2.08e-29	Mood instability;
BRCA	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg06766960	chr11:133703094	NA	-0.51	-11.5	-0.41	6.1e-28	Childhood ear infection;
BRCA	cis	rs2191566	0.540	rs391267	chr19:44492487	C/T	cg20607764	chr19:44506953	ZNF230	0.37	7.9	0.3	1.19e-14	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6908034	0.607	rs76525593	chr6:19809170	G/T	cg02682789	chr6:19804855	NA	0.75	8.8	0.33	1.25e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
BRCA	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg16606324	chr3:10149918	C3orf24	-0.51	-10.57	-0.39	3.54e-24	Alzheimer's disease;
BRCA	cis	rs243505	0.762	rs734002	chr7:148505788	A/G	cg09806900	chr7:148480153	CUL1	0.48	10.18	0.37	1.13e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.19	-0.43	6.98e-31	Alzheimer's disease;
BRCA	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-10.88	-0.4	2.04e-25	Alzheimer's disease;
BRCA	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg07395648	chr5:131743802	NA	-0.39	-9.59	-0.35	1.93e-20	Blood metabolite levels;
BRCA	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg11764359	chr7:65958608	NA	-0.62	-13.41	-0.47	2.62e-36	Aortic root size;
BRCA	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg18132916	chr6:79620363	NA	-0.44	-10.07	-0.37	3.15e-22	Intelligence (multi-trait analysis);
BRCA	trans	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg25042112	chr7:64838748	ZNF92	0.46	8.4	0.32	2.96e-16	Pain;
BRCA	cis	rs4478858	0.684	rs4949369	chr1:31723845	T/A	cg00250761	chr1:31883323	NA	-0.31	-8.14	-0.31	2.02e-15	Alcohol dependence;
BRCA	cis	rs10242455	0.557	rs45492501	chr7:99047030	T/A	cg18809830	chr7:99032528	PTCD1	-0.61	-8.86	-0.33	7.76e-18	Blood metabolite levels;
BRCA	cis	rs61935443	0.832	rs10859778	chr12:95268010	C/G	cg21533806	chr12:95267307	NA	0.45	8.56	0.32	8.66e-17	Schizophrenia;
BRCA	trans	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg06521331	chr12:34319734	NA	-0.47	-8.59	-0.32	6.55e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7246657	0.606	rs2972439	chr19:38212581	T/C	cg14683738	chr19:37701593	ZNF585B	-0.47	-8.02	-0.3	5.04e-15	Coronary artery calcification;
BRCA	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.42	0.35	8.17e-20	Tonsillectomy;
BRCA	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00149659	chr3:10157352	C3orf10	0.71	12.11	0.43	1.54e-30	Alzheimer's disease;
BRCA	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg25358565	chr5:93447407	FAM172A	1.23	19.18	0.6	4.21e-65	Diabetic retinopathy;
BRCA	cis	rs7737355	0.898	rs1016068	chr5:131100246	T/C	cg06307176	chr5:131281290	NA	0.53	10.2	0.37	9.47e-23	Life satisfaction;
BRCA	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg05714579	chr10:131428358	MGMT	-0.59	-14.59	-0.5	7.6e-42	Response to temozolomide;
BRCA	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.65	-0.36	1.18e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs56399783	0.614	rs11765492	chr7:2771642	G/A	cg19731401	chr7:2775893	GNA12	0.53	8.43	0.32	2.34e-16	Childhood ear infection;
BRCA	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.66e-18	Motion sickness;
BRCA	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.28	0.56	3.52e-55	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg06521331	chr12:34319734	NA	-0.49	-9.15	-0.34	7.35e-19	Bladder cancer;
BRCA	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.71	13.17	0.46	3.35e-35	Lung function (FEV1/FVC);
BRCA	cis	rs701145	0.585	rs1527800	chr3:153875075	A/G	cg17054900	chr3:154042577	DHX36	0.55	9.29	0.35	2.32e-19	Coronary artery disease;
BRCA	cis	rs7254827	0.826	rs62127867	chr19:17223260	C/T	cg19418318	chr19:17219073	MYO9B	-0.51	-10.32	-0.38	3.28e-23	Mean platelet volume;
BRCA	trans	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg13565492	chr6:43139072	SRF	-0.89	-16.05	-0.54	5.92e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6910061	0.830	rs7753943	chr6:11133496	T/G	cg27233058	chr6:11094804	LOC221710	0.51	8.73	0.33	2.24e-17	Diabetic kidney disease;
BRCA	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg12573674	chr2:1569213	NA	-0.58	-12.76	-0.45	2.18e-33	IgG glycosylation;
BRCA	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg03929089	chr4:120376271	NA	0.72	14.67	0.5	3.35e-42	Coronary artery disease;
BRCA	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.59	13.19	0.46	2.71e-35	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg06197492	chr11:2016605	H19	-0.39	-8.72	-0.33	2.49e-17	DNA methylation (parent-of-origin);DNA methylation (variation);
BRCA	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg15485101	chr11:133734466	NA	0.38	10.33	0.38	3.21e-23	Childhood ear infection;
BRCA	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.07e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg03146154	chr1:46216737	IPP	-0.45	-10.13	-0.37	1.84e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4664304	0.620	rs10929958	chr2:160720538	A/G	cg01092293	chr2:160761427	LY75	0.36	8.51	0.32	1.24e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg01305625	chr5:131593812	PDLIM4	0.34	8.07	0.3	3.4e-15	Acylcarnitine levels;
BRCA	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg21475434	chr5:93447410	FAM172A	0.66	8.46	0.32	1.84e-16	Diabetic retinopathy;
BRCA	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.07	-0.34	1.47e-18	Total body bone mineral density;
BRCA	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg06026331	chr20:60912101	LAMA5	0.46	8.46	0.32	1.89e-16	Colorectal cancer;
BRCA	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg00631329	chr6:26305371	NA	-0.44	-12.86	-0.45	8.01e-34	Educational attainment;
BRCA	cis	rs7617773	0.780	rs71323396	chr3:48374734	T/G	cg11946769	chr3:48343235	NME6	0.65	13.41	0.47	2.71e-36	Coronary artery disease;
BRCA	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg00631329	chr6:26305371	NA	-0.43	-12.72	-0.45	3.34e-33	Educational attainment;
BRCA	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg01256987	chr12:42539512	GXYLT1	-0.41	-8.11	-0.31	2.64e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg07828340	chr4:882639	GAK	0.99	12.74	0.45	2.68e-33	Intelligence (multi-trait analysis);
BRCA	trans	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg26384229	chr12:38710491	ALG10B	0.46	10.13	0.37	1.85e-22	Morning vs. evening chronotype;
BRCA	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg21226059	chr5:178986404	RUFY1	0.36	8.35	0.31	4.27e-16	Lung cancer;
BRCA	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.19	-0.34	5.27e-19	Bipolar disorder;
BRCA	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg24130564	chr14:104152367	KLC1	0.61	17.33	0.57	1.84e-55	Intelligence (multi-trait analysis);
BRCA	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg09462578	chr12:12878428	APOLD1	-0.63	-11.19	-0.4	1.13e-26	Systemic lupus erythematosus;
BRCA	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08219700	chr8:58056026	NA	0.44	7.91	0.3	1.12e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg17063962	chr7:91808500	NA	0.53	12.48	0.44	3.65e-32	Breast cancer;
BRCA	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.06	0.49	2.57e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg11812906	chr14:75593930	NEK9	-0.62	-14.24	-0.49	3.57e-40	Height;
BRCA	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg21132104	chr15:45694354	SPATA5L1	0.75	16.9	0.56	2.9e-53	Homoarginine levels;
BRCA	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg13010199	chr12:38710504	ALG10B	0.41	8.36	0.31	3.82e-16	Bladder cancer;
BRCA	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg21609526	chr1:3105151	PRDM16	0.36	8.61	0.32	5.72e-17	Migraine;
BRCA	cis	rs2859741	0.587	rs516139	chr1:37471617	C/G	cg09363841	chr1:37513479	NA	-0.4	-8.28	-0.31	7.36e-16	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-9.14	-0.34	8.07e-19	Morning vs. evening chronotype;
BRCA	cis	rs672059	1.000	rs652753	chr1:183156569	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.64	0.32	4.48e-17	Hypertriglyceridemia;
BRCA	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	-0.41	-8.01	-0.3	5.6e-15	Resistin levels;
BRCA	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.29e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg06115741	chr20:33292138	TP53INP2	0.39	8.57	0.32	7.52e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs6546550	0.935	rs6546551	chr2:70073703	C/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-10.37	-0.38	2.07e-23	Prevalent atrial fibrillation;
BRCA	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg25358565	chr5:93447407	FAM172A	1.16	18.32	0.59	1.36e-60	Diabetic retinopathy;
BRCA	cis	rs13418410	0.539	rs11695597	chr2:33840024	A/G	cg04131969	chr2:33951647	MYADML	0.52	10.42	0.38	1.33e-23	Non-response to antidepressants and depression;
BRCA	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg09307838	chr4:120376055	NA	0.75	16.17	0.54	1.48e-49	Corneal astigmatism;
BRCA	cis	rs2249625	0.874	rs2463747	chr6:72878113	T/A	cg18830697	chr6:72922368	RIMS1	-0.38	-8.06	-0.3	3.72e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.69	-0.33	2.99e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23978390	chr7:1156363	C7orf50	0.47	10.83	0.39	3.36e-25	Longevity;Endometriosis;
BRCA	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg22535103	chr8:58192502	C8orf71	0.49	8.68	0.32	3.18e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.1	0.31	2.78e-15	Uric acid levels;
BRCA	cis	rs4742903	0.967	rs2274725	chr9:106864570	C/T	cg14250997	chr9:106856677	SMC2	0.34	10.68	0.39	1.31e-24	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg18279126	chr7:2041391	MAD1L1	0.37	8.51	0.32	1.28e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg12311346	chr5:56204834	C5orf35	-0.5	-10.15	-0.37	1.48e-22	Coronary artery disease;
BRCA	trans	rs12517041	1.000	rs7736335	chr5:23288232	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.14	-0.31	2.11e-15	Calcium levels;
BRCA	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg08601574	chr20:25228251	PYGB	0.34	8.15	0.31	1.86e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17253792	0.915	rs78089630	chr14:56178584	G/C	cg01858014	chr14:56050164	KTN1	-0.67	-8.51	-0.32	1.22e-16	Putamen volume;
BRCA	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg11279151	chr3:101281821	RG9MTD1	0.36	8.22	0.31	1.13e-15	Colorectal cancer;
BRCA	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg22491629	chr6:157744540	C6orf35	-0.45	-9.33	-0.35	1.65e-19	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg04553112	chr3:125709451	NA	-0.55	-8.34	-0.31	4.41e-16	Blood pressure (smoking interaction);
BRCA	cis	rs8170	0.603	rs971693	chr19:17422649	G/C	cg04749549	chr19:17459798	NA	-0.36	-9.8	-0.36	3.09e-21	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
BRCA	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg26384229	chr12:38710491	ALG10B	-0.41	-9.46	-0.35	5.69e-20	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs8002861	0.664	rs4941474	chr13:44450289	C/T	cg17145862	chr1:211918768	LPGAT1	0.49	11.08	0.4	3.12e-26	Leprosy;
BRCA	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.05	15.93	0.53	2.27e-48	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg27535305	chr1:53392650	SCP2	-0.37	-8.94	-0.33	4.07e-18	Monocyte count;
BRCA	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-11.65	-0.42	1.44e-28	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg18252515	chr7:66147081	NA	-0.87	-12.06	-0.43	2.43e-30	Diabetic kidney disease;
BRCA	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23221052	chr5:179740743	GFPT2	-0.64	-13.35	-0.47	5.05e-36	Height;
BRCA	trans	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg21659725	chr3:3221576	CRBN	0.48	8.7	0.33	2.83e-17	Menarche (age at onset);
BRCA	trans	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	14.38	0.49	7.95e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg26818010	chr10:134567672	INPP5A	-0.63	-13.42	-0.47	2.33e-36	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9400271	0.632	rs9374071	chr6:109588681	T/C	cg01475377	chr6:109611718	NA	-0.44	-10.41	-0.38	1.56e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.75	16.16	0.54	1.65e-49	Total cholesterol levels;
BRCA	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg02551604	chr5:131831745	NA	-0.31	-11.37	-0.41	2.17e-27	Breast cancer;Mosquito bite size;
BRCA	cis	rs7560272	0.501	rs2421674	chr2:73955432	G/A	cg20560298	chr2:73613845	ALMS1	0.34	8.7	0.33	2.9e-17	Schizophrenia;
BRCA	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.76	15.75	0.53	1.79e-47	HIV-1 control;
BRCA	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg08514558	chr10:81106712	PPIF	0.38	8.39	0.31	3.21e-16	Height;
BRCA	cis	rs9487051	0.768	rs399561	chr6:109524979	G/A	cg01475377	chr6:109611718	NA	-0.44	-11.11	-0.4	2.5e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-19.65	-0.61	1.36e-67	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1577917	0.958	rs34230196	chr6:86526022	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.54	-0.42	4.21e-28	Response to antipsychotic treatment;
BRCA	cis	rs311392	0.867	rs367108	chr8:55093142	G/A	cg11783602	chr8:55087084	NA	-0.31	-9.12	-0.34	9.47e-19	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.49	11.44	0.41	1.08e-27	HIV-1 control;
BRCA	cis	rs10911363	0.592	rs10911354	chr1:183489278	G/A	cg09173681	chr1:183549694	NCF2	0.53	11.1	0.4	2.72e-26	Systemic lupus erythematosus;
BRCA	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg26384229	chr12:38710491	ALG10B	0.49	12.32	0.44	1.84e-31	Morning vs. evening chronotype;
BRCA	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg12463550	chr7:65579703	CRCP	0.38	8.15	0.31	1.96e-15	Aortic root size;
BRCA	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg10556349	chr10:835070	NA	0.73	9.71	0.36	6.8e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03517284	chr6:25882590	NA	0.39	9.18	0.34	5.73e-19	Blood metabolite levels;
BRCA	cis	rs6543140	0.964	rs4851578	chr2:103028951	T/G	cg04239558	chr2:103089729	SLC9A4	0.34	9.38	0.35	1.16e-19	Blood protein levels;
BRCA	cis	rs3820928	0.874	rs67513858	chr2:227804819	A/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.85	-0.33	8.28e-18	Pulmonary function;
BRCA	cis	rs2066819	0.786	rs116934693	chr12:56696545	T/G	cg26734620	chr12:56694298	CS	0.87	10.06	0.37	3.46e-22	Psoriasis vulgaris;
BRCA	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21659725	chr3:3221576	CRBN	-0.71	-21.59	-0.65	4.63e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg18512352	chr11:47633146	NA	-0.36	-8.81	-0.33	1.15e-17	Subjective well-being;
BRCA	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg13010199	chr12:38710504	ALG10B	0.45	9.63	0.36	1.42e-20	Morning vs. evening chronotype;
BRCA	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg21427119	chr20:30132790	HM13	0.41	8.71	0.33	2.49e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg13319975	chr6:146136371	FBXO30	0.44	10.15	0.37	1.59e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6545883	0.895	rs796597	chr2:61681060	A/G	cg15711740	chr2:61764176	XPO1	-0.53	-12.8	-0.45	1.44e-33	Tuberculosis;
BRCA	cis	rs4944092	1.000	rs4944092	chr11:75909619	C/T	cg04588336	chr11:75916460	WNT11	-0.49	-11.87	-0.42	1.74e-29	PR interval;
BRCA	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08219700	chr8:58056026	NA	0.45	8.33	0.31	5.12e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs13102973	0.867	rs4429776	chr4:135883394	G/T	cg14419869	chr4:135874104	NA	0.46	9.1	0.34	1.15e-18	Subjective well-being;
BRCA	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg25358565	chr5:93447407	FAM172A	1.17	18.76	0.6	6.73e-63	Diabetic retinopathy;
BRCA	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg13319975	chr6:146136371	FBXO30	-0.42	-9.62	-0.36	1.5e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.818	rs423692	chr1:153005681	T/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.56	-0.32	8.46e-17	Inflammatory skin disease;
BRCA	cis	rs7246657	0.722	rs10404031	chr19:38035954	A/G	cg23950597	chr19:37808831	NA	-0.51	-8.65	-0.32	4.11e-17	Coronary artery calcification;
BRCA	trans	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg07817883	chr1:32538562	TMEM39B	-0.44	-8.59	-0.32	6.41e-17	Monocyte percentage of white cells;
BRCA	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg00383909	chr3:49044727	WDR6	0.78	13.01	0.46	1.69e-34	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs68170813	0.559	rs79543528	chr7:106891090	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.5	-0.32	1.3e-16	Coronary artery disease;
BRCA	cis	rs4690686	0.500	rs11723131	chr4:177268602	G/A	cg17059388	chr4:177262070	NA	0.51	10.7	0.39	1.05e-24	Essential tremor;
BRCA	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg04842962	chr6:43655489	MRPS18A	1.13	38.18	0.83	5.2e-167	IgG glycosylation;
BRCA	cis	rs4908760	0.965	rs12080583	chr1:8524877	G/A	cg20416874	chr1:8611966	RERE	-0.28	-8.08	-0.3	3.31e-15	Vitiligo;
BRCA	cis	rs6772849	0.805	rs61159406	chr3:128336009	G/A	cg16766828	chr3:128327626	NA	-0.37	-8.59	-0.32	6.43e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg23029597	chr12:123009494	RSRC2	-0.59	-11.69	-0.42	9.28e-29	Body mass index;
BRCA	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-8.14	-0.31	2.02e-15	Longevity;Endometriosis;
BRCA	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg13736514	chr6:26305472	NA	-0.35	-11.92	-0.43	1.01e-29	Educational attainment;
BRCA	cis	rs17767294	0.615	rs72845058	chr6:27647420	T/C	cg08851530	chr6:28072375	NA	1.11	10.02	0.37	4.78e-22	Parkinson's disease;
BRCA	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg13010199	chr12:38710504	ALG10B	0.41	8.42	0.32	2.54e-16	Morning vs. evening chronotype;
BRCA	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.34	-0.41	2.88e-27	Electroencephalogram traits;
BRCA	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	14.08	0.49	2.12e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	14.99	0.51	9.36e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg23029597	chr12:123009494	RSRC2	0.62	11.97	0.43	6e-30	Body mass index;
BRCA	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg06627628	chr2:24431161	ITSN2	-0.84	-15.49	-0.52	3.48e-46	Asthma;
BRCA	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg05343316	chr1:45956843	TESK2	0.62	12.54	0.44	2.15e-32	Platelet count;
BRCA	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg06885757	chr1:42089581	HIVEP3	0.3	10.85	0.39	2.8e-25	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs2505998	0.833	rs2565204	chr10:43603173	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.39	-7.87	-0.3	1.51e-14	Hirschsprung disease;
BRCA	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg19622623	chr12:86230825	RASSF9	-0.33	-9.17	-0.34	6.19e-19	Major depressive disorder;
BRCA	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs73242632	1.000	rs114513553	chr4:57858458	G/A	cg20415529	chr4:57845134	POLR2B;C4orf14	0.7	8.49	0.32	1.4e-16	Congenital heart disease (maternal effect);
BRCA	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg04450456	chr4:17643702	FAM184B	0.34	9.77	0.36	4.31e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9462027	0.628	rs2814970	chr6:34713500	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.0	-0.3	6.02e-15	Systemic lupus erythematosus;
BRCA	cis	rs13394619	0.775	rs10200851	chr2:11722082	C/T	cg07314298	chr2:11723111	GREB1	-0.55	-12.38	-0.44	1.04e-31	Endometriosis;
BRCA	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg09021430	chr5:549028	NA	-0.66	-16.47	-0.55	4.57e-51	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg24558204	chr6:135376177	HBS1L	0.57	15.55	0.52	1.67e-46	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg00074818	chr8:8560427	CLDN23	0.38	8.27	0.31	7.59e-16	Obesity-related traits;
BRCA	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg16950941	chr11:66035639	RAB1B	0.46	12.3	0.44	2.24e-31	Gout;
BRCA	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg05347473	chr6:146136440	FBXO30	0.41	7.96	0.3	8.08e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg11168104	chr5:1857477	NA	-0.37	-9.55	-0.35	2.63e-20	Cardiovascular disease risk factors;
BRCA	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-10.13	-0.37	1.79e-22	Morning vs. evening chronotype;
BRCA	cis	rs1113500	0.933	rs10881497	chr1:108634515	A/G	cg06207961	chr1:108661230	NA	-0.46	-11.19	-0.4	1.2e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs1997103	1.000	rs2331068	chr7:55408220	G/A	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-21.27	-0.64	2.64e-76	Height;
BRCA	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg08213375	chr14:104286397	PPP1R13B	0.41	8.81	0.33	1.16e-17	Reticulocyte count;
BRCA	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	15.35	0.52	1.64e-45	Colorectal cancer;
BRCA	cis	rs1799922	0.693	rs339085	chr7:128423763	T/C	cg02354431	chr7:128423266	NA	0.37	9.4	0.35	9.22e-20	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
BRCA	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg10621924	chr7:39171070	POU6F2	0.38	7.93	0.3	9.68e-15	IgG glycosylation;
BRCA	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg22875332	chr1:76189707	ACADM	0.65	12.42	0.44	7.12e-32	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs2562456	0.876	rs11085465	chr19:21751790	A/G	cg25042112	chr7:64838748	ZNF92	0.45	8.31	0.31	5.93e-16	Pain;
BRCA	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg22875332	chr1:76189707	ACADM	0.66	15.77	0.53	1.41e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg17420585	chr12:42539391	GXYLT1	-0.49	-10.57	-0.39	3.52e-24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs67981189	0.896	rs2526882	chr14:71374702	G/A	cg15816911	chr14:71606274	NA	-0.38	-8.31	-0.31	5.77e-16	Schizophrenia;
BRCA	cis	rs3857067	0.773	rs10023115	chr4:95095502	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.44	-0.35	6.72e-20	QT interval;
BRCA	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-16.68	-0.55	4.02e-52	Axial length;
BRCA	cis	rs250677	0.522	rs10042466	chr5:148393634	T/C	cg12140854	chr5:148520817	ABLIM3	-0.4	-8.34	-0.31	4.41e-16	Breast cancer;
BRCA	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg23711669	chr6:146136114	FBXO30	0.71	17.15	0.56	1.55e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg09307838	chr4:120376055	NA	0.44	9.63	0.36	1.43e-20	Diastolic blood pressure;
BRCA	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg15556689	chr8:8085844	FLJ10661	-0.42	-12.03	-0.43	3.42e-30	Joint mobility (Beighton score);
BRCA	cis	rs9807989	0.507	rs2310300	chr2:103049074	A/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.38	0.31	3.39e-16	Asthma;
BRCA	cis	rs2882667	0.858	rs6882112	chr5:138413735	C/T	cg04439458	chr5:138467593	SIL1	0.41	10.7	0.39	1.08e-24	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3784262	0.631	rs3742961	chr15:58247977	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.77	-0.36	4.26e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg21475434	chr5:93447410	FAM172A	-0.61	-8.12	-0.31	2.43e-15	Diabetic retinopathy;
BRCA	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11644478	chr21:40555479	PSMG1	-0.68	-14.6	-0.5	7.17e-42	Cognitive function;
BRCA	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.09	0.4	2.84e-26	Rheumatoid arthritis;
BRCA	trans	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg26043149	chr18:55253948	FECH	0.39	8.36	0.31	3.78e-16	Bone mineral density;
BRCA	cis	rs6545883	0.540	rs11687956	chr2:61851342	T/C	cg15711740	chr2:61764176	XPO1	0.45	10.77	0.39	5.86e-25	Tuberculosis;
BRCA	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.85	-0.53	5.78e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg03929089	chr4:120376271	NA	-0.86	-21.63	-0.65	2.89e-78	Coronary artery disease;
BRCA	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg05294307	chr14:35346193	BAZ1A	-0.63	-10.62	-0.39	2.34e-24	Psoriasis;
BRCA	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03188948	chr7:1209495	NA	0.64	13.23	0.46	1.76e-35	Longevity;Endometriosis;
BRCA	cis	rs6545883	0.826	rs777591	chr2:61417617	A/G	cg15711740	chr2:61764176	XPO1	-0.51	-12.87	-0.45	7.37e-34	Tuberculosis;
BRCA	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs459571	0.606	rs457420	chr9:136909261	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.53	-11.64	-0.42	1.48e-28	Platelet distribution width;
BRCA	cis	rs6909752	0.651	rs34930763	chr6:22557915	C/G	cg13666174	chr6:22585274	NA	-0.35	-7.95	-0.3	8.62e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
BRCA	cis	rs2742234	0.590	rs2505557	chr10:43666016	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.55	-10.93	-0.4	1.27e-25	Hirschsprung disease;
BRCA	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg20469991	chr17:27169893	C17orf63	-0.45	-8.88	-0.33	6.75e-18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	trans	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg26384229	chr12:38710491	ALG10B	0.53	11.49	0.41	6.32e-28	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7633770	0.786	rs4234464	chr3:46679675	C/T	cg11219411	chr3:46661640	NA	-0.62	-16.26	-0.54	5.43e-50	Coronary artery disease;
BRCA	cis	rs9560113	1.000	rs2104790	chr13:112177412	C/T	cg10483660	chr13:112241077	NA	0.31	7.84	0.3	1.88e-14	Menarche (age at onset);
BRCA	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg26384229	chr12:38710491	ALG10B	0.65	13.96	0.48	7.74e-39	Morning vs. evening chronotype;
BRCA	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg24631222	chr15:78858424	CHRNA5	-0.5	-9.91	-0.37	1.2e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg06238570	chr21:40685208	BRWD1	-0.39	-7.87	-0.3	1.47e-14	Menarche (age at onset);
BRCA	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.58	-12.87	-0.45	7.18e-34	IgG glycosylation;
BRCA	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg03733263	chr8:22462867	KIAA1967	1.0	24.43	0.69	1.35e-93	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg18850127	chr7:39170497	POU6F2	0.38	7.96	0.3	7.63e-15	IgG glycosylation;
BRCA	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg10495392	chr1:46806563	NSUN4	0.43	7.87	0.3	1.51e-14	Menopause (age at onset);
BRCA	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg11887960	chr12:57824829	NA	0.55	8.57	0.32	7.74e-17	Lung disease severity in cystic fibrosis;
BRCA	trans	rs526821	0.595	rs499446	chr11:55355722	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.35	-7.82	-0.3	2.22e-14	Pediatric bone mineral density (spine);
BRCA	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg26446133	chr18:72167187	CNDP2	-0.76	-14.49	-0.5	2.49e-41	Refractive error;
BRCA	trans	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg27600084	chr12:12264075	NA	0.37	8.53	0.32	1.06e-16	Breast size;
BRCA	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.62	-13.18	-0.46	3.04e-35	Lymphocyte counts;
BRCA	cis	rs2130392	0.962	rs7660116	chr4:185626542	G/A	cg21366198	chr4:185655624	MLF1IP	-0.39	-9.29	-0.34	2.42e-19	Kawasaki disease;
BRCA	cis	rs2108225	0.837	rs7810937	chr7:107447500	A/G	cg18560240	chr7:107437656	SLC26A3	-0.54	-11.27	-0.41	5.44e-27	Ulcerative colitis;
BRCA	cis	rs4730250	0.707	rs3729876	chr7:106786952	T/C	cg02696742	chr7:106810147	HBP1	0.62	9.93	0.37	1.04e-21	Osteoarthritis;
BRCA	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg24642439	chr20:33292090	TP53INP2	0.73	16.63	0.55	6.93e-52	Coronary artery disease;
BRCA	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg20387954	chr3:183756860	HTR3D	0.45	10.28	0.38	4.88e-23	Anterior chamber depth;
BRCA	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg22189786	chr22:42395067	WBP2NL	0.41	8.32	0.31	5.17e-16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.57	9.67	0.36	9.54e-21	Gut microbiome composition (summer);
BRCA	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.38	-8.22	-0.31	1.14e-15	Longevity;Endometriosis;
BRCA	cis	rs3743102	0.591	rs12148608	chr15:83382102	A/G	cg00614314	chr15:82944287	LOC80154	0.59	8.39	0.32	3.09e-16	Colorectal adenoma (advanced);
BRCA	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg06784218	chr1:46089804	CCDC17	-0.45	-10.49	-0.38	7.02e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg22920501	chr2:26401640	FAM59B	-0.95	-16.58	-0.55	1.27e-51	Gut microbiome composition (summer);
BRCA	cis	rs644148	0.676	rs2571114	chr19:44997579	A/G	cg15540054	chr19:45004280	ZNF180	-0.42	-8.7	-0.33	2.71e-17	Personality dimensions;
BRCA	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg03342759	chr3:160939853	NMD3	-0.64	-14.77	-0.5	1.11e-42	Morning vs. evening chronotype;
BRCA	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-10.76	-0.39	6.47e-25	IgG glycosylation;
BRCA	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg13770153	chr20:60521292	NA	-0.39	-9.17	-0.34	6.38e-19	Body mass index;
BRCA	cis	rs250677	0.522	rs10040598	chr5:148365720	C/A	cg18129178	chr5:148520854	ABLIM3	0.54	10.35	0.38	2.49e-23	Breast cancer;
BRCA	cis	rs1691799	0.899	rs4762091	chr12:66747863	A/G	cg16791601	chr12:66731901	HELB	-0.69	-19.39	-0.61	3.39e-66	White blood cell count (basophil);
BRCA	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg11812906	chr14:75593930	NEK9	-0.61	-13.96	-0.48	7.78e-39	Height;
BRCA	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-10.89	-0.4	1.84e-25	Bone mineral density;
BRCA	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.83	-0.51	5.41e-43	Chronic sinus infection;
BRCA	trans	rs1422110	0.543	rs10035841	chr5:85419597	T/C	cg01787110	chr1:109008453	NBPF6	0.48	10.56	0.39	3.77e-24	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg03923535	chr7:1197113	ZFAND2A	0.4	8.3	0.31	5.99e-16	Longevity;Endometriosis;
BRCA	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg24060327	chr5:131705240	SLC22A5	-0.44	-8.95	-0.33	3.84e-18	Blood metabolite levels;
BRCA	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg13877915	chr19:58951672	ZNF132	0.47	11.13	0.4	2.03e-26	Uric acid clearance;
BRCA	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg24558204	chr6:135376177	HBS1L	0.45	12.27	0.44	3.13e-31	Red blood cell count;
BRCA	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.33	-0.31	5.02e-16	Monocyte percentage of white cells;
BRCA	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg00666640	chr1:248458726	OR2T12	0.32	8.94	0.33	4.09e-18	Common traits (Other);
BRCA	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg23018236	chr17:30244563	NA	-0.69	-11.83	-0.42	2.43e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.38	8.99	0.34	2.81e-18	Breast cancer;
BRCA	trans	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg01620082	chr3:125678407	NA	-0.57	-8.24	-0.31	1.01e-15	Depression;
BRCA	cis	rs9359856	0.510	rs78649003	chr6:90454644	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.72	-10.97	-0.4	8.69e-26	Bipolar disorder;
BRCA	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg26168224	chr5:2018326	NA	0.64	17.7	0.57	2.48e-57	Gut microbiome composition (winter);
BRCA	cis	rs11190604	0.767	rs7090150	chr10:102173446	G/T	cg07080220	chr10:102295463	HIF1AN	0.49	10.14	0.37	1.61e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg23711669	chr6:146136114	FBXO30	-0.77	-18.14	-0.58	1.18e-59	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg24069376	chr3:38537580	EXOG	0.4	11.21	0.41	9.31e-27	Electrocardiographic conduction measures;
BRCA	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg15501526	chr10:2543763	NA	0.39	9.11	0.34	1.06e-18	Age-related hearing impairment;
BRCA	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg23950597	chr19:37808831	NA	0.6	10.59	0.39	2.91e-24	Coronary artery calcification;
BRCA	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.4	-0.35	9.22e-20	Body mass index;
BRCA	cis	rs8141797	0.901	rs176159	chr22:24514352	A/G	cg00411358	chr22:24577142	SUSD2	0.61	8.21	0.31	1.21e-15	Amyotrophic lateral sclerosis;Coronary artery disease;
BRCA	cis	rs2658782	0.724	rs2248020	chr11:93259965	A/C	cg15737290	chr11:93063684	CCDC67	0.49	10.0	0.37	5.54e-22	Pulmonary function decline;
BRCA	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg26647111	chr11:31128758	NA	-0.44	-9.68	-0.36	9.03e-21	Red blood cell count;
BRCA	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg21475434	chr5:93447410	FAM172A	0.67	8.74	0.33	2.02e-17	Diabetic retinopathy;
BRCA	cis	rs66731853	0.769	rs530104	chr1:20895721	A/G	cg24502330	chr1:20914028	CDA	0.32	7.92	0.3	1.08e-14	Mean corpuscular volume;
BRCA	cis	rs34891900	0.507	rs2587084	chr22:18140644	T/G	cg19898043	chr22:18121309	BCL2L13	0.45	9.05	0.34	1.66e-18	Sum neutrophil eosinophil counts;
BRCA	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.3	0.44	2.25e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg14349672	chr11:133703707	NA	-0.42	-9.39	-0.35	9.98e-20	Childhood ear infection;
BRCA	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.68	-0.36	8.73e-21	Alcohol dependence;
BRCA	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg25427524	chr10:38739819	LOC399744	0.5	9.34	0.35	1.6e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs8016982	0.855	rs10149681	chr14:81686319	G/A	cg01989461	chr14:81687754	GTF2A1	0.52	11.19	0.4	1.1e-26	Schizophrenia;
BRCA	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.75	-0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs11971779	1.000	rs75919582	chr7:139054919	G/A	cg07862535	chr7:139043722	LUC7L2	0.51	11.36	0.41	2.29e-27	Diisocyanate-induced asthma;
BRCA	cis	rs208520	0.690	rs176289	chr6:66766522	C/T	cg07460842	chr6:66804631	NA	-1.0	-19.99	-0.62	2.12e-69	Exhaled nitric oxide output;
BRCA	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-9.98	-0.37	6.84e-22	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg06521331	chr12:34319734	NA	-0.47	-8.7	-0.33	2.8e-17	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg26043149	chr18:55253948	FECH	0.41	9.09	0.34	1.24e-18	Bone mineral density;
BRCA	cis	rs17092148	1.000	rs57131731	chr20:33392739	C/T	cg16810054	chr20:33298113	TP53INP2	0.49	11.17	0.4	1.35e-26	Neuroticism;
BRCA	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg18904891	chr8:8559673	CLDN23	0.64	12.45	0.44	5.08e-32	Obesity-related traits;
BRCA	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11890956	chr21:40555474	PSMG1	-0.6	-13.39	-0.47	3.1e-36	Menarche (age at onset);
BRCA	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg20607287	chr7:12443886	VWDE	-0.6	-8.53	-0.32	1.08e-16	Coronary artery disease;
BRCA	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.39	-8.13	-0.31	2.16e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg26384229	chr12:38710491	ALG10B	0.65	13.81	0.48	3.93e-38	Morning vs. evening chronotype;
BRCA	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg02297831	chr4:17616191	MED28	-0.36	-8.31	-0.31	5.94e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.54	-0.32	9.97e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg04450456	chr4:17643702	FAM184B	0.42	12.53	0.44	2.21e-32	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg08999081	chr20:33150536	PIGU	0.35	9.14	0.34	8.06e-19	Coronary artery disease;
BRCA	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.91	-0.43	1.17e-29	Response to antipsychotic treatment;
BRCA	cis	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg06521331	chr12:34319734	NA	-0.65	-14.09	-0.49	1.84e-39	Morning vs. evening chronotype;
BRCA	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg05985134	chr18:33552581	C18orf21	0.62	10.88	0.4	2.1e-25	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs2625529	0.938	rs4238447	chr15:72131880	C/T	cg16672083	chr15:72433130	SENP8	-0.82	-17.03	-0.56	6.91e-54	Red blood cell count;
BRCA	cis	rs4742903	0.967	rs2274725	chr9:106864570	C/T	cg21169611	chr9:106856078	SMC2	0.36	9.32	0.35	1.85e-19	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.53	8.56	0.32	8.66e-17	Renal function-related traits (BUN);
BRCA	cis	rs4845570	1.000	rs1054479	chr1:151746079	A/T	cg07092448	chr1:151763213	TDRKH	-0.86	-16.92	-0.56	2.44e-53	Coronary artery disease;
BRCA	cis	rs10924970	0.967	rs2185020	chr1:235440289	A/G	cg26050004	chr1:235667680	B3GALNT2	0.35	8.69	0.33	3.01e-17	Asthma;
BRCA	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg04025307	chr7:1156635	C7orf50	0.58	13.73	0.48	8.83e-38	Longevity;Endometriosis;
BRCA	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg25358565	chr5:93447407	FAM172A	1.15	19.28	0.61	1.24e-65	Diabetic retinopathy;
BRCA	cis	rs4363385	0.818	rs4845512	chr1:152995241	C/T	cg24667326	chr1:152973720	SPRR3	-0.32	-9.0	-0.34	2.54e-18	Inflammatory skin disease;
BRCA	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.83	18.14	0.58	1.31e-59	Smoking behavior;
BRCA	cis	rs57590327	0.555	rs6795133	chr3:81756267	A/G	cg07356753	chr3:81810745	GBE1	-0.46	-11.07	-0.4	3.54e-26	Extraversion;
BRCA	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07080220	chr10:102295463	HIF1AN	0.49	10.97	0.4	8.83e-26	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg16606324	chr3:10149918	C3orf24	0.52	10.29	0.38	4.44e-23	Alzheimer's disease;
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23708337	chr7:1209742	NA	0.6	13.79	0.48	4.85e-38	Longevity;Endometriosis;
BRCA	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg08859206	chr1:53392774	SCP2	0.45	10.09	0.37	2.5e-22	Monocyte count;
BRCA	trans	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.6	-0.36	1.77e-20	Bladder cancer;
BRCA	cis	rs17641971	0.684	rs1511367	chr8:49949412	T/C	cg00325661	chr8:49890786	NA	0.38	10.67	0.39	1.43e-24	Blood metabolite levels;
BRCA	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21659725	chr3:3221576	CRBN	-0.48	-10.29	-0.38	4.33e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7599312	0.963	rs10184221	chr2:213409014	G/A	cg20637307	chr2:213403960	ERBB4	0.47	9.68	0.36	8.69e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs7980799	0.935	rs9888363	chr12:33529288	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-8.4	-0.32	2.82e-16	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg13010199	chr12:38710504	ALG10B	-0.41	-8.76	-0.33	1.74e-17	Morning vs. evening chronotype;
BRCA	trans	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.37	-9.02	-0.34	2.24e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg05083358	chr7:2394359	EIF3B	-0.51	-8.04	-0.3	4.52e-15	Multiple sclerosis;
BRCA	cis	rs698833	0.819	rs12053381	chr2:44570804	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	11.5	0.41	6.06e-28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg18479299	chr3:125709523	NA	-0.56	-8.74	-0.33	2.06e-17	Blood pressure (smoking interaction);
BRCA	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg14675211	chr2:100938903	LONRF2	0.43	9.54	0.35	2.92e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg11266682	chr4:10021025	SLC2A9	0.5	13.18	0.46	3.04e-35	Bone mineral density;
BRCA	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06544989	chr22:39130855	UNC84B	0.35	7.95	0.3	8.74e-15	Menopause (age at onset);
BRCA	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg20991723	chr1:152506922	NA	0.37	8.32	0.31	5.36e-16	Hair morphology;
BRCA	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg07636037	chr3:49044803	WDR6	0.87	23.54	0.68	1.05e-88	Parkinson's disease;
BRCA	cis	rs2073300	1.000	rs74273799	chr20:23444492	T/C	cg12062639	chr20:23401060	NAPB	0.89	10.63	0.39	2.06e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg16325326	chr1:53192061	ZYG11B	-0.9	-24.67	-0.7	6.58e-95	Monocyte count;
BRCA	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg03188948	chr7:1209495	NA	0.45	8.23	0.31	1.06e-15	Longevity;Endometriosis;
BRCA	cis	rs2580764	0.540	rs10210840	chr2:55226009	G/A	cg09592903	chr2:55203963	RTN4	-0.33	-8.67	-0.32	3.46e-17	Mean platelet volume;
BRCA	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-11.55	-0.42	3.73e-28	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3820928	0.874	rs2229813	chr2:227892720	C/T	cg11843606	chr2:227700838	RHBDD1	-0.35	-7.92	-0.3	1.06e-14	Pulmonary function;
BRCA	trans	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg00953403	chr17:74099816	EXOC7	0.46	8.63	0.32	4.88e-17	Psychosis in Alzheimer's disease;
BRCA	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05926928	chr17:57297772	GDPD1	1.34	17.48	0.57	3.25e-56	Opioid sensitivity;
BRCA	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg26384229	chr12:38710491	ALG10B	-0.78	-18.18	-0.58	7.41e-60	Bladder cancer;
BRCA	trans	rs12517041	1.000	rs10805750	chr5:23300753	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-7.85	-0.3	1.72e-14	Calcium levels;
BRCA	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.71	-0.48	1.12e-37	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2617583	0.904	rs2937639	chr5:1443728	A/G	cg07151155	chr5:1473589	LPCAT1	-0.38	-8.53	-0.32	1.09e-16	Breast cancer;
BRCA	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg23587288	chr2:27483067	SLC30A3	-0.38	-8.84	-0.33	9.12e-18	Blood metabolite levels;
BRCA	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg18876405	chr7:65276391	NA	-0.53	-11.99	-0.43	5.04e-30	Calcium levels;
BRCA	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg18876405	chr7:65276391	NA	-0.57	-13.38	-0.47	3.53e-36	Aortic root size;
BRCA	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21659725	chr3:3221576	CRBN	-0.47	-11.94	-0.43	8.12e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg18904891	chr8:8559673	CLDN23	0.61	11.99	0.43	5.2e-30	Obesity-related traits;
BRCA	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg15640734	chr5:494837	SLC9A3	0.31	7.89	0.3	1.29e-14	Cystic fibrosis severity;
BRCA	cis	rs35995292	0.534	rs2392604	chr7:38918012	C/T	cg19327137	chr7:38886074	VPS41	0.4	13.32	0.47	6.51e-36	Subjective well-being (multi-trait analysis);
BRCA	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg03477792	chr4:77819574	ANKRD56	0.62	14.78	0.5	9.7e-43	Emphysema distribution in smoking;
BRCA	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg25019033	chr10:957182	NA	-0.41	-7.96	-0.3	7.6e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.66	-0.32	3.82e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.69	0.33	3.02e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg18252515	chr7:66147081	NA	1.06	15.97	0.53	1.49e-48	Diabetic kidney disease;
BRCA	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg15017067	chr4:17643749	FAM184B	0.34	10.35	0.38	2.6e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg14784868	chr12:69753453	YEATS4	0.47	9.26	0.34	3.1e-19	Response to diuretic therapy;
BRCA	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26314531	chr2:26401878	FAM59B	-0.66	-11.27	-0.41	5.58e-27	Gut microbiome composition (summer);
BRCA	cis	rs17401966	1.000	rs4846210	chr1:10322153	A/G	cg03954927	chr1:10346856	KIF1B	0.45	12.8	0.45	1.41e-33	Hepatocellular carcinoma;
BRCA	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg13114125	chr14:105738426	BRF1	-0.49	-10.42	-0.38	1.36e-23	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg00484396	chr16:3507460	NAT15	-0.44	-8.97	-0.33	3.34e-18	Tuberculosis;
BRCA	trans	rs225245	0.782	rs178649	chr17:33908197	C/G	cg19694781	chr19:47549865	TMEM160	-0.33	-8.02	-0.3	4.96e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	7.93e-19	Lymphocyte counts;
BRCA	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg12193833	chr17:30244370	NA	-0.56	-8.77	-0.33	1.63e-17	Hip circumference adjusted for BMI;
BRCA	trans	rs783540	0.632	rs17356528	chr15:83305550	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.31	-8.5	-0.32	1.37e-16	Schizophrenia;
BRCA	cis	rs9503598	0.636	rs6596974	chr6:3465833	C/T	cg00476032	chr6:3446245	SLC22A23	0.38	9.32	0.35	1.9e-19	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg25019033	chr10:957182	NA	-0.41	-7.99	-0.3	6.46e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.6	13.62	0.47	2.84e-37	Breast cancer;
BRCA	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	8.2	0.31	1.31e-15	Educational attainment;
BRCA	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg11584989	chr19:19387371	SF4	-0.31	-8.11	-0.31	2.5e-15	Tonsillectomy;
BRCA	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.41	-9.33	-0.35	1.72e-19	Alzheimer's disease (late onset);
BRCA	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg08888203	chr3:10149979	C3orf24	0.61	13.03	0.46	1.34e-34	Alzheimer's disease;
BRCA	cis	rs7756236	0.521	rs9394368	chr6:36630525	C/G	cg08179530	chr6:36648295	CDKN1A	-0.55	-12.47	-0.44	4.29e-32	QRS duration;
BRCA	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03517284	chr6:25882590	NA	-0.53	-12.2	-0.43	6.33e-31	Blood metabolite levels;
BRCA	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg18904891	chr8:8559673	CLDN23	0.65	13.06	0.46	1.02e-34	Obesity-related traits;
BRCA	trans	rs9944715	0.911	rs9956574	chr18:43782203	C/T	cg01718231	chr17:29326311	RNF135	-0.46	-8.96	-0.33	3.62e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg02544614	chr20:61657117	NA	0.29	8.2	0.31	1.34e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg00530320	chr1:46809349	NSUN4	0.48	9.78	0.36	3.87e-21	Menopause (age at onset);
BRCA	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg15017067	chr4:17643749	FAM184B	0.35	10.79	0.39	4.74e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg02030672	chr11:45687055	CHST1	0.45	9.52	0.35	3.58e-20	Obesity-related traits;
BRCA	cis	rs427394	0.659	rs419128	chr5:6739791	G/A	cg10857441	chr5:6722123	POLS	-0.32	-10.19	-0.37	1.09e-22	Menopause (age at onset);
BRCA	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg01528321	chr10:82214614	TSPAN14	0.63	13.23	0.46	1.65e-35	Post bronchodilator FEV1;
BRCA	cis	rs4363385	0.755	rs1933382	chr1:153003295	G/T	cg24667326	chr1:152973720	SPRR3	0.31	8.35	0.31	4.19e-16	Inflammatory skin disease;
BRCA	cis	rs3099143	1.000	rs3099137	chr15:77123626	G/A	cg21673338	chr15:77095150	SCAPER	-0.53	-9.51	-0.35	3.9e-20	Recalcitrant atopic dermatitis;
BRCA	cis	rs9324022	0.929	rs12888043	chr14:101170436	A/G	cg18089426	chr14:101175970	NA	-0.63	-11.93	-0.43	8.85e-30	Plateletcrit;
BRCA	trans	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg19862616	chr7:65841803	NCRNA00174	0.84	27.77	0.74	6.05e-112	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7020830	0.898	rs12555207	chr9:37315476	C/T	cg14294708	chr9:37120828	ZCCHC7	1.11	34.75	0.81	2.19e-149	Schizophrenia;
BRCA	cis	rs4642101	0.855	rs9873475	chr3:12845422	A/G	cg24848339	chr3:12840334	CAND2	0.41	10.56	0.39	3.86e-24	QRS complex (12-leadsum);
BRCA	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	25.51	0.71	1.6e-99	Chronic sinus infection;
BRCA	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.99	14.86	0.51	4.23e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg12927641	chr6:109611667	NA	0.4	10.41	0.38	1.48e-23	Reticulocyte fraction of red cells;
BRCA	cis	rs10267417	0.603	rs6976553	chr7:19869113	T/C	cg05791153	chr7:19748676	TWISTNB	0.5	9.69	0.36	8.11e-21	Night sleep phenotypes;
BRCA	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg16339924	chr4:17578868	LAP3	0.66	16.58	0.55	1.36e-51	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg20701182	chr2:24300061	SF3B14	0.7	13.17	0.46	3.29e-35	Lymphocyte counts;
BRCA	cis	rs9381107	0.505	rs13208500	chr6:9479707	T/C	cg14735645	chr6:9486422	NA	-0.44	-8.61	-0.32	5.52e-17	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs10267417	0.657	rs7800274	chr7:19871184	G/T	cg05791153	chr7:19748676	TWISTNB	0.5	9.51	0.35	3.92e-20	Night sleep phenotypes;
BRCA	cis	rs6714710	0.603	rs11691494	chr2:98419726	T/A	cg26665480	chr2:98280029	ACTR1B	0.58	13.62	0.47	2.86e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.66	9.56	0.35	2.57e-20	Crohn's disease;
BRCA	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.44	-10.85	-0.39	2.79e-25	Type 2 diabetes;
BRCA	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg24642439	chr20:33292090	TP53INP2	0.65	14.62	0.5	5.44e-42	Coronary artery disease;
BRCA	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg23992470	chr4:843637	GAK	0.5	8.09	0.3	3.05e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17253792	0.822	rs80085988	chr14:56096173	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg06671706	chr8:8559999	CLDN23	0.43	8.36	0.31	3.99e-16	Obesity-related traits;
BRCA	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg16322792	chr1:120165303	ZNF697	-0.57	-15.02	-0.51	7.17e-44	Systemic lupus erythematosus;
BRCA	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.04	-0.3	4.35e-15	Total body bone mineral density;
BRCA	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg00677455	chr12:58241039	CTDSP2	0.63	14.18	0.49	7.02e-40	Multiple sclerosis;
BRCA	cis	rs73001065	0.818	rs10500212	chr19:19723215	C/T	cg03709012	chr19:19516395	GATAD2A	0.75	9.37	0.35	1.18e-19	LDL cholesterol;
BRCA	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg15432903	chr11:17409602	KCNJ11	0.56	11.81	0.42	2.92e-29	Type 2 diabetes;
BRCA	cis	rs7714584	1.000	rs4579248	chr5:150268151	C/T	cg22134413	chr5:150180641	NA	0.8	10.95	0.4	1.09e-25	Crohn's disease;
BRCA	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.65	-0.42	1.4e-28	Platelet count;
BRCA	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg08601574	chr20:25228251	PYGB	-0.37	-8.91	-0.33	5.35e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg27170947	chr2:26402098	FAM59B	-0.81	-13.05	-0.46	1.1e-34	Gut microbiome composition (summer);
BRCA	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	15.75	0.53	1.89e-47	Colorectal cancer;
BRCA	cis	rs758324	0.947	rs476428	chr5:131301615	G/A	cg06307176	chr5:131281290	NA	-0.54	-10.34	-0.38	2.75e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.95	0.3	8.44e-15	Aortic root size;
BRCA	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg12463550	chr7:65579703	CRCP	-0.37	-8.01	-0.3	5.46e-15	Aortic root size;
BRCA	trans	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg25214090	chr10:38739885	LOC399744	0.45	10.62	0.39	2.18e-24	Corneal astigmatism;
BRCA	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg14228332	chr4:119757509	SEC24D	0.71	8.46	0.32	1.81e-16	Cannabis dependence symptom count;
BRCA	cis	rs4240897	0.935	rs3766744	chr1:12043717	G/A	cg13216073	chr1:12042593	MFN2	0.56	13.65	0.48	2.02e-37	Tuberculosis;
BRCA	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	11.38	0.41	1.9e-27	Multiple sclerosis;
BRCA	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg08470875	chr2:26401718	FAM59B	0.6	7.95	0.3	8.26e-15	Gut microbiome composition (summer);
BRCA	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg21905437	chr5:178450457	ZNF879	0.54	11.14	0.4	1.81e-26	Pubertal anthropometrics;
BRCA	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.59	-0.32	6.54e-17	Total body bone mineral density;
BRCA	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.7	0.36	7.46e-21	Morning vs. evening chronotype;
BRCA	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-16.91	-0.56	2.79e-53	Intelligence (multi-trait analysis);
BRCA	trans	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg01620082	chr3:125678407	NA	-0.59	-8.22	-0.31	1.14e-15	Depression;
BRCA	cis	rs4891159	0.548	rs12454625	chr18:74128751	A/G	cg24786174	chr18:74118243	ZNF516	0.84	25.35	0.71	1.24e-98	Longevity;
BRCA	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg21770322	chr7:97807741	LMTK2	0.43	11.35	0.41	2.57e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02176678	chr2:219576539	TTLL4	0.46	12.16	0.43	9.47e-31	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg26597838	chr10:835615	NA	1.01	18.11	0.58	1.87e-59	Eosinophil percentage of granulocytes;
BRCA	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg13736514	chr6:26305472	NA	-0.4	-12.69	-0.45	4.75e-33	Educational attainment;
BRCA	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg11663144	chr21:46675770	NA	-0.55	-12.95	-0.46	3.3e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs16858210	0.607	rs57874587	chr3:183584749	C/T	cg25686905	chr3:183603175	PARL	-0.39	-8.5	-0.32	1.34e-16	Menopause (age at onset);
BRCA	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	10.01	0.37	5.01e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs11229555	0.574	rs12272310	chr11:58186462	A/C	cg15696309	chr11:58395628	NA	-0.45	-9.71	-0.36	7.23e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9309473	0.607	rs11686504	chr2:73579812	T/C	cg20560298	chr2:73613845	ALMS1	-0.42	-10.94	-0.4	1.15e-25	Metabolite levels;
BRCA	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg13047869	chr3:10149882	C3orf24	0.59	12.27	0.44	3.13e-31	Alzheimer's disease;
BRCA	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs9318086	0.935	rs2025701	chr13:24440581	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.3	8.77	0.33	1.57e-17	Myopia (pathological);
BRCA	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18876405	chr7:65276391	NA	-0.57	-13.19	-0.46	2.55e-35	Aortic root size;
BRCA	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg25358565	chr5:93447407	FAM172A	-1.16	-18.49	-0.59	1.87e-61	Diabetic retinopathy;
BRCA	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.25	7.91	0.3	1.15e-14	Parkinson's disease;
BRCA	cis	rs7255436	0.965	rs7254882	chr19:8453822	A/G	cg10174797	chr19:8464628	RAB11B	0.35	9.07	0.34	1.47e-18	HDL cholesterol;
BRCA	cis	rs10193935	0.901	rs62142639	chr2:42600019	C/G	cg27598129	chr2:42591480	NA	-0.87	-14.44	-0.5	4.05e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg15017067	chr4:17643749	FAM184B	0.28	8.41	0.32	2.61e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg18270830	chr10:32634957	EPC1	0.58	9.97	0.37	7.26e-22	Sexual dysfunction (female);
BRCA	cis	rs9341808	0.718	rs2179842	chr6:80979053	T/C	cg08355045	chr6:80787529	NA	0.37	9.65	0.36	1.16e-20	Sitting height ratio;
BRCA	cis	rs11674184	0.525	rs4669755	chr2:11748585	A/C	cg07314298	chr2:11723111	GREB1	0.62	12.52	0.44	2.51e-32	Endometriosis;
BRCA	cis	rs6840360	0.615	rs3828546	chr4:152679816	A/G	cg22705602	chr4:152727874	NA	-0.38	-10.4	-0.38	1.68e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs586533	0.837	rs670426	chr11:99499308	C/T	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10838687	0.736	rs3781619	chr11:47255317	C/T	cg25783544	chr11:47291846	MADD	0.43	7.93	0.3	1e-14	Proinsulin levels;
BRCA	cis	rs897984	0.520	rs4889622	chr16:30870957	A/G	cg02466173	chr16:30829666	NA	0.46	9.35	0.35	1.43e-19	Dementia with Lewy bodies;
BRCA	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg02733842	chr7:1102375	C7orf50	-0.65	-12.04	-0.43	3.25e-30	Bronchopulmonary dysplasia;
BRCA	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03517284	chr6:25882590	NA	-0.38	-8.29	-0.31	6.48e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg06360820	chr2:242988706	NA	-0.9	-16.91	-0.56	2.63e-53	Obesity-related traits;
BRCA	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	7.92	0.3	1.04e-14	Retinal vascular caliber;
BRCA	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.42	-0.61	2.35e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	-0.36	-8.22	-0.31	1.16e-15	Corneal astigmatism;
BRCA	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg03929089	chr4:120376271	NA	-0.68	-13.54	-0.47	6.36e-37	Coronary artery disease;
BRCA	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.77	-13.25	-0.46	1.46e-35	Platelet count;
BRCA	trans	rs783540	1.000	rs11631963	chr15:83318202	T/C	cg18393722	chr15:85113863	UBE2QP1	0.26	8.28	0.31	6.99e-16	Schizophrenia;
BRCA	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg11822812	chr5:140052017	DND1	-0.3	-8.22	-0.31	1.16e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg13256891	chr4:100009986	ADH5	0.52	9.79	0.36	3.48e-21	Alcohol dependence;
BRCA	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg25036284	chr2:26402008	FAM59B	-0.95	-16.07	-0.54	4.82e-49	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.19	0.49	6.12e-40	Motion sickness;
BRCA	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg14166395	chr21:42792516	MX1	-0.52	-12.05	-0.43	2.84e-30	IgG glycosylation;
BRCA	cis	rs4671400	0.571	rs4672428	chr2:61478497	C/T	cg15711740	chr2:61764176	XPO1	0.44	8.77	0.33	1.56e-17	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs1198430	1.000	rs1198432	chr1:23756155	C/T	cg19827787	chr1:23763612	ASAP3	-0.36	-9.61	-0.36	1.7e-20	Total cholesterol levels;
BRCA	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.2e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-10.05	-0.37	3.79e-22	Crohn's disease;
BRCA	cis	rs909002	0.830	rs10914461	chr1:32113217	G/A	cg11573219	chr1:32083031	HCRTR1	0.29	9.18	0.34	6.11e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.2	0.37	9.63e-23	Aortic root size;
BRCA	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-18.5	-0.59	1.6e-61	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs870825	0.616	rs7683799	chr4:185632164	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	16.91	0.56	2.63e-53	Blood protein levels;
BRCA	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg08888203	chr3:10149979	C3orf24	0.57	11.96	0.43	6.77e-30	Alzheimer's disease;
BRCA	cis	rs12618769	0.597	rs4851133	chr2:99050519	T/C	cg10123293	chr2:99228465	UNC50	0.4	8.17	0.31	1.71e-15	Bipolar disorder;
BRCA	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg16576083	chr14:105354267	KIAA0284	0.44	11.43	0.41	1.22e-27	IgG glycosylation;
BRCA	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.91	0.3	1.16e-14	Axial length;
BRCA	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.61	-12.91	-0.45	4.86e-34	Personality dimensions;
BRCA	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.99	0.37	6.16e-22	Bipolar disorder;
BRCA	cis	rs7633857	0.512	rs1374787	chr3:160700144	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-11.43	-0.41	1.17e-27	Educational attainment (years of education);
BRCA	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05890377	chr2:74357713	NA	0.52	11.11	0.4	2.49e-26	Gestational age at birth (maternal effect);
BRCA	cis	rs10504073	0.584	rs4873300	chr8:49902201	C/G	cg00325661	chr8:49890786	NA	0.54	15.56	0.52	1.52e-46	Blood metabolite ratios;
BRCA	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg24675658	chr1:53192096	ZYG11B	-0.71	-15.9	-0.53	3.3e-48	Monocyte count;
BRCA	trans	rs3857536	0.642	rs7755840	chr6:66891913	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-9.49	-0.35	4.6e-20	Blood trace element (Cu levels);
BRCA	cis	rs7254827	0.826	rs12978850	chr19:17222753	C/T	cg19418318	chr19:17219073	MYO9B	-0.51	-10.29	-0.38	4.28e-23	Mean platelet volume;
BRCA	cis	rs654950	1.000	rs621680	chr1:41984584	C/T	cg06885757	chr1:42089581	HIVEP3	-0.23	-8.04	-0.3	4.5e-15	Airway imaging phenotypes;
BRCA	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg17143192	chr8:8559678	CLDN23	0.57	11.1	0.4	2.58e-26	Obesity-related traits;
BRCA	cis	rs6684428	0.706	rs10888942	chr1:56335432	C/G	cg11651538	chr1:56320950	NA	-0.49	-8.47	-0.32	1.69e-16	Airflow obstruction;
BRCA	cis	rs858239	0.539	rs2178139	chr7:23191636	A/G	cg23682824	chr7:23144976	KLHL7	0.41	10.94	0.4	1.21e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	17.25	0.56	4.8e-55	Alzheimer's disease;
BRCA	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18876405	chr7:65276391	NA	0.62	15.37	0.52	1.28e-45	Aortic root size;
BRCA	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg15704280	chr7:45808275	SEPT13	-0.76	-16.78	-0.55	1.18e-52	Coronary artery disease;
BRCA	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11890956	chr21:40555474	PSMG1	1.09	33.76	0.8	3.49e-144	Cognitive function;
BRCA	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg18811423	chr2:55921094	PNPT1	0.71	23.15	0.68	1.47e-86	Metabolic syndrome;
BRCA	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg23018236	chr17:30244563	NA	-0.68	-10.6	-0.39	2.7e-24	Hip circumference adjusted for BMI;
BRCA	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	11.19	0.4	1.15e-26	Rheumatoid arthritis;
BRCA	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg12386194	chr3:101231763	SENP7	0.46	9.7	0.36	7.74e-21	Colorectal cancer;
BRCA	cis	rs7254827	0.737	rs62126055	chr19:17166344	C/T	cg19418318	chr19:17219073	MYO9B	-0.48	-10.05	-0.37	3.52e-22	Mean platelet volume;
BRCA	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg08807101	chr21:30365312	RNF160	-0.45	-7.84	-0.3	1.96e-14	Cognitive test performance;
BRCA	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg18904891	chr8:8559673	CLDN23	0.65	13.06	0.46	1.04e-34	Obesity-related traits;
BRCA	cis	rs2455799	0.574	rs2470534	chr3:15701054	C/G	cg16303742	chr3:15540471	COLQ	0.36	8.74	0.33	2.1e-17	Mean platelet volume;
BRCA	cis	rs7011049	0.722	rs11985689	chr8:53832615	G/A	cg26025543	chr8:53854495	NA	0.53	9.71	0.36	7.26e-21	Systolic blood pressure;
BRCA	trans	rs12517041	1.000	rs10805749	chr5:23300740	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-7.85	-0.3	1.72e-14	Calcium levels;
BRCA	cis	rs4074536	0.574	rs10923361	chr1:116292882	T/G	cg21648376	chr1:116311395	CASQ2	-0.49	-8.63	-0.32	5e-17	QRS duration;
BRCA	trans	rs12517041	1.000	rs10052113	chr5:23287871	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.36	-0.31	4.04e-16	Calcium levels;
BRCA	cis	rs72781680	0.716	rs72788284	chr2:24097539	A/G	cg08917208	chr2:24149416	ATAD2B	0.61	10.36	0.38	2.39e-23	Lymphocyte counts;
BRCA	cis	rs17401966	0.898	rs12117635	chr1:10317445	C/T	cg03954927	chr1:10346856	KIF1B	0.4	12.63	0.45	8.07e-33	Hepatocellular carcinoma;
BRCA	cis	rs12618769	0.597	rs10496327	chr2:99066827	A/G	cg10123293	chr2:99228465	UNC50	0.41	7.9	0.3	1.21e-14	Bipolar disorder;
BRCA	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs11920090	0.800	rs12486657	chr3:170738349	T/A	cg09710316	chr3:170744871	SLC2A2	0.47	8.75	0.33	1.86e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg12769354	chr4:140004069	ELF2	0.33	8.83	0.33	1.04e-17	Mosquito bite size;
BRCA	cis	rs1891275	0.515	rs6583784	chr10:93491576	A/G	cg07889827	chr10:93443413	NA	0.41	11.1	0.4	2.68e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg11584989	chr19:19387371	SF4	0.54	12.05	0.43	2.74e-30	Bipolar disorder;
BRCA	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	12.02	0.43	3.79e-30	Multiple sclerosis;
BRCA	trans	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg07211511	chr3:129823064	LOC729375	-1.05	-18.4	-0.59	5.22e-61	Blood pressure (smoking interaction);
BRCA	cis	rs7833986	0.501	rs72653957	chr8:56990048	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	13.25	0.46	1.44e-35	Height;
BRCA	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	8.29	0.31	6.67e-16	Breast cancer;
BRCA	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg02733842	chr7:1102375	C7orf50	-0.73	-12.6	-0.45	1.17e-32	Bronchopulmonary dysplasia;
BRCA	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg16405210	chr4:1374714	KIAA1530	-0.94	-20.9	-0.64	2.54e-74	Longevity;
BRCA	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg17410650	chr12:54324560	NA	-0.54	-15.55	-0.52	1.76e-46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
BRCA	cis	rs17095355	1.000	rs55897175	chr10:111699190	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.4	-10.46	-0.38	9.56e-24	Biliary atresia;
BRCA	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg11584989	chr19:19387371	SF4	0.63	13.44	0.47	1.83e-36	Bipolar disorder;
BRCA	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg26838691	chr2:24397539	C2orf84	-0.54	-9.54	-0.35	2.89e-20	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg05347473	chr6:146136440	FBXO30	-0.41	-8.05	-0.3	3.93e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs4596713	0.507	rs2275428	chr9:71792582	A/T	cg16512924	chr15:28394682	HERC2	0.45	10.8	0.39	4.51e-25	Headache;
BRCA	cis	rs1451375	0.698	rs56233242	chr7:50634053	C/A	cg18232548	chr7:50535776	DDC	0.4	9.34	0.35	1.59e-19	Malaria;
BRCA	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.74	-0.36	5.24e-21	IgG glycosylation;
BRCA	cis	rs2281845	0.507	rs1536127	chr1:201086894	C/A	cg06714761	chr1:201096289	NA	0.56	13.95	0.48	8.58e-39	Permanent tooth development;
BRCA	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.29	0.31	6.78e-16	Cognitive ability;
BRCA	cis	rs7582720	0.945	rs2351524	chr2:203880992	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.74	-12.26	-0.44	3.61e-31	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs698833	0.518	rs4953085	chr2:44554724	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.4	0.32	2.92e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg24006582	chr15:45444508	DUOX1	-0.53	-10.93	-0.4	1.34e-25	Uric acid levels;
BRCA	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08564027	chr20:61660810	NA	0.85	22.91	0.67	2.99e-85	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg20290983	chr6:43655470	MRPS18A	1.11	40.51	0.85	1.18e-178	IgG glycosylation;
BRCA	cis	rs7246657	0.722	rs2972437	chr19:38210511	G/T	cg23950597	chr19:37808831	NA	-0.49	-8.45	-0.32	1.96e-16	Coronary artery calcification;
BRCA	cis	rs9868809	0.881	rs2276850	chr3:48669648	G/A	cg00383909	chr3:49044727	WDR6	0.55	8.38	0.31	3.29e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg04511125	chr2:88470314	THNSL2	-0.52	-10.73	-0.39	8.43e-25	Response to metformin (IC50);
BRCA	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	18.45	0.59	3e-61	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.49	-0.44	3.3e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs4363385	0.669	rs2937264	chr1:153011026	C/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.87	-0.33	7.31e-18	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg16606324	chr3:10149918	C3orf24	-0.52	-10.57	-0.39	3.4e-24	Alzheimer's disease;
BRCA	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg00990874	chr7:1149470	C7orf50	-0.52	-9.41	-0.35	8.74e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg12923728	chr3:195709715	SDHAP1	0.38	7.85	0.3	1.72e-14	Mean corpuscular volume;
BRCA	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg12011299	chr4:100065546	ADH4	0.48	10.68	0.39	1.28e-24	Alcohol dependence;
BRCA	cis	rs16867321	0.694	rs4666853	chr2:181439671	C/T	cg23363182	chr2:181467187	NA	0.46	10.17	0.37	1.24e-22	Obesity;
BRCA	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	16.87	0.56	4.55e-53	Colorectal cancer;
BRCA	cis	rs3784262	0.631	rs4646584	chr15:58305402	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.07	-0.37	3.07e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.52	8.68	0.32	3.27e-17	Lung function (FEV1/FVC);
BRCA	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	11.69	0.42	9.48e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs11603020	0.904	rs4926	chr11:57381989	G/A	cg19752551	chr11:57585705	CTNND1	-0.42	-9.63	-0.36	1.41e-20	Blood protein levels;
BRCA	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg16479474	chr6:28041457	NA	0.42	7.81	0.3	2.41e-14	Depression;
BRCA	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg21775007	chr8:11205619	TDH	0.55	10.58	0.39	3.22e-24	Retinal vascular caliber;
BRCA	cis	rs4664304	1.000	rs6735923	chr2:160769588	A/G	cg18514922	chr2:160761262	LY75	-0.38	-8.74	-0.33	2e-17	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg06212747	chr3:49208901	KLHDC8B	0.47	9.75	0.36	5.12e-21	Parkinson's disease;
BRCA	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	8.36	0.31	3.97e-16	Schizophrenia;
BRCA	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg21856205	chr7:94953877	PON1	-0.37	-8.17	-0.31	1.68e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs698813	0.674	rs4953080	chr2:44500849	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	8.68	0.32	3.24e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.64	0.55	6.24e-52	Colorectal cancer;
BRCA	cis	rs858239	0.539	rs4504540	chr7:23186198	C/G	cg23682824	chr7:23144976	KLHL7	0.41	10.65	0.39	1.72e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg21770322	chr7:97807741	LMTK2	0.42	11.28	0.41	4.81e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07308232	chr7:1071921	C7orf50	0.52	11.07	0.4	3.63e-26	Longevity;Endometriosis;
BRCA	trans	rs7279771	0.736	rs41315475	chr21:35884633	G/A	cg03797705	chr17:79604227	NPLOC4	-0.36	-7.89	-0.3	1.34e-14	Cancer;
BRCA	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.61	9.67	0.36	9.67e-21	Renal function-related traits (BUN);
BRCA	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15664640	chr17:80829946	TBCD	0.4	10.74	0.39	7.73e-25	Breast cancer;
BRCA	cis	rs10851411	0.697	rs11630625	chr15:42819175	A/T	cg21293051	chr15:42870591	STARD9	0.52	8.61	0.32	5.53e-17	Glucose homeostasis traits;
BRCA	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg13770153	chr20:60521292	NA	-0.35	-8.19	-0.31	1.46e-15	Body mass index;
BRCA	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05890377	chr2:74357713	NA	0.51	12.01	0.43	4.38e-30	Gestational age at birth (maternal effect);
BRCA	cis	rs71636778	0.596	rs2095637	chr1:27232845	A/G	cg12203394	chr1:27248618	NUDC	0.6	9.46	0.35	5.7e-20	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-12.5	-0.44	2.98e-32	Bipolar disorder;
BRCA	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg12219531	chr12:120966889	COQ5	0.55	11.44	0.41	1.11e-27	High light scatter reticulocyte count;
BRCA	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg03433033	chr1:76189801	ACADM	0.76	17.02	0.56	7.81e-54	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-9.84	-0.36	2.3e-21	Tonsillectomy;
BRCA	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg24829409	chr8:58192753	C8orf71	-0.43	-8.64	-0.32	4.64e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg16950941	chr11:66035639	RAB1B	-0.4	-11.2	-0.41	9.96e-27	Gout;
BRCA	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12379764	chr21:47803548	PCNT	0.39	8.56	0.32	8.18e-17	Testicular germ cell tumor;
BRCA	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	9.29	0.34	2.48e-19	Rheumatoid arthritis;
BRCA	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.76e-21	Alcohol dependence;
BRCA	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg02176678	chr2:219576539	TTLL4	-0.47	-12.22	-0.44	5.01e-31	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg15017067	chr4:17643749	FAM184B	0.3	8.34	0.31	4.42e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs350251	0.899	rs350285	chr16:12228735	G/A	cg06014057	chr16:12226852	SNX29	0.3	8.08	0.3	3.15e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg11707556	chr5:10655725	ANKRD33B	0.6	16.04	0.54	6.4e-49	Height;
BRCA	cis	rs2599510	0.840	rs466146	chr2:32539236	A/C	cg02381751	chr2:32503542	YIPF4	0.39	8.08	0.3	3.22e-15	Interleukin-18 levels;
BRCA	cis	rs55665837	1.000	rs7121171	chr11:14446420	A/G	cg19336497	chr11:14380999	RRAS2	-0.36	-9.32	-0.35	1.82e-19	Vitamin D levels;
BRCA	cis	rs6580649	0.941	rs1793931	chr12:48396505	G/T	cg24011408	chr12:48396354	COL2A1	0.55	9.26	0.34	3.07e-19	Lung cancer;
BRCA	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg03894339	chr8:19674705	INTS10	0.44	8.72	0.33	2.4e-17	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6942756	0.806	rs9641846	chr7:128873679	G/A	cg02491457	chr7:128862824	NA	0.59	12.91	0.45	4.84e-34	White matter hyperintensity burden;
BRCA	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg11879182	chr18:77439856	CTDP1	0.64	13.9	0.48	1.38e-38	Monocyte count;
BRCA	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07636037	chr3:49044803	WDR6	-0.75	-16.19	-0.54	1.2e-49	Menarche (age at onset);
BRCA	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.05	0.3	3.95e-15	Menarche (age at onset);
BRCA	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	10.58	0.39	3.1e-24	Bone mineral density;
BRCA	cis	rs7011049	1.000	rs72640865	chr8:53842471	C/T	cg26025543	chr8:53854495	NA	0.53	9.13	0.34	8.77e-19	Systolic blood pressure;
BRCA	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg10223061	chr2:219282414	VIL1	0.32	9.18	0.34	6.07e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.87	0.36	1.75e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg09307838	chr4:120376055	NA	0.74	16.05	0.54	5.6e-49	Corneal astigmatism;
BRCA	cis	rs3106136	0.546	rs7685121	chr4:95175682	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-10.3	-0.38	3.91e-23	Capecitabine sensitivity;
BRCA	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg24642439	chr20:33292090	TP53INP2	0.56	12.27	0.44	3.24e-31	Coronary artery disease;
BRCA	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg04013093	chr6:42928303	GNMT	-0.29	-9.19	-0.34	5.55e-19	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg17372223	chr3:52568218	NT5DC2	0.34	7.84	0.3	1.96e-14	Electroencephalogram traits;
BRCA	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg26384229	chr12:38710491	ALG10B	0.66	13.93	0.48	1.04e-38	Morning vs. evening chronotype;
BRCA	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg03806693	chr22:41940476	POLR3H	0.92	16.99	0.56	1.11e-53	Vitiligo;
BRCA	cis	rs9837602	1.000	rs923471	chr3:99757853	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.58	10.39	0.38	1.8e-23	Breast cancer;
BRCA	cis	rs17095355	0.818	rs56367935	chr10:111783266	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.45	-9.66	-0.36	1.07e-20	Biliary atresia;
BRCA	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg24829409	chr8:58192753	C8orf71	-0.48	-9.14	-0.34	8.26e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg04944784	chr2:26401820	FAM59B	-0.66	-11.21	-0.41	9.53e-27	Gut microbiome composition (summer);
BRCA	cis	rs7737355	1.000	rs9327608	chr5:130650134	G/A	cg06307176	chr5:131281290	NA	0.45	8.81	0.33	1.15e-17	Life satisfaction;
BRCA	cis	rs34779708	0.931	rs4934533	chr10:35359619	A/G	cg03585969	chr10:35415529	CREM	0.46	9.6	0.35	1.82e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg01877450	chr7:97915802	BRI3	-0.39	-8.87	-0.33	7.43e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-9.47	-0.35	5.37e-20	Chronic sinus infection;
BRCA	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.66	-0.32	3.86e-17	Alzheimer's disease (late onset);
BRCA	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg13628971	chr7:2884303	GNA12	0.4	9.02	0.34	2.15e-18	Height;
BRCA	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-12.07	-0.43	2.38e-30	Chronic sinus infection;
BRCA	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21659725	chr3:3221576	CRBN	0.5	12.9	0.45	5.33e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg03711944	chr11:47377212	SPI1	-0.41	-9.75	-0.36	5.1e-21	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.85	-0.33	8.34e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg18232548	chr7:50535776	DDC	0.42	9.12	0.34	9.32e-19	Malaria;
BRCA	trans	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg17145862	chr1:211918768	LPGAT1	0.47	10.82	0.39	3.74e-25	Leprosy;
BRCA	cis	rs4594175	0.926	rs113095693	chr14:51600511	G/C	cg23942311	chr14:51606299	NA	0.34	8.47	0.32	1.72e-16	Cancer;
BRCA	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg13073564	chr4:8508604	NA	-0.39	-10.7	-0.39	1.12e-24	Response to antineoplastic agents;
BRCA	cis	rs4642101	0.561	rs4560285	chr3:12809066	G/A	cg24848339	chr3:12840334	CAND2	0.33	8.5	0.32	1.33e-16	QRS complex (12-leadsum);
BRCA	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg22535103	chr8:58192502	C8orf71	-0.46	-8.96	-0.33	3.58e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs365132	1.000	rs353493	chr5:176432585	T/C	cg16309518	chr5:176445507	NA	-0.51	-13.27	-0.46	1.08e-35	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg27433088	chr4:174089019	GALNT7	0.34	9.21	0.34	4.71e-19	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.57	-8.16	-0.31	1.75e-15	Yeast infection;
BRCA	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg17366294	chr4:99064904	C4orf37	0.42	9.49	0.35	4.33e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg24812749	chr6:127587940	RNF146	0.88	20.06	0.62	9.03e-70	Breast cancer;
BRCA	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.79	13.01	0.46	1.73e-34	Platelet count;
BRCA	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs113835537	0.597	rs2075792	chr11:66334556	G/A	cg24851651	chr11:66362959	CCS	0.44	8.41	0.32	2.62e-16	Airway imaging phenotypes;
BRCA	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg00666640	chr1:248458726	OR2T12	0.32	8.71	0.33	2.59e-17	Common traits (Other);
BRCA	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg03060546	chr3:49711283	APEH	0.5	10.79	0.39	4.73e-25	Resting heart rate;
BRCA	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs364477	0.762	rs9299103	chr9:1001231	G/T	cg13952963	chr9:998547	NA	-0.47	-8.57	-0.32	7.57e-17	Major depressive disorder;
BRCA	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg15704280	chr7:45808275	SEPT13	0.54	9.11	0.34	1.01e-18	Axial length;
BRCA	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg13010199	chr12:38710504	ALG10B	0.41	8.54	0.32	9.72e-17	Bladder cancer;
BRCA	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg16586182	chr3:47516702	SCAP	-0.59	-12.98	-0.46	2.43e-34	Colorectal cancer;
BRCA	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.76	0.39	6.44e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg12310025	chr6:25882481	NA	-0.42	-10.48	-0.38	7.77e-24	Height;
BRCA	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg16586182	chr3:47516702	SCAP	-0.55	-12.21	-0.43	5.88e-31	Colorectal cancer;
BRCA	cis	rs4363385	0.818	rs435633	chr1:153011811	A/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs7246967	0.673	rs7248107	chr19:22878529	G/T	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.73e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs943466	0.614	rs4711345	chr6:33730954	G/A	cg25922239	chr6:33757077	LEMD2	-0.33	-8.2	-0.31	1.35e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg17971929	chr21:40555470	PSMG1	-0.62	-14.55	-0.5	1.22e-41	Cognitive function;
BRCA	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg18252515	chr7:66147081	NA	0.98	14.67	0.5	3.3e-42	Diabetic kidney disease;
BRCA	cis	rs1891275	0.550	rs4933694	chr10:93499213	C/T	cg07889827	chr10:93443413	NA	-0.41	-11.11	-0.4	2.42e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg04362960	chr10:104952993	NT5C2	0.4	9.72	0.36	6.3e-21	Arsenic metabolism;
BRCA	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08219700	chr8:58056026	NA	0.45	8.09	0.3	3.01e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-8.66	-0.32	3.71e-17	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6545883	0.811	rs778753	chr2:61780200	T/A	cg15711740	chr2:61764176	XPO1	-0.48	-11.98	-0.43	5.47e-30	Tuberculosis;
BRCA	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	12.18	0.43	7.98e-31	Personality dimensions;
BRCA	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg11789530	chr4:8429930	ACOX3	-0.55	-12.59	-0.45	1.26e-32	Response to antineoplastic agents;
BRCA	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg09307838	chr4:120376055	NA	0.63	13.59	0.47	3.72e-37	Corneal astigmatism;
BRCA	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg10645314	chr2:3704589	ALLC	0.5	9.06	0.34	1.62e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg14675211	chr2:100938903	LONRF2	0.5	11.42	0.41	1.35e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg25554036	chr4:6271136	WFS1	0.4	9.33	0.35	1.7e-19	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg18811423	chr2:55921094	PNPT1	0.75	25.08	0.7	3.5e-97	Metabolic syndrome;
BRCA	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg10556349	chr10:835070	NA	0.64	9.31	0.35	1.97e-19	Eosinophil percentage of granulocytes;
BRCA	cis	rs11971779	0.680	rs4077889	chr7:139033914	A/G	cg07862535	chr7:139043722	LUC7L2	0.39	10.46	0.38	9.65e-24	Diisocyanate-induced asthma;
BRCA	trans	rs1997103	1.000	rs1997103	chr7:55395390	C/G	cg20935933	chr6:143382018	AIG1	0.6	11.48	0.41	7.49e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs495337	0.786	rs6125820	chr20:48545831	T/C	cg17835207	chr20:48524531	SPATA2	-0.69	-16.8	-0.55	1.04e-52	Psoriasis;
BRCA	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15541040	chr2:3486749	NA	-0.46	-10.21	-0.37	8.86e-23	Neurofibrillary tangles;
BRCA	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg00071950	chr4:10020882	SLC2A9	0.54	13.37	0.47	3.86e-36	Bone mineral density;
BRCA	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11644478	chr21:40555479	PSMG1	-0.66	-14.13	-0.49	1.17e-39	Cognitive function;
BRCA	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg18351406	chr4:77819688	ANKRD56	0.54	11.72	0.42	6.82e-29	Emphysema distribution in smoking;
BRCA	cis	rs10463316	0.779	rs6861968	chr5:150817725	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-8.84	-0.33	9.3e-18	Metabolite levels (Pyroglutamine);
BRCA	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg00012203	chr2:219082015	ARPC2	0.49	9.26	0.34	3.15e-19	Colorectal cancer;
BRCA	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg27398817	chr8:82754497	SNX16	-0.37	-8.0	-0.3	5.93e-15	Diastolic blood pressure;
BRCA	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg05340658	chr4:99064831	C4orf37	0.49	10.75	0.39	6.87e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-16.38	-0.54	1.31e-50	Body mass index;
BRCA	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06022373	chr22:39101656	GTPBP1	0.7	15.93	0.53	2.26e-48	Menopause (age at onset);
BRCA	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg02297831	chr4:17616191	MED28	0.36	8.36	0.31	4.03e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03452623	chr4:187889614	NA	-0.34	-10.98	-0.4	8.06e-26	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg26384229	chr12:38710491	ALG10B	-0.61	-14.23	-0.49	4.04e-40	Morning vs. evening chronotype;
BRCA	trans	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg06521331	chr12:34319734	NA	-0.5	-9.1	-0.34	1.16e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg24130564	chr14:104152367	KLC1	-0.37	-8.71	-0.33	2.64e-17	Body mass index;
BRCA	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg06618935	chr21:46677482	NA	-0.37	-7.97	-0.3	7.53e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg01483505	chr11:975446	AP2A2	0.33	9.05	0.34	1.75e-18	Alzheimer's disease (late onset);
BRCA	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-12.47	-0.44	4.33e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs11971779	0.680	rs4732373	chr7:139086535	T/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg18132916	chr6:79620363	NA	-0.5	-11.48	-0.41	7.25e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs10857712	0.528	rs2265638	chr10:135217175	A/G	cg00491522	chr10:135256596	NA	0.56	12.01	0.43	4.02e-30	Systemic lupus erythematosus;
BRCA	cis	rs4664304	0.966	rs925407	chr2:160767502	A/C	cg02280532	chr2:160761244	LY75	-0.4	-8.9	-0.33	5.63e-18	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06108461	chr20:60628389	TAF4	-0.97	-21.81	-0.65	3.05e-79	Body mass index;
BRCA	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg05623727	chr3:50126028	RBM5	-0.49	-11.97	-0.43	6.16e-30	Body mass index;
BRCA	cis	rs1891275	0.515	rs10786010	chr10:93443773	G/A	cg07889827	chr10:93443413	NA	-0.44	-12.37	-0.44	1.2e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg12463550	chr7:65579703	CRCP	0.38	8.12	0.31	2.38e-15	Aortic root size;
BRCA	cis	rs10046574	0.519	rs17403948	chr7:135215169	C/T	cg27474649	chr7:135195673	CNOT4	-0.64	-10.69	-0.39	1.17e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.82	0.55	8.15e-53	Axial length;
BRCA	trans	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg25214090	chr10:38739885	LOC399744	0.56	12.85	0.45	9.28e-34	Corneal astigmatism;
BRCA	cis	rs7246657	0.551	rs4806413	chr19:37617716	A/T	cg23950597	chr19:37808831	NA	-0.65	-9.68	-0.36	8.75e-21	Coronary artery calcification;
BRCA	trans	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-21.31	-0.64	1.47e-76	Exhaled nitric oxide output;
BRCA	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg09307838	chr4:120376055	NA	0.72	15.33	0.52	2.08e-45	Corneal astigmatism;
BRCA	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03517284	chr6:25882590	NA	-0.78	-18.61	-0.59	4.43e-62	Urate levels;
BRCA	cis	rs6973256	0.897	rs7776986	chr7:133345635	A/G	cg07491979	chr7:133331646	EXOC4	-0.36	-8.46	-0.32	1.89e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg18252515	chr7:66147081	NA	-1.07	-15.5	-0.52	3.05e-46	Diabetic kidney disease;
BRCA	trans	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg26043149	chr18:55253948	FECH	1.1	23.28	0.68	2.89e-87	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg23173402	chr1:227635558	NA	-0.45	-8.33	-0.31	4.89e-16	Major depressive disorder;
BRCA	trans	rs61931739	0.570	rs7315655	chr12:33912869	G/A	cg26384229	chr12:38710491	ALG10B	0.4	8.98	0.33	3.05e-18	Morning vs. evening chronotype;
BRCA	trans	rs2797160	1.000	rs2747724	chr6:126004935	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.35	-7.83	-0.3	2.01e-14	Endometrial cancer;
BRCA	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg16006841	chr5:176797999	RGS14	0.58	11.7	0.42	9.01e-29	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs9296092	0.538	rs9461879	chr6:33516907	C/T	cg13560919	chr6:33536144	NA	-0.85	-17.45	-0.57	4.51e-56	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg13010199	chr12:38710504	ALG10B	0.51	10.57	0.39	3.6e-24	Bladder cancer;
BRCA	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	26.42	0.72	1.58e-104	Chronic sinus infection;
BRCA	cis	rs495337	0.760	rs515686	chr20:48515789	G/A	cg17835207	chr20:48524531	SPATA2	-0.67	-15.9	-0.53	3.16e-48	Psoriasis;
BRCA	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.05	16.21	0.54	9.29e-50	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg04117972	chr1:227635322	NA	0.45	8.16	0.31	1.82e-15	Major depressive disorder;
BRCA	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	11.96	0.43	6.84e-30	Iron status biomarkers;
BRCA	trans	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg25214090	chr10:38739885	LOC399744	0.53	11.47	0.41	7.94e-28	Corneal astigmatism;
BRCA	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg15934090	chr1:100435551	SLC35A3	0.36	8.38	0.31	3.28e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg14863265	chr7:2801509	GNA12	-0.47	-10.02	-0.37	4.93e-22	Height;
BRCA	cis	rs943466	1.000	rs12524768	chr6:33760478	G/A	cg25922239	chr6:33757077	LEMD2	-0.37	-8.35	-0.31	4.17e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs1355223	0.545	rs7123029	chr11:34874815	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-9.48	-0.35	4.85e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.04	-0.3	4.31e-15	Total body bone mineral density;
BRCA	cis	rs9392556	0.829	rs660560	chr6:4125941	A/G	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.38	-8.2	-0.31	1.3e-15	Blood metabolite levels;
BRCA	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.7	-0.39	1.12e-24	Tonsillectomy;
BRCA	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs877529	0.967	rs139386	chr22:39530859	T/C	cg18708252	chr22:39545030	CBX7	-0.31	-7.99	-0.3	6.49e-15	Multiple myeloma;
BRCA	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg11502198	chr6:26597334	ABT1	0.48	9.53	0.35	3.15e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.37	0.38	2.14e-23	Motion sickness;
BRCA	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	16.77	0.55	1.48e-52	Bone mineral density;
BRCA	cis	rs2806561	0.780	rs6650086	chr1:23338384	T/C	cg19743168	chr1:23544995	NA	-0.4	-9.48	-0.35	4.96e-20	Height;
BRCA	trans	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.73	-0.36	5.73e-21	Morning vs. evening chronotype;
BRCA	cis	rs2625529	0.761	rs8028532	chr15:72348054	G/A	cg16672083	chr15:72433130	SENP8	-0.84	-17.37	-0.57	1.23e-55	Red blood cell count;
BRCA	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg21252483	chr19:49399788	TULP2	-0.51	-10.86	-0.39	2.46e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg20587970	chr11:113659929	NA	-1.23	-22.49	-0.66	5.65e-83	Hip circumference adjusted for BMI;
BRCA	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.65	-13.51	-0.47	8.93e-37	Platelet distribution width;
BRCA	cis	rs61990749	0.544	rs8003979	chr14:78211290	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.64	9.76	0.36	4.52e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs13046373	0.535	rs1911571	chr21:32031538	A/C	cg14062083	chr21:31802829	KRTAP13-4	0.36	9.88	0.36	1.65e-21	HDL cholesterol;
BRCA	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-9.12	-0.34	1e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg26248373	chr2:1572462	NA	-0.49	-9.81	-0.36	3.02e-21	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.47	10.31	0.38	3.68e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	14.75	0.5	1.35e-42	Platelet count;
BRCA	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg21252483	chr19:49399788	TULP2	-0.51	-11.08	-0.4	3.1e-26	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7617773	0.817	rs9853804	chr3:48327729	T/C	cg11946769	chr3:48343235	NME6	0.63	13.47	0.47	1.45e-36	Coronary artery disease;
BRCA	cis	rs34779708	0.931	rs11010083	chr10:35351531	C/G	cg03585969	chr10:35415529	CREM	0.48	10.12	0.37	1.94e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-11.37	-0.41	2.14e-27	Chronic sinus infection;
BRCA	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-12.91	-0.45	4.55e-34	Lymphocyte counts;
BRCA	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-8.51	-0.32	1.27e-16	Bladder cancer;
BRCA	cis	rs4664304	0.620	rs10929957	chr2:160716508	A/G	cg01092293	chr2:160761427	LY75	0.36	8.41	0.32	2.61e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg09654669	chr8:57350985	NA	-0.39	-8.74	-0.33	2.11e-17	Obesity-related traits;
BRCA	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	11.18	0.4	1.23e-26	Height;
BRCA	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg26893861	chr17:41843967	DUSP3	-1.06	-29.82	-0.76	4.49e-123	Triglycerides;
BRCA	trans	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	9.49	0.35	4.63e-20	Mean corpuscular volume;
BRCA	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-11.39	-0.41	1.69e-27	Mean corpuscular volume;
BRCA	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	11.83	0.42	2.56e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg24112000	chr20:60950667	NA	-0.55	-10.62	-0.39	2.35e-24	Colorectal cancer;
BRCA	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg06935464	chr4:38784597	TLR10	0.51	8.2	0.31	1.32e-15	Breast cancer;
BRCA	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.54	13.28	0.47	1.01e-35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg25358565	chr5:93447407	FAM172A	1.22	18.51	0.59	1.51e-61	Diabetic retinopathy;
BRCA	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg05234568	chr11:5960015	NA	-0.52	-10.33	-0.38	3.18e-23	DNA methylation (variation);
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.47	-10.13	-0.37	1.84e-22	Longevity;Endometriosis;
BRCA	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.98	0.3	6.92e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg22153745	chr1:153894579	GATAD2B	-0.5	-10.3	-0.38	4.2e-23	Total cholesterol levels;
BRCA	cis	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.18	-0.4	1.22e-26	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg20607798	chr8:58055168	NA	0.53	8.3	0.31	6.13e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.14	0.46	4.34e-35	Bipolar disorder;
BRCA	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg08601574	chr20:25228251	PYGB	-0.34	-8.04	-0.3	4.42e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg06521331	chr12:34319734	NA	-0.47	-9.1	-0.34	1.12e-18	Bladder cancer;
BRCA	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg01283332	chr5:1856932	NA	-0.33	-7.98	-0.3	6.59e-15	Cardiovascular disease risk factors;
BRCA	cis	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg07460842	chr6:66804631	NA	-1.0	-20.03	-0.62	1.21e-69	Exhaled nitric oxide output;
BRCA	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg25664220	chr3:72788482	NA	-0.51	-10.71	-0.39	1.01e-24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg16850897	chr7:100343110	ZAN	0.62	13.18	0.46	2.9e-35	Other erythrocyte phenotypes;
BRCA	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	14.49	0.5	2.52e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg13565492	chr6:43139072	SRF	-0.79	-10.95	-0.4	1.07e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg08213375	chr14:104286397	PPP1R13B	0.61	16.63	0.55	7.5e-52	Schizophrenia;
BRCA	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-13.06	-0.46	1.04e-34	Chronic sinus infection;
BRCA	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.45	-0.38	1.08e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg23978390	chr7:1156363	C7orf50	0.4	8.2	0.31	1.36e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs365132	0.905	rs10068703	chr5:176377069	T/A	cg16309518	chr5:176445507	NA	-0.53	-13.48	-0.47	1.2e-36	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg07460842	chr6:66804631	NA	-0.95	-19.1	-0.6	1.16e-64	Exhaled nitric oxide output;
BRCA	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg24747557	chr10:131355152	MGMT	-0.31	-7.81	-0.3	2.38e-14	Response to temozolomide;
BRCA	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg20908204	chr19:46285434	DMPK	-0.27	-8.11	-0.31	2.58e-15	Coronary artery disease;
BRCA	cis	rs586533	0.881	rs634379	chr11:99497472	C/T	cg22878054	chr11:99397252	CNTN5	0.32	8.11	0.31	2.64e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22496380	chr5:211416	CCDC127	-0.99	-14.41	-0.5	5.83e-41	Breast cancer;
BRCA	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg22764044	chr5:178986830	RUFY1	-0.51	-14.24	-0.49	3.53e-40	Lung cancer;
BRCA	cis	rs672059	1.000	rs522372	chr1:183157449	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.37	-8.4	-0.32	2.87e-16	Hypertriglyceridemia;
BRCA	cis	rs28595532	0.623	rs34284204	chr4:119227672	C/T	cg21605333	chr4:119757512	SEC24D	0.81	8.48	0.32	1.58e-16	Cannabis dependence symptom count;
BRCA	cis	rs9323205	0.954	rs4898682	chr14:51639577	C/T	cg23942311	chr14:51606299	NA	-0.38	-8.87	-0.33	7.22e-18	Cancer;
BRCA	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg00074818	chr8:8560427	CLDN23	0.39	8.52	0.32	1.14e-16	Obesity-related traits;
BRCA	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg27170947	chr2:26402098	FAM59B	-0.66	-11.24	-0.41	7.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.8	0.39	4.3e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg01191920	chr7:158217561	PTPRN2	-0.36	-8.62	-0.32	5.41e-17	Obesity-related traits;
BRCA	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.58	9.79	0.36	3.53e-21	Gut microbiome composition (summer);
BRCA	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg07741184	chr6:167504864	NA	0.28	8.07	0.3	3.58e-15	Crohn's disease;
BRCA	cis	rs708547	0.647	rs1718830	chr4:57888510	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.38	9.81	0.36	2.89e-21	Response to bleomycin (chromatid breaks);
BRCA	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg04990556	chr1:26633338	UBXN11	0.54	8.77	0.33	1.64e-17	Obesity-related traits;
BRCA	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19626725	chr5:178986131	RUFY1	0.35	10.72	0.39	9.34e-25	Lung cancer;
BRCA	cis	rs9296092	0.517	rs3912041	chr6:33521271	T/C	cg13560919	chr6:33536144	NA	-0.85	-18.66	-0.59	2.26e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs738321	0.790	rs4820317	chr22:38543287	T/C	cg20207973	chr22:38506712	BAIAP2L2	0.37	9.21	0.34	4.72e-19	Breast cancer;
BRCA	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-10.63	-0.39	2.11e-24	Gut microbiome composition (summer);
BRCA	trans	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17712092	chr4:129076599	LARP1B	0.62	14.61	0.5	6.27e-42	Eosinophil percentage of white cells;
BRCA	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-11.43	-0.41	1.18e-27	Platelet count;
BRCA	cis	rs7737355	1.000	rs11242077	chr5:130771037	G/A	cg06307176	chr5:131281290	NA	-0.53	-10.33	-0.38	3.07e-23	Life satisfaction;
BRCA	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.12	-0.43	1.38e-30	Total cholesterol levels;
BRCA	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.05	0.37	3.72e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg07636037	chr3:49044803	WDR6	-0.6	-8.16	-0.31	1.84e-15	Cognitive function;
BRCA	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg24130564	chr14:104152367	KLC1	0.39	8.94	0.33	4.31e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs708547	0.671	rs1718863	chr4:57887586	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.38	9.79	0.36	3.44e-21	Response to bleomycin (chromatid breaks);
BRCA	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-11.69	-0.42	9.71e-29	Schizophrenia;
BRCA	cis	rs701145	0.878	rs355774	chr3:154036196	A/G	cg17054900	chr3:154042577	DHX36	0.68	11.88	0.43	1.56e-29	Coronary artery disease;
BRCA	cis	rs12949688	0.967	rs7220397	chr17:55823522	C/G	cg12582317	chr17:55822272	NA	0.32	7.93	0.3	9.64e-15	Schizophrenia;
BRCA	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg18252515	chr7:66147081	NA	-0.42	-9.05	-0.34	1.75e-18	Corneal structure;
BRCA	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg02659138	chr7:134003124	SLC35B4	0.32	10.09	0.37	2.59e-22	Mean platelet volume;
BRCA	cis	rs829883	0.966	rs249815	chr12:98893709	A/G	cg25150519	chr12:98850993	NA	0.59	11.9	0.43	1.19e-29	Colorectal adenoma (advanced);
BRCA	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.22	-0.31	1.13e-15	Depression;
BRCA	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg13073564	chr4:8508604	NA	0.31	7.82	0.3	2.11e-14	Response to antineoplastic agents;
BRCA	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg11812906	chr14:75593930	NEK9	-0.6	-13.7	-0.48	1.22e-37	Height;
BRCA	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.55	17.84	0.58	4.29e-58	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs243505	0.559	rs10215159	chr7:148479071	G/C	cg09806900	chr7:148480153	CUL1	0.56	11.31	0.41	3.71e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg19418458	chr7:158789849	NA	0.44	9.85	0.36	2.16e-21	Facial morphology (factor 20);
BRCA	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg20607798	chr8:58055168	NA	0.47	8.35	0.31	4.28e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7247513	1.000	rs7247513	chr19:12691185	C/T	cg01871581	chr19:12707946	ZNF490	-0.7	-16.54	-0.55	2.07e-51	Bipolar disorder;
BRCA	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-8.76	-0.33	1.79e-17	Monocyte percentage of white cells;
BRCA	cis	rs10949834	0.793	rs810534	chr7:73505045	A/G	cg07137043	chr7:73588983	EIF4H	0.51	8.06	0.3	3.87e-15	Verbal memory performance (residualized delayed recall change);
BRCA	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00149659	chr3:10157352	C3orf10	0.82	14.4	0.49	6.66e-41	Alzheimer's disease;
BRCA	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg02733842	chr7:1102375	C7orf50	-0.64	-12.44	-0.44	5.73e-32	Bronchopulmonary dysplasia;
BRCA	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.45	10.2	0.37	9.64e-23	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg15839431	chr19:19639596	YJEFN3	-0.43	-9.25	-0.34	3.44e-19	Bipolar disorder;
BRCA	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg14683738	chr19:37701593	ZNF585B	0.46	8.08	0.3	3.31e-15	Coronary artery calcification;
BRCA	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.76	0.33	1.7e-17	Motion sickness;
BRCA	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg06606381	chr12:133084897	FBRSL1	-0.85	-8.84	-0.33	9.03e-18	Depression;
BRCA	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.86	0.42	1.86e-29	Homoarginine levels;
BRCA	cis	rs74377301	1	rs74377301	chr7:123232495	C/T	cg03229431	chr7:123269106	ASB15	-0.61	-13.21	-0.46	2.2e-35	Left ventricular obstructive tract defect (inherited effect);
BRCA	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg06108461	chr20:60628389	TAF4	-0.8	-17.39	-0.57	9.22e-56	Body mass index;
BRCA	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.7	0.36	7.73e-21	Bipolar disorder;
BRCA	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.56	11.74	0.42	5.83e-29	Monocyte percentage of white cells;
BRCA	cis	rs72772090	0.634	rs12186366	chr5:96088850	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-13.27	-0.46	1.14e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg01028140	chr2:1542097	TPO	-0.58	-11.9	-0.43	1.19e-29	IgG glycosylation;
BRCA	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg25664220	chr3:72788482	NA	-0.55	-11.8	-0.42	3.33e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2742234	0.554	rs1254963	chr10:43696086	C/T	cg15436174	chr10:43711423	RASGEF1A	0.57	11.53	0.41	4.62e-28	Hirschsprung disease;
BRCA	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg18225595	chr11:63971243	STIP1	0.5	9.1	0.34	1.15e-18	Mean platelet volume;
BRCA	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg13256891	chr4:100009986	ADH5	0.53	9.77	0.36	4.33e-21	Alcohol dependence;
BRCA	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg00750074	chr16:89608354	SPG7	-0.38	-10.21	-0.37	9e-23	Multiple myeloma (IgH translocation);
BRCA	cis	rs1468333	1.000	rs2967782	chr5:137529682	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.43	9.19	0.34	5.64e-19	Resting heart rate;
BRCA	cis	rs6546550	0.867	rs4401231	chr2:70063563	G/C	cg02498382	chr2:70120550	SNRNP27	-0.51	-10.63	-0.39	2.05e-24	Prevalent atrial fibrillation;
BRCA	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg14558114	chr2:88469736	THNSL2	0.63	9.12	0.34	9.38e-19	Plasma clusterin levels;
BRCA	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04267008	chr7:1944627	MAD1L1	-0.52	-11.05	-0.4	4.37e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg14683738	chr19:37701593	ZNF585B	0.44	7.86	0.3	1.63e-14	Coronary artery calcification;
BRCA	cis	rs7953249	0.935	rs7135337	chr12:121404155	A/C	cg02403541	chr12:121454288	C12orf43	-0.39	-8.01	-0.3	5.43e-15	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
BRCA	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg08859206	chr1:53392774	SCP2	-0.42	-8.43	-0.32	2.36e-16	Monocyte count;
BRCA	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg20503657	chr10:835505	NA	1.0	15.57	0.52	1.4e-46	Eosinophil percentage of granulocytes;
BRCA	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	25.48	0.71	2.27e-99	Platelet count;
BRCA	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg13902645	chr11:5959945	NA	-0.56	-11.48	-0.41	7.11e-28	DNA methylation (variation);
BRCA	cis	rs7539409	0.915	rs4001467	chr1:84275858	A/T	cg10977910	chr1:84465055	TTLL7	-0.55	-8.17	-0.31	1.6e-15	Alzheimer's disease;
BRCA	cis	rs2625529	0.824	rs12903484	chr15:72299481	G/A	cg16672083	chr15:72433130	SENP8	-0.85	-17.97	-0.58	9.79e-59	Red blood cell count;
BRCA	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg10876282	chr6:28092338	ZSCAN16	0.42	8.38	0.31	3.4e-16	Cardiac Troponin-T levels;
BRCA	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg26384229	chr12:38710491	ALG10B	0.54	13.71	0.48	1.05e-37	Morning vs. evening chronotype;
BRCA	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg04518342	chr5:131593106	PDLIM4	0.37	9.13	0.34	9.14e-19	Breast cancer;
BRCA	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg11301795	chr4:187892539	NA	-0.31	-10.25	-0.38	6.51e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg25237894	chr2:233734115	C2orf82	0.39	11.22	0.41	8.76e-27	Coronary artery disease;
BRCA	cis	rs1538970	0.961	rs4660854	chr1:45854087	A/T	cg05343316	chr1:45956843	TESK2	0.55	11.51	0.41	5.57e-28	Platelet count;
BRCA	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08045932	chr20:61659980	NA	0.49	11.41	0.41	1.46e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2880765	0.835	rs7180213	chr15:86021187	G/A	cg10818794	chr15:86012489	AKAP13	-0.3	-8.29	-0.31	6.75e-16	Coronary artery disease;
BRCA	cis	rs6142102	0.886	rs6059583	chr20:32532114	T/G	cg24642439	chr20:33292090	TP53INP2	0.43	7.84	0.3	1.85e-14	Skin pigmentation;
BRCA	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	9.49	0.35	4.4e-20	Rheumatoid arthritis;
BRCA	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg06191203	chr2:152266755	RIF1	-0.31	-9.05	-0.34	1.67e-18	Lung cancer;
BRCA	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg23788917	chr6:8435910	SLC35B3	0.47	10.35	0.38	2.53e-23	Motion sickness;
BRCA	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.6	-14.06	-0.49	2.66e-39	Hemoglobin concentration;
BRCA	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-13.33	-0.47	6.01e-36	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg23711669	chr6:146136114	FBXO30	0.77	17.3	0.56	2.73e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2625529	0.824	rs7182776	chr15:72462831	A/G	cg16672083	chr15:72433130	SENP8	0.73	16.59	0.55	1.16e-51	Red blood cell count;
BRCA	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg15934090	chr1:100435551	SLC35A3	0.35	8.16	0.31	1.83e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.29	-0.41	4.62e-27	Gut microbiome composition (summer);
BRCA	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11644478	chr21:40555479	PSMG1	-0.52	-10.88	-0.4	2.07e-25	Menarche (age at onset);
BRCA	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg13902645	chr11:5959945	NA	-0.57	-11.57	-0.42	3.16e-28	DNA methylation (variation);
BRCA	cis	rs208520	0.690	rs864314	chr6:66814830	G/A	cg07460842	chr6:66804631	NA	-1.16	-37.74	-0.83	8.76e-165	Exhaled nitric oxide output;
BRCA	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg06713675	chr4:122721982	EXOSC9	-0.53	-12.43	-0.44	6.6e-32	Type 2 diabetes;
BRCA	cis	rs1577917	0.958	rs28442244	chr6:86701236	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.44	11.84	0.42	2.29e-29	Response to antipsychotic treatment;
BRCA	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg11764359	chr7:65958608	NA	0.65	11.75	0.42	5.35e-29	Aortic root size;
BRCA	trans	rs4650994	1.000	rs10798616	chr1:178515642	G/C	cg05059571	chr16:84539110	KIAA1609	-0.43	-9.77	-0.36	4.24e-21	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs72627509	0.904	rs7687767	chr4:57824932	C/T	cg26694713	chr4:57773883	REST	-0.5	-9.72	-0.36	6.3e-21	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg04511125	chr2:88470314	THNSL2	-0.45	-9.21	-0.34	4.63e-19	Response to metformin (IC50);
BRCA	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg09455208	chr3:40491958	NA	0.39	9.28	0.34	2.58e-19	Renal cell carcinoma;
BRCA	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg11502198	chr6:26597334	ABT1	0.58	12.51	0.44	2.71e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg06115741	chr20:33292138	TP53INP2	0.46	10.37	0.38	2.11e-23	Coronary artery disease;
BRCA	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg19539972	chr4:7069911	GRPEL1	-0.62	-12.07	-0.43	2.35e-30	Monocyte percentage of white cells;
BRCA	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-9.01	-0.34	2.37e-18	Chronic sinus infection;
BRCA	cis	rs738321	0.757	rs2284062	chr22:38544221	A/G	cg20207973	chr22:38506712	BAIAP2L2	0.38	9.39	0.35	1e-19	Breast cancer;
BRCA	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.05	0.3	3.95e-15	Menarche (age at onset);
BRCA	cis	rs78487399	0.908	rs73925554	chr2:43810739	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-7.86	-0.3	1.66e-14	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs4363385	0.747	rs6689609	chr1:152967588	G/A	cg25856811	chr1:152973957	SPRR3	-0.36	-9.64	-0.36	1.28e-20	Inflammatory skin disease;
BRCA	cis	rs1355223	0.506	rs7131272	chr11:34869548	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.48	9.29	0.35	2.32e-19	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	trans	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.1	0.31	2.74e-15	Mean corpuscular volume;
BRCA	cis	rs6723226	0.842	rs1901355	chr2:32835664	A/G	cg02381751	chr2:32503542	YIPF4	-0.57	-11.35	-0.41	2.4e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs7011049	1.000	rs77668788	chr8:53856407	C/T	cg26025543	chr8:53854495	NA	0.55	9.49	0.35	4.66e-20	Systolic blood pressure;
BRCA	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg08888203	chr3:10149979	C3orf24	0.66	14.05	0.49	2.73e-39	Alzheimer's disease;
BRCA	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg00540400	chr15:79124168	NA	0.28	7.97	0.3	7.19e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs6430585	0.759	rs4954623	chr2:136535876	G/A	cg07169764	chr2:136633963	MCM6	-1.08	-22.04	-0.66	1.76e-80	Corneal structure;
BRCA	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg20129853	chr10:51489980	NA	-0.32	-8.34	-0.31	4.57e-16	Prostate-specific antigen levels;
BRCA	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-12.95	-0.46	3.16e-34	Migraine;Coronary artery disease;
BRCA	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.44	-9.41	-0.35	8.99e-20	Iron status biomarkers;
BRCA	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.13	-0.37	1.85e-22	IgG glycosylation;
BRCA	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18404041	chr3:52824283	ITIH1	0.52	16.42	0.54	8.26e-51	Bipolar disorder;
BRCA	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	trans	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg06521331	chr12:34319734	NA	-0.51	-9.09	-0.34	1.2e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg11608241	chr8:8085544	FLJ10661	-0.37	-10.17	-0.37	1.28e-22	Neuroticism;
BRCA	cis	rs6740322	0.843	rs6727237	chr2:43562000	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-12.03	-0.43	3.49e-30	Coronary artery disease;
BRCA	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg26816564	chr1:7831052	VAMP3	0.73	12.92	0.46	4.29e-34	Inflammatory bowel disease;
BRCA	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg24060327	chr5:131705240	SLC22A5	-0.46	-9.15	-0.34	7.57e-19	Acylcarnitine levels;
BRCA	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg25319279	chr11:5960081	NA	-0.44	-8.55	-0.32	9.13e-17	DNA methylation (variation);
BRCA	cis	rs7973719	0.868	rs12825629	chr12:7355583	T/C	cg07052231	chr12:7363540	PEX5	0.36	8.17	0.31	1.66e-15	IgG glycosylation;
BRCA	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg10523679	chr1:76189770	ACADM	-0.61	-11.66	-0.42	1.34e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg21659725	chr3:3221576	CRBN	-0.46	-8.54	-0.32	9.54e-17	Menarche (age at onset);
BRCA	trans	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg06521331	chr12:34319734	NA	-0.53	-9.45	-0.35	6.4e-20	Bladder cancer;
BRCA	cis	rs9300255	0.679	rs28583837	chr12:123863620	G/A	cg00376283	chr12:123451042	ABCB9	-0.52	-10.65	-0.39	1.74e-24	Neutrophil percentage of white cells;
BRCA	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg21427119	chr20:30132790	HM13	-0.41	-8.75	-0.33	1.93e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg03433033	chr1:76189801	ACADM	-0.74	-16.28	-0.54	4.36e-50	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4363385	0.747	rs1015995	chr1:152976114	G/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.32	-0.31	5.23e-16	Inflammatory skin disease;
BRCA	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg26384229	chr12:38710491	ALG10B	0.74	17.39	0.57	1.01e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs28830936	1.000	rs17678767	chr15:42096422	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.37	-10.09	-0.37	2.67e-22	Diastolic blood pressure;
BRCA	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg16606324	chr3:10149918	C3orf24	0.5	9.56	0.35	2.53e-20	Alzheimer's disease;
BRCA	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg20108693	chr8:143823809	SLURP1	0.26	7.83	0.3	1.99e-14	Urinary tract infection frequency;
BRCA	trans	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg07211511	chr3:129823064	LOC729375	-0.6	-10.94	-0.4	1.23e-25	Blood pressure (smoking interaction);
BRCA	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.81e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4664304	1.000	rs55977890	chr2:160776866	C/T	cg02280532	chr2:160761244	LY75	-0.38	-8.41	-0.32	2.71e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg03929089	chr4:120376271	NA	0.61	10.56	0.39	3.97e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg27279351	chr12:120934652	DYNLL1	0.56	13.41	0.47	2.63e-36	High light scatter reticulocyte count;
BRCA	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg06484146	chr7:12443880	VWDE	-0.75	-10.63	-0.39	2.15e-24	Coronary artery disease;
BRCA	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg11845111	chr2:191398756	TMEM194B	-0.71	-13.83	-0.48	2.95e-38	Diastolic blood pressure;
BRCA	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg11845111	chr2:191398756	TMEM194B	-0.71	-13.61	-0.47	3.01e-37	Diastolic blood pressure;
BRCA	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg08000102	chr2:233561755	GIGYF2	-0.63	-13.61	-0.47	3.18e-37	Coronary artery disease;
BRCA	cis	rs12579753	0.917	rs12311988	chr12:82177209	C/A	cg07988820	chr12:82153109	PPFIA2	-0.47	-8.09	-0.3	3.05e-15	Resting heart rate;
BRCA	cis	rs738322	0.804	rs2076116	chr22:38517405	A/G	cg20207973	chr22:38506712	BAIAP2L2	0.39	10.22	0.37	7.86e-23	Cutaneous nevi;
BRCA	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg18154014	chr19:37997991	ZNF793	0.48	9.56	0.35	2.54e-20	Coronary artery calcification;
BRCA	cis	rs6088813	0.922	rs4911493	chr20:33960799	A/G	cg14752227	chr20:34000481	UQCC	-0.42	-8.95	-0.33	3.77e-18	Height;
BRCA	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg03709012	chr19:19516395	GATAD2A	0.8	18.71	0.6	1.21e-62	Tonsillectomy;
BRCA	cis	rs7408868	1.000	rs7247906	chr19:15271135	T/G	cg14696996	chr19:15285081	NOTCH3	0.99	14.46	0.5	3.39e-41	Pulse pressure;
BRCA	cis	rs329648	0.667	rs11223616	chr11:133772838	C/T	cg03392386	chr11:133800800	IGSF9B	0.39	8.11	0.31	2.62e-15	Parkinson's disease;
BRCA	cis	rs7580658	0.963	rs62157555	chr2:128107176	C/T	cg09760422	chr2:128146352	NA	-0.35	-7.88	-0.3	1.43e-14	Protein C levels;
BRCA	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg17425144	chr1:10567563	PEX14	0.47	11.39	0.41	1.73e-27	Prostate cancer;
BRCA	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg23992470	chr4:843637	GAK	0.54	8.16	0.31	1.84e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg09307838	chr4:120376055	NA	0.72	15.32	0.52	2.36e-45	Corneal astigmatism;
BRCA	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	18.18	0.58	7.82e-60	Platelet count;
BRCA	cis	rs10193935	0.901	rs1044562	chr2:42516884	C/G	cg27598129	chr2:42591480	NA	-0.92	-14.7	-0.5	2.33e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg22920501	chr2:26401640	FAM59B	0.94	16.23	0.54	7.34e-50	Gut microbiome composition (summer);
BRCA	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.57	11.02	0.4	5.42e-26	HDL cholesterol;
BRCA	cis	rs7737355	0.947	rs13163091	chr5:130836041	A/G	cg06307176	chr5:131281290	NA	-0.51	-10.24	-0.38	6.83e-23	Life satisfaction;
BRCA	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg06640241	chr16:89574553	SPG7	0.86	22.17	0.66	3.15e-81	Multiple myeloma (IgH translocation);
BRCA	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg06494592	chr3:125709126	NA	-0.52	-8.14	-0.31	2.08e-15	Blood pressure (smoking interaction);
BRCA	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-7.97	-0.3	7.2e-15	Obesity-related traits;
BRCA	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21659725	chr3:3221576	CRBN	0.5	12.61	0.45	9.97e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs3815700	1.000	rs3815700	chr19:33093252	T/C	cg02997394	chr19:33096574	ANKRD27	0.69	11.5	0.41	6.21e-28	Eosinophilic esophagitis;
BRCA	cis	rs2836950	0.805	rs62223042	chr21:40683740	A/G	cg11644478	chr21:40555479	PSMG1	-0.42	-8.28	-0.31	7.08e-16	Menarche (age at onset);
BRCA	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg02931644	chr1:25747376	RHCE	0.4	11.34	0.41	2.83e-27	Erythrocyte sedimentation rate;
BRCA	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg05340658	chr4:99064831	C4orf37	0.62	14.58	0.5	8.71e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg02574844	chr11:5959923	NA	-0.42	-8.29	-0.31	6.93e-16	DNA methylation (variation);
BRCA	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.87	0.4	2.17e-25	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg13565492	chr6:43139072	SRF	-0.87	-15.94	-0.53	1.99e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9649465	0.934	rs34030532	chr7:123274992	A/G	cg03229431	chr7:123269106	ASB15	-0.36	-8.37	-0.31	3.59e-16	Migraine;
BRCA	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg23708337	chr7:1209742	NA	0.51	8.71	0.33	2.56e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1577917	0.917	rs1584273	chr6:86524577	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.54	-0.42	4.21e-28	Response to antipsychotic treatment;
BRCA	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg13550731	chr2:172543902	DYNC1I2	0.89	27.6	0.74	5.37e-111	Schizophrenia;
BRCA	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg06627628	chr2:24431161	ITSN2	-0.66	-12.14	-0.43	1.13e-30	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18876405	chr7:65276391	NA	0.48	10.83	0.39	3.43e-25	Aortic root size;
BRCA	cis	rs9443189	0.570	rs7770824	chr6:76408189	G/A	cg01950844	chr6:76311363	SENP6	0.84	13.57	0.47	5.09e-37	Prostate cancer;
BRCA	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg26893861	chr17:41843967	DUSP3	1.07	31.68	0.78	3.92e-133	Triglycerides;
BRCA	cis	rs9297145	0.585	rs10953281	chr7:98772131	C/T	cg05967295	chr7:98741636	SMURF1	-0.61	-13.92	-0.48	1.13e-38	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs7617773	0.780	rs6793239	chr3:48351618	G/T	cg11946769	chr3:48343235	NME6	0.69	14.01	0.48	4.54e-39	Coronary artery disease;
BRCA	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg14019146	chr3:50243930	SLC38A3	-0.68	-16.96	-0.56	1.47e-53	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-12.58	-0.45	1.41e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05901451	chr6:126070800	HEY2	0.41	9.84	0.36	2.37e-21	Endometrial cancer;
BRCA	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.89	-0.48	1.66e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg25036284	chr2:26402008	FAM59B	-0.63	-10.22	-0.37	8.23e-23	Gut microbiome composition (summer);
BRCA	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg00105475	chr2:10696890	NA	-0.39	-8.91	-0.33	5.27e-18	Prostate cancer;
BRCA	trans	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	27.71	0.74	1.28e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	8.36	0.31	3.8e-16	Personality dimensions;
BRCA	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg21905437	chr5:178450457	ZNF879	0.5	10.59	0.39	2.93e-24	Pubertal anthropometrics;
BRCA	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	12.95	0.46	3.3e-34	Personality dimensions;
BRCA	cis	rs35740288	0.929	rs3858927	chr15:86301616	C/G	cg20737812	chr15:86336631	KLHL25	-0.32	-8.01	-0.3	5.53e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg03060546	chr3:49711283	APEH	0.58	8.42	0.32	2.57e-16	Menarche (age at onset);
BRCA	cis	rs6598955	0.543	rs6699798	chr1:26556442	G/T	cg04990556	chr1:26633338	UBXN11	0.71	11.98	0.43	5.61e-30	Obesity-related traits;
BRCA	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.82	16.6	0.55	1.03e-51	HIV-1 control;
BRCA	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg03733263	chr8:22462867	KIAA1967	0.79	17.9	0.58	2.27e-58	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg00631329	chr6:26305371	NA	-0.44	-13.0	-0.46	1.8e-34	Educational attainment;
BRCA	trans	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg25214090	chr10:38739885	LOC399744	0.44	10.29	0.38	4.34e-23	Corneal astigmatism;
BRCA	cis	rs7577696	0.568	rs177082	chr2:32438350	A/T	cg02381751	chr2:32503542	YIPF4	0.47	8.59	0.32	6.72e-17	Inflammatory biomarkers;
BRCA	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg23711669	chr6:146136114	FBXO30	-0.77	-17.86	-0.58	3.55e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-11.11	-0.4	2.42e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504073	0.647	rs2292399	chr8:49987230	A/G	cg00325661	chr8:49890786	NA	0.44	12.52	0.44	2.55e-32	Blood metabolite ratios;
BRCA	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.08e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg10523679	chr1:76189770	ACADM	0.63	10.29	0.38	4.49e-23	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9308433	0.529	rs4655244	chr1:214497580	A/G	cg06198575	chr1:214491504	SMYD2	0.56	12.24	0.44	4.43e-31	IgG glycosylation;
BRCA	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.05	-19.05	-0.6	1.99e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg25482853	chr8:67687455	SGK3	1.02	17.31	0.56	2.46e-55	Lung disease severity in cystic fibrosis;
BRCA	cis	rs4919087	0.926	rs953097	chr10:98981914	T/C	cg25902810	chr10:99078978	FRAT1	0.41	8.82	0.33	1.07e-17	Monocyte count;
BRCA	cis	rs12611088	0.602	rs2599455	chr19:44025235	T/A	cg15012607	chr19:44012195	ETHE1	-0.34	-8.31	-0.31	5.57e-16	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs654351	0.572	rs556578	chr6:10388755	T/C	cg17959970	chr6:10383164	NA	-0.41	-8.55	-0.32	8.77e-17	Squamous cell lung carcinoma;
BRCA	cis	rs778371	0.723	rs35491427	chr2:233688542	C/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-17.01	-0.56	8.62e-54	Schizophrenia;
BRCA	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg08213375	chr14:104286397	PPP1R13B	0.66	18.7	0.59	1.49e-62	Schizophrenia;
BRCA	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.18	-0.31	1.54e-15	Total body bone mineral density;
BRCA	cis	rs754466	0.914	rs4595491	chr10:79685833	G/A	cg17075019	chr10:79541650	NA	-0.63	-11.97	-0.43	6.22e-30	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg13010199	chr12:38710504	ALG10B	0.4	9.17	0.34	6.36e-19	Morning vs. evening chronotype;
BRCA	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg16479474	chr6:28041457	NA	0.42	7.82	0.3	2.18e-14	Parkinson's disease;
BRCA	cis	rs12541635	0.966	rs1496182	chr8:107024505	C/T	cg10147462	chr8:107024639	NA	0.37	10.39	0.38	1.73e-23	Age of smoking initiation;
BRCA	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg13010199	chr12:38710504	ALG10B	0.43	9.16	0.34	6.75e-19	Morning vs. evening chronotype;
BRCA	cis	rs4268898	0.552	rs11125454	chr2:24373669	T/C	cg06627628	chr2:24431161	ITSN2	0.41	8.61	0.32	5.54e-17	Asthma;
BRCA	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg05340658	chr4:99064831	C4orf37	0.5	10.86	0.39	2.59e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg23131131	chr22:24373011	LOC391322	-0.46	-11.07	-0.4	3.39e-26	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg00080972	chr5:178986291	RUFY1	0.51	14.01	0.48	4.23e-39	Lung cancer;
BRCA	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12292205	chr6:26970375	C6orf41	-0.48	-8.25	-0.31	8.81e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg12573674	chr2:1569213	NA	-0.54	-11.41	-0.41	1.46e-27	IgG glycosylation;
BRCA	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg25036284	chr2:26402008	FAM59B	-0.96	-16.12	-0.54	2.62e-49	Gut microbiome composition (summer);
BRCA	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg16414030	chr3:133502952	NA	-0.54	-12.51	-0.44	2.88e-32	Iron status biomarkers;
BRCA	cis	rs16866061	1.000	rs11694987	chr2:225397409	C/G	cg12698349	chr2:225449008	CUL3	0.74	18.5	0.59	1.72e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	9.13	0.34	8.91e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg09904177	chr6:26538194	HMGN4	0.43	13.28	0.46	1.06e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs11920090	0.722	rs5404	chr3:170724955	A/G	cg09710316	chr3:170744871	SLC2A2	-0.57	-9.94	-0.37	9.37e-22	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg09658497	chr7:2847517	GNA12	-0.41	-8.62	-0.32	5.29e-17	Height;
BRCA	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg23625390	chr15:77176239	SCAPER	-0.51	-12.95	-0.46	3.12e-34	Blood metabolite levels;
BRCA	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.5	11.2	0.41	9.96e-27	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs4845875	0.563	rs11121829	chr1:11834765	A/G	cg24844545	chr1:11908347	NPPA	0.37	8.53	0.32	1.05e-16	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg04362960	chr10:104952993	NT5C2	0.4	9.57	0.35	2.2e-20	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs7580658	0.963	rs10803585	chr2:128130108	G/A	cg09760422	chr2:128146352	NA	-0.35	-7.84	-0.3	1.83e-14	Protein C levels;
BRCA	trans	rs8002861	0.664	rs9567292	chr13:44444816	A/G	cg17145862	chr1:211918768	LPGAT1	0.48	10.82	0.39	3.68e-25	Leprosy;
BRCA	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03264133	chr6:25882463	NA	0.43	9.05	0.34	1.73e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs13315871	1.000	rs12330157	chr3:58364562	C/T	cg20936604	chr3:58311152	NA	-0.62	-7.94	-0.3	9.28e-15	Cholesterol, total;
BRCA	cis	rs9359856	0.564	rs17228548	chr6:90439164	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.71	-8.58	-0.32	7.04e-17	Bipolar disorder;
BRCA	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg23505145	chr19:12996616	KLF1	0.53	12.23	0.44	4.91e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg06637938	chr14:75390232	RPS6KL1	0.58	12.3	0.44	2.4e-31	Caffeine consumption;
BRCA	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg07636037	chr3:49044803	WDR6	-0.59	-8.13	-0.31	2.31e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.68	0.57	3.11e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg02176678	chr2:219576539	TTLL4	-0.54	-13.62	-0.47	2.78e-37	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs9290065	0.519	rs6808386	chr3:160673263	A/T	cg03342759	chr3:160939853	NMD3	-0.46	-9.37	-0.35	1.22e-19	Kawasaki disease;
BRCA	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg24692254	chr21:30365293	RNF160	0.79	22.31	0.66	5.3e-82	Dental caries;
BRCA	cis	rs8077889	0.763	rs4792913	chr17:41854497	T/C	cg26893861	chr17:41843967	DUSP3	0.9	23.21	0.68	6.78e-87	Triglycerides;
BRCA	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg20607798	chr8:58055168	NA	0.45	7.88	0.3	1.38e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg21143896	chr7:2802374	GNA12	-0.37	-9.33	-0.35	1.7e-19	Height;
BRCA	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23583168	chr7:148888333	NA	0.85	19.95	0.62	3.23e-69	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-11.76	-0.42	5.05e-29	Brugada syndrome;
BRCA	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.29	0.31	6.59e-16	Aortic root size;
BRCA	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.4	8.39	0.32	3.08e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	9.2	0.34	5.08e-19	Systemic lupus erythematosus;
BRCA	cis	rs12611088	0.515	rs2599454	chr19:44025201	T/C	cg13740135	chr19:44006432	PHLDB3	-0.3	-7.88	-0.3	1.39e-14	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	trans	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.61	10.81	0.39	3.81e-25	Type 2 diabetes;
BRCA	cis	rs7851660	0.967	rs7851552	chr9:100610652	C/A	cg13688889	chr9:100608707	NA	-0.36	-8.7	-0.33	2.81e-17	Strep throat;
BRCA	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11764359	chr7:65958608	NA	0.6	12.91	0.45	4.97e-34	Aortic root size;
BRCA	cis	rs11971779	0.715	rs55714903	chr7:139074590	T/C	cg07862535	chr7:139043722	LUC7L2	0.41	11.16	0.4	1.46e-26	Diisocyanate-induced asthma;
BRCA	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg23708337	chr7:1209742	NA	0.37	7.8	0.3	2.44e-14	Longevity;Endometriosis;
BRCA	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg03342759	chr3:160939853	NMD3	-0.64	-13.34	-0.47	5.41e-36	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.818	rs382653	chr1:153006761	G/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.18e-19	Inflammatory skin disease;
BRCA	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg07988820	chr12:82153109	PPFIA2	-0.63	-10.8	-0.39	4.46e-25	Resting heart rate;
BRCA	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg24829409	chr8:58192753	C8orf71	-0.46	-7.85	-0.3	1.78e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg04166393	chr7:2884313	GNA12	0.49	9.39	0.35	1.03e-19	Height;
BRCA	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg05294307	chr14:35346193	BAZ1A	-0.63	-10.5	-0.38	6.59e-24	Psoriasis;
BRCA	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg04709771	chr16:646395	RAB40C	0.42	10.4	0.38	1.7e-23	Height;
BRCA	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.63	0.36	1.43e-20	Menopause (age at onset);
BRCA	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg12893428	chr3:195717962	SDHAP1	0.33	8.2	0.31	1.34e-15	Pancreatic cancer;
BRCA	cis	rs7631605	0.905	rs1468713	chr3:37106115	A/G	cg15934958	chr3:37212084	LRRFIP2	0.46	10.74	0.39	7.41e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg00071950	chr4:10020882	SLC2A9	0.57	14.21	0.49	5.29e-40	Bone mineral density;
BRCA	cis	rs17401966	0.838	rs9332414	chr1:10326963	C/T	cg03954927	chr1:10346856	KIF1B	0.43	13.95	0.48	8.08e-39	Hepatocellular carcinoma;
BRCA	cis	rs757081	0.671	rs214090	chr11:17297161	C/T	cg15432903	chr11:17409602	KCNJ11	-0.47	-8.1	-0.31	2.75e-15	Systolic blood pressure;
BRCA	cis	rs13102973	0.965	rs13108037	chr4:135885643	A/G	cg14419869	chr4:135874104	NA	-0.5	-10.52	-0.38	5.72e-24	Subjective well-being;
BRCA	cis	rs2249625	0.545	rs2249021	chr6:72889472	A/G	cg18830697	chr6:72922368	RIMS1	-0.63	-14.34	-0.49	1.19e-40	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs9287719	0.649	rs11684537	chr2:10734832	C/T	cg00105475	chr2:10696890	NA	0.42	9.42	0.35	8.18e-20	Prostate cancer;
BRCA	cis	rs2066819	1.000	rs11171806	chr12:56733531	A/G	cg26714650	chr12:56694279	CS	1.18	15.57	0.52	1.35e-46	Psoriasis vulgaris;
BRCA	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg22907277	chr7:1156413	C7orf50	0.59	9.19	0.34	5.4e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7809950	0.954	rs3779494	chr7:107250355	G/A	cg23024343	chr7:107201750	COG5	0.41	8.94	0.33	4.19e-18	Coronary artery disease;
BRCA	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-11.14	-0.4	1.77e-26	Personality dimensions;
BRCA	cis	rs897080	0.515	rs786417	chr2:44688766	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	9.95	0.37	8.78e-22	Height;
BRCA	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg25036284	chr2:26402008	FAM59B	-0.95	-16.1	-0.54	3.42e-49	Gut microbiome composition (summer);
BRCA	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg18252515	chr7:66147081	NA	-0.96	-10.69	-0.39	1.15e-24	Gout;
BRCA	cis	rs4742903	0.967	rs7871759	chr9:106865438	A/G	cg21169611	chr9:106856078	SMC2	0.36	9.43	0.35	7.52e-20	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs858239	0.601	rs929507	chr7:23166664	G/C	cg23682824	chr7:23144976	KLHL7	0.45	11.94	0.43	8.21e-30	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg21138405	chr5:131827807	IRF1	0.39	12.9	0.45	5.51e-34	Asthma (sex interaction);
BRCA	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg14844989	chr11:31128820	NA	-0.45	-9.66	-0.36	1.11e-20	Red blood cell count;
BRCA	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg16482183	chr6:26056742	HIST1H1C	0.5	10.23	0.38	7.45e-23	Height;
BRCA	cis	rs1941023	0.503	rs11230288	chr11:60128968	G/A	cg08716584	chr11:60157161	MS4A7	-0.42	-9.91	-0.36	1.28e-21	Congenital heart disease (maternal effect);
BRCA	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg21770322	chr7:97807741	LMTK2	0.45	11.78	0.42	4.14e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs17253792	0.822	rs10147380	chr14:56054354	T/C	cg01858014	chr14:56050164	KTN1	-0.73	-10.81	-0.39	3.79e-25	Putamen volume;
BRCA	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	17.27	0.56	3.83e-55	Alzheimer's disease;
BRCA	cis	rs6496044	0.568	rs12898783	chr15:86066100	G/C	cg10818794	chr15:86012489	AKAP13	-0.29	-7.91	-0.3	1.1e-14	Interstitial lung disease;
BRCA	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg06159980	chr1:16340746	HSPB7	-0.38	-7.86	-0.3	1.63e-14	Dilated cardiomyopathy;
BRCA	cis	rs7851660	0.933	rs13302470	chr9:100615553	A/G	cg13688889	chr9:100608707	NA	-0.36	-8.72	-0.33	2.42e-17	Strep throat;
BRCA	cis	rs12541635	0.677	rs10086055	chr8:107024129	C/T	cg10147462	chr8:107024639	NA	0.37	10.13	0.37	1.89e-22	Age of smoking initiation;
BRCA	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg22920501	chr2:26401640	FAM59B	-0.65	-11.24	-0.41	7.02e-27	Gut microbiome composition (summer);
BRCA	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg13770153	chr20:60521292	NA	-0.45	-10.4	-0.38	1.71e-23	Body mass index;
BRCA	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg20224285	chr3:52813920	ITIH1	0.32	8.02	0.3	5.01e-15	Bipolar disorder;
BRCA	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.49	10.76	0.39	6.15e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9309711	0.736	rs9678647	chr2:3497036	A/G	cg10845886	chr2:3471009	TTC15	0.55	10.75	0.39	7.08e-25	Neurofibrillary tangles;
BRCA	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg08213375	chr14:104286397	PPP1R13B	0.65	18.25	0.59	3.49e-60	Schizophrenia;
BRCA	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg21427119	chr20:30132790	HM13	-0.41	-8.78	-0.33	1.53e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs941764	1.000	rs941764	chr14:91841069	C/T	cg10511902	chr14:91842949	CCDC88C	-0.43	-10.22	-0.37	8.27e-23	Breast cancer;
BRCA	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg22467129	chr15:76604101	ETFA	0.53	12.36	0.44	1.27e-31	Blood metabolite levels;
BRCA	cis	rs4363385	0.747	rs61811427	chr1:152968419	C/T	cg24667326	chr1:152973720	SPRR3	-0.35	-9.6	-0.36	1.74e-20	Inflammatory skin disease;
BRCA	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg25358565	chr5:93447407	FAM172A	1.16	18.51	0.59	1.37e-61	Diabetic retinopathy;
BRCA	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg19539972	chr4:7069911	GRPEL1	0.69	16.97	0.56	1.43e-53	Monocyte percentage of white cells;
BRCA	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg05234568	chr11:5960015	NA	-0.44	-9.54	-0.35	2.85e-20	DNA methylation (variation);
BRCA	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg00383909	chr3:49044727	WDR6	0.59	11.1	0.4	2.62e-26	Cognitive function;
BRCA	cis	rs2625529	0.730	rs2957368	chr15:72329906	C/T	cg16672083	chr15:72433130	SENP8	-0.7	-16.56	-0.55	1.55e-51	Red blood cell count;
BRCA	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg22875332	chr1:76189707	ACADM	0.61	11.64	0.42	1.57e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1691799	0.836	rs1168334	chr12:66760972	A/G	cg16791601	chr12:66731901	HELB	-0.64	-17.28	-0.56	3.69e-55	White blood cell count (basophil);
BRCA	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	11.6	0.42	2.26e-28	Monocyte percentage of white cells;
BRCA	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg24642439	chr20:33292090	TP53INP2	0.53	11.6	0.42	2.23e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg23289794	chr7:2394357	EIF3B	-0.65	-11.94	-0.43	8.07e-30	Multiple sclerosis;
BRCA	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg04034577	chr2:241836375	C2orf54	-0.53	-12.07	-0.43	2.35e-30	Urinary metabolites;
BRCA	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	5.67e-52	Morning vs. evening chronotype;
BRCA	trans	rs6479891	0.822	rs6479892	chr10:65052232	A/G	cg14819942	chr15:35414228	NA	-0.34	-8.45	-0.32	1.93e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.74	0.36	5.54e-21	Menopause (age at onset);
BRCA	cis	rs495337	1.000	rs6125829	chr20:48568929	A/C	cg17835207	chr20:48524531	SPATA2	0.57	12.96	0.46	2.83e-34	Psoriasis;
BRCA	trans	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg06521331	chr12:34319734	NA	-0.46	-8.38	-0.31	3.31e-16	Bladder cancer;
BRCA	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-8.17	-0.31	1.61e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24549020	chr5:56110836	MAP3K1	0.64	13.26	0.46	1.29e-35	Initial pursuit acceleration;
BRCA	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.61	-0.32	5.59e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg14983838	chr19:29218262	NA	0.54	10.08	0.37	2.78e-22	Methadone dose in opioid dependence;
BRCA	cis	rs72781680	0.898	rs72786270	chr2:24059049	G/A	cg20701182	chr2:24300061	SF3B14	0.58	8.98	0.33	2.94e-18	Lymphocyte counts;
BRCA	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.35	9.12	0.34	9.44e-19	IgG glycosylation;
BRCA	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	8.36	0.31	3.86e-16	Neuroticism;
BRCA	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg15448220	chr1:150897856	SETDB1	0.35	7.98	0.3	6.75e-15	Melanoma;
BRCA	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-13.9	-0.48	1.42e-38	Blood metabolite levels;
BRCA	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-11.66	-0.42	1.23e-28	Chronic sinus infection;
BRCA	cis	rs13102973	0.932	rs6858552	chr4:135864734	C/T	cg14419869	chr4:135874104	NA	-0.59	-12.9	-0.45	5.35e-34	Subjective well-being;
BRCA	cis	rs8028182	0.636	rs4564532	chr15:75706296	C/G	cg20655648	chr15:75932815	IMP3	0.4	7.88	0.3	1.39e-14	Sudden cardiac arrest;
BRCA	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.39	8.3	0.31	6.09e-16	Bipolar disorder;
BRCA	cis	rs9837602	1.000	rs9851645	chr3:99767409	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.24	0.41	7.07e-27	Breast cancer;
BRCA	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs3784262	0.967	rs4646612	chr15:58265077	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.48	-12.81	-0.45	1.28e-33	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs1997103	1.000	rs2331064	chr7:55408610	C/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs9409565	0.821	rs9299419	chr9:97066584	C/T	cg05679027	chr9:99775184	HIATL2	0.36	7.92	0.3	1.03e-14	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs7818345	0.967	rs4481612	chr8:19285336	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.2	0.31	1.34e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs17092148	1.000	rs62211612	chr20:33386156	C/T	cg16810054	chr20:33298113	TP53INP2	0.49	11.17	0.4	1.35e-26	Neuroticism;
BRCA	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg12011299	chr4:100065546	ADH4	0.53	12.95	0.46	3.03e-34	Alcohol dependence;
BRCA	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26314531	chr2:26401878	FAM59B	-0.88	-15.31	-0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	9.96	0.37	8.28e-22	Lung cancer in ever smokers;
BRCA	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg05234568	chr11:5960015	NA	-0.42	-8.73	-0.33	2.23e-17	DNA methylation (variation);
BRCA	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-9.5	-0.35	4.13e-20	Axial length;
BRCA	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg13319975	chr6:146136371	FBXO30	-0.39	-8.89	-0.33	6.2e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	8.55	0.32	8.86e-17	Height;
BRCA	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.49	-10.85	-0.39	2.62e-25	IgG glycosylation;
BRCA	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg03146154	chr1:46216737	IPP	0.52	11.69	0.42	1e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg03585969	chr10:35415529	CREM	0.56	11.49	0.41	6.62e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg25703541	chr22:24373054	LOC391322	-0.7	-16.09	-0.54	3.64e-49	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4664304	0.620	rs11895141	chr2:160716449	T/A	cg14819504	chr2:160761413	LY75	0.34	8.47	0.32	1.65e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9300255	0.722	rs67624109	chr12:123824635	C/T	cg00376283	chr12:123451042	ABCB9	-0.52	-10.76	-0.39	6.03e-25	Neutrophil percentage of white cells;
BRCA	cis	rs6546886	0.957	rs6546887	chr2:74250781	C/G	cg14702570	chr2:74259524	NA	-0.32	-7.96	-0.3	7.94e-15	Dialysis-related mortality;
BRCA	cis	rs1499972	0.941	rs62263122	chr3:117630669	T/C	cg07612923	chr3:117604196	NA	0.6	8.15	0.31	1.97e-15	Schizophrenia;
BRCA	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs11229555	0.874	rs12800710	chr11:58314540	C/T	cg15696309	chr11:58395628	NA	-0.54	-11.69	-0.42	9.47e-29	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1371614	0.523	rs11904656	chr2:27173249	G/A	cg00617064	chr2:27272375	NA	-0.31	-7.9	-0.3	1.22e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg22431228	chr1:16359049	CLCNKA	-0.49	-11.07	-0.4	3.64e-26	Systolic blood pressure;
BRCA	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg26031613	chr14:104095156	KLC1	-0.46	-8.93	-0.33	4.4e-18	Schizophrenia;
BRCA	cis	rs9463078	0.727	rs9463054	chr6:44917197	T/C	cg25276700	chr6:44698697	NA	-0.36	-8.43	-0.32	2.36e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.46	-8.84	-0.33	9.59e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	11.16	0.4	1.5e-26	Rheumatoid arthritis;
BRCA	cis	rs28735056	1.000	rs4798922	chr18:77628953	G/C	cg20368463	chr18:77673604	PQLC1	-0.34	-8.19	-0.31	1.41e-15	Schizophrenia;
BRCA	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg04317338	chr11:64019027	PLCB3	0.55	9.46	0.35	5.59e-20	Mean platelet volume;
BRCA	cis	rs11690935	0.843	rs9784070	chr2:172785007	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.8	-22.92	-0.67	2.73e-85	Schizophrenia;
BRCA	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg23711669	chr6:146136114	FBXO30	-0.79	-18.92	-0.6	1.03e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg05373962	chr22:49881684	NA	-0.31	-8.57	-0.32	7.96e-17	Monocyte count;Monocyte percentage of white cells;
BRCA	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.19	-0.31	1.47e-15	Total body bone mineral density;
BRCA	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg05340658	chr4:99064831	C4orf37	0.69	17.37	0.57	1.25e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3857067	0.772	rs10516947	chr4:95110897	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.49	-0.35	4.67e-20	QT interval;
BRCA	trans	rs3857536	0.740	rs4710574	chr6:66890631	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-9.49	-0.35	4.6e-20	Blood trace element (Cu levels);
BRCA	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg16576597	chr16:28551801	NUPR1	0.33	9.2	0.34	4.87e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg11168104	chr5:1857477	NA	-0.34	-8.88	-0.33	6.75e-18	Cardiovascular disease risk factors;
BRCA	cis	rs17401966	1.000	rs4846210	chr1:10322153	A/G	cg15208524	chr1:10270712	KIF1B	0.39	8.43	0.32	2.24e-16	Hepatocellular carcinoma;
BRCA	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.41	0.35	8.46e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg23711669	chr6:146136114	FBXO30	0.8	19.26	0.61	1.59e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg10057126	chr4:77819792	ANKRD56	0.67	15.54	0.52	1.96e-46	Emphysema distribution in smoking;
BRCA	cis	rs6594713	0.717	rs8180416	chr5:112868440	A/G	cg12552261	chr5:112820674	MCC	0.48	8.21	0.31	1.22e-15	Brain cytoarchitecture;
BRCA	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.57	13.68	0.48	1.57e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg14582100	chr15:45693742	SPATA5L1	0.37	11.97	0.43	6.19e-30	Homoarginine levels;
BRCA	cis	rs10463316	0.862	rs10062928	chr5:150768355	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.33	-0.31	4.92e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg12292205	chr6:26970375	C6orf41	-0.81	-19.89	-0.62	7.21e-69	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2712184	0.729	rs2541397	chr2:217646693	G/A	cg05032264	chr2:217675019	NA	-0.38	-9.21	-0.34	4.73e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg05340658	chr4:99064831	C4orf37	0.68	17.2	0.56	8.57e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	8.69	0.32	3.15e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.5	-0.52	3.03e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs12618769	0.625	rs4850877	chr2:99112154	C/T	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.08	-24.99	-0.7	1.08e-96	Ulcerative colitis;
BRCA	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg25554036	chr4:6271136	WFS1	0.42	9.97	0.37	7.45e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs2882667	0.858	rs6596460	chr5:138414180	G/A	cg04439458	chr5:138467593	SIL1	-0.4	-10.68	-0.39	1.25e-24	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg26168224	chr5:2018326	NA	0.64	17.71	0.57	2.02e-57	Gut microbiome composition (winter);
BRCA	cis	rs6772849	0.930	rs4857914	chr3:128350684	C/T	cg16766828	chr3:128327626	NA	-0.38	-8.44	-0.32	2.15e-16	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg25664220	chr3:72788482	NA	-0.55	-11.39	-0.41	1.72e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg03396347	chr1:1875803	NA	0.47	11.84	0.42	2.19e-29	Body mass index;
BRCA	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg05472934	chr7:22766657	IL6	0.54	13.86	0.48	2.28e-38	Lung cancer;
BRCA	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.21e-47	Alzheimer's disease (late onset);
BRCA	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg13319975	chr6:146136371	FBXO30	-0.34	-8.04	-0.3	4.44e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.01	0.3	5.47e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg13319975	chr6:146136371	FBXO30	0.41	9.44	0.35	7.04e-20	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.3	-8.23	-0.31	1.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.03	-0.3	4.68e-15	Total body bone mineral density;
BRCA	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg05347473	chr6:146136440	FBXO30	0.4	8.13	0.31	2.22e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12995491	0.933	rs13023008	chr2:88530933	G/A	cg04511125	chr2:88470314	THNSL2	-0.45	-9.11	-0.34	1.06e-18	Response to metformin (IC50);
BRCA	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg05347473	chr6:146136440	FBXO30	0.42	8.47	0.32	1.63e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.54	-8.89	-0.33	6.21e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10819733	chr22:24237672	NA	-0.31	-8.75	-0.33	1.84e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.37	-0.41	2.01e-27	Personality dimensions;
BRCA	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg26031613	chr14:104095156	KLC1	-0.43	-8.42	-0.32	2.39e-16	Schizophrenia;
BRCA	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg27170947	chr2:26402098	FAM59B	-0.81	-12.91	-0.45	5e-34	Gut microbiome composition (summer);
BRCA	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg23719950	chr11:63933701	MACROD1	-0.53	-8.32	-0.31	5.25e-16	Mean platelet volume;
BRCA	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg00530320	chr1:46809349	NSUN4	0.49	9.76	0.36	4.52e-21	Menopause (age at onset);
BRCA	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07080220	chr10:102295463	HIF1AN	0.49	11.11	0.4	2.36e-26	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg11168104	chr5:1857477	NA	-0.36	-9.5	-0.35	4.16e-20	Cardiovascular disease risk factors;
BRCA	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.68	-0.42	1.08e-28	Gut microbiome composition (summer);
BRCA	cis	rs724568	0.508	rs1430773	chr2:67943520	G/A	cg17945962	chr2:67939740	NA	-0.4	-10.69	-0.39	1.15e-24	Major depressive disorder (broad);
BRCA	cis	rs7707921	0.881	rs1428940	chr5:81447995	A/G	cg15871215	chr5:81402204	ATG10	-0.41	-8.56	-0.32	8.18e-17	Breast cancer;
BRCA	cis	rs5766691	0.644	rs6007607	chr22:47529288	C/T	cg15757745	chr22:47558489	TBC1D22A	0.43	8.81	0.33	1.18e-17	Longevity;
BRCA	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.6	-0.32	6.31e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg08601574	chr20:25228251	PYGB	-0.35	-8.38	-0.31	3.3e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.19	0.31	1.4e-15	Tonsillectomy;
BRCA	cis	rs9596863	1.000	rs1977889	chr13:54442809	C/T	ch.13.53330881F	chr13:54432880	NA	-0.48	-7.97	-0.3	7.59e-15	Epilepsy and lamotrigine-induced maculopapular eruptions;
BRCA	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.81	0.3	2.43e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1434579	0.526	rs204547	chr19:44947184	T/C	cg15540054	chr19:45004280	ZNF180	-0.42	-8.73	-0.33	2.3e-17	Tuberculosis;
BRCA	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.98	-0.3	6.79e-15	Bipolar disorder;
BRCA	cis	rs71636778	0.524	rs78614739	chr1:27174180	C/T	cg12203394	chr1:27248618	NUDC	0.53	8.02	0.3	4.94e-15	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7131987	0.650	rs11050188	chr12:29473108	A/C	cg09582351	chr12:29534625	ERGIC2	-0.43	-9.85	-0.36	2.03e-21	QT interval;
BRCA	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.54	-9.64	-0.36	1.26e-20	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.48	-10.85	-0.39	2.82e-25	Cognitive ability;
BRCA	trans	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.28	0.31	7.45e-16	Corneal astigmatism;
BRCA	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg08313168	chr12:7315531	NA	0.5	8.09	0.3	2.95e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6785206	0.614	rs2712430	chr3:128337438	A/C	cg16766828	chr3:128327626	NA	-0.8	-11.66	-0.42	1.34e-28	Lymphocyte percentage of white cells;
BRCA	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11890956	chr21:40555474	PSMG1	-0.81	-19.33	-0.61	7.14e-66	Cognitive function;
BRCA	trans	rs4714291	0.802	rs3008833	chr6:39986303	G/A	cg02267698	chr19:7991119	CTXN1	-0.46	-9.38	-0.35	1.1e-19	Strep throat;
BRCA	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg19622623	chr12:86230825	RASSF9	-0.29	-8.18	-0.31	1.57e-15	Major depressive disorder;
BRCA	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg23711669	chr6:146136114	FBXO30	0.74	15.69	0.53	3.47e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg24642844	chr7:1081250	C7orf50	-0.51	-10.87	-0.4	2.29e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2387326	0.717	rs10829339	chr10:129943681	C/T	cg16087940	chr10:129947807	NA	-0.45	-7.94	-0.3	8.99e-15	Select biomarker traits;
BRCA	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg11502198	chr6:26597334	ABT1	0.48	9.62	0.36	1.45e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg03806693	chr22:41940476	POLR3H	-0.55	-9.67	-0.36	1e-20	Neuroticism;
BRCA	cis	rs9815354	0.812	rs73828254	chr3:41810180	T/A	cg03022575	chr3:42003672	ULK4	0.7	9.61	0.36	1.66e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg23285459	chr7:2802560	GNA12	-0.38	-9.53	-0.35	3.19e-20	Height;
BRCA	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg25237894	chr2:233734115	C2orf82	-0.38	-10.96	-0.4	1.01e-25	Coronary artery disease;
BRCA	cis	rs11030122	0.702	rs10835406	chr11:3992954	G/T	cg18678763	chr11:4115507	RRM1	0.35	7.9	0.3	1.19e-14	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.21	-0.41	9.2e-27	Gut microbiome composition (summer);
BRCA	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-13.77	-0.48	5.93e-38	Bipolar disorder;
BRCA	cis	rs9790314	0.779	rs1599376	chr3:160900533	C/G	cg04691961	chr3:161091175	C3orf57	-0.49	-10.89	-0.4	1.87e-25	Morning vs. evening chronotype;
BRCA	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg08859206	chr1:53392774	SCP2	0.4	8.8	0.33	1.32e-17	Monocyte count;
BRCA	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg17410650	chr12:54324560	NA	0.44	11.32	0.41	3.42e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
BRCA	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg24130564	chr14:104152367	KLC1	-0.39	-8.94	-0.33	4.18e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg24450063	chr1:156163899	SLC25A44	1.08	33.86	0.8	1.07e-144	Testicular germ cell tumor;
BRCA	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg12935359	chr14:103987150	CKB	-0.58	-13.72	-0.48	1.01e-37	Body mass index;
BRCA	cis	rs2737618	0.651	rs2249156	chr1:200083541	A/G	cg21825944	chr1:200113062	NR5A2	0.4	9.32	0.35	1.9e-19	Uric acid levels;
BRCA	cis	rs7523050	0.730	rs41279678	chr1:109440215	G/A	cg08274380	chr1:109419600	GPSM2	1.18	16.84	0.55	6.47e-53	Fat distribution (HIV);
BRCA	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.58	13.57	0.47	4.82e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg25801113	chr15:45476975	SHF	-0.33	-8.26	-0.31	8.31e-16	Uric acid levels;
BRCA	cis	rs7560272	0.501	rs7210	chr2:73957124	A/G	cg20560298	chr2:73613845	ALMS1	0.34	8.81	0.33	1.15e-17	Schizophrenia;
BRCA	cis	rs68170813	0.559	rs80341862	chr7:106934731	C/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.99	-0.33	2.84e-18	Coronary artery disease;
BRCA	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg10523679	chr1:76189770	ACADM	0.91	22.31	0.66	5.55e-82	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7903847	0.544	rs61861865	chr10:99144867	C/G	cg20016023	chr10:99160130	RRP12	-0.27	-8.61	-0.32	5.82e-17	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.13	0.31	2.28e-15	Corneal astigmatism;
BRCA	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg08601574	chr20:25228251	PYGB	-0.35	-8.27	-0.31	7.68e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg06784218	chr1:46089804	CCDC17	0.5	12.08	0.43	2.02e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs870825	1.000	rs870823	chr4:185588195	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	13.85	0.48	2.44e-38	Blood protein levels;
BRCA	cis	rs870825	0.616	rs55674580	chr4:185626605	C/G	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-14.26	-0.49	3.05e-40	Response to antipsychotic treatment;
BRCA	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg27446573	chr6:127587934	RNF146	0.9	21.02	0.64	5.71e-75	Breast cancer;
BRCA	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg06484146	chr7:12443880	VWDE	-0.56	-8.27	-0.31	7.87e-16	Coronary artery disease;
BRCA	cis	rs12200560	0.505	rs4240555	chr6:97076274	T/C	cg06623918	chr6:96969491	KIAA0776	0.53	12.7	0.45	4.04e-33	Coronary heart disease;
BRCA	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.67	0.5	3.49e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs738322	0.836	rs4821741	chr22:38514745	A/G	cg25457927	chr22:38595422	NA	-0.31	-10.97	-0.4	8.91e-26	Cutaneous nevi;
BRCA	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg03609598	chr5:56110824	MAP3K1	-0.45	-8.03	-0.3	4.59e-15	Initial pursuit acceleration;
BRCA	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg24250549	chr1:154909240	PMVK	0.63	15.9	0.53	3.18e-48	Prostate cancer;
BRCA	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18876405	chr7:65276391	NA	0.56	13.34	0.47	5.75e-36	Aortic root size;
BRCA	trans	rs4714291	0.963	rs1923489	chr6:40023088	T/C	cg02267698	chr19:7991119	CTXN1	0.41	7.87	0.3	1.57e-14	Strep throat;
BRCA	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.83	-0.39	3.35e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-15.45	-0.52	5.35e-46	Total cholesterol levels;
BRCA	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.88	16.4	0.54	1.06e-50	Lymphocyte percentage of white cells;
BRCA	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg18850127	chr7:39170497	POU6F2	0.55	12.09	0.43	1.91e-30	IgG glycosylation;
BRCA	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.33	-0.35	1.72e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs7200543	0.583	rs4985149	chr16:15147338	A/T	cg24683922	chr1:11983373	KIAA2013	-0.36	-8.33	-0.31	4.99e-16	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg02734326	chr4:10020555	SLC2A9	0.4	8.72	0.33	2.41e-17	Bone mineral density;
BRCA	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg26384229	chr12:38710491	ALG10B	0.47	12.22	0.44	5.41e-31	Morning vs. evening chronotype;
BRCA	cis	rs367943	0.799	rs13154055	chr5:112971516	A/T	cg12552261	chr5:112820674	MCC	0.5	9.9	0.36	1.3e-21	Type 2 diabetes;
BRCA	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.1e-19	Total body bone mineral density;
BRCA	cis	rs6910061	1.000	rs9468452	chr6:11121993	A/G	cg27233058	chr6:11094804	LOC221710	0.53	9.57	0.35	2.26e-20	Diabetic kidney disease;
BRCA	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg09537434	chr19:41945824	ATP5SL	1.03	25.65	0.71	2.69e-100	Height;
BRCA	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg02153584	chr22:29168773	CCDC117	0.48	10.55	0.39	4.45e-24	Red cell distribution width;
BRCA	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.87	0.56	4.31e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4727443	1.000	rs4727443	chr7:99593346	C/A	cg22004693	chr7:99632812	ZKSCAN1	0.39	8.93	0.33	4.62e-18	Interstitial lung disease;
BRCA	cis	rs6545883	0.929	rs3732171	chr2:61749690	C/T	cg15711740	chr2:61764176	XPO1	-0.53	-13.56	-0.47	5.12e-37	Tuberculosis;
BRCA	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	11.67	0.42	1.12e-28	Schizophrenia;
BRCA	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg18252515	chr7:66147081	NA	-1.06	-15.7	-0.53	3.07e-47	Gout;
BRCA	trans	rs3857536	0.741	rs9363558	chr6:66937260	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs71636778	0.543	rs10493037	chr1:27248645	A/G	cg12203394	chr1:27248618	NUDC	0.61	9.5	0.35	4.25e-20	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg09911534	chr15:67153556	NA	0.67	10.41	0.38	1.45e-23	Lung cancer (smoking interaction);
BRCA	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg19717773	chr7:2847554	GNA12	-0.41	-8.99	-0.34	2.68e-18	Height;
BRCA	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	8.35	0.31	4.16e-16	Educational attainment;
BRCA	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg08888203	chr3:10149979	C3orf24	0.56	11.7	0.42	9.05e-29	Alzheimer's disease;
BRCA	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.59	9.37	0.35	1.2e-19	Renal function-related traits (BUN);
BRCA	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg19077165	chr18:44547161	KATNAL2	-0.58	-12.97	-0.46	2.58e-34	Personality dimensions;
BRCA	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg08888203	chr3:10149979	C3orf24	-0.63	-11.79	-0.42	3.46e-29	Alzheimer's disease;
BRCA	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg24812749	chr6:127587940	RNF146	0.69	14.95	0.51	1.46e-43	Breast cancer;
BRCA	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.28e-23	Prostate cancer;
BRCA	cis	rs4880487	0.853	rs883490	chr10:1249567	G/C	cg03183215	chr10:1252341	ADARB2	-0.38	-8.51	-0.32	1.25e-16	Migraine;
BRCA	cis	rs7246967	0.673	rs34174596	chr19:22933519	G/A	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08219700	chr8:58056026	NA	0.59	9.53	0.35	3.3e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg24692254	chr21:30365293	RNF160	-0.46	-8.03	-0.3	4.54e-15	Cognitive test performance;
BRCA	trans	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg26043149	chr18:55253948	FECH	-0.41	-9.18	-0.34	5.9e-19	Bone mineral density;
BRCA	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	ch.11.42038R	chr11:967971	AP2A2	0.5	15.77	0.53	1.38e-47	Alzheimer's disease (late onset);
BRCA	cis	rs9986765	1.000	rs10243198	chr7:142822210	C/T	cg21852589	chr7:142981689	TMEM139	0.57	10.22	0.37	8.1e-23	Cancer;Dermatomyositis;
BRCA	cis	rs6878727	0.665	rs1363306	chr5:123657899	A/G	cg01806427	chr5:123737813	NA	-0.35	-8.0	-0.3	5.93e-15	Breast cancer;
BRCA	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg18806716	chr10:30721971	MAP3K8	-0.46	-11.07	-0.4	3.62e-26	Inflammatory bowel disease;
BRCA	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg00666640	chr1:248458726	OR2T12	0.33	8.99	0.34	2.73e-18	Common traits (Other);
BRCA	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-9.73	-0.36	5.86e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs600806	0.850	rs3768493	chr1:109935505	C/T	cg20591472	chr1:110008990	SYPL2	0.33	8.22	0.31	1.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.74	-0.33	2.11e-17	Colorectal cancer;
BRCA	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg01689657	chr7:91764605	CYP51A1	0.22	8.11	0.31	2.52e-15	Breast cancer;
BRCA	cis	rs2019216	1.000	rs3751916	chr17:21909270	T/C	cg22648282	chr17:21454238	C17orf51	-0.35	-8.1	-0.31	2.78e-15	Pelvic organ prolapse;
BRCA	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg24562669	chr7:97807699	LMTK2	0.46	12.25	0.44	3.78e-31	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg15704280	chr7:45808275	SEPT13	-0.46	-8.81	-0.33	1.16e-17	HDL cholesterol;
BRCA	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg19761014	chr17:28927070	LRRC37B2	0.56	8.0	0.3	5.79e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.68	0.42	1.1e-28	Homoarginine levels;
BRCA	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg08999081	chr20:33150536	PIGU	0.36	9.28	0.34	2.53e-19	Coronary artery disease;
BRCA	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11644478	chr21:40555479	PSMG1	0.74	14.89	0.51	3.04e-43	Cognitive function;
BRCA	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	13.03	0.46	1.43e-34	Colorectal cancer;
BRCA	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg10523679	chr1:76189770	ACADM	0.76	15.96	0.53	1.62e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.91	14.09	0.49	1.89e-39	Body mass index;
BRCA	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg10818794	chr15:86012489	AKAP13	-0.3	-8.5	-0.32	1.32e-16	Coronary artery disease;
BRCA	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg21252483	chr19:49399788	TULP2	-0.51	-10.86	-0.39	2.46e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs9612	1.000	rs3786954	chr19:44272346	A/G	cg08581076	chr19:44259116	C19orf61	0.49	9.21	0.34	4.7e-19	Exhaled nitric oxide output;
BRCA	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg07636037	chr3:49044803	WDR6	0.52	8.46	0.32	1.81e-16	Menarche (age at onset);
BRCA	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.83	0.39	3.4e-25	Bipolar disorder;
BRCA	cis	rs870825	0.616	rs6810635	chr4:185616859	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	16.89	0.56	3.47e-53	Blood protein levels;
BRCA	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg20818283	chr2:191399100	TMEM194B	-0.39	-8.98	-0.33	2.95e-18	Pulse pressure;
BRCA	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg18230493	chr5:56204884	C5orf35	0.62	13.07	0.46	8.87e-35	Initial pursuit acceleration;
BRCA	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.59	-10.31	-0.38	3.67e-23	Gut microbiome composition (summer);
BRCA	cis	rs3771570	0.901	rs3771585	chr2:242400723	G/A	cg21155796	chr2:242212141	HDLBP	0.51	8.94	0.33	4.18e-18	Prostate cancer;
BRCA	cis	rs8032158	0.963	rs56333939	chr15:56124535	T/C	cg02198044	chr15:56286336	NEDD4	-0.38	-9.19	-0.34	5.31e-19	Keloid;
BRCA	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg05347473	chr6:146136440	FBXO30	0.43	8.64	0.32	4.67e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08045932	chr20:61659980	NA	0.5	11.46	0.41	8.76e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg18301423	chr5:131593218	PDLIM4	0.31	8.19	0.31	1.39e-15	Breast cancer;
BRCA	cis	rs36052053	0.908	rs13203020	chr6:109584645	C/A	cg12927641	chr6:109611667	NA	-0.5	-7.95	-0.3	8.31e-15	Red cell distribution width;
BRCA	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg17971929	chr21:40555470	PSMG1	-0.71	-15.88	-0.53	4.02e-48	Cognitive function;
BRCA	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.68	0.57	3.2e-57	Fuchs's corneal dystrophy;
BRCA	trans	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg25214090	chr10:38739885	LOC399744	0.5	10.91	0.4	1.53e-25	Corneal astigmatism;
BRCA	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg04450456	chr4:17643702	FAM184B	-0.32	-9.38	-0.35	1.18e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3820928	0.967	rs2396435	chr2:227778397	G/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.55	-0.32	8.87e-17	Pulmonary function;
BRCA	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.04	21.08	0.64	2.75e-75	Gut microbiome composition (summer);
BRCA	trans	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.42	-8.77	-0.33	1.65e-17	Body mass index;
BRCA	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg01028140	chr2:1542097	TPO	-0.81	-16.05	-0.54	5.9e-49	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg03146154	chr1:46216737	IPP	0.52	11.59	0.42	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-12.93	-0.46	3.89e-34	Bipolar disorder and schizophrenia;
BRCA	cis	rs9470366	0.509	rs4713996	chr6:36629714	C/T	cg08179530	chr6:36648295	CDKN1A	-0.54	-12.41	-0.44	7.68e-32	QRS duration;
BRCA	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg11901034	chr3:128598214	ACAD9	-0.37	-8.94	-0.33	4.19e-18	IgG glycosylation;
BRCA	cis	rs77972916	0.611	rs6709988	chr2:43601317	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-10.54	-0.38	4.57e-24	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.92	0.56	2.57e-53	Hypertriglyceridemia;
BRCA	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.29	0.31	6.86e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg10729496	chr3:10149963	C3orf24	0.48	9.0	0.34	2.49e-18	Alzheimer's disease;
BRCA	trans	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.58	-0.35	2.16e-20	Morning vs. evening chronotype;
BRCA	cis	rs8017423	0.647	rs12883357	chr14:90815032	A/G	cg04374321	chr14:90722782	PSMC1	-0.52	-12.61	-0.45	1.01e-32	Mortality in heart failure;
BRCA	cis	rs6484504	0.576	rs208088	chr11:31192686	T/C	cg26647111	chr11:31128758	NA	-0.44	-9.62	-0.36	1.5e-20	Red blood cell count;
BRCA	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11890956	chr21:40555474	PSMG1	-0.82	-19.57	-0.61	3.6e-67	Cognitive function;
BRCA	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.17	0.31	1.61e-15	Tonsillectomy;
BRCA	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.43	-9.13	-0.34	8.96e-19	IgG glycosylation;
BRCA	cis	rs1018836	0.884	rs13279263	chr8:91648780	T/C	cg16814680	chr8:91681699	NA	-0.49	-10.37	-0.38	2.17e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg20503657	chr10:835505	NA	1.05	18.68	0.59	1.79e-62	Eosinophil percentage of granulocytes;
BRCA	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.75	0.62	3.7e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg05347473	chr6:146136440	FBXO30	0.53	10.36	0.38	2.32e-23	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs79911532	0.515	rs17148983	chr7:75649821	C/G	cg19862616	chr7:65841803	NCRNA00174	0.62	8.66	0.32	3.73e-17	Mononucleosis;
BRCA	trans	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg25214090	chr10:38739885	LOC399744	0.54	12.26	0.44	3.39e-31	Corneal astigmatism;
BRCA	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg16339924	chr4:17578868	LAP3	0.57	13.74	0.48	7.85e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg10820045	chr2:198174542	NA	-0.46	-10.88	-0.4	2.11e-25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg10370574	chr19:1840461	REXO1	0.37	8.58	0.32	7.21e-17	Bipolar disorder;
BRCA	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	11.74	0.42	5.99e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11764359	chr7:65958608	NA	-0.7	-14.8	-0.51	8.13e-43	Aortic root size;
BRCA	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg03474202	chr17:45855739	NA	-0.46	-12.23	-0.44	4.53e-31	IgG glycosylation;
BRCA	cis	rs2463822	0.748	rs2513053	chr11:62109473	T/A	cg06239285	chr11:62104954	ASRGL1	0.67	11.15	0.4	1.7e-26	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs7301826	0.651	rs10744483	chr12:131298206	C/A	cg11011512	chr12:131303247	STX2	0.51	13.62	0.47	3e-37	Plasma plasminogen activator levels;
BRCA	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg16405210	chr4:1374714	KIAA1530	-0.92	-20.97	-0.64	1.12e-74	Longevity;
BRCA	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg16482183	chr6:26056742	HIST1H1C	0.53	11.4	0.41	1.56e-27	Height;
BRCA	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.69e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs919433	0.617	rs10931793	chr2:198577585	G/A	cg00792783	chr2:198669748	PLCL1	-0.44	-9.73	-0.36	5.78e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs3818285	0.504	rs4917547	chr10:111652285	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.34	-8.83	-0.33	9.8e-18	Superior crus of antihelix expression;
BRCA	cis	rs8014204	0.762	rs12889665	chr14:75234830	T/G	cg06637938	chr14:75390232	RPS6KL1	0.42	8.69	0.33	3e-17	Caffeine consumption;
BRCA	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg20503657	chr10:835505	NA	1.02	17.81	0.58	6.43e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs9283706	0.608	rs10053537	chr5:66332543	T/C	cg11590213	chr5:66331682	MAST4	0.37	7.89	0.3	1.32e-14	Coronary artery disease;
BRCA	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	5.1e-16	Tonsillectomy;
BRCA	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs7520050	0.966	rs6700597	chr1:46284246	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.85	0.36	2.07e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs921968	0.565	rs2272191	chr2:219609776	G/A	cg02176678	chr2:219576539	TTLL4	-0.41	-10.97	-0.4	8.68e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg17063962	chr7:91808500	NA	0.57	13.6	0.47	3.52e-37	Breast cancer;
BRCA	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.96	0.58	1.14e-58	Fuchs's corneal dystrophy;
BRCA	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11905131	chr22:24372483	LOC391322	0.55	12.22	0.44	5.47e-31	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2041840	0.597	rs10865124	chr2:37576553	A/G	cg25727520	chr2:37576821	QPCT	-0.29	-8.08	-0.3	3.16e-15	Chronic lymphocytic leukemia;
BRCA	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg13736514	chr6:26305472	NA	-0.33	-10.16	-0.37	1.45e-22	Educational attainment;
BRCA	cis	rs4908768	0.501	rs6702060	chr1:8607024	G/A	cg20416874	chr1:8611966	RERE	-0.29	-8.32	-0.31	5.26e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg02297831	chr4:17616191	MED28	0.38	8.53	0.32	1.03e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7520050	0.966	rs6656992	chr1:46333068	C/G	cg24296786	chr1:45957014	TESK2	0.44	9.89	0.36	1.5e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7833986	0.501	rs72653981	chr8:57027814	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	12.88	0.45	6.83e-34	Height;
BRCA	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.25	0.31	9.38e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1371614	0.632	rs6708148	chr2:27167320	A/G	cg00617064	chr2:27272375	NA	-0.33	-8.75	-0.33	1.85e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg25319279	chr11:5960081	NA	-0.43	-8.38	-0.31	3.29e-16	DNA methylation (variation);
BRCA	cis	rs752010	0.871	rs2038976	chr1:42094498	A/G	cg06885757	chr1:42089581	HIVEP3	0.3	10.34	0.38	2.82e-23	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg25019033	chr10:957182	NA	-0.41	-7.9	-0.3	1.24e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs16854884	0.657	rs6791078	chr3:143736876	A/G	cg06585982	chr3:143692056	C3orf58	0.43	8.99	0.33	2.87e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg03342759	chr3:160939853	NMD3	-0.65	-14.89	-0.51	3.03e-43	Morning vs. evening chronotype;
BRCA	cis	rs7617773	0.780	rs13067450	chr3:48337206	C/T	cg11946769	chr3:48343235	NME6	0.68	14.05	0.49	2.93e-39	Coronary artery disease;
BRCA	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg05868516	chr6:26286170	HIST1H4H	0.49	11.03	0.4	4.95e-26	Educational attainment;
BRCA	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg19678392	chr7:94953810	PON1	-0.41	-8.77	-0.33	1.66e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg00105475	chr2:10696890	NA	0.44	10.27	0.38	5.22e-23	Prostate cancer;
BRCA	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	8.14	0.31	2.1e-15	Diabetic retinopathy;
BRCA	cis	rs7809950	0.773	rs2237668	chr7:107050209	A/G	cg23024343	chr7:107201750	COG5	-0.49	-10.11	-0.37	2.13e-22	Coronary artery disease;
BRCA	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08704250	chr15:31115839	NA	-0.36	-8.87	-0.33	7.53e-18	Huntington's disease progression;
BRCA	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg12011299	chr4:100065546	ADH4	0.48	10.82	0.39	3.58e-25	Smoking initiation;
BRCA	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg09367891	chr1:107599246	PRMT6	0.4	7.96	0.3	7.79e-15	Facial morphology (factor 21, depth of nasal alae);
BRCA	trans	rs4596713	0.538	rs7048095	chr9:71745663	G/A	cg16512924	chr15:28394682	HERC2	0.4	9.45	0.35	6.24e-20	Headache;
BRCA	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-11.01	-0.4	5.95e-26	Mean corpuscular volume;
BRCA	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg09658497	chr7:2847517	GNA12	-0.41	-8.61	-0.32	5.63e-17	Height;
BRCA	trans	rs7786808	0.579	rs12669482	chr7:158188813	G/A	cg02030672	chr11:45687055	CHST1	0.48	10.53	0.38	4.92e-24	Obesity-related traits;
BRCA	cis	rs7246967	0.673	rs36029703	chr19:22906188	C/A	cg23217946	chr19:22817039	ZNF492	0.51	9.41	0.35	8.44e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.49	-10.12	-0.37	2.07e-22	Parkinson's disease;
BRCA	cis	rs13046373	0.535	rs1911571	chr21:32031538	A/C	cg27071517	chr21:31768726	KRTAP13-1	0.29	8.13	0.31	2.24e-15	HDL cholesterol;
BRCA	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.51	11.58	0.42	2.76e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.18	0.34	5.98e-19	Platelet count;
BRCA	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg01877450	chr7:97915802	BRI3	-0.39	-8.77	-0.33	1.58e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18876405	chr7:65276391	NA	-0.5	-11.23	-0.41	7.86e-27	Aortic root size;
BRCA	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26314531	chr2:26401878	FAM59B	-0.61	-10.26	-0.38	5.75e-23	Gut microbiome composition (summer);
BRCA	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg22705602	chr4:152727874	NA	-0.35	-8.58	-0.32	7.06e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg00012203	chr2:219082015	ARPC2	0.47	9.18	0.34	5.9e-19	Ulcerative colitis;
BRCA	cis	rs4363385	0.818	rs3795381	chr1:153004848	T/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.59	-0.32	6.84e-17	Inflammatory skin disease;
BRCA	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg13319975	chr6:146136371	FBXO30	-0.37	-8.38	-0.31	3.41e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	8.79	0.33	1.36e-17	Iron status biomarkers;
BRCA	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg09754948	chr16:28834200	ATXN2L	0.45	8.9	0.33	5.77e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs939658	0.875	rs2177057	chr15:79441441	G/C	cg17916960	chr15:79447300	NA	-0.43	-10.98	-0.4	8.11e-26	Refractive error;
BRCA	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-11.25	-0.41	6.34e-27	IgG glycosylation;
BRCA	cis	rs7246657	0.722	rs2972447	chr19:38129736	C/T	cg23950597	chr19:37808831	NA	0.52	8.87	0.33	7.37e-18	Coronary artery calcification;
BRCA	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg23711669	chr6:146136114	FBXO30	-0.79	-18.87	-0.6	1.77e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12760731	0.641	rs12038910	chr1:178444907	C/T	cg00404053	chr1:178313656	RASAL2	0.57	8.29	0.31	6.67e-16	Obesity-related traits;
BRCA	cis	rs10504073	0.647	rs12546839	chr8:50009020	C/T	cg00325661	chr8:49890786	NA	0.44	12.4	0.44	8.53e-32	Blood metabolite ratios;
BRCA	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg05340658	chr4:99064831	C4orf37	0.58	11.71	0.42	7.64e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.38	0.49	7.79e-41	Motion sickness;
BRCA	trans	rs7980799	0.935	rs2389194	chr12:33529164	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-8.47	-0.32	1.65e-16	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg26874164	chr19:58962979	ZNF324B	0.68	15.24	0.52	5.87e-45	Mean platelet volume;
BRCA	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg18867708	chr6:26865862	GUSBL1	0.42	8.26	0.31	8.42e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg06784218	chr1:46089804	CCDC17	0.45	10.8	0.39	4.43e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg03342759	chr3:160939853	NMD3	-0.52	-11.16	-0.4	1.47e-26	Morning vs. evening chronotype;
BRCA	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg01689657	chr7:91764605	CYP51A1	0.22	8.17	0.31	1.7e-15	Breast cancer;
BRCA	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg13385794	chr1:248469461	NA	0.27	7.94	0.3	8.8e-15	Common traits (Other);
BRCA	cis	rs6546550	0.869	rs6712827	chr2:70156540	C/G	cg02498382	chr2:70120550	SNRNP27	-0.51	-11.22	-0.41	8.33e-27	Prevalent atrial fibrillation;
BRCA	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg11584989	chr19:19387371	SF4	0.66	14.26	0.49	2.94e-40	Bipolar disorder;
BRCA	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg19622623	chr12:86230825	RASSF9	0.35	9.76	0.36	4.35e-21	Major depressive disorder;
BRCA	trans	rs8002861	0.664	rs2218497	chr13:44428793	G/A	cg17145862	chr1:211918768	LPGAT1	0.47	10.77	0.39	5.62e-25	Leprosy;
BRCA	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00166722	chr3:10149974	C3orf24	0.6	12.19	0.43	6.74e-31	Alzheimer's disease;
BRCA	trans	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg06521331	chr12:34319734	NA	-0.52	-9.37	-0.35	1.22e-19	Bladder cancer;
BRCA	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg04166393	chr7:2884313	GNA12	0.4	8.81	0.33	1.19e-17	Height;
BRCA	cis	rs11072805	1	rs11072805	chr15:79078518	T/C	cg04896959	chr15:78267971	NA	0.37	8.59	0.32	6.68e-17	Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg06092702	chr1:163392909	NA	-0.32	-8.6	-0.32	6.23e-17	Motion sickness;
BRCA	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	10.85	0.39	2.86e-25	Rheumatoid arthritis;
BRCA	cis	rs10851411	0.606	rs11635889	chr15:42818987	T/C	cg21293051	chr15:42870591	STARD9	0.51	8.45	0.32	1.92e-16	Glucose homeostasis traits;
BRCA	cis	rs12472274	0.941	rs11677230	chr2:239092054	T/C	cg17459225	chr2:239074497	NA	0.64	13.25	0.46	1.35e-35	Phospholipid levels (plasma);
BRCA	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg13010199	chr12:38710504	ALG10B	0.4	8.67	0.32	3.56e-17	Bladder cancer;
BRCA	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26314531	chr2:26401878	FAM59B	0.9	15.14	0.51	1.7e-44	Gut microbiome composition (summer);
BRCA	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg01236616	chr12:121019343	POP5	1.24	27.85	0.74	2.17e-112	Type 1 diabetes nephropathy;
BRCA	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg04586622	chr2:25135609	ADCY3	0.46	11.66	0.42	1.26e-28	Body mass index;
BRCA	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.35	8.58	0.32	7.37e-17	Resting heart rate;
BRCA	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg26597838	chr10:835615	NA	-0.51	-9.36	-0.35	1.33e-19	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg09904177	chr6:26538194	HMGN4	0.55	17.64	0.57	4.82e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.02	14.72	0.5	1.9e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-19.37	-0.61	4.25e-66	Electrocardiographic conduction measures;
BRCA	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	13.24	0.46	1.53e-35	Ileal carcinoids;
BRCA	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	8.88	0.33	6.96e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg21475434	chr5:93447410	FAM172A	0.69	8.72	0.33	2.43e-17	Diabetic retinopathy;
BRCA	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.82	0.3	2.12e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg16482183	chr6:26056742	HIST1H1C	0.45	9.21	0.34	4.61e-19	Iron status biomarkers;
BRCA	cis	rs1868673	1.000	rs9813752	chr3:150151120	G/A	cg04908077	chr3:150187338	NA	-0.33	-8.99	-0.34	2.8e-18	Waist circumference;
BRCA	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07636037	chr3:49044803	WDR6	0.75	16.38	0.54	1.31e-50	Menarche (age at onset);
BRCA	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg13256891	chr4:100009986	ADH5	0.47	9.06	0.34	1.52e-18	Alcohol dependence;
BRCA	trans	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg26384229	chr12:38710491	ALG10B	0.4	8.58	0.32	7.38e-17	Resting heart rate;
BRCA	cis	rs17854409	0.764	rs16983293	chr20:61479056	A/G	cg06598544	chr20:61472147	COL9A3	-0.82	-8.11	-0.31	2.6e-15	Obesity-related traits;
BRCA	cis	rs2479724	0.870	rs6902650	chr6:41764080	G/A	cg17623882	chr6:41773611	USP49	0.35	9.42	0.35	8.37e-20	Menarche (age at onset);
BRCA	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg12062639	chr20:23401060	NAPB	0.94	13.51	0.47	9.47e-37	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs3849570	1.000	rs3860595	chr3:81811784	A/G	cg07356753	chr3:81810745	GBE1	-0.42	-10.02	-0.37	4.68e-22	Waist circumference;Body mass index;
BRCA	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg05791153	chr7:19748676	TWISTNB	0.58	10.81	0.39	3.94e-25	Thyroid stimulating hormone;
BRCA	cis	rs12050794	0.671	rs62022788	chr15:72559326	T/G	cg16672083	chr15:72433130	SENP8	0.61	14.65	0.5	3.9e-42	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs7572733	0.534	rs700664	chr2:198671145	C/T	cg00792783	chr2:198669748	PLCL1	0.47	10.27	0.38	5.27e-23	Dermatomyositis;
BRCA	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg19622623	chr12:86230825	RASSF9	-0.33	-9.32	-0.35	1.81e-19	Major depressive disorder;
BRCA	cis	rs10992471	0.702	rs10820967	chr9:95101729	C/G	cg14631576	chr9:95140430	CENPP	-0.37	-8.76	-0.33	1.69e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg15704280	chr7:45808275	SEPT13	0.54	9.13	0.34	8.85e-19	Axial length;
BRCA	cis	rs1113500	0.897	rs4628530	chr1:108638708	T/G	cg06207961	chr1:108661230	NA	0.44	10.84	0.39	2.89e-25	Growth-regulated protein alpha levels;
BRCA	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg26168224	chr5:2018326	NA	0.65	18.31	0.59	1.61e-60	Gut microbiome composition (winter);
BRCA	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg01877450	chr7:97915802	BRI3	-0.39	-8.67	-0.32	3.44e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs977987	0.778	rs4888412	chr16:75443196	A/G	cg03315344	chr16:75512273	CHST6	0.53	12.52	0.44	2.54e-32	Dupuytren's disease;
BRCA	cis	rs3820928	1.000	rs61067328	chr2:227761256	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.81	-0.33	1.18e-17	Pulmonary function;
BRCA	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg13010199	chr12:38710504	ALG10B	0.42	8.1	0.31	2.86e-15	Bladder cancer;
BRCA	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11644478	chr21:40555479	PSMG1	0.87	20.27	0.63	6.32e-71	Cognitive function;
BRCA	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11764359	chr7:65958608	NA	0.75	16.78	0.55	1.26e-52	Aortic root size;
BRCA	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg25358565	chr5:93447407	FAM172A	1.14	19.34	0.61	5.82e-66	Diabetic retinopathy;
BRCA	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg26838691	chr2:24397539	C2orf84	-0.48	-8.67	-0.32	3.46e-17	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs1949733	0.582	rs61258495	chr4:8534017	G/A	cg11789530	chr4:8429930	ACOX3	-0.49	-11.57	-0.42	3.09e-28	Response to antineoplastic agents;
BRCA	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg20701182	chr2:24300061	SF3B14	0.62	8.83	0.33	1e-17	Lymphocyte counts;
BRCA	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.84	-0.39	2.9e-25	Mean corpuscular volume;
BRCA	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.95	0.33	3.68e-18	Motion sickness;
BRCA	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.4	0.35	9.69e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg19539972	chr4:7069911	GRPEL1	0.6	12.05	0.43	2.83e-30	Monocyte percentage of white cells;
BRCA	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg13319975	chr6:146136371	FBXO30	0.41	9.35	0.35	1.49e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.818	rs10788854	chr1:153002320	C/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.32	-0.31	5.19e-16	Inflammatory skin disease;
BRCA	cis	rs13418410	0.539	rs35866672	chr2:33842174	G/A	cg04131969	chr2:33951647	MYADML	-0.55	-10.87	-0.39	2.35e-25	Non-response to antidepressants and depression;
BRCA	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.42	0.32	2.43e-16	Rheumatoid arthritis;
BRCA	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg01529538	chr14:23388837	RBM23	0.42	11.48	0.41	7.01e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06108461	chr20:60628389	TAF4	-0.73	-15.3	-0.52	3e-45	Body mass index;
BRCA	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg11833968	chr6:79620685	NA	-0.46	-10.15	-0.37	1.5e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs1997103	1.000	rs6976824	chr7:55396115	A/C	cg17469321	chr7:55412551	NA	0.48	8.98	0.33	3.09e-18	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs1018836	0.892	rs4735224	chr8:91567046	C/A	cg16814680	chr8:91681699	NA	-0.57	-12.35	-0.44	1.39e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg23205692	chr1:25664452	TMEM50A	0.43	10.28	0.38	4.78e-23	Erythrocyte sedimentation rate;
BRCA	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg24829409	chr8:58192753	C8orf71	-0.47	-8.96	-0.33	3.45e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg26384229	chr12:38710491	ALG10B	0.76	16.99	0.56	1.09e-53	Bladder cancer;
BRCA	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.84e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg05340658	chr4:99064831	C4orf37	-0.67	-16.97	-0.56	1.27e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg17063962	chr7:91808500	NA	0.54	12.62	0.45	9.63e-33	Breast cancer;
BRCA	cis	rs11955398	0.563	rs1117676	chr5:60034824	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.38	-9.11	-0.34	1.08e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg24069376	chr3:38537580	EXOG	-0.33	-9.43	-0.35	7.59e-20	Electrocardiographic conduction measures;
BRCA	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg23711669	chr6:146136114	FBXO30	0.65	15.41	0.52	8.21e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2764980	1.000	rs11251794	chr10:3283931	C/T	cg18054281	chr10:3284093	NA	-0.32	-8.04	-0.3	4.25e-15	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs8028182	0.636	rs7495610	chr15:75784441	T/C	cg20655648	chr15:75932815	IMP3	0.42	8.09	0.3	2.91e-15	Sudden cardiac arrest;
BRCA	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.32	0.38	3.49e-23	Motion sickness;
BRCA	cis	rs738322	0.600	rs6001031	chr22:38556260	G/T	cg25457927	chr22:38595422	NA	0.35	12.9	0.45	5.54e-34	Cutaneous nevi;
BRCA	cis	rs2882667	0.690	rs288028	chr5:138221989	C/G	cg04439458	chr5:138467593	SIL1	-0.33	-8.09	-0.3	2.9e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-11.19	-0.4	1.19e-26	Gut microbiome composition (summer);
BRCA	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.73	-0.33	2.15e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg16606324	chr3:10149918	C3orf24	0.54	10.48	0.38	8.25e-24	Alzheimer's disease;
BRCA	cis	rs11229555	0.574	rs11229454	chr11:58203682	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg25358565	chr5:93447407	FAM172A	1.18	17.27	0.56	3.74e-55	Diabetic retinopathy;
BRCA	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg15017067	chr4:17643749	FAM184B	0.32	9.66	0.36	1.06e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg07636037	chr3:49044803	WDR6	-0.57	-7.86	-0.3	1.61e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.22	-0.37	8.01e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs524281	0.861	rs7943911	chr11:65943054	G/A	cg16950941	chr11:66035639	RAB1B	-0.37	-7.84	-0.3	1.92e-14	Electroencephalogram traits;
BRCA	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg12379764	chr21:47803548	PCNT	-0.4	-9.12	-0.34	9.98e-19	Testicular germ cell tumor;
BRCA	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg09021430	chr5:549028	NA	-0.67	-15.13	-0.51	1.98e-44	Lung disease severity in cystic fibrosis;
BRCA	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg13334819	chr7:99746414	C7orf59	0.34	8.05	0.3	4.16e-15	Coronary artery disease;
BRCA	cis	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg07460842	chr6:66804631	NA	-0.94	-17.59	-0.57	8.51e-57	Exhaled nitric oxide output;
BRCA	cis	rs548181	0.736	rs1941558	chr11:125425606	C/T	cg03464685	chr11:125439445	EI24	1.12	17.48	0.57	3.36e-56	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs4780401	0.609	rs8063099	chr16:11806714	T/G	cg01061890	chr16:11836724	TXNDC11	-0.55	-13.07	-0.46	9.31e-35	Rheumatoid arthritis;
BRCA	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg10932868	chr11:921992	NA	0.49	12.63	0.45	8.39e-33	Alzheimer's disease (late onset);
BRCA	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg15485101	chr11:133734466	NA	0.41	9.71	0.36	6.96e-21	Childhood ear infection;
BRCA	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.52	9.05	0.34	1.71e-18	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	18.89	0.6	1.4e-63	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	11.23	0.41	7.85e-27	Schizophrenia;
BRCA	cis	rs4930561	0.765	rs4930229	chr11:67944080	G/A	cg16338278	chr11:67432957	ALDH3B2	0.43	8.81	0.33	1.13e-17	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.15	0.4	1.74e-26	Rheumatoid arthritis;
BRCA	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg06064525	chr11:970664	AP2A2	-0.49	-16.07	-0.54	4.92e-49	Alzheimer's disease (late onset);
BRCA	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg04546413	chr19:29218101	NA	0.44	8.16	0.31	1.83e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg05340658	chr4:99064831	C4orf37	0.61	14.7	0.5	2.43e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg21747090	chr2:27597821	SNX17	-0.45	-9.7	-0.36	7.9e-21	Total body bone mineral density;
BRCA	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg21573476	chr21:45109991	RRP1B	-0.36	-9.48	-0.35	4.82e-20	Mean corpuscular volume;
BRCA	cis	rs3784262	0.565	rs9635350	chr15:58298412	G/A	cg12031962	chr15:58353849	ALDH1A2	0.32	8.5	0.32	1.3e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-11.04	-0.4	4.7e-26	IgG glycosylation;
BRCA	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.84	-0.3	1.92e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs3857067	0.680	rs1509946	chr4:95109078	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.38	-9.2	-0.34	4.82e-19	QT interval;
BRCA	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg07741184	chr6:167504864	NA	0.36	9.95	0.37	9.05e-22	Primary biliary cholangitis;
BRCA	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg00074818	chr8:8560427	CLDN23	0.38	8.45	0.32	2.02e-16	Obesity-related traits;
BRCA	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg09307838	chr4:120376055	NA	0.6	11.15	0.4	1.65e-26	Corneal astigmatism;
BRCA	cis	rs9815354	0.812	rs56728371	chr3:41999381	T/A	cg03022575	chr3:42003672	ULK4	0.65	9.34	0.35	1.53e-19	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg05347473	chr6:146136440	FBXO30	-0.41	-8.05	-0.3	3.92e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-8.77	-0.33	1.56e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg22903471	chr2:27725779	GCKR	-0.34	-8.21	-0.31	1.22e-15	Total body bone mineral density;
BRCA	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg26384229	chr12:38710491	ALG10B	0.68	14.16	0.49	8.91e-40	Morning vs. evening chronotype;
BRCA	cis	rs6963495	0.585	rs1728653	chr7:105191335	A/G	cg19920283	chr7:105172520	RINT1	0.57	11.4	0.41	1.56e-27	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg24812749	chr6:127587940	RNF146	0.88	20.44	0.63	8.18e-72	Breast cancer;
BRCA	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg22920501	chr2:26401640	FAM59B	0.94	16.57	0.55	1.46e-51	Gut microbiome composition (summer);
BRCA	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg02773041	chr1:40204384	PPIE	0.43	9.25	0.34	3.34e-19	Blood protein levels;
BRCA	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.07e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2559856	1.000	rs2695299	chr12:102082664	G/A	cg12924262	chr12:102091054	CHPT1	0.35	7.94	0.3	8.88e-15	Blood protein levels;
BRCA	cis	rs6973256	0.897	rs9656424	chr7:133325031	A/T	cg07491979	chr7:133331646	EXOC4	-0.38	-8.8	-0.33	1.28e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg06064525	chr11:970664	AP2A2	0.48	16.27	0.54	4.42e-50	Alzheimer's disease (late onset);
BRCA	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14442939	chr10:27389572	ANKRD26	0.68	9.37	0.35	1.22e-19	Breast cancer;
BRCA	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg12292205	chr6:26970375	C6orf41	-0.49	-8.07	-0.3	3.56e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1568889	1.000	rs61889026	chr11:28274803	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	13.27	0.46	1.18e-35	Bipolar disorder;
BRCA	cis	rs9649465	1.000	rs2299983	chr7:123356642	C/G	cg04330084	chr7:123175371	IQUB	-0.33	-9.01	-0.34	2.32e-18	Migraine;
BRCA	cis	rs2302729	0.578	rs2302728	chr12:2774668	A/C	cg19945202	chr12:2788847	CACNA1C	0.43	9.63	0.36	1.38e-20	Sleep quality;
BRCA	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg01028140	chr2:1542097	TPO	-0.56	-11.48	-0.41	7.52e-28	IgG glycosylation;
BRCA	trans	rs75804782	0.641	rs72987304	chr2:239345532	C/T	cg01134436	chr17:81009848	B3GNTL1	0.78	9.79	0.36	3.57e-21	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs2979489	1.000	rs2979469	chr8:30285091	C/G	cg26383811	chr8:30366931	RBPMS	0.47	11.07	0.4	3.53e-26	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
BRCA	cis	rs17767294	0.708	rs6908688	chr6:27886051	A/G	cg08851530	chr6:28072375	NA	0.78	8.04	0.3	4.51e-15	Parkinson's disease;
BRCA	cis	rs9462027	0.628	rs2764208	chr6:34714322	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.06	-0.3	3.75e-15	Systemic lupus erythematosus;
BRCA	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.22e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.99	0.33	2.85e-18	Motion sickness;
BRCA	cis	rs62229266	0.804	rs12483151	chr21:37419578	C/T	cg12218747	chr21:37451666	NA	-0.33	-7.92	-0.3	1.08e-14	Mitral valve prolapse;
BRCA	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-8.87	-0.33	7.03e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg02659138	chr7:134003124	SLC35B4	-0.36	-10.11	-0.37	2.11e-22	Mean platelet volume;
BRCA	cis	rs7904985	1.000	rs10887586	chr10:88113521	G/A	cg07322936	chr10:88137208	NA	-0.42	-8.41	-0.32	2.78e-16	Barrett's esophagus;
BRCA	cis	rs1997103	1.000	rs9649851	chr7:55398692	C/A	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.72e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4653767	1.000	rs10916030	chr1:226919908	C/T	cg05049329	chr1:226924846	ITPKB	0.34	9.59	0.35	1.92e-20	Parkinson's disease;
BRCA	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-8.83	-0.33	1.04e-17	Response to antipsychotic treatment;
BRCA	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.57	-0.42	3.03e-28	Bipolar disorder;
BRCA	cis	rs2191566	1.000	rs7256908	chr19:44528898	C/T	cg20607764	chr19:44506953	ZNF230	-0.37	-7.88	-0.3	1.46e-14	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs2882667	0.858	rs13177503	chr5:138432759	G/C	cg04439458	chr5:138467593	SIL1	-0.41	-10.29	-0.38	4.29e-23	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg17830980	chr10:43048298	ZNF37B	0.42	9.91	0.36	1.26e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs922182	0.617	rs55694045	chr15:64245943	T/C	cg24729988	chr15:64271149	DAPK2	0.49	10.36	0.38	2.46e-23	Blood protein levels;
BRCA	cis	rs8062405	0.723	rs762633	chr16:28608341	T/C	cg16576597	chr16:28551801	NUPR1	0.34	9.04	0.34	1.92e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg21659725	chr3:3221576	CRBN	-0.49	-8.5	-0.32	1.31e-16	Menarche (age at onset);
BRCA	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg04455712	chr21:45112962	RRP1B	0.41	10.88	0.4	2.11e-25	Mean corpuscular volume;
BRCA	cis	rs17270561	0.636	rs9379779	chr6:25695441	G/T	cg16482183	chr6:26056742	HIST1H1C	0.45	8.52	0.32	1.13e-16	Iron status biomarkers;
BRCA	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.35	7.91	0.3	1.12e-14	Coronary artery disease;
BRCA	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg01689657	chr7:91764605	CYP51A1	-0.22	-8.18	-0.31	1.51e-15	Breast cancer;
BRCA	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.5	8.34	0.31	4.7e-16	HIV-1 control;
BRCA	cis	rs7737355	1.000	rs798416	chr5:130693100	T/C	cg06307176	chr5:131281290	NA	-0.47	-9.11	-0.34	1.01e-18	Life satisfaction;
BRCA	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg20487152	chr13:99095054	FARP1	-0.42	-11.5	-0.41	5.89e-28	Neuroticism;
BRCA	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg23711669	chr6:146136114	FBXO30	0.8	18.97	0.6	5.73e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	9.08	0.34	1.34e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg08999081	chr20:33150536	PIGU	0.35	9.07	0.34	1.4e-18	Coronary artery disease;
BRCA	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.69	0.63	3.71e-73	Electrocardiographic conduction measures;
BRCA	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg09462578	chr12:12878428	APOLD1	-0.58	-10.46	-0.38	9.69e-24	Systemic lupus erythematosus;
BRCA	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg05340658	chr4:99064831	C4orf37	-0.69	-17.23	-0.56	6.39e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs71636778	0.543	rs34409791	chr1:27245363	A/G	cg12203394	chr1:27248618	NUDC	0.6	9.42	0.35	7.92e-20	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg03474202	chr17:45855739	NA	-0.46	-12.5	-0.44	3.21e-32	IgG glycosylation;
BRCA	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg16325326	chr1:53192061	ZYG11B	-0.9	-25.01	-0.7	9.36e-97	Monocyte count;
BRCA	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg02753203	chr1:228287806	NA	-0.57	-12.12	-0.43	1.46e-30	Diastolic blood pressure;
BRCA	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg25767906	chr1:53392781	SCP2	-0.46	-10.3	-0.38	4.13e-23	Monocyte count;
BRCA	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.37	-8.68	-0.32	3.25e-17	Longevity;Endometriosis;
BRCA	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.68	-18.5	-0.59	1.63e-61	Longevity;Endometriosis;
BRCA	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.44	-9.02	-0.34	2.16e-18	Body mass index;
BRCA	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg24675658	chr1:53192096	ZYG11B	-0.52	-11.55	-0.42	3.57e-28	Monocyte count;
BRCA	cis	rs9400271	0.632	rs9374072	chr6:109591586	A/G	cg01475377	chr6:109611718	NA	-0.44	-10.4	-0.38	1.7e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs295140	0.506	rs4673855	chr2:201136143	A/G	cg23649088	chr2:200775458	C2orf69	-0.39	-8.25	-0.31	9.08e-16	QT interval;
BRCA	cis	rs9309473	1.000	rs13421462	chr2:73719875	A/C	cg20560298	chr2:73613845	ALMS1	-0.46	-11.34	-0.41	2.66e-27	Metabolite levels;
BRCA	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg20887711	chr4:1340912	KIAA1530	0.66	14.34	0.49	1.28e-40	Longevity;
BRCA	cis	rs34779708	0.931	rs17582416	chr10:35287650	A/C	cg03585969	chr10:35415529	CREM	0.47	9.69	0.36	7.98e-21	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18876405	chr7:65276391	NA	0.5	11.1	0.4	2.63e-26	Aortic root size;
BRCA	cis	rs3772130	1.000	rs7427165	chr3:121364624	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.53	9.44	0.35	6.61e-20	Cognitive performance;
BRCA	cis	rs1499972	0.878	rs817513	chr3:117733823	A/T	cg07612923	chr3:117604196	NA	-0.6	-7.85	-0.3	1.79e-14	Schizophrenia;
BRCA	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-11.47	-0.41	8.14e-28	Gut microbiome composition (summer);
BRCA	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg05623727	chr3:50126028	RBM5	-0.42	-9.82	-0.36	2.79e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg06697600	chr4:7070879	GRPEL1	-0.62	-12.55	-0.44	1.97e-32	Monocyte percentage of white cells;
BRCA	trans	rs10805346	0.505	rs35995899	chr4:10112862	T/C	cg26043149	chr18:55253948	FECH	0.46	10.63	0.39	2.06e-24	Urate levels in overweight individuals;Urate levels in obese individuals;
BRCA	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-11.85	-0.42	2.11e-29	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg15556689	chr8:8085844	FLJ10661	-0.35	-8.53	-0.32	1.05e-16	Retinal vascular caliber;
BRCA	trans	rs8073060	0.963	rs35614987	chr17:33869466	A/C	cg19694781	chr19:47549865	TMEM160	0.57	12.24	0.44	4.24e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs9290065	0.519	rs6441346	chr3:160709229	C/T	cg03342759	chr3:160939853	NMD3	-0.5	-10.16	-0.37	1.36e-22	Kawasaki disease;
BRCA	trans	rs6600671	1.000	rs2185281	chr1:121179991	A/G	cg17023122	chr1:144479586	NA	0.33	7.9	0.3	1.22e-14	Hip geometry;
BRCA	cis	rs4713675	0.565	rs4713674	chr6:33708169	C/T	cg14003231	chr6:33640908	ITPR3	-0.34	-8.18	-0.31	1.54e-15	Plateletcrit;
BRCA	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg00409905	chr10:38381863	ZNF37A	0.47	8.52	0.32	1.16e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.3	-0.44	2.32e-31	Breast cancer;
BRCA	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.66	-0.5	3.76e-42	Chronic sinus infection;
BRCA	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg18225595	chr11:63971243	STIP1	0.52	9.44	0.35	6.78e-20	Mean platelet volume;
BRCA	cis	rs7520050	0.966	rs1768803	chr1:46546208	T/C	cg24296786	chr1:45957014	TESK2	0.41	9.19	0.34	5.33e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg08999081	chr20:33150536	PIGU	0.38	9.66	0.36	1.05e-20	Coronary artery disease;
BRCA	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.5	-12.78	-0.45	1.73e-33	Longevity;Endometriosis;
BRCA	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg26384229	chr12:38710491	ALG10B	0.67	14.19	0.49	6.23e-40	Morning vs. evening chronotype;
BRCA	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	13.87	0.48	2.04e-38	Alzheimer's disease;
BRCA	cis	rs875622	0.556	rs4808047	chr19:16527834	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	-0.55	-9.97	-0.37	7.22e-22	White matter integrity;Neutrophil percentage of white cells;
BRCA	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.22	-0.31	1.17e-15	Depression;
BRCA	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg08885076	chr2:99613938	TSGA10	0.44	10.29	0.38	4.46e-23	Chronic sinus infection;
BRCA	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg15133208	chr4:90757351	SNCA	-0.39	-7.85	-0.3	1.74e-14	Neuroticism;
BRCA	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg22920501	chr2:26401640	FAM59B	-0.65	-11.31	-0.41	3.64e-27	Gut microbiome composition (summer);
BRCA	trans	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg15556689	chr8:8085844	FLJ10661	-0.32	-8.47	-0.32	1.68e-16	Monocyte count;
BRCA	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg23533926	chr12:111358616	MYL2	-0.39	-8.13	-0.31	2.29e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1506636	1.000	rs12333705	chr7:123356062	C/T	cg03229431	chr7:123269106	ASB15	-0.61	-13.96	-0.48	7.91e-39	Plateletcrit;Platelet count;
BRCA	cis	rs6942756	0.688	rs2718089	chr7:128927022	G/T	cg02491457	chr7:128862824	NA	0.56	11.72	0.42	7.37e-29	White matter hyperintensity burden;
BRCA	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.37	8.11	0.31	2.51e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9942416	0.660	rs166183	chr5:74977845	T/C	cg19683494	chr5:74908142	NA	-0.48	-8.93	-0.33	4.6e-18	Age-related disease endophenotypes;
BRCA	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.63	-0.39	2.1e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg22974920	chr21:40686053	BRWD1	-0.4	-8.81	-0.33	1.21e-17	Cognitive function;
BRCA	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg08132940	chr7:1081526	C7orf50	-0.59	-8.77	-0.33	1.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg08807101	chr21:30365312	RNF160	-0.38	-8.17	-0.31	1.61e-15	Pancreatic cancer;
BRCA	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	9.98	0.37	6.64e-22	Retinal vascular caliber;
BRCA	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg08514558	chr10:81106712	PPIF	0.38	8.42	0.32	2.46e-16	Height;
BRCA	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11890956	chr21:40555474	PSMG1	0.67	15.51	0.52	2.7e-46	Cognitive function;
BRCA	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg09307838	chr4:120376055	NA	0.6	11.05	0.4	4.23e-26	Corneal astigmatism;
BRCA	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg16586182	chr3:47516702	SCAP	0.39	8.2	0.31	1.31e-15	Birth weight;
BRCA	cis	rs7395581	0.918	rs10838692	chr11:47345100	T/C	cg25783544	chr11:47291846	MADD	0.43	9.58	0.35	2.09e-20	HDL cholesterol;
BRCA	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11890956	chr21:40555474	PSMG1	-0.6	-13.57	-0.47	4.64e-37	Menarche (age at onset);
BRCA	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg26384229	chr12:38710491	ALG10B	0.58	13.3	0.47	8.01e-36	Morning vs. evening chronotype;
BRCA	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.33	0.31	4.94e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.47	0.32	1.66e-16	Parkinson's disease;
BRCA	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg00757033	chr12:89920650	WDR51B	0.54	10.78	0.39	5.25e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg11366901	chr6:160182831	ACAT2	0.7	13.05	0.46	1.09e-34	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg25358565	chr5:93447407	FAM172A	-0.68	-11.63	-0.42	1.67e-28	Diabetic retinopathy;
BRCA	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25427524	chr10:38739819	LOC399744	-0.7	-16.92	-0.56	2.46e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1403694	0.655	rs3806688	chr3:186434819	T/C	cg12454167	chr3:186435060	KNG1	0.29	7.9	0.3	1.22e-14	Blood protein levels;
BRCA	trans	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg26384229	chr12:38710491	ALG10B	0.51	11.03	0.4	4.98e-26	Morning vs. evening chronotype;
BRCA	cis	rs11608355	0.545	rs2302703	chr12:109898832	G/A	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs11229555	0.645	rs11229463	chr11:58210147	A/G	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-8.86	-0.33	7.77e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg03676636	chr4:99064102	C4orf37	0.23	8.2	0.31	1.31e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7520050	1.000	rs785511	chr1:46534498	T/C	cg24296786	chr1:45957014	TESK2	0.41	9.19	0.34	5.41e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9473147	0.516	rs7749167	chr6:47493940	G/A	cg12968598	chr6:47444699	CD2AP	0.44	9.59	0.35	1.93e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	7.15e-19	Alzheimer's disease (late onset);
BRCA	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-9.48	-0.35	4.92e-20	Alzheimer's disease (late onset);
BRCA	cis	rs17253792	0.822	rs77415412	chr14:56154146	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-9.53	-0.35	3.34e-20	Putamen volume;
BRCA	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg09184832	chr6:79620586	NA	-0.52	-11.41	-0.41	1.44e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs9682041	0.740	rs6444929	chr3:170150076	C/T	cg11886554	chr3:170076028	SKIL	0.78	12.65	0.45	6.7e-33	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.06	-0.34	1.6e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg14835575	chr10:16859367	RSU1	0.51	11.52	0.41	4.89e-28	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg23422044	chr7:1970798	MAD1L1	-0.56	-9.32	-0.35	1.85e-19	Neuroticism;
BRCA	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs4308124	0.708	rs6727313	chr2:111971540	G/A	cg04571233	chr2:111982156	NA	-0.45	-9.62	-0.36	1.52e-20	Vitiligo;
BRCA	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg03684893	chr10:554711	DIP2C	-0.43	-10.37	-0.38	2.1e-23	Psychosis in Alzheimer's disease;
BRCA	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg12310025	chr6:25882481	NA	-0.57	-13.9	-0.48	1.51e-38	Blood metabolite levels;
BRCA	cis	rs11969893	0.737	rs6930051	chr6:101406108	A/G	cg12253828	chr6:101329408	ASCC3	0.98	13.88	0.48	1.78e-38	Economic and political preferences (immigration/crime);
BRCA	cis	rs117623576	0.618	rs211413	chr10:32396902	C/A	cg03047570	chr10:32398778	NA	0.57	8.82	0.33	1.1e-17	Anti-saccade response;
BRCA	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	trans	rs75804782	0.630	rs56354063	chr2:239253919	A/G	cg01134436	chr17:81009848	B3GNTL1	0.78	8.13	0.31	2.21e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg03060546	chr3:49711283	APEH	0.56	8.77	0.33	1.65e-17	Menarche (age at onset);
BRCA	cis	rs1568889	0.667	rs16917914	chr11:28459909	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	9.6	0.35	1.83e-20	Bipolar disorder;
BRCA	cis	rs16867335	0.625	rs7573877	chr2:181478111	A/G	cg23363182	chr2:181467187	NA	-0.43	-9.26	-0.34	3e-19	Survival in rectal cancer;
BRCA	cis	rs17641971	0.684	rs12545097	chr8:49951977	A/G	cg00325661	chr8:49890786	NA	0.37	10.29	0.38	4.37e-23	Blood metabolite levels;
BRCA	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg09307838	chr4:120376055	NA	0.66	14.35	0.49	1.09e-40	Corneal astigmatism;
BRCA	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22857025	chr5:266934	NA	-1.04	-19.68	-0.61	9.4e-68	Breast cancer;
BRCA	cis	rs2731664	0.756	rs2545796	chr5:176864269	T/C	cg23176889	chr5:176863531	GRK6	-0.6	-16.02	-0.54	8.41e-49	Intelligence (multi-trait analysis);
BRCA	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg21475434	chr5:93447410	FAM172A	0.73	9.25	0.34	3.42e-19	Diabetic retinopathy;
BRCA	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.58	9.9	0.36	1.32e-21	Lung function (FEV1/FVC);
BRCA	cis	rs9815354	0.767	rs73071238	chr3:41992243	A/G	cg03022575	chr3:42003672	ULK4	0.73	10.02	0.37	4.78e-22	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	12.74	0.45	2.81e-33	Mean platelet volume;
BRCA	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02176678	chr2:219576539	TTLL4	0.45	11.62	0.42	1.97e-28	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.84	18.23	0.59	4e-60	IgG glycosylation;
BRCA	cis	rs58785573	0.624	rs337605	chr4:38647753	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.48	10.22	0.37	7.88e-23	Lymphocyte percentage of white cells;
BRCA	cis	rs700651	0.789	rs892514	chr2:198905270	T/C	cg00792783	chr2:198669748	PLCL1	0.37	8.2	0.31	1.32e-15	Intracranial aneurysm;
BRCA	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	18.11	0.58	1.89e-59	Menopause (age at onset);
BRCA	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg18132916	chr6:79620363	NA	-0.46	-10.63	-0.39	2e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.55	12.72	0.45	3.46e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg04455712	chr21:45112962	RRP1B	0.39	10.41	0.38	1.5e-23	Mean corpuscular volume;
BRCA	cis	rs1953600	0.870	rs2788296	chr10:81937889	G/A	cg04850286	chr10:81895943	PLAC9	0.31	8.8	0.33	1.27e-17	Sarcoidosis;
BRCA	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg08999081	chr20:33150536	PIGU	-0.46	-12.8	-0.45	1.48e-33	Glomerular filtration rate (creatinine);
BRCA	cis	rs2806561	1.000	rs1571466	chr1:23449183	T/C	cg19743168	chr1:23544995	NA	0.4	9.66	0.36	1.03e-20	Height;
BRCA	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	8.4	0.32	2.86e-16	Iron status biomarkers;
BRCA	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg05283184	chr6:79620031	NA	-0.43	-11.1	-0.4	2.69e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7833986	1.000	rs13281873	chr8:57101799	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.45	8.14	0.31	2.13e-15	Height;
BRCA	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg09184832	chr6:79620586	NA	-0.48	-10.5	-0.38	6.52e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg01416388	chr22:39784598	NA	0.42	8.15	0.31	1.9e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg08999081	chr20:33150536	PIGU	0.36	9.13	0.34	8.7e-19	Coronary artery disease;
BRCA	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg03433033	chr1:76189801	ACADM	-0.4	-8.17	-0.31	1.65e-15	Daytime sleep phenotypes;
BRCA	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg17986701	chr20:44574422	PCIF1	0.36	8.84	0.33	9.3e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg24069376	chr3:38537580	EXOG	0.4	11.37	0.41	2.13e-27	Electrocardiographic conduction measures;
BRCA	cis	rs6714710	0.603	rs12104810	chr2:98443658	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	13.62	0.47	2.79e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27286337	chr10:134555280	INPP5A	0.64	11.36	0.41	2.38e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs35847492	1.000	rs35847492	chr8:9276025	G/C	cg06636001	chr8:8085503	FLJ10661	0.49	9.45	0.35	6.52e-20	Neuroticism;
BRCA	cis	rs4908760	0.827	rs7513420	chr1:8681044	T/C	cg20416874	chr1:8611966	RERE	-0.28	-8.1	-0.31	2.74e-15	Vitiligo;
BRCA	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg02493740	chr2:85810744	VAMP5	-0.39	-8.28	-0.31	7.38e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg21770322	chr7:97807741	LMTK2	0.48	11.97	0.43	6.17e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg07169764	chr2:136633963	MCM6	1.22	23.71	0.68	1.27e-89	Corneal structure;
BRCA	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg01181863	chr3:195395398	SDHAP2	-0.58	-10.61	-0.39	2.47e-24	Pancreatic cancer;
BRCA	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg15556689	chr8:8085844	FLJ10661	-0.37	-10.14	-0.37	1.6e-22	Neuroticism;
BRCA	cis	rs4664304	0.966	rs925407	chr2:160767502	A/C	cg01092293	chr2:160761427	LY75	-0.44	-10.49	-0.38	7.12e-24	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg06115741	chr20:33292138	TP53INP2	0.4	8.94	0.33	4.12e-18	Coronary artery disease;
BRCA	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg08085267	chr17:45401833	C17orf57	-0.6	-12.38	-0.44	1.1e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg18512352	chr11:47633146	NA	-0.35	-8.48	-0.32	1.56e-16	Subjective well-being;
BRCA	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg13073564	chr4:8508604	NA	0.42	11.44	0.41	1.08e-27	Response to antineoplastic agents;
BRCA	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.37	7.93	0.3	9.51e-15	Total cholesterol levels;
BRCA	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg16262614	chr3:133464971	TF	0.24	7.91	0.3	1.13e-14	Iron status biomarkers (transferrin levels);
BRCA	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	14.41	0.5	5.76e-41	Colorectal cancer;
BRCA	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg22980127	chr19:33182716	NUDT19	0.91	20.72	0.63	2.29e-73	Red blood cell traits;
BRCA	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12310025	chr6:25882481	NA	-0.56	-12.31	-0.44	2.2e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.08e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg23791538	chr6:167370224	RNASET2	-0.36	-8.51	-0.32	1.28e-16	Crohn's disease;
BRCA	cis	rs10744422	1.000	rs7138398	chr12:123341833	G/C	cg25930673	chr12:123319894	HIP1R	-0.53	-8.14	-0.31	2.06e-15	Schizophrenia;
BRCA	trans	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg00938859	chr5:1591904	SDHAP3	0.64	8.89	0.33	6.41e-18	Breast cancer;
BRCA	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg08508325	chr11:3079039	CARS	0.28	8.58	0.32	7.38e-17	Calcium levels;
BRCA	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06022373	chr22:39101656	GTPBP1	-0.67	-17.12	-0.56	2.3e-54	Menopause (age at onset);
BRCA	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg19773385	chr1:10388646	KIF1B	-0.38	-8.27	-0.31	7.87e-16	Hepatocellular carcinoma;
BRCA	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-10.15	-0.37	1.47e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg11764359	chr7:65958608	NA	-0.67	-14.91	-0.51	2.34e-43	Aortic root size;
BRCA	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg17330251	chr7:94953956	PON1	-0.4	-8.46	-0.32	1.84e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs11690935	0.550	rs6746701	chr2:172869255	G/A	cg13550731	chr2:172543902	DYNC1I2	0.49	12.1	0.43	1.76e-30	Schizophrenia;
BRCA	trans	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg06521331	chr12:34319734	NA	-0.47	-8.68	-0.32	3.19e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs62158211	1.000	rs4618068	chr2:114109355	C/T	cg17784749	chr2:114082611	LOC440839	0.48	8.41	0.32	2.75e-16	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
BRCA	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg22974920	chr21:40686053	BRWD1	-0.4	-8.91	-0.33	5.17e-18	Cognitive function;
BRCA	cis	rs6484504	0.512	rs2761594	chr11:31318244	A/G	cg06552810	chr11:31128660	NA	0.4	8.89	0.33	6.19e-18	Red blood cell count;
BRCA	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg22563815	chr15:78856949	CHRNA5	-0.35	-8.41	-0.32	2.65e-16	Sudden cardiac arrest;
BRCA	cis	rs7737355	1.000	rs7719126	chr5:130613749	T/C	cg06307176	chr5:131281290	NA	0.47	9.08	0.34	1.36e-18	Life satisfaction;
BRCA	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg12698349	chr2:225449008	CUL3	0.62	13.54	0.47	6.86e-37	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg06115741	chr20:33292138	TP53INP2	0.39	8.62	0.32	5.23e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg00666640	chr1:248458726	OR2T12	0.32	8.95	0.33	3.99e-18	Common traits (Other);
BRCA	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg08807101	chr21:30365312	RNF160	0.59	15.15	0.51	1.55e-44	Dental caries;
BRCA	cis	rs7903847	0.596	rs10786340	chr10:99156563	G/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.83	-0.33	9.93e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg20607798	chr8:58055168	NA	0.48	8.39	0.31	3.13e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4803468	1.000	rs55986560	chr19:41939835	C/T	cg09537434	chr19:41945824	ATP5SL	1.03	25.42	0.71	4.7e-99	Height;
BRCA	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.41	8.77	0.33	1.66e-17	IgG glycosylation;
BRCA	cis	rs1506636	0.924	rs2402668	chr7:123296605	T/A	cg03229431	chr7:123269106	ASB15	-0.64	-14.3	-0.49	1.95e-40	Plateletcrit;Platelet count;
BRCA	cis	rs367943	0.723	rs1965429	chr5:112679373	G/T	cg12552261	chr5:112820674	MCC	-0.4	-8.72	-0.33	2.33e-17	Type 2 diabetes;
BRCA	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg25036284	chr2:26402008	FAM59B	0.77	10.67	0.39	1.41e-24	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.82e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08219700	chr8:58056026	NA	0.45	8.1	0.31	2.86e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-8.82	-0.33	1.09e-17	Response to antipsychotic treatment;
BRCA	cis	rs6910061	0.830	rs41270602	chr6:11094690	G/T	cg27233058	chr6:11094804	LOC221710	0.49	8.32	0.31	5.48e-16	Diabetic kidney disease;
BRCA	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg25554036	chr4:6271136	WFS1	0.42	9.99	0.37	6.36e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg05623727	chr3:50126028	RBM5	0.49	11.61	0.42	2.07e-28	Body mass index;
BRCA	cis	rs1043763	0.826	rs10847689	chr12:122613000	A/G	cg14400030	chr12:122498111	BCL7A	-0.6	-13.65	-0.48	2.04e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
BRCA	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg15839431	chr19:19639596	YJEFN3	-0.43	-8.67	-0.32	3.64e-17	Bipolar disorder;
BRCA	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg20790798	chr5:1857306	NA	-0.38	-8.78	-0.33	1.55e-17	Cardiovascular disease risk factors;
BRCA	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg21475434	chr5:93447410	FAM172A	0.66	8.49	0.32	1.43e-16	Diabetic retinopathy;
BRCA	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg11663144	chr21:46675770	NA	-0.61	-13.91	-0.48	1.22e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg01420254	chr6:26195488	NA	0.55	8.64	0.32	4.59e-17	Gout;Renal underexcretion gout;
BRCA	trans	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg23762105	chr12:34175262	ALG10	-0.34	-8.45	-0.32	1.96e-16	Morning vs. evening chronotype;
BRCA	cis	rs701145	0.585	rs1713854	chr3:153848030	T/C	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.22e-14	Coronary artery disease;
BRCA	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.16e-47	Alzheimer's disease (late onset);
BRCA	cis	rs12760731	0.641	rs12691479	chr1:178328754	G/A	cg00404053	chr1:178313656	RASAL2	0.62	8.66	0.32	3.96e-17	Obesity-related traits;
BRCA	cis	rs6878727	0.850	rs7712066	chr5:123717754	A/G	cg01806427	chr5:123737813	NA	0.38	8.79	0.33	1.42e-17	Breast cancer;
BRCA	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg13397359	chr6:42928475	GNMT	-0.51	-12.2	-0.43	6.31e-31	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg22105103	chr4:187893119	NA	0.3	9.61	0.36	1.61e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.59	-0.39	2.84e-24	Mean corpuscular volume;
BRCA	trans	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg06521331	chr12:34319734	NA	-0.47	-8.72	-0.33	2.46e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11890956	chr21:40555474	PSMG1	1.06	30.43	0.77	2.04e-126	Cognitive function;
BRCA	cis	rs939658	0.776	rs68147688	chr15:79443848	G/A	cg17916960	chr15:79447300	NA	-0.46	-11.45	-0.41	9.24e-28	Refractive error;
BRCA	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.33e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10463316	0.894	rs3905511	chr5:150768204	G/A	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.33	-0.31	4.91e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs73416724	1.000	rs17209407	chr6:43358362	A/G	cg26312998	chr6:43337775	ZNF318	0.49	7.97	0.3	7.26e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg23992470	chr4:843637	GAK	0.56	8.43	0.32	2.31e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6815814	0.851	rs73236644	chr4:38863193	A/G	cg02016764	chr4:38805732	TLR1	-0.53	-8.34	-0.31	4.67e-16	Breast cancer;
BRCA	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg01304814	chr3:48885189	PRKAR2A	0.57	7.96	0.3	7.88e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05901451	chr6:126070800	HEY2	-0.41	-10.08	-0.37	2.73e-22	Endometrial cancer;
BRCA	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg27478167	chr7:817139	HEATR2	-0.44	-9.52	-0.35	3.55e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs113835537	0.529	rs3816492	chr11:66297363	C/T	cg24851651	chr11:66362959	CCS	0.52	8.98	0.33	2.9e-18	Airway imaging phenotypes;
BRCA	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg04705435	chr11:17411270	KCNJ11	0.44	9.37	0.35	1.23e-19	Type 2 diabetes;
BRCA	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg05526886	chr2:227700861	RHBDD1	-0.38	-7.86	-0.3	1.62e-14	Pulmonary function;
BRCA	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg21535247	chr6:8435926	SLC35B3	-0.37	-8.37	-0.31	3.54e-16	Motion sickness;
BRCA	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg08859206	chr1:53392774	SCP2	-0.39	-8.25	-0.31	9.33e-16	Monocyte count;
BRCA	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg26031613	chr14:104095156	KLC1	0.73	15.91	0.53	2.85e-48	Body mass index;
BRCA	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.33	-8.19	-0.31	1.39e-15	Total body bone mineral density;
BRCA	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.63	0.39	2.14e-24	Motion sickness;
BRCA	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg14289826	chr9:140003911	NA	-0.49	-12.77	-0.45	2e-33	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg05340658	chr4:99064831	C4orf37	0.67	16.82	0.55	8.11e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.79	-0.33	1.39e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg18252515	chr7:66147081	NA	-1.07	-15.7	-0.53	3.09e-47	Diabetic kidney disease;
BRCA	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg06784218	chr1:46089804	CCDC17	-0.52	-12.5	-0.44	3.03e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg11707556	chr5:10655725	ANKRD33B	0.33	8.02	0.3	5.04e-15	Height;
BRCA	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg27398817	chr8:82754497	SNX16	-0.45	-8.94	-0.33	4.02e-18	Diastolic blood pressure;
BRCA	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00339695	chr16:24857497	SLC5A11	0.34	7.92	0.3	1.03e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7572733	0.555	rs2341778	chr2:198776546	G/A	cg00792783	chr2:198669748	PLCL1	-0.48	-10.32	-0.38	3.35e-23	Dermatomyositis;
BRCA	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg20587970	chr11:113659929	NA	-0.96	-18.65	-0.59	2.81e-62	Hip circumference adjusted for BMI;
BRCA	cis	rs6426558	0.537	rs7523167	chr1:227365304	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.47	-9.32	-0.35	1.9e-19	Neutrophil percentage of white cells;
BRCA	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg03425785	chr20:62221387	GMEB2	0.52	8.32	0.31	5.51e-16	Glioblastoma;
BRCA	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg18252515	chr7:66147081	NA	-1.06	-15.7	-0.53	3.07e-47	Gout;
BRCA	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg07395648	chr5:131743802	NA	-0.39	-9.66	-0.36	1.08e-20	Blood metabolite levels;
BRCA	cis	rs11945232	1.000	rs28630962	chr4:88336386	C/T	cg23841344	chr4:88312519	HSD17B11	-0.5	-9.73	-0.36	6.04e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4285028	0.699	rs2689285	chr3:121586486	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.7	13.06	0.46	1.05e-34	Multiple sclerosis;
BRCA	cis	rs490234	0.841	rs476819	chr9:128362737	C/T	cg14078157	chr9:128172775	NA	-0.33	-7.86	-0.3	1.66e-14	Mean arterial pressure;
BRCA	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg26384229	chr12:38710491	ALG10B	0.77	17.45	0.57	4.59e-56	Bladder cancer;
BRCA	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.04	-0.3	4.35e-15	Extrinsic epigenetic age acceleration;
BRCA	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg26384229	chr12:38710491	ALG10B	-0.75	-16.09	-0.54	3.89e-49	Morning vs. evening chronotype;
BRCA	cis	rs524281	0.647	rs2302883	chr11:65824994	T/C	cg16950941	chr11:66035639	RAB1B	-0.41	-8.88	-0.33	6.83e-18	Electroencephalogram traits;
BRCA	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.8	-0.36	3.31e-21	IgG glycosylation;
BRCA	trans	rs9951602	0.512	rs9949512	chr18:76641845	T/C	cg02800362	chr5:177631904	HNRNPAB	0.76	17.58	0.57	1.01e-56	Obesity-related traits;
BRCA	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	9.19	0.34	5.32e-19	Height;
BRCA	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg18196295	chr10:418757	DIP2C	-0.49	-11.07	-0.4	3.45e-26	Psychosis in Alzheimer's disease;
BRCA	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg02659138	chr7:134003124	SLC35B4	0.32	9.78	0.36	3.74e-21	Mean platelet volume;
BRCA	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg04455712	chr21:45112962	RRP1B	0.46	12.35	0.44	1.44e-31	Mean corpuscular volume;
BRCA	cis	rs7727544	0.582	rs4361509	chr5:131536753	A/G	cg14196790	chr5:131705035	SLC22A5	-0.37	-9.27	-0.34	2.87e-19	Blood metabolite levels;
BRCA	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08045932	chr20:61659980	NA	0.5	11.43	0.41	1.2100000000000001e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.82	0.3	2.11e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg24296786	chr1:45957014	TESK2	0.46	10.37	0.38	2.17e-23	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	18.01	0.58	5.88e-59	Alzheimer's disease;
BRCA	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg13010199	chr12:38710504	ALG10B	0.41	8.36	0.31	3.97e-16	Bladder cancer;
BRCA	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-16.25	-0.54	5.74e-50	Total cholesterol levels;
BRCA	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg21475434	chr5:93447410	FAM172A	0.72	8.89	0.33	6e-18	Diabetic retinopathy;
BRCA	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg24399712	chr22:39784796	NA	0.58	12.51	0.44	2.82e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs6450176	1.000	rs7736354	chr5:53297591	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-15.18	-0.51	1.2e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs4787491	0.765	rs8054507	chr16:30046042	G/A	cg06326092	chr16:30034487	C16orf92	0.38	9.9	0.36	1.36e-21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg26516362	chr5:178986906	RUFY1	0.35	8.72	0.33	2.37e-17	Lung cancer;
BRCA	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg24642439	chr20:33292090	TP53INP2	0.4	7.87	0.3	1.52e-14	Height;
BRCA	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg11789530	chr4:8429930	ACOX3	-0.65	-16.87	-0.56	4.21e-53	Response to antineoplastic agents;
BRCA	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg11663144	chr21:46675770	NA	-0.61	-14.23	-0.49	4.28e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs1973993	0.745	rs7512263	chr1:96941158	C/A	cg10631902	chr5:14652156	NA	-0.48	-13.58	-0.47	4.28e-37	Weight;
BRCA	cis	rs9283706	0.595	rs6866433	chr5:66324152	A/G	cg11590213	chr5:66331682	MAST4	0.39	8.13	0.31	2.26e-15	Coronary artery disease;
BRCA	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg26384229	chr12:38710491	ALG10B	0.69	15.69	0.53	3.64e-47	Bladder cancer;
BRCA	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg08601574	chr20:25228251	PYGB	0.36	8.34	0.31	4.67e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg20607798	chr8:58055168	NA	0.56	8.64	0.32	4.37e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg03146154	chr1:46216737	IPP	0.53	11.75	0.42	5.61e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg22029157	chr1:209979665	IRF6	0.44	8.33	0.31	4.95e-16	Cleft lip with or without cleft palate;
BRCA	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg07549590	chr16:15018862	NA	0.5	12.55	0.44	1.98e-32	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg16423285	chr20:60520624	NA	0.44	8.34	0.31	4.57e-16	Body mass index;
BRCA	cis	rs9359856	0.564	rs72915946	chr6:90447924	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.7	-8.43	-0.32	2.23e-16	Bipolar disorder;
BRCA	cis	rs10789491	0.565	rs2897107	chr1:47206178	A/T	cg15501359	chr1:47185051	KIAA0494	0.69	17.09	0.56	3.45e-54	Response to hepatitis C treatment;
BRCA	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg26384229	chr12:38710491	ALG10B	0.42	9.37	0.35	1.19e-19	Morning vs. evening chronotype;
BRCA	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.79	-13.54	-0.47	6.94e-37	Schizophrenia;
BRCA	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	19.45	0.61	1.5e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10193935	1.000	rs10195776	chr2:42425098	G/A	cg27598129	chr2:42591480	NA	-0.96	-15.3	-0.52	2.9e-45	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg11663144	chr21:46675770	NA	-0.59	-13.79	-0.48	4.77e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg12935359	chr14:103987150	CKB	-0.56	-13.96	-0.48	7.33e-39	Body mass index;
BRCA	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg08738300	chr3:44038990	NA	0.44	8.67	0.32	3.42e-17	Coronary artery disease;
BRCA	trans	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg04565464	chr8:145669602	NFKBIL2	0.44	10.34	0.38	2.9e-23	Schizophrenia;
BRCA	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24531977	chr5:56204891	C5orf35	-0.86	-17.83	-0.58	4.82e-58	Initial pursuit acceleration;
BRCA	cis	rs654351	0.541	rs533746	chr6:10388968	C/T	cg17959970	chr6:10383164	NA	0.41	8.73	0.33	2.22e-17	Squamous cell lung carcinoma;
BRCA	cis	rs290268	0.838	rs290989	chr9:93561836	T/C	cg02608019	chr9:93564028	SYK	0.55	12.23	0.44	4.54e-31	Platelet count;
BRCA	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg24747557	chr10:131355152	MGMT	-0.32	-7.91	-0.3	1.15e-14	Response to temozolomide;
BRCA	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.6	-0.32	5.99e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs911186	0.812	rs35454259	chr6:27254475	G/A	cg12292205	chr6:26970375	C6orf41	-0.61	-10.09	-0.37	2.7e-22	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23583168	chr7:148888333	NA	-0.96	-25.3	-0.71	2.15e-98	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.61	13.64	0.47	2.35e-37	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs3771570	0.901	rs3815262	chr2:242352582	A/T	cg21155796	chr2:242212141	HDLBP	0.46	8.04	0.3	4.47e-15	Prostate cancer;
BRCA	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg17063962	chr7:91808500	NA	0.58	13.16	0.46	3.5e-35	Breast cancer;
BRCA	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg12292205	chr6:26970375	C6orf41	0.74	17.4	0.57	8.19e-56	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg22467129	chr15:76604101	ETFA	-0.49	-10.72	-0.39	8.78e-25	Blood metabolite levels;
BRCA	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.51	0.35	3.85e-20	Morning vs. evening chronotype;
BRCA	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-10.04	-0.37	4.13e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs754466	0.605	rs10824578	chr10:79578244	G/C	cg17075019	chr10:79541650	NA	-0.86	-24.03	-0.69	2.09e-91	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.34	0.41	2.88e-27	Electroencephalogram traits;
BRCA	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg11608241	chr8:8085544	FLJ10661	0.3	7.84	0.3	1.91e-14	Retinal vascular caliber;
BRCA	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-12.2	-0.43	6.61e-31	Morning vs. evening chronotype;
BRCA	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg27446573	chr6:127587934	RNF146	0.88	20.71	0.63	2.59e-73	Breast cancer;
BRCA	cis	rs7633770	0.965	rs6804112	chr3:46686248	C/T	cg11219411	chr3:46661640	NA	0.65	15.48	0.52	3.71e-46	Coronary artery disease;
BRCA	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg10011062	chr15:43941034	CATSPER2	-0.53	-7.82	-0.3	2.14e-14	Lung cancer in ever smokers;
BRCA	trans	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.14e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg25214090	chr10:38739885	LOC399744	0.48	10.63	0.39	2.06e-24	Corneal astigmatism;
BRCA	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg24006582	chr15:45444508	DUOX1	0.55	10.72	0.39	8.88e-25	Uric acid levels;
BRCA	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.15	0.31	1.95e-15	Axial length;
BRCA	cis	rs2652834	0.904	rs2937859	chr15:63366282	C/T	cg05507819	chr15:63340323	TPM1	0.54	9.86	0.36	1.94e-21	HDL cholesterol;
BRCA	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg23711669	chr6:146136114	FBXO30	0.71	16.84	0.55	6.04e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg26816564	chr1:7831052	VAMP3	0.69	12.74	0.45	2.62e-33	Inflammatory bowel disease;
BRCA	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg03711944	chr11:47377212	SPI1	-0.47	-12.01	-0.43	4.14e-30	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	19.88	0.62	8.05e-69	Platelet count;
BRCA	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.41	-10.4	-0.38	1.6e-23	Schizophrenia;
BRCA	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	13.28	0.46	1.07e-35	Schizophrenia;
BRCA	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	17.02	0.56	7.29e-54	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	11.67	0.42	1.16e-28	Exhaled nitric oxide output;
BRCA	cis	rs2625529	0.938	rs2723343	chr15:72108269	C/T	cg16672083	chr15:72433130	SENP8	-0.81	-16.22	-0.54	7.98e-50	Red blood cell count;
BRCA	cis	rs754466	0.580	rs2289311	chr10:79565655	G/A	cg17075019	chr10:79541650	NA	-0.76	-18.94	-0.6	8.15e-64	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg14530993	chr4:882597	GAK	0.51	8.59	0.32	6.49e-17	Parkinson's disease;
BRCA	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg12219531	chr12:120966889	COQ5	0.53	11.52	0.41	4.88e-28	High light scatter reticulocyte count;
BRCA	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.97	0.37	7.08e-22	Bladder cancer;
BRCA	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg21951975	chr1:209979733	IRF6	0.54	18.1	0.58	2.13e-59	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
BRCA	cis	rs6545883	0.507	rs12478192	chr2:61591175	A/G	cg15711740	chr2:61764176	XPO1	0.32	7.91	0.3	1.16e-14	Tuberculosis;
BRCA	cis	rs11971779	0.680	rs7792752	chr7:139066196	G/C	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs1568889	1.000	rs7102106	chr11:28343953	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	13.13	0.46	4.84e-35	Bipolar disorder;
BRCA	cis	rs400736	0.562	rs12711516	chr1:8181227	G/C	cg25007680	chr1:8021821	PARK7	-0.36	-8.68	-0.32	3.21e-17	Response to antidepressants and depression;
BRCA	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-12.4	-0.44	8.46e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg23229984	chr5:148520753	ABLIM3	0.36	8.79	0.33	1.34e-17	Breast cancer;
BRCA	trans	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg25214090	chr10:38739885	LOC399744	0.57	13.01	0.46	1.79e-34	Corneal astigmatism;
BRCA	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg23505145	chr19:12996616	KLF1	-0.54	-11.66	-0.42	1.26e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg27029518	chr18:72166324	CNDP2	-0.31	-8.68	-0.32	3.35e-17	Refractive error;
BRCA	cis	rs80130819	0.515	rs1793912	chr12:48387052	A/C	cg05342945	chr12:48394962	COL2A1	-0.47	-9.34	-0.35	1.52e-19	Prostate cancer;
BRCA	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.36	-0.35	1.29e-19	Total body bone mineral density;
BRCA	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg05347473	chr6:146136440	FBXO30	-0.46	-9.26	-0.34	3.08e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6942756	0.806	rs2718093	chr7:128939582	G/A	cg02491457	chr7:128862824	NA	-0.56	-11.81	-0.42	2.99e-29	White matter hyperintensity burden;
BRCA	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.92	0.33	4.98e-18	Motion sickness;
BRCA	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg26384229	chr12:38710491	ALG10B	0.69	15.69	0.53	3.64e-47	Bladder cancer;
BRCA	cis	rs3849570	0.922	rs3772895	chr3:81769493	A/G	cg07356753	chr3:81810745	GBE1	-0.47	-11.38	-0.41	1.97e-27	Waist circumference;Body mass index;
BRCA	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	12.51	0.44	2.84e-32	Platelet count;
BRCA	cis	rs17253792	0.822	rs8009239	chr14:56062490	A/G	cg01858014	chr14:56050164	KTN1	-0.73	-9.19	-0.34	5.56e-19	Putamen volume;
BRCA	cis	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg06521331	chr12:34319734	NA	-0.57	-11.15	-0.4	1.67e-26	Morning vs. evening chronotype;
BRCA	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.2	-0.34	4.88e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg03877680	chr5:178157825	ZNF354A	0.79	14.61	0.5	6.69e-42	Neutrophil percentage of white cells;
BRCA	cis	rs36051895	0.554	rs11789744	chr9:5134213	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-8.59	-0.32	6.52e-17	Pediatric autoimmune diseases;
BRCA	cis	rs600806	0.815	rs10858094	chr1:109950858	T/C	cg20591472	chr1:110008990	SYPL2	0.33	8.28	0.31	7.1e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs919433	0.963	rs4850430	chr2:198182796	A/T	cg10820045	chr2:198174542	NA	-0.38	-7.86	-0.3	1.66e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg14983838	chr19:29218262	NA	0.54	10.06	0.37	3.51e-22	Methadone dose in opioid dependence;
BRCA	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg18016565	chr1:150552671	MCL1	0.35	8.01	0.3	5.26e-15	Melanoma;
BRCA	cis	rs8030485	0.728	rs28415942	chr15:79384850	C/T	cg17916960	chr15:79447300	NA	0.34	7.91	0.3	1.17e-14	Left ventricle wall thickness;
BRCA	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg26384229	chr12:38710491	ALG10B	0.68	14.09	0.49	1.77e-39	Morning vs. evening chronotype;
BRCA	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg17063962	chr7:91808500	NA	0.53	12.45	0.44	5.08e-32	Breast cancer;
BRCA	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg08885076	chr2:99613938	TSGA10	0.41	9.63	0.36	1.4e-20	Chronic sinus infection;
BRCA	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-16.68	-0.55	3.81e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24110177	chr3:50126178	RBM5	0.37	10.01	0.37	5.15e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6450176	1.000	rs4311394	chr5:53300662	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-15.09	-0.51	3.14e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg06521331	chr12:34319734	NA	-0.63	-11.57	-0.42	2.98e-28	Morning vs. evening chronotype;
BRCA	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg13010199	chr12:38710504	ALG10B	0.42	8.96	0.33	3.52e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18876405	chr7:65276391	NA	-0.5	-11.2	-0.41	1.06e-26	Aortic root size;
BRCA	cis	rs9815354	0.812	rs967619	chr3:41876710	C/G	cg03022575	chr3:42003672	ULK4	0.71	9.71	0.36	7.25e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg23029597	chr12:123009494	RSRC2	-0.48	-10.09	-0.37	2.62e-22	Body mass index;
BRCA	cis	rs4566357	0.595	rs6707286	chr2:227911400	A/G	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.12	-0.31	2.34e-15	Coronary artery disease;
BRCA	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21659725	chr3:3221576	CRBN	0.48	12.67	0.45	5.72e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg10495392	chr1:46806563	NSUN4	0.45	8.12	0.31	2.48e-15	Menopause (age at onset);
BRCA	cis	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg06521331	chr12:34319734	NA	-0.63	-12.2	-0.43	6.34e-31	Morning vs. evening chronotype;
BRCA	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.69	-16.62	-0.55	7.96e-52	Ulcerative colitis;
BRCA	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg16049864	chr8:95962084	TP53INP1	-0.49	-12.03	-0.43	3.43e-30	Type 2 diabetes;
BRCA	cis	rs3772130	0.775	rs6769102	chr3:121560722	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.74	0.39	7.27e-25	Cognitive performance;
BRCA	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg05526886	chr2:227700861	RHBDD1	-0.54	-9.46	-0.35	6.02e-20	Coronary artery disease;
BRCA	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	13.19	0.46	2.62e-35	Bone mineral density;
BRCA	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg06937882	chr20:24974362	C20orf3	-0.48	-9.46	-0.35	5.84e-20	Blood protein levels;
BRCA	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg16339924	chr4:17578868	LAP3	0.62	15.46	0.52	4.72e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00166722	chr3:10149974	C3orf24	0.65	11.36	0.41	2.25e-27	Alzheimer's disease;
BRCA	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg12927641	chr6:109611667	NA	-0.36	-8.87	-0.33	7.18e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs1983170	0.736	rs12127718	chr1:91997490	A/T	cg25838465	chr1:92012736	NA	0.48	8.23	0.31	1.05e-15	Eosinophil percentage of white cells;
BRCA	cis	rs7945718	0.934	rs7114040	chr11:12781659	C/T	cg25843174	chr11:12811716	TEAD1	-0.22	-8.63	-0.32	5.02e-17	Educational attainment (years of education);
BRCA	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23583168	chr7:148888333	NA	-0.81	-19.71	-0.61	6.31e-68	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg07169764	chr2:136633963	MCM6	0.76	16.32	0.54	2.74e-50	Mosquito bite size;
BRCA	cis	rs1122900	1.000	rs1122900	chr5:36689181	A/C	cg24186104	chr5:36689192	NA	-0.37	-9.53	-0.35	3.31e-20	Aggressive periodontitis;
BRCA	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg08668359	chr10:1443807	ADARB2	0.48	9.36	0.35	1.35e-19	Radiation response;
BRCA	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg17063962	chr7:91808500	NA	0.52	12.33	0.44	1.68e-31	Breast cancer;
BRCA	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg17420585	chr12:42539391	GXYLT1	-0.49	-10.56	-0.39	3.75e-24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg10556349	chr10:835070	NA	0.63	8.74	0.33	2.06e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs7818345	0.845	rs4256608	chr8:19267560	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.35	8.72	0.33	2.31e-17	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	12.25	0.44	3.89e-31	Bone mineral density;
BRCA	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	16.76	0.55	1.61e-52	Bone mineral density;
BRCA	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg00074818	chr8:8560427	CLDN23	0.37	8.22	0.31	1.11e-15	Obesity-related traits;
BRCA	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-14.85	-0.51	4.28e-43	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg08885076	chr2:99613938	TSGA10	-0.6	-13.45	-0.47	1.74e-36	Chronic sinus infection;
BRCA	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg09658497	chr7:2847517	GNA12	-0.41	-8.48	-0.32	1.62e-16	Height;
BRCA	cis	rs3125734	0.633	rs4979782	chr10:63998527	C/T	cg19640130	chr10:64028056	RTKN2	-0.28	-8.1	-0.31	2.75e-15	Rheumatoid arthritis;
BRCA	trans	rs2665103	0.589	rs2134046	chr15:82524544	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.31	-7.87	-0.3	1.52e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2625529	0.730	rs1481860	chr15:72241857	T/C	cg16672083	chr15:72433130	SENP8	0.72	16.73	0.55	2.17e-52	Red blood cell count;
BRCA	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg06028605	chr16:24865363	SLC5A11	0.33	7.83	0.3	2.05e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs68170813	0.562	rs11770061	chr7:107071310	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.18	-0.31	1.58e-15	Coronary artery disease;
BRCA	cis	rs6820391	1.000	rs6820391	chr4:54414696	G/T	cg04173182	chr4:54446035	LNX1	0.4	8.34	0.31	4.67e-16	Cervical artery dissection;
BRCA	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.48	-9.12	-0.34	9.75e-19	Chronic sinus infection;
BRCA	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24110177	chr3:50126178	RBM5	0.4	10.89	0.4	1.83e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.85	-0.3	1.81e-14	Aortic root size;
BRCA	cis	rs55788414	0.932	rs9929253	chr16:81181641	C/T	cg06400318	chr16:81190750	PKD1L2	-0.46	-7.99	-0.3	6.22e-15	Left ventricular obstructive tract defect (maternal effect);
BRCA	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-13.99	-0.48	5.6e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg12463550	chr7:65579703	CRCP	-0.36	-7.83	-0.3	2.06e-14	Aortic root size;
BRCA	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg08742575	chr21:47604166	C21orf56	0.4	7.83	0.3	2e-14	Testicular germ cell tumor;
BRCA	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg04450456	chr4:17643702	FAM184B	0.33	9.49	0.35	4.5e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg14983838	chr19:29218262	NA	0.54	10.19	0.37	1.07e-22	Methadone dose in opioid dependence;
BRCA	cis	rs3820928	0.874	rs10189579	chr2:227864876	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.37	-0.31	3.62e-16	Pulmonary function;
BRCA	cis	rs6882046	0.513	rs1081158	chr5:88004616	C/T	cg22951263	chr5:87985283	NA	-0.39	-11.01	-0.4	5.96e-26	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.27	-0.31	7.52e-16	Total body bone mineral density;
BRCA	cis	rs332507	0.789	rs13097459	chr3:124398112	C/T	cg05980111	chr3:124395277	KALRN	0.38	8.58	0.32	6.93e-17	Plateletcrit;
BRCA	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-10.04	-0.37	3.86e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.7	0.33	2.91e-17	Tonsillectomy;
BRCA	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.96	22.06	0.66	1.26e-80	Smoking behavior;
BRCA	cis	rs67981189	0.752	rs221902	chr14:71601079	G/T	cg15816911	chr14:71606274	NA	-0.36	-8.09	-0.3	2.96e-15	Schizophrenia;
BRCA	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-8.12	-0.31	2.35e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg21573476	chr21:45109991	RRP1B	-0.4	-11.16	-0.4	1.54e-26	Mean corpuscular volume;
BRCA	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg26597838	chr10:835615	NA	0.65	11.02	0.4	5.44e-26	Eosinophil percentage of granulocytes;
BRCA	cis	rs7903847	0.596	rs7922512	chr10:99155685	C/A	cg20016023	chr10:99160130	RRP12	-0.26	-8.53	-0.32	1.03e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg22903471	chr2:27725779	GCKR	-0.4	-9.82	-0.36	2.6e-21	Total body bone mineral density;
BRCA	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg10876282	chr6:28092338	ZSCAN16	0.42	8.17	0.31	1.68e-15	Cardiac Troponin-T levels;
BRCA	cis	rs672059	1.000	rs575474	chr1:183158599	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.56	0.32	8.28e-17	Hypertriglyceridemia;
BRCA	trans	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.16	0.31	1.74e-15	Corneal astigmatism;
BRCA	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08564027	chr20:61660810	NA	0.85	22.85	0.67	6.19e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.52	12.61	0.45	1.06e-32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg02079420	chr8:82753780	SNX16	0.31	8.44	0.32	2.1e-16	Diastolic blood pressure;
BRCA	cis	rs6973256	0.865	rs11975290	chr7:133335144	C/A	cg07491979	chr7:133331646	EXOC4	-0.39	-8.91	-0.33	5.11e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11112613	0.713	rs73184083	chr12:105952593	T/A	cg03607813	chr12:105948248	NA	0.55	10.43	0.38	1.25e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	10.65	0.39	1.78e-24	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg20368463	chr18:77673604	PQLC1	-0.34	-8.08	-0.3	3.36e-15	Schizophrenia;
BRCA	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg24692254	chr21:30365293	RNF160	0.42	9.6	0.35	1.81e-20	Pancreatic cancer;
BRCA	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg11812906	chr14:75593930	NEK9	0.65	15.01	0.51	7.86e-44	Height;
BRCA	cis	rs1506636	1.000	rs646753	chr7:123401237	G/T	cg03229431	chr7:123269106	ASB15	0.61	13.78	0.48	4.97e-38	Plateletcrit;Platelet count;
BRCA	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg10862848	chr6:42927986	GNMT	0.31	13.75	0.48	7.51e-38	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg12386194	chr3:101231763	SENP7	0.46	9.57	0.35	2.36e-20	Colorectal cancer;
BRCA	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg23649088	chr2:200775458	C2orf69	0.6	8.89	0.33	6.23e-18	Schizophrenia;
BRCA	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.14	0.37	1.71e-22	Aortic root size;
BRCA	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg23978390	chr7:1156363	C7orf50	0.34	8.08	0.3	3.19e-15	Longevity;Endometriosis;
BRCA	cis	rs68170813	0.559	rs7804979	chr7:106999453	C/G	cg02696742	chr7:106810147	HBP1	-0.49	-8.27	-0.31	7.91e-16	Coronary artery disease;
BRCA	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg00071950	chr4:10020882	SLC2A9	0.52	12.35	0.44	1.46e-31	Bone mineral density;
BRCA	cis	rs8030485	0.536	rs12595749	chr15:79432359	A/G	cg17916960	chr15:79447300	NA	0.39	9.6	0.36	1.75e-20	Left ventricle wall thickness;
BRCA	cis	rs887829	0.569	rs3806597	chr2:234637569	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.31	8.24	0.31	9.9e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg02659138	chr7:134003124	SLC35B4	0.34	10.72	0.39	9.27e-25	Mean platelet volume;
BRCA	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	16.6	0.55	9.86e-52	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg12573674	chr2:1569213	NA	0.5	9.38	0.35	1.12e-19	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg13010199	chr12:38710504	ALG10B	0.52	10.81	0.39	3.81e-25	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg24642439	chr20:33292090	TP53INP2	0.4	8.02	0.3	4.97e-15	Height;
BRCA	trans	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.79	-0.33	1.39e-17	Bladder cancer;
BRCA	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg07308232	chr7:1071921	C7orf50	-0.36	-7.82	-0.3	2.16e-14	Longevity;Endometriosis;
BRCA	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.93	0.3	9.65e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1459104	1.000	rs12793778	chr11:55085722	T/C	cg15704280	chr7:45808275	SEPT13	0.7	8.7	0.33	2.73e-17	Body mass index;
BRCA	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg24060327	chr5:131705240	SLC22A5	0.51	10.66	0.39	1.51e-24	Blood metabolite levels;
BRCA	cis	rs9942416	0.660	rs194137	chr5:74978857	G/A	cg19683494	chr5:74908142	NA	-0.48	-8.95	-0.33	3.81e-18	Age-related disease endophenotypes;
BRCA	cis	rs1451375	0.617	rs1807066	chr7:50543683	T/C	cg18232548	chr7:50535776	DDC	-0.42	-8.76	-0.33	1.76e-17	Malaria;
BRCA	cis	rs8038465	0.638	rs12591473	chr15:73967485	A/T	cg15420318	chr15:73925796	NPTN	0.4	9.12	0.34	9.77e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg00983440	chr10:79422392	NA	0.57	10.73	0.39	8.59e-25	Bone mineral density;
BRCA	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg01292856	chr11:65242576	NA	0.33	8.3	0.31	6.08e-16	Bone mineral density;
BRCA	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg18132916	chr6:79620363	NA	-0.48	-10.88	-0.4	2.04e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg09307838	chr4:120376055	NA	0.69	14.03	0.49	3.41e-39	Corneal astigmatism;
BRCA	cis	rs7561273	0.609	rs6720226	chr2:24295853	A/G	cg04809136	chr2:24300158	SF3B14	-0.4	-9.24	-0.34	3.46e-19	Quantitative traits;
BRCA	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-10.17	-0.37	1.26e-22	Monocyte percentage of white cells;
BRCA	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg27279351	chr12:120934652	DYNLL1	0.56	13.13	0.46	4.75e-35	High light scatter reticulocyte count;
BRCA	cis	rs6840258	1.000	rs72667754	chr4:87942061	T/C	cg08197287	chr4:87952173	AFF1	-0.44	-8.56	-0.32	8.22e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.21	-0.34	4.63e-19	Bipolar disorder;
BRCA	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	9.95	0.37	8.73e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg13852791	chr20:30311386	BCL2L1	0.83	16.35	0.54	1.76e-50	Mean corpuscular hemoglobin;
BRCA	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg18758796	chr5:131593413	PDLIM4	0.36	9.47	0.35	5.38e-20	Breast cancer;
BRCA	cis	rs11229555	0.598	rs12269888	chr11:58184336	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2901460	0.509	rs56944298	chr2:62090001	A/G	cg02183531	chr2:62113199	CCT4	-0.45	-8.81	-0.33	1.18e-17	Mean corpuscular volume;
BRCA	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.39	-8.36	-0.31	4.07e-16	IgG glycosylation;
BRCA	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg05623727	chr3:50126028	RBM5	0.44	10.43	0.38	1.25e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg08493051	chr2:3487164	NA	-0.4	-8.47	-0.32	1.67e-16	Neurofibrillary tangles;
BRCA	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.5	-0.32	1.31e-16	Menopause (age at onset);
BRCA	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.79	13.01	0.46	1.73e-34	Platelet count;
BRCA	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg25036284	chr2:26402008	FAM59B	0.96	16.0	0.53	1.08e-48	Gut microbiome composition (summer);
BRCA	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg18252515	chr7:66147081	NA	-0.99	-13.97	-0.48	6.87e-39	Diabetic kidney disease;
BRCA	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.55	11.96	0.43	6.6e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14442939	chr10:27389572	ANKRD26	-0.68	-10.86	-0.39	2.56e-25	Breast cancer;
BRCA	cis	rs754466	0.580	rs10430530	chr10:79582812	T/C	cg17075019	chr10:79541650	NA	-0.83	-21.89	-0.65	1.06e-79	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4363385	0.747	rs1415959	chr1:152973690	C/T	cg24667326	chr1:152973720	SPRR3	0.35	9.98	0.37	6.96e-22	Inflammatory skin disease;
BRCA	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg21770322	chr7:97807741	LMTK2	0.58	17.05	0.56	5.41e-54	Breast cancer;
BRCA	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg15128208	chr22:42549153	NA	-0.31	-7.96	-0.3	7.78e-15	Cognitive function;
BRCA	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg10223061	chr2:219282414	VIL1	-0.27	-8.1	-0.31	2.71e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6882046	0.513	rs679232	chr5:88054763	A/C	cg22951263	chr5:87985283	NA	0.38	10.69	0.39	1.18e-24	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	trans	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg06521331	chr12:34319734	NA	0.46	9.08	0.34	1.35e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	8.27	0.31	7.75e-16	Uric acid levels;
BRCA	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg11693508	chr17:37793320	STARD3	0.6	11.11	0.4	2.42e-26	Bipolar disorder;
BRCA	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9359856	0.510	rs17293240	chr6:90396370	C/T	cg13799429	chr6:90582589	CASP8AP2	0.71	11.17	0.4	1.41e-26	Bipolar disorder;
BRCA	cis	rs595982	0.517	rs4801779	chr19:49406651	T/G	cg21252483	chr19:49399788	TULP2	-0.27	-8.39	-0.31	3.17e-16	Red cell distribution width;
BRCA	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.08	-0.37	2.75e-22	Psoriasis;
BRCA	trans	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg21775007	chr8:11205619	TDH	-0.38	-7.83	-0.3	2.01e-14	Joint mobility (Beighton score);
BRCA	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg19077165	chr18:44547161	KATNAL2	-0.39	-8.38	-0.31	3.27e-16	Educational attainment;
BRCA	trans	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.49	0.5	2.5e-41	Exhaled nitric oxide output;
BRCA	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.96	-0.3	7.72e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg17372223	chr3:52568218	NT5DC2	0.35	8.17	0.31	1.62e-15	Electroencephalogram traits;
BRCA	cis	rs67981189	0.896	rs2526874	chr14:71381219	G/A	cg15816911	chr14:71606274	NA	-0.37	-8.17	-0.31	1.65e-15	Schizophrenia;
BRCA	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.67	0.42	1.15e-28	Tonsillectomy;
BRCA	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg05084668	chr3:125655381	ALG1L	-0.49	-9.3	-0.35	2.24e-19	Blood pressure (smoking interaction);
BRCA	cis	rs36051895	0.632	rs10815166	chr9:5149920	T/G	cg02405213	chr9:5042618	JAK2	-0.44	-8.6	-0.32	6.14e-17	Pediatric autoimmune diseases;
BRCA	cis	rs936229	0.768	rs12442901	chr15:75083912	A/G	cg10253484	chr15:75165896	SCAMP2	-0.53	-10.13	-0.37	1.84e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg24675658	chr1:53192096	ZYG11B	0.56	12.72	0.45	3.45e-33	Monocyte count;
BRCA	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg00981070	chr1:2046702	PRKCZ	0.31	8.31	0.31	5.81e-16	Height;
BRCA	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg12751644	chr20:60527061	NA	-0.33	-7.95	-0.3	8.19e-15	Body mass index;
BRCA	cis	rs7582720	1.000	rs72936323	chr2:204050474	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	12.25	0.44	3.99e-31	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg22467129	chr15:76604101	ETFA	0.45	10.04	0.37	4.08e-22	Blood metabolite levels;
BRCA	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs72781680	0.821	rs55948613	chr2:24094787	A/G	cg08917208	chr2:24149416	ATAD2B	0.61	10.3	0.38	4.02e-23	Lymphocyte counts;
BRCA	cis	rs220324	0.647	rs55877840	chr21:43560383	T/C	cg09727148	chr21:43560719	UMODL1	0.5	8.88	0.33	6.65e-18	Idiopathic osteonecrosis of the femoral head;
BRCA	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg05340658	chr4:99064831	C4orf37	-0.49	-11.35	-0.41	2.46e-27	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg26597838	chr10:835615	NA	0.91	16.21	0.54	9.27e-50	Eosinophil percentage of granulocytes;
BRCA	cis	rs7020830	0.931	rs6476613	chr9:37084340	A/G	cg14294708	chr9:37120828	ZCCHC7	1.09	33.86	0.8	1.04e-144	Schizophrenia;
BRCA	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg10556349	chr10:835070	NA	-0.61	-8.4	-0.32	2.82e-16	Eosinophil percentage of granulocytes;
BRCA	trans	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg26043149	chr18:55253948	FECH	0.39	8.38	0.31	3.34e-16	Bone mineral density;
BRCA	cis	rs2637030	0.559	rs256117	chr5:52916684	G/A	cg06476337	chr5:52856530	NDUFS4	0.38	8.82	0.33	1.09e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs11112613	0.775	rs7299470	chr12:105961773	G/A	cg03607813	chr12:105948248	NA	0.53	10.23	0.38	7.36e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs4588572	0.643	rs13155648	chr5:77755343	A/G	cg11547950	chr5:77652471	NA	-0.47	-8.36	-0.31	4e-16	Triglycerides;
BRCA	cis	rs8028182	0.636	rs8036884	chr15:75862893	T/C	cg20655648	chr15:75932815	IMP3	0.45	8.83	0.33	1.01e-17	Sudden cardiac arrest;
BRCA	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg26384229	chr12:38710491	ALG10B	0.69	15.69	0.53	3.64e-47	Bladder cancer;
BRCA	cis	rs6484504	0.576	rs208071	chr11:31144996	C/T	cg14844989	chr11:31128820	NA	-0.44	-9.27	-0.34	2.83e-19	Red blood cell count;
BRCA	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg12219531	chr12:120966889	COQ5	0.55	11.42	0.41	1.25e-27	High light scatter reticulocyte count;
BRCA	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg14926445	chr8:58193284	C8orf71	-0.47	-8.92	-0.33	4.83e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg11822812	chr5:140052017	DND1	-0.31	-8.4	-0.32	2.86e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg14036092	chr11:66035641	RAB1B	0.39	10.25	0.38	6.51e-23	Gout;
BRCA	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg27284194	chr4:1044797	NA	0.43	9.38	0.35	1.09e-19	Recombination rate (males);
BRCA	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.09	0.34	1.24e-18	Tonsillectomy;
BRCA	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	8.93	0.33	4.39e-18	Educational attainment;
BRCA	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg20887711	chr4:1340912	KIAA1530	0.72	15.92	0.53	2.56e-48	Longevity;
BRCA	cis	rs2505998	0.957	rs2506005	chr10:43581980	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.4	-7.96	-0.3	7.77e-15	Hirschsprung disease;
BRCA	trans	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.14	0.31	2.02e-15	Corneal astigmatism;
BRCA	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg27446573	chr6:127587934	RNF146	0.69	14.93	0.51	1.83e-43	Breast cancer;
BRCA	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg26597838	chr10:835615	NA	0.98	17.24	0.56	5.71e-55	Eosinophil percentage of granulocytes;
BRCA	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg18252515	chr7:66147081	NA	0.97	14.42	0.5	5.43e-41	Diabetic kidney disease;
BRCA	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg18357645	chr12:58087776	OS9	0.43	12.09	0.43	1.85e-30	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs2289583	0.642	rs8034281	chr15:75384227	A/G	cg14664628	chr15:75095509	CSK	-0.38	-8.8	-0.33	1.26e-17	Systemic lupus erythematosus;
BRCA	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg26384229	chr12:38710491	ALG10B	0.42	9.5	0.35	4.14e-20	Morning vs. evening chronotype;
BRCA	trans	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg14791747	chr16:20752902	THUMPD1	-0.41	-12.58	-0.45	1.47e-32	Cognitive test performance;
BRCA	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.45	-0.35	6.26e-20	Alzheimer's disease;
BRCA	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg14196790	chr5:131705035	SLC22A5	0.3	7.85	0.3	1.73e-14	Blood metabolite levels;
BRCA	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg25237894	chr2:233734115	C2orf82	0.31	9.04	0.34	1.91e-18	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg08601574	chr20:25228251	PYGB	0.34	8.35	0.31	4.15e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.07	0.3	3.49e-15	Endometrial cancer;
BRCA	cis	rs7617773	0.743	rs7621785	chr3:48343708	T/C	cg11946769	chr3:48343235	NME6	0.68	13.73	0.48	9.09e-38	Coronary artery disease;
BRCA	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg21573476	chr21:45109991	RRP1B	-0.35	-9.04	-0.34	1.92e-18	Mean corpuscular volume;
BRCA	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg24920358	chr1:40204285	PPIE	0.35	8.21	0.31	1.25e-15	Blood protein levels;
BRCA	cis	rs2637266	0.935	rs2583054	chr10:78401442	A/G	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg22713356	chr15:30763199	NA	1.25	20.77	0.63	1.25e-73	Uric acid levels;
BRCA	cis	rs6484504	0.576	rs2447671	chr11:31334323	A/G	cg26647111	chr11:31128758	NA	-0.39	-8.65	-0.32	4.1e-17	Red blood cell count;
BRCA	cis	rs12618769	0.625	rs72821955	chr2:99159792	G/A	cg10123293	chr2:99228465	UNC50	0.44	8.57	0.32	7.88e-17	Bipolar disorder;
BRCA	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.76	12.68	0.45	4.89e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs36051895	0.659	rs11999076	chr9:5037694	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-9.36	-0.35	1.36e-19	Pediatric autoimmune diseases;
BRCA	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg23719950	chr11:63933701	MACROD1	-0.59	-9.69	-0.36	8.6e-21	Mean platelet volume;
BRCA	cis	rs208520	0.661	rs207079	chr6:66770462	C/T	cg07460842	chr6:66804631	NA	-1.01	-20.27	-0.63	6.22e-71	Exhaled nitric oxide output;
BRCA	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg14707162	chr11:17036581	PLEKHA7	-0.38	-9.51	-0.35	3.95e-20	Coronary artery disease;
BRCA	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg02176678	chr2:219576539	TTLL4	-0.47	-12.25	-0.44	4e-31	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23708337	chr7:1209742	NA	0.5	9.78	0.36	3.7e-21	Longevity;Endometriosis;
BRCA	cis	rs4074536	0.574	rs10737734	chr1:116292091	A/G	cg21648376	chr1:116311395	CASQ2	-0.49	-8.66	-0.32	3.83e-17	QRS duration;
BRCA	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg08999081	chr20:33150536	PIGU	0.42	11.85	0.42	1.97e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.7	0.39	1.09e-24	Bipolar disorder;
BRCA	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg09436375	chr6:42928200	GNMT	-0.3	-10.86	-0.39	2.6e-25	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6005807	0.719	rs58542867	chr22:28988260	A/G	cg12565055	chr22:29076175	TTC28	0.5	9.32	0.35	1.87e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg09455208	chr3:40491958	NA	0.39	9.25	0.34	3.24e-19	Renal cell carcinoma;
BRCA	cis	rs10504073	0.669	rs341799	chr8:50036574	A/G	cg00325661	chr8:49890786	NA	0.38	10.89	0.4	1.81e-25	Blood metabolite ratios;
BRCA	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg16743903	chr16:89593216	SPG7	-0.34	-8.53	-0.32	1.09e-16	Multiple myeloma (IgH translocation);
BRCA	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg24829409	chr8:58192753	C8orf71	-0.5	-8.24	-0.31	1e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg10495392	chr1:46806563	NSUN4	0.45	8.41	0.32	2.59e-16	Menopause (age at onset);
BRCA	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg15556689	chr8:8085844	FLJ10661	-0.35	-8.81	-0.33	1.18e-17	Neuroticism;
BRCA	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg26384229	chr12:38710491	ALG10B	0.74	16.45	0.55	5.77e-51	Morning vs. evening chronotype;
BRCA	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg23533926	chr12:111358616	MYL2	-0.43	-9.14	-0.34	8.32e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7975161	0.630	rs7138317	chr12:104650271	G/A	cg25273343	chr12:104657179	TXNRD1	-0.6	-9.34	-0.35	1.5700000000000001e-19	Toenail selenium levels;
BRCA	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg23711669	chr6:146136114	FBXO30	0.78	18.67	0.59	1.96e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2120243	0.935	rs9681270	chr3:157143996	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	8.96	0.33	3.68e-18	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.52	0.55	2.45e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4690686	0.500	rs4690431	chr4:177264251	G/A	cg17059388	chr4:177262070	NA	0.51	10.68	0.39	1.34e-24	Essential tremor;
BRCA	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.46	-0.77	1.51e-126	Schizophrenia;
BRCA	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg15017067	chr4:17643749	FAM184B	-0.28	-8.06	-0.3	3.79e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03264133	chr6:25882463	NA	0.51	11.35	0.41	2.49e-27	Blood metabolite levels;
BRCA	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg24812749	chr6:127587940	RNF146	0.69	15.21	0.52	8.24e-45	Breast cancer;
BRCA	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg14963724	chr18:72166303	CNDP2	-0.34	-9.48	-0.35	4.94e-20	Refractive error;
BRCA	cis	rs7524258	0.900	rs6577426	chr1:7306451	A/G	cg07173049	chr1:7289937	CAMTA1	0.4	9.79	0.36	3.41e-21	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg12826209	chr6:26865740	GUSBL1	0.59	9.97	0.37	7.36e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg08888203	chr3:10149979	C3orf24	0.61	12.47	0.44	4.3e-32	Alzheimer's disease;
BRCA	cis	rs6545883	0.859	rs62149714	chr2:61603869	T/G	cg15711740	chr2:61764176	XPO1	0.5	12.18	0.43	8.05e-31	Tuberculosis;
BRCA	cis	rs490234	0.718	rs2133386	chr9:128173838	C/A	cg14078157	chr9:128172775	NA	-0.35	-7.91	-0.3	1.13e-14	Mean arterial pressure;
BRCA	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg13010199	chr12:38710504	ALG10B	0.41	8.42	0.32	2.42e-16	Bladder cancer;
BRCA	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26314531	chr2:26401878	FAM59B	-0.66	-11.29	-0.41	4.42e-27	Gut microbiome composition (summer);
BRCA	cis	rs7903847	0.642	rs10786339	chr10:99153076	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.54	-0.32	1.01e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg11789530	chr4:8429930	ACOX3	0.59	14.69	0.5	2.68e-42	Response to antineoplastic agents;
BRCA	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg26597838	chr10:835615	NA	0.95	14.86	0.51	4.14e-43	Eosinophil percentage of granulocytes;
BRCA	trans	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.93	0.3	1.01e-14	Corneal astigmatism;
BRCA	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg21918786	chr6:109611834	NA	-0.49	-14.04	-0.49	3.1e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg21770322	chr7:97807741	LMTK2	0.42	11.11	0.4	2.39e-26	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-13.88	-0.48	1.75e-38	Morning vs. evening chronotype;
BRCA	trans	rs877282	0.533	rs10904565	chr10:819991	G/T	cg22713356	chr15:30763199	NA	1.02	16.38	0.54	1.25e-50	Uric acid levels;
BRCA	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg17366294	chr4:99064904	C4orf37	0.43	10.09	0.37	2.68e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg20503657	chr10:835505	NA	1.03	18.41	0.59	4.71e-61	Eosinophil percentage of granulocytes;
BRCA	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.09	0.49	1.94e-39	Motion sickness;
BRCA	trans	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.95	0.3	8.59e-15	Endometrial cancer;
BRCA	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.57	-8.23	-0.31	1.09e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg04553112	chr3:125709451	NA	-0.55	-8.34	-0.31	4.47e-16	Blood pressure (smoking interaction);
BRCA	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg03676636	chr4:99064102	C4orf37	0.24	8.28	0.31	7.44e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.06	-26.3	-0.72	7.48e-104	Ulcerative colitis;
BRCA	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg10862848	chr6:42927986	GNMT	-0.36	-15.01	-0.51	7.95e-44	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg24060327	chr5:131705240	SLC22A5	-0.49	-10.17	-0.37	1.28e-22	Blood metabolite levels;
BRCA	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg13047869	chr3:10149882	C3orf24	0.52	11.01	0.4	6.24e-26	Alzheimer's disease;
BRCA	cis	rs61990749	0.597	rs2267768	chr14:78216014	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.44	7.97	0.3	7.44e-15	Fibroblast growth factor basic levels;
BRCA	cis	rs4363385	0.720	rs1338179	chr1:152981548	T/C	cg25856811	chr1:152973957	SPRR3	-0.34	-9.1	-0.34	1.11e-18	Inflammatory skin disease;
BRCA	cis	rs7246657	0.722	rs13744	chr19:38077912	C/T	cg23950597	chr19:37808831	NA	-0.5	-8.64	-0.32	4.63e-17	Coronary artery calcification;
BRCA	cis	rs7809615	0.901	rs10235235	chr7:99075831	T/C	cg12290671	chr7:99195819	NA	-0.51	-8.85	-0.33	8.35e-18	Blood metabolite ratios;
BRCA	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg24879335	chr3:133465180	TF	0.33	10.92	0.4	1.44e-25	Iron status biomarkers (transferrin levels);
BRCA	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg15934090	chr1:100435551	SLC35A3	0.36	8.43	0.32	2.38e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg26116260	chr4:7069785	GRPEL1	-0.85	-19.74	-0.62	4.23e-68	Monocyte percentage of white cells;
BRCA	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg04025307	chr7:1156635	C7orf50	0.77	20.46	0.63	5.91e-72	Longevity;Endometriosis;
BRCA	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg17366294	chr4:99064904	C4orf37	0.52	11.16	0.4	1.48e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg05343316	chr1:45956843	TESK2	0.7	13.85	0.48	2.33e-38	Platelet count;
BRCA	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg19077165	chr18:44547161	KATNAL2	-0.5	-10.76	-0.39	6.06e-25	Personality dimensions;
BRCA	cis	rs2294693	0.891	rs1072119	chr6:40993072	G/A	cg14418226	chr6:40996092	UNC5CL	0.44	7.82	0.3	2.16e-14	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-10.07	-0.37	3.07e-22	Tonsillectomy;
BRCA	cis	rs700651	0.789	rs1371663	chr2:198900305	C/T	cg00792783	chr2:198669748	PLCL1	-0.43	-9.17	-0.34	6.18e-19	Intracranial aneurysm;
BRCA	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.48	9.56	0.35	2.39e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3784262	0.669	rs3784257	chr15:58262974	C/T	cg12031962	chr15:58353849	ALDH1A2	0.37	10.13	0.37	1.86e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg26384229	chr12:38710491	ALG10B	-0.41	-9.74	-0.36	5.31e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg08885076	chr2:99613938	TSGA10	0.44	10.47	0.38	9.11e-24	Chronic sinus infection;
BRCA	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.45	-0.35	6.47e-20	Alzheimer's disease;
BRCA	cis	rs6450176	0.830	rs7718193	chr5:53291591	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-14.06	-0.49	2.45e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs62458065	0.513	rs10268149	chr7:32575499	T/C	cg20159608	chr7:32802032	NA	-0.51	-9.77	-0.36	4.05e-21	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.05	-0.3	4.13e-15	Prostate cancer;
BRCA	cis	rs8032158	0.963	rs1912398	chr15:56159103	T/G	cg02198044	chr15:56286336	NEDD4	-0.37	-8.93	-0.33	4.47e-18	Keloid;
BRCA	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg11366901	chr6:160182831	ACAT2	0.78	15.09	0.51	3.06e-44	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg12310025	chr6:25882481	NA	-0.54	-13.07	-0.46	9.5e-35	Blood metabolite levels;
BRCA	cis	rs3771570	1.000	rs57196672	chr2:242235193	G/A	cg21155796	chr2:242212141	HDLBP	0.59	8.96	0.33	3.43e-18	Prostate cancer;
BRCA	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg04234412	chr22:24373322	LOC391322	-0.58	-14.41	-0.5	6.03e-41	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg01689657	chr7:91764605	CYP51A1	-0.22	-8.0	-0.3	6.03e-15	Breast cancer;
BRCA	cis	rs17095355	1.000	rs56273398	chr10:111708183	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.36	-8.69	-0.33	3.07e-17	Biliary atresia;
BRCA	cis	rs4321325	0.733	rs78516281	chr2:127944564	G/C	cg11380483	chr2:127933992	NA	0.45	8.85	0.33	8.57e-18	Protein C levels;
BRCA	trans	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg15704280	chr7:45808275	SEPT13	0.55	8.11	0.31	2.57e-15	Axial length;
BRCA	cis	rs12042938	0.600	rs1094655	chr1:231774362	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	8.88	0.33	6.48e-18	Neuranatomic and neurocognitive phenotypes;
BRCA	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-9.89	-0.36	1.43e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.65	-0.32	4.25e-17	Monocyte percentage of white cells;
BRCA	cis	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.54	-0.32	9.97e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.92	0.4	1.47e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg13319975	chr6:146136371	FBXO30	0.44	10.04	0.37	3.89e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg00677455	chr12:58241039	CTDSP2	0.5	11.13	0.4	1.94e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs5167	0.504	rs3760627	chr19:45457180	T/C	cg09555818	chr19:45449301	APOC2	0.46	12.09	0.43	1.98e-30	Blood protein levels;
BRCA	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.1	-0.31	2.79e-15	Total body bone mineral density;
BRCA	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg08470875	chr2:26401718	FAM59B	-0.51	-8.24	-0.31	9.46e-16	Gut microbiome composition (summer);
BRCA	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg16482183	chr6:26056742	HIST1H1C	0.54	11.1	0.4	2.7e-26	Height;
BRCA	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg07395648	chr5:131743802	NA	0.37	9.28	0.34	2.49e-19	Blood metabolite levels;
BRCA	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg10932868	chr11:921992	NA	0.49	12.63	0.45	8.39e-33	Alzheimer's disease (late onset);
BRCA	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg26384229	chr12:38710491	ALG10B	-0.43	-9.85	-0.36	2.05e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg24692254	chr21:30365293	RNF160	-0.45	-10.06	-0.37	3.33e-22	Pancreatic cancer;
BRCA	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg06784218	chr1:46089804	CCDC17	0.5	11.94	0.43	8.52e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10992471	0.651	rs2296669	chr9:95373790	A/G	cg14631576	chr9:95140430	CENPP	0.33	8.1	0.31	2.81e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	trans	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.14e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21659725	chr3:3221576	CRBN	-0.71	-21.91	-0.65	8.31e-80	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg04691961	chr3:161091175	C3orf57	-0.59	-14.0	-0.48	4.87e-39	Morning vs. evening chronotype;
BRCA	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg11843238	chr5:131593191	PDLIM4	-0.34	-7.84	-0.3	1.88e-14	Breast cancer;
BRCA	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg01028140	chr2:1542097	TPO	-0.62	-12.85	-0.45	8.52e-34	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg05283184	chr6:79620031	NA	-0.44	-11.24	-0.41	7.48e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg05535760	chr7:792225	HEATR2	-0.74	-11.81	-0.42	2.94e-29	Cerebrospinal P-tau181p levels;
BRCA	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg18225595	chr11:63971243	STIP1	0.43	10.97	0.4	9.19e-26	Platelet count;
BRCA	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg21782813	chr7:2030301	MAD1L1	0.43	12.34	0.44	1.53e-31	Bipolar disorder and schizophrenia;
BRCA	trans	rs8002861	0.664	rs1808097	chr13:44424766	A/G	cg12856521	chr11:46389249	DGKZ	0.37	8.11	0.31	2.5e-15	Leprosy;
BRCA	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	19.84	0.62	1.24e-68	Smoking behavior;
BRCA	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21659725	chr3:3221576	CRBN	-0.47	-9.99	-0.37	6.41e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg24692254	chr21:30365293	RNF160	0.79	22.07	0.66	1.09e-80	Dental caries;
BRCA	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00149659	chr3:10157352	C3orf10	0.78	13.92	0.48	1.16e-38	Alzheimer's disease;
BRCA	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11764359	chr7:65958608	NA	0.8	19.65	0.61	1.36e-67	Aortic root size;
BRCA	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.52	-9.86	-0.36	1.87e-21	Response to bleomycin (chromatid breaks);
BRCA	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg12935359	chr14:103987150	CKB	0.53	13.03	0.46	1.4e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg18451016	chr1:38461880	NA	0.41	8.31	0.31	5.62e-16	Coronary artery disease;
BRCA	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg22496339	chr2:162101262	NA	0.58	13.14	0.46	4.44e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	trans	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.59	13.32	0.47	6.92e-36	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	12.95	0.46	3.2e-34	Lymphocyte counts;
BRCA	cis	rs8038465	0.662	rs7497012	chr15:73968719	G/A	cg15420318	chr15:73925796	NPTN	0.38	8.24	0.31	9.56e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg22875332	chr1:76189707	ACADM	0.6	11.02	0.4	5.56e-26	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18876405	chr7:65276391	NA	-0.51	-11.63	-0.42	1.78e-28	Aortic root size;
BRCA	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg27478167	chr7:817139	HEATR2	-0.42	-9.05	-0.34	1.73e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs13064411	0.696	rs6768979	chr3:113204149	G/A	cg18753928	chr3:113234510	CCDC52	-0.59	-12.52	-0.44	2.53e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg09036531	chr10:96991505	NA	-0.66	-15.45	-0.52	5.34e-46	Immune response to smallpox vaccine (IL-6);
BRCA	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.77	0.67	1.63e-84	Chronic sinus infection;
BRCA	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	10.43	0.38	1.21e-23	Neuroticism;
BRCA	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg10932868	chr11:921992	NA	0.49	12.4	0.44	8.43e-32	Alzheimer's disease (late onset);
BRCA	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-11.94	-0.43	8.33e-30	Tonsillectomy;
BRCA	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	12.69	0.45	4.45e-33	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs1322639	0.657	rs9355135	chr6:169573006	C/T	cg03254818	chr6:169586852	NA	0.48	7.98	0.3	6.77e-15	Pulse pressure;
BRCA	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.6	0.42	2.29e-28	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs654950	0.806	rs1535505	chr1:42026152	A/G	cg06885757	chr1:42089581	HIVEP3	0.27	9.11	0.34	1.06e-18	Airway imaging phenotypes;
BRCA	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg11764359	chr7:65958608	NA	0.65	11.91	0.43	1.1e-29	Aortic root size;
BRCA	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg07741184	chr6:167504864	NA	0.33	9.88	0.36	1.64e-21	Primary biliary cholangitis;
BRCA	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.64	0.39	1.9e-24	Motion sickness;
BRCA	cis	rs11690935	0.550	rs11676438	chr2:172826668	G/A	cg13550731	chr2:172543902	DYNC1I2	0.51	12.39	0.44	9.29e-32	Schizophrenia;
BRCA	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	13.22	0.46	1.97e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16680214	chr1:154839983	KCNN3	-0.43	-11.66	-0.42	1.28e-28	Prostate cancer;
BRCA	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg02297831	chr4:17616191	MED28	0.36	8.46	0.32	1.75e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg07211511	chr3:129823064	LOC729375	-0.62	-10.85	-0.39	2.79e-25	Blood pressure (smoking interaction);
BRCA	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg18252515	chr7:66147081	NA	1.04	15.68	0.53	3.89e-47	Diabetic kidney disease;
BRCA	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.39	11.03	0.4	5.21e-26	Response to antipsychotic treatment;
BRCA	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.25	7.91	0.3	1.16e-14	Cardiac Troponin-T levels;
BRCA	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.5	10.92	0.4	1.47e-25	Cognitive ability;
BRCA	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	8.19	0.31	1.45e-15	Aortic root size;
BRCA	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.4	8.41	0.32	2.66e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg11843238	chr5:131593191	PDLIM4	0.35	7.93	0.3	1.01e-14	Breast cancer;
BRCA	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18876405	chr7:65276391	NA	0.62	15.37	0.52	1.28e-45	Aortic root size;
BRCA	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26314531	chr2:26401878	FAM59B	0.9	16.17	0.54	1.47e-49	Gut microbiome composition (summer);
BRCA	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg19539972	chr4:7069911	GRPEL1	0.69	16.91	0.56	2.59e-53	Monocyte percentage of white cells;
BRCA	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.6	13.36	0.47	4.47e-36	Colorectal cancer;
BRCA	cis	rs13046373	0.505	rs2832962	chr21:32008332	T/C	cg22337977	chr21:31811175	KRTAP15-1	0.33	7.9	0.3	1.25e-14	HDL cholesterol;
BRCA	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg04455712	chr21:45112962	RRP1B	0.42	11.06	0.4	3.72e-26	Mean corpuscular volume;
BRCA	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.85	0.45	8.83e-34	Bipolar disorder;
BRCA	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg03923535	chr7:1197113	ZFAND2A	0.52	11.25	0.41	6.61e-27	Longevity;Endometriosis;
BRCA	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.47	9.62	0.36	1.45e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs3818285	0.610	rs642938	chr10:111633025	A/C	cg00817464	chr10:111662876	XPNPEP1	0.45	14.74	0.5	1.53e-42	Superior crus of antihelix expression;
BRCA	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg06453172	chr10:134556979	INPP5A	-0.59	-11.68	-0.42	1.07e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2797160	1.000	rs9401843	chr6:126004124	T/C	cg05901451	chr6:126070800	HEY2	-0.39	-9.42	-0.35	7.86e-20	Endometrial cancer;
BRCA	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.83	0.39	3.19e-25	Bipolar disorder;
BRCA	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg09184832	chr6:79620586	NA	-0.51	-11.12	-0.4	2.32e-26	Intelligence (multi-trait analysis);
BRCA	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg15704280	chr7:45808275	SEPT13	0.7	14.28	0.49	2.29e-40	Coronary artery disease;
BRCA	trans	rs6479891	0.915	rs10740110	chr10:65043221	A/G	cg14819942	chr15:35414228	NA	-0.32	-8.33	-0.31	5.08e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg10932868	chr11:921992	NA	-0.41	-10.12	-0.37	2.01e-22	Alzheimer's disease (late onset);
BRCA	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg02743256	chr7:2109353	MAD1L1	-0.43	-8.19	-0.31	1.43e-15	Bipolar disorder;
BRCA	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	11.51	0.41	5.19e-28	Height;
BRCA	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg08085267	chr17:45401833	C17orf57	0.62	13.23	0.46	1.81e-35	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.5	-9.71	-0.36	7.18e-21	Body mass index;
BRCA	cis	rs11025559	0.773	rs16906274	chr11:20470142	T/C	cg19653624	chr11:20408972	PRMT3	-0.45	-10.4	-0.38	1.61e-23	Pursuit maintenance gain;
BRCA	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg04450456	chr4:17643702	FAM184B	0.35	9.68	0.36	8.79e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.68	-0.42	1.08e-28	Gut microbiome composition (summer);
BRCA	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg05340658	chr4:99064831	C4orf37	0.42	9.14	0.34	8.22e-19	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs870825	0.616	rs36022027	chr4:185639192	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	17.27	0.56	3.85e-55	Blood protein levels;
BRCA	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg12219531	chr12:120966889	COQ5	0.54	11.46	0.41	8.87e-28	High light scatter reticulocyte count;
BRCA	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.62	0.32	5.39e-17	Personality dimensions;
BRCA	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg20307385	chr11:47447363	PSMC3	-0.41	-8.68	-0.32	3.32e-17	Subjective well-being;
BRCA	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg04944784	chr2:26401820	FAM59B	0.99	16.67	0.55	4.37e-52	Gut microbiome composition (summer);
BRCA	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg16586182	chr3:47516702	SCAP	-0.63	-14.71	-0.5	2.23e-42	Colorectal cancer;
BRCA	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.3	-0.35	2.28e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg17143192	chr8:8559678	CLDN23	0.55	10.42	0.38	1.33e-23	Obesity-related traits;
BRCA	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.62	-15.45	-0.52	5.41e-46	Multiple sclerosis;
BRCA	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg23029597	chr12:123009494	RSRC2	-0.62	-11.96	-0.43	6.82e-30	Body mass index;
BRCA	cis	rs2882667	0.587	rs288015	chr5:138195217	T/C	cg04439458	chr5:138467593	SIL1	0.31	7.96	0.3	7.72e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg26043149	chr18:55253948	FECH	0.39	8.34	0.31	4.61e-16	Bone mineral density;
BRCA	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg25482853	chr8:67687455	SGK3	1.05	16.94	0.56	1.94e-53	Lung disease severity in cystic fibrosis;
BRCA	cis	rs10501293	1.000	rs12222341	chr11:43126722	T/G	cg03447554	chr11:43094025	NA	-0.47	-8.54	-0.32	9.91e-17	Cognitive performance;
BRCA	cis	rs367615	0.918	rs10054960	chr5:108866448	C/A	cg17395555	chr5:108820864	NA	0.38	9.75	0.36	4.83e-21	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg03188948	chr7:1209495	NA	0.86	11.78	0.42	3.91e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7927771	0.524	rs10838775	chr11:47856382	C/G	cg20307385	chr11:47447363	PSMC3	0.42	9.49	0.35	4.34e-20	Subjective well-being;
BRCA	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg25554036	chr4:6271136	WFS1	0.42	9.99	0.37	6.36e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg27129171	chr3:47204927	SETD2	0.72	17.52	0.57	2.13e-56	Colorectal cancer;
BRCA	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-13.4	-0.47	2.92e-36	Bipolar disorder and schizophrenia;
BRCA	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg15395560	chr15:45543142	SLC28A2	-0.29	-7.83	-0.3	2.02e-14	Uric acid levels;
BRCA	cis	rs17095355	1.000	rs17126931	chr10:111754633	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.44	-9.41	-0.35	9.12e-20	Biliary atresia;
BRCA	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.29	-0.35	2.32e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg06484146	chr7:12443880	VWDE	-0.75	-10.68	-0.39	1.35e-24	Coronary artery disease;
BRCA	trans	rs7395662	0.824	rs4882180	chr11:48749357	C/A	cg00717180	chr2:96193071	NA	-0.28	-7.86	-0.3	1.68e-14	HDL cholesterol;
BRCA	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.64	-13.45	-0.47	1.74e-36	Lung cancer;
BRCA	cis	rs6594713	0.717	rs13174075	chr5:112795352	A/T	cg12552261	chr5:112820674	MCC	0.47	8.01	0.3	5.52e-15	Brain cytoarchitecture;
BRCA	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg16680214	chr1:154839983	KCNN3	-0.45	-12.5	-0.44	3.03e-32	Prostate cancer;
BRCA	cis	rs7927771	0.524	rs10838740	chr11:47679980	A/G	cg20307385	chr11:47447363	PSMC3	0.42	9.56	0.35	2.43e-20	Subjective well-being;
BRCA	cis	rs73086581	1.000	rs73086540	chr20:3950850	T/C	cg02187196	chr20:3869020	PANK2	0.54	9.62	0.36	1.48e-20	Response to antidepressants in depression;
BRCA	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg23649088	chr2:200775458	C2orf69	-0.59	-8.81	-0.33	1.21e-17	Schizophrenia;
BRCA	cis	rs9463078	0.656	rs227838	chr6:44684621	C/A	cg25276700	chr6:44698697	NA	0.38	8.53	0.32	1.1e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg12219531	chr12:120966889	COQ5	0.55	11.49	0.41	6.69e-28	High light scatter reticulocyte count;
BRCA	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg20307385	chr11:47447363	PSMC3	0.7	15.55	0.52	1.81e-46	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs1371614	0.550	rs2384508	chr2:27143056	T/A	cg12368169	chr2:27073192	DPYSL5	0.28	8.24	0.31	1e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg03923535	chr7:1197113	ZFAND2A	0.4	7.89	0.3	1.31e-14	Longevity;Endometriosis;
BRCA	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg19901468	chr14:105411992	AHNAK2	-0.49	-12.02	-0.43	3.73e-30	Rheumatoid arthritis;
BRCA	cis	rs870825	0.549	rs28542773	chr4:185617935	A/G	cg04058563	chr4:185651563	MLF1IP	0.78	17.28	0.56	3.69e-55	Blood protein levels;
BRCA	cis	rs11702148	0.552	rs6517178	chr21:34888621	C/T	cg14850771	chr21:34775459	IFNGR2	-0.37	-8.1	-0.31	2.76e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg15704280	chr7:45808275	SEPT13	0.71	14.36	0.49	9.81e-41	Coronary artery disease;
BRCA	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.49	9.71	0.36	7.07e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6942756	0.680	rs691555	chr7:129135770	C/T	cg02491457	chr7:128862824	NA	-0.52	-10.92	-0.4	1.41e-25	White matter hyperintensity burden;
BRCA	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg22974920	chr21:40686053	BRWD1	-0.35	-7.85	-0.3	1.81e-14	Menarche (age at onset);
BRCA	trans	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04565464	chr8:145669602	NFKBIL2	0.37	8.69	0.33	2.93e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs1011018	0.628	rs740818	chr7:139452390	C/T	cg03224163	chr7:139420300	HIPK2	-0.59	-8.91	-0.33	5.15e-18	Systolic blood pressure;
BRCA	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.49	0.38	7.36e-24	Motion sickness;
BRCA	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg21724239	chr8:58056113	NA	0.46	8.08	0.3	3.13e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.04	21.08	0.64	2.75e-75	Gut microbiome composition (summer);
BRCA	cis	rs1891275	0.515	rs1080496	chr10:93444262	C/T	cg07889827	chr10:93443413	NA	0.43	12.24	0.44	4.36e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg18538332	chr22:24372958	LOC391322	0.55	13.5	0.47	1.02e-36	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-16.69	-0.55	3.69e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs273218	1.000	rs274366	chr5:53374636	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.42	8.68	0.32	3.31e-17	Migraine;
BRCA	cis	rs10080237	0.564	rs2490232	chr6:80814802	C/T	cg08355045	chr6:80787529	NA	-0.41	-10.7	-0.39	1.11e-24	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
BRCA	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02187348	chr16:89574699	SPG7	0.5	11.69	0.42	9.21e-29	Multiple myeloma (IgH translocation);
BRCA	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg00531865	chr16:30841666	NA	0.4	9.39	0.35	1.03e-19	Dementia with Lewy bodies;
BRCA	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg08999081	chr20:33150536	PIGU	0.5	14.21	0.49	5.31e-40	Coronary artery disease;
BRCA	cis	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg23422044	chr7:1970798	MAD1L1	-0.41	-8.71	-0.33	2.68e-17	Neuroticism;
BRCA	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	20.79	0.64	9.64e-74	Smoking behavior;
BRCA	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.82	0.3	2.21e-14	Aortic root size;
BRCA	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg26893861	chr17:41843967	DUSP3	-0.87	-15.62	-0.53	7.89e-47	Triglycerides;
BRCA	cis	rs708547	0.581	rs781661	chr4:57780307	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.34	-8.54	-0.32	9.91e-17	Response to bleomycin (chromatid breaks);
BRCA	cis	rs36051895	0.664	rs3780381	chr9:5114523	A/C	cg02405213	chr9:5042618	JAK2	-0.5	-9.03	-0.34	2.02e-18	Pediatric autoimmune diseases;
BRCA	trans	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.25	0.31	9.3e-16	Corneal astigmatism;
BRCA	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg13271783	chr10:134563150	INPP5A	-0.48	-9.24	-0.34	3.54e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg03213289	chr20:61660250	NA	0.61	15.95	0.53	1.82e-48	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.39	8.77	0.33	1.66e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1018836	0.886	rs4734246	chr8:91569028	A/C	cg16814680	chr8:91681699	NA	-0.64	-14.25	-0.49	3.37e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg26384229	chr12:38710491	ALG10B	0.84	22.67	0.67	5.83e-84	Heart rate;
BRCA	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.47	-8.32	-0.31	5.48e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg09307838	chr4:120376055	NA	0.63	13.59	0.47	3.72e-37	Corneal astigmatism;
BRCA	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg03342759	chr3:160939853	NMD3	-0.81	-19.0	-0.6	3.77e-64	Parkinson's disease;
BRCA	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg14349672	chr11:133703707	NA	-0.4	-8.99	-0.33	2.84e-18	Childhood ear infection;
BRCA	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg00750074	chr16:89608354	SPG7	-0.35	-8.46	-0.32	1.79e-16	Multiple myeloma (IgH translocation);
BRCA	cis	rs1691799	0.899	rs1168300	chr12:66736467	C/A	cg16791601	chr12:66731901	HELB	-0.64	-17.29	-0.56	3.01e-55	White blood cell count (basophil);
BRCA	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08219700	chr8:58056026	NA	0.64	15.16	0.51	1.48e-44	Developmental language disorder (linguistic errors);
BRCA	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg12564285	chr5:131593104	PDLIM4	0.38	10.38	0.38	1.93e-23	Breast cancer;
BRCA	cis	rs2594714	0.515	rs10411270	chr19:13940838	A/T	cg18576835	chr19:13944261	NA	-0.37	-10.04	-0.37	4.14e-22	Breast cancer;
BRCA	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg08085267	chr17:45401833	C17orf57	0.57	11.98	0.43	5.64e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg08508325	chr11:3079039	CARS	-0.43	-15.65	-0.53	5.49e-47	Longevity;
BRCA	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg11764359	chr7:65958608	NA	-0.62	-13.14	-0.46	4.35e-35	Aortic root size;
BRCA	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg25664220	chr3:72788482	NA	-0.55	-11.68	-0.42	1.03e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7617773	0.817	rs6794644	chr3:48330037	T/C	cg11946769	chr3:48343235	NME6	0.63	13.53	0.47	7.1e-37	Coronary artery disease;
BRCA	cis	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-9.76	-0.36	4.52e-21	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg21573476	chr21:45109991	RRP1B	-0.38	-9.74	-0.36	5.23e-21	Mean corpuscular volume;
BRCA	cis	rs2425143	1.000	rs2425078	chr20:34298163	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.14	-0.37	1.7e-22	Blood protein levels;
BRCA	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-12.04	-0.43	3.17e-30	Total cholesterol levels;
BRCA	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	11.03	0.4	5.01e-26	Rheumatoid arthritis;
BRCA	cis	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg07460842	chr6:66804631	NA	1.0	19.85	0.62	1.2e-68	Exhaled nitric oxide output;
BRCA	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg27147174	chr7:100797783	AP1S1	-0.55	-11.05	-0.4	4.11e-26	Life satisfaction;
BRCA	cis	rs36051895	0.658	rs10974912	chr9:5010885	A/C	cg02405213	chr9:5042618	JAK2	-0.53	-9.17	-0.34	6.52e-19	Pediatric autoimmune diseases;
BRCA	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg26384229	chr12:38710491	ALG10B	0.48	12.36	0.44	1.27e-31	Morning vs. evening chronotype;
BRCA	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.15	-0.4	1.74e-26	Schizophrenia;
BRCA	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	11.33	0.41	2.98e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs17092148	0.943	rs4911160	chr20:33349940	G/A	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.26	-0.41	5.82e-27	Neuroticism;
BRCA	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg06808227	chr14:105710500	BRF1	-0.79	-16.38	-0.54	1.26e-50	Mean platelet volume;Platelet distribution width;
BRCA	trans	rs1459104	1.000	rs12789864	chr11:55197211	A/C	cg15704280	chr7:45808275	SEPT13	-0.66	-8.27	-0.31	7.57e-16	Body mass index;
BRCA	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg24558204	chr6:135376177	HBS1L	-0.46	-12.53	-0.44	2.38e-32	Red blood cell count;
BRCA	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg25036284	chr2:26402008	FAM59B	0.95	16.07	0.54	4.82e-49	Gut microbiome composition (summer);
BRCA	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg02527881	chr3:46936655	PTH1R	0.35	8.2	0.31	1.35e-15	Birth weight;
BRCA	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg25319279	chr11:5960081	NA	-0.43	-8.37	-0.31	3.51e-16	DNA methylation (variation);
BRCA	cis	rs12464559	0.649	rs4664496	chr2:152522556	T/C	cg01189475	chr2:152685088	ARL5A	-0.51	-7.88	-0.3	1.38e-14	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg27398817	chr8:82754497	SNX16	-0.35	-8.02	-0.3	5.06e-15	Diastolic blood pressure;
BRCA	cis	rs16976116	0.901	rs2899582	chr15:55491734	T/C	cg11288833	chr15:55489084	RSL24D1	0.47	10.57	0.39	3.49e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-16.27	-0.54	4.67e-50	Alzheimer's disease (late onset);
BRCA	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg22875332	chr1:76189707	ACADM	0.64	11.95	0.43	7.2e-30	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2421770	0.530	rs2421764	chr11:35364578	A/T	cg13971030	chr11:35366721	SLC1A2	-0.45	-10.12	-0.37	2.02e-22	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg10932868	chr11:921992	NA	0.5	12.88	0.45	6.41e-34	Alzheimer's disease (late onset);
BRCA	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg05835009	chr4:710272	PCGF3	0.47	10.45	0.38	1.02e-23	White blood cell count;
BRCA	trans	rs8002861	0.664	rs9533686	chr13:44468494	A/G	cg17145862	chr1:211918768	LPGAT1	0.53	12.0	0.43	4.61e-30	Leprosy;
BRCA	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg12310025	chr6:25882481	NA	0.74	17.89	0.58	2.58e-58	Blood metabolite levels;
BRCA	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg25237894	chr2:233734115	C2orf82	0.32	9.11	0.34	1.08e-18	Coronary artery disease;
BRCA	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg25319279	chr11:5960081	NA	-0.43	-8.4	-0.32	2.92e-16	DNA methylation (variation);
BRCA	trans	rs4596713	0.507	rs2275427	chr9:71792581	G/A	cg16512924	chr15:28394682	HERC2	0.45	10.8	0.39	4.51e-25	Headache;
BRCA	cis	rs7953249	1.000	rs7953249	chr12:121403724	A/G	cg02403541	chr12:121454288	C12orf43	0.4	8.34	0.31	4.67e-16	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
BRCA	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Tonsillectomy;
BRCA	cis	rs503734	0.502	rs513154	chr3:100953212	T/G	cg27318481	chr3:100970896	IMPG2	-0.35	-8.32	-0.31	5.34e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg26384229	chr12:38710491	ALG10B	0.72	17.02	0.56	7.11e-54	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs6479891	1.000	rs16918575	chr10:65301325	C/T	cg14819942	chr15:35414228	NA	-0.34	-8.25	-0.31	9.01e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.23	0.31	1.07e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg01528321	chr10:82214614	TSPAN14	-0.68	-14.76	-0.5	1.26e-42	Post bronchodilator FEV1;
BRCA	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.59	-10.01	-0.37	5.33e-22	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-18.92	-0.6	9.8e-64	Gut microbiome composition (summer);
BRCA	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg17971929	chr21:40555470	PSMG1	-0.62	-14.35	-0.49	1.1e-40	Cognitive function;
BRCA	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.05	-15.64	-0.53	6.17e-47	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	trans	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg15704280	chr7:45808275	SEPT13	0.54	8.11	0.31	2.55e-15	Axial length;
BRCA	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.63	13.93	0.48	1.01e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg25174290	chr11:3078921	CARS	0.44	13.56	0.47	5.29e-37	Longevity;
BRCA	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg12564285	chr5:131593104	PDLIM4	-0.34	-7.97	-0.3	7.56e-15	Breast cancer;
BRCA	cis	rs60843830	0.508	rs300750	chr2:208794	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	9.61	0.36	1.63e-20	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg18270830	chr10:32634957	EPC1	0.6	10.44	0.38	1.1e-23	Sexual dysfunction (female);
BRCA	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg08917208	chr2:24149416	ATAD2B	0.55	8.53	0.32	1.1e-16	Lymphocyte counts;
BRCA	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg03433033	chr1:76189801	ACADM	-0.71	-15.89	-0.53	3.49e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg03709012	chr19:19516395	GATAD2A	0.81	18.74	0.6	9.07e-63	Tonsillectomy;
BRCA	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg14820908	chr5:178986412	RUFY1	-0.46	-12.32	-0.44	1.9e-31	Lung cancer;
BRCA	cis	rs7267979	0.714	rs3787082	chr20:25235736	A/T	cg08601574	chr20:25228251	PYGB	0.34	8.02	0.3	5.08e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-12.18	-0.43	7.73e-31	Platelet count;
BRCA	cis	rs7127900	0.583	rs11043140	chr11:2233951	T/C	cg12428727	chr11:2234665	NA	0.54	13.2	0.46	2.34e-35	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
BRCA	trans	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg26043149	chr18:55253948	FECH	-0.38	-8.34	-0.31	4.43e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1003719	0.715	rs2212742	chr21:38578685	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.73	-0.5	1.77e-42	Eye color traits;
BRCA	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.04	-0.37	4.08e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7523050	0.730	rs34254854	chr1:109419875	C/T	cg08274380	chr1:109419600	GPSM2	1.18	16.6	0.55	1.05e-51	Fat distribution (HIV);
BRCA	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-9.61	-0.36	1.59e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg09307838	chr4:120376055	NA	0.72	15.28	0.52	3.69e-45	Corneal astigmatism;
BRCA	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg08755490	chr11:65554678	OVOL1	0.53	10.96	0.4	9.69e-26	Acne (severe);
BRCA	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11764359	chr7:65958608	NA	-0.79	-19.23	-0.61	2.32e-65	Aortic root size;
BRCA	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18876405	chr7:65276391	NA	-0.51	-11.69	-0.42	9.89e-29	Aortic root size;
BRCA	cis	rs897984	0.762	rs8062719	chr16:31002664	A/G	cg00531865	chr16:30841666	NA	0.35	7.93	0.3	1.01e-14	Dementia with Lewy bodies;
BRCA	cis	rs9503598	0.636	rs6596976	chr6:3466022	C/T	cg00476032	chr6:3446245	SLC22A23	0.36	8.88	0.33	6.94e-18	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs10242455	0.557	rs77997620	chr7:99070415	G/T	cg18809830	chr7:99032528	PTCD1	-0.62	-8.67	-0.32	3.57e-17	Blood metabolite levels;
BRCA	cis	rs1904096	0.506	rs28522293	chr4:95167087	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-9.85	-0.36	2.06e-21	Type 2 diabetes;
BRCA	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	17.14	0.56	1.76e-54	Intelligence (multi-trait analysis);
BRCA	trans	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-20.94	-0.64	1.49e-74	Exhaled nitric oxide output;
BRCA	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg26818010	chr10:134567672	INPP5A	-0.77	-15.57	-0.52	1.4e-46	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.68	0.57	3.2e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg24692254	chr21:30365293	RNF160	0.78	21.21	0.64	5.62e-76	Dental caries;
BRCA	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.25	0.38	6.57e-23	Bladder cancer;
BRCA	cis	rs1003719	0.715	rs8128387	chr21:38556787	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.54	-0.5	1.43e-41	Eye color traits;
BRCA	cis	rs2302729	0.578	rs11062298	chr12:2771709	A/C	cg19945202	chr12:2788847	CACNA1C	-0.44	-9.71	-0.36	6.78e-21	Sleep quality;
BRCA	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.06	0.74	1.58e-113	Chronic sinus infection;
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg07308232	chr7:1071921	C7orf50	-0.45	-9.37	-0.35	1.27e-19	Longevity;Endometriosis;
BRCA	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14442939	chr10:27389572	ANKRD26	0.7	11.0	0.4	6.54e-26	Breast cancer;
BRCA	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg22920501	chr2:26401640	FAM59B	0.91	16.27	0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	trans	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg26384229	chr12:38710491	ALG10B	0.56	12.1	0.43	1.69e-30	Morning vs. evening chronotype;
BRCA	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg08999081	chr20:33150536	PIGU	-0.44	-12.13	-0.43	1.31e-30	Glomerular filtration rate (creatinine);
BRCA	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg23719950	chr11:63933701	MACROD1	-0.57	-9.5	-0.35	4.3e-20	Mean platelet volume;
BRCA	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg17063962	chr7:91808500	NA	0.53	12.53	0.44	2.32e-32	Breast cancer;
BRCA	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg23933602	chr10:16859644	RSU1	0.59	9.02	0.34	2.13e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg08847533	chr14:75593920	NEK9	-0.84	-20.9	-0.64	2.57e-74	Height;
BRCA	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg23950597	chr19:37808831	NA	-0.7	-12.08	-0.43	2.13e-30	Coronary artery calcification;
BRCA	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg17470723	chr8:74884337	TCEB1	0.44	9.14	0.34	8.44e-19	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs919433	0.679	rs13394214	chr2:198527371	C/T	cg00792783	chr2:198669748	PLCL1	0.41	9.04	0.34	1.83e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6545883	0.899	rs12473030	chr2:61720497	T/A	cg15711740	chr2:61764176	XPO1	-0.55	-13.96	-0.48	7.18e-39	Tuberculosis;
BRCA	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg08392591	chr16:89556376	ANKRD11	0.52	12.54	0.44	1.99e-32	Multiple myeloma (IgH translocation);
BRCA	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg26384229	chr12:38710491	ALG10B	-0.64	-14.13	-0.49	1.24e-39	Morning vs. evening chronotype;
BRCA	cis	rs17601876	1.000	rs17601876	chr15:51553909	C/T	cg19946085	chr15:51559439	CYP19A1	0.31	8.59	0.32	6.58e-17	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg06271696	chr7:157225062	NA	-0.39	-10.37	-0.38	2.18e-23	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg06784218	chr1:46089804	CCDC17	-0.49	-11.81	-0.42	3.11e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.54	-10.97	-0.4	8.59e-26	Lymphocyte counts;
BRCA	cis	rs7131987	0.718	rs7976961	chr12:29463088	C/T	cg09582351	chr12:29534625	ERGIC2	-0.46	-10.63	-0.39	1.99e-24	QT interval;
BRCA	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	18.98	0.6	4.85e-64	Electrocardiographic conduction measures;
BRCA	cis	rs1113500	0.933	rs10881498	chr1:108634984	C/A	cg06207961	chr1:108661230	NA	0.46	11.28	0.41	4.71e-27	Growth-regulated protein alpha levels;
BRCA	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg17063962	chr7:91808500	NA	0.51	11.31	0.41	3.6e-27	Breast cancer;
BRCA	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg08601574	chr20:25228251	PYGB	-0.34	-8.08	-0.3	3.18e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.2	0.49	5.86e-40	Motion sickness;
BRCA	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg08885076	chr2:99613938	TSGA10	-0.59	-13.07	-0.46	9.15e-35	Chronic sinus infection;
BRCA	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg02297831	chr4:17616191	MED28	0.37	8.61	0.32	5.47e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4478858	0.698	rs7543348	chr1:31804805	A/C	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs4494114	0.875	rs7518432	chr1:39363522	G/C	cg25970120	chr1:39325951	RRAGC	-0.37	-7.84	-0.3	1.84e-14	Blood protein levels;
BRCA	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg02734326	chr4:10020555	SLC2A9	0.39	8.59	0.32	6.4e-17	Bone mineral density;
BRCA	cis	rs7246657	0.550	rs9941475	chr19:38064517	C/T	cg18154014	chr19:37997991	ZNF793	0.48	9.16	0.34	7.24e-19	Coronary artery calcification;
BRCA	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	14.0	0.48	5.06e-39	Personality dimensions;
BRCA	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg20476274	chr7:133979776	SLC35B4	0.56	14.19	0.49	6.48e-40	Mean platelet volume;
BRCA	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg12463550	chr7:65579703	CRCP	-0.38	-8.21	-0.31	1.26e-15	Aortic root size;
BRCA	cis	rs9831754	0.704	rs1512491	chr3:78470954	T/C	cg06138941	chr3:78371609	NA	0.52	11.52	0.41	4.78e-28	Calcium levels;
BRCA	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg01262667	chr19:19385393	TM6SF2	-0.38	-9.7	-0.36	7.6e-21	Tonsillectomy;
BRCA	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.42	-8.72	-0.33	2.33e-17	Cognitive ability;
BRCA	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg10729496	chr3:10149963	C3orf24	0.48	8.94	0.33	4.05e-18	Alzheimer's disease;
BRCA	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-9.05	-0.34	1.75e-18	Tonsillectomy;
BRCA	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg25036284	chr2:26402008	FAM59B	-0.93	-15.85	-0.53	5.8e-48	Gut microbiome composition (summer);
BRCA	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg18402987	chr7:1209562	NA	0.84	12.05	0.43	2.8e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6088813	1.000	rs6088799	chr20:33934301	T/C	cg14752227	chr20:34000481	UQCC	-0.41	-8.74	-0.33	2.11e-17	Height;
BRCA	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg25173405	chr17:45401733	C17orf57	-0.57	-12.29	-0.44	2.69e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9649465	0.846	rs13044	chr7:123322716	T/A	cg04330084	chr7:123175371	IQUB	-0.3	-8.38	-0.31	3.26e-16	Migraine;
BRCA	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg00071950	chr4:10020882	SLC2A9	0.6	15.02	0.51	6.86e-44	Bone mineral density;
BRCA	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.84	-0.3	1.86e-14	Aortic root size;
BRCA	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg23711669	chr6:146136114	FBXO30	0.64	14.59	0.5	8.38e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2070997	0.607	rs13294646	chr9:133715206	C/G	cg11464064	chr9:133710261	ABL1	0.55	9.99	0.37	6.09e-22	Response to amphetamines;
BRCA	trans	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg26384229	chr12:38710491	ALG10B	0.46	10.25	0.38	6.32e-23	Morning vs. evening chronotype;
BRCA	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg08917208	chr2:24149416	ATAD2B	0.9	12.95	0.46	3.2e-34	Lymphocyte counts;
BRCA	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08045932	chr20:61659980	NA	0.5	11.43	0.41	1.2100000000000001e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3760982	0.585	rs11673490	chr19:44298885	C/A	cg11993925	chr19:44307056	LYPD5	0.38	8.98	0.33	3e-18	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.74	15.44	0.52	6.27e-46	Smoking behavior;
BRCA	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24549020	chr5:56110836	MAP3K1	0.58	11.71	0.42	7.8e-29	Initial pursuit acceleration;
BRCA	cis	rs6714710	0.603	rs11692010	chr2:98397301	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	13.53	0.47	7.02e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.76	0.5	1.21e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg06159980	chr1:16340746	HSPB7	-0.38	-8.83	-0.33	1.04e-17	Dilated cardiomyopathy;
BRCA	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.02	22.6	0.67	1.46e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs6973256	0.865	rs2909225	chr7:133331952	C/T	cg07491979	chr7:133331646	EXOC4	-0.39	-8.8	-0.33	1.26e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg20701182	chr2:24300061	SF3B14	0.66	9.71	0.36	6.96e-21	Lymphocyte counts;
BRCA	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg09307838	chr4:120376055	NA	0.71	15.0	0.51	8.2e-44	Corneal astigmatism;
BRCA	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg07988820	chr12:82153109	PPFIA2	-0.65	-10.97	-0.4	8.6e-26	Resting heart rate;
BRCA	cis	rs929596	0.755	rs4148325	chr2:234673309	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-10.91	-0.4	1.57e-25	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg13770153	chr20:60521292	NA	0.38	9.37	0.35	1.19e-19	Body mass index;
BRCA	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg14820908	chr5:178986412	RUFY1	0.35	8.04	0.3	4.34e-15	Lung cancer;
BRCA	cis	rs965469	0.895	rs12626130	chr20:3393192	G/T	cg25506879	chr20:3388711	C20orf194	-0.52	-9.46	-0.35	5.57e-20	IFN-related cytopenia;
BRCA	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg00631329	chr6:26305371	NA	-0.44	-13.0	-0.46	1.8e-34	Educational attainment;
BRCA	cis	rs7149337	0.805	rs2999355	chr14:51607084	A/G	cg23942311	chr14:51606299	NA	0.45	13.31	0.47	7.73e-36	Cancer;
BRCA	cis	rs6782228	0.606	rs2811490	chr3:128351755	C/T	cg16766828	chr3:128327626	NA	-0.43	-9.56	-0.35	2.44e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs2742234	0.590	rs2505506	chr10:43645854	C/T	cg02780029	chr10:43622663	RET	-0.35	-8.08	-0.3	3.2e-15	Hirschsprung disease;
BRCA	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03264133	chr6:25882463	NA	-0.49	-10.97	-0.4	9.28e-26	Blood metabolite levels;
BRCA	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg11822812	chr5:140052017	DND1	-0.3	-8.28	-0.31	7.25e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3087591	1.000	rs2905877	chr17:29543269	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.47	-9.63	-0.36	1.39e-20	Hip circumference;
BRCA	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg00277334	chr10:82204260	NA	-0.49	-10.48	-0.38	8e-24	Post bronchodilator FEV1;
BRCA	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18876405	chr7:65276391	NA	0.52	11.65	0.42	1.43e-28	Aortic root size;
BRCA	cis	rs7301826	0.651	rs4514465	chr12:131313669	T/A	cg11011512	chr12:131303247	STX2	0.53	13.81	0.48	3.91e-38	Plasma plasminogen activator levels;
BRCA	cis	rs495337	0.646	rs6067267	chr20:48528237	G/A	cg17835207	chr20:48524531	SPATA2	-0.68	-16.81	-0.55	9.28e-53	Psoriasis;
BRCA	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.52	-0.38	5.79e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg22972055	chr7:872293	UNC84A	-0.37	-8.32	-0.31	5.42e-16	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg17366294	chr4:99064904	C4orf37	0.42	9.6	0.35	1.83e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg08508325	chr11:3079039	CARS	0.27	8.15	0.31	1.92e-15	Calcium levels;
BRCA	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.84	-20.89	-0.64	2.91e-74	Body mass index (adult);
BRCA	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg11632617	chr15:75315747	PPCDC	-0.38	-8.39	-0.32	3.01e-16	Blood trace element (Zn levels);
BRCA	cis	rs9796	0.516	rs28473405	chr15:41293170	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.4	-8.0	-0.3	5.73e-15	Menopause (age at onset);
BRCA	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg05347473	chr6:146136440	FBXO30	0.46	9.07	0.34	1.48e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.02	20.86	0.64	4.1e-74	Mean corpuscular hemoglobin;
BRCA	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.85	0.45	8.78e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs30380	1.000	rs26510	chr5:96125910	C/T	cg16492584	chr5:96139282	ERAP1	-0.31	-7.99	-0.3	6.4e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg22563815	chr15:78856949	CHRNA5	-0.38	-8.79	-0.33	1.41e-17	Sudden cardiac arrest;
BRCA	trans	rs75804782	0.521	rs72994970	chr2:239426992	G/A	cg01134436	chr17:81009848	B3GNTL1	0.7	8.78	0.33	1.5e-17	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg11812906	chr14:75593930	NEK9	-0.69	-16.23	-0.54	7.23e-50	Height;
BRCA	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg10553204	chr2:20871195	GDF7	-0.32	-8.75	-0.33	1.88e-17	Abdominal aortic aneurysm;
BRCA	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.49	-0.38	7.35e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg13565492	chr6:43139072	SRF	-0.78	-12.07	-0.43	2.34e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11165623	0.792	rs12132069	chr1:96918809	A/C	cg10631902	chr5:14652156	NA	-0.52	-16.97	-0.56	1.36e-53	Hip circumference;Waist circumference;
BRCA	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.43	-9.56	-0.35	2.57e-20	Coronary artery disease;
BRCA	cis	rs6424115	0.546	rs35993651	chr1:24180613	C/G	cg10978503	chr1:24200527	CNR2	-0.52	-13.74	-0.48	8.06e-38	Immature fraction of reticulocytes;
BRCA	cis	rs77633900	0.614	rs280024	chr15:77034518	A/C	cg21673338	chr15:77095150	SCAPER	-0.53	-9.67	-0.36	1.02e-20	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg05025164	chr4:1340916	KIAA1530	0.4	8.69	0.33	3.01e-17	Longevity;
BRCA	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg09904177	chr6:26538194	HMGN4	0.55	17.65	0.57	4.4e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs9420	0.703	rs10896661	chr11:57679029	C/A	cg19752551	chr11:57585705	CTNND1	-0.41	-8.98	-0.33	3.11e-18	Schizophrenia;
BRCA	cis	rs7264396	0.790	rs3746410	chr20:34190870	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-11.95	-0.43	7.81e-30	Total cholesterol levels;
BRCA	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg23788917	chr6:8435910	SLC35B3	0.47	10.32	0.38	3.45e-23	Motion sickness;
BRCA	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg12311346	chr5:56204834	C5orf35	-0.74	-14.86	-0.51	3.96e-43	Initial pursuit acceleration;
BRCA	cis	rs3772130	0.564	rs9817555	chr3:121406327	G/A	cg20356878	chr3:121714668	ILDR1	0.38	8.6	0.32	6.17e-17	Cognitive performance;
BRCA	cis	rs28830936	0.966	rs1107858	chr15:41968226	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.33	-9.09	-0.34	1.2e-18	Diastolic blood pressure;
BRCA	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg27129171	chr3:47204927	SETD2	-0.67	-14.82	-0.51	6.36e-43	Colorectal cancer;
BRCA	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.03	-0.54	7.33e-49	Alzheimer's disease (late onset);
BRCA	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg20362242	chr5:692897	TPPP	0.52	8.45	0.32	1.92e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg19318889	chr4:1322082	MAEA	-0.57	-12.12	-0.43	1.47e-30	Longevity;
BRCA	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03188948	chr7:1209495	NA	0.67	14.11	0.49	1.55e-39	Longevity;Endometriosis;
BRCA	cis	rs870825	0.616	rs67641203	chr4:185623845	A/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg20307385	chr11:47447363	PSMC3	-0.41	-8.42	-0.32	2.46e-16	Subjective well-being;
BRCA	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	13.36	0.47	4.56e-36	Height;
BRCA	cis	rs4363385	0.791	rs489323	chr1:153006047	G/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.56	-0.32	8.46e-17	Inflammatory skin disease;
BRCA	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	11.04	0.4	4.77e-26	Tonsillectomy;
BRCA	cis	rs11888559	0.573	rs7602826	chr2:203860716	G/A	cg24605529	chr2:203879461	NBEAL1	0.45	8.52	0.32	1.12e-16	Height;
BRCA	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg04349561	chr1:21808255	NBPF3	-0.33	-7.96	-0.3	7.63e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg16512390	chr1:228756714	NA	0.57	9.08	0.34	1.39e-18	Chronic lymphocytic leukemia;
BRCA	cis	rs10193935	0.901	rs6752455	chr2:42543577	A/C	cg27598129	chr2:42591480	NA	-0.91	-14.46	-0.5	3.21e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg23029597	chr12:123009494	RSRC2	-0.43	-8.9	-0.33	5.5e-18	Body mass index;
BRCA	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg02175503	chr12:58329896	NA	0.74	15.82	0.53	8.21e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg09307838	chr4:120376055	NA	0.69	14.05	0.49	2.88e-39	Corneal astigmatism;
BRCA	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.67	-9.72	-0.36	6.19e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg12292205	chr6:26970375	C6orf41	-0.63	-9.94	-0.37	9.58e-22	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg22907277	chr7:1156413	C7orf50	0.58	8.91	0.33	5.37e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2580764	0.678	rs2255112	chr2:55200800	T/G	cg09592903	chr2:55203963	RTN4	0.42	10.68	0.39	1.28e-24	Mean platelet volume;
BRCA	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg13010199	chr12:38710504	ALG10B	0.45	9.28	0.34	2.51e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.63	-13.54	-0.47	6.76e-37	Lymphocyte counts;
BRCA	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg07636037	chr3:49044803	WDR6	-0.5	-8.23	-0.31	1.03e-15	Menarche (age at onset);
BRCA	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg21856205	chr7:94953877	PON1	-0.37	-7.93	-0.3	9.5e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs8022179	0.566	rs959083	chr14:103822687	A/G	cg12935359	chr14:103987150	CKB	-0.46	-8.51	-0.32	1.27e-16	Monocyte count;
BRCA	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg09455208	chr3:40491958	NA	-0.35	-8.78	-0.33	1.5e-17	Renal cell carcinoma;
BRCA	cis	rs4363385	0.818	rs368912	chr1:153016204	C/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.46	-0.32	1.88e-16	Inflammatory skin disease;
BRCA	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	17.72	0.57	1.83e-57	Electrocardiographic conduction measures;
BRCA	cis	rs4730250	0.707	rs257372	chr7:106796977	T/G	cg02696742	chr7:106810147	HBP1	-0.58	-9.57	-0.35	2.29e-20	Osteoarthritis;
BRCA	cis	rs7408868	1.000	rs6512018	chr19:15282138	T/C	cg14696996	chr19:15285081	NOTCH3	1.01	14.59	0.5	8.07e-42	Pulse pressure;
BRCA	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg26384229	chr12:38710491	ALG10B	0.69	14.65	0.5	4.31e-42	Morning vs. evening chronotype;
BRCA	cis	rs7590368	0.962	rs13431633	chr2:10960225	T/C	cg15705551	chr2:10952987	PDIA6	0.44	8.14	0.31	2.02e-15	Educational attainment (years of education);
BRCA	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg16586182	chr3:47516702	SCAP	-0.55	-12.34	-0.44	1.63e-31	Colorectal cancer;
BRCA	cis	rs7011049	1.000	rs74457055	chr8:53842669	T/G	cg26025543	chr8:53854495	NA	0.56	9.66	0.36	1.11e-20	Systolic blood pressure;
BRCA	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg02493740	chr2:85810744	VAMP5	-0.54	-11.2	-0.41	1.01e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg11189052	chr15:85197271	WDR73	0.38	9.36	0.35	1.29e-19	P wave terminal force;
BRCA	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg05340658	chr4:99064831	C4orf37	0.63	15.18	0.51	1.17e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg00074818	chr8:8560427	CLDN23	0.37	8.09	0.3	3.08e-15	Obesity-related traits;
BRCA	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg27535305	chr1:53392650	SCP2	-0.35	-8.67	-0.32	3.47e-17	Monocyte count;
BRCA	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08704250	chr15:31115839	NA	-0.5	-12.71	-0.45	3.75e-33	Huntington's disease progression;
BRCA	cis	rs3761847	0.622	rs10818498	chr9:123787566	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	7.86	0.3	1.67e-14	Rheumatoid arthritis;
BRCA	cis	rs1941023	0.584	rs2241921	chr11:60164302	C/T	cg08716584	chr11:60157161	MS4A7	-0.44	-10.44	-0.38	1.16e-23	Congenital heart disease (maternal effect);
BRCA	cis	rs7572733	0.534	rs700687	chr2:198721560	A/T	cg00792783	chr2:198669748	PLCL1	0.47	10.12	0.37	1.95e-22	Dermatomyositis;
BRCA	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg24747557	chr10:131355152	MGMT	-0.4	-10.03	-0.37	4.4e-22	Response to temozolomide;
BRCA	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-11.27	-0.41	5.36e-27	IgG glycosylation;
BRCA	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg17509989	chr5:176798049	RGS14	0.66	13.04	0.46	1.22e-34	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08704250	chr15:31115839	NA	0.33	8.68	0.32	3.28e-17	Huntington's disease progression;
BRCA	cis	rs736801	0.964	rs17622656	chr5:131820997	A/G	cg14196790	chr5:131705035	SLC22A5	-0.37	-8.66	-0.32	3.75e-17	Breast cancer;Mosquito bite size;
BRCA	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg23649088	chr2:200775458	C2orf69	0.56	8.11	0.31	2.5e-15	Schizophrenia;
BRCA	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.31	10.2	0.37	9.91e-23	Electroencephalogram traits;
BRCA	trans	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg06521331	chr12:34319734	NA	-0.43	-8.49	-0.32	1.39e-16	Bladder cancer;
BRCA	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-15.83	-0.53	7e-48	Heart rate;
BRCA	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg05552183	chr6:42928497	GNMT	0.79	19.11	0.6	9.96e-65	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg04362960	chr10:104952993	NT5C2	0.42	10.14	0.37	1.67e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg21770322	chr7:97807741	LMTK2	0.58	16.99	0.56	1.12e-53	Breast cancer;
BRCA	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg15017067	chr4:17643749	FAM184B	0.29	8.97	0.33	3.19e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg22535103	chr8:58192502	C8orf71	-0.6	-13.06	-0.46	1.01e-34	Developmental language disorder (linguistic errors);
BRCA	trans	rs6076960	0.652	rs6085441	chr20:6211383	A/G	cg21095983	chr6:86352623	SYNCRIP	0.37	8.21	0.31	1.2e-15	Smooth-surface caries;
BRCA	cis	rs11051970	0.879	rs2733682	chr12:32574608	G/A	cg02745156	chr12:32552066	NA	0.28	9.14	0.34	8.14e-19	Response to tocilizumab in rheumatoid arthritis;
BRCA	trans	rs8002861	0.664	rs2218497	chr13:44428793	G/A	cg12856521	chr11:46389249	DGKZ	0.37	8.12	0.31	2.49e-15	Leprosy;
BRCA	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg04990556	chr1:26633338	UBXN11	0.78	17.51	0.57	2.34e-56	Obesity-related traits;
BRCA	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg23029597	chr12:123009494	RSRC2	-0.62	-12.62	-0.45	9.4e-33	Body mass index;
BRCA	cis	rs7903847	0.642	rs10882915	chr10:99142184	A/G	cg20016023	chr10:99160130	RRP12	-0.27	-8.62	-0.32	5.46e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6785206	0.803	rs6774512	chr3:128415868	C/T	cg16766828	chr3:128327626	NA	-0.76	-11.23	-0.41	8.17e-27	Lymphocyte percentage of white cells;
BRCA	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg10253484	chr15:75165896	SCAMP2	-0.48	-9.32	-0.35	1.86e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg08601574	chr20:25228251	PYGB	0.41	9.62	0.36	1.49e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24549020	chr5:56110836	MAP3K1	0.38	8.13	0.31	2.28e-15	Coronary artery disease;
BRCA	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg26384229	chr12:38710491	ALG10B	0.68	14.28	0.49	2.34e-40	Morning vs. evening chronotype;
BRCA	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg03213289	chr20:61660250	NA	0.62	15.98	0.53	1.29e-48	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg00999904	chr2:3704751	ALLC	0.44	8.27	0.31	7.52e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	trans	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg01620082	chr3:125678407	NA	-0.98	-11.11	-0.4	2.38e-26	Depression;
BRCA	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg12311346	chr5:56204834	C5orf35	-0.78	-15.47	-0.52	4.44e-46	Initial pursuit acceleration;
BRCA	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	9.95	0.37	8.73e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg17724175	chr1:150552817	MCL1	-0.26	-8.47	-0.32	1.74e-16	Tonsillectomy;
BRCA	cis	rs9329289	0.510	rs9733402	chr10:2551532	G/A	cg15501526	chr10:2543763	NA	0.44	10.24	0.38	7.15e-23	Age-related hearing impairment;
BRCA	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg03433033	chr1:76189801	ACADM	0.75	16.95	0.56	1.74e-53	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00166722	chr3:10149974	C3orf24	0.65	11.23	0.41	7.83e-27	Alzheimer's disease;
BRCA	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg11663144	chr21:46675770	NA	-0.47	-10.97	-0.4	8.73e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg12386194	chr3:101231763	SENP7	0.55	11.25	0.41	6.75e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7512552	0.839	rs6662108	chr1:150420541	G/T	cg15654264	chr1:150340011	RPRD2	0.4	8.61	0.32	5.71e-17	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg18512352	chr11:47633146	NA	-0.37	-8.83	-0.33	9.99e-18	Subjective well-being;
BRCA	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.13	0.31	2.17e-15	Breast cancer;
BRCA	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18876405	chr7:65276391	NA	-0.55	-13.31	-0.47	7.27e-36	Aortic root size;
BRCA	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg21775007	chr8:11205619	TDH	0.61	11.79	0.42	3.49e-29	Retinal vascular caliber;
BRCA	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.66	-14.34	-0.49	1.2e-40	Lung cancer;
BRCA	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01171360	chr6:293285	DUSP22	0.56	11.53	0.41	4.52e-28	Menopause (age at onset);
BRCA	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg13319975	chr6:146136371	FBXO30	0.34	7.95	0.3	8.78e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9612	1.000	rs346544	chr19:44256205	A/G	cg08581076	chr19:44259116	C19orf61	0.51	9.65	0.36	1.15e-20	Exhaled nitric oxide output;
BRCA	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.54	-11.02	-0.4	5.61e-26	Lymphocyte counts;
BRCA	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07636037	chr3:49044803	WDR6	-0.73	-15.84	-0.53	6.49e-48	Menarche (age at onset);
BRCA	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg05347473	chr6:146136440	FBXO30	0.43	8.44	0.32	2.08e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg18230493	chr5:56204884	C5orf35	-0.68	-13.56	-0.47	5.11e-37	Initial pursuit acceleration;
BRCA	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-10.27	-0.38	5.4e-23	Calcium levels;
BRCA	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.59	-0.32	6.88e-17	Total body bone mineral density;
BRCA	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg16230307	chr14:35515116	FAM177A1	0.73	15.28	0.52	3.85e-45	Psoriasis;
BRCA	cis	rs6942756	0.876	rs822038	chr7:129065477	A/G	cg02491457	chr7:128862824	NA	-0.57	-11.84	-0.42	2.31e-29	White matter hyperintensity burden;
BRCA	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg05234568	chr11:5960015	NA	-0.51	-11.35	-0.41	2.59e-27	DNA methylation (variation);
BRCA	trans	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg21775007	chr8:11205619	TDH	0.43	8.83	0.33	9.81e-18	Mood instability;
BRCA	cis	rs2882667	0.858	rs17207870	chr5:138387737	T/C	cg04439458	chr5:138467593	SIL1	-0.43	-10.78	-0.39	5.25e-25	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg10223061	chr2:219282414	VIL1	-0.27	-8.08	-0.3	3.13e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg03146154	chr1:46216737	IPP	0.45	10.04	0.37	4.15e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1577917	1.000	rs6914463	chr6:86653415	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.3	-0.41	3.95e-27	Response to antipsychotic treatment;
BRCA	trans	rs8002861	0.641	rs2028813	chr13:44422126	G/T	cg12856521	chr11:46389249	DGKZ	0.4	8.69	0.33	3.11e-17	Leprosy;
BRCA	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg15556689	chr8:8085844	FLJ10661	0.34	8.17	0.31	1.6e-15	Neuroticism;
BRCA	trans	rs1459104	0.706	rs35228933	chr11:55027673	G/A	cg03929089	chr4:120376271	NA	0.65	7.86	0.3	1.65e-14	Body mass index;
BRCA	cis	rs17401966	0.838	rs17034643	chr1:10332102	A/G	cg03954927	chr1:10346856	KIF1B	-0.44	-13.92	-0.48	1.19e-38	Hepatocellular carcinoma;
BRCA	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-9.47	-0.35	5.45e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg12661370	chr5:149340060	SLC26A2	-0.56	-8.18	-0.31	1.49e-15	HIV-1 control;
BRCA	trans	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04565464	chr8:145669602	NFKBIL2	0.43	9.85	0.36	2.16e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg08213375	chr14:104286397	PPP1R13B	0.66	18.66	0.59	2.41e-62	Schizophrenia;
BRCA	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-12.61	-0.45	9.93e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg12927641	chr6:109611667	NA	-0.42	-10.81	-0.39	4.03e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs9359856	0.564	rs72915918	chr6:90430792	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.7	-8.45	-0.32	1.95e-16	Bipolar disorder;
BRCA	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02353165	chr6:42928485	GNMT	0.77	18.94	0.6	8.14e-64	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg22920501	chr2:26401640	FAM59B	-0.63	-11.25	-0.41	6.42e-27	Gut microbiome composition (summer);
BRCA	cis	rs17401966	1.000	rs3753037	chr1:10355834	C/T	cg03954927	chr1:10346856	KIF1B	0.44	13.01	0.46	1.7e-34	Hepatocellular carcinoma;
BRCA	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-9.04	-0.34	1.88e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg25214090	chr10:38739885	LOC399744	0.53	11.71	0.42	7.51e-29	Corneal astigmatism;
BRCA	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11890956	chr21:40555474	PSMG1	1.06	31.74	0.78	1.95e-133	Cognitive function;
BRCA	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg04545296	chr12:48745243	ZNF641	0.24	7.92	0.3	1.06e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs3784262	0.528	rs11071367	chr15:58354152	G/A	cg12031962	chr15:58353849	ALDH1A2	0.35	8.96	0.33	3.51e-18	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-8.42	-0.32	2.48e-16	Response to antipsychotic treatment;
BRCA	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg23131131	chr22:24373011	LOC391322	-0.48	-11.66	-0.42	1.27e-28	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg02493740	chr2:85810744	VAMP5	-0.54	-11.23	-0.41	8.17e-27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs501916	0.605	rs17332642	chr15:48080805	G/A	cg16110827	chr15:48056943	SEMA6D	-0.39	-8.22	-0.31	1.16e-15	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.21	0.41	9.5e-27	Bipolar disorder;
BRCA	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg06046430	chr4:77819534	ANKRD56	0.61	13.63	0.47	2.57e-37	Emphysema distribution in smoking;
BRCA	cis	rs7131987	0.845	rs7299861	chr12:29409667	G/A	cg09582351	chr12:29534625	ERGIC2	-0.39	-9.37	-0.35	1.26e-19	QT interval;
BRCA	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg18270830	chr10:32634957	EPC1	0.53	9.32	0.35	1.93e-19	Sexual dysfunction (female);
BRCA	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg11530693	chr1:120165357	ZNF697	0.62	14.96	0.51	1.36e-43	Systemic lupus erythematosus;
BRCA	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg03161606	chr19:29218774	NA	0.42	7.95	0.3	8.74e-15	Methadone dose in opioid dependence;
BRCA	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.58	-13.62	-0.47	2.91e-37	Eye color traits;
BRCA	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	19.51	0.61	7.86e-67	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg03713592	chr11:72463424	ARAP1	1.13	16.23	0.54	7.74e-50	Type 2 diabetes;
BRCA	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24549020	chr5:56110836	MAP3K1	0.66	13.4	0.47	2.87e-36	Initial pursuit acceleration;
BRCA	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.74	16.03	0.54	7.56e-49	Lymphocyte counts;
BRCA	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg13319975	chr6:146136371	FBXO30	-0.41	-9.34	-0.35	1.5700000000000001e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg25382214	chr1:3105252	PRDM16	-0.33	-7.93	-0.3	9.93e-15	Migraine;
BRCA	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg04842962	chr6:43655489	MRPS18A	1.11	39.06	0.84	1.91e-171	IgG glycosylation;
BRCA	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10802521	chr3:52805072	NEK4	-0.36	-9.91	-0.36	1.25e-21	Bipolar disorder;
BRCA	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg21770322	chr7:97807741	LMTK2	0.44	11.84	0.42	2.14e-29	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg06636001	chr8:8085503	FLJ10661	0.53	10.1	0.37	2.39e-22	Myopia (pathological);
BRCA	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg20607798	chr8:58055168	NA	0.59	9.44	0.35	6.62e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg16989086	chr20:62203971	PRIC285	0.53	8.94	0.33	4.21e-18	Glioblastoma;
BRCA	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg05535760	chr7:792225	HEATR2	0.71	12.84	0.45	9.94e-34	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg16606324	chr3:10149918	C3orf24	0.56	10.95	0.4	1.12e-25	Alzheimer's disease;
BRCA	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg07636037	chr3:49044803	WDR6	0.94	26.3	0.72	6.87e-104	Parkinson's disease;
BRCA	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg18904891	chr8:8559673	CLDN23	0.65	12.88	0.45	6.56e-34	Obesity-related traits;
BRCA	cis	rs9487051	0.768	rs435611	chr6:109527755	C/T	cg21918786	chr6:109611834	NA	-0.34	-9.0	-0.34	2.53e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs9649213	0.614	rs62479858	chr7:97924226	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.6	-15.65	-0.53	5.37e-47	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	22.12	0.66	6.09e-81	Chronic sinus infection;
BRCA	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg19539972	chr4:7069911	GRPEL1	-0.59	-12.42	-0.44	6.77e-32	Monocyte percentage of white cells;
BRCA	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg26384229	chr12:38710491	ALG10B	0.66	13.9	0.48	1.49e-38	Morning vs. evening chronotype;
BRCA	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06544989	chr22:39130855	UNC84B	0.35	8.35	0.31	4.17e-16	Menopause (age at onset);
BRCA	cis	rs754466	0.510	rs10824579	chr10:79590685	C/T	cg17075019	chr10:79541650	NA	-0.64	-16.57	-0.55	1.38e-51	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg17143192	chr8:8559678	CLDN23	0.57	11.08	0.4	3.3e-26	Obesity-related traits;
BRCA	cis	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg00852783	chr1:26633632	UBXN11	-0.47	-8.51	-0.32	1.22e-16	Obesity-related traits;
BRCA	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.75	-13.02	-0.46	1.58e-34	Platelet count;
BRCA	cis	rs2046867	0.862	rs6788139	chr3:72835630	A/G	cg25664220	chr3:72788482	NA	0.38	8.42	0.32	2.54e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs34779708	0.733	rs7081597	chr10:35546331	G/C	cg03585969	chr10:35415529	CREM	0.44	8.95	0.33	3.77e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11229555	0.645	rs7946522	chr11:58197905	G/C	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg02574844	chr11:5959923	NA	-0.38	-8.33	-0.31	4.91e-16	DNA methylation (variation);
BRCA	cis	rs9942416	0.630	rs253388	chr5:74975912	A/G	cg19683494	chr5:74908142	NA	-0.5	-8.88	-0.33	6.73e-18	Age-related disease endophenotypes;
BRCA	cis	rs6088813	1.000	rs6088813	chr20:33975181	C/A	cg14752227	chr20:34000481	UQCC	-0.41	-8.65	-0.32	4.1e-17	Height;
BRCA	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg17063962	chr7:91808500	NA	0.57	13.47	0.47	1.4e-36	Breast cancer;
BRCA	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg15704280	chr7:45808275	SEPT13	0.6	8.88	0.33	6.87e-18	Axial length;
BRCA	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.03	0.49	3.72e-39	Eye color traits;
BRCA	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg09904177	chr6:26538194	HMGN4	-0.55	-17.29	-0.56	3.25e-55	Intelligence (multi-trait analysis);
BRCA	cis	rs30380	0.553	rs27527	chr5:96151968	C/A	cg16492584	chr5:96139282	ERAP1	-0.47	-10.78	-0.39	5.13e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg27170947	chr2:26402098	FAM59B	-0.91	-15.7	-0.53	3.27e-47	Gut microbiome composition (summer);
BRCA	cis	rs858239	0.600	rs6961406	chr7:23134891	C/T	cg23682824	chr7:23144976	KLHL7	0.45	11.89	0.43	1.36e-29	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00149659	chr3:10157352	C3orf10	0.69	10.34	0.38	2.81e-23	Alzheimer's disease;
BRCA	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg11502198	chr6:26597334	ABT1	0.48	9.53	0.35	3.13e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg18016565	chr1:150552671	MCL1	0.34	8.14	0.31	2e-15	Tonsillectomy;
BRCA	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11764359	chr7:65958608	NA	-0.75	-16.59	-0.55	1.12e-51	Aortic root size;
BRCA	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg08885076	chr2:99613938	TSGA10	0.45	10.46	0.38	9.8599999999999993e-24	Chronic sinus infection;
BRCA	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg06713675	chr4:122721982	EXOSC9	-0.53	-12.5	-0.44	3.08e-32	Type 2 diabetes;
BRCA	cis	rs7178424	0.905	rs7177173	chr15:62236804	T/A	cg00456672	chr15:62358751	C2CD4A	0.43	9.82	0.36	2.82e-21	Height;
BRCA	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.44	0.35	6.97e-20	Tonsillectomy;
BRCA	cis	rs7300001	0.667	rs7298716	chr12:110506181	A/T	cg12870014	chr12:110450643	ANKRD13A	0.59	8.05	0.3	3.99e-15	Headache;
BRCA	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg17063962	chr7:91808500	NA	0.55	12.92	0.46	4.12e-34	Breast cancer;
BRCA	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg21132104	chr15:45694354	SPATA5L1	0.75	17.09	0.56	3.4e-54	Homoarginine levels;
BRCA	cis	rs3815308	0.530	rs2240129	chr19:2197734	C/T	cg09261902	chr19:2140048	AP3D1	0.34	8.5	0.32	1.39e-16	Breast cancer;
BRCA	cis	rs6684514	1.000	rs12038217	chr1:156248297	C/T	cg16558208	chr1:156270281	VHLL	0.35	7.95	0.3	8.56e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg03474202	chr17:45855739	NA	-0.46	-12.02	-0.43	3.9e-30	IgG glycosylation;
BRCA	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg09754948	chr16:28834200	ATXN2L	0.45	8.85	0.33	8.64e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs367943	1.000	rs348931	chr5:112812864	G/C	cg12552261	chr5:112820674	MCC	-0.56	-12.28	-0.44	2.97e-31	Type 2 diabetes;
BRCA	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg11941060	chr3:133502564	NA	0.59	14.85	0.51	4.55e-43	Iron status biomarkers;
BRCA	cis	rs1451375	0.652	rs1470747	chr7:50627009	C/T	cg18232548	chr7:50535776	DDC	0.38	7.98	0.3	6.84e-15	Malaria;
BRCA	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg12935359	chr14:103987150	CKB	-0.61	-13.9	-0.48	1.51e-38	Intelligence (multi-trait analysis);
BRCA	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg12756686	chr19:29218302	NA	0.47	8.3	0.31	6.15e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs35740288	0.895	rs3743332	chr15:86303751	T/C	cg20737812	chr15:86336631	KLHL25	-0.32	-8.01	-0.3	5.33e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg23708337	chr7:1209742	NA	0.43	8.29	0.31	6.92e-16	Longevity;Endometriosis;
BRCA	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg15839431	chr19:19639596	YJEFN3	0.35	8.05	0.3	4.14e-15	Bipolar disorder;
BRCA	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg25767906	chr1:53392781	SCP2	0.38	8.71	0.33	2.68e-17	Monocyte count;
BRCA	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg17063962	chr7:91808500	NA	0.52	12.38	0.44	1.05e-31	Breast cancer;
BRCA	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg08645402	chr16:4508243	NA	0.39	9.17	0.34	6.27e-19	Schizophrenia;
BRCA	cis	rs36051895	0.659	rs62541540	chr9:5040080	A/G	cg02405213	chr9:5042618	JAK2	-0.48	-8.65	-0.32	4.22e-17	Pediatric autoimmune diseases;
BRCA	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	9.85	0.36	2.15e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs61931739	1.000	rs61931739	chr12:34089973	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-8.99	-0.34	2.77e-18	Morning vs. evening chronotype;
BRCA	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	13.41	0.47	2.53e-36	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg18904891	chr8:8559673	CLDN23	0.62	12.18	0.43	7.77e-31	Obesity-related traits;
BRCA	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.24	-0.34	3.54e-19	Menopause (age at onset);
BRCA	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg23289794	chr7:2394357	EIF3B	-0.46	-9.55	-0.35	2.62e-20	Multiple sclerosis;
BRCA	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02475777	chr4:1388615	CRIPAK	0.56	11.16	0.4	1.45e-26	Longevity;
BRCA	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg25036284	chr2:26402008	FAM59B	-0.63	-10.48	-0.38	8.25e-24	Gut microbiome composition (summer);
BRCA	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg12483005	chr1:23474871	LUZP1	0.46	10.24	0.38	6.83e-23	Height;
BRCA	cis	rs7267979	0.932	rs1985737	chr20:25591468	T/A	cg08601574	chr20:25228251	PYGB	0.33	7.95	0.3	8.29e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg11062466	chr8:58055876	NA	0.44	10.42	0.38	1.42e-23	Developmental language disorder (linguistic errors);
BRCA	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg20887711	chr4:1340912	KIAA1530	0.35	8.23	0.31	1.05e-15	Longevity;
BRCA	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	8.91	0.33	5.35e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18404041	chr3:52824283	ITIH1	-0.43	-12.81	-0.45	1.32e-33	Bipolar disorder;
BRCA	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-8.71	-0.33	2.55e-17	Height;
BRCA	cis	rs600806	0.778	rs891379	chr1:110003605	A/G	cg20591472	chr1:110008990	SYPL2	0.31	7.89	0.3	1.31e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg06671706	chr8:8559999	CLDN23	0.45	8.76	0.33	1.69e-17	Obesity-related traits;
BRCA	cis	rs7729447	0.776	rs4867472	chr5:32693566	C/T	cg16267343	chr5:32710456	NPR3	0.41	8.27	0.31	7.85e-16	Blood pressure;
BRCA	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	30.54	0.77	5.46e-127	Chronic sinus infection;
BRCA	cis	rs2882667	0.690	rs7736925	chr5:138154530	C/G	cg04439458	chr5:138467593	SIL1	0.36	8.88	0.33	6.46e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-15.69	-0.53	3.55e-47	Chronic sinus infection;
BRCA	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg24069376	chr3:38537580	EXOG	-0.33	-9.43	-0.35	7.59e-20	Electrocardiographic conduction measures;
BRCA	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg26587870	chr6:27730563	NA	-0.49	-7.86	-0.3	1.69e-14	Breast cancer;
BRCA	cis	rs6142102	0.961	rs6059587	chr20:32542926	C/G	cg24642439	chr20:33292090	TP53INP2	0.42	7.84	0.3	1.93e-14	Skin pigmentation;
BRCA	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg27129171	chr3:47204927	SETD2	-0.69	-16.24	-0.54	6.31e-50	Colorectal cancer;
BRCA	cis	rs7737355	0.947	rs3776004	chr5:130879431	G/C	cg06307176	chr5:131281290	NA	0.54	10.66	0.39	1.53e-24	Life satisfaction;
BRCA	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg24558204	chr6:135376177	HBS1L	0.45	12.26	0.44	3.46e-31	Red blood cell count;
BRCA	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg11608241	chr8:8085544	FLJ10661	0.31	8.63	0.32	4.79e-17	Mood instability;
BRCA	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.56	-0.32	8.13e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.06	-0.3	3.81e-15	Prostate cancer;
BRCA	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg17691542	chr6:26056736	HIST1H1C	0.51	10.43	0.38	1.29e-23	Height;
BRCA	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg26587870	chr6:27730563	NA	-0.4	-8.39	-0.31	3.2e-16	Parkinson's disease;
BRCA	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg10792982	chr14:105748885	BRF1	0.5	11.54	0.42	3.97e-28	Mean platelet volume;Platelet distribution width;
BRCA	trans	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg00938859	chr5:1591904	SDHAP3	0.74	9.39	0.35	1.07e-19	Breast cancer;
BRCA	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg03877680	chr5:178157825	ZNF354A	0.8	14.77	0.5	1.05e-42	Neutrophil percentage of white cells;
BRCA	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg18351406	chr4:77819688	ANKRD56	0.62	13.96	0.48	7.71e-39	Emphysema distribution in smoking;
BRCA	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-10.05	-0.37	3.56e-22	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg03929089	chr4:120376271	NA	0.49	8.2	0.31	1.36e-15	Axial length;
BRCA	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg08822215	chr16:89438651	ANKRD11	0.45	9.51	0.35	3.88e-20	Multiple myeloma (IgH translocation);
BRCA	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg11843238	chr5:131593191	PDLIM4	0.35	7.95	0.3	8.19e-15	Breast cancer;
BRCA	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.6	-9.6	-0.35	1.84e-20	Resting heart rate;
BRCA	cis	rs919433	0.680	rs1116734	chr2:198365043	C/G	cg00792783	chr2:198669748	PLCL1	0.38	8.53	0.32	1.08e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg09307838	chr4:120376055	NA	0.75	16.17	0.54	1.48e-49	Corneal astigmatism;
BRCA	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06022373	chr22:39101656	GTPBP1	0.72	15.36	0.52	1.52e-45	Menopause (age at onset);
BRCA	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.52	0.32	1.13e-16	Cognitive ability;
BRCA	cis	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg09307838	chr4:120376055	NA	0.6	11.11	0.4	2.42e-26	Corneal astigmatism;
BRCA	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg20607287	chr7:12443886	VWDE	-0.57	-8.09	-0.3	3.06e-15	Coronary artery disease;
BRCA	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg03342759	chr3:160939853	NMD3	-0.81	-18.07	-0.58	2.79e-59	Parkinson's disease;
BRCA	trans	rs1459104	0.929	rs67114977	chr11:55223023	T/G	cg15704280	chr7:45808275	SEPT13	0.67	7.9	0.3	1.21e-14	Body mass index;
BRCA	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12826209	chr6:26865740	GUSBL1	0.58	10.3	0.38	3.9699999999999997e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg07262247	chr5:131593730	PDLIM4	-0.34	-8.12	-0.31	2.35e-15	Acylcarnitine levels;
BRCA	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	19.76	0.62	3.45e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs13046373	0.508	rs1507393	chr21:31992779	A/G	cg06468780	chr21:31798236	KRTAP13-3	0.33	8.27	0.31	7.64e-16	HDL cholesterol;
BRCA	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.34	9.46	0.35	5.66e-20	Response to antipsychotic treatment;
BRCA	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.34	0.59	1.07e-60	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	11.0	0.4	6.58e-26	Rheumatoid arthritis;
BRCA	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.61	9.89	0.36	1.53e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.42	-0.61	2.35e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.32	8.7	0.33	2.88e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg06212747	chr3:49208901	KLHDC8B	0.47	9.52	0.35	3.62e-20	Parkinson's disease;
BRCA	cis	rs807669	0.525	rs2073740	chr22:19196112	A/C	cg02655711	chr22:19163373	SLC25A1	-0.42	-9.52	-0.35	3.37e-20	Metabolite levels;
BRCA	cis	rs9341808	0.718	rs3805922	chr6:80891989	A/G	cg08355045	chr6:80787529	NA	0.39	9.94	0.37	9.37e-22	Sitting height ratio;
BRCA	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg01689657	chr7:91764605	CYP51A1	0.26	9.33	0.35	1.68e-19	Breast cancer;
BRCA	cis	rs4948102	0.642	rs766333	chr7:56126704	T/A	cg09872392	chr7:56161020	PHKG1	-0.48	-12.04	-0.43	3.12e-30	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs4478858	0.684	rs2271074	chr1:31734841	C/T	cg00250761	chr1:31883323	NA	-0.32	-8.26	-0.31	8.42e-16	Alcohol dependence;
BRCA	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg16482183	chr6:26056742	HIST1H1C	0.49	9.66	0.36	1.1e-20	Iron status biomarkers;
BRCA	cis	rs495337	1.000	rs653423	chr20:48514174	C/T	cg17835207	chr20:48524531	SPATA2	-0.6	-13.75	-0.48	6.93e-38	Psoriasis;
BRCA	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg08085267	chr17:45401833	C17orf57	0.62	12.78	0.45	1.83e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg08999081	chr20:33150536	PIGU	-0.33	-8.53	-0.32	1.05e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs4363385	0.818	rs382292	chr1:153006641	G/A	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.08e-14	Inflammatory skin disease;
BRCA	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	11.58	0.42	2.79e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.58	-0.32	7.15e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg11247378	chr22:39784982	NA	0.63	13.89	0.48	1.67e-38	Intelligence (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg11789530	chr4:8429930	ACOX3	0.58	13.75	0.48	7.12e-38	Response to antineoplastic agents;
BRCA	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.99	0.3	6.41e-15	Depression;
BRCA	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.4	0.32	2.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7091068	0.671	rs591392	chr10:95406081	G/A	cg20715218	chr10:95462985	C10orf4	-0.47	-8.49	-0.32	1.5e-16	Urinary tract infection frequency;
BRCA	cis	rs6963495	0.615	rs2697021	chr7:105151029	A/C	cg19920283	chr7:105172520	RINT1	0.43	8.93	0.33	4.67e-18	Bipolar disorder (body mass index interaction);
BRCA	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg08888203	chr3:10149979	C3orf24	-0.62	-13.72	-0.48	1.01e-37	Alzheimer's disease;
BRCA	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg24558204	chr6:135376177	HBS1L	0.45	12.31	0.44	2.06e-31	Red blood cell count;
BRCA	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg10295955	chr4:187884368	NA	-0.95	-27.58	-0.74	6.69e-111	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7336332	0.598	rs7669	chr13:28009851	C/T	cg01674679	chr13:27998804	GTF3A	-0.46	-7.88	-0.3	1.39e-14	Weight;
BRCA	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	12.44	0.44	5.64e-32	Monocyte percentage of white cells;
BRCA	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs7246657	0.722	rs10412510	chr19:38075944	A/G	cg23950597	chr19:37808831	NA	-0.5	-8.64	-0.32	4.63e-17	Coronary artery calcification;
BRCA	trans	rs4596713	0.538	rs4744829	chr9:71748416	G/C	cg16512924	chr15:28394682	HERC2	0.41	9.85	0.36	2.06e-21	Headache;
BRCA	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg09307838	chr4:120376055	NA	0.59	12.89	0.45	5.65e-34	Educational attainment;
BRCA	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.68	-0.36	8.73e-21	Alcohol dependence;
BRCA	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg22800045	chr5:56110881	MAP3K1	-0.47	-9.34	-0.35	1.54e-19	Initial pursuit acceleration;
BRCA	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg05373962	chr22:49881684	NA	-0.29	-8.06	-0.3	3.75e-15	Monocyte count;Monocyte percentage of white cells;
BRCA	cis	rs1011018	0.628	rs17177358	chr7:139456812	A/G	cg03224163	chr7:139420300	HIPK2	-0.6	-9.06	-0.34	1.53e-18	Systolic blood pressure;
BRCA	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg14863265	chr7:2801509	GNA12	-0.49	-10.81	-0.39	4.07e-25	Height;
BRCA	cis	rs4285028	0.699	rs12629742	chr3:121614895	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.73	-13.17	-0.46	3.23e-35	Multiple sclerosis;
BRCA	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg21252483	chr19:49399788	TULP2	-0.51	-10.75	-0.39	7e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg25208724	chr1:156163844	SLC25A44	0.88	17.78	0.58	9.67e-58	Testicular germ cell tumor;
BRCA	cis	rs897080	0.518	rs1067330	chr2:44627822	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	10.5	0.38	6.83e-24	Height;
BRCA	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg27588902	chr6:42928151	GNMT	-0.31	-10.19	-0.37	1.07e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03264133	chr6:25882463	NA	0.41	8.71	0.33	2.61e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg12437481	chr16:420112	MRPL28	-0.48	-11.59	-0.42	2.43e-28	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg01420254	chr6:26195488	NA	0.56	8.79	0.33	1.41e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg21782813	chr7:2030301	MAD1L1	0.35	9.49	0.35	4.36e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs2859741	0.546	rs2133910	chr1:37478785	G/T	cg09363841	chr1:37513479	NA	-0.5	-10.81	-0.39	3.88e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	trans	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg13010199	chr12:38710504	ALG10B	0.4	8.08	0.3	3.19e-15	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg14926445	chr8:58193284	C8orf71	-0.47	-8.92	-0.33	4.83e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2505998	0.833	rs12767776	chr10:43589513	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.43	-8.45	-0.32	2.02e-16	Hirschsprung disease;
BRCA	cis	rs7095944	0.614	rs61872084	chr10:126439062	C/T	cg08799069	chr10:126477246	METTL10	-0.4	-9.49	-0.35	4.41e-20	Asthma;
BRCA	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.2	0.37	1.01e-22	Calcium levels;
BRCA	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg06552810	chr11:31128660	NA	-0.39	-8.74	-0.33	1.98e-17	Red blood cell count;
BRCA	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.24	0.49	3.5e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg18252515	chr7:66147081	NA	-0.83	-12.64	-0.45	7.22e-33	Diabetic kidney disease;
BRCA	cis	rs7598759	0.527	rs7571691	chr2:232369401	C/T	cg19187155	chr2:232395269	NMUR1	0.68	16.39	0.54	1.21e-50	Noise-induced hearing loss;
BRCA	trans	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg20637307	chr2:213403960	ERBB4	0.7	19.23	0.61	2.33e-65	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg03213289	chr20:61660250	NA	0.62	16.27	0.54	4.5e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg01877450	chr7:97915802	BRI3	-0.37	-8.33	-0.31	4.82e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.77	-0.42	4.32e-29	Alcohol dependence;
BRCA	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg00686598	chr14:53173677	PSMC6	1.17	15.83	0.53	7.63e-48	Alzheimer's disease (late onset);
BRCA	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg08213375	chr14:104286397	PPP1R13B	0.65	18.25	0.59	3.25e-60	Schizophrenia;
BRCA	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.87	0.36	1.75e-21	Lung cancer in ever smokers;
BRCA	trans	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg26043149	chr18:55253948	FECH	-0.38	-8.14	-0.31	2.03e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.56	-8.21	-0.31	1.24e-15	Schizophrenia;
BRCA	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg08132940	chr7:1081526	C7orf50	-0.6	-8.99	-0.34	2.69e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg06521331	chr12:34319734	NA	-0.47	-9.24	-0.34	3.67e-19	Bladder cancer;
BRCA	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.66	14.69	0.5	2.57e-42	Chronic sinus infection;
BRCA	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-11.1	-0.4	2.77e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg23711669	chr6:146136114	FBXO30	0.74	17.77	0.58	1.06e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.35	0.59	9.41e-61	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1451375	1.000	rs2329340	chr7:50620229	C/T	cg18232548	chr7:50535776	DDC	0.44	10.2	0.37	9.99e-23	Malaria;
BRCA	cis	rs1784581	0.721	rs9365356	chr6:162414789	A/G	cg17173639	chr6:162384350	PARK2	0.39	9.12	0.34	9.27e-19	Itch intensity from mosquito bite;
BRCA	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	10.63	0.39	2.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg04691961	chr3:161091175	C3orf57	-0.42	-10.43	-0.38	1.25e-23	Morning vs. evening chronotype;
BRCA	cis	rs7408868	0.520	rs10417567	chr19:15308068	C/T	cg14696996	chr19:15285081	NOTCH3	-0.82	-12.08	-0.43	2.05e-30	Pulse pressure;
BRCA	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg06671706	chr8:8559999	CLDN23	0.45	8.66	0.32	3.72e-17	Obesity-related traits;
BRCA	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	9.79	0.36	3.49e-21	Tonsillectomy;
BRCA	trans	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg09904177	chr6:26538194	HMGN4	0.42	11.91	0.43	1.09e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs524281	0.647	rs2302883	chr11:65824994	T/C	cg14036092	chr11:66035641	RAB1B	-0.41	-8.95	-0.33	3.89e-18	Electroencephalogram traits;
BRCA	cis	rs752010	0.905	rs4525030	chr1:42091307	G/C	cg06885757	chr1:42089581	HIVEP3	0.24	8.66	0.32	3.9e-17	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.83	0.3	2.1e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg11843238	chr5:131593191	PDLIM4	0.41	10.35	0.38	2.63e-23	Acylcarnitine levels;
BRCA	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg13550731	chr2:172543902	DYNC1I2	0.94	32.1	0.79	2.31e-135	Schizophrenia;
BRCA	cis	rs12579753	0.917	rs2401002	chr12:82215870	C/T	cg07988820	chr12:82153109	PPFIA2	-0.51	-8.62	-0.32	5.17e-17	Resting heart rate;
BRCA	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg23711669	chr6:146136114	FBXO30	0.65	15.3	0.52	3.01e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg07460842	chr6:66804631	NA	0.87	14.42	0.5	5.11e-41	Exhaled nitric oxide output;
BRCA	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg24692254	chr21:30365293	RNF160	0.61	15.62	0.53	7.67e-47	Dental caries;
BRCA	cis	rs9790314	0.572	rs13073571	chr3:160665720	G/A	cg03342759	chr3:160939853	NMD3	0.44	8.5	0.32	1.35e-16	Morning vs. evening chronotype;
BRCA	cis	rs4787491	0.729	rs7191849	chr16:30023157	T/C	cg06326092	chr16:30034487	C16orf92	0.34	8.5	0.32	1.34e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg08645402	chr16:4508243	NA	0.44	11.31	0.41	3.51e-27	Schizophrenia;
BRCA	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg07080220	chr10:102295463	HIF1AN	0.56	13.06	0.46	9.66e-35	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-20.03	-0.62	1.28e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.37	8.31	0.31	5.85e-16	Endometrial cancer;
BRCA	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-16.53	-0.55	2.29e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06634786	chr22:41940651	POLR3H	-0.57	-8.5	-0.32	1.3e-16	Vitiligo;
BRCA	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.24	-0.31	9.68e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-13.08	-0.46	8.05e-35	Migraine;Coronary artery disease;
BRCA	cis	rs8014204	0.762	rs10138360	chr14:75293386	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.42	-8.82	-0.33	1.13e-17	Caffeine consumption;
BRCA	cis	rs490234	0.812	rs13288963	chr9:128295198	G/A	cg14078157	chr9:128172775	NA	-0.49	-11.04	-0.4	4.47e-26	Mean arterial pressure;
BRCA	cis	rs1043763	0.826	rs9668430	chr12:122623595	A/G	cg14400030	chr12:122498111	BCL7A	-0.62	-13.4	-0.47	3.06e-36	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
BRCA	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg23711669	chr6:146136114	FBXO30	0.64	14.85	0.51	4.32e-43	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg19862616	chr7:65841803	NCRNA00174	0.86	28.7	0.75	5.2e-117	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg18196295	chr10:418757	DIP2C	-0.55	-12.41	-0.44	7.56e-32	Psychosis in Alzheimer's disease;
BRCA	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg10057126	chr4:77819792	ANKRD56	0.68	15.42	0.52	7.78e-46	Emphysema distribution in smoking;
BRCA	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg06784218	chr1:46089804	CCDC17	-0.51	-12.23	-0.44	4.9e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.09e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg20219911	chr3:52813652	ITIH1	0.3	8.45	0.32	1.9e-16	Bipolar disorder;
BRCA	cis	rs73001065	0.792	rs16996148	chr19:19658472	G/T	cg03709012	chr19:19516395	GATAD2A	0.83	10.72	0.39	9.3e-25	LDL cholesterol;
BRCA	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg26031613	chr14:104095156	KLC1	-0.42	-8.33	-0.31	4.82e-16	Schizophrenia;
BRCA	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg16586182	chr3:47516702	SCAP	-0.59	-13.54	-0.47	6.9e-37	Colorectal cancer;
BRCA	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg15145296	chr3:125709740	NA	-0.55	-8.7	-0.33	2.73e-17	Blood pressure (smoking interaction);
BRCA	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.78	0.45	1.82e-33	Bipolar disorder;
BRCA	cis	rs9443189	0.570	rs7755068	chr6:76405700	A/G	cg01950844	chr6:76311363	SENP6	0.84	13.53	0.47	7.52e-37	Prostate cancer;
BRCA	trans	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg06521331	chr12:34319734	NA	-0.48	-8.73	-0.33	2.13e-17	Bladder cancer;
BRCA	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg24692254	chr21:30365293	RNF160	0.37	8.39	0.31	3.19e-16	Pancreatic cancer;
BRCA	cis	rs858239	0.601	rs6461702	chr7:23249273	C/G	cg23682824	chr7:23144976	KLHL7	0.35	8.67	0.32	3.49e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg11057378	chr10:81107060	PPIF	0.38	9.34	0.35	1.6e-19	Height;
BRCA	cis	rs11608355	0.545	rs4766604	chr12:109892179	T/C	cg05360138	chr12:110035743	NA	0.71	13.18	0.46	2.85e-35	Neuroticism;
BRCA	cis	rs6910061	1.000	rs6913027	chr6:11107276	G/A	cg27233058	chr6:11094804	LOC221710	0.53	9.35	0.35	1.43e-19	Diabetic kidney disease;
BRCA	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg04450456	chr4:17643702	FAM184B	0.38	11.15	0.4	1.66e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg01620082	chr3:125678407	NA	-0.56	-7.93	-0.3	9.71e-15	Depression;
BRCA	cis	rs870825	0.616	rs6552802	chr4:185620751	C/G	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg07541023	chr7:19748670	TWISTNB	0.63	10.52	0.38	5.51e-24	Thyroid stimulating hormone;
BRCA	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.73	-0.33	2.15e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.32	-0.31	5.51e-16	Total body bone mineral density;
BRCA	trans	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg26043149	chr18:55253948	FECH	1.1	23.27	0.68	3.3e-87	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg22764044	chr5:178986830	RUFY1	-0.46	-12.83	-0.45	1.12e-33	Lung cancer;
BRCA	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg26384229	chr12:38710491	ALG10B	0.76	17.01	0.56	8.73e-54	Morning vs. evening chronotype;
BRCA	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg20887711	chr4:1340912	KIAA1530	0.39	9.3	0.35	2.26e-19	Longevity;
BRCA	trans	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg26043149	chr18:55253948	FECH	0.37	8.05	0.3	3.95e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.1	0.46	6.97e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs847577	0.715	rs12665986	chr7:97719676	A/G	cg21770322	chr7:97807741	LMTK2	-0.47	-12.7	-0.45	4.12e-33	Breast cancer;
BRCA	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.06	0.34	1.61e-18	Platelet count;
BRCA	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	12.99	0.46	2.1e-34	Migraine;Coronary artery disease;
BRCA	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.8	-10.58	-0.39	3.16e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs919433	0.680	rs2124317	chr2:198477606	G/A	cg00792783	chr2:198669748	PLCL1	0.35	8.09	0.3	3.07e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	19.18	0.6	4.14e-65	Platelet count;
BRCA	cis	rs57590327	0.555	rs2053805	chr3:81738414	T/C	cg07356753	chr3:81810745	GBE1	-0.47	-11.2	-0.41	1.01e-26	Extraversion;
BRCA	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg12751644	chr20:60527061	NA	-0.33	-7.91	-0.3	1.12e-14	Body mass index;
BRCA	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.41	-9.79	-0.36	3.36e-21	Lymphocyte counts;
BRCA	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg06697600	chr4:7070879	GRPEL1	0.61	10.78	0.39	5.1e-25	Monocyte percentage of white cells;
BRCA	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-13.19	-0.46	2.72e-35	Platelet count;
BRCA	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg16576597	chr16:28551801	NUPR1	0.3	8.0	0.3	5.85e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg00409905	chr10:38381863	ZNF37A	-0.49	-9.14	-0.34	7.87e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg11366901	chr6:160182831	ACAT2	0.78	15.21	0.52	8.47e-45	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg24011408	chr12:48396354	COL2A1	-0.43	-9.43	-0.35	7.26e-20	Plateletcrit;
BRCA	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg26384229	chr12:38710491	ALG10B	0.76	17.28	0.56	3.49e-55	Bladder cancer;
BRCA	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg10578991	chr7:12443926	VWDE	-0.57	-8.06	-0.3	3.71e-15	Coronary artery disease;
BRCA	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg08132940	chr7:1081526	C7orf50	-0.45	-8.04	-0.3	4.3e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg00530320	chr1:46809349	NSUN4	0.48	9.7	0.36	7.74e-21	Menopause (age at onset);
BRCA	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00166722	chr3:10149974	C3orf24	0.63	11.33	0.41	3.12e-27	Alzheimer's disease;
BRCA	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg06212747	chr3:49208901	KLHDC8B	0.46	9.56	0.35	2.45e-20	Parkinson's disease;
BRCA	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-10.02	-0.37	4.67e-22	Alzheimer's disease (late onset);
BRCA	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg09184832	chr6:79620586	NA	-0.41	-8.25	-0.31	9.35e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg25019033	chr10:957182	NA	-0.43	-8.23	-0.31	1.02e-15	Eosinophil percentage of granulocytes;
BRCA	trans	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg01620082	chr3:125678407	NA	-0.91	-10.26	-0.38	5.88e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg25358565	chr5:93447407	FAM172A	1.23	18.35	0.59	1.04e-60	Diabetic retinopathy;
BRCA	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg12648201	chr2:27665141	KRTCAP3	0.33	8.23	0.31	1.05e-15	Total body bone mineral density;
BRCA	cis	rs1829883	0.898	rs13184400	chr5:98784722	G/A	cg08333243	chr5:99726346	NA	-0.35	-8.35	-0.31	4.39e-16	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs9420	0.961	rs11601320	chr11:57642617	T/C	cg19752551	chr11:57585705	CTNND1	-0.5	-12.23	-0.44	4.57e-31	Schizophrenia;
BRCA	cis	rs887829	0.570	rs4347832	chr2:234593041	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.32	-8.31	-0.31	5.65e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs758324	0.648	rs152126	chr5:131383667	A/C	cg06307176	chr5:131281290	NA	-0.44	-8.71	-0.33	2.54e-17	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg14835575	chr10:16859367	RSU1	0.62	12.38	0.44	1.1e-31	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	11.52	0.41	5.17e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg17063962	chr7:91808500	NA	0.61	14.5	0.5	2.19e-41	Breast cancer;
BRCA	cis	rs7631605	0.905	rs6550457	chr3:37182198	T/C	cg15934958	chr3:37212084	LRRFIP2	0.4	9.51	0.35	3.91e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs13046373	0.535	rs13051529	chr21:32029743	G/C	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.07	0.3	3.48e-15	HDL cholesterol;
BRCA	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg00409905	chr10:38381863	ZNF37A	-0.57	-12.41	-0.44	7.44e-32	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.62	13.44	0.47	1.86e-36	Lymphocyte percentage of white cells;
BRCA	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg20701182	chr2:24300061	SF3B14	0.57	8.95	0.33	3.91e-18	Lymphocyte counts;
BRCA	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-10.52	-0.38	5.62e-24	Bladder cancer;
BRCA	cis	rs10129255	0.518	rs8010020	chr14:107186255	A/G	cg07958169	chr14:107095056	NA	-0.4	-8.48	-0.32	1.59e-16	Kawasaki disease;
BRCA	cis	rs2882667	0.690	rs1828188	chr5:138171996	A/G	cg04439458	chr5:138467593	SIL1	0.31	7.81	0.3	2.44e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs17401966	1.000	rs4846208	chr1:10313839	T/C	cg03954927	chr1:10346856	KIF1B	0.45	12.8	0.45	1.41e-33	Hepatocellular carcinoma;
BRCA	trans	rs12517041	1.000	rs34515966	chr5:23310388	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.49	-8.62	-0.32	5.14e-17	Calcium levels;
BRCA	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg14844989	chr11:31128820	NA	0.47	9.96	0.37	7.98e-22	Red blood cell count;
BRCA	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg03877680	chr5:178157825	ZNF354A	0.86	17.27	0.56	4.03e-55	Neutrophil percentage of white cells;
BRCA	trans	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg04374321	chr14:90722782	PSMC1	-0.47	-11.32	-0.41	3.41e-27	Mortality in heart failure;
BRCA	cis	rs1829883	1.000	rs1916599	chr5:98774240	C/G	cg08333243	chr5:99726346	NA	-0.36	-8.68	-0.32	3.19e-17	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-14.2	-0.49	5.94e-40	Monocyte count;
BRCA	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg08992911	chr2:238395768	MLPH	0.6	10.35	0.38	2.61e-23	Prostate cancer;
BRCA	trans	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg06521331	chr12:34319734	NA	0.46	8.91	0.33	5.31e-18	Morning vs. evening chronotype;
BRCA	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg26384229	chr12:38710491	ALG10B	-0.55	-13.64	-0.47	2.39e-37	Morning vs. evening chronotype;
BRCA	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg14675211	chr2:100938903	LONRF2	0.44	9.65	0.36	1.17e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg03188948	chr7:1209495	NA	0.61	12.06	0.43	2.62e-30	Longevity;Endometriosis;
BRCA	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12292205	chr6:26970375	C6orf41	-0.47	-7.97	-0.3	7.21e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.46	-10.98	-0.4	7.88e-26	IgG glycosylation;
BRCA	cis	rs1018836	0.923	rs4735230	chr8:91574184	G/C	cg16814680	chr8:91681699	NA	-0.64	-14.31	-0.49	1.62e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.52	-0.32	1.12e-16	Height;
BRCA	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg01017244	chr2:74357527	NA	0.56	13.2	0.46	2.49e-35	Gestational age at birth (maternal effect);
BRCA	trans	rs9944715	0.954	rs7228365	chr18:43817832	A/G	cg01718231	chr17:29326311	RNF135	-0.46	-9.08	-0.34	1.34e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18876405	chr7:65276391	NA	0.6	15.14	0.51	1.7e-44	Aortic root size;
BRCA	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg25036284	chr2:26402008	FAM59B	-0.87	-14.49	-0.5	2.47e-41	Gut microbiome composition (summer);
BRCA	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg24631222	chr15:78858424	CHRNA5	-0.57	-11.6	-0.42	2.23e-28	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg23229984	chr5:148520753	ABLIM3	-0.37	-9.05	-0.34	1.66e-18	Breast cancer;
BRCA	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg11262906	chr1:85462892	MCOLN2	-0.47	-8.78	-0.33	1.45e-17	Serum sulfate level;
BRCA	trans	rs459571	0.959	rs465535	chr9:136910905	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-14.6	-0.5	7.25e-42	Platelet distribution width;
BRCA	cis	rs597583	0.709	rs7940527	chr11:117398202	C/G	cg27161313	chr11:117392002	DSCAML1	0.37	7.83	0.3	2.05e-14	Putamen volume;
BRCA	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg19508488	chr2:152266495	RIF1	0.38	8.22	0.31	1.18e-15	Lung cancer;
BRCA	cis	rs6442522	0.768	rs3821638	chr3:15511044	A/G	cg16303742	chr3:15540471	COLQ	0.34	8.07	0.3	3.46e-15	Uric acid levels;
BRCA	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02176678	chr2:219576539	TTLL4	0.47	12.43	0.44	6.07e-32	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg11764359	chr7:65958608	NA	-0.68	-15.1	-0.51	2.92e-44	Aortic root size;
BRCA	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg04842962	chr6:43655489	MRPS18A	1.12	39.23	0.84	2.61e-172	IgG glycosylation;
BRCA	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg23711669	chr6:146136114	FBXO30	0.74	16.99	0.56	1.09e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.34	-0.31	4.49e-16	Colorectal cancer;
BRCA	cis	rs7107174	0.792	rs10899488	chr11:78088754	A/G	cg27205649	chr11:78285834	NARS2	-0.3	-8.26	-0.31	8.6e-16	Testicular germ cell tumor;
BRCA	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg23505145	chr19:12996616	KLF1	0.56	12.69	0.45	4.46e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg21226059	chr5:178986404	RUFY1	0.52	14.59	0.5	8.03e-42	Lung cancer;
BRCA	cis	rs698833	0.926	rs698827	chr2:44730496	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.48	-9.95	-0.37	8.52e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs921968	0.565	rs7599945	chr2:219641528	G/T	cg02176678	chr2:219576539	TTLL4	-0.41	-10.96	-0.4	9.9e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg13319975	chr6:146136371	FBXO30	-0.41	-9.38	-0.35	1.15e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg26647111	chr11:31128758	NA	-0.45	-9.77	-0.36	4.35e-21	Red blood cell count;
BRCA	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.42	-8.2	-0.31	1.31e-15	Monocyte percentage of white cells;
BRCA	cis	rs28374715	0.532	rs316606	chr15:41772202	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.08	-24.9	-0.7	3.69e-96	Ulcerative colitis;
BRCA	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg04944784	chr2:26401820	FAM59B	0.67	11.15	0.4	1.67e-26	Gut microbiome composition (summer);
BRCA	trans	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg26043149	chr18:55253948	FECH	-0.38	-8.36	-0.31	3.96e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2882667	0.858	rs11949916	chr5:138396277	T/G	cg04439458	chr5:138467593	SIL1	-0.43	-10.88	-0.4	2.01e-25	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9341808	0.754	rs3805907	chr6:80973665	A/G	cg08355045	chr6:80787529	NA	-0.37	-9.56	-0.35	2.41e-20	Sitting height ratio;
BRCA	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg20503657	chr10:835505	NA	1.3	21.68	0.65	1.53e-78	Eosinophil percentage of granulocytes;
BRCA	cis	rs7927771	0.524	rs7943213	chr11:47715524	T/C	cg20307385	chr11:47447363	PSMC3	0.42	9.52	0.35	3.42e-20	Subjective well-being;
BRCA	cis	rs698833	0.926	rs1067342	chr2:44622256	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	11.29	0.41	4.49e-27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg23711669	chr6:146136114	FBXO30	0.73	17.21	0.56	7.78e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7617773	0.779	rs9833309	chr3:48327450	C/T	cg11946769	chr3:48343235	NME6	0.63	13.47	0.47	1.45e-36	Coronary artery disease;
BRCA	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg24060327	chr5:131705240	SLC22A5	0.61	11.36	0.41	2.18e-27	Blood metabolite levels;
BRCA	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg18252515	chr7:66147081	NA	-0.96	-13.72	-0.48	9.52e-38	Diabetic kidney disease;
BRCA	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.93	24.04	0.69	1.93e-91	Birth weight;
BRCA	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-10.28	-0.38	4.74e-23	Neuroticism;
BRCA	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.6	-0.67	1.57e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg23978390	chr7:1156363	C7orf50	0.41	8.18	0.31	1.5e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg19622623	chr12:86230825	RASSF9	-0.34	-9.54	-0.35	2.85e-20	Major depressive disorder;
BRCA	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18404041	chr3:52824283	ITIH1	-0.28	-8.18	-0.31	1.51e-15	Electroencephalogram traits;
BRCA	trans	rs4650994	0.544	rs4652301	chr1:178499799	T/C	cg05059571	chr16:84539110	KIAA1609	-0.57	-12.59	-0.45	1.2e-32	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs6901250	1.000	rs615199	chr6:117113653	T/C	cg12892004	chr6:117198278	RFX6	0.49	11.14	0.4	1.83e-26	C-reactive protein levels;
BRCA	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.33	9.09	0.34	1.19e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg15704280	chr7:45808275	SEPT13	-0.49	-9.64	-0.36	1.29e-20	HDL cholesterol;
BRCA	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg03433033	chr1:76189801	ACADM	0.75	17.32	0.57	2.23e-55	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7617773	0.780	rs34589064	chr3:48339549	G/A	cg11946769	chr3:48343235	NME6	0.68	14.05	0.49	2.93e-39	Coronary artery disease;
BRCA	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.53	8.42	0.32	2.57e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	26.58	0.72	2.01e-105	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg12927641	chr6:109611667	NA	-0.38	-9.61	-0.36	1.63e-20	Reticulocyte fraction of red cells;
BRCA	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21659725	chr3:3221576	CRBN	0.49	11.06	0.4	3.9e-26	Resting heart rate;
BRCA	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg13256891	chr4:100009986	ADH5	0.52	10.7	0.39	1.07e-24	Alcohol dependence;
BRCA	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.84	-0.3	1.86e-14	Aortic root size;
BRCA	trans	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg26043149	chr18:55253948	FECH	-0.39	-8.66	-0.32	3.89e-17	Bone mineral density;
BRCA	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.66	0.57	3.67e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg13402656	chr8:1511478	DLGAP2	-0.59	-14.12	-0.49	1.28e-39	Lung cancer;
BRCA	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg06453172	chr10:134556979	INPP5A	-0.6	-11.77	-0.42	4.54e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6542838	0.641	rs6757098	chr2:99471399	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.37	-8.4	-0.32	2.78e-16	Fear of minor pain;
BRCA	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05901451	chr6:126070800	HEY2	-0.56	-14.88	-0.51	3.19e-43	Brugada syndrome;
BRCA	cis	rs75229567	0.618	rs78294090	chr12:70209959	G/T	cg10114359	chr12:70132523	RAB3IP	0.84	10.43	0.38	1.29e-23	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
BRCA	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg09537434	chr19:41945824	ATP5SL	-0.98	-24.22	-0.69	2.02e-92	Height;
BRCA	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg05340658	chr4:99064831	C4orf37	0.66	16.1	0.54	3.26e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg03342759	chr3:160939853	NMD3	0.61	12.96	0.46	2.89e-34	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg21770322	chr7:97807741	LMTK2	0.42	11.14	0.4	1.88e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12760731	0.565	rs12037925	chr1:178160268	C/T	cg00404053	chr1:178313656	RASAL2	0.65	7.96	0.3	8.01e-15	Obesity-related traits;
BRCA	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg14440974	chr22:39074834	NA	-0.39	-9.14	-0.34	8.25e-19	Menopause (age at onset);
BRCA	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16680214	chr1:154839983	KCNN3	-0.41	-11.29	-0.41	4.48e-27	Prostate cancer;
BRCA	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.41	0.35	8.46e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.22	0.31	1.17e-15	Cognitive ability;
BRCA	cis	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg06521331	chr12:34319734	NA	0.56	11.06	0.4	3.99e-26	Morning vs. evening chronotype;
BRCA	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-19.27	-0.61	1.44e-65	Chronic sinus infection;
BRCA	cis	rs16854884	0.584	rs59768870	chr3:143738366	G/A	cg06585982	chr3:143692056	C3orf58	0.42	8.92	0.33	4.98e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg05313129	chr8:58192883	C8orf71	-0.46	-9.63	-0.36	1.33e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.5	9.61	0.36	1.66e-20	Birth weight;
BRCA	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg13010199	chr12:38710504	ALG10B	0.51	9.99	0.37	6.28e-22	Morning vs. evening chronotype;
BRCA	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg25358565	chr5:93447407	FAM172A	1.18	19.95	0.62	3.47e-69	Diabetic retinopathy;
BRCA	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg00745463	chr17:30367425	LRRC37B	-0.54	-8.88	-0.33	6.88e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg01206211	chr2:36825736	FEZ2	0.44	10.64	0.39	1.94e-24	Height;
BRCA	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg22713356	chr15:30763199	NA	1.25	20.77	0.63	1.25e-73	Uric acid levels;
BRCA	cis	rs727479	0.502	rs8029120	chr15:51504934	A/C	cg19946085	chr15:51559439	CYP19A1	-0.31	-8.59	-0.32	6.53e-17	Estradiol levels;
BRCA	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg19628046	chr18:33552617	C18orf21	0.58	11.83	0.42	2.55e-29	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.78	-0.36	3.82e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs11887277	0.868	rs6717682	chr2:27069211	A/G	cg08802533	chr2:27073253	DPYSL5	-0.29	-7.82	-0.3	2.16e-14	Obesity-related traits;
BRCA	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg04455712	chr21:45112962	RRP1B	0.39	10.17	0.37	1.25e-22	Mean corpuscular volume;
BRCA	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.15	-0.34	7.6e-19	Myopia (pathological);
BRCA	cis	rs7247513	0.964	rs8100964	chr19:12720631	C/T	cg01871581	chr19:12707946	ZNF490	-0.68	-15.73	-0.53	2.21e-47	Bipolar disorder;
BRCA	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg02544614	chr20:61657117	NA	0.29	8.12	0.31	2.36e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg20129853	chr10:51489980	NA	0.33	8.92	0.33	4.78e-18	Prostate-specific antigen levels;
BRCA	trans	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg20935933	chr6:143382018	AIG1	0.6	11.57	0.42	3.18e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs10754283	0.967	rs6428562	chr1:90102665	G/A	cg21401794	chr1:90099060	LRRC8C	0.46	11.11	0.4	2.33e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg09184832	chr6:79620586	NA	0.52	11.16	0.4	1.57e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs6700896	0.931	rs59508186	chr1:66107881	C/A	cg04111102	chr1:66153794	NA	0.33	8.11	0.31	2.58e-15	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs250677	0.522	rs10038913	chr5:148354224	A/G	cg18129178	chr5:148520854	ABLIM3	0.53	10.07	0.37	2.99e-22	Breast cancer;
BRCA	trans	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.92	-0.3	1.02e-14	Corneal astigmatism;
BRCA	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg16606324	chr3:10149918	C3orf24	0.54	10.94	0.4	1.18e-25	Alzheimer's disease;
BRCA	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg11814155	chr7:99998594	ZCWPW1	0.49	8.74	0.33	2.06e-17	Platelet count;
BRCA	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg26031613	chr14:104095156	KLC1	-0.63	-13.94	-0.48	9.44e-39	Intelligence (multi-trait analysis);
BRCA	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg15819921	chr19:927150	ARID3A	-0.48	-9.4	-0.35	9.38e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg00983440	chr10:79422392	NA	-0.54	-10.24	-0.38	7.11e-23	Bone mineral density;
BRCA	cis	rs778371	0.676	rs17164	chr2:233593499	C/T	cg08000102	chr2:233561755	GIGYF2	0.77	16.99	0.56	1.11e-53	Schizophrenia;
BRCA	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg21518248	chr2:162101506	NA	0.53	11.28	0.41	5.07e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23583168	chr7:148888333	NA	-0.83	-18.87	-0.6	1.94e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7781557	1.000	rs2041094	chr7:102495434	C/T	cg18108683	chr7:102477205	FBXL13	-0.44	-8.08	-0.3	3.14e-15	Colorectal adenoma (advanced);
BRCA	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.09	0.56	3.2e-54	Fuchs's corneal dystrophy;
BRCA	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.62	-15.26	-0.52	4.84e-45	Colorectal cancer;
BRCA	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg25173405	chr17:45401733	C17orf57	0.5	10.13	0.37	1.88e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.49e-34	Alzheimer's disease (late onset);
BRCA	cis	rs2120243	0.967	rs7648322	chr3:157143684	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	8.88	0.33	6.56e-18	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs11997175	1.000	rs7464996	chr8:33770925	G/T	ch.8.33884649F	chr8:33765107	NA	0.46	11.58	0.42	2.84e-28	Body mass index;
BRCA	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24531977	chr5:56204891	C5orf35	0.7	15.6	0.53	1.01e-46	Initial pursuit acceleration;
BRCA	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg03342759	chr3:160939853	NMD3	-0.64	-13.57	-0.47	4.61e-37	Morning vs. evening chronotype;
BRCA	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26314531	chr2:26401878	FAM59B	-0.66	-11.27	-0.41	5.28e-27	Gut microbiome composition (summer);
BRCA	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg25554036	chr4:6271136	WFS1	0.4	9.55	0.35	2.73e-20	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.68	0.39	1.35e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg19862616	chr7:65841803	NCRNA00174	0.81	25.64	0.71	3.13e-100	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4853036	0.951	rs6710444	chr2:70120632	G/A	cg02498382	chr2:70120550	SNRNP27	-0.54	-10.79	-0.39	4.9e-25	Colorectal or endometrial cancer;
BRCA	trans	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg15556689	chr8:8085844	FLJ10661	-0.34	-8.8	-0.33	1.31e-17	Monocyte count;
BRCA	cis	rs887829	0.569	rs6711351	chr2:234634916	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-8.93	-0.33	4.64e-18	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs2463822	0.925	rs17157227	chr11:62169772	A/G	cg06239285	chr11:62104954	ASRGL1	0.62	8.79	0.33	1.34e-17	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs9400271	0.632	rs9487020	chr6:109587672	A/G	cg01475377	chr6:109611718	NA	-0.44	-10.49	-0.38	7.17e-24	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs9837602	0.592	rs1606481	chr3:99427552	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.44	-8.38	-0.31	3.41e-16	Breast cancer;
BRCA	trans	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-9.44	-0.35	6.83e-20	Triglycerides;
BRCA	cis	rs2276314	0.553	rs12964535	chr18:33611691	A/C	cg05985134	chr18:33552581	C18orf21	-0.42	-7.96	-0.3	8.15e-15	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs4233802	1.000	rs4366927	chr2:151138525	T/C	cg25300694	chr2:151184358	NA	0.76	8.12	0.31	2.34e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs6782228	0.527	rs2712371	chr3:128346214	G/A	cg16766828	chr3:128327626	NA	-0.42	-9.49	-0.35	4.35e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs7833986	1.000	rs34952804	chr8:57097399	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.46	8.22	0.31	1.14e-15	Height;
BRCA	cis	rs1941023	0.584	rs10750937	chr11:60172087	C/T	cg08716584	chr11:60157161	MS4A7	-0.42	-9.73	-0.36	5.75e-21	Congenital heart disease (maternal effect);
BRCA	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.95	21.66	0.65	1.92e-78	Smoking behavior;
BRCA	trans	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg26043149	chr18:55253948	FECH	0.36	7.93	0.3	9.56e-15	Bone mineral density;
BRCA	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg23029597	chr12:123009494	RSRC2	-0.38	-7.89	-0.3	1.29e-14	Body mass index;
BRCA	cis	rs4561483	0.815	rs7198817	chr16:11945778	C/A	cg08843971	chr16:11963173	GSPT1	0.49	10.84	0.39	2.95e-25	Testicular germ cell tumor;
BRCA	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg05283184	chr6:79620031	NA	-0.43	-11.12	-0.4	2.29e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg12140854	chr5:148520817	ABLIM3	0.45	9.48	0.35	4.98e-20	Breast cancer;
BRCA	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg16325326	chr1:53192061	ZYG11B	0.64	14.65	0.5	4.11e-42	Monocyte count;
BRCA	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.39	2.33e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg05340658	chr4:99064831	C4orf37	0.59	12.76	0.45	2.28e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg13628971	chr7:2884303	GNA12	0.57	12.5	0.44	3.08e-32	Height;
BRCA	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg18196295	chr10:418757	DIP2C	-0.48	-9.86	-0.36	1.91e-21	Psychosis in Alzheimer's disease;
BRCA	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6087990	0.842	rs4911105	chr20:31330413	G/A	cg13636640	chr20:31349939	DNMT3B	0.71	21.31	0.64	1.55e-76	Ulcerative colitis;
BRCA	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg09436375	chr6:42928200	GNMT	-0.28	-10.54	-0.38	4.63e-24	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg03146154	chr1:46216737	IPP	0.5	10.93	0.4	1.28e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg18132916	chr6:79620363	NA	-0.39	-7.99	-0.3	6.22e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4595586	0.566	rs7135104	chr12:39411086	C/T	cg26384229	chr12:38710491	ALG10B	0.37	8.22	0.31	1.1e-15	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.2e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-10.28	-0.38	4.68e-23	Neuroticism;
BRCA	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-7.81	-0.3	2.39e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs754466	0.580	rs12357670	chr10:79558180	T/C	cg17075019	chr10:79541650	NA	-0.83	-20.69	-0.63	3.62e-73	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.32	0.41	3.45e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg24531977	chr5:56204891	C5orf35	-0.41	-8.37	-0.31	3.57e-16	Coronary artery disease;
BRCA	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg26384229	chr12:38710491	ALG10B	0.68	14.43	0.5	4.38e-41	Morning vs. evening chronotype;
BRCA	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg06784218	chr1:46089804	CCDC17	0.45	10.78	0.39	5.36e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.85e-29	Chronic sinus infection;
BRCA	cis	rs9296092	0.538	rs9461887	chr6:33526827	C/T	cg13560919	chr6:33536144	NA	-0.85	-17.98	-0.58	8.28e-59	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg11584989	chr19:19387371	SF4	0.66	14.37	0.49	9.05e-41	Bipolar disorder;
BRCA	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.42	0.41	1.25e-27	Homoarginine levels;
BRCA	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg23711669	chr6:146136114	FBXO30	0.68	13.55	0.47	5.76e-37	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg24692254	chr21:30365293	RNF160	-0.45	-7.96	-0.3	8.04e-15	Cognitive test performance;
BRCA	trans	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg14791747	chr16:20752902	THUMPD1	0.4	12.25	0.44	3.99e-31	Cognitive test performance;
BRCA	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg11057378	chr10:81107060	PPIF	0.42	9.75	0.36	5.07e-21	Height;
BRCA	cis	rs6750795	0.746	rs2916579	chr2:232421159	A/G	cg19187155	chr2:232395269	NMUR1	0.81	21.1	0.64	2.23e-75	Height;
BRCA	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg15017067	chr4:17643749	FAM184B	0.31	9.45	0.35	6.05e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-8.03	-0.3	4.65e-15	Menarche (age at onset);
BRCA	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg20476274	chr7:133979776	SLC35B4	0.66	19.16	0.6	5.54e-65	Mean platelet volume;
BRCA	cis	rs6815814	0.808	rs4833093	chr4:38789740	G/T	cg06935464	chr4:38784597	TLR10	0.5	10.02	0.37	4.81e-22	Breast cancer;
BRCA	cis	rs6546550	0.935	rs60207187	chr2:70093910	G/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-9.4	-0.35	9.49e-20	Prevalent atrial fibrillation;
BRCA	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11644478	chr21:40555479	PSMG1	0.73	14.49	0.5	2.4e-41	Cognitive function;
BRCA	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg13010199	chr12:38710504	ALG10B	-0.42	-10.16	-0.37	1.43e-22	Morning vs. evening chronotype;
BRCA	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24110177	chr3:50126178	RBM5	0.53	15.83	0.53	7.31e-48	Body mass index;
BRCA	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg02493740	chr2:85810744	VAMP5	-0.53	-10.98	-0.4	8.43e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs36051895	0.559	rs7850228	chr9:5210671	C/G	cg02405213	chr9:5042618	JAK2	0.44	8.38	0.31	3.26e-16	Pediatric autoimmune diseases;
BRCA	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.95	-0.3	8.34e-15	Bipolar disorder;
BRCA	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg11663144	chr21:46675770	NA	-0.61	-14.24	-0.49	3.81e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11585357	0.895	rs72633806	chr1:17617943	A/G	cg19159961	chr1:17633534	PADI4	0.58	9.06	0.34	1.56e-18	Hair shape;
BRCA	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg19077165	chr18:44547161	KATNAL2	-0.56	-12.24	-0.44	4.24e-31	Personality dimensions;
BRCA	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg24296786	chr1:45957014	TESK2	0.45	10.35	0.38	2.6e-23	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg18270830	chr10:32634957	EPC1	0.57	9.92	0.37	1.1e-21	Sexual dysfunction (female);
BRCA	cis	rs2742234	0.915	rs2742233	chr10:43610558	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.43	-9.16	-0.34	6.83e-19	Hirschsprung disease;
BRCA	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.67e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3739998	0.686	rs2505084	chr10:30335520	C/T	cg00730780	chr10:30316187	KIAA1462	-0.44	-9.58	-0.35	2.04e-20	Coronary heart disease;
BRCA	cis	rs2625529	0.824	rs4411469	chr15:72421689	A/G	cg16672083	chr15:72433130	SENP8	-0.85	-17.68	-0.57	3.19e-57	Red blood cell count;
BRCA	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg13319975	chr6:146136371	FBXO30	-0.59	-13.43	-0.47	2.09e-36	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs3858145	0.588	rs7081284	chr10:70044792	C/G	cg04882175	chr6:131122610	NA	-0.34	-7.83	-0.3	1.99e-14	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
BRCA	cis	rs9463078	0.526	rs9472337	chr6:44711576	C/A	cg25276700	chr6:44698697	NA	0.36	8.18	0.31	1.56e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6433857	0.505	rs1542036	chr2:181350009	A/C	cg23363182	chr2:181467187	NA	-0.37	-7.87	-0.3	1.57e-14	Body mass index;
BRCA	cis	rs752010	0.967	rs4083593	chr1:42099583	A/G	cg06885757	chr1:42089581	HIVEP3	0.25	8.77	0.33	1.55e-17	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg13319975	chr6:146136371	FBXO30	0.42	9.26	0.34	3e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4253311	0.520	rs10000459	chr4:187124459	A/C	cg24794857	chr4:187113578	CYP4V2	0.36	7.94	0.3	8.97e-15	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
BRCA	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg13852791	chr20:30311386	BCL2L1	-0.84	-16.66	-0.55	5.05e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.4	-8.0	-0.3	5.85e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg09911534	chr15:67153556	NA	-0.67	-11.21	-0.41	9.9e-27	Lung cancer (smoking interaction);
BRCA	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg14019146	chr3:50243930	SLC38A3	-0.57	-11.9	-0.43	1.24e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg26408565	chr15:76604113	ETFA	-0.49	-10.38	-0.38	2.01e-23	Blood metabolite levels;
BRCA	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg09307838	chr4:120376055	NA	0.62	12.76	0.45	2.16e-33	Corneal astigmatism;
BRCA	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.17	-0.34	6.4e-19	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.37	0.57	1.25e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03576123	chr11:487126	PTDSS2	1.16	17.83	0.58	4.99e-58	Body mass index;
BRCA	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg06627628	chr2:24431161	ITSN2	-0.54	-8.82	-0.33	1.08e-17	Lymphocyte counts;
BRCA	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.39	7.97	0.3	7.41e-15	Personality dimensions;
BRCA	cis	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg21775007	chr8:11205619	TDH	-0.54	-10.59	-0.39	2.87e-24	Retinal vascular caliber;
BRCA	cis	rs7394190	0.748	rs60212594	chr10:75414344	G/C	cg07699608	chr10:75541558	CHCHD1	0.56	8.73	0.33	2.21e-17	Incident atrial fibrillation;
BRCA	cis	rs9649213	0.586	rs11768599	chr7:97974555	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.59	-15.88	-0.53	4.34e-48	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg11645453	chr3:52864694	ITIH4	0.49	11.98	0.43	5.43e-30	Schizophrenia;
BRCA	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg26384229	chr12:38710491	ALG10B	0.74	17.53	0.57	1.85e-56	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.63	-14.76	-0.5	1.19e-42	Longevity;Endometriosis;
BRCA	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg03709012	chr19:19516395	GATAD2A	0.81	18.83	0.6	3.08e-63	Tonsillectomy;
BRCA	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg00981070	chr1:2046702	PRKCZ	0.31	8.25	0.31	9.06e-16	Height;
BRCA	cis	rs6430585	0.591	rs12466487	chr2:136407078	C/T	cg07169764	chr2:136633963	MCM6	-1.12	-19.58	-0.61	3.21e-67	Corneal structure;
BRCA	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.06	-0.34	1.6e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11229555	0.645	rs12226725	chr11:58246332	G/A	cg15696309	chr11:58395628	NA	-0.51	-10.71	-0.39	1.03e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7903847	0.642	rs11817852	chr10:99158426	C/T	cg20016023	chr10:99160130	RRP12	-0.26	-8.41	-0.32	2.58e-16	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg19862616	chr7:65841803	NCRNA00174	0.85	27.76	0.74	6.66e-112	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4780401	0.609	rs4781142	chr16:11808806	T/C	cg01061890	chr16:11836724	TXNDC11	-0.55	-13.08	-0.46	8.08e-35	Rheumatoid arthritis;
BRCA	cis	rs9880211	0.948	rs13326151	chr3:136261744	C/T	cg21827317	chr3:136751795	NA	-0.44	-7.97	-0.3	7.13e-15	Body mass index;Height;
BRCA	trans	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg21167628	chr1:45308625	PTCH2	-0.31	-7.85	-0.3	1.78e-14	Facial morphology (factor 20);
BRCA	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg22907277	chr7:1156413	C7orf50	0.59	9.19	0.34	5.33e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg06784218	chr1:46089804	CCDC17	0.44	10.29	0.38	4.51e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg23992470	chr4:843637	GAK	0.54	8.28	0.31	7.3e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1475718	0.526	rs7854734	chr9:137122410	C/G	cg21243944	chr9:137118148	NA	0.34	9.25	0.34	3.37e-19	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs365132	1.000	rs2055619	chr5:176415964	A/G	cg16309518	chr5:176445507	NA	-0.52	-13.35	-0.47	4.77e-36	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	8.43	0.32	2.35e-16	Rheumatoid arthritis;
BRCA	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg03709012	chr19:19516395	GATAD2A	0.71	15.15	0.51	1.54e-44	Tonsillectomy;
BRCA	cis	rs36051895	0.664	rs3780371	chr9:5095191	T/A	cg02405213	chr9:5042618	JAK2	-0.5	-9.09	-0.34	1.24e-18	Pediatric autoimmune diseases;
BRCA	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	14.57	0.5	9.5e-42	Motion sickness;
BRCA	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18404041	chr3:52824283	ITIH1	-0.4	-12.17	-0.43	8.89e-31	Bipolar disorder;
BRCA	cis	rs9986765	1.000	rs4565384	chr7:142811564	C/A	cg15652212	chr7:142981776	TMEM139	0.57	9.35	0.35	1.44e-19	Cancer;Dermatomyositis;
BRCA	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22857025	chr5:266934	NA	-1.1	-19.12	-0.6	8.29e-65	Breast cancer;
BRCA	cis	rs9287719	0.601	rs6755281	chr2:10769855	T/C	cg00105475	chr2:10696890	NA	0.47	10.28	0.38	4.96e-23	Prostate cancer;
BRCA	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg26384229	chr12:38710491	ALG10B	0.71	16.45	0.55	5.52e-51	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg18512352	chr11:47633146	NA	-0.34	-8.19	-0.31	1.38e-15	Subjective well-being;
BRCA	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg13334819	chr7:99746414	C7orf59	0.34	8.05	0.3	4.16e-15	Coronary artery disease;
BRCA	cis	rs28493229	0.522	rs2287692	chr19:41289756	G/A	cg21869046	chr19:41225005	ITPKC	0.4	9.81	0.36	2.93e-21	Kawasaki disease;
BRCA	cis	rs66530629	1.000	rs1316829	chr1:25051225	C/T	cg01905478	chr1:25040257	NA	0.37	8.34	0.31	4.52e-16	Plateletcrit;
BRCA	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg23029597	chr12:123009494	RSRC2	0.62	12.14	0.43	1.2e-30	Body mass index;
BRCA	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg22920501	chr2:26401640	FAM59B	-0.8	-13.02	-0.46	1.55e-34	Gut microbiome composition (summer);
BRCA	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.58	0.32	7.01e-17	Rheumatoid arthritis;
BRCA	cis	rs490234	0.702	rs13284551	chr9:128411969	C/T	cg14078157	chr9:128172775	NA	-0.51	-11.3	-0.41	3.88e-27	Mean arterial pressure;
BRCA	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg04166393	chr7:2884313	GNA12	-0.54	-11.02	-0.4	5.56e-26	Height;
BRCA	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-11.97	-0.43	6.35e-30	Alzheimer's disease;
BRCA	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg05985134	chr18:33552581	C18orf21	0.64	12.12	0.43	1.41e-30	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg08508325	chr11:3079039	CARS	-0.43	-15.61	-0.53	8.94e-47	Longevity;
BRCA	cis	rs919433	0.647	rs6741205	chr2:198525997	G/C	cg00792783	chr2:198669748	PLCL1	0.39	9.03	0.34	2.08e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg05340658	chr4:99064831	C4orf37	0.6	13.01	0.46	1.7e-34	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg11530693	chr1:120165357	ZNF697	0.62	14.94	0.51	1.68e-43	Systemic lupus erythematosus;
BRCA	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.08	-0.51	3.63e-44	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg15595755	chr5:1867978	NA	0.35	8.38	0.31	3.48e-16	Cardiovascular disease risk factors;
BRCA	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg24562669	chr7:97807699	LMTK2	0.45	12.28	0.44	2.88e-31	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg03929089	chr4:120376271	NA	0.88	22.44	0.66	1.1e-82	Height;
BRCA	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg06115741	chr20:33292138	TP53INP2	0.5	11.11	0.4	2.41e-26	Coronary artery disease;
BRCA	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg22552966	chr17:19620595	SLC47A2	-0.38	-10.72	-0.39	8.79e-25	Response to paliperidone in schizophrenia (CGI-S score);
BRCA	trans	rs877282	1.000	rs11253361	chr10:770387	T/C	cg22713356	chr15:30763199	NA	1.11	21.73	0.65	8.61e-79	Uric acid levels;
BRCA	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg26384229	chr12:38710491	ALG10B	0.54	13.73	0.48	9.25e-38	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.747	rs4240868	chr1:152981599	G/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.36	-0.31	3.79e-16	Inflammatory skin disease;
BRCA	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25427524	chr10:38739819	LOC399744	-0.73	-18.1	-0.58	2.1e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.55	0.55	1.84e-51	Alzheimer's disease (late onset);
BRCA	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	14.17	0.49	7.92e-40	Colorectal cancer;
BRCA	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08109568	chr15:31115862	NA	-0.44	-10.28	-0.38	4.62e-23	Huntington's disease progression;
BRCA	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg08999081	chr20:33150536	PIGU	-0.35	-9.12	-0.34	9.92e-19	Coronary artery disease;
BRCA	cis	rs1555322	0.530	rs2275275	chr20:33872311	G/C	cg03689076	chr20:33865952	NA	0.44	8.08	0.3	3.26e-15	Attention deficit hyperactivity disorder;
BRCA	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg09915433	chr19:53449742	NA	-0.74	-17.03	-0.56	6.96e-54	Psoriasis;
BRCA	cis	rs4363385	0.720	rs1611755	chr1:152956420	T/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.47	-0.32	1.73e-16	Inflammatory skin disease;
BRCA	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.38	-8.13	-0.31	2.23e-15	Insulin-like growth factors;
BRCA	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg02659138	chr7:134003124	SLC35B4	0.35	10.85	0.39	2.84e-25	Mean platelet volume;
BRCA	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.43	-0.32	2.27e-16	Monocyte percentage of white cells;
BRCA	trans	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-8.52	-0.32	1.12e-16	Menarche (age at onset);
BRCA	cis	rs6750047	0.678	rs4670811	chr2:38277376	C/A	cg07380506	chr2:38303506	CYP1B1	0.42	9.34	0.35	1.61e-19	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg23950597	chr19:37808831	NA	-0.75	-13.01	-0.46	1.65e-34	Coronary artery calcification;
BRCA	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-11.09	-0.4	2.83e-26	Gut microbiome composition (summer);
BRCA	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg27129171	chr3:47204927	SETD2	-0.69	-15.98	-0.53	1.3e-48	Colorectal cancer;
BRCA	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg09904177	chr6:26538194	HMGN4	-0.46	-13.15	-0.46	4.1e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.83	18.09	0.58	2.32e-59	Smoking behavior;
BRCA	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05926928	chr17:57297772	GDPD1	1.2	16.06	0.54	5.5e-49	Opioid sensitivity;
BRCA	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.17	-0.4	1.33e-26	Schizophrenia;
BRCA	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg15103426	chr22:29168792	CCDC117	0.54	12.61	0.45	1.02e-32	Lymphocyte counts;
BRCA	cis	rs9560113	1.000	rs9555806	chr13:112179954	G/A	cg10483660	chr13:112241077	NA	0.31	7.84	0.3	1.91e-14	Menarche (age at onset);
BRCA	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg21395723	chr22:39101663	GTPBP1	0.38	8.32	0.31	5.17e-16	Menopause (age at onset);
BRCA	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23583168	chr7:148888333	NA	-0.86	-20.07	-0.62	7.29e-70	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18876405	chr7:65276391	NA	0.52	12.14	0.43	1.14e-30	Aortic root size;
BRCA	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg25237894	chr2:233734115	C2orf82	-0.44	-13.7	-0.48	1.17e-37	Coronary artery disease;
BRCA	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.49	0.38	7.33e-24	Bladder cancer;
BRCA	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg18132916	chr6:79620363	NA	-0.48	-10.87	-0.4	2.27e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg24642439	chr20:33292090	TP53INP2	0.41	8.0	0.3	5.83e-15	Height;
BRCA	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg10495392	chr1:46806563	NSUN4	0.46	8.46	0.32	1.82e-16	Menopause (age at onset);
BRCA	cis	rs7301826	1.000	rs7301826	chr12:131291101	C/T	cg11011512	chr12:131303247	STX2	0.42	10.88	0.4	2.03e-25	Plasma plasminogen activator levels;
BRCA	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg18512352	chr11:47633146	NA	-0.34	-8.1	-0.31	2.72e-15	Subjective well-being;
BRCA	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg23711669	chr6:146136114	FBXO30	-0.7	-16.49	-0.55	3.76e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2904967	0.929	rs3016001	chr11:65008771	G/A	cg09225861	chr11:65069680	NA	-0.38	-7.86	-0.3	1.67e-14	Mean corpuscular volume;
BRCA	cis	rs7940866	0.903	rs1433980	chr11:130870956	A/G	cg12179176	chr11:130786555	SNX19	0.58	13.47	0.47	1.36e-36	Schizophrenia;
BRCA	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg05283184	chr6:79620031	NA	-0.44	-11.35	-0.41	2.46e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg08470875	chr2:26401718	FAM59B	-0.51	-8.48	-0.32	1.5e-16	Gut microbiome composition (summer);
BRCA	cis	rs10197940	0.578	rs2432956	chr2:152287831	C/T	cg19508488	chr2:152266495	RIF1	-0.41	-8.49	-0.32	1.44e-16	Lung cancer;
BRCA	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg00012203	chr2:219082015	ARPC2	-0.4	-7.83	-0.3	2.1e-14	Ulcerative colitis;
BRCA	cis	rs2712184	0.756	rs2712164	chr2:217659916	G/A	cg05032264	chr2:217675019	NA	-0.37	-9.07	-0.34	1.47e-18	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg09307838	chr4:120376055	NA	0.59	12.97	0.46	2.47e-34	Corneal astigmatism;
BRCA	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.93	20.61	0.63	9.63e-73	Smoking behavior;
BRCA	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg23788917	chr6:8435910	SLC35B3	0.47	10.31	0.38	3.56e-23	Motion sickness;
BRCA	cis	rs13095912	0.925	rs11924016	chr3:185307879	A/T	cg11274856	chr3:185301563	NA	0.35	8.51	0.32	1.24e-16	Systolic blood pressure;
BRCA	cis	rs10838687	0.736	rs11039144	chr11:47264044	G/A	cg25783544	chr11:47291846	MADD	0.42	7.82	0.3	2.17e-14	Proinsulin levels;
BRCA	cis	rs9443189	0.570	rs523465	chr6:76330434	G/C	cg01950844	chr6:76311363	SENP6	0.84	13.7	0.48	1.24e-37	Prostate cancer;
BRCA	cis	rs921968	0.565	rs3755045	chr2:219609162	T/G	cg02176678	chr2:219576539	TTLL4	-0.41	-11.01	-0.4	6.11e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg12935359	chr14:103987150	CKB	0.63	14.56	0.5	1.13e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs1451375	0.617	rs2060763	chr7:50542359	G/A	cg18232548	chr7:50535776	DDC	-0.43	-8.93	-0.33	4.42e-18	Malaria;
BRCA	cis	rs2882667	0.858	rs11242448	chr5:138443154	C/A	cg04439458	chr5:138467593	SIL1	-0.43	-10.83	-0.39	3.27e-25	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg23711669	chr6:146136114	FBXO30	0.72	17.54	0.57	1.58e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504073	0.647	rs4873096	chr8:49995201	A/G	cg00325661	chr8:49890786	NA	0.44	12.49	0.44	3.6e-32	Blood metabolite ratios;
BRCA	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg22535103	chr8:58192502	C8orf71	-0.42	-8.65	-0.32	4.24e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg24006582	chr15:45444508	DUOX1	-0.54	-11.11	-0.4	2.54e-26	Uric acid levels;
BRCA	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-7.99	-0.3	6.11e-15	Red blood cell count;Reticulocyte count;
BRCA	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg24110177	chr3:50126178	RBM5	-0.46	-10.26	-0.38	5.66e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs2832191	0.545	rs2251381	chr21:30530692	T/G	cg08807101	chr21:30365312	RNF160	0.39	8.71	0.33	2.63e-17	Dental caries;
BRCA	cis	rs11677370	0.603	rs10178523	chr2:3854169	G/A	cg17052675	chr2:3827356	NA	-0.5	-12.09	-0.43	1.93e-30	Type 2 diabetes;
BRCA	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18918831	chr3:195489782	MUC4	-0.62	-9.71	-0.36	7.23e-21	Lung disease severity in cystic fibrosis;
BRCA	cis	rs12042938	0.935	rs1417585	chr1:231803604	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.36	7.91	0.3	1.12e-14	Neuranatomic and neurocognitive phenotypes;
BRCA	cis	rs754466	0.510	rs55893027	chr10:79588209	C/T	cg17075019	chr10:79541650	NA	-0.66	-16.84	-0.55	6.1e-53	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.26	-0.31	8.33e-16	Monocyte percentage of white cells;
BRCA	trans	rs6479891	1.000	rs16918567	chr10:65294670	A/C	cg14819942	chr15:35414228	NA	0.35	8.48	0.32	1.58e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs1957429	0.520	rs72625648	chr14:65344602	A/G	cg23373153	chr14:65346875	NA	-0.79	-8.45	-0.32	2.04e-16	Pediatric areal bone mineral density (radius);
BRCA	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg21573476	chr21:45109991	RRP1B	-0.36	-9.42	-0.35	7.88e-20	Mean corpuscular volume;
BRCA	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg04553112	chr3:125709451	NA	-0.55	-8.43	-0.32	2.24e-16	Blood pressure (smoking interaction);
BRCA	trans	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg25214090	chr10:38739885	LOC399744	0.5	10.93	0.4	1.34e-25	Corneal astigmatism;
BRCA	cis	rs13046373	0.535	rs9980934	chr21:31982988	C/T	cg22337977	chr21:31811175	KRTAP15-1	0.33	7.96	0.3	7.95e-15	HDL cholesterol;
BRCA	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg18758796	chr5:131593413	PDLIM4	0.37	9.14	0.34	8.44e-19	Acylcarnitine levels;
BRCA	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg11766577	chr21:47581405	C21orf56	0.49	10.64	0.39	1.83e-24	Testicular germ cell tumor;
BRCA	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg18446336	chr7:2847575	GNA12	-0.34	-8.25	-0.31	9.28e-16	Height;
BRCA	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg13047869	chr3:10149882	C3orf24	0.57	11.64	0.42	1.5e-28	Alzheimer's disease;
BRCA	cis	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg21775007	chr8:11205619	TDH	0.39	8.26	0.31	8.18e-16	Neuroticism;
BRCA	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg20862496	chr8:143823734	SLURP1	0.36	8.91	0.33	5.24e-18	Urinary tract infection frequency;
BRCA	cis	rs9309473	1.000	rs10187192	chr2:73713500	T/C	cg20560298	chr2:73613845	ALMS1	-0.5	-12.21	-0.43	5.94e-31	Metabolite levels;
BRCA	cis	rs6005807	0.719	rs9625509	chr22:28989246	G/C	cg12565055	chr22:29076175	TTC28	0.51	9.44	0.35	7.12e-20	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg22907277	chr7:1156413	C7orf50	0.49	10.31	0.38	3.73e-23	Longevity;Endometriosis;
BRCA	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg20007245	chr22:24372913	LOC391322	0.64	14.49	0.5	2.43e-41	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.48	-13.87	-0.48	1.88e-38	Total body bone mineral density;
BRCA	cis	rs6942756	0.774	rs2566885	chr7:128917587	C/T	cg02491457	chr7:128862824	NA	0.57	12.04	0.43	3.02e-30	White matter hyperintensity burden;
BRCA	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	30.52	0.77	6.7e-127	Chronic sinus infection;
BRCA	trans	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg17675199	chr6:35436792	RPL10A	-0.3	-8.02	-0.3	5.05e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg10523679	chr1:76189770	ACADM	-0.49	-9.62	-0.36	1.49e-20	Daytime sleep phenotypes;
BRCA	trans	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.41	0.5	5.6e-41	Exhaled nitric oxide output;
BRCA	trans	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg13565492	chr6:43139072	SRF	-0.89	-16.44	-0.55	6.9e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg22105103	chr4:187893119	NA	0.37	11.69	0.42	9.77e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2806561	0.929	rs2903545	chr1:23541108	C/T	cg19743168	chr1:23544995	NA	-0.47	-11.85	-0.42	1.93e-29	Height;
BRCA	trans	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.8	-0.33	1.3e-17	Breast cancer;
BRCA	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg16325326	chr1:53192061	ZYG11B	-0.57	-12.69	-0.45	4.67e-33	Monocyte count;
BRCA	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg18230493	chr5:56204884	C5orf35	0.91	17.71	0.57	2.24e-57	Initial pursuit acceleration;
BRCA	trans	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.07	0.37	3.03e-22	Mean corpuscular volume;
BRCA	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg06623918	chr6:96969491	KIAA0776	0.72	14.05	0.49	2.84e-39	Migraine;Coronary artery disease;
BRCA	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.53	0.32	1.09e-16	Rheumatoid arthritis;
BRCA	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg01884057	chr2:25150051	NA	0.35	9.26	0.34	2.97e-19	Body mass index;
BRCA	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg24812749	chr6:127587940	RNF146	0.86	20.26	0.63	7.08e-71	Breast cancer;
BRCA	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21659725	chr3:3221576	CRBN	-0.46	-11.67	-0.42	1.17e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg16339924	chr4:17578868	LAP3	0.63	15.65	0.53	5.75e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.13	0.37	1.76e-22	Aortic root size;
BRCA	cis	rs10411936	0.626	rs8109817	chr19:16587889	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.47	9.71	0.36	6.85e-21	White blood cell count;Multiple sclerosis;
BRCA	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs17604090	0.550	rs111649163	chr7:29689176	C/T	cg19413766	chr7:29689036	LOC646762	-0.6	-8.43	-0.32	2.27e-16	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs2882667	0.931	rs11955952	chr5:138329119	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-9.11	-0.34	1.07e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7072216	0.727	rs6584199	chr10:100169983	A/G	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.71	-0.36	7.24e-21	Metabolite levels;
BRCA	cis	rs56399783	0.614	rs116929101	chr7:2760325	G/A	cg19731401	chr7:2775893	GNA12	0.5	7.89	0.3	1.34e-14	Childhood ear infection;
BRCA	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg21573476	chr21:45109991	RRP1B	0.37	9.24	0.34	3.55e-19	Mean corpuscular volume;
BRCA	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg24848339	chr3:12840334	CAND2	0.5	13.52	0.47	8.3e-37	QRS complex (12-leadsum);
BRCA	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg19508488	chr2:152266495	RIF1	-0.43	-9.11	-0.34	1.05e-18	Lung cancer;
BRCA	cis	rs243505	1.000	rs243516	chr7:148426271	T/G	cg09806900	chr7:148480153	CUL1	-0.4	-8.35	-0.31	4.36e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs858239	0.600	rs10233039	chr7:23143113	G/A	cg23682824	chr7:23144976	KLHL7	0.43	11.61	0.42	2.11e-28	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.54	0.42	4.13e-28	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs483180	0.531	rs539708	chr1:120208503	G/T	cg19096424	chr1:120255104	PHGDH	-0.43	-9.41	-0.35	8.47e-20	Macular telangiectasia type 2;
BRCA	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-8.85	-0.33	8.78e-18	Height;
BRCA	cis	rs41005	0.805	rs10469618	chr2:8117622	C/T	cg03155496	chr2:8117019	LOC339788	-0.59	-16.59	-0.55	1.13e-51	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg17888033	chr8:143858414	LYNX1	-0.41	-9.65	-0.36	1.21e-20	Urinary tract infection frequency;
BRCA	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg27129171	chr3:47204927	SETD2	-0.73	-18.04	-0.58	4.36e-59	Colorectal cancer;
BRCA	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg10523679	chr1:76189770	ACADM	0.77	15.94	0.53	2.09e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg00757033	chr12:89920650	WDR51B	0.52	10.52	0.38	5.84e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs754466	1.000	rs12220311	chr10:79681507	C/T	cg17075019	chr10:79541650	NA	-0.68	-12.85	-0.45	9.14e-34	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg03808351	chr9:123631620	PHF19	0.4	7.85	0.3	1.7e-14	Rheumatoid arthritis;
BRCA	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	20.15	0.62	2.88e-70	Platelet count;
BRCA	cis	rs6763687	0.828	rs8179884	chr3:171781535	C/G	cg16233210	chr3:171778391	FNDC3B	0.39	8.54	0.32	9.61e-17	Red cell distribution width;
BRCA	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg19508488	chr2:152266495	RIF1	0.42	8.76	0.33	1.8e-17	Squamous cell lung carcinoma;
BRCA	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg06784218	chr1:46089804	CCDC17	0.46	10.98	0.4	8.22e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17092148	1.000	rs6060025	chr20:33326876	A/G	cg16810054	chr20:33298113	TP53INP2	-0.49	-11.24	-0.41	6.88e-27	Neuroticism;
BRCA	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg24154853	chr7:158122151	PTPRN2	0.35	8.11	0.31	2.66e-15	Calcium levels;
BRCA	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg20701182	chr2:24300061	SF3B14	0.59	9.08	0.34	1.3e-18	Lymphocyte counts;
BRCA	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.42	-9.96	-0.37	8.16e-22	Lymphocyte counts;
BRCA	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg20290983	chr6:43655470	MRPS18A	-0.8	-20.63	-0.63	7.83e-73	IgG glycosylation;
BRCA	cis	rs36051895	0.632	rs10815164	chr9:5131312	T/A	cg02405213	chr9:5042618	JAK2	-0.49	-8.89	-0.33	6.14e-18	Pediatric autoimmune diseases;
BRCA	cis	rs2354432	0.943	rs6660219	chr1:146691404	A/T	cg25205988	chr1:146714368	CHD1L	0.94	15.76	0.53	1.59e-47	Mitochondrial DNA levels;
BRCA	trans	rs8073060	0.586	rs225264	chr17:33961335	A/G	cg19694781	chr19:47549865	TMEM160	-1.05	-21.13	-0.64	1.41e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs12210905	0.688	rs114188783	chr6:27449604	T/C	cg08851530	chr6:28072375	NA	0.82	7.99	0.3	6.52e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg26248373	chr2:1572462	NA	-0.62	-14.37	-0.49	8.48e-41	IgG glycosylation;
BRCA	cis	rs367615	0.659	rs13435970	chr5:108884660	C/T	cg17395555	chr5:108820864	NA	0.34	8.98	0.33	2.91e-18	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg07636037	chr3:49044803	WDR6	-0.9	-23.13	-0.68	1.89e-86	Parkinson's disease;
BRCA	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08280861	chr8:58055591	NA	0.44	9.62	0.36	1.5e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs72627509	0.951	rs17087335	chr4:57838583	G/T	cg26694713	chr4:57773883	REST	0.47	8.64	0.32	4.4e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26314531	chr2:26401878	FAM59B	-0.9	-15.71	-0.53	2.96e-47	Gut microbiome composition (summer);
BRCA	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg00106254	chr7:1943704	MAD1L1	0.35	9.63	0.36	1.41e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs7119038	0.818	rs10892287	chr11:118642999	C/T	cg19308663	chr11:118741387	NA	-0.4	-9.18	-0.34	5.9e-19	Sjögren's syndrome;
BRCA	trans	rs61931739	1.000	rs11052967	chr12:34020030	T/G	cg26384229	chr12:38710491	ALG10B	-0.42	-9.43	-0.35	7.6e-20	Morning vs. evening chronotype;
BRCA	cis	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg07460842	chr6:66804631	NA	0.92	18.44	0.59	3.16e-61	Exhaled nitric oxide output;
BRCA	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg06808227	chr14:105710500	BRF1	0.8	15.88	0.53	4.2e-48	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg03474202	chr17:45855739	NA	-0.48	-12.72	-0.45	3.53e-33	IgG glycosylation;
BRCA	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg24296786	chr1:45957014	TESK2	0.47	10.67	0.39	1.49e-24	Red blood cell count;Reticulocyte count;
BRCA	trans	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg25214090	chr10:38739885	LOC399744	0.57	12.94	0.46	3.6e-34	Corneal astigmatism;
BRCA	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg18132916	chr6:79620363	NA	0.46	10.48	0.38	7.91e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg17211192	chr8:82754475	SNX16	0.5	11.26	0.41	5.69e-27	Diastolic blood pressure;
BRCA	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg25173405	chr17:45401733	C17orf57	0.53	11.18	0.4	1.31e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.55	-0.32	8.94e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-10.41	-0.38	1.53e-23	Blood metabolite levels;
BRCA	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg00383909	chr3:49044727	WDR6	0.64	10.42	0.38	1.4e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg13010199	chr12:38710504	ALG10B	0.51	10.4	0.38	1.61e-23	Bladder cancer;
BRCA	cis	rs4363385	0.791	rs10788855	chr1:153002359	A/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.06	-0.34	1.62e-18	Inflammatory skin disease;
BRCA	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg22974920	chr21:40686053	BRWD1	-0.39	-8.77	-0.33	1.59e-17	Cognitive function;
BRCA	cis	rs9790314	0.690	rs9860738	chr3:160843290	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-11.33	-0.41	3.02e-27	Morning vs. evening chronotype;
BRCA	cis	rs41005	1.000	rs41005	chr2:8111231	A/G	cg03155496	chr2:8117019	LOC339788	-0.55	-14.97	-0.51	1.25e-43	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs1003719	0.680	rs2835619	chr21:38505380	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.19	-0.49	6.29e-40	Eye color traits;
BRCA	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.0	22.82	0.67	8.71e-85	Lymphocyte percentage of white cells;
BRCA	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg09640425	chr7:158790006	NA	-0.4	-8.47	-0.32	1.63e-16	Facial morphology (factor 20);
BRCA	cis	rs36051895	0.664	rs7847141	chr9:5097171	A/T	cg02405213	chr9:5042618	JAK2	-0.51	-9.71	-0.36	7.13e-21	Pediatric autoimmune diseases;
BRCA	cis	rs758324	0.947	rs380182	chr5:131319036	A/G	cg06307176	chr5:131281290	NA	-0.52	-10.33	-0.38	2.99e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs9815354	0.812	rs17217746	chr3:41926021	A/G	cg03022575	chr3:42003672	ULK4	0.69	9.49	0.35	4.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.83	-0.33	1.01e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs926392	0.640	rs2867899	chr20:37694622	C/A	cg16355469	chr20:37678765	NA	0.51	11.73	0.42	6.22e-29	Dialysis-related mortality;
BRCA	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg17971929	chr21:40555470	PSMG1	-0.5	-11.02	-0.4	5.6e-26	Menarche (age at onset);
BRCA	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg00071950	chr4:10020882	SLC2A9	0.39	8.35	0.31	4.27e-16	Blood metabolite levels;
BRCA	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13064411	0.696	rs9869318	chr3:113146271	T/C	cg18753928	chr3:113234510	CCDC52	-0.52	-9.73	-0.36	5.87e-21	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg26384229	chr12:38710491	ALG10B	0.67	14.16	0.49	8.93e-40	Morning vs. evening chronotype;
BRCA	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg26597838	chr10:835615	NA	1.02	17.21	0.56	7.67e-55	Eosinophil percentage of granulocytes;
BRCA	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11764359	chr7:65958608	NA	0.61	13.37	0.47	4.18e-36	Calcium levels;
BRCA	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg07917127	chr4:99064746	C4orf37	0.44	8.11	0.31	2.59e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs887829	0.569	rs4148326	chr2:234673462	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.31	-8.24	-0.31	9.97e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg19784903	chr17:45786737	TBKBP1	0.34	8.06	0.3	3.7e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.77	-0.42	4.23e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg18811423	chr2:55921094	PNPT1	0.72	23.31	0.68	1.83e-87	Metabolic syndrome;
BRCA	trans	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg23762105	chr12:34175262	ALG10	0.36	8.4	0.32	2.81e-16	Morning vs. evening chronotype;
BRCA	cis	rs13006833	0.668	rs291447	chr2:191177005	A/C	cg11845111	chr2:191398756	TMEM194B	0.34	7.82	0.3	2.24e-14	Urinary metabolites;
BRCA	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg08601574	chr20:25228251	PYGB	-0.33	-8.13	-0.31	2.24e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7707921	0.881	rs73134747	chr5:81378294	C/T	cg15871215	chr5:81402204	ATG10	-0.4	-8.25	-0.31	9.27e-16	Breast cancer;
BRCA	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg11663144	chr21:46675770	NA	-0.61	-14.32	-0.49	1.47e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg27129171	chr3:47204927	SETD2	-0.68	-15.7	-0.53	3.31e-47	Colorectal cancer;
BRCA	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.53	-8.98	-0.33	3.02e-18	Birth weight;
BRCA	trans	rs225245	0.782	rs321617	chr17:33915246	A/G	cg19694781	chr19:47549865	TMEM160	-0.32	-7.85	-0.3	1.8e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs57590327	0.503	rs1464790	chr3:81852923	A/T	cg07356753	chr3:81810745	GBE1	0.43	10.08	0.37	2.78e-22	Extraversion;
BRCA	trans	rs3857536	0.813	rs6455091	chr6:66949127	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	2.02e-14	Blood trace element (Cu levels);
BRCA	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.43	-0.38	1.25e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg24692254	chr21:30365293	RNF160	0.68	18.19	0.58	6.97e-60	Dental caries;
BRCA	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg24558204	chr6:135376177	HBS1L	0.46	12.65	0.45	6.82e-33	Red blood cell count;
BRCA	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg05340658	chr4:99064831	C4orf37	0.6	12.93	0.46	3.99e-34	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.21e-47	Alzheimer's disease (late onset);
BRCA	cis	rs7301016	0.802	rs11613011	chr12:63023078	T/C	cg01804193	chr12:63026212	NA	0.47	8.29	0.31	6.7e-16	IgG glycosylation;
BRCA	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg03433033	chr1:76189801	ACADM	0.6	10.78	0.39	5.18e-25	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.19	0.49	6.21e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2652834	0.950	rs2729789	chr15:63400345	G/A	cg05507819	chr15:63340323	TPM1	0.45	8.06	0.3	3.83e-15	HDL cholesterol;
BRCA	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg18357645	chr12:58087776	OS9	-0.34	-8.35	-0.31	4.39e-16	Multiple sclerosis;
BRCA	cis	rs1829883	0.862	rs2460655	chr5:98797742	C/T	cg08333243	chr5:99726346	NA	-0.35	-8.05	-0.3	3.91e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg22705602	chr4:152727874	NA	-0.32	-8.31	-0.31	5.88e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg27535305	chr1:53392650	SCP2	0.32	7.84	0.3	1.93e-14	Monocyte count;
BRCA	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.62	-0.36	1.46e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg00106254	chr7:1943704	MAD1L1	-0.32	-8.17	-0.31	1.6e-15	Schizophrenia;
BRCA	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.83	-0.48	2.9e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3784262	1.000	rs4646622	chr15:58257199	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.48	-12.68	-0.45	4.82e-33	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg03060546	chr3:49711283	APEH	-0.54	-10.99	-0.4	7.38e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08045932	chr20:61659980	NA	0.51	11.6	0.42	2.23e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.74	0.36	5.54e-21	Menopause (age at onset);
BRCA	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.52	0.41	4.9e-28	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs1505368	0.781	rs10197836	chr2:213274278	T/C	cg20637307	chr2:213403960	ERBB4	0.38	9.19	0.34	5.4e-19	Symmetrical dimethylarginine levels;
BRCA	cis	rs9649465	1.000	rs9649465	chr7:123376560	G/A	cg04330084	chr7:123175371	IQUB	-0.33	-9.0	-0.34	2.52e-18	Migraine;
BRCA	cis	rs758324	0.947	rs422291	chr5:131320942	A/T	cg06307176	chr5:131281290	NA	-0.54	-10.67	-0.39	1.42e-24	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs300703	0.542	rs376385	chr2:190245	G/A	cg21211680	chr2:198530	NA	0.4	8.81	0.33	1.21e-17	Blood protein levels;
BRCA	cis	rs2742234	0.590	rs741968	chr10:43611708	A/G	cg02780029	chr10:43622663	RET	-0.36	-8.06	-0.3	3.84e-15	Hirschsprung disease;
BRCA	cis	rs12347191	0.500	rs925485	chr9:100619561	G/C	cg13688889	chr9:100608707	NA	-0.49	-9.92	-0.37	1.19e-21	Orofacial clefts;
BRCA	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg04362960	chr10:104952993	NT5C2	0.44	10.71	0.39	1.02e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	11.04	0.4	4.7e-26	Height;
BRCA	cis	rs17604090	0.878	rs4000281	chr7:29726287	A/G	cg19413766	chr7:29689036	LOC646762	-0.61	-8.69	-0.33	2.95e-17	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg06623918	chr6:96969491	KIAA0776	0.75	16.86	0.55	4.99e-53	Migraine;Coronary artery disease;
BRCA	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg26373071	chr5:1325741	CLPTM1L	0.4	9.47	0.35	5.31e-20	Lung cancer;
BRCA	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg18811423	chr2:55921094	PNPT1	0.73	23.59	0.68	5.34e-89	Metabolic syndrome;
BRCA	cis	rs10746514	0.833	rs1888601	chr1:232266922	C/T	cg09506761	chr1:232265262	NA	-0.43	-8.75	-0.33	1.93e-17	Response to statin therapy;
BRCA	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.89	-17.78	-0.58	9.64e-58	Body mass index;
BRCA	trans	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg13565492	chr6:43139072	SRF	-0.79	-11.09	-0.4	3.05e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs62380364	0.565	rs617944	chr5:88057915	T/C	cg22951263	chr5:87985283	NA	-0.37	-10.28	-0.38	4.86e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs12200560	0.505	rs211173	chr6:97070804	C/T	cg06623918	chr6:96969491	KIAA0776	0.52	12.25	0.44	3.94e-31	Coronary heart disease;
BRCA	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11764359	chr7:65958608	NA	-0.76	-16.82	-0.55	7.85e-53	Aortic root size;
BRCA	cis	rs6878727	0.626	rs696477	chr5:123672578	C/T	cg01806427	chr5:123737813	NA	-0.36	-8.17	-0.31	1.62e-15	Breast cancer;
BRCA	trans	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg25214090	chr10:38739885	LOC399744	0.51	11.59	0.42	2.45e-28	Corneal astigmatism;
BRCA	cis	rs7586879	1.000	rs7608185	chr2:25115432	G/C	cg04586622	chr2:25135609	ADCY3	0.4	9.39	0.35	1.05e-19	Body mass index;
BRCA	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg25358565	chr5:93447407	FAM172A	1.25	19.24	0.61	1.94e-65	Diabetic retinopathy;
BRCA	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03517284	chr6:25882590	NA	-0.47	-10.66	-0.39	1.57e-24	Blood metabolite levels;
BRCA	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.26	-0.31	8.39e-16	Depression;
BRCA	cis	rs4363385	0.818	rs61811862	chr1:152995668	G/A	cg24667326	chr1:152973720	SPRR3	-0.32	-8.91	-0.33	5.17e-18	Inflammatory skin disease;
BRCA	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg18753928	chr3:113234510	CCDC52	-0.58	-12.31	-0.44	2.2e-31	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg02734326	chr4:10020555	SLC2A9	0.42	9.07	0.34	1.43e-18	Bone mineral density;
BRCA	trans	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg18876405	chr7:65276391	NA	0.43	8.24	0.31	9.61e-16	Corneal structure;
BRCA	trans	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg25206134	chr2:45395956	NA	0.52	8.99	0.34	2.8e-18	Neuroticism;
BRCA	cis	rs36051895	0.632	rs7038813	chr9:5177685	A/G	cg02405213	chr9:5042618	JAK2	-0.48	-9.26	-0.34	2.95e-19	Pediatric autoimmune diseases;
BRCA	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg06618935	chr21:46677482	NA	-0.37	-8.14	-0.31	2.07e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg06191203	chr2:152266755	RIF1	-0.33	-10.11	-0.37	2.11e-22	Lung cancer;
BRCA	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg08470875	chr2:26401718	FAM59B	-0.52	-8.58	-0.32	6.93e-17	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg23711669	chr6:146136114	FBXO30	0.74	17.76	0.57	1.14e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.32	0.59	1.4e-60	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs3857536	0.740	rs9354391	chr6:66890183	C/T	cg07460842	chr6:66804631	NA	0.45	8.8	0.33	1.22e-17	Blood trace element (Cu levels);
BRCA	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg13010199	chr12:38710504	ALG10B	0.47	9.49	0.35	4.42e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23708337	chr7:1209742	NA	0.5	9.82	0.36	2.71e-21	Longevity;Endometriosis;
BRCA	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg26031613	chr14:104095156	KLC1	-0.43	-8.51	-0.32	1.19e-16	Schizophrenia;
BRCA	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg07395648	chr5:131743802	NA	0.37	9.35	0.35	1.4e-19	Blood metabolite levels;
BRCA	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	12.06	0.43	2.62e-30	Rheumatoid arthritis;
BRCA	cis	rs9379850	0.528	rs67575965	chr6:26196593	A/G	cg01420254	chr6:26195488	NA	0.45	7.81	0.3	2.32e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs17401966	1.000	rs17401924	chr1:10384439	A/G	cg15208524	chr1:10270712	KIF1B	0.38	8.18	0.31	1.53e-15	Hepatocellular carcinoma;
BRCA	cis	rs13136331	0.641	rs2627685	chr4:88657792	T/C	cg12990093	chr4:88570587	DMP1	-0.4	-8.22	-0.31	1.14e-15	Sitting height ratio;
BRCA	trans	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.13	-38.83	-0.84	2.69e-170	Exhaled nitric oxide output;
BRCA	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.62e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24110177	chr3:50126178	RBM5	-0.37	-9.9	-0.36	1.36e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs17209837	0.607	rs45553044	chr7:87085613	A/G	cg00919237	chr7:87102261	ABCB4	-0.53	-10.24	-0.38	6.86e-23	Gallbladder cancer;
BRCA	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg27446573	chr6:127587934	RNF146	-0.54	-12.01	-0.43	4.06e-30	Breast cancer;
BRCA	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-13.92	-0.48	1.16e-38	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg08132940	chr7:1081526	C7orf50	-0.52	-8.33	-0.31	4.99e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs8017423	0.647	rs12882973	chr14:90820502	G/A	cg04374321	chr14:90722782	PSMC1	-0.5	-11.92	-0.43	9.86e-30	Mortality in heart failure;
BRCA	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg18357645	chr12:58087776	OS9	0.47	13.88	0.48	1.82e-38	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10150615	chr22:24372951	LOC391322	-0.44	-9.85	-0.36	2.02e-21	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-13.45	-0.47	1.66e-36	Personality dimensions;
BRCA	trans	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg25214090	chr10:38739885	LOC399744	0.57	11.64	0.42	1.56e-28	Corneal astigmatism;
BRCA	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg12219531	chr12:120966889	COQ5	0.56	11.49	0.41	6.72e-28	High light scatter reticulocyte count;
BRCA	cis	rs1375194	0.606	rs2044644	chr2:33817559	A/G	cg04131969	chr2:33951647	MYADML	-0.42	-8.16	-0.31	1.76e-15	Response to antidepressants in depression;
BRCA	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg27129171	chr3:47204927	SETD2	-0.65	-14.35	-0.49	1.1e-40	Colorectal cancer;
BRCA	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg10523679	chr1:76189770	ACADM	0.75	15.64	0.53	6.2e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg05347473	chr6:146136440	FBXO30	0.43	8.57	0.32	7.57e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg10729496	chr3:10149963	C3orf24	0.47	8.84	0.33	8.98e-18	Alzheimer's disease;
BRCA	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-10.72	-0.39	8.94e-25	Calcium levels;
BRCA	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg23625390	chr15:77176239	SCAPER	0.44	10.97	0.4	9.14e-26	Blood metabolite levels;
BRCA	trans	rs3857536	0.813	rs9354403	chr6:66943426	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.31e-15	Blood trace element (Cu levels);
BRCA	cis	rs57590327	0.503	rs13062741	chr3:81887124	C/T	cg07356753	chr3:81810745	GBE1	-0.43	-10.08	-0.37	2.9e-22	Extraversion;
BRCA	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg26384229	chr12:38710491	ALG10B	0.59	13.39	0.47	3.37e-36	Heart rate;
BRCA	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.02e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2282802	0.685	rs7715538	chr5:139665181	T/C	cg26211634	chr5:139558579	C5orf32	0.35	8.22	0.31	1.15e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6088813	0.961	rs981819	chr20:33924112	C/T	cg14752227	chr20:34000481	UQCC	0.41	8.61	0.32	5.48e-17	Height;
BRCA	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg18904891	chr8:8559673	CLDN23	0.58	11.06	0.4	3.75e-26	Obesity-related traits;
BRCA	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.78	-0.36	3.74e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg03425785	chr20:62221387	GMEB2	0.51	8.25	0.31	8.77e-16	Glioblastoma;
BRCA	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg00278107	chr5:1061253	SLC12A7	-0.73	-16.07	-0.54	4.83e-49	QT interval;
BRCA	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg16850897	chr7:100343110	ZAN	0.37	8.46	0.32	1.85e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg09307838	chr4:120376055	NA	0.64	14.08	0.49	1.96e-39	Corneal astigmatism;
BRCA	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.96	0.3	7.77e-15	Parkinson's disease;
BRCA	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	13.99	0.48	5.27e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs870825	0.616	rs4444873	chr4:185628406	A/G	cg04058563	chr4:185651563	MLF1IP	0.78	16.81	0.55	8.5e-53	Blood protein levels;
BRCA	cis	rs965469	0.779	rs6133031	chr20:3300857	A/C	cg25506879	chr20:3388711	C20orf194	-0.44	-8.73	-0.33	2.27e-17	IFN-related cytopenia;
BRCA	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg18225595	chr11:63971243	STIP1	-0.53	-9.93	-0.37	1.04e-21	Mean platelet volume;
BRCA	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg05623727	chr3:50126028	RBM5	0.49	11.63	0.42	1.64e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg16482183	chr6:26056742	HIST1H1C	0.54	11.27	0.41	5.3e-27	Height;
BRCA	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	11.18	0.4	1.23e-26	Height;
BRCA	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	trans	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg26043149	chr18:55253948	FECH	-0.36	-7.87	-0.3	1.52e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg03146154	chr1:46216737	IPP	0.54	12.02	0.43	3.92e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03264133	chr6:25882463	NA	-0.43	-9.43	-0.35	7.6e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg12365402	chr11:9010492	NRIP3	-0.39	-9.01	-0.34	2.33e-18	Hemoglobin concentration;
BRCA	cis	rs9463078	0.803	rs2396380	chr6:45043557	T/A	cg25276700	chr6:44698697	NA	-0.36	-8.33	-0.31	5.08e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg07741184	chr6:167504864	NA	0.28	8.23	0.31	1.09e-15	Crohn's disease;
BRCA	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg09256448	chr16:638327	NA	0.3	7.94	0.3	9.28e-15	Height;
BRCA	cis	rs490234	0.966	rs569408	chr9:128304824	G/A	cg14078157	chr9:128172775	NA	0.33	7.89	0.3	1.3e-14	Mean arterial pressure;
BRCA	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.54	-11.51	-0.41	5.36e-28	Colorectal cancer;
BRCA	trans	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg06521331	chr12:34319734	NA	-0.44	-8.35	-0.31	4.37e-16	Bladder cancer;
BRCA	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg13010199	chr12:38710504	ALG10B	0.5	9.82	0.36	2.8e-21	Morning vs. evening chronotype;
BRCA	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg07211511	chr3:129823064	LOC729375	-0.58	-10.64	-0.39	1.84e-24	Blood pressure (smoking interaction);
BRCA	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.02e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg10596483	chr8:143751796	JRK	0.4	8.6	0.32	6.13e-17	Schizophrenia;
BRCA	cis	rs586533	0.881	rs631338	chr11:99498158	T/G	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	14.35	0.49	1.16e-40	Response to antipsychotic treatment;
BRCA	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg02574844	chr11:5959923	NA	-0.44	-8.66	-0.32	3.75e-17	DNA methylation (variation);
BRCA	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg09537434	chr19:41945824	ATP5SL	1.03	24.89	0.7	3.9e-96	Height;
BRCA	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg22920501	chr2:26401640	FAM59B	-0.91	-16.27	-0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs6738485	1.000	rs6738485	chr2:106809960	C/T	cg16099169	chr2:106886729	NA	-0.4	-8.04	-0.3	4.24e-15	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
BRCA	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg06521331	chr12:34319734	NA	-0.56	-10.28	-0.38	4.75e-23	Morning vs. evening chronotype;
BRCA	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg15448220	chr1:150897856	SETDB1	0.35	7.87	0.3	1.52e-14	Melanoma;
BRCA	cis	rs600806	0.815	rs3768495	chr1:109935325	C/T	cg20591472	chr1:110008990	SYPL2	0.33	8.22	0.31	1.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg24006582	chr15:45444508	DUOX1	0.56	10.78	0.39	5.32e-25	Uric acid levels;
BRCA	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.95	0.33	3.69e-18	Platelet count;
BRCA	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg07952391	chr2:88470173	THNSL2	0.56	7.86	0.3	1.66e-14	Plasma clusterin levels;
BRCA	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.72	-19.58	-0.61	2.96e-67	Electrocardiographic conduction measures;
BRCA	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.6	-0.67	1.57e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.43	-9.12	-0.34	9.63e-19	Longevity;Endometriosis;
BRCA	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg15556689	chr8:8085844	FLJ10661	0.49	13.61	0.47	3.2e-37	Mood instability;
BRCA	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.12	-0.31	2.37e-15	Depression;
BRCA	trans	rs78049276	0.512	rs6820938	chr4:148395903	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.54	-11.33	-0.41	2.95e-27	Pulse pressure;
BRCA	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg04586622	chr2:25135609	ADCY3	0.44	11.31	0.41	3.75e-27	Body mass index;
BRCA	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg02551604	chr5:131831745	NA	0.38	13.78	0.48	5.02e-38	Asthma (sex interaction);
BRCA	cis	rs9394841	0.667	rs9471667	chr6:41776681	T/C	cg08135965	chr6:41755394	TOMM6	0.5	8.21	0.31	1.19e-15	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.58	9.78	0.36	3.7e-21	Gut microbiome composition (summer);
BRCA	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-8.86	-0.33	7.77e-18	Alzheimer's disease (late onset);
BRCA	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg19077165	chr18:44547161	KATNAL2	0.56	12.25	0.44	3.76e-31	Personality dimensions;
BRCA	trans	rs208520	0.837	rs208489	chr6:66927584	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.36	-0.54	1.72e-50	Exhaled nitric oxide output;
BRCA	cis	rs73242632	1.000	rs2276896	chr4:57845091	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.71	8.59	0.32	6.46e-17	Congenital heart disease (maternal effect);
BRCA	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg01884057	chr2:25150051	NA	-0.34	-9.02	-0.34	2.09e-18	Body mass index in non-asthmatics;
BRCA	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg13944838	chr5:179740914	GFPT2	-0.69	-14.48	-0.5	2.77e-41	Height;
BRCA	cis	rs10193935	0.901	rs222469	chr2:42640235	T/C	cg27598129	chr2:42591480	NA	-0.85	-14.33	-0.49	1.4e-40	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.69	-15.14	-0.51	1.82e-44	Homoarginine levels;
BRCA	cis	rs11971779	0.564	rs6467841	chr7:139066092	T/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs17741873	0.779	rs3812635	chr10:75594302	T/G	cg07699608	chr10:75541558	CHCHD1	0.5	8.19	0.31	1.38e-15	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	14.79	0.51	8.56e-43	Electrocardiographic conduction measures;
BRCA	cis	rs9612	1.000	rs16976747	chr19:44238152	G/A	cg08581076	chr19:44259116	C19orf61	0.62	10.99	0.4	7.77e-26	Exhaled nitric oxide output;
BRCA	cis	rs28374715	0.562	rs8036686	chr15:41550333	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.56	-12.26	-0.44	3.34e-31	Ulcerative colitis;
BRCA	cis	rs1468333	1.000	rs1468333	chr5:137552970	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.44	9.34	0.35	1.55e-19	Resting heart rate;
BRCA	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg23711669	chr6:146136114	FBXO30	0.74	16.17	0.54	1.48e-49	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg19717773	chr7:2847554	GNA12	-0.43	-9.49	-0.35	4.36e-20	Height;
BRCA	cis	rs34779708	0.897	rs11010131	chr10:35513316	A/C	cg03585969	chr10:35415529	CREM	0.48	9.7	0.36	7.42e-21	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg12386194	chr3:101231763	SENP7	0.45	9.52	0.35	3.48e-20	Colorectal cancer;
BRCA	cis	rs2066819	1.000	rs74673257	chr12:56638077	T/C	cg26714650	chr12:56694279	CS	-1.18	-15.33	-0.52	2.13e-45	Psoriasis vulgaris;
BRCA	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg13010199	chr12:38710504	ALG10B	0.44	9.39	0.35	1.07e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.7	-19.21	-0.61	2.91e-65	Electrocardiographic conduction measures;
BRCA	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg20790798	chr5:1857306	NA	-0.38	-9.09	-0.34	1.23e-18	Cardiovascular disease risk factors;
BRCA	cis	rs13064411	0.696	rs6438156	chr3:113206929	C/A	cg18753928	chr3:113234510	CCDC52	-0.59	-12.34	-0.44	1.56e-31	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg27478167	chr7:817139	HEATR2	-0.42	-9.03	-0.34	2.01e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs10463316	0.817	rs6880228	chr5:150778145	A/T	cg03212797	chr5:150827313	SLC36A1	0.39	7.85	0.3	1.7e-14	Metabolite levels (Pyroglutamine);
BRCA	cis	rs72781680	0.678	rs56145919	chr2:24088489	A/G	cg08917208	chr2:24149416	ATAD2B	0.61	10.23	0.38	7.31e-23	Lymphocyte counts;
BRCA	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg20503657	chr10:835505	NA	1.03	18.42	0.59	4.53e-61	Eosinophil percentage of granulocytes;
BRCA	trans	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	20.74	0.63	1.96e-73	Exhaled nitric oxide output;
BRCA	cis	rs3857067	0.806	rs10008044	chr4:95092850	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.45	-0.35	6.42e-20	QT interval;
BRCA	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22307029	chr19:49891270	CCDC155	0.68	12.33	0.44	1.65e-31	Multiple sclerosis;
BRCA	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.42	-8.42	-0.32	2.54e-16	Monocyte percentage of white cells;
BRCA	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg18252515	chr7:66147081	NA	-0.82	-11.87	-0.42	1.69e-29	Diabetic kidney disease;
BRCA	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg02880119	chr16:3481970	NA	0.45	8.38	0.31	3.47e-16	Body mass index (adult);
BRCA	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg10932868	chr11:921992	NA	0.49	12.63	0.45	8.39e-33	Alzheimer's disease (late onset);
BRCA	cis	rs6973256	0.897	rs10231829	chr7:133348338	T/A	cg07491979	chr7:133331646	EXOC4	-0.39	-9.04	-0.34	1.92e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.91	-14.98	-0.51	1.08e-43	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	8.51	0.32	1.25e-16	Mean corpuscular volume;
BRCA	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.5	-0.32	1.33e-16	Retinal vascular caliber;
BRCA	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg27170947	chr2:26402098	FAM59B	-0.65	-11.21	-0.41	9.48e-27	Gut microbiome composition (summer);
BRCA	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	9.89	0.36	1.45e-21	Neuroticism;
BRCA	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg24060327	chr5:131705240	SLC22A5	-0.47	-10.04	-0.37	3.91e-22	Blood metabolite levels;
BRCA	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg01877450	chr7:97915802	BRI3	-0.37	-8.31	-0.31	5.64e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg20283391	chr11:68216788	NA	-0.46	-9.07	-0.34	1.49e-18	Total body bone mineral density;
BRCA	cis	rs6121246	0.559	rs6060716	chr20:30274847	C/G	cg13852791	chr20:30311386	BCL2L1	0.95	23.18	0.68	9.54e-87	Mean corpuscular hemoglobin;
BRCA	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg23285459	chr7:2802560	GNA12	-0.38	-9.44	-0.35	6.97e-20	Height;
BRCA	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg13010199	chr12:38710504	ALG10B	0.43	9.18	0.34	5.72e-19	Morning vs. evening chronotype;
BRCA	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg20701182	chr2:24300061	SF3B14	0.55	8.51	0.32	1.21e-16	Lymphocyte counts;
BRCA	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg26384229	chr12:38710491	ALG10B	0.65	15.36	0.52	1.48e-45	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08045932	chr20:61659980	NA	0.49	11.35	0.41	2.41e-27	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg15704280	chr7:45808275	SEPT13	-0.44	-8.4	-0.32	2.79e-16	HDL cholesterol;
BRCA	cis	rs11051970	0.679	rs2733696	chr12:32554635	A/G	cg02745156	chr12:32552066	NA	0.25	8.47	0.32	1.65e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg11645453	chr3:52864694	ITIH4	0.37	9.9	0.36	1.4e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg05340658	chr4:99064831	C4orf37	0.66	16.11	0.54	3.02e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg25174290	chr11:3078921	CARS	0.44	12.78	0.45	1.86e-33	Longevity;
BRCA	cis	rs3916	0.794	rs3021337	chr12:121163261	C/T	cg21892295	chr12:121157589	UNC119B	-0.4	-11.45	-0.41	9.41e-28	Urinary metabolites (H-NMR features);
BRCA	cis	rs7631605	0.586	rs56990886	chr3:37298243	G/A	cg15934958	chr3:37212084	LRRFIP2	0.39	8.29	0.31	6.92e-16	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.97	25.76	0.71	7.07e-101	Body mass index (adult);
BRCA	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg24130564	chr14:104152367	KLC1	-0.38	-9.07	-0.34	1.4e-18	Body mass index;
BRCA	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg05283184	chr6:79620031	NA	-0.43	-11.1	-0.4	2.77e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2425143	1.000	rs117010355	chr20:34343442	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.11	-0.34	1.09e-18	Blood protein levels;
BRCA	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg12219531	chr12:120966889	COQ5	0.55	11.44	0.41	1.11e-27	High light scatter reticulocyte count;
BRCA	cis	rs490234	0.934	rs571675	chr9:128297692	C/T	cg14078157	chr9:128172775	NA	0.33	7.97	0.3	7.46e-15	Mean arterial pressure;
BRCA	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	8.05	0.3	4.09e-15	Aortic root size;
BRCA	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	15.81	0.53	9.71e-48	Fuchs's corneal dystrophy;
BRCA	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg01877450	chr7:97915802	BRI3	-0.39	-8.9	-0.33	5.88e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg01858014	chr14:56050164	KTN1	-0.77	-11.27	-0.41	5.52e-27	Putamen volume;
BRCA	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.44	9.15	0.34	7.77e-19	Cognitive ability;
BRCA	cis	rs9443645	0.527	rs9343870	chr6:79789473	T/G	cg05283184	chr6:79620031	NA	-0.35	-8.0	-0.3	5.75e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg26043149	chr18:55253948	FECH	0.4	8.53	0.32	1.07e-16	Bone mineral density;
BRCA	cis	rs887829	0.570	rs10168155	chr2:234596836	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.29	-0.31	6.48e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg03188948	chr7:1209495	NA	0.86	11.81	0.42	3.02e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2710642	0.962	rs6545972	chr2:63084682	G/A	cg17519650	chr2:63277830	OTX1	0.37	8.16	0.31	1.8e-15	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-11.61	-0.42	2.06e-28	Alzheimer's disease;
BRCA	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg11789530	chr4:8429930	ACOX3	-0.68	-17.89	-0.58	2.47e-58	Response to antineoplastic agents;
BRCA	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24549020	chr5:56110836	MAP3K1	0.55	10.96	0.4	9.58e-26	Initial pursuit acceleration;
BRCA	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg12219531	chr12:120966889	COQ5	0.54	11.32	0.41	3.35e-27	High light scatter reticulocyte count;
BRCA	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg03585969	chr10:35415529	CREM	0.56	11.55	0.42	3.74e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.63e-15	Menopause (age at onset);
BRCA	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg22903471	chr2:27725779	GCKR	-0.32	-7.85	-0.3	1.77e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg02753203	chr1:228287806	NA	-0.6	-13.03	-0.46	1.4e-34	Diastolic blood pressure;
BRCA	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg02631126	chr6:28058918	ZSCAN12L1	-0.27	-7.94	-0.3	9.23e-15	Depression;
BRCA	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.86	-0.36	1.92e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7179456	0.545	rs585192	chr15:59052210	T/C	cg05156742	chr15:59063176	FAM63B	0.48	9.68	0.36	8.92e-21	Asperger disorder;
BRCA	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg14349672	chr11:133703707	NA	-0.43	-9.58	-0.35	2.16e-20	Childhood ear infection;
BRCA	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg16606324	chr3:10149918	C3orf24	0.57	11.01	0.4	5.98e-26	Alzheimer's disease;
BRCA	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg16586182	chr3:47516702	SCAP	0.53	11.4	0.41	1.62e-27	Colorectal cancer;
BRCA	cis	rs9318086	0.673	rs7981928	chr13:24435180	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.33	9.63	0.36	1.33e-20	Myopia (pathological);
BRCA	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg17366294	chr4:99064904	C4orf37	0.45	10.81	0.39	3.91e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg13393036	chr8:95962371	TP53INP1	-0.3	-8.07	-0.3	3.54e-15	Type 2 diabetes;
BRCA	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg25554036	chr4:6271136	WFS1	-0.41	-9.76	-0.36	4.38e-21	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg05347473	chr6:146136440	FBXO30	0.41	8.07	0.3	3.41e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg23711669	chr6:146136114	FBXO30	0.78	17.99	0.58	7.28e-59	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg05519781	chr21:40033154	ERG	0.38	8.06	0.3	3.63e-15	Coronary artery disease;
BRCA	cis	rs7131987	0.507	rs3782507	chr12:29445530	T/C	cg09582351	chr12:29534625	ERGIC2	-0.35	-8.18	-0.31	1.52e-15	QT interval;
BRCA	cis	rs2019216	0.564	rs907707	chr17:21910083	G/C	cg22648282	chr17:21454238	C17orf51	-0.41	-9.38	-0.35	1.13e-19	Pelvic organ prolapse;
BRCA	cis	rs7246657	0.663	rs10408619	chr19:38070474	C/T	cg23950597	chr19:37808831	NA	-0.51	-8.78	-0.33	1.44e-17	Coronary artery calcification;
BRCA	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	11.03	0.4	4.9e-26	Bipolar disorder;
BRCA	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg03433033	chr1:76189801	ACADM	-0.52	-10.28	-0.38	4.82e-23	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg20701182	chr2:24300061	SF3B14	0.7	13.37	0.47	4.01e-36	Lymphocyte counts;
BRCA	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18404041	chr3:52824283	ITIH1	-0.4	-11.9	-0.43	1.26e-29	Bipolar disorder;
BRCA	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg07741184	chr6:167504864	NA	-0.32	-9.2	-0.34	4.84e-19	Primary biliary cholangitis;
BRCA	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg11584989	chr19:19387371	SF4	0.63	13.52	0.47	7.85e-37	Bipolar disorder;
BRCA	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24838063	chr12:130822603	PIWIL1	0.68	16.73	0.55	2.13e-52	Menopause (age at onset);
BRCA	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg01262667	chr19:19385393	TM6SF2	0.38	7.95	0.3	8.64e-15	Nonalcoholic fatty liver disease;
BRCA	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg09754948	chr16:28834200	ATXN2L	0.47	9.17	0.34	6.53e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg19338460	chr6:170058176	WDR27	-0.76	-10.64	-0.39	1.91e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg11189052	chr15:85197271	WDR73	-0.5	-12.41	-0.44	7.48e-32	P wave terminal force;
BRCA	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg15605315	chr1:45957053	TESK2	-0.46	-9.28	-0.34	2.54e-19	High light scatter reticulocyte count;
BRCA	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.52	0.38	5.68e-24	Motion sickness;
BRCA	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg21747090	chr2:27597821	SNX17	-0.38	-8.08	-0.3	3.29e-15	Menopause (age at onset);
BRCA	cis	rs2882667	0.898	rs13163536	chr5:138377219	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-8.87	-0.33	7.19e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg00106254	chr7:1943704	MAD1L1	-0.38	-8.81	-0.33	1.16e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg01579765	chr21:45077557	HSF2BP	0.44	11.13	0.4	2.08e-26	Mean corpuscular volume;
BRCA	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg05340658	chr4:99064831	C4orf37	0.62	14.75	0.5	1.38e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs926392	0.799	rs742274	chr20:37680944	T/C	cg16355469	chr20:37678765	NA	0.33	8.28	0.31	7.43e-16	Dialysis-related mortality;
BRCA	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg13699009	chr12:122356056	WDR66	-0.36	-8.27	-0.31	8.05e-16	Mean corpuscular volume;
BRCA	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24531977	chr5:56204891	C5orf35	0.71	15.65	0.53	5.85e-47	Initial pursuit acceleration;
BRCA	cis	rs7586879	0.719	rs7565468	chr2:25130092	C/T	cg01884057	chr2:25150051	NA	0.31	7.83	0.3	2.1e-14	Body mass index;
BRCA	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg03676636	chr4:99064102	C4orf37	0.21	7.98	0.3	6.94e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg17971929	chr21:40555470	PSMG1	0.61	14.0	0.48	4.72e-39	Cognitive function;
BRCA	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.87	0.36	1.75e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg26898376	chr11:64110657	CCDC88B	0.38	8.18	0.31	1.53e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg12419862	chr22:24373484	LOC391322	-0.65	-14.78	-0.5	9.86e-43	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg04267008	chr7:1944627	MAD1L1	-0.57	-12.59	-0.45	1.2e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg07460842	chr6:66804631	NA	0.6	10.2	0.37	1.01e-22	Type 2 diabetes;
BRCA	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg07741184	chr6:167504864	NA	0.33	9.88	0.36	1.64e-21	Primary biliary cholangitis;
BRCA	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg20290983	chr6:43655470	MRPS18A	1.11	40.5	0.85	1.23e-178	IgG glycosylation;
BRCA	cis	rs2658782	0.756	rs3019205	chr11:93109553	A/G	cg15737290	chr11:93063684	CCDC67	0.49	9.85	0.36	2.07e-21	Pulmonary function decline;
BRCA	cis	rs2668423	0.502	rs2074898	chr19:1391361	A/G	cg02639931	chr19:1387894	NDUFS7	-0.87	-26.5	-0.72	5.97e-105	Nonalcoholic fatty liver disease;
BRCA	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.47	-9.95	-0.37	8.88e-22	Colorectal cancer;
BRCA	cis	rs17741873	0.836	rs17630952	chr10:75601414	T/A	cg07699608	chr10:75541558	CHCHD1	0.53	8.49	0.32	1.4e-16	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	trans	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg26384229	chr12:38710491	ALG10B	0.56	12.05	0.43	2.7e-30	Morning vs. evening chronotype;
BRCA	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg10223061	chr2:219282414	VIL1	-0.27	-8.13	-0.31	2.21e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1035144	0.505	rs6574617	chr14:81457615	G/A	cg06600135	chr14:81408086	NA	-0.47	-11.07	-0.4	3.56e-26	Male sexual orientation;
BRCA	trans	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg25214090	chr10:38739885	LOC399744	0.51	10.48	0.38	7.8e-24	Corneal astigmatism;
BRCA	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg01097406	chr16:89675127	NA	0.38	8.66	0.32	3.85e-17	Vitiligo;
BRCA	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg18132916	chr6:79620363	NA	-0.48	-10.89	-0.4	1.89e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg04565464	chr8:145669602	NFKBIL2	0.37	8.14	0.31	2.09e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.52	7.99	0.3	6.18e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg04545296	chr12:48745243	ZNF641	0.25	8.3	0.31	5.97e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs7520050	0.966	rs7539932	chr1:46292354	C/T	cg24296786	chr1:45957014	TESK2	0.44	9.9	0.36	1.38e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.29e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg08000102	chr2:233561755	GIGYF2	0.62	13.71	0.48	1.15e-37	Coronary artery disease;
BRCA	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg08508325	chr11:3079039	CARS	-0.41	-14.4	-0.5	6.31e-41	Longevity;
BRCA	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg15145296	chr3:125709740	NA	-0.55	-8.64	-0.32	4.36e-17	Blood pressure (smoking interaction);
BRCA	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.26	7.99	0.3	6.19e-15	Parkinson's disease;
BRCA	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	9.44	0.35	6.68e-20	Rheumatoid arthritis;
BRCA	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg17644776	chr2:200775616	C2orf69	0.45	9.07	0.34	1.47e-18	Schizophrenia;
BRCA	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.09	0.34	1.21e-18	Tonsillectomy;
BRCA	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg07080220	chr10:102295463	HIF1AN	0.56	12.25	0.44	4e-31	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg03146154	chr1:46216737	IPP	0.47	10.51	0.38	6.17e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	8.3	0.31	6.15e-16	Educational attainment;
BRCA	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.09	0.49	1.91e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3771570	1.000	rs3771564	chr2:242355701	G/A	cg21155796	chr2:242212141	HDLBP	0.6	9.21	0.34	4.65e-19	Prostate cancer;
BRCA	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg04362960	chr10:104952993	NT5C2	0.46	10.4	0.38	1.58e-23	Arsenic metabolism;
BRCA	trans	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.92	-0.3	1.02e-14	Corneal astigmatism;
BRCA	cis	rs9790314	0.659	rs13066683	chr3:160847410	A/G	cg04691961	chr3:161091175	C3orf57	-0.37	-8.18	-0.31	1.49e-15	Morning vs. evening chronotype;
BRCA	cis	rs6700896	0.931	rs12042807	chr1:66134052	T/C	cg04111102	chr1:66153794	NA	0.36	8.67	0.32	3.57e-17	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.6	12.56	0.45	1.65e-32	Personality dimensions;
BRCA	cis	rs7586879	0.828	rs2384056	chr2:25092649	G/A	cg04586622	chr2:25135609	ADCY3	0.38	9.11	0.34	1.06e-18	Body mass index;
BRCA	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg17691542	chr6:26056736	HIST1H1C	0.51	10.34	0.38	2.87e-23	Height;
BRCA	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06002616	chr8:101225028	SPAG1	-0.32	-7.96	-0.3	7.95e-15	Atrioventricular conduction;
BRCA	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg20607798	chr8:58055168	NA	0.54	8.41	0.32	2.71e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs9951602	0.512	rs7232551	chr18:76650702	G/A	cg02800362	chr5:177631904	HNRNPAB	0.77	18.01	0.58	5.8e-59	Obesity-related traits;
BRCA	cis	rs7851660	0.901	rs7873389	chr9:100609230	C/T	cg13688889	chr9:100608707	NA	-0.35	-8.5	-0.32	1.3e-16	Strep throat;
BRCA	cis	rs870825	0.616	rs4616798	chr4:185634144	C/T	cg04058563	chr4:185651563	MLF1IP	-0.76	-17.51	-0.57	2.31e-56	Blood protein levels;
BRCA	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg09307838	chr4:120376055	NA	0.74	16.17	0.54	1.53e-49	Corneal astigmatism;
BRCA	trans	rs11227306	0.934	rs2303385	chr11:65640562	G/A	cg17712092	chr4:129076599	LARP1B	-0.38	-8.19	-0.31	1.47e-15	DNA methylation (variation);
BRCA	cis	rs870825	0.616	rs7678849	chr4:185648868	T/C	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs4363385	0.747	rs7529110	chr1:152966247	A/C	cg25856811	chr1:152973957	SPRR3	-0.35	-9.53	-0.35	3.12e-20	Inflammatory skin disease;
BRCA	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg10932868	chr11:921992	NA	0.38	9.02	0.34	2.13e-18	Alzheimer's disease (late onset);
BRCA	trans	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.36	7.99	0.3	6.53e-15	Endometrial cancer;
BRCA	cis	rs4803468	0.967	rs2304243	chr19:41942708	C/G	cg09537434	chr19:41945824	ATP5SL	1.03	25.67	0.71	2.15e-100	Height;
BRCA	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.22	-0.37	8.46e-23	Psoriasis;
BRCA	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.69	-16.12	-0.54	2.54e-49	Axial length;
BRCA	cis	rs6546550	0.901	rs6546558	chr2:70145717	C/T	cg02498382	chr2:70120550	SNRNP27	-0.54	-11.7	-0.42	8.85e-29	Prevalent atrial fibrillation;
BRCA	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg23950597	chr19:37808831	NA	0.66	11.4	0.41	1.63e-27	Coronary artery calcification;
BRCA	cis	rs698833	0.886	rs4953090	chr2:44565194	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	10.55	0.39	4.13e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs3760982	0.585	rs11673490	chr19:44298885	C/A	cg12072164	chr19:44306565	LYPD5	0.37	8.71	0.33	2.57e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg15412446	chr2:106886593	NA	-0.49	-9.03	-0.34	2.05e-18	Facial morphology (factor 23);
BRCA	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.62	-0.32	5.3e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-9.88	-0.36	1.65e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1468333	1.000	rs2057831	chr5:137535133	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.43	9.12	0.34	9.58e-19	Resting heart rate;
BRCA	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.46	8.02	0.3	5.09e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg03146154	chr1:46216737	IPP	0.53	11.88	0.43	1.46e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs877282	0.947	rs7923867	chr10:768094	G/A	cg22713356	chr15:30763199	NA	1.35	26.99	0.73	1.24e-107	Uric acid levels;
BRCA	cis	rs7766436	0.885	rs13211957	chr6:22573415	C/T	cg13666174	chr6:22585274	NA	-0.45	-9.63	-0.36	1.35e-20	Coronary artery disease;
BRCA	cis	rs9462027	0.628	rs2764207	chr6:34712998	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.83	-0.3	2e-14	Systemic lupus erythematosus;
BRCA	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18357526	chr6:26021779	HIST1H4A	0.46	8.22	0.31	1.11e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg00277334	chr10:82204260	NA	-0.48	-10.1	-0.37	2.42e-22	Post bronchodilator FEV1;
BRCA	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.95	0.46	3.16e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg14196790	chr5:131705035	SLC22A5	0.44	11.33	0.41	3.17e-27	Blood metabolite levels;
BRCA	cis	rs7635838	0.654	rs4684766	chr3:11285474	G/A	cg00170343	chr3:11313890	ATG7	0.43	8.37	0.31	3.65e-16	HDL cholesterol;
BRCA	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	8.26	0.31	8.28e-16	Aortic root size;
BRCA	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-18.66	-0.59	2.46e-62	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	10.46	0.38	9.23e-24	Eosinophil percentage of white cells;
BRCA	cis	rs79839061	0.611	rs2279183	chr4:882404	T/C	cg07828340	chr4:882639	GAK	0.6	9.57	0.35	2.35e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.747	rs1015996	chr1:152976108	C/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.32	-0.31	5.23e-16	Inflammatory skin disease;
BRCA	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg20203395	chr5:56204925	C5orf35	-0.51	-10.24	-0.38	6.6e-23	Initial pursuit acceleration;
BRCA	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg06453172	chr10:134556979	INPP5A	-0.51	-10.85	-0.39	2.71e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs3815700	1.000	rs8109990	chr19:33095636	A/G	cg02997394	chr19:33096574	ANKRD27	0.69	11.38	0.41	1.83e-27	Eosinophilic esophagitis;
BRCA	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg07080220	chr10:102295463	HIF1AN	0.61	14.5	0.5	2.12e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs1493916	0.805	rs1452648	chr18:31411003	G/T	cg15819921	chr19:927150	ARID3A	-0.41	-8.11	-0.31	2.57e-15	Life satisfaction;
BRCA	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg22800045	chr5:56110881	MAP3K1	-0.41	-8.28	-0.31	7.28e-16	Initial pursuit acceleration;
BRCA	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg00409905	chr10:38381863	ZNF37A	-0.51	-9.54	-0.35	2.94e-20	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg13880726	chr7:1868755	MAD1L1	0.53	9.85	0.36	2.14e-21	Bipolar disorder and schizophrenia;
BRCA	trans	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg06521331	chr12:34319734	NA	-0.5	-9.06	-0.34	1.58e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2953174	1.000	rs1133353	chr2:241522267	A/T	cg07929629	chr2:241523174	NA	-0.49	-7.99	-0.3	6.29e-15	Bipolar disorder;
BRCA	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg11833968	chr6:79620685	NA	-0.38	-8.45	-0.32	1.9e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg20476274	chr7:133979776	SLC35B4	0.66	19.45	0.61	1.48e-66	Mean platelet volume;
BRCA	cis	rs7072216	0.763	rs10732782	chr10:100166506	C/A	cg26618903	chr10:100175079	PYROXD2	-0.31	-8.96	-0.33	3.58e-18	Metabolite levels;
BRCA	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg18016565	chr1:150552671	MCL1	0.34	7.86	0.3	1.59e-14	Melanoma;
BRCA	cis	rs929596	0.755	rs887829	chr2:234668570	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.41	10.41	0.38	1.51e-23	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs1371614	0.632	rs920437	chr2:27157396	G/A	cg00617064	chr2:27272375	NA	0.31	8.08	0.3	3.15e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs6942756	0.806	rs68184415	chr7:128988862	C/T	cg02491457	chr7:128862824	NA	-0.59	-12.39	-0.44	9.26e-32	White matter hyperintensity burden;
BRCA	cis	rs10463316	0.894	rs6891272	chr5:150762842	G/T	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.22	-0.31	1.12e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg22029157	chr1:209979665	IRF6	0.55	11.27	0.41	5.13e-27	Cleft lip with or without cleft palate;
BRCA	cis	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg05901451	chr6:126070800	HEY2	0.4	9.65	0.36	1.2e-20	Endometrial cancer;
BRCA	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg04450456	chr4:17643702	FAM184B	-0.34	-9.59	-0.35	1.97e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg06623918	chr6:96969491	KIAA0776	0.87	24.36	0.69	3.16e-93	Headache;
BRCA	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	10.06	0.37	3.27e-22	Lung cancer in ever smokers;
BRCA	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg22800045	chr5:56110881	MAP3K1	0.41	8.2	0.31	1.28e-15	Coronary artery disease;
BRCA	trans	rs12517041	0.935	rs36035239	chr5:23294107	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	trans	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg25214090	chr10:38739885	LOC399744	0.56	12.85	0.45	9.31e-34	Corneal astigmatism;
BRCA	cis	rs67981189	0.513	rs7154395	chr14:71566300	G/A	cg15816911	chr14:71606274	NA	0.37	8.27	0.31	7.93e-16	Schizophrenia;
BRCA	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg02734326	chr4:10020555	SLC2A9	0.4	8.61	0.32	5.56e-17	Bone mineral density;
BRCA	cis	rs1499972	0.941	rs62263082	chr3:117605611	C/T	cg07612923	chr3:117604196	NA	0.59	7.94	0.3	9.02e-15	Schizophrenia;
BRCA	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg03929089	chr4:120376271	NA	-0.76	-17.18	-0.56	1.19e-54	Coronary artery disease;
BRCA	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	8.72	0.33	2.44e-17	Iron status biomarkers;
BRCA	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.2	0.34	5.04e-19	Tonsillectomy;
BRCA	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg15017067	chr4:17643749	FAM184B	0.29	8.26	0.31	8.68e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg25036284	chr2:26402008	FAM59B	0.95	15.98	0.53	1.27e-48	Gut microbiome composition (summer);
BRCA	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-11.93	-0.43	9.16e-30	Chronic sinus infection;
BRCA	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.37	8.76	0.33	1.68e-17	Tonsillectomy;
BRCA	cis	rs68170813	0.559	rs76843318	chr7:106863173	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.47	-0.32	1.72e-16	Coronary artery disease;
BRCA	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	13.46	0.47	1.5e-36	Lymphocyte counts;
BRCA	cis	rs9649465	0.967	rs11769381	chr7:123264804	C/T	cg03229431	chr7:123269106	ASB15	-0.35	-8.08	-0.3	3.17e-15	Migraine;
BRCA	cis	rs3845702	1.000	rs3845702	chr2:180848488	A/C	cg01881094	chr2:180872142	CWC22	0.65	13.47	0.47	1.32e-36	Schizophrenia;
BRCA	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.14	-44.85	-0.87	1.43e-199	Myeloid white cell count;
BRCA	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg03354898	chr7:1950403	MAD1L1	-0.44	-9.14	-0.34	8.4e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg11789530	chr4:8429930	ACOX3	-0.69	-17.87	-0.58	3.07e-58	Response to antineoplastic agents;
BRCA	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg20283391	chr11:68216788	NA	-0.46	-8.98	-0.33	3.03e-18	Total body bone mineral density;
BRCA	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg11843238	chr5:131593191	PDLIM4	0.32	7.87	0.3	1.52e-14	Blood metabolite levels;
BRCA	cis	rs7178424	1.000	rs7177276	chr15:62379668	C/T	cg00456672	chr15:62358751	C2CD4A	-0.34	-8.16	-0.31	1.81e-15	Height;
BRCA	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg20607287	chr7:12443886	VWDE	-0.54	-8.16	-0.31	1.83e-15	Coronary artery disease;
BRCA	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg06697600	chr4:7070879	GRPEL1	-0.53	-10.64	-0.39	1.82e-24	Monocyte percentage of white cells;
BRCA	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg23029597	chr12:123009494	RSRC2	-0.61	-12.46	-0.44	4.66e-32	Body mass index;
BRCA	trans	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg26384229	chr12:38710491	ALG10B	0.52	11.18	0.4	1.28e-26	Morning vs. evening chronotype;
BRCA	cis	rs7520050	0.966	rs7556615	chr1:46461369	G/A	cg24296786	chr1:45957014	TESK2	0.43	9.66	0.36	1.03e-20	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg26384229	chr12:38710491	ALG10B	-0.58	-13.44	-0.47	1.83e-36	Morning vs. evening chronotype;
BRCA	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg25358565	chr5:93447407	FAM172A	1.22	18.58	0.59	6.16e-62	Diabetic retinopathy;
BRCA	cis	rs10504073	0.647	rs62507247	chr8:50013554	T/G	cg00325661	chr8:49890786	NA	0.47	13.22	0.46	1.95e-35	Blood metabolite ratios;
BRCA	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg11752832	chr7:134001865	SLC35B4	0.52	13.55	0.47	6.19e-37	Mean platelet volume;
BRCA	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg14582100	chr15:45693742	SPATA5L1	0.37	11.95	0.43	7.89e-30	Homoarginine levels;
BRCA	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.02	0.48	4.01e-39	Motion sickness;
BRCA	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg01877450	chr7:97915802	BRI3	-0.39	-8.63	-0.32	5e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg07541023	chr7:19748670	TWISTNB	0.54	9.85	0.36	2.18e-21	Thyroid stimulating hormone;
BRCA	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-22.11	-0.66	7.01e-81	Chronic sinus infection;
BRCA	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02018176	chr4:1364513	KIAA1530	0.41	8.24	0.31	1.01e-15	Longevity;
BRCA	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg17143192	chr8:8559678	CLDN23	0.5	9.62	0.36	1.54e-20	Obesity-related traits;
BRCA	cis	rs16976116	0.901	rs28535372	chr15:55500602	T/C	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg00071950	chr4:10020882	SLC2A9	0.64	15.96	0.53	1.59e-48	Bone mineral density;
BRCA	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg23625390	chr15:77176239	SCAPER	0.38	9.64	0.36	1.29e-20	Blood metabolite levels;
BRCA	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg09904177	chr6:26538194	HMGN4	0.51	14.84	0.51	5.26e-43	Intelligence (multi-trait analysis);
BRCA	trans	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg06521331	chr12:34319734	NA	-0.51	-9.19	-0.34	5.34e-19	Bladder cancer;
BRCA	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg10862848	chr6:42927986	GNMT	0.27	8.8	0.33	1.3e-17	Blood protein levels;
BRCA	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg27398817	chr8:82754497	SNX16	0.45	8.72	0.33	2.34e-17	Diastolic blood pressure;
BRCA	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg09877947	chr5:131593287	PDLIM4	0.41	10.46	0.38	9.65e-24	Breast cancer;
BRCA	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg21905437	chr5:178450457	ZNF879	0.51	10.66	0.39	1.53e-24	Pubertal anthropometrics;
BRCA	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.89e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg02734326	chr4:10020555	SLC2A9	0.39	8.3	0.31	6.29e-16	Bone mineral density;
BRCA	cis	rs2625529	0.824	rs4777470	chr15:72207518	T/A	cg16672083	chr15:72433130	SENP8	-0.83	-17.19	-0.56	9.91e-55	Red blood cell count;
BRCA	cis	rs2559856	1.000	rs2251187	chr12:102081889	G/A	cg12924262	chr12:102091054	CHPT1	0.36	8.13	0.31	2.22e-15	Blood protein levels;
BRCA	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.39	0.49	6.83e-41	Motion sickness;
BRCA	cis	rs926392	0.547	rs8118808	chr20:37674996	C/G	cg16355469	chr20:37678765	NA	0.49	10.92	0.4	1.42e-25	Dialysis-related mortality;
BRCA	cis	rs897080	0.515	rs698790	chr2:44683018	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	9.36	0.35	1.33e-19	Height;
BRCA	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg27411982	chr8:10470053	RP1L1	0.34	8.07	0.3	3.49e-15	Retinal vascular caliber;
BRCA	cis	rs2559856	0.935	rs7957666	chr12:102081551	T/C	cg12924262	chr12:102091054	CHPT1	0.36	8.16	0.31	1.81e-15	Blood protein levels;
BRCA	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	17.93	0.58	1.63e-58	Alzheimer's disease;
BRCA	cis	rs701145	0.585	rs1713822	chr3:153863505	A/G	cg12800244	chr3:153838788	SGEF	0.62	7.83	0.3	2.1e-14	Coronary artery disease;
BRCA	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg16850897	chr7:100343110	ZAN	-0.61	-13.08	-0.46	8.34e-35	Other erythrocyte phenotypes;
BRCA	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg18225595	chr11:63971243	STIP1	0.53	9.59	0.35	1.8899999999999998e-20	Mean platelet volume;
BRCA	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.4	-7.92	-0.3	1.04e-14	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02187348	chr16:89574699	SPG7	0.52	12.47	0.44	4.35e-32	Multiple myeloma (IgH translocation);
BRCA	cis	rs4363385	0.747	rs2339491	chr1:152985322	T/C	cg24667326	chr1:152973720	SPRR3	-0.35	-9.93	-0.37	1.06e-21	Inflammatory skin disease;
BRCA	cis	rs6782228	0.527	rs2811491	chr3:128353950	C/A	cg16766828	chr3:128327626	NA	-0.44	-9.81	-0.36	2.95e-21	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs534126	0.736	rs10239488	chr7:142949599	C/G	cg15652212	chr7:142981776	TMEM139	0.46	10.44	0.38	1.12e-23	Cancer;
BRCA	trans	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17712092	chr4:129076599	LARP1B	0.56	13.51	0.47	9.06e-37	Eosinophil percentage of white cells;
BRCA	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07080220	chr10:102295463	HIF1AN	0.49	11.31	0.41	3.76e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs10501293	1.000	rs4755695	chr11:43108344	C/A	cg03447554	chr11:43094025	NA	-0.47	-8.81	-0.33	1.22e-17	Cognitive performance;
BRCA	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg13010199	chr12:38710504	ALG10B	0.5	10.0	0.37	5.7e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg12661370	chr5:149340060	SLC26A2	0.57	8.32	0.31	5.49e-16	HIV-1 control;
BRCA	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg20891558	chr2:74357851	NA	0.51	12.11	0.43	1.53e-30	Gestational age at birth (maternal effect);
BRCA	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.63	10.07	0.37	2.95e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg20503657	chr10:835505	NA	0.56	10.1	0.37	2.43e-22	Response to angiotensin II receptor blocker therapy;
BRCA	trans	rs800082	0.690	rs2118001	chr3:144336609	T/C	cg24215973	chr2:240111563	HDAC4	-0.4	-10.09	-0.37	2.61e-22	Smoking behavior;
BRCA	trans	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg26043149	chr18:55253948	FECH	0.43	9.22	0.34	4.29e-19	Bone mineral density;
BRCA	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg01236616	chr12:121019343	POP5	-1.15	-25.16	-0.71	1.34e-97	Type 1 diabetes nephropathy;
BRCA	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.22	-0.46	1.88e-35	Migraine;Coronary artery disease;
BRCA	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg16339924	chr4:17578868	LAP3	-0.53	-12.68	-0.45	5.22e-33	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6087990	0.735	rs2889703	chr20:31379184	C/A	cg13636640	chr20:31349939	DNMT3B	0.56	16.14	0.54	1.99e-49	Ulcerative colitis;
BRCA	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg13902645	chr11:5959945	NA	-0.54	-10.74	-0.39	7.65e-25	DNA methylation (variation);
BRCA	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.16e-47	Alzheimer's disease (late onset);
BRCA	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.67	-0.61	9.89e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs4650994	1.000	rs4076205	chr1:178534157	G/A	cg05059571	chr16:84539110	KIAA1609	-0.37	-8.38	-0.31	3.45e-16	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg08888203	chr3:10149979	C3orf24	0.66	14.05	0.49	2.73e-39	Alzheimer's disease;
BRCA	trans	rs66887589	0.967	rs13104219	chr4:120438174	G/T	cg25214090	chr10:38739885	LOC399744	0.36	8.17	0.31	1.7e-15	Diastolic blood pressure;
BRCA	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19748678	chr4:122722346	EXOSC9	0.71	14.93	0.51	1.79e-43	Type 2 diabetes;
BRCA	cis	rs35995292	0.500	rs2392606	chr7:38926955	C/A	cg19327137	chr7:38886074	VPS41	0.38	12.69	0.45	4.63e-33	Subjective well-being (multi-trait analysis);
BRCA	trans	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg17145862	chr1:211918768	LPGAT1	0.69	18.15	0.58	1.04e-59	Leprosy;
BRCA	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg01475377	chr6:109611718	NA	-0.6	-16.14	-0.54	1.98e-49	Reticulocyte fraction of red cells;
BRCA	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.11e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.56	0.63	1.72e-72	Electrocardiographic conduction measures;
BRCA	trans	rs9409565	0.658	rs2809768	chr9:97128369	G/A	cg05679027	chr9:99775184	HIATL2	0.43	9.43	0.35	7.23e-20	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg02544614	chr20:61657117	NA	0.28	7.93	0.3	1.01e-14	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg15083037	chr5:83017644	HAPLN1	-0.51	-9.92	-0.37	1.13e-21	Prostate cancer;
BRCA	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg06784218	chr1:46089804	CCDC17	0.46	11.0	0.4	6.86e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg18402987	chr7:1209562	NA	0.66	11.19	0.4	1.1e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs7408868	1.000	rs7254735	chr19:15263385	A/G	cg14696996	chr19:15285081	NOTCH3	0.81	12.89	0.45	5.86e-34	Pulse pressure;
BRCA	cis	rs7011049	1.000	rs11997538	chr8:53832663	A/C	cg26025543	chr8:53854495	NA	0.56	10.31	0.38	3.84e-23	Systolic blood pressure;
BRCA	cis	rs9811920	0.965	rs9849632	chr3:99867211	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.52	12.42	0.44	7.18e-32	Axial length;
BRCA	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg09904177	chr6:26538194	HMGN4	0.47	14.83	0.51	5.48e-43	Intelligence (multi-trait analysis);
BRCA	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg08508325	chr11:3079039	CARS	0.29	8.69	0.32	3.15e-17	Calcium levels;
BRCA	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	8.02	0.3	5.09e-15	Menarche (age at onset);
BRCA	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.79	-12.49	-0.44	3.49e-32	Platelet count;
BRCA	cis	rs2479724	0.811	rs8393	chr6:41757836	C/A	cg17623882	chr6:41773611	USP49	0.33	8.92	0.33	5.04e-18	Menarche (age at onset);
BRCA	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg08999081	chr20:33150536	PIGU	0.5	14.24	0.49	3.57e-40	Coronary artery disease;
BRCA	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg18132916	chr6:79620363	NA	-0.5	-11.5	-0.41	5.87e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg22875332	chr1:76189707	ACADM	0.68	14.73	0.5	1.7e-42	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2617583	0.509	rs10630	chr5:1462720	G/A	cg07148919	chr5:1466943	LPCAT1	-0.37	-7.86	-0.3	1.68e-14	Breast cancer;
BRCA	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-11.16	-0.4	1.58e-26	Colorectal cancer;
BRCA	cis	rs919433	1.000	rs7422899	chr2:198163527	G/C	cg10820045	chr2:198174542	NA	-0.39	-8.22	-0.31	1.14e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.05	-27.04	-0.73	6.42e-108	Ulcerative colitis;
BRCA	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.51	-0.32	1.19e-16	Bipolar disorder;
BRCA	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg05729581	chr11:3078854	CARS	-0.33	-7.89	-0.3	1.31e-14	Longevity;
BRCA	trans	rs208520	1.000	rs208529	chr6:66957549	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-13.59	-0.47	3.96e-37	Exhaled nitric oxide output;
BRCA	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg19156104	chr2:198669113	PLCL1	-0.44	-8.24	-0.31	9.67e-16	Ulcerative colitis;
BRCA	cis	rs7149337	0.780	rs4369569	chr14:51689181	C/G	cg23942311	chr14:51606299	NA	-0.51	-14.42	-0.5	5.39e-41	Cancer;
BRCA	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg23711669	chr6:146136114	FBXO30	0.61	13.85	0.48	2.51e-38	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg22800045	chr5:56110881	MAP3K1	0.45	8.94	0.33	4.13e-18	Initial pursuit acceleration;
BRCA	cis	rs698813	0.674	rs7590224	chr2:44501209	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	8.04	0.3	4.32e-15	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02176678	chr2:219576539	TTLL4	-0.51	-12.98	-0.46	2.41e-34	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.28e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2882667	0.690	rs4835703	chr5:138150737	T/G	cg04439458	chr5:138467593	SIL1	0.35	8.47	0.32	1.63e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg01475377	chr6:109611718	NA	0.6	16.69	0.55	3.45e-52	Reticulocyte fraction of red cells;
BRCA	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg23711669	chr6:146136114	FBXO30	-0.66	-14.74	-0.5	1.46e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4891159	0.790	rs689885	chr18:74110563	T/G	cg24786174	chr18:74118243	ZNF516	0.73	18.22	0.58	4.81e-60	Longevity;
BRCA	cis	rs12541635	1.000	rs12541635	chr8:107090000	C/T	cg10147462	chr8:107024639	NA	-0.3	-8.34	-0.31	4.64e-16	Age of smoking initiation;
BRCA	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.08	-0.43	2.06e-30	Total cholesterol levels;
BRCA	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18404041	chr3:52824283	ITIH1	-0.41	-12.03	-0.43	3.6e-30	Bipolar disorder;
BRCA	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg26587870	chr6:27730563	NA	-0.52	-8.02	-0.3	5.04e-15	Breast cancer;
BRCA	cis	rs724568	0.546	rs737359	chr2:67950714	A/G	cg14046302	chr2:67939758	NA	0.39	10.28	0.38	4.66e-23	Major depressive disorder (broad);
BRCA	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.09	0.49	1.87e-39	Motion sickness;
BRCA	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg07636037	chr3:49044803	WDR6	0.58	8.27	0.31	7.6e-16	Menarche (age at onset);
BRCA	cis	rs2030401	0.604	rs2682427	chr12:123656809	C/T	cg00376283	chr12:123451042	ABCB9	0.35	8.26	0.31	8.28e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs96067	0.805	rs3767705	chr1:36602044	A/T	cg24686825	chr1:36642396	MAP7D1	-0.44	-8.35	-0.31	4.37e-16	Corneal structure;
BRCA	cis	rs7937840	0.581	rs4963286	chr11:61887232	C/A	cg01969543	chr11:61895209	INCENP	-0.39	-8.53	-0.32	1.08e-16	Breast cancer;
BRCA	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.96	0.3	7.77e-15	Depression;
BRCA	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	9.25	0.34	3.19e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg21385522	chr1:16154831	NA	-0.46	-9.96	-0.37	7.89e-22	Systolic blood pressure;
BRCA	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg00686598	chr14:53173677	PSMC6	1.15	16.59	0.55	1.11e-51	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg08470875	chr2:26401718	FAM59B	-0.72	-11.43	-0.41	1.14e-27	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.32	0.49	1.51e-40	Motion sickness;
BRCA	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19346786	chr7:2764209	NA	-0.35	-10.19	-0.37	1.03e-22	Height;
BRCA	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg14458575	chr2:238380390	NA	0.55	12.32	0.44	1.87e-31	Prostate cancer;
BRCA	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg13319975	chr6:146136371	FBXO30	0.41	9.27	0.34	2.82e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19626725	chr5:178986131	RUFY1	0.32	9.64	0.36	1.29e-20	Lung cancer;
BRCA	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg18132916	chr6:79620363	NA	-0.39	-8.09	-0.3	3.05e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs36051895	0.632	rs10758674	chr9:5163645	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-9.07	-0.34	1.5e-18	Pediatric autoimmune diseases;
BRCA	cis	rs9469578	0.681	rs78748610	chr6:33714412	T/C	cg18708504	chr6:33715942	IP6K3	0.7	10.23	0.38	7.52e-23	Phosphorus levels;
BRCA	cis	rs1003719	0.715	rs2156077	chr21:38539357	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.36	-0.49	1e-40	Eye color traits;
BRCA	cis	rs9443189	0.570	rs6931578	chr6:76272310	C/T	cg01950844	chr6:76311363	SENP6	0.86	14.11	0.49	1.52e-39	Prostate cancer;
BRCA	trans	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.66	-0.36	1.04e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9649465	1.000	rs1073670	chr7:123345029	A/C	cg04330084	chr7:123175371	IQUB	-0.3	-8.32	-0.31	5.51e-16	Migraine;
BRCA	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg11663144	chr21:46675770	NA	-0.61	-14.26	-0.49	3.01e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9341808	0.754	rs6907729	chr6:81004922	A/T	cg08355045	chr6:80787529	NA	-0.35	-9.08	-0.34	1.32e-18	Sitting height ratio;
BRCA	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.29	-0.41	4.46e-27	Schizophrenia;
BRCA	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg17063962	chr7:91808500	NA	0.53	12.5	0.44	3.23e-32	Breast cancer;
BRCA	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg18252515	chr7:66147081	NA	-0.82	-11.85	-0.42	1.97e-29	Diabetic kidney disease;
BRCA	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg13256891	chr4:100009986	ADH5	0.54	10.14	0.37	1.61e-22	Smoking initiation;
BRCA	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg08000102	chr2:233561755	GIGYF2	0.61	13.06	0.46	1.02e-34	Coronary artery disease;
BRCA	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg27446573	chr6:127587934	RNF146	0.78	17.3	0.56	2.75e-55	Breast cancer;
BRCA	cis	rs36051895	0.632	rs7040806	chr9:5174782	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-8.82	-0.33	1.04e-17	Pediatric autoimmune diseases;
BRCA	cis	rs72928364	0.929	rs62275197	chr3:100683147	C/T	cg10123952	chr3:100791384	NA	0.53	7.88	0.3	1.39e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.41	-9.37	-0.35	1.2e-19	Longevity;Endometriosis;
BRCA	cis	rs312274	0.630	rs913831	chr12:41227935	T/G	cg17827154	chr12:41323612	CNTN1	0.41	9.95	0.37	8.9e-22	Metabolite levels  (X-11787);
BRCA	cis	rs13046373	0.508	rs2253516	chr21:31993317	C/T	cg24082983	chr21:31802169	KRTAP13-4	0.32	8.05	0.3	3.96e-15	HDL cholesterol;
BRCA	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg03342759	chr3:160939853	NMD3	-0.66	-15.38	-0.52	1.23e-45	Morning vs. evening chronotype;
BRCA	cis	rs12973672	1.000	rs10421599	chr19:35767933	G/A	cg12095397	chr19:35769544	USF2	0.37	8.37	0.31	3.71e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.13	0.37	1.79e-22	Bipolar disorder;
BRCA	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg24130564	chr14:104152367	KLC1	-0.34	-7.94	-0.3	8.91e-15	Bone mineral density;
BRCA	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg24562669	chr7:97807699	LMTK2	0.46	12.25	0.44	3.78e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg08917208	chr2:24149416	ATAD2B	0.52	8.16	0.31	1.77e-15	Lymphocyte counts;
BRCA	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.45	-9.04	-0.34	1.9e-18	Rheumatoid arthritis;
BRCA	cis	rs34779708	0.733	rs61449529	chr10:35543914	T/C	cg03585969	chr10:35415529	CREM	0.45	9.17	0.34	6.54e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg25358565	chr5:93447407	FAM172A	1.16	18.27	0.59	2.58e-60	Diabetic retinopathy;
BRCA	cis	rs4478858	0.775	rs6701861	chr1:31708125	A/C	cg00250761	chr1:31883323	NA	-0.32	-8.55	-0.32	9.16e-17	Alcohol dependence;
BRCA	cis	rs9796	0.576	rs13329511	chr15:41299121	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.41	-8.25	-0.31	8.85e-16	Menopause (age at onset);
BRCA	cis	rs36051895	0.589	rs4560849	chr9:5203866	C/G	cg02405213	chr9:5042618	JAK2	-0.44	-8.27	-0.31	7.94e-16	Pediatric autoimmune diseases;
BRCA	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg23950597	chr19:37808831	NA	-0.75	-13.09	-0.46	7.64e-35	Coronary artery calcification;
BRCA	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.9	0.4	1.73e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg24562669	chr7:97807699	LMTK2	0.47	12.47	0.44	4.08e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg27432699	chr2:27873401	GPN1	0.46	9.7	0.36	7.89e-21	Oral cavity cancer;
BRCA	cis	rs11690935	0.550	rs55653103	chr2:172861816	T/C	cg13550731	chr2:172543902	DYNC1I2	0.5	12.21	0.43	5.77e-31	Schizophrenia;
BRCA	cis	rs16854884	0.657	rs1025984	chr3:143756187	C/G	cg06585982	chr3:143692056	C3orf58	-0.39	-8.45	-0.32	1.97e-16	Economic and political preferences (feminism/equality);
BRCA	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.74	16.27	0.54	4.62e-50	Lymphocyte counts;
BRCA	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg08999081	chr20:33150536	PIGU	0.38	8.73	0.33	2.29e-17	Coronary artery disease;
BRCA	trans	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg26043149	chr18:55253948	FECH	0.4	8.71	0.33	2.63e-17	Bone mineral density;
BRCA	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg20701182	chr2:24300061	SF3B14	0.58	9.0	0.34	2.55e-18	Lymphocyte counts;
BRCA	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg23649088	chr2:200775458	C2orf69	-0.56	-8.69	-0.32	3.13e-17	Schizophrenia;
BRCA	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg26384229	chr12:38710491	ALG10B	0.59	13.53	0.47	7.42e-37	Morning vs. evening chronotype;
BRCA	cis	rs4588572	0.644	rs10942856	chr5:77746199	A/G	cg11547950	chr5:77652471	NA	0.45	8.65	0.32	4.12e-17	Triglycerides;
BRCA	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg26061582	chr7:22766209	IL6	0.38	8.85	0.33	8.21e-18	Lung cancer;
BRCA	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.06	-0.34	1.6e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03517284	chr6:25882590	NA	-0.78	-18.61	-0.59	4.43e-62	Urate levels;
BRCA	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg01017244	chr2:74357527	NA	0.58	13.79	0.48	4.85e-38	Gestational age at birth (maternal effect);
BRCA	cis	rs757081	0.667	rs7108067	chr11:17200220	G/A	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.67	-0.32	3.54e-17	Systolic blood pressure;
BRCA	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg14349672	chr11:133703707	NA	0.38	8.92	0.33	5.06e-18	Childhood ear infection;
BRCA	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg02551604	chr5:131831745	NA	0.39	14.96	0.51	1.37e-43	Asthma (sex interaction);
BRCA	cis	rs4409675	0.576	rs11247706	chr1:28213983	G/C	cg23691781	chr1:28212827	C1orf38	0.33	11.27	0.41	5.42e-27	Corneal astigmatism;
BRCA	cis	rs7950696	1	rs7950696	chr11:47481533	T/C	cg20307385	chr11:47447363	PSMC3	0.45	10.11	0.37	2.07e-22	Platelet count;
BRCA	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg04586622	chr2:25135609	ADCY3	0.45	10.96	0.4	9.9e-26	Body mass index;
BRCA	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg19920283	chr7:105172520	RINT1	0.59	9.43	0.35	7.47e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.25	0.34	3.42e-19	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-9.73	-0.36	5.76e-21	Joint mobility (Beighton score);
BRCA	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.17	0.31	1.67e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2191566	0.576	rs420355	chr19:44495325	C/T	cg20607764	chr19:44506953	ZNF230	0.37	8.03	0.3	4.64e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs113835537	0.529	rs2305533	chr11:66298623	A/C	cg24851651	chr11:66362959	CCS	0.48	8.72	0.33	2.46e-17	Airway imaging phenotypes;
BRCA	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.69	10.52	0.38	5.55e-24	Mean platelet volume;
BRCA	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg03934865	chr2:198174659	NA	-0.38	-8.26	-0.31	8.11e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7598759	0.679	rs6437018	chr2:232327691	A/C	cg19187155	chr2:232395269	NMUR1	0.37	7.92	0.3	1.04e-14	Noise-induced hearing loss;
BRCA	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg09184832	chr6:79620586	NA	-0.49	-10.52	-0.38	5.45e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs9487051	0.768	rs458185	chr6:109524074	A/G	cg21918786	chr6:109611834	NA	-0.35	-9.26	-0.34	3.09e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.9e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg27347728	chr4:17578864	LAP3	0.45	8.84	0.33	9.43e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10267417	0.603	rs10233354	chr7:19895372	C/T	cg05791153	chr7:19748676	TWISTNB	0.47	9.04	0.34	1.9e-18	Night sleep phenotypes;
BRCA	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg26384229	chr12:38710491	ALG10B	0.74	17.65	0.57	4.53e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs2249625	0.545	rs9791273	chr6:72891016	G/T	cg18830697	chr6:72922368	RIMS1	0.66	14.77	0.5	1.06e-42	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	19.37	0.61	4.02e-66	Platelet count;
BRCA	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg21918786	chr6:109611834	NA	0.45	12.09	0.43	1.92e-30	Reticulocyte fraction of red cells;
BRCA	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg22834771	chr12:69754056	YEATS4	-0.43	-10.63	-0.39	2.04e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.89	0.33	6.41e-18	Ovarian reserve;
BRCA	cis	rs7903847	0.642	rs12359257	chr10:99136359	A/T	cg20016023	chr10:99160130	RRP12	-0.26	-8.04	-0.3	4.29e-15	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.41	-0.32	2.73e-16	Retinal vascular caliber;
BRCA	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg04455712	chr21:45112962	RRP1B	-0.42	-10.84	-0.39	2.88e-25	Mean corpuscular volume;
BRCA	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg03146154	chr1:46216737	IPP	0.46	10.38	0.38	2.03e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg08888203	chr3:10149979	C3orf24	0.65	11.93	0.43	8.91e-30	Alzheimer's disease;
BRCA	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg15103426	chr22:29168792	CCDC117	-0.46	-11.32	-0.41	3.43e-27	Red cell distribution width;
BRCA	cis	rs4845875	0.513	rs198397	chr1:11883332	A/G	cg24844545	chr1:11908347	NPPA	-0.31	-8.29	-0.31	6.59e-16	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs6087990	0.966	rs1883730	chr20:31337487	T/A	cg13636640	chr20:31349939	DNMT3B	0.77	25.09	0.7	3.37e-97	Ulcerative colitis;
BRCA	cis	rs7561273	0.586	rs7589717	chr2:24357463	G/A	cg04809136	chr2:24300158	SF3B14	-0.4	-8.97	-0.33	3.37e-18	Quantitative traits;
BRCA	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.66	-18.37	-0.59	7.45e-61	Electrocardiographic conduction measures;
BRCA	cis	rs1555322	0.530	rs6060347	chr20:33874151	A/G	cg03689076	chr20:33865952	NA	0.44	8.05	0.3	4.01e-15	Attention deficit hyperactivity disorder;
BRCA	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg02734326	chr4:10020555	SLC2A9	0.42	9.07	0.34	1.43e-18	Bone mineral density;
BRCA	cis	rs708547	0.836	rs1612191	chr4:57724320	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.48	-10.81	-0.39	3.96e-25	Response to bleomycin (chromatid breaks);
BRCA	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg14228332	chr4:119757509	SEC24D	0.68	8.1	0.31	2.78e-15	Cannabis dependence symptom count;
BRCA	cis	rs7520050	0.966	rs6701614	chr1:46309420	G/C	cg24296786	chr1:45957014	TESK2	0.44	9.9	0.36	1.37e-21	Red blood cell count;Reticulocyte count;
BRCA	trans	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg15704280	chr7:45808275	SEPT13	0.52	7.86	0.3	1.62e-14	Axial length;
BRCA	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg14675211	chr2:100938903	LONRF2	0.44	9.74	0.36	5.6e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.27	-0.38	5.25e-23	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.22e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg22800045	chr5:56110881	MAP3K1	0.73	13.44	0.47	1.97e-36	Initial pursuit acceleration;
BRCA	cis	rs10484885	0.878	rs111664889	chr6:90566427	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.77	-9.47	-0.35	5.11e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4478858	0.735	rs6670067	chr1:31842947	C/T	cg00250761	chr1:31883323	NA	-0.32	-8.28	-0.31	7e-16	Alcohol dependence;
BRCA	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg11789530	chr4:8429930	ACOX3	-0.55	-12.62	-0.45	9.65e-33	Response to antineoplastic agents;
BRCA	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg11271282	chr2:238384023	NA	-0.43	-7.92	-0.3	1.07e-14	Prostate cancer;
BRCA	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.53	-7.88	-0.3	1.46e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg08085267	chr17:45401833	C17orf57	0.67	14.61	0.5	6.47e-42	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg10253484	chr15:75165896	SCAMP2	-0.52	-9.72	-0.36	6.6e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.54	0.59	9.68e-62	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs17384381	1.000	rs12743049	chr1:85897386	G/A	cg16011679	chr1:85725395	C1orf52	0.53	8.26	0.31	8.7e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.85	18.9	0.6	1.31e-63	Smoking behavior;
BRCA	cis	rs17401966	1.000	rs12130220	chr1:10359944	T/G	cg15208524	chr1:10270712	KIF1B	0.37	8.27	0.31	7.77e-16	Hepatocellular carcinoma;
BRCA	cis	rs7553864	0.614	rs1886634	chr1:87614821	C/T	cg17420885	chr1:87600446	LOC339524	0.39	7.83	0.3	1.97e-14	Smoking behavior;
BRCA	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-12.26	-0.44	3.58e-31	Gut microbiome composition (summer);
BRCA	cis	rs7149337	0.805	rs71422017	chr14:51612417	A/T	cg23942311	chr14:51606299	NA	0.45	13.31	0.47	7.73e-36	Cancer;
BRCA	trans	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg25214090	chr10:38739885	LOC399744	0.44	10.27	0.38	5.09e-23	Corneal astigmatism;
BRCA	cis	rs10501293	0.956	rs11037235	chr11:43100381	G/C	cg03447554	chr11:43094025	NA	-0.46	-8.64	-0.32	4.47e-17	Cognitive performance;
BRCA	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg17330251	chr7:94953956	PON1	-0.42	-8.87	-0.33	7.37e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg18132916	chr6:79620363	NA	-0.48	-10.9	-0.4	1.71e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg25214090	chr10:38739885	LOC399744	0.54	12.59	0.45	1.29e-32	Corneal astigmatism;
BRCA	cis	rs1568889	0.667	rs7123947	chr11:28399908	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	9.78	0.36	3.92e-21	Bipolar disorder;
BRCA	cis	rs13053817	0.948	rs13058415	chr22:29848481	G/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.48	-8.93	-0.33	4.52e-18	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs1799922	0.693	rs339088	chr7:128422986	A/G	cg02354431	chr7:128423266	NA	-0.36	-9.31	-0.35	1.98e-19	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
BRCA	cis	rs9287719	0.649	rs10188373	chr2:10718802	A/G	cg00105475	chr2:10696890	NA	0.41	9.18	0.34	5.97e-19	Prostate cancer;
BRCA	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg17628894	chr11:804452	LRDD	-0.25	-8.04	-0.3	4.43e-15	Breast cancer;
BRCA	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg20307385	chr11:47447363	PSMC3	0.74	16.8	0.55	9.88e-53	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg20887711	chr4:1340912	KIAA1530	0.74	16.13	0.54	2.46e-49	Longevity;
BRCA	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg21132104	chr15:45694354	SPATA5L1	0.74	16.29	0.54	3.85e-50	Homoarginine levels;
BRCA	cis	rs9403521	1.000	rs12208927	chr6:143993634	A/G	cg18240653	chr6:144019428	PHACTR2	-0.41	-8.18	-0.31	1.53e-15	Obesity-related traits;
BRCA	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs10504073	0.525	rs10081464	chr8:50058707	A/G	cg00325661	chr8:49890786	NA	0.35	9.59	0.35	1.95e-20	Blood metabolite ratios;
BRCA	cis	rs9443189	0.570	rs569731	chr6:76357593	G/A	cg01950844	chr6:76311363	SENP6	0.83	13.39	0.47	3.38e-36	Prostate cancer;
BRCA	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg09074113	chr2:20870087	GDF7	-0.33	-7.96	-0.3	7.69e-15	Abdominal aortic aneurysm;
BRCA	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg09359103	chr1:154839909	KCNN3	-0.56	-14.62	-0.5	5.84e-42	Prostate cancer;
BRCA	cis	rs13102973	0.965	rs9998499	chr4:135869362	G/A	cg14419869	chr4:135874104	NA	-0.58	-12.84	-0.45	1.02e-33	Subjective well-being;
BRCA	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg00684032	chr4:1343700	KIAA1530	0.32	8.12	0.31	2.47e-15	Obesity-related traits;
BRCA	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	11.47	0.41	7.63e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg00757033	chr12:89920650	WDR51B	0.54	11.1	0.4	2.76e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7149337	0.836	rs11622116	chr14:51670744	C/T	cg23942311	chr14:51606299	NA	0.42	12.02	0.43	3.96e-30	Cancer;
BRCA	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg21775007	chr8:11205619	TDH	-0.63	-14.02	-0.49	3.89e-39	Neuroticism;
BRCA	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03264133	chr6:25882463	NA	0.7	16.06	0.54	5.36e-49	Blood metabolite levels;
BRCA	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06022373	chr22:39101656	GTPBP1	0.74	18.2	0.58	5.93e-60	Menopause (age at onset);
BRCA	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg21775007	chr8:11205619	TDH	0.65	12.84	0.45	1.01e-33	Retinal vascular caliber;
BRCA	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.84e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.18	-0.31	1.56e-15	Aortic root size;
BRCA	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg06618935	chr21:46677482	NA	-0.37	-7.94	-0.3	9e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg08999081	chr20:33150536	PIGU	-0.47	-12.95	-0.46	3.13e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.21	-0.37	9.22e-23	Psoriasis;
BRCA	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg20019720	chr6:154832845	CNKSR3	0.56	13.11	0.46	5.95e-35	Lipoprotein (a) levels;
BRCA	cis	rs2979489	0.945	rs11992441	chr8:30313649	A/G	cg26383811	chr8:30366931	RBPMS	0.5	11.46	0.41	8.95e-28	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
BRCA	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10789491	1.000	rs1440487	chr1:47167075	C/T	cg15501359	chr1:47185051	KIAA0494	-0.64	-18.03	-0.58	4.51e-59	Response to hepatitis C treatment;
BRCA	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03934478	chr11:495069	RNH1	0.82	11.93	0.43	9.54e-30	Body mass index;
BRCA	cis	rs9341808	0.935	rs4706113	chr6:80839315	C/T	cg08355045	chr6:80787529	NA	0.32	8.15	0.31	1.92e-15	Sitting height ratio;
BRCA	cis	rs4363385	0.720	rs1134220	chr1:152976306	T/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.1	-0.34	1.11e-18	Inflammatory skin disease;
BRCA	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02187348	chr16:89574699	SPG7	0.5	12.38	0.44	1e-31	Multiple myeloma (IgH translocation);
BRCA	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg19748678	chr4:122722346	EXOSC9	0.42	8.75	0.33	1.89e-17	Type 2 diabetes;
BRCA	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.78e-21	Total body bone mineral density;
BRCA	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg11952622	chr19:58962976	ZNF324B	0.42	8.68	0.32	3.22e-17	Uric acid clearance;
BRCA	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg25427524	chr10:38739819	LOC399744	0.6	13.69	0.48	1.35e-37	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	11.39	0.41	1.66e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11764359	chr7:65958608	NA	0.8	19.53	0.61	6.05e-67	Aortic root size;
BRCA	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg11952622	chr19:58962976	ZNF324B	0.51	10.65	0.39	1.69e-24	Uric acid clearance;
BRCA	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg26597838	chr10:835615	NA	1.29	21.77	0.65	4.84e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg09060608	chr5:178986726	RUFY1	-0.44	-10.42	-0.38	1.44e-23	Lung cancer;
BRCA	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs12210905	0.688	rs72843177	chr6:27367414	A/G	cg08851530	chr6:28072375	NA	0.84	8.27	0.31	7.64e-16	Hip circumference adjusted for BMI;
BRCA	trans	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg02030672	chr11:45687055	CHST1	-0.41	-9.15	-0.34	7.78e-19	Obesity-related traits;
BRCA	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg08213375	chr14:104286397	PPP1R13B	0.66	18.7	0.59	1.49e-62	Schizophrenia;
BRCA	trans	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg25206134	chr2:45395956	NA	0.52	8.78	0.33	1.5e-17	Bipolar disorder;
BRCA	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg01689657	chr7:91764605	CYP51A1	0.24	8.62	0.32	5.28e-17	Breast cancer;
BRCA	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.51	0.38	5.98e-24	IgG glycosylation;
BRCA	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg23719950	chr11:63933701	MACROD1	-0.54	-9.05	-0.34	1.76e-18	Attention deficit hyperactivity disorder;
BRCA	cis	rs9649213	0.614	rs12539761	chr7:98013839	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.58	-14.83	-0.51	5.42e-43	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs921968	0.565	rs6436082	chr2:219639430	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-10.93	-0.4	1.27e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7336332	0.598	rs1885988	chr13:28010262	C/T	cg22138327	chr13:27999177	GTF3A	-0.59	-10.29	-0.38	4.23e-23	Weight;
BRCA	cis	rs1003719	0.667	rs2835606	chr21:38490851	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.52	10.91	0.4	1.56e-25	Eye color traits;
BRCA	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg26816564	chr1:7831052	VAMP3	-0.63	-11.79	-0.42	3.48e-29	Inflammatory bowel disease;
BRCA	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg07080220	chr10:102295463	HIF1AN	0.6	13.03	0.46	1.44e-34	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg26384229	chr12:38710491	ALG10B	0.75	16.93	0.56	2.16e-53	Bladder cancer;
BRCA	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg02079420	chr8:82753780	SNX16	0.31	8.33	0.31	5.07e-16	Diastolic blood pressure;
BRCA	cis	rs1499972	0.941	rs62264774	chr3:117647906	C/G	cg07612923	chr3:117604196	NA	0.6	8.11	0.31	2.57e-15	Schizophrenia;
BRCA	trans	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg06521331	chr12:34319734	NA	-0.43	-7.82	-0.3	2.16e-14	Bladder cancer;
BRCA	cis	rs701145	0.585	rs398512	chr3:153909988	T/C	cg17054900	chr3:154042577	DHX36	0.57	9.59	0.35	1.96e-20	Coronary artery disease;
BRCA	cis	rs7301826	0.571	rs4759788	chr12:131296314	T/C	cg11011512	chr12:131303247	STX2	0.5	12.92	0.46	4.11e-34	Plasma plasminogen activator levels;
BRCA	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg20503657	chr10:835505	NA	1.01	17.8	0.58	7.03e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs6815814	0.861	rs28690449	chr4:38789132	C/T	cg06935464	chr4:38784597	TLR10	0.49	10.06	0.37	3.39e-22	Breast cancer;
BRCA	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg06808227	chr14:105710500	BRF1	-0.8	-16.05	-0.54	6.1e-49	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg24675658	chr1:53192096	ZYG11B	-0.64	-14.07	-0.49	2.43e-39	Monocyte count;
BRCA	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg11530693	chr1:120165357	ZNF697	0.61	14.5	0.5	2.07e-41	Systemic lupus erythematosus;
BRCA	cis	rs965469	1.000	rs6051792	chr20:3343519	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-10.52	-0.38	5.66e-24	IFN-related cytopenia;
BRCA	trans	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.4	8.13	0.31	2.22e-15	Menarche (age at onset);
BRCA	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-12.86	-0.45	8e-34	Gut microbiome composition (summer);
BRCA	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06108461	chr20:60628389	TAF4	-1.01	-23.06	-0.67	4.48e-86	Body mass index;
BRCA	trans	rs61931739	1.000	rs1852223	chr12:34013251	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-9.28	-0.34	2.5e-19	Morning vs. evening chronotype;
BRCA	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-12.21	-0.43	5.77e-31	Tonsillectomy;
BRCA	cis	rs4664304	0.966	rs925407	chr2:160767502	A/C	cg18514922	chr2:160761262	LY75	-0.39	-8.96	-0.33	3.62e-18	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg26395211	chr5:140044315	WDR55	0.35	7.95	0.3	8.39e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg01689657	chr7:91764605	CYP51A1	-0.22	-7.99	-0.3	6.12e-15	Breast cancer;
BRCA	cis	rs36051895	0.695	rs7851556	chr9:5022807	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-8.55	-0.32	8.91e-17	Pediatric autoimmune diseases;
BRCA	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg13319975	chr6:146136371	FBXO30	-0.41	-9.4	-0.35	9.35e-20	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-10.06	-0.37	3.2800000000000002e-22	Endometrial cancer;
BRCA	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg16850897	chr7:100343110	ZAN	-0.49	-11.09	-0.4	2.81e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg09467607	chr2:36825704	FEZ2	0.62	15.18	0.51	1.1e-44	Height;
BRCA	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg25319279	chr11:5960081	NA	-0.4	-8.2	-0.31	1.37e-15	DNA methylation (variation);
BRCA	cis	rs7646881	1.000	rs7646881	chr3:158453279	C/A	cg19483011	chr3:158453295	NA	-0.49	-9.32	-0.35	1.81e-19	Tetralogy of Fallot;
BRCA	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg02297831	chr4:17616191	MED28	0.35	8.17	0.31	1.62e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs919433	0.647	rs13404366	chr2:198522632	A/G	cg00792783	chr2:198669748	PLCL1	0.37	8.47	0.32	1.67e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg16049864	chr8:95962084	TP53INP1	-0.39	-9.13	-0.34	9.11e-19	Type 2 diabetes;
BRCA	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.87e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg18252515	chr7:66147081	NA	0.91	13.02	0.46	1.61e-34	Diabetic kidney disease;
BRCA	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg12219531	chr12:120966889	COQ5	-0.55	-11.71	-0.42	7.9e-29	High light scatter reticulocyte count;
BRCA	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.52e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg16576597	chr16:28551801	NUPR1	0.29	8.19	0.31	1.4e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.37	-9.24	-0.34	3.75e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-32.47	-0.79	2.47e-137	Height;
BRCA	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.31	10.07	0.37	3.1e-22	Electroencephalogram traits;
BRCA	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02176678	chr2:219576539	TTLL4	0.47	12.16	0.43	9.04e-31	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6028335	0.610	rs12626028	chr20:37553900	G/C	cg16355469	chr20:37678765	NA	0.45	8.1	0.31	2.84e-15	Alcohol and nicotine co-dependence;
BRCA	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg09307838	chr4:120376055	NA	0.72	15.28	0.52	3.69e-45	Corneal astigmatism;
BRCA	cis	rs6684428	0.706	rs10493183	chr1:56333648	T/C	cg11651538	chr1:56320950	NA	-0.49	-8.47	-0.32	1.69e-16	Airflow obstruction;
BRCA	cis	rs6782228	0.675	rs6806687	chr3:128391789	C/T	cg16766828	chr3:128327626	NA	0.4	9.21	0.34	4.49e-19	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.4e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-15.85	-0.53	6.02e-48	Systemic lupus erythematosus;
BRCA	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg10621924	chr7:39171070	POU6F2	0.38	7.89	0.3	1.27e-14	IgG glycosylation;
BRCA	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg14196790	chr5:131705035	SLC22A5	-0.42	-10.16	-0.37	1.39e-22	Breast cancer;Mosquito bite size;
BRCA	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg20283391	chr11:68216788	NA	-0.43	-8.38	-0.31	3.31e-16	Total body bone mineral density;
BRCA	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26314531	chr2:26401878	FAM59B	-0.89	-15.41	-0.52	8.82e-46	Gut microbiome composition (summer);
BRCA	cis	rs17253792	0.822	rs75232282	chr14:56067290	G/C	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08859206	chr1:53392774	SCP2	-0.6	-13.09	-0.46	7.75e-35	Monocyte count;
BRCA	cis	rs11608355	0.545	rs34737994	chr12:109901621	C/T	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs6973256	0.897	rs2066924	chr7:133338462	C/A	cg07491979	chr7:133331646	EXOC4	-0.39	-9.01	-0.34	2.41e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg08000102	chr2:233561755	GIGYF2	0.64	13.8	0.48	4.01e-38	Coronary artery disease;
BRCA	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg19628046	chr18:33552617	C18orf21	0.54	11.15	0.4	1.69e-26	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg05863683	chr7:1912471	MAD1L1	-0.35	-8.28	-0.31	7.23e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg02153584	chr22:29168773	CCDC117	0.51	10.72	0.39	8.74e-25	Lymphocyte counts;
BRCA	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg10932868	chr11:921992	NA	0.49	12.59	0.45	1.21e-32	Alzheimer's disease (late onset);
BRCA	cis	rs524281	0.861	rs11227403	chr11:65858428	T/C	cg16950941	chr11:66035639	RAB1B	-0.38	-8.05	-0.3	4.15e-15	Electroencephalogram traits;
BRCA	cis	rs7524258	0.867	rs916392	chr1:7271930	T/C	cg07173049	chr1:7289937	CAMTA1	0.55	13.21	0.46	2.04e-35	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs6546550	0.835	rs13002091	chr2:70118388	C/T	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.55	-0.42	3.72e-28	Prevalent atrial fibrillation;
BRCA	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-11.85	-0.42	2e-29	Tonsillectomy;
BRCA	trans	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg19862616	chr7:65841803	NCRNA00174	0.83	27.27	0.73	3.26e-109	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.44	9.99	0.37	6.37e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg06627628	chr2:24431161	ITSN2	-0.56	-8.87	-0.33	7.52e-18	Lymphocyte counts;
BRCA	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.31	-0.35	2.04e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs57590327	0.555	rs3772909	chr3:81707264	T/C	cg07356753	chr3:81810745	GBE1	-0.43	-9.89	-0.36	1.43e-21	Extraversion;
BRCA	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg20283391	chr11:68216788	NA	-0.46	-9.19	-0.34	5.49e-19	Total body bone mineral density;
BRCA	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg01877450	chr7:97915802	BRI3	-0.37	-8.29	-0.31	6.85e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg03213289	chr20:61660250	NA	0.62	16.22	0.54	8.55e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs427394	1.000	rs182135	chr5:6747453	G/A	cg10857441	chr5:6722123	POLS	-0.31	-10.33	-0.38	3.14e-23	Menopause (age at onset);
BRCA	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.31	0.49	1.68e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg01877450	chr7:97915802	BRI3	-0.36	-8.15	-0.31	1.99e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9393777	0.502	rs3823427	chr6:27256346	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.31	-0.31	5.87e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg24675658	chr1:53192096	ZYG11B	0.68	14.69	0.5	2.61e-42	Monocyte count;
BRCA	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg08859206	chr1:53392774	SCP2	0.49	10.84	0.39	3e-25	Monocyte count;
BRCA	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	8.51	0.32	1.19e-16	Mean platelet volume;
BRCA	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15506890	chr2:3487001	NA	-0.58	-13.21	-0.46	2.15e-35	Neurofibrillary tangles;
BRCA	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.09	0.49	1.96e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.65	0.32	4.01e-17	Rheumatoid arthritis;
BRCA	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg03585969	chr10:35415529	CREM	0.56	11.6	0.42	2.32e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6066835	1.000	rs2223684	chr20:47354880	A/C	cg18078177	chr20:47281410	PREX1	0.65	8.41	0.32	2.76e-16	Multiple myeloma;
BRCA	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg03060546	chr3:49711283	APEH	-0.51	-10.03	-0.37	4.39e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg06784218	chr1:46089804	CCDC17	0.5	11.89	0.43	1.4e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs28493229	0.708	rs73546845	chr19:41158717	C/T	cg21869046	chr19:41225005	ITPKC	0.32	9.17	0.34	6.31e-19	Kawasaki disease;
BRCA	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg01017244	chr2:74357527	NA	0.6	13.49	0.47	1.11e-36	Gestational age at birth (maternal effect);
BRCA	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18876405	chr7:65276391	NA	-0.57	-13.62	-0.47	3e-37	Aortic root size;
BRCA	cis	rs2479724	0.846	rs2254474	chr6:41843044	T/G	cg17623882	chr6:41773611	USP49	-0.34	-9.13	-0.34	8.98e-19	Menarche (age at onset);
BRCA	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg11752832	chr7:134001865	SLC35B4	0.53	13.77	0.48	5.7800000000000005e-38	Mean platelet volume;
BRCA	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg15103426	chr22:29168792	CCDC117	-0.49	-11.26	-0.41	5.71e-27	Lymphocyte counts;
BRCA	cis	rs7580658	0.545	rs13001179	chr2:127952193	A/C	cg16751203	chr2:127950803	CYP27C1	0.28	8.19	0.31	1.44e-15	Protein C levels;
BRCA	cis	rs11718455	0.921	rs35872933	chr3:44028515	T/G	cg08738300	chr3:44038990	NA	0.47	8.82	0.33	1.12e-17	Coronary artery disease;
BRCA	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg06627628	chr2:24431161	ITSN2	-0.79	-15.05	-0.51	5.04e-44	Asthma;
BRCA	trans	rs1325195	0.920	rs2816183	chr1:179116474	C/G	cg11624085	chr17:8464688	MYH10	0.26	7.98	0.3	7.01e-15	IgE grass sensitization;
BRCA	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg00105475	chr2:10696890	NA	0.44	10.25	0.38	6.46e-23	Prostate cancer;
BRCA	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg11833968	chr6:79620685	NA	-0.4	-9.05	-0.34	1.75e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg07952391	chr2:88470173	THNSL2	0.67	9.2	0.34	5.22e-19	Plasma clusterin levels;
BRCA	cis	rs2282802	0.651	rs10060071	chr5:139599097	T/C	cg26211634	chr5:139558579	C5orf32	0.34	8.41	0.32	2.75e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs3936840	0.565	rs8011721	chr14:102986388	C/G	cg18135206	chr14:102964638	TECPR2	-0.49	-9.96	-0.37	7.88e-22	Plateletcrit;
BRCA	cis	rs62229266	0.835	rs998384	chr21:37445526	G/C	cg12218747	chr21:37451666	NA	-0.38	-8.9	-0.33	5.67e-18	Mitral valve prolapse;
BRCA	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.66	16.99	0.56	1.09e-53	Fuchs's corneal dystrophy;
BRCA	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg23711669	chr6:146136114	FBXO30	-0.79	-18.82	-0.6	3.37e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg17173187	chr15:85201210	NMB	0.42	8.85	0.33	8.83e-18	Schizophrenia;
BRCA	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg07148914	chr20:33460835	GGT7	0.38	8.62	0.32	5.1e-17	Height;
BRCA	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.41	8.98	0.33	3.01e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12667521	chr19:29218732	NA	0.47	8.71	0.33	2.55e-17	Methadone dose in opioid dependence;
BRCA	cis	rs7246657	0.722	rs2972430	chr19:38182111	C/T	cg23950597	chr19:37808831	NA	0.51	8.69	0.33	2.96e-17	Coronary artery calcification;
BRCA	cis	rs11608355	0.515	rs4766605	chr12:109895636	C/A	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg18230493	chr5:56204884	C5orf35	-0.75	-14.81	-0.51	7.42e-43	Initial pursuit acceleration;
BRCA	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.59	-10.38	-0.38	1.89e-23	Gut microbiome composition (summer);
BRCA	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	12.34	0.44	1.53e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg25319279	chr11:5960081	NA	-0.43	-8.39	-0.32	3e-16	DNA methylation (variation);
BRCA	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg14675211	chr2:100938903	LONRF2	0.51	11.41	0.41	1.39e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg08888203	chr3:10149979	C3orf24	0.67	14.09	0.49	1.93e-39	Alzheimer's disease;
BRCA	cis	rs6714710	0.580	rs35564270	chr2:98602165	A/G	cg26665480	chr2:98280029	ACTR1B	0.59	13.43	0.47	2.03e-36	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs28735056	0.967	rs11660941	chr18:77630600	G/C	cg20368463	chr18:77673604	PQLC1	-0.34	-8.11	-0.31	2.67e-15	Schizophrenia;
BRCA	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg13256891	chr4:100009986	ADH5	0.5	10.49	0.38	7.61e-24	Alcohol dependence;
BRCA	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.67	13.7	0.48	1.16e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10911363	0.592	rs2782411	chr1:183476929	G/A	cg09173681	chr1:183549694	NCF2	0.53	11.12	0.4	2.19e-26	Systemic lupus erythematosus;
BRCA	cis	rs11997175	0.704	rs11775534	chr8:33695232	G/A	ch.8.33884649F	chr8:33765107	NA	0.35	8.32	0.31	5.3e-16	Body mass index;
BRCA	trans	rs11976180	1.000	rs1533268	chr7:143766358	A/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.26	-0.31	8.66e-16	Obesity-related traits;
BRCA	cis	rs41005	1.000	rs41007	chr2:8109043	A/G	cg03155496	chr2:8117019	LOC339788	-0.59	-15.95	-0.53	1.88e-48	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs4722585	0.533	rs2049843	chr7:26196963	G/A	cg07876897	chr7:26191696	NFE2L3	0.4	8.64	0.32	4.59e-17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
BRCA	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.94	-0.3	8.88e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
BRCA	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg00383909	chr3:49044727	WDR6	0.86	12.51	0.44	2.83e-32	Blood protein levels;
BRCA	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg05347473	chr6:146136440	FBXO30	0.58	11.0	0.4	6.64e-26	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6973256	0.569	rs6944149	chr7:133381365	A/C	cg07491979	chr7:133331646	EXOC4	0.35	7.93	0.3	9.85e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17712092	chr4:129076599	LARP1B	0.56	13.65	0.48	2.06e-37	Eosinophil percentage of white cells;
BRCA	trans	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg00938859	chr5:1591904	SDHAP3	0.66	9.1	0.34	1.14e-18	Breast cancer;
BRCA	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg08470875	chr2:26401718	FAM59B	0.76	11.99	0.43	5.11e-30	Gut microbiome composition (summer);
BRCA	cis	rs7851660	0.548	rs1156850	chr9:100573164	G/A	cg13688889	chr9:100608707	NA	-0.5	-11.4	-0.41	1.55e-27	Strep throat;
BRCA	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg15017067	chr4:17643749	FAM184B	0.27	8.07	0.3	3.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg14784868	chr12:69753453	YEATS4	0.46	8.96	0.33	3.63e-18	Response to diuretic therapy;
BRCA	cis	rs17818399	0.645	rs35870739	chr2:46784231	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.61	11.22	0.41	8.22e-27	Height;
BRCA	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg06238570	chr21:40685208	BRWD1	-0.41	-8.42	-0.32	2.55e-16	Menarche (age at onset);
BRCA	cis	rs2637266	0.935	rs2583049	chr10:78403962	T/C	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg08755490	chr11:65554678	OVOL1	0.52	10.88	0.4	2.11e-25	Acne (severe);
BRCA	trans	rs877282	0.583	rs11253425	chr10:815173	G/A	cg22713356	chr15:30763199	NA	1.03	17.01	0.56	8.9e-54	Uric acid levels;
BRCA	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-13.95	-0.48	8.1e-39	Total cholesterol levels;
BRCA	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg13010199	chr12:38710504	ALG10B	0.51	10.14	0.37	1.62e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7635838	0.617	rs184700	chr3:11293061	A/G	cg00170343	chr3:11313890	ATG7	0.4	8.1	0.31	2.77e-15	HDL cholesterol;
BRCA	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg23950597	chr19:37808831	NA	-0.62	-11.45	-0.41	9.99e-28	Coronary artery calcification;
BRCA	cis	rs58785573	0.624	rs2126526	chr4:38618689	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.45	9.28	0.34	2.7e-19	Lymphocyte percentage of white cells;
BRCA	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg01256987	chr12:42539512	GXYLT1	-0.57	-11.69	-0.42	9.75e-29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg07636037	chr3:49044803	WDR6	0.93	26.85	0.73	6.92e-107	Parkinson's disease;
BRCA	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg26597838	chr10:835615	NA	-0.99	-18.27	-0.59	2.66e-60	Eosinophil percentage of granulocytes;
BRCA	trans	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg05926928	chr17:57297772	GDPD1	-0.57	-8.83	-0.33	1.02e-17	Opioid sensitivity;
BRCA	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00149659	chr3:10157352	C3orf10	0.65	9.86	0.36	1.84e-21	Alzheimer's disease;
BRCA	trans	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.14	0.31	2.07e-15	Corneal astigmatism;
BRCA	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg18876405	chr7:65276391	NA	-0.68	-17.96	-0.58	1.09e-58	Corneal structure;
BRCA	cis	rs11051970	0.879	rs2171373	chr12:32575777	C/T	cg02745156	chr12:32552066	NA	0.27	8.99	0.33	2.86e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg18132916	chr6:79620363	NA	-0.45	-10.45	-0.38	1.02e-23	Intelligence (multi-trait analysis);
BRCA	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.38	-9.98	-0.37	6.5600000000000005e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.17	-0.31	1.66e-15	Breast cancer;
BRCA	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg21798802	chr22:38057573	PDXP	0.29	7.9	0.3	1.23e-14	Fat distribution (HIV);
BRCA	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.33	-11.18	-0.4	1.29e-26	Systemic lupus erythematosus;
BRCA	trans	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.6	0.39	2.78e-24	Type 2 diabetes;
BRCA	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11764359	chr7:65958608	NA	-0.79	-19.35	-0.61	5.48e-66	Aortic root size;
BRCA	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg00383909	chr3:49044727	WDR6	0.74	12.49	0.44	3.58e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg03954927	chr1:10346856	KIF1B	0.48	15.12	0.51	2.19e-44	Hepatocellular carcinoma;
BRCA	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.58	10.28	0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg14582100	chr15:45693742	SPATA5L1	0.38	12.35	0.44	1.4e-31	Homoarginine levels;
BRCA	cis	rs12995491	0.933	rs7590305	chr2:88513131	C/T	cg04511125	chr2:88470314	THNSL2	-0.47	-9.51	-0.35	3.96e-20	Response to metformin (IC50);
BRCA	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.86	13.48	0.47	1.24e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3768617	0.782	rs10911211	chr1:183022299	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	9.7	0.36	7.76e-21	Fuchs's corneal dystrophy;
BRCA	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18876405	chr7:65276391	NA	0.57	14.23	0.49	4.22e-40	Aortic root size;
BRCA	cis	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg07460842	chr6:66804631	NA	0.97	19.56	0.61	3.88e-67	Exhaled nitric oxide output;
BRCA	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg16680214	chr1:154839983	KCNN3	-0.4	-10.96	-0.4	9.71e-26	Prostate cancer;
BRCA	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg18402987	chr7:1209562	NA	0.67	11.69	0.42	9.92e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9487051	0.768	rs1269172	chr6:109522080	G/C	cg01475377	chr6:109611718	NA	-0.45	-11.4	-0.41	1.58e-27	Reticulocyte fraction of red cells;
BRCA	cis	rs7103648	0.695	rs12577643	chr11:47467172	A/T	cg03711944	chr11:47377212	SPI1	-0.36	-8.53	-0.32	1.1e-16	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg12311346	chr5:56204834	C5orf35	-0.8	-15.97	-0.53	1.43e-48	Initial pursuit acceleration;
BRCA	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg05714579	chr10:131428358	MGMT	0.56	13.85	0.48	2.53e-38	Response to temozolomide;
BRCA	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg12311346	chr5:56204834	C5orf35	0.61	12.73	0.45	3.11e-33	Initial pursuit acceleration;
BRCA	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg27147174	chr7:100797783	AP1S1	-0.54	-10.87	-0.4	2.38e-25	Life satisfaction;
BRCA	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg14689365	chr7:158441557	NCAPG2	-0.42	-8.78	-0.33	1.54e-17	Height;
BRCA	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	4.15e-15	Alzheimer's disease (late onset);
BRCA	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00149659	chr3:10157352	C3orf10	0.71	12.36	0.44	1.34e-31	Alzheimer's disease;
BRCA	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg23173402	chr1:227635558	NA	0.51	9.21	0.34	4.66e-19	Major depressive disorder;
BRCA	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11890956	chr21:40555474	PSMG1	1.01	25.14	0.71	1.75e-97	Cognitive function;
BRCA	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg08917208	chr2:24149416	ATAD2B	1.07	14.82	0.51	5.99e-43	Lymphocyte counts;
BRCA	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg10578991	chr7:12443926	VWDE	-0.49	-8.24	-0.31	1.01e-15	Coronary artery disease;
BRCA	trans	rs6479891	0.915	rs4281380	chr10:64987698	C/A	cg14819942	chr15:35414228	NA	-0.35	-8.6	-0.32	6.07e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg13010199	chr12:38710504	ALG10B	0.41	8.34	0.31	4.59e-16	Resting heart rate;
BRCA	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.18	-0.49	7.04e-40	Extrinsic epigenetic age acceleration;
BRCA	trans	rs9929218	1.000	rs13330350	chr16:68800849	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-13.93	-0.48	1.03e-38	Colorectal cancer;
BRCA	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	13.95	0.48	8.22e-39	Alzheimer's disease;
BRCA	cis	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg06521331	chr12:34319734	NA	0.51	9.99	0.37	6.41e-22	Morning vs. evening chronotype;
BRCA	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg09307838	chr4:120376055	NA	0.74	16.0	0.53	1.04e-48	Corneal astigmatism;
BRCA	trans	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.87	0.3	1.47e-14	Corneal astigmatism;
BRCA	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg00106254	chr7:1943704	MAD1L1	-0.39	-10.58	-0.39	3.37e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.35	0.49	1.13e-40	Motion sickness;
BRCA	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg03929089	chr4:120376271	NA	0.49	8.18	0.31	1.59e-15	Axial length;
BRCA	cis	rs12760731	0.720	rs10913544	chr1:178350980	C/T	cg00404053	chr1:178313656	RASAL2	0.58	7.9	0.3	1.26e-14	Obesity-related traits;
BRCA	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg24011408	chr12:48396354	COL2A1	-0.39	-7.89	-0.3	1.36e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg16339924	chr4:17578868	LAP3	0.6	14.62	0.5	5.83e-42	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.46	10.46	0.38	9.71e-24	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg21427119	chr20:30132790	HM13	-0.42	-8.92	-0.33	4.92e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg00945666	chr1:160990265	F11R	-0.3	-8.65	-0.32	4.27e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg24324837	chr19:49891574	CCDC155	0.48	8.67	0.32	3.42e-17	Multiple sclerosis;
BRCA	cis	rs501916	0.796	rs75186419	chr15:48043934	G/A	cg16110827	chr15:48056943	SEMA6D	-0.43	-9.16	-0.34	7.02e-19	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg22920501	chr2:26401640	FAM59B	-0.65	-11.32	-0.41	3.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg21427119	chr20:30132790	HM13	-0.41	-8.67	-0.32	3.45e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs7264396	0.561	rs6058387	chr20:34568092	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-10.61	-0.39	2.41e-24	Total cholesterol levels;
BRCA	cis	rs7246657	0.722	rs10406379	chr19:38036725	G/A	cg18154014	chr19:37997991	ZNF793	0.48	9.17	0.34	6.65e-19	Coronary artery calcification;
BRCA	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	ch.11.42038R	chr11:967971	AP2A2	0.5	15.42	0.52	7.98e-46	Alzheimer's disease (late onset);
BRCA	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.14	0.31	2.08e-15	Parkinson's disease;
BRCA	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg26384229	chr12:38710491	ALG10B	-0.54	-13.47	-0.47	1.4e-36	Morning vs. evening chronotype;
BRCA	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg12419862	chr22:24373484	LOC391322	0.75	17.48	0.57	3.45e-56	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg00530320	chr1:46809349	NSUN4	0.48	9.47	0.35	5.28e-20	Menopause (age at onset);
BRCA	cis	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg07460842	chr6:66804631	NA	0.97	19.41	0.61	2.42e-66	Exhaled nitric oxide output;
BRCA	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg03188948	chr7:1209495	NA	0.42	8.21	0.31	1.2e-15	Longevity;Endometriosis;
BRCA	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.39	8.01	0.3	5.29e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10193935	0.901	rs997288	chr2:42525582	C/G	cg27598129	chr2:42591480	NA	-0.88	-14.57	-0.5	1.01e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg12641515	chr19:46296257	DMWD	-0.39	-8.0	-0.3	5.91e-15	Coronary artery disease;
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11141652	chr22:24348549	GSTTP1	-0.42	-8.68	-0.32	3.3e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00149659	chr3:10157352	C3orf10	0.7	12.42	0.44	6.99e-32	Alzheimer's disease;
BRCA	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.65	-0.45	6.63e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7551345	0.653	rs16834266	chr1:31698668	C/T	cg19084893	chr1:31688959	NA	-0.46	-10.04	-0.37	4.17e-22	Schizophrenia;
BRCA	cis	rs9807989	0.507	rs6706002	chr2:103006104	A/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.42	0.32	2.4e-16	Asthma;
BRCA	cis	rs6987853	0.787	rs2974335	chr8:42417272	C/T	cg09913449	chr8:42400586	C8orf40	0.42	9.38	0.35	1.11e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	14.41	0.5	5.54e-41	Colorectal cancer;
BRCA	cis	rs919433	0.617	rs12619333	chr2:198567638	C/G	cg00792783	chr2:198669748	PLCL1	-0.44	-9.77	-0.36	4.26e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.59	-12.26	-0.44	3.49e-31	Lymphocyte counts;
BRCA	cis	rs10501293	0.703	rs4237640	chr11:42990542	G/A	cg03447554	chr11:43094025	NA	0.42	7.92	0.3	1.02e-14	Cognitive performance;
BRCA	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg26838691	chr2:24397539	C2orf84	-0.49	-8.87	-0.33	7.07e-18	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs7707921	0.881	rs73136782	chr5:81443520	T/G	cg15871215	chr5:81402204	ATG10	-0.4	-8.54	-0.32	1.02e-16	Breast cancer;
BRCA	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg10223061	chr2:219282414	VIL1	-0.27	-8.21	-0.31	1.21e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	8.02	0.3	5.12e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg22920501	chr2:26401640	FAM59B	-0.6	-9.95	-0.37	8.57e-22	Gut microbiome composition (summer);
BRCA	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg03433033	chr1:76189801	ACADM	-0.6	-12.15	-0.43	1.08e-30	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg05347473	chr6:146136440	FBXO30	0.39	7.93	0.3	9.59e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.93	-0.33	4.37e-18	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.16e-47	Alzheimer's disease (late onset);
BRCA	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	17.04	0.56	5.99e-54	Colorectal cancer;
BRCA	cis	rs4728302	0.869	rs7779370	chr7:133595702	T/C	cg07491979	chr7:133331646	EXOC4	0.37	7.91	0.3	1.13e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg00814883	chr7:100076585	TSC22D4	-0.55	-10.74	-0.39	7.84e-25	Platelet count;
BRCA	cis	rs1568889	1.000	rs66857704	chr11:28212346	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	13.28	0.47	9.78e-36	Bipolar disorder;
BRCA	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.3	-0.44	2.46e-31	Alzheimer's disease;
BRCA	cis	rs6138458	0.962	rs6036976	chr20:24901567	T/G	cg06937882	chr20:24974362	C20orf3	0.44	8.38	0.31	3.34e-16	Blood protein levels;
BRCA	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg24130564	chr14:104152367	KLC1	-0.34	-7.91	-0.3	1.15e-14	Body mass index;
BRCA	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg12386194	chr3:101231763	SENP7	0.46	9.66	0.36	1.05e-20	Colorectal cancer;
BRCA	cis	rs9815354	0.556	rs60966614	chr3:42005166	A/G	cg03022575	chr3:42003672	ULK4	0.74	10.27	0.38	5.43e-23	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg09658497	chr7:2847517	GNA12	-0.41	-8.63	-0.32	4.82e-17	Height;
BRCA	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg09307838	chr4:120376055	NA	0.59	12.89	0.45	5.65e-34	Corneal astigmatism;
BRCA	cis	rs4727443	1.000	rs6974373	chr7:99590893	C/G	cg22004693	chr7:99632812	ZKSCAN1	0.39	8.89	0.33	6.05e-18	Interstitial lung disease;
BRCA	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg18230493	chr5:56204884	C5orf35	0.4	8.09	0.3	2.91e-15	Coronary artery disease;
BRCA	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.54	10.92	0.4	1.45e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg05863683	chr7:1912471	MAD1L1	0.38	8.41	0.32	2.77e-16	Bipolar disorder and schizophrenia;
BRCA	trans	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg25517755	chr10:38738941	LOC399744	-0.38	-7.82	-0.3	2.25e-14	Corneal astigmatism;
BRCA	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg07395648	chr5:131743802	NA	-0.37	-9.22	-0.34	4.19e-19	Blood metabolite levels;
BRCA	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg14820908	chr5:178986412	RUFY1	0.41	9.64	0.36	1.31e-20	Lung cancer;
BRCA	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.06	-0.34	1.53e-18	Total body bone mineral density;
BRCA	cis	rs6772849	0.930	rs9873888	chr3:128360987	G/A	cg16766828	chr3:128327626	NA	-0.4	-8.77	-0.33	1.67e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs4363385	0.747	rs3806219	chr1:152972522	C/T	cg24667326	chr1:152973720	SPRR3	0.35	9.84	0.36	2.19e-21	Inflammatory skin disease;
BRCA	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg01256987	chr12:42539512	GXYLT1	-0.68	-16.26	-0.54	4.98e-50	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03452623	chr4:187889614	NA	0.34	10.82	0.39	3.68e-25	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg14196790	chr5:131705035	SLC22A5	0.42	10.75	0.39	6.98e-25	Blood metabolite levels;
BRCA	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06634786	chr22:41940651	POLR3H	-0.55	-9.62	-0.36	1.52e-20	Vitiligo;
BRCA	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg04455712	chr21:45112962	RRP1B	-0.4	-10.03	-0.37	4.45e-22	Mean corpuscular volume;
BRCA	cis	rs68170813	0.559	rs17350182	chr7:106909637	T/A	cg02696742	chr7:106810147	HBP1	-0.53	-8.53	-0.32	1.07e-16	Coronary artery disease;
BRCA	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg22713356	chr15:30763199	NA	1.32	24.9	0.7	3.56e-96	Uric acid levels;
BRCA	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.78	0.5	9.45e-43	Colorectal cancer;
BRCA	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg17120908	chr11:65337727	SSSCA1	0.53	9.69	0.36	8.6e-21	Bone mineral density;
BRCA	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-12.78	-0.45	1.88e-33	Bipolar disorder;
BRCA	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg01475377	chr6:109611718	NA	-0.52	-13.27	-0.46	1.09e-35	Reticulocyte fraction of red cells;
BRCA	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg21644426	chr2:191273491	MFSD6	0.46	11.62	0.42	1.93e-28	Pulse pressure;
BRCA	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	10.85	0.39	2.77e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg23029597	chr12:123009494	RSRC2	-0.6	-11.69	-0.42	9.17e-29	Body mass index;
BRCA	cis	rs7851660	0.935	rs4460498	chr9:100620412	T/C	cg13688889	chr9:100608707	NA	-0.36	-8.78	-0.33	1.46e-17	Strep throat;
BRCA	cis	rs12949688	0.870	rs9906591	chr17:55816832	T/C	cg12582317	chr17:55822272	NA	0.32	8.05	0.3	4.01e-15	Schizophrenia;
BRCA	cis	rs698833	0.886	rs4953086	chr2:44561532	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	11.23	0.41	7.59e-27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs870825	0.616	rs79884757	chr4:185621454	A/G	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg20469991	chr17:27169893	C17orf63	-0.44	-8.54	-0.32	9.95e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg27446573	chr6:127587934	RNF146	0.89	20.34	0.63	2.6e-71	Breast cancer;
BRCA	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg21573476	chr21:45109991	RRP1B	-0.34	-8.68	-0.32	3.23e-17	Mean corpuscular volume;
BRCA	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg05234568	chr11:5960015	NA	-0.48	-9.49	-0.35	4.69e-20	DNA methylation (variation);
BRCA	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg05527609	chr1:210001259	C1orf107	0.82	19.15	0.6	6.01e-65	Orofacial clefts;
BRCA	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.42	-9.29	-0.34	2.49e-19	Personality dimensions;
BRCA	cis	rs6878727	0.665	rs256852	chr5:123662671	A/C	cg01806427	chr5:123737813	NA	-0.35	-7.89	-0.3	1.36e-14	Breast cancer;
BRCA	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.51e-36	High light scatter reticulocyte count;
BRCA	cis	rs35110281	0.667	rs4819293	chr21:45125863	A/G	cg04455712	chr21:45112962	RRP1B	0.45	11.05	0.4	4.46e-26	Mean corpuscular volume;
BRCA	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg14675211	chr2:100938903	LONRF2	-0.43	-9.69	-0.36	7.98e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg23229984	chr5:148520753	ABLIM3	0.35	8.77	0.33	1.66e-17	Breast cancer;
BRCA	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.61	-15.19	-0.51	1.08e-44	Longevity;Endometriosis;
BRCA	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg13628971	chr7:2884303	GNA12	-0.4	-9.29	-0.35	2.3e-19	Plateletcrit;
BRCA	trans	rs1997103	1.000	rs6958664	chr7:55404958	T/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4664304	0.658	rs2667008	chr2:160865095	C/T	cg01092293	chr2:160761427	LY75	-0.36	-8.75	-0.33	1.86e-17	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs5753037	0.653	rs140123	chr22:30143206	A/G	cg01021169	chr22:30184971	ASCC2	0.35	8.19	0.31	1.39e-15	Type 1 diabetes;
BRCA	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.56	-12.86	-0.45	8.08e-34	Longevity;Endometriosis;
BRCA	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg08822215	chr16:89438651	ANKRD11	-0.4	-8.52	-0.32	1.15e-16	Multiple myeloma (IgH translocation);
BRCA	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg24829409	chr8:58192753	C8orf71	0.47	9.1	0.34	1.15e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	14.68	0.5	3.1e-42	Motion sickness;
BRCA	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05025164	chr4:1340916	KIAA1530	0.77	15.82	0.53	8.2e-48	Longevity;
BRCA	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg08213375	chr14:104286397	PPP1R13B	0.41	8.94	0.33	4.26e-18	Reticulocyte count;
BRCA	cis	rs2979489	0.740	rs17554408	chr8:30427531	A/G	cg26383811	chr8:30366931	RBPMS	0.51	11.57	0.42	3.09e-28	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
BRCA	trans	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg26043149	chr18:55253948	FECH	-0.37	-8.17	-0.31	1.59e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg26043149	chr18:55253948	FECH	-0.41	-8.73	-0.33	2.19e-17	Bone mineral density;
BRCA	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg03146154	chr1:46216737	IPP	0.43	9.22	0.34	4.12e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11651000	0.947	rs59216876	chr17:45832965	G/A	cg03474202	chr17:45855739	NA	-0.43	-7.83	-0.3	2.06e-14	IgG glycosylation;
BRCA	cis	rs12541635	0.639	rs1032545	chr8:107005825	C/T	cg10147462	chr8:107024639	NA	0.4	10.78	0.39	5.05e-25	Age of smoking initiation;
BRCA	cis	rs68170813	0.641	rs4730228	chr7:106904077	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.54	-0.32	9.46e-17	Coronary artery disease;
BRCA	cis	rs68170813	0.559	rs11773514	chr7:106958469	T/C	cg02696742	chr7:106810147	HBP1	-0.54	-8.56	-0.32	8.57e-17	Coronary artery disease;
BRCA	cis	rs61990749	0.597	rs176980	chr14:78198449	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	-0.66	-10.58	-0.39	3.19e-24	Fibroblast growth factor basic levels;
BRCA	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg01528321	chr10:82214614	TSPAN14	0.64	14.47	0.5	3e-41	Post bronchodilator FEV1;
BRCA	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg01420254	chr6:26195488	NA	0.58	9.06	0.34	1.53e-18	Gout;Renal underexcretion gout;
BRCA	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	13.35	0.47	4.99e-36	Schizophrenia;
BRCA	cis	rs72781680	0.665	rs2675356	chr2:24074734	C/T	cg08917208	chr2:24149416	ATAD2B	0.6	10.25	0.38	6.06e-23	Lymphocyte counts;
BRCA	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.42	-0.32	2.4e-16	Monocyte percentage of white cells;
BRCA	cis	rs6435161	0.879	rs72928949	chr2:203570761	G/C	cg18429434	chr2:203499731	FAM117B	-0.45	-8.86	-0.33	7.61e-18	Total cholesterol levels;
BRCA	cis	rs8005677	1.000	rs11157930	chr14:23403171	T/G	cg01529538	chr14:23388837	RBM23	0.41	11.03	0.4	5.25e-26	Cognitive ability (multi-trait analysis);
BRCA	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg16339924	chr4:17578868	LAP3	-0.53	-12.68	-0.45	5.22e-33	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9649213	0.614	rs9641236	chr7:97998124	T/A	cg09267113	chr7:98030324	BAIAP2L1	-0.58	-14.76	-0.5	1.17e-42	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg08917208	chr2:24149416	ATAD2B	0.89	12.98	0.46	2.32e-34	Lymphocyte counts;
BRCA	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18876405	chr7:65276391	NA	-0.71	-18.53	-0.59	1.11e-61	Aortic root size;
BRCA	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg05985134	chr18:33552581	C18orf21	0.69	13.25	0.46	1.44e-35	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg17063962	chr7:91808500	NA	0.53	12.56	0.44	1.78e-32	Breast cancer;
BRCA	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.52	-0.32	1.15e-16	Aortic root size;
BRCA	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg13770153	chr20:60521292	NA	-0.39	-9.17	-0.34	6.38e-19	Body mass index;
BRCA	cis	rs9612	1.000	rs7246677	chr19:44248625	G/A	cg08581076	chr19:44259116	C19orf61	0.53	9.2	0.34	5.06e-19	Exhaled nitric oxide output;
BRCA	cis	rs2481665	0.546	rs927531	chr1:62634797	C/G	cg18591186	chr1:62594603	INADL	0.38	8.1	0.31	2.78e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.67	17.7	0.57	2.49e-57	Electrocardiographic conduction measures;
BRCA	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg12311346	chr5:56204834	C5orf35	0.61	12.65	0.45	7.17e-33	Initial pursuit acceleration;
BRCA	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg21064579	chr19:49206444	FUT2	0.37	9.25	0.34	3.4e-19	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
BRCA	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11890956	chr21:40555474	PSMG1	0.82	20.73	0.63	2.25e-73	Cognitive function;
BRCA	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg25767906	chr1:53392781	SCP2	0.34	7.88	0.3	1.42e-14	Monocyte count;
BRCA	cis	rs2625529	0.730	rs6494990	chr15:72401074	T/A	cg16672083	chr15:72433130	SENP8	0.72	17.15	0.56	1.55e-54	Red blood cell count;
BRCA	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg02659138	chr7:134003124	SLC35B4	0.41	12.03	0.43	3.53e-30	Mean platelet volume;
BRCA	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-11.79	-0.42	3.7e-29	Alzheimer's disease;
BRCA	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg26384229	chr12:38710491	ALG10B	0.67	15.37	0.52	1.35e-45	Bladder cancer;
BRCA	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg15704280	chr7:45808275	SEPT13	0.6	10.02	0.37	4.9e-22	Axial length;
BRCA	trans	rs6479891	1.000	rs4525102	chr10:65086273	C/T	cg14819942	chr15:35414228	NA	-0.34	-8.48	-0.32	1.54e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg04362960	chr10:104952993	NT5C2	0.43	10.48	0.38	7.79e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs9287719	0.649	rs10208103	chr2:10720867	G/A	cg00105475	chr2:10696890	NA	0.41	9.19	0.34	5.52e-19	Prostate cancer;
BRCA	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg01475377	chr6:109611718	NA	-0.61	-16.79	-0.55	1.15e-52	Reticulocyte fraction of red cells;
BRCA	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.13	0.37	1.75e-22	Bladder cancer;
BRCA	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg12927641	chr6:109611667	NA	-0.36	-8.92	-0.33	4.92e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg25767906	chr1:53392781	SCP2	0.38	8.63	0.32	4.85e-17	Monocyte count;
BRCA	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg22903471	chr2:27725779	GCKR	-0.38	-9.44	-0.35	6.78e-20	Total body bone mineral density;
BRCA	cis	rs870825	0.520	rs10022842	chr4:185649459	A/G	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs600806	0.778	rs891380	chr1:110003286	T/G	cg20591472	chr1:110008990	SYPL2	0.31	7.9	0.3	1.21e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs4478858	0.684	rs11579845	chr1:31736248	A/G	cg00250761	chr1:31883323	NA	-0.31	-8.17	-0.31	1.63e-15	Alcohol dependence;
BRCA	trans	rs6479891	1.000	rs9415708	chr10:65190042	G/C	cg14819942	chr15:35414228	NA	0.35	8.58	0.32	6.95e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg14847009	chr1:175162515	KIAA0040	-0.24	-9.07	-0.34	1.41e-18	Alcohol dependence;
BRCA	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.57	-14.09	-0.49	1.94e-39	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs61990749	0.597	rs10148373	chr14:78280199	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.66	9.48	0.35	4.79e-20	Fibroblast growth factor basic levels;
BRCA	cis	rs13046373	0.535	rs1605428	chr21:32028976	T/C	cg27071517	chr21:31768726	KRTAP13-1	0.3	7.86	0.3	1.61e-14	HDL cholesterol;
BRCA	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg18252515	chr7:66147081	NA	-1.04	-13.91	-0.48	1.27e-38	Diabetic kidney disease;
BRCA	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.21	0.41	9.04e-27	Bipolar disorder;
BRCA	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg06627628	chr2:24431161	ITSN2	0.43	8.98	0.33	3.03e-18	Asthma;
BRCA	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.47	-8.16	-0.31	1.76e-15	Schizophrenia;
BRCA	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.3	-0.44	2.46e-31	Alzheimer's disease;
BRCA	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg13628971	chr7:2884303	GNA12	0.4	9.13	0.34	8.76e-19	Height;
BRCA	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24308560	chr3:49941425	MST1R	-0.4	-8.47	-0.32	1.74e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg04691961	chr3:161091175	C3orf57	-0.59	-14.03	-0.49	3.4e-39	Morning vs. evening chronotype;
BRCA	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg03060546	chr3:49711283	APEH	-0.57	-11.37	-0.41	2.01e-27	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-12.2	-0.43	6.19e-31	Platelet count;
BRCA	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.53	0.32	1.1e-16	Aortic root size;
BRCA	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg22875332	chr1:76189707	ACADM	-0.7	-14.87	-0.51	3.49e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	9.84	0.36	2.32e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs13046373	0.507	rs2832959	chr21:31982934	C/T	cg22337977	chr21:31811175	KRTAP15-1	0.35	8.57	0.32	7.68e-17	HDL cholesterol;
BRCA	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.64	10.23	0.38	7.76e-23	Renal function-related traits (BUN);
BRCA	cis	rs3768617	0.811	rs10911200	chr1:182998377	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	9.53	0.35	3.18e-20	Fuchs's corneal dystrophy;
BRCA	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg22535103	chr8:58192502	C8orf71	0.53	9.28	0.34	2.69e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg01802117	chr1:53393560	SCP2	-0.36	-8.39	-0.31	3.16e-16	Monocyte count;
BRCA	cis	rs507080	0.885	rs7926959	chr11:118559866	T/C	cg08498647	chr11:118550644	TREH	-0.38	-8.3	-0.31	6e-16	Serum metabolite levels;
BRCA	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg11789530	chr4:8429930	ACOX3	-0.56	-13.41	-0.47	2.72e-36	Response to antineoplastic agents;
BRCA	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg24324837	chr19:49891574	CCDC155	0.5	9.23	0.34	4.08e-19	Multiple sclerosis;
BRCA	cis	rs4908760	0.860	rs11121202	chr1:8639357	T/C	cg20416874	chr1:8611966	RERE	-0.29	-8.22	-0.31	1.15e-15	Vitiligo;
BRCA	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg25427524	chr10:38739819	LOC399744	0.52	9.79	0.36	3.47e-21	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs36051895	0.560	rs1575281	chr9:5219131	T/C	cg02405213	chr9:5042618	JAK2	-0.41	-7.94	-0.3	8.95e-15	Pediatric autoimmune diseases;
BRCA	cis	rs7617773	0.817	rs4131361	chr3:48328812	T/C	cg11946769	chr3:48343235	NME6	0.63	13.53	0.47	7.37e-37	Coronary artery disease;
BRCA	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	15.63	0.53	7.54e-47	Smoking behavior;
BRCA	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg03929089	chr4:120376271	NA	-0.74	-15.94	-0.53	2.09e-48	Coronary artery disease;
BRCA	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg01877450	chr7:97915802	BRI3	-0.39	-8.8	-0.33	1.25e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg27490568	chr2:178487706	NA	0.52	8.4	0.32	2.9e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg06521331	chr12:34319734	NA	-0.53	-10.64	-0.39	1.79e-24	Morning vs. evening chronotype;
BRCA	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08109568	chr15:31115862	NA	-0.44	-10.16	-0.37	1.44e-22	Huntington's disease progression;
BRCA	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-14.94	-0.51	1.72e-43	Morning vs. evening chronotype;
BRCA	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg12219531	chr12:120966889	COQ5	0.55	11.49	0.41	6.52e-28	High light scatter reticulocyte count;
BRCA	cis	rs4363385	0.747	rs1611753	chr1:152956381	C/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.26	-0.31	8.39e-16	Inflammatory skin disease;
BRCA	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg24011408	chr12:48396354	COL2A1	-0.43	-9.65	-0.36	1.13e-20	Plateletcrit;
BRCA	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-8.11	-0.31	2.51e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-7.9	-0.3	1.26e-14	Colorectal cancer;
BRCA	trans	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg25214090	chr10:38739885	LOC399744	0.53	11.93	0.43	9.32e-30	Corneal astigmatism;
BRCA	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg14004847	chr7:1930337	MAD1L1	0.42	8.12	0.31	2.44e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg27432699	chr2:27873401	GPN1	0.43	8.98	0.33	3.01e-18	Oral cavity cancer;
BRCA	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg21132104	chr15:45694354	SPATA5L1	0.73	16.29	0.54	3.75e-50	Homoarginine levels;
BRCA	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg08601574	chr20:25228251	PYGB	-0.34	-8.09	-0.3	2.97e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1215050	0.791	rs4699318	chr4:98664370	T/G	cg05340658	chr4:99064831	C4orf37	-0.44	-10.13	-0.37	1.76e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg05966235	chr16:28915196	ATP2A1	0.4	7.89	0.3	1.33e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.0	0.34	2.57e-18	Motion sickness;
BRCA	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg14963724	chr18:72166303	CNDP2	-0.34	-7.97	-0.3	7.22e-15	Refractive error;
BRCA	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg11502198	chr6:26597334	ABT1	0.56	11.92	0.43	1e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs62458065	0.513	rs10265319	chr7:32571564	A/C	cg20159608	chr7:32802032	NA	-0.51	-9.77	-0.36	4.05e-21	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg26647111	chr11:31128758	NA	-0.44	-9.68	-0.36	9.03e-21	Red blood cell count;
BRCA	cis	rs7520050	0.966	rs6662641	chr1:46571509	T/A	cg24296786	chr1:45957014	TESK2	0.43	9.71	0.36	6.81e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1953600	0.870	rs2245168	chr10:81921918	T/C	cg04850286	chr10:81895943	PLAC9	-0.32	-9.17	-0.34	6.24e-19	Sarcoidosis;
BRCA	cis	rs3125734	0.633	rs6479792	chr10:63983264	T/G	cg19640130	chr10:64028056	RTKN2	-0.29	-8.41	-0.32	2.68e-16	Rheumatoid arthritis;
BRCA	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.12	0.31	2.49e-15	Uric acid levels;
BRCA	cis	rs11229555	0.874	rs11605683	chr11:58350794	T/A	cg15696309	chr11:58395628	NA	-0.54	-11.75	-0.42	5.45e-29	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs938554	0.612	rs7669607	chr4:9997801	C/T	cg00071950	chr4:10020882	SLC2A9	-0.41	-7.88	-0.3	1.46e-14	Blood metabolite levels;
BRCA	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00166722	chr3:10149974	C3orf24	0.66	13.13	0.46	5.04e-35	Alzheimer's disease;
BRCA	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18876405	chr7:65276391	NA	0.62	15.48	0.52	4e-46	Aortic root size;
BRCA	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg11247378	chr22:39784982	NA	-0.63	-14.03	-0.49	3.47e-39	Intelligence (multi-trait analysis);
BRCA	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg04553112	chr3:125709451	NA	-0.56	-8.47	-0.32	1.68e-16	Blood pressure (smoking interaction);
BRCA	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg08085267	chr17:45401833	C17orf57	-0.58	-11.98	-0.43	5.79e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs701145	0.585	rs1713804	chr3:153799122	A/G	cg17054900	chr3:154042577	DHX36	0.54	9.14	0.34	8.17e-19	Coronary artery disease;
BRCA	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	16.75	0.55	1.82e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg13319975	chr6:146136371	FBXO30	0.59	13.31	0.47	7.71e-36	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9297145	0.678	rs62473051	chr7:98781955	C/T	cg05967295	chr7:98741636	SMURF1	0.96	17.83	0.58	5.33e-58	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs2012796	0.956	rs10450940	chr14:81825326	C/A	cg02996355	chr14:81879375	NA	0.5	9.79	0.36	3.63e-21	Night sleep phenotypes;
BRCA	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg01448562	chr3:133502909	NA	-0.64	-14.94	-0.51	1.7e-43	Iron status biomarkers;
BRCA	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg14683738	chr19:37701593	ZNF585B	0.44	7.9	0.3	1.22e-14	Coronary artery calcification;
BRCA	cis	rs2742417	0.603	rs2742398	chr3:45759036	A/G	cg04837898	chr3:45731254	SACM1L	-0.42	-8.73	-0.33	2.23e-17	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg11845111	chr2:191398756	TMEM194B	-0.83	-14.85	-0.51	4.69e-43	Diastolic blood pressure;
BRCA	cis	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-8.22	-0.31	1.14e-15	Neuroticism;
BRCA	trans	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg25042112	chr7:64838748	ZNF92	-0.45	-8.23	-0.31	1.03e-15	Pain;
BRCA	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg11812906	chr14:75593930	NEK9	-0.61	-13.8	-0.48	4.24e-38	Height;
BRCA	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg11062466	chr8:58055876	NA	0.4	7.84	0.3	1.84e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg17845761	chr1:175162550	KIAA0040	-0.27	-10.05	-0.37	3.53e-22	Alcohol dependence;
BRCA	cis	rs7512552	0.646	rs1694367	chr1:150329469	T/A	cg15654264	chr1:150340011	RPRD2	0.38	8.4	0.32	2.81e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg08885076	chr2:99613938	TSGA10	-0.52	-11.96	-0.43	6.96e-30	Chronic sinus infection;
BRCA	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.96	0.3	7.63e-15	Depression;
BRCA	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg06627628	chr2:24431161	ITSN2	-0.85	-15.66	-0.53	5.08e-47	Asthma;
BRCA	cis	rs7727544	0.582	rs2278398	chr5:131530441	C/T	cg14196790	chr5:131705035	SLC22A5	-0.37	-9.15	-0.34	7.33e-19	Blood metabolite levels;
BRCA	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg02734326	chr4:10020555	SLC2A9	0.39	8.45	0.32	1.96e-16	Bone mineral density;
BRCA	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05731713	chr7:157510257	PTPRN2	0.39	9.9	0.36	1.37e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg18198730	chr1:247681584	NA	0.49	11.23	0.41	8.03e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg04166393	chr7:2884313	GNA12	0.39	8.33	0.31	4.92e-16	Height;
BRCA	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.9	-28.1	-0.74	9.91e-114	Schizophrenia;
BRCA	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg16850897	chr7:100343110	ZAN	0.38	8.48	0.32	1.5e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.53	-0.61	5.49e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg00012203	chr2:219082015	ARPC2	0.58	12.37	0.44	1.21e-31	Colorectal cancer;
BRCA	cis	rs9790314	0.746	rs898680	chr3:160772853	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-9.77	-0.36	4.24e-21	Morning vs. evening chronotype;
BRCA	trans	rs1493916	0.744	rs7504560	chr18:31312148	A/G	cg27147174	chr7:100797783	AP1S1	-0.41	-8.14	-0.31	2.1e-15	Life satisfaction;
BRCA	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg03146154	chr1:46216737	IPP	0.46	10.12	0.37	1.99e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg16230307	chr14:35515116	FAM177A1	0.71	14.43	0.5	4.8e-41	Psoriasis;
BRCA	cis	rs7552167	0.925	rs3932664	chr1:24511663	G/T	cg01960748	chr1:24522592	NA	-0.63	-10.88	-0.4	2.07e-25	Psoriasis vulgaris;
BRCA	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-9.31	-0.35	2.06e-19	Monocyte percentage of white cells;
BRCA	cis	rs6429082	0.715	rs2153204	chr1:235580382	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.55	-13.8	-0.48	4.23e-38	Adiposity;
BRCA	cis	rs2997447	0.655	rs2275950	chr1:26385003	T/C	cg19633962	chr1:26362018	EXTL1	-0.55	-9.92	-0.37	1.16e-21	QRS complex (12-leadsum);
BRCA	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg24642439	chr20:33292090	TP53INP2	0.41	8.65	0.32	4e-17	Height;
BRCA	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg26031613	chr14:104095156	KLC1	0.72	15.39	0.52	1.13e-45	Body mass index;
BRCA	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	11.23	0.41	7.85e-27	Schizophrenia;
BRCA	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg21782813	chr7:2030301	MAD1L1	-0.4	-10.59	-0.39	2.96e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg04317338	chr11:64019027	PLCB3	0.54	9.57	0.35	2.32e-20	Mean platelet volume;
BRCA	cis	rs7264396	0.616	rs6060744	chr20:34581555	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-11.03	-0.4	5.34e-26	Total cholesterol levels;
BRCA	cis	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-8.86	-0.33	8.2e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.53	-9.49	-0.35	4.41e-20	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-10.85	-0.39	2.62e-25	Personality dimensions;
BRCA	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg16576597	chr16:28551801	NUPR1	0.34	9.13	0.34	8.58e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg27336068	chr10:1336103	ADARB2	-0.29	-7.99	-0.3	6.44e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs208520	0.754	rs851594	chr6:66876695	A/G	cg07460842	chr6:66804631	NA	-0.98	-18.46	-0.59	2.69e-61	Exhaled nitric oxide output;
BRCA	cis	rs3771570	1.000	rs56052835	chr2:242243251	T/G	cg21155796	chr2:242212141	HDLBP	0.61	9.63	0.36	1.42e-20	Prostate cancer;
BRCA	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg00277334	chr10:82204260	NA	-0.42	-8.34	-0.31	4.51e-16	Post bronchodilator FEV1;
BRCA	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg03060546	chr3:49711283	APEH	0.49	10.58	0.39	3.14e-24	Resting heart rate;
BRCA	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg01689657	chr7:91764605	CYP51A1	0.23	8.13	0.31	2.16e-15	Breast cancer;
BRCA	cis	rs17228212	1.000	rs11630297	chr15:67443964	C/G	cg26876701	chr15:67458665	SMAD3	-0.47	-9.14	-0.34	8.13e-19	Coronary heart disease;
BRCA	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg01689657	chr7:91764605	CYP51A1	0.24	8.58	0.32	7.26e-17	Breast cancer;
BRCA	cis	rs1371614	0.635	rs4316900	chr2:27140342	C/T	cg12368169	chr2:27073192	DPYSL5	-0.29	-8.65	-0.32	4.02e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.49	-10.85	-0.39	2.78e-25	Urate levels in overweight individuals;
BRCA	cis	rs17253792	0.822	rs9972178	chr14:56073480	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.91	0.3	1.15e-14	Putamen volume;
BRCA	cis	rs11231017	0.507	rs11231027	chr11:62080042	C/T	cg23876832	chr11:62092739	NA	0.32	8.05	0.3	4e-15	HIV-1 viral setpoint;
BRCA	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.21	-0.31	1.26e-15	Breast cancer;
BRCA	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg11584989	chr19:19387371	SF4	-0.63	-13.5	-0.47	1e-36	Bipolar disorder;
BRCA	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg03585969	chr10:35415529	CREM	0.49	10.36	0.38	2.43e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2274471	0.582	rs57839907	chr9:5082671	T/A	cg03390472	chr9:5043263	JAK2	-0.49	-8.94	-0.33	4.31e-18	Crohn's disease;
BRCA	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.96	-0.46	2.7200000000000002e-34	Migraine;Coronary artery disease;
BRCA	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg06238570	chr21:40685208	BRWD1	-0.4	-8.08	-0.3	3.23e-15	Cognitive function;
BRCA	cis	rs3768617	0.706	rs9943067	chr1:182975102	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.5	11.6	0.42	2.24e-28	Fuchs's corneal dystrophy;
BRCA	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18404041	chr3:52824283	ITIH1	0.36	11.21	0.41	9.35e-27	Electroencephalogram traits;
BRCA	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg22920501	chr2:26401640	FAM59B	0.76	10.85	0.39	2.68e-25	Gut microbiome composition (summer);
BRCA	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg20991723	chr1:152506922	NA	-0.41	-9.25	-0.34	3.29e-19	Hair morphology;
BRCA	cis	rs17401966	0.838	rs1556917	chr1:10400990	G/T	cg03954927	chr1:10346856	KIF1B	0.44	13.59	0.47	3.94e-37	Hepatocellular carcinoma;
BRCA	trans	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.83	27.56	0.74	8.71e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg17830980	chr10:43048298	ZNF37B	0.42	9.91	0.36	1.23e-21	Extrinsic epigenetic age acceleration;
BRCA	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg23505145	chr19:12996616	KLF1	0.54	12.28	0.44	2.74e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.26	0.34	3.03e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg05343316	chr1:45956843	TESK2	0.7	14.5	0.5	2.1e-41	Platelet count;
BRCA	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg26597838	chr10:835615	NA	1.0	15.69	0.53	3.62e-47	Eosinophil percentage of granulocytes;
BRCA	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg21535247	chr6:8435926	SLC35B3	0.4	8.99	0.33	2.86e-18	Motion sickness;
BRCA	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg18402987	chr7:1209562	NA	0.86	14.02	0.48	3.98e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg06937548	chr11:34938143	PDHX;APIP	0.45	8.49	0.32	1.49e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6028335	0.610	rs73110616	chr20:37552943	C/T	cg16355469	chr20:37678765	NA	0.45	8.12	0.31	2.46e-15	Alcohol and nicotine co-dependence;
BRCA	cis	rs2249625	0.545	rs2463746	chr6:72876954	C/G	cg18830697	chr6:72922368	RIMS1	-0.64	-14.66	-0.5	3.57e-42	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg08601574	chr20:25228251	PYGB	-0.39	-9.05	-0.34	1.77e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.5	0.57	2.57e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.61	14.94	0.51	1.6700000000000001e-43	Colorectal cancer;
BRCA	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg21475434	chr5:93447410	FAM172A	0.68	8.6	0.32	6.23e-17	Diabetic retinopathy;
BRCA	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.33	-0.61	6.56e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg04607235	chr12:12878440	APOLD1	-0.7	-10.83	-0.39	3.27e-25	Systemic lupus erythematosus;
BRCA	cis	rs2625529	0.701	rs2306490	chr15:72227837	A/G	cg16672083	chr15:72433130	SENP8	-0.84	-17.34	-0.57	1.67e-55	Red blood cell count;
BRCA	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg01475735	chr3:40494733	NA	0.47	9.88	0.36	1.65e-21	Renal cell carcinoma;
BRCA	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg00321850	chr1:175162397	KIAA0040	0.43	12.25	0.44	3.99e-31	Alcohol dependence;
BRCA	trans	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg18279126	chr7:2041391	MAD1L1	0.37	8.21	0.31	1.22e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.95	-0.3	8.66e-15	Total body bone mineral density;
BRCA	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24110177	chr3:50126178	RBM5	-0.52	-14.65	-0.5	4.16e-42	Body mass index;
BRCA	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg15704280	chr7:45808275	SEPT13	-0.74	-15.15	-0.51	1.55e-44	Coronary artery disease;
BRCA	cis	rs9837602	1.000	rs6799379	chr3:99762840	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	10.54	0.38	4.86e-24	Breast cancer;
BRCA	cis	rs7246967	0.673	rs55684269	chr19:22924547	C/T	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg27029518	chr18:72166324	CNDP2	-0.31	-8.68	-0.32	3.35e-17	Refractive error;
BRCA	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	8.69	0.33	3.07e-17	Platelet count;
BRCA	cis	rs3820928	1.000	rs11686072	chr2:227777493	A/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.49	-0.32	1.47e-16	Pulmonary function;
BRCA	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg08847533	chr14:75593920	NEK9	-0.92	-24.52	-0.7	4.24e-94	Height;
BRCA	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	22.89	0.67	3.9e-85	Chronic sinus infection;
BRCA	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.64	9.48	0.35	4.92e-20	Initial pursuit acceleration;
BRCA	cis	rs1863824	0.625	rs2018507	chr10:88163251	A/G	cg07322936	chr10:88137208	NA	0.45	9.24	0.34	3.76e-19	Schizophrenia;
BRCA	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg17757837	chr7:157058334	UBE3C	-0.72	-17.78	-0.58	9.39e-58	Body mass index;
BRCA	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg00106254	chr7:1943704	MAD1L1	-0.34	-8.4	-0.32	2.95e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg25237894	chr2:233734115	C2orf82	-0.39	-11.39	-0.41	1.64e-27	Coronary artery disease;
BRCA	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	16.31	0.54	2.86e-50	Tonsillectomy;
BRCA	cis	rs1788820	0.917	rs1788826	chr18:21154024	G/A	cg14672496	chr18:21087552	C18orf8	0.34	8.11	0.31	2.6e-15	Body mass index;
BRCA	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	13.88	0.48	1.73e-38	Coronary artery disease;
BRCA	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg06026331	chr20:60912101	LAMA5	-0.61	-12.26	-0.44	3.65e-31	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg26031613	chr14:104095156	KLC1	-0.44	-8.72	-0.33	2.36e-17	Schizophrenia;
BRCA	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg05457628	chr5:178986728	RUFY1	0.49	11.79	0.42	3.55e-29	Lung cancer;
BRCA	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	8.18	0.31	1.53e-15	Uric acid levels;
BRCA	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg23625390	chr15:77176239	SCAPER	-0.56	-12.99	-0.46	2.04e-34	Blood metabolite levels;
BRCA	cis	rs977987	0.806	rs4888411	chr16:75443183	T/A	cg03315344	chr16:75512273	CHST6	0.53	12.48	0.44	3.9e-32	Dupuytren's disease;
BRCA	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg16339924	chr4:17578868	LAP3	0.66	16.9	0.56	3.1e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.7	-19.13	-0.6	7.98e-65	Electrocardiographic conduction measures;
BRCA	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg24296786	chr1:45957014	TESK2	-0.46	-10.54	-0.38	4.86e-24	Red blood cell count;Reticulocyte count;
BRCA	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg06145435	chr7:1022769	CYP2W1	0.48	8.88	0.33	6.82e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03517284	chr6:25882590	NA	0.48	9.95	0.37	8.66e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	4.04e-15	Alzheimer's disease (late onset);
BRCA	cis	rs12410462	0.792	rs994666	chr1:227651454	C/T	cg23173402	chr1:227635558	NA	-0.46	-8.31	-0.31	5.64e-16	Major depressive disorder;
BRCA	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-12.9	-0.45	5.23e-34	Lymphocyte counts;
BRCA	cis	rs4862307	0.836	rs11132220	chr4:184997247	A/T	cg06737308	chr4:185021514	ENPP6	-0.4	-9.22	-0.34	4.12e-19	Serum dimethylarginine levels (asymmetric/symetric ratio);
BRCA	cis	rs427394	0.802	rs274692	chr5:6734625	C/T	cg10857441	chr5:6722123	POLS	-0.33	-10.91	-0.4	1.54e-25	Menopause (age at onset);
BRCA	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg17691542	chr6:26056736	HIST1H1C	0.5	10.33	0.38	3.05e-23	Height;
BRCA	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg09307838	chr4:120376055	NA	0.77	17.12	0.56	2.42e-54	Corneal astigmatism;
BRCA	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg11584989	chr19:19387371	SF4	-0.6	-13.51	-0.47	9.58e-37	Bipolar disorder;
BRCA	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.89	-0.3	1.36e-14	Aortic root size;
BRCA	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg19622623	chr12:86230825	RASSF9	-0.3	-8.16	-0.31	1.84e-15	Major depressive disorder;
BRCA	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg18904891	chr8:8559673	CLDN23	0.65	12.9	0.45	5.46e-34	Obesity-related traits;
BRCA	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg00666640	chr1:248458726	OR2T12	0.3	8.55	0.32	9.3e-17	Common traits (Other);
BRCA	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg13175981	chr1:150552382	MCL1	0.41	9.15	0.34	7.57e-19	Tonsillectomy;
BRCA	cis	rs4764124	0.646	rs10744078	chr12:14978535	T/G	cg19759883	chr12:14956454	WBP11;C12orf60	-0.52	-11.69	-0.42	9.73e-29	Pubertal anthropometrics;
BRCA	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg01939980	chr4:1354348	KIAA1530	0.37	9.59	0.35	1.93e-20	Longevity;
BRCA	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.96	-0.3	7.79e-15	Prostate cancer;
BRCA	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg13906792	chr15:75199810	C15orf17	-0.4	-9.5	-0.35	4.16e-20	Breast cancer;
BRCA	cis	rs9463078	0.774	rs9381383	chr6:45271893	G/A	cg25276700	chr6:44698697	NA	-0.36	-8.14	-0.31	2.01e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.62	-14.36	-0.49	9.47e-41	Ulcerative colitis;
BRCA	trans	rs7939886	0.920	rs79521305	chr11:55811332	G/A	cg15704280	chr7:45808275	SEPT13	0.62	7.95	0.3	8.52e-15	Myopia (pathological);
BRCA	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg23358479	chr7:1110784	C7orf50	-0.47	-7.94	-0.3	9.1e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07988820	chr12:82153109	PPFIA2	0.65	11.07	0.4	3.46e-26	Resting heart rate;
BRCA	cis	rs2859741	1.000	rs1773575	chr1:37505129	T/C	cg09363841	chr1:37513479	NA	-0.66	-16.27	-0.54	4.95e-50	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	trans	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg15556689	chr8:8085844	FLJ10661	0.34	8.07	0.3	3.55e-15	Neuroticism;
BRCA	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg24558204	chr6:135376177	HBS1L	0.6	16.25	0.54	5.98e-50	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs300703	0.542	rs300697	chr2:184496	C/T	cg21211680	chr2:198530	NA	-0.39	-8.15	-0.31	1.98e-15	Blood protein levels;
BRCA	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg25554036	chr4:6271136	WFS1	0.41	9.7	0.36	7.82e-21	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-12.95	-0.46	3.08e-34	Lymphocyte counts;
BRCA	cis	rs8114671	0.935	rs945960	chr20:33762854	A/G	cg07148914	chr20:33460835	GGT7	0.38	8.03	0.3	4.77e-15	Height;
BRCA	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.52	-0.32	1.14e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg11625262	chr3:156393772	TIPARP;LOC100287227	0.35	8.36	0.31	4e-16	Mosquito bite size;
BRCA	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg26384229	chr12:38710491	ALG10B	-0.58	-13.6	-0.47	3.66e-37	Bladder cancer;
BRCA	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg03146154	chr1:46216737	IPP	0.45	9.95	0.37	8.9e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg08917208	chr2:24149416	ATAD2B	0.58	9.11	0.34	1.09e-18	Lymphocyte counts;
BRCA	cis	rs7737355	1.000	rs6596010	chr5:130625411	G/A	cg06307176	chr5:131281290	NA	0.46	9.04	0.34	1.83e-18	Life satisfaction;
BRCA	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg15448220	chr1:150897856	SETDB1	0.37	8.3	0.31	6.19e-16	Melanoma;
BRCA	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg03709012	chr19:19516395	GATAD2A	0.82	19.22	0.61	2.52e-65	Tonsillectomy;
BRCA	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg18232548	chr7:50535776	DDC	-0.54	-13.36	-0.47	4.59e-36	Response to zileuton treatment in asthma (FEV1 change interaction);
BRCA	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs17641971	0.684	rs4873100	chr8:50025772	G/A	cg00325661	chr8:49890786	NA	0.36	10.09	0.37	2.54e-22	Blood metabolite levels;
BRCA	cis	rs4660306	0.961	rs1337902	chr1:45952066	G/A	cg24296786	chr1:45957014	TESK2	0.42	8.39	0.32	3.08e-16	Homocysteine levels;
BRCA	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg22800045	chr5:56110881	MAP3K1	0.66	12.19	0.43	7.23e-31	Initial pursuit acceleration;
BRCA	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg08213375	chr14:104286397	PPP1R13B	0.65	18.58	0.59	5.9e-62	Schizophrenia;
BRCA	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg20307385	chr11:47447363	PSMC3	0.4	9.08	0.34	1.39e-18	Subjective well-being;
BRCA	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26314531	chr2:26401878	FAM59B	-0.63	-10.65	-0.39	1.69e-24	Gut microbiome composition (summer);
BRCA	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.72	0.6	1.16e-62	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs12431939	0.947	rs55974960	chr14:51633742	T/C	cg23942311	chr14:51606299	NA	-0.45	-8.5	-0.32	1.33e-16	Cancer;
BRCA	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg12564285	chr5:131593104	PDLIM4	0.35	7.89	0.3	1.35e-14	Breast cancer;
BRCA	cis	rs17253792	0.822	rs76557162	chr14:56064701	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.98	0.3	7e-15	Putamen volume;
BRCA	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.19	-0.34	5.31e-19	Menopause (age at onset);
BRCA	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg21724239	chr8:58056113	NA	0.58	9.44	0.35	7.02e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs11608355	0.545	rs11066737	chr12:109904792	A/G	cg05360138	chr12:110035743	NA	-0.72	-13.07	-0.46	9.05e-35	Neuroticism;
BRCA	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.36	-8.2	-0.31	1.31e-15	Colorectal cancer;
BRCA	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	6.95e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg17971929	chr21:40555470	PSMG1	-0.64	-14.87	-0.51	3.48e-43	Cognitive function;
BRCA	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg03929089	chr4:120376271	NA	-0.5	-9.33	-0.35	1.66e-19	Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.66	-0.36	1.04e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11890956	chr21:40555474	PSMG1	1.06	31.88	0.78	3.44e-134	Cognitive function;
BRCA	cis	rs7617773	0.817	rs6787500	chr3:48299439	T/C	cg11946769	chr3:48343235	NME6	0.51	11.65	0.42	1.41e-28	Coronary artery disease;
BRCA	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.51	-0.52	2.66e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs911119	1.000	rs34897231	chr20:23620268	A/G	cg16589663	chr20:23618590	CST3	0.47	8.81	0.33	1.2e-17	Chronic kidney disease;
BRCA	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg16325326	chr1:53192061	ZYG11B	-0.56	-11.45	-0.41	1.01e-27	Monocyte count;
BRCA	cis	rs13046373	0.535	rs9636840	chr21:32029979	A/G	cg16812893	chr21:31813075	KRTAP15-1	-0.35	-8.73	-0.33	2.22e-17	HDL cholesterol;
BRCA	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg11645453	chr3:52864694	ITIH4	0.37	9.66	0.36	1.07e-20	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg11663144	chr21:46675770	NA	-0.6	-13.84	-0.48	2.6e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg21573476	chr21:45109991	RRP1B	-0.35	-9.21	-0.34	4.5e-19	Mean corpuscular volume;
BRCA	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg08000102	chr2:233561755	GIGYF2	0.63	13.98	0.48	6.09e-39	Coronary artery disease;
BRCA	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg24562669	chr7:97807699	LMTK2	0.46	12.35	0.44	1.36e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg09021430	chr5:549028	NA	-0.64	-15.31	-0.52	2.54e-45	Obesity-related traits;
BRCA	trans	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg21167628	chr1:45308625	PTCH2	0.31	8.19	0.31	1.41e-15	Facial morphology (factor 20);
BRCA	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	10.25	0.38	6.13e-23	Lymphocyte counts;
BRCA	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg04034577	chr2:241836375	C2orf54	0.53	12.33	0.44	1.69e-31	Urinary metabolites;
BRCA	cis	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg05084668	chr3:125655381	ALG1L	-0.81	-11.22	-0.41	8.48e-27	Blood pressure (smoking interaction);
BRCA	cis	rs36051895	0.623	rs62541541	chr9:5040817	G/C	cg02405213	chr9:5042618	JAK2	-0.51	-9.18	-0.34	5.92e-19	Pediatric autoimmune diseases;
BRCA	trans	rs2736345	0.788	rs2618476	chr8:11352541	A/G	cg15556689	chr8:8085844	FLJ10661	0.34	8.06	0.3	3.66e-15	Sjögren's syndrome;Systemic lupus erythematosus;
BRCA	cis	rs6973256	0.897	rs7780456	chr7:133328782	C/T	cg07491979	chr7:133331646	EXOC4	-0.38	-8.78	-0.33	1.54e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg16586182	chr3:47516702	SCAP	0.66	15.18	0.51	1.11e-44	Colorectal cancer;
BRCA	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05926928	chr17:57297772	GDPD1	1.17	16.02	0.54	7.9e-49	Opioid sensitivity;
BRCA	cis	rs6815814	0.950	rs11722788	chr4:38810738	C/G	cg02016764	chr4:38805732	TLR1	-0.6	-9.46	-0.35	6.03e-20	Breast cancer;
BRCA	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg14343924	chr8:8086146	FLJ10661	0.41	8.55	0.32	9.27e-17	Mood instability;
BRCA	cis	rs2505998	0.868	rs2505991	chr10:43566360	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.42	-7.86	-0.3	1.58e-14	Hirschsprung disease;
BRCA	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg02544614	chr20:61657117	NA	0.3	8.38	0.31	3.49e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg17063962	chr7:91808500	NA	0.57	13.09	0.46	7.76e-35	Breast cancer;
BRCA	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.41	9.06	0.34	1.63e-18	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg20307385	chr11:47447363	PSMC3	0.82	20.88	0.64	3.43e-74	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg05623727	chr3:50126028	RBM5	0.49	11.63	0.42	1.64e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs4268898	0.896	rs2702042	chr2:24546542	C/T	cg06627628	chr2:24431161	ITSN2	-0.51	-10.31	-0.38	3.53e-23	Asthma;
BRCA	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg12310025	chr6:25882481	NA	-0.54	-13.04	-0.46	1.21e-34	Blood metabolite levels;
BRCA	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg11822812	chr5:140052017	DND1	0.31	8.41	0.32	2.68e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3849570	1.000	rs9826270	chr3:81841869	C/T	cg07356753	chr3:81810745	GBE1	-0.47	-11.26	-0.41	5.86e-27	Waist circumference;Body mass index;
BRCA	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg04362960	chr10:104952993	NT5C2	0.92	14.83	0.51	5.5e-43	Arsenic metabolism;
BRCA	trans	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg26384229	chr12:38710491	ALG10B	0.52	11.22	0.41	8.47e-27	Morning vs. evening chronotype;
BRCA	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg16179182	chr5:140090404	VTRNA1-1	0.43	10.29	0.38	4.32e-23	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4285028	0.948	rs10934565	chr3:121664661	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.84	-0.39	2.9e-25	Multiple sclerosis;
BRCA	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.4	9.61	0.36	1.7e-20	Eosinophil percentage of white cells;
BRCA	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg06623918	chr6:96969491	KIAA0776	-0.93	-27.35	-0.73	1.21e-109	Headache;
BRCA	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg13010199	chr12:38710504	ALG10B	0.42	9.04	0.34	1.83e-18	Morning vs. evening chronotype;
BRCA	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg15839431	chr19:19639596	YJEFN3	0.41	8.9	0.33	5.7e-18	Bipolar disorder;
BRCA	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-12.91	-0.45	4.98e-34	Blood metabolite levels;
BRCA	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg09307838	chr4:120376055	NA	0.61	12.32	0.44	1.99e-31	Corneal astigmatism;
BRCA	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg00101154	chr16:420108	MRPL28	-0.4	-8.59	-0.32	6.63e-17	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg03342759	chr3:160939853	NMD3	-0.61	-13.64	-0.47	2.37e-37	Morning vs. evening chronotype;
BRCA	trans	rs7178375	1.000	rs7178375	chr15:31215935	C/T	cg04373760	chr16:53404718	NA	0.5	9.22	0.34	4.37e-19	Hypertriglyceridemia;
BRCA	cis	rs11249608	0.548	rs34881171	chr5:178451932	C/T	cg21905437	chr5:178450457	ZNF879	0.55	11.34	0.41	2.83e-27	Pubertal anthropometrics;
BRCA	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg01528321	chr10:82214614	TSPAN14	0.83	18.6	0.59	5.14e-62	Post bronchodilator FEV1;
BRCA	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.72	0.39	9.15e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10463316	0.894	rs7729216	chr5:150762277	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.22	-0.31	1.12e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg12165864	chr7:66369176	NA	0.43	9.49	0.35	4.53e-20	Corneal structure;
BRCA	cis	rs3820928	0.845	rs4234065	chr2:227882006	C/T	cg11843606	chr2:227700838	RHBDD1	-0.36	-7.89	-0.3	1.28e-14	Pulmonary function;
BRCA	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-8.03	-0.3	4.72e-15	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-11.64	-0.42	1.58e-28	Gut microbiome composition (summer);
BRCA	cis	rs73001065	0.792	rs17216525	chr19:19662220	C/T	cg03709012	chr19:19516395	GATAD2A	0.86	9.37	0.35	1.21e-19	LDL cholesterol;
BRCA	cis	rs6700896	0.931	rs4420065	chr1:66161461	T/C	cg04111102	chr1:66153794	NA	-0.35	-8.5	-0.32	1.35e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-10.39	-0.38	1.83e-23	Monocyte count;
BRCA	cis	rs6142102	0.625	rs6141431	chr20:32540314	G/A	cg24642439	chr20:33292090	TP53INP2	0.39	7.83	0.3	2.04e-14	Skin pigmentation;
BRCA	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg22974920	chr21:40686053	BRWD1	-0.39	-8.56	-0.32	8.48e-17	Cognitive function;
BRCA	cis	rs6893300	0.785	rs7705530	chr5:179190994	C/T	cg14593053	chr5:179126677	CANX	-0.36	-8.09	-0.3	2.9e-15	Resting heart rate;
BRCA	cis	rs524281	0.861	rs10791854	chr11:65963543	A/T	cg16950941	chr11:66035639	RAB1B	-0.38	-8.03	-0.3	4.85e-15	Electroencephalogram traits;
BRCA	cis	rs2066819	0.786	rs111580405	chr12:56739557	A/G	cg26714650	chr12:56694279	CS	-1.2	-15.49	-0.52	3.36e-46	Psoriasis vulgaris;
BRCA	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg06671706	chr8:8559999	CLDN23	0.44	8.33	0.31	4.87e-16	Obesity-related traits;
BRCA	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg25664220	chr3:72788482	NA	-0.55	-11.7	-0.42	8.66e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg04450456	chr4:17643702	FAM184B	0.33	9.51	0.35	3.74e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg26384229	chr12:38710491	ALG10B	0.47	10.42	0.38	1.35e-23	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg21535247	chr6:8435926	SLC35B3	0.42	9.61	0.36	1.65e-20	Motion sickness;
BRCA	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.88	0.64	3.29e-74	Chronic sinus infection;
BRCA	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-9.27	-0.34	2.71e-19	Chronic sinus infection;
BRCA	cis	rs9287719	0.614	rs12329184	chr2:10722764	T/C	cg00105475	chr2:10696890	NA	0.41	9.17	0.34	6.17e-19	Prostate cancer;
BRCA	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg23711669	chr6:146136114	FBXO30	0.71	17.01	0.56	8.7e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.67	10.46	0.38	9.82e-24	Schizophrenia;
BRCA	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg06784218	chr1:46089804	CCDC17	-0.52	-12.68	-0.45	5.18e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1829883	0.748	rs1916598	chr5:98743288	G/A	cg08333243	chr5:99726346	NA	0.34	8.41	0.32	2.65e-16	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg06484146	chr7:12443880	VWDE	-0.71	-9.98	-0.37	6.65e-22	Coronary artery disease;
BRCA	cis	rs926392	0.640	rs7268716	chr20:37693214	C/T	cg16355469	chr20:37678765	NA	0.53	11.62	0.42	1.98e-28	Dialysis-related mortality;
BRCA	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg15028436	chr7:37888078	TXNDC3	0.34	7.87	0.3	1.47e-14	Alzheimer's disease (late onset);
BRCA	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg12219531	chr12:120966889	COQ5	0.55	11.43	0.41	1.17e-27	High light scatter reticulocyte count;
BRCA	trans	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg19862616	chr7:65841803	NCRNA00174	0.84	27.77	0.74	6.62e-112	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg26384229	chr12:38710491	ALG10B	0.67	14.29	0.49	2.1e-40	Morning vs. evening chronotype;
BRCA	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.39	0.35	1e-19	Tonsillectomy;
BRCA	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.32	0.61	7.31e-66	Alzheimer's disease;
BRCA	cis	rs55883249	0.958	rs17362734	chr2:9730208	A/G	cg23886495	chr2:9695866	ADAM17	0.55	7.93	0.3	9.58e-15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
BRCA	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg11707556	chr5:10655725	ANKRD33B	0.42	9.39	0.35	1.06e-19	Coronary artery disease;
BRCA	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg23711669	chr6:146136114	FBXO30	0.72	16.38	0.54	1.28e-50	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12579753	0.879	rs7971664	chr12:82264101	T/C	cg07988820	chr12:82153109	PPFIA2	-0.49	-8.06	-0.3	3.76e-15	Resting heart rate;
BRCA	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg05863683	chr7:1912471	MAD1L1	-0.41	-8.7	-0.33	2.75e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg11663144	chr21:46675770	NA	0.59	13.94	0.48	9.39e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg20090143	chr19:45452003	APOC2	0.27	8.1	0.31	2.69e-15	Blood protein levels;
BRCA	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg12573674	chr2:1569213	NA	-0.5	-9.59	-0.35	2.01e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7903847	0.619	rs9888116	chr10:99159482	G/A	cg20016023	chr10:99160130	RRP12	-0.26	-8.43	-0.32	2.23e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg21573476	chr21:45109991	RRP1B	-0.37	-9.64	-0.36	1.32e-20	Mean corpuscular volume;
BRCA	cis	rs1030877	0.515	rs2576741	chr2:105897964	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.67	12.76	0.45	2.24e-33	Obesity-related traits;
BRCA	cis	rs61612642	0.537	rs73434275	chr6:42156239	G/A	cg10382835	chr6:42185730	MRPS10	0.53	8.04	0.3	4.34e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
BRCA	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-8.09	-0.3	2.91e-15	Blood pressure (smoking interaction);
BRCA	trans	rs4714291	0.802	rs2984430	chr6:39983741	A/G	cg02267698	chr19:7991119	CTXN1	-0.45	-9.32	-0.35	1.92e-19	Strep throat;
BRCA	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg02153584	chr22:29168773	CCDC117	0.58	12.3	0.44	2.24e-31	Lymphocyte counts;
BRCA	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.49	0.38	7.52e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg17143192	chr8:8559678	CLDN23	-0.51	-9.81	-0.36	2.92e-21	Obesity-related traits;
BRCA	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg18512352	chr11:47633146	NA	-0.37	-9.13	-0.34	9.17e-19	Subjective well-being;
BRCA	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg24296786	chr1:45957014	TESK2	0.62	15.39	0.52	1.12e-45	High light scatter reticulocyte count;
BRCA	trans	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg25214090	chr10:38739885	LOC399744	0.45	9.68	0.36	9.14e-21	Corneal astigmatism;
BRCA	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-9.86	-0.36	1.86e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg14024328	chr4:719362	PCGF3	-0.45	-11.49	-0.41	6.88e-28	White blood cell count;
BRCA	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg12011299	chr4:100065546	ADH4	0.48	10.76	0.39	6.33e-25	Smoking initiation;
BRCA	cis	rs1953600	0.870	rs2789695	chr10:81946840	C/T	cg04850286	chr10:81895943	PLAC9	0.32	9.0	0.34	2.57e-18	Sarcoidosis;
BRCA	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg15691649	chr6:25882328	NA	-0.45	-8.58	-0.32	7.41e-17	Urate levels;
BRCA	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg16482183	chr6:26056742	HIST1H1C	-0.41	-8.78	-0.33	1.49e-17	Iron status biomarkers;
BRCA	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18404041	chr3:52824283	ITIH1	0.38	11.57	0.42	3.05e-28	Bipolar disorder;
BRCA	cis	rs2073300	1.000	rs114718317	chr20:23442620	T/C	cg12062639	chr20:23401060	NAPB	0.87	10.4	0.38	1.58e-23	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg02176678	chr2:219576539	TTLL4	0.38	10.24	0.38	7.1e-23	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4911259	0.507	rs8118663	chr20:31398876	A/G	cg13636640	chr20:31349939	DNMT3B	0.49	11.68	0.42	1.08e-28	Inflammatory bowel disease;
BRCA	cis	rs3784262	0.528	rs34556514	chr15:58333769	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-9.68	-0.36	8.65e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg23711669	chr6:146136114	FBXO30	0.71	16.94	0.56	1.95e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg07905965	chr19:39260460	NA	0.57	13.79	0.48	4.91e-38	Heart rate;
BRCA	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg18678763	chr11:4115507	RRM1	-0.37	-8.33	-0.31	5.12e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11644478	chr21:40555479	PSMG1	0.85	19.42	0.61	2.19e-66	Cognitive function;
BRCA	cis	rs11605924	0.792	rs10838524	chr11:45870177	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.47	-10.12	-0.37	1.93e-22	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs10911363	0.592	rs2702203	chr1:183462513	A/T	cg09173681	chr1:183549694	NCF2	0.49	10.68	0.39	1.27e-24	Systemic lupus erythematosus;
BRCA	cis	rs9487051	0.834	rs436880	chr6:109553069	C/T	cg01475377	chr6:109611718	NA	-0.4	-9.6	-0.36	1.75e-20	Reticulocyte fraction of red cells;
BRCA	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg13902645	chr11:5959945	NA	-0.48	-10.23	-0.38	7.75e-23	DNA methylation (variation);
BRCA	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg17628894	chr11:804452	LRDD	0.29	9.28	0.34	2.53e-19	Breast cancer;
BRCA	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.97	13.87	0.48	1.97e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4285028	0.948	rs34837785	chr3:121657776	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.61	-11.05	-0.4	4.18e-26	Multiple sclerosis;
BRCA	cis	rs7011049	1.000	rs7011049	chr8:53834012	C/A	cg26025543	chr8:53854495	NA	0.54	9.86	0.36	1.85e-21	Systolic blood pressure;
BRCA	cis	rs13190036	1.000	rs71601343	chr5:176632107	G/A	cg06733329	chr5:176740039	MXD3	0.46	8.3	0.31	6.26e-16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg08017756	chr2:100939284	LONRF2	-0.31	-8.02	-0.3	4.88e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00166722	chr3:10149974	C3orf24	0.65	12.84	0.45	9.71e-34	Alzheimer's disease;
BRCA	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg25036284	chr2:26402008	FAM59B	-0.88	-15.06	-0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25427524	chr10:38739819	LOC399744	-0.69	-16.71	-0.55	2.82e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs72772090	0.634	rs10515246	chr5:96099265	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-13.2	-0.46	2.34e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.42	-9.53	-0.35	3.22e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.76	12.67	0.45	5.84e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg12292205	chr6:26970375	C6orf41	0.54	11.79	0.42	3.62e-29	Schizophrenia;
BRCA	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg23625390	chr15:77176239	SCAPER	-0.54	-12.71	-0.45	3.89e-33	Blood metabolite levels;
BRCA	cis	rs17604090	0.701	rs60930239	chr7:29688544	A/G	cg19413766	chr7:29689036	LOC646762	-0.5	-8.12	-0.31	2.43e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg00677455	chr12:58241039	CTDSP2	0.56	13.05	0.46	1.18e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg04775059	chr7:64541387	NA	0.44	8.16	0.31	1.79e-15	Calcium levels;
BRCA	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg25358565	chr5:93447407	FAM172A	1.21	18.79	0.6	5.1e-63	Diabetic retinopathy;
BRCA	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg14343924	chr8:8086146	FLJ10661	0.41	8.32	0.31	5.3e-16	Mood instability;
BRCA	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg23708337	chr7:1209742	NA	0.6	13.68	0.48	1.45e-37	Longevity;Endometriosis;
BRCA	trans	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.62	13.89	0.48	1.66e-38	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg02574844	chr11:5959923	NA	0.41	8.27	0.31	7.85e-16	DNA methylation (variation);
BRCA	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.62	-0.32	5.3e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs311392	0.902	rs411371	chr8:55092609	G/A	cg11783602	chr8:55087084	NA	-0.31	-9.04	-0.34	1.8e-18	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg26384229	chr12:38710491	ALG10B	-0.51	-12.31	-0.44	2.19e-31	Morning vs. evening chronotype;
BRCA	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg06026331	chr20:60912101	LAMA5	0.44	8.33	0.31	4.8e-16	Colorectal cancer;
BRCA	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11644478	chr21:40555479	PSMG1	-0.67	-14.27	-0.49	2.78e-40	Cognitive function;
BRCA	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.65	-0.36	1.17e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg15832292	chr6:96025679	MANEA	-0.57	-8.77	-0.33	1.65e-17	Behavioural disinhibition (generation interaction);
BRCA	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg09307838	chr4:120376055	NA	0.72	15.31	0.52	2.61e-45	Corneal astigmatism;
BRCA	cis	rs6121246	0.559	rs6060932	chr20:30350545	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	23.37	0.68	8.7e-88	Mean corpuscular hemoglobin;
BRCA	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-12.11	-0.43	1.51e-30	Chronic sinus infection;
BRCA	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg19156104	chr2:198669113	PLCL1	-0.43	-7.95	-0.3	8.24e-15	Ulcerative colitis;
BRCA	cis	rs4285028	0.948	rs12630486	chr3:121685267	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-11.01	-0.4	6.18e-26	Multiple sclerosis;
BRCA	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg04450456	chr4:17643702	FAM184B	0.35	9.53	0.35	3.09e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03264133	chr6:25882463	NA	-0.49	-11.01	-0.4	6.3e-26	Blood metabolite levels;
BRCA	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg06935464	chr4:38784597	TLR10	0.51	8.2	0.31	1.32e-15	Breast cancer;
BRCA	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg04166393	chr7:2884313	GNA12	0.41	8.68	0.32	3.19e-17	Height;
BRCA	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	15.61	0.53	9.38e-47	Multiple sclerosis;
BRCA	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg23978390	chr7:1156363	C7orf50	0.38	8.89	0.33	6.28e-18	Longevity;Endometriosis;
BRCA	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.39	8.9	0.33	5.61e-18	Height;Educational attainment;Head circumference (infant);
BRCA	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg18230493	chr5:56204884	C5orf35	-0.42	-8.71	-0.33	2.54e-17	Coronary artery disease;
BRCA	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg19622623	chr12:86230825	RASSF9	-0.33	-9.32	-0.35	1.84e-19	Major depressive disorder;
BRCA	cis	rs6700896	0.931	rs11208711	chr1:66147846	G/T	cg04111102	chr1:66153794	NA	0.34	8.46	0.32	1.89e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs12612619	0.732	rs13020526	chr2:27204650	C/T	cg00617064	chr2:27272375	NA	-0.34	-8.86	-0.33	8.02e-18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg21573476	chr21:45109991	RRP1B	-0.37	-9.36	-0.35	1.31e-19	Mean corpuscular volume;
BRCA	trans	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg06521331	chr12:34319734	NA	-0.47	-8.68	-0.32	3.27e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg12081754	chr8:22256438	SLC39A14	0.51	10.33	0.38	2.97e-23	Verbal declarative memory;
BRCA	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.78	-13.31	-0.47	7.83e-36	Mean platelet volume;
BRCA	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg24110177	chr3:50126178	RBM5	-0.38	-10.16	-0.37	1.41e-22	Menarche (age at onset);
BRCA	cis	rs62458065	0.513	rs7805536	chr7:32573570	T/C	cg20159608	chr7:32802032	NA	-0.51	-9.77	-0.36	4.05e-21	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg11584989	chr19:19387371	SF4	0.64	13.48	0.47	1.25e-36	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.39	0.57	9.59e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg18225595	chr11:63971243	STIP1	0.47	8.91	0.33	5.2e-18	Mean platelet volume;
BRCA	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg08470875	chr2:26401718	FAM59B	-0.72	-11.48	-0.41	7.58e-28	Gut microbiome composition (summer);
BRCA	cis	rs6545883	0.894	rs2463102	chr2:61571295	G/C	cg15711740	chr2:61764176	XPO1	0.52	13.27	0.46	1.15e-35	Tuberculosis;
BRCA	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.47	-0.32	1.65e-16	Total body bone mineral density;
BRCA	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12379764	chr21:47803548	PCNT	-0.48	-10.2	-0.37	9.72e-23	Testicular germ cell tumor;
BRCA	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg23533926	chr12:111358616	MYL2	-0.44	-9.18	-0.34	5.78e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg24562669	chr7:97807699	LMTK2	0.44	11.75	0.42	5.51e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4363385	0.747	rs3753454	chr1:152973776	T/C	cg21543102	chr1:152974771	SPRR3	-0.28	-7.85	-0.3	1.74e-14	Inflammatory skin disease;
BRCA	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg17143192	chr8:8559678	CLDN23	0.57	11.17	0.4	1.35e-26	Obesity-related traits;
BRCA	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg00745463	chr17:30367425	LRRC37B	-0.6	-9.77	-0.36	4.04e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.63	9.87	0.36	1.8e-21	Lung function (FEV1/FVC);
BRCA	cis	rs4363385	0.740	rs1697428	chr1:153015761	C/A	cg24667326	chr1:152973720	SPRR3	-0.33	-8.71	-0.33	2.58e-17	Inflammatory skin disease;
BRCA	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg07148914	chr20:33460835	GGT7	0.47	10.01	0.37	5.42e-22	Height;
BRCA	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.28	-0.34	2.52e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	18.52	0.59	1.22e-61	Platelet count;
BRCA	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg08738300	chr3:44038990	NA	0.45	8.7	0.33	2.79e-17	Coronary artery disease;
BRCA	trans	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg06521331	chr12:34319734	NA	-0.53	-9.51	-0.35	3.7e-20	Bladder cancer;
BRCA	cis	rs3741151	0.773	rs73542967	chr11:73123512	C/T	cg17517138	chr11:73019481	ARHGEF17	0.88	12.73	0.45	3.1e-33	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg11814155	chr7:99998594	ZCWPW1	0.43	8.19	0.31	1.38e-15	Platelet count;
BRCA	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-11.62	-0.42	1.89e-28	Lymphocyte counts;
BRCA	cis	rs7766436	0.614	rs7775936	chr6:22566151	T/C	cg13666174	chr6:22585274	NA	-0.41	-8.66	-0.32	3.86e-17	Coronary artery disease;
BRCA	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg13047869	chr3:10149882	C3orf24	0.51	11.06	0.4	3.79e-26	Alzheimer's disease;
BRCA	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg09904177	chr6:26538194	HMGN4	0.42	11.99	0.43	5.17e-30	Intelligence (multi-trait analysis);
BRCA	trans	rs11088226	0.750	rs2833885	chr21:33923161	A/G	cg09050820	chr6:167586206	TCP10L2	0.54	9.32	0.35	1.91e-19	Gastritis;
BRCA	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg01877450	chr7:97915802	BRI3	-0.39	-8.93	-0.33	4.63e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg24130564	chr14:104152367	KLC1	0.35	7.82	0.3	2.23e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.59	0.57	9.06e-57	Bladder cancer;
BRCA	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-9.74	-0.36	5.28e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg04944784	chr2:26401820	FAM59B	-0.95	-16.25	-0.54	5.83e-50	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.39	0.35	1.01e-19	Tonsillectomy;
BRCA	cis	rs9831754	0.906	rs1588650	chr3:78410750	T/G	cg06138941	chr3:78371609	NA	-0.74	-16.39	-0.54	1.18e-50	Calcium levels;
BRCA	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.27	-0.31	7.52e-16	Total body bone mineral density;
BRCA	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg03146154	chr1:46216737	IPP	0.53	11.84	0.42	2.3e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg24562669	chr7:97807699	LMTK2	0.47	12.58	0.45	1.38e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24549020	chr5:56110836	MAP3K1	0.41	8.65	0.32	4.22e-17	Initial pursuit acceleration;
BRCA	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg15017067	chr4:17643749	FAM184B	0.28	8.48	0.32	1.51e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg00825309	chr19:58991885	ZNF446	-0.58	-13.2	-0.46	2.46e-35	Uric acid clearance;
BRCA	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg07917127	chr4:99064746	C4orf37	0.42	8.0	0.3	6e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	1.94e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.39	0.57	9.59e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg08888203	chr3:10149979	C3orf24	0.68	14.46	0.5	3.2e-41	Alzheimer's disease;
BRCA	cis	rs9815354	0.812	rs57209010	chr3:41854743	A/T	cg03022575	chr3:42003672	ULK4	0.65	8.98	0.33	2.95e-18	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg07371521	chr5:154026371	NA	0.41	8.1	0.31	2.79e-15	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs7586879	0.752	rs11683748	chr2:25130434	C/T	cg01884057	chr2:25150051	NA	0.31	7.87	0.3	1.51e-14	Body mass index;
BRCA	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg20387954	chr3:183756860	HTR3D	0.45	10.09	0.37	2.51e-22	Anterior chamber depth;
BRCA	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg08470875	chr2:26401718	FAM59B	-0.51	-8.54	-0.32	9.56e-17	Gut microbiome composition (summer);
BRCA	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	18.24	0.59	3.9e-60	Platelet count;
BRCA	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg06552810	chr11:31128660	NA	-0.38	-8.73	-0.33	2.15e-17	Red blood cell count;
BRCA	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg23978390	chr7:1156363	C7orf50	0.4	8.17	0.31	1.6e-15	Bronchopulmonary dysplasia;
BRCA	trans	rs2262909	0.925	rs73019900	chr19:22286680	G/A	cg17074339	chr11:11642133	GALNTL4	0.44	8.5	0.32	1.33e-16	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.43	0.5	4.39e-41	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg23505145	chr19:12996616	KLF1	0.54	12.19	0.43	7.29e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.35	0.49	1.1e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg01689657	chr7:91764605	CYP51A1	0.23	8.51	0.32	1.2e-16	Breast cancer;
BRCA	cis	rs12760731	0.668	rs10913548	chr1:178372286	G/A	cg00404053	chr1:178313656	RASAL2	0.7	8.36	0.31	3.93e-16	Obesity-related traits;
BRCA	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22029157	chr1:209979665	IRF6	-0.55	-12.42	-0.44	7e-32	Cleft lip with or without cleft palate;
BRCA	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg19784903	chr17:45786737	TBKBP1	-0.4	-10.02	-0.37	4.94e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg11663144	chr21:46675770	NA	-0.6	-13.93	-0.48	1.04e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02176678	chr2:219576539	TTLL4	0.45	11.86	0.42	1.75e-29	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg21573476	chr21:45109991	RRP1B	-0.37	-9.35	-0.35	1.43e-19	Mean corpuscular volume;
BRCA	trans	rs1997103	0.911	rs6945663	chr7:55407011	C/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs9944715	0.954	rs9959905	chr18:43811050	A/G	cg01718231	chr17:29326311	RNF135	-0.46	-8.84	-0.33	9.57e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg24642439	chr20:33292090	TP53INP2	0.43	9.11	0.34	1.03e-18	Height;
BRCA	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg23029597	chr12:123009494	RSRC2	-0.44	-8.98	-0.33	2.9e-18	Body mass index;
BRCA	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg20307385	chr11:47447363	PSMC3	0.86	25.57	0.71	7.1e-100	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs877529	1.000	rs139396	chr22:39538485	G/T	cg12193277	chr22:39547181	CBX7	0.46	12.6	0.45	1.1e-32	Multiple myeloma;
BRCA	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg07636037	chr3:49044803	WDR6	0.98	29.06	0.75	6.01e-119	Parkinson's disease;
BRCA	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg22800045	chr5:56110881	MAP3K1	0.65	12.34	0.44	1.62e-31	Initial pursuit acceleration;
BRCA	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg08999081	chr20:33150536	PIGU	0.47	13.04	0.46	1.22e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs12549902	0.800	rs7825494	chr8:41507350	C/T	cg21772509	chr8:41503840	NKX6-3	0.43	10.4	0.38	1.71e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
BRCA	trans	rs11088226	0.645	rs78172258	chr21:33936539	T/G	cg09050820	chr6:167586206	TCP10L2	0.77	13.24	0.46	1.49e-35	Gastritis;
BRCA	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg11608241	chr8:8085544	FLJ10661	0.36	9.72	0.36	6.5e-21	Neuroticism;
BRCA	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-7.97	-0.3	7.28e-15	Longevity;Endometriosis;
BRCA	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.36	9.44	0.35	6.86e-20	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg11502198	chr6:26597334	ABT1	0.48	9.52	0.35	3.46e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg21784768	chr11:537496	LRRC56	-0.66	-8.37	-0.31	3.62e-16	Body mass index;
BRCA	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg04025307	chr7:1156635	C7orf50	0.58	9.0	0.34	2.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1451375	0.698	rs11489734	chr7:50635730	A/T	cg18232548	chr7:50535776	DDC	0.39	9.26	0.34	3.11e-19	Malaria;
BRCA	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11764359	chr7:65958608	NA	-0.61	-13.52	-0.47	7.99e-37	Corneal structure;
BRCA	cis	rs7789940	0.951	rs7779014	chr7:75975586	C/T	cg10167463	chr7:75959203	YWHAG	-0.44	-8.86	-0.33	7.66e-18	Multiple sclerosis;
BRCA	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.23	-0.31	1.08e-15	Depression;
BRCA	cis	rs7551345	0.653	rs2377730	chr1:31697779	A/G	cg19084893	chr1:31688959	NA	-0.46	-10.04	-0.37	4.13e-22	Schizophrenia;
BRCA	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg08085267	chr17:45401833	C17orf57	0.61	12.75	0.45	2.36e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs34779708	0.931	rs2244100	chr10:35323636	G/A	cg03585969	chr10:35415529	CREM	-0.46	-9.61	-0.36	1.65e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg06521331	chr12:34319734	NA	-0.55	-9.97	-0.37	7.12e-22	Morning vs. evening chronotype;
BRCA	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02176678	chr2:219576539	TTLL4	0.41	10.97	0.4	9.22e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg18132916	chr6:79620363	NA	0.47	10.93	0.4	1.26e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs2882667	0.518	rs10041986	chr5:138424437	A/G	cg04439458	chr5:138467593	SIL1	-0.31	-8.65	-0.32	4.3e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg26373071	chr5:1325741	CLPTM1L	0.49	12.08	0.43	2.13e-30	Lung cancer;
BRCA	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-12.17	-0.43	8.58e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs12431939	1.000	rs12432466	chr14:51638873	T/C	cg23942311	chr14:51606299	NA	-0.44	-8.35	-0.31	4.31e-16	Cancer;
BRCA	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg21427119	chr20:30132790	HM13	-0.43	-8.89	-0.33	6.33e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg14004847	chr7:1930337	MAD1L1	0.44	9.44	0.35	6.59e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs2859741	1.000	rs543121	chr1:37497098	T/C	cg09363841	chr1:37513479	NA	-0.66	-16.5	-0.55	3.44e-51	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs2625529	0.730	rs2957373	chr15:72340929	T/C	cg16672083	chr15:72433130	SENP8	0.72	17.18	0.56	1.1e-54	Red blood cell count;
BRCA	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg11584989	chr19:19387371	SF4	0.63	13.52	0.47	7.85e-37	Bipolar disorder;
BRCA	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg18806716	chr10:30721971	MAP3K8	-0.6	-14.12	-0.49	1.3e-39	Inflammatory bowel disease;
BRCA	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg26116260	chr4:7069785	GRPEL1	0.93	25.73	0.71	9.81e-101	Monocyte percentage of white cells;
BRCA	cis	rs68170813	0.559	rs80017637	chr7:107050660	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.07	-0.3	3.44e-15	Coronary artery disease;
BRCA	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg02297831	chr4:17616191	MED28	-0.37	-7.98	-0.3	6.71e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1568889	0.838	rs4572130	chr11:28371794	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	19.93	0.62	4.13e-69	Bipolar disorder;
BRCA	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg18404041	chr3:52824283	ITIH1	-0.35	-9.49	-0.35	4.53e-20	Bipolar disorder;
BRCA	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg02951883	chr7:2050386	MAD1L1	-0.49	-10.84	-0.39	2.98e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg19338460	chr6:170058176	WDR27	-0.44	-7.97	-0.3	7.26e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg22920501	chr2:26401640	FAM59B	-0.61	-10.7	-0.39	1.13e-24	Gut microbiome composition (summer);
BRCA	cis	rs16976116	0.901	rs1061874	chr15:55496287	A/T	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg22875332	chr1:76189707	ACADM	0.64	11.68	0.42	1.08e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg18154014	chr19:37997991	ZNF793	0.61	11.1	0.4	2.79e-26	Coronary artery calcification;
BRCA	cis	rs17688601	1.000	rs13230202	chr7:40865219	T/C	cg05119115	chr7:40866195	C7orf10	-0.6	-11.68	-0.42	1.1e-28	Pancreatic cancer;
BRCA	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.03	-0.3	4.61e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.45	0.35	6.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1568889	0.938	rs12795971	chr11:28355104	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	13.07	0.46	9.15e-35	Bipolar disorder;
BRCA	trans	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.92	-0.3	1.02e-14	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2652834	1.000	rs2729781	chr15:63404265	T/A	cg05507819	chr15:63340323	TPM1	0.45	8.26	0.31	8.31e-16	HDL cholesterol;
BRCA	cis	rs6005807	0.719	rs2881496	chr22:28921265	C/G	cg12565055	chr22:29076175	TTC28	-0.41	-7.95	-0.3	8.73e-15	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg07051648	chr19:49177693	NTN5;SEC1	-0.43	-8.26	-0.31	8.57e-16	Dietary macronutrient intake;
BRCA	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg19346786	chr7:2764209	NA	-0.3	-9.42	-0.35	8.35e-20	Height;
BRCA	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.2	-18.89	-0.6	1.42e-63	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs4588572	0.643	rs2012562	chr5:77768088	T/A	cg11547950	chr5:77652471	NA	-0.48	-8.56	-0.32	8.15e-17	Triglycerides;
BRCA	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-9.88	-0.36	1.6e-21	Alzheimer's disease (late onset);
BRCA	cis	rs4948102	0.597	rs12669623	chr7:56139179	G/C	cg09872392	chr7:56161020	PHKG1	-0.49	-12.23	-0.44	4.74e-31	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg14675211	chr2:100938903	LONRF2	0.44	9.7	0.36	7.48e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg08807101	chr21:30365312	RNF160	-0.6	-15.37	-0.52	1.35e-45	Dental caries;
BRCA	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg24006582	chr15:45444508	DUOX1	0.55	10.71	0.39	9.9e-25	Uric acid levels;
BRCA	cis	rs9790314	0.746	rs898680	chr3:160772853	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-8.78	-0.33	1.5e-17	Morning vs. evening chronotype;
BRCA	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg17063962	chr7:91808500	NA	0.55	13.17	0.46	3.18e-35	Breast cancer;
BRCA	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.61	-0.32	5.7e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21659725	chr3:3221576	CRBN	-0.46	-10.15	-0.37	1.55e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9296092	0.538	rs9469491	chr6:33521545	A/G	cg13560919	chr6:33536144	NA	0.84	18.39	0.59	6.5e-61	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.7	-17.06	-0.56	4.59e-54	Survival in pancreatic cancer;
BRCA	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg04998671	chr14:104000505	TRMT61A	-0.43	-9.5	-0.35	4.27e-20	Coronary artery disease;
BRCA	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-10.36	-0.38	2.36e-23	Blood metabolite levels;
BRCA	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg20991723	chr1:152506922	NA	-0.38	-8.92	-0.33	4.94e-18	Hair morphology;
BRCA	cis	rs1018836	0.892	rs5005585	chr8:91581975	A/G	cg16814680	chr8:91681699	NA	-0.56	-12.15	-0.43	1.01e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg12935359	chr14:103987150	CKB	0.64	15.0	0.51	8.63e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-8.0	-0.3	6.08e-15	Prostate cancer;
BRCA	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg23625390	chr15:77176239	SCAPER	-0.53	-12.65	-0.45	6.52e-33	Blood metabolite levels;
BRCA	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg12863693	chr15:85201151	NMB	-0.33	-7.98	-0.3	7.02e-15	P wave terminal force;
BRCA	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.47	8.8	0.33	1.24e-17	Breast cancer;
BRCA	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-8.42	-0.32	2.41e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	9.36	0.35	1.29e-19	Renal function-related traits (BUN);
BRCA	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg19784903	chr17:45786737	TBKBP1	-0.39	-9.51	-0.35	3.68e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs28735056	0.587	rs8093548	chr18:77636451	G/A	cg20368463	chr18:77673604	PQLC1	-0.42	-10.79	-0.39	4.62e-25	Schizophrenia;
BRCA	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05890377	chr2:74357713	NA	0.48	11.65	0.42	1.4e-28	Gestational age at birth (maternal effect);
BRCA	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg05925327	chr15:68127851	NA	0.35	8.72	0.33	2.41e-17	Restless legs syndrome;
BRCA	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	15.05	0.51	5.12e-44	Hip circumference adjusted for BMI;
BRCA	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg08508325	chr11:3079039	CARS	-0.47	-17.81	-0.58	6.52e-58	Longevity;
BRCA	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg15208524	chr1:10270712	KIF1B	0.37	7.89	0.3	1.32e-14	Hepatocellular carcinoma;
BRCA	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	14.28	0.49	2.37e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7432375	0.641	rs1971397	chr3:136527300	C/G	cg21827317	chr3:136751795	NA	0.35	7.83	0.3	2.04e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs67981189	0.896	rs34049963	chr14:71440746	A/G	cg15816911	chr14:71606274	NA	0.35	7.89	0.3	1.29e-14	Schizophrenia;
BRCA	trans	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	21.05	0.64	4.24e-75	Exhaled nitric oxide output;
BRCA	cis	rs586533	0.881	rs640790	chr11:99503264	T/C	cg22878054	chr11:99397252	CNTN5	0.32	8.12	0.31	2.34e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg08997352	chr12:9597637	DDX12	-0.58	-11.76	-0.42	4.92e-29	Breast size;
BRCA	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg03060546	chr3:49711283	APEH	-0.59	-10.21	-0.37	9.07e-23	Menarche (age at onset);
BRCA	cis	rs7520050	0.966	rs1707321	chr1:46505309	A/G	cg24296786	chr1:45957014	TESK2	0.41	9.13	0.34	8.86e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.2e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg11766577	chr21:47581405	C21orf56	-0.4	-8.35	-0.31	4.37e-16	Testicular germ cell tumor;
BRCA	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg22800045	chr5:56110881	MAP3K1	0.62	11.85	0.42	2.01e-29	Initial pursuit acceleration;
BRCA	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg17366294	chr4:99064904	C4orf37	-0.45	-10.81	-0.39	3.98e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs427394	0.802	rs200841	chr5:6737134	A/G	cg10857441	chr5:6722123	POLS	-0.33	-11.0	-0.4	6.52e-26	Menopause (age at onset);
BRCA	cis	rs36051895	0.659	rs72701605	chr9:5062056	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-8.91	-0.33	5.44e-18	Pediatric autoimmune diseases;
BRCA	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-14.31	-0.49	1.69e-40	Morning vs. evening chronotype;
BRCA	cis	rs3771570	1.000	rs62193197	chr2:242294301	G/A	cg21155796	chr2:242212141	HDLBP	0.6	9.3	0.35	2.25e-19	Prostate cancer;
BRCA	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg12751644	chr20:60527061	NA	-0.33	-7.95	-0.3	8.44e-15	Body mass index;
BRCA	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg07978099	chr16:83986941	OSGIN1	0.36	8.28	0.31	7e-16	Pursuit maintenance gain;
BRCA	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg06627628	chr2:24431161	ITSN2	-0.55	-8.89	-0.33	6.25e-18	Lymphocyte counts;
BRCA	cis	rs3784262	0.669	rs2414530	chr15:58356362	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.39	-10.55	-0.39	4.3e-24	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	trans	rs61332075	0.501	rs55706928	chr2:239445806	T/C	cg01134436	chr17:81009848	B3GNTL1	0.69	8.99	0.34	2.69e-18	Lung function (FEV1/FVC);
BRCA	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.95	0.4	1.13e-25	Birth weight;
BRCA	cis	rs758324	0.947	rs615305	chr5:131291856	A/G	cg06307176	chr5:131281290	NA	-0.53	-10.4	-0.38	1.68e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg03711944	chr11:47377212	SPI1	-0.44	-10.34	-0.38	2.81e-23	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg04733989	chr22:42467013	NAGA	-0.41	-9.6	-0.36	1.77e-20	Cognitive function;
BRCA	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.56	-0.44	1.75e-32	Type 2 diabetes;
BRCA	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg24812749	chr6:127587940	RNF146	0.88	20.06	0.62	9.03e-70	Breast cancer;
BRCA	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg11833968	chr6:79620685	NA	-0.43	-9.55	-0.35	2.75e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs12612619	0.732	rs10865461	chr2:27292651	T/C	cg00617064	chr2:27272375	NA	-0.32	-8.37	-0.31	3.74e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg02753203	chr1:228287806	NA	-0.6	-13.24	-0.46	1.61e-35	Diastolic blood pressure;
BRCA	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-9.56	-0.35	2.58e-20	Schizophrenia;
BRCA	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	15.06	0.51	4.25e-44	Mean corpuscular hemoglobin;
BRCA	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24838063	chr12:130822603	PIWIL1	0.75	18.55	0.59	8.36e-62	Menopause (age at onset);
BRCA	cis	rs11229555	0.598	rs4519112	chr11:58176386	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.76	-0.36	4.48e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg24747557	chr10:131355152	MGMT	0.38	9.6	0.36	1.76e-20	Response to temozolomide;
BRCA	cis	rs495337	1.000	rs2235617	chr20:48554977	C/G	cg17835207	chr20:48524531	SPATA2	-0.58	-13.13	-0.46	5e-35	Psoriasis;
BRCA	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg22535103	chr8:58192502	C8orf71	-0.61	-13.25	-0.46	1.34e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg17971929	chr21:40555470	PSMG1	-0.64	-14.91	-0.51	2.37e-43	Cognitive function;
BRCA	cis	rs68170813	0.559	rs11764448	chr7:106924928	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.45	-0.32	1.99e-16	Coronary artery disease;
BRCA	cis	rs9468199	0.510	rs72845064	chr6:27654970	C/A	cg08851530	chr6:28072375	NA	1.11	10.02	0.37	4.78e-22	Parkinson's disease;
BRCA	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg23422044	chr7:1970798	MAD1L1	-0.7	-12.58	-0.45	1.44e-32	Bipolar disorder;
BRCA	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03452623	chr4:187889614	NA	-0.31	-10.01	-0.37	5.07e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.49	-0.32	1.4e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.88	-0.3	1.45e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg12432903	chr7:1882776	MAD1L1	0.45	8.03	0.3	4.66e-15	Bipolar disorder;
BRCA	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-11.42	-0.41	1.35e-27	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg23711669	chr6:146136114	FBXO30	0.73	16.76	0.55	1.49e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg18357645	chr12:58087776	OS9	0.41	11.43	0.41	1.16e-27	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs2742234	0.590	rs2503848	chr10:43672785	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.54	-10.87	-0.4	2.23e-25	Hirschsprung disease;
BRCA	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26314531	chr2:26401878	FAM59B	-0.88	-15.31	-0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	trans	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg06521331	chr12:34319734	NA	-0.54	-10.21	-0.37	8.63e-23	Bladder cancer;
BRCA	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg13319975	chr6:146136371	FBXO30	0.41	9.42	0.35	8.08e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7577696	0.524	rs212696	chr2:32441685	A/G	cg02381751	chr2:32503542	YIPF4	0.49	8.87	0.33	7.4e-18	Inflammatory biomarkers;
BRCA	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg26516362	chr5:178986906	RUFY1	0.47	13.95	0.48	8.1e-39	Lung cancer;
BRCA	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg23711669	chr6:146136114	FBXO30	0.65	15.23	0.52	6.75e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.88	22.27	0.66	9.04e-82	Body mass index (adult);
BRCA	cis	rs12540874	0.542	rs3807562	chr7:50566671	G/A	cg18232548	chr7:50535776	DDC	-0.51	-12.97	-0.46	2.61e-34	Systemic sclerosis;
BRCA	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg22713356	chr15:30763199	NA	1.21	24.66	0.7	7.87e-95	Uric acid levels;
BRCA	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.62	10.57	0.39	3.45e-24	Lung function (FEV1/FVC);
BRCA	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	18.64	0.59	2.92e-62	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	trans	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.36	-8.49	-0.32	1.4e-16	Corneal astigmatism;
BRCA	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg06784218	chr1:46089804	CCDC17	-0.48	-11.52	-0.41	4.93e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-23.45	-0.68	3.31e-88	Gut microbiome composition (summer);
BRCA	cis	rs6545883	0.783	rs7355640	chr2:61845485	C/T	cg15711740	chr2:61764176	XPO1	-0.48	-11.71	-0.42	8.09e-29	Tuberculosis;
BRCA	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.5	-0.44	3.1e-32	Type 2 diabetes;
BRCA	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11644478	chr21:40555479	PSMG1	-0.68	-15.48	-0.52	3.82e-46	Cognitive function;
BRCA	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg12935359	chr14:103987150	CKB	-0.57	-13.32	-0.47	6.85e-36	Body mass index;
BRCA	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	8.11	0.31	2.53e-15	Mean platelet volume;
BRCA	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg14440974	chr22:39074834	NA	-0.38	-9.0	-0.34	2.64e-18	Menopause (age at onset);
BRCA	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg00339695	chr16:24857497	SLC5A11	-0.35	-8.03	-0.3	4.85e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.747	rs1413848	chr1:152970210	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-8.91	-0.33	5.11e-18	Inflammatory skin disease;
BRCA	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg10729496	chr3:10149963	C3orf24	0.49	9.02	0.34	2.21e-18	Alzheimer's disease;
BRCA	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg07741184	chr6:167504864	NA	-0.32	-9.23	-0.34	3.94e-19	Primary biliary cholangitis;
BRCA	cis	rs10045504	0.502	rs17352898	chr5:38745498	C/T	cg15396434	chr5:38725168	NA	-0.57	-10.77	-0.39	5.62e-25	Night sleep phenotypes;
BRCA	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg24531977	chr5:56204891	C5orf35	-0.56	-12.01	-0.43	4.01e-30	Coronary artery disease;
BRCA	cis	rs2901460	0.509	rs35056428	chr2:62061943	A/T	cg02183531	chr2:62113199	CCT4	-0.46	-8.93	-0.33	4.4e-18	Mean corpuscular volume;
BRCA	cis	rs9807989	0.507	rs7581119	chr2:103049865	G/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.38	0.31	3.39e-16	Asthma;
BRCA	cis	rs600231	0.706	rs1111934	chr11:65329392	A/G	cg17120908	chr11:65337727	SSSCA1	-0.52	-9.31	-0.35	2.03e-19	Bone mineral density;
BRCA	cis	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.35	-0.41	2.62e-27	Morning vs. evening chronotype;
BRCA	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg16576597	chr16:28551801	NUPR1	0.31	8.5	0.32	1.32e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.39	0.49	7.25e-41	Exhaled nitric oxide output;
BRCA	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg18402987	chr7:1209562	NA	0.53	9.43	0.35	7.19e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-15.13	-0.51	2.04e-44	Total cholesterol levels;
BRCA	cis	rs7246657	0.722	rs968073	chr19:38192021	G/A	cg23950597	chr19:37808831	NA	0.51	8.63	0.32	4.82e-17	Coronary artery calcification;
BRCA	cis	rs7301826	0.603	rs7975825	chr12:131288444	C/T	cg11011512	chr12:131303247	STX2	0.44	10.84	0.39	2.99e-25	Plasma plasminogen activator levels;
BRCA	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg25173405	chr17:45401733	C17orf57	0.51	10.65	0.39	1.66e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg13628971	chr7:2884303	GNA12	0.46	9.77	0.36	4.01e-21	Height;
BRCA	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.62	9.77	0.36	4.3e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7103648	0.567	rs12287076	chr11:47606865	G/C	cg20307385	chr11:47447363	PSMC3	-0.66	-15.65	-0.53	5.88e-47	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg09065629	chr16:1709722	CRAMP1L	0.37	8.45	0.32	1.96e-16	Coronary artery disease;
BRCA	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.53	-0.41	4.51e-28	Platelet count;
BRCA	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg00666640	chr1:248458726	OR2T12	0.32	8.95	0.33	3.99e-18	Common traits (Other);
BRCA	cis	rs11634851	0.933	rs2627319	chr15:81040330	C/T	cg03950166	chr15:80988613	FAM108C1	-0.35	-8.02	-0.3	5.14e-15	Systolic blood pressure;
BRCA	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg09658497	chr7:2847517	GNA12	-0.4	-8.41	-0.32	2.7e-16	Height;
BRCA	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-9.48	-0.35	4.72e-20	Response to bleomycin (chromatid breaks);
BRCA	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg22903471	chr2:27725779	GCKR	-0.36	-8.77	-0.33	1.65e-17	Total body bone mineral density;
BRCA	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg17830980	chr10:43048298	ZNF37B	-0.54	-13.16	-0.46	3.53e-35	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17401966	0.838	rs12120042	chr1:10345325	A/T	cg03954927	chr1:10346856	KIF1B	0.44	14.09	0.49	1.93e-39	Hepatocellular carcinoma;
BRCA	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.36	-8.31	-0.31	5.69e-16	Bipolar disorder;
BRCA	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.28	7.82	0.3	2.11e-14	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg09658497	chr7:2847517	GNA12	-0.4	-7.9	-0.3	1.22e-14	Height;
BRCA	trans	rs8073060	0.544	rs225252	chr17:33952401	G/A	cg19694781	chr19:47549865	TMEM160	-1.05	-21.07	-0.64	3.14e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg16586182	chr3:47516702	SCAP	0.61	14.02	0.48	4e-39	Colorectal cancer;
BRCA	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00149659	chr3:10157352	C3orf10	1.03	13.81	0.48	3.71e-38	Alzheimer's disease;
BRCA	cis	rs2249625	0.526	rs17725666	chr6:72889711	G/A	cg18830697	chr6:72922368	RIMS1	0.66	14.74	0.5	1.59e-42	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg25358565	chr5:93447407	FAM172A	1.15	18.46	0.59	2.7e-61	Diabetic retinopathy;
BRCA	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.05	0.3	4.12e-15	Axial length;
BRCA	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg24642439	chr20:33292090	TP53INP2	0.53	11.49	0.41	6.56e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg08470875	chr2:26401718	FAM59B	-0.76	-11.99	-0.43	4.93e-30	Gut microbiome composition (summer);
BRCA	cis	rs2070433	0.752	rs11701058	chr21:47776382	T/C	cg12379764	chr21:47803548	PCNT	0.58	10.28	0.38	4.85e-23	Lymphocyte counts;
BRCA	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg01689657	chr7:91764605	CYP51A1	0.24	8.48	0.32	1.59e-16	Breast cancer;
BRCA	cis	rs1499972	0.941	rs56256549	chr3:117612102	A/G	cg07612923	chr3:117604196	NA	0.6	8.16	0.31	1.78e-15	Schizophrenia;
BRCA	cis	rs12118280	0.612	rs591141	chr1:108694894	A/G	cg11967332	chr1:108735228	SLC25A24	0.54	10.21	0.37	9.1e-23	Myeloid white cell count;
BRCA	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg13789015	chr9:136890014	NCRNA00094	0.73	15.05	0.51	4.88e-44	Platelet distribution width;
BRCA	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg13010199	chr12:38710504	ALG10B	0.56	12.22	0.44	5.11e-31	Heart rate;
BRCA	cis	rs6005807	0.719	rs6005809	chr22:28942227	C/T	cg12565055	chr22:29076175	TTC28	-0.41	-7.92	-0.3	1.05e-14	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs7927771	0.507	rs10838754	chr11:47758532	A/C	cg20307385	chr11:47447363	PSMC3	0.42	9.55	0.35	2.8e-20	Subjective well-being;
BRCA	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg02951883	chr7:2050386	MAD1L1	-0.38	-8.48	-0.32	1.56e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg11752832	chr7:134001865	SLC35B4	0.52	13.55	0.47	6.19e-37	Mean platelet volume;
BRCA	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg13319975	chr6:146136371	FBXO30	0.45	10.43	0.38	1.24e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2230307	0.572	rs6677080	chr1:100633469	A/T	cg24955406	chr1:100503596	HIAT1	0.46	8.49	0.32	1.5e-16	Carotid intima media thickness;
BRCA	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg26874164	chr19:58962979	ZNF324B	0.43	9.16	0.34	6.7e-19	Uric acid clearance;
BRCA	trans	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg15704280	chr7:45808275	SEPT13	0.55	8.05	0.3	4.09e-15	Intraocular pressure;
BRCA	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg21361702	chr7:150065534	REPIN1	-0.44	-7.85	-0.3	1.71e-14	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.74	0.33	2.01e-17	Rheumatoid arthritis;
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10150615	chr22:24372951	LOC391322	0.42	9.08	0.34	1.37e-18	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-9.25	-0.34	3.25e-19	Fear of minor pain;
BRCA	cis	rs3739998	0.509	rs4749523	chr10:30332445	C/T	cg12786570	chr10:30316432	KIAA1462	-0.46	-9.29	-0.34	2.39e-19	Coronary heart disease;
BRCA	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg08885076	chr2:99613938	TSGA10	0.44	10.29	0.38	4.46e-23	Chronic sinus infection;
BRCA	cis	rs483180	0.531	rs662243	chr1:120209564	A/C	cg19096424	chr1:120255104	PHGDH	0.43	9.44	0.35	6.73e-20	Macular telangiectasia type 2;
BRCA	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg03188948	chr7:1209495	NA	0.58	8.64	0.32	4.5e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg27661571	chr11:113659931	NA	-0.5	-8.5	-0.32	1.38e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9875589	0.509	rs2733548	chr3:14094478	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.97	0.33	3.18e-18	Ovarian reserve;
BRCA	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg16606324	chr3:10149918	C3orf24	0.57	10.04	0.37	3.9e-22	Alzheimer's disease;
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg03923535	chr7:1197113	ZFAND2A	0.5	10.08	0.37	2.89e-22	Longevity;Endometriosis;
BRCA	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg13175981	chr1:150552382	MCL1	0.54	11.79	0.42	3.56e-29	Tonsillectomy;
BRCA	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg25237894	chr2:233734115	C2orf82	0.38	11.1	0.4	2.62e-26	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.14	0.49	1.09e-39	Motion sickness;
BRCA	cis	rs1949733	0.635	rs4358384	chr4:8536913	C/T	cg11789530	chr4:8429930	ACOX3	-0.56	-13.13	-0.46	4.85e-35	Response to antineoplastic agents;
BRCA	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg11366901	chr6:160182831	ACAT2	0.81	15.96	0.53	1.75e-48	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17712092	chr4:129076599	LARP1B	0.54	13.14	0.46	4.55e-35	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs919433	0.963	rs6738836	chr2:198182432	A/G	cg10820045	chr2:198174542	NA	-0.39	-8.12	-0.31	2.37e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs17092148	0.887	rs6059936	chr20:33184249	C/T	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.67	-0.39	1.46e-24	Neuroticism;
BRCA	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-15.44	-0.52	6.09e-46	Total cholesterol levels;
BRCA	cis	rs11112613	0.713	rs871220	chr12:105938558	G/A	cg03607813	chr12:105948248	NA	0.59	10.82	0.39	3.7e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs6088813	1.000	rs6142359	chr20:33960450	T/C	cg14752227	chr20:34000481	UQCC	-0.41	-8.71	-0.33	2.57e-17	Height;
BRCA	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg03733263	chr8:22462867	KIAA1967	0.91	19.75	0.62	3.88e-68	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs6138458	1.000	rs227627	chr20:24912107	T/C	cg26195577	chr20:24973756	C20orf3	0.98	24.66	0.7	7.18e-95	Blood protein levels;
BRCA	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg04607235	chr12:12878440	APOLD1	0.55	10.81	0.39	3.78e-25	Pulse pressure;
BRCA	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg11062466	chr8:58055876	NA	0.5	8.75	0.33	1.96e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	9.36	0.35	1.32e-19	Height;
BRCA	trans	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg07817883	chr1:32538562	TMEM39B	0.92	13.93	0.48	1.04e-38	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.24	-20.55	-0.63	2.08e-72	Hemostatic factors and hematological phenotypes;
BRCA	trans	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg17830980	chr10:43048298	ZNF37B	0.45	9.88	0.36	1.6e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06108461	chr20:60628389	TAF4	-0.97	-22.03	-0.66	1.96e-80	Body mass index;
BRCA	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg05340658	chr4:99064831	C4orf37	0.59	11.9	0.43	1.29e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg22705602	chr4:152727874	NA	-0.32	-8.14	-0.31	2.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2637030	0.559	rs256116	chr5:52962251	C/T	cg06476337	chr5:52856530	NDUFS4	0.35	7.96	0.3	8.08e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg16482183	chr6:26056742	HIST1H1C	0.55	11.52	0.41	4.98e-28	Height;
BRCA	cis	rs4629180	1.000	rs4851457	chr2:102091220	C/T	cg04415270	chr2:102091202	RFX8	0.35	8.35	0.31	4.08e-16	Chronic rhinosinusitis with nasal polyps;
BRCA	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg17420585	chr12:42539391	GXYLT1	-0.4	-8.33	-0.31	4.88e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg02951883	chr7:2050386	MAD1L1	-0.61	-15.14	-0.51	1.71e-44	Bipolar disorder and schizophrenia;
BRCA	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg13319975	chr6:146136371	FBXO30	0.4	9.08	0.34	1.38e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	14.13	0.49	1.18e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.49	-0.52	3.39e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg17971929	chr21:40555470	PSMG1	-0.62	-14.42	-0.5	5.12e-41	Cognitive function;
BRCA	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	14.98	0.51	1.08e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg07395648	chr5:131743802	NA	-0.38	-9.48	-0.35	4.89e-20	Blood metabolite levels;
BRCA	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11890956	chr21:40555474	PSMG1	-0.62	-13.8	-0.48	4.27e-38	Menarche (age at onset);
BRCA	cis	rs897080	0.515	rs1067325	chr2:44628997	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.43	0.35	7.21e-20	Height;
BRCA	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg10523679	chr1:76189770	ACADM	0.7	12.33	0.44	1.8e-31	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11605275	0.581	rs11606785	chr11:20030430	A/C	cg14835545	chr11:20032148	NAV2	-0.64	-9.0	-0.34	2.58e-18	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg05343316	chr1:45956843	TESK2	0.62	12.4	0.44	8.18e-32	Platelet count;
BRCA	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg01448562	chr3:133502909	NA	-0.41	-9.41	-0.35	9.13e-20	Iron status biomarkers;
BRCA	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg05340658	chr4:99064831	C4orf37	0.68	17.2	0.56	8.57e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9309711	0.883	rs13429373	chr2:3477014	G/A	cg16153549	chr2:3496821	NA	-0.4	-9.1	-0.34	1.1e-18	Neurofibrillary tangles;
BRCA	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg12463550	chr7:65579703	CRCP	0.37	7.9	0.3	1.23e-14	Aortic root size;
BRCA	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg12011299	chr4:100065546	ADH4	0.48	10.87	0.4	2.26e-25	Alcohol dependence;
BRCA	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg24060327	chr5:131705240	SLC22A5	-0.49	-10.17	-0.37	1.28e-22	Blood metabolite levels;
BRCA	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	13.15	0.46	3.99e-35	Mood instability;
BRCA	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.33	-7.82	-0.3	2.21e-14	Electroencephalogram traits;
BRCA	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13012494	chr21:47604986	C21orf56	-0.44	-8.89	-0.33	6.35e-18	Testicular germ cell tumor;
BRCA	cis	rs10501293	1.000	rs10501293	chr11:43086094	G/T	cg03447554	chr11:43094025	NA	0.48	9.03	0.34	2.09e-18	Cognitive performance;
BRCA	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-10.41	-0.38	1.51e-23	IgG glycosylation;
BRCA	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg23625390	chr15:77176239	SCAPER	0.4	9.38	0.35	1.17e-19	Blood metabolite levels;
BRCA	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg13010199	chr12:38710504	ALG10B	-0.37	-8.95	-0.33	3.81e-18	Morning vs. evening chronotype;
BRCA	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27286337	chr10:134555280	INPP5A	0.64	11.23	0.41	7.67e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.67	0.5	3.35e-42	Colorectal cancer;
BRCA	cis	rs4889855	0.530	rs12946972	chr17:78618922	A/G	cg16591659	chr17:78472290	NA	-0.32	-8.14	-0.31	2e-15	Fractional excretion of uric acid;
BRCA	trans	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.46	-8.62	-0.32	5.42e-17	Monocyte count;
BRCA	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	trans	rs1941687	0.509	rs7238029	chr18:31317755	A/G	cg15819921	chr19:927150	ARID3A	-0.46	-8.53	-0.32	1.07e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	trans	rs11088226	0.681	rs2833903	chr21:33940819	C/T	cg09050820	chr6:167586206	TCP10L2	0.77	13.18	0.46	2.77e-35	Gastritis;
BRCA	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg08501292	chr6:25962987	TRIM38	0.59	8.03	0.3	4.71e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg22705602	chr4:152727874	NA	-0.33	-8.22	-0.31	1.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	17.95	0.58	1.16e-58	Platelet count;
BRCA	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg26605046	chr4:2439731	NA	-0.4	-9.31	-0.35	2.07e-19	Cognitive function;
BRCA	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12923728	chr3:195709715	SDHAP1	-0.59	-12.46	-0.44	4.85e-32	Pancreatic cancer;
BRCA	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08564027	chr20:61660810	NA	0.83	21.84	0.65	2.18e-79	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.58	-8.37	-0.31	3.75e-16	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg05340658	chr4:99064831	C4orf37	0.66	16.11	0.54	3.1e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg17971929	chr21:40555470	PSMG1	-0.61	-14.19	-0.49	6.36e-40	Cognitive function;
BRCA	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg10523679	chr1:76189770	ACADM	-0.45	-8.06	-0.3	3.69e-15	Daytime sleep phenotypes;
BRCA	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.85	-0.53	5.78e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg15017067	chr4:17643749	FAM184B	0.33	9.68	0.36	8.88e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21659725	chr3:3221576	CRBN	-0.49	-10.44	-0.38	1.11e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.04	0.4	4.63e-26	Bipolar disorder;
BRCA	cis	rs12200560	0.505	rs11153095	chr6:97078592	T/C	cg06623918	chr6:96969491	KIAA0776	-0.46	-10.65	-0.39	1.65e-24	Coronary heart disease;
BRCA	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.21	20.12	0.62	3.97e-70	Platelet count;
BRCA	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg00080972	chr5:178986291	RUFY1	0.47	12.46	0.44	4.73e-32	Lung cancer;
BRCA	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-8.01	-0.3	5.32e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg03585969	chr10:35415529	CREM	0.5	10.46	0.38	9.93e-24	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg19748678	chr4:122722346	EXOSC9	0.47	10.41	0.38	1.57e-23	Type 2 diabetes;
BRCA	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	12.02	0.43	3.74e-30	Tonsillectomy;
BRCA	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg00339695	chr16:24857497	SLC5A11	0.36	7.85	0.3	1.76e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	13.95	0.48	8.22e-39	Alzheimer's disease;
BRCA	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg21573476	chr21:45109991	RRP1B	-0.33	-8.68	-0.32	3.22e-17	Mean corpuscular volume;
BRCA	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03264133	chr6:25882463	NA	0.41	9.61	0.36	1.6e-20	Blood metabolite levels;
BRCA	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg12386194	chr3:101231763	SENP7	0.45	9.45	0.35	6.14e-20	Colorectal cancer;
BRCA	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg21395723	chr22:39101663	GTPBP1	0.39	8.33	0.31	4.9e-16	Menopause (age at onset);
BRCA	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.4	8.0	0.3	5.88e-15	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.08	30.61	0.77	2.13e-127	Cognitive ability;
BRCA	cis	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg07460842	chr6:66804631	NA	0.77	14.02	0.48	4.08e-39	Exhaled nitric oxide levels;
BRCA	cis	rs1997103	1.000	rs6966183	chr7:55407546	A/C	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs6060717	0.536	rs2425104	chr20:34312346	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.96	-0.33	3.53e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	9.01	0.34	2.41e-18	Educational attainment;
BRCA	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg08493051	chr2:3487164	NA	-0.41	-8.34	-0.31	4.59e-16	Neurofibrillary tangles;
BRCA	cis	rs7945718	0.967	rs12417886	chr11:12811731	A/C	cg25843174	chr11:12811716	TEAD1	-0.25	-9.53	-0.35	3.12e-20	Educational attainment (years of education);
BRCA	cis	rs11971779	0.680	rs6961812	chr7:139043808	A/C	cg07862535	chr7:139043722	LUC7L2	0.38	10.37	0.38	2.13e-23	Diisocyanate-induced asthma;
BRCA	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg10845886	chr2:3471009	TTC15	-0.54	-12.07	-0.43	2.23e-30	Neurofibrillary tangles;
BRCA	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.28	0.31	7.49e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.56	-13.95	-0.48	8.07e-39	Longevity;Endometriosis;
BRCA	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg25039879	chr17:56429692	SUPT4H1	0.36	7.85	0.3	1.71e-14	Primary tooth development (time to first tooth eruption);
BRCA	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg21226059	chr5:178986404	RUFY1	0.47	12.69	0.45	4.58e-33	Lung cancer;
BRCA	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg14458575	chr2:238380390	NA	-0.52	-11.71	-0.42	8.09e-29	Prostate cancer;
BRCA	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg18132916	chr6:79620363	NA	-0.48	-11.02	-0.4	5.75e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg03146154	chr1:46216737	IPP	0.51	11.14	0.4	1.86e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg23533926	chr12:111358616	MYL2	-0.44	-9.18	-0.34	5.78e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10492096	0.947	rs61918020	chr12:6605514	C/T	cg13857086	chr12:6580257	VAMP1	0.43	8.45	0.32	2.01e-16	Hip geometry;
BRCA	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg05340658	chr4:99064831	C4orf37	0.68	16.67	0.55	4.74e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	25.91	0.72	1.01e-101	Chronic sinus infection;
BRCA	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.8e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7944584	0.552	rs12361415	chr11:47474146	T/G	cg20307385	chr11:47447363	PSMC3	0.75	16.4	0.54	1.03e-50	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.68	14.15	0.49	9.69e-40	Chronic sinus infection;
BRCA	cis	rs10789491	1.000	rs1545206	chr1:47185082	C/G	cg15501359	chr1:47185051	KIAA0494	0.66	18.21	0.58	5.23e-60	Response to hepatitis C treatment;
BRCA	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-14.13	-0.49	1.17e-39	Hemoglobin concentration;
BRCA	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08109568	chr15:31115862	NA	-0.47	-10.84	-0.39	2.96e-25	Huntington's disease progression;
BRCA	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg11663144	chr21:46675770	NA	-0.64	-15.28	-0.52	3.72e-45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00149659	chr3:10157352	C3orf10	0.8	13.88	0.48	1.79e-38	Alzheimer's disease;
BRCA	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg05714579	chr10:131428358	MGMT	0.5	10.98	0.4	8.55e-26	Response to temozolomide;
BRCA	cis	rs798766	1.000	rs798767	chr4:1734281	A/G	cg10756475	chr4:1757242	NA	0.37	8.39	0.31	3.21e-16	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-9.01	-0.34	2.35e-18	Mean corpuscular volume;
BRCA	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg16584290	chr5:462447	EXOC3	0.53	14.58	0.5	9.26e-42	Cystic fibrosis severity;
BRCA	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg08885076	chr2:99613938	TSGA10	0.45	10.61	0.39	2.51e-24	Chronic sinus infection;
BRCA	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05901451	chr6:126070800	HEY2	-0.48	-11.52	-0.41	4.85e-28	Endometrial cancer;
BRCA	trans	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	9.21	0.34	4.47e-19	Mean corpuscular volume;
BRCA	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg05347473	chr6:146136440	FBXO30	0.41	8.14	0.31	2.07e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg12935359	chr14:103987150	CKB	-0.59	-13.92	-0.48	1.19e-38	Body mass index;
BRCA	cis	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg18154014	chr19:37997991	ZNF793	0.53	10.64	0.39	1.82e-24	Coronary artery calcification;
BRCA	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	13.73	0.48	8.4e-38	Lymphocyte counts;
BRCA	cis	rs4478037	0.822	rs9827863	chr3:33118951	C/T	cg19404215	chr3:33155277	CRTAP	-0.41	-8.44	-0.32	2.12e-16	Major depressive disorder;
BRCA	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg08992911	chr2:238395768	MLPH	0.38	8.34	0.31	4.68e-16	Prostate cancer;
BRCA	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.4	0.57	8.33e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg16006841	chr5:176797999	RGS14	-0.79	-15.63	-0.53	7.53e-47	Urinary electrolytes (magnesium/calcium ratio);
BRCA	cis	rs2522056	1.000	rs62385693	chr5:131773674	T/C	cg24060327	chr5:131705240	SLC22A5	0.45	7.9	0.3	1.23e-14	Lymphocyte counts;Fibrinogen;
BRCA	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg20701182	chr2:24300061	SF3B14	0.59	9.24	0.34	3.67e-19	Lymphocyte counts;
BRCA	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.43	9.66	0.36	1.03e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs6973256	0.865	rs763645	chr7:133343428	C/T	cg07491979	chr7:133331646	EXOC4	-0.39	-9.05	-0.34	1.69e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg16325326	chr1:53192061	ZYG11B	-0.95	-26.57	-0.72	2.4e-105	Monocyte count;
BRCA	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.31	0.57	2.38e-55	Bladder cancer;
BRCA	cis	rs1499972	0.941	rs62263114	chr3:117617722	T/A	cg07612923	chr3:117604196	NA	0.58	7.87	0.3	1.54e-14	Schizophrenia;
BRCA	cis	rs4363385	0.818	rs946096	chr1:153006529	T/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.26	-0.34	3.19e-19	Inflammatory skin disease;
BRCA	cis	rs926392	0.666	rs912179	chr20:37710775	G/A	cg16355469	chr20:37678765	NA	0.43	9.96	0.37	7.78e-22	Dialysis-related mortality;
BRCA	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.03	0.49	3.72e-39	Eye color traits;
BRCA	cis	rs752010	0.644	rs7541348	chr1:42113215	T/G	cg06885757	chr1:42089581	HIVEP3	0.26	9.12	0.34	9.73e-19	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg08999081	chr20:33150536	PIGU	0.44	12.24	0.44	4.12e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg26116260	chr4:7069785	GRPEL1	0.32	7.9	0.3	1.2e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
BRCA	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg25358565	chr5:93447407	FAM172A	1.19	17.77	0.58	1.07e-57	Diabetic retinopathy;
BRCA	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.8e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg21772509	chr8:41503840	NKX6-3	0.48	11.32	0.41	3.34e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
BRCA	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg07636037	chr3:49044803	WDR6	-0.5	-8.25	-0.31	9.35e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.32	-8.59	-0.32	6.72e-17	Crohn's disease;
BRCA	cis	rs6063312	0.518	rs6122718	chr20:47346225	A/G	cg18078177	chr20:47281410	PREX1	-0.69	-16.94	-0.56	2.02e-53	Tonometry;
BRCA	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg14784868	chr12:69753453	YEATS4	-0.42	-8.24	-0.31	9.770000000000001e-16	Response to diuretic therapy;
BRCA	cis	rs9644630	0.658	rs4427190	chr8:19321385	C/T	cg06562184	chr8:19319451	CSGALNACT1	-0.33	-7.88	-0.3	1.44e-14	Oropharynx cancer;
BRCA	cis	rs3857067	0.806	rs12513267	chr4:95109545	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.39	-0.35	1.02e-19	QT interval;
BRCA	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg23711669	chr6:146136114	FBXO30	0.63	14.8	0.51	7.87e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2859741	0.967	rs822854	chr1:37485788	A/G	cg09363841	chr1:37513479	NA	-0.64	-16.23	-0.54	7.32e-50	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs3768617	0.966	rs10797850	chr1:183094802	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.46	10.27	0.38	5.24e-23	Fuchs's corneal dystrophy;
BRCA	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg00814883	chr7:100076585	TSC22D4	-0.49	-10.37	-0.38	2.07e-23	Platelet count;
BRCA	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg03146154	chr1:46216737	IPP	0.53	11.57	0.42	2.94e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4853036	1.000	rs4853036	chr2:70059824	G/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-8.84	-0.33	9.6e-18	Colorectal or endometrial cancer;
BRCA	cis	rs7633857	0.512	rs745707	chr3:160652672	G/T	cg03342759	chr3:160939853	NMD3	-0.52	-10.92	-0.4	1.45e-25	Educational attainment (years of education);
BRCA	trans	rs8002861	0.619	rs9562516	chr13:44431738	T/C	cg12856521	chr11:46389249	DGKZ	0.4	8.71	0.33	2.51e-17	Leprosy;
BRCA	cis	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.1e-22	Morning vs. evening chronotype;
BRCA	cis	rs4594175	0.926	rs11851960	chr14:51598610	A/G	cg23942311	chr14:51606299	NA	0.34	8.47	0.32	1.72e-16	Cancer;
BRCA	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11764359	chr7:65958608	NA	-0.78	-18.87	-0.6	1.8e-63	Aortic root size;
BRCA	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg00677455	chr12:58241039	CTDSP2	0.46	10.35	0.38	2.51e-23	Multiple sclerosis;
BRCA	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg03060546	chr3:49711283	APEH	-0.51	-10.38	-0.38	2.04e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.31	9.8	0.36	3.21e-21	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.15	-0.31	1.89e-15	Total body bone mineral density;
BRCA	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg24531977	chr5:56204891	C5orf35	-0.51	-10.52	-0.38	5.38e-24	Coronary artery disease;
BRCA	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg18016565	chr1:150552671	MCL1	0.34	7.83	0.3	2.06e-14	Melanoma;
BRCA	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02176678	chr2:219576539	TTLL4	0.46	11.94	0.43	8.48e-30	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17712092	chr4:129076599	LARP1B	0.49	12.05	0.43	2.96e-30	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg08992911	chr2:238395768	MLPH	0.54	8.29	0.31	6.93e-16	Prostate cancer;
BRCA	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23583168	chr7:148888333	NA	-0.85	-19.79	-0.62	2.44e-68	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg24558204	chr6:135376177	HBS1L	0.44	11.89	0.43	1.41e-29	Red blood cell count;
BRCA	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	8.18	0.31	1.48e-15	Menarche (age at onset);
BRCA	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg14530993	chr4:882597	GAK	0.42	8.23	0.31	1.07e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg17691542	chr6:26056736	HIST1H1C	0.51	10.55	0.39	4.23e-24	Height;
BRCA	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg00409905	chr10:38381863	ZNF37A	-0.5	-10.5	-0.38	6.43e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg00631329	chr6:26305371	NA	-0.42	-12.61	-0.45	1.07e-32	Educational attainment;
BRCA	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.55	0.42	3.76e-28	Rheumatoid arthritis;
BRCA	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg08601574	chr20:25228251	PYGB	-0.35	-8.3	-0.31	6.34e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg03060546	chr3:49711283	APEH	0.5	10.93	0.4	1.34e-25	Resting heart rate;
BRCA	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.99	22.65	0.67	8.12e-84	Lymphocyte percentage of white cells;
BRCA	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg23131131	chr22:24373011	LOC391322	-0.46	-11.16	-0.4	1.45e-26	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	9.1e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	12.68	0.45	5e-33	Mean platelet volume;
BRCA	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg23711669	chr6:146136114	FBXO30	-0.7	-16.72	-0.55	2.38e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs16976116	0.901	rs28541469	chr15:55500788	G/A	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1997103	0.871	rs1997100	chr7:55399656	C/G	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.72e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg15556689	chr8:8085844	FLJ10661	0.38	9.18	0.34	6.14e-19	Neuroticism;
BRCA	cis	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg07460842	chr6:66804631	NA	0.98	19.66	0.61	1.18e-67	Exhaled nitric oxide output;
BRCA	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.52	8.63	0.32	5.05e-17	Renal function-related traits (BUN);
BRCA	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg17063962	chr7:91808500	NA	0.52	12.38	0.44	1.1e-31	Breast cancer;
BRCA	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11764359	chr7:65958608	NA	-0.65	-14.3	-0.49	1.84e-40	Aortic root size;
BRCA	cis	rs912057	0.526	rs746453	chr6:6734221	C/A	cg06612196	chr6:6737390	NA	0.56	13.28	0.47	9.91e-36	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg04025307	chr7:1156635	C7orf50	-0.69	-17.04	-0.56	5.94e-54	Longevity;Endometriosis;
BRCA	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg23750338	chr8:142222470	SLC45A4	-0.52	-12.63	-0.45	8.12e-33	Immature fraction of reticulocytes;
BRCA	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg18402987	chr7:1209562	NA	0.41	8.26	0.31	8.1e-16	Longevity;Endometriosis;
BRCA	cis	rs13046373	0.508	rs1012969	chr21:31996108	G/A	cg14062083	chr21:31802829	KRTAP13-4	0.34	9.27	0.34	2.93e-19	HDL cholesterol;
BRCA	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg24130564	chr14:104152367	KLC1	-0.6	-16.71	-0.55	2.83e-52	Intelligence (multi-trait analysis);
BRCA	cis	rs10181042	0.565	rs3108630	chr2:61268160	A/G	cg15711740	chr2:61764176	XPO1	0.36	9.2	0.34	5.2e-19	Crohn's disease;
BRCA	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg04450003	chr12:50355995	AQP5	0.42	8.86	0.33	7.64e-18	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg14689365	chr7:158441557	NCAPG2	0.39	8.05	0.3	3.95e-15	Height;
BRCA	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.52	0.32	1.17e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg15704280	chr7:45808275	SEPT13	-0.57	-9.66	-0.36	1.04e-20	Axial length;
BRCA	cis	rs7737355	0.898	rs4706030	chr5:130957486	A/G	cg06307176	chr5:131281290	NA	0.52	10.21	0.37	8.78e-23	Life satisfaction;
BRCA	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.29	0.31	6.59e-16	Aortic root size;
BRCA	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg03709012	chr19:19516395	GATAD2A	-0.8	-18.91	-0.6	1.07e-63	Tonsillectomy;
BRCA	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg17063962	chr7:91808500	NA	0.54	12.3	0.44	2.35e-31	Breast cancer;
BRCA	trans	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.11	0.31	2.58e-15	Mean corpuscular volume;
BRCA	cis	rs367943	1.000	rs348944	chr5:112822925	C/T	cg12552261	chr5:112820674	MCC	-0.55	-12.07	-0.43	2.28e-30	Type 2 diabetes;
BRCA	cis	rs2859741	0.528	rs6686296	chr1:37489380	G/T	cg09363841	chr1:37513479	NA	0.5	10.9	0.4	1.79e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg20203395	chr5:56204925	C5orf35	-0.5	-10.25	-0.38	6.25e-23	Initial pursuit acceleration;
BRCA	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08219700	chr8:58056026	NA	0.53	12.29	0.44	2.67e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg00031303	chr3:195681400	NA	0.46	8.6	0.32	6.32e-17	Pancreatic cancer;
BRCA	cis	rs4285028	1.000	rs4285028	chr3:121660664	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.61	-11.24	-0.41	7.02e-27	Multiple sclerosis;
BRCA	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-10.46	-0.38	9.82e-24	Aortic root size;
BRCA	cis	rs2637030	0.559	rs423014	chr5:52894598	A/G	cg06476337	chr5:52856530	NDUFS4	0.38	8.62	0.32	5.24e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs7255436	1.000	rs7255436	chr19:8433196	C/A	cg10174797	chr19:8464628	RAB11B	0.35	8.85	0.33	8.35e-18	HDL cholesterol;
BRCA	cis	rs6750047	0.546	rs2082255	chr2:38273758	C/A	cg07380506	chr2:38303506	CYP1B1	0.48	10.54	0.38	4.58e-24	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg06671706	chr8:8559999	CLDN23	0.43	8.3	0.31	6.23e-16	Obesity-related traits;
BRCA	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg16145915	chr7:1198662	ZFAND2A	0.49	11.03	0.4	5.17e-26	Longevity;Endometriosis;
BRCA	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.44	-0.41	1.04e-27	Mean corpuscular volume;
BRCA	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.56	11.53	0.42	4.35e-28	Lymphocyte counts;
BRCA	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg20503657	chr10:835505	NA	0.93	16.59	0.55	1.08e-51	Eosinophil percentage of granulocytes;
BRCA	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11890956	chr21:40555474	PSMG1	1.04	29.76	0.76	8.7e-123	Cognitive function;
BRCA	cis	rs919433	0.680	rs788018	chr2:198265526	A/G	cg00792783	chr2:198669748	PLCL1	0.38	8.52	0.32	1.11e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg26818010	chr10:134567672	INPP5A	-0.78	-15.53	-0.52	2.14e-46	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7917772	0.582	rs3977756	chr10:104398582	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.37	-9.99	-0.37	6.07e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg05863683	chr7:1912471	MAD1L1	0.41	8.62	0.32	5.42e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08219700	chr8:58056026	NA	0.44	7.94	0.3	8.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2011503	0.739	rs10412176	chr19:19689164	T/C	cg11584989	chr19:19387371	SF4	-0.48	-9.84	-0.36	2.23e-21	Bipolar disorder;
BRCA	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg00852783	chr1:26633632	UBXN11	0.51	11.0	0.4	6.85e-26	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4742903	0.933	rs10820608	chr9:106890840	A/G	cg14250997	chr9:106856677	SMC2	0.35	11.17	0.4	1.32e-26	High-grade serous ovarian cancer;Breast cancer;
BRCA	trans	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg06521331	chr12:34319734	NA	-0.51	-9.27	-0.34	2.75e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg16230307	chr14:35515116	FAM177A1	0.69	14.5	0.5	2.22e-41	Psoriasis;
BRCA	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.95	0.3	8.55e-15	Parkinson's disease;
BRCA	cis	rs10504073	0.647	rs7817571	chr8:50003218	T/C	cg00325661	chr8:49890786	NA	0.39	11.44	0.41	1.05e-27	Blood metabolite ratios;
BRCA	cis	rs16976116	0.855	rs28522816	chr15:55495114	C/G	cg11288833	chr15:55489084	RSL24D1	0.48	10.68	0.39	1.25e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg23533926	chr12:111358616	MYL2	-0.43	-9.14	-0.34	8.32e-19	Extrinsic epigenetic age acceleration;
BRCA	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.9	-0.3	1.25e-14	Neuroticism;
BRCA	trans	rs2840044	1.000	rs2840044	chr17:33892068	A/G	cg19694781	chr19:47549865	TMEM160	0.45	10.65	0.39	1.76e-24	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs6977660	0.714	rs10249477	chr7:19805388	T/A	cg07541023	chr7:19748670	TWISTNB	0.57	9.72	0.36	6.52e-21	Thyroid stimulating hormone;
BRCA	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-10.14	-0.37	1.7e-22	Schizophrenia;
BRCA	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	10.87	0.4	2.21e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg20503657	chr10:835505	NA	1.05	18.42	0.59	4.21e-61	Eosinophil percentage of granulocytes;
BRCA	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21385522	chr1:16154831	NA	0.46	8.43	0.32	2.37e-16	Dilated cardiomyopathy;
BRCA	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	10.04	0.37	4.01e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg04025307	chr7:1156635	C7orf50	0.45	10.61	0.39	2.44e-24	Longevity;Endometriosis;
BRCA	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.5	0.63	3.81e-72	Chronic sinus infection;
BRCA	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg21918786	chr6:109611834	NA	-0.49	-14.14	-0.49	1.03e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg24692254	chr21:30365293	RNF160	0.42	9.46	0.35	5.61e-20	Pancreatic cancer;
BRCA	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-19.0	-0.6	3.8e-64	Chronic sinus infection;
BRCA	cis	rs34779708	0.766	rs35308730	chr10:35549796	C/T	cg03585969	chr10:35415529	CREM	0.43	8.71	0.33	2.56e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg23711669	chr6:146136114	FBXO30	-0.76	-17.44	-0.57	5.18e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25427524	chr10:38739819	LOC399744	0.67	16.32	0.54	2.52e-50	Extrinsic epigenetic age acceleration;
BRCA	trans	rs8062405	0.721	rs151303	chr16:28492510	C/A	cg09719594	chr16:21412588	NA	-0.35	-7.94	-0.3	8.97e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs877282	0.898	rs11253341	chr10:765008	G/C	cg17470449	chr10:769945	NA	0.47	7.96	0.3	8.16e-15	Uric acid levels;
BRCA	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg02544614	chr20:61657117	NA	0.28	7.93	0.3	1.01e-14	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.4	9.47	0.35	5.14e-20	Eosinophil percentage of white cells;
BRCA	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg12292205	chr6:26970375	C6orf41	-0.63	-9.87	-0.36	1.71e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg25554036	chr4:6271136	WFS1	0.42	9.91	0.36	1.24e-21	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs62380364	0.602	rs606393	chr5:88058163	T/C	cg22951263	chr5:87985283	NA	-0.37	-10.32	-0.38	3.34e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.36	-0.35	1.33e-19	Bipolar disorder;
BRCA	cis	rs700651	0.821	rs770661	chr2:198725444	A/G	cg00792783	chr2:198669748	PLCL1	0.47	10.18	0.37	1.21e-22	Intracranial aneurysm;
BRCA	cis	rs3106136	0.527	rs4235050	chr4:95157156	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.08	-0.37	2.85e-22	Capecitabine sensitivity;
BRCA	cis	rs897080	0.515	rs698813	chr2:44705615	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	8.74	0.33	1.99e-17	Height;
BRCA	cis	rs6088765	0.606	rs2425024	chr20:33844938	G/T	cg24642439	chr20:33292090	TP53INP2	-0.43	-8.76	-0.33	1.69e-17	Ulcerative colitis;
BRCA	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg22974920	chr21:40686053	BRWD1	-0.36	-8.25	-0.31	9.2e-16	Cognitive function;
BRCA	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg09085632	chr11:111637200	PPP2R1B	0.76	16.24	0.54	6.46e-50	Primary sclerosing cholangitis;
BRCA	cis	rs36051895	0.632	rs10974993	chr9:5182159	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-9.37	-0.35	1.22e-19	Pediatric autoimmune diseases;
BRCA	cis	rs12348691	0.503	rs10983975	chr9:100614188	A/C	cg13688889	chr9:100608707	NA	-0.49	-9.92	-0.37	1.14e-21	Alopecia areata;
BRCA	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg01874867	chr7:94954059	PON1	0.38	7.88	0.3	1.37e-14	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6546886	0.912	rs6745792	chr2:74284033	G/A	cg14702570	chr2:74259524	NA	-0.32	-8.02	-0.3	4.98e-15	Dialysis-related mortality;
BRCA	cis	rs11971779	0.680	rs7795520	chr7:139079207	A/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg21535247	chr6:8435926	SLC35B3	0.4	9.09	0.34	1.25e-18	Motion sickness;
BRCA	cis	rs10465746	0.967	rs6576956	chr1:84343885	T/G	cg10977910	chr1:84465055	TTLL7	0.51	10.28	0.38	4.89e-23	Obesity-related traits;
BRCA	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	trans	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg07211511	chr3:129823064	LOC729375	-0.96	-13.62	-0.47	2.72e-37	Blood pressure (smoking interaction);
BRCA	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg14675211	chr2:100938903	LONRF2	0.53	12.03	0.43	3.34e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs6426558	0.537	rs12039370	chr1:227326472	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.47	-9.3	-0.35	2.13e-19	Neutrophil percentage of white cells;
BRCA	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg21782813	chr7:2030301	MAD1L1	0.42	12.01	0.43	4.21e-30	Bipolar disorder and schizophrenia;
BRCA	cis	rs3784262	0.528	rs1994926	chr15:58334587	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-10.22	-0.37	8.02e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs4919694	1.000	rs80327774	chr10:104656671	T/C	cg04362960	chr10:104952993	NT5C2	0.95	14.84	0.51	5.3e-43	Arsenic metabolism;
BRCA	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg08807101	chr21:30365312	RNF160	-0.76	-19.72	-0.62	5.84e-68	Dental caries;
BRCA	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg15017067	chr4:17643749	FAM184B	0.31	9.7	0.36	7.64e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9790314	0.690	rs1903423	chr3:160842252	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-11.39	-0.41	1.79e-27	Morning vs. evening chronotype;
BRCA	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg06627628	chr2:24431161	ITSN2	-0.57	-9.08	-0.34	1.29e-18	Lymphocyte counts;
BRCA	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg15605315	chr1:45957053	TESK2	-0.46	-9.26	-0.34	2.99e-19	High light scatter reticulocyte count;
BRCA	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-10.53	-0.38	5.31e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.47	-0.32	1.73e-16	Total body bone mineral density;
BRCA	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg22105103	chr4:187893119	NA	-0.39	-12.09	-0.43	1.95e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	6.95e-17	Lymphocyte counts;
BRCA	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg21475434	chr5:93447410	FAM172A	0.66	8.27	0.31	7.53e-16	Diabetic retinopathy;
BRCA	trans	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.69	-16.68	-0.55	3.79e-52	Obesity-related traits;
BRCA	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03264133	chr6:25882463	NA	-0.52	-11.75	-0.42	5.15e-29	Blood metabolite levels;
BRCA	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg07395648	chr5:131743802	NA	0.39	9.67	0.36	9.85e-21	Blood metabolite levels;
BRCA	cis	rs4742903	0.904	rs7028408	chr9:106859811	G/A	cg21169611	chr9:106856078	SMC2	0.36	9.32	0.35	1.83e-19	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs7944584	0.632	rs11606683	chr11:47302733	C/T	cg20307385	chr11:47447363	PSMC3	0.59	11.78	0.42	4.15e-29	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-14.06	-0.49	2.43e-39	Platelet count;
BRCA	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg01206211	chr2:36825736	FEZ2	0.44	10.34	0.38	2.86e-23	Height;
BRCA	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.78	0.39	5.41e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg23625390	chr15:77176239	SCAPER	-0.54	-13.69	-0.48	1.33e-37	Blood metabolite levels;
BRCA	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.38	-0.38	1.93e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13126279	chr21:47581558	C21orf56	0.5	10.83	0.39	3.42e-25	Testicular germ cell tumor;
BRCA	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg22676075	chr6:135203613	NA	0.44	8.62	0.32	5.21e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs4728302	0.583	rs58955798	chr7:133158420	C/T	cg10665199	chr7:133106180	EXOC4	0.47	10.09	0.37	2.51e-22	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg05234568	chr11:5960015	NA	-0.5	-9.94	-0.37	9.5e-22	DNA methylation (variation);
BRCA	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg10295955	chr4:187884368	NA	-0.86	-24.64	-0.7	1.01e-94	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.48	-10.19	-0.37	1.08e-22	Bipolar disorder;
BRCA	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg26116260	chr4:7069785	GRPEL1	0.91	26.37	0.72	3.06e-104	Monocyte percentage of white cells;
BRCA	cis	rs13161895	1.000	rs17079966	chr5:179443190	G/T	cg02702477	chr5:179499311	RNF130	0.45	8.59	0.32	6.9e-17	LDL cholesterol;
BRCA	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	12.77	0.45	1.93e-33	Response to antipsychotic treatment;
BRCA	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg08755490	chr11:65554678	OVOL1	0.5	10.06	0.37	3.44e-22	Acne (severe);
BRCA	cis	rs6429082	0.715	rs2172718	chr1:235580727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.55	-13.78	-0.48	4.97e-38	Adiposity;
BRCA	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg00495681	chr13:53174319	NA	0.41	8.73	0.33	2.22e-17	Lewy body disease;
BRCA	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03452623	chr4:187889614	NA	0.36	11.69	0.42	9.6e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg24060327	chr5:131705240	SLC22A5	-0.5	-10.34	-0.38	2.74e-23	Blood metabolite levels;
BRCA	cis	rs2415984	0.622	rs10147795	chr14:46936528	C/T	cg14871534	chr14:47121158	RPL10L	-0.33	-8.05	-0.3	3.91e-15	Number of children ever born;
BRCA	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg21724239	chr8:58056113	NA	0.57	9.3	0.35	2.24e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.44	-0.32	2.12e-16	Height;
BRCA	cis	rs312274	0.588	rs12424493	chr12:41299694	A/G	cg17827154	chr12:41323612	CNTN1	-0.45	-11.31	-0.41	3.66e-27	Metabolite levels  (X-11787);
BRCA	trans	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg06521331	chr12:34319734	NA	-0.55	-9.76	-0.36	4.59e-21	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-8.62	-0.32	5.23e-17	Schizophrenia;
BRCA	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.79	-0.36	3.51e-21	IgG glycosylation;
BRCA	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg21573476	chr21:45109991	RRP1B	-0.35	-9.15	-0.34	7.57e-19	Mean corpuscular volume;
BRCA	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.3	0.35	2.23e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11997175	0.646	rs55898196	chr8:33765862	A/G	ch.8.33884649F	chr8:33765107	NA	0.43	10.05	0.37	3.83e-22	Body mass index;
BRCA	cis	rs77972916	0.505	rs6736400	chr2:43500804	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-11.88	-0.43	1.47e-29	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7092929	0.883	rs551307	chr10:3597542	T/C	cg14308648	chr10:3568949	NA	0.46	8.48	0.32	1.59e-16	Coronary artery calcification;
BRCA	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg03060546	chr3:49711283	APEH	-0.59	-12.08	-0.43	2.06e-30	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9323205	0.871	rs2999393	chr14:51655167	G/T	cg23942311	chr14:51606299	NA	0.33	7.8	0.3	2.44e-14	Cancer;
BRCA	cis	rs9359856	0.564	rs41273329	chr6:90393483	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.7	-8.77	-0.33	1.67e-17	Bipolar disorder;
BRCA	cis	rs644148	0.738	rs2686767	chr19:44995037	G/C	cg15540054	chr19:45004280	ZNF180	-0.4	-8.41	-0.32	2.65e-16	Personality dimensions;
BRCA	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg20387954	chr3:183756860	HTR3D	-0.4	-8.96	-0.33	3.42e-18	Anterior chamber depth;
BRCA	cis	rs2066819	1.000	rs76430365	chr12:56699993	A/C	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg25358565	chr5:93447407	FAM172A	1.25	17.59	0.57	8.68e-57	Diabetic retinopathy;
BRCA	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg17211192	chr8:82754475	SNX16	0.64	12.03	0.43	3.56e-30	Diastolic blood pressure;
BRCA	trans	rs1973993	0.561	rs3862909	chr1:96987091	T/G	cg10631902	chr5:14652156	NA	-0.41	-10.15	-0.37	1.56e-22	Weight;
BRCA	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg09307838	chr4:120376055	NA	0.7	14.91	0.51	2.39e-43	Corneal astigmatism;
BRCA	cis	rs600806	0.813	rs6664236	chr1:109986672	C/A	cg20591472	chr1:110008990	SYPL2	0.33	8.25	0.31	9.23e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1011018	0.628	rs10224408	chr7:139415723	G/A	cg03224163	chr7:139420300	HIPK2	-0.54	-8.84	-0.33	9.06e-18	Systolic blood pressure;
BRCA	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.17	0.56	1.26e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.0	0.34	2.59e-18	Motion sickness;
BRCA	cis	rs34779708	0.733	rs12249814	chr10:35542757	T/C	cg03585969	chr10:35415529	CREM	0.45	9.18	0.34	5.96e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24531977	chr5:56204891	C5orf35	-0.88	-18.18	-0.58	7.95e-60	Initial pursuit acceleration;
BRCA	trans	rs853679	0.546	rs2232423	chr6:28366151	A/G	cg01620082	chr3:125678407	NA	-0.97	-11.01	-0.4	6.21e-26	Depression;
BRCA	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg27279351	chr12:120934652	DYNLL1	0.57	13.5	0.47	1.05e-36	High light scatter reticulocyte count;
BRCA	cis	rs35995292	0.500	rs8180877	chr7:38931258	G/A	cg19327137	chr7:38886074	VPS41	0.38	12.63	0.45	8.59e-33	Subjective well-being (multi-trait analysis);
BRCA	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg00383909	chr3:49044727	WDR6	0.59	10.59	0.39	2.88e-24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6484504	0.532	rs2616799	chr11:31319044	T/C	cg14844989	chr11:31128820	NA	0.46	9.91	0.36	1.27e-21	Red blood cell count;
BRCA	cis	rs17401966	0.965	rs12751375	chr1:10291874	C/G	cg03954927	chr1:10346856	KIF1B	0.45	12.9	0.45	5.47e-34	Hepatocellular carcinoma;
BRCA	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg00745463	chr17:30367425	LRRC37B	-0.54	-8.89	-0.33	6.17e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg18446336	chr7:2847575	GNA12	-0.4	-9.94	-0.37	9.34e-22	Height;
BRCA	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg00071950	chr4:10020882	SLC2A9	0.66	16.74	0.55	1.91e-52	Bone mineral density;
BRCA	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg12386194	chr3:101231763	SENP7	0.46	9.65	0.36	1.12e-20	Colorectal cancer;
BRCA	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg20476274	chr7:133979776	SLC35B4	-0.55	-13.19	-0.46	2.54e-35	Mean platelet volume;
BRCA	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg20701182	chr2:24300061	SF3B14	0.66	9.54	0.35	3.02e-20	Lymphocyte counts;
BRCA	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg06115741	chr20:33292138	TP53INP2	0.49	10.99	0.4	7.55e-26	Coronary artery disease;
BRCA	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11890956	chr21:40555474	PSMG1	0.96	24.35	0.69	3.62e-93	Cognitive function;
BRCA	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg13852791	chr20:30311386	BCL2L1	-0.83	-16.35	-0.54	1.85e-50	Mean corpuscular hemoglobin;
BRCA	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg18357645	chr12:58087776	OS9	0.44	12.43	0.44	6.32e-32	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg02503808	chr4:7069936	GRPEL1	0.8	18.49	0.59	1.73e-61	Monocyte percentage of white cells;
BRCA	cis	rs6750795	0.507	rs1667320	chr2:232418314	G/T	cg19187155	chr2:232395269	NMUR1	0.69	17.23	0.56	6.33e-55	Height;
BRCA	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-12.83	-0.45	1.04e-33	Monocyte percentage of white cells;
BRCA	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg09699651	chr6:150184138	LRP11	0.38	8.8	0.33	1.32e-17	Testicular germ cell tumor;
BRCA	trans	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	20.79	0.64	1.05e-73	Exhaled nitric oxide output;
BRCA	cis	rs34779708	0.931	rs13376871	chr10:35369056	A/G	cg03585969	chr10:35415529	CREM	0.49	10.33	0.38	3.17e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7193541	0.691	rs3851728	chr16:74480660	C/T	cg01733217	chr16:74700730	RFWD3	0.61	16.01	0.54	9e-49	Multiple myeloma;
BRCA	cis	rs4888262	0.545	rs12716768	chr16:74556486	A/G	cg01733217	chr16:74700730	RFWD3	-0.68	-17.49	-0.57	2.84e-56	Testicular germ cell tumor;
BRCA	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg18016565	chr1:150552671	MCL1	0.35	7.99	0.3	6.13e-15	Melanoma;
BRCA	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg24851651	chr11:66362959	CCS	-0.45	-9.07	-0.34	1.4e-18	Bipolar disorder;
BRCA	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg22800045	chr5:56110881	MAP3K1	0.71	13.19	0.46	2.57e-35	Initial pursuit acceleration;
BRCA	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg24642844	chr7:1081250	C7orf50	-0.89	-16.0	-0.53	1.07e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg11833968	chr6:79620685	NA	-0.42	-9.3	-0.35	2.27e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs17253792	0.749	rs45458197	chr14:56145018	A/T	cg01858014	chr14:56050164	KTN1	-0.75	-9.37	-0.35	1.25e-19	Putamen volume;
BRCA	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-10.66	-0.39	1.51e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs925228	0.504	rs6755030	chr2:24318343	C/T	cg20701182	chr2:24300061	SF3B14	-0.52	-8.52	-0.32	1.13e-16	Reticulocyte fraction of red cells;Reticulocyte count;
BRCA	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg10223061	chr2:219282414	VIL1	-0.27	-8.12	-0.31	2.37e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg25801113	chr15:45476975	SHF	-0.32	-8.06	-0.3	3.75e-15	Uric acid levels;
BRCA	cis	rs72781680	0.821	rs56064672	chr2:24156769	G/T	cg08917208	chr2:24149416	ATAD2B	0.64	10.69	0.39	1.17e-24	Lymphocyte counts;
BRCA	cis	rs2066819	1.000	rs77032009	chr12:56679971	A/G	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	trans	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg06521331	chr12:34319734	NA	-0.42	-7.93	-0.3	9.54e-15	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.61	-0.32	5.56e-17	Aortic root size;
BRCA	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg09658497	chr7:2847517	GNA12	-0.41	-8.58	-0.32	6.93e-17	Height;
BRCA	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg24692254	chr21:30365293	RNF160	-0.46	-10.84	-0.39	2.95e-25	Dental caries;
BRCA	cis	rs870825	0.616	rs35533356	chr4:185639134	A/G	cg04058563	chr4:185651563	MLF1IP	0.76	16.85	0.55	5.72e-53	Blood protein levels;
BRCA	trans	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	8.49	0.32	1.44e-16	Mean corpuscular volume;
BRCA	cis	rs12348691	0.503	rs3021523	chr9:100616583	T/C	cg13688889	chr9:100608707	NA	-0.49	-9.9	-0.36	1.32e-21	Alopecia areata;
BRCA	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg16586182	chr3:47516702	SCAP	0.65	15.17	0.51	1.27e-44	Colorectal cancer;
BRCA	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.67	0.61	1.03e-67	Alzheimer's disease;
BRCA	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.98	0.37	6.93e-22	Bipolar disorder;
BRCA	cis	rs8017423	0.647	rs4904679	chr14:90821801	C/T	cg04374321	chr14:90722782	PSMC1	-0.49	-11.96	-0.43	6.75e-30	Mortality in heart failure;
BRCA	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.27	0.31	7.86e-16	Menarche (age at onset);
BRCA	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.86e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs73001065	0.636	rs8182472	chr19:19539891	A/G	cg03709012	chr19:19516395	GATAD2A	0.98	14.06	0.49	2.65e-39	LDL cholesterol;
BRCA	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs4596713	0.508	rs59620993	chr9:71771911	C/T	cg16512924	chr15:28394682	HERC2	0.45	10.66	0.39	1.52e-24	Headache;
BRCA	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27286337	chr10:134555280	INPP5A	0.8	13.17	0.46	3.21e-35	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs3857536	0.673	rs7759888	chr6:66891922	T/C	cg07460842	chr6:66804631	NA	-0.46	-8.86	-0.33	8.14e-18	Blood trace element (Cu levels);
BRCA	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.51	-10.65	-0.39	1.65e-24	Rheumatoid arthritis;
BRCA	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	21.71	0.65	1.08e-78	Platelet count;
BRCA	cis	rs4891159	0.790	rs17059379	chr18:74160316	A/T	cg24786174	chr18:74118243	ZNF516	0.75	17.73	0.57	1.77e-57	Longevity;
BRCA	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.18	-0.43	7.78e-31	Bipolar disorder;
BRCA	trans	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg21659725	chr3:3221576	CRBN	-0.47	-9.99	-0.37	6.33e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs558133	1.000	rs506500	chr5:78414337	C/T	cg25119155	chr5:78426943	BHMT	-0.47	-10.72	-0.39	9.15e-25	Blood and toenail selenium levels;
BRCA	cis	rs6433895	0.601	rs13033038	chr2:182052555	C/T	cg00481216	chr2:181971175	NA	0.41	7.87	0.3	1.51e-14	Lymphocyte counts;
BRCA	cis	rs6700896	0.931	rs11208717	chr1:66158994	T/C	cg04111102	chr1:66153794	NA	0.34	8.5	0.32	1.3e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs10788264	0.652	rs9633732	chr10:124056473	G/T	cg09507567	chr10:124027408	NA	0.4	8.24	0.31	9.5e-16	Total body bone mineral density;
BRCA	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg04691961	chr3:161091175	C3orf57	-0.39	-8.82	-0.33	1.06e-17	Parkinson's disease;
BRCA	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	12.78	0.45	1.83e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg03733263	chr8:22462867	KIAA1967	-0.89	-21.1	-0.64	2.01e-75	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	12.17	0.43	8.98e-31	Mean corpuscular hemoglobin;
BRCA	cis	rs939658	0.776	rs35382567	chr15:79440897	C/T	cg17916960	chr15:79447300	NA	-0.43	-10.98	-0.4	8.11e-26	Refractive error;
BRCA	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg08132940	chr7:1081526	C7orf50	-0.59	-8.84	-0.33	9.37e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1400816	0.850	rs1878583	chr2:172725301	C/T	cg13550731	chr2:172543902	DYNC1I2	0.51	7.92	0.3	1.04e-14	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg14789911	chr21:47582049	C21orf56	-0.38	-8.07	-0.3	3.61e-15	Testicular germ cell tumor;
BRCA	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg01256987	chr12:42539512	GXYLT1	-0.57	-11.71	-0.42	7.85e-29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs1506636	0.962	rs17623873	chr7:123417100	C/A	cg03229431	chr7:123269106	ASB15	0.63	12.87	0.45	7.59e-34	Plateletcrit;Platelet count;
BRCA	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.51	-0.32	1.23e-16	Monocyte percentage of white cells;
BRCA	cis	rs652260	1.000	rs604938	chr19:7903484	A/G	cg26014689	chr19:7917955	EVI5L	0.52	12.15	0.43	1.02e-30	Menarche (age at onset);
BRCA	cis	rs2282802	0.685	rs2337081	chr5:139642414	A/C	cg26211634	chr5:139558579	C5orf32	0.35	8.22	0.31	1.12e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11890956	chr21:40555474	PSMG1	-0.81	-19.7	-0.61	7.23e-68	Cognitive function;
BRCA	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24531977	chr5:56204891	C5orf35	-0.72	-15.87	-0.53	4.38e-48	Initial pursuit acceleration;
BRCA	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.33	10.62	0.39	2.18e-24	Bipolar disorder;
BRCA	cis	rs7580658	0.963	rs6732279	chr2:128089540	G/T	cg09760422	chr2:128146352	NA	-0.35	-7.85	-0.3	1.71e-14	Protein C levels;
BRCA	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg21017887	chr14:105400489	NA	0.66	17.48	0.57	3.47e-56	Rheumatoid arthritis;
BRCA	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.77	10.41	0.38	1.48e-23	Initial pursuit acceleration;
BRCA	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.67	0.39	1.41e-24	Bipolar disorder;
BRCA	cis	rs490234	0.841	rs521119	chr9:128314394	T/C	cg14078157	chr9:128172775	NA	0.34	8.11	0.31	2.66e-15	Mean arterial pressure;
BRCA	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg02187348	chr16:89574699	SPG7	-0.35	-8.39	-0.32	3.07e-16	Multiple myeloma (IgH translocation);
BRCA	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg18512352	chr11:47633146	NA	-0.34	-7.99	-0.3	6.27e-15	Subjective well-being;
BRCA	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg21573476	chr21:45109991	RRP1B	0.37	9.29	0.34	2.44e-19	Mean corpuscular volume;
BRCA	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.44	12.93	0.46	3.95e-34	Response to antipsychotic treatment;
BRCA	cis	rs72627123	0.867	rs77320708	chr14:74478482	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.66	7.93	0.3	9.93e-15	Morning vs. evening chronotype;
BRCA	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg20307385	chr11:47447363	PSMC3	0.89	27.11	0.73	2.41e-108	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs9309711	0.736	rs28619526	chr2:3496804	T/C	cg10845886	chr2:3471009	TTC15	-0.64	-13.18	-0.46	2.87e-35	Neurofibrillary tangles;
BRCA	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg08888203	chr3:10149979	C3orf24	0.67	14.07	0.49	2.42e-39	Alzheimer's disease;
BRCA	cis	rs10992471	0.535	rs10117041	chr9:95282331	A/G	cg14631576	chr9:95140430	CENPP	-0.35	-8.37	-0.31	3.71e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18876405	chr7:65276391	NA	0.5	11.2	0.4	1.09e-26	Aortic root size;
BRCA	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg20387954	chr3:183756860	HTR3D	0.38	8.8	0.33	1.29e-17	Anterior chamber depth;
BRCA	cis	rs7246967	0.673	rs2112610	chr19:22916851	C/T	cg23217946	chr19:22817039	ZNF492	0.49	9.0	0.34	2.48e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.04	-0.37	3.99e-22	Mean corpuscular volume;
BRCA	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg12863693	chr15:85201151	NMB	-0.35	-8.43	-0.32	2.27e-16	P wave terminal force;
BRCA	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg26384229	chr12:38710491	ALG10B	0.41	9.13	0.34	8.88e-19	Morning vs. evening chronotype;
BRCA	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg00684032	chr4:1343700	KIAA1530	0.33	8.42	0.32	2.55e-16	Obesity-related traits;
BRCA	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg27489772	chr12:121021490	NA	0.45	8.02	0.3	5.07e-15	Type 1 diabetes nephropathy;
BRCA	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.36	8.73	0.33	2.2e-17	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs6545883	0.862	rs1880866	chr2:61698972	G/C	cg15711740	chr2:61764176	XPO1	-0.52	-13.2	-0.46	2.42e-35	Tuberculosis;
BRCA	cis	rs113835537	0.502	rs7104378	chr11:66216675	A/G	cg24851651	chr11:66362959	CCS	0.41	7.99	0.3	6.24e-15	Airway imaging phenotypes;
BRCA	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.37e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11890956	chr21:40555474	PSMG1	-0.84	-21.45	-0.65	2.87e-77	Cognitive function;
BRCA	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg03342759	chr3:160939853	NMD3	-0.8	-17.63	-0.57	5.28e-57	Parkinson's disease;
BRCA	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg05084668	chr3:125655381	ALG1L	-0.47	-8.12	-0.31	2.43e-15	Blood pressure (smoking interaction);
BRCA	cis	rs6445967	1.000	rs14927	chr3:58305033	G/T	cg23715586	chr3:58305044	RPP14	-0.34	-8.55	-0.32	9.09e-17	Platelet count;
BRCA	cis	rs7737355	0.947	rs31584	chr5:130993124	A/G	cg06307176	chr5:131281290	NA	0.53	10.39	0.38	1.87e-23	Life satisfaction;
BRCA	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg24531977	chr5:56204891	C5orf35	-0.41	-8.53	-0.32	1.03e-16	Breast cancer;Breast cancer (early onset);
BRCA	trans	rs2262909	0.853	rs56207853	chr19:22292357	C/T	cg17074339	chr11:11642133	GALNTL4	0.44	8.55	0.32	9.34e-17	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg08213375	chr14:104286397	PPP1R13B	0.58	15.19	0.52	1e-44	Schizophrenia;
BRCA	cis	rs2637266	1.000	rs7098929	chr10:78361194	T/G	cg18941641	chr10:78392320	NA	0.35	7.84	0.3	1.83e-14	Pulmonary function;
BRCA	cis	rs11997175	0.624	rs6996590	chr8:33680486	A/G	ch.8.33884649F	chr8:33765107	NA	0.4	9.27	0.34	2.82e-19	Body mass index;
BRCA	cis	rs6142102	0.961	rs973409	chr20:32536364	A/G	cg24642439	chr20:33292090	TP53INP2	0.44	8.07	0.3	3.57e-15	Skin pigmentation;
BRCA	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-18.5	-0.59	1.6e-61	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg24011408	chr12:48396354	COL2A1	-0.39	-7.83	-0.3	2.07e-14	Glycated hemoglobin levels;
BRCA	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg21475434	chr5:93447410	FAM172A	0.66	8.48	0.32	1.51e-16	Diabetic retinopathy;
BRCA	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg08885076	chr2:99613938	TSGA10	-0.59	-13.12	-0.46	5.39e-35	Chronic sinus infection;
BRCA	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg25319279	chr11:5960081	NA	-0.39	-7.95	-0.3	8.58e-15	DNA methylation (variation);
BRCA	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	10.66	0.39	1.55e-24	Rheumatoid arthritis;
BRCA	cis	rs11958404	0.932	rs72816563	chr5:157427447	C/T	cg05962755	chr5:157440814	NA	0.54	10.24	0.38	7.1e-23	IgG glycosylation;
BRCA	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg14530993	chr4:882597	GAK	0.59	9.68	0.36	8.77e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg02297831	chr4:17616191	MED28	0.34	7.86	0.3	1.64e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs870825	0.860	rs2705886	chr4:185608591	T/C	cg04058563	chr4:185651563	MLF1IP	-0.66	-11.65	-0.42	1.44e-28	Blood protein levels;
BRCA	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg08508325	chr11:3079039	CARS	0.28	8.43	0.32	2.22e-16	Calcium levels;
BRCA	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg12573674	chr2:1569213	NA	-0.64	-14.48	-0.5	2.8e-41	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg04025307	chr7:1156635	C7orf50	0.71	18.43	0.59	3.62e-61	Longevity;Endometriosis;
BRCA	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	8.22	0.31	1.11e-15	Menarche (age at onset);
BRCA	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg22535103	chr8:58192502	C8orf71	-0.46	-8.2	-0.31	1.31e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9462027	0.675	rs9296132	chr6:34777531	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.89	-0.3	1.33e-14	Systemic lupus erythematosus;
BRCA	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11764359	chr7:65958608	NA	0.81	19.65	0.61	1.26e-67	Aortic root size;
BRCA	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg17063962	chr7:91808500	NA	0.56	12.65	0.45	7.2e-33	Breast cancer;
BRCA	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg04476341	chr5:669733	TPPP	-0.38	-10.33	-0.38	3.01e-23	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
BRCA	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.85e-29	Chronic sinus infection;
BRCA	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg26031613	chr14:104095156	KLC1	-0.55	-9.38	-0.35	1.1e-19	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4722166	0.532	rs1404008	chr7:22756000	A/T	cg05472934	chr7:22766657	IL6	0.44	11.04	0.4	4.52e-26	Lung cancer;
BRCA	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24549020	chr5:56110836	MAP3K1	0.58	11.73	0.42	6.76e-29	Initial pursuit acceleration;
BRCA	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-12.57	-0.45	1.62e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs73036520	0.560	rs346750	chr19:45737218	G/T	cg01416317	chr19:45737208	EXOC3L2	-0.51	-11.7	-0.42	8.28e-29	Monocyte percentage of white cells;
BRCA	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg24531977	chr5:56204891	C5orf35	-0.43	-8.98	-0.33	2.97e-18	Breast cancer;Breast cancer (early onset);
BRCA	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg15704280	chr7:45808275	SEPT13	-0.47	-8.38	-0.31	3.49e-16	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg21775007	chr8:11205619	TDH	-0.5	-10.34	-0.38	2.77e-23	Triglycerides;
BRCA	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26314531	chr2:26401878	FAM59B	-0.63	-10.77	-0.39	5.9e-25	Gut microbiome composition (summer);
BRCA	trans	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg25214090	chr10:38739885	LOC399744	0.45	10.62	0.39	2.18e-24	Corneal astigmatism;
BRCA	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg11764359	chr7:65958608	NA	0.66	12.0	0.43	4.83e-30	Aortic root size;
BRCA	trans	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.0	0.3	5.71e-15	Corneal astigmatism;
BRCA	cis	rs9831754	0.906	rs9869812	chr3:78385679	G/A	cg06138941	chr3:78371609	NA	-0.76	-16.6	-0.55	9.62e-52	Calcium levels;
BRCA	cis	rs3784262	0.654	rs4646568	chr15:58344290	A/G	cg12031962	chr15:58353849	ALDH1A2	0.5	13.06	0.46	1.04e-34	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg01483505	chr11:975446	AP2A2	0.33	9.07	0.34	1.44e-18	Alzheimer's disease (late onset);
BRCA	cis	rs2066819	1.000	rs76430365	chr12:56699993	A/C	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg03929089	chr4:120376271	NA	0.71	14.75	0.5	1.37e-42	Coronary artery disease;
BRCA	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.42	-0.38	1.34e-23	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg21475434	chr5:93447410	FAM172A	0.69	8.49	0.32	1.43e-16	Diabetic retinopathy;
BRCA	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg24848339	chr3:12840334	CAND2	0.43	11.4	0.41	1.5e-27	QRS complex (12-leadsum);
BRCA	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg25554036	chr4:6271136	WFS1	0.37	8.83	0.33	1.01e-17	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21545522	chr1:205238299	TMCC2	0.4	8.34	0.31	4.62e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg26384229	chr12:38710491	ALG10B	0.74	16.31	0.54	2.84e-50	Morning vs. evening chronotype;
BRCA	cis	rs9612	0.950	rs7256472	chr19:44246970	C/T	cg08581076	chr19:44259116	C19orf61	0.52	8.99	0.34	2.75e-18	Exhaled nitric oxide output;
BRCA	cis	rs243505	1.000	rs243510	chr7:148432534	A/G	cg09806900	chr7:148480153	CUL1	-0.44	-8.86	-0.33	8.14e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg08888203	chr3:10149979	C3orf24	0.67	14.27	0.49	2.74e-40	Alzheimer's disease;
BRCA	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg12386194	chr3:101231763	SENP7	-0.7	-12.78	-0.45	1.85e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.92	0.56	2.52e-53	Hypertriglyceridemia;
BRCA	cis	rs4423214	0.879	rs10898144	chr11:71151540	A/T	cg05163923	chr11:71159392	DHCR7	-0.56	-11.8	-0.42	3.4e-29	Vitamin D levels;
BRCA	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg22491629	chr6:157744540	C6orf35	-0.67	-12.4	-0.44	8.87e-32	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-12.19	-0.43	7.03e-31	Schizophrenia;
BRCA	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg09754948	chr16:28834200	ATXN2L	-0.46	-9.12	-0.34	9.95e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg03433033	chr1:76189801	ACADM	-0.88	-27.75	-0.74	7.61e-112	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02176678	chr2:219576539	TTLL4	-0.54	-13.72	-0.48	9.6e-38	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2625529	0.652	rs8030815	chr15:72403001	T/C	cg16672083	chr15:72433130	SENP8	0.64	15.42	0.52	8.08e-46	Red blood cell count;
BRCA	cis	rs4423214	0.802	rs4402322	chr11:71184015	C/G	cg05163923	chr11:71159392	DHCR7	-0.56	-11.35	-0.41	2.58e-27	Vitamin D levels;
BRCA	trans	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg25214090	chr10:38739885	LOC399744	0.53	11.71	0.42	7.51e-29	Corneal astigmatism;
BRCA	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg16230307	chr14:35515116	FAM177A1	0.76	15.24	0.52	6.03e-45	Psoriasis;
BRCA	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg09367891	chr1:107599246	PRMT6	0.41	7.99	0.3	6.15e-15	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg23711669	chr6:146136114	FBXO30	0.71	16.82	0.55	7.67e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg25358565	chr5:93447407	FAM172A	1.19	19.37	0.61	4.15e-66	Diabetic retinopathy;
BRCA	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg04691961	chr3:161091175	C3orf57	0.59	14.33	0.49	1.45e-40	Morning vs. evening chronotype;
BRCA	cis	rs10129255	0.500	rs11628999	chr14:107208446	C/T	cg07958169	chr14:107095056	NA	-0.39	-8.45	-0.32	1.95e-16	Kawasaki disease;
BRCA	trans	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg25214090	chr10:38739885	LOC399744	0.44	10.27	0.38	5.09e-23	Corneal astigmatism;
BRCA	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg05340658	chr4:99064831	C4orf37	0.67	16.62	0.55	8.5e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg24642439	chr20:33292090	TP53INP2	0.43	9.11	0.34	1.03e-18	Height;
BRCA	cis	rs367943	0.966	rs348924	chr5:112817930	T/G	cg12552261	chr5:112820674	MCC	-0.55	-12.1	-0.43	1.7e-30	Type 2 diabetes;
BRCA	cis	rs367943	1.000	rs348925	chr5:112817533	T/A	cg12552261	chr5:112820674	MCC	-0.56	-12.28	-0.44	2.97e-31	Type 2 diabetes;
BRCA	cis	rs12618769	0.625	rs3769709	chr2:99187433	A/T	cg10123293	chr2:99228465	UNC50	0.44	8.67	0.32	3.42e-17	Bipolar disorder;
BRCA	cis	rs4588572	0.686	rs67689570	chr5:77676843	T/C	cg11547950	chr5:77652471	NA	0.44	7.83	0.3	2.01e-14	Triglycerides;
BRCA	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg20503657	chr10:835505	NA	1.3	21.64	0.65	2.49e-78	Eosinophil percentage of granulocytes;
BRCA	cis	rs708547	1.000	rs708547	chr4:57821309	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.5	-8.59	-0.32	6.59e-17	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg06238570	chr21:40685208	BRWD1	-0.42	-8.45	-0.32	1.95e-16	Cognitive function;
BRCA	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg25554036	chr4:6271136	WFS1	0.42	9.8	0.36	3.29e-21	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs4363385	0.818	rs946095	chr1:153006470	T/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.49	-0.32	1.4e-16	Inflammatory skin disease;
BRCA	cis	rs727479	0.543	rs56097510	chr15:51533478	C/G	cg19946085	chr15:51559439	CYP19A1	-0.28	-7.85	-0.3	1.72e-14	Estradiol levels;
BRCA	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.84	-0.33	9.56e-18	Total body bone mineral density;
BRCA	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg27170947	chr2:26402098	FAM59B	0.73	12.26	0.44	3.34e-31	Gut microbiome composition (summer);
BRCA	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg06618935	chr21:46677482	NA	-0.37	-8.04	-0.3	4.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	10.06	0.37	3.27e-22	Lung cancer in ever smokers;
BRCA	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg24130564	chr14:104152367	KLC1	-0.34	-7.92	-0.3	1.09e-14	Body mass index;
BRCA	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg22920501	chr2:26401640	FAM59B	-0.65	-11.27	-0.41	5.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-12.89	-0.45	6.01e-34	Response to antipsychotic treatment;
BRCA	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-13.56	-0.47	5.11e-37	Personality dimensions;
BRCA	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg13010199	chr12:38710504	ALG10B	0.49	9.63	0.36	1.35e-20	Morning vs. evening chronotype;
BRCA	cis	rs701145	0.585	rs1727940	chr3:153827257	C/G	cg12800244	chr3:153838788	SGEF	0.61	7.81	0.3	2.3e-14	Coronary artery disease;
BRCA	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg12444411	chr7:2802554	GNA12	-0.33	-8.29	-0.31	6.49e-16	Height;
BRCA	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg20587970	chr11:113659929	NA	-1.35	-24.74	-0.7	2.87e-95	Hip circumference adjusted for BMI;
BRCA	trans	rs3857536	0.813	rs7771716	chr6:66946769	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	2.02e-14	Blood trace element (Cu levels);
BRCA	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg03146154	chr1:46216737	IPP	-0.47	-9.99	-0.37	6.14e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9796	0.621	rs1659228	chr15:41471978	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.37	-7.94	-0.3	9.04e-15	Menopause (age at onset);
BRCA	cis	rs7246657	0.722	rs35863684	chr19:38109777	C/T	cg14683738	chr19:37701593	ZNF585B	0.46	8.01	0.3	5.5e-15	Coronary artery calcification;
BRCA	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg06212747	chr3:49208901	KLHDC8B	0.48	9.71	0.36	6.69e-21	Parkinson's disease;
BRCA	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-9.32	-0.35	1.91e-19	Menopause (age at onset);
BRCA	cis	rs9649465	1.000	rs9641715	chr7:123348623	A/G	cg04330084	chr7:123175371	IQUB	-0.3	-8.33	-0.31	5.11e-16	Migraine;
BRCA	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg20916646	chr4:852691	GAK	0.41	9.77	0.36	4.1e-21	Sjögren's syndrome;
BRCA	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg11057378	chr10:81107060	PPIF	0.36	8.74	0.33	1.97e-17	Height;
BRCA	trans	rs11039798	0.778	rs7944523	chr11:48911019	G/A	cg15704280	chr7:45808275	SEPT13	0.6	8.89	0.33	6.42e-18	Axial length;
BRCA	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg01283332	chr5:1856932	NA	-0.35	-8.71	-0.33	2.64e-17	Cardiovascular disease risk factors;
BRCA	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg10818794	chr15:86012489	AKAP13	-0.31	-8.61	-0.32	5.47e-17	Coronary artery disease;
BRCA	cis	rs4363385	0.720	rs6704498	chr1:152964740	C/A	cg21543102	chr1:152974771	SPRR3	-0.3	-8.64	-0.32	4.48e-17	Inflammatory skin disease;
BRCA	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg09877947	chr5:131593287	PDLIM4	0.35	8.59	0.32	6.55e-17	Blood metabolite levels;
BRCA	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg23358479	chr7:1110784	C7orf50	-0.48	-8.17	-0.31	1.68e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9318086	0.904	rs9580769	chr13:24439724	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.29	-8.42	-0.32	2.52e-16	Myopia (pathological);
BRCA	cis	rs67981189	0.656	rs2810113	chr14:71395770	C/T	cg15816911	chr14:71606274	NA	-0.35	-8.09	-0.3	3e-15	Schizophrenia;
BRCA	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg24596788	chr1:163392923	NA	-0.4	-10.74	-0.39	7.26e-25	Motion sickness;
BRCA	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.56	9.34	0.35	1.6e-19	Renal function-related traits (BUN);
BRCA	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg10932868	chr11:921992	NA	0.47	12.11	0.43	1.62e-30	Alzheimer's disease (late onset);
BRCA	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg25358565	chr5:93447407	FAM172A	1.08	17.55	0.57	1.38e-56	Diabetic retinopathy;
BRCA	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.6	8.31	0.31	5.91e-16	Schizophrenia;
BRCA	cis	rs9837602	1.000	rs9864437	chr3:99764754	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.16	0.4	1.5e-26	Breast cancer;
BRCA	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.47	-0.32	1.66e-16	Breast cancer;
BRCA	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg23358479	chr7:1110784	C7orf50	-0.47	-7.99	-0.3	6.1e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg08847533	chr14:75593920	NEK9	-0.83	-20.59	-0.63	1.18e-72	Height;
BRCA	cis	rs9868809	0.881	rs3806694	chr3:48672334	G/C	cg00383909	chr3:49044727	WDR6	0.56	8.43	0.32	2.28e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs12618769	0.597	rs3729568	chr2:99100196	T/G	cg10123293	chr2:99228465	UNC50	0.41	8.52	0.32	1.14e-16	Bipolar disorder;
BRCA	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg15839431	chr19:19639596	YJEFN3	0.36	8.21	0.31	1.19e-15	Bipolar disorder;
BRCA	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg18154014	chr19:37997991	ZNF793	0.48	9.56	0.35	2.54e-20	Coronary artery calcification;
BRCA	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.38	-0.31	3.39e-16	Colorectal cancer;
BRCA	cis	rs1953600	0.870	rs2573356	chr10:81949363	C/T	cg04850286	chr10:81895943	PLAC9	0.32	9.0	0.34	2.57e-18	Sarcoidosis;
BRCA	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg23708337	chr7:1209742	NA	0.55	11.79	0.42	3.73e-29	Longevity;Endometriosis;
BRCA	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26314531	chr2:26401878	FAM59B	-0.79	-12.55	-0.44	1.89e-32	Gut microbiome composition (summer);
BRCA	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg02951883	chr7:2050386	MAD1L1	-0.57	-14.68	-0.5	3.04e-42	Bipolar disorder and schizophrenia;
BRCA	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg14004847	chr7:1930337	MAD1L1	0.42	8.06	0.3	3.63e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	27.6	0.74	5.62e-111	Chronic sinus infection;
BRCA	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg00071950	chr4:10020882	SLC2A9	0.42	8.92	0.33	4.73e-18	Blood metabolite levels;
BRCA	cis	rs3125734	0.653	rs1007976	chr10:63970144	C/T	cg19640130	chr10:64028056	RTKN2	0.31	8.96	0.33	3.45e-18	Rheumatoid arthritis;
BRCA	cis	rs7246967	0.673	rs3844578	chr19:22880610	G/C	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg17366294	chr4:99064904	C4orf37	0.41	9.48	0.35	4.76e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs3956705	0.762	rs13311608	chr7:32999601	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.44	-8.62	-0.32	5.16e-17	Red cell distribution width;
BRCA	cis	rs812925	0.519	rs2463099	chr2:61618311	T/C	cg15711740	chr2:61764176	XPO1	0.33	8.31	0.31	5.88e-16	Immature fraction of reticulocytes;
BRCA	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.61	-0.32	5.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg04315214	chr1:2043799	PRKCZ	-0.47	-12.48	-0.44	3.93e-32	Height;
BRCA	cis	rs6570726	0.526	rs9376934	chr6:145738702	A/G	cg23711669	chr6:146136114	FBXO30	0.47	10.11	0.37	2.17e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg13319975	chr6:146136371	FBXO30	0.41	9.28	0.34	2.63e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg27279351	chr12:120934652	DYNLL1	0.56	13.41	0.47	2.63e-36	High light scatter reticulocyte count;
BRCA	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg25019033	chr10:957182	NA	-0.41	-7.89	-0.3	1.33e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg13010199	chr12:38710504	ALG10B	0.5	10.17	0.37	1.23e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs367943	1.000	rs348962	chr5:112819086	C/T	cg12552261	chr5:112820674	MCC	0.55	12.1	0.43	1.68e-30	Type 2 diabetes;
BRCA	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.5	-0.32	1.31e-16	Total body bone mineral density;
BRCA	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.6	-12.36	-0.44	1.25e-31	Lymphocyte counts;
BRCA	cis	rs11779988	0.545	rs411531	chr8:17795934	A/G	cg01800426	chr8:17659068	MTUS1	-0.4	-8.11	-0.31	2.58e-15	Breast cancer;
BRCA	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.66	-14.85	-0.51	4.54e-43	Hip circumference adjusted for BMI;
BRCA	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg09184832	chr6:79620586	NA	0.51	11.52	0.41	4.97e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.66	11.48	0.41	7.03e-28	Lung function (FEV1/FVC);
BRCA	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg22705602	chr4:152727874	NA	-0.32	-7.84	-0.3	1.88e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg13852791	chr20:30311386	BCL2L1	0.86	16.75	0.55	1.82e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg14675211	chr2:100938903	LONRF2	0.44	10.11	0.37	2.18e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6684514	1.000	rs12117903	chr1:156311165	G/T	cg16558208	chr1:156270281	VHLL	0.35	8.08	0.3	3.34e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-21.8	-0.65	3.57e-79	Height;
BRCA	cis	rs3857067	0.806	rs17302467	chr4:95112056	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.49	-0.35	4.67e-20	QT interval;
BRCA	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg03433033	chr1:76189801	ACADM	-0.75	-16.95	-0.56	1.64e-53	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2425143	1.000	rs73902908	chr20:34365112	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.2	-0.34	5.11e-19	Blood protein levels;
BRCA	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg01884057	chr2:25150051	NA	0.35	9.41	0.35	9e-20	Body mass index;
BRCA	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg13319975	chr6:146136371	FBXO30	-0.43	-10.1	-0.37	2.46e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.45	8.04	0.3	4.45e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg22563815	chr15:78856949	CHRNA5	-0.35	-8.39	-0.31	3.18e-16	Sudden cardiac arrest;
BRCA	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg22535103	chr8:58192502	C8orf71	-0.42	-8.76	-0.33	1.72e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.01	0.56	8.73e-54	Morning vs. evening chronotype;
BRCA	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg11657440	chr19:46296263	DMWD	-0.56	-13.37	-0.47	4.15e-36	Coronary artery disease;
BRCA	cis	rs3818285	0.679	rs612155	chr10:111630731	C/G	cg00817464	chr10:111662876	XPNPEP1	0.44	14.21	0.49	4.82e-40	Superior crus of antihelix expression;
BRCA	trans	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg25214090	chr10:38739885	LOC399744	0.5	10.94	0.4	1.2e-25	Corneal astigmatism;
BRCA	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg13770153	chr20:60521292	NA	-0.46	-11.04	-0.4	4.75e-26	Body mass index;
BRCA	cis	rs41005	1.000	rs193931	chr2:8107435	A/G	cg03155496	chr2:8117019	LOC339788	-0.57	-15.25	-0.52	5.22e-45	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs1043763	0.826	rs4758689	chr12:122611004	A/T	cg14400030	chr12:122498111	BCL7A	-0.62	-13.76	-0.48	6.7e-38	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
BRCA	cis	rs10754283	0.967	rs10922685	chr1:90118320	A/G	cg21401794	chr1:90099060	LRRC8C	0.48	11.71	0.42	7.68e-29	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	11.88	0.43	1.45e-29	Personality dimensions;
BRCA	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg10495392	chr1:46806563	NSUN4	-0.43	-8.06	-0.3	3.74e-15	Menopause (age at onset);
BRCA	cis	rs10489202	0.608	rs16828093	chr1:168078384	C/T	cg24449463	chr1:168025552	DCAF6	-0.46	-15.32	-0.52	2.28e-45	Schizophrenia;
BRCA	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg16482183	chr6:26056742	HIST1H1C	0.48	9.62	0.36	1.54e-20	Iron status biomarkers;
BRCA	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11764359	chr7:65958608	NA	-0.75	-16.48	-0.55	4.02e-51	Aortic root size;
BRCA	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs700651	0.624	rs12105927	chr2:198937258	G/A	cg00792783	chr2:198669748	PLCL1	0.38	8.29	0.31	6.61e-16	Intracranial aneurysm;
BRCA	cis	rs858239	0.539	rs28624974	chr7:23188936	T/C	cg23682824	chr7:23144976	KLHL7	0.42	10.94	0.4	1.21e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.38	8.33	0.31	4.97e-16	Cognitive ability;
BRCA	cis	rs10740039	0.804	rs894383	chr10:62443117	A/G	cg02922035	chr10:62493342	NA	0.41	7.83	0.3	1.98e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.69	-0.33	3.09e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	9.58	0.35	2.04e-20	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.59	-10.32	-0.38	3.49e-23	Menarche (age at onset);
BRCA	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg13880726	chr7:1868755	MAD1L1	0.41	8.11	0.31	2.69e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.63	-0.32	4.85e-17	Schizophrenia;
BRCA	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.87	-0.33	7.27e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs7528419	0.927	rs660240	chr1:109817838	T/C	cg00908766	chr1:109817496	CELSR2	0.62	18.08	0.58	2.45e-59	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
BRCA	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg12219531	chr12:120966889	COQ5	0.55	11.43	0.41	1.22e-27	High light scatter reticulocyte count;
BRCA	trans	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	21.05	0.64	4.24e-75	Exhaled nitric oxide output;
BRCA	cis	rs4363385	0.747	rs1415962	chr1:152958731	T/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.44	-0.35	7e-20	Inflammatory skin disease;
BRCA	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg24675658	chr1:53192096	ZYG11B	0.63	15.23	0.52	6.76e-45	Monocyte count;
BRCA	cis	rs4285028	0.747	rs3772126	chr3:121354583	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.82	-15.59	-0.52	1.13e-46	Multiple sclerosis;
BRCA	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.76	-0.39	6.05e-25	Mean corpuscular volume;
BRCA	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg17135325	chr3:160939158	NMD3	0.45	8.58	0.32	7.26e-17	Parkinson's disease;
BRCA	cis	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg06521331	chr12:34319734	NA	-0.55	-9.36	-0.35	1.36e-19	Resting heart rate;
BRCA	cis	rs3767633	0.748	rs6667896	chr1:161837407	G/A	cg09175582	chr1:161736000	ATF6	0.52	8.39	0.32	3.09e-16	IgG glycosylation;
BRCA	trans	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg25214090	chr10:38739885	LOC399744	0.56	12.2	0.43	6.68e-31	Corneal astigmatism;
BRCA	trans	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.95	-0.3	8.25e-15	Corneal astigmatism;
BRCA	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-14.98	-0.51	1.01e-43	Total cholesterol levels;
BRCA	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg15017067	chr4:17643749	FAM184B	0.35	10.59	0.39	2.91e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg17848003	chr1:3704513	LRRC47	0.24	7.86	0.3	1.61e-14	Red cell distribution width;
BRCA	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.15	0.31	1.87e-15	Tonsillectomy;
BRCA	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg05347473	chr6:146136440	FBXO30	0.42	8.48	0.32	1.57e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3824867	0.959	rs4237544	chr11:47454271	G/T	cg20307385	chr11:47447363	PSMC3	-0.52	-11.59	-0.42	2.56e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg17063962	chr7:91808500	NA	0.53	12.47	0.44	4.19e-32	Breast cancer;
BRCA	cis	rs2997447	0.655	rs55820521	chr1:26374286	C/T	cg19633962	chr1:26362018	EXTL1	-0.69	-11.43	-0.41	1.2100000000000001e-27	QRS complex (12-leadsum);
BRCA	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.24	-0.31	9.74e-16	Axial length;
BRCA	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg09065629	chr16:1709722	CRAMP1L	0.37	8.57	0.32	7.54e-17	Coronary artery disease;
BRCA	cis	rs2016266	0.859	rs56225815	chr12:53740090	C/G	cg26875137	chr12:53738046	NA	-0.44	-9.67	-0.36	9.75e-21	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg16606324	chr3:10149918	C3orf24	0.48	9.47	0.35	5.5e-20	Alzheimer's disease;
BRCA	trans	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg25214090	chr10:38739885	LOC399744	0.51	11.51	0.41	5.53e-28	Corneal astigmatism;
BRCA	cis	rs7123876	0.587	rs11602616	chr11:72364077	T/C	cg03713592	chr11:72463424	ARAP1	0.65	9.98	0.37	6.94e-22	Body mass index;
BRCA	cis	rs6450176	0.625	rs67656636	chr5:53288455	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-15.05	-0.51	4.97e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs9649465	0.967	rs3757505	chr7:123391641	C/T	cg04330084	chr7:123175371	IQUB	-0.3	-8.13	-0.31	2.21e-15	Migraine;
BRCA	trans	rs75804782	0.521	rs56373856	chr2:239437926	C/T	cg01134436	chr17:81009848	B3GNTL1	0.66	8.59	0.32	6.84e-17	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs1030877	0.515	rs2679893	chr2:105909554	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.62	11.97	0.43	6.3e-30	Obesity-related traits;
BRCA	cis	rs243505	0.867	rs243526	chr7:148417073	C/T	cg09806900	chr7:148480153	CUL1	-0.39	-8.16	-0.31	1.84e-15	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg05729581	chr11:3078854	CARS	-0.35	-8.69	-0.32	3.11e-17	Longevity;
BRCA	cis	rs11785693	0.866	rs11782170	chr8:4976942	A/G	cg26367366	chr8:4980734	NA	-0.57	-9.88	-0.36	1.63e-21	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg00383909	chr3:49044727	WDR6	0.98	15.61	0.53	9.41e-47	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg21775007	chr8:11205619	TDH	0.61	11.8	0.42	3.3e-29	Retinal vascular caliber;
BRCA	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	9.21	0.34	4.74e-19	Mean platelet volume;
BRCA	cis	rs7953508	0.506	rs10859532	chr12:93960917	G/C	cg18151635	chr12:93972918	NA	-0.47	-9.28	-0.34	2.68e-19	Pubertal anthropometrics;
BRCA	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18876405	chr7:65276391	NA	0.58	14.46	0.5	3.36e-41	Aortic root size;
BRCA	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg25427524	chr10:38739819	LOC399744	-0.55	-9.93	-0.37	1.09e-21	Obesity (extreme);
BRCA	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg02012338	chr4:187126139	CYP4V2	0.86	9.59	0.35	1.86e-20	Blood protein levels;
BRCA	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.3	-0.44	2.46e-31	Alzheimer's disease;
BRCA	cis	rs4588572	0.643	rs1159929	chr5:77768820	A/G	cg11547950	chr5:77652471	NA	0.47	8.45	0.32	2.01e-16	Triglycerides;
BRCA	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg12311346	chr5:56204834	C5orf35	-0.81	-16.7	-0.55	3.32e-52	Initial pursuit acceleration;
BRCA	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg14784868	chr12:69753453	YEATS4	0.79	25.23	0.71	5.18e-98	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.86e-24	Motion sickness;
BRCA	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg18252515	chr7:66147081	NA	-0.55	-11.03	-0.4	4.99e-26	Corneal structure;
BRCA	cis	rs10463316	0.894	rs4099170	chr5:150766583	G/A	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.32	-0.31	5.17e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs10789491	1.000	rs2083485	chr1:47170091	G/C	cg15501359	chr1:47185051	KIAA0494	0.65	18.2	0.58	5.93e-60	Response to hepatitis C treatment;
BRCA	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg03433033	chr1:76189801	ACADM	0.86	22.18	0.66	2.75e-81	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs13046373	0.535	rs7281767	chr21:32022062	T/C	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.28	0.34	2.58e-19	HDL cholesterol;
BRCA	cis	rs6426558	0.537	rs12139758	chr1:227260519	A/G	cg10327440	chr1:227177885	CDC42BPA	0.47	9.36	0.35	1.33e-19	Neutrophil percentage of white cells;
BRCA	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg26647111	chr11:31128758	NA	0.44	9.66	0.36	1.07e-20	Red blood cell count;
BRCA	cis	rs3820928	0.934	rs16822890	chr2:227761477	G/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.36	-0.31	3.79e-16	Pulmonary function;
BRCA	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg05283184	chr6:79620031	NA	-0.35	-7.95	-0.3	8.28e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg14631576	chr9:95140430	CENPP	-0.37	-8.99	-0.34	2.71e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs990171	0.506	rs6543107	chr2:102750730	A/T	cg22835712	chr2:102737379	NA	0.59	11.26	0.41	6.15e-27	Lymphocyte counts;
BRCA	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg08508325	chr11:3079039	CARS	-0.45	-16.07	-0.54	4.92e-49	Longevity;
BRCA	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.58	10.28	0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs12618769	0.597	rs3754893	chr2:99063149	T/A	cg10123293	chr2:99228465	UNC50	0.41	8.14	0.31	2.05e-15	Bipolar disorder;
BRCA	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg13047869	chr3:10149882	C3orf24	0.57	10.42	0.38	1.43e-23	Alzheimer's disease;
BRCA	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg06271696	chr7:157225062	NA	-0.37	-9.73	-0.36	5.9e-21	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	cis	rs4478858	0.735	rs1566963	chr1:31772206	G/A	cg00250761	chr1:31883323	NA	-0.32	-8.31	-0.31	5.91e-16	Alcohol dependence;
BRCA	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg18357645	chr12:58087776	OS9	0.43	12.02	0.43	3.75e-30	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02353165	chr6:42928485	GNMT	0.78	18.88	0.6	1.69e-63	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg02297831	chr4:17616191	MED28	0.34	7.98	0.3	6.95e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg15556689	chr8:8085844	FLJ10661	0.37	8.83	0.33	1.02e-17	Retinal vascular caliber;
BRCA	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg12386194	chr3:101231763	SENP7	0.46	9.79	0.36	3.64e-21	Colorectal cancer;
BRCA	cis	rs7973719	0.769	rs61917956	chr12:7348659	T/C	cg07052231	chr12:7363540	PEX5	0.35	7.9	0.3	1.23e-14	IgG glycosylation;
BRCA	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03264133	chr6:25882463	NA	-0.55	-11.36	-0.41	2.29e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg27286337	chr10:134555280	INPP5A	-0.84	-20.47	-0.63	5.46e-72	Migraine;
BRCA	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.16	-48.97	-0.89	1.81e-218	Myeloid white cell count;
BRCA	cis	rs7408868	1.000	rs1548554	chr19:15277938	C/T	cg14696996	chr19:15285081	NOTCH3	1.01	14.77	0.5	1.08e-42	Pulse pressure;
BRCA	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24549020	chr5:56110836	MAP3K1	0.67	13.55	0.47	6.1e-37	Initial pursuit acceleration;
BRCA	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg03060546	chr3:49711283	APEH	0.6	10.31	0.38	3.56e-23	Menarche (age at onset);
BRCA	cis	rs10267417	0.603	rs12668717	chr7:19932912	G/T	cg05791153	chr7:19748676	TWISTNB	0.43	8.09	0.3	3.01e-15	Night sleep phenotypes;
BRCA	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg06784218	chr1:46089804	CCDC17	-0.42	-9.75	-0.36	5.15e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg23018236	chr17:30244563	NA	-0.49	-9.09	-0.34	1.2e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.89	-0.33	6.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg01475377	chr6:109611718	NA	-0.59	-16.43	-0.54	7.68e-51	Reticulocyte fraction of red cells;
BRCA	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg06627628	chr2:24431161	ITSN2	-0.5	-8.26	-0.31	8.39e-16	Lymphocyte counts;
BRCA	cis	rs4363385	0.818	rs454993	chr1:153008992	C/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg09184832	chr6:79620586	NA	-0.43	-8.45	-0.32	2.03e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.47	10.54	0.38	4.85e-24	Colorectal cancer;
BRCA	cis	rs9309473	0.948	rs13392691	chr2:73748980	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-11.63	-0.42	1.75e-28	Metabolite levels;
BRCA	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg15448220	chr1:150897856	SETDB1	0.36	8.26	0.31	8.31e-16	Melanoma;
BRCA	cis	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg06521331	chr12:34319734	NA	-0.63	-12.5	-0.44	3.27e-32	Morning vs. evening chronotype;
BRCA	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg13906792	chr15:75199810	C15orf17	-0.39	-9.05	-0.34	1.73e-18	Breast cancer;
BRCA	trans	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.33	-8.69	-0.33	2.98e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg00745463	chr17:30367425	LRRC37B	-0.49	-8.44	-0.32	2.09e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg17366294	chr4:99064904	C4orf37	0.53	11.38	0.41	1.85e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg05347473	chr6:146136440	FBXO30	-0.41	-8.27	-0.31	7.6e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23583168	chr7:148888333	NA	-0.82	-18.74	-0.6	9.08e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7408868	0.831	rs1548555	chr19:15278057	A/G	cg14696996	chr19:15285081	NOTCH3	1.01	14.77	0.5	1.08e-42	Pulse pressure;
BRCA	cis	rs13102973	0.965	rs4597893	chr4:135863043	C/T	cg14419869	chr4:135874104	NA	-0.59	-12.91	-0.45	4.85e-34	Subjective well-being;
BRCA	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.42	-8.36	-0.31	4e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg14844989	chr11:31128820	NA	-0.44	-9.8	-0.36	3.24e-21	Red blood cell count;
BRCA	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs829883	0.659	rs11109517	chr12:98921574	A/C	cg25150519	chr12:98850993	NA	0.49	9.01	0.34	2.36e-18	Colorectal adenoma (advanced);
BRCA	cis	rs10267417	0.535	rs6960731	chr7:19869379	C/G	cg05791153	chr7:19748676	TWISTNB	-0.49	-9.55	-0.35	2.61e-20	Night sleep phenotypes;
BRCA	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg06697600	chr4:7070879	GRPEL1	-0.53	-10.8	-0.39	4.4e-25	Monocyte percentage of white cells;
BRCA	cis	rs10489202	1.000	rs10489202	chr1:167903079	A/C	cg24449463	chr1:168025552	DCAF6	0.42	11.04	0.4	4.51e-26	Schizophrenia;
BRCA	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg22105103	chr4:187893119	NA	-0.39	-12.83	-0.45	1.06e-33	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs897080	0.515	rs786405	chr2:44710367	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	9.42	0.35	8.41e-20	Height;
BRCA	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.33	0.31	5.09e-16	Mean corpuscular volume;
BRCA	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg14829155	chr15:31115871	NA	-0.43	-9.69	-0.36	8.15e-21	Huntington's disease progression;
BRCA	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.8e-21	Developmental language disorder (linguistic errors);
BRCA	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21659725	chr3:3221576	CRBN	-0.47	-11.94	-0.43	8.58e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs6138458	1.000	rs2387361	chr20:24899905	C/T	cg26195577	chr20:24973756	C20orf3	-0.98	-24.65	-0.7	8.06e-95	Blood protein levels;
BRCA	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.39	7.82	0.3	2.23e-14	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg08601574	chr20:25228251	PYGB	-0.39	-8.95	-0.33	3.74e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg05025164	chr4:1340916	KIAA1530	0.36	7.86	0.3	1.68e-14	Longevity;
BRCA	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg08213375	chr14:104286397	PPP1R13B	0.66	18.66	0.59	2.4e-62	Schizophrenia;
BRCA	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg21573476	chr21:45109991	RRP1B	-0.37	-9.31	-0.35	1.97e-19	Mean corpuscular volume;
BRCA	cis	rs7395581	0.918	rs3816725	chr11:47305669	T/G	cg25783544	chr11:47291846	MADD	0.43	9.6	0.36	1.71e-20	HDL cholesterol;
BRCA	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg04362960	chr10:104952993	NT5C2	0.46	10.7	0.39	1.08e-24	Arsenic metabolism;
BRCA	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-8.71	-0.33	2.67e-17	Schizophrenia;
BRCA	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg23719950	chr11:63933701	MACROD1	-0.52	-8.76	-0.33	1.8e-17	Mean platelet volume;
BRCA	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg16339924	chr4:17578868	LAP3	0.59	14.37	0.49	8.75e-41	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	13.53	0.47	7.03e-37	Platelet count;
BRCA	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg12463550	chr7:65579703	CRCP	0.38	8.11	0.31	2.54e-15	Aortic root size;
BRCA	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-18.07	-0.58	3e-59	Chronic sinus infection;
BRCA	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-8.59	-0.32	6.86e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9462027	0.628	rs4601124	chr6:34776910	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.84	-0.3	1.96e-14	Systemic lupus erythematosus;
BRCA	cis	rs6815814	0.851	rs11466617	chr4:38780471	T/C	cg02016764	chr4:38805732	TLR1	-0.5	-7.82	-0.3	2.17e-14	Breast cancer;
BRCA	trans	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg15704280	chr7:45808275	SEPT13	0.59	8.76	0.33	1.72e-17	Axial length;
BRCA	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg25801113	chr15:45476975	SHF	-0.34	-8.33	-0.31	4.76e-16	Uric acid levels;
BRCA	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg00540400	chr15:79124168	NA	-0.28	-8.0	-0.3	5.94e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg25036284	chr2:26402008	FAM59B	-0.64	-10.63	-0.39	2.11e-24	Gut microbiome composition (summer);
BRCA	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg02403541	chr12:121454288	C12orf43	0.67	12.72	0.45	3.34e-33	N-glycan levels;
BRCA	cis	rs11920090	0.858	rs12633935	chr3:170674865	A/C	cg09710316	chr3:170744871	SLC2A2	0.49	8.31	0.31	5.56e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs6545883	0.894	rs4672431	chr2:61519922	C/A	cg15711740	chr2:61764176	XPO1	0.49	12.12	0.43	1.38e-30	Tuberculosis;
BRCA	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18402987	chr7:1209562	NA	0.47	9.85	0.36	2.05e-21	Longevity;Endometriosis;
BRCA	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.48	-8.16	-0.31	1.72e-15	Schizophrenia;
BRCA	trans	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg25214090	chr10:38739885	LOC399744	0.43	9.99	0.37	6.03e-22	Corneal astigmatism;
BRCA	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg23505145	chr19:12996616	KLF1	0.53	12.08	0.43	2.01e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg10523679	chr1:76189770	ACADM	-0.46	-8.09	-0.3	3.08e-15	Daytime sleep phenotypes;
BRCA	cis	rs4664304	0.620	rs1039932	chr2:160712772	G/A	cg01092293	chr2:160761427	LY75	0.35	8.28	0.31	7.19e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-13.73	-0.48	8.95e-38	Bipolar disorder and schizophrenia;
BRCA	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.36	-8.38	-0.31	3.41e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg20203395	chr5:56204925	C5orf35	-0.43	-9.66	-0.36	1.04e-20	Initial pursuit acceleration;
BRCA	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg09184832	chr6:79620586	NA	-0.51	-11.3	-0.41	3.86e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg05340658	chr4:99064831	C4orf37	0.69	17.43	0.57	6.11e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg04511125	chr2:88470314	THNSL2	0.95	13.67	0.48	1.76e-37	Plasma clusterin levels;
BRCA	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg24060327	chr5:131705240	SLC22A5	-0.64	-12.48	-0.44	3.78e-32	Breast cancer;
BRCA	cis	rs7737355	0.947	rs32110	chr5:131045835	T/C	cg06307176	chr5:131281290	NA	0.52	10.16	0.37	1.45e-22	Life satisfaction;
BRCA	cis	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-9.64	-0.36	1.3e-20	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-17.64	-0.57	5.09e-57	Parkinson's disease;
BRCA	trans	rs6479891	1.000	rs2719815	chr10:65210294	G/C	cg14819942	chr15:35414228	NA	0.35	8.55	0.32	9.19e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg09462578	chr12:12878428	APOLD1	-0.61	-10.85	-0.39	2.65e-25	Systemic lupus erythematosus;
BRCA	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.67	-0.32	3.67e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.93	0.4	1.36e-25	Rheumatoid arthritis;
BRCA	cis	rs7248779	0.512	rs7250002	chr19:2413188	A/G	cg22729335	chr19:2427816	TIMM13	1.01	25.49	0.71	2.1e-99	Cortisol levels (saliva);
BRCA	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg04455712	chr21:45112962	RRP1B	0.38	9.82	0.36	2.74e-21	Mean corpuscular volume;
BRCA	trans	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	19.78	0.62	2.75e-68	Exhaled nitric oxide output;
BRCA	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg23625390	chr15:77176239	SCAPER	-0.52	-12.59	-0.45	1.32e-32	Blood metabolite levels;
BRCA	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg03477792	chr4:77819574	ANKRD56	0.66	16.15	0.54	1.8e-49	Emphysema distribution in smoking;
BRCA	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.29	7.84	0.3	1.9e-14	Electroencephalogram traits;
BRCA	cis	rs11785693	0.862	rs11781233	chr8:4993653	C/G	cg26367366	chr8:4980734	NA	-0.64	-11.01	-0.4	6.4e-26	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.34	-0.38	2.72e-23	Schizophrenia;
BRCA	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg06623918	chr6:96969491	KIAA0776	0.74	12.19	0.43	6.85e-31	Migraine;Coronary artery disease;
BRCA	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg10518543	chr12:38710700	ALG10B	0.36	7.92	0.3	1.03e-14	Morning vs. evening chronotype;
BRCA	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg27366882	chr3:133540807	NA	0.32	7.95	0.3	8.43e-15	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs1691799	0.799	rs10784525	chr12:66772766	G/A	cg16791601	chr12:66731901	HELB	-0.58	-15.14	-0.51	1.75e-44	White blood cell count (basophil);
BRCA	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg05985134	chr18:33552581	C18orf21	0.64	12.21	0.43	5.7e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.81	0.3	2.28e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2070488	0.662	rs6599203	chr3:38487802	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	12.6	0.45	1.17e-32	Electrocardiographic conduction measures;
BRCA	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg18132916	chr6:79620363	NA	-0.46	-10.5	-0.38	6.89e-24	Intelligence (multi-trait analysis);
BRCA	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.68	-0.48	1.51e-37	Extrinsic epigenetic age acceleration;
BRCA	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg09307838	chr4:120376055	NA	0.59	12.9	0.45	5.45e-34	Corneal astigmatism;
BRCA	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.41	0.38	1.45e-23	Bladder cancer;
BRCA	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg08213375	chr14:104286397	PPP1R13B	0.63	17.42	0.57	6.31e-56	Schizophrenia;
BRCA	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-10.04	-0.37	4.1e-22	Heart rate;
BRCA	cis	rs7973719	0.773	rs6486911	chr12:7356494	G/C	cg07052231	chr12:7363540	PEX5	0.36	8.17	0.31	1.63e-15	IgG glycosylation;
BRCA	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg06618935	chr21:46677482	NA	-0.36	-8.04	-0.3	4.32e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg07636037	chr3:49044803	WDR6	0.98	28.73	0.75	3.58e-117	Parkinson's disease;
BRCA	cis	rs72627509	1.000	rs57265257	chr4:57839280	A/T	cg26694713	chr4:57773883	REST	0.45	8.35	0.31	4.26e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg11645453	chr3:52864694	ITIH4	0.34	8.51	0.32	1.27e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9811920	0.965	rs9837131	chr3:99854514	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.52	12.45	0.44	4.99e-32	Axial length;
BRCA	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.65	17.01	0.56	8.71e-54	Hypertriglyceridemia;
BRCA	trans	rs4714291	0.802	rs2983140	chr6:40017224	A/G	cg02267698	chr19:7991119	CTXN1	-0.46	-9.41	-0.35	9.16e-20	Strep throat;
BRCA	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg00074818	chr8:8560427	CLDN23	0.38	8.29	0.31	6.87e-16	Obesity-related traits;
BRCA	cis	rs13102973	0.899	rs17496	chr4:135900227	C/T	cg14419869	chr4:135874104	NA	-0.53	-10.84	-0.39	2.93e-25	Subjective well-being;
BRCA	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg23033748	chr14:75592666	NEK9	-0.36	-8.46	-0.32	1.84e-16	Height;
BRCA	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg21573476	chr21:45109991	RRP1B	-0.33	-8.3	-0.31	6.15e-16	Mean corpuscular volume;
BRCA	cis	rs1030877	0.515	rs2576736	chr2:105890971	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.64	12.01	0.43	4.33e-30	Obesity-related traits;
BRCA	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg07148914	chr20:33460835	GGT7	-0.42	-9.11	-0.34	1.09e-18	Height;
BRCA	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg13256891	chr4:100009986	ADH5	-0.53	-10.01	-0.37	5.33e-22	Alcohol dependence;
BRCA	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.8	13.46	0.47	1.5e-36	Schizophrenia;
BRCA	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.65	-9.72	-0.36	6.56e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7020830	0.931	rs7027473	chr9:37132462	A/G	cg14294708	chr9:37120828	ZCCHC7	1.19	43.18	0.86	1.27e-191	Schizophrenia;
BRCA	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.38	-0.38	2.0500000000000001e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg18898632	chr2:242989856	NA	0.46	8.25	0.31	8.95e-16	Obesity-related traits;
BRCA	cis	rs17818399	0.533	rs13420857	chr2:46798005	C/G	cg02822958	chr2:46747628	ATP6V1E2	-0.51	-10.62	-0.39	2.18e-24	Height;
BRCA	trans	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	9.93	0.37	1.07e-21	Mean corpuscular volume;
BRCA	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.95	0.3	8.6e-15	Depression;
BRCA	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg13010199	chr12:38710504	ALG10B	-0.34	-7.91	-0.3	1.16e-14	Morning vs. evening chronotype;
BRCA	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08859206	chr1:53392774	SCP2	-0.51	-11.23	-0.41	7.8e-27	Monocyte count;
BRCA	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg20933634	chr6:27740509	NA	0.44	8.34	0.31	4.63e-16	Parkinson's disease;
BRCA	trans	rs2797160	1.000	rs2797154	chr6:126005197	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.35	-7.83	-0.3	2.01e-14	Endometrial cancer;
BRCA	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-9.63	-0.36	1.34e-20	Alzheimer's disease (late onset);
BRCA	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	15.68	0.53	4.14e-47	Tonsillectomy;
BRCA	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg05347473	chr6:146136440	FBXO30	0.45	8.95	0.33	3.74e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1030877	0.515	rs2576742	chr2:105898822	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.65	12.47	0.44	4.41e-32	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg05340658	chr4:99064831	C4orf37	0.67	16.77	0.55	1.44e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs68170813	0.559	rs78064065	chr7:106967440	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-8.74	-0.33	2.07e-17	Coronary artery disease;
BRCA	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg08213375	chr14:104286397	PPP1R13B	0.63	18.06	0.58	3.25e-59	Schizophrenia;
BRCA	cis	rs4363385	0.747	rs9919276	chr1:152968654	A/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.69	-0.33	2.92e-17	Inflammatory skin disease;
BRCA	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg26384229	chr12:38710491	ALG10B	-0.48	-11.1	-0.4	2.57e-26	Morning vs. evening chronotype;
BRCA	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg03954927	chr1:10346856	KIF1B	0.43	13.7	0.48	1.16e-37	Hepatocellular carcinoma;
BRCA	cis	rs2625529	0.762	rs1384007	chr15:72229534	T/C	cg16672083	chr15:72433130	SENP8	-0.84	-17.33	-0.57	2.03e-55	Red blood cell count;
BRCA	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-12.02	-0.43	3.8e-30	Electroencephalogram traits;
BRCA	cis	rs7408868	1.000	rs7250232	chr19:15277199	C/T	cg14696996	chr19:15285081	NOTCH3	0.89	12.8	0.45	1.47e-33	Pulse pressure;
BRCA	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg01475735	chr3:40494733	NA	0.46	9.42	0.35	8.04e-20	Renal cell carcinoma;
BRCA	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg07930552	chr6:133119739	C6orf192	0.8	11.15	0.4	1.61e-26	Type 2 diabetes nephropathy;
BRCA	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg24531977	chr5:56204891	C5orf35	0.71	15.44	0.52	6.37e-46	Initial pursuit acceleration;
BRCA	cis	rs919433	1.000	rs7422899	chr2:198163527	G/C	cg00792783	chr2:198669748	PLCL1	-0.37	-7.87	-0.3	1.55e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg23029597	chr12:123009494	RSRC2	-0.56	-11.21	-0.41	9.39e-27	Body mass index;
BRCA	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg13010199	chr12:38710504	ALG10B	0.52	10.5	0.38	6.6e-24	Heart rate;
BRCA	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg26838691	chr2:24397539	C2orf84	0.47	8.6	0.32	5.94e-17	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg13047869	chr3:10149882	C3orf24	0.57	12.42	0.44	6.69e-32	Alzheimer's disease;
BRCA	trans	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg21659725	chr3:3221576	CRBN	-0.47	-8.44	-0.32	2.17e-16	Menarche (age at onset);
BRCA	cis	rs6594499	0.500	rs12514810	chr5:110455357	T/A	cg04022379	chr5:110408740	TSLP	0.42	9.09	0.34	1.22e-18	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg24558204	chr6:135376177	HBS1L	0.44	11.87	0.42	1.69e-29	Red blood cell count;
BRCA	cis	rs7523050	0.730	rs67312582	chr1:109423976	A/G	cg08274380	chr1:109419600	GPSM2	1.18	16.89	0.56	3.31e-53	Fat distribution (HIV);
BRCA	cis	rs7903847	0.596	rs9787426	chr10:99155327	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.53	-0.32	1.03e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg00012203	chr2:219082015	ARPC2	-0.47	-9.12	-0.34	9.9e-19	Colorectal cancer;
BRCA	cis	rs922692	0.744	rs4886592	chr15:79082547	T/C	cg04896959	chr15:78267971	NA	0.37	8.59	0.32	6.75e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg04013093	chr6:42928303	GNMT	-0.29	-8.83	-0.33	9.68e-18	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg20283391	chr11:68216788	NA	-0.47	-9.52	-0.35	3.41e-20	Total body bone mineral density;
BRCA	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg08000102	chr2:233561755	GIGYF2	-0.61	-13.4	-0.47	3.02e-36	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00149659	chr3:10157352	C3orf10	-0.8	-13.7	-0.48	1.21e-37	Alzheimer's disease;
BRCA	cis	rs7178424	1.000	rs11629596	chr15:62370113	G/A	cg00456672	chr15:62358751	C2CD4A	-0.36	-8.44	-0.32	2.18e-16	Height;
BRCA	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg19676328	chr12:49525230	TUBA1B	-0.53	-11.88	-0.43	1.45e-29	Total cholesterol levels;
BRCA	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg13010199	chr12:38710504	ALG10B	0.42	9.03	0.34	1.94e-18	Morning vs. evening chronotype;
BRCA	cis	rs11690935	0.798	rs13018768	chr2:172598592	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-30.91	-0.77	5.4e-129	Schizophrenia;
BRCA	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg23711669	chr6:146136114	FBXO30	0.71	16.56	0.55	1.59e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.06	-0.34	1.61e-18	Bipolar disorder;
BRCA	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg04842962	chr6:43655489	MRPS18A	0.99	22.01	0.66	2.54e-80	IgG glycosylation;
BRCA	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg00080972	chr5:178986291	RUFY1	-0.48	-13.6	-0.47	3.34e-37	Lung cancer;
BRCA	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg08999081	chr20:33150536	PIGU	0.32	8.37	0.31	3.62e-16	Glomerular filtration rate (creatinine);
BRCA	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.34	9.43	0.35	7.46e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg09035930	chr12:129282057	SLC15A4	0.49	14.09	0.49	1.77e-39	Systemic lupus erythematosus;
BRCA	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12667521	chr19:29218732	NA	0.47	8.75	0.33	1.93e-17	Methadone dose in opioid dependence;
BRCA	cis	rs1997103	1.000	rs1965556	chr7:55403584	C/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2797160	1.000	rs983543	chr6:126005767	G/A	cg05901451	chr6:126070800	HEY2	-0.39	-9.49	-0.35	4.46e-20	Endometrial cancer;
BRCA	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg06640241	chr16:89574553	SPG7	0.83	20.56	0.63	1.69e-72	Multiple myeloma (IgH translocation);
BRCA	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg16339924	chr4:17578868	LAP3	0.56	13.83	0.48	3.07e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24531977	chr5:56204891	C5orf35	-0.72	-16.05	-0.54	5.62e-49	Initial pursuit acceleration;
BRCA	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg20307385	chr11:47447363	PSMC3	0.82	20.62	0.63	8.85e-73	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg23229984	chr5:148520753	ABLIM3	0.36	8.74	0.33	2.06e-17	Breast cancer;
BRCA	trans	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg00938859	chr5:1591904	SDHAP3	0.63	8.84	0.33	9.45e-18	Breast cancer;
BRCA	cis	rs4363385	0.747	rs1611753	chr1:152956381	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.86	-0.33	7.58e-18	Inflammatory skin disease;
BRCA	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg17971929	chr21:40555470	PSMG1	0.72	15.64	0.53	6.29e-47	Cognitive function;
BRCA	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg26031613	chr14:104095156	KLC1	-0.43	-8.48	-0.32	1.57e-16	Schizophrenia;
BRCA	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00166722	chr3:10149974	C3orf24	0.56	10.01	0.37	5.23e-22	Alzheimer's disease;
BRCA	trans	rs877282	0.945	rs11253390	chr10:788678	A/G	cg22713356	chr15:30763199	NA	1.42	28.54	0.75	3.84e-116	Uric acid levels;
BRCA	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg11645453	chr3:52864694	ITIH4	0.37	9.75	0.36	4.98e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg14343924	chr8:8086146	FLJ10661	-0.46	-9.27	-0.34	2.88e-19	Schizophrenia;
BRCA	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	28.21	0.74	2.43e-114	Chronic sinus infection;
BRCA	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.33	0.49	1.39e-40	Motion sickness;
BRCA	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.48	-0.32	1.51e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg26031613	chr14:104095156	KLC1	-0.54	-9.58	-0.35	2.12e-20	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg26384229	chr12:38710491	ALG10B	0.4	8.76	0.33	1.71e-17	Morning vs. evening chronotype;
BRCA	cis	rs67460515	0.665	rs28384382	chr3:160939141	C/T	cg03342759	chr3:160939853	NMD3	-0.81	-17.59	-0.57	8.74e-57	Parkinson's disease;
BRCA	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	7.95	0.3	8.42e-15	Axial length;
BRCA	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg24642844	chr7:1081250	C7orf50	-0.71	-13.92	-0.48	1.13e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs13046373	0.535	rs1354866	chr21:31981559	A/T	cg22337977	chr21:31811175	KRTAP15-1	0.34	8.34	0.31	4.6e-16	HDL cholesterol;
BRCA	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.56	0.32	8.33e-17	Rheumatoid arthritis;
BRCA	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg03281426	chr2:240109471	HDAC4	0.56	12.33	0.44	1.68e-31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg16230307	chr14:35515116	FAM177A1	0.71	14.39	0.49	7.18e-41	Psoriasis;
BRCA	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg20701182	chr2:24300061	SF3B14	0.55	8.53	0.32	1.09e-16	Lymphocyte counts;
BRCA	cis	rs55962025	0.883	rs82334	chr4:3225371	A/C	cg27319971	chr4:3255056	C4orf44	-0.4	-7.82	-0.3	2.24e-14	Parental longevity (mother's age at death);
BRCA	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg10495392	chr1:46806563	NSUN4	0.46	8.43	0.32	2.32e-16	Menopause (age at onset);
BRCA	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.19e-47	Alzheimer's disease (late onset);
BRCA	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg07501729	chr16:846077	CHTF18	0.5	12.14	0.43	1.13e-30	Mean corpuscular volume;
BRCA	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-8.7	-0.33	2.72e-17	Monocyte percentage of white cells;
BRCA	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.64	14.09	0.49	1.81e-39	Lymphocyte percentage of white cells;
BRCA	cis	rs9309711	0.737	rs9284795	chr2:3492065	G/A	cg16153549	chr2:3496821	NA	-0.4	-9.28	-0.34	2.67e-19	Neurofibrillary tangles;
BRCA	cis	rs10924970	0.967	rs4659721	chr1:235426917	C/T	cg26050004	chr1:235667680	B3GALNT2	0.34	8.52	0.32	1.18e-16	Asthma;
BRCA	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.07	0.49	2.26e-39	Motion sickness;
BRCA	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg25019033	chr10:957182	NA	-0.41	-7.86	-0.3	1.64e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg21960279	chr19:17905606	B3GNT3	0.49	11.2	0.41	1.04e-26	Tumor biomarkers;
BRCA	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg03146154	chr1:46216737	IPP	0.46	10.14	0.37	1.67e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg27661571	chr11:113659931	NA	-0.71	-10.93	-0.4	1.31e-25	Hip circumference adjusted for BMI;
BRCA	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-8.84	-0.33	9.39e-18	Morning vs. evening chronotype;
BRCA	cis	rs36051895	0.622	rs12686652	chr9:5071942	C/G	cg02405213	chr9:5042618	JAK2	-0.53	-9.62	-0.36	1.5e-20	Pediatric autoimmune diseases;
BRCA	cis	rs36051895	0.593	rs62541903	chr9:5146952	G/C	cg02405213	chr9:5042618	JAK2	-0.51	-9.26	-0.34	3e-19	Pediatric autoimmune diseases;
BRCA	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.54e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.17	-0.4	1.44e-26	Morning vs. evening chronotype;
BRCA	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.78	-11.29	-0.41	4.61e-27	Initial pursuit acceleration;
BRCA	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg12463550	chr7:65579703	CRCP	0.37	7.93	0.3	9.93e-15	Aortic root size;
BRCA	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg02527881	chr3:46936655	PTH1R	-0.36	-8.32	-0.31	5.3e-16	Birth weight;
BRCA	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg20476274	chr7:133979776	SLC35B4	0.65	19.09	0.6	1.22e-64	Mean platelet volume;
BRCA	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg24642439	chr20:33292090	TP53INP2	0.71	16.22	0.54	8e-50	Coronary artery disease;
BRCA	cis	rs7975161	0.638	rs10861170	chr12:104615957	A/G	cg25273343	chr12:104657179	TXNRD1	-0.38	-8.99	-0.34	2.67e-18	Toenail selenium levels;
BRCA	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg17330251	chr7:94953956	PON1	-0.43	-8.9	-0.33	5.84e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18876405	chr7:65276391	NA	0.71	18.7	0.59	1.48e-62	Aortic root size;
BRCA	trans	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.38	8.59	0.32	6.41e-17	Corneal astigmatism;
BRCA	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg09594475	chr20:60884601	LAMA5	0.5	11.57	0.42	3.21e-28	Pelvic organ prolapse;
BRCA	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg25036284	chr2:26402008	FAM59B	-0.81	-14.53	-0.5	1.5e-41	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg14791747	chr16:20752902	THUMPD1	0.41	9.59	0.35	1.96e-20	Cognitive test performance;
BRCA	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg23933602	chr10:16859644	RSU1	0.55	8.63	0.32	4.98e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg26384229	chr12:38710491	ALG10B	0.58	13.27	0.46	1.1e-35	Morning vs. evening chronotype;
BRCA	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.57	-0.32	7.63e-17	Monocyte percentage of white cells;
BRCA	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg03146154	chr1:46216737	IPP	0.52	11.61	0.42	2.03e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4919694	0.667	rs75890466	chr10:105076383	C/T	cg04362960	chr10:104952993	NT5C2	0.75	10.4	0.38	1.69e-23	Arsenic metabolism;
BRCA	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.71e-23	Motion sickness;
BRCA	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	11.16	0.4	1.47e-26	Personality dimensions;
BRCA	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg23033748	chr14:75592666	NEK9	-0.42	-10.06	-0.37	3.33e-22	Height;
BRCA	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg12011299	chr4:100065546	ADH4	-0.37	-10.65	-0.39	1.71e-24	Alcohol dependence;
BRCA	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.85	-0.33	8.72e-18	Breast cancer;
BRCA	trans	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg21659725	chr3:3221576	CRBN	0.48	8.7	0.33	2.83e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg12365402	chr11:9010492	NRIP3	-0.41	-9.47	-0.35	5.2e-20	Hemoglobin concentration;
BRCA	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg10518572	chr11:65560635	OVOL1	-0.3	-8.44	-0.32	2.07e-16	Acne (severe);
BRCA	cis	rs9400271	0.632	rs9384705	chr6:109588244	T/C	cg21918786	chr6:109611834	NA	-0.32	-8.06	-0.3	3.67e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg22920501	chr2:26401640	FAM59B	-0.84	-16.01	-0.54	9.42e-49	Gut microbiome composition (summer);
BRCA	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg11822812	chr5:140052017	DND1	0.31	8.4	0.32	2.86e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg08859206	chr1:53392774	SCP2	0.41	8.25	0.31	9.33e-16	Monocyte count;
BRCA	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg00277334	chr10:82204260	NA	-0.85	-24.82	-0.7	9.19e-96	Post bronchodilator FEV1;
BRCA	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg13319975	chr6:146136371	FBXO30	-0.42	-9.57	-0.35	2.32e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs698833	0.962	rs1067387	chr2:44642797	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	10.71	0.39	1.02e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7395581	1.000	rs7395581	chr11:47246397	G/A	cg25783544	chr11:47291846	MADD	-0.43	-9.56	-0.35	2.45e-20	HDL cholesterol;
BRCA	cis	rs9403521	1.000	rs9403521	chr6:143994199	C/T	cg18240653	chr6:144019428	PHACTR2	0.42	8.54	0.32	9.63e-17	Obesity-related traits;
BRCA	cis	rs3784262	0.528	rs4238327	chr15:58336218	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.13	-0.37	1.86e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg26597838	chr10:835615	NA	1.01	15.56	0.52	1.59e-46	Eosinophil percentage of granulocytes;
BRCA	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs11955398	0.585	rs4700384	chr5:60032471	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.38	-8.96	-0.33	3.63e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1865721	1.000	rs62089508	chr18:73193344	C/T	cg26385618	chr18:73139727	C18orf62	-0.39	-9.0	-0.34	2.66e-18	Intelligence;
BRCA	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg24558204	chr6:135376177	HBS1L	-0.49	-13.85	-0.48	2.52e-38	Red blood cell count;
BRCA	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg25036284	chr2:26402008	FAM59B	0.95	15.83	0.53	7.3e-48	Mean corpuscular hemoglobin;
BRCA	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg06618935	chr21:46677482	NA	-0.36	-8.0	-0.3	5.85e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1568889	0.838	rs716366	chr11:28121536	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	20.06	0.62	9.05e-70	Bipolar disorder;
BRCA	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg23933602	chr10:16859644	RSU1	0.97	28.12	0.74	7.8e-114	Platelet distribution width;
BRCA	cis	rs6763687	0.725	rs9841998	chr3:171802979	C/T	cg16233210	chr3:171778391	FNDC3B	0.35	7.97	0.3	7.57e-15	Red cell distribution width;
BRCA	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg11879182	chr18:77439856	CTDP1	-0.66	-14.2	-0.49	5.6e-40	Monocyte count;
BRCA	cis	rs6893300	0.826	rs7734102	chr5:179153797	A/G	cg14593053	chr5:179126677	CANX	0.34	7.88	0.3	1.37e-14	Resting heart rate;
BRCA	cis	rs7799006	0.862	rs3757439	chr7:2272122	C/T	cg08027265	chr7:2291960	NA	-0.4	-10.25	-0.38	6.08e-23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.35	-0.41	2.61e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2806561	0.828	rs944509	chr1:23542242	C/T	cg12483005	chr1:23474871	LUZP1	-0.37	-8.04	-0.3	4.35e-15	Height;
BRCA	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg08738300	chr3:44038990	NA	0.45	8.7	0.33	2.74e-17	Coronary artery disease;
BRCA	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg27478167	chr7:817139	HEATR2	-0.55	-11.37	-0.41	2.15e-27	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.63	0.36	1.41e-20	Menopause (age at onset);
BRCA	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.11	0.43	1.51e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg07460842	chr6:66804631	NA	0.87	14.19	0.49	6.35e-40	Exhaled nitric oxide output;
BRCA	cis	rs11229555	1.000	rs8373	chr11:58378424	A/G	cg15696309	chr11:58395628	NA	-0.53	-11.62	-0.42	1.95e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg19920283	chr7:105172520	RINT1	0.59	9.54	0.35	2.83e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	13.43	0.47	2.22e-36	Mean platelet volume;
BRCA	trans	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.92	-0.3	1.03e-14	Corneal astigmatism;
BRCA	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg26874164	chr19:58962979	ZNF324B	0.51	11.19	0.4	1.16e-26	Uric acid clearance;
BRCA	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg12373951	chr3:133503437	NA	0.45	10.49	0.38	7.13e-24	Iron status biomarkers;
BRCA	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	13.38	0.47	3.55e-36	Lymphocyte counts;
BRCA	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg05535760	chr7:792225	HEATR2	0.73	13.12	0.46	5.7e-35	Cerebrospinal P-tau181p levels;
BRCA	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11764359	chr7:65958608	NA	-0.77	-17.65	-0.57	4.23e-57	Aortic root size;
BRCA	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-16.18	-0.54	1.25e-49	Alzheimer's disease (late onset);
BRCA	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.89	-0.33	6e-18	Total body bone mineral density;
BRCA	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg17691542	chr6:26056736	HIST1H1C	0.47	9.74	0.36	5.38e-21	Height;
BRCA	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg02176678	chr2:219576539	TTLL4	0.44	11.2	0.41	1.05e-26	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26314531	chr2:26401878	FAM59B	-0.63	-11.15	-0.4	1.74e-26	Gut microbiome composition (summer);
BRCA	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.29	-8.49	-0.32	1.47e-16	Homoarginine levels;
BRCA	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg08470875	chr2:26401718	FAM59B	-0.58	-9.23	-0.34	3.84e-19	Gut microbiome composition (summer);
BRCA	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.59	-13.84	-0.48	2.76e-38	Longevity;Endometriosis;
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.37	-8.3	-0.31	6.43e-16	Longevity;Endometriosis;
BRCA	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg27661571	chr11:113659931	NA	-0.73	-11.22	-0.41	8.36e-27	Hip circumference adjusted for BMI;
BRCA	cis	rs77741769	0.571	rs3883901	chr12:121256520	A/G	cg02419362	chr12:121203948	SPPL3	0.34	8.01	0.3	5.65e-15	Mean corpuscular volume;
BRCA	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg00383909	chr3:49044727	WDR6	1.02	15.12	0.51	2.11e-44	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs7927771	0.524	rs7116346	chr11:47883880	G/A	cg20307385	chr11:47447363	PSMC3	-0.39	-9.17	-0.34	6.2800000000000005e-19	Subjective well-being;
BRCA	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg27446573	chr6:127587934	RNF146	0.86	19.7	0.61	7.62e-68	Breast cancer;
BRCA	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg01114163	chr5:1856713	NA	-0.36	-8.08	-0.3	3.36e-15	Cardiovascular disease risk factors;
BRCA	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.36	-8.32	-0.31	5.32e-16	Colorectal cancer;
BRCA	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg15704280	chr7:45808275	SEPT13	-0.71	-13.46	-0.47	1.55e-36	Coronary artery disease;
BRCA	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg05347473	chr6:146136440	FBXO30	0.6	11.4	0.41	1.55e-27	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.667	rs78426057	chr1:152964528	T/C	cg25856811	chr1:152973957	SPRR3	-0.34	-9.15	-0.34	7.37e-19	Inflammatory skin disease;
BRCA	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg02659138	chr7:134003124	SLC35B4	0.33	10.34	0.38	2.74e-23	Mean platelet volume;
BRCA	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21582582	chr3:182698605	DCUN1D1	0.38	9.84	0.36	2.34e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg03146154	chr1:46216737	IPP	0.53	11.75	0.42	5.61e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg04455712	chr21:45112962	RRP1B	0.41	10.5	0.38	6.56e-24	Mean corpuscular volume;
BRCA	cis	rs6750047	0.609	rs2121259	chr2:38269475	T/C	cg07380506	chr2:38303506	CYP1B1	0.47	10.19	0.37	1.09e-22	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg04455712	chr21:45112962	RRP1B	0.41	11.09	0.4	2.84e-26	Mean corpuscular volume;
BRCA	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg10818794	chr15:86012489	AKAP13	-0.3	-8.5	-0.32	1.34e-16	Coronary artery disease;
BRCA	cis	rs9549260	0.564	rs6563844	chr13:41298190	T/C	cg21288729	chr13:41239152	FOXO1	0.5	10.19	0.37	1.04e-22	Red blood cell count;
BRCA	cis	rs2386661	0.603	rs11259704	chr10:5646999	C/T	cg17085576	chr10:5658249	NA	-0.32	-8.15	-0.31	1.99e-15	Breast cancer;
BRCA	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.3e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs877529	0.625	rs713841	chr22:39529029	A/G	cg12193277	chr22:39547181	CBX7	0.36	8.49	0.32	1.49e-16	Multiple myeloma;
BRCA	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg18876405	chr7:65276391	NA	-0.54	-11.97	-0.43	6.03e-30	Calcium levels;
BRCA	cis	rs829883	0.659	rs4762495	chr12:98934105	C/T	cg25150519	chr12:98850993	NA	-0.5	-9.1	-0.34	1.1e-18	Colorectal adenoma (advanced);
BRCA	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.22	0.31	1.15e-15	Cognitive ability;
BRCA	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.28e-23	Prostate cancer;
BRCA	trans	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.9	-0.3	1.26e-14	Corneal astigmatism;
BRCA	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	16.03	0.54	7.54e-49	Smoking behavior;
BRCA	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg20290983	chr6:43655470	MRPS18A	1.1	40.23	0.85	2.86e-177	IgG glycosylation;
BRCA	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg18230493	chr5:56204884	C5orf35	-0.4	-8.2	-0.31	1.36e-15	Coronary artery disease;
BRCA	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2625529	0.526	rs8032222	chr15:72479178	C/G	cg16672083	chr15:72433130	SENP8	0.66	15.56	0.52	1.6e-46	Red blood cell count;
BRCA	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg25664220	chr3:72788482	NA	-0.55	-11.84	-0.42	2.17e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg11707556	chr5:10655725	ANKRD33B	0.44	9.72	0.36	6.14e-21	Height;
BRCA	cis	rs7927771	0.524	rs6485786	chr11:47837408	G/C	cg20307385	chr11:47447363	PSMC3	0.41	9.4	0.35	9.67e-20	Subjective well-being;
BRCA	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22496380	chr5:211416	CCDC127	-0.98	-12.36	-0.44	1.25e-31	Breast cancer;
BRCA	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg04362960	chr10:104952993	NT5C2	0.94	14.57	0.5	1.05e-41	Arsenic metabolism;
BRCA	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg03864215	chr11:17408437	KCNJ11	-0.27	-8.07	-0.3	3.43e-15	Type 2 diabetes;
BRCA	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg14004847	chr7:1930337	MAD1L1	-0.44	-8.97	-0.33	3.35e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.14	-20.54	-0.63	2.19e-72	Platelet count;
BRCA	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg19901468	chr14:105411992	AHNAK2	-0.51	-12.45	-0.44	5.15e-32	Rheumatoid arthritis;
BRCA	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg04709771	chr16:646395	RAB40C	0.43	10.73	0.39	8.15e-25	Height;
BRCA	cis	rs9287719	0.649	rs6717431	chr2:10726046	A/G	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	5.17e-19	Prostate cancer;
BRCA	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg09658497	chr7:2847517	GNA12	-0.4	-8.04	-0.3	4.27e-15	Height;
BRCA	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	11.97	0.43	5.92e-30	Lung cancer in ever smokers;
BRCA	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg03711944	chr11:47377212	SPI1	0.47	11.97	0.43	6.52e-30	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	7.88	0.3	1.37e-14	Tonsillectomy;
BRCA	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg21427119	chr20:30132790	HM13	-0.41	-8.78	-0.33	1.53e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg14004847	chr7:1930337	MAD1L1	-0.44	-8.95	-0.33	3.78e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs1891275	0.515	rs10881957	chr10:93501876	C/T	cg07889827	chr10:93443413	NA	-0.4	-10.82	-0.39	3.59e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg20673091	chr1:2541236	MMEL1	0.33	8.7	0.33	2.74e-17	Ulcerative colitis;
BRCA	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg23711669	chr6:146136114	FBXO30	0.84	20.16	0.62	2.62e-70	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg01420254	chr6:26195488	NA	0.58	9.04	0.34	1.8e-18	Gout;Renal underexcretion gout;
BRCA	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg12193833	chr17:30244370	NA	-0.55	-8.18	-0.31	1.53e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg06115741	chr20:33292138	TP53INP2	0.39	8.58	0.32	7.18e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg13047869	chr3:10149882	C3orf24	0.58	12.11	0.43	1.53e-30	Alzheimer's disease;
BRCA	cis	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-9.17	-0.34	6.34e-19	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg23711669	chr6:146136114	FBXO30	-0.75	-17.43	-0.57	5.61e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00166722	chr3:10149974	C3orf24	0.56	9.97	0.37	7.6e-22	Alzheimer's disease;
BRCA	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg24642439	chr20:33292090	TP53INP2	0.68	15.27	0.52	4.35e-45	Coronary artery disease;
BRCA	cis	rs1003719	0.699	rs1015549	chr21:38448880	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.25	0.49	3.26e-40	Eye color traits;
BRCA	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg25427524	chr10:38739819	LOC399744	0.6	13.52	0.47	7.88e-37	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2625529	0.590	rs2607090	chr15:72496011	C/A	cg16672083	chr15:72433130	SENP8	-0.83	-17.35	-0.57	1.52e-55	Red blood cell count;
BRCA	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg08888203	chr3:10149979	C3orf24	0.57	12.08	0.43	2.15e-30	Alzheimer's disease;
BRCA	cis	rs738322	0.511	rs5756947	chr22:38573230	G/A	cg25457927	chr22:38595422	NA	-0.36	-12.03	-0.43	3.59e-30	Cutaneous nevi;
BRCA	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg22800045	chr5:56110881	MAP3K1	0.63	10.98	0.4	7.99e-26	Initial pursuit acceleration;
BRCA	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg20307385	chr11:47447363	PSMC3	0.8	19.15	0.6	6.32e-65	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs6066825	0.644	rs6090894	chr20:47334688	G/T	cg18078177	chr20:47281410	PREX1	0.39	9.45	0.35	6.45e-20	Colorectal cancer;
BRCA	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg22535103	chr8:58192502	C8orf71	-0.49	-8.71	-0.33	2.62e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg19676328	chr12:49525230	TUBA1B	-0.53	-11.8	-0.42	3.3e-29	Total cholesterol levels;
BRCA	trans	rs75804782	0.521	rs72982590	chr2:239451826	T/C	cg01134436	chr17:81009848	B3GNTL1	0.68	8.89	0.33	6.04e-18	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg26384229	chr12:38710491	ALG10B	-0.5	-11.13	-0.4	2.02e-26	Morning vs. evening chronotype;
BRCA	trans	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg26043149	chr18:55253948	FECH	-0.37	-8.14	-0.31	2e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg05863683	chr7:1912471	MAD1L1	0.36	8.37	0.31	3.6e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10802521	chr3:52805072	NEK4	-0.34	-9.24	-0.34	3.68e-19	Bipolar disorder;
BRCA	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.35	0.38	2.49e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg24642439	chr20:33292090	TP53INP2	-0.43	-8.74	-0.33	2.01e-17	Height;
BRCA	trans	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg25214090	chr10:38739885	LOC399744	0.55	11.82	0.42	2.68e-29	Corneal astigmatism;
BRCA	cis	rs6901250	0.851	rs6938235	chr6:117147946	G/T	cg12892004	chr6:117198278	RFX6	0.47	10.92	0.4	1.44e-25	C-reactive protein levels;
BRCA	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18876405	chr7:65276391	NA	0.61	15.16	0.51	1.42e-44	Aortic root size;
BRCA	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.94	-0.46	3.55e-34	Migraine;Coronary artery disease;
BRCA	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg05234568	chr11:5960015	NA	0.4	8.43	0.32	2.35e-16	DNA methylation (variation);
BRCA	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg24642439	chr20:33292090	TP53INP2	-0.55	-11.83	-0.42	2.57e-29	Glomerular filtration rate (creatinine);
BRCA	trans	rs8002861	0.905	rs9525869	chr13:44467210	A/G	cg17145862	chr1:211918768	LPGAT1	0.73	19.51	0.61	7.82e-67	Leprosy;
BRCA	trans	rs1941687	0.505	rs12605642	chr18:31313965	G/T	cg15819921	chr19:927150	ARID3A	-0.42	-8.1	-0.31	2.77e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg26384229	chr12:38710491	ALG10B	0.59	13.61	0.47	3.04e-37	Morning vs. evening chronotype;
BRCA	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg18806716	chr10:30721971	MAP3K8	-0.55	-13.09	-0.46	7.4e-35	Inflammatory bowel disease;
BRCA	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg05347473	chr6:146136440	FBXO30	0.61	12.12	0.43	1.47e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg02403541	chr12:121454288	C12orf43	-0.54	-11.69	-0.42	9.97e-29	Subjective well-being;Cardiovascular disease risk factors;
BRCA	cis	rs9649465	1.000	rs627689	chr7:123400543	C/T	cg04330084	chr7:123175371	IQUB	-0.3	-8.28	-0.31	7.3e-16	Migraine;
BRCA	cis	rs7789940	0.810	rs12533978	chr7:75943352	T/C	cg10167463	chr7:75959203	YWHAG	-0.45	-8.85	-0.33	8.55e-18	Multiple sclerosis;
BRCA	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06022373	chr22:39101656	GTPBP1	0.66	15.17	0.51	1.21e-44	Menopause (age at onset);
BRCA	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg01448562	chr3:133502909	NA	0.48	10.6	0.39	2.7e-24	Iron status biomarkers;
BRCA	cis	rs7715811	1.000	rs2896103	chr5:13764419	G/A	cg07548982	chr5:13769939	DNAH5	-0.38	-8.46	-0.32	1.87e-16	Subclinical atherosclerosis traits (other);
BRCA	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.23e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg11693508	chr17:37793320	STARD3	0.59	11.14	0.4	1.92e-26	Bipolar disorder;
BRCA	cis	rs1568889	0.641	rs34857148	chr11:28481976	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	8.78	0.33	1.51e-17	Bipolar disorder;
BRCA	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-12.28	-0.44	2.94e-31	Morning vs. evening chronotype;
BRCA	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08564027	chr20:61660810	NA	0.85	22.97	0.67	1.42e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg07395648	chr5:131743802	NA	0.38	9.51	0.35	3.67e-20	Blood metabolite levels;
BRCA	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg02221750	chr19:17393354	ANKLE1	0.66	12.53	0.44	2.28e-32	Systemic lupus erythematosus;
BRCA	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26314531	chr2:26401878	FAM59B	-0.63	-10.75	-0.39	7.14e-25	Gut microbiome composition (summer);
BRCA	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg22920501	chr2:26401640	FAM59B	-0.66	-11.44	-0.41	1.1e-27	Gut microbiome composition (summer);
BRCA	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.49e-52	Hypertriglyceridemia;
BRCA	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg11812906	chr14:75593930	NEK9	-0.6	-13.43	-0.47	2.1e-36	Height;
BRCA	trans	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg25214090	chr10:38739885	LOC399744	0.37	8.54	0.32	1e-16	Diastolic blood pressure;
BRCA	cis	rs2901460	0.509	rs66481227	chr2:62117600	C/T	cg02183531	chr2:62113199	CCT4	-0.45	-9.01	-0.34	2.31e-18	Mean corpuscular volume;
BRCA	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg01283332	chr5:1856932	NA	-0.32	-7.96	-0.3	7.68e-15	Cardiovascular disease risk factors;
BRCA	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg18512352	chr11:47633146	NA	-0.37	-9.1	-0.34	1.1e-18	Subjective well-being;
BRCA	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg18351406	chr4:77819688	ANKRD56	0.61	13.3	0.47	7.98e-36	Emphysema distribution in smoking;
BRCA	trans	rs4650994	0.524	rs2476558	chr1:178580953	C/T	cg05059571	chr16:84539110	KIAA1609	0.52	11.58	0.42	2.69e-28	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.24	-0.41	7.16e-27	Schizophrenia;
BRCA	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg04317338	chr11:64019027	PLCB3	0.59	9.95	0.37	9.1e-22	Mean platelet volume;
BRCA	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg22980127	chr19:33182716	NUDT19	0.89	17.96	0.58	1.09e-58	Red blood cell traits;
BRCA	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	20.3	0.63	4.28e-71	Electrocardiographic conduction measures;
BRCA	cis	rs7020830	0.789	rs17408112	chr9:37114065	A/G	cg14294708	chr9:37120828	ZCCHC7	1.17	41.02	0.85	3.52e-181	Schizophrenia;
BRCA	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg11833968	chr6:79620685	NA	0.43	9.66	0.36	1.04e-20	Intelligence (multi-trait analysis);
BRCA	trans	rs8073060	0.963	rs11080354	chr17:33872407	A/G	cg19694781	chr19:47549865	TMEM160	-0.57	-11.93	-0.43	9.48e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.37	7.86	0.3	1.62e-14	Total cholesterol levels;
BRCA	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-13.53	-0.47	7.69e-37	Bipolar disorder and schizophrenia;
BRCA	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg25024717	chr12:54324583	NA	-0.3	-8.15	-0.31	1.88e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
BRCA	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg13397359	chr6:42928475	GNMT	0.66	15.96	0.53	1.66e-48	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.61	-0.32	5.73e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.36	-8.47	-0.32	1.63e-16	Electroencephalogram traits;
BRCA	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.08	-0.4	3.32e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg04727924	chr7:799746	HEATR2	-0.53	-9.28	-0.34	2.62e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg24450063	chr1:156163899	SLC25A44	1.12	36.14	0.82	1.26e-156	Testicular germ cell tumor;
BRCA	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11890956	chr21:40555474	PSMG1	0.94	23.07	0.67	3.71e-86	Cognitive function;
BRCA	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg13334819	chr7:99746414	C7orf59	0.34	7.96	0.3	8.13e-15	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg08888203	chr3:10149979	C3orf24	0.67	14.11	0.49	1.55e-39	Alzheimer's disease;
BRCA	cis	rs13136331	0.606	rs7686829	chr4:88639710	A/G	cg22416721	chr4:88570574	DMP1	-0.47	-11.53	-0.41	4.65e-28	Sitting height ratio;
BRCA	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.48e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-14.12	-0.49	1.34e-39	Morning vs. evening chronotype;
BRCA	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg08917208	chr2:24149416	ATAD2B	-0.55	-8.44	-0.32	2.19e-16	Lymphocyte counts;
BRCA	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg02951883	chr7:2050386	MAD1L1	0.51	11.96	0.43	7.03e-30	Bipolar disorder and schizophrenia;
BRCA	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.54	-11.56	-0.42	3.29e-28	Colorectal cancer;
BRCA	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18876405	chr7:65276391	NA	-0.51	-11.63	-0.42	1.67e-28	Aortic root size;
BRCA	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	trans	rs8073060	0.586	rs4796101	chr17:33998593	C/T	cg19694781	chr19:47549865	TMEM160	-1.02	-21.14	-0.64	1.31e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.7	-0.45	4.32e-33	Type 2 diabetes;
BRCA	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg07148914	chr20:33460835	GGT7	-0.41	-9.07	-0.34	1.5e-18	Height;
BRCA	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg17366294	chr4:99064904	C4orf37	0.46	10.89	0.4	1.87e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg25173405	chr17:45401733	C17orf57	-0.54	-11.12	-0.4	2.26e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	12.49	0.44	3.38e-32	Colorectal cancer;
BRCA	cis	rs858239	0.600	rs7784929	chr7:23124277	T/C	cg23682824	chr7:23144976	KLHL7	0.45	11.82	0.42	2.65e-29	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg11663144	chr21:46675770	NA	-0.6	-14.01	-0.48	4.47e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg25214090	chr10:38739885	LOC399744	0.43	10.08	0.37	2.74e-22	Corneal astigmatism;
BRCA	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg11266682	chr4:10021025	SLC2A9	0.42	11.31	0.41	3.68e-27	Bone mineral density;
BRCA	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg17063962	chr7:91808500	NA	0.52	12.31	0.44	2.06e-31	Breast cancer;
BRCA	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg13047869	chr3:10149882	C3orf24	0.57	10.44	0.38	1.15e-23	Alzheimer's disease;
BRCA	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg20503657	chr10:835505	NA	0.61	10.44	0.38	1.14e-23	Eosinophil percentage of granulocytes;
BRCA	cis	rs5167	0.504	rs3760628	chr19:45457225	G/A	cg13119609	chr19:45449297	APOC2	0.47	13.11	0.46	6.03e-35	Blood protein levels;
BRCA	cis	rs3820928	0.874	rs2177593	chr2:227833869	G/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.41	-0.32	2.71e-16	Pulmonary function;
BRCA	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg18402987	chr7:1209562	NA	0.42	8.63	0.32	4.77e-17	Longevity;Endometriosis;
BRCA	trans	rs1459104	1.000	rs17580126	chr11:55289993	C/G	cg15704280	chr7:45808275	SEPT13	-0.63	-8.07	-0.3	3.6e-15	Body mass index;
BRCA	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg08601574	chr20:25228251	PYGB	-0.4	-9.21	-0.34	4.65e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1949733	0.554	rs4259044	chr4:8536188	A/G	cg11789530	chr4:8429930	ACOX3	-0.45	-10.59	-0.39	3.09e-24	Response to antineoplastic agents;
BRCA	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg02297831	chr4:17616191	MED28	0.36	8.33	0.31	4.85e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs926392	0.965	rs6129168	chr20:37689360	T/C	cg16355469	chr20:37678765	NA	0.33	8.16	0.31	1.72e-15	Dialysis-related mortality;
BRCA	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg01256987	chr12:42539512	GXYLT1	-0.42	-8.08	-0.3	3.18e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	trans	rs7395662	0.681	rs2865641	chr11:48941099	A/C	cg00717180	chr2:96193071	NA	-0.31	-8.59	-0.32	6.53e-17	HDL cholesterol;
BRCA	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg14500267	chr11:67383377	NA	0.4	8.34	0.31	4.53e-16	Mean corpuscular volume;
BRCA	cis	rs7520050	0.966	rs61783220	chr1:46335312	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.89	0.36	1.5e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg16006841	chr5:176797999	RGS14	0.59	11.72	0.42	7e-29	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg01028140	chr2:1542097	TPO	-0.68	-13.38	-0.47	3.41e-36	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14442939	chr10:27389572	ANKRD26	0.69	10.94	0.4	1.24e-25	Breast cancer;
BRCA	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg26384229	chr12:38710491	ALG10B	0.69	15.68	0.53	4.01e-47	Bladder cancer;
BRCA	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg08470875	chr2:26401718	FAM59B	-0.7	-11.27	-0.41	5.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs7523273	0.606	rs2488254	chr1:207941539	A/G	cg22525895	chr1:207977042	MIR29B2	0.47	12.0	0.43	4.8e-30	Schizophrenia;
BRCA	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg24130564	chr14:104152367	KLC1	-0.34	-7.93	-0.3	9.92e-15	Body mass index;
BRCA	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.3	-0.38	4.09e-23	Psoriasis;
BRCA	cis	rs3824344	0.545	rs6476606	chr9:37005561	A/G	cg14294708	chr9:37120828	ZCCHC7	0.44	8.94	0.33	4.1e-18	Intelligence;
BRCA	trans	rs208520	0.690	rs207096	chr6:66797287	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-21.01	-0.64	6.5e-75	Exhaled nitric oxide output;
BRCA	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	11.21	0.41	9.78e-27	Personality dimensions;
BRCA	cis	rs9487051	0.768	rs1766814	chr6:109526696	G/A	cg01475377	chr6:109611718	NA	-0.41	-10.29	-0.38	4.52e-23	Reticulocyte fraction of red cells;
BRCA	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg14675211	chr2:100938903	LONRF2	0.44	9.73	0.36	5.87e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg22875332	chr1:76189707	ACADM	0.78	21.31	0.64	1.53e-76	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9296092	0.560	rs9469511	chr6:33530930	T/G	cg13560919	chr6:33536144	NA	-0.85	-17.98	-0.58	8.28e-59	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-8.7	-0.33	2.89e-17	Pulmonary function;
BRCA	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg01849466	chr14:104193079	ZFYVE21	0.35	7.9	0.3	1.26e-14	Reticulocyte count;
BRCA	cis	rs77972916	0.505	rs6756575	chr2:43528519	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-11.55	-0.42	3.55e-28	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg25214090	chr10:38739885	LOC399744	0.43	9.99	0.37	6.39e-22	Corneal astigmatism;
BRCA	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.88	0.56	3.66e-53	Colorectal cancer;
BRCA	cis	rs813218	0.523	rs10935917	chr3:99441241	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.41	-9.3	-0.35	2.16e-19	Orofacial clefts;
BRCA	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg00745463	chr17:30367425	LRRC37B	-0.5	-8.55	-0.32	9.36e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs10754283	0.934	rs6428563	chr1:90111583	T/A	cg21401794	chr1:90099060	LRRC8C	0.45	10.93	0.4	1.25e-25	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg14458575	chr2:238380390	NA	0.48	9.99	0.37	5.99e-22	Prostate cancer;
BRCA	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg17470723	chr8:74884337	TCEB1	0.4	8.63	0.32	4.92e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg02079420	chr8:82753780	SNX16	0.32	8.64	0.32	4.33e-17	Diastolic blood pressure;
BRCA	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.1	0.49	1.73e-39	Motion sickness;
BRCA	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg23205692	chr1:25664452	TMEM50A	0.38	9.15	0.34	7.39e-19	Erythrocyte sedimentation rate;
BRCA	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00152838	chr16:24741724	TNRC6A	0.36	8.14	0.31	2.06e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10504073	0.647	rs4873314	chr8:50011656	A/C	cg00325661	chr8:49890786	NA	0.47	13.22	0.46	1.95e-35	Blood metabolite ratios;
BRCA	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.37	0.49	8.98e-41	Motion sickness;
BRCA	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg13114125	chr14:105738426	BRF1	-0.5	-10.41	-0.38	1.44e-23	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.35	0.49	1.13e-40	Motion sickness;
BRCA	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg24692254	chr21:30365293	RNF160	0.63	13.91	0.48	1.32e-38	Selective IgA deficiency;
BRCA	cis	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg04990556	chr1:26633338	UBXN11	0.55	8.51	0.32	1.19e-16	Obesity-related traits;
BRCA	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg03146154	chr1:46216737	IPP	-0.44	-9.62	-0.36	1.5e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg11366901	chr6:160182831	ACAT2	0.8	14.99	0.51	9.73e-44	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg13902645	chr11:5959945	NA	-0.57	-11.54	-0.42	4e-28	DNA methylation (variation);
BRCA	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg25554036	chr4:6271136	WFS1	0.39	9.58	0.35	2.11e-20	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12756686	chr19:29218302	NA	0.57	10.93	0.4	1.36e-25	Methadone dose in opioid dependence;
BRCA	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg12310025	chr6:25882481	NA	-0.54	-12.83	-0.45	1.04e-33	Blood metabolite levels;
BRCA	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg17330251	chr7:94953956	PON1	-0.42	-9.0	-0.34	2.53e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg08601574	chr20:25228251	PYGB	0.36	8.73	0.33	2.23e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg08888203	chr3:10149979	C3orf24	0.57	10.66	0.39	1.5e-24	Alzheimer's disease;
BRCA	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg16586182	chr3:47516702	SCAP	-0.56	-12.47	-0.44	4.1e-32	Colorectal cancer;
BRCA	cis	rs4363385	0.740	rs1338181	chr1:153010301	C/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.17	-0.34	6.49e-19	Inflammatory skin disease;
BRCA	cis	rs36051895	0.664	rs11788834	chr9:5092466	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-9.19	-0.34	5.31e-19	Pediatric autoimmune diseases;
BRCA	cis	rs10911363	0.592	rs10797886	chr1:183479090	T/C	cg09173681	chr1:183549694	NCF2	0.49	10.71	0.39	9.9e-25	Systemic lupus erythematosus;
BRCA	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg13770153	chr20:60521292	NA	-0.39	-9.39	-0.35	1.08e-19	Body mass index;
BRCA	cis	rs7633770	0.664	rs11130101	chr3:46685895	T/A	cg11219411	chr3:46661640	NA	-0.51	-12.02	-0.43	3.69e-30	Coronary artery disease;
BRCA	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg01475377	chr6:109611718	NA	-0.51	-13.04	-0.46	1.3e-34	Reticulocyte fraction of red cells;
BRCA	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg20203395	chr5:56204925	C5orf35	-0.5	-10.17	-0.37	1.31e-22	Initial pursuit acceleration;
BRCA	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg14675211	chr2:100938903	LONRF2	0.49	11.19	0.4	1.12e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08045932	chr20:61659980	NA	0.5	11.43	0.41	1.2100000000000001e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg16586182	chr3:47516702	SCAP	-0.6	-13.94	-0.48	9.4e-39	Colorectal cancer;
BRCA	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg22676075	chr6:135203613	NA	0.44	8.64	0.32	4.4e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.35	-8.14	-0.31	2.04e-15	Eosinophil percentage of white cells;
BRCA	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg23888215	chr10:79422304	NA	-0.6	-11.3	-0.41	3.93e-27	Bone mineral density;
BRCA	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg07395648	chr5:131743802	NA	-0.36	-9.08	-0.34	1.32e-18	Blood metabolite levels;
BRCA	cis	rs9815354	0.812	rs56290987	chr3:42004882	T/C	cg03022575	chr3:42003672	ULK4	0.74	10.27	0.38	5.43e-23	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs3771570	1.000	rs62193208	chr2:242322430	G/A	cg21155796	chr2:242212141	HDLBP	0.6	9.18	0.34	5.69e-19	Prostate cancer;
BRCA	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg10518572	chr11:65560635	OVOL1	-0.28	-8.13	-0.31	2.19e-15	Acne (severe);
BRCA	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08704250	chr15:31115839	NA	-0.34	-8.62	-0.32	5.15e-17	Huntington's disease progression;
BRCA	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg02640540	chr1:67518911	SLC35D1	0.52	11.45	0.41	9.86e-28	Lymphocyte percentage of white cells;
BRCA	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg00677455	chr12:58241039	CTDSP2	-0.35	-8.02	-0.3	5e-15	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg12573674	chr2:1569213	NA	-0.61	-13.32	-0.47	6.5e-36	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg24069376	chr3:38537580	EXOG	-0.31	-8.69	-0.33	2.93e-17	Electrocardiographic conduction measures;
BRCA	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg11663144	chr21:46675770	NA	-0.62	-14.09	-0.49	1.86e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4690686	0.538	rs11730551	chr4:177259182	A/G	cg17059388	chr4:177262070	NA	0.49	9.93	0.37	1.07e-21	Essential tremor;
BRCA	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.26	8.62	0.32	5.23e-17	Electroencephalogram traits;
BRCA	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg26384229	chr12:38710491	ALG10B	-0.44	-10.03	-0.37	4.37e-22	Bladder cancer;
BRCA	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	8.97	0.33	3.13e-18	Motion sickness;
BRCA	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg20587970	chr11:113659929	NA	-0.94	-13.85	-0.48	2.34e-38	Hip circumference adjusted for BMI;
BRCA	cis	rs8028182	0.525	rs9920028	chr15:75927717	G/A	cg20655648	chr15:75932815	IMP3	0.48	9.3	0.35	2.24e-19	Sudden cardiac arrest;
BRCA	cis	rs17270561	0.636	rs10946793	chr6:25699999	A/G	cg17691542	chr6:26056736	HIST1H1C	0.47	8.96	0.33	3.47e-18	Iron status biomarkers;
BRCA	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg23033748	chr14:75592666	NEK9	-0.43	-10.46	-0.38	9.28e-24	Height;
BRCA	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.43	-10.63	-0.39	2e-24	Schizophrenia;
BRCA	cis	rs6028335	0.610	rs67621213	chr20:37582553	G/A	cg16355469	chr20:37678765	NA	0.43	7.84	0.3	1.96e-14	Alcohol and nicotine co-dependence;
BRCA	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08564027	chr20:61660810	NA	-0.76	-20.12	-0.62	4.25e-70	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	12.24	0.44	4.33e-31	Mean platelet volume;
BRCA	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg11941060	chr3:133502564	NA	-0.38	-8.62	-0.32	5.37e-17	Iron status biomarkers;
BRCA	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08859206	chr1:53392774	SCP2	-0.51	-11.23	-0.41	7.8e-27	Monocyte count;
BRCA	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg04691961	chr3:161091175	C3orf57	-0.6	-14.51	-0.5	1.84e-41	Morning vs. evening chronotype;
BRCA	cis	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.69	-0.33	3.09e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg05044414	chr3:183734942	ABCC5	-0.4	-7.83	-0.3	2.01e-14	Anterior chamber depth;
BRCA	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg24562669	chr7:97807699	LMTK2	0.44	11.8	0.42	3.4e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg24060327	chr5:131705240	SLC22A5	-0.61	-11.54	-0.42	4.26e-28	Breast cancer;
BRCA	cis	rs6598955	0.543	rs60433268	chr1:26548055	A/C	cg12744634	chr1:26560303	CCDC21	0.3	7.99	0.3	6.34e-15	Obesity-related traits;
BRCA	cis	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg07460842	chr6:66804631	NA	0.87	14.18	0.49	6.74e-40	Exhaled nitric oxide output;
BRCA	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg08508325	chr11:3079039	CARS	0.28	8.51	0.32	1.24e-16	Calcium levels;
BRCA	cis	rs4363385	0.747	rs6671524	chr1:152974247	C/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.29	-0.31	6.67e-16	Inflammatory skin disease;
BRCA	cis	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg09307838	chr4:120376055	NA	0.46	9.58	0.35	2.03e-20	Diastolic blood pressure;
BRCA	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	13.77	0.48	6.03e-38	Lymphocyte counts;
BRCA	cis	rs7809950	0.723	rs62483634	chr7:106878516	G/A	cg23024343	chr7:107201750	COG5	-0.42	-9.24	-0.34	3.61e-19	Coronary artery disease;
BRCA	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18876405	chr7:65276391	NA	0.7	18.44	0.59	3.37e-61	Calcium levels;
BRCA	trans	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg26043149	chr18:55253948	FECH	0.41	8.93	0.33	4.33e-18	Bone mineral density;
BRCA	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg11247378	chr22:39784982	NA	-0.61	-14.19	-0.49	6.56e-40	Intelligence (multi-trait analysis);
BRCA	cis	rs9359856	0.564	rs72915944	chr6:90447226	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.67	-8.39	-0.31	3.13e-16	Bipolar disorder;
BRCA	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg07884673	chr3:53033167	SFMBT1	0.68	8.76	0.33	1.71e-17	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg18850127	chr7:39170497	POU6F2	0.39	8.26	0.31	8.58e-16	IgG glycosylation;
BRCA	cis	rs9790314	0.747	rs1599378	chr3:160874511	A/C	cg04691961	chr3:161091175	C3orf57	-0.41	-9.18	-0.34	5.84e-19	Morning vs. evening chronotype;
BRCA	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg24088639	chr11:34937564	PDHX;APIP	-0.4	-9.03	-0.34	2.08e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7246657	0.765	rs4803262	chr19:38066760	G/A	cg18154014	chr19:37997991	ZNF793	0.48	9.16	0.34	7.24e-19	Coronary artery calcification;
BRCA	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-12.57	-0.45	1.5e-32	Bipolar disorder;
BRCA	cis	rs6723226	0.698	rs13409142	chr2:32666137	C/T	cg02381751	chr2:32503542	YIPF4	0.69	15.33	0.52	2.09e-45	Intelligence (multi-trait analysis);
BRCA	trans	rs8002861	0.810	rs2275252	chr13:44454374	A/C	cg17145862	chr1:211918768	LPGAT1	0.69	17.46	0.57	3.96e-56	Leprosy;
BRCA	cis	rs3771570	1.000	rs59496049	chr2:242260756	G/C	cg21155796	chr2:242212141	HDLBP	0.53	8.96	0.33	3.67e-18	Prostate cancer;
BRCA	cis	rs6586163	0.527	rs3740286	chr10:90751340	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.57	13.05	0.46	1.08e-34	Chronic lymphocytic leukemia;
BRCA	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg00071950	chr4:10020882	SLC2A9	0.66	16.64	0.55	6.69e-52	Bone mineral density;
BRCA	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg18016565	chr1:150552671	MCL1	-0.38	-8.68	-0.32	3.29e-17	Tonsillectomy;
BRCA	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15084286	chr11:17036142	PLEKHA7	0.88	23.93	0.69	7.91e-91	Coronary artery disease;
BRCA	cis	rs2421770	0.530	rs3858470	chr11:35365444	T/C	cg13971030	chr11:35366721	SLC1A2	-0.45	-10.12	-0.37	1.94e-22	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22590775	chr19:49891494	CCDC155	0.44	8.04	0.3	4.39e-15	Multiple sclerosis;
BRCA	trans	rs4596713	0.568	rs7034303	chr9:71746871	A/G	cg16512924	chr15:28394682	HERC2	-0.39	-9.53	-0.35	3.1e-20	Headache;
BRCA	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.61	-11.79	-0.42	3.66e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08109568	chr15:31115862	NA	-0.42	-9.98	-0.37	6.72e-22	Huntington's disease progression;
BRCA	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11890956	chr21:40555474	PSMG1	-0.83	-20.37	-0.63	1.78e-71	Cognitive function;
BRCA	trans	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.89	-0.3	1.33e-14	Corneal astigmatism;
BRCA	cis	rs7524258	0.868	rs4243824	chr1:7289777	G/A	cg07173049	chr1:7289937	CAMTA1	0.51	12.43	0.44	6.32e-32	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg06521331	chr12:34319734	NA	-0.52	-10.17	-0.37	1.3e-22	Morning vs. evening chronotype;
BRCA	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg07169764	chr2:136633963	MCM6	1.32	32.9	0.79	1.21e-139	Corneal structure;
BRCA	cis	rs11025559	0.812	rs16906280	chr11:20472242	T/C	cg19653624	chr11:20408972	PRMT3	-0.44	-10.06	-0.37	3.48e-22	Pursuit maintenance gain;
BRCA	cis	rs5167	0.504	rs892101	chr19:45455458	G/A	cg09555818	chr19:45449301	APOC2	0.47	12.17	0.43	8.55e-31	Blood protein levels;
BRCA	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24549020	chr5:56110836	MAP3K1	0.62	11.57	0.42	2.97e-28	Initial pursuit acceleration;
BRCA	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg06046430	chr4:77819534	ANKRD56	0.58	13.04	0.46	1.28e-34	Emphysema distribution in smoking;
BRCA	cis	rs9462027	0.651	rs6940395	chr6:34736553	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.93	-0.3	9.96e-15	Systemic lupus erythematosus;
BRCA	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs4650994	0.505	rs2811291	chr1:178574217	C/T	cg05059571	chr16:84539110	KIAA1609	0.57	12.49	0.44	3.53e-32	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs13136331	0.680	rs2732206	chr4:88652504	T/A	cg12990093	chr4:88570587	DMP1	-0.39	-8.06	-0.3	3.9e-15	Sitting height ratio;
BRCA	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg25358565	chr5:93447407	FAM172A	1.23	19.52	0.61	6.5e-67	Diabetic retinopathy;
BRCA	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg14675211	chr2:100938903	LONRF2	0.49	11.18	0.4	1.22e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	19.98	0.62	2.34e-69	Platelet count;
BRCA	cis	rs2282802	0.685	rs6889283	chr5:139653439	G/T	cg26211634	chr5:139558579	C5orf32	0.35	8.37	0.31	3.61e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4911259	0.513	rs6057665	chr20:31463460	A/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-11.89	-0.43	1.36e-29	Inflammatory bowel disease;
BRCA	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg16606324	chr3:10149918	C3orf24	-0.57	-11.23	-0.41	7.83e-27	Alzheimer's disease;
BRCA	cis	rs9549328	0.756	rs2993291	chr13:113653846	C/T	cg01248385	chr13:113636953	MCF2L	-0.41	-8.2	-0.31	1.27e-15	Systolic blood pressure;
BRCA	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg25427524	chr10:38739819	LOC399744	0.61	11.84	0.42	2.27e-29	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg24397884	chr7:158709396	WDR60	0.69	15.1	0.51	2.7e-44	Height;
BRCA	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg11764359	chr7:65958608	NA	-0.68	-15.19	-0.52	9.74e-45	Aortic root size;
BRCA	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg22907277	chr7:1156413	C7orf50	0.59	9.1	0.34	1.11e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg00409905	chr10:38381863	ZNF37A	-0.48	-9.43	-0.35	7.62e-20	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00684032	chr4:1343700	KIAA1530	0.4	9.79	0.36	3.4e-21	Obesity-related traits;
BRCA	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg17135325	chr3:160939158	NMD3	0.39	7.82	0.3	2.14e-14	Parkinson's disease;
BRCA	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg24296786	chr1:45957014	TESK2	0.63	15.75	0.53	1.72e-47	High light scatter reticulocyte count;
BRCA	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs13082711	0.871	rs13061912	chr3:27495586	A/G	cg02860705	chr3:27208620	NA	0.53	10.56	0.39	3.86e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg05340658	chr4:99064831	C4orf37	0.48	10.6	0.39	2.77e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8170	0.603	rs7249329	chr19:17423373	G/T	cg02455703	chr19:17412272	ABHD8	-0.35	-7.91	-0.3	1.12e-14	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
BRCA	cis	rs4730250	0.655	rs4727671	chr7:106876045	A/G	cg02696742	chr7:106810147	HBP1	-0.47	-7.89	-0.3	1.3e-14	Osteoarthritis;
BRCA	cis	rs7255436	0.965	rs7249624	chr19:8446135	G/A	cg10174797	chr19:8464628	RAB11B	0.35	8.91	0.33	5.31e-18	HDL cholesterol;
BRCA	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg15704280	chr7:45808275	SEPT13	-0.79	-18.55	-0.59	9e-62	Coronary artery disease;
BRCA	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg23033748	chr14:75592666	NEK9	0.4	9.35	0.35	1.42e-19	Height;
BRCA	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02475777	chr4:1388615	CRIPAK	-0.51	-10.03	-0.37	4.45e-22	Obesity-related traits;
BRCA	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg12573674	chr2:1569213	NA	-0.42	-8.1	-0.31	2.84e-15	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.77	0.55	1.34e-52	Fuchs's corneal dystrophy;
BRCA	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.65	-14.14	-0.49	1.06e-39	Lung cancer;
BRCA	trans	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg23762105	chr12:34175262	ALG10	-0.36	-9.03	-0.34	2.06e-18	Morning vs. evening chronotype;
BRCA	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg04944784	chr2:26401820	FAM59B	-0.84	-13.14	-0.46	4.37e-35	Gut microbiome composition (summer);
BRCA	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.48	-8.42	-0.32	2.41e-16	Renal function-related traits (BUN);
BRCA	trans	rs526821	0.595	rs565859	chr11:55297367	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-8.19	-0.31	1.47e-15	Pediatric bone mineral density (spine);
BRCA	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg16586182	chr3:47516702	SCAP	-0.56	-12.9	-0.45	5.53e-34	Colorectal cancer;
BRCA	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-11.77	-0.42	4.19e-29	Systolic blood pressure;
BRCA	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg17470723	chr8:74884337	TCEB1	0.4	8.67	0.32	3.6e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg17063962	chr7:91808500	NA	-0.51	-11.93	-0.43	8.99e-30	Breast cancer;
BRCA	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03264133	chr6:25882463	NA	-0.54	-12.21	-0.43	5.71e-31	Blood metabolite levels;
BRCA	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg27446573	chr6:127587934	RNF146	0.9	21.32	0.64	1.39e-76	Breast cancer;
BRCA	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg04546413	chr19:29218101	NA	0.62	10.42	0.38	1.34e-23	Methadone dose in opioid dependence;
BRCA	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-13.55	-0.47	5.9e-37	Morning vs. evening chronotype;
BRCA	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	18.6	0.59	4.7e-62	Platelet count;
BRCA	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18404041	chr3:52824283	ITIH1	-0.39	-12.11	-0.43	1.49e-30	Bipolar disorder;
BRCA	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	18.71	0.59	1.32e-62	Alzheimer's disease;
BRCA	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.55	13.59	0.47	4e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-10.62	-0.39	2.2e-24	Longevity;Endometriosis;
BRCA	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg10483660	chr13:112241077	NA	-0.37	-10.68	-0.39	1.29e-24	Menarche (age at onset);
BRCA	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg15556689	chr8:8085844	FLJ10661	-0.34	-8.97	-0.33	3.32e-18	Neuroticism;
BRCA	cis	rs9790314	0.581	rs6806054	chr3:160724978	C/T	cg03342759	chr3:160939853	NMD3	-0.44	-9.13	-0.34	8.97e-19	Morning vs. evening chronotype;
BRCA	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg08422745	chr4:174089978	GALNT7	-0.81	-18.47	-0.59	2.37e-61	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs7188861	0.768	rs430966	chr16:11389482	C/T	cg01510278	chr16:11456238	NA	0.43	8.29	0.31	6.63e-16	HDL cholesterol;
BRCA	cis	rs4363385	0.747	rs1577963	chr1:152961882	T/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.68	-0.32	3.27e-17	Inflammatory skin disease;
BRCA	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg25237894	chr2:233734115	C2orf82	-0.38	-11.18	-0.4	1.21e-26	Coronary artery disease;
BRCA	cis	rs7512552	0.839	rs1498308	chr1:150295131	G/T	cg15654264	chr1:150340011	RPRD2	0.37	8.4	0.32	2.78e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg13010199	chr12:38710504	ALG10B	0.39	8.1	0.31	2.69e-15	Morning vs. evening chronotype;
BRCA	trans	rs6479891	1.000	rs4469774	chr10:65309777	G/T	cg14819942	chr15:35414228	NA	0.35	8.47	0.32	1.74e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg00106254	chr7:1943704	MAD1L1	0.39	9.61	0.36	1.6e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs4363385	0.818	rs426360	chr1:153014710	C/T	cg21543102	chr1:152974771	SPRR3	-0.28	-7.81	-0.3	2.28e-14	Inflammatory skin disease;
BRCA	cis	rs2354432	0.556	rs7520661	chr1:146793149	A/G	cg25205988	chr1:146714368	CHD1L	-0.82	-11.24	-0.41	7.1e-27	Mitochondrial DNA levels;
BRCA	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.03	-21.13	-0.64	1.44e-75	Ulcerative colitis;
BRCA	trans	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg06521331	chr12:34319734	NA	0.46	9.19	0.34	5.52e-19	Bladder cancer;
BRCA	trans	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg26043149	chr18:55253948	FECH	0.42	9.12	0.34	9.57e-19	Bone mineral density;
BRCA	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg10621924	chr7:39171070	POU6F2	0.39	7.97	0.3	7.16e-15	IgG glycosylation;
BRCA	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg09537434	chr19:41945824	ATP5SL	1.02	23.92	0.69	8.77e-91	Height;
BRCA	cis	rs6987853	0.749	rs13250124	chr8:42404737	G/A	cg09913449	chr8:42400586	C8orf40	0.42	9.36	0.35	1.35e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs654950	0.875	rs586055	chr1:41999076	T/C	cg06885757	chr1:42089581	HIVEP3	0.23	7.89	0.3	1.32e-14	Airway imaging phenotypes;
BRCA	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg24130564	chr14:104152367	KLC1	-0.4	-9.03	-0.34	1.95e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg20587970	chr11:113659929	NA	-1.19	-21.49	-0.65	1.61e-77	Hip circumference adjusted for BMI;
BRCA	trans	rs11976180	1.000	rs1919950	chr7:143767898	T/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.2	-0.31	1.32e-15	Obesity-related traits;
BRCA	cis	rs4730250	0.707	rs4730222	chr7:106810293	G/C	cg02696742	chr7:106810147	HBP1	-0.6	-9.44	-0.35	6.58e-20	Osteoarthritis;
BRCA	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg23262073	chr20:60523788	NA	-0.4	-8.7	-0.33	2.71e-17	Body mass index;
BRCA	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg01819863	chr10:32635814	EPC1	1.21	20.81	0.64	8.38e-74	Sexual dysfunction (female);
BRCA	cis	rs1568889	0.838	rs11030220	chr11:28145769	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	20.15	0.62	2.8e-70	Bipolar disorder;
BRCA	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg07917127	chr4:99064746	C4orf37	0.43	8.0	0.3	5.74e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg13010199	chr12:38710504	ALG10B	0.51	9.97	0.37	7.62e-22	Bladder cancer;
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.45	-9.94	-0.37	9.37e-22	Longevity;Endometriosis;
BRCA	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg26031613	chr14:104095156	KLC1	0.65	14.3	0.49	1.91e-40	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg03146154	chr1:46216737	IPP	0.51	11.39	0.41	1.65e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.84	0.36	2.36e-21	Bipolar disorder;
BRCA	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	8.03	0.3	4.62e-15	Tonsillectomy;
BRCA	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-13.68	-0.48	1.49e-37	Bipolar disorder and schizophrenia;
BRCA	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg13119609	chr19:45449297	APOC2	0.46	12.98	0.46	2.24e-34	Blood protein levels;
BRCA	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.41	-8.75	-0.33	1.87e-17	Longevity;Endometriosis;
BRCA	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg03877680	chr5:178157825	ZNF354A	0.79	14.61	0.5	6.69e-42	Neutrophil percentage of white cells;
BRCA	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg26384229	chr12:38710491	ALG10B	0.68	14.16	0.49	8.91e-40	Morning vs. evening chronotype;
BRCA	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg18876405	chr7:65276391	NA	0.43	8.68	0.32	3.2e-17	Corneal structure;
BRCA	cis	rs68170813	0.559	rs75723759	chr7:106962407	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-8.58	-0.32	6.93e-17	Coronary artery disease;
BRCA	cis	rs11874712	1.000	rs13381709	chr18:43670988	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.18	0.31	1.57e-15	Migraine - clinic-based;
BRCA	trans	rs11227306	0.934	rs11227313	chr11:65588938	C/T	cg17712092	chr4:129076599	LARP1B	0.42	8.61	0.32	5.5e-17	DNA methylation (variation);
BRCA	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.74e-16	Menopause (age at onset);
BRCA	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg03934865	chr2:198174659	NA	-0.39	-8.38	-0.31	3.34e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg00666640	chr1:248458726	OR2T12	0.33	8.84	0.33	9.49e-18	Common traits (Other);
BRCA	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg24006582	chr15:45444508	DUOX1	-0.56	-11.58	-0.42	2.72e-28	Uric acid levels;
BRCA	trans	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg17470723	chr8:74884337	TCEB1	0.41	8.6	0.32	6.17e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6694270	0.529	rs35941610	chr1:19104930	C/T	cg26220594	chr1:19110978	NA	-0.44	-7.98	-0.3	6.76e-15	Drug-induced liver injury (nitrofurantoin);
BRCA	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.25	0.34	3.42e-19	Tonsillectomy;
BRCA	cis	rs28830936	1.000	rs17676742	chr15:41903048	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.33	-9.28	-0.34	2.65e-19	Diastolic blood pressure;
BRCA	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg02297831	chr4:17616191	MED28	-0.37	-8.35	-0.31	4.21e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-9.65	-0.36	1.15e-20	IgG glycosylation;
BRCA	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg06627628	chr2:24431161	ITSN2	0.46	9.57	0.35	2.26e-20	Asthma;
BRCA	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg17366294	chr4:99064904	C4orf37	0.46	8.31	0.31	5.87e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg24803719	chr17:45855879	NA	-0.3	-7.84	-0.3	1.88e-14	IgG glycosylation;
BRCA	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg22974920	chr21:40686053	BRWD1	-0.41	-9.07	-0.34	1.47e-18	Cognitive function;
BRCA	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.42	9.77	0.36	4.21e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-10.65	-0.39	1.75e-24	Uric acid levels;
BRCA	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.43	10.01	0.37	5.03e-22	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg18402987	chr7:1209562	NA	0.39	7.83	0.3	1.97e-14	Longevity;Endometriosis;
BRCA	cis	rs9290065	0.519	rs9857743	chr3:160677732	G/A	cg03342759	chr3:160939853	NMD3	-0.5	-10.26	-0.38	5.91e-23	Kawasaki disease;
BRCA	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.41	-8.41	-0.32	2.63e-16	Ulcerative colitis;
BRCA	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg06115741	chr20:33292138	TP53INP2	-0.46	-9.57	-0.35	2.38e-20	Coronary artery disease;
BRCA	trans	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg26043149	chr18:55253948	FECH	0.97	21.16	0.64	1.08e-75	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg00409905	chr10:38381863	ZNF37A	0.49	10.48	0.38	7.75e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.54	11.2	0.41	1e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-16.78	-0.55	1.31e-52	Migraine;Coronary artery disease;
BRCA	cis	rs11229555	0.645	rs34530191	chr11:58200854	A/G	cg15696309	chr11:58395628	NA	-0.52	-10.83	-0.39	3.19e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg18402987	chr7:1209562	NA	0.45	8.58	0.32	7.29e-17	Longevity;Endometriosis;
BRCA	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg01884057	chr2:25150051	NA	0.34	9.16	0.34	7.08e-19	Body mass index;
BRCA	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08109568	chr15:31115862	NA	-0.59	-14.04	-0.49	3.24e-39	Huntington's disease progression;
BRCA	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg18446336	chr7:2847575	GNA12	-0.42	-10.66	-0.39	1.61e-24	Height;
BRCA	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	trans	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.04	0.3	4.39e-15	Mean corpuscular volume;
BRCA	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg00071950	chr4:10020882	SLC2A9	0.66	16.72	0.55	2.39e-52	Bone mineral density;
BRCA	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg17847044	chr15:42102381	MAPKBP1	0.46	16.5	0.55	3.18e-51	Diastolic blood pressure;
BRCA	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg12386194	chr3:101231763	SENP7	0.46	9.91	0.36	1.29e-21	Colorectal cancer;
BRCA	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	10.26	0.38	5.87e-23	Height;
BRCA	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg19077165	chr18:44547161	KATNAL2	-0.51	-10.83	-0.39	3.21e-25	Personality dimensions;
BRCA	cis	rs7809950	1.000	rs2712201	chr7:107145564	T/C	cg23024343	chr7:107201750	COG5	-0.41	-9.43	-0.35	7.5599999999999994e-20	Coronary artery disease;
BRCA	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg00012203	chr2:219082015	ARPC2	0.46	9.05	0.34	1.76e-18	Colorectal cancer;
BRCA	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg14675211	chr2:100938903	LONRF2	-0.4	-8.93	-0.33	4.41e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.32	-0.38	3.23e-23	Psoriasis;
BRCA	cis	rs2629540	0.847	rs12763093	chr10:126395688	C/G	cg08799069	chr10:126477246	METTL10	-0.46	-9.28	-0.34	2.56e-19	Cocaine dependence;
BRCA	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg04362960	chr10:104952993	NT5C2	0.44	10.73	0.39	8.22e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs11984145	0.614	rs11972387	chr7:38836970	C/A	cg19327137	chr7:38886074	VPS41	0.48	8.79	0.33	1.41e-17	Cognitive performance;
BRCA	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg18944383	chr4:111397179	ENPEP	-0.35	-7.91	-0.3	1.16e-14	Height;
BRCA	trans	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.48	9.36	0.35	1.35e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg11764359	chr7:65958608	NA	0.68	15.14	0.51	1.77e-44	Aortic root size;
BRCA	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg23533926	chr12:111358616	MYL2	-0.42	-8.84	-0.33	9.21e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18876405	chr7:65276391	NA	0.52	12.19	0.43	7e-31	Aortic root size;
BRCA	cis	rs6942756	0.758	rs13226649	chr7:128977598	C/T	cg02491457	chr7:128862824	NA	-0.57	-12.08	-0.43	2.11e-30	White matter hyperintensity burden;
BRCA	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg04450456	chr4:17643702	FAM184B	0.31	9.07	0.34	1.4e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg24505687	chr6:33548425	BAK1	0.56	12.15	0.43	1.09e-30	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
BRCA	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg20476274	chr7:133979776	SLC35B4	0.67	19.75	0.62	4.09e-68	Mean platelet volume;
BRCA	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg21479132	chr6:26055353	NA	0.59	7.93	0.3	9.92e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2652834	0.950	rs2729787	chr15:63401493	G/T	cg05507819	chr15:63340323	TPM1	0.44	7.96	0.3	8.07e-15	HDL cholesterol;
BRCA	cis	rs1595825	0.891	rs7580003	chr2:198517893	C/T	cg19156104	chr2:198669113	PLCL1	-0.43	-8.23	-0.31	1.03e-15	Ulcerative colitis;
BRCA	cis	rs1577917	0.837	rs10944157	chr6:86577199	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-11.05	-0.4	4.09e-26	Response to antipsychotic treatment;
BRCA	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg03433033	chr1:76189801	ACADM	0.75	17.32	0.57	2.23e-55	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg13010199	chr12:38710504	ALG10B	0.48	9.33	0.35	1.76e-19	Bladder cancer;
BRCA	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.08	-0.43	2.05e-30	Total cholesterol levels;
BRCA	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11644478	chr21:40555479	PSMG1	0.85	19.42	0.61	2.12e-66	Cognitive function;
BRCA	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.57	10.46	0.38	9.52e-24	Gut microbiome composition (summer);
BRCA	trans	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.49	-10.27	-0.38	5.4e-23	Mean corpuscular volume;
BRCA	cis	rs4363385	0.747	rs1415970	chr1:152965741	G/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.49	-0.32	1.42e-16	Inflammatory skin disease;
BRCA	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg24562669	chr7:97807699	LMTK2	0.47	12.51	0.44	2.76e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6684514	1.000	rs28372828	chr1:156253031	G/C	cg16558208	chr1:156270281	VHLL	0.35	7.95	0.3	8.56e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs28374715	0.532	rs3204853	chr15:41689166	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.09	-25.42	-0.71	4.97e-99	Ulcerative colitis;
BRCA	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	16.69	0.55	3.7e-52	Alzheimer's disease;
BRCA	cis	rs9381107	0.932	rs2103674	chr6:9451701	G/A	cg14735645	chr6:9486422	NA	-0.45	-7.92	-0.3	1.09e-14	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs7395581	0.775	rs2269434	chr11:47360412	T/C	cg25783544	chr11:47291846	MADD	0.37	8.29	0.31	6.66e-16	HDL cholesterol;
BRCA	trans	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg06521331	chr12:34319734	NA	-0.52	-9.45	-0.35	6.17e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg08859206	chr1:53392774	SCP2	-0.42	-8.54	-0.32	9.56e-17	Monocyte count;
BRCA	cis	rs10754283	0.967	rs4658302	chr1:90103336	A/G	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.2e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg25237894	chr2:233734115	C2orf82	0.39	10.96	0.4	1.03e-25	Coronary artery disease;
BRCA	cis	rs858239	0.932	rs858275	chr7:23294144	T/C	cg23682824	chr7:23144976	KLHL7	0.33	8.49	0.32	1.42e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1371614	0.632	rs6707735	chr2:27166822	T/C	cg00617064	chr2:27272375	NA	-0.32	-8.41	-0.32	2.73e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs4664304	0.620	rs10929956	chr2:160714615	C/T	cg02280532	chr2:160761244	LY75	0.35	7.85	0.3	1.78e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs1568889	0.774	rs11030235	chr11:28212375	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.37	0.63	1.82e-71	Bipolar disorder;
BRCA	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg27478167	chr7:817139	HEATR2	0.53	9.65	0.36	1.13e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs16866061	1.000	rs72974203	chr2:225408430	G/A	cg12698349	chr2:225449008	CUL3	0.78	21.22	0.64	4.75e-76	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.53	-0.35	3.1e-20	Total body bone mineral density;
BRCA	cis	rs6545883	0.801	rs778142	chr2:61681428	G/T	cg15711740	chr2:61764176	XPO1	-0.52	-12.51	-0.44	2.8e-32	Tuberculosis;
BRCA	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.51	-10.49	-0.38	7.01e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg05925327	chr15:68127851	NA	-0.37	-8.01	-0.3	5.37e-15	Obesity;
BRCA	cis	rs6684428	1.000	rs12145137	chr1:56370557	A/T	cg11651538	chr1:56320950	NA	-0.46	-7.81	-0.3	2.32e-14	Airflow obstruction;
BRCA	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg16339924	chr4:17578868	LAP3	0.58	13.68	0.48	1.48e-37	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.25	7.9	0.3	1.25e-14	Parkinson's disease;
BRCA	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg00684032	chr4:1343700	KIAA1530	0.53	12.44	0.44	5.61e-32	Obesity-related traits;
BRCA	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	trans	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg04565464	chr8:145669602	NFKBIL2	0.4	8.63	0.32	4.75e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg06784218	chr1:46089804	CCDC17	-0.45	-10.84	-0.39	2.92e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9359856	0.510	rs2768940	chr6:90436319	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.68	-10.78	-0.39	5.02e-25	Bipolar disorder;
BRCA	cis	rs1003719	0.751	rs10154032	chr21:38453459	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.07	0.49	2.27e-39	Eye color traits;
BRCA	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg27170947	chr2:26402098	FAM59B	-0.65	-11.21	-0.41	9.48e-27	Gut microbiome composition (summer);
BRCA	cis	rs3892630	0.500	rs6510301	chr19:33359791	A/T	cg22980127	chr19:33182716	NUDT19	0.74	13.93	0.48	1.02e-38	Red blood cell traits;
BRCA	trans	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04565464	chr8:145669602	NFKBIL2	0.37	8.49	0.32	1.43e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs4363385	0.747	rs9919227	chr1:152970867	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.22	-0.31	1.17e-15	Inflammatory skin disease;
BRCA	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg05340658	chr4:99064831	C4orf37	-0.5	-11.63	-0.42	1.75e-28	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.58	8.37	0.31	3.69e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2455799	0.533	rs2470550	chr3:15743721	C/T	cg16303742	chr3:15540471	COLQ	-0.35	-8.35	-0.31	4.09e-16	Mean platelet volume;
BRCA	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg25036284	chr2:26402008	FAM59B	0.7	12.36	0.44	1.35e-31	Gut microbiome composition (summer);
BRCA	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg01304814	chr3:48885189	PRKAR2A	0.57	8.01	0.3	5.25e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg21395723	chr22:39101663	GTPBP1	0.4	8.62	0.32	5.08e-17	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg03676636	chr4:99064102	C4orf37	-0.21	-8.2	-0.31	1.29e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg03146154	chr1:46216737	IPP	-0.49	-10.67	-0.39	1.45e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg00750074	chr16:89608354	SPG7	-0.41	-11.14	-0.4	1.84e-26	Multiple myeloma (IgH translocation);
BRCA	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	19.38	0.61	3.86e-66	Electrocardiographic conduction measures;
BRCA	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.8	-0.36	3.32e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg03709012	chr19:19516395	GATAD2A	-0.75	-16.77	-0.55	1.34e-52	Tonsillectomy;
BRCA	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg06552810	chr11:31128660	NA	-0.4	-8.84	-0.33	9.43e-18	Bone mineral density (spine);
BRCA	cis	rs12760731	0.720	rs12039605	chr1:178433368	C/T	cg00404053	chr1:178313656	RASAL2	0.61	7.99	0.3	6.12e-15	Obesity-related traits;
BRCA	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg06671706	chr8:8559999	CLDN23	0.44	8.51	0.32	1.27e-16	Obesity-related traits;
BRCA	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.49	-9.71	-0.36	7.26e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg04727924	chr7:799746	HEATR2	-0.56	-10.11	-0.37	2.1e-22	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1691799	0.867	rs1168309	chr12:66726439	A/G	cg16791601	chr12:66731901	HELB	0.68	19.3	0.61	1.02e-65	White blood cell count (basophil);
BRCA	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.67	-0.61	9.89e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg13770153	chr20:60521292	NA	-0.45	-10.81	-0.39	4.09e-25	Body mass index;
BRCA	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24397884	chr7:158709396	WDR60	-0.95	-23.99	-0.69	3.74e-91	Height;
BRCA	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.16	0.37	1.45e-22	Aortic root size;
BRCA	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.84	-0.3	1.9e-14	Aortic root size;
BRCA	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11644478	chr21:40555479	PSMG1	-0.66	-14.28	-0.49	2.5e-40	Cognitive function;
BRCA	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg25173405	chr17:45401733	C17orf57	0.49	9.96	0.37	8.04e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg13010199	chr12:38710504	ALG10B	0.5	10.3	0.38	4.14e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg16606324	chr3:10149918	C3orf24	0.56	11.15	0.4	1.74e-26	Alzheimer's disease;
BRCA	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg13047869	chr3:10149882	C3orf24	0.53	11.33	0.41	2.9e-27	Alzheimer's disease;
BRCA	trans	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg17675199	chr6:35436792	RPL10A	-0.29	-8.0	-0.3	5.77e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs71636778	0.543	rs12749822	chr1:27221963	T/C	cg12203394	chr1:27248618	NUDC	0.61	9.53	0.35	3.3e-20	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg05347473	chr6:146136440	FBXO30	0.41	8.03	0.3	4.85e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9788682	0.747	rs11072766	chr15:78771546	C/T	cg24631222	chr15:78858424	CHRNA5	0.47	9.32	0.35	1.86e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.25	8.61	0.32	5.68e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg23758822	chr17:41437982	NA	-0.76	-19.63	-0.61	1.61e-67	Menopause (age at onset);
BRCA	cis	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg06521331	chr12:34319734	NA	-0.56	-10.01	-0.37	5.04e-22	Morning vs. evening chronotype;
BRCA	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg27446573	chr6:127587934	RNF146	0.9	21.22	0.64	4.53e-76	Breast cancer;
BRCA	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	11.64	0.42	1.62e-28	Mean platelet volume;
BRCA	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.87	-0.3	1.48e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg10578991	chr7:12443926	VWDE	-0.53	-7.89	-0.3	1.34e-14	Coronary artery disease;
BRCA	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg17971929	chr21:40555470	PSMG1	-0.51	-11.34	-0.41	2.75e-27	Menarche (age at onset);
BRCA	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg27446573	chr6:127587934	RNF146	0.9	21.49	0.65	1.64e-77	Breast cancer;
BRCA	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg26384229	chr12:38710491	ALG10B	0.84	22.54	0.67	2.99e-83	Heart rate;
BRCA	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg27661571	chr11:113659931	NA	-0.7	-10.79	-0.39	4.93e-25	Hip circumference adjusted for BMI;
BRCA	trans	rs75804782	0.520	rs34058921	chr2:239318665	C/T	cg01134436	chr17:81009848	B3GNTL1	0.77	9.69	0.36	8.3e-21	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg03709012	chr19:19516395	GATAD2A	-0.75	-16.72	-0.55	2.46e-52	Tonsillectomy;
BRCA	cis	rs672059	1.000	rs625917	chr1:183157991	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.56	0.32	8.08e-17	Hypertriglyceridemia;
BRCA	cis	rs912057	1.000	rs912056	chr6:6736197	A/T	cg06612196	chr6:6737390	NA	0.45	9.63	0.36	1.43e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	trans	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg21659725	chr3:3221576	CRBN	-0.46	-9.94	-0.37	9.86e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg06115741	chr20:33292138	TP53INP2	0.46	10.19	0.37	1.09e-22	Coronary artery disease;
BRCA	cis	rs4853036	0.680	rs12612925	chr2:70112580	C/T	cg02498382	chr2:70120550	SNRNP27	-0.59	-9.6	-0.35	1.8e-20	Colorectal or endometrial cancer;
BRCA	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg04546413	chr19:29218101	NA	-0.47	-8.23	-0.31	1.04e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg11663144	chr21:46675770	NA	-0.62	-14.75	-0.5	1.35e-42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.36	-8.34	-0.31	4.49e-16	Longevity;Endometriosis;
BRCA	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg04362960	chr10:104952993	NT5C2	0.44	10.01	0.37	5.06e-22	Arsenic metabolism;
BRCA	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg05340658	chr4:99064831	C4orf37	-0.49	-11.36	-0.41	2.25e-27	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs1459104	1.000	rs12577269	chr11:55062905	C/T	cg15704280	chr7:45808275	SEPT13	0.69	8.63	0.32	4.7e-17	Body mass index;
BRCA	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg08000102	chr2:233561755	GIGYF2	-0.44	-9.62	-0.36	1.48e-20	Coronary artery disease;
BRCA	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg24631222	chr15:78858424	CHRNA5	-0.5	-9.95	-0.37	9.13e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	trans	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg25214090	chr10:38739885	LOC399744	0.54	11.83	0.42	2.49e-29	Corneal astigmatism;
BRCA	cis	rs1868673	1.000	rs28514580	chr3:150154365	G/T	cg04908077	chr3:150187338	NA	-0.33	-8.99	-0.34	2.8e-18	Waist circumference;
BRCA	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg26608667	chr7:1196370	ZFAND2A	0.45	10.75	0.39	7.09e-25	Longevity;Endometriosis;
BRCA	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg07080220	chr10:102295463	HIF1AN	0.61	14.51	0.5	1.97e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg21535247	chr6:8435926	SLC35B3	0.41	9.38	0.35	1.09e-19	Motion sickness;
BRCA	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg06623918	chr6:96969491	KIAA0776	0.73	12.85	0.45	8.92e-34	Migraine;Coronary artery disease;
BRCA	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg18252515	chr7:66147081	NA	-0.82	-11.88	-0.43	1.52e-29	Diabetic kidney disease;
BRCA	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg13770153	chr20:60521292	NA	-0.35	-8.22	-0.31	1.1e-15	Body mass index;
BRCA	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2710642	0.927	rs2539980	chr2:63208460	T/C	cg17519650	chr2:63277830	OTX1	0.45	10.01	0.37	5.09e-22	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg23888215	chr10:79422304	NA	0.53	10.46	0.38	9.8e-24	Bone mineral density;
BRCA	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	12.94	0.46	3.57e-34	Lung cancer in ever smokers;
BRCA	cis	rs4363385	0.818	rs1334849	chr1:153004652	A/G	cg24667326	chr1:152973720	SPRR3	0.32	9.01	0.34	2.34e-18	Inflammatory skin disease;
BRCA	cis	rs7523050	0.643	rs17563938	chr1:109401654	C/T	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg12483005	chr1:23474871	LUZP1	0.38	8.15	0.31	1.87e-15	Height;
BRCA	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg18301423	chr5:131593218	PDLIM4	0.34	8.74	0.33	2.05e-17	Breast cancer;
BRCA	trans	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg24812749	chr6:127587940	RNF146	0.88	20.63	0.63	7.68e-73	Breast cancer;
BRCA	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26314531	chr2:26401878	FAM59B	0.95	16.42	0.54	8.01e-51	Gut microbiome composition (summer);
BRCA	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg20701182	chr2:24300061	SF3B14	0.7	13.41	0.47	2.62e-36	Lymphocyte counts;
BRCA	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13053817	0.948	rs67613029	chr22:29836569	T/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.5	-9.91	-0.36	1.29e-21	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.14	-0.31	2.03e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs4561483	0.864	rs190461	chr16:12005745	A/G	cg08843971	chr16:11963173	GSPT1	-0.46	-9.23	-0.34	3.93e-19	Testicular germ cell tumor;
BRCA	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg09654669	chr8:57350985	NA	-0.38	-8.34	-0.31	4.55e-16	Obesity-related traits;
BRCA	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.29	-0.31	6.76e-16	Total body bone mineral density;
BRCA	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg12011299	chr4:100065546	ADH4	0.53	12.88	0.45	6.56e-34	Alcohol dependence;
BRCA	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg15145296	chr3:125709740	NA	-0.54	-8.58	-0.32	7.1e-17	Blood pressure (smoking interaction);
BRCA	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg05714579	chr10:131428358	MGMT	0.56	13.76	0.48	6.25e-38	Response to temozolomide;
BRCA	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg22875332	chr1:76189707	ACADM	0.79	18.87	0.6	1.86e-63	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg22638593	chr5:131593259	PDLIM4	0.3	7.82	0.3	2.18e-14	Breast cancer;
BRCA	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg24110177	chr3:50126178	RBM5	-0.36	-9.52	-0.35	3.41e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg03213289	chr20:61660250	NA	0.63	16.54	0.55	2.05e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11644478	chr21:40555479	PSMG1	0.84	18.76	0.6	7.26e-63	Cognitive function;
BRCA	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.74	10.3	0.38	3.96e-23	Initial pursuit acceleration;
BRCA	trans	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg06521331	chr12:34319734	NA	-0.49	-9.07	-0.34	1.51e-18	Bladder cancer;
BRCA	cis	rs61990749	0.597	rs17106157	chr14:78146878	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.64	-10.05	-0.37	3.59e-22	Fibroblast growth factor basic levels;
BRCA	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.57	-9.35	-0.35	1.48e-19	Alzheimer's disease;
BRCA	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24229701	chr12:130821962	PIWIL1	0.39	8.89	0.33	6.08e-18	Menopause (age at onset);
BRCA	cis	rs10992471	0.603	rs11792019	chr9:95195229	C/T	cg14631576	chr9:95140430	CENPP	-0.39	-9.32	-0.35	1.83e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg06766960	chr11:133703094	NA	-0.64	-13.18	-0.46	2.89e-35	Childhood ear infection;
BRCA	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg22800045	chr5:56110881	MAP3K1	-0.41	-8.25	-0.31	9.22e-16	Initial pursuit acceleration;
BRCA	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	13.04	0.46	1.23e-34	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-12.15	-0.43	9.96e-31	Chronic sinus infection;
BRCA	cis	rs2171564	0.557	rs3846043	chr3:112436847	A/C	cg06685282	chr3:112453648	NA	-0.48	-11.22	-0.41	8.9e-27	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs9420	0.961	rs71484468	chr11:57632799	G/C	cg19752551	chr11:57585705	CTNND1	-0.51	-12.68	-0.45	5.05e-33	Schizophrenia;
BRCA	cis	rs28830936	1.000	rs112896623	chr15:42001845	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.35	-9.72	-0.36	6.26e-21	Diastolic blood pressure;
BRCA	trans	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-7.81	-0.3	2.32e-14	Corneal astigmatism;
BRCA	cis	rs6087990	0.735	rs1040554	chr20:31380073	C/T	cg13636640	chr20:31349939	DNMT3B	0.61	18.01	0.58	5.63e-59	Ulcerative colitis;
BRCA	cis	rs3784262	0.528	rs4553566	chr15:58336319	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-9.99	-0.37	6.14e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg15448220	chr1:150897856	SETDB1	0.35	7.81	0.3	2.32e-14	Melanoma;
BRCA	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08704250	chr15:31115839	NA	-0.36	-8.98	-0.33	2.91e-18	Huntington's disease progression;
BRCA	cis	rs41307935	0.722	rs12724052	chr1:27234682	G/A	cg12203394	chr1:27248618	NUDC	0.6	9.35	0.35	1.44e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	9.94	0.37	9.35e-22	Lung cancer in ever smokers;
BRCA	cis	rs757081	0.738	rs1073443	chr11:17350394	C/T	cg15432903	chr11:17409602	KCNJ11	-0.52	-9.34	-0.35	1.61e-19	Systolic blood pressure;
BRCA	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg03877680	chr5:178157825	ZNF354A	0.58	9.6	0.35	1.82e-20	Neutrophil percentage of white cells;
BRCA	cis	rs6429082	0.749	rs291362	chr1:235686690	T/A	cg26050004	chr1:235667680	B3GALNT2	0.55	14.41	0.5	5.73e-41	Adiposity;
BRCA	cis	rs672059	1.000	rs559476	chr1:183160704	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.56	0.32	8.46e-17	Hypertriglyceridemia;
BRCA	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.69	0.39	1.24e-24	IgG glycosylation;
BRCA	cis	rs295137	0.725	rs1729413	chr2:201086663	T/G	cg23649088	chr2:200775458	C2orf69	0.42	9.07	0.34	1.48e-18	Asthma (bronchodilator response);
BRCA	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg20007245	chr22:24372913	LOC391322	0.55	12.1	0.43	1.77e-30	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg26384229	chr12:38710491	ALG10B	-0.56	-13.95	-0.48	8.26e-39	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg22903471	chr2:27725779	GCKR	-0.39	-9.42	-0.35	8.08e-20	Total body bone mineral density;
BRCA	cis	rs2066819	0.892	rs117305040	chr12:56657888	A/G	cg26714650	chr12:56694279	CS	-1.16	-15.21	-0.52	8.38e-45	Psoriasis vulgaris;
BRCA	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.05	21.9	0.65	9.95e-80	Gut microbiome composition (summer);
BRCA	cis	rs312274	0.657	rs932908	chr12:41213186	C/G	cg17827154	chr12:41323612	CNTN1	0.36	8.84	0.33	9.17e-18	Metabolite levels  (X-11787);
BRCA	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg08999081	chr20:33150536	PIGU	-0.34	-8.8	-0.33	1.26e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg27490568	chr2:178487706	NA	0.5	8.4	0.32	2.91e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg08847533	chr14:75593920	NEK9	0.83	20.57	0.63	1.56e-72	Height;
BRCA	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg03188948	chr7:1209495	NA	0.8	11.58	0.42	2.84e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg09537434	chr19:41945824	ATP5SL	-1.02	-23.64	-0.68	2.82e-89	Height;
BRCA	cis	rs7246657	0.653	rs4805208	chr19:37674259	G/A	cg23950597	chr19:37808831	NA	-0.66	-10.18	-0.37	1.21e-22	Coronary artery calcification;
BRCA	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg24692254	chr21:30365293	RNF160	0.6	15.6	0.53	9.82e-47	Dental caries;
BRCA	cis	rs1018836	0.923	rs10808615	chr8:91569704	A/T	cg16814680	chr8:91681699	NA	-0.64	-14.25	-0.49	3.37e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg20503657	chr10:835505	NA	0.88	16.06	0.54	5.38e-49	Eosinophil percentage of granulocytes;
BRCA	trans	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg14791747	chr16:20752902	THUMPD1	0.45	14.26	0.49	3.08e-40	Cognitive test performance;
BRCA	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg21782813	chr7:2030301	MAD1L1	0.32	8.56	0.32	8.63e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg12365402	chr11:9010492	NRIP3	0.44	9.7	0.36	7.45e-21	Hemoglobin concentration;
BRCA	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg19052272	chr2:3704530	ALLC	-0.46	-10.37	-0.38	2.13e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs367943	1.000	rs348963	chr5:112819027	A/G	cg12552261	chr5:112820674	MCC	-0.55	-12.21	-0.43	5.85e-31	Type 2 diabetes;
BRCA	cis	rs495337	0.760	rs615868	chr20:48519224	C/T	cg17835207	chr20:48524531	SPATA2	-0.67	-16.04	-0.54	6.74e-49	Psoriasis;
BRCA	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg23711669	chr6:146136114	FBXO30	0.74	17.75	0.57	1.29e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9287719	0.649	rs2884232	chr2:10719679	C/A	cg00105475	chr2:10696890	NA	0.41	9.19	0.34	5.62e-19	Prostate cancer;
BRCA	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg17063962	chr7:91808500	NA	0.61	14.56	0.5	1.08e-41	Breast cancer;
BRCA	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg17691542	chr6:26056736	HIST1H1C	0.76	13.47	0.47	1.44e-36	Iron status biomarkers;
BRCA	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.87	0.3	1.53e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.12	-40.27	-0.85	1.8e-177	Myeloid white cell count;
BRCA	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg18904891	chr8:8559673	CLDN23	0.57	11.36	0.41	2.35e-27	Obesity-related traits;
BRCA	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg03474202	chr17:45855739	NA	-0.43	-11.29	-0.41	4.35e-27	IgG glycosylation;
BRCA	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	17.01	0.56	8.74e-54	Hypertriglyceridemia;
BRCA	trans	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg06636001	chr8:8085503	FLJ10661	0.48	9.37	0.35	1.25e-19	Neuroticism;
BRCA	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg01849466	chr14:104193079	ZFYVE21	0.42	10.74	0.39	7.67e-25	Schizophrenia;
BRCA	cis	rs1506636	1.000	rs767637	chr7:123321978	C/A	cg03229431	chr7:123269106	ASB15	-0.62	-14.06	-0.49	2.56e-39	Plateletcrit;Platelet count;
BRCA	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03517284	chr6:25882590	NA	-0.51	-10.21	-0.37	8.72e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4845875	0.529	rs6680385	chr1:11831756	A/G	cg24844545	chr1:11908347	NPPA	0.36	8.26	0.31	8.62e-16	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg04511125	chr2:88470314	THNSL2	-0.51	-10.57	-0.39	3.57e-24	Response to metformin (IC50);
BRCA	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24308560	chr3:49941425	MST1R	-0.4	-8.55	-0.32	9.36e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs1555322	0.530	rs2297789	chr20:33867248	A/T	cg17927777	chr20:33865990	NA	0.43	8.21	0.31	1.21e-15	Attention deficit hyperactivity disorder;
BRCA	cis	rs701145	0.585	rs1713846	chr3:153787632	C/T	cg17054900	chr3:154042577	DHX36	0.53	9.19	0.34	5.62e-19	Coronary artery disease;
BRCA	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg00012203	chr2:219082015	ARPC2	0.72	16.03	0.54	7.42e-49	Colorectal cancer;
BRCA	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08219700	chr8:58056026	NA	0.55	9.0	0.34	2.66e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg05347473	chr6:146136440	FBXO30	0.41	8.11	0.31	2.55e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.18	-17.87	-0.58	3.08e-58	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7254827	1.000	rs12977780	chr19:17213558	A/T	cg19418318	chr19:17219073	MYO9B	-0.49	-10.25	-0.38	6.25e-23	Mean platelet volume;
BRCA	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg14092571	chr14:90743983	NA	0.75	19.87	0.62	9.14e-69	Gut microbiota (bacterial taxa);
BRCA	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.55	8.81	0.33	1.21e-17	Renal function-related traits (BUN);
BRCA	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg08888203	chr3:10149979	C3orf24	0.59	12.5	0.44	3.15e-32	Alzheimer's disease;
BRCA	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	12.98	0.46	2.24e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg04025307	chr7:1156635	C7orf50	0.59	9.3	0.35	2.29e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg20933634	chr6:27740509	NA	0.46	8.99	0.34	2.71e-18	Parkinson's disease;
BRCA	cis	rs9463078	0.683	rs6458412	chr6:44735834	A/G	cg25276700	chr6:44698697	NA	0.37	8.04	0.3	4.37e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	trans	rs783540	0.843	rs9652567	chr15:83368514	T/G	cg18393722	chr15:85113863	UBE2QP1	0.28	8.62	0.32	5.34e-17	Schizophrenia;
BRCA	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12292205	chr6:26970375	C6orf41	-0.47	-7.97	-0.3	7.21e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg04025307	chr7:1156635	C7orf50	0.76	19.61	0.61	2.15e-67	Longevity;Endometriosis;
BRCA	cis	rs4363385	0.747	rs4845509	chr1:152981900	T/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.85	-0.36	2.03e-21	Inflammatory skin disease;
BRCA	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg11887960	chr12:57824829	NA	0.52	8.65	0.32	4.06e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.76	-0.42	5.05e-29	Alcohol dependence;
BRCA	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg22431228	chr1:16359049	CLCNKA	-0.45	-9.02	-0.34	2.26e-18	Dilated cardiomyopathy;
BRCA	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg07636037	chr3:49044803	WDR6	-0.5	-8.25	-0.31	9.35e-16	Menarche (age at onset);
BRCA	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18402987	chr7:1209562	NA	0.62	13.01	0.46	1.67e-34	Longevity;Endometriosis;
BRCA	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-9.94	-0.37	9.81e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24531977	chr5:56204891	C5orf35	-0.87	-17.88	-0.58	2.78e-58	Initial pursuit acceleration;
BRCA	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg01017244	chr2:74357527	NA	0.64	12.56	0.45	1.67e-32	Gestational age at birth (maternal effect);
BRCA	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.68	16.42	0.54	8.25e-51	Ileal carcinoids;
BRCA	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg12011299	chr4:100065546	ADH4	0.42	10.52	0.38	5.65e-24	Alcohol dependence;
BRCA	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg10523679	chr1:76189770	ACADM	0.91	22.32	0.66	4.84e-82	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg22117172	chr7:91764530	CYP51A1	-0.23	-7.87	-0.3	1.5e-14	Breast cancer;
BRCA	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg04944784	chr2:26401820	FAM59B	0.65	11.0	0.4	7.05e-26	Gut microbiome composition (summer);
BRCA	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.71	-0.33	2.59e-17	Breast cancer;
BRCA	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-11.96	-0.43	6.53e-30	Alzheimer's disease;
BRCA	cis	rs16958440	0.867	rs3809965	chr18:44676872	G/A	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs16854884	0.657	rs16854819	chr3:143736126	C/T	cg06585982	chr3:143692056	C3orf58	-0.41	-8.7	-0.33	2.8e-17	Economic and political preferences (feminism/equality);
BRCA	cis	rs965469	0.843	rs6051698	chr20:3248983	T/C	cg25506879	chr20:3388711	C20orf194	-0.46	-9.14	-0.34	7.88e-19	IFN-related cytopenia;
BRCA	cis	rs2651899	0.902	rs1736522	chr1:3080940	C/G	cg07622451	chr1:3079886	PRDM16	0.28	7.83	0.3	2.05e-14	Migraine;
BRCA	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg08888203	chr3:10149979	C3orf24	0.66	14.05	0.49	2.73e-39	Alzheimer's disease;
BRCA	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg08999081	chr20:33150536	PIGU	-0.39	-10.12	-0.37	2.07e-22	Coronary artery disease;
BRCA	cis	rs77972916	0.505	rs34247383	chr2:43532780	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-10.15	-0.37	1.53e-22	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg06623918	chr6:96969491	KIAA0776	0.9	26.0	0.72	3.17e-102	Headache;
BRCA	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg00686598	chr14:53173677	PSMC6	1.2	15.67	0.53	4.28e-47	Alzheimer's disease (late onset);
BRCA	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-13.45	-0.47	1.78e-36	Systemic lupus erythematosus;
BRCA	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg21775007	chr8:11205619	TDH	-0.4	-8.19	-0.31	1.41e-15	Neuroticism;
BRCA	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.11	-0.34	1.09e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.15	-0.49	1.01e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9807989	0.507	rs6745614	chr2:102991213	A/G	cg03938978	chr2:103052716	IL18RAP	0.28	8.28	0.31	7.17e-16	Asthma;
BRCA	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg09417038	chr21:47716443	C21orf57	0.32	8.3	0.31	6.23e-16	Testicular germ cell tumor;
BRCA	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg20387954	chr3:183756860	HTR3D	0.44	9.77	0.36	4.25e-21	Anterior chamber depth;
BRCA	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08280861	chr8:58055591	NA	0.56	8.74	0.33	2.09e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg23711669	chr6:146136114	FBXO30	-0.69	-16.0	-0.53	1.06e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	8.42	0.32	2.47e-16	Rheumatoid arthritis;
BRCA	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg13010199	chr12:38710504	ALG10B	0.42	8.94	0.33	4.26e-18	Morning vs. evening chronotype;
BRCA	cis	rs1975991	0.576	rs4449306	chr3:187952376	G/T	cg15417654	chr3:187959138	LPP	-0.36	-9.45	-0.35	6.32e-20	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg01262667	chr19:19385393	TM6SF2	-0.42	-10.94	-0.4	1.16e-25	Tonsillectomy;
BRCA	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.78	-12.54	-0.44	2.13e-32	Platelet count;
BRCA	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg01689657	chr7:91764605	CYP51A1	0.21	7.86	0.3	1.61e-14	Breast cancer;
BRCA	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg18357645	chr12:58087776	OS9	0.42	11.95	0.43	7.78e-30	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg00750074	chr16:89608354	SPG7	-0.36	-9.47	-0.35	5.19e-20	Multiple myeloma (IgH translocation);
BRCA	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg16339924	chr4:17578868	LAP3	0.68	17.26	0.56	4.44e-55	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9503598	1.000	rs9503598	chr6:3446263	A/G	cg00476032	chr6:3446245	SLC22A23	-0.47	-11.76	-0.42	4.98e-29	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs9831754	1.000	rs112170848	chr3:78359996	G/A	cg06138941	chr3:78371609	NA	-0.81	-17.54	-0.57	1.59e-56	Calcium levels;
BRCA	cis	rs4664304	0.620	rs4665125	chr2:160714314	C/G	cg14819504	chr2:160761413	LY75	0.34	8.37	0.31	3.66e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg15556689	chr8:8085844	FLJ10661	0.37	9.99	0.37	6.28e-22	Recombination measurement;
BRCA	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg17971929	chr21:40555470	PSMG1	-0.6	-13.43	-0.47	2.11e-36	Cognitive function;
BRCA	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00934597	chr7:893267	UNC84A	-0.54	-12.03	-0.43	3.42e-30	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg17063962	chr7:91808500	NA	0.53	12.5	0.44	3.23e-32	Breast cancer;
BRCA	cis	rs17253792	0.822	rs79291233	chr14:56065302	G/C	cg01858014	chr14:56050164	KTN1	-0.73	-9.19	-0.34	5.56e-19	Putamen volume;
BRCA	cis	rs3845702	0.800	rs6744281	chr2:180844382	G/A	cg01881094	chr2:180872142	CWC22	-1.01	-18.23	-0.58	4.24e-60	Schizophrenia;
BRCA	cis	rs4363385	0.747	rs2879488	chr1:152975241	G/A	cg24667326	chr1:152973720	SPRR3	-0.35	-9.82	-0.36	2.63e-21	Inflammatory skin disease;
BRCA	cis	rs4742903	0.527	rs10991112	chr9:106878906	C/T	cg14250997	chr9:106856677	SMC2	0.29	8.47	0.32	1.66e-16	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg13271783	chr10:134563150	INPP5A	-0.46	-9.52	-0.35	3.37e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.33	0.41	2.94e-27	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.14e-19	Total body bone mineral density;
BRCA	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22496380	chr5:211416	CCDC127	-1.01	-14.34	-0.49	1.26e-40	Breast cancer;
BRCA	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg17135325	chr3:160939158	NMD3	0.45	8.64	0.32	4.35e-17	Parkinson's disease;
BRCA	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.33	11.38	0.41	1.87e-27	Systemic lupus erythematosus;
BRCA	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.69	0.5	2.56e-42	Colorectal cancer;
BRCA	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg16482183	chr6:26056742	HIST1H1C	0.45	8.67	0.32	3.53e-17	Iron status biomarkers;
BRCA	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg24675658	chr1:53192096	ZYG11B	-0.69	-15.56	-0.52	1.56e-46	Monocyte count;
BRCA	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg21905437	chr5:178450457	ZNF879	0.51	10.65	0.39	1.68e-24	Pubertal anthropometrics;
BRCA	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg14228332	chr4:119757509	SEC24D	0.67	7.95	0.3	8.23e-15	Cannabis dependence symptom count;
BRCA	cis	rs17095355	1.000	rs12265204	chr10:111752163	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.4	-9.98	-0.37	6.53e-22	Biliary atresia;
BRCA	cis	rs858239	0.665	rs858306	chr7:23242754	A/T	cg23682824	chr7:23144976	KLHL7	0.31	8.0	0.3	5.71e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs3125734	0.633	rs3765002	chr10:64006124	G/T	cg19640130	chr10:64028056	RTKN2	-0.29	-8.25	-0.31	9.12e-16	Rheumatoid arthritis;
BRCA	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg04450456	chr4:17643702	FAM184B	0.32	9.43	0.35	7.47e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23583168	chr7:148888333	NA	0.85	19.93	0.62	4.17e-69	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	11.29	0.41	4.35e-27	Hip circumference adjusted for BMI;
BRCA	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg00071950	chr4:10020882	SLC2A9	0.62	15.02	0.51	6.62e-44	Bone mineral density;
BRCA	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.35	-7.92	-0.3	1.07e-14	Tonsillectomy;
BRCA	cis	rs9394841	0.692	rs13193235	chr6:41792659	T/C	cg08135965	chr6:41755394	TOMM6	0.5	8.3	0.31	6.25e-16	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs7631605	0.905	rs11920928	chr3:37210874	T/C	cg15934958	chr3:37212084	LRRFIP2	0.42	9.87	0.36	1.69e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9815354	0.812	rs78342280	chr3:41948810	G/A	cg03022575	chr3:42003672	ULK4	0.68	9.48	0.35	4.82e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	11.94	0.43	8.34e-30	Tonsillectomy;
BRCA	cis	rs939658	1.000	rs939658	chr15:79451869	A/G	cg17916960	chr15:79447300	NA	0.38	9.58	0.35	2.03e-20	Refractive error;
BRCA	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg05714579	chr10:131428358	MGMT	0.5	11.24	0.41	7.21e-27	Response to temozolomide;
BRCA	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.89	-0.3	1.33e-14	Triglycerides;
BRCA	trans	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg26384229	chr12:38710491	ALG10B	0.4	8.6	0.32	6.3e-17	Resting heart rate;
BRCA	trans	rs6479891	1.000	rs9415707	chr10:65188290	T/C	cg14819942	chr15:35414228	NA	0.35	8.58	0.32	7.31e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs7737355	0.898	rs2161414	chr5:131063073	C/T	cg06307176	chr5:131281290	NA	0.52	10.07	0.37	3.09e-22	Life satisfaction;
BRCA	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg18357645	chr12:58087776	OS9	0.47	13.49	0.47	1.19e-36	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg03711944	chr11:47377212	SPI1	-0.42	-11.31	-0.41	3.51e-27	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22509189	chr2:225307070	NA	-0.47	-10.07	-0.37	3e-22	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs2880765	0.677	rs7181410	chr15:86006335	A/G	cg10818794	chr15:86012489	AKAP13	0.29	8.02	0.3	5.02e-15	Coronary artery disease;
BRCA	trans	rs9951602	0.512	rs9952372	chr18:76656295	A/G	cg02800362	chr5:177631904	HNRNPAB	0.77	17.81	0.58	6.42e-58	Obesity-related traits;
BRCA	cis	rs4285028	0.699	rs1920298	chr3:121597888	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-13.16	-0.46	3.63e-35	Multiple sclerosis;
BRCA	trans	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.53	0.32	1.05e-16	Corneal astigmatism;
BRCA	cis	rs8017423	0.935	rs3783838	chr14:90733012	A/G	cg04374321	chr14:90722782	PSMC1	-0.71	-18.51	-0.59	1.37e-61	Mortality in heart failure;
BRCA	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg11584989	chr19:19387371	SF4	0.63	13.46	0.47	1.53e-36	Bipolar disorder;
BRCA	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg00106254	chr7:1943704	MAD1L1	-0.42	-10.21	-0.37	8.77e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs17767294	0.614	rs41269291	chr6:28251539	A/G	cg08851530	chr6:28072375	NA	1.14	10.34	0.38	2.73e-23	Parkinson's disease;
BRCA	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg00666640	chr1:248458726	OR2T12	0.34	9.12	0.34	9.72e-19	Common traits (Other);
BRCA	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg23711669	chr6:146136114	FBXO30	0.62	14.06	0.49	2.59e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg08601574	chr20:25228251	PYGB	-0.37	-8.84	-0.33	9.28e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7254827	0.784	rs4808570	chr19:17220720	G/A	cg19418318	chr19:17219073	MYO9B	-0.51	-10.29	-0.38	4.28e-23	Mean platelet volume;
BRCA	cis	rs7246657	0.722	rs2927742	chr19:38133618	T/C	cg18154014	chr19:37997991	ZNF793	-0.49	-9.24	-0.34	3.72e-19	Coronary artery calcification;
BRCA	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg27446573	chr6:127587934	RNF146	0.89	20.53	0.63	2.62e-72	Breast cancer;
BRCA	cis	rs3784262	0.647	rs2414529	chr15:58317094	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.31	-0.38	3.63e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs13095912	1.000	rs13340181	chr3:185325612	T/C	cg11274856	chr3:185301563	NA	0.34	8.56	0.32	8.61e-17	Systolic blood pressure;
BRCA	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg04691961	chr3:161091175	C3orf57	-0.44	-10.57	-0.39	3.54e-24	Morning vs. evening chronotype;
BRCA	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-12.46	-0.44	4.76e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs4363385	0.720	rs1970328	chr1:152975829	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.32	-0.31	5.23e-16	Inflammatory skin disease;
BRCA	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.83	-0.3	2.04e-14	Aortic root size;
BRCA	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.47	8.41	0.32	2.72e-16	Body mass index (adult);
BRCA	cis	rs2629540	0.924	rs2629541	chr10:126425866	G/A	cg08799069	chr10:126477246	METTL10	0.49	9.68	0.36	8.67e-21	Cocaine dependence;
BRCA	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg03213289	chr20:61660250	NA	0.63	16.62	0.55	7.73e-52	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg11502198	chr6:26597334	ABT1	0.46	8.97	0.33	3.22e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.55	8.26	0.31	8.57e-16	Platelet count;
BRCA	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.87e-21	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-18.36	-0.59	8.41e-61	Exhaled nitric oxide output;
BRCA	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg23719950	chr11:63933701	MACROD1	-0.53	-8.74	-0.33	2.07e-17	Mean platelet volume;
BRCA	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg12483005	chr1:23474871	LUZP1	0.46	10.22	0.37	7.96e-23	Height;
BRCA	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg25174290	chr11:3078921	CARS	0.4	11.14	0.4	1.75e-26	Longevity;
BRCA	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg00277334	chr10:82204260	NA	0.4	8.09	0.3	2.92e-15	Post bronchodilator FEV1;
BRCA	cis	rs877282	0.583	rs10904566	chr10:821662	C/G	cg15764593	chr10:829463	NA	-0.64	-10.26	-0.38	6.01e-23	Uric acid levels;
BRCA	cis	rs7677751	0.806	rs6850748	chr4:55099164	T/G	cg17187183	chr4:55093834	PDGFRA	0.44	9.06	0.34	1.53e-18	Corneal astigmatism;
BRCA	cis	rs13102973	0.932	rs28801464	chr4:135876630	A/G	cg14419869	chr4:135874104	NA	-0.59	-13.0	-0.46	1.93e-34	Subjective well-being;
BRCA	cis	rs208520	0.674	rs207103	chr6:66795568	G/T	cg07460842	chr6:66804631	NA	-1.02	-20.41	-0.63	1.11e-71	Exhaled nitric oxide output;
BRCA	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg11764359	chr7:65958608	NA	-0.68	-15.39	-0.52	1.07e-45	Aortic root size;
BRCA	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg12386194	chr3:101231763	SENP7	0.45	9.45	0.35	6.14e-20	Colorectal cancer;
BRCA	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.31	7.92	0.3	1.03e-14	IgG glycosylation;
BRCA	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg20607798	chr8:58055168	NA	0.48	8.31	0.31	5.67e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4711336	1.000	rs2296742	chr6:33659793	G/A	cg14003231	chr6:33640908	ITPR3	0.32	7.87	0.3	1.51e-14	Height;
BRCA	cis	rs7512552	0.698	rs12028001	chr1:150407820	C/T	cg15654264	chr1:150340011	RPRD2	0.37	8.21	0.31	1.24e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg23018236	chr17:30244563	NA	-0.48	-9.06	-0.34	1.52e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs600231	0.542	rs11227198	chr11:65237974	G/A	cg01292856	chr11:65242576	NA	0.66	14.93	0.51	1.76e-43	Bone mineral density;
BRCA	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-9.73	-0.36	6.09e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	ch.11.42038R	chr11:967971	AP2A2	0.49	15.39	0.52	1.13e-45	Alzheimer's disease (late onset);
BRCA	cis	rs9547692	1.000	rs493248	chr13:37473386	C/T	cg01493522	chr13:37497338	NA	-0.45	-9.72	-0.36	6.54e-21	Coronary artery disease;
BRCA	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg22907277	chr7:1156413	C7orf50	0.52	11.23	0.41	8.09e-27	Longevity;Endometriosis;
BRCA	cis	rs4363385	0.747	rs4255332	chr1:152958745	G/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.31	-0.31	5.84e-16	Inflammatory skin disease;
BRCA	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10802521	chr3:52805072	NEK4	-0.36	-9.84	-0.36	2.29e-21	Bipolar disorder;
BRCA	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg22535103	chr8:58192502	C8orf71	-0.47	-8.3	-0.31	5.99e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg17366294	chr4:99064904	C4orf37	0.42	9.58	0.35	2.14e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg11952622	chr19:58962976	ZNF324B	0.5	10.44	0.38	1.16e-23	Uric acid clearance;
BRCA	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg08917208	chr2:24149416	ATAD2B	1.08	15.0	0.51	8.89e-44	Lymphocyte counts;
BRCA	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	15.04	0.51	5.67e-44	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9790314	0.663	rs5004752	chr3:160748380	A/T	cg03342759	chr3:160939853	NMD3	-0.46	-8.7	-0.33	2.86e-17	Morning vs. evening chronotype;
BRCA	cis	rs507080	0.845	rs509641	chr11:118558952	T/C	cg08498647	chr11:118550644	TREH	-0.38	-8.26	-0.31	8.53e-16	Serum metabolite levels;
BRCA	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.84	-0.33	9.56e-18	Total body bone mineral density;
BRCA	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg08859206	chr1:53392774	SCP2	0.45	10.09	0.37	2.5e-22	Monocyte count;
BRCA	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg11941060	chr3:133502564	NA	0.46	11.26	0.41	6.01e-27	Iron status biomarkers;
BRCA	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg21475434	chr5:93447410	FAM172A	0.66	8.48	0.32	1.51e-16	Diabetic retinopathy;
BRCA	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg08885076	chr2:99613938	TSGA10	-0.51	-9.98	-0.37	6.95e-22	Chronic sinus infection;
BRCA	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.91	0.4	1.63e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2421770	0.530	rs7930134	chr11:35367017	A/C	cg13971030	chr11:35366721	SLC1A2	-0.45	-10.12	-0.37	1.9e-22	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg19743168	chr1:23544995	NA	0.35	8.15	0.31	1.89e-15	Height;
BRCA	cis	rs6138458	0.816	rs2151463	chr20:24911819	A/C	cg26195577	chr20:24973756	C20orf3	0.98	24.72	0.7	3.46e-95	Blood protein levels;
BRCA	trans	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.48	-10.46	-0.38	9.94e-24	Mean corpuscular volume;
BRCA	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg03213289	chr20:61660250	NA	0.61	16.28	0.54	4.14e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.55	0.55	1.84e-51	Hypertriglyceridemia;
BRCA	cis	rs9649465	0.967	rs13230230	chr7:123329603	G/A	cg04330084	chr7:123175371	IQUB	-0.3	-8.38	-0.31	3.26e-16	Migraine;
BRCA	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg22974920	chr21:40686053	BRWD1	-0.39	-8.76	-0.33	1.73e-17	Cognitive function;
BRCA	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.67	0.61	1.05e-67	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg19418458	chr7:158789849	NA	0.43	9.67	0.36	9.4e-21	Facial morphology (factor 20);
BRCA	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.04	0.4	4.78e-26	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	17.47	0.57	3.6e-56	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs877282	0.891	rs11253406	chr10:796297	G/A	cg17470449	chr10:769945	NA	0.51	8.71	0.33	2.54e-17	Uric acid levels;
BRCA	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg02951883	chr7:2050386	MAD1L1	-0.35	-8.04	-0.3	4.43e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg09367891	chr1:107599246	PRMT6	-0.43	-8.39	-0.32	3.01e-16	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.49	0.32	1.48e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg05793240	chr7:2802953	GNA12	-0.31	-7.87	-0.3	1.56e-14	Height;
BRCA	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg13736514	chr6:26305472	NA	-0.33	-11.43	-0.41	1.2e-27	Educational attainment;
BRCA	trans	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-7.84	-0.3	1.91e-14	Corneal astigmatism;
BRCA	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	11.14	0.4	1.78e-26	Schizophrenia;
BRCA	cis	rs8014204	0.816	rs10144023	chr14:75291531	T/C	cg06637938	chr14:75390232	RPS6KL1	0.43	9.0	0.34	2.55e-18	Caffeine consumption;
BRCA	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg26384229	chr12:38710491	ALG10B	0.56	11.61	0.42	2.05e-28	Morning vs. evening chronotype;
BRCA	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-10.74	-0.39	7.54e-25	IgG glycosylation;
BRCA	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg03146154	chr1:46216737	IPP	0.53	11.64	0.42	1.6e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4363385	0.818	rs10788856	chr1:153011517	G/C	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.38	-7.96	-0.3	7.82e-15	Educational attainment;
BRCA	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg17143192	chr8:8559678	CLDN23	0.53	10.29	0.38	4.47e-23	Obesity-related traits;
BRCA	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg20307385	chr11:47447363	PSMC3	-0.43	-9.11	-0.34	1.08e-18	Subjective well-being;
BRCA	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg11764359	chr7:65958608	NA	-0.68	-15.38	-0.52	1.14e-45	Aortic root size;
BRCA	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg00814883	chr7:100076585	TSC22D4	-0.49	-10.38	-0.38	2e-23	Platelet count;
BRCA	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg10802521	chr3:52805072	NEK4	-0.31	-7.86	-0.3	1.63e-14	Bipolar disorder;
BRCA	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg01256987	chr12:42539512	GXYLT1	-0.57	-11.69	-0.42	9.68e-29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg27170947	chr2:26402098	FAM59B	-0.92	-16.52	-0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg05347473	chr6:146136440	FBXO30	0.43	8.54	0.32	9.64e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08219700	chr8:58056026	NA	0.44	8.0	0.3	5.74e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12579753	0.917	rs10778834	chr12:82199742	A/C	cg07988820	chr12:82153109	PPFIA2	-0.47	-8.33	-0.31	5.03e-16	Resting heart rate;
BRCA	trans	rs12517041	1.000	rs10054768	chr5:23278161	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.45	-8.11	-0.31	2.68e-15	Calcium levels;
BRCA	cis	rs17641971	0.708	rs974781	chr8:49931055	T/A	cg00325661	chr8:49890786	NA	0.35	9.59	0.35	1.98e-20	Blood metabolite levels;
BRCA	cis	rs838147	0.844	rs12975033	chr19:49249443	A/T	cg03531100	chr19:49260119	FGF21;FUT1	-0.36	-7.92	-0.3	1.04e-14	Dietary macronutrient intake;
BRCA	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg06618935	chr21:46677482	NA	-0.37	-8.38	-0.31	3.39e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.74	-0.36	5.3e-21	IgG glycosylation;
BRCA	cis	rs1971762	0.523	rs3852562	chr12:54085750	T/C	cg23533419	chr12:54090519	NA	-0.33	-8.39	-0.32	3.07e-16	Height;
BRCA	cis	rs7944584	0.837	rs11039149	chr11:47276675	A/G	cg03711944	chr11:47377212	SPI1	-0.41	-8.69	-0.32	3.12e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	trans	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg06521331	chr12:34319734	NA	-0.54	-10.21	-0.37	8.63e-23	Bladder cancer;
BRCA	cis	rs4845570	1.000	rs6683364	chr1:151746202	T/A	cg07092448	chr1:151763213	TDRKH	-0.86	-16.92	-0.56	2.44e-53	Coronary artery disease;
BRCA	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg21573476	chr21:45109991	RRP1B	-0.32	-8.12	-0.31	2.48e-15	Mean corpuscular volume;
BRCA	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg18301423	chr5:131593218	PDLIM4	0.31	7.98	0.3	6.78e-15	Breast cancer;
BRCA	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-14.14	-0.49	1.04e-39	Morning vs. evening chronotype;
BRCA	cis	rs701145	0.556	rs355762	chr3:154012614	G/A	cg16511985	chr3:153974050	SGEF	0.43	9.82	0.36	2.61e-21	Coronary artery disease;
BRCA	trans	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg25214090	chr10:38739885	LOC399744	-0.52	-11.51	-0.41	5.19e-28	Corneal astigmatism;
BRCA	cis	rs7246657	0.722	rs10417576	chr19:38119212	A/C	cg23950597	chr19:37808831	NA	-0.49	-8.51	-0.32	1.28e-16	Coronary artery calcification;
BRCA	cis	rs3784262	0.565	rs2642630	chr15:58316960	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.34	-8.96	-0.33	3.62e-18	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg10382835	chr6:42185730	MRPS10	0.53	8.89	0.33	6.39e-18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
BRCA	cis	rs9283706	0.608	rs13171572	chr5:66334552	T/A	cg11590213	chr5:66331682	MAST4	0.38	7.98	0.3	6.69e-15	Coronary artery disease;
BRCA	cis	rs35740288	0.580	rs34635893	chr15:86340248	C/T	cg20737812	chr15:86336631	KLHL25	-0.39	-9.45	-0.35	6.3e-20	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11764359	chr7:65958608	NA	-0.79	-18.7	-0.59	1.41e-62	Aortic root size;
BRCA	cis	rs11608355	0.545	rs55902232	chr12:109902305	G/A	cg05360138	chr12:110035743	NA	0.71	13.03	0.46	1.38e-34	Neuroticism;
BRCA	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-9.66	-0.36	1.03e-20	Mean corpuscular volume;
BRCA	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-11.18	-0.4	1.24e-26	Colorectal cancer;
BRCA	cis	rs919433	0.680	rs699319	chr2:198281776	C/A	cg00792783	chr2:198669748	PLCL1	0.38	8.57	0.32	7.95e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs9290065	0.538	rs898682	chr3:160773133	G/C	cg03342759	chr3:160939853	NMD3	-0.52	-10.27	-0.38	5.24e-23	Kawasaki disease;
BRCA	cis	rs700651	0.789	rs1976772	chr2:198868201	G/T	cg00792783	chr2:198669748	PLCL1	0.43	9.44	0.35	6.76e-20	Intracranial aneurysm;
BRCA	cis	rs11112613	0.713	rs11112591	chr12:105951620	C/T	cg03607813	chr12:105948248	NA	0.55	10.38	0.38	1.91e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg24829409	chr8:58192753	C8orf71	-0.48	-8.0	-0.3	6e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg21770322	chr7:97807741	LMTK2	0.42	11.31	0.41	3.74e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs758324	0.947	rs56081930	chr5:131235274	T/G	cg06307176	chr5:131281290	NA	-0.57	-11.98	-0.43	5.62e-30	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs11955398	0.606	rs56137970	chr5:59873462	C/T	cg02684056	chr5:59996105	DEPDC1B	0.35	8.25	0.31	9.29e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg00383909	chr3:49044727	WDR6	0.71	12.7	0.45	4.18e-33	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg22713356	chr15:30763199	NA	1.25	20.77	0.63	1.25e-73	Uric acid levels;
BRCA	cis	rs7095944	0.584	rs4962693	chr10:126424835	C/T	cg08799069	chr10:126477246	METTL10	-0.38	-8.85	-0.33	8.32e-18	Asthma;
BRCA	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg17366294	chr4:99064904	C4orf37	0.45	10.76	0.39	6.07e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11764359	chr7:65958608	NA	-0.76	-17.43	-0.57	5.6e-56	Aortic root size;
BRCA	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg09307838	chr4:120376055	NA	0.62	12.99	0.46	2.07e-34	Corneal astigmatism;
BRCA	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg25036284	chr2:26402008	FAM59B	-0.88	-15.25	-0.52	5.02e-45	Gut microbiome composition (summer);
BRCA	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg20469991	chr17:27169893	C17orf63	-0.45	-8.8	-0.33	1.32e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs965469	1.000	rs1040727	chr20:3264292	G/A	cg25506879	chr20:3388711	C20orf194	-0.52	-9.51	-0.35	3.7e-20	IFN-related cytopenia;
BRCA	cis	rs1558643	0.527	rs1861283	chr2:102728716	A/G	cg22835712	chr2:102737379	NA	-0.37	-7.89	-0.3	1.31e-14	Fibrinogen levels;
BRCA	trans	rs4714291	0.792	rs9471241	chr6:40080211	C/T	cg02267698	chr19:7991119	CTXN1	-0.45	-9.3	-0.35	2.11e-19	Strep throat;
BRCA	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11890956	chr21:40555474	PSMG1	0.66	15.41	0.52	8.23e-46	Cognitive function;
BRCA	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg02951883	chr7:2050386	MAD1L1	-0.37	-8.86	-0.33	7.75e-18	Schizophrenia;
BRCA	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg14004847	chr7:1930337	MAD1L1	-0.4	-7.89	-0.3	1.3e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg21395723	chr22:39101663	GTPBP1	-0.36	-8.19	-0.31	1.43e-15	Menopause (age at onset);
BRCA	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11764359	chr7:65958608	NA	0.74	16.63	0.55	7.55e-52	Aortic root size;
BRCA	cis	rs312274	0.630	rs1822599	chr12:41231299	T/C	cg17827154	chr12:41323612	CNTN1	0.39	9.82	0.36	2.72e-21	Metabolite levels  (X-11787);
BRCA	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg05283184	chr6:79620031	NA	-0.45	-11.42	-0.41	1.26e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg12826209	chr6:26865740	GUSBL1	0.73	7.8	0.3	2.44e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2797160	1.000	rs1739357	chr6:126019655	T/G	cg05901451	chr6:126070800	HEY2	0.42	10.25	0.38	6.55e-23	Endometrial cancer;
BRCA	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg26384229	chr12:38710491	ALG10B	0.55	11.69	0.42	9.17e-29	Morning vs. evening chronotype;
BRCA	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg00677455	chr12:58241039	CTDSP2	0.63	14.45	0.5	3.74e-41	Multiple sclerosis;
BRCA	cis	rs4690686	0.500	rs4690688	chr4:177264192	G/C	cg17059388	chr4:177262070	NA	0.51	10.68	0.39	1.34e-24	Essential tremor;
BRCA	cis	rs7903847	0.642	rs11817875	chr10:99158414	G/A	cg20016023	chr10:99160130	RRP12	-0.26	-8.41	-0.32	2.58e-16	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21659725	chr3:3221576	CRBN	0.71	21.66	0.65	1.89e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg10556349	chr10:835070	NA	0.63	9.21	0.34	4.66e-19	Eosinophil percentage of granulocytes;
BRCA	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.72	11.14	0.4	1.79e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg25214090	chr10:38739885	LOC399744	0.44	10.29	0.38	4.34e-23	Corneal astigmatism;
BRCA	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	21.11	0.64	1.86e-75	Platelet count;
BRCA	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.81	12.37	0.44	1.14e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs9944715	0.954	rs8098751	chr18:43850587	G/A	cg01718231	chr17:29326311	RNF135	-0.43	-8.63	-0.32	4.74e-17	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg19920283	chr7:105172520	RINT1	0.58	9.39	0.35	1.07e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	cg01483505	chr11:975446	AP2A2	0.3	8.18	0.31	1.56e-15	Alzheimer's disease (late onset);
BRCA	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg13319975	chr6:146136371	FBXO30	-0.44	-10.1	-0.37	2.4e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6484504	0.600	rs972714	chr11:31358875	T/G	cg26647111	chr11:31128758	NA	0.45	9.64	0.36	1.25e-20	Red blood cell count;
BRCA	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg12310025	chr6:25882481	NA	-0.37	-8.67	-0.32	3.5e-17	Height;
BRCA	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg20307385	chr11:47447363	PSMC3	0.82	20.84	0.64	5.25e-74	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg18252515	chr7:66147081	NA	-0.91	-13.01	-0.46	1.64e-34	Diabetic kidney disease;
BRCA	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg01304814	chr3:48885189	PRKAR2A	0.56	7.84	0.3	1.89e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04565464	chr8:145669602	NFKBIL2	0.39	9.02	0.34	2.23e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg03146154	chr1:46216737	IPP	0.52	11.61	0.42	2.03e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg03146154	chr1:46216737	IPP	0.45	10.2	0.37	9.86e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg04025307	chr7:1156635	C7orf50	0.59	9.36	0.35	1.38e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.45	0.55	5.92e-51	Colorectal cancer;
BRCA	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.56	10.74	0.39	7.62e-25	Height;
BRCA	cis	rs1832871	0.672	rs9457363	chr6:158777515	C/T	cg07165851	chr6:158734300	TULP4	0.63	12.97	0.46	2.46e-34	Height;
BRCA	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03188948	chr7:1209495	NA	0.68	14.5	0.5	2.22e-41	Longevity;Endometriosis;
BRCA	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg05535760	chr7:792225	HEATR2	0.72	13.37	0.47	4.09e-36	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg18132916	chr6:79620363	NA	-0.4	-8.09	-0.3	2.92e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg24848339	chr3:12840334	CAND2	0.43	11.4	0.41	1.62e-27	QRS complex (12-leadsum);
BRCA	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg21918786	chr6:109611834	NA	-0.49	-14.34	-0.49	1.27e-40	Reticulocyte fraction of red cells;
BRCA	cis	rs11971779	0.680	rs7783619	chr7:139061437	G/A	cg07862535	chr7:139043722	LUC7L2	0.37	9.94	0.37	9.2e-22	Diisocyanate-induced asthma;
BRCA	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	11.78	0.42	3.81e-29	Coronary artery disease;
BRCA	cis	rs2070997	0.667	rs10901291	chr9:133717881	C/T	cg11464064	chr9:133710261	ABL1	0.53	9.6	0.35	1.81e-20	Response to amphetamines;
BRCA	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg17420585	chr12:42539391	GXYLT1	-0.38	-8.1	-0.31	2.77e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg04450456	chr4:17643702	FAM184B	0.37	10.78	0.39	5.4e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs629535	0.814	rs62513376	chr8:70086881	C/T	cg21567404	chr3:27674614	NA	-1.01	-21.11	-0.64	1.93e-75	Dupuytren's disease;
BRCA	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg05234568	chr11:5960015	NA	-0.49	-9.9	-0.36	1.37e-21	DNA methylation (variation);
BRCA	cis	rs829883	0.659	rs11109520	chr12:98928646	C/T	cg25150519	chr12:98850993	NA	0.5	9.15	0.34	7.65e-19	Colorectal adenoma (advanced);
BRCA	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.87	-28.25	-0.75	1.44e-114	Chronic sinus infection;
BRCA	cis	rs7617773	0.780	rs11714176	chr3:48360862	C/T	cg11946769	chr3:48343235	NME6	0.7	14.13	0.49	1.21e-39	Coronary artery disease;
BRCA	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg11766577	chr21:47581405	C21orf56	-0.5	-10.8	-0.39	4.3e-25	Testicular germ cell tumor;
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg26608667	chr7:1196370	ZFAND2A	0.37	8.21	0.31	1.21e-15	Longevity;Endometriosis;
BRCA	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg10932868	chr11:921992	NA	0.5	12.89	0.45	5.66e-34	Alzheimer's disease (late onset);
BRCA	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg11707556	chr5:10655725	ANKRD33B	0.4	9.63	0.36	1.32e-20	Coronary artery disease;
BRCA	cis	rs9810890	1.000	rs114261227	chr3:128469760	A/C	cg15033153	chr3:128514015	RAB7A	0.7	8.08	0.3	3.34e-15	Dental caries;
BRCA	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg04362960	chr10:104952993	NT5C2	0.41	9.78	0.36	3.87e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-14.18	-0.49	7.24e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs700651	0.789	rs62277902	chr2:198879443	T/A	cg00792783	chr2:198669748	PLCL1	-0.44	-9.4	-0.35	9.6e-20	Intracranial aneurysm;
BRCA	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg17691542	chr6:26056736	HIST1H1C	0.48	9.61	0.36	1.67e-20	Iron status biomarkers;
BRCA	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	9.27	0.34	2.86e-19	Height;
BRCA	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg14675211	chr2:100938903	LONRF2	0.47	10.81	0.39	3.94e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs2806561	0.704	rs6426779	chr1:23310485	T/C	cg19743168	chr1:23544995	NA	-0.41	-9.78	-0.36	3.87e-21	Height;
BRCA	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg15017067	chr4:17643749	FAM184B	-0.27	-7.98	-0.3	6.66e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs4074536	0.574	rs10801968	chr1:116287055	C/T	cg21648376	chr1:116311395	CASQ2	-0.48	-8.43	-0.32	2.24e-16	QRS duration;
BRCA	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.41	0.35	8.87e-20	Morning vs. evening chronotype;
BRCA	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg16102102	chr5:83017553	HAPLN1	-0.7	-15.6	-0.53	9.66e-47	Prostate cancer;
BRCA	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg01689657	chr7:91764605	CYP51A1	0.21	7.85	0.3	1.74e-14	Breast cancer;
BRCA	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.16	0.31	1.74e-15	Aortic root size;
BRCA	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg00677455	chr12:58241039	CTDSP2	0.56	12.8	0.45	1.56e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg23711669	chr6:146136114	FBXO30	-0.62	-14.17	-0.49	7.89e-40	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg01874867	chr7:94954059	PON1	-0.4	-8.17	-0.31	1.6e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg22705602	chr4:152727874	NA	-0.32	-8.3	-0.31	6.2e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg12379764	chr21:47803548	PCNT	-0.37	-7.84	-0.3	1.84e-14	Testicular germ cell tumor;
BRCA	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg09654669	chr8:57350985	NA	-0.39	-8.4	-0.32	2.82e-16	Obesity-related traits;
BRCA	cis	rs2882667	0.824	rs11748097	chr5:138479887	C/A	cg04439458	chr5:138467593	SIL1	-0.44	-11.11	-0.4	2.38e-26	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs758324	0.947	rs10054618	chr5:131195002	C/T	cg06307176	chr5:131281290	NA	0.54	10.46	0.38	9.95e-24	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg22875332	chr1:76189707	ACADM	0.79	18.77	0.6	6.1e-63	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg06698575	chr12:117470875	NA	0.45	7.99	0.3	6.34e-15	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg05868516	chr6:26286170	HIST1H4H	0.5	11.25	0.41	6.6e-27	Educational attainment;
BRCA	cis	rs13315871	0.929	rs13075746	chr3:58293867	G/A	cg20936604	chr3:58311152	NA	-0.66	-8.47	-0.32	1.65e-16	Cholesterol, total;
BRCA	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg00105475	chr2:10696890	NA	0.45	10.36	0.38	2.42e-23	Prostate cancer;
BRCA	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16405210	chr4:1374714	KIAA1530	-0.51	-11.97	-0.43	5.95e-30	Longevity;
BRCA	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18876405	chr7:65276391	NA	0.71	18.64	0.59	3.12e-62	Aortic root size;
BRCA	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	29.81	0.76	4.96e-123	Chronic sinus infection;
BRCA	cis	rs9790314	0.663	rs796609	chr3:160705600	C/G	cg03342759	chr3:160939853	NMD3	-0.46	-8.83	-0.33	1.02e-17	Morning vs. evening chronotype;
BRCA	cis	rs9649465	1.000	rs13224762	chr7:123370710	A/G	cg04330084	chr7:123175371	IQUB	-0.33	-8.98	-0.33	2.94e-18	Migraine;
BRCA	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg11663144	chr21:46675770	NA	-0.59	-13.83	-0.48	3.07e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg02996355	chr14:81879375	NA	0.53	10.57	0.39	3.58e-24	Night sleep phenotypes;
BRCA	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg16414030	chr3:133502952	NA	0.44	10.65	0.39	1.77e-24	Iron status biomarkers;
BRCA	cis	rs10788264	0.569	rs10749454	chr10:124029654	C/T	cg09507567	chr10:124027408	NA	0.41	8.94	0.33	4.15e-18	Total body bone mineral density;
BRCA	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00149659	chr3:10157352	C3orf10	1.06	17.88	0.58	2.77e-58	Alzheimer's disease;
BRCA	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg26384229	chr12:38710491	ALG10B	0.58	13.2	0.46	2.25e-35	Morning vs. evening chronotype;
BRCA	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg19920283	chr7:105172520	RINT1	-0.58	-9.82	-0.36	2.83e-21	Bipolar disorder (body mass index interaction);
BRCA	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg08645402	chr16:4508243	NA	0.43	10.04	0.37	4.09e-22	Schizophrenia;
BRCA	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg00898013	chr13:113819073	PROZ	-0.36	-8.64	-0.32	4.44e-17	Platelet distribution width;
BRCA	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.27e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07930192	chr7:1003750	NA	0.41	8.81	0.33	1.18e-17	Longevity;Endometriosis;
BRCA	cis	rs6087990	0.769	rs17123658	chr20:31390840	C/A	cg13636640	chr20:31349939	DNMT3B	0.62	18.59	0.59	5.53e-62	Ulcerative colitis;
BRCA	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24110177	chr3:50126178	RBM5	-0.4	-10.86	-0.39	2.6e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg23711669	chr6:146136114	FBXO30	0.79	18.95	0.6	6.68e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg16586182	chr3:47516702	SCAP	0.65	14.86	0.51	4.2e-43	Colorectal cancer;
BRCA	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.23	0.31	1.07e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg21399703	chr1:247681439	NA	0.42	9.37	0.35	1.22e-19	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.08	-0.3	3.26e-15	Total body bone mineral density;
BRCA	trans	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg25214090	chr10:38739885	LOC399744	0.52	12.14	0.43	1.21e-30	Corneal astigmatism;
BRCA	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.42	0.5	5.06e-41	Personality dimensions;
BRCA	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14240646	chr10:27532245	ACBD5	0.56	9.46	0.35	5.99e-20	Breast cancer;
BRCA	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg12310025	chr6:25882481	NA	-0.5	-11.19	-0.4	1.16e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg14820908	chr5:178986412	RUFY1	-0.45	-11.91	-0.43	1.07e-29	Lung cancer;
BRCA	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg19052272	chr2:3704530	ALLC	-0.32	-7.88	-0.3	1.45e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg16586182	chr3:47516702	SCAP	0.65	15.17	0.51	1.34e-44	Colorectal cancer;
BRCA	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.33	0.31	4.94e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg22903471	chr2:27725779	GCKR	-0.39	-9.44	-0.35	6.93e-20	Total body bone mineral density;
BRCA	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.38	-9.55	-0.35	2.75e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6450176	0.951	rs5013866	chr5:53300947	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.62	-15.07	-0.51	3.71e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg20573242	chr4:122745356	CCNA2	0.49	10.86	0.39	2.41e-25	Type 2 diabetes;
BRCA	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg23711669	chr6:146136114	FBXO30	0.76	17.88	0.58	2.71e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25427524	chr10:38739819	LOC399744	-0.73	-17.48	-0.57	3.1e-56	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg06784218	chr1:46089804	CCDC17	0.44	10.61	0.39	2.5300000000000002e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14169450	chr9:139327907	INPP5E	-0.46	-11.07	-0.4	3.65e-26	Monocyte percentage of white cells;
BRCA	cis	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg07460842	chr6:66804631	NA	-0.95	-17.73	-0.57	1.73e-57	Exhaled nitric oxide output;
BRCA	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	16.62	0.55	7.62e-52	Bone mineral density;
BRCA	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg25251562	chr2:3704773	ALLC	0.42	8.34	0.31	4.45e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg12165864	chr7:66369176	NA	-0.46	-10.44	-0.38	1.13e-23	Corneal structure;
BRCA	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg05896524	chr21:47604654	C21orf56	0.44	8.91	0.33	5.08e-18	Testicular germ cell tumor;
BRCA	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg05283184	chr6:79620031	NA	-0.42	-10.83	-0.39	3.4e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs12618769	0.597	rs3769730	chr2:99101453	T/C	cg10123293	chr2:99228465	UNC50	0.42	8.18	0.31	1.53e-15	Bipolar disorder;
BRCA	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg21138405	chr5:131827807	IRF1	-0.4	-13.19	-0.46	2.66e-35	Asthma (sex interaction);
BRCA	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg26384229	chr12:38710491	ALG10B	0.82	21.71	0.65	1.09e-78	Heart rate;
BRCA	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg00012203	chr2:219082015	ARPC2	-0.49	-9.44	-0.35	6.57e-20	Colorectal cancer;
BRCA	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08564027	chr20:61660810	NA	0.85	22.97	0.67	1.42e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs16958440	0.867	rs12386092	chr18:44672058	C/T	cg17192377	chr18:44677553	HDHD2	0.99	13.87	0.48	1.94e-38	Sitting height ratio;
BRCA	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	ch.11.42038R	chr11:967971	AP2A2	0.56	17.82	0.58	5.73e-58	Alzheimer's disease (late onset);
BRCA	cis	rs6060717	0.536	rs6060683	chr20:34507921	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.12	-0.31	2.41e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs4891159	0.548	rs660342	chr18:74130896	C/G	cg24786174	chr18:74118243	ZNF516	0.83	25.27	0.71	3.13e-98	Longevity;
BRCA	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg15556689	chr8:8085844	FLJ10661	0.46	13.24	0.46	1.58e-35	Mood instability;
BRCA	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg21724239	chr8:58056113	NA	0.59	9.59	0.35	1.92e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26314531	chr2:26401878	FAM59B	0.82	11.83	0.42	2.55e-29	Gut microbiome composition (summer);
BRCA	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg16586182	chr3:47516702	SCAP	0.65	15.21	0.52	8.39e-45	Colorectal cancer;
BRCA	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18876405	chr7:65276391	NA	0.53	12.29	0.44	2.69e-31	Aortic root size;
BRCA	cis	rs9283706	0.689	rs6889240	chr5:66320940	A/G	cg11590213	chr5:66331682	MAST4	0.43	8.19	0.31	1.4e-15	Coronary artery disease;
BRCA	cis	rs9470366	0.883	rs7756236	chr6:36627053	A/G	cg08179530	chr6:36648295	CDKN1A	0.49	9.7	0.36	7.77e-21	QRS duration;
BRCA	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg00750074	chr16:89608354	SPG7	-0.39	-10.31	-0.38	3.81e-23	Multiple myeloma (IgH translocation);
BRCA	cis	rs11051970	0.877	rs2651360	chr12:32588920	C/T	cg24626660	chr12:32551988	NA	0.29	8.22	0.31	1.14e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	trans	rs10242455	0.702	rs55927283	chr7:99057191	G/C	cg09045935	chr12:6379348	NA	0.89	9.35	0.35	1.43e-19	Blood metabolite levels;
BRCA	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg23029597	chr12:123009494	RSRC2	0.53	10.92	0.4	1.5e-25	Body mass index;
BRCA	cis	rs11622475	1.000	rs8021692	chr14:104428576	C/G	cg12183467	chr14:104352244	NA	-0.46	-9.24	-0.34	3.5e-19	Bipolar disorder;
BRCA	cis	rs7246657	0.722	rs13744	chr19:38077912	C/T	cg18154014	chr19:37997991	ZNF793	0.48	9.16	0.34	7.24e-19	Coronary artery calcification;
BRCA	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg21143896	chr7:2802374	GNA12	-0.35	-8.61	-0.32	5.65e-17	Height;
BRCA	cis	rs13082711	0.522	rs574955	chr3:27351000	T/C	cg02860705	chr3:27208620	NA	0.43	8.84	0.33	8.89e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs4363385	0.818	rs2711	chr1:153005156	C/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.26	-0.34	3.19e-19	Inflammatory skin disease;
BRCA	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	30.18	0.77	5e-125	Chronic sinus infection;
BRCA	trans	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg21775007	chr8:11205619	TDH	0.4	8.52	0.32	1.15e-16	Mood instability;
BRCA	cis	rs4865169	0.783	rs7668814	chr4:57825190	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.41	-8.57	-0.32	7.88e-17	Breast cancer;
BRCA	cis	rs897080	0.515	rs1067343	chr2:44621042	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	10.43	0.38	1.2e-23	Height;
BRCA	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg11645453	chr3:52864694	ITIH4	0.38	10.08	0.37	2.83e-22	Body mass index;
BRCA	cis	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg05901451	chr6:126070800	HEY2	0.39	9.52	0.35	3.54e-20	Endometrial cancer;
BRCA	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg09307838	chr4:120376055	NA	0.6	11.15	0.4	1.65e-26	Corneal astigmatism;
BRCA	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg11843238	chr5:131593191	PDLIM4	0.34	8.98	0.33	3.01e-18	Breast cancer;
BRCA	cis	rs11955398	0.563	rs1816864	chr5:60011273	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.37	-9.04	-0.34	1.9e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs16867321	0.950	rs4667228	chr2:181498824	T/A	cg23363182	chr2:181467187	NA	-0.44	-8.32	-0.31	5.39e-16	Obesity;
BRCA	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg05340658	chr4:99064831	C4orf37	0.63	15.05	0.51	5.01e-44	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg01620082	chr3:125678407	NA	-0.86	-10.28	-0.38	4.77e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg10523679	chr1:76189770	ACADM	-0.77	-15.65	-0.53	5.97e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg25214090	chr10:38739885	LOC399744	0.48	10.62	0.39	2.18e-24	Corneal astigmatism;
BRCA	cis	rs3772130	0.962	rs6784571	chr3:121539991	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.91	0.4	1.52e-25	Cognitive performance;
BRCA	cis	rs2625529	0.824	rs12916951	chr15:72252498	C/T	cg16672083	chr15:72433130	SENP8	-0.79	-17.0	-0.56	9.9e-54	Red blood cell count;
BRCA	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.41	8.32	0.31	5.44e-16	Tonsillectomy;
BRCA	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg08392591	chr16:89556376	ANKRD11	0.37	8.85	0.33	8.58e-18	Multiple myeloma (IgH translocation);
BRCA	cis	rs939658	0.967	rs7172074	chr15:79452726	T/C	cg17916960	chr15:79447300	NA	0.39	9.82	0.36	2.73e-21	Refractive error;
BRCA	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg24531977	chr5:56204891	C5orf35	-0.47	-9.64	-0.36	1.27e-20	Coronary artery disease;
BRCA	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg17971929	chr21:40555470	PSMG1	0.82	19.79	0.62	2.45e-68	Cognitive function;
BRCA	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.44	-0.32	2.09e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4302748	0.818	rs11771125	chr7:36190426	C/T	cg24442661	chr7:36192818	EEPD1	0.51	9.24	0.34	3.65e-19	Platelet count;
BRCA	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg03146154	chr1:46216737	IPP	0.53	11.73	0.42	6.59e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2046867	0.661	rs9861834	chr3:72909272	C/T	cg25664220	chr3:72788482	NA	-0.44	-10.34	-0.38	2.77e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.0	-22.82	-0.67	9.01e-85	Lymphocyte percentage of white cells;
BRCA	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg24296786	chr1:45957014	TESK2	0.46	10.77	0.39	5.78e-25	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1941023	0.503	rs4528348	chr11:60129505	C/G	cg08716584	chr11:60157161	MS4A7	-0.42	-9.83	-0.36	2.58e-21	Congenital heart disease (maternal effect);
BRCA	trans	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.38	-9.56	-0.35	2.57e-20	Obesity-related traits;
BRCA	cis	rs2463822	1.000	rs2513747	chr11:62098735	T/C	cg06239285	chr11:62104954	ASRGL1	0.67	11.13	0.4	1.92e-26	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg23711669	chr6:146136114	FBXO30	-0.77	-16.23	-0.54	7.49e-50	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-8.43	-0.32	2.28e-16	Longevity;Endometriosis;
BRCA	cis	rs7927771	0.507	rs12366244	chr11:47882130	C/A	cg20307385	chr11:47447363	PSMC3	0.42	9.46	0.35	5.68e-20	Subjective well-being;
BRCA	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.66	0.36	1.08e-20	Morning vs. evening chronotype;
BRCA	cis	rs2249625	0.844	rs2496515	chr6:72905741	C/T	cg18830697	chr6:72922368	RIMS1	0.4	8.51	0.32	1.2e-16	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06022373	chr22:39101656	GTPBP1	0.71	16.3	0.54	3.39e-50	Menopause (age at onset);
BRCA	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-9.09	-0.34	1.23e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.3	-0.31	6.03e-16	Colorectal cancer;
BRCA	cis	rs36051895	0.664	rs17425637	chr9:5110000	C/T	cg02405213	chr9:5042618	JAK2	-0.49	-9.12	-0.34	1e-18	Pediatric autoimmune diseases;
BRCA	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg25358565	chr5:93447407	FAM172A	1.23	18.9	0.6	1.26e-63	Diabetic retinopathy;
BRCA	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg01262667	chr19:19385393	TM6SF2	0.4	10.33	0.38	3.12e-23	Tonsillectomy;
BRCA	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg23711669	chr6:146136114	FBXO30	-0.78	-18.65	-0.59	2.56e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.86	-0.36	1.91e-21	Bladder cancer;
BRCA	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg19773385	chr1:10388646	KIF1B	-0.38	-8.14	-0.31	2.12e-15	Hepatocellular carcinoma;
BRCA	cis	rs3784262	0.528	rs6493979	chr15:58338052	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-9.42	-0.35	7.79e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs11030122	0.702	rs1452047	chr11:3991648	A/C	cg18678763	chr11:4115507	RRM1	-0.36	-8.06	-0.3	3.85e-15	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs2249625	1.000	rs2249625	chr6:72906753	C/T	cg18830697	chr6:72922368	RIMS1	0.41	8.81	0.33	1.21e-17	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs9868809	0.881	rs34368826	chr3:48670827	G/T	cg00383909	chr3:49044727	WDR6	0.55	8.38	0.31	3.29e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg09184832	chr6:79620586	NA	0.48	10.95	0.4	1.13e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs1904096	0.506	rs10024642	chr4:95179295	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-8.21	-0.31	1.25e-15	Type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.55	0.39	4.28e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg14791747	chr16:20752902	THUMPD1	0.45	14.23	0.49	4.17e-40	Cognitive test performance;
BRCA	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg11584989	chr19:19387371	SF4	0.67	14.73	0.5	1.78e-42	Bipolar disorder;
BRCA	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg24642844	chr7:1081250	C7orf50	-0.88	-16.14	-0.54	2.03e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg25517755	chr10:38738941	LOC399744	-0.37	-7.88	-0.3	1.45e-14	Corneal astigmatism;
BRCA	cis	rs7677751	0.806	rs7679903	chr4:55097373	T/C	cg17187183	chr4:55093834	PDGFRA	0.44	9.06	0.34	1.53e-18	Corneal astigmatism;
BRCA	cis	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg21775007	chr8:11205619	TDH	-0.45	-8.78	-0.33	1.51e-17	Retinal vascular caliber;
BRCA	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg08477640	chr19:41863820	B9D2	-0.39	-8.09	-0.3	3.02e-15	Migraine;Coronary artery disease;
BRCA	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg27446573	chr6:127587934	RNF146	0.69	15.88	0.53	4e-48	Breast cancer;
BRCA	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.79	19.13	0.6	7.56e-65	Multiple sclerosis;
BRCA	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg00383909	chr3:49044727	WDR6	0.73	12.61	0.45	1.01e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs6901250	0.851	rs339313	chr6:117179501	C/T	cg12892004	chr6:117198278	RFX6	-0.5	-11.41	-0.41	1.44e-27	C-reactive protein levels;
BRCA	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg12011299	chr4:100065546	ADH4	0.43	11.44	0.41	1.09e-27	Alcohol dependence;
BRCA	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg16386425	chr10:429943	DIP2C	-0.42	-8.96	-0.33	3.49e-18	Psychosis in Alzheimer's disease;
BRCA	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg11057378	chr10:81107060	PPIF	0.43	10.16	0.37	1.35e-22	Height;
BRCA	cis	rs887829	0.588	rs4663971	chr2:234674252	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.31	-8.28	-0.31	7.13e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs2147904	0.934	rs783629	chr1:42363275	C/T	cg16685388	chr1:42384056	HIVEP3	0.32	8.92	0.33	5.06e-18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
BRCA	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg10495392	chr1:46806563	NSUN4	0.47	8.53	0.32	1.06e-16	Menopause (age at onset);
BRCA	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06108461	chr20:60628389	TAF4	-0.98	-22.38	-0.66	2.42e-82	Body mass index;
BRCA	trans	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg19676328	chr12:49525230	TUBA1B	-0.53	-11.61	-0.42	2.02e-28	Total cholesterol levels;
BRCA	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.52	-0.44	2.53e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg10556349	chr10:835070	NA	0.6	8.41	0.32	2.75e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg08000102	chr2:233561755	GIGYF2	-0.55	-11.28	-0.41	4.77e-27	Coronary artery disease;
BRCA	cis	rs11696845	0.626	rs6073537	chr20:43378270	A/G	cg25301532	chr20:43378953	KCNK15	-0.43	-10.27	-0.38	5.38e-23	Obesity-related traits;
BRCA	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.13	0.31	2.27e-15	Depression;
BRCA	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg20203395	chr5:56204925	C5orf35	0.64	12.65	0.45	6.77e-33	Initial pursuit acceleration;
BRCA	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg02297831	chr4:17616191	MED28	-0.34	-7.91	-0.3	1.11e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4594175	0.926	rs9323207	chr14:51621908	A/G	cg23942311	chr14:51606299	NA	-0.32	-8.26	-0.31	8.64e-16	Cancer;
BRCA	cis	rs66887589	0.777	rs4643791	chr4:120265619	A/G	cg09307838	chr4:120376055	NA	-0.46	-9.91	-0.36	1.29e-21	Diastolic blood pressure;
BRCA	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg17063962	chr7:91808500	NA	0.56	13.38	0.47	3.55e-36	Breast cancer;
BRCA	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg18402987	chr7:1209562	NA	0.66	11.36	0.41	2.29e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg15208524	chr1:10270712	KIF1B	0.37	8.19	0.31	1.41e-15	Hepatocellular carcinoma;
BRCA	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg03711944	chr11:47377212	SPI1	-0.41	-9.76	-0.36	4.42e-21	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs3815700	1.000	rs8104729	chr19:33093979	C/T	cg02997394	chr19:33096574	ANKRD27	0.69	11.52	0.41	4.75e-28	Eosinophilic esophagitis;
BRCA	cis	rs758324	0.947	rs6596039	chr5:131198652	C/A	cg06307176	chr5:131281290	NA	0.53	10.32	0.38	3.51e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03517284	chr6:25882590	NA	-0.51	-11.51	-0.41	5.28e-28	Blood metabolite levels;
BRCA	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18876405	chr7:65276391	NA	0.48	10.7	0.39	1.12e-24	Aortic root size;
BRCA	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.42	-8.39	-0.32	3.06e-16	Monocyte percentage of white cells;
BRCA	cis	rs4363385	0.818	rs574649	chr1:153008471	G/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	trans	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg25214090	chr10:38739885	LOC399744	0.45	10.64	0.39	1.93e-24	Corneal astigmatism;
BRCA	cis	rs1829883	1.000	rs2460683	chr5:98778568	A/G	cg08333243	chr5:99726346	NA	-0.37	-8.79	-0.33	1.33e-17	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23583168	chr7:148888333	NA	-0.83	-18.73	-0.6	9.66e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg11541897	chr5:78281793	ARSB	0.42	8.83	0.33	1e-17	Blood and toenail selenium levels;Blood trace element (Se levels);
BRCA	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg09307838	chr4:120376055	NA	0.6	13.04	0.46	1.24e-34	Corneal astigmatism;
BRCA	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg06627628	chr2:24431161	ITSN2	-0.56	-9.03	-0.34	1.94e-18	Lymphocyte counts;
BRCA	cis	rs4728302	0.838	rs10225115	chr7:133591435	C/T	cg07491979	chr7:133331646	EXOC4	0.36	7.82	0.3	2.17e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg13385794	chr1:248469461	NA	0.28	7.88	0.3	1.4e-14	Common traits (Other);
BRCA	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg11266682	chr4:10021025	SLC2A9	0.39	10.36	0.38	2.45e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg05313129	chr8:58192883	C8orf71	-0.43	-8.88	-0.33	6.55e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg07395648	chr5:131743802	NA	-0.39	-8.88	-0.33	6.54e-18	Breast cancer;Mosquito bite size;
BRCA	cis	rs1891275	0.515	rs7093728	chr10:93443617	C/T	cg07889827	chr10:93443413	NA	-0.44	-12.37	-0.44	1.2e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs57590327	0.508	rs10511101	chr3:81950302	A/C	cg07356753	chr3:81810745	GBE1	-0.36	-8.46	-0.32	1.8e-16	Extraversion;
BRCA	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg09307838	chr4:120376055	NA	0.69	13.91	0.48	1.24e-38	Corneal astigmatism;
BRCA	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg06766960	chr11:133703094	NA	-0.63	-13.39	-0.47	3.35e-36	Childhood ear infection;
BRCA	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg04362960	chr10:104952993	NT5C2	0.44	10.47	0.38	8.45e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg19920283	chr7:105172520	RINT1	0.59	9.53	0.35	3.29e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg13397359	chr6:42928475	GNMT	0.76	19.52	0.61	6.66e-67	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg18876405	chr7:65276391	NA	0.58	13.95	0.48	8.13e-39	Aortic root size;
BRCA	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-14.13	-0.49	1.19e-39	Lymphocyte percentage of white cells;
BRCA	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	13.72	0.48	1.02e-37	Colorectal cancer;
BRCA	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-15.08	-0.51	3.43e-44	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7568458	0.783	rs2166529	chr2:85742175	A/C	cg02493740	chr2:85810744	VAMP5	0.39	8.21	0.31	1.19e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg20701182	chr2:24300061	SF3B14	0.66	9.65	0.36	1.17e-20	Lymphocyte percentage of white cells;
BRCA	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.33	11.31	0.41	3.62e-27	Systemic lupus erythematosus;
BRCA	cis	rs7000551	0.689	rs12545909	chr8:22310052	A/G	cg12081754	chr8:22256438	SLC39A14	-0.44	-8.63	-0.32	4.93e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.42	-8.02	-0.3	5.01e-15	Dietary macronutrient intake;
BRCA	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg08807101	chr21:30365312	RNF160	-0.58	-14.35	-0.49	1.13e-40	Dental caries;
BRCA	cis	rs61990749	0.597	rs176944	chr14:78176211	G/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.64	-10.03	-0.37	4.19e-22	Fibroblast growth factor basic levels;
BRCA	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg18850127	chr7:39170497	POU6F2	0.52	11.68	0.42	1.02e-28	IgG glycosylation;
BRCA	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.63	-0.42	1.77e-28	Platelet count;
BRCA	cis	rs8032158	1.000	rs11633313	chr15:56135709	A/G	cg02198044	chr15:56286336	NEDD4	-0.39	-9.24	-0.34	3.65e-19	Keloid;
BRCA	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg21535247	chr6:8435926	SLC35B3	0.42	9.64	0.36	1.22e-20	Motion sickness;
BRCA	cis	rs13046373	0.508	rs1911572	chr21:32031648	A/G	cg16431978	chr21:31797932	KRTAP13-3	-0.36	-9.14	-0.34	8.12e-19	HDL cholesterol;
BRCA	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10802521	chr3:52805072	NEK4	-0.34	-9.33	-0.35	1.71e-19	Bipolar disorder;
BRCA	cis	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg08601574	chr20:25228251	PYGB	0.39	9.36	0.35	1.32e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs870825	0.655	rs28555435	chr4:185647300	C/A	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs1256061	0.654	rs1256033	chr14:64745399	A/G	cg23250157	chr14:64679961	SYNE2	0.29	7.84	0.3	1.9e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg11814155	chr7:99998594	ZCWPW1	0.48	8.49	0.32	1.47e-16	Platelet count;
BRCA	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18876405	chr7:65276391	NA	-0.5	-11.54	-0.42	3.9e-28	Aortic root size;
BRCA	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21659725	chr3:3221576	CRBN	-0.47	-11.96	-0.43	6.89e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg16339924	chr4:17578868	LAP3	0.58	14.13	0.49	1.17e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-12.04	-0.43	3.04e-30	Response to antipsychotic treatment;
BRCA	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg07080220	chr10:102295463	HIF1AN	0.65	15.39	0.52	1.04e-45	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg12311346	chr5:56204834	C5orf35	-0.81	-16.16	-0.54	1.71e-49	Initial pursuit acceleration;
BRCA	trans	rs11976180	1.000	rs67239267	chr7:143745116	G/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.24	-0.31	9.58e-16	Obesity-related traits;
BRCA	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	11.86	0.42	1.87e-29	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11051970	0.636	rs10844198	chr12:32563479	G/T	cg02745156	chr12:32552066	NA	0.25	8.4	0.32	2.93e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs6446731	0.500	rs2858085	chr4:3271226	T/G	cg08886695	chr4:3369023	RGS12	0.37	9.87	0.36	1.8e-21	Mean platelet volume;
BRCA	trans	rs9929218	1.000	rs8056538	chr16:68802282	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-13.88	-0.48	1.69e-38	Colorectal cancer;
BRCA	cis	rs4478858	0.735	rs4531329	chr1:31817810	A/T	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg18132916	chr6:79620363	NA	-0.48	-10.88	-0.4	2.04e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg11941060	chr3:133502564	NA	0.49	11.95	0.43	7.67e-30	Iron status biomarkers;
BRCA	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg24154853	chr7:158122151	PTPRN2	-0.34	-8.04	-0.3	4.53e-15	Calcium levels;
BRCA	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-10.03	-0.37	4.33e-22	Triglycerides;
BRCA	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg26384229	chr12:38710491	ALG10B	0.67	13.91	0.48	1.34e-38	Morning vs. evening chronotype;
BRCA	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-10.02	-0.37	4.67e-22	Alzheimer's disease (late onset);
BRCA	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.8	0.62	2.22e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.48	-12.5	-0.44	3.15e-32	Height;
BRCA	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg27398817	chr8:82754497	SNX16	-0.35	-7.97	-0.3	7.26e-15	Diastolic blood pressure;
BRCA	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg10560079	chr2:191398806	TMEM194B	-0.73	-13.47	-0.47	1.46e-36	Diastolic blood pressure;
BRCA	trans	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg06521331	chr12:34319734	NA	-0.47	-8.68	-0.32	3.27e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.22	-0.31	1.13e-15	Depression;
BRCA	cis	rs17253792	0.822	rs75016910	chr14:56050466	C/G	cg01858014	chr14:56050164	KTN1	-0.73	-9.45	-0.35	6.29e-20	Putamen volume;
BRCA	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg03877680	chr5:178157825	ZNF354A	0.8	14.85	0.51	4.43e-43	Neutrophil percentage of white cells;
BRCA	cis	rs11229555	0.645	rs11229443	chr11:58197188	G/C	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-14.94	-0.51	1.73e-43	Morning vs. evening chronotype;
BRCA	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg27588902	chr6:42928151	GNMT	0.3	10.05	0.37	3.53e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg06159980	chr1:16340746	HSPB7	-0.39	-8.85	-0.33	8.44e-18	Dilated cardiomyopathy;
BRCA	cis	rs17767294	0.708	rs72848753	chr6:27878269	C/G	cg08851530	chr6:28072375	NA	0.92	8.91	0.33	5.15e-18	Parkinson's disease;
BRCA	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg23719950	chr11:63933701	MACROD1	-0.53	-8.54	-0.32	9.58e-17	Mean platelet volume;
BRCA	trans	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.17	0.31	1.61e-15	Corneal astigmatism;
BRCA	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg07988820	chr12:82153109	PPFIA2	0.57	9.21	0.34	4.77e-19	Resting heart rate;
BRCA	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg01802117	chr1:53393560	SCP2	0.4	9.01	0.34	2.29e-18	Monocyte count;
BRCA	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg14863265	chr7:2801509	GNA12	-0.42	-9.65	-0.36	1.2e-20	Height;
BRCA	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg09307838	chr4:120376055	NA	0.72	15.31	0.52	2.78e-45	Corneal astigmatism;
BRCA	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg23229984	chr5:148520753	ABLIM3	-0.35	-8.39	-0.32	3.02e-16	Breast cancer;
BRCA	trans	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs3772130	1.000	rs3772128	chr3:121345094	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	9.65	0.36	1.15e-20	Cognitive performance;
BRCA	cis	rs7246967	0.611	rs2361022	chr19:22816533	A/G	cg23217946	chr19:22817039	ZNF492	0.47	8.45	0.32	2e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg12386194	chr3:101231763	SENP7	0.41	8.75	0.33	1.86e-17	Colorectal cancer;
BRCA	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg03733263	chr8:22462867	KIAA1967	0.79	18.19	0.58	6.41e-60	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	trans	rs11165623	0.564	rs7555035	chr1:96996026	T/C	cg10631902	chr5:14652156	NA	-0.43	-12.17	-0.43	8.99e-31	Hip circumference;Waist circumference;
BRCA	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.71	-0.33	2.66e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.41	8.88	0.33	6.46e-18	Alzheimer's disease (late onset);
BRCA	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg20701182	chr2:24300061	SF3B14	0.62	8.83	0.33	9.71e-18	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.35	0.57	1.59e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg06550200	chr5:1325588	CLPTM1L	-0.6	-12.42	-0.44	7.1e-32	Lung cancer;
BRCA	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg19274703	chr22:41806451	NA	-0.36	-9.13	-0.34	8.88e-19	Vitiligo;
BRCA	cis	rs2742234	0.541	rs10793424	chr10:43717116	G/T	cg02780029	chr10:43622663	RET	0.35	7.86	0.3	1.69e-14	Hirschsprung disease;
BRCA	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg13770153	chr20:60521292	NA	0.8	20.89	0.64	2.98e-74	Obesity-related traits;
BRCA	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	20.11	0.62	4.61e-70	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.82	0.3	2.21e-14	Aortic root size;
BRCA	cis	rs7927771	0.524	rs6485763	chr11:47627302	C/T	cg20307385	chr11:47447363	PSMC3	0.45	10.38	0.38	1.91e-23	Subjective well-being;
BRCA	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	15.9	0.53	3.46e-48	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11608355	0.515	rs7955932	chr12:109941303	G/A	cg05360138	chr12:110035743	NA	0.72	13.3	0.47	8.56e-36	Neuroticism;
BRCA	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg08601574	chr20:25228251	PYGB	0.36	8.2	0.31	1.36e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg17366294	chr4:99064904	C4orf37	0.48	8.45	0.32	1.99e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg02733842	chr7:1102375	C7orf50	-0.65	-12.01	-0.43	4.31e-30	Bronchopulmonary dysplasia;
BRCA	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg11584989	chr19:19387371	SF4	0.63	13.52	0.47	7.85e-37	Bipolar disorder;
BRCA	trans	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg26043149	chr18:55253948	FECH	0.36	7.9	0.3	1.2e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg23533926	chr12:111358616	MYL2	-0.42	-8.73	-0.33	2.27e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3771570	0.901	rs4675969	chr2:242217627	C/T	cg21155796	chr2:242212141	HDLBP	0.48	8.32	0.31	5.48e-16	Prostate cancer;
BRCA	cis	rs13040088	1.000	rs910831	chr20:61558775	T/C	cg23096297	chr20:61557774	DIDO1	0.92	18.53	0.59	1.17e-61	Menopause (age at onset);
BRCA	cis	rs4908768	0.501	rs12756257	chr1:8616933	C/A	cg20416874	chr1:8611966	RERE	-0.28	-8.17	-0.31	1.6e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg03146154	chr1:46216737	IPP	0.52	11.59	0.42	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg04586622	chr2:25135609	ADCY3	0.46	11.59	0.42	2.61e-28	Body mass index;
BRCA	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg24596788	chr1:163392923	NA	-0.39	-10.78	-0.39	5.09e-25	Motion sickness;
BRCA	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg17971929	chr21:40555470	PSMG1	-0.61	-13.76	-0.48	6.54e-38	Cognitive function;
BRCA	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05926928	chr17:57297772	GDPD1	1.2	16.07	0.54	4.68e-49	Opioid sensitivity;
BRCA	trans	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.78	-0.33	1.44e-17	Depression;
BRCA	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.57	0.35	2.25e-20	Lung cancer in ever smokers;
BRCA	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg24060327	chr5:131705240	SLC22A5	0.62	11.61	0.42	2.12e-28	Breast cancer;
BRCA	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg21535247	chr6:8435926	SLC35B3	0.42	9.61	0.36	1.65e-20	Motion sickness;
BRCA	cis	rs9469578	1.000	rs9469580	chr6:33715837	A/G	cg18708504	chr6:33715942	IP6K3	-0.66	-9.94	-0.37	9.58e-22	Phosphorus levels;
BRCA	cis	rs365132	0.875	rs3923879	chr5:176355312	C/T	cg16309518	chr5:176445507	NA	-0.39	-9.61	-0.36	1.59e-20	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs6977660	0.598	rs10239147	chr7:19787459	T/C	cg07541023	chr7:19748670	TWISTNB	0.55	9.35	0.35	1.41e-19	Thyroid stimulating hormone;
BRCA	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.66	13.75	0.48	6.93e-38	Lymphocyte counts;
BRCA	cis	rs2010099	0.941	rs73191618	chr3:124301840	G/A	cg14688451	chr3:124303035	KALRN	0.57	9.01	0.34	2.37e-18	Thyroid peroxidase antibody levels;
BRCA	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg12463550	chr7:65579703	CRCP	0.37	8.04	0.3	4.35e-15	Aortic root size;
BRCA	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.35	-9.08	-0.34	1.29e-18	Total body bone mineral density;
BRCA	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg08470875	chr2:26401718	FAM59B	-0.52	-8.54	-0.32	1.02e-16	Gut microbiome composition (summer);
BRCA	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg23029597	chr12:123009494	RSRC2	-0.43	-8.8	-0.33	1.29e-17	Body mass index;
BRCA	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.77e-24	Motion sickness;
BRCA	trans	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg20993868	chr7:22813445	NA	0.56	15.51	0.52	2.78e-46	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg07930192	chr7:1003750	NA	0.38	8.46	0.32	1.82e-16	Longevity;Endometriosis;
BRCA	trans	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg11693508	chr17:37793320	STARD3	0.37	8.11	0.31	2.6e-15	Bipolar disorder;
BRCA	cis	rs600806	0.850	rs10858092	chr1:109943893	A/G	cg20591472	chr1:110008990	SYPL2	-0.32	-7.86	-0.3	1.63e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs11051970	0.655	rs7298381	chr12:32530257	G/T	cg24626660	chr12:32551988	NA	0.27	7.97	0.3	7.34e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-10.32	-0.38	3.36e-23	Schizophrenia;
BRCA	cis	rs1832871	0.711	rs9459826	chr6:158680396	C/G	cg07165851	chr6:158734300	TULP4	-0.62	-13.14	-0.46	4.29e-35	Height;
BRCA	cis	rs698833	0.509	rs12987415	chr2:44530423	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.91	0.33	5.2e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg00024416	chr22:24240387	NA	-0.32	-8.07	-0.3	3.62e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg24692254	chr21:30365293	RNF160	0.79	22.15	0.66	4.17e-81	Dental caries;
BRCA	trans	rs6479891	0.818	rs11815969	chr10:65265855	C/T	cg14819942	chr15:35414228	NA	0.35	8.59	0.32	6.62e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs34779708	0.966	rs4934737	chr10:35512799	T/C	cg03585969	chr10:35415529	CREM	0.49	9.96	0.37	8.03e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3917254	0.596	rs871658	chr2:102771865	G/C	cg22835712	chr2:102737379	NA	-0.51	-8.76	-0.33	1.81e-17	Blood protein levels;
BRCA	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg14289826	chr9:140003911	NA	0.35	8.46	0.32	1.81e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg06238570	chr21:40685208	BRWD1	-0.41	-8.37	-0.31	3.57e-16	Cognitive function;
BRCA	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	12.03	0.43	3.29e-30	Monocyte percentage of white cells;
BRCA	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg06197492	chr11:2016605	H19	0.39	8.5	0.32	1.35e-16	DNA methylation (parent-of-origin);DNA methylation (variation);
BRCA	cis	rs12579753	0.872	rs12319937	chr12:82182545	T/G	cg07988820	chr12:82153109	PPFIA2	-0.48	-8.46	-0.32	1.83e-16	Resting heart rate;
BRCA	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-16.41	-0.54	9.05e-51	Alzheimer's disease (late onset);
BRCA	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.01	-0.3	5.38e-15	Total body bone mineral density;
BRCA	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg23711669	chr6:146136114	FBXO30	0.63	14.31	0.49	1.72e-40	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg10253484	chr15:75165896	SCAMP2	-0.45	-9.06	-0.34	1.61e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-12.26	-0.44	3.51e-31	Bipolar disorder;
BRCA	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.41	-0.32	2.64e-16	Total body bone mineral density;
BRCA	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg25767906	chr1:53392781	SCP2	0.39	8.79	0.33	1.34e-17	Monocyte count;
BRCA	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.91	-0.3	1.13e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg15017067	chr4:17643749	FAM184B	0.29	8.47	0.32	1.74e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs28374715	0.662	rs691906	chr15:41474636	T/A	cg18705301	chr15:41695430	NDUFAF1	0.78	16.64	0.55	6.31e-52	Ulcerative colitis;
BRCA	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	1.01e-40	Motion sickness;
BRCA	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.94e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg21535247	chr6:8435926	SLC35B3	0.42	9.64	0.36	1.22e-20	Motion sickness;
BRCA	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-7.9	-0.3	1.21e-14	Height;
BRCA	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg16586182	chr3:47516702	SCAP	0.55	12.36	0.44	1.3e-31	Colorectal cancer;
BRCA	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.98	-0.33	2.91e-18	Triglycerides;
BRCA	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.64	-13.82	-0.48	3.31e-38	Lung cancer;
BRCA	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-10.93	-0.4	1.27e-25	Neuroticism;
BRCA	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg19346786	chr7:2764209	NA	-0.37	-10.83	-0.39	3.33e-25	Height;
BRCA	cis	rs897080	0.552	rs1067375	chr2:44650118	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.44	-8.31	-0.31	5.83e-16	Height;
BRCA	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg09184832	chr6:79620586	NA	-0.52	-11.36	-0.41	2.21e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg26384229	chr12:38710491	ALG10B	0.66	15.31	0.52	2.75e-45	Bladder cancer;
BRCA	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.31	-7.89	-0.3	1.31e-14	Total body bone mineral density;
BRCA	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg17330251	chr7:94953956	PON1	-0.42	-8.71	-0.33	2.55e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	9.7	0.36	7.44e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.74	-0.5	1.48e-42	Total cholesterol levels;
BRCA	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg08999081	chr20:33150536	PIGU	-0.35	-8.92	-0.33	4.7e-18	Coronary artery disease;
BRCA	trans	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg21659725	chr3:3221576	CRBN	-0.46	-9.97	-0.37	7.7e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.63	13.65	0.48	1.98e-37	Lymphocyte percentage of white cells;
BRCA	cis	rs10484885	0.878	rs72921916	chr6:90555990	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.77	-9.47	-0.35	5.11e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.38	-8.18	-0.31	1.55e-15	Osteoporosis;
BRCA	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg04362960	chr10:104952993	NT5C2	0.94	14.51	0.5	1.96e-41	Arsenic metabolism;
BRCA	trans	rs12517041	1.000	rs6894688	chr5:23312285	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-8.27	-0.31	7.52e-16	Calcium levels;
BRCA	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg07636037	chr3:49044803	WDR6	0.98	29.45	0.76	4.46e-121	Parkinson's disease;
BRCA	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg13319975	chr6:146136371	FBXO30	-0.43	-10.06	-0.37	3.38e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17023223	0.537	rs12065809	chr1:119724535	A/T	cg05756136	chr1:119680316	WARS2	-0.41	-7.98	-0.3	6.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	trans	rs9951602	0.541	rs56882694	chr18:76647010	C/T	cg02800362	chr5:177631904	HNRNPAB	0.76	17.65	0.57	4.21e-57	Obesity-related traits;
BRCA	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg17410650	chr12:54324560	NA	-0.54	-15.46	-0.52	4.8e-46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
BRCA	cis	rs6893300	0.785	rs55654737	chr5:179218842	G/A	cg14593053	chr5:179126677	CANX	-0.36	-7.88	-0.3	1.38e-14	Resting heart rate;
BRCA	cis	rs4664304	0.620	rs10929956	chr2:160714615	C/T	cg14819504	chr2:160761413	LY75	0.34	8.51	0.32	1.29e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs796364	0.616	rs769955	chr2:200692595	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	8.07	0.3	3.4e-15	Schizophrenia;
BRCA	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.95	26.26	0.72	1.19e-103	Birth weight;
BRCA	cis	rs6840360	0.555	rs4554052	chr4:152726610	T/C	cg22705602	chr4:152727874	NA	0.39	10.36	0.38	2.27e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg12311346	chr5:56204834	C5orf35	-0.81	-16.16	-0.54	1.65e-49	Initial pursuit acceleration;
BRCA	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg24829409	chr8:58192753	C8orf71	-0.5	-10.28	-0.38	5.02e-23	Developmental language disorder (linguistic errors);
BRCA	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27286337	chr10:134555280	INPP5A	0.61	10.21	0.37	8.7e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg07741184	chr6:167504864	NA	0.36	10.39	0.38	1.72e-23	Crohn's disease;
BRCA	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg03060546	chr3:49711283	APEH	-0.52	-10.92	-0.4	1.46e-25	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg19628046	chr18:33552617	C18orf21	0.54	11.0	0.4	6.86e-26	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg23711669	chr6:146136114	FBXO30	0.79	18.96	0.6	5.82e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg00071950	chr4:10020882	SLC2A9	0.55	12.94	0.46	3.68e-34	Bone mineral density;
BRCA	cis	rs8016982	0.963	rs7149672	chr14:81657336	A/G	cg01989461	chr14:81687754	GTF2A1	0.48	10.16	0.37	1.43e-22	Schizophrenia;
BRCA	cis	rs2479724	0.901	rs6458244	chr6:41790455	C/T	cg17623882	chr6:41773611	USP49	0.36	9.87	0.36	1.83e-21	Menarche (age at onset);
BRCA	trans	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg01620082	chr3:125678407	NA	-0.69	-9.09	-0.34	1.21e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs8077889	0.672	rs2106764	chr17:41852717	T/A	cg26893861	chr17:41843967	DUSP3	0.9	23.14	0.68	1.63e-86	Triglycerides;
BRCA	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg09184832	chr6:79620586	NA	-0.42	-8.45	-0.32	1.93e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9649465	1.000	rs1468656	chr7:123375505	G/C	cg04330084	chr7:123175371	IQUB	-0.31	-8.64	-0.32	4.49e-17	Migraine;
BRCA	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg12573674	chr2:1569213	NA	-0.43	-7.87	-0.3	1.55e-14	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.97	-0.3	7.23e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg21770322	chr7:97807741	LMTK2	0.44	11.74	0.42	6.15e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg08885076	chr2:99613938	TSGA10	-0.59	-13.08	-0.46	8e-35	Chronic sinus infection;
BRCA	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	16.0	0.53	9.87e-49	Platelet count;
BRCA	cis	rs9318086	0.648	rs9510927	chr13:24467641	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.31	8.61	0.32	5.72e-17	Myopia (pathological);
BRCA	cis	rs6484504	0.652	rs578666	chr11:31404484	C/T	cg06552810	chr11:31128660	NA	0.37	8.2	0.31	1.36e-15	Red blood cell count;
BRCA	cis	rs4363385	0.747	rs2225919	chr1:152969603	A/G	cg21543102	chr1:152974771	SPRR3	-0.3	-8.52	-0.32	1.18e-16	Inflammatory skin disease;
BRCA	trans	rs9951602	0.512	rs56009939	chr18:76644497	T/G	cg02800362	chr5:177631904	HNRNPAB	0.75	17.49	0.57	2.96e-56	Obesity-related traits;
BRCA	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg00147160	chr1:26503991	CNKSR1	0.28	9.24	0.34	3.71e-19	Height;
BRCA	cis	rs10046574	0.831	rs7810503	chr7:135142285	T/C	cg27474649	chr7:135195673	CNOT4	0.61	8.71	0.33	2.65e-17	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.54	13.37	0.47	3.92e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-11.12	-0.4	2.2e-26	Schizophrenia;
BRCA	cis	rs1568889	1.000	rs7112860	chr11:28151609	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	14.94	0.51	1.63e-43	Bipolar disorder;
BRCA	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg15556689	chr8:8085844	FLJ10661	0.39	9.56	0.35	2.51e-20	Retinal vascular caliber;
BRCA	cis	rs1997103	1.000	rs2877284	chr7:55408778	A/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.84	0.36	2.34e-21	Bipolar disorder;
BRCA	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-20.07	-0.62	7.18e-70	Electrocardiographic conduction measures;
BRCA	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.43	9.66	0.36	1.07e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg17366294	chr4:99064904	C4orf37	0.45	10.67	0.39	1.48e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg16339924	chr4:17578868	LAP3	0.56	13.89	0.48	1.62e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs922182	0.633	rs12592702	chr15:64271882	C/T	cg24729988	chr15:64271149	DAPK2	-0.65	-16.7	-0.55	3.04e-52	Blood protein levels;
BRCA	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg05313129	chr8:58192883	C8orf71	-0.46	-9.53	-0.35	3.34e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg08470875	chr2:26401718	FAM59B	-0.72	-10.35	-0.38	2.56e-23	Gut microbiome composition (summer);
BRCA	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23708337	chr7:1209742	NA	0.58	12.58	0.45	1.34e-32	Longevity;Endometriosis;
BRCA	cis	rs858239	0.601	rs929508	chr7:23166709	C/A	cg23682824	chr7:23144976	KLHL7	0.45	11.94	0.43	8.21e-30	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7590368	0.924	rs72779464	chr2:10963159	T/C	cg15705551	chr2:10952987	PDIA6	0.43	8.06	0.3	3.89e-15	Educational attainment (years of education);
BRCA	cis	rs858239	0.600	rs7776649	chr7:23119317	C/T	cg23682824	chr7:23144976	KLHL7	0.45	11.95	0.43	7.85e-30	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs858239	0.831	rs7796541	chr7:23389073	G/T	cg23682824	chr7:23144976	KLHL7	0.32	8.13	0.31	2.29e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg00290607	chr11:67383545	NA	0.52	11.5	0.41	5.78e-28	Mean corpuscular volume;
BRCA	trans	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg06521331	chr12:34319734	NA	-0.46	-8.53	-0.32	1.08e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11890956	chr21:40555474	PSMG1	-0.84	-21.45	-0.65	2.87e-77	Cognitive function;
BRCA	cis	rs9287719	0.649	rs2024433	chr2:10731504	G/C	cg00105475	chr2:10696890	NA	0.41	9.07	0.34	1.44e-18	Prostate cancer;
BRCA	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg18512352	chr11:47633146	NA	-0.35	-8.38	-0.31	3.41e-16	Subjective well-being;
BRCA	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg21045802	chr8:109455806	TTC35	0.34	7.87	0.3	1.52e-14	Dupuytren's disease;
BRCA	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.02	0.48	4.03e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg19274703	chr22:41806451	NA	0.35	9.09	0.34	1.19e-18	Vitiligo;
BRCA	cis	rs2249625	0.564	rs2496489	chr6:72877338	G/A	cg18830697	chr6:72922368	RIMS1	-0.64	-14.59	-0.5	8.31e-42	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs3106136	0.546	rs2276910	chr4:95129238	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.41	-8.49	-0.32	1.4e-16	Capecitabine sensitivity;
BRCA	trans	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.85	0.33	8.55e-18	Mean corpuscular volume;
BRCA	trans	rs629535	0.783	rs538832	chr8:70033817	A/G	cg21567404	chr3:27674614	NA	1.0	21.1	0.64	2.04e-75	Dupuytren's disease;
BRCA	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.47	-0.32	1.67e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs1568889	0.938	rs1464898	chr11:28034748	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.58	0.5	8.73e-42	Bipolar disorder;
BRCA	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.83	12.84	0.45	9.76e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.39	-8.27	-0.31	8.03e-16	IgG glycosylation;
BRCA	trans	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg26043149	chr18:55253948	FECH	0.4	8.71	0.33	2.66e-17	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-10.75	-0.39	6.6e-25	Alzheimer's disease;
BRCA	cis	rs6430585	0.527	rs2254780	chr2:136435526	C/T	cg07169764	chr2:136633963	MCM6	0.9	17.31	0.56	2.5e-55	Corneal structure;
BRCA	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg21132104	chr15:45694354	SPATA5L1	-0.73	-16.48	-0.55	3.9e-51	Homoarginine levels;
BRCA	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.92	0.4	1.41e-25	Bipolar disorder;
BRCA	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg09658497	chr7:2847517	GNA12	-0.41	-8.47	-0.32	1.75e-16	Height;
BRCA	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12756686	chr19:29218302	NA	0.51	8.83	0.33	1.04e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs2742234	1.000	rs2742234	chr10:43612609	A/G	cg15436174	chr10:43711423	RASGEF1A	0.44	9.73	0.36	5.83e-21	Hirschsprung disease;
BRCA	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg18811423	chr2:55921094	PNPT1	-0.71	-23.32	-0.68	1.67e-87	Metabolic syndrome;
BRCA	cis	rs117623576	0.941	rs211409	chr10:32393213	T/C	cg03047570	chr10:32398778	NA	0.65	9.79	0.36	3.53e-21	Anti-saccade response;
BRCA	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg22705602	chr4:152727874	NA	-0.35	-8.52	-0.32	1.19e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg04586622	chr2:25135609	ADCY3	0.47	11.8	0.42	3.31e-29	Body mass index in non-asthmatics;
BRCA	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg06784218	chr1:46089804	CCDC17	-0.44	-10.42	-0.38	1.32e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-8.65	-0.32	4.17e-17	Blood metabolite levels;
BRCA	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg07211511	chr3:129823064	LOC729375	-0.58	-10.64	-0.39	1.84e-24	Blood pressure (smoking interaction);
BRCA	cis	rs6878727	0.549	rs920997	chr5:123648021	A/G	cg01806427	chr5:123737813	NA	-0.4	-8.86	-0.33	7.6e-18	Breast cancer;
BRCA	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.47	-10.25	-0.38	6.41e-23	Longevity;Endometriosis;
BRCA	cis	rs2066819	0.786	rs111580405	chr12:56739557	A/G	cg26734620	chr12:56694298	CS	0.88	9.96	0.37	8.09e-22	Psoriasis vulgaris;
BRCA	trans	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg07211511	chr3:129823064	LOC729375	-0.63	-11.04	-0.4	4.71e-26	Blood pressure (smoking interaction);
BRCA	trans	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg25214090	chr10:38739885	LOC399744	0.37	8.6	0.32	6.27e-17	Diastolic blood pressure;
BRCA	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.56	11.59	0.42	2.54e-28	Lymphocyte counts;
BRCA	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-9.26	-0.34	3.03e-19	Tonsillectomy;
BRCA	trans	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg13565492	chr6:43139072	SRF	-0.79	-10.95	-0.4	1.07e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg10523679	chr1:76189770	ACADM	0.71	12.12	0.43	1.35e-30	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg13047869	chr3:10149882	C3orf24	0.6	12.53	0.44	2.23e-32	Alzheimer's disease;
BRCA	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg04727924	chr7:799746	HEATR2	-0.52	-10.49	-0.38	7.54e-24	Cerebrospinal P-tau181p levels;
BRCA	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg21433313	chr16:3507492	NAT15	-0.55	-8.16	-0.31	1.78e-15	Tuberculosis;
BRCA	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg10057126	chr4:77819792	ANKRD56	0.64	14.82	0.51	6.13e-43	Emphysema distribution in smoking;
BRCA	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg23719950	chr11:63933701	MACROD1	-0.53	-8.49	-0.32	1.4e-16	Mean platelet volume;
BRCA	cis	rs6543140	0.964	rs6736135	chr2:103064924	A/G	cg04239558	chr2:103089729	SLC9A4	0.34	9.42	0.35	8.32e-20	Blood protein levels;
BRCA	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg01802117	chr1:53393560	SCP2	0.41	8.57	0.32	7.72e-17	Monocyte count;
BRCA	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg23978390	chr7:1156363	C7orf50	0.41	9.36	0.35	1.28e-19	Longevity;Endometriosis;
BRCA	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg01420254	chr6:26195488	NA	0.56	8.74	0.33	2.03e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.33	8.53	0.32	1.03e-16	IgG glycosylation;
BRCA	cis	rs10193935	0.901	rs2286702	chr2:42555473	C/T	cg27598129	chr2:42591480	NA	-0.97	-14.96	-0.51	1.34e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs654950	0.934	rs665223	chr1:42000654	A/T	cg06885757	chr1:42089581	HIVEP3	-0.28	-9.78	-0.36	3.89e-21	Airway imaging phenotypes;
BRCA	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg20701182	chr2:24300061	SF3B14	0.58	9.1	0.34	1.12e-18	Lymphocyte counts;
BRCA	cis	rs4808199	0.649	rs34755166	chr19:19665581	G/A	cg03709012	chr19:19516395	GATAD2A	0.75	11.93	0.43	8.93e-30	Nonalcoholic fatty liver disease;
BRCA	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg00666640	chr1:248458726	OR2T12	0.29	8.26	0.31	8.47e-16	Common traits (Other);
BRCA	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg18402987	chr7:1209562	NA	0.84	11.92	0.43	9.85e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg25482853	chr8:67687455	SGK3	1.05	16.94	0.56	1.94e-53	Lung disease severity in cystic fibrosis;
BRCA	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg09307838	chr4:120376055	NA	0.69	14.86	0.51	3.94e-43	Corneal astigmatism;
BRCA	trans	rs75804782	0.581	rs3191996	chr2:239344412	A/G	cg01134436	chr17:81009848	B3GNTL1	-0.77	-9.93	-0.37	1.04e-21	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11764359	chr7:65958608	NA	0.78	18.57	0.59	7.06e-62	Aortic root size;
BRCA	trans	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg02030672	chr11:45687055	CHST1	0.51	11.5	0.41	6.23e-28	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg05340658	chr4:99064831	C4orf37	0.62	14.59	0.5	7.73e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg07460842	chr6:66804631	NA	0.73	12.19	0.43	7.02e-31	Exhaled nitric oxide output;
BRCA	cis	rs7729447	0.813	rs7715779	chr5:32690199	T/G	cg16267343	chr5:32710456	NPR3	0.44	9.09	0.34	1.2e-18	Blood pressure;
BRCA	cis	rs2191566	0.576	rs420584	chr19:44495257	C/T	cg20607764	chr19:44506953	ZNF230	0.37	8.03	0.3	4.64e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg21433313	chr16:3507492	NAT15	-0.46	-10.23	-0.38	7.31e-23	Tuberculosis;
BRCA	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	10.53	0.38	5.1900000000000004e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg17971929	chr21:40555470	PSMG1	-0.49	-10.84	-0.39	3.13e-25	Menarche (age at onset);
BRCA	cis	rs7617773	0.817	rs11130163	chr3:48312658	T/C	cg11946769	chr3:48343235	NME6	0.52	11.71	0.42	7.56e-29	Coronary artery disease;
BRCA	trans	rs12517041	1.000	rs2081951	chr5:23287576	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.36	-0.31	4.04e-16	Calcium levels;
BRCA	cis	rs4930561	0.714	rs7945995	chr11:67938302	A/G	cg04465784	chr11:67976953	SUV420H1	-0.26	-8.59	-0.32	6.51e-17	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg01256987	chr12:42539512	GXYLT1	-0.57	-11.6	-0.42	2.3e-28	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg20587970	chr11:113659929	NA	-1.37	-24.64	-0.7	9.94e-95	Hip circumference adjusted for BMI;
BRCA	cis	rs17092148	1.000	rs7265992	chr20:33525407	G/A	cg16810054	chr20:33298113	TP53INP2	0.48	10.47	0.38	8.67e-24	Neuroticism;
BRCA	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-12.43	-0.44	6.22e-32	Response to antipsychotic treatment;
BRCA	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg03161606	chr19:29218774	NA	0.47	8.0	0.3	5.92e-15	Methadone dose in opioid dependence;
BRCA	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg06115741	chr20:33292138	TP53INP2	0.5	11.22	0.41	8.59e-27	Coronary artery disease;
BRCA	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg08470875	chr2:26401718	FAM59B	0.76	11.92	0.43	1.02e-29	Gut microbiome composition (summer);
BRCA	trans	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg25214090	chr10:38739885	LOC399744	0.46	10.61	0.39	2.52e-24	Corneal astigmatism;
BRCA	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg08999081	chr20:33150536	PIGU	0.46	12.93	0.46	3.95e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg10523679	chr1:76189770	ACADM	-0.77	-18.43	-0.59	4.01e-61	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg18850127	chr7:39170497	POU6F2	0.48	10.72	0.39	9.06e-25	IgG glycosylation;
BRCA	cis	rs13046373	0.535	rs9980934	chr21:31982988	C/T	cg06468780	chr21:31798236	KRTAP13-3	0.35	8.74	0.33	2.02e-17	HDL cholesterol;
BRCA	cis	rs2882667	0.690	rs288011	chr5:138199939	C/T	cg04439458	chr5:138467593	SIL1	0.31	7.94	0.3	8.86e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11644478	chr21:40555479	PSMG1	-0.5	-10.46	-0.38	1e-23	Menarche (age at onset);
BRCA	cis	rs2637030	0.559	rs256108	chr5:52874253	C/T	cg06476337	chr5:52856530	NDUFS4	0.38	8.62	0.32	5.24e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08564027	chr20:61660810	NA	0.84	22.77	0.67	1.63e-84	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6942756	1.000	rs6467233	chr7:128868656	C/T	cg02491457	chr7:128862824	NA	-0.71	-14.29	-0.49	2.22e-40	White matter hyperintensity burden;
BRCA	cis	rs7520050	0.966	rs10749860	chr1:46328210	C/G	cg24296786	chr1:45957014	TESK2	0.44	9.89	0.36	1.5e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg06618935	chr21:46677482	NA	-0.37	-8.14	-0.31	2e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-14.13	-0.49	1.23e-39	Morning vs. evening chronotype;
BRCA	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg22681709	chr2:178499509	PDE11A	-0.38	-8.4	-0.32	2.92e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg21475434	chr5:93447410	FAM172A	0.71	9.09	0.34	1.27e-18	Diabetic retinopathy;
BRCA	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg26597838	chr10:835615	NA	1.31	21.51	0.65	1.36e-77	Eosinophil percentage of granulocytes;
BRCA	cis	rs3857536	0.740	rs7745163	chr6:66889936	A/G	cg07460842	chr6:66804631	NA	-0.47	-9.09	-0.34	1.25e-18	Blood trace element (Cu levels);
BRCA	cis	rs12541635	0.966	rs7839239	chr8:107020406	C/T	cg10147462	chr8:107024639	NA	0.36	9.88	0.36	1.63e-21	Age of smoking initiation;
BRCA	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-9.67	-0.36	9.71e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg14530993	chr4:882597	GAK	0.58	9.27	0.34	2.84e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs61990749	0.597	rs11624101	chr14:78138059	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.63	-9.58	-0.35	2.19e-20	Fibroblast growth factor basic levels;
BRCA	cis	rs10189230	1.000	rs10189230	chr2:222357961	T/A	cg14652038	chr2:222343519	EPHA4	0.48	13.32	0.47	6.72e-36	Urate levels in lean individuals;
BRCA	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg25036284	chr2:26402008	FAM59B	0.88	15.06	0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-9.88	-0.36	1.55e-21	Alzheimer's disease (late onset);
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg12419862	chr22:24373484	LOC391322	0.92	24.22	0.69	2.05e-92	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg23505145	chr19:12996616	KLF1	0.54	11.84	0.42	2.18e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	11.15	0.4	1.63e-26	Multiple sclerosis;
BRCA	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg26838691	chr2:24397539	C2orf84	-0.48	-8.75	-0.33	1.92e-17	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs2637266	1.000	rs10219107	chr10:78364369	T/C	cg18941641	chr10:78392320	NA	0.35	7.82	0.3	2.18e-14	Pulmonary function;
BRCA	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg15698299	chr3:52233019	ALAS1	-0.39	-9.13	-0.34	8.86e-19	Electroencephalogram traits;
BRCA	cis	rs6565180	1.000	rs11862806	chr16:30364071	A/G	cg17640201	chr16:30407289	ZNF48	-0.78	-19.88	-0.62	7.99e-69	Tonsillectomy;
BRCA	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-10.48	-0.38	7.7e-24	Resting heart rate;
BRCA	trans	rs629535	0.821	rs650267	chr8:70029160	C/T	cg21567404	chr3:27674614	NA	1.0	20.96	0.64	1.17e-74	Dupuytren's disease;
BRCA	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg09307838	chr4:120376055	NA	0.68	13.66	0.48	1.79e-37	Corneal astigmatism;
BRCA	trans	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg09719594	chr16:21412588	NA	-0.32	-7.82	-0.3	2.19e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	25.91	0.72	1.01e-101	Chronic sinus infection;
BRCA	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg11366901	chr6:160182831	ACAT2	0.78	14.82	0.51	6.21e-43	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.35	-7.97	-0.3	7.06e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-8.12	-0.31	2.37e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7737355	0.947	rs11242078	chr5:130792035	A/C	cg06307176	chr5:131281290	NA	-0.53	-10.6	-0.39	2.62e-24	Life satisfaction;
BRCA	cis	rs6700896	0.931	rs17127849	chr1:66105512	A/G	cg04111102	chr1:66153794	NA	0.34	8.27	0.31	7.98e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24308560	chr3:49941425	MST1R	-0.4	-8.53	-0.32	1.09e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg03060546	chr3:49711283	APEH	-0.53	-10.58	-0.39	3.33e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg11764359	chr7:65958608	NA	-0.68	-15.19	-0.52	9.74e-45	Aortic root size;
BRCA	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg03354898	chr7:1950403	MAD1L1	0.52	10.96	0.4	9.93e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg06885757	chr1:42089581	HIVEP3	-0.31	-11.37	-0.41	2.08e-27	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg27432699	chr2:27873401	GPN1	0.46	9.73	0.36	6.08e-21	Oral cavity cancer;
BRCA	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg22508957	chr16:3507546	NAT15	0.42	9.5	0.35	4.28e-20	Tuberculosis;
BRCA	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg26818010	chr10:134567672	INPP5A	-0.64	-13.42	-0.47	2.38e-36	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg18357645	chr12:58087776	OS9	0.49	14.05	0.49	2.8e-39	Celiac disease or Rheumatoid arthritis;
BRCA	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.19	-19.18	-0.6	4.17e-65	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs870825	0.616	rs57086463	chr4:185639525	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	17.43	0.57	5.93e-56	Blood protein levels;
BRCA	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-11.08	-0.4	3.25e-26	Neuroticism;
BRCA	cis	rs4728302	0.869	rs12707129	chr7:133593177	A/G	cg07491979	chr7:133331646	EXOC4	0.36	7.89	0.3	1.31e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg26384229	chr12:38710491	ALG10B	0.68	14.37	0.49	9.31e-41	Morning vs. evening chronotype;
BRCA	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg24596788	chr1:163392923	NA	-0.39	-10.55	-0.39	4.4e-24	Motion sickness;
BRCA	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.18	-0.34	6e-19	Bipolar disorder;
BRCA	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg08885076	chr2:99613938	TSGA10	-0.44	-8.68	-0.32	3.35e-17	Chronic sinus infection;
BRCA	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg12379764	chr21:47803548	PCNT	-0.41	-8.48	-0.32	1.51e-16	Testicular germ cell tumor;
BRCA	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg23029597	chr12:123009494	RSRC2	0.58	11.45	0.41	9.89e-28	Body mass index;
BRCA	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg06618935	chr21:46677482	NA	-0.38	-8.56	-0.32	8.2e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs28830936	1.000	rs9672298	chr15:41912368	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.32	-9.23	-0.34	3.76e-19	Diastolic blood pressure;
BRCA	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.43	-0.38	1.23e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg04990556	chr1:26633338	UBXN11	-0.47	-9.21	-0.34	4.72e-19	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg24562669	chr7:97807699	LMTK2	0.46	12.25	0.44	4e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.78	0.42	4.15e-29	Tonsillectomy;
BRCA	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg08805041	chr16:621841	PIGQ	-0.31	-8.58	-0.32	7.02e-17	Height;
BRCA	cis	rs17095355	1.000	rs17126877	chr10:111672786	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.42	-8.95	-0.33	3.83e-18	Biliary atresia;
BRCA	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.11	-0.34	1.01e-18	Joint mobility (Beighton score);
BRCA	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg14683738	chr19:37701593	ZNF585B	0.44	7.84	0.3	1.91e-14	Coronary artery calcification;
BRCA	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	17.01	0.56	8.75e-54	Alzheimer's disease;
BRCA	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg03609598	chr5:56110824	MAP3K1	-0.49	-8.22	-0.31	1.16e-15	Initial pursuit acceleration;
BRCA	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg00071950	chr4:10020882	SLC2A9	0.58	14.11	0.49	1.55e-39	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs919433	0.519	rs700658	chr2:198655007	A/T	cg00792783	chr2:198669748	PLCL1	0.47	10.33	0.38	3.09e-23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg09455208	chr3:40491958	NA	-0.39	-9.34	-0.35	1.5700000000000001e-19	Renal cell carcinoma;
BRCA	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg14019146	chr3:50243930	SLC38A3	-0.64	-15.93	-0.53	2.41e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs2860975	0.905	rs10786182	chr10:96789775	C/T	cg09036531	chr10:96991505	NA	-0.39	-8.34	-0.31	4.65e-16	Immune response to smallpox vaccine (IL-6);
BRCA	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	20.42	0.63	1.05e-71	Smoking behavior;
BRCA	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg26597838	chr10:835615	NA	0.91	16.27	0.54	4.77e-50	Eosinophil percentage of granulocytes;
BRCA	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	15.65	0.53	5.5e-47	Cognitive ability;
BRCA	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.64	0.39	1.95e-24	Tonsillectomy;
BRCA	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg12573674	chr2:1569213	NA	-0.51	-9.63	-0.36	1.34e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg00074818	chr8:8560427	CLDN23	0.38	8.3	0.31	6.14e-16	Obesity-related traits;
BRCA	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.33	9.03	0.34	1.99e-18	Response to antipsychotic treatment;
BRCA	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg15704280	chr7:45808275	SEPT13	0.6	10.69	0.39	1.21e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg11189052	chr15:85197271	WDR73	0.42	8.71	0.33	2.55e-17	Schizophrenia;
BRCA	cis	rs3781663	0.500	rs7931752	chr11:70022846	T/C	cg06393558	chr11:69982916	ANO1	-0.39	-8.96	-0.33	3.55e-18	Survival in rectal cancer;
BRCA	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg20290983	chr6:43655470	MRPS18A	1.12	41.57	0.85	6.92e-184	IgG glycosylation;
BRCA	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg08807101	chr21:30365312	RNF160	-0.39	-8.37	-0.31	3.69e-16	Pancreatic cancer;
BRCA	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg08470875	chr2:26401718	FAM59B	-0.52	-8.54	-0.32	1.02e-16	Gut microbiome composition (summer);
BRCA	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.94	0.33	4.3e-18	Tonsillectomy;
BRCA	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-13.19	-0.46	2.51e-35	Response to antipsychotic treatment;
BRCA	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg14926445	chr8:58193284	C8orf71	-0.47	-9.0	-0.34	2.48e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg13047869	chr3:10149882	C3orf24	0.58	12.26	0.44	3.53e-31	Alzheimer's disease;
BRCA	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg23649088	chr2:200775458	C2orf69	0.56	8.11	0.31	2.5e-15	Schizophrenia;
BRCA	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg08470875	chr2:26401718	FAM59B	-0.72	-11.89	-0.43	1.31e-29	Gut microbiome composition (summer);
BRCA	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.26	-0.34	3.06e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg10495392	chr1:46806563	NSUN4	0.44	8.11	0.31	2.59e-15	Menopause (age at onset);
BRCA	cis	rs7092929	0.680	rs24401	chr10:3584829	A/G	cg14308648	chr10:3568949	NA	-0.42	-8.18	-0.31	1.5e-15	Coronary artery calcification;
BRCA	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11890956	chr21:40555474	PSMG1	-0.65	-14.71	-0.5	2.13e-42	Menarche (age at onset);
BRCA	cis	rs870825	0.860	rs55974219	chr4:185600733	G/A	cg04058563	chr4:185651563	MLF1IP	0.82	13.82	0.48	3.56e-38	Blood protein levels;
BRCA	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg12444411	chr7:2802554	GNA12	-0.35	-8.6	-0.32	6.13e-17	Height;
BRCA	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg11584989	chr19:19387371	SF4	0.6	13.8	0.48	3.99e-38	Bipolar disorder;
BRCA	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg13010199	chr12:38710504	ALG10B	0.55	12.01	0.43	4.36e-30	Heart rate;
BRCA	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg26384229	chr12:38710491	ALG10B	0.59	13.61	0.47	3.04e-37	Morning vs. evening chronotype;
BRCA	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg19077165	chr18:44547161	KATNAL2	-0.39	-8.41	-0.32	2.65e-16	Educational attainment;
BRCA	cis	rs7147624	0.882	rs1956008	chr14:66085429	G/T	cg03016385	chr14:66212404	NA	-0.59	-9.06	-0.34	1.57e-18	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs9296092	0.538	rs62405942	chr6:33517346	G/A	cg13560919	chr6:33536144	NA	-0.85	-18.39	-0.59	6.37e-61	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs3857067	0.806	rs11943926	chr4:95136512	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-9.72	-0.36	6.56e-21	QT interval;
BRCA	cis	rs72634258	0.554	rs34305100	chr1:7913029	A/G	cg00042356	chr1:8021962	PARK7	0.55	8.35	0.31	4.25e-16	Inflammatory bowel disease;
BRCA	cis	rs4660306	1.000	rs1044717	chr1:45976587	A/G	cg24296786	chr1:45957014	TESK2	0.43	8.56	0.32	8.52e-17	Homocysteine levels;
BRCA	cis	rs250677	0.687	rs2963485	chr5:148452043	A/G	cg18129178	chr5:148520854	ABLIM3	0.46	9.08	0.34	1.38e-18	Breast cancer;
BRCA	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg08859206	chr1:53392774	SCP2	-0.41	-8.24	-0.31	9.49e-16	Monocyte count;
BRCA	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg10862848	chr6:42927986	GNMT	-0.35	-14.69	-0.5	2.78e-42	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs11984145	1.000	rs60354841	chr7:38873461	T/C	cg19327137	chr7:38886074	VPS41	0.5	7.91	0.3	1.15e-14	Cognitive performance;
BRCA	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.14e-15	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7939886	0.920	rs74699881	chr11:55913852	A/T	cg15704280	chr7:45808275	SEPT13	0.63	7.84	0.3	1.88e-14	Myopia (pathological);
BRCA	cis	rs4690686	0.534	rs11133147	chr4:177281718	A/G	cg17059388	chr4:177262070	NA	0.36	8.23	0.31	1.06e-15	Essential tremor;
BRCA	cis	rs12760731	0.565	rs35038893	chr1:178168417	C/T	cg00404053	chr1:178313656	RASAL2	0.64	7.82	0.3	2.11e-14	Obesity-related traits;
BRCA	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg13047869	chr3:10149882	C3orf24	0.53	11.24	0.41	6.83e-27	Alzheimer's disease;
BRCA	trans	rs1325195	0.879	rs2793798	chr1:179094843	G/A	cg11624085	chr17:8464688	MYH10	-0.26	-7.84	-0.3	1.9e-14	IgE grass sensitization;
BRCA	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	14.29	0.49	2.03e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg21770322	chr7:97807741	LMTK2	0.45	11.71	0.42	7.96e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1595825	0.891	rs73056840	chr2:198783466	C/A	cg19156104	chr2:198669113	PLCL1	-0.41	-7.84	-0.3	1.89e-14	Ulcerative colitis;
BRCA	cis	rs4919087	1.000	rs10786333	chr10:99090390	A/G	cg25902810	chr10:99078978	FRAT1	-0.45	-9.49	-0.35	4.54e-20	Monocyte count;
BRCA	trans	rs1459104	1.000	rs35726021	chr11:55191206	G/A	cg15704280	chr7:45808275	SEPT13	0.66	8.14	0.31	2.03e-15	Body mass index;
BRCA	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg27279351	chr12:120934652	DYNLL1	0.57	13.28	0.47	1.01e-35	High light scatter reticulocyte count;
BRCA	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	13.85	0.48	2.55e-38	Alzheimer's disease;
BRCA	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg12386194	chr3:101231763	SENP7	-0.62	-12.1	-0.43	1.67e-30	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	20.16	0.62	2.4e-70	Platelet count;
BRCA	cis	rs367615	0.731	rs58241713	chr5:108853664	G/A	cg17395555	chr5:108820864	NA	0.37	11.39	0.41	1.78e-27	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-18.01	-0.58	6.03e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg14019146	chr3:50243930	SLC38A3	-0.57	-11.7	-0.42	8.46e-29	Intelligence (multi-trait analysis);
BRCA	trans	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04565464	chr8:145669602	NFKBIL2	0.42	9.49	0.35	4.57e-20	Bipolar disorder and schizophrenia;
BRCA	trans	rs1997103	0.871	rs6956733	chr7:55393032	A/C	cg20935933	chr6:143382018	AIG1	0.58	10.26	0.38	5.88e-23	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs629535	0.773	rs568159	chr8:70032908	C/G	cg21567404	chr3:27674614	NA	1.0	21.1	0.64	2.04e-75	Dupuytren's disease;
BRCA	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.2	0.68	7.62e-87	Chronic sinus infection;
BRCA	cis	rs4363385	0.782	rs4845336	chr1:153003853	C/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.36	-0.31	3.83e-16	Inflammatory skin disease;
BRCA	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg16414030	chr3:133502952	NA	0.46	10.82	0.39	3.66e-25	Iron status biomarkers;
BRCA	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-11.29	-0.41	4.5e-27	Gut microbiome composition (summer);
BRCA	cis	rs752010	0.967	rs2038978	chr1:42094719	A/G	cg06885757	chr1:42089581	HIVEP3	0.24	8.67	0.32	3.61e-17	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg00666640	chr1:248458726	OR2T12	0.29	8.23	0.31	1.08e-15	Common traits (Other);
BRCA	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg24110177	chr3:50126178	RBM5	-0.52	-15.46	-0.52	4.74e-46	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg22535103	chr8:58192502	C8orf71	-0.61	-13.25	-0.46	1.34e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg08470875	chr2:26401718	FAM59B	0.74	12.04	0.43	2.96e-30	Gut microbiome composition (summer);
BRCA	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	12.99	0.46	2.07e-34	Ileal carcinoids;
BRCA	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg00666640	chr1:248458726	OR2T12	0.33	8.48	0.32	1.51e-16	Common traits (Other);
BRCA	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg24692254	chr21:30365293	RNF160	-0.66	-17.95	-0.58	1.26e-58	Dental caries;
BRCA	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26314531	chr2:26401878	FAM59B	0.9	15.14	0.51	1.7e-44	Gut microbiome composition (summer);
BRCA	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11890956	chr21:40555474	PSMG1	-0.83	-21.45	-0.65	2.57e-77	Cognitive function;
BRCA	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-12.19	-0.43	6.96e-31	Electroencephalogram traits;
BRCA	cis	rs724568	0.509	rs10203976	chr2:67941638	T/G	cg14046302	chr2:67939758	NA	-0.4	-10.95	-0.4	1.06e-25	Major depressive disorder (broad);
BRCA	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10802521	chr3:52805072	NEK4	-0.33	-8.47	-0.32	1.73e-16	Bipolar disorder;
BRCA	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg01939980	chr4:1354348	KIAA1530	-0.32	-8.77	-0.33	1.56e-17	Obesity-related traits;
BRCA	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.32	-7.92	-0.3	1.05e-14	Total body bone mineral density;
BRCA	cis	rs9400271	0.527	rs4946954	chr6:109639656	A/G	cg01475377	chr6:109611718	NA	-0.37	-8.32	-0.31	5.32e-16	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg05025164	chr4:1340916	KIAA1530	0.6	12.33	0.44	1.82e-31	Longevity;
BRCA	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.03	0.3	4.61e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg07460842	chr6:66804631	NA	-1.02	-19.91	-0.62	5.44e-69	Exhaled nitric oxide output;
BRCA	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05901451	chr6:126070800	HEY2	0.48	12.02	0.43	3.69e-30	Endometrial cancer;
BRCA	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg06623918	chr6:96969491	KIAA0776	0.74	12.19	0.43	6.85e-31	Migraine;Coronary artery disease;
BRCA	cis	rs3857067	0.806	rs6825522	chr4:95108140	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.34	-0.35	1.56e-19	QT interval;
BRCA	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg26384229	chr12:38710491	ALG10B	-0.63	-16.51	-0.55	2.79e-51	Heart rate;
BRCA	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4363385	0.620	rs4388644	chr1:152983674	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.32	-0.31	5.52e-16	Inflammatory skin disease;
BRCA	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg08132940	chr7:1081526	C7orf50	-0.58	-8.81	-0.33	1.21e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	17.75	0.57	1.25e-57	Alzheimer's disease;
BRCA	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11644478	chr21:40555479	PSMG1	0.85	19.37	0.61	3.91e-66	Cognitive function;
BRCA	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg14675211	chr2:100938903	LONRF2	0.52	11.5	0.41	5.78e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg05084668	chr3:125655381	ALG1L	-0.47	-8.1	-0.31	2.77e-15	Blood pressure (smoking interaction);
BRCA	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg18252515	chr7:66147081	NA	-1.07	-15.35	-0.52	1.71e-45	Diabetic kidney disease;
BRCA	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03264133	chr6:25882463	NA	-0.53	-11.93	-0.43	9.61e-30	Blood metabolite levels;
BRCA	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg20503657	chr10:835505	NA	1.02	15.54	0.52	1.96e-46	Eosinophil percentage of granulocytes;
BRCA	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.0	-0.46	1.92e-34	Migraine;Coronary artery disease;
BRCA	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	-0.52	-9.96	-0.37	8.35e-22	Resistin levels;
BRCA	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.43	0.32	2.29e-16	Rheumatoid arthritis;
BRCA	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	ch.11.42038R	chr11:967971	AP2A2	0.52	16.68	0.55	4.22e-52	Alzheimer's disease (late onset);
BRCA	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg04362960	chr10:104952993	NT5C2	0.44	10.12	0.37	1.97e-22	Arsenic metabolism;
BRCA	cis	rs2046867	0.818	rs1502754	chr3:72895345	G/T	cg25664220	chr3:72788482	NA	-0.44	-10.0	-0.37	5.75e-22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg26818010	chr10:134567672	INPP5A	-0.77	-15.13	-0.51	1.95e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg11812906	chr14:75593930	NEK9	-0.65	-14.64	-0.5	4.74e-42	Height;
BRCA	cis	rs12530845	0.673	rs73725437	chr7:135327853	G/A	cg23117316	chr7:135346802	PL-5283	-0.39	-8.02	-0.3	5.07e-15	Red blood cell traits;
BRCA	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg09307838	chr4:120376055	NA	0.72	15.26	0.52	4.91e-45	Corneal astigmatism;
BRCA	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-12.62	-0.45	9.25e-33	Longevity;
BRCA	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.31	0.49	1.76e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg11266682	chr4:10021025	SLC2A9	-0.42	-10.91	-0.4	1.51e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.29	-0.31	6.8e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg11822812	chr5:140052017	DND1	-0.3	-8.4	-0.32	2.8e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.91	0.62	5.12e-69	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs67981189	0.865	rs2810115	chr14:71394787	A/G	cg15816911	chr14:71606274	NA	-0.37	-8.23	-0.31	1.04e-15	Schizophrenia;
BRCA	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-11.19	-0.4	1.15e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs11229555	0.645	rs11229430	chr11:58181104	G/C	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg15448220	chr1:150897856	SETDB1	0.35	7.9	0.3	1.26e-14	Melanoma;
BRCA	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.78	0.39	5.07e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg02297831	chr4:17616191	MED28	0.39	8.59	0.32	6.41e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg15083037	chr5:83017644	HAPLN1	-0.51	-10.07	-0.37	3.1e-22	Prostate cancer;
BRCA	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00149659	chr3:10157352	C3orf10	1.06	17.88	0.58	2.77e-58	Alzheimer's disease;
BRCA	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg24692254	chr21:30365293	RNF160	0.38	8.8	0.33	1.27e-17	Pancreatic cancer;
BRCA	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg06784218	chr1:46089804	CCDC17	-0.44	-10.27	-0.38	5.21e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-9.28	-0.34	2.53e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	trans	rs7178375	1.000	rs7169064	chr15:31210862	C/T	cg04373760	chr16:53404718	NA	0.47	8.78	0.33	1.53e-17	Hypertriglyceridemia;
BRCA	cis	rs3741151	0.773	rs7925226	chr11:73137362	A/G	cg17517138	chr11:73019481	ARHGEF17	0.88	12.73	0.45	3.1e-33	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg12140854	chr5:148520817	ABLIM3	0.42	9.19	0.34	5.51e-19	Breast cancer;
BRCA	cis	rs6450176	1.000	rs3776715	chr5:53299095	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.62	-15.07	-0.51	3.71e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg13175981	chr1:150552382	MCL1	0.43	9.4	0.35	9.24e-20	Tonsillectomy;
BRCA	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg18154014	chr19:37997991	ZNF793	0.48	9.56	0.35	2.54e-20	Coronary artery calcification;
BRCA	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg01483505	chr11:975446	AP2A2	0.33	8.98	0.33	2.93e-18	Alzheimer's disease (late onset);
BRCA	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg26384229	chr12:38710491	ALG10B	0.68	14.33	0.49	1.34e-40	Morning vs. evening chronotype;
BRCA	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg20203395	chr5:56204925	C5orf35	-0.37	-8.52	-0.32	1.1e-16	Coronary artery disease;
BRCA	cis	rs9469578	1.000	rs73743326	chr6:33709980	C/A	cg18708504	chr6:33715942	IP6K3	0.71	10.36	0.38	2.31e-23	Phosphorus levels;
BRCA	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11890956	chr21:40555474	PSMG1	0.94	21.62	0.65	3.39e-78	Cognitive function;
BRCA	cis	rs7582720	1.000	rs72936353	chr2:204070956	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	12.22	0.44	5.16e-31	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs6484504	0.600	rs2761593	chr11:31326752	G/T	cg06552810	chr11:31128660	NA	0.37	8.52	0.32	1.18e-16	Red blood cell count;
BRCA	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg04117972	chr1:227635322	NA	-0.46	-8.39	-0.31	3.13e-16	Major depressive disorder;
BRCA	cis	rs72627123	0.867	rs61522544	chr14:74481953	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.68	8.1	0.31	2.87e-15	Morning vs. evening chronotype;
BRCA	cis	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg06521331	chr12:34319734	NA	-0.43	-7.89	-0.3	1.36e-14	Resting heart rate;
BRCA	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.45	-10.51	-0.38	6.16e-24	Urate levels in overweight individuals;
BRCA	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg24642439	chr20:33292090	TP53INP2	0.53	11.5	0.41	5.99e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg07537917	chr2:241836409	C2orf54	-0.49	-11.69	-0.42	9.91e-29	Urinary metabolites;
BRCA	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg04267008	chr7:1944627	MAD1L1	-0.51	-10.64	-0.39	1.82e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.5	7.97	0.3	7.32e-15	Renal function-related traits (BUN);
BRCA	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg13010199	chr12:38710504	ALG10B	0.51	10.65	0.39	1.76e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4363385	0.747	rs2339493	chr1:152975277	G/A	cg24667326	chr1:152973720	SPRR3	-0.35	-9.82	-0.36	2.63e-21	Inflammatory skin disease;
BRCA	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.48	0.38	8.08e-24	Motion sickness;
BRCA	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-17.97	-0.58	9.17e-59	Morning vs. evening chronotype;
BRCA	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg26384229	chr12:38710491	ALG10B	0.79	17.92	0.58	1.7e-58	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.86	0.45	7.85e-34	Bipolar disorder;
BRCA	trans	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.06	0.3	3.79e-15	Corneal astigmatism;
BRCA	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg22189786	chr22:42395067	WBP2NL	0.41	8.07	0.3	3.52e-15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	trans	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.35	0.31	4.27e-16	Corneal astigmatism;
BRCA	cis	rs829883	0.664	rs829864	chr12:98850195	C/T	cg25150519	chr12:98850993	NA	0.68	16.49	0.55	3.84e-51	Colorectal adenoma (advanced);
BRCA	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg26116260	chr4:7069785	GRPEL1	0.89	24.19	0.69	2.79e-92	Monocyte percentage of white cells;
BRCA	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg11752832	chr7:134001865	SLC35B4	0.52	11.92	0.43	1.05e-29	Mean platelet volume;
BRCA	cis	rs1505368	0.534	rs10185241	chr2:213244124	C/T	cg20637307	chr2:213403960	ERBB4	0.33	7.89	0.3	1.28e-14	Symmetrical dimethylarginine levels;
BRCA	cis	rs4268898	0.552	rs12621083	chr2:24367540	C/T	cg26838691	chr2:24397539	C2orf84	0.39	7.96	0.3	8.05e-15	Asthma;
BRCA	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg23950597	chr19:37808831	NA	-0.63	-11.53	-0.41	4.51e-28	Coronary artery calcification;
BRCA	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg03146154	chr1:46216737	IPP	0.46	10.2	0.37	9.95e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24531977	chr5:56204891	C5orf35	0.72	16.03	0.54	7.19e-49	Initial pursuit acceleration;
BRCA	cis	rs3771570	1.000	rs17386555	chr2:242371825	G/A	cg21155796	chr2:242212141	HDLBP	0.63	9.54	0.35	3e-20	Prostate cancer;
BRCA	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg05863683	chr7:1912471	MAD1L1	0.37	8.49	0.32	1.4e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.89	-0.33	6.44e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	12.86	0.45	8.26e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-7.96	-0.3	7.93e-15	Total body bone mineral density;
BRCA	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg19678392	chr7:94953810	PON1	-0.42	-8.93	-0.33	4.37e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-12.92	-0.45	4.51e-34	Lymphocyte counts;
BRCA	cis	rs4363385	0.747	rs6671414	chr1:152974119	C/T	cg24667326	chr1:152973720	SPRR3	-0.35	-9.84	-0.36	2.32e-21	Inflammatory skin disease;
BRCA	cis	rs2953174	0.786	rs2953145	chr2:241515596	C/G	cg07929629	chr2:241523174	NA	-0.46	-8.61	-0.32	5.84e-17	Bipolar disorder;
BRCA	cis	rs738322	0.555	rs2284063	chr22:38544298	C/T	cg25457927	chr22:38595422	NA	0.37	13.54	0.47	6.32e-37	Cutaneous nevi;
BRCA	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg03146154	chr1:46216737	IPP	0.45	9.99	0.37	6.25e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg10495392	chr1:46806563	NSUN4	0.44	8.11	0.31	2.59e-15	Menopause (age at onset);
BRCA	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg23173402	chr1:227635558	NA	0.53	9.62	0.36	1.46e-20	Major depressive disorder;
BRCA	cis	rs208520	0.874	rs208518	chr6:66948501	C/G	cg07460842	chr6:66804631	NA	0.9	15.91	0.53	2.84e-48	Exhaled nitric oxide output;
BRCA	cis	rs7617773	0.780	rs13085251	chr3:48340045	C/T	cg11946769	chr3:48343235	NME6	0.68	14.05	0.49	2.93e-39	Coronary artery disease;
BRCA	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg08213375	chr14:104286397	PPP1R13B	0.42	9.07	0.34	1.43e-18	Reticulocyte count;
BRCA	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.6	14.32	0.49	1.49e-40	Hemoglobin concentration;
BRCA	cis	rs6120849	0.754	rs6088678	chr20:33607551	A/G	cg24642439	chr20:33292090	TP53INP2	-0.6	-10.45	-0.38	1.04e-23	Protein C levels;
BRCA	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg14683738	chr19:37701593	ZNF585B	0.44	7.89	0.3	1.3e-14	Coronary artery calcification;
BRCA	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg27129171	chr3:47204927	SETD2	-0.62	-14.06	-0.49	2.46e-39	Colorectal cancer;
BRCA	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg11584989	chr19:19387371	SF4	0.62	14.04	0.49	3.03e-39	Bipolar disorder;
BRCA	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg22431228	chr1:16359049	CLCNKA	-0.4	-8.14	-0.31	2.15e-15	Dilated cardiomyopathy;
BRCA	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg26395211	chr5:140044315	WDR55	0.38	8.56	0.32	8.22e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.54	0.32	9.54e-17	Rheumatoid arthritis;
BRCA	cis	rs6009527	0.752	rs7288176	chr22:49568462	A/G	cg12746016	chr22:49560550	NA	-0.42	-9.99	-0.37	6.04e-22	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
BRCA	cis	rs2882667	0.858	rs11957527	chr5:138404895	T/C	cg04439458	chr5:138467593	SIL1	-0.41	-10.29	-0.38	4.4e-23	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9462027	0.606	rs3777752	chr6:34772212	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.83	-0.3	1.98e-14	Systemic lupus erythematosus;
BRCA	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg05340658	chr4:99064831	C4orf37	0.51	9.74	0.36	5.42e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs921968	0.565	rs12611632	chr2:219621258	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-11.06	-0.4	3.78e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18876405	chr7:65276391	NA	-0.55	-13.42	-0.47	2.26e-36	Aortic root size;
BRCA	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.67	0.42	1.15e-28	Tonsillectomy;
BRCA	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg04545296	chr12:48745243	ZNF641	0.25	8.2	0.31	1.33e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	13.49	0.47	1.13e-36	Personality dimensions;
BRCA	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.51	9.52	0.35	3.35e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg25703541	chr22:24373054	LOC391322	-0.66	-14.5	-0.5	2.07e-41	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg08085267	chr17:45401833	C17orf57	-0.66	-14.62	-0.5	6.05e-42	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.46	-10.66	-0.39	1.6e-24	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18876405	chr7:65276391	NA	0.5	11.1	0.4	2.7e-26	Aortic root size;
BRCA	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.49	0.41	6.46e-28	Bipolar disorder;
BRCA	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg27490568	chr2:178487706	NA	-0.5	-8.4	-0.32	2.92e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg23029597	chr12:123009494	RSRC2	-0.46	-9.34	-0.35	1.58e-19	Body mass index;
BRCA	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg11663144	chr21:46675770	NA	-0.6	-13.87	-0.48	2.05e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7766436	0.885	rs1954272	chr6:22586499	A/G	cg13666174	chr6:22585274	NA	-0.48	-11.34	-0.41	2.75e-27	Coronary artery disease;
BRCA	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.19e-47	Alzheimer's disease (late onset);
BRCA	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg17691542	chr6:26056736	HIST1H1C	0.69	14.14	0.49	1.08e-39	Iron status biomarkers;
BRCA	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18876405	chr7:65276391	NA	0.63	15.51	0.52	2.79e-46	Aortic root size;
BRCA	trans	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg25214090	chr10:38739885	LOC399744	0.54	12.59	0.45	1.29e-32	Corneal astigmatism;
BRCA	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.81	-0.45	1.36e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg13402656	chr8:1511478	DLGAP2	-0.44	-10.42	-0.38	1.41e-23	Lung cancer;
BRCA	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg20891283	chr12:69753455	YEATS4	0.72	21.14	0.64	1.26e-75	Blood protein levels;
BRCA	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg15556689	chr8:8085844	FLJ10661	-0.36	-9.58	-0.35	2.08e-20	Monocyte count;
BRCA	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg16339924	chr4:17578868	LAP3	0.63	15.65	0.53	5.38e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg06521331	chr12:34319734	NA	-0.52	-9.55	-0.35	2.81e-20	Bladder cancer;
BRCA	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg14844989	chr11:31128820	NA	-0.45	-9.56	-0.35	2.55e-20	Red blood cell count;
BRCA	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-13.47	-0.47	1.39e-36	Response to antipsychotic treatment;
BRCA	cis	rs12579753	0.917	rs10862360	chr12:82187411	A/G	cg07988820	chr12:82153109	PPFIA2	-0.49	-8.57	-0.32	7.74e-17	Resting heart rate;
BRCA	cis	rs2066819	1.000	rs78495928	chr12:56635080	G/C	cg26714650	chr12:56694279	CS	-1.18	-15.33	-0.52	2.13e-45	Psoriasis vulgaris;
BRCA	trans	rs8073060	0.545	rs3859282	chr17:34006111	T/C	cg19694781	chr19:47549865	TMEM160	-1.03	-21.09	-0.64	2.33e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg04450456	chr4:17643702	FAM184B	0.33	9.62	0.36	1.44e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.37	-7.98	-0.3	6.78e-15	Total cholesterol levels;
BRCA	cis	rs7092929	0.883	rs651750	chr10:3577178	A/G	cg14308648	chr10:3568949	NA	0.41	7.85	0.3	1.73e-14	Coronary artery calcification;
BRCA	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11890956	chr21:40555474	PSMG1	-0.62	-13.8	-0.48	4.27e-38	Menarche (age at onset);
BRCA	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg24069376	chr3:38537580	EXOG	0.41	11.81	0.42	2.91e-29	Electrocardiographic conduction measures;
BRCA	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22307029	chr19:49891270	CCDC155	-0.47	-8.13	-0.31	2.22e-15	Multiple sclerosis;
BRCA	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg15704280	chr7:45808275	SEPT13	0.59	8.86	0.33	8.1e-18	Axial length;
BRCA	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg13628971	chr7:2884303	GNA12	0.6	13.62	0.47	2.96e-37	Height;
BRCA	trans	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg04565464	chr8:145669602	NFKBIL2	0.37	8.14	0.31	2.09e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg13556452	chr1:2391241	NA	-0.34	-8.08	-0.3	3.27e-15	Schizophrenia;
BRCA	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg27211696	chr2:191398769	TMEM194B	0.5	11.59	0.42	2.53e-28	Pulse pressure;
BRCA	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg21475434	chr5:93447410	FAM172A	0.66	8.49	0.32	1.45e-16	Diabetic retinopathy;
BRCA	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg24642439	chr20:33292090	TP53INP2	0.61	13.48	0.47	1.27e-36	Coronary artery disease;
BRCA	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.07	-14.42	-0.5	5.18e-41	Reticulocyte fraction of red cells;Reticulocyte count;
BRCA	cis	rs28830936	1.000	rs17678138	chr15:42043067	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.37	-11.34	-0.41	2.69e-27	Diastolic blood pressure;
BRCA	cis	rs61935443	0.832	rs7308359	chr12:95272904	G/T	cg21533806	chr12:95267307	NA	0.46	8.8	0.33	1.26e-17	Schizophrenia;
BRCA	trans	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg25214090	chr10:38739885	LOC399744	0.46	10.55	0.39	4.16e-24	Corneal astigmatism;
BRCA	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg10820045	chr2:198174542	NA	-0.41	-9.35	-0.35	1.42e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.4	8.44	0.32	2.05e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg12863693	chr15:85201151	NMB	-0.33	-7.93	-0.3	9.7e-15	P wave terminal force;
BRCA	cis	rs17641971	0.645	rs186891	chr8:50038758	T/C	cg00325661	chr8:49890786	NA	0.35	9.51	0.35	3.71e-20	Blood metabolite levels;
BRCA	cis	rs2629540	0.781	rs11245362	chr10:126458649	T/C	cg08799069	chr10:126477246	METTL10	-0.53	-11.66	-0.42	1.29e-28	Cocaine dependence;
BRCA	cis	rs67460515	0.500	rs9832109	chr3:160723364	T/C	cg03342759	chr3:160939853	NMD3	-0.6	-11.99	-0.43	5.24e-30	Parkinson's disease;
BRCA	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg21064579	chr19:49206444	FUT2	0.37	9.3	0.35	2.18e-19	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
BRCA	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg04362960	chr10:104952993	NT5C2	0.38	8.9	0.33	5.58e-18	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg01475377	chr6:109611718	NA	-0.59	-16.41	-0.54	9.2e-51	Reticulocyte fraction of red cells;
BRCA	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg24692254	chr21:30365293	RNF160	-0.6	-15.77	-0.53	1.51e-47	Dental caries;
BRCA	cis	rs7586879	0.789	rs13398155	chr2:25128550	C/T	cg01884057	chr2:25150051	NA	0.31	7.89	0.3	1.34e-14	Body mass index;
BRCA	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg05793240	chr7:2802953	GNA12	-0.34	-8.65	-0.32	4.22e-17	Height;
BRCA	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg21226059	chr5:178986404	RUFY1	-0.48	-13.5	-0.47	1.06e-36	Lung cancer;
BRCA	cis	rs4919694	0.808	rs4918001	chr10:105013147	G/T	cg04362960	chr10:104952993	NT5C2	-0.79	-12.89	-0.45	5.62e-34	Arsenic metabolism;
BRCA	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg11845111	chr2:191398756	TMEM194B	-0.73	-13.84	-0.48	2.62e-38	Diastolic blood pressure;
BRCA	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg08213375	chr14:104286397	PPP1R13B	0.63	17.14	0.56	1.79e-54	Schizophrenia;
BRCA	cis	rs757081	0.634	rs17472942	chr11:17094702	A/G	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.63	-0.32	4.87e-17	Systolic blood pressure;
BRCA	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg01689657	chr7:91764605	CYP51A1	0.22	7.91	0.3	1.13e-14	Breast cancer;
BRCA	cis	rs7011049	0.908	rs11986701	chr8:53833480	G/T	cg26025543	chr8:53854495	NA	0.54	9.85	0.36	2.09e-21	Systolic blood pressure;
BRCA	trans	rs11088226	0.681	rs9622	chr21:33951068	T/C	cg09050820	chr6:167586206	TCP10L2	0.85	15.88	0.53	4.06e-48	Gastritis;
BRCA	cis	rs10193935	0.901	rs59984817	chr2:42566909	C/G	cg27598129	chr2:42591480	NA	-0.91	-14.58	-0.5	9.14e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03264133	chr6:25882463	NA	-0.49	-11.01	-0.4	6.3e-26	Blood metabolite levels;
BRCA	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg12591125	chr7:1885375	MAD1L1	0.52	9.02	0.34	2.24e-18	Bipolar disorder;
BRCA	cis	rs2422052	0.729	rs967252	chr2:118643492	T/G	cg22545206	chr2:118617499	NA	0.39	9.51	0.35	3.89e-20	Mosquito bite size;
BRCA	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg04317338	chr11:64019027	PLCB3	0.57	9.71	0.36	7.01e-21	Mean platelet volume;
BRCA	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg13334819	chr7:99746414	C7orf59	0.39	9.01	0.34	2.32e-18	Coronary artery disease;
BRCA	cis	rs2505998	0.833	rs1864403	chr10:43604950	C/T	cg15436174	chr10:43711423	RASGEF1A	0.43	8.46	0.32	1.85e-16	Hirschsprung disease;
BRCA	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg20701182	chr2:24300061	SF3B14	0.71	13.25	0.46	1.48e-35	Lymphocyte counts;
BRCA	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg11366901	chr6:160182831	ACAT2	0.83	16.16	0.54	1.67e-49	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg03929089	chr4:120376271	NA	0.48	8.1	0.31	2.74e-15	Axial length;
BRCA	cis	rs250677	1.000	rs36069	chr5:148417253	G/C	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.98	-0.33	3.02e-18	Breast cancer;
BRCA	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	11.35	0.41	2.61e-27	Height;
BRCA	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg23649088	chr2:200775458	C2orf69	-0.63	-10.5	-0.38	6.71e-24	Schizophrenia;
BRCA	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg18154014	chr19:37997991	ZNF793	0.62	11.61	0.42	2.07e-28	Coronary artery calcification;
BRCA	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg19678392	chr7:94953810	PON1	-0.42	-8.62	-0.32	5.29e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg08917208	chr2:24149416	ATAD2B	1.07	14.8	0.51	7.91e-43	Lymphocyte counts;
BRCA	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg01877450	chr7:97915802	BRI3	-0.37	-8.29	-0.31	6.85e-16	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21659725	chr3:3221576	CRBN	0.71	21.66	0.65	1.89e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs7301826	1.000	rs10773822	chr12:131289107	C/G	cg11011512	chr12:131303247	STX2	0.42	10.88	0.4	2.07e-25	Plasma plasminogen activator levels;
BRCA	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg21427119	chr20:30132790	HM13	-0.42	-8.67	-0.32	3.64e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg03709012	chr19:19516395	GATAD2A	-0.81	-18.81	-0.6	4.03e-63	Tonsillectomy;
BRCA	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.44	-10.14	-0.37	1.62e-22	Lymphocyte counts;
BRCA	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg00012203	chr2:219082015	ARPC2	0.71	16.21	0.54	9.22e-50	Colorectal cancer;
BRCA	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg23285459	chr7:2802560	GNA12	-0.36	-9.11	-0.34	1.08e-18	Height;
BRCA	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg17063962	chr7:91808500	NA	0.54	12.28	0.44	2.93e-31	Breast cancer;
BRCA	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg20387954	chr3:183756860	HTR3D	0.47	10.56	0.39	4e-24	Anterior chamber depth;
BRCA	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg23533926	chr12:111358616	MYL2	-0.44	-9.19	-0.34	5.5e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7264396	0.836	rs1886695	chr20:34180535	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.57	11.98	0.43	5.73e-30	Total cholesterol levels;
BRCA	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.43	11.86	0.42	1.84e-29	Response to antipsychotic treatment;
BRCA	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.46	-8.12	-0.31	2.34e-15	Body mass index (adult);
BRCA	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.3	-8.05	-0.3	4.1e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1050631	0.564	rs1785934	chr18:33718326	A/C	cg19453250	chr18:33710783	SLC39A6;ELP2	-0.29	-7.99	-0.3	6.25e-15	Esophageal squamous cell cancer (length of survival);
BRCA	cis	rs738322	0.640	rs738321	chr22:38568833	C/G	cg20207973	chr22:38506712	BAIAP2L2	0.31	7.93	0.3	9.93e-15	Cutaneous nevi;
BRCA	cis	rs7631605	0.819	rs4678922	chr3:37022864	A/T	cg15934958	chr3:37212084	LRRFIP2	0.42	9.82	0.36	2.61e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg22875332	chr1:76189707	ACADM	-0.54	-10.17	-0.37	1.32e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22455342	chr2:225449267	CUL3	-0.63	-15.82	-0.53	7.95e-48	IgE levels in asthmatics (D.p. specific);
BRCA	trans	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg26384229	chr12:38710491	ALG10B	0.59	11.85	0.42	1.94e-29	Resting heart rate;
BRCA	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26168224	chr5:2018326	NA	0.64	17.98	0.58	8.6e-59	Gut microbiome composition (winter);
BRCA	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.67	0.42	1.12e-28	Homoarginine levels;
BRCA	cis	rs12618769	0.597	rs4851140	chr2:99079339	T/C	cg10123293	chr2:99228465	UNC50	0.41	8.09	0.3	3.05e-15	Bipolar disorder;
BRCA	cis	rs73198271	0.740	rs10092600	chr8:8649023	A/G	cg15556689	chr8:8085844	FLJ10661	-0.32	-7.85	-0.3	1.78e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg12564285	chr5:131593104	PDLIM4	0.36	9.68	0.36	9.33e-21	Breast cancer;
BRCA	cis	rs9463078	0.683	rs227850	chr6:44699068	C/T	cg25276700	chr6:44698697	NA	0.36	7.94	0.3	9.19e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs27434	0.539	rs40604	chr5:96155900	G/A	cg16492584	chr5:96139282	ERAP1	-0.51	-12.82	-0.45	1.22e-33	Ankylosing spondylitis;
BRCA	cis	rs1568889	0.838	rs11030230	chr11:28174631	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.62	0.63	8.22e-73	Bipolar disorder;
BRCA	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg26597838	chr10:835615	NA	0.96	14.45	0.5	3.55e-41	Eosinophil percentage of granulocytes;
BRCA	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg03929089	chr4:120376271	NA	0.47	7.94	0.3	9.07e-15	Axial length;
BRCA	cis	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg06521331	chr12:34319734	NA	-0.56	-11.0	-0.4	6.82e-26	Morning vs. evening chronotype;
BRCA	cis	rs35123781	0.955	rs34530707	chr5:139059016	G/A	cg05227215	chr5:139057496	CXXC5	0.36	8.67	0.32	3.66e-17	Schizophrenia;
BRCA	cis	rs6435161	1.000	rs6748088	chr2:203556526	A/G	cg18429434	chr2:203499731	FAM117B	-0.44	-8.78	-0.33	1.54e-17	Total cholesterol levels;
BRCA	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg13256891	chr4:100009986	ADH5	-0.5	-9.53	-0.35	3.33e-20	Smoking initiation;
BRCA	trans	rs800082	0.668	rs7643301	chr3:144293612	G/A	cg24215973	chr2:240111563	HDAC4	-0.43	-10.32	-0.38	3.26e-23	Smoking behavior;
BRCA	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.81	-18.93	-0.6	8.94e-64	Ulcerative colitis;
BRCA	cis	rs4363385	0.747	rs1577962	chr1:152962013	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.36	-0.31	4.06e-16	Inflammatory skin disease;
BRCA	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11764359	chr7:65958608	NA	0.76	16.83	0.55	7.34e-53	Aortic root size;
BRCA	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.14e-19	Total body bone mineral density;
BRCA	cis	rs999943	0.846	rs1570760	chr6:33622933	C/T	cg14003231	chr6:33640908	ITPR3	0.67	15.06	0.51	4.43e-44	Obesity (extreme);
BRCA	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.52	0.38	5.68e-24	Motion sickness;
BRCA	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg24642439	chr20:33292090	TP53INP2	0.52	11.43	0.41	1.2e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg04450456	chr4:17643702	FAM184B	0.31	9.06	0.34	1.52e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7255436	0.965	rs7254882	chr19:8453822	A/G	cg10811474	chr19:8428787	ANGPTL4	-0.31	-7.86	-0.3	1.69e-14	HDL cholesterol;
BRCA	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.46	8.24	0.31	9.64e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24110177	chr3:50126178	RBM5	-0.36	-9.59	-0.35	1.96e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg00666640	chr1:248458726	OR2T12	-0.31	-8.54	-0.32	1.01e-16	Common traits (Other);
BRCA	cis	rs78707713	0.560	rs61848397	chr10:71225584	C/A	cg12610070	chr10:71211762	TSPAN15	-0.33	-10.15	-0.37	1.54e-22	Venous thromboembolism;
BRCA	cis	rs4363385	0.818	rs558363	chr1:153010431	C/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg04315214	chr1:2043799	PRKCZ	-0.47	-12.52	-0.44	2.44e-32	Height;
BRCA	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg26248373	chr2:1572462	NA	-0.63	-14.68	-0.5	2.88e-42	IgG glycosylation;
BRCA	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg01236616	chr12:121019343	POP5	1.25	27.71	0.74	1.32e-111	Type 1 diabetes nephropathy;
BRCA	cis	rs11051970	0.636	rs325424	chr12:32570193	C/T	cg02745156	chr12:32552066	NA	0.25	8.27	0.31	7.81e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg19077165	chr18:44547161	KATNAL2	-0.58	-12.91	-0.45	4.74e-34	Personality dimensions;
BRCA	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg24829409	chr8:58192753	C8orf71	-0.47	-9.12	-0.34	9.38e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg06618935	chr21:46677482	NA	0.37	8.45	0.32	1.9e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg14683738	chr19:37701593	ZNF585B	0.45	8.02	0.3	4.94e-15	Coronary artery calcification;
BRCA	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.61	12.24	0.44	4.33e-31	Lymphocyte counts;
BRCA	cis	rs4268898	0.552	rs35331966	chr2:24367828	C/T	cg26838691	chr2:24397539	C2orf84	0.39	7.96	0.3	8.05e-15	Asthma;
BRCA	cis	rs7572733	0.534	rs734037	chr2:198749269	G/A	cg00792783	chr2:198669748	PLCL1	0.47	10.25	0.38	6.42e-23	Dermatomyositis;
BRCA	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg11584989	chr19:19387371	SF4	-0.64	-13.77	-0.48	5.92e-38	Bipolar disorder;
BRCA	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.28	-0.31	7.47e-16	Bipolar disorder;
BRCA	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg19920283	chr7:105172520	RINT1	0.59	9.54	0.35	2.83e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg05472934	chr7:22766657	IL6	-0.55	-14.63	-0.5	5.25e-42	Lung cancer;
BRCA	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	7.15e-19	Alzheimer's disease (late onset);
BRCA	cis	rs6484504	0.625	rs7940420	chr11:31366700	T/A	cg26647111	chr11:31128758	NA	0.43	9.25	0.34	3.3e-19	Red blood cell count;
BRCA	cis	rs4919087	1.000	rs7078288	chr10:99086361	C/T	cg25902810	chr10:99078978	FRAT1	-0.45	-9.49	-0.35	4.33e-20	Monocyte count;
BRCA	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg11693508	chr17:37793320	STARD3	0.57	10.84	0.39	2.88e-25	Bipolar disorder;
BRCA	cis	rs9790314	0.905	rs7632797	chr3:161002694	C/T	cg04691961	chr3:161091175	C3orf57	0.58	14.23	0.49	3.92e-40	Morning vs. evening chronotype;
BRCA	cis	rs28374715	0.662	rs113913466	chr15:41483100	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.87	-18.16	-0.58	9.85e-60	Ulcerative colitis;
BRCA	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11764359	chr7:65958608	NA	-0.75	-16.67	-0.55	4.55e-52	Aortic root size;
BRCA	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg18964960	chr10:1102726	WDR37	-0.48	-8.59	-0.32	6.65e-17	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg11366901	chr6:160182831	ACAT2	0.7	13.8	0.48	4.34e-38	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg27170947	chr2:26402098	FAM59B	-0.81	-12.91	-0.45	5e-34	Gut microbiome composition (summer);
BRCA	trans	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg17830980	chr10:43048298	ZNF37B	0.43	10.03	0.37	4.21e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg14456004	chr13:21872349	NA	-1.14	-21.74	-0.65	7.13e-79	White matter hyperintensity burden;
BRCA	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg24675658	chr1:53192096	ZYG11B	-0.6	-14.38	-0.49	8.36e-41	Monocyte count;
BRCA	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg17063962	chr7:91808500	NA	0.53	12.45	0.44	5.38e-32	Breast cancer;
BRCA	cis	rs7715811	1.000	rs1502050	chr5:13779743	A/G	cg07548982	chr5:13769939	DNAH5	-0.38	-8.63	-0.32	4.86e-17	Subclinical atherosclerosis traits (other);
BRCA	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg25174290	chr11:3078921	CARS	0.43	12.97	0.46	2.53e-34	Longevity;
BRCA	cis	rs10733682	0.524	rs10987418	chr9:129462563	A/G	cg00232160	chr9:129468157	NA	0.35	8.03	0.3	4.62e-15	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg08392591	chr16:89556376	ANKRD11	-0.39	-8.97	-0.33	3.39e-18	Multiple myeloma (IgH translocation);
BRCA	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-16.04	-0.54	6.86e-49	Alzheimer's disease (late onset);
BRCA	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg18446336	chr7:2847575	GNA12	-0.35	-8.25	-0.31	8.78e-16	Height;
BRCA	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg19717773	chr7:2847554	GNA12	-0.43	-9.69	-0.36	8.32e-21	Height;
BRCA	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.64	-0.36	1.27e-20	Alcohol dependence;
BRCA	cis	rs9462027	0.628	rs58671447	chr6:34752351	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.94	-0.3	9.2e-15	Systemic lupus erythematosus;
BRCA	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg14844989	chr11:31128820	NA	-0.45	-9.77	-0.36	4.21e-21	Red blood cell count;
BRCA	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg07636037	chr3:49044803	WDR6	-0.58	-8.29	-0.31	6.64e-16	Cognitive ability (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.82	0.3	2.22e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs16854884	0.837	rs989665	chr3:143792854	C/T	cg06585982	chr3:143692056	C3orf58	0.39	7.86	0.3	1.61e-14	Economic and political preferences (feminism/equality);
BRCA	cis	rs2012796	0.957	rs8009083	chr14:81818289	A/G	cg02996355	chr14:81879375	NA	0.4	8.08	0.3	3.14e-15	Night sleep phenotypes;
BRCA	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg03709012	chr19:19516395	GATAD2A	1.1	20.81	0.64	7.57e-74	Nonalcoholic fatty liver disease;
BRCA	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.93	-0.3	9.52e-15	Prostate cancer;
BRCA	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg20307385	chr11:47447363	PSMC3	-0.4	-8.48	-0.32	1.52e-16	Subjective well-being;
BRCA	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.34	-0.35	1.55e-19	Menopause (age at onset);
BRCA	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.78	-0.36	3.67e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs11605924	1.000	rs12794698	chr11:45871861	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.46	-10.09	-0.37	2.55e-22	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21582582	chr3:182698605	DCUN1D1	0.36	9.48	0.35	5.09e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.71e-21	Menopause (age at onset);
BRCA	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg09469691	chr10:81107165	PPIF	0.43	9.39	0.35	1.02e-19	Height;
BRCA	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg17845761	chr1:175162550	KIAA0040	0.26	9.9	0.36	1.35e-21	Alcohol dependence;
BRCA	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.38	0.54	1.25e-50	Colorectal cancer;
BRCA	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.57	-0.35	2.21e-20	Total body bone mineral density;
BRCA	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg20628663	chr10:43360327	NA	-0.7	-13.62	-0.47	2.75e-37	Blood protein levels;
BRCA	cis	rs2625529	0.586	rs2306489	chr15:72227471	G/A	cg16672083	chr15:72433130	SENP8	0.69	16.74	0.55	2.04e-52	Red blood cell count;
BRCA	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg05347473	chr6:146136440	FBXO30	-0.4	-7.95	-0.3	8.78e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9296092	0.517	rs55963187	chr6:33523778	G/C	cg13560919	chr6:33536144	NA	-0.85	-17.72	-0.57	1.88e-57	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	20.35	0.63	2.32e-71	Platelet count;
BRCA	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	13.79	0.48	4.84e-38	Platelet count;
BRCA	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg22920501	chr2:26401640	FAM59B	0.91	16.27	0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.28	0.31	7.22e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2880765	0.525	rs35899940	chr15:86053697	A/G	cg10818794	chr15:86012489	AKAP13	-0.31	-7.82	-0.3	2.12e-14	Coronary artery disease;
BRCA	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg19156104	chr2:198669113	PLCL1	-0.44	-8.12	-0.31	2.35e-15	Ulcerative colitis;
BRCA	trans	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.37	8.11	0.31	2.57e-15	Mean corpuscular volume;
BRCA	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	14.09	0.49	1.82e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11764359	chr7:65958608	NA	-0.77	-17.65	-0.57	4.23e-57	Aortic root size;
BRCA	cis	rs4742903	0.935	rs1507515	chr9:106989653	A/G	cg14250997	chr9:106856677	SMC2	-0.3	-9.31	-0.35	1.97e-19	High-grade serous ovarian cancer;Breast cancer;
BRCA	trans	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg25214090	chr10:38739885	LOC399744	0.51	10.5	0.38	6.89e-24	Corneal astigmatism;
BRCA	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg07606381	chr6:8435919	SLC35B3	-0.57	-12.19	-0.43	7.19e-31	Motion sickness;
BRCA	cis	rs12220238	1.000	rs4320897	chr10:76017732	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.49	8.1	0.31	2.72e-15	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg13319975	chr6:146136371	FBXO30	-0.41	-9.39	-0.35	1e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg12615879	chr12:58013172	SLC26A10	0.39	10.74	0.39	7.5e-25	Multiple sclerosis;
BRCA	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg24578937	chr1:2090814	PRKCZ	-0.33	-10.31	-0.38	3.82e-23	Height;
BRCA	trans	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg25214090	chr10:38739885	LOC399744	0.36	8.2	0.31	1.29e-15	Diastolic blood pressure;
BRCA	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg08493051	chr2:3487164	NA	-0.43	-9.22	-0.34	4.1e-19	Neurofibrillary tangles;
BRCA	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg18357645	chr12:58087776	OS9	0.47	13.55	0.47	6.3e-37	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg18404041	chr3:52824283	ITIH1	-0.37	-9.19	-0.34	5.31e-19	Schizophrenia;
BRCA	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg18252515	chr7:66147081	NA	-0.85	-12.36	-0.44	1.23e-31	Diabetic kidney disease;
BRCA	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.62	-14.1	-0.49	1.67e-39	Ulcerative colitis;
BRCA	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg11764359	chr7:65958608	NA	0.65	11.9	0.43	1.21e-29	Aortic root size;
BRCA	cis	rs11051970	0.636	rs2651368	chr12:32561506	T/C	cg02745156	chr12:32552066	NA	0.25	8.4	0.32	2.93e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs3857067	0.772	rs4692999	chr4:95107644	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.34	-0.35	1.56e-19	QT interval;
BRCA	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg21475434	chr5:93447410	FAM172A	-0.69	-8.9	-0.33	5.94e-18	Diabetic retinopathy;
BRCA	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.31	8.46	0.32	1.8e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs3771570	1.000	rs16843590	chr2:242298228	G/A	cg21155796	chr2:242212141	HDLBP	0.6	9.37	0.35	1.26e-19	Prostate cancer;
BRCA	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	17.29	0.56	3.16e-55	Hip circumference adjusted for BMI;
BRCA	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg23625390	chr15:77176239	SCAPER	0.45	11.19	0.4	1.1e-26	Blood metabolite levels;
BRCA	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg05340658	chr4:99064831	C4orf37	0.49	10.82	0.39	3.59e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7903847	0.620	rs3737194	chr10:99130127	A/G	cg08345082	chr10:99160200	RRP12	-0.28	-7.96	-0.3	7.88e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg08999081	chr20:33150536	PIGU	0.35	8.89	0.33	6e-18	Coronary artery disease;
BRCA	cis	rs9487051	0.676	rs11964178	chr6:109562035	A/G	cg01475377	chr6:109611718	NA	-0.38	-9.09	-0.34	1.25e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.85	-0.53	5.78e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg16584290	chr5:462447	EXOC3	0.53	15.08	0.51	3.48e-44	Cystic fibrosis severity;
BRCA	cis	rs752010	0.714	rs6658500	chr1:42088344	A/G	cg06885757	chr1:42089581	HIVEP3	-0.29	-10.38	-0.38	2.0500000000000001e-23	Lupus nephritis in systemic lupus erythematosus;
BRCA	trans	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-29.08	-0.75	4.29e-119	Exhaled nitric oxide output;
BRCA	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg21573476	chr21:45109991	RRP1B	-0.32	-8.41	-0.32	2.69e-16	Mean corpuscular volume;
BRCA	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg03676636	chr4:99064102	C4orf37	0.2	7.82	0.3	2.11e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18876405	chr7:65276391	NA	-0.64	-15.46	-0.52	4.91e-46	Calcium levels;
BRCA	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg11502198	chr6:26597334	ABT1	0.47	9.39	0.35	1.03e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg22800045	chr5:56110881	MAP3K1	0.62	11.83	0.42	2.4e-29	Initial pursuit acceleration;
BRCA	cis	rs3771570	1.000	rs73002111	chr2:242277833	C/T	cg21155796	chr2:242212141	HDLBP	0.6	9.3	0.35	2.25e-19	Prostate cancer;
BRCA	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg22920501	chr2:26401640	FAM59B	-0.67	-11.06	-0.4	3.98e-26	Gut microbiome composition (summer);
BRCA	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg23505145	chr19:12996616	KLF1	0.56	12.86	0.45	7.8e-34	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.75	-0.33	1.83e-17	Depression;
BRCA	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg26384229	chr12:38710491	ALG10B	-0.5	-13.02	-0.46	1.56e-34	Morning vs. evening chronotype;
BRCA	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg13902645	chr11:5959945	NA	0.52	10.35	0.38	2.69e-23	DNA methylation (variation);
BRCA	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg00750074	chr16:89608354	SPG7	-0.36	-9.58	-0.35	2.03e-20	Multiple myeloma (IgH translocation);
BRCA	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24308560	chr3:49941425	MST1R	-0.41	-8.67	-0.32	3.58e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs8073060	0.586	rs4795086	chr17:34042190	G/A	cg19694781	chr19:47549865	TMEM160	1.05	20.27	0.63	6.46e-71	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg16325326	chr1:53192061	ZYG11B	-0.95	-26.1	-0.72	8.67e-103	Monocyte count;
BRCA	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg00717180	chr2:96193071	NA	-0.38	-10.08	-0.37	2.87e-22	Height;
BRCA	trans	rs4650994	1.000	rs4354501	chr1:178524596	T/C	cg05059571	chr16:84539110	KIAA1609	-0.42	-9.47	-0.35	5.14e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs6820391	0.663	rs10021838	chr4:54448833	A/G	cg04173182	chr4:54446035	LNX1	0.47	10.71	0.39	9.76e-25	Cervical artery dissection;
BRCA	cis	rs698833	0.548	rs6544760	chr2:44553014	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.43	0.32	2.33e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg00105475	chr2:10696890	NA	0.44	10.3	0.38	4.11e-23	Prostate cancer;
BRCA	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg12444411	chr7:2802554	GNA12	-0.35	-8.79	-0.33	1.37e-17	Height;
BRCA	cis	rs1030877	0.515	rs2576735	chr2:105888839	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.65	12.56	0.45	1.68e-32	Obesity-related traits;
BRCA	cis	rs736801	0.759	rs11741255	chr5:131811182	G/A	cg14196790	chr5:131705035	SLC22A5	0.41	9.58	0.35	2.02e-20	Breast cancer;Mosquito bite size;
BRCA	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg24690094	chr11:67383802	NA	0.44	9.5	0.35	4.12e-20	Mean corpuscular volume;
BRCA	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg18252515	chr7:66147081	NA	-0.84	-12.12	-0.43	1.34e-30	Diabetic kidney disease;
BRCA	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg21772509	chr8:41503840	NKX6-3	0.48	11.25	0.41	6.71e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
BRCA	cis	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg09307838	chr4:120376055	NA	0.6	11.04	0.4	4.7e-26	Corneal astigmatism;
BRCA	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	11.34	0.41	2.89e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg17971929	chr21:40555470	PSMG1	0.75	16.14	0.54	2.12e-49	Cognitive function;
BRCA	trans	rs8073060	0.544	rs225274	chr17:33971221	C/T	cg19694781	chr19:47549865	TMEM160	0.96	20.65	0.63	5.71e-73	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg00383909	chr3:49044727	WDR6	0.96	13.25	0.46	1.39e-35	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg00086871	chr4:6988644	TBC1D14	0.93	14.54	0.5	1.41e-41	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.81	-18.94	-0.6	8e-64	Ulcerative colitis;
BRCA	cis	rs2455799	0.613	rs2166759	chr3:15856285	A/G	cg16303742	chr3:15540471	COLQ	0.38	9.2	0.34	4.91e-19	Mean platelet volume;
BRCA	cis	rs897984	0.511	rs7196726	chr16:31092075	G/A	cg00531865	chr16:30841666	NA	-0.38	-8.88	-0.33	6.55e-18	Dementia with Lewy bodies;
BRCA	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg23711669	chr6:146136114	FBXO30	0.76	17.46	0.57	3.96e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.34	-0.31	4.53e-16	Total body bone mineral density;
BRCA	trans	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg07211511	chr3:129823064	LOC729375	-0.62	-10.82	-0.39	3.47e-25	Blood pressure (smoking interaction);
BRCA	cis	rs586533	0.837	rs627917	chr11:99503825	A/G	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.31	2.78e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg07395648	chr5:131743802	NA	-0.37	-8.17	-0.31	1.7e-15	Breast cancer;
BRCA	cis	rs701145	0.585	rs6769099	chr3:153852442	T/C	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.82e-18	Coronary artery disease;
BRCA	cis	rs11229555	0.609	rs11229434	chr11:58185501	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg01448562	chr3:133502909	NA	-0.41	-9.48	-0.35	4.98e-20	Iron status biomarkers;
BRCA	cis	rs6484504	0.576	rs208091	chr11:31190099	G/C	cg26647111	chr11:31128758	NA	-0.44	-9.62	-0.36	1.5e-20	Red blood cell count;
BRCA	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	8.32	0.31	5.28e-16	Mean platelet volume;
BRCA	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg19077165	chr18:44547161	KATNAL2	-0.42	-9.05	-0.34	1.68e-18	Educational attainment;
BRCA	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg09455208	chr3:40491958	NA	0.4	9.41	0.35	8.63e-20	Renal cell carcinoma;
BRCA	trans	rs4650994	1.000	rs17276527	chr1:178520680	G/A	cg05059571	chr16:84539110	KIAA1609	-0.42	-9.6	-0.36	1.71e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs965469	1.000	rs6051737	chr20:3296992	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-10.13	-0.37	1.77e-22	IFN-related cytopenia;
BRCA	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	13.2	0.46	2.28e-35	Lymphocyte counts;
BRCA	cis	rs2882667	0.537	rs13181793	chr5:138408956	G/A	cg04439458	chr5:138467593	SIL1	-0.33	-8.99	-0.33	2.89e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7523050	0.908	rs12404382	chr1:109397129	G/A	cg08274380	chr1:109419600	GPSM2	0.84	12.88	0.45	6.8e-34	Fat distribution (HIV);
BRCA	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg21475434	chr5:93447410	FAM172A	0.69	9.27	0.34	2.78e-19	Diabetic retinopathy;
BRCA	cis	rs6005807	0.719	rs7293232	chr22:29015590	T/G	cg12565055	chr22:29076175	TTC28	0.49	9.33	0.35	1.65e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg11214544	chr1:2391121	NA	-0.42	-9.87	-0.36	1.82e-21	Non-obstructive azoospermia;
BRCA	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg21573476	chr21:45109991	RRP1B	-0.35	-9.21	-0.34	4.54e-19	Mean corpuscular volume;
BRCA	cis	rs12618769	0.597	rs2309390	chr2:99114310	T/C	cg10123293	chr2:99228465	UNC50	0.42	8.37	0.31	3.53e-16	Bipolar disorder;
BRCA	cis	rs10193935	1.000	rs72796507	chr2:42409840	A/G	cg27598129	chr2:42591480	NA	-0.87	-14.04	-0.49	3.25e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg22963979	chr7:1858916	MAD1L1	0.37	8.03	0.3	4.87e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.48e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.59e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs365132	0.818	rs6879982	chr5:176351330	A/T	cg16309518	chr5:176445507	NA	-0.37	-8.9	-0.33	5.58e-18	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg04025307	chr7:1156635	C7orf50	0.72	18.2	0.58	5.88e-60	Longevity;Endometriosis;
BRCA	cis	rs6543140	0.964	rs6748390	chr2:103062175	A/G	cg04239558	chr2:103089729	SLC9A4	0.34	9.43	0.35	7.61e-20	Blood protein levels;
BRCA	cis	rs11971779	0.680	rs6954547	chr7:139054734	C/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.24	0.38	6.65e-23	Diisocyanate-induced asthma;
BRCA	cis	rs9300255	0.602	rs2695478	chr12:123689521	C/T	cg00376283	chr12:123451042	ABCB9	0.56	10.81	0.39	3.86e-25	Neutrophil percentage of white cells;
BRCA	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18876405	chr7:65276391	NA	0.54	12.77	0.45	2.1e-33	Aortic root size;
BRCA	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	20.29	0.63	4.8e-71	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7178424	0.967	rs35123892	chr15:62303982	C/T	cg00456672	chr15:62358751	C2CD4A	-0.39	-8.78	-0.33	1.52e-17	Height;
BRCA	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.89	-0.43	1.43e-29	Response to antipsychotic treatment;
BRCA	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg08999081	chr20:33150536	PIGU	-0.34	-8.69	-0.33	2.93e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg10253484	chr15:75165896	SCAMP2	-0.48	-9.65	-0.36	1.12e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg24642439	chr20:33292090	TP53INP2	-0.55	-11.83	-0.42	2.57e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg20701182	chr2:24300061	SF3B14	0.62	8.86	0.33	8.1e-18	Lymphocyte counts;
BRCA	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg11062466	chr8:58055876	NA	0.44	8.53	0.32	1.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg14675211	chr2:100938903	LONRF2	0.52	11.67	0.42	1.21e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs13394619	0.935	rs12468019	chr2:11725049	T/C	cg07314298	chr2:11723111	GREB1	-0.53	-11.94	-0.43	7.96e-30	Endometriosis;
BRCA	cis	rs7301826	0.627	rs1077317	chr12:131314977	C/T	cg11011512	chr12:131303247	STX2	0.52	13.68	0.48	1.44e-37	Plasma plasminogen activator levels;
BRCA	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg18230493	chr5:56204884	C5orf35	0.91	17.71	0.57	2.24e-57	Initial pursuit acceleration;
BRCA	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg24324837	chr19:49891574	CCDC155	0.47	7.94	0.3	9.35e-15	Multiple sclerosis;
BRCA	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-8.62	-0.32	5.25e-17	Monocyte percentage of white cells;
BRCA	cis	rs34779708	0.966	rs6481941	chr10:35440141	G/A	cg03585969	chr10:35415529	CREM	0.45	9.43	0.35	7.65e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs73001065	1.000	rs56255430	chr19:19477877	A/C	cg03709012	chr19:19516395	GATAD2A	0.91	9.47	0.35	5.16e-20	LDL cholesterol;
BRCA	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12016809	chr21:47604291	C21orf56	-0.4	-8.1	-0.31	2.73e-15	Testicular germ cell tumor;
BRCA	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.59	8.01	0.3	5.54e-15	Yeast infection;
BRCA	cis	rs877282	0.947	rs7475589	chr10:767479	C/G	cg17470449	chr10:769945	NA	0.49	8.5	0.32	1.37e-16	Uric acid levels;
BRCA	cis	rs870825	0.860	rs61165411	chr4:185604461	G/A	cg04058563	chr4:185651563	MLF1IP	0.82	13.8	0.48	4.24e-38	Blood protein levels;
BRCA	cis	rs877282	0.583	rs10904562	chr10:819058	T/C	cg15764593	chr10:829463	NA	-0.63	-10.16	-0.37	1.35e-22	Uric acid levels;
BRCA	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg26384229	chr12:38710491	ALG10B	0.67	15.15	0.51	1.56e-44	Morning vs. evening chronotype;
BRCA	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg16325326	chr1:53192061	ZYG11B	0.86	25.24	0.71	4.71e-98	Monocyte count;
BRCA	cis	rs4766646	0.640	rs10850891	chr12:110299223	G/A	cg01252219	chr12:110302105	GLTP	0.35	7.85	0.3	1.7e-14	Metabolite levels (MHPG);
BRCA	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg10932868	chr11:921992	NA	0.49	12.38	0.44	1.09e-31	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.8	0.39	4.23e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.37	7.86	0.3	1.62e-14	Total cholesterol levels;
BRCA	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg22875332	chr1:76189707	ACADM	-0.52	-10.14	-0.37	1.6400000000000001e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg17052675	chr2:3827356	NA	-0.49	-14.28	-0.49	2.35e-40	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs758324	0.947	rs10478989	chr5:131116055	A/G	cg06307176	chr5:131281290	NA	0.53	10.26	0.38	5.85e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg08601574	chr20:25228251	PYGB	-0.34	-8.18	-0.31	1.53e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg01657329	chr11:68192670	LRP5	-0.34	-7.82	-0.3	2.18e-14	Total body bone mineral density;
BRCA	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg08999081	chr20:33150536	PIGU	-0.46	-12.64	-0.45	7.32e-33	Glomerular filtration rate (creatinine);
BRCA	cis	rs2387326	0.629	rs12261739	chr10:129945520	A/G	cg16087940	chr10:129947807	NA	-0.46	-8.17	-0.31	1.69e-15	Select biomarker traits;
BRCA	cis	rs35123781	1.000	rs585101	chr5:139058454	T/C	cg05227215	chr5:139057496	CXXC5	0.33	8.1	0.31	2.74e-15	Schizophrenia;
BRCA	cis	rs4664304	0.620	rs2357691	chr2:160725139	A/G	cg18514922	chr2:160761262	LY75	-0.34	-7.87	-0.3	1.47e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg25517755	chr10:38738941	LOC399744	-0.4	-7.91	-0.3	1.1e-14	Corneal astigmatism;
BRCA	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg13010199	chr12:38710504	ALG10B	0.57	12.53	0.44	2.36e-32	Heart rate;
BRCA	cis	rs4965272	1.000	rs2418487	chr15:100585610	T/G	cg27344315	chr15:100560801	ADAMTS17	-0.38	-8.0	-0.3	5.74e-15	Gastroesophageal reflux disease;
BRCA	trans	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg01620082	chr3:125678407	NA	-0.71	-8.8	-0.33	1.28e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.51	0.41	5.2e-28	Homoarginine levels;
BRCA	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg04414720	chr1:150670196	GOLPH3L	0.37	8.42	0.32	2.43e-16	Tonsillectomy;
BRCA	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg23711669	chr6:146136114	FBXO30	0.71	17.0	0.56	9.9e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7737355	1.000	rs30736	chr5:130724240	A/G	cg06307176	chr5:131281290	NA	-0.47	-9.17	-0.34	6.18e-19	Life satisfaction;
BRCA	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg23950597	chr19:37808831	NA	-0.74	-13.05	-0.46	1.07e-34	Coronary artery calcification;
BRCA	cis	rs887829	0.570	rs6753569	chr2:234595817	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.32	-8.28	-0.31	7e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-9.84	-0.36	2.35e-21	Mood instability;
BRCA	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg03146154	chr1:46216737	IPP	0.45	10.04	0.37	4.15e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg11502198	chr6:26597334	ABT1	0.57	12.08	0.43	2.03e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg09307838	chr4:120376055	NA	0.74	16.17	0.54	1.53e-49	Corneal astigmatism;
BRCA	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg20007245	chr22:24372913	LOC391322	-0.53	-11.97	-0.43	6.09e-30	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	19.4	0.61	2.8e-66	Platelet count;
BRCA	cis	rs9790314	0.663	rs778657	chr3:160719577	C/A	cg03342759	chr3:160939853	NMD3	-0.44	-9.07	-0.34	1.39e-18	Morning vs. evening chronotype;
BRCA	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg01528321	chr10:82214614	TSPAN14	0.62	14.12	0.49	1.3e-39	Post bronchodilator FEV1;
BRCA	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg23029597	chr12:123009494	RSRC2	0.44	8.92	0.33	5.03e-18	Body mass index;
BRCA	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg27490568	chr2:178487706	NA	0.51	8.57	0.32	7.54e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.77	-0.36	4.24e-21	IgG glycosylation;
BRCA	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg14983838	chr19:29218262	NA	0.53	10.07	0.37	3.02e-22	Methadone dose in opioid dependence;
BRCA	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg11814155	chr7:99998594	ZCWPW1	0.48	8.7	0.33	2.76e-17	Platelet count;
BRCA	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26314531	chr2:26401878	FAM59B	-0.57	-10.19	-0.37	1.06e-22	Gut microbiome composition (summer);
BRCA	trans	rs4650994	0.544	rs6675811	chr1:178499068	T/A	cg05059571	chr16:84539110	KIAA1609	-0.49	-11.09	-0.4	2.87e-26	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg03060546	chr3:49711283	APEH	-0.57	-10.03	-0.37	4.32e-22	Menarche (age at onset);
BRCA	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg11271282	chr2:238384023	NA	0.45	8.23	0.31	1.09e-15	Prostate cancer;
BRCA	trans	rs853679	0.546	rs2232429	chr6:28359632	T/G	cg01620082	chr3:125678407	NA	-0.97	-11.01	-0.4	6.21e-26	Depression;
BRCA	cis	rs7560272	0.501	rs12713789	chr2:73945600	A/G	cg20560298	chr2:73613845	ALMS1	0.33	8.4	0.32	2.84e-16	Schizophrenia;
BRCA	cis	rs925228	0.504	rs7568176	chr2:24313758	T/A	cg01493198	chr2:24299560	SF3B14	0.63	9.97	0.37	7.22e-22	Reticulocyte fraction of red cells;Reticulocyte count;
BRCA	cis	rs4566357	0.595	rs6707159	chr2:227909339	T/A	cg05526886	chr2:227700861	RHBDD1	-0.38	-7.83	-0.3	2.08e-14	Coronary artery disease;
BRCA	cis	rs6028335	0.610	rs67882716	chr20:37573239	T/C	cg16355469	chr20:37678765	NA	0.45	8.17	0.31	1.66e-15	Alcohol and nicotine co-dependence;
BRCA	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg18305652	chr10:134549665	INPP5A	0.48	11.83	0.42	2.39e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9473147	0.516	rs7767350	chr6:47485126	C/T	cg12968598	chr6:47444699	CD2AP	0.46	9.83	0.36	2.47e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs9462027	0.628	rs2764211	chr6:34704613	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.26	7.85	0.3	1.71e-14	Systemic lupus erythematosus;
BRCA	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg23711669	chr6:146136114	FBXO30	0.75	18.35	0.59	9.94e-61	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-11.3	-0.41	3.97e-27	Systolic blood pressure;
BRCA	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg08501292	chr6:25962987	TRIM38	0.6	8.36	0.31	3.93e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs12681287	0.604	rs41469550	chr8:87406544	G/T	cg27223183	chr8:87520930	FAM82B	0.43	8.43	0.32	2.36e-16	Caudate activity during reward;
BRCA	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg24060327	chr5:131705240	SLC22A5	-0.63	-12.24	-0.44	4.25e-31	Breast cancer;
BRCA	cis	rs4901869	0.902	rs10149194	chr14:59308198	A/G	cg02291164	chr14:59296302	NA	-0.32	-8.84	-0.33	9.6e-18	Panic disorder;
BRCA	cis	rs66887589	0.870	rs2389875	chr4:120557014	G/T	cg09307838	chr4:120376055	NA	-0.46	-9.55	-0.35	2.64e-20	Diastolic blood pressure;
BRCA	cis	rs6594713	0.643	rs10077431	chr5:112927686	A/C	cg12552261	chr5:112820674	MCC	-0.49	-8.27	-0.31	7.73e-16	Brain cytoarchitecture;
BRCA	cis	rs9463078	0.753	rs3778507	chr6:44896803	G/A	cg25276700	chr6:44698697	NA	-0.37	-8.56	-0.32	8.23e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6496044	0.568	rs6496039	chr15:86061963	A/T	cg10818794	chr15:86012489	AKAP13	-0.28	-7.83	-0.3	2.03e-14	Interstitial lung disease;
BRCA	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg08614441	chr13:113633676	MCF2L	-0.36	-8.41	-0.32	2.68e-16	Systolic blood pressure;
BRCA	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg08885076	chr2:99613938	TSGA10	-0.45	-10.36	-0.38	2.3e-23	Chronic sinus infection;
BRCA	cis	rs9318086	0.712	rs12875437	chr13:24453956	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.3	8.63	0.32	5.03e-17	Myopia (pathological);
BRCA	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs7131987	0.650	rs7954871	chr12:29459732	G/A	cg09582351	chr12:29534625	ERGIC2	-0.43	-9.93	-0.37	1.07e-21	QT interval;
BRCA	cis	rs1298908	0.639	rs2994388	chr10:82034262	A/G	cg01528321	chr10:82214614	TSPAN14	-0.47	-10.13	-0.37	1.8e-22	Diabetic kidney disease;
BRCA	cis	rs9790314	0.715	rs7622047	chr3:160770505	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-9.79	-0.36	3.62e-21	Morning vs. evening chronotype;
BRCA	cis	rs13064411	0.735	rs722392	chr3:113228294	A/G	cg18753928	chr3:113234510	CCDC52	-0.58	-12.17	-0.43	8.82e-31	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs72928364	0.929	rs35850913	chr3:100775080	T/A	cg10123952	chr3:100791384	NA	0.58	8.47	0.32	1.63e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg03733263	chr8:22462867	KIAA1967	0.78	18.09	0.58	2.18e-59	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.66e-18	Motion sickness;
BRCA	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg01236616	chr12:121019343	POP5	-1.17	-22.55	-0.67	2.65e-83	Type 1 diabetes nephropathy;
BRCA	cis	rs3099143	1.000	rs3102709	chr15:77072260	C/T	cg21673338	chr15:77095150	SCAPER	-0.54	-9.77	-0.36	4.18e-21	Recalcitrant atopic dermatitis;
BRCA	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.07	0.37	3.06e-22	Bipolar disorder;
BRCA	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg15448220	chr1:150897856	SETDB1	0.35	7.81	0.3	2.42e-14	Melanoma;
BRCA	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg24692254	chr21:30365293	RNF160	-0.46	-10.16	-0.37	1.42e-22	Dental caries;
BRCA	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-9.29	-0.34	2.45e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg04775059	chr7:64541387	NA	0.44	8.16	0.31	1.81e-15	Calcium levels;
BRCA	cis	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg05901451	chr6:126070800	HEY2	0.39	9.6	0.36	1.76e-20	Endometrial cancer;
BRCA	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg19628046	chr18:33552617	C18orf21	0.56	10.97	0.4	8.71e-26	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.99	-0.3	6.39e-15	Prostate cancer;
BRCA	cis	rs2625529	0.824	rs12592364	chr15:72284647	C/A	cg16672083	chr15:72433130	SENP8	-0.85	-17.53	-0.57	1.86e-56	Red blood cell count;
BRCA	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg13736514	chr6:26305472	NA	-0.46	-14.82	-0.51	6.38e-43	Educational attainment;
BRCA	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.52	0.38	5.68e-24	Motion sickness;
BRCA	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg05340658	chr4:99064831	C4orf37	0.62	14.8	0.51	7.93e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg11814155	chr7:99998594	ZCWPW1	0.49	8.74	0.33	2.1e-17	Platelet count;
BRCA	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg01324343	chr3:183735012	ABCC5	0.84	21.29	0.64	2.1e-76	Anterior chamber depth;
BRCA	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg03188948	chr7:1209495	NA	0.45	8.31	0.31	5.57e-16	Longevity;Endometriosis;
BRCA	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.71	0.39	1.01e-24	Cognitive ability;
BRCA	cis	rs2882667	0.628	rs13171173	chr5:138042464	A/C	cg04439458	chr5:138467593	SIL1	0.32	7.82	0.3	2.13e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg07460842	chr6:66804631	NA	0.88	14.14	0.49	1.11e-39	Exhaled nitric oxide output;
BRCA	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00166722	chr3:10149974	C3orf24	0.66	13.26	0.46	1.33e-35	Alzheimer's disease;
BRCA	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.78	-0.53	1.24e-47	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9341808	0.727	rs9352809	chr6:80999316	C/T	cg08355045	chr6:80787529	NA	0.36	9.14	0.34	8.08e-19	Sitting height ratio;
BRCA	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg01528321	chr10:82214614	TSPAN14	0.62	14.02	0.49	3.76e-39	Post bronchodilator FEV1;
BRCA	cis	rs7149337	0.805	rs3007164	chr14:51646935	A/G	cg23942311	chr14:51606299	NA	0.42	12.02	0.43	3.77e-30	Cancer;
BRCA	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11890956	chr21:40555474	PSMG1	1.04	29.3	0.76	2.92e-120	Cognitive function;
BRCA	cis	rs7520050	0.966	rs10789481	chr1:46383583	C/G	cg24296786	chr1:45957014	TESK2	0.43	9.59	0.35	1.97e-20	Red blood cell count;Reticulocyte count;
BRCA	cis	rs10129255	0.500	rs2105989	chr14:107138216	C/T	cg07958169	chr14:107095056	NA	-0.43	-9.06	-0.34	1.6e-18	Kawasaki disease;
BRCA	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg17063962	chr7:91808500	NA	0.52	12.33	0.44	1.69e-31	Breast cancer;
BRCA	cis	rs7092929	0.883	rs835960	chr10:3586532	G/C	cg14308648	chr10:3568949	NA	0.44	8.01	0.3	5.47e-15	Coronary artery calcification;
BRCA	cis	rs2230307	0.518	rs12046458	chr1:100703069	C/T	cg24955406	chr1:100503596	HIAT1	-0.46	-8.29	-0.31	6.9e-16	Carotid intima media thickness;
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg09033563	chr22:24373618	LOC391322	0.58	12.64	0.45	7.68e-33	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg15839431	chr19:19639596	YJEFN3	-0.38	-8.47	-0.32	1.67e-16	Bipolar disorder;
BRCA	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg16386425	chr10:429943	DIP2C	-0.42	-8.96	-0.33	3.59e-18	Psychosis in Alzheimer's disease;
BRCA	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg01528321	chr10:82214614	TSPAN14	0.6	12.94	0.46	3.36e-34	Post bronchodilator FEV1;
BRCA	cis	rs6545883	0.894	rs4672436	chr2:61603357	A/C	cg15711740	chr2:61764176	XPO1	0.5	12.18	0.43	8.05e-31	Tuberculosis;
BRCA	cis	rs9790314	0.747	rs9848239	chr3:160823488	A/C	cg04691961	chr3:161091175	C3orf57	-0.45	-9.77	-0.36	4.03e-21	Morning vs. evening chronotype;
BRCA	cis	rs7572733	0.534	rs11899188	chr2:198740121	C/T	cg00792783	chr2:198669748	PLCL1	0.47	10.22	0.37	8.34e-23	Dermatomyositis;
BRCA	trans	rs8073060	0.660	rs34184070	chr17:34003810	A/G	cg19694781	chr19:47549865	TMEM160	-1.03	-21.11	-0.64	1.9e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg26850624	chr5:429559	AHRR	0.33	7.89	0.3	1.29e-14	Cystic fibrosis severity;
BRCA	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.42	-8.02	-0.3	5.01e-15	Dietary macronutrient intake;
BRCA	cis	rs7618915	0.547	rs11719685	chr3:52676065	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-11.96	-0.43	6.91e-30	Bipolar disorder;
BRCA	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg18132916	chr6:79620363	NA	-0.48	-10.76	-0.39	6.37e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg09537434	chr19:41945824	ATP5SL	-0.99	-23.66	-0.68	2.33e-89	Height;
BRCA	cis	rs7020830	0.894	rs28766572	chr9:37093872	G/T	cg14294708	chr9:37120828	ZCCHC7	1.09	33.89	0.8	7.43e-145	Schizophrenia;
BRCA	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	16.14	0.54	2.01e-49	Homoarginine levels;
BRCA	trans	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.37	-7.84	-0.3	1.83e-14	Mean corpuscular volume;
BRCA	cis	rs3806843	0.900	rs3756334	chr5:140213796	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.78	-0.36	3.93e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10193935	0.901	rs12620021	chr2:42477034	T/C	cg27598129	chr2:42591480	NA	-0.98	-15.05	-0.51	5.11e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg02733842	chr7:1102375	C7orf50	-0.63	-11.93	-0.43	9e-30	Bronchopulmonary dysplasia;
BRCA	cis	rs2737618	0.674	rs2249150	chr1:200083654	G/A	cg21825944	chr1:200113062	NR5A2	-0.39	-9.07	-0.34	1.4e-18	Uric acid levels;
BRCA	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.17	-0.31	1.7e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.53	10.71	0.39	9.83e-25	Personality dimensions;
BRCA	trans	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg04565464	chr8:145669602	NFKBIL2	0.38	8.22	0.31	1.11e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs701145	0.585	rs436852	chr3:153913403	G/A	cg17054900	chr3:154042577	DHX36	0.51	8.93	0.33	4.54e-18	Coronary artery disease;
BRCA	cis	rs7575217	0.697	rs796067	chr2:101707009	C/T	cg23907051	chr2:101730305	TBC1D8	-0.2	-7.93	-0.3	9.72e-15	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.09	0.37	2.61e-22	Calcium levels;
BRCA	trans	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg25214090	chr10:38739885	LOC399744	0.47	10.8	0.39	4.5e-25	Corneal astigmatism;
BRCA	cis	rs757081	0.608	rs214938	chr11:17188516	C/T	cg15432903	chr11:17409602	KCNJ11	-0.45	-8.51	-0.32	1.25e-16	Systolic blood pressure;
BRCA	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg11814155	chr7:99998594	ZCWPW1	0.5	8.63	0.32	4.74e-17	Platelet count;
BRCA	cis	rs7520050	0.966	rs7524495	chr1:46266932	T/C	cg24296786	chr1:45957014	TESK2	0.44	9.96	0.37	8.03e-22	Red blood cell count;Reticulocyte count;
BRCA	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg24642844	chr7:1081250	C7orf50	-0.87	-15.93	-0.53	2.34e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18404041	chr3:52824283	ITIH1	-0.52	-16.79	-0.55	1.16e-52	Bipolar disorder;
BRCA	trans	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.37	-8.27	-0.31	7.59e-16	Endometrial cancer;
BRCA	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.67	-16.24	-0.54	6.98e-50	Ulcerative colitis;
BRCA	trans	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg13010199	chr12:38710504	ALG10B	0.4	8.09	0.3	3.05e-15	Morning vs. evening chronotype;
BRCA	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.42	-9.55	-0.35	2.76e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.82	-0.39	3.62e-25	Mean corpuscular volume;
BRCA	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08048268	chr3:133502702	NA	-0.34	-8.4	-0.32	2.92e-16	Iron status biomarkers;
BRCA	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26314531	chr2:26401878	FAM59B	0.75	10.51	0.38	6.22e-24	Gut microbiome composition (summer);
BRCA	cis	rs4409675	0.576	rs6662916	chr1:28219873	G/T	cg23691781	chr1:28212827	C1orf38	0.33	11.14	0.4	1.88e-26	Corneal astigmatism;
BRCA	cis	rs7011049	1.000	rs72643583	chr8:53847269	C/G	cg26025543	chr8:53854495	NA	0.55	9.57	0.35	2.31e-20	Systolic blood pressure;
BRCA	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg27661571	chr11:113659931	NA	-0.7	-10.89	-0.4	1.93e-25	Hip circumference adjusted for BMI;
BRCA	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.89	-0.36	1.53e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4812048	0.649	rs6070706	chr20:57628239	C/T	cg14073986	chr20:57617431	SLMO2	0.75	10.75	0.39	6.71e-25	Mean platelet volume;
BRCA	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18876405	chr7:65276391	NA	0.71	18.63	0.59	3.25e-62	Aortic root size;
BRCA	trans	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs2279817	0.743	rs12023874	chr1:18025612	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.51	15.94	0.53	2.01e-48	Neuroticism;
BRCA	cis	rs11984145	1.000	rs11970960	chr7:38883838	A/G	cg19327137	chr7:38886074	VPS41	0.5	8.81	0.33	1.19e-17	Cognitive performance;
BRCA	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg20607287	chr7:12443886	VWDE	-0.58	-8.24	-0.31	9.69e-16	Coronary artery disease;
BRCA	cis	rs7617773	0.817	rs3729577	chr3:48228994	A/C	cg11946769	chr3:48343235	NME6	0.68	13.78	0.48	5.29e-38	Coronary artery disease;
BRCA	cis	rs9649465	1.000	rs3958047	chr7:123327936	G/C	cg04330084	chr7:123175371	IQUB	-0.3	-8.38	-0.31	3.26e-16	Migraine;
BRCA	cis	rs61990749	0.597	rs3783980	chr14:78219807	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.64	9.82	0.36	2.75e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.01	0.58	5.98e-59	Colorectal cancer;
BRCA	cis	rs11997175	0.740	rs4733462	chr8:33679904	A/G	ch.8.33884649F	chr8:33765107	NA	0.35	8.18	0.31	1.49e-15	Body mass index;
BRCA	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg02880119	chr16:3481970	NA	0.51	9.3	0.35	2.29e-19	Body mass index (adult);
BRCA	cis	rs72781680	0.821	rs1022346	chr2:24127849	T/C	cg08917208	chr2:24149416	ATAD2B	0.62	10.54	0.38	4.72e-24	Lymphocyte counts;
BRCA	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg02475777	chr4:1388615	CRIPAK	0.42	9.62	0.36	1.49e-20	Longevity;
BRCA	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg03342759	chr3:160939853	NMD3	0.72	14.88	0.51	3.21e-43	Parkinson's disease;
BRCA	trans	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.13	0.31	2.28e-15	Corneal astigmatism;
BRCA	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg23358479	chr7:1110784	C7orf50	-0.48	-8.17	-0.31	1.68e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7577696	0.568	rs462878	chr2:32438655	A/G	cg02381751	chr2:32503542	YIPF4	0.47	8.58	0.32	7.11e-17	Inflammatory biomarkers;
BRCA	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg22834771	chr12:69754056	YEATS4	-0.4	-10.04	-0.37	3.89e-22	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6546550	0.935	rs4241261	chr2:70063660	A/G	cg02498382	chr2:70120550	SNRNP27	-0.5	-10.55	-0.39	4.24e-24	Prevalent atrial fibrillation;
BRCA	cis	rs6570726	0.516	rs9322025	chr6:145729196	C/T	cg23711669	chr6:146136114	FBXO30	0.47	9.8	0.36	3.31e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg03676636	chr4:99064102	C4orf37	0.21	7.98	0.3	6.8e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.31	0.41	3.69e-27	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg08514558	chr10:81106712	PPIF	0.37	8.5	0.32	1.39e-16	Height;
BRCA	cis	rs7131987	0.934	rs2216854	chr12:29423460	G/A	cg09582351	chr12:29534625	ERGIC2	-0.39	-9.42	-0.35	7.97e-20	QT interval;
BRCA	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06022373	chr22:39101656	GTPBP1	0.7	15.83	0.53	7.43e-48	Menopause (age at onset);
BRCA	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18876405	chr7:65276391	NA	-0.5	-11.15	-0.4	1.6e-26	Aortic root size;
BRCA	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11644478	chr21:40555479	PSMG1	-0.51	-10.9	-0.4	1.75e-25	Menarche (age at onset);
BRCA	cis	rs10499694	0.933	rs11575356	chr7:50594821	T/C	cg18232548	chr7:50535776	DDC	-0.39	-9.42	-0.35	7.95e-20	Body mass index;
BRCA	cis	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg06521331	chr12:34319734	NA	-0.52	-10.21	-0.37	9.32e-23	Morning vs. evening chronotype;
BRCA	cis	rs9649465	0.807	rs11770249	chr7:123286412	T/C	cg04330084	chr7:123175371	IQUB	-0.31	-8.55	-0.32	8.77e-17	Migraine;
BRCA	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-12.57	-0.45	1.56e-32	Bipolar disorder;
BRCA	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg17420585	chr12:42539391	GXYLT1	-0.49	-10.42	-0.38	1.36e-23	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-9.52	-0.35	3.5e-20	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg21770322	chr7:97807741	LMTK2	0.41	10.87	0.4	2.17e-25	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg08470875	chr2:26401718	FAM59B	-0.5	-8.17	-0.31	1.65e-15	Gut microbiome composition (summer);
BRCA	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg21770322	chr7:97807741	LMTK2	0.42	11.14	0.4	1.85e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg06484146	chr7:12443880	VWDE	-0.61	-10.32	-0.38	3.37e-23	Coronary artery disease;
BRCA	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24549020	chr5:56110836	MAP3K1	0.65	13.12	0.46	5.57e-35	Type 2 diabetes;
BRCA	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.1	0.31	2.81e-15	Tonsillectomy;
BRCA	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21518248	chr2:162101506	NA	0.71	17.56	0.57	1.35e-56	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg20019720	chr6:154832845	CNKSR3	0.52	10.31	0.38	3.64e-23	Lipoprotein (a) levels;
BRCA	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.68	-0.39	1.29e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6580649	0.771	rs1635535	chr12:48386241	A/G	cg05342945	chr12:48394962	COL2A1	-0.48	-9.46	-0.35	5.59e-20	Lung cancer;
BRCA	cis	rs17490626	0.568	rs12416520	chr10:71211945	A/G	cg12610070	chr10:71211762	TSPAN15	-0.34	-11.96	-0.43	6.75e-30	Thrombosis;
BRCA	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg13319975	chr6:146136371	FBXO30	-0.34	-7.89	-0.3	1.3e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg05340658	chr4:99064831	C4orf37	0.68	17.05	0.56	5.48e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg14983838	chr19:29218262	NA	0.55	9.36	0.35	1.32e-19	Methadone dose in opioid dependence;
BRCA	cis	rs7945718	0.967	rs11022496	chr11:12789561	G/A	cg25843174	chr11:12811716	TEAD1	0.24	9.24	0.34	3.65e-19	Educational attainment (years of education);
BRCA	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg02176678	chr2:219576539	TTLL4	-0.45	-11.81	-0.42	2.89e-29	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg23950597	chr19:37808831	NA	-0.62	-11.45	-0.41	9.7e-28	Coronary artery calcification;
BRCA	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.64	-0.32	4.45e-17	Obesity-related traits;
BRCA	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg18876405	chr7:65276391	NA	-0.52	-11.7	-0.42	8.87e-29	Aortic root size;
BRCA	cis	rs7523273	0.565	rs11118451	chr1:207887493	A/G	cg22525895	chr1:207977042	MIR29B2	0.33	7.87	0.3	1.56e-14	Schizophrenia;
BRCA	cis	rs6740322	0.748	rs6727631	chr2:43470408	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-12.8	-0.45	1.52e-33	Coronary artery disease;
BRCA	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	17.2	0.56	9.22e-55	Platelet count;
BRCA	cis	rs16958440	0.708	rs62096465	chr18:44629624	C/T	cg17192377	chr18:44677553	HDHD2	0.48	8.0	0.3	5.82e-15	Sitting height ratio;
BRCA	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.02	-0.34	2.21e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10504073	0.647	rs62507252	chr8:50028795	C/G	cg00325661	chr8:49890786	NA	0.47	12.85	0.45	9.3e-34	Blood metabolite ratios;
BRCA	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg14675211	chr2:100938903	LONRF2	0.42	9.62	0.36	1.44e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs11608355	0.515	rs1045263	chr12:109974191	A/G	cg05360138	chr12:110035743	NA	0.73	13.3	0.47	8.17e-36	Neuroticism;
BRCA	cis	rs35740288	0.580	rs34526042	chr15:86339956	C/T	cg20737812	chr15:86336631	KLHL25	-0.39	-9.39	-0.35	1e-19	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22307029	chr19:49891270	CCDC155	0.53	9.07	0.34	1.42e-18	Multiple sclerosis;
BRCA	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.66	-9.58	-0.35	2.1e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg14036092	chr11:66035641	RAB1B	0.4	11.02	0.4	5.49e-26	Gout;
BRCA	cis	rs9309711	0.961	rs11692184	chr2:3480710	C/T	cg10845886	chr2:3471009	TTC15	-0.75	-16.36	-0.54	1.72e-50	Neurofibrillary tangles;
BRCA	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg12444411	chr7:2802554	GNA12	-0.32	-8.13	-0.31	2.19e-15	Height;
BRCA	trans	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg23762105	chr12:34175262	ALG10	0.34	7.96	0.3	7.76e-15	Morning vs. evening chronotype;
BRCA	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-10.49	-0.38	7.35e-24	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg24060327	chr5:131705240	SLC22A5	-0.48	-10.17	-0.37	1.28e-22	Blood metabolite levels;
BRCA	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg21385522	chr1:16154831	NA	-0.47	-9.94	-0.37	9.68e-22	Systolic blood pressure;
BRCA	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg24642844	chr7:1081250	C7orf50	-0.91	-16.39	-0.54	1.21e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg06917634	chr15:78832804	PSMA4	0.57	12.31	0.44	2.22e-31	Sudden cardiac arrest;
BRCA	cis	rs877282	0.891	rs34383514	chr10:800181	T/C	cg17470449	chr10:769945	NA	0.49	8.41	0.32	2.62e-16	Uric acid levels;
BRCA	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.62	13.51	0.47	8.88e-37	Lymphocyte percentage of white cells;
BRCA	trans	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg26384229	chr12:38710491	ALG10B	0.61	11.94	0.43	8.11e-30	Resting heart rate;
BRCA	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg07080220	chr10:102295463	HIF1AN	0.5	10.25	0.38	6.26e-23	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg23978390	chr7:1156363	C7orf50	-0.4	-8.17	-0.31	1.66e-15	Bronchopulmonary dysplasia;
BRCA	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21659725	chr3:3221576	CRBN	-0.49	-12.46	-0.44	4.49e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.78	0.36	3.87e-21	Menopause (age at onset);
BRCA	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg09537434	chr19:41945824	ATP5SL	-0.96	-22.64	-0.67	9.45e-84	Height;
BRCA	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg18016565	chr1:150552671	MCL1	0.34	7.98	0.3	6.95e-15	Tonsillectomy;
BRCA	cis	rs4988958	0.565	rs885088	chr2:103039044	A/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.34	0.31	4.74e-16	Asthma (childhood onset);
BRCA	trans	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg23762105	chr12:34175262	ALG10	-0.37	-9.47	-0.35	5.23e-20	Morning vs. evening chronotype;
BRCA	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14442939	chr10:27389572	ANKRD26	0.66	10.92	0.4	1.5e-25	Breast cancer;
BRCA	cis	rs7572733	0.576	rs4850441	chr2:198913413	A/G	cg00792783	chr2:198669748	PLCL1	-0.4	-8.67	-0.32	3.6e-17	Dermatomyositis;
BRCA	cis	rs68170813	0.559	rs58319984	chr7:106965794	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-8.95	-0.33	3.93e-18	Coronary artery disease;
BRCA	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26314531	chr2:26401878	FAM59B	0.75	12.64	0.45	7.73e-33	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg06671706	chr8:8559999	CLDN23	0.43	8.41	0.32	2.77e-16	Obesity-related traits;
BRCA	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg06346307	chr22:19949965	COMT	0.31	8.85	0.33	8.71e-18	Blood metabolite levels;
BRCA	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg05707623	chr12:122985044	ZCCHC8	0.45	8.8	0.33	1.23e-17	Body mass index;
BRCA	cis	rs2236918	1.000	rs2236918	chr1:242017826	C/G	cg17736920	chr1:242011382	EXO1	-0.45	-10.08	-0.37	2.82e-22	Menopause (age at onset);
BRCA	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.63	10.34	0.38	2.77e-23	Renal function-related traits (BUN);
BRCA	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg18404041	chr3:52824283	ITIH1	-0.29	-8.31	-0.31	5.69e-16	Electroencephalogram traits;
BRCA	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg17971929	chr21:40555470	PSMG1	0.79	18.93	0.6	8.5e-64	Cognitive function;
BRCA	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg02175503	chr12:58329896	NA	0.53	11.14	0.4	1.88e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9469578	0.892	rs73743334	chr6:33714094	G/C	cg18708504	chr6:33715942	IP6K3	0.7	10.18	0.37	1.12e-22	Phosphorus levels;
BRCA	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg10792982	chr14:105748885	BRF1	0.47	10.96	0.4	9.68e-26	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs10129255	0.500	rs8014529	chr14:107192302	G/A	cg07958169	chr14:107095056	NA	-0.41	-8.77	-0.33	1.58e-17	Kawasaki disease;
BRCA	trans	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.35	0.31	4.21e-16	Corneal astigmatism;
BRCA	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.46	-0.38	9.45e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-7.81	-0.3	2.35e-14	Total body bone mineral density;
BRCA	cis	rs4722404	0.620	rs6978200	chr7:3118835	A/G	cg19214707	chr7:3157722	NA	-0.36	-8.12	-0.31	2.43e-15	Atopic dermatitis;
BRCA	trans	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.36	-0.35	1.38e-19	Bladder cancer;
BRCA	trans	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg25214090	chr10:38739885	LOC399744	-0.51	-11.64	-0.42	1.52e-28	Corneal astigmatism;
BRCA	cis	rs751728	0.664	rs6929696	chr6:33759290	C/T	cg25922239	chr6:33757077	LEMD2	-0.48	-12.06	-0.43	2.48e-30	Crohn's disease;
BRCA	trans	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	27.58	0.74	6.51e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs738322	0.554	rs6001033	chr22:38557513	T/A	cg25457927	chr22:38595422	NA	-0.35	-12.93	-0.46	3.76e-34	Cutaneous nevi;
BRCA	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.06	-0.43	2.49e-30	Alzheimer's disease;
BRCA	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg19052272	chr2:3704530	ALLC	-0.45	-9.95	-0.37	8.86e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs2147904	0.866	rs1886729	chr1:42363966	G/A	cg16685388	chr1:42384056	HIVEP3	0.31	8.78	0.33	1.46e-17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
BRCA	cis	rs2882667	0.690	rs1567313	chr5:138110702	A/G	cg04439458	chr5:138467593	SIL1	0.31	7.85	0.3	1.74e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg01884057	chr2:25150051	NA	0.31	8.15	0.31	1.85e-15	Body mass index in non-asthmatics;
BRCA	cis	rs921968	0.565	rs7573999	chr2:219601392	A/G	cg02176678	chr2:219576539	TTLL4	-0.41	-11.02	-0.4	5.55e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg11833968	chr6:79620685	NA	-0.43	-9.47	-0.35	5.49e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg01689657	chr7:91764605	CYP51A1	0.23	8.07	0.3	3.58e-15	Breast cancer;
BRCA	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.09	0.4	3.05e-26	Bipolar disorder;
BRCA	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg26769984	chr7:1090371	C7orf50	0.64	11.44	0.41	1.06e-27	Bronchopulmonary dysplasia;
BRCA	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	cis	rs586533	0.881	rs676553	chr11:99506436	T/C	cg22878054	chr11:99397252	CNTN5	0.32	8.13	0.31	2.3e-15	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.69	-16.43	-0.54	7.06e-51	Obesity-related traits;
BRCA	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg01939980	chr4:1354348	KIAA1530	-0.34	-8.28	-0.31	7.39e-16	Obesity-related traits;
BRCA	cis	rs12050794	0.671	rs2052713	chr15:72520392	G/C	cg16672083	chr15:72433130	SENP8	0.63	14.91	0.51	2.26e-43	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	14.38	0.49	8.14e-41	Colorectal cancer;
BRCA	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	10.83	0.39	3.28e-25	Neuroticism;
BRCA	cis	rs9788721	0.836	rs17483548	chr15:78730313	G/A	cg18825076	chr15:78729989	IREB2	-0.44	-8.34	-0.31	4.41e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg05791153	chr7:19748676	TWISTNB	-0.57	-10.45	-0.38	1.1e-23	Thyroid stimulating hormone;
BRCA	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg05340658	chr4:99064831	C4orf37	0.45	10.39	0.38	1.79e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.26	-0.31	8.29e-16	Gut microbiome composition (summer);
BRCA	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg17971929	chr21:40555470	PSMG1	0.79	18.48	0.59	2.14e-61	Cognitive function;
BRCA	cis	rs7246657	0.678	rs4802024	chr19:38052193	T/C	cg18154014	chr19:37997991	ZNF793	0.48	9.13	0.34	8.69e-19	Coronary artery calcification;
BRCA	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.18	-0.31	1.57e-15	Depression;
BRCA	cis	rs11112613	0.762	rs73184077	chr12:105949999	G/A	cg03607813	chr12:105948248	NA	0.6	11.21	0.41	9.41e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg02733842	chr7:1102375	C7orf50	-0.58	-10.96	-0.4	1e-25	Bronchopulmonary dysplasia;
BRCA	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.52	-7.89	-0.3	1.31e-14	Birth weight;
BRCA	cis	rs7572733	0.534	rs4850815	chr2:198786167	G/T	cg00792783	chr2:198669748	PLCL1	-0.46	-9.98	-0.37	7.05e-22	Dermatomyositis;
BRCA	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg12311346	chr5:56204834	C5orf35	-0.8	-15.68	-0.53	4.12e-47	Initial pursuit acceleration;
BRCA	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-16.69	-0.55	3.69e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1003719	0.788	rs2835578	chr21:38457671	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.18	0.49	7.11e-40	Eye color traits;
BRCA	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg26384229	chr12:38710491	ALG10B	0.76	17.1	0.56	2.83e-54	Bladder cancer;
BRCA	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.89e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	8.24	0.31	1e-15	Personality dimensions;
BRCA	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-13.61	-0.47	3e-37	Bone mineral density;
BRCA	cis	rs2336384	1.000	rs1810563	chr1:12054030	A/G	cg13216073	chr1:12042593	MFN2	-0.51	-10.83	-0.39	3.37e-25	Platelet count;
BRCA	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	12.89	0.45	5.95e-34	Ileal carcinoids;
BRCA	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg13206674	chr6:150067644	NUP43	0.45	14.12	0.49	1.32e-39	Lung cancer;
BRCA	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.77	-0.36	4.14e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7072216	0.763	rs10736129	chr10:100171571	C/T	cg26618903	chr10:100175079	PYROXD2	0.33	9.78	0.36	3.85e-21	Metabolite levels;
BRCA	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.15	0.37	1.53e-22	Bladder cancer;
BRCA	cis	rs1843834	0.898	rs2014887	chr2:225520082	A/G	cg22455342	chr2:225449267	CUL3	0.34	8.41	0.32	2.62e-16	IgE levels in asthmatics (D.p. specific);
BRCA	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg07211511	chr3:129823064	LOC729375	-0.58	-10.66	-0.39	1.58e-24	Blood pressure (smoking interaction);
BRCA	cis	rs965469	0.843	rs6051842	chr20:3397434	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-10.6	-0.39	2.73e-24	IFN-related cytopenia;
BRCA	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg02733842	chr7:1102375	C7orf50	-0.71	-12.19	-0.43	6.91e-31	Bronchopulmonary dysplasia;
BRCA	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	19.67	0.61	1.01e-67	Platelet count;
BRCA	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Tonsillectomy;
BRCA	cis	rs4363385	0.747	rs10399896	chr1:152975083	T/A	cg25856811	chr1:152973957	SPRR3	-0.34	-9.01	-0.34	2.4e-18	Inflammatory skin disease;
BRCA	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg23711669	chr6:146136114	FBXO30	-0.79	-19.25	-0.61	1.82e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg26597838	chr10:835615	NA	0.87	15.67	0.53	4.71e-47	Eosinophil percentage of granulocytes;
BRCA	cis	rs10851411	0.697	rs56069741	chr15:42855057	G/A	cg21293051	chr15:42870591	STARD9	0.52	8.79	0.33	1.4e-17	Glucose homeostasis traits;
BRCA	trans	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg06606381	chr12:133084897	FBRSL1	0.79	8.57	0.32	7.6e-17	Depression;
BRCA	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg15704280	chr7:45808275	SEPT13	0.48	9.28	0.34	2.53e-19	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg27535305	chr1:53392650	SCP2	-0.48	-11.74	-0.42	6.05e-29	Monocyte count;
BRCA	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.7	-14.09	-0.49	1.94e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg18252515	chr7:66147081	NA	-0.81	-11.34	-0.41	2.84e-27	Diabetic kidney disease;
BRCA	cis	rs2559856	1.000	rs2695298	chr12:102082589	G/A	cg12213457	chr12:102090980	CHPT1	-0.37	-8.03	-0.3	4.74e-15	Blood protein levels;
BRCA	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg11584989	chr19:19387371	SF4	0.63	13.5	0.47	1e-36	Bipolar disorder;
BRCA	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.28	-0.34	2.52e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs926392	0.896	rs7268772	chr20:37684501	A/G	cg16355469	chr20:37678765	NA	0.32	8.07	0.3	3.43e-15	Dialysis-related mortality;
BRCA	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.34	0.41	2.88e-27	Electroencephalogram traits;
BRCA	trans	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg25214090	chr10:38739885	LOC399744	0.51	11.51	0.41	5.53e-28	Corneal astigmatism;
BRCA	cis	rs8038465	0.638	rs7495543	chr15:73955133	G/C	cg15420318	chr15:73925796	NPTN	0.41	9.25	0.34	3.31e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7617773	0.743	rs13081633	chr3:48357281	A/G	cg11946769	chr3:48343235	NME6	0.69	13.89	0.48	1.68e-38	Coronary artery disease;
BRCA	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.33	-0.35	1.77e-19	Body mass index;
BRCA	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg06623918	chr6:96969491	KIAA0776	-0.88	-24.18	-0.69	3.15e-92	Headache;
BRCA	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg23950597	chr19:37808831	NA	-0.62	-11.37	-0.41	2.02e-27	Coronary artery calcification;
BRCA	cis	rs10733682	0.659	rs4358894	chr9:129464802	C/G	cg00232160	chr9:129468157	NA	0.39	9.14	0.34	7.93e-19	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1691799	0.899	rs1168305	chr12:66738714	A/G	cg16791601	chr12:66731901	HELB	-0.64	-17.29	-0.56	3.01e-55	White blood cell count (basophil);
BRCA	cis	rs4363385	0.818	rs2711	chr1:153005156	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.56	-0.32	8.46e-17	Inflammatory skin disease;
BRCA	cis	rs58785573	0.504	rs12646137	chr4:38609650	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.42	8.16	0.31	1.78e-15	Lymphocyte percentage of white cells;
BRCA	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg12386194	chr3:101231763	SENP7	0.45	9.68	0.36	8.74e-21	Colorectal cancer;
BRCA	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg12935359	chr14:103987150	CKB	-0.58	-13.22	-0.46	1.86e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.49	-10.06	-0.37	3.44e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.66	0.5	3.88e-42	Colorectal cancer;
BRCA	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg23711669	chr6:146136114	FBXO30	0.74	17.59	0.57	8.91e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6546550	0.901	rs6750488	chr2:70146125	C/T	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.47	-0.41	7.73e-28	Prevalent atrial fibrillation;
BRCA	cis	rs708547	0.575	rs6847086	chr4:57791864	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	0.41	8.01	0.3	5.48e-15	Response to bleomycin (chromatid breaks);
BRCA	cis	rs7633770	0.786	rs6808214	chr3:46682746	T/C	cg11219411	chr3:46661640	NA	0.65	16.87	0.56	4.29e-53	Coronary artery disease;
BRCA	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg03188948	chr7:1209495	NA	0.84	11.6	0.42	2.4e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg03060546	chr3:49711283	APEH	-0.6	-10.38	-0.38	1.96e-23	Menarche (age at onset);
BRCA	cis	rs7607369	0.536	rs4674344	chr2:219669875	A/T	cg02176678	chr2:219576539	TTLL4	-0.38	-10.12	-0.37	1.96e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs13046373	0.508	rs1012969	chr21:31996108	G/A	cg22337977	chr21:31811175	KRTAP15-1	0.34	8.16	0.31	1.81e-15	HDL cholesterol;
BRCA	cis	rs708547	0.578	rs781665	chr4:57831461	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.38	9.52	0.35	3.39e-20	Response to bleomycin (chromatid breaks);
BRCA	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg20701182	chr2:24300061	SF3B14	0.53	8.8	0.33	1.29e-17	Lymphocyte counts;
BRCA	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.51	8.39	0.32	3.04e-16	Lung function (FEV1/FVC);
BRCA	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg27535305	chr1:53392650	SCP2	-0.38	-9.12	-0.34	9.59e-19	Monocyte count;
BRCA	trans	rs4596713	0.538	rs10781456	chr9:71782869	G/A	cg16512924	chr15:28394682	HERC2	0.45	10.86	0.39	2.46e-25	Headache;
BRCA	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	3.94e-15	Alzheimer's disease (late onset);
BRCA	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg04553112	chr3:125709451	NA	-0.56	-8.54	-0.32	9.87e-17	Blood pressure (smoking interaction);
BRCA	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg23788917	chr6:8435910	SLC35B3	-0.48	-10.65	-0.39	1.64e-24	Motion sickness;
BRCA	cis	rs6495367	1.000	rs4778634	chr15:79380822	C/T	cg17916960	chr15:79447300	NA	0.33	8.07	0.3	3.5e-15	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4363385	0.818	rs1890285	chr1:153015396	T/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.08	-0.34	1.37e-18	Inflammatory skin disease;
BRCA	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg10932868	chr11:921992	NA	0.47	12.08	0.43	2.14e-30	Alzheimer's disease (late onset);
BRCA	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-11.43	-0.41	1.23e-27	Hip circumference adjusted for BMI;
BRCA	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg07148914	chr20:33460835	GGT7	0.45	9.86	0.36	1.9e-21	Height;
BRCA	cis	rs3784262	0.669	rs12905608	chr15:58314139	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.16	-0.37	1.38e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg26516362	chr5:178986906	RUFY1	0.45	12.79	0.45	1.67e-33	Lung cancer;
BRCA	cis	rs3820928	0.874	rs10207404	chr2:227794420	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.85	-0.33	8.46e-18	Pulmonary function;
BRCA	trans	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg06521331	chr12:34319734	NA	0.43	8.44	0.32	2.07e-16	Bladder cancer;
BRCA	cis	rs2249625	0.874	rs2254147	chr6:72920943	C/G	cg18830697	chr6:72922368	RIMS1	-0.37	-7.9	-0.3	1.2e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg09184832	chr6:79620586	NA	-0.53	-11.72	-0.42	7.35e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs4566357	0.615	rs12328876	chr2:227918899	G/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-9.69	-0.36	8.15e-21	Coronary artery disease;
BRCA	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-7.96	-0.3	8.12e-15	Homocysteine levels;
BRCA	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.57	-11.69	-0.42	9.32e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.0	22.67	0.67	5.75e-84	Lymphocyte percentage of white cells;
BRCA	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg23711669	chr6:146136114	FBXO30	-0.81	-20.04	-0.62	1.05e-69	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6960043	0.738	rs12540947	chr7:15059326	T/C	cg19272540	chr7:15055459	NA	0.25	8.38	0.31	3.3e-16	Type 2 diabetes;
BRCA	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg26818010	chr10:134567672	INPP5A	-0.78	-15.37	-0.52	1.39e-45	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	12.69	0.45	4.34e-33	Mean platelet volume;
BRCA	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg18196295	chr10:418757	DIP2C	0.47	10.67	0.39	1.44e-24	Psychosis in Alzheimer's disease;
BRCA	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg18252515	chr7:66147081	NA	-0.82	-11.88	-0.43	1.52e-29	Diabetic kidney disease;
BRCA	cis	rs4302748	0.862	rs73335288	chr7:36185070	C/T	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.88	-0.3	1.4e-14	Aortic root size;
BRCA	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg18252515	chr7:66147081	NA	1.06	15.63	0.53	6.79e-47	Diabetic kidney disease;
BRCA	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg23018236	chr17:30244563	NA	0.56	9.45	0.35	6.15e-20	Hip circumference adjusted for BMI;
BRCA	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg06766960	chr11:133703094	NA	-0.61	-12.71	-0.45	3.76e-33	Childhood ear infection;
BRCA	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg10950524	chr7:2139216	MAD1L1	0.28	7.96	0.3	7.73e-15	Schizophrenia;
BRCA	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg02175503	chr12:58329896	NA	0.51	10.66	0.39	1.58e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg26597838	chr10:835615	NA	1.3	21.91	0.65	8.86e-80	Eosinophil percentage of granulocytes;
BRCA	trans	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg14791747	chr16:20752902	THUMPD1	0.41	9.75	0.36	4.9e-21	Cognitive test performance;
BRCA	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26818010	chr10:134567672	INPP5A	-0.63	-13.61	-0.47	3.22e-37	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg13175981	chr1:150552382	MCL1	0.54	11.73	0.42	6.51e-29	Tonsillectomy;
BRCA	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.07	0.4	3.59e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs921968	0.565	rs3770219	chr2:219619766	T/C	cg02176678	chr2:219576539	TTLL4	-0.41	-11.06	-0.4	4.01e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg05347473	chr6:146136440	FBXO30	0.53	11.18	0.4	1.31e-26	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg24296786	chr1:45957014	TESK2	-0.43	-9.64	-0.36	1.29e-20	Red blood cell count;Reticulocyte count;
BRCA	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg23711669	chr6:146136114	FBXO30	0.79	18.86	0.6	2.07e-63	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	15.87	0.53	4.53e-48	Exhaled nitric oxide levels;
BRCA	cis	rs2652834	1.000	rs36116701	chr15:63397494	T/C	cg05507819	chr15:63340323	TPM1	0.45	8.09	0.3	3.04e-15	HDL cholesterol;
BRCA	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.5	0.32	1.34e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11733284	0.515	rs10025104	chr4:47855999	T/C	cg21463140	chr4:47913142	NFXL1	-0.4	-10.8	-0.39	4.19e-25	Renal underexcretion gout;Gout;
BRCA	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg25358565	chr5:93447407	FAM172A	1.17	18.34	0.59	1.17e-60	Diabetic retinopathy;
BRCA	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg14844989	chr11:31128820	NA	-0.43	-9.73	-0.36	5.79e-21	Red blood cell count;
BRCA	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg15839431	chr19:19639596	YJEFN3	-0.38	-8.47	-0.32	1.74e-16	Bipolar disorder;
BRCA	cis	rs7551345	0.653	rs7528098	chr1:31699435	A/G	cg19084893	chr1:31688959	NA	-0.47	-10.07	-0.37	3.05e-22	Schizophrenia;
BRCA	cis	rs7264396	0.563	rs2425146	chr20:34355268	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.54	-0.42	3.97e-28	Total cholesterol levels;
BRCA	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg20283391	chr11:68216788	NA	-0.44	-8.59	-0.32	6.6e-17	Total body bone mineral density;
BRCA	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.88	-17.75	-0.57	1.3e-57	Body mass index;
BRCA	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12292205	chr6:26970375	C6orf41	-0.47	-7.97	-0.3	7.21e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg04450456	chr4:17643702	FAM184B	0.34	9.26	0.34	2.99e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg23711669	chr6:146136114	FBXO30	0.64	14.99	0.51	9.22e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-8.9	-0.33	5.58e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.66	-14.14	-0.49	1.13e-39	Lung cancer;
BRCA	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg23033748	chr14:75592666	NEK9	-0.33	-7.86	-0.3	1.65e-14	Height;
BRCA	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg06618935	chr21:46677482	NA	-0.37	-8.04	-0.3	4.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.41	0.35	8.46e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg08807101	chr21:30365312	RNF160	0.4	8.53	0.32	1.08e-16	Pancreatic cancer;
BRCA	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg00383909	chr3:49044727	WDR6	0.6	10.99	0.4	7.27e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg07169764	chr2:136633963	MCM6	1.03	21.49	0.65	1.75e-77	Corneal structure;
BRCA	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.55	13.73	0.48	8.44e-38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg13880726	chr7:1868755	MAD1L1	0.51	10.14	0.37	1.6e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	20.46	0.63	6.24e-72	Smoking behavior;
BRCA	cis	rs4285028	0.747	rs7610298	chr3:121419100	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-13.97	-0.48	6.66e-39	Multiple sclerosis;
BRCA	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.47	-9.29	-0.35	2.35e-19	IgG glycosylation;
BRCA	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.48	0.35	4.92e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03264133	chr6:25882463	NA	-0.54	-12.19	-0.43	6.7e-31	Blood metabolite levels;
BRCA	cis	rs7520050	0.966	rs6675946	chr1:46371774	G/T	cg24296786	chr1:45957014	TESK2	0.43	9.85	0.36	2.18e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg08917208	chr2:24149416	ATAD2B	1.05	14.29	0.49	2.21e-40	Lymphocyte counts;
BRCA	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg08859206	chr1:53392774	SCP2	-0.51	-11.15	-0.4	1.68e-26	Monocyte count;
BRCA	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	14.11	0.49	1.47e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08219700	chr8:58056026	NA	0.45	8.24	0.31	9.41e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg01877450	chr7:97915802	BRI3	-0.39	-8.84	-0.33	9.37e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4722166	0.598	rs4722179	chr7:22803861	C/A	cg05472934	chr7:22766657	IL6	0.4	9.83	0.36	2.51e-21	Lung cancer;
BRCA	cis	rs909002	0.886	rs10798880	chr1:32097088	G/T	cg13919466	chr1:32135498	COL16A1	-0.27	-9.03	-0.34	1.98e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.92	0.56	2.52e-53	Hypertriglyceridemia;
BRCA	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg16586182	chr3:47516702	SCAP	0.52	11.75	0.42	5.36e-29	Colorectal cancer;
BRCA	cis	rs13053817	1.000	rs78186489	chr22:29845703	C/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.49	-9.62	-0.36	1.48e-20	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs67460515	0.500	rs1562464	chr3:160681614	G/A	cg03342759	chr3:160939853	NMD3	-0.64	-12.76	-0.45	2.28e-33	Parkinson's disease;
BRCA	cis	rs56399783	0.901	rs17132594	chr7:2775102	G/A	cg19731401	chr7:2775893	GNA12	0.5	8.01	0.3	5.52e-15	Childhood ear infection;
BRCA	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.65	13.81	0.48	3.62e-38	Lymphocyte counts;
BRCA	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg02951883	chr7:2050386	MAD1L1	0.54	12.37	0.44	1.15e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.75	-0.33	1.92e-17	Total body bone mineral density;
BRCA	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg23625390	chr15:77176239	SCAPER	-0.56	-14.11	-0.49	1.5e-39	Blood metabolite levels;
BRCA	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.97	-22.39	-0.66	1.98e-82	Lymphocyte percentage of white cells;
BRCA	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21659725	chr3:3221576	CRBN	0.45	11.16	0.4	1.49e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg25036284	chr2:26402008	FAM59B	0.91	15.8	0.53	1.06e-47	Gut microbiome composition (summer);
BRCA	cis	rs926392	0.640	rs4616534	chr20:37693564	G/A	cg16355469	chr20:37678765	NA	0.53	11.59	0.42	2.56e-28	Dialysis-related mortality;
BRCA	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg23018236	chr17:30244563	NA	-0.72	-11.87	-0.42	1.74e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs290268	0.874	rs290990	chr9:93561695	A/G	cg02608019	chr9:93564028	SYK	-0.44	-9.57	-0.35	2.36e-20	Platelet count;
BRCA	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg03060546	chr3:49711283	APEH	0.56	9.84	0.36	2.25e-21	Menarche (age at onset);
BRCA	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg12863693	chr15:85201151	NMB	0.45	8.41	0.32	2.63e-16	Schizophrenia;
BRCA	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg20503657	chr10:835505	NA	0.9	16.21	0.54	9.35e-50	Eosinophil percentage of granulocytes;
BRCA	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg12386194	chr3:101231763	SENP7	0.46	9.7	0.36	7.74e-21	Colorectal cancer;
BRCA	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg03433033	chr1:76189801	ACADM	0.69	12.93	0.46	3.86e-34	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2066819	1.000	rs77120931	chr12:56646213	A/C	cg26734620	chr12:56694298	CS	0.86	10.01	0.37	5.16e-22	Psoriasis vulgaris;
BRCA	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.07e-21	Developmental language disorder (linguistic errors);
BRCA	trans	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg14791747	chr16:20752902	THUMPD1	-0.41	-12.5	-0.44	3.2e-32	Cognitive test performance;
BRCA	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17467752	chr17:38218738	THRA	0.68	17.57	0.57	1.13e-56	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
BRCA	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg03864215	chr11:17408437	KCNJ11	-0.26	-7.82	-0.3	2.13e-14	Type 2 diabetes;
BRCA	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg12698349	chr2:225449008	CUL3	0.6	13.21	0.46	2.17e-35	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs4478137	0.931	rs3967762	chr4:164244976	T/C	cg06758707	chr4:164254230	NPY1R	0.56	12.25	0.44	3.81e-31	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	trans	rs931812	0.895	rs4734016	chr8:101910071	C/T	cg20993868	chr7:22813445	NA	0.57	16.07	0.54	4.87e-49	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg26769984	chr7:1090371	C7orf50	0.59	10.49	0.38	7.51e-24	Bronchopulmonary dysplasia;
BRCA	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg21427119	chr20:30132790	HM13	-0.43	-9.25	-0.34	3.28e-19	Mean corpuscular hemoglobin;
BRCA	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg20887711	chr4:1340912	KIAA1530	-0.62	-13.73	-0.48	8.45e-38	Longevity;
BRCA	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg08847533	chr14:75593920	NEK9	-0.88	-22.45	-0.66	9.64e-83	Height;
BRCA	trans	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg04565464	chr8:145669602	NFKBIL2	0.34	8.48	0.32	1.55e-16	Schizophrenia;
BRCA	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-9.41	-0.35	9.05e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg25358565	chr5:93447407	FAM172A	1.19	18.52	0.59	1.28e-61	Diabetic retinopathy;
BRCA	cis	rs965469	0.779	rs2207995	chr20:3294484	T/C	cg25506879	chr20:3388711	C20orf194	-0.43	-8.71	-0.33	2.61e-17	IFN-related cytopenia;
BRCA	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg02196730	chr15:80188777	MTHFS	0.37	8.53	0.32	1.05e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
BRCA	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg09184832	chr6:79620586	NA	-0.52	-11.62	-0.42	1.89e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg16586182	chr3:47516702	SCAP	0.61	14.15	0.49	9.21e-40	Colorectal cancer;
BRCA	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg24558204	chr6:135376177	HBS1L	0.45	12.42	0.44	7.31e-32	Red blood cell count;
BRCA	cis	rs2404618	0.624	rs28439223	chr8:1476901	C/G	cg13402656	chr8:1511478	DLGAP2	-0.5	-11.64	-0.42	1.62e-28	Lung cancer;
BRCA	cis	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.43	-9.66	-0.36	1.03e-20	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg03213289	chr20:61660250	NA	0.62	16.47	0.55	4.8e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4268898	0.552	rs12621083	chr2:24367540	C/T	cg06627628	chr2:24431161	ITSN2	0.4	8.51	0.32	1.24e-16	Asthma;
BRCA	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg05985134	chr18:33552581	C18orf21	0.64	11.57	0.42	2.93e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs6088813	1.000	rs6087698	chr20:33948919	A/G	cg14752227	chr20:34000481	UQCC	-0.41	-8.77	-0.33	1.65e-17	Height;
BRCA	cis	rs6066835	1.000	rs6122720	chr20:47351095	G/A	cg18078177	chr20:47281410	PREX1	0.67	8.08	0.3	3.14e-15	Multiple myeloma;
BRCA	trans	rs61931739	0.635	rs7979207	chr12:33910566	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-8.93	-0.33	4.58e-18	Morning vs. evening chronotype;
BRCA	cis	rs73086581	1.000	rs6116130	chr20:3947026	A/T	cg02187196	chr20:3869020	PANK2	0.51	9.28	0.34	2.51e-19	Response to antidepressants in depression;
BRCA	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-12.15	-0.43	1.04e-30	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26384229	chr12:38710491	ALG10B	0.75	16.67	0.55	4.32e-52	Morning vs. evening chronotype;
BRCA	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.44	0.44	5.83e-32	Bipolar disorder;
BRCA	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg05340658	chr4:99064831	C4orf37	0.45	10.28	0.38	4.98e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg13256891	chr4:100009986	ADH5	0.54	9.99	0.37	6.16e-22	Smoking initiation;
BRCA	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg12641515	chr19:46296257	DMWD	-0.57	-12.86	-0.45	7.72e-34	Coronary artery disease;
BRCA	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	18.57	0.59	6.57e-62	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-14.14	-0.49	1.14e-39	Morning vs. evening chronotype;
BRCA	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg19628046	chr18:33552617	C18orf21	0.52	10.82	0.39	3.6e-25	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs10496034	1.000	rs79756117	chr2:55156858	C/T	cg16098955	chr2:55172992	EML6	0.51	9.15	0.34	7.68e-19	Refractive astigmatism;
BRCA	trans	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg25214090	chr10:38739885	LOC399744	0.57	13.01	0.46	1.79e-34	Corneal astigmatism;
BRCA	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-8.34	-0.31	4.63e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs6684514	1.000	rs12041164	chr1:156279811	G/A	cg16558208	chr1:156270281	VHLL	0.34	8.07	0.3	3.48e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg09060608	chr5:178986726	RUFY1	0.54	13.13	0.46	4.75e-35	Lung cancer;
BRCA	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg03146154	chr1:46216737	IPP	-0.44	-9.64	-0.36	1.27e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg11584989	chr19:19387371	SF4	0.65	13.84	0.48	2.88e-38	Bipolar disorder;
BRCA	trans	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg23762105	chr12:34175262	ALG10	-0.36	-9.06	-0.34	1.58e-18	Morning vs. evening chronotype;
BRCA	cis	rs9368481	0.524	rs9393768	chr6:26885619	A/G	cg12292205	chr6:26970375	C6orf41	0.64	14.51	0.5	1.84e-41	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs12367572	0.965	rs10785539	chr12:45233023	G/C	cg04608330	chr12:45269318	NELL2	-0.6	-13.41	-0.47	2.66e-36	Gut microbiome composition (summer);
BRCA	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	12.07	0.43	2.31e-30	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg01236616	chr12:121019343	POP5	-1.18	-26.56	-0.72	2.67e-105	Type 1 diabetes nephropathy;
BRCA	cis	rs12612619	0.704	rs3769139	chr2:27315714	C/T	cg00617064	chr2:27272375	NA	-0.33	-8.53	-0.32	1.02e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg06064525	chr11:970664	AP2A2	-0.48	-16.23	-0.54	7.7e-50	Alzheimer's disease (late onset);
BRCA	trans	rs783540	0.967	rs783523	chr15:83283555	A/G	cg18393722	chr15:85113863	UBE2QP1	0.27	8.34	0.31	4.57e-16	Schizophrenia;
BRCA	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.31	0.49	1.68e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9807989	0.507	rs2058659	chr2:103054556	A/G	cg03938978	chr2:103052716	IL18RAP	-0.3	-8.53	-0.32	1.03e-16	Asthma;
BRCA	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.37	-9.2	-0.34	5.08e-19	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg23587288	chr2:27483067	SLC30A3	0.38	8.89	0.33	6.27e-18	Blood metabolite levels;
BRCA	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-13.57	-0.47	4.61e-37	Morning vs. evening chronotype;
BRCA	cis	rs600231	0.577	rs12269965	chr11:65232087	C/T	cg01292856	chr11:65242576	NA	0.67	14.92	0.51	2.15e-43	Bone mineral density;
BRCA	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg21918786	chr6:109611834	NA	-0.44	-11.86	-0.42	1.9e-29	Reticulocyte fraction of red cells;
BRCA	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18404041	chr3:52824283	ITIH1	-0.42	-12.46	-0.44	4.72e-32	Bipolar disorder;
BRCA	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.88	0.62	8.32e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs700651	0.789	rs882954	chr2:198907444	A/G	cg00792783	chr2:198669748	PLCL1	0.39	8.59	0.32	6.61e-17	Intracranial aneurysm;
BRCA	cis	rs3772130	0.962	rs13433692	chr3:121484714	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.75	0.39	7.12e-25	Cognitive performance;
BRCA	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg18016565	chr1:150552671	MCL1	-0.42	-9.61	-0.36	1.64e-20	Urate levels;
BRCA	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.45	8.02	0.3	5.1e-15	Schizophrenia;
BRCA	cis	rs2882667	0.690	rs288010	chr5:138200029	A/C	cg04439458	chr5:138467593	SIL1	0.31	7.94	0.3	8.86e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-10.07	-0.37	3.01e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-9.28	-0.34	2.59e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.49	9.74	0.36	5.36e-21	Height;
BRCA	cis	rs9815354	0.812	rs73069240	chr3:41950973	A/T	cg03022575	chr3:42003672	ULK4	0.69	9.62	0.36	1.44e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00149659	chr3:10157352	C3orf10	0.79	13.72	0.48	9.42e-38	Alzheimer's disease;
BRCA	cis	rs9420	0.809	rs11600169	chr11:57464945	T/A	cg19752551	chr11:57585705	CTNND1	-0.5	-12.27	-0.44	3.09e-31	Schizophrenia;
BRCA	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg06238570	chr21:40685208	BRWD1	-0.47	-9.38	-0.35	1.14e-19	Cognitive function;
BRCA	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg26031613	chr14:104095156	KLC1	-0.43	-8.5	-0.32	1.36e-16	Schizophrenia;
BRCA	cis	rs9462027	0.630	rs9469871	chr6:34745007	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.0	-0.3	5.77e-15	Systemic lupus erythematosus;
BRCA	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	10.61	0.39	2.39e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg23711669	chr6:146136114	FBXO30	-0.73	-15.02	-0.51	6.63e-44	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs12517041	1.000	rs10068478	chr5:23297003	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-12.58	-0.45	1.41e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs10911363	0.592	rs2275675	chr1:183439483	C/T	cg09173681	chr1:183549694	NCF2	-0.48	-10.39	-0.38	1.79e-23	Systemic lupus erythematosus;
BRCA	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg17470723	chr8:74884337	TCEB1	0.44	9.07	0.34	1.4e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs12474201	0.928	rs12998753	chr2:46938385	A/G	cg06386533	chr2:46925753	SOCS5	0.91	19.84	0.62	1.33e-68	Height;
BRCA	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08219700	chr8:58056026	NA	0.57	9.6	0.35	1.83e-20	Developmental language disorder (linguistic errors);
BRCA	trans	rs783540	0.967	rs1864699	chr15:83323318	A/G	cg18393722	chr15:85113863	UBE2QP1	0.26	8.18	0.31	1.56e-15	Schizophrenia;
BRCA	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg04733989	chr22:42467013	NAGA	0.37	8.43	0.32	2.23e-16	Cognitive function;
BRCA	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg08822215	chr16:89438651	ANKRD11	0.41	9.1	0.34	1.16e-18	Multiple myeloma (IgH translocation);
BRCA	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg20933634	chr6:27740509	NA	0.47	9.3	0.35	2.17e-19	Parkinson's disease;
BRCA	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg15133208	chr4:90757351	SNCA	-0.39	-7.97	-0.3	7.33e-15	Neuroticism;
BRCA	cis	rs9463078	0.774	rs7740083	chr6:45274742	G/A	cg25276700	chr6:44698697	NA	-0.36	-8.11	-0.31	2.64e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg05973401	chr12:123451056	ABCB9	0.41	7.94	0.3	9.17e-15	Neutrophil percentage of white cells;
BRCA	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg05872129	chr22:39784769	NA	0.52	11.69	0.42	9.13e-29	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg13010199	chr12:38710504	ALG10B	0.45	9.39	0.35	1.08e-19	Bladder cancer;
BRCA	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg24642844	chr7:1081250	C7orf50	-0.89	-16.33	-0.54	2.28e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.48e-23	Motion sickness;
BRCA	cis	rs9831754	0.704	rs9836909	chr3:78451594	A/G	cg06138941	chr3:78371609	NA	-0.61	-12.97	-0.46	2.67e-34	Calcium levels;
BRCA	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.85	-20.78	-0.64	1.13e-73	Body mass index (adult);
BRCA	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	16.04	0.54	6.96e-49	Coronary artery disease;
BRCA	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg10556349	chr10:835070	NA	0.73	9.88	0.36	1.6e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs1983170	0.736	rs4484968	chr1:92012005	C/A	cg25838465	chr1:92012736	NA	0.46	8.13	0.31	2.19e-15	Eosinophil percentage of white cells;
BRCA	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg23711669	chr6:146136114	FBXO30	0.71	16.85	0.55	5.23e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-9.72	-0.36	6.63e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.33	0.35	1.64e-19	Tonsillectomy;
BRCA	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-12.2	-0.43	6.44e-31	Alzheimer's disease;
BRCA	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.36	11.86	0.42	1.89e-29	Bipolar disorder;
BRCA	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-9.44	-0.35	6.59e-20	Joint mobility (Beighton score);
BRCA	cis	rs6820391	0.816	rs6826933	chr4:54445715	C/T	cg04173182	chr4:54446035	LNX1	0.53	12.13	0.43	1.27e-30	Cervical artery dissection;
BRCA	cis	rs11585357	0.947	rs6684387	chr1:17611519	T/C	cg08277548	chr1:17600880	PADI3	0.6	10.87	0.4	2.22e-25	Hair shape;
BRCA	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg25036284	chr2:26402008	FAM59B	-0.63	-10.51	-0.38	6.14e-24	Gut microbiome composition (summer);
BRCA	cis	rs524281	0.861	rs10750778	chr11:65948648	T/C	cg16950941	chr11:66035639	RAB1B	-0.37	-7.82	-0.3	2.14e-14	Electroencephalogram traits;
BRCA	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg14664628	chr15:75095509	CSK	-0.78	-19.13	-0.6	7.7e-65	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg05343316	chr1:45956843	TESK2	0.7	14.51	0.5	1.98e-41	Platelet count;
BRCA	trans	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.15	0.31	1.88e-15	Corneal astigmatism;
BRCA	trans	rs12517041	0.935	rs10061491	chr5:23296773	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-15.0	-0.51	8.89e-44	Total cholesterol levels;
BRCA	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	11.15	0.4	1.7e-26	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg00012203	chr2:219082015	ARPC2	-0.5	-9.63	-0.36	1.42e-20	Colorectal cancer;
BRCA	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg27446573	chr6:127587934	RNF146	0.89	20.5	0.63	3.86e-72	Breast cancer;
BRCA	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.33	9.93	0.37	1.07e-21	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg04944784	chr2:26401820	FAM59B	1.0	16.79	0.55	1.16e-52	Gut microbiome composition (summer);
BRCA	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg23587288	chr2:27483067	SLC30A3	0.37	8.61	0.32	5.8e-17	Blood metabolite levels;
BRCA	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg24296786	chr1:45957014	TESK2	0.47	11.04	0.4	4.49e-26	Red blood cell count;Reticulocyte count;
BRCA	trans	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg25214090	chr10:38739885	LOC399744	-0.37	-8.5	-0.32	1.36e-16	Diastolic blood pressure;
BRCA	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	10.87	0.39	2.33e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg11752832	chr7:134001865	SLC35B4	0.52	13.48	0.47	1.31e-36	Mean platelet volume;
BRCA	cis	rs17620991	1.000	rs66651482	chr7:40851242	G/T	cg05119115	chr7:40866195	C7orf10	-0.56	-8.67	-0.32	3.66e-17	Alcohol dependence;
BRCA	cis	rs760805	1.000	rs11249204	chr1:25261740	C/T	cg22509179	chr1:25234806	RUNX3	0.57	14.74	0.5	1.49e-42	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg20476274	chr7:133979776	SLC35B4	-0.45	-11.64	-0.42	1.54e-28	Mean platelet volume;
BRCA	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg24642439	chr20:33292090	TP53INP2	0.54	11.77	0.42	4.49e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs28669119	0.749	rs244750	chr5:88147192	T/C	cg18498987	chr5:88179539	MEF2C	0.44	8.04	0.3	4.32e-15	Schizophrenia;
BRCA	cis	rs877282	0.945	rs11253396	chr10:789754	C/T	cg17470449	chr10:769945	NA	0.51	8.62	0.32	5.29e-17	Uric acid levels;
BRCA	cis	rs919433	0.680	rs788023	chr2:198283305	T/C	cg00792783	chr2:198669748	PLCL1	0.38	8.39	0.32	3.12e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg18765753	chr7:1198926	ZFAND2A	-0.4	-7.99	-0.3	6.11e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg06238570	chr21:40685208	BRWD1	-0.4	-8.14	-0.31	2.02e-15	Menarche (age at onset);
BRCA	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg26031613	chr14:104095156	KLC1	-0.55	-9.5	-0.35	4.09e-20	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9649465	1.000	rs3807640	chr7:123338713	G/C	cg04330084	chr7:123175371	IQUB	-0.33	-8.82	-0.33	1.05e-17	Migraine;
BRCA	cis	rs7737355	0.947	rs31257	chr5:130828715	C/G	cg06307176	chr5:131281290	NA	0.52	10.4	0.38	1.71e-23	Life satisfaction;
BRCA	cis	rs4664304	0.620	rs10929958	chr2:160720538	A/G	cg14819504	chr2:160761413	LY75	0.34	8.47	0.32	1.65e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs1864400	0.696	rs2742239	chr10:43621712	A/G	cg02780029	chr10:43622663	RET	-0.35	-7.86	-0.3	1.64e-14	Hirschsprung disease;
BRCA	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg18154014	chr19:37997991	ZNF793	0.61	11.38	0.41	1.85e-27	Coronary artery calcification;
BRCA	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg12483005	chr1:23474871	LUZP1	0.37	8.02	0.3	4.97e-15	Height;
BRCA	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.26	0.34	3.1e-19	Tonsillectomy;
BRCA	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg14458575	chr2:238380390	NA	0.53	8.68	0.32	3.27e-17	Prostate cancer;
BRCA	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.48	8.75	0.33	1.9e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	11.18	0.4	1.24e-26	Birth weight;
BRCA	cis	rs9341808	0.718	rs9361584	chr6:80819946	G/C	cg08355045	chr6:80787529	NA	0.37	9.35	0.35	1.43e-19	Sitting height ratio;
BRCA	cis	rs13046373	0.535	rs9980934	chr21:31982988	C/T	cg27071517	chr21:31768726	KRTAP13-1	0.28	7.87	0.3	1.53e-14	HDL cholesterol;
BRCA	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg24692254	chr21:30365293	RNF160	0.78	21.63	0.65	2.97e-78	Dental caries;
BRCA	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.19	-0.34	5.52e-19	Total body bone mineral density;
BRCA	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.05	29.56	0.76	1.12e-121	Cognitive ability;
BRCA	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg02820040	chr2:241836501	C2orf54	-0.49	-8.96	-0.33	3.63e-18	Urinary metabolites;
BRCA	cis	rs12541635	0.677	rs7460291	chr8:107057861	A/G	cg10147462	chr8:107024639	NA	0.39	10.31	0.38	3.63e-23	Age of smoking initiation;
BRCA	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg12373951	chr3:133503437	NA	0.44	10.4	0.38	1.68e-23	Iron status biomarkers;
BRCA	cis	rs9400271	0.632	rs9384703	chr6:109586803	A/G	cg01475377	chr6:109611718	NA	-0.42	-10.13	-0.37	1.81e-22	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg16586182	chr3:47516702	SCAP	-0.44	-8.84	-0.33	9.43e-18	Birth weight;
BRCA	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg15605315	chr1:45957053	TESK2	-0.46	-9.27	-0.34	2.92e-19	High light scatter reticulocyte count;
BRCA	cis	rs4635969	0.718	rs27068	chr5:1347239	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.35	-8.06	-0.3	3.81e-15	Testicular germ cell tumor;Testicular germ cell cancer;
BRCA	cis	rs9296092	0.517	rs7775914	chr6:33518110	T/C	cg13560919	chr6:33536144	NA	-0.85	-18.53	-0.59	1.1e-61	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11644478	chr21:40555479	PSMG1	0.85	19.85	0.62	1.1e-68	Cognitive function;
BRCA	cis	rs9649465	0.967	rs12539091	chr7:123291314	C/T	cg04330084	chr7:123175371	IQUB	-0.33	-9.05	-0.34	1.71e-18	Migraine;
BRCA	cis	rs28830936	1.000	rs4923905	chr15:41909889	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.32	-9.23	-0.34	3.76e-19	Diastolic blood pressure;
BRCA	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.12	0.62	4.1e-70	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg01448562	chr3:133502909	NA	-0.62	-14.85	-0.51	4.63e-43	Iron status biomarkers;
BRCA	cis	rs9682041	0.660	rs13089256	chr3:170113601	G/A	cg11886554	chr3:170076028	SKIL	0.51	10.13	0.37	1.76e-22	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg15704280	chr7:45808275	SEPT13	0.8	18.66	0.59	2.37e-62	Coronary artery disease;
BRCA	cis	rs10929956	0.760	rs2729704	chr2:160707866	T/A	cg02280532	chr2:160761244	LY75	-0.35	-7.81	-0.3	2.29e-14	Crohn's disease-related phenotypes;
BRCA	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	14.42	0.5	5.42e-41	Hip circumference adjusted for BMI;
BRCA	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg18404041	chr3:52824283	ITIH1	-0.35	-9.15	-0.34	7.52e-19	Schizophrenia;
BRCA	cis	rs6977660	0.652	rs10267417	chr7:19843797	C/T	cg05791153	chr7:19748676	TWISTNB	0.59	10.72	0.39	8.76e-25	Thyroid stimulating hormone;
BRCA	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg13393036	chr8:95962371	TP53INP1	-0.29	-7.84	-0.3	1.91e-14	Type 2 diabetes;
BRCA	cis	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg21775007	chr8:11205619	TDH	-0.48	-9.41	-0.35	9.09e-20	Retinal vascular caliber;
BRCA	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.61	7.81	0.3	2.34e-14	Yeast infection;
BRCA	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.73	-0.33	2.17e-17	Neuroticism;
BRCA	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	19.2	0.6	3.14e-65	Alzheimer's disease;
BRCA	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg26384229	chr12:38710491	ALG10B	0.85	23.11	0.67	2.4700000000000002e-86	Heart rate;
BRCA	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10802521	chr3:52805072	NEK4	-0.31	-8.45	-0.32	1.94e-16	Electroencephalogram traits;
BRCA	cis	rs4908760	0.730	rs10779704	chr1:8693537	A/C	cg20416874	chr1:8611966	RERE	-0.29	-8.29	-0.31	6.66e-16	Vitiligo;
BRCA	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	16.58	0.55	1.35e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg24531977	chr5:56204891	C5orf35	-0.44	-8.66	-0.32	3.74e-17	Coronary artery disease;
BRCA	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg08088566	chr11:430123	ANO9	0.56	8.3	0.31	6.17e-16	Body mass index;
BRCA	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	19.33	0.61	6.67e-66	Smoking behavior;
BRCA	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg21699342	chr2:239360505	ASB1	0.53	14.06	0.49	2.49e-39	Multiple system atrophy;
BRCA	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg15934090	chr1:100435551	SLC35A3	0.36	8.36	0.31	3.82e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg21573476	chr21:45109991	RRP1B	-0.36	-9.63	-0.36	1.36e-20	Mean corpuscular volume;
BRCA	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg20701182	chr2:24300061	SF3B14	0.68	12.9	0.45	5.2e-34	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg05340658	chr4:99064831	C4orf37	0.62	14.74	0.5	1.55e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg23029597	chr12:123009494	RSRC2	-0.63	-12.71	-0.45	3.78e-33	Body mass index;
BRCA	cis	rs10504073	0.647	rs10504072	chr8:49993083	G/A	cg00325661	chr8:49890786	NA	0.44	12.45	0.44	5.05e-32	Blood metabolite ratios;
BRCA	cis	rs7172677	0.737	rs11855234	chr15:75446834	C/A	cg10253484	chr15:75165896	SCAMP2	-0.42	-7.94	-0.3	9.09e-15	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs27434	0.561	rs151910	chr5:96156956	C/A	cg16492584	chr5:96139282	ERAP1	-0.51	-12.75	-0.45	2.4e-33	Ankylosing spondylitis;
BRCA	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg22535103	chr8:58192502	C8orf71	-0.46	-8.2	-0.31	1.31e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs11608355	0.515	rs2287184	chr12:109970251	T/C	cg05360138	chr12:110035743	NA	0.73	13.59	0.47	3.77e-37	Neuroticism;
BRCA	trans	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg05926928	chr17:57297772	GDPD1	0.47	9.11	0.34	1.04e-18	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
BRCA	cis	rs13046373	0.562	rs12627602	chr21:32022924	G/A	cg24082983	chr21:31802169	KRTAP13-4	0.32	8.17	0.31	1.69e-15	HDL cholesterol;
BRCA	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg05552183	chr6:42928497	GNMT	0.85	21.59	0.65	4.79e-78	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs11690935	0.571	rs13020884	chr2:172901699	T/G	cg13550731	chr2:172543902	DYNC1I2	0.56	13.91	0.48	1.22e-38	Schizophrenia;
BRCA	cis	rs1975991	0.765	rs4634106	chr3:187953513	C/G	cg15417654	chr3:187959138	LPP	0.33	7.88	0.3	1.46e-14	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg04455712	chr21:45112962	RRP1B	0.38	9.76	0.36	4.48e-21	Mean corpuscular volume;
BRCA	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg01324343	chr3:183735012	ABCC5	0.81	20.44	0.63	8.24e-72	Anterior chamber depth;
BRCA	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg13334819	chr7:99746414	C7orf59	0.34	7.92	0.3	1.06e-14	Coronary artery disease;
BRCA	cis	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.42	-0.32	2.51e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7246657	0.679	rs12461113	chr19:38083188	G/A	cg18154014	chr19:37997991	ZNF793	0.48	9.16	0.34	7.24e-19	Coronary artery calcification;
BRCA	cis	rs6763687	0.756	rs4894522	chr3:171770001	A/G	cg16233210	chr3:171778391	FNDC3B	0.37	7.91	0.3	1.13e-14	Red cell distribution width;
BRCA	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg03929089	chr4:120376271	NA	0.71	16.53	0.55	2.38e-51	Height;
BRCA	cis	rs4302748	0.862	rs58221920	chr7:36181963	C/A	cg24442661	chr7:36192818	EEPD1	0.46	8.74	0.33	2.11e-17	Platelet count;
BRCA	cis	rs68170813	0.559	rs76145119	chr7:107052368	C/T	cg02696742	chr7:106810147	HBP1	-0.54	-8.13	-0.31	2.17e-15	Coronary artery disease;
BRCA	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg04851639	chr8:1020857	NA	-0.34	-10.57	-0.39	3.55e-24	Schizophrenia;
BRCA	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg13010199	chr12:38710504	ALG10B	0.52	10.31	0.38	3.8e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2559856	0.967	rs2695297	chr12:102082218	T/C	cg12213457	chr12:102090980	CHPT1	-0.37	-8.03	-0.3	4.74e-15	Blood protein levels;
BRCA	cis	rs2274273	1.000	rs8011834	chr14:55625977	A/C	cg04306507	chr14:55594613	LGALS3	0.31	8.64	0.32	4.37e-17	Protein biomarker;
BRCA	cis	rs9323205	0.862	rs11629399	chr14:51612814	T/C	cg23942311	chr14:51606299	NA	-0.44	-9.26	-0.34	3.06e-19	Cancer;
BRCA	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg03146154	chr1:46216737	IPP	0.53	11.86	0.42	1.84e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg03060546	chr3:49711283	APEH	-0.58	-10.21	-0.37	8.95e-23	Menarche (age at onset);
BRCA	cis	rs16976116	0.851	rs11855907	chr15:55494634	A/C	cg11288833	chr15:55489084	RSL24D1	0.48	10.68	0.39	1.25e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg18252515	chr7:66147081	NA	1.03	15.25	0.52	5.04e-45	Diabetic kidney disease;
BRCA	trans	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg00938859	chr5:1591904	SDHAP3	0.69	9.4	0.35	9.53e-20	Breast cancer;
BRCA	cis	rs12431939	1.000	rs12433445	chr14:51666091	G/A	cg23942311	chr14:51606299	NA	-0.43	-8.08	-0.3	3.2e-15	Cancer;
BRCA	cis	rs6815814	0.950	rs113465719	chr4:38808045	A/T	cg06935464	chr4:38784597	TLR10	0.5	8.27	0.31	7.76e-16	Breast cancer;
BRCA	trans	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg25214090	chr10:38739885	LOC399744	0.55	12.61	0.45	1.08e-32	Corneal astigmatism;
BRCA	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.22	0.34	4.35e-19	Tonsillectomy;
BRCA	cis	rs7586879	0.828	rs13012304	chr2:25122246	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.35	0.35	1.43e-19	Body mass index;
BRCA	cis	rs758324	0.947	rs2088719	chr5:131184439	C/T	cg06307176	chr5:131281290	NA	0.53	10.13	0.37	1.87e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg12573674	chr2:1569213	NA	-0.54	-11.41	-0.41	1.46e-27	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg27279351	chr12:120934652	DYNLL1	0.56	13.26	0.46	1.28e-35	High light scatter reticulocyte count;
BRCA	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg16230307	chr14:35515116	FAM177A1	0.69	14.47	0.5	3.14e-41	Psoriasis;
BRCA	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg12386194	chr3:101231763	SENP7	0.48	10.04	0.37	4.03e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.42	9.32	0.35	1.83e-19	Colorectal cancer;
BRCA	cis	rs7927771	0.524	rs10838732	chr11:47607940	C/G	cg20307385	chr11:47447363	PSMC3	0.45	10.38	0.38	1.9e-23	Subjective well-being;
BRCA	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg19784903	chr17:45786737	TBKBP1	0.34	8.11	0.31	2.54e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	11.83	0.42	2.57e-29	Schizophrenia;
BRCA	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg04317338	chr11:64019027	PLCB3	0.53	9.21	0.34	4.46e-19	Mean platelet volume;
BRCA	cis	rs2066819	1.000	rs2291361	chr12:56717805	G/A	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	trans	rs4596713	0.568	rs6560584	chr9:71747172	A/G	cg16512924	chr15:28394682	HERC2	0.39	9.39	0.35	1.04e-19	Headache;
BRCA	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg09537434	chr19:41945824	ATP5SL	-1.0	-25.54	-0.71	1.07e-99	Height;
BRCA	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg04691961	chr3:161091175	C3orf57	-0.59	-14.28	-0.49	2.26e-40	Morning vs. evening chronotype;
BRCA	trans	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg01620082	chr3:125678407	NA	0.8	9.25	0.34	3.35e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7833986	0.501	rs2719255	chr8:57036658	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	13.06	0.46	9.86e-35	Height;
BRCA	cis	rs2882667	0.861	rs11959727	chr5:138396965	C/T	cg04439458	chr5:138467593	SIL1	-0.35	-9.55	-0.35	2.83e-20	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg08822215	chr16:89438651	ANKRD11	0.43	9.53	0.35	3.26e-20	Multiple myeloma (IgH translocation);
BRCA	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-10.82	-0.39	3.74e-25	Monocyte count;
BRCA	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg07537917	chr2:241836409	C2orf54	0.45	10.04	0.37	3.99e-22	Urinary metabolites;
BRCA	cis	rs7572733	0.555	rs7600269	chr2:198923468	C/G	cg00792783	chr2:198669748	PLCL1	0.39	8.45	0.32	2e-16	Dermatomyositis;
BRCA	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg26373071	chr5:1325741	CLPTM1L	0.51	12.46	0.44	4.92e-32	Lung cancer;
BRCA	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg16325326	chr1:53192061	ZYG11B	0.78	21.0	0.64	7.22e-75	Monocyte count;
BRCA	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs2559856	1.000	rs2695299	chr12:102082664	G/A	cg12213457	chr12:102090980	CHPT1	-0.37	-8.07	-0.3	3.56e-15	Blood protein levels;
BRCA	cis	rs9287719	0.649	rs6732429	chr2:10758972	C/T	cg00105475	chr2:10696890	NA	-0.39	-8.94	-0.33	4.31e-18	Prostate cancer;
BRCA	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.46	8.24	0.31	9.8e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg02176678	chr2:219576539	TTLL4	0.39	10.47	0.38	8.56e-24	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	9.7	0.36	7.35e-21	Aortic root size;
BRCA	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg26384229	chr12:38710491	ALG10B	0.66	13.93	0.48	1.04e-38	Morning vs. evening chronotype;
BRCA	cis	rs1691799	0.831	rs6581678	chr12:66776656	A/G	cg16791601	chr12:66731901	HELB	-0.61	-16.54	-0.55	2.04e-51	White blood cell count (basophil);
BRCA	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.84	-0.3	1.9e-14	Aortic root size;
BRCA	cis	rs6426558	0.515	rs7412928	chr1:227332148	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.46	-9.04	-0.34	1.89e-18	Neutrophil percentage of white cells;
BRCA	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg21782813	chr7:2030301	MAD1L1	-0.32	-8.83	-0.33	9.9e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs17767294	0.708	rs72845896	chr6:27697645	C/G	cg08851530	chr6:28072375	NA	1.11	10.08	0.37	2.81e-22	Parkinson's disease;
BRCA	trans	rs4942242	0.659	rs1105586	chr13:44232633	C/T	cg19169023	chr15:41853346	TYRO3	0.6	12.97	0.46	2.58e-34	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg06618935	chr21:46677482	NA	0.38	8.35	0.31	4.36e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.25	0.41	6.72e-27	Bipolar disorder;
BRCA	cis	rs3857536	0.740	rs7751095	chr6:66891318	A/G	cg07460842	chr6:66804631	NA	-0.46	-8.86	-0.33	8.14e-18	Blood trace element (Cu levels);
BRCA	trans	rs1997103	0.954	rs2030807	chr7:55378485	A/G	cg20935933	chr6:143382018	AIG1	0.59	11.3	0.41	4.23e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.61	0.55	9.32e-52	Colorectal cancer;
BRCA	cis	rs11690935	0.921	rs908670	chr2:172690180	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.9	-29.49	-0.76	2.5e-121	Schizophrenia;
BRCA	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg10876282	chr6:28092338	ZSCAN16	0.41	8.14	0.31	2.06e-15	Parkinson's disease;
BRCA	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg11262906	chr1:85462892	MCOLN2	-0.53	-10.94	-0.4	1.22e-25	Serum sulfate level;
BRCA	cis	rs10754283	0.967	rs1320563	chr1:90121032	G/A	cg21401794	chr1:90099060	LRRC8C	0.47	11.01	0.4	5.97e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs586533	0.724	rs680914	chr11:99501982	A/G	cg22878054	chr11:99397252	CNTN5	0.32	8.11	0.31	2.53e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg09324608	chr17:30823087	MYO1D	0.5	11.95	0.43	7.91e-30	Schizophrenia;
BRCA	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg24675658	chr1:53192096	ZYG11B	0.64	14.02	0.49	3.92e-39	Monocyte count;
BRCA	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg13319975	chr6:146136371	FBXO30	-0.4	-8.93	-0.33	4.5e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg08508325	chr11:3079039	CARS	-0.36	-11.95	-0.43	7.2e-30	Longevity;
BRCA	cis	rs7572733	0.534	rs770662	chr2:198729283	T/C	cg00792783	chr2:198669748	PLCL1	0.47	10.18	0.37	1.21e-22	Dermatomyositis;
BRCA	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg10560079	chr2:191398806	TMEM194B	-0.76	-12.54	-0.44	2.17e-32	Diastolic blood pressure;
BRCA	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg07395648	chr5:131743802	NA	-0.37	-9.49	-0.35	4.33e-20	Blood metabolite levels;
BRCA	cis	rs524281	0.692	rs10791845	chr11:65834340	C/G	cg14036092	chr11:66035641	RAB1B	0.4	8.95	0.33	3.95e-18	Electroencephalogram traits;
BRCA	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg02016764	chr4:38805732	TLR1	-0.6	-9.19	-0.34	5.47e-19	Breast cancer;
BRCA	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg00012203	chr2:219082015	ARPC2	-0.55	-11.28	-0.41	5.04e-27	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg11814155	chr7:99998594	ZCWPW1	0.43	8.1	0.31	2.72e-15	Platelet count;
BRCA	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg24110177	chr3:50126178	RBM5	-0.51	-14.57	-0.5	9.9e-42	Body mass index;
BRCA	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg08875078	chr22:50639485	SELO	-0.3	-7.83	-0.3	1.97e-14	Obesity-related traits;
BRCA	trans	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg23762105	chr12:34175262	ALG10	-0.36	-9.08	-0.34	1.29e-18	Morning vs. evening chronotype;
BRCA	cis	rs7715806	0.500	rs17649266	chr5:75001252	C/T	cg19683494	chr5:74908142	NA	-0.51	-8.46	-0.32	1.81e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg02820040	chr2:241836501	C2orf54	-0.54	-10.25	-0.38	6.25e-23	Urinary metabolites;
BRCA	cis	rs13064411	0.696	rs13066742	chr3:113208423	T/C	cg18753928	chr3:113234510	CCDC52	-0.59	-12.34	-0.44	1.56e-31	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03517284	chr6:25882590	NA	-0.47	-10.66	-0.39	1.57e-24	Blood metabolite levels;
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg03923535	chr7:1197113	ZFAND2A	-0.45	-8.9	-0.33	5.59e-18	Longevity;Endometriosis;
BRCA	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg23711669	chr6:146136114	FBXO30	0.79	18.95	0.6	6.68e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs965469	0.895	rs6051843	chr20:3400538	A/G	cg25506879	chr20:3388711	C20orf194	-0.54	-10.6	-0.39	2.73e-24	IFN-related cytopenia;
BRCA	cis	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg21775007	chr8:11205619	TDH	-0.62	-13.37	-0.47	4.04e-36	Retinal vascular caliber;
BRCA	cis	rs12541635	0.677	rs6997487	chr8:106965511	A/C	cg10147462	chr8:107024639	NA	0.39	10.46	0.38	9.3e-24	Age of smoking initiation;
BRCA	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg07395648	chr5:131743802	NA	-0.35	-7.87	-0.3	1.58e-14	Breast cancer;
BRCA	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg10978503	chr1:24200527	CNR2	0.47	12.35	0.44	1.49e-31	Immature fraction of reticulocytes;
BRCA	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg22903471	chr2:27725779	GCKR	-0.36	-8.73	-0.33	2.29e-17	Total body bone mineral density;
BRCA	cis	rs9341808	1.000	rs9341808	chr6:80953257	C/A	cg08355045	chr6:80787529	NA	0.34	9.09	0.34	1.19e-18	Sitting height ratio;
BRCA	cis	rs9649465	0.967	rs6966470	chr7:123299855	C/T	cg04330084	chr7:123175371	IQUB	0.3	8.21	0.31	1.19e-15	Migraine;
BRCA	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg03146154	chr1:46216737	IPP	0.5	11.16	0.4	1.55e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-9.6	-0.36	1.77e-20	Coronary artery disease;
BRCA	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	17.21	0.56	8.02e-55	Intelligence (multi-trait analysis);
BRCA	cis	rs7766436	0.553	rs62391069	chr6:22610835	C/T	cg13666174	chr6:22585274	NA	-0.44	-7.99	-0.3	6.33e-15	Coronary artery disease;
BRCA	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.09e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7586879	0.964	rs6545795	chr2:25116783	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.36	0.35	1.34e-19	Body mass index;
BRCA	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg04691961	chr3:161091175	C3orf57	-0.59	-14.81	-0.51	6.87e-43	Morning vs. evening chronotype;
BRCA	cis	rs4730250	0.654	rs6947857	chr7:106787266	T/G	cg02696742	chr7:106810147	HBP1	0.62	9.87	0.36	1.82e-21	Osteoarthritis;
BRCA	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-8.25	-0.31	8.74e-16	Response to antipsychotic treatment;
BRCA	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg15212455	chr7:39170539	POU6F2	0.45	9.88	0.36	1.57e-21	IgG glycosylation;
BRCA	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg19077165	chr18:44547161	KATNAL2	0.63	14.24	0.49	3.49e-40	Personality dimensions;
BRCA	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg13010199	chr12:38710504	ALG10B	0.44	8.93	0.33	4.46e-18	Bladder cancer;
BRCA	cis	rs483180	0.512	rs606312	chr1:120222582	G/A	cg19096424	chr1:120255104	PHGDH	0.45	9.83	0.36	2.5e-21	Macular telangiectasia type 2;
BRCA	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg04025307	chr7:1156635	C7orf50	0.52	10.06	0.37	3.32e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg07460842	chr6:66804631	NA	-1.01	-27.66	-0.74	2.55e-111	Exhaled nitric oxide output;
BRCA	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.46	0.32	1.86e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4363385	0.818	rs423692	chr1:153005681	T/G	cg21543102	chr1:152974771	SPRR3	-0.28	-7.81	-0.3	2.39e-14	Inflammatory skin disease;
BRCA	cis	rs2742234	0.590	rs2505506	chr10:43645854	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.55	-11.25	-0.41	6.55e-27	Hirschsprung disease;
BRCA	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg25019033	chr10:957182	NA	-0.4	-8.57	-0.32	7.85e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg05283184	chr6:79620031	NA	-0.35	-8.38	-0.31	3.38e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg21045802	chr8:109455806	TTC35	0.35	8.02	0.3	5.19e-15	Dupuytren's disease;
BRCA	cis	rs1371614	0.635	rs877273	chr2:27140022	C/T	cg00617064	chr2:27272375	NA	0.31	8.01	0.3	5.29e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-15.27	-0.52	3.95e-45	Mood instability;
BRCA	cis	rs8038465	0.622	rs56712926	chr15:73886849	G/T	cg15420318	chr15:73925796	NPTN	0.49	10.28	0.38	4.8e-23	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg13010199	chr12:38710504	ALG10B	0.56	12.58	0.45	1.42e-32	Heart rate;
BRCA	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg13550731	chr2:172543902	DYNC1I2	0.93	30.62	0.77	1.89e-127	Schizophrenia;
BRCA	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg09184832	chr6:79620586	NA	-0.54	-12.0	-0.43	4.8e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg17063962	chr7:91808500	NA	0.53	12.47	0.44	4.15e-32	Breast cancer;
BRCA	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.41	-9.63	-0.36	1.43e-20	Tonsillectomy;
BRCA	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.33	-0.35	1.77e-19	Body mass index;
BRCA	trans	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg26043149	chr18:55253948	FECH	-0.39	-8.11	-0.31	2.65e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg08392591	chr16:89556376	ANKRD11	0.41	9.39	0.35	1.02e-19	Multiple myeloma (IgH translocation);
BRCA	cis	rs68170813	0.559	rs79978998	chr7:106845482	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.46	-0.32	1.78e-16	Coronary artery disease;
BRCA	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg14789911	chr21:47582049	C21orf56	-0.38	-8.07	-0.3	3.61e-15	Testicular germ cell tumor;
BRCA	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	28.21	0.74	2.43e-114	Chronic sinus infection;
BRCA	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-8.03	-0.3	4.72e-15	Response to antipsychotic treatment;
BRCA	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg16423285	chr20:60520624	NA	-0.54	-10.81	-0.39	4.04e-25	Obesity-related traits;
BRCA	cis	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg07460842	chr6:66804631	NA	0.86	13.83	0.48	3.16e-38	Exhaled nitric oxide output;
BRCA	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.16	-0.31	1.77e-15	Total body bone mineral density;
BRCA	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	12.02	0.43	3.77e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs58799304	0.531	rs12035615	chr1:156055344	C/T	cg15685922	chr1:156045208	MEX3A	-0.42	-8.75	-0.33	1.92e-17	Ischemic stroke;
BRCA	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg00484396	chr16:3507460	NAT15	0.57	8.36	0.31	3.84e-16	Tuberculosis;
BRCA	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.68e-18	Motion sickness;
BRCA	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg11584989	chr19:19387371	SF4	0.64	13.49	0.47	1.14e-36	Bipolar disorder;
BRCA	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.02	-0.3	5.02e-15	Total body bone mineral density;
BRCA	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg24578937	chr1:2090814	PRKCZ	0.35	11.39	0.41	1.71e-27	Height;
BRCA	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-8.99	-0.33	2.87e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9811920	0.809	rs793443	chr3:99573547	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.55	-13.02	-0.46	1.59e-34	Axial length;
BRCA	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18252515	chr7:66147081	NA	-0.56	-11.32	-0.41	3.38e-27	Corneal structure;
BRCA	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg13660082	chr14:53194042	PSMC6	-0.57	-8.64	-0.32	4.61e-17	Alzheimer's disease (late onset);
BRCA	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg18252515	chr7:66147081	NA	-1.07	-15.54	-0.52	2.03e-46	Diabetic kidney disease;
BRCA	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg06697600	chr4:7070879	GRPEL1	0.54	10.63	0.39	1.98e-24	Monocyte percentage of white cells;
BRCA	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26314531	chr2:26401878	FAM59B	-0.88	-15.31	-0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg11814155	chr7:99998594	ZCWPW1	0.54	9.32	0.35	1.81e-19	Platelet count;
BRCA	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-15.61	-0.53	9.29e-47	Chronic sinus infection;
BRCA	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	9.1e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg14343924	chr8:8086146	FLJ10661	0.39	8.1	0.31	2.81e-15	Mood instability;
BRCA	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg01689657	chr7:91764605	CYP51A1	0.22	8.15	0.31	1.96e-15	Breast cancer;
BRCA	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg11663144	chr21:46675770	NA	-0.64	-15.28	-0.52	3.72e-45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1997103	1.000	rs6968966	chr7:55411356	A/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	22.72	0.67	3.41e-84	Platelet count;
BRCA	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	7.99	0.3	6.37e-15	Menarche (age at onset);
BRCA	cis	rs13136331	0.607	rs7680291	chr4:88638522	G/T	cg22416721	chr4:88570574	DMP1	-0.6	-13.89	-0.48	1.68e-38	Sitting height ratio;
BRCA	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.87	-0.3	1.49e-14	Electroencephalogram traits;
BRCA	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg22713356	chr15:30763199	NA	1.25	20.77	0.63	1.25e-73	Uric acid levels;
BRCA	cis	rs2282802	0.685	rs1347143	chr5:139669386	A/G	cg26211634	chr5:139558579	C5orf32	-0.33	-7.98	-0.3	7.01e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs783540	0.934	rs783530	chr15:83266549	G/C	cg18393722	chr15:85113863	UBE2QP1	-0.27	-8.37	-0.31	3.7e-16	Schizophrenia;
BRCA	trans	rs3960554	0.808	rs867973	chr7:75686007	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	11.98	0.43	5.53e-30	Eotaxin levels;
BRCA	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.53	8.89	0.33	6.37e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.31	8.36	0.31	3.78e-16	Birth weight;
BRCA	cis	rs7715811	1.000	rs13436952	chr5:13773993	A/G	cg07548982	chr5:13769939	DNAH5	-0.4	-9.07	-0.34	1.5e-18	Subclinical atherosclerosis traits (other);
BRCA	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg14675211	chr2:100938903	LONRF2	0.52	11.51	0.41	5.62e-28	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	8.92e-15	Corneal astigmatism;
BRCA	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg13736514	chr6:26305472	NA	-0.46	-14.79	-0.5	8.88e-43	Educational attainment;
BRCA	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-9.92	-0.37	1.1e-21	Monocyte percentage of white cells;
BRCA	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	8.42	0.32	2.47e-16	Axial length;
BRCA	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.58	-10.68	-0.39	1.36e-24	Aortic root size;
BRCA	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg18964960	chr10:1102726	WDR37	0.66	9.22	0.34	4.25e-19	Eosinophil percentage of granulocytes;
BRCA	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg09307838	chr4:120376055	NA	0.69	14.25	0.49	3.17e-40	Corneal astigmatism;
BRCA	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg06636001	chr8:8085503	FLJ10661	0.52	10.28	0.38	4.8e-23	Retinal vascular caliber;
BRCA	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	24.74	0.7	2.79e-95	Platelet count;
BRCA	cis	rs754466	1.000	rs56256440	chr10:79698207	A/G	cg17075019	chr10:79541650	NA	-0.65	-12.26	-0.44	3.56e-31	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs698761	0.505	rs7609180	chr2:44538484	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	7.85	0.3	1.74e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg08000102	chr2:233561755	GIGYF2	0.62	13.69	0.48	1.36e-37	Coronary artery disease;
BRCA	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg18230493	chr5:56204884	C5orf35	-0.91	-17.93	-0.58	1.55e-58	Initial pursuit acceleration;
BRCA	cis	rs2882667	0.838	rs11958529	chr5:138395068	C/T	cg04439458	chr5:138467593	SIL1	-0.33	-8.91	-0.33	5.29e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.94	-0.33	4.19e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg02176678	chr2:219576539	TTLL4	-0.44	-11.56	-0.42	3.44e-28	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg13010199	chr12:38710504	ALG10B	0.51	9.97	0.37	7.62e-22	Bladder cancer;
BRCA	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03517284	chr6:25882590	NA	0.68	15.32	0.52	2.44e-45	Blood metabolite levels;
BRCA	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg05729581	chr11:3078854	CARS	-0.34	-8.18	-0.31	1.5e-15	Longevity;
BRCA	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg06618935	chr21:46677482	NA	-0.36	-7.99	-0.3	6.31e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-12.22	-0.44	5.2e-31	Gut microbiome composition (summer);
BRCA	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg06046430	chr4:77819534	ANKRD56	0.59	13.27	0.46	1.13e-35	Emphysema distribution in smoking;
BRCA	cis	rs4478858	0.684	rs10753245	chr1:31731208	A/G	cg00250761	chr1:31883323	NA	-0.33	-8.64	-0.32	4.66e-17	Alcohol dependence;
BRCA	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg08601574	chr20:25228251	PYGB	-0.39	-9.0	-0.34	2.47e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg18479299	chr3:125709523	NA	-0.53	-8.33	-0.31	5.07e-16	Blood pressure (smoking interaction);
BRCA	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00149659	chr3:10157352	C3orf10	0.79	13.72	0.48	9.42e-38	Alzheimer's disease;
BRCA	cis	rs7178424	0.870	rs12898423	chr15:62251451	T/C	cg00456672	chr15:62358751	C2CD4A	0.43	9.78	0.36	3.78e-21	Height;
BRCA	cis	rs7246967	0.673	rs35731237	chr19:22820510	G/T	cg23217946	chr19:22817039	ZNF492	0.47	8.48	0.32	1.56e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg04518342	chr5:131593106	PDLIM4	0.38	8.78	0.33	1.48e-17	Acylcarnitine levels;
BRCA	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg15432903	chr11:17409602	KCNJ11	0.71	15.93	0.53	2.28e-48	Type 2 diabetes;
BRCA	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg22431228	chr1:16359049	CLCNKA	-0.45	-9.2	-0.34	4.89e-19	Dilated cardiomyopathy;
BRCA	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg23711669	chr6:146136114	FBXO30	-0.75	-17.43	-0.57	5.61e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-16.73	-0.55	2.24e-52	Axial length;
BRCA	cis	rs1371614	0.611	rs7557229	chr2:27130891	T/C	cg12368169	chr2:27073192	DPYSL5	-0.29	-8.66	-0.32	3.86e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9487051	0.676	rs9386774	chr6:109561646	C/T	cg01475377	chr6:109611718	NA	-0.37	-8.87	-0.33	7.04e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	11.35	0.41	2.6e-27	Systemic lupus erythematosus;
BRCA	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg22764044	chr5:178986830	RUFY1	0.39	10.14	0.37	1.67e-22	Lung cancer;
BRCA	trans	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg25214090	chr10:38739885	LOC399744	0.53	12.03	0.43	3.51e-30	Corneal astigmatism;
BRCA	cis	rs6433895	1.000	rs56169464	chr2:182012828	A/C	cg00481216	chr2:181971175	NA	0.37	8.54	0.32	9.6e-17	Lymphocyte counts;
BRCA	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	10.98	0.4	8.41e-26	Rheumatoid arthritis;
BRCA	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg20701182	chr2:24300061	SF3B14	0.58	9.04	0.34	1.86e-18	Lymphocyte counts;
BRCA	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26314531	chr2:26401878	FAM59B	0.96	16.36	0.54	1.59e-50	Gut microbiome composition (summer);
BRCA	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg22508957	chr16:3507546	NAT15	0.46	11.3	0.41	3.97e-27	Tuberculosis;
BRCA	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg18512352	chr11:47633146	NA	-0.33	-8.09	-0.3	2.98e-15	Subjective well-being;
BRCA	cis	rs62458065	0.640	rs10241303	chr7:32534203	T/G	cg20159608	chr7:32802032	NA	-0.46	-8.33	-0.31	5e-16	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.82e-21	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6479891	0.778	rs10761735	chr10:65043918	A/G	cg14819942	chr15:35414228	NA	-0.35	-8.57	-0.32	7.85e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg23018236	chr17:30244563	NA	-0.61	-10.02	-0.37	4.87e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg20307385	chr11:47447363	PSMC3	0.77	21.99	0.66	2.96e-80	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs17253792	0.731	rs74823888	chr14:56049800	T/C	cg01858014	chr14:56050164	KTN1	-0.73	-9.45	-0.35	6.29e-20	Putamen volume;
BRCA	trans	rs61931739	1.000	rs12305700	chr12:34036332	T/C	cg26384229	chr12:38710491	ALG10B	-0.42	-9.4	-0.35	9.36e-20	Morning vs. evening chronotype;
BRCA	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg03684893	chr10:554711	DIP2C	-0.4	-9.95	-0.37	9.07e-22	Psychosis in Alzheimer's disease;
BRCA	cis	rs11690935	0.571	rs1008151	chr2:172912098	G/A	cg13550731	chr2:172543902	DYNC1I2	0.59	14.78	0.5	9.94e-43	Schizophrenia;
BRCA	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg13010199	chr12:38710504	ALG10B	-0.37	-8.87	-0.33	7.5e-18	Morning vs. evening chronotype;
BRCA	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg03060546	chr3:49711283	APEH	-0.56	-11.48	-0.41	7.03e-28	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.64	-0.36	1.27e-20	Alcohol dependence;
BRCA	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03517284	chr6:25882590	NA	-0.48	-9.81	-0.36	2.95e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg22906224	chr7:99728672	NA	0.43	8.23	0.31	1.04e-15	Coronary artery disease;
BRCA	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24531977	chr5:56204891	C5orf35	-0.72	-16.11	-0.54	2.79e-49	Initial pursuit acceleration;
BRCA	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21659725	chr3:3221576	CRBN	-0.71	-21.67	-0.65	1.76e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg27446573	chr6:127587934	RNF146	0.9	21.16	0.64	9.91e-76	Breast cancer;
BRCA	cis	rs72766638	0.895	rs72766630	chr9:136926791	G/T	cg13789015	chr9:136890014	NCRNA00094	0.54	8.28	0.31	7.34e-16	Mosquito bite size;
BRCA	cis	rs7666738	0.688	rs35739409	chr4:98576934	C/T	cg05340658	chr4:99064831	C4orf37	0.52	8.39	0.32	3.12e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.8	0.39	4.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg06521331	chr12:34319734	NA	-0.46	-8.9	-0.33	5.68e-18	Resting heart rate;
BRCA	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg10169327	chr19:45448959	APOC2	-0.33	-8.09	-0.3	3.05e-15	Blood protein levels;
BRCA	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.68	0.42	1.03e-28	Homoarginine levels;
BRCA	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg21724239	chr8:58056113	NA	0.43	7.82	0.3	2.18e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10802521	chr3:52805072	NEK4	-0.34	-9.41	-0.35	8.52e-20	Electroencephalogram traits;
BRCA	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg20991723	chr1:152506922	NA	0.39	9.07	0.34	1.4e-18	Hair morphology;
BRCA	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg06453172	chr10:134556979	INPP5A	-0.53	-11.31	-0.41	3.57e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs8032158	1.000	rs7162435	chr15:56121334	C/T	cg02198044	chr15:56286336	NEDD4	0.36	8.82	0.33	1.06e-17	Keloid;
BRCA	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	11.3	0.41	4.01e-27	Personality dimensions;
BRCA	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg08807101	chr21:30365312	RNF160	-0.6	-14.84	-0.51	4.91e-43	Dental caries;
BRCA	trans	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.14	0.31	2.04e-15	Corneal astigmatism;
BRCA	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.05	29.7	0.76	1.84e-122	Cognitive ability;
BRCA	cis	rs34891900	0.507	rs12167771	chr22:18124332	G/A	cg19898043	chr22:18121309	BCL2L13	0.46	9.24	0.34	3.75e-19	Sum neutrophil eosinophil counts;
BRCA	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg13010199	chr12:38710504	ALG10B	0.52	10.56	0.39	3.91e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.31	7.81	0.3	2.41e-14	Response to antipsychotic treatment;
BRCA	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg09307838	chr4:120376055	NA	0.75	16.18	0.54	1.37e-49	Corneal astigmatism;
BRCA	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg07636037	chr3:49044803	WDR6	0.77	15.46	0.52	4.7e-46	Menarche (age at onset);
BRCA	cis	rs4363385	0.818	rs574649	chr1:153008471	G/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs4285028	0.848	rs4118376	chr3:121636450	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.63	-11.11	-0.4	2.34e-26	Multiple sclerosis;
BRCA	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg05343316	chr1:45956843	TESK2	0.64	13.16	0.46	3.46e-35	Platelet count;
BRCA	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	11.63	0.42	1.77e-28	Multiple sclerosis;
BRCA	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.4	-8.19	-0.31	1.41e-15	Aortic root size;
BRCA	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg11584989	chr19:19387371	SF4	0.6	13.54	0.47	6.94e-37	Bipolar disorder;
BRCA	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.24	0.49	3.5e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg12661370	chr5:149340060	SLC26A2	0.56	8.27	0.31	8.04e-16	HIV-1 control;
BRCA	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.55	13.65	0.48	2.07e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg01620082	chr3:125678407	NA	-0.98	-11.11	-0.4	2.38e-26	Depression;
BRCA	cis	rs11031096	0.502	rs720571	chr11:4001328	G/T	cg18678763	chr11:4115507	RRM1	-0.35	-7.96	-0.3	8.16e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg23033748	chr14:75592666	NEK9	-0.39	-9.42	-0.35	7.86e-20	Height;
BRCA	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.45	0.55	5.92e-51	Colorectal cancer;
BRCA	cis	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg07460842	chr6:66804631	NA	0.98	18.01	0.58	6.12e-59	Exhaled nitric oxide output;
BRCA	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg00376283	chr12:123451042	ABCB9	0.52	10.22	0.37	8.49e-23	Neutrophil percentage of white cells;
BRCA	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg20307385	chr11:47447363	PSMC3	0.41	9.0	0.34	2.5e-18	Subjective well-being;
BRCA	trans	rs1325195	0.881	rs10913690	chr1:179067071	G/T	cg11624085	chr17:8464688	MYH10	-0.25	-7.96	-0.3	7.88e-15	IgE grass sensitization;
BRCA	cis	rs36051895	0.632	rs1590803	chr9:5177533	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-9.06	-0.34	1.52e-18	Pediatric autoimmune diseases;
BRCA	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg18279126	chr7:2041391	MAD1L1	0.39	8.64	0.32	4.47e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-8.51	-0.32	1.19e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.12	-0.43	1.38e-30	Total cholesterol levels;
BRCA	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	14.01	0.48	4.39e-39	Coronary artery disease;
BRCA	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg24324837	chr19:49891574	CCDC155	0.47	8.12	0.31	2.47e-15	Multiple sclerosis;
BRCA	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg06636001	chr8:8085503	FLJ10661	0.55	11.92	0.43	1.03e-29	Mood instability;
BRCA	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.43	-0.32	2.28e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg13010199	chr12:38710504	ALG10B	0.5	9.53	0.35	3.31e-20	Morning vs. evening chronotype;
BRCA	cis	rs7633857	0.512	rs7611005	chr3:160698549	A/T	cg03342759	chr3:160939853	NMD3	-0.54	-11.38	-0.41	1.98e-27	Educational attainment (years of education);
BRCA	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.48	-0.32	1.6e-16	Breast cancer;
BRCA	cis	rs6495367	1.000	rs1007366	chr15:79379541	G/A	cg17916960	chr15:79447300	NA	0.34	8.13	0.31	2.2e-15	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg18252515	chr7:66147081	NA	1.02	15.12	0.51	2.32e-44	Diabetic kidney disease;
BRCA	cis	rs10465746	0.967	rs1475263	chr1:84339497	A/T	cg10977910	chr1:84465055	TTLL7	0.51	10.28	0.38	4.89e-23	Obesity-related traits;
BRCA	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg12386194	chr3:101231763	SENP7	0.45	9.65	0.36	1.12e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.68	11.5	0.41	6.24e-28	Schizophrenia;
BRCA	cis	rs56399783	0.901	rs17132624	chr7:2778496	G/A	cg19731401	chr7:2775893	GNA12	0.51	8.16	0.31	1.76e-15	Childhood ear infection;
BRCA	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg00814883	chr7:100076585	TSC22D4	-0.55	-10.83	-0.39	3.35e-25	Platelet count;
BRCA	cis	rs1568889	0.838	rs11030185	chr11:28041904	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.33	0.63	2.95e-71	Bipolar disorder;
BRCA	cis	rs4423214	0.559	rs10898201	chr11:71201527	C/A	cg05163923	chr11:71159392	DHCR7	-0.5	-8.83	-0.33	1.04e-17	Vitamin D levels;
BRCA	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg03709012	chr19:19516395	GATAD2A	0.73	16.19	0.54	1.16e-49	Tonsillectomy;
BRCA	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg04518342	chr5:131593106	PDLIM4	0.35	8.57	0.32	7.69e-17	Blood metabolite levels;
BRCA	cis	rs10746514	0.804	rs11122429	chr1:232261532	G/A	cg09506761	chr1:232265262	NA	-0.41	-8.36	-0.31	4e-16	Response to statin therapy;
BRCA	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg23708337	chr7:1209742	NA	0.64	8.94	0.33	4.31e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7249921	0.833	rs62111373	chr19:35660844	G/C	cg15419183	chr19:35660584	FXYD5	0.45	10.25	0.38	6.37e-23	Platelet count;
BRCA	cis	rs4363385	0.510	rs7532166	chr1:153046851	C/G	cg25856811	chr1:152973957	SPRR3	-0.32	-7.83	-0.3	2.11e-14	Inflammatory skin disease;
BRCA	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg12011299	chr4:100065546	ADH4	0.51	11.77	0.42	4.27e-29	Alcohol dependence;
BRCA	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg00717180	chr2:96193071	NA	0.3	8.25	0.31	8.85e-16	Coronary artery disease;
BRCA	cis	rs365132	0.517	rs7706790	chr5:176359136	C/T	cg16309518	chr5:176445507	NA	-0.43	-9.91	-0.36	1.25e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg15242686	chr22:24348715	GSTTP1	-0.51	-13.03	-0.46	1.4e-34	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7575217	0.767	rs6543018	chr2:101730288	A/G	cg23907051	chr2:101730305	TBC1D8	0.2	7.82	0.3	2.23e-14	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.49	0.57	2.8e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg26043149	chr18:55253948	FECH	0.99	23.46	0.68	2.99e-88	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs6908034	0.607	rs76413455	chr6:19808964	T/G	cg02682789	chr6:19804855	NA	0.75	8.8	0.33	1.25e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
BRCA	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.33	0.38	3.11e-23	Bipolar disorder;
BRCA	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg17507749	chr15:85114479	UBE2QP1	0.53	9.83	0.36	2.41e-21	Schizophrenia;
BRCA	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg23992470	chr4:843637	GAK	0.57	8.44	0.32	2.2e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg23711669	chr6:146136114	FBXO30	0.71	14.58	0.5	8.61e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2580764	0.565	rs7562292	chr2:55230219	C/T	cg09592903	chr2:55203963	RTN4	-0.4	-10.3	-0.38	4.13e-23	Mean platelet volume;
BRCA	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg16339924	chr4:17578868	LAP3	0.57	14.0	0.48	4.74e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg11845111	chr2:191398756	TMEM194B	0.79	14.79	0.5	9.06e-43	Diastolic blood pressure;
BRCA	cis	rs13102973	0.640	rs13140829	chr4:135838818	T/C	cg14419869	chr4:135874104	NA	0.45	9.09	0.34	1.24e-18	Subjective well-being;
BRCA	trans	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.25	0.31	9.3e-16	Corneal astigmatism;
BRCA	cis	rs858239	0.539	rs10254544	chr7:23220235	T/C	cg23682824	chr7:23144976	KLHL7	0.35	9.12	0.34	9.91e-19	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg06115741	chr20:33292138	TP53INP2	-0.4	-8.75	-0.33	1.86e-17	Glomerular filtration rate (creatinine);
BRCA	trans	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg17675199	chr6:35436792	RPL10A	-0.3	-8.14	-0.31	2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.58e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4237845	0.537	rs7969844	chr12:58278271	C/T	cg00677455	chr12:58241039	CTDSP2	0.64	15.92	0.53	2.54e-48	Intelligence (multi-trait analysis);
BRCA	trans	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-10.04	-0.37	4.1e-22	Morning vs. evening chronotype;
BRCA	cis	rs3806933	0.522	rs17553936	chr5:110454681	A/G	cg04022379	chr5:110408740	TSLP	0.47	10.07	0.37	3.04e-22	Eosinophilic esophagitis;
BRCA	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg00990874	chr7:1149470	C7orf50	0.52	10.17	0.37	1.33e-22	Bronchopulmonary dysplasia;
BRCA	cis	rs67478160	0.506	rs6575998	chr14:104250417	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.48	-12.44	-0.44	6.03e-32	Schizophrenia;
BRCA	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg26384229	chr12:38710491	ALG10B	0.67	14.35	0.49	1.15e-40	Morning vs. evening chronotype;
BRCA	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg01262667	chr19:19385393	TM6SF2	-0.4	-10.33	-0.38	3.1e-23	Tonsillectomy;
BRCA	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	14.78	0.5	9.71e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg08755490	chr11:65554678	OVOL1	-0.53	-11.18	-0.4	1.29e-26	Acne (severe);
BRCA	cis	rs1003719	0.680	rs2835670	chr21:38581114	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.51	-0.5	1.83e-41	Eye color traits;
BRCA	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.82	0.3	2.22e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg00290607	chr11:67383545	NA	0.42	9.36	0.35	1.29e-19	Mean corpuscular volume;
BRCA	cis	rs867371	1.000	rs6495643	chr15:82479254	C/G	cg00614314	chr15:82944287	LOC80154	0.43	9.06	0.34	1.52e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg26384229	chr12:38710491	ALG10B	0.85	22.89	0.67	3.77e-85	Heart rate;
BRCA	cis	rs6782228	0.509	rs2811495	chr3:128359957	A/G	cg16766828	chr3:128327626	NA	-0.42	-9.51	-0.35	3.94e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.25e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.56	-0.44	1.79e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg16606324	chr3:10149918	C3orf24	0.52	10.19	0.37	1.1e-22	Alzheimer's disease;
BRCA	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.64	-0.32	4.66e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.07	16.3	0.54	3.19e-50	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12579753	0.917	rs4842410	chr12:82219225	A/T	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.69	-0.33	3.01e-17	Resting heart rate;
BRCA	cis	rs6142102	0.923	rs6059586	chr20:32540501	G/A	cg24642439	chr20:33292090	TP53INP2	0.43	8.37	0.31	3.76e-16	Skin pigmentation;
BRCA	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.53	8.54	0.32	9.47e-17	HIV-1 control;
BRCA	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg09307838	chr4:120376055	NA	0.59	12.36	0.44	1.22e-31	Corneal astigmatism;
BRCA	cis	rs9811920	0.625	rs9290003	chr3:99906993	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.38	8.78	0.33	1.53e-17	Axial length;
BRCA	cis	rs6723226	0.806	rs6543658	chr2:32718849	G/A	cg02381751	chr2:32503542	YIPF4	0.7	15.59	0.53	1.08e-46	Intelligence (multi-trait analysis);
BRCA	cis	rs738321	0.725	rs9622738	chr22:38542346	G/A	cg20207973	chr22:38506712	BAIAP2L2	0.41	9.7	0.36	7.51e-21	Breast cancer;
BRCA	cis	rs17741873	0.779	rs10458656	chr10:75592662	A/G	cg07699608	chr10:75541558	CHCHD1	0.51	8.1	0.31	2.86e-15	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs12760731	0.565	rs116253445	chr1:178216962	C/T	cg00404053	chr1:178313656	RASAL2	0.65	7.92	0.3	1.09e-14	Obesity-related traits;
BRCA	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-9.83	-0.36	2.47e-21	Tonsillectomy;
BRCA	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg26597838	chr10:835615	NA	1.02	17.18	0.56	1.08e-54	Eosinophil percentage of granulocytes;
BRCA	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg27624424	chr6:160112604	SOD2	0.4	8.2	0.31	1.36e-15	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg05340658	chr4:99064831	C4orf37	-0.69	-17.51	-0.57	2.27e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg24558204	chr6:135376177	HBS1L	0.46	12.59	0.45	1.31e-32	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg26384229	chr12:38710491	ALG10B	0.77	18.03	0.58	4.4e-59	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs798766	1.000	rs7682402	chr4:1743343	G/A	cg10756475	chr4:1757242	NA	0.38	8.59	0.32	6.73e-17	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs440932	1.000	rs365309	chr8:9026940	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.49	-0.32	1.43e-16	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg09754948	chr16:28834200	ATXN2L	0.45	8.86	0.33	7.7e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg10729496	chr3:10149963	C3orf24	-0.44	-8.55	-0.32	9.38e-17	Alzheimer's disease;
BRCA	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg02503808	chr4:7069936	GRPEL1	0.78	17.54	0.57	1.69e-56	Monocyte percentage of white cells;
BRCA	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg04362960	chr10:104952993	NT5C2	0.46	10.65	0.39	1.71e-24	Arsenic metabolism;
BRCA	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg11812906	chr14:75593930	NEK9	-0.7	-16.19	-0.54	1.19e-49	Height;
BRCA	cis	rs858239	0.601	rs6962526	chr7:23158233	G/A	cg23682824	chr7:23144976	KLHL7	0.42	11.09	0.4	2.96e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-10.23	-0.38	7.5e-23	Mean corpuscular volume;
BRCA	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg13334819	chr7:99746414	C7orf59	0.39	9.01	0.34	2.32e-18	Coronary artery disease;
BRCA	cis	rs7737355	0.947	rs79018835	chr5:130798461	C/A	cg06307176	chr5:131281290	NA	-0.53	-10.51	-0.38	6.05e-24	Life satisfaction;
BRCA	trans	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg26043149	chr18:55253948	FECH	1.08	23.32	0.68	1.71e-87	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19723775	chr5:179050963	HNRNPH1	-0.35	-8.34	-0.31	4.45e-16	Lung cancer;
BRCA	cis	rs2599510	0.783	rs2710630	chr2:32765997	A/C	cg02381751	chr2:32503542	YIPF4	-0.43	-8.48	-0.32	1.51e-16	Interleukin-18 levels;
BRCA	cis	rs17095355	1.000	rs72828232	chr10:111725298	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.44	-9.48	-0.35	4.86e-20	Biliary atresia;
BRCA	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg24558204	chr6:135376177	HBS1L	0.44	12.07	0.43	2.37e-30	Red blood cell count;
BRCA	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg10560079	chr2:191398806	TMEM194B	0.4	8.69	0.32	3.15e-17	Pulse pressure;
BRCA	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-13.74	-0.48	7.99e-38	Morning vs. evening chronotype;
BRCA	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg09307838	chr4:120376055	NA	0.61	12.35	0.44	1.44e-31	Corneal astigmatism;
BRCA	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	12.02	0.43	3.77e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg04450456	chr4:17643702	FAM184B	0.36	10.63	0.39	2.04e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg10932868	chr11:921992	NA	0.49	12.59	0.45	1.21e-32	Alzheimer's disease (late onset);
BRCA	cis	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg04455712	chr21:45112962	RRP1B	0.41	10.6	0.39	2.69e-24	Mean corpuscular volume;
BRCA	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg07636037	chr3:49044803	WDR6	0.69	17.04	0.56	6.17e-54	Menarche (age at onset);
BRCA	trans	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg19862616	chr7:65841803	NCRNA00174	0.85	27.75	0.74	7.88e-112	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6987853	0.761	rs2923391	chr8:42415942	G/A	cg09913449	chr8:42400586	C8orf40	0.42	9.38	0.35	1.11e-19	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs1941687	0.509	rs2282632	chr18:31320229	A/G	cg15819921	chr19:927150	ARID3A	-0.41	-7.87	-0.3	1.57e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs754466	0.580	rs10762765	chr10:79566407	T/C	cg17075019	chr10:79541650	NA	-0.76	-18.77	-0.6	5.94e-63	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7523273	0.606	rs7144	chr1:207967719	A/G	cg22525895	chr1:207977042	MIR29B2	-0.49	-12.3	-0.44	2.44e-31	Schizophrenia;
BRCA	trans	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-7.87	-0.3	1.53e-14	Corneal astigmatism;
BRCA	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.58	12.38	0.44	1.07e-31	Lymphocyte percentage of white cells;
BRCA	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.52	-0.32	1.11e-16	Monocyte percentage of white cells;
BRCA	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg13010199	chr12:38710504	ALG10B	-0.38	-8.53	-0.32	1.06e-16	Morning vs. evening chronotype;
BRCA	cis	rs9581857	0.685	rs9319372	chr13:28042796	C/T	cg22138327	chr13:27999177	GTF3A	-0.63	-9.84	-0.36	2.29e-21	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
BRCA	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.0	-0.46	1.92e-34	Migraine;Coronary artery disease;
BRCA	cis	rs4409675	0.576	rs11247705	chr1:28212272	G/A	cg23691781	chr1:28212827	C1orf38	0.33	11.03	0.4	5.38e-26	Corneal astigmatism;
BRCA	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.05	0.3	3.95e-15	Total cholesterol levels;
BRCA	cis	rs1863824	0.625	rs11202024	chr10:88168024	C/A	cg07322936	chr10:88137208	NA	-0.45	-8.85	-0.33	8.25e-18	Schizophrenia;
BRCA	cis	rs7246657	0.525	rs997516	chr19:37474264	T/C	cg23950597	chr19:37808831	NA	-0.6	-9.41	-0.35	8.83e-20	Coronary artery calcification;
BRCA	cis	rs600806	0.850	rs10745354	chr1:109931908	C/T	cg20591472	chr1:110008990	SYPL2	0.33	8.22	0.31	1.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs698833	0.819	rs1372078	chr2:44543389	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.48	-9.7	-0.36	7.88e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.77	0.39	5.63e-25	Bipolar disorder;
BRCA	cis	rs13095912	0.819	rs11918734	chr3:185296602	T/C	cg11274856	chr3:185301563	NA	0.54	12.87	0.45	7.58e-34	Systolic blood pressure;
BRCA	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg15557168	chr22:42548783	NA	0.33	9.33	0.35	1.67e-19	Cognitive function;
BRCA	cis	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-8.89	-0.33	5.97e-18	Eosinophil percentage of white cells;
BRCA	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.58	12.74	0.45	2.75e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg13010199	chr12:38710504	ALG10B	0.41	8.37	0.31	3.59e-16	Bladder cancer;
BRCA	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg22920501	chr2:26401640	FAM59B	-0.65	-11.32	-0.41	3.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg21211680	chr2:198530	NA	-0.45	-7.88	-0.3	1.4e-14	Blood protein levels;
BRCA	cis	rs7520050	0.966	rs7550746	chr1:46351719	T/A	cg24296786	chr1:45957014	TESK2	0.44	9.81	0.36	3.08e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1595825	0.891	rs59938443	chr2:198497105	C/T	cg19156104	chr2:198669113	PLCL1	-0.43	-8.1	-0.31	2.76e-15	Ulcerative colitis;
BRCA	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg13628971	chr7:2884303	GNA12	0.58	11.93	0.43	9.27e-30	Height;
BRCA	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg21395723	chr22:39101663	GTPBP1	0.4	8.67	0.32	3.55e-17	Menopause (age at onset);
BRCA	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg13271783	chr10:134563150	INPP5A	-0.44	-9.18	-0.34	6.01e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs76419734	0.510	rs2553463	chr4:106730663	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.44	-9.59	-0.35	1.96e-20	Post bronchodilator FEV1;
BRCA	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22857025	chr5:266934	NA	-1.03	-19.86	-0.62	9.84e-69	Breast cancer;
BRCA	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-12.81	-0.45	1.31e-33	Response to antipsychotic treatment;
BRCA	cis	rs6815814	0.950	rs67719080	chr4:38787252	A/G	cg06935464	chr4:38784597	TLR10	0.51	9.57	0.35	2.32e-20	Breast cancer;
BRCA	cis	rs733592	0.504	rs2261608	chr12:48721634	A/T	cg24011408	chr12:48396354	COL2A1	0.41	8.31	0.31	5.55e-16	Plateletcrit;
BRCA	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.34	-8.88	-0.33	6.85e-18	Crohn's disease;
BRCA	cis	rs10864907	0.614	rs12711745	chr2:113700355	T/C	cg12858261	chr2:113808755	IL1F8	0.35	7.82	0.3	2.18e-14	Pulmonary function;
BRCA	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg08132940	chr7:1081526	C7orf50	-0.58	-8.7	-0.33	2.79e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg07423050	chr13:99094983	FARP1	-0.45	-10.22	-0.37	8.3e-23	Longevity;
BRCA	cis	rs13136331	0.680	rs2732178	chr4:88654589	T/C	cg22416721	chr4:88570574	DMP1	-0.57	-13.56	-0.47	5.42e-37	Sitting height ratio;
BRCA	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.38	-9.53	-0.35	3.21e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9287719	0.614	rs10929680	chr2:10723126	C/T	cg00105475	chr2:10696890	NA	0.41	9.12	0.34	9.77e-19	Prostate cancer;
BRCA	cis	rs3824867	1.000	rs3824867	chr11:47468569	A/G	cg20307385	chr11:47447363	PSMC3	0.55	12.1	0.43	1.7e-30	Mean corpuscular hemoglobin;
BRCA	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg01528321	chr10:82214614	TSPAN14	-0.8	-16.83	-0.55	7.17e-53	Post bronchodilator FEV1;
BRCA	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg08999081	chr20:33150536	PIGU	0.34	8.83	0.33	9.78e-18	Coronary artery disease;
BRCA	cis	rs6460942	0.597	rs17448193	chr7:12525641	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-7.8	-0.3	2.45e-14	Coronary artery disease;
BRCA	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	10.85	0.39	2.81e-25	Rheumatoid arthritis;
BRCA	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-23.15	-0.68	1.4e-86	Monocyte count;
BRCA	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg17366294	chr4:99064904	C4orf37	0.44	10.27	0.38	5.19e-23	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg26043149	chr18:55253948	FECH	-0.37	-8.22	-0.31	1.17e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs11585357	0.895	rs4625336	chr1:17630964	G/T	cg19159961	chr1:17633534	PADI4	0.55	9.43	0.35	7.22e-20	Hair shape;
BRCA	cis	rs7617773	0.963	rs12493256	chr3:48176747	C/T	cg11946769	chr3:48343235	NME6	-0.39	-8.43	-0.32	2.33e-16	Coronary artery disease;
BRCA	cis	rs644148	0.967	rs2686778	chr19:44972257	G/A	cg15540054	chr19:45004280	ZNF180	-0.57	-12.12	-0.43	1.37e-30	Personality dimensions;
BRCA	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg17802220	chr15:77601643	NA	-0.47	-10.27	-0.38	5.3e-23	Type 2 diabetes;
BRCA	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg03146154	chr1:46216737	IPP	0.53	11.73	0.42	6.59e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg10523679	chr1:76189770	ACADM	0.71	12.35	0.44	1.38e-31	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.78	-0.53	1.24e-47	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.0	0.48	4.83e-39	Motion sickness;
BRCA	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg04450456	chr4:17643702	FAM184B	0.34	9.66	0.36	1.04e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg11301795	chr4:187892539	NA	0.29	9.84	0.36	2.35e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs838147	0.815	rs28400015	chr19:49250633	G/A	cg03531100	chr19:49260119	FGF21;FUT1	-0.37	-8.21	-0.31	1.19e-15	Dietary macronutrient intake;
BRCA	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg12564285	chr5:131593104	PDLIM4	0.35	7.9	0.3	1.19e-14	Breast cancer;
BRCA	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg02574844	chr11:5959923	NA	-0.42	-8.73	-0.33	2.22e-17	DNA methylation (variation);
BRCA	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-11.55	-0.42	3.79e-28	Hemoglobin concentration;
BRCA	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg14196790	chr5:131705035	SLC22A5	0.33	8.66	0.32	3.86e-17	Breast cancer;
BRCA	cis	rs2130392	0.926	rs4610379	chr4:185624388	A/G	cg21366198	chr4:185655624	MLF1IP	-0.4	-9.76	-0.36	4.36e-21	Kawasaki disease;
BRCA	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg23625390	chr15:77176239	SCAPER	0.39	9.04	0.34	1.9e-18	Blood metabolite levels;
BRCA	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg06766960	chr11:133703094	NA	-0.64	-13.42	-0.47	2.26e-36	Childhood ear infection;
BRCA	cis	rs9400271	0.527	rs57749539	chr6:109640667	T/C	cg01475377	chr6:109611718	NA	0.36	7.96	0.3	7.97e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs6121246	0.559	rs6060857	chr20:30300222	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	23.38	0.68	7.83e-88	Mean corpuscular hemoglobin;
BRCA	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg03146154	chr1:46216737	IPP	0.52	11.61	0.42	2.16e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs13136331	0.721	rs2627714	chr4:88687693	C/T	cg22416721	chr4:88570574	DMP1	-0.51	-11.8	-0.42	3.33e-29	Sitting height ratio;
BRCA	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	8.44	0.32	2.12e-16	Rheumatoid arthritis;
BRCA	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg02475777	chr4:1388615	CRIPAK	0.4	8.69	0.33	3.06e-17	Longevity;
BRCA	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg20283391	chr11:68216788	NA	0.44	9.35	0.35	1.43e-19	Total body bone mineral density;
BRCA	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg27446573	chr6:127587934	RNF146	0.9	21.49	0.65	1.56e-77	Breast cancer;
BRCA	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg04362960	chr10:104952993	NT5C2	0.43	10.39	0.38	1.88e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg10223061	chr2:219282414	VIL1	-0.31	-9.21	-0.34	4.57e-19	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.86	-0.36	1.91e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg18301423	chr5:131593218	PDLIM4	0.32	8.25	0.31	9.2e-16	Breast cancer;
BRCA	trans	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg26043149	chr18:55253948	FECH	0.46	9.79	0.36	3.65e-21	Bone mineral density;
BRCA	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.05	-0.34	1.65e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg23711669	chr6:146136114	FBXO30	0.65	14.71	0.5	2.12e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg17971929	chr21:40555470	PSMG1	-0.5	-11.13	-0.4	2.07e-26	Menarche (age at onset);
BRCA	cis	rs6714710	0.663	rs71429376	chr2:98534412	T/C	cg26665480	chr2:98280029	ACTR1B	0.56	13.12	0.46	5.65e-35	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg04691961	chr3:161091175	C3orf57	-0.59	-14.24	-0.49	3.58e-40	Morning vs. evening chronotype;
BRCA	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg10729496	chr3:10149963	C3orf24	0.44	8.13	0.31	2.21e-15	Alzheimer's disease;
BRCA	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg09307838	chr4:120376055	NA	0.73	15.57	0.52	1.36e-46	Corneal astigmatism;
BRCA	cis	rs7520050	0.966	rs11211230	chr1:46406767	G/T	cg24296786	chr1:45957014	TESK2	0.44	9.89	0.36	1.48e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs870825	0.616	rs4443323	chr4:185629805	C/A	cg04058563	chr4:185651563	MLF1IP	0.86	16.4	0.54	1.05e-50	Blood protein levels;
BRCA	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg16850897	chr7:100343110	ZAN	-0.62	-13.11	-0.46	5.85e-35	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-11.24	-0.41	7.02e-27	Mood instability;
BRCA	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg11502198	chr6:26597334	ABT1	-0.47	-9.48	-0.35	4.94e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg24562669	chr7:97807699	LMTK2	0.45	12.09	0.43	1.83e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs495337	0.736	rs2149278	chr20:48447153	A/G	cg17835207	chr20:48524531	SPATA2	0.51	11.3	0.41	4.19e-27	Psoriasis;
BRCA	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg15704280	chr7:45808275	SEPT13	-0.7	-14.25	-0.49	3.26e-40	Coronary artery disease;
BRCA	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.43	9.09	0.34	1.24e-18	Cognitive ability;
BRCA	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg04317338	chr11:64019027	PLCB3	0.58	9.99	0.37	6.17e-22	Mean platelet volume;
BRCA	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11644478	chr21:40555479	PSMG1	-0.5	-10.55	-0.39	4.43e-24	Menarche (age at onset);
BRCA	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	18.88	0.6	1.57e-63	Tonsillectomy;
BRCA	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.31	-0.31	5.8e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg18758796	chr5:131593413	PDLIM4	0.37	8.62	0.32	5.1e-17	Acylcarnitine levels;
BRCA	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg09658497	chr7:2847517	GNA12	-0.4	-8.48	-0.32	1.55e-16	Height;
BRCA	cis	rs1210638	0.756	rs2518800	chr22:18973471	C/T	cg06148736	chr22:18985691	NA	-0.34	-8.79	-0.33	1.34e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
BRCA	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg16989086	chr20:62203971	PRIC285	0.53	8.84	0.33	9.3e-18	Glioblastoma;
BRCA	cis	rs12760731	0.720	rs10913545	chr1:178360201	G/A	cg00404053	chr1:178313656	RASAL2	0.62	8.26	0.31	8.55e-16	Obesity-related traits;
BRCA	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg03146154	chr1:46216737	IPP	0.45	9.77	0.36	4.16e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.07	-0.56	4.11e-54	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.0	0.3	5.96e-15	Corneal astigmatism;
BRCA	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00802000	chr16:706648	WDR90	-0.41	-9.52	-0.35	3.52e-20	Height;
BRCA	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg26893861	chr17:41843967	DUSP3	-0.62	-11.9	-0.43	1.27e-29	Triglycerides;
BRCA	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.21	0.68	7.15e-87	Chronic sinus infection;
BRCA	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	13.36	0.47	4.22e-36	Bone mineral density;
BRCA	cis	rs4664304	0.802	rs1511224	chr2:160750861	C/T	cg14819504	chr2:160761413	LY75	-0.33	-7.8	-0.3	2.44e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-13.32	-0.47	6.83e-36	Morning vs. evening chronotype;
BRCA	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25427524	chr10:38739819	LOC399744	-0.69	-16.71	-0.55	2.82e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6545883	0.868	rs6748003	chr2:61806700	T/G	cg15711740	chr2:61764176	XPO1	-0.57	-14.41	-0.5	5.58e-41	Tuberculosis;
BRCA	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg26408565	chr15:76604113	ETFA	-0.46	-10.0	-0.37	5.92e-22	Blood metabolite levels;
BRCA	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg02574844	chr11:5959923	NA	0.45	9.99	0.37	5.95e-22	DNA methylation (variation);
BRCA	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.27	-0.31	7.52e-16	Total body bone mineral density;
BRCA	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg08392591	chr16:89556376	ANKRD11	-0.38	-9.13	-0.34	8.81e-19	Multiple myeloma (IgH translocation);
BRCA	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.12	-0.31	2.39e-15	Total body bone mineral density;
BRCA	cis	rs2070997	0.607	rs2261468	chr9:133708873	T/C	cg11464064	chr9:133710261	ABL1	0.51	9.49	0.35	4.48e-20	Response to amphetamines;
BRCA	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg27129171	chr3:47204927	SETD2	-0.69	-16.61	-0.55	9.17e-52	Colorectal cancer;
BRCA	cis	rs524281	0.861	rs10750779	chr11:65974591	C/G	cg16950941	chr11:66035639	RAB1B	-0.38	-8.11	-0.31	2.58e-15	Electroencephalogram traits;
BRCA	cis	rs9392556	0.829	rs659025	chr6:4119051	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.38	-8.0	-0.3	5.96e-15	Blood metabolite levels;
BRCA	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.55	0.39	4.26e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.89	0.33	6.17e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg21138405	chr5:131827807	IRF1	0.4	12.97	0.46	2.5e-34	Asthma (sex interaction);
BRCA	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg03354898	chr7:1950403	MAD1L1	-0.47	-10.02	-0.37	4.88e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg24450063	chr1:156163899	SLC25A44	0.93	18.37	0.59	7.4e-61	Testicular germ cell tumor;
BRCA	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.0	-0.34	2.59e-18	Total body bone mineral density;
BRCA	cis	rs9649465	0.561	rs603060	chr7:123427568	A/G	cg03229431	chr7:123269106	ASB15	-0.43	-9.62	-0.36	1.48e-20	Migraine;
BRCA	cis	rs9420	1.000	rs9420	chr11:57510294	A/G	cg19752551	chr11:57585705	CTNND1	0.42	10.72	0.39	8.96e-25	Schizophrenia;
BRCA	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg18252515	chr7:66147081	NA	-0.56	-11.36	-0.41	2.27e-27	Corneal structure;
BRCA	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21545522	chr1:205238299	TMCC2	0.4	8.7	0.33	2.85e-17	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg17971929	chr21:40555470	PSMG1	0.79	18.92	0.6	1.04e-63	Cognitive function;
BRCA	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg00106254	chr7:1943704	MAD1L1	-0.39	-9.5	-0.35	4.17e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.12	-0.34	1e-18	Bipolar disorder;
BRCA	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg18252515	chr7:66147081	NA	-1.05	-15.41	-0.52	8.53e-46	Gout;
BRCA	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.04	21.12	0.64	1.61e-75	Gut microbiome composition (summer);
BRCA	cis	rs12791968	0.765	rs2279359	chr11:44999605	A/G	cg11846598	chr11:44996168	LOC221122	0.45	8.35	0.31	4.15e-16	Inhibitory control;
BRCA	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg20637307	chr2:213403960	ERBB4	0.51	12.01	0.43	4.07e-30	Symmetrical dimethylarginine levels;
BRCA	cis	rs3799379	0.530	rs10456045	chr6:26404958	A/G	cg09904177	chr6:26538194	HMGN4	0.36	8.5	0.32	1.39e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-11.93	-0.43	9.53e-30	Morning vs. evening chronotype;
BRCA	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg18811423	chr2:55921094	PNPT1	0.73	23.39	0.68	7.41e-88	Metabolic syndrome;
BRCA	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	9.3	0.35	2.14e-19	Lung cancer in ever smokers;
BRCA	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-9.96	-0.37	8.28e-22	Mean corpuscular volume;
BRCA	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg08000102	chr2:233561755	GIGYF2	0.64	13.93	0.48	1.03e-38	Coronary artery disease;
BRCA	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg07636037	chr3:49044803	WDR6	0.5	8.23	0.31	1.02e-15	Menarche (age at onset);
BRCA	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-9.26	-0.34	3.02e-19	Colorectal cancer;
BRCA	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.52	-0.52	2.54e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11890956	chr21:40555474	PSMG1	-0.81	-19.44	-0.61	1.8e-66	Cognitive function;
BRCA	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg18357645	chr12:58087776	OS9	0.42	11.96	0.43	6.97e-30	Celiac disease or Rheumatoid arthritis;
BRCA	trans	rs2840044	1.000	rs9913003	chr17:33893904	C/A	cg19694781	chr19:47549865	TMEM160	0.47	11.07	0.4	3.55e-26	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg11812906	chr14:75593930	NEK9	0.56	12.76	0.45	2.14e-33	Height;
BRCA	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg18230493	chr5:56204884	C5orf35	-0.73	-14.13	-0.49	1.17e-39	Initial pursuit acceleration;
BRCA	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	9.41	0.35	8.56e-20	Renal function-related traits (BUN);
BRCA	cis	rs13046373	0.535	rs7281489	chr21:31978125	C/T	cg14062083	chr21:31802829	KRTAP13-4	0.36	9.81	0.36	2.86e-21	HDL cholesterol;
BRCA	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg15017067	chr4:17643749	FAM184B	0.29	8.28	0.31	6.96e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg06937882	chr20:24974362	C20orf3	-0.47	-8.9	-0.33	5.59e-18	Blood protein levels;
BRCA	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg18230493	chr5:56204884	C5orf35	0.62	13.04	0.46	1.3e-34	Initial pursuit acceleration;
BRCA	cis	rs11051970	0.879	rs2651378	chr12:32581794	A/G	cg24626660	chr12:32551988	NA	0.28	7.98	0.3	7.03e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg09526685	chr4:187126073	CYP4V2	1.0	12.21	0.44	5.49e-31	Blood protein levels;
BRCA	cis	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05901451	chr6:126070800	HEY2	0.45	11.01	0.4	6.04e-26	Endometrial cancer;
BRCA	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg10818794	chr15:86012489	AKAP13	-0.31	-8.57	-0.32	8.05e-17	Coronary artery disease;
BRCA	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg10224037	chr5:178157518	ZNF354A	-0.75	-16.08	-0.54	4.24e-49	Neutrophil percentage of white cells;
BRCA	cis	rs2835872	0.758	rs1709818	chr21:39036211	T/C	cg06728970	chr21:39037746	KCNJ6	0.45	12.88	0.45	6.44e-34	Electroencephalographic traits in alcoholism;
BRCA	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.66	-9.58	-0.35	2.1e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg08917208	chr2:24149416	ATAD2B	0.87	12.43	0.44	6.24e-32	Lymphocyte counts;
BRCA	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg12444411	chr7:2802554	GNA12	-0.36	-8.62	-0.32	5.23e-17	Height;
BRCA	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs4780401	0.587	rs9931332	chr16:11807517	G/C	cg01061890	chr16:11836724	TXNDC11	-0.55	-13.02	-0.46	1.49e-34	Rheumatoid arthritis;
BRCA	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26314531	chr2:26401878	FAM59B	0.84	15.12	0.51	2.23e-44	Gut microbiome composition (summer);
BRCA	cis	rs7818345	0.935	rs4633071	chr8:19275852	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.3	7.84	0.3	1.91e-14	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.51	9.82	0.36	2.8e-21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg05340658	chr4:99064831	C4orf37	0.62	14.74	0.5	1.55e-42	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs4714291	0.674	rs3008837	chr6:40046725	C/T	cg02267698	chr19:7991119	CTXN1	-0.44	-8.85	-0.33	8.61e-18	Strep throat;
BRCA	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg04944784	chr2:26401820	FAM59B	-0.96	-16.27	-0.54	4.82e-50	Gut microbiome composition (summer);
BRCA	cis	rs12348691	0.503	rs4743138	chr9:100614296	C/T	cg13688889	chr9:100608707	NA	0.49	9.96	0.37	8.39e-22	Alopecia areata;
BRCA	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.58	-11.09	-0.4	3.02e-26	Lung cancer in ever smokers;
BRCA	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg22139774	chr2:100720529	AFF3	-0.31	-8.66	-0.32	3.82e-17	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg06606381	chr12:133084897	FBRSL1	-0.88	-8.82	-0.33	1.13e-17	Depression;
BRCA	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg00339695	chr16:24857497	SLC5A11	0.53	9.85	0.36	2.15e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs34779708	0.931	rs11010130	chr10:35513307	T/C	cg03585969	chr10:35415529	CREM	0.48	9.7	0.36	7.42e-21	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	8.26	0.31	8.71e-16	Mean platelet volume;
BRCA	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg15997130	chr1:24165203	NA	0.5	13.18	0.46	2.82e-35	Immature fraction of reticulocytes;
BRCA	cis	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg06521331	chr12:34319734	NA	-0.52	-10.53	-0.38	4.89e-24	Morning vs. evening chronotype;
BRCA	cis	rs4660306	0.961	rs4660862	chr1:45955056	C/T	cg24296786	chr1:45957014	TESK2	0.42	8.38	0.31	3.31e-16	Homocysteine levels;
BRCA	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg04455712	chr21:45112962	RRP1B	0.4	10.68	0.39	1.31e-24	Mean corpuscular volume;
BRCA	cis	rs2014572	1.000	rs2014572	chr19:57760018	G/A	cg24459738	chr19:57751996	ZNF805	-0.36	-8.54	-0.32	9.71e-17	Hyperactive-impulsive symptoms;
BRCA	trans	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.29	0.31	6.89e-16	Corneal astigmatism;
BRCA	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6815814	0.851	rs11466645	chr4:38778203	A/T	cg02016764	chr4:38805732	TLR1	-0.5	-7.82	-0.3	2.17e-14	Breast cancer;
BRCA	cis	rs4660306	1.000	rs6429569	chr1:46001330	A/C	cg24296786	chr1:45957014	TESK2	0.44	9.51	0.35	3.65e-20	Homocysteine levels;
BRCA	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg12311346	chr5:56204834	C5orf35	-0.54	-11.28	-0.41	4.68e-27	Coronary artery disease;
BRCA	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg11887960	chr12:57824829	NA	0.55	8.55	0.32	8.82e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg02176678	chr2:219576539	TTLL4	-0.48	-12.79	-0.45	1.64e-33	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs7172677	0.737	rs4886668	chr15:75448034	T/C	cg10253484	chr15:75165896	SCAMP2	-0.42	-8.04	-0.3	4.51e-15	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs10949834	0.793	rs810532	chr7:73505188	A/G	cg07137043	chr7:73588983	EIF4H	-0.49	-7.83	-0.3	2.06e-14	Verbal memory performance (residualized delayed recall change);
BRCA	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs6546886	0.912	rs7584777	chr2:74317747	T/C	cg14702570	chr2:74259524	NA	-0.3	-7.85	-0.3	1.78e-14	Dialysis-related mortality;
BRCA	cis	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg06521331	chr12:34319734	NA	-0.62	-11.26	-0.41	5.86e-27	Morning vs. evening chronotype;
BRCA	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg05234568	chr11:5960015	NA	-0.38	-7.92	-0.3	1.05e-14	DNA methylation (variation);
BRCA	trans	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg07211511	chr3:129823064	LOC729375	-0.92	-14.58	-0.5	9.08e-42	Blood pressure (smoking interaction);
BRCA	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg23649088	chr2:200775458	C2orf69	0.6	8.86	0.33	7.79e-18	Schizophrenia;
BRCA	cis	rs36051895	0.632	rs12340617	chr9:5164492	G/C	cg02405213	chr9:5042618	JAK2	-0.48	-8.86	-0.33	7.74e-18	Pediatric autoimmune diseases;
BRCA	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.14	0.37	1.62e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs72781680	0.821	rs12616257	chr2:24135034	A/G	cg08917208	chr2:24149416	ATAD2B	0.63	10.71	0.39	9.66e-25	Lymphocyte counts;
BRCA	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg04034577	chr2:241836375	C2orf54	-0.54	-12.33	-0.44	1.79e-31	Urinary metabolites;
BRCA	cis	rs887829	0.569	rs871514	chr2:234628529	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.52	-0.32	1.19e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-8.24	-0.31	9.75e-16	Response to antipsychotic treatment;
BRCA	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg04362960	chr10:104952993	NT5C2	0.43	9.09	0.34	1.28e-18	Arsenic metabolism;
BRCA	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg17691542	chr6:26056736	HIST1H1C	0.47	9.74	0.36	5.38e-21	Height;
BRCA	trans	rs783540	0.867	rs10906984	chr15:83366296	A/C	cg18393722	chr15:85113863	UBE2QP1	0.27	8.26	0.31	8.11e-16	Schizophrenia;
BRCA	cis	rs4285028	0.699	rs2689290	chr3:121585146	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.65	-12.61	-0.45	1e-32	Multiple sclerosis;
BRCA	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11764359	chr7:65958608	NA	-0.81	-19.52	-0.61	6.53e-67	Aortic root size;
BRCA	cis	rs10496034	1.000	rs79948790	chr2:55159484	C/A	cg16098955	chr2:55172992	EML6	0.52	9.66	0.36	1.08e-20	Refractive astigmatism;
BRCA	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg04013093	chr6:42928303	GNMT	-0.29	-8.9	-0.33	5.83e-18	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg22496339	chr2:162101262	NA	-0.4	-8.15	-0.31	1.86e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1538970	0.961	rs884962	chr1:45847981	G/A	cg05343316	chr1:45956843	TESK2	0.58	11.77	0.42	4.31e-29	Platelet count;
BRCA	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg18016565	chr1:150552671	MCL1	0.34	7.83	0.3	2.03e-14	Melanoma;
BRCA	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg05535760	chr7:792225	HEATR2	0.77	13.6	0.47	3.44e-37	Cerebrospinal P-tau181p levels;
BRCA	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg22105103	chr4:187893119	NA	0.41	13.28	0.47	1.03e-35	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3815700	1.000	rs7247420	chr19:33096786	G/A	cg02997394	chr19:33096574	ANKRD27	0.69	11.53	0.41	4.49e-28	Eosinophilic esophagitis;
BRCA	cis	rs870825	0.721	rs72703528	chr4:185607311	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	14.29	0.49	2.16e-40	Blood protein levels;
BRCA	cis	rs11051970	0.679	rs2931554	chr12:32556162	G/A	cg02745156	chr12:32552066	NA	0.25	8.49	0.32	1.48e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg23533926	chr12:111358616	MYL2	-0.38	-8.03	-0.3	4.76e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	trans	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg25482853	chr8:67687455	SGK3	0.78	13.07	0.46	8.85e-35	Obesity-related traits;
BRCA	cis	rs6060717	0.528	rs73905955	chr20:34332938	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.96	-0.33	3.53e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg13877915	chr19:58951672	ZNF132	0.47	11.09	0.4	2.96e-26	Uric acid clearance;
BRCA	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg24848339	chr3:12840334	CAND2	0.45	12.05	0.43	2.7e-30	QRS complex (12-leadsum);
BRCA	cis	rs7781557	1.000	rs12113073	chr7:102482527	T/C	cg18108683	chr7:102477205	FBXL13	-0.44	-8.04	-0.3	4.36e-15	Colorectal adenoma (advanced);
BRCA	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg05340658	chr4:99064831	C4orf37	0.63	15.32	0.52	2.3e-45	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6930083	0.510	rs4713994	chr6:36621533	A/G	cg08179530	chr6:36648295	CDKN1A	-0.55	-11.81	-0.42	3.13e-29	Coronary artery disease;
BRCA	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg04414720	chr1:150670196	GOLPH3L	0.35	7.91	0.3	1.17e-14	Tonsillectomy;
BRCA	cis	rs490234	0.934	rs12553637	chr9:128277258	A/G	cg14078157	chr9:128172775	NA	-0.33	-7.84	-0.3	1.88e-14	Mean arterial pressure;
BRCA	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg24531977	chr5:56204891	C5orf35	0.47	9.63	0.36	1.41e-20	Coronary artery disease;
BRCA	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg08508325	chr11:3079039	CARS	0.28	8.51	0.32	1.24e-16	Calcium levels;
BRCA	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-10.16	-0.37	1.44e-22	Neuroticism;
BRCA	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg21573476	chr21:45109991	RRP1B	0.41	11.04	0.4	4.52e-26	Mean corpuscular volume;
BRCA	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03517284	chr6:25882590	NA	0.37	7.83	0.3	2.07e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg27535305	chr1:53392650	SCP2	-0.38	-9.25	-0.34	3.41e-19	Monocyte count;
BRCA	cis	rs56399783	0.901	rs73049305	chr7:2778755	C/T	cg19731401	chr7:2775893	GNA12	0.51	8.16	0.31	1.76e-15	Childhood ear infection;
BRCA	cis	rs10789491	1.000	rs12794	chr1:47141718	T/C	cg15501359	chr1:47185051	KIAA0494	0.65	18.2	0.58	5.97e-60	Response to hepatitis C treatment;
BRCA	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	9.24	0.34	3.52e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg00031303	chr3:195681400	NA	0.45	8.54	0.32	9.64e-17	Pancreatic cancer;
BRCA	cis	rs637571	0.510	rs3892696	chr11:65582341	G/C	cg26695010	chr11:65641043	EFEMP2	0.38	8.15	0.31	1.91e-15	Eosinophil percentage of white cells;
BRCA	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg06784218	chr1:46089804	CCDC17	0.51	12.16	0.43	9.79e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg17063962	chr7:91808500	NA	0.54	12.72	0.45	3.47e-33	Breast cancer;
BRCA	cis	rs57590327	0.528	rs7642112	chr3:81674927	C/T	cg07356753	chr3:81810745	GBE1	-0.45	-10.16	-0.37	1.46e-22	Extraversion;
BRCA	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg25036284	chr2:26402008	FAM59B	-0.88	-15.06	-0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18876405	chr7:65276391	NA	0.48	10.7	0.39	1.12e-24	Aortic root size;
BRCA	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg08888203	chr3:10149979	C3orf24	0.57	12.08	0.43	2.15e-30	Alzheimer's disease;
BRCA	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18876405	chr7:65276391	NA	0.52	11.65	0.42	1.43e-28	Aortic root size;
BRCA	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-9.83	-0.36	2.47e-21	Tonsillectomy;
BRCA	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg08888203	chr3:10149979	C3orf24	0.63	11.82	0.42	2.73e-29	Alzheimer's disease;
BRCA	cis	rs11718455	0.881	rs17076257	chr3:44006787	C/T	cg08738300	chr3:44038990	NA	0.46	8.8	0.33	1.29e-17	Coronary artery disease;
BRCA	trans	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.6	0.39	2.78e-24	Type 2 diabetes;
BRCA	cis	rs4919087	0.926	rs10882884	chr10:99025611	T/A	cg25902810	chr10:99078978	FRAT1	0.44	9.27	0.34	2.88e-19	Monocyte count;
BRCA	cis	rs4423214	0.592	rs1790349	chr11:71142350	A/G	cg05163923	chr11:71159392	DHCR7	-0.48	-8.24	-0.31	9.87e-16	Vitamin D levels;
BRCA	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-11.52	-0.41	4.79e-28	Lymphocyte counts;
BRCA	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg26031613	chr14:104095156	KLC1	-0.42	-8.39	-0.32	3.01e-16	Schizophrenia;
BRCA	cis	rs6545883	0.929	rs1186710	chr2:61688727	T/A	cg15711740	chr2:61764176	XPO1	-0.54	-13.66	-0.48	1.81e-37	Tuberculosis;
BRCA	cis	rs10754283	0.934	rs1934043	chr1:90106645	C/T	cg21401794	chr1:90099060	LRRC8C	0.46	11.13	0.4	2e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs243505	0.661	rs887570	chr7:148505255	A/G	cg09806900	chr7:148480153	CUL1	0.5	10.6	0.39	2.7e-24	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg04546413	chr19:29218101	NA	-0.56	-9.72	-0.36	6.32e-21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg04998671	chr14:104000505	TRMT61A	0.49	10.13	0.37	1.75e-22	Coronary artery disease;
BRCA	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-10.51	-0.38	6.01e-24	Personality dimensions;
BRCA	cis	rs1371614	0.632	rs3769135	chr2:27168411	G/A	cg00617064	chr2:27272375	NA	0.32	8.29	0.31	6.53e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg06521331	chr12:34319734	NA	-0.65	-11.92	-0.43	1.03e-29	Morning vs. evening chronotype;
BRCA	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg16230307	chr14:35515116	FAM177A1	0.73	15.12	0.51	2.22e-44	Psoriasis;
BRCA	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08109568	chr15:31115862	NA	-0.43	-9.58	-0.35	2.13e-20	Huntington's disease progression;
BRCA	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.77	-0.36	4.06e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4363385	0.747	rs6704105	chr1:152964397	C/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.63	-0.32	4.79e-17	Inflammatory skin disease;
BRCA	cis	rs6546886	0.957	rs4853005	chr2:74258049	G/C	cg14702570	chr2:74259524	NA	-0.32	-8.17	-0.31	1.63e-15	Dialysis-related mortality;
BRCA	cis	rs4664304	0.658	rs2667016	chr2:160868855	C/T	cg14819504	chr2:160761413	LY75	-0.33	-8.14	-0.31	2.13e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	18.46	0.59	2.64e-61	Alzheimer's disease;
BRCA	cis	rs2425143	1.000	rs6060572	chr20:34294015	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.92	-0.37	1.12e-21	Blood protein levels;
BRCA	trans	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg04565464	chr8:145669602	NFKBIL2	0.41	9.85	0.36	2.08e-21	Schizophrenia;
BRCA	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03923535	chr7:1197113	ZFAND2A	0.5	10.88	0.4	2.05e-25	Longevity;Endometriosis;
BRCA	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg08132940	chr7:1081526	C7orf50	-0.58	-8.81	-0.33	1.21e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7394190	0.748	rs11000780	chr10:75559077	G/A	cg07699608	chr10:75541558	CHCHD1	0.7	10.37	0.38	2.25e-23	Incident atrial fibrillation;
BRCA	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg00666640	chr1:248458726	OR2T12	0.3	8.58	0.32	7.32e-17	Common traits (Other);
BRCA	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg21045802	chr8:109455806	TTC35	0.35	7.96	0.3	8.09e-15	Dupuytren's disease;
BRCA	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.22	-0.31	1.13e-15	Depression;
BRCA	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.64	16.38	0.54	1.32e-50	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs73001065	0.901	rs73004962	chr19:19713069	A/T	cg03709012	chr19:19516395	GATAD2A	0.79	9.81	0.36	2.96e-21	LDL cholesterol;
BRCA	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08704250	chr15:31115839	NA	-0.36	-9.02	-0.34	2.23e-18	Huntington's disease progression;
BRCA	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg20203395	chr5:56204925	C5orf35	0.43	9.6	0.35	1.85e-20	Initial pursuit acceleration;
BRCA	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg07757535	chr4:1339547	NA	0.25	8.07	0.3	3.45e-15	Longevity;
BRCA	cis	rs700651	0.753	rs10207232	chr2:198893813	A/G	cg00792783	chr2:198669748	PLCL1	0.42	9.31	0.35	1.98e-19	Intracranial aneurysm;
BRCA	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg18270830	chr10:32634957	EPC1	0.58	10.11	0.37	2.1e-22	Sexual dysfunction (female);
BRCA	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg19338460	chr6:170058176	WDR27	-0.45	-7.85	-0.3	1.72e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs68092024	0.731	rs793479	chr3:99488232	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-10.56	-0.39	3.85e-24	Cleft lip with or without cleft palate;
BRCA	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-12.92	-0.46	4.2e-34	Developmental language disorder (linguistic errors);
BRCA	cis	rs751728	0.687	rs943471	chr6:33738314	C/T	cg25922239	chr6:33757077	LEMD2	0.52	13.18	0.46	2.84e-35	Crohn's disease;
BRCA	cis	rs858239	0.601	rs15775	chr7:23164701	C/T	cg23682824	chr7:23144976	KLHL7	0.45	11.93	0.43	8.98e-30	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg07134254	chr20:33865797	NA	-0.42	-7.99	-0.3	6.54e-15	Attention deficit hyperactivity disorder;
BRCA	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.52	8.44	0.32	2.2e-16	Renal function-related traits (BUN);
BRCA	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg18404041	chr3:52824283	ITIH1	-0.35	-9.09	-0.34	1.23e-18	Schizophrenia;
BRCA	cis	rs9462027	0.628	rs2814942	chr6:34644261	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.91	-0.3	1.1e-14	Systemic lupus erythematosus;
BRCA	trans	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs16866061	1.000	rs72974222	chr2:225424143	C/T	cg12698349	chr2:225449008	CUL3	0.78	21.13	0.64	1.39e-75	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs2742234	0.915	rs2742233	chr10:43610558	C/T	cg02780029	chr10:43622663	RET	-0.41	-10.21	-0.37	9.01e-23	Hirschsprung disease;
BRCA	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	8.0	0.3	5.89e-15	Diabetic retinopathy;
BRCA	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10802521	chr3:52805072	NEK4	-0.3	-7.91	-0.3	1.12e-14	Electroencephalogram traits;
BRCA	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs17253792	0.822	rs10083431	chr14:56068348	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-10.5	-0.38	6.49e-24	Putamen volume;
BRCA	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg01191920	chr7:158217561	PTPRN2	-0.47	-10.96	-0.4	9.69e-26	Obesity-related traits;
BRCA	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-12.03	-0.43	3.55e-30	Pulmonary function;
BRCA	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg23711669	chr6:146136114	FBXO30	-0.77	-18.05	-0.58	3.66e-59	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg13752114	chr3:195489708	MUC4	-0.57	-9.16	-0.34	6.84e-19	Lung disease severity in cystic fibrosis;
BRCA	cis	rs17604090	0.941	rs114036198	chr7:29676300	C/T	cg19413766	chr7:29689036	LOC646762	-0.64	-8.76	-0.33	1.77e-17	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg04691961	chr3:161091175	C3orf57	-0.59	-14.04	-0.49	3.32e-39	Morning vs. evening chronotype;
BRCA	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg01324343	chr3:183735012	ABCC5	0.83	21.19	0.64	6.89e-76	Anterior chamber depth;
BRCA	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-12.58	-0.45	1.34e-32	Migraine;Coronary artery disease;
BRCA	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.98	0.43	5.89e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6700896	0.931	rs10789193	chr1:66129646	A/T	cg04111102	chr1:66153794	NA	0.36	8.82	0.33	1.08e-17	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	trans	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-39.43	-0.84	2.74e-173	Exhaled nitric oxide output;
BRCA	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.34	-0.38	2.82e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	16.9	0.56	3.23e-53	Electrocardiographic conduction measures;
BRCA	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg11764359	chr7:65958608	NA	0.67	12.68	0.45	5.19e-33	Aortic root size;
BRCA	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15506890	chr2:3487001	NA	-0.57	-12.67	-0.45	5.82e-33	Neurofibrillary tangles;
BRCA	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg05623727	chr3:50126028	RBM5	0.41	9.75	0.36	4.97e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs17023223	0.537	rs12064137	chr1:119709749	G/A	cg05756136	chr1:119680316	WARS2	-0.42	-8.05	-0.3	3.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.43	-0.32	2.25e-16	Monocyte percentage of white cells;
BRCA	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg08392591	chr16:89556376	ANKRD11	0.46	10.93	0.4	1.32e-25	Multiple myeloma (IgH translocation);
BRCA	cis	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.49	9.35	0.35	1.4e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg08992911	chr2:238395768	MLPH	0.4	8.65	0.32	4.3e-17	Prostate cancer;
BRCA	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg20283391	chr11:68216788	NA	-0.46	-9.01	-0.34	2.42e-18	Total body bone mineral density;
BRCA	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg02951883	chr7:2050386	MAD1L1	-0.41	-9.43	-0.35	7.72e-20	Bipolar disorder and schizophrenia;
BRCA	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	16.92	0.56	2.51e-53	Intelligence (multi-trait analysis);
BRCA	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg21918786	chr6:109611834	NA	-0.44	-12.21	-0.44	5.58e-31	Reticulocyte fraction of red cells;
BRCA	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-16.27	-0.54	4.64e-50	Alzheimer's disease (late onset);
BRCA	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg10792982	chr14:105748885	BRF1	0.48	11.26	0.41	5.66e-27	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs10465746	1.000	rs10465746	chr1:84387632	T/G	cg10977910	chr1:84465055	TTLL7	0.5	10.16	0.37	1.38e-22	Obesity-related traits;
BRCA	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg16230307	chr14:35515116	FAM177A1	0.73	15.12	0.51	2.22e-44	Psoriasis;
BRCA	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg23033748	chr14:75592666	NEK9	-0.35	-8.22	-0.31	1.14e-15	Height;
BRCA	cis	rs9807989	0.524	rs7591246	chr2:102999403	C/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.41	0.32	2.59e-16	Asthma;
BRCA	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg26384229	chr12:38710491	ALG10B	0.57	12.76	0.45	2.24e-33	Morning vs. evening chronotype;
BRCA	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	10.85	0.39	2.75e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26168224	chr5:2018326	NA	0.53	12.94	0.46	3.34e-34	Gut microbiome composition (winter);
BRCA	cis	rs67981189	0.896	rs2526877	chr14:71433322	T/C	cg15816911	chr14:71606274	NA	-0.35	-7.84	-0.3	1.95e-14	Schizophrenia;
BRCA	cis	rs4363385	0.669	rs2937264	chr1:153011026	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg27170947	chr2:26402098	FAM59B	-0.92	-16.84	-0.55	6.2e-53	Gut microbiome composition (summer);
BRCA	trans	rs3858145	0.588	rs731063	chr10:70043190	A/G	cg04882175	chr6:131122610	NA	0.34	8.23	0.31	1.08e-15	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
BRCA	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg24812749	chr6:127587940	RNF146	0.89	20.97	0.64	1.08e-74	Breast cancer;
BRCA	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.46	-8.76	-0.33	1.71e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18404041	chr3:52824283	ITIH1	-0.32	-9.55	-0.35	2.65e-20	Bipolar disorder;
BRCA	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg09904177	chr6:26538194	HMGN4	-0.47	-13.34	-0.47	5.25e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs13064411	0.542	rs2087130	chr3:113226983	T/A	cg18753928	chr3:113234510	CCDC52	-0.45	-9.59	-0.35	2.01e-20	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs6714710	0.580	rs17489915	chr2:98420431	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	13.62	0.47	2.86e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	trans	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg25214090	chr10:38739885	LOC399744	0.54	12.64	0.45	7.24e-33	Corneal astigmatism;
BRCA	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg16590910	chr6:42928470	GNMT	0.42	9.24	0.34	3.62e-19	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.3	9.93	0.37	1.02e-21	Cognitive function;
BRCA	trans	rs6479891	1.000	rs12411988	chr10:65315397	C/G	cg14819942	chr15:35414228	NA	-0.34	-7.98	-0.3	6.83e-15	Arthritis (juvenile idiopathic);
BRCA	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg06627628	chr2:24431161	ITSN2	-0.82	-14.83	-0.51	5.87e-43	Asthma;
BRCA	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11890956	chr21:40555474	PSMG1	1.04	28.93	0.75	2.84e-118	Cognitive function;
BRCA	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg11301795	chr4:187892539	NA	-0.31	-9.99	-0.37	6.25e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg04317338	chr11:64019027	PLCB3	-0.54	-9.79	-0.36	3.57e-21	Mean platelet volume;
BRCA	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.0	-12.5	-0.44	3.26e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.6	-0.61	2.57e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs72772090	0.539	rs17481856	chr5:96116808	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.18	-0.43	7.64e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs11874712	1.000	rs1800637	chr18:43670190	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.18	0.31	1.57e-15	Migraine - clinic-based;
BRCA	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg16506815	chr2:162101123	NA	0.72	17.97	0.58	9.94e-59	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.65	-9.9	-0.36	1.3e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs6763687	0.651	rs4894800	chr3:171798127	A/C	cg16233210	chr3:171778391	FNDC3B	0.35	7.82	0.3	2.16e-14	Red cell distribution width;
BRCA	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg04234412	chr22:24373322	LOC391322	-0.62	-15.66	-0.53	5.05e-47	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg03146154	chr1:46216737	IPP	0.45	10.08	0.37	2.88e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6942756	0.876	rs6953598	chr7:129033741	A/G	cg02491457	chr7:128862824	NA	0.61	12.47	0.44	4.12e-32	White matter hyperintensity burden;
BRCA	cis	rs2522056	0.808	rs1016988	chr5:131744574	T/C	cg24060327	chr5:131705240	SLC22A5	0.55	8.97	0.33	3.16e-18	Lymphocyte counts;Fibrinogen;
BRCA	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg12292205	chr6:26970375	C6orf41	-0.64	-9.97	-0.37	7.21e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg27478167	chr7:817139	HEATR2	-0.43	-9.09	-0.34	1.23e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.33	9.02	0.34	2.09e-18	Response to antipsychotic treatment;
BRCA	cis	rs7631605	0.608	rs116724099	chr3:37431641	C/T	cg15934958	chr3:37212084	LRRFIP2	0.37	8.11	0.31	2.61e-15	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg23711669	chr6:146136114	FBXO30	0.65	15.07	0.51	3.93e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg17845761	chr1:175162550	KIAA0040	-0.26	-9.84	-0.36	2.24e-21	Alcohol dependence;
BRCA	cis	rs894734	1.000	rs894734	chr12:54319727	A/G	cg17410650	chr12:54324560	NA	-0.31	-8.04	-0.3	4.46e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
BRCA	cis	rs78487399	0.908	rs61754256	chr2:43805739	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-7.95	-0.3	8.45e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs2180341	0.595	rs7771391	chr6:127749656	C/G	cg27446573	chr6:127587934	RNF146	0.61	13.19	0.46	2.51e-35	Breast cancer;
BRCA	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg01475735	chr3:40494733	NA	0.42	8.5	0.32	1.36e-16	Renal cell carcinoma;
BRCA	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	12.11	0.43	1.63e-30	Personality dimensions;
BRCA	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-23.63	-0.68	3.27e-89	Headache;
BRCA	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.73	-0.33	2.17e-17	Total body bone mineral density;
BRCA	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.33	0.35	1.76e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.43	-9.5	-0.35	4.19e-20	Personality dimensions;
BRCA	cis	rs1971762	0.583	rs7979659	chr12:54086579	A/G	cg23533419	chr12:54090519	NA	-0.31	-7.81	-0.3	2.32e-14	Height;
BRCA	cis	rs877529	0.932	rs139398	chr22:39544970	C/G	cg18708252	chr22:39545030	CBX7	-0.32	-8.05	-0.3	4.13e-15	Multiple myeloma;
BRCA	cis	rs11971779	0.616	rs6949963	chr7:139054325	C/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.24	0.38	6.65e-23	Diisocyanate-induced asthma;
BRCA	cis	rs490234	0.729	rs10819050	chr9:128237178	G/T	cg14078157	chr9:128172775	NA	-0.37	-8.79	-0.33	1.38e-17	Mean arterial pressure;
BRCA	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg16576597	chr16:28551801	NUPR1	0.35	9.66	0.36	1.11e-20	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs68170813	0.599	rs12532514	chr7:107000952	C/T	cg02696742	chr7:106810147	HBP1	-0.55	-8.6	-0.32	6.09e-17	Coronary artery disease;
BRCA	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg25838465	chr1:92012736	NA	-0.45	-9.91	-0.36	1.24e-21	Eosinophil percentage of white cells;
BRCA	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg27489772	chr12:121021490	NA	-0.49	-8.35	-0.31	4.24e-16	Type 1 diabetes nephropathy;
BRCA	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg23587288	chr2:27483067	SLC30A3	-0.38	-8.85	-0.33	8.76e-18	Blood metabolite levels;
BRCA	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-12.2	-0.43	6.44e-31	Alzheimer's disease;
BRCA	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg14196790	chr5:131705035	SLC22A5	0.32	8.64	0.32	4.5e-17	Breast cancer;
BRCA	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.05	21.87	0.65	1.42e-79	Gut microbiome composition (summer);
BRCA	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	19.49	0.61	9.83e-67	Lymphocyte percentage of white cells;
BRCA	cis	rs2386661	0.547	rs57893347	chr10:5646191	G/A	cg17085576	chr10:5658249	NA	-0.33	-8.23	-0.31	1.04e-15	Breast cancer;
BRCA	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.82	0.55	7.52e-53	Hypertriglyceridemia;
BRCA	cis	rs13033859	0.526	rs6548221	chr2:295255	C/T	cg12623918	chr2:306882	NA	-0.36	-8.3	-0.31	6.1e-16	Mitochondrial DNA levels;
BRCA	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg26116260	chr4:7069785	GRPEL1	0.41	10.13	0.37	1.77e-22	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
BRCA	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg12927641	chr6:109611667	NA	-0.43	-11.08	-0.4	3.29e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11890956	chr21:40555474	PSMG1	-0.6	-13.51	-0.47	8.99e-37	Menarche (age at onset);
BRCA	cis	rs2629540	0.543	rs2559515	chr10:126513925	A/G	cg08799069	chr10:126477246	METTL10	0.48	8.63	0.32	4.87e-17	Cocaine dependence;
BRCA	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg04450456	chr4:17643702	FAM184B	-0.34	-9.62	-0.36	1.51e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.03	26.87	0.73	5.14e-107	Cognitive ability;
BRCA	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg09469691	chr10:81107165	PPIF	0.45	9.76	0.36	4.69e-21	Height;
BRCA	trans	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg23762105	chr12:34175262	ALG10	0.34	7.81	0.3	2.39e-14	Morning vs. evening chronotype;
BRCA	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	13.54	0.47	6.61e-37	Parkinson's disease;
BRCA	cis	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg00852783	chr1:26633632	UBXN11	-0.47	-8.51	-0.32	1.22e-16	Obesity-related traits;
BRCA	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg24829409	chr8:58192753	C8orf71	-0.44	-8.45	-0.32	2e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.61	-11.36	-0.41	2.34e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9283706	0.562	rs6881240	chr5:66331471	G/A	cg11590213	chr5:66331682	MAST4	0.4	7.99	0.3	6.5e-15	Coronary artery disease;
BRCA	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg22907277	chr7:1156413	C7orf50	0.45	10.48	0.38	7.93e-24	Longevity;Endometriosis;
BRCA	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	18.89	0.6	1.52e-63	Tonsillectomy;
BRCA	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg20307385	chr11:47447363	PSMC3	0.74	17.0	0.56	9.98e-54	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs2625529	0.824	rs16953769	chr15:72463325	G/A	cg16672083	chr15:72433130	SENP8	-0.84	-17.78	-0.58	8.71e-58	Red blood cell count;
BRCA	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg26384229	chr12:38710491	ALG10B	0.51	13.55	0.47	5.92e-37	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg13010199	chr12:38710504	ALG10B	0.46	9.02	0.34	2.14e-18	Morning vs. evening chronotype;
BRCA	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg14530993	chr4:882597	GAK	0.57	10.17	0.37	1.28e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-8.11	-0.31	2.53e-15	Alzheimer's disease (late onset);
BRCA	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04063615	chr12:132293388	NA	-0.47	-10.23	-0.38	7.56e-23	Migraine;
BRCA	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.53	-11.93	-0.43	9.64e-30	Personality dimensions;
BRCA	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg14349672	chr11:133703707	NA	-0.35	-8.49	-0.32	1.47e-16	Childhood ear infection;
BRCA	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg24642844	chr7:1081250	C7orf50	-0.68	-12.77	-0.45	2.03e-33	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg14675211	chr2:100938903	LONRF2	0.51	11.7	0.42	9.02e-29	Intelligence (multi-trait analysis);
BRCA	trans	rs11165623	0.564	rs7541109	chr1:96995960	C/A	cg10631902	chr5:14652156	NA	-0.43	-12.17	-0.43	8.99e-31	Hip circumference;Waist circumference;
BRCA	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg23029597	chr12:123009494	RSRC2	-0.6	-11.6	-0.42	2.38e-28	Body mass index;
BRCA	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg04025307	chr7:1156635	C7orf50	0.46	8.86	0.33	8.12e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg19338460	chr6:170058176	WDR27	-0.75	-10.0	-0.37	5.47e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.35	-9.18	-0.34	6.08e-19	Total body bone mineral density;
BRCA	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7523273	0.606	rs2796262	chr1:207915180	G/A	cg22525895	chr1:207977042	MIR29B2	0.47	12.04	0.43	2.97e-30	Schizophrenia;
BRCA	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06022373	chr22:39101656	GTPBP1	0.51	12.19	0.43	7.34e-31	Menopause (age at onset);
BRCA	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg18964960	chr10:1102726	WDR37	0.66	9.22	0.34	4.25e-19	Eosinophil percentage of granulocytes;
BRCA	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg27446573	chr6:127587934	RNF146	0.7	15.78	0.53	1.3e-47	Breast cancer;
BRCA	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg15704280	chr7:45808275	SEPT13	0.62	10.32	0.38	3.42e-23	Axial length;
BRCA	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg11266682	chr4:10021025	SLC2A9	0.48	12.76	0.45	2.23e-33	Bone mineral density;
BRCA	cis	rs13102973	0.899	rs13104539	chr4:135904385	G/A	cg14419869	chr4:135874104	NA	0.46	9.16	0.34	7.08e-19	Subjective well-being;
BRCA	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg14004847	chr7:1930337	MAD1L1	0.42	8.49	0.32	1.41e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs1707322	1.000	rs1707303	chr1:46598273	A/C	cg06784218	chr1:46089804	CCDC17	-0.43	-9.67	-0.36	1.02e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg21770322	chr7:97807741	LMTK2	0.42	11.16	0.4	1.58e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg08999081	chr20:33150536	PIGU	-0.46	-12.8	-0.45	1.5e-33	Glomerular filtration rate (creatinine);
BRCA	cis	rs897080	0.515	rs1067333	chr2:44626710	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	10.5	0.38	6.83e-24	Height;
BRCA	cis	rs2249625	0.874	rs1819067	chr6:72849139	A/C	cg18830697	chr6:72922368	RIMS1	-0.37	-7.89	-0.3	1.31e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs2559856	0.935	rs2559864	chr12:102084710	C/G	cg12924262	chr12:102091054	CHPT1	0.36	8.15	0.31	1.88e-15	Blood protein levels;
BRCA	cis	rs4728302	0.583	rs12707091	chr7:133185749	A/G	cg10665199	chr7:133106180	EXOC4	0.45	9.33	0.35	1.7e-19	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg16482183	chr6:26056742	HIST1H1C	0.46	9.22	0.34	4.19e-19	Iron status biomarkers;
BRCA	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg09537434	chr19:41945824	ATP5SL	-0.99	-23.66	-0.68	2.33e-89	Height;
BRCA	trans	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.85	-0.3	1.79e-14	Corneal astigmatism;
BRCA	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg12927641	chr6:109611667	NA	-0.42	-10.89	-0.4	1.94e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg13880726	chr7:1868755	MAD1L1	0.52	10.54	0.38	4.87e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs2625529	0.617	rs7175373	chr15:72203517	G/T	cg16672083	chr15:72433130	SENP8	0.64	15.4	0.52	9.29e-46	Red blood cell count;
BRCA	cis	rs7246657	0.551	rs28462002	chr19:37634462	A/G	cg23950597	chr19:37808831	NA	-0.6	-9.18	-0.34	5.78e-19	Coronary artery calcification;
BRCA	cis	rs3845702	0.736	rs12693214	chr2:180825685	G/A	cg01881094	chr2:180872142	CWC22	-1.02	-17.23	-0.56	6.17e-55	Schizophrenia;
BRCA	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg09654669	chr8:57350985	NA	-0.38	-8.34	-0.31	4.55e-16	Obesity-related traits;
BRCA	cis	rs7651039	1.000	rs7651039	chr3:15648004	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-9.33	-0.35	1.69e-19	Coronary heart disease;
BRCA	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	7.86	0.3	1.66e-14	Menarche (age at onset);
BRCA	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg20469991	chr17:27169893	C17orf63	-0.45	-8.82	-0.33	1.08e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg08470875	chr2:26401718	FAM59B	-0.71	-11.35	-0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08045932	chr20:61659980	NA	0.5	11.54	0.42	4.01e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs365132	0.846	rs812246	chr5:176327644	G/A	cg16309518	chr5:176445507	NA	-0.39	-9.59	-0.35	1.87e-20	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.5	10.26	0.38	5.7e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs4363385	0.747	rs12048412	chr1:152977092	A/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.49	-0.35	4.45e-20	Inflammatory skin disease;
BRCA	cis	rs7092929	0.883	rs588410	chr10:3618792	T/C	cg14308648	chr10:3568949	NA	0.46	8.57	0.32	7.73e-17	Coronary artery calcification;
BRCA	cis	rs7677751	0.806	rs4864859	chr4:55090015	A/G	cg17187183	chr4:55093834	PDGFRA	0.44	9.35	0.35	1.48e-19	Corneal astigmatism;
BRCA	cis	rs3818285	0.556	rs3758409	chr10:111669239	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.42	-10.6	-0.39	2.65e-24	Superior crus of antihelix expression;
BRCA	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-13.48	-0.47	1.21e-36	Morning vs. evening chronotype;
BRCA	cis	rs2066819	1.000	rs80317430	chr12:56727705	G/A	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg24531977	chr5:56204891	C5orf35	-0.43	-8.52	-0.32	1.1e-16	Coronary artery disease;
BRCA	cis	rs74181299	0.819	rs2723086	chr2:65297686	C/T	cg05010058	chr2:65284262	CEP68	0.3	8.38	0.31	3.37e-16	Pulse pressure;
BRCA	cis	rs73001065	0.591	rs11668386	chr19:19531910	A/G	cg03709012	chr19:19516395	GATAD2A	1.04	14.3	0.49	1.98e-40	LDL cholesterol;
BRCA	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg18876405	chr7:65276391	NA	0.47	10.53	0.38	5.26e-24	Aortic root size;
BRCA	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg11062466	chr8:58055876	NA	0.57	9.63	0.36	1.44e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs4268898	0.552	rs4665663	chr2:24372139	G/C	cg26838691	chr2:24397539	C2orf84	0.4	8.14	0.31	2.11e-15	Asthma;
BRCA	trans	rs3960554	0.529	rs1859795	chr7:75877354	A/G	cg19862616	chr7:65841803	NCRNA00174	0.43	9.97	0.37	7.55e-22	Eotaxin levels;
BRCA	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg16339924	chr4:17578868	LAP3	0.66	15.53	0.52	2.29e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg05872129	chr22:39784769	NA	-0.57	-13.0	-0.46	1.81e-34	Intelligence (multi-trait analysis);
BRCA	trans	rs7980799	0.653	rs11052722	chr12:33626530	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-8.93	-0.33	4.51e-18	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	30.65	0.77	1.32e-127	Chronic sinus infection;
BRCA	trans	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg11693508	chr17:37793320	STARD3	0.61	11.44	0.41	1.04e-27	Bipolar disorder;
BRCA	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19346786	chr7:2764209	NA	0.32	9.6	0.35	1.83e-20	Height;
BRCA	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg21782813	chr7:2030301	MAD1L1	0.42	11.34	0.41	2.83e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs9283706	0.608	rs71626484	chr5:66334502	A/T	cg11590213	chr5:66331682	MAST4	0.38	7.98	0.3	6.69e-15	Coronary artery disease;
BRCA	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg00074818	chr8:8560427	CLDN23	0.38	8.37	0.31	3.69e-16	Obesity-related traits;
BRCA	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg18270830	chr10:32634957	EPC1	0.59	9.71	0.36	6.86e-21	Sexual dysfunction (female);
BRCA	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg26384229	chr12:38710491	ALG10B	0.55	11.69	0.42	9.73e-29	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.77e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg18758796	chr5:131593413	PDLIM4	0.39	9.94	0.37	9.96e-22	Acylcarnitine levels;
BRCA	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg11271282	chr2:238384023	NA	0.44	8.4	0.32	2.91e-16	Prostate cancer;
BRCA	cis	rs9649465	0.967	rs13239184	chr7:123314618	G/T	cg04330084	chr7:123175371	IQUB	-0.3	-8.38	-0.31	3.26e-16	Migraine;
BRCA	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-11.44	-0.41	1.04e-27	Personality dimensions;
BRCA	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg15017067	chr4:17643749	FAM184B	0.31	8.63	0.32	4.73e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4900538	0.963	rs8017980	chr14:102961341	C/G	cg18135206	chr14:102964638	TECPR2	1.05	29.55	0.76	1.18e-121	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12826209	chr6:26865740	GUSBL1	0.59	10.31	0.38	3.81e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg17691542	chr6:26056736	HIST1H1C	0.53	11.44	0.41	1.1e-27	Height;
BRCA	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg14458575	chr2:238380390	NA	-0.54	-12.09	-0.43	1.91e-30	Prostate cancer;
BRCA	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg22907277	chr7:1156413	C7orf50	0.6	11.71	0.42	8e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10746514	0.786	rs9308486	chr1:232246418	A/G	cg09506761	chr1:232265262	NA	0.48	10.38	0.38	1.95e-23	Response to statin therapy;
BRCA	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg12564285	chr5:131593104	PDLIM4	0.42	10.12	0.37	1.96e-22	Acylcarnitine levels;
BRCA	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg18512352	chr11:47633146	NA	-0.35	-8.4	-0.32	2.88e-16	Subjective well-being;
BRCA	cis	rs6772849	0.930	rs12487604	chr3:128337075	T/A	cg16766828	chr3:128327626	NA	-0.41	-8.44	-0.32	2.14e-16	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg08847533	chr14:75593920	NEK9	-0.87	-22.33	-0.66	4.66e-82	Height;
BRCA	cis	rs10851411	0.697	rs41315252	chr15:42837497	A/G	cg21293051	chr15:42870591	STARD9	0.51	8.68	0.32	3.27e-17	Glucose homeostasis traits;
BRCA	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg18446336	chr7:2847575	GNA12	-0.35	-8.26	-0.31	8.47e-16	Height;
BRCA	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg08668359	chr10:1443807	ADARB2	0.49	9.46	0.35	5.91e-20	Radiation response;
BRCA	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06873352	chr17:61820015	STRADA	-0.36	-7.96	-0.3	7.62e-15	Height;
BRCA	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7580658	0.521	rs2404535	chr2:127947709	A/G	cg16751203	chr2:127950803	CYP27C1	-0.28	-7.95	-0.3	8.2e-15	Protein C levels;
BRCA	cis	rs10242455	0.557	rs45529541	chr7:99048143	C/A	cg18809830	chr7:99032528	PTCD1	-0.58	-8.7	-0.33	2.87e-17	Blood metabolite levels;
BRCA	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg00106254	chr7:1943704	MAD1L1	-0.42	-11.49	-0.41	6.57e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs600550	0.528	rs7102260	chr11:59846035	A/T	cg02771260	chr11:59836817	MS4A3	-0.52	-11.28	-0.41	4.8e-27	Lipoprotein-associated phospholipase A2 activity and mass;
BRCA	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg26384229	chr12:38710491	ALG10B	0.67	14.21	0.49	5.23e-40	Morning vs. evening chronotype;
BRCA	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11890956	chr21:40555474	PSMG1	1.04	29.87	0.76	2.31e-123	Cognitive function;
BRCA	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg16586182	chr3:47516702	SCAP	-0.55	-12.35	-0.44	1.4e-31	Colorectal cancer;
BRCA	cis	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.5	-0.32	1.31e-16	Obesity-related traits;
BRCA	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg24112000	chr20:60950667	NA	-0.54	-10.57	-0.39	3.55e-24	Colorectal cancer;
BRCA	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06028605	chr16:24865363	SLC5A11	-0.41	-9.37	-0.35	1.22e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08564027	chr20:61660810	NA	0.85	22.97	0.67	1.42e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg21918786	chr6:109611834	NA	-0.49	-14.04	-0.49	3.1e-39	Reticulocyte fraction of red cells;
BRCA	trans	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg21659725	chr3:3221576	CRBN	0.47	8.74	0.33	2.11e-17	Menarche (age at onset);
BRCA	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg09658497	chr7:2847517	GNA12	-0.42	-8.69	-0.33	3.02e-17	Height;
BRCA	cis	rs10267417	0.657	rs28833898	chr7:19861022	G/A	cg05791153	chr7:19748676	TWISTNB	0.52	9.83	0.36	2.55e-21	Night sleep phenotypes;
BRCA	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg15212455	chr7:39170539	POU6F2	0.45	9.89	0.36	1.53e-21	IgG glycosylation;
BRCA	cis	rs7523273	0.548	rs3109808	chr1:207948477	C/A	cg22525895	chr1:207977042	MIR29B2	0.46	11.54	0.42	4.08e-28	Schizophrenia;
BRCA	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.83	-0.3	1.98e-14	Bipolar disorder;
BRCA	cis	rs6977660	0.714	rs7798760	chr7:19803487	T/C	cg07541023	chr7:19748670	TWISTNB	0.55	9.54	0.35	2.93e-20	Thyroid stimulating hormone;
BRCA	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7714584	1.000	rs4958842	chr5:150224877	G/A	cg22134413	chr5:150180641	NA	0.67	10.07	0.37	2.97e-22	Crohn's disease;
BRCA	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	26.56	0.72	2.85e-105	Chronic sinus infection;
BRCA	cis	rs2710642	0.927	rs6705798	chr2:63259881	C/T	cg17519650	chr2:63277830	OTX1	0.38	8.15	0.31	1.91e-15	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11890956	chr21:40555474	PSMG1	0.82	20.7	0.63	3.24e-73	Cognitive function;
BRCA	cis	rs1506636	0.525	rs7812023	chr7:123260228	C/T	cg03229431	chr7:123269106	ASB15	-0.57	-11.39	-0.41	1.76e-27	Plateletcrit;Platelet count;
BRCA	cis	rs1267303	0.675	rs1267313	chr1:46986322	G/T	cg25110126	chr1:46999211	NA	-0.5	-9.53	-0.35	3.34e-20	Monobrow;
BRCA	cis	rs6088813	1.000	rs4911178	chr20:33952620	C/T	cg14752227	chr20:34000481	UQCC	-0.41	-8.83	-0.33	9.99e-18	Height;
BRCA	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-9.9	-0.36	1.39e-21	Retinal vascular caliber;
BRCA	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg18252515	chr7:66147081	NA	1.06	16.03	0.54	7.81e-49	Diabetic kidney disease;
BRCA	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg19773385	chr1:10388646	KIF1B	0.38	8.21	0.31	1.26e-15	Hepatocellular carcinoma;
BRCA	trans	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg19862616	chr7:65841803	NCRNA00174	0.83	27.27	0.73	3.26e-109	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg21167628	chr1:45308625	PTCH2	-0.32	-8.21	-0.31	1.24e-15	Facial morphology (factor 20);
BRCA	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg21017887	chr14:105400489	NA	0.66	17.48	0.57	3.47e-56	Rheumatoid arthritis;
BRCA	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg05313129	chr8:58192883	C8orf71	-0.48	-9.84	-0.36	2.23e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg24154853	chr7:158122151	PTPRN2	0.35	8.08	0.3	3.14e-15	Calcium levels;
BRCA	cis	rs6032067	0.673	rs6017532	chr20:43904095	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	0.33	8.23	0.31	1.09e-15	Blood protein levels;
BRCA	cis	rs9324022	0.929	rs9635298	chr14:101172542	C/T	cg18089426	chr14:101175970	NA	0.68	13.0	0.46	1.86e-34	Plateletcrit;
BRCA	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg12386194	chr3:101231763	SENP7	0.69	12.41	0.44	7.42e-32	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12986413	0.967	rs1015670	chr19:2171490	G/A	cg09261902	chr19:2140048	AP3D1	0.38	10.06	0.37	3.37e-22	Height;
BRCA	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg25664220	chr3:72788482	NA	-0.55	-11.66	-0.42	1.29e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6785206	0.667	rs6439139	chr3:128410285	T/C	cg16766828	chr3:128327626	NA	-0.76	-11.27	-0.41	5.43e-27	Lymphocyte percentage of white cells;
BRCA	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg07395648	chr5:131743802	NA	-0.35	-7.87	-0.3	1.58e-14	Breast cancer;
BRCA	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg00677455	chr12:58241039	CTDSP2	0.68	15.96	0.53	1.66e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg16339924	chr4:17578868	LAP3	0.62	15.46	0.52	4.66e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-12.46	-0.44	4.47e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.73	-0.33	2.15e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg04455712	chr21:45112962	RRP1B	-0.4	-10.98	-0.4	8.39e-26	Mean corpuscular volume;
BRCA	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg03560586	chr2:239334908	ASB1	-0.51	-11.37	-0.41	2.17e-27	Multiple system atrophy;
BRCA	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.51	0.5	1.85e-41	Motion sickness;
BRCA	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg26384229	chr12:38710491	ALG10B	0.74	17.59	0.57	9.06e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.22	0.49	4.65e-40	Motion sickness;
BRCA	trans	rs7980799	0.935	rs10844582	chr12:33560873	A/G	cg26384229	chr12:38710491	ALG10B	-0.41	-8.56	-0.32	8.72e-17	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg23231163	chr10:75533350	FUT11	-0.33	-8.64	-0.32	4.33e-17	Inflammatory bowel disease;
BRCA	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg04362960	chr10:104952993	NT5C2	0.43	10.45	0.38	1.03e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg02733842	chr7:1102375	C7orf50	-0.72	-12.47	-0.44	4.4e-32	Bronchopulmonary dysplasia;
BRCA	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg21280719	chr6:42927975	GNMT	-0.33	-13.93	-0.48	1e-38	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-10.63	-0.39	2.11e-24	Gut microbiome composition (summer);
BRCA	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg12483005	chr1:23474871	LUZP1	0.43	9.45	0.35	6.12e-20	Height;
BRCA	cis	rs6910061	1.000	rs9468415	chr6:11100885	T/A	cg27233058	chr6:11094804	LOC221710	0.52	9.3	0.35	2.15e-19	Diabetic kidney disease;
BRCA	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.52	-0.32	1.12e-16	Height;
BRCA	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg08807892	chr2:162101083	NA	0.72	16.51	0.55	2.85e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs16976116	0.901	rs28591259	chr15:55498940	T/A	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs672059	0.934	rs641057	chr1:183156859	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.38	8.74	0.33	2.01e-17	Hypertriglyceridemia;
BRCA	cis	rs2652822	0.935	rs2292038	chr15:63449680	C/G	cg02713581	chr15:63449717	RPS27L	-0.5	-10.37	-0.38	2.25e-23	Metabolic traits;
BRCA	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.59	-0.32	6.69e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg22535103	chr8:58192502	C8orf71	-0.43	-8.61	-0.32	5.71e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs68170813	0.523	rs11762152	chr7:106811374	G/A	cg02696742	chr7:106810147	HBP1	-0.52	-9.17	-0.34	6.41e-19	Coronary artery disease;
BRCA	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-11.76	-0.42	4.88e-29	Alzheimer's disease;
BRCA	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.73	-0.33	2.29e-17	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg02106180	chr16:845767	CHTF18	0.28	8.14	0.31	2e-15	Mean corpuscular volume;
BRCA	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.91	-0.33	5.29e-18	Height;
BRCA	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg21385522	chr1:16154831	NA	-0.46	-10.02	-0.37	4.77e-22	Systolic blood pressure;
BRCA	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.49	-12.09	-0.43	1.98e-30	Longevity;Endometriosis;
BRCA	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg23033748	chr14:75592666	NEK9	-0.43	-10.34	-0.38	2.92e-23	Height;
BRCA	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg19508488	chr2:152266495	RIF1	0.43	9.39	0.35	1.01e-19	Lung cancer;
BRCA	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg07080220	chr10:102295463	HIF1AN	0.6	13.02	0.46	1.49e-34	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg20476274	chr7:133979776	SLC35B4	0.62	17.89	0.58	2.39e-58	Mean platelet volume;
BRCA	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.98	-0.48	6.13e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs250677	0.522	rs17109208	chr5:148378475	G/A	cg18129178	chr5:148520854	ABLIM3	-0.55	-10.51	-0.38	6.36e-24	Breast cancer;
BRCA	cis	rs17095355	0.818	rs59339754	chr10:111800116	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.44	-9.51	-0.35	3.91e-20	Biliary atresia;
BRCA	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.61	-13.87	-0.48	1.89e-38	Ulcerative colitis;
BRCA	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg27446573	chr6:127587934	RNF146	0.9	21.32	0.64	1.39e-76	Breast cancer;
BRCA	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg24692254	chr21:30365293	RNF160	0.44	9.9	0.36	1.41e-21	Pancreatic cancer;
BRCA	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg03188948	chr7:1209495	NA	0.44	8.84	0.33	9.58e-18	Longevity;Endometriosis;
BRCA	trans	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg01620082	chr3:125678407	NA	-0.7	-8.3	-0.31	6.39e-16	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	8.54	0.32	9.59e-17	Mean corpuscular volume;
BRCA	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03264133	chr6:25882463	NA	-0.53	-11.17	-0.4	1.32e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs13064411	0.696	rs1486897	chr3:113215818	G/A	cg18753928	chr3:113234510	CCDC52	-0.58	-12.0	-0.43	4.67e-30	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs6545883	0.965	rs3771261	chr2:61762161	A/G	cg15711740	chr2:61764176	XPO1	-0.54	-13.78	-0.48	5.1e-38	Tuberculosis;
BRCA	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg02734326	chr4:10020555	SLC2A9	0.35	7.83	0.3	2.07e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.61	-12.78	-0.45	1.82e-33	Lymphocyte counts;
BRCA	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.32	0.49	1.55e-40	Motion sickness;
BRCA	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.75	0.33	1.93e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg27284194	chr4:1044797	NA	0.43	9.29	0.35	2.35e-19	Recombination rate (males);
BRCA	cis	rs6484504	0.576	rs2756191	chr11:31135882	A/T	cg06552810	chr11:31128660	NA	0.37	8.17	0.31	1.66e-15	Red blood cell count;
BRCA	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg27661571	chr11:113659931	NA	-0.81	-12.13	-0.43	1.25e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.24	7.83	0.3	1.99e-14	Cardiac Troponin-T levels;
BRCA	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg11843238	chr5:131593191	PDLIM4	-0.36	-7.86	-0.3	1.58e-14	Breast cancer;
BRCA	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg18252515	chr7:66147081	NA	-0.97	-13.95	-0.48	8.76e-39	Diabetic kidney disease;
BRCA	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.63	0.32	4.71e-17	Motion sickness;
BRCA	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.67	-0.32	3.44e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.05	29.57	0.76	9.6e-122	Cognitive ability;
BRCA	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg22875332	chr1:76189707	ACADM	0.44	8.62	0.32	5.24e-17	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg07460842	chr6:66804631	NA	0.88	14.29	0.49	2.04e-40	Exhaled nitric oxide output;
BRCA	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg23711669	chr6:146136114	FBXO30	0.65	15.23	0.52	6.75e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg27446573	chr6:127587934	RNF146	0.9	21.22	0.64	4.53e-76	Breast cancer;
BRCA	cis	rs13095912	0.785	rs6791954	chr3:185335709	C/T	cg11274856	chr3:185301563	NA	-0.5	-12.16	-0.43	9.91e-31	Systolic blood pressure;
BRCA	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg26031613	chr14:104095156	KLC1	-0.45	-8.73	-0.33	2.17e-17	Schizophrenia;
BRCA	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg23422044	chr7:1970798	MAD1L1	-0.43	-8.92	-0.33	4.76e-18	Bipolar disorder;
BRCA	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg01028140	chr2:1542097	TPO	-0.56	-11.48	-0.41	7.52e-28	IgG glycosylation;
BRCA	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg09307838	chr4:120376055	NA	0.64	14.09	0.49	1.94e-39	Corneal astigmatism;
BRCA	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06002616	chr8:101225028	SPAG1	-0.32	-7.96	-0.3	7.95e-15	Atrioventricular conduction;
BRCA	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg15557168	chr22:42548783	NA	0.31	8.49	0.32	1.44e-16	Cognitive function;
BRCA	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.74	0.39	7.82e-25	Tonsillectomy;
BRCA	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg17691542	chr6:26056736	HIST1H1C	0.47	9.6	0.35	1.83e-20	Height;
BRCA	trans	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg06521331	chr12:34319734	NA	-0.47	-9.15	-0.34	7.29e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7851660	0.967	rs3758249	chr9:100614140	T/C	cg13688889	chr9:100608707	NA	-0.36	-8.71	-0.33	2.56e-17	Strep throat;
BRCA	cis	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg06521331	chr12:34319734	NA	-0.58	-11.47	-0.41	7.88e-28	Morning vs. evening chronotype;
BRCA	cis	rs7131987	0.650	rs7311912	chr12:29475703	G/C	cg09582351	chr12:29534625	ERGIC2	-0.43	-9.85	-0.36	2.03e-21	QT interval;
BRCA	cis	rs3820928	0.967	rs4675114	chr2:227768362	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.57	-0.32	7.82e-17	Pulmonary function;
BRCA	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg20891283	chr12:69753455	YEATS4	0.84	28.19	0.74	3.23e-114	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg12386194	chr3:101231763	SENP7	0.6	12.27	0.44	3.32e-31	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	8.82e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg11266682	chr4:10021025	SLC2A9	-0.34	-8.97	-0.33	3.28e-18	Bone mineral density;
BRCA	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg08601574	chr20:25228251	PYGB	-0.37	-8.59	-0.32	6.76e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg24558204	chr6:135376177	HBS1L	0.53	14.79	0.51	8.65e-43	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs72772090	1.000	rs72772092	chr5:96046912	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.52	-11.42	-0.41	1.25e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs12517041	1.000	rs10059818	chr5:23292940	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	12.97	0.46	2.61e-34	Migraine;Coronary artery disease;
BRCA	trans	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.0	0.3	5.96e-15	Corneal astigmatism;
BRCA	cis	rs7631605	0.935	rs6780799	chr3:37162758	G/A	cg15934958	chr3:37212084	LRRFIP2	0.41	9.51	0.35	3.8e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg04691961	chr3:161091175	C3orf57	-0.58	-13.95	-0.48	8.48e-39	Morning vs. evening chronotype;
BRCA	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06022373	chr22:39101656	GTPBP1	0.71	17.71	0.57	2.24e-57	Menopause (age at onset);
BRCA	cis	rs4664304	0.658	rs2667016	chr2:160868855	C/T	cg01092293	chr2:160761427	LY75	-0.36	-8.66	-0.32	3.83e-17	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs999943	0.810	rs62407648	chr6:33622436	C/G	cg14003231	chr6:33640908	ITPR3	0.75	16.84	0.55	6.14e-53	Obesity (extreme);
BRCA	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg17127132	chr2:85788382	GGCX	0.36	8.05	0.3	4.08e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg11502198	chr6:26597334	ABT1	0.64	10.36	0.38	2.43e-23	Small cell lung carcinoma;
BRCA	cis	rs12431939	0.947	rs59298295	chr14:51659047	T/G	cg23942311	chr14:51606299	NA	-0.44	-8.0	-0.3	5.96e-15	Cancer;
BRCA	cis	rs1113500	0.933	rs2077259	chr1:108629551	T/C	cg06207961	chr1:108661230	NA	0.45	11.05	0.4	4.25e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs9473147	0.516	rs9395283	chr6:47551444	T/C	cg12968598	chr6:47444699	CD2AP	0.44	9.59	0.35	1.92e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg17691542	chr6:26056736	HIST1H1C	0.48	9.55	0.35	2.75e-20	Iron status biomarkers;
BRCA	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg22139774	chr2:100720529	AFF3	0.3	8.63	0.32	4.95e-17	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs11051970	0.636	rs2733703	chr12:32561794	C/T	cg02745156	chr12:32552066	NA	0.25	8.31	0.31	5.6e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.06	0.37	3.23e-22	Bladder cancer;
BRCA	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11890956	chr21:40555474	PSMG1	0.98	23.16	0.68	1.22e-86	Cognitive function;
BRCA	trans	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg06521331	chr12:34319734	NA	-0.47	-8.73	-0.33	2.14e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg25809561	chr17:30822961	MYO1D	-0.37	-8.68	-0.32	3.36e-17	Schizophrenia;
BRCA	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg10011062	chr15:43941034	CATSPER2	-0.55	-8.09	-0.3	2.94e-15	Lung cancer in ever smokers;
BRCA	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg07988820	chr12:82153109	PPFIA2	-0.68	-11.35	-0.41	2.49e-27	Resting heart rate;
BRCA	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg11812906	chr14:75593930	NEK9	-0.62	-14.2	-0.49	5.61e-40	Height;
BRCA	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.79	0.55	1.14e-52	Hypertriglyceridemia;
BRCA	cis	rs7737355	0.947	rs56228197	chr5:130805475	C/T	cg06307176	chr5:131281290	NA	-0.53	-10.55	-0.39	4.16e-24	Life satisfaction;
BRCA	cis	rs7617773	0.817	rs11720622	chr3:48246679	G/A	cg11946769	chr3:48343235	NME6	0.5	11.32	0.41	3.29e-27	Coronary artery disease;
BRCA	cis	rs6942756	0.955	rs2056694	chr7:128923817	C/T	cg02491457	chr7:128862824	NA	-0.71	-14.0	-0.48	4.79e-39	White matter hyperintensity burden;
BRCA	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg10876282	chr6:28092338	ZSCAN16	0.4	7.89	0.3	1.29e-14	Parkinson's disease;
BRCA	cis	rs68170813	0.559	rs6967745	chr7:106850548	G/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.4	-0.32	2.81e-16	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.81e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs367943	0.901	rs171180	chr5:112817093	A/C	cg12552261	chr5:112820674	MCC	-0.55	-12.21	-0.44	5.6e-31	Type 2 diabetes;
BRCA	cis	rs4953318	1.000	rs4953318	chr2:46355051	A/C	cg12428440	chr2:46370979	PRKCE	0.39	9.4	0.35	9.59e-20	Red blood cell count;Hematocrit;Red blood cell traits;
BRCA	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg13852791	chr20:30311386	BCL2L1	0.73	13.4	0.47	2.76e-36	Mean corpuscular hemoglobin;
BRCA	cis	rs10189230	0.967	rs12990760	chr2:222354725	G/T	cg14652038	chr2:222343519	EPHA4	0.47	13.12	0.46	5.49e-35	Urate levels in lean individuals;
BRCA	cis	rs250677	0.522	rs891920	chr5:148369418	G/T	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.19	-0.31	1.38e-15	Breast cancer;
BRCA	cis	rs3741151	0.773	rs73544710	chr11:73162273	A/G	cg17517138	chr11:73019481	ARHGEF17	0.87	12.43	0.44	6.65e-32	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.33	-8.02	-0.3	5.08e-15	Personality dimensions;
BRCA	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg08470875	chr2:26401718	FAM59B	-0.64	-9.58	-0.35	2.09e-20	Gut microbiome composition (summer);
BRCA	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	10.07	0.37	3.16e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.81	-0.48	3.57e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg19274703	chr22:41806451	NA	-0.35	-8.59	-0.32	6.87e-17	Vitiligo;
BRCA	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	13.35	0.47	4.89e-36	Platelet count;
BRCA	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-8.75	-0.33	1.95e-17	Morning vs. evening chronotype;
BRCA	trans	rs6076960	0.629	rs6054008	chr20:6212370	C/T	cg21095983	chr6:86352623	SYNCRIP	0.44	9.36	0.35	1.34e-19	Smooth-surface caries;
BRCA	cis	rs1883415	0.534	rs2253794	chr6:24479642	C/A	cg20631270	chr6:24437470	GPLD1	0.4	8.18	0.31	1.53e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.68	-0.32	3.33e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg06212747	chr3:49208901	KLHDC8B	0.48	9.79	0.36	3.47e-21	Parkinson's disease;
BRCA	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg09307838	chr4:120376055	NA	0.61	12.31	0.44	2.09e-31	Corneal astigmatism;
BRCA	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg15133208	chr4:90757351	SNCA	-0.39	-7.97	-0.3	7.48e-15	Neuroticism;
BRCA	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg19622623	chr12:86230825	RASSF9	-0.33	-9.39	-0.35	1.05e-19	Major depressive disorder;
BRCA	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg18154014	chr19:37997991	ZNF793	0.48	9.65	0.36	1.2e-20	Coronary artery calcification;
BRCA	cis	rs12413816	0.517	rs4750400	chr10:13765923	A/G	cg16485048	chr10:13749193	FRMD4A	0.44	10.89	0.4	1.85e-25	Red cell distribution width;
BRCA	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21518248	chr2:162101506	NA	0.71	17.41	0.57	7.28e-56	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs13064411	0.696	rs6798938	chr3:113218206	C/T	cg18753928	chr3:113234510	CCDC52	-0.6	-12.58	-0.45	1.37e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs483180	0.512	rs1163251	chr1:120209755	T/C	cg19096424	chr1:120255104	PHGDH	-0.43	-9.52	-0.35	3.61e-20	Macular telangiectasia type 2;
BRCA	cis	rs2637266	0.935	rs2252661	chr10:78404793	A/G	cg18941641	chr10:78392320	NA	0.36	8.36	0.31	4.05e-16	Pulmonary function;
BRCA	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg19920283	chr7:105172520	RINT1	0.59	9.54	0.35	2.83e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg20476274	chr7:133979776	SLC35B4	0.6	14.97	0.51	1.17e-43	Mean platelet volume;
BRCA	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg05896524	chr21:47604654	C21orf56	0.42	8.04	0.3	4.33e-15	Testicular germ cell tumor;
BRCA	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg03929089	chr4:120376271	NA	-0.43	-8.03	-0.3	4.79e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg18230493	chr5:56204884	C5orf35	0.61	12.87	0.45	7.3e-34	Initial pursuit acceleration;
BRCA	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg26818010	chr10:134567672	INPP5A	0.37	8.82	0.33	1.06e-17	Migraine;
BRCA	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg27129171	chr3:47204927	SETD2	-0.71	-17.08	-0.56	3.81e-54	Colorectal cancer;
BRCA	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.4	0.35	9.79e-20	Tonsillectomy;
BRCA	cis	rs61990749	0.597	rs13379065	chr14:78141295	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.64	-10.05	-0.37	3.59e-22	Fibroblast growth factor basic levels;
BRCA	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg01065977	chr19:18549689	ISYNA1	-0.3	-9.04	-0.34	1.91e-18	Breast cancer;
BRCA	cis	rs6446731	0.593	rs2530601	chr4:3272378	C/G	cg08886695	chr4:3369023	RGS12	-0.38	-9.95	-0.37	8.78e-22	Mean platelet volume;
BRCA	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg09307838	chr4:120376055	NA	0.59	12.84	0.45	1.01e-33	Corneal astigmatism;
BRCA	trans	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg23762105	chr12:34175262	ALG10	0.36	8.45	0.32	2.02e-16	Morning vs. evening chronotype;
BRCA	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg08888203	chr3:10149979	C3orf24	0.65	11.93	0.43	8.91e-30	Alzheimer's disease;
BRCA	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.84	0.36	2.33e-21	Bipolar disorder;
BRCA	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg17063962	chr7:91808500	NA	-0.53	-12.08	-0.43	2.16e-30	Breast cancer;
BRCA	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg18252515	chr7:66147081	NA	-0.89	-13.15	-0.46	3.84e-35	Diabetic kidney disease;
BRCA	cis	rs9811920	0.535	rs792835	chr3:99476295	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-9.96	-0.37	8.22e-22	Axial length;
BRCA	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg23711669	chr6:146136114	FBXO30	0.72	17.08	0.56	3.59e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg21605333	chr4:119757512	SEC24D	1.34	13.89	0.48	1.64e-38	Cannabis dependence symptom count;
BRCA	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg11764359	chr7:65958608	NA	0.67	15.25	0.52	5.44e-45	Aortic root size;
BRCA	cis	rs6942756	1.000	rs4440569	chr7:128923907	T/A	cg02491457	chr7:128862824	NA	-0.71	-14.01	-0.48	4.36e-39	White matter hyperintensity burden;
BRCA	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.35	8.23	0.31	1.09e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6973256	0.897	rs9656423	chr7:133324987	C/T	cg07491979	chr7:133331646	EXOC4	0.39	8.88	0.33	6.54e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs13064411	0.542	rs7650671	chr3:113201216	C/T	cg18753928	chr3:113234510	CCDC52	-0.41	-9.19	-0.34	5.27e-19	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs877282	1.000	rs34257857	chr10:772993	C/A	cg17470449	chr10:769945	NA	0.5	9.35	0.35	1.44e-19	Uric acid levels;
BRCA	cis	rs11971779	0.680	rs6467840	chr7:139065401	A/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs9942416	0.660	rs17563863	chr5:74998334	G/A	cg19683494	chr5:74908142	NA	0.47	8.89	0.33	6.04e-18	Age-related disease endophenotypes;
BRCA	trans	rs11976180	1.000	rs13226728	chr7:143746578	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.42	-7.91	-0.3	1.16e-14	Obesity-related traits;
BRCA	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg15133208	chr4:90757351	SNCA	-0.38	-8.03	-0.3	4.61e-15	Neuroticism;
BRCA	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.24	-0.41	7.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg05729581	chr11:3078854	CARS	-0.34	-8.49	-0.32	1.39e-16	Longevity;
BRCA	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.69	0.39	1.24e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.85	-0.42	2e-29	Response to antipsychotic treatment;
BRCA	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg24562669	chr7:97807699	LMTK2	0.62	18.68	0.59	1.78e-62	Breast cancer;
BRCA	cis	rs4321325	0.733	rs79995601	chr2:127947452	T/C	cg11380483	chr2:127933992	NA	0.43	8.92	0.33	5.06e-18	Protein C levels;
BRCA	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-9.4	-0.35	9.47e-20	Menopause (age at onset);
BRCA	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg08558340	chr7:100472263	SRRT	0.47	7.89	0.3	1.31e-14	Resting heart rate;
BRCA	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg16743903	chr16:89593216	SPG7	-0.33	-8.34	-0.31	4.44e-16	Multiple myeloma (IgH translocation);
BRCA	cis	rs7973719	0.833	rs11044332	chr12:7358768	C/A	cg07052231	chr12:7363540	PEX5	0.36	8.17	0.31	1.66e-15	IgG glycosylation;
BRCA	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg24879335	chr3:133465180	TF	0.25	7.81	0.3	2.42e-14	Iron status biomarkers;
BRCA	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24838063	chr12:130822603	PIWIL1	0.69	16.86	0.55	4.77e-53	Menopause (age at onset);
BRCA	cis	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg08807101	chr21:30365312	RNF160	-0.47	-7.98	-0.3	6.73e-15	Cognitive test performance;
BRCA	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg08422745	chr4:174089978	GALNT7	-0.78	-16.06	-0.54	5.51e-49	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs858239	0.730	rs858290	chr7:23248036	A/G	cg23682824	chr7:23144976	KLHL7	0.31	7.98	0.3	7.03e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7818345	0.967	rs6999786	chr8:19277817	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.3	7.83	0.3	1.97e-14	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg06627628	chr2:24431161	ITSN2	0.45	9.43	0.35	7.36e-20	Asthma;
BRCA	cis	rs61160187	0.522	rs2045356	chr5:59947354	C/T	cg02684056	chr5:59996105	DEPDC1B	0.39	9.1	0.34	1.14e-18	Educational attainment (years of education);Educational attainment (college completion);
BRCA	cis	rs2625529	0.713	rs12903980	chr15:72165549	C/T	cg16672083	chr15:72433130	SENP8	-0.84	-17.41	-0.57	7.82e-56	Red blood cell count;
BRCA	cis	rs7903847	0.642	rs11189206	chr10:99167802	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.76	-0.33	1.77e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10496034	1.000	rs2304687	chr2:55138282	C/T	cg16098955	chr2:55172992	EML6	0.49	8.58	0.32	7e-17	Refractive astigmatism;
BRCA	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11890956	chr21:40555474	PSMG1	0.84	21.54	0.65	9.3e-78	Cognitive function;
BRCA	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	9.1	0.34	1.18e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg11663144	chr21:46675770	NA	-0.6	-13.82	-0.48	3.24e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs701145	0.585	rs2596629	chr3:153931142	A/C	cg17054900	chr3:154042577	DHX36	0.57	9.59	0.35	1.96e-20	Coronary artery disease;
BRCA	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg20283391	chr11:68216788	NA	-0.46	-8.98	-0.33	3.03e-18	Total body bone mineral density;
BRCA	trans	rs6479891	1.000	rs4745729	chr10:65277083	A/G	cg14819942	chr15:35414228	NA	0.35	8.51	0.32	1.28e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.73	0.55	2.12e-52	Colorectal cancer;
BRCA	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00166722	chr3:10149974	C3orf24	0.57	10.99	0.4	7.79e-26	Alzheimer's disease;
BRCA	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.69	-0.36	8.1e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs61990749	0.597	rs717683	chr14:78255453	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	9.31	0.35	1.98e-19	Fibroblast growth factor basic levels;
BRCA	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg01483505	chr11:975446	AP2A2	0.33	8.68	0.32	3.41e-17	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-12.2	-0.43	6.29e-31	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg22920501	chr2:26401640	FAM59B	0.91	16.27	0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs12541635	0.967	rs4734896	chr8:107075454	T/C	cg10147462	chr8:107024639	NA	-0.31	-8.59	-0.32	6.77e-17	Age of smoking initiation;
BRCA	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg21918786	chr6:109611834	NA	-0.45	-12.14	-0.43	1.11e-30	Reticulocyte fraction of red cells;
BRCA	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg17366294	chr4:99064904	C4orf37	0.39	8.79	0.33	1.4e-17	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-8.29	-0.31	6.72e-16	Alzheimer's disease (late onset);
BRCA	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg12927641	chr6:109611667	NA	-0.38	-9.31	-0.35	2.1e-19	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
BRCA	trans	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg25214090	chr10:38739885	LOC399744	0.54	12.26	0.44	3.47e-31	Corneal astigmatism;
BRCA	cis	rs1018836	0.851	rs12548741	chr8:91628878	G/A	cg16814680	chr8:91681699	NA	-0.6	-12.81	-0.45	1.32e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg12311346	chr5:56204834	C5orf35	-0.74	-14.6	-0.5	7.07e-42	Initial pursuit acceleration;
BRCA	cis	rs10129255	0.500	rs59939897	chr14:107191651	A/G	cg07958169	chr14:107095056	NA	-0.4	-8.67	-0.32	3.69e-17	Kawasaki disease;
BRCA	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg13319975	chr6:146136371	FBXO30	0.39	9.06	0.34	1.53e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg24006582	chr15:45444508	DUOX1	-0.56	-11.54	-0.42	4.12e-28	Uric acid levels;
BRCA	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg24812749	chr6:127587940	RNF146	0.87	19.82	0.62	1.62e-68	Breast cancer;
BRCA	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.92	-17.22	-0.56	7.02e-55	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.29	0.44	2.59e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04565464	chr8:145669602	NFKBIL2	0.38	8.79	0.33	1.36e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-9.68	-0.36	9.11e-21	Alzheimer's disease (late onset);
BRCA	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.85	-0.53	5.78e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6740322	0.895	rs6711966	chr2:43561989	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-11.77	-0.42	4.19e-29	Coronary artery disease;
BRCA	trans	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg06521331	chr12:34319734	NA	-0.53	-10.02	-0.37	4.82e-22	Bladder cancer;
BRCA	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25427524	chr10:38739819	LOC399744	-0.69	-16.85	-0.55	5.3e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg12927641	chr6:109611667	NA	-0.39	-9.76	-0.36	4.39e-21	Reticulocyte fraction of red cells;
BRCA	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg13010199	chr12:38710504	ALG10B	0.41	8.41	0.32	2.74e-16	Bladder cancer;
BRCA	cis	rs2964802	0.505	rs2083232	chr5:10812811	G/A	cg14521931	chr5:10832172	NA	-0.57	-13.12	-0.46	5.59e-35	Major depressive disorder;Recurrent major depressive disorder;
BRCA	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg07169764	chr2:136633963	MCM6	1.02	21.28	0.64	2.32e-76	Corneal structure;
BRCA	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.97	-0.3	7.41e-15	Parkinson's disease;
BRCA	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.86	21.18	0.64	8.1e-76	Body mass index (adult);
BRCA	trans	rs1973993	0.507	rs2759670	chr1:97002864	A/G	cg10631902	chr5:14652156	NA	0.48	14.84	0.51	5.25e-43	Weight;
BRCA	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg07169764	chr2:136633963	MCM6	1.24	26.7	0.73	4.33e-106	Corneal structure;
BRCA	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg01448562	chr3:133502909	NA	-0.39	-8.96	-0.33	3.53e-18	Iron status biomarkers;
BRCA	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg02659138	chr7:134003124	SLC35B4	0.37	11.11	0.4	2.38e-26	Mean platelet volume;
BRCA	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg09904177	chr6:26538194	HMGN4	0.46	14.64	0.5	4.45e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg17971929	chr21:40555470	PSMG1	-0.49	-10.82	-0.39	3.54e-25	Menarche (age at onset);
BRCA	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg17063962	chr7:91808500	NA	0.53	12.49	0.44	3.51e-32	Breast cancer;
BRCA	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg00409905	chr10:38381863	ZNF37A	-0.51	-10.92	-0.4	1.44e-25	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7975161	0.638	rs4592489	chr12:104619699	C/T	cg25273343	chr12:104657179	TXNRD1	-0.4	-9.58	-0.35	2.04e-20	Toenail selenium levels;
BRCA	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg13010199	chr12:38710504	ALG10B	-0.37	-8.64	-0.32	4.33e-17	Morning vs. evening chronotype;
BRCA	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg05347473	chr6:146136440	FBXO30	0.43	8.48	0.32	1.56e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg13628971	chr7:2884303	GNA12	-0.46	-9.08	-0.34	1.36e-18	Height;
BRCA	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg13770153	chr20:60521292	NA	-0.39	-9.17	-0.34	6.38e-19	Body mass index;
BRCA	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg12935359	chr14:103987150	CKB	-0.58	-13.78	-0.48	5.19e-38	Body mass index;
BRCA	cis	rs867371	0.762	rs1846910	chr15:82571780	G/A	cg00614314	chr15:82944287	LOC80154	0.48	9.74	0.36	5.48e-21	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg22800045	chr5:56110881	MAP3K1	-0.47	-9.29	-0.34	2.37e-19	Initial pursuit acceleration;
BRCA	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg23018236	chr17:30244563	NA	-0.46	-8.36	-0.31	3.92e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.17	-0.43	8.86e-31	Total cholesterol levels;
BRCA	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg18279126	chr7:2041391	MAD1L1	0.37	8.21	0.31	1.22e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	17.28	0.56	3.5e-55	Electrocardiographic conduction measures;
BRCA	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg24060327	chr5:131705240	SLC22A5	-0.46	-9.29	-0.34	2.38e-19	Blood metabolite levels;
BRCA	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg25036284	chr2:26402008	FAM59B	-0.9	-15.23	-0.52	6.86e-45	Gut microbiome composition (summer);
BRCA	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg03477792	chr4:77819574	ANKRD56	0.61	14.83	0.51	5.6e-43	Emphysema distribution in smoking;
BRCA	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg03433033	chr1:76189801	ACADM	0.67	13.55	0.47	5.82e-37	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg08885076	chr2:99613938	TSGA10	-0.6	-13.45	-0.47	1.74e-36	Chronic sinus infection;
BRCA	cis	rs7927771	0.524	rs10838763	chr11:47794802	C/T	cg20307385	chr11:47447363	PSMC3	0.42	9.56	0.35	2.48e-20	Subjective well-being;
BRCA	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg06453172	chr10:134556979	INPP5A	-0.61	-11.92	-0.43	9.85e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1971762	0.583	rs1864448	chr12:54087856	T/G	cg23533419	chr12:54090519	NA	-0.33	-8.3	-0.31	6.04e-16	Height;
BRCA	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.45	-10.65	-0.39	1.77e-24	IgG glycosylation;
BRCA	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.94	-0.33	4.29e-18	Total body bone mineral density;
BRCA	cis	rs9837602	1.000	rs9841186	chr3:99795651	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-11.27	-0.41	5.63e-27	Breast cancer;
BRCA	cis	rs926392	0.932	rs6513588	chr20:37686281	T/C	cg16355469	chr20:37678765	NA	0.33	8.19	0.31	1.41e-15	Dialysis-related mortality;
BRCA	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg01420254	chr6:26195488	NA	0.59	9.16	0.34	6.84e-19	Gout;Renal underexcretion gout;
BRCA	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg08470875	chr2:26401718	FAM59B	0.58	9.85	0.36	2.13e-21	Gut microbiome composition (summer);
BRCA	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-9.7	-0.36	7.71e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg00376283	chr12:123451042	ABCB9	-0.49	-11.27	-0.41	5.56e-27	Neutrophil percentage of white cells;
BRCA	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg03709012	chr19:19516395	GATAD2A	0.72	15.58	0.52	1.25e-46	Tonsillectomy;
BRCA	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.66	-14.25	-0.49	3.22e-40	Hip circumference adjusted for BMI;
BRCA	cis	rs9462027	0.583	rs912716	chr6:34715761	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.05	-0.3	3.97e-15	Systemic lupus erythematosus;
BRCA	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg13010199	chr12:38710504	ALG10B	-0.38	-8.5	-0.32	1.32e-16	Morning vs. evening chronotype;
BRCA	cis	rs943466	1.000	rs751096	chr6:33742838	C/T	cg25922239	chr6:33757077	LEMD2	0.38	8.09	0.3	3.01e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.53	12.97	0.46	2.68e-34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	12.29	0.44	2.66e-31	Lung cancer in ever smokers;
BRCA	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg16576597	chr16:28551801	NUPR1	0.31	8.5	0.32	1.32e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.63	16.62	0.55	7.71e-52	Electrocardiographic conduction measures;
BRCA	cis	rs3784262	0.765	rs8026952	chr15:58276950	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.27	-0.38	5.13e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg02631126	chr6:28058918	ZSCAN12L1	-0.27	-7.86	-0.3	1.69e-14	Parkinson's disease;
BRCA	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.27	-0.34	2.71e-19	Total body bone mineral density;
BRCA	cis	rs16958440	1.000	rs62096471	chr18:44643814	T/C	cg17192377	chr18:44677553	HDHD2	0.67	9.8	0.36	3.33e-21	Sitting height ratio;
BRCA	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg14675211	chr2:100938903	LONRF2	0.45	10.26	0.38	5.77e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg04025307	chr7:1156635	C7orf50	0.71	17.84	0.58	4.58e-58	Longevity;Endometriosis;
BRCA	cis	rs6977660	0.714	rs728156	chr7:19826309	G/C	cg07541023	chr7:19748670	TWISTNB	0.55	9.56	0.35	2.41e-20	Thyroid stimulating hormone;
BRCA	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.72	11.87	0.42	1.71e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg10756475	chr4:1757242	NA	-0.38	-8.72	-0.33	2.43e-17	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs11249608	0.548	rs6859936	chr5:178451214	T/C	cg21905437	chr5:178450457	ZNF879	0.53	10.99	0.4	7.14e-26	Pubertal anthropometrics;
BRCA	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.02	0.4	5.6e-26	Bipolar disorder;
BRCA	trans	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.95	-0.37	8.43e-22	Neuroticism;
BRCA	cis	rs2742234	0.955	rs2435384	chr10:43673731	G/T	cg02780029	chr10:43622663	RET	-0.39	-9.59	-0.35	1.95e-20	Hirschsprung disease;
BRCA	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg10729496	chr3:10149963	C3orf24	0.49	9.41	0.35	8.99e-20	Alzheimer's disease;
BRCA	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.65	0.32	4.14e-17	Motion sickness;
BRCA	cis	rs367943	0.871	rs348938	chr5:112825032	C/A	cg12552261	chr5:112820674	MCC	-0.46	-10.43	-0.38	1.25e-23	Type 2 diabetes;
BRCA	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg04998671	chr14:104000505	TRMT61A	-0.43	-9.5	-0.35	4.27e-20	Coronary artery disease;
BRCA	cis	rs2806561	1.000	rs1757048	chr1:23510601	A/C	cg19743168	chr1:23544995	NA	0.42	10.25	0.38	6.4e-23	Height;
BRCA	cis	rs3820928	0.839	rs10197773	chr2:227824835	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-8.94	-0.33	4.3e-18	Pulmonary function;
BRCA	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg27661571	chr11:113659931	NA	-0.69	-10.72	-0.39	8.84e-25	Hip circumference adjusted for BMI;
BRCA	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.22	0.31	1.13e-15	Total cholesterol levels;
BRCA	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg24812749	chr6:127587940	RNF146	0.7	15.23	0.52	6.71e-45	Breast cancer;
BRCA	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg00757033	chr12:89920650	WDR51B	0.44	9.54	0.35	2.85e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg06453172	chr10:134556979	INPP5A	-0.55	-11.5	-0.41	5.87e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.74	0.55	2.04e-52	Hypertriglyceridemia;
BRCA	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg02734326	chr4:10020555	SLC2A9	0.39	8.57	0.32	7.62e-17	Bone mineral density;
BRCA	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg15605315	chr1:45957053	TESK2	0.49	10.11	0.37	2.11e-22	High light scatter reticulocyte count;
BRCA	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.49	9.73	0.36	6.05e-21	Tonsillectomy;
BRCA	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.6	-14.06	-0.49	2.59e-39	Hemoglobin concentration;
BRCA	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg06618935	chr21:46677482	NA	-0.36	-8.01	-0.3	5.55e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg11663144	chr21:46675770	NA	-0.61	-14.35	-0.49	1.16e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg09307838	chr4:120376055	NA	-0.44	-9.13	-0.34	8.58e-19	Diastolic blood pressure;
BRCA	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4919087	0.962	rs10882883	chr10:99013312	A/G	cg25902810	chr10:99078978	FRAT1	0.43	9.15	0.34	7.66e-19	Monocyte count;
BRCA	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg13944838	chr5:179740914	GFPT2	-0.68	-14.41	-0.5	5.43e-41	Height;
BRCA	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.61	8.52	0.32	1.17e-16	Yeast infection;
BRCA	cis	rs3857067	0.806	rs7678054	chr4:95093855	A/G	cg11021082	chr4:95130006	SMARCAD1	0.39	8.99	0.33	2.88e-18	QT interval;
BRCA	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	13.47	0.47	1.33e-36	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg05343316	chr1:45956843	TESK2	0.7	14.24	0.49	3.83e-40	Platelet count;
BRCA	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg09469691	chr10:81107165	PPIF	0.49	10.3	0.38	4.02e-23	Height;
BRCA	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg01528321	chr10:82214614	TSPAN14	0.72	16.31	0.54	2.85e-50	Post bronchodilator FEV1;
BRCA	cis	rs10496034	1.000	rs1012603	chr2:55274531	C/T	cg16098955	chr2:55172992	EML6	0.51	8.21	0.31	1.27e-15	Refractive astigmatism;
BRCA	cis	rs11051970	0.545	rs2651375	chr12:32582652	G/T	cg24626660	chr12:32551988	NA	-0.3	-8.97	-0.33	3.27e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg17063962	chr7:91808500	NA	0.53	12.53	0.44	2.32e-32	Breast cancer;
BRCA	cis	rs1776421	0.760	rs61768414	chr1:53906995	C/T	cg10892335	chr1:53966318	NA	0.5	8.36	0.31	3.8e-16	PR interval in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.99	-0.46	2.14e-34	Migraine;Coronary artery disease;
BRCA	cis	rs6060717	0.536	rs11696912	chr20:34497660	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.57	8.0	0.3	5.97e-15	Hip circumference adjusted for BMI;
BRCA	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21659725	chr3:3221576	CRBN	0.37	9.09	0.34	1.27e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs877282	0.898	rs11253344	chr10:765162	C/T	cg17470449	chr10:769945	NA	0.47	7.96	0.3	8.16e-15	Uric acid levels;
BRCA	cis	rs9837602	0.810	rs13093776	chr3:99842140	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.44	8.13	0.31	2.29e-15	Breast cancer;
BRCA	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-9.79	-0.36	3.43e-21	Joint mobility (Beighton score);
BRCA	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg02734326	chr4:10020555	SLC2A9	0.41	8.83	0.33	9.81e-18	Bone mineral density;
BRCA	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg23358479	chr7:1110784	C7orf50	-0.48	-8.17	-0.31	1.68e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg03560586	chr2:239334908	ASB1	-0.41	-7.87	-0.3	1.55e-14	Multiple system atrophy;
BRCA	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg24112000	chr20:60950667	NA	-0.53	-10.04	-0.37	4.01e-22	Colorectal cancer;
BRCA	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg16482183	chr6:26056742	HIST1H1C	0.49	9.66	0.36	1.1e-20	Iron status biomarkers;
BRCA	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	22.01	0.66	2.4e-80	Platelet count;
BRCA	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg05025164	chr4:1340916	KIAA1530	0.51	10.83	0.39	3.2e-25	Longevity;
BRCA	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg22920501	chr2:26401640	FAM59B	0.93	16.09	0.54	3.86e-49	Mean corpuscular hemoglobin;
BRCA	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg06238570	chr21:40685208	BRWD1	-0.42	-8.52	-0.32	1.19e-16	Cognitive function;
BRCA	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03713592	chr11:72463424	ARAP1	0.79	11.63	0.42	1.69e-28	Type 2 diabetes;
BRCA	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.44	10.4	0.38	1.6e-23	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg06784218	chr1:46089804	CCDC17	0.5	12.17	0.43	8.36e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7246657	0.722	rs3101746	chr19:38146400	T/A	cg23950597	chr19:37808831	NA	0.51	8.72	0.33	2.42e-17	Coronary artery calcification;
BRCA	trans	rs61931739	0.513	rs10772116	chr12:33897795	G/C	cg13010199	chr12:38710504	ALG10B	0.37	8.12	0.31	2.49e-15	Morning vs. evening chronotype;
BRCA	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg13902645	chr11:5959945	NA	-0.56	-11.34	-0.41	2.65e-27	DNA methylation (variation);
BRCA	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg03676636	chr4:99064102	C4orf37	0.21	7.97	0.3	7.55e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs965469	0.895	rs6051729	chr20:3290615	A/G	cg25506879	chr20:3388711	C20orf194	-0.49	-9.72	-0.36	6.34e-21	IFN-related cytopenia;
BRCA	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg18850127	chr7:39170497	POU6F2	0.45	10.19	0.37	1.04e-22	IgG glycosylation;
BRCA	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg08470875	chr2:26401718	FAM59B	-0.72	-11.89	-0.43	1.31e-29	Gut microbiome composition (summer);
BRCA	cis	rs9549260	0.564	rs9646110	chr13:41308301	A/T	cg21288729	chr13:41239152	FOXO1	-0.49	-10.13	-0.37	1.76e-22	Red blood cell count;
BRCA	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg11502198	chr6:26597334	ABT1	-0.48	-9.56	-0.35	2.6e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6723226	0.708	rs2710627	chr2:32758627	A/G	cg02381751	chr2:32503542	YIPF4	0.64	13.91	0.48	1.24e-38	Intelligence (multi-trait analysis);
BRCA	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-12.36	-0.44	1.26e-31	Response to antipsychotic treatment;
BRCA	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg03433033	chr1:76189801	ACADM	-0.76	-17.43	-0.57	5.73e-56	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs652260	1.000	rs652260	chr19:7900562	C/T	cg26014689	chr19:7917955	EVI5L	-0.52	-11.7	-0.42	8.98e-29	Menarche (age at onset);
BRCA	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg05340658	chr4:99064831	C4orf37	0.61	14.56	0.5	1.14e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4363385	0.747	rs4845333	chr1:152982877	G/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.36	-0.31	3.82e-16	Inflammatory skin disease;
BRCA	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg17366294	chr4:99064904	C4orf37	0.42	9.51	0.35	3.85e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg06521331	chr12:34319734	NA	-0.65	-11.99	-0.43	5.28e-30	Morning vs. evening chronotype;
BRCA	cis	rs4664304	0.620	rs10186586	chr2:160715334	T/C	cg02280532	chr2:160761244	LY75	0.35	7.81	0.3	2.4e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg25019033	chr10:957182	NA	-0.43	-8.81	-0.33	1.21e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs4919087	1.000	rs11189127	chr10:99079023	G/A	cg25902810	chr10:99078978	FRAT1	0.52	11.44	0.41	1.09e-27	Monocyte count;
BRCA	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg21747090	chr2:27597821	SNX17	-0.38	-8.38	-0.31	3.49e-16	Total body bone mineral density;
BRCA	cis	rs849141	0.890	rs481806	chr7:28207300	G/T	cg22892036	chr7:28189139	JAZF1	0.46	8.32	0.31	5.14e-16	Height;Hip circumference adjusted for BMI;
BRCA	cis	rs7178424	0.967	rs11639482	chr15:62282114	C/T	cg00456672	chr15:62358751	C2CD4A	-0.38	-8.74	-0.33	2.04e-17	Height;
BRCA	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg01877450	chr7:97915802	BRI3	0.4	9.12	0.34	9.59e-19	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9359856	0.510	rs3736984	chr6:90408589	C/T	cg13799429	chr6:90582589	CASP8AP2	0.7	10.71	0.39	1.01e-24	Bipolar disorder;
BRCA	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg13010199	chr12:38710504	ALG10B	0.5	10.43	0.38	1.31e-23	Bladder cancer;
BRCA	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg03342759	chr3:160939853	NMD3	-0.8	-17.95	-0.58	1.2e-58	Morning vs. evening chronotype;
BRCA	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg13047869	chr3:10149882	C3orf24	0.59	12.27	0.44	3.13e-31	Alzheimer's disease;
BRCA	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg23289794	chr7:2394357	EIF3B	-0.64	-11.99	-0.43	5.32e-30	Multiple sclerosis;
BRCA	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg16989086	chr20:62203971	PRIC285	0.53	8.9	0.33	5.65e-18	Glioblastoma;
BRCA	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.53	-0.32	1.09e-16	Electroencephalogram traits;
BRCA	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg13334819	chr7:99746414	C7orf59	-0.35	-8.03	-0.3	4.65e-15	Coronary artery disease;
BRCA	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03934478	chr11:495069	RNH1	0.84	13.02	0.46	1.47e-34	Body mass index;
BRCA	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg16325326	chr1:53192061	ZYG11B	-0.66	-16.27	-0.54	4.55e-50	Monocyte count;
BRCA	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg20848291	chr7:100343083	ZAN	-0.62	-12.72	-0.45	3.44e-33	Other erythrocyte phenotypes;
BRCA	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg08027265	chr7:2291960	NA	-0.34	-8.48	-0.32	1.61e-16	Schizophrenia;
BRCA	cis	rs921968	0.565	rs4674330	chr2:219595710	T/C	cg02176678	chr2:219576539	TTLL4	-0.41	-11.07	-0.4	3.48e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9649213	0.533	rs62478235	chr7:98030349	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.6	-15.79	-0.53	1.21e-47	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg00080972	chr5:178986291	RUFY1	0.5	12.64	0.45	7.38e-33	Lung cancer;
BRCA	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg13047869	chr3:10149882	C3orf24	0.54	10.1	0.37	2.34e-22	Alzheimer's disease;
BRCA	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg10932868	chr11:921992	NA	0.5	12.76	0.45	2.15e-33	Alzheimer's disease (late onset);
BRCA	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03452623	chr4:187889614	NA	-0.31	-10.01	-0.37	5.07e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11764359	chr7:65958608	NA	-0.71	-15.17	-0.51	1.32e-44	Aortic root size;
BRCA	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	13.48	0.47	1.27e-36	Eosinophil percentage of white cells;
BRCA	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg13385794	chr1:248469461	NA	0.29	7.88	0.3	1.44e-14	Common traits (Other);
BRCA	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.74	-0.42	5.93e-29	Electroencephalogram traits;
BRCA	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg03342759	chr3:160939853	NMD3	-0.64	-13.56	-0.47	5.21e-37	Morning vs. evening chronotype;
BRCA	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg18402987	chr7:1209562	NA	0.66	11.29	0.41	4.66e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg05623727	chr3:50126028	RBM5	0.51	12.1	0.43	1.64e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs4660306	1.000	rs7522705	chr1:45992300	C/G	cg24296786	chr1:45957014	TESK2	-0.48	-10.01	-0.37	5.38e-22	Homocysteine levels;
BRCA	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg20991723	chr1:152506922	NA	0.35	7.89	0.3	1.33e-14	Hair morphology;
BRCA	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg18904891	chr8:8559673	CLDN23	0.6	11.68	0.42	1.02e-28	Obesity-related traits;
BRCA	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg19678392	chr7:94953810	PON1	-0.42	-8.62	-0.32	5.29e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg21782813	chr7:2030301	MAD1L1	0.32	9.17	0.34	6.18e-19	Schizophrenia;
BRCA	cis	rs34779708	0.733	rs12243593	chr10:35549045	C/T	cg03585969	chr10:35415529	CREM	0.44	9.1	0.34	1.17e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg04315214	chr1:2043799	PRKCZ	-0.44	-12.14	-0.43	1.18e-30	Height;
BRCA	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.49	-8.01	-0.3	5.28e-15	Parkinson's disease;
BRCA	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg07395648	chr5:131743802	NA	0.38	8.37	0.31	3.67e-16	Breast cancer;
BRCA	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg05347473	chr6:146136440	FBXO30	0.41	8.27	0.31	7.88e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg21573476	chr21:45109991	RRP1B	-0.48	-12.13	-0.43	1.24e-30	Mean corpuscular volume;
BRCA	cis	rs7760949	0.889	rs9396272	chr6:13938080	C/T	cg27413430	chr6:13925136	RNF182	-0.42	-8.45	-0.32	1.92e-16	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4478858	0.684	rs12121165	chr1:31725542	G/A	cg00250761	chr1:31883323	NA	-0.32	-8.3	-0.31	6.08e-16	Alcohol dependence;
BRCA	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg17724175	chr1:150552817	MCL1	-0.25	-8.36	-0.31	3.94e-16	Tonsillectomy;
BRCA	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	8.52	0.32	1.16e-16	Neuroticism;
BRCA	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10150615	chr22:24372951	LOC391322	-0.45	-10.27	-0.38	5.38e-23	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg22535103	chr8:58192502	C8orf71	-0.47	-8.26	-0.31	8.38e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	11.95	0.43	7.45e-30	Tonsillectomy;
BRCA	cis	rs7301826	0.651	rs10848210	chr12:131312020	G/A	cg11011512	chr12:131303247	STX2	0.52	13.72	0.48	9.48e-38	Plasma plasminogen activator levels;
BRCA	cis	rs9359856	0.564	rs72915904	chr6:90421412	C/A	cg13799429	chr6:90582589	CASP8AP2	-0.65	-8.08	-0.3	3.14e-15	Bipolar disorder;
BRCA	cis	rs35123781	1.000	rs600848	chr5:139057270	T/C	cg05227215	chr5:139057496	CXXC5	0.35	8.42	0.32	2.46e-16	Schizophrenia;
BRCA	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg06697600	chr4:7070879	GRPEL1	0.49	8.83	0.33	9.92e-18	Monocyte percentage of white cells;
BRCA	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11764359	chr7:65958608	NA	-0.75	-16.73	-0.55	2.18e-52	Aortic root size;
BRCA	cis	rs2463822	1.000	rs2463825	chr11:62094493	G/A	cg06239285	chr11:62104954	ASRGL1	0.66	11.05	0.4	4.1e-26	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg23229984	chr5:148520753	ABLIM3	0.37	9.17	0.34	6.47e-19	Breast cancer;
BRCA	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg20891283	chr12:69753455	YEATS4	0.56	11.38	0.41	1.82e-27	Response to diuretic therapy;
BRCA	cis	rs11608355	0.545	rs7316375	chr12:109906998	G/C	cg05360138	chr12:110035743	NA	0.69	12.79	0.45	1.72e-33	Neuroticism;
BRCA	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14240646	chr10:27532245	ACBD5	-0.62	-9.56	-0.35	2.58e-20	Breast cancer;
BRCA	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg03146154	chr1:46216737	IPP	0.45	10.1	0.37	2.28e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3740540	0.685	rs61870248	chr10:126267523	T/C	cg04949429	chr10:126290192	LHPP	-0.38	-7.99	-0.3	6.54e-15	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg14675211	chr2:100938903	LONRF2	0.48	11.05	0.4	4.14e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg22920501	chr2:26401640	FAM59B	-0.67	-11.5	-0.41	5.96e-28	Gut microbiome composition (summer);
BRCA	trans	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg00717180	chr2:96193071	NA	-0.38	-10.23	-0.38	7.55e-23	HDL cholesterol;
BRCA	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-13.45	-0.47	1.75e-36	Morning vs. evening chronotype;
BRCA	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg22907277	chr7:1156413	C7orf50	0.61	11.9	0.43	1.25e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg11608241	chr8:8085544	FLJ10661	0.28	7.82	0.3	2.19e-14	Mood instability;
BRCA	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	4.01e-15	Alzheimer's disease (late onset);
BRCA	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg24829409	chr8:58192753	C8orf71	-0.47	-9.12	-0.34	9.38e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.22	-0.31	1.12e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	12.41	0.44	8.15e-32	Platelet count;
BRCA	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	18.98	0.6	4.6e-64	Platelet count;
BRCA	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19748678	chr4:122722346	EXOSC9	0.74	16.02	0.54	8.68e-49	Type 2 diabetes;
BRCA	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.35	-0.31	4.34e-16	Colorectal cancer;
BRCA	cis	rs644148	0.836	rs2686776	chr19:45000366	T/C	cg15540054	chr19:45004280	ZNF180	-0.57	-12.28	-0.44	2.76e-31	Personality dimensions;
BRCA	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg18230493	chr5:56204884	C5orf35	-0.72	-14.12	-0.49	1.37e-39	Initial pursuit acceleration;
BRCA	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg07080220	chr10:102295463	HIF1AN	0.5	11.25	0.41	6.35e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg05340658	chr4:99064831	C4orf37	0.45	10.16	0.37	1.34e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs1003719	0.762	rs11701556	chr21:38455153	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.18	0.49	7.08e-40	Eye color traits;
BRCA	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg18357645	chr12:58087776	OS9	0.41	11.43	0.41	1.16e-27	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs13046373	0.535	rs9980934	chr21:31982988	C/T	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.4	0.35	9.41e-20	HDL cholesterol;
BRCA	cis	rs9309473	0.500	rs12996463	chr2:73655496	T/C	cg20560298	chr2:73613845	ALMS1	0.42	11.45	0.41	9.23e-28	Metabolite levels;
BRCA	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg03060546	chr3:49711283	APEH	0.59	10.36	0.38	2.36e-23	Menarche (age at onset);
BRCA	cis	rs1784581	0.761	rs7741581	chr6:162435250	C/T	cg17173639	chr6:162384350	PARK2	0.37	8.79	0.33	1.38e-17	Itch intensity from mosquito bite;
BRCA	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg11189052	chr15:85197271	WDR73	-0.33	-7.89	-0.3	1.35e-14	P wave terminal force;
BRCA	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg11764359	chr7:65958608	NA	-0.62	-13.14	-0.46	4.35e-35	Aortic root size;
BRCA	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.22	-0.31	1.16e-15	Axial length;
BRCA	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18876405	chr7:65276391	NA	-0.62	-15.48	-0.52	3.8e-46	Aortic root size;
BRCA	cis	rs11887277	0.507	rs7602471	chr2:27050727	G/A	cg12368169	chr2:27073192	DPYSL5	-0.28	-8.06	-0.3	3.76e-15	Obesity-related traits;
BRCA	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg03954927	chr1:10346856	KIF1B	0.48	15.23	0.52	6.45e-45	Hepatocellular carcinoma;
BRCA	cis	rs6433857	0.536	rs7557023	chr2:181350474	G/A	cg23363182	chr2:181467187	NA	-0.37	-7.87	-0.3	1.57e-14	Body mass index;
BRCA	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.63	13.69	0.48	1.36e-37	Lymphocyte percentage of white cells;
BRCA	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg22508957	chr16:3507546	NAT15	0.47	11.59	0.42	2.53e-28	Tuberculosis;
BRCA	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.02	0.48	4.03e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg27432699	chr2:27873401	GPN1	0.46	9.7	0.36	7.89e-21	Oral cavity cancer;
BRCA	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11644478	chr21:40555479	PSMG1	-0.5	-10.6	-0.39	2.81e-24	Menarche (age at onset);
BRCA	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.13	0.37	1.82e-22	Aortic root size;
BRCA	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg27147174	chr7:100797783	AP1S1	0.52	10.47	0.38	8.96e-24	Life satisfaction;
BRCA	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg04362960	chr10:104952993	NT5C2	0.43	9.84	0.36	2.32e-21	Arsenic metabolism;
BRCA	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg11366901	chr6:160182831	ACAT2	0.86	16.32	0.54	2.59e-50	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg06623918	chr6:96969491	KIAA0776	0.71	12.75	0.45	2.44e-33	Migraine;Coronary artery disease;
BRCA	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg07636037	chr3:49044803	WDR6	0.97	28.33	0.75	5.26e-115	Parkinson's disease;
BRCA	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.76	0.33	1.78e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6426558	0.537	rs2813969	chr1:227404082	T/C	cg10327440	chr1:227177885	CDC42BPA	0.46	9.18	0.34	5.86e-19	Neutrophil percentage of white cells;
BRCA	trans	rs61931739	0.591	rs4931764	chr12:33979423	A/G	cg26384229	chr12:38710491	ALG10B	0.4	8.94	0.33	4.07e-18	Morning vs. evening chronotype;
BRCA	cis	rs10465746	0.780	rs12145258	chr1:84401211	G/A	cg10977910	chr1:84465055	TTLL7	0.57	11.87	0.42	1.7e-29	Obesity-related traits;
BRCA	cis	rs12711979	0.509	rs10192699	chr2:3824297	A/G	cg17052675	chr2:3827356	NA	-0.7	-23.65	-0.68	2.6e-89	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs2066819	1.000	rs77447765	chr12:56690662	G/A	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-8.59	-0.32	6.79e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.77	0.39	5.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs208520	0.837	rs208471	chr6:66916749	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.3	-0.54	3.22e-50	Exhaled nitric oxide output;
BRCA	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg20203395	chr5:56204925	C5orf35	-0.5	-10.17	-0.37	1.24e-22	Initial pursuit acceleration;
BRCA	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg09754948	chr16:28834200	ATXN2L	0.45	9.03	0.34	2.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg06784218	chr1:46089804	CCDC17	0.52	12.56	0.44	1.72e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6545883	0.929	rs1209434	chr2:61672958	G/A	cg15711740	chr2:61764176	XPO1	-0.53	-13.35	-0.47	4.87e-36	Tuberculosis;
BRCA	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg02640540	chr1:67518911	SLC35D1	0.51	11.21	0.41	9.92e-27	Lymphocyte percentage of white cells;
BRCA	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.8	-0.33	1.23e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs490234	0.932	rs577026	chr9:128341023	C/T	cg14078157	chr9:128172775	NA	-0.38	-9.2	-0.34	5.19e-19	Mean arterial pressure;
BRCA	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg02659138	chr7:134003124	SLC35B4	0.4	11.58	0.42	2.85e-28	Mean platelet volume;
BRCA	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg00677455	chr12:58241039	CTDSP2	0.7	16.32	0.54	2.75e-50	Intelligence (multi-trait analysis);
BRCA	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg27446573	chr6:127587934	RNF146	0.78	17.09	0.56	3.21e-54	Breast cancer;
BRCA	cis	rs3750965	0.920	rs10896421	chr11:68863048	T/C	cg06818126	chr11:68850279	TPCN2	-0.37	-8.86	-0.33	7.61e-18	Hair color;
BRCA	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.62	-0.32	5.4e-17	Total body bone mineral density;
BRCA	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg23018236	chr17:30244563	NA	-0.71	-11.06	-0.4	3.71e-26	Hip circumference adjusted for BMI;
BRCA	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg22535103	chr8:58192502	C8orf71	-0.6	-13.26	-0.46	1.29e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.39	0.35	1e-19	Tonsillectomy;
BRCA	cis	rs34779708	0.771	rs12098283	chr10:35478115	G/T	cg03585969	chr10:35415529	CREM	0.48	10.03	0.37	4.52e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs877282	0.786	rs10904558	chr10:797509	C/T	cg22713356	chr15:30763199	NA	1.37	28.02	0.74	2.84e-113	Uric acid levels;
BRCA	cis	rs6543140	0.929	rs11465700	chr2:103057668	G/A	cg04239558	chr2:103089729	SLC9A4	0.34	9.41	0.35	8.88e-20	Blood protein levels;
BRCA	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg20607798	chr8:58055168	NA	0.47	8.02	0.3	5.03e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1538970	0.924	rs2088100	chr1:45877575	C/T	cg05343316	chr1:45956843	TESK2	0.63	12.76	0.45	2.21e-33	Platelet count;
BRCA	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-12.38	-0.44	1.08e-31	Morning vs. evening chronotype;
BRCA	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg22713356	chr15:30763199	NA	1.29	24.18	0.69	3.39e-92	Uric acid levels;
BRCA	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg20887711	chr4:1340912	KIAA1530	-0.7	-15.64	-0.53	6.52e-47	Longevity;
BRCA	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg26384229	chr12:38710491	ALG10B	0.57	13.16	0.46	3.66e-35	Morning vs. evening chronotype;
BRCA	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-14.8	-0.51	7.6e-43	Menarche (age at onset);
BRCA	trans	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg17145862	chr1:211918768	LPGAT1	-0.46	-10.67	-0.39	1.46e-24	Leprosy;
BRCA	cis	rs6450176	1.000	rs3776717	chr5:53298762	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.62	-15.07	-0.51	3.71e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs6546550	0.901	rs10496174	chr2:70153436	T/G	cg02498382	chr2:70120550	SNRNP27	-0.51	-11.12	-0.4	2.26e-26	Prevalent atrial fibrillation;
BRCA	cis	rs7264396	0.943	rs11167267	chr20:34109273	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-7.84	-0.3	1.96e-14	Total cholesterol levels;
BRCA	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg21573476	chr21:45109991	RRP1B	-0.36	-9.48	-0.35	4.75e-20	Mean corpuscular volume;
BRCA	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.86e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg01689657	chr7:91764605	CYP51A1	0.22	8.11	0.31	2.58e-15	Breast cancer;
BRCA	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg23018236	chr17:30244563	NA	-0.61	-10.04	-0.37	4.1e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-9.27	-0.34	2.75e-19	Colorectal cancer;
BRCA	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.62e-18	Alzheimer's disease (late onset);
BRCA	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	10.45	0.38	1.01e-23	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.58	0.55	1.23e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4594175	0.926	rs11157803	chr14:51627700	C/T	cg23942311	chr14:51606299	NA	0.32	8.22	0.31	1.16e-15	Cancer;
BRCA	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg03146154	chr1:46216737	IPP	-0.49	-10.82	-0.39	3.59e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg08000102	chr2:233561755	GIGYF2	0.63	13.47	0.47	1.35e-36	Coronary artery disease;
BRCA	cis	rs2455601	0.638	rs2742484	chr11:8988083	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-7.97	-0.3	7.19e-15	Schizophrenia;
BRCA	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg08601574	chr20:25228251	PYGB	0.34	8.32	0.31	5.21e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.35	-0.31	4.35e-16	Breast cancer;
BRCA	cis	rs1997103	1.000	rs1997103	chr7:55395390	C/G	cg17469321	chr7:55412551	NA	0.49	9.25	0.34	3.45e-19	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg20933634	chr6:27740509	NA	0.45	9.01	0.34	2.3e-18	Parkinson's disease;
BRCA	cis	rs4588572	0.606	rs4290994	chr5:77742253	C/T	cg11547950	chr5:77652471	NA	-0.42	-8.04	-0.3	4.5e-15	Triglycerides;
BRCA	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.79	-11.29	-0.41	4.28e-27	Schizophrenia;
BRCA	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg08213375	chr14:104286397	PPP1R13B	0.63	17.07	0.56	4.11e-54	Schizophrenia;
BRCA	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	10.02	0.37	4.78e-22	Bipolar disorder;
BRCA	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg04511125	chr2:88470314	THNSL2	0.92	13.36	0.47	4.43e-36	Plasma clusterin levels;
BRCA	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg02187348	chr16:89574699	SPG7	0.43	9.89	0.36	1.52e-21	Multiple myeloma (IgH translocation);
BRCA	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-16.69	-0.55	3.49e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	13.89	0.48	1.54e-38	Lymphocyte counts;
BRCA	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.56	-0.52	1.55e-46	Chronic sinus infection;
BRCA	trans	rs12517041	1.000	rs10079487	chr5:23294939	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg23711669	chr6:146136114	FBXO30	-0.76	-17.44	-0.57	5.18e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443189	0.570	rs6903448	chr6:76173832	C/T	cg01950844	chr6:76311363	SENP6	0.75	11.63	0.42	1.75e-28	Prostate cancer;
BRCA	trans	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.26	0.31	8.38e-16	Corneal astigmatism;
BRCA	cis	rs495337	0.965	rs2056991	chr20:48561280	T/C	cg17835207	chr20:48524531	SPATA2	-0.57	-12.93	-0.46	3.72e-34	Psoriasis;
BRCA	cis	rs11112613	0.713	rs11112587	chr12:105941285	G/A	cg03607813	chr12:105948248	NA	0.6	11.21	0.41	9.3e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs11229555	0.645	rs6591475	chr11:58193551	G/T	cg15696309	chr11:58395628	NA	0.45	9.64	0.36	1.31e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg25214090	chr10:38739885	LOC399744	0.56	12.25	0.44	3.95e-31	Corneal astigmatism;
BRCA	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.89e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg10556349	chr10:835070	NA	0.74	9.72	0.36	6.6e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs12995491	0.843	rs1878809	chr2:88518315	C/T	cg04511125	chr2:88470314	THNSL2	-0.45	-9.09	-0.34	1.2e-18	Response to metformin (IC50);
BRCA	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg24829409	chr8:58192753	C8orf71	-0.61	-12.6	-0.45	1.13e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18876405	chr7:65276391	NA	-0.55	-13.31	-0.47	7.27e-36	Aortic root size;
BRCA	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg01657329	chr11:68192670	LRP5	0.38	8.57	0.32	7.61e-17	Bone mineral density (spine);
BRCA	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg08738300	chr3:44038990	NA	0.44	8.6	0.32	6.11e-17	Coronary artery disease;
BRCA	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg13660082	chr14:53194042	PSMC6	-0.58	-8.74	-0.33	2.05e-17	Alzheimer's disease (late onset);
BRCA	cis	rs12579753	0.917	rs11610365	chr12:82218108	C/T	cg07988820	chr12:82153109	PPFIA2	-0.51	-8.64	-0.32	4.61e-17	Resting heart rate;
BRCA	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg21252483	chr19:49399788	TULP2	-0.42	-9.44	-0.35	7.09e-20	Red cell distribution width;
BRCA	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg23229984	chr5:148520753	ABLIM3	0.36	9.03	0.34	1.96e-18	Breast cancer;
BRCA	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.98	0.37	6.93e-22	Bipolar disorder;
BRCA	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg03709012	chr19:19516395	GATAD2A	0.81	19.12	0.6	8.79e-65	Tonsillectomy;
BRCA	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg04374321	chr14:90722782	PSMC1	0.75	21.12	0.64	1.65e-75	Mortality in heart failure;
BRCA	cis	rs4722166	0.532	rs1546763	chr7:22757843	G/A	cg05472934	chr7:22766657	IL6	0.42	10.54	0.38	4.6e-24	Lung cancer;
BRCA	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg22834771	chr12:69754056	YEATS4	-0.37	-9.06	-0.34	1.6e-18	Blood protein levels;
BRCA	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg21361702	chr7:150065534	REPIN1	0.49	9.99	0.37	6.08e-22	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs112217694	1.000	rs17196218	chr4:104658371	C/T	cg00875511	chr4:104641146	TACR3	-0.79	-8.51	-0.32	1.23e-16	Menarche (age at onset);
BRCA	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.81	13.5	0.47	9.75e-37	Schizophrenia;
BRCA	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.22e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.3e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-20.03	-0.62	1.28e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7131987	0.903	rs7970390	chr12:29398655	A/G	cg09582351	chr12:29534625	ERGIC2	-0.37	-8.89	-0.33	6.25e-18	QT interval;
BRCA	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg16325326	chr1:53192061	ZYG11B	0.9	23.98	0.69	4.18e-91	Monocyte count;
BRCA	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.59e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg12292205	chr6:26970375	C6orf41	-0.4	-8.08	-0.3	3.33e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9473147	0.516	rs6903331	chr6:47562915	A/G	cg12968598	chr6:47444699	CD2AP	0.44	9.62	0.36	1.56e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11764359	chr7:65958608	NA	0.78	18.6	0.59	4.85e-62	Aortic root size;
BRCA	cis	rs4594175	0.926	rs12432356	chr14:51631223	T/G	cg23942311	chr14:51606299	NA	0.33	8.3	0.31	6.24e-16	Cancer;
BRCA	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg09184832	chr6:79620586	NA	-0.48	-10.52	-0.38	5.72e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg09307838	chr4:120376055	NA	0.51	10.45	0.38	1.03e-23	Educational attainment;
BRCA	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg25237894	chr2:233734115	C2orf82	0.4	11.5	0.41	6.01e-28	Coronary artery disease;
BRCA	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg25019033	chr10:957182	NA	-0.41	-7.82	-0.3	2.14e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs9810890	1.000	rs73196999	chr3:128460581	G/A	cg15033153	chr3:128514015	RAB7A	0.7	8.08	0.3	3.34e-15	Dental caries;
BRCA	cis	rs13223928	0.621	rs4722440	chr7:3155901	C/T	cg19214707	chr7:3157722	NA	0.43	10.61	0.39	2.58e-24	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
BRCA	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg20307385	chr11:47447363	PSMC3	-0.43	-9.14	-0.34	8.32e-19	Subjective well-being;
BRCA	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg08470875	chr2:26401718	FAM59B	-0.63	-9.45	-0.35	6.52e-20	Gut microbiome composition (summer);
BRCA	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-14.8	-0.51	7.97e-43	Total cholesterol levels;
BRCA	cis	rs11229555	0.574	rs12292024	chr11:58186716	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.71	-0.36	7.23e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg20991723	chr1:152506922	NA	0.39	8.95	0.33	3.87e-18	Hair morphology;
BRCA	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg02753203	chr1:228287806	NA	-0.6	-13.01	-0.46	1.74e-34	Diastolic blood pressure;
BRCA	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg17366294	chr4:99064904	C4orf37	0.44	10.37	0.38	2.18e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg12310025	chr6:25882481	NA	0.71	17.2	0.56	8.61e-55	Blood metabolite levels;
BRCA	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	20.02	0.62	1.47e-69	Chronic sinus infection;
BRCA	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg14926445	chr8:58193284	C8orf71	-0.44	-8.25	-0.31	8.87e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg01256987	chr12:42539512	GXYLT1	-0.42	-8.08	-0.3	3.18e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg23978390	chr7:1156363	C7orf50	0.41	10.01	0.37	5.05e-22	Longevity;Endometriosis;
BRCA	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg00074818	chr8:8560427	CLDN23	0.38	8.27	0.31	7.99e-16	Obesity-related traits;
BRCA	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg04166393	chr7:2884313	GNA12	0.48	9.2	0.34	5.15e-19	Height;
BRCA	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	10.81	0.39	4.08e-25	Personality dimensions;
BRCA	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg04607235	chr12:12878440	APOLD1	-0.56	-9.06	-0.34	1.55e-18	Systemic lupus erythematosus;
BRCA	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.13	0.37	1.76e-22	Aortic root size;
BRCA	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-15.16	-0.51	1.47e-44	Bipolar disorder and schizophrenia;
BRCA	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg09307838	chr4:120376055	NA	0.69	13.97	0.48	6.93e-39	Corneal astigmatism;
BRCA	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-9.71	-0.36	6.91e-21	Tonsillectomy;
BRCA	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.59e-24	Motion sickness;
BRCA	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg00717180	chr2:96193071	NA	-0.38	-10.34	-0.38	2.9e-23	HDL cholesterol;
BRCA	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.45	8.56	0.32	8.61e-17	Lung disease severity in cystic fibrosis;
BRCA	trans	rs7980799	0.682	rs1447873	chr12:33615236	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-10.61	-0.39	2.49e-24	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg15017067	chr4:17643749	FAM184B	0.26	7.88	0.3	1.46e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg05347473	chr6:146136440	FBXO30	-0.41	-7.97	-0.3	7.08e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg13256891	chr4:100009986	ADH5	-0.5	-9.49	-0.35	4.68e-20	Alcohol dependence;
BRCA	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.68	0.42	1.07e-28	Tonsillectomy;
BRCA	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg26769984	chr7:1090371	C7orf50	0.49	8.99	0.34	2.82e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs13223928	0.605	rs10951052	chr7:3155301	A/G	cg19214707	chr7:3157722	NA	-0.37	-8.08	-0.3	3.36e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
BRCA	cis	rs7766436	0.614	rs11753682	chr6:22566908	C/T	cg13666174	chr6:22585274	NA	-0.41	-8.66	-0.32	3.86e-17	Coronary artery disease;
BRCA	trans	rs12517041	1.000	rs10941982	chr5:23298902	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs897984	0.574	rs11647284	chr16:31077335	G/A	cg00531865	chr16:30841666	NA	-0.38	-8.79	-0.33	1.42e-17	Dementia with Lewy bodies;
BRCA	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg23625390	chr15:77176239	SCAPER	-0.56	-14.11	-0.49	1.55e-39	Blood metabolite levels;
BRCA	cis	rs3857067	0.806	rs2171379	chr4:95100243	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-8.99	-0.33	2.87e-18	QT interval;
BRCA	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg05340658	chr4:99064831	C4orf37	0.51	9.66	0.36	1.03e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg25326776	chr5:148520934	ABLIM3	-0.44	-8.07	-0.3	3.41e-15	Breast cancer;
BRCA	cis	rs9649465	0.561	rs631445	chr7:123413707	C/T	cg03229431	chr7:123269106	ASB15	-0.44	-9.99	-0.37	6.24e-22	Migraine;
BRCA	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.05	21.83	0.65	2.38e-79	Gut microbiome composition (summer);
BRCA	cis	rs10193935	1.000	rs58962161	chr2:42400278	T/A	cg27598129	chr2:42591480	NA	-0.59	-9.82	-0.36	2.69e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00149659	chr3:10157352	C3orf10	0.77	13.27	0.46	1.17e-35	Alzheimer's disease;
BRCA	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.19	0.4	1.19e-26	Homoarginine levels;
BRCA	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.47	-0.32	1.73e-16	Total body bone mineral density;
BRCA	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19748678	chr4:122722346	EXOSC9	0.74	16.41	0.54	9.23e-51	Type 2 diabetes;
BRCA	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.78	-0.42	4.09e-29	Bipolar disorder;
BRCA	cis	rs250677	1.000	rs190378	chr5:148434275	G/T	cg12140854	chr5:148520817	ABLIM3	-0.4	-8.45	-0.32	2.04e-16	Breast cancer;
BRCA	cis	rs3820928	0.874	rs10169717	chr2:227796911	T/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.84	-0.33	9.34e-18	Pulmonary function;
BRCA	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg06784218	chr1:46089804	CCDC17	0.45	10.91	0.4	1.54e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg08888203	chr3:10149979	C3orf24	0.58	11.86	0.42	1.8e-29	Alzheimer's disease;
BRCA	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg03676636	chr4:99064102	C4orf37	0.21	7.98	0.3	6.8e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04565464	chr8:145669602	NFKBIL2	0.35	8.72	0.33	2.47e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs17228212	1.000	rs10152987	chr15:67451721	G/A	cg26876701	chr15:67458665	SMAD3	-0.44	-8.41	-0.32	2.66e-16	Coronary heart disease;
BRCA	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.08e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs311392	0.902	rs681000	chr8:55094043	C/T	cg11783602	chr8:55087084	NA	-0.32	-9.36	-0.35	1.36e-19	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.02	-0.34	2.15e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg10224037	chr5:178157518	ZNF354A	0.77	17.65	0.57	4.35e-57	Neutrophil percentage of white cells;
BRCA	cis	rs17023223	0.537	rs11487668	chr1:119726796	T/C	cg05756136	chr1:119680316	WARS2	-0.42	-8.05	-0.3	3.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg11663144	chr21:46675770	NA	-0.55	-12.77	-0.45	2.06e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs36096196	0.891	rs12082516	chr1:2251160	C/T	cg18313694	chr15:45480185	SHF	-0.43	-8.44	-0.32	2.17e-16	Coronary artery disease;
BRCA	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.53	11.59	0.42	2.61e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg20991723	chr1:152506922	NA	0.38	8.61	0.32	5.89e-17	Hair morphology;
BRCA	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	11.44	0.41	1.07e-27	Multiple sclerosis;
BRCA	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg16049864	chr8:95962084	TP53INP1	-0.49	-12.19	-0.43	6.83e-31	Type 2 diabetes;
BRCA	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.51	-9.89	-0.36	1.52e-21	Body mass index;
BRCA	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg03264133	chr6:25882463	NA	0.38	8.19	0.31	1.45e-15	Blood metabolite levels;
BRCA	cis	rs6546550	0.935	rs2168115	chr2:70034793	A/G	cg02498382	chr2:70120550	SNRNP27	-0.48	-10.0	-0.37	5.72e-22	Prevalent atrial fibrillation;
BRCA	trans	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	8.92e-15	Corneal astigmatism;
BRCA	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg06115741	chr20:33292138	TP53INP2	-0.4	-8.78	-0.33	1.47e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg05340658	chr4:99064831	C4orf37	-0.46	-10.55	-0.39	4.27e-24	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg17675199	chr6:35436792	RPL10A	-0.31	-8.3	-0.31	6.43e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.45	-0.32	2.03e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg24044776	chr19:53454761	ZNF816A	0.42	9.51	0.35	3.89e-20	Psoriasis;
BRCA	cis	rs9902453	0.791	rs3115086	chr17:28025949	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	14.3	0.49	1.88e-40	Coffee consumption (cups per day);
BRCA	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.8e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs4285028	0.948	rs12493952	chr3:121708497	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.58	-10.85	-0.39	2.82e-25	Multiple sclerosis;
BRCA	cis	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg17168535	chr8:21777572	XPO7	0.42	9.23	0.34	4.02e-19	Mean corpuscular volume;
BRCA	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg20203395	chr5:56204925	C5orf35	-0.42	-9.42	-0.35	8.19e-20	Initial pursuit acceleration;
BRCA	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg23285459	chr7:2802560	GNA12	-0.29	-7.81	-0.3	2.44e-14	Height;
BRCA	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18404041	chr3:52824283	ITIH1	-0.48	-15.12	-0.51	2.21e-44	Bipolar disorder;
BRCA	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-15.84	-0.53	6.63e-48	Systemic lupus erythematosus;
BRCA	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg20818283	chr2:191399100	TMEM194B	0.38	8.94	0.33	4.06e-18	Pulse pressure;
BRCA	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg15395560	chr15:45543142	SLC28A2	0.3	8.32	0.31	5.4e-16	Uric acid levels;
BRCA	trans	rs9409565	0.826	rs4744345	chr9:97207669	G/A	cg05679027	chr9:99775184	HIATL2	-0.43	-9.44	-0.35	6.67e-20	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs7560272	0.501	rs2421675	chr2:73955301	C/A	cg20560298	chr2:73613845	ALMS1	0.33	8.5	0.32	1.3e-16	Schizophrenia;
BRCA	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg17971929	chr21:40555470	PSMG1	-0.61	-13.46	-0.47	1.59e-36	Cognitive function;
BRCA	cis	rs977987	0.735	rs166013	chr16:75434146	C/T	cg07303275	chr16:75499416	TMEM170A	-0.36	-7.98	-0.3	6.95e-15	Dupuytren's disease;
BRCA	trans	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.06	0.3	3.87e-15	Endometrial cancer;
BRCA	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-13.05	-0.46	1.11e-34	Joint mobility (Beighton score);
BRCA	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23583168	chr7:148888333	NA	-0.96	-25.88	-0.72	1.37e-101	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6088813	1.000	rs6142373	chr20:33983314	T/A	cg14752227	chr20:34000481	UQCC	-0.39	-8.33	-0.31	4.79e-16	Height;
BRCA	cis	rs3771570	1.000	rs73002147	chr2:242302934	T/C	cg21155796	chr2:242212141	HDLBP	0.6	9.23	0.34	3.83e-19	Prostate cancer;
BRCA	cis	rs795544	0.507	rs1995389	chr5:13785118	G/A	cg07548982	chr5:13769939	DNAH5	-0.38	-7.94	-0.3	9.17e-15	Corneal astigmatism;
BRCA	trans	rs9951602	0.512	rs4799249	chr18:76654370	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	18.3	0.59	1.73e-60	Obesity-related traits;
BRCA	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg18016565	chr1:150552671	MCL1	0.37	8.68	0.32	3.35e-17	Tonsillectomy;
BRCA	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.2	0.68	7.62e-87	Chronic sinus infection;
BRCA	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg12444411	chr7:2802554	GNA12	-0.33	-8.27	-0.31	7.86e-16	Height;
BRCA	cis	rs490234	0.966	rs545900	chr9:128341278	C/T	cg14078157	chr9:128172775	NA	0.37	9.11	0.34	1.01e-18	Mean arterial pressure;
BRCA	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg18252515	chr7:66147081	NA	-1.06	-15.85	-0.53	6.1e-48	Diabetic kidney disease;
BRCA	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.14	0.49	1.04e-39	Eye color traits;
BRCA	cis	rs977987	0.778	rs4888413	chr16:75443223	C/A	cg03315344	chr16:75512273	CHST6	0.53	12.52	0.44	2.66e-32	Dupuytren's disease;
BRCA	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	14.38	0.49	7.85e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs877529	0.932	rs139403	chr22:39547021	G/A	cg18708252	chr22:39545030	CBX7	-0.31	-8.17	-0.31	1.66e-15	Multiple myeloma;
BRCA	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg21951975	chr1:209979733	IRF6	0.38	9.14	0.34	8.28e-19	Cleft lip with or without cleft palate;
BRCA	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg23285459	chr7:2802560	GNA12	-0.34	-8.64	-0.32	4.6e-17	Height;
BRCA	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg15934090	chr1:100435551	SLC35A3	0.35	8.15	0.31	1.91e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg15133208	chr4:90757351	SNCA	-0.38	-7.85	-0.3	1.73e-14	Neuroticism;
BRCA	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.39	2.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7833986	0.501	rs72653959	chr8:56996516	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	12.99	0.46	2.13e-34	Height;
BRCA	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-12.55	-0.44	1.8e-32	Personality dimensions;
BRCA	trans	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg17675199	chr6:35436792	RPL10A	0.3	7.89	0.3	1.31e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg17848003	chr1:3704513	LRRC47	0.25	7.81	0.3	2.3e-14	Red cell distribution width;
BRCA	cis	rs12579753	0.871	rs12822050	chr12:82183041	C/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-8.46	-0.32	1.8e-16	Resting heart rate;
BRCA	cis	rs2637266	0.935	rs1866891	chr10:78396941	C/A	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18876405	chr7:65276391	NA	-0.57	-13.62	-0.47	3e-37	Aortic root size;
BRCA	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg02743256	chr7:2109353	MAD1L1	-0.45	-8.4	-0.32	2.95e-16	Bipolar disorder;
BRCA	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg12483005	chr1:23474871	LUZP1	0.47	10.25	0.38	6.45e-23	Height;
BRCA	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg22903471	chr2:27725779	GCKR	-0.38	-9.45	-0.35	6.07e-20	Total body bone mineral density;
BRCA	cis	rs877282	0.898	rs11253339	chr10:759640	C/T	cg17470449	chr10:769945	NA	0.48	8.19	0.31	1.45e-15	Uric acid levels;
BRCA	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg11266682	chr4:10021025	SLC2A9	0.5	13.18	0.46	3.04e-35	Bone mineral density;
BRCA	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg23711669	chr6:146136114	FBXO30	0.65	14.82	0.51	6.27e-43	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg22713356	chr15:30763199	NA	1.19	24.18	0.69	3.39e-92	Uric acid levels;
BRCA	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-9.61	-0.36	1.58e-20	Schizophrenia;
BRCA	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	8.08	0.3	3.22e-15	Uric acid levels;
BRCA	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg05347473	chr6:146136440	FBXO30	0.54	10.31	0.38	3.7e-23	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg06521331	chr12:34319734	NA	-0.47	-8.74	-0.33	2e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10193935	0.901	rs55978605	chr2:42573402	C/A	cg27598129	chr2:42591480	NA	-0.86	-14.02	-0.49	3.8e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg13852791	chr20:30311386	BCL2L1	0.84	16.58	0.55	1.35e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02475777	chr4:1388615	CRIPAK	0.69	13.02	0.46	1.51e-34	Longevity;
BRCA	trans	rs75804782	0.630	rs3739070	chr2:239306268	A/C	cg01134436	chr17:81009848	B3GNTL1	0.76	8.18	0.31	1.48e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs6484504	0.576	rs2756191	chr11:31135882	A/T	cg14844989	chr11:31128820	NA	0.42	9.16	0.34	6.83e-19	Red blood cell count;
BRCA	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg03684893	chr10:554711	DIP2C	-0.4	-10.02	-0.37	4.73e-22	Psychosis in Alzheimer's disease;
BRCA	trans	rs208520	0.690	rs851458	chr6:66813279	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-21.04	-0.64	4.74e-75	Exhaled nitric oxide output;
BRCA	cis	rs2882667	0.690	rs825761	chr5:138138007	A/G	cg04439458	chr5:138467593	SIL1	0.31	7.89	0.3	1.27e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs367615	0.918	rs72797472	chr5:108881343	C/T	cg17395555	chr5:108820864	NA	0.38	9.57	0.35	2.31e-20	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg26149184	chr10:133730230	NA	0.41	8.15	0.31	1.9e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg11833968	chr6:79620685	NA	-0.41	-9.02	-0.34	2.16e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs12618769	0.652	rs6736755	chr2:99204428	A/G	cg10123293	chr2:99228465	UNC50	-0.41	-8.53	-0.32	1.06e-16	Bipolar disorder;
BRCA	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg03688085	chr1:1910585	KIAA1751	-0.54	-11.42	-0.41	1.29e-27	Severe influenza A (H1N1) infection;
BRCA	trans	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg19862616	chr7:65841803	NCRNA00174	0.85	28.37	0.75	3.22e-115	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg21248554	chr2:27665150	KRTCAP3	-0.36	-9.26	-0.34	2.94e-19	Total body bone mineral density;
BRCA	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26314531	chr2:26401878	FAM59B	-0.84	-15.68	-0.53	3.92e-47	Gut microbiome composition (summer);
BRCA	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg05457628	chr5:178986728	RUFY1	0.45	9.75	0.36	4.96e-21	Lung cancer;
BRCA	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg13319975	chr6:146136371	FBXO30	0.41	9.3	0.35	2.13e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg18301423	chr5:131593218	PDLIM4	0.35	8.75	0.33	1.93e-17	Acylcarnitine levels;
BRCA	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg03954927	chr1:10346856	KIF1B	0.47	14.99	0.51	1e-43	Hepatocellular carcinoma;
BRCA	cis	rs3892630	0.878	rs66788054	chr19:33190146	G/T	cg22980127	chr19:33182716	NUDT19	0.9	18.06	0.58	3.08e-59	Red blood cell traits;
BRCA	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg23205692	chr1:25664452	TMEM50A	0.42	10.0	0.37	5.9e-22	Plateletcrit;Mean corpuscular volume;
BRCA	cis	rs7246657	0.551	rs10419174	chr19:37605341	A/G	cg23950597	chr19:37808831	NA	-0.64	-9.53	-0.35	3.31e-20	Coronary artery calcification;
BRCA	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg12658694	chr1:38397304	INPP5B	0.4	8.46	0.32	1.83e-16	Coronary artery disease;
BRCA	cis	rs1829883	0.898	rs1464639	chr5:98786821	A/G	cg08333243	chr5:99726346	NA	-0.35	-7.97	-0.3	7.41e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg16482183	chr6:26056742	HIST1H1C	0.47	9.31	0.35	2.05e-19	Iron status biomarkers;
BRCA	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg08805041	chr16:621841	PIGQ	-0.32	-8.87	-0.33	7.31e-18	Height;
BRCA	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg23711669	chr6:146136114	FBXO30	0.65	15.3	0.52	2.9e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg26587870	chr6:27730563	NA	-0.42	-9.05	-0.34	1.75e-18	Parkinson's disease;
BRCA	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.22	-0.44	5.29e-31	Chronic sinus infection;
BRCA	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18876405	chr7:65276391	NA	-0.61	-14.9	-0.51	2.7e-43	Aortic root size;
BRCA	cis	rs847649	0.842	rs869332	chr7:102632247	A/G	cg18108683	chr7:102477205	FBXL13	-0.4	-9.49	-0.35	4.61e-20	Morning vs. evening chronotype;
BRCA	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg08000102	chr2:233561755	GIGYF2	-0.47	-10.35	-0.38	2.51e-23	Coronary artery disease;
BRCA	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg16339924	chr4:17578868	LAP3	0.71	16.87	0.56	4.12e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7851660	0.935	rs12347191	chr9:100619719	C/T	cg13688889	chr9:100608707	NA	-0.36	-8.74	-0.33	2.08e-17	Strep throat;
BRCA	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg12365402	chr11:9010492	NRIP3	0.38	8.28	0.31	7.25e-16	Hemoglobin concentration;
BRCA	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.63e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg13010199	chr12:38710504	ALG10B	0.5	10.42	0.38	1.39e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4363385	0.747	rs4319267	chr1:152972699	T/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.22	-0.31	1.13e-15	Inflammatory skin disease;
BRCA	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg16558253	chr16:72132732	DHX38	0.37	9.1	0.34	1.1e-18	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	trans	rs10411161	0.690	rs7252336	chr19:52389514	C/T	cg22319618	chr22:45562946	NUP50	-0.42	-8.02	-0.3	4.89e-15	Breast cancer;
BRCA	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg08975724	chr8:8085496	FLJ10661	0.5	11.13	0.4	1.93e-26	Mood instability;
BRCA	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	22.21	0.66	2e-81	Platelet count;
BRCA	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg14004847	chr7:1930337	MAD1L1	-0.44	-8.95	-0.33	3.78e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg20307385	chr11:47447363	PSMC3	-0.38	-8.04	-0.3	4.24e-15	Subjective well-being;
BRCA	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg09754948	chr16:28834200	ATXN2L	0.47	9.44	0.35	6.65e-20	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-10.17	-0.37	1.23e-22	Morning vs. evening chronotype;
BRCA	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg22834771	chr12:69754056	YEATS4	-0.42	-10.58	-0.39	3.25e-24	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs629535	0.814	rs488231	chr8:70064993	T/C	cg21567404	chr3:27674614	NA	1.01	20.79	0.64	9.62e-74	Dupuytren's disease;
BRCA	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg23260525	chr10:116636907	FAM160B1	0.3	7.91	0.3	1.12e-14	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg06046430	chr4:77819534	ANKRD56	0.62	14.01	0.48	4.21e-39	Emphysema distribution in smoking;
BRCA	cis	rs17023223	0.509	rs56195272	chr1:119713997	A/T	cg05756136	chr1:119680316	WARS2	-0.42	-8.05	-0.3	3.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs7474896	0.537	rs1022449	chr10:38279467	T/A	cg25427524	chr10:38739819	LOC399744	0.54	9.63	0.36	1.4e-20	Obesity (extreme);
BRCA	cis	rs7904368	0.806	rs7899923	chr10:16857394	G/A	cg14835575	chr10:16859367	RSU1	0.61	12.44	0.44	5.82e-32	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg20307385	chr11:47447363	PSMC3	-0.41	-9.68	-0.36	9.19e-21	Subjective well-being;
BRCA	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	10.9	0.4	1.8e-25	Rheumatoid arthritis;
BRCA	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-8.19	-0.31	1.37e-15	Response to antipsychotic treatment;
BRCA	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg11846333	chr4:119757529	SEC24D	0.61	7.97	0.3	7.34e-15	Cannabis dependence symptom count;
BRCA	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.04	21.12	0.64	1.61e-75	Gut microbiome composition (summer);
BRCA	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.55	10.5	0.38	6.63e-24	HDL cholesterol;
BRCA	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05926928	chr17:57297772	GDPD1	1.2	16.06	0.54	5.5e-49	Opioid sensitivity;
BRCA	cis	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg19338460	chr6:170058176	WDR27	-0.44	-7.89	-0.3	1.28e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs10851411	0.559	rs17767270	chr15:42898612	A/G	cg21293051	chr15:42870591	STARD9	-0.46	-7.94	-0.3	8.97e-15	Glucose homeostasis traits;
BRCA	cis	rs9658691	0.607	rs3740281	chr10:90772150	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.55	-8.04	-0.3	4.34e-15	Mosquito bite size;
BRCA	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg10523679	chr1:76189770	ACADM	0.76	15.96	0.53	1.58e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg21475434	chr5:93447410	FAM172A	0.67	8.51	0.32	1.24e-16	Diabetic retinopathy;
BRCA	trans	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg04565464	chr8:145669602	NFKBIL2	0.35	8.71	0.33	2.55e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs2012796	1.000	rs8009171	chr14:81820060	G/A	cg02996355	chr14:81879375	NA	0.49	9.72	0.36	6.62e-21	Night sleep phenotypes;
BRCA	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.33	8.66	0.32	3.97e-17	IgG glycosylation;
BRCA	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.63	0.36	1.41e-20	Menopause (age at onset);
BRCA	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg09307838	chr4:120376055	NA	0.71	14.51	0.5	1.94e-41	Corneal astigmatism;
BRCA	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg07700843	chr1:2391317	NA	-0.38	-8.87	-0.33	7.4e-18	Schizophrenia;
BRCA	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg18252515	chr7:66147081	NA	-0.82	-11.87	-0.43	1.67e-29	Diabetic kidney disease;
BRCA	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	13.19	0.46	2.51e-35	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs208520	0.661	rs207079	chr6:66770462	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-21.29	-0.64	2.05e-76	Exhaled nitric oxide output;
BRCA	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg16590910	chr6:42928470	GNMT	0.42	9.3	0.35	2.26e-19	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg08975724	chr8:8085496	FLJ10661	0.5	10.64	0.39	1.9e-24	Mood instability;
BRCA	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-9.08	-0.34	1.37e-18	Retinal vascular caliber;
BRCA	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg21138405	chr5:131827807	IRF1	0.4	13.0	0.46	1.85e-34	Asthma (sex interaction);
BRCA	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.24	0.34	3.64e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00149659	chr3:10157352	C3orf10	0.74	12.95	0.46	3.21e-34	Alzheimer's disease;
BRCA	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.34	8.08	0.3	3.21e-15	Tonsillectomy;
BRCA	cis	rs13102973	0.931	rs4608864	chr4:135883488	G/A	cg14419869	chr4:135874104	NA	0.55	11.41	0.41	1.41e-27	Subjective well-being;
BRCA	trans	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg15704280	chr7:45808275	SEPT13	0.55	8.22	0.31	1.18e-15	Axial length;
BRCA	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11764359	chr7:65958608	NA	0.75	16.57	0.55	1.37e-51	Aortic root size;
BRCA	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.8	-0.62	2.12e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg23033748	chr14:75592666	NEK9	-0.35	-8.17	-0.31	1.7e-15	Height;
BRCA	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg14789911	chr21:47582049	C21orf56	0.38	8.14	0.31	2.04e-15	Testicular germ cell tumor;
BRCA	cis	rs1707322	1.000	rs1707303	chr1:46598273	A/C	cg03146154	chr1:46216737	IPP	-0.42	-8.82	-0.33	1.08e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.02	-0.49	3.98e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7246657	0.722	rs1564208	chr19:38041221	A/G	cg23950597	chr19:37808831	NA	-0.51	-8.79	-0.33	1.43e-17	Coronary artery calcification;
BRCA	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg13789015	chr9:136890014	NCRNA00094	-0.73	-15.22	-0.52	7.46e-45	Platelet distribution width;
BRCA	cis	rs9902453	0.791	rs3115090	chr17:28035014	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	14.47	0.5	2.96e-41	Coffee consumption (cups per day);
BRCA	cis	rs965469	1.000	rs3310	chr20:3237232	C/T	cg25506879	chr20:3388711	C20orf194	-0.54	-10.45	-0.38	1.02e-23	IFN-related cytopenia;
BRCA	cis	rs2637266	0.967	rs2579748	chr10:78328313	T/C	cg18941641	chr10:78392320	NA	0.35	7.99	0.3	6.18e-15	Pulmonary function;
BRCA	trans	rs3857536	0.740	rs7763555	chr6:66889930	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-9.67	-0.36	1.01e-20	Blood trace element (Cu levels);
BRCA	cis	rs897984	0.683	rs729482	chr16:31016970	T/C	cg00531865	chr16:30841666	NA	-0.35	-8.01	-0.3	5.56e-15	Dementia with Lewy bodies;
BRCA	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg17063962	chr7:91808500	NA	0.59	12.44	0.44	5.65e-32	Breast cancer;
BRCA	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg12310025	chr6:25882481	NA	0.71	17.25	0.56	4.82e-55	Blood metabolite levels;
BRCA	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg12648201	chr2:27665141	KRTCAP3	0.36	8.82	0.33	1.1e-17	Total body bone mineral density;
BRCA	cis	rs586533	0.881	rs623710	chr11:99505577	G/A	cg22878054	chr11:99397252	CNTN5	0.32	8.12	0.31	2.44e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs11971779	0.648	rs28754644	chr7:139065057	C/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.21	0.37	9.03e-23	Diisocyanate-induced asthma;
BRCA	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg24558204	chr6:135376177	HBS1L	0.46	12.62	0.45	8.89e-33	Red blood cell count;
BRCA	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	19.95	0.62	3.19e-69	Smoking behavior;
BRCA	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.1	0.31	2.83e-15	Parkinson's disease;
BRCA	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg22535103	chr8:58192502	C8orf71	-0.46	-9.03	-0.34	1.97e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.13	0.31	2.29e-15	Breast cancer;
BRCA	cis	rs3857067	0.806	rs7654919	chr4:95136164	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.58	-0.35	2.04e-20	QT interval;
BRCA	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10802521	chr3:52805072	NEK4	-0.33	-8.8	-0.33	1.3e-17	Bipolar disorder;
BRCA	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg04234412	chr22:24373322	LOC391322	-0.57	-13.56	-0.47	5.19e-37	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg26408565	chr15:76604113	ETFA	-0.53	-12.22	-0.44	5.34e-31	Blood metabolite levels;
BRCA	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg26528668	chr16:1614120	IFT140	-0.36	-8.01	-0.3	5.64e-15	Coronary artery disease;
BRCA	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11764359	chr7:65958608	NA	-0.77	-17.78	-0.58	9.24e-58	Aortic root size;
BRCA	cis	rs798766	1.000	rs3752749	chr4:1737262	T/C	cg10756475	chr4:1757242	NA	0.37	8.47	0.32	1.64e-16	Bladder cancer;Urinary bladder cancer;
BRCA	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg13010199	chr12:38710504	ALG10B	0.49	9.41	0.35	8.94e-20	Morning vs. evening chronotype;
BRCA	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg12373951	chr3:133503437	NA	0.53	12.86	0.45	8.33e-34	Iron status biomarkers;
BRCA	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-16.22	-0.54	7.89e-50	Alzheimer's disease (late onset);
BRCA	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg25319279	chr11:5960081	NA	-0.42	-8.43	-0.32	2.29e-16	DNA methylation (variation);
BRCA	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs7617773	0.817	rs35414021	chr3:48293524	G/C	cg11946769	chr3:48343235	NME6	0.67	13.85	0.48	2.39e-38	Coronary artery disease;
BRCA	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-10.22	-0.37	8.01e-23	Schizophrenia;
BRCA	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg26587870	chr6:27730563	NA	-0.4	-8.59	-0.32	6.5e-17	Parkinson's disease;
BRCA	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg00277334	chr10:82204260	NA	-0.43	-8.18	-0.31	1.58e-15	Post bronchodilator FEV1;
BRCA	cis	rs4930561	0.739	rs10896303	chr11:67974292	C/A	cg16338278	chr11:67432957	ALDH3B2	0.44	8.87	0.33	7.39e-18	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.42	-8.69	-0.33	2.96e-17	Rheumatoid arthritis;
BRCA	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg21770322	chr7:97807741	LMTK2	0.43	11.54	0.42	4.06e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11051970	0.679	rs2651377	chr12:32556919	A/C	cg02745156	chr12:32552066	NA	0.25	8.49	0.32	1.48e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg20607798	chr8:58055168	NA	0.46	8.08	0.3	3.19e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.57	11.09	0.4	2.88e-26	Birth weight;
BRCA	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21659725	chr3:3221576	CRBN	-0.47	-9.71	-0.36	7.05e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg13319975	chr6:146136371	FBXO30	-0.44	-10.12	-0.37	2e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg10523679	chr1:76189770	ACADM	0.74	15.17	0.51	1.25e-44	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg17063962	chr7:91808500	NA	0.55	12.95	0.46	3.28e-34	Breast cancer;
BRCA	cis	rs9815354	0.812	rs4434125	chr3:42004681	A/G	cg03022575	chr3:42003672	ULK4	0.74	10.27	0.38	5.43e-23	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg07169764	chr2:136633963	MCM6	1.07	23.76	0.68	6.81e-90	Corneal structure;
BRCA	cis	rs698833	0.547	rs1067355	chr2:44663152	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.47	-8.41	-0.32	2.6e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg23625390	chr15:77176239	SCAPER	-0.55	-12.83	-0.45	1.08e-33	Blood metabolite levels;
BRCA	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21582582	chr3:182698605	DCUN1D1	0.37	9.54	0.35	2.88e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg23018236	chr17:30244563	NA	-0.61	-10.02	-0.37	4.87e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.68	-16.27	-0.54	4.94e-50	Ileal carcinoids;
BRCA	cis	rs6878727	0.665	rs698181	chr5:123667269	T/C	cg01806427	chr5:123737813	NA	-0.37	-8.27	-0.31	7.92e-16	Breast cancer;
BRCA	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg22535103	chr8:58192502	C8orf71	-0.61	-13.8	-0.48	4.41e-38	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg25214090	chr10:38739885	LOC399744	0.54	12.1	0.43	1.72e-30	Corneal astigmatism;
BRCA	cis	rs9868809	0.772	rs9836462	chr3:48712791	C/T	cg00383909	chr3:49044727	WDR6	-0.4	-7.83	-0.3	2.07e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg13393036	chr8:95962371	TP53INP1	0.34	8.5	0.32	1.38e-16	Type 2 diabetes;
BRCA	cis	rs9815354	0.812	rs73083333	chr3:41927505	G/A	cg03022575	chr3:42003672	ULK4	0.69	9.49	0.35	4.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg04727924	chr7:799746	HEATR2	-0.54	-9.47	-0.35	5.45e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs2731664	0.792	rs2545795	chr5:176887106	A/C	cg23176889	chr5:176863531	GRK6	-0.62	-17.23	-0.56	6.44e-55	Intelligence (multi-trait analysis);
BRCA	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg14019146	chr3:50243930	SLC38A3	-0.42	-10.19	-0.37	1.1e-22	Body mass index;
BRCA	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg05279229	chr7:1896384	MAD1L1	-0.43	-8.24	-0.31	9.88e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg01689657	chr7:91764605	CYP51A1	0.21	7.86	0.3	1.66e-14	Breast cancer;
BRCA	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg25358565	chr5:93447407	FAM172A	1.23	18.97	0.6	5.63e-64	Diabetic retinopathy;
BRCA	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg23262073	chr20:60523788	NA	0.4	8.5	0.32	1.35e-16	Body mass index;
BRCA	cis	rs1941023	0.503	rs7944025	chr11:60142538	C/A	cg08716584	chr11:60157161	MS4A7	-0.44	-10.27	-0.38	5.37e-23	Congenital heart disease (maternal effect);
BRCA	trans	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.81	-25.32	-0.71	1.65e-98	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.48	-9.32	-0.35	1.9e-19	Chronic sinus infection;
BRCA	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg25817165	chr18:72167213	CNDP2	-0.76	-14.21	-0.49	4.8e-40	Refractive error;
BRCA	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg05234568	chr11:5960015	NA	-0.49	-9.72	-0.36	6.67e-21	DNA methylation (variation);
BRCA	cis	rs752010	0.714	rs10789403	chr1:42085869	G/A	cg06885757	chr1:42089581	HIVEP3	0.3	10.72	0.39	9.1e-25	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg23711669	chr6:146136114	FBXO30	0.72	17.37	0.57	1.22e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs68170813	0.559	rs12537785	chr7:107050221	T/C	cg02696742	chr7:106810147	HBP1	-0.5	-8.02	-0.3	5.24e-15	Coronary artery disease;
BRCA	cis	rs5771225	0.544	rs1555048	chr22:50688348	A/G	cg16473166	chr22:50639996	SELO	0.5	8.98	0.33	2.97e-18	Late-onset Alzheimer's disease;
BRCA	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.07	-0.3	3.48e-15	Prostate cancer;
BRCA	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg03433033	chr1:76189801	ACADM	0.86	22.18	0.66	2.75e-81	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg16606324	chr3:10149918	C3orf24	0.58	10.28	0.38	4.75e-23	Alzheimer's disease;
BRCA	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg00074818	chr8:8560427	CLDN23	0.38	8.37	0.31	3.69e-16	Obesity-related traits;
BRCA	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	9.21	0.34	4.54e-19	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs2797160	1.000	rs1777195	chr6:126006861	A/C	cg05901451	chr6:126070800	HEY2	0.39	9.51	0.35	3.92e-20	Endometrial cancer;
BRCA	trans	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.72	-0.36	6.57e-21	Bladder cancer;
BRCA	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.69	-0.33	2.96e-17	Breast cancer;
BRCA	trans	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg26043149	chr18:55253948	FECH	1.15	27.71	0.74	1.32e-111	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg05347473	chr6:146136440	FBXO30	0.39	7.93	0.3	9.59e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.63	0.36	1.43e-20	Menopause (age at onset);
BRCA	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg26597838	chr10:835615	NA	-0.57	-10.48	-0.38	7.93e-24	Eosinophil percentage of granulocytes;
BRCA	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.66	-0.32	3.87e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg09307838	chr4:120376055	NA	0.69	14.08	0.49	2.13e-39	Corneal astigmatism;
BRCA	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.44	0.35	6.85e-20	Tonsillectomy;
BRCA	cis	rs1506636	1.000	rs1911145	chr7:123363658	A/G	cg03229431	chr7:123269106	ASB15	-0.61	-13.77	-0.48	5.52e-38	Plateletcrit;Platelet count;
BRCA	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18876405	chr7:65276391	NA	0.62	15.35	0.52	1.76e-45	Aortic root size;
BRCA	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-10.41	-0.38	1.48e-23	Mean corpuscular volume;
BRCA	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.38	9.14	0.34	8.45e-19	Platelet count;
BRCA	cis	rs1868673	1.000	rs1868673	chr3:150187314	A/C	cg04908077	chr3:150187338	NA	-0.34	-8.92	-0.33	4.69e-18	Waist circumference;
BRCA	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg05347473	chr6:146136440	FBXO30	-0.41	-8.06	-0.3	3.75e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg09904177	chr6:26538194	HMGN4	0.55	17.65	0.57	4.4e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg20991723	chr1:152506922	NA	0.37	8.29	0.31	6.78e-16	Hair morphology;
BRCA	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg04013166	chr16:89971882	TCF25	0.52	9.51	0.35	3.81e-20	Skin colour saturation;
BRCA	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.47	10.31	0.38	3.68e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg26384229	chr12:38710491	ALG10B	0.59	13.47	0.47	1.41e-36	Morning vs. evening chronotype;
BRCA	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.96	0.3	7.63e-15	Depression;
BRCA	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg01689657	chr7:91764605	CYP51A1	0.23	8.3	0.31	6.06e-16	Breast cancer;
BRCA	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg13770153	chr20:60521292	NA	-0.39	-9.17	-0.34	6.38e-19	Body mass index;
BRCA	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg04455712	chr21:45112962	RRP1B	0.4	10.54	0.38	4.55e-24	Mean corpuscular volume;
BRCA	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.1e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6430585	0.640	rs6716070	chr2:136544651	G/T	cg07169764	chr2:136633963	MCM6	-1.16	-26.17	-0.72	3.58e-103	Corneal structure;
BRCA	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg10223061	chr2:219282414	VIL1	-0.27	-7.83	-0.3	2.02e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6450176	1.000	rs3776705	chr5:53304955	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-15.55	-0.52	1.79e-46	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.38	-9.98	-0.37	6.5600000000000005e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs1538970	1.000	rs4660853	chr1:45849090	C/T	cg05343316	chr1:45956843	TESK2	0.56	11.54	0.42	4.02e-28	Platelet count;
BRCA	cis	rs36051895	0.622	rs13440043	chr9:5268264	A/G	cg02405213	chr9:5042618	JAK2	-0.45	-7.99	-0.3	6.1e-15	Pediatric autoimmune diseases;
BRCA	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg03354898	chr7:1950403	MAD1L1	-0.39	-8.73	-0.33	2.21e-17	Schizophrenia;
BRCA	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg25482853	chr8:67687455	SGK3	1.01	17.39	0.57	1.01e-55	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg11266682	chr4:10021025	SLC2A9	0.48	12.55	0.44	1.83e-32	Bone mineral density;
BRCA	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.53	-11.27	-0.41	5.3e-27	IgG glycosylation;
BRCA	cis	rs10193935	0.901	rs222488	chr2:42648570	T/G	cg27598129	chr2:42591480	NA	-0.8	-13.51	-0.47	8.88e-37	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.75	-0.33	1.85e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs68170813	0.559	rs12540475	chr7:106886295	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.47	-0.32	1.68e-16	Coronary artery disease;
BRCA	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-17.83	-0.58	5.39e-58	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg08470875	chr2:26401718	FAM59B	-0.72	-11.43	-0.41	1.17e-27	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.52	0.5	1.78e-41	Motion sickness;
BRCA	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg06108461	chr20:60628389	TAF4	-0.64	-13.19	-0.46	2.75e-35	Body mass index;
BRCA	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg12292205	chr6:26970375	C6orf41	0.64	14.48	0.5	2.69e-41	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg00383909	chr3:49044727	WDR6	0.56	9.75	0.36	4.93e-21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.05	16.09	0.54	3.73e-49	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg11766577	chr21:47581405	C21orf56	-0.38	-8.22	-0.31	1.13e-15	Testicular germ cell tumor;
BRCA	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg13397359	chr6:42928475	GNMT	0.75	19.21	0.61	2.78e-65	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-11.59	-0.42	2.52e-28	Lymphocyte counts;
BRCA	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.33	8.53	0.32	1.05e-16	IgG glycosylation;
BRCA	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg02403541	chr12:121454288	C12orf43	0.64	12.16	0.43	9.39e-31	N-glycan levels;
BRCA	trans	rs783540	0.867	rs7167880	chr15:83294436	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.29	-9.03	-0.34	1.97e-18	Schizophrenia;
BRCA	cis	rs10864907	0.614	rs7557537	chr2:113702530	T/C	cg12858261	chr2:113808755	IL1F8	0.35	7.86	0.3	1.59e-14	Pulmonary function;
BRCA	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.83	-0.36	2.58e-21	Schizophrenia;
BRCA	trans	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg17830980	chr10:43048298	ZNF37B	-0.43	-9.94	-0.37	9.4e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7246657	0.722	rs2909098	chr19:38204248	G/A	cg23950597	chr19:37808831	NA	0.52	8.84	0.33	9.02e-18	Coronary artery calcification;
BRCA	trans	rs1997103	0.906	rs4618644	chr7:55402037	T/G	cg20935933	chr6:143382018	AIG1	0.6	11.42	0.41	1.32e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg08807101	chr21:30365312	RNF160	-0.59	-14.68	-0.5	3.1e-42	Dental caries;
BRCA	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg09904177	chr6:26538194	HMGN4	-0.56	-18.15	-0.58	1.13e-59	Intelligence (multi-trait analysis);
BRCA	cis	rs701145	0.537	rs1713815	chr3:153872445	T/C	cg17054900	chr3:154042577	DHX36	0.41	8.21	0.31	1.19e-15	Coronary artery disease;
BRCA	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg10862848	chr6:42927986	GNMT	-0.36	-14.95	-0.51	1.44e-43	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.35	0.49	1.13e-40	Motion sickness;
BRCA	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg04455712	chr21:45112962	RRP1B	0.39	10.19	0.37	1.06e-22	Mean corpuscular volume;
BRCA	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	8.4	0.32	3e-16	Breast cancer;
BRCA	cis	rs1030877	0.557	rs2278501	chr2:105979506	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.46	-10.16	-0.37	1.38e-22	Obesity-related traits;
BRCA	cis	rs11690935	0.595	rs788171	chr2:172921832	A/G	cg13550731	chr2:172543902	DYNC1I2	0.55	14.0	0.48	4.94e-39	Schizophrenia;
BRCA	cis	rs73001065	0.901	rs10401969	chr19:19407718	A/G	cg03709012	chr19:19516395	GATAD2A	0.78	9.68	0.36	8.72e-21	LDL cholesterol;
BRCA	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg17063962	chr7:91808500	NA	-0.53	-12.53	-0.44	2.43e-32	Breast cancer;
BRCA	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.34	-0.44	1.5e-31	Bipolar disorder;
BRCA	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg13628971	chr7:2884303	GNA12	0.61	13.75	0.48	7.46e-38	Height;
BRCA	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-16.58	-0.55	1.23e-51	Heart rate;
BRCA	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg00339695	chr16:24857497	SLC5A11	-0.5	-10.98	-0.4	8.17e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg21280719	chr6:42927975	GNMT	-0.31	-12.7	-0.45	4.13e-33	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.36	7.85	0.3	1.75e-14	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg24296786	chr1:45957014	TESK2	0.43	8.71	0.33	2.67e-17	Homocysteine levels;
BRCA	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10465746	0.780	rs10874424	chr1:84424033	C/T	cg10977910	chr1:84465055	TTLL7	0.58	11.99	0.43	5.17e-30	Obesity-related traits;
BRCA	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg09624528	chr10:1369823	ADARB2	0.41	8.47	0.32	1.71e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg00383909	chr3:49044727	WDR6	0.52	10.13	0.37	1.85e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg14675211	chr2:100938903	LONRF2	0.46	10.44	0.38	1.12e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.22	0.56	7.27e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7633770	0.786	rs1520488	chr3:46677459	C/T	cg11219411	chr3:46661640	NA	0.61	15.6	0.53	9.55e-47	Coronary artery disease;
BRCA	cis	rs2882667	0.898	rs11952020	chr5:138395156	A/T	cg04439458	chr5:138467593	SIL1	-0.33	-9.07	-0.34	1.44e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6460942	1.000	rs7792759	chr7:12311715	A/G	cg06484146	chr7:12443880	VWDE	0.61	8.57	0.32	7.47e-17	Coronary artery disease;
BRCA	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg09526685	chr4:187126073	CYP4V2	0.99	11.49	0.41	6.76e-28	Blood protein levels;
BRCA	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg13902645	chr11:5959945	NA	-0.46	-9.46	-0.35	5.87e-20	DNA methylation (variation);
BRCA	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg26248373	chr2:1572462	NA	-0.62	-14.4	-0.49	6.48e-41	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-11.24	-0.41	6.85e-27	Gut microbiome composition (summer);
BRCA	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.84	-0.33	9.56e-18	Total body bone mineral density;
BRCA	cis	rs208520	0.706	rs851601	chr6:66893853	G/A	cg07460842	chr6:66804631	NA	-0.93	-16.92	-0.56	2.38e-53	Exhaled nitric oxide output;
BRCA	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg09307838	chr4:120376055	NA	0.7	13.97	0.48	7.08e-39	Corneal astigmatism;
BRCA	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	9.09	0.34	1.19e-18	Personality dimensions;
BRCA	trans	rs1459104	0.571	rs10459012	chr11:55091574	C/A	cg15704280	chr7:45808275	SEPT13	0.55	9.87	0.36	1.74e-21	Body mass index;
BRCA	trans	rs4596713	0.539	rs953812	chr9:71787631	T/C	cg16512924	chr15:28394682	HERC2	0.45	10.56	0.39	3.97e-24	Headache;
BRCA	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg20283391	chr11:68216788	NA	-0.46	-9.02	-0.34	2.24e-18	Total body bone mineral density;
BRCA	cis	rs2764980	1.000	rs2764979	chr10:3283882	T/C	cg11630169	chr10:3283847	NA	-0.41	-9.36	-0.35	1.37e-19	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg27170947	chr2:26402098	FAM59B	0.97	16.86	0.55	4.94e-53	Gut microbiome composition (summer);
BRCA	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	17.83	0.58	5.12e-58	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-13.86	-0.48	2.15e-38	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg20607287	chr7:12443886	VWDE	-0.54	-8.21	-0.31	1.22e-15	Coronary artery disease;
BRCA	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg10523679	chr1:76189770	ACADM	-0.46	-8.73	-0.33	2.25e-17	Daytime sleep phenotypes;
BRCA	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03934478	chr11:495069	RNH1	0.79	11.76	0.42	5.06e-29	Body mass index;
BRCA	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg09060608	chr5:178986726	RUFY1	0.45	9.86	0.36	1.92e-21	Lung cancer;
BRCA	cis	rs9837602	1.000	rs13069311	chr3:99801628	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	11.21	0.41	9.34e-27	Breast cancer;
BRCA	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg06115741	chr20:33292138	TP53INP2	0.39	8.69	0.33	3.04e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg03060546	chr3:49711283	APEH	0.47	10.06	0.37	3.3e-22	Resting heart rate;
BRCA	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg20387954	chr3:183756860	HTR3D	0.39	8.73	0.33	2.23e-17	Anterior chamber depth;
BRCA	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg00376283	chr12:123451042	ABCB9	0.49	10.05	0.37	3.82e-22	Neutrophil percentage of white cells;
BRCA	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg14847009	chr1:175162515	KIAA0040	0.25	9.46	0.35	5.95e-20	Alcohol dependence;
BRCA	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg12483005	chr1:23474871	LUZP1	0.46	10.27	0.38	5.48e-23	Height;
BRCA	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg27535305	chr1:53392650	SCP2	-0.38	-9.28	-0.34	2.59e-19	Monocyte count;
BRCA	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.44	-8.9	-0.33	5.92e-18	Tonsillectomy;
BRCA	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg14349672	chr11:133703707	NA	0.36	8.46	0.32	1.88e-16	Childhood ear infection;
BRCA	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg08917208	chr2:24149416	ATAD2B	1.1	15.68	0.53	3.91e-47	Lymphocyte counts;
BRCA	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg24558204	chr6:135376177	HBS1L	0.43	11.65	0.42	1.4e-28	Red blood cell count;
BRCA	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg17330251	chr7:94953956	PON1	-0.42	-8.81	-0.33	1.22e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs858239	0.600	rs4409314	chr7:23127952	T/C	cg23682824	chr7:23144976	KLHL7	0.42	11.21	0.41	9.6e-27	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg18016565	chr1:150552671	MCL1	-0.41	-9.52	-0.35	3.58e-20	Tonsillectomy;
BRCA	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-11.98	-0.43	5.79e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1997103	1.000	rs12532070	chr7:55407698	A/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg02773041	chr1:40204384	PPIE	0.45	9.72	0.36	6.63e-21	Blood protein levels;
BRCA	trans	rs1997103	1.000	rs6593238	chr7:55411048	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.51	-16.12	-0.54	2.64e-49	Alzheimer's disease (late onset);
BRCA	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg02153584	chr22:29168773	CCDC117	0.51	11.44	0.41	1.06e-27	Red cell distribution width;
BRCA	cis	rs2040771	0.745	rs2283646	chr22:19273902	A/G	cg02655711	chr22:19163373	SLC25A1	-0.37	-8.49	-0.32	1.41e-16	Metabolite levels (small molecules and protein measures);
BRCA	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg24296786	chr1:45957014	TESK2	0.64	15.77	0.53	1.48e-47	High light scatter reticulocyte count;
BRCA	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18404041	chr3:52824283	ITIH1	-0.37	-11.27	-0.41	5.23e-27	Electroencephalogram traits;
BRCA	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg04450456	chr4:17643702	FAM184B	0.38	11.37	0.41	1.99e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg07606381	chr6:8435919	SLC35B3	-0.64	-14.08	-0.49	2.01e-39	Motion sickness;
BRCA	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg04455712	chr21:45112962	RRP1B	0.38	9.69	0.36	8.36e-21	Mean corpuscular volume;
BRCA	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.58	0.55	1.23e-51	Hypertriglyceridemia;
BRCA	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg06064525	chr11:970664	AP2A2	-0.47	-15.48	-0.52	3.87e-46	Alzheimer's disease (late onset);
BRCA	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg12365402	chr11:9010492	NRIP3	-0.4	-9.38	-0.35	1.14e-19	Hemoglobin concentration;
BRCA	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg24562669	chr7:97807699	LMTK2	0.45	11.94	0.43	8.29e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg04414720	chr1:150670196	GOLPH3L	0.35	8.06	0.3	3.82e-15	Tonsillectomy;
BRCA	cis	rs6728642	1.000	rs17037402	chr2:98014883	C/T	cg26665480	chr2:98280029	ACTR1B	-0.67	-7.91	-0.3	1.17e-14	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg24977027	chr2:88469347	THNSL2	0.46	8.01	0.3	5.36e-15	Plasma clusterin levels;
BRCA	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg22920501	chr2:26401640	FAM59B	-0.69	-11.69	-0.42	9.6e-29	Gut microbiome composition (summer);
BRCA	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18404041	chr3:52824283	ITIH1	-0.43	-12.8	-0.45	1.42e-33	Bipolar disorder;
BRCA	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	10.75	0.39	7.13e-25	Iron status biomarkers;
BRCA	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	11.31	0.41	3.56e-27	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs67981189	0.727	rs221903	chr14:71600208	A/G	cg15816911	chr14:71606274	NA	-0.36	-8.01	-0.3	5.46e-15	Schizophrenia;
BRCA	cis	rs2294693	0.945	rs9369252	chr6:40986028	C/T	cg14418226	chr6:40996092	UNC5CL	-0.45	-8.12	-0.31	2.44e-15	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg03433033	chr1:76189801	ACADM	0.6	10.51	0.38	6.19e-24	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.49	9.42	0.35	8.36e-20	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22509189	chr2:225307070	NA	-0.47	-9.97	-0.37	7.32e-22	IgE levels in asthmatics (D.p. specific);
BRCA	trans	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg06521331	chr12:34319734	NA	-0.47	-8.73	-0.33	2.15e-17	Bladder cancer;
BRCA	cis	rs829883	0.724	rs11109508	chr12:98905985	T/C	cg25150519	chr12:98850993	NA	-0.51	-9.46	-0.35	5.81e-20	Colorectal adenoma (advanced);
BRCA	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg21770322	chr7:97807741	LMTK2	0.44	11.54	0.42	3.92e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.63	13.66	0.48	1.77e-37	Lymphocyte percentage of white cells;
BRCA	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg23950597	chr19:37808831	NA	-0.75	-13.04	-0.46	1.25e-34	Coronary artery calcification;
BRCA	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg27336068	chr10:1336103	ADARB2	-0.29	-7.99	-0.3	6.44e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg14963724	chr18:72166303	CNDP2	-0.34	-7.85	-0.3	1.81e-14	Refractive error;
BRCA	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg13319975	chr6:146136371	FBXO30	0.4	9.31	0.35	1.97e-19	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs9951602	0.512	rs4799248	chr18:76653459	G/A	cg02800362	chr5:177631904	HNRNPAB	0.77	18.16	0.58	9.67e-60	Obesity-related traits;
BRCA	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg03433033	chr1:76189801	ACADM	0.86	22.1	0.66	7.87e-81	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.06	-18.86	-0.6	1.99e-63	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg23711669	chr6:146136114	FBXO30	0.77	17.46	0.57	4.4e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg06108461	chr20:60628389	TAF4	-0.79	-17.05	-0.56	5.51e-54	Body mass index;
BRCA	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg13073564	chr4:8508604	NA	-0.44	-12.09	-0.43	1.85e-30	Response to antineoplastic agents;
BRCA	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg26384229	chr12:38710491	ALG10B	0.58	13.18	0.46	2.85e-35	Morning vs. evening chronotype;
BRCA	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11764359	chr7:65958608	NA	-0.8	-19.29	-0.61	1.12e-65	Aortic root size;
BRCA	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg09455208	chr3:40491958	NA	-0.48	-11.61	-0.42	2e-28	Renal cell carcinoma;
BRCA	cis	rs1322639	0.574	rs9689193	chr6:169588074	A/G	cg03254818	chr6:169586852	NA	0.52	8.11	0.31	2.65e-15	Pulse pressure;
BRCA	cis	rs7927771	0.524	rs7114813	chr11:47801101	A/G	cg20307385	chr11:47447363	PSMC3	0.42	9.56	0.35	2.48e-20	Subjective well-being;
BRCA	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.57	11.34	0.41	2.86e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg07460842	chr6:66804631	NA	-1.02	-20.25	-0.63	8.06e-71	Exhaled nitric oxide output;
BRCA	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.47	0.35	5.29e-20	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg05347473	chr6:146136440	FBXO30	0.4	7.82	0.3	2.26e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs911119	0.913	rs3810575	chr20:23583392	G/A	cg16589663	chr20:23618590	CST3	0.4	7.83	0.3	2.02e-14	Chronic kidney disease;
BRCA	cis	rs1784581	0.802	rs9365355	chr6:162414604	A/G	cg17173639	chr6:162384350	PARK2	0.39	9.12	0.34	9.27e-19	Itch intensity from mosquito bite;
BRCA	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg20628663	chr10:43360327	NA	0.71	13.74	0.48	8.06e-38	Blood protein levels;
BRCA	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg16576597	chr16:28551801	NUPR1	0.35	8.8	0.33	1.32e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-15.35	-0.52	1.63e-45	Total cholesterol levels;
BRCA	cis	rs7246967	0.673	rs57736314	chr19:22880272	T/G	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg07636037	chr3:49044803	WDR6	0.98	29.03	0.75	8.19e-119	Parkinson's disease;
BRCA	cis	rs6430585	0.527	rs2278731	chr2:136396300	T/C	cg07169764	chr2:136633963	MCM6	0.98	19.22	0.61	2.54e-65	Corneal structure;
BRCA	cis	rs7607369	0.719	rs7567622	chr2:219624549	A/T	cg02176678	chr2:219576539	TTLL4	-0.4	-10.98	-0.4	8.27e-26	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	trans	rs1997103	0.834	rs10274457	chr7:55390199	G/A	cg20935933	chr6:143382018	AIG1	0.61	11.61	0.42	2.03e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.61	8.47	0.32	1.71e-16	Putamen volume;
BRCA	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-13.5	-0.47	1.07e-36	Morning vs. evening chronotype;
BRCA	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg11764359	chr7:65958608	NA	0.66	11.77	0.42	4.36e-29	Aortic root size;
BRCA	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.4	-0.66	1.71e-82	Lymphocyte percentage of white cells;
BRCA	cis	rs7814319	0.646	rs938828	chr8:97316821	A/C	cg20787634	chr8:97240163	UQCRB	-0.36	-7.95	-0.3	8.26e-15	Lung function (FVC);
BRCA	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.71	-0.53	2.72e-47	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg17063962	chr7:91808500	NA	-0.51	-11.81	-0.42	3.1e-29	Breast cancer;
BRCA	cis	rs6910061	1.000	rs9468416	chr6:11100978	T/C	cg27233058	chr6:11094804	LOC221710	0.52	9.3	0.35	2.15e-19	Diabetic kidney disease;
BRCA	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	16.31	0.54	2.86e-50	Tonsillectomy;
BRCA	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11764359	chr7:65958608	NA	0.77	17.35	0.57	1.46e-55	Aortic root size;
BRCA	cis	rs12618769	0.597	rs3769713	chr2:99151434	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.33	0.31	5e-16	Bipolar disorder;
BRCA	cis	rs7246967	0.673	rs34726149	chr19:22952111	A/G	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	trans	rs1325195	0.920	rs2793797	chr1:179097206	A/G	cg11624085	chr17:8464688	MYH10	0.26	7.85	0.3	1.81e-14	IgE grass sensitization;
BRCA	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg22903471	chr2:27725779	GCKR	-0.39	-9.75	-0.36	5.1e-21	Total body bone mineral density;
BRCA	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg23711669	chr6:146136114	FBXO30	0.81	19.41	0.61	2.43e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg24296786	chr1:45957014	TESK2	0.45	10.35	0.38	2.6e-23	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9309473	0.519	rs2178154	chr2:73661738	C/T	cg20560298	chr2:73613845	ALMS1	0.42	11.32	0.41	3.42e-27	Metabolite levels;
BRCA	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg20701182	chr2:24300061	SF3B14	0.63	9.18	0.34	6.15e-19	Lymphocyte counts;
BRCA	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg11584989	chr19:19387371	SF4	-0.62	-13.5	-0.47	1e-36	Bipolar disorder;
BRCA	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg01689657	chr7:91764605	CYP51A1	0.22	8.03	0.3	4.78e-15	Breast cancer;
BRCA	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg11764359	chr7:65958608	NA	-0.67	-14.7	-0.5	2.39e-42	Aortic root size;
BRCA	cis	rs1371614	0.635	rs9309558	chr2:27141504	C/T	cg00617064	chr2:27272375	NA	0.31	8.03	0.3	4.78e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2425143	1.000	rs11696369	chr20:34378629	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.96	-0.37	8.33e-22	Blood protein levels;
BRCA	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg24642844	chr7:1081250	C7orf50	-0.89	-16.0	-0.53	1.07e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.0	-0.34	2.59e-18	Total body bone mineral density;
BRCA	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg07395648	chr5:131743802	NA	-0.36	-8.03	-0.3	4.6e-15	Acylcarnitine levels;
BRCA	cis	rs13315871	1.000	rs11708590	chr3:58336635	A/G	cg20936604	chr3:58311152	NA	0.62	8.05	0.3	3.94e-15	Cholesterol, total;
BRCA	trans	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.27	0.31	7.64e-16	Aortic root size;
BRCA	cis	rs7903847	0.620	rs17112676	chr10:99122288	G/A	cg08345082	chr10:99160200	RRP12	-0.28	-8.04	-0.3	4.32e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs78761021	0.720	rs874307	chr17:9798074	C/G	cg26853458	chr17:9805074	RCVRN	0.47	9.6	0.35	1.81e-20	Type 2 diabetes;
BRCA	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg09184832	chr6:79620586	NA	-0.5	-11.14	-0.4	1.91e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg11822812	chr5:140052017	DND1	-0.3	-8.37	-0.31	3.58e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-8.59	-0.32	6.86e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.55	-0.32	9.24e-17	Total body bone mineral density;
BRCA	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.54	-11.51	-0.41	5.36e-28	Colorectal cancer;
BRCA	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg24558204	chr6:135376177	HBS1L	0.45	12.26	0.44	3.59e-31	Red blood cell count;
BRCA	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg21475434	chr5:93447410	FAM172A	0.73	9.1	0.34	1.14e-18	Diabetic retinopathy;
BRCA	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg04455712	chr21:45112962	RRP1B	0.45	12.16	0.43	9.3e-31	Mean corpuscular volume;
BRCA	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg24812749	chr6:127587940	RNF146	0.88	20.75	0.63	1.58e-73	Breast cancer;
BRCA	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	9.16	0.34	7.19e-19	Platelet count;
BRCA	cis	rs6430585	0.640	rs3816155	chr2:136552526	A/C	cg07169764	chr2:136633963	MCM6	-1.15	-25.86	-0.72	1.77e-101	Corneal structure;
BRCA	cis	rs7809950	1.000	rs2520271	chr7:107194949	C/T	cg23024343	chr7:107201750	COG5	-0.4	-9.05	-0.34	1.71e-18	Coronary artery disease;
BRCA	cis	rs11608355	0.515	rs2270361	chr12:109935894	G/C	cg05360138	chr12:110035743	NA	0.72	13.3	0.47	8.56e-36	Neuroticism;
BRCA	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg18129178	chr5:148520854	ABLIM3	-0.65	-13.22	-0.46	1.85e-35	Breast cancer;
BRCA	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg07080220	chr10:102295463	HIF1AN	0.54	12.43	0.44	6.6e-32	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg25036284	chr2:26402008	FAM59B	-0.64	-10.59	-0.39	3.03e-24	Gut microbiome composition (summer);
BRCA	cis	rs7246657	0.722	rs8103647	chr19:38100452	C/A	cg14683738	chr19:37701593	ZNF585B	0.47	8.07	0.3	3.44e-15	Coronary artery calcification;
BRCA	cis	rs8018808	0.935	rs12436593	chr14:77928476	C/T	cg20045696	chr14:77926864	AHSA1	0.36	8.4	0.32	2.91e-16	Myeloid white cell count;
BRCA	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg00677455	chr12:58241039	CTDSP2	0.52	11.61	0.42	1.98e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg18305652	chr10:134549665	INPP5A	0.51	13.31	0.47	7.68e-36	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg10932868	chr11:921992	NA	0.5	12.8	0.45	1.56e-33	Alzheimer's disease (late onset);
BRCA	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg01802117	chr1:53393560	SCP2	0.37	8.17	0.31	1.7e-15	Monocyte count;
BRCA	cis	rs6429082	0.818	rs291341	chr1:235663174	G/T	cg26050004	chr1:235667680	B3GALNT2	0.58	13.5	0.47	9.72e-37	Adiposity;
BRCA	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg17063962	chr7:91808500	NA	0.52	12.41	0.44	7.57e-32	Breast cancer;
BRCA	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.47	-9.62	-0.36	1.45e-20	Height;
BRCA	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg05340658	chr4:99064831	C4orf37	0.45	10.23	0.38	7.78e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-17.64	-0.57	5.13e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7677751	0.806	rs73252942	chr4:55104604	T/C	cg17187183	chr4:55093834	PDGFRA	0.44	9.1	0.34	1.14e-18	Corneal astigmatism;
BRCA	cis	rs912057	0.833	rs1294426	chr6:6744477	T/C	cg06612196	chr6:6737390	NA	0.4	8.87	0.33	7.1e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02176678	chr2:219576539	TTLL4	0.46	11.86	0.42	1.84e-29	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.8	-0.33	1.28e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4664304	0.739	rs2162500	chr2:160708645	C/G	cg18514922	chr2:160761262	LY75	0.33	7.81	0.3	2.41e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.79	-0.33	1.38e-17	Total body bone mineral density;
BRCA	cis	rs2279817	1.000	rs1339800	chr1:18020201	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.55	-16.49	-0.55	3.48e-51	Neuroticism;
BRCA	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27286337	chr10:134555280	INPP5A	0.79	12.8	0.45	1.5e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg00857998	chr1:205179979	DSTYK	0.41	8.03	0.3	4.67e-15	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg06618935	chr21:46677482	NA	-0.38	-8.24	-0.31	9.59e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg07828340	chr4:882639	GAK	1.04	12.4	0.44	8.99e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.31	-7.85	-0.3	1.74e-14	Total body bone mineral density;
BRCA	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg11062466	chr8:58055876	NA	0.5	8.72	0.33	2.44e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg07169764	chr2:136633963	MCM6	1.22	28.8	0.75	1.57e-117	Corneal structure;
BRCA	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18876405	chr7:65276391	NA	0.52	11.65	0.42	1.43e-28	Aortic root size;
BRCA	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg19539972	chr4:7069911	GRPEL1	0.72	17.53	0.57	1.79e-56	Monocyte percentage of white cells;
BRCA	cis	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg09307838	chr4:120376055	NA	0.67	14.49	0.5	2.48e-41	Corneal astigmatism;
BRCA	cis	rs796364	0.570	rs4673491	chr2:200669108	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.58	8.72	0.33	2.3e-17	Schizophrenia;
BRCA	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg09307838	chr4:120376055	NA	-0.75	-15.75	-0.53	1.77e-47	Corneal astigmatism;
BRCA	cis	rs12711979	0.765	rs897069	chr2:3818947	C/T	cg17052675	chr2:3827356	NA	0.48	14.17	0.49	8.2e-40	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg04944784	chr2:26401820	FAM59B	1.0	16.52	0.55	2.51e-51	Gut microbiome composition (summer);
BRCA	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg01483505	chr11:975446	AP2A2	0.3	8.18	0.31	1.58e-15	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg04944784	chr2:26401820	FAM59B	1.01	16.64	0.55	6.66e-52	Gut microbiome composition (summer);
BRCA	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg23711669	chr6:146136114	FBXO30	0.74	15.78	0.53	1.37e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg08601574	chr20:25228251	PYGB	-0.35	-8.51	-0.32	1.21e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4363385	0.693	rs418550	chr1:153048045	A/T	cg24667326	chr1:152973720	SPRR3	-0.29	-7.87	-0.3	1.56e-14	Inflammatory skin disease;
BRCA	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg09469691	chr10:81107165	PPIF	0.46	9.98	0.37	6.89e-22	Height;
BRCA	trans	rs7241530	0.623	rs2411419	chr18:75917133	C/T	cg25697769	chr22:39097335	JOSD1	-0.37	-8.06	-0.3	3.89e-15	Educational attainment (years of education);
BRCA	cis	rs4363385	0.747	rs11205151	chr1:152961496	G/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.39	-0.32	3.01e-16	Inflammatory skin disease;
BRCA	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-10.84	-0.39	2.9e-25	Longevity;
BRCA	cis	rs2859741	0.546	rs2134846	chr1:37500723	G/A	cg09363841	chr1:37513479	NA	-0.53	-11.38	-0.41	1.93e-27	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg16414030	chr3:133502952	NA	-0.48	-11.23	-0.41	7.89e-27	Iron status biomarkers;
BRCA	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg02880119	chr16:3481970	NA	0.42	7.97	0.3	7.52e-15	Body mass index (adult);
BRCA	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.88	-0.3	1.46e-14	Menopause (age at onset);
BRCA	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg22508957	chr16:3507546	NAT15	-0.39	-9.05	-0.34	1.74e-18	Tuberculosis;
BRCA	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-8.97	-0.33	3.21e-18	IgG glycosylation;
BRCA	cis	rs3772130	0.962	rs6776670	chr3:121543120	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.95	0.4	1.05e-25	Cognitive performance;
BRCA	cis	rs4660306	1.000	rs882803	chr1:45976147	G/A	cg24296786	chr1:45957014	TESK2	0.43	8.98	0.33	3.04e-18	Homocysteine levels;
BRCA	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg12011299	chr4:100065546	ADH4	-0.5	-11.63	-0.42	1.67e-28	Alcohol dependence;
BRCA	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg22676075	chr6:135203613	NA	0.45	8.89	0.33	6.18e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs400736	0.602	rs4601608	chr1:8168808	A/G	cg25007680	chr1:8021821	PARK7	-0.35	-8.68	-0.32	3.37e-17	Response to antidepressants and depression;
BRCA	cis	rs11051970	0.838	rs2651369	chr12:32552769	C/G	cg24626660	chr12:32551988	NA	0.33	9.08	0.34	1.39e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-11.9	-0.43	1.26e-29	Bipolar disorder;
BRCA	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg01802117	chr1:53393560	SCP2	-0.36	-8.38	-0.31	3.43e-16	Monocyte count;
BRCA	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg26384229	chr12:38710491	ALG10B	0.76	16.91	0.56	2.6e-53	Bladder cancer;
BRCA	cis	rs829883	1.000	rs2908843	chr12:98889332	C/G	cg25150519	chr12:98850993	NA	-0.58	-11.93	-0.43	9e-30	Colorectal adenoma (advanced);
BRCA	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.94	-0.3	9.42e-15	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.96	0.4	9.71e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	9.11	0.34	1.03e-18	Height;
BRCA	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg25237894	chr2:233734115	C2orf82	0.4	11.38	0.41	1.84e-27	Coronary artery disease;
BRCA	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg21573476	chr21:45109991	RRP1B	0.35	9.07	0.34	1.49e-18	Mean corpuscular volume;
BRCA	cis	rs6433895	0.677	rs35725888	chr2:181998627	T/C	cg00481216	chr2:181971175	NA	0.46	8.68	0.32	3.35e-17	Lymphocyte counts;
BRCA	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg05347473	chr6:146136440	FBXO30	0.41	7.93	0.3	1.01e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs495337	0.797	rs2025958	chr20:48456238	G/A	cg17835207	chr20:48524531	SPATA2	0.5	10.94	0.4	1.22e-25	Psoriasis;
BRCA	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.68	0.57	3.1e-57	Fuchs's corneal dystrophy;
BRCA	trans	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg23762105	chr12:34175262	ALG10	0.36	8.41	0.32	2.64e-16	Morning vs. evening chronotype;
BRCA	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg07308232	chr7:1071921	C7orf50	-0.36	-7.98	-0.3	6.88e-15	Longevity;Endometriosis;
BRCA	cis	rs1003719	0.680	rs1034357	chr21:38571482	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.73	-0.5	1.77e-42	Eye color traits;
BRCA	trans	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs12541635	1.000	rs4734897	chr8:107075518	G/A	cg10147462	chr8:107024639	NA	-0.31	-8.59	-0.32	6.77e-17	Age of smoking initiation;
BRCA	cis	rs4363385	0.747	rs7529110	chr1:152966247	A/C	cg24667326	chr1:152973720	SPRR3	-0.34	-9.6	-0.35	1.81e-20	Inflammatory skin disease;
BRCA	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg09904177	chr6:26538194	HMGN4	0.56	18.25	0.59	3.23e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg23708337	chr7:1209742	NA	0.43	8.23	0.31	1.05e-15	Longevity;Endometriosis;
BRCA	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg18811423	chr2:55921094	PNPT1	0.77	26.65	0.73	8.68e-106	Metabolic syndrome;
BRCA	cis	rs1113500	0.548	rs7541433	chr1:108645641	G/A	cg06207961	chr1:108661230	NA	0.36	7.83	0.3	2.03e-14	Growth-regulated protein alpha levels;
BRCA	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-11.03	-0.4	5.02e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2882667	0.929	rs34846849	chr5:138360578	T/C	cg04439458	chr5:138467593	SIL1	-0.42	-10.59	-0.39	2.86e-24	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs11976180	1.000	rs1533267	chr7:143766440	A/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.44	-8.25	-0.31	9.11e-16	Obesity-related traits;
BRCA	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg26149184	chr10:133730230	NA	0.41	8.27	0.31	7.64e-16	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-10.83	-0.39	3.37e-25	Chronic sinus infection;
BRCA	cis	rs7301826	0.651	rs10848209	chr12:131311272	A/G	cg11011512	chr12:131303247	STX2	0.49	12.97	0.46	2.58e-34	Plasma plasminogen activator levels;
BRCA	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg24562669	chr7:97807699	LMTK2	-0.49	-13.28	-0.46	1.07e-35	Breast cancer;
BRCA	cis	rs12612619	0.579	rs6756245	chr2:27083489	C/T	cg12368169	chr2:27073192	DPYSL5	0.34	10.51	0.38	5.99e-24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs7903847	0.642	rs11189192	chr10:99149403	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-8.86	-0.33	7.8e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.23	0.34	4.02e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-15.93	-0.53	2.21e-48	Colorectal cancer;
BRCA	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.56	12.79	0.45	1.56e-33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs12760731	0.720	rs12755909	chr1:178305298	G/A	cg00404053	chr1:178313656	RASAL2	0.69	8.64	0.32	4.35e-17	Obesity-related traits;
BRCA	cis	rs701145	0.585	rs1624917	chr3:153827300	T/A	cg17054900	chr3:154042577	DHX36	0.53	9.04	0.34	1.88e-18	Coronary artery disease;
BRCA	cis	rs11920090	0.932	rs16855578	chr3:170684592	A/G	cg09710316	chr3:170744871	SLC2A2	0.41	7.93	0.3	9.56e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg19920283	chr7:105172520	RINT1	0.58	9.35	0.35	1.42e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg04362960	chr10:104952993	NT5C2	0.38	9.17	0.34	6.42e-19	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18252515	chr7:66147081	NA	-0.35	-7.82	-0.3	2.15e-14	Aortic root size;
BRCA	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg26248373	chr2:1572462	NA	-0.62	-14.37	-0.49	8.48e-41	IgG glycosylation;
BRCA	trans	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg21659725	chr3:3221576	CRBN	-0.49	-8.5	-0.32	1.31e-16	Menarche (age at onset);
BRCA	cis	rs2249625	0.545	rs2496488	chr6:72875985	A/T	cg18830697	chr6:72922368	RIMS1	-0.64	-14.66	-0.5	3.57e-42	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg10495392	chr1:46806563	NSUN4	0.46	8.31	0.31	5.8e-16	Menopause (age at onset);
BRCA	cis	rs113835537	0.529	rs2276406	chr11:66283257	C/T	cg24851651	chr11:66362959	CCS	0.44	8.29	0.31	6.92e-16	Airway imaging phenotypes;
BRCA	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-9.16	-0.34	6.97e-19	Schizophrenia;
BRCA	cis	rs476633	0.691	rs28568756	chr15:41539371	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.39	-8.61	-0.32	5.68e-17	Glomerular filtration rate (creatinine);
BRCA	trans	rs6601327	0.573	rs13278824	chr8:9646119	T/A	cg06636001	chr8:8085503	FLJ10661	0.38	7.99	0.3	6.18e-15	Multiple myeloma (hyperdiploidy);
BRCA	cis	rs9403521	0.947	rs7741424	chr6:143981662	G/A	cg18240653	chr6:144019428	PHACTR2	-0.4	-7.81	-0.3	2.34e-14	Obesity-related traits;
BRCA	cis	rs6543140	0.865	rs6760275	chr2:103079607	C/T	cg04239558	chr2:103089729	SLC9A4	0.35	9.74	0.36	5.21e-21	Blood protein levels;
BRCA	cis	rs13046373	0.535	rs2832970	chr21:32020767	T/C	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.28	0.34	2.58e-19	HDL cholesterol;
BRCA	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg13010199	chr12:38710504	ALG10B	0.41	8.87	0.33	7.01e-18	Bladder cancer;
BRCA	cis	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg07460842	chr6:66804631	NA	-0.6	-10.43	-0.38	1.22e-23	Type 2 diabetes;
BRCA	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.13	0.62	3.46e-70	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg19773385	chr1:10388646	KIF1B	-0.36	-7.92	-0.3	1.05e-14	Hepatocellular carcinoma;
BRCA	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-10.29	-0.38	4.23e-23	Joint mobility (Beighton score);
BRCA	cis	rs4680	1.000	rs4680	chr22:19951271	C/T	cg23601416	chr22:19950040	COMT	0.3	10.18	0.37	1.12e-22	Blood metabolite levels;
BRCA	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg07080220	chr10:102295463	HIF1AN	0.5	10.36	0.38	2.43e-23	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs8038465	0.622	rs60696711	chr15:73873005	C/A	cg15420318	chr15:73925796	NPTN	0.46	10.0	0.37	5.74e-22	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs17641971	0.684	rs7011891	chr8:49983538	A/C	cg00325661	chr8:49890786	NA	0.38	10.58	0.39	3.22e-24	Blood metabolite levels;
BRCA	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg03342759	chr3:160939853	NMD3	-0.74	-15.69	-0.53	3.72e-47	Parkinson's disease;
BRCA	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg24829409	chr8:58192753	C8orf71	-0.48	-9.14	-0.34	7.94e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13732083	chr21:47605072	C21orf56	-0.4	-8.16	-0.31	1.79e-15	Testicular germ cell tumor;
BRCA	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg20387954	chr3:183756860	HTR3D	0.45	10.08	0.37	2.84e-22	Anterior chamber depth;
BRCA	cis	rs7945705	0.806	rs12224436	chr11:8815825	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.49	10.44	0.38	1.18e-23	Hemoglobin concentration;
BRCA	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.15	0.37	1.53e-22	Bladder cancer;
BRCA	cis	rs57590327	0.555	rs11127740	chr3:81743062	A/C	cg07356753	chr3:81810745	GBE1	-0.46	-10.93	-0.4	1.32e-25	Extraversion;
BRCA	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg01262667	chr19:19385393	TM6SF2	0.38	8.16	0.31	1.83e-15	Nonalcoholic fatty liver disease;
BRCA	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg25173405	chr17:45401733	C17orf57	0.55	11.33	0.41	3.06e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs67981189	0.593	rs2526883	chr14:71369575	T/G	cg15816911	chr14:71606274	NA	-0.39	-8.92	-0.33	5.03e-18	Schizophrenia;
BRCA	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg04733989	chr22:42467013	NAGA	-0.37	-8.27	-0.31	7.52e-16	Cognitive function;
BRCA	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.09	0.56	3.19e-54	Bladder cancer;
BRCA	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-8.12	-0.31	2.37e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg14675211	chr2:100938903	LONRF2	0.43	9.72	0.36	6.38e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg02659138	chr7:134003124	SLC35B4	0.35	10.85	0.39	2.84e-25	Mean platelet volume;
BRCA	trans	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg06521331	chr12:34319734	NA	-0.5	-9.31	-0.35	1.97e-19	Bladder cancer;
BRCA	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg03213289	chr20:61660250	NA	0.6	15.7	0.53	3.15e-47	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg16989086	chr20:62203971	PRIC285	-0.51	-8.61	-0.32	5.85e-17	Glioblastoma;
BRCA	cis	rs10493773	0.618	rs17394091	chr1:86075098	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.43	-8.15	-0.31	1.96e-15	Urate levels in overweight individuals;
BRCA	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.46	9.2	0.34	5e-19	Lymphocyte counts;
BRCA	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg23788917	chr6:8435910	SLC35B3	0.49	10.61	0.39	2.48e-24	Motion sickness;
BRCA	cis	rs7560272	0.723	rs13386124	chr2:73771695	C/G	cg20560298	chr2:73613845	ALMS1	-0.37	-9.14	-0.34	7.93e-19	Schizophrenia;
BRCA	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg26408565	chr15:76604113	ETFA	0.37	7.92	0.3	1.03e-14	Blood metabolite levels;
BRCA	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg02153584	chr22:29168773	CCDC117	0.46	9.85	0.36	2.09e-21	Red cell distribution width;
BRCA	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg21143896	chr7:2802374	GNA12	-0.36	-8.98	-0.33	2.94e-18	Height;
BRCA	trans	rs208520	0.661	rs851466	chr6:66840476	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-21.02	-0.64	6.06e-75	Exhaled nitric oxide output;
BRCA	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg13319975	chr6:146136371	FBXO30	-0.34	-7.99	-0.3	6.52e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9811920	0.515	rs792836	chr3:99476384	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-9.96	-0.37	8.22e-22	Axial length;
BRCA	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg25251562	chr2:3704773	ALLC	0.43	8.0	0.3	5.97e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs6543140	0.964	rs4851593	chr2:103089227	C/T	cg04239558	chr2:103089729	SLC9A4	-0.35	-9.81	-0.36	2.88e-21	Blood protein levels;
BRCA	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-14.56	-0.5	1.05e-41	Parkinson's disease;
BRCA	cis	rs12549902	0.966	rs4317621	chr8:41516581	A/G	cg21772509	chr8:41503840	NKX6-3	0.44	10.27	0.38	5.16e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
BRCA	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg06636001	chr8:8085503	FLJ10661	-0.37	-7.84	-0.3	1.92e-14	Retinal vascular caliber;
BRCA	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg00409905	chr10:38381863	ZNF37A	0.45	9.21	0.34	4.65e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg00631329	chr6:26305371	NA	0.44	13.11	0.46	6.06e-35	Educational attainment;
BRCA	cis	rs6840360	0.554	rs6849111	chr4:152708874	T/C	cg22705602	chr4:152727874	NA	-0.4	-10.76	-0.39	6.21e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg11663144	chr21:46675770	NA	-0.47	-11.33	-0.41	2.93e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg04034577	chr2:241836375	C2orf54	-0.57	-13.89	-0.48	1.58e-38	Urinary metabolites;
BRCA	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	7.97	0.3	7.27e-15	Menarche (age at onset);
BRCA	cis	rs2637266	0.935	rs751770	chr10:78393956	A/G	cg18941641	chr10:78392320	NA	0.35	7.89	0.3	1.33e-14	Pulmonary function;
BRCA	cis	rs943466	1.000	rs61662306	chr6:33746697	G/A	cg25922239	chr6:33757077	LEMD2	-0.39	-7.84	-0.3	1.85e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.09	31.24	0.78	8.57e-131	Cognitive ability;
BRCA	cis	rs9790314	0.638	rs17236725	chr3:160637935	C/T	cg03342759	chr3:160939853	NMD3	0.43	8.63	0.32	4.89e-17	Morning vs. evening chronotype;
BRCA	cis	rs295140	0.546	rs295137	chr2:201150040	C/T	cg23649088	chr2:200775458	C2orf69	0.41	8.53	0.32	1.03e-16	QT interval;
BRCA	cis	rs2933343	0.553	rs35979399	chr3:128697313	G/A	cg11901034	chr3:128598214	ACAD9	-0.34	-8.09	-0.3	3.12e-15	IgG glycosylation;
BRCA	trans	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.89	-0.3	1.33e-14	Corneal astigmatism;
BRCA	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg23033748	chr14:75592666	NEK9	-0.42	-10.06	-0.37	3.33e-22	Height;
BRCA	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg09307838	chr4:120376055	NA	0.69	15.42	0.52	7.61e-46	Corneal astigmatism;
BRCA	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg22907277	chr7:1156413	C7orf50	0.59	9.19	0.34	5.4e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg13010199	chr12:38710504	ALG10B	0.49	9.4	0.35	9.65e-20	Morning vs. evening chronotype;
BRCA	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg12386194	chr3:101231763	SENP7	0.62	12.23	0.44	4.82e-31	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs701145	0.585	rs357482	chr3:153889855	A/G	cg17054900	chr3:154042577	DHX36	0.55	9.17	0.34	6.32e-19	Coronary artery disease;
BRCA	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-12.19	-0.43	6.74e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg00105475	chr2:10696890	NA	0.44	10.25	0.38	6.03e-23	Prostate cancer;
BRCA	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11764359	chr7:65958608	NA	-0.61	-13.26	-0.46	1.22e-35	Aortic root size;
BRCA	cis	rs2479724	0.846	rs2254805	chr6:41846110	T/G	cg17623882	chr6:41773611	USP49	-0.34	-9.11	-0.34	1.08e-18	Menarche (age at onset);
BRCA	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	16.34	0.54	2.15e-50	Platelet count;
BRCA	cis	rs17601876	0.545	rs10851498	chr15:51537012	T/C	cg19946085	chr15:51559439	CYP19A1	-0.31	-8.28	-0.31	6.98e-16	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg03877680	chr5:178157825	ZNF354A	0.76	14.28	0.49	2.49e-40	Neutrophil percentage of white cells;
BRCA	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg14458575	chr2:238380390	NA	0.55	12.29	0.44	2.55e-31	Prostate cancer;
BRCA	cis	rs6430585	0.527	rs62168833	chr2:136449254	G/A	cg07169764	chr2:136633963	MCM6	1.0	19.33	0.61	6.73e-66	Corneal structure;
BRCA	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg23711669	chr6:146136114	FBXO30	0.78	18.68	0.59	1.85e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg18357645	chr12:58087776	OS9	0.47	13.47	0.47	1.45e-36	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs10740039	0.768	rs7895268	chr10:62463237	T/C	cg02922035	chr10:62493342	NA	0.41	7.93	0.3	1.01e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg08213375	chr14:104286397	PPP1R13B	0.64	17.88	0.58	2.77e-58	Schizophrenia;
BRCA	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.17	-0.34	6.31e-19	Bipolar disorder;
BRCA	cis	rs13046373	0.507	rs8133828	chr21:32033046	C/G	cg24082983	chr21:31802169	KRTAP13-4	0.34	8.12	0.31	2.41e-15	HDL cholesterol;
BRCA	cis	rs71386921	1	rs71386921	chr10:27478698	AAT/A	cg14442939	chr10:27389572	ANKRD26	0.68	12.58	0.45	1.45e-32	Breast cancer;
BRCA	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg12373951	chr3:133503437	NA	-0.43	-10.32	-0.38	3.42e-23	Iron status biomarkers;
BRCA	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11764359	chr7:65958608	NA	0.74	16.83	0.55	6.92e-53	Aortic root size;
BRCA	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg03894339	chr8:19674705	INTS10	0.44	8.65	0.32	4.29e-17	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg11645453	chr3:52864694	ITIH4	-0.38	-9.89	-0.36	1.44e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	8.19	0.31	1.45e-15	Mean platelet volume;
BRCA	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg17211192	chr8:82754475	SNX16	-0.54	-11.56	-0.42	3.52e-28	Diastolic blood pressure;
BRCA	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg07395648	chr5:131743802	NA	-0.39	-8.4	-0.32	2.91e-16	Breast cancer;
BRCA	cis	rs4363385	0.818	rs426360	chr1:153014710	C/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.14	-0.34	7.95e-19	Inflammatory skin disease;
BRCA	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-16.68	-0.55	3.96e-52	Colorectal cancer;
BRCA	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg03342759	chr3:160939853	NMD3	-0.55	-12.11	-0.43	1.58e-30	Morning vs. evening chronotype;
BRCA	cis	rs6580649	1.000	rs9805048	chr12:48403692	C/T	cg24011408	chr12:48396354	COL2A1	0.53	9.62	0.36	1.48e-20	Lung cancer;
BRCA	cis	rs7474896	0.515	rs594594	chr10:38307723	A/G	cg25427524	chr10:38739819	LOC399744	0.55	10.12	0.37	1.94e-22	Obesity (extreme);
BRCA	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-16.76	-0.55	1.65e-52	Colorectal cancer;
BRCA	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg18252515	chr7:66147081	NA	-1.04	-15.49	-0.52	3.67e-46	Diabetic kidney disease;
BRCA	cis	rs4389656	0.857	rs274715	chr5:6723429	C/T	cg10857441	chr5:6722123	POLS	0.25	7.83	0.3	1.98e-14	Coronary artery disease;
BRCA	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.44	0.32	2.13e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs758324	0.891	rs652839	chr5:131281106	G/C	cg06307176	chr5:131281290	NA	-0.58	-12.25	-0.44	3.79e-31	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.63	10.15	0.37	1.5e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg13736514	chr6:26305472	NA	-0.46	-14.83	-0.51	5.7e-43	Educational attainment;
BRCA	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.31	8.4	0.32	2.99e-16	Ovarian reserve;
BRCA	cis	rs877282	0.735	rs111609055	chr10:826539	A/G	cg15764593	chr10:829463	NA	-0.6	-10.12	-0.37	1.94e-22	Uric acid levels;
BRCA	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11644478	chr21:40555479	PSMG1	-0.67	-15.12	-0.51	2.35e-44	Cognitive function;
BRCA	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12516959	chr21:47718080	NA	-0.43	-9.91	-0.37	1.21e-21	Testicular germ cell tumor;
BRCA	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg26587870	chr6:27730563	NA	-0.41	-8.79	-0.33	1.38e-17	Parkinson's disease;
BRCA	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	10.95	0.4	1.1e-25	Rheumatoid arthritis;
BRCA	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	19.49	0.61	9.39e-67	Platelet count;
BRCA	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg15352829	chr14:105391018	PLD4	-0.36	-11.51	-0.41	5.24e-28	Rheumatoid arthritis;
BRCA	cis	rs13046373	0.535	rs9977510	chr21:32027920	A/G	cg06468780	chr21:31798236	KRTAP13-3	0.34	8.29	0.31	6.65e-16	HDL cholesterol;
BRCA	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg12386194	chr3:101231763	SENP7	0.45	9.55	0.35	2.72e-20	Colorectal cancer;
BRCA	cis	rs1506636	0.646	rs805779	chr7:123214835	C/T	cg03229431	chr7:123269106	ASB15	-0.59	-12.65	-0.45	6.73e-33	Plateletcrit;Platelet count;
BRCA	trans	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg23762105	chr12:34175262	ALG10	0.36	8.41	0.32	2.64e-16	Morning vs. evening chronotype;
BRCA	cis	rs11585357	0.501	rs17458002	chr1:17591524	A/G	cg08277548	chr1:17600880	PADI3	-0.57	-8.0	-0.3	5.66e-15	Hair shape;
BRCA	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg10523679	chr1:76189770	ACADM	0.78	18.67	0.59	1.96e-62	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg06386533	chr2:46925753	SOCS5	-0.4	-7.82	-0.3	2.17e-14	HDL cholesterol;
BRCA	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	10.38	0.38	1.95e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg06521331	chr12:34319734	NA	-0.53	-9.52	-0.35	3.46e-20	Morning vs. evening chronotype;
BRCA	cis	rs16976116	0.851	rs28784096	chr15:55503312	C/T	cg11288833	chr15:55489084	RSL24D1	0.47	10.52	0.38	5.59e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs75229567	0.618	rs11177849	chr12:70182473	C/T	cg10114359	chr12:70132523	RAB3IP	-0.75	-10.27	-0.38	5.28e-23	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
BRCA	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.75	-0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.79	-0.33	1.35e-17	Breast cancer;
BRCA	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg13385794	chr1:248469461	NA	0.28	7.81	0.3	2.28e-14	Common traits (Other);
BRCA	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-9.48	-0.35	5.07e-20	Blood metabolite levels;
BRCA	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.56	-0.32	8.45e-17	Total body bone mineral density;
BRCA	cis	rs7555523	0.887	rs2790053	chr1:165737704	C/G	cg24409356	chr1:165738333	TMCO1	0.51	8.29	0.31	6.9e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	trans	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg25214090	chr10:38739885	LOC399744	0.54	12.23	0.44	4.84e-31	Corneal astigmatism;
BRCA	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	11.23	0.41	7.91e-27	Height;
BRCA	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg00631329	chr6:26305371	NA	-0.44	-12.83	-0.45	1.14e-33	Educational attainment;
BRCA	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg11766577	chr21:47581405	C21orf56	-0.48	-10.81	-0.39	3.81e-25	Testicular germ cell tumor;
BRCA	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-12.58	-0.45	1.41e-32	Developmental language disorder (linguistic errors);
BRCA	trans	rs62103177	0.564	rs1715230	chr18:77848002	C/T	cg05926928	chr17:57297772	GDPD1	0.72	10.55	0.39	4.29e-24	Opioid sensitivity;
BRCA	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg00383909	chr3:49044727	WDR6	0.76	12.57	0.45	1.6e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg19622623	chr12:86230825	RASSF9	-0.33	-9.32	-0.35	1.83e-19	Major depressive disorder;
BRCA	cis	rs9649465	1.000	rs6951138	chr7:123362070	G/A	cg04330084	chr7:123175371	IQUB	-0.33	-9.01	-0.34	2.43e-18	Migraine;
BRCA	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.43	-0.38	1.21e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04565464	chr8:145669602	NFKBIL2	0.38	8.97	0.33	3.25e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs7677751	0.767	rs890204	chr4:55064439	C/G	cg17187183	chr4:55093834	PDGFRA	0.41	8.62	0.32	5.22e-17	Corneal astigmatism;
BRCA	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg17420585	chr12:42539391	GXYLT1	-0.49	-10.61	-0.39	2.54e-24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19346786	chr7:2764209	NA	-0.33	-9.56	-0.35	2.58e-20	Height;
BRCA	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg22307297	chr20:60903441	LAMA5	0.36	9.93	0.37	1.02e-21	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.63	-0.36	1.35e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs9400271	0.632	rs9374070	chr6:109586455	G/A	cg01475377	chr6:109611718	NA	-0.43	-10.39	-0.38	1.73e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg13393036	chr8:95962371	TP53INP1	-0.34	-9.12	-0.34	9.64e-19	Type 2 diabetes;
BRCA	trans	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg23762105	chr12:34175262	ALG10	0.34	7.93	0.3	9.49e-15	Morning vs. evening chronotype;
BRCA	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.21	-0.34	4.44e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg00631329	chr6:26305371	NA	-0.35	-10.07	-0.37	3e-22	Educational attainment;
BRCA	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg27446573	chr6:127587934	RNF146	0.68	15.54	0.52	1.94e-46	Breast cancer;
BRCA	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	11.22	0.41	8.85e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg01689657	chr7:91764605	CYP51A1	-0.21	-7.81	-0.3	2.4e-14	Breast cancer;
BRCA	cis	rs250677	1.000	rs40525	chr5:148432932	G/T	cg12140854	chr5:148520817	ABLIM3	0.4	8.25	0.31	9.17e-16	Breast cancer;
BRCA	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg07741184	chr6:167504864	NA	0.3	8.5	0.32	1.32e-16	Crohn's disease;
BRCA	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg23018236	chr17:30244563	NA	-0.46	-8.65	-0.32	4.07e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg06238570	chr21:40685208	BRWD1	-0.39	-7.9	-0.3	1.2e-14	Menarche (age at onset);
BRCA	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg03733263	chr8:22462867	KIAA1967	0.91	19.82	0.62	1.74e-68	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs9811920	0.809	rs4928235	chr3:99706870	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.55	-13.41	-0.47	2.69e-36	Axial length;
BRCA	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg14343924	chr8:8086146	FLJ10661	-0.39	-7.91	-0.3	1.16e-14	Neuroticism;
BRCA	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg13628971	chr7:2884303	GNA12	0.6	13.71	0.48	1.12e-37	Height;
BRCA	trans	rs747782	0.639	rs17198985	chr11:48183565	T/C	cg15704280	chr7:45808275	SEPT13	0.58	8.44	0.32	2.16e-16	Intraocular pressure;
BRCA	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.48	9.99	0.37	6.12e-22	Multiple sclerosis;
BRCA	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg07395648	chr5:131743802	NA	-0.36	-8.04	-0.3	4.31e-15	Breast cancer;
BRCA	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg11057378	chr10:81107060	PPIF	0.37	9.1	0.34	1.11e-18	Height;
BRCA	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg07169764	chr2:136633963	MCM6	1.22	23.94	0.69	6.91e-91	Corneal structure;
BRCA	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg24296786	chr1:45957014	TESK2	0.65	16.12	0.54	2.5e-49	High light scatter reticulocyte count;
BRCA	cis	rs4074536	0.622	rs28849080	chr1:116319387	C/T	cg21648376	chr1:116311395	CASQ2	-0.55	-9.01	-0.34	2.42e-18	QRS duration;
BRCA	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg22920501	chr2:26401640	FAM59B	-0.81	-13.12	-0.46	5.3e-35	Gut microbiome composition (summer);
BRCA	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg24642439	chr20:33292090	TP53INP2	0.5	10.64	0.39	1.96e-24	Glomerular filtration rate (creatinine);
BRCA	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg18305652	chr10:134549665	INPP5A	0.5	12.97	0.46	2.64e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08219700	chr8:58056026	NA	0.44	8.13	0.31	2.22e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	16.63	0.55	7.04e-52	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs4302748	0.862	rs60346569	chr7:36184201	C/T	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs10046574	0.831	rs10250306	chr7:135165275	G/A	cg27474649	chr7:135195673	CNOT4	0.51	7.97	0.3	7.4e-15	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg13628971	chr7:2884303	GNA12	-0.59	-12.55	-0.44	1.94e-32	Height;
BRCA	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg10523679	chr1:76189770	ACADM	0.91	22.19	0.66	2.64e-81	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.97	-0.3	7.41e-15	Depression;
BRCA	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg06671706	chr8:8559999	CLDN23	0.44	8.59	0.32	6.56e-17	Obesity-related traits;
BRCA	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	12.26	0.44	3.47e-31	Lung cancer in ever smokers;
BRCA	cis	rs17741873	0.836	rs2254266	chr10:75601688	T/C	cg07699608	chr10:75541558	CHCHD1	0.53	8.49	0.32	1.4e-16	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg16606324	chr3:10149918	C3orf24	0.56	11.2	0.4	1.08e-26	Alzheimer's disease;
BRCA	trans	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.68	-0.36	9.28e-21	Bladder cancer;
BRCA	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg04450456	chr4:17643702	FAM184B	0.39	10.86	0.39	2.38e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg05340658	chr4:99064831	C4orf37	0.69	17.52	0.57	2.09e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.51	0.41	5.68e-28	Homoarginine levels;
BRCA	cis	rs943466	0.955	rs11757524	chr6:33766212	A/G	cg25922239	chr6:33757077	LEMD2	-0.38	-7.97	-0.3	7.55e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg08017756	chr2:100939284	LONRF2	-0.3	-7.91	-0.3	1.13e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7523050	0.643	rs7519293	chr1:109399543	A/G	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs7582720	1.000	rs72934573	chr2:204005072	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	12.75	0.45	2.48e-33	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs7953508	0.506	rs12425869	chr12:93961353	A/G	cg18151635	chr12:93972918	NA	-0.45	-9.15	-0.34	7.59e-19	Pubertal anthropometrics;
BRCA	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs701145	0.938	rs189588	chr3:153995855	T/G	cg17054900	chr3:154042577	DHX36	0.68	11.79	0.42	3.71e-29	Coronary artery disease;
BRCA	trans	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg25214090	chr10:38739885	LOC399744	0.52	11.52	0.41	4.81e-28	Corneal astigmatism;
BRCA	trans	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg01620082	chr3:125678407	NA	-0.56	-7.93	-0.3	9.71e-15	Depression;
BRCA	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-12.03	-0.43	3.29e-30	Mood instability;
BRCA	trans	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg25214090	chr10:38739885	LOC399744	0.56	12.39	0.44	9.8e-32	Corneal astigmatism;
BRCA	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg13010199	chr12:38710504	ALG10B	0.44	9.22	0.34	4.31e-19	Morning vs. evening chronotype;
BRCA	trans	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.78	0.33	1.46e-17	Mean corpuscular volume;
BRCA	trans	rs1200821	0.704	rs9888115	chr10:37658351	C/T	cg25427524	chr10:38739819	LOC399744	0.38	8.04	0.3	4.51e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6545883	0.868	rs2518933	chr2:61797030	C/A	cg15711740	chr2:61764176	XPO1	-0.57	-14.37	-0.49	9.19e-41	Tuberculosis;
BRCA	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg19052272	chr2:3704530	ALLC	-0.46	-10.36	-0.38	2.32e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.88	-0.4	2.09e-25	Mean corpuscular volume;
BRCA	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg07520158	chr7:32535189	LSM5;AVL9	0.5	11.18	0.4	1.21e-26	Cognitive ability;
BRCA	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26314531	chr2:26401878	FAM59B	0.96	16.34	0.54	2.18e-50	Gut microbiome composition (summer);
BRCA	cis	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05901451	chr6:126070800	HEY2	-0.4	-9.48	-0.35	4.82e-20	Endometrial cancer;
BRCA	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	13.78	0.48	5.33e-38	Platelet count;
BRCA	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg04851639	chr8:1020857	NA	-0.35	-10.69	-0.39	1.14e-24	Schizophrenia;
BRCA	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg24642439	chr20:33292090	TP53INP2	0.64	14.58	0.5	8.83e-42	Coronary artery disease;
BRCA	trans	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg19862616	chr7:65841803	NCRNA00174	0.65	17.57	0.57	1.18e-56	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg23029597	chr12:123009494	RSRC2	0.65	11.53	0.41	4.49e-28	Body mass index;
BRCA	cis	rs11168351	0.517	rs10875754	chr12:48557922	G/C	cg24011408	chr12:48396354	COL2A1	0.44	9.77	0.36	4.3e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.41	11.53	0.42	4.3e-28	Monocyte percentage of white cells;
BRCA	cis	rs10779751	0.770	rs12097293	chr1:11197467	A/G	cg08854313	chr1:11322531	MTOR	-0.71	-14.14	-0.49	1.05e-39	Body mass index;
BRCA	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg19156104	chr2:198669113	PLCL1	-0.45	-8.26	-0.31	8.46e-16	Ulcerative colitis;
BRCA	cis	rs2108225	0.872	rs6980029	chr7:107446127	T/C	cg18560240	chr7:107437656	SLC26A3	-0.54	-11.29	-0.41	4.55e-27	Ulcerative colitis;
BRCA	cis	rs760805	0.965	rs11249203	chr1:25258585	G/C	cg22509179	chr1:25234806	RUNX3	-0.57	-14.56	-0.5	1.12e-41	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21659725	chr3:3221576	CRBN	-0.7	-20.95	-0.64	1.37e-74	Intelligence (multi-trait analysis);
BRCA	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.45	-10.2	-0.37	9.65e-23	Reticulocyte count;
BRCA	trans	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.39	8.02	0.3	5.14e-15	Menarche (age at onset);
BRCA	cis	rs6088813	1.000	rs725908	chr20:33968067	T/C	cg14752227	chr20:34000481	UQCC	-0.39	-7.97	-0.3	7.46e-15	Height;
BRCA	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.4	8.3	0.31	6.39e-16	Aortic root size;
BRCA	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-9.14	-0.34	8.07e-19	Morning vs. evening chronotype;
BRCA	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg22117172	chr7:91764530	CYP51A1	0.23	7.87	0.3	1.52e-14	Breast cancer;
BRCA	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg12310025	chr6:25882481	NA	-0.51	-11.14	-0.4	1.8e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	6.95e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg17830980	chr10:43048298	ZNF37B	0.4	8.52	0.32	1.18e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6901250	0.851	rs339324	chr6:117195024	C/T	cg12892004	chr6:117198278	RFX6	-0.48	-11.03	-0.4	5.35e-26	C-reactive protein levels;
BRCA	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg03709012	chr19:19516395	GATAD2A	-0.8	-18.59	-0.59	5.39e-62	Tonsillectomy;
BRCA	cis	rs4930561	0.714	rs11228151	chr11:67949371	C/G	cg04465784	chr11:67976953	SUV420H1	-0.26	-8.57	-0.32	8.05e-17	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg08000102	chr2:233561755	GIGYF2	-0.63	-13.61	-0.47	3.18e-37	Coronary artery disease;
BRCA	cis	rs17601876	0.814	rs17523527	chr15:51554032	C/T	cg19946085	chr15:51559439	CYP19A1	-0.36	-9.91	-0.37	1.2e-21	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs1691799	0.899	rs1185244	chr12:66725160	C/T	cg16791601	chr12:66731901	HELB	-0.64	-17.25	-0.56	5.11e-55	White blood cell count (basophil);
BRCA	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.66	-0.53	4.96e-47	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg11266682	chr4:10021025	SLC2A9	0.39	10.36	0.38	2.41e-23	Bone mineral density;
BRCA	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18876405	chr7:65276391	NA	-0.51	-11.59	-0.42	2.49e-28	Aortic root size;
BRCA	cis	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.13	-0.4	2.05e-26	Morning vs. evening chronotype;
BRCA	cis	rs939658	0.728	rs11637459	chr15:79413554	A/G	cg17916960	chr15:79447300	NA	-0.44	-10.54	-0.38	4.78e-24	Refractive error;
BRCA	cis	rs9649465	1.000	rs11765478	chr7:123362872	A/C	cg04330084	chr7:123175371	IQUB	-0.31	-8.44	-0.32	2.13e-16	Migraine;
BRCA	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	ch.11.42038R	chr11:967971	AP2A2	0.5	15.52	0.52	2.53e-46	Alzheimer's disease (late onset);
BRCA	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-12.28	-0.44	2.87e-31	Personality dimensions;
BRCA	cis	rs4074536	0.536	rs12737145	chr1:116284602	G/A	cg21648376	chr1:116311395	CASQ2	-0.48	-8.23	-0.31	1.02e-15	QRS duration;
BRCA	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg13010199	chr12:38710504	ALG10B	0.51	9.8	0.36	3.24e-21	Bladder cancer;
BRCA	cis	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05901451	chr6:126070800	HEY2	0.4	9.69	0.36	8.04e-21	Endometrial cancer;
BRCA	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg26384229	chr12:38710491	ALG10B	0.72	17.02	0.56	7.11e-54	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9682041	0.597	rs62295834	chr3:170075701	G/A	cg11886554	chr3:170076028	SKIL	0.51	10.21	0.37	9.31e-23	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs55894533	0.597	rs2645408	chr8:11746358	A/G	cg21281001	chr8:11725306	CTSB	0.54	11.47	0.41	8.09e-28	Leprosy;
BRCA	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg00745463	chr17:30367425	LRRC37B	-0.6	-9.77	-0.36	4.04e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg20503657	chr10:835505	NA	0.92	15.45	0.52	5.23e-46	Eosinophil percentage of granulocytes;
BRCA	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg22834771	chr12:69754056	YEATS4	-0.42	-10.56	-0.39	3.79e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg00325661	chr8:49890786	NA	0.33	8.81	0.33	1.19e-17	Sudden cardiac arrest;
BRCA	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.35	9.01	0.34	2.32e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg22920501	chr2:26401640	FAM59B	0.89	16.09	0.54	3.71e-49	Gut microbiome composition (summer);
BRCA	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	14.22	0.49	4.76e-40	Colorectal cancer;
BRCA	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.34	-8.96	-0.33	3.48e-18	Total body bone mineral density;
BRCA	cis	rs3771570	1.000	rs3771570	chr2:242382864	C/T	cg21155796	chr2:242212141	HDLBP	0.61	9.33	0.35	1.79e-19	Prostate cancer;
BRCA	cis	rs7617773	0.780	rs7653152	chr3:48362097	G/C	cg11946769	chr3:48343235	NME6	0.69	13.74	0.48	8.05e-38	Coronary artery disease;
BRCA	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.41	-9.28	-0.34	2.59e-19	Longevity;Endometriosis;
BRCA	cis	rs62005083	0.541	rs61059815	chr14:74536465	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.52	7.92	0.3	1.03e-14	Mean corpuscular volume;
BRCA	cis	rs9815354	0.812	rs73073234	chr3:42012071	C/T	cg03022575	chr3:42003672	ULK4	0.73	10.09	0.37	2.52e-22	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg23711669	chr6:146136114	FBXO30	0.73	17.14	0.56	1.74e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02353165	chr6:42928485	GNMT	0.89	24.06	0.69	1.41e-91	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg04450456	chr4:17643702	FAM184B	0.36	9.85	0.36	2.08e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg08917208	chr2:24149416	ATAD2B	0.58	9.19	0.34	5.5e-19	Lymphocyte counts;
BRCA	cis	rs4285028	0.948	rs34181646	chr3:121705373	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.58	-10.84	-0.39	3.02e-25	Multiple sclerosis;
BRCA	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg25326776	chr5:148520934	ABLIM3	-0.42	-7.96	-0.3	8.11e-15	Breast cancer;
BRCA	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-13.02	-0.46	1.53e-34	Blood metabolite levels;
BRCA	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	10.72	0.39	9.22e-25	Iron status biomarkers;
BRCA	cis	rs10504073	0.647	rs10808744	chr8:49988984	A/G	cg00325661	chr8:49890786	NA	0.44	12.49	0.44	3.46e-32	Blood metabolite ratios;
BRCA	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24110177	chr3:50126178	RBM5	0.36	9.65	0.36	1.19e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11890956	chr21:40555474	PSMG1	-0.62	-13.82	-0.48	3.3e-38	Menarche (age at onset);
BRCA	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-9.06	-0.34	1.55e-18	Alzheimer's disease (late onset);
BRCA	cis	rs754466	0.580	rs12354903	chr10:79536465	T/C	cg17075019	chr10:79541650	NA	-0.87	-23.88	-0.69	1.36e-90	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19346786	chr7:2764209	NA	-0.39	-11.16	-0.4	1.53e-26	Height;
BRCA	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg00757033	chr12:89920650	WDR51B	0.52	10.52	0.38	5.8e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg08601574	chr20:25228251	PYGB	-0.38	-9.07	-0.34	1.41e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg08508325	chr11:3079039	CARS	0.28	8.48	0.32	1.56e-16	Calcium levels;
BRCA	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg12379764	chr21:47803548	PCNT	-0.37	-7.86	-0.3	1.61e-14	Testicular germ cell tumor;
BRCA	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg11301795	chr4:187892539	NA	-0.31	-10.2	-0.37	1.01e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg00071950	chr4:10020882	SLC2A9	0.64	16.0	0.53	1.06e-48	Bone mineral density;
BRCA	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.82	-0.39	3.44e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs3767633	0.528	rs6671373	chr1:161890796	C/G	cg27519958	chr1:161735129	ATF6	-0.49	-11.73	-0.42	6.39e-29	IgG glycosylation;
BRCA	cis	rs17253792	0.822	rs13379342	chr14:56050452	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.61	8.47	0.32	1.68e-16	Putamen volume;
BRCA	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.04	-0.3	4.46e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs11945232	1.000	rs28406846	chr4:88343468	C/G	cg23841344	chr4:88312519	HSD17B11	-0.49	-9.57	-0.35	2.29e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg12365402	chr11:9010492	NRIP3	0.45	9.93	0.37	1.07e-21	Hemoglobin concentration;
BRCA	cis	rs427394	0.664	rs274701	chr5:6728707	C/A	cg10857441	chr5:6722123	POLS	-0.32	-10.9	-0.4	1.66e-25	Menopause (age at onset);
BRCA	trans	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.01	30.72	0.77	5.71e-128	Colorectal cancer;
BRCA	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg20891283	chr12:69753455	YEATS4	0.7	18.91	0.6	1.18e-63	Blood protein levels;
BRCA	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.02	18.02	0.58	5.32e-59	Gut microbiome composition (summer);
BRCA	cis	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg05901451	chr6:126070800	HEY2	0.4	9.7	0.36	7.73e-21	Endometrial cancer;
BRCA	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg05340658	chr4:99064831	C4orf37	-0.5	-11.74	-0.42	5.85e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	15.47	0.52	4.16e-46	Coronary artery disease;
BRCA	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg12935359	chr14:103987150	CKB	0.62	14.54	0.5	1.45e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs9427116	0.502	rs9426827	chr1:154589965	T/C	cg17218026	chr1:154582156	ADAR	0.28	8.38	0.31	3.46e-16	Blood protein levels;
BRCA	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg06618935	chr21:46677482	NA	-0.37	-7.99	-0.3	6.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg23231163	chr10:75533350	FUT11	-0.34	-8.89	-0.33	6e-18	Inflammatory bowel disease;
BRCA	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg13319975	chr6:146136371	FBXO30	0.36	8.46	0.32	1.85e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11971779	0.680	rs6954531	chr7:139054706	C/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.24	0.38	6.65e-23	Diisocyanate-induced asthma;
BRCA	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.6	0.39	2.61e-24	Cognitive ability;
BRCA	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg03146154	chr1:46216737	IPP	-0.45	-10.04	-0.37	3.89e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7617773	0.539	rs12486935	chr3:48390164	C/T	cg11946769	chr3:48343235	NME6	0.45	9.48	0.35	4.8e-20	Coronary artery disease;
BRCA	cis	rs10465746	0.780	rs1871924	chr1:84398466	T/A	cg10977910	chr1:84465055	TTLL7	0.56	11.63	0.42	1.77e-28	Obesity-related traits;
BRCA	trans	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg01620082	chr3:125678407	NA	-0.57	-8.08	-0.3	3.19e-15	Depression;
BRCA	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.34	-7.82	-0.3	2.26e-14	High light scatter reticulocyte count;
BRCA	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg21475434	chr5:93447410	FAM172A	0.65	8.65	0.32	4e-17	Diabetic retinopathy;
BRCA	trans	rs7939886	0.920	rs61742348	chr11:55905078	C/T	cg15704280	chr7:45808275	SEPT13	0.63	7.84	0.3	1.88e-14	Myopia (pathological);
BRCA	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	7.9	0.3	1.21e-14	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.76	0.39	6.07e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg06521331	chr12:34319734	NA	-0.57	-11.06	-0.4	4e-26	Morning vs. evening chronotype;
BRCA	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg13319975	chr6:146136371	FBXO30	-0.36	-8.34	-0.31	4.63e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	8.63	0.32	4.92e-17	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6815814	0.950	rs73236633	chr4:38839319	T/C	cg02016764	chr4:38805732	TLR1	-0.52	-7.83	-0.3	2e-14	Breast cancer;
BRCA	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-9.6	-0.35	1.81e-20	Fear of minor pain;
BRCA	cis	rs877282	0.945	rs10904550	chr10:774177	C/T	cg17470449	chr10:769945	NA	0.5	9.49	0.35	4.33e-20	Uric acid levels;
BRCA	cis	rs36051895	0.632	rs7871515	chr9:5175288	A/G	cg02405213	chr9:5042618	JAK2	0.44	8.57	0.32	7.91e-17	Pediatric autoimmune diseases;
BRCA	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.13	0.31	2.24e-15	Breast cancer;
BRCA	cis	rs75804782	0.641	rs72987304	chr2:239345532	C/T	cg18131467	chr2:239335373	ASB1	-0.62	-7.98	-0.3	6.89e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23221052	chr5:179740743	GFPT2	0.64	13.55	0.47	5.94e-37	Height;
BRCA	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg26384229	chr12:38710491	ALG10B	0.78	18.11	0.58	1.71e-59	Bladder cancer;
BRCA	cis	rs4557202	0.509	rs12690576	chr3:160647912	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-11.05	-0.4	4.35e-26	Menarche (age at onset);
BRCA	cis	rs73001065	0.818	rs73004966	chr19:19716558	C/T	cg03709012	chr19:19516395	GATAD2A	0.76	9.65	0.36	1.16e-20	LDL cholesterol;
BRCA	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg25358565	chr5:93447407	FAM172A	1.2	19.94	0.62	3.82e-69	Diabetic retinopathy;
BRCA	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24549020	chr5:56110836	MAP3K1	0.64	12.81	0.45	1.29e-33	Initial pursuit acceleration;
BRCA	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg12011299	chr4:100065546	ADH4	0.49	11.06	0.4	3.83e-26	Smoking initiation;
BRCA	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg08859206	chr1:53392774	SCP2	0.41	8.17	0.31	1.66e-15	Monocyte count;
BRCA	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg23533926	chr12:111358616	MYL2	-0.43	-9.14	-0.34	8.32e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg26248373	chr2:1572462	NA	-0.47	-9.29	-0.35	2.34e-19	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs701145	0.556	rs355763	chr3:154012881	C/T	cg16511985	chr3:153974050	SGEF	0.46	10.55	0.39	4.19e-24	Coronary artery disease;
BRCA	cis	rs698833	0.532	rs2616444	chr2:44605518	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.93	0.37	1.02e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.39	0.38	1.75e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg10223061	chr2:219282414	VIL1	-0.27	-7.94	-0.3	8.88e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.28	0.38	4.77e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs724568	0.546	rs1367457	chr2:67951861	C/T	cg17945962	chr2:67939740	NA	0.38	9.96	0.37	7.95e-22	Major depressive disorder (broad);
BRCA	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18876405	chr7:65276391	NA	-0.54	-12.69	-0.45	4.52e-33	Aortic root size;
BRCA	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg22563815	chr15:78856949	CHRNA5	-0.35	-8.1	-0.31	2.86e-15	Sudden cardiac arrest;
BRCA	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg16482183	chr6:26056742	HIST1H1C	0.51	10.95	0.4	1.11e-25	Height;
BRCA	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg24558204	chr6:135376177	HBS1L	0.48	13.36	0.47	4.64e-36	Red blood cell count;
BRCA	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg04455712	chr21:45112962	RRP1B	0.48	13.11	0.46	6.17e-35	Mean corpuscular volume;
BRCA	cis	rs12618769	0.543	rs72819980	chr2:99040522	A/G	cg10123293	chr2:99228465	UNC50	0.4	8.17	0.31	1.62e-15	Bipolar disorder;
BRCA	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg11764359	chr7:65958608	NA	0.65	11.9	0.43	1.21e-29	Aortic root size;
BRCA	trans	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg26043149	chr18:55253948	FECH	-0.4	-9.1	-0.34	1.11e-18	Bone mineral density;
BRCA	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg08999081	chr20:33150536	PIGU	-0.44	-12.28	-0.44	2.85e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.01	-0.46	1.66e-34	Migraine;Coronary artery disease;
BRCA	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg02079420	chr8:82753780	SNX16	0.31	8.43	0.32	2.27e-16	Diastolic blood pressure;
BRCA	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-9.37	-0.35	1.2e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg24060327	chr5:131705240	SLC22A5	0.51	10.7	0.39	1.05e-24	Blood metabolite levels;
BRCA	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg09184832	chr6:79620586	NA	-0.46	-10.02	-0.37	4.81e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg00383909	chr3:49044727	WDR6	0.6	10.99	0.4	7.23e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6594499	1.000	rs1438673	chr5:110467499	C/T	cg04022379	chr5:110408740	TSLP	0.37	8.04	0.3	4.52e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7903847	0.596	rs10786340	chr10:99156563	G/C	cg20016023	chr10:99160130	RRP12	-0.26	-8.47	-0.32	1.68e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4363385	0.818	rs378010	chr1:153007987	A/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.5	-0.32	1.38e-16	Inflammatory skin disease;
BRCA	trans	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-8.7	-0.33	2.89e-17	Retinal vascular caliber;
BRCA	cis	rs4853036	0.586	rs35286755	chr2:70005173	T/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-7.99	-0.3	6.39e-15	Colorectal or endometrial cancer;
BRCA	cis	rs4812048	0.793	rs62205397	chr20:57597011	C/T	cg14073986	chr20:57617431	SLMO2	0.56	8.5	0.32	1.3e-16	Mean platelet volume;
BRCA	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-11.69	-0.42	9.33e-29	Pulmonary function;
BRCA	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg12463550	chr7:65579703	CRCP	0.36	8.01	0.3	5.52e-15	Aortic root size;
BRCA	cis	rs965469	0.895	rs6139123	chr20:3396634	C/T	cg25506879	chr20:3388711	C20orf194	-0.54	-10.6	-0.39	2.73e-24	IFN-related cytopenia;
BRCA	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18876405	chr7:65276391	NA	-0.6	-15.01	-0.51	7.84e-44	Aortic root size;
BRCA	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg04944784	chr2:26401820	FAM59B	-0.85	-13.27	-0.46	1.19e-35	Gut microbiome composition (summer);
BRCA	cis	rs4363385	0.747	rs3753454	chr1:152973776	T/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.09	-0.34	1.22e-18	Inflammatory skin disease;
BRCA	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.83	0.39	3.27e-25	Bipolar disorder;
BRCA	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg08213375	chr14:104286397	PPP1R13B	0.4	8.59	0.32	6.75e-17	Reticulocyte count;
BRCA	cis	rs708547	0.581	rs10020462	chr4:57825593	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.36	-8.97	-0.33	3.31e-18	Response to bleomycin (chromatid breaks);
BRCA	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg18301423	chr5:131593218	PDLIM4	0.34	8.66	0.32	3.71e-17	Breast cancer;
BRCA	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg12927641	chr6:109611667	NA	-0.42	-10.99	-0.4	7.54e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.87	0.3	1.56e-14	Depression;
BRCA	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg13647721	chr17:30228624	UTP6	0.5	9.02	0.34	2.15e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg20487152	chr13:99095054	FARP1	-0.34	-7.84	-0.3	1.93e-14	Longevity;
BRCA	trans	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.94	-14.33	-0.49	1.37e-40	Obesity-related traits;
BRCA	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg15395560	chr15:45543142	SLC28A2	-0.29	-7.83	-0.3	2.02e-14	Uric acid levels;
BRCA	cis	rs7833986	1.000	rs66796428	chr8:57094797	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.46	8.27	0.31	7.62e-16	Height;
BRCA	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08219700	chr8:58056026	NA	0.44	8.01	0.3	5.57e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	trans	rs17685	0.753	rs8200	chr7:75696606	C/G	cg19862616	chr7:65841803	NCRNA00174	-0.84	-27.72	-0.74	1.12e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7520050	0.966	rs12021587	chr1:46472759	G/T	cg24296786	chr1:45957014	TESK2	0.44	9.84	0.36	2.33e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg00409905	chr10:38381863	ZNF37A	0.45	9.38	0.35	1.12e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg09307838	chr4:120376055	NA	0.68	14.12	0.49	1.28e-39	Corneal astigmatism;
BRCA	cis	rs2712184	0.756	rs2024489	chr2:217661530	A/G	cg05032264	chr2:217675019	NA	-0.36	-8.69	-0.33	3e-17	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-12.41	-0.44	7.98e-32	Bipolar disorder;
BRCA	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg24642439	chr20:33292090	TP53INP2	0.41	8.0	0.3	5.83e-15	Height;
BRCA	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg07636037	chr3:49044803	WDR6	0.55	8.74	0.33	2.09e-17	Menarche (age at onset);
BRCA	cis	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg04990556	chr1:26633338	UBXN11	0.54	8.86	0.33	8.17e-18	Obesity-related traits;
BRCA	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg03711944	chr11:47377212	SPI1	-0.41	-9.75	-0.36	5.1e-21	Diastolic blood pressure;Systolic blood pressure;
BRCA	trans	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg26384229	chr12:38710491	ALG10B	0.54	11.92	0.43	1e-29	Morning vs. evening chronotype;
BRCA	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg10223061	chr2:219282414	VIL1	0.29	8.15	0.31	1.92e-15	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	11.79	0.42	3.66e-29	Lung cancer in ever smokers;
BRCA	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11890956	chr21:40555474	PSMG1	1.02	27.95	0.74	6.78e-113	Cognitive function;
BRCA	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg23711669	chr6:146136114	FBXO30	0.72	14.36	0.49	9.97e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.31	0.49	1.68e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg27284194	chr4:1044797	NA	-0.41	-8.98	-0.33	2.9e-18	Recombination rate (males);
BRCA	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.04	0.34	1.81e-18	Tonsillectomy;
BRCA	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg26384229	chr12:38710491	ALG10B	0.59	13.62	0.47	2.98e-37	Morning vs. evening chronotype;
BRCA	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg00990874	chr7:1149470	C7orf50	-0.56	-10.62	-0.39	2.19e-24	Bronchopulmonary dysplasia;
BRCA	cis	rs1011018	0.628	rs12374779	chr7:139453505	T/C	cg03224163	chr7:139420300	HIPK2	-0.59	-8.97	-0.33	3.35e-18	Systolic blood pressure;
BRCA	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg17420585	chr12:42539391	GXYLT1	-0.48	-10.4	-0.38	1.66e-23	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7715811	1.000	rs6554813	chr5:13763039	G/A	cg07548982	chr5:13769939	DNAH5	-0.38	-8.3	-0.31	6.2e-16	Subclinical atherosclerosis traits (other);
BRCA	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg25801113	chr15:45476975	SHF	-0.33	-8.3	-0.31	6.21e-16	Uric acid levels;
BRCA	cis	rs534126	0.744	rs10248147	chr7:142941023	C/G	cg15652212	chr7:142981776	TMEM139	-0.46	-10.34	-0.38	2.84e-23	Cancer;
BRCA	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.2	-0.41	1.02e-26	Schizophrenia;
BRCA	cis	rs11971779	0.680	rs2355785	chr7:139070983	C/A	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg08601574	chr20:25228251	PYGB	0.34	8.15	0.31	1.86e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2901460	0.509	rs12470090	chr2:62094367	T/C	cg02183531	chr2:62113199	CCT4	-0.45	-8.83	-0.33	9.75e-18	Mean corpuscular volume;
BRCA	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.37	-0.31	3.62e-16	Total body bone mineral density;
BRCA	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg24829409	chr8:58192753	C8orf71	-0.48	-9.25	-0.34	3.23e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg10876282	chr6:28092338	ZSCAN16	0.42	8.17	0.31	1.64e-15	Parkinson's disease;
BRCA	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.33	-7.85	-0.3	1.77e-14	Total body bone mineral density;
BRCA	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg15017067	chr4:17643749	FAM184B	0.26	7.98	0.3	6.95e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2742417	0.624	rs2673029	chr3:45758867	A/G	cg04837898	chr3:45731254	SACM1L	-0.4	-8.11	-0.31	2.59e-15	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs3796352	0.571	rs71301816	chr3:53142071	G/A	cg07884673	chr3:53033167	SFMBT1	0.7	8.55	0.32	9.23e-17	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11764359	chr7:65958608	NA	-0.75	-16.8	-0.55	9.56e-53	Aortic root size;
BRCA	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg04450456	chr4:17643702	FAM184B	0.35	10.14	0.37	1.66e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg00074818	chr8:8560427	CLDN23	0.38	8.35	0.31	4.17e-16	Obesity-related traits;
BRCA	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg08493051	chr2:3487164	NA	-0.43	-9.19	-0.34	5.56e-19	Neurofibrillary tangles;
BRCA	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg24558204	chr6:135376177	HBS1L	0.45	12.42	0.44	7.31e-32	Red blood cell count;
BRCA	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg00814883	chr7:100076585	TSC22D4	-0.49	-9.97	-0.37	7.61e-22	Platelet count;
BRCA	cis	rs835154	0.845	rs835156	chr5:14875813	C/A	cg18064842	chr5:14874549	NA	-0.48	-13.04	-0.46	1.31e-34	Blood metabolite levels;
BRCA	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg02196655	chr2:10830764	NOL10	-0.3	-8.16	-0.31	1.79e-15	Prostate cancer;
BRCA	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg20503657	chr10:835505	NA	0.88	16.0	0.53	1.02e-48	Eosinophil percentage of granulocytes;
BRCA	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg04450456	chr4:17643702	FAM184B	-0.36	-10.24	-0.38	7.07e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg14547644	chr6:28411285	ZSCAN23	-0.35	-7.91	-0.3	1.17e-14	Pubertal anthropometrics;
BRCA	cis	rs1003719	0.591	rs2835633	chr21:38525019	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.57	-13.2	-0.46	2.26e-35	Eye color traits;
BRCA	trans	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	14.83	0.51	5.64e-43	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.07	23.75	0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08564027	chr20:61660810	NA	0.85	22.97	0.67	1.42e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.62	10.61	0.39	2.37e-24	Lung function (FEV1/FVC);
BRCA	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	16.71	0.55	2.98e-52	Alzheimer's disease;
BRCA	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.06	-0.34	1.53e-18	Total body bone mineral density;
BRCA	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.39	0.35	1.01e-19	Tonsillectomy;
BRCA	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg04455712	chr21:45112962	RRP1B	0.41	10.7	0.39	1.07e-24	Mean corpuscular volume;
BRCA	cis	rs7607369	0.536	rs12990447	chr2:219667413	T/C	cg02176678	chr2:219576539	TTLL4	-0.38	-10.13	-0.37	1.75e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs2625529	0.878	rs71395051	chr15:72239789	C/T	cg16672083	chr15:72433130	SENP8	-0.84	-17.27	-0.56	3.79e-55	Red blood cell count;
BRCA	cis	rs10181042	0.514	rs1177289	chr2:61353256	T/C	cg15711740	chr2:61764176	XPO1	-0.37	-8.76	-0.33	1.8e-17	Crohn's disease;
BRCA	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg20891283	chr12:69753455	YEATS4	0.47	10.92	0.4	1.39e-25	Response to diuretic therapy;
BRCA	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg01262667	chr19:19385393	TM6SF2	0.41	10.54	0.38	4.75e-24	Tonsillectomy;
BRCA	cis	rs9807989	0.507	rs6543133	chr2:103040177	A/T	cg03938978	chr2:103052716	IL18RAP	0.29	8.3	0.31	6.11e-16	Asthma;
BRCA	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.75	11.64	0.42	1.51e-28	Gut microbiome composition (summer);
BRCA	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg00031303	chr3:195681400	NA	0.45	8.57	0.32	7.88e-17	Pancreatic cancer;
BRCA	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg26384229	chr12:38710491	ALG10B	-0.44	-10.14	-0.37	1.63e-22	Heart rate;
BRCA	cis	rs9837602	0.938	rs9814359	chr3:99797013	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	10.36	0.38	2.3e-23	Breast cancer;
BRCA	cis	rs7560272	0.538	rs2421575	chr2:73919522	G/A	cg20560298	chr2:73613845	ALMS1	0.36	9.26	0.34	3.06e-19	Schizophrenia;
BRCA	cis	rs7903847	0.642	rs7092499	chr10:99140313	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.34	-0.31	4.57e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg13385794	chr1:248469461	NA	0.28	8.11	0.31	2.62e-15	Common traits (Other);
BRCA	cis	rs3947	0.906	rs709822	chr8:11702313	C/G	cg00262122	chr8:11665843	FDFT1	-0.43	-8.39	-0.32	3.1e-16	Blood protein levels;
BRCA	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg24642439	chr20:33292090	TP53INP2	0.69	15.69	0.53	3.65e-47	Coronary artery disease;
BRCA	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg18252515	chr7:66147081	NA	1.01	15.2	0.52	9.4e-45	Diabetic kidney disease;
BRCA	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg05714579	chr10:131428358	MGMT	0.5	11.21	0.41	9.49e-27	Response to temozolomide;
BRCA	cis	rs36051895	0.589	rs6476948	chr9:5204404	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-8.33	-0.31	4.81e-16	Pediatric autoimmune diseases;
BRCA	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	10.5	0.38	6.75e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs350251	0.899	rs350277	chr16:12232547	C/T	cg06014057	chr16:12226852	SNX29	0.29	7.97	0.3	7.57e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg21724239	chr8:58056113	NA	0.58	9.44	0.35	7.02e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg15556689	chr8:8085844	FLJ10661	-0.33	-8.88	-0.33	6.75e-18	Joint mobility (Beighton score);
BRCA	cis	rs11971779	0.680	rs73154134	chr7:139039951	G/A	cg07862535	chr7:139043722	LUC7L2	0.39	10.33	0.38	3.14e-23	Diisocyanate-induced asthma;
BRCA	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg09184832	chr6:79620586	NA	-0.48	-10.4	-0.38	1.69e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg23711669	chr6:146136114	FBXO30	0.64	14.49	0.5	2.31e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg08645402	chr16:4508243	NA	0.34	8.26	0.31	8.63e-16	Schizophrenia;
BRCA	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.36	-0.41	2.32e-27	Schizophrenia;
BRCA	cis	rs7523273	0.606	rs2796271	chr1:207941927	A/G	cg22525895	chr1:207977042	MIR29B2	0.47	12.01	0.43	4.14e-30	Schizophrenia;
BRCA	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg04727924	chr7:799746	HEATR2	-0.52	-9.07	-0.34	1.47e-18	Cerebrospinal P-tau181p levels;
BRCA	trans	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg11693508	chr17:37793320	STARD3	0.52	10.45	0.38	1.09e-23	Neuroticism;
BRCA	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg18446336	chr7:2847575	GNA12	-0.34	-8.2	-0.31	1.36e-15	Height;
BRCA	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg24130564	chr14:104152367	KLC1	0.36	8.04	0.3	4.42e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7737355	0.947	rs58991576	chr5:130589540	T/C	cg06307176	chr5:131281290	NA	-0.43	-8.48	-0.32	1.54e-16	Life satisfaction;
BRCA	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg24558204	chr6:135376177	HBS1L	0.6	16.25	0.54	5.98e-50	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg25358565	chr5:93447407	FAM172A	1.25	19.16	0.6	5.42e-65	Diabetic retinopathy;
BRCA	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg08470875	chr2:26401718	FAM59B	0.68	10.26	0.38	5.63e-23	Gut microbiome composition (summer);
BRCA	cis	rs6424115	0.557	rs35904775	chr1:24180623	T/C	cg15997130	chr1:24165203	NA	-0.51	-13.39	-0.47	3.11e-36	Immature fraction of reticulocytes;
BRCA	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg20607287	chr7:12443886	VWDE	-0.58	-8.24	-0.31	9.69e-16	Coronary artery disease;
BRCA	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.26	-0.31	8.16e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg12311346	chr5:56204834	C5orf35	0.61	12.59	0.45	1.29e-32	Initial pursuit acceleration;
BRCA	cis	rs733592	1.000	rs733592	chr12:48429776	C/T	cg24011408	chr12:48396354	COL2A1	-0.44	-9.43	-0.35	7.26e-20	Plateletcrit;
BRCA	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg14863265	chr7:2801509	GNA12	-0.47	-10.22	-0.37	8.53e-23	Height;
BRCA	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg18129178	chr5:148520854	ABLIM3	-0.59	-11.98	-0.43	5.71e-30	Breast cancer;
BRCA	cis	rs9649465	0.967	rs7791183	chr7:123343719	A/G	cg04330084	chr7:123175371	IQUB	-0.3	-8.32	-0.31	5.51e-16	Migraine;
BRCA	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg11887960	chr12:57824829	NA	0.53	8.26	0.31	8.2e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg13073564	chr4:8508604	NA	-0.39	-10.61	-0.39	2.43e-24	Response to antineoplastic agents;
BRCA	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg24558204	chr6:135376177	HBS1L	0.46	12.62	0.45	8.89e-33	Red blood cell count;
BRCA	cis	rs877282	1.000	rs11253366	chr10:773386	C/T	cg17470449	chr10:769945	NA	0.49	9.36	0.35	1.37e-19	Uric acid levels;
BRCA	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14442939	chr10:27389572	ANKRD26	-0.68	-10.81	-0.39	3.87e-25	Breast cancer;
BRCA	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.32	8.94	0.33	4.24e-18	Response to antipsychotic treatment;
BRCA	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10802521	chr3:52805072	NEK4	-0.33	-8.52	-0.32	1.12e-16	Bipolar disorder;
BRCA	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg13334819	chr7:99746414	C7orf59	0.4	9.17	0.34	6.36e-19	Coronary artery disease;
BRCA	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-9.56	-0.35	2.58e-20	Schizophrenia;
BRCA	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg09307838	chr4:120376055	NA	0.64	13.3	0.47	8.45e-36	Corneal astigmatism;
BRCA	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.63	-10.3	-0.38	3.96e-23	Resting heart rate;
BRCA	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg26384229	chr12:38710491	ALG10B	0.43	9.68	0.36	8.95e-21	Morning vs. evening chronotype;
BRCA	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg09307838	chr4:120376055	NA	0.62	13.23	0.46	1.74e-35	Corneal astigmatism;
BRCA	cis	rs1215050	0.755	rs9991112	chr4:98651479	A/C	cg05340658	chr4:99064831	C4orf37	-0.41	-8.82	-0.33	1.05e-17	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.97	-0.33	3.26e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6429082	0.755	rs291384	chr1:235644300	C/T	cg26050004	chr1:235667680	B3GALNT2	0.57	13.51	0.47	9.05e-37	Adiposity;
BRCA	cis	rs6450176	0.909	rs66872223	chr5:53292730	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-14.11	-0.49	1.51e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg12062639	chr20:23401060	NAPB	0.96	13.42	0.47	2.36e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.83	-0.33	1.01e-17	Mood instability;
BRCA	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg13010199	chr12:38710504	ALG10B	0.44	8.93	0.33	4.46e-18	Bladder cancer;
BRCA	cis	rs10754283	0.901	rs10047070	chr1:90098715	G/C	cg21401794	chr1:90099060	LRRC8C	0.49	11.82	0.42	2.58e-29	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg04851639	chr8:1020857	NA	-0.3	-8.42	-0.32	2.52e-16	Schizophrenia;
BRCA	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	8.17	0.31	1.67e-15	Uric acid levels;
BRCA	trans	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg26043149	chr18:55253948	FECH	-0.36	-7.97	-0.3	7.39e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg06552810	chr11:31128660	NA	0.41	8.92	0.33	4.71e-18	Bone mineral density (spine);
BRCA	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04267008	chr7:1944627	MAD1L1	0.53	12.06	0.43	2.52e-30	Bipolar disorder and schizophrenia;
BRCA	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg23205692	chr1:25664452	TMEM50A	0.42	10.25	0.38	6.05e-23	Erythrocyte sedimentation rate;
BRCA	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg09060608	chr5:178986726	RUFY1	0.45	10.93	0.4	1.35e-25	Lung cancer;
BRCA	cis	rs4718428	0.705	rs13227468	chr7:66433563	T/C	cg12165864	chr7:66369176	NA	-0.44	-9.74	-0.36	5.51e-21	Corneal structure;
BRCA	cis	rs10754283	0.967	rs10754285	chr1:90116587	A/G	cg21401794	chr1:90099060	LRRC8C	0.44	10.75	0.39	6.73e-25	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg17640201	chr16:30407289	ZNF48	0.79	20.72	0.63	2.41e-73	Tonsillectomy;
BRCA	cis	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.75	-0.33	1.96e-17	Resting heart rate;
BRCA	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg14847009	chr1:175162515	KIAA0040	0.25	9.67	0.36	1.01e-20	Alcohol dependence;
BRCA	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21659725	chr3:3221576	CRBN	-0.49	-12.59	-0.45	1.28e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs4653767	1.000	rs708775	chr1:226923264	G/A	cg05049329	chr1:226924846	ITPKB	0.34	9.68	0.36	8.64e-21	Parkinson's disease;
BRCA	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg18811423	chr2:55921094	PNPT1	0.65	19.5	0.61	8.25e-67	Metabolic syndrome;
BRCA	cis	rs7809950	1.000	rs7782057	chr7:107098877	T/A	cg23024343	chr7:107201750	COG5	-0.41	-9.64	-0.36	1.22e-20	Coronary artery disease;
BRCA	cis	rs897984	0.520	rs12928081	chr16:30885159	T/G	cg02466173	chr16:30829666	NA	0.46	9.11	0.34	1.01e-18	Dementia with Lewy bodies;
BRCA	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg23711669	chr6:146136114	FBXO30	0.71	17.04	0.56	5.94e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9815354	0.812	rs59476821	chr3:41946481	A/G	cg03022575	chr3:42003672	ULK4	0.68	9.48	0.35	4.82e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.34	-10.96	-0.4	9.61e-26	Bipolar disorder;
BRCA	cis	rs7851660	0.870	rs55960649	chr9:100598695	C/A	cg13688889	chr9:100608707	NA	-0.37	-8.88	-0.33	6.82e-18	Strep throat;
BRCA	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg23033748	chr14:75592666	NEK9	-0.35	-8.09	-0.3	3.04e-15	Height;
BRCA	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg13902645	chr11:5959945	NA	0.49	9.86	0.36	1.85e-21	DNA methylation (variation);
BRCA	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08280861	chr8:58055591	NA	0.53	11.56	0.42	3.4e-28	Developmental language disorder (linguistic errors);
BRCA	cis	rs113835537	0.529	rs3892818	chr11:66240191	C/T	cg24851651	chr11:66362959	CCS	0.41	8.02	0.3	5.11e-15	Airway imaging phenotypes;
BRCA	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg14558114	chr2:88469736	THNSL2	0.63	9.14	0.34	8.32e-19	Plasma clusterin levels;
BRCA	cis	rs7131987	0.644	rs6487817	chr12:29548210	G/A	cg09582351	chr12:29534625	ERGIC2	0.43	9.82	0.36	2.7e-21	QT interval;
BRCA	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg08392591	chr16:89556376	ANKRD11	0.41	9.45	0.35	6.38e-20	Multiple myeloma (IgH translocation);
BRCA	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.53	-11.84	-0.42	2.13e-29	Personality dimensions;
BRCA	trans	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.39	0.49	7.25e-41	Exhaled nitric oxide output;
BRCA	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg06115741	chr20:33292138	TP53INP2	0.46	10.06	0.37	3.49e-22	Coronary artery disease;
BRCA	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg13010199	chr12:38710504	ALG10B	-0.48	-9.43	-0.35	7.55e-20	Morning vs. evening chronotype;
BRCA	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg21782813	chr7:2030301	MAD1L1	-0.33	-9.59	-0.35	1.88e-20	Bipolar disorder and schizophrenia;
BRCA	trans	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg25214090	chr10:38739885	LOC399744	0.45	10.06	0.37	3.22e-22	Corneal astigmatism;
BRCA	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg16606324	chr3:10149918	C3orf24	0.5	10.02	0.37	4.84e-22	Alzheimer's disease;
BRCA	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.4	0.47	2.88e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg06521331	chr12:34319734	NA	0.44	8.55	0.32	8.78e-17	Bladder cancer;
BRCA	cis	rs2625529	0.824	rs12899485	chr15:72143215	A/G	cg16672083	chr15:72433130	SENP8	0.8	17.14	0.56	1.84e-54	Red blood cell count;
BRCA	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg24562669	chr7:97807699	LMTK2	0.47	12.38	0.44	1.05e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-11.36	-0.41	2.3e-27	Morning vs. evening chronotype;
BRCA	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg10295955	chr4:187884368	NA	0.95	27.98	0.74	4.52e-113	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.26	-0.41	6.16e-27	Colorectal cancer;
BRCA	cis	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg06521331	chr12:34319734	NA	-0.63	-12.16	-0.43	9.6e-31	Morning vs. evening chronotype;
BRCA	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg18357645	chr12:58087776	OS9	0.45	13.23	0.46	1.76e-35	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg11266682	chr4:10021025	SLC2A9	0.44	11.51	0.41	5.4e-28	Bone mineral density;
BRCA	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg00105475	chr2:10696890	NA	0.44	10.41	0.38	1.56e-23	Prostate cancer;
BRCA	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.38	-8.74	-0.33	2.05e-17	Longevity;Endometriosis;
BRCA	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.27	-0.34	2.9e-19	Alzheimer's disease (late onset);
BRCA	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg11301795	chr4:187892539	NA	-0.29	-9.86	-0.36	1.99e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7246657	0.509	rs10426093	chr19:37615629	G/A	cg18154014	chr19:37997991	ZNF793	0.5	8.06	0.3	3.66e-15	Coronary artery calcification;
BRCA	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg06618935	chr21:46677482	NA	0.36	7.87	0.3	1.58e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	19.78	0.62	2.67e-68	Platelet count;
BRCA	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.82	13.02	0.46	1.47e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9790314	0.613	rs1447619	chr3:160616077	A/T	cg03342759	chr3:160939853	NMD3	0.43	8.56	0.32	8.3e-17	Morning vs. evening chronotype;
BRCA	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.52	-0.32	1.15e-16	Aortic root size;
BRCA	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.83	0.3	2.1e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9487051	0.621	rs9374076	chr6:109597826	G/T	cg01475377	chr6:109611718	NA	-0.41	-8.17	-0.31	1.65e-15	Reticulocyte fraction of red cells;
BRCA	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg18129178	chr5:148520854	ABLIM3	-0.59	-12.14	-0.43	1.19e-30	Breast cancer;
BRCA	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.68	-14.9	-0.51	2.51e-43	Homoarginine levels;
BRCA	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.2	0.68	7.62e-87	Chronic sinus infection;
BRCA	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg18758796	chr5:131593413	PDLIM4	0.36	8.97	0.33	3.24e-18	Acylcarnitine levels;
BRCA	cis	rs6745190	0.575	rs6710650	chr2:181972807	T/G	cg00481216	chr2:181971175	NA	0.4	9.48	0.35	4.95e-20	White blood cell count;
BRCA	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg25358565	chr5:93447407	FAM172A	1.18	18.2	0.58	5.96e-60	Diabetic retinopathy;
BRCA	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg04450456	chr4:17643702	FAM184B	0.39	11.59	0.42	2.46e-28	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.55	-0.39	4.19e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg08422745	chr4:174089978	GALNT7	-0.76	-14.9	-0.51	2.71e-43	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg23933602	chr10:16859644	RSU1	0.93	26.58	0.72	2.17e-105	Platelet distribution width;
BRCA	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg15352829	chr14:105391018	PLD4	-0.38	-12.39	-0.44	9.37e-32	Rheumatoid arthritis;
BRCA	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg21138405	chr5:131827807	IRF1	0.4	12.88	0.45	6.23e-34	Asthma (sex interaction);
BRCA	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg16586182	chr3:47516702	SCAP	0.65	15.26	0.52	4.89e-45	Colorectal cancer;
BRCA	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg00757033	chr12:89920650	WDR51B	0.54	11.08	0.4	3.24e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg00012203	chr2:219082015	ARPC2	0.57	12.2	0.43	6.67e-31	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs7178424	0.817	rs62007368	chr15:62318178	A/G	cg00456672	chr15:62358751	C2CD4A	-0.36	-8.02	-0.3	5.17e-15	Height;
BRCA	cis	rs897080	0.552	rs1067392	chr2:44639097	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	8.89	0.33	6.19e-18	Height;
BRCA	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg11266682	chr4:10021025	SLC2A9	-0.45	-11.52	-0.41	4.73e-28	Bone mineral density;
BRCA	trans	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg07817883	chr1:32538562	TMEM39B	0.48	7.86	0.3	1.67e-14	Monocyte percentage of white cells;
BRCA	cis	rs10499694	0.901	rs6975453	chr7:50585211	A/T	cg18232548	chr7:50535776	DDC	-0.38	-9.09	-0.34	1.22e-18	Body mass index;
BRCA	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg05340658	chr4:99064831	C4orf37	0.62	14.93	0.51	1.92e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg02297831	chr4:17616191	MED28	0.38	9.01	0.34	2.35e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.57	-0.42	3.04e-28	Mean corpuscular volume;
BRCA	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg21138405	chr5:131827807	IRF1	0.4	12.97	0.46	2.65e-34	Asthma (sex interaction);
BRCA	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg18016565	chr1:150552671	MCL1	-0.33	-8.04	-0.3	4.39e-15	Tonsillectomy;
BRCA	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06636551	chr8:101224915	SPAG1	-0.38	-8.59	-0.32	6.6e-17	Atrioventricular conduction;
BRCA	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg03433033	chr1:76189801	ACADM	-0.39	-8.09	-0.3	3.06e-15	Daytime sleep phenotypes;
BRCA	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.68	-0.42	1.08e-28	Gut microbiome composition (summer);
BRCA	cis	rs17095355	0.792	rs61881587	chr10:111759710	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.75	-0.36	5.07e-21	Biliary atresia;
BRCA	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.81	0.55	8.35e-53	Axial length;
BRCA	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23583168	chr7:148888333	NA	-0.79	-18.98	-0.6	4.88e-64	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6700896	0.931	rs11208715	chr1:66154414	G/T	cg04111102	chr1:66153794	NA	0.41	9.87	0.36	1.83e-21	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.61	-0.32	5.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07636037	chr3:49044803	WDR6	0.89	20.89	0.64	2.82e-74	Subjective well-being (multi-trait analysis);Menarche (age at onset);
BRCA	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg14675211	chr2:100938903	LONRF2	0.51	11.37	0.41	2e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg13010199	chr12:38710504	ALG10B	0.35	8.42	0.32	2.5e-16	Morning vs. evening chronotype;
BRCA	cis	rs4234798	0.500	rs7661066	chr4:7219878	C/T	cg18431297	chr4:7219810	SORCS2	0.38	10.67	0.39	1.43e-24	Insulin-like growth factors;
BRCA	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-16.12	-0.54	2.5e-49	Heart rate;
BRCA	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03517284	chr6:25882590	NA	-0.51	-11.55	-0.42	3.53e-28	Blood metabolite levels;
BRCA	cis	rs11249608	0.600	rs13359570	chr5:178449249	T/G	cg21905437	chr5:178450457	ZNF879	0.51	10.66	0.39	1.59e-24	Pubertal anthropometrics;
BRCA	cis	rs7301826	1.000	rs4759523	chr12:131315412	T/C	cg11011512	chr12:131303247	STX2	0.43	10.92	0.4	1.37e-25	Plasma plasminogen activator levels;
BRCA	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg09658497	chr7:2847517	GNA12	-0.39	-8.21	-0.31	1.23e-15	Height;
BRCA	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg23711669	chr6:146136114	FBXO30	-0.78	-18.65	-0.59	2.56e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg04234412	chr22:24373322	LOC391322	-0.59	-14.47	-0.5	2.83e-41	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg04691961	chr3:161091175	C3orf57	-0.38	-8.87	-0.33	7.09e-18	Morning vs. evening chronotype;
BRCA	cis	rs1003719	0.680	rs8130069	chr21:38552116	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.49	-0.5	2.46e-41	Eye color traits;
BRCA	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.01	-0.3	5.32e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-12.74	-0.45	2.71e-33	Total cholesterol levels;
BRCA	cis	rs10242455	0.702	rs73711280	chr7:99039604	C/T	cg18809830	chr7:99032528	PTCD1	-0.63	-8.98	-0.33	3.13e-18	Blood metabolite levels;
BRCA	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg20503657	chr10:835505	NA	0.86	15.59	0.52	1.16e-46	Eosinophil percentage of granulocytes;
BRCA	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg04842962	chr6:43655489	MRPS18A	1.12	39.23	0.84	2.61e-172	IgG glycosylation;
BRCA	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18876405	chr7:65276391	NA	-0.55	-13.1	-0.46	6.87e-35	Aortic root size;
BRCA	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg04944784	chr2:26401820	FAM59B	0.98	16.32	0.54	2.5e-50	Mean corpuscular hemoglobin;
BRCA	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg02896835	chr1:92012615	NA	-0.4	-8.21	-0.31	1.18e-15	Eosinophil percentage of white cells;
BRCA	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	13.58	0.47	4.5e-37	Platelet count;
BRCA	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-9.31	-0.35	1.95e-19	Tonsillectomy;
BRCA	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg06627628	chr2:24431161	ITSN2	-0.56	-9.06	-0.34	1.6e-18	Lymphocyte counts;
BRCA	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg16850897	chr7:100343110	ZAN	-0.58	-10.98	-0.4	8.04e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg04414720	chr1:150670196	GOLPH3L	0.36	8.11	0.31	2.62e-15	Tonsillectomy;
BRCA	cis	rs13046373	0.535	rs8129571	chr21:31980646	G/A	cg24082983	chr21:31802169	KRTAP13-4	0.34	8.64	0.32	4.59e-17	HDL cholesterol;
BRCA	cis	rs9469578	0.636	rs16869463	chr6:33714983	A/G	cg18708504	chr6:33715942	IP6K3	-0.62	-9.51	-0.35	3.72e-20	Phosphorus levels;
BRCA	trans	rs1997103	1.000	rs9649851	chr7:55398692	C/A	cg20935933	chr6:143382018	AIG1	0.6	11.52	0.41	4.77e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	11.37	0.41	2.05e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs364477	0.762	rs9299104	chr9:1001254	C/T	cg13952963	chr9:998547	NA	-0.45	-8.13	-0.31	2.16e-15	Major depressive disorder;
BRCA	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-12.28	-0.44	2.99e-31	Personality dimensions;
BRCA	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg06784218	chr1:46089804	CCDC17	-0.42	-9.75	-0.36	4.8e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg07080220	chr10:102295463	HIF1AN	0.65	15.51	0.52	2.69e-46	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg11498726	chr8:26250323	BNIP3L	0.57	13.67	0.48	1.62e-37	Red cell distribution width;
BRCA	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg12564285	chr5:131593104	PDLIM4	0.35	7.94	0.3	9.16e-15	Breast cancer;
BRCA	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg09307838	chr4:120376055	NA	0.69	14.08	0.49	2.13e-39	Corneal astigmatism;
BRCA	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg07636037	chr3:49044803	WDR6	0.5	8.26	0.31	8.19e-16	Menarche (age at onset);
BRCA	trans	rs1493916	0.744	rs7504560	chr18:31312148	A/G	cg15819921	chr19:927150	ARID3A	-0.44	-8.41	-0.32	2.72e-16	Life satisfaction;
BRCA	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.8	-0.33	1.23e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg04362960	chr10:104952993	NT5C2	0.45	10.42	0.38	1.39e-23	Arsenic metabolism;
BRCA	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00166722	chr3:10149974	C3orf24	0.65	12.8	0.45	1.54e-33	Alzheimer's disease;
BRCA	cis	rs17095355	1.000	rs11194941	chr10:111744810	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.38	-9.64	-0.36	1.26e-20	Biliary atresia;
BRCA	cis	rs67981189	0.896	rs17108822	chr14:71445906	C/T	cg15816911	chr14:71606274	NA	0.35	7.83	0.3	2.02e-14	Schizophrenia;
BRCA	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg05283184	chr6:79620031	NA	-0.42	-10.86	-0.39	2.46e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.53e-19	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.963	rs12298565	chr12:34036188	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.38	-0.35	1.09e-19	Morning vs. evening chronotype;
BRCA	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.85	0.36	2.13e-21	Lung cancer in ever smokers;
BRCA	trans	rs12517041	1.000	rs1428618	chr5:23282263	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.32	-0.31	5.27e-16	Calcium levels;
BRCA	cis	rs36051895	0.659	rs59225790	chr9:5042757	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-8.99	-0.34	2.67e-18	Pediatric autoimmune diseases;
BRCA	cis	rs27434	0.583	rs468130	chr5:96156029	A/G	cg16492584	chr5:96139282	ERAP1	-0.51	-12.82	-0.45	1.22e-33	Ankylosing spondylitis;
BRCA	cis	rs925228	0.504	rs7568272	chr2:24313785	T/C	cg01493198	chr2:24299560	SF3B14	0.62	9.94	0.37	9.39e-22	Reticulocyte fraction of red cells;Reticulocyte count;
BRCA	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.54	-0.32	9.79e-17	Total body bone mineral density;
BRCA	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.46	-0.32	1.8e-16	Monocyte percentage of white cells;
BRCA	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-9.39	-0.35	1e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg08392591	chr16:89556376	ANKRD11	0.54	13.31	0.47	7.17e-36	Multiple myeloma (IgH translocation);
BRCA	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg23029597	chr12:123009494	RSRC2	-0.63	-12.62	-0.45	9.28e-33	Body mass index;
BRCA	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg19920283	chr7:105172520	RINT1	0.68	13.69	0.48	1.32e-37	Bipolar disorder (body mass index interaction);
BRCA	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.33	10.3	0.38	3.9699999999999997e-23	Bipolar disorder;
BRCA	trans	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg01620082	chr3:125678407	NA	-0.71	-8.38	-0.31	3.37e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg03354898	chr7:1950403	MAD1L1	-0.5	-10.1	-0.37	2.46e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg08999081	chr20:33150536	PIGU	-0.33	-8.38	-0.31	3.37e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg18850127	chr7:39170497	POU6F2	0.54	11.82	0.42	2.62e-29	IgG glycosylation;
BRCA	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg24450063	chr1:156163899	SLC25A44	0.66	13.05	0.46	1.17e-34	Testicular germ cell tumor;
BRCA	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.39	2.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs367943	0.871	rs348940	chr5:112824530	C/A	cg12552261	chr5:112820674	MCC	-0.46	-10.43	-0.38	1.25e-23	Type 2 diabetes;
BRCA	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg03929089	chr4:120376271	NA	0.75	17.1	0.56	2.77e-54	Coronary artery disease;
BRCA	cis	rs9976767	0.637	rs2277799	chr21:43824123	G/C	cg23042151	chr21:43824109	UBASH3A	-0.28	-8.69	-0.33	2.99e-17	Type 1 diabetes;
BRCA	cis	rs925228	0.550	rs11125393	chr2:24276736	T/C	cg20701182	chr2:24300061	SF3B14	-0.47	-9.84	-0.36	2.27e-21	Reticulocyte fraction of red cells;Reticulocyte count;
BRCA	cis	rs7264396	0.563	rs2425137	chr20:34345396	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-9.95	-0.37	8.98e-22	Total cholesterol levels;
BRCA	cis	rs2625529	0.617	rs2306576	chr15:72170686	C/T	cg16672083	chr15:72433130	SENP8	0.65	15.62	0.53	8.44e-47	Red blood cell count;
BRCA	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg09307838	chr4:120376055	NA	0.73	15.87	0.53	4.5e-48	Corneal astigmatism;
BRCA	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-9.14	-0.34	8.09e-19	Chronic sinus infection;
BRCA	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg27432699	chr2:27873401	GPN1	0.45	9.7	0.36	7.44e-21	Oral cavity cancer;
BRCA	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.29	-8.3	-0.31	6.23e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg08999081	chr20:33150536	PIGU	-0.31	-8.05	-0.3	4.12e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.53	-9.23	-0.34	3.8e-19	Schizophrenia;
BRCA	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg16006841	chr5:176797999	RGS14	-0.7	-11.53	-0.42	4.43e-28	Urate levels in lean individuals;
BRCA	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg24562669	chr7:97807699	LMTK2	0.61	18.04	0.58	4.1e-59	Breast cancer;
BRCA	trans	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs7131987	0.650	rs10843384	chr12:29472409	C/T	cg09582351	chr12:29534625	ERGIC2	-0.43	-9.85	-0.36	2.03e-21	QT interval;
BRCA	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg08742575	chr21:47604166	C21orf56	-0.4	-8.02	-0.3	5.11e-15	Testicular germ cell tumor;
BRCA	trans	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg26384229	chr12:38710491	ALG10B	0.55	11.45	0.41	9.86e-28	Resting heart rate;
BRCA	cis	rs12472274	0.646	rs11688732	chr2:239096622	G/T	cg17459225	chr2:239074497	NA	0.59	10.32	0.38	3.45e-23	Phospholipid levels (plasma);
BRCA	cis	rs2742234	0.541	rs11238479	chr10:43717423	C/T	cg15436174	chr10:43711423	RASGEF1A	0.54	10.61	0.39	2.56e-24	Hirschsprung disease;
BRCA	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg20887711	chr4:1340912	KIAA1530	0.35	8.29	0.31	6.64e-16	Longevity;
BRCA	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.57	-0.47	4.99e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg00814883	chr7:100076585	TSC22D4	-0.47	-9.19	-0.34	5.45e-19	Platelet count;
BRCA	cis	rs4780401	0.609	rs4781143	chr16:11809721	T/G	cg01061890	chr16:11836724	TXNDC11	-0.55	-13.08	-0.46	8.07e-35	Rheumatoid arthritis;
BRCA	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg13628971	chr7:2884303	GNA12	0.4	9.13	0.34	9.09e-19	Height;
BRCA	cis	rs6435862	0.500	rs12477063	chr2:215673664	C/T	cg04004882	chr2:215674386	BARD1	-0.68	-15.62	-0.53	8.21e-47	Neuroblastoma (high-risk);
BRCA	cis	rs1829883	0.729	rs2548087	chr5:98907745	C/G	cg08333243	chr5:99726346	NA	0.34	8.18	0.31	1.48e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg21573476	chr21:45109991	RRP1B	-0.39	-10.14	-0.37	1.73e-22	Mean corpuscular volume;
BRCA	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg06636001	chr8:8085503	FLJ10661	0.67	15.47	0.52	4.47e-46	Mood instability;
BRCA	cis	rs751728	0.664	rs943478	chr6:33750940	T/A	cg25922239	chr6:33757077	LEMD2	0.5	12.69	0.45	4.5e-33	Crohn's disease;
BRCA	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.03	0.49	3.64e-39	Motion sickness;
BRCA	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg08885076	chr2:99613938	TSGA10	-0.35	-7.96	-0.3	7.92e-15	Fear of minor pain;
BRCA	cis	rs13102973	0.640	rs13151892	chr4:135831375	G/A	cg14419869	chr4:135874104	NA	0.46	9.34	0.35	1.56e-19	Subjective well-being;
BRCA	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.26	8.24	0.31	9.41e-16	Electroencephalogram traits;
BRCA	trans	rs1997103	0.906	rs6593231	chr7:55402914	T/A	cg20935933	chr6:143382018	AIG1	0.6	11.42	0.41	1.32e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg08822215	chr16:89438651	ANKRD11	-0.38	-8.09	-0.3	3.07e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg18357645	chr12:58087776	OS9	0.47	13.56	0.47	5.44e-37	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg20203395	chr5:56204925	C5orf35	-0.5	-10.11	-0.37	2.13e-22	Initial pursuit acceleration;
BRCA	cis	rs2066819	1.000	rs79436528	chr12:56686997	C/T	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg15485101	chr11:133734466	NA	-0.36	-8.48	-0.32	1.62e-16	Childhood ear infection;
BRCA	cis	rs6121246	0.559	rs6060716	chr20:30274847	C/G	cg21427119	chr20:30132790	HM13	-0.35	-7.9	-0.3	1.19e-14	Mean corpuscular hemoglobin;
BRCA	cis	rs12579753	0.871	rs4255611	chr12:82215969	C/A	cg07988820	chr12:82153109	PPFIA2	-0.51	-8.62	-0.32	5.17e-17	Resting heart rate;
BRCA	trans	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg26043149	chr18:55253948	FECH	-0.36	-7.91	-0.3	1.12e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg22974920	chr21:40686053	BRWD1	-0.38	-8.59	-0.32	6.53e-17	Cognitive function;
BRCA	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg15704280	chr7:45808275	SEPT13	0.69	13.99	0.48	5.45e-39	Coronary artery disease;
BRCA	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg08085267	chr17:45401833	C17orf57	0.59	12.11	0.43	1.53e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg18479299	chr3:125709523	NA	0.53	8.21	0.31	1.26e-15	Blood pressure (smoking interaction);
BRCA	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg12698349	chr2:225449008	CUL3	-0.59	-12.88	-0.45	6.46e-34	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg13319975	chr6:146136371	FBXO30	0.34	7.87	0.3	1.47e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11608355	0.515	rs7311488	chr12:109930905	C/G	cg05360138	chr12:110035743	NA	-0.75	-13.92	-0.48	1.19e-38	Neuroticism;
BRCA	cis	rs939658	0.683	rs1474256	chr15:79463847	C/T	cg17916960	chr15:79447300	NA	0.37	8.95	0.33	3.71e-18	Refractive error;
BRCA	cis	rs12367572	0.965	rs7952764	chr12:45246211	C/A	cg04608330	chr12:45269318	NELL2	-0.58	-12.58	-0.45	1.33e-32	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg27170947	chr2:26402098	FAM59B	0.98	17.25	0.56	4.73e-55	Gut microbiome composition (summer);
BRCA	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg03954927	chr1:10346856	KIF1B	0.49	15.14	0.51	1.78e-44	Hepatocellular carcinoma;
BRCA	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg18512352	chr11:47633146	NA	-0.35	-8.37	-0.31	3.64e-16	Subjective well-being;
BRCA	cis	rs600806	0.888	rs11102971	chr1:109872370	C/T	cg20591472	chr1:110008990	SYPL2	0.32	8.12	0.31	2.5e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg05294307	chr14:35346193	BAZ1A	-0.6	-10.34	-0.38	2.91e-23	Psoriasis;
BRCA	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg21782813	chr7:2030301	MAD1L1	0.38	9.77	0.36	4.24e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg09307838	chr4:120376055	NA	0.64	13.93	0.48	1.02e-38	Corneal astigmatism;
BRCA	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg16325326	chr1:53192061	ZYG11B	0.9	24.8	0.7	1.28e-95	Monocyte count;
BRCA	cis	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.4	1.46e-26	Morning vs. evening chronotype;
BRCA	cis	rs2625529	0.824	rs12901886	chr15:72408069	G/A	cg16672083	chr15:72433130	SENP8	-0.84	-17.57	-0.57	1.13e-56	Red blood cell count;
BRCA	cis	rs427394	0.659	rs274725	chr5:6717408	C/G	cg10857441	chr5:6722123	POLS	-0.31	-9.97	-0.37	7.44e-22	Menopause (age at onset);
BRCA	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg17524180	chr13:113633600	MCF2L	-0.38	-9.4	-0.35	9.21e-20	Systolic blood pressure;
BRCA	cis	rs2481665	0.546	rs2666504	chr1:62635081	T/C	cg18591186	chr1:62594603	INADL	0.39	8.34	0.31	4.41e-16	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.2	0.41	1.02e-26	Bipolar disorder;
BRCA	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg26373071	chr5:1325741	CLPTM1L	0.4	9.32	0.35	1.92e-19	Lung cancer;
BRCA	cis	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg06521331	chr12:34319734	NA	-0.6	-11.18	-0.4	1.21e-26	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.720	rs6665527	chr1:152967009	C/A	cg21543102	chr1:152974771	SPRR3	-0.3	-8.47	-0.32	1.7e-16	Inflammatory skin disease;
BRCA	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg05623727	chr3:50126028	RBM5	0.46	8.63	0.32	4.96e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg17145862	chr1:211918768	LPGAT1	0.69	18.15	0.58	1.04e-59	Leprosy;
BRCA	cis	rs724568	0.546	rs1549778	chr2:67951297	G/T	cg17945962	chr2:67939740	NA	-0.38	-10.13	-0.37	1.8e-22	Major depressive disorder (broad);
BRCA	trans	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.14	-38.41	-0.84	3.67e-168	Exhaled nitric oxide output;
BRCA	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg24296786	chr1:45957014	TESK2	-0.56	-13.19	-0.46	2.75e-35	High light scatter reticulocyte count;
BRCA	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg08807101	chr21:30365312	RNF160	-0.55	-12.39	-0.44	9.7e-32	Cognitive test performance;
BRCA	trans	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.8	-25.3	-0.71	2.23e-98	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg07460842	chr6:66804631	NA	-0.55	-9.91	-0.36	1.3e-21	Blood trace element (Cu levels);
BRCA	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg01884057	chr2:25150051	NA	0.35	9.26	0.34	3.07e-19	Body mass index;
BRCA	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg25174290	chr11:3078921	CARS	-0.31	-8.17	-0.31	1.71e-15	Calcium levels;
BRCA	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg06484146	chr7:12443880	VWDE	-0.75	-10.68	-0.39	1.35e-24	Coronary artery disease;
BRCA	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	11.36	0.41	2.24e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg24558204	chr6:135376177	HBS1L	0.45	12.33	0.44	1.77e-31	Red blood cell count;
BRCA	cis	rs11677370	0.561	rs10191326	chr2:3827524	G/C	cg17052675	chr2:3827356	NA	-0.56	-13.7	-0.48	1.2e-37	Type 2 diabetes;
BRCA	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-8.96	-0.33	3.49e-18	Chronic sinus infection;
BRCA	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg13047869	chr3:10149882	C3orf24	0.58	12.06	0.43	2.65e-30	Alzheimer's disease;
BRCA	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg21475434	chr5:93447410	FAM172A	0.69	8.56	0.32	8.45e-17	Diabetic retinopathy;
BRCA	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg12311346	chr5:56204834	C5orf35	-0.48	-9.84	-0.36	2.34e-21	Coronary artery disease;
BRCA	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-13.58	-0.47	4.27e-37	Morning vs. evening chronotype;
BRCA	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg19274703	chr22:41806451	NA	-0.36	-9.07	-0.34	1.42e-18	Vitiligo;
BRCA	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00166722	chr3:10149974	C3orf24	-0.63	-11.07	-0.4	3.62e-26	Alzheimer's disease;
BRCA	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg11502198	chr6:26597334	ABT1	0.48	9.63	0.36	1.36e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg13852791	chr20:30311386	BCL2L1	0.79	10.44	0.38	1.11e-23	Mean corpuscular hemoglobin;
BRCA	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg01017244	chr2:74357527	NA	0.51	12.6	0.45	1.16e-32	Gestational age at birth (maternal effect);
BRCA	cis	rs11249608	0.789	rs6868425	chr5:178446708	A/G	cg21905437	chr5:178450457	ZNF879	0.52	10.76	0.39	6.33e-25	Pubertal anthropometrics;
BRCA	trans	rs4718428	0.705	rs13227468	chr7:66433563	T/C	cg18876405	chr7:65276391	NA	0.44	8.5	0.32	1.33e-16	Corneal structure;
BRCA	cis	rs912057	0.671	rs1294428	chr6:6744623	A/G	cg06612196	chr6:6737390	NA	0.46	10.85	0.39	2.81e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg10862848	chr6:42927986	GNMT	-0.36	-14.93	-0.51	1.89e-43	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg04025307	chr7:1156635	C7orf50	0.57	10.03	0.37	4.35e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs1459104	0.925	rs114730832	chr11:55189642	T/G	cg15704280	chr7:45808275	SEPT13	0.66	8.14	0.31	2.03e-15	Body mass index;
BRCA	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg21782813	chr7:2030301	MAD1L1	0.35	9.38	0.35	1.1e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg25237894	chr2:233734115	C2orf82	-0.43	-13.56	-0.47	5.32e-37	Coronary artery disease;
BRCA	cis	rs919433	0.680	rs4685	chr2:198257795	C/T	cg00792783	chr2:198669748	PLCL1	-0.38	-8.66	-0.32	3.79e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg17063962	chr7:91808500	NA	0.54	12.65	0.45	7.13e-33	Breast cancer;
BRCA	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg27535305	chr1:53392650	SCP2	-0.38	-9.25	-0.34	3.4e-19	Monocyte count;
BRCA	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg03146154	chr1:46216737	IPP	0.52	11.57	0.42	3.06e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg08085267	chr17:45401833	C17orf57	0.56	11.31	0.41	3.81e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg18129178	chr5:148520854	ABLIM3	0.58	12.1	0.43	1.73e-30	Breast cancer;
BRCA	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.78	0.36	3.87e-21	Menopause (age at onset);
BRCA	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg03709012	chr19:19516395	GATAD2A	0.72	15.68	0.53	4.14e-47	Tonsillectomy;
BRCA	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg23711669	chr6:146136114	FBXO30	-0.72	-17.34	-0.57	1.7e-55	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.38	-9.24	-0.34	3.51e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg06636001	chr8:8085503	FLJ10661	0.73	16.08	0.54	4.22e-49	Neuroticism;
BRCA	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg03146154	chr1:46216737	IPP	0.54	12.05	0.43	2.82e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs8073060	0.586	rs4796098	chr17:33913436	T/C	cg19694781	chr19:47549865	TMEM160	1.05	21.6	0.65	4.24e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg14019146	chr3:50243930	SLC38A3	0.44	10.68	0.39	1.28e-24	Body mass index;
BRCA	cis	rs2652834	0.904	rs2729827	chr15:63360564	C/T	cg05507819	chr15:63340323	TPM1	0.5	9.76	0.36	4.7e-21	HDL cholesterol;
BRCA	cis	rs6142102	0.625	rs4911381	chr20:32550345	C/G	cg24642439	chr20:33292090	TP53INP2	-0.39	-7.85	-0.3	1.77e-14	Skin pigmentation;
BRCA	cis	rs6433895	1.000	rs7566256	chr2:182013274	G/A	cg00481216	chr2:181971175	NA	0.37	8.72	0.33	2.49e-17	Lymphocyte counts;
BRCA	cis	rs4742903	0.904	rs7028408	chr9:106859811	G/A	cg14250997	chr9:106856677	SMC2	0.34	10.74	0.39	7.43e-25	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs2288912	0.808	rs35670684	chr19:45455985	A/C	cg13119609	chr19:45449297	APOC2	0.47	13.1	0.46	6.65e-35	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	cis	rs2131877	0.529	rs4677810	chr3:194856747	G/C	cg13868855	chr3:194833887	C3orf21	-0.36	-8.53	-0.32	1.1e-16	Non-small cell lung cancer;
BRCA	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg27129171	chr3:47204927	SETD2	-0.69	-16.2	-0.54	1.08e-49	Colorectal cancer;
BRCA	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg11941060	chr3:133502564	NA	-0.6	-14.63	-0.5	5.32e-42	Iron status biomarkers;
BRCA	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg18016565	chr1:150552671	MCL1	0.34	7.83	0.3	2.03e-14	Melanoma;
BRCA	cis	rs812925	0.519	rs2694627	chr2:61625506	A/G	cg15711740	chr2:61764176	XPO1	0.33	8.1	0.31	2.86e-15	Immature fraction of reticulocytes;
BRCA	cis	rs13046373	0.535	rs2832957	chr21:31973140	C/T	cg27071517	chr21:31768726	KRTAP13-1	0.29	7.96	0.3	8.12e-15	HDL cholesterol;
BRCA	cis	rs6815814	0.851	rs11466617	chr4:38780471	T/C	cg06935464	chr4:38784597	TLR10	0.47	7.83	0.3	2e-14	Breast cancer;
BRCA	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg08085267	chr17:45401833	C17orf57	0.6	12.26	0.44	3.47e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs12618769	0.652	rs72823796	chr2:99227812	C/T	cg10123293	chr2:99228465	UNC50	0.4	7.98	0.3	6.99e-15	Bipolar disorder;
BRCA	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg21775007	chr8:11205619	TDH	0.65	12.68	0.45	5.2e-33	Retinal vascular caliber;
BRCA	cis	rs6700896	0.897	rs2375805	chr1:66156567	C/T	cg04111102	chr1:66153794	NA	0.34	8.49	0.32	1.48e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.72	0.39	9.15e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg11266682	chr4:10021025	SLC2A9	0.49	12.86	0.45	8.33e-34	Bone mineral density;
BRCA	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg05347473	chr6:146136440	FBXO30	-0.6	-11.56	-0.42	3.47e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg01741372	chr11:783889	NA	-0.42	-9.6	-0.36	1.75e-20	Breast cancer;
BRCA	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg24060327	chr5:131705240	SLC22A5	0.61	11.36	0.41	2.18e-27	Blood metabolite levels;
BRCA	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg24399712	chr22:39784796	NA	-0.54	-12.04	-0.43	3.13e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg23711669	chr6:146136114	FBXO30	0.77	17.91	0.58	2.01e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.56	-13.04	-0.46	1.22e-34	Longevity;Endometriosis;
BRCA	cis	rs55882075	0.967	rs12656648	chr5:179152106	C/A	cg14593053	chr5:179126677	CANX	0.4	10.16	0.37	1.37e-22	Monocyte percentage of white cells;
BRCA	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.29	8.03	0.3	4.6e-15	Electroencephalogram traits;
BRCA	cis	rs3784262	0.669	rs12915821	chr15:58315685	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.18	-0.37	1.16e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg05874882	chr4:1763078	NA	0.45	8.25	0.31	8.9e-16	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs35740288	0.539	rs11629991	chr15:86336664	A/G	cg20737812	chr15:86336631	KLHL25	-0.4	-9.8	-0.36	3.18e-21	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg11843238	chr5:131593191	PDLIM4	0.4	9.51	0.35	3.81e-20	Acylcarnitine levels;
BRCA	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-14.03	-0.49	3.54e-39	Lymphocyte percentage of white cells;
BRCA	cis	rs6893300	0.524	rs12374446	chr5:179131143	A/G	cg14593053	chr5:179126677	CANX	0.45	11.91	0.43	1.18e-29	Resting heart rate;
BRCA	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11890956	chr21:40555474	PSMG1	-0.59	-12.85	-0.45	9.25e-34	Menarche (age at onset);
BRCA	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg25173405	chr17:45401733	C17orf57	-0.51	-10.66	-0.39	1.57e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.41	-11.6	-0.42	2.3e-28	Monocyte count;
BRCA	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg09307838	chr4:120376055	NA	0.69	14.25	0.49	3.17e-40	Corneal astigmatism;
BRCA	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg25358565	chr5:93447407	FAM172A	1.22	19.39	0.61	3.06e-66	Diabetic retinopathy;
BRCA	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg11887960	chr12:57824829	NA	0.55	8.5	0.32	1.29e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg24578937	chr1:2090814	PRKCZ	0.59	17.73	0.57	1.76e-57	Height;
BRCA	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg25173405	chr17:45401733	C17orf57	0.54	11.03	0.4	4.96e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs8114671	0.647	rs1124511	chr20:33736697	A/C	cg07148914	chr20:33460835	GGT7	0.35	7.9	0.3	1.22e-14	Height;
BRCA	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	ch.11.42038R	chr11:967971	AP2A2	0.47	14.32	0.49	1.45e-40	Alzheimer's disease (late onset);
BRCA	cis	rs4363385	0.818	rs423692	chr1:153005681	T/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.26	-0.34	3.19e-19	Inflammatory skin disease;
BRCA	cis	rs2806561	0.769	rs2235547	chr1:23406485	C/G	cg19743168	chr1:23544995	NA	-0.41	-9.67	-0.36	9.66e-21	Height;
BRCA	cis	rs4363385	0.747	rs9919276	chr1:152968654	A/T	cg21543102	chr1:152974771	SPRR3	-0.28	-7.82	-0.3	2.21e-14	Inflammatory skin disease;
BRCA	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg13256891	chr4:100009986	ADH5	0.43	8.88	0.33	6.76e-18	Alcohol dependence;
BRCA	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg21535247	chr6:8435926	SLC35B3	-0.37	-8.37	-0.31	3.54e-16	Motion sickness;
BRCA	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg15556689	chr8:8085844	FLJ10661	0.37	9.92	0.37	1.13e-21	Neuroticism;
BRCA	cis	rs6594499	0.872	rs1379300	chr5:110441439	A/G	cg04022379	chr5:110408740	TSLP	0.36	7.99	0.3	6.14e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.32	-0.35	1.91e-19	Alzheimer's disease (late onset);
BRCA	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg17173187	chr15:85201210	NMB	0.43	8.92	0.33	4.78e-18	Schizophrenia;
BRCA	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.03	0.4	5.08e-26	Electroencephalogram traits;
BRCA	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg06623918	chr6:96969491	KIAA0776	0.74	15.45	0.52	5.39e-46	Migraine;Coronary artery disease;
BRCA	cis	rs4285028	0.656	rs2141487	chr3:121482765	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.89	16.79	0.55	1.07e-52	Multiple sclerosis;
BRCA	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg11266682	chr4:10021025	SLC2A9	0.49	13.11	0.46	5.99e-35	Bone mineral density;
BRCA	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg21427119	chr20:30132790	HM13	0.41	8.75	0.33	1.9e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.63	-17.06	-0.56	4.52e-54	Fuchs's corneal dystrophy;
BRCA	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.6	-0.32	6.09e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg24812749	chr6:127587940	RNF146	0.68	15.5	0.52	2.95e-46	Breast cancer;
BRCA	trans	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg26043149	chr18:55253948	FECH	0.4	8.9	0.33	5.72e-18	Bone mineral density;
BRCA	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg00814883	chr7:100076585	TSC22D4	-0.49	-10.18	-0.37	1.13e-22	Platelet count;
BRCA	cis	rs13394619	0.605	rs12476152	chr2:11747960	T/C	cg07314298	chr2:11723111	GREB1	0.36	8.12	0.31	2.39e-15	Endometriosis;
BRCA	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	10.56	0.39	3.9e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs11051970	0.879	rs2728680	chr12:32583512	T/C	cg24626660	chr12:32551988	NA	0.29	8.2	0.31	1.28e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	trans	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg19862616	chr7:65841803	NCRNA00174	0.79	24.67	0.7	6.78e-95	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg00106254	chr7:1943704	MAD1L1	0.4	10.34	0.38	2.91e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg06784218	chr1:46089804	CCDC17	0.52	12.3	0.44	2.31e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.96	-0.33	3.65e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg04851639	chr8:1020857	NA	-0.29	-8.23	-0.31	1.07e-15	Schizophrenia;
BRCA	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg06784218	chr1:46089804	CCDC17	-0.45	-10.84	-0.39	2.92e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg17063962	chr7:91808500	NA	-0.54	-12.26	-0.44	3.46e-31	Breast cancer;
BRCA	cis	rs10838687	0.736	rs7118396	chr11:47269936	C/T	cg25783544	chr11:47291846	MADD	0.46	8.62	0.32	5.23e-17	Proinsulin levels;
BRCA	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg16558253	chr16:72132732	DHX38	0.48	11.14	0.4	1.81e-26	Fibrinogen levels;
BRCA	cis	rs2835872	0.758	rs1709833	chr21:39037805	C/T	cg06728970	chr21:39037746	KCNJ6	-0.45	-13.2	-0.46	2.31e-35	Electroencephalographic traits in alcoholism;
BRCA	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg23711669	chr6:146136114	FBXO30	0.65	15.23	0.52	6.75e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4566357	0.615	rs12621808	chr2:227909522	A/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-9.29	-0.34	2.48e-19	Coronary artery disease;
BRCA	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg03585969	chr10:35415529	CREM	0.56	11.55	0.42	3.82e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg05234568	chr11:5960015	NA	-0.42	-8.79	-0.33	1.35e-17	DNA methylation (variation);
BRCA	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg05868516	chr6:26286170	HIST1H4H	0.46	10.07	0.37	3.01e-22	Educational attainment;
BRCA	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg20090143	chr19:45452003	APOC2	0.27	8.04	0.3	4.44e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	8.59	0.32	6.82e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.54	8.59	0.32	6.7e-17	Renal function-related traits (BUN);
BRCA	cis	rs3857536	0.740	rs9354390	chr6:66890162	C/T	cg07460842	chr6:66804631	NA	0.46	8.83	0.33	9.74e-18	Blood trace element (Cu levels);
BRCA	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11890956	chr21:40555474	PSMG1	1.1	34.02	0.8	1.5e-145	Cognitive function;
BRCA	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18876405	chr7:65276391	NA	-0.5	-11.18	-0.4	1.25e-26	Aortic root size;
BRCA	trans	rs8073060	0.586	rs7217533	chr17:34015876	A/G	cg19694781	chr19:47549865	TMEM160	-1.06	-21.42	-0.65	4.16e-77	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11890956	chr21:40555474	PSMG1	1.05	29.65	0.76	3.7e-122	Cognitive function;
BRCA	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05901451	chr6:126070800	HEY2	-0.55	-14.54	-0.5	1.4e-41	Brugada syndrome;
BRCA	cis	rs1555322	0.530	rs6060347	chr20:33874151	A/G	cg17927777	chr20:33865990	NA	0.42	7.86	0.3	1.64e-14	Attention deficit hyperactivity disorder;
BRCA	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.74	0.39	7.86e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg04455712	chr21:45112962	RRP1B	0.46	12.52	0.44	2.52e-32	Mean corpuscular volume;
BRCA	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg19077165	chr18:44547161	KATNAL2	-0.58	-12.67	-0.45	5.65e-33	Personality dimensions;
BRCA	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg22117172	chr7:91764530	CYP51A1	0.23	7.83	0.3	1.99e-14	Breast cancer;
BRCA	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13012494	chr21:47604986	C21orf56	0.44	8.71	0.33	2.53e-17	Testicular germ cell tumor;
BRCA	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg27478167	chr7:817139	HEATR2	-0.43	-9.06	-0.34	1.63e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg02153584	chr22:29168773	CCDC117	-0.45	-8.93	-0.33	4.46e-18	Lymphocyte counts;
BRCA	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg16145915	chr7:1198662	ZFAND2A	0.62	14.93	0.51	1.93e-43	Longevity;Endometriosis;
BRCA	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.24	-0.31	9.76e-16	Bipolar disorder;
BRCA	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg18225595	chr11:63971243	STIP1	0.5	9.25	0.34	3.21e-19	Mean platelet volume;
BRCA	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg03425785	chr20:62221387	GMEB2	0.52	8.36	0.31	4.02e-16	Glioblastoma;
BRCA	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg05234568	chr11:5960015	NA	-0.49	-10.26	-0.38	5.69e-23	DNA methylation (variation);
BRCA	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg01483505	chr11:975446	AP2A2	0.34	9.1	0.34	1.17e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7945718	0.967	rs10831906	chr11:12783042	C/T	cg25843174	chr11:12811716	TEAD1	0.23	8.89	0.33	6.39e-18	Educational attainment (years of education);
BRCA	cis	rs965469	1.000	rs2236087	chr20:3255905	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-9.84	-0.36	2.38e-21	IFN-related cytopenia;
BRCA	trans	rs11088226	0.846	rs2154500	chr21:33926391	T/C	cg09050820	chr6:167586206	TCP10L2	0.57	10.84	0.39	3.03e-25	Gastritis;
BRCA	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg23649088	chr2:200775458	C2orf69	-0.48	-8.06	-0.3	3.74e-15	Schizophrenia;
BRCA	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg02951883	chr7:2050386	MAD1L1	0.55	12.55	0.44	1.9e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs2625529	0.652	rs2034879	chr15:72429989	A/G	cg16672083	chr15:72433130	SENP8	-0.72	-17.52	-0.57	1.96e-56	Red blood cell count;
BRCA	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg00701064	chr4:6280414	WFS1	0.71	18.37	0.59	7.35e-61	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs507080	0.883	rs563549	chr11:118558953	G/A	cg08498647	chr11:118550644	TREH	-0.38	-8.26	-0.31	8.53e-16	Serum metabolite levels;
BRCA	cis	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg06521331	chr12:34319734	NA	-0.51	-10.11	-0.37	2.15e-22	Morning vs. evening chronotype;
BRCA	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg06784218	chr1:46089804	CCDC17	-0.47	-10.55	-0.39	4.12e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg11843238	chr5:131593191	PDLIM4	0.35	7.99	0.3	6.49e-15	Breast cancer;
BRCA	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.9	0.33	5.92e-18	Tonsillectomy;
BRCA	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg04267008	chr7:1944627	MAD1L1	0.66	13.96	0.48	7.44e-39	Bipolar disorder and schizophrenia;
BRCA	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg03929089	chr4:120376271	NA	0.61	10.41	0.38	1.52e-23	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs758324	0.617	rs9717078	chr5:131170891	G/A	cg06307176	chr5:131281290	NA	0.53	10.3	0.38	3.86e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg20848291	chr7:100343083	ZAN	-0.62	-12.98	-0.46	2.44e-34	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs6545883	0.929	rs778140	chr2:61682976	C/T	cg15711740	chr2:61764176	XPO1	-0.53	-12.75	-0.45	2.49e-33	Tuberculosis;
BRCA	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	11.38	0.41	1.82e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg10862848	chr6:42927986	GNMT	-0.36	-15.04	-0.51	5.55e-44	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1953600	0.870	rs2573370	chr10:81951366	C/T	cg04850286	chr10:81895943	PLAC9	0.32	9.0	0.34	2.57e-18	Sarcoidosis;
BRCA	cis	rs3849570	0.961	rs11710970	chr3:81693489	T/C	cg07356753	chr3:81810745	GBE1	-0.45	-10.65	-0.39	1.75e-24	Waist circumference;Body mass index;
BRCA	cis	rs528301	0.613	rs4143310	chr2:45124563	C/A	cg02372786	chr2:45167549	SIX3	-0.42	-9.29	-0.34	2.4e-19	Alcohol and nicotine co-dependence;
BRCA	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03923535	chr7:1197113	ZFAND2A	0.52	11.39	0.41	1.73e-27	Longevity;Endometriosis;
BRCA	cis	rs1538970	0.962	rs2153608	chr1:45813941	C/T	cg05343316	chr1:45956843	TESK2	-0.49	-10.14	-0.37	1.74e-22	Platelet count;
BRCA	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.19	-0.4	1.12e-26	Total cholesterol levels;
BRCA	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-9.45	-0.35	6.3e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg10523679	chr1:76189770	ACADM	0.7	12.64	0.45	7.81e-33	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs919433	0.713	rs13411968	chr2:198467141	C/T	cg00792783	chr2:198669748	PLCL1	0.35	8.04	0.3	4.49e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs8005677	1.000	rs11157930	chr14:23403171	T/G	cg23176270	chr14:23476067	C14orf93	0.38	7.85	0.3	1.8e-14	Cognitive ability (multi-trait analysis);
BRCA	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.73	0.57	1.73e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.48	-8.97	-0.33	3.33e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg11663144	chr21:46675770	NA	-0.57	-13.58	-0.47	4.41e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7246657	0.722	rs10404031	chr19:38035954	A/G	cg18154014	chr19:37997991	ZNF793	0.48	9.17	0.34	6.65e-19	Coronary artery calcification;
BRCA	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg21918786	chr6:109611834	NA	-0.49	-14.04	-0.49	3.14e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs7246967	0.673	rs2361023	chr19:22816867	C/T	cg23217946	chr19:22817039	ZNF492	0.47	8.45	0.32	2e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.66e-18	Motion sickness;
BRCA	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg24130564	chr14:104152367	KLC1	-0.41	-8.73	-0.33	2.2e-17	Reticulocyte count;
BRCA	cis	rs2522056	1.000	rs6874639	chr5:131778716	C/T	cg24060327	chr5:131705240	SLC22A5	-0.45	-8.13	-0.31	2.3e-15	Lymphocyte counts;Fibrinogen;
BRCA	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg20701182	chr2:24300061	SF3B14	0.67	9.72	0.36	6.39e-21	Lymphocyte counts;
BRCA	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg01304814	chr3:48885189	PRKAR2A	0.63	7.81	0.3	2.43e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	trans	rs72766638	0.895	rs72766630	chr9:136926791	G/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-9.41	-0.35	9.04e-20	Mosquito bite size;
BRCA	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg26384229	chr12:38710491	ALG10B	-0.44	-10.06	-0.37	3.4e-22	Bladder cancer;
BRCA	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-14.05	-0.49	2.85e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg11822812	chr5:140052017	DND1	-0.29	-8.06	-0.3	3.63e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg09184832	chr6:79620586	NA	-0.43	-8.45	-0.32	2.03e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg14036092	chr11:66035641	RAB1B	0.39	10.56	0.39	4e-24	Gout;
BRCA	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg06108461	chr20:60628389	TAF4	-0.79	-17.05	-0.56	5.51e-54	Body mass index;
BRCA	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg08213375	chr14:104286397	PPP1R13B	0.51	11.4	0.41	1.5e-27	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg12311346	chr5:56204834	C5orf35	-0.71	-13.71	-0.48	1.08e-37	Initial pursuit acceleration;
BRCA	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg08999081	chr20:33150536	PIGU	-0.46	-12.58	-0.45	1.44e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11644478	chr21:40555479	PSMG1	0.66	14.67	0.5	3.4e-42	Cognitive function;
BRCA	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg17366294	chr4:99064904	C4orf37	0.44	10.44	0.38	1.1e-23	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg27147174	chr7:100797783	AP1S1	-0.54	-10.89	-0.4	1.83e-25	Life satisfaction;
BRCA	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg15605315	chr1:45957053	TESK2	0.5	10.26	0.38	5.99e-23	High light scatter reticulocyte count;
BRCA	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg11663144	chr21:46675770	NA	-0.64	-15.28	-0.52	3.78e-45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg00105475	chr2:10696890	NA	-0.38	-8.75	-0.33	1.89e-17	Prostate cancer;
BRCA	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.52	10.44	0.38	1.18e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg05863683	chr7:1912471	MAD1L1	0.38	8.45	0.32	1.98e-16	Schizophrenia;
BRCA	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg00277334	chr10:82204260	NA	-0.85	-25.12	-0.7	2.25e-97	Post bronchodilator FEV1;
BRCA	cis	rs1003719	0.715	rs8126941	chr21:38551542	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.56	-12.58	-0.45	1.38e-32	Eye color traits;
BRCA	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg12011299	chr4:100065546	ADH4	0.52	15.4	0.52	9.48e-46	Alcohol dependence;
BRCA	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.23e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6920965	0.527	rs584032	chr6:126165003	G/A	cg05901451	chr6:126070800	HEY2	0.37	8.98	0.33	3.08e-18	High light scatter reticulocyte count;
BRCA	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg24803719	chr17:45855879	NA	-0.31	-8.44	-0.32	2.05e-16	IgG glycosylation;
BRCA	trans	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg07817883	chr1:32538562	TMEM39B	-0.47	-8.73	-0.33	2.17e-17	Monocyte percentage of white cells;
BRCA	cis	rs7551345	0.851	rs10914330	chr1:31691577	A/C	cg19084893	chr1:31688959	NA	0.41	8.15	0.31	1.89e-15	Schizophrenia;
BRCA	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg07080220	chr10:102295463	HIF1AN	0.5	10.36	0.38	2.43e-23	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs3125734	0.633	rs4979754	chr10:64048959	G/A	cg09941381	chr10:64027924	RTKN2	-0.3	-8.34	-0.31	4.72e-16	Rheumatoid arthritis;
BRCA	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg09904177	chr6:26538194	HMGN4	0.57	18.5	0.59	1.63e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg17691542	chr6:26056736	HIST1H1C	0.48	9.83	0.36	2.59e-21	Height;
BRCA	cis	rs9470366	0.816	rs1321311	chr6:36622900	C/A	cg08179530	chr6:36648295	CDKN1A	0.5	10.27	0.38	5.13e-23	QRS duration;
BRCA	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg03342759	chr3:160939853	NMD3	-0.63	-14.2	-0.49	5.41e-40	Morning vs. evening chronotype;
BRCA	trans	rs11976180	1.000	rs2961118	chr7:143755443	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.44	-8.25	-0.31	9.38e-16	Obesity-related traits;
BRCA	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24110177	chr3:50126178	RBM5	-0.37	-9.86	-0.36	1.85e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg08807101	chr21:30365312	RNF160	-0.74	-19.7	-0.61	6.94e-68	Dental caries;
BRCA	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg22496339	chr2:162101262	NA	0.58	13.1	0.46	6.84e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg22875332	chr1:76189707	ACADM	0.79	18.87	0.6	1.86e-63	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.4	-0.61	2.69e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.06	-0.37	3.26e-22	Mean corpuscular volume;
BRCA	trans	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	14.68	0.5	3.07e-42	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg09307838	chr4:120376055	NA	0.69	14.53	0.5	1.49e-41	Corneal astigmatism;
BRCA	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg03425785	chr20:62221387	GMEB2	0.51	8.28	0.31	7.22e-16	Glioblastoma;
BRCA	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg03060546	chr3:49711283	APEH	-0.58	-10.13	-0.37	1.81e-22	Menarche (age at onset);
BRCA	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg11584989	chr19:19387371	SF4	0.3	7.85	0.3	1.71e-14	Tonsillectomy;
BRCA	trans	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.89	19.71	0.61	6.44e-68	Cognitive ability;
BRCA	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11764359	chr7:65958608	NA	-0.75	-16.67	-0.55	4.55e-52	Aortic root size;
BRCA	cis	rs3768617	0.811	rs12066082	chr1:183054863	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.87	0.36	1.82e-21	Fuchs's corneal dystrophy;
BRCA	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg08885076	chr2:99613938	TSGA10	-0.6	-13.45	-0.47	1.67e-36	Chronic sinus infection;
BRCA	cis	rs524281	0.861	rs10896091	chr11:65950825	T/C	cg16950941	chr11:66035639	RAB1B	-0.37	-7.87	-0.3	1.57e-14	Electroencephalogram traits;
BRCA	cis	rs7551222	0.752	rs4951407	chr1:204558070	G/T	cg20240347	chr1:204465584	NA	0.29	9.28	0.34	2.58e-19	Schizophrenia;
BRCA	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg24578937	chr1:2090814	PRKCZ	0.59	17.96	0.58	1.12e-58	Height;
BRCA	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg09307838	chr4:120376055	NA	-0.59	-12.96	-0.46	2.85e-34	Corneal astigmatism;
BRCA	trans	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg21659725	chr3:3221576	CRBN	-0.46	-10.04	-0.37	4.1e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-12.21	-0.43	6.04e-31	Mood instability;
BRCA	cis	rs9309473	1.000	rs6753344	chr2:73653138	C/T	cg20560298	chr2:73613845	ALMS1	0.41	10.12	0.37	1.97e-22	Metabolite levels;
BRCA	cis	rs724568	0.546	rs6717648	chr2:67939688	C/T	cg14046302	chr2:67939758	NA	-0.4	-10.63	-0.39	2.06e-24	Major depressive disorder (broad);
BRCA	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg00166722	chr3:10149974	C3orf24	0.64	11.12	0.4	2.21e-26	Alzheimer's disease;
BRCA	cis	rs2859741	0.967	rs575939	chr1:37513854	T/C	cg09363841	chr1:37513479	NA	-0.67	-16.97	-0.56	1.3e-53	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg05863683	chr7:1912471	MAD1L1	0.42	9.79	0.36	3.48e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg06115741	chr20:33292138	TP53INP2	0.36	8.13	0.31	2.23e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg13852791	chr20:30311386	BCL2L1	0.83	17.89	0.58	2.39e-58	Mean corpuscular hemoglobin;
BRCA	cis	rs2964802	0.505	rs13180011	chr5:10824615	T/C	cg14521931	chr5:10832172	NA	-0.58	-12.62	-0.45	8.97e-33	Major depressive disorder;Recurrent major depressive disorder;
BRCA	cis	rs2073300	1.000	rs6137962	chr20:23443966	T/C	cg12062639	chr20:23401060	NAPB	0.89	10.63	0.39	2.06e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7147624	1.000	rs10873192	chr14:66110653	A/G	cg03016385	chr14:66212404	NA	-0.58	-8.97	-0.33	3.27e-18	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	15.97	0.53	1.54e-48	Platelet count;
BRCA	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg19913688	chr11:428466	ANO9	0.64	9.3	0.35	2.11e-19	Body mass index;
BRCA	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24308560	chr3:49941425	MST1R	-0.4	-8.57	-0.32	7.82e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs11971779	1.000	rs11971779	chr7:139040258	A/G	cg07862535	chr7:139043722	LUC7L2	-0.49	-12.01	-0.43	4.3e-30	Diisocyanate-induced asthma;
BRCA	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg18252515	chr7:66147081	NA	1.02	14.96	0.51	1.27e-43	Diabetic kidney disease;
BRCA	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24110177	chr3:50126178	RBM5	0.41	11.39	0.41	1.74e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg05294307	chr14:35346193	BAZ1A	-0.6	-11.68	-0.42	1.04e-28	Psoriasis;
BRCA	cis	rs11229555	0.645	rs61905183	chr11:58228463	T/A	cg15696309	chr11:58395628	NA	-0.53	-10.99	-0.4	7.54e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg08999081	chr20:33150536	PIGU	0.49	13.81	0.48	3.59e-38	Coronary artery disease;
BRCA	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.43	0.35	7.61e-20	Tonsillectomy;
BRCA	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg16230307	chr14:35515116	FAM177A1	0.62	14.02	0.48	4.11e-39	Psoriasis;
BRCA	cis	rs9329289	0.510	rs1155447	chr10:2553240	C/T	cg15501526	chr10:2543763	NA	0.41	9.51	0.35	3.69e-20	Age-related hearing impairment;
BRCA	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg11645453	chr3:52864694	ITIH4	0.45	10.7	0.39	1.05e-24	Schizophrenia;
BRCA	cis	rs2354432	0.505	rs3737845	chr1:146724408	A/G	cg25205988	chr1:146714368	CHD1L	0.92	12.09	0.43	1.85e-30	Mitochondrial DNA levels;
BRCA	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg23029597	chr12:123009494	RSRC2	-0.61	-11.21	-0.41	9.18e-27	Body mass index;
BRCA	cis	rs3768617	0.811	rs12138049	chr1:182979546	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.88	0.36	1.55e-21	Fuchs's corneal dystrophy;
BRCA	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg11764359	chr7:65958608	NA	0.67	14.96	0.51	1.34e-43	Aortic root size;
BRCA	cis	rs7524258	0.868	rs4908610	chr1:7311260	C/A	cg07173049	chr1:7289937	CAMTA1	0.42	10.34	0.38	2.9e-23	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.6	-12.71	-0.45	3.81e-33	Lymphocyte counts;
BRCA	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg12463550	chr7:65579703	CRCP	0.37	7.92	0.3	1.02e-14	Aortic root size;
BRCA	trans	rs75804782	0.521	rs72993056	chr2:239404671	G/T	cg01134436	chr17:81009848	B3GNTL1	0.67	8.56	0.32	8.1e-17	Morning vs. evening chronotype;Chronotype;
BRCA	trans	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg07211511	chr3:129823064	LOC729375	-0.6	-11.19	-0.4	1.11e-26	Blood pressure (smoking interaction);
BRCA	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.59	-14.13	-0.49	1.23e-39	Colorectal cancer;
BRCA	cis	rs637571	0.510	rs3892696	chr11:65582341	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-8.79	-0.33	1.37e-17	Eosinophil percentage of white cells;
BRCA	cis	rs7561273	0.609	rs1056122	chr2:24342505	C/T	cg04809136	chr2:24300158	SF3B14	0.4	8.84	0.33	9.07e-18	Quantitative traits;
BRCA	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg12219531	chr12:120966889	COQ5	0.55	11.68	0.42	1.06e-28	High light scatter reticulocyte count;
BRCA	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg18479299	chr3:125709523	NA	-0.54	-8.36	-0.31	4.05e-16	Blood pressure (smoking interaction);
BRCA	trans	rs1459104	1.000	rs34382934	chr11:55315256	C/T	cg15704280	chr7:45808275	SEPT13	0.63	7.91	0.3	1.13e-14	Body mass index;
BRCA	cis	rs2625529	0.761	rs11853268	chr15:72238973	T/C	cg16672083	chr15:72433130	SENP8	-0.84	-17.52	-0.57	2.13e-56	Red blood cell count;
BRCA	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg15556689	chr8:8085844	FLJ10661	0.36	9.57	0.35	2.28e-20	Neuroticism;
BRCA	cis	rs2016266	1.000	rs10783573	chr12:53728369	G/A	cg26875137	chr12:53738046	NA	0.4	10.56	0.39	3.91e-24	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs6740322	1.000	rs4128209	chr2:43554729	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-12.14	-0.43	1.13e-30	Coronary artery disease;
BRCA	cis	rs911119	0.909	rs111360484	chr20:23618984	G/C	cg16589663	chr20:23618590	CST3	0.47	8.84	0.33	9.27e-18	Chronic kidney disease;
BRCA	cis	rs66530629	1.000	rs16829945	chr1:25040315	C/T	cg01905478	chr1:25040257	NA	0.38	8.91	0.33	5.28e-18	Plateletcrit;
BRCA	cis	rs2066819	1.000	rs117683816	chr12:56638267	T/C	cg26734620	chr12:56694298	CS	0.86	9.88	0.36	1.64e-21	Psoriasis vulgaris;
BRCA	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg09367891	chr1:107599246	PRMT6	-0.47	-8.66	-0.32	3.81e-17	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg13319975	chr6:146136371	FBXO30	-0.37	-8.41	-0.32	2.69e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg15133208	chr4:90757351	SNCA	-0.4	-7.91	-0.3	1.15e-14	Neuroticism;
BRCA	cis	rs367943	0.608	rs7705084	chr5:112990748	G/A	cg12552261	chr5:112820674	MCC	0.36	7.84	0.3	1.91e-14	Type 2 diabetes;
BRCA	cis	rs2742234	0.614	rs3026750	chr10:43607756	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.4	-8.49	-0.32	1.44e-16	Hirschsprung disease;
BRCA	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg19717773	chr7:2847554	GNA12	0.54	11.57	0.42	3e-28	Loneliness (linear analysis);
BRCA	cis	rs9487051	0.735	rs419106	chr6:109520067	C/G	cg21918786	chr6:109611834	NA	-0.36	-9.69	-0.36	8.06e-21	Reticulocyte fraction of red cells;
BRCA	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg13010199	chr12:38710504	ALG10B	0.44	9.32	0.35	1.88e-19	Bladder cancer;
BRCA	cis	rs9560113	0.806	rs9560112	chr13:112183320	A/G	cg10483660	chr13:112241077	NA	0.32	8.13	0.31	2.26e-15	Menarche (age at onset);
BRCA	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.03	0.4	5e-26	Rheumatoid arthritis;
BRCA	cis	rs77972916	0.505	rs6753197	chr2:43527962	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-11.35	-0.41	2.56e-27	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg27347728	chr4:17578864	LAP3	-0.43	-8.22	-0.31	1.16e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg12365402	chr11:9010492	NRIP3	-0.42	-9.34	-0.35	1.6e-19	Hemoglobin concentration;
BRCA	cis	rs4363385	0.747	rs7529110	chr1:152966247	A/C	cg21543102	chr1:152974771	SPRR3	-0.3	-8.64	-0.32	4.51e-17	Inflammatory skin disease;
BRCA	trans	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-20.79	-0.64	1.07e-73	Exhaled nitric oxide output;
BRCA	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.17	-0.43	8.62e-31	Alzheimer's disease;
BRCA	cis	rs68170813	0.559	rs4515482	chr7:107072681	A/C	cg02696742	chr7:106810147	HBP1	-0.46	-8.18	-0.31	1.58e-15	Coronary artery disease;
BRCA	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg06618935	chr21:46677482	NA	-0.38	-8.39	-0.32	3.11e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.05	-0.3	4.13e-15	Prostate cancer;
BRCA	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg27535305	chr1:53392650	SCP2	0.36	8.97	0.33	3.17e-18	Monocyte count;
BRCA	cis	rs1864400	0.645	rs2249005	chr10:43627280	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.55	-10.96	-0.4	9.53e-26	Hirschsprung disease;
BRCA	trans	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg04565464	chr8:145669602	NFKBIL2	0.36	8.22	0.31	1.12e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg13319975	chr6:146136371	FBXO30	-0.44	-10.15	-0.37	1.47e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg17330251	chr7:94953956	PON1	-0.42	-8.9	-0.33	5.76e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg00012203	chr2:219082015	ARPC2	-0.48	-9.27	-0.34	2.92e-19	Colorectal cancer;
BRCA	cis	rs4908768	0.501	rs11121194	chr1:8569906	C/T	cg20416874	chr1:8611966	RERE	-0.28	-8.22	-0.31	1.12e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs2011503	0.739	rs4808973	chr19:19725456	A/G	cg11584989	chr19:19387371	SF4	-0.44	-9.35	-0.35	1.51e-19	Bipolar disorder;
BRCA	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.37	8.51	0.32	1.23e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg06046430	chr4:77819534	ANKRD56	0.61	13.63	0.47	2.57e-37	Emphysema distribution in smoking;
BRCA	cis	rs8016982	0.632	rs7142641	chr14:81677454	A/G	cg01989461	chr14:81687754	GTF2A1	0.48	8.61	0.32	5.73e-17	Schizophrenia;
BRCA	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg22535103	chr8:58192502	C8orf71	-0.54	-11.76	-0.42	4.75e-29	Developmental language disorder (linguistic errors);
BRCA	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg00277334	chr10:82204260	NA	-0.44	-8.66	-0.32	3.75e-17	Post bronchodilator FEV1;
BRCA	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-7.95	-0.3	8.23e-15	Ulcerative colitis;
BRCA	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg11663144	chr21:46675770	NA	-0.47	-11.15	-0.4	1.69e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9790314	0.747	rs9990242	chr3:160838461	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-10.32	-0.38	3.44e-23	Morning vs. evening chronotype;
BRCA	cis	rs6546886	0.912	rs10200470	chr2:74284687	A/G	cg14702570	chr2:74259524	NA	-0.32	-8.01	-0.3	5.29e-15	Dialysis-related mortality;
BRCA	cis	rs77633900	0.614	rs280005	chr15:77009185	G/C	cg21673338	chr15:77095150	SCAPER	-0.54	-9.85	-0.36	2.03e-21	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	14.52	0.5	1.73e-41	Motion sickness;
BRCA	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	15.63	0.53	7.54e-47	Colorectal cancer;
BRCA	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg05623727	chr3:50126028	RBM5	-0.49	-12.16	-0.43	9.5e-31	Body mass index;
BRCA	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	11.88	0.43	1.44e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7474896	0.559	rs1208645	chr10:38132087	C/T	cg25427524	chr10:38739819	LOC399744	0.57	10.33	0.38	3.2e-23	Obesity (extreme);
BRCA	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.5	-14.22	-0.49	4.46e-40	Lung cancer;
BRCA	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.67	0.55	4.32e-52	Morning vs. evening chronotype;
BRCA	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg19622623	chr12:86230825	RASSF9	-0.28	-7.91	-0.3	1.14e-14	Major depressive disorder;
BRCA	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-9.4	-0.35	9.85e-20	Schizophrenia;
BRCA	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg18402987	chr7:1209562	NA	0.8	8.61	0.32	5.54e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs4650994	0.544	rs4075631	chr1:178506594	C/A	cg05059571	chr16:84539110	KIAA1609	-0.5	-11.14	-0.4	1.75e-26	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg24879335	chr3:133465180	TF	0.33	11.07	0.4	3.48e-26	Iron status biomarkers (transferrin levels);
BRCA	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg26384229	chr12:38710491	ALG10B	-0.58	-13.43	-0.47	2.13e-36	Morning vs. evening chronotype;
BRCA	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg00484396	chr16:3507460	NAT15	0.43	9.07	0.34	1.42e-18	Tuberculosis;
BRCA	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-8.43	-0.32	2.29e-16	Schizophrenia;
BRCA	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg02734326	chr4:10020555	SLC2A9	0.41	8.92	0.33	4.81e-18	Bone mineral density;
BRCA	cis	rs2455601	0.786	rs3763914	chr11:8940703	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-8.94	-0.33	4.19e-18	Schizophrenia;
BRCA	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg04166393	chr7:2884313	GNA12	-0.62	-12.74	-0.45	2.66e-33	Height;
BRCA	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.47	-11.37	-0.41	2.14e-27	Longevity;Endometriosis;
BRCA	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg24558204	chr6:135376177	HBS1L	0.59	15.89	0.53	3.8e-48	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06221963	chr1:154839813	KCNN3	-0.59	-16.35	-0.54	1.85e-50	Prostate cancer;
BRCA	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg26248373	chr2:1572462	NA	-0.53	-10.89	-0.4	1.82e-25	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs654950	0.783	rs640688	chr1:42001831	A/G	cg06885757	chr1:42089581	HIVEP3	-0.23	-8.41	-0.32	2.77e-16	Airway imaging phenotypes;
BRCA	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-7.97	-0.3	7.18e-15	Response to antipsychotic treatment;
BRCA	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-12.58	-0.45	1.39e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg04691961	chr3:161091175	C3orf57	-0.39	-9.02	-0.34	2.24e-18	Morning vs. evening chronotype;
BRCA	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	7.98	0.3	6.81e-15	Diabetic retinopathy;
BRCA	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.13	0.37	1.86e-22	Bipolar disorder;
BRCA	trans	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg06521331	chr12:34319734	NA	-0.48	-8.78	-0.33	1.47e-17	Bladder cancer;
BRCA	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg17366294	chr4:99064904	C4orf37	0.52	11.61	0.42	2.09e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9470366	0.527	rs10807170	chr6:36629444	C/T	cg08179530	chr6:36648295	CDKN1A	-0.52	-11.45	-0.41	9.28e-28	QRS duration;
BRCA	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg16070123	chr10:51489643	NA	-0.35	-7.81	-0.3	2.31e-14	Prostate-specific antigen levels;
BRCA	cis	rs6570726	0.533	rs1832374	chr6:145717752	A/G	cg23711669	chr6:146136114	FBXO30	0.44	8.83	0.33	9.67e-18	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg23762105	chr12:34175262	ALG10	-0.4	-9.81	-0.36	2.96e-21	Morning vs. evening chronotype;
BRCA	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	trans	rs8002861	0.905	rs80209017	chr13:44473182	T/C	cg17145862	chr1:211918768	LPGAT1	0.7	18.22	0.58	4.67e-60	Leprosy;
BRCA	cis	rs8023845	0.954	rs1680156	chr15:40447265	T/C	cg20259534	chr15:40453036	BUB1B	0.5	8.01	0.3	5.54e-15	Chronic lymphocytic leukemia;
BRCA	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.2	-0.31	1.28e-15	Depression;
BRCA	cis	rs1864400	0.690	rs7098237	chr10:43740513	T/A	cg02780029	chr10:43622663	RET	0.35	7.91	0.3	1.14e-14	Hirschsprung disease;
BRCA	cis	rs10504073	0.647	rs9643394	chr8:50014427	A/G	cg00325661	chr8:49890786	NA	0.38	11.32	0.41	3.24e-27	Blood metabolite ratios;
BRCA	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19346786	chr7:2764209	NA	-0.34	-9.7	-0.36	7.84e-21	Height;
BRCA	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg21770322	chr7:97807741	LMTK2	0.43	11.43	0.41	1.13e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12210905	0.688	rs78285097	chr6:27374644	G/C	cg08851530	chr6:28072375	NA	0.84	8.2	0.31	1.36e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs2617583	0.967	rs2550946	chr5:1450513	A/G	cg07151155	chr5:1473589	LPCAT1	-0.42	-9.12	-0.34	9.53e-19	Breast cancer;
BRCA	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg17724175	chr1:150552817	MCL1	0.31	9.97	0.37	7.42e-22	Urate levels;
BRCA	cis	rs12760731	0.720	rs10798607	chr1:178373110	C/T	cg00404053	chr1:178313656	RASAL2	0.7	8.36	0.31	3.81e-16	Obesity-related traits;
BRCA	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg17063962	chr7:91808500	NA	-0.55	-12.67	-0.45	5.41e-33	Breast cancer;
BRCA	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg00857998	chr1:205179979	DSTYK	0.41	8.05	0.3	3.94e-15	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.48	-0.35	4.74e-20	Alzheimer's disease (late onset);
BRCA	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	20.7	0.63	3.04e-73	Lymphocyte percentage of white cells;
BRCA	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22496380	chr5:211416	CCDC127	-1.0	-14.08	-0.49	1.99e-39	Breast cancer;
BRCA	cis	rs12545109	0.671	rs35500854	chr8:57424303	G/A	cg09654669	chr8:57350985	NA	-0.42	-8.01	-0.3	5.62e-15	Obesity-related traits;
BRCA	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg01236616	chr12:121019343	POP5	1.24	27.85	0.74	2.17e-112	Type 1 diabetes nephropathy;
BRCA	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11764359	chr7:65958608	NA	0.77	17.36	0.57	1.4e-55	Aortic root size;
BRCA	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg24110177	chr3:50126178	RBM5	-0.51	-14.23	-0.49	4.24e-40	Intelligence (multi-trait analysis);
BRCA	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06108461	chr20:60628389	TAF4	-0.68	-14.3	-0.49	1.93e-40	Body mass index;
BRCA	cis	rs858239	1.000	rs199357	chr7:23288309	A/G	cg23682824	chr7:23144976	KLHL7	-0.34	-8.43	-0.32	2.3e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11890956	chr21:40555474	PSMG1	-0.95	-24.07	-0.69	1.23e-91	Cognitive function;
BRCA	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.67	0.42	1.12e-28	Homoarginine levels;
BRCA	cis	rs9473147	0.543	rs7738044	chr6:47469273	A/G	cg12968598	chr6:47444699	CD2AP	0.44	9.59	0.35	1.93e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg04709771	chr16:646395	RAB40C	0.45	11.25	0.41	6.76e-27	Height;
BRCA	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg00074818	chr8:8560427	CLDN23	0.38	8.31	0.31	5.64e-16	Obesity-related traits;
BRCA	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11644478	chr21:40555479	PSMG1	0.53	11.53	0.42	4.44e-28	Cognitive function;
BRCA	trans	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg23762105	chr12:34175262	ALG10	-0.37	-9.21	-0.34	4.72e-19	Morning vs. evening chronotype;
BRCA	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg23033748	chr14:75592666	NEK9	-0.34	-7.99	-0.3	6.45e-15	Height;
BRCA	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.6	-0.32	6.14e-17	Total body bone mineral density;
BRCA	cis	rs66530629	0.917	rs11249178	chr1:25171719	G/C	cg01905478	chr1:25040257	NA	0.34	7.88	0.3	1.4e-14	Plateletcrit;
BRCA	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg09307838	chr4:120376055	NA	0.75	16.07	0.54	4.89e-49	Corneal astigmatism;
BRCA	cis	rs1451375	0.755	rs6969081	chr7:50624505	A/T	cg18232548	chr7:50535776	DDC	0.44	11.09	0.4	2.89e-26	Malaria;
BRCA	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg24112000	chr20:60950667	NA	0.5	9.92	0.37	1.14e-21	Colorectal cancer;
BRCA	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16680214	chr1:154839983	KCNN3	0.44	11.75	0.42	5.18e-29	Prostate cancer;
BRCA	cis	rs586533	0.813	rs11220769	chr11:99507548	G/C	cg22878054	chr11:99397252	CNTN5	0.31	7.85	0.3	1.79e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg21798802	chr22:38057573	PDXP	0.29	7.9	0.3	1.23e-14	Fat distribution (HIV);
BRCA	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg21366198	chr4:185655624	MLF1IP	-0.42	-9.95	-0.37	8.75e-22	Kawasaki disease;
BRCA	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg04025307	chr7:1156635	C7orf50	0.58	9.08	0.34	1.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08045932	chr20:61659980	NA	0.49	11.35	0.41	2.57e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg23306229	chr2:178417860	TTC30B	0.47	7.82	0.3	2.19e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	14.17	0.49	7.77e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg03188948	chr7:1209495	NA	0.53	9.17	0.34	6.4e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg09184832	chr6:79620586	NA	-0.5	-11.04	-0.4	4.74e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs6878727	0.545	rs2591383	chr5:123687171	G/A	cg01806427	chr5:123737813	NA	-0.37	-8.23	-0.31	1.07e-15	Breast cancer;
BRCA	cis	rs10421328	0.848	rs867616	chr19:19757682	C/T	cg11584989	chr19:19387371	SF4	0.41	8.1	0.31	2.75e-15	Parental longevity (combined parental age at death);
BRCA	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg21535247	chr6:8435926	SLC35B3	0.42	9.42	0.35	7.86e-20	Motion sickness;
BRCA	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.6	-0.39	2.64e-24	Tonsillectomy;
BRCA	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Tonsillectomy;
BRCA	cis	rs7560272	0.538	rs12052539	chr2:73937153	C/T	cg20560298	chr2:73613845	ALMS1	-0.34	-8.97	-0.33	3.23e-18	Schizophrenia;
BRCA	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.26	-0.31	8.46e-16	Bipolar disorder;
BRCA	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg24450063	chr1:156163899	SLC25A44	1.12	36.14	0.82	1.26e-156	Testicular germ cell tumor;
BRCA	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg09307838	chr4:120376055	NA	0.7	14.87	0.51	3.55e-43	Corneal astigmatism;
BRCA	trans	rs208520	0.690	rs207108	chr6:66794096	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.23	-0.64	4.44e-76	Exhaled nitric oxide output;
BRCA	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg22638593	chr5:131593259	PDLIM4	0.32	7.86	0.3	1.7e-14	Acylcarnitine levels;
BRCA	cis	rs10045504	0.502	rs17456635	chr5:38745456	G/A	cg15396434	chr5:38725168	NA	-0.57	-10.76	-0.39	6.11e-25	Night sleep phenotypes;
BRCA	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg15103426	chr22:29168792	CCDC117	-0.54	-12.57	-0.45	1.48e-32	Lymphocyte counts;
BRCA	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg13271783	chr10:134563150	INPP5A	-0.51	-9.59	-0.35	1.99e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.16	0.49	8.34e-40	Eye color traits;
BRCA	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.63	-12.81	-0.45	1.31e-33	Lymphocyte counts;
BRCA	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg24558204	chr6:135376177	HBS1L	0.57	15.5	0.52	3.25e-46	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg15103426	chr22:29168792	CCDC117	0.51	12.15	0.43	1.06e-30	Lymphocyte counts;
BRCA	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg15145296	chr3:125709740	NA	-0.54	-8.68	-0.32	3.28e-17	Blood pressure (smoking interaction);
BRCA	cis	rs34779708	0.966	rs2505639	chr10:35474421	A/G	cg03585969	chr10:35415529	CREM	-0.47	-9.96	-0.37	8.26e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-16.05	-0.54	5.71e-49	Heart rate;
BRCA	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg00105475	chr2:10696890	NA	0.44	10.13	0.37	1.88e-22	Prostate cancer;
BRCA	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg07636037	chr3:49044803	WDR6	0.97	28.35	0.75	4.41e-115	Parkinson's disease;
BRCA	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg18132916	chr6:79620363	NA	-0.41	-8.27	-0.31	7.84e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs11585357	0.895	rs72633812	chr1:17623140	T/C	cg08277548	chr1:17600880	PADI3	-0.75	-12.35	-0.44	1.43e-31	Hair shape;
BRCA	trans	rs1478897	0.898	rs2248932	chr8:11391650	A/G	cg15556689	chr8:8085844	FLJ10661	-0.33	-8.52	-0.32	1.13e-16	Systemic lupus erythematosus;
BRCA	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.66	-13.42	-0.47	2.48e-36	Lymphocyte counts;
BRCA	trans	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.97	0.3	7.33e-15	Corneal astigmatism;
BRCA	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.58	-0.35	2.19e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.46	9.39	0.35	1.03e-19	IgG glycosylation;
BRCA	cis	rs113835537	0.529	rs11821155	chr11:66246337	C/T	cg24851651	chr11:66362959	CCS	-0.42	-7.96	-0.3	7.81e-15	Airway imaging phenotypes;
BRCA	cis	rs12210905	0.614	rs12199685	chr6:27323486	G/A	cg08851530	chr6:28072375	NA	0.91	8.7	0.33	2.7e-17	Hip circumference adjusted for BMI;
BRCA	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21659725	chr3:3221576	CRBN	0.52	12.31	0.44	2.19e-31	Resting heart rate;
BRCA	cis	rs1878931	0.580	rs7194596	chr16:3404408	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.81	19.15	0.6	5.85e-65	Body mass index (adult);
BRCA	cis	rs7715811	1.000	rs1502052	chr5:13774908	G/A	cg07548982	chr5:13769939	DNAH5	-0.4	-9.0	-0.34	2.62e-18	Subclinical atherosclerosis traits (other);
BRCA	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg15017067	chr4:17643749	FAM184B	0.32	9.82	0.36	2.75e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg06521331	chr12:34319734	NA	0.44	8.49	0.32	1.44e-16	Morning vs. evening chronotype;
BRCA	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg03433033	chr1:76189801	ACADM	0.69	16.99	0.56	1.04e-53	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.35	0.57	1.6e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs16958440	0.867	rs75901436	chr18:44689644	C/T	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg18512352	chr11:47633146	NA	-0.34	-8.3	-0.31	6.28e-16	Neuroticism;
BRCA	cis	rs2742234	0.955	rs2503841	chr10:43675721	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.41	-8.73	-0.33	2.24e-17	Hirschsprung disease;
BRCA	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24549020	chr5:56110836	MAP3K1	0.59	11.92	0.43	9.99e-30	Initial pursuit acceleration;
BRCA	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg06064525	chr11:970664	AP2A2	-0.49	-16.22	-0.54	7.89e-50	Alzheimer's disease (late onset);
BRCA	cis	rs795544	0.608	rs1502048	chr5:13788282	C/T	cg07548982	chr5:13769939	DNAH5	0.38	8.26	0.31	8.48e-16	Corneal astigmatism;
BRCA	cis	rs4988958	0.527	rs6756161	chr2:103048417	C/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.38	0.31	3.39e-16	Asthma (childhood onset);
BRCA	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg14530993	chr4:882597	GAK	0.59	9.68	0.36	9.2e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs912057	0.833	rs1024245	chr6:6743319	A/G	cg06612196	chr6:6737390	NA	0.4	8.86	0.33	7.98e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.99	0.3	6.41e-15	Depression;
BRCA	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg00701064	chr4:6280414	WFS1	0.7	18.2	0.58	5.6899999999999994e-60	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.12	-0.31	2.39e-15	Menopause (age at onset);
BRCA	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg00106254	chr7:1943704	MAD1L1	-0.4	-10.76	-0.39	6.08e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs2014572	0.967	rs10411941	chr19:57762886	C/T	cg24459738	chr19:57751996	ZNF805	-0.37	-8.71	-0.33	2.59e-17	Hyperactive-impulsive symptoms;
BRCA	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg02297831	chr4:17616191	MED28	-0.35	-7.99	-0.3	6.33e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg04511125	chr2:88470314	THNSL2	0.79	11.38	0.41	1.8e-27	Plasma clusterin levels;
BRCA	cis	rs72772090	0.522	rs113433514	chr5:95995022	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-8.5	-0.32	1.3e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg03954927	chr1:10346856	KIF1B	0.48	14.87	0.51	3.63e-43	Hepatocellular carcinoma;
BRCA	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg17366294	chr4:99064904	C4orf37	0.54	11.6	0.42	2.2e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg17366294	chr4:99064904	C4orf37	0.45	10.63	0.39	2.13e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.78	-13.04	-0.46	1.28e-34	Schizophrenia;
BRCA	trans	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg26043149	chr18:55253948	FECH	0.37	7.84	0.3	1.85e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg08807101	chr21:30365312	RNF160	-0.38	-8.13	-0.31	2.21e-15	Selective IgA deficiency;
BRCA	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-8.54	-0.32	9.82e-17	Longevity;Endometriosis;
BRCA	cis	rs7254827	0.737	rs35005380	chr19:17158056	G/A	cg19418318	chr19:17219073	MYO9B	-0.48	-10.17	-0.37	1.29e-22	Mean platelet volume;
BRCA	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	15.63	0.53	6.83e-47	Colorectal cancer;
BRCA	cis	rs11971779	0.648	rs6947309	chr7:139035830	C/T	cg07862535	chr7:139043722	LUC7L2	0.35	9.28	0.34	2.56e-19	Diisocyanate-induced asthma;
BRCA	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg24324837	chr19:49891574	CCDC155	0.51	9.05	0.34	1.68e-18	Multiple sclerosis;
BRCA	cis	rs3784262	0.669	rs4646580	chr15:58329211	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-9.87	-0.36	1.78e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg23422044	chr7:1970798	MAD1L1	-0.47	-9.76	-0.36	4.36e-21	Bipolar disorder;
BRCA	trans	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg04565464	chr8:145669602	NFKBIL2	0.38	8.36	0.31	4.02e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg02297831	chr4:17616191	MED28	0.36	8.42	0.32	2.41e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9462846	0.959	rs7750915	chr6:42882067	C/T	cg02353165	chr6:42928485	GNMT	0.54	9.49	0.35	4.61e-20	Blood protein levels;
BRCA	cis	rs911119	1.000	rs13039536	chr20:23612305	A/G	cg16589663	chr20:23618590	CST3	0.46	8.72	0.33	2.32e-17	Chronic kidney disease;
BRCA	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg26248373	chr2:1572462	NA	-0.53	-11.61	-0.42	1.98e-28	IgG glycosylation;
BRCA	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.84	0.36	2.26e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2658782	0.547	rs3020054	chr11:93055556	C/T	cg15737290	chr11:93063684	CCDC67	0.57	13.87	0.48	1.91e-38	Pulmonary function decline;
BRCA	trans	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg01620082	chr3:125678407	NA	-0.85	-10.01	-0.37	5.21e-22	Depression;
BRCA	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg09877947	chr5:131593287	PDLIM4	0.42	10.73	0.39	8.24e-25	Breast cancer;
BRCA	cis	rs1003719	0.715	rs2835613	chr21:38496883	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.24	-0.49	3.83e-40	Eye color traits;
BRCA	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg14403583	chr14:105418241	AHNAK2	-0.38	-8.98	-0.33	3.12e-18	Rheumatoid arthritis;
BRCA	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg07741184	chr6:167504864	NA	-0.29	-8.51	-0.32	1.21e-16	Crohn's disease;
BRCA	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg27588902	chr6:42928151	GNMT	-0.31	-10.16	-0.37	1.43e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg11062466	chr8:58055876	NA	-0.52	-9.08	-0.34	1.37e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11644478	chr21:40555479	PSMG1	-0.54	-11.53	-0.42	4.39e-28	Menarche (age at onset);
BRCA	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20916646	chr4:852691	GAK	0.37	9.09	0.34	1.27e-18	Sjögren's syndrome;
BRCA	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg15485101	chr11:133734466	NA	0.4	9.77	0.36	4.32e-21	Childhood ear infection;
BRCA	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-9.25	-0.34	3.45e-19	Bipolar disorder;
BRCA	cis	rs13046373	0.535	rs2832970	chr21:32020767	T/C	cg06468780	chr21:31798236	KRTAP13-3	0.33	8.37	0.31	3.62e-16	HDL cholesterol;
BRCA	cis	rs2745967	0.740	rs2785645	chr1:208067420	A/G	cg09788693	chr1:208063733	CD34	0.37	7.84	0.3	1.86e-14	Resting heart rate;
BRCA	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg07828340	chr4:882639	GAK	-0.97	-12.4	-0.44	8.43e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg13319975	chr6:146136371	FBXO30	-0.54	-12.08	-0.43	2.06e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6750795	0.542	rs1797388	chr2:232415981	T/G	cg19187155	chr2:232395269	NMUR1	0.69	17.45	0.57	4.92e-56	Height;
BRCA	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-17.97	-0.58	9.09e-59	Morning vs. evening chronotype;
BRCA	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.25	-0.34	3.46e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs754466	0.606	rs11002308	chr10:79594796	A/T	cg17075019	chr10:79541650	NA	-0.81	-20.56	-0.63	1.76e-72	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg02659138	chr7:134003124	SLC35B4	0.34	10.47	0.38	8.74e-24	Mean platelet volume;
BRCA	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg17691542	chr6:26056736	HIST1H1C	0.45	8.64	0.32	4.67e-17	Iron status biomarkers;
BRCA	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24549020	chr5:56110836	MAP3K1	0.62	10.47	0.38	8.45e-24	Type 2 diabetes;
BRCA	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg26597838	chr10:835615	NA	-0.64	-13.07	-0.46	8.77e-35	Eosinophil percentage of granulocytes;
BRCA	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26384229	chr12:38710491	ALG10B	0.75	16.63	0.55	7.23e-52	Morning vs. evening chronotype;
BRCA	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg07917127	chr4:99064746	C4orf37	0.41	7.85	0.3	1.7e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3857067	0.806	rs9996975	chr4:95101338	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.36	-0.35	1.31e-19	QT interval;
BRCA	cis	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg06521331	chr12:34319734	NA	-0.56	-10.01	-0.37	5.22e-22	Morning vs. evening chronotype;
BRCA	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg14675211	chr2:100938903	LONRF2	0.44	10.11	0.37	2.18e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9837602	0.935	rs17392948	chr3:99754498	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	10.53	0.38	5.24e-24	Breast cancer;
BRCA	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg25173405	chr17:45401733	C17orf57	-0.53	-10.94	-0.4	1.24e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-16.05	-0.54	5.93e-49	Colorectal cancer;
BRCA	cis	rs4730250	0.707	rs6977868	chr7:106790555	T/G	cg02696742	chr7:106810147	HBP1	0.61	9.52	0.35	3.54e-20	Osteoarthritis;
BRCA	cis	rs1034435	0.723	rs713946	chr22:48891376	T/C	cg05992904	chr22:48892994	FAM19A5	-0.79	-20.42	-0.63	1.04e-71	Late-onset Alzheimer's disease;
BRCA	cis	rs9473147	0.543	rs4715019	chr6:47447041	T/A	cg12968598	chr6:47444699	CD2AP	0.45	9.69	0.36	8.52e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs858239	0.539	rs6971673	chr7:23159523	C/G	cg23682824	chr7:23144976	KLHL7	0.42	11.09	0.4	2.96e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6450176	0.909	rs3776721	chr5:53292522	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-14.11	-0.49	1.51e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs7818345	0.967	rs11204040	chr8:19288525	T/A	cg11303988	chr8:19266685	CSGALNACT1	0.3	7.97	0.3	7.15e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg12386194	chr3:101231763	SENP7	0.46	9.81	0.36	2.87e-21	Colorectal cancer;
BRCA	cis	rs2430307	0.556	rs3905501	chr7:76542080	C/T	cg15770687	chr7:76625569	PMS2L11	-0.54	-9.51	-0.35	3.96e-20	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg17366294	chr4:99064904	C4orf37	0.51	11.46	0.41	8.52e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	7.97	0.3	7.13e-15	Total cholesterol levels;
BRCA	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2014572	0.967	rs10427146	chr19:57755998	T/C	cg24459738	chr19:57751996	ZNF805	-0.33	-7.98	-0.3	6.85e-15	Hyperactive-impulsive symptoms;
BRCA	cis	rs10044254	0.614	rs11750054	chr5:15733602	T/C	cg07238450	chr5:15720153	FBXL7	-0.37	-7.94	-0.3	9.34e-15	Asthma (corticosteroid response);
BRCA	cis	rs12617721	0.645	rs114544871	chr2:99045485	T/G	cg10123293	chr2:99228465	UNC50	0.41	8.14	0.31	2.05e-15	Bipolar disorder with mood-incongruent psychosis;
BRCA	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11644478	chr21:40555479	PSMG1	0.78	17.03	0.56	7.03e-54	Cognitive function;
BRCA	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg10729496	chr3:10149963	C3orf24	0.49	9.14	0.34	8.18e-19	Alzheimer's disease;
BRCA	cis	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg07988820	chr12:82153109	PPFIA2	-0.56	-9.21	-0.34	4.59e-19	Resting heart rate;
BRCA	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21659725	chr3:3221576	CRBN	-0.71	-21.87	-0.65	1.35e-79	Intelligence (multi-trait analysis);
BRCA	cis	rs2422052	0.792	rs4849637	chr2:118645575	A/G	cg22545206	chr2:118617499	NA	0.39	9.54	0.35	2.98e-20	Mosquito bite size;
BRCA	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08564027	chr20:61660810	NA	0.86	22.97	0.67	1.43e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg13010199	chr12:38710504	ALG10B	0.5	9.89	0.36	1.54e-21	Bladder cancer;
BRCA	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg11764359	chr7:65958608	NA	0.68	15.21	0.52	8.16e-45	Aortic root size;
BRCA	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg24692254	chr21:30365293	RNF160	-0.48	-10.99	-0.4	7.54e-26	Cognitive test performance;
BRCA	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg25427524	chr10:38739819	LOC399744	0.51	9.44	0.35	6.74e-20	Obesity (extreme);
BRCA	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg10224037	chr5:178157518	ZNF354A	0.76	15.97	0.53	1.55e-48	Neutrophil percentage of white cells;
BRCA	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg01689657	chr7:91764605	CYP51A1	0.22	8.16	0.31	1.78e-15	Breast cancer;
BRCA	cis	rs1003719	0.680	rs2835621	chr21:38510616	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.32	-0.49	1.46e-40	Eye color traits;
BRCA	cis	rs6815814	0.950	rs5743580	chr4:38804405	C/T	cg02016764	chr4:38805732	TLR1	-0.61	-9.73	-0.36	5.9e-21	Breast cancer;
BRCA	cis	rs1505368	0.817	rs1283310	chr2:213273891	A/G	cg20637307	chr2:213403960	ERBB4	0.39	9.09	0.34	1.24e-18	Symmetrical dimethylarginine levels;
BRCA	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg24631222	chr15:78858424	CHRNA5	-0.48	-9.62	-0.36	1.56e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.2	0.68	7.62e-87	Chronic sinus infection;
BRCA	cis	rs365132	1.000	rs2292256	chr5:176333126	C/T	cg16309518	chr5:176445507	NA	-0.52	-13.45	-0.47	1.76e-36	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs2414095	0.527	rs8041967	chr15:51544324	G/A	cg19946085	chr15:51559439	CYP19A1	-0.3	-7.82	-0.3	2.27e-14	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
BRCA	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg05623727	chr3:50126028	RBM5	-0.49	-12.16	-0.43	9.5e-31	Body mass index;
BRCA	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg09307838	chr4:120376055	NA	0.61	12.3	0.44	2.34e-31	Corneal astigmatism;
BRCA	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg26384229	chr12:38710491	ALG10B	0.42	9.44	0.35	6.82e-20	Morning vs. evening chronotype;
BRCA	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.1	0.31	2.71e-15	Uric acid levels;
BRCA	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg15432903	chr11:17409602	KCNJ11	0.71	15.49	0.52	3.35e-46	Type 2 diabetes;
BRCA	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg03711944	chr11:47377212	SPI1	-0.41	-9.84	-0.36	2.26e-21	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs6893300	0.785	rs58386410	chr5:179205704	T/C	cg14593053	chr5:179126677	CANX	-0.36	-8.02	-0.3	4.9e-15	Resting heart rate;
BRCA	cis	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg07988820	chr12:82153109	PPFIA2	-0.6	-9.76	-0.36	4.55e-21	Resting heart rate;
BRCA	cis	rs78487399	0.710	rs72881068	chr2:43690860	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-7.87	-0.3	1.56e-14	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg20469991	chr17:27169893	C17orf63	-0.45	-8.82	-0.33	1.08e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	trans	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg25214090	chr10:38739885	LOC399744	0.53	11.98	0.43	5.76e-30	Corneal astigmatism;
BRCA	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	11.29	0.41	4.31e-27	Alzheimer's disease;
BRCA	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg21535247	chr6:8435926	SLC35B3	0.4	8.96	0.33	3.57e-18	Motion sickness;
BRCA	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg27170947	chr2:26402098	FAM59B	0.97	17.09	0.56	3.41e-54	Gut microbiome composition (summer);
BRCA	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg00666640	chr1:248458726	OR2T12	0.3	8.58	0.32	7.32e-17	Common traits (Other);
BRCA	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg00074818	chr8:8560427	CLDN23	0.39	8.54	0.32	1.02e-16	Obesity-related traits;
BRCA	cis	rs3820928	1.000	rs10193404	chr2:227777757	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.48	-0.32	1.53e-16	Pulmonary function;
BRCA	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg10845886	chr2:3471009	TTC15	-0.54	-12.22	-0.44	5.48e-31	Neurofibrillary tangles;
BRCA	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg08885076	chr2:99613938	TSGA10	-0.52	-11.85	-0.42	1.95e-29	Chronic sinus infection;
BRCA	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg02079420	chr8:82753780	SNX16	0.31	8.45	0.32	1.9e-16	Diastolic blood pressure;
BRCA	trans	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	9.23	0.34	4.08e-19	Mean corpuscular volume;
BRCA	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg01324343	chr3:183735012	ABCC5	0.65	15.67	0.53	4.3e-47	Anterior chamber depth;
BRCA	cis	rs1832871	0.619	rs262823	chr6:158676149	G/C	cg07215822	chr6:158701037	NA	-0.49	-10.33	-0.38	3.06e-23	Height;
BRCA	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.43	-9.75	-0.36	4.83e-21	Electroencephalogram traits;
BRCA	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg03188948	chr7:1209495	NA	0.92	14.25	0.49	3.13e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg05234568	chr11:5960015	NA	-0.46	-9.09	-0.34	1.2e-18	DNA methylation (variation);
BRCA	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg04267008	chr7:1944627	MAD1L1	0.57	12.61	0.45	1.05e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.87	0.56	4.51e-53	Colorectal cancer;
BRCA	cis	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg21775007	chr8:11205619	TDH	-0.5	-10.07	-0.37	3.09e-22	Triglycerides;
BRCA	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg15934090	chr1:100435551	SLC35A3	0.38	8.55	0.32	9.17e-17	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7980799	0.618	rs1482983	chr12:33690326	A/C	cg26384229	chr12:38710491	ALG10B	0.53	11.29	0.41	4.33e-27	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs17209837	0.607	rs1558375	chr7:87079069	T/C	cg00919237	chr7:87102261	ABCB4	-0.53	-10.22	-0.37	8.0700000000000006e-23	Gallbladder cancer;
BRCA	cis	rs2629540	0.806	rs10901812	chr10:126419384	A/G	cg08799069	chr10:126477246	METTL10	-0.44	-8.9	-0.33	5.82e-18	Cocaine dependence;
BRCA	cis	rs11785693	0.862	rs11774099	chr8:4988218	C/T	cg26367366	chr8:4980734	NA	0.61	11.04	0.4	4.75e-26	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	19.93	0.62	4.18e-69	Alzheimer's disease;
BRCA	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg26248373	chr2:1572462	NA	-0.67	-15.83	-0.53	7.21e-48	IgG glycosylation;
BRCA	cis	rs12579753	0.917	rs11612874	chr12:82212649	A/C	cg07988820	chr12:82153109	PPFIA2	0.5	8.55	0.32	9.12e-17	Resting heart rate;
BRCA	cis	rs7301826	0.651	rs12228959	chr12:131296068	T/G	cg11011512	chr12:131303247	STX2	0.52	13.65	0.48	2.18e-37	Plasma plasminogen activator levels;
BRCA	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg17971929	chr21:40555470	PSMG1	0.53	11.81	0.42	2.93e-29	Cognitive function;
BRCA	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	14.55	0.5	1.24e-41	Motion sickness;
BRCA	cis	rs4588572	0.643	rs10043027	chr5:77792707	T/C	cg11547950	chr5:77652471	NA	-0.5	-8.98	-0.33	2.9e-18	Triglycerides;
BRCA	cis	rs11971779	0.523	rs10279160	chr7:139090761	A/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.36	0.38	2.36e-23	Diisocyanate-induced asthma;
BRCA	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg20701182	chr2:24300061	SF3B14	0.6	9.39	0.35	1.02e-19	Lymphocyte counts;
BRCA	cis	rs9837602	0.882	rs9875664	chr3:99729130	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	10.45	0.38	1.07e-23	Breast cancer;
BRCA	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg22638593	chr5:131593259	PDLIM4	0.32	7.86	0.3	1.7e-14	Acylcarnitine levels;
BRCA	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg05340658	chr4:99064831	C4orf37	0.42	9.55	0.35	2.83e-20	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs701145	0.585	rs1713811	chr3:153874566	G/A	cg17054900	chr3:154042577	DHX36	0.55	9.29	0.35	2.32e-19	Coronary artery disease;
BRCA	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.6e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.3	0.49	1.87e-40	Motion sickness;
BRCA	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.44	-0.35	6.87e-20	Menopause (age at onset);
BRCA	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg20607798	chr8:58055168	NA	0.63	9.54	0.35	2.86e-20	Developmental language disorder (linguistic errors);
BRCA	trans	rs4714291	0.963	rs2395543	chr6:39965020	A/G	cg02267698	chr19:7991119	CTXN1	0.43	8.47	0.32	1.64e-16	Strep throat;
BRCA	cis	rs7246967	0.673	rs6511383	chr19:22956900	C/T	cg23217946	chr19:22817039	ZNF492	0.5	9.06	0.34	1.58e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg00074818	chr8:8560427	CLDN23	0.38	8.3	0.31	6.14e-16	Obesity-related traits;
BRCA	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg04756594	chr16:24857601	SLC5A11	-0.35	-8.42	-0.32	2.51e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.56	-14.73	-0.5	1.64e-42	Colorectal cancer;
BRCA	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg04517722	chr19:17905589	B3GNT3	0.43	8.45	0.32	1.92e-16	Tumor biomarkers;
BRCA	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg14847009	chr1:175162515	KIAA0040	-0.26	-9.66	-0.36	1.03e-20	Alcohol dependence;
BRCA	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg11663144	chr21:46675770	NA	0.6	13.87	0.48	2.01e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs13046373	0.534	rs9305426	chr21:31964916	A/C	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.36	0.35	1.34e-19	HDL cholesterol;
BRCA	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	14.09	0.49	1.8e-39	Colorectal cancer;
BRCA	cis	rs35740288	0.721	rs4843093	chr15:86237433	G/A	cg20737812	chr15:86336631	KLHL25	-0.32	-7.82	-0.3	2.22e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg08997352	chr12:9597637	DDX12	-0.5	-9.68	-0.36	8.83e-21	Breast size;
BRCA	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg21573476	chr21:45109991	RRP1B	-0.35	-9.01	-0.34	2.42e-18	Mean corpuscular volume;
BRCA	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.02e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg00383909	chr3:49044727	WDR6	0.53	10.13	0.37	1.81e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs311392	0.966	rs404354	chr8:55087196	A/G	cg11783602	chr8:55087084	NA	-0.33	-9.59	-0.35	1.94e-20	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg13902645	chr11:5959945	NA	-0.55	-10.77	-0.39	5.53e-25	DNA methylation (variation);
BRCA	cis	rs2191566	0.576	rs381091	chr19:44495315	G/A	cg20607764	chr19:44506953	ZNF230	0.37	8.03	0.3	4.64e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg19653624	chr11:20408972	PRMT3	0.41	9.81	0.36	3.01e-21	Pursuit maintenance gain;
BRCA	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg23711669	chr6:146136114	FBXO30	0.78	18.61	0.59	4.47e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg13770153	chr20:60521292	NA	-0.4	-9.44	-0.35	6.84e-20	Body mass index;
BRCA	cis	rs11025559	0.812	rs10766679	chr11:20509190	T/C	cg19653624	chr11:20408972	PRMT3	-0.44	-10.41	-0.38	1.55e-23	Pursuit maintenance gain;
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg18538332	chr22:24372958	LOC391322	0.53	12.75	0.45	2.4e-33	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg20933634	chr6:27740509	NA	-0.43	-8.57	-0.32	7.65e-17	Parkinson's disease;
BRCA	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.94	0.58	1.43e-58	Colorectal cancer;
BRCA	cis	rs7760949	0.925	rs9464420	chr6:13925892	C/T	cg27413430	chr6:13925136	RNF182	0.45	9.06	0.34	1.57e-18	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2880765	0.743	rs12906308	chr15:86008059	C/T	cg10818794	chr15:86012489	AKAP13	0.31	8.37	0.31	3.57e-16	Coronary artery disease;
BRCA	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg10729496	chr3:10149963	C3orf24	0.49	9.01	0.34	2.35e-18	Alzheimer's disease;
BRCA	cis	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg06521331	chr12:34319734	NA	-0.53	-10.29	-0.38	4.23e-23	Morning vs. evening chronotype;
BRCA	cis	rs1595825	0.786	rs77773624	chr2:198514845	G/A	cg19156104	chr2:198669113	PLCL1	-0.42	-8.15	-0.31	1.96e-15	Ulcerative colitis;
BRCA	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg05340658	chr4:99064831	C4orf37	0.69	16.84	0.55	6.06e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4742903	0.935	rs10820602	chr9:106861282	C/T	cg14250997	chr9:106856677	SMC2	0.34	10.67	0.39	1.48e-24	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs4285028	0.948	rs35737776	chr3:121677856	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.82	-0.39	3.64e-25	Multiple sclerosis;
BRCA	trans	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.96	0.3	7.64e-15	Corneal astigmatism;
BRCA	cis	rs78663649	0.908	rs79641498	chr19:16521143	C/A	cg05286348	chr19:16641544	CHERP	-0.72	-9.68	-0.36	9.07e-21	White blood cell count;
BRCA	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-17.86	-0.58	3.46e-58	Chronic sinus infection;
BRCA	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg07988820	chr12:82153109	PPFIA2	-0.67	-11.4	-0.41	1.52e-27	Resting heart rate;
BRCA	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg25237894	chr2:233734115	C2orf82	-0.41	-11.63	-0.42	1.69e-28	Coronary artery disease;
BRCA	cis	rs7072216	0.763	rs2274246	chr10:100175060	C/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.68	-0.36	8.8e-21	Metabolite levels;
BRCA	cis	rs10465746	0.967	rs12757632	chr1:84416408	T/C	cg10977910	chr1:84465055	TTLL7	0.51	10.2	0.37	1.02e-22	Obesity-related traits;
BRCA	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24531977	chr5:56204891	C5orf35	-0.86	-17.83	-0.58	4.82e-58	Initial pursuit acceleration;
BRCA	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18876405	chr7:65276391	NA	-0.49	-10.65	-0.39	1.73e-24	Aortic root size;
BRCA	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg01420254	chr6:26195488	NA	0.59	9.01	0.34	2.36e-18	Gout;Renal underexcretion gout;
BRCA	cis	rs7408868	1.000	rs757472	chr19:15273221	T/C	cg14696996	chr19:15285081	NOTCH3	0.83	13.22	0.46	1.99e-35	Pulse pressure;
BRCA	cis	rs7633770	0.841	rs11130100	chr3:46679198	A/T	cg11219411	chr3:46661640	NA	-0.7	-19.42	-0.61	2.26e-66	Coronary artery disease;
BRCA	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg14683738	chr19:37701593	ZNF585B	0.45	7.98	0.3	6.97e-15	Coronary artery calcification;
BRCA	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg08000102	chr2:233561755	GIGYF2	-0.62	-13.59	-0.47	3.88e-37	Coronary artery disease;
BRCA	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.31	-0.38	3.85e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03517284	chr6:25882590	NA	-0.67	-15.82	-0.53	8.25e-48	Blood metabolite levels;
BRCA	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg07741184	chr6:167504864	NA	0.27	8.06	0.3	3.74e-15	Crohn's disease;
BRCA	cis	rs9309711	0.883	rs13429373	chr2:3477014	G/A	cg10845886	chr2:3471009	TTC15	-0.81	-17.02	-0.56	7.83e-54	Neurofibrillary tangles;
BRCA	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg22906224	chr7:99728672	NA	0.39	7.94	0.3	9.14e-15	Coronary artery disease;
BRCA	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg10932868	chr11:921992	NA	0.39	9.36	0.35	1.33e-19	Alzheimer's disease (late onset);
BRCA	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.68	-0.32	3.21e-17	Breast cancer;
BRCA	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg06784218	chr1:46089804	CCDC17	0.49	11.86	0.42	1.88e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	8.31e-21	Bladder cancer;
BRCA	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-12.14	-0.43	1.1e-30	Response to antipsychotic treatment;
BRCA	cis	rs9790314	0.613	rs34297047	chr3:160631478	A/G	cg03342759	chr3:160939853	NMD3	0.43	8.69	0.33	2.92e-17	Morning vs. evening chronotype;
BRCA	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg08807101	chr21:30365312	RNF160	0.77	20.2	0.62	1.45e-70	Dental caries;
BRCA	cis	rs6700896	0.897	rs11208701	chr1:66134698	C/T	cg04111102	chr1:66153794	NA	0.36	8.67	0.32	3.57e-17	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs724568	0.527	rs11126147	chr2:67934313	C/A	cg14046302	chr2:67939758	NA	-0.38	-10.14	-0.37	1.72e-22	Major depressive disorder (broad);
BRCA	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg11584989	chr19:19387371	SF4	0.64	13.5	0.47	1.03e-36	Bipolar disorder;
BRCA	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg17425144	chr1:10567563	PEX14	0.57	14.63	0.5	5.28e-42	Prostate cancer;
BRCA	cis	rs9297145	0.715	rs62473008	chr7:98751541	A/G	cg05967295	chr7:98741636	SMURF1	0.94	17.15	0.56	1.55e-54	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	trans	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg19862616	chr7:65841803	NCRNA00174	0.84	27.37	0.73	9.39e-110	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg16325326	chr1:53192061	ZYG11B	-0.7	-18.17	-0.58	8.7e-60	Monocyte count;
BRCA	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg13010199	chr12:38710504	ALG10B	0.56	12.33	0.44	1.71e-31	Heart rate;
BRCA	cis	rs13095912	0.778	rs7651346	chr3:185300395	G/A	cg11274856	chr3:185301563	NA	0.56	13.58	0.47	4.55e-37	Systolic blood pressure;
BRCA	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	11.52	0.41	4.72e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg17830980	chr10:43048298	ZNF37B	-0.54	-12.95	-0.46	3.01e-34	Extrinsic epigenetic age acceleration;
BRCA	cis	rs965469	1.000	rs2236107	chr20:3285821	C/T	cg25506879	chr20:3388711	C20orf194	-0.52	-9.78	-0.36	3.89e-21	IFN-related cytopenia;
BRCA	cis	rs6840258	0.660	rs10516786	chr4:87892341	A/G	cg08197287	chr4:87952173	AFF1	-0.44	-8.17	-0.31	1.65e-15	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg24069376	chr3:38537580	EXOG	0.39	11.16	0.4	1.52e-26	Electrocardiographic conduction measures;
BRCA	cis	rs9831754	0.906	rs6782626	chr3:78406178	T/C	cg06138941	chr3:78371609	NA	-0.74	-16.08	-0.54	4.24e-49	Calcium levels;
BRCA	cis	rs4803468	1.000	rs9304593	chr19:41942875	A/C	cg09537434	chr19:41945824	ATP5SL	1.03	25.67	0.71	2.15e-100	Height;
BRCA	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg22920501	chr2:26401640	FAM59B	0.76	10.85	0.39	2.71e-25	Gut microbiome composition (summer);
BRCA	cis	rs1874326	0.545	rs6467769	chr7:138109790	G/A	cg18008034	chr7:138118925	NA	-0.44	-9.22	-0.34	4.2e-19	Quantitative traits;
BRCA	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg14036092	chr11:66035641	RAB1B	0.39	10.23	0.38	7.55e-23	Gout;
BRCA	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	10.12	0.37	1.94e-22	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs11690935	0.843	rs9784123	chr2:172785005	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.8	-22.9	-0.67	3.24e-85	Schizophrenia;
BRCA	cis	rs16854884	0.837	rs13083224	chr3:143801696	C/T	cg06585982	chr3:143692056	C3orf58	0.39	7.83	0.3	2.02e-14	Economic and political preferences (feminism/equality);
BRCA	cis	rs10046574	0.764	rs28422979	chr7:135145924	C/T	cg27474649	chr7:135195673	CNOT4	0.6	8.25	0.31	8.88e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.74	16.29	0.54	3.67e-50	Lymphocyte counts;
BRCA	cis	rs7246657	0.722	rs16958861	chr19:38124179	G/A	cg18154014	chr19:37997991	ZNF793	0.49	9.38	0.35	1.14e-19	Coronary artery calcification;
BRCA	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg18230493	chr5:56204884	C5orf35	-0.41	-8.14	-0.31	2.01e-15	Coronary artery disease;
BRCA	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg21856205	chr7:94953877	PON1	-0.38	-8.25	-0.31	8.78e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12016809	chr21:47604291	C21orf56	0.4	7.94	0.3	9.19e-15	Testicular germ cell tumor;
BRCA	cis	rs10489202	0.513	rs4657731	chr1:168081255	C/T	cg24449463	chr1:168025552	DCAF6	-0.46	-15.12	-0.51	2.29e-44	Schizophrenia;
BRCA	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.31	8.38	0.31	3.27e-16	Birth weight;
BRCA	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-21.7	-0.65	1.17e-78	Headache;
BRCA	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg17691542	chr6:26056736	HIST1H1C	0.54	11.71	0.42	8.01e-29	Height;
BRCA	trans	rs1459104	0.636	rs12577480	chr11:54986004	A/C	cg15704280	chr7:45808275	SEPT13	0.67	8.33	0.31	4.86e-16	Body mass index;
BRCA	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg21427119	chr20:30132790	HM13	-0.42	-8.71	-0.33	2.62e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg23950597	chr19:37808831	NA	-0.75	-13.25	-0.46	1.43e-35	Coronary artery calcification;
BRCA	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08704250	chr15:31115839	NA	-0.36	-8.97	-0.33	3.23e-18	Huntington's disease progression;
BRCA	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg25036284	chr2:26402008	FAM59B	-0.8	-12.42	-0.44	7.32e-32	Gut microbiome composition (summer);
BRCA	cis	rs3768617	0.811	rs12138053	chr1:182979560	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.98	0.37	6.55e-22	Fuchs's corneal dystrophy;
BRCA	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg07636037	chr3:49044803	WDR6	0.97	28.42	0.75	1.72e-115	Parkinson's disease;
BRCA	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg19622623	chr12:86230825	RASSF9	-0.3	-8.67	-0.32	3.6e-17	Major depressive disorder;
BRCA	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.49	10.96	0.4	1e-25	Cognitive ability;
BRCA	cis	rs965469	1.000	rs6051747	chr20:3307945	T/C	cg25506879	chr20:3388711	C20orf194	-0.52	-10.36	-0.38	2.45e-23	IFN-related cytopenia;
BRCA	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg02038168	chr22:39784481	NA	0.39	7.93	0.3	9.62e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.33	0.41	2.95e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.01	0.3	5.35e-15	Breast cancer;
BRCA	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	22.44	0.66	1.16e-82	Chronic sinus infection;
BRCA	cis	rs68170813	0.559	rs2894459	chr7:106960166	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.53	-0.32	1.09e-16	Coronary artery disease;
BRCA	cis	rs1434579	0.572	rs926052	chr19:44952236	A/T	cg15540054	chr19:45004280	ZNF180	0.51	11.19	0.4	1.15e-26	Tuberculosis;
BRCA	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg19077165	chr18:44547161	KATNAL2	-0.5	-10.59	-0.39	3.09e-24	Personality dimensions;
BRCA	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg15448220	chr1:150897856	SETDB1	0.35	7.87	0.3	1.49e-14	Melanoma;
BRCA	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	11.36	0.41	2.26e-27	Joint mobility (Beighton score);
BRCA	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24531977	chr5:56204891	C5orf35	-0.87	-18.02	-0.58	5.39e-59	Initial pursuit acceleration;
BRCA	cis	rs6893300	0.785	rs6895902	chr5:179201847	C/T	cg14593053	chr5:179126677	CANX	-0.35	-7.82	-0.3	2.14e-14	Resting heart rate;
BRCA	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.53	7.89	0.3	1.31e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg11764359	chr7:65958608	NA	-0.79	-18.16	-0.58	9.93e-60	Aortic root size;
BRCA	cis	rs6005807	0.719	rs28818228	chr22:29042025	G/A	cg12565055	chr22:29076175	TTC28	0.5	9.36	0.35	1.32e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	11.21	0.41	9.1e-27	Bipolar disorder;
BRCA	cis	rs13136331	0.532	rs2615478	chr4:88579072	T/C	cg22416721	chr4:88570574	DMP1	-0.6	-14.52	-0.5	1.71e-41	Sitting height ratio;
BRCA	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg23173402	chr1:227635558	NA	0.55	9.37	0.35	1.22e-19	Major depressive disorder;
BRCA	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg16325326	chr1:53192061	ZYG11B	0.9	25.07	0.7	3.93e-97	Monocyte count;
BRCA	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg05623727	chr3:50126028	RBM5	-0.43	-10.14	-0.37	1.71e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg18230493	chr5:56204884	C5orf35	-0.44	-9.01	-0.34	2.29e-18	Coronary artery disease;
BRCA	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	15.7	0.53	3.09e-47	Lymphocyte counts;
BRCA	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg07636037	chr3:49044803	WDR6	0.97	29.54	0.76	1.35e-121	Parkinson's disease;
BRCA	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg12661370	chr5:149340060	SLC26A2	0.57	8.3	0.31	6.42e-16	HIV-1 control;
BRCA	trans	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg25214090	chr10:38739885	LOC399744	0.49	10.65	0.39	1.69e-24	Corneal astigmatism;
BRCA	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.3	-8.08	-0.3	3.28e-15	Total body bone mineral density;
BRCA	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.37	0.41	2.08e-27	Electroencephalogram traits;
BRCA	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg17691542	chr6:26056736	HIST1H1C	0.45	8.64	0.32	4.52e-17	Iron status biomarkers;
BRCA	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02353165	chr6:42928485	GNMT	-0.77	-18.97	-0.6	5.57e-64	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-13.87	-0.48	1.9e-38	Personality dimensions;
BRCA	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19748678	chr4:122722346	EXOSC9	0.74	15.9	0.53	3.11e-48	Type 2 diabetes;
BRCA	trans	rs3960554	0.740	rs10216079	chr7:75690988	A/C	cg19862616	chr7:65841803	NCRNA00174	0.6	12.53	0.44	2.34e-32	Eotaxin levels;
BRCA	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.47	8.29	0.31	6.45e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4742903	0.509	rs6479223	chr9:106921023	T/C	cg14250997	chr9:106856677	SMC2	0.27	7.93	0.3	9.64e-15	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs17021463	0.902	rs36099342	chr4:95239783	T/C	cg11021082	chr4:95130006	SMARCAD1	0.39	8.3	0.31	5.98e-16	Testicular germ cell tumor;
BRCA	cis	rs9323205	0.911	rs60034431	chr14:51622437	C/A	cg23942311	chr14:51606299	NA	-0.44	-9.14	-0.34	8.24e-19	Cancer;
BRCA	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg01304814	chr3:48885189	PRKAR2A	0.71	7.81	0.3	2.28e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs6066835	1.000	rs6125448	chr20:47353178	G/A	cg18078177	chr20:47281410	PREX1	0.72	8.48	0.32	1.5e-16	Multiple myeloma;
BRCA	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg07150166	chr2:30669952	LCLAT1	0.79	9.78	0.36	3.92e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
BRCA	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg03213289	chr20:61660250	NA	0.63	16.78	0.55	1.19e-52	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg24558204	chr6:135376177	HBS1L	0.45	12.33	0.44	1.77e-31	Red blood cell count;
BRCA	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg25237894	chr2:233734115	C2orf82	0.4	11.51	0.41	5.56e-28	Coronary artery disease;
BRCA	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg18512352	chr11:47633146	NA	-0.34	-8.25	-0.31	9.16e-16	Subjective well-being;
BRCA	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg18252515	chr7:66147081	NA	-0.87	-12.08	-0.43	2.13e-30	Diabetic kidney disease;
BRCA	cis	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg06521331	chr12:34319734	NA	-0.61	-11.11	-0.4	2.37e-26	Morning vs. evening chronotype;
BRCA	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs6878727	0.850	rs10067094	chr5:123725725	C/T	cg01806427	chr5:123737813	NA	0.42	9.63	0.36	1.39e-20	Breast cancer;
BRCA	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg20302533	chr7:39170763	POU6F2	0.37	7.88	0.3	1.4e-14	IgG glycosylation;
BRCA	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg12011299	chr4:100065546	ADH4	0.5	11.44	0.41	1.08e-27	Alcohol dependence;
BRCA	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.82	0.62	1.64e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg17691542	chr6:26056736	HIST1H1C	0.8	14.44	0.5	4.29e-41	Iron status biomarkers;
BRCA	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg02734326	chr4:10020555	SLC2A9	0.41	8.92	0.33	4.81e-18	Bone mineral density;
BRCA	cis	rs7523050	0.908	rs17621621	chr1:109398917	G/T	cg08274380	chr1:109419600	GPSM2	0.82	12.5	0.44	3.02e-32	Fat distribution (HIV);
BRCA	cis	rs2294693	0.945	rs9369253	chr6:40986538	A/G	cg14769373	chr6:40998127	UNC5CL	-0.39	-7.84	-0.3	1.83e-14	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs2712184	0.660	rs10164732	chr2:217645669	A/T	cg05032264	chr2:217675019	NA	0.34	8.16	0.31	1.72e-15	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs7524258	0.900	rs7514988	chr1:7271651	C/T	cg07173049	chr1:7289937	CAMTA1	0.39	9.74	0.36	5.21e-21	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg13906792	chr15:75199810	C15orf17	0.34	8.03	0.3	4.63e-15	Caffeine consumption;
BRCA	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg04553112	chr3:125709451	NA	-0.51	-8.33	-0.31	4.9e-16	Blood pressure (smoking interaction);
BRCA	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg23711669	chr6:146136114	FBXO30	-0.67	-15.71	-0.53	2.83e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6028335	0.674	rs16987779	chr20:37671455	C/T	cg16355469	chr20:37678765	NA	0.51	9.08	0.34	1.37e-18	Alcohol and nicotine co-dependence;
BRCA	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg24879335	chr3:133465180	TF	0.34	11.3	0.41	4.09e-27	Iron status biomarkers (transferrin levels);
BRCA	cis	rs9420	0.961	rs7121169	chr11:57452543	G/A	cg19752551	chr11:57585705	CTNND1	-0.51	-12.51	-0.44	2.91e-32	Schizophrenia;
BRCA	cis	rs35306767	0.807	rs1013505	chr10:953273	C/T	cg20503657	chr10:835505	NA	1.04	17.61	0.57	6.61e-57	Eosinophil percentage of granulocytes;
BRCA	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg16576597	chr16:28551801	NUPR1	0.3	8.41	0.32	2.72e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg03264133	chr6:25882463	NA	0.38	8.31	0.31	5.71e-16	Blood metabolite levels;
BRCA	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg22920501	chr2:26401640	FAM59B	-0.66	-11.52	-0.41	4.74e-28	Gut microbiome composition (summer);
BRCA	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg18154014	chr19:37997991	ZNF793	0.61	11.41	0.41	1.48e-27	Coronary artery calcification;
BRCA	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg15017067	chr4:17643749	FAM184B	0.31	9.7	0.36	7.64e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.62	-15.84	-0.53	6.24e-48	Colorectal cancer;
BRCA	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.31	-0.31	5.88e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg04990556	chr1:26633338	UBXN11	0.54	8.81	0.33	1.19e-17	Obesity-related traits;
BRCA	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.7	-19.18	-0.6	4.39e-65	Longevity;Endometriosis;
BRCA	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-8.51	-0.32	1.19e-16	Hepatocellular carcinoma;
BRCA	cis	rs11031096	0.502	rs7935824	chr11:4046900	C/G	cg18678763	chr11:4115507	RRM1	-0.35	-8.27	-0.31	7.96e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg00383909	chr3:49044727	WDR6	0.55	10.57	0.39	3.57e-24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03517284	chr6:25882590	NA	-0.66	-15.45	-0.52	5.51e-46	Blood metabolite levels;
BRCA	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg01028140	chr2:1542097	TPO	-0.81	-15.85	-0.53	5.82e-48	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.32	-0.38	3.3e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg11062466	chr8:58055876	NA	0.41	8.01	0.3	5.44e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12618769	0.652	rs72823788	chr2:99213080	C/T	cg10123293	chr2:99228465	UNC50	0.44	8.69	0.32	3.15e-17	Bipolar disorder;
BRCA	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg06766960	chr11:133703094	NA	-0.62	-12.87	-0.45	7.37e-34	Childhood ear infection;
BRCA	cis	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg20368463	chr18:77673604	PQLC1	-0.5	-12.39	-0.44	9.7e-32	Schizophrenia;
BRCA	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg27165867	chr14:105738592	BRF1	-0.35	-8.28	-0.31	7.39e-16	Mean platelet volume;Platelet distribution width;
BRCA	trans	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg27600084	chr12:12264075	NA	0.36	7.96	0.3	8.09e-15	Breast size;
BRCA	cis	rs17641971	0.708	rs10957317	chr8:49888870	C/T	cg00325661	chr8:49890786	NA	-0.34	-9.37	-0.35	1.25e-19	Blood metabolite levels;
BRCA	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg26597838	chr10:835615	NA	1.03	18.04	0.58	3.99e-59	Eosinophil percentage of granulocytes;
BRCA	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	17.04	0.56	5.6e-54	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg24675658	chr1:53192096	ZYG11B	-0.62	-13.41	-0.47	2.5e-36	Monocyte count;
BRCA	cis	rs6694270	0.529	rs4076925	chr1:19113026	C/T	cg26220594	chr1:19110978	NA	0.44	8.25	0.31	8.85e-16	Drug-induced liver injury (nitrofurantoin);
BRCA	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg20701182	chr2:24300061	SF3B14	0.6	9.39	0.35	1.02e-19	Lymphocyte counts;
BRCA	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	9.4	0.35	9.49e-20	Rheumatoid arthritis;
BRCA	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.62	11.39	0.41	1.75e-27	Height;
BRCA	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg15819921	chr19:927150	ARID3A	-0.47	-8.63	-0.32	4.91e-17	Life satisfaction;
BRCA	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg02403541	chr12:121454288	C12orf43	0.53	9.91	0.36	1.26e-21	N-glycan levels;
BRCA	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	13.32	0.47	6.86e-36	Mean platelet volume;
BRCA	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg11584989	chr19:19387371	SF4	0.63	13.51	0.47	8.75e-37	Bipolar disorder;
BRCA	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.67	-9.73	-0.36	5.99e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg04842962	chr6:43655489	MRPS18A	1.11	39.06	0.84	1.91e-171	IgG glycosylation;
BRCA	cis	rs12618769	0.652	rs3754872	chr2:99223925	A/T	cg10123293	chr2:99228465	UNC50	0.42	8.58	0.32	7.36e-17	Bipolar disorder;
BRCA	cis	rs290268	0.669	rs10993693	chr9:93557698	C/T	cg02608019	chr9:93564028	SYK	0.51	11.39	0.41	1.65e-27	Platelet count;
BRCA	cis	rs61935443	0.720	rs10859783	chr12:95285339	A/G	cg21533806	chr12:95267307	NA	0.47	8.98	0.33	3.08e-18	Schizophrenia;
BRCA	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08109568	chr15:31115862	NA	-0.44	-10.03	-0.37	4.22e-22	Huntington's disease progression;
BRCA	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg24006582	chr15:45444508	DUOX1	0.52	10.22	0.37	8.47e-23	Uric acid levels;
BRCA	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg06671706	chr8:8559999	CLDN23	0.42	8.22	0.31	1.18e-15	Obesity-related traits;
BRCA	cis	rs28595532	0.623	rs34958556	chr4:119222074	C/T	cg21605333	chr4:119757512	SEC24D	0.82	8.56	0.32	8.11e-17	Cannabis dependence symptom count;
BRCA	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg02574844	chr11:5959923	NA	-0.43	-8.42	-0.32	2.55e-16	DNA methylation (variation);
BRCA	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11764359	chr7:65958608	NA	0.79	18.77	0.6	6.04e-63	Aortic root size;
BRCA	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg21143896	chr7:2802374	GNA12	-0.37	-9.33	-0.35	1.68e-19	Height;
BRCA	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg08807101	chr21:30365312	RNF160	0.37	7.84	0.3	1.86e-14	Pancreatic cancer;
BRCA	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg19773385	chr1:10388646	KIF1B	-0.38	-8.27	-0.31	7.81e-16	Hepatocellular carcinoma;
BRCA	trans	rs61931739	1.000	rs12304768	chr12:34000986	T/G	cg26384229	chr12:38710491	ALG10B	-0.42	-9.46	-0.35	5.97e-20	Morning vs. evening chronotype;
BRCA	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg04455712	chr21:45112962	RRP1B	0.41	11.01	0.4	6.27e-26	Mean corpuscular volume;
BRCA	trans	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg01620082	chr3:125678407	NA	-0.99	-11.44	-0.41	1.06e-27	Lung cancer in ever smokers;
BRCA	trans	rs2736345	0.755	rs2736340	chr8:11343973	C/T	cg15556689	chr8:8085844	FLJ10661	0.37	8.25	0.31	8.8e-16	Sjögren's syndrome;Systemic lupus erythematosus;
BRCA	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg10523679	chr1:76189770	ACADM	-0.41	-7.83	-0.3	2.02e-14	Daytime sleep phenotypes;
BRCA	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg02951883	chr7:2050386	MAD1L1	-0.37	-8.81	-0.33	1.19e-17	Schizophrenia;
BRCA	cis	rs3087591	0.919	rs2953004	chr17:29502723	C/T	cg24425628	chr17:29625626	OMG;NF1	0.42	8.3	0.31	6.23e-16	Hip circumference;
BRCA	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-13.42	-0.47	2.3e-36	Response to antipsychotic treatment;
BRCA	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg20637307	chr2:213403960	ERBB4	-0.49	-11.67	-0.42	1.13e-28	Symmetrical dimethylarginine levels;
BRCA	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg13628971	chr7:2884303	GNA12	0.49	9.89	0.36	1.44e-21	Height;
BRCA	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg03452623	chr4:187889614	NA	-0.32	-10.71	-0.39	1.04e-24	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg19847866	chr10:1019161	NA	0.51	10.67	0.39	1.39e-24	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs2421770	0.530	rs3847621	chr11:35364435	G/A	cg13971030	chr11:35366721	SLC1A2	-0.45	-10.12	-0.37	2.02e-22	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs586533	0.813	rs642457	chr11:99502908	T/C	cg22878054	chr11:99397252	CNTN5	0.32	8.12	0.31	2.45e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg12661370	chr5:149340060	SLC26A2	0.55	8.0	0.3	5.65e-15	HIV-1 control;
BRCA	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.15e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg10295955	chr4:187884368	NA	-0.87	-24.82	-0.7	9.34e-96	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg03585969	chr10:35415529	CREM	0.5	10.31	0.38	3.66e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs11069349	0.608	rs9585056	chr13:100081766	A/G	cg25919922	chr13:100150906	NA	-0.5	-9.68	-0.36	8.7e-21	Self-reported allergy;
BRCA	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg20848291	chr7:100343083	ZAN	-0.6	-12.68	-0.45	5.02e-33	Other erythrocyte phenotypes;
BRCA	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg05340658	chr4:99064831	C4orf37	0.68	16.96	0.56	1.53e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg10495392	chr1:46806563	NSUN4	0.44	8.2	0.31	1.37e-15	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg13397359	chr6:42928475	GNMT	0.81	21.88	0.65	1.3e-79	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-9.84	-0.36	2.22e-21	Schizophrenia;
BRCA	cis	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg17469321	chr7:55412551	NA	0.49	9.31	0.35	1.98e-19	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07308232	chr7:1071921	C7orf50	-0.41	-8.39	-0.32	3.01e-16	Longevity;Endometriosis;
BRCA	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg26061582	chr7:22766209	IL6	0.36	8.45	0.32	1.92e-16	Lung cancer;
BRCA	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg05234568	chr11:5960015	NA	-0.51	-10.04	-0.37	4.16e-22	DNA methylation (variation);
BRCA	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg01324343	chr3:183735012	ABCC5	0.85	21.59	0.65	4.75e-78	Anterior chamber depth;
BRCA	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg04455712	chr21:45112962	RRP1B	-0.37	-9.57	-0.35	2.36e-20	Mean corpuscular volume;
BRCA	cis	rs897080	0.515	rs786403	chr2:44710788	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	9.07	0.34	1.41e-18	Height;
BRCA	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs727479	0.523	rs7176330	chr15:51530458	A/G	cg19946085	chr15:51559439	CYP19A1	-0.29	-7.98	-0.3	6.61e-15	Estradiol levels;
BRCA	cis	rs870825	0.616	rs7682505	chr4:185640648	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	17.18	0.56	1.08e-54	Blood protein levels;
BRCA	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	10.62	0.39	2.16e-24	Rheumatoid arthritis;
BRCA	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	10.06	0.37	3.42e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs9296092	0.538	rs7761464	chr6:33519417	C/A	cg13560919	chr6:33536144	NA	-0.84	-18.43	-0.59	3.8e-61	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs72772090	0.539	rs72775818	chr5:96193215	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-11.04	-0.4	4.51e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg20283391	chr11:68216788	NA	-0.44	-8.96	-0.33	3.43e-18	Total body bone mineral density;
BRCA	trans	rs7939886	0.920	rs11231901	chr11:55811529	A/G	cg15704280	chr7:45808275	SEPT13	0.63	8.07	0.3	3.51e-15	Myopia (pathological);
BRCA	cis	rs7572263	0.724	rs6749281	chr2:209050696	C/A	cg23998903	chr2:209048830	C2orf80	-0.42	-8.68	-0.32	3.16e-17	Glioma;Non-glioblastoma glioma;
BRCA	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg05340658	chr4:99064831	C4orf37	0.62	14.78	0.5	9.4e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs16910800	0.731	rs59333536	chr11:23191649	G/A	cg20040320	chr11:23191996	NA	-0.59	-10.23	-0.38	7.61e-23	Cancer;
BRCA	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg25208724	chr1:156163844	SLC25A44	0.89	18.06	0.58	3.34e-59	Testicular germ cell tumor;
BRCA	trans	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg06521331	chr12:34319734	NA	-0.54	-10.31	-0.38	3.6e-23	Bladder cancer;
BRCA	cis	rs17401966	1.000	rs7530167	chr1:10453374	A/G	cg03954927	chr1:10346856	KIF1B	0.45	12.59	0.45	1.28e-32	Hepatocellular carcinoma;
BRCA	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg25482853	chr8:67687455	SGK3	1.05	16.95	0.56	1.78e-53	Lung disease severity in cystic fibrosis;
BRCA	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg20607798	chr8:58055168	NA	0.48	8.43	0.32	2.29e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg20476274	chr7:133979776	SLC35B4	0.66	19.34	0.61	5.83e-66	Mean platelet volume;
BRCA	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.41	-9.09	-0.34	1.19e-18	Personality dimensions;
BRCA	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg05340658	chr4:99064831	C4orf37	0.65	15.73	0.53	2.24e-47	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs524281	0.861	rs7946917	chr11:65956577	A/G	cg16950941	chr11:66035639	RAB1B	-0.38	-7.96	-0.3	7.71e-15	Electroencephalogram traits;
BRCA	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18402987	chr7:1209562	NA	0.45	9.53	0.35	3.15e-20	Longevity;Endometriosis;
BRCA	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19723775	chr5:179050963	HNRNPH1	0.37	8.91	0.33	5.42e-18	Lung cancer;
BRCA	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg03342759	chr3:160939853	NMD3	-0.63	-14.08	-0.49	2.13e-39	Morning vs. evening chronotype;
BRCA	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-12.33	-0.44	1.78e-31	Hemoglobin concentration;
BRCA	cis	rs11229555	0.645	rs12802960	chr11:58174775	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.66	-0.36	1.11e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg23708337	chr7:1209742	NA	0.63	8.85	0.33	8.71e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg23625390	chr15:77176239	SCAPER	0.39	9.19	0.34	5.6e-19	Blood metabolite levels;
BRCA	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00149659	chr3:10157352	C3orf10	0.8	13.84	0.48	2.74e-38	Alzheimer's disease;
BRCA	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg00339695	chr16:24857497	SLC5A11	-0.53	-11.3	-0.41	3.87e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-10.26	-0.38	5.83e-23	Alzheimer's disease (late onset);
BRCA	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	15.19	0.52	1.04e-44	Colorectal cancer;
BRCA	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg19678392	chr7:94953810	PON1	-0.43	-8.98	-0.33	2.9e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg08213375	chr14:104286397	PPP1R13B	0.63	17.11	0.56	2.55e-54	Schizophrenia;
BRCA	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	10.9	0.4	1.77e-25	Rheumatoid arthritis;
BRCA	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg02743256	chr7:2109353	MAD1L1	-0.45	-8.0	-0.3	6.04e-15	Bipolar disorder;
BRCA	cis	rs6120849	0.901	rs6088737	chr20:33745938	A/G	cg24642439	chr20:33292090	TP53INP2	0.47	8.45	0.32	1.99e-16	Protein C levels;
BRCA	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg21535247	chr6:8435926	SLC35B3	0.41	9.14	0.34	8.33e-19	Motion sickness;
BRCA	cis	rs7729447	0.804	rs116090595	chr5:32698148	T/G	cg16267343	chr5:32710456	NPR3	0.47	9.89	0.36	1.43e-21	Blood pressure;
BRCA	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg01028140	chr2:1542097	TPO	-0.67	-14.19	-0.49	6e-40	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg05340658	chr4:99064831	C4orf37	0.7	17.5	0.57	2.71e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg26043149	chr18:55253948	FECH	0.4	8.71	0.33	2.66e-17	Bone mineral density;
BRCA	cis	rs9875589	0.509	rs1488375	chr3:14061563	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.29	7.81	0.3	2.32e-14	Ovarian reserve;
BRCA	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg26727032	chr16:67993705	SLC12A4	0.37	7.86	0.3	1.62e-14	HDL cholesterol;Metabolic syndrome;
BRCA	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg13395646	chr4:1353034	KIAA1530	-0.49	-9.05	-0.34	1.74e-18	Obesity-related traits;
BRCA	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.71	0.33	2.63e-17	Motion sickness;
BRCA	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-9.28	-0.34	2.68e-19	Multiple sclerosis;
BRCA	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg06618935	chr21:46677482	NA	-0.38	-8.46	-0.32	1.85e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg04455712	chr21:45112962	RRP1B	0.47	11.33	0.41	3.05e-27	Mean corpuscular volume;
BRCA	cis	rs8038465	0.622	rs62004587	chr15:73859016	A/C	cg15420318	chr15:73925796	NPTN	0.46	9.52	0.35	3.4e-20	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg09904177	chr6:26538194	HMGN4	0.55	17.63	0.57	5.8e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs939658	0.776	rs11631411	chr15:79445816	C/T	cg17916960	chr15:79447300	NA	-0.47	-11.88	-0.43	1.45e-29	Refractive error;
BRCA	cis	rs10504073	0.669	rs12548464	chr8:50023867	C/T	cg00325661	chr8:49890786	NA	0.38	11.04	0.4	4.49e-26	Blood metabolite ratios;
BRCA	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-13.48	-0.47	1.29e-36	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	11.35	0.41	2.44e-27	Glomerular filtration rate (creatinine);
BRCA	trans	rs6964833	0.935	rs34630792	chr7:74061197	G/C	cg07504079	chr7:72649617	NCF1B	-0.48	-9.4	-0.35	9.18e-20	Menarche (age at onset);
BRCA	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg06494592	chr3:125709126	NA	-0.53	-8.32	-0.31	5.28e-16	Blood pressure (smoking interaction);
BRCA	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg08132940	chr7:1081526	C7orf50	-0.6	-8.99	-0.34	2.69e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg11822812	chr5:140052017	DND1	-0.3	-8.41	-0.32	2.7e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs11229555	0.645	rs7116007	chr11:58218701	C/T	cg15696309	chr11:58395628	NA	-0.52	-10.83	-0.39	3.29e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg24130564	chr14:104152367	KLC1	0.58	15.89	0.53	3.71e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg17971929	chr21:40555470	PSMG1	0.79	18.15	0.58	1.14e-59	Cognitive function;
BRCA	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg10862848	chr6:42927986	GNMT	-0.34	-14.37	-0.49	8.6e-41	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs16976116	0.901	rs1061824	chr15:55495963	T/C	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg14266287	chr2:239334506	ASB1	0.33	8.03	0.3	4.77e-15	Multiple system atrophy;
BRCA	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg08470875	chr2:26401718	FAM59B	-0.51	-8.31	-0.31	5.76e-16	Gut microbiome composition (summer);
BRCA	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg19077165	chr18:44547161	KATNAL2	-0.64	-14.93	-0.51	1.89e-43	Personality dimensions;
BRCA	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.09	-38.02	-0.83	3.29e-166	Myeloid white cell count;
BRCA	cis	rs1557765	0.527	rs4756887	chr11:17394597	T/G	cg15432903	chr11:17409602	KCNJ11	0.4	8.63	0.32	4.7e-17	Body mass index;Social communication problems;
BRCA	trans	rs4650994	0.525	rs2493864	chr1:178545003	A/C	cg05059571	chr16:84539110	KIAA1609	-0.54	-12.5	-0.44	3.18e-32	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-15.12	-0.51	2.13e-44	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg20607798	chr8:58055168	NA	0.48	8.37	0.31	3.52e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.31	8.72	0.33	2.38e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg05347473	chr6:146136440	FBXO30	-0.42	-8.3	-0.31	6.12e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg15083037	chr5:83017644	HAPLN1	-0.53	-10.58	-0.39	3.15e-24	Prostate cancer;
BRCA	cis	rs365132	1.000	rs601923	chr5:176417386	C/G	cg16309518	chr5:176445507	NA	-0.52	-13.39	-0.47	3.14e-36	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg23505145	chr19:12996616	KLF1	0.56	12.69	0.45	4.46e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7945705	0.875	rs10769957	chr11:8809016	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-10.43	-0.38	1.23e-23	Hemoglobin concentration;
BRCA	cis	rs1420338	1.000	rs918038	chr7:34153768	A/G	cg01275685	chr7:34179230	BMPER	-0.47	-10.21	-0.37	8.89e-23	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs7553864	0.667	rs10873820	chr1:87605973	C/G	cg17420885	chr1:87600446	LOC339524	0.43	9.09	0.34	1.28e-18	Smoking behavior;
BRCA	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg21475434	chr5:93447410	FAM172A	0.68	9.2	0.34	5e-19	Diabetic retinopathy;
BRCA	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg25124228	chr12:125621409	AACS	-0.55	-11.99	-0.43	5.26e-30	Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg08999081	chr20:33150536	PIGU	0.36	9.35	0.35	1.51e-19	Coronary artery disease;
BRCA	trans	rs6964833	1.000	rs4717906	chr7:74086247	G/A	cg07504079	chr7:72649617	NCF1B	-0.47	-9.24	-0.34	3.67e-19	Menarche (age at onset);
BRCA	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.35	-0.44	1.49e-31	Response to antipsychotic treatment;
BRCA	cis	rs17021463	0.966	rs7657789	chr4:95178589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-10.3	-0.38	3.91e-23	Testicular germ cell tumor;
BRCA	cis	rs17092148	0.887	rs6059931	chr20:33175338	A/G	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.28	-0.38	5e-23	Neuroticism;
BRCA	cis	rs7737355	0.947	rs39600	chr5:130828649	A/T	cg06307176	chr5:131281290	NA	0.52	10.4	0.38	1.71e-23	Life satisfaction;
BRCA	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg24642439	chr20:33292090	TP53INP2	0.54	11.68	0.42	1.02e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg02951883	chr7:2050386	MAD1L1	-0.49	-11.37	-0.41	2.03e-27	Schizophrenia;
BRCA	cis	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg00576331	chr11:65640516	EFEMP2	0.37	7.91	0.3	1.1e-14	DNA methylation (variation);
BRCA	cis	rs55882075	0.535	rs67484565	chr5:179110574	G/T	cg14593053	chr5:179126677	CANX	0.38	9.49	0.35	4.65e-20	Monocyte percentage of white cells;
BRCA	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg05347473	chr6:146136440	FBXO30	0.4	7.97	0.3	7.27e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg11814155	chr7:99998594	ZCWPW1	0.52	9.23	0.34	3.8e-19	Platelet count;
BRCA	cis	rs7246657	0.722	rs2291002	chr19:38033926	G/A	cg23950597	chr19:37808831	NA	-0.51	-8.65	-0.32	4.11e-17	Coronary artery calcification;
BRCA	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg08885076	chr2:99613938	TSGA10	-0.44	-10.42	-0.38	1.38e-23	Chronic sinus infection;
BRCA	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg10295955	chr4:187884368	NA	-0.89	-26.18	-0.72	3.29e-103	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4900538	0.821	rs7012	chr14:102814945	C/T	cg18135206	chr14:102964638	TECPR2	-0.91	-21.74	-0.65	7.34e-79	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.1	0.56	2.99e-54	Bladder cancer;
BRCA	cis	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg07460842	chr6:66804631	NA	0.88	14.08	0.49	2.06e-39	Exhaled nitric oxide output;
BRCA	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg00666640	chr1:248458726	OR2T12	0.35	9.11	0.34	1.02e-18	Common traits (Other);
BRCA	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg01877450	chr7:97915802	BRI3	-0.37	-8.31	-0.31	5.8e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.47	8.76	0.33	1.77e-17	Breast cancer;
BRCA	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg13010199	chr12:38710504	ALG10B	0.57	12.58	0.45	1.44e-32	Heart rate;
BRCA	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg10495392	chr1:46806563	NSUN4	0.45	8.4	0.32	2.97e-16	Menopause (age at onset);
BRCA	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg08392591	chr16:89556376	ANKRD11	0.53	13.04	0.46	1.26e-34	Multiple myeloma (IgH translocation);
BRCA	cis	rs7586879	0.796	rs36071142	chr2:25080570	C/T	cg04586622	chr2:25135609	ADCY3	0.38	9.13	0.34	9.06e-19	Body mass index;
BRCA	cis	rs911186	0.812	rs6932590	chr6:27248931	T/C	cg12292205	chr6:26970375	C6orf41	-0.55	-9.73	-0.36	5.79e-21	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg18357645	chr12:58087776	OS9	0.42	11.89	0.43	1.39e-29	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs735860	0.763	rs1429146	chr6:53130285	C/T	cg10236188	chr6:53219634	NA	-0.41	-8.89	-0.33	6.41e-18	Glaucoma;
BRCA	cis	rs9611519	0.566	rs4821981	chr22:41415644	A/C	cg03806693	chr22:41940476	POLR3H	0.41	8.01	0.3	5.52e-15	Neuroticism;
BRCA	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.91	0.33	5.45e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg07460842	chr6:66804631	NA	0.61	10.47	0.38	8.69e-24	Type 2 diabetes;
BRCA	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg12935359	chr14:103987150	CKB	-0.59	-13.94	-0.48	9.65e-39	Body mass index;
BRCA	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg02175503	chr12:58329896	NA	0.48	10.23	0.38	7.31e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-11.53	-0.41	4.6e-28	Gut microbiome composition (summer);
BRCA	cis	rs10504073	0.584	rs72641612	chr8:49947986	C/T	cg00325661	chr8:49890786	NA	0.51	14.59	0.5	8.25e-42	Blood metabolite ratios;
BRCA	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg01262667	chr19:19385393	TM6SF2	-0.42	-10.65	-0.39	1.71e-24	Tonsillectomy;
BRCA	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.46	-0.32	1.88e-16	Schizophrenia;
BRCA	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03264133	chr6:25882463	NA	-0.5	-10.9	-0.4	1.77e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	-0.56	-11.9	-0.43	1.23e-29	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs11971779	0.616	rs6974907	chr7:139068729	G/C	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12379764	chr21:47803548	PCNT	-0.44	-9.62	-0.36	1.51e-20	Testicular germ cell tumor;
BRCA	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg16989086	chr20:62203971	PRIC285	0.52	8.8	0.33	1.3e-17	Glioblastoma;
BRCA	cis	rs3767633	0.925	rs1553444	chr1:161813515	C/T	cg09175582	chr1:161736000	ATF6	0.54	9.74	0.36	5.51e-21	IgG glycosylation;
BRCA	trans	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg06521331	chr12:34319734	NA	-0.49	-9.11	-0.34	1.06e-18	Bladder cancer;
BRCA	cis	rs9361491	0.543	rs1507153	chr6:79484386	C/A	cg05283184	chr6:79620031	NA	-0.35	-8.11	-0.31	2.61e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg03433033	chr1:76189801	ACADM	0.7	13.1	0.46	6.8000000000000005e-35	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg17971929	chr21:40555470	PSMG1	0.79	18.52	0.59	1.25e-61	Cognitive function;
BRCA	trans	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg06521331	chr12:34319734	NA	-0.51	-9.35	-0.35	1.41e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg11843238	chr5:131593191	PDLIM4	0.35	9.05	0.34	1.71e-18	Breast cancer;
BRCA	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg13010199	chr12:38710504	ALG10B	-0.39	-8.42	-0.32	2.41e-16	Bladder cancer;
BRCA	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg02551604	chr5:131831745	NA	-0.4	-14.94	-0.51	1.73e-43	Asthma (sex interaction);
BRCA	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg10621924	chr7:39171070	POU6F2	0.38	8.06	0.3	3.69e-15	IgG glycosylation;
BRCA	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.59	-8.57	-0.32	7.59e-17	Schizophrenia;
BRCA	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.89e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg00339695	chr16:24857497	SLC5A11	0.49	9.75	0.36	5.07e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.74	-0.36	5.32e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-16.87	-0.56	4.17e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	13.02	0.46	1.47e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg08601574	chr20:25228251	PYGB	-0.39	-9.05	-0.34	1.77e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg18252515	chr7:66147081	NA	-1.08	-16.09	-0.54	3.78e-49	Diabetic kidney disease;
BRCA	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.89	-0.33	6.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg10932868	chr11:921992	NA	0.39	9.45	0.35	6.39e-20	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.56	0.39	3.97e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg26043149	chr18:55253948	FECH	0.42	8.99	0.34	2.84e-18	Bone mineral density;
BRCA	cis	rs701145	0.640	rs2122365	chr3:153930808	T/G	cg17054900	chr3:154042577	DHX36	0.43	8.18	0.31	1.59e-15	Coronary artery disease;
BRCA	cis	rs12612619	0.732	rs3754734	chr2:27299598	G/T	cg00617064	chr2:27272375	NA	-0.32	-8.38	-0.31	3.35e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg08085267	chr17:45401833	C17orf57	-0.63	-13.77	-0.48	5.88e-38	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs708547	0.766	rs781545	chr4:57732025	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.48	-10.79	-0.39	4.84e-25	Response to bleomycin (chromatid breaks);
BRCA	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.38	-0.38	2.0500000000000001e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2860975	1.000	rs2860975	chr10:96766934	G/T	cg09036531	chr10:96991505	NA	0.38	8.04	0.3	4.39e-15	Immune response to smallpox vaccine (IL-6);
BRCA	cis	rs965469	1.000	rs6051723	chr20:3278512	C/A	cg25506879	chr20:3388711	C20orf194	-0.54	-10.52	-0.38	5.35e-24	IFN-related cytopenia;
BRCA	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg08999081	chr20:33150536	PIGU	-0.47	-12.95	-0.46	3.13e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg22907277	chr7:1156413	C7orf50	0.62	10.82	0.39	3.66e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg24642439	chr20:33292090	TP53INP2	-0.44	-8.82	-0.33	1.12e-17	Height;
BRCA	cis	rs870825	0.616	rs7658186	chr4:185622509	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	16.89	0.56	3.35e-53	Blood protein levels;
BRCA	cis	rs13394619	0.605	rs12476319	chr2:11748406	A/G	cg07314298	chr2:11723111	GREB1	0.36	8.06	0.3	3.77e-15	Endometriosis;
BRCA	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg10729496	chr3:10149963	C3orf24	0.49	9.34	0.35	1.5700000000000001e-19	Alzheimer's disease;
BRCA	cis	rs6782228	0.606	rs2712405	chr3:128332082	T/C	cg16766828	chr3:128327626	NA	-0.42	-9.22	-0.34	4.22e-19	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs9308433	0.529	rs4655246	chr1:214502898	G/C	cg06198575	chr1:214491504	SMYD2	0.56	12.29	0.44	2.71e-31	IgG glycosylation;
BRCA	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg16339924	chr4:17578868	LAP3	0.76	18.78	0.6	5.3e-63	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg22875332	chr1:76189707	ACADM	0.7	14.59	0.5	7.98e-42	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg08859206	chr1:53392774	SCP2	-0.42	-8.44	-0.32	2.14e-16	Monocyte count;
BRCA	cis	rs7520050	1.000	rs12143096	chr1:46469763	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.82	0.36	2.68e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11764359	chr7:65958608	NA	-0.62	-13.6	-0.47	3.49e-37	Aortic root size;
BRCA	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.13	0.31	2.28e-15	Total cholesterol levels;
BRCA	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg02476566	chr12:106696527	TCP11L2	0.53	10.04	0.37	3.84e-22	Tourette syndrome;
BRCA	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	20.15	0.62	2.91e-70	Chronic sinus infection;
BRCA	trans	rs11976180	0.953	rs2961127	chr7:143762737	G/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.26	-0.31	8.66e-16	Obesity-related traits;
BRCA	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg11812906	chr14:75593930	NEK9	0.62	14.16	0.49	8.36e-40	Height;
BRCA	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg06521331	chr12:34319734	NA	-0.49	-8.88	-0.33	6.67e-18	Bladder cancer;
BRCA	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.18	-0.31	1.57e-15	Depression;
BRCA	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg20587970	chr11:113659929	NA	-1.35	-24.25	-0.69	1.34e-92	Hip circumference adjusted for BMI;
BRCA	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.97	0.3	7.05e-15	Depression;
BRCA	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg17143192	chr8:8559678	CLDN23	0.53	10.27	0.38	5.21e-23	Obesity-related traits;
BRCA	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg20387954	chr3:183756860	HTR3D	0.45	10.12	0.37	2.06e-22	Anterior chamber depth;
BRCA	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.43	12.04	0.43	3.15e-30	Monocyte percentage of white cells;
BRCA	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg26384229	chr12:38710491	ALG10B	0.75	16.74	0.55	2e-52	Morning vs. evening chronotype;
BRCA	cis	rs8017423	0.647	rs12587362	chr14:90821227	G/T	cg04374321	chr14:90722782	PSMC1	-0.49	-11.89	-0.43	1.3e-29	Mortality in heart failure;
BRCA	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg24692254	chr21:30365293	RNF160	0.78	21.58	0.65	5.52e-78	Dental caries;
BRCA	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg05340658	chr4:99064831	C4orf37	0.68	16.98	0.56	1.21e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9467773	0.595	rs3846845	chr6:26444915	G/A	cg09904177	chr6:26538194	HMGN4	-0.37	-9.81	-0.36	3.06e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7590720	1.000	rs4674048	chr2:216900023	G/A	cg12620499	chr2:216877984	MREG	0.79	22.34	0.66	3.64e-82	Alcohol dependence;
BRCA	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg08847533	chr14:75593920	NEK9	-0.46	-9.35	-0.35	1.4e-19	Neuroticism;
BRCA	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.68	-14.27	-0.49	2.76e-40	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.84e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg09469691	chr10:81107165	PPIF	0.54	11.38	0.41	1.83e-27	Height;
BRCA	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.29	-8.48	-0.32	1.57e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7523273	1.000	rs12184327	chr1:207978780	A/G	cg22525895	chr1:207977042	MIR29B2	-0.48	-11.81	-0.42	3e-29	Schizophrenia;
BRCA	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg10818794	chr15:86012489	AKAP13	-0.29	-8.05	-0.3	3.93e-15	Coronary artery disease;
BRCA	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg02751453	chr18:77725136	HSBP1L1	0.38	9.2	0.34	4.99e-19	Opioid sensitivity;
BRCA	cis	rs877282	0.945	rs71491303	chr10:772884	G/T	cg17470449	chr10:769945	NA	0.5	9.35	0.35	1.44e-19	Uric acid levels;
BRCA	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg21252483	chr19:49399788	TULP2	-0.51	-10.75	-0.39	7e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	trans	rs1459104	1.000	rs116220196	chr11:55293221	C/T	cg15704280	chr7:45808275	SEPT13	0.63	7.91	0.3	1.11e-14	Body mass index;
BRCA	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg18230493	chr5:56204884	C5orf35	-0.62	-13.3	-0.47	8.67e-36	Initial pursuit acceleration;
BRCA	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg12463550	chr7:65579703	CRCP	-0.37	-7.84	-0.3	1.88e-14	Aortic root size;
BRCA	cis	rs2012796	1.000	rs8008024	chr14:81818492	A/G	cg02996355	chr14:81879375	NA	0.52	10.08	0.37	2.83e-22	Night sleep phenotypes;
BRCA	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.79	-12.42	-0.44	6.74e-32	Platelet count;
BRCA	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.88	-0.3	1.41e-14	Prostate cancer;
BRCA	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	10.7	0.39	1.12e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg27490568	chr2:178487706	NA	0.5	8.52	0.32	1.17e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.64	-13.0	-0.46	1.85e-34	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg00277334	chr10:82204260	NA	-0.47	-7.91	-0.3	1.15e-14	Post bronchodilator FEV1;
BRCA	cis	rs13095912	0.889	rs6778977	chr3:185302532	T/G	cg11274856	chr3:185301563	NA	0.35	8.76	0.33	1.72e-17	Systolic blood pressure;
BRCA	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-14.17	-0.49	7.43e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	14.69	0.5	2.66e-42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.68e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg20628663	chr10:43360327	NA	0.71	13.78	0.48	5.25e-38	Blood protein levels;
BRCA	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg21724239	chr8:58056113	NA	0.62	9.78	0.36	3.87e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.3	-0.38	3.98e-23	Psoriasis;
BRCA	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24549020	chr5:56110836	MAP3K1	-0.39	-8.13	-0.31	2.18e-15	Initial pursuit acceleration;
BRCA	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg05340658	chr4:99064831	C4orf37	0.61	14.56	0.5	1.14e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.55	12.71	0.45	3.8e-33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg08213375	chr14:104286397	PPP1R13B	0.66	18.7	0.59	1.49e-62	Schizophrenia;
BRCA	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg14343924	chr8:8086146	FLJ10661	0.39	8.39	0.31	3.19e-16	Mood instability;
BRCA	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	10.04	0.37	3.87e-22	Tonsillectomy;
BRCA	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg14675211	chr2:100938903	LONRF2	0.52	11.65	0.42	1.45e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20887711	chr4:1340912	KIAA1530	-0.59	-12.99	-0.46	1.99e-34	Obesity-related traits;
BRCA	trans	rs629535	0.814	rs78813708	chr8:70073977	A/G	cg21567404	chr3:27674614	NA	1.0	20.79	0.64	1e-73	Dupuytren's disease;
BRCA	cis	rs10746514	0.833	rs12039526	chr1:232272599	C/T	cg09506761	chr1:232265262	NA	-0.43	-8.46	-0.32	1.85e-16	Response to statin therapy;
BRCA	trans	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg26384229	chr12:38710491	ALG10B	0.39	9.22	0.34	4.38e-19	Morning vs. evening chronotype;
BRCA	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.65	-0.45	6.65e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs72634258	0.842	rs7545745	chr1:8165667	T/A	cg00042356	chr1:8021962	PARK7	-0.52	-9.25	-0.34	3.34e-19	Inflammatory bowel disease;
BRCA	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg12373951	chr3:133503437	NA	-0.45	-10.54	-0.38	4.62e-24	Iron status biomarkers;
BRCA	cis	rs883565	0.610	rs4676600	chr3:39157011	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	0.38	8.17	0.31	1.61e-15	Handedness;
BRCA	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg15017067	chr4:17643749	FAM184B	0.31	9.61	0.36	1.64e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-9.95	-0.37	9.01e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg24631222	chr15:78858424	CHRNA5	0.49	9.5	0.35	4.08e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs12617721	0.718	rs1857745	chr2:99016975	T/C	cg10123293	chr2:99228465	UNC50	0.5	9.11	0.34	1.06e-18	Bipolar disorder with mood-incongruent psychosis;
BRCA	cis	rs12618769	0.597	rs3769729	chr2:99102810	T/C	cg10123293	chr2:99228465	UNC50	0.42	8.37	0.31	3.7e-16	Bipolar disorder;
BRCA	cis	rs9942416	0.660	rs67803720	chr5:74984408	A/T	cg19683494	chr5:74908142	NA	0.48	9.1	0.34	1.15e-18	Age-related disease endophenotypes;
BRCA	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg19628046	chr18:33552617	C18orf21	0.54	10.88	0.4	2e-25	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs73001065	0.688	rs59148799	chr19:19484008	A/G	cg03709012	chr19:19516395	GATAD2A	1.03	15.1	0.51	2.74e-44	LDL cholesterol;
BRCA	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.85	-0.39	2.71e-25	Personality dimensions;
BRCA	cis	rs6120849	0.802	rs6087682	chr20:33752897	A/T	cg24642439	chr20:33292090	TP53INP2	0.48	8.56	0.32	8.7e-17	Protein C levels;
BRCA	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg04166393	chr7:2884313	GNA12	0.5	9.53	0.35	3.29e-20	Height;
BRCA	cis	rs10045504	0.502	rs17456482	chr5:38737783	G/C	cg15396434	chr5:38725168	NA	-0.57	-11.05	-0.4	4.13e-26	Night sleep phenotypes;
BRCA	trans	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg26043149	chr18:55253948	FECH	-0.4	-9.07	-0.34	1.42e-18	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs17604090	0.818	rs28390296	chr7:29687091	C/T	cg19413766	chr7:29689036	LOC646762	-0.52	-8.06	-0.3	3.86e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.58	-0.32	6.99e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	17.62	0.57	5.88e-57	Platelet count;
BRCA	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg03146154	chr1:46216737	IPP	0.52	11.52	0.41	4.93e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs13064411	0.696	rs9839921	chr3:113199093	G/C	cg18753928	chr3:113234510	CCDC52	-0.59	-12.52	-0.44	2.53e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg20991723	chr1:152506922	NA	-0.36	-8.2	-0.31	1.27e-15	Hair morphology;
BRCA	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg20129853	chr10:51489980	NA	0.31	8.53	0.32	1.09e-16	Prostate-specific antigen levels;
BRCA	cis	rs7246967	0.673	rs12979173	chr19:22820681	C/T	cg23217946	chr19:22817039	ZNF492	0.47	8.48	0.32	1.56e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	11.04	0.4	4.6e-26	Platelet count;
BRCA	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.24	-0.31	9.74e-16	Axial length;
BRCA	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.43	-9.18	-0.34	5.82e-19	IgG glycosylation;
BRCA	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	14.98	0.51	1.08e-43	Mean corpuscular hemoglobin;
BRCA	cis	rs870825	0.860	rs72703518	chr4:185602109	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	13.82	0.48	3.56e-38	Blood protein levels;
BRCA	cis	rs2712184	0.756	rs2712181	chr2:217654869	C/T	cg05032264	chr2:217675019	NA	0.37	9.03	0.34	1.95e-18	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg21226059	chr5:178986404	RUFY1	-0.48	-13.32	-0.47	6.82e-36	Lung cancer;
BRCA	trans	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.97	-0.3	7.4e-15	Corneal astigmatism;
BRCA	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg04944784	chr2:26401820	FAM59B	-0.96	-16.33	-0.54	2.27e-50	Gut microbiome composition (summer);
BRCA	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg04362960	chr10:104952993	NT5C2	0.44	10.05	0.37	3.83e-22	Arsenic metabolism;
BRCA	cis	rs2191566	1.000	rs367499	chr19:44504981	G/A	cg20607764	chr19:44506953	ZNF230	0.49	10.85	0.39	2.77e-25	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs13046373	0.505	rs2832962	chr21:32008332	T/C	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.39	0.35	1.02e-19	HDL cholesterol;
BRCA	cis	rs9462027	0.628	rs9689820	chr6:34752963	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.94	-0.3	9.2e-15	Systemic lupus erythematosus;
BRCA	cis	rs10193935	0.901	rs222478	chr2:42656919	G/T	cg27598129	chr2:42591480	NA	-0.69	-11.85	-0.42	2.09e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg18230493	chr5:56204884	C5orf35	-0.72	-14.12	-0.49	1.41e-39	Initial pursuit acceleration;
BRCA	cis	rs4988958	0.565	rs10206291	chr2:103038863	T/C	cg03938978	chr2:103052716	IL18RAP	0.29	8.35	0.31	4.15e-16	Asthma (childhood onset);
BRCA	cis	rs7172677	0.960	rs1602360	chr15:75420761	G/A	cg14664628	chr15:75095509	CSK	-0.39	-8.24	-0.31	9.45e-16	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg05343316	chr1:45956843	TESK2	0.69	14.39	0.49	7.2e-41	Platelet count;
BRCA	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg20701182	chr2:24300061	SF3B14	0.56	8.61	0.32	5.89e-17	Lymphocyte counts;
BRCA	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg03433033	chr1:76189801	ACADM	0.45	8.91	0.33	5.21e-18	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg10556349	chr10:835070	NA	0.6	8.41	0.32	2.75e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs2882667	0.929	rs17207828	chr5:138299835	A/G	cg04439458	chr5:138467593	SIL1	-0.39	-10.13	-0.37	1.87e-22	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg13010199	chr12:38710504	ALG10B	0.48	9.46	0.35	5.82e-20	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.818	rs9659389	chr1:152989844	T/C	cg24667326	chr1:152973720	SPRR3	-0.32	-8.75	-0.33	1.95e-17	Inflammatory skin disease;
BRCA	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg12444411	chr7:2802554	GNA12	-0.38	-9.28	-0.34	2.62e-19	Height;
BRCA	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg24692254	chr21:30365293	RNF160	-0.45	-8.15	-0.31	1.99e-15	Cognitive test performance;
BRCA	trans	rs208520	1.000	rs208521	chr6:66953625	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-14.49	-0.5	2.3e-41	Exhaled nitric oxide output;
BRCA	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg00071950	chr4:10020882	SLC2A9	0.54	13.37	0.47	4e-36	Bone mineral density;
BRCA	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.3	8.15	0.31	1.91e-15	Response to antipsychotic treatment;
BRCA	cis	rs7633770	0.664	rs7373994	chr3:46701114	C/G	cg11219411	chr3:46661640	NA	-0.54	-13.41	-0.47	2.74e-36	Coronary artery disease;
BRCA	cis	rs11227306	0.934	rs2303384	chr11:65640204	C/T	cg00576331	chr11:65640516	EFEMP2	0.44	9.82	0.36	2.61e-21	DNA methylation (variation);
BRCA	trans	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg25214090	chr10:38739885	LOC399744	0.51	10.99	0.4	7.57e-26	Corneal astigmatism;
BRCA	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg12011299	chr4:100065546	ADH4	0.39	10.32	0.38	3.31e-23	Alcohol dependence;
BRCA	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.94e-24	Motion sickness;
BRCA	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg23032229	chr12:42720167	PPHLN1;ZCRB1	-0.33	-7.95	-0.3	8.28e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7677751	0.767	rs6846502	chr4:55062090	T/C	cg17187183	chr4:55093834	PDGFRA	0.4	8.27	0.31	7.59e-16	Corneal astigmatism;
BRCA	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg18404041	chr3:52824283	ITIH1	-0.35	-9.31	-0.35	2.02e-19	Schizophrenia;
BRCA	cis	rs3857067	0.806	rs4693375	chr4:95133241	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-9.64	-0.36	1.3e-20	QT interval;
BRCA	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg09307838	chr4:120376055	NA	0.72	15.26	0.52	4.8e-45	Corneal astigmatism;
BRCA	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg17366294	chr4:99064904	C4orf37	-0.53	-11.37	-0.41	2.17e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg03433033	chr1:76189801	ACADM	0.69	13.59	0.47	3.92e-37	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg20573242	chr4:122745356	CCNA2	0.49	10.92	0.4	1.43e-25	Type 2 diabetes;
BRCA	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.75	-0.55	1.78e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg05863683	chr7:1912471	MAD1L1	0.38	8.32	0.31	5.21e-16	Schizophrenia;
BRCA	cis	rs1420338	1.000	rs1420338	chr7:34143256	G/A	cg01275685	chr7:34179230	BMPER	-0.45	-9.89	-0.36	1.54e-21	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg03342759	chr3:160939853	NMD3	-0.8	-18.89	-0.6	1.45e-63	Parkinson's disease;
BRCA	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg08847533	chr14:75593920	NEK9	-0.86	-22.05	-0.66	1.46e-80	Height;
BRCA	cis	rs11690935	0.688	rs7600835	chr2:172521827	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.58	-14.49	-0.5	2.48e-41	Schizophrenia;
BRCA	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-18.13	-0.58	1.42e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg19346786	chr7:2764209	NA	-0.29	-8.1	-0.31	2.84e-15	Height;
BRCA	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	7.84	0.3	1.86e-14	Diabetic retinopathy;
BRCA	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg16339924	chr4:17578868	LAP3	0.56	13.86	0.48	2.31e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg11266682	chr4:10021025	SLC2A9	0.44	11.75	0.42	5.11e-29	Bone mineral density;
BRCA	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg15017067	chr4:17643749	FAM184B	0.31	9.26	0.34	3.15e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg12573674	chr2:1569213	NA	-0.49	-9.75	-0.36	4.88e-21	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-8.87	-0.33	7.32e-18	Alzheimer's disease (late onset);
BRCA	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg05834845	chr3:195489306	MUC4	0.52	8.2	0.31	1.33e-15	Lung disease severity in cystic fibrosis;
BRCA	trans	rs11165623	0.602	rs4127309	chr1:97006892	T/C	cg10631902	chr5:14652156	NA	-0.42	-12.01	-0.43	4.36e-30	Hip circumference;Waist circumference;
BRCA	cis	rs9400271	0.632	rs9374070	chr6:109586455	G/A	cg21918786	chr6:109611834	NA	-0.32	-7.93	-0.3	9.7e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-11.93	-0.43	9.18e-30	Tonsillectomy;
BRCA	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.6	-0.32	5.96e-17	Total body bone mineral density;
BRCA	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-9.73	-0.36	6.05e-21	IgG glycosylation;
BRCA	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg15556689	chr8:8085844	FLJ10661	-0.36	-9.62	-0.36	1.45e-20	Joint mobility (Beighton score);
BRCA	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg21132104	chr15:45694354	SPATA5L1	0.73	16.14	0.54	2.01e-49	Homoarginine levels;
BRCA	cis	rs2559856	0.967	rs2695290	chr12:102087844	A/G	cg15068132	chr12:102092402	CHPT1	0.28	7.89	0.3	1.28e-14	Blood protein levels;
BRCA	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg05340658	chr4:99064831	C4orf37	-0.48	-11.16	-0.4	1.56e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg17063962	chr7:91808500	NA	0.53	12.43	0.44	6.47e-32	Breast cancer;
BRCA	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg27029518	chr18:72166324	CNDP2	-0.33	-7.81	-0.3	2.3e-14	Refractive error;
BRCA	cis	rs2580764	0.566	rs2968793	chr2:55285024	C/T	cg09592903	chr2:55203963	RTN4	0.35	8.96	0.33	3.42e-18	Mean platelet volume;
BRCA	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg10876282	chr6:28092338	ZSCAN16	0.42	8.32	0.31	5.24e-16	Cardiac Troponin-T levels;
BRCA	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg17063962	chr7:91808500	NA	-0.55	-12.65	-0.45	6.88e-33	Breast cancer;
BRCA	cis	rs858239	0.600	rs4628176	chr7:23142566	C/T	cg23682824	chr7:23144976	KLHL7	0.42	11.23	0.41	7.86e-27	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs921968	0.565	rs1078803	chr2:219606538	A/C	cg02176678	chr2:219576539	TTLL4	0.4	10.8	0.39	4.22e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.6	-11.82	-0.42	2.77e-29	Multiple sclerosis;
BRCA	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.74e-16	Menopause (age at onset);
BRCA	cis	rs11955398	0.585	rs4398599	chr5:60032413	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.38	-8.96	-0.33	3.63e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1371614	0.679	rs4441421	chr2:27142091	G/A	cg12368169	chr2:27073192	DPYSL5	0.3	8.86	0.33	7.98e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-13.28	-0.47	1.05e-35	Systolic blood pressure;
BRCA	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	13.99	0.48	5.4e-39	Eosinophil percentage of white cells;
BRCA	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg22963979	chr7:1858916	MAD1L1	-0.4	-8.37	-0.31	3.72e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg23229984	chr5:148520753	ABLIM3	-0.34	-8.46	-0.32	1.89e-16	Breast cancer;
BRCA	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-9.29	-0.34	2.46e-19	Alzheimer's disease (late onset);
BRCA	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23583168	chr7:148888333	NA	-0.83	-18.96	-0.6	6.51e-64	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.53	-15.15	-0.51	1.68e-44	Lung cancer;
BRCA	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg24977027	chr2:88469347	THNSL2	0.57	9.56	0.35	2.48e-20	Plasma clusterin levels;
BRCA	cis	rs2882667	0.690	rs2693963	chr5:138106326	T/G	cg04439458	chr5:138467593	SIL1	0.31	7.85	0.3	1.74e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6813479	0.524	rs2612114	chr4:137745484	G/T	cg16185213	chr4:137733633	NA	0.34	8.2	0.31	1.3e-15	Longevity;
BRCA	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg11693508	chr17:37793320	STARD3	-0.67	-13.29	-0.47	8.8e-36	Bipolar disorder;
BRCA	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg23205692	chr1:25664452	TMEM50A	0.43	10.44	0.38	1.1e-23	Erythrocyte sedimentation rate;
BRCA	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.43	8.77	0.33	1.65e-17	Eosinophil percentage of white cells;
BRCA	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-9.86	-0.36	1.91e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs11690935	0.549	rs796839	chr2:172916214	A/C	cg13550731	chr2:172543902	DYNC1I2	0.54	13.6	0.47	3.6e-37	Schizophrenia;
BRCA	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg18230493	chr5:56204884	C5orf35	-0.72	-14.02	-0.49	3.82e-39	Initial pursuit acceleration;
BRCA	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg15605315	chr1:45957053	TESK2	0.45	9.17	0.34	6.57e-19	High light scatter reticulocyte count;
BRCA	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.84	-0.33	9.56e-18	Total body bone mineral density;
BRCA	cis	rs7617773	0.779	rs3731487	chr3:48229624	C/T	cg11946769	chr3:48343235	NME6	0.67	13.92	0.48	1.13e-38	Coronary artery disease;
BRCA	cis	rs2070433	0.539	rs721131	chr21:47957767	T/C	cg12379764	chr21:47803548	PCNT	0.56	11.99	0.43	5.14e-30	Lymphocyte counts;
BRCA	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg23950597	chr19:37808831	NA	-0.71	-12.54	-0.44	2.16e-32	Coronary artery calcification;
BRCA	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg11764359	chr7:65958608	NA	-0.61	-10.5	-0.38	6.84e-24	Aortic root size;
BRCA	cis	rs73086581	1.000	rs6107393	chr20:3987738	C/T	cg02187196	chr20:3869020	PANK2	0.49	8.9	0.33	5.72e-18	Response to antidepressants in depression;
BRCA	cis	rs2505998	0.833	rs1864404	chr10:43604390	A/T	cg15436174	chr10:43711423	RASGEF1A	-0.43	-8.33	-0.31	4.83e-16	Hirschsprung disease;
BRCA	trans	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg16049864	chr8:95962084	TP53INP1	-0.48	-11.95	-0.43	7.9e-30	Type 2 diabetes;
BRCA	cis	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.49	9.23	0.34	3.77e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-13.45	-0.47	1.81e-36	Bipolar disorder and schizophrenia;
BRCA	cis	rs6542838	0.703	rs7593332	chr2:99467991	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.36	-8.23	-0.31	1.04e-15	Fear of minor pain;
BRCA	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg21095983	chr6:86352623	SYNCRIP	0.41	9.14	0.34	8.34e-19	Smooth-surface caries;
BRCA	cis	rs281408	0.559	rs204248	chr19:49216224	G/C	cg13540341	chr19:49222985	MAMSTR	0.4	10.18	0.37	1.15e-22	Urinary metabolites (H-NMR features);
BRCA	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-9.7	-0.36	7.41e-21	Retinal vascular caliber;
BRCA	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg16423285	chr20:60520624	NA	0.58	11.69	0.42	9.39e-29	Obesity-related traits;
BRCA	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg11057378	chr10:81107060	PPIF	0.38	9.47	0.35	5.36e-20	Height;
BRCA	cis	rs11874712	0.966	rs9962380	chr18:43678706	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.33	7.85	0.3	1.74e-14	Migraine - clinic-based;
BRCA	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg17063962	chr7:91808500	NA	-0.5	-11.74	-0.42	5.93e-29	Breast cancer;
BRCA	cis	rs17023223	0.537	rs12087987	chr1:119734821	C/A	cg05756136	chr1:119680316	WARS2	-0.41	-7.94	-0.3	8.97e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.58	-15.4	-0.52	9.17e-46	Colorectal cancer;
BRCA	trans	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg06521331	chr12:34319734	NA	-0.51	-9.78	-0.36	3.77e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg03161606	chr19:29218774	NA	0.44	8.19	0.31	1.42e-15	Methadone dose in opioid dependence;
BRCA	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	21.0	0.64	7.09e-75	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg06784218	chr1:46089804	CCDC17	0.5	12.02	0.43	3.67e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6598955	0.543	rs12125620	chr1:26552238	G/A	cg04990556	chr1:26633338	UBXN11	0.71	11.96	0.43	6.87e-30	Obesity-related traits;
BRCA	cis	rs1953600	0.870	rs1049550	chr10:81926702	G/A	cg04850286	chr10:81895943	PLAC9	-0.32	-9.08	-0.34	1.31e-18	Sarcoidosis;
BRCA	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19346786	chr7:2764209	NA	-0.33	-9.73	-0.36	5.7e-21	Height;
BRCA	cis	rs495337	0.736	rs633829	chr20:48493291	G/A	cg17835207	chr20:48524531	SPATA2	-0.52	-11.34	-0.41	2.64e-27	Psoriasis;
BRCA	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg18850127	chr7:39170497	POU6F2	0.56	12.17	0.43	8.72e-31	IgG glycosylation;
BRCA	trans	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg18225595	chr11:63971243	STIP1	0.5	8.89	0.33	6.45e-18	Mean platelet volume;
BRCA	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg14019146	chr3:50243930	SLC38A3	-0.33	-7.84	-0.3	1.95e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs10267417	0.657	rs28833898	chr7:19861022	G/A	cg07541023	chr7:19748670	TWISTNB	0.51	9.11	0.34	1.05e-18	Night sleep phenotypes;
BRCA	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.29	0.31	6.9e-16	Parkinson's disease;
BRCA	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg26395211	chr5:140044315	WDR55	0.36	8.17	0.31	1.71e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.71	0.39	9.54e-25	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg26384229	chr12:38710491	ALG10B	0.68	14.08	0.49	1.99e-39	Morning vs. evening chronotype;
BRCA	cis	rs6546550	0.935	rs3771541	chr2:70031797	C/G	cg02498382	chr2:70120550	SNRNP27	-0.48	-9.86	-0.36	1.88e-21	Prevalent atrial fibrillation;
BRCA	cis	rs9533799	1.000	rs9533798	chr13:44802505	C/G	cg19190762	chr13:44806055	NA	-0.4	-8.65	-0.32	4.13e-17	Amyotrophic lateral sclerosis;
BRCA	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs2625529	0.668	rs8192386	chr15:72513148	A/C	cg16672083	chr15:72433130	SENP8	0.81	17.03	0.56	6.64e-54	Red blood cell count;
BRCA	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg18230493	chr5:56204884	C5orf35	-0.73	-14.18	-0.49	7.38e-40	Initial pursuit acceleration;
BRCA	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg25237894	chr2:233734115	C2orf82	-0.41	-11.93	-0.43	9.26e-30	Coronary artery disease;
BRCA	cis	rs812925	0.519	rs967968	chr2:61656056	C/G	cg15711740	chr2:61764176	XPO1	0.33	8.05	0.3	4.05e-15	Immature fraction of reticulocytes;
BRCA	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15320075	chr8:145703422	NA	-0.56	-12.8	-0.45	1.41e-33	Age at first birth;
BRCA	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg23649088	chr2:200775458	C2orf69	-0.61	-11.42	-0.41	1.25e-27	Schizophrenia;
BRCA	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg06636551	chr8:101224915	SPAG1	-0.33	-7.81	-0.3	2.43e-14	Atrioventricular conduction;
BRCA	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	15.16	0.51	1.39e-44	Platelet count;
BRCA	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg18305652	chr10:134549665	INPP5A	0.51	13.24	0.46	1.52e-35	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs586533	0.846	rs1790267	chr11:99501018	G/T	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.62	0.36	1.54e-20	Menopause (age at onset);
BRCA	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg13393036	chr8:95962371	TP53INP1	-0.33	-9.02	-0.34	2.2e-18	Type 2 diabetes;
BRCA	trans	rs11165623	0.602	rs12120893	chr1:97007132	C/T	cg10631902	chr5:14652156	NA	-0.4	-11.14	-0.4	1.91e-26	Hip circumference;Waist circumference;
BRCA	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg04944784	chr2:26401820	FAM59B	0.89	12.36	0.44	1.33e-31	Gut microbiome composition (summer);
BRCA	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg07080220	chr10:102295463	HIF1AN	0.44	9.69	0.36	8.15e-21	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg00990874	chr7:1149470	C7orf50	-0.43	-8.7	-0.33	2.74e-17	Bronchopulmonary dysplasia;
BRCA	cis	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg09307838	chr4:120376055	NA	0.47	10.13	0.37	1.8e-22	Diastolic blood pressure;
BRCA	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.78e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg09085632	chr11:111637200	PPP2R1B	1.01	23.71	0.68	1.19e-89	Primary sclerosing cholangitis;
BRCA	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg26395211	chr5:140044315	WDR55	0.38	8.69	0.32	3.14e-17	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg06521331	chr12:34319734	NA	-0.54	-10.29	-0.38	4.42e-23	Morning vs. evening chronotype;
BRCA	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.46	-9.23	-0.34	4.03e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03517284	chr6:25882590	NA	-0.51	-11.52	-0.41	4.72e-28	Blood metabolite levels;
BRCA	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg10223061	chr2:219282414	VIL1	-0.27	-8.15	-0.31	1.91e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.66	-12.95	-0.46	3.03e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.46e-34	Alzheimer's disease (late onset);
BRCA	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg13010199	chr12:38710504	ALG10B	-0.36	-8.77	-0.33	1.6e-17	Morning vs. evening chronotype;
BRCA	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg06191203	chr2:152266755	RIF1	0.43	12.29	0.44	2.48e-31	Lung cancer;
BRCA	cis	rs1997103	1.000	rs6954474	chr7:55404847	A/G	cg17469321	chr7:55412551	NA	0.49	9.16	0.34	6.81e-19	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-12.04	-0.43	3.07e-30	Chronic sinus infection;
BRCA	trans	rs1493916	0.748	rs4799355	chr18:31313124	G/T	cg15819921	chr19:927150	ARID3A	-0.42	-8.18	-0.31	1.5e-15	Life satisfaction;
BRCA	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg27446573	chr6:127587934	RNF146	-0.84	-17.31	-0.57	2.36e-55	Breast cancer;
BRCA	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.61	14.37	0.49	8.64e-41	Colorectal cancer;
BRCA	cis	rs9811920	0.809	rs796976	chr3:99621002	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.57	14.0	0.48	4.68e-39	Axial length;
BRCA	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	22.04	0.66	1.58e-80	Chronic sinus infection;
BRCA	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg27170947	chr2:26402098	FAM59B	-0.94	-16.89	-0.56	3.36e-53	Gut microbiome composition (summer);
BRCA	cis	rs17401966	0.522	rs2027330	chr1:10275592	C/T	cg03954927	chr1:10346856	KIF1B	0.35	10.61	0.39	2.41e-24	Hepatocellular carcinoma;
BRCA	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg24692254	chr21:30365293	RNF160	-0.52	-11.83	-0.42	2.44e-29	Cognitive test performance;
BRCA	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	27.08	0.73	3.96e-108	Chronic sinus infection;
BRCA	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg03709012	chr19:19516395	GATAD2A	0.81	19.13	0.6	8.08e-65	Tonsillectomy;
BRCA	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.68	-0.5	2.95e-42	Chronic sinus infection;
BRCA	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg06494592	chr3:125709126	NA	-0.53	-8.25	-0.31	9.2e-16	Blood pressure (smoking interaction);
BRCA	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg03146154	chr1:46216737	IPP	0.46	10.15	0.37	1.56e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg12386194	chr3:101231763	SENP7	0.45	9.5	0.35	4.28e-20	Colorectal cancer;
BRCA	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg02503808	chr4:7069936	GRPEL1	0.86	19.93	0.62	4.13e-69	Monocyte percentage of white cells;
BRCA	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.13e-15	Tonsillectomy;
BRCA	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg11062466	chr8:58055876	NA	-0.5	-8.54	-0.32	9.85e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs965469	1.000	rs6139088	chr20:3329063	G/A	cg25506879	chr20:3388711	C20orf194	-0.55	-10.7	-0.39	1.07e-24	IFN-related cytopenia;
BRCA	cis	rs1018836	0.770	rs13266461	chr8:91652817	T/C	cg16814680	chr8:91681699	NA	-0.76	-16.92	-0.56	2.5e-53	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1499972	0.941	rs6807173	chr3:117642281	T/G	cg07612923	chr3:117604196	NA	0.6	8.1	0.31	2.82e-15	Schizophrenia;
BRCA	cis	rs6878727	0.815	rs988409	chr5:123730483	G/A	cg01806427	chr5:123737813	NA	0.4	9.02	0.34	2.15e-18	Breast cancer;
BRCA	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.87	-0.36	1.72e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.54	8.62	0.32	5.39e-17	Renal function-related traits (BUN);
BRCA	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg08601574	chr20:25228251	PYGB	0.36	8.58	0.32	7.01e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	14.31	0.49	1.79e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg19729930	chr2:74357872	NA	0.58	14.65	0.5	3.99e-42	Gestational age at birth (maternal effect);
BRCA	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18876405	chr7:65276391	NA	-0.57	-13.67	-0.48	1.64e-37	Aortic root size;
BRCA	cis	rs4285028	0.747	rs1920299	chr3:121593769	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	12.83	0.45	1.05e-33	Multiple sclerosis;
BRCA	cis	rs36051895	0.589	rs62543573	chr9:5201675	A/G	cg02405213	chr9:5042618	JAK2	-0.42	-7.81	-0.3	2.43e-14	Pediatric autoimmune diseases;
BRCA	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg13010199	chr12:38710504	ALG10B	0.44	9.26	0.34	2.96e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7537052	0.669	rs6686192	chr1:36642991	C/T	cg24686825	chr1:36642396	MAP7D1	-0.53	-12.07	-0.43	2.35e-30	Schizophrenia;
BRCA	cis	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg05623727	chr3:50126028	RBM5	0.43	10.16	0.37	1.38e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg20503657	chr10:835505	NA	-0.54	-9.89	-0.36	1.42e-21	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg11845111	chr2:191398756	TMEM194B	-0.35	-7.93	-0.3	1.01e-14	Pulse pressure;
BRCA	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg14343924	chr8:8086146	FLJ10661	-0.39	-8.11	-0.31	2.58e-15	Monocyte count;
BRCA	trans	rs1972460	0.506	rs62012050	chr15:82532274	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.42	-10.37	-0.38	2.24e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg23649088	chr2:200775458	C2orf69	0.6	11.57	0.42	3.14e-28	Schizophrenia;
BRCA	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg12193833	chr17:30244370	NA	-0.53	-8.53	-0.32	1.08e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs701145	0.938	rs355788	chr3:154000612	T/C	cg17054900	chr3:154042577	DHX36	0.68	11.79	0.42	3.71e-29	Coronary artery disease;
BRCA	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg21045802	chr8:109455806	TTC35	0.35	8.0	0.3	5.85e-15	Dupuytren's disease;
BRCA	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg04166393	chr7:2884313	GNA12	0.41	8.96	0.33	3.58e-18	Height;
BRCA	cis	rs7264396	1.000	rs224437	chr20:34154371	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-9.96	-0.37	8.39e-22	Total cholesterol levels;
BRCA	cis	rs586533	0.881	rs603255	chr11:99499846	A/G	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	10.84	0.39	3e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg04586622	chr2:25135609	ADCY3	-0.41	-10.04	-0.37	3.88e-22	Body mass index in non-asthmatics;
BRCA	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg03433033	chr1:76189801	ACADM	0.61	11.23	0.41	8.04e-27	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.41	8.76	0.33	1.81e-17	Cognitive ability;
BRCA	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg26384229	chr12:38710491	ALG10B	-0.51	-11.47	-0.41	8.36e-28	Morning vs. evening chronotype;
BRCA	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg08917208	chr2:24149416	ATAD2B	0.53	8.33	0.31	5.01e-16	Asthma;
BRCA	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg01475377	chr6:109611718	NA	0.61	16.92	0.56	2.31e-53	Reticulocyte fraction of red cells;
BRCA	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	8.15e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg26384229	chr12:38710491	ALG10B	0.65	13.91	0.48	1.34e-38	Morning vs. evening chronotype;
BRCA	cis	rs7944584	0.632	rs11039159	chr11:47294021	G/T	cg20307385	chr11:47447363	PSMC3	0.57	11.41	0.41	1.42e-27	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg17294928	chr15:75287854	SCAMP5	-0.75	-16.42	-0.54	7.94e-51	Blood trace element (Zn levels);
BRCA	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg20991723	chr1:152506922	NA	0.38	8.62	0.32	5.36e-17	Hair morphology;
BRCA	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg14349672	chr11:133703707	NA	-0.41	-9.09	-0.34	1.23e-18	Childhood ear infection;
BRCA	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg21905437	chr5:178450457	ZNF879	0.51	10.64	0.39	1.95e-24	Pubertal anthropometrics;
BRCA	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg05623727	chr3:50126028	RBM5	-0.42	-9.96	-0.37	8.18e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg06784218	chr1:46089804	CCDC17	0.45	10.91	0.4	1.54e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg12386194	chr3:101231763	SENP7	0.45	9.52	0.35	3.64e-20	Colorectal cancer;
BRCA	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	9.2	0.34	5.04e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs2270927	0.510	rs4566771	chr5:75576522	C/T	cg13563193	chr19:33072644	PDCD5	0.85	10.08	0.37	2.72e-22	Mean corpuscular volume;
BRCA	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg13319975	chr6:146136371	FBXO30	0.41	9.44	0.35	7.04e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg24110177	chr3:50126178	RBM5	-0.44	-9.81	-0.36	3.06e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg03188948	chr7:1209495	NA	0.69	11.64	0.42	1.59e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg21770322	chr7:97807741	LMTK2	0.41	10.95	0.4	1.09e-25	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.45	0.38	1.07e-23	Motion sickness;
BRCA	cis	rs3768617	0.811	rs4285667	chr1:182970225	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	9.77	0.36	4.24e-21	Fuchs's corneal dystrophy;
BRCA	cis	rs1775715	0.678	rs2105360	chr10:32210198	C/T	cg14930904	chr10:32216787	ARHGAP12	0.34	7.84	0.3	1.95e-14	Bipolar disorder with mood-incongruent psychosis;
BRCA	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg12379764	chr21:47803548	PCNT	-0.39	-8.54	-0.32	1.01e-16	Testicular germ cell tumor;
BRCA	cis	rs4588572	0.688	rs2115436	chr5:77692617	A/T	cg11547950	chr5:77652471	NA	-0.43	-8.48	-0.32	1.56e-16	Triglycerides;
BRCA	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-12.04	-0.43	3.17e-30	Total cholesterol levels;
BRCA	cis	rs6028335	0.674	rs66526549	chr20:37588360	A/G	cg16355469	chr20:37678765	NA	0.46	8.02	0.3	5.2e-15	Alcohol and nicotine co-dependence;
BRCA	cis	rs1891275	0.515	rs7911755	chr10:93489817	G/A	cg07889827	chr10:93443413	NA	-0.4	-11.0	-0.4	6.64e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg04553112	chr3:125709451	NA	-0.55	-8.36	-0.31	4.02e-16	Blood pressure (smoking interaction);
BRCA	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg12365402	chr11:9010492	NRIP3	-0.37	-8.43	-0.32	2.34e-16	Hemoglobin concentration;
BRCA	cis	rs9649465	0.561	rs688242	chr7:123420442	C/A	cg03229431	chr7:123269106	ASB15	0.42	9.54	0.35	2.95e-20	Migraine;
BRCA	cis	rs2230307	0.656	rs114775204	chr1:100463030	T/C	cg24955406	chr1:100503596	HIAT1	0.54	9.42	0.35	8.29e-20	Carotid intima media thickness;
BRCA	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-14.83	-0.51	5.73e-43	Hemoglobin concentration;
BRCA	cis	rs7178424	0.875	rs28411984	chr15:62221592	A/C	cg00456672	chr15:62358751	C2CD4A	0.4	8.9	0.33	5.86e-18	Height;
BRCA	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg24558204	chr6:135376177	HBS1L	-0.43	-11.73	-0.42	6.32e-29	Red blood cell count;
BRCA	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg16339924	chr4:17578868	LAP3	0.56	13.9	0.48	1.42e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4662945	0.603	rs13002385	chr2:130276865	T/C	cg05903289	chr2:130345205	NA	-0.34	-8.54	-0.32	1.01e-16	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg21918786	chr6:109611834	NA	-0.46	-12.99	-0.46	2.13e-34	Reticulocyte fraction of red cells;
BRCA	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg07395648	chr5:131743802	NA	0.4	9.69	0.36	8.07e-21	Blood metabolite levels;
BRCA	cis	rs524281	0.861	rs3825067	chr11:65878419	A/G	cg16950941	chr11:66035639	RAB1B	0.39	8.19	0.31	1.47e-15	Electroencephalogram traits;
BRCA	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg23422044	chr7:1970798	MAD1L1	-0.72	-13.3	-0.47	8.72e-36	Bipolar disorder;
BRCA	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg12826209	chr6:26865740	GUSBL1	0.55	9.0	0.34	2.5e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg07211511	chr3:129823064	LOC729375	-0.63	-11.15	-0.4	1.72e-26	Blood pressure (smoking interaction);
BRCA	cis	rs7903847	0.673	rs3818908	chr10:99132701	A/G	cg20016023	chr10:99160130	RRP12	-0.27	-8.7	-0.33	2.8e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	15.85	0.53	5.57e-48	Platelet count;
BRCA	trans	rs12310956	0.510	rs4931743	chr12:33867588	T/C	cg26384229	chr12:38710491	ALG10B	0.39	9.14	0.34	8.42e-19	Morning vs. evening chronotype;
BRCA	cis	rs7677751	0.806	rs1800812	chr4:55094629	G/T	cg17187183	chr4:55093834	PDGFRA	0.44	9.03	0.34	2.03e-18	Corneal astigmatism;
BRCA	cis	rs1018836	0.923	rs756569	chr8:91610957	G/A	cg16814680	chr8:91681699	NA	-0.58	-12.38	-0.44	1.07e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.59	-0.42	2.5e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg06713675	chr4:122721982	EXOSC9	-0.55	-13.03	-0.46	1.45e-34	Type 2 diabetes;
BRCA	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.67	-13.67	-0.48	1.7e-37	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg03733263	chr8:22462867	KIAA1967	-0.66	-14.76	-0.5	1.16e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg07080220	chr10:102295463	HIF1AN	0.49	10.12	0.37	1.96e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg05313129	chr8:58192883	C8orf71	-0.46	-9.53	-0.35	3.34e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs7178424	0.967	rs12440524	chr15:62369507	T/C	cg00456672	chr15:62358751	C2CD4A	-0.42	-9.48	-0.35	4.81e-20	Height;
BRCA	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24549020	chr5:56110836	MAP3K1	0.41	8.56	0.32	8.17e-17	Initial pursuit acceleration;
BRCA	cis	rs2637030	0.515	rs256103	chr5:53012475	A/G	cg06476337	chr5:52856530	NDUFS4	0.35	7.92	0.3	1.04e-14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg08807101	chr21:30365312	RNF160	0.5	11.15	0.4	1.64e-26	Cognitive test performance;
BRCA	cis	rs477692	0.673	rs10764889	chr10:131341521	G/A	cg05714579	chr10:131428358	MGMT	0.48	10.36	0.38	2.4e-23	Response to temozolomide;
BRCA	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg13010199	chr12:38710504	ALG10B	0.48	9.56	0.35	2.45e-20	Morning vs. evening chronotype;
BRCA	cis	rs2014572	0.967	rs10413037	chr19:57771883	A/G	cg24459738	chr19:57751996	ZNF805	-0.35	-8.06	-0.3	3.63e-15	Hyperactive-impulsive symptoms;
BRCA	trans	rs853679	0.607	rs67998226	chr6:28238059	T/C	cg01620082	chr3:125678407	NA	-0.87	-10.59	-0.39	2.87e-24	Depression;
BRCA	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg23625390	chr15:77176239	SCAPER	-0.55	-13.86	-0.48	2.21e-38	Blood metabolite levels;
BRCA	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg11502198	chr6:26597334	ABT1	0.49	9.73	0.36	5.93e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.45	-9.47	-0.35	5.36e-20	Colorectal cancer;
BRCA	cis	rs67981189	0.896	rs34731365	chr14:71449594	C/T	cg15816911	chr14:71606274	NA	0.35	7.83	0.3	2.02e-14	Schizophrenia;
BRCA	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg21770322	chr7:97807741	LMTK2	0.41	10.87	0.4	2.17e-25	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg12219531	chr12:120966889	COQ5	0.54	11.66	0.42	1.29e-28	High light scatter reticulocyte count;
BRCA	trans	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg15556689	chr8:8085844	FLJ10661	0.35	8.6	0.32	6.04e-17	Neuroticism;
BRCA	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg06159980	chr1:16340746	HSPB7	-0.39	-8.86	-0.33	7.77e-18	Systolic blood pressure;
BRCA	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg10223061	chr2:219282414	VIL1	-0.27	-8.07	-0.3	3.41e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg12011299	chr4:100065546	ADH4	0.5	11.51	0.41	5.61e-28	Alcohol dependence;
BRCA	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg00530320	chr1:46809349	NSUN4	-0.47	-9.45	-0.35	6.31e-20	Menopause (age at onset);
BRCA	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg00383909	chr3:49044727	WDR6	0.89	12.83	0.45	1.12e-33	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg23933602	chr10:16859644	RSU1	0.6	14.47	0.5	3.03e-41	Platelet distribution width;
BRCA	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.49e-52	Hypertriglyceridemia;
BRCA	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08564027	chr20:61660810	NA	0.84	22.84	0.67	7.41e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	14.07	0.49	2.42e-39	Lymphocyte counts;
BRCA	cis	rs7639513	0.767	rs9861472	chr3:12707776	A/T	cg23032965	chr3:12705835	RAF1	-0.69	-15.16	-0.51	1.36e-44	Itch intensity from mosquito bite;
BRCA	cis	rs1451375	0.617	rs2329366	chr7:50544966	G/A	cg18232548	chr7:50535776	DDC	-0.42	-8.87	-0.33	7.23e-18	Malaria;
BRCA	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.41	0.38	1.45e-23	Bladder cancer;
BRCA	trans	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-27.79	-0.74	4.91e-112	Exhaled nitric oxide output;
BRCA	cis	rs929596	0.755	rs3771341	chr2:234673239	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-11.93	-0.43	9.54e-30	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.13e-15	Tonsillectomy;
BRCA	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	19.18	0.6	4.26e-65	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg17330251	chr7:94953956	PON1	-0.4	-8.54	-0.32	9.69e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs490234	0.702	rs35129945	chr9:128320134	C/T	cg14078157	chr9:128172775	NA	-0.51	-11.39	-0.41	1.77e-27	Mean arterial pressure;
BRCA	cis	rs11718455	0.960	rs4682713	chr3:44013191	G/C	cg08738300	chr3:44038990	NA	0.47	8.84	0.33	9.23e-18	Coronary artery disease;
BRCA	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26314531	chr2:26401878	FAM59B	-0.96	-16.08	-0.54	4.13e-49	Gut microbiome composition (summer);
BRCA	cis	rs2797160	1.000	rs2747723	chr6:126010790	C/T	cg05901451	chr6:126070800	HEY2	0.4	9.79	0.36	3.51e-21	Endometrial cancer;
BRCA	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs10504073	0.584	rs7823690	chr8:49943831	G/A	cg00325661	chr8:49890786	NA	0.45	13.13	0.46	4.96e-35	Blood metabolite ratios;
BRCA	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg21951975	chr1:209979733	IRF6	0.4	9.26	0.34	2.98e-19	Cleft lip with or without cleft palate;
BRCA	cis	rs2108225	0.967	rs7785790	chr7:107449896	C/T	cg18560240	chr7:107437656	SLC26A3	0.52	10.81	0.39	3.96e-25	Ulcerative colitis;
BRCA	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.53	-11.83	-0.42	2.34e-29	Personality dimensions;
BRCA	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg03877680	chr5:178157825	ZNF354A	0.78	14.44	0.5	3.96e-41	Neutrophil percentage of white cells;
BRCA	cis	rs7927771	0.524	rs7118747	chr11:47889545	C/T	cg20307385	chr11:47447363	PSMC3	-0.39	-9.29	-0.34	2.38e-19	Subjective well-being;
BRCA	cis	rs17095355	1.000	rs734164	chr10:111698160	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.4	-10.36	-0.38	2.34e-23	Biliary atresia;
BRCA	cis	rs10046574	0.516	rs7802453	chr7:135200638	T/C	cg27474649	chr7:135195673	CNOT4	0.67	11.09	0.4	3.01e-26	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg24130564	chr14:104152367	KLC1	0.35	7.98	0.3	6.97e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg25036284	chr2:26402008	FAM59B	0.96	16.03	0.54	7.08e-49	Gut microbiome composition (summer);
BRCA	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg12698349	chr2:225449008	CUL3	0.59	12.7	0.45	4.29e-33	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg17724175	chr1:150552817	MCL1	0.25	7.88	0.3	1.46e-14	Melanoma;
BRCA	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg09307838	chr4:120376055	NA	0.62	13.08	0.46	8.24e-35	Corneal astigmatism;
BRCA	cis	rs10754283	0.934	rs6684676	chr1:90102173	C/T	cg21401794	chr1:90099060	LRRC8C	0.46	11.11	0.4	2.33e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05890377	chr2:74357713	NA	0.49	11.8	0.42	3.18e-29	Gestational age at birth (maternal effect);
BRCA	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg01191920	chr7:158217561	PTPRN2	0.33	8.12	0.31	2.42e-15	Obesity-related traits;
BRCA	cis	rs67460515	0.596	rs35127376	chr3:160927289	T/C	cg17135325	chr3:160939158	NMD3	0.45	8.4	0.32	2.9e-16	Parkinson's disease;
BRCA	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg00277334	chr10:82204260	NA	-0.42	-8.23	-0.31	1.04e-15	Post bronchodilator FEV1;
BRCA	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg26587870	chr6:27730563	NA	0.41	8.72	0.33	2.46e-17	Parkinson's disease;
BRCA	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.39	9.11	0.34	1.06e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg25838465	chr1:92012736	NA	-0.47	-9.41	-0.35	8.95e-20	Eosinophil percentage of white cells;
BRCA	cis	rs701145	0.585	rs1727893	chr3:153849866	A/C	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.82e-18	Coronary artery disease;
BRCA	cis	rs10193935	0.901	rs6727657	chr2:42632117	A/G	cg27598129	chr2:42591480	NA	-0.72	-12.7	-0.45	4.13e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg13319975	chr6:146136371	FBXO30	-0.35	-8.11	-0.31	2.52e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1505368	0.789	rs13419353	chr2:213271459	A/T	cg20637307	chr2:213403960	ERBB4	-0.37	-8.94	-0.33	4.03e-18	Symmetrical dimethylarginine levels;
BRCA	cis	rs11585357	0.947	rs3003441	chr1:17611869	C/T	cg08277548	chr1:17600880	PADI3	0.6	10.9	0.4	1.69e-25	Hair shape;
BRCA	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg12751644	chr20:60527061	NA	-0.33	-7.95	-0.3	8.19e-15	Body mass index;
BRCA	trans	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-15.27	-0.52	4.23e-45	Obesity-related traits;
BRCA	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg19318889	chr4:1322082	MAEA	0.35	7.99	0.3	6.36e-15	Longevity;
BRCA	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.24	0.34	3.64e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1511802	0.666	rs4862663	chr4:187119228	T/A	cg24794857	chr4:187113578	CYP4V2	0.38	8.27	0.31	7.56e-16	Blood protein levels;
BRCA	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.68	-15.85	-0.53	6.14e-48	Systemic lupus erythematosus;
BRCA	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	9.84	0.36	2.21e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg17845761	chr1:175162550	KIAA0040	0.27	10.26	0.38	5.52e-23	Alcohol dependence;
BRCA	cis	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg06521331	chr12:34319734	NA	-0.61	-12.02	-0.43	3.63e-30	Morning vs. evening chronotype;
BRCA	cis	rs11072804	1	rs11072804	chr15:79078486	T/G	cg04896959	chr15:78267971	NA	0.37	8.63	0.32	4.8e-17	Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg07460842	chr6:66804631	NA	0.85	15.31	0.52	2.76e-45	Exhaled nitric oxide levels;
BRCA	cis	rs13064411	0.518	rs7646188	chr3:113219272	C/T	cg18753928	chr3:113234510	CCDC52	-0.41	-9.15	-0.34	7.7e-19	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	trans	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg01620082	chr3:125678407	NA	-0.63	-8.39	-0.32	3.12e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.05	0.3	3.98e-15	Breast cancer;
BRCA	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg21699342	chr2:239360505	ASB1	0.53	14.05	0.49	2.92e-39	Multiple system atrophy;
BRCA	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg10523679	chr1:76189770	ACADM	0.76	15.75	0.53	1.89e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg00677455	chr12:58241039	CTDSP2	0.47	11.51	0.41	5.58e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs10463316	0.894	rs10476980	chr5:150764157	A/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.4	-0.32	2.96e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12292205	chr6:26970375	C6orf41	-0.49	-8.23	-0.31	1.08e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg09021430	chr5:549028	NA	-0.68	-14.14	-0.49	1.07e-39	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg05340658	chr4:99064831	C4orf37	0.64	15.51	0.52	2.73e-46	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08859206	chr1:53392774	SCP2	0.66	13.75	0.48	6.86e-38	Monocyte count;
BRCA	trans	rs1493916	0.837	rs2172626	chr18:31410478	C/T	cg15819921	chr19:927150	ARID3A	-0.41	-8.07	-0.3	3.37e-15	Life satisfaction;
BRCA	cis	rs3857067	0.773	rs2865344	chr4:95103040	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.38	-8.83	-0.33	1.01e-17	QT interval;
BRCA	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg13073564	chr4:8508604	NA	0.43	11.82	0.42	2.72e-29	Response to antineoplastic agents;
BRCA	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-12.91	-0.45	4.64e-34	Morning vs. evening chronotype;
BRCA	cis	rs897080	0.515	rs1067401	chr2:44676541	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	8.43	0.32	2.24e-16	Height;
BRCA	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg22508957	chr16:3507546	NAT15	0.45	10.65	0.39	1.68e-24	Tuberculosis;
BRCA	cis	rs3925075	0.525	rs929868	chr16:31280282	G/A	cg02846316	chr16:31340340	ITGAM	0.43	8.78	0.33	1.55e-17	IgA nephropathy;
BRCA	cis	rs2625529	0.701	rs62025574	chr15:72236075	C/T	cg16672083	chr15:72433130	SENP8	-0.84	-17.27	-0.56	3.79e-55	Red blood cell count;
BRCA	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg18132916	chr6:79620363	NA	0.48	10.99	0.4	7.19e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg01262667	chr19:19385393	TM6SF2	0.42	10.96	0.4	9.96e-26	Tonsillectomy;
BRCA	cis	rs11031096	0.782	rs10767845	chr11:4156922	C/T	cg18678763	chr11:4115507	RRM1	-0.38	-8.58	-0.32	7.01e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00166722	chr3:10149974	C3orf24	0.64	11.32	0.41	3.47e-27	Alzheimer's disease;
BRCA	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.06	-0.3	3.67e-15	Total body bone mineral density;
BRCA	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg03433033	chr1:76189801	ACADM	-0.49	-10.05	-0.37	3.79e-22	Daytime sleep phenotypes;
BRCA	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg07274523	chr3:49395745	GPX1	0.46	7.92	0.3	1.07e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7131987	0.650	rs67146951	chr12:29450553	C/A	cg09582351	chr12:29534625	ERGIC2	-0.47	-10.87	-0.39	2.36e-25	QT interval;
BRCA	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg22875332	chr1:76189707	ACADM	0.79	18.87	0.6	1.86e-63	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12464559	0.522	rs4414677	chr2:152624932	A/C	cg01189475	chr2:152685088	ARL5A	-0.58	-8.92	-0.33	5.06e-18	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg08470875	chr2:26401718	FAM59B	0.71	11.35	0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs1400816	0.850	rs16859721	chr2:172536172	A/G	cg13550731	chr2:172543902	DYNC1I2	0.51	7.89	0.3	1.34e-14	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg17366294	chr4:99064904	C4orf37	0.41	9.64	0.36	1.23e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg18904891	chr8:8559673	CLDN23	0.66	13.13	0.46	4.67e-35	Obesity-related traits;
BRCA	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg11993925	chr19:44307056	LYPD5	0.51	11.3	0.41	4.02e-27	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg08999081	chr20:33150536	PIGU	0.36	9.21	0.34	4.64e-19	Coronary artery disease;
BRCA	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg27661571	chr11:113659931	NA	-0.7	-10.82	-0.39	3.5e-25	Hip circumference adjusted for BMI;
BRCA	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-8.01	-0.3	5.62e-15	Response to antipsychotic treatment;
BRCA	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.84	0.3	1.95e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg23711669	chr6:146136114	FBXO30	0.74	15.93	0.53	2.41e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg05313129	chr8:58192883	C8orf71	-0.46	-9.56	-0.35	2.5e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs6496044	0.547	rs7173125	chr15:86055445	C/G	cg10818794	chr15:86012489	AKAP13	0.3	8.09	0.3	2.98e-15	Interstitial lung disease;
BRCA	cis	rs654351	0.541	rs533746	chr6:10388968	C/T	cg04978078	chr6:10383147	NA	0.43	8.36	0.31	3.83e-16	Squamous cell lung carcinoma;
BRCA	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	14.13	0.49	1.18e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2652834	1.000	rs2652834	chr15:63396867	A/G	cg05507819	chr15:63340323	TPM1	0.44	8.08	0.3	3.16e-15	HDL cholesterol;
BRCA	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.49	7.92	0.3	1.07e-14	HIV-1 control;
BRCA	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-8.09	-0.3	3.04e-15	Prostate cancer;
BRCA	trans	rs7980799	0.716	rs1351683	chr12:33598563	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-11.03	-0.4	5.03e-26	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs250677	0.522	rs1007400	chr5:148382635	C/T	cg18129178	chr5:148520854	ABLIM3	0.55	10.69	0.39	1.2e-24	Breast cancer;
BRCA	trans	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg25206134	chr2:45395956	NA	0.41	7.84	0.3	1.9e-14	Bipolar disorder;
BRCA	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.35	0.35	1.49e-19	Tonsillectomy;
BRCA	cis	rs858239	0.730	rs10255155	chr7:23402147	A/T	cg23682824	chr7:23144976	KLHL7	-0.31	-8.06	-0.3	3.72e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7172677	0.737	rs7169545	chr15:75436123	A/G	cg14664628	chr15:75095509	CSK	-0.38	-8.02	-0.3	5.21e-15	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs10911363	0.592	rs2702180	chr1:183517971	T/C	cg09173681	chr1:183549694	NCF2	0.48	10.19	0.37	1.03e-22	Systemic lupus erythematosus;
BRCA	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.52	-0.32	1.12e-16	Height;
BRCA	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-13.02	-0.46	1.53e-34	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	11.14	0.4	1.78e-26	Schizophrenia;
BRCA	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.18	-0.31	1.57e-15	Depression;
BRCA	trans	rs4650994	1.000	rs4650999	chr1:178532188	A/C	cg05059571	chr16:84539110	KIAA1609	0.37	8.55	0.32	8.92e-17	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg01448562	chr3:133502909	NA	-0.5	-10.86	-0.39	2.6e-25	Iron status biomarkers;
BRCA	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03713592	chr11:72463424	ARAP1	0.83	12.32	0.44	1.99e-31	Type 2 diabetes;
BRCA	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-13.96	-0.48	7.8e-39	Bipolar disorder and schizophrenia;
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-8.26	-0.31	8.52e-16	Longevity;Endometriosis;
BRCA	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg10523679	chr1:76189770	ACADM	0.77	15.94	0.53	2.03e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.9	0.33	5.51e-18	Tonsillectomy;
BRCA	cis	rs698813	0.674	rs6544751	chr2:44495845	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	8.7	0.33	2.82e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg11168104	chr5:1857477	NA	-0.32	-8.17	-0.31	1.63e-15	Cardiovascular disease risk factors;
BRCA	cis	rs2016266	0.859	rs4759061	chr12:53738214	C/T	cg26875137	chr12:53738046	NA	-0.46	-10.16	-0.37	1.38e-22	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg05340658	chr4:99064831	C4orf37	0.63	14.57	0.5	9.57e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10911363	0.570	rs2702204	chr1:183457396	A/G	cg09173681	chr1:183549694	NCF2	0.54	11.31	0.41	3.61e-27	Systemic lupus erythematosus;
BRCA	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg23533926	chr12:111358616	MYL2	-0.41	-8.54	-0.32	9.72e-17	Extrinsic epigenetic age acceleration;
BRCA	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg20290983	chr6:43655470	MRPS18A	1.1	40.32	0.85	9.69e-178	IgG glycosylation;
BRCA	trans	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	20.85	0.64	4.63e-74	Exhaled nitric oxide output;
BRCA	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-11.36	-0.41	2.22e-27	Systolic blood pressure;
BRCA	trans	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg04565464	chr8:145669602	NFKBIL2	0.45	10.86	0.39	2.57e-25	Schizophrenia;
BRCA	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg04362960	chr10:104952993	NT5C2	0.53	11.0	0.4	7.09e-26	Arsenic metabolism;
BRCA	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/T	cg04362960	chr10:104952993	NT5C2	0.74	12.68	0.45	5.21e-33	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.52	-0.32	1.18e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg13010199	chr12:38710504	ALG10B	-0.39	-8.7	-0.33	2.87e-17	Morning vs. evening chronotype;
BRCA	cis	rs11112613	0.713	rs2374502	chr12:105938939	T/C	cg03607813	chr12:105948248	NA	0.59	10.95	0.4	1.1e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.49	0.32	1.48e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg25358565	chr5:93447407	FAM172A	1.22	18.72	0.6	1.12e-62	Diabetic retinopathy;
BRCA	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg00071950	chr4:10020882	SLC2A9	0.59	14.75	0.5	1.35e-42	Bone mineral density;
BRCA	cis	rs2625529	0.617	rs8557	chr15:72115733	T/C	cg16672083	chr15:72433130	SENP8	-0.64	-15.07	-0.51	4.06e-44	Red blood cell count;
BRCA	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg15112475	chr7:1198522	ZFAND2A	-0.39	-8.37	-0.31	3.69e-16	Longevity;Endometriosis;
BRCA	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.74	0.36	5.46e-21	Morning vs. evening chronotype;
BRCA	cis	rs6840360	0.593	rs10013612	chr4:152693622	A/G	cg22705602	chr4:152727874	NA	-0.38	-10.58	-0.39	3.14e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg25358565	chr5:93447407	FAM172A	1.16	18.45	0.59	2.99e-61	Diabetic retinopathy;
BRCA	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	21.45	0.65	2.56e-77	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs10193935	0.901	rs1390609	chr2:42666230	G/T	cg27598129	chr2:42591480	NA	0.8	13.48	0.47	1.24e-36	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg17211192	chr8:82754475	SNX16	-0.49	-11.13	-0.4	1.94e-26	Diastolic blood pressure;
BRCA	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06627557	chr7:32535165	LSM5;AVL9	1.05	28.7	0.75	5.06e-117	Cognitive ability;
BRCA	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg23711669	chr6:146136114	FBXO30	0.76	17.27	0.56	3.72e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7683537	0.673	rs1401363	chr4:185643862	A/G	cg04058563	chr4:185651563	MLF1IP	0.76	16.78	0.55	1.26e-52	Systemic lupus erythematosus;
BRCA	cis	rs7631605	0.586	rs62241896	chr3:37368755	T/A	cg15934958	chr3:37212084	LRRFIP2	0.38	8.09	0.3	2.95e-15	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg24812749	chr6:127587940	RNF146	0.89	20.86	0.64	4.5e-74	Breast cancer;
BRCA	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	18.56	0.59	7.75e-62	Alzheimer's disease;
BRCA	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg22496339	chr2:162101262	NA	-0.39	-8.13	-0.31	2.26e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg12826209	chr6:26865740	GUSBL1	0.56	9.22	0.34	4.42e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs3820928	0.874	rs4675133	chr2:227843010	A/G	cg11843606	chr2:227700838	RHBDD1	0.37	8.15	0.31	1.86e-15	Pulmonary function;
BRCA	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.35	-0.35	1.45e-19	Bipolar disorder;
BRCA	cis	rs6743226	0.870	rs4675966	chr2:242244342	T/C	cg10021735	chr2:242295487	FARP2	0.37	10.03	0.37	4.43e-22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs7903847	0.620	rs10882904	chr10:99115683	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.11	-0.31	2.62e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs3815308	0.530	rs12973409	chr19:2196963	A/G	cg09261902	chr19:2140048	AP3D1	0.34	8.25	0.31	9.09e-16	Breast cancer;
BRCA	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg01884057	chr2:25150051	NA	0.31	8.14	0.31	2.14e-15	Body mass index;
BRCA	trans	rs629535	0.590	rs56200825	chr8:70123450	G/A	cg21567404	chr3:27674614	NA	-0.97	-17.77	-0.58	1.09e-57	Dupuytren's disease;
BRCA	cis	rs17620991	1.000	rs17620991	chr7:40836521	G/C	cg05119115	chr7:40866195	C7orf10	-0.56	-8.71	-0.33	2.66e-17	Alcohol dependence;
BRCA	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg08975724	chr8:8085496	FLJ10661	0.38	8.37	0.31	3.52e-16	Mood instability;
BRCA	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg13119609	chr19:45449297	APOC2	0.48	13.29	0.47	9.51e-36	Blood protein levels;
BRCA	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg04025307	chr7:1156635	C7orf50	0.6	10.36	0.38	2.27e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg09904177	chr6:26538194	HMGN4	-0.47	-13.47	-0.47	1.37e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs4478137	0.824	rs4691905	chr4:164221437	T/C	cg06758707	chr4:164254230	NPY1R	0.57	12.29	0.44	2.57e-31	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg14582100	chr15:45693742	SPATA5L1	0.37	11.85	0.42	2.07e-29	Homoarginine levels;
BRCA	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-8.52	-0.32	1.1e-16	Schizophrenia;
BRCA	cis	rs10795061	0.576	rs6601744	chr10:3711563	C/A	cg22632523	chr10:3711048	NA	0.43	10.04	0.37	4.12e-22	Subjective well-being;
BRCA	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg22705602	chr4:152727874	NA	-0.36	-9.79	-0.36	3.38e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg22907277	chr7:1156413	C7orf50	0.6	11.41	0.41	1.46e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg15704280	chr7:45808275	SEPT13	0.69	14.18	0.49	6.74e-40	Height;
BRCA	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	13.44	0.47	1.87e-36	Hip circumference adjusted for BMI;
BRCA	trans	rs60843830	0.661	rs11674477	chr2:105822	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.47	9.24	0.34	3.69e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	trans	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.23	0.31	1.07e-15	Mean corpuscular volume;
BRCA	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg23283495	chr1:209979779	IRF6	0.39	9.19	0.34	5.38e-19	Cleft lip with or without cleft palate;
BRCA	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg24110177	chr3:50126178	RBM5	-0.52	-14.79	-0.51	8.67e-43	Body mass index;
BRCA	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	11.19	0.4	1.13e-26	Platelet count;
BRCA	cis	rs6594499	0.872	rs1379298	chr5:110435726	T/C	cg04022379	chr5:110408740	TSLP	0.35	8.06	0.3	3.73e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg11189052	chr15:85197271	WDR73	0.44	9.05	0.34	1.66e-18	Schizophrenia;
BRCA	cis	rs4363385	0.720	rs11205150	chr1:152959266	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.82	-0.33	1.06e-17	Inflammatory skin disease;
BRCA	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg25482853	chr8:67687455	SGK3	0.78	13.01	0.46	1.67e-34	Obesity-related traits;
BRCA	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg03146154	chr1:46216737	IPP	0.44	9.84	0.36	2.35e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.31	-8.46	-0.32	1.81e-16	Monocyte percentage of white cells;
BRCA	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg02228329	chr11:64053129	BAD;GPR137	0.53	11.77	0.42	4.42e-29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs2230307	0.536	rs7518943	chr1:100463422	G/T	cg24955406	chr1:100503596	HIAT1	0.59	11.65	0.42	1.4e-28	Carotid intima media thickness;
BRCA	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg06547715	chr2:218990976	CXCR2	0.32	7.94	0.3	9.05e-15	Ulcerative colitis;
BRCA	cis	rs2625529	0.730	rs3759900	chr15:72451827	A/C	cg16672083	chr15:72433130	SENP8	0.7	16.8	0.55	9.69e-53	Red blood cell count;
BRCA	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg04842962	chr6:43655489	MRPS18A	1.13	39.0	0.84	3.68e-171	IgG glycosylation;
BRCA	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.09	0.4	2.82e-26	Electroencephalogram traits;
BRCA	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg05340658	chr4:99064831	C4orf37	0.62	14.9	0.51	2.47e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg00701064	chr4:6280414	WFS1	0.68	18.23	0.58	4.13e-60	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs9649213	0.555	rs6955259	chr7:97892356	T/A	cg24562669	chr7:97807699	LMTK2	0.47	11.97	0.43	5.95e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg23711669	chr6:146136114	FBXO30	0.72	17.2	0.56	9.47e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg05347473	chr6:146136440	FBXO30	0.4	7.99	0.3	6.36e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10802521	chr3:52805072	NEK4	-0.33	-8.76	-0.33	1.75e-17	Bipolar disorder;
BRCA	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg26248373	chr2:1572462	NA	-0.67	-15.83	-0.53	7.21e-48	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg17366294	chr4:99064904	C4orf37	0.45	10.36	0.38	2.41e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg05340658	chr4:99064831	C4orf37	0.63	15.04	0.51	5.63e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1198430	1.000	rs1198439	chr1:23749593	A/T	cg19827787	chr1:23763612	ASAP3	0.35	9.7	0.36	7.71e-21	Total cholesterol levels;
BRCA	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24549020	chr5:56110836	MAP3K1	0.67	13.67	0.48	1.63e-37	Initial pursuit acceleration;
BRCA	cis	rs208520	0.661	rs207111	chr6:66792513	C/T	cg07460842	chr6:66804631	NA	-1.02	-20.41	-0.63	1.11e-71	Exhaled nitric oxide output;
BRCA	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg21280719	chr6:42927975	GNMT	-0.31	-12.84	-0.45	1.01e-33	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs28374715	0.662	rs111522288	chr15:41480169	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.86	-18.17	-0.58	8.71e-60	Ulcerative colitis;
BRCA	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg23029597	chr12:123009494	RSRC2	-0.58	-12.04	-0.43	3.07e-30	Body mass index;
BRCA	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	cis	rs4285028	0.699	rs1920297	chr3:121598000	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.71	-13.2	-0.46	2.4e-35	Multiple sclerosis;
BRCA	cis	rs9790314	0.645	rs10936224	chr3:160902531	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-14.07	-0.49	2.3e-39	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	11.8	0.42	3.22e-29	Schizophrenia;
BRCA	cis	rs17209837	0.646	rs4148818	chr7:87083738	T/C	cg00919237	chr7:87102261	ABCB4	-0.52	-10.19	-0.37	1.03e-22	Gallbladder cancer;
BRCA	cis	rs724568	0.546	rs966443	chr2:67940867	G/A	cg14046302	chr2:67939758	NA	-0.41	-10.97	-0.4	9.16e-26	Major depressive disorder (broad);
BRCA	trans	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg01620082	chr3:125678407	NA	-0.85	-9.89	-0.36	1.52e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg16586182	chr3:47516702	SCAP	0.57	12.97	0.46	2.7e-34	Colorectal cancer;
BRCA	cis	rs17401966	1.000	rs4845934	chr1:10468946	G/A	cg03954927	chr1:10346856	KIF1B	0.45	12.41	0.44	7.63e-32	Hepatocellular carcinoma;
BRCA	cis	rs495337	1.000	rs644013	chr20:48515838	T/C	cg17835207	chr20:48524531	SPATA2	-0.64	-14.6	-0.5	6.85e-42	Psoriasis;
BRCA	trans	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg06521331	chr12:34319734	NA	-0.55	-9.39	-0.35	9.99e-20	Bladder cancer;
BRCA	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg15819921	chr19:927150	ARID3A	-0.52	-10.09	-0.37	2.52e-22	Life satisfaction;
BRCA	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg13010199	chr12:38710504	ALG10B	0.46	9.02	0.34	2.17e-18	Morning vs. evening chronotype;
BRCA	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg24154853	chr7:158122151	PTPRN2	0.37	8.18	0.31	1.59e-15	Calcium levels;
BRCA	cis	rs6542838	0.641	rs6704682	chr2:99499602	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-9.13	-0.34	9.24e-19	Fear of minor pain;
BRCA	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg13319975	chr6:146136371	FBXO30	-0.4	-9.17	-0.34	6.2800000000000005e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg03585969	chr10:35415529	CREM	0.49	10.22	0.37	8.03e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg13047869	chr3:10149882	C3orf24	0.59	12.5	0.44	3.18e-32	Alzheimer's disease;
BRCA	cis	rs7809950	1.000	rs2808	chr7:107260856	A/G	cg23024343	chr7:107201750	COG5	0.37	8.46	0.32	1.86e-16	Coronary artery disease;
BRCA	trans	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg16011800	chr17:1958478	HIC1	0.53	8.77	0.33	1.67e-17	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg18132916	chr6:79620363	NA	-0.49	-11.12	-0.4	2.12e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg12863693	chr15:85201151	NMB	0.32	7.84	0.3	1.95e-14	P wave terminal force;
BRCA	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg08132940	chr7:1081526	C7orf50	-0.59	-8.77	-0.33	1.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg05791153	chr7:19748676	TWISTNB	0.62	10.94	0.4	1.21e-25	Thyroid stimulating hormone;
BRCA	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg14403583	chr14:105418241	AHNAK2	-0.38	-8.9	-0.33	5.67e-18	Rheumatoid arthritis;
BRCA	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg20503657	chr10:835505	NA	1.3	21.17	0.64	8.88e-76	Eosinophil percentage of granulocytes;
BRCA	trans	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg25214090	chr10:38739885	LOC399744	0.35	7.92	0.3	1.04e-14	Diastolic blood pressure;
BRCA	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg01689657	chr7:91764605	CYP51A1	-0.22	-7.85	-0.3	1.74e-14	Breast cancer;
BRCA	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.7	-0.36	7.54e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg05340658	chr4:99064831	C4orf37	0.59	12.8	0.45	1.47e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg01256987	chr12:42539512	GXYLT1	-0.57	-11.69	-0.42	9.68e-29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg26384229	chr12:38710491	ALG10B	0.76	16.94	0.56	1.95e-53	Bladder cancer;
BRCA	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	9.25	0.34	3.28e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs367943	0.966	rs348947	chr5:112822795	C/G	cg12552261	chr5:112820674	MCC	-0.55	-12.07	-0.43	2.28e-30	Type 2 diabetes;
BRCA	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg23708337	chr7:1209742	NA	0.64	8.82	0.33	1.09e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7833986	1.000	rs34608229	chr8:57097017	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.46	8.3	0.31	6.17e-16	Height;
BRCA	cis	rs9815354	1.000	rs28702390	chr3:41889920	C/A	cg03022575	chr3:42003672	ULK4	0.49	7.99	0.3	6.4e-15	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs4481887	0.893	rs10888337	chr1:248428227	A/G	cg00666640	chr1:248458726	OR2T12	-0.3	-8.8	-0.33	1.28e-17	Common traits (Other);
BRCA	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg17063962	chr7:91808500	NA	0.57	13.14	0.46	4.55e-35	Breast cancer;
BRCA	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-14.9	-0.51	2.52e-43	Bladder cancer;
BRCA	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg22875332	chr1:76189707	ACADM	0.69	14.27	0.49	2.63e-40	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg04455712	chr21:45112962	RRP1B	0.4	10.68	0.39	1.35e-24	Mean corpuscular volume;
BRCA	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg04166393	chr7:2884313	GNA12	0.6	12.22	0.44	5.26e-31	Height;
BRCA	trans	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.05	0.3	3.92e-15	Corneal astigmatism;
BRCA	cis	rs7572733	0.534	rs7557203	chr2:198795650	A/G	cg00792783	chr2:198669748	PLCL1	0.44	9.71	0.36	6.89e-21	Dermatomyositis;
BRCA	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg25664220	chr3:72788482	NA	-0.55	-11.74	-0.42	5.88e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg14835575	chr10:16859367	RSU1	0.64	13.08	0.46	8.16e-35	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs754466	1.000	rs2278218	chr10:79680399	G/A	cg17075019	chr10:79541650	NA	-0.68	-12.85	-0.45	8.95e-34	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg07138768	chr7:917805	C7orf20	0.29	8.32	0.31	5.13e-16	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs6942756	0.747	rs691435	chr7:129097352	C/T	cg02491457	chr7:128862824	NA	0.53	11.08	0.4	3.13e-26	White matter hyperintensity burden;
BRCA	cis	rs921968	0.565	rs3770220	chr2:219619550	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-11.06	-0.4	3.87e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg09184832	chr6:79620586	NA	-0.43	-8.6	-0.32	6.25e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg07606381	chr6:8435919	SLC35B3	-0.65	-14.56	-0.5	1.16e-41	Motion sickness;
BRCA	cis	rs708547	0.735	rs1277280	chr4:57866872	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	13.96	0.48	7.17e-39	Response to bleomycin (chromatid breaks);
BRCA	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg01324343	chr3:183735012	ABCC5	0.85	21.53	0.65	1.06e-77	Anterior chamber depth;
BRCA	trans	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg26043149	chr18:55253948	FECH	1.19	27.92	0.74	9.06e-113	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs2051211	0.895	rs17037798	chr3:38555474	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.48	-9.46	-0.35	5.86e-20	QRS duration;
BRCA	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg26384229	chr12:38710491	ALG10B	0.65	14.21	0.49	5e-40	Morning vs. evening chronotype;
BRCA	cis	rs9463078	0.764	rs9367211	chr6:44885305	T/C	cg25276700	chr6:44698697	NA	-0.36	-8.3	-0.31	6.38e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs13046373	0.508	rs13048637	chr21:31999055	T/G	cg16431978	chr21:31797932	KRTAP13-3	0.35	8.97	0.33	3.31e-18	HDL cholesterol;
BRCA	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	1.9e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7809950	1.000	rs10276604	chr7:107216738	C/T	cg23024343	chr7:107201750	COG5	0.37	8.08	0.3	3.24e-15	Coronary artery disease;
BRCA	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg13660082	chr14:53194042	PSMC6	-0.55	-8.15	-0.31	1.92e-15	Alzheimer's disease (late onset);
BRCA	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg11502198	chr6:26597334	ABT1	0.56	11.96	0.43	6.82e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.12	-0.31	2.39e-15	Total body bone mineral density;
BRCA	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg21475434	chr5:93447410	FAM172A	0.68	9.19	0.34	5.41e-19	Diabetic retinopathy;
BRCA	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	12.28	0.44	2.74e-31	Response to antipsychotic treatment;
BRCA	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg20607287	chr7:12443886	VWDE	-0.58	-8.36	-0.31	4.04e-16	Coronary artery disease;
BRCA	cis	rs250677	0.687	rs250679	chr5:148434952	A/T	cg18129178	chr5:148520854	ABLIM3	0.58	11.66	0.42	1.25e-28	Breast cancer;
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10819733	chr22:24237672	NA	0.32	8.56	0.32	8.64e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg17366294	chr4:99064904	C4orf37	0.41	9.24	0.34	3.51e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16405210	chr4:1374714	KIAA1530	-0.59	-13.67	-0.48	1.72e-37	Longevity;
BRCA	cis	rs9297145	0.761	rs112155177	chr7:98747963	C/T	cg05967295	chr7:98741636	SMURF1	0.84	15.8	0.53	9.76e-48	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg13798780	chr7:105162888	PUS7	-0.43	-8.08	-0.3	3.16e-15	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.33	0.49	1.31e-40	Motion sickness;
BRCA	cis	rs743757	1.000	rs734767	chr3:50431410	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.49	8.95	0.33	3.91e-18	Diastolic blood pressure;
BRCA	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg18252515	chr7:66147081	NA	-1.07	-15.54	-0.52	2.03e-46	Diabetic kidney disease;
BRCA	cis	rs36051895	0.659	rs12339666	chr9:5063296	A/C	cg02405213	chr9:5042618	JAK2	0.48	9.31	0.35	1.97e-19	Pediatric autoimmune diseases;
BRCA	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg06191203	chr2:152266755	RIF1	0.31	9.11	0.34	1.08e-18	Lung cancer;
BRCA	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg15556689	chr8:8085844	FLJ10661	0.46	13.09	0.46	7.14e-35	Mood instability;
BRCA	trans	rs8073060	0.544	rs17550716	chr17:33893208	A/G	cg19694781	chr19:47549865	TMEM160	0.99	21.09	0.64	2.51e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg26384229	chr12:38710491	ALG10B	0.67	14.02	0.49	4.13e-39	Morning vs. evening chronotype;
BRCA	cis	rs877529	1.000	rs139402	chr22:39546145	T/C	cg12193277	chr22:39547181	CBX7	0.46	12.59	0.45	1.3e-32	Multiple myeloma;
BRCA	trans	rs1941687	0.563	rs1586987	chr18:31338661	A/G	cg15819921	chr19:927150	ARID3A	-0.4	-8.11	-0.31	2.56e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg01324343	chr3:183735012	ABCC5	0.85	21.64	0.65	2.62e-78	Anterior chamber depth;
BRCA	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.43	0.57	6.27e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg06784218	chr1:46089804	CCDC17	0.45	10.78	0.39	5.36e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg21782813	chr7:2030301	MAD1L1	0.4	10.45	0.38	1.09e-23	Schizophrenia;
BRCA	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg20607798	chr8:58055168	NA	0.47	8.02	0.3	5.03e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg01579765	chr21:45077557	HSF2BP	-0.37	-9.9	-0.36	1.3e-21	Mean corpuscular volume;
BRCA	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg23950597	chr19:37808831	NA	-0.75	-13.01	-0.46	1.65e-34	Coronary artery calcification;
BRCA	trans	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg06521331	chr12:34319734	NA	-0.49	-9.37	-0.35	1.23e-19	Bladder cancer;
BRCA	cis	rs6785206	1.000	rs2712370	chr3:128425204	C/G	cg16766828	chr3:128327626	NA	-0.65	-9.97	-0.37	7.65e-22	Lymphocyte percentage of white cells;
BRCA	cis	rs1953600	1.000	rs1953600	chr10:81911725	A/G	cg04850286	chr10:81895943	PLAC9	0.34	9.97	0.37	7.4e-22	Sarcoidosis;
BRCA	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.56	-10.79	-0.39	4.95e-25	Response to bleomycin (chromatid breaks);
BRCA	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.39	-0.44	9.32e-32	Chronic sinus infection;
BRCA	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19346786	chr7:2764209	NA	-0.3	-9.38	-0.35	1.09e-19	Height;
BRCA	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg02659138	chr7:134003124	SLC35B4	0.36	11.27	0.41	5.18e-27	Mean platelet volume;
BRCA	trans	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg26384229	chr12:38710491	ALG10B	0.56	12.16	0.43	9.7e-31	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg23788917	chr6:8435910	SLC35B3	-0.48	-10.43	-0.38	1.21e-23	Motion sickness;
BRCA	cis	rs9462027	0.628	rs2492860	chr6:34705530	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.87	-0.3	1.55e-14	Systemic lupus erythematosus;
BRCA	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg09035930	chr12:129282057	SLC15A4	0.56	16.18	0.54	1.4e-49	Systemic lupus erythematosus;
BRCA	cis	rs6542838	0.583	rs7565819	chr2:99519265	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-8.91	-0.33	5.14e-18	Fear of minor pain;
BRCA	cis	rs7646881	1.000	rs73015654	chr3:158451654	G/A	cg19483011	chr3:158453295	NA	-0.49	-9.34	-0.35	1.61e-19	Tetralogy of Fallot;
BRCA	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg15017067	chr4:17643749	FAM184B	0.35	11.0	0.4	7.1e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg21573476	chr21:45109991	RRP1B	-0.4	-11.05	-0.4	4.27e-26	Mean corpuscular volume;
BRCA	trans	rs4650994	1.000	rs10913572	chr1:178526718	C/T	cg05059571	chr16:84539110	KIAA1609	-0.41	-9.22	-0.34	4.12e-19	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg18154014	chr19:37997991	ZNF793	0.55	10.28	0.38	4.63e-23	Coronary artery calcification;
BRCA	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg14993813	chr1:46806288	NSUN4	-0.47	-9.0	-0.34	2.6e-18	Menopause (age at onset);
BRCA	cis	rs616402	0.564	rs7419116	chr1:10578606	G/A	cg17425144	chr1:10567563	PEX14	0.57	15.36	0.52	1.54e-45	Breast size;
BRCA	cis	rs701145	0.938	rs701133	chr3:154070312	A/G	cg17054900	chr3:154042577	DHX36	0.66	11.41	0.41	1.46e-27	Coronary artery disease;
BRCA	cis	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.14	-0.4	1.81e-26	Morning vs. evening chronotype;
BRCA	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-11.63	-0.42	1.67e-28	Monocyte percentage of white cells;
BRCA	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg20203395	chr5:56204925	C5orf35	-0.5	-10.4	-0.38	1.59e-23	Initial pursuit acceleration;
BRCA	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg09184832	chr6:79620586	NA	-0.54	-11.97	-0.43	6.23e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg00677455	chr12:58241039	CTDSP2	0.62	14.49	0.5	2.27e-41	Multiple sclerosis;
BRCA	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.74	-0.39	7.44e-25	Mean corpuscular volume;
BRCA	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg16339924	chr4:17578868	LAP3	0.63	15.78	0.53	1.29e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7103648	0.567	rs12287076	chr11:47606865	G/C	cg03711944	chr11:47377212	SPI1	0.35	8.65	0.32	4.18e-17	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg26647111	chr11:31128758	NA	-0.42	-9.44	-0.35	6.61e-20	Red blood cell count;
BRCA	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg02153584	chr22:29168773	CCDC117	0.51	10.38	0.38	1.96e-23	Lymphocyte counts;
BRCA	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg25036284	chr2:26402008	FAM59B	-0.63	-10.53	-0.38	4.91e-24	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.59e-24	Motion sickness;
BRCA	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg18252515	chr7:66147081	NA	-0.96	-13.74	-0.48	8.26e-38	Diabetic kidney disease;
BRCA	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg08859206	chr1:53392774	SCP2	0.43	8.61	0.32	5.52e-17	Monocyte count;
BRCA	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg24531977	chr5:56204891	C5orf35	-0.5	-10.43	-0.38	1.24e-23	Coronary artery disease;
BRCA	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg08885076	chr2:99613938	TSGA10	-0.52	-11.73	-0.42	6.2e-29	Chronic sinus infection;
BRCA	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg18301423	chr5:131593218	PDLIM4	0.32	8.32	0.31	5.28e-16	Breast cancer;
BRCA	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg09904177	chr6:26538194	HMGN4	0.55	17.65	0.57	4.4e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg21045802	chr8:109455806	TTC35	0.35	7.89	0.3	1.32e-14	Dupuytren's disease;
BRCA	cis	rs300703	0.542	rs300696	chr2:183330	G/A	cg21211680	chr2:198530	NA	-0.39	-8.15	-0.31	1.98e-15	Blood protein levels;
BRCA	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15664640	chr17:80829946	TBCD	0.4	10.86	0.39	2.46e-25	Breast cancer;
BRCA	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-11.12	-0.4	2.2e-26	Schizophrenia;
BRCA	cis	rs919433	0.617	rs10460394	chr2:198548741	G/A	cg00792783	chr2:198669748	PLCL1	-0.43	-9.49	-0.35	4.38e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7809950	0.678	rs3801966	chr7:106824580	G/A	cg23024343	chr7:107201750	COG5	-0.45	-8.87	-0.33	7.51e-18	Coronary artery disease;
BRCA	cis	rs758324	0.898	rs7725041	chr5:131188503	C/A	cg06307176	chr5:131281290	NA	0.53	10.33	0.38	3.21e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs7246967	0.611	rs16999598	chr19:22943125	A/G	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg13660082	chr14:53194042	PSMC6	-0.56	-8.16	-0.31	1.79e-15	Alzheimer's disease (late onset);
BRCA	cis	rs58785573	0.570	rs1824652	chr4:38644597	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.52	11.5	0.41	5.79e-28	Lymphocyte percentage of white cells;
BRCA	cis	rs1003719	0.788	rs1543748	chr21:38446581	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.19	0.49	6.61e-40	Eye color traits;
BRCA	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	10.19	0.37	1.04e-22	Lung cancer in ever smokers;
BRCA	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.82	-13.7	-0.48	1.17e-37	Platelet count;
BRCA	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg14675211	chr2:100938903	LONRF2	0.5	11.1	0.4	2.58e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg07606381	chr6:8435919	SLC35B3	-0.58	-12.54	-0.44	2.13e-32	Motion sickness;
BRCA	cis	rs6743226	0.934	rs4234100	chr2:242265273	A/G	cg10021735	chr2:242295487	FARP2	-0.35	-9.59	-0.35	1.9e-20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs7945718	1.000	rs7945718	chr11:12748819	A/G	cg25843174	chr11:12811716	TEAD1	0.23	8.52	0.32	1.19e-16	Educational attainment (years of education);
BRCA	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg09184832	chr6:79620586	NA	-0.54	-12.1	-0.43	1.77e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg18446336	chr7:2847575	GNA12	-0.37	-7.96	-0.3	7.73e-15	Height;
BRCA	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.36	-0.38	2.35e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.54	0.57	1.68e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg23711669	chr6:146136114	FBXO30	0.71	17.22	0.56	7.25e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9462846	0.919	rs9462851	chr6:42890602	A/G	cg02353165	chr6:42928485	GNMT	0.5	9.64	0.36	1.3e-20	Blood protein levels;
BRCA	cis	rs10924970	0.687	rs28593631	chr1:235354572	A/T	cg26050004	chr1:235667680	B3GALNT2	0.35	8.66	0.32	3.81e-17	Asthma;
BRCA	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg06060754	chr5:176797920	RGS14	-0.66	-10.53	-0.38	5.03e-24	Urate levels in lean individuals;
BRCA	cis	rs17253792	0.822	rs10483643	chr14:56089931	G/C	cg01858014	chr14:56050164	KTN1	-0.75	-10.3	-0.38	4.01e-23	Putamen volume;
BRCA	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-11.77	-0.42	4.46e-29	Tonsillectomy;
BRCA	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	11.47	0.41	7.93e-28	Coronary artery disease;
BRCA	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs12348691	0.503	rs7023267	chr9:100603935	G/A	cg13688889	chr9:100608707	NA	-0.45	-9.29	-0.34	2.36e-19	Alopecia areata;
BRCA	cis	rs2882667	0.659	rs11750067	chr5:138256278	C/T	cg04439458	chr5:138467593	SIL1	-0.35	-8.54	-0.32	9.46e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg04546413	chr19:29218101	NA	0.64	12.33	0.44	1.75e-31	Methadone dose in opioid dependence;
BRCA	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-13.69	-0.48	1.4e-37	Mood instability;
BRCA	trans	rs1973993	0.691	rs2985636	chr1:96889884	T/A	cg10631902	chr5:14652156	NA	0.57	19.7	0.61	7.41e-68	Weight;
BRCA	cis	rs6586163	0.527	rs12775501	chr10:90750909	C/T	cg03111039	chr10:90751583	FAS;ACTA2	0.56	12.86	0.45	7.73e-34	Chronic lymphocytic leukemia;
BRCA	cis	rs6743226	0.748	rs12620606	chr2:242154015	A/G	cg10021735	chr2:242295487	FARP2	0.32	8.6	0.32	6.06e-17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.37	7.91	0.3	1.11e-14	Osteoporosis;
BRCA	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.69	14.08	0.49	2.18e-39	Lymphocyte counts;
BRCA	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg24130564	chr14:104152367	KLC1	0.36	8.04	0.3	4.49e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg18016565	chr1:150552671	MCL1	-0.38	-8.77	-0.33	1.57e-17	Tonsillectomy;
BRCA	cis	rs965469	0.779	rs6037534	chr20:3269832	G/A	cg25506879	chr20:3388711	C20orf194	-0.44	-8.81	-0.33	1.17e-17	IFN-related cytopenia;
BRCA	cis	rs911119	0.955	rs6048933	chr20:23595637	T/G	cg16589663	chr20:23618590	CST3	0.43	7.95	0.3	8.67e-15	Chronic kidney disease;
BRCA	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg08999081	chr20:33150536	PIGU	-0.45	-12.23	-0.44	4.51e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg08514558	chr10:81106712	PPIF	0.39	8.85	0.33	8.34e-18	Height;
BRCA	cis	rs495337	1.000	rs4810997	chr20:48579348	G/T	cg17835207	chr20:48524531	SPATA2	-0.62	-14.44	-0.5	4.02e-41	Psoriasis;
BRCA	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.56	-14.93	-0.51	1.85e-43	Longevity;Endometriosis;
BRCA	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg25358565	chr5:93447407	FAM172A	-1.0	-16.29	-0.54	3.91e-50	Diabetic retinopathy;
BRCA	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.82e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs74181299	0.750	rs58342673	chr2:65347584	T/C	cg05010058	chr2:65284262	CEP68	-0.3	-8.36	-0.31	3.9e-16	Pulse pressure;
BRCA	cis	rs4664304	0.620	rs11895141	chr2:160716449	T/A	cg01092293	chr2:160761427	LY75	0.36	8.51	0.32	1.24e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg04234412	chr22:24373322	LOC391322	0.69	17.79	0.58	7.87e-58	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.14	0.34	8.5e-19	Tonsillectomy;
BRCA	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-10.6	-0.39	2.74e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27286337	chr10:134555280	INPP5A	0.79	12.95	0.46	3.09e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg04362960	chr10:104952993	NT5C2	0.57	11.46	0.41	8.85e-28	Arsenic metabolism;
BRCA	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg14440974	chr22:39074834	NA	-0.38	-9.0	-0.34	2.64e-18	Menopause (age at onset);
BRCA	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-13.69	-0.48	1.39e-37	Hemoglobin concentration;
BRCA	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.55	10.69	0.39	1.21e-24	HDL cholesterol;
BRCA	cis	rs867371	1.000	rs8041868	chr15:82472326	C/T	cg00614314	chr15:82944287	LOC80154	0.44	9.3	0.35	2.19e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg20607798	chr8:58055168	NA	0.55	8.55	0.32	9.05e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.96	20.91	0.64	2.36e-74	Lymphocyte percentage of white cells;
BRCA	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.51	-14.88	-0.51	3.07e-43	Lung cancer;
BRCA	cis	rs7011049	1.000	rs72643599	chr8:53854434	A/G	cg26025543	chr8:53854495	NA	0.55	9.49	0.35	4.66e-20	Systolic blood pressure;
BRCA	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg12935359	chr14:103987150	CKB	0.64	14.95	0.51	1.57e-43	Intelligence (multi-trait analysis);
BRCA	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg26446133	chr18:72167187	CNDP2	-0.74	-12.9	-0.45	5.07e-34	Refractive error;
BRCA	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	1.98e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg03433033	chr1:76189801	ACADM	0.76	17.01	0.56	8.25e-54	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg01191920	chr7:158217561	PTPRN2	0.36	8.54	0.32	1.02e-16	Obesity-related traits;
BRCA	cis	rs7301826	0.651	rs10734979	chr12:131288954	T/C	cg11011512	chr12:131303247	STX2	0.51	13.62	0.47	2.86e-37	Plasma plasminogen activator levels;
BRCA	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg03684893	chr10:554711	DIP2C	0.36	8.04	0.3	4.49e-15	Psychosis in Alzheimer's disease;
BRCA	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg18402987	chr7:1209562	NA	0.43	8.5	0.32	1.39e-16	Longevity;Endometriosis;
BRCA	cis	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg17469321	chr7:55412551	NA	0.52	9.89	0.36	1.49e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg04455712	chr21:45112962	RRP1B	0.39	10.6	0.39	2.59e-24	Mean corpuscular volume;
BRCA	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg04450456	chr4:17643702	FAM184B	0.37	11.06	0.4	3.78e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9287719	0.614	rs10929679	chr2:10723108	C/T	cg00105475	chr2:10696890	NA	0.41	9.12	0.34	9.77e-19	Prostate cancer;
BRCA	trans	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg07211511	chr3:129823064	LOC729375	-0.57	-10.27	-0.38	5.06e-23	Blood pressure (smoking interaction);
BRCA	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg24399712	chr22:39784796	NA	-0.58	-12.43	-0.44	6.41e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-10.48	-0.38	7.97e-24	Mean corpuscular volume;
BRCA	cis	rs11690935	0.921	rs10200608	chr2:172597929	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.93	-30.93	-0.77	4.04e-129	Schizophrenia;
BRCA	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg14664628	chr15:75095509	CSK	-0.94	-27.33	-0.73	1.67e-109	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg11645453	chr3:52864694	ITIH4	-0.38	-10.07	-0.37	3.01e-22	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6973256	0.901	rs2991231	chr7:133321915	T/C	cg07491979	chr7:133331646	EXOC4	-0.38	-8.57	-0.32	7.97e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg23950597	chr19:37808831	NA	-0.62	-11.37	-0.41	2.02e-27	Coronary artery calcification;
BRCA	cis	rs17685	0.712	rs869805	chr7:75688596	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-8.94	-0.33	4.08e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2882667	0.658	rs288003	chr5:138231955	T/G	cg04439458	chr5:138467593	SIL1	-0.34	-8.4	-0.32	2.97e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6763687	0.828	rs6773362	chr3:171779873	T/G	cg16233210	chr3:171778391	FNDC3B	0.38	8.33	0.31	4.78e-16	Red cell distribution width;
BRCA	cis	rs9549260	0.753	rs61963266	chr13:41171036	G/A	cg21288729	chr13:41239152	FOXO1	0.55	8.8	0.33	1.3e-17	Red blood cell count;
BRCA	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03517284	chr6:25882590	NA	-0.45	-9.45	-0.35	6.5e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg17724175	chr1:150552817	MCL1	0.26	8.25	0.31	8.94e-16	Tonsillectomy;
BRCA	trans	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg25214090	chr10:38739885	LOC399744	0.51	10.62	0.39	2.34e-24	Corneal astigmatism;
BRCA	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-9.26	-0.34	3.05e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg11789530	chr4:8429930	ACOX3	0.69	18.07	0.58	2.75e-59	Response to antineoplastic agents;
BRCA	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg19717773	chr7:2847554	GNA12	-0.43	-9.68	-0.36	8.72e-21	Height;
BRCA	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-9.2	-0.34	5.07e-19	Total body bone mineral density;
BRCA	trans	rs629535	0.735	rs525610	chr8:70074535	A/G	cg21567404	chr3:27674614	NA	1.01	21.1	0.64	2.2100000000000001e-75	Dupuytren's disease;
BRCA	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg17063962	chr7:91808500	NA	0.54	12.71	0.45	3.65e-33	Breast cancer;
BRCA	trans	rs2840044	0.963	rs225247	chr17:33944590	T/A	cg19694781	chr19:47549865	TMEM160	-0.45	-10.52	-0.38	5.73e-24	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg01483505	chr11:975446	AP2A2	-0.3	-8.12	-0.31	2.43e-15	Alzheimer's disease (late onset);
BRCA	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	11.3	0.41	3.91e-27	Multiple sclerosis;
BRCA	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg24829409	chr8:58192753	C8orf71	-0.57	-11.87	-0.43	1.6e-29	Developmental language disorder (linguistic errors);
BRCA	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg02733842	chr7:1102375	C7orf50	-0.71	-12.41	-0.44	8.08e-32	Bronchopulmonary dysplasia;
BRCA	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg00686598	chr14:53173677	PSMC6	1.23	16.58	0.55	1.3e-51	Alzheimer's disease (late onset);
BRCA	cis	rs4719841	0.651	rs7789194	chr7:25992510	T/C	cg24254488	chr7:25991654	NA	-0.26	-7.94	-0.3	9.05e-15	Triglyceride levels;
BRCA	cis	rs7809950	1.000	rs10251808	chr7:107120453	G/A	cg23024343	chr7:107201750	COG5	-0.43	-9.95	-0.37	8.6e-22	Coronary artery disease;
BRCA	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg13010199	chr12:38710504	ALG10B	0.51	10.0	0.37	5.84e-22	Bladder cancer;
BRCA	cis	rs17253792	0.822	rs10142497	chr14:56047948	C/T	cg01858014	chr14:56050164	KTN1	0.78	11.54	0.42	3.89e-28	Putamen volume;
BRCA	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg08603382	chr10:743973	NA	0.42	7.91	0.3	1.13e-14	Psychosis in Alzheimer's disease;
BRCA	cis	rs858239	0.899	rs28635122	chr7:23310181	C/T	cg23682824	chr7:23144976	KLHL7	0.36	9.1	0.34	1.12e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-10.55	-0.39	4.31e-24	Mood instability;
BRCA	trans	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg06521331	chr12:34319734	NA	-0.44	-8.35	-0.31	4.37e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg10932868	chr11:921992	NA	-0.5	-12.92	-0.46	4.26e-34	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	1.9e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2455601	0.882	rs11042105	chr11:8894510	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-8.25	-0.31	8.83e-16	Schizophrenia;
BRCA	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg19847866	chr10:1019161	NA	-0.51	-10.06	-0.37	3.33e-22	Response to angiotensin II receptor blocker therapy;
BRCA	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg13010199	chr12:38710504	ALG10B	-0.48	-9.3	-0.35	2.11e-19	Morning vs. evening chronotype;
BRCA	cis	rs2479724	0.811	rs6905726	chr6:41750812	T/C	cg17623882	chr6:41773611	USP49	0.33	8.85	0.33	8.72e-18	Menarche (age at onset);
BRCA	cis	rs10496034	1.000	rs76438263	chr2:55160965	G/A	cg16098955	chr2:55172992	EML6	0.53	9.73	0.36	6.01e-21	Refractive astigmatism;
BRCA	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11764359	chr7:65958608	NA	0.75	17.42	0.57	7.03e-56	Aortic root size;
BRCA	cis	rs4268898	0.760	rs4665675	chr2:24468132	C/T	cg06627628	chr2:24431161	ITSN2	-0.4	-8.57	-0.32	8.06e-17	Asthma;
BRCA	cis	rs9309473	1.000	rs13384952	chr2:73723959	C/T	cg20560298	chr2:73613845	ALMS1	0.45	9.42	0.35	8.16e-20	Metabolite levels;
BRCA	cis	rs4499344	0.633	rs259229	chr19:33134425	A/G	cg22980127	chr19:33182716	NUDT19	0.45	9.16	0.34	6.85e-19	Mean platelet volume;
BRCA	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-10.15	-0.37	1.53e-22	Alzheimer's disease;
BRCA	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg22764044	chr5:178986830	RUFY1	0.4	9.6	0.36	1.72e-20	Lung cancer;
BRCA	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg06191203	chr2:152266755	RIF1	0.34	9.93	0.37	1.08e-21	Squamous cell lung carcinoma;
BRCA	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg13010199	chr12:38710504	ALG10B	-0.36	-8.47	-0.32	1.68e-16	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.66e-18	Motion sickness;
BRCA	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs870825	0.587	rs58332461	chr4:185639742	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	17.43	0.57	5.93e-56	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.56	0.39	3.97e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs701145	0.585	rs12493885	chr3:153839866	G/C	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.82e-18	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg24829409	chr8:58192753	C8orf71	-0.49	-9.25	-0.34	3.23e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-14.19	-0.49	6.19e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg16586182	chr3:47516702	SCAP	0.65	15.13	0.51	1.95e-44	Colorectal cancer;
BRCA	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs501916	0.605	rs2118917	chr15:48078992	C/T	cg16110827	chr15:48056943	SEMA6D	-0.4	-8.6	-0.32	6.13e-17	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs10431058	1.000	rs10431058	chr11:107481518	A/G	cg18204760	chr11:107461044	ELMOD1;LOC643923	-0.42	-9.39	-0.35	1.04e-19	Common traits (Other);
BRCA	cis	rs9790314	0.639	rs6769642	chr3:160763469	C/A	cg03342759	chr3:160939853	NMD3	-0.5	-9.48	-0.35	4.95e-20	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.35	0.57	1.52e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg24562669	chr7:97807699	LMTK2	0.5	12.51	0.44	2.8e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs17253792	0.822	rs12323476	chr14:56172722	C/T	cg01858014	chr14:56050164	KTN1	0.53	8.72	0.33	2.38e-17	Putamen volume;
BRCA	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg18016565	chr1:150552671	MCL1	0.34	8.12	0.31	2.43e-15	Tonsillectomy;
BRCA	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg05313129	chr8:58192883	C8orf71	-0.45	-9.71	-0.36	7.17e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg18252515	chr7:66147081	NA	-0.56	-11.32	-0.41	3.29e-27	Corneal structure;
BRCA	cis	rs7633857	0.536	rs1447609	chr3:160696311	A/G	cg03342759	chr3:160939853	NMD3	-0.45	-9.34	-0.35	1.55e-19	Educational attainment (years of education);
BRCA	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg04944784	chr2:26401820	FAM59B	-0.68	-11.19	-0.4	1.19e-26	Gut microbiome composition (summer);
BRCA	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg13385521	chr17:29058706	SUZ12P	0.74	10.21	0.37	9.16e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg00857998	chr1:205179979	DSTYK	0.41	8.19	0.31	1.42e-15	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-9.61	-0.36	1.69e-20	Menopause (age at onset);
BRCA	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg11752832	chr7:134001865	SLC35B4	0.54	13.85	0.48	2.58e-38	Mean platelet volume;
BRCA	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.24	0.38	6.86e-23	Heart rate;
BRCA	cis	rs919433	0.680	rs1563340	chr2:198414713	A/T	cg00792783	chr2:198669748	PLCL1	0.38	8.48	0.32	1.55e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg12591125	chr7:1885375	MAD1L1	0.5	8.69	0.33	3.1e-17	Bipolar disorder;
BRCA	cis	rs11945232	1.000	rs28372775	chr4:88343704	G/A	cg23841344	chr4:88312519	HSD17B11	-0.49	-9.56	-0.35	2.43e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6580649	0.843	rs3803184	chr12:48398002	G/C	cg05342945	chr12:48394962	COL2A1	-0.47	-9.55	-0.35	2.64e-20	Lung cancer;
BRCA	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg02820040	chr2:241836501	C2orf54	-0.48	-8.68	-0.32	3.33e-17	Urinary metabolites;
BRCA	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.56	-14.06	-0.49	2.53e-39	Electrocardiographic conduction measures;
BRCA	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg06115741	chr20:33292138	TP53INP2	0.49	11.17	0.4	1.43e-26	Coronary artery disease;
BRCA	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg09307838	chr4:120376055	NA	0.7	14.3	0.49	1.96e-40	Corneal astigmatism;
BRCA	cis	rs11051970	0.636	rs1045751	chr12:32569496	T/C	cg24626660	chr12:32551988	NA	0.31	8.97	0.33	3.16e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg06640241	chr16:89574553	SPG7	0.75	17.65	0.57	4.11e-57	Multiple myeloma (IgH translocation);
BRCA	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.44	-9.6	-0.36	1.77e-20	IgG glycosylation;
BRCA	trans	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg26043149	chr18:55253948	FECH	-0.37	-8.3	-0.31	6.41e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg01939980	chr4:1354348	KIAA1530	0.38	10.6	0.39	2.79e-24	Longevity;
BRCA	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-14.0	-0.48	4.93e-39	Platelet count;
BRCA	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg10223061	chr2:219282414	VIL1	-0.27	-8.01	-0.3	5.33e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4713675	0.584	rs7739505	chr6:33670370	G/A	cg14003231	chr6:33640908	ITPR3	0.33	8.11	0.31	2.53e-15	Plateletcrit;
BRCA	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg18811423	chr2:55921094	PNPT1	0.69	21.1	0.64	2.14e-75	Metabolic syndrome;
BRCA	cis	rs10504073	0.647	rs4873312	chr8:49991145	A/G	cg00325661	chr8:49890786	NA	0.44	12.39	0.44	9.81e-32	Blood metabolite ratios;
BRCA	cis	rs1883415	0.534	rs760906	chr6:24479845	C/T	cg20631270	chr6:24437470	GPLD1	-0.39	-8.04	-0.3	4.52e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11644478	chr21:40555479	PSMG1	-0.5	-10.5	-0.38	6.41e-24	Menarche (age at onset);
BRCA	cis	rs10045504	0.502	rs72746031	chr5:38743161	G/A	cg15396434	chr5:38725168	NA	-0.57	-10.76	-0.39	6.43e-25	Night sleep phenotypes;
BRCA	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg15839431	chr19:19639596	YJEFN3	0.41	9.0	0.34	2.54e-18	Bipolar disorder;
BRCA	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.43	-0.32	2.27e-16	Monocyte percentage of white cells;
BRCA	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg00757033	chr12:89920650	WDR51B	0.52	10.54	0.38	4.66e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7714584	1.000	rs11167515	chr5:150239471	G/T	cg22134413	chr5:150180641	NA	0.69	10.58	0.39	3.26e-24	Crohn's disease;
BRCA	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg07828340	chr4:882639	GAK	-1.04	-14.73	-0.5	1.68e-42	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg25214090	chr10:38739885	LOC399744	0.54	12.12	0.43	1.39e-30	Corneal astigmatism;
BRCA	trans	rs4942242	1.000	rs9562501	chr13:44205683	C/T	cg19169023	chr15:41853346	TYRO3	-0.48	-11.22	-0.41	8.89e-27	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg24562669	chr7:97807699	LMTK2	-0.45	-12.0	-0.43	4.77e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg23950597	chr19:37808831	NA	-0.62	-11.45	-0.41	9.99e-28	Coronary artery calcification;
BRCA	cis	rs965469	1.000	rs6051702	chr20:3251924	A/C	cg25506879	chr20:3388711	C20orf194	-0.56	-10.92	-0.4	1.46e-25	IFN-related cytopenia;
BRCA	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7131987	0.650	rs11050208	chr12:29510369	T/G	cg09582351	chr12:29534625	ERGIC2	-0.49	-10.26	-0.38	5.53e-23	QT interval;
BRCA	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.96	-0.3	8.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs965469	1.000	rs2281494	chr20:3235494	A/G	cg25506879	chr20:3388711	C20orf194	-0.55	-10.28	-0.38	4.89e-23	IFN-related cytopenia;
BRCA	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.54	-11.95	-0.43	7.32e-30	Longevity;Endometriosis;
BRCA	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.23	0.74	1.93e-114	Chronic sinus infection;
BRCA	cis	rs2294693	0.947	rs742492	chr6:40996381	G/A	cg14418226	chr6:40996092	UNC5CL	0.45	8.24	0.31	1.01e-15	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg05283184	chr6:79620031	NA	-0.43	-10.99	-0.4	7.52e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs10242455	0.702	rs45461000	chr7:99052710	A/G	cg18809830	chr7:99032528	PTCD1	-0.64	-9.09	-0.34	1.18e-18	Blood metabolite levels;
BRCA	cis	rs2882667	0.858	rs11957633	chr5:138364394	T/C	cg04439458	chr5:138467593	SIL1	-0.42	-10.63	-0.39	2.11e-24	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg13902645	chr11:5959945	NA	-0.55	-12.76	-0.45	2.19e-33	DNA methylation (variation);
BRCA	cis	rs2625529	0.824	rs1074330	chr15:72250741	C/T	cg16672083	chr15:72433130	SENP8	-0.84	-17.46	-0.57	4.01e-56	Red blood cell count;
BRCA	cis	rs13064411	0.518	rs1552433	chr3:113225730	C/A	cg18753928	chr3:113234510	CCDC52	-0.4	-9.05	-0.34	1.77e-18	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	13.56	0.47	5.28e-37	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg24069376	chr3:38537580	EXOG	0.43	12.16	0.43	9.35e-31	Electrocardiographic conduction measures;
BRCA	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	10.02	0.37	4.7e-22	Breast cancer;
BRCA	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-10.76	-0.39	6.44e-25	Longevity;Endometriosis;
BRCA	cis	rs11112613	0.713	rs58066965	chr12:105952505	C/G	cg03607813	chr12:105948248	NA	0.55	10.43	0.38	1.25e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg11271282	chr2:238384023	NA	-0.44	-8.09	-0.3	2.99e-15	Prostate cancer;
BRCA	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.56	-13.42	-0.47	2.26e-36	Mean platelet volume;
BRCA	cis	rs2882667	0.824	rs13189485	chr5:138475401	C/T	cg04439458	chr5:138467593	SIL1	-0.44	-11.09	-0.4	2.93e-26	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs17270561	0.609	rs9379778	chr6:25687579	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	8.87	0.33	7.32e-18	Iron status biomarkers;
BRCA	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg26818010	chr10:134567672	INPP5A	-0.78	-15.71	-0.53	2.93e-47	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2964802	0.505	rs6897847	chr5:10831632	T/C	cg14521931	chr5:10832172	NA	-0.58	-13.23	-0.46	1.79e-35	Major depressive disorder;Recurrent major depressive disorder;
BRCA	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg27535305	chr1:53392650	SCP2	0.32	7.89	0.3	1.28e-14	Monocyte count;
BRCA	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.25	-0.31	9.02e-16	Bipolar disorder;
BRCA	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11764359	chr7:65958608	NA	-0.76	-16.73	-0.55	2.33e-52	Aortic root size;
BRCA	cis	rs9487051	0.834	rs6919423	chr6:109558471	C/T	cg21918786	chr6:109611834	NA	-0.33	-8.52	-0.32	1.12e-16	Reticulocyte fraction of red cells;
BRCA	cis	rs41005	1.000	rs12692349	chr2:8114312	G/A	cg03155496	chr2:8117019	LOC339788	-0.56	-15.07	-0.51	3.76e-44	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg26408565	chr15:76604113	ETFA	0.52	11.91	0.43	1.08e-29	Blood metabolite levels;
BRCA	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg20790798	chr5:1857306	NA	-0.38	-8.96	-0.33	3.51e-18	Cardiovascular disease risk factors;
BRCA	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg06623918	chr6:96969491	KIAA0776	0.74	12.97	0.46	2.61e-34	Migraine;Coronary artery disease;
BRCA	cis	rs12579753	1.000	rs10862373	chr12:82250657	A/G	cg07988820	chr12:82153109	PPFIA2	-0.52	-8.7	-0.33	2.74e-17	Resting heart rate;
BRCA	cis	rs7520050	0.931	rs6686134	chr1:46378268	A/G	cg24296786	chr1:45957014	TESK2	0.43	9.78	0.36	3.77e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs877529	0.932	rs139398	chr22:39544970	C/G	cg12193277	chr22:39547181	CBX7	0.48	12.96	0.46	2.87e-34	Multiple myeloma;
BRCA	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg06115741	chr20:33292138	TP53INP2	0.39	8.58	0.32	7.19e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.39	-0.41	1.75e-27	Gut microbiome composition (summer);
BRCA	cis	rs2625529	0.652	rs7497104	chr15:72154000	C/T	cg16672083	chr15:72433130	SENP8	-0.69	-16.53	-0.55	2.25e-51	Red blood cell count;
BRCA	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg23791538	chr6:167370224	RNASET2	0.5	12.63	0.45	8.12e-33	Crohn's disease;
BRCA	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg13047869	chr3:10149882	C3orf24	0.51	11.08	0.4	3.1e-26	Alzheimer's disease;
BRCA	cis	rs4812048	0.901	rs151355	chr20:57607645	G/C	cg14073986	chr20:57617431	SLMO2	0.45	8.38	0.31	3.38e-16	Mean platelet volume;
BRCA	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26168224	chr5:2018326	NA	0.64	17.92	0.58	1.81e-58	Gut microbiome composition (winter);
BRCA	cis	rs912057	0.797	rs1294430	chr6:6744698	A/G	cg06612196	chr6:6737390	NA	0.4	8.86	0.33	7.98e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg05340658	chr4:99064831	C4orf37	0.45	10.39	0.38	1.87e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2880765	0.835	rs4843062	chr15:86040137	A/G	cg10818794	chr15:86012489	AKAP13	-0.29	-8.1	-0.31	2.84e-15	Coronary artery disease;
BRCA	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg20908204	chr19:46285434	DMPK	-0.27	-8.05	-0.3	4.19e-15	Coronary artery disease;
BRCA	cis	rs6815814	0.851	rs9715769	chr4:38774489	A/C	cg06935464	chr4:38784597	TLR10	0.48	8.15	0.31	1.96e-15	Breast cancer;
BRCA	cis	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg07460842	chr6:66804631	NA	0.57	9.87	0.36	1.74e-21	Type 2 diabetes;
BRCA	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg00631329	chr6:26305371	NA	-0.41	-11.31	-0.41	3.51e-27	Educational attainment;
BRCA	trans	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.46	-8.75	-0.33	1.92e-17	Monocyte count;
BRCA	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	8.14	0.31	2.1e-15	Diabetic retinopathy;
BRCA	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-9.21	-0.34	4.59e-19	Menopause (age at onset);
BRCA	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.62e-18	Alzheimer's disease (late onset);
BRCA	cis	rs4363385	0.747	rs6671414	chr1:152974119	C/T	cg25856811	chr1:152973957	SPRR3	-0.35	-9.3	-0.35	2.18e-19	Inflammatory skin disease;
BRCA	cis	rs3767633	0.925	rs10733044	chr1:161903534	A/G	cg09175582	chr1:161736000	ATF6	-0.52	-8.34	-0.31	4.41e-16	IgG glycosylation;
BRCA	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.47	-8.98	-0.33	2.98e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg04990556	chr1:26633338	UBXN11	0.68	11.87	0.42	1.7e-29	Obesity-related traits;
BRCA	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-1.1	-20.09	-0.62	5.61e-70	Platelet count;
BRCA	cis	rs9463078	0.838	rs9395066	chr6:45095163	A/C	cg25276700	chr6:44698697	NA	-0.36	-8.2	-0.31	1.36e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg23950597	chr19:37808831	NA	-0.74	-13.09	-0.46	7.77e-35	Coronary artery calcification;
BRCA	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg23505145	chr19:12996616	KLF1	0.54	12.31	0.44	2.07e-31	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg13565492	chr6:43139072	SRF	-0.9	-16.34	-0.54	2.14e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg18252515	chr7:66147081	NA	-0.86	-12.34	-0.44	1.53e-31	Diabetic kidney disease;
BRCA	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg19077165	chr18:44547161	KATNAL2	-0.56	-12.2	-0.43	6.06e-31	Personality dimensions;
BRCA	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10802521	chr3:52805072	NEK4	-0.33	-9.1	-0.34	1.13e-18	Bipolar disorder;
BRCA	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg00677455	chr12:58241039	CTDSP2	-0.35	-7.88	-0.3	1.39e-14	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs3820928	0.904	rs6735069	chr2:227893660	A/G	cg11843606	chr2:227700838	RHBDD1	-0.36	-7.82	-0.3	2.15e-14	Pulmonary function;
BRCA	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.73e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg27129171	chr3:47204927	SETD2	0.72	17.71	0.57	2.19e-57	Colorectal cancer;
BRCA	trans	rs783540	0.967	rs2567635	chr15:83262181	T/G	cg18393722	chr15:85113863	UBE2QP1	-0.26	-8.16	-0.31	1.83e-15	Schizophrenia;
BRCA	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg06046430	chr4:77819534	ANKRD56	0.6	13.28	0.47	1.01e-35	Emphysema distribution in smoking;
BRCA	cis	rs3739998	0.647	rs7920686	chr10:30317838	A/G	cg00730780	chr10:30316187	KIAA1462	0.54	11.53	0.41	4.5e-28	Coronary heart disease;
BRCA	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-10.87	-0.4	2.25e-25	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.45	8.02	0.3	5e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.7	16.4	0.54	9.98e-51	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7640424	0.620	rs7637244	chr3:107815763	T/A	cg09227934	chr3:107805635	CD47	-0.43	-8.19	-0.31	1.44e-15	Body mass index;
BRCA	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg12564285	chr5:131593104	PDLIM4	0.31	8.2	0.31	1.34e-15	Blood metabolite levels;
BRCA	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05025164	chr4:1340916	KIAA1530	0.77	15.84	0.53	6.32e-48	Longevity;
BRCA	cis	rs6087990	0.806	rs6088008	chr20:31382860	A/G	cg13636640	chr20:31349939	DNMT3B	0.61	19.0	0.6	3.93e-64	Ulcerative colitis;
BRCA	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg02389323	chr16:88786976	FAM38A	0.97	13.73	0.48	8.67e-38	Plateletcrit;
BRCA	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg20607798	chr8:58055168	NA	0.53	8.3	0.31	6.13e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.41	-8.96	-0.33	3.61e-18	Cognitive ability;
BRCA	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg23033748	chr14:75592666	NEK9	0.36	8.52	0.32	1.18e-16	Height;
BRCA	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg15017067	chr4:17643749	FAM184B	0.32	9.99	0.37	5.99e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-14.71	-0.5	2.23e-42	Hemoglobin concentration;
BRCA	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg19508488	chr2:152266495	RIF1	0.51	10.48	0.38	8.25e-24	Lung cancer;
BRCA	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg20283391	chr11:68216788	NA	-0.48	-9.33	-0.35	1.74e-19	Total body bone mineral density;
BRCA	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-11.08	-0.4	3.19e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs34779708	0.931	rs34087268	chr10:35346724	T/G	cg03585969	chr10:35415529	CREM	0.56	11.49	0.41	6.91e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-9.89	-0.36	1.43e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7590368	0.961	rs2357815	chr2:10959769	C/T	cg15705551	chr2:10952987	PDIA6	0.44	8.14	0.31	2.02e-15	Educational attainment (years of education);
BRCA	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	20.35	0.63	2.46e-71	Platelet count;
BRCA	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg06784218	chr1:46089804	CCDC17	-0.52	-12.51	-0.44	2.7e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.34	9.44	0.35	6.71e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg00857998	chr1:205179979	DSTYK	0.45	8.42	0.32	2.42e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg24006582	chr15:45444508	DUOX1	0.6	11.65	0.42	1.42e-28	Uric acid levels;
BRCA	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.56	0.35	2.56e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03264133	chr6:25882463	NA	-0.49	-11.01	-0.4	6.3e-26	Blood metabolite levels;
BRCA	cis	rs7572733	0.534	rs700673	chr2:198692929	A/G	cg00792783	chr2:198669748	PLCL1	0.47	10.16	0.37	1.34e-22	Dermatomyositis;
BRCA	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg08999081	chr20:33150536	PIGU	0.46	12.85	0.45	8.96e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg13660082	chr14:53194042	PSMC6	-0.57	-8.16	-0.31	1.8e-15	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg25036284	chr2:26402008	FAM59B	0.96	15.93	0.53	2.36e-48	Gut microbiome composition (summer);
BRCA	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg03060546	chr3:49711283	APEH	-0.57	-7.85	-0.3	1.79e-14	Cognitive function;
BRCA	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.15	0.31	1.99e-15	Axial length;
BRCA	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg11766577	chr21:47581405	C21orf56	-0.45	-10.15	-0.37	1.53e-22	Testicular germ cell tumor;
BRCA	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.66	-0.57	3.68e-57	Chronic sinus infection;
BRCA	cis	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg06521331	chr12:34319734	NA	-0.63	-12.2	-0.43	6.34e-31	Morning vs. evening chronotype;
BRCA	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg15556689	chr8:8085844	FLJ10661	-0.32	-8.68	-0.32	3.37e-17	Neuroticism;
BRCA	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg11584989	chr19:19387371	SF4	0.62	12.66	0.45	6.47e-33	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.64e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg18402987	chr7:1209562	NA	-0.44	-8.41	-0.32	2.75e-16	Longevity;Endometriosis;
BRCA	cis	rs11690935	0.632	rs6433323	chr2:172873060	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.54	-13.66	-0.48	1.86e-37	Schizophrenia;
BRCA	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg26116260	chr4:7069785	GRPEL1	-0.84	-16.4	-0.54	1.08e-50	Monocyte percentage of white cells;
BRCA	cis	rs1882538	0.503	rs13240997	chr7:133135373	C/A	cg10665199	chr7:133106180	EXOC4	0.47	9.53	0.35	3.15e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.747	rs61811427	chr1:152968419	C/T	cg21543102	chr1:152974771	SPRR3	-0.3	-8.22	-0.31	1.16e-15	Inflammatory skin disease;
BRCA	cis	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg07460842	chr6:66804631	NA	0.98	19.59	0.61	2.75e-67	Exhaled nitric oxide output;
BRCA	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg05343316	chr1:45956843	TESK2	0.7	14.26	0.49	2.98e-40	Platelet count;
BRCA	cis	rs11997175	0.766	rs56803376	chr8:33687676	T/C	ch.8.33884649F	chr8:33765107	NA	0.35	8.09	0.3	3.04e-15	Body mass index;
BRCA	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg21827317	chr3:136751795	NA	0.61	15.04	0.51	5.4e-44	Schizophrenia;
BRCA	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg22705602	chr4:152727874	NA	-0.38	-10.35	-0.38	2.51e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg06238570	chr21:40685208	BRWD1	-0.43	-8.6	-0.32	6.14e-17	Cognitive function;
BRCA	cis	rs3849570	0.925	rs1464791	chr3:81893929	A/C	cg07356753	chr3:81810745	GBE1	0.41	9.85	0.36	2.07e-21	Waist circumference;Body mass index;
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg25703541	chr22:24373054	LOC391322	0.89	23.11	0.67	2.3e-86	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg24642844	chr7:1081250	C7orf50	-0.87	-15.93	-0.53	2.34e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg05665937	chr4:1216051	CTBP1	0.41	8.48	0.32	1.6e-16	Obesity-related traits;
BRCA	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.6	0.32	6.11e-17	Personality dimensions;
BRCA	cis	rs10046574	0.561	rs7781454	chr7:135205422	A/G	cg27474649	chr7:135195673	CNOT4	0.61	10.32	0.38	3.39e-23	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	trans	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg26043149	chr18:55253948	FECH	0.37	8.12	0.31	2.39e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg06713675	chr4:122721982	EXOSC9	-0.39	-9.69	-0.36	8.07e-21	Type 2 diabetes;
BRCA	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg23018236	chr17:30244563	NA	0.46	7.86	0.3	1.66e-14	Hip circumference adjusted for BMI;
BRCA	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg16414030	chr3:133502952	NA	0.44	10.41	0.38	1.52e-23	Iron status biomarkers;
BRCA	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg15819921	chr19:927150	ARID3A	-0.48	-9.12	-0.34	1e-18	Life satisfaction;
BRCA	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06022373	chr22:39101656	GTPBP1	0.75	18.37	0.59	7.91e-61	Menopause (age at onset);
BRCA	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg21475434	chr5:93447410	FAM172A	0.68	8.81	0.33	1.17e-17	Diabetic retinopathy;
BRCA	cis	rs13046373	0.505	rs2832934	chr21:31899760	A/G	cg16812893	chr21:31813075	KRTAP15-1	0.4	9.74	0.36	5.28e-21	HDL cholesterol;
BRCA	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.84	0.33	9.45e-18	Motion sickness;
BRCA	cis	rs7179456	0.547	rs6494036	chr15:59015961	A/T	cg05156742	chr15:59063176	FAM63B	0.51	10.2	0.37	1.02e-22	Asperger disorder;
BRCA	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24531977	chr5:56204891	C5orf35	-0.72	-16.07	-0.54	4.64e-49	Initial pursuit acceleration;
BRCA	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-16.18	-0.54	1.25e-49	Alzheimer's disease (late onset);
BRCA	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg17644776	chr2:200775616	C2orf69	0.43	8.92	0.33	4.78e-18	Osteoporosis;
BRCA	trans	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.48	-0.35	4.76e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.48	8.75	0.33	1.9e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9309711	0.698	rs9750503	chr2:3491772	A/G	cg10845886	chr2:3471009	TTC15	0.77	16.14	0.54	2.14e-49	Neurofibrillary tangles;
BRCA	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg00106254	chr7:1943704	MAD1L1	-0.45	-11.35	-0.41	2.54e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg18132916	chr6:79620363	NA	-0.5	-11.37	-0.41	2.03e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg07384165	chr1:10488281	NA	-0.4	-8.5	-0.32	1.32e-16	Prostate cancer;
BRCA	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg03146154	chr1:46216737	IPP	0.52	11.58	0.42	2.72e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg18850127	chr7:39170497	POU6F2	0.47	10.24	0.38	6.63e-23	IgG glycosylation;
BRCA	cis	rs7639513	0.767	rs7648488	chr3:12708946	T/C	cg23032965	chr3:12705835	RAF1	0.7	15.4	0.52	1e-45	Itch intensity from mosquito bite;
BRCA	cis	rs6815814	0.950	rs3924112	chr4:38795810	C/T	cg02016764	chr4:38805732	TLR1	-0.64	-9.91	-0.37	1.23e-21	Breast cancer;
BRCA	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg14004847	chr7:1930337	MAD1L1	-0.39	-8.22	-0.31	1.16e-15	Schizophrenia;
BRCA	cis	rs7560272	0.538	rs17434655	chr2:73923089	C/T	cg20560298	chr2:73613845	ALMS1	-0.34	-9.11	-0.34	1.06e-18	Schizophrenia;
BRCA	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg03808351	chr9:123631620	PHF19	0.61	12.65	0.45	6.68e-33	Birth weight;
BRCA	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg06115741	chr20:33292138	TP53INP2	0.39	8.68	0.32	3.31e-17	Glomerular filtration rate (creatinine);
BRCA	trans	rs3960554	0.808	rs78811105	chr7:75702795	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	12.35	0.44	1.37e-31	Eotaxin levels;
BRCA	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg21045802	chr8:109455806	TTC35	0.35	8.02	0.3	5.19e-15	Dupuytren's disease;
BRCA	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg17366294	chr4:99064904	C4orf37	0.44	10.39	0.38	1.77e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg17366294	chr4:99064904	C4orf37	0.42	9.76	0.36	4.44e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg00666640	chr1:248458726	OR2T12	0.3	8.45	0.32	2e-16	Common traits (Other);
BRCA	cis	rs13082711	0.689	rs34946790	chr3:27345170	G/A	cg02860705	chr3:27208620	NA	0.82	15.0	0.51	8.87e-44	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg17971929	chr21:40555470	PSMG1	-0.62	-14.61	-0.5	6.07e-42	Cognitive function;
BRCA	cis	rs701145	0.938	rs789380	chr3:154081424	G/A	cg17054900	chr3:154042577	DHX36	0.68	11.84	0.42	2.31e-29	Coronary artery disease;
BRCA	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg03146154	chr1:46216737	IPP	0.46	10.34	0.38	2.89e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg24069376	chr3:38537580	EXOG	0.4	11.58	0.42	2.78e-28	Electrocardiographic conduction measures;
BRCA	trans	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.65	-14.24	-0.49	3.55e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs1405069	0.809	rs1046279	chr6:36932571	C/T	cg26433444	chr6:36932349	PI16	-0.47	-12.38	-0.44	1.01e-31	Chemerin levels;
BRCA	cis	rs7095944	0.554	rs11245344	chr10:126418782	C/T	cg08799069	chr10:126477246	METTL10	-0.37	-8.72	-0.33	2.31e-17	Asthma;
BRCA	cis	rs1595825	0.891	rs7584475	chr2:198577424	A/C	cg19156104	chr2:198669113	PLCL1	-0.46	-8.34	-0.31	4.54e-16	Ulcerative colitis;
BRCA	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg27147174	chr7:100797783	AP1S1	-0.56	-10.7	-0.39	1.07e-24	Life satisfaction;
BRCA	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg25036284	chr2:26402008	FAM59B	0.75	10.47	0.38	8.46e-24	Gut microbiome composition (summer);
BRCA	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg23711669	chr6:146136114	FBXO30	-0.72	-16.98	-0.56	1.25e-53	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg15934090	chr1:100435551	SLC35A3	0.36	8.43	0.32	2.38e-16	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg25214090	chr10:38739885	LOC399744	0.42	9.67	0.36	9.88e-21	Corneal astigmatism;
BRCA	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg23649088	chr2:200775458	C2orf69	0.42	8.97	0.33	3.21e-18	Asthma (bronchodilator response);
BRCA	cis	rs10992471	0.580	rs7030920	chr9:95122952	A/G	cg14631576	chr9:95140430	CENPP	-0.4	-9.69	-0.36	8.29e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg26384229	chr12:38710491	ALG10B	0.75	17.2	0.56	8.9e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg11502198	chr6:26597334	ABT1	0.48	9.55	0.35	2.78e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg13073564	chr4:8508604	NA	-0.39	-10.58	-0.39	3.34e-24	Response to antineoplastic agents;
BRCA	cis	rs2248020	0.501	rs2263368	chr11:93264680	A/C	cg15737290	chr11:93063684	CCDC67	0.35	8.2	0.31	1.31e-15	Insulin levels in response to oral glucose tolerance test (30 minutes);
BRCA	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-11.8	-0.42	3.35e-29	Gut microbiome composition (summer);
BRCA	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.2	-0.37	1.02e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs9951602	0.833	rs9953548	chr18:76640601	C/T	cg02800362	chr5:177631904	HNRNPAB	0.73	12.5	0.44	3.24e-32	Obesity-related traits;
BRCA	cis	rs7560272	0.501	rs11894953	chr2:73964631	A/G	cg20560298	chr2:73613845	ALMS1	-0.33	-8.64	-0.32	4.47e-17	Schizophrenia;
BRCA	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg00981070	chr1:2046702	PRKCZ	0.31	8.25	0.31	9.06e-16	Height;
BRCA	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.81	-0.45	1.36e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs936229	0.768	rs936226	chr15:75069282	C/T	cg10253484	chr15:75165896	SCAMP2	-0.53	-9.87	-0.36	1.73e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg08470875	chr2:26401718	FAM59B	-0.51	-8.26	-0.31	8.29e-16	Gut microbiome composition (summer);
BRCA	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg04267008	chr7:1944627	MAD1L1	0.52	11.47	0.41	7.72e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg24558204	chr6:135376177	HBS1L	0.59	15.93	0.53	2.3e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11764359	chr7:65958608	NA	-0.79	-19.22	-0.61	2.44e-65	Aortic root size;
BRCA	cis	rs690037	0.528	rs568833	chr3:16367836	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.38	-8.34	-0.31	4.42e-16	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
BRCA	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.56	8.35	0.31	4.2e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg08917208	chr2:24149416	ATAD2B	0.59	9.22	0.34	4.41e-19	Lymphocyte counts;
BRCA	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg14196790	chr5:131705035	SLC22A5	-0.41	-10.1	-0.37	2.35e-22	Breast cancer;Mosquito bite size;
BRCA	cis	rs858239	0.932	rs1624451	chr7:23262435	A/T	cg23682824	chr7:23144976	KLHL7	-0.33	-8.44	-0.32	2.13e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	9.5	0.35	4.3e-20	Rheumatoid arthritis;
BRCA	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg06784218	chr1:46089804	CCDC17	-0.44	-10.47	-0.38	8.95e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg17063962	chr7:91808500	NA	-0.52	-12.14	-0.43	1.1e-30	Breast cancer;
BRCA	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg06212747	chr3:49208901	KLHDC8B	0.47	9.66	0.36	1.09e-20	Parkinson's disease;
BRCA	cis	rs16854884	0.632	rs35716467	chr3:143684993	C/A	cg06585982	chr3:143692056	C3orf58	0.44	9.28	0.34	2.58e-19	Economic and political preferences (feminism/equality);
BRCA	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg26395211	chr5:140044315	WDR55	0.37	8.52	0.32	1.16e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg26343298	chr8:95960752	TP53INP1	0.28	7.93	0.3	1.01e-14	Type 2 diabetes;
BRCA	cis	rs7631605	0.935	rs9861967	chr3:37158798	C/T	cg15934958	chr3:37212084	LRRFIP2	0.41	9.52	0.35	3.64e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg22139774	chr2:100720529	AFF3	-0.29	-8.1	-0.31	2.86e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs2463822	1.000	rs1406384	chr11:62083530	A/G	cg06239285	chr11:62104954	ASRGL1	-0.64	-11.19	-0.4	1.11e-26	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs939658	0.805	rs8035606	chr15:79420245	C/T	cg17916960	chr15:79447300	NA	-0.47	-11.69	-0.42	9.96e-29	Refractive error;
BRCA	cis	rs6920965	0.563	rs1544292	chr6:126175093	G/C	cg05901451	chr6:126070800	HEY2	-0.36	-8.69	-0.33	2.94e-17	High light scatter reticulocyte count;
BRCA	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg17330251	chr7:94953956	PON1	-0.42	-8.78	-0.33	1.54e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg04362960	chr10:104952993	NT5C2	-0.33	-7.97	-0.3	7.46e-15	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs4268898	0.529	rs4426488	chr2:24372815	A/G	cg26838691	chr2:24397539	C2orf84	0.4	8.16	0.31	1.75e-15	Asthma;
BRCA	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg03146154	chr1:46216737	IPP	-0.51	-11.37	-0.41	2.11e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs360798	0.512	rs17027429	chr2:63079983	C/T	cg17519650	chr2:63277830	OTX1	0.37	8.25	0.31	8.86e-16	Coronary artery disease;
BRCA	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg13010199	chr12:38710504	ALG10B	0.52	10.48	0.38	8.03e-24	Bladder cancer;
BRCA	cis	rs6942756	1.000	rs68076553	chr7:128959632	A/G	cg02491457	chr7:128862824	NA	-0.71	-14.03	-0.49	3.56e-39	White matter hyperintensity burden;
BRCA	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.33	-9.98	-0.37	6.82e-22	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg19622623	chr12:86230825	RASSF9	-0.29	-8.15	-0.31	1.97e-15	Major depressive disorder;
BRCA	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg18230493	chr5:56204884	C5orf35	-0.74	-14.92	-0.51	2.06e-43	Initial pursuit acceleration;
BRCA	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg23205692	chr1:25664452	TMEM50A	-0.37	-8.81	-0.33	1.17e-17	Plateletcrit;Mean corpuscular volume;
BRCA	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.59	-13.49	-0.47	1.12e-36	Height;
BRCA	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg18230493	chr5:56204884	C5orf35	-0.44	-9.01	-0.34	2.32e-18	Coronary artery disease;
BRCA	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg08885076	chr2:99613938	TSGA10	-0.59	-13.21	-0.46	2.12e-35	Chronic sinus infection;
BRCA	cis	rs6080550	1.000	rs6080550	chr20:1759590	A/G	cg03128590	chr20:1760507	NA	0.54	9.52	0.35	3.46e-20	Non-obstructive azoospermia;
BRCA	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg11833968	chr6:79620685	NA	-0.43	-9.6	-0.35	1.8e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg09537434	chr19:41945824	ATP5SL	-1.0	-23.17	-0.68	1.08e-86	Height;
BRCA	trans	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg26043149	chr18:55253948	FECH	-0.37	-8.29	-0.31	6.69e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg26384229	chr12:38710491	ALG10B	-0.48	-11.21	-0.41	9.33e-27	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.94	-0.33	4.29e-18	Total body bone mineral density;
BRCA	cis	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg07460842	chr6:66804631	NA	-0.59	-12.76	-0.45	2.24e-33	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg08885076	chr2:99613938	TSGA10	0.51	10.03	0.37	4.33e-22	Chronic sinus infection;
BRCA	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg03188948	chr7:1209495	NA	0.84	11.6	0.42	2.4e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs113835537	0.559	rs74933537	chr11:66274958	A/C	cg24851651	chr11:66362959	CCS	0.44	8.32	0.31	5.13e-16	Airway imaging phenotypes;
BRCA	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg04362960	chr10:104952993	NT5C2	0.4	9.71	0.36	7.17e-21	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs698833	0.828	rs4952710	chr2:44524575	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	10.1	0.37	2.34e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg13010199	chr12:38710504	ALG10B	0.56	12.33	0.44	1.71e-31	Heart rate;
BRCA	cis	rs2387326	0.717	rs10829338	chr10:129943625	C/T	cg16087940	chr10:129947807	NA	-0.45	-7.94	-0.3	8.99e-15	Select biomarker traits;
BRCA	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg22974920	chr21:40686053	BRWD1	-0.34	-7.87	-0.3	1.54e-14	Menarche (age at onset);
BRCA	cis	rs6545883	0.895	rs4430924	chr2:61703856	A/G	cg15711740	chr2:61764176	XPO1	-0.55	-13.22	-0.46	1.89e-35	Tuberculosis;
BRCA	cis	rs965469	1.000	rs6051806	chr20:3350319	C/T	cg25506879	chr20:3388711	C20orf194	-0.56	-10.79	-0.39	4.92e-25	IFN-related cytopenia;
BRCA	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg01483505	chr11:975446	AP2A2	-0.31	-8.54	-0.32	9.66e-17	Alzheimer's disease (late onset);
BRCA	cis	rs7729447	0.776	rs17442964	chr5:32693916	G/A	cg16267343	chr5:32710456	NPR3	0.44	9.1	0.34	1.15e-18	Blood pressure;
BRCA	trans	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg06636001	chr8:8085503	FLJ10661	0.42	8.52	0.32	1.14e-16	Retinal vascular caliber;
BRCA	cis	rs977987	0.806	rs766521	chr16:75424154	A/G	cg03315344	chr16:75512273	CHST6	-0.5	-11.96	-0.43	7.13e-30	Dupuytren's disease;
BRCA	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg13073564	chr4:8508604	NA	-0.39	-10.79	-0.39	4.87e-25	Response to antineoplastic agents;
BRCA	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg26384229	chr12:38710491	ALG10B	0.66	15.12	0.51	2.34e-44	Bladder cancer;
BRCA	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg04511125	chr2:88470314	THNSL2	0.95	13.58	0.47	4.48e-37	Plasma clusterin levels;
BRCA	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg16006841	chr5:176797999	RGS14	0.94	19.66	0.61	1.24e-67	Urinary electrolytes (magnesium/calcium ratio);
BRCA	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg24905316	chr10:135186343	ECHS1	0.51	8.05	0.3	4.02e-15	Lifespan;
BRCA	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg24812749	chr6:127587940	RNF146	0.82	18.9	0.6	1.35e-63	Breast cancer;
BRCA	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg12386194	chr3:101231763	SENP7	0.46	9.79	0.36	3.64e-21	Colorectal cancer;
BRCA	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg16586182	chr3:47516702	SCAP	-0.55	-12.42	-0.44	7.15e-32	Colorectal cancer;
BRCA	cis	rs6815814	0.898	rs5743562	chr4:38806096	T/C	cg02016764	chr4:38805732	TLR1	-0.61	-9.73	-0.36	5.9e-21	Breast cancer;
BRCA	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg11262906	chr1:85462892	MCOLN2	-0.49	-9.3	-0.35	2.28e-19	Serum sulfate level;
BRCA	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg17366294	chr4:99064904	C4orf37	0.42	9.92	0.37	1.13e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg08470875	chr2:26401718	FAM59B	-0.5	-8.17	-0.31	1.65e-15	Gut microbiome composition (summer);
BRCA	cis	rs9308433	0.798	rs10157166	chr1:214484950	C/T	cg06198575	chr1:214491504	SMYD2	0.43	10.06	0.37	3.34e-22	IgG glycosylation;
BRCA	trans	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg06521331	chr12:34319734	NA	-0.51	-9.41	-0.35	9.14e-20	Morning vs. evening chronotype;
BRCA	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg03342759	chr3:160939853	NMD3	-0.55	-12.11	-0.43	1.58e-30	Morning vs. evening chronotype;
BRCA	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg21782813	chr7:2030301	MAD1L1	0.33	9.1	0.34	1.09e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg00757033	chr12:89920650	WDR51B	0.54	11.07	0.4	3.53e-26	NT-proBNP levels in acute coronary syndrome;
BRCA	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg24399712	chr22:39784796	NA	-0.58	-13.4	-0.47	2.79e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.39	-0.32	3.09e-16	Total body bone mineral density;
BRCA	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg04362960	chr10:104952993	NT5C2	0.43	10.42	0.38	1.4e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs3106136	0.527	rs2632410	chr4:95149507	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.08	-0.37	2.85e-22	Capecitabine sensitivity;
BRCA	cis	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg07460842	chr6:66804631	NA	1.01	27.16	0.73	1.4e-108	Exhaled nitric oxide output;
BRCA	cis	rs7737355	0.947	rs7706785	chr5:130954860	T/C	cg06307176	chr5:131281290	NA	0.52	10.03	0.37	4.47e-22	Life satisfaction;
BRCA	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg20476274	chr7:133979776	SLC35B4	0.67	19.69	0.61	8.42e-68	Mean platelet volume;
BRCA	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.34	-0.31	4.74e-16	Breast cancer;
BRCA	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg12062639	chr20:23401060	NAPB	0.95	13.22	0.46	1.89e-35	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00166722	chr3:10149974	C3orf24	0.6	12.19	0.43	6.74e-31	Alzheimer's disease;
BRCA	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	9.35	0.35	1.45e-19	Parkinson's disease;
BRCA	cis	rs11971779	0.680	rs17691238	chr7:139052284	A/G	cg07862535	chr7:139043722	LUC7L2	-0.36	-9.75	-0.36	5.04e-21	Diisocyanate-induced asthma;
BRCA	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/C	cg10818794	chr15:86012489	AKAP13	-0.32	-8.3	-0.31	6.08e-16	Central corneal thickness;Corneal structure;
BRCA	trans	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.89	-0.3	1.27e-14	Corneal astigmatism;
BRCA	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg01579765	chr21:45077557	HSF2BP	-0.33	-8.78	-0.33	1.45e-17	Mean corpuscular volume;
BRCA	cis	rs27434	0.583	rs151954	chr5:96157689	A/G	cg16492584	chr5:96139282	ERAP1	-0.5	-12.76	-0.45	2.31e-33	Ankylosing spondylitis;
BRCA	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg19920283	chr7:105172520	RINT1	0.59	9.4	0.35	9.51e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs867371	1.000	rs2088858	chr15:82474749	C/T	cg00614314	chr15:82944287	LOC80154	0.43	9.09	0.34	1.21e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04398451	chr17:18023971	MYO15A	0.82	18.98	0.6	5e-64	Total body bone mineral density;
BRCA	cis	rs7809950	0.678	rs2237661	chr7:106863123	T/C	cg23024343	chr7:107201750	COG5	-0.44	-8.84	-0.33	9.37e-18	Coronary artery disease;
BRCA	cis	rs7077164	1.000	rs1227764	chr10:71583223	G/A	cg07630274	chr10:71583235	COL13A1	-0.25	-8.41	-0.32	2.71e-16	Non-alcoholic fatty liver disease histology (lobular);
BRCA	trans	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg25517755	chr10:38738941	LOC399744	-0.38	-7.92	-0.3	1.02e-14	Corneal astigmatism;
BRCA	cis	rs9790314	0.605	rs13089559	chr3:160641688	T/A	cg03342759	chr3:160939853	NMD3	0.45	8.74	0.33	2.1e-17	Morning vs. evening chronotype;
BRCA	trans	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg05926928	chr17:57297772	GDPD1	-0.6	-9.32	-0.35	1.86e-19	Opioid sensitivity;
BRCA	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg23788917	chr6:8435910	SLC35B3	-0.43	-9.27	-0.34	2.91e-19	Motion sickness;
BRCA	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg01939980	chr4:1354348	KIAA1530	0.35	9.28	0.34	2.52e-19	Longevity;
BRCA	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg22491629	chr6:157744540	C6orf35	-0.67	-12.57	-0.45	1.59e-32	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg14196790	chr5:131705035	SLC22A5	0.31	8.05	0.3	4.16e-15	Blood metabolite levels;
BRCA	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg22906224	chr7:99728672	NA	-0.42	-7.98	-0.3	6.88e-15	Coronary artery disease;
BRCA	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg23711669	chr6:146136114	FBXO30	0.77	17.59	0.57	9.28e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg16322792	chr1:120165303	ZNF697	0.58	15.08	0.51	3.41e-44	Systemic lupus erythematosus;
BRCA	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg02574844	chr11:5959923	NA	-0.42	-8.27	-0.31	7.94e-16	DNA methylation (variation);
BRCA	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg03342759	chr3:160939853	NMD3	-0.81	-19.09	-0.6	1.33e-64	Parkinson's disease;
BRCA	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23583168	chr7:148888333	NA	-0.84	-19.54	-0.61	5.16e-67	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs34891900	0.507	rs1008378	chr22:18207251	T/C	cg19898043	chr22:18121309	BCL2L13	0.46	9.43	0.35	7.55e-20	Sum neutrophil eosinophil counts;
BRCA	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg00666640	chr1:248458726	OR2T12	0.33	9.04	0.34	1.79e-18	Common traits (Other);
BRCA	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.52	0.41	5.18e-28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs10484885	0.690	rs292236	chr6:90528422	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.79	-12.37	-0.44	1.19e-31	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg00701064	chr4:6280414	WFS1	0.68	17.63	0.57	5.82e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.31	-0.31	5.64e-16	Total body bone mineral density;
BRCA	cis	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg09307838	chr4:120376055	NA	0.47	9.77	0.36	4.19e-21	Diastolic blood pressure;
BRCA	cis	rs1003719	0.715	rs2835667	chr21:38579914	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.51	-0.5	1.83e-41	Eye color traits;
BRCA	cis	rs10733682	0.633	rs869500	chr9:129465898	G/A	cg00232160	chr9:129468157	NA	0.41	9.45	0.35	6.48e-20	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg12935359	chr14:103987150	CKB	-0.48	-10.98	-0.4	7.94e-26	Body mass index;
BRCA	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.31	-0.38	3.71e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.36	-0.61	4.51e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.46	-13.04	-0.46	1.21e-34	Lung cancer;
BRCA	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22496380	chr5:211416	CCDC127	-0.99	-14.41	-0.5	5.83e-41	Breast cancer;
BRCA	trans	rs2270927	0.510	rs34596551	chr5:75577143	C/T	cg13563193	chr19:33072644	PDCD5	0.87	10.18	0.37	1.16e-22	Mean corpuscular volume;
BRCA	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg25517755	chr10:38738941	LOC399744	-0.37	-7.94	-0.3	8.93e-15	Corneal astigmatism;
BRCA	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg03146154	chr1:46216737	IPP	0.45	9.87	0.36	1.72e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs751728	0.687	rs943479	chr6:33752013	A/G	cg25922239	chr6:33757077	LEMD2	0.49	12.55	0.44	1.92e-32	Crohn's disease;
BRCA	cis	rs11955398	0.669	rs11952735	chr5:59939146	T/C	cg02684056	chr5:59996105	DEPDC1B	0.38	9.31	0.35	1.94e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg10932868	chr11:921992	NA	0.39	9.6	0.36	1.75e-20	Alzheimer's disease (late onset);
BRCA	trans	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg16606324	chr3:10149918	C3orf24	-0.58	-11.42	-0.41	1.34e-27	Alzheimer's disease;
BRCA	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.27	0.31	7.93e-16	Aortic root size;
BRCA	cis	rs9296092	0.521	rs6929165	chr6:33515958	T/G	cg13560919	chr6:33536144	NA	-0.74	-15.8	-0.53	1.08e-47	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	trans	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.48	-10.13	-0.37	1.77e-22	Mean corpuscular volume;
BRCA	cis	rs524281	0.861	rs7929909	chr11:65951698	C/T	cg16950941	chr11:66035639	RAB1B	-0.38	-8.0	-0.3	5.97e-15	Electroencephalogram traits;
BRCA	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg15017067	chr4:17643749	FAM184B	0.32	9.67	0.36	9.73e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10411936	0.626	rs8113060	chr19:16596795	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.47	9.73	0.36	6.06e-21	White blood cell count;Multiple sclerosis;
BRCA	cis	rs12612619	0.732	rs11688708	chr2:27199608	T/G	cg00617064	chr2:27272375	NA	-0.31	-8.22	-0.31	1.12e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg04455712	chr21:45112962	RRP1B	0.41	10.54	0.38	4.71e-24	Mean corpuscular volume;
BRCA	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg20607798	chr8:58055168	NA	0.46	8.04	0.3	4.35e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg11764359	chr7:65958608	NA	-0.61	-10.38	-0.38	1.95e-23	Aortic root size;
BRCA	trans	rs3960554	0.808	rs60481386	chr7:75700962	A/G	cg19862616	chr7:65841803	NCRNA00174	0.56	12.08	0.43	2.11e-30	Eotaxin levels;
BRCA	cis	rs2318131	0.505	rs4663691	chr2:237900552	A/G	cg01069648	chr2:237906688	NA	0.37	8.08	0.3	3.27e-15	Motion sickness;
BRCA	trans	rs2262909	0.962	rs436662	chr19:22232107	C/T	cg17074339	chr11:11642133	GALNTL4	-0.41	-7.98	-0.3	6.96e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg13114125	chr14:105738426	BRF1	-0.54	-11.47	-0.41	8.22e-28	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Tonsillectomy;
BRCA	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg03060546	chr3:49711283	APEH	0.46	9.7	0.36	7.76e-21	Resting heart rate;
BRCA	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg15017067	chr4:17643749	FAM184B	0.32	9.86	0.36	1.92e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-12.53	-0.44	2.36e-32	Bipolar disorder;
BRCA	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg13628971	chr7:2884303	GNA12	0.47	9.44	0.35	6.73e-20	Height;
BRCA	cis	rs4588572	0.643	rs10063319	chr5:77758425	T/C	cg11547950	chr5:77652471	NA	-0.48	-8.41	-0.32	2.77e-16	Triglycerides;
BRCA	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.42e-34	Alzheimer's disease (late onset);
BRCA	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg14675211	chr2:100938903	LONRF2	0.52	11.67	0.42	1.21e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs12618769	0.652	rs17033813	chr2:99196483	A/G	cg10123293	chr2:99228465	UNC50	-0.42	-8.4	-0.32	2.86e-16	Bipolar disorder;
BRCA	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg23533926	chr12:111358616	MYL2	-0.42	-8.84	-0.33	9.21e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg13334819	chr7:99746414	C7orf59	-0.34	-8.11	-0.31	2.68e-15	Coronary artery disease;
BRCA	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.37	-0.41	2.06e-27	Schizophrenia;
BRCA	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg25036284	chr2:26402008	FAM59B	-0.69	-11.12	-0.4	2.25e-26	Gut microbiome composition (summer);
BRCA	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.33	11.23	0.41	7.54e-27	Systemic lupus erythematosus;
BRCA	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg07988820	chr12:82153109	PPFIA2	-0.58	-9.34	-0.35	1.53e-19	Resting heart rate;
BRCA	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg17971929	chr21:40555470	PSMG1	0.76	16.33	0.54	2.32e-50	Cognitive function;
BRCA	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg21782813	chr7:2030301	MAD1L1	0.41	10.83	0.39	3.14e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs370915	0.564	rs10027461	chr4:187837608	T/C	cg19519643	chr4:187840862	NA	-0.37	-8.7	-0.33	2.82e-17	Gout;
BRCA	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg05342682	chr7:94953680	PON1	-0.4	-9.98	-0.37	6.71e-22	Paraoxonase activity;
BRCA	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg12564285	chr5:131593104	PDLIM4	-0.39	-9.97	-0.37	7.2e-22	Acylcarnitine levels;
BRCA	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.47	-0.32	1.73e-16	Total body bone mineral density;
BRCA	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg09307838	chr4:120376055	NA	-0.62	-13.05	-0.46	1.13e-34	Corneal astigmatism;
BRCA	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.47	0.32	1.68e-16	Rheumatoid arthritis;
BRCA	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.76	12.67	0.45	5.84e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9875589	0.509	rs2731336	chr3:14091908	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.99	0.34	2.8e-18	Ovarian reserve;
BRCA	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg05340658	chr4:99064831	C4orf37	0.65	16.04	0.54	6.49e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg05340658	chr4:99064831	C4orf37	0.56	11.07	0.4	3.6e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg04553112	chr3:125709451	NA	-0.55	-8.34	-0.31	4.41e-16	Blood pressure (smoking interaction);
BRCA	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg24642439	chr20:33292090	TP53INP2	0.43	8.82	0.33	1.08e-17	Height;
BRCA	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg02153584	chr22:29168773	CCDC117	0.56	11.68	0.42	1.02e-28	Lymphocyte counts;
BRCA	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg17892150	chr10:133769511	PPP2R2D	0.71	15.72	0.53	2.57e-47	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg21827317	chr3:136751795	NA	0.35	7.88	0.3	1.44e-14	Neuroticism;
BRCA	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-14.39	-0.49	7.43e-41	Bladder cancer;
BRCA	cis	rs4363385	0.818	rs2879487	chr1:152985360	C/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.74	-0.33	2.1e-17	Inflammatory skin disease;
BRCA	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg07917127	chr4:99064746	C4orf37	0.44	8.0	0.3	6.01e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.26	-0.31	8.29e-16	Gut microbiome composition (summer);
BRCA	cis	rs8044868	0.586	rs7199261	chr16:72082788	A/G	cg16558253	chr16:72132732	DHX38	-0.45	-10.76	-0.39	6.27e-25	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg24642844	chr7:1081250	C7orf50	-0.6	-12.35	-0.44	1.46e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg07930192	chr7:1003750	NA	0.39	8.48	0.32	1.51e-16	Longevity;Endometriosis;
BRCA	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg23950597	chr19:37808831	NA	-0.62	-11.33	-0.41	3.02e-27	Coronary artery calcification;
BRCA	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21659725	chr3:3221576	CRBN	0.71	21.69	0.65	1.41e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18876405	chr7:65276391	NA	0.52	12.14	0.43	1.11e-30	Aortic root size;
BRCA	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg17328964	chr8:145687451	CYHR1	0.64	15.62	0.53	8.24e-47	Age at first birth;
BRCA	cis	rs17052344	0.543	rs2342183	chr17:21738349	G/T	cg18423549	chr17:21743878	NA	-0.64	-13.83	-0.48	3.02e-38	Cutaneous psoriasis;
BRCA	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg02176678	chr2:219576539	TTLL4	0.39	10.42	0.38	1.35e-23	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4561483	0.801	rs8061189	chr16:11951749	C/G	cg08843971	chr16:11963173	GSPT1	0.51	11.41	0.41	1.42e-27	Testicular germ cell tumor;
BRCA	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg08999081	chr20:33150536	PIGU	-0.47	-12.95	-0.46	3.03e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.52	-0.32	1.14e-16	Monocyte percentage of white cells;
BRCA	cis	rs61990749	0.597	rs1048147	chr14:78139988	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.63	-9.61	-0.36	1.65e-20	Fibroblast growth factor basic levels;
BRCA	cis	rs2953174	0.786	rs2953177	chr2:241516616	A/G	cg07929629	chr2:241523174	NA	0.49	8.62	0.32	5.31e-17	Bipolar disorder;
BRCA	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg17063962	chr7:91808500	NA	0.54	12.82	0.45	1.26e-33	Breast cancer;
BRCA	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-8.22	-0.31	1.12e-15	Multiple sclerosis;
BRCA	cis	rs56399783	0.614	rs11772508	chr7:2771504	A/C	cg23627948	chr7:2760692	NA	-0.48	-8.04	-0.3	4.45e-15	Childhood ear infection;
BRCA	cis	rs1883415	0.534	rs760905	chr6:24479782	T/C	cg20631270	chr6:24437470	GPLD1	0.4	8.16	0.31	1.78e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00149659	chr3:10157352	C3orf10	0.69	10.32	0.38	3.26e-23	Alzheimer's disease;
BRCA	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg13114125	chr14:105738426	BRF1	0.54	11.39	0.41	1.78e-27	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg07636037	chr3:49044803	WDR6	0.98	28.74	0.75	3.03e-117	Parkinson's disease;
BRCA	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs56159542	1	rs56159542	chr19:19682971	T/C	cg15839431	chr19:19639596	YJEFN3	0.38	8.4	0.32	2.8e-16	Attention deficit hyperactivity disorder symptom score;
BRCA	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.39	-9.44	-0.35	6.97e-20	Tonsillectomy;
BRCA	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg27624424	chr6:160112604	SOD2	-0.37	-8.06	-0.3	3.66e-15	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.42	9.69	0.36	8.56e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.29	-7.81	-0.3	2.33e-14	Dupuytren's disease;
BRCA	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.44	-0.38	1.13e-23	Psoriasis;
BRCA	cis	rs3768617	0.706	rs6678517	chr1:183002639	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.49	11.28	0.41	4.89e-27	Fuchs's corneal dystrophy;
BRCA	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-15.34	-0.52	1.93e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg16339924	chr4:17578868	LAP3	0.67	16.57	0.55	1.5e-51	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg19508488	chr2:152266495	RIF1	0.38	8.23	0.31	1.03e-15	Lung cancer;
BRCA	trans	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg26043149	chr18:55253948	FECH	1.1	23.69	0.68	1.63e-89	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03264133	chr6:25882463	NA	0.49	11.12	0.4	2.24e-26	Blood metabolite levels;
BRCA	cis	rs4845875	0.535	rs198408	chr1:11898130	T/A	cg24844545	chr1:11908347	NPPA	-0.31	-8.08	-0.3	3.13e-15	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18876405	chr7:65276391	NA	-0.54	-12.55	-0.44	1.94e-32	Aortic root size;
BRCA	cis	rs4363385	0.747	rs2339494	chr1:152975143	G/C	cg25856811	chr1:152973957	SPRR3	-0.34	-9.01	-0.34	2.4e-18	Inflammatory skin disease;
BRCA	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	7.15e-19	Alzheimer's disease (late onset);
BRCA	cis	rs7737355	0.645	rs184950	chr5:130852847	G/A	cg06307176	chr5:131281290	NA	0.53	10.72	0.39	8.97e-25	Life satisfaction;
BRCA	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg24642439	chr20:33292090	TP53INP2	0.42	8.28	0.31	7.48e-16	Height;
BRCA	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg16230307	chr14:35515116	FAM177A1	0.69	14.26	0.49	3.01e-40	Psoriasis;
BRCA	cis	rs4853036	0.951	rs13393656	chr2:70119255	C/A	cg02498382	chr2:70120550	SNRNP27	-0.54	-10.62	-0.39	2.32e-24	Colorectal or endometrial cancer;
BRCA	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-13.19	-0.46	2.66e-35	Gut microbiome composition (summer);
BRCA	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg18904891	chr8:8559673	CLDN23	-0.65	-12.98	-0.46	2.36e-34	Obesity-related traits;
BRCA	cis	rs724568	0.509	rs10179159	chr2:67923516	T/C	cg17945962	chr2:67939740	NA	-0.36	-9.14	-0.34	8.32e-19	Major depressive disorder (broad);
BRCA	cis	rs17401966	1.000	rs11121533	chr1:10292888	G/C	cg15208524	chr1:10270712	KIF1B	0.37	8.24	0.31	9.770000000000001e-16	Hepatocellular carcinoma;
BRCA	trans	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg01620082	chr3:125678407	NA	-0.92	-10.33	-0.38	2.97e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	trans	rs1459104	1.000	rs35097999	chr11:55048103	C/T	cg15704280	chr7:45808275	SEPT13	0.69	8.57	0.32	7.47e-17	Body mass index;
BRCA	trans	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.13	-38.88	-0.84	1.45e-170	Exhaled nitric oxide output;
BRCA	cis	rs4363385	0.747	rs1577964	chr1:152961784	C/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.04	-0.3	4.39e-15	Inflammatory skin disease;
BRCA	cis	rs2066819	1.000	rs41392645	chr12:56696742	A/G	cg26734620	chr12:56694298	CS	0.87	10.24	0.38	6.61e-23	Psoriasis vulgaris;
BRCA	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00149659	chr3:10157352	C3orf10	1.07	18.1	0.58	2.08e-59	Alzheimer's disease;
BRCA	cis	rs495337	0.662	rs6020072	chr20:48445454	A/G	cg17835207	chr20:48524531	SPATA2	0.52	11.9	0.43	1.26e-29	Psoriasis;
BRCA	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.54	10.53	0.38	5.11e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg00908766	chr1:109817496	CELSR2	0.62	19.4	0.61	2.87e-66	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
BRCA	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg13395646	chr4:1353034	KIAA1530	-0.51	-9.13	-0.34	9.19e-19	Obesity-related traits;
BRCA	trans	rs1422110	0.879	rs1363268	chr5:85469695	C/T	cg01787110	chr1:109008453	NBPF6	-0.44	-8.84	-0.33	9.59e-18	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg01483505	chr11:975446	AP2A2	0.33	9.07	0.34	1.44e-18	Alzheimer's disease (late onset);
BRCA	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg00677455	chr12:58241039	CTDSP2	0.62	14.45	0.5	3.59e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs1113500	0.787	rs12047429	chr1:108633239	C/T	cg06207961	chr1:108661230	NA	0.36	8.89	0.33	6.4e-18	Growth-regulated protein alpha levels;
BRCA	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg03676636	chr4:99064102	C4orf37	0.21	8.01	0.3	5.49e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	1.02e-40	Motion sickness;
BRCA	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.69	0.55	3.67e-52	Hypertriglyceridemia;
BRCA	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg20307385	chr11:47447363	PSMC3	0.89	26.28	0.72	9.8e-104	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs6504950	0.705	rs17745123	chr17:52988232	G/T	cg26251398	chr17:52985966	TOM1L1	0.32	8.22	0.31	1.1e-15	Breast cancer;
BRCA	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg03733263	chr8:22462867	KIAA1967	0.78	18.0	0.58	6.91e-59	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.12	-0.31	2.49e-15	Depression;
BRCA	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.51	0.38	6.29e-24	Tonsillectomy;
BRCA	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg10295955	chr4:187884368	NA	-0.99	-31.58	-0.78	1.4e-132	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg06521331	chr12:34319734	NA	-0.63	-12.48	-0.44	3.67e-32	Morning vs. evening chronotype;
BRCA	cis	rs2354432	0.607	rs4950385	chr1:146656292	A/G	cg25205988	chr1:146714368	CHD1L	0.86	10.43	0.38	1.23e-23	Mitochondrial DNA levels;
BRCA	cis	rs250677	0.522	rs4705301	chr5:148354902	C/G	cg12140854	chr5:148520817	ABLIM3	-0.39	-7.97	-0.3	7.41e-15	Breast cancer;
BRCA	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.79	-0.33	1.35e-17	Total body bone mineral density;
BRCA	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg18252515	chr7:66147081	NA	-0.84	-12.14	-0.43	1.2e-30	Diabetic kidney disease;
BRCA	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg09658497	chr7:2847517	GNA12	-0.45	-9.9	-0.36	1.35e-21	Height;
BRCA	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.03	18.68	0.59	1.84e-62	Gut microbiome composition (summer);
BRCA	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg01236616	chr12:121019343	POP5	-1.24	-25.05	-0.7	5.12e-97	Type 1 diabetes nephropathy;
BRCA	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10802521	chr3:52805072	NEK4	-0.33	-8.58	-0.32	7.26e-17	Bipolar disorder;
BRCA	cis	rs911119	0.955	rs6048952	chr20:23607257	A/G	cg16589663	chr20:23618590	CST3	0.4	8.2	0.31	1.34e-15	Chronic kidney disease;
BRCA	trans	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg01620082	chr3:125678407	NA	-0.72	-8.46	-0.32	1.78e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.17	-0.4	1.44e-26	Morning vs. evening chronotype;
BRCA	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-10.12	-0.37	2.03e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg11814155	chr7:99998594	ZCWPW1	0.48	8.7	0.33	2.76e-17	Platelet count;
BRCA	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03517284	chr6:25882590	NA	-0.47	-9.81	-0.36	2.88e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	9.87	0.36	1.77e-21	Tonsillectomy;
BRCA	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.51	8.76	0.33	1.79e-17	Body mass index (adult);
BRCA	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg14847009	chr1:175162515	KIAA0040	-0.24	-8.86	-0.33	7.64e-18	Alcohol dependence;
BRCA	cis	rs9300255	0.770	rs7980687	chr12:123822711	G/A	cg00376283	chr12:123451042	ABCB9	-0.52	-11.2	-0.41	9.95e-27	Neutrophil percentage of white cells;
BRCA	cis	rs36051895	0.632	rs10974982	chr9:5149382	G/C	cg02405213	chr9:5042618	JAK2	-0.45	-8.61	-0.32	5.67e-17	Pediatric autoimmune diseases;
BRCA	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.17	-0.43	8.86e-31	Blood protein levels;
BRCA	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg16325326	chr1:53192061	ZYG11B	0.89	24.61	0.7	1.43e-94	Monocyte count;
BRCA	cis	rs28735056	1.000	rs28735056	chr18:77622879	A/G	cg03682112	chr18:77623598	KCNG2	-0.37	-8.48	-0.32	1.6e-16	Schizophrenia;
BRCA	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03264133	chr6:25882463	NA	-0.58	-11.86	-0.42	1.83e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs10992471	0.756	rs10992303	chr9:95082804	A/G	cg14631576	chr9:95140430	CENPP	-0.37	-8.97	-0.33	3.22e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.69	0.39	1.24e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs651907	0.712	rs796410	chr3:101610189	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.36	9.21	0.34	4.47e-19	Colorectal cancer;
BRCA	cis	rs3820928	1.000	rs978909	chr2:227771389	A/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.75	-0.33	1.82e-17	Pulmonary function;
BRCA	trans	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg23762105	chr12:34175262	ALG10	0.38	9.66	0.36	1.06e-20	Morning vs. evening chronotype;
BRCA	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	13.42	0.47	2.39e-36	Eosinophil percentage of white cells;
BRCA	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg25358565	chr5:93447407	FAM172A	0.7	12.13	0.43	1.23e-30	Diabetic retinopathy;
BRCA	trans	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.36	7.99	0.3	6.53e-15	Endometrial cancer;
BRCA	cis	rs708547	0.697	rs67479587	chr4:57878884	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.38	9.82	0.36	2.67e-21	Response to bleomycin (chromatid breaks);
BRCA	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs4363385	0.818	rs1048296	chr1:153012240	A/C	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs16866061	1.000	rs10498163	chr2:225434445	A/G	cg12698349	chr2:225449008	CUL3	0.78	21.19	0.64	6.7e-76	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs12472274	0.941	rs4663861	chr2:239105203	C/T	cg17459225	chr2:239074497	NA	0.63	12.88	0.45	6.5e-34	Phospholipid levels (plasma);
BRCA	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-15.41	-0.52	8.19e-46	Body mass index;
BRCA	trans	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.91	-0.36	1.23e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg08888203	chr3:10149979	C3orf24	0.65	11.93	0.43	8.91e-30	Alzheimer's disease;
BRCA	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg20587970	chr11:113659929	NA	-1.24	-22.64	-0.67	8.57e-84	Hip circumference adjusted for BMI;
BRCA	cis	rs757081	0.637	rs586785	chr11:17208714	T/C	cg15432903	chr11:17409602	KCNJ11	-0.45	-8.46	-0.32	1.78e-16	Systolic blood pressure;
BRCA	trans	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.45	-0.35	6.17e-20	Bladder cancer;
BRCA	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg20933634	chr6:27740509	NA	0.44	8.22	0.31	1.11e-15	Parkinson's disease;
BRCA	trans	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	8.83	0.33	1e-17	Mean corpuscular volume;
BRCA	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.69	16.12	0.54	2.57e-49	Axial length;
BRCA	trans	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	16.05	0.54	5.66e-49	Exhaled nitric oxide levels;
BRCA	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg08847533	chr14:75593920	NEK9	0.46	8.51	0.32	1.28e-16	Caffeine consumption;
BRCA	cis	rs847649	0.621	rs2222539	chr7:102674786	G/A	cg18108683	chr7:102477205	FBXL13	0.36	7.94	0.3	9.36e-15	Morning vs. evening chronotype;
BRCA	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.43	8.36	0.31	3.82e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.56	-0.61	4.21e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-9.03	-0.34	1.99e-18	Alzheimer's disease (late onset);
BRCA	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg18252515	chr7:66147081	NA	-1.06	-15.7	-0.53	3.07e-47	Gout;
BRCA	trans	rs9951602	0.512	rs4799245	chr18:76653397	T/C	cg02800362	chr5:177631904	HNRNPAB	0.77	18.23	0.58	4.3e-60	Obesity-related traits;
BRCA	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.03	0.34	2.04e-18	Platelet count;
BRCA	cis	rs4566357	0.615	rs3769643	chr2:227917270	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-9.55	-0.35	2.65e-20	Coronary artery disease;
BRCA	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg06784218	chr1:46089804	CCDC17	0.5	11.89	0.43	1.32e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.92	0.3	1.03e-14	Corneal astigmatism;
BRCA	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg24631222	chr15:78858424	CHRNA5	-0.5	-10.01	-0.37	5.19e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg13798912	chr7:905769	UNC84A	-0.5	-7.88	-0.3	1.42e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1355223	0.525	rs12280958	chr11:34872799	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-9.48	-0.35	4.85e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg17691542	chr6:26056736	HIST1H1C	0.48	9.55	0.35	2.75e-20	Iron status biomarkers;
BRCA	cis	rs11249608	0.548	rs10479520	chr5:178451447	C/A	cg21905437	chr5:178450457	ZNF879	0.51	10.78	0.39	5.39e-25	Pubertal anthropometrics;
BRCA	cis	rs11690935	0.959	rs6754817	chr2:172663394	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.87	-26.37	-0.72	2.97e-104	Schizophrenia;
BRCA	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.09	-38.67	-0.84	1.67e-169	Myeloid white cell count;
BRCA	cis	rs3857067	0.806	rs4693001	chr4:95115097	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.49	-0.35	4.67e-20	QT interval;
BRCA	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg04455712	chr21:45112962	RRP1B	0.39	10.3	0.38	4.21e-23	Mean corpuscular volume;
BRCA	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg25237894	chr2:233734115	C2orf82	-0.41	-11.82	-0.42	2.77e-29	Coronary artery disease;
BRCA	cis	rs16976116	0.901	rs1061822	chr15:55496058	A/C	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg00101154	chr16:420108	MRPL28	0.45	11.02	0.4	5.74e-26	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.46	-0.32	1.82e-16	Monocyte percentage of white cells;
BRCA	cis	rs72772090	0.539	rs55996659	chr5:96114150	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.32	-0.44	1.91e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs62380364	0.565	rs40504	chr5:88011139	G/C	cg22951263	chr5:87985283	NA	-0.38	-10.45	-0.38	1.08e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs2421770	0.530	rs6484784	chr11:35368347	A/C	cg13971030	chr11:35366721	SLC1A2	0.43	9.35	0.35	1.41e-19	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs6714710	0.603	rs2044459	chr2:98447004	T/C	cg26665480	chr2:98280029	ACTR1B	0.6	13.82	0.48	3.49e-38	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg06547715	chr2:218990976	CXCR2	0.32	7.89	0.3	1.3e-14	Ulcerative colitis;
BRCA	cis	rs9469578	1.000	rs9469578	chr6:33706479	C/T	cg18708504	chr6:33715942	IP6K3	0.72	10.42	0.38	1.43e-23	Phosphorus levels;
BRCA	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg04553112	chr3:125709451	NA	-0.56	-8.5	-0.32	1.34e-16	Blood pressure (smoking interaction);
BRCA	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg13334819	chr7:99746414	C7orf59	0.4	9.04	0.34	1.84e-18	Coronary artery disease;
BRCA	cis	rs1163251	0.902	rs839605	chr1:120217524	C/A	cg19096424	chr1:120255104	PHGDH	0.44	9.73	0.36	5.98e-21	Blood metabolite levels;
BRCA	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.0	26.98	0.73	1.26e-107	Body mass index (adult);
BRCA	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg00530320	chr1:46809349	NSUN4	0.48	9.74	0.36	5.54e-21	Menopause (age at onset);
BRCA	cis	rs4481887	0.790	rs4382760	chr1:248422343	A/C	cg00666640	chr1:248458726	OR2T12	-0.27	-7.99	-0.3	6.1e-15	Common traits (Other);
BRCA	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.39	8.62	0.32	5.44e-17	Multiple sclerosis;
BRCA	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg06627628	chr2:24431161	ITSN2	-0.8	-15.37	-0.52	1.35e-45	Asthma;
BRCA	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.42	-8.42	-0.32	2.49e-16	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg19678392	chr7:94953810	PON1	-0.41	-8.88	-0.33	6.78e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.35	7.97	0.3	7.09e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs3925075	0.531	rs7206295	chr16:31336519	T/C	cg02846316	chr16:31340340	ITGAM	0.43	8.61	0.32	5.71e-17	IgA nephropathy;
BRCA	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg22907277	chr7:1156413	C7orf50	0.58	8.91	0.33	5.37e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4803468	0.967	rs13344547	chr19:41945848	G/T	cg09537434	chr19:41945824	ATP5SL	1.02	25.43	0.71	4.25e-99	Height;
BRCA	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.64	0.57	4.83e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg17366294	chr4:99064904	C4orf37	0.45	10.61	0.39	2.44e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg08975724	chr8:8085496	FLJ10661	0.42	9.27	0.34	2.73e-19	Mood instability;
BRCA	cis	rs12464559	0.522	rs10180065	chr2:152619007	A/G	cg01189475	chr2:152685088	ARL5A	-0.57	-8.52	-0.32	1.14e-16	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg03585969	chr10:35415529	CREM	0.56	11.52	0.41	4.97e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg22535103	chr8:58192502	C8orf71	-0.49	-8.66	-0.32	3.91e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg04842962	chr6:43655489	MRPS18A	1.07	34.28	0.8	6.17e-147	IgG glycosylation;
BRCA	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg07884673	chr3:53033167	SFMBT1	0.72	8.94	0.33	4.2e-18	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg03146154	chr1:46216737	IPP	-0.44	-9.62	-0.36	1.5e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg07148914	chr20:33460835	GGT7	-0.38	-8.7	-0.33	2.9e-17	Height;
BRCA	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg11833968	chr6:79620685	NA	-0.46	-10.44	-0.38	1.11e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg23711669	chr6:146136114	FBXO30	0.64	14.88	0.51	3.07e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-10.29	-0.38	4.53e-23	Alzheimer's disease (late onset);
BRCA	cis	rs4664304	0.620	rs2048436	chr2:160712119	A/G	cg01092293	chr2:160761427	LY75	0.36	8.52	0.32	1.14e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs1493916	0.837	rs9952002	chr18:31414314	C/G	cg27147174	chr7:100797783	AP1S1	-0.43	-8.73	-0.33	2.16e-17	Life satisfaction;
BRCA	cis	rs73001065	0.591	rs56273306	chr19:19621004	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	14.22	0.49	4.65e-40	LDL cholesterol;
BRCA	cis	rs4742903	0.904	rs10991187	chr9:106996271	C/T	cg14250997	chr9:106856677	SMC2	0.3	9.61	0.36	1.58e-20	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg12379764	chr21:47803548	PCNT	-0.37	-7.96	-0.3	7.88e-15	Testicular germ cell tumor;
BRCA	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg07384165	chr1:10488281	NA	-0.41	-8.76	-0.33	1.77e-17	Prostate cancer;
BRCA	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg05623727	chr3:50126028	RBM5	0.44	8.42	0.32	2.56e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg13047869	chr3:10149882	C3orf24	0.61	12.82	0.45	1.18e-33	Alzheimer's disease;
BRCA	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.42	9.13	0.34	9.17e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs870825	0.860	rs72703521	chr4:185603080	T/C	cg04058563	chr4:185651563	MLF1IP	0.65	11.26	0.41	5.77e-27	Blood protein levels;
BRCA	cis	rs3760982	0.585	rs1386502	chr19:44293356	T/C	cg12072164	chr19:44306565	LYPD5	0.37	8.8	0.33	1.32e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	trans	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.35	-8.78	-0.33	1.5e-17	Obesity-related traits;
BRCA	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-12.97	-0.46	2.5e-34	Lymphocyte counts;
BRCA	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg03213289	chr20:61660250	NA	0.62	16.4	0.54	1.09e-50	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.12	0.31	2.32e-15	Mean corpuscular volume;
BRCA	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg27446573	chr6:127587934	RNF146	0.63	13.85	0.48	2.56e-38	Breast cancer;
BRCA	trans	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-11.72	-0.42	7.19e-29	Brugada syndrome;
BRCA	cis	rs9287719	0.649	rs6720112	chr2:10725719	T/C	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	5.17e-19	Prostate cancer;
BRCA	trans	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg25214090	chr10:38739885	LOC399744	0.52	11.78	0.42	4.13e-29	Corneal astigmatism;
BRCA	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg18270830	chr10:32634957	EPC1	0.61	10.26	0.38	5.64e-23	Sexual dysfunction (female);
BRCA	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.66	-0.61	1.21e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg17143192	chr8:8559678	CLDN23	-0.55	-10.78	-0.39	5.35e-25	Obesity-related traits;
BRCA	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.4	-0.41	1.57e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6840360	0.593	rs59350867	chr4:152695935	G/A	cg22705602	chr4:152727874	NA	-0.38	-10.54	-0.38	4.79e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg09307838	chr4:120376055	NA	0.69	14.85	0.51	4.67e-43	Corneal astigmatism;
BRCA	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg12826209	chr6:26865740	GUSBL1	0.56	9.23	0.34	3.9e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs17253792	0.822	rs79024594	chr14:56092997	T/G	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs208520	0.661	rs207099	chr6:66796373	A/C	cg07460842	chr6:66804631	NA	-1.01	-20.17	-0.62	2.18e-70	Exhaled nitric oxide output;
BRCA	cis	rs6430585	0.702	rs1042712	chr2:136545844	C/G	cg07169764	chr2:136633963	MCM6	-1.15	-25.92	-0.72	8.96e-102	Corneal structure;
BRCA	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg26384229	chr12:38710491	ALG10B	0.66	15.1	0.51	2.91e-44	Bladder cancer;
BRCA	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13126279	chr21:47581558	C21orf56	0.5	10.75	0.39	6.84e-25	Testicular germ cell tumor;
BRCA	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.32	-10.19	-0.37	1.03e-22	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.38	9.75	0.36	4.76e-21	IgG glycosylation;
BRCA	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-10.37	-0.38	2.23e-23	Blood metabolite levels;
BRCA	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.76	-0.5	1.19e-42	Chronic sinus infection;
BRCA	cis	rs507080	0.922	rs555356	chr11:118558078	G/T	cg08498647	chr11:118550644	TREH	-0.37	-8.11	-0.31	2.55e-15	Serum metabolite levels;
BRCA	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg21747090	chr2:27597821	SNX17	-0.37	-7.86	-0.3	1.64e-14	Menopause (age at onset);
BRCA	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.26	-0.61	1.53e-65	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg27326032	chr3:127006922	NA	-0.53	-9.11	-0.34	1.09e-18	Interleukin-10 levels;Interleukin-13 levels;
BRCA	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg04317338	chr11:64019027	PLCB3	0.52	7.97	0.3	7.56e-15	Mean platelet volume;
BRCA	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg11752832	chr7:134001865	SLC35B4	0.52	13.42	0.47	2.29e-36	Mean platelet volume;
BRCA	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-9.1	-0.34	1.15e-18	Alzheimer's disease (late onset);
BRCA	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	15.18	0.51	1.16e-44	Colorectal cancer;
BRCA	cis	rs13064411	0.518	rs1471884	chr3:113212041	G/A	cg18753928	chr3:113234510	CCDC52	-0.41	-9.18	-0.34	6.13e-19	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05890377	chr2:74357713	NA	0.47	11.66	0.42	1.32e-28	Gestational age at birth (maternal effect);
BRCA	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg21475434	chr5:93447410	FAM172A	0.61	7.97	0.3	7.32e-15	Diabetic retinopathy;
BRCA	trans	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg23762105	chr12:34175262	ALG10	0.35	8.15	0.31	1.98e-15	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.24	0.49	3.83e-40	Motion sickness;
BRCA	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19723775	chr5:179050963	HNRNPH1	0.36	8.54	0.32	9.75e-17	Lung cancer;
BRCA	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg01448562	chr3:133502909	NA	0.34	8.0	0.3	5.78e-15	Iron status biomarkers;
BRCA	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg03188948	chr7:1209495	NA	0.83	11.33	0.41	2.93e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg04727924	chr7:799746	HEATR2	-0.54	-9.32	-0.35	1.82e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg08999081	chr20:33150536	PIGU	0.44	12.51	0.44	2.96e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg26528668	chr16:1614120	IFT140	0.36	8.23	0.31	1.06e-15	Coronary artery disease;
BRCA	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg02466173	chr16:30829666	NA	-0.64	-15.38	-0.52	1.2e-45	Dementia with Lewy bodies;
BRCA	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg06784218	chr1:46089804	CCDC17	0.45	10.87	0.4	2.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg26446133	chr18:72167187	CNDP2	-0.79	-19.96	-0.62	3.06e-69	Refractive error;
BRCA	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg10729496	chr3:10149963	C3orf24	0.48	8.9	0.33	5.72e-18	Alzheimer's disease;
BRCA	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg08085267	chr17:45401833	C17orf57	0.61	13.1	0.46	6.42e-35	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg25214090	chr10:38739885	LOC399744	-0.53	-11.86	-0.42	1.81e-29	Corneal astigmatism;
BRCA	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg05313129	chr8:58192883	C8orf71	-0.46	-9.46	-0.35	5.73e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs3820928	0.874	rs11685983	chr2:227799853	A/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.6	-0.32	6.39e-17	Pulmonary function;
BRCA	cis	rs6835098	0.608	rs2332668	chr4:174163360	A/G	cg08422745	chr4:174089978	GALNT7	-0.65	-13.37	-0.47	4.14e-36	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg07828340	chr4:882639	GAK	1.01	12.35	0.44	1.37e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg10729496	chr3:10149963	C3orf24	0.48	9.0	0.34	2.49e-18	Alzheimer's disease;
BRCA	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00166722	chr3:10149974	C3orf24	0.65	12.94	0.46	3.49e-34	Alzheimer's disease;
BRCA	cis	rs9487051	0.735	rs455839	chr6:109524221	G/A	cg21918786	chr6:109611834	NA	-0.34	-8.97	-0.33	3.25e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg09307838	chr4:120376055	NA	0.7	14.19	0.49	5.99e-40	Corneal astigmatism;
BRCA	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg08085267	chr17:45401833	C17orf57	-0.61	-12.41	-0.44	7.5e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.52	0.5	1.78e-41	Motion sickness;
BRCA	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg09307838	chr4:120376055	NA	0.65	13.35	0.47	4.79e-36	Corneal astigmatism;
BRCA	cis	rs943466	1.000	rs55775340	chr6:33751784	C/G	cg25922239	chr6:33757077	LEMD2	-0.37	-8.04	-0.3	4.23e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg13877915	chr19:58951672	ZNF132	0.46	10.81	0.39	3.98e-25	Uric acid clearance;
BRCA	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg12292205	chr6:26970375	C6orf41	-0.8	-19.53	-0.61	6.14e-67	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg18357645	chr12:58087776	OS9	0.48	13.8	0.48	4.11e-38	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	20.79	0.64	9.64e-74	Smoking behavior;
BRCA	cis	rs698833	0.962	rs1065785	chr2:44660699	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	9.87	0.36	1.7e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs9473147	0.516	rs7754971	chr6:47590476	C/T	cg12968598	chr6:47444699	CD2AP	0.44	9.65	0.36	1.21e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs9463078	0.764	rs976699	chr6:44952852	G/T	cg25276700	chr6:44698697	NA	-0.37	-8.54	-0.32	9.74e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs9308433	0.529	rs1391553	chr1:214474119	T/C	cg06198575	chr1:214491504	SMYD2	0.57	12.4	0.44	8.68e-32	IgG glycosylation;
BRCA	cis	rs1568889	1.000	rs12796293	chr11:28177723	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.64	-14.02	-0.49	3.77e-39	Bipolar disorder;
BRCA	cis	rs6433895	1.000	rs13033467	chr2:182016757	A/G	cg00481216	chr2:181971175	NA	0.39	8.91	0.33	5.34e-18	Lymphocyte counts;
BRCA	cis	rs10484885	0.824	rs112817281	chr6:90555658	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.77	-9.72	-0.36	6.63e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg19862616	chr7:65841803	NCRNA00174	0.81	25.02	0.7	8.16e-97	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs55883249	1.000	rs62119428	chr2:9743332	T/C	cg23886495	chr2:9695866	ADAM17	0.55	7.89	0.3	1.27e-14	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
BRCA	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12310025	chr6:25882481	NA	-0.52	-11.97	-0.43	6.14e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs3784262	0.679	rs11071366	chr15:58334244	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.54	-13.57	-0.47	4.7e-37	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24531977	chr5:56204891	C5orf35	-0.86	-17.41	-0.57	7.19e-56	Initial pursuit acceleration;
BRCA	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg01528321	chr10:82214614	TSPAN14	0.79	17.39	0.57	9.73e-56	Post bronchodilator FEV1;
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg23978390	chr7:1156363	C7orf50	0.52	12.33	0.44	1.68e-31	Longevity;Endometriosis;
BRCA	cis	rs2016266	0.787	rs4520636	chr12:53752133	G/T	cg26875137	chr12:53738046	NA	0.43	10.92	0.4	1.37e-25	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg09021430	chr5:549028	NA	-0.64	-15.26	-0.52	4.49e-45	Obesity-related traits;
BRCA	cis	rs12612619	0.732	rs1465881	chr2:27237614	A/G	cg00617064	chr2:27272375	NA	-0.31	-8.09	-0.3	2.9e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00149659	chr3:10157352	C3orf10	0.72	12.75	0.45	2.51e-33	Alzheimer's disease;
BRCA	cis	rs470119	1.000	rs131801	chr22:50966634	G/T	cg12969734	chr22:50962224	SCO2	0.38	9.15	0.34	7.3e-19	Mean corpuscular hemoglobin;
BRCA	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg21918786	chr6:109611834	NA	-0.44	-11.84	-0.42	2.33e-29	Reticulocyte fraction of red cells;
BRCA	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg25036284	chr2:26402008	FAM59B	-0.79	-12.41	-0.44	7.62e-32	Gut microbiome composition (summer);
BRCA	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg11168104	chr5:1857477	NA	-0.34	-8.89	-0.33	6.07e-18	Cardiovascular disease risk factors;
BRCA	trans	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.78	-0.33	1.46e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12042938	0.579	rs980394	chr1:231779507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.39	-8.51	-0.32	1.26e-16	Neuranatomic and neurocognitive phenotypes;
BRCA	trans	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.86	0.3	1.6e-14	Endometrial cancer;
BRCA	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg06697600	chr4:7070879	GRPEL1	-0.53	-10.77	-0.39	5.68e-25	Monocyte percentage of white cells;
BRCA	cis	rs1997103	1.000	rs2177803	chr7:55410773	A/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg11266682	chr4:10021025	SLC2A9	0.48	12.8	0.45	1.51e-33	Bone mineral density;
BRCA	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg04851639	chr8:1020857	NA	-0.3	-8.35	-0.31	4.29e-16	Schizophrenia;
BRCA	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03264133	chr6:25882463	NA	-0.53	-10.84	-0.39	3.11e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18876405	chr7:65276391	NA	-0.63	-15.61	-0.53	8.75e-47	Aortic root size;
BRCA	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg10523679	chr1:76189770	ACADM	-0.47	-9.19	-0.34	5.31e-19	Daytime sleep phenotypes;
BRCA	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18404041	chr3:52824283	ITIH1	0.47	14.53	0.5	1.53e-41	Bipolar disorder;
BRCA	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg17063962	chr7:91808500	NA	0.51	11.59	0.42	2.56e-28	Breast cancer;
BRCA	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg08213375	chr14:104286397	PPP1R13B	0.42	9.07	0.34	1.47e-18	Reticulocyte count;
BRCA	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.52	0.35	3.47e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg21770322	chr7:97807741	LMTK2	0.45	11.74	0.42	5.91e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.61	8.06	0.3	3.77e-15	Yeast infection;
BRCA	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg24675658	chr1:53192096	ZYG11B	-0.49	-10.3	-0.38	3.9699999999999997e-23	Monocyte count;
BRCA	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg18225595	chr11:63971243	STIP1	-0.47	-11.32	-0.41	3.4e-27	Platelet count;
BRCA	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.87	-0.4	2.22e-25	Personality dimensions;
BRCA	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.36	-0.31	3.87e-16	Colorectal cancer;
BRCA	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-10.29	-0.38	4.53e-23	Schizophrenia;
BRCA	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.5	-7.92	-0.3	1.04e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg06552810	chr11:31128660	NA	0.39	8.71	0.33	2.63e-17	Red blood cell count;
BRCA	cis	rs735860	0.572	rs186003	chr6:53185124	A/C	cg10236188	chr6:53219634	NA	0.4	8.33	0.31	4.81e-16	Glaucoma;
BRCA	cis	rs7975161	0.624	rs11111943	chr12:104632418	T/C	cg25273343	chr12:104657179	TXNRD1	-0.6	-9.46	-0.35	5.94e-20	Toenail selenium levels;
BRCA	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg25173405	chr17:45401733	C17orf57	-0.57	-12.24	-0.44	4.19e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg11764359	chr7:65958608	NA	-0.68	-15.38	-0.52	1.14e-45	Aortic root size;
BRCA	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg00376283	chr12:123451042	ABCB9	0.56	14.55	0.5	1.17e-41	Platelet count;
BRCA	cis	rs73086581	1.000	rs113812453	chr20:3963193	T/C	cg02187196	chr20:3869020	PANK2	0.54	9.56	0.35	2.59e-20	Response to antidepressants in depression;
BRCA	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg17366294	chr4:99064904	C4orf37	0.45	10.63	0.39	2.04e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg15704280	chr7:45808275	SEPT13	-0.78	-17.48	-0.57	3.23e-56	Coronary artery disease;
BRCA	cis	rs9790314	0.715	rs980976	chr3:160771668	T/G	cg04691961	chr3:161091175	C3orf57	-0.42	-8.78	-0.33	1.5e-17	Morning vs. evening chronotype;
BRCA	cis	rs4285028	0.747	rs4048699	chr3:121404483	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.83	15.89	0.53	3.73e-48	Multiple sclerosis;
BRCA	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg06671706	chr8:8559999	CLDN23	0.45	8.64	0.32	4.48e-17	Obesity-related traits;
BRCA	cis	rs4566357	0.615	rs2396445	chr2:227917726	C/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-9.87	-0.36	1.83e-21	Coronary artery disease;
BRCA	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg11366901	chr6:160182831	ACAT2	0.77	14.83	0.51	5.47e-43	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6785206	0.772	rs6439134	chr3:128323504	C/T	cg16766828	chr3:128327626	NA	-0.81	-11.71	-0.42	7.78e-29	Lymphocyte percentage of white cells;
BRCA	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-8.11	-0.31	2.52e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2710642	0.566	rs2710651	chr2:63166379	G/A	cg17519650	chr2:63277830	OTX1	0.42	9.84	0.36	2.25e-21	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.45	-10.51	-0.38	6.06e-24	Longevity;Endometriosis;
BRCA	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg26248373	chr2:1572462	NA	-0.53	-10.85	-0.39	2.73e-25	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg16423285	chr20:60520624	NA	0.63	13.24	0.46	1.48e-35	Obesity-related traits;
BRCA	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.04	-0.3	4.34e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg24675658	chr1:53192096	ZYG11B	0.66	14.87	0.51	3.46e-43	Monocyte count;
BRCA	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg20503657	chr10:835505	NA	0.88	16.0	0.53	1.06e-48	Eosinophil percentage of granulocytes;
BRCA	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg18132916	chr6:79620363	NA	-0.49	-11.12	-0.4	2.26e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg06238570	chr21:40685208	BRWD1	-0.4	-8.18	-0.31	1.55e-15	Menarche (age at onset);
BRCA	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg17971929	chr21:40555470	PSMG1	-0.47	-10.18	-0.37	1.19e-22	Menarche (age at onset);
BRCA	cis	rs3820928	0.874	rs1949807	chr2:227891861	A/G	cg11843606	chr2:227700838	RHBDD1	-0.36	-8.21	-0.31	1.24e-15	Pulmonary function;
BRCA	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg05340658	chr4:99064831	C4orf37	0.56	10.8	0.39	4.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs600231	0.542	rs12360896	chr11:65238306	G/T	cg01292856	chr11:65242576	NA	0.66	14.96	0.51	1.27e-43	Bone mineral density;
BRCA	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg07741184	chr6:167504864	NA	0.27	7.98	0.3	7.04e-15	Crohn's disease;
BRCA	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00166722	chr3:10149974	C3orf24	0.58	8.65	0.32	4.08e-17	Alzheimer's disease;
BRCA	cis	rs3772130	0.886	rs9825248	chr3:121568711	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.68	0.39	1.33e-24	Cognitive performance;
BRCA	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00149659	chr3:10157352	C3orf10	0.71	12.5	0.44	3.07e-32	Alzheimer's disease;
BRCA	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg03146154	chr1:46216737	IPP	-0.45	-9.49	-0.35	4.35e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-13.16	-0.46	3.75e-35	Lymphocyte counts;
BRCA	cis	rs2425143	1.000	rs7273174	chr20:34350306	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.09	-0.34	1.23e-18	Blood protein levels;
BRCA	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26314531	chr2:26401878	FAM59B	-0.97	-16.88	-0.56	3.96e-53	Gut microbiome composition (summer);
BRCA	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg04450456	chr4:17643702	FAM184B	0.42	12.53	0.44	2.21e-32	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10416265	0.528	rs3826906	chr19:33620897	C/T	cg17764715	chr19:33622953	WDR88	0.51	8.15	0.31	1.86e-15	Bone properties (heel);
BRCA	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg03709012	chr19:19516395	GATAD2A	1.08	20.66	0.63	4.98e-73	Nonalcoholic fatty liver disease;
BRCA	cis	rs1029738	0.659	rs1608553	chr7:22896231	G/C	cg06980547	chr7:22894557	NA	-0.38	-8.09	-0.3	3.05e-15	Fibrinogen levels;
BRCA	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg00701064	chr4:6280414	WFS1	0.64	16.21	0.54	8.82e-50	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	trans	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.43	8.98	0.33	3.11e-18	Mean corpuscular volume;
BRCA	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.42	0.54	7.95e-51	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs4930561	0.714	rs7130844	chr11:67927517	C/T	cg04465784	chr11:67976953	SUV420H1	-0.27	-8.72	-0.33	2.4e-17	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.33	9.56	0.35	2.45e-20	Monocyte percentage of white cells;
BRCA	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg19010396	chr19:19431384	KIAA0892;SF4	-0.45	-8.89	-0.33	6.39e-18	Tonsillectomy;
BRCA	cis	rs11958404	0.858	rs72818142	chr5:157474934	C/T	cg05962755	chr5:157440814	NA	0.54	9.55	0.35	2.72e-20	IgG glycosylation;
BRCA	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg18867708	chr6:26865862	GUSBL1	0.4	8.07	0.3	3.47e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7617773	0.780	rs36121690	chr3:48345511	C/T	cg11946769	chr3:48343235	NME6	0.68	13.91	0.48	1.31e-38	Coronary artery disease;
BRCA	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02018176	chr4:1364513	KIAA1530	0.39	8.2	0.31	1.37e-15	Longevity;
BRCA	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg05863683	chr7:1912471	MAD1L1	0.39	7.98	0.3	6.83e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg21905437	chr5:178450457	ZNF879	0.51	10.65	0.39	1.75e-24	Pubertal anthropometrics;
BRCA	cis	rs4853036	0.680	rs35413900	chr2:70113900	C/G	cg02498382	chr2:70120550	SNRNP27	-0.59	-9.55	-0.35	2.75e-20	Colorectal or endometrial cancer;
BRCA	cis	rs16976116	0.851	rs28889339	chr15:55503205	T/G	cg11288833	chr15:55489084	RSL24D1	0.47	10.52	0.38	5.59e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg24631222	chr15:78858424	CHRNA5	-0.5	-9.95	-0.37	9.07e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg21138405	chr5:131827807	IRF1	0.38	11.46	0.41	8.9e-28	Asthma (sex interaction);
BRCA	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg13010199	chr12:38710504	ALG10B	0.39	8.44	0.32	2.08e-16	Bladder cancer;
BRCA	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-16.86	-0.55	5.07e-53	Neuroticism;
BRCA	cis	rs2625529	0.652	rs2957728	chr15:72236432	G/T	cg16672083	chr15:72433130	SENP8	0.67	16.14	0.54	2.14e-49	Red blood cell count;
BRCA	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.56	-13.68	-0.48	1.48e-37	Longevity;Endometriosis;
BRCA	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg08917208	chr2:24149416	ATAD2B	0.52	8.06	0.3	3.64e-15	Asthma;
BRCA	cis	rs9815354	0.812	rs4264702	chr3:41952539	T/A	cg03022575	chr3:42003672	ULK4	0.69	9.62	0.36	1.44e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15506890	chr2:3487001	NA	-0.57	-12.89	-0.45	5.88e-34	Neurofibrillary tangles;
BRCA	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.77	-0.5	1.05e-42	Total cholesterol levels;
BRCA	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg06917634	chr15:78832804	PSMA4	-0.76	-17.8	-0.58	7.59e-58	Sudden cardiac arrest;
BRCA	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg08847533	chr14:75593920	NEK9	-0.82	-19.05	-0.6	2.15e-64	Height;
BRCA	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-11.04	-0.4	4.63e-26	Lymphocyte counts;
BRCA	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg19901468	chr14:105411992	AHNAK2	-0.51	-12.4	-0.44	8.92e-32	Rheumatoid arthritis;
BRCA	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.15	0.31	1.97e-15	Breast cancer;
BRCA	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.19	-0.34	5.61e-19	Neuroticism;
BRCA	cis	rs9560113	1.000	rs9560113	chr13:112183348	A/G	cg10483660	chr13:112241077	NA	0.32	8.16	0.31	1.79e-15	Menarche (age at onset);
BRCA	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg16325326	chr1:53192061	ZYG11B	-0.7	-18.31	-0.59	1.56e-60	Monocyte count;
BRCA	cis	rs7129727	1	rs7129727	chr11:57484660	G/A	cg19752551	chr11:57585705	CTNND1	-0.42	-10.8	-0.39	4.38e-25	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg10932868	chr11:921992	NA	0.47	12.11	0.43	1.62e-30	Alzheimer's disease (late onset);
BRCA	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg17509989	chr5:176798049	RGS14	-0.74	-11.99	-0.43	5.26e-30	Urate levels in lean individuals;
BRCA	cis	rs13053817	1.000	rs71329487	chr22:29833469	A/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.51	-9.6	-0.36	1.7e-20	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg07080220	chr10:102295463	HIF1AN	0.49	10.31	0.38	3.54e-23	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.72	-11.38	-0.41	1.88e-27	Red cell distribution width;
BRCA	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	13.75	0.48	7.09e-38	Alzheimer's disease;
BRCA	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg14983838	chr19:29218262	NA	0.49	9.81	0.36	2.86e-21	Methadone dose in opioid dependence;
BRCA	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg11764359	chr7:65958608	NA	0.64	11.52	0.41	5.18e-28	Aortic root size;
BRCA	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg27433088	chr4:174089019	GALNT7	0.33	8.91	0.33	5.2e-18	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	10.2	0.37	9.38e-23	Lung cancer in ever smokers;
BRCA	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg05234568	chr11:5960015	NA	-0.49	-9.66	-0.36	1.04e-20	DNA methylation (variation);
BRCA	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-11.35	-0.41	2.5e-27	Neuroticism;
BRCA	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.01	0.34	2.36e-18	Motion sickness;
BRCA	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg12379764	chr21:47803548	PCNT	0.37	8.06	0.3	3.78e-15	Testicular germ cell tumor;
BRCA	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg04248312	chr19:17393744	ANKLE1	0.91	20.45	0.63	6.59e-72	Systemic lupus erythematosus;
BRCA	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg06271696	chr7:157225062	NA	-0.39	-10.35	-0.38	2.6e-23	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg12386194	chr3:101231763	SENP7	0.46	9.91	0.36	1.29e-21	Colorectal cancer;
BRCA	cis	rs6901250	0.655	rs9384990	chr6:117126941	A/G	cg12892004	chr6:117198278	RFX6	0.38	9.28	0.34	2.5e-19	C-reactive protein levels;
BRCA	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg04944784	chr2:26401820	FAM59B	-0.96	-16.37	-0.54	1.41e-50	Gut microbiome composition (summer);
BRCA	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg18154014	chr19:37997991	ZNF793	0.48	9.41	0.35	8.46e-20	Coronary artery calcification;
BRCA	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg08601574	chr20:25228251	PYGB	0.34	8.15	0.31	1.86e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6450176	0.909	rs10940353	chr5:53299959	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-14.52	-0.5	1.65e-41	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg13010199	chr12:38710504	ALG10B	0.47	8.99	0.34	2.82e-18	Morning vs. evening chronotype;
BRCA	cis	rs36051895	0.659	rs10815150	chr9:5067301	C/A	cg02405213	chr9:5042618	JAK2	-0.49	-9.43	-0.35	7.63e-20	Pediatric autoimmune diseases;
BRCA	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-10.3	-0.38	4e-23	Reticulocyte count;
BRCA	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg17063962	chr7:91808500	NA	-0.56	-12.82	-0.45	1.23e-33	Breast cancer;
BRCA	trans	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-8.67	-0.32	3.65e-17	Triglycerides;
BRCA	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.74e-16	Menopause (age at onset);
BRCA	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg03929089	chr4:120376271	NA	0.56	9.69	0.36	8.39e-21	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs11051970	0.879	rs950079	chr12:32588620	A/G	cg24626660	chr12:32551988	NA	0.29	8.36	0.31	4e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	trans	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg15556689	chr8:8085844	FLJ10661	-0.36	-8.37	-0.31	3.68e-16	Triglycerides;
BRCA	cis	rs2964802	0.505	rs7729989	chr5:10822246	A/G	cg14521931	chr5:10832172	NA	-0.58	-12.68	-0.45	5.14e-33	Major depressive disorder;Recurrent major depressive disorder;
BRCA	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg06713675	chr4:122721982	EXOSC9	-0.53	-12.07	-0.43	2.42e-30	Type 2 diabetes;
BRCA	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg03676636	chr4:99064102	C4orf37	0.23	8.26	0.31	8.09e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg09060608	chr5:178986726	RUFY1	0.61	15.62	0.53	8.06e-47	Lung cancer;
BRCA	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg01256987	chr12:42539512	GXYLT1	-0.47	-9.24	-0.34	3.68e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg00531865	chr16:30841666	NA	-0.5	-10.99	-0.4	7.23e-26	Multiple myeloma;
BRCA	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg04267008	chr7:1944627	MAD1L1	-0.46	-9.79	-0.36	3.56e-21	Schizophrenia;
BRCA	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg23788917	chr6:8435910	SLC35B3	0.49	10.55	0.39	4.36e-24	Motion sickness;
BRCA	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg19622623	chr12:86230825	RASSF9	-0.33	-9.31	-0.35	2.09e-19	Major depressive disorder;
BRCA	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg11502198	chr6:26597334	ABT1	0.48	9.57	0.35	2.28e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg11663144	chr21:46675770	NA	-0.55	-12.98	-0.46	2.41e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2230307	0.536	rs554742	chr1:100512568	G/A	cg24955406	chr1:100503596	HIAT1	0.53	10.09	0.37	2.55e-22	Carotid intima media thickness;
BRCA	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg05623727	chr3:50126028	RBM5	0.43	8.97	0.33	3.23e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-11.1	-0.4	2.77e-26	Glomerular filtration rate (creatinine);
BRCA	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.76	12.5	0.44	3.29e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2742234	0.590	rs1254960	chr10:43699657	C/T	cg15436174	chr10:43711423	RASGEF1A	0.57	11.53	0.41	4.62e-28	Hirschsprung disease;
BRCA	cis	rs9381107	1.000	rs9381212	chr6:9476532	C/T	cg14735645	chr6:9486422	NA	-0.45	-8.01	-0.3	5.47e-15	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg01877450	chr7:97915802	BRI3	-0.37	-8.33	-0.31	4.82e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.86	0.39	2.42e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg12219531	chr12:120966889	COQ5	0.53	11.33	0.41	2.99e-27	High light scatter reticulocyte count;
BRCA	cis	rs7945718	0.967	rs7931147	chr11:12748884	C/A	cg25843174	chr11:12811716	TEAD1	0.21	8.02	0.3	4.91e-15	Educational attainment (years of education);
BRCA	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg12062639	chr20:23401060	NAPB	0.89	12.67	0.45	5.41e-33	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	trans	rs877282	0.945	rs11253397	chr10:789774	A/G	cg22713356	chr15:30763199	NA	1.42	28.55	0.75	3.22e-116	Uric acid levels;
BRCA	cis	rs6545883	0.894	rs2600660	chr2:61549600	G/T	cg15711740	chr2:61764176	XPO1	0.5	12.15	0.43	1.1e-30	Tuberculosis;
BRCA	trans	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg23762105	chr12:34175262	ALG10	-0.38	-9.72	-0.36	6.49e-21	Morning vs. evening chronotype;
BRCA	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg02389323	chr16:88786976	FAM38A	-0.61	-10.68	-0.39	1.28e-24	Plateletcrit;
BRCA	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg16339924	chr4:17578868	LAP3	0.64	16.18	0.54	1.37e-49	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03517284	chr6:25882590	NA	-0.45	-9.31	-0.35	2.09e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.39	8.33	0.31	4.96e-16	Osteoporosis;
BRCA	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.94	-0.37	9.36e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg11062466	chr8:58055876	NA	0.49	8.53	0.32	1.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg09263875	chr16:632152	PIGQ	0.73	21.35	0.65	9.35e-77	Height;
BRCA	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.6	-11.64	-0.42	1.54e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7246657	0.722	rs3829688	chr19:38077100	T/C	cg18154014	chr19:37997991	ZNF793	0.48	9.16	0.34	7.24e-19	Coronary artery calcification;
BRCA	cis	rs7572733	0.555	rs2342558	chr2:198920142	T/C	cg00792783	chr2:198669748	PLCL1	0.39	8.75	0.33	1.94e-17	Dermatomyositis;
BRCA	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg10729496	chr3:10149963	C3orf24	0.49	9.27	0.34	2.92e-19	Alzheimer's disease;
BRCA	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg21132104	chr15:45694354	SPATA5L1	0.75	16.48	0.55	4.24e-51	Homoarginine levels;
BRCA	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-9.92	-0.37	1.1e-21	Alzheimer's disease (late onset);
BRCA	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg14963724	chr18:72166303	CNDP2	-0.34	-9.53	-0.35	3.34e-20	Refractive error;
BRCA	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg17063962	chr7:91808500	NA	-0.55	-12.54	-0.44	2.02e-32	Breast cancer;
BRCA	cis	rs27434	0.583	rs149431	chr5:96157541	T/C	cg16492584	chr5:96139282	ERAP1	-0.5	-12.76	-0.45	2.31e-33	Ankylosing spondylitis;
BRCA	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg12564285	chr5:131593104	PDLIM4	0.32	7.98	0.3	6.58e-15	Blood metabolite levels;
BRCA	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg15839431	chr19:19639596	YJEFN3	-0.41	-8.93	-0.33	4.43e-18	Bipolar disorder;
BRCA	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg09307838	chr4:120376055	NA	0.63	13.53	0.47	7.67e-37	Educational attainment;
BRCA	cis	rs698833	0.859	rs1302175	chr2:44657024	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	9.9	0.36	1.36e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-9.11	-0.34	1.06e-18	Alzheimer's disease;
BRCA	cis	rs501916	0.604	rs616871	chr15:48058259	T/A	cg16110827	chr15:48056943	SEMA6D	-0.42	-9.2	-0.34	5.1e-19	Inflammatory bowel disease;Ulcerative colitis;
BRCA	trans	rs8073060	0.586	rs225265	chr17:33961972	C/T	cg19694781	chr19:47549865	TMEM160	-1.05	-21.13	-0.64	1.41e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg00666640	chr1:248458726	OR2T12	0.32	8.92	0.33	5.05e-18	Common traits (Other);
BRCA	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg27170947	chr2:26402098	FAM59B	0.65	11.43	0.41	1.22e-27	Gut microbiome composition (summer);
BRCA	trans	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg11693508	chr17:37793320	STARD3	-0.43	-8.89	-0.33	6.1e-18	Bipolar disorder;
BRCA	cis	rs13064411	0.696	rs6769516	chr3:113219905	T/C	cg18753928	chr3:113234510	CCDC52	-0.59	-12.52	-0.44	2.53e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	19.54	0.61	4.85e-67	Platelet count;
BRCA	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.19	0.37	1.03e-22	Aortic root size;
BRCA	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.46	-0.32	1.82e-16	Monocyte percentage of white cells;
BRCA	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	18.79	0.6	5.12e-63	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg03929089	chr4:120376271	NA	-0.69	-13.76	-0.48	6.25e-38	Coronary artery disease;
BRCA	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg09060608	chr5:178986726	RUFY1	0.47	11.24	0.41	7.32e-27	Lung cancer;
BRCA	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg17691542	chr6:26056736	HIST1H1C	0.49	10.08	0.37	2.84e-22	Height;
BRCA	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg24579218	chr15:68104479	NA	0.37	8.12	0.31	2.5e-15	Restless legs syndrome;
BRCA	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg21747090	chr2:27597821	SNX17	-0.37	-7.89	-0.3	1.33e-14	Total body bone mineral density;
BRCA	cis	rs4363385	0.791	rs372490	chr1:153008971	A/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.94	-0.51	1.6e-43	Total cholesterol levels;
BRCA	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg11843238	chr5:131593191	PDLIM4	0.36	8.01	0.3	5.43e-15	Blood metabolite levels;
BRCA	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg26838691	chr2:24397539	C2orf84	0.41	8.26	0.31	8.66e-16	Asthma;
BRCA	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	10.01	0.37	5.21e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4780401	0.573	rs8045673	chr16:11804385	C/A	cg01061890	chr16:11836724	TXNDC11	-0.54	-12.29	-0.44	2.51e-31	Rheumatoid arthritis;
BRCA	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg18225595	chr11:63971243	STIP1	0.6	15.04	0.51	5.18e-44	Platelet count;
BRCA	cis	rs10501293	1.000	rs7111028	chr11:43060516	C/T	cg03447554	chr11:43094025	NA	0.5	9.15	0.34	7.78e-19	Cognitive performance;
BRCA	cis	rs367943	0.965	rs458044	chr5:112797779	A/G	cg12552261	chr5:112820674	MCC	-0.55	-12.11	-0.43	1.5e-30	Type 2 diabetes;
BRCA	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-8.77	-0.33	1.65e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.64	-0.42	1.55e-28	Mean corpuscular volume;
BRCA	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg14963724	chr18:72166303	CNDP2	-0.33	-9.1	-0.34	1.16e-18	Refractive error;
BRCA	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26314531	chr2:26401878	FAM59B	-0.9	-16.15	-0.54	1.92e-49	Gut microbiome composition (summer);
BRCA	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg13010199	chr12:38710504	ALG10B	0.44	8.8	0.33	1.24e-17	Morning vs. evening chronotype;
BRCA	cis	rs870825	0.929	rs55880126	chr4:185591237	T/G	cg20176042	chr4:185552304	CASP3	-0.62	-8.51	-0.32	1.27e-16	Blood protein levels;
BRCA	cis	rs11191270	0.784	rs11191264	chr10:104096732	A/T	cg15320455	chr10:103880129	LDB1	0.49	8.0	0.3	5.96e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs8002861	0.619	rs9567289	chr13:44437104	C/T	cg12856521	chr11:46389249	DGKZ	0.37	8.14	0.31	2.09e-15	Leprosy;
BRCA	cis	rs586533	0.846	rs644737	chr11:99502337	G/C	cg22878054	chr11:99397252	CNTN5	0.32	8.06	0.3	3.65e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9473147	0.516	rs9381579	chr6:47556680	C/T	cg12968598	chr6:47444699	CD2AP	0.44	9.62	0.36	1.56e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	30.46	0.77	1.4e-126	Chronic sinus infection;
BRCA	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14829155	chr15:31115871	NA	-0.43	-10.05	-0.37	3.67e-22	Huntington's disease progression;
BRCA	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg24829409	chr8:58192753	C8orf71	-0.43	-8.55	-0.32	9.12e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg08213375	chr14:104286397	PPP1R13B	0.61	16.2	0.54	1.06e-49	Schizophrenia;
BRCA	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-10.28	-0.38	4.7e-23	Schizophrenia;
BRCA	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg02820040	chr2:241836501	C2orf54	-0.51	-9.79	-0.36	3.56e-21	Urinary metabolites;
BRCA	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg25036284	chr2:26402008	FAM59B	-0.91	-15.44	-0.52	6.18e-46	Gut microbiome composition (summer);
BRCA	cis	rs77972916	0.536	rs6751209	chr2:43588302	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-10.8	-0.39	4.49e-25	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg14683738	chr19:37701593	ZNF585B	0.45	8.02	0.3	4.94e-15	Coronary artery calcification;
BRCA	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.1	0.34	1.13e-18	Tonsillectomy;
BRCA	trans	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	11.81	0.42	2.92e-29	Exhaled nitric oxide output;
BRCA	cis	rs9807989	0.507	rs1420105	chr2:103035119	A/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.51	0.32	1.28e-16	Asthma;
BRCA	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg13334819	chr7:99746414	C7orf59	-0.34	-8.11	-0.31	2.68e-15	Coronary artery disease;
BRCA	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg26384229	chr12:38710491	ALG10B	0.55	13.73	0.48	8.81e-38	Morning vs. evening chronotype;
BRCA	cis	rs4908768	0.539	rs1061039	chr1:8642588	T/C	cg20416874	chr1:8611966	RERE	-0.27	-7.87	-0.3	1.51e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg22676075	chr6:135203613	NA	0.43	8.51	0.32	1.21e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg12310025	chr6:25882481	NA	0.41	9.36	0.35	1.34e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg17691542	chr6:26056736	HIST1H1C	0.64	11.23	0.41	7.48e-27	Iron status biomarkers;
BRCA	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11644478	chr21:40555479	PSMG1	0.83	19.17	0.6	4.6e-65	Cognitive function;
BRCA	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg03806693	chr22:41940476	POLR3H	-1.11	-21.97	-0.66	3.88e-80	Vitiligo;
BRCA	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-9.8	-0.36	3.28e-21	Alzheimer's disease (late onset);
BRCA	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	9.51	0.35	3.93e-20	Iron status biomarkers;
BRCA	cis	rs877282	0.898	rs11253338	chr10:759559	C/T	cg17470449	chr10:769945	NA	0.47	7.99	0.3	6.3e-15	Uric acid levels;
BRCA	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs68170813	0.559	rs6967638	chr7:106929356	T/G	cg02696742	chr7:106810147	HBP1	-0.54	-8.66	-0.32	3.83e-17	Coronary artery disease;
BRCA	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg25809561	chr17:30822961	MYO1D	-0.38	-9.26	-0.34	2.98e-19	Schizophrenia;
BRCA	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg17063962	chr7:91808500	NA	0.56	11.76	0.42	4.86e-29	Breast cancer;
BRCA	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg13010199	chr12:38710504	ALG10B	-0.36	-8.59	-0.32	6.9e-17	Morning vs. evening chronotype;
BRCA	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg25174290	chr11:3078921	CARS	-0.3	-7.85	-0.3	1.72e-14	Calcium levels;
BRCA	cis	rs7617773	0.780	rs4511916	chr3:48350366	G/A	cg11946769	chr3:48343235	NME6	0.69	14.01	0.48	4.54e-39	Coronary artery disease;
BRCA	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-15.16	-0.51	1.43e-44	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg03264133	chr6:25882463	NA	-0.37	-8.1	-0.31	2.85e-15	Height;
BRCA	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg06238570	chr21:40685208	BRWD1	-0.47	-9.31	-0.35	1.97e-19	Cognitive function;
BRCA	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg23649088	chr2:200775458	C2orf69	0.6	8.92	0.33	4.8e-18	Schizophrenia;
BRCA	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg11584989	chr19:19387371	SF4	0.66	14.59	0.5	8.19e-42	Bipolar disorder;
BRCA	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg13902645	chr11:5959945	NA	-0.49	-10.01	-0.37	5.17e-22	DNA methylation (variation);
BRCA	cis	rs3784262	0.631	rs6493980	chr15:58352290	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.23	-0.38	7.54e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs3125734	0.660	rs4979780	chr10:63992740	A/C	cg19640130	chr10:64028056	RTKN2	-0.29	-8.24	-0.31	9.67e-16	Rheumatoid arthritis;
BRCA	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg22907277	chr7:1156413	C7orf50	0.58	8.91	0.33	5.37e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7715811	0.913	rs10513154	chr5:13780601	T/C	cg07548982	chr5:13769939	DNAH5	-0.4	-8.74	-0.33	2.08e-17	Subclinical atherosclerosis traits (other);
BRCA	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.89	0.56	3.56e-53	Colorectal cancer;
BRCA	cis	rs11971779	0.793	rs11772447	chr7:139033589	T/G	cg07862535	chr7:139043722	LUC7L2	0.44	11.63	0.42	1.73e-28	Diisocyanate-induced asthma;
BRCA	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg25358565	chr5:93447407	FAM172A	1.18	17.78	0.58	9.73e-58	Diabetic retinopathy;
BRCA	cis	rs12760731	0.565	rs35926996	chr1:178075351	A/G	cg00404053	chr1:178313656	RASAL2	0.66	8.05	0.3	4.02e-15	Obesity-related traits;
BRCA	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg14675211	chr2:100938903	LONRF2	0.52	11.77	0.42	4.22e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07343612	chr16:622815	PIGQ	-0.68	-22.12	-0.66	6.49e-81	Height;
BRCA	cis	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg05901451	chr6:126070800	HEY2	-0.39	-9.41	-0.35	9.06e-20	Endometrial cancer;
BRCA	cis	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.75	-0.33	1.96e-17	Resting heart rate;
BRCA	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.16	-0.31	1.74e-15	Total body bone mineral density;
BRCA	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg06046430	chr4:77819534	ANKRD56	0.61	13.63	0.47	2.57e-37	Emphysema distribution in smoking;
BRCA	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.38	-0.38	1.93e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9649465	0.967	rs1008539	chr7:123305518	G/A	cg04330084	chr7:123175371	IQUB	-0.3	-8.34	-0.31	4.66e-16	Migraine;
BRCA	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.67	-0.36	9.82e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs36051895	0.664	rs2274649	chr9:5090934	A/T	cg02405213	chr9:5042618	JAK2	-0.5	-8.91	-0.33	5.35e-18	Pediatric autoimmune diseases;
BRCA	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg16102102	chr5:83017553	HAPLN1	-0.9	-18.33	-0.59	1.26e-60	Prostate cancer;
BRCA	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg04455712	chr21:45112962	RRP1B	0.39	10.01	0.37	5.14e-22	Mean corpuscular volume;
BRCA	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg22972055	chr7:872293	UNC84A	0.38	8.51	0.32	1.24e-16	Cerebrospinal P-tau181p levels;
BRCA	cis	rs858239	0.568	rs6970694	chr7:23250828	T/C	cg23682824	chr7:23144976	KLHL7	0.34	8.56	0.32	8.41e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7254827	1.000	rs4808566	chr19:17214051	T/G	cg19418318	chr19:17219073	MYO9B	-0.49	-10.25	-0.38	6.25e-23	Mean platelet volume;
BRCA	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.94	-0.33	4.23e-18	Alzheimer's disease (late onset);
BRCA	trans	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg21775007	chr8:11205619	TDH	0.39	8.04	0.3	4.41e-15	Mood instability;
BRCA	cis	rs7177699	0.557	rs7403728	chr15:79112016	T/G	cg00540400	chr15:79124168	NA	-0.28	-7.81	-0.3	2.4e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-16.53	-0.55	2.17e-51	Lymphocyte percentage of white cells;
BRCA	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg10518543	chr12:38710700	ALG10B	0.36	7.97	0.3	7.37e-15	Morning vs. evening chronotype;
BRCA	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg00677455	chr12:58241039	CTDSP2	0.67	15.08	0.51	3.6e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.52	0.38	5.68e-24	Motion sickness;
BRCA	cis	rs9815354	0.812	rs61661916	chr3:41921915	T/C	cg03022575	chr3:42003672	ULK4	0.69	9.49	0.35	4.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg25237894	chr2:233734115	C2orf82	-0.4	-11.34	-0.41	2.66e-27	Coronary artery disease;
BRCA	cis	rs7945718	0.839	rs763373	chr11:12840342	C/G	cg25843174	chr11:12811716	TEAD1	-0.21	-8.1	-0.3	2.9e-15	Educational attainment (years of education);
BRCA	trans	rs1997103	1.000	rs1997102	chr7:55399322	A/C	cg20935933	chr6:143382018	AIG1	-0.61	-11.42	-0.41	1.31e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-10.58	-0.39	3.11e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg24006582	chr15:45444508	DUOX1	-0.53	-10.98	-0.4	7.9e-26	Uric acid levels;
BRCA	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg13175981	chr1:150552382	MCL1	0.42	9.4	0.35	9.26e-20	Tonsillectomy;
BRCA	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25427524	chr10:38739819	LOC399744	-0.61	-13.9	-0.48	1.45e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg02734326	chr4:10020555	SLC2A9	0.39	8.48	0.32	1.59e-16	Bone mineral density;
BRCA	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg08805041	chr16:621841	PIGQ	-0.32	-8.52	-0.32	1.14e-16	Height;
BRCA	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg09654669	chr8:57350985	NA	-0.38	-8.35	-0.31	4.27e-16	Obesity-related traits;
BRCA	trans	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg25214090	chr10:38739885	LOC399744	0.45	10.36	0.38	2.38e-23	Corneal astigmatism;
BRCA	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-13.47	-0.47	1.36e-36	Morning vs. evening chronotype;
BRCA	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg00012203	chr2:219082015	ARPC2	0.69	15.41	0.52	8.8e-46	Colorectal cancer;
BRCA	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg05623727	chr3:50126028	RBM5	0.43	10.11	0.37	2.24e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7552167	1.000	rs59960858	chr1:24519437	C/A	cg01960748	chr1:24522592	NA	0.63	10.48	0.38	8.28e-24	Psoriasis vulgaris;
BRCA	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg00105475	chr2:10696890	NA	0.42	9.61	0.36	1.65e-20	Prostate cancer;
BRCA	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg18252515	chr7:66147081	NA	-1.06	-15.7	-0.53	3.29e-47	Diabetic kidney disease;
BRCA	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg07308232	chr7:1071921	C7orf50	-0.36	-7.9	-0.3	1.26e-14	Longevity;Endometriosis;
BRCA	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-10.32	-0.38	3.37e-23	Blood metabolite levels;
BRCA	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg16141378	chr3:129829833	LOC729375	0.32	7.9	0.3	1.19e-14	Neuroticism;
BRCA	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	15.57	0.52	1.4e-46	Colorectal cancer;
BRCA	trans	rs9409565	0.826	rs9409556	chr9:97239268	T/C	cg05679027	chr9:99775184	HIATL2	-0.43	-9.42	-0.35	8.31e-20	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs6714710	0.603	rs35505530	chr2:98506910	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	13.47	0.47	1.4e-36	Posterior cortical atrophy and Alzheimer's disease;
BRCA	trans	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg25214090	chr10:38739885	LOC399744	0.57	12.97	0.46	2.58e-34	Corneal astigmatism;
BRCA	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.35e-15	Prostate cancer;
BRCA	cis	rs7818345	0.967	rs12543061	chr8:19286181	G/T	cg11303988	chr8:19266685	CSGALNACT1	-0.31	-8.23	-0.31	1.01e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg05347473	chr6:146136440	FBXO30	-0.42	-8.36	-0.31	3.91e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-12.6	-0.45	1.13e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs11229555	0.645	rs61903159	chr11:58184475	G/A	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg06627628	chr2:24431161	ITSN2	-0.54	-8.81	-0.33	1.15e-17	Lymphocyte counts;
BRCA	cis	rs9790314	0.747	rs7619011	chr3:160855676	A/G	cg04691961	chr3:161091175	C3orf57	-0.37	-8.01	-0.3	5.29e-15	Morning vs. evening chronotype;
BRCA	cis	rs13046373	0.535	rs1605428	chr21:32028976	T/C	cg16812893	chr21:31813075	KRTAP15-1	0.38	9.18	0.34	5.98e-19	HDL cholesterol;
BRCA	cis	rs6450176	1.000	rs4588541	chr5:53300640	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-15.14	-0.51	1.8e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg22920501	chr2:26401640	FAM59B	-0.67	-11.5	-0.41	5.96e-28	Gut microbiome composition (summer);
BRCA	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg07741184	chr6:167504864	NA	0.33	9.87	0.36	1.8e-21	Primary biliary cholangitis;
BRCA	cis	rs490234	0.783	rs13284243	chr9:128381785	A/G	cg14078157	chr9:128172775	NA	-0.46	-10.58	-0.39	3.23e-24	Mean arterial pressure;
BRCA	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.49	-8.72	-0.33	2.4e-17	Schizophrenia;
BRCA	cis	rs6740322	0.895	rs13384080	chr2:43557363	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-12.11	-0.43	1.53e-30	Coronary artery disease;
BRCA	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg12927641	chr6:109611667	NA	-0.37	-9.15	-0.34	7.79e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg05985134	chr18:33552581	C18orf21	0.64	11.51	0.41	5.2e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-9.06	-0.34	1.56e-18	Retinal vascular caliber;
BRCA	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg04518342	chr5:131593106	PDLIM4	-0.37	-9.22	-0.34	4.32e-19	Breast cancer;
BRCA	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg14004847	chr7:1930337	MAD1L1	-0.47	-9.94	-0.37	9.49e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg05347473	chr6:146136440	FBXO30	0.41	8.05	0.3	3.92e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg11266682	chr4:10021025	SLC2A9	0.44	11.28	0.41	5.03e-27	Bone mineral density;
BRCA	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12826209	chr6:26865740	GUSBL1	0.72	12.83	0.45	1.08e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs4722166	0.598	rs4722180	chr7:22805072	A/G	cg05472934	chr7:22766657	IL6	0.4	9.87	0.36	1.69e-21	Lung cancer;
BRCA	cis	rs7617773	0.780	rs3731489	chr3:48228906	C/A	cg11946769	chr3:48343235	NME6	0.67	13.95	0.48	8.71e-39	Coronary artery disease;
BRCA	cis	rs503734	0.504	rs348873	chr3:100930665	C/T	cg27318481	chr3:100970896	IMPG2	-0.37	-8.84	-0.33	9.1e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg14847009	chr1:175162515	KIAA0040	0.25	9.67	0.36	1.01e-20	Alcohol dependence;
BRCA	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.68	-0.32	3.22e-17	Total body bone mineral density;
BRCA	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg23711669	chr6:146136114	FBXO30	0.77	17.81	0.58	6.21e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg01877450	chr7:97915802	BRI3	-0.39	-8.98	-0.33	3.1e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg18404041	chr3:52824283	ITIH1	-0.35	-9.13	-0.34	8.95e-19	Schizophrenia;
BRCA	cis	rs11893307	0.599	rs11900857	chr2:191659011	T/C	cg05765582	chr2:191677683	NA	0.44	8.08	0.3	3.34e-15	Mean platelet volume;
BRCA	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg04990556	chr1:26633338	UBXN11	0.54	8.85	0.33	8.36e-18	Obesity-related traits;
BRCA	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg18230493	chr5:56204884	C5orf35	-0.69	-13.43	-0.47	2.18e-36	Initial pursuit acceleration;
BRCA	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	21.9	0.65	9.33e-80	Platelet count;
BRCA	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	13.58	0.47	4.44e-37	Mood instability;
BRCA	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg01262667	chr19:19385393	TM6SF2	0.38	8.18	0.31	1.52e-15	Nonalcoholic fatty liver disease;
BRCA	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.52	0.44	2.49e-32	Electroencephalogram traits;
BRCA	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs3762637	1.000	rs28434553	chr3:122229515	C/A	cg24169773	chr3:122142474	KPNA1	-0.43	-8.03	-0.3	4.75e-15	LDL cholesterol levels;
BRCA	cis	rs7927771	0.524	rs11039419	chr11:47851354	C/T	cg20307385	chr11:47447363	PSMC3	0.41	9.4	0.35	9.67e-20	Subjective well-being;
BRCA	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.06	-0.34	1.53e-18	Total body bone mineral density;
BRCA	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg01877450	chr7:97915802	BRI3	-0.37	-8.6	-0.32	6.32e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.81	0.39	3.95e-25	Bipolar disorder;
BRCA	cis	rs870825	0.616	rs4256263	chr4:185622959	C/A	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24549020	chr5:56110836	MAP3K1	0.41	8.66	0.32	3.76e-17	Initial pursuit acceleration;
BRCA	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg10523679	chr1:76189770	ACADM	0.76	16.11	0.54	2.87e-49	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs78487399	0.908	rs73925552	chr2:43810564	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-7.89	-0.3	1.33e-14	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg18811423	chr2:55921094	PNPT1	0.78	26.77	0.73	1.8e-106	Metabolic syndrome;
BRCA	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.35	-12.1	-0.43	1.72e-30	Electroencephalogram traits;
BRCA	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg24531977	chr5:56204891	C5orf35	-0.44	-9.25	-0.34	3.45e-19	Coronary artery disease;
BRCA	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	8.1	0.3	2.89e-15	Diabetic retinopathy;
BRCA	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg14683738	chr19:37701593	ZNF585B	0.44	7.89	0.3	1.3e-14	Coronary artery calcification;
BRCA	cis	rs877529	0.967	rs139414	chr22:39553819	G/A	cg12193277	chr22:39547181	CBX7	0.47	12.96	0.46	2.86e-34	Multiple myeloma;
BRCA	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.6	-0.36	1.78e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg06521331	chr12:34319734	NA	-0.56	-10.12	-0.37	2.01e-22	Morning vs. evening chronotype;
BRCA	cis	rs1011018	0.628	rs17262662	chr7:139468767	A/G	cg03224163	chr7:139420300	HIPK2	-0.52	-8.37	-0.31	3.63e-16	Systolic blood pressure;
BRCA	cis	rs6570726	0.526	rs9376928	chr6:145724403	T/G	cg23711669	chr6:146136114	FBXO30	-0.44	-9.52	-0.35	3.58e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg14675211	chr2:100938903	LONRF2	0.51	11.32	0.41	3.34e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.43	-0.47	2.03e-36	Developmental language disorder (linguistic errors);
BRCA	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.98	-0.48	6.13e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg21395723	chr22:39101663	GTPBP1	-0.42	-9.1	-0.34	1.15e-18	Menopause (age at onset);
BRCA	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg08738300	chr3:44038990	NA	0.47	9.28	0.34	2.53e-19	Coronary artery disease;
BRCA	cis	rs28735056	0.933	rs56181785	chr18:77633629	G/A	cg20368463	chr18:77673604	PQLC1	-0.35	-8.06	-0.3	3.66e-15	Schizophrenia;
BRCA	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	10.58	0.39	3.13e-24	Aortic root size;
BRCA	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.06	-25.8	-0.71	4.21e-101	Ulcerative colitis;
BRCA	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg10295955	chr4:187884368	NA	0.9	26.7	0.73	4.65e-106	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs490234	0.841	rs7856366	chr9:128442229	A/G	cg14078157	chr9:128172775	NA	-0.4	-9.23	-0.34	3.83e-19	Mean arterial pressure;
BRCA	cis	rs7789940	0.904	rs56919252	chr7:75937520	T/C	cg10167463	chr7:75959203	YWHAG	-0.44	-8.68	-0.32	3.3e-17	Multiple sclerosis;
BRCA	cis	rs701145	0.556	rs355758	chr3:154007682	C/G	cg16511985	chr3:153974050	SGEF	-0.42	-9.6	-0.36	1.71e-20	Coronary artery disease;
BRCA	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg21905437	chr5:178450457	ZNF879	-0.49	-10.43	-0.38	1.27e-23	Pubertal anthropometrics;
BRCA	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg27279351	chr12:120934652	DYNLL1	0.51	12.31	0.44	2.14e-31	High light scatter reticulocyte count;
BRCA	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.38	-0.38	2.0500000000000001e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.34	-8.57	-0.32	7.64e-17	Total body bone mineral density;
BRCA	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg10057126	chr4:77819792	ANKRD56	0.67	15.48	0.52	3.96e-46	Emphysema distribution in smoking;
BRCA	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg15017067	chr4:17643749	FAM184B	0.35	10.93	0.4	1.31e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg19539972	chr4:7069911	GRPEL1	-0.63	-11.91	-0.43	1.08e-29	Monocyte percentage of white cells;
BRCA	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.83	-0.36	2.46e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg26384229	chr12:38710491	ALG10B	0.84	22.66	0.67	6.72e-84	Heart rate;
BRCA	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18876405	chr7:65276391	NA	0.55	13.35	0.47	4.99e-36	Aortic root size;
BRCA	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.94e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9309711	0.961	rs11890651	chr2:3482796	T/G	cg10845886	chr2:3471009	TTC15	-0.74	-16.35	-0.54	1.89e-50	Neurofibrillary tangles;
BRCA	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg02297831	chr4:17616191	MED28	0.38	8.97	0.33	3.37e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg26597838	chr10:835615	NA	1.04	17.84	0.58	4.61e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs10193935	0.901	rs10200353	chr2:42509554	A/G	cg27598129	chr2:42591480	NA	-0.95	-14.65	-0.5	4.33e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6546550	0.933	rs6546554	chr2:70135706	G/A	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.62	-0.42	1.93e-28	Prevalent atrial fibrillation;
BRCA	cis	rs2742234	1.000	rs1864395	chr10:43655697	G/A	cg02780029	chr10:43622663	RET	-0.4	-10.05	-0.37	3.61e-22	Hirschsprung disease;
BRCA	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg04166393	chr7:2884313	GNA12	0.5	9.55	0.35	2.61e-20	Height;
BRCA	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg16386425	chr10:429943	DIP2C	-0.42	-9.06	-0.34	1.6e-18	Psychosis in Alzheimer's disease;
BRCA	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg21775007	chr8:11205619	TDH	0.75	18.71	0.59	1.27e-62	Retinal vascular caliber;
BRCA	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.32	-9.63	-0.36	1.43e-20	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg21573476	chr21:45109991	RRP1B	0.45	11.53	0.42	4.35e-28	Mean corpuscular volume;
BRCA	cis	rs1003719	0.715	rs2835640	chr21:38537380	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.54	-0.5	1.43e-41	Eye color traits;
BRCA	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	9.21	0.34	4.77e-19	Mean platelet volume;
BRCA	cis	rs10165862	0.537	rs17009372	chr2:73955571	A/G	cg20560298	chr2:73613845	ALMS1	0.4	8.25	0.31	8.93e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7809950	0.784	rs7803102	chr7:107248929	T/G	cg23024343	chr7:107201750	COG5	0.4	8.97	0.33	3.17e-18	Coronary artery disease;
BRCA	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.56	-10.47	-0.38	8.67e-24	Renal function-related traits (BUN);
BRCA	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg24829409	chr8:58192753	C8orf71	-0.49	-9.25	-0.34	3.45e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg27411982	chr8:10470053	RP1L1	0.32	7.88	0.3	1.42e-14	Neuroticism;
BRCA	cis	rs7246967	0.673	rs12978794	chr19:22812134	C/T	cg23217946	chr19:22817039	ZNF492	0.47	8.43	0.32	2.22e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00475322	chr7:917719	C7orf20	0.45	11.92	0.43	1.01e-29	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg05347473	chr6:146136440	FBXO30	0.44	8.65	0.32	4.22e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4988958	0.525	rs3771159	chr2:103004958	T/C	cg03938978	chr2:103052716	IL18RAP	0.29	8.42	0.32	2.39e-16	Asthma (childhood onset);
BRCA	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-11.77	-0.42	4.21e-29	Monocyte percentage of white cells;
BRCA	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.52	-10.97	-0.4	9.19e-26	Lymphocyte counts;
BRCA	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs858239	0.539	rs57864591	chr7:23184424	T/A	cg23682824	chr7:23144976	KLHL7	0.41	10.68	0.39	1.3e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.42	0.5	5.24e-41	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg23625390	chr15:77176239	SCAPER	-0.36	-8.59	-0.32	6.64e-17	Blood metabolite levels;
BRCA	cis	rs7714584	1.000	rs1000113	chr5:150240076	C/T	cg22134413	chr5:150180641	NA	0.65	9.83	0.36	2.57e-21	Crohn's disease;
BRCA	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	15.48	0.52	3.74e-46	Colorectal cancer;
BRCA	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg11645453	chr3:52864694	ITIH4	0.32	8.26	0.31	8.48e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	trans	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg21659725	chr3:3221576	CRBN	0.48	8.84	0.33	9.32e-18	Menarche (age at onset);
BRCA	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.59	-12.31	-0.44	2.08e-31	Lymphocyte counts;
BRCA	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.51	-0.47	9.38e-37	Developmental language disorder (linguistic errors);
BRCA	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.18	-0.49	7.04e-40	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg05340658	chr4:99064831	C4orf37	0.68	17.15	0.56	1.63e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg20701182	chr2:24300061	SF3B14	0.63	9.04	0.34	1.79e-18	Lymphocyte counts;
BRCA	cis	rs672059	1.000	rs638781	chr1:183157358	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.64	0.32	4.48e-17	Hypertriglyceridemia;
BRCA	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg23708337	chr7:1209742	NA	0.57	8.46	0.32	1.78e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg04455712	chr21:45112962	RRP1B	0.44	11.78	0.42	3.96e-29	Mean corpuscular volume;
BRCA	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg06784218	chr1:46089804	CCDC17	0.44	10.5	0.38	6.74e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.63	-13.09	-0.46	7.22e-35	Lymphocyte counts;
BRCA	cis	rs2066819	1.000	rs1802236	chr12:56679751	A/G	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs2882667	0.690	rs311601	chr5:138053386	G/A	cg04439458	chr5:138467593	SIL1	-0.34	-8.08	-0.3	3.12e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6750047	0.691	rs336032	chr2:38264788	T/C	cg07380506	chr2:38303506	CYP1B1	-0.44	-9.61	-0.36	1.64e-20	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg23711669	chr6:146136114	FBXO30	0.79	18.94	0.6	7.88e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg00409905	chr10:38381863	ZNF37A	0.5	10.72	0.39	9.22e-25	Extrinsic epigenetic age acceleration;
BRCA	trans	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.92	0.3	1.05e-14	Endometrial cancer;
BRCA	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg06453172	chr10:134556979	INPP5A	-0.55	-11.5	-0.41	5.87e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-14.0	-0.48	4.93e-39	Platelet count;
BRCA	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08219700	chr8:58056026	NA	0.61	9.78	0.36	3.73e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs593982	0.920	rs1151500	chr11:65481166	T/C	cg08755490	chr11:65554678	OVOL1	1.13	17.16	0.56	1.47e-54	Atopic dermatitis;
BRCA	trans	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.38	8.57	0.32	7.97e-17	Endometrial cancer;
BRCA	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	2.04e-23	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1459104	1.000	rs12574577	chr11:55306742	G/A	cg15704280	chr7:45808275	SEPT13	0.64	7.94	0.3	9.33e-15	Body mass index;
BRCA	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg06627628	chr2:24431161	ITSN2	-0.51	-8.28	-0.31	7.01e-16	Lymphocyte counts;
BRCA	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.85	-0.33	8.29e-18	Alzheimer's disease (late onset);
BRCA	cis	rs10992471	0.603	rs1980848	chr9:95248571	A/G	cg14631576	chr9:95140430	CENPP	0.38	9.28	0.34	2.59e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg21770322	chr7:97807741	LMTK2	0.45	11.73	0.42	6.33e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg17366294	chr4:99064904	C4orf37	0.42	9.82	0.36	2.73e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg06212747	chr3:49208901	KLHDC8B	0.47	9.52	0.35	3.53e-20	Parkinson's disease;
BRCA	cis	rs6973256	0.828	rs17167210	chr7:133339343	G/A	cg07491979	chr7:133331646	EXOC4	-0.38	-8.55	-0.32	8.9e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg23202291	chr11:1979235	NA	-0.35	-8.27	-0.31	7.62e-16	DNA methylation (variation);
BRCA	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg21518248	chr2:162101506	NA	-0.49	-10.43	-0.38	1.3e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs13046373	0.535	rs9636840	chr21:32029979	A/G	cg14062083	chr21:31802829	KRTAP13-4	-0.32	-8.59	-0.32	6.58e-17	HDL cholesterol;
BRCA	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg01324343	chr3:183735012	ABCC5	0.83	21.1	0.64	2.27e-75	Anterior chamber depth;
BRCA	cis	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg07460842	chr6:66804631	NA	0.87	15.63	0.53	7.42e-47	Exhaled nitric oxide levels;
BRCA	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.89	-0.33	6.1e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	13.71	0.48	1.05e-37	Alzheimer's disease;
BRCA	cis	rs7809950	0.817	rs2712224	chr7:107181235	C/A	cg23024343	chr7:107201750	COG5	-0.49	-9.91	-0.36	1.26e-21	Coronary artery disease;
BRCA	cis	rs16854884	0.657	rs1867609	chr3:143752916	A/G	cg06585982	chr3:143692056	C3orf58	0.42	8.93	0.33	4.41e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs73001065	0.901	rs8107974	chr19:19388500	A/T	cg03709012	chr19:19516395	GATAD2A	0.79	9.3	0.35	2.11e-19	LDL cholesterol;
BRCA	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg05472934	chr7:22766657	IL6	0.52	13.78	0.48	4.96e-38	Lung cancer;
BRCA	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg07636037	chr3:49044803	WDR6	-0.49	-8.13	-0.31	2.23e-15	Menarche (age at onset);
BRCA	cis	rs6063312	0.667	rs9679994	chr20:47281853	T/C	cg18078177	chr20:47281410	PREX1	0.75	17.85	0.58	3.93e-58	Tonometry;
BRCA	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg13271783	chr10:134563150	INPP5A	-0.46	-9.72	-0.36	6.22e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.45	-0.38	1.07e-23	Aortic root size;
BRCA	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg11833968	chr6:79620685	NA	-0.41	-9.21	-0.34	4.65e-19	Intelligence (multi-trait analysis);
BRCA	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.7	-0.33	2.88e-17	Triglycerides;
BRCA	trans	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg25214090	chr10:38739885	LOC399744	0.54	12.13	0.43	1.31e-30	Corneal astigmatism;
BRCA	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.63	9.83	0.36	2.48e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg07460842	chr6:66804631	NA	0.68	11.41	0.41	1.47e-27	Exhaled nitric oxide output;
BRCA	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.59	-12.56	-0.45	1.64e-32	Lung cancer;
BRCA	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.49e-52	Hypertriglyceridemia;
BRCA	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg25554036	chr4:6271136	WFS1	0.42	10.16	0.37	1.35e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs9487051	0.724	rs13200047	chr6:109633244	T/C	cg21918786	chr6:109611834	NA	-0.36	-8.75	-0.33	1.94e-17	Reticulocyte fraction of red cells;
BRCA	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg12193833	chr17:30244370	NA	-0.55	-8.69	-0.33	2.99e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	14.36	0.49	1.03e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00684032	chr4:1343700	KIAA1530	0.52	12.51	0.44	2.94e-32	Obesity-related traits;
BRCA	cis	rs7209700	0.745	rs8074348	chr17:45353413	G/C	cg08085267	chr17:45401833	C17orf57	0.43	8.2	0.31	1.33e-15	IgG glycosylation;
BRCA	cis	rs9462846	0.919	rs6936722	chr6:42891311	A/G	cg02353165	chr6:42928485	GNMT	-0.49	-9.49	-0.35	4.38e-20	Blood protein levels;
BRCA	cis	rs7945705	0.905	rs7947631	chr11:8844909	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-9.0	-0.34	2.61e-18	Hemoglobin concentration;
BRCA	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg15448220	chr1:150897856	SETDB1	0.35	7.9	0.3	1.24e-14	Melanoma;
BRCA	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26314531	chr2:26401878	FAM59B	0.65	11.38	0.41	1.83e-27	Gut microbiome composition (summer);
BRCA	cis	rs2354432	0.607	rs7523812	chr1:146673489	A/G	cg25205988	chr1:146714368	CHD1L	-0.81	-10.84	-0.39	2.93e-25	Mitochondrial DNA levels;
BRCA	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg05527609	chr1:210001259	C1orf107	0.7	15.04	0.51	5.66e-44	Orofacial clefts;
BRCA	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg04756594	chr16:24857601	SLC5A11	0.34	8.53	0.32	1.09e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg22903471	chr2:27725779	GCKR	-0.35	-8.58	-0.32	7.26e-17	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg24101359	chr6:42928495	GNMT	-0.64	-15.09	-0.51	2.97e-44	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg23750338	chr8:142222470	SLC45A4	0.51	12.48	0.44	3.85e-32	Immature fraction of reticulocytes;
BRCA	cis	rs3771570	1.000	rs59536819	chr2:242272388	A/G	cg21155796	chr2:242212141	HDLBP	0.61	9.41	0.35	8.68e-20	Prostate cancer;
BRCA	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg12193833	chr17:30244370	NA	-0.54	-8.72	-0.33	2.47e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs897984	0.513	rs17839568	chr16:31099783	T/C	cg02466173	chr16:30829666	NA	-0.43	-9.69	-0.36	8.6e-21	Dementia with Lewy bodies;
BRCA	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg13393036	chr8:95962371	TP53INP1	-0.3	-8.07	-0.3	3.54e-15	Type 2 diabetes;
BRCA	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg26769984	chr7:1090371	C7orf50	0.65	11.49	0.41	6.73e-28	Bronchopulmonary dysplasia;
BRCA	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg20701182	chr2:24300061	SF3B14	0.57	8.95	0.33	3.98e-18	Lymphocyte counts;
BRCA	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	11.92	0.43	9.97e-30	Mean platelet volume;
BRCA	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg12373951	chr3:133503437	NA	0.35	8.03	0.3	4.64e-15	Iron status biomarkers;
BRCA	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg15103426	chr22:29168792	CCDC117	0.52	12.24	0.44	4.21e-31	Lymphocyte counts;
BRCA	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg22307297	chr20:60903441	LAMA5	-0.29	-7.89	-0.3	1.33e-14	Colorectal cancer;
BRCA	trans	rs6600671	0.932	rs6600663	chr1:121222437	A/T	cg17023122	chr1:144479586	NA	0.35	8.04	0.3	4.29e-15	Hip geometry;
BRCA	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-12.1	-0.43	1.7e-30	Morning vs. evening chronotype;
BRCA	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg24130564	chr14:104152367	KLC1	-0.39	-8.8	-0.33	1.28e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg24633833	chr3:10029261	TMEM111	0.4	7.91	0.3	1.15e-14	Alzheimer's disease;
BRCA	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-12.27	-0.44	3.18e-31	Chronic sinus infection;
BRCA	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg26818010	chr10:134567672	INPP5A	-0.71	-15.13	-0.51	2.06e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.63	-0.42	1.67e-28	Electroencephalogram traits;
BRCA	cis	rs6028335	0.610	rs1130247	chr20:37581437	A/G	cg16355469	chr20:37678765	NA	0.44	8.11	0.31	2.55e-15	Alcohol and nicotine co-dependence;
BRCA	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg10792982	chr14:105748885	BRF1	0.5	11.45	0.41	9.38e-28	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11764359	chr7:65958608	NA	-0.76	-16.82	-0.55	7.85e-53	Aortic root size;
BRCA	cis	rs9487051	0.735	rs351745	chr6:109529169	C/T	cg21918786	chr6:109611834	NA	0.36	9.72	0.36	6.32e-21	Reticulocyte fraction of red cells;
BRCA	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.73	0.42	6.61e-29	Tonsillectomy;
BRCA	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	18.13	0.58	1.36e-59	Alzheimer's disease;
BRCA	cis	rs4363385	0.510	rs6677674	chr1:153037601	A/G	cg25856811	chr1:152973957	SPRR3	-0.32	-7.96	-0.3	7.69e-15	Inflammatory skin disease;
BRCA	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg02574844	chr11:5959923	NA	-0.43	-8.65	-0.32	4.08e-17	DNA methylation (variation);
BRCA	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-10.94	-0.4	1.21e-25	Mean corpuscular volume;
BRCA	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg14019146	chr3:50243930	SLC38A3	0.63	16.11	0.54	2.85e-49	Intelligence (multi-trait analysis);
BRCA	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg15145296	chr3:125709740	NA	-0.54	-8.58	-0.32	7.1e-17	Blood pressure (smoking interaction);
BRCA	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg24006582	chr15:45444508	DUOX1	0.5	10.18	0.37	1.19e-22	Uric acid levels;
BRCA	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-16.27	-0.54	4.61e-50	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.72	0.39	8.75e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg03146154	chr1:46216737	IPP	0.53	11.89	0.43	1.37e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.11	0.4	2.4e-26	Bipolar disorder;
BRCA	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg25174290	chr11:3078921	CARS	-0.3	-7.88	-0.3	1.45e-14	Calcium levels;
BRCA	cis	rs708547	0.957	rs781667	chr4:57798469	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.48	-8.33	-0.31	4.91e-16	Response to bleomycin (chromatid breaks);
BRCA	cis	rs4363385	0.747	rs6668215	chr1:152964498	A/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.44	-0.35	6.77e-20	Inflammatory skin disease;
BRCA	cis	rs9341808	0.718	rs9448908	chr6:80898069	C/T	cg08355045	chr6:80787529	NA	0.39	9.87	0.36	1.83e-21	Sitting height ratio;
BRCA	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg01689657	chr7:91764605	CYP51A1	0.21	7.84	0.3	1.9e-14	Breast cancer;
BRCA	cis	rs4900538	0.855	rs60215817	chr14:102873886	A/G	cg18135206	chr14:102964638	TECPR2	-0.92	-21.74	-0.65	7.08e-79	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	trans	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04565464	chr8:145669602	NFKBIL2	0.43	9.72	0.36	6.5e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg14403583	chr14:105418241	AHNAK2	0.38	9.0	0.34	2.66e-18	Rheumatoid arthritis;
BRCA	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg05294307	chr14:35346193	BAZ1A	-0.58	-10.21	-0.37	8.65e-23	Psoriasis;
BRCA	cis	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg05901451	chr6:126070800	HEY2	0.4	9.65	0.36	1.2e-20	Endometrial cancer;
BRCA	cis	rs36051895	0.559	rs7858422	chr9:5209797	G/T	cg02405213	chr9:5042618	JAK2	-0.43	-8.23	-0.31	1.08e-15	Pediatric autoimmune diseases;
BRCA	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg20673091	chr1:2541236	MMEL1	0.36	9.3	0.35	2.12e-19	Ulcerative colitis;
BRCA	cis	rs11785693	0.862	rs11784262	chr8:4996942	G/A	cg26367366	chr8:4980734	NA	0.63	11.37	0.41	2.05e-27	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	trans	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	20.19	0.62	1.64e-70	Exhaled nitric oxide output;
BRCA	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18876405	chr7:65276391	NA	-0.62	-15.37	-0.52	1.33e-45	Aortic root size;
BRCA	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg09904177	chr6:26538194	HMGN4	-0.46	-14.45	-0.5	3.55e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg12463550	chr7:65579703	CRCP	-0.39	-8.19	-0.31	1.42e-15	Aortic root size;
BRCA	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	13.14	0.46	4.57e-35	Lymphocyte counts;
BRCA	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg14863265	chr7:2801509	GNA12	-0.45	-9.76	-0.36	4.5e-21	Height;
BRCA	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.0	-0.34	2.59e-18	Menopause (age at onset);
BRCA	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg03188948	chr7:1209495	NA	0.43	7.86	0.3	1.65e-14	Longevity;Endometriosis;
BRCA	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg18876405	chr7:65276391	NA	0.48	10.03	0.37	4.45e-22	Calcium levels;
BRCA	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg24692254	chr21:30365293	RNF160	-0.79	-21.73	-0.65	8.08e-79	Dental caries;
BRCA	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg15448220	chr1:150897856	SETDB1	0.36	8.09	0.3	3.11e-15	Melanoma;
BRCA	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg10223061	chr2:219282414	VIL1	-0.27	-8.02	-0.3	5.02e-15	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg24558204	chr6:135376177	HBS1L	0.58	15.53	0.52	2.27e-46	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg16339924	chr4:17578868	LAP3	-0.55	-13.5	-0.47	1.03e-36	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.53	-11.91	-0.43	1.16e-29	Personality dimensions;
BRCA	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg12310025	chr6:25882481	NA	-0.55	-12.23	-0.44	4.93e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg11189052	chr15:85197271	WDR73	-0.36	-8.55	-0.32	8.77e-17	P wave terminal force;
BRCA	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg01874867	chr7:94954059	PON1	-0.39	-7.97	-0.3	7.31e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs858239	0.601	rs6971002	chr7:23172304	C/G	cg23682824	chr7:23144976	KLHL7	0.42	11.24	0.41	7.05e-27	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg07080220	chr10:102295463	HIF1AN	0.57	13.31	0.47	7.63e-36	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7737355	0.947	rs28720007	chr5:131077709	C/T	cg06307176	chr5:131281290	NA	0.52	10.08	0.37	2.86e-22	Life satisfaction;
BRCA	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.49	10.02	0.37	4.91e-22	Height;
BRCA	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.52	8.2	0.31	1.35e-15	Renal function-related traits (BUN);
BRCA	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg11584989	chr19:19387371	SF4	0.63	13.36	0.47	4.2500000000000003e-36	Bipolar disorder;
BRCA	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg24558204	chr6:135376177	HBS1L	0.45	12.23	0.44	4.56e-31	Red blood cell count;
BRCA	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.92	0.56	2.39e-53	Hypertriglyceridemia;
BRCA	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg02951883	chr7:2050386	MAD1L1	-0.43	-10.44	-0.38	1.18e-23	Schizophrenia;
BRCA	cis	rs7246967	0.673	rs12979848	chr19:22820798	G/A	cg23217946	chr19:22817039	ZNF492	0.47	8.48	0.32	1.56e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg08601574	chr20:25228251	PYGB	0.34	8.13	0.31	2.25e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg04317338	chr11:64019027	PLCB3	0.53	9.35	0.35	1.41e-19	Mean platelet volume;
BRCA	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00166722	chr3:10149974	C3orf24	0.65	13.02	0.46	1.52e-34	Alzheimer's disease;
BRCA	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.38	-9.35	-0.35	1.42e-19	Coronary artery disease;
BRCA	cis	rs35123781	0.654	rs356486	chr5:139085103	C/G	cg10513866	chr5:139070639	NA	-0.44	-9.94	-0.37	9.98e-22	Schizophrenia;
BRCA	cis	rs6750047	0.647	rs11124632	chr2:38276412	G/C	cg07380506	chr2:38303506	CYP1B1	0.48	10.53	0.38	4.98e-24	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs1997103	0.911	rs11238361	chr7:55395981	A/G	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.72e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg24642439	chr20:33292090	TP53INP2	0.43	9.11	0.34	1.02e-18	Height;
BRCA	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	11.4	0.41	1.61e-27	Bone mineral density;
BRCA	cis	rs2286885	1.000	rs7851961	chr9:129249140	G/A	cg15282417	chr9:129245246	FAM125B	0.31	7.87	0.3	1.5e-14	Intraocular pressure;
BRCA	cis	rs12618769	0.597	rs56197140	chr2:99113740	T/C	cg10123293	chr2:99228465	UNC50	0.42	8.37	0.31	3.53e-16	Bipolar disorder;
BRCA	cis	rs724568	0.546	rs974482	chr2:67946520	C/A	cg17945962	chr2:67939740	NA	-0.39	-10.5	-0.38	6.74e-24	Major depressive disorder (broad);
BRCA	cis	rs6763687	0.725	rs11717882	chr3:171804170	T/A	cg16233210	chr3:171778391	FNDC3B	0.36	8.0	0.3	6.05e-15	Red cell distribution width;
BRCA	cis	rs921968	0.565	rs4674329	chr2:219595507	A/G	cg02176678	chr2:219576539	TTLL4	-0.41	-11.07	-0.4	3.49e-26	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs11088226	0.645	rs7281844	chr21:33932435	T/C	cg09050820	chr6:167586206	TCP10L2	0.76	13.46	0.47	1.6e-36	Gastritis;
BRCA	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg05552183	chr6:42928497	GNMT	0.7	15.75	0.53	1.77e-47	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs9463078	0.774	rs9357480	chr6:45219512	G/A	cg25276700	chr6:44698697	NA	-0.35	-7.92	-0.3	1.03e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00684032	chr4:1343700	KIAA1530	0.43	10.44	0.38	1.16e-23	Obesity-related traits;
BRCA	cis	rs7561273	0.609	rs6545285	chr2:24340029	T/C	cg04809136	chr2:24300158	SF3B14	-0.4	-8.98	-0.33	2.99e-18	Quantitative traits;
BRCA	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-23.19	-0.68	9.1e-87	Chronic sinus infection;
BRCA	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg02951883	chr7:2050386	MAD1L1	-0.38	-9.13	-0.34	8.9e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg19077165	chr18:44547161	KATNAL2	-0.5	-10.86	-0.39	2.48e-25	Personality dimensions;
BRCA	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	19.67	0.61	1.01e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg09307838	chr4:120376055	NA	0.74	15.98	0.53	1.38e-48	Corneal astigmatism;
BRCA	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18876405	chr7:65276391	NA	-0.5	-11.2	-0.41	1.06e-26	Aortic root size;
BRCA	cis	rs11971779	0.680	rs11768023	chr7:139054395	T/A	cg07862535	chr7:139043722	LUC7L2	0.39	10.55	0.39	4.26e-24	Diisocyanate-induced asthma;
BRCA	cis	rs12618769	0.652	rs4851146	chr2:99237439	A/G	cg10123293	chr2:99228465	UNC50	0.41	8.09	0.3	2.9e-15	Bipolar disorder;
BRCA	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03452623	chr4:187889614	NA	-0.3	-9.47	-0.35	5.37e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7766436	0.770	rs11751669	chr6:22571037	A/G	cg13666174	chr6:22585274	NA	-0.44	-9.63	-0.36	1.32e-20	Coronary artery disease;
BRCA	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.22	-0.37	8.46e-23	Psoriasis;
BRCA	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg21475434	chr5:93447410	FAM172A	0.68	9.22	0.34	4.38e-19	Diabetic retinopathy;
BRCA	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-9.24	-0.34	3.53e-19	Schizophrenia;
BRCA	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg23131131	chr22:24373011	LOC391322	0.41	9.44	0.35	6.98e-20	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs13136331	0.684	rs12505482	chr4:88730210	T/C	cg22416721	chr4:88570574	DMP1	0.39	8.09	0.3	3.09e-15	Sitting height ratio;
BRCA	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg18252515	chr7:66147081	NA	-1.07	-15.7	-0.53	3.09e-47	Diabetic kidney disease;
BRCA	cis	rs3771570	0.901	rs4675964	chr2:242324760	A/C	cg21155796	chr2:242212141	HDLBP	0.47	8.22	0.31	1.1e-15	Prostate cancer;
BRCA	cis	rs4930561	0.714	rs6591335	chr11:67976812	T/C	cg04465784	chr11:67976953	SUV420H1	-0.26	-8.49	-0.32	1.43e-16	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg00071950	chr4:10020882	SLC2A9	0.44	10.33	0.38	3.22e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-10.53	-0.38	5.16e-24	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1568889	0.712	rs10835306	chr11:28302410	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	19.55	0.61	4.51e-67	Bipolar disorder;
BRCA	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.75	-12.92	-0.46	4.37e-34	Platelet count;
BRCA	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg23708337	chr7:1209742	NA	0.55	11.64	0.42	1.58e-28	Longevity;Endometriosis;
BRCA	trans	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg17712092	chr4:129076599	LARP1B	-0.68	-17.22	-0.56	7.36e-55	Eosinophil percentage of white cells;
BRCA	cis	rs1506636	0.962	rs1472808	chr7:123354536	A/G	cg03229431	chr7:123269106	ASB15	-0.61	-13.96	-0.48	7.91e-39	Plateletcrit;Platelet count;
BRCA	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg00631329	chr6:26305371	NA	-0.48	-13.63	-0.47	2.57e-37	Educational attainment;
BRCA	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg20887711	chr4:1340912	KIAA1530	0.75	16.07	0.54	4.43e-49	Longevity;
BRCA	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg20991723	chr1:152506922	NA	0.36	8.13	0.31	2.24e-15	Hair morphology;
BRCA	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg25767906	chr1:53392781	SCP2	0.38	8.79	0.33	1.4e-17	Monocyte count;
BRCA	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg12564285	chr5:131593104	PDLIM4	0.35	9.13	0.34	8.68e-19	Blood metabolite levels;
BRCA	cis	rs8028182	0.636	rs28737338	chr15:75768679	C/T	cg20655648	chr15:75932815	IMP3	0.4	8.0	0.3	5.97e-15	Sudden cardiac arrest;
BRCA	cis	rs7179456	0.515	rs602602	chr15:59057023	T/A	cg05156742	chr15:59063176	FAM63B	0.41	8.14	0.31	2.02e-15	Asperger disorder;
BRCA	cis	rs1003719	0.788	rs2835577	chr21:38457457	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.18	0.49	7.11e-40	Eye color traits;
BRCA	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg17691542	chr6:26056736	HIST1H1C	0.48	9.76	0.36	4.41e-21	Height;
BRCA	trans	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg17675199	chr6:35436792	RPL10A	-0.3	-8.03	-0.3	4.8e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg04362960	chr10:104952993	NT5C2	0.44	9.85	0.36	2.09e-21	Arsenic metabolism;
BRCA	cis	rs9649465	0.688	rs34967330	chr7:123318560	A/C	cg04330084	chr7:123175371	IQUB	-0.33	-8.89	-0.33	6.2e-18	Migraine;
BRCA	cis	rs9283706	0.689	rs1030231	chr5:66317265	A/G	cg11590213	chr5:66331682	MAST4	0.41	8.23	0.31	1.07e-15	Coronary artery disease;
BRCA	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	13.17	0.46	3.37e-35	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs365132	1.000	rs402511	chr5:176434440	G/A	cg16309518	chr5:176445507	NA	-0.52	-13.35	-0.47	4.77e-36	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	15.49	0.52	3.55e-46	Colorectal cancer;
BRCA	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg11833968	chr6:79620685	NA	-0.45	-10.02	-0.37	4.82e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.45	0.38	1.08e-23	Motion sickness;
BRCA	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg18964960	chr10:1102726	WDR37	0.63	8.71	0.33	2.65e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.53	15.29	0.52	3.15e-45	Total body bone mineral density;
BRCA	cis	rs243505	0.898	rs243529	chr7:148413801	G/A	cg09806900	chr7:148480153	CUL1	-0.4	-8.23	-0.31	1.07e-15	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-9.85	-0.36	2.07e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12756686	chr19:29218302	NA	0.57	10.98	0.4	8.46e-26	Methadone dose in opioid dependence;
BRCA	cis	rs4764124	0.646	rs11610238	chr12:14975721	C/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.51	12.34	0.44	1.51e-31	Pubertal anthropometrics;
BRCA	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg06623918	chr6:96969491	KIAA0776	-0.76	-13.41	-0.47	2.67e-36	Migraine;Coronary artery disease;
BRCA	cis	rs10193935	0.901	rs13384885	chr2:42536646	G/C	cg27598129	chr2:42591480	NA	-0.94	-14.87	-0.51	3.63e-43	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs12458462	0.812	rs34583578	chr18:77491070	C/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.45	-8.25	-0.31	9.07e-16	Monocyte count;
BRCA	trans	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg06521331	chr12:34319734	NA	0.44	8.72	0.33	2.48e-17	Bladder cancer;
BRCA	cis	rs757110	0.933	rs7124355	chr11:17412960	C/T	cg15432903	chr11:17409602	KCNJ11	-0.54	-11.24	-0.41	6.97e-27	Type 2 diabetes;
BRCA	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg03929089	chr4:120376271	NA	-0.44	-8.25	-0.31	8.93e-16	HDL cholesterol;
BRCA	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg14664628	chr15:75095509	CSK	-0.89	-24.29	-0.69	7.7e-93	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs858239	0.899	rs2268747	chr7:23313462	A/G	cg23682824	chr7:23144976	KLHL7	0.35	8.8	0.33	1.32e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	16.45	0.55	5.62e-51	Platelet count;
BRCA	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.46	-10.98	-0.4	7.88e-26	IgG glycosylation;
BRCA	cis	rs13394619	1.000	rs13394619	chr2:11727507	A/G	cg07314298	chr2:11723111	GREB1	0.52	11.71	0.42	8.27e-29	Endometriosis;
BRCA	cis	rs10465746	0.967	rs11163879	chr1:84444051	T/C	cg10977910	chr1:84465055	TTLL7	0.51	10.36	0.38	2.4e-23	Obesity-related traits;
BRCA	cis	rs6542838	0.641	rs12467189	chr2:99495820	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-9.11	-0.34	1.05e-18	Fear of minor pain;
BRCA	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	8.35	0.31	4.12e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs897984	0.762	rs2054213	chr16:30971810	A/G	cg00531865	chr16:30841666	NA	0.4	9.49	0.35	4.62e-20	Dementia with Lewy bodies;
BRCA	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs11608355	0.545	rs12823587	chr12:109896390	A/G	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	14.88	0.51	3.38e-43	Platelet count;
BRCA	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11764359	chr7:65958608	NA	0.8	19.29	0.61	1.15e-65	Aortic root size;
BRCA	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.75	12.18	0.43	7.6e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.51	-11.84	-0.42	2.19e-29	Longevity;Endometriosis;
BRCA	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg10729496	chr3:10149963	C3orf24	0.48	9.0	0.34	2.49e-18	Alzheimer's disease;
BRCA	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg01483505	chr11:975446	AP2A2	0.3	7.9	0.3	1.27e-14	Alzheimer's disease (late onset);
BRCA	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg07460842	chr6:66804631	NA	0.99	19.84	0.62	1.25e-68	Exhaled nitric oxide output;
BRCA	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg25036284	chr2:26402008	FAM59B	-0.79	-12.4	-0.44	8.96e-32	Gut microbiome composition (summer);
BRCA	cis	rs870825	0.616	rs7678616	chr4:185648714	T/G	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs10267417	0.603	rs10229973	chr7:19894778	G/A	cg05791153	chr7:19748676	TWISTNB	0.47	9.04	0.34	1.9e-18	Night sleep phenotypes;
BRCA	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg27129171	chr3:47204927	SETD2	-0.67	-15.6	-0.53	1.06e-46	Colorectal cancer;
BRCA	cis	rs700651	0.752	rs1850631	chr2:198829468	T/G	cg00792783	chr2:198669748	PLCL1	0.45	9.89	0.36	1.47e-21	Intracranial aneurysm;
BRCA	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg00990874	chr7:1149470	C7orf50	-0.6	-12.13	-0.43	1.22e-30	Bronchopulmonary dysplasia;
BRCA	cis	rs72634258	0.554	rs7556518	chr1:7847846	G/A	cg26816564	chr1:7831052	VAMP3	0.68	12.52	0.44	2.45e-32	Inflammatory bowel disease;
BRCA	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg25237894	chr2:233734115	C2orf82	-0.38	-11.06	-0.4	3.89e-26	Coronary artery disease;
BRCA	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	11.12	0.4	2.29e-26	Monocyte percentage of white cells;
BRCA	cis	rs7520050	0.933	rs6666743	chr1:46311275	C/T	cg24296786	chr1:45957014	TESK2	0.41	9.34	0.35	1.51e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs870825	0.860	rs72703525	chr4:185605154	T/C	cg04058563	chr4:185651563	MLF1IP	0.65	11.26	0.41	5.77e-27	Blood protein levels;
BRCA	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg21535247	chr6:8435926	SLC35B3	0.42	9.42	0.35	7.86e-20	Motion sickness;
BRCA	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.25	7.9	0.3	1.25e-14	Parkinson's disease;
BRCA	cis	rs1127311	1.000	rs10908419	chr1:154567699	G/A	cg17218026	chr1:154582156	ADAR	0.28	8.42	0.32	2.5e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
BRCA	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg03060546	chr3:49711283	APEH	0.57	9.92	0.37	1.17e-21	Menarche (age at onset);
BRCA	trans	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.07	0.3	3.49e-15	Endometrial cancer;
BRCA	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg21280719	chr6:42927975	GNMT	-0.33	-13.75	-0.48	7.26e-38	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg16576597	chr16:28551801	NUPR1	0.35	9.46	0.35	5.9e-20	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs13095912	0.778	rs11914529	chr3:185296513	C/T	cg11274856	chr3:185301563	NA	0.55	13.27	0.46	1.18e-35	Systolic blood pressure;
BRCA	cis	rs922692	0.710	rs1994016	chr15:79080234	C/T	cg04896959	chr15:78267971	NA	0.38	8.82	0.33	1.05e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	trans	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.24	0.31	9.83e-16	Corneal astigmatism;
BRCA	cis	rs9811920	0.931	rs7629487	chr3:99860401	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	12.78	0.45	1.81e-33	Axial length;
BRCA	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg06191203	chr2:152266755	RIF1	-0.41	-11.18	-0.4	1.27e-26	Lung cancer;
BRCA	cis	rs965469	1.000	rs6051827	chr20:3372007	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-10.08	-0.37	2.77e-22	IFN-related cytopenia;
BRCA	cis	rs55883249	0.957	rs10495572	chr2:9734859	C/G	cg23886495	chr2:9695866	ADAM17	-0.54	-7.92	-0.3	1.04e-14	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
BRCA	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg00717180	chr2:96193071	NA	-0.37	-10.27	-0.38	5.04e-23	Height;
BRCA	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg19717773	chr7:2847554	GNA12	-0.43	-9.55	-0.35	2.75e-20	Height;
BRCA	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.05e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6714710	0.580	rs55886305	chr2:98495661	T/G	cg26665480	chr2:98280029	ACTR1B	0.58	13.49	0.47	1.14e-36	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs3772130	0.540	rs7649436	chr3:121562304	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.67	14.61	0.5	6.27e-42	Cognitive performance;
BRCA	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	8.57	0.32	7.75e-17	Schizophrenia;
BRCA	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-8.18	-0.31	1.59e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.73e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg15832292	chr6:96025679	MANEA	0.55	8.29	0.31	6.76e-16	Behavioural disinhibition (generation interaction);
BRCA	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg26384229	chr12:38710491	ALG10B	0.6	13.71	0.48	1.06e-37	Morning vs. evening chronotype;
BRCA	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.36	12.44	0.44	5.6e-32	Electroencephalogram traits;
BRCA	trans	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.25	0.31	9.3e-16	Corneal astigmatism;
BRCA	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg06108461	chr20:60628389	TAF4	-0.75	-15.75	-0.53	1.73e-47	Body mass index;
BRCA	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg06784218	chr1:46089804	CCDC17	0.52	12.61	0.45	1.01e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg25214090	chr10:38739885	LOC399744	0.59	12.67	0.45	5.44e-33	Corneal astigmatism;
BRCA	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.06	0.34	1.53e-18	Tonsillectomy;
BRCA	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg03146154	chr1:46216737	IPP	0.45	10.14	0.37	1.69e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2288912	0.808	rs35670684	chr19:45455985	A/C	cg20090143	chr19:45452003	APOC2	0.27	7.87	0.3	1.47e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04565464	chr8:145669602	NFKBIL2	0.37	8.75	0.33	1.96e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	16.69	0.55	3.7e-52	Alzheimer's disease;
BRCA	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg21573476	chr21:45109991	RRP1B	-0.37	-9.61	-0.36	1.65e-20	Mean corpuscular volume;
BRCA	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg18252515	chr7:66147081	NA	0.94	13.98	0.48	6.12e-39	Diabetic kidney disease;
BRCA	cis	rs4664304	0.710	rs9636280	chr2:160717852	C/T	cg18514922	chr2:160761262	LY75	-0.35	-8.28	-0.31	7.44e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg10523679	chr1:76189770	ACADM	-0.59	-11.06	-0.4	3.76e-26	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10504073	0.647	rs55920380	chr8:50026353	G/A	cg00325661	chr8:49890786	NA	0.44	12.37	0.44	1.21e-31	Blood metabolite ratios;
BRCA	cis	rs1577917	0.958	rs12202712	chr6:86578541	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.29	-0.41	4.61e-27	Response to antipsychotic treatment;
BRCA	cis	rs1863824	0.595	rs61859067	chr10:88159997	G/A	cg07322936	chr10:88137208	NA	-0.45	-9.02	-0.34	2.23e-18	Schizophrenia;
BRCA	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.52	-0.32	1.11e-16	Monocyte percentage of white cells;
BRCA	cis	rs9359856	0.564	rs72913975	chr6:90387116	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.68	-8.82	-0.33	1.07e-17	Bipolar disorder;
BRCA	cis	rs9875589	0.509	rs2129888	chr3:14013826	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.33	8.6	0.32	6.24e-17	Ovarian reserve;
BRCA	cis	rs68170813	0.641	rs61511581	chr7:106948091	T/A	cg02696742	chr7:106810147	HBP1	-0.49	-8.54	-0.32	9.54e-17	Coronary artery disease;
BRCA	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg22875332	chr1:76189707	ACADM	0.57	10.64	0.39	1.88e-24	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-10.82	-0.39	3.57e-25	Monocyte percentage of white cells;
BRCA	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07636037	chr3:49044803	WDR6	0.74	15.91	0.53	3.01e-48	Menarche (age at onset);
BRCA	trans	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.43	-0.35	7.17e-20	Morning vs. evening chronotype;
BRCA	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg23033748	chr14:75592666	NEK9	-0.39	-9.19	-0.34	5.61e-19	Height;
BRCA	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg03929089	chr4:120376271	NA	-0.47	-8.98	-0.33	2.9e-18	HDL cholesterol;
BRCA	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.9e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.3e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg18230493	chr5:56204884	C5orf35	0.72	13.7	0.48	1.2e-37	Initial pursuit acceleration;
BRCA	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.53	0.35	3.32e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg26043149	chr18:55253948	FECH	-0.38	-8.3	-0.31	6.34e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7301826	0.651	rs12228957	chr12:131296066	T/C	cg11011512	chr12:131303247	STX2	0.52	13.65	0.48	2.18e-37	Plasma plasminogen activator levels;
BRCA	cis	rs752010	0.806	rs6696511	chr1:42110888	T/C	cg06885757	chr1:42089581	HIVEP3	0.31	10.11	0.37	2.16e-22	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.91	-29.23	-0.76	6.7e-120	Schizophrenia;
BRCA	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg10223061	chr2:219282414	VIL1	-0.27	-8.05	-0.3	4.05e-15	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	trans	rs1973993	0.537	rs11165664	chr1:97001427	G/T	cg10631902	chr5:14652156	NA	-0.41	-10.19	-0.37	1.03e-22	Weight;
BRCA	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg16102102	chr5:83017553	HAPLN1	-0.91	-17.92	-0.58	1.78e-58	Prostate cancer;
BRCA	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg27170947	chr2:26402098	FAM59B	0.96	14.89	0.51	2.92e-43	Gut microbiome composition (summer);
BRCA	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-8.46	-0.32	1.81e-16	Total body bone mineral density;
BRCA	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg05863683	chr7:1912471	MAD1L1	0.38	8.63	0.32	4.83e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9309473	1.000	rs1403284	chr2:73726662	A/G	cg20560298	chr2:73613845	ALMS1	0.46	11.37	0.41	2.07e-27	Metabolite levels;
BRCA	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg18402987	chr7:1209562	NA	0.9	14.07	0.49	2.31e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg06671706	chr8:8559999	CLDN23	0.43	8.43	0.32	2.33e-16	Obesity-related traits;
BRCA	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg20503657	chr10:835505	NA	0.61	10.38	0.38	1.89e-23	Eosinophil percentage of granulocytes;
BRCA	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg21433313	chr16:3507492	NAT15	0.42	8.63	0.32	4.99e-17	Tuberculosis;
BRCA	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02176678	chr2:219576539	TTLL4	0.45	11.73	0.42	6.24e-29	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7474896	0.526	rs1208716	chr10:38089273	T/A	cg25427524	chr10:38739819	LOC399744	-0.53	-9.06	-0.34	1.57e-18	Obesity (extreme);
BRCA	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg12863693	chr15:85201151	NMB	-0.33	-7.93	-0.3	9.96e-15	P wave terminal force;
BRCA	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg06636001	chr8:8085503	FLJ10661	0.44	9.05	0.34	1.65e-18	Joint mobility (Beighton score);
BRCA	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg22920501	chr2:26401640	FAM59B	-0.65	-11.32	-0.41	3.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs9487051	0.676	rs9320278	chr6:109562589	T/C	cg01475377	chr6:109611718	NA	-0.37	-8.77	-0.33	1.65e-17	Reticulocyte fraction of red cells;
BRCA	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08280861	chr8:58055591	NA	0.54	8.85	0.33	8.57e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg25214090	chr10:38739885	LOC399744	0.56	12.39	0.44	9.8e-32	Corneal astigmatism;
BRCA	cis	rs7246657	0.663	rs4803276	chr19:38072330	C/A	cg23950597	chr19:37808831	NA	-0.51	-8.69	-0.33	3e-17	Coronary artery calcification;
BRCA	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg04586622	chr2:25135609	ADCY3	0.46	11.61	0.42	2.11e-28	Body mass index;
BRCA	cis	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg06521331	chr12:34319734	NA	-0.62	-11.25	-0.41	6.25e-27	Morning vs. evening chronotype;
BRCA	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg13010199	chr12:38710504	ALG10B	0.5	9.95	0.37	8.54e-22	Bladder cancer;
BRCA	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg23711669	chr6:146136114	FBXO30	0.74	15.38	0.52	1.27e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg08601574	chr20:25228251	PYGB	0.35	8.43	0.32	2.33e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg01028140	chr2:1542097	TPO	-0.59	-12.55	-0.44	1.88e-32	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg02551604	chr5:131831745	NA	-0.39	-14.68	-0.5	2.84e-42	Asthma (sex interaction);
BRCA	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.37	-8.15	-0.31	1.97e-15	Bipolar disorder;
BRCA	cis	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.8	-0.36	3.33e-21	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg23711669	chr6:146136114	FBXO30	0.67	15.63	0.53	7.19e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7095944	0.614	rs12570348	chr10:126438963	A/C	cg08799069	chr10:126477246	METTL10	0.37	8.59	0.32	6.56e-17	Asthma;
BRCA	cis	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.56	-10.43	-0.38	1.21e-23	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.41	-0.32	2.73e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg25204440	chr1:209979598	IRF6	0.42	8.52	0.32	1.16e-16	Cleft lip with or without cleft palate;
BRCA	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.02	0.34	2.16e-18	Tonsillectomy;
BRCA	cis	rs11051970	0.879	rs2467065	chr12:32586065	A/G	cg02745156	chr12:32552066	NA	0.27	8.81	0.33	1.16e-17	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	9.59	0.35	1.87e-20	Rheumatoid arthritis;
BRCA	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg21918786	chr6:109611834	NA	-0.44	-11.63	-0.42	1.73e-28	Reticulocyte fraction of red cells;
BRCA	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.7	-19.18	-0.6	3.96e-65	Electrocardiographic conduction measures;
BRCA	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.44	10.91	0.4	1.58e-25	Menarche (age at onset);
BRCA	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg21770322	chr7:97807741	LMTK2	0.45	11.72	0.42	6.88e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs16976116	0.851	rs28699327	chr15:55500335	A/G	cg11288833	chr15:55489084	RSL24D1	0.48	10.68	0.39	1.25e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6429082	1.000	rs2055127	chr1:235598973	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.38	-9.05	-0.34	1.71e-18	Adiposity;
BRCA	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg11645453	chr3:52864694	ITIH4	0.42	9.26	0.34	3.09e-19	Schizophrenia;
BRCA	cis	rs3784262	1.000	rs4646640	chr15:58247563	C/G	cg12031962	chr15:58353849	ALDH1A2	0.47	12.66	0.45	6.25e-33	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg06484146	chr7:12443880	VWDE	-0.72	-9.94	-0.37	9.57e-22	Coronary artery disease;
BRCA	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg18904891	chr8:8559673	CLDN23	0.66	13.18	0.46	2.92e-35	Obesity-related traits;
BRCA	cis	rs12540874	0.931	rs4245555	chr7:50661409	A/G	cg18232548	chr7:50535776	DDC	-0.36	-7.9	-0.3	1.26e-14	Systemic sclerosis;
BRCA	cis	rs7809950	0.817	rs34325395	chr7:107113808	C/G	cg23024343	chr7:107201750	COG5	-0.53	-10.99	-0.4	7.39e-26	Coronary artery disease;
BRCA	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg22681709	chr2:178499509	PDE11A	-0.38	-8.24	-0.31	9.86e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs36051895	0.626	rs12349785	chr9:5076613	G/C	cg02405213	chr9:5042618	JAK2	-0.55	-9.84	-0.36	2.32e-21	Pediatric autoimmune diseases;
BRCA	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg20607287	chr7:12443886	VWDE	-0.58	-8.5	-0.32	1.36e-16	Coronary artery disease;
BRCA	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.97	0.33	3.39e-18	Ovarian reserve;
BRCA	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.02e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.2e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4930561	1.000	rs4930561	chr11:67931761	C/T	cg04465784	chr11:67976953	SUV420H1	-0.24	-8.09	-0.3	3e-15	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs1691799	0.806	rs1168319	chr12:66744857	T/A	cg16791601	chr12:66731901	HELB	-0.69	-19.67	-0.61	1.03e-67	White blood cell count (basophil);
BRCA	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg18850127	chr7:39170497	POU6F2	0.39	8.26	0.31	8.58e-16	IgG glycosylation;
BRCA	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg00376283	chr12:123451042	ABCB9	0.49	11.23	0.41	8.03e-27	Neutrophil percentage of white cells;
BRCA	cis	rs1499972	0.941	rs62263112	chr3:117615515	T/C	cg07612923	chr3:117604196	NA	0.59	7.96	0.3	7.85e-15	Schizophrenia;
BRCA	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg13393036	chr8:95962371	TP53INP1	-0.3	-8.06	-0.3	3.7e-15	Type 2 diabetes;
BRCA	cis	rs2414095	0.527	rs35241865	chr15:51541301	C/T	cg19946085	chr15:51559439	CYP19A1	-0.3	-7.92	-0.3	1.06e-14	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
BRCA	cis	rs778371	0.723	rs1078323	chr2:233681512	T/G	cg08000102	chr2:233561755	GIGYF2	-0.74	-17.03	-0.56	6.87e-54	Schizophrenia;
BRCA	cis	rs939658	0.683	rs11634726	chr15:79465894	A/G	cg17916960	chr15:79447300	NA	-0.37	-9.21	-0.34	4.68e-19	Refractive error;
BRCA	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg11764359	chr7:65958608	NA	0.76	17.54	0.57	1.67e-56	Aortic root size;
BRCA	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs7523273	0.586	rs2796276	chr1:207951513	G/A	cg22525895	chr1:207977042	MIR29B2	0.48	12.09	0.43	1.96e-30	Schizophrenia;
BRCA	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-10.99	-0.4	7.77e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs877529	0.627	rs139426	chr22:39560666	C/T	cg12193277	chr22:39547181	CBX7	0.38	8.91	0.33	5.28e-18	Multiple myeloma;
BRCA	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg15704280	chr7:45808275	SEPT13	0.82	19.68	0.61	8.74e-68	Height;
BRCA	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg21644426	chr2:191273491	MFSD6	0.45	11.47	0.41	8.3e-28	Pulse pressure;
BRCA	cis	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg00852783	chr1:26633632	UBXN11	-0.46	-8.09	-0.3	2.9e-15	Obesity-related traits;
BRCA	cis	rs4953318	0.619	rs13406901	chr2:46363066	T/G	cg12428440	chr2:46370979	PRKCE	0.49	10.67	0.39	1.44e-24	Red blood cell count;Hematocrit;Red blood cell traits;
BRCA	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18876405	chr7:65276391	NA	0.48	10.77	0.39	5.57e-25	Aortic root size;
BRCA	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg21475434	chr5:93447410	FAM172A	0.69	8.96	0.33	3.44e-18	Diabetic retinopathy;
BRCA	cis	rs10496034	1.000	rs4672006	chr2:55251511	C/G	cg16098955	chr2:55172992	EML6	0.53	8.81	0.33	1.17e-17	Refractive astigmatism;
BRCA	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-16.76	-0.55	1.62e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1499972	0.941	rs62263121	chr3:117630348	T/C	cg07612923	chr3:117604196	NA	0.6	8.15	0.31	1.97e-15	Schizophrenia;
BRCA	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-11.15	-0.4	1.67e-26	Neuroticism;
BRCA	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg08355456	chr11:67383691	NA	-0.42	-8.48	-0.32	1.55e-16	Mean corpuscular volume;
BRCA	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg06697600	chr4:7070879	GRPEL1	-0.55	-10.62	-0.39	2.27e-24	Monocyte percentage of white cells;
BRCA	cis	rs2625529	0.526	rs8040828	chr15:72492779	C/A	cg16672083	chr15:72433130	SENP8	0.65	15.59	0.52	1.13e-46	Red blood cell count;
BRCA	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg13334819	chr7:99746414	C7orf59	0.35	8.26	0.31	8.17e-16	Coronary artery disease;
BRCA	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg08807101	chr21:30365312	RNF160	-0.59	-14.68	-0.5	3.1e-42	Dental caries;
BRCA	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg04691961	chr3:161091175	C3orf57	-0.53	-12.27	-0.44	3.14e-31	Morning vs. evening chronotype;
BRCA	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11644478	chr21:40555479	PSMG1	0.77	16.75	0.55	1.81e-52	Cognitive function;
BRCA	cis	rs10754283	0.967	rs4658307	chr1:90117586	G/T	cg21401794	chr1:90099060	LRRC8C	0.5	12.05	0.43	2.76e-30	Amyotrophic lateral sclerosis (sporadic);
BRCA	trans	rs877282	0.583	rs11253441	chr10:828288	C/T	cg22713356	chr15:30763199	NA	-1.01	-16.1	-0.54	3.23e-49	Uric acid levels;
BRCA	cis	rs312273	0.682	rs1442188	chr12:41342928	A/T	cg17827154	chr12:41323612	CNTN1	-0.42	-10.99	-0.4	7.79e-26	Bipolar disorder;
BRCA	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18404041	chr3:52824283	ITIH1	-0.32	-9.55	-0.35	2.67e-20	Bipolar disorder;
BRCA	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.58	0.35	2.14e-20	Morning vs. evening chronotype;
BRCA	trans	rs2018683	0.835	rs7782264	chr7:28978986	A/G	cg19402173	chr7:128379420	CALU	0.46	11.3	0.41	4.14e-27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs858239	0.965	rs156429	chr7:23306020	A/G	cg23682824	chr7:23144976	KLHL7	0.39	9.54	0.35	2.92e-20	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg06212747	chr3:49208901	KLHDC8B	0.51	10.72	0.39	9.42e-25	Parkinson's disease;
BRCA	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg00074818	chr8:8560427	CLDN23	0.38	8.35	0.31	4.32e-16	Obesity-related traits;
BRCA	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05926928	chr17:57297772	GDPD1	1.43	18.2	0.58	5.7e-60	Opioid sensitivity;
BRCA	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg06784218	chr1:46089804	CCDC17	0.49	11.73	0.42	6.43e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg26043149	chr18:55253948	FECH	0.4	8.64	0.32	4.54e-17	Bone mineral density;
BRCA	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg02176678	chr2:219576539	TTLL4	0.36	9.45	0.35	6.13e-20	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg01528321	chr10:82214614	TSPAN14	-0.82	-18.72	-0.6	1.15e-62	Post bronchodilator FEV1;
BRCA	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.19	-0.4	1.19e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.26	-0.61	1.53e-65	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg11584989	chr19:19387371	SF4	0.63	13.4	0.47	2.87e-36	Bipolar disorder;
BRCA	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg20283391	chr11:68216788	NA	-0.46	-9.32	-0.35	1.9e-19	Total body bone mineral density;
BRCA	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg02951883	chr7:2050386	MAD1L1	-0.61	-15.14	-0.51	1.71e-44	Bipolar disorder and schizophrenia;
BRCA	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15664640	chr17:80829946	TBCD	0.41	10.96	0.4	9.79e-26	Breast cancer;
BRCA	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg12386194	chr3:101231763	SENP7	0.45	9.1	0.34	1.16e-18	Colorectal cancer;
BRCA	trans	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21659725	chr3:3221576	CRBN	-0.71	-21.61	-0.65	3.9e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg04362960	chr10:104952993	NT5C2	-0.34	-7.97	-0.3	7.15e-15	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg04518342	chr5:131593106	PDLIM4	0.37	9.45	0.35	6.26e-20	Breast cancer;
BRCA	cis	rs4891159	0.513	rs2554831	chr18:74113513	C/G	cg24786174	chr18:74118243	ZNF516	0.81	23.38	0.68	7.66e-88	Longevity;
BRCA	cis	rs593982	0.843	rs552312	chr11:65477349	C/T	cg08755490	chr11:65554678	OVOL1	1.21	17.62	0.57	6.01e-57	Atopic dermatitis;
BRCA	cis	rs6714710	0.603	rs13008968	chr2:98435982	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	13.65	0.48	1.99e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs1011018	0.590	rs10278124	chr7:139416939	C/G	cg03224163	chr7:139420300	HIPK2	-0.55	-9.01	-0.34	2.39e-18	Systolic blood pressure;
BRCA	cis	rs1003719	0.680	rs2835620	chr21:38505581	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.19	-0.49	6.29e-40	Eye color traits;
BRCA	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg03433033	chr1:76189801	ACADM	0.59	11.29	0.41	4.47e-27	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.23	0.34	4.05e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg09455208	chr3:40491958	NA	-0.49	-11.88	-0.43	1.43e-29	Renal cell carcinoma;
BRCA	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23583168	chr7:148888333	NA	-0.86	-20.12	-0.62	4.07e-70	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.4	0.35	9.9e-20	Morning vs. evening chronotype;
BRCA	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.39	9.03	0.34	2.01e-18	Alzheimer's disease (late onset);
BRCA	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg08975724	chr8:8085496	FLJ10661	0.39	8.24	0.31	9.6e-16	Neuroticism;
BRCA	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg05022225	chr19:49866942	DKKL1;TEAD2	0.39	8.38	0.31	3.45e-16	Multiple sclerosis;
BRCA	trans	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg06521331	chr12:34319734	NA	-0.51	-9.39	-0.35	1.01e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg11057378	chr10:81107060	PPIF	0.43	10.22	0.37	8.19e-23	Height;
BRCA	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg04944784	chr2:26401820	FAM59B	-1.01	-16.9	-0.56	3.04e-53	Gut microbiome composition (summer);
BRCA	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg25174290	chr11:3078921	CARS	0.45	13.55	0.47	6.13e-37	Longevity;
BRCA	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg06784218	chr1:46089804	CCDC17	0.49	11.58	0.42	2.67e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg10494973	chr17:80897199	TBCD	-0.36	-8.27	-0.31	7.87e-16	Breast cancer;
BRCA	cis	rs870825	0.616	rs9631783	chr4:185626511	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs7809950	0.593	rs62482503	chr7:106987988	A/G	cg23024343	chr7:107201750	COG5	-0.46	-9.48	-0.35	4.74e-20	Coronary artery disease;
BRCA	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg00105475	chr2:10696890	NA	0.44	10.4	0.38	1.66e-23	Prostate cancer;
BRCA	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg12591125	chr7:1885375	MAD1L1	0.5	8.81	0.33	1.2e-17	Bipolar disorder;
BRCA	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg12744634	chr1:26560303	CCDC21	0.31	8.7	0.33	2.81e-17	Obesity-related traits;
BRCA	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg04166393	chr7:2884313	GNA12	0.41	8.46	0.32	1.86e-16	Height;
BRCA	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.29	-0.31	6.7e-16	Colorectal cancer;
BRCA	cis	rs12579753	0.917	rs12822036	chr12:82183009	C/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-8.57	-0.32	7.78e-17	Resting heart rate;
BRCA	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg19077165	chr18:44547161	KATNAL2	0.55	12.19	0.43	6.77e-31	Personality dimensions;
BRCA	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg23711669	chr6:146136114	FBXO30	0.77	17.91	0.58	1.88e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2019216	0.872	rs6565384	chr17:21897456	T/C	cg22648282	chr17:21454238	C17orf51	-0.35	-8.07	-0.3	3.53e-15	Pelvic organ prolapse;
BRCA	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18876405	chr7:65276391	NA	-0.51	-11.43	-0.41	1.12e-27	Aortic root size;
BRCA	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.47	0.32	1.64e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6743226	0.901	rs4675968	chr2:242222492	T/C	cg10021735	chr2:242295487	FARP2	0.36	9.85	0.36	2.03e-21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg03923535	chr7:1197113	ZFAND2A	0.53	10.64	0.39	1.83e-24	Longevity;Endometriosis;
BRCA	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg01884057	chr2:25150051	NA	0.34	9.04	0.34	1.88e-18	Body mass index;
BRCA	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg17971929	chr21:40555470	PSMG1	-0.61	-13.51	-0.47	9.06e-37	Cognitive function;
BRCA	cis	rs7474896	0.526	rs1742235	chr10:38052256	T/C	cg25427524	chr10:38739819	LOC399744	-0.54	-9.73	-0.36	6.02e-21	Obesity (extreme);
BRCA	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	8.78	0.33	1.45e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs17604090	0.793	rs17150665	chr7:29688860	T/G	cg19413766	chr7:29689036	LOC646762	-0.51	-8.2	-0.31	1.33e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs9296092	0.517	rs62405949	chr6:33522800	G/A	cg13560919	chr6:33536144	NA	-0.85	-17.72	-0.57	1.88e-57	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg01884057	chr2:25150051	NA	0.34	8.98	0.33	3.03e-18	Body mass index;
BRCA	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12893428	chr3:195717962	SDHAP1	0.34	8.33	0.31	4.77e-16	Pancreatic cancer;
BRCA	cis	rs4363385	0.818	rs3806223	chr1:153002646	T/C	cg24667326	chr1:152973720	SPRR3	-0.32	-8.81	-0.33	1.17e-17	Inflammatory skin disease;
BRCA	cis	rs4664304	0.620	rs2048436	chr2:160712119	A/G	cg14819504	chr2:160761413	LY75	0.34	8.5	0.32	1.38e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg17971929	chr21:40555470	PSMG1	0.79	18.57	0.59	7.02e-62	Cognitive function;
BRCA	cis	rs524281	0.861	rs2293121	chr11:65961347	T/G	cg16950941	chr11:66035639	RAB1B	-0.38	-8.05	-0.3	4e-15	Electroencephalogram traits;
BRCA	cis	rs290268	0.874	rs290997	chr9:93559351	G/A	cg02608019	chr9:93564028	SYK	0.56	12.3	0.44	2.4e-31	Platelet count;
BRCA	cis	rs1997103	1.000	rs12718956	chr7:55407763	A/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg01689657	chr7:91764605	CYP51A1	0.22	8.05	0.3	3.98e-15	Breast cancer;
BRCA	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03264133	chr6:25882463	NA	-0.51	-10.46	-0.38	9.67e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs586533	0.881	rs7935457	chr11:99512337	C/T	cg22878054	chr11:99397252	CNTN5	-0.31	-7.83	-0.3	2.06e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg26513180	chr16:89883248	FANCA	-0.72	-18.33	-0.59	1.33e-60	Vitiligo;
BRCA	cis	rs10463316	0.894	rs4099168	chr5:150766467	A/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.32	-0.31	5.17e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs13006833	0.668	rs2582746	chr2:191163784	T/C	cg21644426	chr2:191273491	MFSD6	0.32	7.83	0.3	2.06e-14	Urinary metabolites;
BRCA	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg13010199	chr12:38710504	ALG10B	0.44	8.82	0.33	1.11e-17	Bladder cancer;
BRCA	cis	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs6977660	0.714	rs13230381	chr7:19833896	T/C	cg05791153	chr7:19748676	TWISTNB	0.58	10.74	0.39	7.76e-25	Thyroid stimulating hormone;
BRCA	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg03146154	chr1:46216737	IPP	0.52	11.44	0.41	1.1e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7572733	0.534	rs1436131	chr2:198731230	A/C	cg00792783	chr2:198669748	PLCL1	0.46	10.08	0.37	2.93e-22	Dermatomyositis;
BRCA	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03517284	chr6:25882590	NA	-0.62	-13.63	-0.47	2.59e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.78	-0.58	9.4e-58	Chronic sinus infection;
BRCA	trans	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg19862616	chr7:65841803	NCRNA00174	0.84	27.93	0.74	8.11e-113	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6450176	1.000	rs10805455	chr5:53302302	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.62	-15.07	-0.51	3.71e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs12711979	0.566	rs6706842	chr2:3853962	G/C	cg17052675	chr2:3827356	NA	-0.34	-8.21	-0.31	1.24e-15	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs778371	0.659	rs2289911	chr2:233704252	A/G	cg08000102	chr2:233561755	GIGYF2	-0.77	-16.67	-0.55	4.68e-52	Schizophrenia;
BRCA	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg03929089	chr4:120376271	NA	-0.44	-8.83	-0.33	1.03e-17	Coronary artery disease;
BRCA	trans	rs7181230	0.885	rs9919974	chr15:40337462	T/G	cg22705835	chr10:65332833	REEP3	-0.43	-9.3	-0.35	2.24e-19	Dehydroepiandrosterone sulphate levels;
BRCA	cis	rs62380364	0.558	rs34319	chr5:88023349	A/T	cg22951263	chr5:87985283	NA	-0.38	-10.66	-0.39	1.57e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7903847	0.619	rs10786336	chr10:99134953	A/C	cg20016023	chr10:99160130	RRP12	-0.27	-8.67	-0.32	3.62e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9837602	1.000	rs4571265	chr3:99705111	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.59	-11.28	-0.41	4.85e-27	Breast cancer;
BRCA	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg08501292	chr6:25962987	TRIM38	0.59	8.02	0.3	4.97e-15	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg26384229	chr12:38710491	ALG10B	0.74	16.55	0.55	1.74e-51	Morning vs. evening chronotype;
BRCA	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg09307838	chr4:120376055	NA	0.61	11.22	0.41	8.68e-27	Corneal astigmatism;
BRCA	trans	rs9329221	0.576	rs1986972	chr8:10268805	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	9.21	0.34	4.48e-19	Neuroticism;
BRCA	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.5	-12.3	-0.44	2.24e-31	Lung cancer;
BRCA	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26314531	chr2:26401878	FAM59B	0.95	16.32	0.54	2.59e-50	Mean corpuscular hemoglobin;
BRCA	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-17.53	-0.57	1.87e-56	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.56	13.48	0.47	1.31e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21659725	chr3:3221576	CRBN	-0.34	-7.91	-0.3	1.13e-14	Body mass index;
BRCA	trans	rs12517041	1.000	rs1428625	chr5:23290664	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.36	-0.31	4.04e-16	Calcium levels;
BRCA	cis	rs1997103	1.000	rs6593238	chr7:55411048	A/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7707921	0.505	rs12516434	chr5:81428072	T/A	cg15871215	chr5:81402204	ATG10	0.39	9.17	0.34	6.27e-19	Breast cancer;
BRCA	trans	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.89	-0.3	1.27e-14	Corneal astigmatism;
BRCA	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg26384229	chr12:38710491	ALG10B	0.69	16.03	0.54	7.2e-49	Bladder cancer;
BRCA	cis	rs1030877	0.960	rs3792047	chr2:105901553	A/G	cg02079111	chr2:105885981	TGFBRAP1	-0.65	-15.43	-0.52	6.96e-46	Obesity-related traits;
BRCA	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg19622623	chr12:86230825	RASSF9	-0.29	-8.11	-0.31	2.57e-15	Major depressive disorder;
BRCA	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02176678	chr2:219576539	TTLL4	0.46	11.82	0.42	2.72e-29	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg23029597	chr12:123009494	RSRC2	-0.63	-12.61	-0.45	1.06e-32	Body mass index;
BRCA	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg20701182	chr2:24300061	SF3B14	0.56	8.61	0.32	5.89e-17	Lymphocyte counts;
BRCA	cis	rs73242632	1.000	rs41344750	chr4:57830213	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.65	8.15	0.31	1.97e-15	Congenital heart disease (maternal effect);
BRCA	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg26597838	chr10:835615	NA	1.3	21.86	0.65	1.6e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg18196295	chr10:418757	DIP2C	-0.46	-9.35	-0.35	1.5e-19	Psychosis in Alzheimer's disease;
BRCA	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg14196790	chr5:131705035	SLC22A5	0.35	9.18	0.34	5.93e-19	Breast cancer;
BRCA	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.69	-19.25	-0.61	1.86e-65	Longevity;Endometriosis;
BRCA	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg09904177	chr6:26538194	HMGN4	0.55	17.64	0.57	4.63e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg26384229	chr12:38710491	ALG10B	0.49	10.72	0.39	8.69e-25	Morning vs. evening chronotype;
BRCA	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-11.06	-0.4	3.97e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	17.44	0.57	5.18e-56	Platelet count;
BRCA	cis	rs4800452	1.000	rs4800452	chr18:20727611	C/T	cg26136497	chr18:20735537	CABLES1	-0.41	-10.4	-0.38	1.68e-23	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg08975724	chr8:8085496	FLJ10661	0.49	10.51	0.38	6.04e-24	Mood instability;
BRCA	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg26384229	chr12:38710491	ALG10B	0.48	11.27	0.41	5.27e-27	Heart rate;
BRCA	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg20701182	chr2:24300061	SF3B14	0.51	8.65	0.32	4.27e-17	Lymphocyte counts;
BRCA	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg27432699	chr2:27873401	GPN1	0.47	9.94	0.37	9.8e-22	Oral cavity cancer;
BRCA	cis	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg06521331	chr12:34319734	NA	-0.57	-10.33	-0.38	3.02e-23	Morning vs. evening chronotype;
BRCA	cis	rs4074536	0.536	rs10754353	chr1:116292387	C/T	cg21648376	chr1:116311395	CASQ2	-0.49	-8.63	-0.32	4.94e-17	QRS duration;
BRCA	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg24296786	chr1:45957014	TESK2	0.45	10.21	0.37	9.1e-23	Red blood cell count;Reticulocyte count;
BRCA	trans	rs11165623	0.564	rs6593612	chr1:97002041	C/A	cg10631902	chr5:14652156	NA	-0.43	-12.14	-0.43	1.18e-30	Hip circumference;Waist circumference;
BRCA	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg16506815	chr2:162101123	NA	0.47	9.69	0.36	8.46e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg17425144	chr1:10567563	PEX14	-0.56	-14.37	-0.49	8.57e-41	Prostate cancer;
BRCA	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.97	-0.33	3.32e-18	Bipolar disorder;
BRCA	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.6	0.39	2.82e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs16854884	0.632	rs1910691	chr3:143656905	G/A	cg06585982	chr3:143692056	C3orf58	0.44	8.95	0.33	3.97e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	13.05	0.46	1.08e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11608355	0.545	rs4766475	chr12:109908373	G/A	cg05360138	chr12:110035743	NA	0.71	13.09	0.46	7.36e-35	Neuroticism;
BRCA	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	16.86	0.55	4.87e-53	Tonsillectomy;
BRCA	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg18252515	chr7:66147081	NA	-1.06	-15.85	-0.53	6.1e-48	Diabetic kidney disease;
BRCA	cis	rs644148	0.836	rs2686770	chr19:44998773	A/G	cg15540054	chr19:45004280	ZNF180	-0.55	-12.04	-0.43	3.15e-30	Personality dimensions;
BRCA	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg00383909	chr3:49044727	WDR6	0.96	13.41	0.47	2.68e-36	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs4363385	0.765	rs1094409	chr1:153021040	T/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.4	-0.32	2.92e-16	Inflammatory skin disease;
BRCA	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg07741184	chr6:167504864	NA	0.33	9.88	0.36	1.68e-21	Primary biliary cholangitis;
BRCA	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg23649088	chr2:200775458	C2orf69	0.57	8.47	0.32	1.67e-16	Schizophrenia;
BRCA	trans	rs3960554	0.867	rs79359354	chr7:75702597	G/A	cg19862616	chr7:65841803	NCRNA00174	0.56	12.08	0.43	2.11e-30	Eotaxin levels;
BRCA	cis	rs9815354	0.812	rs4547673	chr3:41952303	A/C	cg03022575	chr3:42003672	ULK4	0.69	9.62	0.36	1.44e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2422052	0.766	rs1583330	chr2:118650028	T/C	cg22545206	chr2:118617499	NA	0.4	9.83	0.36	2.56e-21	Mosquito bite size;
BRCA	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.5	-0.32	1.37e-16	Total body bone mineral density;
BRCA	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg22117172	chr7:91764530	CYP51A1	0.23	7.88	0.3	1.46e-14	Breast cancer;
BRCA	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-11.43	-0.41	1.17e-27	Alzheimer's disease;
BRCA	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg25173405	chr17:45401733	C17orf57	0.52	11.12	0.4	2.15e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg23283495	chr1:209979779	IRF6	0.37	8.81	0.33	1.16e-17	Cleft lip with or without cleft palate;
BRCA	cis	rs965469	1.000	rs6051715	chr20:3266548	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-10.19	-0.37	1.08e-22	IFN-related cytopenia;
BRCA	cis	rs8114671	0.740	rs3761141	chr20:33737824	A/C	cg24642439	chr20:33292090	TP53INP2	0.42	8.89	0.33	6.39e-18	Height;
BRCA	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.45	-8.77	-0.33	1.65e-17	Cognitive ability;
BRCA	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21659725	chr3:3221576	CRBN	0.66	19.26	0.61	1.65e-65	Intelligence (multi-trait analysis);
BRCA	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg22875332	chr1:76189707	ACADM	0.66	15.74	0.53	2.04e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg04267008	chr7:1944627	MAD1L1	-0.48	-10.15	-0.37	1.46e-22	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg05340658	chr4:99064831	C4orf37	0.62	14.81	0.51	6.76e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7677751	0.806	rs7673984	chr4:55088761	C/T	cg17187183	chr4:55093834	PDGFRA	0.45	8.65	0.32	4.21e-17	Corneal astigmatism;
BRCA	cis	rs7586879	0.929	rs6545807	chr2:25124358	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.24	0.34	3.73e-19	Body mass index;
BRCA	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg06552810	chr11:31128660	NA	0.39	8.74	0.33	2.01e-17	Red blood cell count;
BRCA	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg26597838	chr10:835615	NA	0.62	10.45	0.38	1.09e-23	Eosinophil percentage of granulocytes;
BRCA	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-9.6	-0.36	1.76e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg07541023	chr7:19748670	TWISTNB	-0.57	-9.86	-0.36	1.97e-21	Thyroid stimulating hormone;
BRCA	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg02574844	chr11:5959923	NA	-0.38	-7.94	-0.3	9.09e-15	DNA methylation (variation);
BRCA	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg24812749	chr6:127587940	RNF146	0.86	20.21	0.62	1.41e-70	Breast cancer;
BRCA	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	11.71	0.42	7.92e-29	Glomerular filtration rate (creatinine);
BRCA	trans	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg23762105	chr12:34175262	ALG10	0.37	8.53	0.32	1.1e-16	Morning vs. evening chronotype;
BRCA	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg18252515	chr7:66147081	NA	-1.06	-15.68	-0.53	3.88e-47	Diabetic kidney disease;
BRCA	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22496380	chr5:211416	CCDC127	-0.99	-14.31	-0.49	1.63e-40	Breast cancer;
BRCA	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg24642844	chr7:1081250	C7orf50	-0.89	-16.21	-0.54	9.83e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg08999081	chr20:33150536	PIGU	-0.45	-12.2	-0.43	6.33e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg24130564	chr14:104152367	KLC1	-0.41	-8.79	-0.33	1.43e-17	Reticulocyte count;
BRCA	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg03676636	chr4:99064102	C4orf37	0.21	7.95	0.3	8.36e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1003719	0.688	rs2000416	chr21:38540089	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-13.71	-0.48	1.05e-37	Eye color traits;
BRCA	cis	rs6088813	1.000	rs2425065	chr20:33926268	A/T	cg14752227	chr20:34000481	UQCC	0.41	8.85	0.33	8.24e-18	Height;
BRCA	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg16325326	chr1:53192061	ZYG11B	-0.95	-26.1	-0.72	8.67e-103	Monocyte count;
BRCA	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg05340658	chr4:99064831	C4orf37	-0.43	-9.8	-0.36	3.27e-21	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg18225595	chr11:63971243	STIP1	0.4	10.2	0.37	1.02e-22	Platelet count;
BRCA	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.54	0.42	4.13e-28	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg05234568	chr11:5960015	NA	-0.45	-9.33	-0.35	1.73e-19	DNA methylation (variation);
BRCA	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg24692254	chr21:30365293	RNF160	0.78	21.27	0.64	2.52e-76	Dental caries;
BRCA	cis	rs17095355	1.000	rs11194924	chr10:111695773	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.39	-10.06	-0.37	3.42e-22	Biliary atresia;
BRCA	cis	rs3820928	1.000	rs7592387	chr2:227777095	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.46	-0.32	1.8e-16	Pulmonary function;
BRCA	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg21770322	chr7:97807741	LMTK2	0.41	10.96	0.4	1.02e-25	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg06115741	chr20:33292138	TP53INP2	0.4	8.82	0.33	1.07e-17	Coronary artery disease;
BRCA	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg24154853	chr7:158122151	PTPRN2	0.34	7.91	0.3	1.12e-14	Calcium levels;
BRCA	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg09307838	chr4:120376055	NA	0.69	14.02	0.49	3.82e-39	Corneal astigmatism;
BRCA	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-9.63	-0.36	1.42e-20	Menopause (age at onset);
BRCA	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-10.19	-0.37	1.07e-22	Alzheimer's disease (late onset);
BRCA	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg05714579	chr10:131428358	MGMT	-0.66	-16.54	-0.55	2.15e-51	Response to temozolomide;
BRCA	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg18904891	chr8:8559673	CLDN23	0.61	12.04	0.43	3.06e-30	Obesity-related traits;
BRCA	cis	rs7124681	0.546	rs7941399	chr11:47890421	A/T	cg20307385	chr11:47447363	PSMC3	0.41	9.44	0.35	6.57e-20	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg24675658	chr1:53192096	ZYG11B	0.56	12.76	0.45	2.24e-33	Monocyte count;
BRCA	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg22800045	chr5:56110881	MAP3K1	0.66	12.37	0.44	1.22e-31	Initial pursuit acceleration;
BRCA	cis	rs6750047	0.771	rs1056837	chr2:38298150	A/G	cg07380506	chr2:38303506	CYP1B1	0.52	12.67	0.45	5.8e-33	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg22764044	chr5:178986830	RUFY1	0.36	8.55	0.32	8.92e-17	Lung cancer;
BRCA	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg01119278	chr6:110721349	DDO	-0.42	-10.25	-0.38	6.5e-23	Platelet distribution width;
BRCA	cis	rs1506636	1.000	rs2299984	chr7:123356921	G/T	cg03229431	chr7:123269106	ASB15	0.61	13.74	0.48	7.93e-38	Plateletcrit;Platelet count;
BRCA	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg11764359	chr7:65958608	NA	-0.77	-17.3	-0.56	2.66e-55	Aortic root size;
BRCA	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg25801113	chr15:45476975	SHF	-0.34	-8.14	-0.31	2.01e-15	Uric acid levels;
BRCA	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.4	0.57	8.7e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg21095983	chr6:86352623	SYNCRIP	0.45	9.87	0.36	1.74e-21	Smooth-surface caries;
BRCA	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg06115741	chr20:33292138	TP53INP2	0.49	11.05	0.4	4.27e-26	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg13047869	chr3:10149882	C3orf24	0.53	11.24	0.41	6.83e-27	Alzheimer's disease;
BRCA	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg26384229	chr12:38710491	ALG10B	0.48	12.29	0.44	2.61e-31	Morning vs. evening chronotype;
BRCA	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.93	0.46	3.84e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12618769	0.652	rs3754871	chr2:99224309	A/T	cg10123293	chr2:99228465	UNC50	0.43	8.6	0.32	6.35e-17	Bipolar disorder;
BRCA	cis	rs12210905	0.688	rs12212632	chr6:27472416	T/C	cg08851530	chr6:28072375	NA	0.81	8.01	0.3	5.53e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg11993925	chr19:44307056	LYPD5	0.38	8.95	0.33	3.73e-18	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg11941060	chr3:133502564	NA	-0.39	-8.81	-0.33	1.21e-17	Iron status biomarkers;
BRCA	cis	rs965469	1.000	rs6037583	chr20:3360632	G/A	cg25506879	chr20:3388711	C20orf194	-0.52	-10.32	-0.38	3.25e-23	IFN-related cytopenia;
BRCA	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26314531	chr2:26401878	FAM59B	-0.96	-16.62	-0.55	8.34e-52	Gut microbiome composition (summer);
BRCA	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	ch.11.42038R	chr11:967971	AP2A2	0.52	16.71	0.55	2.87e-52	Alzheimer's disease (late onset);
BRCA	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg20307385	chr11:47447363	PSMC3	0.4	8.4	0.32	2.82e-16	Subjective well-being;
BRCA	cis	rs3857067	0.806	rs72665608	chr4:95093501	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.44	-0.35	6.72e-20	QT interval;
BRCA	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg00530320	chr1:46809349	NSUN4	0.49	9.7	0.36	7.91e-21	Menopause (age at onset);
BRCA	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg15556689	chr8:8085844	FLJ10661	0.37	8.71	0.33	2.66e-17	Retinal vascular caliber;
BRCA	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg06212747	chr3:49208901	KLHDC8B	0.47	9.64	0.36	1.24e-20	Parkinson's disease;
BRCA	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg04586622	chr2:25135609	ADCY3	0.46	11.51	0.41	5.31e-28	Body mass index;
BRCA	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg06640241	chr16:89574553	SPG7	0.58	12.73	0.45	2.99e-33	Multiple myeloma (IgH translocation);
BRCA	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg21775007	chr8:11205619	TDH	0.71	17.3	0.56	2.9e-55	Retinal vascular caliber;
BRCA	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24229701	chr12:130821962	PIWIL1	0.39	8.81	0.33	1.15e-17	Menopause (age at onset);
BRCA	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07636037	chr3:49044803	WDR6	0.75	16.43	0.54	7.51e-51	Menarche (age at onset);
BRCA	cis	rs10046574	0.561	rs7789858	chr7:135212285	A/G	cg27474649	chr7:135195673	CNOT4	0.64	10.75	0.39	6.98e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg26597838	chr10:835615	NA	0.83	15.2	0.52	9.58e-45	Eosinophil percentage of granulocytes;
BRCA	cis	rs1079204	1.000	rs1017697	chr2:219170462	C/T	cg05728596	chr2:219128475	GPBAR1	0.73	9.55	0.35	2.8e-20	Smooth-surface caries;
BRCA	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg23950597	chr19:37808831	NA	-0.65	-11.95	-0.43	7.76e-30	Coronary artery calcification;
BRCA	cis	rs6840360	0.533	rs13121178	chr4:152729047	T/C	cg22705602	chr4:152727874	NA	0.38	9.86	0.36	1.91e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg17807903	chr1:86174739	ZNHIT6	-0.55	-13.79	-0.48	4.85e-38	Urate levels in overweight individuals;
BRCA	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	27.54	0.74	1.1e-110	Chronic sinus infection;
BRCA	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-14.18	-0.49	6.74e-40	Bipolar disorder and schizophrenia;
BRCA	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg05234568	chr11:5960015	NA	-0.49	-9.32	-0.35	1.85e-19	DNA methylation (variation);
BRCA	trans	rs34421088	0.623	rs2572433	chr8:11101041	C/T	cg06636001	chr8:8085503	FLJ10661	0.45	8.99	0.34	2.87e-18	Neuroticism;
BRCA	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg27535305	chr1:53392650	SCP2	-0.32	-7.94	-0.3	9.43e-15	Monocyte count;
BRCA	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg16606324	chr3:10149918	C3orf24	0.49	9.94	0.37	9.86e-22	Alzheimer's disease;
BRCA	cis	rs2425143	1.000	rs2425142	chr20:34350346	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.83	-0.36	2.51e-21	Blood protein levels;
BRCA	cis	rs4900538	0.963	rs4906205	chr14:102932447	A/G	cg18135206	chr14:102964638	TECPR2	1.05	30.45	0.77	1.64e-126	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg07636037	chr3:49044803	WDR6	0.94	26.36	0.72	3.23e-104	Parkinson's disease;
BRCA	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-13.31	-0.47	7.34e-36	Morning vs. evening chronotype;
BRCA	cis	rs705471	0.932	rs1106278	chr10:3677358	A/G	cg14308648	chr10:3568949	NA	0.35	7.86	0.3	1.6e-14	Capecitabine sensitivity;
BRCA	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg07414643	chr4:187882934	NA	0.28	9.65	0.36	1.2e-20	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-10.33	-0.38	3.19e-23	Neuroticism;
BRCA	cis	rs7975161	0.535	rs6539138	chr12:104735928	G/A	cg25273343	chr12:104657179	TXNRD1	-0.5	-9.97	-0.37	7.46e-22	Toenail selenium levels;
BRCA	cis	rs887829	0.570	rs10445704	chr2:234600274	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.48	-0.32	1.53e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg14863265	chr7:2801509	GNA12	-0.39	-8.74	-0.33	2.02e-17	Height;
BRCA	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	29.48	0.76	2.96e-121	Chronic sinus infection;
BRCA	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-13.45	-0.47	1.65e-36	Crohn's disease;
BRCA	cis	rs3750965	0.920	rs10896420	chr11:68863047	G/A	cg06818126	chr11:68850279	TPCN2	-0.37	-8.86	-0.33	7.61e-18	Hair color;
BRCA	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15541040	chr2:3486749	NA	-0.45	-10.1	-0.37	2.36e-22	Neurofibrillary tangles;
BRCA	cis	rs7598759	0.527	rs12987949	chr2:232367511	A/G	cg19187155	chr2:232395269	NMUR1	0.7	16.64	0.55	6.43e-52	Noise-induced hearing loss;
BRCA	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg05535760	chr7:792225	HEATR2	0.77	14.02	0.48	4e-39	Cerebrospinal P-tau181p levels;
BRCA	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.42	-0.38	1.38e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs36051895	0.658	rs10974914	chr9:5014332	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-8.77	-0.33	1.63e-17	Pediatric autoimmune diseases;
BRCA	cis	rs7131987	0.650	rs12366527	chr12:29474256	C/G	cg09582351	chr12:29534625	ERGIC2	-0.43	-9.85	-0.36	2.03e-21	QT interval;
BRCA	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-9.07	-0.34	1.42e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	17.01	0.56	8.2e-54	Platelet count;
BRCA	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18404041	chr3:52824283	ITIH1	-0.31	-9.44	-0.35	7.05e-20	Bipolar disorder;
BRCA	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.24	-0.34	3.68e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs3820928	1.000	rs1835158	chr2:227763993	C/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.42	-0.32	2.55e-16	Pulmonary function;
BRCA	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg26384229	chr12:38710491	ALG10B	-0.65	-14.94	-0.51	1.75e-43	Bladder cancer;
BRCA	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.43	-10.65	-0.39	1.68e-24	Longevity;Endometriosis;
BRCA	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26314531	chr2:26401878	FAM59B	-0.63	-10.83	-0.39	3.28e-25	Gut microbiome composition (summer);
BRCA	cis	rs1003719	0.688	rs2835660	chr21:38568882	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.73	-0.5	1.77e-42	Eye color traits;
BRCA	cis	rs9880211	0.948	rs9844666	chr3:135974216	G/A	cg21827317	chr3:136751795	NA	-0.46	-8.04	-0.3	4.3e-15	Body mass index;Height;
BRCA	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg01304814	chr3:48885189	PRKAR2A	0.77	7.91	0.3	1.13e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg00530320	chr1:46809349	NSUN4	0.49	9.76	0.36	4.52e-21	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.94e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg16850897	chr7:100343110	ZAN	-0.58	-11.75	-0.42	5.29e-29	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs708547	0.647	rs781666	chr4:57830981	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-8.16	-0.31	1.74e-15	Response to bleomycin (chromatid breaks);
BRCA	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg12311346	chr5:56204834	C5orf35	-0.81	-16.7	-0.55	3.32e-52	Initial pursuit acceleration;
BRCA	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg17366294	chr4:99064904	C4orf37	0.45	10.77	0.39	5.85e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11890956	chr21:40555474	PSMG1	1.06	31.42	0.78	1.02e-131	Cognitive function;
BRCA	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.38	0.49	7.79e-41	Motion sickness;
BRCA	cis	rs1691799	0.867	rs1168348	chr12:66757168	G/A	cg16791601	chr12:66731901	HELB	-0.66	-18.09	-0.58	2.15e-59	White blood cell count (basophil);
BRCA	cis	rs1559088	0.501	rs35599132	chr19:33570554	G/A	cg17764715	chr19:33622953	WDR88	0.51	8.37	0.31	3.71e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19346786	chr7:2764209	NA	-0.32	-9.26	-0.34	2.96e-19	Height;
BRCA	trans	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.37	-9.13	-0.34	8.58e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg23950597	chr19:37808831	NA	-0.65	-11.6	-0.42	2.36e-28	Coronary artery calcification;
BRCA	trans	rs11039798	0.764	rs2089208	chr11:48899860	C/T	cg15704280	chr7:45808275	SEPT13	0.59	8.82	0.33	1.07e-17	Axial length;
BRCA	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg16325326	chr1:53192061	ZYG11B	0.93	25.57	0.71	7.65e-100	Monocyte count;
BRCA	cis	rs758324	0.947	rs6596041	chr5:131198860	C/T	cg06307176	chr5:131281290	NA	0.53	10.4	0.38	1.61e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg11752832	chr7:134001865	SLC35B4	-0.49	-12.25	-0.44	3.92e-31	Mean platelet volume;
BRCA	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg12165864	chr7:66369176	NA	-0.44	-9.83	-0.36	2.56e-21	Corneal structure;
BRCA	cis	rs6901250	0.610	rs9400964	chr6:117144808	G/T	cg12892004	chr6:117198278	RFX6	0.37	8.98	0.33	3.07e-18	C-reactive protein levels;
BRCA	cis	rs6700896	0.897	rs11208696	chr1:66121781	T/G	cg04111102	chr1:66153794	NA	0.36	8.86	0.33	7.79e-18	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs1018836	0.923	rs7013893	chr8:91563137	G/A	cg16814680	chr8:91681699	NA	-0.58	-12.41	-0.44	7.45e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg14530993	chr4:882597	GAK	0.49	8.75	0.33	1.9e-17	Parkinson's disease;
BRCA	cis	rs858239	1.000	rs156425	chr7:23309119	C/T	cg23682824	chr7:23144976	KLHL7	-0.35	-9.02	-0.34	2.2e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg06115741	chr20:33292138	TP53INP2	0.48	10.72	0.39	8.71e-25	Coronary artery disease;
BRCA	trans	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.09	0.3	3.09e-15	Corneal astigmatism;
BRCA	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg05985134	chr18:33552581	C18orf21	0.63	11.95	0.43	7.58e-30	Endometriosis;Drug-induced torsades de pointes;
BRCA	trans	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.43	0.32	2.34e-16	Corneal astigmatism;
BRCA	cis	rs10499694	0.933	rs7778349	chr7:50593157	C/T	cg18232548	chr7:50535776	DDC	-0.39	-9.33	-0.35	1.72e-19	Body mass index;
BRCA	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24308560	chr3:49941425	MST1R	0.39	8.4	0.32	2.86e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg10011062	chr15:43941034	CATSPER2	-0.55	-8.09	-0.3	2.94e-15	Lung cancer in ever smokers;
BRCA	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.58	-11.69	-0.42	9.31e-29	Body mass index (adult);
BRCA	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.49	0.47	1.16e-36	Colorectal cancer;
BRCA	cis	rs600231	0.542	rs11227199	chr11:65238121	G/A	cg01292856	chr11:65242576	NA	0.66	14.93	0.51	1.76e-43	Bone mineral density;
BRCA	cis	rs4845875	0.600	rs11805138	chr1:11833159	T/C	cg24844545	chr1:11908347	NPPA	0.36	8.39	0.32	3.07e-16	Midregional pro atrial natriuretic peptide levels;
BRCA	trans	rs4596713	0.536	rs10217168	chr9:71794956	A/G	cg16512924	chr15:28394682	HERC2	0.45	10.74	0.39	7.63e-25	Headache;
BRCA	cis	rs7809950	1.000	rs7809950	chr7:107237807	T/C	cg23024343	chr7:107201750	COG5	0.43	9.28	0.34	2.58e-19	Coronary artery disease;
BRCA	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg08470875	chr2:26401718	FAM59B	-0.5	-8.19	-0.31	1.4e-15	Gut microbiome composition (summer);
BRCA	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg27432699	chr2:27873401	GPN1	0.38	7.95	0.3	8.41e-15	Oral cavity cancer;
BRCA	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg22467129	chr15:76604101	ETFA	-0.44	-9.83	-0.36	2.5e-21	Blood metabolite levels;
BRCA	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.52	-15.04	-0.51	5.51e-44	Lung cancer;
BRCA	cis	rs9649465	1.000	rs6963231	chr7:123374766	A/G	cg04330084	chr7:123175371	IQUB	-0.33	-8.98	-0.33	2.94e-18	Migraine;
BRCA	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg01579765	chr21:45077557	HSF2BP	0.4	10.52	0.38	5.7e-24	Mean corpuscular volume;
BRCA	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg24920358	chr1:40204285	PPIE	0.33	7.81	0.3	2.3e-14	Blood protein levels;
BRCA	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg20503657	chr10:835505	NA	0.91	15.14	0.51	1.88e-44	Eosinophil percentage of granulocytes;
BRCA	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.68	-0.48	1.51e-37	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg17063962	chr7:91808500	NA	0.56	13.32	0.47	6.69e-36	Breast cancer;
BRCA	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-13.4	-0.47	2.88e-36	Migraine;Coronary artery disease;
BRCA	cis	rs6930083	0.527	rs9470367	chr6:36626932	G/C	cg08179530	chr6:36648295	CDKN1A	-0.53	-11.45	-0.41	1.01e-27	Coronary artery disease;
BRCA	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg24692254	chr21:30365293	RNF160	-0.46	-10.21	-0.37	9.05e-23	Dental caries;
BRCA	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-18.89	-0.6	1.45e-63	Morning vs. evening chronotype;
BRCA	cis	rs9875589	0.509	rs1488377	chr3:14073178	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.32	8.09	0.3	2.95e-15	Ovarian reserve;
BRCA	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg17135325	chr3:160939158	NMD3	0.41	8.0	0.3	5.93e-15	Parkinson's disease;
BRCA	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg25019033	chr10:957182	NA	-0.42	-8.05	-0.3	4.14e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs7127900	0.583	rs11043147	chr11:2234169	C/G	cg12428727	chr11:2234665	NA	0.54	13.6	0.47	3.53e-37	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
BRCA	cis	rs4363385	0.818	rs1334850	chr1:153004519	G/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.22	-0.34	4.33e-19	Inflammatory skin disease;
BRCA	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg03425785	chr20:62221387	GMEB2	0.51	8.23	0.31	1.07e-15	Glioblastoma;
BRCA	cis	rs6977660	0.598	rs10239147	chr7:19787459	T/C	cg05791153	chr7:19748676	TWISTNB	0.56	10.21	0.37	9.28e-23	Thyroid stimulating hormone;
BRCA	trans	rs7178375	1.000	rs1474382	chr15:31214649	A/G	cg04373760	chr16:53404718	NA	0.5	9.3	0.35	2.24e-19	Hypertriglyceridemia;
BRCA	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg01420254	chr6:26195488	NA	0.56	8.73	0.33	2.19e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg05347473	chr6:146136440	FBXO30	0.42	8.48	0.32	1.57e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg18225595	chr11:63971243	STIP1	0.52	12.95	0.46	3.16e-34	Platelet count;
BRCA	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg11812906	chr14:75593930	NEK9	0.67	15.2	0.52	9.49e-45	Height;
BRCA	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg24812749	chr6:127587940	RNF146	0.68	15.55	0.52	1.82e-46	Breast cancer;
BRCA	cis	rs17741873	0.779	rs2242255	chr10:75597289	T/A	cg07699608	chr10:75541558	CHCHD1	0.5	8.19	0.31	1.38e-15	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg24130564	chr14:104152367	KLC1	-0.34	-7.96	-0.3	8.14e-15	Body mass index;
BRCA	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg15017067	chr4:17643749	FAM184B	0.3	8.4	0.32	2.79e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9815354	0.904	rs9852991	chr3:41875455	C/A	cg03022575	chr3:42003672	ULK4	0.49	7.99	0.3	6.4e-15	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg04362960	chr10:104952993	NT5C2	0.46	10.03	0.37	4.55e-22	Arsenic metabolism;
BRCA	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg02196655	chr2:10830764	NOL10	-0.29	-7.83	-0.3	1.98e-14	Prostate cancer;
BRCA	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs4389656	0.784	rs274723	chr5:6718563	A/G	cg10857441	chr5:6722123	POLS	-0.24	-7.86	-0.3	1.65e-14	Coronary artery disease;
BRCA	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg25173405	chr17:45401733	C17orf57	0.52	11.24	0.41	7.13e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg25817165	chr18:72167213	CNDP2	-0.74	-18.35	-0.59	9.85e-61	Refractive error;
BRCA	cis	rs6546550	0.901	rs6721891	chr2:70146121	A/G	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.47	-0.41	7.73e-28	Prevalent atrial fibrillation;
BRCA	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg08822215	chr16:89438651	ANKRD11	-0.37	-7.89	-0.3	1.33e-14	Multiple myeloma (IgH translocation);
BRCA	trans	rs412658	0.668	rs7253490	chr19:22293706	A/C	cg17074339	chr11:11642133	GALNTL4	0.4	8.87	0.33	7.06e-18	Telomere length;
BRCA	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg11502198	chr6:26597334	ABT1	0.52	9.98	0.37	6.79e-22	Intelligence (multi-trait analysis);
BRCA	trans	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg06521331	chr12:34319734	NA	-0.51	-9.14	-0.34	8.45e-19	Bladder cancer;
BRCA	cis	rs13102973	0.899	rs13119071	chr4:135909862	G/T	cg14419869	chr4:135874104	NA	0.45	8.96	0.33	3.41e-18	Subjective well-being;
BRCA	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg02297831	chr4:17616191	MED28	0.38	8.88	0.33	6.9e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg13010199	chr12:38710504	ALG10B	0.52	9.88	0.36	1.64e-21	Bladder cancer;
BRCA	cis	rs6815814	0.898	rs2174284	chr4:38859339	C/T	cg02016764	chr4:38805732	TLR1	-0.53	-8.12	-0.31	2.43e-15	Breast cancer;
BRCA	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg17173187	chr15:85201210	NMB	0.41	8.68	0.32	3.18e-17	Schizophrenia;
BRCA	cis	rs7572733	0.534	rs700674	chr2:198693703	C/T	cg00792783	chr2:198669748	PLCL1	0.47	10.19	0.37	1.11e-22	Dermatomyositis;
BRCA	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-10.28	-0.38	4.86e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11890956	chr21:40555474	PSMG1	-0.81	-19.28	-0.61	1.25e-65	Cognitive function;
BRCA	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.71	-12.44	-0.44	5.58e-32	Lung cancer in ever smokers;
BRCA	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg07169764	chr2:136633963	MCM6	1.32	33.29	0.8	1.04e-141	Corneal structure;
BRCA	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg08000102	chr2:233561755	GIGYF2	-0.46	-10.03	-0.37	4.4e-22	Coronary artery disease;
BRCA	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	13.3	0.47	8.12e-36	Schizophrenia;
BRCA	cis	rs7520050	0.931	rs35743647	chr1:46407252	T/C	cg24296786	chr1:45957014	TESK2	0.44	9.87	0.36	1.71e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg21138405	chr5:131827807	IRF1	0.39	12.34	0.44	1.6e-31	Asthma (sex interaction);
BRCA	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg19653624	chr11:20408972	PRMT3	-0.45	-10.37	-0.38	2.07e-23	Pursuit maintenance gain;
BRCA	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg07741184	chr6:167504864	NA	0.27	8.0	0.3	5.67e-15	Crohn's disease;
BRCA	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg02403541	chr12:121454288	C12orf43	-0.46	-9.07	-0.34	1.48e-18	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
BRCA	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg05340658	chr4:99064831	C4orf37	0.54	8.71	0.33	2.52e-17	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg02175503	chr12:58329896	NA	-0.42	-8.99	-0.34	2.82e-18	Multiple sclerosis;
BRCA	cis	rs2742234	0.868	rs2505512	chr10:43633596	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.42	-8.91	-0.33	5.14e-18	Hirschsprung disease;
BRCA	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	19.97	0.62	2.74e-69	Platelet count;
BRCA	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg05868516	chr6:26286170	HIST1H4H	-0.48	-10.97	-0.4	9.05e-26	Educational attainment;
BRCA	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg08000102	chr2:233561755	GIGYF2	0.62	13.54	0.47	6.92e-37	Coronary artery disease;
BRCA	cis	rs3741151	0.773	rs58334887	chr11:73171510	A/C	cg17517138	chr11:73019481	ARHGEF17	0.88	12.46	0.44	4.72e-32	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg21724239	chr8:58056113	NA	0.64	9.9	0.36	1.34e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs13040088	0.518	rs2427452	chr20:61577275	T/C	cg23096297	chr20:61557774	DIDO1	-0.67	-14.15	-0.49	9.39e-40	Menopause (age at onset);
BRCA	trans	rs9944715	0.954	rs4453594	chr18:43788332	G/T	cg01718231	chr17:29326311	RNF135	-0.46	-8.96	-0.33	3.58e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03188948	chr7:1209495	NA	0.69	15.13	0.51	1.98e-44	Longevity;Endometriosis;
BRCA	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg02544614	chr20:61657117	NA	0.29	8.18	0.31	1.53e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.21	-0.34	4.63e-19	Bipolar disorder;
BRCA	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg03146154	chr1:46216737	IPP	0.53	11.89	0.43	1.37e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg05340658	chr4:99064831	C4orf37	0.62	14.87	0.51	3.69e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9816226	0.618	rs869399	chr3:185826764	C/T	cg00760338	chr3:185826511	ETV5	0.55	12.06	0.43	2.61e-30	Obesity;Body mass index;
BRCA	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	18.67	0.59	2.04e-62	Platelet count;
BRCA	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg24768116	chr2:27665128	KRTCAP3	-0.31	-7.85	-0.3	1.74e-14	Total body bone mineral density;
BRCA	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08859206	chr1:53392774	SCP2	0.61	12.69	0.45	4.64e-33	Monocyte count;
BRCA	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg04756594	chr16:24857601	SLC5A11	0.48	10.1	0.37	2.35e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs10911251	0.528	rs10911264	chr1:183115040	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.36	0.54	1.69e-50	Colorectal cancer;
BRCA	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg26168224	chr5:2018326	NA	-0.55	-14.23	-0.49	3.94e-40	Gut microbiome composition (winter);
BRCA	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg17971929	chr21:40555470	PSMG1	0.81	19.72	0.62	5.65e-68	Cognitive function;
BRCA	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9403521	1.000	rs6907410	chr6:143995142	A/G	cg18240653	chr6:144019428	PHACTR2	-0.42	-8.28	-0.31	7.18e-16	Obesity-related traits;
BRCA	cis	rs11887277	0.708	rs12470698	chr2:27063261	A/G	cg12368169	chr2:27073192	DPYSL5	-0.33	-9.98	-0.37	6.77e-22	Obesity-related traits;
BRCA	cis	rs4363385	0.747	rs4845332	chr1:152982632	C/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.36	-0.31	3.82e-16	Inflammatory skin disease;
BRCA	cis	rs1298062	0.563	rs2445828	chr19:50941807	A/G	cg11430371	chr19:50961752	MYBPC2	0.31	7.94	0.3	9.04e-15	Age of smoking initiation;
BRCA	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg22800045	chr5:56110881	MAP3K1	0.46	9.1	0.34	1.14e-18	Initial pursuit acceleration;
BRCA	trans	rs2270927	0.510	rs67771044	chr5:75577819	A/G	cg13563193	chr19:33072644	PDCD5	0.91	11.21	0.41	9.34e-27	Mean corpuscular volume;
BRCA	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg13047869	chr3:10149882	C3orf24	0.59	12.55	0.44	1.94e-32	Alzheimer's disease;
BRCA	cis	rs72634258	0.842	rs4908727	chr1:8163122	C/T	cg00042356	chr1:8021962	PARK7	0.57	9.51	0.35	3.7e-20	Inflammatory bowel disease;
BRCA	trans	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs977987	0.527	rs62059844	chr16:75429737	T/C	cg03315344	chr16:75512273	CHST6	0.52	12.36	0.44	1.31e-31	Dupuytren's disease;
BRCA	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	16.22	0.54	8.5e-50	Intelligence (multi-trait analysis);
BRCA	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg16414030	chr3:133502952	NA	-0.53	-12.33	-0.44	1.77e-31	Iron status biomarkers;
BRCA	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg11645453	chr3:52864694	ITIH4	0.49	11.98	0.43	5.43e-30	Schizophrenia;
BRCA	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg02820040	chr2:241836501	C2orf54	-0.46	-9.12	-0.34	9.28e-19	Urinary metabolites;
BRCA	trans	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg25214090	chr10:38739885	LOC399744	0.53	11.71	0.42	7.51e-29	Corneal astigmatism;
BRCA	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.54	-9.73	-0.36	6.13e-21	Renal function-related traits (BUN);
BRCA	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg25358565	chr5:93447407	FAM172A	-1.12	-18.1	-0.58	1.99e-59	Diabetic retinopathy;
BRCA	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg12011299	chr4:100065546	ADH4	-0.46	-10.57	-0.39	3.61e-24	Smoking initiation;
BRCA	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	22.42	0.66	1.41e-82	Platelet count;
BRCA	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg13441142	chr10:134499734	INPP5A	0.4	8.11	0.31	2.5e-15	Primary sclerosing cholangitis;
BRCA	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08048268	chr3:133502702	NA	-0.43	-10.97	-0.4	9.38e-26	Iron status biomarkers;
BRCA	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg05775895	chr3:12838266	CAND2	0.35	7.82	0.3	2.24e-14	QRS complex (12-leadsum);
BRCA	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg21535247	chr6:8435926	SLC35B3	0.38	8.67	0.32	3.58e-17	Motion sickness;
BRCA	cis	rs6545883	0.826	rs2694617	chr2:61537214	G/A	cg15711740	chr2:61764176	XPO1	0.51	13.07	0.46	9.58e-35	Tuberculosis;
BRCA	cis	rs1829883	0.898	rs2511899	chr5:98776319	G/A	cg08333243	chr5:99726346	NA	-0.36	-8.48	-0.32	1.58e-16	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	8.15	0.31	1.88e-15	Schizophrenia;
BRCA	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.38	8.34	0.31	4.57e-16	Cognitive ability;
BRCA	cis	rs6840258	0.660	rs72667737	chr4:87876416	C/T	cg08197287	chr4:87952173	AFF1	-0.47	-8.47	-0.32	1.71e-16	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs7737355	0.898	rs13164236	chr5:131079808	C/T	cg06307176	chr5:131281290	NA	0.52	10.08	0.37	2.86e-22	Life satisfaction;
BRCA	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg09307838	chr4:120376055	NA	0.72	15.2	0.52	9.32e-45	Corneal astigmatism;
BRCA	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.77	0.42	4.43e-29	Tonsillectomy;
BRCA	trans	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg19862616	chr7:65841803	NCRNA00174	0.81	25.64	0.71	3.13e-100	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.03	-0.34	2.09e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24308560	chr3:49941425	MST1R	-0.4	-8.57	-0.32	7.83e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg10820045	chr2:198174542	NA	-0.46	-10.82	-0.39	3.75e-25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs1691799	0.899	rs2951656	chr12:66732273	T/G	cg16791601	chr12:66731901	HELB	-0.63	-16.85	-0.55	5.7e-53	White blood cell count (basophil);
BRCA	cis	rs66887589	0.776	rs10518337	chr4:120574874	A/C	cg09307838	chr4:120376055	NA	-0.4	-8.07	-0.3	3.5e-15	Diastolic blood pressure;
BRCA	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg17971929	chr21:40555470	PSMG1	0.46	10.2	0.37	9.9e-23	Menarche (age at onset);
BRCA	cis	rs4363385	0.747	rs2879488	chr1:152975241	G/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.32	-0.31	5.23e-16	Inflammatory skin disease;
BRCA	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg03060546	chr3:49711283	APEH	-0.58	-11.81	-0.42	3.12e-29	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg03929089	chr4:120376271	NA	0.73	14.63	0.5	5.09e-42	Coronary artery disease;
BRCA	trans	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg07211511	chr3:129823064	LOC729375	-0.62	-10.91	-0.4	1.56e-25	Blood pressure (smoking interaction);
BRCA	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg07169764	chr2:136633963	MCM6	1.08	23.95	0.69	5.98e-91	Corneal structure;
BRCA	cis	rs68170813	0.559	rs12537730	chr7:106844281	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.49	-0.32	1.44e-16	Coronary artery disease;
BRCA	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-11.12	-0.4	2.2e-26	Schizophrenia;
BRCA	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg08917208	chr2:24149416	ATAD2B	1.05	13.78	0.48	5.29e-38	Lymphocyte counts;
BRCA	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg02734326	chr4:10020555	SLC2A9	0.37	8.42	0.32	2.51e-16	Bone mineral density;
BRCA	cis	rs7715806	0.500	rs4704233	chr5:75000792	G/A	cg19683494	chr5:74908142	NA	0.5	8.06	0.3	3.69e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.08	-0.43	2.06e-30	Total cholesterol levels;
BRCA	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg07810366	chr2:100720526	AFF3	0.31	8.08	0.3	3.28e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg02551604	chr5:131831745	NA	-0.4	-14.95	-0.51	1.56e-43	Asthma (sex interaction);
BRCA	cis	rs6728642	1.000	rs113934577	chr2:97888047	G/A	cg26665480	chr2:98280029	ACTR1B	-0.65	-7.83	-0.3	2.06e-14	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg11941060	chr3:133502564	NA	-0.5	-11.81	-0.42	2.87e-29	Iron status biomarkers;
BRCA	cis	rs11608355	0.545	rs7139106	chr12:109908640	G/A	cg05360138	chr12:110035743	NA	0.71	13.05	0.46	1.11e-34	Neuroticism;
BRCA	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg24558204	chr6:135376177	HBS1L	0.6	16.25	0.54	5.98e-50	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs1405069	0.809	rs1063021	chr6:36932327	A/G	cg26433444	chr6:36932349	PI16	0.47	12.18	0.43	7.67e-31	Chemerin levels;
BRCA	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg14863265	chr7:2801509	GNA12	0.43	9.72	0.36	6.57e-21	Height;
BRCA	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05890377	chr2:74357713	NA	0.48	11.39	0.41	1.79e-27	Gestational age at birth (maternal effect);
BRCA	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg23625390	chr15:77176239	SCAPER	-0.54	-12.71	-0.45	3.63e-33	Blood metabolite levels;
BRCA	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg18154014	chr19:37997991	ZNF793	0.62	11.82	0.42	2.78e-29	Coronary artery calcification;
BRCA	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.13	-0.43	1.25e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg03213289	chr20:61660250	NA	0.62	15.94	0.53	1.99e-48	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10484885	0.775	rs72919985	chr6:90534641	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-9.87	-0.36	1.72e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.94	0.58	1.43e-58	Colorectal cancer;
BRCA	cis	rs495337	0.699	rs6020074	chr20:48448659	T/C	cg17835207	chr20:48524531	SPATA2	0.52	11.74	0.42	5.97e-29	Psoriasis;
BRCA	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg22705602	chr4:152727874	NA	-0.32	-8.07	-0.3	3.39e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.79	0.36	3.53e-21	Bipolar disorder;
BRCA	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg01529538	chr14:23388837	RBM23	-0.41	-11.3	-0.41	4.22e-27	Cognitive ability (multi-trait analysis);
BRCA	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg06627628	chr2:24431161	ITSN2	-0.64	-11.86	-0.42	1.91e-29	Asthma;
BRCA	trans	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg25214090	chr10:38739885	LOC399744	0.56	12.39	0.44	9.8e-32	Corneal astigmatism;
BRCA	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.81	0.55	8.35e-53	Axial length;
BRCA	cis	rs2425143	1.000	rs2378409	chr20:34392464	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.6	-0.32	6.23e-17	Blood protein levels;
BRCA	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-16.79	-0.55	1.06e-52	Colorectal cancer;
BRCA	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg13385794	chr1:248469461	NA	0.27	8.04	0.3	4.37e-15	Common traits (Other);
BRCA	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg03585969	chr10:35415529	CREM	0.56	11.6	0.42	2.21e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg14926445	chr8:58193284	C8orf71	-0.47	-8.92	-0.33	4.83e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	10.53	0.38	4.94e-24	Bipolar disorder;
BRCA	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg05347473	chr6:146136440	FBXO30	0.6	11.65	0.42	1.37e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg16339924	chr4:17578868	LAP3	0.62	15.37	0.52	1.29e-45	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg06671706	chr8:8559999	CLDN23	0.43	8.38	0.31	3.48e-16	Obesity-related traits;
BRCA	cis	rs13095912	0.785	rs6783023	chr3:185330189	A/G	cg11274856	chr3:185301563	NA	0.54	13.0	0.46	1.87e-34	Systolic blood pressure;
BRCA	cis	rs12541635	0.639	rs10955408	chr8:107020789	G/A	cg10147462	chr8:107024639	NA	0.38	10.53	0.38	5.01e-24	Age of smoking initiation;
BRCA	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg25554036	chr4:6271136	WFS1	0.43	10.24	0.38	6.65e-23	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	trans	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg26043149	chr18:55253948	FECH	-0.41	-8.96	-0.33	3.44e-18	Bone mineral density;
BRCA	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-13.05	-0.46	1.15e-34	Bipolar disorder;
BRCA	trans	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg26043149	chr18:55253948	FECH	-0.36	-8.07	-0.3	3.6e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.64	-0.39	1.88e-24	Tonsillectomy;
BRCA	cis	rs3772130	0.962	rs7629369	chr3:121566282	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.83	0.39	3.25e-25	Cognitive performance;
BRCA	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.34	0.59	1.17e-60	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs78487399	0.908	rs17031092	chr2:43809248	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-8.32	-0.31	5.29e-16	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg03354898	chr7:1950403	MAD1L1	-0.48	-9.73	-0.36	5.68e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	17.7	0.57	2.46e-57	Electrocardiographic conduction measures;
BRCA	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg20891283	chr12:69753455	YEATS4	0.56	11.03	0.4	5.19e-26	Response to diuretic therapy;
BRCA	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg14019146	chr3:50243930	SLC38A3	0.41	10.03	0.37	4.33e-22	Body mass index;
BRCA	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg00409905	chr10:38381863	ZNF37A	-0.5	-9.25	-0.34	3.21e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg06197492	chr11:2016605	H19	0.44	8.96	0.33	3.6e-18	DNA methylation (parent-of-origin);DNA methylation (variation);
BRCA	trans	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg26384229	chr12:38710491	ALG10B	0.39	9.05	0.34	1.69e-18	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg22535103	chr8:58192502	C8orf71	-0.52	-8.84	-0.33	9.3e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10267417	0.603	rs116877803	chr7:19925205	C/T	cg05791153	chr7:19748676	TWISTNB	0.42	7.86	0.3	1.66e-14	Night sleep phenotypes;
BRCA	trans	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg06521331	chr12:34319734	NA	-0.51	-9.75	-0.36	4.86e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17401966	0.540	rs4846221	chr1:10472026	C/A	cg03954927	chr1:10346856	KIF1B	0.35	10.44	0.38	1.18e-23	Hepatocellular carcinoma;
BRCA	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg08999081	chr20:33150536	PIGU	0.5	14.24	0.49	3.57e-40	Coronary artery disease;
BRCA	trans	rs28735056	0.587	rs8093548	chr18:77636451	G/A	cg05926928	chr17:57297772	GDPD1	-0.51	-10.44	-0.38	1.15e-23	Schizophrenia;
BRCA	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg12564285	chr5:131593104	PDLIM4	-0.41	-10.29	-0.38	4.27e-23	Acylcarnitine levels;
BRCA	trans	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.97	0.3	7.32e-15	Corneal astigmatism;
BRCA	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	19.08	0.6	1.51e-64	Tonsillectomy;
BRCA	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.87	-0.36	1.83e-21	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs225245	0.817	rs225273	chr17:33970935	A/T	cg19694781	chr19:47549865	TMEM160	-0.33	-8.2	-0.31	1.36e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg25019033	chr10:957182	NA	-0.41	-7.9	-0.3	1.23e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg21252483	chr19:49399788	TULP2	-0.52	-11.28	-0.41	4.76e-27	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg16576597	chr16:28551801	NUPR1	0.32	8.89	0.33	6.37e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.4	-8.09	-0.3	3.08e-15	Body mass index;
BRCA	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg00990874	chr7:1149470	C7orf50	-0.54	-9.76	-0.36	4.41e-21	Bronchopulmonary dysplasia;
BRCA	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg02376097	chr19:46275166	DMPK	0.41	9.24	0.34	3.47e-19	Coronary artery disease;
BRCA	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg08392591	chr16:89556376	ANKRD11	0.56	13.83	0.48	3.03e-38	Multiple myeloma (IgH translocation);
BRCA	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg22705602	chr4:152727874	NA	-0.32	-8.0	-0.3	6.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.74	16.08	0.54	4.26e-49	Cognitive ability;
BRCA	cis	rs1499972	0.941	rs1456182	chr3:117659680	C/T	cg07612923	chr3:117604196	NA	0.58	7.9	0.3	1.25e-14	Schizophrenia;
BRCA	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg09455208	chr3:40491958	NA	0.41	9.75	0.36	5.14e-21	Renal cell carcinoma;
BRCA	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25427524	chr10:38739819	LOC399744	0.7	17.16	0.56	1.48e-54	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg18404041	chr3:52824283	ITIH1	-0.33	-8.27	-0.31	7.52e-16	Schizophrenia;
BRCA	cis	rs796825	0.695	rs2673712	chr3:120015214	A/T	cg21790991	chr3:120137480	FSTL1	-0.32	-7.94	-0.3	9.32e-15	HIV-1 susceptibility;
BRCA	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg08975724	chr8:8085496	FLJ10661	0.47	8.81	0.33	1.16e-17	Red cell distribution width;
BRCA	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.96	-0.4	9.74e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	1.01e-40	Motion sickness;
BRCA	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.82	-14.65	-0.5	4.32e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9311474	0.596	rs524986	chr3:52228496	T/C	cg15698299	chr3:52233019	ALAS1	-0.36	-8.36	-0.31	3.8e-16	Electroencephalogram traits;
BRCA	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg17063962	chr7:91808500	NA	0.55	12.64	0.45	7.77e-33	Breast cancer;
BRCA	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg11632617	chr15:75315747	PPCDC	-0.38	-8.43	-0.32	2.22e-16	Blood trace element (Zn levels);
BRCA	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg21775007	chr8:11205619	TDH	-0.41	-8.56	-0.32	8.14e-17	Neuroticism;
BRCA	cis	rs6684514	0.961	rs10908503	chr1:156300683	C/T	cg16558208	chr1:156270281	VHLL	0.35	8.08	0.3	3.34e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg11586189	chr1:201857591	SHISA4	0.32	8.41	0.32	2.58e-16	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
BRCA	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-12.66	-0.45	6.18e-33	Platelet count;
BRCA	cis	rs151349	0.555	rs151343	chr20:57583298	C/G	cg23907860	chr20:57583709	CTSZ	0.61	15.07	0.51	3.89e-44	Platelet distribution width;
BRCA	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg05623727	chr3:50126028	RBM5	0.43	8.19	0.31	1.43e-15	Menarche (age at onset);
BRCA	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24531977	chr5:56204891	C5orf35	-0.81	-16.77	-0.55	1.38e-52	Initial pursuit acceleration;
BRCA	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg24060327	chr5:131705240	SLC22A5	-0.59	-11.42	-0.41	1.28e-27	Breast cancer;
BRCA	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.61	-0.42	1.99e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs7975161	0.638	rs7137288	chr12:104591886	C/A	cg25273343	chr12:104657179	TXNRD1	-0.38	-9.06	-0.34	1.63e-18	Toenail selenium levels;
BRCA	cis	rs9394841	0.692	rs9381097	chr6:41847800	A/G	cg08135965	chr6:41755394	TOMM6	-0.47	-7.88	-0.3	1.42e-14	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg22535103	chr8:58192502	C8orf71	-0.6	-13.08	-0.46	8.35e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs11920090	0.858	rs11929535	chr3:170710456	C/T	cg09710316	chr3:170744871	SLC2A2	0.5	8.0	0.3	5.93e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.1	-0.4	2.73e-26	Schizophrenia;
BRCA	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg08601574	chr20:25228251	PYGB	-0.39	-9.05	-0.34	1.77e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg17330251	chr7:94953956	PON1	-0.42	-8.58	-0.32	7.32e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.94	0.58	1.31e-58	Fuchs's corneal dystrophy;
BRCA	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg21775007	chr8:11205619	TDH	0.6	12.99	0.46	2.11e-34	Retinal vascular caliber;
BRCA	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15369054	chr17:80825471	TBCD	0.55	13.21	0.46	2.13e-35	Breast cancer;
BRCA	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11764359	chr7:65958608	NA	0.79	19.31	0.61	8.49e-66	Aortic root size;
BRCA	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg26384229	chr12:38710491	ALG10B	0.57	13.41	0.47	2.49e-36	Bladder cancer;
BRCA	cis	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg06521331	chr12:34319734	NA	0.53	10.31	0.38	3.68e-23	Morning vs. evening chronotype;
BRCA	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs7246657	0.653	rs10425441	chr19:37670648	T/C	cg18154014	chr19:37997991	ZNF793	0.56	9.36	0.35	1.38e-19	Coronary artery calcification;
BRCA	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.47	0.32	1.71e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9420	0.961	rs2847308	chr11:57498232	C/T	cg19752551	chr11:57585705	CTNND1	0.42	10.79	0.39	4.69e-25	Schizophrenia;
BRCA	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg07148914	chr20:33460835	GGT7	0.41	8.63	0.32	4.75e-17	Height;
BRCA	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg21573476	chr21:45109991	RRP1B	-0.43	-11.5	-0.41	5.94e-28	Mean corpuscular volume;
BRCA	cis	rs4363385	0.720	rs1338179	chr1:152981548	T/C	cg24667326	chr1:152973720	SPRR3	-0.35	-9.87	-0.36	1.81e-21	Inflammatory skin disease;
BRCA	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11764359	chr7:65958608	NA	-0.76	-16.7	-0.55	3.01e-52	Aortic root size;
BRCA	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg03711944	chr11:47377212	SPI1	-0.42	-11.54	-0.42	3.99e-28	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg27279351	chr12:120934652	DYNLL1	0.56	13.41	0.47	2.63e-36	High light scatter reticulocyte count;
BRCA	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11644478	chr21:40555479	PSMG1	0.8	17.53	0.57	1.72e-56	Cognitive function;
BRCA	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg19920283	chr7:105172520	RINT1	0.66	13.35	0.47	4.8e-36	Bipolar disorder (body mass index interaction);
BRCA	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.41	-0.32	2.64e-16	Height;
BRCA	trans	rs208520	0.754	rs851592	chr6:66875175	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-19.39	-0.61	3.14e-66	Exhaled nitric oxide output;
BRCA	cis	rs7945718	0.805	rs6486059	chr11:12824581	A/G	cg25843174	chr11:12811716	TEAD1	-0.22	-8.39	-0.32	3.05e-16	Educational attainment (years of education);
BRCA	cis	rs6942756	1.000	rs66864889	chr7:128952560	G/A	cg02491457	chr7:128862824	NA	-0.71	-13.98	-0.48	5.85e-39	White matter hyperintensity burden;
BRCA	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg21775007	chr8:11205619	TDH	-0.44	-9.32	-0.35	1.84e-19	Neuroticism;
BRCA	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg21138405	chr5:131827807	IRF1	0.4	12.97	0.46	2.65e-34	Asthma (sex interaction);
BRCA	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg13010199	chr12:38710504	ALG10B	0.57	12.61	0.45	1.06e-32	Heart rate;
BRCA	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg09035930	chr12:129282057	SLC15A4	-0.48	-12.71	-0.45	3.67e-33	Systemic lupus erythematosus;
BRCA	cis	rs12474201	0.925	rs1058157	chr2:46988275	G/A	cg06386533	chr2:46925753	SOCS5	0.87	18.87	0.6	1.84e-63	Height;
BRCA	cis	rs4664304	1.000	rs6735923	chr2:160769588	A/G	cg14819504	chr2:160761413	LY75	-0.4	-9.71	-0.36	7.01e-21	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.05	22.15	0.66	4.01e-81	Gut microbiome composition (summer);
BRCA	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg22713356	chr15:30763199	NA	-1.37	-28.0	-0.74	3.4e-113	Uric acid levels;
BRCA	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08219700	chr8:58056026	NA	0.44	7.92	0.3	1.08e-14	Developmental language disorder (linguistic errors);
BRCA	trans	rs11039798	0.841	rs10839174	chr11:48931185	G/A	cg15704280	chr7:45808275	SEPT13	0.6	8.93	0.33	4.6e-18	Axial length;
BRCA	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg21951975	chr1:209979733	IRF6	0.37	7.97	0.3	7.12e-15	Cleft lip with or without cleft palate;
BRCA	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.96	-0.3	7.72e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-16.76	-0.55	1.62e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg23950597	chr19:37808831	NA	0.7	12.54	0.44	2.07e-32	Coronary artery calcification;
BRCA	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.59	11.42	0.41	1.35e-27	Multiple sclerosis;
BRCA	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.8	-0.33	1.31e-17	Monocyte percentage of white cells;
BRCA	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg18479299	chr3:125709523	NA	-0.51	-8.28	-0.31	7.32e-16	Blood pressure (smoking interaction);
BRCA	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg08999081	chr20:33150536	PIGU	0.48	13.39	0.47	3.09e-36	Coronary artery disease;
BRCA	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.49e-52	Hypertriglyceridemia;
BRCA	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg00071950	chr4:10020882	SLC2A9	0.63	15.69	0.53	3.79e-47	Bone mineral density;
BRCA	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg08975724	chr8:8085496	FLJ10661	0.42	8.74	0.33	2.03e-17	Neuroticism;
BRCA	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.09e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-18.89	-0.6	1.45e-63	Parkinson's disease;
BRCA	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.43	-0.41	1.22e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg25036284	chr2:26402008	FAM59B	0.89	15.6	0.53	1.03e-46	Gut microbiome composition (summer);
BRCA	cis	rs2637266	0.935	rs1978927	chr10:78399786	A/T	cg18941641	chr10:78392320	NA	0.35	8.12	0.31	2.41e-15	Pulmonary function;
BRCA	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg11189052	chr15:85197271	WDR73	-0.34	-7.98	-0.3	6.63e-15	P wave terminal force;
BRCA	cis	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg06521331	chr12:34319734	NA	-0.56	-10.84	-0.39	2.95e-25	Morning vs. evening chronotype;
BRCA	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg04450456	chr4:17643702	FAM184B	0.38	11.2	0.41	9.94e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10465746	0.780	rs7529293	chr1:84331981	A/G	cg10977910	chr1:84465055	TTLL7	0.57	11.95	0.43	7.86e-30	Obesity-related traits;
BRCA	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-7.98	-0.3	6.69e-15	Blood pressure (smoking interaction);
BRCA	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.43	-0.38	1.21e-23	Psoriasis;
BRCA	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-7.89	-0.3	1.35e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Tonsillectomy;
BRCA	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg17330251	chr7:94953956	PON1	0.41	8.24	0.31	9.91e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs12541635	0.966	rs7812766	chr8:107057033	G/A	cg10147462	chr8:107024639	NA	0.37	9.78	0.36	3.84e-21	Age of smoking initiation;
BRCA	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.21	-0.37	8.71e-23	Psoriasis;
BRCA	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg23711669	chr6:146136114	FBXO30	0.62	14.47	0.5	2.94e-41	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs1941687	0.509	rs7230319	chr18:31321289	A/T	cg27147174	chr7:100797783	AP1S1	-0.45	-8.84	-0.33	8.89e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs4730250	0.595	rs7789500	chr7:106915723	A/C	cg02696742	chr7:106810147	HBP1	-0.47	-7.91	-0.3	1.1e-14	Osteoarthritis;
BRCA	cis	rs9300255	0.739	rs12824957	chr12:123750228	T/C	cg00376283	chr12:123451042	ABCB9	-0.56	-10.78	-0.39	5.39e-25	Neutrophil percentage of white cells;
BRCA	cis	rs6088813	0.767	rs4911179	chr20:33972899	A/C	cg14752227	chr20:34000481	UQCC	-0.41	-8.65	-0.32	4.1e-17	Height;
BRCA	trans	rs8073060	0.586	rs7221203	chr17:34015532	T/C	cg19694781	chr19:47549865	TMEM160	-1.04	-21.05	-0.64	4.18e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	trans	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg01065977	chr19:18549689	ISYNA1	0.28	8.26	0.31	8.45e-16	Breast cancer;
BRCA	cis	rs3760982	0.585	rs11673534	chr19:44298884	G/A	cg11993925	chr19:44307056	LYPD5	0.38	8.98	0.33	3e-18	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11764359	chr7:65958608	NA	0.8	19.49	0.61	9.4e-67	Aortic root size;
BRCA	trans	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	20.74	0.63	1.96e-73	Exhaled nitric oxide output;
BRCA	cis	rs6893300	0.776	rs55868831	chr5:179157296	T/C	cg14593053	chr5:179126677	CANX	-0.35	-7.9	-0.3	1.19e-14	Resting heart rate;
BRCA	cis	rs713587	0.520	rs512419	chr2:25310155	G/T	cg01884057	chr2:25150051	NA	-0.32	-8.39	-0.32	3.04e-16	Body mass index in non-asthmatics;
BRCA	trans	rs1459104	1.000	rs12577269	chr11:55062905	C/T	cg03929089	chr4:120376271	NA	0.64	7.84	0.3	1.95e-14	Body mass index;
BRCA	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.66	0.36	1.07e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11677370	0.561	rs11687254	chr2:3830906	C/T	cg17052675	chr2:3827356	NA	-0.59	-14.89	-0.51	2.84e-43	Type 2 diabetes;
BRCA	cis	rs1467026	0.691	rs9985266	chr3:12803162	C/T	cg24848339	chr3:12840334	CAND2	-0.36	-9.09	-0.34	1.19e-18	P wave duration;
BRCA	cis	rs1997103	1.000	rs6958022	chr7:55397389	G/A	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.72e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg23711669	chr6:146136114	FBXO30	0.73	17.3	0.56	2.77e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs113084984	0.816	rs4669749	chr2:11692664	A/C	cg07314298	chr2:11723111	GREB1	-0.39	-7.97	-0.3	7.08e-15	Breast cancer;
BRCA	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg18402987	chr7:1209562	NA	0.85	12.24	0.44	4.4e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs7980799	0.682	rs7303356	chr12:33633599	C/G	cg26384229	chr12:38710491	ALG10B	-0.4	-9.04	-0.34	1.88e-18	Heart rate;Heart rate variability traits (RMSSD);
BRCA	trans	rs9951602	0.512	rs9946115	chr18:76654531	A/C	cg02800362	chr5:177631904	HNRNPAB	0.78	18.3	0.59	1.73e-60	Obesity-related traits;
BRCA	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.79	0.5	8.81e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.42	11.28	0.41	4.93e-27	Response to antipsychotic treatment;
BRCA	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.29	0.31	6.93e-16	Aortic root size;
BRCA	cis	rs1011018	0.628	rs76486291	chr7:139473684	T/C	cg03224163	chr7:139420300	HIPK2	-0.59	-8.92	-0.33	5.04e-18	Systolic blood pressure;
BRCA	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg22852734	chr6:133119734	C6orf192	0.9	13.42	0.47	2.44e-36	Type 2 diabetes nephropathy;
BRCA	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.71	16.86	0.55	4.78e-53	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg05552183	chr6:42928497	GNMT	-0.7	-16.05	-0.54	6.07e-49	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg00484396	chr16:3507460	NAT15	0.47	10.24	0.38	6.96e-23	Tuberculosis;
BRCA	cis	rs7131987	0.650	rs6487808	chr12:29463359	C/T	cg09582351	chr12:29534625	ERGIC2	0.48	11.17	0.4	1.43e-26	QT interval;
BRCA	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg08601574	chr20:25228251	PYGB	-0.39	-9.05	-0.34	1.77e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg20891558	chr2:74357851	NA	0.56	12.65	0.45	6.99e-33	Gestational age at birth (maternal effect);
BRCA	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23978390	chr7:1156363	C7orf50	0.38	9.24	0.34	3.68e-19	Longevity;Endometriosis;
BRCA	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg07384165	chr1:10488281	NA	-0.41	-8.64	-0.32	4.63e-17	Prostate cancer;
BRCA	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02353165	chr6:42928485	GNMT	0.76	18.58	0.59	6.18e-62	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg17063962	chr7:91808500	NA	0.55	12.92	0.46	4.12e-34	Breast cancer;
BRCA	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg06092702	chr1:163392909	NA	-0.36	-9.54	-0.35	2.93e-20	Motion sickness;
BRCA	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg09877947	chr5:131593287	PDLIM4	0.42	10.8	0.39	4.52e-25	Breast cancer;
BRCA	cis	rs6820391	0.663	rs4864474	chr4:54450380	G/A	cg04173182	chr4:54446035	LNX1	0.48	10.82	0.39	3.52e-25	Cervical artery dissection;
BRCA	trans	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg26384229	chr12:38710491	ALG10B	0.51	11.2	0.41	1.05e-26	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.54	-0.32	9.88e-17	Total body bone mineral density;
BRCA	trans	rs3857536	0.813	rs7768944	chr6:66951088	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	2.02e-14	Blood trace element (Cu levels);
BRCA	cis	rs9487051	0.735	rs455839	chr6:109524221	G/A	cg01475377	chr6:109611718	NA	-0.44	-11.14	-0.4	1.86e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.65	0.32	4.14e-17	Motion sickness;
BRCA	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg07741184	chr6:167504864	NA	0.31	9.4	0.35	9.86e-20	Primary biliary cholangitis;
BRCA	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg24110177	chr3:50126178	RBM5	-0.52	-15.3	-0.52	2.97e-45	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg06064525	chr11:970664	AP2A2	-0.48	-16.03	-0.54	7.33e-49	Alzheimer's disease (late onset);
BRCA	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg24642439	chr20:33292090	TP53INP2	0.55	12.15	0.43	1.06e-30	Coronary artery disease;
BRCA	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg20908204	chr19:46285434	DMPK	-0.29	-8.56	-0.32	8.36e-17	Coronary artery disease;
BRCA	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-14.1	-0.49	1.63e-39	Monocyte count;
BRCA	cis	rs919433	0.679	rs6737060	chr2:198524885	G/C	cg00792783	chr2:198669748	PLCL1	0.39	9.03	0.34	2.08e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg08132940	chr7:1081526	C7orf50	-0.49	-7.87	-0.3	1.47e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg09537434	chr19:41945824	ATP5SL	-0.99	-22.6	-0.67	1.4e-83	Height;
BRCA	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21659725	chr3:3221576	CRBN	0.5	12.62	0.45	9.62e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg23992470	chr4:843637	GAK	0.5	8.04	0.3	4.48e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg23649088	chr2:200775458	C2orf69	0.72	15.81	0.53	9.7e-48	Osteoporosis;
BRCA	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg00409905	chr10:38381863	ZNF37A	0.49	10.49	0.38	7.43e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg08470875	chr2:26401718	FAM59B	0.77	11.99	0.43	4.89e-30	Gut microbiome composition (summer);
BRCA	cis	rs2882667	0.931	rs1433009	chr5:138333784	G/A	cg04439458	chr5:138467593	SIL1	-0.36	-10.09	-0.37	2.58e-22	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7809950	0.817	rs2237671	chr7:107131528	A/T	cg23024343	chr7:107201750	COG5	-0.5	-10.61	-0.39	2.38e-24	Coronary artery disease;
BRCA	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg11764359	chr7:65958608	NA	-0.67	-14.79	-0.51	8.34e-43	Aortic root size;
BRCA	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg17366294	chr4:99064904	C4orf37	0.45	10.77	0.39	5.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg07169764	chr2:136633963	MCM6	0.99	20.06	0.62	8.32e-70	Corneal structure;
BRCA	cis	rs7134594	0.677	rs9668180	chr12:109860597	T/G	cg01703884	chr12:109878174	MYO1H	-0.35	-7.87	-0.3	1.49e-14	HDL cholesterol;
BRCA	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg06108461	chr20:60628389	TAF4	-0.77	-16.73	-0.55	2.37e-52	Body mass index;
BRCA	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg05527609	chr1:210001259	C1orf107	0.7	15.04	0.51	5.66e-44	Orofacial clefts;
BRCA	cis	rs9612	1.000	rs347519	chr19:44273516	T/C	cg08581076	chr19:44259116	C19orf61	0.48	8.98	0.33	3.08e-18	Exhaled nitric oxide output;
BRCA	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.29	0.31	6.59e-16	Aortic root size;
BRCA	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg18252515	chr7:66147081	NA	-1.04	-15.49	-0.52	3.67e-46	Diabetic kidney disease;
BRCA	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg23173402	chr1:227635558	NA	0.53	9.6	0.36	1.78e-20	Major depressive disorder;
BRCA	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg15448220	chr1:150897856	SETDB1	0.37	8.35	0.31	4.25e-16	Melanoma;
BRCA	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg20503657	chr10:835505	NA	1.05	18.79	0.6	4.85e-63	Eosinophil percentage of granulocytes;
BRCA	trans	rs1973993	0.561	rs1475173	chr1:96993374	C/A	cg10631902	chr5:14652156	NA	-0.41	-10.05	-0.37	3.59e-22	Weight;
BRCA	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg00409905	chr10:38381863	ZNF37A	0.48	10.27	0.38	5.47e-23	Extrinsic epigenetic age acceleration;
BRCA	cis	rs13190036	1.000	rs13157667	chr5:176613877	C/T	cg06733329	chr5:176740039	MXD3	0.46	8.28	0.31	6.96e-16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg20503657	chr10:835505	NA	1.01	17.47	0.57	3.73e-56	Eosinophil percentage of granulocytes;
BRCA	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.89e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg20933634	chr6:27740509	NA	0.43	8.48	0.32	1.53e-16	Parkinson's disease;
BRCA	cis	rs701145	0.585	rs1727954	chr3:153871272	T/A	cg17054900	chr3:154042577	DHX36	0.55	9.29	0.35	2.32e-19	Coronary artery disease;
BRCA	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg22920501	chr2:26401640	FAM59B	-0.91	-16.26	-0.54	5.23e-50	Gut microbiome composition (summer);
BRCA	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.47	-10.29	-0.38	4.29e-23	Alzheimer's disease (late onset);
BRCA	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg08000102	chr2:233561755	GIGYF2	-0.62	-13.97	-0.48	6.75e-39	Coronary artery disease;
BRCA	cis	rs7512552	0.839	rs698919	chr1:150387000	A/G	cg15654264	chr1:150340011	RPRD2	0.37	8.17	0.31	1.62e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg08917208	chr2:24149416	ATAD2B	1.09	15.57	0.52	1.48e-46	Lymphocyte counts;
BRCA	cis	rs3820928	1.000	rs10167422	chr2:227777554	G/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.49	-0.32	1.47e-16	Pulmonary function;
BRCA	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg08470875	chr2:26401718	FAM59B	-0.52	-8.34	-0.31	4.48e-16	Gut microbiome composition (summer);
BRCA	cis	rs4074536	0.574	rs10754349	chr1:116291876	C/T	cg21648376	chr1:116311395	CASQ2	-0.5	-8.72	-0.33	2.4e-17	QRS duration;
BRCA	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.22	-0.31	1.13e-15	Depression;
BRCA	cis	rs1003719	0.788	rs4817845	chr21:38447132	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.25	0.49	3.17e-40	Eye color traits;
BRCA	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg24747557	chr10:131355152	MGMT	-0.36	-8.86	-0.33	7.82e-18	Response to temozolomide;
BRCA	cis	rs3857536	0.740	rs4710574	chr6:66890631	T/G	cg07460842	chr6:66804631	NA	-0.46	-8.86	-0.33	8.14e-18	Blood trace element (Cu levels);
BRCA	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.62	-0.42	1.85e-28	Response to antipsychotic treatment;
BRCA	cis	rs62158211	0.691	rs1964463	chr2:114069021	C/T	cg17784749	chr2:114082611	LOC440839	-0.52	-9.36	-0.35	1.36e-19	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
BRCA	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg10932868	chr11:921992	NA	0.49	12.59	0.45	1.21e-32	Alzheimer's disease (late onset);
BRCA	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	13.81	0.48	3.8e-38	Hip circumference adjusted for BMI;
BRCA	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg26384229	chr12:38710491	ALG10B	0.41	9.1	0.34	1.18e-18	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08219700	chr8:58056026	NA	0.44	8.0	0.3	5.75e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs11809207	0.501	rs3762460	chr1:26495550	A/G	cg00147160	chr1:26503991	CNKSR1	0.24	7.88	0.3	1.46e-14	Height;
BRCA	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg23708337	chr7:1209742	NA	0.68	10.7	0.39	1.13e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg13628971	chr7:2884303	GNA12	0.49	9.93	0.37	1.08e-21	Height;
BRCA	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg05147244	chr20:61493195	TCFL5	-0.82	-11.23	-0.41	7.52e-27	Obesity-related traits;
BRCA	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg19077165	chr18:44547161	KATNAL2	-0.39	-8.25	-0.31	9.35e-16	Educational attainment;
BRCA	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg05340658	chr4:99064831	C4orf37	0.68	16.98	0.56	1.21e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6867032	0.527	rs4975790	chr5:2010376	C/T	cg26168224	chr5:2018326	NA	0.44	11.66	0.42	1.33e-28	Gut microbiome composition (winter);
BRCA	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg23018236	chr17:30244563	NA	-0.45	-8.23	-0.31	1.07e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	8.91	0.33	5.35e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs3771570	0.901	rs62190413	chr2:242417950	G/A	cg21155796	chr2:242212141	HDLBP	0.62	9.56	0.35	2.44e-20	Prostate cancer;
BRCA	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg13319975	chr6:146136371	FBXO30	0.42	9.76	0.36	4.71e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg26384229	chr12:38710491	ALG10B	0.4	8.6	0.32	6.3e-17	Resting heart rate;
BRCA	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg18446336	chr7:2847575	GNA12	-0.35	-8.09	-0.3	3.03e-15	Height;
BRCA	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00908189	chr16:619842	PIGQ	0.69	17.41	0.57	7.16e-56	Height;
BRCA	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11890956	chr21:40555474	PSMG1	-0.61	-13.14	-0.46	4.2e-35	Menarche (age at onset);
BRCA	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg13010199	chr12:38710504	ALG10B	0.51	9.89	0.36	1.45e-21	Morning vs. evening chronotype;
BRCA	cis	rs34779708	0.931	rs3740083	chr10:35320383	C/T	cg03585969	chr10:35415529	CREM	0.49	10.29	0.38	4.39e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg24812749	chr6:127587940	RNF146	0.88	20.56	0.63	1.81e-72	Breast cancer;
BRCA	cis	rs6761276	0.866	rs12469822	chr2:113830563	C/T	cg02302587	chr2:113829866	IL1F10	0.38	8.13	0.31	2.25e-15	Protein quantitative trait loci;
BRCA	trans	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg06521331	chr12:34319734	NA	-0.46	-8.52	-0.32	1.16e-16	Bladder cancer;
BRCA	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg16109817	chr1:16162209	FLJ37453	-0.29	-8.11	-0.31	2.6e-15	Systolic blood pressure;
BRCA	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg04455712	chr21:45112962	RRP1B	0.42	10.91	0.4	1.52e-25	Mean corpuscular volume;
BRCA	cis	rs3820928	0.874	rs1114562	chr2:227788592	T/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.62	-0.32	5.09e-17	Pulmonary function;
BRCA	trans	rs1422110	0.543	rs768240	chr5:85420954	C/T	cg01787110	chr1:109008453	NBPF6	-0.45	-9.99	-0.37	6.43e-22	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs2742234	1.000	rs1864399	chr10:43610455	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.43	-8.94	-0.33	4.08e-18	Hirschsprung disease;
BRCA	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg24642844	chr7:1081250	C7orf50	-0.89	-16.33	-0.54	2.28e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg15704280	chr7:45808275	SEPT13	0.6	8.92	0.33	5.03e-18	Axial length;
BRCA	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.67	13.86	0.48	2.19e-38	Lymphocyte counts;
BRCA	cis	rs68170813	0.559	rs114221457	chr7:107019913	C/G	cg02696742	chr7:106810147	HBP1	-0.5	-7.91	-0.3	1.17e-14	Coronary artery disease;
BRCA	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg13010199	chr12:38710504	ALG10B	0.43	9.12	0.34	9.85e-19	Morning vs. evening chronotype;
BRCA	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.22	-0.34	4.3e-19	Menopause (age at onset);
BRCA	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08704250	chr15:31115839	NA	0.36	8.98	0.33	2.93e-18	Huntington's disease progression;
BRCA	cis	rs12347191	0.500	rs907579	chr9:100622723	G/T	cg13688889	chr9:100608707	NA	-0.48	-9.76	-0.36	4.62e-21	Orofacial clefts;
BRCA	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg18512352	chr11:47633146	NA	-0.33	-7.98	-0.3	6.68e-15	Subjective well-being;
BRCA	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-11.89	-0.43	1.38e-29	Gut microbiome composition (summer);
BRCA	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg19729930	chr2:74357872	NA	-0.54	-12.17	-0.43	8.23e-31	Gestational age at birth (maternal effect);
BRCA	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02187348	chr16:89574699	SPG7	0.49	11.81	0.42	3.01e-29	Multiple myeloma (IgH translocation);
BRCA	trans	rs2262909	0.962	rs408687	chr19:22231123	T/C	cg17074339	chr11:11642133	GALNTL4	-0.41	-7.98	-0.3	6.96e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13046373	0.535	rs2226377	chr21:32031915	T/C	cg16431978	chr21:31797932	KRTAP13-3	0.36	8.81	0.33	1.2e-17	HDL cholesterol;
BRCA	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg23711669	chr6:146136114	FBXO30	-0.81	-19.47	-0.61	1.23e-66	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs629535	0.547	rs72654095	chr8:70120770	A/G	cg21567404	chr3:27674614	NA	-0.93	-17.83	-0.58	5.03e-58	Dupuytren's disease;
BRCA	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg14926445	chr8:58193284	C8orf71	-0.44	-8.07	-0.3	3.57e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg16576597	chr16:28551801	NUPR1	0.35	9.67	0.36	9.93e-21	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg21775007	chr8:11205619	TDH	-0.5	-10.14	-0.37	1.69e-22	Triglycerides;
BRCA	trans	rs629535	0.773	rs686683	chr8:70070364	G/A	cg21567404	chr3:27674614	NA	1.01	20.96	0.64	1.2e-74	Dupuytren's disease;
BRCA	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg26149184	chr10:133730230	NA	0.41	8.3	0.31	5.97e-16	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg11663144	chr21:46675770	NA	-0.64	-15.28	-0.52	3.69e-45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.02	-0.34	2.13e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg19000871	chr14:103996768	TRMT61A	-0.35	-8.04	-0.3	4.21e-15	Coronary artery disease;
BRCA	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg13010199	chr12:38710504	ALG10B	-0.42	-9.82	-0.36	2.7e-21	Heart rate;
BRCA	cis	rs600231	0.508	rs11227201	chr11:65242548	G/A	cg01292856	chr11:65242576	NA	0.66	14.84	0.51	5.26e-43	Bone mineral density;
BRCA	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.4	0.57	8.98e-56	Bladder cancer;
BRCA	trans	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg25517755	chr10:38738941	LOC399744	-0.38	-7.91	-0.3	1.11e-14	Corneal astigmatism;
BRCA	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.35	-0.38	2.53e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.39	0.32	3.04e-16	Corneal astigmatism;
BRCA	cis	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg23950597	chr19:37808831	NA	-0.62	-11.29	-0.41	4.33e-27	Coronary artery calcification;
BRCA	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg00254258	chr1:3105189	PRDM16	0.45	10.64	0.39	1.83e-24	Migraine;
BRCA	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg19508488	chr2:152266495	RIF1	0.45	9.32	0.35	1.94e-19	Squamous cell lung carcinoma;
BRCA	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg00750074	chr16:89608354	SPG7	-0.4	-10.88	-0.4	1.99e-25	Multiple myeloma (IgH translocation);
BRCA	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg17724175	chr1:150552817	MCL1	0.27	8.84	0.33	9.01e-18	Tonsillectomy;
BRCA	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24308560	chr3:49941425	MST1R	-0.4	-8.54	-0.32	9.6e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg00530320	chr1:46809349	NSUN4	0.45	8.99	0.34	2.76e-18	Menopause (age at onset);
BRCA	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.45	10.04	0.37	4.15e-22	Alzheimer's disease (late onset);
BRCA	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg10876282	chr6:28092338	ZSCAN16	0.41	8.13	0.31	2.17e-15	Parkinson's disease;
BRCA	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg00677455	chr12:58241039	CTDSP2	0.69	16.63	0.55	7.19e-52	Intelligence (multi-trait analysis);
BRCA	cis	rs9902453	0.933	rs7224199	chr17:28523726	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.46	11.5	0.41	6.22e-28	Coffee consumption (cups per day);
BRCA	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg04719120	chr6:96025338	MANEA	0.52	7.85	0.3	1.74e-14	Behavioural disinhibition (generation interaction);
BRCA	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs4409675	0.576	rs6691656	chr1:28221130	C/G	cg23691781	chr1:28212827	C1orf38	0.32	11.0	0.4	6.87e-26	Corneal astigmatism;
BRCA	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg16006841	chr5:176797999	RGS14	-0.69	-10.95	-0.4	1.08e-25	Urate levels in lean individuals;
BRCA	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10802521	chr3:52805072	NEK4	-0.33	-8.48	-0.32	1.61e-16	Bipolar disorder;
BRCA	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg04362960	chr10:104952993	NT5C2	0.44	10.06	0.37	3.34e-22	Arsenic metabolism;
BRCA	cis	rs3125734	0.719	rs1835861	chr10:64056141	T/A	cg19640130	chr10:64028056	RTKN2	-0.29	-7.98	-0.3	6.94e-15	Rheumatoid arthritis;
BRCA	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18404041	chr3:52824283	ITIH1	-0.37	-11.3	-0.41	4.19e-27	Bipolar disorder;
BRCA	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg27661571	chr11:113659931	NA	-0.8	-12.01	-0.43	4.07e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs1975991	0.765	rs6444271	chr3:187955738	G/A	cg15417654	chr3:187959138	LPP	0.36	9.37	0.35	1.25e-19	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs877282	1.000	rs11253362	chr10:770979	G/T	cg17470449	chr10:769945	NA	0.52	9.01	0.34	2.43e-18	Uric acid levels;
BRCA	cis	rs6570726	0.516	rs9376932	chr6:145729490	T/C	cg23711669	chr6:146136114	FBXO30	0.45	9.46	0.35	5.94e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs654950	0.776	rs2759254	chr1:42035683	G/C	cg06885757	chr1:42089581	HIVEP3	-0.33	-10.94	-0.4	1.21e-25	Airway imaging phenotypes;
BRCA	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.84	-0.3	1.9e-14	Aortic root size;
BRCA	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	19.57	0.61	3.62e-67	Platelet count;
BRCA	cis	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg24692254	chr21:30365293	RNF160	-0.48	-8.31	-0.31	5.95e-16	Cognitive test performance;
BRCA	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg14993813	chr1:46806288	NSUN4	-0.5	-9.69	-0.36	8.4e-21	Menopause (age at onset);
BRCA	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg09184832	chr6:79620586	NA	-0.52	-11.41	-0.41	1.44e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.47	-8.86	-0.33	7.76e-18	Blood trace element (Cu levels);
BRCA	cis	rs10189230	0.967	rs13026380	chr2:222352715	G/A	cg14652038	chr2:222343519	EPHA4	0.46	12.75	0.45	2.57e-33	Urate levels in lean individuals;
BRCA	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg20701182	chr2:24300061	SF3B14	0.67	9.86	0.36	1.91e-21	Lymphocyte counts;
BRCA	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg20362242	chr5:692897	TPPP	0.52	8.45	0.32	1.92e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs701145	0.586	rs181443	chr3:153959028	G/T	cg16511985	chr3:153974050	SGEF	0.45	10.33	0.38	3.18e-23	Coronary artery disease;
BRCA	cis	rs7523050	0.643	rs35520362	chr1:109419841	C/T	cg08274380	chr1:109419600	GPSM2	1.17	16.64	0.55	6.3e-52	Fat distribution (HIV);
BRCA	cis	rs13136331	0.641	rs2627682	chr4:88662490	A/G	cg22416721	chr4:88570574	DMP1	-0.56	-13.31	-0.47	7.43e-36	Sitting height ratio;
BRCA	cis	rs10193935	0.792	rs7559001	chr2:42474301	C/T	cg27598129	chr2:42591480	NA	-0.62	-10.5	-0.38	6.86e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg16586182	chr3:47516702	SCAP	0.52	11.54	0.42	3.92e-28	Colorectal cancer;
BRCA	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06028605	chr16:24865363	SLC5A11	-0.46	-10.07	-0.37	3.22e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.74	-16.26	-0.54	5.33e-50	Lymphocyte counts;
BRCA	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg00071950	chr4:10020882	SLC2A9	-0.4	-8.57	-0.32	7.52e-17	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg00981070	chr1:2046702	PRKCZ	0.31	8.22	0.31	1.09e-15	Height;
BRCA	cis	rs4742903	0.527	rs2122576	chr9:106870187	G/T	cg14250997	chr9:106856677	SMC2	-0.28	-8.35	-0.31	4.26e-16	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs2108225	0.934	rs4730269	chr7:107455719	T/G	cg18560240	chr7:107437656	SLC26A3	-0.49	-9.85	-0.36	2.04e-21	Ulcerative colitis;
BRCA	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg00777063	chr17:45855553	NA	0.29	7.96	0.3	7.9e-15	IgG glycosylation;
BRCA	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.1	0.31	2.86e-15	Tonsillectomy;
BRCA	cis	rs870825	0.860	rs2696044	chr4:185595988	C/G	cg04058563	chr4:185651563	MLF1IP	0.66	11.61	0.42	2.07e-28	Blood protein levels;
BRCA	cis	rs7684253	0.565	rs12641030	chr4:57803505	A/G	cg11939399	chr4:57773300	REST	0.29	7.94	0.3	8.96e-15	Migraine;
BRCA	cis	rs400736	0.637	rs2300428	chr1:7996894	A/G	cg25007680	chr1:8021821	PARK7	-0.44	-10.82	-0.39	3.51e-25	Response to antidepressants and depression;
BRCA	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.4	-8.2	-0.31	1.3e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.55	-0.32	9.08e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs926392	0.896	rs742276	chr20:37679849	C/T	cg16355469	chr20:37678765	NA	0.32	8.1	0.31	2.77e-15	Dialysis-related mortality;
BRCA	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.67	10.44	0.38	1.13e-23	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.81	0.39	3.9e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg20607287	chr7:12443886	VWDE	-0.49	-8.56	-0.32	8.27e-17	Coronary artery disease;
BRCA	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	19.19	0.6	3.67e-65	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg10523679	chr1:76189770	ACADM	0.76	15.91	0.53	2.83e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg05347473	chr6:146136440	FBXO30	0.44	8.7	0.33	2.8e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg13114125	chr14:105738426	BRF1	-0.57	-11.81	-0.42	3.01e-29	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg16230307	chr14:35515116	FAM177A1	0.73	15.12	0.51	2.22e-44	Psoriasis;
BRCA	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg04166393	chr7:2884313	GNA12	0.63	13.77	0.48	5.94e-38	Height;
BRCA	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24110177	chr3:50126178	RBM5	-0.53	-15.92	-0.53	2.64e-48	Body mass index;
BRCA	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg09184832	chr6:79620586	NA	-0.53	-11.69	-0.42	9.66e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs2249625	0.874	rs1852704	chr6:72880088	C/T	cg18830697	chr6:72922368	RIMS1	-0.37	-7.99	-0.3	6.29e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg11584989	chr19:19387371	SF4	0.64	13.49	0.47	1.14e-36	Bipolar disorder;
BRCA	cis	rs698833	0.562	rs10182045	chr2:44704236	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	8.89	0.33	6.36e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg14863265	chr7:2801509	GNA12	-0.42	-9.72	-0.36	6.44e-21	Height;
BRCA	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.64	0.32	4.45e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg23096020	chr7:158799433	NA	-0.36	-8.56	-0.32	8.35e-17	Facial morphology (factor 20);
BRCA	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.05e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7555523	1.000	rs7555523	chr1:165718979	C/A	cg24409356	chr1:165738333	TMCO1	0.5	8.33	0.31	4.9e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg12444411	chr7:2802554	GNA12	-0.38	-9.4	-0.35	9.34e-20	Height;
BRCA	trans	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg25482853	chr8:67687455	SGK3	0.78	13.07	0.46	8.85e-35	Obesity-related traits;
BRCA	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.65	-10.77	-0.39	5.68e-25	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	19.2	0.6	3.47e-65	Electrocardiographic conduction measures;
BRCA	trans	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg26384229	chr12:38710491	ALG10B	-0.39	-8.56	-0.32	8.51e-17	Resting heart rate;
BRCA	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg24069376	chr3:38537580	EXOG	-0.42	-12.04	-0.43	3.26e-30	Electrocardiographic conduction measures;
BRCA	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg09904177	chr6:26538194	HMGN4	0.47	14.7	0.5	2.27e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs13046373	0.535	rs13051135	chr21:32005278	G/A	cg14062083	chr21:31802829	KRTAP13-4	0.34	9.37	0.35	1.28e-19	HDL cholesterol;
BRCA	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg26384229	chr12:38710491	ALG10B	0.69	16.15	0.54	1.9e-49	Bladder cancer;
BRCA	cis	rs7945718	0.839	rs11022511	chr11:12834638	A/T	cg25843174	chr11:12811716	TEAD1	0.23	8.62	0.32	5.11e-17	Educational attainment (years of education);
BRCA	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21659725	chr3:3221576	CRBN	-0.71	-21.8	-0.65	3.28e-79	Intelligence (multi-trait analysis);
BRCA	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg24879335	chr3:133465180	TF	0.32	10.83	0.39	3.36e-25	Iron status biomarkers (transferrin levels);
BRCA	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg23711669	chr6:146136114	FBXO30	-0.78	-18.2	-0.58	6.16e-60	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg15145296	chr3:125709740	NA	-0.53	-8.83	-0.33	1.04e-17	Blood pressure (smoking interaction);
BRCA	cis	rs7264396	0.563	rs6058322	chr20:34367277	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.67	11.56	0.42	3.46e-28	Total cholesterol levels;
BRCA	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-9.38	-0.35	1.11e-19	Mean corpuscular volume;
BRCA	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg08601574	chr20:25228251	PYGB	0.36	8.37	0.31	3.65e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6545883	1.000	rs6742276	chr2:61768745	G/A	cg15711740	chr2:61764176	XPO1	-0.55	-14.11	-0.49	1.49e-39	Tuberculosis;
BRCA	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg04362960	chr10:104952993	NT5C2	-0.47	-11.2	-0.4	1.07e-26	Arsenic metabolism;
BRCA	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg24562669	chr7:97807699	LMTK2	0.62	18.68	0.59	1.8e-62	Breast cancer;
BRCA	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg07520158	chr7:32535189	LSM5;AVL9	0.49	10.92	0.4	1.39e-25	Cognitive ability;
BRCA	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg27478167	chr7:817139	HEATR2	-0.55	-11.11	-0.4	2.39e-26	Cerebrospinal P-tau181p levels;
BRCA	trans	rs12517041	1.000	rs71611219	chr5:23280981	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.85	-0.3	1.72e-14	Calcium levels;
BRCA	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg25206134	chr2:45395956	NA	0.55	9.06	0.34	1.56e-18	Bipolar disorder;
BRCA	trans	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg25214090	chr10:38739885	LOC399744	0.51	10.48	0.38	7.8e-24	Corneal astigmatism;
BRCA	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg08885076	chr2:99613938	TSGA10	0.42	9.8	0.36	3.11e-21	Chronic sinus infection;
BRCA	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg11845111	chr2:191398756	TMEM194B	-0.81	-15.47	-0.52	4.54e-46	Diastolic blood pressure;
BRCA	trans	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg04565464	chr8:145669602	NFKBIL2	0.38	9.35	0.35	1.42e-19	Schizophrenia;
BRCA	cis	rs77633900	0.614	rs280028	chr15:77031466	A/G	cg21673338	chr15:77095150	SCAPER	-0.53	-9.72	-0.36	6.2e-21	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg08997352	chr12:9597637	DDX12	-0.54	-10.21	-0.37	8.78e-23	Breast size;
BRCA	trans	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.43	0.38	1.27e-23	Mean corpuscular volume;
BRCA	cis	rs4953076	0.573	rs920519	chr2:44452344	T/C	cg04920474	chr2:44395004	PPM1B	0.51	10.6	0.39	2.83e-24	Height;
BRCA	cis	rs13064411	0.542	rs4396864	chr3:113212562	C/T	cg18753928	chr3:113234510	CCDC52	-0.46	-9.87	-0.36	1.81e-21	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.84	0.39	3.02e-25	Bipolar disorder;
BRCA	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg01448562	chr3:133502909	NA	-0.37	-8.54	-0.32	9.9e-17	Iron status biomarkers;
BRCA	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg16586182	chr3:47516702	SCAP	-0.56	-12.49	-0.44	3.39e-32	Colorectal cancer;
BRCA	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg24558204	chr6:135376177	HBS1L	0.59	15.6	0.53	1.04e-46	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg23978390	chr7:1156363	C7orf50	0.44	10.15	0.37	1.53e-22	Longevity;Endometriosis;
BRCA	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg05347473	chr6:146136440	FBXO30	-0.42	-8.37	-0.31	3.58e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg00677455	chr12:58241039	CTDSP2	-0.4	-9.39	-0.35	1.06e-19	Multiple sclerosis;
BRCA	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-11.57	-0.42	3.12e-28	Gut microbiome composition (summer);
BRCA	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg22903471	chr2:27725779	GCKR	0.35	8.72	0.33	2.46e-17	Total body bone mineral density;
BRCA	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg02176678	chr2:219576539	TTLL4	0.39	10.47	0.38	8.53e-24	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg26031613	chr14:104095156	KLC1	-0.42	-8.45	-0.32	1.94e-16	Schizophrenia;
BRCA	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg03342759	chr3:160939853	NMD3	-0.81	-19.11	-0.6	1.04e-64	Parkinson's disease;
BRCA	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.66	-13.23	-0.46	1.8e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg21659725	chr3:3221576	CRBN	-0.47	-8.44	-0.32	2.17e-16	Menarche (age at onset);
BRCA	cis	rs72772090	0.539	rs116360011	chr5:96117797	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.12	-0.43	1.37e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-14.27	-0.49	2.7e-40	Platelet count;
BRCA	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.77	16.24	0.54	6.44e-50	Smoking behavior;
BRCA	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07308232	chr7:1071921	C7orf50	-0.51	-10.65	-0.39	1.72e-24	Longevity;Endometriosis;
BRCA	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.08	-0.4	3.36e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18876405	chr7:65276391	NA	0.55	12.96	0.46	2.73e-34	Aortic root size;
BRCA	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg00071950	chr4:10020882	SLC2A9	-0.41	-9.74	-0.36	5.42e-21	Bone mineral density;
BRCA	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.63	-0.32	4.78e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6842047	1.000	rs4862668	chr4:187136443	A/T	cg23442198	chr4:187126114	CYP4V2	0.65	8.93	0.33	4.4e-18	Blood protein levels;
BRCA	cis	rs12118280	0.581	rs545593	chr1:108720242	G/A	cg11967332	chr1:108735228	SLC25A24	-0.54	-10.18	-0.37	1.2e-22	Myeloid white cell count;
BRCA	cis	rs1468333	0.964	rs2967785	chr5:137543713	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.44	9.23	0.34	4.04e-19	Resting heart rate;
BRCA	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-9.73	-0.36	5.71e-21	IgG glycosylation;
BRCA	cis	rs7131987	0.650	rs3782509	chr12:29453778	G/A	cg09582351	chr12:29534625	ERGIC2	-0.46	-10.78	-0.39	5.18e-25	QT interval;
BRCA	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	8.65e-21	Menopause (age at onset);
BRCA	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-11.19	-0.4	1.19e-26	Gut microbiome composition (summer);
BRCA	cis	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.4	8.97	0.33	3.13e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg22903471	chr2:27725779	GCKR	-0.39	-9.33	-0.35	1.71e-19	Total body bone mineral density;
BRCA	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	8.1	0.3	2.89e-15	Diabetic retinopathy;
BRCA	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg18811423	chr2:55921094	PNPT1	0.71	22.68	0.67	5.59e-84	Metabolic syndrome;
BRCA	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg20607287	chr7:12443886	VWDE	-0.54	-8.16	-0.31	1.83e-15	Coronary artery disease;
BRCA	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.68	0.39	1.28e-24	Tonsillectomy;
BRCA	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg13175981	chr1:150552382	MCL1	0.42	9.34	0.35	1.54e-19	Tonsillectomy;
BRCA	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.06	-0.49	2.48e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs1595825	0.891	rs6733834	chr2:198518709	C/G	cg19156104	chr2:198669113	PLCL1	0.42	7.99	0.3	6.48e-15	Ulcerative colitis;
BRCA	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg25358565	chr5:93447407	FAM172A	-1.23	-18.94	-0.6	7.57e-64	Diabetic retinopathy;
BRCA	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg11657440	chr19:46296263	DMWD	-0.57	-13.56	-0.47	5.49e-37	Coronary artery disease;
BRCA	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.36	-8.47	-0.32	1.67e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg24110177	chr3:50126178	RBM5	0.37	10.05	0.37	3.74e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg11764359	chr7:65958608	NA	-0.64	-11.45	-0.41	9.95e-28	Aortic root size;
BRCA	cis	rs10056811	0.538	rs56174528	chr5:74400516	G/C	cg19683494	chr5:74908142	NA	0.56	8.48	0.32	1.53e-16	Coronary artery disease;
BRCA	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg21132104	chr15:45694354	SPATA5L1	0.61	11.88	0.43	1.44e-29	Homoarginine levels;
BRCA	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg26597838	chr10:835615	NA	0.92	14.37	0.49	8.81e-41	Eosinophil percentage of granulocytes;
BRCA	cis	rs939658	0.805	rs35462901	chr15:79442201	C/T	cg17916960	chr15:79447300	NA	-0.43	-10.98	-0.4	8.11e-26	Refractive error;
BRCA	cis	rs11887277	0.513	rs13016313	chr2:27045207	C/A	cg12368169	chr2:27073192	DPYSL5	-0.28	-8.07	-0.3	3.5e-15	Obesity-related traits;
BRCA	cis	rs6060717	0.536	rs11697851	chr20:34524494	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.03	-0.3	4.56e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg20503657	chr10:835505	NA	1.01	17.75	0.57	1.28e-57	Eosinophil percentage of granulocytes;
BRCA	cis	rs9942416	0.660	rs34905687	chr5:74997736	A/G	cg19683494	chr5:74908142	NA	0.49	9.11	0.34	1.09e-18	Age-related disease endophenotypes;
BRCA	cis	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg07460842	chr6:66804631	NA	0.98	19.59	0.61	2.75e-67	Exhaled nitric oxide output;
BRCA	cis	rs919433	0.653	rs700651	chr2:198631714	G/A	cg00792783	chr2:198669748	PLCL1	0.46	9.95	0.37	9.06e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg10876282	chr6:28092338	ZSCAN16	0.42	8.07	0.3	3.54e-15	Parkinson's disease;
BRCA	cis	rs16866061	0.517	rs7580488	chr2:225473263	C/T	cg12698349	chr2:225449008	CUL3	0.45	11.11	0.4	2.39e-26	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg18225595	chr11:63971243	STIP1	0.49	8.57	0.32	7.88e-17	Mean platelet volume;
BRCA	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16405210	chr4:1374714	KIAA1530	-0.53	-12.51	-0.44	2.91e-32	Longevity;
BRCA	trans	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg07817883	chr1:32538562	TMEM39B	0.47	7.91	0.3	1.12e-14	Monocyte percentage of white cells;
BRCA	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg10729496	chr3:10149963	C3orf24	0.42	8.09	0.3	2.94e-15	Alzheimer's disease;
BRCA	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg08992911	chr2:238395768	MLPH	0.64	10.76	0.39	6.08e-25	Prostate cancer;
BRCA	cis	rs735860	0.718	rs209488	chr6:53177540	A/T	cg10236188	chr6:53219634	NA	0.38	7.98	0.3	6.78e-15	Glaucoma;
BRCA	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg12011299	chr4:100065546	ADH4	0.48	10.81	0.39	4.06e-25	Alcohol dependence;
BRCA	trans	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg25042112	chr7:64838748	ZNF92	0.46	8.51	0.32	1.27e-16	Pain;
BRCA	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.31	0.49	1.68e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg12444411	chr7:2802554	GNA12	-0.35	-8.61	-0.32	5.85e-17	Height;
BRCA	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.8	12.09	0.43	1.91e-30	Platelet count;
BRCA	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg20701182	chr2:24300061	SF3B14	0.57	8.95	0.33	3.98e-18	Lymphocyte counts;
BRCA	cis	rs1832871	0.672	rs7750011	chr6:158746802	A/C	cg07165851	chr6:158734300	TULP4	0.63	12.61	0.45	9.79e-33	Height;
BRCA	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg06360820	chr2:242988706	NA	-0.86	-14.99	-0.51	9.3e-44	Obesity-related traits;
BRCA	cis	rs9560113	1.000	rs4773384	chr13:112177987	A/G	cg10483660	chr13:112241077	NA	0.32	7.86	0.3	1.65e-14	Menarche (age at onset);
BRCA	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg18850127	chr7:39170497	POU6F2	0.54	11.95	0.43	7.84e-30	IgG glycosylation;
BRCA	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg23533926	chr12:111358616	MYL2	-0.44	-9.19	-0.34	5.5e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg01304814	chr3:48885189	PRKAR2A	0.58	7.99	0.3	6.11e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.83e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.69	12.75	0.45	2.36e-33	Chronic sinus infection;
BRCA	cis	rs870825	0.616	rs28524599	chr4:185647414	A/G	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg23933602	chr10:16859644	RSU1	0.52	8.29	0.31	6.93e-16	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs1420338	0.967	rs10807873	chr7:34171276	C/T	cg01275685	chr7:34179230	BMPER	-0.46	-10.08	-0.37	2.71e-22	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.52	-11.23	-0.41	7.51e-27	Longevity;Endometriosis;
BRCA	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.35	-0.31	4.24e-16	Menopause (age at onset);
BRCA	trans	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg25214090	chr10:38739885	LOC399744	0.55	12.09	0.43	1.97e-30	Corneal astigmatism;
BRCA	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg25237894	chr2:233734115	C2orf82	-0.39	-11.02	-0.4	5.58e-26	Coronary artery disease;
BRCA	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06002616	chr8:101225028	SPAG1	-0.34	-8.38	-0.31	3.33e-16	Atrioventricular conduction;
BRCA	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg25482853	chr8:67687455	SGK3	0.97	15.32	0.52	2.31e-45	Lung disease severity in cystic fibrosis;
BRCA	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg11764359	chr7:65958608	NA	-0.67	-14.9	-0.51	2.48e-43	Aortic root size;
BRCA	cis	rs3125734	0.633	rs1873685	chr10:64032126	C/T	cg19640130	chr10:64028056	RTKN2	-0.32	-8.89	-0.33	6.2e-18	Rheumatoid arthritis;
BRCA	cis	rs10985070	0.504	rs2296077	chr9:123944943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	8.24	0.31	9.46e-16	Rheumatoid arthritis;
BRCA	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg08859206	chr1:53392774	SCP2	-0.48	-9.71	-0.36	6.75e-21	Monocyte count;
BRCA	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg15212455	chr7:39170539	POU6F2	0.45	10.0	0.37	5.72e-22	IgG glycosylation;
BRCA	cis	rs7247513	0.964	rs8105902	chr19:12718351	G/A	cg01871581	chr19:12707946	ZNF490	-0.69	-15.61	-0.53	9.27e-47	Bipolar disorder;
BRCA	trans	rs3858145	0.588	rs61854833	chr10:70037327	C/G	cg04882175	chr6:131122610	NA	-0.35	-8.31	-0.31	5.79e-16	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
BRCA	trans	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg26043149	chr18:55253948	FECH	0.42	9.08	0.34	1.33e-18	Bone mineral density;
BRCA	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg06623918	chr6:96969491	KIAA0776	-0.82	-21.97	-0.66	3.93e-80	Headache;
BRCA	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.28e-23	Prostate cancer;
BRCA	cis	rs724568	0.527	rs12612262	chr2:67934125	G/C	cg17945962	chr2:67939740	NA	-0.37	-9.76	-0.36	4.61e-21	Major depressive disorder (broad);
BRCA	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12756686	chr19:29218302	NA	0.54	9.43	0.35	7.26e-20	Methadone dose in opioid dependence;
BRCA	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg04756594	chr16:24857601	SLC5A11	0.51	11.52	0.41	4.87e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg24060327	chr5:131705240	SLC22A5	0.62	11.61	0.42	2.12e-28	Breast cancer;
BRCA	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg26384229	chr12:38710491	ALG10B	0.66	13.95	0.48	8.57e-39	Morning vs. evening chronotype;
BRCA	cis	rs8005677	1.000	rs1956881	chr14:23394069	A/C	cg01529538	chr14:23388837	RBM23	0.42	11.45	0.41	9.99e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg20469991	chr17:27169893	C17orf63	-0.45	-8.97	-0.33	3.31e-18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg04842962	chr6:43655489	MRPS18A	1.12	38.92	0.84	9.6e-171	IgG glycosylation;
BRCA	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg24829409	chr8:58192753	C8orf71	-0.47	-9.0	-0.34	2.61e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.58	9.04	0.34	1.89e-18	Lung function (FEV1/FVC);
BRCA	cis	rs17401966	0.809	rs12406943	chr1:10308545	T/C	cg03954927	chr1:10346856	KIF1B	0.43	13.57	0.47	4.69e-37	Hepatocellular carcinoma;
BRCA	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24549020	chr5:56110836	MAP3K1	0.64	13.06	0.46	9.94e-35	Initial pursuit acceleration;
BRCA	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg01939980	chr4:1354348	KIAA1530	0.29	7.84	0.3	1.94e-14	Obesity-related traits;
BRCA	cis	rs849141	0.890	rs849143	chr7:28186473	G/T	cg22892036	chr7:28189139	JAZF1	0.47	8.5	0.32	1.29e-16	Height;Hip circumference adjusted for BMI;
BRCA	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.23e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11890956	chr21:40555474	PSMG1	-0.62	-13.7	-0.48	1.18e-37	Menarche (age at onset);
BRCA	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg11057378	chr10:81107060	PPIF	0.43	10.22	0.37	8.19e-23	Height;
BRCA	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg06026331	chr20:60912101	LAMA5	0.59	11.93	0.43	9.2e-30	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg03146154	chr1:46216737	IPP	0.47	10.41	0.38	1.44e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg26248373	chr2:1572462	NA	-0.51	-10.54	-0.38	4.48e-24	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg11764359	chr7:65958608	NA	0.62	10.67	0.39	1.44e-24	Aortic root size;
BRCA	cis	rs28595532	0.623	rs71608363	chr4:119227259	T/C	cg21605333	chr4:119757512	SEC24D	0.81	8.48	0.32	1.58e-16	Cannabis dependence symptom count;
BRCA	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11764359	chr7:65958608	NA	0.74	16.57	0.55	1.44e-51	Aortic root size;
BRCA	cis	rs593982	0.920	rs488170	chr11:65481544	T/C	cg08755490	chr11:65554678	OVOL1	1.2	17.73	0.57	1.76e-57	Atopic dermatitis;
BRCA	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg24558204	chr6:135376177	HBS1L	0.45	12.33	0.44	1.66e-31	Red blood cell count;
BRCA	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg19539972	chr4:7069911	GRPEL1	-0.64	-12.74	-0.45	2.68e-33	Monocyte percentage of white cells;
BRCA	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg05863683	chr7:1912471	MAD1L1	-0.38	-8.63	-0.32	4.71e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	14.35	0.49	1.15e-40	Mean corpuscular hemoglobin;
BRCA	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.33	0.31	4.77e-16	Axial length;
BRCA	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg04362960	chr10:104952993	NT5C2	0.44	9.89	0.36	1.42e-21	Arsenic metabolism;
BRCA	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg26597838	chr10:835615	NA	1.03	18.35	0.59	1e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg17135325	chr3:160939158	NMD3	0.42	7.91	0.3	1.14e-14	Parkinson's disease;
BRCA	cis	rs4499344	0.730	rs417823	chr19:33104561	A/G	cg22980127	chr19:33182716	NUDT19	-0.39	-8.49	-0.32	1.45e-16	Mean platelet volume;
BRCA	cis	rs2629540	0.847	rs34032724	chr10:126408869	T/G	cg08799069	chr10:126477246	METTL10	0.46	9.34	0.35	1.53e-19	Cocaine dependence;
BRCA	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	9.59	0.35	1.87e-20	Rheumatoid arthritis;
BRCA	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg08992911	chr2:238395768	MLPH	0.54	8.28	0.31	7.01e-16	Prostate cancer;
BRCA	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg25251562	chr2:3704773	ALLC	0.52	9.78	0.36	3.86e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs4363385	0.782	rs10788857	chr1:153024941	T/G	cg24667326	chr1:152973720	SPRR3	-0.31	-8.27	-0.31	7.99e-16	Inflammatory skin disease;
BRCA	cis	rs13161895	0.818	rs116463976	chr5:179484519	G/C	cg02702477	chr5:179499311	RNF130	0.58	10.11	0.37	2.19e-22	LDL cholesterol;
BRCA	cis	rs6878727	0.850	rs6881377	chr5:123731759	G/A	cg01806427	chr5:123737813	NA	0.42	9.72	0.36	6.39e-21	Breast cancer;
BRCA	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg06060754	chr5:176797920	RGS14	-0.89	-16.67	-0.55	4.39e-52	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.64	0.32	4.61e-17	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23583168	chr7:148888333	NA	-0.96	-25.09	-0.7	3.35e-97	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg05665937	chr4:1216051	CTBP1	0.5	10.12	0.37	1.93e-22	Obesity-related traits;
BRCA	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg07148914	chr20:33460835	GGT7	-0.42	-9.07	-0.34	1.44e-18	Height;
BRCA	cis	rs3784262	0.692	rs12914388	chr15:58283843	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.86	-0.36	1.97e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg05025164	chr4:1340916	KIAA1530	0.47	10.29	0.38	4.44e-23	Longevity;
BRCA	cis	rs3857067	0.772	rs10018905	chr4:95076767	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.38	-8.8	-0.33	1.28e-17	QT interval;
BRCA	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg05347473	chr6:146136440	FBXO30	0.39	8.04	0.3	4.22e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg00738919	chr7:1100172	C7orf50	0.46	7.84	0.3	1.94e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg12365402	chr11:9010492	NRIP3	-0.39	-9.01	-0.34	2.29e-18	Hemoglobin concentration;
BRCA	cis	rs10046574	0.908	rs28418917	chr7:135124905	T/C	cg27474649	chr7:135195673	CNOT4	0.6	8.54	0.32	9.88e-17	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg04374321	chr14:90722782	PSMC1	0.48	11.42	0.41	1.33e-27	Mortality in heart failure;
BRCA	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg13010199	chr12:38710504	ALG10B	0.44	8.93	0.33	4.46e-18	Bladder cancer;
BRCA	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg04691961	chr3:161091175	C3orf57	-0.38	-8.49	-0.32	1.43e-16	Morning vs. evening chronotype;
BRCA	cis	rs72720396	1.000	rs72720396	chr1:91191582	A/G	cg13456504	chr1:91191583	NA	0.58	10.38	0.38	1.95e-23	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs2625529	0.761	rs972028	chr15:72173092	C/T	cg16672083	chr15:72433130	SENP8	-0.75	-15.97	-0.53	1.53e-48	Red blood cell count;
BRCA	cis	rs1018836	0.923	rs9643308	chr8:91625399	A/C	cg16814680	chr8:91681699	NA	-0.59	-12.7	-0.45	4.08e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs17092148	0.887	rs6059937	chr20:33186200	G/C	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.69	-0.39	1.17e-24	Neuroticism;
BRCA	trans	rs4714291	0.963	rs1767672	chr6:40104107	G/T	cg02267698	chr19:7991119	CTXN1	0.43	8.33	0.31	5e-16	Strep throat;
BRCA	cis	rs7607369	0.718	rs6727147	chr2:219639024	G/A	cg02176678	chr2:219576539	TTLL4	-0.41	-10.96	-0.4	9.9e-26	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs7408868	0.908	rs10416777	chr19:15276923	C/T	cg14696996	chr19:15285081	NOTCH3	0.99	14.49	0.5	2.35e-41	Pulse pressure;
BRCA	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	ch.11.42038R	chr11:967971	AP2A2	0.5	15.52	0.52	2.5e-46	Alzheimer's disease (late onset);
BRCA	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.97	-0.37	7.48e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.85	0.36	2.09e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1003719	0.591	rs1053966	chr21:38568009	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-11.6	-0.42	2.24e-28	Eye color traits;
BRCA	cis	rs6691722	0.506	rs12030365	chr1:24739220	T/A	cg18323236	chr1:24743029	NIPAL3	0.37	10.36	0.38	2.33e-23	Response to interferon beta in multiple sclerosis;
BRCA	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg12292205	chr6:26970375	C6orf41	0.72	16.32	0.54	2.51e-50	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.38	-8.33	-0.31	5.11e-16	HDL cholesterol;
BRCA	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg16606324	chr3:10149918	C3orf24	0.53	10.41	0.38	1.54e-23	Alzheimer's disease;
BRCA	cis	rs6740322	0.748	rs6720087	chr2:43468745	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.74	14.4	0.49	6.68e-41	Coronary artery disease;
BRCA	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg02951883	chr7:2050386	MAD1L1	-0.52	-11.86	-0.42	1.8e-29	Bipolar disorder and schizophrenia;
BRCA	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg20891558	chr2:74357851	NA	0.51	12.13	0.43	1.31e-30	Gestational age at birth (maternal effect);
BRCA	trans	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg25214090	chr10:38739885	LOC399744	0.48	10.68	0.39	1.29e-24	Corneal astigmatism;
BRCA	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg24130564	chr14:104152367	KLC1	-0.34	-7.86	-0.3	1.63e-14	Body mass index;
BRCA	cis	rs11971779	0.680	rs11980313	chr7:139034643	C/G	cg07862535	chr7:139043722	LUC7L2	0.39	10.46	0.38	9.65e-24	Diisocyanate-induced asthma;
BRCA	trans	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg21475434	chr5:93447410	FAM172A	-0.64	-8.28	-0.31	7.29e-16	Diabetic retinopathy;
BRCA	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-11.17	-0.4	1.4e-26	Gut microbiome composition (summer);
BRCA	trans	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17712092	chr4:129076599	LARP1B	0.56	13.46	0.47	1.62e-36	Eosinophil percentage of white cells;
BRCA	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24531977	chr5:56204891	C5orf35	-0.88	-18.88	-0.6	1.53e-63	Initial pursuit acceleration;
BRCA	cis	rs7561273	0.609	rs10200844	chr2:24293363	A/C	cg04809136	chr2:24300158	SF3B14	-0.4	-9.28	-0.34	2.62e-19	Quantitative traits;
BRCA	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg11814155	chr7:99998594	ZCWPW1	0.48	8.63	0.32	5.04e-17	Platelet count;
BRCA	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg07636037	chr3:49044803	WDR6	0.41	8.39	0.32	3.03e-16	Resting heart rate;
BRCA	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg17410650	chr12:54324560	NA	-0.43	-10.83	-0.39	3.32e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
BRCA	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg15704280	chr7:45808275	SEPT13	0.52	8.96	0.33	3.48e-18	Axial length;
BRCA	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg04691961	chr3:161091175	C3orf57	-0.59	-14.04	-0.49	3.32e-39	Morning vs. evening chronotype;
BRCA	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg17747265	chr1:1875780	NA	0.52	15.21	0.52	7.8e-45	Body mass index;
BRCA	cis	rs1506636	0.720	rs633590	chr7:123442156	G/A	cg03229431	chr7:123269106	ASB15	0.4	9.28	0.34	2.66e-19	Plateletcrit;Platelet count;
BRCA	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg09035930	chr12:129282057	SLC15A4	0.56	16.41	0.54	9e-51	Systemic lupus erythematosus;
BRCA	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26314531	chr2:26401878	FAM59B	0.91	16.11	0.54	3.05e-49	Gut microbiome composition (summer);
BRCA	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg18252515	chr7:66147081	NA	-0.9	-12.91	-0.45	4.63e-34	Diabetic kidney disease;
BRCA	cis	rs2463822	0.688	rs7121684	chr11:62162389	T/C	cg06239285	chr11:62104954	ASRGL1	-0.67	-8.91	-0.33	5.21e-18	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs57590327	0.555	rs13099615	chr3:81729101	T/A	cg07356753	chr3:81810745	GBE1	-0.47	-11.26	-0.41	5.89e-27	Extraversion;
BRCA	cis	rs7178424	1.000	rs8039651	chr15:62359350	C/T	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.43	-0.32	2.26e-16	Height;
BRCA	cis	rs922182	0.579	rs4620909	chr15:64192739	C/T	cg24729988	chr15:64271149	DAPK2	-0.43	-9.62	-0.36	1.49e-20	Blood protein levels;
BRCA	cis	rs11252926	0.831	rs816570	chr10:680475	C/T	cg08603382	chr10:743973	NA	-0.43	-8.84	-0.33	9.34e-18	Psychosis in Alzheimer's disease;
BRCA	cis	rs10751667	0.621	rs7396049	chr11:1001561	G/A	ch.11.42038R	chr11:967971	AP2A2	0.47	14.3	0.49	1.94e-40	Alzheimer's disease (late onset);
BRCA	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg17063962	chr7:91808500	NA	0.48	10.83	0.39	3.24e-25	Breast cancer;
BRCA	cis	rs2425143	1.000	rs11696527	chr20:34245379	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.97	-0.33	3.3e-18	Blood protein levels;
BRCA	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg06698575	chr12:117470875	NA	0.44	8.23	0.31	1.09e-15	Subcortical brain region volumes;Hippocampal volume;
BRCA	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg17470723	chr8:74884337	TCEB1	0.42	9.06	0.34	1.62e-18	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.98	29.84	0.76	3.12e-123	Colorectal cancer;
BRCA	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg02544614	chr20:61657117	NA	0.28	8.15	0.31	1.93e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs250677	0.958	rs17109282	chr5:148416677	A/G	cg23229984	chr5:148520753	ABLIM3	-0.32	-7.93	-0.3	9.61e-15	Breast cancer;
BRCA	cis	rs3784262	1.000	rs7495968	chr15:58244103	C/G	cg12031962	chr15:58353849	ALDH1A2	0.44	11.78	0.42	3.96e-29	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg12564285	chr5:131593104	PDLIM4	0.34	7.96	0.3	7.96e-15	Breast cancer;
BRCA	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg05343316	chr1:45956843	TESK2	0.69	13.86	0.48	2.33e-38	Platelet count;
BRCA	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg23711669	chr6:146136114	FBXO30	0.71	16.86	0.55	4.95e-53	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.12	-18.93	-0.6	8.81e-64	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg03146154	chr1:46216737	IPP	-0.44	-9.81	-0.36	2.94e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg21775007	chr8:11205619	TDH	-0.39	-8.0	-0.3	5.89e-15	Joint mobility (Beighton score);
BRCA	trans	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg06521331	chr12:34319734	NA	-0.54	-9.56	-0.35	2.48e-20	Bladder cancer;
BRCA	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg07169764	chr2:136633963	MCM6	1.23	24.05	0.69	1.56e-91	Corneal structure;
BRCA	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg12193833	chr17:30244370	NA	-0.58	-8.89	-0.33	6.38e-18	Hip circumference adjusted for BMI;
BRCA	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg04842962	chr6:43655489	MRPS18A	1.13	39.17	0.84	5.01e-172	IgG glycosylation;
BRCA	cis	rs7677751	0.806	rs6836215	chr4:55102741	T/C	cg17187183	chr4:55093834	PDGFRA	0.44	9.1	0.34	1.14e-18	Corneal astigmatism;
BRCA	cis	rs4478137	0.931	rs7687423	chr4:164250797	C/T	cg06758707	chr4:164254230	NPY1R	-0.52	-11.49	-0.41	6.61e-28	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg08999081	chr20:33150536	PIGU	0.47	13.03	0.46	1.35e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs17641971	0.662	rs13268440	chr8:50000873	C/T	cg00325661	chr8:49890786	NA	0.36	10.07	0.37	3.09e-22	Blood metabolite levels;
BRCA	cis	rs4478858	0.698	rs4949204	chr1:31800415	A/G	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg08999081	chr20:33150536	PIGU	0.47	12.92	0.46	4.18e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg15112475	chr7:1198522	ZFAND2A	0.51	11.5	0.41	5.92e-28	Longevity;Endometriosis;
BRCA	cis	rs847577	0.646	rs10270222	chr7:97781799	C/T	cg24562669	chr7:97807699	LMTK2	-0.49	-13.2	-0.46	2.36e-35	Breast cancer;
BRCA	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg02527881	chr3:46936655	PTH1R	-0.36	-9.25	-0.34	3.45e-19	Colorectal cancer;
BRCA	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg00106254	chr7:1943704	MAD1L1	0.45	11.53	0.42	4.43e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.22	0.37	8.18e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4363385	0.747	rs4845509	chr1:152981900	T/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.32	-0.31	5.28e-16	Inflammatory skin disease;
BRCA	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg18964960	chr10:1102726	WDR37	-0.54	-9.33	-0.35	1.76e-19	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg13010199	chr12:38710504	ALG10B	0.45	9.23	0.34	3.83e-19	Bladder cancer;
BRCA	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.21	-0.37	9.1e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.69	-0.33	3.09e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-10.29	-0.38	4.4e-23	Alzheimer's disease (late onset);
BRCA	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg13319975	chr6:146136371	FBXO30	-0.34	-7.86	-0.3	1.68e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.8	-0.42	3.24e-29	Response to antipsychotic treatment;
BRCA	cis	rs4363385	0.782	rs394859	chr1:153025704	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.52	-0.32	1.18e-16	Inflammatory skin disease;
BRCA	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg15083037	chr5:83017644	HAPLN1	-0.51	-9.92	-0.37	1.11e-21	Prostate cancer;
BRCA	cis	rs12541635	0.966	rs1603363	chr8:107031319	A/G	cg10147462	chr8:107024639	NA	0.36	9.69	0.36	8.28e-21	Age of smoking initiation;
BRCA	cis	rs701145	0.585	rs1713854	chr3:153848030	T/C	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.82e-18	Coronary artery disease;
BRCA	cis	rs11191270	0.554	rs77616533	chr10:104055983	A/G	cg15320455	chr10:103880129	LDB1	0.75	11.19	0.4	1.12e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg24006582	chr15:45444508	DUOX1	0.55	10.56	0.39	3.77e-24	Uric acid levels;
BRCA	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg13010199	chr12:38710504	ALG10B	0.5	9.68	0.36	9.21e-21	Morning vs. evening chronotype;
BRCA	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11644478	chr21:40555479	PSMG1	0.82	18.77	0.6	6.19e-63	Cognitive function;
BRCA	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.76	12.77	0.45	2.1e-33	Schizophrenia;
BRCA	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg16230307	chr14:35515116	FAM177A1	0.73	15.06	0.51	4.55e-44	Psoriasis;
BRCA	cis	rs17001868	0.568	rs760700	chr22:40800071	C/T	cg07138101	chr22:40742427	ADSL	-0.53	-10.13	-0.37	1.79e-22	Mammographic density (dense area);
BRCA	trans	rs4650994	1.000	rs12138541	chr1:178518707	G/A	cg05059571	chr16:84539110	KIAA1609	-0.43	-9.61	-0.36	1.6e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg02880119	chr16:3481970	NA	0.43	8.2	0.31	1.35e-15	Body mass index (adult);
BRCA	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg09307838	chr4:120376055	NA	0.74	15.99	0.53	1.16e-48	Corneal astigmatism;
BRCA	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg12386194	chr3:101231763	SENP7	0.66	12.97	0.46	2.58e-34	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.98	-0.33	3.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg07308232	chr7:1071921	C7orf50	-0.4	-8.79	-0.33	1.37e-17	Longevity;Endometriosis;
BRCA	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg12310025	chr6:25882481	NA	-0.46	-10.36	-0.38	2.32e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.5	-9.14	-0.34	8.47e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs311392	0.902	rs413667	chr8:55091908	C/A	cg11783602	chr8:55087084	NA	-0.32	-9.11	-0.34	1.03e-18	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg17691542	chr6:26056736	HIST1H1C	0.51	10.43	0.38	1.29e-23	Height;
BRCA	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg18806716	chr10:30721971	MAP3K8	0.5	11.99	0.43	4.99e-30	Inflammatory bowel disease;
BRCA	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg25036284	chr2:26402008	FAM59B	-0.63	-10.61	-0.39	2.36e-24	Gut microbiome composition (summer);
BRCA	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	10.58	0.39	3.17e-24	Height;
BRCA	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg23711669	chr6:146136114	FBXO30	0.79	19.22	0.61	2.48e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4880487	0.853	rs1876898	chr10:1249986	C/T	cg03183215	chr10:1252341	ADARB2	-0.37	-8.42	-0.32	2.57e-16	Migraine;
BRCA	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg24812749	chr6:127587940	RNF146	0.86	20.21	0.62	1.41e-70	Breast cancer;
BRCA	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg17366294	chr4:99064904	C4orf37	0.44	10.46	0.38	9.36e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2742234	0.518	rs2505514	chr10:43633248	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.55	-11.08	-0.4	3.33e-26	Hirschsprung disease;
BRCA	cis	rs4423214	0.840	rs1790344	chr11:71176897	A/G	cg05163923	chr11:71159392	DHCR7	-0.57	-11.6	-0.42	2.31e-28	Vitamin D levels;
BRCA	cis	rs7799006	0.723	rs2270052	chr7:2291399	C/T	cg08027265	chr7:2291960	NA	-0.49	-12.83	-0.45	1.11e-33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs6987853	0.787	rs2974309	chr8:42426961	G/A	cg09913449	chr8:42400586	C8orf40	0.42	9.29	0.34	2.43e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.07	29.9	0.76	1.47e-123	Cognitive ability;
BRCA	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg12573674	chr2:1569213	NA	-0.56	-12.07	-0.43	2.35e-30	IgG glycosylation;
BRCA	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.48	8.86	0.33	8.1e-18	Multiple sclerosis;
BRCA	cis	rs68170813	0.559	rs79778437	chr7:107004972	T/A	cg02696742	chr7:106810147	HBP1	-0.5	-8.41	-0.32	2.65e-16	Coronary artery disease;
BRCA	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg26818010	chr10:134567672	INPP5A	-0.71	-14.83	-0.51	5.95e-43	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7246967	0.673	rs34003335	chr19:22925602	T/C	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs10193935	0.901	rs9808509	chr2:42479644	T/C	cg27598129	chr2:42591480	NA	-0.99	-14.48	-0.5	2.77e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg05714579	chr10:131428358	MGMT	-0.72	-18.25	-0.59	3.12e-60	Response to temozolomide;
BRCA	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg05707623	chr12:122985044	ZCCHC8	0.49	9.42	0.35	7.79e-20	Body mass index;
BRCA	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.02	-0.34	2.13e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2282802	0.660	rs6873248	chr5:139683762	A/G	cg26211634	chr5:139558579	C5orf32	-0.34	-8.17	-0.31	1.62e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg11764359	chr7:65958608	NA	0.68	15.19	0.52	1.01e-44	Aortic root size;
BRCA	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg15934090	chr1:100435551	SLC35A3	0.35	8.15	0.31	1.91e-15	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.9	0.3	1.22e-14	Corneal astigmatism;
BRCA	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg26597838	chr10:835615	NA	0.85	15.53	0.52	2.34e-46	Eosinophil percentage of granulocytes;
BRCA	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg22974920	chr21:40686053	BRWD1	0.39	8.92	0.33	5.06e-18	Cognitive function;
BRCA	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg19508488	chr2:152266495	RIF1	0.38	8.23	0.31	1.03e-15	Lung cancer;
BRCA	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg12311346	chr5:56204834	C5orf35	0.58	12.15	0.43	1.07e-30	Initial pursuit acceleration;
BRCA	cis	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg07460842	chr6:66804631	NA	0.99	19.85	0.62	1.08e-68	Exhaled nitric oxide output;
BRCA	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg04944784	chr2:26401820	FAM59B	-0.85	-13.31	-0.47	7.68e-36	Gut microbiome composition (summer);
BRCA	cis	rs2617583	0.935	rs2975223	chr5:1443603	T/C	cg07151155	chr5:1473589	LPCAT1	-0.38	-8.24	-0.31	1.01e-15	Breast cancer;
BRCA	cis	rs6763687	0.725	rs9842575	chr3:171803152	G/A	cg16233210	chr3:171778391	FNDC3B	0.35	7.99	0.3	6.15e-15	Red cell distribution width;
BRCA	cis	rs2712184	1.000	rs2712184	chr2:217682779	G/T	cg05032264	chr2:217675019	NA	-0.46	-11.42	-0.41	1.24e-27	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs17384381	1.000	rs12135333	chr1:85890494	C/A	cg16011679	chr1:85725395	C1orf52	0.54	8.33	0.31	4.9e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9420	0.961	rs17455520	chr11:57540458	C/A	cg19752551	chr11:57585705	CTNND1	-0.51	-12.55	-0.44	1.96e-32	Schizophrenia;
BRCA	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg03684893	chr10:554711	DIP2C	-0.4	-9.52	-0.35	3.46e-20	Psychosis in Alzheimer's disease;
BRCA	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg00105475	chr2:10696890	NA	0.44	10.37	0.38	2.16e-23	Prostate cancer;
BRCA	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg16606324	chr3:10149918	C3orf24	0.57	11.37	0.41	2.08e-27	Alzheimer's disease;
BRCA	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg16576597	chr16:28551801	NUPR1	0.32	8.92	0.33	4.94e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg08888203	chr3:10149979	C3orf24	0.62	12.78	0.45	1.79e-33	Alzheimer's disease;
BRCA	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg14863265	chr7:2801509	GNA12	-0.45	-9.73	-0.36	5.68e-21	Height;
BRCA	cis	rs9647379	1.000	rs9647379	chr3:171785168	C/G	cg16233210	chr3:171778391	FNDC3B	0.38	8.5	0.32	1.37e-16	Heart rate;
BRCA	cis	rs600806	0.713	rs10745305	chr1:110012148	A/G	cg20591472	chr1:110008990	SYPL2	0.31	7.85	0.3	1.77e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs897080	0.515	rs1067402	chr2:44676226	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.52	-9.2	-0.34	4.94e-19	Height;
BRCA	cis	rs2108225	1.000	rs2108225	chr7:107453103	G/A	cg18560240	chr7:107437656	SLC26A3	-0.51	-10.24	-0.38	7.07e-23	Ulcerative colitis;
BRCA	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	11.25	0.41	6.53e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08045932	chr20:61659980	NA	0.48	10.9	0.4	1.68e-25	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24838063	chr12:130822603	PIWIL1	0.68	16.73	0.55	2.13e-52	Menopause (age at onset);
BRCA	cis	rs36051895	0.659	rs12343867	chr9:5074189	T/C	cg02405213	chr9:5042618	JAK2	-0.52	-9.56	-0.35	2.58e-20	Pediatric autoimmune diseases;
BRCA	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.7	-19.36	-0.61	4.69e-66	Electrocardiographic conduction measures;
BRCA	cis	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg05901451	chr6:126070800	HEY2	0.4	9.63	0.36	1.39e-20	Endometrial cancer;
BRCA	trans	rs6479891	1.000	rs4466712	chr10:64933268	G/C	cg14819942	chr15:35414228	NA	0.35	8.42	0.32	2.46e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00684032	chr4:1343700	KIAA1530	0.52	11.98	0.43	5.37e-30	Obesity-related traits;
BRCA	cis	rs6772849	0.930	rs9813197	chr3:128369104	G/A	cg16766828	chr3:128327626	NA	-0.39	-8.59	-0.32	6.9e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs68170813	0.559	rs11761181	chr7:106954879	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.53	-0.32	1.02e-16	Coronary artery disease;
BRCA	trans	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.31	-8.28	-0.31	7.36e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7577696	0.597	rs11691939	chr2:32339561	A/G	cg02381751	chr2:32503542	YIPF4	0.42	8.07	0.3	3.59e-15	Inflammatory biomarkers;
BRCA	cis	rs16858210	0.607	rs60244260	chr3:183570734	G/A	cg25686905	chr3:183603175	PARL	-0.39	-8.43	-0.32	2.35e-16	Menopause (age at onset);
BRCA	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg22491629	chr6:157744540	C6orf35	0.6	10.84	0.39	3.09e-25	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	13.43	0.47	2.02e-36	Response to antipsychotic treatment;
BRCA	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg16339924	chr4:17578868	LAP3	0.57	13.8	0.48	4.26e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs921968	0.565	rs7599568	chr2:219607819	A/G	cg02176678	chr2:219576539	TTLL4	-0.41	-11.01	-0.4	5.98e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10503871	1.000	rs10503872	chr8:30437031	C/G	cg26383811	chr8:30366931	RBPMS	-0.31	-8.49	-0.32	1.45e-16	Metabolite levels  (X-11787);
BRCA	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-14.48	-0.5	2.63e-41	Hemoglobin concentration;
BRCA	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg11822812	chr5:140052017	DND1	-0.32	-8.72	-0.33	2.3e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg02153584	chr22:29168773	CCDC117	-0.54	-11.43	-0.41	1.19e-27	Lymphocyte counts;
BRCA	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg23649088	chr2:200775458	C2orf69	0.56	8.22	0.31	1.1e-15	Schizophrenia;
BRCA	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg02951883	chr7:2050386	MAD1L1	-0.61	-15.77	-0.53	1.47e-47	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs733175	0.855	rs9291640	chr4:10007086	C/T	cg00071950	chr4:10020882	SLC2A9	0.42	8.79	0.33	1.41e-17	Psychosis and Alzheimer's disease;
BRCA	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg22705602	chr4:152727874	NA	-0.33	-8.22	-0.31	1.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.09	0.49	1.94e-39	Motion sickness;
BRCA	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg06784218	chr1:46089804	CCDC17	0.44	10.65	0.39	1.76e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs965469	0.779	rs1884563	chr20:3335540	T/C	cg25506879	chr20:3388711	C20orf194	-0.44	-8.77	-0.33	1.66e-17	IFN-related cytopenia;
BRCA	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg04944784	chr2:26401820	FAM59B	0.99	16.56	0.55	1.61e-51	Gut microbiome composition (summer);
BRCA	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg12292205	chr6:26970375	C6orf41	-0.8	-19.63	-0.61	1.68e-67	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg08601574	chr20:25228251	PYGB	-0.34	-8.19	-0.31	1.4e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg25457927	chr22:38595422	NA	0.36	13.48	0.47	1.2e-36	Cutaneous nevi;
BRCA	cis	rs1577917	0.917	rs13213603	chr6:86534758	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.54	-0.42	4.21e-28	Response to antipsychotic treatment;
BRCA	cis	rs919433	0.963	rs4850428	chr2:198169772	G/A	cg10820045	chr2:198174542	NA	-0.38	-7.82	-0.3	2.17e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg04450456	chr4:17643702	FAM184B	0.36	10.4	0.38	1.59e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9807989	0.507	rs6726985	chr2:103048580	G/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.38	0.31	3.39e-16	Asthma;
BRCA	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg10523679	chr1:76189770	ACADM	0.67	11.15	0.4	1.73e-26	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9837602	1.000	rs62285461	chr3:99767642	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.18	0.4	1.29e-26	Breast cancer;
BRCA	cis	rs9462027	0.651	rs9469884	chr6:34758703	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.94	-0.3	9.2e-15	Systemic lupus erythematosus;
BRCA	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-11.11	-0.4	2.43e-26	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11764359	chr7:65958608	NA	-0.77	-17.73	-0.57	1.71e-57	Aortic root size;
BRCA	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02018176	chr4:1364513	KIAA1530	0.41	8.24	0.31	1.01e-15	Longevity;
BRCA	trans	rs3857536	0.813	rs9453639	chr6:66933538	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.17	-0.31	1.66e-15	Blood trace element (Cu levels);
BRCA	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg15934090	chr1:100435551	SLC35A3	0.37	8.48	0.32	1.57e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24308560	chr3:49941425	MST1R	0.39	8.33	0.31	4.92e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs939658	0.805	rs11638625	chr15:79434787	T/G	cg17916960	chr15:79447300	NA	-0.44	-10.74	-0.39	7.83e-25	Refractive error;
BRCA	cis	rs11893307	0.599	rs13423600	chr2:191668301	C/T	cg05765582	chr2:191677683	NA	0.44	7.98	0.3	6.64e-15	Mean platelet volume;
BRCA	cis	rs367943	0.966	rs455435	chr5:112799412	T/C	cg12552261	chr5:112820674	MCC	-0.55	-12.22	-0.44	4.98e-31	Type 2 diabetes;
BRCA	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg23029597	chr12:123009494	RSRC2	-0.59	-11.94	-0.43	8.67e-30	Body mass index;
BRCA	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg04691961	chr3:161091175	C3orf57	-0.46	-10.85	-0.39	2.66e-25	Morning vs. evening chronotype;
BRCA	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg09754948	chr16:28834200	ATXN2L	0.38	7.82	0.3	2.13e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg18225595	chr11:63971243	STIP1	-0.52	-9.17	-0.34	6.58e-19	Mean platelet volume;
BRCA	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.96	0.4	9.71e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg16482183	chr6:26056742	HIST1H1C	0.53	11.26	0.41	5.76e-27	Height;
BRCA	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26314531	chr2:26401878	FAM59B	0.95	16.32	0.54	2.75e-50	Gut microbiome composition (summer);
BRCA	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg04546413	chr19:29218101	NA	0.49	8.34	0.31	4.55e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	trans	rs2018683	0.834	rs2012754	chr7:29026257	G/A	cg19402173	chr7:128379420	CALU	-0.54	-12.97	-0.46	2.45e-34	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg21395723	chr22:39101663	GTPBP1	0.38	8.32	0.31	5.17e-16	Menopause (age at onset);
BRCA	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg11833968	chr6:79620685	NA	-0.42	-9.55	-0.35	2.81e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg15432903	chr11:17409602	KCNJ11	0.72	15.86	0.53	5.11e-48	Type 2 diabetes;
BRCA	cis	rs6580649	0.941	rs1859441	chr12:48423233	C/T	cg24011408	chr12:48396354	COL2A1	-0.49	-7.98	-0.3	6.99e-15	Lung cancer;
BRCA	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg14196790	chr5:131705035	SLC22A5	0.45	11.58	0.42	2.81e-28	Blood metabolite levels;
BRCA	cis	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg05623727	chr3:50126028	RBM5	0.42	9.94	0.37	9.6e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.33	0.49	1.32e-40	Motion sickness;
BRCA	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.37	0.57	1.25e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs919433	0.854	rs13013049	chr2:198208664	C/T	cg00792783	chr2:198669748	PLCL1	-0.39	-8.22	-0.31	1.1e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs9811920	0.893	rs720688	chr3:99880569	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.5	11.59	0.42	2.57e-28	Axial length;
BRCA	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.25	0.31	9.17e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg06521331	chr12:34319734	NA	-0.44	-8.56	-0.32	8.17e-17	Resting heart rate;
BRCA	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg21475434	chr5:93447410	FAM172A	0.66	8.48	0.32	1.51e-16	Diabetic retinopathy;
BRCA	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	9.14	0.34	8.49e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7827545	1.000	rs4909910	chr8:135565201	T/C	cg17885191	chr8:135476712	NA	0.47	9.19	0.34	5.3e-19	Hypertension (SNP x SNP interaction);
BRCA	trans	rs2018683	0.683	rs12538606	chr7:28969408	T/C	cg19402173	chr7:128379420	CALU	-0.42	-10.06	-0.37	3.47e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs2835872	0.584	rs1709816	chr21:39077259	A/C	cg06728970	chr21:39037746	KCNJ6	0.32	8.32	0.31	5.24e-16	Electroencephalographic traits in alcoholism;
BRCA	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg26408565	chr15:76604113	ETFA	-0.47	-10.06	-0.37	3.23e-22	Blood metabolite levels;
BRCA	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25427524	chr10:38739819	LOC399744	-0.68	-16.41	-0.54	9.23e-51	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6987853	0.787	rs2974300	chr8:42440532	C/T	cg09913449	chr8:42400586	C8orf40	0.37	7.84	0.3	1.83e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1832871	0.672	rs7745596	chr6:158732991	T/A	cg07165851	chr6:158734300	TULP4	0.63	12.66	0.45	6.25e-33	Height;
BRCA	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.21	0.46	2.22e-35	Bipolar disorder;
BRCA	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg20587970	chr11:113659929	NA	-1.34	-24.49	-0.7	6.49e-94	Hip circumference adjusted for BMI;
BRCA	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.1	-0.34	1.14e-18	Bipolar disorder;
BRCA	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg18016565	chr1:150552671	MCL1	-0.41	-9.39	-0.35	1.08e-19	Urate levels;
BRCA	cis	rs367615	0.840	rs113540823	chr5:108879084	C/T	cg17395555	chr5:108820864	NA	0.37	9.39	0.35	1.03e-19	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg13319975	chr6:146136371	FBXO30	0.39	8.84	0.33	9.25e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg06092702	chr1:163392909	NA	-0.35	-9.39	-0.35	1.02e-19	Motion sickness;
BRCA	cis	rs7737355	0.947	rs9327619	chr5:130921781	A/G	cg06307176	chr5:131281290	NA	0.52	10.37	0.38	2.19e-23	Life satisfaction;
BRCA	cis	rs926392	0.692	rs6028259	chr20:37696977	T/A	cg16355469	chr20:37678765	NA	0.49	11.75	0.42	5.51e-29	Dialysis-related mortality;
BRCA	cis	rs9644630	1.000	rs9644630	chr8:19370598	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.38	8.37	0.31	3.6e-16	Oropharynx cancer;
BRCA	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg22467129	chr15:76604101	ETFA	-0.39	-8.62	-0.32	5.14e-17	Blood metabolite levels;
BRCA	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.91	-30.23	-0.77	2.47e-125	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.81	0.33	1.14e-17	Motion sickness;
BRCA	cis	rs6545883	0.868	rs6752938	chr2:61841588	C/T	cg15711740	chr2:61764176	XPO1	-0.49	-12.19	-0.43	7.25e-31	Tuberculosis;
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg26608667	chr7:1196370	ZFAND2A	0.42	9.44	0.35	6.81e-20	Longevity;Endometriosis;
BRCA	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg09184832	chr6:79620586	NA	-0.52	-11.41	-0.41	1.44e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.47	-10.51	-0.38	6.05e-24	Urate levels in overweight individuals;
BRCA	cis	rs2742234	0.541	rs2742235	chr10:43616325	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.53	-10.69	-0.39	1.18e-24	Hirschsprung disease;
BRCA	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg08313168	chr12:7315531	NA	0.5	8.06	0.3	3.68e-15	Lung disease severity in cystic fibrosis;
BRCA	trans	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	11.59	0.42	2.45e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs12472274	0.941	rs2880131	chr2:239089151	A/C	cg17459225	chr2:239074497	NA	0.63	13.38	0.47	3.69e-36	Phospholipid levels (plasma);
BRCA	cis	rs4478858	0.735	rs6676354	chr1:31800746	A/T	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg05340658	chr4:99064831	C4orf37	0.45	10.24	0.38	7.17e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10267417	0.603	rs10263119	chr7:19872844	C/G	cg07541023	chr7:19748670	TWISTNB	0.47	8.45	0.32	2e-16	Night sleep phenotypes;
BRCA	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg16325326	chr1:53192061	ZYG11B	0.65	16.11	0.54	2.83e-49	Monocyte count;
BRCA	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-18.64	-0.59	3.1e-62	Monocyte count;
BRCA	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.51	0.35	3.88e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg03433033	chr1:76189801	ACADM	-0.45	-8.69	-0.33	2.92e-17	Daytime sleep phenotypes;
BRCA	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg27170947	chr2:26402098	FAM59B	-0.8	-12.95	-0.46	3.1e-34	Gut microbiome composition (summer);
BRCA	cis	rs1043763	0.826	rs2017594	chr12:122631208	A/C	cg14400030	chr12:122498111	BCL7A	-0.46	-10.47	-0.38	8.41e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
BRCA	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.53	11.41	0.41	1.4e-27	Colorectal cancer;
BRCA	trans	rs6479891	1.000	rs7081275	chr10:65106551	G/T	cg14819942	chr15:35414228	NA	-0.34	-8.27	-0.31	7.77e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.89	-17.62	-0.57	6.1e-57	Body mass index;
BRCA	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg17971929	chr21:40555470	PSMG1	0.73	16.34	0.54	1.99e-50	Cognitive function;
BRCA	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg15017067	chr4:17643749	FAM184B	0.3	9.3	0.35	2.18e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg10495392	chr1:46806563	NSUN4	0.44	8.02	0.3	5.11e-15	Menopause (age at onset);
BRCA	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.62	-15.45	-0.52	5.35e-46	Colorectal cancer;
BRCA	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24531977	chr5:56204891	C5orf35	-0.87	-18.04	-0.58	4.2e-59	Initial pursuit acceleration;
BRCA	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg13628971	chr7:2884303	GNA12	0.4	9.02	0.34	2.22e-18	Height;
BRCA	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg06453172	chr10:134556979	INPP5A	-0.6	-11.77	-0.42	4.54e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg14458575	chr2:238380390	NA	0.53	8.63	0.32	4.85e-17	Prostate cancer;
BRCA	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg00071950	chr4:10020882	SLC2A9	0.54	13.35	0.47	4.83e-36	Bone mineral density;
BRCA	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.79	-0.42	3.6e-29	Alcohol dependence;
BRCA	cis	rs6743226	1.000	rs6743226	chr2:242236972	T/C	cg10021735	chr2:242295487	FARP2	0.36	9.99	0.37	6.3e-22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs34779708	0.931	rs2384275	chr10:35297142	A/G	cg03585969	chr10:35415529	CREM	0.45	9.38	0.35	1.11e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg24675658	chr1:53192096	ZYG11B	0.55	12.64	0.45	7.42e-33	Monocyte count;
BRCA	cis	rs10911363	0.592	rs12117885	chr1:183494214	C/T	cg09173681	chr1:183549694	NCF2	-0.52	-11.11	-0.4	2.4e-26	Systemic lupus erythematosus;
BRCA	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	12.01	0.43	4.39e-30	Schizophrenia;
BRCA	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18876405	chr7:65276391	NA	0.71	18.71	0.59	1.35e-62	Calcium levels;
BRCA	trans	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg18876405	chr7:65276391	NA	0.46	10.03	0.37	4.49e-22	Corneal structure;
BRCA	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg00666640	chr1:248458726	OR2T12	0.29	8.29	0.31	6.65e-16	Common traits (Other);
BRCA	cis	rs4363385	0.747	rs7521181	chr1:152955223	G/A	cg21543102	chr1:152974771	SPRR3	-0.3	-8.63	-0.32	4.99e-17	Inflammatory skin disease;
BRCA	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg05283184	chr6:79620031	NA	-0.36	-8.22	-0.31	1.17e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg26043149	chr18:55253948	FECH	-0.42	-9.35	-0.35	1.47e-19	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.35	0.59	9.88e-61	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs72928364	0.929	rs13059867	chr3:100765548	T/C	cg10123952	chr3:100791384	NA	0.59	8.67	0.32	3.55e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7246657	0.525	rs997516	chr19:37474264	T/C	cg18154014	chr19:37997991	ZNF793	0.49	8.39	0.32	3.11e-16	Coronary artery calcification;
BRCA	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.9	-0.33	5.58e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg22601191	chr20:60968625	CABLES2	0.36	8.92	0.33	4.74e-18	Colorectal cancer;
BRCA	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-10.44	-0.38	1.19e-23	Blood metabolite levels;
BRCA	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.92	0.4	1.41e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs11677370	0.561	rs13015012	chr2:3821252	C/G	cg17052675	chr2:3827356	NA	0.59	15.03	0.51	6.31e-44	Type 2 diabetes;
BRCA	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg00383909	chr3:49044727	WDR6	0.57	10.92	0.4	1.41e-25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg07080220	chr10:102295463	HIF1AN	0.51	10.51	0.38	6.08e-24	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs701145	0.537	rs1358403	chr3:153862757	C/T	cg17054900	chr3:154042577	DHX36	0.55	9.23	0.34	3.79e-19	Coronary artery disease;
BRCA	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg00383909	chr3:49044727	WDR6	0.7	12.27	0.44	3.2e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg07460842	chr6:66804631	NA	0.63	11.23	0.41	8.2e-27	Type 2 diabetes;
BRCA	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg27129171	chr3:47204927	SETD2	0.73	17.78	0.58	8.77e-58	Colorectal cancer;
BRCA	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg11764359	chr7:65958608	NA	-0.74	-16.09	-0.54	3.77e-49	Aortic root size;
BRCA	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg21132104	chr15:45694354	SPATA5L1	0.75	16.79	0.55	1.18e-52	Homoarginine levels;
BRCA	cis	rs6062509	0.839	rs6062298	chr20:62301970	G/A	cg03425785	chr20:62221387	GMEB2	-0.44	-8.31	-0.31	5.78e-16	Prostate cancer;
BRCA	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg07741184	chr6:167504864	NA	0.34	10.05	0.37	3.65e-22	Primary biliary cholangitis;
BRCA	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.02	-0.34	2.13e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11890956	chr21:40555474	PSMG1	-0.59	-13.27	-0.46	1.09e-35	Menarche (age at onset);
BRCA	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24549020	chr5:56110836	MAP3K1	0.41	8.58	0.32	7.34e-17	Initial pursuit acceleration;
BRCA	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg13047869	chr3:10149882	C3orf24	0.6	12.76	0.45	2.33e-33	Alzheimer's disease;
BRCA	cis	rs895636	0.756	rs10192373	chr2:45191962	G/A	cg16198908	chr2:45192207	NA	0.49	9.32	0.35	1.81e-19	Metabolite levels;Fasting plasma glucose;
BRCA	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.96	0.3	7.96e-15	Depression;
BRCA	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg23029597	chr12:123009494	RSRC2	-0.6	-11.65	-0.42	1.35e-28	Body mass index;
BRCA	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg27170947	chr2:26402098	FAM59B	0.97	16.89	0.56	3.52e-53	Gut microbiome composition (summer);
BRCA	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.03	0.51	6.14e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.12	-0.31	2.39e-15	Depression;
BRCA	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg05294307	chr14:35346193	BAZ1A	-0.62	-10.54	-0.38	4.7e-24	Psoriasis;
BRCA	cis	rs3767633	0.528	rs4417044	chr1:161888955	T/C	cg27519958	chr1:161735129	ATF6	-0.49	-11.73	-0.42	6.39e-29	IgG glycosylation;
BRCA	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg06115741	chr20:33292138	TP53INP2	0.5	10.82	0.39	3.72e-25	Coronary artery disease;
BRCA	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg10523679	chr1:76189770	ACADM	0.47	9.15	0.34	7.37e-19	Daytime sleep phenotypes;
BRCA	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg26597838	chr10:835615	NA	1.01	17.83	0.58	5.39e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs13266463	0.830	rs7014552	chr8:143410423	A/G	cg16886403	chr8:143471632	TSNARE1	0.45	9.54	0.35	2.95e-20	Schizophrenia;
BRCA	cis	rs17209837	0.607	rs4148821	chr7:87079602	G/C	cg00919237	chr7:87102261	ABCB4	-0.5	-8.99	-0.33	2.84e-18	Gallbladder cancer;
BRCA	cis	rs752010	0.668	rs10890147	chr1:42089725	A/T	cg06885757	chr1:42089581	HIVEP3	0.41	13.57	0.47	4.76e-37	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs2859741	0.967	rs522481	chr1:37488337	C/T	cg09363841	chr1:37513479	NA	-0.65	-16.71	-0.55	2.76e-52	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg18402987	chr7:1209562	NA	0.66	11.33	0.41	3.06e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.13	-0.49	1.22e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg04267008	chr7:1944627	MAD1L1	0.57	12.63	0.45	8.04e-33	Bipolar disorder and schizophrenia;
BRCA	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.04	-0.3	4.3e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs16858210	0.874	rs10937153	chr3:183562925	A/G	cg25686905	chr3:183603175	PARL	0.37	9.04	0.34	1.83e-18	Menopause (age at onset);
BRCA	cis	rs9560113	1.000	rs9560109	chr13:112180468	C/T	cg10483660	chr13:112241077	NA	0.31	7.88	0.3	1.45e-14	Menarche (age at onset);
BRCA	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02018176	chr4:1364513	KIAA1530	0.37	8.01	0.3	5.41e-15	Longevity;
BRCA	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06022373	chr22:39101656	GTPBP1	-0.5	-11.15	-0.4	1.6e-26	Menopause (age at onset);
BRCA	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg04586622	chr2:25135609	ADCY3	0.46	11.66	0.42	1.31e-28	Body mass index;
BRCA	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	13.93	0.48	1.06e-38	Coronary artery disease;
BRCA	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg26384229	chr12:38710491	ALG10B	0.69	16.07	0.54	4.72e-49	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg04025307	chr7:1156635	C7orf50	0.57	13.38	0.47	3.7e-36	Longevity;Endometriosis;
BRCA	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.42	-9.42	-0.35	8.15e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg03808351	chr9:123631620	PHF19	0.39	7.83	0.3	1.99e-14	Rheumatoid arthritis;
BRCA	cis	rs7264396	0.697	rs6142416	chr20:34174092	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.42	8.86	0.33	7.88e-18	Total cholesterol levels;
BRCA	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.56	-12.67	-0.45	5.74e-33	Colorectal cancer;
BRCA	cis	rs7809950	0.906	rs62483723	chr7:107186358	A/C	cg23024343	chr7:107201750	COG5	-0.39	-8.96	-0.33	3.55e-18	Coronary artery disease;
BRCA	trans	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg26043149	chr18:55253948	FECH	0.37	8.23	0.31	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg07148914	chr20:33460835	GGT7	0.36	7.99	0.3	6.34e-15	Height;
BRCA	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg08885076	chr2:99613938	TSGA10	-0.52	-11.8	-0.42	3.27e-29	Chronic sinus infection;
BRCA	trans	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg23762105	chr12:34175262	ALG10	0.35	7.86	0.3	1.66e-14	Morning vs. evening chronotype;
BRCA	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg10224037	chr5:178157518	ZNF354A	0.76	16.12	0.54	2.66e-49	Neutrophil percentage of white cells;
BRCA	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg23711669	chr6:146136114	FBXO30	0.63	14.8	0.51	7.87e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05025164	chr4:1340916	KIAA1530	0.77	15.67	0.53	4.35e-47	Longevity;
BRCA	cis	rs2712184	0.756	rs2712163	chr2:217660346	G/A	cg05032264	chr2:217675019	NA	-0.38	-9.14	-0.34	8.4e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg10932868	chr11:921992	NA	0.47	12.11	0.43	1.62e-30	Alzheimer's disease (late onset);
BRCA	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg27432699	chr2:27873401	GPN1	0.47	9.9	0.36	1.34e-21	Oral cavity cancer;
BRCA	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg27170947	chr2:26402098	FAM59B	-0.9	-17.26	-0.56	4.45e-55	Gut microbiome composition (summer);
BRCA	cis	rs1371614	0.635	rs9309559	chr2:27141515	G/T	cg00617064	chr2:27272375	NA	-0.3	-7.94	-0.3	9.11e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg24006582	chr15:45444508	DUOX1	0.56	11.23	0.41	8.18e-27	Uric acid levels;
BRCA	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07080220	chr10:102295463	HIF1AN	0.49	11.33	0.41	2.98e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg00321850	chr1:175162397	KIAA0040	-0.41	-11.47	-0.41	8.16e-28	Alcohol dependence;
BRCA	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.74e-18	Motion sickness;
BRCA	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.62	-0.61	1.95e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs17253792	0.822	rs77420254	chr14:56069646	C/T	cg01858014	chr14:56050164	KTN1	-0.74	-9.35	-0.35	1.43e-19	Putamen volume;
BRCA	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.67	-0.61	9.89e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg03560586	chr2:239334908	ASB1	-0.41	-7.87	-0.3	1.55e-14	Multiple system atrophy;
BRCA	cis	rs758324	0.947	rs683749	chr5:131283376	C/T	cg06307176	chr5:131281290	NA	-0.54	-10.46	-0.38	9.42e-24	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg00071950	chr4:10020882	SLC2A9	0.57	14.04	0.49	3.22e-39	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg14863265	chr7:2801509	GNA12	-0.46	-9.76	-0.36	4.45e-21	Height;
BRCA	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.94	0.58	1.43e-58	Fuchs's corneal dystrophy;
BRCA	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg05340658	chr4:99064831	C4orf37	0.5	11.62	0.42	1.81e-28	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg13010199	chr12:38710504	ALG10B	0.44	9.62	0.36	1.45e-20	Morning vs. evening chronotype;
BRCA	cis	rs7918232	0.662	rs10741125	chr10:27288925	G/A	cg14442939	chr10:27389572	ANKRD26	0.52	8.96	0.33	3.52e-18	Breast cancer;
BRCA	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.75	16.18	0.54	1.29e-49	Total cholesterol levels;
BRCA	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg13319975	chr6:146136371	FBXO30	-0.4	-9.21	-0.34	4.7e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	ch.11.42038R	chr11:967971	AP2A2	0.52	16.66	0.55	5.33e-52	Alzheimer's disease (late onset);
BRCA	trans	rs8073060	0.586	rs225286	chr17:33930458	G/A	cg19694781	chr19:47549865	TMEM160	-1.06	-21.28	-0.64	2.4e-76	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg08888203	chr3:10149979	C3orf24	0.67	14.07	0.49	2.26e-39	Alzheimer's disease;
BRCA	cis	rs7131987	0.650	rs4331146	chr12:29440083	G/T	cg09582351	chr12:29534625	ERGIC2	-0.46	-10.62	-0.39	2.23e-24	QT interval;
BRCA	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg13628971	chr7:2884303	GNA12	0.42	9.66	0.36	1.06e-20	Height;
BRCA	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg26116260	chr4:7069785	GRPEL1	0.82	17.47	0.57	3.85e-56	Monocyte percentage of white cells;
BRCA	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11764359	chr7:65958608	NA	0.8	19.2	0.6	3.43e-65	Aortic root size;
BRCA	cis	rs4363385	0.720	rs1415967	chr1:152965585	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-9.37	-0.35	1.23e-19	Inflammatory skin disease;
BRCA	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.53	-11.47	-0.41	7.68e-28	Menarche (age at onset);
BRCA	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg03433033	chr1:76189801	ACADM	-0.77	-17.67	-0.57	3.38e-57	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24531977	chr5:56204891	C5orf35	0.72	15.75	0.53	1.83e-47	Initial pursuit acceleration;
BRCA	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.38	0.49	8.02e-41	Motion sickness;
BRCA	cis	rs758324	0.741	rs10075660	chr5:131240843	C/A	cg06307176	chr5:131281290	NA	-0.49	-9.56	-0.35	2.52e-20	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs877282	0.898	rs36064821	chr10:760952	C/T	cg17470449	chr10:769945	NA	0.47	8.0	0.3	5.93e-15	Uric acid levels;
BRCA	cis	rs4800452	0.549	rs9947743	chr18:20708321	G/A	cg26136497	chr18:20735537	CABLES1	-0.41	-9.35	-0.35	1.48e-19	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
BRCA	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg12386194	chr3:101231763	SENP7	0.47	9.87	0.36	1.82e-21	Colorectal cancer;
BRCA	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg10518572	chr11:65560635	OVOL1	-0.3	-8.34	-0.31	4.5e-16	Acne (severe);
BRCA	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.61	-13.68	-0.48	1.51e-37	Platelet count;
BRCA	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg18811423	chr2:55921094	PNPT1	0.77	26.48	0.72	7.31e-105	Metabolic syndrome;
BRCA	cis	rs7512552	0.803	rs2454286	chr1:150355538	G/A	cg15654264	chr1:150340011	RPRD2	0.38	8.37	0.31	3.61e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg18512352	chr11:47633146	NA	-0.33	-8.0	-0.3	5.8e-15	Subjective well-being;
BRCA	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg26838691	chr2:24397539	C2orf84	-0.39	-8.01	-0.3	5.27e-15	Asthma;
BRCA	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-14.84	-0.51	4.81e-43	Height;
BRCA	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg05340658	chr4:99064831	C4orf37	0.59	12.11	0.43	1.63e-30	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6820391	0.962	rs2280119	chr4:54415438	C/T	cg04173182	chr4:54446035	LNX1	0.4	8.17	0.31	1.63e-15	Cervical artery dissection;
BRCA	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-18.16	-0.58	1.03e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.6	-0.32	6e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg22491629	chr6:157744540	C6orf35	0.61	12.0	0.43	4.64e-30	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg00814883	chr7:100076585	TSC22D4	-0.52	-11.78	-0.42	3.88e-29	Platelet count;
BRCA	cis	rs9381107	0.505	rs9394957	chr6:9484928	C/G	cg14735645	chr6:9486422	NA	-0.45	-8.7	-0.33	2.75e-17	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg20283391	chr11:68216788	NA	-0.39	-7.88	-0.3	1.45e-14	Total body bone mineral density;
BRCA	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg22705602	chr4:152727874	NA	-0.33	-8.24	-0.31	9.6e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg20503657	chr10:835505	NA	0.96	14.32	0.49	1.6e-40	Eosinophil percentage of granulocytes;
BRCA	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg15017067	chr4:17643749	FAM184B	-0.27	-8.05	-0.3	4.09e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg02659138	chr7:134003124	SLC35B4	0.34	10.67	0.39	1.46e-24	Mean platelet volume;
BRCA	cis	rs10465746	0.780	rs6703493	chr1:84435812	G/A	cg10977910	chr1:84465055	TTLL7	0.56	11.72	0.42	7.17e-29	Obesity-related traits;
BRCA	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.96	0.58	1.14e-58	Fuchs's corneal dystrophy;
BRCA	trans	rs1459104	0.636	rs559362	chr11:55275456	T/G	cg15704280	chr7:45808275	SEPT13	0.55	8.58	0.32	7.34e-17	Body mass index;
BRCA	cis	rs13064411	0.696	rs9814395	chr3:113188885	C/T	cg18753928	chr3:113234510	CCDC52	-0.53	-11.1	-0.4	2.69e-26	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg19077165	chr18:44547161	KATNAL2	-0.58	-12.77	-0.45	1.94e-33	Personality dimensions;
BRCA	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg13852791	chr20:30311386	BCL2L1	0.84	16.43	0.55	7.17e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.46	12.48	0.44	3.76e-32	Response to antipsychotic treatment;
BRCA	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-12.07	-0.43	2.23e-30	Gut microbiome composition (summer);
BRCA	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg27366882	chr3:133540807	NA	-0.32	-8.01	-0.3	5.51e-15	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.72	11.59	0.42	2.59e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs6964833	0.935	rs34762099	chr7:74050694	T/C	cg07504079	chr7:72649617	NCF1B	-0.45	-8.65	-0.32	4.27e-17	Menarche (age at onset);
BRCA	cis	rs2288073	0.801	rs6757275	chr2:24375230	A/G	cg26838691	chr2:24397539	C2orf84	-0.43	-8.03	-0.3	4.72e-15	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg13334819	chr7:99746414	C7orf59	-0.43	-10.05	-0.37	3.76e-22	Coronary artery disease;
BRCA	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg23533926	chr12:111358616	MYL2	-0.42	-8.77	-0.33	1.62e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg01475377	chr6:109611718	NA	-0.6	-16.64	-0.55	6.5e-52	Reticulocyte fraction of red cells;
BRCA	trans	rs7916697	0.520	rs10762201	chr10:70040111	A/G	cg04882175	chr6:131122610	NA	0.32	8.1	0.31	2.69e-15	Optic disc area;
BRCA	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg01028140	chr2:1542097	TPO	-0.58	-11.82	-0.42	2.63e-29	IgG glycosylation;
BRCA	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg26384229	chr12:38710491	ALG10B	0.68	14.05	0.49	2.73e-39	Morning vs. evening chronotype;
BRCA	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg20701182	chr2:24300061	SF3B14	0.54	8.42	0.32	2.55e-16	Lymphocyte counts;
BRCA	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18876405	chr7:65276391	NA	-0.51	-11.52	-0.41	4.75e-28	Aortic root size;
BRCA	cis	rs4853036	0.951	rs10185266	chr2:70152407	C/G	cg02498382	chr2:70120550	SNRNP27	-0.52	-10.11	-0.37	2.21e-22	Colorectal or endometrial cancer;
BRCA	trans	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg23762105	chr12:34175262	ALG10	0.37	8.59	0.32	6.66e-17	Morning vs. evening chronotype;
BRCA	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.84	-0.33	9.18e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02176678	chr2:219576539	TTLL4	0.46	11.92	0.43	9.84e-30	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7809950	0.862	rs12112877	chr7:106941324	T/C	cg23024343	chr7:107201750	COG5	-0.38	-8.51	-0.32	1.26e-16	Coronary artery disease;
BRCA	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg04756594	chr16:24857601	SLC5A11	-0.46	-9.22	-0.34	4.1e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg27170947	chr2:26402098	FAM59B	-0.67	-10.89	-0.4	1.81e-25	Gut microbiome composition (summer);
BRCA	cis	rs4363385	0.747	rs6670614	chr1:152964338	A/G	cg25856811	chr1:152973957	SPRR3	-0.35	-9.64	-0.36	1.27e-20	Inflammatory skin disease;
BRCA	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg05519781	chr21:40033154	ERG	0.46	9.83	0.36	2.38e-21	Coronary artery disease;
BRCA	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-12.6	-0.45	1.13e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg23950597	chr19:37808831	NA	-0.61	-10.78	-0.39	5.21e-25	Coronary artery calcification;
BRCA	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg08000102	chr2:233561755	GIGYF2	-0.46	-9.79	-0.36	3.47e-21	Coronary artery disease;
BRCA	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg27102117	chr16:15229624	NA	0.42	10.05	0.37	3.72e-22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg07395648	chr5:131743802	NA	-0.38	-8.29	-0.31	6.7e-16	Breast cancer;
BRCA	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	0.52	13.7	0.48	1.24e-37	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-14.95	-0.51	1.48e-43	Dental caries;
BRCA	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg08508325	chr11:3079039	CARS	-0.45	-16.2	-0.54	1.06e-49	Longevity;
BRCA	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg12311346	chr5:56204834	C5orf35	-0.75	-14.76	-0.5	1.21e-42	Initial pursuit acceleration;
BRCA	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg08132940	chr7:1081526	C7orf50	-0.47	-8.4	-0.32	2.97e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg18225595	chr11:63971243	STIP1	0.5	9.27	0.34	2.72e-19	Attention deficit hyperactivity disorder;
BRCA	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	18.92	0.6	9.45e-64	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs28735056	0.933	rs72980085	chr18:77631679	A/C	cg20368463	chr18:77673604	PQLC1	-0.34	-8.0	-0.3	5.75e-15	Schizophrenia;
BRCA	cis	rs698813	0.637	rs7579841	chr2:44498887	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	7.96	0.3	8.16e-15	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg16850897	chr7:100343110	ZAN	-0.58	-12.25	-0.44	3.98e-31	Other erythrocyte phenotypes;
BRCA	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg11846333	chr4:119757529	SEC24D	0.61	7.97	0.3	7.34e-15	Cannabis dependence symptom count;
BRCA	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	22.37	0.66	2.62e-82	Chronic sinus infection;
BRCA	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg12564285	chr5:131593104	PDLIM4	0.32	7.96	0.3	8.12e-15	Blood metabolite levels;
BRCA	trans	rs9951602	0.512	rs12458828	chr18:76648522	C/T	cg02800362	chr5:177631904	HNRNPAB	-0.8	-18.73	-0.6	1.02e-62	Obesity-related traits;
BRCA	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg08085267	chr17:45401833	C17orf57	0.6	12.31	0.44	2.05e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7301826	0.610	rs36051740	chr12:131292722	G/A	cg11011512	chr12:131303247	STX2	-0.47	-12.01	-0.43	4.3e-30	Plasma plasminogen activator levels;
BRCA	trans	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg19862616	chr7:65841803	NCRNA00174	0.83	27.56	0.74	8.71e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.51	-10.17	-0.37	1.3e-22	Body mass index;
BRCA	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg19077165	chr18:44547161	KATNAL2	-0.64	-14.85	-0.51	4.42e-43	Personality dimensions;
BRCA	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-10.38	-0.38	1.97e-23	Neuroticism;
BRCA	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.32	0.38	3.48e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs400736	0.930	rs2745722	chr1:8056669	G/A	cg25007680	chr1:8021821	PARK7	0.48	12.03	0.43	3.34e-30	Response to antidepressants and depression;
BRCA	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.37	9.01	0.34	2.35e-18	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg03709012	chr19:19516395	GATAD2A	1.08	20.88	0.64	3.37e-74	Nonalcoholic fatty liver disease;
BRCA	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg03213289	chr20:61660250	NA	0.61	16.24	0.54	6.67e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg13319975	chr6:146136371	FBXO30	-0.35	-8.12	-0.31	2.36e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7301826	1.000	rs4759793	chr12:131297238	A/G	cg11011512	chr12:131303247	STX2	0.42	10.88	0.4	2.08e-25	Plasma plasminogen activator levels;
BRCA	cis	rs10465746	0.747	rs34155960	chr1:84447539	T/G	cg10977910	chr1:84465055	TTLL7	0.57	11.98	0.43	5.4e-30	Obesity-related traits;
BRCA	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg20476274	chr7:133979776	SLC35B4	-0.65	-18.58	-0.59	6.06e-62	Mean platelet volume;
BRCA	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg11693508	chr17:37793320	STARD3	0.71	13.47	0.47	1.44e-36	Bipolar disorder;
BRCA	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg03060546	chr3:49711283	APEH	0.6	10.38	0.38	1.97e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.49	-0.38	7.21e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2882667	0.931	rs10074461	chr5:138319815	G/T	cg04439458	chr5:138467593	SIL1	-0.35	-9.84	-0.36	2.29e-21	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg16414030	chr3:133502952	NA	0.54	13.02	0.46	1.58e-34	Iron status biomarkers;
BRCA	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg21775007	chr8:11205619	TDH	-0.39	-8.05	-0.3	4.11e-15	Neuroticism;
BRCA	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg00814883	chr7:100076585	TSC22D4	-0.55	-11.85	-0.42	2.08e-29	Platelet count;
BRCA	cis	rs59698941	0.527	rs7719428	chr5:132180919	C/G	cg14825688	chr5:132208181	LEAP2	0.35	8.08	0.3	3.14e-15	Apolipoprotein A-IV levels;
BRCA	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg25554036	chr4:6271136	WFS1	0.41	9.72	0.36	6.57e-21	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	8.97	0.33	3.36e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg11502198	chr6:26597334	ABT1	0.56	12.03	0.43	3.53e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs2066819	1.000	rs77853814	chr12:56687572	G/T	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18357526	chr6:26021779	HIST1H4A	0.51	9.49	0.35	4.57e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg23029597	chr12:123009494	RSRC2	-0.61	-11.81	-0.42	3e-29	Body mass index;
BRCA	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.48	0.35	4.92e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs2901460	0.509	rs12463815	chr2:62087165	C/T	cg02183531	chr2:62113199	CCT4	-0.45	-8.81	-0.33	1.18e-17	Mean corpuscular volume;
BRCA	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg24829409	chr8:58192753	C8orf71	-0.5	-8.19	-0.31	1.41e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg26384229	chr12:38710491	ALG10B	0.82	21.62	0.65	3.19e-78	Heart rate;
BRCA	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11644478	chr21:40555479	PSMG1	-0.68	-14.54	-0.5	1.39e-41	Cognitive function;
BRCA	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg21960279	chr19:17905606	B3GNT3	0.5	11.37	0.41	2.12e-27	Tumor biomarkers;
BRCA	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-7.88	-0.3	1.47e-14	Colorectal cancer;
BRCA	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-19.76	-0.62	3.46e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs7715806	0.500	rs72633986	chr5:75006449	T/A	cg19683494	chr5:74908142	NA	0.5	8.1	0.31	2.81e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs332507	0.830	rs4678144	chr3:124404399	C/T	cg05980111	chr3:124395277	KALRN	-0.37	-8.66	-0.32	3.73e-17	Plateletcrit;
BRCA	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.43	-10.35	-0.38	2.64e-23	Longevity;Endometriosis;
BRCA	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg17143192	chr8:8559678	CLDN23	0.56	10.8	0.39	4.26e-25	Obesity-related traits;
BRCA	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg09035930	chr12:129282057	SLC15A4	0.5	13.99	0.48	5.46e-39	Systemic lupus erythematosus;
BRCA	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg24562669	chr7:97807699	LMTK2	0.67	19.95	0.62	3.52e-69	Breast cancer;
BRCA	cis	rs11608355	0.515	rs7310945	chr12:109946012	G/A	cg05360138	chr12:110035743	NA	0.74	13.68	0.48	1.56e-37	Neuroticism;
BRCA	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11644478	chr21:40555479	PSMG1	0.83	18.88	0.6	1.63e-63	Cognitive function;
BRCA	cis	rs6700896	0.931	rs1938497	chr1:66100450	G/A	cg04111102	chr1:66153794	NA	0.33	8.23	0.31	1.09e-15	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs17095355	1.000	rs958086	chr10:111752548	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.4	-9.98	-0.37	6.53e-22	Biliary atresia;
BRCA	trans	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg25214090	chr10:38739885	LOC399744	0.54	12.24	0.44	4.06e-31	Corneal astigmatism;
BRCA	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.13	-0.37	1.77e-22	Aortic root size;
BRCA	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18357526	chr6:26021779	HIST1H4A	0.47	8.65	0.32	4.1e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs3857067	0.806	rs6532472	chr4:95110113	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.49	-0.35	4.67e-20	QT interval;
BRCA	cis	rs9986765	1.000	rs28672333	chr7:142826798	G/A	cg15652212	chr7:142981776	TMEM139	0.56	9.28	0.34	2.65e-19	Cancer;Dermatomyositis;
BRCA	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.34	-0.49	1.29e-40	Chronic sinus infection;
BRCA	trans	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg05926928	chr17:57297772	GDPD1	0.4	7.93	0.3	9.53e-15	Schizophrenia;
BRCA	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg15704280	chr7:45808275	SEPT13	-0.97	-27.88	-0.74	1.63e-112	Height;
BRCA	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.32	-0.38	3.3e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2625529	0.617	rs8025939	chr15:72460339	T/A	cg16672083	chr15:72433130	SENP8	0.66	16.15	0.54	1.76e-49	Red blood cell count;
BRCA	cis	rs10751667	0.677	rs11246386	chr11:1044938	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.38	-8.79	-0.33	1.33e-17	Alzheimer's disease (late onset);
BRCA	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg07741184	chr6:167504864	NA	0.33	9.88	0.36	1.64e-21	Primary biliary cholangitis;
BRCA	cis	rs2070997	0.667	rs7851946	chr9:133719256	A/T	cg11464064	chr9:133710261	ABL1	-0.48	-8.79	-0.33	1.38e-17	Response to amphetamines;
BRCA	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg04586622	chr2:25135609	ADCY3	0.46	11.84	0.42	2.3e-29	Body mass index in non-asthmatics;
BRCA	cis	rs9463078	0.845	rs9369514	chr6:44797271	C/A	cg25276700	chr6:44698697	NA	-0.37	-8.45	-0.32	1.94e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs4790333	0.967	rs2002863	chr17:2269769	C/T	cg02569219	chr17:2266849	SGSM2	0.45	10.92	0.4	1.46e-25	Proinsulin levels;
BRCA	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg26384229	chr12:38710491	ALG10B	0.85	22.93	0.67	2.44e-85	Heart rate;
BRCA	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg09307838	chr4:120376055	NA	0.69	14.25	0.49	3.17e-40	Corneal astigmatism;
BRCA	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg03929089	chr4:120376271	NA	-0.47	-9.04	-0.34	1.9e-18	HDL cholesterol;
BRCA	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg08885076	chr2:99613938	TSGA10	-0.6	-13.12	-0.46	5.45e-35	Chronic sinus infection;
BRCA	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg05343316	chr1:45956843	TESK2	0.71	14.38	0.49	8.1e-41	Platelet count;
BRCA	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21659725	chr3:3221576	CRBN	-0.45	-9.94	-0.37	9.89e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.48	-10.24	-0.38	6.82e-23	Mean corpuscular volume;
BRCA	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg03146154	chr1:46216737	IPP	0.48	10.49	0.38	7.03e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg19784903	chr17:45786737	TBKBP1	0.34	8.26	0.31	8.68e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg03474202	chr17:45855739	NA	0.45	11.82	0.42	2.77e-29	IgG glycosylation;
BRCA	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg17063962	chr7:91808500	NA	-0.55	-12.32	-0.44	1.88e-31	Breast cancer;
BRCA	cis	rs4363385	0.747	rs1577962	chr1:152962013	A/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.8	-0.33	1.3e-17	Inflammatory skin disease;
BRCA	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg08917208	chr2:24149416	ATAD2B	1.11	15.76	0.53	1.69e-47	Lymphocyte counts;
BRCA	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg18016565	chr1:150552671	MCL1	0.36	8.13	0.31	2.2e-15	Melanoma;
BRCA	cis	rs4919694	0.611	rs75182663	chr10:105058104	A/G	cg04362960	chr10:104952993	NT5C2	0.72	11.19	0.4	1.14e-26	Arsenic metabolism;
BRCA	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg08885076	chr2:99613938	TSGA10	0.45	10.61	0.39	2.51e-24	Chronic sinus infection;
BRCA	cis	rs1003719	0.788	rs9981226	chr21:38452127	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.25	0.49	3.23e-40	Eye color traits;
BRCA	trans	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg01620082	chr3:125678407	NA	-0.66	-8.19	-0.31	1.43e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs35740288	0.929	rs11630684	chr15:86306256	C/A	cg20737812	chr15:86336631	KLHL25	-0.32	-7.95	-0.3	8.56e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg24044776	chr19:53454761	ZNF816A	-0.41	-9.29	-0.35	2.31e-19	Psoriasis;
BRCA	cis	rs10754283	0.967	rs10737706	chr1:90112579	G/T	cg21401794	chr1:90099060	LRRC8C	0.48	11.55	0.42	3.59e-28	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs4363385	0.550	rs2050673	chr1:152923698	C/T	cg21543102	chr1:152974771	SPRR3	-0.28	-7.85	-0.3	1.79e-14	Inflammatory skin disease;
BRCA	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg08645402	chr16:4508243	NA	0.37	8.77	0.33	1.65e-17	Schizophrenia;
BRCA	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg13319975	chr6:146136371	FBXO30	-0.35	-8.11	-0.31	2.52e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-8.0	-0.3	5.88e-15	Coronary artery disease;
BRCA	cis	rs11112613	0.775	rs10778413	chr12:105962118	G/A	cg03607813	chr12:105948248	NA	0.59	10.29	0.38	4.31e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg13010199	chr12:38710504	ALG10B	0.42	8.81	0.33	1.16e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg04518342	chr5:131593106	PDLIM4	-0.38	-9.13	-0.34	8.91e-19	Acylcarnitine levels;
BRCA	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	9.4	0.35	9.32e-20	Renal function-related traits (BUN);
BRCA	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	13.87	0.48	2e-38	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.58e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg16576597	chr16:28551801	NUPR1	0.29	8.27	0.31	7.65e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg01236616	chr12:121019343	POP5	1.24	27.02	0.73	8.09e-108	Type 1 diabetes nephropathy;
BRCA	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg11812906	chr14:75593930	NEK9	-0.58	-13.02	-0.46	1.49e-34	Height;
BRCA	cis	rs12431939	1.000	rs56220306	chr14:51648738	A/T	cg23942311	chr14:51606299	NA	-0.42	-7.95	-0.3	8.27e-15	Cancer;
BRCA	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg04586622	chr2:25135609	ADCY3	0.47	11.94	0.43	8.18e-30	Body mass index;
BRCA	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg21782813	chr7:2030301	MAD1L1	0.32	8.52	0.32	1.18e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg18132916	chr6:79620363	NA	-0.49	-10.98	-0.4	8.25e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg03954927	chr1:10346856	KIF1B	-0.42	-13.67	-0.48	1.65e-37	Hepatocellular carcinoma;
BRCA	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.05	-0.3	4.13e-15	Prostate cancer;
BRCA	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg20387954	chr3:183756860	HTR3D	0.45	10.11	0.37	2.26e-22	Anterior chamber depth;
BRCA	cis	rs2230307	0.656	rs12145880	chr1:100446008	C/G	cg24955406	chr1:100503596	HIAT1	0.54	9.38	0.35	1.18e-19	Carotid intima media thickness;
BRCA	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-18.23	-0.58	4.15e-60	Morning vs. evening chronotype;
BRCA	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg11764359	chr7:65958608	NA	0.62	11.22	0.41	8.61e-27	Aortic root size;
BRCA	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg18850127	chr7:39170497	POU6F2	0.55	11.48	0.41	7.05e-28	IgG glycosylation;
BRCA	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg01802117	chr1:53393560	SCP2	0.36	8.33	0.31	5.04e-16	Monocyte count;
BRCA	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg23711669	chr6:146136114	FBXO30	-0.72	-17.33	-0.57	1.9e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	15.43	0.52	6.96e-46	Colorectal cancer;
BRCA	cis	rs12950390	0.512	rs11655306	chr17:45858744	C/T	cg03474202	chr17:45855739	NA	-0.45	-8.24	-0.31	9.58e-16	IgG glycosylation;
BRCA	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.58	13.19	0.46	2.64e-35	Hemoglobin concentration;
BRCA	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	8.02e-19	Lymphocyte counts;
BRCA	cis	rs10782582	0.586	rs12130324	chr1:76370012	A/G	cg03433033	chr1:76189801	ACADM	-0.39	-7.98	-0.3	6.58e-15	Daytime sleep phenotypes;
BRCA	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-9.89	-0.36	1.48e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg00701064	chr4:6280414	WFS1	0.69	19.04	0.6	2.21e-64	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs28735056	1.000	rs59183289	chr18:77631198	A/G	cg03682112	chr18:77623598	KCNG2	-0.38	-8.74	-0.33	1.98e-17	Schizophrenia;
BRCA	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg27165867	chr14:105738592	BRF1	-0.36	-8.76	-0.33	1.77e-17	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs9463078	0.774	rs9369558	chr6:45274021	A/C	cg25276700	chr6:44698697	NA	-0.35	-8.06	-0.3	3.7e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.17	-0.43	8.86e-31	Total cholesterol levels;
BRCA	cis	rs58235267	0.591	rs2162014	chr2:63345507	C/A	cg17519650	chr2:63277830	OTX1	0.37	7.81	0.3	2.32e-14	Prostate-specific antigen levels (conditioned on lead SNPs);
BRCA	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg01475377	chr6:109611718	NA	-0.58	-15.92	-0.53	2.61e-48	Reticulocyte fraction of red cells;
BRCA	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg11125805	chr5:150678162	SLC36A3	0.73	19.65	0.61	1.34e-67	Skin aging (microtopography measurement);
BRCA	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg01262667	chr19:19385393	TM6SF2	0.38	9.77	0.36	4.29e-21	Tonsillectomy;
BRCA	cis	rs701145	0.585	rs921318	chr3:153856775	T/G	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.82e-18	Coronary artery disease;
BRCA	trans	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg25214090	chr10:38739885	LOC399744	0.54	12.59	0.45	1.29e-32	Corneal astigmatism;
BRCA	cis	rs17095355	1.000	rs11194920	chr10:111695412	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.38	-9.89	-0.36	1.48e-21	Biliary atresia;
BRCA	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.43	0.35	7.76e-20	Tonsillectomy;
BRCA	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg04362960	chr10:104952993	NT5C2	0.44	10.15	0.37	1.55e-22	Arsenic metabolism;
BRCA	cis	rs2425143	1.000	rs1970357	chr20:34339200	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	8.83	0.33	1e-17	Blood protein levels;
BRCA	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.68	0.57	3.2e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg06521331	chr12:34319734	NA	-0.51	-10.02	-0.37	4.68e-22	Morning vs. evening chronotype;
BRCA	cis	rs7267979	0.816	rs443009	chr20:25499817	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.28	-7.96	-0.3	8.15e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.69	0.39	1.24e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.95	0.4	1.13e-25	Iron status biomarkers;
BRCA	cis	rs4285028	0.747	rs1128163	chr3:121350573	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.69	-13.47	-0.47	1.45e-36	Multiple sclerosis;
BRCA	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg14675211	chr2:100938903	LONRF2	0.51	11.68	0.42	1.07e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.59	11.41	0.41	1.37e-27	HDL cholesterol;
BRCA	trans	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg09719594	chr16:21412588	NA	-0.35	-7.97	-0.3	7.23e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg23978390	chr7:1156363	C7orf50	0.39	7.99	0.3	6.46e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05901451	chr6:126070800	HEY2	0.57	15.02	0.51	6.99e-44	Brugada syndrome;
BRCA	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.23	0.56	6.19e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg08975724	chr8:8085496	FLJ10661	0.52	11.18	0.4	1.21e-26	Mood instability;
BRCA	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.68	0.61	9.04e-68	Alzheimer's disease;
BRCA	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	11.78	0.42	4.16e-29	Systemic lupus erythematosus;
BRCA	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg03433033	chr1:76189801	ACADM	0.75	17.23	0.56	6.46e-55	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs3741151	0.773	rs73544720	chr11:73173496	A/G	cg17517138	chr11:73019481	ARHGEF17	0.87	12.39	0.44	9.72e-32	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-10.0	-0.37	5.91e-22	Bladder cancer;
BRCA	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg02659138	chr7:134003124	SLC35B4	0.34	10.77	0.39	5.91e-25	Mean platelet volume;
BRCA	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg07988820	chr12:82153109	PPFIA2	-0.67	-11.22	-0.41	8.97e-27	Resting heart rate;
BRCA	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg18479299	chr3:125709523	NA	-0.54	-8.33	-0.31	4.84e-16	Blood pressure (smoking interaction);
BRCA	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26818010	chr10:134567672	INPP5A	-0.66	-14.15	-0.49	9.81e-40	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs9944715	1.000	rs4890320	chr18:43814124	T/C	cg01718231	chr17:29326311	RNF135	-0.46	-9.07	-0.34	1.51e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg12311346	chr5:56204834	C5orf35	-0.79	-15.95	-0.53	1.96e-48	Initial pursuit acceleration;
BRCA	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	cis	rs367943	0.698	rs2115208	chr5:112973994	A/G	cg12552261	chr5:112820674	MCC	0.37	7.88	0.3	1.41e-14	Type 2 diabetes;
BRCA	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg05340658	chr4:99064831	C4orf37	0.48	11.11	0.4	2.54e-26	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg19920283	chr7:105172520	RINT1	0.59	9.28	0.34	2.58e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg26647111	chr11:31128758	NA	-0.45	-9.92	-0.37	1.15e-21	Red blood cell count;
BRCA	cis	rs4664304	0.649	rs12692570	chr2:160726599	C/T	cg14819504	chr2:160761413	LY75	0.32	8.1	0.31	2.83e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.6	-0.32	6.36e-17	Glomerular filtration rate (creatinine);
BRCA	trans	rs3857536	0.707	rs9345793	chr6:66929807	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.04	-0.3	4.28e-15	Blood trace element (Cu levels);
BRCA	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	20.4	0.63	1.35e-71	Smoking behavior;
BRCA	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg18964960	chr10:1102726	WDR37	0.59	8.0	0.3	5.7e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs72772090	0.539	rs10515249	chr5:96125259	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.13	-0.43	1.28e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg22906224	chr7:99728672	NA	0.45	8.63	0.32	4.75e-17	Coronary artery disease;
BRCA	cis	rs4363385	0.714	rs4845329	chr1:152974454	G/C	cg25856811	chr1:152973957	SPRR3	-0.35	-9.3	-0.35	2.24e-19	Inflammatory skin disease;
BRCA	cis	rs9815354	1.000	rs73081364	chr3:41913616	G/C	cg03022575	chr3:42003672	ULK4	0.51	8.31	0.31	5.54e-16	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22029157	chr1:209979665	IRF6	0.53	11.96	0.43	6.96e-30	Cleft lip with or without cleft palate;
BRCA	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg13319975	chr6:146136371	FBXO30	-0.63	-14.62	-0.5	5.47e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg08807101	chr21:30365312	RNF160	-0.56	-13.35	-0.47	5.07e-36	Dental caries;
BRCA	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg17971929	chr21:40555470	PSMG1	0.81	19.6	0.61	2.36e-67	Cognitive function;
BRCA	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg20701182	chr2:24300061	SF3B14	0.71	13.18	0.46	2.82e-35	Lymphocyte counts;
BRCA	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg04546413	chr19:29218101	NA	0.49	8.36	0.31	3.87e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg12311346	chr5:56204834	C5orf35	1.01	20.24	0.62	9.81e-71	Initial pursuit acceleration;
BRCA	trans	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg25214090	chr10:38739885	LOC399744	0.53	10.82	0.39	3.7e-25	Corneal astigmatism;
BRCA	cis	rs7192750	0.583	rs8046916	chr16:72047751	C/G	cg14768367	chr16:72042858	DHODH	-0.56	-9.15	-0.34	7.26e-19	LDL cholesterol levels;Total cholesterol levels;
BRCA	cis	rs4719841	0.662	rs9639523	chr7:25991977	A/C	cg10085138	chr7:25991722	NA	0.3	8.43	0.32	2.23e-16	Triglyceride levels;
BRCA	trans	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg25214090	chr10:38739885	LOC399744	0.55	11.73	0.42	6.63e-29	Corneal astigmatism;
BRCA	cis	rs7072216	0.763	rs10883091	chr10:100167239	C/T	cg26618903	chr10:100175079	PYROXD2	-0.31	-8.9	-0.33	5.54e-18	Metabolite levels;
BRCA	cis	rs2204008	0.549	rs12312109	chr12:38228251	G/T	cg26384229	chr12:38710491	ALG10B	-0.44	-9.85	-0.36	2.09e-21	Bladder cancer;
BRCA	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg02659138	chr7:134003124	SLC35B4	0.36	10.3	0.38	4.02e-23	Mean platelet volume;
BRCA	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg06115741	chr20:33292138	TP53INP2	0.49	10.92	0.4	1.49e-25	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg27147174	chr7:100797783	AP1S1	-0.55	-11.05	-0.4	4.11e-26	Life satisfaction;
BRCA	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg14349672	chr11:133703707	NA	-0.35	-8.66	-0.32	3.72e-17	Childhood ear infection;
BRCA	cis	rs78663649	0.908	rs113779505	chr19:16527982	G/A	cg05286348	chr19:16641544	CHERP	-0.72	-9.75	-0.36	4.81e-21	White blood cell count;
BRCA	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg03060546	chr3:49711283	APEH	-0.57	-8.96	-0.33	3.6e-18	Menarche (age at onset);
BRCA	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg24112000	chr20:60950667	NA	0.47	9.93	0.37	1.08e-21	Colorectal cancer;
BRCA	trans	rs141342723	1	rs141342723	chr6:27622084	T/C	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.5	-0.32	1.31e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs13082711	0.911	rs2887926	chr3:27494475	T/C	cg02860705	chr3:27208620	NA	0.53	10.56	0.39	3.86e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24308560	chr3:49941425	MST1R	-0.4	-8.52	-0.32	1.16e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs11718455	0.960	rs13081767	chr3:44004468	T/C	cg08738300	chr3:44038990	NA	0.46	8.86	0.33	8.12e-18	Coronary artery disease;
BRCA	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08280861	chr8:58055591	NA	-0.51	-8.25	-0.31	8.82e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs9951602	0.512	rs8098115	chr18:76653986	G/T	cg02800362	chr5:177631904	HNRNPAB	0.78	18.28	0.59	2.25e-60	Obesity-related traits;
BRCA	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-9.8	-0.36	3.23e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg00745463	chr17:30367425	LRRC37B	-0.54	-8.94	-0.33	4.03e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-9.66	-0.36	1.05e-20	Fear of minor pain;
BRCA	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-9.01	-0.34	2.35e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	13.23	0.46	1.68e-35	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg20701182	chr2:24300061	SF3B14	0.67	9.77	0.36	4.33e-21	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg17366294	chr4:99064904	C4orf37	0.44	10.31	0.38	3.57e-23	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2262909	0.962	rs425781	chr19:22229306	A/G	cg17074339	chr11:11642133	GALNTL4	-0.43	-8.4	-0.32	3e-16	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13046373	0.535	rs1911571	chr21:32031538	A/C	cg06468780	chr21:31798236	KRTAP13-3	0.34	8.47	0.32	1.65e-16	HDL cholesterol;
BRCA	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg26061582	chr7:22766209	IL6	0.35	8.2	0.31	1.34e-15	Lung cancer;
BRCA	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg11752832	chr7:134001865	SLC35B4	-0.52	-12.26	-0.44	3.58e-31	Mean platelet volume;
BRCA	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg19077165	chr18:44547161	KATNAL2	-0.58	-12.83	-0.45	1.05e-33	Personality dimensions;
BRCA	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg19678392	chr7:94953810	PON1	-0.43	-8.96	-0.33	3.42e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs12347191	0.500	rs907578	chr9:100622883	A/G	cg13688889	chr9:100608707	NA	-0.48	-9.76	-0.36	4.62e-21	Orofacial clefts;
BRCA	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg12927641	chr6:109611667	NA	0.37	9.24	0.34	3.48e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg12386194	chr3:101231763	SENP7	0.46	9.7	0.36	7.62e-21	Colorectal cancer;
BRCA	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg13010199	chr12:38710504	ALG10B	0.53	11.06	0.4	4.06e-26	Heart rate;
BRCA	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg18016565	chr1:150552671	MCL1	0.35	8.41	0.32	2.67e-16	Tonsillectomy;
BRCA	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-8.98	-0.33	3.08e-18	Alzheimer's disease (late onset);
BRCA	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg05340658	chr4:99064831	C4orf37	-0.49	-11.35	-0.41	2.46e-27	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg04990556	chr1:26633338	UBXN11	0.54	8.92	0.33	4.77e-18	Obesity-related traits;
BRCA	trans	rs330048	0.545	rs11774353	chr8:9153127	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	9.98	0.37	6.59e-22	Systemic lupus erythematosus;
BRCA	cis	rs507080	0.922	rs555356	chr11:118558078	G/T	cg09144398	chr11:118550485	TREH	-0.38	-9.08	-0.34	1.37e-18	Serum metabolite levels;
BRCA	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg23711669	chr6:146136114	FBXO30	0.69	16.02	0.54	7.97e-49	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg23505145	chr19:12996616	KLF1	0.56	12.69	0.45	4.46e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12474201	0.894	rs4952842	chr2:46925730	C/A	cg06386533	chr2:46925753	SOCS5	0.91	19.72	0.62	5.41e-68	Height;
BRCA	cis	rs12893597	0.821	rs12896434	chr14:76816746	C/T	cg20290672	chr14:76816747	NA	-0.36	-7.81	-0.3	2.37e-14	Maximal oxygen uptake response;
BRCA	cis	rs16958440	0.867	rs75808931	chr18:44693042	C/T	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	trans	rs7980799	0.649	rs10772088	chr12:33663849	A/T	cg26384229	chr12:38710491	ALG10B	-0.52	-10.91	-0.4	1.6e-25	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg01448562	chr3:133502909	NA	0.61	14.41	0.5	6.03e-41	Iron status biomarkers;
BRCA	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg21138405	chr5:131827807	IRF1	0.33	10.43	0.38	1.25e-23	Breast cancer;Mosquito bite size;
BRCA	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg04691961	chr3:161091175	C3orf57	-0.64	-16.65	-0.55	5.99e-52	Morning vs. evening chronotype;
BRCA	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg20387954	chr3:183756860	HTR3D	-0.45	-10.04	-0.37	3.88e-22	Anterior chamber depth;
BRCA	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg19913688	chr11:428466	ANO9	-0.71	-10.09	-0.37	2.59e-22	Body mass index;
BRCA	trans	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	7.84	0.3	1.9e-14	Corneal astigmatism;
BRCA	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg04586622	chr2:25135609	ADCY3	0.42	10.79	0.39	4.73e-25	Body mass index in non-asthmatics;
BRCA	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg15704280	chr7:45808275	SEPT13	0.5	8.63	0.32	4.95e-17	Axial length;
BRCA	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.31	-8.3	-0.31	6.15e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.66	0.36	1.03e-20	Bladder cancer;
BRCA	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.81	-0.51	7.19e-43	Chronic sinus infection;
BRCA	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg13736514	chr6:26305472	NA	-0.35	-11.99	-0.43	4.93e-30	Educational attainment;
BRCA	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	18.98	0.6	4.56e-64	Platelet count;
BRCA	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg24069376	chr3:38537580	EXOG	0.42	11.98	0.43	5.45e-30	Electrocardiographic conduction measures;
BRCA	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21659725	chr3:3221576	CRBN	-0.47	-10.21	-0.37	9.35e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs509477	1.000	rs11660848	chr18:32574010	T/C	cg23791764	chr18:32556832	MAPRE2	-0.34	-7.88	-0.3	1.42e-14	Cerebrospinal fluid AB1-42 levels;
BRCA	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg16339924	chr4:17578868	LAP3	0.57	14.15	0.49	1e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3824867	0.920	rs7108143	chr11:47453722	T/G	cg20307385	chr11:47447363	PSMC3	-0.51	-11.51	-0.41	5.63e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs2404602	0.530	rs11072614	chr15:76967205	G/A	cg23625390	chr15:77176239	SCAPER	-0.55	-12.65	-0.45	7e-33	Blood metabolite levels;
BRCA	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.28	-0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22496380	chr5:211416	CCDC127	-1.0	-14.08	-0.49	1.99e-39	Breast cancer;
BRCA	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg14092988	chr3:52407081	DNAH1	0.33	7.87	0.3	1.51e-14	Bipolar disorder;
BRCA	cis	rs2294693	0.947	rs736793	chr6:40997919	A/T	cg14418226	chr6:40996092	UNC5CL	0.45	8.35	0.31	4.32e-16	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12667521	chr19:29218732	NA	0.42	8.32	0.31	5.22e-16	Methadone dose in opioid dependence;
BRCA	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-7.96	-0.3	8.15e-15	Total body bone mineral density;
BRCA	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg00277334	chr10:82204260	NA	-0.48	-8.09	-0.3	2.93e-15	Post bronchodilator FEV1;
BRCA	cis	rs7640424	0.618	rs35798995	chr3:107914313	G/A	cg09227934	chr3:107805635	CD47	-0.38	-7.88	-0.3	1.39e-14	Body mass index;
BRCA	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg15557168	chr22:42548783	NA	-0.31	-8.58	-0.32	7.15e-17	Cognitive function;
BRCA	cis	rs4478858	0.735	rs6676682	chr1:31809816	C/T	cg00250761	chr1:31883323	NA	-0.33	-8.54	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00166722	chr3:10149974	C3orf24	0.65	13.07	0.46	8.76e-35	Alzheimer's disease;
BRCA	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08219700	chr8:58056026	NA	0.45	8.32	0.31	5.3e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg18811423	chr2:55921094	PNPT1	0.78	26.56	0.72	2.64e-105	Metabolic syndrome;
BRCA	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg08888203	chr3:10149979	C3orf24	0.67	14.48	0.5	2.56e-41	Alzheimer's disease;
BRCA	cis	rs3784262	1.000	rs7165247	chr15:58251786	C/T	cg12031962	chr15:58353849	ALDH1A2	0.47	12.89	0.45	5.8e-34	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg23358479	chr7:1110784	C7orf50	-0.49	-8.2	-0.31	1.27e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10046574	0.831	rs17403220	chr7:135191705	A/G	cg27474649	chr7:135195673	CNOT4	0.63	9.16	0.34	7.22e-19	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9462846	1.000	rs9471942	chr6:42861532	C/T	cg02353165	chr6:42928485	GNMT	0.48	8.61	0.32	5.61e-17	Blood protein levels;
BRCA	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.12	-0.37	1.97e-22	IgG glycosylation;
BRCA	cis	rs208520	0.802	rs208516	chr6:66946119	T/C	cg07460842	chr6:66804631	NA	-0.89	-15.83	-0.53	7.13e-48	Exhaled nitric oxide output;
BRCA	cis	rs6138458	1.000	rs227629	chr20:24913551	G/T	cg26195577	chr20:24973756	C20orf3	0.98	24.67	0.7	6.47e-95	Blood protein levels;
BRCA	cis	rs1691799	0.863	rs1168291	chr12:66732488	T/C	cg16791601	chr12:66731901	HELB	-0.65	-17.57	-0.57	1.16e-56	White blood cell count (basophil);
BRCA	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg22431228	chr1:16359049	CLCNKA	-0.5	-11.1	-0.4	2.65e-26	Systolic blood pressure;
BRCA	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	8.22	0.31	1.18e-15	Personality dimensions;
BRCA	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg05925327	chr15:68127851	NA	-0.44	-9.48	-0.35	4.78e-20	Restless legs syndrome;
BRCA	cis	rs9815354	0.812	rs17284313	chr3:41986787	G/T	cg03022575	chr3:42003672	ULK4	-0.69	-9.69	-0.36	8.4e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7011049	1.000	rs72640863	chr8:53841706	A/T	cg26025543	chr8:53854495	NA	0.55	9.64	0.36	1.29e-20	Systolic blood pressure;
BRCA	cis	rs13394619	1.000	rs2358040	chr2:11731774	G/T	cg07314298	chr2:11723111	GREB1	0.53	12.09	0.43	1.93e-30	Endometriosis;
BRCA	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg03354898	chr7:1950403	MAD1L1	-0.48	-9.48	-0.35	4.89e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg26384229	chr12:38710491	ALG10B	-0.43	-9.98	-0.37	6.74e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg13902645	chr11:5959945	NA	-0.54	-10.85	-0.39	2.78e-25	DNA methylation (variation);
BRCA	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	16.12	0.54	2.62e-49	Platelet count;
BRCA	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg19748678	chr4:122722346	EXOSC9	0.69	14.05	0.49	3e-39	Type 2 diabetes;
BRCA	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg08017756	chr2:100939284	LONRF2	-0.32	-8.23	-0.31	1.02e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-22.33	-0.66	4.66e-82	Height;
BRCA	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00149659	chr3:10157352	C3orf10	0.79	13.71	0.48	1.05e-37	Alzheimer's disease;
BRCA	cis	rs6867032	0.527	rs13153217	chr5:2012788	G/T	cg26168224	chr5:2018326	NA	-0.39	-10.6	-0.39	2.77e-24	Gut microbiome composition (winter);
BRCA	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg11062466	chr8:58055876	NA	0.54	9.08	0.34	1.34e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg22713356	chr15:30763199	NA	1.36	27.11	0.73	2.72e-108	Uric acid levels;
BRCA	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg20203395	chr5:56204925	C5orf35	-0.36	-8.17	-0.31	1.68e-15	Coronary artery disease;
BRCA	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg02772935	chr3:125709198	NA	-0.47	-7.96	-0.3	7.6e-15	Blood pressure (smoking interaction);
BRCA	cis	rs2625529	0.824	rs12439900	chr15:72373640	A/G	cg16672083	chr15:72433130	SENP8	-0.84	-17.86	-0.58	3.45e-58	Red blood cell count;
BRCA	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15369054	chr17:80825471	TBCD	0.57	12.96	0.46	2.8e-34	Breast cancer;
BRCA	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg20891283	chr12:69753455	YEATS4	0.73	21.96	0.66	4.86e-80	Blood protein levels;
BRCA	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg20469991	chr17:27169893	C17orf63	-0.45	-8.77	-0.33	1.66e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs3806843	0.762	rs3756337	chr5:140186438	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.39	-8.57	-0.32	7.85e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg24110177	chr3:50126178	RBM5	-0.37	-10.04	-0.37	3.92e-22	Intelligence (multi-trait analysis);
BRCA	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg26384229	chr12:38710491	ALG10B	-0.66	-13.92	-0.48	1.19e-38	Morning vs. evening chronotype;
BRCA	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-9.44	-0.35	7.1e-20	Menopause (age at onset);
BRCA	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg01819863	chr10:32635814	EPC1	1.16	20.46	0.63	6.39e-72	Sexual dysfunction (female);
BRCA	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg26031613	chr14:104095156	KLC1	-0.43	-8.5	-0.32	1.29e-16	Schizophrenia;
BRCA	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg22153463	chr1:85462885	MCOLN2	-0.57	-10.2	-0.37	1.01e-22	Serum sulfate level;
BRCA	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.71	9.93	0.37	1.09e-21	Initial pursuit acceleration;
BRCA	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg04374321	chr14:90722782	PSMC1	0.72	18.48	0.59	2.03e-61	Mortality in heart failure;
BRCA	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.07	-0.43	2.37e-30	Response to antipsychotic treatment;
BRCA	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg01689657	chr7:91764605	CYP51A1	-0.22	-7.96	-0.3	7.92e-15	Breast cancer;
BRCA	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg19678392	chr7:94953810	PON1	-0.43	-9.18	-0.34	5.82e-19	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg04998671	chr14:104000505	TRMT61A	0.44	9.73	0.36	5.95e-21	Coronary artery disease;
BRCA	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg20933634	chr6:27740509	NA	0.47	9.34	0.35	1.64e-19	Parkinson's disease;
BRCA	cis	rs6684514	1.000	rs12023704	chr1:156294149	C/A	cg16558208	chr1:156270281	VHLL	0.36	8.16	0.31	1.78e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.24	-7.94	-0.3	9.04e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2274273	0.840	rs6573020	chr14:55871452	C/T	cg04306507	chr14:55594613	LGALS3	0.29	8.37	0.31	3.68e-16	Protein biomarker;
BRCA	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg03709012	chr19:19516395	GATAD2A	1.06	19.7	0.61	7.64e-68	Nonalcoholic fatty liver disease;
BRCA	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg27170947	chr2:26402098	FAM59B	0.92	16.89	0.56	3.63e-53	Gut microbiome composition (summer);
BRCA	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.87	0.56	4.51e-53	Colorectal cancer;
BRCA	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00166722	chr3:10149974	C3orf24	-0.61	-12.36	-0.44	1.32e-31	Alzheimer's disease;
BRCA	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg04414720	chr1:150670196	GOLPH3L	0.35	7.94	0.3	9.29e-15	Tonsillectomy;
BRCA	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-13.7	-0.48	1.27e-37	Total cholesterol levels;
BRCA	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg04455712	chr21:45112962	RRP1B	0.43	10.91	0.4	1.61e-25	Mean corpuscular volume;
BRCA	cis	rs34779708	0.931	rs7099036	chr10:35349574	C/T	cg03585969	chr10:35415529	CREM	0.5	10.4	0.38	1.59e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4845570	0.831	rs11588258	chr1:151780728	A/T	cg07092448	chr1:151763213	TDRKH	-0.79	-13.6	-0.47	3.54e-37	Coronary artery disease;
BRCA	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-12.46	-0.44	4.72e-32	Bipolar disorder;
BRCA	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg11843238	chr5:131593191	PDLIM4	0.36	9.43	0.35	7.53e-20	Breast cancer;
BRCA	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.45	-0.38	1.05e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg19338460	chr6:170058176	WDR27	-0.45	-8.03	-0.3	4.64e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg01292856	chr11:65242576	NA	0.32	8.15	0.31	1.86e-15	Bone mineral density;
BRCA	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg03585969	chr10:35415529	CREM	0.5	10.44	0.38	1.16e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-8.72	-0.33	2.48e-17	Monocyte percentage of white cells;
BRCA	cis	rs9880211	1.000	rs9883189	chr3:136289466	T/C	cg21827317	chr3:136751795	NA	-0.44	-7.94	-0.3	8.89e-15	Body mass index;Height;
BRCA	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg20307385	chr11:47447363	PSMC3	-0.41	-8.75	-0.33	1.87e-17	Subjective well-being;
BRCA	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.08e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg11752832	chr7:134001865	SLC35B4	0.53	13.77	0.48	5.95e-38	Mean platelet volume;
BRCA	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg21535247	chr6:8435926	SLC35B3	0.42	9.42	0.35	7.86e-20	Motion sickness;
BRCA	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg15704280	chr7:45808275	SEPT13	0.63	11.24	0.41	6.97e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg22875332	chr1:76189707	ACADM	0.69	14.57	0.5	9.55e-42	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg12863693	chr15:85201151	NMB	0.52	10.98	0.4	8.49e-26	Schizophrenia;
BRCA	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg13256891	chr4:100009986	ADH5	-0.53	-9.87	-0.36	1.82e-21	Alcohol dependence;
BRCA	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg01475377	chr6:109611718	NA	-0.51	-13.13	-0.46	4.95e-35	Reticulocyte fraction of red cells;
BRCA	cis	rs2882667	0.931	rs7706391	chr5:138349164	G/A	cg04439458	chr5:138467593	SIL1	-0.36	-9.76	-0.36	4.54e-21	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11764359	chr7:65958608	NA	0.77	17.35	0.57	1.5e-55	Aortic root size;
BRCA	cis	rs965469	1.000	rs6051763	chr20:3321616	T/G	cg25506879	chr20:3388711	C20orf194	-0.55	-10.84	-0.39	3.09e-25	IFN-related cytopenia;
BRCA	cis	rs367943	0.608	rs4705564	chr5:112980196	G/C	cg12552261	chr5:112820674	MCC	0.37	8.01	0.3	5.27e-15	Type 2 diabetes;
BRCA	cis	rs4642101	0.694	rs12631514	chr3:12838293	G/C	cg24848339	chr3:12840334	CAND2	0.51	13.55	0.47	5.77e-37	QRS complex (12-leadsum);
BRCA	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg05283184	chr6:79620031	NA	-0.43	-10.99	-0.4	7.76e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg20607798	chr8:58055168	NA	0.48	8.33	0.31	4.87e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg16339924	chr4:17578868	LAP3	0.57	14.06	0.49	2.45e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg13073564	chr4:8508604	NA	-0.44	-12.01	-0.43	4.27e-30	Response to antineoplastic agents;
BRCA	cis	rs2835872	0.758	rs1787398	chr21:39037504	A/C	cg06728970	chr21:39037746	KCNJ6	0.45	12.93	0.46	3.95e-34	Electroencephalographic traits in alcoholism;
BRCA	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.58	0.35	2.14e-20	Morning vs. evening chronotype;
BRCA	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21659725	chr3:3221576	CRBN	-0.48	-10.35	-0.38	2.53e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs877282	0.891	rs11253393	chr10:788824	G/T	cg22713356	chr15:30763199	NA	1.42	28.55	0.75	3.22e-116	Uric acid levels;
BRCA	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg16506815	chr2:162101123	NA	-0.48	-10.17	-0.37	1.24e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.03e-57	Colorectal cancer;
BRCA	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg21475434	chr5:93447410	FAM172A	0.69	8.96	0.33	3.56e-18	Diabetic retinopathy;
BRCA	cis	rs36051895	0.623	rs10283467	chr9:5244356	C/G	cg02405213	chr9:5042618	JAK2	0.42	8.02	0.3	4.89e-15	Pediatric autoimmune diseases;
BRCA	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.08e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	20.11	0.62	4.61e-70	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs11608355	0.515	rs34038572	chr12:109901657	A/G	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs2637266	1.000	rs6480827	chr10:78356333	T/G	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	cis	rs12618769	0.597	rs4851131	chr2:99036802	A/C	cg10123293	chr2:99228465	UNC50	0.41	8.11	0.31	2.52e-15	Bipolar disorder;
BRCA	trans	rs961253	0.522	rs2225115	chr20:6360465	C/T	cg21095983	chr6:86352623	SYNCRIP	0.38	7.87	0.3	1.53e-14	Colorectal cancer;
BRCA	cis	rs7011049	1.000	rs6988927	chr8:53837496	T/C	cg26025543	chr8:53854495	NA	0.54	9.53	0.35	3.26e-20	Systolic blood pressure;
BRCA	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	9.89	0.36	1.43e-21	Tonsillectomy;
BRCA	cis	rs3768617	0.740	rs28533496	chr1:183019885	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	9.7	0.36	7.76e-21	Fuchs's corneal dystrophy;
BRCA	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.45	-11.6	-0.42	2.19e-28	Schizophrenia;
BRCA	cis	rs2066819	1.000	rs78149779	chr12:56694817	A/G	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs427394	0.735	rs416689	chr5:6740855	C/T	cg10857441	chr5:6722123	POLS	-0.34	-11.18	-0.4	1.27e-26	Menopause (age at onset);
BRCA	cis	rs2463822	1.000	rs2513052	chr11:62108248	C/G	cg06239285	chr11:62104954	ASRGL1	0.69	11.68	0.42	1.05e-28	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg27661571	chr11:113659931	NA	-0.69	-10.61	-0.39	2.52e-24	Hip circumference adjusted for BMI;
BRCA	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg05340658	chr4:99064831	C4orf37	0.54	8.92	0.33	4.99e-18	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7246967	0.551	rs7257333	chr19:22881149	C/T	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg22920501	chr2:26401640	FAM59B	0.95	16.66	0.55	4.8e-52	Gut microbiome composition (summer);
BRCA	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg00677455	chr12:58241039	CTDSP2	-0.35	-7.95	-0.3	8.42e-15	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg07507251	chr3:52567010	NT5DC2	0.39	9.39	0.35	1.06e-19	Electroencephalogram traits;
BRCA	cis	rs925228	0.550	rs7568163	chr2:24278841	T/G	cg20701182	chr2:24300061	SF3B14	-0.46	-9.57	-0.35	2.32e-20	Reticulocyte fraction of red cells;Reticulocyte count;
BRCA	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.49	0.35	4.65e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	25.91	0.72	1.01e-101	Chronic sinus infection;
BRCA	trans	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.81	0.3	2.29e-14	Corneal astigmatism;
BRCA	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18404041	chr3:52824283	ITIH1	-0.43	-12.62	-0.45	9.47e-33	Bipolar disorder;
BRCA	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg04851639	chr8:1020857	NA	-0.36	-11.01	-0.4	6.48e-26	Schizophrenia;
BRCA	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg08847533	chr14:75593920	NEK9	-0.85	-21.38	-0.65	6.31e-77	Height;
BRCA	cis	rs6738485	0.552	rs62146770	chr2:106854277	C/T	cg16099169	chr2:106886729	NA	-0.42	-9.04	-0.34	1.9e-18	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
BRCA	cis	rs2282802	0.635	rs397463	chr5:139584275	C/G	cg26211634	chr5:139558579	C5orf32	-0.34	-8.35	-0.31	4.34e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12756686	chr19:29218302	NA	0.59	11.77	0.42	4.24e-29	Methadone dose in opioid dependence;
BRCA	cis	rs4919694	0.901	rs74376228	chr10:104677662	G/C	cg04362960	chr10:104952993	NT5C2	0.99	13.51	0.47	9.53e-37	Arsenic metabolism;
BRCA	cis	rs9807989	0.507	rs1833174	chr2:103034843	T/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.35	0.31	4.31e-16	Asthma;
BRCA	cis	rs7903847	0.642	rs10882909	chr10:99137998	G/C	cg08345082	chr10:99160200	RRP12	-0.29	-8.61	-0.32	5.71e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg27170947	chr2:26402098	FAM59B	-0.96	-17.33	-0.57	1.94e-55	Gut microbiome composition (summer);
BRCA	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg12311346	chr5:56204834	C5orf35	-0.62	-13.08	-0.46	7.94e-35	Initial pursuit acceleration;
BRCA	cis	rs4363385	0.679	rs6686285	chr1:152984561	T/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.4	-0.32	2.89e-16	Inflammatory skin disease;
BRCA	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.32	-8.79	-0.33	1.42e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg20701182	chr2:24300061	SF3B14	0.68	10.09	0.37	2.63e-22	Lymphocyte counts;
BRCA	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg11764359	chr7:65958608	NA	-0.62	-10.58	-0.39	3.35e-24	Aortic root size;
BRCA	cis	rs2463822	0.858	rs2513037	chr11:62084822	A/T	cg06239285	chr11:62104954	ASRGL1	-0.64	-10.77	-0.39	5.46e-25	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg07636037	chr3:49044803	WDR6	0.94	27.29	0.73	2.81e-109	Parkinson's disease;
BRCA	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg01448562	chr3:133502909	NA	-0.63	-14.57	-0.5	1.02e-41	Iron status biomarkers;
BRCA	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	12.02	0.43	3.77e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg00677455	chr12:58241039	CTDSP2	-0.35	-7.91	-0.3	1.1e-14	Celiac disease or Rheumatoid arthritis;
BRCA	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21659725	chr3:3221576	CRBN	0.5	12.9	0.45	5.2e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.81	-0.36	3.06e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs73416724	1.000	rs4714675	chr6:43287893	T/C	cg26312998	chr6:43337775	ZNF318	-0.47	-7.81	-0.3	2.32e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.31	0.49	1.68e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg10729496	chr3:10149963	C3orf24	0.41	7.88	0.3	1.44e-14	Alzheimer's disease;
BRCA	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.7	0.36	7.73e-21	Bipolar disorder;
BRCA	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.32	8.46	0.32	1.89e-16	Monocyte percentage of white cells;
BRCA	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.61	0.55	8.94e-52	Alzheimer's disease (late onset);
BRCA	cis	rs1267303	0.642	rs6696219	chr1:47000408	T/C	cg25110126	chr1:46999211	NA	0.57	11.0	0.4	6.62e-26	Monobrow;
BRCA	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg06627628	chr2:24431161	ITSN2	0.42	8.67	0.32	3.51e-17	Asthma;
BRCA	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg26647111	chr11:31128758	NA	0.4	9.15	0.34	7.36e-19	Red blood cell count;
BRCA	trans	rs9944715	1.000	rs4890634	chr18:43854259	C/T	cg01718231	chr17:29326311	RNF135	-0.45	-8.97	-0.33	3.23e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	19.82	0.62	1.71e-68	Platelet count;
BRCA	cis	rs11997175	1.000	rs11997175	chr8:33770070	A/G	ch.8.33884649F	chr8:33765107	NA	-0.45	-11.37	-0.41	2.16e-27	Body mass index;
BRCA	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg05347473	chr6:146136440	FBXO30	0.39	8.06	0.3	3.81e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg16339924	chr4:17578868	LAP3	-0.57	-13.24	-0.46	1.59e-35	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23583168	chr7:148888333	NA	-0.78	-18.82	-0.6	3.22e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg22676075	chr6:135203613	NA	-0.38	-7.85	-0.3	1.81e-14	Red blood cell count;
BRCA	cis	rs3772130	0.624	rs56382357	chr3:121452339	T/C	cg20356878	chr3:121714668	ILDR1	0.37	8.32	0.31	5.23e-16	Cognitive performance;
BRCA	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	11.25	0.41	6.58e-27	Platelet count;
BRCA	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg05623727	chr3:50126028	RBM5	0.43	10.14	0.37	1.71e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg10556349	chr10:835070	NA	0.73	9.85	0.36	2.08e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.33	-7.82	-0.3	2.21e-14	Electroencephalogram traits;
BRCA	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg03213289	chr20:61660250	NA	0.62	16.45	0.55	5.93e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6429082	0.875	rs4659524	chr1:235583354	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.35	-8.39	-0.31	3.16e-16	Adiposity;
BRCA	cis	rs4908768	0.539	rs7526171	chr1:8650185	T/C	cg20416874	chr1:8611966	RERE	-0.3	-8.28	-0.31	6.99e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs2387326	0.672	rs12254264	chr10:129945519	C/T	cg16087940	chr10:129947807	NA	-0.45	-8.04	-0.3	4.23e-15	Select biomarker traits;
BRCA	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19346786	chr7:2764209	NA	-0.37	-11.07	-0.4	3.7e-26	Height;
BRCA	cis	rs58799304	0.531	rs74965833	chr1:156054119	C/T	cg15685922	chr1:156045208	MEX3A	-0.42	-8.21	-0.31	1.26e-15	Ischemic stroke;
BRCA	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09263875	chr16:632152	PIGQ	0.72	20.67	0.63	4.71e-73	Height;
BRCA	cis	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05901451	chr6:126070800	HEY2	0.4	9.71	0.36	6.73e-21	Endometrial cancer;
BRCA	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.4	0.35	9.76e-20	Tonsillectomy;
BRCA	cis	rs2425143	1.000	rs12480408	chr20:34234800	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.0	-0.34	2.49e-18	Blood protein levels;
BRCA	cis	rs9473147	0.516	rs9296561	chr6:47488938	G/A	cg12968598	chr6:47444699	CD2AP	0.44	9.59	0.35	1.93e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg06115741	chr20:33292138	TP53INP2	0.38	8.61	0.32	5.8e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg09469691	chr10:81107165	PPIF	0.44	9.71	0.36	6.73e-21	Height;
BRCA	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.63	-0.32	4.71e-17	Myopia (pathological);
BRCA	cis	rs9986765	1.000	rs73452567	chr7:142816043	T/G	cg22531018	chr7:142981779	TMEM139	0.66	10.39	0.38	1.75e-23	Cancer;Dermatomyositis;
BRCA	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.55	-0.32	9.4e-17	Monocyte percentage of white cells;
BRCA	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg01475377	chr6:109611718	NA	-0.59	-16.52	-0.55	2.62e-51	Reticulocyte fraction of red cells;
BRCA	cis	rs67981189	0.789	rs2810073	chr14:71383848	A/G	cg15816911	chr14:71606274	NA	-0.36	-7.94	-0.3	9.44e-15	Schizophrenia;
BRCA	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	13.59	0.47	3.74e-37	Lymphocyte counts;
BRCA	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg27129171	chr3:47204927	SETD2	0.66	15.39	0.52	1.13e-45	QT interval;
BRCA	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg04414720	chr1:150670196	GOLPH3L	0.35	7.84	0.3	1.88e-14	Tonsillectomy;
BRCA	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg23625390	chr15:77176239	SCAPER	-0.55	-12.83	-0.45	1.1e-33	Blood metabolite levels;
BRCA	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg03709012	chr19:19516395	GATAD2A	-0.5	-9.91	-0.36	1.26e-21	Tonsillectomy;
BRCA	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg23649088	chr2:200775458	C2orf69	0.43	9.31	0.35	1.95e-19	Asthma (bronchodilator response);
BRCA	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg00106254	chr7:1943704	MAD1L1	-0.3	-8.15	-0.31	1.94e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.63	-13.35	-0.47	4.92e-36	Lymphocyte counts;
BRCA	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg03146154	chr1:46216737	IPP	-0.44	-9.85	-0.36	2.04e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg24812749	chr6:127587940	RNF146	0.87	19.95	0.62	3.44e-69	Breast cancer;
BRCA	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg07741184	chr6:167504864	NA	0.36	10.5	0.38	6.63e-24	Crohn's disease;
BRCA	trans	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg11693508	chr17:37793320	STARD3	0.6	11.34	0.41	2.73e-27	Bipolar disorder;
BRCA	cis	rs2354432	0.607	rs7537279	chr1:146673642	A/G	cg25205988	chr1:146714368	CHD1L	0.84	10.87	0.4	2.19e-25	Mitochondrial DNA levels;
BRCA	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-9.98	-0.37	7.01e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg18876405	chr7:65276391	NA	0.46	10.29	0.38	4.53e-23	Aortic root size;
BRCA	trans	rs8073060	0.855	rs12150450	chr17:33868896	A/T	cg19694781	chr19:47549865	TMEM160	0.56	11.9	0.43	1.22e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs34779708	0.931	rs4934710	chr10:35350416	T/C	cg03585969	chr10:35415529	CREM	0.55	11.41	0.41	1.41e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.59	12.03	0.43	3.58e-30	Body mass index (adult);
BRCA	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.82	-13.69	-0.48	1.34e-37	Platelet count;
BRCA	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg18200150	chr17:30822561	MYO1D	-0.35	-8.96	-0.33	3.4e-18	Schizophrenia;
BRCA	cis	rs11585357	0.947	rs72646789	chr1:17610030	C/T	cg08277548	chr1:17600880	PADI3	-0.74	-12.32	-0.44	2e-31	Hair shape;
BRCA	cis	rs6763687	0.664	rs9841859	chr3:171806523	A/G	cg16233210	chr3:171778391	FNDC3B	0.39	9.19	0.34	5.47e-19	Red cell distribution width;
BRCA	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg24069376	chr3:38537580	EXOG	-0.34	-9.45	-0.35	6.23e-20	Electrocardiographic conduction measures;
BRCA	cis	rs4423214	0.840	rs1790343	chr11:71177207	T/C	cg05163923	chr11:71159392	DHCR7	-0.57	-11.6	-0.42	2.31e-28	Vitamin D levels;
BRCA	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg03609598	chr5:56110824	MAP3K1	-0.49	-8.2	-0.31	1.31e-15	Initial pursuit acceleration;
BRCA	cis	rs13102973	0.965	rs7656631	chr4:135869921	C/T	cg14419869	chr4:135874104	NA	-0.59	-12.99	-0.46	2.18e-34	Subjective well-being;
BRCA	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.29	-0.35	2.32e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg04450456	chr4:17643702	FAM184B	0.33	9.52	0.35	3.37e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg25358565	chr5:93447407	FAM172A	-0.66	-11.32	-0.41	3.21e-27	Diabetic retinopathy;
BRCA	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg01420254	chr6:26195488	NA	0.57	7.89	0.3	1.3e-14	Gout;Renal underexcretion gout;
BRCA	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.12	-0.34	1e-18	Bipolar disorder;
BRCA	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs9310732	0.657	rs9310730	chr3:24215414	C/G	cg15359321	chr3:24203479	THRB	0.41	10.02	0.37	4.93e-22	Schizophrenia;
BRCA	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg26587870	chr6:27730563	NA	-0.53	-8.14	-0.31	2.06e-15	Depression;
BRCA	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg15556689	chr8:8085844	FLJ10661	0.41	11.66	0.42	1.28e-28	Mood instability;
BRCA	cis	rs7560272	0.529	rs2421672	chr2:73955540	G/A	cg20560298	chr2:73613845	ALMS1	0.33	8.61	0.32	5.87e-17	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	8.29	0.31	6.67e-16	Breast cancer;
BRCA	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.37	0.57	1.19e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg00071950	chr4:10020882	SLC2A9	0.66	16.76	0.55	1.6e-52	Bone mineral density;
BRCA	cis	rs7737355	1.000	rs7737355	chr5:130604811	T/A	cg06307176	chr5:131281290	NA	0.47	9.22	0.34	4.3e-19	Life satisfaction;
BRCA	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg00990874	chr7:1149470	C7orf50	-0.52	-9.49	-0.35	4.61e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg07741184	chr6:167504864	NA	0.36	10.52	0.38	5.61e-24	Crohn's disease;
BRCA	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg23505145	chr19:12996616	KLF1	0.55	12.62	0.45	9.42e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg10223061	chr2:219282414	VIL1	-0.27	-7.92	-0.3	1.04e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs870825	0.616	rs4416519	chr4:185639502	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.43	0.57	5.93e-56	Blood protein levels;
BRCA	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg27147174	chr7:100797783	AP1S1	-0.56	-10.93	-0.4	1.28e-25	Life satisfaction;
BRCA	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.32	-10.2	-0.37	9.69e-23	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg21573476	chr21:45109991	RRP1B	0.43	10.14	0.37	1.73e-22	Mean corpuscular volume;
BRCA	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-11.63	-0.42	1.75e-28	Personality dimensions;
BRCA	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg08885076	chr2:99613938	TSGA10	-0.52	-11.8	-0.42	3.27e-29	Chronic sinus infection;
BRCA	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.66	14.9	0.51	2.47e-43	Breast cancer;
BRCA	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg23978390	chr7:1156363	C7orf50	0.42	9.49	0.35	4.53e-20	Longevity;Endometriosis;
BRCA	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	12.18	0.43	7.69e-31	Tonsillectomy;
BRCA	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg18230493	chr5:56204884	C5orf35	-0.41	-8.21	-0.31	1.26e-15	Coronary artery disease;
BRCA	trans	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg06521331	chr12:34319734	NA	-0.47	-8.5	-0.32	1.29e-16	Bladder cancer;
BRCA	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg09877947	chr5:131593287	PDLIM4	0.36	7.88	0.3	1.46e-14	Breast cancer;
BRCA	cis	rs9788682	0.747	rs2938674	chr15:78757913	C/A	cg24631222	chr15:78858424	CHRNA5	0.47	9.3	0.35	2.11e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10802521	chr3:52805072	NEK4	-0.34	-9.35	-0.35	1.45e-19	Bipolar disorder;
BRCA	cis	rs17253792	0.822	rs9972178	chr14:56073480	A/G	cg01858014	chr14:56050164	KTN1	-0.78	-10.82	-0.39	3.74e-25	Putamen volume;
BRCA	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg02475777	chr4:1388615	CRIPAK	0.36	7.92	0.3	1.07e-14	Longevity;
BRCA	cis	rs7246657	0.524	rs10411251	chr19:37428755	C/T	cg23950597	chr19:37808831	NA	-0.51	-8.29	-0.31	6.94e-16	Coronary artery calcification;
BRCA	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg08668359	chr10:1443807	ADARB2	0.47	9.26	0.34	3.06e-19	Radiation response;
BRCA	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg11833968	chr6:79620685	NA	-0.45	-9.92	-0.37	1.18e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg26384229	chr12:38710491	ALG10B	0.52	11.18	0.4	1.26e-26	Morning vs. evening chronotype;
BRCA	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg12591125	chr7:1885375	MAD1L1	0.51	8.92	0.33	4.87e-18	Bipolar disorder;
BRCA	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg17971929	chr21:40555470	PSMG1	0.53	11.28	0.41	4.71e-27	Cognitive function;
BRCA	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg02544614	chr20:61657117	NA	0.29	8.12	0.31	2.5e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg07636037	chr3:49044803	WDR6	0.52	8.46	0.32	1.81e-16	Menarche (age at onset);
BRCA	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg22907277	chr7:1156413	C7orf50	0.61	12.03	0.43	3.51e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.24e-23	Motion sickness;
BRCA	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	12.2	0.43	6.14e-31	Lung cancer in ever smokers;
BRCA	trans	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg19894588	chr14:64061835	NA	0.46	9.72	0.36	6.23e-21	Optic cup area;Vertical cup-disc ratio;
BRCA	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg03711944	chr11:47377212	SPI1	-0.44	-10.29	-0.38	4.51e-23	Diastolic blood pressure;Systolic blood pressure;
BRCA	trans	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg25214090	chr10:38739885	LOC399744	0.51	10.51	0.38	5.99e-24	Corneal astigmatism;
BRCA	cis	rs1020064	0.609	rs2576748	chr2:105911258	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.42	-8.24	-0.31	9.73e-16	AIDS;
BRCA	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.66	-0.57	3.68e-57	Chronic sinus infection;
BRCA	cis	rs11585357	0.501	rs17458091	chr1:17595925	A/G	cg08277548	chr1:17600880	PADI3	-0.52	-8.32	-0.31	5.21e-16	Hair shape;
BRCA	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18867708	chr6:26865862	GUSBL1	-0.4	-7.85	-0.3	1.76e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2742417	0.603	rs2673062	chr3:45763635	A/G	cg04837898	chr3:45731254	SACM1L	-0.39	-7.98	-0.3	6.71e-15	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.33	0.38	3.05e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg03433033	chr1:76189801	ACADM	0.86	22.27	0.66	8.81e-82	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-12.58	-0.45	1.41e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg07262247	chr5:131593730	PDLIM4	0.36	8.58	0.32	7.25e-17	Acylcarnitine levels;
BRCA	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11644478	chr21:40555479	PSMG1	0.84	19.08	0.6	1.5e-64	Cognitive function;
BRCA	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg24558204	chr6:135376177	HBS1L	0.45	12.21	0.43	5.8e-31	Red blood cell count;
BRCA	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	21.16	0.64	9.69e-76	Lymphocyte percentage of white cells;
BRCA	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg15103426	chr22:29168792	CCDC117	0.47	9.14	0.34	8.32e-19	Lymphocyte counts;
BRCA	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg18196295	chr10:418757	DIP2C	-0.46	-9.43	-0.35	7.66e-20	Psychosis in Alzheimer's disease;
BRCA	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00166722	chr3:10149974	C3orf24	0.56	11.16	0.4	1.5e-26	Alzheimer's disease;
BRCA	cis	rs600806	0.850	rs10858091	chr1:109935578	T/C	cg20591472	chr1:110008990	SYPL2	0.33	8.22	0.31	1.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg24692254	chr21:30365293	RNF160	-0.59	-15.06	-0.51	4.24e-44	Dental caries;
BRCA	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg16230307	chr14:35515116	FAM177A1	0.77	15.53	0.52	2.2e-46	Psoriasis;
BRCA	trans	rs6479901	0.512	rs6415875	chr10:64986417	A/G	cg14819942	chr15:35414228	NA	-0.35	-8.65	-0.32	4.26e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.24	-0.34	3.69e-19	Total body bone mineral density;
BRCA	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg08807101	chr21:30365312	RNF160	0.38	8.23	0.31	1.03e-15	Pancreatic cancer;
BRCA	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg24324837	chr19:49891574	CCDC155	0.47	7.91	0.3	1.16e-14	Multiple sclerosis;
BRCA	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.68	-0.32	3.36e-17	Bipolar disorder;
BRCA	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg13256891	chr4:100009986	ADH5	-0.55	-10.07	-0.37	3.09e-22	Smoking initiation;
BRCA	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg22875332	chr1:76189707	ACADM	0.64	11.68	0.42	1.08e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-12.02	-0.43	3.96e-30	Total cholesterol levels;
BRCA	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg12072164	chr19:44306565	LYPD5	0.36	8.55	0.32	8.85e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs8038465	0.592	rs1542579	chr15:73935897	A/G	cg15420318	chr15:73925796	NPTN	0.42	9.33	0.35	1.65e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.77	0.5	1.09e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg13271783	chr10:134563150	INPP5A	-0.47	-9.89	-0.36	1.46e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg05535760	chr7:792225	HEATR2	-0.72	-11.64	-0.42	1.59e-28	Cerebrospinal P-tau181p levels;
BRCA	trans	rs629535	0.767	rs62513418	chr8:70114376	G/T	cg21567404	chr3:27674614	NA	-0.96	-20.34	-0.63	2.85e-71	Dupuytren's disease;
BRCA	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg24675658	chr1:53192096	ZYG11B	0.68	14.68	0.5	2.81e-42	Monocyte count;
BRCA	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg23711669	chr6:146136114	FBXO30	0.79	18.95	0.6	6.68e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.35	-8.96	-0.33	3.59e-18	Total body bone mineral density;
BRCA	cis	rs67981189	0.593	rs9806042	chr14:71530993	G/C	cg15816911	chr14:71606274	NA	0.38	8.55	0.32	9.13e-17	Schizophrenia;
BRCA	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg11764359	chr7:65958608	NA	-0.68	-15.16	-0.51	1.37e-44	Aortic root size;
BRCA	trans	rs8002861	0.619	rs9567289	chr13:44437104	C/T	cg17145862	chr1:211918768	LPGAT1	0.47	10.77	0.39	5.47e-25	Leprosy;
BRCA	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg08755490	chr11:65554678	OVOL1	0.53	10.95	0.4	1.12e-25	Acne (severe);
BRCA	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.32	-0.35	1.84e-19	Bipolar disorder;
BRCA	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg12179176	chr11:130786555	SNX19	-0.5	-10.76	-0.39	6e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.11	-0.34	1.09e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs460214	0.553	rs9976546	chr21:40028193	C/G	cg21578987	chr21:40029669	ERG	0.35	8.28	0.31	7.12e-16	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	8.11	0.31	2.67e-15	Monocyte percentage of white cells;
BRCA	cis	rs13102973	0.640	rs11099303	chr4:135887709	C/A	cg14419869	chr4:135874104	NA	-0.5	-9.79	-0.36	3.37e-21	Subjective well-being;
BRCA	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg27433088	chr4:174089019	GALNT7	-0.33	-8.27	-0.31	7.84e-16	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs12200560	0.505	rs211176	chr6:97073821	G/A	cg06623918	chr6:96969491	KIAA0776	0.53	12.8	0.45	1.43e-33	Coronary heart disease;
BRCA	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-15.04	-0.51	5.54e-44	Chronic sinus infection;
BRCA	cis	rs8038465	0.615	rs6495075	chr15:73981005	A/G	cg15420318	chr15:73925796	NPTN	0.38	8.51	0.32	1.26e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg14835575	chr10:16859367	RSU1	0.5	11.59	0.42	2.43e-28	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg10940203	chr5:177434438	FAM153C	0.42	10.84	0.39	3e-25	Methadone dose in opioid dependence;
BRCA	cis	rs929596	0.574	rs75444879	chr2:234587848	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.36	-9.1	-0.34	1.18e-18	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.6	13.12	0.46	5.34e-35	Hemoglobin concentration;
BRCA	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-9.74	-0.36	5.28e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg10253484	chr15:75165896	SCAMP2	-0.51	-9.86	-0.36	1.99e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs16958440	0.867	rs16949157	chr18:44691324	A/G	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs7593730	1.000	rs2966379	chr2:161123251	C/T	cg22609984	chr2:161126801	NA	0.4	8.01	0.3	5.57e-15	Type 2 diabetes;
BRCA	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg20701182	chr2:24300061	SF3B14	0.68	12.9	0.45	5.2e-34	Lymphocyte counts;
BRCA	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15664640	chr17:80829946	TBCD	-0.32	-8.11	-0.31	2.56e-15	Breast cancer;
BRCA	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18357526	chr6:26021779	HIST1H4A	0.46	8.24	0.31	9.47e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg08822215	chr16:89438651	ANKRD11	-0.42	-8.16	-0.31	1.76e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs6120849	0.754	rs3746435	chr20:33587198	G/C	cg24642439	chr20:33292090	TP53INP2	0.6	10.35	0.38	2.61e-23	Protein C levels;
BRCA	cis	rs2625529	0.627	rs12902661	chr15:72480158	T/G	cg16672083	chr15:72433130	SENP8	-0.82	-17.32	-0.57	2.27e-55	Red blood cell count;
BRCA	trans	rs61931739	0.635	rs1852225	chr12:33963004	C/T	cg26384229	chr12:38710491	ALG10B	0.39	8.87	0.33	7e-18	Morning vs. evening chronotype;
BRCA	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg13319975	chr6:146136371	FBXO30	-0.4	-9.15	-0.34	7.47e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2882667	0.728	rs10068766	chr5:138276784	G/A	cg04439458	chr5:138467593	SIL1	-0.32	-8.14	-0.31	2.04e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1215050	0.791	rs165239	chr4:98682549	C/T	cg05340658	chr4:99064831	C4orf37	0.45	10.23	0.38	7.67e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg10057126	chr4:77819792	ANKRD56	0.68	15.42	0.52	7.78e-46	Emphysema distribution in smoking;
BRCA	cis	rs11779988	0.545	rs427168	chr8:17784829	G/A	cg01800426	chr8:17659068	MTUS1	-0.4	-8.4	-0.32	2.97e-16	Breast cancer;
BRCA	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.51	-10.17	-0.37	1.29e-22	Body mass index;
BRCA	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg23711669	chr6:146136114	FBXO30	0.64	15.19	0.52	1.03e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg24101359	chr6:42928495	GNMT	-0.53	-9.96	-0.37	8.3e-22	Blood protein levels;
BRCA	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.52	-0.35	3.54e-20	Total body bone mineral density;
BRCA	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.9	0.36	1.36e-21	Bipolar disorder;
BRCA	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09263875	chr16:632152	PIGQ	0.72	20.62	0.63	8.06e-73	Height;
BRCA	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg02466173	chr16:30829666	NA	-0.53	-11.6	-0.42	2.25e-28	Multiple myeloma;
BRCA	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg04450456	chr4:17643702	FAM184B	-0.37	-10.65	-0.39	1.69e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg24060327	chr5:131705240	SLC22A5	0.51	10.66	0.39	1.51e-24	Blood metabolite levels;
BRCA	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg22676075	chr6:135203613	NA	0.61	13.18	0.46	2.93e-35	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg13010199	chr12:38710504	ALG10B	0.44	9.21	0.34	4.78e-19	Morning vs. evening chronotype;
BRCA	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.37	-8.12	-0.31	2.42e-15	Cognitive ability;
BRCA	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg13902645	chr11:5959945	NA	0.58	13.54	0.47	6.56e-37	DNA methylation (variation);
BRCA	cis	rs5167	0.504	rs10426750	chr19:45457684	G/C	cg09555818	chr19:45449301	APOC2	0.46	12.07	0.43	2.2e-30	Blood protein levels;
BRCA	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg04756594	chr16:24857601	SLC5A11	0.46	9.47	0.35	5.24e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.71	-0.61	6.44e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg11693508	chr17:37793320	STARD3	0.38	7.99	0.3	6.21e-15	Neuroticism;
BRCA	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg05283184	chr6:79620031	NA	-0.44	-11.41	-0.41	1.44e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg25174290	chr11:3078921	CARS	0.45	13.83	0.48	3.15e-38	Longevity;
BRCA	cis	rs6545883	0.929	rs1900572	chr2:61650715	T/G	cg15711740	chr2:61764176	XPO1	0.54	13.6	0.47	3.52e-37	Tuberculosis;
BRCA	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg26384229	chr12:38710491	ALG10B	0.71	16.86	0.55	4.84e-53	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg25281562	chr12:121454272	C12orf43	0.36	9.42	0.35	8.34e-20	N-glycan levels;
BRCA	cis	rs2997447	0.688	rs3008431	chr1:26371281	A/G	cg19633962	chr1:26362018	EXTL1	-0.59	-10.48	-0.38	8.19e-24	QRS complex (12-leadsum);
BRCA	trans	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg06521331	chr12:34319734	NA	-0.45	-8.36	-0.31	3.83e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg01028140	chr2:1542097	TPO	-0.65	-13.29	-0.47	9.44e-36	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.46	-0.32	1.8e-16	Monocyte percentage of white cells;
BRCA	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg02297831	chr4:17616191	MED28	0.34	7.82	0.3	2.19e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	14.25	0.49	3.14e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-13.11	-0.46	5.75e-35	Platelet count;
BRCA	trans	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg25214090	chr10:38739885	LOC399744	0.45	10.36	0.38	2.36e-23	Corneal astigmatism;
BRCA	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.7	-13.92	-0.48	1.21e-38	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	12.75	0.45	2.5e-33	Lung cancer in ever smokers;
BRCA	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg27631724	chr1:11040367	C1orf127	0.3	7.81	0.3	2.32e-14	Ewing sarcoma;
BRCA	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg08392591	chr16:89556376	ANKRD11	0.39	9.07	0.34	1.46e-18	Multiple myeloma (IgH translocation);
BRCA	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg05863683	chr7:1912471	MAD1L1	0.37	8.37	0.31	3.72e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs6763687	0.637	rs12696328	chr3:171814645	C/G	cg16233210	chr3:171778391	FNDC3B	0.39	9.19	0.34	5.42e-19	Red cell distribution width;
BRCA	cis	rs921968	0.565	rs11896209	chr2:219599268	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-11.22	-0.41	8.62e-27	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.5e-36	High light scatter reticulocyte count;
BRCA	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-8.16	-0.31	1.83e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.15	0.62	2.7e-70	Electrocardiographic conduction measures;
BRCA	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg07493874	chr5:1342172	CLPTM1L	0.45	12.5	0.44	3.09e-32	Lung cancer;
BRCA	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-11.04	-0.4	4.65e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9462027	0.628	rs6942040	chr6:34761809	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.88	-0.3	1.44e-14	Systemic lupus erythematosus;
BRCA	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-8.87	-0.33	7.01e-18	Mean corpuscular volume;
BRCA	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg18904891	chr8:8559673	CLDN23	0.65	12.91	0.45	4.83e-34	Obesity-related traits;
BRCA	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg23711669	chr6:146136114	FBXO30	0.64	15.09	0.51	3.23e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg00814883	chr7:100076585	TSC22D4	-0.49	-9.62	-0.36	1.5e-20	Platelet count;
BRCA	cis	rs7572263	0.959	rs12995271	chr2:209048136	T/C	cg23998903	chr2:209048830	C2orf80	-0.32	-8.13	-0.31	2.19e-15	Glioma;Non-glioblastoma glioma;
BRCA	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg05347473	chr6:146136440	FBXO30	0.54	10.31	0.38	3.66e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-14.71	-0.5	2.11e-42	Personality dimensions;
BRCA	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg11845111	chr2:191398756	TMEM194B	0.8	15.28	0.52	3.68e-45	Diastolic blood pressure;
BRCA	cis	rs312274	0.515	rs56294359	chr12:41311120	T/C	cg17827154	chr12:41323612	CNTN1	-0.43	-10.59	-0.39	2.93e-24	Metabolite levels  (X-11787);
BRCA	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.66	11.17	0.4	1.36e-26	Schizophrenia;
BRCA	cis	rs12474201	0.832	rs11695058	chr2:46978349	A/G	cg06386533	chr2:46925753	SOCS5	0.83	17.61	0.57	7.05e-57	Height;
BRCA	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00684032	chr4:1343700	KIAA1530	0.53	12.35	0.44	1.47e-31	Obesity-related traits;
BRCA	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21582582	chr3:182698605	DCUN1D1	0.39	10.16	0.37	1.38e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs13095912	1.000	rs36066570	chr3:185314454	C/A	cg11274856	chr3:185301563	NA	0.34	8.53	0.32	1.1e-16	Systolic blood pressure;
BRCA	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.21e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg04727924	chr7:799746	HEATR2	0.56	11.14	0.4	1.85e-26	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9815354	0.812	rs17217536	chr3:41923300	A/C	cg03022575	chr3:42003672	ULK4	0.69	9.49	0.35	4.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.64	-16.73	-0.55	2.16e-52	Longevity;Endometriosis;
BRCA	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.0	0.34	2.65e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.5	0.35	4e-20	Menopause (age at onset);
BRCA	cis	rs752010	0.619	rs1123483	chr1:42114198	C/T	cg06885757	chr1:42089581	HIVEP3	-0.33	-10.78	-0.39	5.23e-25	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg06808227	chr14:105710500	BRF1	-0.79	-16.07	-0.54	4.74e-49	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg08859206	chr1:53392774	SCP2	0.4	7.86	0.3	1.69e-14	Monocyte count;
BRCA	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/A	cg00383909	chr3:49044727	WDR6	0.59	10.59	0.39	2.88e-24	Parkinson's disease;
BRCA	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg01448562	chr3:133502909	NA	-0.4	-9.25	-0.34	3.22e-19	Iron status biomarkers (transferrin levels);
BRCA	cis	rs739496	0.542	rs7300400	chr12:111792179	A/C	cg10833066	chr12:111807467	FAM109A	0.35	8.1	0.31	2.77e-15	Platelet count;
BRCA	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg02951883	chr7:2050386	MAD1L1	-0.51	-11.36	-0.41	2.35e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg06784218	chr1:46089804	CCDC17	0.45	10.8	0.39	4.35e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	7.95e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs72627509	0.904	rs17081935	chr4:57823476	C/T	cg26694713	chr4:57773883	REST	0.46	8.34	0.31	4.45e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	14.7	0.5	2.41e-42	Motion sickness;
BRCA	cis	rs7809950	0.678	rs62483640	chr7:106900214	T/G	cg23024343	chr7:107201750	COG5	-0.45	-8.8	-0.33	1.28e-17	Coronary artery disease;
BRCA	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg06060754	chr5:176797920	RGS14	-0.67	-10.25	-0.38	6.05e-23	Urate levels in lean individuals;
BRCA	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg12062639	chr20:23401060	NAPB	0.87	10.46	0.38	9.93e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	ch.11.42038R	chr11:967971	AP2A2	0.57	18.52	0.59	1.28e-61	Alzheimer's disease (late onset);
BRCA	trans	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	8.47e-21	Bladder cancer;
BRCA	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg06808227	chr14:105710500	BRF1	-0.79	-16.08	-0.54	4.34e-49	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg17507749	chr15:85114479	UBE2QP1	0.55	10.43	0.38	1.24e-23	Schizophrenia;
BRCA	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs4594175	0.926	rs4243570	chr14:51624243	C/T	cg23942311	chr14:51606299	NA	0.33	8.31	0.31	5.55e-16	Cancer;
BRCA	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg15017067	chr4:17643749	FAM184B	0.32	9.84	0.36	2.29e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg08508325	chr11:3079039	CARS	-0.41	-14.67	-0.5	3.45e-42	Longevity;
BRCA	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg20933634	chr6:27740509	NA	0.49	9.71	0.36	6.8e-21	Parkinson's disease;
BRCA	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03264133	chr6:25882463	NA	-0.44	-10.18	-0.37	1.14e-22	Blood metabolite levels;
BRCA	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg02880119	chr16:3481970	NA	-0.42	-7.89	-0.3	1.31e-14	Body mass index (adult);
BRCA	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.76	12.77	0.45	2.1e-33	Schizophrenia;
BRCA	trans	rs1974653	0.781	rs9605062	chr22:20089880	T/C	cg20152630	chr19:46405944	MYPOP	0.38	8.48	0.32	1.61e-16	Schizophrenia;
BRCA	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg22903471	chr2:27725779	GCKR	-0.36	-8.7	-0.33	2.82e-17	Total body bone mineral density;
BRCA	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg12292205	chr6:26970375	C6orf41	-0.8	-19.63	-0.61	1.68e-67	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg06618935	chr21:46677482	NA	-0.36	-8.09	-0.3	3.1e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6484504	0.576	rs208067	chr11:31153578	C/T	cg26647111	chr11:31128758	NA	-0.43	-9.25	-0.34	3.43e-19	Red blood cell count;
BRCA	cis	rs9287719	0.624	rs10199635	chr2:10726640	T/C	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	5.17e-19	Prostate cancer;
BRCA	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg24829409	chr8:58192753	C8orf71	-0.5	-8.24	-0.31	1e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	7.9e-19	Lymphocyte counts;
BRCA	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg18154014	chr19:37997991	ZNF793	0.61	11.38	0.41	1.85e-27	Coronary artery calcification;
BRCA	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg23711669	chr6:146136114	FBXO30	-0.83	-20.4	-0.63	1.31e-71	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00149659	chr3:10157352	C3orf10	0.77	13.26	0.46	1.31e-35	Alzheimer's disease;
BRCA	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-9.28	-0.34	2.64e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg00383909	chr3:49044727	WDR6	0.5	9.76	0.36	4.62e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7646881	1.000	rs73015651	chr3:158450922	C/T	cg19483011	chr3:158453295	NA	-0.48	-8.94	-0.33	4.17e-18	Tetralogy of Fallot;
BRCA	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg13393036	chr8:95962371	TP53INP1	0.35	8.46	0.32	1.85e-16	Type 2 diabetes;
BRCA	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg09307838	chr4:120376055	NA	0.62	11.62	0.42	1.92e-28	Corneal astigmatism;
BRCA	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-16.99	-0.56	1.08e-53	Colorectal cancer;
BRCA	trans	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.62	11.7	0.42	8.7e-29	Type 2 diabetes;
BRCA	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg04025307	chr7:1156635	C7orf50	0.47	8.96	0.33	3.46e-18	Bronchopulmonary dysplasia;
BRCA	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg26384229	chr12:38710491	ALG10B	0.69	14.65	0.5	4.31e-42	Morning vs. evening chronotype;
BRCA	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg20891283	chr12:69753455	YEATS4	0.71	20.98	0.64	9.04e-75	Blood protein levels;
BRCA	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg07636037	chr3:49044803	WDR6	0.56	9.16	0.34	7.19e-19	Menarche (age at onset);
BRCA	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg05347473	chr6:146136440	FBXO30	-0.44	-8.81	-0.33	1.17e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg03188948	chr7:1209495	NA	0.87	11.85	0.42	2.11e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg22535103	chr8:58192502	C8orf71	-0.51	-8.75	-0.33	1.85e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg06521331	chr12:34319734	NA	-0.46	-8.53	-0.32	1.08e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	11.29	0.41	4.65e-27	Alzheimer's disease;
BRCA	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg15352829	chr14:105391018	PLD4	-0.38	-12.3	-0.44	2.45e-31	Rheumatoid arthritis;
BRCA	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg15212455	chr7:39170539	POU6F2	0.36	7.88	0.3	1.45e-14	IgG glycosylation;
BRCA	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg08645402	chr16:4508243	NA	0.38	9.05	0.34	1.72e-18	Schizophrenia;
BRCA	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg24112000	chr20:60950667	NA	-0.59	-12.76	-0.45	2.21e-33	Colorectal cancer;
BRCA	cis	rs9462027	0.628	rs2814959	chr6:34705947	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.87	-0.3	1.55e-14	Systemic lupus erythematosus;
BRCA	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg12744634	chr1:26560303	CCDC21	0.33	8.96	0.33	3.59e-18	Obesity-related traits;
BRCA	cis	rs9487051	0.839	rs13196590	chr6:109561918	T/C	cg21918786	chr6:109611834	NA	-0.36	-9.02	-0.34	2.23e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg08999081	chr20:33150536	PIGU	0.48	13.2	0.46	2.33e-35	Coronary artery disease;
BRCA	cis	rs250677	0.522	rs6872701	chr5:148359086	C/G	cg18129178	chr5:148520854	ABLIM3	0.54	10.41	0.38	1.48e-23	Breast cancer;
BRCA	cis	rs9309473	1.000	rs62151652	chr2:73700131	A/C	cg20560298	chr2:73613845	ALMS1	-0.44	-10.65	-0.39	1.67e-24	Metabolite levels;
BRCA	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg06784218	chr1:46089804	CCDC17	-0.48	-11.42	-0.41	1.29e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg21132104	chr15:45694354	SPATA5L1	0.73	16.14	0.54	2.01e-49	Homoarginine levels;
BRCA	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg27398817	chr8:82754497	SNX16	-0.43	-8.53	-0.32	1.04e-16	Diastolic blood pressure;
BRCA	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	11.54	0.42	3.99e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg07741184	chr6:167504864	NA	0.34	9.97	0.37	7.51e-22	Primary biliary cholangitis;
BRCA	cis	rs6087990	0.584	rs6058897	chr20:31398105	G/T	cg13636640	chr20:31349939	DNMT3B	-0.49	-12.32	-0.44	1.85e-31	Ulcerative colitis;
BRCA	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg01292856	chr11:65242576	NA	0.33	8.2	0.31	1.36e-15	Bone mineral density;
BRCA	cis	rs6484504	0.576	rs169623	chr11:31184157	T/C	cg26647111	chr11:31128758	NA	-0.44	-9.5	-0.35	4.05e-20	Red blood cell count;
BRCA	cis	rs490234	0.702	rs12553882	chr9:128195044	G/A	cg14078157	chr9:128172775	NA	-0.53	-11.28	-0.41	4.71e-27	Mean arterial pressure;
BRCA	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14442939	chr10:27389572	ANKRD26	-0.68	-11.41	-0.41	1.35e-27	Breast cancer;
BRCA	trans	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg07211511	chr3:129823064	LOC729375	-0.77	-14.86	-0.51	4.12e-43	Blood pressure (smoking interaction);
BRCA	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg03585969	chr10:35415529	CREM	0.5	10.37	0.38	2.11e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7178424	0.742	rs2414755	chr15:62172429	C/T	cg00456672	chr15:62358751	C2CD4A	-0.36	-8.73	-0.33	2.14e-17	Height;
BRCA	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg18904891	chr8:8559673	CLDN23	0.64	12.86	0.45	8.07e-34	Obesity-related traits;
BRCA	cis	rs4727443	0.866	rs35228488	chr7:99617852	G/C	cg22004693	chr7:99632812	ZKSCAN1	0.4	8.98	0.33	2.92e-18	Interstitial lung disease;
BRCA	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg12935359	chr14:103987150	CKB	0.63	14.53	0.5	1.58e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg18876405	chr7:65276391	NA	0.52	12.1	0.43	1.76e-30	Aortic root size;
BRCA	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg03929089	chr4:120376271	NA	0.49	8.2	0.31	1.36e-15	Axial length;
BRCA	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg26850624	chr5:429559	AHRR	-0.36	-8.03	-0.3	4.82e-15	Cystic fibrosis severity;
BRCA	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-15.97	-0.53	1.5e-48	Total cholesterol levels;
BRCA	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.6	-14.57	-0.5	1.02e-41	Longevity;Endometriosis;
BRCA	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg12573674	chr2:1569213	NA	-0.58	-12.99	-0.46	2.16e-34	IgG glycosylation;
BRCA	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg09307838	chr4:120376055	NA	-0.7	-14.01	-0.48	4.22e-39	Corneal astigmatism;
BRCA	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-8.36	-0.31	4.04e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs367943	0.698	rs2217296	chr5:112973829	A/T	cg12552261	chr5:112820674	MCC	0.37	7.88	0.3	1.41e-14	Type 2 diabetes;
BRCA	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-9.97	-0.37	7.37e-22	Alzheimer's disease (late onset);
BRCA	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg11752832	chr7:134001865	SLC35B4	0.54	13.89	0.48	1.54e-38	Mean platelet volume;
BRCA	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.6	0.35	1.83e-20	Menopause (age at onset);
BRCA	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg03954927	chr1:10346856	KIF1B	0.43	13.72	0.48	9.36e-38	Hepatocellular carcinoma;
BRCA	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg26116260	chr4:7069785	GRPEL1	0.81	17.7	0.57	2.36e-57	Monocyte percentage of white cells;
BRCA	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-12.07	-0.43	2.24e-30	Response to antipsychotic treatment;
BRCA	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg21475434	chr5:93447410	FAM172A	-0.69	-8.88	-0.33	6.49e-18	Diabetic retinopathy;
BRCA	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26314531	chr2:26401878	FAM59B	-0.63	-10.83	-0.39	3.28e-25	Gut microbiome composition (summer);
BRCA	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg20933634	chr6:27740509	NA	0.45	8.24	0.31	9.74e-16	Parkinson's disease;
BRCA	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg17330251	chr7:94953956	PON1	-0.42	-9.0	-0.34	2.53e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs11971779	0.680	rs4728467	chr7:139120562	G/A	cg07862535	chr7:139043722	LUC7L2	0.38	10.22	0.37	8.01e-23	Diisocyanate-induced asthma;
BRCA	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg12011299	chr4:100065546	ADH4	0.41	10.78	0.39	5.13e-25	Alcohol dependence;
BRCA	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg08470875	chr2:26401718	FAM59B	0.72	11.26	0.41	6.14e-27	Gut microbiome composition (summer);
BRCA	trans	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	10.66	0.39	1.53e-24	Mean corpuscular volume;
BRCA	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.79e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.83	0.33	9.66e-18	Motion sickness;
BRCA	cis	rs6429082	0.818	rs210037	chr1:235649501	A/G	cg26050004	chr1:235667680	B3GALNT2	0.57	13.54	0.47	6.94e-37	Adiposity;
BRCA	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.45	-0.35	6.47e-20	Alzheimer's disease;
BRCA	cis	rs495337	1.000	rs11086299	chr20:48548870	G/A	cg17835207	chr20:48524531	SPATA2	-0.6	-13.97	-0.48	6.73e-39	Psoriasis;
BRCA	cis	rs12618769	0.652	rs2276603	chr2:99205962	C/T	cg10123293	chr2:99228465	UNC50	-0.45	-8.78	-0.33	1.51e-17	Bipolar disorder;
BRCA	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.34	-8.2	-0.31	1.36e-15	Personality dimensions;
BRCA	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg20203395	chr5:56204925	C5orf35	-0.63	-12.62	-0.45	9.31e-33	Initial pursuit acceleration;
BRCA	cis	rs6901250	0.759	rs9489040	chr6:117131740	G/A	cg12892004	chr6:117198278	RFX6	0.37	9.02	0.34	2.15e-18	C-reactive protein levels;
BRCA	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg03060546	chr3:49711283	APEH	-0.58	-11.63	-0.42	1.77e-28	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7246967	0.673	rs4933026	chr19:22874492	A/T	cg23217946	chr19:22817039	ZNF492	0.46	8.43	0.32	2.38e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg20701182	chr2:24300061	SF3B14	0.65	9.34	0.35	1.64e-19	Lymphocyte counts;
BRCA	cis	rs7582720	1.000	rs6725887	chr2:203745885	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.8	-12.27	-0.44	3.17e-31	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.35	0.59	9.88e-61	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10129255	0.500	rs11627315	chr14:107210420	T/C	cg07958169	chr14:107095056	NA	-0.37	-8.11	-0.31	2.62e-15	Kawasaki disease;
BRCA	cis	rs2625529	0.503	rs7162299	chr15:72414065	A/G	cg16672083	chr15:72433130	SENP8	0.66	15.89	0.53	3.87e-48	Red blood cell count;
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg04025307	chr7:1156635	C7orf50	0.61	14.64	0.5	4.41e-42	Longevity;Endometriosis;
BRCA	trans	rs783540	0.632	rs17356528	chr15:83305550	A/G	cg16105309	chr15:79090380	ADAMTS7	0.33	9.1	0.34	1.15e-18	Schizophrenia;
BRCA	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg04518342	chr5:131593106	PDLIM4	0.35	8.57	0.32	7.71e-17	Blood metabolite levels;
BRCA	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg22491629	chr6:157744540	C6orf35	-0.61	-11.13	-0.4	2.06e-26	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg22535103	chr8:58192502	C8orf71	-0.45	-9.03	-0.34	2.02e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg03146154	chr1:46216737	IPP	0.52	11.59	0.42	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs151349	1.000	rs151344	chr20:57585301	A/G	cg23907860	chr20:57583709	CTSZ	-0.45	-11.06	-0.4	3.78e-26	Platelet distribution width;
BRCA	cis	rs1595825	0.838	rs58576043	chr2:198524149	C/T	cg19156104	chr2:198669113	PLCL1	-0.42	-8.15	-0.31	1.91e-15	Ulcerative colitis;
BRCA	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg06115741	chr20:33292138	TP53INP2	0.39	8.68	0.32	3.31e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs10739663	0.520	rs13294786	chr9:128156961	A/G	cg14078157	chr9:128172775	NA	-0.45	-10.44	-0.38	1.12e-23	Resting heart rate;
BRCA	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06002616	chr8:101225028	SPAG1	-0.34	-8.34	-0.31	4.47e-16	Atrioventricular conduction;
BRCA	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg26516362	chr5:178986906	RUFY1	0.47	13.56	0.47	5.29e-37	Lung cancer;
BRCA	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg07828340	chr4:882639	GAK	1.05	12.4	0.44	8.47e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg10560079	chr2:191398806	TMEM194B	0.68	11.9	0.43	1.23e-29	Diastolic blood pressure;
BRCA	cis	rs12541635	1.000	rs7817197	chr8:107089633	T/G	cg10147462	chr8:107024639	NA	-0.3	-8.35	-0.31	4.26e-16	Age of smoking initiation;
BRCA	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg09184832	chr6:79620586	NA	-0.49	-10.56	-0.39	3.84e-24	Intelligence (multi-trait analysis);
BRCA	trans	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg14791747	chr16:20752902	THUMPD1	0.43	10.27	0.38	5.16e-23	Cognitive test performance;
BRCA	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg26031613	chr14:104095156	KLC1	-0.43	-8.5	-0.32	1.34e-16	Schizophrenia;
BRCA	cis	rs3772130	0.962	rs4311252	chr3:121514161	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.56	10.58	0.39	3.14e-24	Cognitive performance;
BRCA	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg10932868	chr11:921992	NA	0.49	12.53	0.44	2.39e-32	Alzheimer's disease (late onset);
BRCA	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg19052272	chr2:3704530	ALLC	0.54	11.67	0.42	1.21e-28	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg23033748	chr14:75592666	NEK9	-0.4	-9.72	-0.36	6.46e-21	Height;
BRCA	cis	rs2191566	0.960	rs367209	chr19:44506249	A/G	cg20607764	chr19:44506953	ZNF230	0.49	10.89	0.4	1.88e-25	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg00701064	chr4:6280414	WFS1	0.63	16.27	0.54	4.64e-50	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs3845702	1.000	rs259808	chr2:180791419	T/G	cg01881094	chr2:180872142	CWC22	-0.64	-11.99	-0.43	5.27e-30	Schizophrenia;
BRCA	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg04944784	chr2:26401820	FAM59B	0.97	16.04	0.54	6.42e-49	Gut microbiome composition (summer);
BRCA	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg15704280	chr7:45808275	SEPT13	0.6	10.66	0.39	1.57e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9815354	0.812	rs10510732	chr3:42007339	C/T	cg03022575	chr3:42003672	ULK4	0.7	9.86	0.36	1.84e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg02475777	chr4:1388615	CRIPAK	0.4	8.8	0.33	1.28e-17	Longevity;
BRCA	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07080220	chr10:102295463	HIF1AN	0.48	10.95	0.4	1.07e-25	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	13.4	0.47	2.76e-36	Platelet count;
BRCA	cis	rs10208940	0.920	rs13417100	chr2:68821725	C/T	cg12452813	chr2:68675892	NA	-0.46	-8.21	-0.31	1.27e-15	Urate levels in lean individuals;
BRCA	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.22	0.37	7.86e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs701145	0.585	rs1727949	chr3:153875713	A/G	cg17054900	chr3:154042577	DHX36	0.38	7.85	0.3	1.72e-14	Coronary artery disease;
BRCA	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg07080220	chr10:102295463	HIF1AN	0.49	10.19	0.37	1.07e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18876405	chr7:65276391	NA	-0.51	-11.71	-0.42	7.59e-29	Aortic root size;
BRCA	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs1865760	0.688	rs1436310	chr6:25969958	G/C	cg16482183	chr6:26056742	HIST1H1C	0.5	10.55	0.39	4.35e-24	Height;
BRCA	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg11764359	chr7:65958608	NA	0.62	10.67	0.39	1.44e-24	Aortic root size;
BRCA	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-15.14	-0.51	1.86e-44	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.31	-7.88	-0.3	1.43e-14	Response to antipsychotic treatment;
BRCA	cis	rs11229555	1.000	rs2275993	chr11:58379987	A/G	cg15696309	chr11:58395628	NA	-0.53	-11.58	-0.42	2.85e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	8.59	0.32	6.43e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs4711336	1.000	rs3818523	chr6:33660371	G/A	cg14003231	chr6:33640908	ITPR3	0.32	7.85	0.3	1.79e-14	Height;
BRCA	trans	rs12310956	0.527	rs1608910	chr12:33895414	T/C	cg26384229	chr12:38710491	ALG10B	0.46	10.71	0.39	9.85e-25	Morning vs. evening chronotype;
BRCA	cis	rs1011018	0.590	rs76304235	chr7:139456611	C/T	cg03224163	chr7:139420300	HIPK2	-0.59	-8.83	-0.33	1.01e-17	Systolic blood pressure;
BRCA	cis	rs4891159	0.548	rs609487	chr18:74134382	C/G	cg24786174	chr18:74118243	ZNF516	-0.83	-24.36	-0.69	3.19e-93	Longevity;
BRCA	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg15145296	chr3:125709740	NA	-0.56	-8.89	-0.33	6.25e-18	Blood pressure (smoking interaction);
BRCA	cis	rs6545883	0.831	rs1186704	chr2:61672991	A/G	cg15711740	chr2:61764176	XPO1	-0.57	-14.41	-0.5	5.74e-41	Tuberculosis;
BRCA	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg24829409	chr8:58192753	C8orf71	-0.47	-9.12	-0.34	9.38e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs56399783	0.614	rs55776032	chr7:2762255	T/C	cg19731401	chr7:2775893	GNA12	0.54	8.37	0.31	3.76e-16	Childhood ear infection;
BRCA	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg12444411	chr7:2802554	GNA12	-0.36	-8.83	-0.33	9.63e-18	Height;
BRCA	cis	rs4285028	0.948	rs34696871	chr3:121671880	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.6	-11.09	-0.4	2.81e-26	Multiple sclerosis;
BRCA	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg21535247	chr6:8435926	SLC35B3	0.41	9.38	0.35	1.09e-19	Motion sickness;
BRCA	cis	rs778371	0.630	rs13007579	chr2:233725364	G/A	cg08000102	chr2:233561755	GIGYF2	-0.78	-16.46	-0.55	5.45e-51	Schizophrenia;
BRCA	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-9.85	-0.36	2.02e-21	Daytime sleep phenotypes;
BRCA	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg08999081	chr20:33150536	PIGU	-0.39	-10.82	-0.39	3.64e-25	Glomerular filtration rate (creatinine);
BRCA	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg00106254	chr7:1943704	MAD1L1	-0.31	-8.32	-0.31	5.13e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg16339924	chr4:17578868	LAP3	0.63	15.65	0.53	5.38e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg11057378	chr10:81107060	PPIF	0.43	10.07	0.37	3.02e-22	Height;
BRCA	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg00530320	chr1:46809349	NSUN4	0.49	9.65	0.36	1.16e-20	Menopause (age at onset);
BRCA	trans	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg25214090	chr10:38739885	LOC399744	0.45	10.11	0.37	2.1e-22	Corneal astigmatism;
BRCA	cis	rs10242455	0.702	rs73401510	chr7:99065812	A/C	cg18809830	chr7:99032528	PTCD1	-0.6	-8.57	-0.32	7.71e-17	Blood metabolite levels;
BRCA	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg21775007	chr8:11205619	TDH	0.64	12.66	0.45	6.04e-33	Retinal vascular caliber;
BRCA	cis	rs9304742	0.573	rs10415950	chr19:53465100	C/T	cg09915433	chr19:53449742	NA	-0.45	-9.05	-0.34	1.74e-18	Psoriasis;
BRCA	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg23029597	chr12:123009494	RSRC2	-0.59	-12.19	-0.43	6.95e-31	Body mass index;
BRCA	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg13880726	chr7:1868755	MAD1L1	0.52	9.67	0.36	9.98e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs4363385	0.747	rs4845332	chr1:152982632	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-9.1	-0.34	1.15e-18	Inflammatory skin disease;
BRCA	cis	rs9420	0.807	rs12807357	chr11:57656902	C/T	cg19752551	chr11:57585705	CTNND1	-0.52	-12.36	-0.44	1.32e-31	Schizophrenia;
BRCA	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-18.12	-0.58	1.55e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg11812906	chr14:75593930	NEK9	0.7	16.14	0.54	2.21e-49	Height;
BRCA	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11644478	chr21:40555479	PSMG1	0.67	15.08	0.51	3.37e-44	Cognitive function;
BRCA	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.84	-19.64	-0.61	1.6e-67	Ulcerative colitis;
BRCA	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg13334819	chr7:99746414	C7orf59	-0.43	-10.03	-0.37	4.43e-22	Coronary artery disease;
BRCA	cis	rs1499972	0.941	rs62266129	chr3:117590704	G/C	cg07612923	chr3:117604196	NA	0.58	7.85	0.3	1.75e-14	Schizophrenia;
BRCA	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg02544614	chr20:61657117	NA	0.28	8.0	0.3	5.65e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7072216	0.763	rs2147900	chr10:100174721	T/C	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.63	-0.36	1.38e-20	Metabolite levels;
BRCA	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg21132104	chr15:45694354	SPATA5L1	0.7	15.33	0.52	2.18e-45	Homoarginine levels;
BRCA	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg22875332	chr1:76189707	ACADM	0.69	14.82	0.51	6.29e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg05340658	chr4:99064831	C4orf37	0.62	14.94	0.51	1.58e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg18252515	chr7:66147081	NA	-1.06	-15.33	-0.52	2.15e-45	Diabetic kidney disease;
BRCA	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.51	0.35	3.8e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-11.8	-0.42	3.35e-29	Gut microbiome composition (summer);
BRCA	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg27433088	chr4:174089019	GALNT7	0.34	9.13	0.34	8.82e-19	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg03929089	chr4:120376271	NA	0.58	9.32	0.35	1.86e-19	Axial length;
BRCA	cis	rs2652834	1.000	rs2729830	chr15:63395812	G/C	cg05507819	chr15:63340323	TPM1	0.45	8.39	0.32	3.12e-16	HDL cholesterol;
BRCA	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg00530320	chr1:46809349	NSUN4	0.49	9.7	0.36	7.91e-21	Menopause (age at onset);
BRCA	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg05347473	chr6:146136440	FBXO30	0.42	8.35	0.31	4.18e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg13010199	chr12:38710504	ALG10B	0.52	10.89	0.4	1.89e-25	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2882667	0.690	rs1976562	chr5:138110594	G/A	cg04439458	chr5:138467593	SIL1	0.34	8.41	0.32	2.59e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg11663144	chr21:46675770	NA	-0.54	-12.7	-0.45	4.17e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg21433313	chr16:3507492	NAT15	-0.59	-8.03	-0.3	4.64e-15	Tuberculosis;
BRCA	cis	rs2625529	0.730	rs7177242	chr15:72184114	A/G	cg16672083	chr15:72433130	SENP8	0.7	16.35	0.54	1.85e-50	Red blood cell count;
BRCA	cis	rs3099143	1.000	rs3102710	chr15:77061148	T/C	cg21673338	chr15:77095150	SCAPER	-0.54	-9.77	-0.36	4.18e-21	Recalcitrant atopic dermatitis;
BRCA	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg20503657	chr10:835505	NA	-0.65	-13.31	-0.47	7.34e-36	Eosinophil percentage of granulocytes;
BRCA	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.48	-7.84	-0.3	1.91e-14	Gut microbiome composition (summer);
BRCA	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.72	16.84	0.55	6e-53	Multiple sclerosis;
BRCA	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg27170947	chr2:26402098	FAM59B	0.65	11.1	0.4	2.63e-26	Gut microbiome composition (summer);
BRCA	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg19678392	chr7:94953810	PON1	-0.42	-8.91	-0.33	5.18e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs9469890	0.604	rs11758420	chr6:34503279	A/C	cg14254433	chr6:34482411	PACSIN1	-0.44	-9.07	-0.34	1.44e-18	Pubertal anthropometrics;Coronary artery disease;
BRCA	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg08601574	chr20:25228251	PYGB	0.33	8.2	0.31	1.37e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg05283184	chr6:79620031	NA	-0.43	-10.98	-0.4	8.25e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg00666640	chr1:248458726	OR2T12	0.31	8.54	0.32	1.01e-16	Common traits (Other);
BRCA	cis	rs921968	0.643	rs485765	chr2:219480804	C/G	cg02176678	chr2:219576539	TTLL4	0.37	9.58	0.35	2.15e-20	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs922692	0.744	rs11072806	chr15:79079074	G/A	cg04896959	chr15:78267971	NA	0.37	8.61	0.32	5.5e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg12365402	chr11:9010492	NRIP3	0.43	9.11	0.34	1.06e-18	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3820928	0.874	rs4675128	chr2:227814757	T/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.31	-0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	19.05	0.6	1.94e-64	Platelet count;
BRCA	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg01475377	chr6:109611718	NA	-0.52	-13.09	-0.46	7.37e-35	Reticulocyte fraction of red cells;
BRCA	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg04025307	chr7:1156635	C7orf50	0.58	9.08	0.34	1.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.7	10.61	0.39	2.47e-24	Lung function (FEV1/FVC);
BRCA	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-8.52	-0.32	1.11e-16	Response to antipsychotic treatment;
BRCA	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg04455712	chr21:45112962	RRP1B	0.36	9.4	0.35	9.96e-20	Mean corpuscular volume;
BRCA	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg20991723	chr1:152506922	NA	0.39	9.07	0.34	1.4e-18	Hair morphology;
BRCA	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	14.7	0.5	2.4e-42	Platelet count;
BRCA	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.52	-9.01	-0.34	2.37e-18	Body mass index (adult);
BRCA	trans	rs11976180	1.000	rs2961125	chr7:143761770	T/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.26	-0.31	8.66e-16	Obesity-related traits;
BRCA	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	10.06	0.37	3.43e-22	Personality dimensions;
BRCA	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg08822215	chr16:89438651	ANKRD11	-0.4	-8.51	-0.32	1.28e-16	Multiple myeloma (IgH translocation);
BRCA	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg23708337	chr7:1209742	NA	0.64	8.74	0.33	2.05e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.36	-8.88	-0.33	6.52e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg06784218	chr1:46089804	CCDC17	0.5	12.11	0.43	1.61e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7254114	0.578	rs35248735	chr19:11312238	G/A	cg06870470	chr19:11315767	DOCK6	-0.36	-8.35	-0.31	4.25e-16	Immature fraction of reticulocytes;
BRCA	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg12373951	chr3:133503437	NA	0.45	10.74	0.39	7.77e-25	Iron status biomarkers;
BRCA	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg17366294	chr4:99064904	C4orf37	0.42	9.88	0.36	1.61e-21	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	13.25	0.46	1.4e-35	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-10.21	-0.37	8.93e-23	Mood instability;
BRCA	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg27170947	chr2:26402098	FAM59B	0.92	16.84	0.55	6.2e-53	Gut microbiome composition (summer);
BRCA	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.55	-0.32	8.83e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.19	0.58	6.66e-60	Fuchs's corneal dystrophy;
BRCA	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg05234568	chr11:5960015	NA	-0.47	-9.29	-0.34	2.45e-19	DNA methylation (variation);
BRCA	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	11.32	0.41	3.31e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	14.58	0.5	9.37e-42	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg26195577	chr20:24973756	C20orf3	1.03	26.67	0.73	6.44e-106	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12210905	0.688	rs12191373	chr6:27484330	C/T	cg08851530	chr6:28072375	NA	0.81	7.82	0.3	2.22e-14	Hip circumference adjusted for BMI;
BRCA	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg15448220	chr1:150897856	SETDB1	0.36	8.1	0.31	2.79e-15	Melanoma;
BRCA	cis	rs3768617	0.727	rs12066735	chr1:183101451	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.47	10.56	0.39	3.97e-24	Fuchs's corneal dystrophy;
BRCA	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg10523679	chr1:76189770	ACADM	-0.46	-8.86	-0.33	7.57e-18	Daytime sleep phenotypes;
BRCA	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg20891283	chr12:69753455	YEATS4	0.73	22.1	0.66	7.57e-81	Blood protein levels;
BRCA	cis	rs7301826	0.580	rs61938969	chr12:131316070	A/G	cg11011512	chr12:131303247	STX2	-0.44	-11.11	-0.4	2.52e-26	Plasma plasminogen activator levels;
BRCA	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg14558114	chr2:88469736	THNSL2	-0.54	-11.32	-0.41	3.22e-27	Response to metformin (IC50);
BRCA	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg01206211	chr2:36825736	FEZ2	0.41	9.92	0.37	1.11e-21	Height;
BRCA	cis	rs4845570	1.000	rs6659705	chr1:151769750	T/C	cg07092448	chr1:151763213	TDRKH	-0.88	-18.58	-0.59	6.15e-62	Coronary artery disease;
BRCA	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26314531	chr2:26401878	FAM59B	-0.63	-10.83	-0.39	3.28e-25	Gut microbiome composition (summer);
BRCA	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg12365402	chr11:9010492	NRIP3	-0.42	-9.85	-0.36	2.09e-21	Hemoglobin concentration;
BRCA	cis	rs7178424	1.000	rs12438690	chr15:62380390	T/C	cg00456672	chr15:62358751	C2CD4A	-0.34	-8.2	-0.31	1.28e-15	Height;
BRCA	cis	rs3820928	0.904	rs1835159	chr2:227764057	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.35	-0.31	4.31e-16	Pulmonary function;
BRCA	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg21573476	chr21:45109991	RRP1B	-0.33	-8.47	-0.32	1.71e-16	Mean corpuscular volume;
BRCA	cis	rs3008870	0.628	rs2755257	chr1:67515309	C/T	cg02640540	chr1:67518911	SLC35D1	0.41	8.79	0.33	1.39e-17	Lymphocyte percentage of white cells;
BRCA	cis	rs13315871	1.000	rs9821570	chr3:58335919	C/G	cg20936604	chr3:58311152	NA	-0.62	-8.04	-0.3	4.5e-15	Cholesterol, total;
BRCA	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg09904177	chr6:26538194	HMGN4	0.57	18.57	0.59	6.99e-62	Intelligence (multi-trait analysis);
BRCA	cis	rs724568	0.546	rs974482	chr2:67946520	C/A	cg14046302	chr2:67939758	NA	-0.4	-10.78	-0.39	5.03e-25	Major depressive disorder (broad);
BRCA	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg08000102	chr2:233561755	GIGYF2	-0.47	-10.15	-0.37	1.53e-22	Coronary artery disease;
BRCA	cis	rs57590327	0.503	rs11711024	chr3:81910207	T/C	cg07356753	chr3:81810745	GBE1	-0.45	-10.47	-0.38	9.1e-24	Extraversion;
BRCA	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.64	-0.36	1.21e-20	Total body bone mineral density;
BRCA	trans	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg26043149	chr18:55253948	FECH	0.38	8.33	0.31	4.8e-16	Bone mineral density;
BRCA	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg22903471	chr2:27725779	GCKR	-0.39	-9.68	-0.36	8.76e-21	Total body bone mineral density;
BRCA	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg19920283	chr7:105172520	RINT1	0.65	12.93	0.46	3.95e-34	Bipolar disorder (body mass index interaction);
BRCA	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg00383909	chr3:49044727	WDR6	0.97	15.72	0.53	2.46e-47	Cognitive function;
BRCA	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg11502198	chr6:26597334	ABT1	0.56	12.0	0.43	4.68e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg15133208	chr4:90757351	SNCA	-0.44	-9.01	-0.34	2.31e-18	Neuroticism;
BRCA	cis	rs867371	1.000	rs1846911	chr15:82468650	G/A	cg00614314	chr15:82944287	LOC80154	0.43	9.06	0.34	1.52e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.42	-0.38	1.34e-23	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg23289794	chr7:2394357	EIF3B	-0.57	-10.98	-0.4	8.42e-26	Multiple sclerosis;
BRCA	cis	rs600806	0.778	rs11101962	chr1:110014187	A/T	cg20591472	chr1:110008990	SYPL2	0.31	7.9	0.3	1.25e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg13880726	chr7:1868755	MAD1L1	0.51	10.14	0.37	1.6e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg09436375	chr6:42928200	GNMT	-0.28	-10.49	-0.38	7.59e-24	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	12.1	0.43	1.72e-30	Mean platelet volume;
BRCA	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg08601574	chr20:25228251	PYGB	0.33	7.94	0.3	9.38e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg02475777	chr4:1388615	CRIPAK	0.41	9.0	0.34	2.57e-18	Longevity;
BRCA	cis	rs6545883	0.868	rs6545887	chr2:61828818	C/G	cg15711740	chr2:61764176	XPO1	-0.55	-14.16	-0.49	8.88e-40	Tuberculosis;
BRCA	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg21782813	chr7:2030301	MAD1L1	-0.39	-10.13	-0.37	1.8e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.43	8.89	0.33	6.34e-18	Cognitive ability;
BRCA	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	11.48	0.41	7.31e-28	Mean platelet volume;
BRCA	cis	rs4363385	0.747	rs4845507	chr1:152968414	T/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.08	-0.34	1.35e-18	Inflammatory skin disease;
BRCA	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg11843238	chr5:131593191	PDLIM4	-0.43	-11.24	-0.41	7.28e-27	Acylcarnitine levels;
BRCA	cis	rs9287719	0.578	rs62127189	chr2:10761326	T/C	cg00105475	chr2:10696890	NA	0.47	10.32	0.38	3.51e-23	Prostate cancer;
BRCA	cis	rs312274	0.588	rs7309918	chr12:41306612	A/G	cg17827154	chr12:41323612	CNTN1	-0.44	-11.03	-0.4	5.14e-26	Metabolite levels  (X-11787);
BRCA	trans	rs66887589	0.934	rs12648182	chr4:120503891	T/A	cg25214090	chr10:38739885	LOC399744	-0.36	-8.35	-0.31	4.21e-16	Diastolic blood pressure;
BRCA	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg07636037	chr3:49044803	WDR6	0.94	26.68	0.73	6.17e-106	Parkinson's disease;
BRCA	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-15.75	-0.53	1.79e-47	Chronic sinus infection;
BRCA	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.07	0.4	3.59e-26	Bipolar disorder;
BRCA	cis	rs55665837	1.000	rs10832269	chr11:14465069	C/A	cg19336497	chr11:14380999	RRAS2	-0.37	-9.77	-0.36	4.22e-21	Vitamin D levels;
BRCA	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg27129171	chr3:47204927	SETD2	0.71	17.18	0.56	1.13e-54	Colorectal cancer;
BRCA	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07256732	chr16:621771	PIGQ	-0.35	-9.4	-0.35	9.36e-20	Height;
BRCA	cis	rs11229555	0.645	rs7929028	chr11:58188258	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.74	-0.36	5.49e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.45	-9.06	-0.34	1.6e-18	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4664304	0.620	rs10929957	chr2:160716508	A/G	cg14819504	chr2:160761413	LY75	0.34	8.22	0.31	1.17e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6545883	0.899	rs1562309	chr2:61770126	C/A	cg15711740	chr2:61764176	XPO1	-0.57	-14.53	-0.5	1.51e-41	Tuberculosis;
BRCA	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.77	-0.42	4.23e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-13.06	-0.46	1.04e-34	Chronic sinus infection;
BRCA	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs4728302	0.869	rs7792492	chr7:133595316	C/T	cg07491979	chr7:133331646	EXOC4	0.36	7.86	0.3	1.66e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg16989086	chr20:62203971	PRIC285	0.52	8.77	0.33	1.61e-17	Glioblastoma;
BRCA	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08219700	chr8:58056026	NA	0.44	7.94	0.3	8.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg13047869	chr3:10149882	C3orf24	0.6	12.62	0.45	9.38e-33	Alzheimer's disease;
BRCA	cis	rs17741873	0.779	rs12573092	chr10:75600016	A/G	cg07699608	chr10:75541558	CHCHD1	0.49	8.03	0.3	4.73e-15	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg13010199	chr12:38710504	ALG10B	-0.36	-8.77	-0.33	1.6e-17	Morning vs. evening chronotype;
BRCA	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	11.02	0.4	5.61e-26	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4891159	0.790	rs72975930	chr18:74144645	G/A	cg24786174	chr18:74118243	ZNF516	-0.77	-18.16	-0.58	1.02e-59	Longevity;
BRCA	cis	rs10788264	0.621	rs9633734	chr10:124057667	T/C	cg09507567	chr10:124027408	NA	0.41	8.43	0.32	2.27e-16	Total body bone mineral density;
BRCA	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg09904177	chr6:26538194	HMGN4	0.44	13.69	0.48	1.41e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg11952622	chr19:58962976	ZNF324B	0.43	8.8	0.33	1.31e-17	Uric acid clearance;
BRCA	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.66	-15.99	-0.53	1.22e-48	Ulcerative colitis;
BRCA	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.15	-0.37	1.5e-22	IgG glycosylation;
BRCA	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg17063962	chr7:91808500	NA	0.53	12.5	0.44	3.28e-32	Breast cancer;
BRCA	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg12365402	chr11:9010492	NRIP3	-0.37	-8.5	-0.32	1.39e-16	Hemoglobin concentration;
BRCA	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg12564285	chr5:131593104	PDLIM4	0.36	9.78	0.36	3.97e-21	Breast cancer;
BRCA	cis	rs11585357	0.947	rs11585119	chr1:17605792	C/A	cg08277548	chr1:17600880	PADI3	-0.74	-12.09	-0.43	1.9e-30	Hair shape;
BRCA	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg23978390	chr7:1156363	C7orf50	0.37	8.79	0.33	1.42e-17	Longevity;Endometriosis;
BRCA	cis	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg07460842	chr6:66804631	NA	0.64	13.81	0.48	3.7e-38	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs870825	0.929	rs72689255	chr4:185590141	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.47	0.5	3.03e-41	Blood protein levels;
BRCA	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg21699342	chr2:239360505	ASB1	0.52	13.74	0.48	8.19e-38	Multiple system atrophy;
BRCA	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg18132916	chr6:79620363	NA	-0.44	-10.07	-0.37	3.15e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg26850624	chr5:429559	AHRR	0.33	7.92	0.3	1.09e-14	Cystic fibrosis severity;
BRCA	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg13010199	chr12:38710504	ALG10B	-0.39	-8.42	-0.32	2.49e-16	Bladder cancer;
BRCA	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg09021430	chr5:549028	NA	-0.64	-15.31	-0.52	2.54e-45	Obesity-related traits;
BRCA	cis	rs6761276	0.674	rs3811056	chr2:113831183	T/C	cg12858261	chr2:113808755	IL1F8	0.43	8.53	0.32	1.1e-16	Protein quantitative trait loci;
BRCA	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.46	0.35	5.62e-20	Lung cancer in ever smokers;
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.57	-12.96	-0.46	2.86e-34	Longevity;Endometriosis;
BRCA	cis	rs1467026	0.563	rs58674721	chr3:12811233	G/A	cg24848339	chr3:12840334	CAND2	0.38	9.49	0.35	4.69e-20	P wave duration;
BRCA	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg16482183	chr6:26056742	HIST1H1C	0.44	9.03	0.34	1.93e-18	Iron status biomarkers;
BRCA	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg01877450	chr7:97915802	BRI3	0.38	8.6	0.32	5.98e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg21280719	chr6:42927975	GNMT	-0.33	-13.97	-0.48	6.79e-39	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs586533	0.837	rs637745	chr11:99495452	C/G	cg22878054	chr11:99397252	CNTN5	0.32	8.03	0.3	4.8e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9296095	0.747	rs12206050	chr6:33564296	A/T	cg14003231	chr6:33640908	ITPR3	0.45	9.48	0.35	4.99e-20	Platelet count;
BRCA	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.97	-0.33	3.26e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1595825	0.891	rs79845692	chr2:198523541	T/C	cg19156104	chr2:198669113	PLCL1	-0.42	-8.15	-0.31	1.91e-15	Ulcerative colitis;
BRCA	cis	rs7633770	0.841	rs11709020	chr3:46680063	A/G	cg11219411	chr3:46661640	NA	-0.68	-18.04	-0.58	3.99e-59	Coronary artery disease;
BRCA	cis	rs600231	0.542	rs10896010	chr11:65246220	C/A	cg01292856	chr11:65242576	NA	0.65	14.99	0.51	9.61e-44	Bone mineral density;
BRCA	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.69	0.39	1.24e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg00677455	chr12:58241039	CTDSP2	0.68	15.77	0.53	1.38e-47	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19717773	chr7:2847554	GNA12	-0.41	-7.94	-0.3	9.46e-15	Height;
BRCA	trans	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg23762105	chr12:34175262	ALG10	0.36	8.49	0.32	1.45e-16	Morning vs. evening chronotype;
BRCA	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg12483005	chr1:23474871	LUZP1	0.44	9.7	0.36	7.48e-21	Height;
BRCA	cis	rs11622475	1.000	rs10149651	chr14:104394440	A/G	cg12183467	chr14:104352244	NA	0.47	9.79	0.36	3.65e-21	Bipolar disorder;
BRCA	cis	rs4478858	0.595	rs4949387	chr1:31803440	T/A	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	trans	rs867371	0.502	rs7176926	chr15:82538094	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.31	-8.5	-0.32	1.38e-16	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs1971762	0.563	rs10747678	chr12:54077687	A/C	cg23533419	chr12:54090519	NA	0.32	8.11	0.31	2.52e-15	Height;
BRCA	cis	rs10044254	0.563	rs16867538	chr5:15680744	A/G	cg07238450	chr5:15720153	FBXL7	-0.46	-11.04	-0.4	4.79e-26	Asthma (corticosteroid response);
BRCA	cis	rs72781680	0.716	rs78332127	chr2:24150163	C/G	cg08917208	chr2:24149416	ATAD2B	0.63	10.68	0.39	1.25e-24	Lymphocyte counts;
BRCA	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg23711669	chr6:146136114	FBXO30	0.72	14.6	0.5	7.21e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7607369	0.536	rs13033409	chr2:219666509	T/G	cg02176678	chr2:219576539	TTLL4	-0.38	-10.09	-0.37	2.52e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs4988958	0.565	rs1035125	chr2:103033839	C/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.37	0.31	3.62e-16	Asthma (childhood onset);
BRCA	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg15839431	chr19:19639596	YJEFN3	0.42	8.55	0.32	8.9e-17	Bipolar disorder;
BRCA	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg27170947	chr2:26402098	FAM59B	0.78	11.19	0.4	1.16e-26	Gut microbiome composition (summer);
BRCA	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.12	0.34	9.39e-19	Tonsillectomy;
BRCA	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg05896524	chr21:47604654	C21orf56	0.51	10.49	0.38	7.13e-24	Testicular germ cell tumor;
BRCA	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.38	-0.31	3.46e-16	Axial length;
BRCA	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.66	-9.58	-0.35	2.1e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg03711944	chr11:47377212	SPI1	-0.4	-10.97	-0.4	9.34e-26	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	7.81	0.3	2.33e-14	Schizophrenia;
BRCA	cis	rs7809950	0.906	rs2395907	chr7:107253304	A/G	cg23024343	chr7:107201750	COG5	0.38	8.37	0.31	3.66e-16	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg03676636	chr4:99064102	C4orf37	-0.22	-8.36	-0.31	3.82e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg12379764	chr21:47803548	PCNT	-0.37	-7.86	-0.3	1.61e-14	Testicular germ cell tumor;
BRCA	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-18.16	-0.58	1.03e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg20607798	chr8:58055168	NA	0.47	8.07	0.3	3.41e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg14403583	chr14:105418241	AHNAK2	-0.39	-9.05	-0.34	1.75e-18	Rheumatoid arthritis;
BRCA	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg11663144	chr21:46675770	NA	-0.55	-12.96	-0.46	2.93e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg06784218	chr1:46089804	CCDC17	0.49	11.73	0.42	6.5e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg26446133	chr18:72167187	CNDP2	-0.78	-14.29	-0.49	2.2e-40	Refractive error;
BRCA	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25427524	chr10:38739819	LOC399744	-0.73	-18.08	-0.58	2.61e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg08422745	chr4:174089978	GALNT7	0.81	15.25	0.52	4.94e-45	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.32	-0.38	3.23e-23	Psoriasis;
BRCA	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg20290983	chr6:43655470	MRPS18A	1.12	40.58	0.85	5.18e-179	IgG glycosylation;
BRCA	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	14.17	0.49	7.97e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg03709012	chr19:19516395	GATAD2A	1.08	21.21	0.64	5.21e-76	Nonalcoholic fatty liver disease;
BRCA	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg03188948	chr7:1209495	NA	0.82	11.41	0.41	1.43e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.9	-0.4	1.77e-25	Bone mineral density;
BRCA	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg05347473	chr6:146136440	FBXO30	0.41	7.97	0.3	7.08e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg02733842	chr7:1102375	C7orf50	0.61	11.69	0.42	9.39e-29	Bronchopulmonary dysplasia;
BRCA	cis	rs9341808	0.935	rs2298307	chr6:80816296	A/G	cg08355045	chr6:80787529	NA	0.32	8.21	0.31	1.27e-15	Sitting height ratio;
BRCA	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg09307838	chr4:120376055	NA	0.73	16.05	0.54	6.21e-49	Corneal astigmatism;
BRCA	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg07395648	chr5:131743802	NA	-0.39	-9.67	-0.36	9.64e-21	Blood metabolite levels;
BRCA	cis	rs4363385	0.818	rs946096	chr1:153006529	T/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.56	-0.32	8.46e-17	Inflammatory skin disease;
BRCA	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg05347473	chr6:146136440	FBXO30	0.43	8.73	0.33	2.26e-17	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg15704280	chr7:45808275	SEPT13	-0.68	-12.81	-0.45	1.39e-33	Coronary artery disease;
BRCA	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.13	0.37	1.82e-22	Aortic root size;
BRCA	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg03585969	chr10:35415529	CREM	0.55	11.46	0.41	8.4e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.96	0.56	1.53e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs28830936	0.966	rs62002090	chr15:42092326	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.36	-9.67	-0.36	9.65e-21	Diastolic blood pressure;
BRCA	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg06917634	chr15:78832804	PSMA4	-0.76	-17.81	-0.58	6.52e-58	Sudden cardiac arrest;
BRCA	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.37	-8.62	-0.32	5.4e-17	Longevity;Endometriosis;
BRCA	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg17470723	chr8:74884337	TCEB1	0.4	8.62	0.32	5.44e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs17092148	0.887	rs6059928	chr20:33167349	A/G	cg16810054	chr20:33298113	TP53INP2	-0.45	-10.26	-0.38	5.94e-23	Neuroticism;
BRCA	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg00105475	chr2:10696890	NA	-0.45	-10.5	-0.38	6.47e-24	Prostate cancer;
BRCA	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg04811098	chr7:155088454	INSIG1	0.39	10.26	0.38	5.76e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg21573476	chr21:45109991	RRP1B	-0.37	-9.55	-0.35	2.62e-20	Mean corpuscular volume;
BRCA	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg17724175	chr1:150552817	MCL1	0.25	8.34	0.31	4.51e-16	Tonsillectomy;
BRCA	cis	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg09307838	chr4:120376055	NA	0.47	9.82	0.36	2.6e-21	Diastolic blood pressure;
BRCA	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18876405	chr7:65276391	NA	-0.57	-13.43	-0.47	2.16e-36	Aortic root size;
BRCA	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg07741184	chr6:167504864	NA	-0.3	-9.32	-0.35	1.83e-19	Crohn's disease;
BRCA	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg23625390	chr15:77176239	SCAPER	-0.48	-11.45	-0.41	9.25e-28	Blood metabolite levels;
BRCA	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg21782813	chr7:2030301	MAD1L1	0.38	9.71	0.36	6.79e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs11711311	0.747	rs9882193	chr3:113349451	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.4	8.86	0.33	7.9e-18	IgG glycosylation;
BRCA	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg19729930	chr2:74357872	NA	0.54	13.63	0.47	2.51e-37	Gestational age at birth (maternal effect);
BRCA	cis	rs12618769	0.597	rs3769725	chr2:99105967	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.43	0.32	2.38e-16	Bipolar disorder;
BRCA	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06022373	chr22:39101656	GTPBP1	-0.63	-16.42	-0.54	8.59e-51	Menopause (age at onset);
BRCA	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg15704280	chr7:45808275	SEPT13	-0.71	-14.29	-0.49	2.19e-40	Coronary artery disease;
BRCA	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24549020	chr5:56110836	MAP3K1	0.63	12.25	0.44	3.71e-31	Initial pursuit acceleration;
BRCA	trans	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg25214090	chr10:38739885	LOC399744	0.56	12.33	0.44	1.68e-31	Corneal astigmatism;
BRCA	cis	rs250677	0.522	rs6580589	chr5:148360335	C/G	cg18129178	chr5:148520854	ABLIM3	0.54	10.41	0.38	1.57e-23	Breast cancer;
BRCA	cis	rs11690935	1.000	rs35549875	chr2:172532392	A/G	cg13550731	chr2:172543902	DYNC1I2	0.93	29.85	0.76	2.88e-123	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	1.02e-40	Motion sickness;
BRCA	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg08917208	chr2:24149416	ATAD2B	0.83	12.76	0.45	2.17e-33	Lymphocyte counts;
BRCA	cis	rs427394	0.802	rs274712	chr5:6723950	G/A	cg10857441	chr5:6722123	POLS	-0.33	-10.97	-0.4	8.68e-26	Menopause (age at onset);
BRCA	cis	rs16944613	0.541	rs4288973	chr15:91093676	G/A	cg26821196	chr15:91095069	CRTC3	0.48	8.81	0.33	1.22e-17	Colorectal cancer;
BRCA	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg25036284	chr2:26402008	FAM59B	0.63	10.44	0.38	1.16e-23	Gut microbiome composition (summer);
BRCA	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.42	-9.02	-0.34	2.15e-18	Longevity;Endometriosis;
BRCA	cis	rs12541635	0.966	rs4416800	chr8:106996677	T/C	cg10147462	chr8:107024639	NA	0.37	9.92	0.37	1.19e-21	Age of smoking initiation;
BRCA	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.54	-0.32	1.01e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg05347473	chr6:146136440	FBXO30	0.44	8.66	0.32	3.75e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1829883	0.804	rs1608435	chr5:98817492	A/G	cg08333243	chr5:99726346	NA	-0.36	-8.79	-0.33	1.38e-17	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.33e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg14664628	chr15:75095509	CSK	-0.52	-12.15	-0.43	1.03e-30	Breast cancer;
BRCA	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg08738300	chr3:44038990	NA	0.44	8.55	0.32	8.81e-17	Coronary artery disease;
BRCA	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06108461	chr20:60628389	TAF4	-0.85	-16.03	-0.54	7.02e-49	Body mass index;
BRCA	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg22496339	chr2:162101262	NA	0.44	9.07	0.34	1.42e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6750795	0.641	rs10933375	chr2:232367296	A/T	cg19187155	chr2:232395269	NMUR1	-0.53	-9.77	-0.36	4.1e-21	Height;
BRCA	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	11.84	0.42	2.14e-29	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg16606324	chr3:10149918	C3orf24	0.48	9.47	0.35	5.5e-20	Alzheimer's disease;
BRCA	cis	rs13040088	1.000	rs12480870	chr20:61543606	A/C	cg23096297	chr20:61557774	DIDO1	0.89	17.74	0.57	1.41e-57	Menopause (age at onset);
BRCA	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg13010199	chr12:38710504	ALG10B	0.58	12.95	0.46	3.27e-34	Heart rate;
BRCA	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03264133	chr6:25882463	NA	-0.47	-11.04	-0.4	4.87e-26	Blood metabolite levels;
BRCA	cis	rs7945718	0.875	rs9888178	chr11:12782643	C/T	cg25843174	chr11:12811716	TEAD1	0.23	8.88	0.33	6.97e-18	Educational attainment (years of education);
BRCA	cis	rs4363385	0.818	rs61811863	chr1:152995721	T/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.27	-0.31	7.84e-16	Inflammatory skin disease;
BRCA	cis	rs3768617	0.811	rs12144261	chr1:183014148	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.44	9.54	0.35	2.99e-20	Fuchs's corneal dystrophy;
BRCA	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg05623727	chr3:50126028	RBM5	0.41	9.7	0.36	7.36e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg19700328	chr14:106028568	NA	-0.44	-9.32	-0.35	1.8e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
BRCA	trans	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg07211511	chr3:129823064	LOC729375	-0.78	-14.88	-0.51	3.36e-43	Blood pressure (smoking interaction);
BRCA	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg08601574	chr20:25228251	PYGB	-0.38	-9.06	-0.34	1.59e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.58	-0.61	3.34e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg08000102	chr2:233561755	GIGYF2	0.64	13.95	0.48	8.76e-39	Coronary artery disease;
BRCA	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.32	-8.08	-0.3	3.25e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs9944715	0.954	rs7231430	chr18:43823472	C/T	cg01718231	chr17:29326311	RNF135	0.42	8.49	0.32	1.45e-16	Red cell distribution width;Mean corpuscular volume;
BRCA	trans	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.08	0.3	3.19e-15	Mean corpuscular volume;
BRCA	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg06784218	chr1:46089804	CCDC17	0.44	10.65	0.39	1.65e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14240646	chr10:27532245	ACBD5	-0.64	-9.36	-0.35	1.38e-19	Breast cancer;
BRCA	cis	rs6444746	1.000	rs6444746	chr3:193495155	A/G	cg22553634	chr3:193489233	NA	-0.54	-8.55	-0.32	8.83e-17	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
BRCA	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg11057378	chr10:81107060	PPIF	0.35	8.48	0.32	1.55e-16	Height;
BRCA	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	11.52	0.41	4.72e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg25214090	chr10:38739885	LOC399744	0.43	10.0	0.37	5.45e-22	Educational attainment;
BRCA	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg26587870	chr6:27730563	NA	-0.46	-8.12	-0.31	2.35e-15	Lung cancer in ever smokers;
BRCA	cis	rs7178424	0.967	rs17271340	chr15:62347885	C/T	cg00456672	chr15:62358751	C2CD4A	-0.41	-9.21	-0.34	4.63e-19	Height;
BRCA	cis	rs10129255	0.536	rs17113249	chr14:107134290	A/G	cg07958169	chr14:107095056	NA	-0.38	-8.17	-0.31	1.72e-15	Kawasaki disease;
BRCA	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg17135325	chr3:160939158	NMD3	0.42	8.06	0.3	3.75e-15	Parkinson's disease;
BRCA	trans	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg23762105	chr12:34175262	ALG10	-0.33	-8.02	-0.3	4.95e-15	Morning vs. evening chronotype;
BRCA	cis	rs3845702	0.736	rs2367990	chr2:180843126	C/T	cg01881094	chr2:180872142	CWC22	-1.01	-18.23	-0.58	4.24e-60	Schizophrenia;
BRCA	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg08477640	chr19:41863820	B9D2	0.39	8.0	0.3	5.99e-15	Migraine;Coronary artery disease;
BRCA	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg06026331	chr20:60912101	LAMA5	0.64	12.37	0.44	1.16e-31	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg10523679	chr1:76189770	ACADM	-0.5	-9.83	-0.36	2.48e-21	Daytime sleep phenotypes;
BRCA	cis	rs2479106	0.727	rs10986139	chr9:126689150	C/G	cg16191174	chr9:126692580	DENND1A	0.47	8.98	0.33	2.99e-18	Polycystic ovary syndrome;
BRCA	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg24006582	chr15:45444508	DUOX1	0.59	11.34	0.41	2.7e-27	Uric acid levels;
BRCA	cis	rs2108225	0.658	rs1476673	chr7:107435945	C/G	cg18560240	chr7:107437656	SLC26A3	-0.57	-12.13	-0.43	1.3e-30	Ulcerative colitis;
BRCA	cis	rs7523050	0.908	rs67425757	chr1:109398656	T/G	cg08274380	chr1:109419600	GPSM2	0.82	12.7	0.45	4.32e-33	Fat distribution (HIV);
BRCA	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg00684032	chr4:1343700	KIAA1530	0.31	8.0	0.3	5.76e-15	Obesity-related traits;
BRCA	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg05347473	chr6:146136440	FBXO30	0.42	8.37	0.31	3.57e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7020830	0.867	rs56098516	chr9:37362220	A/G	cg14294708	chr9:37120828	ZCCHC7	1.12	36.29	0.82	2.38e-157	Schizophrenia;
BRCA	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg13010199	chr12:38710504	ALG10B	0.43	9.12	0.34	9.85e-19	Morning vs. evening chronotype;
BRCA	cis	rs2882667	0.690	rs9327828	chr5:138261548	T/G	cg04439458	chr5:138467593	SIL1	-0.35	-8.54	-0.32	9.54e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.54	-8.6	-0.32	6.35e-17	Lung function (FEV1/FVC);
BRCA	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg03711944	chr11:47377212	SPI1	-0.5	-12.52	-0.44	2.51e-32	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00339695	chr16:24857497	SLC5A11	0.34	8.04	0.3	4.31e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg25588852	chr2:216877276	MREG	-0.28	-7.98	-0.3	6.76e-15	Alcohol dependence;
BRCA	cis	rs7737355	0.947	rs32115	chr5:131051328	A/G	cg06307176	chr5:131281290	NA	0.48	9.34	0.35	1.55e-19	Life satisfaction;
BRCA	cis	rs7072216	0.727	rs942807	chr10:100168219	G/A	cg26618903	chr10:100175079	PYROXD2	-0.31	-8.96	-0.33	3.58e-18	Metabolite levels;
BRCA	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.09	0.56	3.19e-54	Bladder cancer;
BRCA	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg13660082	chr14:53194042	PSMC6	-0.58	-8.63	-0.32	4.8e-17	Alzheimer's disease (late onset);
BRCA	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg21770322	chr7:97807741	LMTK2	0.41	10.94	0.4	1.14e-25	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs8073060	0.521	rs225254	chr17:33953384	G/A	cg19694781	chr19:47549865	TMEM160	-0.46	-10.75	-0.39	6.98e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg09307838	chr4:120376055	NA	0.6	12.42	0.44	7.18e-32	Corneal astigmatism;
BRCA	cis	rs10267417	0.603	rs12669215	chr7:19933427	C/T	cg05791153	chr7:19748676	TWISTNB	0.43	8.09	0.3	3.01e-15	Night sleep phenotypes;
BRCA	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg08992911	chr2:238395768	MLPH	0.59	10.18	0.37	1.18e-22	Prostate cancer;
BRCA	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg05340658	chr4:99064831	C4orf37	0.68	16.98	0.56	1.21e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-12.09	-0.43	1.93e-30	Mood instability;
BRCA	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg13852791	chr20:30311386	BCL2L1	0.86	16.88	0.56	3.89e-53	Mean corpuscular hemoglobin;
BRCA	cis	rs17401966	0.838	rs34565762	chr1:10300119	T/C	cg03954927	chr1:10346856	KIF1B	0.44	13.95	0.48	8.64e-39	Hepatocellular carcinoma;
BRCA	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-11.07	-0.4	3.42e-26	Uric acid levels;
BRCA	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.96	-0.3	7.64e-15	Depression;
BRCA	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.59	10.1	0.37	2.31e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg11663144	chr21:46675770	NA	-0.49	-9.78	-0.36	3.89e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs698833	0.828	rs2850298	chr2:44731590	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	10.03	0.37	4.52e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24549020	chr5:56110836	MAP3K1	0.6	12.38	0.44	1.03e-31	Initial pursuit acceleration;
BRCA	cis	rs2463822	1.000	rs72921498	chr11:62113090	C/T	cg06239285	chr11:62104954	ASRGL1	-0.68	-11.38	-0.41	1.93e-27	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs7617773	0.746	rs6796343	chr3:48282021	C/A	cg11946769	chr3:48343235	NME6	0.67	13.88	0.48	1.83e-38	Coronary artery disease;
BRCA	cis	rs17253792	0.822	rs10143002	chr14:56074278	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-10.6	-0.39	2.74e-24	Putamen volume;
BRCA	cis	rs7833986	1.000	rs13273123	chr8:57100791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	-0.45	-8.14	-0.31	2.13e-15	Height;
BRCA	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg12698349	chr2:225449008	CUL3	0.84	29.39	0.76	8.89e-121	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg12564285	chr5:131593104	PDLIM4	0.36	9.83	0.36	2.57e-21	Breast cancer;
BRCA	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg08601574	chr20:25228251	PYGB	0.34	8.16	0.31	1.79e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg19626725	chr5:178986131	RUFY1	0.31	8.43	0.32	2.3e-16	Lung cancer;
BRCA	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg27398817	chr8:82754497	SNX16	-0.48	-9.14	-0.34	8.31e-19	Diastolic blood pressure;
BRCA	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg04025307	chr7:1156635	C7orf50	0.46	10.35	0.38	2.66e-23	Bronchopulmonary dysplasia;
BRCA	trans	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg26384229	chr12:38710491	ALG10B	0.51	11.13	0.4	1.95e-26	Morning vs. evening chronotype;
BRCA	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg22139774	chr2:100720529	AFF3	-0.28	-7.99	-0.3	6.2e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22455342	chr2:225449267	CUL3	0.65	17.09	0.56	3.49e-54	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg01483505	chr11:975446	AP2A2	0.3	8.09	0.3	2.97e-15	Alzheimer's disease (late onset);
BRCA	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg20387954	chr3:183756860	HTR3D	0.45	10.08	0.37	2.78e-22	Anterior chamber depth;
BRCA	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03517284	chr6:25882590	NA	-0.5	-11.34	-0.41	2.87e-27	Blood metabolite levels;
BRCA	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg18446336	chr7:2847575	GNA12	-0.35	-8.3	-0.31	6.39e-16	Height;
BRCA	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg24633833	chr3:10029261	TMEM111	0.41	7.96	0.3	8.17e-15	Alzheimer's disease;
BRCA	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg05623727	chr3:50126028	RBM5	-0.42	-10.07	-0.37	3.02e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	14.3	0.49	1.82e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24838063	chr12:130822603	PIWIL1	0.67	16.36	0.54	1.6e-50	Menopause (age at onset);
BRCA	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.8	11.47	0.41	7.88e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2255932	1.000	rs11075	chr3:183213236	G/A	cg12326526	chr3:183209927	KLHL6	0.46	7.81	0.3	2.44e-14	Interleukin-1-beta levels;
BRCA	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg13385794	chr1:248469461	NA	0.27	7.89	0.3	1.32e-14	Common traits (Other);
BRCA	trans	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg26043149	chr18:55253948	FECH	0.4	8.71	0.33	2.66e-17	Bone mineral density;
BRCA	cis	rs7011049	1.000	rs72640852	chr8:53838084	G/A	cg26025543	chr8:53854495	NA	0.55	9.64	0.36	1.25e-20	Systolic blood pressure;
BRCA	cis	rs11608355	0.515	rs2287191	chr12:109931741	C/T	cg05360138	chr12:110035743	NA	0.74	13.68	0.48	1.56e-37	Neuroticism;
BRCA	cis	rs738322	0.555	rs2284063	chr22:38544298	C/T	cg20207973	chr22:38506712	BAIAP2L2	-0.33	-8.16	-0.31	1.78e-15	Cutaneous nevi;
BRCA	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg08917208	chr2:24149416	ATAD2B	0.52	8.07	0.3	3.37e-15	Lymphocyte counts;
BRCA	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00166722	chr3:10149974	C3orf24	0.67	13.44	0.47	1.83e-36	Alzheimer's disease;
BRCA	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	9.91	0.37	1.2e-21	Lung cancer in ever smokers;
BRCA	cis	rs17253792	0.545	rs35294669	chr14:56017438	T/A	cg01858014	chr14:56050164	KTN1	-0.61	-7.99	-0.3	6.09e-15	Putamen volume;
BRCA	cis	rs6120849	0.901	rs11696967	chr20:33743609	A/C	cg24642439	chr20:33292090	TP53INP2	0.48	8.51	0.32	1.2e-16	Protein C levels;
BRCA	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg17063962	chr7:91808500	NA	-0.52	-12.15	-0.43	1e-30	Breast cancer;
BRCA	cis	rs7394190	0.748	rs3781216	chr10:75522404	G/A	cg07699608	chr10:75541558	CHCHD1	0.66	9.9	0.36	1.34e-21	Incident atrial fibrillation;
BRCA	cis	rs10465746	0.570	rs2147950	chr1:84465545	C/T	cg10977910	chr1:84465055	TTLL7	0.54	11.15	0.4	1.72e-26	Obesity-related traits;
BRCA	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg00825309	chr19:58991885	ZNF446	-0.64	-14.27	-0.49	2.53e-40	Uric acid clearance;
BRCA	trans	rs8073060	0.544	rs7211724	chr17:33993414	C/G	cg19694781	chr19:47549865	TMEM160	-1.05	-22.33	-0.66	4.41e-82	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg13334819	chr7:99746414	C7orf59	-0.34	-8.11	-0.31	2.68e-15	Coronary artery disease;
BRCA	cis	rs3820928	0.874	rs6706802	chr2:227850776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.79	-0.33	1.35e-17	Pulmonary function;
BRCA	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg06191203	chr2:152266755	RIF1	-0.33	-9.08	-0.34	1.29e-18	Lung cancer;
BRCA	cis	rs13064411	0.542	rs7631335	chr3:113209166	C/T	cg18753928	chr3:113234510	CCDC52	-0.46	-9.92	-0.37	1.14e-21	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs926392	0.572	rs6129158	chr20:37673967	A/G	cg16355469	chr20:37678765	NA	0.49	11.78	0.42	3.81e-29	Dialysis-related mortality;
BRCA	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg13010199	chr12:38710504	ALG10B	0.45	9.09	0.34	1.19e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.58	11.01	0.4	6.48e-26	Height;
BRCA	cis	rs4889855	0.530	rs62068346	chr17:78608052	A/G	cg16591659	chr17:78472290	NA	-0.31	-7.9	-0.3	1.23e-14	Fractional excretion of uric acid;
BRCA	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg27129171	chr3:47204927	SETD2	0.65	14.72	0.5	1.87e-42	Colorectal cancer;
BRCA	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg10223061	chr2:219282414	VIL1	-0.27	-7.83	-0.3	2.02e-14	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs113835537	0.529	rs10896125	chr11:66288733	G/C	cg24851651	chr11:66362959	CCS	0.43	8.16	0.31	1.78e-15	Airway imaging phenotypes;
BRCA	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg03477792	chr4:77819574	ANKRD56	0.62	15.03	0.51	5.79e-44	Emphysema distribution in smoking;
BRCA	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg07274523	chr3:49395745	GPX1	0.45	7.94	0.3	8.82e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg00071950	chr4:10020882	SLC2A9	0.57	13.88	0.48	1.78e-38	Bone mineral density;
BRCA	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg05863683	chr7:1912471	MAD1L1	0.38	8.41	0.32	2.77e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	12.01	0.43	4.39e-30	Schizophrenia;
BRCA	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.65	16.8	0.55	9.85e-53	Colorectal cancer;
BRCA	cis	rs586533	0.881	rs655715	chr11:99500369	A/G	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs12681288	0.676	rs2701913	chr8:999982	A/T	cg04851639	chr8:1020857	NA	-0.38	-10.97	-0.4	8.81e-26	Schizophrenia;
BRCA	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg09555818	chr19:45449301	APOC2	0.47	12.22	0.44	5.19e-31	Blood protein levels;
BRCA	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg05457628	chr5:178986728	RUFY1	0.41	9.36	0.35	1.36e-19	Lung cancer;
BRCA	cis	rs4919694	0.901	rs12264456	chr10:104830634	C/T	cg04362960	chr10:104952993	NT5C2	0.94	14.66	0.5	3.75e-42	Arsenic metabolism;
BRCA	cis	rs7264396	1.000	rs224430	chr20:34153341	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-9.96	-0.37	8.39e-22	Total cholesterol levels;
BRCA	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg06582575	chr6:163149167	PACRG;PARK2	1.01	14.97	0.51	1.25e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4908760	0.827	rs1463053	chr1:8705037	C/T	cg20416874	chr1:8611966	RERE	-0.27	-7.96	-0.3	7.68e-15	Vitiligo;
BRCA	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.37	-0.31	3.54e-16	Bipolar disorder;
BRCA	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg13736514	chr6:26305472	NA	-0.29	-9.67	-0.36	9.42e-21	Educational attainment;
BRCA	cis	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg06521331	chr12:34319734	NA	-0.63	-12.21	-0.43	5.84e-31	Morning vs. evening chronotype;
BRCA	cis	rs12618769	0.597	rs72820002	chr2:99075259	T/A	cg10123293	chr2:99228465	UNC50	0.41	8.27	0.31	8.05e-16	Bipolar disorder;
BRCA	cis	rs1865721	0.771	rs4622605	chr18:73139008	T/C	cg26385618	chr18:73139727	C18orf62	-0.44	-10.78	-0.39	5.22e-25	Intelligence;
BRCA	cis	rs13102973	0.932	rs13149380	chr4:135866539	A/C	cg14419869	chr4:135874104	NA	0.51	10.97	0.4	9.38e-26	Subjective well-being;
BRCA	cis	rs7474896	0.832	rs12357256	chr10:38359501	A/G	cg25427524	chr10:38739819	LOC399744	-0.59	-8.11	-0.31	2.59e-15	Obesity (extreme);
BRCA	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.19	-0.31	1.44e-15	Bipolar disorder;
BRCA	cis	rs2979489	0.786	rs62508366	chr8:30369499	G/A	cg26383811	chr8:30366931	RBPMS	-0.56	-12.83	-0.45	1.07e-33	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
BRCA	trans	rs1973993	0.745	rs986427	chr1:96932736	A/G	cg10631902	chr5:14652156	NA	-0.49	-14.0	-0.48	4.75e-39	Weight;
BRCA	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg17644776	chr2:200775616	C2orf69	-0.46	-8.67	-0.32	3.61e-17	Schizophrenia;
BRCA	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg24848339	chr3:12840334	CAND2	0.46	12.16	0.43	9.01e-31	QRS complex (12-leadsum);
BRCA	cis	rs1784581	0.894	rs1790001	chr6:162387504	G/T	cg17173639	chr6:162384350	PARK2	-0.47	-11.42	-0.41	1.23e-27	Itch intensity from mosquito bite;
BRCA	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03517284	chr6:25882590	NA	0.36	7.98	0.3	6.82e-15	Blood metabolite levels;
BRCA	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg22972055	chr7:872293	UNC84A	0.38	8.63	0.32	4.83e-17	Cerebrospinal P-tau181p levels;
BRCA	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg04944784	chr2:26401820	FAM59B	-0.68	-11.19	-0.4	1.19e-26	Gut microbiome composition (summer);
BRCA	cis	rs1506636	0.962	rs1019220	chr7:123365122	G/A	cg03229431	chr7:123269106	ASB15	-0.61	-13.77	-0.48	5.52e-38	Plateletcrit;Platelet count;
BRCA	cis	rs8016982	0.674	rs1951614	chr14:81672106	A/G	cg01989461	chr14:81687754	GTF2A1	-0.71	-16.3	-0.54	3.23e-50	Schizophrenia;
BRCA	cis	rs7818345	1.000	rs4618712	chr8:19302621	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.32	8.32	0.31	5.4e-16	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg05714579	chr10:131428358	MGMT	0.54	12.77	0.45	2.09e-33	Response to temozolomide;
BRCA	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.89	-0.33	6.07e-18	Total body bone mineral density;
BRCA	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg04234412	chr22:24373322	LOC391322	0.56	13.22	0.46	1.98e-35	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg22834771	chr12:69754056	YEATS4	-0.37	-9.05	-0.34	1.69e-18	Blood protein levels;
BRCA	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg14675211	chr2:100938903	LONRF2	0.49	11.18	0.4	1.22e-26	Intelligence (multi-trait analysis);
BRCA	trans	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg19862616	chr7:65841803	NCRNA00174	0.83	27.56	0.74	8.71e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg08601574	chr20:25228251	PYGB	-0.36	-8.56	-0.32	8.44e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs9944715	0.734	rs9967220	chr18:43780059	C/T	cg01718231	chr17:29326311	RNF135	-0.46	-9.07	-0.34	1.44e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg10932868	chr11:921992	NA	0.39	9.6	0.35	1.84e-20	Alzheimer's disease (late onset);
BRCA	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.76e-18	Motion sickness;
BRCA	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg12661370	chr5:149340060	SLC26A2	-0.58	-8.46	-0.32	1.8e-16	HIV-1 control;
BRCA	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg21573476	chr21:45109991	RRP1B	-0.37	-9.55	-0.35	2.71e-20	Mean corpuscular volume;
BRCA	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg27170947	chr2:26402098	FAM59B	-1.0	-17.53	-0.57	1.82e-56	Gut microbiome composition (summer);
BRCA	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg05340658	chr4:99064831	C4orf37	0.46	10.63	0.39	2.06e-24	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.89	0.3	1.33e-14	Corneal astigmatism;
BRCA	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	9.33	0.35	1.64e-19	Rheumatoid arthritis;
BRCA	cis	rs2625529	0.824	rs11072338	chr15:72245447	T/C	cg16672083	chr15:72433130	SENP8	-0.84	-17.52	-0.57	2.13e-56	Red blood cell count;
BRCA	trans	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.34	0.31	4.69e-16	Corneal astigmatism;
BRCA	cis	rs7524258	0.778	rs12028181	chr1:7315085	C/T	cg07173049	chr1:7289937	CAMTA1	-0.4	-9.89	-0.36	1.48e-21	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg23711669	chr6:146136114	FBXO30	-0.78	-18.82	-0.6	3.19e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.82	0.36	2.79e-21	Lung cancer in ever smokers;
BRCA	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-15.52	-0.52	2.57e-46	Bipolar disorder and schizophrenia;
BRCA	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg22467129	chr15:76604101	ETFA	-0.5	-10.91	-0.4	1.64e-25	Blood metabolite levels;
BRCA	cis	rs6942756	1.000	rs67820265	chr7:128887925	A/G	cg02491457	chr7:128862824	NA	-0.71	-14.06	-0.49	2.64e-39	White matter hyperintensity burden;
BRCA	cis	rs1941023	0.567	rs955019	chr11:60174250	C/T	cg08716584	chr11:60157161	MS4A7	-0.34	-8.01	-0.3	5.33e-15	Congenital heart disease (maternal effect);
BRCA	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg24060327	chr5:131705240	SLC22A5	-0.62	-11.87	-0.43	1.63e-29	Breast cancer;
BRCA	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg21138405	chr5:131827807	IRF1	0.38	12.38	0.44	1.01e-31	Asthma (sex interaction);
BRCA	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg14844989	chr11:31128820	NA	-0.45	-9.65	-0.36	1.14e-20	Red blood cell count;
BRCA	cis	rs11971779	0.680	rs7801613	chr7:139039927	A/G	cg07862535	chr7:139043722	LUC7L2	-0.4	-10.78	-0.39	5.41e-25	Diisocyanate-induced asthma;
BRCA	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.58	-0.32	7.39e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg03676636	chr4:99064102	C4orf37	0.21	7.9	0.3	1.2e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11955398	0.563	rs7730342	chr5:60020645	G/T	cg02684056	chr5:59996105	DEPDC1B	-0.37	-9.0	-0.34	2.58e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs11971779	0.941	rs4732368	chr7:139034207	A/C	cg07862535	chr7:139043722	LUC7L2	0.53	12.94	0.46	3.33e-34	Diisocyanate-induced asthma;
BRCA	cis	rs243505	0.732	rs3800949	chr7:148479648	A/T	cg09806900	chr7:148480153	CUL1	-0.5	-10.44	-0.38	1.1e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.1	0.4	2.68e-26	Bipolar disorder;
BRCA	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg00321850	chr1:175162397	KIAA0040	0.43	12.38	0.44	1.05e-31	Alcohol dependence;
BRCA	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.13	-0.31	2.23e-15	Total body bone mineral density;
BRCA	cis	rs4285028	0.948	rs7640872	chr3:121697168	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.58	-10.41	-0.38	1.49e-23	Multiple sclerosis;
BRCA	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg00277334	chr10:82204260	NA	0.49	8.66	0.32	3.73e-17	Post bronchodilator FEV1;
BRCA	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.91	-0.43	1.13e-29	Total cholesterol levels;
BRCA	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg09904177	chr6:26538194	HMGN4	0.55	17.71	0.57	2.12e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg24642439	chr20:33292090	TP53INP2	0.7	15.65	0.53	5.93e-47	Coronary artery disease;
BRCA	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg23205692	chr1:25664452	TMEM50A	0.41	9.86	0.36	1.87e-21	Erythrocyte sedimentation rate;
BRCA	cis	rs10779751	0.708	rs2746640	chr1:11292952	T/A	cg08854313	chr1:11322531	MTOR	0.77	15.8	0.53	1.06e-47	Body mass index;
BRCA	cis	rs9309473	0.687	rs6748040	chr2:73609928	A/G	cg20560298	chr2:73613845	ALMS1	0.46	12.09	0.43	1.99e-30	Metabolite levels;
BRCA	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.88	-0.33	6.76e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg24675658	chr1:53192096	ZYG11B	-0.53	-11.19	-0.4	1.13e-26	Monocyte count;
BRCA	cis	rs8040855	0.825	rs3964197	chr15:85721912	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.33	-8.3	-0.31	6.1e-16	Bulimia nervosa;
BRCA	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg20587970	chr11:113659929	NA	-1.2	-21.93	-0.66	6.74e-80	Hip circumference adjusted for BMI;
BRCA	cis	rs367615	0.918	rs10070104	chr5:108866438	C/T	cg17395555	chr5:108820864	NA	-0.38	-9.86	-0.36	1.96e-21	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs2712184	0.655	rs1003622	chr2:217653608	A/G	cg05032264	chr2:217675019	NA	-0.38	-9.08	-0.34	1.34e-18	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	trans	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-10.97	-0.4	8.96e-26	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs7586879	0.828	rs1865688	chr2:25108245	C/G	cg04586622	chr2:25135609	ADCY3	0.39	9.39	0.35	1e-19	Body mass index;
BRCA	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.08	0.34	1.38e-18	Platelet count;
BRCA	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg10820045	chr2:198174542	NA	-0.42	-9.6	-0.36	1.75e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg03146154	chr1:46216737	IPP	0.46	10.03	0.37	4.21e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs858239	0.600	rs7790157	chr7:23126998	G/A	cg23682824	chr7:23144976	KLHL7	0.45	12.21	0.44	5.48e-31	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.03	0.3	4.69e-15	Corneal astigmatism;
BRCA	trans	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg24060327	chr5:131705240	SLC22A5	-0.49	-10.21	-0.37	8.98e-23	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg00106254	chr7:1943704	MAD1L1	-0.4	-9.62	-0.36	1.49e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs7394190	0.748	rs16930909	chr10:75561582	T/C	cg07699608	chr10:75541558	CHCHD1	0.67	10.11	0.37	2.24e-22	Incident atrial fibrillation;
BRCA	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg06636001	chr8:8085503	FLJ10661	0.44	8.13	0.31	2.18e-15	Obesity-related traits;
BRCA	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.49	0.5	2.35e-41	Motion sickness;
BRCA	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg08645402	chr16:4508243	NA	-0.4	-9.52	-0.35	3.53e-20	Schizophrenia;
BRCA	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg16576597	chr16:28551801	NUPR1	0.3	8.37	0.31	3.53e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg09307838	chr4:120376055	NA	0.69	14.25	0.49	3.17e-40	Corneal astigmatism;
BRCA	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg20887711	chr4:1340912	KIAA1530	0.72	15.76	0.53	1.72e-47	Longevity;
BRCA	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.67	15.19	0.52	9.84e-45	Axial length;
BRCA	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg04362960	chr10:104952993	NT5C2	0.44	9.95	0.37	8.74e-22	Arsenic metabolism;
BRCA	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg24692254	chr21:30365293	RNF160	-0.63	-16.19	-0.54	1.22e-49	Dental caries;
BRCA	cis	rs4363385	0.782	rs4845336	chr1:153003853	C/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.08	-0.34	1.39e-18	Inflammatory skin disease;
BRCA	cis	rs72772090	0.710	rs17400685	chr5:96066366	A/C	cg17330273	chr5:96107758	CAST;ERAP1	0.6	12.98	0.46	2.4e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg08470875	chr2:26401718	FAM59B	0.77	11.93	0.43	8.92e-30	Gut microbiome composition (summer);
BRCA	trans	rs9951602	0.512	rs1599633	chr18:76643526	T/C	cg02800362	chr5:177631904	HNRNPAB	0.76	17.5	0.57	2.47e-56	Obesity-related traits;
BRCA	cis	rs7555523	0.943	rs4537525	chr1:165711089	T/G	cg24409356	chr1:165738333	TMCO1	0.51	8.21	0.31	1.23e-15	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	22.42	0.66	1.4e-82	Platelet count;
BRCA	cis	rs4363385	0.747	rs1577962	chr1:152962013	A/G	cg24667326	chr1:152973720	SPRR3	-0.33	-9.35	-0.35	1.4e-19	Inflammatory skin disease;
BRCA	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.5	0.63	3.81e-72	Chronic sinus infection;
BRCA	cis	rs501916	0.634	rs3803349	chr15:48064867	T/A	cg16110827	chr15:48056943	SEMA6D	-0.42	-8.82	-0.33	1.08e-17	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg02820040	chr2:241836501	C2orf54	-0.51	-9.57	-0.35	2.34e-20	Urinary metabolites;
BRCA	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg26031613	chr14:104095156	KLC1	0.44	8.38	0.31	3.36e-16	Coronary artery disease;
BRCA	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07080220	chr10:102295463	HIF1AN	0.52	11.45	0.41	9.33e-28	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.77	0.67	1.63e-84	Chronic sinus infection;
BRCA	trans	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.61	10.77	0.39	5.59e-25	Type 2 diabetes;
BRCA	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	8.93	0.33	4.64e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg16414030	chr3:133502952	NA	0.5	11.89	0.43	1.32e-29	Iron status biomarkers;
BRCA	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg15556689	chr8:8085844	FLJ10661	0.42	11.31	0.41	3.78e-27	Retinal vascular caliber;
BRCA	trans	rs61931739	0.513	rs1608908	chr12:33895389	C/A	cg13010199	chr12:38710504	ALG10B	0.37	8.21	0.31	1.24e-15	Morning vs. evening chronotype;
BRCA	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg07741184	chr6:167504864	NA	-0.27	-7.96	-0.3	7.62e-15	Crohn's disease;
BRCA	trans	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg07211511	chr3:129823064	LOC729375	-0.63	-11.05	-0.4	4.13e-26	Blood pressure (smoking interaction);
BRCA	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg06046430	chr4:77819534	ANKRD56	0.58	13.14	0.46	4.56e-35	Emphysema distribution in smoking;
BRCA	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg12072164	chr19:44306565	LYPD5	0.37	8.67	0.32	3.46e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs10045504	0.502	rs57589709	chr5:38733853	C/T	cg15396434	chr5:38725168	NA	-0.59	-11.11	-0.4	2.41e-26	Night sleep phenotypes;
BRCA	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08280861	chr8:58055591	NA	0.54	8.66	0.32	3.79e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg06618935	chr21:46677482	NA	-0.38	-8.45	-0.32	1.89e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26897989	chr16:1907736	C16orf73	-0.52	-9.58	-0.35	2.04e-20	Ankle injury;
BRCA	trans	rs931812	0.895	rs13251731	chr8:101902528	C/G	cg20993868	chr7:22813445	NA	0.55	16.25	0.54	5.7e-50	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg18964960	chr10:1102726	WDR37	0.59	7.86	0.3	1.66e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs7590720	1.000	rs934156	chr2:216901482	C/T	cg12620499	chr2:216877984	MREG	-0.78	-21.0	-0.64	7.6e-75	Alcohol dependence;
BRCA	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg27087555	chr16:88793112	FAM38A	0.74	11.03	0.4	5.37e-26	Plateletcrit;
BRCA	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg08999081	chr20:33150536	PIGU	-0.46	-12.77	-0.45	2.05e-33	Glomerular filtration rate (creatinine);
BRCA	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg27398817	chr8:82754497	SNX16	0.36	8.17	0.31	1.69e-15	Diastolic blood pressure;
BRCA	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg03929089	chr4:120376271	NA	0.47	7.95	0.3	8.43e-15	Axial length;
BRCA	cis	rs1005224	0.889	rs9323617	chr14:76158638	A/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.35	-8.19	-0.31	1.45e-15	Large artery stroke;
BRCA	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	19.28	0.61	1.2e-65	Smoking behavior;
BRCA	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg23711669	chr6:146136114	FBXO30	0.79	18.88	0.6	1.64e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg20848291	chr7:100343083	ZAN	-0.58	-10.7	-0.39	1.09e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08645402	chr16:4508243	NA	0.43	9.71	0.36	7.11e-21	Schizophrenia;
BRCA	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.75	-0.33	1.93e-17	Bipolar disorder and schizophrenia;
BRCA	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg15819921	chr19:927150	ARID3A	-0.47	-9.04	-0.34	1.84e-18	Life satisfaction;
BRCA	cis	rs7555523	0.887	rs4657471	chr1:165686873	T/C	cg24409356	chr1:165738333	TMCO1	0.53	8.4	0.32	2.88e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg08917208	chr2:24149416	ATAD2B	0.94	14.06	0.49	2.61e-39	Lymphocyte counts;
BRCA	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg22875332	chr1:76189707	ACADM	-0.48	-9.13	-0.34	9.22e-19	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg22907277	chr7:1156413	C7orf50	0.38	8.46	0.32	1.76e-16	Longevity;Endometriosis;
BRCA	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg02196655	chr2:10830764	NOL10	0.3	8.15	0.31	1.96e-15	Prostate cancer;
BRCA	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg12011299	chr4:100065546	ADH4	0.48	10.93	0.4	1.34e-25	Smoking initiation;
BRCA	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg18154014	chr19:37997991	ZNF793	0.48	9.45	0.35	6.34e-20	Coronary artery calcification;
BRCA	cis	rs7809950	1.000	rs10258385	chr7:107243350	T/C	cg23024343	chr7:107201750	COG5	0.42	9.1	0.34	1.15e-18	Coronary artery disease;
BRCA	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg12927641	chr6:109611667	NA	-0.42	-10.7	-0.39	1.06e-24	Reticulocyte fraction of red cells;
BRCA	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg08645402	chr16:4508243	NA	-0.37	-8.86	-0.33	7.59e-18	Schizophrenia;
BRCA	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	15.63	0.53	7.54e-47	Smoking behavior;
BRCA	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg22800045	chr5:56110881	MAP3K1	0.55	10.46	0.38	9.49e-24	Initial pursuit acceleration;
BRCA	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.49	-12.05	-0.43	2.92e-30	Longevity;Endometriosis;
BRCA	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg11502198	chr6:26597334	ABT1	0.57	12.09	0.43	1.82e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg18758796	chr5:131593413	PDLIM4	0.33	8.85	0.33	8.25e-18	Breast cancer;
BRCA	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg02574844	chr11:5959923	NA	0.38	8.16	0.31	1.84e-15	DNA methylation (variation);
BRCA	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg18402987	chr7:1209562	NA	0.52	9.45	0.35	6.36e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.57	-0.39	3.68e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg00814883	chr7:100076585	TSC22D4	-0.49	-9.64	-0.36	1.26e-20	Platelet count;
BRCA	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg00677455	chr12:58241039	CTDSP2	0.47	11.51	0.41	5.58e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg24642844	chr7:1081250	C7orf50	-0.89	-16.0	-0.53	1.07e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg22875332	chr1:76189707	ACADM	0.61	11.52	0.41	4.96e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg05535760	chr7:792225	HEATR2	0.72	13.12	0.46	5.64e-35	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-10.15	-0.37	1.59e-22	Personality dimensions;
BRCA	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg26343298	chr8:95960752	TP53INP1	0.3	8.74	0.33	2.07e-17	Type 2 diabetes;
BRCA	cis	rs7646881	1.000	rs61558956	chr3:158452655	T/A	cg19483011	chr3:158453295	NA	-0.41	-8.08	-0.3	3.34e-15	Tetralogy of Fallot;
BRCA	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26168224	chr5:2018326	NA	0.64	17.98	0.58	8.6e-59	Gut microbiome composition (winter);
BRCA	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs243505	0.559	rs7802887	chr7:148494758	C/T	cg09806900	chr7:148480153	CUL1	0.54	11.04	0.4	4.81e-26	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg19628046	chr18:33552617	C18orf21	0.59	12.12	0.43	1.44e-30	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs2963155	0.518	rs853184	chr5:142640901	C/T	cg17617527	chr5:142782415	NR3C1	0.51	7.81	0.3	2.37e-14	Breast cancer;
BRCA	cis	rs7523273	0.606	rs859706	chr1:207962270	G/A	cg22525895	chr1:207977042	MIR29B2	-0.51	-12.9	-0.45	5.23e-34	Schizophrenia;
BRCA	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg11707556	chr5:10655725	ANKRD33B	0.36	8.51	0.32	1.2e-16	Coronary artery disease;
BRCA	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg11366901	chr6:160182831	ACAT2	0.8	15.57	0.52	1.41e-46	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg13010199	chr12:38710504	ALG10B	0.47	9.04	0.34	1.78e-18	Morning vs. evening chronotype;
BRCA	cis	rs2859741	0.608	rs532719	chr1:37477380	C/T	cg09363841	chr1:37513479	NA	0.51	10.93	0.4	1.26e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg03929089	chr4:120376271	NA	0.78	18.17	0.58	8.47e-60	Height;
BRCA	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg17470723	chr8:74884337	TCEB1	0.4	8.58	0.32	6.98e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs752010	0.806	rs10890148	chr1:42091517	T/C	cg06885757	chr1:42089581	HIVEP3	0.28	10.28	0.38	4.88e-23	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs9287719	0.649	rs10175884	chr2:10718534	C/T	cg00105475	chr2:10696890	NA	0.41	9.19	0.34	5.62e-19	Prostate cancer;
BRCA	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25427524	chr10:38739819	LOC399744	-0.65	-15.66	-0.53	5.3e-47	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7408868	1.000	rs10416389	chr19:15278674	G/C	cg14696996	chr19:15285081	NOTCH3	1.0	14.52	0.5	1.76e-41	Pulse pressure;
BRCA	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	19.28	0.61	1.2e-65	Smoking behavior;
BRCA	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.31	-0.35	1.95e-19	Alzheimer's disease (late onset);
BRCA	cis	rs12474201	0.588	rs3768719	chr2:46987935	T/G	cg06386533	chr2:46925753	SOCS5	0.61	12.82	0.45	1.24e-33	Height;
BRCA	cis	rs2249625	0.816	rs2496499	chr6:72884414	T/A	cg18830697	chr6:72922368	RIMS1	-0.37	-7.86	-0.3	1.63e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs4853036	0.953	rs35667002	chr2:70032867	A/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-8.97	-0.33	3.27e-18	Colorectal or endometrial cancer;
BRCA	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.88	-0.33	6.81e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-13.15	-0.46	4.02e-35	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg03146154	chr1:46216737	IPP	0.52	11.59	0.42	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg13385794	chr1:248469461	NA	0.27	7.92	0.3	1.09e-14	Common traits (Other);
BRCA	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	10.05	0.37	3.55e-22	Retinal vascular caliber;
BRCA	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg22681709	chr2:178499509	PDE11A	-0.38	-8.22	-0.31	1.17e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg23033748	chr14:75592666	NEK9	-0.33	-7.9	-0.3	1.27e-14	Height;
BRCA	cis	rs4891159	0.548	rs11150952	chr18:74128188	T/C	cg24786174	chr18:74118243	ZNF516	0.84	25.36	0.71	1.06e-98	Longevity;
BRCA	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg27165867	chr14:105738592	BRF1	0.36	8.79	0.33	1.42e-17	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg22920501	chr2:26401640	FAM59B	-0.64	-10.82	-0.39	3.48e-25	Gut microbiome composition (summer);
BRCA	cis	rs2116941	1.000	rs2033493	chr19:10340854	A/C	cg01850179	chr19:10340795	S1PR2	-0.64	-12.54	-0.44	2.1e-32	Pulse pressure;
BRCA	cis	rs7809950	0.678	rs13230144	chr7:106909172	T/C	cg23024343	chr7:107201750	COG5	-0.44	-9.03	-0.34	1.97e-18	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	18.17	0.58	9.13e-60	Alzheimer's disease;
BRCA	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4730250	0.707	rs6960148	chr7:106786142	A/G	cg02696742	chr7:106810147	HBP1	0.62	9.87	0.36	1.82e-21	Osteoarthritis;
BRCA	cis	rs507080	0.922	rs558907	chr11:118558455	A/G	cg08498647	chr11:118550644	TREH	-0.38	-8.26	-0.31	8.3e-16	Serum metabolite levels;
BRCA	cis	rs4787491	0.729	rs12446378	chr16:30043110	T/G	cg06326092	chr16:30034487	C16orf92	0.38	9.93	0.37	1.07e-21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.04	-0.3	4.32e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg12373951	chr3:133503437	NA	-0.42	-10.05	-0.37	3.63e-22	Iron status biomarkers;
BRCA	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02018176	chr4:1364513	KIAA1530	0.36	7.82	0.3	2.27e-14	Longevity;
BRCA	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg04025307	chr7:1156635	C7orf50	0.54	13.59	0.47	3.89e-37	Longevity;Endometriosis;
BRCA	cis	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg06521331	chr12:34319734	NA	-0.63	-12.21	-0.43	5.84e-31	Morning vs. evening chronotype;
BRCA	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg04362960	chr10:104952993	NT5C2	-0.4	-9.7	-0.36	7.85e-21	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs5167	0.504	rs892101	chr19:45455458	G/A	cg20090143	chr19:45452003	APOC2	0.27	8.07	0.3	3.42e-15	Blood protein levels;
BRCA	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.11	0.31	2.59e-15	Menopause (age at onset);
BRCA	cis	rs66569888	0.523	rs4522599	chr2:106926004	G/C	cg15412446	chr2:106886593	NA	0.45	8.93	0.33	4.61e-18	Facial morphology (factor 23);
BRCA	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg13660082	chr14:53194042	PSMC6	-0.54	-8.45	-0.32	1.96e-16	Alzheimer's disease (late onset);
BRCA	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.87	-0.3	1.57e-14	Aortic root size;
BRCA	trans	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	9.09	0.34	1.27e-18	Systemic lupus erythematosus;
BRCA	trans	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg17675199	chr6:35436792	RPL10A	-0.31	-8.34	-0.31	4.62e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg10556349	chr10:835070	NA	0.67	9.69	0.36	8.31e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg19077165	chr18:44547161	KATNAL2	0.37	7.9	0.3	1.19e-14	Personality dimensions;
BRCA	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg13010199	chr12:38710504	ALG10B	0.42	9.07	0.34	1.45e-18	Bladder cancer;
BRCA	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02353165	chr6:42928485	GNMT	0.89	23.98	0.69	3.97e-91	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs877529	0.683	rs79501	chr22:39522940	A/G	cg12193277	chr22:39547181	CBX7	-0.36	-9.11	-0.34	1.01e-18	Multiple myeloma;
BRCA	cis	rs2882667	0.788	rs11959691	chr5:138481088	C/T	cg04439458	chr5:138467593	SIL1	-0.46	-11.52	-0.41	4.81e-28	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg18758796	chr5:131593413	PDLIM4	0.34	8.96	0.33	3.43e-18	Breast cancer;
BRCA	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12210905	0.688	rs72845232	chr6:27428126	T/G	cg08851530	chr6:28072375	NA	0.81	7.87	0.3	1.49e-14	Hip circumference adjusted for BMI;
BRCA	cis	rs700651	0.789	rs6715070	chr2:198898265	A/G	cg00792783	chr2:198669748	PLCL1	-0.39	-8.93	-0.33	4.38e-18	Intracranial aneurysm;
BRCA	cis	rs427394	0.772	rs274689	chr5:6736215	G/C	cg10857441	chr5:6722123	POLS	-0.33	-11.02	-0.4	5.8e-26	Menopause (age at onset);
BRCA	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.32	-10.13	-0.37	1.87e-22	Bipolar disorder;
BRCA	cis	rs7215564	0.818	rs1531946	chr17:78630807	G/A	cg06153925	chr17:78755379	RPTOR	0.48	8.35	0.31	4.08e-16	Myopia (pathological);
BRCA	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg02175503	chr12:58329896	NA	0.52	10.89	0.4	1.97e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	13.87	0.48	2.01e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9463078	0.764	rs6923519	chr6:44864152	A/G	cg25276700	chr6:44698697	NA	-0.35	-8.01	-0.3	5.38e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg07414643	chr4:187882934	NA	0.28	9.35	0.35	1.45e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg18305652	chr10:134549665	INPP5A	0.5	12.76	0.45	2.32e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs713587	0.520	rs487617	chr2:25309756	C/G	cg01884057	chr2:25150051	NA	-0.32	-8.39	-0.32	3.04e-16	Body mass index in non-asthmatics;
BRCA	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	10.91	0.4	1.61e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg23711669	chr6:146136114	FBXO30	0.69	15.84	0.53	6.37e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg04511125	chr2:88470314	THNSL2	0.77	12.29	0.44	2.67e-31	Plasma clusterin levels;
BRCA	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.84	-0.77	1.3e-128	Schizophrenia;
BRCA	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg17971929	chr21:40555470	PSMG1	-0.49	-10.88	-0.4	2.13e-25	Menarche (age at onset);
BRCA	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.23e-24	Motion sickness;
BRCA	cis	rs7103648	0.695	rs12577643	chr11:47467172	A/T	cg20307385	chr11:47447363	PSMC3	0.83	20.44	0.63	7.75e-72	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs11229555	0.645	rs10896778	chr11:58193925	T/G	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26314531	chr2:26401878	FAM59B	-0.78	-12.38	-0.44	1.07e-31	Gut microbiome composition (summer);
BRCA	cis	rs4818225	0.895	rs2837996	chr21:42626706	C/T	cg21268422	chr21:42620091	BACE2	-0.43	-8.27	-0.31	7.5e-16	Educational attainment;
BRCA	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-7.94	-0.3	9.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1538970	0.884	rs1771551	chr1:45883643	C/G	cg05343316	chr1:45956843	TESK2	0.53	10.88	0.4	2.04e-25	Platelet count;
BRCA	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.59	-12.27	-0.44	3.3e-31	Lymphocyte counts;
BRCA	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg26248373	chr2:1572462	NA	-0.63	-14.28	-0.49	2.45e-40	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg00990874	chr7:1149470	C7orf50	-0.63	-13.34	-0.47	5.48e-36	Bronchopulmonary dysplasia;
BRCA	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg03585969	chr10:35415529	CREM	0.56	11.45	0.41	9.48e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.07	-0.37	3.01e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6558174	0.965	rs4872524	chr8:22489537	A/G	cg03733263	chr8:22462867	KIAA1967	0.42	7.99	0.3	6.35e-15	Breast cancer;
BRCA	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg08085267	chr17:45401833	C17orf57	-0.58	-11.43	-0.41	1.19e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg21395723	chr22:39101663	GTPBP1	-0.38	-8.07	-0.3	3.45e-15	Menopause (age at onset);
BRCA	trans	rs12517041	1.000	rs2081954	chr5:23295705	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.93	-0.3	1.02e-14	Calcium levels;
BRCA	trans	rs783540	1.000	rs11637433	chr15:83321336	A/G	cg18393722	chr15:85113863	UBE2QP1	0.25	7.86	0.3	1.65e-14	Schizophrenia;
BRCA	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg04013093	chr6:42928303	GNMT	-0.28	-8.52	-0.32	1.12e-16	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.26	-0.41	5.68e-27	Morning vs. evening chronotype;
BRCA	cis	rs6942756	1.000	rs10954226	chr7:128953095	T/G	cg02491457	chr7:128862824	NA	-0.71	-14.01	-0.48	4.38e-39	White matter hyperintensity burden;
BRCA	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg00631329	chr6:26305371	NA	-0.42	-12.78	-0.45	1.86e-33	Educational attainment;
BRCA	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg21479132	chr6:26055353	NA	0.56	7.98	0.3	6.99e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg00757033	chr12:89920650	WDR51B	0.54	10.75	0.39	7.11e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.43	8.91	0.33	5.38e-18	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.29	-0.31	6.69e-16	Gut microbiome composition (summer);
BRCA	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	11.34	0.41	2.89e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg06521331	chr12:34319734	NA	-0.63	-12.2	-0.43	6.34e-31	Morning vs. evening chronotype;
BRCA	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg17063962	chr7:91808500	NA	-0.5	-11.7	-0.42	8.41e-29	Breast cancer;
BRCA	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg13256891	chr4:100009986	ADH5	0.4	8.44	0.32	2.08e-16	Alcohol dependence;
BRCA	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg27661571	chr11:113659931	NA	-0.46	-8.02	-0.3	5.2e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.15	0.37	1.53e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg06784218	chr1:46089804	CCDC17	0.49	11.74	0.42	6.06e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.35	-7.83	-0.3	2.06e-14	Longevity;Endometriosis;
BRCA	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg25382214	chr1:3105252	PRDM16	0.33	7.9	0.3	1.26e-14	Migraine;
BRCA	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg13319975	chr6:146136371	FBXO30	0.43	10.05	0.37	3.81e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13102973	0.965	rs10434072	chr4:135867883	C/T	cg14419869	chr4:135874104	NA	-0.59	-12.99	-0.46	2.18e-34	Subjective well-being;
BRCA	trans	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg25214090	chr10:38739885	LOC399744	0.5	10.98	0.4	8.5e-26	Corneal astigmatism;
BRCA	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg08859206	chr1:53392774	SCP2	0.42	8.31	0.31	5.61e-16	Monocyte count;
BRCA	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.26e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg03676636	chr4:99064102	C4orf37	0.21	7.97	0.3	7.55e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg05234568	chr11:5960015	NA	0.45	8.8	0.33	1.28e-17	DNA methylation (variation);
BRCA	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00166722	chr3:10149974	C3orf24	0.64	11.05	0.4	4.19e-26	Alzheimer's disease;
BRCA	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg12591125	chr7:1885375	MAD1L1	-0.49	-8.54	-0.32	9.83e-17	Bipolar disorder;
BRCA	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg15704280	chr7:45808275	SEPT13	-0.46	-8.91	-0.33	5.36e-18	HDL cholesterol;
BRCA	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg24558204	chr6:135376177	HBS1L	0.59	15.94	0.53	2.1e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg27661571	chr11:113659931	NA	-0.75	-11.56	-0.42	3.28e-28	Hip circumference adjusted for BMI;
BRCA	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	10.13	0.37	1.81e-22	Tonsillectomy;
BRCA	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg10729496	chr3:10149963	C3orf24	0.42	8.08	0.3	3.25e-15	Alzheimer's disease;
BRCA	cis	rs11051970	0.545	rs2651374	chr12:32582858	G/A	cg24626660	chr12:32551988	NA	0.28	8.16	0.31	1.78e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	trans	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg25214090	chr10:38739885	LOC399744	0.57	13.01	0.46	1.79e-34	Corneal astigmatism;
BRCA	cis	rs10848704	0.637	rs11062351	chr12:2881763	C/T	cg19995117	chr12:2880862	NA	0.38	9.76	0.36	4.57e-21	Quantitative traits;
BRCA	trans	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg25214090	chr10:38739885	LOC399744	0.53	11.98	0.43	5.76e-30	Corneal astigmatism;
BRCA	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg16482183	chr6:26056742	HIST1H1C	0.52	11.29	0.41	4.38e-27	Iron status biomarkers;
BRCA	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg24558204	chr6:135376177	HBS1L	0.46	12.54	0.44	2.12e-32	Red blood cell count;
BRCA	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg13628971	chr7:2884303	GNA12	0.45	10.16	0.37	1.38e-22	Height;
BRCA	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg11789530	chr4:8429930	ACOX3	-0.63	-15.96	-0.53	1.62e-48	Response to antineoplastic agents;
BRCA	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg27147174	chr7:100797783	AP1S1	-0.52	-10.06	-0.37	3.29e-22	Life satisfaction;
BRCA	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg20701182	chr2:24300061	SF3B14	0.7	13.19	0.46	2.67e-35	Lymphocyte counts;
BRCA	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg04267008	chr7:1944627	MAD1L1	-0.39	-8.47	-0.32	1.66e-16	Schizophrenia;
BRCA	cis	rs9560113	0.959	rs4773385	chr13:112178452	C/T	cg10483660	chr13:112241077	NA	0.32	7.86	0.3	1.65e-14	Menarche (age at onset);
BRCA	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg24130564	chr14:104152367	KLC1	-0.39	-9.01	-0.34	2.39e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.61	13.78	0.48	5.11e-38	Eosinophil percentage of white cells;
BRCA	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg16325326	chr1:53192061	ZYG11B	0.86	25.26	0.71	3.77e-98	Monocyte count;
BRCA	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg06060754	chr5:176797920	RGS14	0.57	10.99	0.4	7.71e-26	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg25554036	chr4:6271136	WFS1	0.37	9.09	0.34	1.26e-18	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg17366294	chr4:99064904	C4orf37	0.49	10.85	0.39	2.84e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg01620082	chr3:125678407	NA	-0.92	-10.33	-0.38	3.07e-23	Breast cancer;
BRCA	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	8.29	0.31	6.45e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg04166393	chr7:2884313	GNA12	0.42	9.09	0.34	1.21e-18	Height;
BRCA	trans	rs2018683	0.739	rs10233884	chr7:28972307	A/G	cg19402173	chr7:128379420	CALU	-0.43	-10.15	-0.37	1.58e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.02	0.48	4.03e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg17063962	chr7:91808500	NA	0.6	14.47	0.5	2.89e-41	Breast cancer;
BRCA	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-11.12	-0.4	2.24e-26	Total cholesterol levels;
BRCA	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg03709012	chr19:19516395	GATAD2A	0.8	18.73	0.6	1.02e-62	Tonsillectomy;
BRCA	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.94	-0.37	9.36e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-12.63	-0.45	8.29e-33	Bone mineral density;
BRCA	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	11.43	0.41	1.2e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9837602	1.000	rs1688766	chr3:99647850	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.43	0.41	1.19e-27	Breast cancer;
BRCA	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg20891283	chr12:69753455	YEATS4	0.84	28.23	0.74	2.01e-114	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg18351406	chr4:77819688	ANKRD56	0.57	12.82	0.45	1.27e-33	Emphysema distribution in smoking;
BRCA	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg24060327	chr5:131705240	SLC22A5	-0.63	-11.79	-0.42	3.77e-29	Breast cancer;
BRCA	cis	rs16958440	1.000	rs16958440	chr18:44632884	C/G	cg17192377	chr18:44677553	HDHD2	0.67	9.75	0.36	4.96e-21	Sitting height ratio;
BRCA	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12379764	chr21:47803548	PCNT	-0.38	-7.87	-0.3	1.49e-14	Testicular germ cell tumor;
BRCA	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-11.44	-0.41	1.03e-27	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9420	0.528	rs7102271	chr11:57396825	G/T	cg19752551	chr11:57585705	CTNND1	-0.38	-9.47	-0.35	5.28e-20	Schizophrenia;
BRCA	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg12193833	chr17:30244370	NA	-0.58	-8.78	-0.33	1.54e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs17253792	0.545	rs12893676	chr14:56016159	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-7.99	-0.3	6.09e-15	Putamen volume;
BRCA	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg13010199	chr12:38710504	ALG10B	-0.38	-8.7	-0.33	2.89e-17	Morning vs. evening chronotype;
BRCA	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.44	-0.44	5.54e-32	Breast cancer;
BRCA	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg19628046	chr18:33552617	C18orf21	0.55	11.22	0.41	8.23e-27	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg08807101	chr21:30365312	RNF160	-0.42	-8.82	-0.33	1.11e-17	Pancreatic cancer;
BRCA	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg02454025	chr1:11042201	C1orf127	1.0	23.33	0.68	1.46e-87	Ewing sarcoma;
BRCA	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg20307385	chr11:47447363	PSMC3	-0.43	-8.83	-0.33	1.04e-17	Subjective well-being;
BRCA	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg12011299	chr4:100065546	ADH4	-0.43	-9.83	-0.36	2.56e-21	Alcohol dependence;
BRCA	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg16576597	chr16:28551801	NUPR1	0.35	9.46	0.35	5.9e-20	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.78	-11.48	-0.41	7.14e-28	Platelet count;
BRCA	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.15	-0.34	7.38e-19	Menopause (age at onset);
BRCA	cis	rs2425143	0.908	rs12480111	chr20:34423186	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.18	-0.31	1.59e-15	Blood protein levels;
BRCA	cis	rs870825	0.929	rs72689262	chr4:185590950	C/G	cg04058563	chr4:185651563	MLF1IP	0.69	11.83	0.42	2.39e-29	Blood protein levels;
BRCA	trans	rs1997103	0.954	rs10246216	chr7:55390479	C/T	cg20935933	chr6:143382018	AIG1	0.61	11.61	0.42	2.03e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg00012203	chr2:219082015	ARPC2	0.46	9.17	0.34	6.48e-19	Ulcerative colitis;
BRCA	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg16989086	chr20:62203971	PRIC285	0.53	8.94	0.33	4.21e-18	Glioblastoma;
BRCA	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg05985134	chr18:33552581	C18orf21	0.65	11.93	0.43	8.81e-30	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg09184832	chr6:79620586	NA	-0.42	-8.45	-0.32	1.93e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.37	-8.8	-0.33	1.22e-17	Tonsillectomy;
BRCA	cis	rs1050631	0.564	rs1785904	chr18:33713132	T/C	cg19453250	chr18:33710783	SLC39A6;ELP2	-0.29	-7.99	-0.3	6.25e-15	Esophageal squamous cell cancer (length of survival);
BRCA	cis	rs6433895	0.710	rs34467063	chr2:182013979	G/A	cg00481216	chr2:181971175	NA	0.45	8.29	0.31	6.5e-16	Lymphocyte counts;
BRCA	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg24399712	chr22:39784796	NA	-0.58	-13.53	-0.47	7.42e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg07636037	chr3:49044803	WDR6	0.4	8.15	0.31	1.98e-15	Resting heart rate;
BRCA	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.52	0.57	2.09e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg04025307	chr7:1156635	C7orf50	0.54	10.56	0.39	3.81e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg25517755	chr10:38738941	LOC399744	-0.38	-7.86	-0.3	1.65e-14	Corneal astigmatism;
BRCA	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg26043149	chr18:55253948	FECH	1.2	28.3	0.75	7.58e-115	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-9.7	-0.36	7.47e-21	Schizophrenia;
BRCA	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg07636037	chr3:49044803	WDR6	0.99	29.87	0.76	2.34e-123	Parkinson's disease;
BRCA	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.65	16.37	0.54	1.54e-50	Colorectal cancer;
BRCA	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.57	0.63	1.58e-72	Electrocardiographic conduction measures;
BRCA	cis	rs3845702	0.736	rs72960701	chr2:180851202	A/T	cg01881094	chr2:180872142	CWC22	1.0	17.29	0.56	3.18e-55	Schizophrenia;
BRCA	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg08085267	chr17:45401833	C17orf57	-0.59	-11.98	-0.43	5.69e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6060717	0.536	rs8125393	chr20:34496162	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.18	-0.31	1.55e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg01448562	chr3:133502909	NA	-0.39	-8.77	-0.33	1.55e-17	Iron status biomarkers;
BRCA	cis	rs7020830	0.898	rs7857936	chr9:37078491	T/C	cg14294708	chr9:37120828	ZCCHC7	1.09	33.73	0.8	4.76e-144	Schizophrenia;
BRCA	cis	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg06521331	chr12:34319734	NA	-0.52	-10.24	-0.38	6.8e-23	Morning vs. evening chronotype;
BRCA	cis	rs9297145	0.678	rs62473048	chr7:98775511	T/C	cg05967295	chr7:98741636	SMURF1	0.98	18.7	0.59	1.37e-62	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg18196295	chr10:418757	DIP2C	0.49	11.7	0.42	9.11e-29	Psychosis in Alzheimer's disease;
BRCA	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.75	-0.5	1.4e-42	Chronic sinus infection;
BRCA	cis	rs9880211	0.821	rs9832813	chr3:136065565	A/G	cg21827317	chr3:136751795	NA	-0.41	-8.3	-0.31	6.07e-16	Body mass index;Height;
BRCA	cis	rs3784262	0.692	rs4646590	chr15:58303137	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.23	-0.38	7.19e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg20362242	chr5:692897	TPPP	0.55	8.25	0.31	9.14e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg14092571	chr14:90743983	NA	-0.33	-8.02	-0.3	5.11e-15	Mortality in heart failure;
BRCA	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg00376283	chr12:123451042	ABCB9	0.53	10.79	0.39	4.69e-25	Neutrophil percentage of white cells;
BRCA	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.07	0.34	1.51e-18	Motion sickness;
BRCA	cis	rs10754283	0.967	rs2185195	chr1:90106697	T/C	cg21401794	chr1:90099060	LRRC8C	0.46	11.13	0.4	2e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.81	0.3	2.32e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7631605	0.846	rs11926768	chr3:36968347	C/T	cg15934958	chr3:37212084	LRRFIP2	-0.46	-10.41	-0.38	1.53e-23	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.83e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg27087555	chr16:88793112	FAM38A	-1.3	-20.17	-0.62	2.3e-70	Plateletcrit;
BRCA	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg16850897	chr7:100343110	ZAN	-0.57	-10.93	-0.4	1.36e-25	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	trans	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg25214090	chr10:38739885	LOC399744	0.44	9.86	0.36	1.84e-21	Corneal astigmatism;
BRCA	trans	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.93	0.3	1.01e-14	Corneal astigmatism;
BRCA	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.64	0.39	1.95e-24	Tonsillectomy;
BRCA	cis	rs16854884	0.770	rs1530477	chr3:143819506	A/G	cg06585982	chr3:143692056	C3orf58	-0.42	-8.22	-0.31	1.14e-15	Economic and political preferences (feminism/equality);
BRCA	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg15448220	chr1:150897856	SETDB1	0.35	7.98	0.3	6.98e-15	Melanoma;
BRCA	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03517284	chr6:25882590	NA	-0.47	-10.66	-0.39	1.57e-24	Blood metabolite levels;
BRCA	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.13	0.56	2.16e-54	Fuchs's corneal dystrophy;
BRCA	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-10.1	-0.37	2.37e-22	Neuroticism;
BRCA	cis	rs6088813	1.000	rs6142376	chr20:33992761	T/A	cg14752227	chr20:34000481	UQCC	-0.42	-8.92	-0.33	4.84e-18	Height;
BRCA	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg10546459	chr2:36825355	FEZ2	-0.4	-7.89	-0.3	1.3e-14	Height;
BRCA	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg05714579	chr10:131428358	MGMT	0.58	14.27	0.49	2.62e-40	Response to temozolomide;
BRCA	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg21132104	chr15:45694354	SPATA5L1	0.75	17.12	0.56	2.4e-54	Homoarginine levels;
BRCA	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.14	0.34	8.5e-19	Tonsillectomy;
BRCA	cis	rs75804782	0.641	rs2340870	chr2:239356026	C/T	cg18131467	chr2:239335373	ASB1	-0.61	-7.98	-0.3	6.63e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg13852791	chr20:30311386	BCL2L1	0.86	16.75	0.55	1.82e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs9420	0.528	rs10896632	chr11:57390302	G/A	cg19752551	chr11:57585705	CTNND1	-0.38	-9.32	-0.35	1.87e-19	Schizophrenia;
BRCA	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.91	-0.33	5.36e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg04025307	chr7:1156635	C7orf50	0.45	9.09	0.34	1.28e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg17366294	chr4:99064904	C4orf37	0.55	11.77	0.42	4.52e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs4787491	0.729	rs8043883	chr16:30044581	G/A	cg06326092	chr16:30034487	C16orf92	0.38	9.9	0.36	1.36e-21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg03676636	chr4:99064102	C4orf37	0.23	8.26	0.31	8.09e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg05283184	chr6:79620031	NA	-0.43	-10.98	-0.4	8.34e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg17425144	chr1:10567563	PEX14	0.58	15.64	0.53	6.23e-47	Breast size;
BRCA	cis	rs9581857	0.685	rs9319371	chr13:28042564	A/G	cg22138327	chr13:27999177	GTF3A	0.63	9.63	0.36	1.33e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
BRCA	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg01191920	chr7:158217561	PTPRN2	-0.42	-9.98	-0.37	6.5e-22	Obesity-related traits;
BRCA	cis	rs6142102	0.602	rs4911380	chr20:32546224	C/T	cg24642439	chr20:33292090	TP53INP2	0.39	7.81	0.3	2.37e-14	Skin pigmentation;
BRCA	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg23029597	chr12:123009494	RSRC2	-0.62	-12.62	-0.45	9.4e-33	Body mass index;
BRCA	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg11814155	chr7:99998594	ZCWPW1	0.51	9.0	0.34	2.51e-18	Platelet count;
BRCA	trans	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg25214090	chr10:38739885	LOC399744	0.55	12.09	0.43	1.97e-30	Corneal astigmatism;
BRCA	cis	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg06521331	chr12:34319734	NA	-0.63	-12.21	-0.43	5.84e-31	Morning vs. evening chronotype;
BRCA	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.97	0.43	6.26e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3768617	0.610	rs10911228	chr1:183049792	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	9.47	0.35	5.23e-20	Fuchs's corneal dystrophy;
BRCA	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg26408565	chr15:76604113	ETFA	-0.49	-10.41	-0.38	1.45e-23	Blood metabolite levels;
BRCA	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-10.72	-0.39	9.19e-25	Morning vs. evening chronotype;
BRCA	cis	rs7737355	0.947	rs10041744	chr5:130860852	C/T	cg06307176	chr5:131281290	NA	0.52	10.39	0.38	1.87e-23	Life satisfaction;
BRCA	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.54	8.42	0.32	2.49e-16	Lung function (FEV1/FVC);
BRCA	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.25	-0.52	5.14e-45	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-10.21	-0.37	8.99e-23	Personality dimensions;
BRCA	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24531977	chr5:56204891	C5orf35	1.01	20.25	0.63	7.72e-71	Initial pursuit acceleration;
BRCA	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg01256987	chr12:42539512	GXYLT1	-0.46	-9.28	-0.34	2.56e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg05347473	chr6:146136440	FBXO30	0.43	8.56	0.32	8.72e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg03433033	chr1:76189801	ACADM	0.69	13.03	0.46	1.35e-34	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs8017423	0.536	rs11625794	chr14:90811229	C/T	cg04374321	chr14:90722782	PSMC1	0.4	8.84	0.33	8.9e-18	Mortality in heart failure;
BRCA	cis	rs332507	0.830	rs2289428	chr3:124412524	T/G	cg05980111	chr3:124395277	KALRN	0.34	8.13	0.31	2.28e-15	Plateletcrit;
BRCA	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg10556349	chr10:835070	NA	0.6	8.31	0.31	5.55e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg23625390	chr15:77176239	SCAPER	0.43	10.5	0.38	6.47e-24	Blood metabolite levels;
BRCA	cis	rs4409675	0.576	rs7356	chr1:28218100	T/C	cg23691781	chr1:28212827	C1orf38	0.33	11.21	0.41	9.92e-27	Corneal astigmatism;
BRCA	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	8.22	0.31	1.17e-15	Mean platelet volume;
BRCA	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg26384229	chr12:38710491	ALG10B	0.68	14.35	0.49	1.06e-40	Morning vs. evening chronotype;
BRCA	cis	rs3849570	1.000	rs9842330	chr3:81814688	G/A	cg07356753	chr3:81810745	GBE1	-0.47	-11.34	-0.41	2.71e-27	Waist circumference;Body mass index;
BRCA	cis	rs9549328	0.765	rs1317506	chr13:113631143	C/T	cg01248385	chr13:113636953	MCF2L	-0.41	-8.78	-0.33	1.54e-17	Systolic blood pressure;
BRCA	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg06784218	chr1:46089804	CCDC17	0.47	11.27	0.41	5.28e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg00852783	chr1:26633632	UBXN11	0.5	10.72	0.39	8.96e-25	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2953174	0.786	rs8662	chr2:241517770	G/A	cg07929629	chr2:241523174	NA	0.49	8.58	0.32	6.97e-17	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg13206674	chr6:150067644	NUP43	0.28	8.42	0.32	2.56e-16	Testicular germ cell tumor;
BRCA	cis	rs3771570	0.901	rs62190407	chr2:242405772	G/A	cg21155796	chr2:242212141	HDLBP	0.51	8.8	0.33	1.23e-17	Prostate cancer;
BRCA	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	12.27	0.44	3.29e-31	Neuroticism;
BRCA	cis	rs6088813	1.000	rs4911496	chr20:33972053	A/G	cg14752227	chr20:34000481	UQCC	0.43	9.23	0.34	3.76e-19	Height;
BRCA	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.43	-9.62	-0.36	1.52e-20	Longevity;Endometriosis;
BRCA	cis	rs1538970	0.962	rs9429160	chr1:45827968	G/T	cg05343316	chr1:45956843	TESK2	0.56	11.32	0.41	3.38e-27	Platelet count;
BRCA	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg24692254	chr21:30365293	RNF160	-0.41	-8.52	-0.32	1.15e-16	Cognitive test performance;
BRCA	cis	rs10484885	0.878	rs17763820	chr6:90569634	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-9.77	-0.36	4.16e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg13660082	chr14:53194042	PSMC6	-0.56	-8.05	-0.3	4.16e-15	Alzheimer's disease (late onset);
BRCA	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg18154014	chr19:37997991	ZNF793	0.55	10.12	0.37	1.92e-22	Coronary artery calcification;
BRCA	cis	rs9815354	0.761	rs73079307	chr3:41862273	A/C	cg03022575	chr3:42003672	ULK4	0.69	9.47	0.35	5.31e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg21918786	chr6:109611834	NA	-0.47	-13.43	-0.47	2.09e-36	Reticulocyte fraction of red cells;
BRCA	cis	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg06521331	chr12:34319734	NA	-0.52	-10.17	-0.37	1.26e-22	Morning vs. evening chronotype;
BRCA	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg00012203	chr2:219082015	ARPC2	0.64	13.16	0.46	3.48e-35	High light scatter reticulocyte percentage of red cells;Plateletcrit;
BRCA	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24110177	chr3:50126178	RBM5	0.4	11.1	0.4	2.56e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9487051	0.834	rs6919423	chr6:109558471	C/T	cg01475377	chr6:109611718	NA	-0.4	-9.92	-0.37	1.13e-21	Reticulocyte fraction of red cells;
BRCA	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24531977	chr5:56204891	C5orf35	-0.74	-14.83	-0.51	5.4e-43	Initial pursuit acceleration;
BRCA	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg05340658	chr4:99064831	C4orf37	0.57	11.39	0.41	1.67e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg02880119	chr16:3481970	NA	0.44	8.16	0.31	1.76e-15	Body mass index (adult);
BRCA	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg02079420	chr8:82753780	SNX16	-0.31	-8.53	-0.32	1.04e-16	Diastolic blood pressure;
BRCA	cis	rs12367572	0.641	rs4285943	chr12:45404768	A/C	cg04608330	chr12:45269318	NELL2	0.45	9.88	0.36	1.59e-21	Gut microbiome composition (summer);
BRCA	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg02574844	chr11:5959923	NA	-0.39	-8.1	-0.31	2.85e-15	DNA methylation (variation);
BRCA	cis	rs911119	1.000	rs6036476	chr20:23610308	C/G	cg16589663	chr20:23618590	CST3	0.45	8.48	0.32	1.51e-16	Chronic kidney disease;
BRCA	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg10560079	chr2:191398806	TMEM194B	-0.73	-13.44	-0.47	1.84e-36	Diastolic blood pressure;
BRCA	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	9.21	0.34	4.81e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7587476	1.000	rs3768707	chr2:215645135	C/T	cg04004882	chr2:215674386	BARD1	0.57	10.92	0.4	1.37e-25	Neuroblastoma;
BRCA	cis	rs351855	0.642	rs2546095	chr5:176509584	G/T	cg19956155	chr5:176511416	NA	0.35	7.89	0.3	1.3e-14	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg24829409	chr8:58192753	C8orf71	-0.5	-9.4	-0.35	9.91e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.52	8.98	0.33	2.94e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs2270927	0.510	rs13188781	chr5:75580409	C/A	cg13563193	chr19:33072644	PDCD5	0.9	10.35	0.38	2.48e-23	Mean corpuscular volume;
BRCA	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg09904177	chr6:26538194	HMGN4	0.47	14.7	0.5	2.29e-42	Intelligence (multi-trait analysis);
BRCA	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-8.97	-0.33	3.17e-18	Axial length;
BRCA	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg13770153	chr20:60521292	NA	-0.38	-9.01	-0.34	2.35e-18	Body mass index;
BRCA	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg06627628	chr2:24431161	ITSN2	-0.63	-12.02	-0.43	3.88e-30	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	11.88	0.43	1.54e-29	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7246657	0.722	rs6508736	chr19:38061757	A/G	cg18154014	chr19:37997991	ZNF793	0.48	9.13	0.34	8.69e-19	Coronary artery calcification;
BRCA	cis	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg05901451	chr6:126070800	HEY2	0.4	9.75	0.36	4.92e-21	Endometrial cancer;
BRCA	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-13.22	-0.46	1.9e-35	Bone mineral density;
BRCA	cis	rs2882667	0.654	rs10044432	chr5:138274896	C/T	cg04439458	chr5:138467593	SIL1	-0.35	-8.5	-0.32	1.33e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg21918786	chr6:109611834	NA	-0.46	-12.86	-0.45	7.78e-34	Reticulocyte fraction of red cells;
BRCA	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg17366294	chr4:99064904	C4orf37	0.41	9.74	0.36	5.42e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.14	-0.4	1.77e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1949733	1.000	rs3103067	chr4:8511223	A/G	cg13073564	chr4:8508604	NA	-0.41	-11.36	-0.41	2.23e-27	Response to antineoplastic agents;
BRCA	trans	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.68	-0.36	9.39e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs798766	1.000	rs798767	chr4:1734281	A/G	cg05874882	chr4:1763078	NA	-0.45	-8.14	-0.31	2.08e-15	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg22705602	chr4:152727874	NA	-0.32	-8.3	-0.31	6.17e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs666930	0.519	rs477992	chr1:120257576	A/G	cg19096424	chr1:120255104	PHGDH	0.54	12.29	0.44	2.71e-31	Breast cancer;
BRCA	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg00383909	chr3:49044727	WDR6	0.77	13.06	0.46	9.67e-35	Cognitive function;
BRCA	trans	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.14	0.31	2.04e-15	Corneal astigmatism;
BRCA	cis	rs9549260	1.000	rs9549260	chr13:41254104	G/T	cg21288729	chr13:41239152	FOXO1	0.5	9.59	0.35	1.97e-20	Red blood cell count;
BRCA	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg05340658	chr4:99064831	C4orf37	0.6	12.93	0.46	3.99e-34	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs977987	0.806	rs4887824	chr16:75441613	T/C	cg03315344	chr16:75512273	CHST6	0.53	12.42	0.44	7.12e-32	Dupuytren's disease;
BRCA	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg12927641	chr6:109611667	NA	-0.42	-10.85	-0.39	2.82e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs6882716	0.636	rs1470023	chr5:10800150	A/G	cg14521931	chr5:10832172	NA	-0.68	-12.03	-0.43	3.33e-30	Alcohol consumption (maxi-drinks);
BRCA	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg06671706	chr8:8559999	CLDN23	0.44	8.63	0.32	4.94e-17	Obesity-related traits;
BRCA	cis	rs11229555	0.645	rs72917641	chr11:58227320	A/C	cg15696309	chr11:58395628	NA	-0.52	-10.85	-0.39	2.81e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.48e-23	Motion sickness;
BRCA	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg08738300	chr3:44038990	NA	0.46	9.01	0.34	2.44e-18	Coronary artery disease;
BRCA	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.03e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs10046574	0.519	rs7799873	chr7:135214030	C/T	cg27474649	chr7:135195673	CNOT4	0.63	10.71	0.39	9.6e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06022373	chr22:39101656	GTPBP1	-0.72	-17.34	-0.57	1.65e-55	Menopause (age at onset);
BRCA	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	14.2	0.49	5.5e-40	Colorectal cancer;
BRCA	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg08999081	chr20:33150536	PIGU	0.46	12.96	0.46	2.82e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg22875332	chr1:76189707	ACADM	0.69	14.94	0.51	1.62e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.51	-16.37	-0.54	1.44e-50	Alzheimer's disease (late onset);
BRCA	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg27129171	chr3:47204927	SETD2	0.72	17.52	0.57	2.13e-56	Colorectal cancer;
BRCA	cis	rs6484504	0.576	rs16922084	chr11:31371109	C/T	cg26647111	chr11:31128758	NA	0.45	9.59	0.35	1.97e-20	Red blood cell count;
BRCA	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03264133	chr6:25882463	NA	0.41	8.8	0.33	1.26e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.61	-8.52	-0.32	1.16e-16	Schizophrenia;
BRCA	trans	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg17712092	chr4:129076599	LARP1B	-0.49	-10.64	-0.39	1.82e-24	Breast cancer;
BRCA	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg04450456	chr4:17643702	FAM184B	0.38	11.15	0.4	1.66e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-20.44	-0.63	7.57e-72	Exhaled nitric oxide output;
BRCA	cis	rs3845702	0.736	rs16867131	chr2:180848651	A/G	cg01881094	chr2:180872142	CWC22	-1.02	-17.25	-0.56	4.87e-55	Schizophrenia;
BRCA	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg07080220	chr10:102295463	HIF1AN	0.49	10.13	0.37	1.82e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.24	-0.31	1e-15	Gut microbiome composition (summer);
BRCA	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg06784218	chr1:46089804	CCDC17	0.5	12.09	0.43	1.87e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg01579765	chr21:45077557	HSF2BP	-0.42	-10.08	-0.37	2.79e-22	Mean corpuscular volume;
BRCA	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	11.88	0.43	1.49e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg18252515	chr7:66147081	NA	-0.91	-12.95	-0.46	3.15e-34	Diabetic kidney disease;
BRCA	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg09904177	chr6:26538194	HMGN4	0.47	14.67	0.5	3.4e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.747	rs12048412	chr1:152977092	A/T	cg21543102	chr1:152974771	SPRR3	-0.28	-8.12	-0.31	2.44e-15	Inflammatory skin disease;
BRCA	cis	rs2066819	1.000	rs75265219	chr12:56640341	G/A	cg26714650	chr12:56694279	CS	-1.18	-15.33	-0.52	2.13e-45	Psoriasis vulgaris;
BRCA	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.85	0.33	8.73e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg05084668	chr3:125655381	ALG1L	-0.65	-12.45	-0.44	5.16e-32	Blood pressure (smoking interaction);
BRCA	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg12292205	chr6:26970375	C6orf41	0.58	13.03	0.46	1.32e-34	Schizophrenia;
BRCA	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.96	-0.3	7.86e-15	Aortic root size;
BRCA	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg23505145	chr19:12996616	KLF1	0.56	12.69	0.45	4.46e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	12.1	0.43	1.76e-30	Mood instability;
BRCA	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg18404041	chr3:52824283	ITIH1	0.46	13.33	0.47	5.9e-36	Bipolar disorder;
BRCA	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg00012203	chr2:219082015	ARPC2	-0.57	-12.06	-0.43	2.51e-30	Colorectal cancer;
BRCA	cis	rs7617773	0.817	rs11709691	chr3:48303669	A/G	cg11946769	chr3:48343235	NME6	0.67	13.86	0.48	2.14e-38	Coronary artery disease;
BRCA	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18404041	chr3:52824283	ITIH1	-0.28	-8.55	-0.32	8.75e-17	Electroencephalogram traits;
BRCA	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg09367891	chr1:107599246	PRMT6	0.55	10.12	0.37	2.02e-22	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.52	0.35	3.42e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg04990556	chr1:26633338	UBXN11	0.71	12.02	0.43	3.79e-30	Obesity-related traits;
BRCA	trans	rs3960554	0.808	rs111714534	chr7:75748896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.59	11.77	0.42	4.43e-29	Eotaxin levels;
BRCA	cis	rs8008758	0.517	rs1772024	chr14:101695220	A/C	cg26224664	chr14:101693935	NA	0.41	11.25	0.41	6.46e-27	Body mass index (alcohol intake interaction);
BRCA	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg07148914	chr20:33460835	GGT7	0.44	9.62	0.36	1.52e-20	Height;
BRCA	cis	rs600806	0.850	rs3931560	chr1:109966718	A/C	cg20591472	chr1:110008990	SYPL2	0.33	8.38	0.31	3.42e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1050631	0.564	rs589213	chr18:33743610	G/A	cg19453250	chr18:33710783	SLC39A6;ELP2	-0.29	-7.86	-0.3	1.6e-14	Esophageal squamous cell cancer (length of survival);
BRCA	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg11814155	chr7:99998594	ZCWPW1	0.48	8.78	0.33	1.48e-17	Platelet count;
BRCA	cis	rs10484885	0.775	rs55926724	chr6:90417450	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.7	-10.65	-0.39	1.79e-24	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg26384229	chr12:38710491	ALG10B	0.7	15.94	0.53	1.97e-48	Bladder cancer;
BRCA	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg00684032	chr4:1343700	KIAA1530	0.32	7.96	0.3	7.86e-15	Obesity-related traits;
BRCA	cis	rs6815814	0.861	rs7658651	chr4:38786002	A/C	cg06935464	chr4:38784597	TLR10	0.49	9.87	0.36	1.76e-21	Breast cancer;
BRCA	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.56	-0.32	8.35e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7524258	0.868	rs10779678	chr1:7300573	A/G	cg07173049	chr1:7289937	CAMTA1	0.53	12.7	0.45	4.06e-33	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg04025307	chr7:1156635	C7orf50	0.59	15.15	0.51	1.55e-44	Longevity;Endometriosis;
BRCA	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-9.45	-0.35	6.43e-20	Menopause (age at onset);
BRCA	cis	rs11229555	0.645	rs12805062	chr11:58214584	A/G	cg15696309	chr11:58395628	NA	-0.45	-9.64	-0.36	1.27e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24549020	chr5:56110836	MAP3K1	-0.58	-10.61	-0.39	2.48e-24	Initial pursuit acceleration;
BRCA	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg10495392	chr1:46806563	NSUN4	0.45	8.49	0.32	1.42e-16	Menopause (age at onset);
BRCA	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-14.1	-0.49	1.71e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11890956	chr21:40555474	PSMG1	-0.61	-13.85	-0.48	2.35e-38	Menarche (age at onset);
BRCA	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg13047869	chr3:10149882	C3orf24	0.52	11.01	0.4	6.24e-26	Alzheimer's disease;
BRCA	cis	rs7524258	0.868	rs6577428	chr1:7314655	C/T	cg07173049	chr1:7289937	CAMTA1	-0.48	-11.44	-0.41	1.11e-27	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs312273	0.806	rs1372542	chr12:41324876	A/G	cg17827154	chr12:41323612	CNTN1	0.44	11.38	0.41	1.88e-27	Bipolar disorder;
BRCA	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg22920501	chr2:26401640	FAM59B	0.65	11.45	0.41	9.48e-28	Gut microbiome composition (summer);
BRCA	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-16.69	-0.55	3.49e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg03954927	chr1:10346856	KIF1B	0.47	14.45	0.5	3.86e-41	Hepatocellular carcinoma;
BRCA	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg24596788	chr1:163392923	NA	-0.35	-9.38	-0.35	1.17e-19	Motion sickness;
BRCA	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg01475735	chr3:40494733	NA	0.49	10.27	0.38	5.34e-23	Renal cell carcinoma;
BRCA	cis	rs7565124	1.000	rs67305930	chr2:20258070	G/C	cg23821541	chr2:20251993	LAPTM4A	0.38	7.98	0.3	6.79e-15	Major depressive disorder;
BRCA	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg10845886	chr2:3471009	TTC15	-0.49	-10.6	-0.39	2.82e-24	Neurofibrillary tangles;
BRCA	cis	rs13082711	0.554	rs4973729	chr3:27390637	G/A	cg02860705	chr3:27208620	NA	0.69	11.86	0.42	1.83e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs16854884	0.538	rs61359084	chr3:143738362	T/C	cg06585982	chr3:143692056	C3orf58	0.42	8.92	0.33	4.98e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.58	13.65	0.48	1.98e-37	Menarche (age at onset);
BRCA	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg26597838	chr10:835615	NA	1.3	21.86	0.65	1.6e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs7301826	0.610	rs9668291	chr12:131296908	C/G	cg11011512	chr12:131303247	STX2	0.5	12.95	0.46	3.24e-34	Plasma plasminogen activator levels;
BRCA	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.52	-0.32	1.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg17691542	chr6:26056736	HIST1H1C	0.55	11.91	0.43	1.13e-29	Height;
BRCA	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg04944784	chr2:26401820	FAM59B	0.95	16.17	0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg25358565	chr5:93447407	FAM172A	1.18	18.79	0.6	4.94e-63	Diabetic retinopathy;
BRCA	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4742903	0.527	rs55909255	chr9:106871788	T/C	cg14250997	chr9:106856677	SMC2	0.28	8.36	0.31	3.82e-16	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg00666640	chr1:248458726	OR2T12	0.3	8.62	0.32	5.06e-17	Common traits (Other);
BRCA	cis	rs12431939	0.947	rs56156789	chr14:51633899	C/G	cg23942311	chr14:51606299	NA	-0.46	-8.55	-0.32	8.92e-17	Cancer;
BRCA	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg14019146	chr3:50243930	SLC38A3	-0.4	-9.84	-0.36	2.31e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	8.59	0.32	6.82e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg21854759	chr1:92012499	NA	-0.41	-9.7	-0.36	7.34e-21	Breast cancer;
BRCA	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg23649088	chr2:200775458	C2orf69	0.49	9.91	0.37	1.2e-21	Osteoporosis;
BRCA	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg13010199	chr12:38710504	ALG10B	0.48	9.31	0.35	2.02e-19	Morning vs. evening chronotype;
BRCA	cis	rs12986413	1.000	rs12982593	chr19:2175891	C/A	cg09261902	chr19:2140048	AP3D1	0.38	10.06	0.37	3.37e-22	Height;
BRCA	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg15103426	chr22:29168792	CCDC117	0.52	12.69	0.45	4.42e-33	Lymphocyte counts;
BRCA	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24110177	chr3:50126178	RBM5	0.37	10.13	0.37	1.8e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs17253792	0.822	rs10151664	chr14:56029533	A/G	cg01858014	chr14:56050164	KTN1	-0.52	-8.23	-0.31	1.05e-15	Putamen volume;
BRCA	cis	rs13136331	0.532	rs1462368	chr4:88570799	A/G	cg22416721	chr4:88570574	DMP1	-0.6	-14.9	-0.51	2.68e-43	Sitting height ratio;
BRCA	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg06115741	chr20:33292138	TP53INP2	0.48	10.65	0.39	1.64e-24	Coronary artery disease;
BRCA	cis	rs1595825	0.891	rs35817167	chr2:198718928	A/T	cg19156104	chr2:198669113	PLCL1	-0.44	-8.18	-0.31	1.57e-15	Ulcerative colitis;
BRCA	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.32	0.38	3.49e-23	Motion sickness;
BRCA	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg25517755	chr10:38738941	LOC399744	-0.38	-7.99	-0.3	6.4e-15	Corneal astigmatism;
BRCA	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg22491629	chr6:157744540	C6orf35	-0.65	-11.68	-0.42	1.07e-28	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs10782582	0.609	rs5745547	chr1:76378275	G/C	cg03433033	chr1:76189801	ACADM	-0.39	-8.01	-0.3	5.44e-15	Daytime sleep phenotypes;
BRCA	cis	rs10193935	1.000	rs10173107	chr2:42420302	A/T	cg27598129	chr2:42591480	NA	-0.96	-15.15	-0.51	1.57e-44	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg15704280	chr7:45808275	SEPT13	-0.46	-8.84	-0.33	9.34e-18	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7587476	0.784	rs13032278	chr2:215698034	G/A	cg04004882	chr2:215674386	BARD1	0.65	11.88	0.43	1.56e-29	Neuroblastoma;
BRCA	cis	rs4363385	0.818	rs2651413	chr1:153012068	T/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.43	9.54	0.35	2.87e-20	Colorectal cancer;
BRCA	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg13271783	chr10:134563150	INPP5A	-0.49	-10.03	-0.37	4.42e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs921968	0.565	rs6436083	chr2:219639719	C/T	cg02176678	chr2:219576539	TTLL4	-0.4	-10.93	-0.4	1.27e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg09033563	chr22:24373618	LOC391322	0.39	8.01	0.3	5.35e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.24	-0.31	1.01e-15	Height;
BRCA	trans	rs8073060	0.559	rs72829925	chr17:34049778	C/A	cg19694781	chr19:47549865	TMEM160	1.06	20.5	0.63	3.66e-72	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.85	0.39	2.74e-25	Bipolar disorder;
BRCA	cis	rs12347191	0.500	rs1465965	chr9:100620326	C/T	cg13688889	chr9:100608707	NA	-0.49	-9.94	-0.37	9.4e-22	Orofacial clefts;
BRCA	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	7.91	0.3	1.11e-14	Menarche (age at onset);
BRCA	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg08888203	chr3:10149979	C3orf24	0.62	11.71	0.42	8.19e-29	Alzheimer's disease;
BRCA	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg08999081	chr20:33150536	PIGU	0.47	12.98	0.46	2.36e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg02176678	chr2:219576539	TTLL4	0.42	11.27	0.41	5.52e-27	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11764359	chr7:65958608	NA	-0.76	-17.52	-0.57	1.94e-56	Aortic root size;
BRCA	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.42	8.3	0.31	6.23e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg08027265	chr7:2291960	NA	-0.36	-8.38	-0.31	3.38e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg03188948	chr7:1209495	NA	0.9	14.22	0.49	4.47e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.51	-0.32	1.19e-16	Monocyte percentage of white cells;
BRCA	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.82	-0.3	2.21e-14	Aortic root size;
BRCA	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg27529037	chr20:44575021	PCIF1	-0.37	-8.6	-0.32	6.24e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg00745463	chr17:30367425	LRRC37B	-0.54	-8.86	-0.33	8.09e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg23711669	chr6:146136114	FBXO30	-0.73	-15.58	-0.52	1.22e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7789940	0.904	rs6948661	chr7:75961647	T/C	cg10167463	chr7:75959203	YWHAG	-0.44	-8.86	-0.33	7.66e-18	Multiple sclerosis;
BRCA	cis	rs74181299	0.648	rs1050676	chr2:65310831	A/T	cg05010058	chr2:65284262	CEP68	-0.29	-7.94	-0.3	9.38e-15	Pulse pressure;
BRCA	cis	rs858239	0.896	rs1637193	chr7:23260251	G/T	cg23682824	chr7:23144976	KLHL7	0.39	9.9	0.36	1.36e-21	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7903847	0.620	rs10882904	chr10:99115683	A/G	cg08345082	chr10:99160200	RRP12	-0.28	-8.03	-0.3	4.59e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7851660	0.527	rs7859751	chr9:100575888	C/T	cg13688889	chr9:100608707	NA	-0.53	-12.05	-0.43	2.77e-30	Strep throat;
BRCA	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-18.45	-0.59	2.85e-61	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-16.76	-0.55	1.62e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg15485101	chr11:133734466	NA	-0.37	-9.38	-0.35	1.13e-19	Childhood ear infection;
BRCA	cis	rs10463316	0.862	rs7700650	chr5:150776473	C/T	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.32	-0.31	5.34e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs738321	0.757	rs5750546	chr22:38542499	C/T	cg20207973	chr22:38506712	BAIAP2L2	0.38	9.25	0.34	3.3e-19	Breast cancer;
BRCA	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg12386194	chr3:101231763	SENP7	0.63	12.27	0.44	3.32e-31	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg21573476	chr21:45109991	RRP1B	-0.49	-12.87	-0.45	7.35e-34	Coronary artery disease;
BRCA	cis	rs10504073	0.584	rs11776843	chr8:49928449	C/T	cg00325661	chr8:49890786	NA	0.5	14.52	0.5	1.66e-41	Blood metabolite ratios;
BRCA	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg05623727	chr3:50126028	RBM5	0.38	9.11	0.34	1.01e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.38	-8.76	-0.33	1.72e-17	Longevity;Endometriosis;
BRCA	cis	rs738321	0.694	rs4821749	chr22:38542074	A/G	cg25457927	chr22:38595422	NA	-0.36	-12.61	-0.45	1.02e-32	Breast cancer;
BRCA	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7715811	0.956	rs5023693	chr5:13767129	T/C	cg07548982	chr5:13769939	DNAH5	-0.41	-9.05	-0.34	1.75e-18	Subclinical atherosclerosis traits (other);
BRCA	cis	rs7246657	0.598	rs10405372	chr19:37668775	A/C	cg18154014	chr19:37997991	ZNF793	0.55	9.25	0.34	3.46e-19	Coronary artery calcification;
BRCA	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg22705602	chr4:152727874	NA	-0.37	-10.2	-0.37	9.7e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.41	0.35	8.81e-20	Tonsillectomy;
BRCA	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.23	0.31	1.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs17401966	0.522	rs912962	chr1:10348712	G/T	cg03954927	chr1:10346856	KIF1B	-0.34	-10.06	-0.37	3.39e-22	Hepatocellular carcinoma;
BRCA	cis	rs7301826	0.651	rs4759525	chr12:131316281	T/C	cg11011512	chr12:131303247	STX2	0.52	13.68	0.48	1.44e-37	Plasma plasminogen activator levels;
BRCA	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg02297831	chr4:17616191	MED28	0.36	8.17	0.31	1.64e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg01324343	chr3:183735012	ABCC5	-0.63	-15.24	-0.52	5.97e-45	Anterior chamber depth;
BRCA	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.45	8.59	0.32	6.5e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg17507749	chr15:85114479	UBE2QP1	0.51	8.49	0.32	1.42e-16	Schizophrenia;
BRCA	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-18.38	-0.59	6.85e-61	Monocyte count;
BRCA	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.44	-9.11	-0.34	1.08e-18	Iron status biomarkers;
BRCA	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg18252515	chr7:66147081	NA	-1.07	-15.92	-0.53	2.69e-48	Diabetic kidney disease;
BRCA	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18876405	chr7:65276391	NA	-0.49	-10.79	-0.39	4.93e-25	Aortic root size;
BRCA	cis	rs6834538	0.597	rs2029211	chr4:113488134	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.41	9.78	0.36	3.89e-21	Free thyroxine concentration;
BRCA	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg21724239	chr8:58056113	NA	0.45	7.98	0.3	6.83e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02475777	chr4:1388615	CRIPAK	0.61	12.02	0.43	3.84e-30	Longevity;
BRCA	cis	rs7903847	0.642	rs11189180	chr10:99143529	A/G	cg20016023	chr10:99160130	RRP12	-0.27	-8.6	-0.32	6.17e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg12292205	chr6:26970375	C6orf41	0.72	16.29	0.54	3.86e-50	Schizophrenia;
BRCA	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg12463550	chr7:65579703	CRCP	0.38	8.08	0.3	3.3e-15	Aortic root size;
BRCA	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	6.83e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.38	-8.49	-0.32	1.42e-16	Longevity;Endometriosis;
BRCA	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg15839431	chr19:19639596	YJEFN3	0.41	8.96	0.33	3.58e-18	Bipolar disorder;
BRCA	cis	rs7727544	0.582	rs7703009	chr5:131552385	C/G	cg14196790	chr5:131705035	SLC22A5	0.37	9.06	0.34	1.59e-18	Blood metabolite levels;
BRCA	cis	rs897984	0.574	rs11647284	chr16:31077335	G/A	cg02466173	chr16:30829666	NA	-0.4	-8.62	-0.32	5.21e-17	Dementia with Lewy bodies;
BRCA	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg05340658	chr4:99064831	C4orf37	0.7	17.55	0.57	1.4e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg10057126	chr4:77819792	ANKRD56	0.65	14.87	0.51	3.66e-43	Emphysema distribution in smoking;
BRCA	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.66	-17.81	-0.58	6.38e-58	Longevity;Endometriosis;
BRCA	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-10.46	-0.38	9.67e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg19338460	chr6:170058176	WDR27	-0.75	-10.03	-0.37	4.55e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs1975991	0.711	rs6809682	chr3:187968192	C/A	cg15417654	chr3:187959138	LPP	0.32	8.17	0.31	1.62e-15	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg18252515	chr7:66147081	NA	-0.81	-11.34	-0.41	2.84e-27	Diabetic kidney disease;
BRCA	cis	rs752010	1.000	rs6656183	chr1:42094025	A/G	cg06885757	chr1:42089581	HIVEP3	0.27	9.6	0.36	1.75e-20	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg04362960	chr10:104952993	NT5C2	-0.44	-10.29	-0.38	4.46e-23	Arsenic metabolism;
BRCA	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.29	-0.35	2.32e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg11502198	chr6:26597334	ABT1	0.47	9.47	0.35	5.19e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg05665937	chr4:1216051	CTBP1	-0.38	-8.14	-0.31	2.05e-15	Obesity-related traits;
BRCA	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg15208524	chr1:10270712	KIF1B	0.37	7.86	0.3	1.63e-14	Hepatocellular carcinoma;
BRCA	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg20891283	chr12:69753455	YEATS4	0.48	11.18	0.4	1.28e-26	Response to diuretic therapy;
BRCA	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02353165	chr6:42928485	GNMT	0.78	18.9	0.6	1.25e-63	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg18758796	chr5:131593413	PDLIM4	0.31	7.9	0.3	1.23e-14	Blood metabolite levels;
BRCA	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg08601574	chr20:25228251	PYGB	-0.34	-8.22	-0.31	1.14e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg11752832	chr7:134001865	SLC35B4	0.52	11.86	0.42	1.76e-29	Mean platelet volume;
BRCA	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg00717180	chr2:96193071	NA	-0.37	-10.22	-0.37	8.08e-23	Height;
BRCA	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	14.67	0.5	3.45e-42	Motion sickness;
BRCA	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.23	0.34	3.94e-19	Morning vs. evening chronotype;
BRCA	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg03923535	chr7:1197113	ZFAND2A	0.4	7.9	0.3	1.24e-14	Longevity;Endometriosis;
BRCA	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08045932	chr20:61659980	NA	0.5	11.48	0.41	7.39e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11716531	0.537	rs7626646	chr3:27268316	G/T	cg02860705	chr3:27208620	NA	0.61	11.88	0.43	1.53e-29	Diastolic blood pressure;
BRCA	cis	rs61990749	0.544	rs3759728	chr14:78230159	A/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.44	7.97	0.3	7.44e-15	Fibroblast growth factor basic levels;
BRCA	cis	rs2985684	0.802	rs8015368	chr14:50020510	G/A	cg04989706	chr14:50066350	PPIL5	-0.5	-9.95	-0.37	9.01e-22	Carotid intima media thickness;
BRCA	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00166722	chr3:10149974	C3orf24	0.67	13.44	0.47	1.83e-36	Alzheimer's disease;
BRCA	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg01448562	chr3:133502909	NA	-0.63	-14.91	-0.51	2.4e-43	Iron status biomarkers;
BRCA	trans	rs4714291	0.775	rs2949019	chr6:40051200	C/T	cg02267698	chr19:7991119	CTXN1	-0.45	-9.35	-0.35	1.46e-19	Strep throat;
BRCA	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg21747090	chr2:27597821	SNX17	-0.43	-9.27	-0.34	2.87e-19	Total body bone mineral density;
BRCA	cis	rs1018836	0.923	rs7833025	chr8:91568470	G/C	cg16814680	chr8:91681699	NA	-0.64	-14.25	-0.49	3.37e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg00504896	chr12:9437009	LOC642846	-0.37	-8.02	-0.3	5.25e-15	Breast size;
BRCA	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg27398817	chr8:82754497	SNX16	-0.46	-8.93	-0.33	4.45e-18	Diastolic blood pressure;
BRCA	cis	rs7520050	0.966	rs785471	chr1:46518677	T/C	cg24296786	chr1:45957014	TESK2	0.43	9.72	0.36	6.27e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg16339924	chr4:17578868	LAP3	-0.56	-13.84	-0.48	2.82e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg20469991	chr17:27169893	C17orf63	-0.45	-8.8	-0.33	1.25e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg24692254	chr21:30365293	RNF160	-0.39	-8.96	-0.33	3.54e-18	Pancreatic cancer;
BRCA	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.1	-0.43	1.73e-30	Response to antipsychotic treatment;
BRCA	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg02527881	chr3:46936655	PTH1R	0.42	10.17	0.37	1.3e-22	Birth weight;
BRCA	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg26384229	chr12:38710491	ALG10B	-0.8	-21.43	-0.65	3.27e-77	Heart rate;
BRCA	cis	rs1865721	0.804	rs72977816	chr18:73146779	A/T	cg26385618	chr18:73139727	C18orf62	-0.44	-10.79	-0.39	4.95e-25	Intelligence;
BRCA	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg04691961	chr3:161091175	C3orf57	-0.63	-16.6	-0.55	9.68e-52	Morning vs. evening chronotype;
BRCA	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg11168104	chr5:1857477	NA	-0.36	-9.5	-0.35	4.16e-20	Cardiovascular disease risk factors;
BRCA	cis	rs3772130	1.000	rs11719458	chr3:121382005	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	9.22	0.34	4.11e-19	Cognitive performance;
BRCA	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00934597	chr7:893267	UNC84A	-0.54	-11.93	-0.43	9.43e-30	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg05283184	chr6:79620031	NA	-0.43	-11.37	-0.41	2.08e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg26516362	chr5:178986906	RUFY1	-0.44	-12.8	-0.45	1.42e-33	Lung cancer;
BRCA	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg24642439	chr20:33292090	TP53INP2	0.41	7.86	0.3	1.65e-14	Height;
BRCA	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg11752832	chr7:134001865	SLC35B4	0.52	13.39	0.47	3.12e-36	Mean platelet volume;
BRCA	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19748678	chr4:122722346	EXOSC9	0.74	16.15	0.54	1.8e-49	Type 2 diabetes;
BRCA	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.49	-0.32	1.4e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11051970	0.636	rs10844198	chr12:32563479	G/T	cg24626660	chr12:32551988	NA	0.31	9.26	0.34	2.98e-19	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg04398451	chr17:18023971	MYO15A	0.74	16.12	0.54	2.69e-49	Total body bone mineral density;
BRCA	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg13789015	chr9:136890014	NCRNA00094	0.57	11.86	0.42	1.9e-29	Platelet distribution width;
BRCA	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-16.63	-0.55	7.15e-52	Intelligence (multi-trait analysis);
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg18538332	chr22:24372958	LOC391322	-0.49	-11.62	-0.42	1.98e-28	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.57	10.85	0.39	2.67e-25	Birth weight;
BRCA	cis	rs1506403	0.685	rs10281506	chr7:142823928	C/T	cg15652212	chr7:142981776	TMEM139	0.43	8.27	0.31	7.95e-16	Cancer;
BRCA	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg08917208	chr2:24149416	ATAD2B	1.07	14.93	0.51	1.89e-43	Lymphocyte counts;
BRCA	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg23033748	chr14:75592666	NEK9	-0.42	-10.27	-0.38	5.49e-23	Height;
BRCA	cis	rs10046574	0.561	rs9656458	chr7:135202300	G/A	cg27474649	chr7:135195673	CNOT4	0.66	11.04	0.4	4.84e-26	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs897984	0.542	rs7199949	chr16:31096164	G/C	cg00531865	chr16:30841666	NA	-0.38	-9.02	-0.34	2.25e-18	Dementia with Lewy bodies;
BRCA	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	8.07	0.3	3.56e-15	Aortic root size;
BRCA	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg07741184	chr6:167504864	NA	0.35	10.37	0.38	2.21e-23	Crohn's disease;
BRCA	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg11941060	chr3:133502564	NA	-0.51	-12.16	-0.43	9.28e-31	Iron status biomarkers;
BRCA	cis	rs6684514	1.000	rs10908499	chr1:156279176	G/C	cg16558208	chr1:156270281	VHLL	0.34	8.07	0.3	3.48e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg08917208	chr2:24149416	ATAD2B	0.94	14.07	0.49	2.2e-39	Lymphocyte counts;
BRCA	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg18225595	chr11:63971243	STIP1	0.51	9.45	0.35	6.24e-20	Mean platelet volume;
BRCA	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg03929089	chr4:120376271	NA	-0.66	-13.01	-0.46	1.68e-34	Coronary artery disease;
BRCA	cis	rs1371614	0.523	rs7585127	chr2:27179371	A/G	cg00617064	chr2:27272375	NA	-0.31	-7.87	-0.3	1.53e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.75	-0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg04025307	chr7:1156635	C7orf50	0.38	9.1	0.34	1.11e-18	Longevity;Endometriosis;
BRCA	cis	rs7582720	1.000	rs72934715	chr2:203713280	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	12.51	0.44	2.8e-32	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs9811920	0.516	rs793486	chr3:99493165	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-9.86	-0.36	1.97e-21	Axial length;
BRCA	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg14196790	chr5:131705035	SLC22A5	0.31	8.03	0.3	4.82e-15	Blood metabolite levels;
BRCA	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg08917208	chr2:24149416	ATAD2B	0.9	12.65	0.45	6.89e-33	Lymphocyte counts;
BRCA	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg20701182	chr2:24300061	SF3B14	0.62	8.87	0.33	7.2e-18	Lymphocyte counts;
BRCA	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg01324343	chr3:183735012	ABCC5	0.83	20.96	0.64	1.25e-74	Anterior chamber depth;
BRCA	cis	rs1011018	0.628	rs7787807	chr7:139433190	T/C	cg03224163	chr7:139420300	HIPK2	-0.54	-9.14	-0.34	8.03e-19	Systolic blood pressure;
BRCA	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg23711669	chr6:146136114	FBXO30	0.8	19.48	0.61	1.05e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-9.24	-0.34	3.62e-19	Colorectal cancer;
BRCA	cis	rs897984	0.762	rs1870293	chr16:30970941	T/C	cg00531865	chr16:30841666	NA	0.35	8.09	0.3	3.03e-15	Dementia with Lewy bodies;
BRCA	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.52	-11.3	-0.41	4.13e-27	IgG glycosylation;
BRCA	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg04455712	chr21:45112962	RRP1B	0.47	11.32	0.41	3.31e-27	Mean corpuscular volume;
BRCA	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg18230493	chr5:56204884	C5orf35	-0.41	-8.18	-0.31	1.55e-15	Coronary artery disease;
BRCA	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg24675658	chr1:53192096	ZYG11B	-0.57	-11.36	-0.41	2.23e-27	Monocyte count;
BRCA	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg01191920	chr7:158217561	PTPRN2	-0.36	-8.59	-0.32	6.65e-17	Obesity-related traits;
BRCA	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.24	0.34	3.64e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg26384229	chr12:38710491	ALG10B	0.67	15.37	0.52	1.35e-45	Bladder cancer;
BRCA	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg25036284	chr2:26402008	FAM59B	-0.63	-10.58	-0.39	3.38e-24	Gut microbiome composition (summer);
BRCA	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg08975724	chr8:8085496	FLJ10661	0.44	8.06	0.3	3.67e-15	Retinal vascular caliber;
BRCA	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg26384229	chr12:38710491	ALG10B	-0.43	-10.05	-0.37	3.79e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.27	-0.38	5.39e-23	Psoriasis;
BRCA	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg02659138	chr7:134003124	SLC35B4	0.32	10.01	0.37	5.17e-22	Mean platelet volume;
BRCA	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg01283332	chr5:1856932	NA	-0.34	-8.37	-0.31	3.52e-16	Cardiovascular disease risk factors;
BRCA	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg00666640	chr1:248458726	OR2T12	0.3	8.42	0.32	2.46e-16	Common traits (Other);
BRCA	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg14926445	chr8:58193284	C8orf71	-0.44	-8.25	-0.31	8.87e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg24450063	chr1:156163899	SLC25A44	0.92	25.16	0.71	1.28e-97	Testicular germ cell tumor;
BRCA	cis	rs11971779	0.616	rs6944244	chr7:139051186	T/C	cg07862535	chr7:139043722	LUC7L2	0.38	10.28	0.38	4.63e-23	Diisocyanate-induced asthma;
BRCA	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg08392591	chr16:89556376	ANKRD11	0.38	8.94	0.33	4.1e-18	Multiple myeloma (IgH translocation);
BRCA	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg13010199	chr12:38710504	ALG10B	0.55	12.23	0.44	4.72e-31	Heart rate;
BRCA	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg08999081	chr20:33150536	PIGU	0.47	12.98	0.46	2.33e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg02931644	chr1:25747376	RHCE	-0.4	-11.01	-0.4	5.96e-26	Plateletcrit;Mean corpuscular volume;
BRCA	trans	rs783540	0.967	rs1259183	chr15:83279433	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.27	-8.5	-0.32	1.29e-16	Schizophrenia;
BRCA	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg08885076	chr2:99613938	TSGA10	0.44	10.29	0.38	4.34e-23	Chronic sinus infection;
BRCA	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.96e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg13385521	chr17:29058706	SUZ12P	-0.76	-11.27	-0.41	5.26e-27	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg11812906	chr14:75593930	NEK9	-0.61	-13.9	-0.48	1.49e-38	Height;
BRCA	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg24060327	chr5:131705240	SLC22A5	-0.49	-10.39	-0.38	1.73e-23	Blood metabolite levels;
BRCA	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	14.49	0.5	2.46e-41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg11366901	chr6:160182831	ACAT2	0.72	13.6	0.47	3.58e-37	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg20203395	chr5:56204925	C5orf35	-0.49	-10.31	-0.38	3.61e-23	Initial pursuit acceleration;
BRCA	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.34	-0.38	2.8e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.86	0.62	1.07e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21659725	chr3:3221576	CRBN	-0.49	-10.32	-0.38	3.47e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg21951975	chr1:209979733	IRF6	0.39	8.23	0.31	1.09e-15	Cleft lip with or without cleft palate;
BRCA	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27286337	chr10:134555280	INPP5A	0.76	12.48	0.44	3.81e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg25427524	chr10:38739819	LOC399744	0.47	9.96	0.37	8.3e-22	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg13906792	chr15:75199810	C15orf17	-0.41	-9.56	-0.35	2.54e-20	Breast cancer;
BRCA	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg02004499	chr7:4244250	SDK1	-0.42	-8.87	-0.33	7.45e-18	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
BRCA	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.59	12.07	0.43	2.27e-30	Body mass index (adult);
BRCA	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg27170947	chr2:26402098	FAM59B	-0.94	-16.89	-0.56	3.36e-53	Gut microbiome composition (summer);
BRCA	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg26384229	chr12:38710491	ALG10B	-0.45	-10.29	-0.38	4.25e-23	Bladder cancer;
BRCA	cis	rs738322	0.804	rs4821742	chr22:38514839	T/C	cg25457927	chr22:38595422	NA	-0.31	-10.86	-0.39	2.51e-25	Cutaneous nevi;
BRCA	cis	rs2625529	0.824	rs11072346	chr15:72400434	G/A	cg16672083	chr15:72433130	SENP8	-0.84	-17.47	-0.57	3.5e-56	Red blood cell count;
BRCA	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg16482183	chr6:26056742	HIST1H1C	0.66	13.55	0.47	5.86e-37	Height;
BRCA	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26314531	chr2:26401878	FAM59B	-0.62	-10.94	-0.4	1.17e-25	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg06552810	chr11:31128660	NA	-0.4	-8.79	-0.33	1.36e-17	Red blood cell count;
BRCA	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.81	-0.33	1.18e-17	Mood instability;
BRCA	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.48e-52	Hypertriglyceridemia;
BRCA	cis	rs4891159	0.548	rs10782013	chr18:74128348	C/T	cg24786174	chr18:74118243	ZNF516	0.84	25.35	0.71	1.24e-98	Longevity;
BRCA	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-15.93	-0.53	2.22e-48	Total cholesterol levels;
BRCA	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg06937882	chr20:24974362	C20orf3	-0.47	-8.88	-0.33	6.66e-18	Blood protein levels;
BRCA	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg04756594	chr16:24857601	SLC5A11	-0.53	-11.87	-0.42	1.72e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	9.16	0.34	7.13e-19	Bipolar disorder;
BRCA	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg17971929	chr21:40555470	PSMG1	0.52	11.66	0.42	1.23e-28	Cognitive function;
BRCA	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg11057378	chr10:81107060	PPIF	-0.43	-10.48	-0.38	7.77e-24	Height;
BRCA	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg22676075	chr6:135203613	NA	0.44	8.7	0.33	2.91e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg14019146	chr3:50243930	SLC38A3	-0.41	-9.77	-0.36	4.25e-21	Body mass index;
BRCA	cis	rs13064411	0.518	rs9852703	chr3:113189368	C/T	cg18753928	chr3:113234510	CCDC52	0.39	8.82	0.33	1.1e-17	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg12826209	chr6:26865740	GUSBL1	0.64	8.42	0.32	2.43e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg26384229	chr12:38710491	ALG10B	0.76	16.91	0.56	2.6e-53	Bladder cancer;
BRCA	cis	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg00086871	chr4:6988644	TBC1D14	0.88	10.8	0.39	4.32e-25	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.97	0.3	7.55e-15	Corneal astigmatism;
BRCA	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	8.67	0.32	3.58e-17	Personality dimensions;
BRCA	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg01881094	chr2:180872142	CWC22	0.65	13.58	0.47	4.19e-37	Schizophrenia;
BRCA	cis	rs72949976	0.646	rs1441170	chr2:214033563	A/G	cg08319019	chr2:214017104	IKZF2	-0.43	-9.3	-0.35	2.12e-19	Lung cancer;Squamous cell lung carcinoma;
BRCA	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg08992911	chr2:238395768	MLPH	0.6	10.16	0.37	1.38e-22	Prostate cancer;
BRCA	trans	rs208520	0.874	rs208481	chr6:66922636	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.3	-0.54	3.22e-50	Exhaled nitric oxide output;
BRCA	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg10523679	chr1:76189770	ACADM	-0.92	-26.97	-0.73	1.53e-107	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7927771	0.524	rs3758655	chr11:47703943	T/C	cg20307385	chr11:47447363	PSMC3	0.42	9.52	0.35	3.42e-20	Subjective well-being;
BRCA	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg00383909	chr3:49044727	WDR6	0.75	12.5	0.44	3e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg04025307	chr7:1156635	C7orf50	0.58	9.08	0.34	1.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs6545883	0.868	rs2427885	chr2:61816777	A/G	cg15711740	chr2:61764176	XPO1	-0.56	-14.38	-0.49	7.74e-41	Tuberculosis;
BRCA	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.39	0.49	7.17e-41	Motion sickness;
BRCA	trans	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.92	-0.3	1.02e-14	Corneal astigmatism;
BRCA	trans	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg25214090	chr10:38739885	LOC399744	0.53	11.77	0.42	4.25e-29	Corneal astigmatism;
BRCA	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg19773385	chr1:10388646	KIF1B	-0.38	-8.27	-0.31	7.81e-16	Hepatocellular carcinoma;
BRCA	trans	rs4714291	0.963	rs1743969	chr6:40096918	A/G	cg02267698	chr19:7991119	CTXN1	0.41	8.14	0.31	2.1e-15	Strep throat;
BRCA	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	8.14	0.31	2.07e-15	Personality dimensions;
BRCA	cis	rs6740322	0.644	rs11690918	chr2:43474112	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-11.86	-0.42	1.78e-29	Coronary artery disease;
BRCA	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.22e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs3820928	0.874	rs12614648	chr2:227785535	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.84	-0.33	8.95e-18	Pulmonary function;
BRCA	cis	rs7903847	0.642	rs7903562	chr10:99154782	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.9	-0.33	5.68e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg25486957	chr4:152246857	NA	-0.36	-7.9	-0.3	1.26e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	18.25	0.59	3.36e-60	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	8.51	0.32	1.23e-16	Bipolar disorder;
BRCA	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg02153584	chr22:29168773	CCDC117	0.5	10.94	0.4	1.2e-25	Lymphocyte counts;
BRCA	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18876405	chr7:65276391	NA	-0.63	-15.45	-0.52	5.27e-46	Aortic root size;
BRCA	cis	rs7020830	0.898	rs13290794	chr9:37183628	C/T	cg14294708	chr9:37120828	ZCCHC7	1.15	37.07	0.83	2.14e-161	Schizophrenia;
BRCA	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.2	-0.31	1.37e-15	Total body bone mineral density;
BRCA	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg18446336	chr7:2847575	GNA12	-0.34	-8.23	-0.31	1.03e-15	Height;
BRCA	trans	rs57046232	0.552	rs932828	chr20:6340080	G/A	cg21095983	chr6:86352623	SYNCRIP	0.37	7.84	0.3	1.88e-14	Colorectal cancer;
BRCA	cis	rs10484885	0.887	rs2273246	chr6:90453263	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.72	-10.97	-0.4	8.69e-26	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg03585969	chr10:35415529	CREM	0.54	11.17	0.4	1.37e-26	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs17818399	0.926	rs1378764	chr2:46839681	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.55	9.92	0.37	1.13e-21	Height;
BRCA	cis	rs13064411	0.542	rs9846539	chr3:113228688	A/G	cg18753928	chr3:113234510	CCDC52	-0.46	-9.82	-0.36	2.66e-21	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg01528321	chr10:82214614	TSPAN14	0.81	17.28	0.56	3.71e-55	Post bronchodilator FEV1;
BRCA	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg26695010	chr11:65641043	EFEMP2	0.36	7.91	0.3	1.13e-14	DNA methylation (variation);
BRCA	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.48	-0.41	7.18e-28	Platelet count;
BRCA	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg20090690	chr10:134436459	INPP5A	0.59	10.87	0.4	2.28e-25	Primary sclerosing cholangitis;
BRCA	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.02	-0.3	5.2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs679087	1.000	rs302317	chr12:29921443	G/A	cg14258853	chr12:29935411	TMTC1	-0.43	-9.02	-0.34	2.2e-18	Schizophrenia;
BRCA	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08564027	chr20:61660810	NA	0.85	22.9	0.67	3.47e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs13315871	0.929	rs7643185	chr3:58311158	A/C	cg20936604	chr3:58311152	NA	0.56	8.99	0.34	2.69e-18	Cholesterol, total;
BRCA	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg24296786	chr1:45957014	TESK2	-0.55	-12.48	-0.44	3.66e-32	High light scatter reticulocyte count;
BRCA	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg11764359	chr7:65958608	NA	0.65	11.01	0.4	6.09e-26	Aortic root size;
BRCA	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-9.96	-0.37	8.21e-22	Fear of minor pain;
BRCA	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg12483005	chr1:23474871	LUZP1	-0.47	-10.42	-0.38	1.33e-23	Height;
BRCA	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08645402	chr16:4508243	NA	0.39	9.14	0.34	8.36e-19	Schizophrenia;
BRCA	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-15.73	-0.53	2.29e-47	Electrocardiographic conduction measures;
BRCA	cis	rs13064411	0.518	rs6769604	chr3:113185064	A/G	cg18753928	chr3:113234510	CCDC52	-0.4	-8.97	-0.33	3.33e-18	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs13046373	0.535	rs1395775	chr21:32025065	G/A	cg22337977	chr21:31811175	KRTAP15-1	0.33	7.87	0.3	1.55e-14	HDL cholesterol;
BRCA	cis	rs11716531	0.574	rs13075192	chr3:27279235	C/T	cg02860705	chr3:27208620	NA	0.59	11.45	0.41	9.6e-28	Diastolic blood pressure;
BRCA	cis	rs7395581	0.959	rs7129661	chr11:47268550	T/G	cg25783544	chr11:47291846	MADD	0.41	9.09	0.34	1.24e-18	HDL cholesterol;
BRCA	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg13256891	chr4:100009986	ADH5	-0.54	-12.47	-0.44	4.15e-32	Alcohol dependence;
BRCA	cis	rs9400271	0.632	rs9374072	chr6:109591586	A/G	cg21918786	chr6:109611834	NA	-0.32	-8.08	-0.3	3.17e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11764359	chr7:65958608	NA	0.75	16.57	0.55	1.37e-51	Aortic root size;
BRCA	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.4	8.4	0.32	2.97e-16	Ulcerative colitis;
BRCA	cis	rs7523050	0.643	rs35885176	chr1:109401868	G/A	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	-0.43	-8.33	-0.31	4.78e-16	Resistin levels;
BRCA	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg02891314	chr5:179741120	GFPT2	-0.64	-12.85	-0.45	9.21e-34	Height;
BRCA	cis	rs6976053	0.518	rs314358	chr7:100410657	A/G	cg03098644	chr7:100410630	EPHB4	-0.44	-8.9	-0.33	5.89e-18	Plasminogen activator inhibitor type 1 levels (PAI-1);
BRCA	trans	rs1493916	0.837	rs4992177	chr18:31407020	C/T	cg27147174	chr7:100797783	AP1S1	-0.42	-8.48	-0.32	1.55e-16	Life satisfaction;
BRCA	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.61	-13.1	-0.46	6.7e-35	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.87	0.3	1.53e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg16230307	chr14:35515116	FAM177A1	0.74	15.5	0.52	3.27e-46	Psoriasis;
BRCA	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg06159980	chr1:16340746	HSPB7	-0.38	-8.75	-0.33	1.92e-17	Dilated cardiomyopathy;
BRCA	cis	rs13102973	0.965	rs4437307	chr4:135861598	C/T	cg14419869	chr4:135874104	NA	-0.58	-12.85	-0.45	8.58e-34	Subjective well-being;
BRCA	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.51	-0.32	1.2e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.58	-9.72	-0.36	6.47e-21	Schizophrenia;
BRCA	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-9.0	-0.34	2.54e-18	Alzheimer's disease (late onset);
BRCA	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg22431228	chr1:16359049	CLCNKA	-0.42	-9.51	-0.35	3.89e-20	Dilated cardiomyopathy;
BRCA	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg06618935	chr21:46677482	NA	-0.34	-8.1	-0.31	2.84e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9467773	0.587	rs12214031	chr6:26376628	T/C	cg09904177	chr6:26538194	HMGN4	-0.31	-8.36	-0.31	3.81e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg18200150	chr17:30822561	MYO1D	0.35	9.04	0.34	1.81e-18	Schizophrenia;
BRCA	trans	rs1941687	0.527	rs6507059	chr18:31303643	A/G	cg27147174	chr7:100797783	AP1S1	-0.47	-9.01	-0.34	2.42e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.14	-0.37	1.63e-22	Heart rate;
BRCA	cis	rs113835537	0.597	rs4576	chr11:66331000	A/G	cg24851651	chr11:66362959	CCS	0.45	8.64	0.32	4.32e-17	Airway imaging phenotypes;
BRCA	cis	rs36051895	0.559	rs72701680	chr9:5207294	A/T	cg02405213	chr9:5042618	JAK2	-0.43	-8.09	-0.3	3.02e-15	Pediatric autoimmune diseases;
BRCA	cis	rs4409675	0.576	rs6660899	chr1:28214281	G/C	cg23691781	chr1:28212827	C1orf38	0.32	10.73	0.39	7.96e-25	Corneal astigmatism;
BRCA	trans	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg06521331	chr12:34319734	NA	-0.43	-8.13	-0.31	2.22e-15	Bladder cancer;
BRCA	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03934478	chr11:495069	RNH1	-0.79	-11.39	-0.41	1.64e-27	Body mass index;
BRCA	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg06917634	chr15:78832804	PSMA4	-0.55	-11.98	-0.43	5.61e-30	Sudden cardiac arrest;
BRCA	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg17640201	chr16:30407289	ZNF48	0.76	16.36	0.54	1.59e-50	Tonsillectomy;
BRCA	cis	rs1476670	0.683	rs2057967	chr1:44515446	T/C	cg09470012	chr1:44509516	NA	0.4	9.02	0.34	2.21e-18	Eotaxin levels;
BRCA	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.55	-0.32	8.79e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg06671706	chr8:8559999	CLDN23	0.44	8.72	0.33	2.42e-17	Obesity-related traits;
BRCA	cis	rs3771570	1.000	rs56222556	chr2:242364119	G/A	cg21155796	chr2:242212141	HDLBP	0.61	9.27	0.34	2.73e-19	Prostate cancer;
BRCA	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.49	-11.01	-0.4	6.47e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg02503808	chr4:7069936	GRPEL1	0.38	8.62	0.32	5.14e-17	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
BRCA	cis	rs9463078	0.809	rs6937317	chr6:45203918	T/C	cg25276700	chr6:44698697	NA	-0.36	-8.01	-0.3	5.54e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg12564285	chr5:131593104	PDLIM4	-0.35	-7.83	-0.3	2.07e-14	Breast cancer;
BRCA	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9400271	0.632	rs4427037	chr6:109585612	G/C	cg01475377	chr6:109611718	NA	-0.43	-10.3	-0.38	4.21e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26314531	chr2:26401878	FAM59B	-0.63	-10.83	-0.39	3.28e-25	Gut microbiome composition (summer);
BRCA	cis	rs870825	0.616	rs7682677	chr4:185640717	C/G	cg04058563	chr4:185651563	MLF1IP	0.76	17.1	0.56	2.99e-54	Blood protein levels;
BRCA	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg10818794	chr15:86012489	AKAP13	-0.41	-11.07	-0.4	3.46e-26	Coronary artery disease;
BRCA	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.22	0.31	1.13e-15	Cognitive ability;
BRCA	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg04166393	chr7:2884313	GNA12	0.48	9.15	0.34	7.36e-19	Height;
BRCA	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg12463550	chr7:65579703	CRCP	-0.37	-8.04	-0.3	4.46e-15	Aortic root size;
BRCA	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11644478	chr21:40555479	PSMG1	-0.66	-14.28	-0.49	2.46e-40	Cognitive function;
BRCA	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg04034577	chr2:241836375	C2orf54	-0.5	-12.59	-0.45	1.21e-32	Urinary metabolites;
BRCA	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.49	0.57	2.8e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg07817883	chr1:32538562	TMEM39B	-0.44	-8.48	-0.32	1.54e-16	Monocyte percentage of white cells;
BRCA	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	14.95	0.51	1.43e-43	Hip circumference adjusted for BMI;
BRCA	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg08997352	chr12:9597637	DDX12	-0.54	-10.35	-0.38	2.57e-23	Breast size;
BRCA	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.63	13.66	0.48	1.83e-37	Lymphocyte percentage of white cells;
BRCA	trans	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.92	0.3	1.05e-14	Endometrial cancer;
BRCA	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg05623727	chr3:50126028	RBM5	-0.41	-9.65	-0.36	1.2e-20	Intelligence (multi-trait analysis);
BRCA	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg21548813	chr6:291882	DUSP22	0.57	12.14	0.43	1.21e-30	Menopause (age at onset);
BRCA	cis	rs4302748	0.862	rs74301277	chr7:36184831	C/G	cg24442661	chr7:36192818	EEPD1	0.48	8.81	0.33	1.2e-17	Platelet count;
BRCA	cis	rs6700896	0.931	rs4655585	chr1:66155627	T/C	cg04111102	chr1:66153794	NA	0.34	8.23	0.31	1.07e-15	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs6987853	0.787	rs2923402	chr8:42445400	G/A	cg09913449	chr8:42400586	C8orf40	0.38	7.94	0.3	9.16e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg08917208	chr2:24149416	ATAD2B	0.52	8.28	0.31	7.42e-16	Asthma;
BRCA	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg07389463	chr12:132296394	NA	-0.49	-13.31	-0.47	7.23e-36	Migraine;
BRCA	cis	rs559928	1.000	rs72926046	chr11:64143387	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	9.65	0.36	1.21e-20	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg14675211	chr2:100938903	LONRF2	0.44	10.11	0.37	2.18e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg27535305	chr1:53392650	SCP2	-0.4	-9.63	-0.36	1.37e-20	Monocyte count;
BRCA	cis	rs4566357	0.615	rs12328876	chr2:227918899	G/T	cg05526886	chr2:227700861	RHBDD1	-0.4	-8.07	-0.3	3.48e-15	Coronary artery disease;
BRCA	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.59	-0.39	2.91e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.69	-0.33	3.09e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9811920	0.838	rs12488245	chr3:99835254	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	12.89	0.45	5.97e-34	Axial length;
BRCA	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.09	-0.34	1.23e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg12923728	chr3:195709715	SDHAP1	0.38	7.84	0.3	1.94e-14	Mean corpuscular volume;
BRCA	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.23	0.31	1.07e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10193935	0.901	rs10201586	chr2:42622594	C/G	cg27598129	chr2:42591480	NA	-0.79	-13.33	-0.47	6.13e-36	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.06	0.3	3.8e-15	Menarche (age at onset);
BRCA	cis	rs909002	0.925	rs4949455	chr1:32114793	C/T	cg13919466	chr1:32135498	COL16A1	-0.24	-8.12	-0.31	2.43e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1691799	0.867	rs1039056	chr12:66760391	C/T	cg16791601	chr12:66731901	HELB	-0.65	-17.61	-0.57	7.24e-57	White blood cell count (basophil);
BRCA	cis	rs793571	0.523	rs7161889	chr15:58983425	C/G	cg05156742	chr15:59063176	FAM63B	0.56	11.43	0.41	1.15e-27	Schizophrenia;
BRCA	cis	rs10189230	0.935	rs1864461	chr2:222347615	A/G	cg14652038	chr2:222343519	EPHA4	0.48	13.27	0.46	1.11e-35	Urate levels in lean individuals;
BRCA	cis	rs9527	0.590	rs7894959	chr10:104756182	C/T	cg04362960	chr10:104952993	NT5C2	0.41	9.51	0.35	3.67e-20	Arsenic metabolism;
BRCA	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg20283391	chr11:68216788	NA	-0.48	-9.32	-0.35	1.88e-19	Total body bone mineral density;
BRCA	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg06784218	chr1:46089804	CCDC17	0.5	12.02	0.43	3.67e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg09904177	chr6:26538194	HMGN4	0.37	7.99	0.3	6.52e-15	Small cell lung carcinoma;
BRCA	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg13770153	chr20:60521292	NA	0.56	11.82	0.42	2.78e-29	Body mass index;
BRCA	cis	rs13136331	0.680	rs2732178	chr4:88654589	T/C	cg12990093	chr4:88570587	DMP1	-0.4	-8.17	-0.31	1.61e-15	Sitting height ratio;
BRCA	cis	rs2289583	0.597	rs12148708	chr15:75384397	G/A	cg14664628	chr15:75095509	CSK	0.39	9.14	0.34	8.45e-19	Systemic lupus erythematosus;
BRCA	cis	rs10267417	0.603	rs1557773	chr7:19908586	A/G	cg07541023	chr7:19748670	TWISTNB	-0.45	-8.18	-0.31	1.5e-15	Night sleep phenotypes;
BRCA	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg11822812	chr5:140052017	DND1	-0.31	-8.4	-0.32	2.86e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg02297831	chr4:17616191	MED28	0.36	8.49	0.32	1.41e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1975991	0.538	rs1479936	chr3:187967064	A/C	cg15417654	chr3:187959138	LPP	0.33	8.41	0.32	2.6e-16	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg23649088	chr2:200775458	C2orf69	0.39	8.36	0.31	3.91e-16	Asthma (bronchodilator response);
BRCA	cis	rs9296092	0.517	rs78978280	chr6:33520747	T/A	cg13560919	chr6:33536144	NA	-0.85	-17.72	-0.57	1.88e-57	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg08917208	chr2:24149416	ATAD2B	0.9	12.95	0.46	3.2e-34	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.7	0.39	1.11e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	13.07	0.46	8.73e-35	Menarche (age at onset);
BRCA	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg01849466	chr14:104193079	ZFYVE21	0.44	11.3	0.41	4.14e-27	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22307029	chr19:49891270	CCDC155	0.53	8.83	0.33	1.04e-17	Multiple sclerosis;
BRCA	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02176678	chr2:219576539	TTLL4	0.46	12.15	0.43	1.04e-30	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.85	-0.3	1.73e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg02503808	chr4:7069936	GRPEL1	0.82	17.61	0.57	7.2e-57	Monocyte percentage of white cells;
BRCA	cis	rs11690935	0.632	rs12991740	chr2:172885996	C/T	cg13550731	chr2:172543902	DYNC1I2	0.53	13.16	0.46	3.58e-35	Schizophrenia;
BRCA	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg23649088	chr2:200775458	C2orf69	-0.57	-8.54	-0.32	9.92e-17	Schizophrenia;
BRCA	trans	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg02030672	chr11:45687055	CHST1	0.39	8.28	0.31	7.49e-16	Obesity-related traits;
BRCA	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg04248312	chr19:17393744	ANKLE1	-0.93	-21.69	-0.65	1.32e-78	Systemic lupus erythematosus;
BRCA	trans	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg26043149	chr18:55253948	FECH	-0.38	-8.35	-0.31	4.17e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6484504	0.625	rs7112412	chr11:31370271	T/C	cg06552810	chr11:31128660	NA	0.38	8.54	0.32	9.53e-17	Red blood cell count;
BRCA	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.59	-0.32	6.69e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4566357	0.615	rs2272200	chr2:227912331	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.41	-0.35	8.84e-20	Coronary artery disease;
BRCA	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg22491629	chr6:157744540	C6orf35	-0.67	-12.57	-0.45	1.58e-32	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg21775007	chr8:11205619	TDH	-0.48	-9.92	-0.37	1.16e-21	Neuroticism;
BRCA	cis	rs72766638	0.895	rs55924785	chr9:136929586	C/T	cg13789015	chr9:136890014	NCRNA00094	0.55	8.7	0.33	2.85e-17	Mosquito bite size;
BRCA	cis	rs9297145	0.565	rs6952161	chr7:98733337	A/G	cg05967295	chr7:98741636	SMURF1	0.64	13.86	0.48	2.1e-38	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs7809950	1.000	rs1544336	chr7:107082415	G/C	cg23024343	chr7:107201750	COG5	-0.42	-9.69	-0.36	8.1899999999999992e-21	Coronary artery disease;
BRCA	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg23231163	chr10:75533350	FUT11	-0.33	-8.7	-0.33	2.73e-17	Inflammatory bowel disease;
BRCA	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg06623918	chr6:96969491	KIAA0776	0.74	12.99	0.46	2.1e-34	Migraine;Coronary artery disease;
BRCA	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.19	-0.4	1.19e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.48	0.38	8.25e-24	Motion sickness;
BRCA	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg05340658	chr4:99064831	C4orf37	0.43	9.24	0.34	3.72e-19	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg22535103	chr8:58192502	C8orf71	-0.54	-9.18	-0.34	6.01e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs1113500	0.933	rs12035689	chr1:108636756	T/C	cg06207961	chr1:108661230	NA	0.45	11.07	0.4	3.47e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg26248373	chr2:1572462	NA	-0.5	-9.65	-0.36	1.16e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs2625529	0.775	rs12913042	chr15:72202309	C/T	cg16672083	chr15:72433130	SENP8	-0.82	-17.01	-0.56	8.39e-54	Red blood cell count;
BRCA	cis	rs870825	0.616	rs28416641	chr4:185617999	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	17.28	0.56	3.69e-55	Blood protein levels;
BRCA	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.37	7.82	0.3	2.19e-14	Total cholesterol levels;
BRCA	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.99	-0.37	6e-22	Neuroticism;
BRCA	cis	rs6834538	1.000	rs7665050	chr4:113521476	G/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.38	8.36	0.31	3.88e-16	Free thyroxine concentration;
BRCA	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.46	-10.53	-0.38	4.88e-24	Urate levels in overweight individuals;
BRCA	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.9	-0.51	2.56e-43	Total cholesterol levels;
BRCA	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg18758796	chr5:131593413	PDLIM4	0.33	8.69	0.33	3.09e-17	Breast cancer;
BRCA	trans	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg01620082	chr3:125678407	NA	-0.83	-9.45	-0.35	6.18e-20	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4953076	0.573	rs6738023	chr2:44405931	T/C	cg04920474	chr2:44395004	PPM1B	0.51	10.52	0.38	5.73e-24	Height;
BRCA	trans	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.91	-0.3	1.15e-14	Corneal astigmatism;
BRCA	cis	rs9290065	0.519	rs7635796	chr3:160674689	G/C	cg03342759	chr3:160939853	NMD3	-0.46	-9.46	-0.35	5.88e-20	Kawasaki disease;
BRCA	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg13010199	chr12:38710504	ALG10B	-0.35	-8.38	-0.31	3.27e-16	Morning vs. evening chronotype;
BRCA	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.46	9.43	0.35	7.55e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg15997130	chr1:24165203	NA	-0.44	-10.21	-0.37	9.2e-23	Immature fraction of reticulocytes;
BRCA	cis	rs6450176	0.859	rs3776719	chr5:53298684	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-14.52	-0.5	1.65e-41	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05901451	chr6:126070800	HEY2	0.38	9.25	0.34	3.23e-19	Endometrial cancer;
BRCA	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg11366901	chr6:160182831	ACAT2	0.82	15.93	0.53	2.45e-48	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg18230493	chr5:56204884	C5orf35	-0.72	-14.03	-0.49	3.47e-39	Initial pursuit acceleration;
BRCA	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg03709012	chr19:19516395	GATAD2A	1.0	18.63	0.59	3.29e-62	Nonalcoholic fatty liver disease;
BRCA	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01570182	chr17:44337453	NA	0.86	13.93	0.48	1.01e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
BRCA	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.89	-27.79	-0.74	4.85e-112	Schizophrenia;
BRCA	cis	rs312274	0.630	rs10784898	chr12:41230722	A/G	cg17827154	chr12:41323612	CNTN1	-0.42	-10.48	-0.38	7.99e-24	Metabolite levels  (X-11787);
BRCA	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg22907277	chr7:1156413	C7orf50	0.63	10.4	0.38	1.6e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9487051	0.768	rs399561	chr6:109524979	G/A	cg21918786	chr6:109611834	NA	-0.34	-9.1	-0.34	1.13e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.11	0.49	1.43e-39	Motion sickness;
BRCA	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.72e-18	Alzheimer's disease (late onset);
BRCA	cis	rs11605924	0.901	rs7105751	chr11:45856973	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.45	-9.68	-0.36	9.25e-21	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.84	-0.33	9.56e-18	Total body bone mineral density;
BRCA	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00149659	chr3:10157352	C3orf10	0.71	12.33	0.44	1.69e-31	Alzheimer's disease;
BRCA	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg01028140	chr2:1542097	TPO	-0.76	-15.19	-0.52	1.04e-44	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg12219531	chr12:120966889	COQ5	0.55	11.64	0.42	1.56e-28	High light scatter reticulocyte count;
BRCA	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg05507819	chr15:63340323	TPM1	-0.43	-9.34	-0.35	1.59e-19	Platelet count;
BRCA	cis	rs1506636	1.000	rs614645	chr7:123442349	T/C	cg03229431	chr7:123269106	ASB15	0.57	12.37	0.44	1.17e-31	Plateletcrit;Platelet count;
BRCA	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.43	-9.58	-0.35	2.08e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg13010199	chr12:38710504	ALG10B	0.45	9.38	0.35	1.16e-19	Bladder cancer;
BRCA	cis	rs9394841	0.646	rs9471676	chr6:41815192	C/T	cg08135965	chr6:41755394	TOMM6	0.5	8.27	0.31	7.76e-16	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs1506636	1.000	rs666266	chr7:123417759	A/G	cg03229431	chr7:123269106	ASB15	0.61	13.54	0.47	6.54e-37	Plateletcrit;Platelet count;
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10150615	chr22:24372951	LOC391322	-0.42	-9.07	-0.34	1.44e-18	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg21518248	chr2:162101506	NA	0.47	9.72	0.36	6.2e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9420	0.961	rs11229148	chr11:57621460	A/T	cg19752551	chr11:57585705	CTNND1	-0.51	-12.59	-0.45	1.21e-32	Schizophrenia;
BRCA	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg24675658	chr1:53192096	ZYG11B	0.61	14.37	0.49	9.19e-41	Monocyte count;
BRCA	trans	rs1459104	1.000	rs12793778	chr11:55085722	T/C	cg03929089	chr4:120376271	NA	0.65	7.9	0.3	1.25e-14	Body mass index;
BRCA	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-10.03	-0.37	4.42e-22	Body mass index;
BRCA	trans	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg26384229	chr12:38710491	ALG10B	0.47	10.43	0.38	1.26e-23	Morning vs. evening chronotype;
BRCA	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg25801113	chr15:45476975	SHF	0.31	7.91	0.3	1.14e-14	Uric acid levels;
BRCA	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.55	0.55	1.84e-51	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg05340658	chr4:99064831	C4orf37	0.63	15.15	0.51	1.51e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.19	-0.43	6.89e-31	Breast cancer;
BRCA	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg19743168	chr1:23544995	NA	0.34	7.86	0.3	1.65e-14	Height;
BRCA	cis	rs7903847	0.642	rs10882922	chr10:99158537	C/T	cg08345082	chr10:99160200	RRP12	-0.3	-8.77	-0.33	1.56e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs3815700	1.000	rs10407204	chr19:33097353	C/T	cg02997394	chr19:33096574	ANKRD27	0.69	11.65	0.42	1.45e-28	Eosinophilic esophagitis;
BRCA	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.36	8.05	0.3	4.19e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7572733	0.534	rs1607374	chr2:198800440	A/G	cg00792783	chr2:198669748	PLCL1	0.45	9.89	0.36	1.47e-21	Dermatomyositis;
BRCA	trans	rs12310956	0.527	rs1608910	chr12:33895414	T/C	cg13010199	chr12:38710504	ALG10B	0.37	8.1	0.31	2.77e-15	Morning vs. evening chronotype;
BRCA	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg15605315	chr1:45957053	TESK2	-0.47	-9.26	-0.34	3.08e-19	High light scatter reticulocyte count;
BRCA	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.33	0.41	2.98e-27	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs68170813	0.523	rs3757713	chr7:107042750	A/C	cg02696742	chr7:106810147	HBP1	-0.52	-8.18	-0.31	1.58e-15	Coronary artery disease;
BRCA	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg03929089	chr4:120376271	NA	-0.52	-10.14	-0.37	1.68e-22	HDL cholesterol;
BRCA	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg04851639	chr8:1020857	NA	-0.36	-10.68	-0.39	1.29e-24	Schizophrenia;
BRCA	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg25206134	chr2:45395956	NA	0.55	8.83	0.33	1.03e-17	Bipolar disorder;
BRCA	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg06784218	chr1:46089804	CCDC17	-0.45	-10.84	-0.39	2.92e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg09367891	chr1:107599246	PRMT6	0.42	8.29	0.31	6.87e-16	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs813218	0.565	rs2449106	chr3:99602087	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.41	8.7	0.33	2.85e-17	Orofacial clefts;
BRCA	cis	rs4285028	0.747	rs7647351	chr3:121422109	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-13.97	-0.48	6.66e-39	Multiple sclerosis;
BRCA	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg13010199	chr12:38710504	ALG10B	0.43	9.07	0.34	1.44e-18	Morning vs. evening chronotype;
BRCA	cis	rs4478137	0.931	rs12509756	chr4:164237464	A/T	cg06758707	chr4:164254230	NPY1R	0.59	12.99	0.46	2.04e-34	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg22974920	chr21:40686053	BRWD1	-0.35	-7.84	-0.3	1.91e-14	Menarche (age at onset);
BRCA	cis	rs11971779	0.616	rs1133068	chr7:139053143	G/A	cg07862535	chr7:139043722	LUC7L2	0.38	10.24	0.38	6.65e-23	Diisocyanate-induced asthma;
BRCA	cis	rs9560113	1.000	rs4773379	chr13:112176088	G/C	cg10483660	chr13:112241077	NA	0.32	7.96	0.3	7.93e-15	Menarche (age at onset);
BRCA	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg20129853	chr10:51489980	NA	-0.3	-8.18	-0.31	1.59e-15	Prostate-specific antigen levels;
BRCA	cis	rs503734	0.502	rs348861	chr3:100955259	G/A	cg27318481	chr3:100970896	IMPG2	-0.4	-9.65	-0.36	1.17e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12291225	0.877	rs11023160	chr11:14264225	T/A	cg19336497	chr11:14380999	RRAS2	-0.36	-8.04	-0.3	4.4e-15	Sense of smell;
BRCA	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	18.23	0.58	4.3e-60	Electrocardiographic conduction measures;
BRCA	cis	rs36051895	0.658	rs7875265	chr9:5033882	C/A	cg02405213	chr9:5042618	JAK2	-0.49	-9.21	-0.34	4.71e-19	Pediatric autoimmune diseases;
BRCA	trans	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg21659725	chr3:3221576	CRBN	0.45	8.1	0.31	2.83e-15	Menarche (age at onset);
BRCA	cis	rs7818345	0.967	rs12678336	chr8:19280552	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.0	0.3	5.85e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg02659138	chr7:134003124	SLC35B4	0.34	10.65	0.39	1.64e-24	Mean platelet volume;
BRCA	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	9.66	0.36	1.02e-20	Renal function-related traits (BUN);
BRCA	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg21573476	chr21:45109991	RRP1B	-0.42	-11.31	-0.41	3.78e-27	Mean corpuscular volume;
BRCA	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-12.73	-0.45	2.96e-33	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg04025307	chr7:1156635	C7orf50	0.6	15.1	0.51	2.65e-44	Longevity;Endometriosis;
BRCA	cis	rs2386661	0.547	rs11259742	chr10:5647078	C/T	cg17085576	chr10:5658249	NA	-0.33	-8.19	-0.31	1.47e-15	Breast cancer;
BRCA	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg21475434	chr5:93447410	FAM172A	0.66	8.69	0.33	2.92e-17	Diabetic retinopathy;
BRCA	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg07169764	chr2:136633963	MCM6	1.06	21.21	0.64	5.63e-76	Corneal structure;
BRCA	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg07917127	chr4:99064746	C4orf37	0.44	8.15	0.31	1.98e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg01236616	chr12:121019343	POP5	1.25	27.71	0.74	1.32e-111	Type 1 diabetes nephropathy;
BRCA	cis	rs6484504	0.625	rs672396	chr11:31386165	A/G	cg06552810	chr11:31128660	NA	0.37	8.47	0.32	1.69e-16	Red blood cell count;
BRCA	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg00101154	chr16:420108	MRPL28	-0.61	-15.09	-0.51	3.22e-44	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs7631605	0.905	rs11711937	chr3:37224838	C/G	cg15934958	chr3:37212084	LRRFIP2	-0.47	-10.84	-0.39	3.07e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs754466	0.580	rs10824576	chr10:79566040	G/C	cg17075019	chr10:79541650	NA	-0.75	-18.91	-0.6	1.08e-63	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7582720	1.000	rs72934554	chr2:203987806	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	12.77	0.45	2.02e-33	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs9443189	0.570	rs7765254	chr6:76398143	T/C	cg01950844	chr6:76311363	SENP6	0.77	10.48	0.38	7.68e-24	Prostate cancer;
BRCA	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.43	8.5	0.32	1.36e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg25801113	chr15:45476975	SHF	-0.34	-8.28	-0.31	7.41e-16	Uric acid levels;
BRCA	cis	rs7927771	0.524	rs11039431	chr11:47872012	G/T	cg20307385	chr11:47447363	PSMC3	0.42	9.49	0.35	4.65e-20	Subjective well-being;
BRCA	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg18154014	chr19:37997991	ZNF793	0.55	10.28	0.38	4.63e-23	Coronary artery calcification;
BRCA	cis	rs9392556	0.829	rs7757606	chr6:4119704	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.37	-7.83	-0.3	2.05e-14	Blood metabolite levels;
BRCA	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.75	15.37	0.52	1.35e-45	Smoking behavior;
BRCA	cis	rs7580658	0.534	rs2089109	chr2:127951458	G/A	cg16751203	chr2:127950803	CYP27C1	0.29	8.29	0.31	6.55e-16	Protein C levels;
BRCA	trans	rs629535	0.814	rs652483	chr8:70055083	G/A	cg21567404	chr3:27674614	NA	1.0	20.87	0.64	3.64e-74	Dupuytren's disease;
BRCA	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg07636037	chr3:49044803	WDR6	-0.67	-13.44	-0.47	1.88e-36	Menarche (age at onset);
BRCA	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.39	-8.92	-0.33	5.07e-18	Fear of minor pain;
BRCA	cis	rs10463316	0.894	rs7707964	chr5:150765475	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.42	-0.32	2.53e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg09307838	chr4:120376055	NA	0.64	13.91	0.48	1.32e-38	Corneal astigmatism;
BRCA	cis	rs1511802	0.501	rs7684025	chr4:187116227	C/T	cg24794857	chr4:187113578	CYP4V2	0.37	8.22	0.31	1.13e-15	Blood protein levels;
BRCA	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg22535103	chr8:58192502	C8orf71	-0.48	-8.39	-0.32	3.09e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg06064525	chr11:970664	AP2A2	-0.48	-16.27	-0.54	4.82e-50	Alzheimer's disease (late onset);
BRCA	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.39	13.32	0.47	6.63e-36	Bipolar disorder;
BRCA	cis	rs75229567	0.618	rs35394896	chr12:70188346	T/A	cg10114359	chr12:70132523	RAB3IP	0.63	9.6	0.36	1.73e-20	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
BRCA	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.3	8.02	0.3	5.15e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs807669	1.000	rs807670	chr22:19154608	A/C	cg02655711	chr22:19163373	SLC25A1	0.55	13.15	0.46	4.02e-35	Metabolite levels;
BRCA	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg26031613	chr14:104095156	KLC1	0.72	15.56	0.52	1.58e-46	Body mass index;
BRCA	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg00677455	chr12:58241039	CTDSP2	-0.38	-8.53	-0.32	1.05e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg08000102	chr2:233561755	GIGYF2	0.63	13.65	0.48	2.14e-37	Coronary artery disease;
BRCA	cis	rs4308124	0.708	rs6716091	chr2:111991133	C/T	cg04571233	chr2:111982156	NA	-0.46	-9.85	-0.36	2.05e-21	Vitiligo;
BRCA	cis	rs11030122	0.702	rs10500590	chr11:3964724	T/C	cg18678763	chr11:4115507	RRM1	-0.36	-8.17	-0.31	1.6e-15	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg27446573	chr6:127587934	RNF146	0.69	15.82	0.53	8.25e-48	Breast cancer;
BRCA	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg20991723	chr1:152506922	NA	-0.37	-8.62	-0.32	5.15e-17	Hair morphology;
BRCA	cis	rs1003719	0.523	rs1063949	chr21:38574675	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.61	-0.5	6.13e-42	Eye color traits;
BRCA	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg20469991	chr17:27169893	C17orf63	-0.45	-8.81	-0.33	1.13e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs7617773	0.743	rs13071960	chr3:48367537	A/G	cg11946769	chr3:48343235	NME6	0.67	13.61	0.47	3.13e-37	Coronary artery disease;
BRCA	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg09307838	chr4:120376055	NA	0.63	12.83	0.45	1.07e-33	Corneal astigmatism;
BRCA	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg15997130	chr1:24165203	NA	-0.48	-13.15	-0.46	3.9e-35	Immature fraction of reticulocytes;
BRCA	cis	rs1535500	0.905	rs2146262	chr6:39283793	C/T	cg03252829	chr6:39282164	KCNK17	-0.3	-7.93	-0.3	9.47e-15	Type 2 diabetes;
BRCA	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg09367891	chr1:107599246	PRMT6	-0.43	-8.52	-0.32	1.17e-16	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg08999081	chr20:33150536	PIGU	-0.4	-10.3	-0.38	4.15e-23	Coronary artery disease;
BRCA	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg06494592	chr3:125709126	NA	-0.53	-8.87	-0.33	7.04e-18	Blood pressure (smoking interaction);
BRCA	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-0.6	-9.54	-0.35	3e-20	Lung function (FEV1/FVC);
BRCA	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg11752832	chr7:134001865	SLC35B4	-0.44	-10.95	-0.4	1.09e-25	Mean platelet volume;
BRCA	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg12011299	chr4:100065546	ADH4	0.48	10.95	0.4	1.07e-25	Smoking initiation;
BRCA	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.16e-47	Alzheimer's disease (late onset);
BRCA	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.11	0.54	2.97e-49	Fuchs's corneal dystrophy;
BRCA	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg14266287	chr2:239334506	ASB1	-0.34	-8.27	-0.31	7.94e-16	Multiple system atrophy;
BRCA	cis	rs9986765	0.737	rs10274253	chr7:142810265	G/C	cg22531018	chr7:142981779	TMEM139	0.69	10.68	0.39	1.35e-24	Cancer;Dermatomyositis;
BRCA	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	1.9e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg10523679	chr1:76189770	ACADM	0.68	12.61	0.45	1.03e-32	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-16.18	-0.54	1.37e-49	Chronic sinus infection;
BRCA	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg22800045	chr5:56110881	MAP3K1	0.65	12.31	0.44	2.11e-31	Initial pursuit acceleration;
BRCA	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg24562669	chr7:97807699	LMTK2	0.46	12.16	0.43	9.2e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg11764359	chr7:65958608	NA	0.63	10.74	0.39	7.39e-25	Aortic root size;
BRCA	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg02951883	chr7:2050386	MAD1L1	-0.36	-8.13	-0.31	2.17e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7561273	0.609	rs2339945	chr2:24348096	G/A	cg04809136	chr2:24300158	SF3B14	-0.4	-8.94	-0.33	4.13e-18	Quantitative traits;
BRCA	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08219700	chr8:58056026	NA	0.45	8.31	0.31	5.78e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg01191920	chr7:158217561	PTPRN2	-0.34	-7.88	-0.3	1.4e-14	Obesity-related traits;
BRCA	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg17470723	chr8:74884337	TCEB1	0.4	8.6	0.32	6.02e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.56	0.42	3.32e-28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18876405	chr7:65276391	NA	-0.51	-11.59	-0.42	2.49e-28	Aortic root size;
BRCA	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10802521	chr3:52805072	NEK4	-0.31	-8.05	-0.3	4.07e-15	Bipolar disorder;
BRCA	cis	rs36051895	0.664	rs10117459	chr9:5094034	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-9.04	-0.34	1.81e-18	Pediatric autoimmune diseases;
BRCA	cis	rs7011049	1.000	rs72640857	chr8:53839067	T/A	cg26025543	chr8:53854495	NA	0.56	9.66	0.36	1.11e-20	Systolic blood pressure;
BRCA	cis	rs11585357	0.947	rs6666990	chr1:17611520	G/A	cg08277548	chr1:17600880	PADI3	0.6	11.03	0.4	5.09e-26	Hair shape;
BRCA	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	11.05	0.4	4.08e-26	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.38	-10.12	-0.37	2.05e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg18538332	chr22:24372958	LOC391322	0.5	11.75	0.42	5.26e-29	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18876405	chr7:65276391	NA	0.52	11.65	0.42	1.43e-28	Aortic root size;
BRCA	cis	rs4285028	0.948	rs71329247	chr3:121681523	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.6	-10.64	-0.39	1.88e-24	Multiple sclerosis;
BRCA	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg24130564	chr14:104152367	KLC1	-0.35	-8.0	-0.3	5.8e-15	Body mass index;
BRCA	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg03433033	chr1:76189801	ACADM	0.73	18.72	0.6	1.08e-62	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.36	-8.02	-0.3	4.9e-15	Longevity;Endometriosis;
BRCA	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg05347473	chr6:146136440	FBXO30	-0.43	-8.55	-0.32	9.35e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02018176	chr4:1364513	KIAA1530	0.37	8.0	0.3	5.89e-15	Longevity;
BRCA	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg13319975	chr6:146136371	FBXO30	-0.41	-9.35	-0.35	1.45e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg01939980	chr4:1354348	KIAA1530	0.33	8.99	0.33	2.88e-18	Longevity;
BRCA	cis	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg16685388	chr1:42384056	HIVEP3	-0.29	-8.24	-0.31	9.76e-16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
BRCA	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg08975724	chr8:8085496	FLJ10661	0.41	7.99	0.3	6.26e-15	Retinal vascular caliber;
BRCA	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg23649088	chr2:200775458	C2orf69	0.61	9.06	0.34	1.54e-18	Schizophrenia;
BRCA	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg04362960	chr10:104952993	NT5C2	0.42	10.08	0.37	2.95e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg12483005	chr1:23474871	LUZP1	0.47	10.43	0.38	1.23e-23	Height;
BRCA	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg13628971	chr7:2884303	GNA12	0.48	9.63	0.36	1.44e-20	Height;
BRCA	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg01483505	chr11:975446	AP2A2	0.34	9.11	0.34	1.02e-18	Alzheimer's disease (late onset);
BRCA	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.76	0.36	4.65e-21	Bladder cancer;
BRCA	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg00321850	chr1:175162397	KIAA0040	0.41	11.37	0.41	2.11e-27	Alcohol dependence;
BRCA	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg21132104	chr15:45694354	SPATA5L1	0.74	16.31	0.54	2.79e-50	Homoarginine levels;
BRCA	cis	rs68170813	0.559	rs7783181	chr7:106977613	A/G	cg02696742	chr7:106810147	HBP1	-0.49	-8.56	-0.32	8.5e-17	Coronary artery disease;
BRCA	trans	rs7181230	0.813	rs4924417	chr15:40366939	G/C	cg22705835	chr10:65332833	REEP3	-0.43	-9.55	-0.35	2.61e-20	Dehydroepiandrosterone sulphate levels;
BRCA	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg09359103	chr1:154839909	KCNN3	-0.58	-15.09	-0.51	3.04e-44	Prostate cancer;
BRCA	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-20.03	-0.62	1.28e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg08755490	chr11:65554678	OVOL1	0.48	9.91	0.37	1.21e-21	Acne (severe);
BRCA	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg09455208	chr3:40491958	NA	-0.48	-11.97	-0.43	6.18e-30	Renal cell carcinoma;
BRCA	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg06238570	chr21:40685208	BRWD1	-0.4	-8.09	-0.3	3.04e-15	Menarche (age at onset);
BRCA	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg26384229	chr12:38710491	ALG10B	-0.55	-13.58	-0.47	4.27e-37	Morning vs. evening chronotype;
BRCA	cis	rs11984145	1.000	rs73121386	chr7:38865235	C/T	cg19327137	chr7:38886074	VPS41	0.5	7.91	0.3	1.15e-14	Cognitive performance;
BRCA	cis	rs7246657	0.551	rs12972146	chr19:37626095	G/T	cg23950597	chr19:37808831	NA	-0.65	-9.75	-0.36	5.12e-21	Coronary artery calcification;
BRCA	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.44	0.35	6.85e-20	Tonsillectomy;
BRCA	cis	rs9811920	0.809	rs793476	chr3:99541747	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.52	-12.56	-0.44	1.72e-32	Axial length;
BRCA	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-8.4	-0.32	2.98e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg24006582	chr15:45444508	DUOX1	-0.55	-11.31	-0.41	3.61e-27	Uric acid levels;
BRCA	cis	rs8030485	0.536	rs4778918	chr15:79434040	T/C	cg17916960	chr15:79447300	NA	0.38	9.24	0.34	3.68e-19	Left ventricle wall thickness;
BRCA	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.06	-0.3	3.69e-15	Bipolar disorder;
BRCA	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.94	-0.62	3.92e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg10556349	chr10:835070	NA	0.61	8.48	0.32	1.59e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg06521331	chr12:34319734	NA	-0.55	-9.93	-0.37	1.04e-21	Morning vs. evening chronotype;
BRCA	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg19729930	chr2:74357872	NA	0.65	14.23	0.49	4e-40	Gestational age at birth (maternal effect);
BRCA	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg24812749	chr6:127587940	RNF146	0.88	20.56	0.63	1.81e-72	Breast cancer;
BRCA	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg13047869	chr3:10149882	C3orf24	0.53	10.94	0.4	1.14e-25	Alzheimer's disease;
BRCA	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg02773041	chr1:40204384	PPIE	0.45	9.65	0.36	1.15e-20	Blood protein levels;
BRCA	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01516881	chr6:292596	DUSP22	0.62	12.19	0.43	7.31e-31	Menopause (age at onset);
BRCA	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-8.99	-0.34	2.73e-18	Alzheimer's disease (late onset);
BRCA	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg03354898	chr7:1950403	MAD1L1	-0.42	-9.08	-0.34	1.39e-18	Schizophrenia;
BRCA	cis	rs12612619	0.658	rs77920959	chr2:27151590	T/C	cg00617064	chr2:27272375	NA	-0.3	-7.95	-0.3	8.67e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs1832871	1.000	rs827864	chr6:158711023	A/G	cg07215822	chr6:158701037	NA	-0.43	-7.83	-0.3	1.97e-14	Height;
BRCA	cis	rs73416724	1.000	rs73416724	chr6:43337802	A/G	cg26312998	chr6:43337775	ZNF318	0.51	8.34	0.31	4.41e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg15556689	chr8:8085844	FLJ10661	-0.31	-8.15	-0.31	1.87e-15	Myopia;Myopia (pathological);
BRCA	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.64	0.42	1.54e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.36	-8.01	-0.3	5.56e-15	Electroencephalogram traits;
BRCA	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.35	9.11	0.34	1.08e-18	Resting heart rate;
BRCA	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	13.17	0.46	3.21e-35	Mean platelet volume;
BRCA	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg18252515	chr7:66147081	NA	-0.98	-11.53	-0.42	4.32e-28	Diabetic kidney disease;
BRCA	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg03060546	chr3:49711283	APEH	-0.57	-11.73	-0.42	6.53e-29	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7301826	1.000	rs1106369	chr12:131300095	G/T	cg11011512	chr12:131303247	STX2	0.41	10.55	0.39	4.12e-24	Plasma plasminogen activator levels;
BRCA	cis	rs6815814	0.950	rs114719937	chr4:38808585	G/C	cg06935464	chr4:38784597	TLR10	0.5	8.27	0.31	7.76e-16	Breast cancer;
BRCA	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg00857998	chr1:205179979	DSTYK	0.4	7.91	0.3	1.13e-14	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.17	0.31	1.65e-15	Tonsillectomy;
BRCA	cis	rs7520050	0.966	rs12564541	chr1:46380237	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.98	0.37	7e-22	Red blood cell count;Reticulocyte count;
BRCA	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg01483505	chr11:975446	AP2A2	0.33	9.07	0.34	1.44e-18	Alzheimer's disease (late onset);
BRCA	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg10295955	chr4:187884368	NA	-0.96	-28.43	-0.75	1.47e-115	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg03474202	chr17:45855739	NA	-0.47	-12.57	-0.45	1.56e-32	IgG glycosylation;
BRCA	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg11814155	chr7:99998594	ZCWPW1	0.45	8.35	0.31	4.16e-16	Platelet count;
BRCA	cis	rs7539409	0.915	rs1977119	chr1:84275509	A/G	cg10977910	chr1:84465055	TTLL7	0.69	9.77	0.36	4.04e-21	Alzheimer's disease;
BRCA	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-14.62	-0.5	5.47e-42	Total cholesterol levels;
BRCA	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.95	0.4	1.07e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg06627628	chr2:24431161	ITSN2	0.43	8.79	0.33	1.42e-17	Asthma;
BRCA	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg05343316	chr1:45956843	TESK2	0.65	13.27	0.46	1.15e-35	Platelet count;
BRCA	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.87	-0.36	1.72e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2505998	0.957	rs2435366	chr10:43571988	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.44	-8.57	-0.32	7.49e-17	Hirschsprung disease;
BRCA	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg18351406	chr4:77819688	ANKRD56	0.62	14.02	0.48	4.08e-39	Emphysema distribution in smoking;
BRCA	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg21724239	chr8:58056113	NA	0.58	9.4	0.35	9.72e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs6973256	0.897	rs10808271	chr7:133352318	C/T	cg07491979	chr7:133331646	EXOC4	0.4	9.28	0.34	2.59e-19	Intelligence (multi-trait analysis);
BRCA	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg15704280	chr7:45808275	SEPT13	0.51	8.64	0.32	4.64e-17	Axial length;
BRCA	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg26384229	chr12:38710491	ALG10B	0.47	12.21	0.43	5.95e-31	Morning vs. evening chronotype;
BRCA	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg14196790	chr5:131705035	SLC22A5	-0.5	-13.59	-0.47	3.95e-37	Blood metabolite levels;
BRCA	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg08885076	chr2:99613938	TSGA10	0.45	10.6	0.39	2.69e-24	Chronic sinus infection;
BRCA	trans	rs6479891	1.000	rs11817689	chr10:64924217	C/T	cg14819942	chr15:35414228	NA	-0.33	-8.24	-0.31	9.68e-16	Arthritis (juvenile idiopathic);
BRCA	trans	rs4650994	0.525	rs4316329	chr1:178509333	C/T	cg05059571	chr16:84539110	KIAA1609	-0.5	-11.12	-0.4	2.29e-26	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg21285383	chr16:89894308	SPIRE2	-0.26	-8.9	-0.33	5.56e-18	Vitiligo;
BRCA	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg25019033	chr10:957182	NA	-0.41	-7.89	-0.3	1.3e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg22974920	chr21:40686053	BRWD1	-0.35	-7.93	-0.3	1.01e-14	Menarche (age at onset);
BRCA	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg26874164	chr19:58962979	ZNF324B	0.52	11.31	0.41	3.52e-27	Uric acid clearance;
BRCA	cis	rs7520050	0.966	rs4076006	chr1:46438076	C/T	cg24296786	chr1:45957014	TESK2	0.44	9.76	0.36	4.56e-21	Red blood cell count;Reticulocyte count;
BRCA	trans	rs9944715	0.954	rs9960378	chr18:43811262	G/A	cg01718231	chr17:29326311	RNF135	-0.46	-9.07	-0.34	1.51e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.54	11.12	0.4	2.29e-26	Monocyte percentage of white cells;
BRCA	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.16	0.31	1.77e-15	Axial length;
BRCA	cis	rs9308433	0.529	rs17022608	chr1:214500907	A/C	cg06198575	chr1:214491504	SMYD2	0.54	11.87	0.43	1.65e-29	IgG glycosylation;
BRCA	cis	rs9309473	1.000	rs7607014	chr2:73730174	C/T	cg20560298	chr2:73613845	ALMS1	0.45	11.27	0.41	5.54e-27	Metabolite levels;
BRCA	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg27432699	chr2:27873401	GPN1	0.46	9.71	0.36	6.83e-21	Oral cavity cancer;
BRCA	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	11.96	0.43	7.09e-30	Mood instability;
BRCA	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg10546459	chr2:36825355	FEZ2	0.46	8.79	0.33	1.38e-17	Height;
BRCA	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg18154014	chr19:37997991	ZNF793	0.61	11.38	0.41	1.85e-27	Coronary artery calcification;
BRCA	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg06598544	chr20:61472147	COL9A3	0.74	10.8	0.39	4.44e-25	Obesity-related traits;
BRCA	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.53	13.44	0.47	2e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg16339924	chr4:17578868	LAP3	0.66	16.9	0.56	3.1e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6546886	0.912	rs6745236	chr2:74283728	C/T	cg14702570	chr2:74259524	NA	-0.32	-7.95	-0.3	8.42e-15	Dialysis-related mortality;
BRCA	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg14926445	chr8:58193284	C8orf71	-0.47	-8.92	-0.33	4.83e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs2018683	0.700	rs13227954	chr7:29017188	A/C	cg19402173	chr7:128379420	CALU	0.44	10.19	0.37	1.05e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	trans	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg21659725	chr3:3221576	CRBN	-0.47	-8.44	-0.32	2.17e-16	Menarche (age at onset);
BRCA	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg18225595	chr11:63971243	STIP1	0.54	9.71	0.36	7.05e-21	Mean platelet volume;
BRCA	trans	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg25214090	chr10:38739885	LOC399744	0.53	11.98	0.43	5.63e-30	Corneal astigmatism;
BRCA	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg16339924	chr4:17578868	LAP3	-0.55	-13.01	-0.46	1.76e-34	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6484504	0.576	rs158146	chr11:31210433	G/A	cg06552810	chr11:31128660	NA	-0.37	-8.47	-0.32	1.65e-16	Red blood cell count;
BRCA	cis	rs9986765	0.737	rs10274253	chr7:142810265	G/C	cg15652212	chr7:142981776	TMEM139	0.67	10.29	0.38	4.31e-23	Cancer;Dermatomyositis;
BRCA	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg00631329	chr6:26305371	NA	-0.41	-12.17	-0.43	8.69e-31	Educational attainment;
BRCA	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg18301423	chr5:131593218	PDLIM4	0.33	8.02	0.3	5.23e-15	Acylcarnitine levels;
BRCA	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg18402987	chr7:1209562	NA	0.87	12.28	0.44	2.89e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs977987	0.771	rs4888387	chr16:75389755	T/G	cg03315344	chr16:75512273	CHST6	0.5	11.7	0.42	8.9e-29	Dupuytren's disease;
BRCA	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.42	10.25	0.38	6.28e-23	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg21143896	chr7:2802374	GNA12	-0.34	-8.49	-0.32	1.42e-16	Height;
BRCA	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg17691542	chr6:26056736	HIST1H1C	0.5	9.69	0.36	7.96e-21	Iron status biomarkers;
BRCA	trans	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg06521331	chr12:34319734	NA	-0.47	-8.56	-0.32	8.19e-17	Bladder cancer;
BRCA	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg08847533	chr14:75593920	NEK9	-0.46	-9.37	-0.35	1.26e-19	Neuroticism;
BRCA	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg23711669	chr6:146136114	FBXO30	0.8	19.0	0.6	3.7e-64	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs9650657	0.737	rs4841436	chr8:10594474	A/C	cg06636001	chr8:8085503	FLJ10661	0.39	7.98	0.3	6.91e-15	Neuroticism;
BRCA	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12379764	chr21:47803548	PCNT	0.49	9.66	0.36	1.1e-20	Testicular germ cell tumor;
BRCA	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg20573242	chr4:122745356	CCNA2	0.48	10.84	0.39	2.88e-25	Type 2 diabetes;
BRCA	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.45	0.32	1.89e-16	Platelet count;
BRCA	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-10.12	-0.37	1.93e-22	Calcium levels;
BRCA	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg20476274	chr7:133979776	SLC35B4	-0.59	-15.93	-0.53	2.44e-48	Mean platelet volume;
BRCA	cis	rs71636778	0.543	rs71636796	chr1:27243095	T/C	cg12203394	chr1:27248618	NUDC	0.6	9.46	0.35	5.7e-20	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7246657	0.722	rs2287229	chr19:38188652	G/A	cg23950597	chr19:37808831	NA	0.51	8.69	0.33	2.96e-17	Coronary artery calcification;
BRCA	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.38	-0.31	3.28e-16	Colorectal cancer;
BRCA	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.36	-8.26	-0.31	8.65e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6121246	0.559	rs6060950	chr20:30378031	T/C	cg13852791	chr20:30311386	BCL2L1	0.96	23.26	0.68	3.39e-87	Mean corpuscular hemoglobin;
BRCA	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg26384229	chr12:38710491	ALG10B	0.76	17.01	0.56	8.73e-54	Morning vs. evening chronotype;
BRCA	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.61	0.32	5.75e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg13565492	chr6:43139072	SRF	-0.87	-13.16	-0.46	3.44e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	18.83	0.6	3.08e-63	Tonsillectomy;
BRCA	cis	rs897984	0.542	rs11864806	chr16:31095204	G/C	cg00531865	chr16:30841666	NA	-0.38	-9.02	-0.34	2.25e-18	Dementia with Lewy bodies;
BRCA	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.31	-0.47	7.11e-36	Extrinsic epigenetic age acceleration;
BRCA	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg01802117	chr1:53393560	SCP2	-0.42	-9.61	-0.36	1.67e-20	Monocyte count;
BRCA	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg05863683	chr7:1912471	MAD1L1	0.38	8.43	0.32	2.34e-16	Schizophrenia;
BRCA	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-9.29	-0.34	2.4e-19	Menopause (age at onset);
BRCA	cis	rs8114671	0.901	rs6119581	chr20:33773689	T/A	cg07148914	chr20:33460835	GGT7	0.37	7.92	0.3	1.08e-14	Height;
BRCA	cis	rs870825	0.616	rs6552801	chr4:185620623	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4853036	1.000	rs11902295	chr2:70084599	C/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-9.02	-0.34	2.26e-18	Colorectal or endometrial cancer;
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg23978390	chr7:1156363	C7orf50	0.49	11.31	0.41	3.7e-27	Longevity;Endometriosis;
BRCA	trans	rs61931739	0.963	rs12307606	chr12:34016365	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.44	-0.35	6.98e-20	Morning vs. evening chronotype;
BRCA	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg13271783	chr10:134563150	INPP5A	-0.51	-9.62	-0.36	1.55e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-12.5	-0.44	2.98e-32	Bipolar disorder;
BRCA	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg07679836	chr6:33548423	BAK1	0.64	13.96	0.48	7.64e-39	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
BRCA	cis	rs2425143	0.908	rs74784474	chr20:34422464	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.97	-0.33	3.14e-18	Blood protein levels;
BRCA	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	8.94	0.33	4.16e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.7	-14.38	-0.49	7.87e-41	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg19318889	chr4:1322082	MAEA	0.56	11.52	0.41	4.74e-28	Longevity;
BRCA	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg16586182	chr3:47516702	SCAP	-0.56	-12.63	-0.45	8.74e-33	Colorectal cancer;
BRCA	cis	rs7091068	0.721	rs618951	chr10:95404967	A/G	cg20715218	chr10:95462985	C10orf4	-0.46	-8.31	-0.31	5.67e-16	Urinary tract infection frequency;
BRCA	trans	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.35	-8.09	-0.3	2.99e-15	Corneal astigmatism;
BRCA	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg09060608	chr5:178986726	RUFY1	0.41	8.88	0.33	6.74e-18	Lung cancer;
BRCA	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg08000102	chr2:233561755	GIGYF2	0.62	13.57	0.47	4.76e-37	Coronary artery disease;
BRCA	cis	rs2580764	0.565	rs6545466	chr2:55228392	C/T	cg09592903	chr2:55203963	RTN4	-0.41	-10.39	-0.38	1.86e-23	Mean platelet volume;
BRCA	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg18811423	chr2:55921094	PNPT1	0.71	22.68	0.67	5.59e-84	Metabolic syndrome;
BRCA	trans	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg23505145	chr19:12996616	KLF1	0.41	7.93	0.3	9.72e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.3	0.38	3.99e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.97	0.33	3.39e-18	Ovarian reserve;
BRCA	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg18357645	chr12:58087776	OS9	-0.41	-11.29	-0.41	4.25e-27	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.27e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2066819	1.000	rs79750959	chr12:56702012	C/A	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg23711669	chr6:146136114	FBXO30	0.74	17.76	0.57	1.14e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1568889	1.000	rs61236373	chr11:28212720	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.74	0.5	1.61e-42	Bipolar disorder;
BRCA	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg06552810	chr11:31128660	NA	-0.39	-8.71	-0.33	2.51e-17	Red blood cell count;
BRCA	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.1e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg23625390	chr15:77176239	SCAPER	-0.55	-12.99	-0.46	2.15e-34	Blood metabolite levels;
BRCA	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18876405	chr7:65276391	NA	0.62	15.37	0.52	1.28e-45	Aortic root size;
BRCA	trans	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg07211511	chr3:129823064	LOC729375	-0.61	-10.74	-0.39	7.24e-25	Blood pressure (smoking interaction);
BRCA	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg00339695	chr16:24857497	SLC5A11	0.34	7.99	0.3	6.38e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-8.9	-0.33	5.77e-18	Personality dimensions;
BRCA	cis	rs4900538	0.892	rs4906208	chr14:102956489	G/C	cg18135206	chr14:102964638	TECPR2	1.05	29.71	0.76	1.64e-122	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs6809651	0.524	rs10937240	chr3:185802823	C/T	cg00760338	chr3:185826511	ETV5	-0.49	-9.74	-0.36	5.17e-21	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
BRCA	cis	rs3784262	0.631	rs12903724	chr15:58310387	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.19	-0.37	1.11e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11764359	chr7:65958608	NA	-0.73	-16.04	-0.54	6.46e-49	Aortic root size;
BRCA	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg02175503	chr12:58329896	NA	0.43	8.14	0.31	2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6545883	0.931	rs12713438	chr2:61725501	G/A	cg15711740	chr2:61764176	XPO1	-0.52	-13.14	-0.46	4.42e-35	Tuberculosis;
BRCA	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg03477792	chr4:77819574	ANKRD56	0.66	16.04	0.54	6.26e-49	Emphysema distribution in smoking;
BRCA	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg21951975	chr1:209979733	IRF6	0.41	9.39	0.35	1.03e-19	Cleft lip with or without cleft palate;
BRCA	cis	rs2014572	0.967	rs8112572	chr19:57759612	T/C	cg24459738	chr19:57751996	ZNF805	-0.36	-8.54	-0.32	9.71e-17	Hyperactive-impulsive symptoms;
BRCA	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg15557168	chr22:42548783	NA	-0.32	-8.81	-0.33	1.16e-17	Cognitive function;
BRCA	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg20503657	chr10:835505	NA	1.03	18.17	0.58	9.16e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.09	-0.37	2.66e-22	IgG glycosylation;
BRCA	cis	rs738322	0.532	rs9622746	chr22:38564041	C/G	cg25457927	chr22:38595422	NA	-0.33	-11.15	-0.4	1.72e-26	Cutaneous nevi;
BRCA	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg05340658	chr4:99064831	C4orf37	0.62	14.71	0.5	2.04e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6484504	0.576	rs208072	chr11:31141288	A/G	cg14844989	chr11:31128820	NA	0.42	8.87	0.33	7.3e-18	Red blood cell count;
BRCA	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg25817165	chr18:72167213	CNDP2	-0.77	-19.53	-0.61	5.84e-67	Refractive error;
BRCA	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.28	8.78	0.33	1.44e-17	Bipolar disorder;
BRCA	cis	rs36051895	0.575	rs7035251	chr9:5133665	T/A	cg02405213	chr9:5042618	JAK2	-0.46	-9.06	-0.34	1.58e-18	Pediatric autoimmune diseases;
BRCA	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg13334819	chr7:99746414	C7orf59	-0.34	-8.11	-0.31	2.68e-15	Coronary artery disease;
BRCA	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg08885076	chr2:99613938	TSGA10	0.45	10.53	0.38	5.18e-24	Chronic sinus infection;
BRCA	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg18230493	chr5:56204884	C5orf35	-0.73	-14.2	-0.49	5.69e-40	Initial pursuit acceleration;
BRCA	cis	rs3857536	0.706	rs7749120	chr6:66889832	T/G	cg07460842	chr6:66804631	NA	-0.47	-9.09	-0.34	1.25e-18	Blood trace element (Cu levels);
BRCA	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-9.73	-0.36	5.71e-21	IgG glycosylation;
BRCA	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg15448220	chr1:150897856	SETDB1	0.36	8.12	0.31	2.45e-15	Melanoma;
BRCA	cis	rs953387	1.000	rs2102896	chr2:136906640	T/C	cg05194412	chr2:137003533	NA	-0.37	-8.54	-0.32	1.01e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.93	0.46	3.84e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg24692254	chr21:30365293	RNF160	-0.46	-10.21	-0.37	9.05e-23	Dental caries;
BRCA	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08564027	chr20:61660810	NA	0.85	22.66	0.67	6.95e-84	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg08807101	chr21:30365312	RNF160	0.44	9.54	0.35	2.94e-20	Pancreatic cancer;
BRCA	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg09307838	chr4:120376055	NA	-0.54	-11.25	-0.41	6.69e-27	Corneal astigmatism;
BRCA	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg25214090	chr10:38739885	LOC399744	0.53	11.76	0.42	4.93e-29	Corneal astigmatism;
BRCA	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg24006582	chr15:45444508	DUOX1	-0.55	-11.32	-0.41	3.19e-27	Uric acid levels;
BRCA	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg24531977	chr5:56204891	C5orf35	-0.43	-8.58	-0.32	7.45e-17	Coronary artery disease;
BRCA	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg04450456	chr4:17643702	FAM184B	0.32	9.42	0.35	7.9e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg23505145	chr19:12996616	KLF1	0.54	12.07	0.43	2.28e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	11.47	0.41	8.15e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-10.14	-0.37	1.63e-22	Heart rate;
BRCA	trans	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg15556689	chr8:8085844	FLJ10661	-0.37	-9.89	-0.36	1.48e-21	Triglycerides;
BRCA	cis	rs332507	0.869	rs3772784	chr3:124394657	A/G	cg05980111	chr3:124395277	KALRN	0.33	7.85	0.3	1.77e-14	Plateletcrit;
BRCA	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg05863683	chr7:1912471	MAD1L1	0.37	8.22	0.31	1.14e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg03146154	chr1:46216737	IPP	0.45	10.06	0.37	3.5e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg18446336	chr7:2847575	GNA12	-0.34	-8.01	-0.3	5.46e-15	Height;
BRCA	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.62	-0.32	5.3e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg11645453	chr3:52864694	ITIH4	0.49	11.98	0.43	5.43e-30	Schizophrenia;
BRCA	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg11833968	chr6:79620685	NA	-0.43	-9.55	-0.35	2.69e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg06627628	chr2:24431161	ITSN2	-0.64	-11.89	-0.43	1.43e-29	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg17971929	chr21:40555470	PSMG1	0.78	18.39	0.59	6.48e-61	Cognitive function;
BRCA	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.68	0.55	4.17e-52	Alzheimer's disease (late onset);
BRCA	trans	rs7746199	0.736	rs13212093	chr6:27606716	C/T	cg01620082	chr3:125678407	NA	-0.91	-10.26	-0.38	5.76e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg26384229	chr12:38710491	ALG10B	0.76	16.93	0.56	2.12e-53	Morning vs. evening chronotype;
BRCA	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg17724175	chr1:150552817	MCL1	-0.25	-8.55	-0.32	9.13e-17	Tonsillectomy;
BRCA	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.85	-0.36	2.02e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg18357645	chr12:58087776	OS9	0.42	11.98	0.43	5.87e-30	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg14196790	chr5:131705035	SLC22A5	-0.41	-10.01	-0.37	5.1e-22	Breast cancer;Mosquito bite size;
BRCA	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg10523679	chr1:76189770	ACADM	-0.62	-11.45	-0.41	1.01e-27	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg26384229	chr12:38710491	ALG10B	0.43	10.27	0.38	5.36e-23	Heart rate;
BRCA	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg27121462	chr16:89883253	FANCA	0.69	16.33	0.54	2.32e-50	Vitiligo;
BRCA	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18876405	chr7:65276391	NA	-0.49	-10.8	-0.39	4.34e-25	Aortic root size;
BRCA	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg13319975	chr6:146136371	FBXO30	0.39	8.96	0.33	3.65e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26314531	chr2:26401878	FAM59B	-0.95	-16.42	-0.54	8.01e-51	Gut microbiome composition (summer);
BRCA	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg22713356	chr15:30763199	NA	1.18	23.59	0.68	5.88e-89	Uric acid levels;
BRCA	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg05294307	chr14:35346193	BAZ1A	-0.58	-10.31	-0.38	3.83e-23	Psoriasis;
BRCA	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg08888203	chr3:10149979	C3orf24	0.68	14.36	0.49	9.39e-41	Alzheimer's disease;
BRCA	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg12379764	chr21:47803548	PCNT	-0.37	-7.86	-0.3	1.61e-14	Testicular germ cell tumor;
BRCA	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg15556689	chr8:8085844	FLJ10661	0.37	9.5	0.35	4.25e-20	Morning vs. evening chronotype;
BRCA	cis	rs11585357	0.947	rs2977304	chr1:17611615	T/C	cg19159961	chr1:17633534	PADI4	-0.5	-8.91	-0.33	5.23e-18	Hair shape;
BRCA	cis	rs3772130	0.540	rs7627354	chr3:121562434	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	14.39	0.49	7.2e-41	Cognitive performance;
BRCA	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg04362960	chr10:104952993	NT5C2	0.44	9.82	0.36	2.72e-21	Arsenic metabolism;
BRCA	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg11789530	chr4:8429930	ACOX3	-0.59	-14.89	-0.51	2.89e-43	Response to antineoplastic agents;
BRCA	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg03354898	chr7:1950403	MAD1L1	-0.44	-9.15	-0.34	7.75e-19	Schizophrenia;
BRCA	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg10224037	chr5:178157518	ZNF354A	0.6	11.17	0.4	1.32e-26	Neutrophil percentage of white cells;
BRCA	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg26384229	chr12:38710491	ALG10B	0.67	14.03	0.49	3.66e-39	Morning vs. evening chronotype;
BRCA	trans	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.88	0.3	1.44e-14	Endometrial cancer;
BRCA	cis	rs11677370	0.603	rs10198219	chr2:3854600	T/C	cg17052675	chr2:3827356	NA	-0.47	-11.57	-0.42	3.17e-28	Type 2 diabetes;
BRCA	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg02951883	chr7:2050386	MAD1L1	-0.4	-9.2	-0.34	5.06e-19	Schizophrenia;
BRCA	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg11608241	chr8:8085544	FLJ10661	-0.27	-7.86	-0.3	1.66e-14	Joint mobility (Beighton score);
BRCA	cis	rs12541635	1.000	rs1366965	chr8:107085224	T/A	cg10147462	chr8:107024639	NA	-0.3	-8.25	-0.31	9.29e-16	Age of smoking initiation;
BRCA	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg03188948	chr7:1209495	NA	0.83	11.33	0.41	2.93e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2882667	0.898	rs3925110	chr5:138371365	C/G	cg04439458	chr5:138467593	SIL1	-0.32	-8.66	-0.32	3.99e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs13315871	1.000	rs36097398	chr3:58367330	G/A	cg20936604	chr3:58311152	NA	-0.62	-7.94	-0.3	9.28e-15	Cholesterol, total;
BRCA	cis	rs4285028	0.948	rs12497349	chr3:121708517	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.94	-0.4	1.16e-25	Multiple sclerosis;
BRCA	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18404041	chr3:52824283	ITIH1	0.43	12.79	0.45	1.6e-33	Bipolar disorder;
BRCA	cis	rs6942756	0.955	rs68187585	chr7:129002211	T/C	cg02491457	chr7:128862824	NA	-0.72	-14.03	-0.49	3.56e-39	White matter hyperintensity burden;
BRCA	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg13334819	chr7:99746414	C7orf59	0.38	8.8	0.33	1.27e-17	Coronary artery disease;
BRCA	cis	rs7474896	0.537	rs1208683	chr10:38093723	A/G	cg25427524	chr10:38739819	LOC399744	0.49	8.67	0.32	3.54e-17	Obesity (extreme);
BRCA	cis	rs7737355	0.773	rs10040578	chr5:130950232	C/T	cg06307176	chr5:131281290	NA	-0.48	-10.01	-0.37	5.01e-22	Life satisfaction;
BRCA	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg19010396	chr19:19431384	KIAA0892;SF4	-0.45	-9.05	-0.34	1.69e-18	Tonsillectomy;
BRCA	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg10495392	chr1:46806563	NSUN4	0.44	8.04	0.3	4.43e-15	Menopause (age at onset);
BRCA	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg18825119	chr6:163149453	PACRG;PARK2	-0.47	-8.28	-0.31	7.45e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	17.23	0.56	6.21e-55	Electrocardiographic conduction measures;
BRCA	cis	rs829883	0.664	rs865509	chr12:98854444	T/A	cg25150519	chr12:98850993	NA	0.68	16.4	0.54	1.01e-50	Colorectal adenoma (advanced);
BRCA	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg24562669	chr7:97807699	LMTK2	0.47	12.52	0.44	2.56e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.51	-10.62	-0.39	2.35e-24	Height;
BRCA	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg05347473	chr6:146136440	FBXO30	0.41	7.98	0.3	7.02e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs738322	0.718	rs3761445	chr22:38595411	G/A	cg25457927	chr22:38595422	NA	0.51	21.86	0.65	1.55e-79	Cutaneous nevi;
BRCA	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	17.32	0.57	2.29e-55	Electrocardiographic conduction measures;
BRCA	cis	rs59698941	0.527	rs1910075	chr5:132180089	A/T	cg14825688	chr5:132208181	LEAP2	-0.37	-8.51	-0.32	1.19e-16	Apolipoprotein A-IV levels;
BRCA	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg13319975	chr6:146136371	FBXO30	0.38	8.64	0.32	4.34e-17	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg15704280	chr7:45808275	SEPT13	-0.48	-9.08	-0.34	1.35e-18	Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg25214090	chr10:38739885	LOC399744	0.55	12.09	0.43	1.97e-30	Corneal astigmatism;
BRCA	cis	rs1468333	1.000	rs2864	chr5:137523430	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.44	8.64	0.32	4.6e-17	Resting heart rate;
BRCA	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.39	-9.28	-0.34	2.53e-19	Tonsillectomy;
BRCA	trans	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg26384229	chr12:38710491	ALG10B	0.53	11.39	0.41	1.68e-27	Morning vs. evening chronotype;
BRCA	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26314531	chr2:26401878	FAM59B	-0.63	-10.83	-0.39	3.28e-25	Gut microbiome composition (summer);
BRCA	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18876405	chr7:65276391	NA	0.71	18.63	0.59	3.45e-62	Calcium levels;
BRCA	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg04362960	chr10:104952993	NT5C2	0.45	10.27	0.38	5.19e-23	Arsenic metabolism;
BRCA	cis	rs2637030	0.559	rs376566	chr5:53005420	G/A	cg06476337	chr5:52856530	NDUFS4	0.35	7.99	0.3	6.1e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	trans	rs2797160	1.000	rs2747714	chr6:126007620	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.01	0.3	5.45e-15	Endometrial cancer;
BRCA	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-10.18	-0.37	1.14e-22	Neuroticism;
BRCA	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.48e-23	Motion sickness;
BRCA	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14240646	chr10:27532245	ACBD5	0.64	9.49	0.35	4.66e-20	Breast cancer;
BRCA	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg25237894	chr2:233734115	C2orf82	0.39	11.24	0.41	7.05e-27	Coronary artery disease;
BRCA	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-11.18	-0.4	1.27e-26	Gut microbiome composition (summer);
BRCA	trans	rs61931739	1.000	rs12427391	chr12:34022891	A/G	cg26384229	chr12:38710491	ALG10B	-0.41	-9.32	-0.35	1.81e-19	Morning vs. evening chronotype;
BRCA	cis	rs314370	1.000	rs10278546	chr7:100516003	G/T	cg10426581	chr7:100472382	SRRT	-0.52	-8.97	-0.33	3.39e-18	Resting heart rate;
BRCA	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg17143192	chr8:8559678	CLDN23	0.52	10.05	0.37	3.82e-22	Obesity-related traits;
BRCA	cis	rs1371614	0.610	rs12615509	chr2:27098766	G/A	cg12368169	chr2:27073192	DPYSL5	-0.3	-8.98	-0.33	3.1e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-9.56	-0.35	2.58e-20	Schizophrenia;
BRCA	trans	rs1973993	0.603	rs3912027	chr1:96993603	G/T	cg10631902	chr5:14652156	NA	-0.4	-10.04	-0.37	4.16e-22	Weight;
BRCA	cis	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg21775007	chr8:11205619	TDH	-0.45	-9.13	-0.34	8.93e-19	Triglycerides;
BRCA	cis	rs6901004	0.935	rs9487602	chr6:111560946	C/T	cg15721981	chr6:111408429	SLC16A10	0.36	8.2	0.31	1.31e-15	Blood metabolite levels;
BRCA	cis	rs11229555	0.645	rs7116847	chr11:58178478	C/A	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg06521331	chr12:34319734	NA	-0.48	-8.66	-0.32	3.93e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs35123781	0.696	rs356433	chr5:139071193	C/T	cg10513866	chr5:139070639	NA	0.43	9.5	0.35	4.18e-20	Schizophrenia;
BRCA	trans	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.39	0.49	7.25e-41	Exhaled nitric oxide output;
BRCA	cis	rs4908768	0.501	rs1473420	chr1:8616838	T/G	cg20416874	chr1:8611966	RERE	-0.29	-8.42	-0.32	2.57e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.74	16.08	0.54	4.26e-49	Cognitive ability;
BRCA	trans	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg26043149	chr18:55253948	FECH	-0.37	-8.21	-0.31	1.2e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15506890	chr2:3487001	NA	-0.58	-13.17	-0.46	3.14e-35	Neurofibrillary tangles;
BRCA	cis	rs9503598	0.778	rs1328688	chr6:3468508	G/A	cg00476032	chr6:3446245	SLC22A23	0.43	10.57	0.39	3.43e-24	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg27129171	chr3:47204927	SETD2	-0.68	-15.83	-0.53	7.58e-48	Colorectal cancer;
BRCA	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg11502198	chr6:26597334	ABT1	0.48	9.59	0.35	2.02e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18876405	chr7:65276391	NA	0.7	18.62	0.59	3.8e-62	Calcium levels;
BRCA	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-8.21	-0.31	1.18e-15	Neuroticism;
BRCA	cis	rs6942756	0.713	rs692597	chr7:129132554	T/G	cg02491457	chr7:128862824	NA	-0.54	-11.28	-0.41	4.87e-27	White matter hyperintensity burden;
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg23131131	chr22:24373011	LOC391322	0.39	8.84	0.33	9.61e-18	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg11608241	chr8:8085544	FLJ10661	0.33	9.78	0.36	3.94e-21	Mood instability;
BRCA	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.39	-8.46	-0.32	1.82e-16	Cognitive ability;
BRCA	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.55	-0.32	9.15e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg20469991	chr17:27169893	C17orf63	0.44	8.78	0.33	1.44e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg06611532	chr13:114900021	NA	0.38	10.15	0.37	1.57e-22	Schizophrenia;
BRCA	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg08738300	chr3:44038990	NA	-0.43	-8.63	-0.32	4.76e-17	Coronary artery disease;
BRCA	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg04455712	chr21:45112962	RRP1B	0.4	9.53	0.35	3.18e-20	Mean corpuscular volume;
BRCA	cis	rs6815814	0.861	rs10004195	chr4:38784724	T/A	cg06935464	chr4:38784597	TLR10	0.46	8.91	0.33	5.15e-18	Breast cancer;
BRCA	trans	rs7980799	0.935	rs10732554	chr12:33533374	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-8.27	-0.31	7.56e-16	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg10857441	chr5:6722123	POLS	-0.3	-9.41	-0.35	9.02e-20	Menopause (age at onset);
BRCA	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg04455712	chr21:45112962	RRP1B	-0.44	-12.0	-0.43	4.64e-30	Mean corpuscular volume;
BRCA	cis	rs17401966	0.931	rs12753426	chr1:10372110	T/C	cg03954927	chr1:10346856	KIF1B	0.43	13.51	0.47	9.16e-37	Hepatocellular carcinoma;
BRCA	cis	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.69	-0.33	3.09e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11890956	chr21:40555474	PSMG1	-0.65	-14.71	-0.5	2.1e-42	Menarche (age at onset);
BRCA	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg16482183	chr6:26056742	HIST1H1C	0.49	10.39	0.38	1.79e-23	Height;
BRCA	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg08807101	chr21:30365312	RNF160	0.55	13.15	0.46	3.96e-35	Dental caries;
BRCA	cis	rs11229555	0.874	rs17567523	chr11:58354081	G/A	cg15696309	chr11:58395628	NA	-0.53	-11.49	-0.41	6.88e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs12517041	1.000	rs2099091	chr5:23295532	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.92	-0.3	1.04e-14	Calcium levels;
BRCA	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	14.63	0.5	4.96e-42	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs17253792	0.822	rs9972180	chr14:56073732	G/T	cg01858014	chr14:56050164	KTN1	-0.78	-10.82	-0.39	3.74e-25	Putamen volume;
BRCA	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg13319975	chr6:146136371	FBXO30	0.35	8.22	0.31	1.12e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08219700	chr8:58056026	NA	0.44	8.0	0.3	5.75e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg17691542	chr6:26056736	HIST1H1C	0.55	11.71	0.42	7.82e-29	Height;
BRCA	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03264133	chr6:25882463	NA	-0.57	-12.02	-0.43	3.65e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11644478	chr21:40555479	PSMG1	0.54	11.72	0.42	7.36e-29	Cognitive function;
BRCA	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg04374321	chr14:90722782	PSMC1	0.72	18.59	0.59	5.19e-62	Mortality in heart failure;
BRCA	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	8.98	0.33	3.04e-18	Bipolar disorder;
BRCA	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg05925327	chr15:68127851	NA	-0.44	-9.5	-0.35	4.19e-20	Restless legs syndrome;
BRCA	cis	rs4423214	0.879	rs1790324	chr11:71150520	A/C	cg05163923	chr11:71159392	DHCR7	-0.58	-12.52	-0.44	2.62e-32	Vitamin D levels;
BRCA	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg16405210	chr4:1374714	KIAA1530	-0.51	-12.08	-0.43	2.15e-30	Longevity;
BRCA	cis	rs965469	0.779	rs6051761	chr20:3321568	A/G	cg25506879	chr20:3388711	C20orf194	0.45	9.19	0.34	5.57e-19	IFN-related cytopenia;
BRCA	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.19	-0.37	1.11e-22	Aortic root size;
BRCA	cis	rs2559856	1.000	rs2695292	chr12:102087290	G/A	cg12924262	chr12:102091054	CHPT1	0.38	8.56	0.32	8.5e-17	Blood protein levels;
BRCA	cis	rs812925	0.502	rs13028833	chr2:61644329	C/G	cg15711740	chr2:61764176	XPO1	0.32	8.02	0.3	5.08e-15	Immature fraction of reticulocytes;
BRCA	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg23711669	chr6:146136114	FBXO30	0.64	14.66	0.5	3.75e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg13256891	chr4:100009986	ADH5	0.52	9.77	0.36	4.15e-21	Alcohol dependence;
BRCA	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg06550200	chr5:1325588	CLPTM1L	-0.62	-12.94	-0.46	3.35e-34	Lung cancer;
BRCA	trans	rs3960554	0.808	rs112962015	chr7:75659303	C/T	cg19862616	chr7:65841803	NCRNA00174	0.59	12.23	0.44	4.52e-31	Eotaxin levels;
BRCA	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg03425785	chr20:62221387	GMEB2	0.52	8.4	0.32	2.99e-16	Glioma;Non-glioblastoma glioma;Glioblastoma;
BRCA	cis	rs7131987	0.903	rs6487796	chr12:29422764	A/G	cg09582351	chr12:29534625	ERGIC2	-0.48	-11.65	-0.42	1.44e-28	QT interval;
BRCA	cis	rs27434	0.660	rs42398	chr5:96120455	C/T	cg16492584	chr5:96139282	ERAP1	-0.39	-7.87	-0.3	1.54e-14	Ankylosing spondylitis;
BRCA	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.39	8.48	0.32	1.62e-16	Multiple sclerosis;
BRCA	cis	rs17095355	1.000	rs55717725	chr10:111666629	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.38	-9.58	-0.35	2.1e-20	Biliary atresia;
BRCA	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.34	-0.38	2.72e-23	Schizophrenia;
BRCA	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg14019146	chr3:50243930	SLC38A3	0.63	16.14	0.54	2.08e-49	Intelligence (multi-trait analysis);
BRCA	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg18225595	chr11:63971243	STIP1	0.59	14.28	0.49	2.37e-40	Platelet count;
BRCA	cis	rs7147624	1.000	rs4902408	chr14:66111901	A/T	cg03016385	chr14:66212404	NA	-0.55	-8.73	-0.33	2.15e-17	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg25427524	chr10:38739819	LOC399744	-0.6	-13.69	-0.48	1.39e-37	Extrinsic epigenetic age acceleration;
BRCA	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg08917208	chr2:24149416	ATAD2B	0.55	8.61	0.32	5.76e-17	Lymphocyte counts;
BRCA	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg00677455	chr12:58241039	CTDSP2	0.76	18.1	0.58	2.01e-59	Multiple sclerosis;
BRCA	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-12.25	-0.44	4.02e-31	Morning vs. evening chronotype;
BRCA	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.75	-0.42	5.12e-29	Platelet count;
BRCA	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg12193833	chr17:30244370	NA	-0.58	-8.89	-0.33	6.38e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg20387954	chr3:183756860	HTR3D	-0.34	-7.97	-0.3	7.22e-15	Anterior chamber depth;
BRCA	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg08807892	chr2:162101083	NA	0.45	8.84	0.33	9.19e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg00757033	chr12:89920650	WDR51B	0.52	10.42	0.38	1.4e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.67	0.5	3.35e-42	Colorectal cancer;
BRCA	cis	rs4919694	1.000	rs11191473	chr10:104710710	C/G	cg04362960	chr10:104952993	NT5C2	0.97	15.09	0.51	3.25e-44	Arsenic metabolism;
BRCA	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.96	-20.31	-0.63	3.82e-71	Cognitive ability;
BRCA	cis	rs367943	1.000	rs348946	chr5:112822814	C/T	cg12552261	chr5:112820674	MCC	-0.55	-12.01	-0.43	4.05e-30	Type 2 diabetes;
BRCA	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg04414720	chr1:150670196	GOLPH3L	0.36	8.28	0.31	7.44e-16	Tonsillectomy;
BRCA	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.81	-0.39	4.11e-25	Mean corpuscular volume;
BRCA	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg22920501	chr2:26401640	FAM59B	0.71	11.93	0.43	8.95e-30	Gut microbiome composition (summer);
BRCA	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg23649088	chr2:200775458	C2orf69	-0.56	-8.32	-0.31	5.18e-16	Schizophrenia;
BRCA	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg12386194	chr3:101231763	SENP7	0.66	12.87	0.45	7.01e-34	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.54	-12.07	-0.43	2.34e-30	Colorectal cancer;
BRCA	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg04691961	chr3:161091175	C3orf57	-0.58	-13.95	-0.48	8.48e-39	Morning vs. evening chronotype;
BRCA	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg11057378	chr10:81107060	PPIF	0.4	9.5	0.35	4.24e-20	Height;
BRCA	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg07080220	chr10:102295463	HIF1AN	0.52	12.02	0.43	3.88e-30	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2992756	0.663	rs2992762	chr1:18804609	A/G	cg14356550	chr1:18808102	KLHDC7A	-0.39	-8.1	-0.3	2.9e-15	Breast cancer;
BRCA	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	14.21	0.49	4.81e-40	Platelet count;
BRCA	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21659725	chr3:3221576	CRBN	-0.72	-22.05	-0.66	1.48e-80	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg04450456	chr4:17643702	FAM184B	0.42	12.21	0.44	5.57e-31	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg09307838	chr4:120376055	NA	0.75	16.17	0.54	1.48e-49	Corneal astigmatism;
BRCA	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03452623	chr4:187889614	NA	-0.35	-11.59	-0.42	2.63e-28	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21659725	chr3:3221576	CRBN	0.35	8.54	0.32	9.47e-17	Body mass index;
BRCA	cis	rs6558530	0.692	rs7818406	chr8:1701250	C/T	cg19131313	chr8:1704013	NA	-0.4	-8.08	-0.3	3.29e-15	Systolic blood pressure;
BRCA	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg22800045	chr5:56110881	MAP3K1	0.68	13.05	0.46	1.14e-34	Initial pursuit acceleration;
BRCA	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.38	0.38	2.03e-23	Motion sickness;
BRCA	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.01	0.34	2.33e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4363385	0.747	rs1415970	chr1:152965741	G/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.38	-0.35	1.14e-19	Inflammatory skin disease;
BRCA	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg12365402	chr11:9010492	NRIP3	-0.39	-8.85	-0.33	8.54e-18	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg26384229	chr12:38710491	ALG10B	0.58	13.26	0.46	1.25e-35	Morning vs. evening chronotype;
BRCA	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.64	-16.56	-0.55	1.55e-51	Longevity;Endometriosis;
BRCA	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg23018236	chr17:30244563	NA	-0.46	-8.36	-0.31	3.92e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18876405	chr7:65276391	NA	-0.62	-15.3	-0.52	2.87e-45	Aortic root size;
BRCA	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg01528321	chr10:82214614	TSPAN14	0.84	18.27	0.59	2.57e-60	Post bronchodilator FEV1;
BRCA	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg08027265	chr7:2291960	NA	-0.4	-9.57	-0.35	2.32e-20	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs7246760	0.867	rs58461110	chr19:9833390	G/A	cg16876255	chr19:9731953	ZNF561	0.64	7.92	0.3	1.07e-14	Pursuit maintenance gain;
BRCA	cis	rs1691799	0.899	rs1183272	chr12:66735421	T/C	cg16791601	chr12:66731901	HELB	-0.7	-19.95	-0.62	3.14e-69	White blood cell count (basophil);
BRCA	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg21535247	chr6:8435926	SLC35B3	0.4	9.0	0.34	2.57e-18	Motion sickness;
BRCA	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg00074818	chr8:8560427	CLDN23	0.38	8.36	0.31	4.03e-16	Obesity-related traits;
BRCA	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.53	13.44	0.47	1.93e-36	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs243505	0.898	rs243537	chr7:148408278	A/G	cg09806900	chr7:148480153	CUL1	-0.43	-8.64	-0.32	4.55e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-11.09	-0.4	3.03e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg12564285	chr5:131593104	PDLIM4	0.46	12.25	0.44	3.94e-31	Acylcarnitine levels;
BRCA	cis	rs11608355	0.515	rs61941591	chr12:109919965	A/C	cg05360138	chr12:110035743	NA	0.74	13.58	0.47	4.43e-37	Neuroticism;
BRCA	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.29	9.85	0.36	2.12e-21	Bipolar disorder;
BRCA	trans	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg26043149	chr18:55253948	FECH	0.39	8.33	0.31	4.89e-16	Bone mineral density;
BRCA	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg21775007	chr8:11205619	TDH	-0.42	-8.69	-0.33	3.15e-17	Mood instability;
BRCA	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	17.25	0.56	4.8e-55	Alzheimer's disease;
BRCA	trans	rs6479891	1.000	rs59246603	chr10:65233942	T/C	cg14819942	chr15:35414228	NA	0.35	8.69	0.33	3.04e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23583168	chr7:148888333	NA	-0.84	-19.93	-0.62	4.16e-69	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg20307385	chr11:47447363	PSMC3	0.9	27.71	0.74	1.27e-111	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg24642439	chr20:33292090	TP53INP2	0.53	11.65	0.42	1.42e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs11190604	0.767	rs3750723	chr10:102172989	T/C	cg07080220	chr10:102295463	HIF1AN	0.49	10.03	0.37	4.26e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs10227331	0.846	rs10807647	chr7:157298007	A/G	cg04156418	chr7:157293606	NA	-0.33	-9.48	-0.35	4.84e-20	Inattentive symptoms;
BRCA	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	10.7	0.39	1.04e-24	Motion sickness;
BRCA	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.81	0.39	3.95e-25	Bipolar disorder;
BRCA	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.38	-8.87	-0.33	7.23e-18	Longevity;Endometriosis;
BRCA	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.56	12.38	0.44	1.1e-31	Menarche (age at onset);
BRCA	cis	rs427394	0.802	rs274698	chr5:6730957	T/G	cg10857441	chr5:6722123	POLS	-0.33	-10.94	-0.4	1.16e-25	Menopause (age at onset);
BRCA	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg08601574	chr20:25228251	PYGB	-0.35	-8.64	-0.32	4.54e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg24531977	chr5:56204891	C5orf35	-0.4	-8.06	-0.3	3.86e-15	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.04	0.34	1.9e-18	Motion sickness;
BRCA	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg15934090	chr1:100435551	SLC35A3	0.36	8.38	0.31	3.28e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg01802117	chr1:53393560	SCP2	-0.36	-8.39	-0.31	3.16e-16	Monocyte count;
BRCA	cis	rs965469	1.000	rs2236123	chr20:3305305	C/G	cg25506879	chr20:3388711	C20orf194	0.51	9.96	0.37	7.89e-22	IFN-related cytopenia;
BRCA	trans	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg06437703	chr8:37914619	EIF4EBP1	0.31	8.13	0.31	2.19e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg18230493	chr5:56204884	C5orf35	-0.72	-14.07	-0.49	2.27e-39	Initial pursuit acceleration;
BRCA	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg14500267	chr11:67383377	NA	-0.4	-8.42	-0.32	2.42e-16	Mean corpuscular volume;
BRCA	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg24596788	chr1:163392923	NA	-0.33	-8.91	-0.33	5.14e-18	Motion sickness;
BRCA	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg26384229	chr12:38710491	ALG10B	0.75	16.88	0.56	3.83e-53	Bladder cancer;
BRCA	cis	rs7851660	0.870	rs1867278	chr9:100615949	C/A	cg13688889	chr9:100608707	NA	-0.36	-8.72	-0.33	2.42e-17	Strep throat;
BRCA	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.62	-0.32	5.36e-17	Total body bone mineral density;
BRCA	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg13880726	chr7:1868755	MAD1L1	0.5	10.15	0.37	1.57e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs365132	0.875	rs2454952	chr5:176376493	C/T	cg16309518	chr5:176445507	NA	-0.4	-9.8	-0.36	3.21e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs7523050	0.730	rs35100394	chr1:109433989	C/G	cg08274380	chr1:109419600	GPSM2	1.18	16.83	0.55	6.67e-53	Fat distribution (HIV);
BRCA	trans	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.07	0.3	3.49e-15	Endometrial cancer;
BRCA	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg01939980	chr4:1354348	KIAA1530	0.37	8.79	0.33	1.41e-17	Obesity-related traits;
BRCA	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg20307385	chr11:47447363	PSMC3	-0.4	-8.48	-0.32	1.52e-16	Subjective well-being;
BRCA	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg21775007	chr8:11205619	TDH	0.58	12.73	0.45	2.93e-33	Retinal vascular caliber;
BRCA	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22455342	chr2:225449267	CUL3	0.63	16.09	0.54	3.88e-49	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs7020830	0.825	rs7036132	chr9:37317241	A/G	cg14294708	chr9:37120828	ZCCHC7	1.17	37.68	0.83	1.76e-164	Schizophrenia;
BRCA	trans	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg06521331	chr12:34319734	NA	-0.51	-9.14	-0.34	8.14e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7580658	0.963	rs867304	chr2:128078488	G/A	cg09760422	chr2:128146352	NA	-0.35	-7.93	-0.3	1e-14	Protein C levels;
BRCA	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.42	-7.83	-0.3	1.99e-14	Renal function-related traits (BUN);
BRCA	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg25358565	chr5:93447407	FAM172A	1.18	17.69	0.57	2.68e-57	Diabetic retinopathy;
BRCA	cis	rs11227306	0.934	rs2303385	chr11:65640562	G/A	cg00576331	chr11:65640516	EFEMP2	0.44	9.83	0.36	2.59e-21	DNA methylation (variation);
BRCA	cis	rs2249625	0.545	rs2496495	chr6:72882414	G/A	cg18830697	chr6:72922368	RIMS1	-0.63	-14.36	-0.49	9.82e-41	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg04450456	chr4:17643702	FAM184B	0.37	10.55	0.39	4.13e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.29	-0.38	4.53e-23	Morning vs. evening chronotype;
BRCA	trans	rs1391576	1	rs1391576	chr11:51394932	C/T	cg03929089	chr4:120376271	NA	0.6	8.05	0.3	3.99e-15	Body mass index;
BRCA	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg19257562	chr1:2043853	PRKCZ	0.35	9.83	0.36	2.41e-21	Height;
BRCA	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.31	-0.38	3.74e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg20469991	chr17:27169893	C17orf63	-0.44	-8.48	-0.32	1.51e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.57	-0.42	3.11e-28	Mean corpuscular volume;
BRCA	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg13660082	chr14:53194042	PSMC6	-0.56	-8.03	-0.3	4.85e-15	Alzheimer's disease (late onset);
BRCA	trans	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg17470723	chr8:74884337	TCEB1	0.39	8.14	0.31	2.15e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2011503	0.739	rs8108659	chr19:19680738	T/A	cg15839431	chr19:19639596	YJEFN3	0.38	8.35	0.31	4.09e-16	Bipolar disorder;
BRCA	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg23711669	chr6:146136114	FBXO30	-0.49	-8.95	-0.33	3.98e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg23029597	chr12:123009494	RSRC2	-0.57	-11.76	-0.42	4.89e-29	Body mass index;
BRCA	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-14.03	-0.49	3.5e-39	Coronary artery disease;
BRCA	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg23029597	chr12:123009494	RSRC2	-0.63	-12.86	-0.45	8.4e-34	Body mass index;
BRCA	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg13010199	chr12:38710504	ALG10B	-0.39	-8.85	-0.33	8.41e-18	Morning vs. evening chronotype;
BRCA	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.03	-0.37	4.32e-22	Mean corpuscular volume;
BRCA	cis	rs10193935	0.901	rs10202848	chr2:42515661	A/G	cg27598129	chr2:42591480	NA	-0.88	-14.14	-0.49	1.05e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12667521	chr19:29218732	NA	0.47	8.75	0.33	1.93e-17	Methadone dose in opioid dependence;
BRCA	cis	rs2637266	1.000	rs7896831	chr10:78366649	A/T	cg18941641	chr10:78392320	NA	0.35	7.82	0.3	2.18e-14	Pulmonary function;
BRCA	cis	rs243505	0.894	rs243504	chr7:148435393	A/G	cg09806900	chr7:148480153	CUL1	-0.4	-8.44	-0.32	2.1e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg26587870	chr6:27730563	NA	-0.55	-8.23	-0.31	1.08e-15	Depression;
BRCA	trans	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.86	0.3	1.6e-14	Corneal astigmatism;
BRCA	cis	rs2425143	1.000	rs73902914	chr20:34432882	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.88	-0.33	6.76e-18	Blood protein levels;
BRCA	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg23029597	chr12:123009494	RSRC2	-0.58	-11.28	-0.41	4.73e-27	Body mass index;
BRCA	trans	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg19862616	chr7:65841803	NCRNA00174	0.85	28.34	0.75	4.9e-115	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs965469	0.948	rs2236094	chr20:3260368	C/G	cg25506879	chr20:3388711	C20orf194	0.53	10.82	0.39	3.56e-25	IFN-related cytopenia;
BRCA	cis	rs829883	0.659	rs11109522	chr12:98930964	C/T	cg25150519	chr12:98850993	NA	-0.5	-9.1	-0.34	1.1e-18	Colorectal adenoma (advanced);
BRCA	trans	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.55	-0.32	8.78e-17	Triglycerides;
BRCA	cis	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg06521331	chr12:34319734	NA	-0.54	-10.84	-0.39	3.04e-25	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg04944784	chr2:26401820	FAM59B	0.95	16.17	0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs698833	0.926	rs786624	chr2:44604941	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.47	-9.46	-0.35	5.71e-20	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg18154014	chr19:37997991	ZNF793	0.6	11.29	0.41	4.35e-27	Coronary artery calcification;
BRCA	cis	rs586533	0.958	rs682120	chr11:99526433	A/G	cg22878054	chr11:99397252	CNTN5	0.31	7.85	0.3	1.82e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1784581	0.775	rs7755404	chr6:162427731	T/C	cg17173639	chr6:162384350	PARK2	0.39	9.16	0.34	7.23e-19	Itch intensity from mosquito bite;
BRCA	cis	rs68170813	0.559	rs4730239	chr7:107056960	A/T	cg02696742	chr7:106810147	HBP1	-0.54	-8.13	-0.31	2.17e-15	Coronary artery disease;
BRCA	cis	rs6973256	0.605	rs10227672	chr7:133326196	G/C	cg07491979	chr7:133331646	EXOC4	-0.35	-7.89	-0.3	1.33e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.32	-8.3	-0.31	6.35e-16	IgG glycosylation;
BRCA	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg21535247	chr6:8435926	SLC35B3	0.38	8.72	0.33	2.34e-17	Motion sickness;
BRCA	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg16230307	chr14:35515116	FAM177A1	0.73	15.06	0.51	4.55e-44	Psoriasis;
BRCA	trans	rs853679	0.546	rs35017208	chr6:28345282	C/T	cg01620082	chr3:125678407	NA	-0.97	-10.99	-0.4	7.12e-26	Depression;
BRCA	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.9	-0.4	1.79e-25	Personality dimensions;
BRCA	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	14.93	0.51	1.86e-43	Colorectal cancer;
BRCA	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg14689365	chr7:158441557	NCAPG2	-0.42	-8.59	-0.32	6.72e-17	Height;
BRCA	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg11657440	chr19:46296263	DMWD	-0.55	-12.75	-0.45	2.44e-33	Coronary artery disease;
BRCA	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg21132104	chr15:45694354	SPATA5L1	0.74	16.35	0.54	1.82e-50	Homoarginine levels;
BRCA	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.4	8.28	0.31	6.96e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26314531	chr2:26401878	FAM59B	-0.65	-11.1	-0.4	2.59e-26	Gut microbiome composition (summer);
BRCA	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg00409905	chr10:38381863	ZNF37A	0.45	9.16	0.34	6.75e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs708547	0.836	rs781554	chr4:57717537	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.48	-10.36	-0.38	2.42e-23	Response to bleomycin (chromatid breaks);
BRCA	cis	rs921968	0.519	rs62191659	chr2:219630510	C/T	cg02176678	chr2:219576539	TTLL4	-0.4	-10.96	-0.4	9.54e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg07423050	chr13:99094983	FARP1	0.63	15.82	0.53	8.3e-48	Neuroticism;
BRCA	cis	rs509477	1.000	rs7240845	chr18:32574960	G/C	cg23791764	chr18:32556832	MAPRE2	-0.34	-7.82	-0.3	2.26e-14	Cerebrospinal fluid AB1-42 levels;
BRCA	trans	rs11088226	0.681	rs2833911	chr21:33949629	C/T	cg09050820	chr6:167586206	TCP10L2	-0.83	-15.43	-0.52	6.66e-46	Gastritis;
BRCA	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg17366294	chr4:99064904	C4orf37	-0.45	-10.67	-0.39	1.4e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1882538	0.506	rs7805858	chr7:133126589	G/T	cg10665199	chr7:133106180	EXOC4	0.43	9.05	0.34	1.66e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg04362960	chr10:104952993	NT5C2	0.46	10.73	0.39	8.24e-25	Arsenic metabolism;
BRCA	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg03676636	chr4:99064102	C4orf37	0.24	8.43	0.32	2.37e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg06784218	chr1:46089804	CCDC17	-0.47	-11.14	-0.4	1.91e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-13.5	-0.47	1.05e-36	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6142102	0.538	rs6142058	chr20:32542801	A/G	cg24642439	chr20:33292090	TP53INP2	0.39	7.81	0.3	2.32e-14	Skin pigmentation;
BRCA	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg21395723	chr22:39101663	GTPBP1	0.4	8.66	0.32	3.7e-17	Menopause (age at onset);
BRCA	cis	rs3784262	0.669	rs4646609	chr15:58274989	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.02	-0.37	4.76e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg22705602	chr4:152727874	NA	-0.38	-10.48	-0.38	7.89e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs2997447	0.655	rs12059101	chr1:26384013	A/G	cg19633962	chr1:26362018	EXTL1	-0.61	-10.51	-0.38	6.3e-24	QRS complex (12-leadsum);
BRCA	cis	rs7927771	0.524	rs11039329	chr11:47684908	A/G	cg20307385	chr11:47447363	PSMC3	0.43	9.77	0.36	4.05e-21	Subjective well-being;
BRCA	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg19729930	chr2:74357872	NA	0.54	13.68	0.48	1.57e-37	Gestational age at birth (maternal effect);
BRCA	cis	rs4363385	0.693	rs76987906	chr1:152964530	A/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.54	-0.35	2.86e-20	Inflammatory skin disease;
BRCA	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06544989	chr22:39130855	UNC84B	-0.37	-8.97	-0.33	3.3e-18	Menopause (age at onset);
BRCA	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	10.36	0.38	2.33e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg04450456	chr4:17643702	FAM184B	0.38	11.09	0.4	3.02e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg24558204	chr6:135376177	HBS1L	0.59	15.94	0.53	1.98e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg04691961	chr3:161091175	C3orf57	-0.36	-7.96	-0.3	7.98e-15	Morning vs. evening chronotype;
BRCA	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg00701064	chr4:6280414	WFS1	0.66	13.22	0.46	1.96e-35	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs2617583	0.967	rs2937640	chr5:1443604	C/T	cg07151155	chr5:1473589	LPCAT1	-0.38	-8.24	-0.31	1.01e-15	Breast cancer;
BRCA	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg23711669	chr6:146136114	FBXO30	0.64	15.03	0.51	5.77e-44	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg09719594	chr16:21412588	NA	-0.33	-8.01	-0.3	5.43e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6878727	0.665	rs698182	chr5:123667142	C/T	cg01806427	chr5:123737813	NA	-0.37	-8.27	-0.31	7.92e-16	Breast cancer;
BRCA	cis	rs858239	0.539	rs10225608	chr7:23188908	A/G	cg23682824	chr7:23144976	KLHL7	0.42	10.94	0.4	1.21e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.91	-0.3	1.14e-14	Colorectal cancer;
BRCA	cis	rs3925075	1.000	rs55742763	chr16:31340368	G/A	cg02846316	chr16:31340340	ITGAM	0.55	13.57	0.47	4.64e-37	IgA nephropathy;
BRCA	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg08859206	chr1:53392774	SCP2	-0.4	-8.63	-0.32	4.8e-17	Monocyte count;
BRCA	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg04842962	chr6:43655489	MRPS18A	1.12	38.53	0.84	8.49e-169	IgG glycosylation;
BRCA	cis	rs6545883	0.929	rs2593626	chr2:61665184	C/A	cg15711740	chr2:61764176	XPO1	-0.56	-14.22	-0.49	4.62e-40	Tuberculosis;
BRCA	cis	rs10949834	0.517	rs810536	chr7:73504233	G/A	cg07137043	chr7:73588983	EIF4H	0.5	8.92	0.33	4.97e-18	Verbal memory performance (residualized delayed recall change);
BRCA	cis	rs10411936	0.712	rs9305079	chr19:16591464	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.45	9.52	0.35	3.45e-20	White blood cell count;Multiple sclerosis;
BRCA	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg15556689	chr8:8085844	FLJ10661	-0.36	-9.04	-0.34	1.79e-18	Retinal vascular caliber;
BRCA	cis	rs34779708	0.931	rs4934711	chr10:35360310	G/A	cg03585969	chr10:35415529	CREM	0.48	10.32	0.38	3.39e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg12935359	chr14:103987150	CKB	0.64	15.0	0.51	8.63e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg07636037	chr3:49044803	WDR6	0.98	29.0	0.75	1.13e-118	Parkinson's disease;
BRCA	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg07828340	chr4:882639	GAK	1.0	11.93	0.43	9.13e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.61	-0.32	5.56e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg06521331	chr12:34319734	NA	-0.63	-11.49	-0.41	6.87e-28	Morning vs. evening chronotype;
BRCA	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg05527609	chr1:210001259	C1orf107	0.65	14.06	0.49	2.5e-39	Orofacial clefts;
BRCA	cis	rs76419734	0.510	rs2544402	chr4:106687733	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.44	-9.49	-0.35	4.45e-20	Post bronchodilator FEV1;
BRCA	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg26384229	chr12:38710491	ALG10B	0.77	17.28	0.56	3.33e-55	Bladder cancer;
BRCA	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg04317338	chr11:64019027	PLCB3	0.55	9.58	0.35	2.08e-20	Mean platelet volume;
BRCA	cis	rs2806561	0.664	rs4620508	chr1:23307438	C/T	cg19743168	chr1:23544995	NA	0.34	8.02	0.3	4.91e-15	Height;
BRCA	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg08645402	chr16:4508243	NA	0.42	9.62	0.36	1.47e-20	Schizophrenia;
BRCA	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-8.65	-0.32	4.13e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6429082	0.871	rs9662392	chr1:235576949	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.34	-8.09	-0.3	3.01e-15	Adiposity;
BRCA	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg15704280	chr7:45808275	SEPT13	0.53	8.97	0.33	3.33e-18	Axial length;
BRCA	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg11822812	chr5:140052017	DND1	-0.31	-8.46	-0.32	1.82e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7975161	0.671	rs7313063	chr12:104602208	G/A	cg25273343	chr12:104657179	TXNRD1	-0.39	-9.29	-0.34	2.36e-19	Toenail selenium levels;
BRCA	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	12.04	0.43	2.96e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6910061	0.957	rs6916541	chr6:11095258	C/A	cg27233058	chr6:11094804	LOC221710	0.52	9.24	0.34	3.71e-19	Diabetic kidney disease;
BRCA	cis	rs3849570	0.925	rs6799080	chr3:81905591	G/A	cg07356753	chr3:81810745	GBE1	-0.43	-10.25	-0.38	6.45e-23	Waist circumference;Body mass index;
BRCA	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg24562669	chr7:97807699	LMTK2	0.43	11.66	0.42	1.3e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7246657	0.722	rs16958863	chr19:38124235	A/G	cg23950597	chr19:37808831	NA	-0.48	-8.35	-0.31	4.2e-16	Coronary artery calcification;
BRCA	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg13319975	chr6:146136371	FBXO30	0.39	8.98	0.33	2.92e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg06623918	chr6:96969491	KIAA0776	-0.77	-13.77	-0.48	5.7800000000000005e-38	Migraine;Coronary artery disease;
BRCA	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	16.77	0.55	1.43e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.65	10.72	0.39	9.05e-25	Renal function-related traits (BUN);
BRCA	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.02	-0.34	2.21e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.61	-0.32	5.73e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg07460842	chr6:66804631	NA	0.68	11.41	0.41	1.47e-27	Exhaled nitric oxide output;
BRCA	cis	rs965469	1.000	rs6037553	chr20:3313884	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-10.35	-0.38	2.54e-23	IFN-related cytopenia;
BRCA	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg13402656	chr8:1511478	DLGAP2	0.54	11.74	0.42	5.64e-29	Lung cancer;
BRCA	cis	rs3820928	0.904	rs4439949	chr2:227764954	T/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.46	-0.32	1.77e-16	Pulmonary function;
BRCA	cis	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg02258303	chr16:87377426	FBXO31	0.36	7.9	0.3	1.25e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
BRCA	cis	rs12618769	0.597	rs72821924	chr2:99114924	C/T	cg10123293	chr2:99228465	UNC50	0.42	8.37	0.31	3.7e-16	Bipolar disorder;
BRCA	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg13175981	chr1:150552382	MCL1	0.45	10.1	0.37	2.37e-22	Tonsillectomy;
BRCA	cis	rs36051895	0.632	rs12337480	chr9:5134567	T/A	cg02405213	chr9:5042618	JAK2	-0.46	-9.01	-0.34	2.43e-18	Pediatric autoimmune diseases;
BRCA	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg03146154	chr1:46216737	IPP	0.45	9.89	0.36	1.46e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg27661571	chr11:113659931	NA	-0.69	-10.98	-0.4	7.83e-26	Hip circumference adjusted for BMI;
BRCA	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.89	0.33	6.19e-18	Iron status biomarkers;
BRCA	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg17063962	chr7:91808500	NA	0.53	12.51	0.44	2.79e-32	Breast cancer;
BRCA	cis	rs68170813	0.559	rs1548524	chr7:106944563	G/T	cg02696742	chr7:106810147	HBP1	0.54	9.08	0.34	1.38e-18	Coronary artery disease;
BRCA	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg18402987	chr7:1209562	NA	0.59	9.12	0.34	9.34e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg20207973	chr22:38506712	BAIAP2L2	0.31	8.05	0.3	4.16e-15	Cutaneous nevi;
BRCA	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	8.97	0.33	3.36e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg20848291	chr7:100343083	ZAN	-0.61	-12.92	-0.46	4.1e-34	Other erythrocyte phenotypes;
BRCA	cis	rs74181299	0.684	rs17040050	chr2:65327042	G/A	cg05010058	chr2:65284262	CEP68	-0.29	-7.91	-0.3	1.16e-14	Pulse pressure;
BRCA	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg03342759	chr3:160939853	NMD3	-0.8	-17.94	-0.58	1.44e-58	Parkinson's disease;
BRCA	cis	rs13223928	0.651	rs4722435	chr7:3152962	C/T	cg19214707	chr7:3157722	NA	0.45	11.36	0.41	2.21e-27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
BRCA	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.65	13.72	0.48	1.03e-37	Lymphocyte counts;
BRCA	cis	rs6987853	0.761	rs2974321	chr8:42424727	A/G	cg09913449	chr8:42400586	C8orf40	0.42	9.34	0.35	1.62e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6545883	0.965	rs6718887	chr2:61727215	G/A	cg15711740	chr2:61764176	XPO1	-0.52	-13.1	-0.46	6.71e-35	Tuberculosis;
BRCA	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg03609598	chr5:56110824	MAP3K1	-0.49	-8.35	-0.31	4.37e-16	Type 2 diabetes;
BRCA	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.35	-11.44	-0.41	1.07e-27	Homoarginine levels;
BRCA	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	20.17	0.62	2.23e-70	Chronic sinus infection;
BRCA	cis	rs16910800	0.731	rs16910754	chr11:23192015	A/G	cg20040320	chr11:23191996	NA	0.59	10.08	0.37	2.84e-22	Cancer;
BRCA	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg06917634	chr15:78832804	PSMA4	-0.76	-17.67	-0.57	3.29e-57	Sudden cardiac arrest;
BRCA	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.86	13.45	0.47	1.79e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12618769	0.597	rs72821946	chr2:99142411	G/C	cg10123293	chr2:99228465	UNC50	0.41	8.24	0.31	9.93e-16	Bipolar disorder;
BRCA	cis	rs1113500	1.000	rs1777483	chr1:108609408	A/C	cg06207961	chr1:108661230	NA	-0.42	-10.48	-0.38	7.97e-24	Growth-regulated protein alpha levels;
BRCA	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg22963979	chr7:1858916	MAD1L1	-0.4	-8.45	-0.32	1.91e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg11502198	chr6:26597334	ABT1	0.56	12.04	0.43	3.01e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs56104184	0.830	rs73061617	chr19:49350984	G/A	cg15549821	chr19:49342101	PLEKHA4	-1.05	-15.64	-0.53	6.44e-47	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs10170846	1.000	rs10170846	chr2:223517705	C/G	cg25565276	chr2:223520875	FARSB	-0.5	-13.49	-0.47	1.08e-36	Schizophrenia (inflammation and infection response interaction);
BRCA	cis	rs12220238	1.000	rs10824083	chr10:75911342	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.5	8.09	0.3	3.05e-15	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs4077515	0.967	rs11794847	chr9:139271747	G/A	cg14019695	chr9:139328340	INPP5E	0.32	8.1	0.31	2.7e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.63	0.32	4.9e-17	Rheumatoid arthritis;
BRCA	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.49	-10.63	-0.39	2.09e-24	Rheumatoid arthritis;
BRCA	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg06159980	chr1:16340746	HSPB7	-0.38	-8.84	-0.33	9.14e-18	Dilated cardiomyopathy;
BRCA	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg06609049	chr19:2785107	THOP1	0.59	12.03	0.43	3.39e-30	Total cholesterol levels;
BRCA	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11644478	chr21:40555479	PSMG1	-0.51	-10.69	-0.39	1.23e-24	Menarche (age at onset);
BRCA	trans	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.44	-8.99	-0.34	2.89e-18	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg13770153	chr20:60521292	NA	-0.38	-9.13	-0.34	8.72e-19	Body mass index;
BRCA	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg02659138	chr7:134003124	SLC35B4	0.34	10.79	0.39	4.94e-25	Mean platelet volume;
BRCA	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11764359	chr7:65958608	NA	0.8	19.51	0.61	7.33e-67	Aortic root size;
BRCA	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg07169764	chr2:136633963	MCM6	0.96	19.26	0.61	1.57e-65	Corneal structure;
BRCA	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.21	0.37	9.18e-23	Aortic root size;
BRCA	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.52	-0.32	1.16e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg18351406	chr4:77819688	ANKRD56	0.61	13.39	0.47	3.13e-36	Emphysema distribution in smoking;
BRCA	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg08999081	chr20:33150536	PIGU	0.44	11.74	0.42	6.07e-29	Coronary artery disease;
BRCA	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.15	-0.31	1.9e-15	Depression;
BRCA	cis	rs9815354	1.000	rs9823254	chr3:41894768	G/C	cg03022575	chr3:42003672	ULK4	0.51	8.28	0.31	6.99e-16	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs3772130	0.583	rs34051021	chr3:121433005	C/A	cg20356878	chr3:121714668	ILDR1	0.37	8.27	0.31	7.51e-16	Cognitive performance;
BRCA	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs3772130	0.564	rs4420917	chr3:121567863	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	14.27	0.49	2.71e-40	Cognitive performance;
BRCA	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg18357645	chr12:58087776	OS9	0.42	11.95	0.43	7.78e-30	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg08601574	chr20:25228251	PYGB	-0.35	-8.51	-0.32	1.23e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg12373951	chr3:133503437	NA	-0.45	-10.63	-0.39	1.98e-24	Iron status biomarkers;
BRCA	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg12444411	chr7:2802554	GNA12	-0.38	-9.5	-0.35	3.99e-20	Height;
BRCA	cis	rs9462846	0.919	rs9471966	chr6:42891022	G/A	cg02353165	chr6:42928485	GNMT	0.49	9.58	0.35	2.02e-20	Blood protein levels;
BRCA	cis	rs775227	0.574	rs2018912	chr3:113060140	A/G	cg18753928	chr3:113234510	CCDC52	-0.55	-9.21	-0.34	4.67e-19	Dental caries;
BRCA	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.89	-0.33	6.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.22	-0.31	1.12e-15	Total body bone mineral density;
BRCA	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg03146154	chr1:46216737	IPP	0.52	11.79	0.42	3.75e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg18129178	chr5:148520854	ABLIM3	0.58	11.69	0.42	9.92e-29	Breast cancer;
BRCA	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg17802220	chr15:77601643	NA	0.47	10.32	0.38	3.38e-23	Type 2 diabetes;
BRCA	trans	rs208520	0.674	rs207103	chr6:66795568	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.23	-0.64	4.44e-76	Exhaled nitric oxide output;
BRCA	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg17366294	chr4:99064904	C4orf37	0.46	10.86	0.39	2.45e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg01028140	chr2:1542097	TPO	-0.61	-12.55	-0.44	1.95e-32	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7809950	0.678	rs7788271	chr7:106985873	A/G	cg23024343	chr7:107201750	COG5	-0.48	-9.58	-0.35	2.03e-20	Coronary artery disease;
BRCA	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg13047869	chr3:10149882	C3orf24	0.53	9.73	0.36	5.63e-21	Alzheimer's disease;
BRCA	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11764359	chr7:65958608	NA	0.77	17.23	0.56	6.13e-55	Aortic root size;
BRCA	cis	rs1451375	0.669	rs4512339	chr7:50646977	C/T	cg18232548	chr7:50535776	DDC	-0.37	-8.67	-0.32	3.54e-17	Malaria;
BRCA	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg12935359	chr14:103987150	CKB	0.65	15.1	0.51	2.88e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg22875332	chr1:76189707	ACADM	0.7	14.85	0.51	4.36e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs629535	0.547	rs62513420	chr8:70122597	G/A	cg21567404	chr3:27674614	NA	-0.96	-17.52	-0.57	2.15e-56	Dupuytren's disease;
BRCA	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg02297831	chr4:17616191	MED28	0.36	8.53	0.32	1.07e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Tonsillectomy;
BRCA	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg04727924	chr7:799746	HEATR2	-0.54	-10.52	-0.38	5.8e-24	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7809950	1.000	rs4727684	chr7:107226470	C/T	cg23024343	chr7:107201750	COG5	-0.44	-9.64	-0.36	1.23e-20	Coronary artery disease;
BRCA	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	18.11	0.58	1.82e-59	Platelet count;
BRCA	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg21395723	chr22:39101663	GTPBP1	0.38	8.22	0.31	1.15e-15	Menopause (age at onset);
BRCA	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg04362960	chr10:104952993	NT5C2	0.47	10.12	0.37	1.97e-22	Arsenic metabolism;
BRCA	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg04896959	chr15:78267971	NA	-0.63	-17.3	-0.56	2.64e-55	Diastolic blood pressure;
BRCA	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg26384229	chr12:38710491	ALG10B	0.76	16.09	0.54	3.75e-49	Morning vs. evening chronotype;
BRCA	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24110177	chr3:50126178	RBM5	0.42	11.53	0.41	4.63e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg04990556	chr1:26633338	UBXN11	-0.76	-18.66	-0.59	2.45e-62	Obesity-related traits;
BRCA	cis	rs10789491	0.588	rs2099766	chr1:47193987	T/C	cg15501359	chr1:47185051	KIAA0494	0.64	15.96	0.53	1.74e-48	Response to hepatitis C treatment;
BRCA	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.4	-8.67	-0.32	3.5e-17	Educational attainment;
BRCA	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg24110177	chr3:50126178	RBM5	0.51	14.43	0.5	4.75e-41	Body mass index;
BRCA	cis	rs1505368	0.836	rs10201067	chr2:213284411	A/G	cg16329650	chr2:213403929	ERBB4	-0.34	-8.34	-0.31	4.61e-16	Symmetrical dimethylarginine levels;
BRCA	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06108461	chr20:60628389	TAF4	-0.96	-21.32	-0.64	1.44e-76	Body mass index;
BRCA	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg09658497	chr7:2847517	GNA12	-0.41	-8.6	-0.32	6.16e-17	Height;
BRCA	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg24562669	chr7:97807699	LMTK2	0.45	12.08	0.43	2.16e-30	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs2018683	0.624	rs6462119	chr7:29003725	G/C	cg19402173	chr7:128379420	CALU	-0.48	-11.66	-0.42	1.34e-28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg05347473	chr6:146136440	FBXO30	-0.41	-8.14	-0.31	2.14e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg09654669	chr8:57350985	NA	-0.42	-9.15	-0.34	7.71e-19	Obesity-related traits;
BRCA	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.07	0.4	3.57e-26	Electroencephalogram traits;
BRCA	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14240646	chr10:27532245	ACBD5	0.69	10.82	0.39	3.48e-25	Breast cancer;
BRCA	cis	rs965469	0.652	rs4507156	chr20:3228460	A/G	cg25506879	chr20:3388711	C20orf194	0.48	9.97	0.37	7.45e-22	IFN-related cytopenia;
BRCA	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	21.3	0.64	1.69e-76	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg25214090	chr10:38739885	LOC399744	0.56	12.39	0.44	9.8e-32	Corneal astigmatism;
BRCA	cis	rs4566357	0.615	rs10190621	chr2:227914484	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-9.59	-0.35	1.95e-20	Coronary artery disease;
BRCA	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg24296786	chr1:45957014	TESK2	0.6	14.53	0.5	1.53e-41	High light scatter reticulocyte count;
BRCA	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg02493740	chr2:85810744	VAMP5	-0.55	-11.34	-0.41	2.68e-27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs7818345	0.967	rs12679712	chr8:19271032	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.32	8.44	0.32	2.06e-16	Language performance in older adults (adjusted for episodic memory);
BRCA	trans	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg26043149	chr18:55253948	FECH	0.38	8.31	0.31	5.95e-16	Bone mineral density;
BRCA	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg24829409	chr8:58192753	C8orf71	0.48	8.04	0.3	4.23e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7552167	0.925	rs78312791	chr1:24513613	C/A	cg01960748	chr1:24522592	NA	0.66	10.72	0.39	9.08e-25	Psoriasis vulgaris;
BRCA	cis	rs4780401	0.609	rs9924522	chr16:11816852	C/A	cg01061890	chr16:11836724	TXNDC11	-0.56	-13.21	-0.46	2.03e-35	Rheumatoid arthritis;
BRCA	cis	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg07460842	chr6:66804631	NA	0.87	15.61	0.53	8.61e-47	Exhaled nitric oxide levels;
BRCA	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.99	-0.3	6.45e-15	Prostate cancer;
BRCA	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg00825309	chr19:58991885	ZNF446	-0.59	-12.86	-0.45	7.7e-34	Uric acid clearance;
BRCA	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg10818794	chr15:86012489	AKAP13	-0.31	-8.56	-0.32	8.12e-17	Coronary artery disease;
BRCA	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg23711669	chr6:146136114	FBXO30	0.77	17.96	0.58	1.11e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26314531	chr2:26401878	FAM59B	0.67	12.17	0.43	8.43e-31	Gut microbiome composition (summer);
BRCA	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.43	-0.32	2.27e-16	Monocyte percentage of white cells;
BRCA	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg00339695	chr16:24857497	SLC5A11	-0.52	-11.36	-0.41	2.25e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg00012203	chr2:219082015	ARPC2	0.42	8.17	0.31	1.7e-15	Ulcerative colitis;
BRCA	cis	rs1595825	0.891	rs76308665	chr2:198518062	C/T	cg19156104	chr2:198669113	PLCL1	-0.43	-8.2	-0.31	1.28e-15	Ulcerative colitis;
BRCA	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-7.82	-0.3	2.13e-14	Height;
BRCA	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg15839431	chr19:19639596	YJEFN3	-0.35	-7.99	-0.3	6.53e-15	Bipolar disorder;
BRCA	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg08885076	chr2:99613938	TSGA10	0.6	13.5	0.47	9.7e-37	Chronic sinus infection;
BRCA	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.18	0.4	1.22e-26	Bipolar disorder;
BRCA	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18876405	chr7:65276391	NA	0.56	13.34	0.47	5.75e-36	Aortic root size;
BRCA	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.95	0.62	3.47e-69	Platelet count;
BRCA	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg03146154	chr1:46216737	IPP	-0.47	-9.99	-0.37	6.14e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs877282	0.945	rs11253397	chr10:789774	A/G	cg17470449	chr10:769945	NA	0.51	8.62	0.32	5.29e-17	Uric acid levels;
BRCA	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.31	10.25	0.38	6.26e-23	Electroencephalogram traits;
BRCA	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg10845886	chr2:3471009	TTC15	0.58	13.22	0.46	2.02e-35	Neurofibrillary tangles;
BRCA	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg24562669	chr7:97807699	LMTK2	0.46	12.37	0.44	1.2e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg00383909	chr3:49044727	WDR6	0.58	10.53	0.38	4.92e-24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg24112000	chr20:60950667	NA	-0.49	-9.33	-0.35	1.7e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg04833646	chr19:10679720	CDKN2D	0.94	20.9	0.64	2.64e-74	Red cell distribution width;
BRCA	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg03676636	chr4:99064102	C4orf37	0.24	8.18	0.31	1.53e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg22633769	chr20:60982531	CABLES2	0.43	8.09	0.3	3.05e-15	Colorectal cancer;
BRCA	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg13010199	chr12:38710504	ALG10B	0.45	9.36	0.35	1.31e-19	Bladder cancer;
BRCA	cis	rs2797160	1.000	rs2747724	chr6:126004935	G/A	cg05901451	chr6:126070800	HEY2	-0.39	-9.49	-0.35	4.46e-20	Endometrial cancer;
BRCA	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	8.77	0.33	1.61e-17	Iron status biomarkers;
BRCA	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.03	0.37	4.34e-22	Aortic root size;
BRCA	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg24006582	chr15:45444508	DUOX1	0.56	11.23	0.41	8.18e-27	Uric acid levels;
BRCA	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg24450063	chr1:156163899	SLC25A44	1.09	34.65	0.81	7.51e-149	Testicular germ cell tumor;
BRCA	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg05623727	chr3:50126028	RBM5	0.5	12.42	0.44	6.87e-32	Body mass index;
BRCA	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg21143896	chr7:2802374	GNA12	-0.38	-9.59	-0.35	1.88e-20	Height;
BRCA	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.51	-10.48	-0.38	7.76e-24	Height;
BRCA	trans	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.37	-8.85	-0.33	8.61e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10802521	chr3:52805072	NEK4	-0.33	-8.51	-0.32	1.19e-16	Bipolar disorder;
BRCA	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-11.19	-0.4	1.19e-26	Gut microbiome composition (summer);
BRCA	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08048268	chr3:133502702	NA	-0.33	-8.33	-0.31	4.86e-16	Iron status biomarkers;
BRCA	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.6	-0.32	6.09e-17	Bipolar disorder;
BRCA	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg24060327	chr5:131705240	SLC22A5	-0.52	-8.97	-0.33	3.33e-18	Breast cancer;
BRCA	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg24596788	chr1:163392923	NA	-0.32	-8.44	-0.32	2.09e-16	Motion sickness;
BRCA	cis	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-10.84	-0.39	2.87e-25	Endometrial cancer;
BRCA	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg06212747	chr3:49208901	KLHDC8B	0.48	9.72	0.36	6.64e-21	Parkinson's disease;
BRCA	cis	rs60843830	0.550	rs300751	chr2:209063	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.42	8.39	0.31	3.21e-16	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08219700	chr8:58056026	NA	0.45	8.38	0.31	3.42e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1018836	0.886	rs10956750	chr8:91621704	G/C	cg16814680	chr8:91681699	NA	-0.6	-12.87	-0.45	7.48e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.34e-24	Motion sickness;
BRCA	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg08470875	chr2:26401718	FAM59B	-0.47	-7.9	-0.3	1.25e-14	Gut microbiome composition (summer);
BRCA	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg15212455	chr7:39170539	POU6F2	0.38	8.67	0.32	3.62e-17	IgG glycosylation;
BRCA	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg27170947	chr2:26402098	FAM59B	-0.81	-13.07	-0.46	9.42e-35	Gut microbiome composition (summer);
BRCA	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.9	0.33	5.62e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.36e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9394841	0.692	rs9381095	chr6:41806708	T/A	cg08135965	chr6:41755394	TOMM6	0.47	7.82	0.3	2.15e-14	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	trans	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.36	-8.06	-0.3	3.8e-15	Endometrial cancer;
BRCA	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.15	-0.31	1.9e-15	Depression;
BRCA	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05025164	chr4:1340916	KIAA1530	0.6	12.24	0.44	4.16e-31	Longevity;
BRCA	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg01262667	chr19:19385393	TM6SF2	0.4	10.38	0.38	1.92e-23	Tonsillectomy;
BRCA	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs7631605	0.905	rs7651033	chr3:37116042	A/G	cg15934958	chr3:37212084	LRRFIP2	-0.45	-10.47	-0.38	8.68e-24	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg10224037	chr5:178157518	ZNF354A	0.76	16.24	0.54	6.3e-50	Neutrophil percentage of white cells;
BRCA	trans	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	10.6	0.39	2.8e-24	Type 2 diabetes;
BRCA	cis	rs12541635	0.966	rs6469031	chr8:107048095	T/C	cg10147462	chr8:107024639	NA	0.37	9.62	0.36	1.52e-20	Age of smoking initiation;
BRCA	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg04374321	chr14:90722782	PSMC1	0.73	19.16	0.6	5.44e-65	Mortality in heart failure;
BRCA	cis	rs7766436	0.885	rs13210010	chr6:22585075	C/T	cg13666174	chr6:22585274	NA	-0.49	-11.63	-0.42	1.65e-28	Coronary artery disease;
BRCA	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.33	10.51	0.38	6.22e-24	Bipolar disorder;
BRCA	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg10978503	chr1:24200527	CNR2	-0.45	-10.3	-0.38	3.98e-23	Immature fraction of reticulocytes;
BRCA	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg22491629	chr6:157744540	C6orf35	-0.65	-11.65	-0.42	1.44e-28	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg11578532	chr1:161008127	TSTD1	0.25	7.97	0.3	7.38e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg20469991	chr17:27169893	C17orf63	-0.45	-8.88	-0.33	6.75e-18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs17401966	0.838	rs61775887	chr1:10284733	T/C	cg03954927	chr1:10346856	KIF1B	0.43	13.65	0.48	2.12e-37	Hepatocellular carcinoma;
BRCA	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.89	-0.58	2.44e-58	Chronic sinus infection;
BRCA	cis	rs9880211	0.948	rs9820621	chr3:136110513	G/A	cg21827317	chr3:136751795	NA	-0.46	-8.04	-0.3	4.51e-15	Body mass index;Height;
BRCA	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg20908204	chr19:46285434	DMPK	0.27	8.02	0.3	4.92e-15	Coronary artery disease;
BRCA	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg24069376	chr3:38537580	EXOG	0.34	9.45	0.35	6.48e-20	Electrocardiographic conduction measures;
BRCA	cis	rs4363385	0.510	rs12083211	chr1:153032131	A/T	cg25856811	chr1:152973957	SPRR3	0.32	8.01	0.3	5.35e-15	Inflammatory skin disease;
BRCA	cis	rs208520	1.000	rs208527	chr6:66957209	A/C	cg07460842	chr6:66804631	NA	-0.86	-14.32	-0.49	1.47e-40	Exhaled nitric oxide output;
BRCA	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.74	10.05	0.37	3.71e-22	Initial pursuit acceleration;
BRCA	cis	rs2835872	0.758	rs1787399	chr21:39037883	A/G	cg06728970	chr21:39037746	KCNJ6	0.45	12.77	0.45	2.03e-33	Electroencephalographic traits in alcoholism;
BRCA	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-12.92	-0.45	4.51e-34	Lymphocyte counts;
BRCA	cis	rs76419734	0.510	rs2553446	chr4:106696476	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.43	-9.34	-0.35	1.56e-19	Post bronchodilator FEV1;
BRCA	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg09184832	chr6:79620586	NA	-0.43	-8.43	-0.32	2.29e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7809950	1.000	rs4727681	chr7:107096144	T/C	cg23024343	chr7:107201750	COG5	-0.41	-9.44	-0.35	6.8e-20	Coronary artery disease;
BRCA	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg18252515	chr7:66147081	NA	0.8	11.78	0.42	3.85e-29	Diabetic kidney disease;
BRCA	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg08508325	chr11:3079039	CARS	0.26	7.88	0.3	1.39e-14	Calcium levels;
BRCA	cis	rs4474465	1.000	rs10899514	chr11:78172695	A/G	cg27205649	chr11:78285834	NARS2	-0.29	-8.82	-0.33	1.12e-17	Alzheimer's disease (survival time);
BRCA	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg18904891	chr8:8559673	CLDN23	-0.65	-13.52	-0.47	8.42e-37	Obesity-related traits;
BRCA	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg13047869	chr3:10149882	C3orf24	0.53	11.24	0.41	6.83e-27	Alzheimer's disease;
BRCA	cis	rs1003719	0.742	rs8129231	chr21:38501034	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.24	-0.49	3.73e-40	Eye color traits;
BRCA	cis	rs78456975	0.739	rs28913003	chr2:1519620	A/T	cg12573674	chr2:1569213	NA	-0.48	-9.48	-0.35	4.9e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg23711669	chr6:146136114	FBXO30	0.68	15.41	0.52	8.51e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.43	-0.44	6.2e-32	Chronic sinus infection;
BRCA	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg24848339	chr3:12840334	CAND2	0.49	13.19	0.46	2.72e-35	QRS complex (12-leadsum);
BRCA	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.2	0.37	1.01e-22	Aortic root size;
BRCA	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg11814155	chr7:99998594	ZCWPW1	-0.45	-8.08	-0.3	3.2e-15	Platelet count;
BRCA	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg22903471	chr2:27725779	GCKR	-0.34	-8.22	-0.31	1.15e-15	Total body bone mineral density;
BRCA	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg05283184	chr6:79620031	NA	-0.44	-11.15	-0.4	1.62e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs12911832	1.000	rs12911832	chr15:58985904	A/T	cg05156742	chr15:59063176	FAM63B	0.49	9.79	0.36	3.51e-21	Schizophrenia;
BRCA	cis	rs8010715	1.000	rs8010715	chr14:24609147	T/C	cg23112188	chr14:24563095	PCK2	-0.36	-8.83	-0.33	1e-17	IgG glycosylation;
BRCA	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg11161846	chr1:160990452	F11R	-0.45	-11.04	-0.4	4.71e-26	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg18357645	chr12:58087776	OS9	0.48	14.32	0.49	1.46e-40	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-10.86	-0.39	2.44e-25	IgG glycosylation;
BRCA	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg11366901	chr6:160182831	ACAT2	0.69	13.55	0.47	5.73e-37	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.55	17.83	0.58	4.99e-58	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg22676075	chr6:135203613	NA	0.45	8.74	0.33	2.05e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg05340658	chr4:99064831	C4orf37	0.69	17.37	0.57	1.25e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10992471	0.528	rs10761158	chr9:95205322	T/G	cg14631576	chr9:95140430	CENPP	-0.35	-8.63	-0.32	4.75e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs7766436	0.727	rs2066339	chr6:22610612	T/C	cg13666174	chr6:22585274	NA	-0.36	-9.25	-0.34	3.33e-19	Coronary artery disease;
BRCA	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24110177	chr3:50126178	RBM5	0.41	11.35	0.41	2.5e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24531977	chr5:56204891	C5orf35	-0.71	-15.57	-0.52	1.41e-46	Initial pursuit acceleration;
BRCA	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg04586622	chr2:25135609	ADCY3	0.44	11.62	0.42	1.83e-28	Body mass index in non-asthmatics;
BRCA	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-10.44	-0.38	1.2e-23	Pancreatic cancer;
BRCA	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg03060546	chr3:49711283	APEH	-0.56	-8.51	-0.32	1.27e-16	Menarche (age at onset);
BRCA	cis	rs4561483	0.624	rs2215928	chr16:11927918	A/T	cg08843971	chr16:11963173	GSPT1	-0.41	-8.86	-0.33	7.61e-18	Testicular germ cell tumor;
BRCA	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-9.87	-0.36	1.74e-21	Daytime sleep phenotypes;
BRCA	cis	rs1997103	0.911	rs6945663	chr7:55407011	C/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9831754	0.704	rs9882111	chr3:78470746	A/G	cg06138941	chr3:78371609	NA	-0.61	-12.92	-0.46	4.17e-34	Calcium levels;
BRCA	cis	rs593982	0.920	rs563427	chr11:65484569	A/G	cg08755490	chr11:65554678	OVOL1	1.18	17.25	0.56	4.81e-55	Atopic dermatitis;
BRCA	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg23533926	chr12:111358616	MYL2	-0.42	-8.72	-0.33	2.32e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00166722	chr3:10149974	C3orf24	0.64	12.62	0.45	9.76e-33	Alzheimer's disease;
BRCA	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	17.42	0.57	6.31e-56	Smoking behavior;
BRCA	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07080220	chr10:102295463	HIF1AN	0.51	11.37	0.41	2.17e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg04362960	chr10:104952993	NT5C2	0.37	8.76	0.33	1.69e-17	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs738322	0.804	rs4821743	chr22:38514906	A/G	cg20207973	chr22:38506712	BAIAP2L2	0.39	9.82	0.36	2.79e-21	Cutaneous nevi;
BRCA	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg01262667	chr19:19385393	TM6SF2	0.42	10.88	0.4	2.08e-25	Tonsillectomy;
BRCA	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.52	-9.94	-0.37	9.72e-22	Response to bleomycin (chromatid breaks);
BRCA	cis	rs17095355	0.901	rs12572168	chr10:111764786	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.47	-10.41	-0.38	1.53e-23	Biliary atresia;
BRCA	cis	rs2279817	1.000	rs1339801	chr1:18020298	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.54	16.21	0.54	8.9e-50	Neuroticism;
BRCA	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.55	-12.19	-0.43	6.82e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs8028182	0.636	rs7163907	chr15:75845097	T/C	cg20655648	chr15:75932815	IMP3	0.43	8.3	0.31	5.99e-16	Sudden cardiac arrest;
BRCA	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg08085267	chr17:45401833	C17orf57	0.61	12.47	0.44	4.32e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg21659725	chr3:3221576	CRBN	0.52	9.83	0.36	2.53e-21	Menarche (age at onset);
BRCA	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg14349672	chr11:133703707	NA	0.41	9.19	0.34	5.49e-19	Childhood ear infection;
BRCA	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg11764359	chr7:65958608	NA	0.67	14.83	0.51	5.66e-43	Aortic root size;
BRCA	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg15448220	chr1:150897856	SETDB1	0.35	7.9	0.3	1.26e-14	Melanoma;
BRCA	cis	rs7617773	0.780	rs13079728	chr3:48339360	A/G	cg11946769	chr3:48343235	NME6	0.69	14.08	0.49	2.16e-39	Coronary artery disease;
BRCA	cis	rs12200560	0.505	rs9400166	chr6:97077101	G/A	cg06623918	chr6:96969491	KIAA0776	0.53	12.7	0.45	4.04e-33	Coronary heart disease;
BRCA	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg01304814	chr3:48885189	PRKAR2A	0.57	7.91	0.3	1.11e-14	Cognitive function;
BRCA	cis	rs7607369	0.559	rs13002060	chr2:219660394	G/T	cg02176678	chr2:219576539	TTLL4	-0.39	-10.35	-0.38	2.52e-23	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27286337	chr10:134555280	INPP5A	0.65	11.42	0.41	1.26e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg16049864	chr8:95962084	TP53INP1	0.44	10.67	0.39	1.39e-24	Type 2 diabetes;
BRCA	cis	rs3772130	0.962	rs9839617	chr3:121516577	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.79	0.39	4.91e-25	Cognitive performance;
BRCA	cis	rs7577696	0.554	rs34835885	chr2:32325414	G/A	cg02381751	chr2:32503542	YIPF4	-0.48	-8.82	-0.33	1.1e-17	Inflammatory biomarkers;
BRCA	cis	rs4679121	0.642	rs76826102	chr3:126185964	C/T	cg05485589	chr3:126194908	ZXDC	-0.76	-8.2	-0.31	1.32e-15	Pursuit maintenance gain;
BRCA	cis	rs6745190	0.512	rs13026070	chr2:181991422	C/A	cg00481216	chr2:181971175	NA	0.47	8.91	0.33	5.29e-18	White blood cell count;
BRCA	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-8.94	-0.33	4.17e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	10.31	0.38	3.74e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2882667	0.756	rs11957953	chr5:138479377	G/T	cg04439458	chr5:138467593	SIL1	-0.46	-11.44	-0.41	1.02e-27	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg05347473	chr6:146136440	FBXO30	0.4	7.86	0.3	1.68e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg18132916	chr6:79620363	NA	-0.48	-10.91	-0.4	1.59e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg26384229	chr12:38710491	ALG10B	0.67	14.35	0.49	1.15e-40	Morning vs. evening chronotype;
BRCA	trans	rs4650994	0.544	rs2476560	chr1:178594919	A/G	cg05059571	chr16:84539110	KIAA1609	0.57	12.4	0.44	8.57e-32	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs7927771	0.542	rs7108479	chr11:47781460	G/T	cg20307385	chr11:47447363	PSMC3	0.42	9.52	0.35	3.43e-20	Subjective well-being;
BRCA	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.14	0.31	2.05e-15	Total cholesterol levels;
BRCA	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg16325326	chr1:53192061	ZYG11B	0.57	12.74	0.45	2.7e-33	Monocyte count;
BRCA	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg11663144	chr21:46675770	NA	-0.49	-9.84	-0.36	2.33e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs13315871	0.790	rs13071148	chr3:58310838	A/C	cg20936604	chr3:58311152	NA	-0.64	-8.25	-0.31	9.38e-16	Cholesterol, total;
BRCA	cis	rs7809950	0.678	rs2237665	chr7:106906998	T/C	cg23024343	chr7:107201750	COG5	-0.46	-9.05	-0.34	1.67e-18	Coronary artery disease;
BRCA	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg08738300	chr3:44038990	NA	0.44	8.56	0.32	8.69e-17	Coronary artery disease;
BRCA	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg04455712	chr21:45112962	RRP1B	0.4	10.47	0.38	9.08e-24	Mean corpuscular volume;
BRCA	trans	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg21775007	chr8:11205619	TDH	0.43	8.77	0.33	1.56e-17	Mood instability;
BRCA	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg04517722	chr19:17905589	B3GNT3	0.42	8.33	0.31	4.98e-16	Tumor biomarkers;
BRCA	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg10223061	chr2:219282414	VIL1	-0.28	-8.19	-0.31	1.43e-15	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs8073060	0.586	rs8077826	chr17:34001139	G/A	cg19694781	chr19:47549865	TMEM160	-1.04	-21.53	-0.65	9.91e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	19.51	0.61	7.34e-67	Smoking behavior;
BRCA	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg18154014	chr19:37997991	ZNF793	0.48	9.41	0.35	8.49e-20	Coronary artery calcification;
BRCA	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg18270830	chr10:32634957	EPC1	-0.5	-8.81	-0.33	1.21e-17	Sexual dysfunction (female);
BRCA	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg22638593	chr5:131593259	PDLIM4	0.35	8.86	0.33	7.84e-18	Acylcarnitine levels;
BRCA	trans	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.13	0.31	2.19e-15	Corneal astigmatism;
BRCA	trans	rs9944715	0.954	rs4890319	chr18:43812644	T/A	cg01718231	chr17:29326311	RNF135	-0.46	-9.07	-0.34	1.5e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs919433	0.680	rs2564383	chr2:198310862	A/G	cg00792783	chr2:198669748	PLCL1	0.39	8.77	0.33	1.56e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg16482183	chr6:26056742	HIST1H1C	0.53	11.49	0.41	6.29e-28	Height;
BRCA	cis	rs1882538	0.551	rs6974618	chr7:133084031	C/A	cg10665199	chr7:133106180	EXOC4	0.43	9.35	0.35	1.49e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg19183879	chr15:85880815	NA	-0.32	-7.81	-0.3	2.3e-14	Coronary artery disease;
BRCA	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg19508488	chr2:152266495	RIF1	-0.38	-8.25	-0.31	8.94e-16	Lung cancer;
BRCA	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg23711669	chr6:146136114	FBXO30	-0.71	-16.77	-0.55	1.44e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-18.5	-0.59	1.6e-61	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg03146154	chr1:46216737	IPP	0.54	12.03	0.43	3.34e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg05791153	chr7:19748676	TWISTNB	-0.66	-11.76	-0.42	4.99e-29	Thyroid stimulating hormone;
BRCA	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg00677455	chr12:58241039	CTDSP2	0.73	17.73	0.57	1.61e-57	Multiple sclerosis;
BRCA	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg17063962	chr7:91808500	NA	0.53	12.4	0.44	8.6e-32	Breast cancer;
BRCA	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.35	-0.41	2.59e-27	Colorectal cancer;
BRCA	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-12.64	-0.45	7.89e-33	Bipolar disorder;
BRCA	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.56	-0.52	1.55e-46	Chronic sinus infection;
BRCA	trans	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg18876405	chr7:65276391	NA	0.43	8.39	0.32	3.04e-16	Corneal structure;
BRCA	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	10.54	0.38	4.59e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05901451	chr6:126070800	HEY2	-0.44	-10.83	-0.39	3.18e-25	Migraine;
BRCA	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg03188948	chr7:1209495	NA	0.49	10.09	0.37	2.69e-22	Longevity;Endometriosis;
BRCA	cis	rs7766436	0.848	rs11759474	chr6:22580980	G/T	cg13666174	chr6:22585274	NA	-0.43	-9.27	-0.34	2.82e-19	Coronary artery disease;
BRCA	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg14440974	chr22:39074834	NA	0.39	9.2	0.34	5.18e-19	Menopause (age at onset);
BRCA	cis	rs838147	0.537	rs503279	chr19:49209010	C/T	cg07051648	chr19:49177693	NTN5;SEC1	0.42	7.96	0.3	8.03e-15	Dietary macronutrient intake;
BRCA	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg25930673	chr12:123319894	HIP1R	-0.53	-8.19	-0.31	1.41e-15	Schizophrenia;
BRCA	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg17366294	chr4:99064904	C4orf37	0.43	10.0	0.37	5.7e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg25358565	chr5:93447407	FAM172A	-0.48	-8.62	-0.32	5.37e-17	Diabetic retinopathy;
BRCA	cis	rs2016266	1.000	rs2016266	chr12:53727955	A/G	cg26875137	chr12:53738046	NA	-0.38	-10.05	-0.37	3.54e-22	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg19539972	chr4:7069911	GRPEL1	-0.63	-12.31	-0.44	2.18e-31	Monocyte percentage of white cells;
BRCA	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg08885076	chr2:99613938	TSGA10	0.44	10.37	0.38	2.09e-23	Chronic sinus infection;
BRCA	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg21045802	chr8:109455806	TTC35	0.39	9.09	0.34	1.27e-18	Dupuytren's disease;
BRCA	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg11502198	chr6:26597334	ABT1	0.48	9.62	0.36	1.45e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg01689657	chr7:91764605	CYP51A1	0.22	8.15	0.31	1.88e-15	Breast cancer;
BRCA	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg15017067	chr4:17643749	FAM184B	0.32	9.82	0.36	2.75e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg00981070	chr1:2046702	PRKCZ	0.31	8.21	0.31	1.24e-15	Height;
BRCA	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg13628971	chr7:2884303	GNA12	0.42	9.32	0.35	1.81e-19	Height;
BRCA	cis	rs73001065	0.636	rs73002960	chr19:19582992	C/T	cg03709012	chr19:19516395	GATAD2A	1.02	14.02	0.49	3.86e-39	LDL cholesterol;
BRCA	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg02297831	chr4:17616191	MED28	-0.35	-8.17	-0.31	1.61e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg24069376	chr3:38537580	EXOG	-0.31	-8.96	-0.33	3.44e-18	Electrocardiographic conduction measures;
BRCA	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg20908204	chr19:46285434	DMPK	-0.28	-8.31	-0.31	5.57e-16	Coronary artery disease;
BRCA	cis	rs12612619	0.579	rs6753540	chr2:27080134	G/A	cg12368169	chr2:27073192	DPYSL5	-0.34	-10.19	-0.37	1.1e-22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg01802117	chr1:53393560	SCP2	0.41	8.55	0.32	8.96e-17	Monocyte count;
BRCA	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12016809	chr21:47604291	C21orf56	-0.39	-7.83	-0.3	2.11e-14	Testicular germ cell tumor;
BRCA	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg00757033	chr12:89920650	WDR51B	0.48	9.83	0.36	2.59e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs919433	0.679	rs6757669	chr2:198530355	C/T	cg00792783	chr2:198669748	PLCL1	0.39	9.01	0.34	2.27e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	11.71	0.42	7.58e-29	Personality dimensions;
BRCA	trans	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.58	-0.32	7e-17	Neuroticism;
BRCA	cis	rs7520050	0.897	rs4440807	chr1:46470878	T/C	cg24296786	chr1:45957014	TESK2	0.44	9.84	0.36	2.31e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7715806	0.500	rs2307115	chr5:74990348	T/C	cg19683494	chr5:74908142	NA	0.53	8.53	0.32	1.07e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg27478167	chr7:817139	HEATR2	0.53	10.5	0.38	6.57e-24	Cerebrospinal P-tau181p levels;
BRCA	trans	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-8.79	-0.33	1.42e-17	Retinal vascular caliber;
BRCA	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	8.62	0.32	5.07e-17	Educational attainment;
BRCA	cis	rs7677751	0.767	rs7676985	chr4:55064573	G/A	cg17187183	chr4:55093834	PDGFRA	0.4	7.99	0.3	6.28e-15	Corneal astigmatism;
BRCA	cis	rs6686889	1	rs6686889	chr1:25030470	C/T	cg01905478	chr1:25040257	NA	0.39	9.01	0.34	2.37e-18	Diastolic blood pressure;
BRCA	trans	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg21659725	chr3:3221576	CRBN	-0.47	-9.99	-0.37	6.33e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs829883	0.659	rs10860342	chr12:98941223	C/T	cg25150519	chr12:98850993	NA	0.5	9.04	0.34	1.78e-18	Colorectal adenoma (advanced);
BRCA	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03517284	chr6:25882590	NA	-0.51	-11.54	-0.42	4.09e-28	Blood metabolite levels;
BRCA	cis	rs965469	0.779	rs6037544	chr20:3290570	A/G	cg25506879	chr20:3388711	C20orf194	-0.43	-8.62	-0.32	5.47e-17	IFN-related cytopenia;
BRCA	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.66	12.12	0.43	1.36e-30	Alzheimer's disease;
BRCA	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.51	11.29	0.41	4.25e-27	Colorectal cancer;
BRCA	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21659725	chr3:3221576	CRBN	0.49	10.92	0.4	1.46e-25	Resting heart rate;
BRCA	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.3	7.98	0.3	6.96e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6854137	0.904	rs13124822	chr4:169737712	G/A	cg20607169	chr4:169750834	PALLD	0.35	8.03	0.3	4.66e-15	Vein graft stenosis in coronary artery bypass grafting;
BRCA	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg11663144	chr21:46675770	NA	-0.56	-12.64	-0.45	7.62e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg14863265	chr7:2801509	GNA12	-0.42	-9.68	-0.36	8.81e-21	Height;
BRCA	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.52	-11.26	-0.41	5.99e-27	IgG glycosylation;
BRCA	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg01324343	chr3:183735012	ABCC5	0.83	20.62	0.63	8.06e-73	Anterior chamber depth;
BRCA	cis	rs4363385	0.818	rs572821	chr1:153008276	G/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg10729496	chr3:10149963	C3orf24	0.48	8.98	0.33	3e-18	Alzheimer's disease;
BRCA	cis	rs36051895	0.659	rs58345215	chr9:5043767	A/T	cg02405213	chr9:5042618	JAK2	-0.51	-9.12	-0.34	9.89e-19	Pediatric autoimmune diseases;
BRCA	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg15017067	chr4:17643749	FAM184B	0.34	10.54	0.38	4.58e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-11.34	-0.41	2.76e-27	Gut microbiome composition (summer);
BRCA	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg11764359	chr7:65958608	NA	-0.77	-17.98	-0.58	8.38e-59	Aortic root size;
BRCA	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg23750338	chr8:142222470	SLC45A4	0.4	9.72	0.36	6.16e-21	Immature fraction of reticulocytes;
BRCA	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg12444411	chr7:2802554	GNA12	-0.35	-8.82	-0.33	1.07e-17	Height;
BRCA	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg22713356	chr15:30763199	NA	1.38	27.92	0.74	9.42e-113	Uric acid levels;
BRCA	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg10862848	chr6:42927986	GNMT	-0.35	-14.85	-0.51	4.73e-43	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	8.96	0.33	3.58e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg17063962	chr7:91808500	NA	0.54	12.39	0.44	9.73e-32	Breast cancer;
BRCA	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg19678392	chr7:94953810	PON1	0.4	8.22	0.31	1.15e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs3849570	1.000	rs2290081	chr3:81810725	C/T	cg07356753	chr3:81810745	GBE1	-0.47	-11.41	-0.41	1.37e-27	Waist circumference;Body mass index;
BRCA	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.46	-10.98	-0.4	7.88e-26	IgG glycosylation;
BRCA	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg04756594	chr16:24857601	SLC5A11	0.48	10.08	0.37	2.94e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7607369	0.559	rs4674342	chr2:219660064	T/C	cg02176678	chr2:219576539	TTLL4	-0.39	-10.33	-0.38	3.04e-23	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs4664304	0.620	rs3951216	chr2:160711045	G/C	cg14819504	chr2:160761413	LY75	0.32	7.94	0.3	9.35e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs68170813	0.559	rs6949961	chr7:106850755	G/T	cg02696742	chr7:106810147	HBP1	0.5	8.22	0.31	1.12e-15	Coronary artery disease;
BRCA	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg07636037	chr3:49044803	WDR6	0.97	28.85	0.75	8.29e-118	Parkinson's disease;
BRCA	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg04362960	chr10:104952993	NT5C2	0.43	10.39	0.38	1.88e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg08645402	chr16:4508243	NA	0.4	9.06	0.34	1.52e-18	Schizophrenia;
BRCA	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.62	0.42	1.95e-28	Tonsillectomy;
BRCA	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg03709012	chr19:19516395	GATAD2A	0.73	16.16	0.54	1.74e-49	Tonsillectomy;
BRCA	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.86e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg25358565	chr5:93447407	FAM172A	1.15	18.07	0.58	2.94e-59	Diabetic retinopathy;
BRCA	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg03711944	chr11:47377212	SPI1	-0.44	-10.23	-0.38	7.49e-23	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs12464559	0.522	rs7583148	chr2:152620986	C/T	cg01189475	chr2:152685088	ARL5A	0.61	9.3	0.35	2.12e-19	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg13628971	chr7:2884303	GNA12	-0.59	-12.88	-0.45	6.2e-34	Height;
BRCA	cis	rs12545109	0.837	rs6474063	chr8:57355545	C/T	cg09654669	chr8:57350985	NA	-0.42	-7.95	-0.3	8.65e-15	Obesity-related traits;
BRCA	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg20628663	chr10:43360327	NA	-0.67	-13.25	-0.46	1.39e-35	Blood protein levels;
BRCA	trans	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg06521331	chr12:34319734	NA	-0.54	-9.6	-0.36	1.77e-20	Bladder cancer;
BRCA	trans	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.53	-0.32	1.1e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg05623727	chr3:50126028	RBM5	0.44	9.09	0.34	1.24e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg08807101	chr21:30365312	RNF160	-0.61	-15.64	-0.53	6.71e-47	Dental caries;
BRCA	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.97	-0.33	3.32e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.13	0.31	2.24e-15	Corneal astigmatism;
BRCA	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.69	14.53	0.5	1.52e-41	Lymphocyte counts;
BRCA	trans	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.82	-0.3	2.11e-14	Corneal astigmatism;
BRCA	cis	rs897984	0.762	rs8062719	chr16:31002664	A/G	cg02466173	chr16:30829666	NA	0.45	9.79	0.36	3.64e-21	Dementia with Lewy bodies;
BRCA	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg01420254	chr6:26195488	NA	0.57	7.89	0.3	1.3e-14	Gout;Renal underexcretion gout;
BRCA	cis	rs10465746	0.967	rs11163868	chr1:84397013	T/G	cg10977910	chr1:84465055	TTLL7	0.49	9.8	0.36	3.11e-21	Obesity-related traits;
BRCA	cis	rs6750047	0.868	rs1431332	chr2:38280253	G/A	cg07380506	chr2:38303506	CYP1B1	0.43	9.91	0.37	1.21e-21	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	12.27	0.44	3.21e-31	Mean platelet volume;
BRCA	cis	rs6450176	0.638	rs16881969	chr5:53300748	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.83	16.54	0.55	2.07e-51	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg01262667	chr19:19385393	TM6SF2	0.38	8.18	0.31	1.52e-15	Nonalcoholic fatty liver disease;
BRCA	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg20891283	chr12:69753455	YEATS4	0.56	13.76	0.48	6.62e-38	Blood protein levels;
BRCA	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg19717773	chr7:2847554	GNA12	-0.41	-8.94	-0.33	4.11e-18	Height;
BRCA	cis	rs1003719	0.725	rs2187101	chr21:38452379	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.25	0.49	3.25e-40	Eye color traits;
BRCA	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg22875332	chr1:76189707	ACADM	0.66	11.96	0.43	6.74e-30	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg13944838	chr5:179740914	GFPT2	-0.67	-13.97	-0.48	7.1e-39	Height;
BRCA	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	10.01	0.37	5.17e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11644478	chr21:40555479	PSMG1	-0.65	-13.71	-0.48	1.04e-37	Cognitive function;
BRCA	cis	rs7766436	0.614	rs16886454	chr6:22562975	T/A	cg13666174	chr6:22585274	NA	-0.41	-8.63	-0.32	4.72e-17	Coronary artery disease;
BRCA	cis	rs36051895	0.589	rs7874785	chr9:5196695	C/T	cg02405213	chr9:5042618	JAK2	0.46	8.79	0.33	1.36e-17	Pediatric autoimmune diseases;
BRCA	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg27572855	chr1:25598939	RHD	0.48	13.54	0.47	6.98e-37	Erythrocyte sedimentation rate;
BRCA	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18876405	chr7:65276391	NA	-0.51	-11.48	-0.41	7.06e-28	Aortic root size;
BRCA	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg23422044	chr7:1970798	MAD1L1	0.59	10.99	0.4	7.7e-26	Bipolar disorder;
BRCA	cis	rs6763687	0.637	rs937511	chr3:171816001	A/C	cg16233210	chr3:171778391	FNDC3B	0.4	9.34	0.35	1.53e-19	Red cell distribution width;
BRCA	cis	rs6542838	0.641	rs4553869	chr2:99505940	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-9.06	-0.34	1.58e-18	Fear of minor pain;
BRCA	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg02466173	chr16:30829666	NA	0.49	11.12	0.4	2.31e-26	Dementia with Lewy bodies;
BRCA	trans	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg23762105	chr12:34175262	ALG10	0.35	7.86	0.3	1.66e-14	Morning vs. evening chronotype;
BRCA	cis	rs9473147	0.516	rs7749271	chr6:47485002	T/C	cg12968598	chr6:47444699	CD2AP	0.43	9.53	0.35	3.18e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg13256891	chr4:100009986	ADH5	0.54	10.01	0.37	5.06e-22	Smoking initiation;
BRCA	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg02659138	chr7:134003124	SLC35B4	0.34	10.65	0.39	1.74e-24	Mean platelet volume;
BRCA	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6545883	0.965	rs2305155	chr2:61729258	A/G	cg15711740	chr2:61764176	XPO1	-0.55	-14.04	-0.49	3.23e-39	Tuberculosis;
BRCA	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg09658497	chr7:2847517	GNA12	0.4	8.48	0.32	1.54e-16	Height;
BRCA	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.43	9.7	0.36	7.47e-21	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.63	0.36	1.43e-20	Menopause (age at onset);
BRCA	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg02659138	chr7:134003124	SLC35B4	0.33	10.38	0.38	1.95e-23	Mean platelet volume;
BRCA	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg14993813	chr1:46806288	NSUN4	-0.49	-9.61	-0.36	1.69e-20	Menopause (age at onset);
BRCA	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg04691961	chr3:161091175	C3orf57	-0.59	-14.28	-0.49	2.26e-40	Morning vs. evening chronotype;
BRCA	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg08807101	chr21:30365312	RNF160	-0.44	-9.36	-0.35	1.36e-19	Dental caries;
BRCA	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg08470875	chr2:26401718	FAM59B	-0.51	-8.17	-0.31	1.62e-15	Gut microbiome composition (summer);
BRCA	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg13010199	chr12:38710504	ALG10B	0.35	8.59	0.32	6.72e-17	Morning vs. evening chronotype;
BRCA	cis	rs12540874	0.522	rs4947641	chr7:50489038	C/T	cg18232548	chr7:50535776	DDC	-0.49	-12.59	-0.45	1.25e-32	Systemic sclerosis;
BRCA	cis	rs9463078	0.790	rs1324531	chr6:45136224	T/C	cg25276700	chr6:44698697	NA	-0.36	-8.17	-0.31	1.64e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg00277334	chr10:82204260	NA	0.4	8.06	0.3	3.86e-15	Post bronchodilator FEV1;
BRCA	cis	rs7587476	1.000	rs1542173	chr2:215657560	C/T	cg04004882	chr2:215674386	BARD1	-0.57	-10.47	-0.38	8.76e-24	Neuroblastoma;
BRCA	cis	rs877529	0.683	rs139379	chr22:39525791	A/T	cg12193277	chr22:39547181	CBX7	-0.4	-10.62	-0.39	2.18e-24	Multiple myeloma;
BRCA	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg00106254	chr7:1943704	MAD1L1	-0.45	-11.91	-0.43	1.17e-29	Bipolar disorder and schizophrenia;
BRCA	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg11366901	chr6:160182831	ACAT2	0.68	13.59	0.47	3.9e-37	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs870825	0.616	rs28620459	chr4:185627132	G/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	7.93e-19	Lymphocyte counts;
BRCA	cis	rs939658	0.728	rs12904789	chr15:79412589	G/A	cg17916960	chr15:79447300	NA	-0.42	-9.82	-0.36	2.78e-21	Refractive error;
BRCA	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg12826209	chr6:26865740	GUSBL1	0.69	9.88	0.36	1.63e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7149337	0.836	rs35345236	chr14:51671817	T/C	cg23942311	chr14:51606299	NA	0.42	12.01	0.43	4.05e-30	Cancer;
BRCA	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.81	0.39	3.9e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg25326776	chr5:148520934	ABLIM3	-0.42	-7.81	-0.3	2.39e-14	Breast cancer;
BRCA	cis	rs4363385	0.747	rs1611760	chr1:152957573	T/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.31	-0.31	5.96e-16	Inflammatory skin disease;
BRCA	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg20587970	chr11:113659929	NA	-1.24	-22.67	-0.67	5.77e-84	Hip circumference adjusted for BMI;
BRCA	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg09184832	chr6:79620586	NA	-0.48	-10.52	-0.38	5.72e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.23	0.31	1.06e-15	Tonsillectomy;
BRCA	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg24675658	chr1:53192096	ZYG11B	0.66	14.44	0.5	3.96e-41	Monocyte count;
BRCA	cis	rs7715811	1.000	rs10039621	chr5:13772457	C/T	cg07548982	chr5:13769939	DNAH5	-0.36	-7.99	-0.3	6.33e-15	Subclinical atherosclerosis traits (other);
BRCA	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.93	-0.3	9.9e-15	Bipolar disorder;
BRCA	cis	rs243505	0.964	rs243509	chr7:148433634	G/A	cg09806900	chr7:148480153	CUL1	-0.4	-8.36	-0.31	3.88e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.66	-0.32	3.85e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg26384229	chr12:38710491	ALG10B	0.66	14.29	0.49	2.01e-40	Morning vs. evening chronotype;
BRCA	cis	rs27434	0.607	rs34753	chr5:96150911	C/T	cg16492584	chr5:96139282	ERAP1	-0.5	-12.71	-0.45	3.7e-33	Ankylosing spondylitis;
BRCA	trans	rs1997103	1.000	rs2877284	chr7:55408778	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg14186256	chr22:23484241	RTDR1	0.75	21.86	0.65	1.61e-79	Bone mineral density;
BRCA	cis	rs12617721	0.718	rs1857746	chr2:99017358	A/G	cg10123293	chr2:99228465	UNC50	0.49	8.94	0.33	4.21e-18	Bipolar disorder with mood-incongruent psychosis;
BRCA	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg03929089	chr4:120376271	NA	0.61	10.56	0.39	3.97e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg01528321	chr10:82214614	TSPAN14	0.67	14.16	0.49	9.13e-40	Post bronchodilator FEV1;
BRCA	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg04166393	chr7:2884313	GNA12	-0.4	-8.66	-0.32	3.86e-17	Height;
BRCA	cis	rs6700896	0.931	rs2889195	chr1:66156730	C/T	cg04111102	chr1:66153794	NA	0.37	9.2	0.34	5e-19	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg24692254	chr21:30365293	RNF160	0.45	10.13	0.37	1.87e-22	Pancreatic cancer;
BRCA	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg16586182	chr3:47516702	SCAP	0.44	8.9	0.33	5.67e-18	Birth weight;
BRCA	cis	rs13315871	0.929	rs11715290	chr3:58298413	C/T	cg20936604	chr3:58311152	NA	-0.65	-8.28	-0.31	7.46e-16	Cholesterol, total;
BRCA	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg17063962	chr7:91808500	NA	-0.52	-12.22	-0.44	5.29e-31	Breast cancer;
BRCA	cis	rs16958440	1.000	rs60422392	chr18:44621473	T/C	cg17192377	chr18:44677553	HDHD2	0.67	9.75	0.36	4.96e-21	Sitting height ratio;
BRCA	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12667521	chr19:29218732	NA	0.41	8.17	0.31	1.6e-15	Methadone dose in opioid dependence;
BRCA	cis	rs926392	0.572	rs6129156	chr20:37672209	A/C	cg16355469	chr20:37678765	NA	0.46	10.43	0.38	1.28e-23	Dialysis-related mortality;
BRCA	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg16950941	chr11:66035639	RAB1B	0.44	12.29	0.44	2.53e-31	Gout;
BRCA	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00149659	chr3:10157352	C3orf10	-0.82	-14.34	-0.49	1.2e-40	Alzheimer's disease;
BRCA	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg19729930	chr2:74357872	NA	0.65	14.34	0.49	1.3e-40	Gestational age at birth (maternal effect);
BRCA	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg13628971	chr7:2884303	GNA12	0.39	8.78	0.33	1.55e-17	Height;
BRCA	cis	rs10736390	1.000	rs11206402	chr1:55104317	G/C	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.59	-14.18	-0.49	7.05e-40	Survival in pancreatic cancer;
BRCA	cis	rs10484885	0.824	rs28372875	chr6:90529343	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.77	-9.87	-0.36	1.7e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs78487399	0.908	rs74501107	chr2:43806012	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-7.97	-0.3	7.36e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg18357645	chr12:58087776	OS9	0.35	9.93	0.37	1e-21	Multiple sclerosis;
BRCA	cis	rs701145	0.938	rs242117	chr3:154026467	T/C	cg17054900	chr3:154042577	DHX36	0.68	11.88	0.43	1.56e-29	Coronary artery disease;
BRCA	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg01420254	chr6:26195488	NA	0.55	8.56	0.32	8.23e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg00677455	chr12:58241039	CTDSP2	-0.34	-7.87	-0.3	1.53e-14	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg11266682	chr4:10021025	SLC2A9	0.38	10.09	0.37	2.66e-22	Bone mineral density;
BRCA	cis	rs7903847	0.642	rs7092350	chr10:99140218	A/T	cg20016023	chr10:99160130	RRP12	-0.26	-8.5	-0.32	1.35e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg05340658	chr4:99064831	C4orf37	0.61	14.11	0.49	1.47e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg09307838	chr4:120376055	NA	0.66	13.33	0.47	6.13e-36	Corneal astigmatism;
BRCA	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg07080220	chr10:102295463	HIF1AN	0.55	12.76	0.45	2.14e-33	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10802521	chr3:52805072	NEK4	-0.29	-7.89	-0.3	1.27e-14	Bipolar disorder;
BRCA	trans	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.42	-8.31	-0.31	5.77e-16	Mean corpuscular volume;
BRCA	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11644478	chr21:40555479	PSMG1	0.76	15.66	0.53	4.79e-47	Cognitive function;
BRCA	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg12927641	chr6:109611667	NA	-0.42	-10.87	-0.39	2.35e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs1506636	1.000	rs644958	chr7:123400873	C/T	cg03229431	chr7:123269106	ASB15	0.61	13.65	0.48	2.16e-37	Plateletcrit;Platelet count;
BRCA	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg06713675	chr4:122721982	EXOSC9	-0.49	-11.74	-0.42	6.17e-29	Type 2 diabetes;
BRCA	cis	rs4988958	0.584	rs7559845	chr2:103046214	T/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.38	0.31	3.39e-16	Asthma (childhood onset);
BRCA	cis	rs6426558	0.524	rs2813948	chr1:227459621	A/T	cg10327440	chr1:227177885	CDC42BPA	0.48	9.58	0.35	2.09e-20	Neutrophil percentage of white cells;
BRCA	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg13010199	chr12:38710504	ALG10B	0.44	8.95	0.33	3.88e-18	Bladder cancer;
BRCA	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg04234412	chr22:24373322	LOC391322	-0.57	-14.17	-0.49	7.51e-40	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg07169764	chr2:136633963	MCM6	1.08	22.88	0.67	4.6e-85	Corneal structure;
BRCA	cis	rs12618769	0.625	rs72819970	chr2:99034554	C/G	cg10123293	chr2:99228465	UNC50	0.41	8.15	0.31	1.88e-15	Bipolar disorder;
BRCA	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg18904891	chr8:8559673	CLDN23	0.66	13.31	0.47	7.14e-36	Obesity-related traits;
BRCA	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08045932	chr20:61659980	NA	0.5	11.21	0.41	9.54e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6120849	0.754	rs6088682	chr20:33615702	A/C	cg24642439	chr20:33292090	TP53INP2	0.6	10.29	0.38	4.57e-23	Protein C levels;
BRCA	cis	rs8030485	0.756	rs1521624	chr15:79412399	C/A	cg17916960	chr15:79447300	NA	0.35	8.23	0.31	1.09e-15	Left ventricle wall thickness;
BRCA	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs72781680	1.000	rs72781654	chr2:24218099	T/C	cg08917208	chr2:24149416	ATAD2B	0.57	9.38	0.35	1.17e-19	Lymphocyte counts;
BRCA	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg19052272	chr2:3704530	ALLC	-0.45	-10.05	-0.37	3.56e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg09367891	chr1:107599246	PRMT6	-0.55	-10.15	-0.37	1.58e-22	Facial morphology (factor 21, depth of nasal alae);
BRCA	trans	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg21659725	chr3:3221576	CRBN	0.47	8.69	0.33	3e-17	Menarche (age at onset);
BRCA	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg03585969	chr10:35415529	CREM	0.56	11.55	0.42	3.74e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs730775	0.505	rs325004	chr6:44270365	C/G	cg21130236	chr6:44246755	TMEM151B	-0.29	-8.23	-0.31	1.02e-15	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs1865721	0.804	rs4510115	chr18:73209635	G/A	cg26385618	chr18:73139727	C18orf62	-0.35	-8.03	-0.3	4.81e-15	Intelligence;
BRCA	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg21138405	chr5:131827807	IRF1	0.39	12.9	0.45	5.51e-34	Asthma (sex interaction);
BRCA	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg25036284	chr2:26402008	FAM59B	-0.79	-12.35	-0.44	1.43e-31	Gut microbiome composition (summer);
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.68	-16.8	-0.55	9.94e-53	Longevity;Endometriosis;
BRCA	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	15.59	0.53	1.06e-46	Colorectal cancer;
BRCA	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-11.22	-0.41	8.42e-27	Gut microbiome composition (summer);
BRCA	cis	rs17620991	1.000	rs17688247	chr7:40832144	C/T	cg05119115	chr7:40866195	C7orf10	-0.57	-8.74	-0.33	2.12e-17	Alcohol dependence;
BRCA	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg09877947	chr5:131593287	PDLIM4	0.43	10.76	0.39	6.06e-25	Breast cancer;
BRCA	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	9.38	0.35	1.11e-19	Height;
BRCA	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg27129171	chr3:47204927	SETD2	0.72	17.54	0.57	1.61e-56	Colorectal cancer;
BRCA	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg01324343	chr3:183735012	ABCC5	0.83	20.95	0.64	1.44e-74	Anterior chamber depth;
BRCA	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.16	0.31	1.77e-15	Breast cancer;
BRCA	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs977987	0.872	rs1559339	chr16:75318646	A/G	cg03315344	chr16:75512273	CHST6	0.51	11.72	0.42	7.51e-29	Dupuytren's disease;
BRCA	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	10.94	0.4	1.23e-25	Mood instability;
BRCA	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.82	16.46	0.55	5.25e-51	HIV-1 control;
BRCA	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg08917208	chr2:24149416	ATAD2B	1.09	15.66	0.53	4.98e-47	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg07395648	chr5:131743802	NA	-0.39	-9.61	-0.36	1.69e-20	Blood metabolite levels;
BRCA	cis	rs727479	0.523	rs700518	chr15:51529112	C/T	cg19946085	chr15:51559439	CYP19A1	0.3	8.31	0.31	5.82e-16	Estradiol levels;
BRCA	cis	rs208520	1.000	rs208523	chr6:66954195	G/C	cg07460842	chr6:66804631	NA	-0.86	-14.32	-0.49	1.47e-40	Exhaled nitric oxide output;
BRCA	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	16.45	0.55	5.74e-51	Intelligence (multi-trait analysis);
BRCA	cis	rs9462846	0.959	rs7750915	chr6:42882067	C/T	cg05552183	chr6:42928497	GNMT	0.48	8.15	0.31	1.99e-15	Blood protein levels;
BRCA	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24531977	chr5:56204891	C5orf35	0.86	18.07	0.58	2.96e-59	Initial pursuit acceleration;
BRCA	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.53	0.5	1.53e-41	Motion sickness;
BRCA	cis	rs7617773	0.780	rs6782166	chr3:48351683	A/G	cg11946769	chr3:48343235	NME6	0.69	14.01	0.48	4.54e-39	Coronary artery disease;
BRCA	cis	rs312273	0.806	rs7955172	chr12:41356309	A/T	cg17827154	chr12:41323612	CNTN1	-0.42	-10.98	-0.4	8.04e-26	Bipolar disorder;
BRCA	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg21535247	chr6:8435926	SLC35B3	-0.37	-8.37	-0.31	3.54e-16	Motion sickness;
BRCA	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	13.5	0.47	9.78e-37	Lymphocyte counts;
BRCA	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg20476274	chr7:133979776	SLC35B4	0.67	19.69	0.61	8.47e-68	Mean platelet volume;
BRCA	cis	rs600806	0.778	rs11101960	chr1:110008778	C/T	cg20591472	chr1:110008990	SYPL2	0.33	8.38	0.31	3.29e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4988958	0.565	rs3771154	chr2:103039360	C/T	cg03938978	chr2:103052716	IL18RAP	0.29	8.3	0.31	6.13e-16	Asthma (childhood onset);
BRCA	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg17470723	chr8:74884337	TCEB1	0.41	8.84	0.33	9.49e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg14664628	chr15:75095509	CSK	-0.92	-27.9	-0.74	1.19e-112	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg01802117	chr1:53393560	SCP2	-0.41	-9.13	-0.34	8.75e-19	Monocyte count;
BRCA	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.44	9.23	0.34	3.82e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg06636001	chr8:8085503	FLJ10661	-0.38	-8.13	-0.31	2.27e-15	Retinal vascular caliber;
BRCA	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg05868516	chr6:26286170	HIST1H4H	0.49	11.03	0.4	4.95e-26	Educational attainment;
BRCA	cis	rs7572733	0.534	rs7604700	chr2:198718630	A/G	cg00792783	chr2:198669748	PLCL1	0.47	10.12	0.37	1.95e-22	Dermatomyositis;
BRCA	cis	rs9309473	0.583	rs6705203	chr2:73574600	T/C	cg20560298	chr2:73613845	ALMS1	-0.42	-10.99	-0.4	7.59e-26	Metabolite levels;
BRCA	trans	rs208520	0.874	rs208514	chr6:66945520	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-15.33	-0.52	2.03e-45	Exhaled nitric oxide output;
BRCA	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.65	16.42	0.54	8.19e-51	Colorectal cancer;
BRCA	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg06784218	chr1:46089804	CCDC17	0.5	12.08	0.43	2.02e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.14	0.37	1.62e-22	Bladder cancer;
BRCA	cis	rs13046373	0.507	rs11088139	chr21:31978884	T/G	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.55	0.35	2.8e-20	HDL cholesterol;
BRCA	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg03354898	chr7:1950403	MAD1L1	-0.49	-9.72	-0.36	6.35e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg14675211	chr2:100938903	LONRF2	0.43	9.51	0.35	3.82e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-10.5	-0.38	6.73e-24	Reticulocyte count;
BRCA	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-11.25	-0.41	6.79e-27	Gut microbiome composition (summer);
BRCA	cis	rs12986413	0.967	rs4807211	chr19:2174643	G/A	cg09261902	chr19:2140048	AP3D1	0.38	10.05	0.37	3.64e-22	Height;
BRCA	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg15017067	chr4:17643749	FAM184B	0.3	8.42	0.32	2.39e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs57590327	0.528	rs11707026	chr3:81694044	C/A	cg07356753	chr3:81810745	GBE1	-0.43	-9.91	-0.37	1.2e-21	Extraversion;
BRCA	cis	rs9815354	1.000	rs56121764	chr3:41883975	T/C	cg03022575	chr3:42003672	ULK4	0.49	7.99	0.3	6.4e-15	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24531977	chr5:56204891	C5orf35	1.01	20.62	0.63	8.79e-73	Initial pursuit acceleration;
BRCA	cis	rs3820928	0.845	rs13419076	chr2:227873028	A/G	cg11843606	chr2:227700838	RHBDD1	-0.36	-7.99	-0.3	6.28e-15	Pulmonary function;
BRCA	cis	rs34779708	0.931	rs7923217	chr10:35309589	A/G	cg03585969	chr10:35415529	CREM	0.44	9.39	0.35	1.02e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	9.04	0.34	1.9e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6087990	0.731	rs2424897	chr20:31338098	A/T	cg13636640	chr20:31349939	DNMT3B	0.72	21.59	0.65	4.76e-78	Ulcerative colitis;
BRCA	cis	rs61990749	0.597	rs8003691	chr14:78211225	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.66	10.54	0.38	4.79e-24	Fibroblast growth factor basic levels;
BRCA	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg03213289	chr20:61660250	NA	0.63	16.23	0.54	7.45e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14442939	chr10:27389572	ANKRD26	-0.68	-10.86	-0.39	2.56e-25	Breast cancer;
BRCA	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg20701182	chr2:24300061	SF3B14	0.68	12.67	0.45	5.66e-33	Lymphocyte counts;
BRCA	cis	rs12986413	0.934	rs6510645	chr19:2158398	T/C	cg09261902	chr19:2140048	AP3D1	0.4	10.6	0.39	2.72e-24	Height;
BRCA	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg01420254	chr6:26195488	NA	0.56	8.92	0.33	5.02e-18	Gout;Renal underexcretion gout;
BRCA	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg16482183	chr6:26056742	HIST1H1C	0.45	8.76	0.33	1.8e-17	Iron status biomarkers;
BRCA	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg03342759	chr3:160939853	NMD3	-0.73	-15.13	-0.51	1.91e-44	Parkinson's disease;
BRCA	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg20283391	chr11:68216788	NA	-0.45	-8.93	-0.33	4.39e-18	Total body bone mineral density;
BRCA	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg17644776	chr2:200775616	C2orf69	0.45	8.59	0.32	6.67e-17	Schizophrenia;
BRCA	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg19748678	chr4:122722346	EXOSC9	0.42	8.67	0.32	3.48e-17	Type 2 diabetes;
BRCA	cis	rs2742417	0.603	rs7631818	chr3:45775931	A/T	cg04837898	chr3:45731254	SACM1L	-0.38	-7.81	-0.3	2.41e-14	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.19	0.4	1.17e-26	Bipolar disorder;
BRCA	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg11752832	chr7:134001865	SLC35B4	0.42	9.19	0.34	5.61e-19	Mean platelet volume;
BRCA	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg09367891	chr1:107599246	PRMT6	-0.41	-8.2	-0.31	1.36e-15	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg20607798	chr8:58055168	NA	0.47	8.1	0.31	2.72e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg13319975	chr6:146136371	FBXO30	-0.38	-8.63	-0.32	4.69e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg14186256	chr22:23484241	RTDR1	0.77	23.66	0.68	2.35e-89	Bone mineral density;
BRCA	cis	rs7590720	1.000	rs4674058	chr2:216909368	A/G	cg12620499	chr2:216877984	MREG	0.79	21.43	0.65	3.41e-77	Alcohol dependence;
BRCA	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.61	14.16	0.49	8.43e-40	Colorectal cancer;
BRCA	cis	rs2882667	0.728	rs10068786	chr5:138276944	C/T	cg04439458	chr5:138467593	SIL1	-0.36	-8.71	-0.33	2.7e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg27129171	chr3:47204927	SETD2	0.76	19.77	0.62	2.89e-68	Colorectal cancer;
BRCA	cis	rs1043763	0.826	rs11043307	chr12:122494845	A/G	cg14400030	chr12:122498111	BCL7A	0.69	15.16	0.51	1.46e-44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
BRCA	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg05340658	chr4:99064831	C4orf37	0.61	14.48	0.5	2.58e-41	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg20587970	chr11:113659929	NA	-0.95	-18.66	-0.59	2.29e-62	Hip circumference adjusted for BMI;
BRCA	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg24848339	chr3:12840334	CAND2	0.46	12.11	0.43	1.59e-30	QRS complex (12-leadsum);
BRCA	cis	rs250677	0.524	rs183140	chr5:148438803	G/T	cg12140854	chr5:148520817	ABLIM3	-0.37	-8.48	-0.32	1.51e-16	Breast cancer;
BRCA	trans	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.53	0.32	1.05e-16	Corneal astigmatism;
BRCA	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg07080220	chr10:102295463	HIF1AN	0.58	13.43	0.47	2.14e-36	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05926928	chr17:57297772	GDPD1	1.43	18.18	0.58	7.57e-60	Opioid sensitivity;
BRCA	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.08	-0.4	3.36e-26	Extrinsic epigenetic age acceleration;
BRCA	trans	rs1973993	0.603	rs2391799	chr1:97024329	A/G	cg10631902	chr5:14652156	NA	0.38	9.52	0.35	3.59e-20	Weight;
BRCA	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg12935359	chr14:103987150	CKB	0.65	15.04	0.51	5.76e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs17253792	0.822	rs9972180	chr14:56073732	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.91	0.3	1.15e-14	Putamen volume;
BRCA	cis	rs4478858	0.735	rs12126725	chr1:31805853	G/T	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg03929089	chr4:120376271	NA	0.57	9.31	0.35	2.07e-19	Axial length;
BRCA	cis	rs1030877	0.521	rs2576747	chr2:105978676	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.49	10.68	0.39	1.25e-24	Obesity-related traits;
BRCA	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg25801113	chr15:45476975	SHF	0.31	8.05	0.3	4.16e-15	Uric acid levels;
BRCA	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg06453172	chr10:134556979	INPP5A	0.56	10.96	0.4	9.93e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25427524	chr10:38739819	LOC399744	-0.68	-16.38	-0.54	1.31e-50	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg13770153	chr20:60521292	NA	-0.44	-9.85	-0.36	2.18e-21	Body mass index;
BRCA	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.41	-8.7	-0.33	2.9e-17	Rheumatoid arthritis;
BRCA	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg04166393	chr7:2884313	GNA12	0.49	9.16	0.34	6.93e-19	Height;
BRCA	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg26384229	chr12:38710491	ALG10B	0.63	13.24	0.46	1.53e-35	Morning vs. evening chronotype;
BRCA	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg17366294	chr4:99064904	C4orf37	0.52	11.56	0.42	3.32e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1997103	1.000	rs2177802	chr7:55410789	G/A	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs16854884	0.606	rs60676654	chr3:143734937	A/G	cg06585982	chr3:143692056	C3orf58	0.43	9.0	0.34	2.63e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg24069376	chr3:38537580	EXOG	0.32	9.08	0.34	1.36e-18	Electrocardiographic conduction measures;
BRCA	cis	rs4662945	0.603	rs10168574	chr2:130267823	C/T	cg05962382	chr2:130345044	NA	-0.34	-8.01	-0.3	5.42e-15	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg08885076	chr2:99613938	TSGA10	-0.54	-12.53	-0.44	2.21e-32	Chronic sinus infection;
BRCA	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg03188948	chr7:1209495	NA	0.67	11.11	0.4	2.52e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg26395211	chr5:140044315	WDR55	0.38	8.72	0.33	2.43e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg24069376	chr3:38537580	EXOG	0.41	11.94	0.43	8.01e-30	Electrocardiographic conduction measures;
BRCA	cis	rs965469	1.000	rs6051736	chr20:3296898	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-10.29	-0.38	4.41e-23	IFN-related cytopenia;
BRCA	cis	rs929596	0.585	rs2018985	chr2:234648860	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.37	-9.29	-0.34	2.44e-19	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs1891275	0.515	rs7098763	chr10:93444827	C/T	cg07889827	chr10:93443413	NA	-0.44	-12.37	-0.44	1.2e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg20701182	chr2:24300061	SF3B14	0.67	9.77	0.36	4.1e-21	Lymphocyte counts;
BRCA	cis	rs2953174	0.744	rs2975748	chr2:241518989	A/G	cg07929629	chr2:241523174	NA	0.49	8.45	0.32	2.04e-16	Bipolar disorder;
BRCA	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18876405	chr7:65276391	NA	0.55	13.29	0.47	8.91e-36	Aortic root size;
BRCA	cis	rs950173	1.000	rs6716901	chr2:172673453	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.64	-9.49	-0.35	4.48e-20	Hippocampal volume;
BRCA	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg26587870	chr6:27730563	NA	-0.56	-8.5	-0.32	1.29e-16	Depression;
BRCA	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg16325326	chr1:53192061	ZYG11B	0.79	22.34	0.66	3.74e-82	Monocyte count;
BRCA	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg09307838	chr4:120376055	NA	0.74	16.17	0.54	1.53e-49	Corneal astigmatism;
BRCA	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.37	-12.84	-0.45	9.66e-34	Bipolar disorder;
BRCA	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg19077165	chr18:44547161	KATNAL2	-0.59	-13.19	-0.46	2.49e-35	Personality dimensions;
BRCA	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg04586622	chr2:25135609	ADCY3	0.46	11.66	0.42	1.31e-28	Body mass index;
BRCA	cis	rs4363385	0.818	rs1334848	chr1:153004721	A/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.22	-0.34	4.37e-19	Inflammatory skin disease;
BRCA	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg04944784	chr2:26401820	FAM59B	0.99	16.56	0.55	1.61e-51	Gut microbiome composition (summer);
BRCA	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg14186256	chr22:23484241	RTDR1	0.72	19.53	0.61	5.59e-67	Bone mineral density;
BRCA	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg09654669	chr8:57350985	NA	-0.4	-8.62	-0.32	5.33e-17	Obesity-related traits;
BRCA	cis	rs13191362	0.573	rs1877769	chr6:163252315	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.47	8.36	0.31	3.9e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg24692254	chr21:30365293	RNF160	-0.64	-14.45	-0.5	3.86e-41	Selective IgA deficiency;
BRCA	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg15704280	chr7:45808275	SEPT13	0.6	10.66	0.39	1.57e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7551345	0.653	rs6425719	chr1:31700777	T/C	cg19084893	chr1:31688959	NA	-0.49	-10.46	-0.38	9.21e-24	Schizophrenia;
BRCA	cis	rs10924970	0.934	rs12402243	chr1:235431792	A/C	cg26050004	chr1:235667680	B3GALNT2	0.34	8.48	0.32	1.59e-16	Asthma;
BRCA	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg13770153	chr20:60521292	NA	-0.41	-9.03	-0.34	2e-18	Body mass index;
BRCA	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg15556689	chr8:8085844	FLJ10661	-0.37	-10.14	-0.37	1.6e-22	Neuroticism;
BRCA	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.66	0.39	1.5e-24	Bipolar disorder;
BRCA	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg18252515	chr7:66147081	NA	-0.87	-12.08	-0.43	2.13e-30	Diabetic kidney disease;
BRCA	cis	rs977987	0.806	rs4888386	chr16:75389740	A/G	cg03315344	chr16:75512273	CHST6	0.51	11.95	0.43	7.54e-30	Dupuytren's disease;
BRCA	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg14456004	chr13:21872349	NA	1.2	22.11	0.66	6.72e-81	White matter hyperintensity burden;
BRCA	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg11822812	chr5:140052017	DND1	-0.3	-8.22	-0.31	1.16e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg27446573	chr6:127587934	RNF146	0.9	21.07	0.64	2.99e-75	Breast cancer;
BRCA	trans	rs75804782	0.521	rs2117691	chr2:239414734	C/T	cg01134436	chr17:81009848	B3GNTL1	0.68	8.55	0.32	9.09e-17	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10802521	chr3:52805072	NEK4	0.34	9.26	0.34	3.03e-19	Bipolar disorder;
BRCA	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg20991723	chr1:152506922	NA	0.37	8.25	0.31	9.17e-16	Hair morphology;
BRCA	cis	rs7903847	0.602	rs7916665	chr10:99157573	T/G	cg08345082	chr10:99160200	RRP12	-0.29	-8.58	-0.32	7.24e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.49	-12.61	-0.45	1.03e-32	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs6435161	0.959	rs10189685	chr2:203488449	G/A	cg18429434	chr2:203499731	FAM117B	-0.43	-9.01	-0.34	2.38e-18	Total cholesterol levels;
BRCA	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05025164	chr4:1340916	KIAA1530	0.75	15.57	0.52	1.36e-46	Longevity;
BRCA	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg06784218	chr1:46089804	CCDC17	0.5	12.14	0.43	1.17e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17253792	0.822	rs112238223	chr14:56056144	C/A	cg01858014	chr14:56050164	KTN1	-0.73	-9.19	-0.34	5.56e-19	Putamen volume;
BRCA	cis	rs11997175	0.766	rs6995220	chr8:33708919	C/A	ch.8.33884649F	chr8:33765107	NA	0.35	8.33	0.31	4.84e-16	Body mass index;
BRCA	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg04553112	chr3:125709451	NA	-0.55	-8.68	-0.32	3.17e-17	Blood pressure (smoking interaction);
BRCA	trans	rs783540	0.967	rs7494860	chr15:83334419	A/G	cg18393722	chr15:85113863	UBE2QP1	0.25	7.84	0.3	1.89e-14	Schizophrenia;
BRCA	cis	rs7715811	1.000	rs6860236	chr5:13762013	C/T	cg07548982	chr5:13769939	DNAH5	-0.38	-8.31	-0.31	5.55e-16	Subclinical atherosclerosis traits (other);
BRCA	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg03146154	chr1:46216737	IPP	-0.36	-8.41	-0.32	2.76e-16	Red blood cell count;Reticulocyte count;
BRCA	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg12935359	chr14:103987150	CKB	0.56	12.72	0.45	3.2e-33	Intelligence (multi-trait analysis);
BRCA	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-10.01	-0.37	5.3e-22	Triglycerides;
BRCA	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg04990556	chr1:26633338	UBXN11	-0.47	-9.32	-0.35	1.84e-19	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23583168	chr7:148888333	NA	-0.81	-18.24	-0.59	3.63e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg22601191	chr20:60968625	CABLES2	0.34	8.5	0.32	1.38e-16	Colorectal cancer;
BRCA	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg00409905	chr10:38381863	ZNF37A	-0.5	-10.44	-0.38	1.14e-23	Extrinsic epigenetic age acceleration;
BRCA	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg19257562	chr1:2043853	PRKCZ	-0.35	-9.36	-0.35	1.38e-19	Height;
BRCA	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00166722	chr3:10149974	C3orf24	0.67	13.49	0.47	1.13e-36	Alzheimer's disease;
BRCA	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg19678392	chr7:94953810	PON1	-0.41	-8.58	-0.32	7.05e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs9487051	0.502	rs9386781	chr6:109584520	G/A	cg01475377	chr6:109611718	NA	-0.44	-10.44	-0.38	1.1e-23	Reticulocyte fraction of red cells;
BRCA	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg08885076	chr2:99613938	TSGA10	0.44	10.29	0.38	4.34e-23	Chronic sinus infection;
BRCA	cis	rs7424096	0.527	rs4670637	chr2:37164857	T/G	cg14987922	chr2:37194071	STRN	0.4	8.57	0.32	8.05e-17	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.68	0.55	4.17e-52	Hypertriglyceridemia;
BRCA	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.84	-20.16	-0.62	2.64e-70	Ulcerative colitis;
BRCA	cis	rs12618769	0.625	rs4850880	chr2:99212417	C/T	cg10123293	chr2:99228465	UNC50	0.42	8.53	0.32	1.07e-16	Bipolar disorder;
BRCA	cis	rs758324	0.617	rs12719447	chr5:131118100	C/A	cg06307176	chr5:131281290	NA	0.57	12.06	0.43	2.55e-30	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg07080220	chr10:102295463	HIF1AN	0.54	12.57	0.45	1.52e-32	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg25019033	chr10:957182	NA	-0.41	-8.67	-0.32	3.58e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs847577	0.646	rs10270222	chr7:97781799	C/T	cg21770322	chr7:97807741	LMTK2	-0.45	-12.0	-0.43	4.64e-30	Breast cancer;
BRCA	cis	rs9815354	0.812	rs73071236	chr3:41992042	A/G	cg03022575	chr3:42003672	ULK4	0.65	9.28	0.34	2.54e-19	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg14061069	chr19:46274453	DMPK	-0.46	-11.56	-0.42	3.37e-28	Coronary artery disease;
BRCA	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg10845886	chr2:3471009	TTC15	-0.54	-11.99	-0.43	4.9e-30	Neurofibrillary tangles;
BRCA	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg13319975	chr6:146136371	FBXO30	0.35	8.09	0.3	3.08e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-9.03	-0.34	2.03e-18	Response to bleomycin (chromatid breaks);
BRCA	trans	rs1459104	1.000	rs12802877	chr11:55270032	C/T	cg15704280	chr7:45808275	SEPT13	0.65	8.14	0.31	2.12e-15	Body mass index;
BRCA	cis	rs6545883	0.525	rs1621048	chr2:61364216	C/G	cg15711740	chr2:61764176	XPO1	0.44	10.61	0.39	2.5300000000000002e-24	Tuberculosis;
BRCA	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	10.37	0.38	2.12e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1003719	0.788	rs9975168	chr21:38450557	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.5	-0.5	2.03e-41	Eye color traits;
BRCA	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-14.28	-0.49	2.33e-40	Response to antipsychotic treatment;
BRCA	cis	rs16857609	0.564	rs1478581	chr2:218292652	C/T	cg15335768	chr2:218268053	DIRC3	-0.42	-9.75	-0.36	5.02e-21	Breast cancer;Breast cancer (estrogen-receptor negative);
BRCA	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg08085267	chr17:45401833	C17orf57	-0.58	-11.73	-0.42	6.75e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg23788917	chr6:8435910	SLC35B3	0.47	10.21	0.37	8.59e-23	Motion sickness;
BRCA	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg17420585	chr12:42539391	GXYLT1	-0.49	-10.61	-0.39	2.57e-24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg16606324	chr3:10149918	C3orf24	0.57	11.29	0.41	4.57e-27	Alzheimer's disease;
BRCA	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg20701182	chr2:24300061	SF3B14	0.55	8.53	0.32	1.09e-16	Lymphocyte counts;
BRCA	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18876405	chr7:65276391	NA	-0.51	-11.63	-0.42	1.67e-28	Aortic root size;
BRCA	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08885201	chr16:69419692	TERF2	0.52	7.86	0.3	1.64e-14	Response to platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg21573476	chr21:45109991	RRP1B	0.36	9.23	0.34	4e-19	Mean corpuscular volume;
BRCA	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg25457927	chr22:38595422	NA	-0.32	-11.68	-0.42	1.02e-28	Cutaneous nevi;
BRCA	trans	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg21659725	chr3:3221576	CRBN	0.47	8.78	0.33	1.54e-17	Menarche (age at onset);
BRCA	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-7.91	-0.3	1.1e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-8.75	-0.33	1.9e-17	Schizophrenia;
BRCA	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg00071950	chr4:10020882	SLC2A9	0.4	9.43	0.35	7.27e-20	Bone mineral density;
BRCA	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg09455208	chr3:40491958	NA	0.4	9.45	0.35	6.22e-20	Renal cell carcinoma;
BRCA	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg12011299	chr4:100065546	ADH4	0.41	10.77	0.39	5.57e-25	Alcohol dependence;
BRCA	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg23950597	chr19:37808831	NA	-0.62	-11.45	-0.41	9.88e-28	Coronary artery calcification;
BRCA	cis	rs13315871	1.000	rs13096020	chr3:58367771	G/A	cg20936604	chr3:58311152	NA	-0.62	-7.94	-0.3	9.28e-15	Cholesterol, total;
BRCA	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg18270830	chr10:32634957	EPC1	0.58	9.94	0.37	9.22e-22	Sexual dysfunction (female);
BRCA	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg16482183	chr6:26056742	HIST1H1C	0.46	8.88	0.33	6.81e-18	Iron status biomarkers;
BRCA	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg23018236	chr17:30244563	NA	-0.61	-10.05	-0.37	3.63e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs4363385	0.720	rs1611764	chr1:152957887	G/A	cg24667326	chr1:152973720	SPRR3	-0.33	-9.42	-0.35	8.35e-20	Inflammatory skin disease;
BRCA	trans	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg24642439	chr20:33292090	TP53INP2	0.42	9.06	0.34	1.58e-18	Height;
BRCA	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.83	-0.3	2.04e-14	Aortic root size;
BRCA	cis	rs13040088	1.000	rs6090159	chr20:61531351	C/G	cg23096297	chr20:61557774	DIDO1	0.89	17.8	0.58	7.44e-58	Menopause (age at onset);
BRCA	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.44	8.45	0.32	2.01e-16	Lymphocyte counts;
BRCA	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-10.12	-0.37	2.01e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg07988820	chr12:82153109	PPFIA2	-0.59	-9.67	-0.36	9.43e-21	Resting heart rate;
BRCA	cis	rs6545883	0.929	rs10200055	chr2:61628017	T/A	cg15711740	chr2:61764176	XPO1	0.54	13.59	0.47	3.73e-37	Tuberculosis;
BRCA	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg26384229	chr12:38710491	ALG10B	0.68	14.54	0.5	1.35e-41	Morning vs. evening chronotype;
BRCA	cis	rs17253792	0.822	rs13379340	chr14:56050346	C/G	cg01858014	chr14:56050164	KTN1	-0.77	-11.27	-0.41	5.52e-27	Putamen volume;
BRCA	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg10253484	chr15:75165896	SCAMP2	-0.56	-11.59	-0.42	2.62e-28	Breast cancer;
BRCA	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg25427524	chr10:38739819	LOC399744	0.59	13.17	0.46	3.36e-35	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs877282	0.838	rs11253373	chr10:774857	A/G	cg17470449	chr10:769945	NA	0.51	8.67	0.32	3.53e-17	Uric acid levels;
BRCA	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg08807101	chr21:30365312	RNF160	0.66	17.14	0.56	1.9e-54	Dental caries;
BRCA	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg05926928	chr17:57297772	GDPD1	1.15	15.12	0.51	2.2e-44	Opioid sensitivity;
BRCA	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg22532475	chr10:104410764	TRIM8	-0.3	-7.84	-0.3	1.89e-14	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21659725	chr3:3221576	CRBN	-0.71	-21.8	-0.65	3.28e-79	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg26395211	chr5:140044315	WDR55	0.35	7.89	0.3	1.35e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg06521331	chr12:34319734	NA	-0.55	-9.98	-0.37	6.63e-22	Morning vs. evening chronotype;
BRCA	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg13175981	chr1:150552382	MCL1	0.51	11.18	0.4	1.21e-26	Tonsillectomy;
BRCA	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.75	15.41	0.52	8.18e-46	Smoking behavior;
BRCA	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg04944784	chr2:26401820	FAM59B	1.0	16.65	0.55	5.96e-52	Gut microbiome composition (summer);
BRCA	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21659725	chr3:3221576	CRBN	-0.49	-11.79	-0.42	3.79e-29	Resting heart rate;
BRCA	cis	rs7246967	0.673	rs55744741	chr19:22959973	C/T	cg23217946	chr19:22817039	ZNF492	0.5	9.11	0.34	1.04e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	13.81	0.48	3.62e-38	Colorectal cancer;
BRCA	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg05340658	chr4:99064831	C4orf37	0.66	16.11	0.54	3.02e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg13206674	chr6:150067644	NUP43	-0.32	-8.7	-0.33	2.79e-17	Lung cancer;
BRCA	cis	rs56399783	0.901	rs6967664	chr7:2816384	A/G	cg19731401	chr7:2775893	GNA12	0.5	8.1	0.31	2.79e-15	Childhood ear infection;
BRCA	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg10057126	chr4:77819792	ANKRD56	0.68	15.42	0.52	7.78e-46	Emphysema distribution in smoking;
BRCA	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg26850624	chr5:429559	AHRR	0.33	7.88	0.3	1.37e-14	Cystic fibrosis severity;
BRCA	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg23939001	chr4:940644	TMEM175	0.39	8.89	0.33	6e-18	Sjögren's syndrome;
BRCA	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.16e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2625529	0.730	rs35713471	chr15:72459971	C/A	cg16672083	chr15:72433130	SENP8	-0.84	-17.75	-0.57	1.34e-57	Red blood cell count;
BRCA	cis	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg07460842	chr6:66804631	NA	-1.11	-34.31	-0.81	4.23e-147	Exhaled nitric oxide output;
BRCA	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.85	0.42	1.99e-29	Homoarginine levels;
BRCA	cis	rs1163251	0.837	rs660073	chr1:120245173	T/C	cg19096424	chr1:120255104	PHGDH	0.45	10.44	0.38	1.2e-23	Blood metabolite levels;
BRCA	cis	rs8048589	0.515	rs12443524	chr16:12239979	A/G	cg02910054	chr16:12241554	SNX29	-0.45	-9.08	-0.34	1.36e-18	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
BRCA	cis	rs113835537	0.597	rs7116921	chr11:66303854	T/C	cg24851651	chr11:66362959	CCS	0.47	8.91	0.33	5.33e-18	Airway imaging phenotypes;
BRCA	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg19052272	chr2:3704530	ALLC	-0.36	-8.41	-0.32	2.71e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg14675211	chr2:100938903	LONRF2	0.43	9.94	0.37	9.92e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.61	9.25	0.34	3.21e-19	Lung function (FEV1/FVC);
BRCA	cis	rs13082711	0.911	rs67104968	chr3:27510304	A/G	cg02860705	chr3:27208620	NA	0.52	10.33	0.38	3.05e-23	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs9560113	0.881	rs9560111	chr13:112181289	C/T	cg10483660	chr13:112241077	NA	0.32	7.98	0.3	6.63e-15	Menarche (age at onset);
BRCA	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg24101359	chr6:42928495	GNMT	0.54	12.59	0.45	1.24e-32	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs2840044	1.000	rs11653310	chr17:33893378	C/G	cg19694781	chr19:47549865	TMEM160	-0.46	-11.1	-0.4	2.56e-26	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.72	16.16	0.54	1.68e-49	Lymphocyte counts;
BRCA	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	12.5	0.44	3.17e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11644478	chr21:40555479	PSMG1	-0.5	-10.7	-0.39	1.09e-24	Menarche (age at onset);
BRCA	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg08601574	chr20:25228251	PYGB	0.35	8.39	0.32	3.06e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg06521331	chr12:34319734	NA	-0.56	-10.84	-0.39	3.03e-25	Morning vs. evening chronotype;
BRCA	cis	rs7715806	0.500	rs10515213	chr5:74980572	C/T	cg19683494	chr5:74908142	NA	-0.52	-8.49	-0.32	1.41e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.68	-11.52	-0.41	5.03e-28	Platelet count;
BRCA	cis	rs9503598	0.636	rs7775474	chr6:3468224	T/C	cg00476032	chr6:3446245	SLC22A23	0.38	9.3	0.35	2.28e-19	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs3820928	0.874	rs7421491	chr2:227839278	C/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.16	-0.31	1.79e-15	Pulmonary function;
BRCA	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg23708337	chr7:1209742	NA	0.55	11.74	0.42	6.08e-29	Longevity;Endometriosis;
BRCA	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12379764	chr21:47803548	PCNT	0.4	8.86	0.33	7.77e-18	Testicular germ cell tumor;
BRCA	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg24812749	chr6:127587940	RNF146	0.87	20.07	0.62	7.99e-70	Breast cancer;
BRCA	cis	rs7512552	0.839	rs698916	chr1:150388385	A/G	cg15654264	chr1:150340011	RPRD2	0.37	8.13	0.31	2.26e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.89	-0.3	1.31e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg13334819	chr7:99746414	C7orf59	0.34	7.85	0.3	1.79e-14	Coronary artery disease;
BRCA	cis	rs2625529	0.824	rs12592044	chr15:72419115	A/G	cg16672083	chr15:72433130	SENP8	-0.84	-17.71	-0.57	2.19e-57	Red blood cell count;
BRCA	cis	rs1198430	0.683	rs1198433	chr1:23756695	A/G	cg19827787	chr1:23763612	ASAP3	0.33	9.32	0.35	1.8e-19	Total cholesterol levels;
BRCA	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg11752832	chr7:134001865	SLC35B4	0.54	13.89	0.48	1.54e-38	Mean platelet volume;
BRCA	cis	rs11608355	0.515	rs7136048	chr12:109903926	A/G	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs72781680	0.821	rs2339887	chr2:24198376	G/A	cg08917208	chr2:24149416	ATAD2B	0.62	10.54	0.38	4.62e-24	Lymphocyte counts;
BRCA	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg14349672	chr11:133703707	NA	0.33	8.34	0.31	4.44e-16	Childhood ear infection;
BRCA	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg00105475	chr2:10696890	NA	-0.39	-8.8	-0.33	1.24e-17	Prostate cancer;
BRCA	cis	rs9470366	0.883	rs9462207	chr6:36627599	T/C	cg08179530	chr6:36648295	CDKN1A	0.51	9.64	0.36	1.3e-20	QRS duration;
BRCA	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-10.81	-0.39	3.91e-25	Longevity;Endometriosis;
BRCA	cis	rs858239	0.601	rs10278700	chr7:23160529	T/C	cg23682824	chr7:23144976	KLHL7	0.42	11.09	0.4	2.96e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg25703541	chr22:24373054	LOC391322	-0.69	-16.04	-0.54	6.43e-49	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg08601574	chr20:25228251	PYGB	0.36	8.8	0.33	1.25e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.05	29.72	0.76	1.44e-122	Cognitive ability;
BRCA	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg12062639	chr20:23401060	NAPB	0.87	10.46	0.38	9.93e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00475322	chr7:917719	C7orf20	-0.43	-11.24	-0.41	6.81e-27	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs10992471	0.603	rs12342019	chr9:95192508	C/T	cg14631576	chr9:95140430	CENPP	-0.39	-9.31	-0.35	1.96e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg01528321	chr10:82214614	TSPAN14	-0.82	-17.96	-0.58	1.1e-58	Post bronchodilator FEV1;
BRCA	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg15605315	chr1:45957053	TESK2	0.47	9.77	0.36	4.19e-21	High light scatter reticulocyte count;
BRCA	cis	rs28830936	0.966	rs2303518	chr15:42109975	T/G	cg17847044	chr15:42102381	MAPKBP1	-0.4	-11.92	-0.43	1.03e-29	Diastolic blood pressure;
BRCA	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg16325326	chr1:53192061	ZYG11B	-0.76	-19.99	-0.62	2.04e-69	Monocyte count;
BRCA	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00802000	chr16:706648	WDR90	-0.4	-9.52	-0.35	3.59e-20	Height;
BRCA	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg18154014	chr19:37997991	ZNF793	0.62	11.64	0.42	1.49e-28	Coronary artery calcification;
BRCA	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg04455712	chr21:45112962	RRP1B	0.36	9.1	0.34	1.16e-18	Mean corpuscular volume;
BRCA	trans	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg06521331	chr12:34319734	NA	-0.47	-8.68	-0.32	3.27e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1865721	0.755	rs3813081	chr18:73185096	A/G	cg26385618	chr18:73139727	C18orf62	-0.33	-7.84	-0.3	1.87e-14	Intelligence;
BRCA	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.85e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2992756	0.663	rs3007718	chr1:18808465	T/A	cg14356550	chr1:18808102	KLHDC7A	-0.4	-8.29	-0.31	6.67e-16	Breast cancer;
BRCA	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg12062639	chr20:23401060	NAPB	0.94	13.34	0.47	5.3e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.68	0.57	3.2e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg13114125	chr14:105738426	BRF1	-0.48	-10.09	-0.37	2.69e-22	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg26587870	chr6:27730563	NA	0.54	8.08	0.3	3.27e-15	Depression;
BRCA	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg14092988	chr3:52407081	DNAH1	0.32	7.85	0.3	1.81e-14	Bipolar disorder;
BRCA	trans	rs10242455	0.702	rs73401510	chr7:99065812	A/C	cg09045935	chr12:6379348	NA	0.84	8.3	0.31	6.1e-16	Blood metabolite levels;
BRCA	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg05025164	chr4:1340916	KIAA1530	0.34	7.85	0.3	1.78e-14	Longevity;
BRCA	cis	rs12210905	0.688	rs12205044	chr6:27478990	A/G	cg08851530	chr6:28072375	NA	0.82	7.92	0.3	1.02e-14	Hip circumference adjusted for BMI;
BRCA	cis	rs4742903	0.967	rs10820605	chr9:106881402	C/T	cg21169611	chr9:106856078	SMC2	0.38	9.87	0.36	1.69e-21	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs6987853	0.761	rs2974322	chr8:42424724	T/C	cg09913449	chr8:42400586	C8orf40	0.42	9.34	0.35	1.62e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg09307838	chr4:120376055	NA	0.7	14.09	0.49	1.96e-39	Corneal astigmatism;
BRCA	cis	rs4891159	1.000	rs4891159	chr18:74101941	A/G	cg24786174	chr18:74118243	ZNF516	0.66	17.42	0.57	6.68e-56	Longevity;
BRCA	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg12219531	chr12:120966889	COQ5	0.55	11.44	0.41	1.11e-27	High light scatter reticulocyte count;
BRCA	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg18016565	chr1:150552671	MCL1	0.34	7.98	0.3	6.59e-15	Tonsillectomy;
BRCA	cis	rs311392	0.902	rs2666874	chr8:55091561	A/T	cg11783602	chr8:55087084	NA	0.31	8.8	0.33	1.25e-17	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg25036284	chr2:26402008	FAM59B	0.94	15.92	0.53	2.57e-48	Gut microbiome composition (summer);
BRCA	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg20701182	chr2:24300061	SF3B14	0.65	9.37	0.35	1.2e-19	Lymphocyte counts;
BRCA	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.39	0.59	5.86e-61	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7575217	0.697	rs34429055	chr2:101703696	G/C	cg23907051	chr2:101730305	TBC1D8	0.2	7.92	0.3	1.06e-14	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14829155	chr15:31115871	NA	-0.43	-9.86	-0.36	1.96e-21	Huntington's disease progression;
BRCA	trans	rs12517041	1.000	rs16892312	chr5:23279764	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.45	-8.11	-0.31	2.68e-15	Calcium levels;
BRCA	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.35	-0.44	1.46e-31	Bipolar disorder;
BRCA	cis	rs7402982	0.934	rs8028620	chr15:99202875	C/T	cg03437748	chr15:99193247	IGF1R	0.71	17.63	0.57	5.23e-57	Birth weight;
BRCA	cis	rs13046373	0.508	rs1012969	chr21:31996108	G/A	cg24082983	chr21:31802169	KRTAP13-4	0.32	8.16	0.31	1.8e-15	HDL cholesterol;
BRCA	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg18357645	chr12:58087776	OS9	-0.32	-7.99	-0.3	6.18e-15	Multiple sclerosis;
BRCA	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg14675211	chr2:100938903	LONRF2	0.47	10.79	0.39	4.9e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs12431939	1.000	rs11850391	chr14:51639759	A/G	cg23942311	chr14:51606299	NA	-0.42	-8.26	-0.31	8.51e-16	Cancer;
BRCA	trans	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	16.05	0.54	5.75e-49	Exhaled nitric oxide levels;
BRCA	cis	rs61990749	0.597	rs1006039	chr14:78263196	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.62	-9.8	-0.36	3.15e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg12444411	chr7:2802554	GNA12	-0.34	-8.66	-0.32	3.81e-17	Height;
BRCA	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg19847866	chr10:1019161	NA	0.51	10.67	0.39	1.39e-24	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs27434	0.561	rs35134	chr5:96159523	A/G	cg16492584	chr5:96139282	ERAP1	-0.51	-12.95	-0.46	3.29e-34	Ankylosing spondylitis;
BRCA	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg10560079	chr2:191398806	TMEM194B	-0.65	-11.98	-0.43	5.89e-30	Diastolic blood pressure;
BRCA	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg08807101	chr21:30365312	RNF160	-0.67	-16.92	-0.56	2.5e-53	Dental caries;
BRCA	cis	rs1865721	0.682	rs7242637	chr18:73147492	A/C	cg26385618	chr18:73139727	C18orf62	-0.38	-9.53	-0.35	3.1e-20	Intelligence;
BRCA	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	12.82	0.45	1.21e-33	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg00105475	chr2:10696890	NA	0.42	9.61	0.36	1.65e-20	Prostate cancer;
BRCA	cis	rs7945705	0.818	rs10769948	chr11:8761782	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-9.42	-0.35	8.12e-20	Hemoglobin concentration;
BRCA	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg07636037	chr3:49044803	WDR6	0.91	23.57	0.68	7.57e-89	Parkinson's disease;
BRCA	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-9.65	-0.36	1.13e-20	Height;
BRCA	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	trans	rs9784649	0.760	rs17343923	chr5:25052414	G/A	cg08600765	chr20:34638493	LOC647979	-0.67	-11.09	-0.4	2.98e-26	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.74	10.1	0.37	2.39e-22	Initial pursuit acceleration;
BRCA	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10802521	chr3:52805072	NEK4	-0.33	-8.51	-0.32	1.19e-16	Bipolar disorder;
BRCA	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.4	-9.04	-0.34	1.84e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.86	13.54	0.47	6.44e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg20701182	chr2:24300061	SF3B14	0.55	8.53	0.32	1.09e-16	Lymphocyte counts;
BRCA	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg22764044	chr5:178986830	RUFY1	0.37	8.56	0.32	8.69e-17	Lung cancer;
BRCA	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.09	0.34	1.21e-18	Tonsillectomy;
BRCA	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg20469991	chr17:27169893	C17orf63	-0.45	-8.82	-0.33	1.08e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg05665937	chr4:1216051	CTBP1	0.42	8.74	0.33	2.04e-17	Obesity-related traits;
BRCA	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24308560	chr3:49941425	MST1R	0.4	8.56	0.32	8.14e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	7.84	0.3	1.88e-14	Tonsillectomy;
BRCA	cis	rs1997103	0.834	rs10274457	chr7:55390199	G/A	cg17469321	chr7:55412551	NA	0.52	9.82	0.36	2.79e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg09307838	chr4:120376055	NA	0.58	10.92	0.4	1.48e-25	Corneal astigmatism;
BRCA	trans	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg25214090	chr10:38739885	LOC399744	0.49	10.87	0.4	2.22e-25	Corneal astigmatism;
BRCA	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg11502198	chr6:26597334	ABT1	0.58	12.48	0.44	4.02e-32	Intelligence (multi-trait analysis);
BRCA	trans	rs6479891	0.915	rs9415699	chr10:65143558	C/T	cg14819942	chr15:35414228	NA	-0.34	-8.53	-0.32	1.09e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg01689657	chr7:91764605	CYP51A1	0.21	7.85	0.3	1.74e-14	Breast cancer;
BRCA	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg17366294	chr4:99064904	C4orf37	0.43	9.79	0.36	3.63e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11764359	chr7:65958608	NA	-0.78	-18.2	-0.58	5.75e-60	Aortic root size;
BRCA	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-13.45	-0.47	1.77e-36	Bladder cancer;
BRCA	cis	rs4474465	0.688	rs4277140	chr11:78285096	G/T	cg27205649	chr11:78285834	NARS2	-0.41	-14.13	-0.49	1.21e-39	Alzheimer's disease (survival time);
BRCA	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg19784903	chr17:45786737	TBKBP1	0.35	8.46	0.32	1.88e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-23.45	-0.68	3.31e-88	Gut microbiome composition (summer);
BRCA	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg17063962	chr7:91808500	NA	0.53	12.58	0.45	1.43e-32	Breast cancer;
BRCA	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg06697600	chr4:7070879	GRPEL1	-0.66	-12.99	-0.46	2.19e-34	Monocyte percentage of white cells;
BRCA	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg21475434	chr5:93447410	FAM172A	0.66	8.6	0.32	5.95e-17	Diabetic retinopathy;
BRCA	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg20818283	chr2:191399100	TMEM194B	0.41	9.39	0.35	1.01e-19	Pulse pressure;
BRCA	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg21475434	chr5:93447410	FAM172A	0.67	8.62	0.32	5.45e-17	Diabetic retinopathy;
BRCA	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.41	-0.32	2.62e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11644478	chr21:40555479	PSMG1	0.84	19.08	0.6	1.5e-64	Cognitive function;
BRCA	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg25208724	chr1:156163844	SLC25A44	0.89	18.06	0.58	3.34e-59	Testicular germ cell tumor;
BRCA	cis	rs9487051	0.676	rs13211313	chr6:109562074	G/C	cg01475377	chr6:109611718	NA	-0.37	-8.87	-0.33	7.04e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26314531	chr2:26401878	FAM59B	0.9	16.15	0.54	1.92e-49	Gut microbiome composition (summer);
BRCA	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.77	12.2	0.43	6.34e-31	Platelet count;
BRCA	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg09021430	chr5:549028	NA	-0.69	-14.55	-0.5	1.3e-41	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6580649	1.000	rs6580647	chr12:48403229	G/T	cg05342945	chr12:48394962	COL2A1	0.49	10.08	0.37	2.86e-22	Lung cancer;
BRCA	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.46	-10.74	-0.39	7.3e-25	Longevity;Endometriosis;
BRCA	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.66	-9.58	-0.35	2.1e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.65	-0.61	1.36e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.13	-0.34	8.85e-19	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg05340658	chr4:99064831	C4orf37	0.63	15.11	0.51	2.45e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg02297831	chr4:17616191	MED28	0.39	8.64	0.32	4.47e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg00071950	chr4:10020882	SLC2A9	0.63	15.51	0.52	2.82e-46	Bone mineral density;
BRCA	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.46	-8.4	-0.32	2.93e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24110177	chr3:50126178	RBM5	0.52	15.68	0.53	4e-47	Body mass index;
BRCA	cis	rs3784262	0.512	rs4646572	chr15:58343021	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.49	-12.41	-0.44	7.74e-32	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg07460842	chr6:66804631	NA	0.87	15.64	0.53	6.69e-47	Exhaled nitric oxide levels;
BRCA	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.45	9.54	0.35	2.95e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-12.09	-0.43	1.9e-30	Chronic sinus infection;
BRCA	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-11.8	-0.42	3.17e-29	Chronic sinus infection;
BRCA	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg23587288	chr2:27483067	SLC30A3	-0.38	-8.9	-0.33	5.91e-18	Blood metabolite levels;
BRCA	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg13073564	chr4:8508604	NA	-0.41	-10.89	-0.4	1.85e-25	Response to antineoplastic agents;
BRCA	cis	rs11249608	0.750	rs6891216	chr5:178447026	G/C	cg21905437	chr5:178450457	ZNF879	0.5	10.32	0.38	3.31e-23	Pubertal anthropometrics;
BRCA	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-10.64	-0.39	1.93e-24	Triglycerides;
BRCA	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg04518342	chr5:131593106	PDLIM4	0.35	8.84	0.33	9.23e-18	Breast cancer;
BRCA	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg13852791	chr20:30311386	BCL2L1	0.76	13.85	0.48	2.57e-38	Mean corpuscular hemoglobin;
BRCA	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg00012203	chr2:219082015	ARPC2	-0.48	-9.33	-0.35	1.78e-19	Colorectal cancer;
BRCA	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-11.44	-0.41	1.09e-27	Mood instability;
BRCA	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.29	-0.41	4.29e-27	Gut microbiome composition (summer);
BRCA	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.56	-0.52	1.55e-46	Chronic sinus infection;
BRCA	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.19	0.54	1.15e-49	Fuchs's corneal dystrophy;
BRCA	trans	rs4819388	0.915	rs6518352	chr21:45646698	A/G	cg17383793	chr5:52405638	MOCS2	0.5	11.22	0.41	8.78e-27	Celiac disease;
BRCA	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg10729496	chr3:10149963	C3orf24	0.49	9.34	0.35	1.5700000000000001e-19	Alzheimer's disease;
BRCA	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	13.94	0.48	9.37e-39	Alzheimer's disease;
BRCA	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	23.03	0.67	6.4e-86	Platelet count;
BRCA	cis	rs11955398	0.716	rs3857236	chr5:59909529	G/A	cg02684056	chr5:59996105	DEPDC1B	0.39	9.38	0.35	1.14e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg08742575	chr21:47604166	C21orf56	-0.42	-8.13	-0.31	2.2e-15	Testicular germ cell tumor;
BRCA	cis	rs727479	0.502	rs2899471	chr15:51506553	G/A	cg19946085	chr15:51559439	CYP19A1	-0.31	-8.62	-0.32	5.16e-17	Estradiol levels;
BRCA	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg04455712	chr21:45112962	RRP1B	0.44	11.39	0.41	1.71e-27	Mean corpuscular volume;
BRCA	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg18402987	chr7:1209562	NA	0.87	12.28	0.44	2.89e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.57	-8.16	-0.31	1.74e-15	Yeast infection;
BRCA	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg03477792	chr4:77819574	ANKRD56	0.66	15.67	0.53	4.35e-47	Emphysema distribution in smoking;
BRCA	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg16989086	chr20:62203971	PRIC285	0.53	8.89	0.33	6.05e-18	Glioblastoma;
BRCA	cis	rs7520050	0.966	rs10789487	chr1:46420221	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.76	0.36	4.47e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs11112613	0.713	rs11112588	chr12:105943801	A/C	cg03607813	chr12:105948248	NA	0.6	11.05	0.4	4.14e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg03709012	chr19:19516395	GATAD2A	1.08	21.19	0.64	7.13e-76	Nonalcoholic fatty liver disease;
BRCA	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg04414720	chr1:150670196	GOLPH3L	0.35	8.06	0.3	3.82e-15	Tonsillectomy;
BRCA	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg08085267	chr17:45401833	C17orf57	-0.67	-14.99	-0.51	9.2e-44	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs16976116	0.901	rs1050931	chr15:55497691	G/A	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11249608	0.548	rs6880315	chr5:178452502	G/A	cg21905437	chr5:178450457	ZNF879	0.52	10.74	0.39	7.62e-25	Pubertal anthropometrics;
BRCA	cis	rs3760982	0.585	rs11673534	chr19:44298884	G/A	cg12072164	chr19:44306565	LYPD5	0.37	8.71	0.33	2.57e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs758324	1.000	rs758324	chr5:131109545	G/T	cg06307176	chr5:131281290	NA	0.53	10.21	0.37	8.75e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg16339924	chr4:17578868	LAP3	0.63	15.93	0.53	2.26e-48	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg12386194	chr3:101231763	SENP7	0.45	9.6	0.36	1.75e-20	Colorectal cancer;
BRCA	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg04455712	chr21:45112962	RRP1B	0.4	10.51	0.38	6e-24	Mean corpuscular volume;
BRCA	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg25319279	chr11:5960081	NA	-0.41	-7.91	-0.3	1.17e-14	DNA methylation (variation);
BRCA	cis	rs11779988	0.545	rs4124900	chr8:17785266	A/G	cg01800426	chr8:17659068	MTUS1	-0.4	-8.4	-0.32	2.97e-16	Breast cancer;
BRCA	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.38	0.38	2.03e-23	Motion sickness;
BRCA	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg16606324	chr3:10149918	C3orf24	0.56	9.97	0.37	7.35e-22	Alzheimer's disease;
BRCA	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg17971929	chr21:40555470	PSMG1	-0.61	-13.92	-0.48	1.19e-38	Cognitive function;
BRCA	cis	rs12022452	0.591	rs12042242	chr1:40993873	A/G	cg25568243	chr1:40974465	DEM1	-0.49	-9.06	-0.34	1.57e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg00409905	chr10:38381863	ZNF37A	-0.5	-10.44	-0.38	1.14e-23	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg02261765	chr11:831170	EFCAB4A	-0.4	-8.68	-0.32	3.35e-17	Mean platelet volume;
BRCA	cis	rs9837602	1.000	rs17379739	chr3:99724792	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	10.6	0.39	2.71e-24	Breast cancer;
BRCA	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg12386194	chr3:101231763	SENP7	0.46	9.66	0.36	1.03e-20	Colorectal cancer;
BRCA	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25427524	chr10:38739819	LOC399744	-0.7	-16.92	-0.56	2.46e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	19.33	0.61	6.67e-66	Smoking behavior;
BRCA	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg02659138	chr7:134003124	SLC35B4	0.33	10.32	0.38	3.47e-23	Mean platelet volume;
BRCA	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.33	-0.31	5.11e-16	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.55	13.06	0.46	1.06e-34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg12011299	chr4:100065546	ADH4	0.48	10.81	0.39	4.06e-25	Smoking initiation;
BRCA	cis	rs8010715	1.000	rs3742500	chr14:24611978	G/T	cg23112188	chr14:24563095	PCK2	-0.34	-8.37	-0.31	3.69e-16	IgG glycosylation;
BRCA	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg23602478	chr1:26503979	CNKSR1	0.23	7.84	0.3	1.91e-14	Height;
BRCA	cis	rs78707713	0.512	rs12772559	chr10:71184356	C/G	cg12610070	chr10:71211762	TSPAN15	-0.32	-10.43	-0.38	1.27e-23	Venous thromboembolism;
BRCA	cis	rs6878727	0.613	rs319627	chr5:123674793	G/T	cg01806427	chr5:123737813	NA	-0.36	-8.15	-0.31	1.97e-15	Breast cancer;
BRCA	cis	rs7178424	0.935	rs3784633	chr15:62259772	C/T	cg00456672	chr15:62358751	C2CD4A	0.35	8.05	0.3	4.12e-15	Height;
BRCA	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg26031613	chr14:104095156	KLC1	-0.45	-8.9	-0.33	5.62e-18	Schizophrenia;
BRCA	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg13798780	chr7:105162888	PUS7	0.45	7.9	0.3	1.21e-14	Bipolar disorder (body mass index interaction);
BRCA	trans	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg02030672	chr11:45687055	CHST1	0.51	11.45	0.41	9.7e-28	Obesity-related traits;
BRCA	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg02711726	chr17:80685570	FN3KRP	0.68	16.5	0.55	3.31e-51	Glycated hemoglobin levels;
BRCA	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg24209194	chr3:40518798	ZNF619	-0.39	-7.92	-0.3	1.07e-14	Renal cell carcinoma;
BRCA	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg24642844	chr7:1081250	C7orf50	-0.89	-16.29	-0.54	3.52e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	15.78	0.53	1.3e-47	Coronary artery disease;
BRCA	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg02574844	chr11:5959923	NA	-0.44	-8.6	-0.32	5.91e-17	DNA methylation (variation);
BRCA	trans	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg19862616	chr7:65841803	NCRNA00174	0.85	28.25	0.75	1.44e-114	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs7980799	0.935	rs12301124	chr12:33543024	T/C	cg26384229	chr12:38710491	ALG10B	-0.39	-7.98	-0.3	6.59e-15	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	9.71	0.36	6.73e-21	Lung cancer in ever smokers;
BRCA	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.22	0.49	4.65e-40	Motion sickness;
BRCA	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	11.29	0.41	4.61e-27	Personality dimensions;
BRCA	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg14926445	chr8:58193284	C8orf71	-0.47	-8.92	-0.33	4.83e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg00071950	chr4:10020882	SLC2A9	0.63	15.51	0.52	2.82e-46	Bone mineral density;
BRCA	trans	rs17685	0.753	rs869806	chr7:75688623	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	28.29	0.75	9.34e-115	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg18512352	chr11:47633146	NA	-0.34	-8.24	-0.31	9.79e-16	Subjective well-being;
BRCA	cis	rs701145	0.585	rs357466	chr3:153902868	A/G	cg17054900	chr3:154042577	DHX36	0.53	9.34	0.35	1.62e-19	Coronary artery disease;
BRCA	cis	rs807669	0.548	rs5746685	chr22:19192596	C/G	cg02655711	chr22:19163373	SLC25A1	-0.66	-15.96	-0.53	1.57e-48	Metabolite levels;
BRCA	cis	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg21775007	chr8:11205619	TDH	-0.47	-9.37	-0.35	1.26e-19	Retinal vascular caliber;
BRCA	trans	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg14791747	chr16:20752902	THUMPD1	0.43	10.46	0.38	9.47e-24	Cognitive test performance;
BRCA	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.81	12.38	0.44	1.05e-31	Gut microbiome composition (summer);
BRCA	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.77	-0.36	4.22e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg24747557	chr10:131355152	MGMT	-0.31	-7.85	-0.3	1.76e-14	Response to temozolomide;
BRCA	cis	rs12367572	0.965	rs10880696	chr12:45234989	A/G	cg04608330	chr12:45269318	NELL2	0.57	12.51	0.44	2.72e-32	Gut microbiome composition (summer);
BRCA	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg04362960	chr10:104952993	NT5C2	0.43	10.25	0.38	6.42e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg25358565	chr5:93447407	FAM172A	1.21	19.75	0.62	3.88e-68	Diabetic retinopathy;
BRCA	cis	rs2859741	0.967	rs592520	chr1:37513503	G/C	cg09363841	chr1:37513479	NA	-0.71	-18.5	-0.59	1.62e-61	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg08888203	chr3:10149979	C3orf24	0.68	14.48	0.5	2.55e-41	Alzheimer's disease;
BRCA	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg21427119	chr20:30132790	HM13	-0.42	-8.79	-0.33	1.38e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs7809950	1.000	rs2237677	chr7:107202502	A/C	cg23024343	chr7:107201750	COG5	-0.38	-8.86	-0.33	7.64e-18	Coronary artery disease;
BRCA	cis	rs6815814	0.904	rs3924113	chr4:38796255	G/T	cg06935464	chr4:38784597	TLR10	0.5	8.04	0.3	4.37e-15	Breast cancer;
BRCA	cis	rs2625529	0.586	rs7175197	chr15:72461648	G/A	cg16672083	chr15:72433130	SENP8	0.66	16.16	0.54	1.62e-49	Red blood cell count;
BRCA	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18876405	chr7:65276391	NA	-0.5	-11.37	-0.41	2.06e-27	Aortic root size;
BRCA	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.39	-9.55	-0.35	2.83e-20	Personality dimensions;
BRCA	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	16.69	0.55	3.7e-52	Alzheimer's disease;
BRCA	cis	rs887829	0.570	rs12623271	chr2:234599941	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.49	-0.32	1.44e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg09184832	chr6:79620586	NA	-0.5	-11.17	-0.4	1.34e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs6450176	1.000	rs67473746	chr5:53296730	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-14.96	-0.51	1.31e-43	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg21573476	chr21:45109991	RRP1B	-0.35	-9.18	-0.34	6.06e-19	Mean corpuscular volume;
BRCA	cis	rs7246967	0.673	rs59621958	chr19:22940659	C/T	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	trans	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-20.65	-0.63	5.57e-73	Exhaled nitric oxide output;
BRCA	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg07080220	chr10:102295463	HIF1AN	-0.44	-10.09	-0.37	2.5e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26818010	chr10:134567672	INPP5A	-0.72	-15.22	-0.52	7.23e-45	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg03188948	chr7:1209495	NA	0.83	11.33	0.41	2.93e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	16.45	0.55	5.54e-51	Colorectal cancer;
BRCA	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg10556349	chr10:835070	NA	0.64	8.74	0.33	1.98e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg23029597	chr12:123009494	RSRC2	-0.46	-9.34	-0.35	1.58e-19	Body mass index;
BRCA	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.45	-10.72	-0.39	8.66e-25	Longevity;Endometriosis;
BRCA	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg02551604	chr5:131831745	NA	-0.4	-14.95	-0.51	1.56e-43	Asthma (sex interaction);
BRCA	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18876405	chr7:65276391	NA	-0.52	-12.53	-0.44	2.3e-32	Aortic root size;
BRCA	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg22875332	chr1:76189707	ACADM	-0.78	-21.35	-0.65	9.97e-77	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.06	-0.43	2.49e-30	Alzheimer's disease;
BRCA	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.48	9.36	0.35	1.35e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6060960	0.537	rs75351461	chr20:30458612	C/T	cg13852791	chr20:30311386	BCL2L1	0.56	8.04	0.3	4.4e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg13852791	chr20:30311386	BCL2L1	0.83	15.48	0.52	3.93e-46	Mean corpuscular hemoglobin;
BRCA	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.32	-0.31	5.32e-16	Bipolar disorder;
BRCA	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-9.27	-0.34	2.84e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg25214090	chr10:38739885	LOC399744	0.55	12.59	0.45	1.26e-32	Corneal astigmatism;
BRCA	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg23978390	chr7:1156363	C7orf50	0.41	9.92	0.37	1.14e-21	Longevity;Endometriosis;
BRCA	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.64	0.55	6.52e-52	Morning vs. evening chronotype;
BRCA	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg04511125	chr2:88470314	THNSL2	0.94	13.18	0.46	2.99e-35	Plasma clusterin levels;
BRCA	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg27489772	chr12:121021490	NA	0.45	8.03	0.3	4.74e-15	Type 1 diabetes nephropathy;
BRCA	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg18252515	chr7:66147081	NA	-0.9	-12.93	-0.46	3.87e-34	Diabetic kidney disease;
BRCA	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.43	-0.35	7.23e-20	Body mass index;
BRCA	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg26384229	chr12:38710491	ALG10B	0.78	17.49	0.57	2.99e-56	Morning vs. evening chronotype;
BRCA	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg14458575	chr2:238380390	NA	0.77	17.31	0.56	2.59e-55	Prostate cancer;
BRCA	cis	rs2766692	1.000	rs2766690	chr14:100682154	A/G	cg14866419	chr14:100704911	YY1	-0.43	-8.87	-0.33	7.23e-18	Electroencephalographic traits in alcoholism;
BRCA	cis	rs3857536	0.740	rs7766407	chr6:66885658	C/A	cg07460842	chr6:66804631	NA	-0.48	-9.27	-0.34	2.78e-19	Blood trace element (Cu levels);
BRCA	cis	rs9359856	0.510	rs2748298	chr6:90436877	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.71	-10.78	-0.39	5.12e-25	Bipolar disorder;
BRCA	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.89	0.36	1.54e-21	Lung cancer in ever smokers;
BRCA	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg13010199	chr12:38710504	ALG10B	0.49	9.38	0.35	1.15e-19	Morning vs. evening chronotype;
BRCA	cis	rs16958440	0.867	rs76922914	chr18:44688454	T/C	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.46e-37	Sitting height ratio;
BRCA	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg08601574	chr20:25228251	PYGB	-0.39	-9.05	-0.34	1.77e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg18252515	chr7:66147081	NA	-1.05	-15.27	-0.52	4.18e-45	Diabetic kidney disease;
BRCA	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg23708337	chr7:1209742	NA	0.48	8.06	0.3	3.76e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.22	-0.31	1.13e-15	Parkinson's disease;
BRCA	cis	rs701145	0.556	rs355756	chr3:154021063	G/A	cg12800244	chr3:153838788	SGEF	0.44	8.9	0.33	5.58e-18	Coronary artery disease;
BRCA	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg00825309	chr19:58991885	ZNF446	-0.58	-12.78	-0.45	1.83e-33	Uric acid clearance;
BRCA	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg21535247	chr6:8435926	SLC35B3	0.41	9.4	0.35	9.75e-20	Motion sickness;
BRCA	cis	rs113835537	0.529	rs11227514	chr11:66286627	G/A	cg24851651	chr11:66362959	CCS	0.42	8.01	0.3	5.37e-15	Airway imaging phenotypes;
BRCA	trans	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg25214090	chr10:38739885	LOC399744	0.54	11.76	0.42	4.92e-29	Corneal astigmatism;
BRCA	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg02493740	chr2:85810744	VAMP5	0.37	7.93	0.3	9.98e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg16606324	chr3:10149918	C3orf24	0.49	9.94	0.37	9.21e-22	Alzheimer's disease;
BRCA	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.29	0.38	4.41e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4561483	0.801	rs33619	chr16:12008941	T/G	cg08843971	chr16:11963173	GSPT1	-0.52	-11.84	-0.42	2.21e-29	Testicular germ cell tumor;
BRCA	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg26384229	chr12:38710491	ALG10B	-0.47	-10.87	-0.39	2.36e-25	Morning vs. evening chronotype;
BRCA	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.65	-9.72	-0.36	6.56e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7524258	0.868	rs7544314	chr1:7266744	G/C	cg07173049	chr1:7289937	CAMTA1	0.53	12.93	0.46	3.98e-34	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.79	0.39	4.76e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs367943	0.644	rs348942	chr5:112824039	T/C	cg12552261	chr5:112820674	MCC	-0.57	-12.42	-0.44	7.14e-32	Type 2 diabetes;
BRCA	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21659725	chr3:3221576	CRBN	-0.35	-8.52	-0.32	1.18e-16	Body mass index;
BRCA	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg16325326	chr1:53192061	ZYG11B	0.69	17.17	0.56	1.36e-54	Monocyte count;
BRCA	cis	rs9308433	0.529	rs11800749	chr1:214499754	A/G	cg06198575	chr1:214491504	SMYD2	-0.52	-11.74	-0.42	6.08e-29	IgG glycosylation;
BRCA	cis	rs7301826	0.932	rs1007246	chr12:131280130	T/A	cg11011512	chr12:131303247	STX2	0.42	10.74	0.39	7.35e-25	Plasma plasminogen activator levels;
BRCA	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg14835575	chr10:16859367	RSU1	0.63	12.92	0.46	4.45e-34	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	14.17	0.49	8.02e-40	Colorectal cancer;
BRCA	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg19773385	chr1:10388646	KIF1B	-0.38	-8.23	-0.31	1.06e-15	Hepatocellular carcinoma;
BRCA	cis	rs9487051	0.646	rs11153167	chr6:109622582	A/T	cg01475377	chr6:109611718	NA	0.41	8.94	0.33	4.3e-18	Reticulocyte fraction of red cells;
BRCA	trans	rs1974653	0.813	rs9606232	chr22:20065370	C/T	cg20152630	chr19:46405944	MYPOP	0.39	8.5	0.32	1.36e-16	Schizophrenia;
BRCA	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00908189	chr16:619842	PIGQ	0.67	16.74	0.55	2.04e-52	Height;
BRCA	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.52	13.23	0.46	1.77e-35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.53	12.09	0.43	1.93e-30	Colorectal cancer;
BRCA	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg21479132	chr6:26055353	NA	0.57	8.02	0.3	4.93e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg23719950	chr11:63933701	MACROD1	-0.58	-9.82	-0.36	2.74e-21	Mean platelet volume;
BRCA	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg24812749	chr6:127587940	RNF146	0.54	12.06	0.43	2.66e-30	Breast cancer;
BRCA	cis	rs1997103	1.000	rs4948011	chr7:55403859	A/G	cg17469321	chr7:55412551	NA	0.48	9.11	0.34	1.05e-18	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7408868	0.764	rs62113791	chr19:15277009	C/T	cg14696996	chr19:15285081	NOTCH3	0.99	14.49	0.5	2.35e-41	Pulse pressure;
BRCA	cis	rs7727544	0.548	rs2069614	chr5:131407601	T/C	cg14196790	chr5:131705035	SLC22A5	0.35	8.77	0.33	1.61e-17	Blood metabolite levels;
BRCA	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg05623727	chr3:50126028	RBM5	0.41	9.7	0.36	7.31e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs6600671	0.899	rs6674392	chr1:121260662	C/G	cg00646200	chr1:148855367	NA	0.32	8.25	0.31	9.14e-16	Hip geometry;
BRCA	trans	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg17712092	chr4:129076599	LARP1B	-0.38	-8.06	-0.3	3.63e-15	DNA methylation (variation);
BRCA	trans	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	8.51	0.32	1.28e-16	Mean corpuscular volume;
BRCA	cis	rs11920090	0.858	rs6808595	chr3:170674678	A/G	cg09710316	chr3:170744871	SLC2A2	0.55	9.24	0.34	3.56e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs9807989	0.524	rs6759479	chr2:103040047	A/C	cg03938978	chr2:103052716	IL18RAP	0.29	8.3	0.31	6.11e-16	Asthma;
BRCA	cis	rs6750047	0.546	rs10192788	chr2:38272672	C/T	cg07380506	chr2:38303506	CYP1B1	0.48	10.62	0.39	2.19e-24	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.65	-0.36	1.12e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14240646	chr10:27532245	ACBD5	-0.6	-9.06	-0.34	1.53e-18	Breast cancer;
BRCA	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.3e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.55	-0.32	8.79e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg02753203	chr1:228287806	NA	-0.6	-12.87	-0.45	7.2e-34	Diastolic blood pressure;
BRCA	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg12310025	chr6:25882481	NA	0.43	9.51	0.35	3.69e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg02079420	chr8:82753780	SNX16	-0.32	-8.64	-0.32	4.33e-17	Diastolic blood pressure;
BRCA	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg13319975	chr6:146136371	FBXO30	0.43	10.04	0.37	4.06e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg13628971	chr7:2884303	GNA12	0.47	9.64	0.36	1.3e-20	Height;
BRCA	cis	rs1568889	0.838	rs7125749	chr11:28154692	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	20.72	0.63	2.49e-73	Bipolar disorder;
BRCA	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg16606324	chr3:10149918	C3orf24	0.57	10.04	0.37	3.9e-22	Alzheimer's disease;
BRCA	cis	rs78456975	0.739	rs11896906	chr2:1519550	A/G	cg12573674	chr2:1569213	NA	-0.48	-9.48	-0.35	4.9e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg23791538	chr6:167370224	RNASET2	0.39	9.2	0.34	4.95e-19	Crohn's disease;
BRCA	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg14582100	chr15:45693742	SPATA5L1	0.29	8.53	0.32	1.08e-16	Homoarginine levels;
BRCA	cis	rs12760731	0.720	rs16852717	chr1:178309723	T/C	cg00404053	chr1:178313656	RASAL2	0.62	8.57	0.32	7.67e-17	Obesity-related traits;
BRCA	cis	rs9309473	0.583	rs6713196	chr2:73576405	T/C	cg20560298	chr2:73613845	ALMS1	-0.44	-11.57	-0.42	3.11e-28	Metabolite levels;
BRCA	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14019695	chr9:139328340	INPP5E	-0.37	-10.25	-0.38	6.24e-23	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg09904177	chr6:26538194	HMGN4	0.55	17.65	0.57	4.53e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs7561273	0.586	rs13418279	chr2:24349218	G/T	cg04809136	chr2:24300158	SF3B14	-0.4	-8.94	-0.33	4.13e-18	Quantitative traits;
BRCA	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg02574844	chr11:5959923	NA	-0.43	-8.46	-0.32	1.76e-16	DNA methylation (variation);
BRCA	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg02734326	chr4:10020555	SLC2A9	0.41	8.99	0.34	2.74e-18	Bone mineral density;
BRCA	cis	rs16958440	1.000	rs62096470	chr18:44641466	G/C	cg17192377	chr18:44677553	HDHD2	0.67	9.8	0.36	3.33e-21	Sitting height ratio;
BRCA	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg18154014	chr19:37997991	ZNF793	0.48	9.65	0.36	1.19e-20	Coronary artery calcification;
BRCA	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg07636037	chr3:49044803	WDR6	0.82	21.71	0.65	9.9e-79	Menarche (age at onset);
BRCA	cis	rs2599510	0.934	rs2710634	chr2:32808804	T/C	cg02381751	chr2:32503542	YIPF4	0.43	8.74	0.33	2.12e-17	Interleukin-18 levels;
BRCA	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg22713356	chr15:30763199	NA	1.18	24.01	0.69	2.83e-91	Uric acid levels;
BRCA	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg18225595	chr11:63971243	STIP1	0.5	8.89	0.33	6.45e-18	Mean platelet volume;
BRCA	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg08508325	chr11:3079039	CARS	0.29	8.54	0.32	1.02e-16	Calcium levels;
BRCA	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg04553112	chr3:125709451	NA	-0.53	-8.69	-0.32	3.12e-17	Blood pressure (smoking interaction);
BRCA	trans	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-35.75	-0.82	1.44e-154	Exhaled nitric oxide output;
BRCA	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg09307838	chr4:120376055	NA	0.69	14.08	0.49	2.13e-39	Corneal astigmatism;
BRCA	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg19784903	chr17:45786737	TBKBP1	0.34	8.13	0.31	2.17e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1710278	0.967	rs1278264	chr10:127746893	G/A	cg22975853	chr10:127789788	ADAM12	0.3	7.88	0.3	1.37e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
BRCA	cis	rs4561483	0.645	rs2192645	chr16:11928019	C/T	cg08843971	chr16:11963173	GSPT1	-0.44	-9.85	-0.36	2.14e-21	Testicular germ cell tumor;
BRCA	cis	rs2505998	0.833	rs2251674	chr10:43605392	A/G	cg15436174	chr10:43711423	RASGEF1A	0.39	8.0	0.3	5.89e-15	Hirschsprung disease;
BRCA	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg21132104	chr15:45694354	SPATA5L1	0.74	16.31	0.54	2.91e-50	Homoarginine levels;
BRCA	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06544989	chr22:39130855	UNC84B	0.38	8.74	0.33	2.04e-17	Menopause (age at onset);
BRCA	cis	rs4077515	0.870	rs11793497	chr9:139271850	A/G	cg14019695	chr9:139328340	INPP5E	0.32	8.13	0.31	2.28e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg13319975	chr6:146136371	FBXO30	0.62	14.44	0.5	4.22e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg24829409	chr8:58192753	C8orf71	-0.5	-10.23	-0.38	7.43e-23	Developmental language disorder (linguistic errors);
BRCA	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg08999081	chr20:33150536	PIGU	-0.46	-12.54	-0.44	2e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08045932	chr20:61659980	NA	0.5	11.43	0.41	1.2100000000000001e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg20607287	chr7:12443886	VWDE	-0.58	-8.36	-0.31	3.96e-16	Coronary artery disease;
BRCA	cis	rs1190552	0.846	rs1044503	chr14:102965996	A/G	cg18135206	chr14:102964638	TECPR2	0.46	8.98	0.33	3.11e-18	Blood protein levels;
BRCA	trans	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.95	0.3	8.6e-15	Corneal astigmatism;
BRCA	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg18758796	chr5:131593413	PDLIM4	0.37	9.22	0.34	4.2e-19	Acylcarnitine levels;
BRCA	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg09307838	chr4:120376055	NA	0.57	10.76	0.39	6.08e-25	Corneal astigmatism;
BRCA	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg03560586	chr2:239334908	ASB1	-0.52	-11.48	-0.41	7.11e-28	Multiple system atrophy;
BRCA	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg09307838	chr4:120376055	NA	0.46	9.53	0.35	3.14e-20	Diastolic blood pressure;
BRCA	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg05347473	chr6:146136440	FBXO30	-0.42	-8.38	-0.31	3.44e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26314531	chr2:26401878	FAM59B	0.73	10.38	0.38	1.93e-23	Gut microbiome composition (summer);
BRCA	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.87	0.3	1.56e-14	Depression;
BRCA	cis	rs68170813	0.559	rs7794598	chr7:106826381	C/T	cg02696742	chr7:106810147	HBP1	-0.54	-9.35	-0.35	1.51e-19	Coronary artery disease;
BRCA	trans	rs12517041	1.000	rs10074124	chr5:23318235	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-8.11	-0.31	2.55e-15	Calcium levels;
BRCA	cis	rs7737355	1.000	rs6872972	chr5:130621533	C/T	cg06307176	chr5:131281290	NA	0.45	8.68	0.32	3.29e-17	Life satisfaction;
BRCA	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.56	0.63	1.72e-72	Electrocardiographic conduction measures;
BRCA	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg13073564	chr4:8508604	NA	0.38	10.34	0.38	2.83e-23	Response to antineoplastic agents;
BRCA	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg27170947	chr2:26402098	FAM59B	0.97	17.09	0.56	3.41e-54	Gut microbiome composition (summer);
BRCA	cis	rs1971762	0.583	rs12810378	chr12:54091838	G/T	cg23533419	chr12:54090519	NA	-0.33	-8.39	-0.31	3.12e-16	Height;
BRCA	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07343612	chr16:622815	PIGQ	-0.67	-21.41	-0.65	4.64e-77	Height;
BRCA	cis	rs698833	0.962	rs786409	chr2:44731344	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	10.3	0.38	3.87e-23	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs3892630	0.529	rs35300319	chr19:33409948	G/A	cg22980127	chr19:33182716	NUDT19	0.68	12.52	0.44	2.46e-32	Red blood cell traits;
BRCA	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg24812749	chr6:127587940	RNF146	0.88	20.63	0.63	7.68e-73	Breast cancer;
BRCA	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg24060327	chr5:131705240	SLC22A5	-0.51	-10.56	-0.39	3.85e-24	Blood metabolite levels;
BRCA	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg10978503	chr1:24200527	CNR2	0.52	13.91	0.48	1.24e-38	Immature fraction of reticulocytes;
BRCA	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg18132916	chr6:79620363	NA	-0.39	-8.02	-0.3	5.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg08601574	chr20:25228251	PYGB	0.36	8.37	0.31	3.65e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4664304	0.620	rs2136977	chr2:160722850	C/T	cg02280532	chr2:160761244	LY75	0.35	7.87	0.3	1.57e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs11997175	0.583	rs12680811	chr8:33778426	A/C	ch.8.33884649F	chr8:33765107	NA	0.38	9.12	0.34	9.64e-19	Body mass index;
BRCA	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.1	0.31	2.75e-15	Total cholesterol levels;
BRCA	cis	rs312273	0.582	rs312267	chr12:41250565	A/G	cg17827154	chr12:41323612	CNTN1	-0.34	-7.89	-0.3	1.31e-14	Bipolar disorder;
BRCA	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.43	9.56	0.35	2.44e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.89	-0.33	6.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1568889	0.838	rs7943538	chr11:28288955	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	18.04	0.58	4.25e-59	Bipolar disorder;
BRCA	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg05623727	chr3:50126028	RBM5	0.43	10.08	0.37	2.74e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg18964960	chr10:1102726	WDR37	0.6	8.04	0.3	4.44e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg06212747	chr3:49208901	KLHDC8B	0.42	7.86	0.3	1.63e-14	Menarche (age at onset);
BRCA	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg13010199	chr12:38710504	ALG10B	0.47	9.03	0.34	2.04e-18	Morning vs. evening chronotype;
BRCA	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg16102102	chr5:83017553	HAPLN1	-0.91	-18.11	-0.58	1.72e-59	Prostate cancer;
BRCA	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	ch.11.42038R	chr11:967971	AP2A2	0.52	16.47	0.55	4.61e-51	Alzheimer's disease (late onset);
BRCA	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg18876405	chr7:65276391	NA	0.71	18.48	0.59	1.96e-61	Aortic root size;
BRCA	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-11.08	-0.4	3.21e-26	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	14.3	0.49	1.97e-40	Ileal carcinoids;
BRCA	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.78	13.1	0.46	6.99e-35	Schizophrenia;
BRCA	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg05347473	chr6:146136440	FBXO30	0.42	8.59	0.32	6.68e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs654950	0.934	rs662999	chr1:42001160	A/C	cg06885757	chr1:42089581	HIVEP3	0.27	9.39	0.35	1.04e-19	Airway imaging phenotypes;
BRCA	cis	rs4908768	0.501	rs6668508	chr1:8574118	C/T	cg20416874	chr1:8611966	RERE	-0.29	-8.3	-0.31	6.25e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	trans	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg23762105	chr12:34175262	ALG10	0.37	8.59	0.32	6.53e-17	Morning vs. evening chronotype;
BRCA	cis	rs1451375	0.617	rs12671474	chr7:50591395	C/A	cg18232548	chr7:50535776	DDC	0.44	9.36	0.35	1.33e-19	Malaria;
BRCA	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	18.79	0.6	4.88e-63	Tonsillectomy;
BRCA	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.69	-0.33	3.04e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.03	-19.63	-0.61	1.69e-67	Platelet count;
BRCA	cis	rs2495707	0.624	rs2489007	chr10:102422046	A/G	cg24024056	chr10:102415556	NA	0.32	7.84	0.3	1.9e-14	Body mass index;
BRCA	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.01	27.66	0.74	2.49e-111	Cognitive ability;
BRCA	trans	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg06521331	chr12:34319734	NA	-0.47	-8.74	-0.33	2e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg00431813	chr7:1051703	C7orf50	-0.39	-11.47	-0.41	8.19e-28	Longevity;Endometriosis;
BRCA	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs812925	0.537	rs10865324	chr2:61621307	G/A	cg15711740	chr2:61764176	XPO1	0.33	8.2	0.31	1.34e-15	Immature fraction of reticulocytes;
BRCA	cis	rs1865721	0.804	rs7229401	chr18:73148127	T/G	cg26385618	chr18:73139727	C18orf62	-0.44	-10.63	-0.39	2.1e-24	Intelligence;
BRCA	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg19748678	chr4:122722346	EXOSC9	0.42	8.67	0.32	3.48e-17	Type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg11663144	chr21:46675770	NA	-0.61	-13.91	-0.48	1.22e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg05340658	chr4:99064831	C4orf37	0.63	15.11	0.51	2.45e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1864400	0.690	rs2565200	chr10:43622933	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.55	-11.03	-0.4	5.22e-26	Hirschsprung disease;
BRCA	trans	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg23762105	chr12:34175262	ALG10	-0.38	-9.68	-0.36	8.87e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg17724175	chr1:150552817	MCL1	0.25	8.36	0.31	3.79e-16	Tonsillectomy;
BRCA	cis	rs7520050	0.933	rs6656022	chr1:46394315	A/G	cg24296786	chr1:45957014	TESK2	0.44	9.82	0.36	2.77e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg06766960	chr11:133703094	NA	-0.61	-12.95	-0.46	3.03e-34	Childhood ear infection;
BRCA	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg21143896	chr7:2802374	GNA12	-0.36	-9.07	-0.34	1.44e-18	Height;
BRCA	cis	rs6496044	0.568	rs12899946	chr15:86066082	C/T	cg10818794	chr15:86012489	AKAP13	-0.29	-7.91	-0.3	1.1e-14	Interstitial lung disease;
BRCA	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.79	-0.5	9.17e-43	Chronic sinus infection;
BRCA	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.22	0.37	8.46e-23	Aortic root size;
BRCA	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg17143192	chr8:8559678	CLDN23	0.56	10.88	0.4	2.06e-25	Obesity-related traits;
BRCA	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg16339924	chr4:17578868	LAP3	0.67	17.04	0.56	6.2e-54	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-8.44	-0.32	2.16e-16	Daytime sleep phenotypes;
BRCA	trans	rs1973993	0.561	rs6593609	chr1:96991652	C/T	cg10631902	chr5:14652156	NA	-0.41	-10.04	-0.37	4.12e-22	Weight;
BRCA	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg00106254	chr7:1943704	MAD1L1	-0.3	-8.03	-0.3	4.78e-15	Bipolar disorder and schizophrenia;
BRCA	trans	rs9409565	0.793	rs2486632	chr9:97196979	A/G	cg05679027	chr9:99775184	HIATL2	-0.42	-9.29	-0.34	2.41e-19	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11890956	chr21:40555474	PSMG1	1.04	29.7	0.76	1.93e-122	Cognitive function;
BRCA	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg12311346	chr5:56204834	C5orf35	1.01	20.24	0.62	9.81e-71	Initial pursuit acceleration;
BRCA	cis	rs243505	0.898	rs243527	chr7:148416104	G/T	cg09806900	chr7:148480153	CUL1	-0.4	-8.34	-0.31	4.42e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg15242686	chr22:24348715	GSTTP1	-0.36	-8.83	-0.33	1e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg06521331	chr12:34319734	NA	-0.48	-9.25	-0.34	3.19e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2836950	0.805	rs62223042	chr21:40683740	A/G	cg17971929	chr21:40555470	PSMG1	-0.43	-8.78	-0.33	1.55e-17	Menarche (age at onset);
BRCA	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg12826209	chr6:26865740	GUSBL1	0.56	9.17	0.34	6.68e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.31	-7.89	-0.3	1.28e-14	Response to antipsychotic treatment;
BRCA	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	15.97	0.53	1.4e-48	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6700896	0.931	rs2211651	chr1:66156021	G/T	cg04111102	chr1:66153794	NA	0.36	8.82	0.33	1.09e-17	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.28	-0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07080220	chr10:102295463	HIF1AN	0.51	11.39	0.41	1.77e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9807989	0.507	rs13021177	chr2:103056493	A/G	cg03938978	chr2:103052716	IL18RAP	0.28	8.13	0.31	2.17e-15	Asthma;
BRCA	cis	rs364477	0.630	rs7031845	chr9:1005131	A/G	cg13952963	chr9:998547	NA	-0.41	-8.7	-0.33	2.87e-17	Major depressive disorder;
BRCA	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg13880726	chr7:1868755	MAD1L1	0.52	10.4	0.38	1.71e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-9.24	-0.34	3.53e-19	Educational attainment;
BRCA	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.02	0.3	5.13e-15	Rheumatoid arthritis;
BRCA	cis	rs12612619	0.579	rs11887277	chr2:27083269	A/G	cg12368169	chr2:27073192	DPYSL5	-0.33	-10.19	-0.37	1.12e-22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg25427524	chr10:38739819	LOC399744	0.51	9.43	0.35	7.31e-20	Obesity (extreme);
BRCA	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg24112000	chr20:60950667	NA	-0.58	-12.61	-0.45	1.02e-32	Colorectal cancer;
BRCA	cis	rs1443512	0.947	rs1822438	chr12:54342326	A/C	cg17410650	chr12:54324560	NA	-0.35	-8.29	-0.31	6.52e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
BRCA	cis	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg24692254	chr21:30365293	RNF160	0.42	9.62	0.36	1.45e-20	Pancreatic cancer;
BRCA	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.35	-7.83	-0.3	2.07e-14	Longevity;Endometriosis;
BRCA	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg09165964	chr15:75287851	SCAMP5	-0.77	-18.03	-0.58	4.7e-59	Blood trace element (Zn levels);
BRCA	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg06453172	chr10:134556979	INPP5A	-0.6	-11.81	-0.42	3e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg11707556	chr5:10655725	ANKRD33B	0.43	9.52	0.35	3.53e-20	Height;
BRCA	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-9.91	-0.36	1.28e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg05340658	chr4:99064831	C4orf37	0.45	10.39	0.38	1.79e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg04545296	chr12:48745243	ZNF641	-0.24	-8.05	-0.3	4.02e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	trans	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg26384229	chr12:38710491	ALG10B	0.57	12.23	0.44	4.52e-31	Morning vs. evening chronotype;
BRCA	cis	rs10501293	0.667	rs4565888	chr11:42986051	G/A	cg03447554	chr11:43094025	NA	0.42	7.94	0.3	8.9e-15	Cognitive performance;
BRCA	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg02175503	chr12:58329896	NA	0.52	11.2	0.4	1.07e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg06064525	chr11:970664	AP2A2	0.48	16.03	0.54	7.75e-49	Alzheimer's disease (late onset);
BRCA	cis	rs2742234	0.955	rs1800861	chr10:43613843	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.43	-9.14	-0.34	7.94e-19	Hirschsprung disease;
BRCA	cis	rs3849570	0.961	rs10154945	chr3:81833766	A/C	cg07356753	chr3:81810745	GBE1	-0.47	-11.29	-0.41	4.35e-27	Waist circumference;Body mass index;
BRCA	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg27535305	chr1:53392650	SCP2	0.33	8.28	0.31	7.16e-16	Monocyte count;
BRCA	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.38	-0.38	2.0500000000000001e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg14675211	chr2:100938903	LONRF2	0.49	11.18	0.4	1.27e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg17971929	chr21:40555470	PSMG1	-0.61	-13.51	-0.47	9.1e-37	Cognitive function;
BRCA	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg17366294	chr4:99064904	C4orf37	0.42	9.9	0.36	1.33e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.45	-9.16	-0.34	7.06e-19	Body mass index;
BRCA	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg23711669	chr6:146136114	FBXO30	0.69	16.02	0.54	7.97e-49	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-9.02	-0.34	2.16e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-14.18	-0.49	7.01e-40	Extrinsic epigenetic age acceleration;
BRCA	cis	rs68170813	0.523	rs10253172	chr7:106786474	C/T	cg02696742	chr7:106810147	HBP1	0.62	9.87	0.36	1.82e-21	Coronary artery disease;
BRCA	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.38	9.35	0.35	1.4e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg21045802	chr8:109455806	TTC35	0.35	8.01	0.3	5.3e-15	Dupuytren's disease;
BRCA	cis	rs11055008	0.620	rs10845608	chr12:12836088	C/T	cg04607235	chr12:12878440	APOLD1	0.43	8.83	0.33	1.03e-17	Pulse pressure;
BRCA	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg05279229	chr7:1896384	MAD1L1	-0.45	-8.78	-0.33	1.55e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg00105475	chr2:10696890	NA	0.44	10.37	0.38	2.16e-23	Prostate cancer;
BRCA	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg22009923	chr11:832065	CD151	-0.46	-9.96	-0.37	8.37e-22	Mean platelet volume;
BRCA	cis	rs9644630	1.000	rs4921657	chr8:19370867	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.42	9.4	0.35	9.23e-20	Oropharynx cancer;
BRCA	cis	rs9309711	0.922	rs7561600	chr2:3486093	G/C	cg16153549	chr2:3496821	NA	-0.36	-8.24	-0.31	9.67e-16	Neurofibrillary tangles;
BRCA	trans	rs3960554	0.529	rs7800970	chr7:75880198	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.44	-10.15	-0.37	1.59e-22	Eotaxin levels;
BRCA	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg05707623	chr12:122985044	ZCCHC8	0.49	9.42	0.35	7.86e-20	Body mass index;
BRCA	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.2	-0.37	1.01e-22	IgG glycosylation;
BRCA	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.65	11.94	0.43	8.2e-30	Gut microbiome composition (summer);
BRCA	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.23	-0.41	8.09e-27	Morning vs. evening chronotype;
BRCA	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.15	0.37	1.53e-22	Bladder cancer;
BRCA	cis	rs733175	0.857	rs7666545	chr4:10012372	C/T	cg00071950	chr4:10020882	SLC2A9	0.43	8.39	0.32	3e-16	Psychosis and Alzheimer's disease;
BRCA	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg08755490	chr11:65554678	OVOL1	0.55	11.5	0.41	5.88e-28	Acne (severe);
BRCA	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.67	-0.61	9.89e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.74	-0.5	1.48e-42	Total cholesterol levels;
BRCA	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	13.8	0.48	4.24e-38	Systolic blood pressure;
BRCA	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg23711669	chr6:146136114	FBXO30	0.79	18.81	0.6	3.73e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg20891283	chr12:69753455	YEATS4	0.73	21.79	0.65	3.72e-79	Blood protein levels;
BRCA	cis	rs2559856	1.000	rs2695282	chr12:102089502	A/G	cg12924262	chr12:102091054	CHPT1	-0.38	-8.65	-0.32	4.2e-17	Blood protein levels;
BRCA	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg00677455	chr12:58241039	CTDSP2	0.8	17.9	0.58	2.32e-58	Multiple sclerosis;
BRCA	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg00012203	chr2:219082015	ARPC2	-0.61	-12.92	-0.46	4.24e-34	Colorectal cancer;
BRCA	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10802521	chr3:52805072	NEK4	-0.31	-8.09	-0.3	3.02e-15	Bipolar disorder;
BRCA	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg03213289	chr20:61660250	NA	0.61	16.2	0.54	1e-49	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-10.39	-0.38	1.79e-23	Blood metabolite levels;
BRCA	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg27170947	chr2:26402098	FAM59B	-0.65	-11.21	-0.41	9.48e-27	Gut microbiome composition (summer);
BRCA	cis	rs2806561	0.754	rs750354	chr1:23297406	T/C	cg19743168	chr1:23544995	NA	-0.4	-9.59	-0.35	1.88e-20	Height;
BRCA	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg17971929	chr21:40555470	PSMG1	0.52	11.69	0.42	9.84e-29	Cognitive function;
BRCA	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg02297831	chr4:17616191	MED28	-0.34	-7.92	-0.3	1.03e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg07148914	chr20:33460835	GGT7	-0.37	-7.97	-0.3	7.47e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs27434	0.529	rs42443	chr5:96156224	G/A	cg16492584	chr5:96139282	ERAP1	-0.51	-12.74	-0.45	2.66e-33	Ankylosing spondylitis;
BRCA	cis	rs730566	1.000	rs730566	chr3:48487048	G/T	cg07636037	chr3:49044803	WDR6	-0.52	-9.84	-0.36	2.19e-21	Prion diseases;
BRCA	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26314531	chr2:26401878	FAM59B	-0.97	-16.88	-0.56	3.74e-53	Gut microbiome composition (summer);
BRCA	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg13660082	chr14:53194042	PSMC6	-0.58	-8.74	-0.33	2.05e-17	Alzheimer's disease (late onset);
BRCA	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg02743256	chr7:2109353	MAD1L1	-0.46	-8.13	-0.31	2.27e-15	Neuroticism;
BRCA	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04267008	chr7:1944627	MAD1L1	0.44	10.02	0.37	4.62e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-11.61	-0.42	2.1e-28	Pulmonary function;
BRCA	trans	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg26384229	chr12:38710491	ALG10B	0.39	9.26	0.34	3.1400000000000002e-19	Morning vs. evening chronotype;
BRCA	cis	rs3106136	0.527	rs2632411	chr4:95149434	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-9.99	-0.37	6.09e-22	Capecitabine sensitivity;
BRCA	cis	rs72781680	0.716	rs7564732	chr2:24034178	C/T	cg08917208	chr2:24149416	ATAD2B	0.61	10.54	0.38	4.7e-24	Lymphocyte counts;
BRCA	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-11.05	-0.4	4.27e-26	Mean corpuscular volume;
BRCA	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.48	-0.32	1.6e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg13256891	chr4:100009986	ADH5	0.5	10.33	0.38	3.05e-23	Alcohol dependence;
BRCA	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg00105475	chr2:10696890	NA	0.44	10.29	0.38	4.39e-23	Prostate cancer;
BRCA	cis	rs7766436	0.687	rs10485012	chr6:22607026	A/C	cg13666174	chr6:22585274	NA	-0.36	-8.48	-0.32	1.54e-16	Coronary artery disease;
BRCA	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg06115741	chr20:33292138	TP53INP2	0.49	10.84	0.39	3.12e-25	Coronary artery disease;
BRCA	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg23711669	chr6:146136114	FBXO30	0.72	17.59	0.57	8.45e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg13010199	chr12:38710504	ALG10B	0.42	8.55	0.32	9.39e-17	Bladder cancer;
BRCA	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg01262667	chr19:19385393	TM6SF2	-0.38	-9.74	-0.36	5.42e-21	Tonsillectomy;
BRCA	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-14.87	-0.51	3.56e-43	Coronary artery disease;
BRCA	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.59	7.99	0.3	6.45e-15	Diabetic retinopathy;
BRCA	cis	rs9355610	0.609	rs62436424	chr6:167374258	A/G	cg23791538	chr6:167370224	RNASET2	0.43	8.47	0.32	1.64e-16	Graves' disease;
BRCA	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg04586622	chr2:25135609	ADCY3	0.46	11.5	0.41	5.76e-28	Body mass index;
BRCA	cis	rs8030485	0.730	rs57488047	chr15:79403002	T/C	cg17916960	chr15:79447300	NA	0.37	8.55	0.32	9.22e-17	Left ventricle wall thickness;
BRCA	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg24829409	chr8:58192753	C8orf71	-0.48	-9.14	-0.34	7.94e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg06640241	chr16:89574553	SPG7	0.88	23.14	0.68	1.7e-86	Multiple myeloma (IgH translocation);
BRCA	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg04944784	chr2:26401820	FAM59B	1.0	16.64	0.55	6.7e-52	Gut microbiome composition (summer);
BRCA	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg06159980	chr1:16340746	HSPB7	-0.39	-8.85	-0.33	8.44e-18	Dilated cardiomyopathy;
BRCA	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg11645453	chr3:52864694	ITIH4	0.32	7.86	0.3	1.63e-14	Bipolar disorder;
BRCA	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg12179176	chr11:130786555	SNX19	-0.72	-18.31	-0.59	1.63e-60	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg24060327	chr5:131705240	SLC22A5	-0.43	-8.85	-0.33	8.32e-18	Acylcarnitine levels;
BRCA	cis	rs6973256	0.834	rs11768150	chr7:133335011	T/G	cg07491979	chr7:133331646	EXOC4	-0.39	-8.91	-0.33	5.11e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7617773	0.963	rs12495221	chr3:48179178	C/T	cg11946769	chr3:48343235	NME6	-0.39	-8.86	-0.33	7.66e-18	Coronary artery disease;
BRCA	cis	rs1003719	0.715	rs2156078	chr21:38546473	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.36	-0.49	1e-40	Eye color traits;
BRCA	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg21475434	chr5:93447410	FAM172A	0.71	8.79	0.33	1.36e-17	Diabetic retinopathy;
BRCA	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.63	13.83	0.48	3.19e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7904985	0.889	rs1078789	chr10:88110247	C/T	cg07322936	chr10:88137208	NA	-0.45	-9.6	-0.36	1.72e-20	Barrett's esophagus;
BRCA	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.12	-0.31	2.39e-15	Total body bone mineral density;
BRCA	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-9.71	-0.36	6.91e-21	Tonsillectomy;
BRCA	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg07148914	chr20:33460835	GGT7	0.48	10.33	0.38	3e-23	Height;
BRCA	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg24642439	chr20:33292090	TP53INP2	-0.4	-7.86	-0.3	1.66e-14	Height;
BRCA	cis	rs6545883	0.894	rs12622458	chr2:61523554	A/C	cg15711740	chr2:61764176	XPO1	0.49	11.92	0.43	9.98e-30	Tuberculosis;
BRCA	cis	rs9788682	0.748	rs569207	chr15:78873119	A/G	cg24631222	chr15:78858424	CHRNA5	-0.49	-10.52	-0.38	5.36e-24	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs7246657	0.663	rs9304568	chr19:38054508	C/A	cg18154014	chr19:37997991	ZNF793	0.47	8.94	0.33	4.16e-18	Coronary artery calcification;
BRCA	trans	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg25214090	chr10:38739885	LOC399744	0.51	11.59	0.42	2.61e-28	Corneal astigmatism;
BRCA	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.69	-0.33	3.04e-17	Breast cancer;
BRCA	cis	rs7572733	0.534	rs1401092	chr2:198792320	C/A	cg00792783	chr2:198669748	PLCL1	-0.46	-9.98	-0.37	7.05e-22	Dermatomyositis;
BRCA	cis	rs13102973	0.899	rs13127659	chr4:135900604	G/A	cg14419869	chr4:135874104	NA	0.46	9.37	0.35	1.18e-19	Subjective well-being;
BRCA	cis	rs11887277	0.528	rs13016101	chr2:27045097	C/T	cg12368169	chr2:27073192	DPYSL5	-0.28	-8.07	-0.3	3.5e-15	Obesity-related traits;
BRCA	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg14440974	chr22:39074834	NA	0.38	8.94	0.33	4.15e-18	Menopause (age at onset);
BRCA	trans	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-7.95	-0.3	8.62e-15	Menarche (age at onset);
BRCA	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg24060327	chr5:131705240	SLC22A5	0.61	11.36	0.41	2.18e-27	Breast cancer;
BRCA	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-11.25	-0.41	6.26e-27	Gut microbiome composition (summer);
BRCA	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.91	-0.36	1.2e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg13175981	chr1:150552382	MCL1	0.47	10.51	0.38	5.93e-24	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.69e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg12564285	chr5:131593104	PDLIM4	0.34	7.87	0.3	1.52e-14	Breast cancer;
BRCA	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg03433033	chr1:76189801	ACADM	0.76	17.39	0.57	9.52e-56	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg09184832	chr6:79620586	NA	-0.52	-11.41	-0.41	1.46e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg23131131	chr22:24373011	LOC391322	-0.39	-8.78	-0.33	1.46e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9287719	0.625	rs12473787	chr2:10717194	G/C	cg00105475	chr2:10696890	NA	0.41	9.19	0.34	5.23e-19	Prostate cancer;
BRCA	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg17063962	chr7:91808500	NA	0.53	12.5	0.44	3.23e-32	Breast cancer;
BRCA	trans	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	15.87	0.53	4.53e-48	Exhaled nitric oxide levels;
BRCA	cis	rs6484504	0.576	rs158139	chr11:31216076	C/T	cg14844989	chr11:31128820	NA	-0.45	-9.62	-0.36	1.51e-20	Red blood cell count;
BRCA	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-9.84	-0.36	2.27e-21	Eosinophil percentage of white cells;
BRCA	cis	rs9815354	0.638	rs76276404	chr3:41931770	A/G	cg03022575	chr3:42003672	ULK4	0.69	9.5	0.35	4.17e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg18225595	chr11:63971243	STIP1	0.56	13.62	0.47	2.81e-37	Platelet count;
BRCA	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg04455712	chr21:45112962	RRP1B	0.38	10.21	0.37	8.61e-23	Mean corpuscular volume;
BRCA	trans	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17712092	chr4:129076599	LARP1B	0.56	13.55	0.47	5.98e-37	Eosinophil percentage of white cells;
BRCA	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.33	-7.89	-0.3	1.35e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
BRCA	cis	rs9815354	0.812	rs73081370	chr3:41916258	G/C	cg03022575	chr3:42003672	ULK4	0.69	9.49	0.35	4.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08048268	chr3:133502702	NA	0.42	10.55	0.39	4.16e-24	Iron status biomarkers;
BRCA	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg23533926	chr12:111358616	MYL2	-0.42	-8.73	-0.33	2.26e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03264133	chr6:25882463	NA	-0.55	-11.58	-0.42	2.84e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg04450456	chr4:17643702	FAM184B	0.39	11.4	0.41	1.57e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg00852783	chr1:26633632	UBXN11	-0.46	-7.98	-0.3	6.7e-15	Obesity-related traits;
BRCA	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg26597838	chr10:835615	NA	1.03	18.41	0.59	5.06e-61	Eosinophil percentage of granulocytes;
BRCA	trans	rs3857536	0.706	rs2157963	chr6:66945449	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	2.02e-14	Blood trace element (Cu levels);
BRCA	cis	rs11622475	1.000	rs2269186	chr14:104379912	C/T	cg12183467	chr14:104352244	NA	-0.5	-10.44	-0.38	1.16e-23	Bipolar disorder;
BRCA	trans	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg25214090	chr10:38739885	LOC399744	0.46	10.45	0.38	1.05e-23	Corneal astigmatism;
BRCA	cis	rs72772090	0.539	rs11748519	chr5:96119328	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.18	-0.43	7.64e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.61	-13.94	-0.48	9.05e-39	Ulcerative colitis;
BRCA	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.61	13.64	0.47	2.35e-37	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.22	-0.34	4.36e-19	Total body bone mineral density;
BRCA	cis	rs4285028	0.747	rs77790376	chr3:121492211	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.9	-16.27	-0.54	4.89e-50	Multiple sclerosis;
BRCA	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg23711669	chr6:146136114	FBXO30	0.72	14.5	0.5	2.19e-41	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.53	0.32	1.05e-16	Corneal astigmatism;
BRCA	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg03146154	chr1:46216737	IPP	0.45	10.01	0.37	5.27e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg06521331	chr12:34319734	NA	-0.54	-10.27	-0.38	5.26e-23	Bladder cancer;
BRCA	cis	rs2336384	1.000	rs2103876	chr1:12053100	C/T	cg13216073	chr1:12042593	MFN2	0.45	9.63	0.36	1.34e-20	Platelet count;
BRCA	cis	rs2658782	0.789	rs3019206	chr11:93111073	A/G	cg15737290	chr11:93063684	CCDC67	0.48	10.03	0.37	4.27e-22	Pulmonary function decline;
BRCA	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.24e-23	Motion sickness;
BRCA	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.79	11.06	0.4	3.84e-26	Initial pursuit acceleration;
BRCA	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02176678	chr2:219576539	TTLL4	0.46	12.21	0.43	5.86e-31	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg22875332	chr1:76189707	ACADM	0.65	15.59	0.52	1.12e-46	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg07549590	chr16:15018862	NA	-0.51	-12.7	-0.45	4.19e-33	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs4363385	0.747	rs2339495	chr1:152975116	A/T	cg24667326	chr1:152973720	SPRR3	-0.35	-9.82	-0.36	2.63e-21	Inflammatory skin disease;
BRCA	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.42	9.68	0.36	9.34e-21	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.4	10.62	0.39	2.33e-24	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	16.14	0.54	2.08e-49	Smoking behavior;
BRCA	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg20476274	chr7:133979776	SLC35B4	0.7	21.15	0.64	1.2e-75	Mean platelet volume;
BRCA	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.18	0.31	1.51e-15	Axial length;
BRCA	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg05283184	chr6:79620031	NA	-0.43	-11.08	-0.4	3.24e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg11833968	chr6:79620685	NA	-0.41	-9.27	-0.34	2.8e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg09307838	chr4:120376055	NA	0.72	15.41	0.52	8.47e-46	Corneal astigmatism;
BRCA	cis	rs1468333	1.000	rs6867242	chr5:137561186	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.44	9.27	0.34	2.74e-19	Resting heart rate;
BRCA	cis	rs17023223	0.581	rs11811859	chr1:119707680	A/G	cg05756136	chr1:119680316	WARS2	-0.41	-7.94	-0.3	9.35e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg12373951	chr3:133503437	NA	0.45	10.64	0.39	1.89e-24	Iron status biomarkers;
BRCA	cis	rs6446731	0.636	rs2157092	chr4:3273092	G/C	cg08886695	chr4:3369023	RGS12	-0.37	-9.7	-0.36	7.62e-21	Mean platelet volume;
BRCA	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg21770322	chr7:97807741	LMTK2	0.41	11.05	0.4	4.26e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg06521331	chr12:34319734	NA	-0.56	-9.91	-0.37	1.24e-21	Morning vs. evening chronotype;
BRCA	trans	rs2270927	0.510	rs35930860	chr5:75579946	T/C	cg13563193	chr19:33072644	PDCD5	0.9	10.35	0.38	2.48e-23	Mean corpuscular volume;
BRCA	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg17366294	chr4:99064904	C4orf37	0.46	10.65	0.39	1.71e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg22139774	chr2:100720529	AFF3	-0.29	-8.16	-0.31	1.72e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg06026331	chr20:60912101	LAMA5	0.63	12.5	0.44	3.03e-32	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs1499972	0.941	rs6794831	chr3:117642484	C/A	cg07612923	chr3:117604196	NA	0.6	8.13	0.31	2.26e-15	Schizophrenia;
BRCA	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg08807101	chr21:30365312	RNF160	-0.42	-8.82	-0.33	1.13e-17	Pancreatic cancer;
BRCA	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg27446573	chr6:127587934	RNF146	0.81	18.44	0.59	3.29e-61	Breast cancer;
BRCA	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg07917127	chr4:99064746	C4orf37	0.46	8.41	0.32	2.61e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9649465	0.967	rs10224062	chr7:123304609	G/A	cg04330084	chr7:123175371	IQUB	-0.3	-8.34	-0.31	4.66e-16	Migraine;
BRCA	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg08807101	chr21:30365312	RNF160	0.74	19.4	0.61	2.77e-66	Dental caries;
BRCA	cis	rs965469	1.000	rs2236098	chr20:3267133	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-10.23	-0.38	7.7e-23	IFN-related cytopenia;
BRCA	trans	rs7200543	1.000	rs16966952	chr16:15135943	C/T	cg24683922	chr1:11983373	KIAA2013	-0.37	-8.42	-0.32	2.42e-16	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.08	-0.4	3.36e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.93	-0.4	1.36e-25	Bipolar disorder;
BRCA	cis	rs7524258	0.868	rs4243825	chr1:7308264	T/C	cg07173049	chr1:7289937	CAMTA1	0.53	12.71	0.45	3.73e-33	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs7246657	0.722	rs4802051	chr19:38072328	C/A	cg14683738	chr19:37701593	ZNF585B	0.46	7.81	0.3	2.31e-14	Coronary artery calcification;
BRCA	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.61	-12.75	-0.45	2.45e-33	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg05340658	chr4:99064831	C4orf37	0.63	14.68	0.5	2.98e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg12935359	chr14:103987150	CKB	0.64	14.95	0.51	1.57e-43	Intelligence (multi-trait analysis);
BRCA	cis	rs2637266	0.935	rs2583053	chr10:78402416	A/G	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.92	-0.37	1.1e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-9.04	-0.34	1.83e-18	Schizophrenia;
BRCA	cis	rs7766436	0.885	rs12111204	chr6:22578227	C/T	cg13666174	chr6:22585274	NA	-0.49	-11.27	-0.41	5.36e-27	Coronary artery disease;
BRCA	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg24920358	chr1:40204285	PPIE	0.34	7.94	0.3	9.15e-15	Blood protein levels;
BRCA	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg18129178	chr5:148520854	ABLIM3	-0.57	-11.84	-0.42	2.29e-29	Breast cancer;
BRCA	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	8.99	0.33	2.88e-18	Motion sickness;
BRCA	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg10433463	chr1:1889099	KIAA1751	0.35	9.33	0.35	1.77e-19	Body mass index;
BRCA	cis	rs1829883	0.804	rs114992703	chr5:98813521	A/G	cg08333243	chr5:99726346	NA	-0.35	-8.0	-0.3	5.99e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs10754283	0.557	rs1215508	chr1:90088697	C/T	cg21401794	chr1:90099060	LRRC8C	0.37	8.41	0.32	2.68e-16	Amyotrophic lateral sclerosis (sporadic);
BRCA	trans	rs11976180	1.000	rs2961119	chr7:143755852	T/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.44	-8.2	-0.31	1.32e-15	Obesity-related traits;
BRCA	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg24069376	chr3:38537580	EXOG	0.3	7.84	0.3	1.92e-14	Electrocardiographic conduction measures;
BRCA	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.72	-20.66	-0.63	5.41e-73	Longevity;Endometriosis;
BRCA	cis	rs17095355	0.901	rs28365866	chr10:111767214	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.45	-9.86	-0.36	1.97e-21	Biliary atresia;
BRCA	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	16.14	0.54	2.01e-49	Homoarginine levels;
BRCA	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg15395560	chr15:45543142	SLC28A2	-0.3	-7.85	-0.3	1.79e-14	Uric acid levels;
BRCA	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	9.88	0.36	1.58e-21	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.59	0.55	1.2e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs911119	1.000	rs71334202	chr20:23618652	A/C	cg16589663	chr20:23618590	CST3	0.46	8.93	0.33	4.59e-18	Chronic kidney disease;
BRCA	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg21475434	chr5:93447410	FAM172A	0.74	8.8	0.33	1.32e-17	Diabetic retinopathy;
BRCA	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.06	-0.3	3.74e-15	Prostate cancer;
BRCA	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg21535247	chr6:8435926	SLC35B3	-0.4	-8.93	-0.33	4.49e-18	Motion sickness;
BRCA	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs2147904	0.867	rs1408947	chr1:42364198	C/T	cg16685388	chr1:42384056	HIVEP3	0.31	8.79	0.33	1.39e-17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
BRCA	cis	rs12474201	0.862	rs7562173	chr2:46976217	C/G	cg06386533	chr2:46925753	SOCS5	-0.83	-18.52	-0.59	1.3e-61	Height;
BRCA	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-16.51	-0.55	3.04e-51	Parkinson's disease;
BRCA	cis	rs2019216	0.521	rs6565386	chr17:21901755	A/G	cg22648282	chr17:21454238	C17orf51	0.41	9.33	0.35	1.68e-19	Pelvic organ prolapse;
BRCA	cis	rs2425143	1.000	rs6058325	chr20:34388806	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.07	-0.34	1.48e-18	Blood protein levels;
BRCA	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25427524	chr10:38739819	LOC399744	-0.7	-17.22	-0.56	6.71e-55	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.17	-0.43	8.62e-31	Alzheimer's disease;
BRCA	cis	rs2455799	0.533	rs924754	chr3:15756215	A/T	cg16303742	chr3:15540471	COLQ	-0.35	-8.37	-0.31	3.76e-16	Mean platelet volume;
BRCA	cis	rs11051970	0.611	rs10844197	chr12:32561015	A/C	cg02745156	chr12:32552066	NA	0.25	8.38	0.31	3.44e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg26384229	chr12:38710491	ALG10B	0.74	17.51	0.57	2.37e-56	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2130392	1.000	rs2130392	chr4:185639169	A/G	cg04058563	chr4:185651563	MLF1IP	0.33	7.82	0.3	2.18e-14	Kawasaki disease;
BRCA	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11764359	chr7:65958608	NA	-0.75	-16.9	-0.56	2.91e-53	Aortic root size;
BRCA	cis	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg06521331	chr12:34319734	NA	-0.63	-11.57	-0.42	2.98e-28	Morning vs. evening chronotype;
BRCA	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg10932868	chr11:921992	NA	0.51	13.18	0.46	2.97e-35	Alzheimer's disease (late onset);
BRCA	cis	rs72772090	0.539	rs17405676	chr5:96182615	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-11.67	-0.42	1.19e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg20607287	chr7:12443886	VWDE	-0.58	-8.36	-0.31	4.04e-16	Coronary artery disease;
BRCA	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg17063962	chr7:91808500	NA	0.54	12.3	0.44	2.35e-31	Breast cancer;
BRCA	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	15.63	0.53	7.54e-47	Smoking behavior;
BRCA	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg20818283	chr2:191399100	TMEM194B	0.42	9.66	0.36	1.03e-20	Pulse pressure;
BRCA	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg09455208	chr3:40491958	NA	0.41	9.75	0.36	5.14e-21	Renal cell carcinoma;
BRCA	trans	rs629535	0.814	rs549643	chr8:70062884	C/T	cg21567404	chr3:27674614	NA	0.89	18.27	0.59	2.64e-60	Dupuytren's disease;
BRCA	cis	rs870825	0.616	rs6817521	chr4:185649827	A/G	cg04058563	chr4:185651563	MLF1IP	-0.77	-17.42	-0.57	6.61e-56	Blood protein levels;
BRCA	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.78	0.62	2.8e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg16506815	chr2:162101123	NA	0.51	11.12	0.4	2.15e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9815354	0.812	rs73073226	chr3:42005838	T/C	cg03022575	chr3:42003672	ULK4	0.65	9.49	0.35	4.62e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg14349672	chr11:133703707	NA	-0.43	-9.58	-0.35	2.11e-20	Childhood ear infection;
BRCA	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26314531	chr2:26401878	FAM59B	-0.91	-15.95	-0.53	1.79e-48	Gut microbiome composition (summer);
BRCA	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg16606324	chr3:10149918	C3orf24	0.56	11.2	0.4	1.08e-26	Alzheimer's disease;
BRCA	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg09035930	chr12:129282057	SLC15A4	-0.44	-11.81	-0.42	2.92e-29	Systemic lupus erythematosus;
BRCA	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg03711944	chr11:47377212	SPI1	-0.43	-11.71	-0.42	8.08e-29	Diastolic blood pressure;Systolic blood pressure;
BRCA	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	8.12	0.31	2.49e-15	Uric acid levels;
BRCA	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg20887711	chr4:1340912	KIAA1530	0.4	9.72	0.36	6.64e-21	Longevity;
BRCA	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg20628663	chr10:43360327	NA	-0.7	-13.62	-0.47	2.75e-37	Blood protein levels;
BRCA	cis	rs2282802	0.685	rs13359519	chr5:139654664	G/A	cg26211634	chr5:139558579	C5orf32	0.35	8.35	0.31	4.13e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6426558	0.502	rs1929858	chr1:227220175	C/A	cg10327440	chr1:227177885	CDC42BPA	0.48	9.33	0.35	1.77e-19	Neutrophil percentage of white cells;
BRCA	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg05535760	chr7:792225	HEATR2	0.73	13.22	0.46	1.96e-35	Cerebrospinal P-tau181p levels;
BRCA	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7020830	0.505	rs12553878	chr9:37095705	C/T	cg14294708	chr9:37120828	ZCCHC7	0.79	18.74	0.6	9.27e-63	Schizophrenia;
BRCA	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg02931644	chr1:25747376	RHCE	0.4	11.18	0.4	1.28e-26	Erythrocyte sedimentation rate;
BRCA	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg21856205	chr7:94953877	PON1	-0.37	-8.03	-0.3	4.78e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.99	0.3	6.41e-15	Depression;
BRCA	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.45	-0.52	5.26e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-14.31	-0.49	1.79e-40	Personality dimensions;
BRCA	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.63	-13.51	-0.47	9.58e-37	Lymphocyte counts;
BRCA	cis	rs9337951	0.556	rs2487927	chr10:30311366	C/T	cg00730780	chr10:30316187	KIAA1462	-0.49	-10.29	-0.38	4.24e-23	Pulse pressure;Coronary artery disease;
BRCA	cis	rs11051970	0.594	rs325418	chr12:32572517	T/C	cg24626660	chr12:32551988	NA	0.28	8.23	0.31	1.01e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs12760731	0.720	rs2862379	chr1:178442906	T/A	cg00404053	chr1:178313656	RASAL2	0.61	8.08	0.3	3.13e-15	Obesity-related traits;
BRCA	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg01262667	chr19:19385393	TM6SF2	0.4	10.27	0.38	5.28e-23	Tonsillectomy;
BRCA	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg15704280	chr7:45808275	SEPT13	0.47	8.94	0.33	4.25e-18	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-13.77	-0.48	5.9e-38	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg26838691	chr2:24397539	C2orf84	-0.48	-8.85	-0.33	8.21e-18	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs7617773	0.817	rs9847953	chr3:48282695	A/G	cg11946769	chr3:48343235	NME6	0.62	13.82	0.48	3.28e-38	Coronary artery disease;
BRCA	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg07051648	chr19:49177693	NTN5;SEC1	-0.42	-8.02	-0.3	5.22e-15	Dietary macronutrient intake;
BRCA	cis	rs3784262	0.669	rs12915508	chr15:58302036	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.09	-0.37	2.64e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18876405	chr7:65276391	NA	0.5	11.08	0.4	3.09e-26	Aortic root size;
BRCA	cis	rs1874326	0.524	rs6467772	chr7:138113643	A/G	cg18008034	chr7:138118925	NA	-0.44	-9.21	-0.34	4.58e-19	Quantitative traits;
BRCA	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg08501292	chr6:25962987	TRIM38	0.59	8.02	0.3	4.97e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	8.07	0.3	3.56e-15	Aortic root size;
BRCA	cis	rs858239	0.601	rs4599714	chr7:23168801	C/T	cg23682824	chr7:23144976	KLHL7	0.45	11.95	0.43	7.21e-30	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs11690935	0.959	rs67204065	chr2:172672624	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.87	-26.72	-0.73	3.72e-106	Schizophrenia;
BRCA	cis	rs6460942	1.000	rs112996286	chr7:12315741	G/C	cg06484146	chr7:12443880	VWDE	-0.63	-8.69	-0.33	2.98e-17	Coronary artery disease;
BRCA	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11890956	chr21:40555474	PSMG1	-0.64	-14.33	-0.49	1.34e-40	Menarche (age at onset);
BRCA	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg24642844	chr7:1081250	C7orf50	-0.91	-16.39	-0.54	1.21e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-12.19	-0.43	7.04e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg26597838	chr10:835615	NA	1.03	17.16	0.56	1.49e-54	Eosinophil percentage of granulocytes;
BRCA	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg04691961	chr3:161091175	C3orf57	-0.6	-15.18	-0.51	1.1e-44	Morning vs. evening chronotype;
BRCA	cis	rs12612619	0.695	rs4665935	chr2:27229892	C/A	cg00617064	chr2:27272375	NA	0.31	8.27	0.31	7.54e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg10876282	chr6:28092338	ZSCAN16	0.42	8.18	0.31	1.53e-15	Cardiac Troponin-T levels;
BRCA	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg17691542	chr6:26056736	HIST1H1C	0.48	9.83	0.36	2.56e-21	Height;
BRCA	trans	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg17675199	chr6:35436792	RPL10A	-0.31	-8.21	-0.31	1.19e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg27129171	chr3:47204927	SETD2	-0.71	-16.79	-0.55	1.08e-52	Colorectal cancer;
BRCA	cis	rs2016266	0.855	rs930900	chr12:53727545	T/C	cg26875137	chr12:53738046	NA	0.38	9.48	0.35	4.78e-20	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg21770322	chr7:97807741	LMTK2	0.58	16.99	0.56	1.12e-53	Breast cancer;
BRCA	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg05340658	chr4:99064831	C4orf37	0.68	16.73	0.55	2.19e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg17691542	chr6:26056736	HIST1H1C	0.48	9.15	0.34	7.35e-19	Iron status biomarkers;
BRCA	trans	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04565464	chr8:145669602	NFKBIL2	0.42	9.47	0.35	5.25e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg23711669	chr6:146136114	FBXO30	-0.78	-18.09	-0.58	2.33e-59	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.45	8.58	0.32	7.4e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg13334819	chr7:99746414	C7orf59	-0.34	-8.11	-0.31	2.68e-15	Coronary artery disease;
BRCA	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg03146154	chr1:46216737	IPP	0.52	11.61	0.42	2.16e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg21535247	chr6:8435926	SLC35B3	-0.39	-8.76	-0.33	1.7e-17	Motion sickness;
BRCA	cis	rs35110281	0.667	rs4818859	chr21:45117120	G/A	cg04455712	chr21:45112962	RRP1B	0.44	11.6	0.42	2.2e-28	Mean corpuscular volume;
BRCA	cis	rs7172677	0.501	rs8041446	chr15:75394517	C/T	cg14664628	chr15:75095509	CSK	0.39	9.11	0.34	1.08e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg23625390	chr15:77176239	SCAPER	0.39	9.07	0.34	1.49e-18	Blood metabolite levels;
BRCA	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.94e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg16486109	chr11:613632	IRF7	0.42	9.0	0.34	2.57e-18	Systemic lupus erythematosus;
BRCA	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg08000102	chr2:233561755	GIGYF2	-0.46	-10.03	-0.37	4.4e-22	Coronary artery disease;
BRCA	trans	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg25214090	chr10:38739885	LOC399744	0.46	10.1	0.37	2.32e-22	Corneal astigmatism;
BRCA	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-14.11	-0.49	1.44e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.08	0.74	1.26e-113	Chronic sinus infection;
BRCA	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg23711669	chr6:146136114	FBXO30	0.63	14.31	0.49	1.72e-40	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2625529	0.775	rs16956273	chr15:72117102	C/T	cg16672083	chr15:72433130	SENP8	-0.7	-16.11	-0.54	3.09e-49	Red blood cell count;
BRCA	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg19077165	chr18:44547161	KATNAL2	0.37	8.0	0.3	5.68e-15	Personality dimensions;
BRCA	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg20290983	chr6:43655470	MRPS18A	1.11	41.24	0.85	2.93e-182	IgG glycosylation;
BRCA	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg18132916	chr6:79620363	NA	-0.4	-8.09	-0.3	2.94e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg22713356	chr15:30763199	NA	1.19	24.18	0.69	3.39e-92	Uric acid levels;
BRCA	cis	rs3739998	0.527	rs4749524	chr10:30332618	G/C	cg00730780	chr10:30316187	KIAA1462	0.56	10.99	0.4	7.22e-26	Coronary heart disease;
BRCA	cis	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	8.5	0.32	1.31e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs16976116	0.901	rs73409853	chr15:55502681	A/T	cg11288833	chr15:55489084	RSL24D1	0.47	10.64	0.39	1.87e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10046574	0.831	rs75959757	chr7:135170755	G/A	cg27474649	chr7:135195673	CNOT4	0.61	8.47	0.32	1.65e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg17063962	chr7:91808500	NA	0.53	12.53	0.44	2.32e-32	Breast cancer;
BRCA	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04155289	chr7:94953770	PON1	-0.43	-9.01	-0.34	2.41e-18	Paraoxonase activity;
BRCA	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg20503657	chr10:835505	NA	0.84	15.27	0.52	4.37e-45	Eosinophil percentage of granulocytes;
BRCA	cis	rs757278	0.646	rs11768272	chr7:117347082	G/A	cg10524701	chr7:117356490	CTTNBP2	0.42	7.85	0.3	1.81e-14	Response to methotrexate in juvenile idiopathic arthritis;
BRCA	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg03954927	chr1:10346856	KIF1B	0.48	15.23	0.52	6.45e-45	Hepatocellular carcinoma;
BRCA	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg02187348	chr16:89574699	SPG7	-0.34	-7.96	-0.3	7.62e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg08847533	chr14:75593920	NEK9	-0.81	-19.39	-0.61	3.22e-66	Height;
BRCA	cis	rs432925	0.600	rs214247	chr16:349221	A/G	cg06233593	chr16:337645	AXIN1	0.44	10.92	0.4	1.49e-25	Morning vs. evening chronotype;
BRCA	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg22974920	chr21:40686053	BRWD1	-0.35	-7.93	-0.3	1.01e-14	Menarche (age at onset);
BRCA	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21659725	chr3:3221576	CRBN	-0.45	-11.46	-0.41	8.87e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg04944784	chr2:26401820	FAM59B	0.9	15.82	0.53	7.91e-48	Gut microbiome composition (summer);
BRCA	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg07080220	chr10:102295463	HIF1AN	0.47	10.75	0.39	6.63e-25	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg12444411	chr7:2802554	GNA12	-0.33	-8.26	-0.31	8.12e-16	Height;
BRCA	trans	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg13565492	chr6:43139072	SRF	-0.79	-10.95	-0.4	1.07e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg03676636	chr4:99064102	C4orf37	0.2	7.87	0.3	1.52e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg07395648	chr5:131743802	NA	0.36	7.99	0.3	6.12e-15	Acylcarnitine levels;
BRCA	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg09904177	chr6:26538194	HMGN4	0.52	15.0	0.51	8.16e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg06494592	chr3:125709126	NA	-0.54	-8.44	-0.32	2.09e-16	Blood pressure (smoking interaction);
BRCA	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.54	13.37	0.47	3.9e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg09021430	chr5:549028	NA	-0.64	-15.31	-0.52	2.54e-45	Obesity-related traits;
BRCA	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.33	-8.57	-0.32	7.57e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-11.59	-0.42	2.52e-28	Lymphocyte counts;
BRCA	cis	rs2637266	1.000	rs1907319	chr10:78337049	A/G	cg18941641	chr10:78392320	NA	-0.35	-7.83	-0.3	1.98e-14	Pulmonary function;
BRCA	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg11789530	chr4:8429930	ACOX3	0.68	17.62	0.57	6.01e-57	Response to antineoplastic agents;
BRCA	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-10.4	-0.38	1.7e-23	Schizophrenia;
BRCA	cis	rs4803468	0.967	rs16975238	chr19:41944985	T/A	cg09537434	chr19:41945824	ATP5SL	1.03	25.66	0.71	2.48e-100	Height;
BRCA	cis	rs7131987	0.903	rs2194519	chr12:29423583	C/T	cg09582351	chr12:29534625	ERGIC2	0.48	11.68	0.42	1.04e-28	QT interval;
BRCA	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg04013093	chr6:42928303	GNMT	-0.27	-8.48	-0.32	1.59e-16	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg26587870	chr6:27730563	NA	-0.55	-8.23	-0.31	1.08e-15	Depression;
BRCA	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg07636037	chr3:49044803	WDR6	0.52	8.46	0.32	1.81e-16	Menarche (age at onset);
BRCA	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg19077165	chr18:44547161	KATNAL2	-0.4	-8.47	-0.32	1.64e-16	Educational attainment;
BRCA	trans	rs2018683	1.000	rs2018683	chr7:29014195	G/T	cg19402173	chr7:128379420	CALU	-0.56	-14.03	-0.49	3.69e-39	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg17470723	chr8:74884337	TCEB1	0.41	8.64	0.32	4.33e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg20628663	chr10:43360327	NA	-0.7	-13.62	-0.47	2.75e-37	Blood protein levels;
BRCA	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg10295955	chr4:187884368	NA	-0.99	-31.58	-0.78	1.4e-132	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg05868516	chr6:26286170	HIST1H4H	0.5	10.87	0.4	2.27e-25	Educational attainment;
BRCA	cis	rs11191205	0.644	rs11191061	chr10:103366069	T/C	cg15320455	chr10:103880129	LDB1	0.47	8.09	0.3	2.92e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs16958440	0.708	rs1434528	chr18:44632323	G/A	cg17192377	chr18:44677553	HDHD2	0.48	8.0	0.3	5.82e-15	Sitting height ratio;
BRCA	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.11	0.34	1.09e-18	Motion sickness;
BRCA	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg09436375	chr6:42928200	GNMT	-0.3	-10.85	-0.39	2.75e-25	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg01256987	chr12:42539512	GXYLT1	-0.46	-9.24	-0.34	3.48e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs3849570	0.925	rs6798680	chr3:81905441	C/A	cg07356753	chr3:81810745	GBE1	-0.43	-10.25	-0.38	6.45e-23	Waist circumference;Body mass index;
BRCA	trans	rs9397585	0.599	rs685826	chr6:153411255	C/T	cg26642667	chr7:127292389	SND1	0.43	7.93	0.3	9.82e-15	Body mass index;
BRCA	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg07741184	chr6:167504864	NA	0.33	9.65	0.36	1.17e-20	Primary biliary cholangitis;
BRCA	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg21138405	chr5:131827807	IRF1	0.39	11.74	0.42	6.16e-29	Asthma (sex interaction);
BRCA	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg14863265	chr7:2801509	GNA12	0.42	9.21	0.34	4.78e-19	Height;
BRCA	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg09877947	chr5:131593287	PDLIM4	0.46	11.17	0.4	1.37e-26	Acylcarnitine levels;
BRCA	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg17063962	chr7:91808500	NA	0.54	12.8	0.45	1.56e-33	Breast cancer;
BRCA	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg08470875	chr2:26401718	FAM59B	0.77	11.95	0.43	7.53e-30	Gut microbiome composition (summer);
BRCA	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-9.38	-0.35	1.11e-19	Reticulocyte count;
BRCA	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg27102117	chr16:15229624	NA	0.33	8.18	0.31	1.58e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs1468333	1.000	rs217274	chr5:137490974	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.43	8.5	0.32	1.35e-16	Resting heart rate;
BRCA	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg27446573	chr6:127587934	RNF146	0.89	20.42	0.63	1e-71	Breast cancer;
BRCA	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg13010199	chr12:38710504	ALG10B	0.55	11.92	0.43	1e-29	Heart rate;
BRCA	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.33	0.35	1.64e-19	Tonsillectomy;
BRCA	cis	rs13136331	0.680	rs2732171	chr4:88655984	A/G	cg22416721	chr4:88570574	DMP1	-0.56	-13.49	-0.47	1.15e-36	Sitting height ratio;
BRCA	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26314531	chr2:26401878	FAM59B	0.96	16.52	0.55	2.62e-51	Gut microbiome composition (summer);
BRCA	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	11.14	0.4	1.9e-26	IgG glycosylation;
BRCA	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg20503657	chr10:835505	NA	-0.54	-10.08	-0.37	2.87e-22	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg24578937	chr1:2090814	PRKCZ	0.34	10.78	0.39	5.16e-25	Height;
BRCA	cis	rs4561483	0.801	rs33643	chr16:11986149	A/G	cg08843971	chr16:11963173	GSPT1	-0.54	-12.21	-0.44	5.56e-31	Testicular germ cell tumor;
BRCA	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg01324343	chr3:183735012	ABCC5	0.7	16.49	0.55	3.68e-51	Anterior chamber depth;
BRCA	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg13047869	chr3:10149882	C3orf24	0.54	11.36	0.41	2.28e-27	Alzheimer's disease;
BRCA	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg09307838	chr4:120376055	NA	0.64	13.3	0.47	8.45e-36	Corneal astigmatism;
BRCA	cis	rs7095944	0.582	rs2303611	chr10:126517989	G/A	cg08799069	chr10:126477246	METTL10	-0.38	-9.12	-0.34	9.67e-19	Asthma;
BRCA	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.4	-8.83	-0.33	9.83e-18	Educational attainment;
BRCA	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24531977	chr5:56204891	C5orf35	-0.72	-16.11	-0.54	2.79e-49	Initial pursuit acceleration;
BRCA	cis	rs701145	0.878	rs355760	chr3:154009933	T/C	cg17054900	chr3:154042577	DHX36	0.68	11.88	0.43	1.56e-29	Coronary artery disease;
BRCA	cis	rs7789940	1.000	rs2072435	chr7:75959188	G/A	cg10167463	chr7:75959203	YWHAG	-0.44	-8.93	-0.33	4.67e-18	Multiple sclerosis;
BRCA	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg13319975	chr6:146136371	FBXO30	-0.4	-8.98	-0.33	3.08e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg25554036	chr4:6271136	WFS1	0.42	9.98	0.37	6.9e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg16339924	chr4:17578868	LAP3	-0.48	-10.95	-0.4	1.04e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg07636037	chr3:49044803	WDR6	0.55	8.7	0.33	2.75e-17	Menarche (age at onset);
BRCA	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg25554036	chr4:6271136	WFS1	0.42	9.99	0.37	6.36e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg00651523	chr6:28411279	ZSCAN23	-0.37	-8.03	-0.3	4.72e-15	Pubertal anthropometrics;
BRCA	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.19	-0.4	1.19e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11890956	chr21:40555474	PSMG1	1.04	29.7	0.76	1.93e-122	Cognitive function;
BRCA	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg26384229	chr12:38710491	ALG10B	0.67	14.01	0.48	4.18e-39	Morning vs. evening chronotype;
BRCA	cis	rs12474201	0.963	rs3829835	chr2:46925789	C/T	cg06386533	chr2:46925753	SOCS5	0.87	18.88	0.6	1.54e-63	Height;
BRCA	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg20307385	chr11:47447363	PSMC3	-0.43	-9.1	-0.34	1.14e-18	Subjective well-being;
BRCA	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg19257562	chr1:2043853	PRKCZ	0.34	9.05	0.34	1.71e-18	Height;
BRCA	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg00666640	chr1:248458726	OR2T12	0.32	8.83	0.33	9.7e-18	Common traits (Other);
BRCA	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg12292205	chr6:26970375	C6orf41	0.64	14.57	0.5	1.04e-41	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7408868	1.000	rs2074622	chr19:15277620	G/C	cg14696996	chr19:15285081	NOTCH3	1.01	14.77	0.5	1.08e-42	Pulse pressure;
BRCA	cis	rs7267979	0.714	rs1555329	chr20:25231858	G/A	cg08601574	chr20:25228251	PYGB	0.34	8.21	0.31	1.19e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg18811423	chr2:55921094	PNPT1	0.7	22.07	0.66	1.22e-80	Metabolic syndrome;
BRCA	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-10.45	-0.38	1.08e-23	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg03676636	chr4:99064102	C4orf37	0.2	7.81	0.3	2.37e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg12564285	chr5:131593104	PDLIM4	0.36	9.65	0.36	1.12e-20	Breast cancer;
BRCA	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg12292205	chr6:26970375	C6orf41	0.58	13.03	0.46	1.32e-34	Schizophrenia;
BRCA	cis	rs600806	0.888	rs3853498	chr1:109860144	T/C	cg20591472	chr1:110008990	SYPL2	0.32	8.14	0.31	2.09e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs28602670	1	rs28602670	chr15:78768167	C/G	cg24631222	chr15:78858424	CHRNA5	0.49	9.67	0.36	1e-20	Post bronchodilator FEV1;
BRCA	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.47	-0.5	3.03e-41	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.97	-0.3	7.07e-15	Depression;
BRCA	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg06494592	chr3:125709126	NA	-0.49	-8.16	-0.31	1.75e-15	Blood pressure (smoking interaction);
BRCA	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg14440974	chr22:39074834	NA	-0.39	-8.93	-0.33	4.37e-18	Menopause (age at onset);
BRCA	cis	rs2859741	0.546	rs2102087	chr1:37482849	G/A	cg09363841	chr1:37513479	NA	-0.51	-11.17	-0.4	1.32e-26	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs10193935	1.000	rs10171023	chr2:42407093	G/C	cg27598129	chr2:42591480	NA	-0.88	-14.09	-0.49	1.84e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs743757	1.000	rs2282754	chr3:50436827	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.37	8.86	0.33	7.7e-18	Diastolic blood pressure;
BRCA	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.54	-0.44	2.04e-32	Bipolar disorder;
BRCA	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg19274703	chr22:41806451	NA	0.36	8.18	0.31	1.5e-15	Vitiligo;
BRCA	cis	rs7631605	0.905	rs1392749	chr3:37205191	A/G	cg15934958	chr3:37212084	LRRFIP2	-0.42	-9.8	-0.36	3.1e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-12.23	-0.44	4.83e-31	Gut microbiome composition (summer);
BRCA	cis	rs6942756	1.000	rs67997229	chr7:128957366	G/C	cg02491457	chr7:128862824	NA	-0.71	-13.92	-0.48	1.12e-38	White matter hyperintensity burden;
BRCA	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.75	-0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg06618935	chr21:46677482	NA	-0.37	-7.94	-0.3	9e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg03929089	chr4:120376271	NA	-0.98	-29.5	-0.76	2.38e-121	Height;
BRCA	cis	rs7975161	0.520	rs4502051	chr12:104695569	A/T	cg25273343	chr12:104657179	TXNRD1	-0.56	-9.04	-0.34	1.89e-18	Toenail selenium levels;
BRCA	trans	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg14791747	chr16:20752902	THUMPD1	0.45	14.24	0.49	3.71e-40	Cognitive test performance;
BRCA	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-11.45	-0.41	9.31e-28	Mood instability;
BRCA	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg09915433	chr19:53449742	NA	0.73	16.71	0.55	2.68e-52	Psoriasis;
BRCA	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.39	0.38	1.75e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7539409	1.000	rs7539409	chr1:84254735	A/G	cg10977910	chr1:84465055	TTLL7	-0.66	-8.59	-0.32	6.83e-17	Alzheimer's disease;
BRCA	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg21798802	chr22:38057573	PDXP	0.29	7.84	0.3	1.93e-14	Fat distribution (HIV);
BRCA	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg13319975	chr6:146136371	FBXO30	0.41	9.29	0.34	2.42e-19	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg25214090	chr10:38739885	LOC399744	0.51	10.68	0.39	1.3e-24	Corneal astigmatism;
BRCA	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg26818010	chr10:134567672	INPP5A	-0.78	-15.37	-0.52	1.39e-45	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg15556689	chr8:8085844	FLJ10661	-0.35	-8.5	-0.32	1.37e-16	Retinal vascular caliber;
BRCA	cis	rs6545883	0.839	rs778764	chr2:61785680	C/T	cg15711740	chr2:61764176	XPO1	-0.46	-11.36	-0.41	2.19e-27	Tuberculosis;
BRCA	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	20.27	0.63	6.19e-71	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg16414030	chr3:133502952	NA	-0.47	-10.95	-0.4	1.12e-25	Iron status biomarkers;
BRCA	trans	rs6479891	1.000	rs4746974	chr10:64892052	G/T	cg14819942	chr15:35414228	NA	0.34	8.39	0.32	3.02e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg21427119	chr20:30132790	HM13	-0.42	-8.89	-0.33	6.37e-18	Mean corpuscular hemoglobin;
BRCA	trans	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04565464	chr8:145669602	NFKBIL2	0.37	8.7	0.33	2.82e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs4930561	0.739	rs12225316	chr11:67976003	T/C	cg16338278	chr11:67432957	ALDH3B2	0.44	8.86	0.33	7.81e-18	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg25767906	chr1:53392781	SCP2	-0.39	-8.49	-0.32	1.47e-16	Monocyte count;
BRCA	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg20362242	chr5:692897	TPPP	0.53	8.0	0.3	5.8e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.35	-0.44	1.36e-31	Bipolar disorder;
BRCA	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg16586182	chr3:47516702	SCAP	-0.56	-12.82	-0.45	1.23e-33	Colorectal cancer;
BRCA	trans	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg09719594	chr16:21412588	NA	-0.35	-8.36	-0.31	3.87e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.2	-0.31	1.37e-15	Menopause (age at onset);
BRCA	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg01601518	chr4:2404284	ZFYVE28	0.54	8.7	0.33	2.83e-17	Influenza A (H1N1) severity;
BRCA	cis	rs919433	0.680	rs11680291	chr2:198409884	A/G	cg00792783	chr2:198669748	PLCL1	0.34	7.9	0.3	1.2e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg03060546	chr3:49711283	APEH	-0.58	-11.74	-0.42	5.82e-29	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg23711669	chr6:146136114	FBXO30	-0.68	-15.4	-0.52	1.02e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1941023	0.503	rs2233238	chr11:60145441	G/C	cg08716584	chr11:60157161	MS4A7	-0.43	-10.37	-0.38	2.17e-23	Congenital heart disease (maternal effect);
BRCA	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg05279229	chr7:1896384	MAD1L1	-0.41	-7.85	-0.3	1.73e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs732716	0.504	rs9352	chr19:4442336	C/T	cg24019073	chr19:4448726	UBXN6	0.36	8.59	0.32	6.63e-17	Mean corpuscular volume;
BRCA	cis	rs62229266	0.804	rs62230821	chr21:37425116	C/T	cg12218747	chr21:37451666	NA	-0.33	-7.94	-0.3	9.24e-15	Mitral valve prolapse;
BRCA	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg18196295	chr10:418757	DIP2C	-0.48	-11.55	-0.42	3.6e-28	Psychosis in Alzheimer's disease;
BRCA	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg03585969	chr10:35415529	CREM	0.56	11.68	0.42	1.08e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg24112000	chr20:60950667	NA	-0.55	-11.01	-0.4	5.98e-26	Colorectal cancer;
BRCA	cis	rs3845702	0.668	rs12693215	chr2:180826007	A/C	cg01881094	chr2:180872142	CWC22	-0.96	-17.33	-0.57	2.01e-55	Schizophrenia;
BRCA	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg07741184	chr6:167504864	NA	0.37	10.6	0.39	2.7e-24	Crohn's disease;
BRCA	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg27129171	chr3:47204927	SETD2	0.66	14.27	0.49	2.65e-40	Birth weight;
BRCA	cis	rs2625529	0.556	rs1552134	chr15:72232898	T/A	cg16672083	chr15:72433130	SENP8	0.67	15.81	0.53	9.1e-48	Red blood cell count;
BRCA	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.69	-15.36	-0.52	1.43e-45	Breast cancer;
BRCA	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-7.97	-0.3	7.2e-15	Ulcerative colitis;
BRCA	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.64	9.75	0.36	4.83e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10845606	1.000	rs10845606	chr12:12834894	G/T	cg09462578	chr12:12878428	APOLD1	-0.63	-11.12	-0.4	2.13e-26	Systemic lupus erythematosus;
BRCA	trans	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	16.04	0.54	6.65e-49	Exhaled nitric oxide levels;
BRCA	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg20503657	chr10:835505	NA	-0.53	-9.67	-0.36	1.01e-20	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs738321	0.725	rs5756926	chr22:38542613	T/C	cg25457927	chr22:38595422	NA	-0.36	-12.62	-0.45	9.31e-33	Breast cancer;
BRCA	cis	rs12541635	0.934	rs11776139	chr8:106983966	A/G	cg10147462	chr8:107024639	NA	0.37	9.86	0.36	1.97e-21	Age of smoking initiation;
BRCA	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	18.83	0.6	3.08e-63	Electrocardiographic conduction measures;
BRCA	cis	rs7572733	0.534	rs700688	chr2:198723833	A/G	cg00792783	chr2:198669748	PLCL1	-0.46	-10.2	-0.37	9.58e-23	Dermatomyositis;
BRCA	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg09455208	chr3:40491958	NA	-0.32	-7.84	-0.3	1.85e-14	Renal cell carcinoma;
BRCA	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	13.31	0.47	7.47e-36	Schizophrenia;
BRCA	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.09	0.4	2.82e-26	Electroencephalogram traits;
BRCA	cis	rs56399783	0.901	rs11764225	chr7:2775607	G/A	cg19731401	chr7:2775893	GNA12	0.49	7.95	0.3	8.57e-15	Childhood ear infection;
BRCA	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-11.95	-0.43	7.82e-30	Chronic sinus infection;
BRCA	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg13736514	chr6:26305472	NA	-0.33	-10.27	-0.38	5.31e-23	Educational attainment;
BRCA	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg15017067	chr4:17643749	FAM184B	0.3	9.07	0.34	1.49e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg08000102	chr2:233561755	GIGYF2	0.63	13.89	0.48	1.59e-38	Coronary artery disease;
BRCA	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg03146154	chr1:46216737	IPP	-0.49	-10.82	-0.39	3.59e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12292205	chr6:26970375	C6orf41	-0.5	-8.56	-0.32	8.67e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs6076960	0.846	rs6053962	chr20:6176915	A/G	cg17788362	chr6:86352627	SYNCRIP	0.38	8.28	0.31	7.16e-16	Smooth-surface caries;
BRCA	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg17507749	chr15:85114479	UBE2QP1	0.55	9.17	0.34	6.21e-19	Schizophrenia;
BRCA	cis	rs30380	0.632	rs26491	chr5:96134113	A/G	cg16492584	chr5:96139282	ERAP1	-0.47	-10.94	-0.4	1.2e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg06784218	chr1:46089804	CCDC17	0.47	11.25	0.41	6.68e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.42	9.69	0.36	7.96e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg21724239	chr8:58056113	NA	-0.61	-9.94	-0.37	9.66e-22	Developmental language disorder (linguistic errors);
BRCA	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.55	8.97	0.33	3.38e-18	Renal function-related traits (BUN);
BRCA	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg24642439	chr20:33292090	TP53INP2	-0.45	-8.46	-0.32	1.83e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs11229555	0.645	rs11229450	chr11:58201629	G/C	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7520050	0.645	rs1768809	chr1:46502836	A/C	cg06784218	chr1:46089804	CCDC17	-0.35	-8.79	-0.33	1.35e-17	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7131987	0.683	rs3782511	chr12:29496224	G/A	cg09582351	chr12:29534625	ERGIC2	-0.48	-10.89	-0.4	1.84e-25	QT interval;
BRCA	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg26647111	chr11:31128758	NA	-0.45	-9.74	-0.36	5.44e-21	Red blood cell count;
BRCA	cis	rs1003719	0.715	rs2835659	chr21:38567902	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.5	-0.5	2.11e-41	Eye color traits;
BRCA	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg09307838	chr4:120376055	NA	0.7	14.64	0.5	4.77e-42	Corneal astigmatism;
BRCA	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg06784218	chr1:46089804	CCDC17	0.51	12.14	0.43	1.11e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg25174290	chr11:3078921	CARS	0.41	12.46	0.44	4.91e-32	Longevity;
BRCA	cis	rs28830936	0.966	rs17678552	chr15:42066190	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.37	-10.58	-0.39	3.35e-24	Diastolic blood pressure;
BRCA	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg08999081	chr20:33150536	PIGU	-0.32	-8.12	-0.31	2.34e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg15208524	chr1:10270712	KIF1B	0.37	8.05	0.3	3.97e-15	Hepatocellular carcinoma;
BRCA	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg23109721	chr2:106886537	NA	-0.46	-8.34	-0.31	4.6e-16	Facial morphology (factor 23);
BRCA	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg13010199	chr12:38710504	ALG10B	0.41	8.41	0.32	2.61e-16	Bladder cancer;
BRCA	cis	rs13315871	0.929	rs71311852	chr3:58298843	G/A	cg20936604	chr3:58311152	NA	-0.66	-8.41	-0.32	2.59e-16	Cholesterol, total;
BRCA	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg14784868	chr12:69753453	YEATS4	0.78	25.0	0.7	9.83e-97	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg03709012	chr19:19516395	GATAD2A	0.81	19.13	0.6	8.08e-65	Tonsillectomy;
BRCA	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg05639522	chr1:247681581	NA	0.47	10.61	0.39	2.39e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs56804039	1.000	rs59620654	chr8:8382632	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-9.25	-0.34	3.36e-19	Cervical cancer;
BRCA	cis	rs9311474	1.000	rs9311474	chr3:52338852	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.36	-8.01	-0.3	5.53e-15	Electroencephalogram traits;
BRCA	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg17971929	chr21:40555470	PSMG1	0.78	18.35	0.59	9.63e-61	Cognitive function;
BRCA	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.9	0.3	1.19e-14	Axial length;
BRCA	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.13	0.31	2.22e-15	Depression;
BRCA	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.45	-0.47	1.68e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.41	8.46	0.32	1.86e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg20476274	chr7:133979776	SLC35B4	0.66	19.45	0.61	1.64e-66	Mean platelet volume;
BRCA	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-10.97	-0.4	8.6e-26	Resting heart rate;
BRCA	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg20503657	chr10:835505	NA	1.03	18.21	0.58	5.62e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg13010199	chr12:38710504	ALG10B	0.52	10.81	0.39	3.81e-25	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg25214090	chr10:38739885	LOC399744	0.49	11.27	0.41	5.2e-27	Corneal astigmatism;
BRCA	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg24069376	chr3:38537580	EXOG	-0.31	-8.94	-0.33	4.32e-18	Electrocardiographic conduction measures;
BRCA	cis	rs250677	0.522	rs10045726	chr5:148352990	C/T	cg18129178	chr5:148520854	ABLIM3	0.54	10.52	0.38	5.62e-24	Breast cancer;
BRCA	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs13102973	0.965	rs6535050	chr4:135874115	A/C	cg14419869	chr4:135874104	NA	-0.59	-12.98	-0.46	2.33e-34	Subjective well-being;
BRCA	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.64	-0.32	4.41e-17	Bipolar disorder;
BRCA	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	20.1	0.62	5.33e-70	Smoking behavior;
BRCA	cis	rs9400271	0.609	rs9386782	chr6:109588643	G/T	cg21918786	chr6:109611834	NA	-0.32	-8.09	-0.3	3.08e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	18.13	0.58	1.36e-59	Alzheimer's disease;
BRCA	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	14.28	0.49	2.44e-40	Alzheimer's disease;
BRCA	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.27	0.34	2.78e-19	Morning vs. evening chronotype;
BRCA	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	16.63	0.55	7.04e-52	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-9.77	-0.36	4.16e-21	Retinal vascular caliber;
BRCA	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg14863265	chr7:2801509	GNA12	-0.41	-8.99	-0.33	2.87e-18	Height;
BRCA	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg16414030	chr3:133502952	NA	-0.49	-11.37	-0.41	2.1e-27	Iron status biomarkers;
BRCA	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs812925	0.533	rs60997156	chr2:61396539	T/A	cg15711740	chr2:61764176	XPO1	-0.32	-7.85	-0.3	1.73e-14	Immature fraction of reticulocytes;
BRCA	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg07988820	chr12:82153109	PPFIA2	-0.59	-9.51	-0.35	3.9e-20	Resting heart rate;
BRCA	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg06606381	chr12:133084897	FBRSL1	-0.85	-8.84	-0.33	9.03e-18	Depression;
BRCA	cis	rs11252926	0.617	rs11253319	chr10:722732	C/T	cg08603382	chr10:743973	NA	-0.54	-10.21	-0.37	9.2e-23	Psychosis in Alzheimer's disease;
BRCA	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.31	-8.67	-0.32	3.63e-17	Birth weight;
BRCA	cis	rs1800682	0.528	rs3903454	chr10:90743434	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.53	12.36	0.44	1.34e-31	Chronic lymphocytic leukemia;
BRCA	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg23029597	chr12:123009494	RSRC2	-0.61	-11.81	-0.42	3e-29	Body mass index;
BRCA	cis	rs9612	0.718	rs346536	chr19:44251470	A/T	cg08581076	chr19:44259116	C19orf61	0.44	7.99	0.3	6.16e-15	Exhaled nitric oxide output;
BRCA	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00149659	chr3:10157352	C3orf10	1.07	18.04	0.58	4.24e-59	Alzheimer's disease;
BRCA	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg27661571	chr11:113659931	NA	-0.82	-12.27	-0.44	3.32e-31	Hip circumference adjusted for BMI;
BRCA	cis	rs4808199	0.895	rs8105984	chr19:19374068	T/C	cg03709012	chr19:19516395	GATAD2A	0.95	15.92	0.53	2.49e-48	Nonalcoholic fatty liver disease;
BRCA	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg13010199	chr12:38710504	ALG10B	0.51	10.44	0.38	1.19e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg21770322	chr7:97807741	LMTK2	0.42	11.13	0.4	2.07e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.55	9.22	0.34	4.22e-19	Renal function-related traits (BUN);
BRCA	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg13397359	chr6:42928475	GNMT	-0.66	-16.02	-0.54	8.01e-49	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26818010	chr10:134567672	INPP5A	-0.79	-16.05	-0.54	5.93e-49	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.6	0.57	7.83e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.61	0.32	5.81e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	4.98e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9393777	0.920	rs34071253	chr6:27391802	C/T	cg01620082	chr3:125678407	NA	-0.68	-9.17	-0.34	6.52e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7524258	0.868	rs1304712	chr1:7270538	C/T	cg07173049	chr1:7289937	CAMTA1	0.45	10.92	0.4	1.43e-25	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-9.71	-0.36	6.84e-21	Menopause (age at onset);
BRCA	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg19077165	chr18:44547161	KATNAL2	-0.5	-10.78	-0.39	5.25e-25	Personality dimensions;
BRCA	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.23e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs11229555	0.874	rs11605269	chr11:58350872	A/G	cg15696309	chr11:58395628	NA	-0.54	-11.75	-0.42	5.45e-29	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	13.87	0.48	2.04e-38	Colorectal cancer;
BRCA	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.47	0.38	9.17e-24	Motion sickness;
BRCA	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-15.65	-0.53	5.84e-47	Total cholesterol levels;
BRCA	trans	rs3857536	0.776	rs2040593	chr6:66944076	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.99	-0.3	6.35e-15	Blood trace element (Cu levels);
BRCA	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.51	-0.41	5.7e-28	Electroencephalogram traits;
BRCA	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.29e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg19717773	chr7:2847554	GNA12	0.41	8.95	0.33	3.82e-18	Loneliness (linear analysis);
BRCA	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg19901468	chr14:105411992	AHNAK2	-0.51	-12.43	-0.44	6.12e-32	Rheumatoid arthritis;
BRCA	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.91	0.4	1.63e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.77	-0.42	4.5e-29	Response to antipsychotic treatment;
BRCA	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.57	-0.47	4.99e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg17063962	chr7:91808500	NA	0.52	11.47	0.41	8.14e-28	Breast cancer;
BRCA	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.39	-9.26	-0.34	2.99e-19	Tonsillectomy;
BRCA	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg18904891	chr8:8559673	CLDN23	0.65	12.88	0.45	6.52e-34	Obesity-related traits;
BRCA	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg26384229	chr12:38710491	ALG10B	0.59	13.62	0.47	2.98e-37	Morning vs. evening chronotype;
BRCA	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg02951883	chr7:2050386	MAD1L1	-0.41	-9.64	-0.36	1.27e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-12.7	-0.45	3.91e-33	Platelet count;
BRCA	cis	rs4363385	0.818	rs435633	chr1:153011811	A/G	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg20503657	chr10:835505	NA	0.9	13.91	0.48	1.26e-38	Eosinophil percentage of granulocytes;
BRCA	cis	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-9.0	-0.34	2.54e-18	Metabolite levels (Pyroglutamine);
BRCA	cis	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg06521331	chr12:34319734	NA	-0.53	-9.32	-0.35	1.87e-19	Resting heart rate;
BRCA	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg21143896	chr7:2802374	GNA12	-0.37	-9.31	-0.35	2.06e-19	Height;
BRCA	cis	rs72720396	0.694	rs6689362	chr1:91203251	T/A	cg13456504	chr1:91191583	NA	-0.39	-7.81	-0.3	2.3e-14	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg19743168	chr1:23544995	NA	0.34	7.86	0.3	1.65e-14	Height;
BRCA	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg04896959	chr15:78267971	NA	-0.48	-11.16	-0.4	1.56e-26	Coronary artery disease or large artery stroke;
BRCA	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg06159980	chr1:16340746	HSPB7	-0.38	-8.74	-0.33	1.98e-17	Dilated cardiomyopathy;
BRCA	cis	rs2882667	0.898	rs6867343	chr5:138374428	C/T	cg04439458	chr5:138467593	SIL1	-0.33	-8.88	-0.33	6.67e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-8.78	-0.33	1.47e-17	Bipolar disorder and schizophrenia;
BRCA	trans	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg21659725	chr3:3221576	CRBN	0.46	8.49	0.32	1.45e-16	Menarche (age at onset);
BRCA	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg13699009	chr12:122356056	WDR66	0.34	7.87	0.3	1.49e-14	Mean corpuscular volume;
BRCA	trans	rs61931739	0.926	rs13377754	chr12:34051765	T/C	cg26384229	chr12:38710491	ALG10B	-0.41	-9.17	-0.34	6.16e-19	Morning vs. evening chronotype;
BRCA	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02176678	chr2:219576539	TTLL4	0.46	12.21	0.43	5.86e-31	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6542838	0.611	rs7588441	chr2:99518858	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-8.91	-0.33	5.14e-18	Fear of minor pain;
BRCA	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg27165867	chr14:105738592	BRF1	-0.35	-8.48	-0.32	1.56e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.59	-14.41	-0.5	5.53e-41	Longevity;Endometriosis;
BRCA	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.9	-0.33	5.81e-18	Alzheimer's disease (late onset);
BRCA	cis	rs28374715	0.783	rs11635269	chr15:41570710	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.0	-22.17	-0.66	3.38e-81	Ulcerative colitis;
BRCA	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg10932868	chr11:921992	NA	0.49	12.52	0.44	2.45e-32	Alzheimer's disease (late onset);
BRCA	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-10.8	-0.39	4.28e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs9290065	0.519	rs7616249	chr3:160679422	T/C	cg03342759	chr3:160939853	NMD3	-0.46	-9.45	-0.35	6.19e-20	Kawasaki disease;
BRCA	cis	rs2421770	0.530	rs4756217	chr11:35366733	C/T	cg13971030	chr11:35366721	SLC1A2	-0.45	-10.12	-0.37	1.9e-22	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.23	0.49	4.09e-40	Motion sickness;
BRCA	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg17063962	chr7:91808500	NA	0.56	13.18	0.46	2.99e-35	Breast cancer;
BRCA	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg12935359	chr14:103987150	CKB	0.62	14.46	0.5	3.25e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.39	2.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	13.14	0.46	4.57e-35	Lymphocyte counts;
BRCA	cis	rs9341808	0.718	rs4437429	chr6:80828592	A/G	cg08355045	chr6:80787529	NA	0.37	9.37	0.35	1.19e-19	Sitting height ratio;
BRCA	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg17971929	chr21:40555470	PSMG1	-0.77	-17.96	-0.58	1.03e-58	Cognitive function;
BRCA	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg03929089	chr4:120376271	NA	-0.47	-9.04	-0.34	1.9e-18	HDL cholesterol;
BRCA	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00166722	chr3:10149974	C3orf24	0.56	11.16	0.4	1.5e-26	Alzheimer's disease;
BRCA	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.28	-0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg13010199	chr12:38710504	ALG10B	0.56	12.23	0.44	4.73e-31	Heart rate;
BRCA	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.51	7.83	0.3	1.97e-14	Renal function-related traits (BUN);
BRCA	cis	rs10463316	0.894	rs7708499	chr5:150765906	A/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.29	-0.31	6.58e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg27129171	chr3:47204927	SETD2	0.72	17.86	0.58	3.59e-58	Colorectal cancer;
BRCA	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg08601574	chr20:25228251	PYGB	0.36	8.37	0.31	3.65e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg17691542	chr6:26056736	HIST1H1C	0.47	9.48	0.35	4.93e-20	Height;
BRCA	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19626725	chr5:178986131	RUFY1	0.32	9.61	0.36	1.65e-20	Lung cancer;
BRCA	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg06623918	chr6:96969491	KIAA0776	0.74	13.04	0.46	1.2e-34	Migraine;Coronary artery disease;
BRCA	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg03213289	chr20:61660250	NA	0.62	16.39	0.54	1.23e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg20848291	chr7:100343083	ZAN	0.36	8.23	0.31	1.02e-15	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg06784218	chr1:46089804	CCDC17	0.5	12.08	0.43	2.02e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10465746	0.935	rs11580836	chr1:84333310	C/T	cg10977910	chr1:84465055	TTLL7	0.5	10.17	0.37	1.29e-22	Obesity-related traits;
BRCA	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.33	11.07	0.4	3.65e-26	Systemic lupus erythematosus;
BRCA	cis	rs7264396	0.943	rs224431	chr20:34153599	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-9.39	-0.35	1e-19	Total cholesterol levels;
BRCA	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg25554036	chr4:6271136	WFS1	0.42	9.91	0.37	1.21e-21	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	trans	rs747782	0.528	rs4370963	chr11:48433943	C/G	cg15704280	chr7:45808275	SEPT13	0.55	8.22	0.31	1.18e-15	Intraocular pressure;
BRCA	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg00757033	chr12:89920650	WDR51B	0.53	10.7	0.39	1.13e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs698833	0.926	rs1067406	chr2:44674450	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	9.05	0.34	1.69e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg09654669	chr8:57350985	NA	-0.39	-8.38	-0.31	3.5e-16	Obesity-related traits;
BRCA	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg03864215	chr11:17408437	KCNJ11	-0.29	-8.28	-0.31	7.09e-16	Type 2 diabetes;
BRCA	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg08917208	chr2:24149416	ATAD2B	1.12	15.98	0.53	1.31e-48	Immature fraction of reticulocytes;
BRCA	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-11.64	-0.42	1.62e-28	Alzheimer's disease;
BRCA	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg17366294	chr4:99064904	C4orf37	0.41	9.33	0.35	1.72e-19	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg13010199	chr12:38710504	ALG10B	0.4	8.08	0.3	3.21e-15	Morning vs. evening chronotype;
BRCA	trans	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.8	0.33	1.25e-17	Mean corpuscular volume;
BRCA	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg11766577	chr21:47581405	C21orf56	-0.49	-10.89	-0.4	1.86e-25	Testicular germ cell tumor;
BRCA	cis	rs7246657	0.678	rs2927740	chr19:38140966	A/G	cg18154014	chr19:37997991	ZNF793	-0.48	-9.12	-0.34	9.67e-19	Coronary artery calcification;
BRCA	cis	rs6878727	0.638	rs698180	chr5:123667977	T/G	cg01806427	chr5:123737813	NA	-0.37	-8.26	-0.31	8.69e-16	Breast cancer;
BRCA	cis	rs870825	0.929	rs72689265	chr4:185590982	A/G	cg04058563	chr4:185651563	MLF1IP	0.69	11.83	0.42	2.39e-29	Blood protein levels;
BRCA	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg03188948	chr7:1209495	NA	0.83	11.33	0.41	2.93e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04565464	chr8:145669602	NFKBIL2	0.38	8.93	0.33	4.59e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg14440974	chr22:39074834	NA	-0.38	-8.97	-0.33	3.24e-18	Menopause (age at onset);
BRCA	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg21138405	chr5:131827807	IRF1	0.38	11.61	0.42	2.06e-28	Asthma (sex interaction);
BRCA	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg07148914	chr20:33460835	GGT7	0.36	7.94	0.3	9.13e-15	Height;
BRCA	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	trans	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg21659725	chr3:3221576	CRBN	-0.47	-10.22	-0.37	8.03e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg26384229	chr12:38710491	ALG10B	0.75	16.51	0.55	2.8e-51	Morning vs. evening chronotype;
BRCA	cis	rs9470361	0.524	rs7740181	chr6:36624111	C/T	cg08179530	chr6:36648295	CDKN1A	0.38	8.17	0.31	1.65e-15	QRS complex (Cornell);QRS duration;Left ventricular fractional shortening;
BRCA	trans	rs2270927	0.510	rs6891108	chr5:75579152	C/A	cg13563193	chr19:33072644	PDCD5	0.88	10.28	0.38	4.77e-23	Mean corpuscular volume;
BRCA	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg15556689	chr8:8085844	FLJ10661	0.41	10.88	0.4	2.09e-25	Neuroticism;
BRCA	cis	rs7248779	1.000	rs7248779	chr19:2403564	G/T	cg13499773	chr19:2433868	LMNB2	0.33	7.95	0.3	8.39e-15	Cortisol levels (saliva);
BRCA	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg26395211	chr5:140044315	WDR55	0.38	8.55	0.32	9.05e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg25173405	chr17:45401733	C17orf57	0.53	11.17	0.4	1.39e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg03477792	chr4:77819574	ANKRD56	0.6	14.03	0.49	3.58e-39	Emphysema distribution in smoking;
BRCA	trans	rs11165623	0.585	rs55896436	chr1:96994162	G/A	cg10631902	chr5:14652156	NA	-0.43	-12.15	-0.43	1.09e-30	Hip circumference;Waist circumference;
BRCA	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	20.97	0.64	1.07e-74	Electrocardiographic conduction measures;
BRCA	trans	rs4714291	0.925	rs847784	chr6:40053272	A/G	cg02267698	chr19:7991119	CTXN1	0.4	7.9	0.3	1.23e-14	Strep throat;
BRCA	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26314531	chr2:26401878	FAM59B	0.94	16.39	0.54	1.24e-50	Gut microbiome composition (summer);
BRCA	cis	rs2882667	0.931	rs10077896	chr5:138356756	G/A	cg04439458	chr5:138467593	SIL1	-0.33	-9.07	-0.34	1.44e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg24675658	chr1:53192096	ZYG11B	-0.51	-11.38	-0.41	1.89e-27	Monocyte count;
BRCA	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg08755490	chr11:65554678	OVOL1	-0.5	-10.28	-0.38	4.93e-23	Acne (severe);
BRCA	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg12311346	chr5:56204834	C5orf35	0.56	10.9	0.4	1.7e-25	Coronary artery disease;
BRCA	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.4	-0.44	8.39e-32	Breast cancer;
BRCA	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.74	11.76	0.42	4.72e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg15352829	chr14:105391018	PLD4	-0.38	-12.43	-0.44	6.67e-32	Rheumatoid arthritis;
BRCA	trans	rs208520	0.874	rs208485	chr6:66925654	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-16.3	-0.54	3.4e-50	Exhaled nitric oxide output;
BRCA	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.01	0.3	5.53e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg08392591	chr16:89556376	ANKRD11	0.53	12.72	0.45	3.2e-33	Multiple myeloma (IgH translocation);
BRCA	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	14.3	0.49	1.81e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg08999081	chr20:33150536	PIGU	0.5	14.13	0.49	1.18e-39	Coronary artery disease;
BRCA	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.47	0.38	9.11e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg25358565	chr5:93447407	FAM172A	1.2	18.59	0.59	5.7e-62	Diabetic retinopathy;
BRCA	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg03354898	chr7:1950403	MAD1L1	-0.39	-8.35	-0.31	4.26e-16	Schizophrenia;
BRCA	cis	rs1029738	0.659	rs1608553	chr7:22896231	G/C	cg04907244	chr7:22894795	SNORD93	-0.39	-9.06	-0.34	1.56e-18	Fibrinogen levels;
BRCA	cis	rs17095355	1.000	rs55683820	chr10:111665376	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.42	-8.88	-0.33	6.56e-18	Biliary atresia;
BRCA	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg17971929	chr21:40555470	PSMG1	0.77	18.23	0.58	4.12e-60	Cognitive function;
BRCA	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07930192	chr7:1003750	NA	0.48	10.71	0.39	1.01e-24	Longevity;Endometriosis;
BRCA	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	12.3	0.44	2.42e-31	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg16339924	chr4:17578868	LAP3	0.62	15.42	0.52	7.56e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs911119	0.909	rs3761279	chr20:23620075	C/G	cg16589663	chr20:23618590	CST3	0.47	8.81	0.33	1.2e-17	Chronic kidney disease;
BRCA	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg03146154	chr1:46216737	IPP	-0.5	-10.99	-0.4	7.55e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.01	0.34	2.33e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg25427524	chr10:38739819	LOC399744	0.67	15.12	0.51	2.17e-44	Extrinsic epigenetic age acceleration;
BRCA	cis	rs698833	0.509	rs1372080	chr2:44540241	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	8.07	0.3	3.45e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg08132940	chr7:1081526	C7orf50	-0.58	-8.7	-0.33	2.79e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg18232548	chr7:50535776	DDC	-0.42	-8.93	-0.33	4.4e-18	Malaria;
BRCA	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.87e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	11.27	0.41	5.56e-27	Mean platelet volume;
BRCA	cis	rs1190552	0.894	rs4906203	chr14:102928991	C/T	cg18135206	chr14:102964638	TECPR2	0.43	8.38	0.31	3.49e-16	Blood protein levels;
BRCA	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.7	14.7	0.5	2.25e-42	Total cholesterol levels;
BRCA	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.52	8.1	0.31	2.74e-15	Lung function (FEV1/FVC);
BRCA	cis	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg07460842	chr6:66804631	NA	-0.95	-17.73	-0.57	1.73e-57	Exhaled nitric oxide output;
BRCA	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-13.52	-0.47	8.57e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg26446133	chr18:72167187	CNDP2	-0.78	-14.43	-0.5	4.7e-41	Refractive error;
BRCA	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg23029597	chr12:123009494	RSRC2	-0.63	-12.26	-0.44	3.49e-31	Body mass index;
BRCA	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg13385794	chr1:248469461	NA	0.28	7.81	0.3	2.28e-14	Common traits (Other);
BRCA	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg04455712	chr21:45112962	RRP1B	-0.44	-11.91	-0.43	1.13e-29	Mean corpuscular volume;
BRCA	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg12310025	chr6:25882481	NA	-0.55	-13.08	-0.46	8.48e-35	Blood metabolite levels;
BRCA	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg18479299	chr3:125709523	NA	-0.56	-8.78	-0.33	1.49e-17	Blood pressure (smoking interaction);
BRCA	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.16	0.31	1.76e-15	Tonsillectomy;
BRCA	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.08	0.62	6.44e-70	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg04025307	chr7:1156635	C7orf50	0.44	9.77	0.36	4.02e-21	Longevity;Endometriosis;
BRCA	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg20487152	chr13:99095054	FARP1	-0.33	-7.86	-0.3	1.68e-14	Longevity;
BRCA	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12379764	chr21:47803548	PCNT	0.39	7.89	0.3	1.29e-14	Testicular germ cell tumor;
BRCA	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg01528321	chr10:82214614	TSPAN14	0.82	17.41	0.57	7.8e-56	Post bronchodilator FEV1;
BRCA	cis	rs4363385	0.747	rs1015996	chr1:152976108	C/T	cg25856811	chr1:152973957	SPRR3	-0.35	-9.29	-0.34	2.4e-19	Inflammatory skin disease;
BRCA	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg03477792	chr4:77819574	ANKRD56	0.64	15.18	0.51	1.19e-44	Emphysema distribution in smoking;
BRCA	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg21918786	chr6:109611834	NA	-0.49	-14.13	-0.49	1.19e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18876405	chr7:65276391	NA	-0.62	-15.42	-0.52	7.35e-46	Aortic root size;
BRCA	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg17470723	chr8:74884337	TCEB1	0.4	8.62	0.32	5.44e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs897984	0.513	rs17839568	chr16:31099783	T/C	cg00531865	chr16:30841666	NA	-0.38	-9.0	-0.34	2.5e-18	Dementia with Lewy bodies;
BRCA	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.65	0.32	4.14e-17	Motion sickness;
BRCA	cis	rs4561483	0.801	rs33631	chr16:11995387	G/C	cg08843971	chr16:11963173	GSPT1	-0.53	-12.05	-0.43	2.93e-30	Testicular germ cell tumor;
BRCA	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg11752832	chr7:134001865	SLC35B4	0.52	13.42	0.47	2.43e-36	Mean platelet volume;
BRCA	trans	rs9784649	1.000	rs9784649	chr5:25011524	G/A	cg08600765	chr20:34638493	LOC647979	-0.56	-9.18	-0.34	5.87e-19	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs6743226	0.934	rs4303713	chr2:242257859	G/A	cg10021735	chr2:242295487	FARP2	0.36	9.97	0.37	7.12e-22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs6840360	0.533	rs11099829	chr4:152727299	A/G	cg22705602	chr4:152727874	NA	0.38	10.02	0.37	4.98e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6580649	0.843	rs3803184	chr12:48398002	G/C	cg24011408	chr12:48396354	COL2A1	0.52	8.85	0.33	8.55e-18	Lung cancer;
BRCA	cis	rs4742903	0.509	rs10991107	chr9:106860969	T/C	cg14250997	chr9:106856677	SMC2	0.27	8.07	0.3	3.41e-15	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs7523050	0.643	rs36052234	chr1:109402943	C/T	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs4478858	0.684	rs4949373	chr1:31741577	G/A	cg00250761	chr1:31883323	NA	-0.31	-8.17	-0.31	1.63e-15	Alcohol dependence;
BRCA	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg09904177	chr6:26538194	HMGN4	0.57	18.45	0.59	2.88e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg23018236	chr17:30244563	NA	-0.71	-11.1	-0.4	2.7e-26	Hip circumference adjusted for BMI;
BRCA	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	14.17	0.49	8.02e-40	Colorectal cancer;
BRCA	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg15605315	chr1:45957053	TESK2	0.45	9.17	0.34	6.57e-19	High light scatter reticulocyte count;
BRCA	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg22800045	chr5:56110881	MAP3K1	-0.59	-9.99	-0.37	6.42e-22	Initial pursuit acceleration;
BRCA	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg26031613	chr14:104095156	KLC1	-0.49	-9.73	-0.36	5.77e-21	Schizophrenia;
BRCA	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs4722404	0.592	rs6461820	chr7:3118246	T/C	cg19214707	chr7:3157722	NA	-0.36	-7.92	-0.3	1.08e-14	Atopic dermatitis;
BRCA	cis	rs11608355	0.515	rs61941631	chr12:109935475	C/T	cg05360138	chr12:110035743	NA	0.72	13.3	0.47	8.56e-36	Neuroticism;
BRCA	cis	rs9341808	0.644	rs59371711	chr6:80942027	G/T	cg08355045	chr6:80787529	NA	-0.32	-7.85	-0.3	1.72e-14	Sitting height ratio;
BRCA	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12379764	chr21:47803548	PCNT	-0.41	-8.92	-0.33	4.84e-18	Testicular germ cell tumor;
BRCA	cis	rs312274	0.698	rs11178967	chr12:41296632	A/G	cg17827154	chr12:41323612	CNTN1	-0.45	-10.99	-0.4	7.37e-26	Metabolite levels  (X-11787);
BRCA	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg12165864	chr7:66369176	NA	-0.44	-9.75	-0.36	4.78e-21	Corneal structure;
BRCA	cis	rs2354432	0.607	rs7537483	chr1:146709877	C/G	cg25205988	chr1:146714368	CHD1L	0.92	11.61	0.42	2.06e-28	Mitochondrial DNA levels;
BRCA	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10802521	chr3:52805072	NEK4	-0.31	-8.46	-0.32	1.89e-16	Electroencephalogram traits;
BRCA	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg04546413	chr19:29218101	NA	0.47	9.69	0.36	7.99e-21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg09184832	chr6:79620586	NA	-0.47	-9.15	-0.34	7.36e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs17023223	0.537	rs6677107	chr1:119708765	C/T	cg05756136	chr1:119680316	WARS2	-0.42	-8.05	-0.3	3.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.87	0.56	4.31e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg03923535	chr7:1197113	ZFAND2A	0.54	10.92	0.4	1.43e-25	Longevity;Endometriosis;
BRCA	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg24006582	chr15:45444508	DUOX1	-0.55	-11.41	-0.41	1.47e-27	Uric acid levels;
BRCA	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg08885076	chr2:99613938	TSGA10	-0.58	-12.84	-0.45	9.62e-34	Chronic sinus infection;
BRCA	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-10.84	-0.39	3e-25	Schizophrenia;
BRCA	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-13.28	-0.47	1.01e-35	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.36	0.35	1.39e-19	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.23e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7737355	0.947	rs739952	chr5:130796568	A/T	cg06307176	chr5:131281290	NA	-0.53	-10.58	-0.39	3.37e-24	Life satisfaction;
BRCA	cis	rs11608355	0.545	rs2302709	chr12:109893697	A/G	cg05360138	chr12:110035743	NA	0.71	13.18	0.46	2.85e-35	Neuroticism;
BRCA	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	9.21	0.34	4.81e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg25214090	chr10:38739885	LOC399744	0.56	12.77	0.45	2.04e-33	Corneal astigmatism;
BRCA	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg14004847	chr7:1930337	MAD1L1	0.46	8.79	0.33	1.41e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg27284194	chr4:1044797	NA	0.44	9.51	0.35	3.86e-20	Recombination rate (males);
BRCA	cis	rs911119	0.657	rs6114214	chr20:23627924	A/T	cg16589663	chr20:23618590	CST3	0.44	8.05	0.3	4.19e-15	Chronic kidney disease;
BRCA	cis	rs11195062	0.521	rs4918485	chr10:111949323	A/T	cg00817464	chr10:111662876	XPNPEP1	0.29	8.38	0.31	3.34e-16	Multiple myeloma;
BRCA	trans	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg26043149	chr18:55253948	FECH	0.38	8.63	0.32	4.87e-17	Bone mineral density;
BRCA	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg08917208	chr2:24149416	ATAD2B	0.9	13.14	0.46	4.57e-35	Lymphocyte counts;
BRCA	cis	rs67981189	0.572	rs2810077	chr14:71363814	A/G	cg15816911	chr14:71606274	NA	-0.38	-8.46	-0.32	1.82e-16	Schizophrenia;
BRCA	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg03146154	chr1:46216737	IPP	-0.5	-10.88	-0.4	2.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg26597838	chr10:835615	NA	1.02	17.69	0.57	2.58e-57	Eosinophil percentage of granulocytes;
BRCA	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18252515	chr7:66147081	NA	-0.35	-7.82	-0.3	2.15e-14	Aortic root size;
BRCA	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg12935359	chr14:103987150	CKB	-0.57	-13.23	-0.46	1.67e-35	Body mass index;
BRCA	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	11.96	0.43	6.56e-30	Tonsillectomy;
BRCA	cis	rs6820391	0.590	rs4864802	chr4:54450331	T/C	cg04173182	chr4:54446035	LNX1	0.48	10.66	0.39	1.6e-24	Cervical artery dissection;
BRCA	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18876405	chr7:65276391	NA	-0.62	-15.48	-0.52	4.02e-46	Aortic root size;
BRCA	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg19773385	chr1:10388646	KIF1B	-0.4	-8.73	-0.33	2.28e-17	Hepatocellular carcinoma;
BRCA	cis	rs4363385	0.747	rs1015996	chr1:152976108	C/T	cg24667326	chr1:152973720	SPRR3	-0.35	-9.82	-0.36	2.63e-21	Inflammatory skin disease;
BRCA	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg22862634	chr11:62369728	EML3;MTA2	-0.5	-10.14	-0.37	1.7e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-11.19	-0.4	1.16e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg16339924	chr4:17578868	LAP3	0.62	15.43	0.52	6.68e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4409675	0.576	rs10751725	chr1:28216191	A/C	cg23691781	chr1:28212827	C1orf38	-0.32	-11.04	-0.4	4.63e-26	Corneal astigmatism;
BRCA	cis	rs870825	0.616	rs745656	chr4:185637523	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	17.32	0.57	2.07e-55	Blood protein levels;
BRCA	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.64e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-25.92	-0.72	8.29e-102	Chronic sinus infection;
BRCA	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg01420254	chr6:26195488	NA	0.53	8.33	0.31	4.78e-16	Gout;Renal underexcretion gout;
BRCA	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg27284194	chr4:1044797	NA	0.44	9.44	0.35	6.57e-20	Recombination rate (males);
BRCA	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	11.27	0.41	5.3e-27	Height;
BRCA	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg21724239	chr8:58056113	NA	0.55	8.83	0.33	9.92e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg13902645	chr11:5959945	NA	-0.45	-8.84	-0.33	9.48e-18	DNA methylation (variation);
BRCA	cis	rs858239	0.699	rs1881200	chr7:23201637	T/C	cg23682824	chr7:23144976	KLHL7	-0.33	-8.57	-0.32	7.56e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg05340658	chr4:99064831	C4orf37	-0.45	-10.25	-0.38	6.17e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-12.34	-0.44	1.52e-31	Tonsillectomy;
BRCA	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11764359	chr7:65958608	NA	-0.77	-17.73	-0.57	1.71e-57	Aortic root size;
BRCA	trans	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg03929089	chr4:120376271	NA	0.51	7.84	0.3	1.88e-14	Intraocular pressure;
BRCA	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg03585969	chr10:35415529	CREM	0.56	11.45	0.41	9.44e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9487051	0.768	rs351742	chr6:109527325	C/T	cg01475377	chr6:109611718	NA	0.39	9.95	0.37	9.11e-22	Reticulocyte fraction of red cells;
BRCA	cis	rs7903847	0.642	rs11189196	chr10:99155079	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.77	-0.33	1.63e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6543140	0.964	rs4851592	chr2:103087641	C/T	cg04239558	chr2:103089729	SLC9A4	0.35	9.95	0.37	8.61e-22	Blood protein levels;
BRCA	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg22029157	chr1:209979665	IRF6	0.51	10.53	0.38	5.01e-24	Cleft lip with or without cleft palate;
BRCA	cis	rs17818399	0.633	rs2242033	chr2:46842410	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.47	9.59	0.35	1.94e-20	Height;
BRCA	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg13073564	chr4:8508604	NA	-0.39	-10.56	-0.39	3.78e-24	Response to antineoplastic agents;
BRCA	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg23950597	chr19:37808831	NA	-0.65	-11.0	-0.4	6.51e-26	Coronary artery calcification;
BRCA	cis	rs66887589	0.967	rs1155577	chr4:120449810	C/T	cg09307838	chr4:120376055	NA	-0.46	-9.53	-0.35	3.23e-20	Diastolic blood pressure;
BRCA	trans	rs7395662	1.000	rs4929903	chr11:48913332	T/G	cg00717180	chr2:96193071	NA	-0.31	-8.66	-0.32	3.73e-17	HDL cholesterol;
BRCA	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.9	0.3	1.19e-14	Axial length;
BRCA	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg12072164	chr19:44306565	LYPD5	0.36	8.7	0.33	2.81e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	ch.11.42038R	chr11:967971	AP2A2	0.47	14.35	0.49	1.07e-40	Alzheimer's disease (late onset);
BRCA	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg03146154	chr1:46216737	IPP	0.53	11.75	0.42	5.61e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg03060546	chr3:49711283	APEH	-0.53	-10.58	-0.39	3.33e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.81	-0.58	6.72e-58	Chronic sinus infection;
BRCA	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-25.61	-0.71	4.29e-100	Ulcerative colitis;
BRCA	cis	rs490234	0.812	rs13286111	chr9:128429951	A/T	cg14078157	chr9:128172775	NA	-0.44	-9.72	-0.36	6.55e-21	Mean arterial pressure;
BRCA	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	13.64	0.47	2.22e-37	Lymphocyte counts;
BRCA	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg15556689	chr8:8085844	FLJ10661	0.39	10.42	0.38	1.36e-23	Neuroticism;
BRCA	cis	rs1209950	1.000	rs1209950	chr21:40173528	A/G	cg01359822	chr21:40176597	ETS2	-0.35	-8.85	-0.33	8.42e-18	Non-small cell lung cancer (survival);
BRCA	cis	rs11874712	1.000	rs7244921	chr18:43667528	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.18	0.31	1.57e-15	Migraine - clinic-based;
BRCA	cis	rs12760731	0.565	rs10913520	chr1:178200760	A/T	cg00404053	chr1:178313656	RASAL2	0.64	7.9	0.3	1.2e-14	Obesity-related traits;
BRCA	cis	rs4566357	0.615	rs12621808	chr2:227909522	A/C	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.07	-0.3	3.55e-15	Coronary artery disease;
BRCA	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.2	-18.94	-0.6	8.26e-64	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs10496034	1.000	rs4671995	chr2:55150883	C/T	cg16098955	chr2:55172992	EML6	0.52	9.17	0.34	6.4e-19	Refractive astigmatism;
BRCA	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg18402987	chr7:1209562	NA	0.81	12.07	0.43	2.32e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg03213289	chr20:61660250	NA	0.63	15.78	0.53	1.24e-47	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.04	0.3	4.34e-15	Breast cancer;
BRCA	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.84e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg08917208	chr2:24149416	ATAD2B	1.12	15.73	0.53	2.41e-47	Lymphocyte counts;
BRCA	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.17	-0.37	1.24e-22	Aortic root size;
BRCA	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg01483505	chr11:975446	AP2A2	0.33	8.87	0.33	7.13e-18	Alzheimer's disease (late onset);
BRCA	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg12219531	chr12:120966889	COQ5	0.55	11.43	0.41	1.17e-27	High light scatter reticulocyte count;
BRCA	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg21573476	chr21:45109991	RRP1B	-0.36	-9.51	-0.35	3.65e-20	Mean corpuscular volume;
BRCA	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg01939980	chr4:1354348	KIAA1530	0.38	8.81	0.33	1.19e-17	Obesity-related traits;
BRCA	cis	rs9815354	0.812	rs73073233	chr3:42010550	A/G	cg03022575	chr3:42003672	ULK4	0.73	10.09	0.37	2.48e-22	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1499972	0.941	rs62264783	chr3:117658033	G/A	cg07612923	chr3:117604196	NA	0.6	8.08	0.3	3.15e-15	Schizophrenia;
BRCA	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg24069376	chr3:38537580	EXOG	0.43	12.22	0.44	5e-31	Electrocardiographic conduction measures;
BRCA	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.74	16.22	0.54	8.69e-50	Lymphocyte counts;
BRCA	cis	rs2742234	1.000	rs2742234	chr10:43612609	A/G	cg02780029	chr10:43622663	RET	0.39	9.9	0.36	1.34e-21	Hirschsprung disease;
BRCA	cis	rs2235642	0.507	rs2235645	chr16:1597924	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.5	-10.62	-0.39	2.28e-24	Coronary artery disease;
BRCA	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg09877947	chr5:131593287	PDLIM4	0.46	11.17	0.4	1.37e-26	Acylcarnitine levels;
BRCA	cis	rs7903847	0.620	rs10882903	chr10:99115584	A/T	cg08345082	chr10:99160200	RRP12	-0.28	-8.03	-0.3	4.55e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	12.34	0.44	1.59e-31	Migraine;Coronary artery disease;
BRCA	trans	rs2262909	0.925	rs73019838	chr19:22247732	T/A	cg17074339	chr11:11642133	GALNTL4	0.42	8.12	0.31	2.45e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs208520	0.742	rs208454	chr6:66907783	T/C	cg07460842	chr6:66804631	NA	-0.89	-15.26	-0.52	4.77e-45	Exhaled nitric oxide output;
BRCA	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg05535760	chr7:792225	HEATR2	0.77	13.65	0.48	2.15e-37	Cerebrospinal P-tau181p levels;
BRCA	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg08917208	chr2:24149416	ATAD2B	1.08	15.26	0.52	4.69e-45	Lymphocyte counts;
BRCA	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08280861	chr8:58055591	NA	-0.53	-8.58	-0.32	7.25e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg12011299	chr4:100065546	ADH4	0.41	9.44	0.35	6.93e-20	Alcohol dependence;
BRCA	cis	rs4891159	0.790	rs72973773	chr18:74115176	T/C	cg24786174	chr18:74118243	ZNF516	-0.76	-18.62	-0.59	4e-62	Longevity;
BRCA	cis	rs858239	0.600	rs10241208	chr7:23144914	G/C	cg23682824	chr7:23144976	KLHL7	0.42	11.22	0.41	8.5e-27	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.75	0.45	2.44e-33	Bipolar disorder;
BRCA	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg15704280	chr7:45808275	SEPT13	-0.4	-8.0	-0.3	5.89e-15	Height;
BRCA	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg24848339	chr3:12840334	CAND2	0.43	11.36	0.41	2.39e-27	QRS complex (12-leadsum);
BRCA	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg24642439	chr20:33292090	TP53INP2	0.62	13.98	0.48	5.92e-39	Coronary artery disease;
BRCA	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg21138405	chr5:131827807	IRF1	0.4	13.23	0.46	1.69e-35	Asthma (sex interaction);
BRCA	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.47	-0.32	1.73e-16	Total body bone mineral density;
BRCA	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg04842962	chr6:43655489	MRPS18A	1.12	38.45	0.84	2.14e-168	IgG glycosylation;
BRCA	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg04025307	chr7:1156635	C7orf50	0.48	11.02	0.4	5.66e-26	Bronchopulmonary dysplasia;
BRCA	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg06064525	chr11:970664	AP2A2	-0.48	-16.27	-0.54	4.72e-50	Alzheimer's disease (late onset);
BRCA	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.1	0.4	2.68e-26	Bipolar disorder;
BRCA	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.32	10.11	0.37	2.22e-22	Bipolar disorder;
BRCA	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg03188948	chr7:1209495	NA	0.45	8.31	0.31	5.57e-16	Longevity;Endometriosis;
BRCA	cis	rs1351164	1.000	rs1351164	chr2:218271898	C/T	cg15335768	chr2:218268053	DIRC3	0.34	8.52	0.32	1.15e-16	Height;
BRCA	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg08885076	chr2:99613938	TSGA10	-0.56	-12.81	-0.45	1.27e-33	Chronic sinus infection;
BRCA	cis	rs507080	0.885	rs533144	chr11:118559247	C/A	cg08498647	chr11:118550644	TREH	-0.38	-8.29	-0.31	6.82e-16	Serum metabolite levels;
BRCA	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg13319975	chr6:146136371	FBXO30	-0.41	-9.29	-0.34	2.39e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19346786	chr7:2764209	NA	-0.36	-11.04	-0.4	4.54e-26	Height;
BRCA	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg10253484	chr15:75165896	SCAMP2	-0.53	-9.96	-0.37	7.98e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs113835537	0.597	rs2305534	chr11:66313203	T/C	cg24851651	chr11:66362959	CCS	0.49	9.06	0.34	1.6e-18	Airway imaging phenotypes;
BRCA	cis	rs3925075	0.531	rs4261553	chr16:31349164	T/C	cg02846316	chr16:31340340	ITGAM	0.42	8.65	0.32	4.12e-17	IgA nephropathy;
BRCA	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00908189	chr16:619842	PIGQ	0.68	16.93	0.56	2.08e-53	Height;
BRCA	cis	rs877282	0.898	rs2004478	chr10:770709	C/A	cg17470449	chr10:769945	NA	0.49	9.09	0.34	1.27e-18	Uric acid levels;
BRCA	cis	rs6977660	0.714	rs9969381	chr7:19827454	C/T	cg05791153	chr7:19748676	TWISTNB	0.6	11.17	0.4	1.37e-26	Thyroid stimulating hormone;
BRCA	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.33	10.34	0.38	2.72e-23	Bipolar disorder;
BRCA	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.34	7.84	0.3	1.95e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs701145	0.585	rs1727920	chr3:153788588	C/T	cg17054900	chr3:154042577	DHX36	0.54	9.14	0.34	8.17e-19	Coronary artery disease;
BRCA	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg24558204	chr6:135376177	HBS1L	-0.42	-11.23	-0.41	7.67e-27	Red blood cell count;
BRCA	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg01819863	chr10:32635814	EPC1	1.22	21.42	0.65	4.1e-77	Sexual dysfunction (female);
BRCA	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11890956	chr21:40555474	PSMG1	0.59	13.12	0.46	5.19e-35	Menarche (age at onset);
BRCA	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg02297831	chr4:17616191	MED28	0.36	8.44	0.32	2.09e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg19508488	chr2:152266495	RIF1	-0.45	-9.38	-0.35	1.14e-19	Squamous cell lung carcinoma;
BRCA	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg26384229	chr12:38710491	ALG10B	0.75	17.81	0.58	6.4e-58	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.43	0.5	4.82e-41	Personality dimensions;
BRCA	cis	rs758324	0.947	rs10052255	chr5:131173106	C/T	cg06307176	chr5:131281290	NA	0.53	10.14	0.37	1.68e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs3762637	0.943	rs28403550	chr3:122251838	C/A	cg24169773	chr3:122142474	KPNA1	-0.43	-7.98	-0.3	6.65e-15	LDL cholesterol levels;
BRCA	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg13944838	chr5:179740914	GFPT2	-0.72	-15.52	-0.52	2.45e-46	Height;
BRCA	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.09	0.56	3.13e-54	Bladder cancer;
BRCA	cis	rs2880765	0.835	rs6497202	chr15:86021375	T/C	cg10818794	chr15:86012489	AKAP13	-0.3	-8.43	-0.32	2.38e-16	Coronary artery disease;
BRCA	cis	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg06521331	chr12:34319734	NA	-0.55	-10.67	-0.39	1.47e-24	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.34	-0.38	2.72e-23	Schizophrenia;
BRCA	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg11764359	chr7:65958608	NA	0.66	12.1	0.43	1.78e-30	Aortic root size;
BRCA	cis	rs4812048	0.649	rs3761257	chr20:57618787	C/T	cg14073986	chr20:57617431	SLMO2	0.81	13.38	0.47	3.75e-36	Mean platelet volume;
BRCA	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg27624424	chr6:160112604	SOD2	0.4	8.22	0.31	1.13e-15	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg06092702	chr1:163392909	NA	-0.36	-9.6	-0.35	1.85e-20	Motion sickness;
BRCA	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg22800045	chr5:56110881	MAP3K1	0.64	11.93	0.43	9.58e-30	Initial pursuit acceleration;
BRCA	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg27170947	chr2:26402098	FAM59B	-0.7	-11.68	-0.42	1.09e-28	Gut microbiome composition (summer);
BRCA	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg05650719	chr12:132293520	NA	-0.4	-8.48	-0.32	1.5e-16	Migraine;
BRCA	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.62	-12.85	-0.45	8.62e-34	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg17366294	chr4:99064904	C4orf37	0.42	10.0	0.37	5.54e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg25174290	chr11:3078921	CARS	-0.3	-7.84	-0.3	1.88e-14	Calcium levels;
BRCA	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	10.33	0.38	2.97e-23	Aortic root size;
BRCA	trans	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg17145862	chr1:211918768	LPGAT1	0.69	18.15	0.58	1.04e-59	Leprosy;
BRCA	cis	rs6545883	0.929	rs2593635	chr2:61634706	A/C	cg15711740	chr2:61764176	XPO1	0.55	13.52	0.47	8.26e-37	Tuberculosis;
BRCA	cis	rs11971779	0.590	rs6944104	chr7:139051120	T/A	cg07862535	chr7:139043722	LUC7L2	0.38	10.28	0.38	4.63e-23	Diisocyanate-induced asthma;
BRCA	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg11301795	chr4:187892539	NA	-0.26	-8.69	-0.33	3.01e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07080220	chr10:102295463	HIF1AN	-0.6	-14.52	-0.5	1.72e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg21770322	chr7:97807741	LMTK2	0.42	11.31	0.41	3.74e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7523273	0.606	rs2724387	chr1:207932617	T/G	cg22525895	chr1:207977042	MIR29B2	0.47	12.05	0.43	2.91e-30	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.52	0.5	1.78e-41	Motion sickness;
BRCA	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.54	8.24	0.31	1.01e-15	Gut microbiome composition (summer);
BRCA	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.59	-13.75	-0.48	6.88e-38	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs3820928	0.874	rs4234064	chr2:227857497	G/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.3	-0.31	6.41e-16	Pulmonary function;
BRCA	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-16.2	-0.54	1.01e-49	Alzheimer's disease (late onset);
BRCA	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg03146154	chr1:46216737	IPP	0.45	9.94	0.37	9.83e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18876405	chr7:65276391	NA	-0.51	-11.75	-0.42	5.48e-29	Aortic root size;
BRCA	cis	rs17401966	0.540	rs4846216	chr1:10447792	A/T	cg03954927	chr1:10346856	KIF1B	-0.34	-10.17	-0.37	1.27e-22	Hepatocellular carcinoma;
BRCA	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-8.74	-0.33	2.06e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4662945	0.525	rs4662951	chr2:130256272	C/T	cg05903289	chr2:130345205	NA	-0.31	-7.81	-0.3	2.44e-14	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs897984	0.609	rs732173	chr16:31050023	C/A	cg02466173	chr16:30829666	NA	-0.45	-9.98	-0.37	6.58e-22	Dementia with Lewy bodies;
BRCA	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg12386194	chr3:101231763	SENP7	0.46	9.88	0.36	1.64e-21	Colorectal cancer;
BRCA	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg22834771	chr12:69754056	YEATS4	-0.43	-10.63	-0.39	2.04e-24	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs8073060	0.505	rs225270	chr17:33968871	A/T	cg19694781	chr19:47549865	TMEM160	-1.06	-21.58	-0.65	5.04e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg13902645	chr11:5959945	NA	0.46	10.07	0.37	3.2e-22	DNA methylation (variation);
BRCA	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg02297831	chr4:17616191	MED28	0.37	8.58	0.32	6.93e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg23750338	chr8:142222470	SLC45A4	-0.5	-11.49	-0.41	6.35e-28	Immature fraction of reticulocytes;
BRCA	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	29.96	0.76	7.16e-124	Cognitive ability;
BRCA	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg17173187	chr15:85201210	NMB	0.44	9.31	0.35	2.1e-19	Schizophrenia;
BRCA	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg22800045	chr5:56110881	MAP3K1	0.65	12.18	0.43	7.48e-31	Initial pursuit acceleration;
BRCA	cis	rs6723226	0.739	rs2069213	chr2:32743084	C/T	cg02381751	chr2:32503542	YIPF4	0.6	12.83	0.45	1.06e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs9341808	0.690	rs6930534	chr6:80896050	C/T	cg08355045	chr6:80787529	NA	0.39	9.88	0.36	1.64e-21	Sitting height ratio;
BRCA	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.38	-0.31	3.39e-16	Colorectal cancer;
BRCA	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg27432699	chr2:27873401	GPN1	-0.5	-10.51	-0.38	6.02e-24	Oral cavity cancer;
BRCA	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg12365402	chr11:9010492	NRIP3	-0.42	-9.76	-0.36	4.46e-21	Hemoglobin concentration;
BRCA	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03452623	chr4:187889614	NA	-0.35	-11.66	-0.42	1.32e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2658782	0.724	rs2605629	chr11:93264037	C/G	cg15737290	chr11:93063684	CCDC67	-0.49	-9.39	-0.35	1.05e-19	Pulmonary function decline;
BRCA	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg25036284	chr2:26402008	FAM59B	0.96	16.04	0.54	6.76e-49	Gut microbiome composition (summer);
BRCA	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	17.77	0.57	1.1e-57	Platelet count;
BRCA	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg27661571	chr11:113659931	NA	-0.5	-8.56	-0.32	8.43e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs1997103	1.000	rs4947500	chr7:55407270	C/A	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg11764359	chr7:65958608	NA	0.65	11.2	0.41	1.03e-26	Aortic root size;
BRCA	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg16325326	chr1:53192061	ZYG11B	-0.65	-16.24	-0.54	6.87e-50	Monocyte count;
BRCA	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg11752832	chr7:134001865	SLC35B4	0.5	12.93	0.46	4.01e-34	Mean platelet volume;
BRCA	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.89	-0.48	1.62e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg09307838	chr4:120376055	NA	0.7	14.19	0.49	5.99e-40	Corneal astigmatism;
BRCA	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-12.1	-0.43	1.65e-30	Morning vs. evening chronotype;
BRCA	cis	rs11605275	1.000	rs11605704	chr11:20032096	A/G	cg14835545	chr11:20032148	NAV2	0.62	10.14	0.37	1.62e-22	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	15.26	0.52	4.71e-45	Platelet count;
BRCA	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs250677	0.522	rs891920	chr5:148369418	G/T	cg18129178	chr5:148520854	ABLIM3	-0.55	-10.42	-0.38	1.4e-23	Breast cancer;
BRCA	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.42	-10.09	-0.37	2.64e-22	Lymphocyte counts;
BRCA	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg01420254	chr6:26195488	NA	-0.52	-8.31	-0.31	5.62e-16	Gout;Renal underexcretion gout;
BRCA	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg12483005	chr1:23474871	LUZP1	0.48	10.46	0.38	9.57e-24	Height;
BRCA	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg19077165	chr18:44547161	KATNAL2	-0.59	-13.26	-0.46	1.25e-35	Personality dimensions;
BRCA	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg00105475	chr2:10696890	NA	0.44	10.23	0.37	7.84e-23	Prostate cancer;
BRCA	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg06697600	chr4:7070879	GRPEL1	-0.56	-10.26	-0.38	5.54e-23	Monocyte percentage of white cells;
BRCA	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg19336497	chr11:14380999	RRAS2	-0.48	-12.07	-0.43	2.25e-30	Sense of smell;
BRCA	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg14019695	chr9:139328340	INPP5E	0.35	8.91	0.33	5.29e-18	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7635838	0.596	rs4684765	chr3:11261085	G/C	cg00170343	chr3:11313890	ATG7	0.41	8.23	0.31	1.08e-15	HDL cholesterol;
BRCA	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg09537434	chr19:41945824	ATP5SL	0.99	23.76	0.68	6.49e-90	Height;
BRCA	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg08997352	chr12:9597637	DDX12	-0.54	-10.21	-0.37	8.78e-23	Breast size;
BRCA	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.51	-0.32	1.2e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-16.04	-0.54	6.86e-49	Alzheimer's disease (late onset);
BRCA	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg09904177	chr6:26538194	HMGN4	0.39	8.76	0.33	1.8e-17	Small cell lung carcinoma;
BRCA	trans	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg15704280	chr7:45808275	SEPT13	0.6	8.83	0.33	1.02e-17	Axial length;
BRCA	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg03146154	chr1:46216737	IPP	0.48	10.66	0.39	1.58e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg17470723	chr8:74884337	TCEB1	0.4	8.67	0.32	3.58e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg03585969	chr10:35415529	CREM	0.55	11.37	0.41	2.17e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24549020	chr5:56110836	MAP3K1	0.67	13.19	0.46	2.64e-35	Initial pursuit acceleration;
BRCA	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	10.2	0.37	1.02e-22	Bipolar disorder;
BRCA	cis	rs6430585	0.527	rs76622824	chr2:136411879	A/G	cg07169764	chr2:136633963	MCM6	1.0	19.69	0.61	7.75e-68	Corneal structure;
BRCA	cis	rs847649	0.731	rs7785272	chr7:102671023	A/G	cg18108683	chr7:102477205	FBXL13	-0.36	-8.05	-0.3	4.03e-15	Morning vs. evening chronotype;
BRCA	cis	rs13046373	0.535	rs1395775	chr21:32025065	G/A	cg06468780	chr21:31798236	KRTAP13-3	0.34	8.47	0.32	1.71e-16	HDL cholesterol;
BRCA	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg01802117	chr1:53393560	SCP2	-0.4	-8.82	-0.33	1.11e-17	Monocyte count;
BRCA	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg05714579	chr10:131428358	MGMT	-0.49	-11.11	-0.4	2.54e-26	Response to temozolomide;
BRCA	cis	rs943466	1.000	rs6933607	chr6:33743997	G/A	cg25922239	chr6:33757077	LEMD2	-0.39	-7.84	-0.3	1.85e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	11.35	0.41	2.61e-27	Height;
BRCA	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg17063962	chr7:91808500	NA	-0.57	-13.43	-0.47	2.05e-36	Breast cancer;
BRCA	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg15017067	chr4:17643749	FAM184B	0.26	7.85	0.3	1.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg14784868	chr12:69753453	YEATS4	0.68	19.81	0.62	1.79e-68	Blood protein levels;
BRCA	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg07080220	chr10:102295463	HIF1AN	0.44	9.8	0.36	3.19e-21	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg15605315	chr1:45957053	TESK2	0.46	9.44	0.35	6.73e-20	High light scatter reticulocyte count;
BRCA	cis	rs7590368	0.961	rs13431852	chr2:10960410	T/C	cg15705551	chr2:10952987	PDIA6	0.44	8.14	0.31	2.02e-15	Educational attainment (years of education);
BRCA	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg24011408	chr12:48396354	COL2A1	-0.44	-9.85	-0.36	2.05e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs7927771	0.524	rs7101597	chr11:47797917	A/T	cg20307385	chr11:47447363	PSMC3	0.42	9.54	0.35	3.01e-20	Subjective well-being;
BRCA	cis	rs1865721	0.771	rs72975986	chr18:73127649	A/G	cg26385618	chr18:73139727	C18orf62	-0.43	-10.29	-0.38	4.6e-23	Intelligence;
BRCA	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg00814883	chr7:100076585	TSC22D4	-0.47	-10.54	-0.38	4.62e-24	Platelet count;
BRCA	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg03060546	chr3:49711283	APEH	-0.5	-10.14	-0.37	1.74e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg25214090	chr10:38739885	LOC399744	0.53	11.74	0.42	5.69e-29	Corneal astigmatism;
BRCA	cis	rs9473147	0.516	rs9367284	chr6:47516369	A/G	cg12968598	chr6:47444699	CD2AP	0.44	9.61	0.36	1.61e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-10.16	-0.37	1.43e-22	Resting heart rate;
BRCA	cis	rs3784262	0.669	rs3742959	chr15:58249113	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.35	-9.64	-0.36	1.29e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg20701182	chr2:24300061	SF3B14	0.58	9.01	0.34	2.37e-18	Lymphocyte counts;
BRCA	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.68	0.32	3.33e-17	Motion sickness;
BRCA	trans	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.45	-0.35	6.11e-20	Bladder cancer;
BRCA	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg06784218	chr1:46089804	CCDC17	0.5	12.05	0.43	2.88e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs4942242	1.000	rs7331003	chr13:44230253	C/T	cg19169023	chr15:41853346	TYRO3	-0.49	-11.45	-0.41	9.61e-28	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs7520050	0.933	rs12045165	chr1:46256022	C/A	cg24296786	chr1:45957014	TESK2	0.45	10.17	0.37	1.32e-22	Red blood cell count;Reticulocyte count;
BRCA	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21385522	chr1:16154831	NA	0.6	11.32	0.41	3.25e-27	Dilated cardiomyopathy;
BRCA	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg13567636	chr1:160991154	F11R	-0.48	-9.36	-0.35	1.35e-19	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg15556689	chr8:8085844	FLJ10661	-0.34	-8.44	-0.32	2.05e-16	Triglycerides;
BRCA	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg01689657	chr7:91764605	CYP51A1	0.22	8.15	0.31	1.88e-15	Breast cancer;
BRCA	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg08975724	chr8:8085496	FLJ10661	0.38	8.13	0.31	2.18e-15	Retinal vascular caliber;
BRCA	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg23711669	chr6:146136114	FBXO30	-0.68	-15.78	-0.53	1.33e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg27279351	chr12:120934652	DYNLL1	0.51	12.39	0.44	9.44e-32	High light scatter reticulocyte count;
BRCA	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-11.83	-0.42	2.44e-29	Longevity;
BRCA	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg07169764	chr2:136633963	MCM6	1.28	28.22	0.74	2.21e-114	Corneal structure;
BRCA	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	10.88	0.4	2.11e-25	Iron status biomarkers;
BRCA	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-11.56	-0.42	3.3e-28	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.21	-0.34	4.63e-19	Bipolar disorder;
BRCA	cis	rs9309711	0.772	rs9752251	chr2:3489869	C/T	cg16153549	chr2:3496821	NA	-0.44	-10.12	-0.37	2.01e-22	Neurofibrillary tangles;
BRCA	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	9.29	0.35	2.32e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.35e-15	Prostate cancer;
BRCA	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.11	0.37	2.23e-22	Aortic root size;
BRCA	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg27535305	chr1:53392650	SCP2	-0.35	-8.68	-0.32	3.16e-17	Monocyte count;
BRCA	trans	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs798766	1.000	rs7682402	chr4:1743343	G/A	cg05874882	chr4:1763078	NA	-0.48	-8.62	-0.32	5.33e-17	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg06784218	chr1:46089804	CCDC17	0.49	11.75	0.42	5.47e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs55882075	0.723	rs56227602	chr5:179179472	A/G	cg14593053	chr5:179126677	CANX	0.48	13.11	0.46	6.03e-35	Monocyte percentage of white cells;
BRCA	cis	rs11690935	0.550	rs7584187	chr2:172866105	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.48	-11.85	-0.42	1.94e-29	Schizophrenia;
BRCA	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg15704280	chr7:45808275	SEPT13	-0.46	-8.0	-0.3	5.7e-15	Axial length;
BRCA	cis	rs6032067	0.673	rs4522674	chr20:43893276	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	0.34	8.17	0.31	1.67e-15	Blood protein levels;
BRCA	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18404041	chr3:52824283	ITIH1	-0.38	-11.78	-0.42	4.09e-29	Bipolar disorder;
BRCA	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg18225595	chr11:63971243	STIP1	0.58	13.84	0.48	2.61e-38	Platelet count;
BRCA	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.1	0.34	1.16e-18	Tonsillectomy;
BRCA	cis	rs10504073	0.669	rs818560	chr8:50035417	C/T	cg00325661	chr8:49890786	NA	0.38	10.92	0.4	1.42e-25	Blood metabolite ratios;
BRCA	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.03	-24.37	-0.69	2.96e-93	Ulcerative colitis;
BRCA	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.62	-13.34	-0.47	5.33e-36	Lymphocyte counts;
BRCA	cis	rs6484504	0.553	rs413067	chr11:31223497	T/C	cg14844989	chr11:31128820	NA	-0.45	-9.6	-0.36	1.76e-20	Red blood cell count;
BRCA	cis	rs3768617	0.811	rs12022720	chr1:183017223	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	9.41	0.35	8.64e-20	Fuchs's corneal dystrophy;
BRCA	cis	rs490234	0.702	rs1339499	chr9:128406453	T/C	cg14078157	chr9:128172775	NA	-0.48	-10.82	-0.39	3.52e-25	Mean arterial pressure;
BRCA	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18876405	chr7:65276391	NA	-0.71	-18.88	-0.6	1.67e-63	Calcium levels;
BRCA	cis	rs1371614	0.589	rs527267	chr2:27119655	G/C	cg12368169	chr2:27073192	DPYSL5	-0.31	-9.14	-0.34	8.23e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg08847533	chr14:75593920	NEK9	0.83	20.57	0.63	1.56e-72	Height;
BRCA	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg10523679	chr1:76189770	ACADM	-0.62	-11.83	-0.42	2.38e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg18252515	chr7:66147081	NA	-1.05	-14.43	-0.5	4.68e-41	Diabetic kidney disease;
BRCA	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg20991723	chr1:152506922	NA	0.36	7.96	0.3	8.02e-15	Hair morphology;
BRCA	trans	rs11722228	0.522	rs12503195	chr4:10082772	T/C	cg26043149	chr18:55253948	FECH	0.68	15.7	0.53	3.08e-47	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.38	-0.38	1.89e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs290268	0.874	rs290994	chr9:93559515	T/A	cg02608019	chr9:93564028	SYK	0.56	12.32	0.44	1.91e-31	Platelet count;
BRCA	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg01483505	chr11:975446	AP2A2	0.3	8.2	0.31	1.31e-15	Alzheimer's disease (late onset);
BRCA	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	8.45	0.32	1.95e-16	Personality dimensions;
BRCA	trans	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg17675199	chr6:35436792	RPL10A	-0.3	-7.91	-0.3	1.13e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg06145435	chr7:1022769	CYP2W1	0.48	8.88	0.33	6.75e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg07506560	chr2:240697449	NA	0.5	11.09	0.4	2.88e-26	Obesity-related traits;
BRCA	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg25358565	chr5:93447407	FAM172A	1.17	18.4	0.59	5.16e-61	Diabetic retinopathy;
BRCA	cis	rs2882667	0.622	rs34645817	chr5:138152633	A/G	cg04439458	chr5:138467593	SIL1	0.36	8.65	0.32	4.3e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg24296786	chr1:45957014	TESK2	-0.57	-13.32	-0.47	6.98e-36	High light scatter reticulocyte count;
BRCA	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg17971929	chr21:40555470	PSMG1	-0.46	-10.24	-0.38	6.93e-23	Menarche (age at onset);
BRCA	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg27478167	chr7:817139	HEATR2	-0.42	-8.97	-0.33	3.39e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs807669	0.505	rs2236759	chr22:19187427	C/G	cg02655711	chr22:19163373	SLC25A1	0.44	10.28	0.38	4.64e-23	Metabolite levels;
BRCA	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg26446133	chr18:72167187	CNDP2	-0.78	-14.01	-0.48	4.17e-39	Refractive error;
BRCA	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.66	-0.53	4.96e-47	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg13736514	chr6:26305472	NA	-0.37	-12.07	-0.43	2.4e-30	Educational attainment;
BRCA	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg03213289	chr20:61660250	NA	0.63	16.54	0.55	2.05e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2637266	1.000	rs2395394	chr10:78360679	G/C	cg18941641	chr10:78392320	NA	0.35	7.82	0.3	2.18e-14	Pulmonary function;
BRCA	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg01802117	chr1:53393560	SCP2	-0.35	-7.91	-0.3	1.12e-14	Monocyte count;
BRCA	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg26384229	chr12:38710491	ALG10B	0.82	21.88	0.65	1.2e-79	Heart rate;
BRCA	cis	rs1018836	0.884	rs7823461	chr8:91581075	T/C	cg16814680	chr8:91681699	NA	-0.64	-14.25	-0.49	3.41e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs735860	0.674	rs209485	chr6:53174448	C/T	cg10236188	chr6:53219634	NA	-0.4	-8.47	-0.32	1.65e-16	Glaucoma;
BRCA	cis	rs2425143	1.000	rs78877130	chr20:34344947	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.9	-0.33	5.76e-18	Blood protein levels;
BRCA	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.54	7.83	0.3	2.07e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6785206	1.000	rs6785206	chr3:128412024	A/G	cg16766828	chr3:128327626	NA	-0.76	-11.19	-0.4	1.12e-26	Lymphocyte percentage of white cells;
BRCA	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg18252515	chr7:66147081	NA	-0.56	-11.27	-0.41	5.37e-27	Corneal structure;
BRCA	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg03433033	chr1:76189801	ACADM	-0.47	-9.6	-0.35	1.85e-20	Daytime sleep phenotypes;
BRCA	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.13	-0.34	8.85e-19	Bipolar disorder;
BRCA	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	13.92	0.48	1.19e-38	Lymphocyte percentage of white cells;
BRCA	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg09307838	chr4:120376055	NA	0.71	15.33	0.52	2.03e-45	Corneal astigmatism;
BRCA	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7560272	0.538	rs4852977	chr2:73938295	C/T	cg20560298	chr2:73613845	ALMS1	0.34	8.77	0.33	1.62e-17	Schizophrenia;
BRCA	cis	rs12367572	1.000	rs10880704	chr12:45318430	C/T	cg04608330	chr12:45269318	NELL2	-0.58	-12.6	-0.45	1.08e-32	Gut microbiome composition (summer);
BRCA	cis	rs2882667	0.964	rs67296915	chr5:138301599	C/T	cg04439458	chr5:138467593	SIL1	-0.32	-8.76	-0.33	1.75e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs4714291	0.832	rs1404002	chr6:40064600	C/T	cg02267698	chr19:7991119	CTXN1	-0.42	-8.63	-0.32	4.96e-17	Strep throat;
BRCA	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg13010199	chr12:38710504	ALG10B	-0.35	-8.54	-0.32	9.47e-17	Morning vs. evening chronotype;
BRCA	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18402987	chr7:1209562	NA	0.65	14.25	0.49	3.38e-40	Longevity;Endometriosis;
BRCA	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg05283184	chr6:79620031	NA	-0.43	-11.02	-0.4	5.89e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg17366294	chr4:99064904	C4orf37	0.45	10.77	0.39	5.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7590720	1.000	rs7559031	chr2:216902583	A/G	cg12620499	chr2:216877984	MREG	0.79	22.14	0.66	4.94e-81	Alcohol dependence;
BRCA	cis	rs6580649	1.000	rs10783227	chr12:48400617	C/T	cg05342945	chr12:48394962	COL2A1	-0.49	-9.9	-0.36	1.33e-21	Lung cancer;
BRCA	trans	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04565464	chr8:145669602	NFKBIL2	0.35	8.82	0.33	1.09e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.45	0.38	1.06e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg10523679	chr1:76189770	ACADM	-0.51	-10.0	-0.37	5.52e-22	Daytime sleep phenotypes;
BRCA	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg06046430	chr4:77819534	ANKRD56	0.58	12.65	0.45	6.89e-33	Emphysema distribution in smoking;
BRCA	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg17470723	chr8:74884337	TCEB1	0.42	8.92	0.33	5.03e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9473147	0.543	rs4711878	chr6:47456118	A/G	cg12968598	chr6:47444699	CD2AP	0.44	9.6	0.36	1.77e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg21573476	chr21:45109991	RRP1B	-0.34	-8.77	-0.33	1.64e-17	Mean corpuscular volume;
BRCA	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg16989086	chr20:62203971	PRIC285	0.53	8.84	0.33	9.3e-18	Glioblastoma;
BRCA	cis	rs1863824	0.502	rs11202058	chr10:88282611	G/A	cg07322936	chr10:88137208	NA	-0.41	-7.99	-0.3	6.28e-15	Schizophrenia;
BRCA	trans	rs6479891	1.000	rs12415984	chr10:64910288	G/A	cg14819942	chr15:35414228	NA	0.35	8.58	0.32	7.2e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs6977660	0.943	rs10254261	chr7:19846001	A/G	cg05791153	chr7:19748676	TWISTNB	-0.42	-8.64	-0.32	4.42e-17	Thyroid stimulating hormone;
BRCA	cis	rs11734570	0.581	rs73808504	chr4:38600593	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.51	9.59	0.35	1.97e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2652822	0.935	rs7162825	chr15:63439186	A/G	cg02713581	chr15:63449717	RPS27L	-0.43	-8.67	-0.32	3.44e-17	Metabolic traits;
BRCA	cis	rs9287719	0.649	rs9973456	chr2:10718130	C/T	cg00105475	chr2:10696890	NA	0.41	9.19	0.34	5.62e-19	Prostate cancer;
BRCA	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-10.6	-0.39	2.68e-24	Lymphocyte counts;
BRCA	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg06671706	chr8:8559999	CLDN23	0.44	8.43	0.32	2.22e-16	Obesity-related traits;
BRCA	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg15556689	chr8:8085844	FLJ10661	-0.31	-8.13	-0.31	2.29e-15	Joint mobility (Beighton score);
BRCA	cis	rs4948102	1.000	rs4948102	chr7:56097265	C/G	cg09872392	chr7:56161020	PHKG1	-0.42	-9.49	-0.35	4.5e-20	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.21	0.56	8.47e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg18758796	chr5:131593413	PDLIM4	0.39	9.94	0.37	9.96e-22	Acylcarnitine levels;
BRCA	trans	rs8002861	0.840	rs1819596	chr13:44429554	A/G	cg17145862	chr1:211918768	LPGAT1	0.63	16.04	0.54	6.57e-49	Leprosy;
BRCA	cis	rs701145	0.550	rs450115	chr3:153923418	A/C	cg17054900	chr3:154042577	DHX36	0.57	9.59	0.35	1.96e-20	Coronary artery disease;
BRCA	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg26384229	chr12:38710491	ALG10B	-0.46	-10.65	-0.39	1.72e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4948102	0.731	rs4535700	chr7:56045448	T/C	cg09872392	chr7:56161020	PHKG1	-0.4	-9.08	-0.34	1.39e-18	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg12310025	chr6:25882481	NA	-0.57	-12.89	-0.45	5.71e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.09	0.34	1.21e-18	Tonsillectomy;
BRCA	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg21747090	chr2:27597821	SNX17	-0.41	-8.99	-0.34	2.69e-18	Total body bone mineral density;
BRCA	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg09555818	chr19:45449301	APOC2	0.47	12.22	0.44	5.4e-31	Blood protein levels;
BRCA	cis	rs11690935	0.531	rs4280428	chr2:172813219	G/A	cg13550731	chr2:172543902	DYNC1I2	0.54	13.01	0.46	1.62e-34	Schizophrenia;
BRCA	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg05340658	chr4:99064831	C4orf37	0.64	14.87	0.51	3.68e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg05985134	chr18:33552581	C18orf21	0.65	12.41	0.44	7.63e-32	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg06623918	chr6:96969491	KIAA0776	0.9	26.16	0.72	4.14e-103	Headache;
BRCA	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06221963	chr1:154839813	KCNN3	-0.6	-16.99	-0.56	1.06e-53	Prostate cancer;
BRCA	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.29	-8.11	-0.31	2.6e-15	Lymphocyte counts;
BRCA	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.18	-0.34	5.9e-19	Neuroticism;
BRCA	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg05313129	chr8:58192883	C8orf71	-0.43	-8.88	-0.33	6.55e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg18230493	chr5:56204884	C5orf35	-0.73	-14.78	-0.5	9.97e-43	Initial pursuit acceleration;
BRCA	cis	rs9837602	0.507	rs1059905	chr3:99516879	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.54	-12.8	-0.45	1.48e-33	Breast cancer;
BRCA	cis	rs4363385	0.818	rs679378	chr1:153011716	G/A	cg21543102	chr1:152974771	SPRR3	-0.28	-7.81	-0.3	2.31e-14	Inflammatory skin disease;
BRCA	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg20503657	chr10:835505	NA	1.01	17.7	0.57	2.31e-57	Eosinophil percentage of granulocytes;
BRCA	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg22974920	chr21:40686053	BRWD1	0.34	7.82	0.3	2.17e-14	Menarche (age at onset);
BRCA	cis	rs4880487	0.888	rs10903405	chr10:1249498	C/G	cg03183215	chr10:1252341	ADARB2	-0.38	-8.54	-0.32	9.54e-17	Migraine;
BRCA	cis	rs2882667	0.690	rs288042	chr5:138203034	T/G	cg04439458	chr5:138467593	SIL1	-0.31	-7.97	-0.3	7.3e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.31	-0.31	5.69e-16	Parkinson's disease;
BRCA	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg26384229	chr12:38710491	ALG10B	0.76	17.07	0.56	4.41e-54	Morning vs. evening chronotype;
BRCA	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.7	0.42	8.72e-29	Tonsillectomy;
BRCA	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.87	15.87	0.53	4.58e-48	Lymphocyte percentage of white cells;
BRCA	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.64	11.62	0.42	1.86e-28	Height;
BRCA	cis	rs4908768	0.539	rs7547411	chr1:8638145	A/G	cg20416874	chr1:8611966	RERE	-0.28	-8.13	-0.31	2.23e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg03474202	chr17:45855739	NA	-0.47	-11.05	-0.4	4.46e-26	IgG glycosylation;
BRCA	cis	rs600806	0.742	rs9429519	chr1:110017105	A/G	cg20591472	chr1:110008990	SYPL2	-0.33	-8.27	-0.31	7.86e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg08975724	chr8:8085496	FLJ10661	0.43	8.01	0.3	5.55e-15	Retinal vascular caliber;
BRCA	cis	rs2901460	0.509	rs6750080	chr2:62071542	C/T	cg02183531	chr2:62113199	CCT4	-0.44	-8.77	-0.33	1.65e-17	Mean corpuscular volume;
BRCA	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg08999081	chr20:33150536	PIGU	-0.45	-12.32	-0.44	1.83e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs600550	0.528	rs10897006	chr11:59851874	C/G	cg02771260	chr11:59836817	MS4A3	-0.53	-11.55	-0.42	3.81e-28	Lipoprotein-associated phospholipase A2 activity and mass;
BRCA	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25427524	chr10:38739819	LOC399744	-0.64	-14.94	-0.51	1.62e-43	Extrinsic epigenetic age acceleration;
BRCA	cis	rs867371	0.717	rs3858954	chr15:82558034	G/C	cg00614314	chr15:82944287	LOC80154	0.48	9.72	0.36	6.19e-21	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg03188948	chr7:1209495	NA	0.53	10.03	0.37	4.52e-22	Longevity;Endometriosis;
BRCA	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.12	0.37	2.07e-22	Aortic root size;
BRCA	cis	rs6700896	0.931	rs11208716	chr1:66158825	C/T	cg04111102	chr1:66153794	NA	0.35	8.81	0.33	1.16e-17	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs6429082	0.689	rs10925965	chr1:235708443	C/A	cg26050004	chr1:235667680	B3GALNT2	-0.52	-11.49	-0.41	6.56e-28	Adiposity;
BRCA	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg26677194	chr12:130822605	PIWIL1	0.67	16.14	0.54	2.2e-49	Menopause (age at onset);
BRCA	cis	rs12367572	0.663	rs4561266	chr12:45415763	C/T	cg04608330	chr12:45269318	NELL2	-0.37	-7.93	-0.3	9.6e-15	Gut microbiome composition (summer);
BRCA	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg16576597	chr16:28551801	NUPR1	0.29	8.21	0.31	1.26e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.35	8.2	0.31	1.28e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg07741184	chr6:167504864	NA	0.33	10.06	0.37	3.48e-22	Crohn's disease;
BRCA	trans	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg15556689	chr8:8085844	FLJ10661	0.33	9.07	0.34	1.49e-18	Retinal vascular caliber;
BRCA	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	17.9	0.58	2.11e-58	Alzheimer's disease;
BRCA	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00475322	chr7:917719	C7orf20	0.48	12.71	0.45	3.61e-33	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07080220	chr10:102295463	HIF1AN	0.48	11.1	0.4	2.65e-26	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg25319279	chr11:5960081	NA	-0.41	-8.08	-0.3	3.36e-15	DNA methylation (variation);
BRCA	cis	rs12611088	0.571	rs8110232	chr19:44027390	T/C	cg15012607	chr19:44012195	ETHE1	-0.34	-8.83	-0.33	9.95e-18	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg22907277	chr7:1156413	C7orf50	0.37	8.3	0.31	6.18e-16	Longevity;Endometriosis;
BRCA	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.65	13.42	0.47	2.28e-36	Lymphocyte counts;
BRCA	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg13319975	chr6:146136371	FBXO30	0.34	8.0	0.3	5.98e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs939658	0.728	rs8031638	chr15:79422726	C/T	cg17916960	chr15:79447300	NA	-0.42	-9.77	-0.36	4.08e-21	Refractive error;
BRCA	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.14e-19	Total body bone mineral density;
BRCA	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg17366294	chr4:99064904	C4orf37	0.44	10.23	0.38	7.37e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg25427524	chr10:38739819	LOC399744	-0.67	-16.05	-0.54	5.72e-49	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg26061582	chr7:22766209	IL6	0.38	8.89	0.33	6.27e-18	Lung cancer;
BRCA	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg18225595	chr11:63971243	STIP1	0.52	9.46	0.35	6.01e-20	Mean platelet volume;
BRCA	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg13047869	chr3:10149882	C3orf24	0.6	12.91	0.45	5.02e-34	Alzheimer's disease;
BRCA	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24110177	chr3:50126178	RBM5	0.42	11.59	0.42	2.5e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7178424	0.967	rs72749770	chr15:62365465	C/T	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.24	-0.31	1.01e-15	Height;
BRCA	cis	rs332507	0.711	rs3772793	chr3:124405723	A/G	cg05980111	chr3:124395277	KALRN	0.37	8.63	0.32	4.83e-17	Plateletcrit;
BRCA	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg08645402	chr16:4508243	NA	0.36	8.0	0.3	5.68e-15	Schizophrenia;
BRCA	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg21798802	chr22:38057573	PDXP	0.5	13.24	0.46	1.6e-35	Fat distribution (HIV);
BRCA	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	11.87	0.43	1.61e-29	Lung cancer in ever smokers;
BRCA	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg10295955	chr4:187884368	NA	-0.99	-31.64	-0.78	6.55e-133	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9790314	0.663	rs7632423	chr3:160738728	A/G	cg03342759	chr3:160939853	NMD3	0.44	9.15	0.34	7.66e-19	Morning vs. evening chronotype;
BRCA	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg22974920	chr21:40686053	BRWD1	0.39	8.81	0.33	1.18e-17	Cognitive function;
BRCA	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg08885076	chr2:99613938	TSGA10	-0.6	-13.45	-0.47	1.67e-36	Chronic sinus infection;
BRCA	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg22961513	chr11:14280813	SPON1	-0.31	-8.07	-0.3	3.58e-15	Mitochondrial DNA levels;
BRCA	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg26408565	chr15:76604113	ETFA	-0.48	-10.31	-0.38	3.72e-23	Blood metabolite levels;
BRCA	cis	rs7560272	0.512	rs2421677	chr2:73965917	G/T	cg20560298	chr2:73613845	ALMS1	0.33	8.44	0.32	2.08e-16	Schizophrenia;
BRCA	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg18357645	chr12:58087776	OS9	0.36	10.14	0.37	1.72e-22	Multiple sclerosis;
BRCA	cis	rs11229555	0.645	rs35735990	chr11:58187371	G/A	cg15696309	chr11:58395628	NA	-0.45	-9.71	-0.36	7.05e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-10.45	-0.38	1.08e-23	Schizophrenia;
BRCA	cis	rs7520050	0.966	rs11211241	chr1:46452683	T/A	cg24296786	chr1:45957014	TESK2	0.44	9.81	0.36	2.89e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs3087591	0.887	rs2905875	chr17:29541339	A/T	cg24425628	chr17:29625626	OMG;NF1	0.46	9.32	0.35	1.88e-19	Hip circumference;
BRCA	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg18230493	chr5:56204884	C5orf35	-0.45	-9.32	-0.35	1.91e-19	Coronary artery disease;
BRCA	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg11789530	chr4:8429930	ACOX3	0.59	14.56	0.5	1.07e-41	Response to antineoplastic agents;
BRCA	cis	rs4535700	0.501	rs10245725	chr7:55976548	C/T	cg09872392	chr7:56161020	PHKG1	-0.35	-8.05	-0.3	4.16e-15	Macular telangiectasia type 2;
BRCA	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg00409905	chr10:38381863	ZNF37A	-0.48	-10.16	-0.37	1.38e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg12386194	chr3:101231763	SENP7	0.41	8.67	0.32	3.49e-17	Colorectal cancer;
BRCA	cis	rs12464559	0.522	rs4664498	chr2:152575417	A/G	cg01189475	chr2:152685088	ARL5A	0.51	7.92	0.3	1.04e-14	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg03954927	chr1:10346856	KIF1B	0.48	14.82	0.51	6.34e-43	Hepatocellular carcinoma;
BRCA	cis	rs724568	0.508	rs1430773	chr2:67943520	G/A	cg14046302	chr2:67939758	NA	-0.41	-11.08	-0.4	3.23e-26	Major depressive disorder (broad);
BRCA	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg25173405	chr17:45401733	C17orf57	-0.49	-9.71	-0.36	7.12e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg26043149	chr18:55253948	FECH	-0.37	-7.86	-0.3	1.67e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs757081	0.667	rs17561348	chr11:17161615	C/T	cg15432903	chr11:17409602	KCNJ11	0.45	8.46	0.32	1.81e-16	Systolic blood pressure;
BRCA	cis	rs11051970	0.879	rs2088807	chr12:32592101	C/G	cg24626660	chr12:32551988	NA	0.3	8.43	0.32	2.3e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg04166393	chr7:2884313	GNA12	0.61	12.61	0.45	9.83e-33	Height;
BRCA	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg20933634	chr6:27740509	NA	0.49	9.82	0.36	2.62e-21	Parkinson's disease;
BRCA	trans	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.8	-0.33	1.3e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg26031613	chr14:104095156	KLC1	0.74	16.01	0.54	8.85e-49	Body mass index;
BRCA	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg00677455	chr12:58241039	CTDSP2	-0.75	-16.85	-0.55	5.63e-53	Multiple sclerosis;
BRCA	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg26516362	chr5:178986906	RUFY1	0.36	9.86	0.36	1.89e-21	Lung cancer;
BRCA	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg15212455	chr7:39170539	POU6F2	0.44	9.82	0.36	2.6e-21	IgG glycosylation;
BRCA	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg15934090	chr1:100435551	SLC35A3	0.36	8.43	0.32	2.38e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24838063	chr12:130822603	PIWIL1	0.69	16.86	0.55	4.67e-53	Menopause (age at onset);
BRCA	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg13628971	chr7:2884303	GNA12	0.44	9.11	0.34	1.07e-18	Height;
BRCA	cis	rs3772130	0.923	rs7649092	chr3:121561950	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.82	0.39	3.58e-25	Cognitive performance;
BRCA	cis	rs7587476	0.906	rs2070096	chr2:215645545	C/G	cg04004882	chr2:215674386	BARD1	0.6	10.57	0.39	3.67e-24	Neuroblastoma;
BRCA	cis	rs12989701	0.825	rs4663097	chr2:127861906	C/G	cg08168897	chr2:127865431	BIN1	-0.6	-11.18	-0.4	1.28e-26	Alzheimer's disease (late onset);
BRCA	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg26769984	chr7:1090371	C7orf50	0.65	11.47	0.41	8.13e-28	Bronchopulmonary dysplasia;
BRCA	cis	rs1568889	1.000	rs12802830	chr11:28321196	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	12.74	0.45	2.79e-33	Bipolar disorder;
BRCA	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg04586622	chr2:25135609	ADCY3	-0.49	-11.58	-0.42	2.67e-28	Body mass index;
BRCA	cis	rs2882667	0.654	rs12517514	chr5:138150119	A/G	cg04439458	chr5:138467593	SIL1	0.31	7.92	0.3	1.09e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18876405	chr7:65276391	NA	0.55	13.35	0.47	4.99e-36	Aortic root size;
BRCA	cis	rs3768617	0.811	rs12738377	chr1:183031256	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	9.47	0.35	5.13e-20	Fuchs's corneal dystrophy;
BRCA	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08045932	chr20:61659980	NA	0.49	11.32	0.41	3.4e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg26874164	chr19:58962979	ZNF324B	0.47	10.0	0.37	5.74e-22	Uric acid clearance;
BRCA	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-9.06	-0.34	1.53e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg06917634	chr15:78832804	PSMA4	-0.75	-17.55	-0.57	1.45e-56	Sudden cardiac arrest;
BRCA	cis	rs698813	0.674	rs6544752	chr2:44499049	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	7.89	0.3	1.36e-14	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg07636037	chr3:49044803	WDR6	0.79	19.47	0.61	1.23e-66	Subjective well-being (multi-trait analysis);Menarche (age at onset);
BRCA	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg13334819	chr7:99746414	C7orf59	-0.38	-9.42	-0.35	8.17e-20	Coronary artery disease;
BRCA	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg13073564	chr4:8508604	NA	-0.39	-10.41	-0.38	1.56e-23	Response to antineoplastic agents;
BRCA	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.87	0.56	4.51e-53	Colorectal cancer;
BRCA	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg02466173	chr16:30829666	NA	-0.53	-11.44	-0.41	1.03e-27	Multiple myeloma;
BRCA	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg21226059	chr5:178986404	RUFY1	0.39	10.29	0.38	4.4e-23	Lung cancer;
BRCA	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.64	10.01	0.37	5.23e-22	Lung function (FEV1/FVC);
BRCA	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg23285459	chr7:2802560	GNA12	-0.34	-8.6	-0.32	6.34e-17	Height;
BRCA	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg00321850	chr1:175162397	KIAA0040	0.43	12.38	0.44	1.05e-31	Alcohol dependence;
BRCA	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.49	-0.47	1.09e-36	Extrinsic epigenetic age acceleration;
BRCA	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg00074818	chr8:8560427	CLDN23	-0.36	-7.87	-0.3	1.52e-14	Obesity-related traits;
BRCA	cis	rs34779708	0.733	rs11010146	chr10:35541561	T/A	cg03585969	chr10:35415529	CREM	0.45	9.19	0.34	5.23e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg13319975	chr6:146136371	FBXO30	-0.36	-8.29	-0.31	6.79e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11112613	0.713	rs11112589	chr12:105951226	C/G	cg03607813	chr12:105948248	NA	-0.55	-10.6	-0.39	2.78e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.07	-23.42	-0.68	5.04e-88	Ulcerative colitis;
BRCA	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg21770322	chr7:97807741	LMTK2	0.45	11.74	0.42	5.91e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.56	8.7	0.33	2.7e-17	HIV-1 control;
BRCA	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.6	0.32	6.35e-17	Cognitive ability;
BRCA	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.49	-10.0	-0.37	5.55e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg23933602	chr10:16859644	RSU1	0.57	8.93	0.33	4.47e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg08847533	chr14:75593920	NEK9	-0.95	-25.11	-0.7	2.47e-97	Height;
BRCA	trans	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.97	0.3	7.33e-15	Corneal astigmatism;
BRCA	cis	rs11971779	0.941	rs7802779	chr7:139122579	G/T	cg07862535	chr7:139043722	LUC7L2	0.41	10.58	0.39	3.19e-24	Diisocyanate-induced asthma;
BRCA	cis	rs4363385	0.818	rs946095	chr1:153006470	T/C	cg24667326	chr1:152973720	SPRR3	-0.34	-9.28	-0.34	2.53e-19	Inflammatory skin disease;
BRCA	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	14.09	0.49	1.89e-39	Lymphocyte counts;
BRCA	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg07211511	chr3:129823064	LOC729375	-1.01	-19.21	-0.61	3.06e-65	Blood pressure (smoking interaction);
BRCA	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg13334819	chr7:99746414	C7orf59	0.4	9.17	0.34	6.36e-19	Coronary artery disease;
BRCA	cis	rs7582720	1.000	rs72934545	chr2:203975958	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	12.77	0.45	2.02e-33	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs698813	0.674	rs11680456	chr2:44497544	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	8.9	0.33	5.59e-18	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg23029597	chr12:123009494	RSRC2	-0.59	-11.4	-0.41	1.52e-27	Body mass index;
BRCA	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.6	0.42	2.25e-28	Homoarginine levels;
BRCA	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg08470875	chr2:26401718	FAM59B	0.71	11.35	0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg00080972	chr5:178986291	RUFY1	-0.35	-9.06	-0.34	1.58e-18	Lung cancer;
BRCA	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg25811766	chr13:21894605	NA	0.61	10.92	0.4	1.44e-25	White matter hyperintensity burden;
BRCA	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg07741184	chr6:167504864	NA	-0.3	-8.94	-0.33	4.21e-18	Primary biliary cholangitis;
BRCA	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg12011299	chr4:100065546	ADH4	0.48	10.81	0.39	4.06e-25	Smoking initiation;
BRCA	cis	rs2882667	0.728	rs10037071	chr5:138277847	A/G	cg04439458	chr5:138467593	SIL1	-0.32	-8.23	-0.31	1.05e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg08000102	chr2:233561755	GIGYF2	-0.59	-12.42	-0.44	7.29e-32	Coronary artery disease;
BRCA	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg12935359	chr14:103987150	CKB	-0.59	-14.08	-0.49	2.02e-39	Body mass index;
BRCA	cis	rs16958440	1.000	rs62096476	chr18:44658621	T/C	cg17192377	chr18:44677553	HDHD2	0.69	10.1	0.37	2.41e-22	Sitting height ratio;
BRCA	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg10518572	chr11:65560635	OVOL1	-0.28	-8.1	-0.31	2.71e-15	Acne (severe);
BRCA	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg27661571	chr11:113659931	NA	-0.83	-12.11	-0.43	1.55e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg02176678	chr2:219576539	TTLL4	0.43	11.46	0.41	8.52e-28	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg26395211	chr5:140044315	WDR55	0.38	8.57	0.32	8.04e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs17401966	0.838	rs4846212	chr1:10370312	T/C	cg03954927	chr1:10346856	KIF1B	0.44	13.7	0.48	1.18e-37	Hepatocellular carcinoma;
BRCA	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06002616	chr8:101225028	SPAG1	-0.34	-8.34	-0.31	4.47e-16	Atrioventricular conduction;
BRCA	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg25703541	chr22:24373054	LOC391322	0.63	13.56	0.47	5.17e-37	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10754283	0.934	rs7529653	chr1:90111851	G/A	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.31e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-12.21	-0.43	5.68e-31	Gut microbiome composition (summer);
BRCA	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg20848291	chr7:100343083	ZAN	0.37	8.26	0.31	8.4e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs4660306	0.961	rs7539253	chr1:45947420	C/T	cg24296786	chr1:45957014	TESK2	0.42	8.39	0.32	3.08e-16	Homocysteine levels;
BRCA	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.95	0.33	3.68e-18	Motion sickness;
BRCA	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg26384229	chr12:38710491	ALG10B	0.69	14.65	0.5	4.31e-42	Morning vs. evening chronotype;
BRCA	cis	rs7246657	0.551	rs4806414	chr19:37638788	T/C	cg23950597	chr19:37808831	NA	-0.62	-9.48	-0.35	4.75e-20	Coronary artery calcification;
BRCA	cis	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg08807101	chr21:30365312	RNF160	-0.47	-7.97	-0.3	7.37e-15	Cognitive test performance;
BRCA	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg11764359	chr7:65958608	NA	-0.74	-16.15	-0.54	1.86e-49	Aortic root size;
BRCA	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg12310025	chr6:25882481	NA	0.5	12.07	0.43	2.41e-30	Blood metabolite levels;
BRCA	cis	rs17685	0.753	rs8200	chr7:75696606	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.4	9.09	0.34	1.2e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg03188948	chr7:1209495	NA	0.68	11.33	0.41	2.99e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2625529	0.730	rs4777485	chr15:72389384	G/C	cg16672083	chr15:72433130	SENP8	-0.76	-17.12	-0.56	2.41e-54	Red blood cell count;
BRCA	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.21	-0.31	1.19e-15	Total body bone mineral density;
BRCA	cis	rs9467773	0.595	rs4320356	chr6:26423560	C/T	cg09904177	chr6:26538194	HMGN4	-0.37	-9.77	-0.36	4.15e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg16606324	chr3:10149918	C3orf24	0.57	11.38	0.41	1.87e-27	Alzheimer's disease;
BRCA	cis	rs7149337	1.000	rs8006432	chr14:51731306	A/T	cg23942311	chr14:51606299	NA	0.37	10.05	0.37	3.8e-22	Cancer;
BRCA	trans	rs208520	0.690	rs207091	chr6:66799847	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-21.01	-0.64	6.5e-75	Exhaled nitric oxide output;
BRCA	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg12927641	chr6:109611667	NA	-0.43	-10.98	-0.4	7.9e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg05084668	chr3:125655381	ALG1L	-0.47	-8.14	-0.31	2.08e-15	Blood pressure (smoking interaction);
BRCA	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.59	-14.03	-0.49	3.61e-39	Longevity;Endometriosis;
BRCA	cis	rs2652834	0.808	rs28583444	chr15:63357852	T/G	cg05507819	chr15:63340323	TPM1	0.53	9.18	0.34	6.07e-19	HDL cholesterol;
BRCA	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg03433033	chr1:76189801	ACADM	0.39	7.91	0.3	1.11e-14	Daytime sleep phenotypes;
BRCA	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg24562669	chr7:97807699	LMTK2	0.44	11.78	0.42	4.07e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.42	0.47	2.35e-36	Colorectal cancer;
BRCA	cis	rs1035144	0.524	rs8009260	chr14:81408591	G/T	cg06600135	chr14:81408086	NA	0.44	10.61	0.39	2.54e-24	Male sexual orientation;
BRCA	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.62	-16.59	-0.55	1.17e-51	Colorectal cancer;
BRCA	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg04727924	chr7:799746	HEATR2	-0.55	-10.85	-0.39	2.85e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg02297831	chr4:17616191	MED28	0.36	8.46	0.32	1.88e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg25214090	chr10:38739885	LOC399744	0.46	10.11	0.37	2.25e-22	Corneal astigmatism;
BRCA	cis	rs7927771	0.524	rs7942074	chr11:47720509	T/C	cg20307385	chr11:47447363	PSMC3	0.42	9.46	0.35	5.7e-20	Subjective well-being;
BRCA	cis	rs4766646	0.640	rs4766640	chr12:110300147	C/T	cg01252219	chr12:110302105	GLTP	-0.38	-8.11	-0.31	2.52e-15	Metabolite levels (MHPG);
BRCA	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg23029597	chr12:123009494	RSRC2	-0.59	-11.54	-0.42	4.27e-28	Body mass index;
BRCA	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg23018236	chr17:30244563	NA	-0.63	-10.24	-0.38	6.8e-23	Hip circumference adjusted for BMI;
BRCA	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.07e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.53	-0.35	3.1e-20	Total body bone mineral density;
BRCA	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg15704280	chr7:45808275	SEPT13	-0.42	-8.28	-0.31	7.29e-16	Height;
BRCA	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.35	8.2	0.31	1.33e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg22974920	chr21:40686053	BRWD1	-0.4	-8.97	-0.33	3.14e-18	Cognitive function;
BRCA	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg06108461	chr20:60628389	TAF4	-0.97	-21.26	-0.64	2.94e-76	Body mass index;
BRCA	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	15.48	0.52	3.92e-46	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs965469	0.779	rs6139048	chr20:3239753	T/G	cg25506879	chr20:3388711	C20orf194	-0.44	-8.7	-0.33	2.78e-17	IFN-related cytopenia;
BRCA	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.69	-15.4	-0.52	1.02e-45	Breast cancer;
BRCA	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.38	0.49	8.4e-41	Colorectal cancer;
BRCA	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg02951883	chr7:2050386	MAD1L1	-0.55	-12.43	-0.44	6.65e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg06212747	chr3:49208901	KLHDC8B	0.49	10.29	0.38	4.3e-23	Parkinson's disease;
BRCA	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg24848339	chr3:12840334	CAND2	0.45	12.15	0.43	1.03e-30	QRS complex (12-leadsum);
BRCA	trans	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.44	-10.52	-0.38	5.44e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11764359	chr7:65958608	NA	-0.75	-16.8	-0.55	9.56e-53	Aortic root size;
BRCA	cis	rs911119	1.000	rs6114209	chr20:23622266	G/C	cg16589663	chr20:23618590	CST3	0.46	8.52	0.32	1.14e-16	Chronic kidney disease;
BRCA	trans	rs17685	0.753	rs10476	chr7:75696420	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.84	-27.5	-0.74	1.99e-110	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg20503657	chr10:835505	NA	1.03	15.66	0.53	4.91e-47	Eosinophil percentage of granulocytes;
BRCA	cis	rs1832871	0.672	rs6933928	chr6:158747071	C/T	cg07165851	chr6:158734300	TULP4	0.63	12.61	0.45	9.79e-33	Height;
BRCA	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.57	-15.03	-0.51	6.02e-44	Electrocardiographic conduction measures;
BRCA	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg15448220	chr1:150897856	SETDB1	0.35	7.99	0.3	6.16e-15	Melanoma;
BRCA	cis	rs6987853	0.787	rs2923442	chr8:42435493	T/C	cg09913449	chr8:42400586	C8orf40	0.42	9.29	0.35	2.33e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg20891283	chr12:69753455	YEATS4	0.48	11.16	0.4	1.45e-26	Response to diuretic therapy;
BRCA	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.56	-0.45	1.64e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs250677	0.522	rs6580589	chr5:148360335	C/G	cg12140854	chr5:148520817	ABLIM3	0.41	8.32	0.31	5.16e-16	Breast cancer;
BRCA	cis	rs2066819	1.000	rs59811639	chr12:56695954	C/T	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg19717773	chr7:2847554	GNA12	-0.43	-9.64	-0.36	1.28e-20	Height;
BRCA	trans	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg06521331	chr12:34319734	NA	-0.49	-9.15	-0.34	7.35e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg03354898	chr7:1950403	MAD1L1	-0.44	-9.24	-0.34	3.74e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg20607798	chr8:58055168	NA	0.47	8.02	0.3	5.03e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	trans	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg17830980	chr10:43048298	ZNF37B	-0.39	-7.86	-0.3	1.68e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg01528321	chr10:82214614	TSPAN14	1.04	20.09	0.62	5.78e-70	Post bronchodilator FEV1;
BRCA	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.02	15.15	0.51	1.65e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg27433088	chr4:174089019	GALNT7	0.34	9.24	0.34	3.48e-19	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-13.14	-0.46	4.35e-35	Chronic sinus infection;
BRCA	cis	rs4713675	0.565	rs4713659	chr6:33667839	A/G	cg14003231	chr6:33640908	ITPR3	0.35	8.92	0.33	5.01e-18	Plateletcrit;
BRCA	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.58	13.44	0.47	1.88e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6543140	0.964	rs10196334	chr2:103090041	T/C	cg04239558	chr2:103089729	SLC9A4	0.36	9.99	0.37	6.11e-22	Blood protein levels;
BRCA	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg03929089	chr4:120376271	NA	-0.44	-8.25	-0.31	9.12e-16	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6120849	0.707	rs6088690	chr20:33633326	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	10.31	0.38	3.78e-23	Protein C levels;
BRCA	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg18129178	chr5:148520854	ABLIM3	0.61	12.5	0.44	3.15e-32	Breast cancer;
BRCA	cis	rs55883249	1.000	rs11692112	chr2:9723732	G/T	cg23886495	chr2:9695866	ADAM17	0.55	7.93	0.3	9.48e-15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
BRCA	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg12927641	chr6:109611667	NA	-0.42	-10.85	-0.39	2.81e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg25457927	chr22:38595422	NA	-0.31	-11.75	-0.42	5.33e-29	Cutaneous nevi;
BRCA	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg08917208	chr2:24149416	ATAD2B	1.12	15.97	0.53	1.45e-48	Lymphocyte counts;
BRCA	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.4	-0.44	8.19e-32	Bipolar disorder;
BRCA	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg04842962	chr6:43655489	MRPS18A	1.12	38.33	0.83	8.9e-168	IgG glycosylation;
BRCA	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg03146154	chr1:46216737	IPP	0.45	10.11	0.37	2.13e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg24596788	chr1:163392923	NA	0.37	10.31	0.38	3.85e-23	Motion sickness;
BRCA	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg09307838	chr4:120376055	NA	0.74	16.02	0.54	8.64e-49	Corneal astigmatism;
BRCA	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.44	-8.25	-0.31	8.95e-16	Renal function-related traits (BUN);
BRCA	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg23422044	chr7:1970798	MAD1L1	-0.44	-9.47	-0.35	5.33e-20	Neuroticism;
BRCA	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg11663144	chr21:46675770	NA	-0.47	-10.97	-0.4	9.13e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7737355	0.898	rs32109	chr5:131041590	C/T	cg06307176	chr5:131281290	NA	0.53	10.73	0.39	8.26e-25	Life satisfaction;
BRCA	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	14.09	0.49	1.88e-39	Lymphocyte percentage of white cells;
BRCA	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg23649088	chr2:200775458	C2orf69	0.61	10.58	0.39	3.19e-24	Schizophrenia;
BRCA	trans	rs4650994	0.525	rs4650991	chr1:178511165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.56	-12.76	-0.45	2.19e-33	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg12179176	chr11:130786555	SNX19	-0.55	-12.2	-0.43	6.6e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	27.67	0.74	2.28e-111	Chronic sinus infection;
BRCA	trans	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.43	0.38	1.21e-23	Mean corpuscular volume;
BRCA	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg18357645	chr12:58087776	OS9	-0.33	-7.99	-0.3	6.21e-15	Multiple sclerosis;
BRCA	cis	rs3099143	1.000	rs4583202	chr15:77161676	G/A	cg21673338	chr15:77095150	SCAPER	0.52	9.19	0.34	5.25e-19	Recalcitrant atopic dermatitis;
BRCA	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg12310025	chr6:25882481	NA	-0.5	-11.96	-0.43	7.16e-30	Blood metabolite levels;
BRCA	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.44	-8.89	-0.33	6.28e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs7172677	0.737	rs12910348	chr15:75437642	A/G	cg10253484	chr15:75165896	SCAMP2	-0.45	-8.35	-0.31	4.37e-16	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg15704280	chr7:45808275	SEPT13	0.53	8.97	0.33	3.33e-18	Axial length;
BRCA	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.59e-23	Motion sickness;
BRCA	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg06115741	chr20:33292138	TP53INP2	-0.38	-8.38	-0.31	3.25e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg24675658	chr1:53192096	ZYG11B	0.63	15.2	0.52	8.74e-45	Monocyte count;
BRCA	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg06784218	chr1:46089804	CCDC17	-0.51	-12.49	-0.44	3.62e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg05665937	chr4:1216051	CTBP1	0.49	9.88	0.36	1.66e-21	Obesity-related traits;
BRCA	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg27170947	chr2:26402098	FAM59B	-0.8	-13.0	-0.46	1.96e-34	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18876405	chr7:65276391	NA	0.52	11.65	0.42	1.43e-28	Aortic root size;
BRCA	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg17724175	chr1:150552817	MCL1	0.26	8.71	0.33	2.69e-17	Tonsillectomy;
BRCA	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg05623727	chr3:50126028	RBM5	0.51	12.48	0.44	3.7e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg27446573	chr6:127587934	RNF146	0.86	19.7	0.61	7.62e-68	Breast cancer;
BRCA	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.31	-0.35	2.07e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg26384229	chr12:38710491	ALG10B	0.69	16.25	0.54	6.19e-50	Bladder cancer;
BRCA	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.57	-0.47	4.99e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg14664628	chr15:75095509	CSK	0.35	7.83	0.3	2.02e-14	Systemic lupus erythematosus;
BRCA	cis	rs7246657	0.722	rs2972438	chr19:38210847	A/G	cg18154014	chr19:37997991	ZNF793	0.47	8.83	0.33	1.02e-17	Coronary artery calcification;
BRCA	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02018176	chr4:1364513	KIAA1530	0.4	8.31	0.31	5.76e-16	Longevity;
BRCA	cis	rs7512552	0.839	rs2867894	chr1:150452912	T/A	cg15654264	chr1:150340011	RPRD2	0.37	8.12	0.31	2.34e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs8038465	0.638	rs8036954	chr15:73974282	T/C	cg15420318	chr15:73925796	NPTN	0.42	9.33	0.35	1.68e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg20203395	chr5:56204925	C5orf35	-0.5	-10.17	-0.37	1.31e-22	Initial pursuit acceleration;
BRCA	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg18758796	chr5:131593413	PDLIM4	0.33	8.73	0.33	2.19e-17	Breast cancer;
BRCA	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg24675658	chr1:53192096	ZYG11B	0.68	14.68	0.5	2.81e-42	Monocyte count;
BRCA	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg12311346	chr5:56204834	C5orf35	0.62	13.01	0.46	1.64e-34	Initial pursuit acceleration;
BRCA	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg11843238	chr5:131593191	PDLIM4	0.36	7.96	0.3	7.92e-15	Breast cancer;
BRCA	cis	rs3772130	0.962	rs9826473	chr3:121556219	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.81	0.39	4.06e-25	Cognitive performance;
BRCA	cis	rs9443189	0.570	rs661229	chr6:76293793	G/A	cg01950844	chr6:76311363	SENP6	0.85	14.09	0.49	1.84e-39	Prostate cancer;
BRCA	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.36	8.33	0.31	5.09e-16	Coronary artery disease;
BRCA	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05890377	chr2:74357713	NA	0.36	8.09	0.3	3e-15	Gestational age at birth (maternal effect);
BRCA	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg14196790	chr5:131705035	SLC22A5	0.31	8.03	0.3	4.82e-15	Blood metabolite levels;
BRCA	cis	rs3820928	0.874	rs13393894	chr2:227880543	A/G	cg11843606	chr2:227700838	RHBDD1	-0.36	-8.03	-0.3	4.57e-15	Pulmonary function;
BRCA	cis	rs1577917	0.883	rs13212415	chr6:86608083	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.34	-8.97	-0.33	3.31e-18	Response to antipsychotic treatment;
BRCA	cis	rs10824037	0.673	rs11000789	chr10:75595226	T/G	cg07699608	chr10:75541558	CHCHD1	0.5	8.04	0.3	4.39e-15	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs4862307	0.808	rs7666346	chr4:185000657	G/A	cg06737308	chr4:185021514	ENPP6	-0.38	-8.23	-0.31	1.04e-15	Serum dimethylarginine levels (asymmetric/symetric ratio);
BRCA	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg16339924	chr4:17578868	LAP3	0.76	18.09	0.58	2.25e-59	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-9.32	-0.35	1.89e-19	Retinal vascular caliber;
BRCA	cis	rs2249625	0.874	rs2463697	chr6:72838760	A/G	cg18830697	chr6:72922368	RIMS1	-0.37	-7.88	-0.3	1.41e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-17.04	-0.56	5.76e-54	Chronic sinus infection;
BRCA	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg06623918	chr6:96969491	KIAA0776	0.74	12.19	0.43	6.85e-31	Migraine;Coronary artery disease;
BRCA	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg18357645	chr12:58087776	OS9	0.48	13.69	0.48	1.4e-37	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7646881	0.812	rs61387735	chr3:158456161	G/A	cg19483011	chr3:158453295	NA	-0.47	-8.3	-0.31	6.28e-16	Tetralogy of Fallot;
BRCA	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg01262667	chr19:19385393	TM6SF2	0.41	10.55	0.39	4.18e-24	Tonsillectomy;
BRCA	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-9.54	-0.35	3.04e-20	Alzheimer's disease (late onset);
BRCA	trans	rs11088226	0.681	rs2833899	chr21:33933263	T/C	cg09050820	chr6:167586206	TCP10L2	0.77	13.25	0.46	1.4e-35	Gastritis;
BRCA	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.6	-14.24	-0.49	3.86e-40	Longevity;Endometriosis;
BRCA	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.5	11.17	0.4	1.41e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7589728	0.858	rs1914734	chr2:88529509	T/C	cg04511125	chr2:88470314	THNSL2	0.58	9.38	0.35	1.15e-19	Plasma clusterin levels;
BRCA	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.73e-18	Motion sickness;
BRCA	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg15017067	chr4:17643749	FAM184B	0.28	8.28	0.31	7.23e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	14.13	0.49	1.18e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	11.41	0.41	1.4e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs727479	0.502	rs2289106	chr15:51507782	T/G	cg19946085	chr15:51559439	CYP19A1	-0.3	-8.38	-0.31	3.38e-16	Estradiol levels;
BRCA	cis	rs6580649	0.941	rs1793931	chr12:48396505	G/T	cg05342945	chr12:48394962	COL2A1	-0.49	-9.84	-0.36	2.38e-21	Lung cancer;
BRCA	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2304069	0.909	rs2544931	chr5:149367837	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.85	-16.22	-0.54	8.79e-50	HIV-1 control;
BRCA	trans	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	18.49	0.59	1.81e-61	Alzheimer's disease;
BRCA	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.17	-0.34	6.4e-19	Menopause (age at onset);
BRCA	cis	rs13102973	0.965	rs28799927	chr4:135867094	A/G	cg14419869	chr4:135874104	NA	-0.59	-12.99	-0.46	2.06e-34	Subjective well-being;
BRCA	cis	rs12973672	1.000	rs10410675	chr19:35768828	T/C	cg12095397	chr19:35769544	USF2	0.37	8.31	0.31	5.95e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	trans	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.52	-0.35	3.46e-20	Morning vs. evening chronotype;
BRCA	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg11266682	chr4:10021025	SLC2A9	0.37	9.97	0.37	7.71e-22	Bone mineral density;
BRCA	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.61	0.39	2.55e-24	Tonsillectomy;
BRCA	cis	rs77861329	1.000	rs352148	chr3:52208898	A/G	cg08692210	chr3:52188851	WDR51A	0.75	11.38	0.41	1.95e-27	Macrophage inflammatory protein 1b levels;
BRCA	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg11645453	chr3:52864694	ITIH4	0.48	11.71	0.42	8.24e-29	Schizophrenia;
BRCA	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.55	11.12	0.4	2.14e-26	Tonsillectomy;
BRCA	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg10578991	chr7:12443926	VWDE	-0.5	-8.61	-0.32	5.55e-17	Coronary artery disease;
BRCA	cis	rs17767294	0.708	rs34957169	chr6:27879397	T/C	cg08851530	chr6:28072375	NA	0.92	8.91	0.33	5.15e-18	Parkinson's disease;
BRCA	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.6	-14.3	-0.49	1.91e-40	Hemoglobin concentration;
BRCA	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg18225595	chr11:63971243	STIP1	0.5	8.9	0.33	5.64e-18	Mean platelet volume;
BRCA	cis	rs2336384	1.000	rs4846085	chr1:12050634	T/C	cg13216073	chr1:12042593	MFN2	0.44	9.66	0.36	1.11e-20	Platelet count;
BRCA	cis	rs2637266	1.000	rs6480824	chr10:78355705	G/A	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg24296786	chr1:45957014	TESK2	0.43	8.66	0.32	3.96e-17	Homocysteine levels;
BRCA	cis	rs68170813	0.559	rs74584447	chr7:106944755	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.64	-0.32	4.46e-17	Coronary artery disease;
BRCA	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg16576597	chr16:28551801	NUPR1	0.3	8.42	0.32	2.52e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-10.74	-0.39	7.54e-25	Mood instability;
BRCA	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.17	0.31	1.67e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg25036284	chr2:26402008	FAM59B	-0.64	-10.59	-0.39	3.03e-24	Gut microbiome composition (summer);
BRCA	cis	rs4662945	0.603	rs2406981	chr2:130305487	A/G	cg05903289	chr2:130345205	NA	-0.34	-8.48	-0.32	1.59e-16	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.81	0.39	3.95e-25	Bipolar disorder;
BRCA	trans	rs1997103	1.000	rs6957984	chr7:55397331	G/A	cg20935933	chr6:143382018	AIG1	0.6	11.52	0.41	4.77e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.56	-0.61	4.23e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg21280719	chr6:42927975	GNMT	0.33	13.9	0.48	1.46e-38	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg26384229	chr12:38710491	ALG10B	-0.44	-10.37	-0.38	2.23e-23	Morning vs. evening chronotype;
BRCA	trans	rs3857536	0.741	rs2097679	chr6:66937994	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg03146154	chr1:46216737	IPP	-0.47	-10.29	-0.38	4.34e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6429082	0.818	rs61836206	chr1:235638754	C/G	cg26050004	chr1:235667680	B3GALNT2	0.57	13.44	0.47	1.95e-36	Adiposity;
BRCA	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.0	0.48	4.84e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.45	-8.41	-0.32	2.7e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs9837602	0.748	rs9289985	chr3:99878116	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.53	-8.78	-0.33	1.53e-17	Breast cancer;
BRCA	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg20848291	chr7:100343083	ZAN	-0.58	-12.53	-0.44	2.2e-32	Other erythrocyte phenotypes;
BRCA	cis	rs312273	0.967	rs1442187	chr12:41251039	C/T	cg17827154	chr12:41323612	CNTN1	-0.42	-10.07	-0.37	2.96e-22	Bipolar disorder;
BRCA	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg11833968	chr6:79620685	NA	-0.4	-8.9	-0.33	5.7e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg09904177	chr6:26538194	HMGN4	-0.48	-14.97	-0.51	1.23e-43	Intelligence (multi-trait analysis);
BRCA	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg23887609	chr12:130822674	PIWIL1	0.43	9.33	0.35	1.71e-19	Menopause (age at onset);
BRCA	cis	rs7395581	1.000	rs830085	chr11:47251199	G/A	cg25783544	chr11:47291846	MADD	-0.44	-9.7	-0.36	7.65e-21	HDL cholesterol;
BRCA	cis	rs9311474	1.000	rs9311474	chr3:52338852	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.26	7.87	0.3	1.56e-14	Electroencephalogram traits;
BRCA	cis	rs870825	0.616	rs2003994	chr4:185636568	G/T	cg04058563	chr4:185651563	MLF1IP	0.77	17.32	0.57	2.07e-55	Blood protein levels;
BRCA	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg25427524	chr10:38739819	LOC399744	0.53	9.63	0.36	1.35e-20	Obesity (extreme);
BRCA	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg00012203	chr2:219082015	ARPC2	-0.48	-9.18	-0.34	5.88e-19	Colorectal cancer;
BRCA	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14240646	chr10:27532245	ACBD5	-0.65	-10.06	-0.37	3.25e-22	Breast cancer;
BRCA	cis	rs4363385	0.818	rs377768	chr1:153016594	T/C	cg24667326	chr1:152973720	SPRR3	-0.32	-8.83	-0.33	1.04e-17	Inflammatory skin disease;
BRCA	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg03342759	chr3:160939853	NMD3	-0.65	-14.14	-0.49	1.05e-39	Morning vs. evening chronotype;
BRCA	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg10932868	chr11:921992	NA	0.49	12.21	0.43	5.68e-31	Alzheimer's disease (late onset);
BRCA	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg12311346	chr5:56204834	C5orf35	-0.65	-12.42	-0.44	7.21e-32	Initial pursuit acceleration;
BRCA	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg03146154	chr1:46216737	IPP	0.53	11.54	0.42	4.24e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg11812906	chr14:75593930	NEK9	-0.6	-13.69	-0.48	1.29e-37	Height;
BRCA	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11644478	chr21:40555479	PSMG1	-0.54	-11.6	-0.42	2.34e-28	Menarche (age at onset);
BRCA	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.46	9.25	0.34	3.33e-19	Tonsillectomy;
BRCA	cis	rs4588572	0.606	rs6859161	chr5:77742776	A/G	cg11547950	chr5:77652471	NA	-0.45	-8.58	-0.32	7.33e-17	Triglycerides;
BRCA	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg13866156	chr1:1669148	SLC35E2	-0.46	-10.18	-0.37	1.18e-22	Body mass index;
BRCA	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg07169764	chr2:136633963	MCM6	1.03	21.82	0.65	2.53e-79	Corneal structure;
BRCA	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg00484396	chr16:3507460	NAT15	0.44	9.29	0.34	2.43e-19	Tuberculosis;
BRCA	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg25036284	chr2:26402008	FAM59B	-0.64	-11.03	-0.4	5.3e-26	Gut microbiome composition (summer);
BRCA	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg03146154	chr1:46216737	IPP	0.51	11.32	0.41	3.23e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.89	0.3	1.35e-14	Endometrial cancer;
BRCA	cis	rs7092929	0.883	rs611890	chr10:3585733	T/C	cg14308648	chr10:3568949	NA	0.45	8.15	0.31	1.98e-15	Coronary artery calcification;
BRCA	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg08888203	chr3:10149979	C3orf24	0.64	13.06	0.46	9.81e-35	Alzheimer's disease;
BRCA	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg04025307	chr7:1156635	C7orf50	0.59	9.36	0.35	1.33e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg12016809	chr21:47604291	C21orf56	0.38	7.92	0.3	1.09e-14	Testicular germ cell tumor;
BRCA	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-10.45	-0.38	1.03e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg07148914	chr20:33460835	GGT7	-0.42	-9.11	-0.34	1.09e-18	Height;
BRCA	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg14847009	chr1:175162515	KIAA0040	-0.25	-9.25	-0.34	3.33e-19	Alcohol dependence;
BRCA	cis	rs10493773	0.502	rs12061951	chr1:86081453	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.42	-8.63	-0.32	4.92e-17	Urate levels in overweight individuals;
BRCA	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg27286337	chr10:134555280	INPP5A	0.47	8.95	0.33	3.81e-18	Gait speed in old age;
BRCA	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-7.88	-0.3	1.4e-14	Colorectal cancer;
BRCA	cis	rs7408868	0.764	rs12610803	chr19:15260682	A/C	cg14696996	chr19:15285081	NOTCH3	0.96	14.34	0.49	1.17e-40	Pulse pressure;
BRCA	cis	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg17507749	chr15:85114479	UBE2QP1	0.49	7.99	0.3	6.34e-15	Schizophrenia;
BRCA	cis	rs1011018	0.628	rs4074826	chr7:139415943	G/A	cg03224163	chr7:139420300	HIPK2	-0.54	-8.84	-0.33	9.06e-18	Systolic blood pressure;
BRCA	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg17063962	chr7:91808500	NA	0.55	12.64	0.45	7.77e-33	Breast cancer;
BRCA	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg12386194	chr3:101231763	SENP7	0.39	8.34	0.31	4.56e-16	Colorectal cancer;
BRCA	trans	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg19862616	chr7:65841803	NCRNA00174	0.86	28.57	0.75	2.5e-116	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg19862616	chr7:65841803	NCRNA00174	0.8	25.28	0.71	3.05e-98	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	22.44	0.66	1.16e-82	Chronic sinus infection;
BRCA	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.47	0.32	1.68e-16	Platelet count;
BRCA	cis	rs7737355	1.000	rs6876350	chr5:130604109	G/T	cg06307176	chr5:131281290	NA	0.47	9.22	0.34	4.3e-19	Life satisfaction;
BRCA	cis	rs73086581	1.000	rs6107386	chr20:3972756	A/C	cg02187196	chr20:3869020	PANK2	0.51	8.89	0.33	6.09e-18	Response to antidepressants in depression;
BRCA	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.48	-9.68	-0.36	9.26e-21	Tonsillectomy;
BRCA	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-8.59	-0.32	6.42e-17	Schizophrenia;
BRCA	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg12011299	chr4:100065546	ADH4	0.43	11.39	0.41	1.66e-27	Alcohol dependence;
BRCA	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11644478	chr21:40555479	PSMG1	-0.7	-15.8	-0.53	1.01e-47	Cognitive function;
BRCA	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg22117172	chr7:91764530	CYP51A1	0.23	7.9	0.3	1.19e-14	Breast cancer;
BRCA	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg17971929	chr21:40555470	PSMG1	-0.6	-13.35	-0.47	4.68e-36	Cognitive function;
BRCA	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24531977	chr5:56204891	C5orf35	-0.88	-19.08	-0.6	1.37e-64	Initial pursuit acceleration;
BRCA	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg13010199	chr12:38710504	ALG10B	0.48	9.72	0.36	6.47e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg11366901	chr6:160182831	ACAT2	-0.78	-15.29	-0.52	3.18e-45	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7903847	0.642	rs12258560	chr10:99137048	T/C	cg20016023	chr10:99160130	RRP12	-0.27	-8.64	-0.32	4.43e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18876405	chr7:65276391	NA	-0.5	-10.98	-0.4	8.51e-26	Aortic root size;
BRCA	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg27535305	chr1:53392650	SCP2	-0.46	-11.38	-0.41	1.82e-27	Monocyte count;
BRCA	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.72	0.36	6.67e-21	Bipolar disorder;
BRCA	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.5	0.57	2.46e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg23711669	chr6:146136114	FBXO30	0.71	17.09	0.56	3.21e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3916	0.794	rs10431386	chr12:121128926	A/G	cg21892295	chr12:121157589	UNC119B	0.33	9.32	0.35	1.86e-19	Urinary metabolites (H-NMR features);
BRCA	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg16586182	chr3:47516702	SCAP	-0.56	-12.92	-0.46	4.48e-34	Colorectal cancer;
BRCA	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg03354898	chr7:1950403	MAD1L1	-0.48	-9.96	-0.37	8.31e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg19077165	chr18:44547161	KATNAL2	-0.59	-13.09	-0.46	7.67e-35	Personality dimensions;
BRCA	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg23788917	chr6:8435910	SLC35B3	0.47	10.24	0.38	6.7e-23	Motion sickness;
BRCA	cis	rs78707713	0.560	rs2394563	chr10:71238618	G/A	cg12610070	chr10:71211762	TSPAN15	-0.33	-10.03	-0.37	4.25e-22	Venous thromboembolism;
BRCA	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.37	-8.35	-0.31	4.35e-16	Axial length;
BRCA	cis	rs4074536	0.622	rs10923440	chr1:116317441	G/A	cg21648376	chr1:116311395	CASQ2	-0.56	-9.29	-0.34	2.48e-19	QRS duration;
BRCA	cis	rs708547	0.533	rs3806746	chr4:57773330	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.34	-8.46	-0.32	1.89e-16	Response to bleomycin (chromatid breaks);
BRCA	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg23950597	chr19:37808831	NA	-0.72	-12.51	-0.44	2.9e-32	Coronary artery calcification;
BRCA	cis	rs61990749	0.597	rs176980	chr14:78198449	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	-0.43	-7.82	-0.3	2.18e-14	Fibroblast growth factor basic levels;
BRCA	trans	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	14.52	0.5	1.73e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06634786	chr22:41940651	POLR3H	0.62	10.52	0.38	5.37e-24	Vitiligo;
BRCA	cis	rs829883	0.867	rs1641640	chr12:98896017	A/G	cg25150519	chr12:98850993	NA	0.59	11.9	0.43	1.19e-29	Colorectal adenoma (advanced);
BRCA	cis	rs698833	0.561	rs698808	chr2:44701901	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	8.6	0.32	5.98e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07256732	chr16:621771	PIGQ	-0.35	-9.38	-0.35	1.1e-19	Height;
BRCA	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg26031613	chr14:104095156	KLC1	-0.42	-8.45	-0.32	1.94e-16	Schizophrenia;
BRCA	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	11.76	0.42	4.77e-29	Schizophrenia;
BRCA	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg20469991	chr17:27169893	C17orf63	-0.45	-8.81	-0.33	1.13e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs67981189	0.574	rs2526848	chr14:71419742	T/C	cg15816911	chr14:71606274	NA	-0.37	-8.36	-0.31	3.98e-16	Schizophrenia;
BRCA	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg18252515	chr7:66147081	NA	-1.06	-15.7	-0.53	3.07e-47	Gout;
BRCA	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg13010199	chr12:38710504	ALG10B	0.42	8.84	0.33	8.99e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4853036	0.629	rs921712	chr2:70017103	G/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.87	-0.3	1.55e-14	Colorectal or endometrial cancer;
BRCA	trans	rs8073060	0.544	rs7210966	chr17:33986334	G/C	cg19694781	chr19:47549865	TMEM160	-1.05	-22.93	-0.67	2.22e-85	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs17253792	0.545	rs35418987	chr14:56017407	T/G	cg01858014	chr14:56050164	KTN1	-0.61	-7.99	-0.3	6.09e-15	Putamen volume;
BRCA	cis	rs2637266	1.000	rs2579746	chr10:78327674	C/T	cg18941641	chr10:78392320	NA	0.35	7.96	0.3	8.01e-15	Pulmonary function;
BRCA	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg08601574	chr20:25228251	PYGB	0.35	8.49	0.32	1.48e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg11814155	chr7:99998594	ZCWPW1	0.58	9.8	0.36	3.16e-21	Platelet count;
BRCA	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg06609049	chr19:2785107	THOP1	0.54	11.37	0.41	2.08e-27	Total cholesterol levels;
BRCA	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg25801113	chr15:45476975	SHF	0.31	8.05	0.3	4.16e-15	Uric acid levels;
BRCA	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg20283391	chr11:68216788	NA	-0.47	-9.15	-0.34	7.86e-19	Total body bone mineral density;
BRCA	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.06	-0.43	2.49e-30	Alzheimer's disease;
BRCA	cis	rs1451375	1.000	rs6949897	chr7:50621920	C/T	cg18232548	chr7:50535776	DDC	0.43	10.13	0.37	1.88e-22	Malaria;
BRCA	trans	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg06521331	chr12:34319734	NA	-0.46	-8.65	-0.32	4.26e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg08601574	chr20:25228251	PYGB	0.35	8.43	0.32	2.33e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg08470875	chr2:26401718	FAM59B	-0.62	-9.25	-0.34	3.21e-19	Gut microbiome composition (summer);
BRCA	cis	rs6028335	0.674	rs59072291	chr20:37622010	T/A	cg16355469	chr20:37678765	NA	0.5	9.03	0.34	1.97e-18	Alcohol and nicotine co-dependence;
BRCA	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg22920501	chr2:26401640	FAM59B	0.65	11.31	0.41	3.62e-27	Gut microbiome composition (summer);
BRCA	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg13010199	chr12:38710504	ALG10B	0.47	9.18	0.34	5.96e-19	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.27	0.34	2.76e-19	Morning vs. evening chronotype;
BRCA	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-13.19	-0.46	2.51e-35	Response to antipsychotic treatment;
BRCA	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg24101359	chr6:42928495	GNMT	0.66	16.61	0.55	8.79e-52	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4233802	1.000	rs6761697	chr2:151141735	A/G	cg25300694	chr2:151184358	NA	0.7	7.9	0.3	1.25e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs7246967	0.673	rs62120313	chr19:22877183	G/C	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg08508325	chr11:3079039	CARS	-0.43	-15.58	-0.52	1.2e-46	Longevity;
BRCA	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg10224037	chr5:178157518	ZNF354A	0.77	16.29	0.54	3.9e-50	Neutrophil percentage of white cells;
BRCA	cis	rs870825	0.655	rs67798981	chr4:185619567	A/T	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg12386194	chr3:101231763	SENP7	0.46	9.88	0.36	1.6e-21	Colorectal cancer;
BRCA	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.71	0.55	2.69e-52	Alzheimer's disease (late onset);
BRCA	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg13880726	chr7:1868755	MAD1L1	0.4	8.11	0.31	2.56e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.32	0.54	2.53e-50	Colorectal cancer;
BRCA	trans	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-9.61	-0.36	1.58e-20	Triglycerides;
BRCA	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.78	13.06	0.46	1.02e-34	Schizophrenia;
BRCA	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg06606381	chr12:133084897	FBRSL1	-0.71	-7.97	-0.3	7.11e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23583168	chr7:148888333	NA	-0.76	-17.59	-0.57	9.07e-57	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg24250549	chr1:154909240	PMVK	0.61	15.35	0.52	1.69e-45	Prostate cancer;
BRCA	cis	rs838147	0.760	rs12979144	chr19:49237547	G/A	cg12258179	chr19:49232187	RASIP1	0.33	8.17	0.31	1.61e-15	Dietary macronutrient intake;
BRCA	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.76	-0.42	4.81e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.78	0.67	1.54e-84	Chronic sinus infection;
BRCA	trans	rs12505749	1.000	rs17756240	chr4:57355192	G/C	cg09583921	chr3:87101925	NA	0.79	9.87	0.36	1.81e-21	Airflow obstruction;
BRCA	cis	rs10267417	0.584	rs10247789	chr7:19863570	G/C	cg05791153	chr7:19748676	TWISTNB	0.49	9.64	0.36	1.24e-20	Night sleep phenotypes;
BRCA	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg16606324	chr3:10149918	C3orf24	0.51	9.86	0.36	1.98e-21	Alzheimer's disease;
BRCA	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg08975724	chr8:8085496	FLJ10661	0.4	8.1	0.31	2.83e-15	Neuroticism;
BRCA	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg04362960	chr10:104952993	NT5C2	0.42	10.02	0.37	4.63e-22	Arsenic metabolism;
BRCA	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg13628971	chr7:2884303	GNA12	0.57	12.03	0.43	3.47e-30	Height;
BRCA	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg06713675	chr4:122721982	EXOSC9	-0.35	-8.08	-0.3	3.18e-15	Type 2 diabetes;
BRCA	cis	rs7927771	0.524	rs10838758	chr11:47771476	T/C	cg20307385	chr11:47447363	PSMC3	0.42	9.56	0.35	2.48e-20	Subjective well-being;
BRCA	cis	rs9788682	0.747	rs28511883	chr15:78783683	C/T	cg24631222	chr15:78858424	CHRNA5	0.46	9.06	0.34	1.6e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs12348691	0.503	rs1348386	chr9:100612807	A/G	cg13688889	chr9:100608707	NA	-0.48	-9.98	-0.37	6.71e-22	Alopecia areata;
BRCA	trans	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg11693508	chr17:37793320	STARD3	0.59	11.02	0.4	5.72e-26	Bipolar disorder;
BRCA	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg22800045	chr5:56110881	MAP3K1	0.65	12.34	0.44	1.62e-31	Initial pursuit acceleration;
BRCA	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.74	0.36	5.54e-21	Menopause (age at onset);
BRCA	cis	rs7408868	0.908	rs10418660	chr19:15278635	A/G	cg14696996	chr19:15285081	NOTCH3	1.0	14.52	0.5	1.76e-41	Pulse pressure;
BRCA	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-28.45	-0.75	1.19e-115	Schizophrenia;
BRCA	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg16339924	chr4:17578868	LAP3	0.66	16.94	0.56	1.87e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.46	0.32	1.81e-16	Menopause (age at onset);
BRCA	trans	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg26384229	chr12:38710491	ALG10B	0.48	10.14	0.37	1.68e-22	Resting heart rate;
BRCA	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg20387954	chr3:183756860	HTR3D	0.39	8.82	0.33	1.08e-17	Anterior chamber depth;
BRCA	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	23.5	0.68	1.78e-88	Platelet count;
BRCA	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	trans	rs931812	0.757	rs34988706	chr8:101907062	C/T	cg20993868	chr7:22813445	NA	0.45	13.42	0.47	2.29e-36	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00166722	chr3:10149974	C3orf24	0.65	12.93	0.46	3.7e-34	Alzheimer's disease;
BRCA	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg11833968	chr6:79620685	NA	-0.41	-9.44	-0.35	6.69e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7172677	0.501	rs56266638	chr15:75393205	T/A	cg14664628	chr15:75095509	CSK	0.39	9.1	0.34	1.1e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.35	-9.78	-0.36	3.81e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24531977	chr5:56204891	C5orf35	-0.88	-18.14	-0.58	1.24e-59	Initial pursuit acceleration;
BRCA	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg20203395	chr5:56204925	C5orf35	-0.47	-8.05	-0.3	3.95e-15	Type 2 diabetes;
BRCA	cis	rs35995292	0.500	rs6955677	chr7:38933942	C/T	cg19327137	chr7:38886074	VPS41	0.38	12.67	0.45	5.76e-33	Subjective well-being (multi-trait analysis);
BRCA	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.34	9.44	0.35	6.71e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg04034577	chr2:241836375	C2orf54	0.56	13.67	0.48	1.6e-37	Urinary metabolites;
BRCA	cis	rs6545883	0.929	rs2600663	chr2:61540687	A/G	cg15711740	chr2:61764176	XPO1	0.52	13.27	0.46	1.12e-35	Tuberculosis;
BRCA	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg21770322	chr7:97807741	LMTK2	0.45	11.7	0.42	8.56e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4363385	0.720	rs6704498	chr1:152964740	C/A	cg25856811	chr1:152973957	SPRR3	-0.34	-9.3	-0.35	2.12e-19	Inflammatory skin disease;
BRCA	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	20.1	0.62	5.33e-70	Smoking behavior;
BRCA	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg01324343	chr3:183735012	ABCC5	0.83	20.88	0.64	3.3e-74	Anterior chamber depth;
BRCA	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10802521	chr3:52805072	NEK4	-0.33	-8.48	-0.32	1.61e-16	Bipolar disorder;
BRCA	cis	rs7818345	0.967	rs4546679	chr8:19283335	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.22	0.31	1.12e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.97	-0.3	7.47e-15	Prostate cancer;
BRCA	cis	rs7707921	0.767	rs6880209	chr5:81574182	C/T	cg15871215	chr5:81402204	ATG10	-0.36	-8.35	-0.31	4.26e-16	Breast cancer;
BRCA	cis	rs6910061	1.000	rs6938870	chr6:11095317	A/G	cg27233058	chr6:11094804	LOC221710	0.52	9.31	0.35	1.94e-19	Diabetic kidney disease;
BRCA	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18876405	chr7:65276391	NA	0.55	13.33	0.47	6.05e-36	Aortic root size;
BRCA	cis	rs2668423	0.501	rs502121	chr19:1387299	T/C	cg02639931	chr19:1387894	NDUFS7	-0.85	-21.92	-0.66	7.3e-80	Nonalcoholic fatty liver disease;
BRCA	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg13010199	chr12:38710504	ALG10B	0.51	9.99	0.37	6.28e-22	Morning vs. evening chronotype;
BRCA	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-11.38	-0.41	1.91e-27	Gut microbiome composition (summer);
BRCA	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg22974920	chr21:40686053	BRWD1	-0.38	-8.76	-0.33	1.71e-17	Cognitive function;
BRCA	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg06238570	chr21:40685208	BRWD1	-0.43	-8.41	-0.32	2.65e-16	Cognitive function;
BRCA	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03264133	chr6:25882463	NA	-0.74	-17.17	-0.56	1.24e-54	Blood metabolite levels;
BRCA	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-13.33	-0.47	6.12e-36	Response to antipsychotic treatment;
BRCA	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.09	-0.3	2.98e-15	Total body bone mineral density;
BRCA	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg23719950	chr11:63933701	MACROD1	-0.5	-8.62	-0.32	5.42e-17	Mean platelet volume;
BRCA	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg26384229	chr12:38710491	ALG10B	-0.39	-9.15	-0.34	7.29e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg09184832	chr6:79620586	NA	-0.44	-8.66	-0.32	3.93e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs3857067	0.806	rs4560373	chr4:95113229	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.49	-0.35	4.67e-20	QT interval;
BRCA	cis	rs4631830	0.863	rs2843549	chr10:51521247	C/A	cg20129853	chr10:51489980	NA	-0.28	-7.84	-0.3	1.88e-14	Prostate-specific antigen levels;
BRCA	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg11584989	chr19:19387371	SF4	0.63	13.52	0.47	7.85e-37	Bipolar disorder;
BRCA	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg24324837	chr19:49891574	CCDC155	0.46	8.35	0.31	4.1e-16	Multiple sclerosis;
BRCA	cis	rs870825	0.860	rs11132253	chr4:185595472	C/T	cg04058563	chr4:185651563	MLF1IP	0.66	11.78	0.42	3.82e-29	Blood protein levels;
BRCA	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg25358565	chr5:93447407	FAM172A	1.14	18.39	0.59	6.32e-61	Diabetic retinopathy;
BRCA	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg24829409	chr8:58192753	C8orf71	-0.48	-9.14	-0.34	7.94e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	8.6	0.32	6.24e-17	Platelet count;
BRCA	cis	rs2012796	1.000	rs10450939	chr14:81825202	A/T	cg02996355	chr14:81879375	NA	0.5	9.79	0.36	3.63e-21	Night sleep phenotypes;
BRCA	cis	rs897080	0.515	rs698800	chr2:44690787	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.16	0.34	7.04e-19	Height;
BRCA	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.52	13.6	0.47	3.57e-37	Response to bleomycin (chromatid breaks);
BRCA	trans	rs8073060	0.586	rs225257	chr17:33956625	G/A	cg19694781	chr19:47549865	TMEM160	-1.06	-21.35	-0.65	9.65e-77	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.51	-0.32	1.2e-16	Breast cancer;
BRCA	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.76e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6740322	0.948	rs6715072	chr2:43562230	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-11.78	-0.42	3.87e-29	Coronary artery disease;
BRCA	cis	rs868036	1.000	rs6494696	chr15:68103206	C/G	cg08079166	chr15:68083412	MAP2K5	-0.34	-9.12	-0.34	9.75e-19	Restless legs syndrome;
BRCA	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg03146154	chr1:46216737	IPP	0.45	10.01	0.37	5.27e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7617773	0.780	rs4541431	chr3:48365218	G/C	cg11946769	chr3:48343235	NME6	0.67	13.61	0.47	3.13e-37	Coronary artery disease;
BRCA	cis	rs922182	1.000	rs922182	chr15:64277642	C/T	cg24729988	chr15:64271149	DAPK2	0.44	9.73	0.36	5.88e-21	Blood protein levels;
BRCA	cis	rs9308433	0.643	rs4655330	chr1:214466068	A/G	cg06198575	chr1:214491504	SMYD2	-0.49	-10.42	-0.38	1.33e-23	IgG glycosylation;
BRCA	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg13175981	chr1:150552382	MCL1	0.53	11.77	0.42	4.36e-29	Tonsillectomy;
BRCA	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg02659138	chr7:134003124	SLC35B4	0.34	10.54	0.38	4.49e-24	Mean platelet volume;
BRCA	cis	rs9462027	0.628	rs9469863	chr6:34739649	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.01	-0.3	5.4e-15	Systemic lupus erythematosus;
BRCA	cis	rs10193935	1.000	rs4494804	chr2:42395946	A/T	cg27598129	chr2:42591480	NA	-0.93	-14.94	-0.51	1.59e-43	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7178375	1.000	rs9806159	chr15:31209654	G/T	cg04373760	chr16:53404718	NA	0.46	8.95	0.33	3.77e-18	Hypertriglyceridemia;
BRCA	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg15485101	chr11:133734466	NA	0.38	10.59	0.39	2.88e-24	Childhood ear infection;
BRCA	cis	rs7523273	0.606	rs761275	chr1:207972154	A/C	cg22525895	chr1:207977042	MIR29B2	-0.5	-12.68	-0.45	5.09e-33	Schizophrenia;
BRCA	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg13334819	chr7:99746414	C7orf59	0.39	8.96	0.33	3.49e-18	Coronary artery disease;
BRCA	cis	rs6543140	1.000	rs6543140	chr2:103074274	G/T	cg04239558	chr2:103089729	SLC9A4	0.34	9.56	0.35	2.4e-20	Blood protein levels;
BRCA	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18876405	chr7:65276391	NA	-0.54	-12.43	-0.44	6.23e-32	Aortic root size;
BRCA	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg06115741	chr20:33292138	TP53INP2	0.39	8.59	0.32	6.82e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs652260	0.663	rs580984	chr19:7881030	C/T	cg26014689	chr19:7917955	EVI5L	-0.45	-10.0	-0.37	5.71e-22	Menarche (age at onset);
BRCA	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.4	-0.44	8.65e-32	Response to antipsychotic treatment;
BRCA	cis	rs2997447	0.655	rs2275947	chr1:26383875	A/G	cg19633962	chr1:26362018	EXTL1	-0.47	-8.48	-0.32	1.59e-16	QRS complex (12-leadsum);
BRCA	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg03709012	chr19:19516395	GATAD2A	0.78	17.72	0.57	2e-57	Tonsillectomy;
BRCA	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg02153584	chr22:29168773	CCDC117	-0.47	-10.48	-0.38	8.1e-24	Red cell distribution width;
BRCA	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.67	-0.77	1.01e-127	Schizophrenia;
BRCA	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg08213375	chr14:104286397	PPP1R13B	0.64	18.25	0.59	3.14e-60	Schizophrenia;
BRCA	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg19628046	chr18:33552617	C18orf21	0.53	9.97	0.37	7.18e-22	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs1034435	0.755	rs713923	chr22:48891519	C/T	cg05992904	chr22:48892994	FAM19A5	0.7	16.31	0.54	2.95e-50	Late-onset Alzheimer's disease;
BRCA	cis	rs1499972	0.941	rs55779525	chr3:117651483	A/C	cg07612923	chr3:117604196	NA	0.6	8.11	0.31	2.61e-15	Schizophrenia;
BRCA	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26314531	chr2:26401878	FAM59B	-0.63	-10.83	-0.39	3.28e-25	Gut microbiome composition (summer);
BRCA	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg07169764	chr2:136633963	MCM6	1.27	26.48	0.72	7.65e-105	Corneal structure;
BRCA	trans	rs9951602	0.512	rs7234283	chr18:76640552	T/G	cg02800362	chr5:177631904	HNRNPAB	0.76	17.67	0.57	3.37e-57	Obesity-related traits;
BRCA	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg17366294	chr4:99064904	C4orf37	0.41	9.33	0.35	1.72e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.47	-0.32	1.73e-16	Total body bone mineral density;
BRCA	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	16.41	0.54	9.31e-51	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg07741184	chr6:167504864	NA	0.33	9.8	0.36	3.32e-21	Primary biliary cholangitis;
BRCA	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg22705602	chr4:152727874	NA	-0.37	-10.01	-0.37	5.03e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.17	0.51	1.28e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.94e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg22974920	chr21:40686053	BRWD1	-0.39	-8.54	-0.32	9.74e-17	Cognitive function;
BRCA	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg15556689	chr8:8085844	FLJ10661	0.38	10.0	0.37	5.54e-22	Retinal vascular caliber;
BRCA	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg08888203	chr3:10149979	C3orf24	0.68	14.45	0.5	3.52e-41	Alzheimer's disease;
BRCA	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg00012203	chr2:219082015	ARPC2	-0.48	-9.27	-0.34	2.75e-19	Colorectal cancer;
BRCA	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg11764359	chr7:65958608	NA	-0.67	-15.1	-0.51	2.69e-44	Aortic root size;
BRCA	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg02297831	chr4:17616191	MED28	0.36	8.35	0.31	4.15e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4728302	0.559	rs12707093	chr7:133200817	C/T	cg10665199	chr7:133106180	EXOC4	0.43	8.63	0.32	4.96e-17	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.62	0.55	8.25e-52	Alzheimer's disease (late onset);
BRCA	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg05283184	chr6:79620031	NA	-0.37	-8.57	-0.32	7.53e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg10556349	chr10:835070	NA	0.58	8.1	0.31	2.86e-15	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg12310025	chr6:25882481	NA	0.72	18.12	0.58	1.55e-59	Blood metabolite levels;
BRCA	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg17724175	chr1:150552817	MCL1	0.24	7.85	0.3	1.73e-14	Melanoma;
BRCA	trans	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg25214090	chr10:38739885	LOC399744	0.54	12.27	0.44	3.29e-31	Corneal astigmatism;
BRCA	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.51e-23	Motion sickness;
BRCA	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.42	-0.41	1.3e-27	Mean corpuscular volume;
BRCA	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.4	-0.35	9.32e-20	Tonsillectomy;
BRCA	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08280861	chr8:58055591	NA	0.53	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9986765	0.609	rs73452600	chr7:142828104	C/A	cg21852589	chr7:142981689	TMEM139	0.61	10.07	0.37	2.97e-22	Cancer;Dermatomyositis;
BRCA	trans	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg06521331	chr12:34319734	NA	-0.47	-8.69	-0.33	3.12e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg23625390	chr15:77176239	SCAPER	0.38	8.86	0.33	7.88e-18	Blood metabolite levels;
BRCA	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg26677194	chr12:130822605	PIWIL1	0.6	14.33	0.49	1.31e-40	Menopause (age at onset);
BRCA	cis	rs76419734	0.510	rs12504088	chr4:106662004	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.57	12.52	0.44	2.65e-32	Post bronchodilator FEV1;
BRCA	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg24562669	chr7:97807699	LMTK2	0.45	11.86	0.42	1.82e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg06115741	chr20:33292138	TP53INP2	0.36	8.12	0.31	2.47e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs586533	0.881	rs10893643	chr11:99512107	C/G	cg22878054	chr11:99397252	CNTN5	0.31	7.84	0.3	1.85e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg24112000	chr20:60950667	NA	-0.54	-11.87	-0.42	1.73e-29	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.69	0.39	1.17e-24	Cognitive ability;
BRCA	cis	rs7301016	0.846	rs73124315	chr12:62970437	C/T	cg01804193	chr12:63026212	NA	0.47	8.56	0.32	8.12e-17	IgG glycosylation;
BRCA	trans	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	28.25	0.75	1.44e-114	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg06521331	chr12:34319734	NA	-0.52	-9.45	-0.35	6.17e-20	Bladder cancer;
BRCA	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-11.12	-0.4	2.2e-26	Schizophrenia;
BRCA	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	17.54	0.57	1.57e-56	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg04025307	chr7:1156635	C7orf50	0.56	10.58	0.39	3.28e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	12.02	0.43	3.94e-30	Tonsillectomy;
BRCA	cis	rs12210905	0.688	rs12213471	chr6:27406063	C/G	cg08851530	chr6:28072375	NA	0.81	7.89	0.3	1.3e-14	Hip circumference adjusted for BMI;
BRCA	cis	rs73086581	1.000	rs73086535	chr20:3944150	T/C	cg02187196	chr20:3869020	PANK2	0.53	9.55	0.35	2.71e-20	Response to antidepressants in depression;
BRCA	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg09307838	chr4:120376055	NA	0.61	12.35	0.44	1.42e-31	Corneal astigmatism;
BRCA	cis	rs5751614	0.557	rs5759666	chr22:23602342	C/T	cg25410636	chr22:23605411	BCR	-0.35	-8.02	-0.3	5.2e-15	Height;
BRCA	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg24920358	chr1:40204285	PPIE	0.34	7.91	0.3	1.12e-14	Blood protein levels;
BRCA	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg20891283	chr12:69753455	YEATS4	0.72	21.14	0.64	1.26e-75	Blood protein levels;
BRCA	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7149337	0.805	rs2999354	chr14:51607179	C/G	cg23942311	chr14:51606299	NA	0.45	13.31	0.47	7.73e-36	Cancer;
BRCA	trans	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg26384229	chr12:38710491	ALG10B	-0.49	-10.61	-0.39	2.49e-24	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.06	0.37	3.23e-22	Bladder cancer;
BRCA	cis	rs4900538	0.963	rs1190554	chr14:102918686	T/C	cg18135206	chr14:102964638	TECPR2	0.99	26.78	0.73	1.65e-106	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs9462846	0.802	rs1819324	chr6:42859723	G/C	cg02353165	chr6:42928485	GNMT	0.44	8.29	0.31	6.67e-16	Blood protein levels;
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg18402987	chr7:1209562	NA	0.44	8.66	0.32	3.86e-17	Longevity;Endometriosis;
BRCA	cis	rs6745190	0.512	rs35482602	chr2:181995321	T/C	cg00481216	chr2:181971175	NA	0.46	8.75	0.33	1.89e-17	White blood cell count;
BRCA	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg11189052	chr15:85197271	WDR73	-0.43	-10.17	-0.37	1.3e-22	P wave terminal force;
BRCA	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.15	0.49	9.38e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4908760	0.832	rs11121209	chr1:8686862	G/A	cg20416874	chr1:8611966	RERE	-0.28	-8.09	-0.3	3.08e-15	Vitiligo;
BRCA	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.8	11.45	0.41	9.53e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg17063962	chr7:91808500	NA	0.58	13.56	0.47	5.22e-37	Breast cancer;
BRCA	cis	rs5771069	0.896	rs137862	chr22:50446550	C/A	cg27068297	chr22:50451975	IL17REL	0.33	7.92	0.3	1.02e-14	Ulcerative colitis;
BRCA	cis	rs3857067	0.806	rs17374832	chr4:95114394	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.49	-0.35	4.67e-20	QT interval;
BRCA	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg26384229	chr12:38710491	ALG10B	0.58	13.28	0.47	1.05e-35	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.65	-9.82	-0.36	2.77e-21	Schizophrenia;
BRCA	cis	rs10463316	0.894	rs6880137	chr5:150755232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.09	-0.3	2.99e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg22800045	chr5:56110881	MAP3K1	0.42	8.61	0.32	5.71e-17	Coronary artery disease;
BRCA	cis	rs758324	0.947	rs1846650	chr5:131158767	C/T	cg06307176	chr5:131281290	NA	0.53	10.19	0.37	1.08e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg13010199	chr12:38710504	ALG10B	0.55	12.08	0.43	2.07e-30	Heart rate;
BRCA	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg06627628	chr2:24431161	ITSN2	0.42	8.61	0.32	5.5e-17	Asthma;
BRCA	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18876405	chr7:65276391	NA	-0.62	-15.43	-0.52	6.52e-46	Aortic root size;
BRCA	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.48	-10.47	-0.38	8.64e-24	IgG glycosylation;
BRCA	cis	rs1003719	0.762	rs1155786	chr21:38448025	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.07	0.49	2.19e-39	Eye color traits;
BRCA	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	12.02	0.43	3.94e-30	Tonsillectomy;
BRCA	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg00071950	chr4:10020882	SLC2A9	-0.43	-9.93	-0.37	1.02e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg09455208	chr3:40491958	NA	-0.34	-8.22	-0.31	1.11e-15	Renal cell carcinoma;
BRCA	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg15395560	chr15:45543142	SLC28A2	0.29	8.17	0.31	1.67e-15	Uric acid levels;
BRCA	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg03342759	chr3:160939853	NMD3	-0.69	-14.11	-0.49	1.53e-39	Parkinson's disease;
BRCA	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg05340658	chr4:99064831	C4orf37	0.47	10.28	0.38	4.96e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg08822215	chr16:89438651	ANKRD11	-0.41	-8.69	-0.33	3e-17	Multiple myeloma (IgH translocation);
BRCA	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-7.98	-0.3	6.61e-15	Total body bone mineral density;
BRCA	cis	rs651907	1.000	rs662792	chr3:101599608	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.35	8.26	0.31	8.26e-16	Colorectal cancer;
BRCA	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg25237894	chr2:233734115	C2orf82	0.4	11.48	0.41	7.43e-28	Coronary artery disease;
BRCA	trans	rs9944715	1.000	rs9963153	chr18:43840064	A/G	cg01718231	chr17:29326311	RNF135	-0.47	-9.26	-0.34	3.06e-19	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.65	11.84	0.42	2.14e-29	Gut microbiome composition (summer);
BRCA	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg26031613	chr14:104095156	KLC1	0.74	16.39	0.54	1.21e-50	Body mass index;
BRCA	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg00105475	chr2:10696890	NA	0.44	10.33	0.38	3.07e-23	Prostate cancer;
BRCA	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg03929089	chr4:120376271	NA	0.6	10.17	0.37	1.26e-22	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9810890	1.000	rs73198827	chr3:128489521	G/T	cg15033153	chr3:128514015	RAB7A	0.7	8.08	0.3	3.34e-15	Dental caries;
BRCA	cis	rs6546550	0.901	rs11893500	chr2:70154187	T/C	cg02498382	chr2:70120550	SNRNP27	-0.52	-11.34	-0.41	2.86e-27	Prevalent atrial fibrillation;
BRCA	cis	rs2599510	0.811	rs176410	chr2:32643437	C/G	cg02381751	chr2:32503542	YIPF4	-0.41	-8.19	-0.31	1.45e-15	Interleukin-18 levels;
BRCA	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg04709771	chr16:646395	RAB40C	0.43	10.63	0.39	2.06e-24	Height;
BRCA	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg08601574	chr20:25228251	PYGB	-0.34	-8.18	-0.31	1.53e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg06784218	chr1:46089804	CCDC17	0.52	12.54	0.44	2.12e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg07169764	chr2:136633963	MCM6	-0.96	-19.3	-0.61	1e-65	Corneal structure;
BRCA	cis	rs73086581	1.000	rs2326289	chr20:3952300	T/C	cg02187196	chr20:3869020	PANK2	0.54	9.62	0.36	1.48e-20	Response to antidepressants in depression;
BRCA	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg13770153	chr20:60521292	NA	-0.44	-9.76	-0.36	4.63e-21	Body mass index;
BRCA	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg12935359	chr14:103987150	CKB	-0.63	-14.82	-0.51	6.19e-43	Intelligence (multi-trait analysis);
BRCA	cis	rs2421770	0.504	rs7943314	chr11:35363823	A/G	cg13971030	chr11:35366721	SLC1A2	-0.44	-9.76	-0.36	4.64e-21	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg09998033	chr7:158218633	PTPRN2	0.37	8.71	0.33	2.57e-17	Obesity-related traits;
BRCA	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg25208724	chr1:156163844	SLC25A44	0.89	18.06	0.58	3.34e-59	Testicular germ cell tumor;
BRCA	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg02297831	chr4:17616191	MED28	0.36	8.41	0.32	2.72e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10924970	0.904	rs10924500	chr1:235351436	T/G	cg26050004	chr1:235667680	B3GALNT2	0.34	8.51	0.32	1.22e-16	Asthma;
BRCA	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg05340658	chr4:99064831	C4orf37	0.64	14.92	0.51	2.01e-43	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-15.49	-0.52	3.38e-46	Obesity-related traits;
BRCA	cis	rs7178424	1.000	rs731820	chr15:62378136	G/A	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.29	-0.31	6.74e-16	Height;
BRCA	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg11663144	chr21:46675770	NA	-0.57	-13.28	-0.47	1.03e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg21475434	chr5:93447410	FAM172A	0.72	9.01	0.34	2.28e-18	Diabetic retinopathy;
BRCA	cis	rs367943	0.933	rs451453	chr5:112808970	G/C	cg12552261	chr5:112820674	MCC	-0.55	-12.22	-0.44	4.98e-31	Type 2 diabetes;
BRCA	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg09307838	chr4:120376055	NA	0.6	13.04	0.46	1.3e-34	Corneal astigmatism;
BRCA	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.79	-0.36	3.63e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg24812749	chr6:127587940	RNF146	0.85	19.76	0.62	3.28e-68	Breast cancer;
BRCA	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg06212747	chr3:49208901	KLHDC8B	0.47	9.63	0.36	1.33e-20	Parkinson's disease;
BRCA	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg18132916	chr6:79620363	NA	-0.46	-10.34	-0.38	2.93e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs9308433	0.529	rs4655243	chr1:214497291	A/G	cg06198575	chr1:214491504	SMYD2	0.56	12.24	0.44	4.43e-31	IgG glycosylation;
BRCA	trans	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg25214090	chr10:38739885	LOC399744	0.55	12.75	0.45	2.35e-33	Corneal astigmatism;
BRCA	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg00666640	chr1:248458726	OR2T12	0.33	9.04	0.34	1.79e-18	Common traits (Other);
BRCA	cis	rs11723261	0.582	rs4634177	chr4:136837	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.34	7.9	0.3	1.2e-14	Immune response to smallpox vaccine (IL-6);
BRCA	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Tonsillectomy;
BRCA	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-16.03	-0.54	7.33e-49	Alzheimer's disease (late onset);
BRCA	cis	rs12973672	0.904	rs12974791	chr19:35767218	A/G	cg12095397	chr19:35769544	USF2	0.37	8.37	0.31	3.71e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-8.63	-0.32	4.74e-17	Total body bone mineral density;
BRCA	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg02734326	chr4:10020555	SLC2A9	0.39	8.48	0.32	1.61e-16	Bone mineral density;
BRCA	cis	rs7646881	0.812	rs73017541	chr3:158460796	T/G	cg19483011	chr3:158453295	NA	-0.47	-8.04	-0.3	4.27e-15	Tetralogy of Fallot;
BRCA	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg08738300	chr3:44038990	NA	0.44	8.56	0.32	8.69e-17	Coronary artery disease;
BRCA	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg16586182	chr3:47516702	SCAP	-0.63	-14.74	-0.5	1.49e-42	Colorectal cancer;
BRCA	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg08859206	chr1:53392774	SCP2	-0.44	-8.91	-0.33	5.37e-18	Monocyte count;
BRCA	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-10.59	-0.39	2.97e-24	Longevity;
BRCA	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03452623	chr4:187889614	NA	0.34	10.9	0.4	1.7e-25	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21659725	chr3:3221576	CRBN	-0.69	-20.84	-0.64	5.71e-74	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg08000102	chr2:233561755	GIGYF2	0.61	12.9	0.45	5.1e-34	Coronary artery disease;
BRCA	cis	rs9469578	1.000	rs16869456	chr6:33714622	G/A	cg18708504	chr6:33715942	IP6K3	0.7	10.19	0.37	1.09e-22	Phosphorus levels;
BRCA	cis	rs17401966	0.540	rs3748581	chr1:10441664	T/C	cg03954927	chr1:10346856	KIF1B	0.34	10.24	0.38	7.1e-23	Hepatocellular carcinoma;
BRCA	cis	rs12714314	0.914	rs12986730	chr2:1959401	G/A	cg22511877	chr2:1942942	MYT1L	0.38	8.09	0.3	2.93e-15	Type 2 diabetes (age of onset);
BRCA	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg27661571	chr11:113659931	NA	-0.7	-10.88	-0.4	2e-25	Hip circumference adjusted for BMI;
BRCA	cis	rs11971779	0.715	rs10954646	chr7:139061069	C/G	cg07862535	chr7:139043722	LUC7L2	-0.37	-10.12	-0.37	1.96e-22	Diisocyanate-induced asthma;
BRCA	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg09436375	chr6:42928200	GNMT	-0.29	-10.37	-0.38	2.15e-23	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18876405	chr7:65276391	NA	-0.5	-11.07	-0.4	3.5e-26	Aortic root size;
BRCA	cis	rs72772090	0.710	rs11750400	chr5:96077968	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.76	-0.45	2.16e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg25036284	chr2:26402008	FAM59B	-0.89	-15.63	-0.53	7.3e-47	Gut microbiome composition (summer);
BRCA	cis	rs813218	0.523	rs497868	chr3:99450187	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.41	-9.33	-0.35	1.68e-19	Orofacial clefts;
BRCA	cis	rs7833986	0.501	rs72653951	chr8:56961837	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	12.43	0.44	6.54e-32	Height;
BRCA	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg26395211	chr5:140044315	WDR55	0.38	8.67	0.32	3.64e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.71	16.86	0.55	4.78e-53	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg20991723	chr1:152506922	NA	0.39	8.9	0.33	5.57e-18	Hair morphology;
BRCA	cis	rs11603020	0.950	rs28362949	chr11:57371911	G/T	cg19752551	chr11:57585705	CTNND1	-0.43	-9.96	-0.37	7.8e-22	Blood protein levels;
BRCA	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg16339924	chr4:17578868	LAP3	0.58	14.2	0.49	5.37e-40	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9309473	0.519	rs7606947	chr2:73909818	C/T	cg20560298	chr2:73613845	ALMS1	-0.38	-9.87	-0.36	1.74e-21	Metabolite levels;
BRCA	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg13852791	chr20:30311386	BCL2L1	-0.86	-16.75	-0.55	1.82e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.49e-52	Hypertriglyceridemia;
BRCA	trans	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.91	-0.3	1.14e-14	Corneal astigmatism;
BRCA	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.64	10.26	0.38	5.86e-23	Renal function-related traits (BUN);
BRCA	cis	rs9612	0.718	rs346531	chr19:44239927	T/C	cg08581076	chr19:44259116	C19orf61	0.44	7.9	0.3	1.23e-14	Exhaled nitric oxide output;
BRCA	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg04455712	chr21:45112962	RRP1B	0.46	11.34	0.41	2.85e-27	Mean corpuscular volume;
BRCA	cis	rs7095944	0.614	rs7898003	chr10:126451385	G/A	cg08799069	chr10:126477246	METTL10	-0.4	-10.16	-0.37	1.43e-22	Asthma;
BRCA	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg20307385	chr11:47447363	PSMC3	0.83	20.74	0.63	1.94e-73	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00149659	chr3:10157352	C3orf10	0.72	12.57	0.45	1.49e-32	Alzheimer's disease;
BRCA	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg00074818	chr8:8560427	CLDN23	0.38	8.37	0.31	3.69e-16	Obesity-related traits;
BRCA	cis	rs6942756	1.000	rs7803052	chr7:128959427	A/G	cg02491457	chr7:128862824	NA	-0.71	-14.03	-0.49	3.61e-39	White matter hyperintensity burden;
BRCA	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg11946769	chr3:48343235	NME6	0.7	14.01	0.48	4.45e-39	Coronary artery disease;
BRCA	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.38	-8.68	-0.32	3.36e-17	Alzheimer's disease (late onset);
BRCA	cis	rs2797160	1.000	rs1777222	chr6:126021030	C/T	cg05901451	chr6:126070800	HEY2	0.39	9.66	0.36	1.04e-20	Endometrial cancer;
BRCA	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg25358565	chr5:93447407	FAM172A	1.15	17.96	0.58	1.13e-58	Diabetic retinopathy;
BRCA	cis	rs11605924	1.000	rs11605924	chr11:45873091	A/C	ch.11.939596F	chr11:45881766	CRY2	-0.47	-10.27	-0.38	5.22e-23	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03264133	chr6:25882463	NA	-0.48	-10.77	-0.39	5.48e-25	Blood metabolite levels;
BRCA	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg07507251	chr3:52567010	NT5DC2	0.35	7.9	0.3	1.19e-14	Electroencephalogram traits;
BRCA	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg22800045	chr5:56110881	MAP3K1	0.61	11.5	0.41	6.04e-28	Initial pursuit acceleration;
BRCA	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.02	-0.34	2.13e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.6	-0.67	1.57e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg04607235	chr12:12878440	APOLD1	-0.66	-10.2	-0.37	9.65e-23	Systemic lupus erythematosus;
BRCA	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg20503657	chr10:835505	NA	1.33	22.01	0.66	2.37e-80	Eosinophil percentage of granulocytes;
BRCA	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg21385522	chr1:16154831	NA	-0.47	-9.98	-0.37	6.85e-22	Systolic blood pressure;
BRCA	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg25036284	chr2:26402008	FAM59B	-0.63	-10.54	-0.38	4.8e-24	Gut microbiome composition (summer);
BRCA	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00166722	chr3:10149974	C3orf24	0.55	10.74	0.39	7.48e-25	Alzheimer's disease;
BRCA	cis	rs2073300	1.000	rs6132625	chr20:23444671	C/T	cg12062639	chr20:23401060	NAPB	0.89	10.63	0.39	2.06e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg23950597	chr19:37808831	NA	-0.74	-13.06	-0.46	1.05e-34	Coronary artery calcification;
BRCA	cis	rs1468333	0.897	rs6888877	chr5:137510357	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	-0.44	-8.53	-0.32	1.05e-16	Resting heart rate;
BRCA	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg14835575	chr10:16859367	RSU1	0.34	8.88	0.33	6.58e-18	Platelet distribution width;
BRCA	cis	rs6714710	0.603	rs11681535	chr2:98488949	G/C	cg26665480	chr2:98280029	ACTR1B	0.58	13.56	0.47	5.34e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs6484504	0.576	rs208090	chr11:31190992	T/C	cg14844989	chr11:31128820	NA	-0.44	-9.51	-0.35	3.92e-20	Red blood cell count;
BRCA	cis	rs7246657	0.722	rs1531549	chr19:38088009	T/C	cg23950597	chr19:37808831	NA	-0.51	-8.72	-0.33	2.31e-17	Coronary artery calcification;
BRCA	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg08917208	chr2:24149416	ATAD2B	0.6	9.36	0.35	1.32e-19	Lymphocyte counts;
BRCA	cis	rs4766646	0.619	rs9645838	chr12:110291572	A/G	cg01252219	chr12:110302105	GLTP	0.36	7.96	0.3	7.8e-15	Metabolite levels (MHPG);
BRCA	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	12.05	0.43	2.68e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg06521331	chr12:34319734	NA	-0.54	-10.23	-0.38	7.72e-23	Morning vs. evening chronotype;
BRCA	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg01528321	chr10:82214614	TSPAN14	0.91	19.91	0.62	5.24e-69	Post bronchodilator FEV1;
BRCA	cis	rs9381107	0.505	rs9369420	chr6:9486467	A/G	cg14735645	chr6:9486422	NA	0.44	8.81	0.33	1.16e-17	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg04990556	chr1:26633338	UBXN11	0.56	8.58	0.32	7.03e-17	Obesity-related traits;
BRCA	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24531977	chr5:56204891	C5orf35	-0.88	-18.3	-0.59	1.84e-60	Initial pursuit acceleration;
BRCA	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg05340658	chr4:99064831	C4orf37	-0.44	-10.18	-0.37	1.21e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs11887277	0.868	rs6717682	chr2:27069211	A/G	cg12368169	chr2:27073192	DPYSL5	-0.33	-10.03	-0.37	4.4e-22	Obesity-related traits;
BRCA	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06544989	chr22:39130855	UNC84B	0.38	9.55	0.35	2.7e-20	Menopause (age at onset);
BRCA	cis	rs7677751	0.806	rs61320297	chr4:55088175	G/A	cg17187183	chr4:55093834	PDGFRA	0.44	9.14	0.34	7.9e-19	Corneal astigmatism;
BRCA	cis	rs11971779	0.584	rs6962029	chr7:139034719	T/C	cg07862535	chr7:139043722	LUC7L2	0.39	10.46	0.38	9.65e-24	Diisocyanate-induced asthma;
BRCA	cis	rs36051895	0.632	rs10217652	chr9:5119939	A/G	cg02405213	chr9:5042618	JAK2	-0.48	-9.42	-0.35	8.12e-20	Pediatric autoimmune diseases;
BRCA	cis	rs7617773	0.780	rs2541	chr3:48339618	A/G	cg11946769	chr3:48343235	NME6	0.68	14.05	0.49	2.93e-39	Coronary artery disease;
BRCA	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-12.02	-0.43	3.84e-30	Mood instability;
BRCA	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26314531	chr2:26401878	FAM59B	0.95	16.42	0.54	8.01e-51	Gut microbiome composition (summer);
BRCA	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg12826209	chr6:26865740	GUSBL1	0.44	9.18	0.34	5.95e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs9467773	0.595	rs6907924	chr6:26438817	T/G	cg09904177	chr6:26538194	HMGN4	-0.37	-9.8	-0.36	3.34e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.64	13.16	0.46	3.68e-35	Lymphocyte counts;
BRCA	cis	rs4363385	0.747	rs7521181	chr1:152955223	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.72	-0.33	2.34e-17	Inflammatory skin disease;
BRCA	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg15212455	chr7:39170539	POU6F2	0.43	9.54	0.35	2.9e-20	IgG glycosylation;
BRCA	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg15605315	chr1:45957053	TESK2	0.49	10.07	0.37	3.02e-22	High light scatter reticulocyte count;
BRCA	trans	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg07211511	chr3:129823064	LOC729375	-0.57	-10.82	-0.39	3.52e-25	Blood pressure (smoking interaction);
BRCA	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.69	0.33	3.02e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4664304	0.620	rs2048437	chr2:160712065	C/T	cg02280532	chr2:160761244	LY75	0.35	7.85	0.3	1.81e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03517284	chr6:25882590	NA	-0.45	-9.64	-0.36	1.22e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg06917634	chr15:78832804	PSMA4	-0.76	-17.72	-0.57	1.79e-57	Sudden cardiac arrest;
BRCA	trans	rs6479891	0.908	rs61853639	chr10:65305113	G/T	cg14819942	chr15:35414228	NA	0.35	8.48	0.32	1.58e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs829883	0.573	rs73136486	chr12:98913727	T/A	cg25150519	chr12:98850993	NA	-0.52	-9.48	-0.35	4.95e-20	Colorectal adenoma (advanced);
BRCA	cis	rs1003719	0.591	rs2040125	chr21:38549236	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.53	11.5	0.41	6.13e-28	Eye color traits;
BRCA	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-11.61	-0.42	2.03e-28	Tonsillectomy;
BRCA	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.16	-0.31	1.79e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.96	0.4	1.03e-25	Rheumatoid arthritis;
BRCA	cis	rs12618769	0.597	rs3754883	chr2:99129451	T/C	cg10123293	chr2:99228465	UNC50	0.41	8.22	0.31	1.1e-15	Bipolar disorder;
BRCA	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18876405	chr7:65276391	NA	0.54	12.92	0.45	4.49e-34	Aortic root size;
BRCA	cis	rs13046373	0.507	rs8133828	chr21:32033046	C/G	cg06468780	chr21:31798236	KRTAP13-3	0.36	8.59	0.32	6.86e-17	HDL cholesterol;
BRCA	cis	rs41005	1.000	rs34505904	chr2:8115159	T/C	cg03155496	chr2:8117019	LOC339788	-0.58	-15.78	-0.53	1.34e-47	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg18357645	chr12:58087776	OS9	0.45	13.14	0.46	4.29e-35	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.49	0.47	1.16e-36	Colorectal cancer;
BRCA	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg25019033	chr10:957182	NA	-0.41	-7.88	-0.3	1.41e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs10838687	0.673	rs59567949	chr11:47300155	G/A	cg25783544	chr11:47291846	MADD	0.41	7.88	0.3	1.43e-14	Proinsulin levels;
BRCA	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg13944838	chr5:179740914	GFPT2	-0.71	-15.13	-0.51	1.96e-44	Height;
BRCA	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg13010199	chr12:38710504	ALG10B	0.54	11.87	0.43	1.61e-29	Heart rate;
BRCA	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg06784218	chr1:46089804	CCDC17	0.45	10.76	0.39	6.28e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1403694	0.695	rs3774291	chr3:186433471	C/T	cg12454167	chr3:186435060	KNG1	0.29	7.91	0.3	1.17e-14	Blood protein levels;
BRCA	trans	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.45	-8.56	-0.32	8.18e-17	Monocyte count;
BRCA	cis	rs6138458	0.887	rs227622	chr20:24910597	T/C	cg26195577	chr20:24973756	C20orf3	0.98	24.76	0.7	2.17e-95	Blood protein levels;
BRCA	trans	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg19862616	chr7:65841803	NCRNA00174	0.83	27.26	0.73	3.84e-109	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg12386194	chr3:101231763	SENP7	0.46	9.84	0.36	2.3e-21	Colorectal cancer;
BRCA	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14442939	chr10:27389572	ANKRD26	0.66	10.92	0.4	1.5e-25	Breast cancer;
BRCA	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg07051648	chr19:49177693	NTN5;SEC1	-0.43	-8.05	-0.3	4.03e-15	Dietary macronutrient intake;
BRCA	cis	rs1975991	0.711	rs1871521	chr3:187966035	G/A	cg15417654	chr3:187959138	LPP	0.34	8.73	0.33	2.23e-17	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg18305652	chr10:134549665	INPP5A	0.48	11.9	0.43	1.28e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg13628971	chr7:2884303	GNA12	0.38	8.32	0.31	5.38e-16	Height;
BRCA	cis	rs9341808	0.718	rs9352806	chr6:80980057	G/T	cg08355045	chr6:80787529	NA	0.4	10.86	0.39	2.47e-25	Sitting height ratio;
BRCA	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg12011299	chr4:100065546	ADH4	0.48	10.94	0.4	1.21e-25	Alcohol dependence;
BRCA	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	11.2	0.41	1.05e-26	Multiple sclerosis;
BRCA	cis	rs9462027	0.628	rs3734268	chr6:34716028	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.96	-0.3	8.03e-15	Systemic lupus erythematosus;
BRCA	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11644478	chr21:40555479	PSMG1	0.55	11.76	0.42	4.99e-29	Cognitive function;
BRCA	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg09307838	chr4:120376055	NA	0.75	16.86	0.55	5.11e-53	Corneal astigmatism;
BRCA	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	12.04	0.43	3.21e-30	Schizophrenia;
BRCA	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg11952622	chr19:58962976	ZNF324B	0.4	8.35	0.31	4.38e-16	Uric acid clearance;
BRCA	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg22974920	chr21:40686053	BRWD1	-0.4	-8.7	-0.33	2.76e-17	Cognitive function;
BRCA	trans	rs7939886	0.920	rs77391761	chr11:55814896	G/C	cg15704280	chr7:45808275	SEPT13	0.62	7.92	0.3	1.07e-14	Myopia (pathological);
BRCA	cis	rs35740288	1.000	rs17577449	chr15:86297185	G/A	cg20737812	chr15:86336631	KLHL25	-0.33	-8.82	-0.33	1.07e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg21045802	chr8:109455806	TTC35	0.35	7.96	0.3	8.09e-15	Dupuytren's disease;
BRCA	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-9.58	-0.35	2.07e-20	Reticulocyte count;
BRCA	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg03709012	chr19:19516395	GATAD2A	0.8	18.72	0.6	1.09e-62	Tonsillectomy;
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg22907277	chr7:1156413	C7orf50	0.5	10.87	0.4	2.23e-25	Longevity;Endometriosis;
BRCA	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	11.35	0.41	2.52e-27	Platelet count;
BRCA	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	11.23	0.41	7.82e-27	Bipolar disorder;
BRCA	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg13010199	chr12:38710504	ALG10B	0.44	8.95	0.33	3.88e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg12661370	chr5:149340060	SLC26A2	0.51	7.85	0.3	1.76e-14	HIV-1 control;
BRCA	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg26587870	chr6:27730563	NA	-0.4	-8.59	-0.32	6.61e-17	Parkinson's disease;
BRCA	cis	rs17253792	0.732	rs28380739	chr14:56088402	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-10.26	-0.38	5.65e-23	Putamen volume;
BRCA	cis	rs8062405	0.755	rs62034325	chr16:28538640	A/G	cg16576597	chr16:28551801	NUPR1	0.35	9.48	0.35	5.09e-20	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-14.8	-0.51	8.05e-43	Parkinson's disease;
BRCA	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg13880726	chr7:1868755	MAD1L1	0.52	10.29	0.38	4.55e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs4664304	0.620	rs1397717	chr2:160720444	G/T	cg18514922	chr2:160761262	LY75	0.33	7.89	0.3	1.29e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs858239	0.601	rs11982002	chr7:23163270	C/T	cg23682824	chr7:23144976	KLHL7	0.42	11.0	0.4	6.55e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg27489772	chr12:121021490	NA	0.43	7.91	0.3	1.1e-14	Type 1 diabetes nephropathy;
BRCA	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg27661571	chr11:113659931	NA	-0.5	-8.56	-0.32	8.43e-17	Hip circumference adjusted for BMI;
BRCA	trans	rs12517041	1.000	rs6879795	chr5:23305275	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.48	-8.6	-0.32	6.01e-17	Calcium levels;
BRCA	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg05025164	chr4:1340916	KIAA1530	0.42	9.34	0.35	1.61e-19	Longevity;
BRCA	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg12365402	chr11:9010492	NRIP3	0.43	9.62	0.36	1.55e-20	Hemoglobin concentration;
BRCA	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.53	-13.23	-0.46	1.68e-35	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg23950597	chr19:37808831	NA	-0.72	-12.58	-0.45	1.42e-32	Coronary artery calcification;
BRCA	cis	rs1371614	0.635	rs10175737	chr2:27139747	C/A	cg12368169	chr2:27073192	DPYSL5	-0.29	-8.73	-0.33	2.13e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.35	0.57	1.53e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13064411	0.696	rs1386336	chr3:113144153	C/T	cg18753928	chr3:113234510	CCDC52	-0.5	-9.36	-0.35	1.39e-19	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs8010715	0.816	rs762093	chr14:24591918	G/C	cg23112188	chr14:24563095	PCK2	-0.32	-8.04	-0.3	4.44e-15	IgG glycosylation;
BRCA	trans	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg15704280	chr7:45808275	SEPT13	0.6	8.89	0.33	6.33e-18	Axial length;
BRCA	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg04352962	chr1:209979756	IRF6	0.47	11.85	0.42	2.08e-29	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
BRCA	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.43	-10.03	-0.37	4.51e-22	Lymphocyte counts;
BRCA	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg27170947	chr2:26402098	FAM59B	0.92	16.52	0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	trans	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg06521331	chr12:34319734	NA	-0.47	-8.79	-0.33	1.33e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs11997175	0.756	rs4739435	chr8:33818818	A/G	ch.8.33884649F	chr8:33765107	NA	0.41	10.05	0.37	3.76e-22	Body mass index;
BRCA	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg11941060	chr3:133502564	NA	-0.51	-12.24	-0.44	4.13e-31	Iron status biomarkers;
BRCA	trans	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg06521331	chr12:34319734	NA	-0.45	-8.58	-0.32	7.02e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg24812749	chr6:127587940	RNF146	0.86	19.78	0.62	2.55e-68	Breast cancer;
BRCA	cis	rs9560113	1.000	rs4773383	chr13:112177764	C/T	cg10483660	chr13:112241077	NA	0.31	7.84	0.3	1.88e-14	Menarche (age at onset);
BRCA	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-12.11	-0.43	1.56e-30	Neuroticism;
BRCA	cis	rs11191205	0.644	rs11191069	chr10:103388129	A/C	cg15320455	chr10:103880129	LDB1	-0.46	-7.9	-0.3	1.25e-14	Intelligence (multi-trait analysis);
BRCA	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg15704280	chr7:45808275	SEPT13	0.91	24.31	0.69	5.97e-93	Height;
BRCA	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.07	0.37	3.1e-22	Bladder cancer;
BRCA	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg24006582	chr15:45444508	DUOX1	-0.55	-11.42	-0.41	1.3e-27	Uric acid levels;
BRCA	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg08885076	chr2:99613938	TSGA10	0.43	10.22	0.37	8.29e-23	Chronic sinus infection;
BRCA	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.26	-8.11	-0.31	2.66e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg26043149	chr18:55253948	FECH	0.47	9.85	0.36	2e-21	Bone mineral density;
BRCA	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg00071950	chr4:10020882	SLC2A9	0.64	15.97	0.53	1.4e-48	Bone mineral density;
BRCA	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg05863683	chr7:1912471	MAD1L1	0.38	8.41	0.32	2.77e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg26816564	chr1:7831052	VAMP3	-0.53	-10.52	-0.38	5.68e-24	Inflammatory bowel disease;
BRCA	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg17063962	chr7:91808500	NA	-0.53	-12.03	-0.43	3.33e-30	Breast cancer;
BRCA	cis	rs73086581	0.898	rs11906452	chr20:3981559	A/G	cg02187196	chr20:3869020	PANK2	0.46	8.49	0.32	1.49e-16	Response to antidepressants in depression;
BRCA	cis	rs9811920	0.535	rs793483	chr3:99489825	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-9.86	-0.36	1.97e-21	Axial length;
BRCA	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg05147244	chr20:61493195	TCFL5	0.85	11.15	0.4	1.74e-26	Obesity-related traits;
BRCA	cis	rs6120849	0.708	rs6087659	chr20:33606383	C/A	cg24642439	chr20:33292090	TP53INP2	0.6	10.33	0.38	3.17e-23	Protein C levels;
BRCA	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg17063962	chr7:91808500	NA	-0.53	-11.48	-0.41	7.25e-28	Breast cancer;
BRCA	cis	rs13315871	1.000	rs11715445	chr3:58343888	T/C	cg20936604	chr3:58311152	NA	-0.65	-7.99	-0.3	6.38e-15	Cholesterol, total;
BRCA	cis	rs9463078	0.809	rs6933553	chr6:45027770	T/C	cg25276700	chr6:44698697	NA	-0.36	-8.21	-0.31	1.19e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs7039377	0.554	rs12351753	chr9:38673105	C/G	cg14625731	chr9:38672608	NA	-0.43	-9.42	-0.35	8.03e-20	Obesity-related traits;
BRCA	cis	rs1030877	0.515	rs1020064	chr2:105897740	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.67	12.76	0.45	2.24e-33	Obesity-related traits;
BRCA	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg13880726	chr7:1868755	MAD1L1	0.41	7.98	0.3	6.85e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs795484	0.633	rs904662	chr12:118581833	C/T	cg16572268	chr12:118583242	PEBP1	0.35	9.31	0.35	2.04e-19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
BRCA	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23583168	chr7:148888333	NA	-0.93	-23.61	-0.68	4.52e-89	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-13.29	-0.47	9.56e-36	Platelet count;
BRCA	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg20290983	chr6:43655470	MRPS18A	1.11	40.57	0.85	5.58e-179	IgG glycosylation;
BRCA	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg25482853	chr8:67687455	SGK3	0.97	15.32	0.52	2.31e-45	Lung disease severity in cystic fibrosis;
BRCA	cis	rs36051895	0.659	rs67006981	chr9:5070401	A/G	cg02405213	chr9:5042618	JAK2	-0.54	-9.71	-0.36	6.84e-21	Pediatric autoimmune diseases;
BRCA	cis	rs7903847	0.642	rs10882908	chr10:99134970	T/C	cg20016023	chr10:99160130	RRP12	-0.27	-8.67	-0.32	3.62e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg13010199	chr12:38710504	ALG10B	0.51	10.32	0.38	3.52e-23	Bladder cancer;
BRCA	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg23711669	chr6:146136114	FBXO30	0.74	17.0	0.56	9.95e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg25358565	chr5:93447407	FAM172A	1.19	18.85	0.6	2.34e-63	Diabetic retinopathy;
BRCA	cis	rs897080	0.552	rs1067323	chr2:44630018	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	9.37	0.35	1.23e-19	Height;
BRCA	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg20007245	chr22:24372913	LOC391322	-0.55	-12.26	-0.44	3.46e-31	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-18.36	-0.59	9.01e-61	Exhaled nitric oxide output;
BRCA	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.08	0.4	3.31e-26	Bipolar disorder;
BRCA	trans	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg06521331	chr12:34319734	NA	0.46	8.92	0.33	4.79e-18	Morning vs. evening chronotype;
BRCA	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	13.02	0.46	1.47e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7756236	0.521	rs6907437	chr6:36625021	A/G	cg08179530	chr6:36648295	CDKN1A	0.38	8.22	0.31	1.1e-15	QRS duration;
BRCA	trans	rs4714291	0.832	rs6917417	chr6:40104628	T/C	cg02267698	chr19:7991119	CTXN1	-0.46	-9.63	-0.36	1.43e-20	Strep throat;
BRCA	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg14993813	chr1:46806288	NSUN4	-0.47	-9.04	-0.34	1.91e-18	Menopause (age at onset);
BRCA	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg26597838	chr10:835615	NA	1.01	18.0	0.58	6.39e-59	Eosinophil percentage of granulocytes;
BRCA	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg15704280	chr7:45808275	SEPT13	-0.42	-8.14	-0.31	2e-15	Height;
BRCA	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-8.09	-0.3	3.03e-15	Personality dimensions;
BRCA	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg07741184	chr6:167504864	NA	0.36	10.39	0.38	1.72e-23	Crohn's disease;
BRCA	cis	rs10129255	0.500	rs12101190	chr14:107192386	C/T	cg07958169	chr14:107095056	NA	-0.4	-8.67	-0.32	3.69e-17	Kawasaki disease;
BRCA	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-9.05	-0.34	1.76e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.39	8.31	0.31	5.95e-16	Total cholesterol levels;
BRCA	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg10876282	chr6:28092338	ZSCAN16	0.41	7.96	0.3	7.79e-15	Parkinson's disease;
BRCA	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg06547715	chr2:218990976	CXCR2	0.32	8.04	0.3	4.49e-15	Ulcerative colitis;
BRCA	cis	rs11191205	0.644	rs11191062	chr10:103366645	T/C	cg15320455	chr10:103880129	LDB1	0.46	8.03	0.3	4.66e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04565464	chr8:145669602	NFKBIL2	0.44	9.87	0.36	1.69e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg18016565	chr1:150552671	MCL1	0.35	8.23	0.31	1.08e-15	Tonsillectomy;
BRCA	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg19628046	chr18:33552617	C18orf21	0.55	10.51	0.38	6.33e-24	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-10.58	-0.39	3.38e-24	Lymphocyte counts;
BRCA	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg05347473	chr6:146136440	FBXO30	0.43	8.63	0.32	4.97e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg21045802	chr8:109455806	TTC35	0.35	8.03	0.3	4.64e-15	Dupuytren's disease;
BRCA	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.59	-14.21	-0.49	4.97e-40	Longevity;Endometriosis;
BRCA	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg26597838	chr10:835615	NA	1.0	15.64	0.53	6.72e-47	Eosinophil percentage of granulocytes;
BRCA	cis	rs7766436	0.885	rs4712699	chr6:22592884	C/A	cg13666174	chr6:22585274	NA	-0.49	-11.49	-0.41	6.42e-28	Coronary artery disease;
BRCA	cis	rs7975161	0.572	rs4614534	chr12:104597917	C/T	cg25273343	chr12:104657179	TXNRD1	0.56	9.6	0.35	1.81e-20	Toenail selenium levels;
BRCA	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-7.82	-0.3	2.13e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg03585969	chr10:35415529	CREM	0.55	11.44	0.41	1.09e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.62	13.48	0.47	1.22e-36	Lymphocyte percentage of white cells;
BRCA	cis	rs6942756	0.774	rs66479871	chr7:129009687	T/C	cg02491457	chr7:128862824	NA	-0.56	-11.83	-0.42	2.47e-29	White matter hyperintensity burden;
BRCA	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg10932868	chr11:921992	NA	0.49	12.51	0.44	2.84e-32	Alzheimer's disease (late onset);
BRCA	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg17971929	chr21:40555470	PSMG1	0.58	9.24	0.34	3.74e-19	Cognitive function;
BRCA	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	17.97	0.58	9.11e-59	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	20.11	0.62	4.61e-70	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-9.33	-0.35	1.65e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs17092148	1.000	rs6088579	chr20:33284624	A/G	cg16810054	chr20:33298113	TP53INP2	-0.5	-10.82	-0.39	3.47e-25	Neuroticism;
BRCA	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg27588902	chr6:42928151	GNMT	-0.31	-10.4	-0.38	1.7e-23	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.93	0.33	4.51e-18	Motion sickness;
BRCA	trans	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	18.25	0.59	3.4e-60	Exhaled nitric oxide output;
BRCA	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg21573476	chr21:45109991	RRP1B	0.36	9.26	0.34	3.08e-19	Mean corpuscular volume;
BRCA	cis	rs8038465	0.615	rs6495074	chr15:73959013	A/G	cg15420318	chr15:73925796	NPTN	0.41	9.19	0.34	5.6e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg13906792	chr15:75199810	C15orf17	0.42	9.88	0.36	1.65e-21	Breast cancer;
BRCA	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg02551604	chr5:131831745	NA	-0.39	-15.08	-0.51	3.31e-44	Asthma (sex interaction);
BRCA	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg15395560	chr15:45543142	SLC28A2	-0.29	-7.93	-0.3	9.69e-15	Uric acid levels;
BRCA	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.68	15.67	0.53	4.73e-47	Axial length;
BRCA	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg22800045	chr5:56110881	MAP3K1	0.68	12.5	0.44	3.23e-32	Initial pursuit acceleration;
BRCA	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg16989086	chr20:62203971	PRIC285	0.53	8.83	0.33	9.74e-18	Glioma;Non-glioblastoma glioma;Glioblastoma;
BRCA	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.62	-0.42	1.8e-28	Gut microbiome composition (summer);
BRCA	cis	rs13102973	0.867	rs12501608	chr4:135896365	T/C	cg14419869	chr4:135874104	NA	0.47	9.41	0.35	9.03e-20	Subjective well-being;
BRCA	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg16606324	chr3:10149918	C3orf24	0.57	11.38	0.41	1.88e-27	Alzheimer's disease;
BRCA	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.77	-0.5	1.14e-42	Chronic sinus infection;
BRCA	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg20503657	chr10:835505	NA	1.05	18.41	0.59	5.1e-61	Eosinophil percentage of granulocytes;
BRCA	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.21	-0.34	4.63e-19	Bipolar disorder;
BRCA	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg27478167	chr7:817139	HEATR2	-0.58	-11.52	-0.41	4.8e-28	Cerebrospinal P-tau181p levels;
BRCA	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg09307838	chr4:120376055	NA	0.7	14.75	0.5	1.38e-42	Corneal astigmatism;
BRCA	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg03929089	chr4:120376271	NA	-0.53	-8.81	-0.33	1.21e-17	Axial length;
BRCA	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg11764359	chr7:65958608	NA	0.65	11.62	0.42	1.81e-28	Aortic root size;
BRCA	cis	rs312274	0.527	rs10879294	chr12:41263818	A/G	cg17827154	chr12:41323612	CNTN1	-0.36	-9.0	-0.34	2.5e-18	Metabolite levels  (X-11787);
BRCA	cis	rs11955398	0.625	rs6874072	chr5:59987682	C/G	cg02684056	chr5:59996105	DEPDC1B	0.39	9.02	0.34	2.25e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-17.57	-0.57	1.18e-56	Colorectal cancer;
BRCA	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg12365402	chr11:9010492	NRIP3	-0.41	-9.31	-0.35	2.08e-19	Hemoglobin concentration;
BRCA	cis	rs9649465	0.561	rs600420	chr7:123408050	G/A	cg03229431	chr7:123269106	ASB15	0.44	10.17	0.37	1.27e-22	Migraine;
BRCA	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.81e-23	Prostate cancer;
BRCA	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg08470875	chr2:26401718	FAM59B	-0.66	-11.41	-0.41	1.4e-27	Gut microbiome composition (summer);
BRCA	trans	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg18876405	chr7:65276391	NA	0.43	8.43	0.32	2.36e-16	Corneal structure;
BRCA	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08219700	chr8:58056026	NA	0.44	8.07	0.3	3.37e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs573521	0.934	rs2155013	chr11:102701858	A/G	cg15619439	chr11:102700944	NA	-0.29	-8.22	-0.31	1.12e-15	Cerebrospinal fluid levels of Alzheimer's disease-related proteins;
BRCA	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg13736514	chr6:26305472	NA	-0.49	-15.67	-0.53	4.69e-47	Educational attainment;
BRCA	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg03934865	chr2:198174659	NA	-0.44	-9.57	-0.35	2.34e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08219700	chr8:58056026	NA	0.45	8.14	0.31	2.05e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12545109	0.837	rs4738500	chr8:57356193	G/A	cg09654669	chr8:57350985	NA	-0.42	-8.03	-0.3	4.79e-15	Obesity-related traits;
BRCA	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg08999081	chr20:33150536	PIGU	0.47	13.11	0.46	6.3e-35	Glomerular filtration rate (creatinine);
BRCA	cis	rs7301016	0.846	rs11174576	chr12:63026436	C/T	cg01804193	chr12:63026212	NA	0.45	7.93	0.3	9.51e-15	IgG glycosylation;
BRCA	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.91	-0.33	5.2e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg26597838	chr10:835615	NA	1.28	21.53	0.65	9.42e-78	Eosinophil percentage of granulocytes;
BRCA	cis	rs6121246	0.559	rs6087782	chr20:30391580	C/T	cg13852791	chr20:30311386	BCL2L1	0.95	22.84	0.67	6.8e-85	Mean corpuscular hemoglobin;
BRCA	cis	rs997295	0.554	rs28568344	chr15:68096527	A/G	cg08079166	chr15:68083412	MAP2K5	0.31	8.32	0.31	5.13e-16	Motion sickness;
BRCA	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.94e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-8.9	-0.33	5.67e-18	Bladder cancer;
BRCA	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg06623918	chr6:96969491	KIAA0776	-0.77	-13.98	-0.48	6.03e-39	Migraine;Coronary artery disease;
BRCA	trans	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.75	0.39	6.67e-25	Type 2 diabetes;
BRCA	cis	rs9309473	0.607	rs1851546	chr2:73591127	C/A	cg20560298	chr2:73613845	ALMS1	-0.46	-12.45	-0.44	5.34e-32	Metabolite levels;
BRCA	cis	rs1691799	0.528	rs1472314	chr12:66788838	C/G	cg16791601	chr12:66731901	HELB	-0.47	-11.05	-0.4	4.12e-26	White blood cell count (basophil);
BRCA	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.61e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg24846343	chr22:24311635	DDTL	-0.44	-9.68	-0.36	8.71e-21	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg23649088	chr2:200775458	C2orf69	-0.58	-9.15	-0.34	7.82e-19	Schizophrenia;
BRCA	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg07541023	chr7:19748670	TWISTNB	0.6	10.47	0.38	8.57e-24	Thyroid stimulating hormone;
BRCA	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg00277334	chr10:82204260	NA	-0.85	-25.05	-0.7	5.02e-97	Post bronchodilator FEV1;
BRCA	cis	rs7617773	0.925	rs7374376	chr3:48172687	T/C	cg11946769	chr3:48343235	NME6	-0.39	-8.51	-0.32	1.24e-16	Coronary artery disease;
BRCA	cis	rs12760731	0.565	rs12048698	chr1:178136792	T/C	cg00404053	chr1:178313656	RASAL2	0.64	7.87	0.3	1.56e-14	Obesity-related traits;
BRCA	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.02	-0.34	2.13e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.53	-0.32	1.05e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg23029597	chr12:123009494	RSRC2	-0.5	-9.8	-0.36	3.33e-21	Body mass index;
BRCA	cis	rs7301826	0.651	rs4759794	chr12:131297348	T/G	cg11011512	chr12:131303247	STX2	0.5	13.03	0.46	1.42e-34	Plasma plasminogen activator levels;
BRCA	cis	rs6546550	0.901	rs11126251	chr2:70163434	A/C	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.59	-0.42	2.59e-28	Prevalent atrial fibrillation;
BRCA	cis	rs3820928	0.874	rs7563644	chr2:227846932	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.39	-0.32	3.08e-16	Pulmonary function;
BRCA	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.11	-0.34	1.08e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.66	-0.5	3.76e-42	Chronic sinus infection;
BRCA	cis	rs2882667	0.867	rs11749045	chr5:138420960	C/T	cg04439458	chr5:138467593	SIL1	-0.36	-9.81	-0.36	2.83e-21	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7903847	0.642	rs11189174	chr10:99139600	C/G	cg08345082	chr10:99160200	RRP12	-0.29	-8.62	-0.32	5.4e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg01689657	chr7:91764605	CYP51A1	0.22	8.0	0.3	5.83e-15	Breast cancer;
BRCA	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg05714579	chr10:131428358	MGMT	0.54	12.38	0.44	1.07e-31	Response to temozolomide;
BRCA	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg02153584	chr22:29168773	CCDC117	0.53	11.01	0.4	6.23e-26	Lymphocyte counts;
BRCA	cis	rs9463078	0.683	rs227847	chr6:44695493	A/G	cg25276700	chr6:44698697	NA	0.36	7.98	0.3	6.74e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg13010199	chr12:38710504	ALG10B	-0.39	-8.39	-0.31	3.22e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg08132940	chr7:1081526	C7orf50	-0.59	-8.77	-0.33	1.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9976767	0.637	rs9984108	chr21:43825628	T/G	cg23042151	chr21:43824109	UBASH3A	-0.27	-8.53	-0.32	1.1e-16	Type 1 diabetes;
BRCA	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg06623918	chr6:96969491	KIAA0776	-0.92	-26.51	-0.72	5.11e-105	Headache;
BRCA	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg08470875	chr2:26401718	FAM59B	0.72	10.08	0.37	2.89e-22	Gut microbiome composition (summer);
BRCA	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	10.97	0.4	8.58e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.35	9.11	0.34	1.02e-18	Resting heart rate;
BRCA	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg11764359	chr7:65958608	NA	0.63	14.07	0.49	2.32e-39	Aortic root size;
BRCA	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg11301795	chr4:187892539	NA	-0.27	-9.11	-0.34	1.08e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg13010199	chr12:38710504	ALG10B	0.45	9.35	0.35	1.5e-19	Bladder cancer;
BRCA	cis	rs4285028	0.699	rs1344279	chr3:121615679	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.69	-12.09	-0.43	1.99e-30	Multiple sclerosis;
BRCA	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg01884057	chr2:25150051	NA	0.35	9.25	0.34	3.24e-19	Body mass index in non-asthmatics;
BRCA	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	14.38	0.49	8.14e-41	Colorectal cancer;
BRCA	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg06115741	chr20:33292138	TP53INP2	-0.38	-8.43	-0.32	2.22e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6543140	0.964	rs13393175	chr2:103078849	T/G	cg04239558	chr2:103089729	SLC9A4	0.35	9.72	0.36	6.24e-21	Blood protein levels;
BRCA	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	ch.11.42038R	chr11:967971	AP2A2	0.52	16.65	0.55	5.42e-52	Alzheimer's disease (late onset);
BRCA	cis	rs9309711	0.961	rs11678655	chr2:3476234	T/G	cg16153549	chr2:3496821	NA	-0.38	-8.63	-0.32	4.86e-17	Neurofibrillary tangles;
BRCA	cis	rs1371614	0.577	rs877274	chr2:27140099	A/C	cg00617064	chr2:27272375	NA	0.3	7.88	0.3	1.41e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg05340658	chr4:99064831	C4orf37	0.57	11.03	0.4	4.93e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg25237894	chr2:233734115	C2orf82	-0.45	-14.15	-0.49	1.02e-39	Coronary artery disease;
BRCA	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.53	13.42	0.47	2.32e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.84	-0.48	2.8e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg22431228	chr1:16359049	CLCNKA	-0.47	-10.81	-0.39	4.01e-25	Systolic blood pressure;
BRCA	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg01939980	chr4:1354348	KIAA1530	0.31	8.13	0.31	2.29e-15	Obesity-related traits;
BRCA	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg01028140	chr2:1542097	TPO	-0.57	-11.59	-0.42	2.6e-28	IgG glycosylation;
BRCA	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg26384229	chr12:38710491	ALG10B	-0.46	-10.58	-0.39	3.31e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg22903471	chr2:27725779	GCKR	-0.36	-8.73	-0.33	2.29e-17	Total body bone mineral density;
BRCA	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg03146154	chr1:46216737	IPP	0.53	11.75	0.42	5.61e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg24642439	chr20:33292090	TP53INP2	0.41	8.1	0.31	2.71e-15	Height;
BRCA	cis	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg07460842	chr6:66804631	NA	-1.02	-20.25	-0.63	8.06e-71	Exhaled nitric oxide output;
BRCA	cis	rs73001065	0.901	rs73004933	chr19:19675696	C/T	cg03709012	chr19:19516395	GATAD2A	0.86	9.47	0.35	5.16e-20	LDL cholesterol;
BRCA	cis	rs1829883	0.737	rs2548105	chr5:98905292	T/C	cg08333243	chr5:99726346	NA	0.36	8.21	0.31	1.26e-15	Hemostatic factors and hematological phenotypes;
BRCA	trans	rs75804782	0.515	rs79557340	chr2:239297952	G/A	cg01134436	chr17:81009848	B3GNTL1	0.74	7.88	0.3	1.38e-14	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg06671706	chr8:8559999	CLDN23	0.46	8.73	0.33	2.22e-17	Obesity-related traits;
BRCA	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27286337	chr10:134555280	INPP5A	0.66	11.48	0.41	7.52e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2249625	0.874	rs6917386	chr6:72898007	T/C	cg18830697	chr6:72922368	RIMS1	0.37	7.86	0.3	1.63e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg18755752	chr8:142205143	DENND3	-0.47	-11.0	-0.4	6.56e-26	Immature fraction of reticulocytes;
BRCA	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg17063962	chr7:91808500	NA	0.53	12.53	0.44	2.28e-32	Breast cancer;
BRCA	cis	rs1865721	0.771	rs7231277	chr18:73136724	A/G	cg26385618	chr18:73139727	C18orf62	-0.43	-10.64	-0.39	1.88e-24	Intelligence;
BRCA	cis	rs11229555	0.645	rs10896774	chr11:58175837	T/G	cg15696309	chr11:58395628	NA	-0.45	-9.77	-0.36	4.3e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24110177	chr3:50126178	RBM5	0.35	9.65	0.36	1.19e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs10227331	0.934	rs2302447	chr7:157295985	A/T	cg04156418	chr7:157293606	NA	0.37	10.7	0.39	1.1e-24	Inattentive symptoms;
BRCA	trans	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	-0.36	-8.13	-0.31	2.31e-15	Corneal astigmatism;
BRCA	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg06238570	chr21:40685208	BRWD1	-0.4	-8.09	-0.3	3.08e-15	Menarche (age at onset);
BRCA	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.32	-9.64	-0.36	1.3e-20	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg00277334	chr10:82204260	NA	-0.48	-10.1	-0.37	2.42e-22	Post bronchodilator FEV1;
BRCA	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.39	-7.85	-0.3	1.73e-14	Bipolar disorder;
BRCA	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-8.91	-0.33	5.3e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg18479299	chr3:125709523	NA	-0.54	-8.41	-0.32	2.74e-16	Blood pressure (smoking interaction);
BRCA	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg16230307	chr14:35515116	FAM177A1	0.73	15.1	0.51	2.94e-44	Psoriasis;
BRCA	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	10.78	0.39	5.39e-25	Parkinson's disease;
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.4	-7.94	-0.3	9.33e-15	Longevity;Endometriosis;
BRCA	cis	rs11955398	0.716	rs10939862	chr5:60001644	A/C	cg02684056	chr5:59996105	DEPDC1B	-0.41	-10.0	-0.37	5.92e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6435161	1.000	rs72928934	chr2:203562740	A/G	cg18429434	chr2:203499731	FAM117B	-0.44	-8.64	-0.32	4.58e-17	Total cholesterol levels;
BRCA	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg03474202	chr17:45855739	NA	-0.48	-12.64	-0.45	7.39e-33	IgG glycosylation;
BRCA	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg08422745	chr4:174089978	GALNT7	-0.64	-13.38	-0.47	3.7e-36	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg04990556	chr1:26633338	UBXN11	0.54	9.04	0.34	1.79e-18	Obesity-related traits;
BRCA	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11764359	chr7:65958608	NA	0.62	13.47	0.47	1.38e-36	Aortic root size;
BRCA	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg15556689	chr8:8085844	FLJ10661	0.38	9.97	0.37	7.35e-22	Triglycerides;
BRCA	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.16	0.62	2.58e-70	Electrocardiographic conduction measures;
BRCA	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.69	-15.4	-0.52	1.02e-45	Breast cancer;
BRCA	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.37	8.06	0.3	3.85e-15	Platelet count;
BRCA	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-12.07	-0.43	2.38e-30	Morning vs. evening chronotype;
BRCA	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg22907277	chr7:1156413	C7orf50	0.59	8.99	0.34	2.77e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1355223	0.525	rs7129517	chr11:34872236	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-9.34	-0.35	1.58e-19	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.83	0.39	3.26e-25	Rheumatoid arthritis;
BRCA	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.62	-16.38	-0.54	1.27e-50	Fuchs's corneal dystrophy;
BRCA	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg01689657	chr7:91764605	CYP51A1	0.25	9.24	0.34	3.52e-19	Breast cancer;
BRCA	cis	rs7565124	1.000	rs12472043	chr2:20256838	G/A	cg23821541	chr2:20251993	LAPTM4A	0.38	7.98	0.3	6.79e-15	Major depressive disorder;
BRCA	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08280861	chr8:58055591	NA	0.53	8.62	0.32	5.17e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-11.02	-0.4	5.41e-26	Oral cavity cancer;
BRCA	cis	rs3125734	0.572	rs7896627	chr10:64046354	T/G	cg09941381	chr10:64027924	RTKN2	-0.29	-8.04	-0.3	4.37e-15	Rheumatoid arthritis;
BRCA	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.33	0.31	4.94e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9788721	0.836	rs11858836	chr15:78783277	G/A	cg18825076	chr15:78729989	IREB2	-0.44	-8.32	-0.31	5.26e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg18357645	chr12:58087776	OS9	-0.36	-9.41	-0.35	8.78e-20	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg00080972	chr5:178986291	RUFY1	0.4	10.54	0.38	4.66e-24	Lung cancer;
BRCA	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg03684893	chr10:554711	DIP2C	-0.37	-8.2	-0.31	1.31e-15	Psychosis in Alzheimer's disease;
BRCA	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.31	-0.35	2.07e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-12.6	-0.45	1.13e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg12292205	chr6:26970375	C6orf41	0.58	13.03	0.46	1.3600000000000001e-34	Schizophrenia;
BRCA	cis	rs61935443	0.832	rs11107773	chr12:95282000	C/T	cg21533806	chr12:95267307	NA	0.44	8.46	0.32	1.76e-16	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.94e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg24642439	chr20:33292090	TP53INP2	0.69	15.22	0.52	7.38e-45	Coronary artery disease;
BRCA	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg23173402	chr1:227635558	NA	0.51	9.21	0.34	4.66e-19	Major depressive disorder;
BRCA	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02176678	chr2:219576539	TTLL4	0.47	12.19	0.43	7.2e-31	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg03676636	chr4:99064102	C4orf37	0.2	7.94	0.3	9.01e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.74	0.36	5.54e-21	Menopause (age at onset);
BRCA	trans	rs13219787	0.915	rs13214703	chr6:27941387	A/G	cg12734449	chr6:30038004	PPP1R11	0.75	7.92	0.3	1.02e-14	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;
BRCA	cis	rs4706831	0.625	rs638056	chr6:80980808	G/A	cg08355045	chr6:80787529	NA	-0.32	-8.35	-0.31	4.27e-16	Joint mobility (Beighton score);
BRCA	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg17366294	chr4:99064904	C4orf37	0.37	8.76	0.33	1.78e-17	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg27600084	chr12:12264075	NA	0.39	9.21	0.34	4.64e-19	Breast size;
BRCA	trans	rs11088226	0.645	rs11702343	chr21:33937888	C/A	cg09050820	chr6:167586206	TCP10L2	0.7	12.54	0.44	2.17e-32	Gastritis;
BRCA	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18876405	chr7:65276391	NA	-0.51	-11.65	-0.42	1.36e-28	Aortic root size;
BRCA	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg05347473	chr6:146136440	FBXO30	-0.39	-7.9	-0.3	1.23e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6878727	0.626	rs161007	chr5:123680383	C/T	cg01806427	chr5:123737813	NA	-0.37	-8.47	-0.32	1.63e-16	Breast cancer;
BRCA	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg26384229	chr12:38710491	ALG10B	0.66	15.06	0.51	4.47e-44	Bladder cancer;
BRCA	cis	rs9469578	0.710	rs73743330	chr6:33713971	G/A	cg18708504	chr6:33715942	IP6K3	0.7	10.18	0.37	1.12e-22	Phosphorus levels;
BRCA	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg25208724	chr1:156163844	SLC25A44	1.04	34.14	0.8	3.67e-146	Testicular germ cell tumor;
BRCA	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.93	0.3	9.74e-15	Triglycerides;
BRCA	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg04450456	chr4:17643702	FAM184B	0.36	10.63	0.39	2.11e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4478137	0.824	rs4057791	chr4:164225132	A/C	cg06758707	chr4:164254230	NPY1R	0.57	12.31	0.44	2.14e-31	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs13046373	0.535	rs1605428	chr21:32028976	T/C	cg06468780	chr21:31798236	KRTAP13-3	0.35	8.46	0.32	1.89e-16	HDL cholesterol;
BRCA	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg08885076	chr2:99613938	TSGA10	0.43	10.22	0.37	8.29e-23	Chronic sinus infection;
BRCA	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg10523679	chr1:76189770	ACADM	0.77	18.7	0.59	1.48e-62	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg24130564	chr14:104152367	KLC1	-0.41	-8.73	-0.33	2.3e-17	Reticulocyte count;
BRCA	cis	rs250677	0.524	rs417413	chr5:148452726	T/C	cg18129178	chr5:148520854	ABLIM3	-0.48	-10.33	-0.38	2.99e-23	Breast cancer;
BRCA	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.04	-0.43	3.02e-30	Alzheimer's disease;
BRCA	cis	rs72772090	0.522	rs111620024	chr5:95998391	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-8.5	-0.32	1.3e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4974559	0.641	rs28647383	chr4:1312908	G/C	cg02980000	chr4:1222292	CTBP1	0.81	13.33	0.47	6.09e-36	Systolic blood pressure;
BRCA	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg10560079	chr2:191398806	TMEM194B	-0.65	-12.18	-0.43	7.7e-31	Diastolic blood pressure;
BRCA	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg20203395	chr5:56204925	C5orf35	0.41	9.14	0.34	7.96e-19	Initial pursuit acceleration;
BRCA	cis	rs9323205	0.911	rs12587611	chr14:51641399	C/T	cg23942311	chr14:51606299	NA	-0.39	-8.92	-0.33	5.07e-18	Cancer;
BRCA	cis	rs1127311	0.905	rs6699729	chr1:154582896	A/T	cg17218026	chr1:154582156	ADAR	0.28	8.68	0.32	3.27e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
BRCA	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23583168	chr7:148888333	NA	-0.82	-18.48	-0.59	2e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10465746	0.570	rs12402130	chr1:84479838	G/A	cg10977910	chr1:84465055	TTLL7	0.52	10.69	0.39	1.19e-24	Obesity-related traits;
BRCA	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg21045802	chr8:109455806	TTC35	0.36	7.99	0.3	6.36e-15	Dupuytren's disease;
BRCA	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg27490568	chr2:178487706	NA	0.51	8.58	0.32	7.29e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.54	11.14	0.4	1.75e-26	Menarche (age at onset);
BRCA	cis	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg19338460	chr6:170058176	WDR27	-0.46	-8.11	-0.31	2.69e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	trans	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04565464	chr8:145669602	NFKBIL2	0.44	9.94	0.37	9.65e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	14.17	0.49	8.02e-40	Colorectal cancer;
BRCA	cis	rs17023223	0.509	rs61806978	chr1:119713215	A/G	cg05756136	chr1:119680316	WARS2	-0.41	-7.98	-0.3	6.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg06784218	chr1:46089804	CCDC17	-0.43	-10.13	-0.37	1.82e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg06521331	chr12:34319734	NA	-0.62	-12.2	-0.43	6.08e-31	Morning vs. evening chronotype;
BRCA	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	19.29	0.61	1.07e-65	Smoking behavior;
BRCA	cis	rs7072216	0.727	rs942808	chr10:100168102	C/A	cg26618903	chr10:100175079	PYROXD2	-0.31	-8.96	-0.33	3.58e-18	Metabolite levels;
BRCA	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg18225595	chr11:63971243	STIP1	0.4	9.86	0.36	1.89e-21	Platelet count;
BRCA	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-11.21	-0.41	9.24e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg07080220	chr10:102295463	HIF1AN	0.62	14.55	0.5	1.2e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	8.05	0.3	4.09e-15	Diabetic retinopathy;
BRCA	trans	rs72766638	0.806	rs56303154	chr9:136936376	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.63	-9.16	-0.34	7e-19	Mosquito bite size;
BRCA	cis	rs1011018	0.628	rs12155449	chr7:139475320	C/T	cg03224163	chr7:139420300	HIPK2	0.59	8.94	0.33	4.08e-18	Systolic blood pressure;
BRCA	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.77	-19.45	-0.61	1.58e-66	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.19	0.4	1.1e-26	Bipolar disorder;
BRCA	cis	rs6088813	1.000	rs6088823	chr20:33994265	G/T	cg14752227	chr20:34000481	UQCC	-0.43	-9.14	-0.34	7.97e-19	Height;
BRCA	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg03676636	chr4:99064102	C4orf37	0.2	7.81	0.3	2.43e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg23231163	chr10:75533350	FUT11	-0.33	-8.65	-0.32	4.1e-17	Inflammatory bowel disease;
BRCA	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg03146154	chr1:46216737	IPP	0.53	11.89	0.43	1.37e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-16.19	-0.54	1.18e-49	Total cholesterol levels;
BRCA	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12516959	chr21:47718080	NA	-0.42	-9.62	-0.36	1.53e-20	Testicular germ cell tumor;
BRCA	cis	rs477692	0.685	rs3852507	chr10:131399616	G/T	cg24747557	chr10:131355152	MGMT	0.38	9.6	0.36	1.79e-20	Response to temozolomide;
BRCA	cis	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg06521331	chr12:34319734	NA	-0.51	-10.09	-0.37	2.62e-22	Morning vs. evening chronotype;
BRCA	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg06627628	chr2:24431161	ITSN2	-0.5	-8.05	-0.3	4.02e-15	Lymphocyte counts;
BRCA	cis	rs9473147	0.516	rs9381575	chr6:47528764	C/G	cg12968598	chr6:47444699	CD2AP	0.44	9.61	0.36	1.61e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg14926445	chr8:58193284	C8orf71	-0.47	-8.92	-0.33	4.83e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg21659725	chr3:3221576	CRBN	0.36	8.21	0.31	1.18e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.78	-11.25	-0.41	6.26e-27	Schizophrenia;
BRCA	cis	rs7737355	0.947	rs40989	chr5:130992284	T/G	cg06307176	chr5:131281290	NA	0.53	10.39	0.38	1.87e-23	Life satisfaction;
BRCA	cis	rs7091068	0.536	rs6583901	chr10:95409998	C/T	cg20715218	chr10:95462985	C10orf4	-0.56	-10.39	-0.38	1.81e-23	Urinary tract infection frequency;
BRCA	cis	rs10181042	0.514	rs1177283	chr2:61348804	A/G	cg15711740	chr2:61764176	XPO1	-0.38	-8.83	-0.33	9.85e-18	Crohn's disease;
BRCA	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg05347473	chr6:146136440	FBXO30	-0.43	-8.57	-0.32	7.59e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08045932	chr20:61659980	NA	0.5	11.48	0.41	7.29e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	8.54	0.32	9.95e-17	Electroencephalogram traits;
BRCA	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12756686	chr19:29218302	NA	0.58	11.74	0.42	6.06e-29	Methadone dose in opioid dependence;
BRCA	cis	rs17092148	0.887	rs6059916	chr20:33148861	T/G	cg16810054	chr20:33298113	TP53INP2	-0.45	-10.13	-0.37	1.75e-22	Neuroticism;
BRCA	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg25237894	chr2:233734115	C2orf82	-0.38	-10.86	-0.39	2.45e-25	Coronary artery disease;
BRCA	cis	rs8064299	0.597	rs4789097	chr17:72781208	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.65	-20.0	-0.62	1.7e-69	Monocyte count;
BRCA	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23583168	chr7:148888333	NA	-0.85	-19.73	-0.62	4.99e-68	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6942756	0.876	rs2303303	chr7:129019736	G/A	cg02491457	chr7:128862824	NA	-0.61	-12.47	-0.44	4.18e-32	White matter hyperintensity burden;
BRCA	cis	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg06521331	chr12:34319734	NA	-0.56	-10.08	-0.37	2.87e-22	Morning vs. evening chronotype;
BRCA	cis	rs4690686	0.500	rs7667671	chr4:177275599	T/C	cg17059388	chr4:177262070	NA	0.51	10.72	0.39	9.33e-25	Essential tremor;
BRCA	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg27129171	chr3:47204927	SETD2	0.71	16.88	0.56	3.83e-53	Colorectal cancer;
BRCA	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg08754654	chr5:154026448	NA	0.43	9.99	0.37	6.1e-22	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg13010199	chr12:38710504	ALG10B	0.5	10.4	0.38	1.67e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.23	0.31	1.02e-15	Uric acid levels;
BRCA	trans	rs12517041	1.000	rs10066885	chr5:23296872	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs912057	0.585	rs1745341	chr6:6744990	T/C	cg06612196	chr6:6737390	NA	0.46	10.79	0.39	4.81e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	trans	rs6479891	1.000	rs77494594	chr10:65197309	A/C	cg14819942	chr15:35414228	NA	0.35	8.6	0.32	6e-17	Arthritis (juvenile idiopathic);
BRCA	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg15556689	chr8:8085844	FLJ10661	-0.37	-9.26	-0.34	3.07e-19	Retinal vascular caliber;
BRCA	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.85	-0.33	8.34e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg01475735	chr3:40494733	NA	-0.4	-8.19	-0.31	1.47e-15	Renal cell carcinoma;
BRCA	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg11062466	chr8:58055876	NA	0.5	8.72	0.33	2.44e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg19729930	chr2:74357872	NA	0.59	14.48	0.5	2.66e-41	Gestational age at birth (maternal effect);
BRCA	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.84e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03264133	chr6:25882463	NA	0.51	11.35	0.41	2.49e-27	Blood metabolite levels;
BRCA	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg08213375	chr14:104286397	PPP1R13B	0.59	16.49	0.55	3.58e-51	Schizophrenia;
BRCA	cis	rs75229567	0.618	rs11177848	chr12:70180892	A/G	cg10114359	chr12:70132523	RAB3IP	1.13	12.96	0.46	2.8e-34	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
BRCA	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-9.06	-0.34	1.6e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs9324022	0.929	rs72698718	chr14:101178555	G/A	cg18089426	chr14:101175970	NA	0.64	12.18	0.43	7.4e-31	Plateletcrit;
BRCA	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg20933634	chr6:27740509	NA	0.43	8.38	0.31	3.39e-16	Parkinson's disease;
BRCA	cis	rs17092148	1.000	rs6060043	chr20:33364584	C/T	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.26	-0.41	5.82e-27	Neuroticism;
BRCA	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.52	-10.65	-0.39	1.65e-24	Systemic lupus erythematosus;
BRCA	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg00814883	chr7:100076585	TSC22D4	-0.55	-11.83	-0.42	2.48e-29	Platelet count;
BRCA	trans	rs9944715	1.000	rs6507690	chr18:43808597	A/G	cg01718231	chr17:29326311	RNF135	-0.44	-8.59	-0.32	6.9e-17	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.66e-18	Motion sickness;
BRCA	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-8.96	-0.33	3.42e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6684514	1.000	rs10908495	chr1:156263940	T/C	cg16558208	chr1:156270281	VHLL	0.35	8.18	0.31	1.57e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	trans	rs6479891	1.000	rs4746149	chr10:65257393	C/T	cg14819942	chr15:35414228	NA	-0.33	-8.09	-0.3	2.97e-15	Arthritis (juvenile idiopathic);
BRCA	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg05340658	chr4:99064831	C4orf37	0.43	9.84	0.36	2.33e-21	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.68	0.61	9.04e-68	Alzheimer's disease;
BRCA	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.8	0.51	7.85e-43	Colorectal cancer;
BRCA	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	trans	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg25214090	chr10:38739885	LOC399744	0.45	10.3	0.38	4.15e-23	Corneal astigmatism;
BRCA	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg00864171	chr11:67383662	NA	0.4	8.25	0.31	9.18e-16	Mean corpuscular volume;
BRCA	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg18446336	chr7:2847575	GNA12	-0.37	-8.58	-0.32	7.39e-17	Height;
BRCA	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.56	-0.32	8.09e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg10523679	chr1:76189770	ACADM	-0.42	-8.01	-0.3	5.55e-15	Daytime sleep phenotypes;
BRCA	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.14	-0.31	2.05e-15	Total body bone mineral density;
BRCA	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg11166453	chr1:247681781	NA	0.41	9.21	0.34	4.64e-19	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-12.28	-0.44	3e-31	Personality dimensions;
BRCA	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg15704280	chr7:45808275	SEPT13	0.51	8.9	0.33	5.58e-18	Axial length;
BRCA	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg06784218	chr1:46089804	CCDC17	-0.52	-12.34	-0.44	1.54e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg17063962	chr7:91808500	NA	0.52	11.98	0.43	5.41e-30	Breast cancer;
BRCA	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.22	0.31	1.13e-15	Total cholesterol levels;
BRCA	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.88	-16.07	-0.54	4.79e-49	Body mass index;
BRCA	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.19	-0.43	6.89e-31	Breast cancer;
BRCA	cis	rs9649465	1.000	rs7803287	chr7:123354807	T/C	cg04330084	chr7:123175371	IQUB	-0.33	-8.99	-0.34	2.7e-18	Migraine;
BRCA	cis	rs72627123	0.867	rs11848920	chr14:74476866	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.66	7.93	0.3	9.8e-15	Morning vs. evening chronotype;
BRCA	cis	rs813218	0.565	rs4244712	chr3:99679461	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.41	-8.7	-0.33	2.74e-17	Orofacial clefts;
BRCA	trans	rs5756813	0.635	rs11089856	chr22:38205784	A/C	cg19894588	chr14:64061835	NA	-0.55	-11.55	-0.42	3.67e-28	Optic cup area;Vertical cup-disc ratio;
BRCA	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg02503808	chr4:7069936	GRPEL1	0.77	14.68	0.5	2.93e-42	Monocyte percentage of white cells;
BRCA	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg26384229	chr12:38710491	ALG10B	-0.41	-9.5	-0.35	4.18e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7631605	0.935	rs4234259	chr3:37048633	A/G	cg15934958	chr3:37212084	LRRFIP2	0.42	9.58	0.35	2.08e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg00990874	chr7:1149470	C7orf50	0.63	13.47	0.47	1.36e-36	Bronchopulmonary dysplasia;
BRCA	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg09307838	chr4:120376055	NA	0.71	14.77	0.5	1.14e-42	Corneal astigmatism;
BRCA	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.15	-0.37	1.55e-22	Psoriasis;
BRCA	cis	rs7707921	0.767	rs862242	chr5:81587566	C/T	cg15871215	chr5:81402204	ATG10	-0.35	-8.32	-0.31	5.3e-16	Breast cancer;
BRCA	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg09537434	chr19:41945824	ATP5SL	-1.0	-24.49	-0.7	6.73e-94	Height;
BRCA	cis	rs6120849	0.707	rs6120798	chr20:33610822	T/G	cg24642439	chr20:33292090	TP53INP2	0.6	10.36	0.38	2.31e-23	Protein C levels;
BRCA	cis	rs1975991	0.711	rs1479935	chr3:187966711	A/G	cg15417654	chr3:187959138	LPP	0.32	8.17	0.31	1.61e-15	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg16102102	chr5:83017553	HAPLN1	0.74	15.13	0.51	1.91e-44	Prostate cancer;
BRCA	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-14.83	-0.51	5.74e-43	Chronic sinus infection;
BRCA	cis	rs990171	0.607	rs871659	chr2:102771855	C/T	cg22835712	chr2:102737379	NA	0.52	9.56	0.35	2.4e-20	Lymphocyte counts;
BRCA	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg18016565	chr1:150552671	MCL1	0.34	7.81	0.3	2.35e-14	Melanoma;
BRCA	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg08477640	chr19:41863820	B9D2	0.39	8.01	0.3	5.29e-15	Migraine;Coronary artery disease;
BRCA	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07930192	chr7:1003750	NA	0.48	10.57	0.39	3.65e-24	Longevity;Endometriosis;
BRCA	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg21856205	chr7:94953877	PON1	-0.37	-8.65	-0.32	4.02e-17	Paraoxonase activity;
BRCA	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg04586622	chr2:25135609	ADCY3	0.46	11.5	0.41	6.1e-28	Body mass index;
BRCA	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg05347473	chr6:146136440	FBXO30	0.4	8.01	0.3	5.27e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4891159	0.570	rs690132	chr18:74117261	T/C	cg24786174	chr18:74118243	ZNF516	0.84	26.02	0.72	2.36e-102	Longevity;
BRCA	cis	rs13064411	0.696	rs3732803	chr3:113211957	T/C	cg18753928	chr3:113234510	CCDC52	-0.59	-12.34	-0.44	1.56e-31	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg26384229	chr12:38710491	ALG10B	-0.61	-14.36	-0.49	9.65e-41	Morning vs. evening chronotype;
BRCA	cis	rs72772090	0.520	rs56325109	chr5:96112295	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.08	-0.43	2.05e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6700896	0.832	rs11208693	chr1:66108063	C/T	cg04111102	chr1:66153794	NA	0.34	8.44	0.32	2.2e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	12.02	0.43	3.94e-30	Tonsillectomy;
BRCA	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.91	-21.7	-0.65	1.23e-78	Ulcerative colitis;
BRCA	cis	rs6815814	0.950	rs5743560	chr4:38806200	G/T	cg02016764	chr4:38805732	TLR1	-0.61	-9.73	-0.36	5.9e-21	Breast cancer;
BRCA	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg00071950	chr4:10020882	SLC2A9	0.55	13.2	0.46	2.4e-35	Bone mineral density;
BRCA	cis	rs10128251	0.625	rs9424204	chr10:5726376	C/G	cg24097872	chr10:5724021	NA	0.47	10.56	0.39	3.9e-24	Childhood ear infection;
BRCA	cis	rs11971779	0.680	rs1986447	chr7:139082080	G/C	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg18964960	chr10:1102726	WDR37	-0.47	-8.45	-0.32	2.02e-16	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg11752832	chr7:134001865	SLC35B4	0.42	9.94	0.37	9.34e-22	Mean platelet volume;
BRCA	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg24562669	chr7:97807699	LMTK2	0.44	11.74	0.42	5.96e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs754466	0.914	rs12218917	chr10:79701479	C/T	cg17075019	chr10:79541650	NA	-0.64	-12.18	-0.43	7.91e-31	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg11584989	chr19:19387371	SF4	0.49	10.97	0.4	8.7e-26	Bipolar disorder;
BRCA	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-13.94	-0.48	9.13e-39	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg12463550	chr7:65579703	CRCP	0.36	7.82	0.3	2.19e-14	Aortic root size;
BRCA	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg09307838	chr4:120376055	NA	0.63	13.63	0.47	2.52e-37	Corneal astigmatism;
BRCA	cis	rs9486719	0.843	rs2499797	chr6:96848669	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	12.25	0.44	3.7e-31	Migraine;Coronary artery disease;
BRCA	cis	rs7945718	0.781	rs10741604	chr11:12840940	C/A	cg25843174	chr11:12811716	TEAD1	0.22	8.39	0.32	3.09e-16	Educational attainment (years of education);
BRCA	cis	rs6598955	0.502	rs6683157	chr1:26545865	G/A	cg12744634	chr1:26560303	CCDC21	0.3	8.19	0.31	1.48e-15	Obesity-related traits;
BRCA	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg04267008	chr7:1944627	MAD1L1	-0.5	-10.92	-0.4	1.42e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.63	13.65	0.48	2.17e-37	Lymphocyte percentage of white cells;
BRCA	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	13.92	0.48	1.16e-38	Bone mineral density;
BRCA	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg13010199	chr12:38710504	ALG10B	0.51	9.99	0.37	6.41e-22	Morning vs. evening chronotype;
BRCA	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg10523679	chr1:76189770	ACADM	0.91	22.34	0.66	4.07e-82	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs57504626	1	rs57504626	chr19:19720399	C/T	cg03709012	chr19:19516395	GATAD2A	0.76	9.66	0.36	1.08e-20	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
BRCA	cis	rs7727544	0.625	rs4705916	chr5:131407493	C/A	cg14196790	chr5:131705035	SLC22A5	0.38	9.35	0.35	1.4e-19	Blood metabolite levels;
BRCA	cis	rs701145	0.640	rs357495	chr3:153939099	A/G	cg17054900	chr3:154042577	DHX36	0.43	8.18	0.31	1.59e-15	Coronary artery disease;
BRCA	cis	rs870825	0.616	rs28558715	chr4:185627761	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs7246657	0.551	rs12978093	chr19:37584416	C/T	cg23950597	chr19:37808831	NA	-0.64	-9.66	-0.36	1.1e-20	Coronary artery calcification;
BRCA	trans	rs629535	0.814	rs651985	chr8:70054966	G/A	cg21567404	chr3:27674614	NA	1.0	21.21	0.64	5.39e-76	Dupuytren's disease;
BRCA	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg27279351	chr12:120934652	DYNLL1	0.56	13.24	0.46	1.54e-35	High light scatter reticulocyte count;
BRCA	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg08999081	chr20:33150536	PIGU	0.47	13.03	0.46	1.35e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.52	11.22	0.41	8.92e-27	Colorectal cancer;
BRCA	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg18854424	chr1:2615690	NA	-0.33	-7.81	-0.3	2.36e-14	Ulcerative colitis;
BRCA	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg11266682	chr4:10021025	SLC2A9	0.42	10.77	0.39	5.93e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11764359	chr7:65958608	NA	-0.79	-19.5	-0.61	8.84e-67	Aortic root size;
BRCA	cis	rs17401966	0.838	rs1556917	chr1:10400990	G/T	cg19773385	chr1:10388646	KIF1B	-0.35	-7.82	-0.3	2.17e-14	Hepatocellular carcinoma;
BRCA	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.45	-0.35	6.47e-20	Alzheimer's disease;
BRCA	cis	rs13394619	0.655	rs7578132	chr2:11718858	C/T	cg07314298	chr2:11723111	GREB1	-0.42	-9.38	-0.35	1.17e-19	Endometriosis;
BRCA	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.14	0.49	1.04e-39	Eye color traits;
BRCA	cis	rs73086581	1.000	rs6052209	chr20:3961747	G/A	cg02187196	chr20:3869020	PANK2	0.51	9.22	0.34	4.42e-19	Response to antidepressants in depression;
BRCA	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg02574844	chr11:5959923	NA	-0.43	-8.44	-0.32	2.11e-16	DNA methylation (variation);
BRCA	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg03713592	chr11:72463424	ARAP1	0.62	11.08	0.4	3.08e-26	Body mass index;
BRCA	cis	rs9612	1.000	rs346527	chr19:44259361	A/G	cg08581076	chr19:44259116	C19orf61	0.53	9.76	0.36	4.57e-21	Exhaled nitric oxide output;
BRCA	cis	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.29	-0.38	4.53e-23	Morning vs. evening chronotype;
BRCA	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg16586182	chr3:47516702	SCAP	0.54	11.96	0.43	6.69e-30	Colorectal cancer;
BRCA	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg05340658	chr4:99064831	C4orf37	0.62	14.77	0.5	1.09e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg00530320	chr1:46809349	NSUN4	0.49	9.76	0.36	4.52e-21	Menopause (age at onset);
BRCA	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	10.25	0.38	6.08e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.37	8.43	0.32	2.37e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs903263	0.601	rs12746741	chr1:84539576	C/T	cg10977910	chr1:84465055	TTLL7	-0.41	-8.11	-0.31	2.6e-15	Breast cancer (male);
BRCA	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.01	-0.46	1.72e-34	Migraine;Coronary artery disease;
BRCA	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-9.58	-0.35	2.2e-20	Gut microbiome composition (summer);
BRCA	trans	rs11039798	1.000	rs7125913	chr11:48984318	G/A	cg15704280	chr7:45808275	SEPT13	0.6	8.88	0.33	6.55e-18	Axial length;
BRCA	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg06671706	chr8:8559999	CLDN23	0.41	8.08	0.3	3.18e-15	Obesity-related traits;
BRCA	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg26384229	chr12:38710491	ALG10B	-0.43	-10.03	-0.37	4.51e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg24110177	chr3:50126178	RBM5	-0.53	-15.89	-0.53	3.57e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs1832871	0.672	rs1342211	chr6:158759496	G/T	cg07165851	chr6:158734300	TULP4	0.63	12.66	0.45	6.08e-33	Height;
BRCA	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg06618935	chr21:46677482	NA	-0.36	-7.98	-0.3	6.65e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg25173405	chr17:45401733	C17orf57	0.52	11.24	0.41	7.13e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg25358565	chr5:93447407	FAM172A	1.18	17.78	0.58	9.73e-58	Diabetic retinopathy;
BRCA	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.29	9.38	0.35	1.13e-19	Systemic lupus erythematosus;
BRCA	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg14458575	chr2:238380390	NA	0.44	9.92	0.37	1.09e-21	Prostate cancer;
BRCA	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg10174797	chr19:8464628	RAB11B	0.35	9.01	0.34	2.4e-18	HDL cholesterol;
BRCA	cis	rs9807989	0.507	rs1035129	chr2:103019785	T/C	cg03938978	chr2:103052716	IL18RAP	0.29	8.51	0.32	1.25e-16	Asthma;
BRCA	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22509189	chr2:225307070	NA	-0.47	-10.07	-0.37	3.17e-22	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs870825	0.616	rs2090590	chr4:185647850	A/C	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs9296092	0.538	rs75501442	chr6:33519493	A/G	cg13560919	chr6:33536144	NA	-0.85	-18.62	-0.59	3.9e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg08508325	chr11:3079039	CARS	-0.42	-15.01	-0.51	7.5e-44	Longevity;
BRCA	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg24531977	chr5:56204891	C5orf35	-0.4	-8.09	-0.3	3.01e-15	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs9790314	0.628	rs1599381	chr3:160867680	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-13.0	-0.46	1.99e-34	Morning vs. evening chronotype;
BRCA	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg26597838	chr10:835615	NA	1.0	17.38	0.57	1.05e-55	Eosinophil percentage of granulocytes;
BRCA	cis	rs2742234	0.911	rs3004214	chr10:43631698	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.47	-9.3	-0.35	2.2e-19	Hirschsprung disease;
BRCA	cis	rs4535700	0.501	rs6943341	chr7:55975182	A/T	cg09872392	chr7:56161020	PHKG1	0.35	7.98	0.3	6.6e-15	Macular telangiectasia type 2;
BRCA	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	10.01	0.37	5.17e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg07460842	chr6:66804631	NA	0.86	15.43	0.52	6.88e-46	Exhaled nitric oxide levels;
BRCA	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg15839431	chr19:19639596	YJEFN3	-0.44	-8.94	-0.33	4.1e-18	Bipolar disorder;
BRCA	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-23.45	-0.68	3.31e-88	Gut microbiome composition (summer);
BRCA	cis	rs365132	0.875	rs4976665	chr5:176352736	C/T	cg16309518	chr5:176445507	NA	-0.39	-9.67	-0.36	9.9e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg06212747	chr3:49208901	KLHDC8B	0.47	9.56	0.35	2.41e-20	Parkinson's disease;
BRCA	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.45	-0.41	9.66e-28	Mean corpuscular volume;
BRCA	trans	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.78	-0.33	1.47e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs72781680	0.768	rs112139157	chr2:24150783	A/C	cg08917208	chr2:24149416	ATAD2B	0.63	10.68	0.39	1.25e-24	Lymphocyte counts;
BRCA	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg04455712	chr21:45112962	RRP1B	0.44	11.82	0.42	2.69e-29	Mean corpuscular volume;
BRCA	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11890956	chr21:40555474	PSMG1	-0.94	-23.53	-0.68	1.25e-88	Cognitive function;
BRCA	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-14.89	-0.51	2.92e-43	Chronic sinus infection;
BRCA	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg18402987	chr7:1209562	NA	0.78	11.73	0.42	6.37e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg21770322	chr7:97807741	LMTK2	-0.41	-10.98	-0.4	8.06e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg00106254	chr7:1943704	MAD1L1	-0.45	-11.77	-0.42	4.4e-29	Bipolar disorder and schizophrenia;
BRCA	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg16327482	chr19:10226339	EIF3G	-0.39	-10.07	-0.37	3.19e-22	Narcolepsy;
BRCA	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg23029597	chr12:123009494	RSRC2	0.62	11.97	0.43	6e-30	Body mass index;
BRCA	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg10818794	chr15:86012489	AKAP13	-0.3	-8.5	-0.32	1.34e-16	Coronary artery disease;
BRCA	cis	rs1538970	0.847	rs1771550	chr1:45883565	C/T	cg05343316	chr1:45956843	TESK2	-0.54	-11.14	-0.4	1.9e-26	Platelet count;
BRCA	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg12165864	chr7:66369176	NA	-0.44	-9.93	-0.37	1.07e-21	Corneal structure;
BRCA	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	11.29	0.41	4.54e-27	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg09184832	chr6:79620586	NA	-0.52	-11.37	-0.41	2.02e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs11955398	0.716	rs12514253	chr5:59998301	G/A	cg02684056	chr5:59996105	DEPDC1B	0.39	9.26	0.34	2.94e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs1368882	0.814	rs1702020	chr1:55105728	C/T	cg01517571	chr1:55089959	ACOT11;FAM151A	0.43	9.12	0.34	9.66e-19	Non-substance related behavioral disinhibition;
BRCA	cis	rs6942756	0.712	rs6467241	chr7:128997838	A/G	cg02491457	chr7:128862824	NA	-0.6	-12.37	-0.44	1.15e-31	White matter hyperintensity burden;
BRCA	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.06	-0.34	1.53e-18	Total body bone mineral density;
BRCA	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg16339924	chr4:17578868	LAP3	0.54	13.0	0.46	1.89e-34	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.66	-0.32	3.86e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg17675199	chr6:35436792	RPL10A	-0.3	-8.14	-0.31	2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg17507749	chr15:85114479	UBE2QP1	0.55	9.01	0.34	2.37e-18	Schizophrenia;
BRCA	cis	rs9400271	0.527	rs11759230	chr6:109640321	A/C	cg01475377	chr6:109611718	NA	0.36	7.96	0.3	7.82e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg20203395	chr5:56204925	C5orf35	-0.52	-10.93	-0.4	1.26e-25	Initial pursuit acceleration;
BRCA	cis	rs490234	0.702	rs5016056	chr9:128310807	C/T	cg14078157	chr9:128172775	NA	-0.53	-11.58	-0.42	2.68e-28	Mean arterial pressure;
BRCA	cis	rs9942416	0.660	rs4704234	chr5:75001432	A/G	cg19683494	chr5:74908142	NA	0.43	8.37	0.31	3.66e-16	Age-related disease endophenotypes;
BRCA	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.34	0.41	2.88e-27	Electroencephalogram traits;
BRCA	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg00071950	chr4:10020882	SLC2A9	0.57	14.09	0.49	1.89e-39	Bone mineral density;
BRCA	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg11764359	chr7:65958608	NA	-0.66	-12.11	-0.43	1.53e-30	Aortic root size;
BRCA	cis	rs4664304	0.620	rs11675122	chr2:160713446	C/A	cg01092293	chr2:160761427	LY75	0.35	8.29	0.31	6.6e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg20673091	chr1:2541236	MMEL1	0.32	8.44	0.32	2.17e-16	Ulcerative colitis;
BRCA	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg21573476	chr21:45109991	RRP1B	-0.36	-9.03	-0.34	2e-18	Mean corpuscular volume;
BRCA	cis	rs9682041	0.696	rs11927807	chr3:170096623	A/G	cg11886554	chr3:170076028	SKIL	0.51	10.2	0.37	9.77e-23	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs9420	0.890	rs547891	chr11:57499065	C/T	cg19752551	chr11:57585705	CTNND1	0.42	10.79	0.39	4.69e-25	Schizophrenia;
BRCA	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg12310025	chr6:25882481	NA	-0.81	-21.07	-0.64	3.01e-75	Urate levels;
BRCA	cis	rs13064411	0.518	rs7637618	chr3:113176122	G/A	cg18753928	chr3:113234510	CCDC52	-0.4	-9.05	-0.34	1.73e-18	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs12986413	0.624	rs2108825	chr19:2136515	T/C	cg09261902	chr19:2140048	AP3D1	0.41	10.83	0.39	3.16e-25	Height;
BRCA	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.53	-0.32	1.1e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg05519781	chr21:40033154	ERG	0.46	9.83	0.36	2.38e-21	Coronary artery disease;
BRCA	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg06784218	chr1:46089804	CCDC17	0.45	10.78	0.39	4.99e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10463316	0.855	rs13359064	chr5:150765575	G/A	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.32	-0.31	5.39e-16	Metabolite levels (Pyroglutamine);
BRCA	trans	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg19862616	chr7:65841803	NCRNA00174	0.86	28.56	0.75	2.88e-116	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2387326	0.717	rs10829341	chr10:129944226	G/A	cg16087940	chr10:129947807	NA	-0.45	-8.01	-0.3	5.47e-15	Select biomarker traits;
BRCA	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg19274703	chr22:41806451	NA	0.38	9.23	0.34	3.87e-19	Vitiligo;
BRCA	cis	rs7560272	0.501	rs12713798	chr2:73986421	C/T	cg20560298	chr2:73613845	ALMS1	0.34	8.85	0.33	8.36e-18	Schizophrenia;
BRCA	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg27284194	chr4:1044797	NA	0.42	9.13	0.34	8.92e-19	Recombination rate (males);
BRCA	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg06636001	chr8:8085503	FLJ10661	0.47	10.16	0.37	1.43e-22	Mood instability;
BRCA	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg13010199	chr12:38710504	ALG10B	0.45	9.3	0.35	2.21e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.57	-14.06	-0.49	2.66e-39	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg10523679	chr1:76189770	ACADM	0.43	8.01	0.3	5.31e-15	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs72772090	0.908	rs76539796	chr5:96038675	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.54	-11.81	-0.42	3.04e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs8073060	0.586	rs225292	chr17:33926383	G/A	cg19694781	chr19:47549865	TMEM160	-0.81	-16.35	-0.54	1.93e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.75	-0.45	2.44e-33	Migraine;Coronary artery disease;
BRCA	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg22800045	chr5:56110881	MAP3K1	0.46	9.1	0.34	1.14e-18	Initial pursuit acceleration;
BRCA	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg11502198	chr6:26597334	ABT1	0.58	12.69	0.45	4.54e-33	Intelligence (multi-trait analysis);
BRCA	trans	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17712092	chr4:129076599	LARP1B	0.56	13.49	0.47	1.07e-36	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg20203395	chr5:56204925	C5orf35	-0.5	-10.45	-0.38	1.09e-23	Initial pursuit acceleration;
BRCA	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg21138405	chr5:131827807	IRF1	0.39	12.9	0.45	5.51e-34	Asthma (sex interaction);
BRCA	cis	rs7646881	1.000	rs73015649	chr3:158450298	C/G	cg19483011	chr3:158453295	NA	-0.5	-9.38	-0.35	1.09e-19	Tetralogy of Fallot;
BRCA	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg24110177	chr3:50126178	RBM5	0.53	14.86	0.51	3.88e-43	Body mass index;
BRCA	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.57	0.55	1.49e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs727479	0.543	rs4324076	chr15:51510868	A/C	cg19946085	chr15:51559439	CYP19A1	-0.29	-8.03	-0.3	4.64e-15	Estradiol levels;
BRCA	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg08807101	chr21:30365312	RNF160	-0.6	-14.78	-0.5	1.03e-42	Dental caries;
BRCA	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-14.11	-0.49	1.44e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg04362960	chr10:104952993	NT5C2	0.44	10.8	0.39	4.26e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg18252515	chr7:66147081	NA	-0.82	-11.88	-0.43	1.52e-29	Diabetic kidney disease;
BRCA	cis	rs9649213	0.519	rs3735258	chr7:97866291	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.51	-12.88	-0.45	6.4e-34	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg07679836	chr6:33548423	BAK1	0.65	13.86	0.48	2.11e-38	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
BRCA	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.72	0.36	6.67e-21	Bipolar disorder;
BRCA	cis	rs6429082	0.585	rs7524848	chr1:235711688	G/C	cg26050004	chr1:235667680	B3GALNT2	-0.54	-12.65	-0.45	7.1e-33	Adiposity;
BRCA	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg06917634	chr15:78832804	PSMA4	-0.6	-13.27	-0.46	1.15e-35	Sudden cardiac arrest;
BRCA	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg01017244	chr2:74357527	NA	0.56	13.4	0.47	2.77e-36	Gestational age at birth (maternal effect);
BRCA	cis	rs8017423	0.647	rs1958346	chr14:90824011	G/T	cg04374321	chr14:90722782	PSMC1	-0.49	-11.86	-0.42	1.75e-29	Mortality in heart failure;
BRCA	cis	rs4566357	0.615	rs2894626	chr2:227916039	T/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.53	-0.35	3.26e-20	Coronary artery disease;
BRCA	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg06238570	chr21:40685208	BRWD1	-0.43	-8.52	-0.32	1.18e-16	Cognitive function;
BRCA	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.95	-0.3	8.4e-15	Depression;
BRCA	cis	rs7633770	0.710	rs34820891	chr3:46698059	A/G	cg11219411	chr3:46661640	NA	-0.45	-10.6	-0.39	2.6e-24	Coronary artery disease;
BRCA	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg23711669	chr6:146136114	FBXO30	-0.77	-17.93	-0.58	1.6e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg10556349	chr10:835070	NA	0.74	9.99	0.37	6.24e-22	Eosinophil percentage of granulocytes;
BRCA	cis	rs17601876	0.814	rs8038715	chr15:51561120	T/A	cg19946085	chr15:51559439	CYP19A1	-0.38	-11.48	-0.41	7.14e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg10523679	chr1:76189770	ACADM	-0.45	-8.23	-0.31	1.04e-15	Daytime sleep phenotypes;
BRCA	cis	rs752010	1.000	rs4999015	chr1:42093547	G/A	cg06885757	chr1:42089581	HIVEP3	0.27	9.66	0.36	1.11e-20	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg01528321	chr10:82214614	TSPAN14	0.85	19.04	0.6	2.32e-64	Post bronchodilator FEV1;
BRCA	cis	rs12612619	0.732	rs6547355	chr2:27210205	G/A	cg00617064	chr2:27272375	NA	-0.32	-8.49	-0.32	1.45e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs16976116	0.901	rs28714578	chr15:55491121	G/A	cg11288833	chr15:55489084	RSL24D1	0.47	10.58	0.39	3.25e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg01181863	chr3:195395398	SDHAP2	-0.46	-8.08	-0.3	3.27e-15	Pancreatic cancer;
BRCA	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.81	-0.33	1.22e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg12373951	chr3:133503437	NA	0.34	8.1	0.31	2.73e-15	Iron status biomarkers;
BRCA	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg01262667	chr19:19385393	TM6SF2	0.42	10.67	0.39	1.49e-24	Tonsillectomy;
BRCA	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg04362960	chr10:104952993	NT5C2	0.94	14.64	0.5	4.47e-42	Arsenic metabolism;
BRCA	cis	rs887829	0.641	rs10197460	chr2:234589190	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.36	-0.31	3.96e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg05340658	chr4:99064831	C4orf37	0.55	10.86	0.39	2.45e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg08085267	chr17:45401833	C17orf57	0.59	12.38	0.44	1.08e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg10932868	chr11:921992	NA	0.49	12.63	0.45	8.39e-33	Alzheimer's disease (late onset);
BRCA	cis	rs2580764	0.503	rs2972097	chr2:55267545	T/C	cg09592903	chr2:55203963	RTN4	0.3	7.82	0.3	2.11e-14	Mean platelet volume;
BRCA	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.7	13.85	0.48	2.52e-38	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg12641515	chr19:46296257	DMWD	-0.52	-11.46	-0.41	8.91e-28	Coronary artery disease;
BRCA	cis	rs12760731	0.720	rs12048790	chr1:178407906	T/C	cg00404053	chr1:178313656	RASAL2	0.61	7.92	0.3	1.09e-14	Obesity-related traits;
BRCA	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.51	0.32	1.26e-16	Cognitive ability;
BRCA	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg05340658	chr4:99064831	C4orf37	0.7	17.34	0.57	1.69e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg12444411	chr7:2802554	GNA12	0.31	7.92	0.3	1.08e-14	Height;
BRCA	cis	rs75804782	0.641	rs56396448	chr2:239335234	C/T	cg18131467	chr2:239335373	ASB1	-0.61	-7.9	-0.3	1.27e-14	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.72e-22	Bladder cancer;
BRCA	cis	rs12618769	0.597	rs3769716	chr2:99133305	G/A	cg10123293	chr2:99228465	UNC50	0.42	8.1	0.31	2.81e-15	Bipolar disorder;
BRCA	cis	rs2555155	0.602	rs2555143	chr11:6541580	G/T	cg24637308	chr11:6592297	DNHD1	-0.34	-7.82	-0.3	2.14e-14	DNA methylation (variation);
BRCA	cis	rs4285028	0.948	rs34566912	chr3:121679626	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.8	-0.39	4.29e-25	Multiple sclerosis;
BRCA	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg05527609	chr1:210001259	C1orf107	0.73	18.16	0.58	9.37e-60	Orofacial clefts;
BRCA	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg23788917	chr6:8435910	SLC35B3	-0.43	-9.27	-0.34	2.91e-19	Motion sickness;
BRCA	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg06494592	chr3:125709126	NA	-0.54	-8.33	-0.31	4.81e-16	Blood pressure (smoking interaction);
BRCA	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg17691542	chr6:26056736	HIST1H1C	0.47	9.48	0.35	4.93e-20	Height;
BRCA	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-8.84	-0.33	9.58e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9473147	0.516	rs13212790	chr6:47576367	T/C	cg12968598	chr6:47444699	CD2AP	0.44	9.62	0.36	1.56e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03934478	chr11:495069	RNH1	0.81	11.62	0.42	1.82e-28	Body mass index;
BRCA	trans	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	20.74	0.63	1.96e-73	Exhaled nitric oxide output;
BRCA	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg12179176	chr11:130786555	SNX19	0.67	16.32	0.54	2.53e-50	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-10.67	-0.39	1.37e-24	Gut microbiome composition (summer);
BRCA	cis	rs6558530	0.799	rs62477060	chr8:1706498	A/T	cg19131313	chr8:1704013	NA	-0.36	-7.87	-0.3	1.55e-14	Systolic blood pressure;
BRCA	cis	rs7945718	0.839	rs2033908	chr11:12838286	G/T	cg25843174	chr11:12811716	TEAD1	0.21	8.09	0.3	3.1e-15	Educational attainment (years of education);
BRCA	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg27211696	chr2:191398769	TMEM194B	0.48	7.92	0.3	1.02e-14	Diastolic blood pressure;
BRCA	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg26248373	chr2:1572462	NA	0.5	9.72	0.36	6.33e-21	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.3	0.41	3.86e-27	Electroencephalogram traits;
BRCA	cis	rs2580764	0.515	rs7570629	chr2:55255935	A/T	cg09592903	chr2:55203963	RTN4	-0.39	-9.98	-0.37	6.9e-22	Mean platelet volume;
BRCA	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg24069376	chr3:38537580	EXOG	0.43	12.31	0.44	2.04e-31	Electrocardiographic conduction measures;
BRCA	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.18	-0.31	1.58e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg07414643	chr4:187882934	NA	0.28	9.72	0.36	6.36e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg17330251	chr7:94953956	PON1	-0.4	-8.4	-0.32	2.93e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg19678392	chr7:94953810	PON1	-0.42	-9.11	-0.34	1.03e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg22349387	chr12:9600060	DDX12	-0.39	-9.03	-0.34	2.05e-18	Breast size;
BRCA	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg14403583	chr14:105418241	AHNAK2	-0.38	-8.94	-0.33	4.19e-18	Rheumatoid arthritis;
BRCA	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg20607798	chr8:58055168	NA	0.46	8.04	0.3	4.35e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg03433033	chr1:76189801	ACADM	0.88	23.02	0.67	7.52e-86	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg20387954	chr3:183756860	HTR3D	0.46	10.34	0.38	2.8e-23	Anterior chamber depth;
BRCA	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.24	0.41	6.88e-27	Bipolar disorder;
BRCA	cis	rs17095355	1.000	rs12267714	chr10:111722052	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.8	-0.36	3.16e-21	Biliary atresia;
BRCA	cis	rs507080	0.922	rs625513	chr11:118555719	A/C	cg08498647	chr11:118550644	TREH	-0.38	-8.14	-0.31	2.1e-15	Serum metabolite levels;
BRCA	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg24558204	chr6:135376177	HBS1L	0.54	14.97	0.51	1.19e-43	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg07636037	chr3:49044803	WDR6	0.4	8.2	0.31	1.33e-15	Resting heart rate;
BRCA	cis	rs6582630	0.538	rs12304844	chr12:38335870	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.45	-0.35	6.24e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	11.81	0.42	3.01e-29	Personality dimensions;
BRCA	cis	rs2421770	0.530	rs3901811	chr11:35365675	C/T	cg13971030	chr11:35366721	SLC1A2	-0.45	-10.12	-0.37	1.94e-22	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg14983838	chr19:29218262	NA	0.53	8.87	0.33	7.27e-18	Methadone dose in opioid dependence;
BRCA	cis	rs4363385	0.658	rs426147	chr1:153045011	G/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.04	-0.3	4.26e-15	Inflammatory skin disease;
BRCA	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18876405	chr7:65276391	NA	-0.5	-11.15	-0.4	1.6e-26	Aortic root size;
BRCA	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.61e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg25174290	chr11:3078921	CARS	-0.3	-7.87	-0.3	1.58e-14	Calcium levels;
BRCA	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg16482183	chr6:26056742	HIST1H1C	0.43	8.46	0.32	1.89e-16	Iron status biomarkers;
BRCA	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg20503657	chr10:835505	NA	1.05	18.77	0.6	5.82e-63	Eosinophil percentage of granulocytes;
BRCA	trans	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg17145862	chr1:211918768	LPGAT1	0.63	16.12	0.54	2.61e-49	Leprosy;
BRCA	cis	rs1691799	0.899	rs1168318	chr12:66745269	A/G	cg16791601	chr12:66731901	HELB	0.64	17.63	0.57	5.82e-57	White blood cell count (basophil);
BRCA	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg18402987	chr7:1209562	NA	0.84	11.92	0.43	9.85e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24549020	chr5:56110836	MAP3K1	0.64	12.98	0.46	2.41e-34	Initial pursuit acceleration;
BRCA	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.12	-0.34	1e-18	Bipolar disorder;
BRCA	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21659725	chr3:3221576	CRBN	-0.35	-8.7	-0.33	2.74e-17	Body mass index;
BRCA	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg18904891	chr8:8559673	CLDN23	0.65	12.97	0.46	2.56e-34	Obesity-related traits;
BRCA	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg06784218	chr1:46089804	CCDC17	-0.48	-11.43	-0.41	1.2e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11958404	0.932	rs61478293	chr5:157426299	G/A	cg05962755	chr5:157440814	NA	0.49	9.67	0.36	1.02e-20	IgG glycosylation;
BRCA	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	10.03	0.37	4.55e-22	Retinal vascular caliber;
BRCA	cis	rs6910061	0.830	rs35281611	chr6:11103232	G/T	cg27233058	chr6:11094804	LOC221710	0.5	8.32	0.31	5.21e-16	Diabetic kidney disease;
BRCA	cis	rs2463822	0.920	rs28678254	chr11:62151875	G/C	cg06239285	chr11:62104954	ASRGL1	-0.64	-9.24	-0.34	3.66e-19	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg02734326	chr4:10020555	SLC2A9	0.39	8.48	0.32	1.61e-16	Bone mineral density;
BRCA	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-12.28	-0.44	2.95e-31	Bipolar disorder;
BRCA	cis	rs870825	0.587	rs6826883	chr4:185616167	A/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.17	0.56	1.32e-54	Blood protein levels;
BRCA	cis	rs6714710	0.603	rs1470483	chr2:98393894	C/T	cg26665480	chr2:98280029	ACTR1B	0.66	14.7	0.5	2.44e-42	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg11822812	chr5:140052017	DND1	-0.29	-7.86	-0.3	1.67e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg12483005	chr1:23474871	LUZP1	0.44	9.77	0.36	4.13e-21	Height;
BRCA	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg05283184	chr6:79620031	NA	-0.43	-10.88	-0.4	2.01e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs881375	0.967	rs3761849	chr9:123690957	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	11.33	0.41	3.18e-27	Rheumatoid arthritis;
BRCA	cis	rs17095355	1.000	rs57440982	chr10:111735772	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.37	-9.19	-0.34	5.56e-19	Biliary atresia;
BRCA	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg18016565	chr1:150552671	MCL1	0.34	7.88	0.3	1.39e-14	Melanoma;
BRCA	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg05340658	chr4:99064831	C4orf37	0.7	17.48	0.57	3.14e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg21475434	chr5:93447410	FAM172A	0.66	8.48	0.32	1.51e-16	Diabetic retinopathy;
BRCA	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg04166393	chr7:2884313	GNA12	0.48	8.92	0.33	5.02e-18	Height;
BRCA	trans	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg25214090	chr10:38739885	LOC399744	0.51	11.56	0.42	3.34e-28	Corneal astigmatism;
BRCA	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-9.73	-0.36	5.71e-21	IgG glycosylation;
BRCA	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg23711669	chr6:146136114	FBXO30	-0.79	-18.4	-0.59	5.66e-61	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg23649088	chr2:200775458	C2orf69	-0.58	-8.76	-0.33	1.81e-17	Schizophrenia;
BRCA	trans	rs8002861	0.713	rs7339417	chr13:44413496	A/T	cg17145862	chr1:211918768	LPGAT1	0.47	10.61	0.39	2.37e-24	Leprosy;
BRCA	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg09904177	chr6:26538194	HMGN4	0.56	18.45	0.59	3.08e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg06784218	chr1:46089804	CCDC17	0.46	10.91	0.4	1.6e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4074536	0.574	rs4564143	chr1:116293963	A/G	cg21648376	chr1:116311395	CASQ2	-0.49	-8.44	-0.32	2.12e-16	QRS duration;
BRCA	cis	rs3784262	0.669	rs4646559	chr15:58354258	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-10.41	-0.38	1.52e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg17063962	chr7:91808500	NA	0.58	13.75	0.48	7.25e-38	Breast cancer;
BRCA	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg20637307	chr2:213403960	ERBB4	0.74	21.48	0.65	1.94e-77	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg08885076	chr2:99613938	TSGA10	0.41	9.63	0.36	1.4e-20	Chronic sinus infection;
BRCA	cis	rs7903847	0.642	rs2275090	chr10:99148151	A/G	cg08345082	chr10:99160200	RRP12	-0.29	-8.57	-0.32	7.87e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg11247378	chr22:39784982	NA	0.66	16.11	0.54	2.9e-49	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg05084668	chr3:125655381	ALG1L	-0.61	-11.85	-0.42	2.09e-29	Blood pressure (smoking interaction);
BRCA	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg08755490	chr11:65554678	OVOL1	0.55	11.45	0.41	9.95e-28	Acne (severe);
BRCA	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	8.9	0.33	5.6e-18	Aortic root size;
BRCA	cis	rs849141	1.000	rs849141	chr7:28185091	C/T	cg22892036	chr7:28189139	JAZF1	-0.47	-8.48	-0.32	1.58e-16	Height;Hip circumference adjusted for BMI;
BRCA	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg22920501	chr2:26401640	FAM59B	0.72	12.27	0.44	3.22e-31	Gut microbiome composition (summer);
BRCA	cis	rs7766436	0.610	rs13195654	chr6:22601416	C/G	cg13666174	chr6:22585274	NA	-0.38	-8.87	-0.33	7.19e-18	Coronary artery disease;
BRCA	cis	rs10046574	0.831	rs77263000	chr7:135099419	C/T	cg27474649	chr7:135195673	CNOT4	0.58	8.33	0.31	5.1e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs600806	0.850	rs10776807	chr1:109956156	A/G	cg20591472	chr1:110008990	SYPL2	-0.34	-8.59	-0.32	6.49e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	15.42	0.52	7.42e-46	Mood instability;
BRCA	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg17470723	chr8:74884337	TCEB1	0.4	8.66	0.32	3.82e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-17.61	-0.57	7.09e-57	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11644478	chr21:40555479	PSMG1	0.82	18.54	0.59	1.05e-61	Cognitive function;
BRCA	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.46	-0.52	5.12e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12756686	chr19:29218302	NA	0.56	11.64	0.42	1.5e-28	Methadone dose in opioid dependence;
BRCA	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg27398817	chr8:82754497	SNX16	-0.37	-8.55	-0.32	8.8e-17	Diastolic blood pressure;
BRCA	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.44	0.38	1.1e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg09436375	chr6:42928200	GNMT	-0.3	-10.99	-0.4	7.31e-26	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg24562669	chr7:97807699	LMTK2	0.62	18.68	0.59	1.78e-62	Breast cancer;
BRCA	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11764359	chr7:65958608	NA	0.75	16.95	0.56	1.7e-53	Aortic root size;
BRCA	trans	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg25214090	chr10:38739885	LOC399744	0.53	11.6	0.42	2.35e-28	Corneal astigmatism;
BRCA	cis	rs6546886	0.957	rs11886928	chr2:74258529	T/G	cg14702570	chr2:74259524	NA	-0.32	-8.21	-0.31	1.22e-15	Dialysis-related mortality;
BRCA	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	ch.11.42038R	chr11:967971	AP2A2	-0.51	-15.61	-0.53	9.03e-47	Alzheimer's disease (late onset);
BRCA	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg18270830	chr10:32634957	EPC1	0.58	10.06	0.37	3.34e-22	Sexual dysfunction (female);
BRCA	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg20387954	chr3:183756860	HTR3D	0.45	10.28	0.38	4.88e-23	Anterior chamber depth;
BRCA	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-10.18	-0.37	1.21e-22	Personality dimensions;
BRCA	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	ch.11.42038R	chr11:967971	AP2A2	0.55	17.89	0.58	2.6e-58	Alzheimer's disease (late onset);
BRCA	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg05343316	chr1:45956843	TESK2	-0.55	-11.03	-0.4	4.98e-26	Platelet count;
BRCA	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg08470875	chr2:26401718	FAM59B	0.77	12.02	0.43	3.96e-30	Gut microbiome composition (summer);
BRCA	cis	rs8028182	0.636	rs11636199	chr15:75825337	A/G	cg20655648	chr15:75932815	IMP3	0.4	7.88	0.3	1.43e-14	Sudden cardiac arrest;
BRCA	cis	rs2235642	0.533	rs9922661	chr16:1605163	C/A	cg03034668	chr16:1723424	CRAMP1L	-0.5	-10.75	-0.39	6.87e-25	Coronary artery disease;
BRCA	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.65	-14.76	-0.5	1.2e-42	Breast cancer;
BRCA	cis	rs72772090	0.539	rs72773923	chr5:96117579	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.18	-0.43	7.64e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2882667	0.654	rs700626	chr5:138117938	A/G	cg04439458	chr5:138467593	SIL1	0.33	8.12	0.31	2.36e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7729447	0.776	rs17540155	chr5:32694033	C/T	cg16267343	chr5:32710456	NPR3	0.44	9.06	0.34	1.6e-18	Blood pressure;
BRCA	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg07606381	chr6:8435919	SLC35B3	-0.64	-13.92	-0.48	1.21e-38	Motion sickness;
BRCA	cis	rs4663969	0.541	rs11902131	chr2:234594269	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.38	-0.31	3.32e-16	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg08470875	chr2:26401718	FAM59B	-0.51	-8.29	-0.31	6.69e-16	Gut microbiome composition (summer);
BRCA	cis	rs4853036	1.000	rs35084691	chr2:70094137	C/T	cg02498382	chr2:70120550	SNRNP27	-0.5	-9.14	-0.34	8.14e-19	Colorectal or endometrial cancer;
BRCA	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg08807101	chr21:30365312	RNF160	0.77	20.54	0.63	2.13e-72	Dental caries;
BRCA	cis	rs490234	0.812	rs17259739	chr9:128456639	C/T	cg14078157	chr9:128172775	NA	0.41	9.08	0.34	1.31e-18	Mean arterial pressure;
BRCA	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg13010199	chr12:38710504	ALG10B	-0.48	-9.4	-0.35	9.48e-20	Morning vs. evening chronotype;
BRCA	cis	rs7512552	0.809	rs696618	chr1:150376139	T/G	cg15654264	chr1:150340011	RPRD2	0.4	8.77	0.33	1.66e-17	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg24069376	chr3:38537580	EXOG	-0.34	-9.45	-0.35	6.53e-20	Electrocardiographic conduction measures;
BRCA	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-11.67	-0.42	1.13e-28	Mood instability;
BRCA	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg20307385	chr11:47447363	PSMC3	0.82	21.33	0.64	1.28e-76	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg11812906	chr14:75593930	NEK9	-0.59	-12.9	-0.45	5.39e-34	Height;
BRCA	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-9.59	-0.35	1.95e-20	Gut microbiome composition (summer);
BRCA	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.23	-0.38	7.48e-23	Psoriasis;
BRCA	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg19784903	chr17:45786737	TBKBP1	0.34	8.16	0.31	1.72e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4409675	0.576	rs2749110	chr1:28235010	T/C	cg23691781	chr1:28212827	C1orf38	0.32	10.61	0.39	2.47e-24	Corneal astigmatism;
BRCA	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.62	-0.36	1.51e-20	Total body bone mineral density;
BRCA	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-7.91	-0.3	1.16e-14	Axial length;
BRCA	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg09307838	chr4:120376055	NA	0.63	13.62	0.47	2.93e-37	Corneal astigmatism;
BRCA	cis	rs2075371	0.871	rs418135	chr7:133949898	A/G	cg02659138	chr7:134003124	SLC35B4	0.33	10.09	0.37	2.62e-22	Mean platelet volume;
BRCA	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg10818794	chr15:86012489	AKAP13	-0.31	-8.58	-0.32	7.38e-17	Coronary artery disease;
BRCA	trans	rs208520	0.690	rs207119	chr6:66786408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.23	-0.64	4.44e-76	Exhaled nitric oxide output;
BRCA	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg00080972	chr5:178986291	RUFY1	-0.47	-12.77	-0.45	1.99e-33	Lung cancer;
BRCA	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.17	-0.31	1.59e-15	Bipolar disorder;
BRCA	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg21770322	chr7:97807741	LMTK2	0.45	11.74	0.42	5.76e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7654585	1.000	rs4692025	chr4:25949759	A/C	cg10409131	chr4:25915609	C4orf52	-0.37	-8.23	-0.31	1.08e-15	Obesity-related traits;
BRCA	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg13010199	chr12:38710504	ALG10B	0.52	10.55	0.39	4.1e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg15395560	chr15:45543142	SLC28A2	0.29	7.99	0.3	6.43e-15	Glomerular filtration rate;
BRCA	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg17971929	chr21:40555470	PSMG1	0.7	14.67	0.5	3.41e-42	Cognitive function;
BRCA	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg21132104	chr15:45694354	SPATA5L1	0.75	16.89	0.56	3.4e-53	Homoarginine levels;
BRCA	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg03433033	chr1:76189801	ACADM	-0.59	-11.81	-0.42	2.98e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23583168	chr7:148888333	NA	-0.79	-18.7	-0.59	1.48e-62	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg05340658	chr4:99064831	C4orf37	0.61	14.63	0.5	5.37e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17620991	1.000	rs67648979	chr7:40851735	T/C	cg05119115	chr7:40866195	C7orf10	-0.56	-8.67	-0.32	3.66e-17	Alcohol dependence;
BRCA	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg12386194	chr3:101231763	SENP7	0.46	9.65	0.36	1.13e-20	Colorectal cancer;
BRCA	cis	rs2859741	0.546	rs3845491	chr1:37497521	C/T	cg09363841	chr1:37513479	NA	-0.53	-11.53	-0.41	4.55e-28	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg10862848	chr6:42927986	GNMT	-0.34	-14.5	-0.5	2.09e-41	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg27170947	chr2:26402098	FAM59B	-0.64	-11.37	-0.41	2.02e-27	Gut microbiome composition (summer);
BRCA	cis	rs9341808	0.935	rs942381	chr6:80880150	T/G	cg08355045	chr6:80787529	NA	0.33	8.5	0.32	1.36e-16	Sitting height ratio;
BRCA	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg06784218	chr1:46089804	CCDC17	0.46	10.9	0.4	1.78e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg22800045	chr5:56110881	MAP3K1	0.65	12.22	0.44	5.19e-31	Initial pursuit acceleration;
BRCA	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.82	-0.45	1.15e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3784262	0.542	rs2899611	chr15:58327347	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.4	-10.55	-0.39	4.24e-24	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg07460842	chr6:66804631	NA	-1.02	-19.97	-0.62	2.53e-69	Exhaled nitric oxide output;
BRCA	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg02659138	chr7:134003124	SLC35B4	0.33	10.38	0.38	1.95e-23	Mean platelet volume;
BRCA	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg00701064	chr4:6280414	WFS1	0.69	19.26	0.61	1.61e-65	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs10056811	0.538	rs4703645	chr5:74361140	A/G	cg19683494	chr5:74908142	NA	0.58	8.76	0.33	1.69e-17	Coronary artery disease;
BRCA	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.36	12.02	0.43	3.79e-30	Bipolar disorder;
BRCA	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg16743903	chr16:89593216	SPG7	-0.31	-7.81	-0.3	2.35e-14	Multiple myeloma (IgH translocation);
BRCA	trans	rs61931739	0.513	rs7956626	chr12:33901640	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.9	0.36	1.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-8.56	-0.32	8.55e-17	Alzheimer's disease (late onset);
BRCA	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg04450456	chr4:17643702	FAM184B	-0.38	-11.24	-0.41	7.26e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12973672	1.000	rs12975284	chr19:35770962	G/C	cg12095397	chr19:35769544	USF2	0.38	8.38	0.31	3.28e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg16606324	chr3:10149918	C3orf24	0.57	10.04	0.37	3.9e-22	Alzheimer's disease;
BRCA	cis	rs73086581	1.000	rs73086581	chr20:3977325	T/C	cg02187196	chr20:3869020	PANK2	0.53	9.16	0.34	6.95e-19	Response to antidepressants in depression;
BRCA	cis	rs1949733	0.543	rs62287446	chr4:8535988	G/A	cg11789530	chr4:8429930	ACOX3	-0.5	-11.75	-0.42	5.52e-29	Response to antineoplastic agents;
BRCA	cis	rs17095355	1.000	rs75079039	chr10:111745121	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.43	-9.1	-0.34	1.16e-18	Biliary atresia;
BRCA	cis	rs4074536	0.574	rs9887853	chr1:116288027	G/T	cg21648376	chr1:116311395	CASQ2	-0.49	-8.68	-0.32	3.25e-17	QRS duration;
BRCA	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	13.89	0.48	1.53e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs250677	0.522	rs4562031	chr5:148368451	A/G	cg12140854	chr5:148520817	ABLIM3	0.39	7.89	0.3	1.33e-14	Breast cancer;
BRCA	cis	rs4664304	0.620	rs1828480	chr2:160720384	G/A	cg18514922	chr2:160761262	LY75	0.33	7.89	0.3	1.29e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg10845886	chr2:3471009	TTC15	-0.55	-12.27	-0.44	3.1e-31	Neurofibrillary tangles;
BRCA	cis	rs7246657	0.722	rs2972437	chr19:38210511	G/T	cg18154014	chr19:37997991	ZNF793	0.49	9.41	0.35	8.47e-20	Coronary artery calcification;
BRCA	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg24675658	chr1:53192096	ZYG11B	0.63	15.14	0.51	1.84e-44	Monocyte count;
BRCA	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.68	-15.51	-0.52	2.8600000000000002e-46	Multiple sclerosis;
BRCA	cis	rs912330	0.825	rs7317938	chr13:99234361	C/T	cg07423050	chr13:99094983	FARP1	-0.34	-7.99	-0.3	6.31e-15	Alzheimer's disease;
BRCA	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07308232	chr7:1071921	C7orf50	-0.5	-10.56	-0.39	4.01e-24	Longevity;Endometriosis;
BRCA	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg18811423	chr2:55921094	PNPT1	0.74	23.24	0.68	4.43e-87	Metabolic syndrome;
BRCA	cis	rs4730250	0.707	rs78472146	chr7:106967491	C/A	cg02696742	chr7:106810147	HBP1	-0.54	-8.74	-0.33	2.03e-17	Osteoarthritis;
BRCA	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg14092571	chr14:90743983	NA	0.34	8.22	0.31	1.11e-15	Mortality in heart failure;
BRCA	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg15704280	chr7:45808275	SEPT13	0.63	11.24	0.41	6.97e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.81	0.39	3.9e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11229555	0.645	rs11229436	chr11:58186009	G/A	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11955398	0.585	rs2100584	chr5:60021487	C/G	cg02684056	chr5:59996105	DEPDC1B	-0.38	-9.13	-0.34	8.56e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg20891558	chr2:74357851	NA	0.51	11.99	0.43	5.06e-30	Gestational age at birth (maternal effect);
BRCA	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg23950597	chr19:37808831	NA	-0.65	-11.6	-0.42	2.38e-28	Coronary artery calcification;
BRCA	cis	rs528301	0.868	rs518853	chr2:45141218	A/G	cg02372786	chr2:45167549	SIX3	0.43	10.47	0.38	8.73e-24	Alcohol and nicotine co-dependence;
BRCA	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.86	-0.39	2.49e-25	Mean corpuscular volume;
BRCA	cis	rs13095912	0.752	rs7613002	chr3:185353235	T/C	cg11274856	chr3:185301563	NA	0.51	11.85	0.42	1.96e-29	Systolic blood pressure;
BRCA	trans	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg25214090	chr10:38739885	LOC399744	0.56	12.31	0.44	2.14e-31	Corneal astigmatism;
BRCA	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg26384229	chr12:38710491	ALG10B	0.81	20.39	0.63	1.52e-71	Heart rate;
BRCA	cis	rs6545883	0.859	rs2694644	chr2:61604856	A/T	cg15711740	chr2:61764176	XPO1	0.5	12.06	0.43	2.5e-30	Tuberculosis;
BRCA	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg06026331	chr20:60912101	LAMA5	0.63	13.17	0.46	3.09e-35	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg02221750	chr19:17393354	ANKLE1	0.65	12.49	0.44	3.52e-32	Systemic lupus erythematosus;
BRCA	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.81	-0.3	2.3e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg18512352	chr11:47633146	NA	-0.33	-7.9	-0.3	1.23e-14	Subjective well-being;
BRCA	cis	rs12618769	0.597	rs4599165	chr2:99144483	G/A	cg10123293	chr2:99228465	UNC50	0.42	8.1	0.31	2.81e-15	Bipolar disorder;
BRCA	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg06064525	chr11:970664	AP2A2	0.48	16.2	0.54	1.02e-49	Alzheimer's disease (late onset);
BRCA	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-9.79	-0.36	3.58e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12310025	chr6:25882481	NA	-0.53	-11.84	-0.42	2.16e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.39	9.84	0.36	2.22e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs12367572	0.930	rs10880695	chr12:45233261	T/C	cg04608330	chr12:45269318	NELL2	-0.61	-12.75	-0.45	2.53e-33	Gut microbiome composition (summer);
BRCA	cis	rs56804039	1.000	rs67180327	chr8:8380754	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-9.19	-0.34	5.42e-19	Cervical cancer;
BRCA	cis	rs7617773	0.780	rs34523942	chr3:48342669	C/T	cg11946769	chr3:48343235	NME6	0.64	13.73	0.48	8.98e-38	Coronary artery disease;
BRCA	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06481639	chr22:41940642	POLR3H	-0.53	-8.77	-0.33	1.64e-17	Vitiligo;
BRCA	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg15485101	chr11:133734466	NA	0.41	9.87	0.36	1.7e-21	Childhood ear infection;
BRCA	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg27433088	chr4:174089019	GALNT7	0.31	8.49	0.32	1.45e-16	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg08601574	chr20:25228251	PYGB	-0.39	-9.0	-0.34	2.47e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11971779	0.555	rs6950143	chr7:139054418	C/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.24	0.38	6.65e-23	Diisocyanate-induced asthma;
BRCA	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18876405	chr7:65276391	NA	0.62	15.48	0.52	3.7e-46	Aortic root size;
BRCA	trans	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg06521331	chr12:34319734	NA	-0.48	-8.66	-0.32	3.93e-17	Bladder cancer;
BRCA	trans	rs7939886	0.920	rs12223248	chr11:55887633	A/C	cg15704280	chr7:45808275	SEPT13	0.62	8.02	0.3	5.13e-15	Myopia (pathological);
BRCA	cis	rs897080	0.515	rs1085450	chr2:44650698	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.81	0.33	1.18e-17	Height;
BRCA	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg01528321	chr10:82214614	TSPAN14	0.79	16.62	0.55	8.24e-52	Post bronchodilator FEV1;
BRCA	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.24	0.49	3.5e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs11677370	0.561	rs10084170	chr2:3820204	G/C	cg17052675	chr2:3827356	NA	-0.6	-15.11	-0.51	2.37e-44	Type 2 diabetes;
BRCA	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg12311346	chr5:56204834	C5orf35	-0.78	-16.17	-0.54	1.4e-49	Initial pursuit acceleration;
BRCA	cis	rs11971779	0.618	rs6943788	chr7:139087697	C/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.64	-13.24	-0.46	1.54e-35	Lung cancer;
BRCA	cis	rs1843834	0.755	rs10194591	chr2:225574276	T/A	cg22455342	chr2:225449267	CUL3	0.35	8.18	0.31	1.52e-15	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg06521331	chr12:34319734	NA	-0.62	-11.17	-0.4	1.44e-26	Morning vs. evening chronotype;
BRCA	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg01689657	chr7:91764605	CYP51A1	0.23	8.08	0.3	3.29e-15	Breast cancer;
BRCA	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg13880726	chr7:1868755	MAD1L1	-0.55	-11.3	-0.41	3.87e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg14458575	chr2:238380390	NA	-0.77	-17.57	-0.57	1.1e-56	Prostate cancer;
BRCA	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03517284	chr6:25882590	NA	-0.48	-10.03	-0.37	4.53e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.02	-0.34	2.13e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg26384229	chr12:38710491	ALG10B	0.77	17.33	0.57	1.91e-55	Bladder cancer;
BRCA	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg15934090	chr1:100435551	SLC35A3	0.35	8.1	0.31	2.72e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.38	-8.69	-0.33	3e-17	Longevity;Endometriosis;
BRCA	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00802000	chr16:706648	WDR90	-0.39	-9.34	-0.35	1.56e-19	Height;
BRCA	trans	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg15556689	chr8:8085844	FLJ10661	0.38	9.12	0.34	9.44e-19	Neuroticism;
BRCA	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.26e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs899997	0.773	rs12595461	chr15:78969172	T/G	cg04896959	chr15:78267971	NA	-0.47	-9.57	-0.35	2.2e-20	Coronary artery disease or large artery stroke;
BRCA	cis	rs62380364	0.557	rs663046	chr5:88036486	C/T	cg22951263	chr5:87985283	NA	-0.38	-10.58	-0.39	3.37e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7177699	0.557	rs6495335	chr15:79117133	G/T	cg00540400	chr15:79124168	NA	0.27	7.81	0.3	2.44e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg20701182	chr2:24300061	SF3B14	0.58	9.04	0.34	1.89e-18	Lymphocyte counts;
BRCA	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.4	7.98	0.3	6.63e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6543140	0.964	rs6761350	chr2:103030776	A/G	cg04239558	chr2:103089729	SLC9A4	0.33	9.25	0.34	3.24e-19	Blood protein levels;
BRCA	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg26384229	chr12:38710491	ALG10B	0.45	10.38	0.38	2.04e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg05526886	chr2:227700861	RHBDD1	0.39	7.98	0.3	6.79e-15	Pulmonary function;
BRCA	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg26850624	chr5:429559	AHRR	0.33	7.88	0.3	1.37e-14	Cystic fibrosis severity;
BRCA	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg12419862	chr22:24373484	LOC391322	-0.65	-14.75	-0.5	1.35e-42	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.93	0.37	1.04e-21	Bipolar disorder;
BRCA	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg08999081	chr20:33150536	PIGU	0.47	13.03	0.46	1.35e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-17.81	-0.58	6.55e-58	Chronic sinus infection;
BRCA	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21545522	chr1:205238299	TMCC2	0.38	8.32	0.31	5.18e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg13628971	chr7:2884303	GNA12	0.45	8.98	0.33	2.99e-18	Height;
BRCA	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18876405	chr7:65276391	NA	-0.5	-11.53	-0.42	4.39e-28	Aortic root size;
BRCA	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/A	cg01304814	chr3:48885189	PRKAR2A	0.56	7.84	0.3	1.89e-14	Parkinson's disease;
BRCA	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg13175981	chr1:150552382	MCL1	0.47	10.38	0.38	1.96e-23	Tonsillectomy;
BRCA	cis	rs9443645	0.527	rs12527806	chr6:79507667	A/T	cg05283184	chr6:79620031	NA	-0.36	-8.36	-0.31	3.87e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg18132916	chr6:79620363	NA	-0.42	-8.49	-0.32	1.46e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg26395211	chr5:140044315	WDR55	0.37	8.54	0.32	9.62e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2531992	0.686	rs2041247	chr16:4032581	A/G	cg05927578	chr16:4029543	ADCY9	0.39	8.43	0.32	2.35e-16	Waist circumference;
BRCA	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs250677	0.522	rs7702695	chr5:148402550	T/A	cg18129178	chr5:148520854	ABLIM3	-0.55	-10.58	-0.39	3.35e-24	Breast cancer;
BRCA	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00166722	chr3:10149974	C3orf24	0.55	10.74	0.39	7.48e-25	Alzheimer's disease;
BRCA	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.42	0.38	1.43e-23	Aortic root size;
BRCA	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10819733	chr22:24237672	NA	0.3	8.28	0.31	7.11e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9308433	0.529	rs9430131	chr1:214481121	C/A	cg06198575	chr1:214491504	SMYD2	0.58	12.67	0.45	5.53e-33	IgG glycosylation;
BRCA	trans	rs1493916	0.748	rs1941684	chr18:31304421	C/G	cg27147174	chr7:100797783	AP1S1	-0.42	-8.28	-0.31	6.98e-16	Life satisfaction;
BRCA	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg16586182	chr3:47516702	SCAP	-0.56	-12.63	-0.45	8.74e-33	Colorectal cancer;
BRCA	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg05793240	chr7:2802953	GNA12	-0.32	-8.07	-0.3	3.38e-15	Height;
BRCA	cis	rs10501293	0.667	rs993904	chr11:42992769	G/T	cg03447554	chr11:43094025	NA	0.42	7.97	0.3	7.27e-15	Cognitive performance;
BRCA	trans	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	9.15	0.34	7.59e-19	Neuroticism;
BRCA	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg06808227	chr14:105710500	BRF1	-0.8	-16.21	-0.54	8.86e-50	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg00852783	chr1:26633632	UBXN11	-0.51	-11.03	-0.4	5.14e-26	Obesity-related traits;
BRCA	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.67	0.32	3.43e-17	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg11764359	chr7:65958608	NA	0.68	15.02	0.51	6.45e-44	Aortic root size;
BRCA	cis	rs7246657	0.653	rs10406612	chr19:37716611	C/T	cg23950597	chr19:37808831	NA	-0.67	-10.14	-0.37	1.59e-22	Coronary artery calcification;
BRCA	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.21	-0.34	4.59e-19	Menopause (age at onset);
BRCA	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg18154014	chr19:37997991	ZNF793	0.53	10.14	0.37	1.74e-22	Coronary artery calcification;
BRCA	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg17063962	chr7:91808500	NA	-0.55	-12.67	-0.45	5.79e-33	Breast cancer;
BRCA	cis	rs13046373	0.534	rs9305426	chr21:31964916	A/C	cg13139843	chr21:31852793	KRTAP19-1	0.34	7.81	0.3	2.37e-14	HDL cholesterol;
BRCA	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg10523679	chr1:76189770	ACADM	-0.49	-9.79	-0.36	3.61e-21	Daytime sleep phenotypes;
BRCA	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg17063962	chr7:91808500	NA	0.51	11.66	0.42	1.29e-28	Breast cancer;
BRCA	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg01028140	chr2:1542097	TPO	0.79	15.4	0.52	9.17e-46	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04267008	chr7:1944627	MAD1L1	-0.48	-10.83	-0.39	3.39e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg23711669	chr6:146136114	FBXO30	0.79	18.93	0.6	9.16e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.740	rs4845518	chr1:153003903	A/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.17	-0.31	1.67e-15	Inflammatory skin disease;
BRCA	trans	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg25214090	chr10:38739885	LOC399744	0.45	10.2	0.37	9.69e-23	Corneal astigmatism;
BRCA	cis	rs6594499	0.500	rs10491424	chr5:110453806	T/C	cg04022379	chr5:110408740	TSLP	0.38	8.76	0.33	1.69e-17	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg14784868	chr12:69753453	YEATS4	0.47	9.32	0.35	1.79e-19	Response to diuretic therapy;
BRCA	cis	rs2668423	0.922	rs266805	chr19:1376723	C/T	cg02639931	chr19:1387894	NDUFS7	-0.68	-15.34	-0.52	1.93e-45	Nonalcoholic fatty liver disease;
BRCA	cis	rs6964587	0.621	rs38799	chr7:92045139	C/T	cg17063962	chr7:91808500	NA	-0.47	-10.34	-0.38	2.84e-23	Breast cancer;
BRCA	cis	rs7131987	0.903	rs11050152	chr12:29404424	G/T	cg09582351	chr12:29534625	ERGIC2	-0.49	-11.76	-0.42	5.03e-29	QT interval;
BRCA	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	15.67	0.53	4.63e-47	Colorectal cancer;
BRCA	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg13902645	chr11:5959945	NA	-0.48	-9.9	-0.36	1.34e-21	DNA methylation (variation);
BRCA	cis	rs4965272	0.830	rs11631646	chr15:100560259	C/T	cg27344315	chr15:100560801	ADAMTS17	0.4	8.68	0.32	3.36e-17	Gastroesophageal reflux disease;
BRCA	cis	rs2737618	0.574	rs2252801	chr1:200076652	C/T	cg21825944	chr1:200113062	NR5A2	-0.4	-8.76	-0.33	1.81e-17	Uric acid levels;
BRCA	cis	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg09307838	chr4:120376055	NA	0.47	9.76	0.36	4.36e-21	Diastolic blood pressure;
BRCA	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg13334819	chr7:99746414	C7orf59	0.35	8.17	0.31	1.63e-15	Coronary artery disease;
BRCA	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg00666640	chr1:248458726	OR2T12	0.33	8.4	0.32	2.87e-16	Common traits (Other);
BRCA	cis	rs10267417	0.603	rs10266969	chr7:19903452	G/A	cg05791153	chr7:19748676	TWISTNB	0.47	9.1	0.34	1.13e-18	Night sleep phenotypes;
BRCA	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.25	0.59	3.22e-60	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg27489772	chr12:121021490	NA	-0.5	-8.7	-0.33	2.9e-17	Type 1 diabetes nephropathy;
BRCA	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-13.16	-0.46	3.59e-35	Gut microbiome composition (summer);
BRCA	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.42	10.61	0.39	2.41e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.84	-0.3	1.9e-14	Aortic root size;
BRCA	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg04317338	chr11:64019027	PLCB3	0.55	9.52	0.35	3.59e-20	Mean platelet volume;
BRCA	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	7.96	0.3	8.07e-15	Glomerular filtration rate;
BRCA	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	9.29	0.34	2.43e-19	Educational attainment;
BRCA	cis	rs6750047	0.771	rs1056836	chr2:38298203	C/G	cg07380506	chr2:38303506	CYP1B1	-0.54	-13.1	-0.46	6.86e-35	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg00012203	chr2:219082015	ARPC2	-0.4	-7.83	-0.3	2.1e-14	Ulcerative colitis;
BRCA	cis	rs8141797	0.901	rs738808	chr22:24488461	C/T	cg00411358	chr22:24577142	SUSD2	-0.74	-8.46	-0.32	1.79e-16	Amyotrophic lateral sclerosis;Coronary artery disease;
BRCA	cis	rs11997175	0.583	rs7460295	chr8:33812288	C/T	ch.8.33884649F	chr8:33765107	NA	0.37	8.34	0.31	4.57e-16	Body mass index;
BRCA	cis	rs2806561	0.929	rs2746556	chr1:23524541	G/A	cg19743168	chr1:23544995	NA	0.45	11.15	0.4	1.74e-26	Height;
BRCA	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	9.44	0.35	6.72e-20	Parkinson's disease;
BRCA	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg06627628	chr2:24431161	ITSN2	-0.82	-14.83	-0.51	5.87e-43	Asthma;
BRCA	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg09904177	chr6:26538194	HMGN4	0.52	14.81	0.51	7.33e-43	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.78	0.62	2.7e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4948102	0.642	rs6593297	chr7:56122058	A/T	cg09872392	chr7:56161020	PHKG1	0.47	12.08	0.43	2.1000000000000002e-30	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.57	0.5	1.03e-41	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg11693508	chr17:37793320	STARD3	-0.59	-11.36	-0.41	2.21e-27	Bipolar disorder;
BRCA	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg00666640	chr1:248458726	OR2T12	0.33	8.63	0.32	4.83e-17	Common traits (Other);
BRCA	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg03146154	chr1:46216737	IPP	-0.47	-10.16	-0.37	1.39e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg05552183	chr6:42928497	GNMT	0.69	15.84	0.53	6.64e-48	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg25173405	chr17:45401733	C17orf57	-0.51	-10.91	-0.4	1.55e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4988958	0.527	rs11465641	chr2:103000868	T/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.41	0.32	2.59e-16	Asthma (childhood onset);
BRCA	cis	rs17641971	0.645	rs341805	chr8:50034658	T/G	cg00325661	chr8:49890786	NA	0.35	9.57	0.35	2.36e-20	Blood metabolite levels;
BRCA	trans	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg21659725	chr3:3221576	CRBN	-0.47	-8.69	-0.33	3.14e-17	Menarche (age at onset);
BRCA	cis	rs7255436	0.830	rs4350678	chr19:8447366	A/G	cg10811474	chr19:8428787	ANGPTL4	-0.32	-8.05	-0.3	4.17e-15	HDL cholesterol;
BRCA	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg13628971	chr7:2884303	GNA12	-0.41	-9.3	-0.35	2.16e-19	Height;
BRCA	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	13.16	0.46	3.41e-35	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs13082711	0.516	rs1388785	chr3:27371843	T/C	cg02860705	chr3:27208620	NA	-0.38	-7.9	-0.3	1.21e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs312274	0.588	rs2897101	chr12:41318620	T/C	cg17827154	chr12:41323612	CNTN1	-0.44	-10.98	-0.4	8.32e-26	Metabolite levels  (X-11787);
BRCA	cis	rs6684514	1.000	rs11264468	chr1:156274585	C/G	cg16558208	chr1:156270281	VHLL	0.36	8.42	0.32	2.48e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs877282	1.000	rs71491304	chr10:772982	C/T	cg17470449	chr10:769945	NA	0.5	9.35	0.35	1.44e-19	Uric acid levels;
BRCA	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg15395560	chr15:45543142	SLC28A2	0.3	8.3	0.31	6.2e-16	Uric acid levels;
BRCA	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg14196676	chr1:1911069	KIAA1751	-0.4	-8.45	-0.32	1.91e-16	Severe influenza A (H1N1) infection;
BRCA	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg23649088	chr2:200775458	C2orf69	0.43	9.21	0.34	4.76e-19	QT interval;
BRCA	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg13385521	chr17:29058706	SUZ12P	0.62	8.49	0.32	1.49e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg03877680	chr5:178157825	ZNF354A	0.82	16.4	0.54	9.89e-51	Neutrophil percentage of white cells;
BRCA	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg03060546	chr3:49711283	APEH	-0.58	-11.81	-0.42	3.12e-29	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4363385	0.818	rs419721	chr1:153006902	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10421328	0.848	rs10415278	chr19:19769157	C/A	cg11584989	chr19:19387371	SF4	0.4	7.96	0.3	7.92e-15	Parental longevity (combined parental age at death);
BRCA	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-10.39	-0.38	1.77e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg07080220	chr10:102295463	HIF1AN	0.6	14.07	0.49	2.28e-39	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs2834485	1.000	rs2834484	chr21:35816941	G/T	cg07474852	chr4:123073612	NA	-0.42	-9.18	-0.34	5.99e-19	Cancer;
BRCA	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21582582	chr3:182698605	DCUN1D1	0.39	10.11	0.37	2.1e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs708547	0.723	rs35982175	chr4:57841365	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.41	-8.04	-0.3	4.28e-15	Response to bleomycin (chromatid breaks);
BRCA	cis	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg07460842	chr6:66804631	NA	-1.02	-19.97	-0.62	2.53e-69	Exhaled nitric oxide output;
BRCA	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg17971929	chr21:40555470	PSMG1	-0.5	-11.24	-0.41	7.4e-27	Menarche (age at onset);
BRCA	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg04058563	chr4:185651563	MLF1IP	0.35	8.75	0.33	1.93e-17	Kawasaki disease;
BRCA	trans	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	7.99e-21	Bladder cancer;
BRCA	cis	rs11690935	1.000	rs312924	chr2:172564021	A/T	cg13550731	chr2:172543902	DYNC1I2	0.87	27.37	0.73	9.34e-110	Schizophrenia;
BRCA	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg11764359	chr7:65958608	NA	-0.69	-15.29	-0.52	3.29e-45	Aortic root size;
BRCA	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.07	0.37	3.07e-22	Morning vs. evening chronotype;
BRCA	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg19077165	chr18:44547161	KATNAL2	-0.52	-11.08	-0.4	3.15e-26	Personality dimensions;
BRCA	cis	rs17601876	0.778	rs4774584	chr15:51562007	G/A	cg19946085	chr15:51559439	CYP19A1	-0.39	-11.65	-0.42	1.47e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg15556689	chr8:8085844	FLJ10661	0.37	8.91	0.33	5.43e-18	Neuroticism;
BRCA	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	14.44	0.5	3.99e-41	Bone mineral density;
BRCA	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg24562669	chr7:97807699	LMTK2	0.45	12.04	0.43	3.16e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-9.36	-0.35	1.31e-19	Mood instability;
BRCA	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.39	0.35	1.05e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg21226059	chr5:178986404	RUFY1	0.53	14.95	0.51	1.56e-43	Lung cancer;
BRCA	trans	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg25214090	chr10:38739885	LOC399744	-0.41	-9.35	-0.35	1.43e-19	Corneal astigmatism;
BRCA	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.62	-15.6	-0.53	9.65e-47	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg12826209	chr6:26865740	GUSBL1	0.55	9.1	0.34	1.09e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs9420	0.961	rs11606396	chr11:57435211	C/T	cg19752551	chr11:57585705	CTNND1	-0.5	-12.23	-0.44	4.61e-31	Schizophrenia;
BRCA	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12292205	chr6:26970375	C6orf41	-0.5	-8.48	-0.32	1.54e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg22764044	chr5:178986830	RUFY1	-0.47	-13.04	-0.46	1.29e-34	Lung cancer;
BRCA	cis	rs751728	0.664	rs12190029	chr6:33749152	T/A	cg25922239	chr6:33757077	LEMD2	0.51	12.87	0.45	6.89e-34	Crohn's disease;
BRCA	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11644478	chr21:40555479	PSMG1	-0.5	-10.46	-0.38	9.91e-24	Menarche (age at onset);
BRCA	cis	rs12545109	0.700	rs2670045	chr8:57393695	A/G	cg09654669	chr8:57350985	NA	-0.39	-8.18	-0.31	1.52e-15	Obesity-related traits;
BRCA	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg11189052	chr15:85197271	WDR73	-0.36	-8.52	-0.32	1.1e-16	P wave terminal force;
BRCA	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg24060327	chr5:131705240	SLC22A5	-0.49	-10.39	-0.38	1.81e-23	Blood metabolite levels;
BRCA	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg07080220	chr10:102295463	HIF1AN	0.63	14.78	0.5	9.71e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg18032046	chr6:28092343	ZSCAN16	0.5	8.22	0.31	1.12e-15	Depression;
BRCA	cis	rs6835098	0.520	rs2127896	chr4:174211285	G/A	cg08422745	chr4:174089978	GALNT7	-0.42	-7.82	-0.3	2.22e-14	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.63	-0.61	1.65e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg17420585	chr12:42539391	GXYLT1	-0.37	-7.85	-0.3	1.81e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs354225	0.565	rs2971880	chr2:54885640	A/T	cg26097391	chr2:54893211	SPTBN1	0.29	8.84	0.33	9.54e-18	Schizophrenia;
BRCA	cis	rs13161895	0.591	rs12655422	chr5:179480825	C/A	cg02702477	chr5:179499311	RNF130	0.57	9.89	0.36	1.45e-21	LDL cholesterol;
BRCA	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-11.92	-0.43	9.81e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs13046373	0.508	rs1911572	chr21:32031648	A/G	cg06468780	chr21:31798236	KRTAP13-3	-0.35	-8.71	-0.33	2.53e-17	HDL cholesterol;
BRCA	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg08601574	chr20:25228251	PYGB	-0.34	-8.25	-0.31	9.18e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg17366294	chr4:99064904	C4orf37	0.46	10.78	0.39	5.16e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4478858	0.735	rs2271072	chr1:31840426	C/G	cg00250761	chr1:31883323	NA	-0.33	-8.49	-0.32	1.45e-16	Alcohol dependence;
BRCA	cis	rs752010	0.695	rs11210508	chr1:42106935	A/G	cg06885757	chr1:42089581	HIVEP3	0.22	8.28	0.31	7.05e-16	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs7760535	0.656	rs1883136	chr6:111907023	G/T	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-8.87	-0.33	7.5e-18	Metabolic traits;
BRCA	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	9.71	0.36	6.71e-21	Aortic root size;
BRCA	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg21433313	chr16:3507492	NAT15	0.42	8.68	0.32	3.16e-17	Tuberculosis;
BRCA	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg13175981	chr1:150552382	MCL1	0.46	10.37	0.38	2.12e-23	Tonsillectomy;
BRCA	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg09307838	chr4:120376055	NA	0.69	14.02	0.49	3.82e-39	Corneal astigmatism;
BRCA	trans	rs7746199	0.736	rs34543938	chr6:27624640	A/G	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.5	-0.32	1.31e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg16586182	chr3:47516702	SCAP	0.57	12.32	0.44	1.93e-31	Colorectal cancer;
BRCA	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg07148914	chr20:33460835	GGT7	-0.44	-9.33	-0.35	1.72e-19	Height;
BRCA	cis	rs16976116	0.901	rs28449712	chr15:55500681	A/C	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.26	0.31	8.13e-16	Platelet count;
BRCA	cis	rs68170813	0.559	rs74906766	chr7:106885236	T/A	cg02696742	chr7:106810147	HBP1	-0.47	-7.92	-0.3	1.04e-14	Coronary artery disease;
BRCA	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11764359	chr7:65958608	NA	0.8	19.36	0.61	4.38e-66	Aortic root size;
BRCA	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18876405	chr7:65276391	NA	0.5	11.07	0.4	3.5e-26	Aortic root size;
BRCA	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00166722	chr3:10149974	C3orf24	0.56	11.17	0.4	1.32e-26	Alzheimer's disease;
BRCA	cis	rs858239	0.600	rs6961131	chr7:23134790	A/G	cg23682824	chr7:23144976	KLHL7	0.45	12.22	0.44	5.34e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4588572	0.643	rs7716529	chr5:77738637	A/T	cg11547950	chr5:77652471	NA	-0.45	-8.17	-0.31	1.63e-15	Triglycerides;
BRCA	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg02176678	chr2:219576539	TTLL4	0.43	11.56	0.42	3.36e-28	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	20.11	0.62	4.61e-70	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg17330251	chr7:94953956	PON1	-0.42	-8.85	-0.33	8.59e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg00677455	chr12:58241039	CTDSP2	0.79	19.91	0.62	5.19e-69	Multiple sclerosis;
BRCA	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg06623918	chr6:96969491	KIAA0776	0.74	12.97	0.46	2.52e-34	Migraine;Coronary artery disease;
BRCA	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg03354898	chr7:1950403	MAD1L1	-0.44	-9.74	-0.36	5.48e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs2073300	1.000	rs6132628	chr20:23446734	G/A	cg12062639	chr20:23401060	NAPB	0.91	10.69	0.39	1.21e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.77	21.31	0.64	1.55e-76	Multiple sclerosis;
BRCA	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg10223061	chr2:219282414	VIL1	-0.27	-8.18	-0.31	1.49e-15	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg24069376	chr3:38537580	EXOG	0.34	9.37	0.35	1.18e-19	Electrocardiographic conduction measures;
BRCA	cis	rs2882667	0.654	rs7710300	chr5:138170482	T/C	cg04439458	chr5:138467593	SIL1	0.34	8.47	0.32	1.73e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.41	0.5	5.62e-41	Exhaled nitric oxide output;
BRCA	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg03146154	chr1:46216737	IPP	-0.54	-12.02	-0.43	3.92e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg26043149	chr18:55253948	FECH	-0.37	-8.14	-0.31	2.06e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg08470875	chr2:26401718	FAM59B	0.71	11.35	0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs2559856	1.000	rs2695296	chr12:102085487	T/C	cg12213457	chr12:102090980	CHPT1	-0.37	-7.99	-0.3	6.15e-15	Blood protein levels;
BRCA	cis	rs6450176	0.597	rs1541682	chr5:53304401	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-15.71	-0.53	2.71e-47	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg08917208	chr2:24149416	ATAD2B	1.03	13.88	0.48	1.83e-38	Lymphocyte counts;
BRCA	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg25036284	chr2:26402008	FAM59B	0.85	13.61	0.47	3.27e-37	Gut microbiome composition (summer);
BRCA	cis	rs7639513	0.767	rs7617041	chr3:12709167	A/G	cg23032965	chr3:12705835	RAF1	0.7	15.4	0.52	1e-45	Itch intensity from mosquito bite;
BRCA	cis	rs2625529	0.775	rs35673773	chr15:72399886	C/A	cg16672083	chr15:72433130	SENP8	-0.84	-17.47	-0.57	3.5e-56	Red blood cell count;
BRCA	cis	rs1499972	0.941	rs56051552	chr3:117613726	C/T	cg07612923	chr3:117604196	NA	0.59	8.01	0.3	5.48e-15	Schizophrenia;
BRCA	cis	rs36051895	0.632	rs10815171	chr9:5172567	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-9.52	-0.35	3.39e-20	Pediatric autoimmune diseases;
BRCA	cis	rs10411936	0.608	rs7259642	chr19:16601926	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.46	9.68	0.36	8.85e-21	White blood cell count;Multiple sclerosis;
BRCA	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg18904891	chr8:8559673	CLDN23	0.64	12.88	0.45	6.38e-34	Obesity-related traits;
BRCA	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.55	-0.32	9.35e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs7178424	0.729	rs12909947	chr15:62248552	C/T	cg00456672	chr15:62358751	C2CD4A	0.38	9.2	0.34	5.15e-19	Height;
BRCA	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-24.72	-0.7	3.55e-95	Monocyte count;
BRCA	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11644478	chr21:40555479	PSMG1	0.87	20.53	0.63	2.67e-72	Cognitive function;
BRCA	cis	rs6545883	0.929	rs13413337	chr2:61747123	A/G	cg15711740	chr2:61764176	XPO1	-0.52	-12.96	-0.46	2.91e-34	Tuberculosis;
BRCA	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11764359	chr7:65958608	NA	0.8	19.35	0.61	5.33e-66	Aortic root size;
BRCA	trans	rs12517041	1.000	rs1428630	chr5:23321186	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-8.11	-0.31	2.55e-15	Calcium levels;
BRCA	cis	rs2806561	0.780	rs4655142	chr1:23333728	T/C	cg19743168	chr1:23544995	NA	-0.39	-9.4	-0.35	9.63e-20	Height;
BRCA	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg23711669	chr6:146136114	FBXO30	-0.7	-16.88	-0.56	3.73e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7586879	1.000	rs6736711	chr2:25116456	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.39	0.35	1.07e-19	Body mass index;
BRCA	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg21782813	chr7:2030301	MAD1L1	0.42	12.13	0.43	1.32e-30	Bipolar disorder and schizophrenia;
BRCA	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg27478167	chr7:817139	HEATR2	-0.47	-9.89	-0.36	1.43e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg22834771	chr12:69754056	YEATS4	0.39	9.79	0.36	3.46e-21	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4671400	0.602	rs2694623	chr2:61553466	C/T	cg15711740	chr2:61764176	XPO1	0.45	8.85	0.33	8.87e-18	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg12011299	chr4:100065546	ADH4	0.48	10.87	0.4	2.26e-25	Smoking initiation;
BRCA	trans	rs3947	0.906	rs709822	chr8:11702313	C/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-8.0	-0.3	6.07e-15	Blood protein levels;
BRCA	cis	rs1451375	0.657	rs12665904	chr7:50635399	A/G	cg18232548	chr7:50535776	DDC	0.39	9.08	0.34	1.39e-18	Malaria;
BRCA	cis	rs68170813	0.559	rs12536574	chr7:106810997	A/T	cg02696742	chr7:106810147	HBP1	-0.54	-8.61	-0.32	5.6e-17	Coronary artery disease;
BRCA	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg18230493	chr5:56204884	C5orf35	-0.72	-13.87	-0.48	1.95e-38	Initial pursuit acceleration;
BRCA	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00166722	chr3:10149974	C3orf24	-0.57	-10.05	-0.37	3.67e-22	Alzheimer's disease;
BRCA	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg03806693	chr22:41940476	POLR3H	-0.61	-12.01	-0.43	4.06e-30	Vitiligo;
BRCA	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.72	-20.63	-0.63	6.98e-73	Longevity;Endometriosis;
BRCA	trans	rs75804782	0.630	rs113725999	chr2:239287651	C/T	cg01134436	chr17:81009848	B3GNTL1	0.74	7.95	0.3	8.38e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg05340658	chr4:99064831	C4orf37	0.69	17.17	0.56	1.28e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg17211192	chr8:82754475	SNX16	0.49	11.12	0.4	2.21e-26	Diastolic blood pressure;
BRCA	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg07080220	chr10:102295463	HIF1AN	0.51	10.54	0.38	4.47e-24	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg19539972	chr4:7069911	GRPEL1	-0.63	-12.03	-0.43	3.45e-30	Monocyte percentage of white cells;
BRCA	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.25	0.31	9.38e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.45	0.55	5.92e-51	Colorectal cancer;
BRCA	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	10.89	0.4	1.82e-25	Rheumatoid arthritis;
BRCA	cis	rs11170631	0.507	rs12307701	chr12:54090724	A/C	cg23533419	chr12:54090519	NA	-0.33	-8.26	-0.31	8.57e-16	Height;
BRCA	cis	rs11051970	0.594	rs325418	chr12:32572517	T/C	cg02745156	chr12:32552066	NA	0.23	7.88	0.3	1.42e-14	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs2712184	0.756	rs2712182	chr2:217647525	T/C	cg05032264	chr2:217675019	NA	-0.37	-8.97	-0.33	3.25e-18	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg03929089	chr4:120376271	NA	0.72	14.7	0.5	2.49e-42	Coronary artery disease;
BRCA	cis	rs939658	0.626	rs11636901	chr15:79446292	T/C	cg17916960	chr15:79447300	NA	-0.39	-9.83	-0.36	2.57e-21	Refractive error;
BRCA	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg04117972	chr1:227635322	NA	-0.5	-9.12	-0.34	9.69e-19	Major depressive disorder;
BRCA	cis	rs12347191	0.500	rs907582	chr9:100621926	T/C	cg13688889	chr9:100608707	NA	-0.48	-9.8	-0.36	3.09e-21	Orofacial clefts;
BRCA	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg24692254	chr21:30365293	RNF160	0.77	21.21	0.64	5.58e-76	Dental caries;
BRCA	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg06623918	chr6:96969491	KIAA0776	0.75	15.83	0.53	7.37e-48	Migraine;Coronary artery disease;
BRCA	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg16339924	chr4:17578868	LAP3	0.63	15.63	0.53	7.33e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg06521331	chr12:34319734	NA	-0.51	-9.24	-0.34	3.5e-19	Bladder cancer;
BRCA	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-10.95	-0.4	1.12e-25	Personality dimensions;
BRCA	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg03609598	chr5:56110824	MAP3K1	-0.45	-7.99	-0.3	6.34e-15	Initial pursuit acceleration;
BRCA	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg21132104	chr15:45694354	SPATA5L1	0.74	16.86	0.55	5.12e-53	Homoarginine levels;
BRCA	cis	rs748404	0.723	rs11853991	chr15:43557549	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.35	8.13	0.31	2.3e-15	Lung cancer;
BRCA	cis	rs4363385	0.668	rs6587717	chr1:152984443	G/C	cg24667326	chr1:152973720	SPRR3	-0.35	-9.89	-0.36	1.52e-21	Inflammatory skin disease;
BRCA	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg10327440	chr1:227177885	CDC42BPA	1.06	38.63	0.84	2.61e-169	Myeloid white cell count;
BRCA	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg04455712	chr21:45112962	RRP1B	0.36	9.44	0.35	6.82e-20	Mean corpuscular volume;
BRCA	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg17420585	chr12:42539391	GXYLT1	-0.58	-14.47	-0.5	2.84e-41	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.71	-11.43	-0.41	1.2100000000000001e-27	Red cell distribution width;
BRCA	trans	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.15	0.31	1.99e-15	Corneal astigmatism;
BRCA	cis	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg06521331	chr12:34319734	NA	-0.62	-11.41	-0.41	1.38e-27	Morning vs. evening chronotype;
BRCA	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg17063962	chr7:91808500	NA	0.51	11.01	0.4	6.08e-26	Breast cancer;
BRCA	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg18132916	chr6:79620363	NA	-0.49	-11.12	-0.4	2.14e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg17509989	chr5:176798049	RGS14	-0.62	-12.55	-0.44	1.9e-32	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg08999081	chr20:33150536	PIGU	-0.45	-12.27	-0.44	3.08e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs9467773	0.526	rs9348710	chr6:26360486	A/C	cg09904177	chr6:26538194	HMGN4	-0.32	-8.72	-0.33	2.41e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs654950	1.000	rs679449	chr1:41988634	G/T	cg06885757	chr1:42089581	HIVEP3	-0.28	-9.46	-0.35	5.78e-20	Airway imaging phenotypes;
BRCA	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg15839431	chr19:19639596	YJEFN3	-0.39	-8.54	-0.32	1.01e-16	Bipolar disorder;
BRCA	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg13010199	chr12:38710504	ALG10B	0.48	9.55	0.35	2.79e-20	Morning vs. evening chronotype;
BRCA	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg06212747	chr3:49208901	KLHDC8B	0.48	9.91	0.37	1.2e-21	Parkinson's disease;
BRCA	trans	rs12517041	1.000	rs12697619	chr5:23288772	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.36	-0.31	4.04e-16	Calcium levels;
BRCA	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21659725	chr3:3221576	CRBN	0.42	10.36	0.38	2.32e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg11812906	chr14:75593930	NEK9	-0.61	-14.21	-0.49	5.25e-40	Height;
BRCA	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25427524	chr10:38739819	LOC399744	-0.67	-16.22	-0.54	8.33e-50	Extrinsic epigenetic age acceleration;
BRCA	trans	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.27	0.38	5.09e-23	Mean corpuscular volume;
BRCA	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.39	8.69	0.33	3.02e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs34779708	0.931	rs12240347	chr10:35359475	A/G	cg03585969	chr10:35415529	CREM	0.46	9.55	0.35	2.69e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4771122	0.728	rs1475221	chr13:28037566	C/T	cg22138327	chr13:27999177	GTF3A	-0.44	-8.53	-0.32	1.05e-16	Body mass index;
BRCA	cis	rs13064411	0.735	rs6438158	chr3:113217290	C/T	cg18753928	chr3:113234510	CCDC52	-0.59	-12.52	-0.44	2.53e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg06784218	chr1:46089804	CCDC17	-0.46	-10.78	-0.39	5.33e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs8002861	0.664	rs4941474	chr13:44450289	C/T	cg12856521	chr11:46389249	DGKZ	0.36	7.87	0.3	1.5e-14	Leprosy;
BRCA	cis	rs3755132	0.929	rs976016	chr2:15772865	A/G	cg12888861	chr2:15731646	DDX1	0.4	8.03	0.3	4.77e-15	Wilms tumor;
BRCA	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg05090351	chr10:126851162	NA	-0.3	-8.24	-0.31	1e-15	Menarche (age at onset);
BRCA	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-11.19	-0.4	1.16e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs17345786	0.520	rs13062677	chr3:101305078	G/A	cg12386194	chr3:101231763	SENP7	0.41	8.97	0.33	3.21e-18	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	9.09	0.34	1.25e-18	Rheumatoid arthritis;
BRCA	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	10.73	0.39	8.38e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	4.04e-15	Alzheimer's disease (late onset);
BRCA	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg26668828	chr6:292823	DUSP22	0.56	12.16	0.43	9.82e-31	Menopause (age at onset);
BRCA	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg15704280	chr7:45808275	SEPT13	0.58	9.99	0.37	5.97e-22	Axial length;
BRCA	cis	rs6005807	0.719	rs7289625	chr22:28896546	G/A	cg12565055	chr22:29076175	TTC28	0.47	8.37	0.31	3.6e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00166722	chr3:10149974	C3orf24	0.57	10.99	0.4	7.79e-26	Alzheimer's disease;
BRCA	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	10.87	0.4	2.23e-25	Rheumatoid arthritis;
BRCA	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18404041	chr3:52824283	ITIH1	-0.43	-12.7	-0.45	3.92e-33	Bipolar disorder;
BRCA	cis	rs2030114	0.531	rs1072858	chr16:51593364	C/T	cg03758633	chr16:51611768	NA	0.36	7.82	0.3	2.17e-14	Blood pressure measurement (high sodium and potassium intervention);
BRCA	cis	rs6484504	0.625	rs10835766	chr11:31374329	C/A	cg14844989	chr11:31128820	NA	0.44	9.7	0.36	7.84e-21	Red blood cell count;
BRCA	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg25554036	chr4:6271136	WFS1	0.37	7.98	0.3	6.95e-15	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.19	0.49	6.57e-40	Eye color traits;
BRCA	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg21361702	chr7:150065534	REPIN1	-0.55	-9.97	-0.37	7.49e-22	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs13046373	0.535	rs1395778	chr21:31985502	G/C	cg14062083	chr21:31802829	KRTAP13-4	0.32	8.58	0.32	6.91e-17	HDL cholesterol;
BRCA	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg18198730	chr1:247681584	NA	0.56	12.4	0.44	8.18e-32	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg22676075	chr6:135203613	NA	0.44	8.66	0.32	3.87e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13126279	chr21:47581558	C21orf56	-0.49	-10.85	-0.39	2.81e-25	Testicular germ cell tumor;
BRCA	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg24558204	chr6:135376177	HBS1L	-0.41	-10.55	-0.39	4.29e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs2979489	0.891	rs2979504	chr8:30386641	C/T	cg26383811	chr8:30366931	RBPMS	-0.55	-12.7	-0.45	4.26e-33	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
BRCA	cis	rs7598759	0.617	rs6437017	chr2:232327584	C/A	cg19187155	chr2:232395269	NMUR1	0.38	7.97	0.3	7.57e-15	Noise-induced hearing loss;
BRCA	cis	rs3106136	0.546	rs4693003	chr4:95145469	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.08	-0.37	2.88e-22	Capecitabine sensitivity;
BRCA	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg14675211	chr2:100938903	LONRF2	0.44	10.29	0.38	4.45e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs2882667	0.654	rs883333	chr5:138155470	C/A	cg04439458	chr5:138467593	SIL1	0.36	8.88	0.33	6.46e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07308232	chr7:1071921	C7orf50	-0.44	-9.18	-0.34	5.73e-19	Longevity;Endometriosis;
BRCA	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7264396	1.000	rs224436	chr20:34154124	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-9.39	-0.35	1e-19	Total cholesterol levels;
BRCA	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg14863265	chr7:2801509	GNA12	-0.45	-9.72	-0.36	6.27e-21	Height;
BRCA	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg17971929	chr21:40555470	PSMG1	-0.48	-10.67	-0.39	1.42e-24	Menarche (age at onset);
BRCA	trans	rs6479891	1.000	rs11814792	chr10:64917559	C/T	cg14819942	chr15:35414228	NA	0.35	8.63	0.32	5.03e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	7.99	0.3	6.19e-15	Menarche (age at onset);
BRCA	trans	rs7200543	1.000	rs1136001	chr16:15131974	G/T	cg24683922	chr1:11983373	KIAA2013	-0.39	-8.71	-0.33	2.69e-17	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs17092148	0.945	rs6060009	chr20:33303974	T/G	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.29	-0.41	4.4e-27	Neuroticism;
BRCA	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg04545296	chr12:48745243	ZNF641	0.24	7.9	0.3	1.21e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18876405	chr7:65276391	NA	-0.55	-13.2	-0.46	2.49e-35	Aortic root size;
BRCA	trans	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg26384229	chr12:38710491	ALG10B	0.46	10.25	0.38	6.32e-23	Morning vs. evening chronotype;
BRCA	trans	rs1973993	0.689	rs67544133	chr1:96971241	G/A	cg10631902	chr5:14652156	NA	-0.48	-13.88	-0.48	1.76e-38	Weight;
BRCA	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.91	-0.43	1.13e-29	Total cholesterol levels;
BRCA	trans	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-21.13	-0.64	1.45e-75	Exhaled nitric oxide output;
BRCA	cis	rs9341808	0.905	rs9343977	chr6:80967001	C/T	cg08355045	chr6:80787529	NA	0.36	9.53	0.35	3.1e-20	Sitting height ratio;
BRCA	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.73	-0.77	4.91e-128	Schizophrenia;
BRCA	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg24578937	chr1:2090814	PRKCZ	-0.3	-9.35	-0.35	1.49e-19	Height;
BRCA	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18876405	chr7:65276391	NA	-0.63	-15.65	-0.53	5.63e-47	Aortic root size;
BRCA	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg18132916	chr6:79620363	NA	-0.5	-11.34	-0.41	2.73e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.49	10.92	0.4	1.39e-25	Cognitive ability;
BRCA	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg20503657	chr10:835505	NA	0.85	15.16	0.51	1.45e-44	Eosinophil percentage of granulocytes;
BRCA	cis	rs9287719	0.624	rs10199831	chr2:10726863	T/C	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	5.17e-19	Prostate cancer;
BRCA	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.32	9.04	0.34	1.79e-18	Response to antipsychotic treatment;
BRCA	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg18252515	chr7:66147081	NA	-1.01	-15.1	-0.51	2.74e-44	Diabetic kidney disease;
BRCA	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg23711669	chr6:146136114	FBXO30	0.65	14.71	0.5	2.12e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg26384229	chr12:38710491	ALG10B	0.77	17.45	0.57	4.59e-56	Bladder cancer;
BRCA	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18876405	chr7:65276391	NA	-0.5	-11.2	-0.41	1.06e-26	Aortic root size;
BRCA	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg13647721	chr17:30228624	UTP6	-0.58	-9.8	-0.36	3.27e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg02187348	chr16:89574699	SPG7	0.43	9.99	0.37	6.21e-22	Multiple myeloma (IgH translocation);
BRCA	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.27	0.41	5.23e-27	Bipolar disorder;
BRCA	trans	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg13565492	chr6:43139072	SRF	-0.79	-10.95	-0.4	1.07e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg11645453	chr3:52864694	ITIH4	0.42	9.93	0.37	1.02e-21	Schizophrenia;
BRCA	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg11843238	chr5:131593191	PDLIM4	0.41	10.35	0.38	2.63e-23	Acylcarnitine levels;
BRCA	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	9.92	0.37	1.18e-21	Aortic root size;
BRCA	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg26248373	chr2:1572462	NA	-0.62	-14.37	-0.49	8.48e-41	IgG glycosylation;
BRCA	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21659725	chr3:3221576	CRBN	-0.47	-11.88	-0.43	1.57e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs3762637	0.943	rs6762156	chr3:122236025	A/C	cg24169773	chr3:122142474	KPNA1	-0.43	-8.01	-0.3	5.54e-15	LDL cholesterol levels;
BRCA	cis	rs9290065	0.519	rs6441345	chr3:160696867	C/T	cg03342759	chr3:160939853	NMD3	-0.48	-9.81	-0.36	3.02e-21	Kawasaki disease;
BRCA	cis	rs169738	1	rs169738	chr6:33537546	A/G	cg07679836	chr6:33548423	BAK1	0.41	9.19	0.34	5.59e-19	Platelet count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.66	-17.82	-0.58	6.01e-58	Electrocardiographic conduction measures;
BRCA	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg04166393	chr7:2884313	GNA12	0.63	13.71	0.48	1.05e-37	Height;
BRCA	trans	rs4650994	0.507	rs12141152	chr1:178514165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.58	-12.87	-0.45	7.42e-34	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs903263	0.562	rs35452337	chr1:84534503	C/A	cg10977910	chr1:84465055	TTLL7	0.42	8.07	0.3	3.6e-15	Breast cancer (male);
BRCA	cis	rs4363385	0.818	rs946096	chr1:153006529	T/A	cg21543102	chr1:152974771	SPRR3	-0.28	-7.81	-0.3	2.39e-14	Inflammatory skin disease;
BRCA	cis	rs17601876	0.843	rs28518777	chr15:51553507	G/A	cg19946085	chr15:51559439	CYP19A1	-0.36	-9.81	-0.36	2.92e-21	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs4363385	0.818	rs370162	chr1:153005488	G/A	cg21543102	chr1:152974771	SPRR3	-0.28	-7.81	-0.3	2.39e-14	Inflammatory skin disease;
BRCA	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg23719950	chr11:63933701	MACROD1	-0.58	-9.45	-0.35	6.17e-20	Mean platelet volume;
BRCA	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg08610935	chr16:1836813	NUBP2	0.46	11.73	0.42	6.42e-29	Insulin-like growth factors;
BRCA	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg09654669	chr8:57350985	NA	0.39	8.57	0.32	7.99e-17	Obesity-related traits;
BRCA	cis	rs7178424	0.790	rs17271305	chr15:62332980	A/G	cg00456672	chr15:62358751	C2CD4A	-0.41	-9.03	-0.34	1.99e-18	Height;
BRCA	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg16482183	chr6:26056742	HIST1H1C	0.59	10.22	0.37	8.25e-23	Iron status biomarkers;
BRCA	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11764359	chr7:65958608	NA	0.79	19.31	0.61	8.49e-66	Aortic root size;
BRCA	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg06060754	chr5:176797920	RGS14	0.7	10.49	0.38	7.52e-24	Urate levels in lean individuals;
BRCA	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg12311346	chr5:56204834	C5orf35	-0.82	-16.75	-0.55	1.84e-52	Initial pursuit acceleration;
BRCA	cis	rs6723226	0.961	rs13010404	chr2:32848854	T/G	cg02381751	chr2:32503542	YIPF4	-0.49	-10.23	-0.38	7.28e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18404041	chr3:52824283	ITIH1	0.48	14.59	0.5	7.94e-42	Bipolar disorder;
BRCA	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27286337	chr10:134555280	INPP5A	0.65	11.66	0.42	1.25e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs4812048	0.649	rs3761255	chr20:57618802	T/C	cg14073986	chr20:57617431	SLMO2	0.78	12.17	0.43	8.34e-31	Mean platelet volume;
BRCA	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg10523679	chr1:76189770	ACADM	0.78	18.67	0.59	2.07e-62	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7851660	0.967	rs10818133	chr9:100610348	C/G	cg13688889	chr9:100608707	NA	-0.36	-8.7	-0.33	2.81e-17	Strep throat;
BRCA	cis	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg14683738	chr19:37701593	ZNF585B	0.46	8.1	0.31	2.86e-15	Coronary artery calcification;
BRCA	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg27535305	chr1:53392650	SCP2	-0.36	-8.87	-0.33	7.19e-18	Monocyte count;
BRCA	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg20991723	chr1:152506922	NA	-0.36	-8.02	-0.3	4.93e-15	Hair morphology;
BRCA	cis	rs36051895	0.659	rs3780365	chr9:5068520	T/C	cg02405213	chr9:5042618	JAK2	-0.5	-9.49	-0.35	4.66e-20	Pediatric autoimmune diseases;
BRCA	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg06092702	chr1:163392909	NA	-0.33	-8.84	-0.33	9.42e-18	Motion sickness;
BRCA	cis	rs96067	0.740	rs10752586	chr1:36614713	C/G	cg24686825	chr1:36642396	MAP7D1	-0.45	-8.4	-0.32	2.79e-16	Corneal structure;
BRCA	cis	rs11676348	0.783	rs13035513	chr2:218960680	C/T	cg00012203	chr2:219082015	ARPC2	-0.41	-7.91	-0.3	1.1e-14	Ulcerative colitis;
BRCA	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.57	-13.37	-0.47	4.1e-36	Mean platelet volume;
BRCA	cis	rs208520	0.874	rs208481	chr6:66922636	A/G	cg07460842	chr6:66804631	NA	-0.89	-15.64	-0.53	6.62e-47	Exhaled nitric oxide output;
BRCA	cis	rs490234	0.867	rs829181	chr9:128288002	A/G	cg14078157	chr9:128172775	NA	0.34	8.05	0.3	3.93e-15	Mean arterial pressure;
BRCA	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg18404041	chr3:52824283	ITIH1	-0.29	-8.14	-0.31	2.08e-15	Electroencephalogram traits;
BRCA	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg10729496	chr3:10149963	C3orf24	0.49	9.41	0.35	8.99e-20	Alzheimer's disease;
BRCA	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg05340658	chr4:99064831	C4orf37	0.64	14.83	0.51	5.78e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs501916	0.634	rs1561482	chr15:48069663	G/A	cg16110827	chr15:48056943	SEMA6D	-0.41	-8.83	-0.33	9.95e-18	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.1e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.43	-9.52	-0.35	3.5e-20	Personality dimensions;
BRCA	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg26446133	chr18:72167187	CNDP2	-0.77	-15.08	-0.51	3.46e-44	Refractive error;
BRCA	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg06784218	chr1:46089804	CCDC17	-0.52	-12.62	-0.45	8.86e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12210905	0.688	rs10456051	chr6:27463436	T/C	cg08851530	chr6:28072375	NA	0.81	7.97	0.3	7.34e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs490234	0.812	rs12553699	chr9:128294526	C/G	cg14078157	chr9:128172775	NA	-0.5	-11.25	-0.41	6.5e-27	Mean arterial pressure;
BRCA	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg06784218	chr1:46089804	CCDC17	-0.46	-10.78	-0.39	5.33e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7246657	0.722	rs8103647	chr19:38100452	C/A	cg18154014	chr19:37997991	ZNF793	0.5	9.54	0.35	2.99e-20	Coronary artery calcification;
BRCA	cis	rs11984145	1.000	rs16879964	chr7:38834868	C/T	cg19327137	chr7:38886074	VPS41	0.45	8.07	0.3	3.58e-15	Cognitive performance;
BRCA	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg05340658	chr4:99064831	C4orf37	0.45	10.39	0.38	1.79e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg01292856	chr11:65242576	NA	0.33	8.32	0.31	5.35e-16	Bone mineral density;
BRCA	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	9.11	0.34	1.09e-18	Lung cancer in ever smokers;
BRCA	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23221052	chr5:179740743	GFPT2	-0.68	-14.44	-0.5	3.97e-41	Height;
BRCA	cis	rs3099143	1.000	rs7172639	chr15:77165288	G/A	cg21673338	chr15:77095150	SCAPER	0.53	9.5	0.35	4.3e-20	Recalcitrant atopic dermatitis;
BRCA	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg03733263	chr8:22462867	KIAA1967	1.02	25.29	0.71	2.68e-98	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs4285028	0.731	rs2332035	chr3:121715432	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.5	-9.02	-0.34	2.12e-18	Multiple sclerosis;
BRCA	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg20307385	chr11:47447363	PSMC3	-0.41	-9.56	-0.35	2.4e-20	Subjective well-being;
BRCA	trans	rs7980799	0.816	rs4587807	chr12:33510115	C/T	cg26384229	chr12:38710491	ALG10B	-0.34	-8.1	-0.31	2.85e-15	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs1975991	0.576	rs6768760	chr3:187957642	A/T	cg15417654	chr3:187959138	LPP	0.36	9.37	0.35	1.18e-19	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.49	10.89	0.4	1.87e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg20503657	chr10:835505	NA	0.52	9.22	0.34	4.4e-19	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg19678392	chr7:94953810	PON1	-0.41	-8.53	-0.32	1.04e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg17644776	chr2:200775616	C2orf69	0.42	8.7	0.33	2.81e-17	Osteoporosis;
BRCA	cis	rs6942756	1.000	rs66538149	chr7:128974061	G/A	cg02491457	chr7:128862824	NA	-0.71	-13.69	-0.48	1.39e-37	White matter hyperintensity burden;
BRCA	cis	rs35740288	0.929	rs11073537	chr15:86312681	G/A	cg20737812	chr15:86336631	KLHL25	-0.33	-7.89	-0.3	1.29e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs919433	0.679	rs6719832	chr2:198533369	C/T	cg00792783	chr2:198669748	PLCL1	-0.4	-9.19	-0.34	5.34e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs2625529	0.824	rs2415121	chr15:72134018	C/T	cg16672083	chr15:72433130	SENP8	-0.68	-16.12	-0.54	2.79e-49	Red blood cell count;
BRCA	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	16.45	0.55	5.62e-51	Platelet count;
BRCA	cis	rs2237234	1.000	rs2237234	chr6:26391394	G/A	cg12826209	chr6:26865740	GUSBL1	0.41	7.9	0.3	1.21e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	8.19	0.31	1.44e-15	Mean platelet volume;
BRCA	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg17509989	chr5:176798049	RGS14	-0.74	-11.79	-0.42	3.79e-29	Urate levels in lean individuals;
BRCA	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.68	0.55	4.17e-52	Alzheimer's disease (late onset);
BRCA	cis	rs666930	0.519	rs532303	chr1:120265444	A/G	cg19096424	chr1:120255104	PHGDH	0.59	13.72	0.48	9.81e-38	Breast cancer;
BRCA	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg03711944	chr11:47377212	SPI1	-0.43	-9.97	-0.37	7.12e-22	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg18252515	chr7:66147081	NA	-1.04	-15.65	-0.53	5.53e-47	Diabetic kidney disease;
BRCA	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg12927641	chr6:109611667	NA	-0.42	-10.87	-0.39	2.35e-25	Reticulocyte fraction of red cells;
BRCA	trans	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg25214090	chr10:38739885	LOC399744	0.5	11.54	0.42	4.06e-28	Corneal astigmatism;
BRCA	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg09035930	chr12:129282057	SLC15A4	0.3	8.07	0.3	3.61e-15	Systemic lupus erythematosus;
BRCA	cis	rs6942756	0.806	rs7794622	chr7:128996268	T/C	cg02491457	chr7:128862824	NA	-0.59	-12.31	-0.44	2.03e-31	White matter hyperintensity burden;
BRCA	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg24069376	chr3:38537580	EXOG	0.43	12.34	0.44	1.55e-31	Electrocardiographic conduction measures;
BRCA	trans	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg26043149	chr18:55253948	FECH	0.39	8.54	0.32	1.02e-16	Bone mineral density;
BRCA	cis	rs7809950	0.817	rs2712195	chr7:107127496	C/T	cg23024343	chr7:107201750	COG5	-0.48	-10.29	-0.38	4.31e-23	Coronary artery disease;
BRCA	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg00757033	chr12:89920650	WDR51B	0.54	10.85	0.39	2.64e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs6545883	0.931	rs778756	chr2:61781994	A/G	cg15711740	chr2:61764176	XPO1	-0.48	-11.74	-0.42	5.71e-29	Tuberculosis;
BRCA	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.18	-0.43	7.96e-31	Total cholesterol levels;
BRCA	cis	rs1568889	0.877	rs7933326	chr11:28288416	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	14.46	0.5	3.17e-41	Bipolar disorder;
BRCA	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg20933634	chr6:27740509	NA	0.43	8.21	0.31	1.22e-15	Parkinson's disease;
BRCA	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.22	0.31	1.16e-15	Axial length;
BRCA	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg13628971	chr7:2884303	GNA12	-0.42	-8.45	-0.32	1.93e-16	Height;
BRCA	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.2	-0.31	1.28e-15	Aortic root size;
BRCA	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg01528321	chr10:82214614	TSPAN14	0.62	13.83	0.48	3.07e-38	Post bronchodilator FEV1;
BRCA	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg26597838	chr10:835615	NA	1.01	17.99	0.58	7.38e-59	Eosinophil percentage of granulocytes;
BRCA	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.42	9.23	0.34	3.85e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs208520	0.779	rs208451	chr6:66906155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-15.98	-0.53	1.37e-48	Exhaled nitric oxide output;
BRCA	cis	rs96067	0.711	rs4653164	chr1:36627542	A/G	cg24686825	chr1:36642396	MAP7D1	0.39	8.44	0.32	2.15e-16	Corneal structure;
BRCA	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg13628971	chr7:2884303	GNA12	0.36	7.94	0.3	9.3e-15	Height;
BRCA	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	20.94	0.64	1.66e-74	Platelet count;
BRCA	cis	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg21775007	chr8:11205619	TDH	-0.47	-9.36	-0.35	1.29e-19	Retinal vascular caliber;
BRCA	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11141652	chr22:24348549	GSTTP1	0.38	7.93	0.3	9.9e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg02297831	chr4:17616191	MED28	0.34	7.86	0.3	1.6e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg01620082	chr3:125678407	NA	-0.65	-8.7	-0.33	2.73e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7927771	0.524	rs10838760	chr11:47786414	A/G	cg20307385	chr11:47447363	PSMC3	0.42	9.56	0.35	2.48e-20	Subjective well-being;
BRCA	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg20283391	chr11:68216788	NA	-0.48	-9.39	-0.35	1.02e-19	Total body bone mineral density;
BRCA	cis	rs7617773	0.710	rs36064160	chr3:48243101	C/G	cg11946769	chr3:48343235	NME6	0.68	13.87	0.48	2.02e-38	Coronary artery disease;
BRCA	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg21856205	chr7:94953877	PON1	-0.38	-8.24	-0.31	9.47e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg06671706	chr8:8559999	CLDN23	0.41	7.91	0.3	1.16e-14	Obesity-related traits;
BRCA	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg11366901	chr6:160182831	ACAT2	0.82	15.63	0.53	7.22e-47	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs17641971	0.619	rs7013425	chr8:49953085	G/A	cg00325661	chr8:49890786	NA	0.38	10.6	0.39	2.59e-24	Blood metabolite levels;
BRCA	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.29	-8.07	-0.3	3.47e-15	Lymphocyte counts;
BRCA	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg07308232	chr7:1071921	C7orf50	-0.35	-7.81	-0.3	2.38e-14	Longevity;Endometriosis;
BRCA	cis	rs4974559	0.739	rs28444605	chr4:1290281	C/A	cg02980000	chr4:1222292	CTBP1	0.81	13.35	0.47	4.74e-36	Systolic blood pressure;
BRCA	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg09462578	chr12:12878428	APOLD1	-0.63	-11.17	-0.4	1.42e-26	Systemic lupus erythematosus;
BRCA	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg05623727	chr3:50126028	RBM5	-0.43	-10.25	-0.38	6.54e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs12612619	0.704	rs6754356	chr2:27315021	G/A	cg00617064	chr2:27272375	NA	-0.34	-8.88	-0.33	6.82e-18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg18016565	chr1:150552671	MCL1	-0.45	-9.97	-0.37	7.3e-22	Tonsillectomy;
BRCA	trans	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg07817883	chr1:32538562	TMEM39B	-0.46	-8.87	-0.33	7.11e-18	Monocyte percentage of white cells;
BRCA	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg20701182	chr2:24300061	SF3B14	0.58	8.98	0.33	2.93e-18	Lymphocyte counts;
BRCA	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg02556042	chr12:117471086	NA	0.58	9.92	0.37	1.16e-21	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs7246657	0.678	rs4802024	chr19:38052193	T/C	cg23950597	chr19:37808831	NA	-0.5	-8.62	-0.32	5.36e-17	Coronary artery calcification;
BRCA	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.14	-0.31	2.1e-15	Parkinson's disease;
BRCA	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.82	0.3	2.22e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg13699009	chr12:122356056	WDR66	0.36	8.27	0.31	7.85e-16	Mean corpuscular volume;
BRCA	cis	rs11997175	0.740	rs4467902	chr8:33693415	G/T	ch.8.33884649F	chr8:33765107	NA	0.35	8.32	0.31	5.3e-16	Body mass index;
BRCA	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg02297831	chr4:17616191	MED28	0.36	8.43	0.32	2.25e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs701145	0.640	rs1657621	chr3:153929795	T/C	cg17054900	chr3:154042577	DHX36	0.52	8.9	0.33	5.83e-18	Coronary artery disease;
BRCA	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg13902645	chr11:5959945	NA	-0.49	-10.43	-0.38	1.24e-23	DNA methylation (variation);
BRCA	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg21427119	chr20:30132790	HM13	-0.43	-9.06	-0.34	1.63e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs11622475	1.000	rs11622475	chr14:104509076	C/T	cg12183467	chr14:104352244	NA	-0.46	-8.8	-0.33	1.28e-17	Bipolar disorder;
BRCA	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.77	0.42	4.57e-29	Tonsillectomy;
BRCA	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg18016565	chr1:150552671	MCL1	0.34	8.01	0.3	5.48e-15	Tonsillectomy;
BRCA	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg08017756	chr2:100939284	LONRF2	0.29	7.83	0.3	2.09e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.69	14.05	0.49	3.01e-39	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-9.12	-0.34	9.58e-19	Neuroticism;
BRCA	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg21252483	chr19:49399788	TULP2	-0.51	-10.84	-0.39	2.92e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs208520	0.754	rs851593	chr6:66875783	C/T	cg07460842	chr6:66804631	NA	1.0	18.64	0.59	2.99e-62	Exhaled nitric oxide output;
BRCA	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.51	-14.96	-0.51	1.27e-43	Lung cancer;
BRCA	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	13.5	0.47	1.06e-36	Personality dimensions;
BRCA	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.11	0.34	1.07e-18	Tonsillectomy;
BRCA	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg13319975	chr6:146136371	FBXO30	-0.62	-14.5	-0.5	2.1e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg00852783	chr1:26633632	UBXN11	0.5	10.96	0.4	9.94e-26	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1829883	0.835	rs2845982	chr5:98879638	C/A	cg08333243	chr5:99726346	NA	0.36	8.37	0.31	3.64e-16	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs4742903	0.935	rs17237053	chr9:106946359	C/T	cg21169611	chr9:106856078	SMC2	-0.33	-8.23	-0.31	1.08e-15	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg13327785	chr12:132219529	SFRS8	-0.34	-8.01	-0.3	5.56e-15	Migraine;
BRCA	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg24829409	chr8:58192753	C8orf71	-0.48	-9.25	-0.34	3.23e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	13.79	0.48	4.68e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2267137	0.835	rs2267133	chr22:29765382	A/T	cg07256473	chr22:29710276	RASL10A	0.36	8.94	0.33	4.15e-18	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	trans	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg26384229	chr12:38710491	ALG10B	0.51	11.26	0.41	5.83e-27	Morning vs. evening chronotype;
BRCA	cis	rs883565	0.792	rs784498	chr3:39180099	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.42	-8.87	-0.33	7.26e-18	Handedness;
BRCA	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg01324343	chr3:183735012	ABCC5	0.81	20.44	0.63	8.24e-72	Anterior chamber depth;
BRCA	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg22676075	chr6:135203613	NA	0.59	10.34	0.38	2.89e-23	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	trans	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg21659725	chr3:3221576	CRBN	-0.47	-9.91	-0.36	1.29e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg14675211	chr2:100938903	LONRF2	0.52	11.82	0.42	2.63e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg19196401	chr6:110721138	DDO	-0.41	-10.11	-0.37	2.1e-22	Platelet distribution width;
BRCA	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg04025307	chr7:1156635	C7orf50	0.58	11.4	0.41	1.51e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg18402987	chr7:1209562	NA	0.66	11.58	0.42	2.75e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg10560079	chr2:191398806	TMEM194B	-0.36	-8.07	-0.3	3.5e-15	Pulse pressure;
BRCA	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg18512352	chr11:47633146	NA	-0.37	-9.13	-0.34	8.95e-19	Subjective well-being;
BRCA	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.34	-7.81	-0.3	2.28e-14	High light scatter reticulocyte count;
BRCA	trans	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	0.46	8.65	0.32	4.09e-17	Monocyte count;
BRCA	cis	rs7617773	0.817	rs3731534	chr3:48211777	C/T	cg11946769	chr3:48343235	NME6	0.68	13.82	0.48	3.24e-38	Coronary artery disease;
BRCA	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	17.31	0.57	2.4e-55	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs10754283	0.967	rs2002883	chr1:90105838	A/G	cg21401794	chr1:90099060	LRRC8C	0.46	11.13	0.4	2e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.2	-0.31	1.3e-15	Total body bone mineral density;
BRCA	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg01745370	chr2:109065127	GCC2	0.42	10.14	0.37	1.66e-22	Mean platelet volume;
BRCA	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.89	-0.43	1.34e-29	Response to antipsychotic treatment;
BRCA	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg21045802	chr8:109455806	TTC35	0.35	7.99	0.3	6.42e-15	Dupuytren's disease;
BRCA	cis	rs4919694	1.000	rs12242000	chr10:104702413	A/C	cg04362960	chr10:104952993	NT5C2	0.97	15.09	0.51	3.25e-44	Arsenic metabolism;
BRCA	cis	rs6942756	0.806	rs2566877	chr7:128897317	G/A	cg02491457	chr7:128862824	NA	0.57	12.18	0.43	7.55e-31	White matter hyperintensity burden;
BRCA	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg13010199	chr12:38710504	ALG10B	0.42	9.04	0.34	1.87e-18	Morning vs. evening chronotype;
BRCA	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.89	0.56	3.65e-53	Colorectal cancer;
BRCA	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.08e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg04013093	chr6:42928303	GNMT	-0.28	-8.68	-0.32	3.16e-17	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg26384229	chr12:38710491	ALG10B	0.85	22.52	0.67	3.94e-83	Heart rate;
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg24846343	chr22:24311635	DDTL	-0.49	-12.12	-0.43	1.42e-30	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg25174290	chr11:3078921	CARS	0.42	12.65	0.45	6.73e-33	Longevity;
BRCA	cis	rs10924970	0.870	rs7531130	chr1:235440556	C/G	cg26050004	chr1:235667680	B3GALNT2	0.35	8.69	0.33	3.01e-17	Asthma;
BRCA	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg09455208	chr3:40491958	NA	0.41	9.75	0.36	4.92e-21	Renal cell carcinoma;
BRCA	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-10.56	-0.39	3.98e-24	Lymphocyte counts;
BRCA	cis	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg07460842	chr6:66804631	NA	0.97	19.47	0.61	1.26e-66	Exhaled nitric oxide output;
BRCA	cis	rs17253792	0.731	rs74829671	chr14:56112759	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.14e-14	Putamen volume;
BRCA	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg22535103	chr8:58192502	C8orf71	-0.51	-8.66	-0.32	3.8e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2303759	0.958	rs1465697	chr19:49837246	C/T	cg24324837	chr19:49891574	CCDC155	0.49	8.57	0.32	7.69e-17	Multiple sclerosis;
BRCA	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg10818794	chr15:86012489	AKAP13	-0.3	-8.43	-0.32	2.33e-16	Coronary artery disease;
BRCA	cis	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg06521331	chr12:34319734	NA	-0.65	-11.92	-0.43	1.01e-29	Morning vs. evening chronotype;
BRCA	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg26752003	chr8:145688521	CYHR1	0.54	13.18	0.46	2.82e-35	Age at first birth;
BRCA	cis	rs9807989	0.507	rs4851004	chr2:103009537	A/G	cg03938978	chr2:103052716	IL18RAP	-0.3	-8.8	-0.33	1.29e-17	Asthma;
BRCA	cis	rs4363385	0.747	rs6684188	chr1:152974285	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.33	-0.31	4.87e-16	Inflammatory skin disease;
BRCA	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg04709771	chr16:646395	RAB40C	0.44	11.29	0.41	4.25e-27	Height;
BRCA	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg10523679	chr1:76189770	ACADM	-0.45	-8.03	-0.3	4.55e-15	Daytime sleep phenotypes;
BRCA	cis	rs58785573	0.570	rs4833078	chr4:38646476	C/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.52	11.36	0.41	2.26e-27	Lymphocyte percentage of white cells;
BRCA	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg23711669	chr6:146136114	FBXO30	0.71	16.97	0.56	1.38e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg22875332	chr1:76189707	ACADM	0.66	15.64	0.53	6.65e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1712517	0.771	rs7074749	chr10:105116056	C/T	cg05636881	chr10:105038444	INA	0.36	7.96	0.3	7.99e-15	Migraine;
BRCA	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg22875332	chr1:76189707	ACADM	0.68	14.38	0.49	7.62e-41	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9880211	0.948	rs17298525	chr3:136193025	G/C	cg21827317	chr3:136751795	NA	-0.45	-8.08	-0.3	3.17e-15	Body mass index;Height;
BRCA	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg05343316	chr1:45956843	TESK2	0.59	12.36	0.44	1.31e-31	Platelet count;
BRCA	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg13010199	chr12:38710504	ALG10B	0.48	9.46	0.35	5.66e-20	Morning vs. evening chronotype;
BRCA	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg22508957	chr16:3507546	NAT15	0.42	9.44	0.35	6.65e-20	Tuberculosis;
BRCA	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg08601574	chr20:25228251	PYGB	0.35	8.49	0.32	1.48e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.32	-0.35	1.81e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg00666640	chr1:248458726	OR2T12	0.3	8.59	0.32	6.62e-17	Common traits (Other);
BRCA	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg10523679	chr1:76189770	ACADM	0.77	18.64	0.59	2.94e-62	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7945718	0.875	rs9888258	chr11:12782716	A/G	cg25843174	chr11:12811716	TEAD1	0.23	8.76	0.33	1.8e-17	Educational attainment (years of education);
BRCA	cis	rs4363385	0.765	rs3806221	chr1:153002555	G/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.36	-0.31	3.83e-16	Inflammatory skin disease;
BRCA	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg24558204	chr6:135376177	HBS1L	0.44	11.91	0.43	1.16e-29	Red blood cell count;
BRCA	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg08859206	chr1:53392774	SCP2	0.45	9.88	0.36	1.56e-21	Monocyte count;
BRCA	cis	rs1577917	0.545	rs9450325	chr6:86475814	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.34	9.31	0.35	2.09e-19	Response to antipsychotic treatment;
BRCA	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg04944784	chr2:26401820	FAM59B	0.85	11.46	0.41	8.7e-28	Gut microbiome composition (summer);
BRCA	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg24112000	chr20:60950667	NA	-0.52	-9.87	-0.36	1.73e-21	Colorectal cancer;
BRCA	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg14664628	chr15:75095509	CSK	-0.95	-29.22	-0.76	7.59e-120	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg26384229	chr12:38710491	ALG10B	0.74	17.17	0.56	1.24e-54	Bladder cancer;
BRCA	cis	rs524281	0.861	rs7120326	chr11:65849256	C/T	cg16950941	chr11:66035639	RAB1B	-0.39	-8.29	-0.31	6.88e-16	Electroencephalogram traits;
BRCA	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	20.05	0.62	9.49e-70	Platelet count;
BRCA	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.07	23.75	0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg08999081	chr20:33150536	PIGU	0.47	12.95	0.46	3.15e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.48	-0.32	1.6e-16	Glomerular filtration rate (creatinine);
BRCA	trans	rs3960554	0.599	rs56090527	chr7:75762125	A/C	cg19862616	chr7:65841803	NCRNA00174	0.61	12.65	0.45	6.84e-33	Eotaxin levels;
BRCA	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg09307838	chr4:120376055	NA	0.6	12.94	0.46	3.6e-34	Corneal astigmatism;
BRCA	cis	rs8028182	0.636	rs4886699	chr15:75692303	A/C	cg20655648	chr15:75932815	IMP3	0.4	7.95	0.3	8.63e-15	Sudden cardiac arrest;
BRCA	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg05347473	chr6:146136440	FBXO30	0.39	7.87	0.3	1.54e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4730250	0.707	rs257385	chr7:106807448	T/C	cg02696742	chr7:106810147	HBP1	-0.61	-9.6	-0.36	1.75e-20	Osteoarthritis;
BRCA	cis	rs10504073	0.584	rs60449482	chr8:49974865	G/A	cg00325661	chr8:49890786	NA	0.48	13.95	0.48	8.13e-39	Blood metabolite ratios;
BRCA	cis	rs990171	0.607	rs10153578	chr2:102764609	C/T	cg22835712	chr2:102737379	NA	-0.54	-9.75	-0.36	5.03e-21	Lymphocyte counts;
BRCA	cis	rs35740288	0.571	rs11629608	chr15:86330124	C/G	cg20737812	chr15:86336631	KLHL25	-0.39	-9.49	-0.35	4.43e-20	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-9.05	-0.34	1.64e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9942416	0.660	rs60423072	chr5:75006113	T/A	cg19683494	chr5:74908142	NA	0.43	8.35	0.31	4.4e-16	Age-related disease endophenotypes;
BRCA	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.98	0.3	6.67e-15	Retinal vascular caliber;
BRCA	cis	rs7020830	0.931	rs13295115	chr9:37157964	T/G	cg14294708	chr9:37120828	ZCCHC7	1.19	37.4	0.83	4.71e-163	Schizophrenia;
BRCA	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	17.75	0.57	1.36e-57	Alzheimer's disease;
BRCA	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg12386194	chr3:101231763	SENP7	0.51	10.15	0.37	1.58e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9463078	0.804	rs6458428	chr6:45179815	A/C	cg25276700	chr6:44698697	NA	-0.36	-8.09	-0.3	3e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11890956	chr21:40555474	PSMG1	1.03	27.9	0.74	1.23e-112	Cognitive function;
BRCA	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg14458575	chr2:238380390	NA	0.59	13.48	0.47	1.21e-36	Prostate cancer;
BRCA	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg11645453	chr3:52864694	ITIH4	0.48	11.78	0.42	4.02e-29	Schizophrenia;
BRCA	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg00677455	chr12:58241039	CTDSP2	0.55	12.33	0.44	1.73e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg13047869	chr3:10149882	C3orf24	0.57	10.42	0.38	1.43e-23	Alzheimer's disease;
BRCA	trans	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg21659725	chr3:3221576	CRBN	-0.35	-8.51	-0.32	1.24e-16	Menarche (age at onset);
BRCA	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg12011299	chr4:100065546	ADH4	0.42	11.11	0.4	2.33e-26	Alcohol dependence;
BRCA	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.09	0.34	1.24e-18	Tonsillectomy;
BRCA	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg20203395	chr5:56204925	C5orf35	0.64	12.56	0.45	1.65e-32	Initial pursuit acceleration;
BRCA	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg25358565	chr5:93447407	FAM172A	0.69	12.05	0.43	2.74e-30	Diabetic retinopathy;
BRCA	cis	rs8040855	0.860	rs7172266	chr15:85716213	C/T	cg04831495	chr15:85060580	GOLGA6L5	0.31	7.81	0.3	2.36e-14	Bulimia nervosa;
BRCA	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11764359	chr7:65958608	NA	-0.73	-16.06	-0.54	5.08e-49	Aortic root size;
BRCA	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-9.88	-0.36	1.6e-21	Heart rate;
BRCA	cis	rs3767633	0.925	rs4657103	chr1:161740483	G/T	cg09175582	chr1:161736000	ATF6	0.5	8.31	0.31	5.76e-16	IgG glycosylation;
BRCA	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg14835575	chr10:16859367	RSU1	0.56	11.87	0.42	1.74e-29	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs68170813	0.559	rs1989814	chr7:107045076	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.18	-0.31	1.58e-15	Coronary artery disease;
BRCA	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.35	0.35	1.48e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17253792	0.822	rs10137364	chr14:56059987	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg00071950	chr4:10020882	SLC2A9	0.46	10.83	0.39	3.42e-25	Bone mineral density;
BRCA	trans	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg26384229	chr12:38710491	ALG10B	0.51	11.03	0.4	4.98e-26	Morning vs. evening chronotype;
BRCA	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg00757033	chr12:89920650	WDR51B	0.52	10.45	0.38	1.03e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs2882667	0.690	rs13174008	chr5:138257909	T/C	cg04439458	chr5:138467593	SIL1	-0.31	-7.93	-0.3	1.01e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2901460	0.509	rs11125898	chr2:62079895	T/C	cg02183531	chr2:62113199	CCT4	-0.44	-8.77	-0.33	1.63e-17	Mean corpuscular volume;
BRCA	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg26384229	chr12:38710491	ALG10B	0.74	17.6	0.57	7.88e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg04989706	chr14:50066350	PPIL5	-0.47	-9.21	-0.34	4.76e-19	Carotid intima media thickness;
BRCA	trans	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg25214090	chr10:38739885	LOC399744	0.43	10.16	0.37	1.43e-22	Corneal astigmatism;
BRCA	cis	rs9902453	0.904	rs12939344	chr17:28328819	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-14.22	-0.49	4.52e-40	Coffee consumption (cups per day);
BRCA	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-8.8	-0.33	1.26e-17	Alzheimer's disease (late onset);
BRCA	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	9.9	0.36	1.31e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg16262614	chr3:133464971	TF	0.25	7.91	0.3	1.14e-14	Iron status biomarkers (transferrin levels);
BRCA	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg07636037	chr3:49044803	WDR6	0.96	27.96	0.74	5.73e-113	Parkinson's disease;
BRCA	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	15.81	0.53	9.56e-48	Lymphocyte counts;
BRCA	cis	rs4664304	0.620	rs2556086	chr2:160708446	G/T	cg01092293	chr2:160761427	LY75	-0.32	-7.89	-0.3	1.3e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg01579765	chr21:45077557	HSF2BP	0.39	9.97	0.37	7.42e-22	Mean corpuscular volume;
BRCA	cis	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg24692254	chr21:30365293	RNF160	-0.46	-8.06	-0.3	3.82e-15	Cognitive test performance;
BRCA	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg05896524	chr21:47604654	C21orf56	-0.42	-8.22	-0.31	1.17e-15	Testicular germ cell tumor;
BRCA	cis	rs727479	0.502	rs2289105	chr15:51507508	C/T	cg19946085	chr15:51559439	CYP19A1	0.31	8.57	0.32	7.5e-17	Estradiol levels;
BRCA	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg02659138	chr7:134003124	SLC35B4	0.32	10.14	0.37	1.65e-22	Mean platelet volume;
BRCA	cis	rs2580764	0.632	rs2588510	chr2:55199248	A/G	cg09592903	chr2:55203963	RTN4	-0.42	-10.66	-0.39	1.53e-24	Mean platelet volume;
BRCA	cis	rs3820928	1.000	rs6723774	chr2:227770592	C/T	cg11843606	chr2:227700838	RHBDD1	0.4	8.87	0.33	7.2e-18	Pulmonary function;
BRCA	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg11952622	chr19:58962976	ZNF324B	0.43	8.7	0.33	2.71e-17	Uric acid clearance;
BRCA	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg16405210	chr4:1374714	KIAA1530	0.91	20.58	0.63	1.37e-72	Longevity;
BRCA	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg02403541	chr12:121454288	C12orf43	0.55	11.82	0.42	2.8e-29	Subjective well-being;Cardiovascular disease risk factors;
BRCA	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg16262614	chr3:133464971	TF	0.24	7.98	0.3	7e-15	Iron status biomarkers (transferrin levels);
BRCA	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	19.08	0.6	1.46e-64	Platelet count;
BRCA	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.71e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg22753661	chr15:79092743	ADAMTS7	-0.4	-8.39	-0.32	3.02e-16	Diastolic blood pressure;
BRCA	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg01236616	chr12:121019343	POP5	1.24	27.85	0.74	2.17e-112	Type 1 diabetes nephropathy;
BRCA	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg03351412	chr1:154909251	PMVK	0.57	12.99	0.46	2.2e-34	Prostate cancer;
BRCA	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	11.39	0.41	1.8e-27	Recombination measurement;
BRCA	trans	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg21659725	chr3:3221576	CRBN	-0.45	-9.86	-0.36	1.94e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs7980799	0.649	rs1601003	chr12:33689436	A/T	cg26384229	chr12:38710491	ALG10B	0.52	11.03	0.4	5.14e-26	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg12310025	chr6:25882481	NA	-0.5	-12.1	-0.43	1.71e-30	Blood metabolite levels;
BRCA	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg08601574	chr20:25228251	PYGB	0.35	8.39	0.32	3.06e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg13010199	chr12:38710504	ALG10B	0.5	9.57	0.35	2.29e-20	Morning vs. evening chronotype;
BRCA	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18876405	chr7:65276391	NA	0.62	15.36	0.52	1.43e-45	Aortic root size;
BRCA	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-13.52	-0.47	8.46e-37	Bipolar disorder and schizophrenia;
BRCA	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg04709771	chr16:646395	RAB40C	0.43	10.99	0.4	7.78e-26	Height;
BRCA	cis	rs73001065	0.536	rs10408596	chr19:19512657	A/T	cg03709012	chr19:19516395	GATAD2A	1.04	15.4	0.52	9.25e-46	LDL cholesterol;
BRCA	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg00684032	chr4:1343700	KIAA1530	0.33	8.29	0.31	6.63e-16	Obesity-related traits;
BRCA	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.63	10.24	0.38	6.59e-23	Renal function-related traits (BUN);
BRCA	cis	rs6743226	0.934	rs7565186	chr2:242249822	A/G	cg10021735	chr2:242295487	FARP2	0.36	10.14	0.37	1.66e-22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg23649088	chr2:200775458	C2orf69	0.55	8.01	0.3	5.58e-15	Schizophrenia;
BRCA	trans	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg26043149	chr18:55253948	FECH	0.41	8.91	0.33	5.34e-18	Bone mineral density;
BRCA	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.78	13.12	0.46	5.41e-35	Schizophrenia;
BRCA	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg15704280	chr7:45808275	SEPT13	0.65	11.42	0.41	1.24e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg23708337	chr7:1209742	NA	0.42	7.96	0.3	8.1e-15	Longevity;Endometriosis;
BRCA	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg26384229	chr12:38710491	ALG10B	-0.46	-10.57	-0.39	3.71e-24	Bladder cancer;
BRCA	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg21252483	chr19:49399788	TULP2	-0.51	-11.08	-0.4	3.1e-26	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs1775715	0.737	rs2808072	chr10:32205504	A/T	cg14930904	chr10:32216787	ARHGAP12	0.34	7.94	0.3	9.14e-15	Bipolar disorder with mood-incongruent psychosis;
BRCA	trans	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg25214090	chr10:38739885	LOC399744	-0.57	-12.32	-0.44	1.86e-31	Corneal astigmatism;
BRCA	cis	rs11605924	0.934	rs7945689	chr11:45879006	C/T	ch.11.939596F	chr11:45881766	CRY2	-0.47	-10.41	-0.38	1.56e-23	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg02196655	chr2:10830764	NOL10	-0.3	-8.2	-0.31	1.35e-15	Prostate cancer;
BRCA	cis	rs796364	0.616	rs6718118	chr2:200691852	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.51	-8.28	-0.31	7.15e-16	Schizophrenia;
BRCA	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg12292205	chr6:26970375	C6orf41	0.64	14.45	0.5	3.77e-41	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg20587970	chr11:113659929	NA	-1.34	-24.49	-0.7	6.49e-94	Hip circumference adjusted for BMI;
BRCA	cis	rs7178424	0.967	rs2162062	chr15:62279937	G/A	cg00456672	chr15:62358751	C2CD4A	-0.38	-8.77	-0.33	1.56e-17	Height;
BRCA	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg00321850	chr1:175162397	KIAA0040	-0.41	-11.28	-0.41	4.85e-27	Alcohol dependence;
BRCA	cis	rs1003719	0.680	rs2835630	chr21:38521842	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.37	-0.49	9.12e-41	Eye color traits;
BRCA	trans	rs66887589	0.967	rs1155577	chr4:120449810	C/T	cg25214090	chr10:38739885	LOC399744	-0.36	-8.34	-0.31	4.72e-16	Diastolic blood pressure;
BRCA	cis	rs9815354	0.638	rs73071259	chr3:42001847	G/A	cg03022575	chr3:42003672	ULK4	0.73	10.08	0.37	2.94e-22	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1003719	0.613	rs9978998	chr21:38535848	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.54	-0.5	1.43e-41	Eye color traits;
BRCA	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	14.17	0.49	7.76e-40	Colorectal cancer;
BRCA	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.89	-0.33	6.27e-18	Alzheimer's disease (late onset);
BRCA	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg09904177	chr6:26538194	HMGN4	0.47	15.07	0.51	3.77e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	14.38	0.49	8.14e-41	Colorectal cancer;
BRCA	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg08508325	chr11:3079039	CARS	0.29	8.69	0.33	3.09e-17	Calcium levels;
BRCA	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg20503657	chr10:835505	NA	0.93	14.29	0.49	2.22e-40	Eosinophil percentage of granulocytes;
BRCA	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg13073564	chr4:8508604	NA	-0.37	-9.55	-0.35	2.76e-20	Response to antineoplastic agents;
BRCA	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg05623727	chr3:50126028	RBM5	0.41	9.7	0.36	7.31e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs17253792	0.822	rs74412558	chr14:56054311	C/T	cg01858014	chr14:56050164	KTN1	-0.73	-9.45	-0.35	6.37e-20	Putamen volume;
BRCA	cis	rs6942407	0.546	rs4140847	chr7:86783263	A/T	cg02420886	chr7:86849541	C7orf23	0.52	7.81	0.3	2.31e-14	Food allergy;
BRCA	cis	rs2204008	0.527	rs8189480	chr12:38345648	C/T	cg26384229	chr12:38710491	ALG10B	-0.38	-8.82	-0.33	1.11e-17	Bladder cancer;
BRCA	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.09	0.46	7.12e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18402987	chr7:1209562	NA	0.61	12.94	0.46	3.45e-34	Longevity;Endometriosis;
BRCA	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg19318889	chr4:1322082	MAEA	0.58	11.55	0.42	3.77e-28	Longevity;
BRCA	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	18.92	0.6	1.05e-63	Platelet count;
BRCA	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg17366294	chr4:99064904	C4orf37	0.42	9.83	0.36	2.51e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3820928	1.000	rs10193316	chr2:227777650	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.57	-0.32	7.7e-17	Pulmonary function;
BRCA	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg20891283	chr12:69753455	YEATS4	-0.45	-11.43	-0.41	1.2e-27	Blood protein levels;
BRCA	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg11416102	chr8:651193	ERICH1	-0.55	-7.92	-0.3	1.07e-14	IgG glycosylation;
BRCA	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg04317338	chr11:64019027	PLCB3	0.54	9.93	0.37	1e-21	Mean platelet volume;
BRCA	cis	rs911119	0.779	rs3761280	chr20:23620076	A/G	cg16589663	chr20:23618590	CST3	0.47	8.81	0.33	1.2e-17	Chronic kidney disease;
BRCA	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg10495392	chr1:46806563	NSUN4	0.44	8.2	0.31	1.37e-15	Menopause (age at onset);
BRCA	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg11502198	chr6:26597334	ABT1	0.56	11.97	0.43	6.47e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs2860975	1.000	rs12781471	chr10:96765362	T/C	cg09036531	chr10:96991505	NA	-0.38	-8.18	-0.31	1.5e-15	Immune response to smallpox vaccine (IL-6);
BRCA	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg16606324	chr3:10149918	C3orf24	0.52	10.03	0.37	4.4e-22	Alzheimer's disease;
BRCA	cis	rs370915	0.542	rs1895844	chr4:187833759	C/T	cg19519643	chr4:187840862	NA	-0.37	-8.74	-0.33	2.05e-17	Gout;
BRCA	cis	rs3784262	0.669	rs4646595	chr15:58302341	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.15	-0.37	1.46e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7587476	0.784	rs13008641	chr2:215698033	T/C	cg04004882	chr2:215674386	BARD1	0.64	11.82	0.42	2.81e-29	Neuroblastoma;
BRCA	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg10253484	chr15:75165896	SCAMP2	-0.48	-9.66	-0.36	1.06e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg07460842	chr6:66804631	NA	0.6	10.27	0.38	5.29e-23	Type 2 diabetes;
BRCA	cis	rs10911363	0.549	rs2794619	chr1:183459670	G/A	cg09173681	chr1:183549694	NCF2	0.54	11.31	0.41	3.64e-27	Systemic lupus erythematosus;
BRCA	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg11645453	chr3:52864694	ITIH4	-0.38	-10.07	-0.37	3.03e-22	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs218264	0.649	rs6554191	chr4:55374968	C/A	cg17105814	chr4:55365203	NA	-0.41	-8.32	-0.31	5.38e-16	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg07460842	chr6:66804631	NA	0.6	10.31	0.38	3.59e-23	Type 2 diabetes;
BRCA	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg26384229	chr12:38710491	ALG10B	0.59	13.53	0.47	7.42e-37	Morning vs. evening chronotype;
BRCA	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg24069376	chr3:38537580	EXOG	0.34	9.36	0.35	1.36e-19	Electrocardiographic conduction measures;
BRCA	cis	rs7178424	0.711	rs7166891	chr15:62239304	A/T	cg00456672	chr15:62358751	C2CD4A	0.41	9.89	0.36	1.46e-21	Height;
BRCA	cis	rs17021463	0.902	rs62320439	chr4:95248721	G/C	cg11021082	chr4:95130006	SMARCAD1	0.38	7.98	0.3	6.56e-15	Testicular germ cell tumor;
BRCA	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg02153584	chr22:29168773	CCDC117	0.53	11.12	0.4	2.18e-26	Lymphocyte counts;
BRCA	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.06	-0.43	2.49e-30	Alzheimer's disease;
BRCA	cis	rs7737355	0.947	rs4706028	chr5:130946227	T/C	cg06307176	chr5:131281290	NA	0.47	9.23	0.34	3.91e-19	Life satisfaction;
BRCA	cis	rs11229555	0.609	rs12273517	chr11:58201094	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4919694	1.000	rs4917986	chr10:104630181	T/C	cg04362960	chr10:104952993	NT5C2	0.83	13.37	0.47	4.2e-36	Arsenic metabolism;
BRCA	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.06	0.54	5.39e-49	Fuchs's corneal dystrophy;
BRCA	trans	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg25214090	chr10:38739885	LOC399744	0.44	10.23	0.38	7.36e-23	Corneal astigmatism;
BRCA	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.45	-0.32	1.99e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00166722	chr3:10149974	C3orf24	0.63	12.77	0.45	2.08e-33	Alzheimer's disease;
BRCA	cis	rs6723226	0.882	rs13035097	chr2:32836362	A/G	cg02381751	chr2:32503542	YIPF4	-0.5	-10.28	-0.38	4.72e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg20387954	chr3:183756860	HTR3D	0.35	8.26	0.31	8.22e-16	Anterior chamber depth;
BRCA	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.42	-8.49	-0.32	1.5e-16	Monocyte percentage of white cells;
BRCA	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.6	12.07	0.43	2.28e-30	Multiple sclerosis;
BRCA	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg03954927	chr1:10346856	KIF1B	0.43	12.7	0.45	4.3e-33	Hepatocellular carcinoma;
BRCA	cis	rs10911251	0.528	rs10911266	chr1:183115097	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.22	0.54	7.92e-50	Colorectal cancer;
BRCA	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg23711669	chr6:146136114	FBXO30	-0.66	-15.6	-0.53	9.98e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg13010199	chr12:38710504	ALG10B	0.53	11.07	0.4	3.38e-26	Heart rate;
BRCA	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg20848291	chr7:100343083	ZAN	-0.59	-12.64	-0.45	7.59e-33	Other erythrocyte phenotypes;
BRCA	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg26528668	chr16:1614120	IFT140	0.36	8.19	0.31	1.43e-15	Coronary artery disease;
BRCA	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg23033748	chr14:75592666	NEK9	0.39	9.5	0.35	3.97e-20	Height;
BRCA	cis	rs4919694	1.000	rs12241091	chr10:104808997	G/A	cg04362960	chr10:104952993	NT5C2	0.95	14.59	0.5	7.86e-42	Arsenic metabolism;
BRCA	cis	rs17209837	0.607	rs1558376	chr7:87079103	T/A	cg00919237	chr7:87102261	ABCB4	-0.53	-10.22	-0.37	8.0700000000000006e-23	Gallbladder cancer;
BRCA	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg24450063	chr1:156163899	SLC25A44	-1.11	-36.21	-0.82	5.57e-157	Testicular germ cell tumor;
BRCA	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg17330251	chr7:94953956	PON1	-0.42	-9.0	-0.34	2.53e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg22189786	chr22:42395067	WBP2NL	0.43	8.59	0.32	6.7e-17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.84	0.42	2.32e-29	Tonsillectomy;
BRCA	cis	rs838147	0.733	rs12978499	chr19:49237552	A/C	cg12258179	chr19:49232187	RASIP1	0.33	8.17	0.31	1.61e-15	Dietary macronutrient intake;
BRCA	trans	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg23505145	chr19:12996616	KLF1	0.53	11.74	0.42	6.03e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3755397	1	rs3755397	chr2:242294913	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.68	-7.82	-0.3	2.13e-14	Chronic lymphocytic leukemia;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
BRCA	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg18016565	chr1:150552671	MCL1	0.35	8.23	0.31	1.08e-15	Tonsillectomy;
BRCA	cis	rs3741798	1.000	rs2160588	chr12:12487447	C/T	cg08615371	chr12:12503544	MANSC1	1.03	15.38	0.52	1.26e-45	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.05	0.49	2.99e-39	Motion sickness;
BRCA	cis	rs9309473	1.000	rs11899740	chr2:73631212	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-11.96	-0.43	6.8e-30	Metabolite levels;
BRCA	trans	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg25214090	chr10:38739885	LOC399744	0.55	12.39	0.44	9.57e-32	Corneal astigmatism;
BRCA	cis	rs1891275	0.515	rs1592051	chr10:93542186	A/G	cg07889827	chr10:93443413	NA	0.4	11.12	0.4	2.25e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.71	0.42	7.88e-29	Homoarginine levels;
BRCA	trans	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg25042112	chr7:64838748	ZNF92	0.45	8.4	0.32	2.97e-16	Pain;
BRCA	cis	rs9470366	0.848	rs9470361	chr6:36623379	G/A	cg08179530	chr6:36648295	CDKN1A	0.52	10.47	0.38	8.51e-24	QRS duration;
BRCA	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg26384229	chr12:38710491	ALG10B	0.71	16.45	0.55	5.52e-51	Bladder cancer;
BRCA	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg21573476	chr21:45109991	RRP1B	-0.47	-12.5	-0.44	3.09e-32	Mean corpuscular volume;
BRCA	cis	rs2652822	0.554	rs11635698	chr15:63478573	G/A	cg02713581	chr15:63449717	RPS27L	0.43	8.61	0.32	5.87e-17	Metabolic traits;
BRCA	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg09754948	chr16:28834200	ATXN2L	0.45	8.82	0.33	1.08e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg00277334	chr10:82204260	NA	-0.43	-8.37	-0.31	3.72e-16	Post bronchodilator FEV1;
BRCA	trans	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg25214090	chr10:38739885	LOC399744	0.49	10.55	0.39	4.29e-24	Corneal astigmatism;
BRCA	cis	rs921968	0.565	rs6436071	chr2:219598041	A/T	cg02176678	chr2:219576539	TTLL4	-0.4	-11.0	-0.4	6.73e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg23788917	chr6:8435910	SLC35B3	0.49	10.69	0.39	1.17e-24	Motion sickness;
BRCA	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg00825309	chr19:58991885	ZNF446	-0.57	-12.2	-0.43	6.55e-31	Uric acid clearance;
BRCA	trans	rs629535	0.814	rs55873935	chr8:70081646	G/A	cg21567404	chr3:27674614	NA	-1.01	-21.49	-0.65	1.59e-77	Dupuytren's disease;
BRCA	cis	rs6028335	0.610	rs72623594	chr20:37576255	G/A	cg16355469	chr20:37678765	NA	0.45	8.0	0.3	5.94e-15	Alcohol and nicotine co-dependence;
BRCA	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg00106254	chr7:1943704	MAD1L1	0.35	9.67	0.36	9.58e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg18225595	chr11:63971243	STIP1	-0.4	-10.07	-0.37	3.21e-22	Platelet count;
BRCA	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg13628971	chr7:2884303	GNA12	0.46	9.28	0.34	2.49e-19	Height;
BRCA	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg20933634	chr6:27740509	NA	0.42	8.2	0.31	1.34e-15	Parkinson's disease;
BRCA	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg20283391	chr11:68216788	NA	-0.42	-8.45	-0.32	1.92e-16	Total body bone mineral density;
BRCA	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg01448562	chr3:133502909	NA	-0.76	-18.85	-0.6	2.21e-63	Iron status biomarkers;
BRCA	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg11887960	chr12:57824829	NA	0.55	8.57	0.32	7.74e-17	Lung disease severity in cystic fibrosis;
BRCA	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg26384229	chr12:38710491	ALG10B	0.67	14.29	0.49	2.1e-40	Morning vs. evening chronotype;
BRCA	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg16339924	chr4:17578868	LAP3	0.76	19.09	0.6	1.32e-64	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3762637	1.000	rs72960431	chr3:122228661	T/C	cg24169773	chr3:122142474	KPNA1	-0.43	-8.03	-0.3	4.75e-15	LDL cholesterol levels;
BRCA	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg21045802	chr8:109455806	TTC35	0.35	8.02	0.3	5.19e-15	Dupuytren's disease;
BRCA	cis	rs870825	0.616	rs72705689	chr4:185639894	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	17.21	0.56	7.75e-55	Blood protein levels;
BRCA	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg14675211	chr2:100938903	LONRF2	0.5	11.42	0.41	1.35e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs17601876	0.814	rs8029537	chr15:51557698	A/G	cg19946085	chr15:51559439	CYP19A1	-0.38	-11.54	-0.42	4.02e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg27129171	chr3:47204927	SETD2	-0.72	-17.3	-0.56	2.67e-55	Colorectal cancer;
BRCA	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	10.47	0.38	8.91e-24	Height;
BRCA	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg24692254	chr21:30365293	RNF160	0.66	18.2	0.58	5.71e-60	Dental caries;
BRCA	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg19678392	chr7:94953810	PON1	0.42	8.55	0.32	9.05e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg26608667	chr7:1196370	ZFAND2A	0.37	9.13	0.34	8.62e-19	Longevity;Endometriosis;
BRCA	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg01448562	chr3:133502909	NA	-0.41	-9.41	-0.35	8.84e-20	Iron status biomarkers;
BRCA	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26314531	chr2:26401878	FAM59B	-0.79	-12.74	-0.45	2.75e-33	Gut microbiome composition (summer);
BRCA	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg13906792	chr15:75199810	C15orf17	-0.39	-9.18	-0.34	5.92e-19	Breast cancer;
BRCA	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.93	0.33	4.64e-18	Tonsillectomy;
BRCA	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg15704280	chr7:45808275	SEPT13	-0.44	-8.2	-0.31	1.32e-15	Intraocular pressure;
BRCA	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg00750074	chr16:89608354	SPG7	-0.34	-9.02	-0.34	2.1e-18	Multiple myeloma (IgH translocation);
BRCA	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.97	-0.3	7.41e-15	Depression;
BRCA	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg24846343	chr22:24311635	DDTL	-0.48	-11.76	-0.42	4.87e-29	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg06108461	chr20:60628389	TAF4	-0.79	-16.84	-0.55	6.46e-53	Body mass index;
BRCA	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg17063962	chr7:91808500	NA	0.53	12.43	0.44	6.26e-32	Breast cancer;
BRCA	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg07636037	chr3:49044803	WDR6	0.46	9.23	0.34	3.96e-19	Resting heart rate;
BRCA	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.28	0.49	2.49e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs4714291	0.963	rs940352	chr6:40113614	C/T	cg02267698	chr19:7991119	CTXN1	-0.42	-8.22	-0.31	1.14e-15	Strep throat;
BRCA	cis	rs4594175	0.962	rs8008182	chr14:51608357	C/T	cg23942311	chr14:51606299	NA	0.34	8.62	0.32	5.33e-17	Cancer;
BRCA	cis	rs7766436	0.767	rs13206434	chr6:22608883	A/G	cg13666174	chr6:22585274	NA	-0.35	-8.2	-0.31	1.35e-15	Coronary artery disease;
BRCA	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11890956	chr21:40555474	PSMG1	-0.54	-11.2	-0.41	1e-26	Menarche (age at onset);
BRCA	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-7.95	-0.3	8.55e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg23711669	chr6:146136114	FBXO30	-0.77	-18.25	-0.59	3.5e-60	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg07817883	chr1:32538562	TMEM39B	1.4	18.96	0.6	6.48e-64	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9814567	0.727	rs4543053	chr3:134351724	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-16.12	-0.54	2.55e-49	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.57	-8.88	-0.33	6.9e-18	HIV-1 control;
BRCA	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg20090143	chr19:45452003	APOC2	0.26	8.01	0.3	5.63e-15	Blood protein levels;
BRCA	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.35	-0.35	1.42e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	13.95	0.48	8.22e-39	Alzheimer's disease;
BRCA	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.63	-0.32	4.99e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg18230493	chr5:56204884	C5orf35	-0.73	-14.83	-0.51	5.96e-43	Initial pursuit acceleration;
BRCA	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg19274703	chr22:41806451	NA	0.29	8.33	0.31	4.89e-16	Vitiligo;
BRCA	cis	rs10267417	0.603	rs12666448	chr7:19859119	G/A	cg05791153	chr7:19748676	TWISTNB	0.48	9.46	0.35	5.96e-20	Night sleep phenotypes;
BRCA	cis	rs9324022	0.858	rs1004573	chr14:101178235	G/C	cg18089426	chr14:101175970	NA	0.63	11.99	0.43	5.19e-30	Plateletcrit;
BRCA	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg13319975	chr6:146136371	FBXO30	-0.41	-9.34	-0.35	1.52e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs965469	0.901	rs6037563	chr20:3326568	G/A	cg25506879	chr20:3388711	C20orf194	-0.55	-10.7	-0.39	1.07e-24	IFN-related cytopenia;
BRCA	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg27661571	chr11:113659931	NA	-0.73	-11.22	-0.41	8.26e-27	Hip circumference adjusted for BMI;
BRCA	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg23358479	chr7:1110784	C7orf50	-0.47	-7.9	-0.3	1.26e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg06636001	chr8:8085503	FLJ10661	0.68	15.43	0.52	7.16e-46	Mood instability;
BRCA	cis	rs4363385	0.818	rs451939	chr1:153006877	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs4730250	0.707	rs10953537	chr7:107027905	G/A	cg02696742	chr7:106810147	HBP1	-0.54	-8.66	-0.32	3.93e-17	Osteoarthritis;
BRCA	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11644478	chr21:40555479	PSMG1	-0.65	-13.8	-0.48	4.09e-38	Cognitive function;
BRCA	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg09163369	chr1:210001066	C1orf107	0.51	9.42	0.35	8.25e-20	Orofacial clefts;
BRCA	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg22920501	chr2:26401640	FAM59B	0.91	16.27	0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg00383909	chr3:49044727	WDR6	0.75	12.18	0.43	7.55e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg17063962	chr7:91808500	NA	0.49	11.35	0.41	2.45e-27	Breast cancer;
BRCA	cis	rs17641971	0.684	rs6984804	chr8:49987910	G/A	cg00325661	chr8:49890786	NA	0.37	10.36	0.38	2.39e-23	Blood metabolite levels;
BRCA	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.22	0.49	4.67e-40	Motion sickness;
BRCA	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.39	-9.36	-0.35	1.37e-19	Tonsillectomy;
BRCA	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg22467129	chr15:76604101	ETFA	-0.48	-10.76	-0.39	6.46e-25	Blood metabolite levels;
BRCA	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg21747090	chr2:27597821	SNX17	-0.45	-9.65	-0.36	1.2e-20	Total body bone mineral density;
BRCA	cis	rs9399401	0.710	rs7765770	chr6:142687305	C/T	cg03128060	chr6:142623767	GPR126	0.31	7.85	0.3	1.77e-14	Chronic obstructive pulmonary disease;
BRCA	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11764359	chr7:65958608	NA	0.61	13.45	0.47	1.75e-36	Aortic root size;
BRCA	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg22705602	chr4:152727874	NA	-0.34	-8.61	-0.32	5.47e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	11.19	0.4	1.17e-26	Monocyte percentage of white cells;
BRCA	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.57	-12.86	-0.45	8.19e-34	IgG glycosylation;
BRCA	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg08470875	chr2:26401718	FAM59B	-0.64	-9.39	-0.35	1.03e-19	Gut microbiome composition (summer);
BRCA	cis	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg07460842	chr6:66804631	NA	-0.95	-17.75	-0.57	1.27e-57	Exhaled nitric oxide output;
BRCA	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg01448562	chr3:133502909	NA	-0.62	-14.81	-0.51	7.04e-43	Iron status biomarkers;
BRCA	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg11789530	chr4:8429930	ACOX3	0.59	14.88	0.51	3.36e-43	Response to antineoplastic agents;
BRCA	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg03354898	chr7:1950403	MAD1L1	-0.4	-8.03	-0.3	4.6e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg08807101	chr21:30365312	RNF160	-0.42	-8.93	-0.33	4.36e-18	Pancreatic cancer;
BRCA	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.17	0.31	1.62e-15	Axial length;
BRCA	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-8.8	-0.33	1.26e-17	Alzheimer's disease (late onset);
BRCA	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11890956	chr21:40555474	PSMG1	1.04	29.81	0.76	5.03e-123	Cognitive function;
BRCA	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg05347473	chr6:146136440	FBXO30	-0.43	-8.58	-0.32	7.4e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-10.14	-0.37	1.7e-22	Alzheimer's disease;
BRCA	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg21475434	chr5:93447410	FAM172A	0.71	9.09	0.34	1.27e-18	Diabetic retinopathy;
BRCA	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg14668821	chr17:77704760	ENPP7	-0.34	-7.88	-0.3	1.41e-14	Menopause (age at onset);
BRCA	cis	rs6546550	0.867	rs726920	chr2:70152027	G/C	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.52	-0.41	5.13e-28	Prevalent atrial fibrillation;
BRCA	trans	rs2562456	0.834	rs2173727	chr19:21673957	C/T	cg25042112	chr7:64838748	ZNF92	0.42	8.11	0.31	2.57e-15	Pain;
BRCA	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18876405	chr7:65276391	NA	0.55	13.18	0.46	3.03e-35	Aortic root size;
BRCA	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg21724239	chr8:58056113	NA	0.57	9.24	0.34	3.72e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs30380	1.000	rs30379	chr5:96122260	T/G	cg16492584	chr5:96139282	ERAP1	-0.31	-7.95	-0.3	8.49e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg25358565	chr5:93447407	FAM172A	1.16	18.09	0.58	2.26e-59	Diabetic retinopathy;
BRCA	cis	rs7310409	0.544	rs1169292	chr12:121426478	C/T	cg02403541	chr12:121454288	C12orf43	0.52	9.63	0.36	1.42e-20	Liver enzyme levels (gamma-glutamyl transferase);C-reactive protein;Pancreatic cancer;
BRCA	cis	rs7395581	0.959	rs2167079	chr11:47270255	C/T	cg25783544	chr11:47291846	MADD	0.38	8.38	0.31	3.38e-16	HDL cholesterol;
BRCA	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg16145915	chr7:1198662	ZFAND2A	0.46	9.2	0.34	4.84e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs332507	0.830	rs879535	chr3:124400107	A/G	cg05980111	chr3:124395277	KALRN	0.36	8.39	0.32	3.03e-16	Plateletcrit;
BRCA	cis	rs6496044	0.568	rs7166642	chr15:86061271	A/G	cg10818794	chr15:86012489	AKAP13	-0.28	-7.83	-0.3	1.98e-14	Interstitial lung disease;
BRCA	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	12.12	0.43	1.42e-30	Mean platelet volume;
BRCA	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg03733263	chr8:22462867	KIAA1967	-0.81	-18.99	-0.6	4.4e-64	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs1904096	0.506	rs12511433	chr4:95162425	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-9.5	-0.35	4.01e-20	Type 2 diabetes;
BRCA	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg12698349	chr2:225449008	CUL3	0.61	13.49	0.47	1.14e-36	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg15017067	chr4:17643749	FAM184B	0.31	9.56	0.35	2.49e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs365132	0.934	rs6861925	chr5:176324729	C/G	cg16309518	chr5:176445507	NA	-0.5	-12.78	-0.45	1.85e-33	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.43	-0.41	1.17e-27	Personality dimensions;
BRCA	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.96	14.06	0.49	2.6e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg03709012	chr19:19516395	GATAD2A	-0.8	-18.34	-0.59	1.16e-60	Tonsillectomy;
BRCA	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg26168224	chr5:2018326	NA	-0.53	-11.91	-0.43	1.07e-29	Gut microbiome composition (winter);
BRCA	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.55	-9.57	-0.35	2.24e-20	Body mass index (adult);
BRCA	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg08213375	chr14:104286397	PPP1R13B	0.51	11.13	0.4	2.09e-26	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg15017067	chr4:17643749	FAM184B	0.31	8.38	0.31	3.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg20701182	chr2:24300061	SF3B14	0.68	10.04	0.37	4e-22	Lymphocyte counts;
BRCA	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg03213289	chr20:61660250	NA	0.61	16.28	0.54	4.14e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg17971929	chr21:40555470	PSMG1	0.8	18.62	0.59	3.74e-62	Cognitive function;
BRCA	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg09307838	chr4:120376055	NA	0.59	12.12	0.43	1.43e-30	Corneal astigmatism;
BRCA	cis	rs7715811	1.000	rs6554812	chr5:13762972	T/C	cg07548982	chr5:13769939	DNAH5	-0.38	-8.33	-0.31	4.85e-16	Subclinical atherosclerosis traits (other);
BRCA	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg00757033	chr12:89920650	WDR51B	0.54	10.87	0.39	2.31e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg25817165	chr18:72167213	CNDP2	-0.77	-19.53	-0.61	5.84e-67	Refractive error;
BRCA	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12292205	chr6:26970375	C6orf41	0.49	8.44	0.32	2.1e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg03161606	chr19:29218774	NA	0.46	8.04	0.3	4.23e-15	Methadone dose in opioid dependence;
BRCA	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg04455712	chr21:45112962	RRP1B	0.42	11.24	0.41	6.99e-27	Mean corpuscular volume;
BRCA	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-24.63	-0.7	1.09e-94	Monocyte count;
BRCA	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg14784868	chr12:69753453	YEATS4	0.77	25.03	0.7	6.89e-97	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg17063962	chr7:91808500	NA	0.57	13.42	0.47	2.28e-36	Breast cancer;
BRCA	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.81	-0.45	1.36e-33	Extrinsic epigenetic age acceleration;
BRCA	trans	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg04565464	chr8:145669602	NFKBIL2	0.37	8.14	0.31	2.06e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs6910061	1.000	rs28542236	chr6:11106966	T/C	cg27233058	chr6:11094804	LOC221710	0.53	9.35	0.35	1.45e-19	Diabetic kidney disease;
BRCA	cis	rs7903847	0.642	rs9888117	chr10:99159963	C/G	cg08345082	chr10:99160200	RRP12	-0.28	-8.39	-0.32	3.06e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7809950	0.817	rs58052742	chr7:107210003	A/G	cg23024343	chr7:107201750	COG5	0.46	9.45	0.35	6.21e-20	Coronary artery disease;
BRCA	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg12661370	chr5:149340060	SLC26A2	-0.51	-8.12	-0.31	2.39e-15	HIV-1 control;
BRCA	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03264133	chr6:25882463	NA	0.55	12.66	0.45	5.89e-33	Blood metabolite levels;
BRCA	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg14675211	chr2:100938903	LONRF2	0.48	11.09	0.4	2.83e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7520050	0.933	rs12565042	chr1:46299110	C/A	cg24296786	chr1:45957014	TESK2	0.41	9.34	0.35	1.55e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg24296786	chr1:45957014	TESK2	-0.39	-8.06	-0.3	3.84e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg26031613	chr14:104095156	KLC1	-0.44	-8.59	-0.32	6.45e-17	Schizophrenia;
BRCA	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg12311346	chr5:56204834	C5orf35	-0.78	-15.97	-0.53	1.52e-48	Initial pursuit acceleration;
BRCA	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg09307838	chr4:120376055	NA	-0.59	-12.16	-0.43	9.03e-31	Corneal astigmatism;
BRCA	cis	rs11874712	1.000	rs2298787	chr18:43669980	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.18	0.31	1.57e-15	Migraine - clinic-based;
BRCA	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.58e-15	Prostate cancer;
BRCA	cis	rs2882667	0.858	rs13176497	chr5:138446074	T/C	cg04439458	chr5:138467593	SIL1	-0.43	-10.75	-0.39	6.7e-25	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00166722	chr3:10149974	C3orf24	0.66	13.38	0.47	3.77e-36	Alzheimer's disease;
BRCA	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-13.06	-0.46	1.02e-34	Response to antipsychotic treatment;
BRCA	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg05707623	chr12:122985044	ZCCHC8	0.5	9.66	0.36	1.02e-20	Body mass index;
BRCA	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-9.94	-0.37	9.42e-22	Personality dimensions;
BRCA	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg25237894	chr2:233734115	C2orf82	0.44	14.19	0.49	6.04e-40	Coronary artery disease;
BRCA	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.95	21.14	0.64	1.34e-75	Smoking behavior;
BRCA	cis	rs78707713	0.535	rs3812705	chr10:71211146	A/G	cg12610070	chr10:71211762	TSPAN15	-0.33	-11.67	-0.42	1.11e-28	Venous thromboembolism;
BRCA	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg22875332	chr1:76189707	ACADM	0.66	15.64	0.53	6.25e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.23	0.38	7.21e-23	Calcium levels;
BRCA	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24110177	chr3:50126178	RBM5	-0.42	-11.32	-0.41	3.39e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg09307838	chr4:120376055	NA	0.75	16.02	0.54	7.92e-49	Corneal astigmatism;
BRCA	cis	rs11887277	0.684	rs2082610	chr2:27033440	G/A	cg12368169	chr2:27073192	DPYSL5	-0.28	-7.82	-0.3	2.12e-14	Obesity-related traits;
BRCA	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg17366294	chr4:99064904	C4orf37	0.41	9.63	0.36	1.39e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg05707623	chr12:122985044	ZCCHC8	-0.44	-8.75	-0.33	1.84e-17	Body mass index;
BRCA	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg04727924	chr7:799746	HEATR2	-0.53	-9.86	-0.36	1.95e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg04990556	chr1:26633338	UBXN11	0.55	8.51	0.32	1.19e-16	Obesity-related traits;
BRCA	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg21433313	chr16:3507492	NAT15	0.64	9.99	0.37	5.96e-22	Tuberculosis;
BRCA	trans	rs4596713	0.538	rs7029627	chr9:71745687	C/T	cg16512924	chr15:28394682	HERC2	0.4	9.45	0.35	6.24e-20	Headache;
BRCA	cis	rs7572733	0.515	rs6726506	chr2:198846486	G/T	cg00792783	chr2:198669748	PLCL1	0.44	9.68	0.36	8.7e-21	Dermatomyositis;
BRCA	cis	rs7631605	0.905	rs6550456	chr3:37181995	A/G	cg15934958	chr3:37212084	LRRFIP2	0.4	9.3	0.35	2.18e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg09455208	chr3:40491958	NA	0.41	9.72	0.36	6.24e-21	Renal cell carcinoma;
BRCA	trans	rs1974653	0.642	rs406086	chr22:20057806	C/T	cg20152630	chr19:46405944	MYPOP	0.39	8.19	0.31	1.44e-15	Schizophrenia;
BRCA	cis	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg14019146	chr3:50243930	SLC38A3	-0.48	-11.65	-0.42	1.42e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg26195577	chr20:24973756	C20orf3	1.02	26.33	0.72	4.96e-104	Blood protein levels;
BRCA	cis	rs7408868	1.000	rs10407320	chr19:15275716	G/C	cg14696996	chr19:15285081	NOTCH3	0.99	14.46	0.5	3.39e-41	Pulse pressure;
BRCA	cis	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg05901451	chr6:126070800	HEY2	0.39	9.6	0.36	1.76e-20	Endometrial cancer;
BRCA	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg14530993	chr4:882597	GAK	0.43	8.54	0.32	9.95e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.6	0.39	2.68e-24	Motion sickness;
BRCA	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg21747090	chr2:27597821	SNX17	-0.44	-9.63	-0.36	1.32e-20	Total body bone mineral density;
BRCA	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	7.93	0.3	9.55e-15	Retinal vascular caliber;
BRCA	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.58	-12.3	-0.44	2.23e-31	Hip circumference adjusted for BMI;
BRCA	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	22.0	0.66	2.67e-80	Chronic sinus infection;
BRCA	cis	rs9790314	0.663	rs778653	chr3:160716041	G/T	cg03342759	chr3:160939853	NMD3	-0.44	-9.09	-0.34	1.2e-18	Morning vs. evening chronotype;
BRCA	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg16325326	chr1:53192061	ZYG11B	0.74	18.85	0.6	2.37e-63	Monocyte count;
BRCA	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg17971929	chr21:40555470	PSMG1	-0.61	-13.4	-0.47	2.82e-36	Cognitive function;
BRCA	cis	rs11958404	0.932	rs72816550	chr5:157418457	A/T	cg05962755	chr5:157440814	NA	0.47	9.28	0.34	2.58e-19	IgG glycosylation;
BRCA	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg03929089	chr4:120376271	NA	0.6	10.4	0.38	1.63e-23	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg03146154	chr1:46216737	IPP	0.49	10.69	0.39	1.15e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7178424	0.967	rs4143842	chr15:62373113	A/C	cg00456672	chr15:62358751	C2CD4A	-0.34	-8.19	-0.31	1.41e-15	Height;
BRCA	cis	rs68170813	0.559	rs77605964	chr7:106962948	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-8.46	-0.32	1.82e-16	Coronary artery disease;
BRCA	cis	rs17021463	0.966	rs1565062	chr4:95183000	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-9.62	-0.36	1.56e-20	Testicular germ cell tumor;
BRCA	trans	rs8073060	0.660	rs58266733	chr17:34003812	A/T	cg19694781	chr19:47549865	TMEM160	-1.03	-21.11	-0.64	1.9e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	trans	rs4819388	0.724	rs4818888	chr21:45645307	C/T	cg17383793	chr5:52405638	MOCS2	0.48	10.75	0.39	6.56e-25	Celiac disease;
BRCA	cis	rs1499972	0.941	rs6769144	chr3:117624517	C/T	cg07612923	chr3:117604196	NA	0.6	8.1	0.31	2.86e-15	Schizophrenia;
BRCA	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg15704280	chr7:45808275	SEPT13	-0.42	-8.19	-0.31	1.39e-15	Height;
BRCA	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.47	0.38	9.08e-24	Motion sickness;
BRCA	cis	rs7520050	0.931	rs7526678	chr1:46374159	A/G	cg24296786	chr1:45957014	TESK2	0.43	9.85	0.36	2.18e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg07414643	chr4:187882934	NA	0.28	9.65	0.36	1.2e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg14343924	chr8:8086146	FLJ10661	0.36	7.93	0.3	9.79e-15	Mood instability;
BRCA	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	16.03	0.54	7.54e-49	Smoking behavior;
BRCA	trans	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg25214090	chr10:38739885	LOC399744	0.57	13.01	0.46	1.79e-34	Corneal astigmatism;
BRCA	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.84	0.42	2.32e-29	Tonsillectomy;
BRCA	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg22535103	chr8:58192502	C8orf71	-0.46	-9.06	-0.34	1.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.47	0.32	1.63e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg26769984	chr7:1090371	C7orf50	0.47	8.88	0.33	6.91e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg18404041	chr3:52824283	ITIH1	-0.29	-8.3	-0.31	6.35e-16	Electroencephalogram traits;
BRCA	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg11812906	chr14:75593930	NEK9	0.65	15.01	0.51	7.86e-44	Height;
BRCA	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25427524	chr10:38739819	LOC399744	-0.71	-17.4	-0.57	8.22e-56	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2180341	0.595	rs7771391	chr6:127749656	C/G	cg24812749	chr6:127587940	RNF146	0.61	13.12	0.46	5.5800000000000005e-35	Breast cancer;
BRCA	cis	rs3857067	0.806	rs7676797	chr4:95099194	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.38	-8.85	-0.33	8.85e-18	QT interval;
BRCA	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.92	0.33	4.94e-18	Motion sickness;
BRCA	trans	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg04565464	chr8:145669602	NFKBIL2	0.42	10.28	0.38	4.87e-23	Schizophrenia;
BRCA	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg08017756	chr2:100939284	LONRF2	-0.32	-8.14	-0.31	2.11e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02176678	chr2:219576539	TTLL4	0.46	11.88	0.43	1.57e-29	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1209950	0.901	rs1209953	chr21:40180383	T/A	cg01359822	chr21:40176597	ETS2	0.35	8.75	0.33	1.9e-17	Non-small cell lung cancer (survival);
BRCA	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg13902645	chr11:5959945	NA	-0.55	-11.16	-0.4	1.56e-26	DNA methylation (variation);
BRCA	cis	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05901451	chr6:126070800	HEY2	-0.4	-9.68	-0.36	8.74e-21	Endometrial cancer;
BRCA	cis	rs2046867	0.818	rs2208	chr3:72871773	A/G	cg25664220	chr3:72788482	NA	0.41	9.24	0.34	3.7e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg08738300	chr3:44038990	NA	0.44	8.63	0.32	4.81e-17	Coronary artery disease;
BRCA	cis	rs4363385	0.747	rs1415959	chr1:152973690	C/T	cg21543102	chr1:152974771	SPRR3	0.29	8.45	0.32	1.91e-16	Inflammatory skin disease;
BRCA	cis	rs7766436	1.000	rs13217022	chr6:22612757	T/C	cg13666174	chr6:22585274	NA	-0.39	-9.59	-0.35	1.97e-20	Coronary artery disease;
BRCA	cis	rs2425143	1.000	rs6060588	chr20:34337480	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.95	-0.33	3.71e-18	Blood protein levels;
BRCA	cis	rs2070433	0.706	rs55696586	chr21:47733918	T/C	cg12379764	chr21:47803548	PCNT	0.54	9.14	0.34	8.47e-19	Lymphocyte counts;
BRCA	cis	rs870825	0.616	rs28607131	chr4:185651617	A/G	cg04058563	chr4:185651563	MLF1IP	0.79	17.79	0.58	7.74e-58	Blood protein levels;
BRCA	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg04545296	chr12:48745243	ZNF641	0.24	7.92	0.3	1.06e-14	Obstructive sleep apnea trait (apnea hypopnea index);
BRCA	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg21573476	chr21:45109991	RRP1B	-0.35	-9.3	-0.35	2.23e-19	Mean corpuscular volume;
BRCA	cis	rs4561483	0.831	rs2018199	chr16:11940968	C/T	cg08843971	chr16:11963173	GSPT1	-0.38	-8.2	-0.31	1.28e-15	Testicular germ cell tumor;
BRCA	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg00277334	chr10:82204260	NA	-0.43	-8.51	-0.32	1.2e-16	Post bronchodilator FEV1;
BRCA	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg17971929	chr21:40555470	PSMG1	-0.47	-10.26	-0.38	5.59e-23	Menarche (age at onset);
BRCA	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg11584989	chr19:19387371	SF4	0.58	13.72	0.48	9.99e-38	Bipolar disorder;
BRCA	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg17420585	chr12:42539391	GXYLT1	-0.57	-14.32	-0.49	1.47e-40	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg11764359	chr7:65958608	NA	-0.47	-9.28	-0.34	2.64e-19	Calcium levels;
BRCA	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.33	-7.86	-0.3	1.63e-14	Personality dimensions;
BRCA	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	11.56	0.42	3.43e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg01689657	chr7:91764605	CYP51A1	0.22	8.12	0.31	2.42e-15	Breast cancer;
BRCA	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg17063962	chr7:91808500	NA	0.57	13.62	0.47	2.97e-37	Breast cancer;
BRCA	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg06784218	chr1:46089804	CCDC17	0.5	11.98	0.43	5.89e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg02297831	chr4:17616191	MED28	0.39	8.5	0.32	1.32e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7975161	0.671	rs7314893	chr12:104597769	C/T	cg25273343	chr12:104657179	TXNRD1	-0.38	-9.26	-0.34	3.09e-19	Toenail selenium levels;
BRCA	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg00745463	chr17:30367425	LRRC37B	-0.57	-9.39	-0.35	1.01e-19	Hip circumference adjusted for BMI;
BRCA	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.5	7.95	0.3	8.38e-15	Renal function-related traits (BUN);
BRCA	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg04545296	chr12:48745243	ZNF641	0.25	8.3	0.31	6.07e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg27535305	chr1:53392650	SCP2	-0.5	-12.31	-0.44	2.08e-31	Monocyte count;
BRCA	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06108461	chr20:60628389	TAF4	-0.73	-15.53	-0.52	2.3e-46	Body mass index;
BRCA	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg05340658	chr4:99064831	C4orf37	0.55	10.6	0.39	2.73e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg25801113	chr15:45476975	SHF	-0.33	-7.94	-0.3	9.26e-15	Uric acid levels;
BRCA	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg22974920	chr21:40686053	BRWD1	0.39	8.78	0.33	1.44e-17	Cognitive function;
BRCA	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg01191920	chr7:158217561	PTPRN2	-0.41	-10.15	-0.37	1.48e-22	Obesity-related traits;
BRCA	cis	rs10911251	0.546	rs20560	chr1:183105534	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.82	0.55	7.86e-53	Colorectal cancer;
BRCA	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg11502198	chr6:26597334	ABT1	0.57	12.22	0.44	5.24e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg14844989	chr11:31128820	NA	-0.44	-9.54	-0.35	3.05e-20	Red blood cell count;
BRCA	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18876405	chr7:65276391	NA	-0.5	-11.18	-0.4	1.25e-26	Aortic root size;
BRCA	cis	rs61990749	0.597	rs2267759	chr14:78147615	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.64	-10.05	-0.37	3.59e-22	Fibroblast growth factor basic levels;
BRCA	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg11843606	chr2:227700838	RHBDD1	0.49	11.32	0.41	3.45e-27	Pulmonary function;
BRCA	trans	rs8073060	0.586	rs72829922	chr17:34044809	G/A	cg19694781	chr19:47549865	TMEM160	1.07	20.64	0.63	6.34e-73	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg05623727	chr3:50126028	RBM5	0.42	8.15	0.31	1.86e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00166722	chr3:10149974	C3orf24	0.65	12.85	0.45	8.73e-34	Alzheimer's disease;
BRCA	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg15704280	chr7:45808275	SEPT13	0.5	8.69	0.33	3.01e-17	Axial length;
BRCA	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg19508488	chr2:152266495	RIF1	0.45	10.23	0.38	7.79e-23	Lung cancer;
BRCA	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg24692254	chr21:30365293	RNF160	-0.52	-11.84	-0.42	2.19e-29	Cognitive test performance;
BRCA	cis	rs68170813	0.559	rs75313693	chr7:106863170	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-8.47	-0.32	1.72e-16	Coronary artery disease;
BRCA	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg12000995	chr2:27665139	KRTCAP3	0.33	8.38	0.31	3.44e-16	Total body bone mineral density;
BRCA	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.95	17.45	0.57	4.5e-56	Gut microbiome composition (summer);
BRCA	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg08601574	chr20:25228251	PYGB	0.34	8.36	0.31	3.94e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1011018	0.590	rs77907480	chr7:139453119	T/C	cg03224163	chr7:139420300	HIPK2	-0.59	-8.94	-0.33	4.27e-18	Systolic blood pressure;
BRCA	cis	rs7633770	0.643	rs1581325	chr3:46691866	T/C	cg11219411	chr3:46661640	NA	-0.47	-11.07	-0.4	3.56e-26	Coronary artery disease;
BRCA	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	13.99	0.48	5.45e-39	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	trans	rs629535	0.821	rs660144	chr8:70035629	T/C	cg21567404	chr3:27674614	NA	1.0	21.1	0.64	2.22e-75	Dupuytren's disease;
BRCA	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg21132104	chr15:45694354	SPATA5L1	0.74	16.82	0.55	7.77e-53	Homoarginine levels;
BRCA	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg11833968	chr6:79620685	NA	-0.41	-9.16	-0.34	6.82e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg08888203	chr3:10149979	C3orf24	-0.57	-11.95	-0.43	7.91e-30	Alzheimer's disease;
BRCA	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18876405	chr7:65276391	NA	-0.63	-15.65	-0.53	5.63e-47	Aortic root size;
BRCA	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg12292205	chr6:26970375	C6orf41	-0.65	-10.63	-0.39	2.02e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg06627628	chr2:24431161	ITSN2	-0.85	-15.66	-0.53	5.08e-47	Asthma;
BRCA	cis	rs919433	0.519	rs700656	chr2:198653667	T/C	cg00792783	chr2:198669748	PLCL1	0.47	10.16	0.37	1.35e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6750795	0.569	rs1667313	chr2:232408018	A/C	cg19187155	chr2:232395269	NMUR1	0.69	17.51	0.57	2.31e-56	Height;
BRCA	cis	rs1971762	0.583	rs11170648	chr12:54089660	C/T	cg23533419	chr12:54090519	NA	-0.33	-8.39	-0.31	3.22e-16	Height;
BRCA	cis	rs4363385	0.818	rs679378	chr1:153011716	G/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.24	-0.34	3.56e-19	Inflammatory skin disease;
BRCA	cis	rs858239	0.537	rs2286272	chr7:23224367	T/C	cg23682824	chr7:23144976	KLHL7	0.34	8.73	0.33	2.28e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg16102102	chr5:83017553	HAPLN1	-0.9	-18.33	-0.59	1.22e-60	Prostate cancer;
BRCA	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg21573476	chr21:45109991	RRP1B	-0.35	-9.04	-0.34	1.85e-18	Mean corpuscular volume;
BRCA	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg09060608	chr5:178986726	RUFY1	-0.62	-16.39	-0.54	1.1e-50	Lung cancer;
BRCA	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg13119609	chr19:45449297	APOC2	0.47	13.08	0.46	8.51e-35	Blood protein levels;
BRCA	cis	rs2011503	0.509	rs73006705	chr19:19781917	A/G	cg11584989	chr19:19387371	SF4	0.4	7.98	0.3	6.96e-15	Bipolar disorder;
BRCA	cis	rs7927771	0.524	rs4752798	chr11:47886364	T/C	cg20307385	chr11:47447363	PSMC3	-0.39	-9.29	-0.34	2.36e-19	Subjective well-being;
BRCA	cis	rs2677744	0.626	rs11857545	chr15:91489705	G/A	cg23684204	chr15:91497937	RCCD1	0.44	8.79	0.33	1.33e-17	Attention deficit hyperactivity disorder;
BRCA	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg09658497	chr7:2847517	GNA12	-0.47	-10.47	-0.38	8.53e-24	Height;
BRCA	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg12386194	chr3:101231763	SENP7	0.46	9.7	0.36	7.74e-21	Colorectal cancer;
BRCA	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg11952622	chr19:58962976	ZNF324B	0.39	8.25	0.31	9.18e-16	Uric acid clearance;
BRCA	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg03188948	chr7:1209495	NA	0.43	8.29	0.31	6.59e-16	Longevity;Endometriosis;
BRCA	cis	rs1997103	1.000	rs4947501	chr7:55407342	C/T	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	14.34	0.49	1.27e-40	Hip circumference adjusted for BMI;
BRCA	cis	rs58785573	0.504	rs3860067	chr4:38611905	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.4	7.81	0.3	2.27e-14	Lymphocyte percentage of white cells;
BRCA	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg06623918	chr6:96969491	KIAA0776	-0.84	-23.15	-0.68	1.44e-86	Headache;
BRCA	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg03954927	chr1:10346856	KIF1B	0.47	14.07	0.49	2.34e-39	Hepatocellular carcinoma;
BRCA	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg04450456	chr4:17643702	FAM184B	0.33	9.51	0.35	3.74e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7072216	0.763	rs7910247	chr10:100172252	C/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.68	-0.36	9.24e-21	Metabolite levels;
BRCA	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg03929089	chr4:120376271	NA	0.49	8.21	0.31	1.24e-15	Axial length;
BRCA	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	8.96	0.33	3.58e-18	Tonsillectomy;
BRCA	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg08999081	chr20:33150536	PIGU	0.49	13.91	0.48	1.22e-38	Coronary artery disease;
BRCA	cis	rs11997175	0.766	rs4733178	chr8:33691899	A/T	ch.8.33884649F	chr8:33765107	NA	0.35	8.32	0.31	5.3e-16	Body mass index;
BRCA	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-8.59	-0.32	6.66e-17	IgG glycosylation;
BRCA	cis	rs7191700	0.644	rs12149160	chr16:11439303	G/T	cg00044050	chr16:11439710	C16orf75	-0.51	-12.17	-0.43	8.75e-31	Multiple sclerosis;
BRCA	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg17971929	chr21:40555470	PSMG1	-0.62	-13.61	-0.47	3.22e-37	Cognitive function;
BRCA	cis	rs56399783	0.901	rs11971014	chr7:2778444	C/T	cg19731401	chr7:2775893	GNA12	0.48	8.29	0.31	6.48e-16	Childhood ear infection;
BRCA	cis	rs4974559	0.739	rs28573879	chr4:1285910	C/T	cg02980000	chr4:1222292	CTBP1	0.81	13.36	0.47	4.34e-36	Systolic blood pressure;
BRCA	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg18876405	chr7:65276391	NA	0.5	11.26	0.41	5.79e-27	Aortic root size;
BRCA	cis	rs10208940	0.920	rs7580719	chr2:68833572	A/G	cg12452813	chr2:68675892	NA	-0.5	-8.77	-0.33	1.57e-17	Urate levels in lean individuals;
BRCA	trans	rs1422110	0.519	rs12055343	chr5:85437684	T/C	cg01787110	chr1:109008453	NBPF6	0.4	8.66	0.32	3.94e-17	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs1997103	1.000	rs6957984	chr7:55397331	G/A	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.72e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg18196295	chr10:418757	DIP2C	-0.58	-13.59	-0.47	3.87e-37	Psychosis in Alzheimer's disease;
BRCA	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg26248373	chr2:1572462	NA	0.46	9.03	0.34	2.08e-18	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg06064525	chr11:970664	AP2A2	-0.34	-10.0	-0.37	5.73e-22	Alzheimer's disease (late onset);
BRCA	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg13010199	chr12:38710504	ALG10B	0.52	10.83	0.39	3.26e-25	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs13046373	0.535	rs1911571	chr21:32031538	A/C	cg16431978	chr21:31797932	KRTAP13-3	0.36	9.22	0.34	4.38e-19	HDL cholesterol;
BRCA	cis	rs4845875	0.600	rs1889293	chr1:11840862	G/A	cg24844545	chr1:11908347	NPPA	0.37	8.66	0.32	3.76e-17	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs8028182	0.636	rs4886716	chr15:75856022	G/C	cg20655648	chr15:75932815	IMP3	0.44	8.42	0.32	2.43e-16	Sudden cardiac arrest;
BRCA	cis	rs3741151	0.773	rs79994237	chr11:73147974	T/C	cg17517138	chr11:73019481	ARHGEF17	0.86	12.12	0.43	1.46e-30	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg26168224	chr5:2018326	NA	0.64	17.74	0.57	1.49e-57	Gut microbiome composition (winter);
BRCA	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg24006582	chr15:45444508	DUOX1	-0.56	-11.55	-0.42	3.82e-28	Uric acid levels;
BRCA	trans	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg25214090	chr10:38739885	LOC399744	0.56	12.96	0.46	2.75e-34	Corneal astigmatism;
BRCA	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00149659	chr3:10157352	C3orf10	0.73	12.63	0.45	8.44e-33	Alzheimer's disease;
BRCA	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg26597838	chr10:835615	NA	0.95	14.86	0.51	4.14e-43	Eosinophil percentage of granulocytes;
BRCA	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg12011299	chr4:100065546	ADH4	0.42	10.56	0.39	3.96e-24	Alcohol dependence;
BRCA	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg20503657	chr10:835505	NA	1.04	18.27	0.59	2.66e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs68170813	0.559	rs12535258	chr7:106971050	T/C	cg02696742	chr7:106810147	HBP1	-0.55	-9.02	-0.34	2.24e-18	Coronary artery disease;
BRCA	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg23711669	chr6:146136114	FBXO30	0.74	17.43	0.57	5.6e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.818	rs407103	chr1:153007106	C/T	cg25856811	chr1:152973957	SPRR3	0.31	8.32	0.31	5.34e-16	Inflammatory skin disease;
BRCA	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg09184832	chr6:79620586	NA	0.48	10.63	0.39	2.1e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.47	-0.41	8.25e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs1005224	0.889	rs2059382	chr14:76158916	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.35	-8.33	-0.31	4.85e-16	Large artery stroke;
BRCA	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg03433033	chr1:76189801	ACADM	-0.5	-9.9	-0.36	1.35e-21	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7020830	0.931	rs7851239	chr9:37138672	A/G	cg14294708	chr9:37120828	ZCCHC7	-1.01	-28.45	-0.75	1.13e-115	Schizophrenia;
BRCA	cis	rs17095355	1.000	rs12247564	chr10:111721400	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.82	-0.36	2.69e-21	Biliary atresia;
BRCA	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.57	-12.81	-0.45	1.3e-33	Longevity;Endometriosis;
BRCA	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg17063962	chr7:91808500	NA	-0.52	-11.75	-0.42	5.13e-29	Breast cancer;
BRCA	cis	rs80130819	0.515	rs917055	chr12:48385576	A/G	cg05342945	chr12:48394962	COL2A1	-0.5	-9.62	-0.36	1.44e-20	Prostate cancer;
BRCA	cis	rs9880211	0.898	rs9870825	chr3:136065720	C/A	cg21827317	chr3:136751795	NA	-0.46	-8.2	-0.31	1.36e-15	Body mass index;Height;
BRCA	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg17971929	chr21:40555470	PSMG1	0.77	18.19	0.58	6.68e-60	Cognitive function;
BRCA	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.9	0.36	1.36e-21	Bipolar disorder;
BRCA	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg14061069	chr19:46274453	DMPK	-0.48	-11.86	-0.42	1.84e-29	Coronary artery disease;
BRCA	cis	rs754466	0.580	rs1054608	chr10:79543308	T/G	cg17075019	chr10:79541650	NA	-0.89	-24.82	-0.7	9.73e-96	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10746514	0.833	rs11122428	chr1:232261417	A/G	cg09506761	chr1:232265262	NA	-0.42	-8.64	-0.32	4.54e-17	Response to statin therapy;
BRCA	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg08422745	chr4:174089978	GALNT7	0.83	15.61	0.53	8.91e-47	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs1577917	1.000	rs7747824	chr6:86647106	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.38	-0.41	1.81e-27	Response to antipsychotic treatment;
BRCA	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	15.87	0.53	4.82e-48	Platelet count;
BRCA	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg06766960	chr11:133703094	NA	-0.61	-12.93	-0.46	4.09e-34	Childhood ear infection;
BRCA	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg18154014	chr19:37997991	ZNF793	-0.54	-10.05	-0.37	3.62e-22	Coronary artery calcification;
BRCA	cis	rs35110281	0.667	rs4818859	chr21:45117120	G/A	cg21573476	chr21:45109991	RRP1B	-0.4	-10.34	-0.38	2.88e-23	Mean corpuscular volume;
BRCA	cis	rs7766436	0.583	rs6939360	chr6:22557097	C/T	cg13666174	chr6:22585274	NA	-0.39	-7.85	-0.3	1.78e-14	Coronary artery disease;
BRCA	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.61	0.42	2.17e-28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg08999081	chr20:33150536	PIGU	0.44	11.76	0.42	4.8e-29	Coronary artery disease;
BRCA	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg02743256	chr7:2109353	MAD1L1	-0.46	-8.1	-0.31	2.78e-15	Neuroticism;
BRCA	cis	rs9649465	0.967	rs13225110	chr7:123340849	C/T	cg04330084	chr7:123175371	IQUB	-0.32	-8.81	-0.33	1.21e-17	Migraine;
BRCA	cis	rs12541635	1.000	rs1864320	chr8:107088979	C/T	cg10147462	chr8:107024639	NA	0.3	8.44	0.32	2.19e-16	Age of smoking initiation;
BRCA	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg26395211	chr5:140044315	WDR55	0.35	7.85	0.3	1.81e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg18132916	chr6:79620363	NA	-0.45	-10.35	-0.38	2.54e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg16576597	chr16:28551801	NUPR1	0.3	8.44	0.32	2.14e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg06238570	chr21:40685208	BRWD1	-0.45	-8.83	-0.33	9.81e-18	Cognitive function;
BRCA	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg12310025	chr6:25882481	NA	-0.61	-13.48	-0.47	1.28e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg12011299	chr4:100065546	ADH4	0.48	10.84	0.39	3.09e-25	Smoking initiation;
BRCA	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg13736514	chr6:26305472	NA	-0.36	-12.21	-0.43	5.69e-31	Educational attainment;
BRCA	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg06115741	chr20:33292138	TP53INP2	0.35	7.89	0.3	1.29e-14	Glomerular filtration rate (creatinine);
BRCA	cis	rs8017423	0.608	rs12588149	chr14:90822676	G/A	cg04374321	chr14:90722782	PSMC1	-0.48	-11.73	-0.42	6.35e-29	Mortality in heart failure;
BRCA	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg09163369	chr1:210001066	C1orf107	0.52	9.62	0.36	1.54e-20	Orofacial clefts;
BRCA	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	27.89	0.74	1.38e-112	Chronic sinus infection;
BRCA	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.85	0.39	2.76e-25	Cognitive ability;
BRCA	cis	rs4363385	0.747	rs9919333	chr1:152968744	G/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.22	-0.31	1.17e-15	Inflammatory skin disease;
BRCA	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14442939	chr10:27389572	ANKRD26	0.66	11.0	0.4	6.68e-26	Breast cancer;
BRCA	cis	rs4363385	0.720	rs6672735	chr1:152981086	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.1	-0.34	1.17e-18	Inflammatory skin disease;
BRCA	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg26031613	chr14:104095156	KLC1	-0.45	-8.62	-0.32	5.1e-17	Schizophrenia;
BRCA	cis	rs10754283	0.557	rs1215511	chr1:90087543	C/A	cg21401794	chr1:90099060	LRRC8C	0.37	8.13	0.31	2.17e-15	Amyotrophic lateral sclerosis (sporadic);
BRCA	trans	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg15704280	chr7:45808275	SEPT13	0.6	8.88	0.33	6.87e-18	Axial length;
BRCA	cis	rs35995292	0.553	rs2392605	chr7:38924670	T/C	cg19327137	chr7:38886074	VPS41	0.39	13.36	0.47	4.46e-36	Subjective well-being (multi-trait analysis);
BRCA	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg12698349	chr2:225449008	CUL3	0.77	21.08	0.64	2.75e-75	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs758324	0.947	rs13170693	chr5:131187826	T/C	cg06307176	chr5:131281290	NA	0.53	10.27	0.38	5.49e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14442939	chr10:27389572	ANKRD26	0.53	9.18	0.34	6.07e-19	Breast cancer;
BRCA	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg04998671	chr14:104000505	TRMT61A	0.48	10.04	0.37	4.12e-22	Coronary artery disease;
BRCA	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg24531977	chr5:56204891	C5orf35	0.52	10.87	0.4	2.2e-25	Coronary artery disease;
BRCA	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg17366294	chr4:99064904	C4orf37	0.47	10.97	0.4	8.76e-26	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg06521331	chr12:34319734	NA	-0.48	-8.78	-0.33	1.47e-17	Bladder cancer;
BRCA	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg03354898	chr7:1950403	MAD1L1	-0.59	-14.17	-0.49	7.65e-40	Bipolar disorder and schizophrenia;
BRCA	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg25237894	chr2:233734115	C2orf82	0.37	10.51	0.38	6.37e-24	Coronary artery disease;
BRCA	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.06	-0.34	1.62e-18	Menopause (age at onset);
BRCA	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg01028140	chr2:1542097	TPO	-0.6	-12.54	-0.44	1.99e-32	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs870825	0.616	rs2090589	chr4:185647731	A/G	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.56	-0.32	8.35e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg17145862	chr1:211918768	LPGAT1	-0.64	-16.46	-0.55	5.46e-51	Leprosy;
BRCA	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg25801113	chr15:45476975	SHF	0.31	7.82	0.3	2.22e-14	Uric acid levels;
BRCA	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg03709012	chr19:19516395	GATAD2A	1.08	20.92	0.64	1.98e-74	Nonalcoholic fatty liver disease;
BRCA	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.88	0.56	3.66e-53	Colorectal cancer;
BRCA	cis	rs6942756	1.000	rs6980385	chr7:128943615	G/A	cg02491457	chr7:128862824	NA	-0.7	-13.72	-0.48	9.57e-38	White matter hyperintensity burden;
BRCA	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg06484146	chr7:12443880	VWDE	-0.75	-10.82	-0.39	3.54e-25	Coronary artery disease;
BRCA	cis	rs735860	0.712	rs9395855	chr6:53176765	G/T	cg10236188	chr6:53219634	NA	-0.41	-8.92	-0.33	4.87e-18	Glaucoma;
BRCA	cis	rs7520050	0.966	rs1707335	chr1:46571921	C/T	cg24296786	chr1:45957014	TESK2	0.43	9.71	0.36	6.81e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4285028	0.948	rs12493408	chr3:121692119	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.88	-0.4	2.15e-25	Multiple sclerosis;
BRCA	cis	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg07460842	chr6:66804631	NA	1.0	20.0	0.62	1.76e-69	Exhaled nitric oxide output;
BRCA	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg03060546	chr3:49711283	APEH	0.41	9.08	0.34	1.31e-18	Menarche (age at onset);
BRCA	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg19336497	chr11:14380999	RRAS2	-0.46	-11.39	-0.41	1.64e-27	Sense of smell;
BRCA	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg02153584	chr22:29168773	CCDC117	-0.51	-10.46	-0.38	9.59e-24	Lymphocyte counts;
BRCA	cis	rs4919694	1.000	rs17727391	chr10:104836101	C/A	cg04362960	chr10:104952993	NT5C2	0.94	14.59	0.5	8.33e-42	Arsenic metabolism;
BRCA	cis	rs654950	0.806	rs2759251	chr1:42041749	C/G	cg06885757	chr1:42089581	HIVEP3	-0.3	-10.31	-0.38	3.8e-23	Airway imaging phenotypes;
BRCA	cis	rs8077889	0.619	rs1230399	chr17:41845403	C/T	cg26893861	chr17:41843967	DUSP3	-0.95	-24.92	-0.7	2.76e-96	Triglycerides;
BRCA	cis	rs939658	0.805	rs1915726	chr15:79420620	C/G	cg17916960	chr15:79447300	NA	-0.45	-10.91	-0.4	1.53e-25	Refractive error;
BRCA	trans	rs61931739	0.513	rs2200555	chr12:33899381	C/G	cg13010199	chr12:38710504	ALG10B	0.37	8.12	0.31	2.49e-15	Morning vs. evening chronotype;
BRCA	cis	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg22729335	chr19:2427816	TIMM13	1.0	25.6	0.71	4.97e-100	Cortisol levels (saliva);
BRCA	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg03808351	chr9:123631620	PHF19	0.4	7.94	0.3	9.06e-15	Rheumatoid arthritis;
BRCA	cis	rs6910061	1.000	rs9468412	chr6:11095876	C/T	cg27233058	chr6:11094804	LOC221710	0.51	9.16	0.34	6.73e-19	Diabetic kidney disease;
BRCA	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg12620499	chr2:216877984	MREG	0.55	14.18	0.49	7.16e-40	Alcohol dependence;
BRCA	trans	rs12517041	1.000	rs10072527	chr5:23318246	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-8.11	-0.31	2.55e-15	Calcium levels;
BRCA	cis	rs722599	0.748	rs1059326	chr14:75369385	C/T	cg08847533	chr14:75593920	NEK9	-0.44	-7.97	-0.3	7.19e-15	IgG glycosylation;
BRCA	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg00666640	chr1:248458726	OR2T12	0.3	8.45	0.32	2e-16	Common traits (Other);
BRCA	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg05283184	chr6:79620031	NA	-0.43	-11.0	-0.4	6.58e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs3784262	0.669	rs4646579	chr15:58329528	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.3	-0.38	3.86e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs672059	1.000	rs510642	chr1:183162776	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.38	8.68	0.32	3.3e-17	Hypertriglyceridemia;
BRCA	cis	rs4588572	0.643	rs13359053	chr5:77690224	T/C	cg11547950	chr5:77652471	NA	0.44	7.82	0.3	2.21e-14	Triglycerides;
BRCA	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.16	-0.37	1.39e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg23762105	chr12:34175262	ALG10	0.35	7.9	0.3	1.22e-14	Morning vs. evening chronotype;
BRCA	cis	rs847577	0.572	rs847573	chr7:97681761	C/T	cg24562669	chr7:97807699	LMTK2	-0.44	-10.41	-0.38	1.45e-23	Breast cancer;
BRCA	cis	rs350251	0.899	rs350274	chr16:12233259	G/C	cg06014057	chr16:12226852	SNX29	0.29	7.91	0.3	1.15e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs3784262	0.565	rs12595410	chr15:58293040	A/G	cg12031962	chr15:58353849	ALDH1A2	0.32	8.4	0.32	2.91e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg10729496	chr3:10149963	C3orf24	0.42	8.08	0.3	3.25e-15	Alzheimer's disease;
BRCA	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs9811920	0.928	rs9865713	chr3:99870299	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.5	11.65	0.42	1.35e-28	Axial length;
BRCA	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg08392591	chr16:89556376	ANKRD11	0.55	13.64	0.47	2.2e-37	Multiple myeloma (IgH translocation);
BRCA	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	9.5	0.35	3.97e-20	Personality dimensions;
BRCA	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg13628971	chr7:2884303	GNA12	0.47	9.45	0.35	6.45e-20	Height;
BRCA	cis	rs1997103	1.000	rs2331063	chr7:55408914	A/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg24296786	chr1:45957014	TESK2	-0.39	-8.13	-0.31	2.17e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs36051895	0.664	rs7852755	chr9:5100862	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-9.92	-0.37	1.17e-21	Pediatric autoimmune diseases;
BRCA	cis	rs7555523	0.887	rs2251768	chr1:165738311	A/T	cg24409356	chr1:165738333	TMCO1	0.5	8.27	0.31	7.87e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.3	-8.02	-0.3	5.19e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg14458575	chr2:238380390	NA	0.52	8.6	0.32	6.28e-17	Prostate cancer;
BRCA	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.47	9.3	0.35	2.17e-19	Hemoglobin concentration;
BRCA	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg13319975	chr6:146136371	FBXO30	0.39	8.93	0.33	4.54e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg23029597	chr12:123009494	RSRC2	-0.47	-9.56	-0.35	2.41e-20	Body mass index;
BRCA	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg23708337	chr7:1209742	NA	0.55	11.5	0.41	5.84e-28	Longevity;Endometriosis;
BRCA	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.25	0.41	6.2e-27	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.57	-0.32	7.58e-17	Monocyte percentage of white cells;
BRCA	cis	rs243505	1.000	rs243505	chr7:148435339	A/G	cg09806900	chr7:148480153	CUL1	-0.39	-8.09	-0.3	3.07e-15	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.43	-0.32	2.26e-16	Monocyte percentage of white cells;
BRCA	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03188948	chr7:1209495	NA	0.65	13.73	0.48	8.98e-38	Longevity;Endometriosis;
BRCA	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg04166393	chr7:2884313	GNA12	0.4	8.26	0.31	8.2e-16	Height;
BRCA	cis	rs4363385	0.747	rs11205149	chr1:152958840	C/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.34	-0.35	1.58e-19	Inflammatory skin disease;
BRCA	cis	rs644148	0.730	rs2571044	chr19:44985573	G/A	cg15540054	chr19:45004280	ZNF180	-0.5	-9.76	-0.36	4.61e-21	Personality dimensions;
BRCA	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg01939980	chr4:1354348	KIAA1530	0.29	7.82	0.3	2.15e-14	Longevity;
BRCA	cis	rs6028335	0.674	rs6028234	chr20:37607869	A/C	cg16355469	chr20:37678765	NA	0.47	8.61	0.32	5.86e-17	Alcohol and nicotine co-dependence;
BRCA	cis	rs9880211	0.898	rs28877020	chr3:136395716	T/G	cg21827317	chr3:136751795	NA	-0.45	-8.15	-0.31	1.92e-15	Body mass index;Height;
BRCA	trans	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg06521331	chr12:34319734	NA	-0.45	-8.39	-0.32	3.11e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg18196295	chr10:418757	DIP2C	0.51	12.3	0.44	2.24e-31	Psychosis in Alzheimer's disease;
BRCA	cis	rs11051970	0.659	rs950081	chr12:32588488	T/G	cg02745156	chr12:32552066	NA	0.27	8.21	0.31	1.27e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs16958440	0.708	rs62096477	chr18:44662310	G/A	cg17192377	chr18:44677553	HDHD2	0.49	8.3	0.31	6.37e-16	Sitting height ratio;
BRCA	cis	rs13095912	1.000	rs2034344	chr3:185337788	T/C	cg11274856	chr3:185301563	NA	0.34	8.38	0.31	3.3e-16	Systolic blood pressure;
BRCA	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg26384229	chr12:38710491	ALG10B	0.43	10.27	0.38	5.36e-23	Heart rate;
BRCA	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.83e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-14.7	-0.5	2.44e-42	Bladder cancer;
BRCA	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.69	13.96	0.48	7.58e-39	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg05340658	chr4:99064831	C4orf37	0.69	17.37	0.57	1.19e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9788721	0.836	rs2009746	chr15:78754102	A/G	cg18825076	chr15:78729989	IREB2	-0.4	-8.26	-0.31	8.4e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg20503657	chr10:835505	NA	1.03	18.0	0.58	6.32e-59	Eosinophil percentage of granulocytes;
BRCA	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg04013093	chr6:42928303	GNMT	-0.29	-8.86	-0.33	7.83e-18	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11890956	chr21:40555474	PSMG1	-0.83	-21.32	-0.64	1.46e-76	Cognitive function;
BRCA	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.16	0.49	8.36e-40	Motion sickness;
BRCA	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.72e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7394190	0.748	rs2306327	chr10:75573778	A/T	cg07699608	chr10:75541558	CHCHD1	0.67	10.06	0.37	3.47e-22	Incident atrial fibrillation;
BRCA	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg08888203	chr3:10149979	C3orf24	0.57	10.26	0.38	5.51e-23	Alzheimer's disease;
BRCA	cis	rs6545883	0.894	rs7572603	chr2:61552145	C/G	cg15711740	chr2:61764176	XPO1	0.51	13.05	0.46	1.16e-34	Tuberculosis;
BRCA	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg21475434	chr5:93447410	FAM172A	0.65	8.54	0.32	1.01e-16	Diabetic retinopathy;
BRCA	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	16.76	0.55	1.6e-52	Bone mineral density;
BRCA	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg12923728	chr3:195709715	SDHAP1	0.52	7.95	0.3	8.25e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg17366294	chr4:99064904	C4orf37	0.42	9.76	0.36	4.45e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg00383909	chr3:49044727	WDR6	0.45	9.62	0.36	1.47e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg25482853	chr8:67687455	SGK3	0.54	10.34	0.38	2.76e-23	Obesity-related traits;
BRCA	cis	rs877282	0.583	rs7072970	chr10:822757	G/A	cg15764593	chr10:829463	NA	-0.64	-10.26	-0.38	6.01e-23	Uric acid levels;
BRCA	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.83	-0.77	1.4e-128	Schizophrenia;
BRCA	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07080220	chr10:102295463	HIF1AN	0.5	11.36	0.41	2.23e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	16.69	0.55	3.74e-52	Alzheimer's disease;
BRCA	cis	rs1420338	0.933	rs10253869	chr7:34149922	A/G	cg01275685	chr7:34179230	BMPER	-0.46	-10.17	-0.37	1.3e-22	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg12311346	chr5:56204834	C5orf35	0.61	12.9	0.45	5.35e-34	Initial pursuit acceleration;
BRCA	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg07636037	chr3:49044803	WDR6	0.98	28.98	0.75	1.45e-118	Parkinson's disease;
BRCA	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg13047869	chr3:10149882	C3orf24	0.57	10.42	0.38	1.43e-23	Alzheimer's disease;
BRCA	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.33	-8.98	-0.33	3.01e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg11584989	chr19:19387371	SF4	0.32	8.25	0.31	9.01e-16	Tonsillectomy;
BRCA	cis	rs7254827	0.737	rs12982665	chr19:17158027	C/T	cg19418318	chr19:17219073	MYO9B	-0.48	-10.17	-0.37	1.29e-22	Mean platelet volume;
BRCA	cis	rs7766436	0.885	rs3734215	chr6:22571323	T/C	cg13666174	chr6:22585274	NA	-0.48	-11.15	-0.4	1.62e-26	Coronary artery disease;
BRCA	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg02569458	chr12:86230093	RASSF9	0.32	7.81	0.3	2.4e-14	Major depressive disorder;
BRCA	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg09307838	chr4:120376055	NA	0.6	13.04	0.46	1.3e-34	Corneal astigmatism;
BRCA	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.34	-10.77	-0.39	5.72e-25	Bipolar disorder;
BRCA	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg05340658	chr4:99064831	C4orf37	-0.48	-11.3	-0.41	3.9e-27	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.84	-0.3	1.87e-14	Retinal vascular caliber;
BRCA	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg00339695	chr16:24857497	SLC5A11	-0.36	-7.87	-0.3	1.57e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg11814155	chr7:99998594	ZCWPW1	0.59	10.08	0.37	2.82e-22	Platelet count;
BRCA	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11644478	chr21:40555479	PSMG1	0.85	19.81	0.62	1.89e-68	Cognitive function;
BRCA	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	16.84	0.55	6.09e-53	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg19920283	chr7:105172520	RINT1	0.59	9.4	0.35	9.51e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg03146154	chr1:46216737	IPP	0.45	10.05	0.37	3.62e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	8.99	0.33	2.88e-18	Systemic lupus erythematosus;
BRCA	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22509189	chr2:225307070	NA	-0.44	-9.46	-0.35	5.9e-20	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18876405	chr7:65276391	NA	-0.63	-15.56	-0.52	1.57e-46	Aortic root size;
BRCA	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg08132940	chr7:1081526	C7orf50	-0.45	-8.12	-0.31	2.46e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs758324	0.947	rs6861732	chr5:131156462	A/C	cg06307176	chr5:131281290	NA	0.53	10.33	0.38	3.07e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.46	-0.32	1.87e-16	Coronary artery disease;
BRCA	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg18811423	chr2:55921094	PNPT1	-0.62	-17.44	-0.57	5.04e-56	Metabolic syndrome;
BRCA	trans	rs6828577	0.626	rs17642633	chr4:119412100	A/G	cg26518628	chr1:97050305	NA	-0.45	-9.79	-0.36	3.39e-21	Perioperative myocardial infarction in coronary artery bypass surgery;
BRCA	trans	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg21775007	chr8:11205619	TDH	0.43	8.78	0.33	1.5e-17	Mood instability;
BRCA	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg14675211	chr2:100938903	LONRF2	0.52	11.59	0.42	2.61e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg24642439	chr20:33292090	TP53INP2	0.43	9.14	0.34	8.2e-19	Height;
BRCA	cis	rs679087	1.000	rs439639	chr12:29917641	A/C	cg14258853	chr12:29935411	TMTC1	-0.42	-8.85	-0.33	8.36e-18	Schizophrenia;
BRCA	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg06197492	chr11:2016605	H19	0.46	9.83	0.36	2.57e-21	DNA methylation (parent-of-origin);DNA methylation (variation);
BRCA	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21659725	chr3:3221576	CRBN	-0.49	-10.57	-0.39	3.56e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.65	17.01	0.56	8.71e-54	Hypertriglyceridemia;
BRCA	cis	rs9309711	0.736	rs9678647	chr2:3497036	A/G	cg16153549	chr2:3496821	NA	0.36	8.21	0.31	1.21e-15	Neurofibrillary tangles;
BRCA	trans	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg02030672	chr11:45687055	CHST1	-0.41	-9.11	-0.34	1.02e-18	Obesity-related traits;
BRCA	cis	rs6025261	0.761	rs3848695	chr20:55513254	C/T	cg04763273	chr20:55502381	NA	0.33	7.97	0.3	7.55e-15	Verbal memory performance (delayed recall level);
BRCA	cis	rs66887589	0.934	rs6817317	chr4:120542827	A/G	cg09307838	chr4:120376055	NA	-0.44	-9.13	-0.34	8.96e-19	Diastolic blood pressure;
BRCA	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg09754948	chr16:28834200	ATXN2L	0.47	9.17	0.34	6.53e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4561483	0.801	rs33620	chr16:12008546	C/G	cg08843971	chr16:11963173	GSPT1	-0.52	-11.93	-0.43	8.99e-30	Testicular germ cell tumor;
BRCA	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg08999081	chr20:33150536	PIGU	0.47	12.94	0.46	3.36e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11905131	chr22:24372483	LOC391322	0.47	10.12	0.37	2.04e-22	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	ch.11.42038R	chr11:967971	AP2A2	0.52	16.55	0.55	1.84e-51	Alzheimer's disease (late onset);
BRCA	cis	rs13102973	0.933	rs7656595	chr4:135875693	G/A	cg14419869	chr4:135874104	NA	0.51	10.86	0.39	2.42e-25	Subjective well-being;
BRCA	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.91	-20.05	-0.62	1.02e-69	Gut microbiome composition (summer);
BRCA	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-14.03	-0.49	3.69e-39	Migraine;Coronary artery disease;
BRCA	cis	rs1868673	0.964	rs2167177	chr3:150135186	C/T	cg04908077	chr3:150187338	NA	-0.32	-8.66	-0.32	3.82e-17	Waist circumference;
BRCA	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg19622623	chr12:86230825	RASSF9	-0.28	-7.99	-0.3	6.37e-15	Major depressive disorder;
BRCA	trans	rs800082	0.668	rs9856190	chr3:144288547	G/C	cg24215973	chr2:240111563	HDAC4	-0.42	-10.21	-0.37	8.98e-23	Smoking behavior;
BRCA	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg21475434	chr5:93447410	FAM172A	0.66	8.56	0.32	8.21e-17	Diabetic retinopathy;
BRCA	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg25482853	chr8:67687455	SGK3	1.05	16.92	0.56	2.29e-53	Lung disease severity in cystic fibrosis;
BRCA	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.46	-8.22	-0.31	1.17e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg08470875	chr2:26401718	FAM59B	-0.51	-8.3	-0.31	6.38e-16	Gut microbiome composition (summer);
BRCA	trans	rs1973993	0.561	rs59429612	chr1:96988808	C/T	cg10631902	chr5:14652156	NA	-0.41	-10.12	-0.37	1.96e-22	Weight;
BRCA	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg02175503	chr12:58329896	NA	0.42	8.09	0.3	3.03e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03452623	chr4:187889614	NA	-0.35	-11.52	-0.41	4.83e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg10556349	chr10:835070	NA	0.61	8.44	0.32	2.08e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg05340658	chr4:99064831	C4orf37	0.67	16.6	0.55	1.05e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2011503	0.509	rs10403579	chr19:19770329	T/C	cg11584989	chr19:19387371	SF4	0.45	8.58	0.32	7.08e-17	Bipolar disorder;
BRCA	cis	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.17	-0.4	1.35e-26	Morning vs. evening chronotype;
BRCA	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.57	11.31	0.41	3.51e-27	HDL cholesterol;
BRCA	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg12661370	chr5:149340060	SLC26A2	-0.54	-7.98	-0.3	6.68e-15	HIV-1 control;
BRCA	cis	rs9560113	1.000	rs914026	chr13:112182029	G/A	cg10483660	chr13:112241077	NA	0.32	7.83	0.3	2.02e-14	Menarche (age at onset);
BRCA	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24531977	chr5:56204891	C5orf35	0.65	14.42	0.5	4.88e-41	Initial pursuit acceleration;
BRCA	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.53	-0.38	5.16e-24	Mean corpuscular volume;
BRCA	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg01939980	chr4:1354348	KIAA1530	0.38	10.73	0.39	8.44e-25	Longevity;
BRCA	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.32	-7.96	-0.3	7.7e-15	Total body bone mineral density;
BRCA	cis	rs701145	0.762	rs896014	chr3:153842691	A/G	cg17054900	chr3:154042577	DHX36	0.54	9.08	0.34	1.36e-18	Coronary artery disease;
BRCA	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg24812749	chr6:127587940	RNF146	0.66	14.91	0.51	2.21e-43	Breast cancer;
BRCA	cis	rs1669338	0.507	rs4685607	chr3:3179400	C/T	cg16797762	chr3:3221439	CRBN	0.7	10.87	0.39	2.35e-25	White matter integrity;
BRCA	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	12.79	0.45	1.71e-33	Multiple sclerosis;
BRCA	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-15.96	-0.53	1.69e-48	Total cholesterol levels;
BRCA	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg05084668	chr3:125655381	ALG1L	-0.49	-9.24	-0.34	3.53e-19	Blood pressure (smoking interaction);
BRCA	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg04727924	chr7:799746	HEATR2	-0.54	-10.75	-0.39	6.98e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs68170813	0.559	rs17429146	chr7:106964281	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.9	-0.33	5.69e-18	Coronary artery disease;
BRCA	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.58	0.55	1.25e-51	Hypertriglyceridemia;
BRCA	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg00701064	chr4:6280414	WFS1	0.68	17.22	0.56	7.14e-55	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-8.93	-0.33	4.51e-18	Monocyte percentage of white cells;
BRCA	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg04025307	chr7:1156635	C7orf50	0.56	13.15	0.46	3.85e-35	Longevity;Endometriosis;
BRCA	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg00814883	chr7:100076585	TSC22D4	-0.52	-11.99	-0.43	4.88e-30	Platelet count;
BRCA	trans	rs526821	0.595	rs624478	chr11:55340778	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.36	-8.08	-0.3	3.15e-15	Pediatric bone mineral density (spine);
BRCA	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.81	-0.36	2.89e-21	Developmental language disorder (linguistic errors);
BRCA	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.65	-0.45	6.63e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg22963979	chr7:1858916	MAD1L1	-0.45	-9.06	-0.34	1.6e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.97	0.46	2.69e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.97	-0.37	7.28e-22	Heart rate;
BRCA	trans	rs877282	0.583	rs10904566	chr10:821662	C/G	cg22713356	chr15:30763199	NA	1.01	15.85	0.53	6.01e-48	Uric acid levels;
BRCA	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg09035930	chr12:129282057	SLC15A4	0.58	17.51	0.57	2.2e-56	Systemic lupus erythematosus;
BRCA	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.72	11.54	0.42	3.99e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.89	-0.33	6.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs36051895	0.593	rs12340303	chr9:5176147	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-8.88	-0.33	6.6e-18	Pediatric autoimmune diseases;
BRCA	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg16680214	chr1:154839983	KCNN3	-0.43	-11.98	-0.43	5.85e-30	Prostate cancer;
BRCA	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02187348	chr16:89574699	SPG7	0.5	11.75	0.42	5.34e-29	Multiple myeloma (IgH translocation);
BRCA	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg27147174	chr7:100797783	AP1S1	-0.55	-11.06	-0.4	4.05e-26	Life satisfaction;
BRCA	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg10792982	chr14:105748885	BRF1	-0.47	-10.62	-0.39	2.16e-24	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg05340658	chr4:99064831	C4orf37	0.65	15.98	0.53	1.27e-48	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg21782813	chr7:2030301	MAD1L1	0.33	8.91	0.33	5.13e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs7246657	0.550	rs10411176	chr19:37686953	G/T	cg23950597	chr19:37808831	NA	-0.66	-9.99	-0.37	6.41e-22	Coronary artery calcification;
BRCA	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.54e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7715811	1.000	rs1502041	chr5:13758529	A/G	cg07548982	chr5:13769939	DNAH5	-0.38	-8.31	-0.31	5.85e-16	Subclinical atherosclerosis traits (other);
BRCA	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg03354898	chr7:1950403	MAD1L1	-0.45	-9.16	-0.34	7.13e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs13046373	0.507	rs2832969	chr21:32019627	A/G	cg14062083	chr21:31802829	KRTAP13-4	0.34	9.18	0.34	6.13e-19	HDL cholesterol;
BRCA	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.15	-0.31	1.99e-15	Depression;
BRCA	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.35	-9.02	-0.34	2.09e-18	Menopause (age at onset);
BRCA	trans	rs4596713	0.538	rs10125494	chr9:71770861	C/G	cg16512924	chr15:28394682	HERC2	0.45	10.66	0.39	1.52e-24	Headache;
BRCA	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg18538332	chr22:24372958	LOC391322	-0.57	-14.39	-0.49	7.06e-41	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1400816	0.702	rs1850031	chr2:172557739	G/A	cg13550731	chr2:172543902	DYNC1I2	0.54	8.48	0.32	1.56e-16	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs9649465	0.967	rs12537989	chr7:123308195	A/G	cg04330084	chr7:123175371	IQUB	-0.3	-8.34	-0.31	4.53e-16	Migraine;
BRCA	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg06784218	chr1:46089804	CCDC17	0.44	10.28	0.38	4.94e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.65	15.69	0.53	3.71e-47	Chronic sinus infection;
BRCA	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg18850127	chr7:39170497	POU6F2	0.55	12.09	0.43	1.99e-30	IgG glycosylation;
BRCA	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg03609598	chr5:56110824	MAP3K1	-0.47	-8.14	-0.31	2.06e-15	Initial pursuit acceleration;
BRCA	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.21	-0.37	8.71e-23	Psoriasis;
BRCA	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.57	13.69	0.48	1.4e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs13136331	0.680	rs2732169	chr4:88656433	C/T	cg22416721	chr4:88570574	DMP1	-0.56	-13.49	-0.47	1.15e-36	Sitting height ratio;
BRCA	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.63	-16.56	-0.55	1.62e-51	Colorectal cancer;
BRCA	trans	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg13010199	chr12:38710504	ALG10B	0.4	8.16	0.31	1.74e-15	Morning vs. evening chronotype;
BRCA	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18404041	chr3:52824283	ITIH1	-0.28	-8.36	-0.31	3.87e-16	Electroencephalogram traits;
BRCA	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg21775007	chr8:11205619	TDH	0.55	11.17	0.4	1.4e-26	Retinal vascular caliber;
BRCA	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg16339924	chr4:17578868	LAP3	0.63	15.68	0.53	4.2e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg18811423	chr2:55921094	PNPT1	0.72	22.97	0.67	1.43e-85	Metabolic syndrome;
BRCA	cis	rs9487051	0.773	rs351749	chr6:109533353	A/T	cg01475377	chr6:109611718	NA	-0.42	-10.54	-0.38	4.75e-24	Reticulocyte fraction of red cells;
BRCA	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg12483005	chr1:23474871	LUZP1	0.46	10.27	0.38	5.48e-23	Height;
BRCA	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg15017067	chr4:17643749	FAM184B	-0.32	-10.0	-0.37	5.45e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg12927641	chr6:109611667	NA	-0.42	-10.98	-0.4	8.52e-26	Reticulocyte fraction of red cells;
BRCA	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-8.71	-0.33	2.6e-17	Coronary artery disease;
BRCA	cis	rs6598955	0.671	rs3924325	chr1:26616320	T/C	cg00852783	chr1:26633632	UBXN11	-0.48	-8.1	-0.31	2.7e-15	Obesity-related traits;
BRCA	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg00857998	chr1:205179979	DSTYK	0.44	8.31	0.31	5.72e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg09754948	chr16:28834200	ATXN2L	0.46	9.13	0.34	9.04e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg27279351	chr12:120934652	DYNLL1	-0.57	-13.66	-0.48	1.83e-37	High light scatter reticulocyte count;
BRCA	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg24829409	chr8:58192753	C8orf71	-0.43	-8.69	-0.33	3.03e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg05507819	chr15:63340323	TPM1	0.42	9.05	0.34	1.76e-18	Platelet count;
BRCA	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.2e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-8.64	-0.32	4.33e-17	Colorectal cancer;
BRCA	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.41	-0.32	2.75e-16	Aortic root size;
BRCA	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg09998033	chr7:158218633	PTPRN2	-0.39	-9.85	-0.36	2.16e-21	Obesity-related traits;
BRCA	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg18016565	chr1:150552671	MCL1	0.35	8.1	0.31	2.71e-15	Melanoma;
BRCA	cis	rs6782228	0.675	rs4857918	chr3:128383960	T/C	cg16766828	chr3:128327626	NA	-0.44	-9.67	-0.36	9.88e-21	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg26384229	chr12:38710491	ALG10B	0.67	14.28	0.49	2.47e-40	Morning vs. evening chronotype;
BRCA	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg03146154	chr1:46216737	IPP	-0.45	-9.89	-0.36	1.53e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg23762105	chr12:34175262	ALG10	0.36	8.45	0.32	2.02e-16	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.44	0.38	1.12e-23	Motion sickness;
BRCA	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg24675658	chr1:53192096	ZYG11B	-0.68	-14.66	-0.5	3.6e-42	Monocyte count;
BRCA	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg20503657	chr10:835505	NA	1.03	18.28	0.59	2.43e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs698813	0.674	rs3738985	chr2:44502788	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	8.78	0.33	1.53e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg09537434	chr19:41945824	ATP5SL	-1.0	-23.64	-0.68	3e-89	Height;
BRCA	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg19622623	chr12:86230825	RASSF9	-0.33	-9.27	-0.34	2.75e-19	Major depressive disorder;
BRCA	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.05	29.56	0.76	1.05e-121	Cognitive ability;
BRCA	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	19.69	0.61	8.42e-68	Mean platelet volume;
BRCA	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.46	-8.66	-0.32	3.86e-17	Iron status biomarkers;
BRCA	cis	rs62380364	0.566	rs1705565	chr5:88048457	C/T	cg22951263	chr5:87985283	NA	-0.38	-10.78	-0.39	5.35e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-10.15	-0.37	1.55e-22	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.84	0.33	9.45e-18	Motion sickness;
BRCA	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg27624424	chr6:160112604	SOD2	0.4	8.25	0.31	8.99e-16	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs34421088	0.576	rs2572432	chr8:11101723	A/G	cg15556689	chr8:8085844	FLJ10661	-0.33	-8.0	-0.3	5.71e-15	Neuroticism;
BRCA	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg08601574	chr20:25228251	PYGB	0.42	9.78	0.36	3.85e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.39	7.92	0.3	1.09e-14	Homocysteine levels;
BRCA	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg09184832	chr6:79620586	NA	-0.49	-10.22	-0.37	7.86e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7572733	0.534	rs1435570	chr2:198731371	T/C	cg00792783	chr2:198669748	PLCL1	0.47	10.2	0.37	9.44e-23	Dermatomyositis;
BRCA	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg19318889	chr4:1322082	MAEA	0.5	10.63	0.39	2.08e-24	Longevity;
BRCA	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg16482183	chr6:26056742	HIST1H1C	0.49	10.2	0.37	9.41e-23	Height;
BRCA	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.29	0.31	6.9e-16	Parkinson's disease;
BRCA	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg12373951	chr3:133503437	NA	0.45	10.74	0.39	7.61e-25	Iron status biomarkers;
BRCA	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg05313129	chr8:58192883	C8orf71	-0.46	-9.46	-0.35	5.73e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs1829883	1.000	rs2461989	chr5:98793999	T/A	cg08333243	chr5:99726346	NA	-0.37	-8.97	-0.33	3.16e-18	Hemostatic factors and hematological phenotypes;
BRCA	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg23533926	chr12:111358616	MYL2	-0.44	-9.2	-0.34	4.85e-19	Extrinsic epigenetic age acceleration;
BRCA	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21659725	chr3:3221576	CRBN	-0.46	-9.82	-0.36	2.77e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.97	-0.33	3.26e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-10.35	-0.38	2.52e-23	Reticulocyte count;
BRCA	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18402987	chr7:1209562	NA	0.71	12.15	0.43	1.07e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.51	-10.17	-0.37	1.33e-22	Body mass index;
BRCA	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg00339695	chr16:24857497	SLC5A11	0.52	11.45	0.41	9.96e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg11764359	chr7:65958608	NA	0.65	11.9	0.43	1.21e-29	Aortic root size;
BRCA	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg11845111	chr2:191398756	TMEM194B	0.42	9.41	0.35	8.81e-20	Pulse pressure;
BRCA	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.63	13.89	0.48	1.68e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg00074818	chr8:8560427	CLDN23	0.38	8.27	0.31	7.99e-16	Obesity-related traits;
BRCA	cis	rs7091068	0.671	rs1764322	chr10:95406276	T/G	cg20715218	chr10:95462985	C10orf4	-0.47	-8.43	-0.32	2.24e-16	Urinary tract infection frequency;
BRCA	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg10818794	chr15:86012489	AKAP13	-0.3	-8.45	-0.32	1.92e-16	Coronary artery disease;
BRCA	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg03254818	chr6:169586852	NA	-0.4	-8.63	-0.32	5e-17	Pulse pressure;
BRCA	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.26	-0.31	8.6e-16	Depression;
BRCA	cis	rs6540556	0.635	rs17389184	chr1:209916789	C/T	cg05527609	chr1:210001259	C1orf107	-0.5	-8.66	-0.32	3.87e-17	Red blood cell count;
BRCA	cis	rs586533	0.781	rs594789	chr11:99498180	G/T	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg22875332	chr1:76189707	ACADM	0.7	14.5	0.5	2.23e-41	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6580649	0.941	rs1793933	chr12:48396450	G/T	cg05342945	chr12:48394962	COL2A1	-0.49	-9.84	-0.36	2.38e-21	Lung cancer;
BRCA	trans	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg25214090	chr10:38739885	LOC399744	-0.46	-9.87	-0.36	1.83e-21	Corneal astigmatism;
BRCA	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.29	0.54	3.6e-50	Morning vs. evening chronotype;
BRCA	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg24812749	chr6:127587940	RNF146	0.88	18.95	0.6	6.97e-64	Breast cancer;
BRCA	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-8.21	-0.31	1.18e-15	Blood pressure (smoking interaction);
BRCA	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg01528321	chr10:82214614	TSPAN14	0.81	17.21	0.56	8.09e-55	Post bronchodilator FEV1;
BRCA	cis	rs72928364	1.000	rs13088524	chr3:100688082	A/C	cg10123952	chr3:100791384	NA	0.53	7.89	0.3	1.3e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11779988	0.545	rs448882	chr8:17794039	C/T	cg01800426	chr8:17659068	MTUS1	-0.41	-8.35	-0.31	4.09e-16	Breast cancer;
BRCA	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg25358565	chr5:93447407	FAM172A	1.16	18.02	0.58	4.93e-59	Diabetic retinopathy;
BRCA	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg18512352	chr11:47633146	NA	-0.34	-7.92	-0.3	1.03e-14	Subjective well-being;
BRCA	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg20476274	chr7:133979776	SLC35B4	0.6	16.15	0.54	1.82e-49	Mean platelet volume;
BRCA	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.84	16.9	0.56	3.16e-53	HIV-1 control;
BRCA	cis	rs13046373	0.535	rs1961491	chr21:31973685	C/T	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.58	0.35	2.03e-20	HDL cholesterol;
BRCA	cis	rs3784262	0.669	rs12909423	chr15:58292433	C/G	cg12031962	chr15:58353849	ALDH1A2	0.35	9.8	0.36	3.14e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg21905437	chr5:178450457	ZNF879	0.51	10.78	0.39	5.29e-25	Pubertal anthropometrics;
BRCA	cis	rs897984	0.609	rs732173	chr16:31050023	C/A	cg00531865	chr16:30841666	NA	-0.4	-9.41	-0.35	9.15e-20	Dementia with Lewy bodies;
BRCA	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg05283184	chr6:79620031	NA	-0.44	-11.46	-0.41	8.63e-28	Intelligence (multi-trait analysis);
BRCA	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg15556689	chr8:8085844	FLJ10661	-0.31	-8.1	-0.31	2.84e-15	Triglycerides;
BRCA	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg01689657	chr7:91764605	CYP51A1	0.21	7.82	0.3	2.14e-14	Breast cancer;
BRCA	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.68	0.36	9.06e-21	Bipolar disorder;
BRCA	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg05347473	chr6:146136440	FBXO30	-0.43	-8.74	-0.33	2.02e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.43	-0.32	2.32e-16	Monocyte percentage of white cells;
BRCA	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg12011299	chr4:100065546	ADH4	0.51	11.73	0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg24399712	chr22:39784796	NA	-0.57	-13.45	-0.47	1.72e-36	Intelligence (multi-trait analysis);
BRCA	trans	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg21659725	chr3:3221576	CRBN	-0.48	-8.93	-0.33	4.35e-18	Menarche (age at onset);
BRCA	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg05623727	chr3:50126028	RBM5	0.43	10.31	0.38	3.7e-23	Intelligence (multi-trait analysis);
BRCA	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg03929089	chr4:120376271	NA	-0.63	-11.51	-0.41	5.26e-28	Coronary artery disease;
BRCA	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg27211696	chr2:191398769	TMEM194B	0.48	7.93	0.3	9.72e-15	Diastolic blood pressure;
BRCA	trans	rs8073060	0.586	rs225303	chr17:33922149	A/G	cg19694781	chr19:47549865	TMEM160	0.97	20.8	0.64	8.96e-74	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg18196295	chr10:418757	DIP2C	0.49	11.78	0.42	4.03e-29	Psychosis in Alzheimer's disease;
BRCA	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs9768139	0.708	rs36064654	chr7:158116632	C/T	cg24154853	chr7:158122151	PTPRN2	0.33	7.81	0.3	2.32e-14	Calcium levels;
BRCA	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg09307838	chr4:120376055	NA	0.6	11.62	0.42	1.91e-28	Corneal astigmatism;
BRCA	trans	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	16.91	0.56	2.78e-53	Exhaled nitric oxide levels;
BRCA	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg20991723	chr1:152506922	NA	0.36	8.13	0.31	2.18e-15	Hair morphology;
BRCA	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7246657	0.722	rs28512414	chr19:38056574	T/A	cg23950597	chr19:37808831	NA	-0.5	-8.62	-0.32	5.36e-17	Coronary artery calcification;
BRCA	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg04586622	chr2:25135609	ADCY3	0.44	10.98	0.4	8.31e-26	Body mass index;
BRCA	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11644478	chr21:40555479	PSMG1	-0.54	-11.6	-0.42	2.38e-28	Menarche (age at onset);
BRCA	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg27170947	chr2:26402098	FAM59B	0.63	11.15	0.4	1.7e-26	Gut microbiome composition (summer);
BRCA	cis	rs8114671	0.967	rs9574	chr20:33764632	C/G	cg07148914	chr20:33460835	GGT7	0.37	7.88	0.3	1.42e-14	Height;
BRCA	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-14.04	-0.49	3.32e-39	Morning vs. evening chronotype;
BRCA	trans	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg17830980	chr10:43048298	ZNF37B	0.42	9.97	0.37	7.49e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg03709012	chr19:19516395	GATAD2A	1.11	21.25	0.64	3.35e-76	Nonalcoholic fatty liver disease;
BRCA	cis	rs4953318	0.796	rs10168349	chr2:46360907	G/C	cg12428440	chr2:46370979	PRKCE	0.41	9.54	0.35	2.93e-20	Red blood cell count;Hematocrit;Red blood cell traits;
BRCA	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.49	-0.32	1.4e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg14863265	chr7:2801509	GNA12	-0.47	-10.2	-0.37	9.64e-23	Height;
BRCA	cis	rs58235267	0.591	rs4671457	chr2:63346356	C/T	cg17519650	chr2:63277830	OTX1	0.37	7.82	0.3	2.19e-14	Prostate-specific antigen levels (conditioned on lead SNPs);
BRCA	trans	rs1974653	0.781	rs9606241	chr22:20075858	A/G	cg20152630	chr19:46405944	MYPOP	0.36	8.24	0.31	9.88e-16	Schizophrenia;
BRCA	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg02659138	chr7:134003124	SLC35B4	0.32	9.78	0.36	3.79e-21	Mean platelet volume;
BRCA	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg24642439	chr20:33292090	TP53INP2	-0.47	-9.75	-0.36	5.01e-21	Glomerular filtration rate (creatinine);
BRCA	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	17.49	0.57	2.78e-56	Alzheimer's disease;
BRCA	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg16482183	chr6:26056742	HIST1H1C	0.53	11.08	0.4	3.21e-26	Height;
BRCA	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	11.86	0.42	1.74e-29	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg23285459	chr7:2802560	GNA12	-0.35	-8.88	-0.33	6.84e-18	Height;
BRCA	cis	rs4074536	0.574	rs10732297	chr1:116289054	C/T	cg21648376	chr1:116311395	CASQ2	-0.49	-8.71	-0.33	2.5e-17	QRS duration;
BRCA	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg27446573	chr6:127587934	RNF146	0.85	20.13	0.62	3.49e-70	Breast cancer;
BRCA	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.33	10.46	0.38	9.81e-24	Bipolar disorder;
BRCA	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg03146154	chr1:46216737	IPP	-0.43	-9.42	-0.35	8.22e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg09184832	chr6:79620586	NA	-0.53	-11.87	-0.43	1.59e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg03954927	chr1:10346856	KIF1B	0.48	14.99	0.51	9.58e-44	Hepatocellular carcinoma;
BRCA	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg15017067	chr4:17643749	FAM184B	0.32	9.79	0.36	3.37e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03452623	chr4:187889614	NA	0.28	9.06	0.34	1.63e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg10556349	chr10:835070	NA	0.75	9.92	0.37	1.09e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg13319975	chr6:146136371	FBXO30	0.41	9.27	0.34	2.82e-19	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs4650994	0.525	rs2493860	chr1:178541492	A/G	cg05059571	chr16:84539110	KIAA1609	-0.57	-12.7	-0.45	4.24e-33	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.69e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg00677455	chr12:58241039	CTDSP2	0.76	17.01	0.56	8.05e-54	Multiple sclerosis;
BRCA	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg03433033	chr1:76189801	ACADM	0.68	12.54	0.44	2.14e-32	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs877282	0.755	rs11253399	chr10:790030	T/A	cg17470449	chr10:769945	NA	0.43	8.09	0.3	3.1e-15	Uric acid levels;
BRCA	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg22713356	chr15:30763199	NA	1.32	26.52	0.72	4.24e-105	Uric acid levels;
BRCA	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg25237894	chr2:233734115	C2orf82	0.38	10.81	0.39	4.08e-25	Coronary artery disease;
BRCA	cis	rs4234798	0.500	rs7661077	chr4:7219889	C/T	cg18431297	chr4:7219810	SORCS2	0.36	10.28	0.38	4.64e-23	Insulin-like growth factors;
BRCA	cis	rs919433	0.713	rs10178946	chr2:198463090	G/T	cg00792783	chr2:198669748	PLCL1	0.36	8.14	0.31	2.12e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7077164	1.000	rs1227775	chr10:71580862	C/G	cg07630274	chr10:71583235	COL13A1	-0.24	-7.92	-0.3	1.05e-14	Non-alcoholic fatty liver disease histology (lobular);
BRCA	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg11502198	chr6:26597334	ABT1	0.57	12.09	0.43	1.82e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs13315871	0.929	rs13322156	chr3:58287620	C/T	cg20936604	chr3:58311152	NA	-0.66	-8.46	-0.32	1.83e-16	Cholesterol, total;
BRCA	cis	rs6558530	0.692	rs10105317	chr8:1701432	G/A	cg19131313	chr8:1704013	NA	-0.4	-8.08	-0.3	3.29e-15	Systolic blood pressure;
BRCA	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	12.81	0.45	1.35e-33	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg09184832	chr6:79620586	NA	-0.52	-11.42	-0.41	1.3e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.14	0.34	7.92e-19	Platelet count;
BRCA	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.56	8.82	0.33	1.05e-17	Renal function-related traits (BUN);
BRCA	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg06637938	chr14:75390232	RPS6KL1	0.78	16.34	0.54	2.13e-50	Caffeine consumption;
BRCA	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg02297831	chr4:17616191	MED28	0.38	8.77	0.33	1.56e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg24634471	chr8:143751801	JRK	0.43	9.06	0.34	1.61e-18	Schizophrenia;
BRCA	cis	rs3857536	0.740	rs7756519	chr6:66892275	A/G	cg07460842	chr6:66804631	NA	-0.46	-8.86	-0.33	8.14e-18	Blood trace element (Cu levels);
BRCA	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg16230307	chr14:35515116	FAM177A1	0.73	15.25	0.52	5.11e-45	Psoriasis;
BRCA	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.24	0.34	3.64e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg18479299	chr3:125709523	NA	-0.56	-8.85	-0.33	8.54e-18	Blood pressure (smoking interaction);
BRCA	cis	rs2066819	1.000	rs59295315	chr12:56708576	G/A	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg13385521	chr17:29058706	SUZ12P	0.76	10.35	0.38	2.52e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	trans	rs4714291	0.963	rs2475496	chr6:39963850	A/G	cg02267698	chr19:7991119	CTXN1	0.42	8.37	0.31	3.72e-16	Strep throat;
BRCA	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00864171	chr11:67383662	NA	0.4	8.34	0.31	4.72e-16	Mean corpuscular volume;
BRCA	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg07828340	chr4:882639	GAK	1.03	12.28	0.44	2.82e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14442939	chr10:27389572	ANKRD26	0.66	10.98	0.4	8.32e-26	Breast cancer;
BRCA	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg24060327	chr5:131705240	SLC22A5	0.45	9.34	0.35	1.55e-19	Acylcarnitine levels;
BRCA	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.95	21.01	0.64	6.82e-75	Smoking behavior;
BRCA	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.32	7.87	0.3	1.55e-14	Resting heart rate;
BRCA	cis	rs34734847	1.000	rs10431385	chr12:121128882	T/C	cg21892295	chr12:121157589	UNC119B	-0.4	-12.28	-0.44	2.78e-31	Mean corpuscular volume;
BRCA	cis	rs6580649	0.824	rs1635534	chr12:48386553	A/G	cg05342945	chr12:48394962	COL2A1	-0.48	-9.53	-0.35	3.12e-20	Lung cancer;
BRCA	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg18446336	chr7:2847575	GNA12	-0.35	-8.31	-0.31	5.71e-16	Height;
BRCA	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg27129171	chr3:47204927	SETD2	-0.71	-16.96	-0.56	1.46e-53	Colorectal cancer;
BRCA	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg04545296	chr12:48745243	ZNF641	-0.24	-7.96	-0.3	7.9e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg11663144	chr21:46675770	NA	-0.6	-13.84	-0.48	2.6e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.39	9.03	0.34	1.97e-18	Eosinophil percentage of white cells;
BRCA	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg18761221	chr20:60518478	NA	-0.34	-8.49	-0.32	1.4e-16	Obesity-related traits;
BRCA	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21659725	chr3:3221576	CRBN	-0.71	-21.49	-0.65	1.55e-77	Intelligence (multi-trait analysis);
BRCA	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.57	11.98	0.43	5.5e-30	Monocyte percentage of white cells;
BRCA	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg27398817	chr8:82754497	SNX16	-0.45	-8.6	-0.32	6.32e-17	Diastolic blood pressure;
BRCA	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg19904058	chr10:135279010	LOC619207	-0.4	-9.41	-0.35	9.14e-20	Systemic lupus erythematosus;
BRCA	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg09307838	chr4:120376055	NA	0.64	13.92	0.48	1.13e-38	Corneal astigmatism;
BRCA	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05901451	chr6:126070800	HEY2	-0.7	-20.07	-0.62	7.64e-70	Brugada syndrome;
BRCA	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg10811474	chr19:8428787	ANGPTL4	-0.33	-8.35	-0.31	4.15e-16	HDL cholesterol;
BRCA	cis	rs877529	0.967	rs139414	chr22:39553819	G/A	cg18708252	chr22:39545030	CBX7	-0.32	-8.42	-0.32	2.42e-16	Multiple myeloma;
BRCA	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg17420585	chr12:42539391	GXYLT1	0.48	10.38	0.38	1.94e-23	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg10729496	chr3:10149963	C3orf24	0.48	9.15	0.34	7.7e-19	Alzheimer's disease;
BRCA	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg12310025	chr6:25882481	NA	-0.5	-11.47	-0.41	7.69e-28	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	8.29	0.31	6.5e-16	Corneal astigmatism;
BRCA	cis	rs1691799	0.867	rs961049	chr12:66762591	A/C	cg16791601	chr12:66731901	HELB	0.57	14.22	0.49	4.63e-40	White blood cell count (basophil);
BRCA	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg20203395	chr5:56204925	C5orf35	-0.5	-10.11	-0.37	2.13e-22	Initial pursuit acceleration;
BRCA	cis	rs1691799	0.899	rs1168314	chr12:66746937	A/G	cg16791601	chr12:66731901	HELB	-0.69	-19.69	-0.61	8.5e-68	White blood cell count (basophil);
BRCA	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.55	8.42	0.32	2.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08219700	chr8:58056026	NA	-0.59	-9.64	-0.36	1.32e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg10169327	chr19:45448959	APOC2	0.31	7.81	0.3	2.31e-14	Blood protein levels;
BRCA	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.23	-0.38	7.61e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg27588902	chr6:42928151	GNMT	0.32	10.56	0.39	3.82e-24	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg21138405	chr5:131827807	IRF1	-0.4	-13.33	-0.47	6.37e-36	Asthma (sex interaction);
BRCA	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg16606324	chr3:10149918	C3orf24	0.53	10.56	0.39	3.77e-24	Alzheimer's disease;
BRCA	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-10.97	-0.4	8.6e-26	Longevity;
BRCA	cis	rs813218	0.647	rs6788750	chr3:99774720	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.39	8.8	0.33	1.25e-17	Orofacial clefts;
BRCA	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-8.14	-0.31	2.02e-15	Daytime sleep phenotypes;
BRCA	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	15.23	0.52	6.26e-45	Hip circumference adjusted for BMI;
BRCA	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg04315214	chr1:2043799	PRKCZ	-0.44	-12.02	-0.43	3.61e-30	Height;
BRCA	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg00012203	chr2:219082015	ARPC2	-0.48	-9.18	-0.34	5.88e-19	Colorectal cancer;
BRCA	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg20790798	chr5:1857306	NA	-0.38	-9.1	-0.34	1.13e-18	Cardiovascular disease risk factors;
BRCA	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Tonsillectomy;
BRCA	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11764359	chr7:65958608	NA	0.81	19.67	0.61	1.05e-67	Aortic root size;
BRCA	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11890956	chr21:40555474	PSMG1	-0.81	-19.3	-0.61	9.88e-66	Cognitive function;
BRCA	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg06212747	chr3:49208901	KLHDC8B	0.48	9.85	0.36	2.06e-21	Parkinson's disease;
BRCA	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg12564285	chr5:131593104	PDLIM4	0.43	11.04	0.4	4.77e-26	Acylcarnitine levels;
BRCA	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	11.63	0.42	1.63e-28	Personality dimensions;
BRCA	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg03929089	chr4:120376271	NA	0.49	8.3	0.31	6.27e-16	Axial length;
BRCA	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.59	-8.62	-0.32	5.4e-17	Schizophrenia;
BRCA	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18876405	chr7:65276391	NA	-0.69	-17.94	-0.58	1.43e-58	Aortic root size;
BRCA	cis	rs4363385	0.747	rs6670614	chr1:152964338	A/G	cg21543102	chr1:152974771	SPRR3	-0.3	-8.84	-0.33	9.32e-18	Inflammatory skin disease;
BRCA	cis	rs9611519	0.558	rs8137906	chr22:41442566	A/G	cg03806693	chr22:41940476	POLR3H	-0.41	-7.81	-0.3	2.29e-14	Neuroticism;
BRCA	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg26384229	chr12:38710491	ALG10B	0.66	13.84	0.48	2.82e-38	Morning vs. evening chronotype;
BRCA	cis	rs7593730	0.636	rs10170600	chr2:161118687	T/C	cg22609984	chr2:161126801	NA	0.43	9.24	0.34	3.53e-19	Type 2 diabetes;
BRCA	cis	rs12220238	1.000	rs8255	chr10:75879750	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.49	8.06	0.3	3.65e-15	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs16958440	0.867	rs16949275	chr18:44700703	A/G	cg17192377	chr18:44677553	HDHD2	0.99	13.47	0.47	1.43e-36	Sitting height ratio;
BRCA	cis	rs2882667	0.728	rs7722413	chr5:138278251	T/C	cg04439458	chr5:138467593	SIL1	-0.32	-8.2	-0.31	1.27e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg16576597	chr16:28551801	NUPR1	0.34	9.0	0.34	2.65e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg12923728	chr3:195709715	SDHAP1	-0.53	-9.17	-0.34	6.47e-19	Pancreatic cancer;
BRCA	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg07080220	chr10:102295463	HIF1AN	0.58	12.05	0.43	2.7e-30	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6005807	0.563	rs9620811	chr22:29058409	T/C	cg12565055	chr22:29076175	TTC28	0.5	9.47	0.35	5.27e-20	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg24642844	chr7:1081250	C7orf50	-0.58	-11.94	-0.43	8.12e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg24296786	chr1:45957014	TESK2	0.62	15.39	0.52	1.08e-45	High light scatter reticulocyte count;
BRCA	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg22535103	chr8:58192502	C8orf71	-0.6	-13.08	-0.46	8.35e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg05863683	chr7:1912471	MAD1L1	-0.35	-8.18	-0.31	1.55e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg24692254	chr21:30365293	RNF160	0.78	21.63	0.65	2.7e-78	Dental caries;
BRCA	trans	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg06521331	chr12:34319734	NA	0.45	8.82	0.33	1.06e-17	Bladder cancer;
BRCA	cis	rs2625529	0.689	rs4526973	chr15:72138719	A/G	cg16672083	chr15:72433130	SENP8	-0.65	-15.54	-0.52	1.95e-46	Red blood cell count;
BRCA	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.38	-0.38	1.89e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg00031303	chr3:195681400	NA	0.49	8.94	0.33	4.18e-18	Pancreatic cancer;
BRCA	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	12.32	0.44	1.93e-31	Calcium levels;
BRCA	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	9.31	0.35	1.96e-19	Personality dimensions;
BRCA	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg16339924	chr4:17578868	LAP3	-0.46	-10.22	-0.37	7.95e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg15704280	chr7:45808275	SEPT13	0.48	8.44	0.32	2.15e-16	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs2070997	0.667	rs12156431	chr9:133719540	A/G	cg11464064	chr9:133710261	ABL1	0.51	9.3	0.35	2.18e-19	Response to amphetamines;
BRCA	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03188948	chr7:1209495	NA	0.63	12.99	0.46	2.06e-34	Longevity;Endometriosis;
BRCA	cis	rs2282802	0.685	rs2053055	chr5:139646776	C/T	cg26211634	chr5:139558579	C5orf32	0.35	8.38	0.31	3.5e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg20891283	chr12:69753455	YEATS4	0.84	28.41	0.75	1.93e-115	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg04025307	chr7:1156635	C7orf50	0.55	11.49	0.41	6.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg04362960	chr10:104952993	NT5C2	-0.34	-8.09	-0.3	3.02e-15	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg25427524	chr10:38739819	LOC399744	0.59	12.56	0.44	1.74e-32	Extrinsic epigenetic age acceleration;
BRCA	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg21143896	chr7:2802374	GNA12	-0.35	-8.9	-0.33	5.81e-18	Height;
BRCA	cis	rs858239	0.600	rs1115941	chr7:23137188	C/T	cg23682824	chr7:23144976	KLHL7	0.46	12.26	0.44	3.34e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2230307	0.572	rs2810419	chr1:100643968	C/A	cg24955406	chr1:100503596	HIAT1	-0.45	-8.45	-0.32	1.91e-16	Carotid intima media thickness;
BRCA	trans	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg26043149	chr18:55253948	FECH	-0.39	-8.73	-0.33	2.17e-17	Bone mineral density;
BRCA	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg22800045	chr5:56110881	MAP3K1	-0.47	-9.35	-0.35	1.47e-19	Initial pursuit acceleration;
BRCA	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03352830	chr11:487213	PTDSS2	0.87	13.62	0.47	2.74e-37	Body mass index;
BRCA	trans	rs800082	0.690	rs2575191	chr3:144279228	G/A	cg24215973	chr2:240111563	HDAC4	0.41	10.67	0.39	1.44e-24	Smoking behavior;
BRCA	cis	rs1371614	0.501	rs4992933	chr2:27178972	C/A	cg00617064	chr2:27272375	NA	-0.31	-8.06	-0.3	3.67e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.89	0.33	5.97e-18	Tonsillectomy;
BRCA	trans	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg07461501	chr17:79650226	HGS;ARL16	0.59	14.51	0.5	1.9e-41	Obesity-related traits;
BRCA	cis	rs13102973	0.931	rs13128765	chr4:135888141	A/G	cg14419869	chr4:135874104	NA	0.53	11.15	0.4	1.69e-26	Subjective well-being;
BRCA	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg13256891	chr4:100009986	ADH5	0.49	9.61	0.36	1.6e-20	Alcohol dependence;
BRCA	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.83	-0.33	9.69e-18	Mood instability;
BRCA	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg06784218	chr1:46089804	CCDC17	-0.45	-10.79	-0.39	4.67e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg19077165	chr18:44547161	KATNAL2	0.64	14.43	0.5	4.44e-41	Personality dimensions;
BRCA	cis	rs2282802	0.651	rs13353827	chr5:139654537	T/C	cg26211634	chr5:139558579	C5orf32	0.35	8.35	0.31	4.13e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.55	9.27	0.34	2.9e-19	Renal function-related traits (BUN);
BRCA	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg04691961	chr3:161091175	C3orf57	-0.4	-9.34	-0.35	1.52e-19	Morning vs. evening chronotype;
BRCA	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg22491629	chr6:157744540	C6orf35	-0.62	-11.75	-0.42	5.16e-29	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6484504	0.600	rs942272	chr11:31364368	C/T	cg06552810	chr11:31128660	NA	0.4	8.73	0.33	2.16e-17	Red blood cell count;
BRCA	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg18490616	chr2:88469792	THNSL2	-0.48	-9.36	-0.35	1.38e-19	Response to metformin (IC50);
BRCA	cis	rs312273	0.582	rs312277	chr12:41256755	A/C	cg17827154	chr12:41323612	CNTN1	-0.34	-7.92	-0.3	1.07e-14	Bipolar disorder;
BRCA	cis	rs586533	0.881	rs10893644	chr11:99512157	G/C	cg22878054	chr11:99397252	CNTN5	0.31	7.89	0.3	1.27e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1298908	0.639	rs2236568	chr10:82035923	C/A	cg01528321	chr10:82214614	TSPAN14	0.48	10.27	0.38	5.11e-23	Diabetic kidney disease;
BRCA	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg19622623	chr12:86230825	RASSF9	-0.29	-8.26	-0.31	8.66e-16	Major depressive disorder;
BRCA	cis	rs11955398	0.625	rs6449485	chr5:59995441	C/T	cg02684056	chr5:59996105	DEPDC1B	0.39	9.11	0.34	1.08e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.37	9.59	0.35	1.87e-20	IgG glycosylation;
BRCA	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg12292205	chr6:26970375	C6orf41	-0.66	-10.99	-0.4	7.63e-26	Intelligence (multi-trait analysis);
BRCA	trans	rs1200821	0.552	rs12253170	chr10:37601063	A/G	cg25427524	chr10:38739819	LOC399744	-0.36	-7.98	-0.3	6.84e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs67072384	1.000	rs7120605	chr11:72444615	A/G	cg04827223	chr11:72435913	ARAP1	-0.69	-11.3	-0.41	3.91e-27	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
BRCA	cis	rs6484504	0.576	rs158144	chr11:31211795	A/C	cg06552810	chr11:31128660	NA	-0.39	-8.54	-0.32	9.9900000000000006e-17	Red blood cell count;
BRCA	cis	rs6942756	0.876	rs7789697	chr7:129060386	T/A	cg02491457	chr7:128862824	NA	-0.57	-11.81	-0.42	3.01e-29	White matter hyperintensity burden;
BRCA	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.36	-9.42	-0.35	7.97e-20	Total body bone mineral density;
BRCA	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg27478167	chr7:817139	HEATR2	-0.42	-8.97	-0.33	3.29e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg24642439	chr20:33292090	TP53INP2	-0.43	-8.51	-0.32	1.23e-16	Height;
BRCA	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg17366294	chr4:99064904	C4orf37	0.55	11.51	0.41	5.33e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg10223061	chr2:219282414	VIL1	-0.27	-7.9	-0.3	1.25e-14	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs10411161	0.702	rs8110531	chr19:52383510	C/T	cg22319618	chr22:45562946	NUP50	-0.41	-7.84	-0.3	1.84e-14	Breast cancer;
BRCA	cis	rs3824344	0.531	rs7870336	chr9:37007769	C/G	cg14294708	chr9:37120828	ZCCHC7	-0.43	-8.7	-0.33	2.87e-17	Intelligence;
BRCA	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg00105475	chr2:10696890	NA	-0.38	-8.83	-0.33	9.85e-18	Prostate cancer;
BRCA	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-12.5	-0.44	2.98e-32	Bipolar disorder;
BRCA	cis	rs4363385	0.818	rs11205176	chr1:153002481	A/G	cg24667326	chr1:152973720	SPRR3	-0.33	-8.81	-0.33	1.19e-17	Inflammatory skin disease;
BRCA	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg02951883	chr7:2050386	MAD1L1	-0.36	-8.13	-0.31	2.17e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.43	8.28	0.31	7.22e-16	Lung cancer in ever smokers;
BRCA	cis	rs9462027	0.628	rs10947531	chr6:34765118	A/C	cg07306190	chr6:34760872	UHRF1BP1	0.26	8.01	0.3	5.37e-15	Systemic lupus erythematosus;
BRCA	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg19622623	chr12:86230825	RASSF9	-0.28	-8.12	-0.31	2.41e-15	Major depressive disorder;
BRCA	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24308560	chr3:49941425	MST1R	-0.39	-8.47	-0.32	1.64e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.5	-0.61	8.85e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg21775007	chr8:11205619	TDH	-0.38	-7.89	-0.3	1.36e-14	Mood instability;
BRCA	cis	rs10504073	0.506	rs7007271	chr8:49941897	T/C	cg00325661	chr8:49890786	NA	0.45	13.06	0.46	1.06e-34	Blood metabolite ratios;
BRCA	cis	rs11245387	0.633	rs2086945	chr10:126543993	C/T	cg08799069	chr10:126477246	METTL10	0.37	8.28	0.31	7.2e-16	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
BRCA	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg14675211	chr2:100938903	LONRF2	0.52	11.82	0.42	2.63e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-11.38	-0.41	1.81e-27	Morning vs. evening chronotype;
BRCA	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg11266682	chr4:10021025	SLC2A9	0.47	12.07	0.43	2.38e-30	Bone mineral density;
BRCA	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg24060327	chr5:131705240	SLC22A5	0.61	11.5	0.41	6.04e-28	Breast cancer;
BRCA	cis	rs829883	0.934	rs249814	chr12:98892964	A/G	cg25150519	chr12:98850993	NA	0.59	11.94	0.43	7.95e-30	Colorectal adenoma (advanced);
BRCA	trans	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg21659725	chr3:3221576	CRBN	-0.36	-8.45	-0.32	1.94e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg03146154	chr1:46216737	IPP	0.5	11.01	0.4	6.46e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.64	10.81	0.39	4.03e-25	Renal function-related traits (BUN);
BRCA	cis	rs4285028	0.747	rs9824235	chr3:121432177	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.71	-13.99	-0.48	5.22e-39	Multiple sclerosis;
BRCA	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg22875332	chr1:76189707	ACADM	0.7	15.05	0.51	5.04e-44	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03517284	chr6:25882590	NA	-0.47	-10.52	-0.38	5.74e-24	Blood metabolite levels;
BRCA	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.44	-0.52	5.81e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.36	0.35	1.34e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg00321850	chr1:175162397	KIAA0040	-0.41	-11.37	-0.41	2.14e-27	Alcohol dependence;
BRCA	cis	rs6942756	1.000	rs6467243	chr7:129001508	A/G	cg02491457	chr7:128862824	NA	-0.64	-12.57	-0.45	1.53e-32	White matter hyperintensity burden;
BRCA	cis	rs9880211	0.948	rs9857966	chr3:136279390	A/G	cg21827317	chr3:136751795	NA	-0.45	-8.22	-0.31	1.1e-15	Body mass index;Height;
BRCA	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.4	-8.78	-0.33	1.49e-17	Longevity;Endometriosis;
BRCA	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg06212747	chr3:49208901	KLHDC8B	0.48	9.78	0.36	3.68e-21	Parkinson's disease;
BRCA	cis	rs1468333	0.824	rs28704868	chr5:137590786	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.4	7.81	0.3	2.28e-14	Resting heart rate;
BRCA	cis	rs4566357	0.521	rs78411533	chr2:227910807	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.48	-0.35	4.75e-20	Coronary artery disease;
BRCA	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07080220	chr10:102295463	HIF1AN	0.49	11.33	0.41	2.98e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	11.11	0.4	2.47e-26	Platelet count;
BRCA	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.68	15.93	0.53	2.4e-48	Systemic lupus erythematosus;
BRCA	cis	rs7246967	0.551	rs8102812	chr19:22879243	A/T	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg13073564	chr4:8508604	NA	-0.37	-9.41	-0.35	8.57e-20	Response to antineoplastic agents;
BRCA	cis	rs7247513	0.797	rs3815914	chr19:12760664	T/C	cg01871581	chr19:12707946	ZNF490	-0.62	-13.16	-0.46	3.53e-35	Bipolar disorder;
BRCA	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg04166393	chr7:2884313	GNA12	0.49	9.56	0.35	2.54e-20	Height;
BRCA	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-14.12	-0.49	1.38e-39	Chronic sinus infection;
BRCA	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg18225595	chr11:63971243	STIP1	0.56	13.6	0.47	3.45e-37	Platelet count;
BRCA	cis	rs9309711	0.736	rs13409102	chr2:3496321	G/A	cg16153549	chr2:3496821	NA	-0.46	-10.46	-0.38	9.24e-24	Neurofibrillary tangles;
BRCA	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg17211192	chr8:82754475	SNX16	-0.62	-11.88	-0.43	1.46e-29	Diastolic blood pressure;
BRCA	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.5	0.55	3.31e-51	Colorectal cancer;
BRCA	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg08859206	chr1:53392774	SCP2	-0.41	-8.76	-0.33	1.76e-17	Monocyte count;
BRCA	cis	rs6811802	1	rs6811802	chr4:78932838	G/C	cg07207937	chr4:78783799	MRPL1	-0.65	-12.22	-0.44	5.23e-31	Left ventricular obstructive tract defect (inherited effect);
BRCA	cis	rs17095355	1.000	rs12570230	chr10:111691614	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.39	-10.14	-0.37	1.71e-22	Biliary atresia;
BRCA	cis	rs56399783	0.901	rs17132741	chr7:2868997	C/T	cg19731401	chr7:2775893	GNA12	-0.48	-8.91	-0.33	5.16e-18	Childhood ear infection;
BRCA	cis	rs13136331	0.879	rs2126650	chr4:88710587	C/T	cg22416721	chr4:88570574	DMP1	0.46	10.04	0.37	4.05e-22	Sitting height ratio;
BRCA	cis	rs1018836	0.847	rs35409073	chr8:91648036	G/T	cg16814680	chr8:91681699	NA	-0.61	-12.82	-0.45	1.2e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.41	-9.14	-0.34	8.39e-19	HDL cholesterol;
BRCA	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg05313129	chr8:58192883	C8orf71	-0.48	-9.81	-0.36	3.01e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg02038168	chr22:39784481	NA	-0.43	-8.99	-0.34	2.71e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg12863693	chr15:85201151	NMB	0.45	8.04	0.3	4.48e-15	Schizophrenia;
BRCA	cis	rs36051895	0.553	rs12338854	chr9:5057568	G/C	cg02405213	chr9:5042618	JAK2	-0.49	-9.52	-0.35	3.56e-20	Pediatric autoimmune diseases;
BRCA	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg23229984	chr5:148520753	ABLIM3	0.35	8.79	0.33	1.39e-17	Breast cancer;
BRCA	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-10.69	-0.39	1.23e-24	Chronic sinus infection;
BRCA	cis	rs17767294	0.708	rs72845897	chr6:27699357	T/C	cg08851530	chr6:28072375	NA	1.11	10.08	0.37	2.81e-22	Parkinson's disease;
BRCA	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg14440974	chr22:39074834	NA	-0.37	-8.43	-0.32	2.24e-16	Menopause (age at onset);
BRCA	cis	rs7903847	0.619	rs76094900	chr10:99158164	G/A	cg20016023	chr10:99160130	RRP12	-0.27	-8.62	-0.32	5.17e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs13046373	0.535	rs1605428	chr21:32028976	T/C	cg16431978	chr21:31797932	KRTAP13-3	0.36	8.76	0.33	1.74e-17	HDL cholesterol;
BRCA	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg00717180	chr2:96193071	NA	0.31	8.67	0.32	3.68e-17	Coronary artery disease;
BRCA	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.5	10.16	0.37	1.44e-22	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg05868516	chr6:26286170	HIST1H4H	0.41	8.1	0.31	2.8e-15	Educational attainment;
BRCA	cis	rs727479	0.502	rs7180552	chr15:51506768	T/G	cg19946085	chr15:51559439	CYP19A1	-0.3	-8.48	-0.32	1.51e-16	Estradiol levels;
BRCA	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg22903471	chr2:27725779	GCKR	-0.37	-9.03	-0.34	2.02e-18	Total body bone mineral density;
BRCA	cis	rs10924970	0.967	rs4481838	chr1:235442626	A/G	cg26050004	chr1:235667680	B3GALNT2	0.35	8.69	0.33	3.01e-17	Asthma;
BRCA	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-8.46	-0.32	1.78e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs73242632	1.000	rs73242618	chr4:57809549	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	0.65	7.93	0.3	9.85e-15	Congenital heart disease (maternal effect);
BRCA	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg04727924	chr7:799746	HEATR2	-0.53	-9.93	-0.37	1.02e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.67	0.39	1.41e-24	Bipolar disorder;
BRCA	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg13047869	chr3:10149882	C3orf24	0.59	12.13	0.43	1.26e-30	Alzheimer's disease;
BRCA	cis	rs7809950	0.637	rs3801964	chr7:106836242	T/C	cg23024343	chr7:107201750	COG5	-0.45	-9.03	-0.34	2.03e-18	Coronary artery disease;
BRCA	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg13010199	chr12:38710504	ALG10B	0.48	9.46	0.35	5.66e-20	Morning vs. evening chronotype;
BRCA	cis	rs3824867	0.920	rs10742805	chr11:47454701	A/G	cg20307385	chr11:47447363	PSMC3	0.51	11.5	0.41	5.87e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg17507749	chr15:85114479	UBE2QP1	0.56	10.59	0.39	3.04e-24	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.74	0.39	7.86e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs5751614	1.000	rs2267018	chr22:23588193	C/T	cg25410636	chr22:23605411	BCR	-0.41	-10.33	-0.38	3.19e-23	Height;
BRCA	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.29	0.44	2.59e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg06521331	chr12:34319734	NA	-0.51	-9.17	-0.34	6.67e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg11833968	chr6:79620685	NA	-0.43	-9.72	-0.36	6.42e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7737355	0.947	rs3776007	chr5:130875085	C/G	cg06307176	chr5:131281290	NA	-0.53	-10.59	-0.39	2.87e-24	Life satisfaction;
BRCA	trans	rs3857536	0.813	rs9354405	chr6:66948575	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.14	-0.31	2.06e-15	Blood trace element (Cu levels);
BRCA	cis	rs7178424	0.905	rs8027751	chr15:62247720	A/T	cg00456672	chr15:62358751	C2CD4A	0.43	9.89	0.36	1.51e-21	Height;
BRCA	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg10932868	chr11:921992	NA	0.48	12.3	0.44	2.45e-31	Alzheimer's disease (late onset);
BRCA	cis	rs13102973	0.797	rs4453983	chr4:135905424	A/C	cg14419869	chr4:135874104	NA	0.45	9.02	0.34	2.26e-18	Subjective well-being;
BRCA	cis	rs1691799	0.899	rs1168329	chr12:66731864	C/A	cg16791601	chr12:66731901	HELB	-0.7	-19.95	-0.62	3.14e-69	White blood cell count (basophil);
BRCA	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.75	-0.55	1.78e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-10.06	-0.37	3.32e-22	Heart rate;
BRCA	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg25664220	chr3:72788482	NA	-0.55	-11.54	-0.42	4.23e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs727479	0.502	rs12591172	chr15:51503727	G/A	cg19946085	chr15:51559439	CYP19A1	-0.3	-8.63	-0.32	5.03e-17	Estradiol levels;
BRCA	cis	rs11608355	0.515	rs11609921	chr12:109918405	A/G	cg05360138	chr12:110035743	NA	0.74	13.58	0.47	4.43e-37	Neuroticism;
BRCA	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg04025307	chr7:1156635	C7orf50	0.48	11.88	0.43	1.43e-29	Longevity;Endometriosis;
BRCA	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg06484146	chr7:12443880	VWDE	-0.7	-9.77	-0.36	4.17e-21	Coronary artery disease;
BRCA	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg12573674	chr2:1569213	NA	-0.44	-8.51	-0.32	1.24e-16	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7178424	0.742	rs963024	chr15:62211450	G/A	cg00456672	chr15:62358751	C2CD4A	0.39	9.33	0.35	1.68e-19	Height;
BRCA	cis	rs7729447	0.813	rs1031648	chr5:32692105	T/A	cg16267343	chr5:32710456	NPR3	0.42	8.5	0.32	1.31e-16	Blood pressure;
BRCA	cis	rs4409675	0.597	rs1000431	chr1:28225114	C/T	cg23691781	chr1:28212827	C1orf38	0.32	10.61	0.39	2.42e-24	Corneal astigmatism;
BRCA	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	21.85	0.65	1.87e-79	Smoking behavior;
BRCA	cis	rs9807989	0.507	rs2160201	chr2:103033961	T/C	cg03938978	chr2:103052716	IL18RAP	0.29	8.37	0.31	3.62e-16	Asthma;
BRCA	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.01	-0.34	2.27e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg06618935	chr21:46677482	NA	-0.36	-8.01	-0.3	5.55e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg26043149	chr18:55253948	FECH	0.42	8.98	0.33	3.07e-18	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2625529	0.816	rs4777467	chr15:72138478	T/C	cg16672083	chr15:72433130	SENP8	-0.8	-16.45	-0.55	5.82e-51	Red blood cell count;
BRCA	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg24812749	chr6:127587940	RNF146	0.87	20.07	0.62	7.99e-70	Breast cancer;
BRCA	cis	rs9790314	0.747	rs4616689	chr3:160856269	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-10.74	-0.39	7.35e-25	Morning vs. evening chronotype;
BRCA	cis	rs7336332	0.569	rs7988412	chr13:28000282	C/T	cg01674679	chr13:27998804	GTF3A	-0.44	-8.58	-0.32	7.02e-17	Weight;
BRCA	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.3	-8.08	-0.3	3.13e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7246967	0.673	rs28649847	chr19:22811540	G/T	cg23217946	chr19:22817039	ZNF492	0.47	8.43	0.32	2.22e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs9811920	0.603	rs2638948	chr3:99501539	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.53	-12.6	-0.45	1.09e-32	Axial length;
BRCA	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg05347473	chr6:146136440	FBXO30	0.55	10.61	0.39	2.39e-24	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg08422745	chr4:174089978	GALNT7	-0.8	-18.39	-0.59	6.24e-61	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs7833986	0.501	rs2719226	chr8:57044066	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	12.93	0.46	3.79e-34	Height;
BRCA	cis	rs7552167	0.789	rs6424162	chr1:24512576	T/C	cg01960748	chr1:24522592	NA	-0.62	-10.08	-0.37	2.78e-22	Psoriasis vulgaris;
BRCA	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg26384229	chr12:38710491	ALG10B	0.68	14.37	0.49	9.31e-41	Morning vs. evening chronotype;
BRCA	cis	rs2625529	0.668	rs12591338	chr15:72556847	T/A	cg16672083	chr15:72433130	SENP8	-0.81	-16.99	-0.56	1.09e-53	Red blood cell count;
BRCA	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg19000871	chr14:103996768	TRMT61A	0.35	8.04	0.3	4.42e-15	Coronary artery disease;
BRCA	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg10224037	chr5:178157518	ZNF354A	0.76	15.88	0.53	4.15e-48	Neutrophil percentage of white cells;
BRCA	cis	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	10.78	0.39	5.18e-25	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	9.29	0.35	2.35e-19	Lung cancer in ever smokers;
BRCA	cis	rs68170813	0.559	rs17429118	chr7:106964052	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.43	-0.32	2.33e-16	Coronary artery disease;
BRCA	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg17830980	chr10:43048298	ZNF37B	-0.48	-11.18	-0.4	1.3e-26	Breast cancer;
BRCA	cis	rs13046373	0.535	rs2226377	chr21:32031915	T/C	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.17	0.34	6.25e-19	HDL cholesterol;
BRCA	trans	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.92	-0.3	1.03e-14	Corneal astigmatism;
BRCA	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.38	-0.31	3.25e-16	Bipolar disorder;
BRCA	trans	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg21659725	chr3:3221576	CRBN	-0.34	-8.23	-0.31	1.05e-15	Menarche (age at onset);
BRCA	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg05623727	chr3:50126028	RBM5	0.51	12.28	0.44	2.91e-31	Body mass index;
BRCA	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg08213375	chr14:104286397	PPP1R13B	0.51	11.43	0.41	1.16e-27	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg21905437	chr5:178450457	ZNF879	0.51	10.17	0.37	1.26e-22	Pubertal anthropometrics;
BRCA	cis	rs2742417	0.609	rs2673066	chr3:45771200	C/T	cg04837898	chr3:45731254	SACM1L	-0.38	-7.86	-0.3	1.61e-14	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15506890	chr2:3487001	NA	-0.58	-13.16	-0.46	3.64e-35	Neurofibrillary tangles;
BRCA	trans	rs12517041	1.000	rs10064991	chr5:23318464	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-8.11	-0.31	2.55e-15	Calcium levels;
BRCA	cis	rs2882667	0.537	rs6887866	chr5:138437696	T/C	cg04439458	chr5:138467593	SIL1	-0.29	-7.85	-0.3	1.81e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18876405	chr7:65276391	NA	-0.62	-15.5	-0.52	3.28e-46	Aortic root size;
BRCA	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg08885076	chr2:99613938	TSGA10	-0.47	-8.99	-0.33	2.88e-18	Chronic sinus infection;
BRCA	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg06115741	chr20:33292138	TP53INP2	0.39	8.62	0.32	5.23e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs6684428	1.000	rs12124871	chr1:56372247	C/T	cg11651538	chr1:56320950	NA	-0.46	-7.81	-0.3	2.32e-14	Airflow obstruction;
BRCA	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.01	0.4	6.12e-26	Bipolar disorder;
BRCA	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg01884057	chr2:25150051	NA	0.34	9.12	0.34	9.39e-19	Body mass index;
BRCA	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg16325326	chr1:53192061	ZYG11B	0.7	16.96	0.56	1.58e-53	Monocyte count;
BRCA	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.52	0.5	1.78e-41	Motion sickness;
BRCA	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg23711669	chr6:146136114	FBXO30	0.7	16.61	0.55	9.15e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg01579765	chr21:45077557	HSF2BP	0.38	10.2	0.37	9.68e-23	Mean corpuscular volume;
BRCA	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.38	-0.38	1.93e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg18876405	chr7:65276391	NA	0.71	18.24	0.59	3.68e-60	Aortic root size;
BRCA	cis	rs7178424	0.806	rs1425270	chr15:62237710	C/T	cg00456672	chr15:62358751	C2CD4A	0.4	9.74	0.36	5.35e-21	Height;
BRCA	cis	rs507080	0.769	rs745663	chr11:118529595	A/G	cg08498647	chr11:118550644	TREH	-0.37	-8.12	-0.31	2.4e-15	Serum metabolite levels;
BRCA	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	12.01	0.43	4.35e-30	Personality dimensions;
BRCA	cis	rs858239	0.899	rs10262243	chr7:23290987	G/A	cg23682824	chr7:23144976	KLHL7	0.33	8.25	0.31	8.73e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg26248373	chr2:1572462	NA	-0.5	-9.8	-0.36	3.14e-21	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg00339695	chr16:24857497	SLC5A11	0.52	11.13	0.4	1.97e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	8.07	0.3	3.38e-15	Schizophrenia;
BRCA	cis	rs2014572	0.870	rs10426580	chr19:57756221	G/A	cg24459738	chr19:57751996	ZNF805	-0.33	-7.98	-0.3	6.73e-15	Hyperactive-impulsive symptoms;
BRCA	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg05970437	chr19:1864622	KLF16	0.44	8.19	0.31	1.43e-15	Bipolar disorder;
BRCA	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.03	21.06	0.64	3.65e-75	Gut microbiome composition (summer);
BRCA	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg12379764	chr21:47803548	PCNT	0.59	14.19	0.49	6.51e-40	Testicular germ cell tumor;
BRCA	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.43e-19	Menopause (age at onset);
BRCA	trans	rs9784649	0.891	rs57355285	chr5:25016384	C/G	cg08600765	chr20:34638493	LOC647979	-0.58	-9.54	-0.35	2.86e-20	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg05283184	chr6:79620031	NA	-0.36	-8.22	-0.31	1.13e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00149659	chr3:10157352	C3orf10	1.07	18.1	0.58	2.08e-59	Alzheimer's disease;
BRCA	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg05234568	chr11:5960015	NA	0.61	13.78	0.48	5.05e-38	DNA methylation (variation);
BRCA	trans	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	11.89	0.43	1.3e-29	Exhaled nitric oxide output;
BRCA	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.17	0.31	1.68e-15	Depression;
BRCA	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg11752832	chr7:134001865	SLC35B4	0.53	13.77	0.48	5.7800000000000005e-38	Mean platelet volume;
BRCA	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg00105475	chr2:10696890	NA	0.44	10.29	0.38	4.38e-23	Prostate cancer;
BRCA	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	11.03	0.4	4.9e-26	Bipolar disorder;
BRCA	trans	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg25214090	chr10:38739885	LOC399744	0.45	10.63	0.39	2.12e-24	Corneal astigmatism;
BRCA	cis	rs9811920	0.715	rs1017967	chr3:99905803	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.4	9.26	0.34	3.1400000000000002e-19	Axial length;
BRCA	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.84	20.32	0.63	3.42e-71	Birth weight;
BRCA	cis	rs4478858	0.684	rs7519766	chr1:31735512	C/A	cg00250761	chr1:31883323	NA	-0.31	-8.13	-0.31	2.2e-15	Alcohol dependence;
BRCA	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg14019146	chr3:50243930	SLC38A3	-0.45	-10.97	-0.4	9.23e-26	Body mass index;
BRCA	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg05472934	chr7:22766657	IL6	0.58	15.07	0.51	4.08e-44	Lung cancer;
BRCA	cis	rs919433	0.617	rs10931791	chr2:198573612	A/C	cg00792783	chr2:198669748	PLCL1	-0.43	-9.56	-0.35	2.58e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg26597838	chr10:835615	NA	0.69	11.22	0.41	8.64e-27	Eosinophil percentage of granulocytes;
BRCA	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.57	-0.47	4.99e-37	Developmental language disorder (linguistic errors);
BRCA	trans	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg15556689	chr8:8085844	FLJ10661	-0.34	-9.0	-0.34	2.61e-18	Neuroticism;
BRCA	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-11.31	-0.41	3.73e-27	Gut microbiome composition (summer);
BRCA	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg05347473	chr6:146136440	FBXO30	0.43	8.74	0.33	2.04e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg07741184	chr6:167504864	NA	0.28	8.19	0.31	1.48e-15	Crohn's disease;
BRCA	cis	rs8054556	0.692	rs4788199	chr16:29970857	C/G	cg06326092	chr16:30034487	C16orf92	0.35	8.75	0.33	1.82e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg24642439	chr20:33292090	TP53INP2	0.41	8.09	0.3	3e-15	Height;
BRCA	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg07930552	chr6:133119739	C6orf192	0.57	8.84	0.33	9.37e-18	Type 2 diabetes nephropathy;
BRCA	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg23711669	chr6:146136114	FBXO30	-0.76	-17.63	-0.57	5.37e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7512552	0.839	rs12045304	chr1:150399818	G/A	cg15654264	chr1:150340011	RPRD2	0.41	8.81	0.33	1.19e-17	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.56	-9.24	-0.34	3.47e-19	Body mass index (adult);
BRCA	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg08822215	chr16:89438651	ANKRD11	-0.44	-9.53	-0.35	3.13e-20	Multiple myeloma (IgH translocation);
BRCA	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg18252515	chr7:66147081	NA	-0.9	-12.94	-0.46	3.62e-34	Diabetic kidney disease;
BRCA	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg11062466	chr8:58055876	NA	0.54	9.12	0.34	9.92e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs9341808	0.905	rs3805903	chr6:80975829	T/C	cg08355045	chr6:80787529	NA	0.33	8.62	0.32	5.28e-17	Sitting height ratio;
BRCA	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg14683738	chr19:37701593	ZNF585B	0.45	7.95	0.3	8.32e-15	Coronary artery calcification;
BRCA	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg17971929	chr21:40555470	PSMG1	-0.45	-9.27	-0.34	2.87e-19	Menarche (age at onset);
BRCA	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg14530993	chr4:882597	GAK	0.53	9.8	0.36	3.34e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.31	-7.85	-0.3	1.77e-14	Personality dimensions;
BRCA	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg13385521	chr17:29058706	SUZ12P	0.62	8.52	0.32	1.15e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg13770153	chr20:60521292	NA	-0.42	-9.39	-0.35	1.02e-19	Body mass index;
BRCA	cis	rs6878727	0.665	rs698184	chr5:123664609	G/T	cg01806427	chr5:123737813	NA	0.36	8.05	0.3	4.06e-15	Breast cancer;
BRCA	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-17.4	-0.57	8.82e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs57590327	0.555	rs13088603	chr3:81791167	A/G	cg07356753	chr3:81810745	GBE1	-0.47	-11.24	-0.41	7.08e-27	Extraversion;
BRCA	cis	rs73086581	0.945	rs6052222	chr20:3972793	G/A	cg02187196	chr20:3869020	PANK2	0.5	8.79	0.33	1.37e-17	Response to antidepressants in depression;
BRCA	cis	rs11585357	0.947	rs11585118	chr1:17605774	C/A	cg08277548	chr1:17600880	PADI3	-0.74	-12.09	-0.43	1.9e-30	Hair shape;
BRCA	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg18761221	chr20:60518478	NA	-0.32	-8.07	-0.3	3.51e-15	Obesity-related traits;
BRCA	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg14582100	chr15:45693742	SPATA5L1	0.36	11.86	0.42	1.86e-29	Homoarginine levels;
BRCA	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.56	-0.32	8.48e-17	Electroencephalogram traits;
BRCA	cis	rs1451375	0.617	rs17733244	chr7:50575495	T/C	cg18232548	chr7:50535776	DDC	0.49	9.22	0.34	4.36e-19	Malaria;
BRCA	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18876405	chr7:65276391	NA	0.54	12.53	0.44	2.39e-32	Aortic root size;
BRCA	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.91	0.56	2.59e-53	Hypertriglyceridemia;
BRCA	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.77	0.39	5.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg08085267	chr17:45401833	C17orf57	0.67	14.82	0.51	6.55e-43	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs312273	0.806	rs4767994	chr12:41349738	A/G	cg17827154	chr12:41323612	CNTN1	-0.42	-10.98	-0.4	8.04e-26	Bipolar disorder;
BRCA	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	14.45	0.5	3.54e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg17063962	chr7:91808500	NA	0.6	14.47	0.5	2.89e-41	Breast cancer;
BRCA	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg26838691	chr2:24397539	C2orf84	0.4	8.01	0.3	5.49e-15	Asthma;
BRCA	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03923535	chr7:1197113	ZFAND2A	0.52	11.36	0.41	2.28e-27	Longevity;Endometriosis;
BRCA	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg00012203	chr2:219082015	ARPC2	-0.48	-9.23	-0.34	3.88e-19	Colorectal cancer;
BRCA	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg08997352	chr12:9597637	DDX12	-0.57	-11.03	-0.4	5.25e-26	Breast size;
BRCA	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg11657440	chr19:46296263	DMWD	0.71	19.07	0.6	1.69e-64	Coronary artery disease;
BRCA	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.02	-0.34	2.26e-18	Total body bone mineral density;
BRCA	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg24803719	chr17:45855879	NA	-0.31	-8.05	-0.3	4.15e-15	IgG glycosylation;
BRCA	cis	rs4919694	1.000	rs12268849	chr10:104737682	G/A	cg04362960	chr10:104952993	NT5C2	0.9	14.85	0.51	4.46e-43	Arsenic metabolism;
BRCA	cis	rs2637266	1.000	rs12784382	chr10:78378348	G/T	cg18941641	chr10:78392320	NA	0.35	7.82	0.3	2.18e-14	Pulmonary function;
BRCA	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg10729496	chr3:10149963	C3orf24	0.45	8.7	0.33	2.8e-17	Alzheimer's disease;
BRCA	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg23649088	chr2:200775458	C2orf69	0.59	8.81	0.33	1.18e-17	Schizophrenia;
BRCA	cis	rs6942756	0.876	rs28636722	chr7:129015151	C/T	cg02491457	chr7:128862824	NA	-0.61	-12.55	-0.44	1.83e-32	White matter hyperintensity burden;
BRCA	cis	rs6546886	0.912	rs10191539	chr2:74269926	T/C	cg14702570	chr2:74259524	NA	-0.32	-8.03	-0.3	4.83e-15	Dialysis-related mortality;
BRCA	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg20503657	chr10:835505	NA	0.95	14.3	0.49	1.8e-40	Eosinophil percentage of granulocytes;
BRCA	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg02153584	chr22:29168773	CCDC117	0.54	11.36	0.41	2.28e-27	Lymphocyte counts;
BRCA	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg03806693	chr22:41940476	POLR3H	-0.55	-9.72	-0.36	6.52e-21	Neuroticism;
BRCA	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg04267008	chr7:1944627	MAD1L1	-0.41	-8.89	-0.33	6.29e-18	Schizophrenia;
BRCA	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg18357645	chr12:58087776	OS9	0.3	7.97	0.3	7.12e-15	Multiple sclerosis;
BRCA	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg00686598	chr14:53173677	PSMC6	-1.23	-16.24	-0.54	6.87e-50	Alzheimer's disease (late onset);
BRCA	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg03146154	chr1:46216737	IPP	0.52	11.59	0.42	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg08807101	chr21:30365312	RNF160	0.75	19.55	0.61	4.56e-67	Dental caries;
BRCA	cis	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg06521331	chr12:34319734	NA	-0.5	-9.78	-0.36	3.81e-21	Morning vs. evening chronotype;
BRCA	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg15839431	chr19:19639596	YJEFN3	-0.35	-7.99	-0.3	6.53e-15	Bipolar disorder;
BRCA	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg27102117	chr16:15229624	NA	0.41	9.98	0.37	6.83e-22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	trans	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg09719594	chr16:21412588	NA	-0.32	-7.81	-0.3	2.33e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg24296786	chr1:45957014	TESK2	0.63	15.73	0.53	2.31e-47	High light scatter reticulocyte count;
BRCA	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg06115741	chr20:33292138	TP53INP2	0.35	7.89	0.3	1.29e-14	Glomerular filtration rate (creatinine);
BRCA	cis	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg08601574	chr20:25228251	PYGB	0.34	8.27	0.31	7.63e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13126279	chr21:47581558	C21orf56	0.43	9.52	0.35	3.5e-20	Testicular germ cell tumor;
BRCA	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg09307838	chr4:120376055	NA	0.7	14.46	0.5	3.32e-41	Corneal astigmatism;
BRCA	cis	rs7572733	0.555	rs1435569	chr2:198718667	G/C	cg00792783	chr2:198669748	PLCL1	0.47	10.12	0.37	1.95e-22	Dermatomyositis;
BRCA	cis	rs6484504	0.512	rs7940020	chr11:31366453	T/G	cg14844989	chr11:31128820	NA	0.46	9.59	0.35	1.95e-20	Red blood cell count;
BRCA	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.13	-0.31	2.19e-15	Retinal vascular caliber;
BRCA	cis	rs427394	0.659	rs274695	chr5:6732252	G/C	cg10857441	chr5:6722123	POLS	-0.31	-9.89	-0.36	1.46e-21	Menopause (age at onset);
BRCA	cis	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg06521331	chr12:34319734	NA	-0.56	-10.18	-0.37	1.14e-22	Morning vs. evening chronotype;
BRCA	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg07389463	chr12:132296394	NA	0.33	8.82	0.33	1.1e-17	Migraine;
BRCA	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg25173405	chr17:45401733	C17orf57	-0.52	-10.74	-0.39	7.82e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs1459104	0.866	rs35456973	chr11:54838812	C/A	cg15704280	chr7:45808275	SEPT13	0.63	8.27	0.31	7.96e-16	Body mass index;
BRCA	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.89	-0.33	6.32e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6138458	1.000	rs227621	chr20:24910528	A/C	cg06937882	chr20:24974362	C20orf3	-0.44	-8.38	-0.31	3.34e-16	Blood protein levels;
BRCA	cis	rs1577917	1.000	rs35760725	chr6:86648985	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.39	-0.41	1.76e-27	Response to antipsychotic treatment;
BRCA	cis	rs4727443	0.866	rs6963345	chr7:99618606	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.4	8.99	0.34	2.73e-18	Interstitial lung disease;
BRCA	cis	rs57590327	0.528	rs3821552	chr3:81702139	A/G	cg07356753	chr3:81810745	GBE1	-0.42	-9.51	-0.35	3.85e-20	Extraversion;
BRCA	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg16482183	chr6:26056742	HIST1H1C	0.49	10.19	0.37	1.07e-22	Height;
BRCA	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg05863683	chr7:1912471	MAD1L1	0.43	9.17	0.34	6.54e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg16325326	chr1:53192061	ZYG11B	0.52	11.12	0.4	2.15e-26	Monocyte count;
BRCA	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg15017067	chr4:17643749	FAM184B	0.34	10.76	0.39	6.45e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.54	14.15	0.49	1e-39	Response to bleomycin (chromatid breaks);
BRCA	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg13628971	chr7:2884303	GNA12	0.49	9.69	0.36	8.11e-21	Height;
BRCA	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg08805041	chr16:621841	PIGQ	-0.3	-7.94	-0.3	8.93e-15	Height;
BRCA	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08045932	chr20:61659980	NA	0.47	10.37	0.38	2.13e-23	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2882667	0.690	rs10067361	chr5:138240874	G/T	cg04439458	chr5:138467593	SIL1	-0.34	-8.36	-0.31	4.05e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-9.98	-0.37	7.04e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg04455712	chr21:45112962	RRP1B	0.41	10.99	0.4	7.35e-26	Mean corpuscular volume;
BRCA	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.34	9.31	0.35	2.08e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg24829409	chr8:58192753	C8orf71	-0.48	-9.14	-0.34	7.94e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg14019146	chr3:50243930	SLC38A3	-0.64	-15.7	-0.53	3.25e-47	Intelligence (multi-trait analysis);
BRCA	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04824913	chr4:887549	GAK	-0.72	-13.47	-0.47	1.47e-36	Systemic sclerosis;
BRCA	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg21856205	chr7:94953877	PON1	-0.37	-7.82	-0.3	2.18e-14	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs11030122	0.645	rs11493482	chr11:4034772	A/G	cg18678763	chr11:4115507	RRM1	-0.35	-7.9	-0.3	1.21e-14	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg06636001	chr8:8085503	FLJ10661	0.64	14.37	0.49	9.01e-41	Mood instability;
BRCA	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.11	0.31	2.54e-15	Tonsillectomy;
BRCA	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg23711669	chr6:146136114	FBXO30	-0.75	-17.18	-0.56	1.18e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg18252515	chr7:66147081	NA	-1.06	-15.7	-0.53	3.29e-47	Diabetic kidney disease;
BRCA	trans	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04565464	chr8:145669602	NFKBIL2	0.34	8.06	0.3	3.7e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7945718	1.000	rs12269900	chr11:12748518	G/A	cg25843174	chr11:12811716	TEAD1	0.23	8.49	0.32	1.4e-16	Educational attainment (years of education);
BRCA	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg11843238	chr5:131593191	PDLIM4	0.37	9.62	0.36	1.56e-20	Breast cancer;
BRCA	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg04362960	chr10:104952993	NT5C2	0.43	10.25	0.38	6.42e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg18806716	chr10:30721971	MAP3K8	-0.44	-9.99	-0.37	6.14e-22	Inflammatory bowel disease;
BRCA	cis	rs3818285	1.000	rs3818285	chr10:111635212	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.34	-8.72	-0.33	2.39e-17	Superior crus of antihelix expression;
BRCA	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg09307838	chr4:120376055	NA	0.61	11.91	0.43	1.15e-29	Corneal astigmatism;
BRCA	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg12311346	chr5:56204834	C5orf35	-0.58	-11.46	-0.41	8.62e-28	Type 2 diabetes;
BRCA	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg18538332	chr22:24372958	LOC391322	-0.56	-14.13	-0.49	1.17e-39	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg00631329	chr6:26305371	NA	-0.45	-13.67	-0.48	1.66e-37	Educational attainment;
BRCA	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg03188948	chr7:1209495	NA	0.86	11.76	0.42	4.8e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg16339924	chr4:17578868	LAP3	-0.56	-13.25	-0.46	1.42e-35	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg05347473	chr6:146136440	FBXO30	-0.4	-7.95	-0.3	8.45e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg04756594	chr16:24857601	SLC5A11	-0.55	-12.43	-0.44	6.24e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1577917	1.000	rs35385043	chr6:86648546	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.39	-0.41	1.76e-27	Response to antipsychotic treatment;
BRCA	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.32	0.31	5.33e-16	Menopause (age at onset);
BRCA	cis	rs6840258	0.660	rs55816619	chr4:87959805	G/A	cg08197287	chr4:87952173	AFF1	-0.48	-8.15	-0.31	1.88e-15	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs6138458	0.626	rs6138473	chr20:25012155	A/G	cg26195577	chr20:24973756	C20orf3	-0.57	-14.19	-0.49	5.97e-40	Blood protein levels;
BRCA	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg20933634	chr6:27740509	NA	0.47	8.93	0.33	4.57e-18	Parkinson's disease;
BRCA	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg03188948	chr7:1209495	NA	0.83	11.33	0.41	2.93e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg26384229	chr12:38710491	ALG10B	0.42	9.43	0.35	7.36e-20	Morning vs. evening chronotype;
BRCA	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.42	-0.5	5.11e-41	Eye color traits;
BRCA	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg09467607	chr2:36825704	FEZ2	0.67	17.89	0.58	2.62e-58	Height;
BRCA	cis	rs9512730	0.553	rs9512702	chr13:28033485	A/G	cg08193333	chr13:27998609	GTF3A	0.41	7.89	0.3	1.31e-14	Schizophrenia;
BRCA	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.83	0.39	3.26e-25	Rheumatoid arthritis;
BRCA	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg15819921	chr19:927150	ARID3A	-0.53	-9.83	-0.36	2.39e-21	Life satisfaction;
BRCA	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg13770153	chr20:60521292	NA	-0.46	-10.9	-0.4	1.66e-25	Body mass index;
BRCA	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg01028140	chr2:1542097	TPO	-0.6	-12.64	-0.45	7.84e-33	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6088813	1.000	rs1570004	chr20:33958253	A/T	cg14752227	chr20:34000481	UQCC	-0.39	-8.27	-0.31	7.69e-16	Height;
BRCA	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.45	-0.52	5.26e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9473147	0.516	rs9349413	chr6:47511491	A/G	cg12968598	chr6:47444699	CD2AP	0.49	9.82	0.36	2.62e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs4363385	0.818	rs370162	chr1:153005488	G/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.56	-0.32	8.46e-17	Inflammatory skin disease;
BRCA	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.7	-11.85	-0.42	1.96e-29	Platelet count;
BRCA	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg09654669	chr8:57350985	NA	-0.38	-8.24	-0.31	9.83e-16	Obesity-related traits;
BRCA	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg02820040	chr2:241836501	C2orf54	0.5	9.03	0.34	1.97e-18	Urinary metabolites;
BRCA	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg19508488	chr2:152266495	RIF1	0.47	9.4	0.35	9.32e-20	Lung cancer;
BRCA	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg22920501	chr2:26401640	FAM59B	-0.95	-16.5	-0.55	3.18e-51	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg04944784	chr2:26401820	FAM59B	1.0	16.5	0.55	3.29e-51	Gut microbiome composition (summer);
BRCA	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00802000	chr16:706648	WDR90	-0.4	-9.31	-0.35	2.04e-19	Height;
BRCA	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg24466277	chr1:23519622	HTR1D	-0.39	-8.56	-0.32	8.26e-17	Height;
BRCA	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-10.89	-0.4	1.97e-25	Mood instability;
BRCA	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.57	8.98	0.33	2.91e-18	Renal function-related traits (BUN);
BRCA	cis	rs6005807	0.719	rs12169880	chr22:29054875	G/C	cg12565055	chr22:29076175	TTC28	0.5	9.47	0.35	5.27e-20	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs4589502	0.557	rs2447300	chr15:67180599	C/T	cg09911534	chr15:67153556	NA	-0.47	-8.15	-0.31	1.86e-15	Lung cancer (smoking interaction);
BRCA	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg14186256	chr22:23484241	RTDR1	0.78	23.94	0.69	6.75e-91	Bone mineral density;
BRCA	cis	rs3780378	0.967	rs10815144	chr9:5010192	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-8.95	-0.33	3.7e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg11879182	chr18:77439856	CTDP1	0.65	14.01	0.48	4.41e-39	Monocyte count;
BRCA	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg18252515	chr7:66147081	NA	-1.03	-15.25	-0.52	5.04e-45	Diabetic kidney disease;
BRCA	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg09307838	chr4:120376055	NA	0.66	14.48	0.5	2.78e-41	Corneal astigmatism;
BRCA	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.82	0.36	2.79e-21	Lung cancer in ever smokers;
BRCA	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg13010199	chr12:38710504	ALG10B	0.44	10.04	0.37	4.14e-22	Heart rate;
BRCA	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg02016764	chr4:38805732	TLR1	-0.6	-9.25	-0.34	3.22e-19	Breast cancer;
BRCA	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg06238570	chr21:40685208	BRWD1	-0.39	-7.9	-0.3	1.2e-14	Menarche (age at onset);
BRCA	cis	rs8044868	0.548	rs3909541	chr16:72201119	C/T	cg16558253	chr16:72132732	DHX38	0.42	10.3	0.38	4.02e-23	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg00105475	chr2:10696890	NA	0.44	10.41	0.38	1.56e-23	Prostate cancer;
BRCA	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg22535103	chr8:58192502	C8orf71	-0.61	-13.4	-0.47	2.92e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs2230307	0.536	rs560659	chr1:100523536	A/G	cg24955406	chr1:100503596	HIAT1	-0.56	-11.18	-0.4	1.28e-26	Carotid intima media thickness;
BRCA	trans	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg25214090	chr10:38739885	LOC399744	0.45	10.3	0.38	4.02e-23	Corneal astigmatism;
BRCA	cis	rs2712381	0.517	rs62273237	chr3:128310107	T/C	cg16766828	chr3:128327626	NA	-0.34	-7.87	-0.3	1.55e-14	Monocyte count;
BRCA	cis	rs9875589	0.957	rs4407395	chr3:13951673	A/G	cg19554555	chr3:13937349	NA	0.43	8.98	0.33	2.92e-18	Ovarian reserve;
BRCA	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-9.47	-0.35	5.48e-20	Reticulocyte count;
BRCA	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg20607287	chr7:12443886	VWDE	-0.58	-8.42	-0.32	2.54e-16	Coronary artery disease;
BRCA	trans	rs931812	0.829	rs13266662	chr8:101916156	C/T	cg20993868	chr7:22813445	NA	0.44	12.87	0.45	7.27e-34	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.71	-16.47	-0.55	4.77e-51	Axial length;
BRCA	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.23e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs36051895	0.632	rs61461940	chr9:5157277	T/C	cg02405213	chr9:5042618	JAK2	-0.52	-10.26	-0.38	5.82e-23	Pediatric autoimmune diseases;
BRCA	cis	rs10044254	0.614	rs35167698	chr5:15737297	T/C	cg07238450	chr5:15720153	FBXL7	-0.38	-8.08	-0.3	3.26e-15	Asthma (corticosteroid response);
BRCA	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg26384229	chr12:38710491	ALG10B	0.62	16.43	0.54	7.77e-51	Heart rate;
BRCA	cis	rs2882667	0.591	rs56322405	chr5:138173382	C/G	cg04439458	chr5:138467593	SIL1	0.31	7.83	0.3	2.05e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg14835575	chr10:16859367	RSU1	0.66	14.03	0.49	3.44e-39	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg05623727	chr3:50126028	RBM5	0.43	10.14	0.37	1.71e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg19336497	chr11:14380999	RRAS2	0.45	11.87	0.43	1.61e-29	Vitamin D levels;
BRCA	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-10.01	-0.37	5.12e-22	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg03676636	chr4:99064102	C4orf37	0.21	7.97	0.3	7.55e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.65	-0.45	6.65e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg01017244	chr2:74357527	NA	0.53	12.71	0.45	3.81e-33	Gestational age at birth (maternal effect);
BRCA	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg26874164	chr19:58962979	ZNF324B	0.51	11.01	0.4	6.36e-26	Uric acid clearance;
BRCA	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	12.27	0.44	3.23e-31	Tonsillectomy;
BRCA	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg02153584	chr22:29168773	CCDC117	0.44	7.9	0.3	1.19e-14	Lymphocyte counts;
BRCA	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg04518342	chr5:131593106	PDLIM4	0.42	10.1	0.37	2.41e-22	Acylcarnitine levels;
BRCA	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.75	17.12	0.56	2.4e-54	Homoarginine levels;
BRCA	cis	rs4891159	0.527	rs690593	chr18:74160408	C/G	cg24786174	chr18:74118243	ZNF516	0.76	20.91	0.64	2.29e-74	Longevity;
BRCA	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg20790798	chr5:1857306	NA	-0.4	-9.39	-0.35	1.04e-19	Cardiovascular disease risk factors;
BRCA	cis	rs17092148	1.000	rs11699062	chr20:33400379	A/T	cg16810054	chr20:33298113	TP53INP2	0.5	11.25	0.41	6.79e-27	Neuroticism;
BRCA	cis	rs12468557	0.545	rs7587701	chr2:211499959	A/G	cg07063745	chr2:211341572	LANCL1;CPS1	-0.36	-8.04	-0.3	4.44e-15	Body mass index in asthmatics;
BRCA	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg18230493	chr5:56204884	C5orf35	-0.65	-10.43	-0.38	1.24e-23	Type 2 diabetes;
BRCA	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg08999081	chr20:33150536	PIGU	0.47	12.86	0.45	7.97e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg14675211	chr2:100938903	LONRF2	0.52	11.73	0.42	6.37e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg24069376	chr3:38537580	EXOG	0.34	9.41	0.35	8.96e-20	Electrocardiographic conduction measures;
BRCA	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg09035930	chr12:129282057	SLC15A4	-0.46	-12.08	-0.43	2.08e-30	Systemic lupus erythematosus;
BRCA	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.37	0.49	9.05e-41	Motion sickness;
BRCA	cis	rs849141	0.925	rs552707	chr7:28205303	A/G	cg22892036	chr7:28189139	JAZF1	0.45	8.19	0.31	1.44e-15	Height;Hip circumference adjusted for BMI;
BRCA	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg04691961	chr3:161091175	C3orf57	-0.59	-14.28	-0.49	2.26e-40	Morning vs. evening chronotype;
BRCA	cis	rs2882667	0.690	rs288004	chr5:138231645	C/T	cg04439458	chr5:138467593	SIL1	-0.31	-7.82	-0.3	2.22e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg25817165	chr18:72167213	CNDP2	-0.73	-14.1	-0.49	1.59e-39	Refractive error;
BRCA	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg12062639	chr20:23401060	NAPB	0.87	10.46	0.38	9.93e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs4730250	0.708	rs74983157	chr7:106823951	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-8.51	-0.32	1.24e-16	Osteoarthritis;
BRCA	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.64e-24	Motion sickness;
BRCA	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	11.13	0.4	2.01e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg26384229	chr12:38710491	ALG10B	-0.43	-9.82	-0.36	2.68e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.22	-0.31	1.17e-15	Depression;
BRCA	cis	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg05901451	chr6:126070800	HEY2	-0.39	-9.33	-0.35	1.66e-19	Endometrial cancer;
BRCA	trans	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.46	-8.63	-0.32	5.01e-17	Monocyte count;
BRCA	cis	rs1113500	0.787	rs10881502	chr1:108641819	C/T	cg06207961	chr1:108661230	NA	-0.37	-9.14	-0.34	8.01e-19	Growth-regulated protein alpha levels;
BRCA	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-10.81	-0.39	3.83e-25	Hemoglobin concentration;
BRCA	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg23711669	chr6:146136114	FBXO30	0.74	16.82	0.55	7.41e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6429082	0.783	rs291365	chr1:235688043	A/G	cg26050004	chr1:235667680	B3GALNT2	0.55	14.4	0.5	6.12e-41	Adiposity;
BRCA	trans	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg01620082	chr3:125678407	NA	-0.69	-8.61	-0.32	5.8e-17	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg03929089	chr4:120376271	NA	0.57	9.82	0.36	2.63e-21	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs708547	0.792	rs7667084	chr4:57727435	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.48	-10.79	-0.39	4.72e-25	Response to bleomycin (chromatid breaks);
BRCA	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.78	-13.99	-0.48	5.22e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg07817648	chr10:79422355	NA	-0.67	-12.49	-0.44	3.56e-32	Bone mineral density;
BRCA	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg05347473	chr6:146136440	FBXO30	-0.41	-8.35	-0.31	4.17e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.43	9.7	0.36	7.47e-21	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.25	7.92	0.3	1.07e-14	Cardiac Troponin-T levels;
BRCA	trans	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg25214090	chr10:38739885	LOC399744	0.54	12.29	0.44	2.66e-31	Corneal astigmatism;
BRCA	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg20503657	chr10:835505	NA	-1.0	-15.33	-0.52	2.04e-45	Eosinophil percentage of granulocytes;
BRCA	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg06212747	chr3:49208901	KLHDC8B	0.53	11.11	0.4	2.43e-26	Parkinson's disease;
BRCA	cis	rs6893300	0.745	rs6639	chr5:179156782	G/T	cg14593053	chr5:179126677	CANX	-0.35	-7.9	-0.3	1.25e-14	Resting heart rate;
BRCA	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg01483505	chr11:975446	AP2A2	-0.32	-8.67	-0.32	3.43e-17	Alzheimer's disease (late onset);
BRCA	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.65	-9.64	-0.36	1.32e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs16910800	0.731	rs1065631	chr11:23186810	T/C	cg20040320	chr11:23191996	NA	-0.58	-10.03	-0.37	4.27e-22	Cancer;
BRCA	cis	rs12540874	0.542	rs4947581	chr7:50565967	G/A	cg18232548	chr7:50535776	DDC	-0.51	-12.91	-0.45	4.58e-34	Systemic sclerosis;
BRCA	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg15595755	chr5:1867978	NA	0.35	8.27	0.31	7.67e-16	Cardiovascular disease risk factors;
BRCA	cis	rs4566357	0.615	rs10178098	chr2:227914425	C/T	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.2	-0.31	1.31e-15	Coronary artery disease;
BRCA	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg26343298	chr8:95960752	TP53INP1	0.3	8.74	0.33	2.07e-17	Type 2 diabetes;
BRCA	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg01579765	chr21:45077557	HSF2BP	-0.44	-11.96	-0.43	6.94e-30	Mean corpuscular volume;
BRCA	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg21427119	chr20:30132790	HM13	-0.4	-8.56	-0.32	8.62e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	12.99	0.46	2.17e-34	Menarche (age at onset);
BRCA	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg08470875	chr2:26401718	FAM59B	0.76	12.04	0.43	3.12e-30	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg04944784	chr2:26401820	FAM59B	0.97	16.04	0.54	6.42e-49	Gut microbiome composition (summer);
BRCA	cis	rs4363385	0.791	rs512198	chr1:153006245	C/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.24	-0.34	3.58e-19	Inflammatory skin disease;
BRCA	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg13010199	chr12:38710504	ALG10B	0.43	9.11	0.34	1.04e-18	Morning vs. evening chronotype;
BRCA	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26314531	chr2:26401878	FAM59B	-0.63	-11.02	-0.4	5.65e-26	Gut microbiome composition (summer);
BRCA	cis	rs9469890	0.604	rs11758426	chr6:34503338	A/G	cg17674042	chr6:34482479	PACSIN1	-0.34	-8.94	-0.33	4.18e-18	Pubertal anthropometrics;Coronary artery disease;
BRCA	cis	rs701145	0.938	rs355780	chr3:153978289	C/T	cg17054900	chr3:154042577	DHX36	0.62	11.02	0.4	5.4e-26	Coronary artery disease;
BRCA	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.05	0.56	5.25e-54	Bladder cancer;
BRCA	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.66	-0.61	1.21e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs8002861	0.781	rs9525857	chr13:44437072	T/C	cg17145862	chr1:211918768	LPGAT1	0.63	16.2	0.54	1.07e-49	Leprosy;
BRCA	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg25427524	chr10:38739819	LOC399744	0.51	9.43	0.35	7.31e-20	Obesity (extreme);
BRCA	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg21573476	chr21:45109991	RRP1B	0.32	8.11	0.31	2.64e-15	Mean corpuscular volume;
BRCA	cis	rs4285028	0.747	rs77570895	chr3:121384565	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.85	-14.99	-0.51	9.27e-44	Multiple sclerosis;
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg04234412	chr22:24373322	LOC391322	0.78	21.67	0.65	1.68e-78	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.8	-0.33	1.23e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.37	8.11	0.31	2.58e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9469578	1.000	rs16869466	chr6:33715265	A/G	cg18708504	chr6:33715942	IP6K3	0.7	10.19	0.37	1.09e-22	Phosphorus levels;
BRCA	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.78	-0.33	1.55e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs4663866	0.901	rs2304672	chr2:239186589	C/G	cg16914508	chr2:239161102	PER2	-0.68	-9.38	-0.35	1.1e-19	Irritable bowel syndrome;
BRCA	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24531977	chr5:56204891	C5orf35	-0.86	-17.89	-0.58	2.57e-58	Initial pursuit acceleration;
BRCA	cis	rs5167	0.504	rs73047641	chr19:45457377	G/A	cg13119609	chr19:45449297	APOC2	0.46	12.78	0.45	1.91e-33	Blood protein levels;
BRCA	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg14019146	chr3:50243930	SLC38A3	-0.57	-11.8	-0.42	3.32e-29	Menarche (age at onset);
BRCA	cis	rs2742417	0.603	rs2742456	chr3:45767176	C/T	cg04837898	chr3:45731254	SACM1L	-0.39	-7.93	-0.3	9.97e-15	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg13073564	chr4:8508604	NA	0.46	12.37	0.44	1.22e-31	Response to antineoplastic agents;
BRCA	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg27478167	chr7:817139	HEATR2	-0.57	-11.58	-0.42	2.69e-28	Cerebrospinal P-tau181p levels;
BRCA	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg03929089	chr4:120376271	NA	0.57	9.25	0.34	3.26e-19	Axial length;
BRCA	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg02493740	chr2:85810744	VAMP5	-0.5	-10.23	-0.38	7.55e-23	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs9287719	0.624	rs10211190	chr2:10725428	A/G	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	5.17e-19	Prostate cancer;
BRCA	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.07	-0.43	2.22e-30	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.48e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg01620082	chr3:125678407	NA	-0.91	-10.37	-0.38	2.19e-23	Lung cancer in ever smokers;
BRCA	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg16506815	chr2:162101123	NA	0.47	10.08	0.37	2.9e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg20628663	chr10:43360327	NA	0.7	13.59	0.47	3.95e-37	Blood protein levels;
BRCA	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg11843238	chr5:131593191	PDLIM4	0.38	9.26	0.34	3.01e-19	Acylcarnitine levels;
BRCA	cis	rs367943	0.966	rs451425	chr5:112808637	A/G	cg12552261	chr5:112820674	MCC	-0.55	-12.22	-0.44	4.98e-31	Type 2 diabetes;
BRCA	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.76	-0.33	1.74e-17	Triglycerides;
BRCA	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg10729496	chr3:10149963	C3orf24	0.49	9.26	0.34	2.95e-19	Alzheimer's disease;
BRCA	cis	rs7523050	0.643	rs17621851	chr1:109400835	C/T	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg07395648	chr5:131743802	NA	-0.37	-8.07	-0.3	3.54e-15	Breast cancer;
BRCA	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg03060546	chr3:49711283	APEH	0.58	9.93	0.37	1.08e-21	Menarche (age at onset);
BRCA	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.39	-10.32	-0.38	3.46e-23	Intelligence (multi-trait analysis);
BRCA	trans	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-7.81	-0.3	2.3e-14	Menarche (age at onset);
BRCA	cis	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg06521331	chr12:34319734	NA	-0.68	-14.95	-0.51	1.46e-43	Morning vs. evening chronotype;
BRCA	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg08645402	chr16:4508243	NA	0.43	9.95	0.37	9.09e-22	Schizophrenia;
BRCA	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg21433313	chr16:3507492	NAT15	0.45	10.16	0.37	1.36e-22	Tuberculosis;
BRCA	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.77	12.95	0.46	3.07e-34	Schizophrenia;
BRCA	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg02016764	chr4:38805732	TLR1	-0.6	-9.19	-0.34	5.47e-19	Breast cancer;
BRCA	cis	rs1891275	0.515	rs7092884	chr10:93483872	A/C	cg07889827	chr10:93443413	NA	0.41	11.21	0.41	9.86e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs887829	0.570	rs6759892	chr2:234601669	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.32	8.33	0.31	4.95e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg02297831	chr4:17616191	MED28	0.36	8.55	0.32	8.99e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg20476274	chr7:133979776	SLC35B4	0.58	16.09	0.54	3.73e-49	Mean platelet volume;
BRCA	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-8.08	-0.3	3.32e-15	Response to antipsychotic treatment;
BRCA	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg00105475	chr2:10696890	NA	0.44	10.3	0.38	4.11e-23	Prostate cancer;
BRCA	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg03060546	chr3:49711283	APEH	-0.6	-11.69	-0.42	9.46e-29	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-10.39	-0.38	1.8e-23	Blood trace element (Cu levels);
BRCA	cis	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg01950844	chr6:76311363	SENP6	0.86	13.95	0.48	8.14e-39	Prostate cancer;
BRCA	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg11663144	chr21:46675770	NA	-0.62	-14.66	-0.5	3.53e-42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9394841	0.667	rs9357366	chr6:41786976	T/G	cg08135965	chr6:41755394	TOMM6	0.47	7.82	0.3	2.19e-14	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg05347473	chr6:146136440	FBXO30	0.41	8.1	0.31	2.78e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-16.2	-0.54	9.96e-50	Total cholesterol levels;
BRCA	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg15556689	chr8:8085844	FLJ10661	0.37	10.48	0.38	8.23e-24	Joint mobility (Beighton score);
BRCA	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg21132104	chr15:45694354	SPATA5L1	0.75	16.89	0.56	3.4e-53	Homoarginine levels;
BRCA	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg11764359	chr7:65958608	NA	0.46	8.97	0.33	3.18e-18	Calcium levels;
BRCA	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg06618935	chr21:46677482	NA	-0.36	-8.0	-0.3	5.83e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg17366294	chr4:99064904	C4orf37	-0.44	-10.63	-0.39	2.09e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6088813	1.000	rs4911180	chr20:33972948	G/A	cg14752227	chr20:34000481	UQCC	-0.4	-8.46	-0.32	1.77e-16	Height;
BRCA	cis	rs61990749	0.597	rs2267758	chr14:78147429	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.63	-9.61	-0.36	1.65e-20	Fibroblast growth factor basic levels;
BRCA	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg18876405	chr7:65276391	NA	0.41	8.66	0.32	3.87e-17	Aortic root size;
BRCA	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg23719950	chr11:63933701	MACROD1	-0.61	-9.74	-0.36	5.38e-21	Mean platelet volume;
BRCA	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg24558204	chr6:135376177	HBS1L	0.44	12.09	0.43	1.94e-30	Red blood cell count;
BRCA	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg02733842	chr7:1102375	C7orf50	-0.61	-11.57	-0.42	2.99e-28	Bronchopulmonary dysplasia;
BRCA	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-12.54	-0.44	2.18e-32	Personality dimensions;
BRCA	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.31	-7.88	-0.3	1.38e-14	Total body bone mineral density;
BRCA	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07930192	chr7:1003750	NA	0.45	10.3	0.38	3.99e-23	Longevity;Endometriosis;
BRCA	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg18357645	chr12:58087776	OS9	0.47	13.52	0.47	8.2e-37	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7818345	0.967	rs7004435	chr8:19282732	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.3	7.99	0.3	6.12e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg02297831	chr4:17616191	MED28	-0.36	-8.21	-0.31	1.24e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs701145	0.938	rs701143	chr3:154060047	A/G	cg17054900	chr3:154042577	DHX36	0.67	11.69	0.42	9.13e-29	Coronary artery disease;
BRCA	cis	rs9811920	0.695	rs793497	chr3:99505610	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.52	-12.56	-0.45	1.63e-32	Axial length;
BRCA	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg16414030	chr3:133502952	NA	-0.54	-12.84	-0.45	9.98e-34	Iron status biomarkers;
BRCA	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg17971929	chr21:40555470	PSMG1	0.77	18.0	0.58	6.76e-59	Cognitive function;
BRCA	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg11764359	chr7:65958608	NA	-0.64	-13.92	-0.48	1.22e-38	Aortic root size;
BRCA	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg23018236	chr17:30244563	NA	-0.66	-9.97	-0.37	7.61e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg01028140	chr2:1542097	TPO	-0.67	-14.19	-0.49	6e-40	IgG glycosylation;
BRCA	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg13047869	chr3:10149882	C3orf24	0.6	12.76	0.45	2.33e-33	Alzheimer's disease;
BRCA	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg24558204	chr6:135376177	HBS1L	0.59	15.8	0.53	1.07e-47	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg24296786	chr1:45957014	TESK2	0.57	13.26	0.46	1.3e-35	High light scatter reticulocyte count;
BRCA	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg08601574	chr20:25228251	PYGB	-0.37	-8.87	-0.33	7.33e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs897080	0.515	rs1067331	chr2:44627626	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	10.5	0.38	6.83e-24	Height;
BRCA	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg11657440	chr19:46296263	DMWD	-0.56	-13.35	-0.47	4.71e-36	Coronary artery disease;
BRCA	cis	rs6580649	0.825	rs4760611	chr12:48421449	A/G	cg24011408	chr12:48396354	COL2A1	0.48	7.96	0.3	8e-15	Lung cancer;
BRCA	trans	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg06521331	chr12:34319734	NA	-0.5	-9.12	-0.34	9.82e-19	Bladder cancer;
BRCA	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg03060546	chr3:49711283	APEH	-0.51	-10.46	-0.38	9.45e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg10523679	chr1:76189770	ACADM	0.75	15.27	0.52	4.39e-45	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg24562669	chr7:97807699	LMTK2	0.44	11.75	0.42	5.51e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7072216	0.763	rs3814142	chr10:100171104	C/G	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.71	-0.36	7.24e-21	Metabolite levels;
BRCA	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	13.45	0.47	1.78e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6942756	0.806	rs2718115	chr7:128871532	A/G	cg02491457	chr7:128862824	NA	0.59	12.91	0.45	4.84e-34	White matter hyperintensity burden;
BRCA	cis	rs68170813	0.559	rs7809508	chr7:107004119	T/C	cg02696742	chr7:106810147	HBP1	-0.54	-8.82	-0.33	1.04e-17	Coronary artery disease;
BRCA	cis	rs586533	0.801	rs605005	chr11:99499485	C/T	cg22878054	chr11:99397252	CNTN5	0.32	8.07	0.3	3.53e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg19717773	chr7:2847554	GNA12	-0.43	-9.3	-0.35	2.18e-19	Height;
BRCA	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12016809	chr21:47604291	C21orf56	0.39	7.86	0.3	1.64e-14	Testicular germ cell tumor;
BRCA	trans	rs36096196	0.891	rs74046969	chr1:2251348	G/A	cg18313694	chr15:45480185	SHF	0.45	8.59	0.32	6.58e-17	Coronary artery disease;
BRCA	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg20019720	chr6:154832845	CNKSR3	0.53	10.45	0.38	1.04e-23	Lipoprotein (a) levels;
BRCA	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg01689657	chr7:91764605	CYP51A1	0.23	7.99	0.3	6.34e-15	Breast cancer;
BRCA	cis	rs17601876	0.545	rs17523270	chr15:51538280	A/C	cg19946085	chr15:51559439	CYP19A1	0.3	8.19	0.31	1.4e-15	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg09307838	chr4:120376055	NA	0.69	14.25	0.49	3.17e-40	Corneal astigmatism;
BRCA	cis	rs367943	0.966	rs444322	chr5:112815399	C/T	cg12552261	chr5:112820674	MCC	-0.56	-12.28	-0.44	2.97e-31	Type 2 diabetes;
BRCA	cis	rs7818345	1.000	rs13278459	chr8:19297583	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.31	7.94	0.3	8.83e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	trans	rs12517041	0.935	rs1835047	chr5:23296627	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.44	-8.1	-0.31	2.75e-15	Calcium levels;
BRCA	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg16850897	chr7:100343110	ZAN	0.38	8.56	0.32	8.64e-17	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	8.51	0.32	1.23e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs738321	0.723	rs9622726	chr22:38506688	A/G	cg20207973	chr22:38506712	BAIAP2L2	0.47	12.05	0.43	2.76e-30	Breast cancer;
BRCA	cis	rs2882667	0.690	rs495638	chr5:138200942	C/T	cg04439458	chr5:138467593	SIL1	0.31	7.97	0.3	7.3e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4908760	0.965	rs10864356	chr1:8569871	A/T	cg20416874	chr1:8611966	RERE	-0.28	-8.22	-0.31	1.12e-15	Vitiligo;
BRCA	cis	rs2637266	0.935	rs2579728	chr10:78395598	A/G	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg10560079	chr2:191398806	TMEM194B	0.36	8.2	0.31	1.31e-15	Pulse pressure;
BRCA	cis	rs3820928	0.904	rs4129884	chr2:227820943	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.75	-0.33	1.9e-17	Pulmonary function;
BRCA	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-12.33	-0.44	1.8e-31	Hemoglobin concentration;
BRCA	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg12573674	chr2:1569213	NA	-0.64	-14.48	-0.5	2.8e-41	IgG glycosylation;
BRCA	cis	rs7178572	0.568	rs11636554	chr15:77608747	C/T	cg22256960	chr15:77711686	NA	-0.39	-8.65	-0.32	4e-17	Type 2 diabetes;
BRCA	cis	rs7756236	0.521	rs9462208	chr6:36627890	T/C	cg08179530	chr6:36648295	CDKN1A	0.37	7.95	0.3	8.55e-15	QRS duration;
BRCA	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg03709012	chr19:19516395	GATAD2A	0.73	16.16	0.54	1.74e-49	Tonsillectomy;
BRCA	trans	rs877282	0.945	rs71491311	chr10:791747	G/A	cg22713356	chr15:30763199	NA	1.41	28.53	0.75	4.39e-116	Uric acid levels;
BRCA	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.61	-15.06	-0.51	4.35e-44	Longevity;Endometriosis;
BRCA	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-10.07	-0.37	3.07e-22	Tonsillectomy;
BRCA	cis	rs7572733	0.534	rs700684	chr2:198713099	C/T	cg00792783	chr2:198669748	PLCL1	0.47	10.18	0.37	1.14e-22	Dermatomyositis;
BRCA	cis	rs68170813	0.559	rs17428071	chr7:106878200	C/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.45	-0.32	1.97e-16	Coronary artery disease;
BRCA	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.42	-0.61	2.35e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9837602	1.000	rs35844878	chr3:99796626	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.13	0.4	1.97e-26	Breast cancer;
BRCA	cis	rs11690935	0.885	rs6727017	chr2:172766847	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.81	-23.88	-0.69	1.38e-90	Schizophrenia;
BRCA	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg02734326	chr4:10020555	SLC2A9	0.39	8.46	0.32	1.78e-16	Bone mineral density;
BRCA	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg03433033	chr1:76189801	ACADM	0.76	17.24	0.56	5.59e-55	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12612619	0.704	rs11680633	chr2:27224209	T/C	cg00617064	chr2:27272375	NA	-0.31	-7.95	-0.3	8.68e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg24699146	chr1:24152579	HMGCL	0.3	8.11	0.31	2.64e-15	Immature fraction of reticulocytes;
BRCA	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.19	0.31	1.45e-15	Tonsillectomy;
BRCA	cis	rs10227331	0.585	rs10240671	chr7:157298637	G/T	cg04156418	chr7:157293606	NA	-0.32	-9.14	-0.34	8.33e-19	Inattentive symptoms;
BRCA	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg22705602	chr4:152727874	NA	-0.38	-10.2	-0.37	9.45e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg03354898	chr7:1950403	MAD1L1	-0.48	-9.95	-0.37	9.05e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs7727544	0.584	rs7714191	chr5:131341541	C/G	cg14196790	chr5:131705035	SLC22A5	0.32	8.1	0.31	2.75e-15	Blood metabolite levels;
BRCA	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg07636037	chr3:49044803	WDR6	0.55	8.7	0.33	2.75e-17	Menarche (age at onset);
BRCA	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	18.37	0.59	7.7e-61	Platelet count;
BRCA	cis	rs870825	0.616	rs10022818	chr4:185619282	A/G	cg04058563	chr4:185651563	MLF1IP	0.76	17.0	0.56	1e-53	Blood protein levels;
BRCA	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg25204440	chr1:209979598	IRF6	-0.41	-8.27	-0.31	7.61e-16	Cleft lip with or without cleft palate;
BRCA	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg06637938	chr14:75390232	RPS6KL1	0.59	12.28	0.44	2.89e-31	Caffeine consumption;
BRCA	cis	rs2652834	0.851	rs11071721	chr15:63350218	T/C	cg05507819	chr15:63340323	TPM1	0.52	9.06	0.34	1.63e-18	HDL cholesterol;
BRCA	cis	rs9325144	0.872	rs11183390	chr12:38729942	G/T	cg26384229	chr12:38710491	ALG10B	-0.41	-9.65	-0.36	1.13e-20	Morning vs. evening chronotype;
BRCA	trans	rs629535	0.862	rs638412	chr8:70047690	C/T	cg21567404	chr3:27674614	NA	1.0	21.1	0.64	2.04e-75	Dupuytren's disease;
BRCA	cis	rs11229555	0.645	rs36002376	chr11:58204809	C/G	cg15696309	chr11:58395628	NA	-0.52	-10.83	-0.39	3.19e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs4819388	0.793	rs4818887	chr21:45644950	C/T	cg17383793	chr5:52405638	MOCS2	-0.46	-10.32	-0.38	3.27e-23	Celiac disease;
BRCA	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg06145435	chr7:1022769	CYP2W1	0.49	9.02	0.34	2.23e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg05564831	chr3:52568323	NT5DC2	0.34	7.99	0.3	6.31e-15	Electroencephalogram traits;
BRCA	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.47	10.62	0.39	2.17e-24	Aortic root size;
BRCA	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg09184832	chr6:79620586	NA	-0.53	-11.53	-0.42	4.46e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg20224285	chr3:52813920	ITIH1	0.32	8.12	0.31	2.37e-15	Cognitive function;
BRCA	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg13628971	chr7:2884303	GNA12	0.39	8.74	0.33	2.01e-17	Height;
BRCA	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg06484146	chr7:12443880	VWDE	-0.76	-10.68	-0.39	1.29e-24	Coronary artery disease;
BRCA	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-9.54	-0.35	2.92e-20	NT-proBNP levels in acute coronary syndrome;
BRCA	cis	rs57590327	0.555	rs13084107	chr3:81833577	T/C	cg07356753	chr3:81810745	GBE1	-0.48	-11.17	-0.4	1.41e-26	Extraversion;
BRCA	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg05340658	chr4:99064831	C4orf37	0.68	16.98	0.56	1.21e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.29	0.31	6.9e-16	Parkinson's disease;
BRCA	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg16339924	chr4:17578868	LAP3	0.63	15.92	0.53	2.55e-48	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg17420585	chr12:42539391	GXYLT1	-0.38	-8.08	-0.3	3.18e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.63e-18	Alzheimer's disease (late onset);
BRCA	cis	rs9400271	0.632	rs9374069	chr6:109586334	A/G	cg01475377	chr6:109611718	NA	-0.44	-10.53	-0.38	5.13e-24	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg08392591	chr16:89556376	ANKRD11	0.55	13.89	0.48	1.6e-38	Multiple myeloma (IgH translocation);
BRCA	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg20573242	chr4:122745356	CCNA2	0.47	10.58	0.39	3.3e-24	Type 2 diabetes;
BRCA	cis	rs16976116	0.803	rs7168737	chr15:55501344	T/C	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2742234	0.590	rs2565201	chr10:43618484	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.53	-10.56	-0.39	3.73e-24	Hirschsprung disease;
BRCA	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12292205	chr6:26970375	C6orf41	-0.47	-7.88	-0.3	1.43e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs332507	0.830	rs12631364	chr3:124405042	A/T	cg05980111	chr3:124395277	KALRN	0.37	8.65	0.32	4.31e-17	Plateletcrit;
BRCA	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.54e-19	Morning vs. evening chronotype;
BRCA	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg16339924	chr4:17578868	LAP3	0.59	14.38	0.49	8.36e-41	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.61	12.93	0.46	3.78e-34	Lymphocyte counts;
BRCA	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-9.97	-0.37	7.34e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.89e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs16854884	0.586	rs7642551	chr3:143732167	C/T	cg06585982	chr3:143692056	C3orf58	0.47	9.83	0.36	2.48e-21	Economic and political preferences (feminism/equality);
BRCA	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg21535247	chr6:8435926	SLC35B3	0.41	9.45	0.35	6.39e-20	Motion sickness;
BRCA	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.36	7.87	0.3	1.49e-14	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg09537434	chr19:41945824	ATP5SL	-1.0	-25.54	-0.71	1.07e-99	Height;
BRCA	cis	rs4280164	0.945	rs4981503	chr14:24786293	T/G	cg16194253	chr14:24768981	DHRS1;C14orf21	0.46	7.94	0.3	8.85e-15	Parent of origin effect on language impairment (paternal);
BRCA	cis	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg21775007	chr8:11205619	TDH	0.42	8.57	0.32	8.01e-17	Triglycerides;
BRCA	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg23711669	chr6:146136114	FBXO30	-0.78	-18.66	-0.59	2.36e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1468333	1.000	rs17171772	chr5:137514853	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.44	9.31	0.35	1.96e-19	Resting heart rate;
BRCA	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg22907277	chr7:1156413	C7orf50	0.38	8.59	0.32	6.84e-17	Longevity;Endometriosis;
BRCA	cis	rs7809950	0.678	rs7777950	chr7:107004672	T/C	cg23024343	chr7:107201750	COG5	-0.47	-9.61	-0.36	1.7e-20	Coronary artery disease;
BRCA	cis	rs2882667	0.690	rs2351463	chr5:138258802	A/C	cg04439458	chr5:138467593	SIL1	-0.32	-8.08	-0.3	3.35e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs72781680	0.665	rs72788298	chr2:24104293	T/C	cg08917208	chr2:24149416	ATAD2B	0.61	10.44	0.38	1.18e-23	Lymphocyte counts;
BRCA	cis	rs6577655	0.517	rs6998749	chr8:135584316	A/G	cg17885191	chr8:135476712	NA	-0.53	-8.99	-0.34	2.8e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs2011503	0.782	rs35545554	chr19:19715613	A/G	cg15839431	chr19:19639596	YJEFN3	0.38	8.31	0.31	5.55e-16	Bipolar disorder;
BRCA	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08048268	chr3:133502702	NA	0.31	8.1	0.31	2.81e-15	Iron status biomarkers;
BRCA	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	9.62	0.36	1.51e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.96	0.4	1.01e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg05347473	chr6:146136440	FBXO30	0.43	8.51	0.32	1.27e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs757081	0.606	rs679201	chr11:17200891	T/C	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.67	-0.32	3.54e-17	Systolic blood pressure;
BRCA	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.51	10.59	0.39	3.04e-24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.9	-0.33	5.94e-18	Schizophrenia;
BRCA	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg03923535	chr7:1197113	ZFAND2A	0.4	8.06	0.3	3.65e-15	Longevity;Endometriosis;
BRCA	cis	rs722599	0.748	rs17093914	chr14:75363641	A/G	cg08847533	chr14:75593920	NEK9	0.42	7.85	0.3	1.74e-14	IgG glycosylation;
BRCA	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	13.35	0.47	4.95e-36	Mean platelet volume;
BRCA	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg09307838	chr4:120376055	NA	0.59	12.12	0.43	1.43e-30	Corneal astigmatism;
BRCA	cis	rs68170813	0.559	rs78404515	chr7:106909126	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-8.61	-0.32	5.62e-17	Coronary artery disease;
BRCA	cis	rs7246657	0.722	rs4802051	chr19:38072328	C/A	cg23950597	chr19:37808831	NA	-0.51	-8.69	-0.33	3e-17	Coronary artery calcification;
BRCA	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg03929089	chr4:120376271	NA	0.54	9.13	0.34	9.23e-19	Axial length;
BRCA	trans	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg06521331	chr12:34319734	NA	-0.43	-8.1	-0.31	2.79e-15	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs3820928	0.874	rs1320407	chr2:227867385	G/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.28	-0.31	7.12e-16	Pulmonary function;
BRCA	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-9.39	-0.35	1.06e-19	Personality dimensions;
BRCA	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg02734326	chr4:10020555	SLC2A9	0.36	7.86	0.3	1.59e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg09658497	chr7:2847517	GNA12	-0.4	-8.6	-0.32	6.26e-17	Height;
BRCA	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg18357645	chr12:58087776	OS9	-0.33	-7.99	-0.3	6.21e-15	Multiple sclerosis;
BRCA	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg24642439	chr20:33292090	TP53INP2	-0.44	-9.12	-0.34	9.85e-19	Glomerular filtration rate (creatinine);
BRCA	cis	rs7520050	0.966	rs785464	chr1:46523089	T/C	cg24296786	chr1:45957014	TESK2	0.41	9.26	0.34	3.13e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4363385	0.667	rs454186	chr1:153049149	C/T	cg25856811	chr1:152973957	SPRR3	-0.31	-8.01	-0.3	5.59e-15	Inflammatory skin disease;
BRCA	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.38	-8.36	-0.31	3.85e-16	Educational attainment;
BRCA	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg06627628	chr2:24431161	ITSN2	0.5	10.43	0.38	1.31e-23	Asthma;
BRCA	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg23711669	chr6:146136114	FBXO30	0.79	18.99	0.6	4.44e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4466137	0.953	rs974023	chr5:83014848	T/C	cg16102102	chr5:83017553	HAPLN1	-0.92	-18.51	-0.59	1.38e-61	Prostate cancer;
BRCA	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg24692254	chr21:30365293	RNF160	-0.48	-8.43	-0.32	2.31e-16	Cognitive test performance;
BRCA	trans	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-8.52	-0.32	1.17e-16	Menarche (age at onset);
BRCA	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.03	0.62	1.31e-69	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs800082	0.698	rs1178943	chr3:144391772	T/G	cg24215973	chr2:240111563	HDAC4	-0.65	-14.88	-0.51	3.18e-43	Smoking behavior;
BRCA	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg26677194	chr12:130822605	PIWIL1	0.59	14.01	0.48	4.4e-39	Menopause (age at onset);
BRCA	cis	rs6430585	0.591	rs12477421	chr2:136433740	A/G	cg07169764	chr2:136633963	MCM6	1.14	22.15	0.66	4.46e-81	Corneal structure;
BRCA	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg02733842	chr7:1102375	C7orf50	-0.71	-12.62	-0.45	9.66e-33	Bronchopulmonary dysplasia;
BRCA	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg22105103	chr4:187893119	NA	0.38	11.66	0.42	1.23e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.09	0.34	1.2e-18	Platelet count;
BRCA	cis	rs72772090	0.539	rs11750671	chr5:96188482	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-11.05	-0.4	4.42e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg04842962	chr6:43655489	MRPS18A	0.84	21.75	0.65	6.05e-79	IgG glycosylation;
BRCA	cis	rs2425143	0.915	rs74355238	chr20:34441541	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.87	-0.33	7.09e-18	Blood protein levels;
BRCA	cis	rs4363385	0.818	rs1415966	chr1:153002864	A/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.36	-0.31	3.83e-16	Inflammatory skin disease;
BRCA	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg00684032	chr4:1343700	KIAA1530	0.34	8.11	0.31	2.52e-15	Obesity-related traits;
BRCA	trans	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg26043149	chr18:55253948	FECH	0.39	8.34	0.31	4.61e-16	Bone mineral density;
BRCA	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg21573476	chr21:45109991	RRP1B	0.49	12.56	0.45	1.66e-32	Mean corpuscular volume;
BRCA	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-8.04	-0.3	4.39e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26913058	chr16:419975	MRPL28	-0.43	-10.33	-0.38	2.99e-23	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs11031096	0.782	rs2284450	chr11:4149214	A/T	cg18678763	chr11:4115507	RRM1	-0.38	-8.58	-0.32	7.24e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs9790314	0.637	rs778649	chr3:160709377	C/T	cg03342759	chr3:160939853	NMD3	-0.47	-8.84	-0.33	9.1e-18	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.45	0.32	1.97e-16	Corneal astigmatism;
BRCA	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg25767906	chr1:53392781	SCP2	0.46	10.39	0.38	1.87e-23	Monocyte count;
BRCA	cis	rs6450176	0.638	rs3822497	chr5:53299693	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-17.71	-0.57	2.03e-57	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	8.12	0.31	2.49e-15	Uric acid levels;
BRCA	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg03146154	chr1:46216737	IPP	0.44	9.75	0.36	4.88e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.52	-0.38	5.78e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.07	-0.3	3.45e-15	Total body bone mineral density;
BRCA	cis	rs698813	0.637	rs4952706	chr2:44500536	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	8.86	0.33	8.06e-18	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg03342759	chr3:160939853	NMD3	-0.69	-14.42	-0.5	5.41e-41	Parkinson's disease;
BRCA	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg13334819	chr7:99746414	C7orf59	-0.34	-8.01	-0.3	5.46e-15	Coronary artery disease;
BRCA	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg04691961	chr3:161091175	C3orf57	-0.37	-7.93	-0.3	9.49e-15	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs17818399	0.888	rs2346419	chr2:46845069	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.48	9.36	0.35	1.3e-19	Height;
BRCA	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg12292205	chr6:26970375	C6orf41	-0.57	-12.7	-0.45	4.09e-33	Schizophrenia;
BRCA	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg04025307	chr7:1156635	C7orf50	0.7	18.01	0.58	6.12e-59	Longevity;Endometriosis;
BRCA	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	14.57	0.5	9.62e-42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7246657	0.663	rs10408619	chr19:38070474	C/T	cg18154014	chr19:37997991	ZNF793	0.48	9.15	0.34	7.72e-19	Coronary artery calcification;
BRCA	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg02574844	chr11:5959923	NA	-0.41	-8.11	-0.31	2.63e-15	DNA methylation (variation);
BRCA	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.53	-0.35	3.1e-20	Total body bone mineral density;
BRCA	cis	rs7255436	0.931	rs7249520	chr19:8446056	G/A	cg10811474	chr19:8428787	ANGPTL4	-0.32	-8.05	-0.3	4.15e-15	HDL cholesterol;
BRCA	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg16586182	chr3:47516702	SCAP	-0.56	-12.49	-0.44	3.39e-32	Colorectal cancer;
BRCA	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-9.17	-0.34	6.33e-19	Monocyte percentage of white cells;
BRCA	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22455342	chr2:225449267	CUL3	0.65	17.12	0.56	2.37e-54	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs490234	0.676	rs12202	chr9:128200299	C/G	cg14078157	chr9:128172775	NA	-0.42	-9.26	-0.34	3.02e-19	Mean arterial pressure;
BRCA	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg21385522	chr1:16154831	NA	0.46	9.8	0.36	3.14e-21	Systolic blood pressure;
BRCA	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg13175981	chr1:150552382	MCL1	0.47	10.5	0.38	6.92e-24	Tonsillectomy;
BRCA	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.42	12.03	0.43	3.34e-30	Response to antipsychotic treatment;
BRCA	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg11266682	chr4:10021025	SLC2A9	-0.43	-11.09	-0.4	2.95e-26	Bone mineral density;
BRCA	cis	rs9283706	0.594	rs10515036	chr5:66343787	A/G	cg11590213	chr5:66331682	MAST4	-0.38	-7.87	-0.3	1.56e-14	Coronary artery disease;
BRCA	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	9.83	0.36	2.58e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg03146154	chr1:46216737	IPP	0.52	11.59	0.42	2.58e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs495337	0.760	rs6125813	chr20:48541183	G/T	cg17835207	chr20:48524531	SPATA2	-0.7	-17.42	-0.57	6.46e-56	Psoriasis;
BRCA	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-16.69	-0.55	3.69e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg15212455	chr7:39170539	POU6F2	0.42	9.62	0.36	1.44e-20	IgG glycosylation;
BRCA	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg25358565	chr5:93447407	FAM172A	1.26	19.33	0.61	6.88e-66	Diabetic retinopathy;
BRCA	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg22906224	chr7:99728672	NA	0.42	8.16	0.31	1.84e-15	Coronary artery disease;
BRCA	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.59	12.82	0.45	1.2e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7633857	0.532	rs9873705	chr3:160768818	A/T	cg03342759	chr3:160939853	NMD3	-0.58	-12.22	-0.44	5.13e-31	Educational attainment (years of education);
BRCA	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg23711669	chr6:146136114	FBXO30	0.75	17.41	0.57	7.7e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	14.13	0.49	1.15e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg03585969	chr10:35415529	CREM	0.56	11.55	0.42	3.74e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-17.3	-0.56	2.68e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg09307838	chr4:120376055	NA	0.72	15.24	0.52	5.6e-45	Corneal astigmatism;
BRCA	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.5	10.27	0.38	5.14e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg20203395	chr5:56204925	C5orf35	-0.49	-10.13	-0.37	1.87e-22	Initial pursuit acceleration;
BRCA	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.01	-0.46	1.66e-34	Migraine;Coronary artery disease;
BRCA	cis	rs67981189	0.593	rs12896829	chr14:71463676	G/C	cg15816911	chr14:71606274	NA	0.36	8.31	0.31	5.6e-16	Schizophrenia;
BRCA	trans	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg02030672	chr11:45687055	CHST1	0.5	11.26	0.41	6.19e-27	Obesity-related traits;
BRCA	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg25801113	chr15:45476975	SHF	0.31	8.05	0.3	4.02e-15	Uric acid levels;
BRCA	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	18.8	0.6	4.08e-63	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg05283184	chr6:79620031	NA	-0.38	-9.58	-0.35	2.13e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg17971929	chr21:40555470	PSMG1	0.79	18.5	0.59	1.72e-61	Cognitive function;
BRCA	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg14092988	chr3:52407081	DNAH1	0.36	8.3	0.31	6e-16	Bipolar disorder;
BRCA	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg26031613	chr14:104095156	KLC1	-0.65	-14.22	-0.49	4.46e-40	Body mass index;
BRCA	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg24642439	chr20:33292090	TP53INP2	0.4	7.87	0.3	1.52e-14	Height;
BRCA	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	11.24	0.41	7.45e-27	IgG glycosylation;
BRCA	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg04025307	chr7:1156635	C7orf50	0.42	9.23	0.34	3.79e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg13010199	chr12:38710504	ALG10B	0.51	10.15	0.37	1.53e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	19.88	0.62	8.13e-69	Platelet count;
BRCA	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-10.27	-0.38	5.26e-23	Heart rate;
BRCA	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg05221455	chr11:829616	EFCAB4A	-0.37	-8.23	-0.31	1.03e-15	Mean platelet volume;
BRCA	cis	rs250677	0.559	rs17109198	chr5:148369712	C/T	cg18129178	chr5:148520854	ABLIM3	-0.55	-10.42	-0.38	1.4e-23	Breast cancer;
BRCA	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg11189052	chr15:85197271	WDR73	-0.36	-8.62	-0.32	5.18e-17	P wave terminal force;
BRCA	cis	rs7474896	0.583	rs34185758	chr10:37990854	T/C	cg25427524	chr10:38739819	LOC399744	-0.55	-9.4	-0.35	9.76e-20	Obesity (extreme);
BRCA	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg03929089	chr4:120376271	NA	0.5	8.3	0.31	6.17e-16	Axial length;
BRCA	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.18	0.49	7.18e-40	Motion sickness;
BRCA	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.67	-15.14	-0.51	1.83e-44	Mean platelet volume;
BRCA	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11764359	chr7:65958608	NA	0.8	19.49	0.61	9.4e-67	Aortic root size;
BRCA	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg11502198	chr6:26597334	ABT1	0.56	11.97	0.43	6.47e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.5	0.63	3.81e-72	Chronic sinus infection;
BRCA	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-15.94	-0.53	2.15e-48	Alzheimer's disease (late onset);
BRCA	cis	rs11051970	0.636	rs1128591	chr12:32569351	T/C	cg24626660	chr12:32551988	NA	0.31	9.1	0.34	1.1e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg11764359	chr7:65958608	NA	-0.63	-11.14	-0.4	1.77e-26	Aortic root size;
BRCA	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg24296786	chr1:45957014	TESK2	0.6	14.53	0.5	1.52e-41	High light scatter reticulocyte count;
BRCA	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg03146154	chr1:46216737	IPP	0.48	10.46	0.38	9.27e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg06521331	chr12:34319734	NA	-0.52	-10.17	-0.37	1.26e-22	Morning vs. evening chronotype;
BRCA	cis	rs220324	0.688	rs9975332	chr21:43559902	C/T	cg09727148	chr21:43560719	UMODL1	-0.53	-9.64	-0.36	1.26e-20	Idiopathic osteonecrosis of the femoral head;
BRCA	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.41	-7.84	-0.3	1.96e-14	Height;
BRCA	cis	rs7520050	0.751	rs592214	chr1:46024505	G/A	cg24296786	chr1:45957014	TESK2	0.48	10.88	0.4	2.16e-25	Red blood cell count;Reticulocyte count;
BRCA	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg27478167	chr7:817139	HEATR2	-0.42	-8.98	-0.33	2.94e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9359856	0.564	rs72913976	chr6:90390233	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.67	-8.57	-0.32	7.79e-17	Bipolar disorder;
BRCA	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg24848339	chr3:12840334	CAND2	0.49	13.14	0.46	4.54e-35	QRS complex (12-leadsum);
BRCA	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg14558114	chr2:88469736	THNSL2	0.59	8.36	0.31	3.96e-16	Plasma clusterin levels;
BRCA	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.61	-8.89	-0.33	6.3e-18	Schizophrenia;
BRCA	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-18.15	-0.58	1.17e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg06108461	chr20:60628389	TAF4	-0.8	-16.97	-0.56	1.34e-53	Body mass index;
BRCA	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg10729496	chr3:10149963	C3orf24	0.49	9.17	0.34	6.54e-19	Alzheimer's disease;
BRCA	cis	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg23942311	chr14:51606299	NA	0.35	9.47	0.35	5.32e-20	Cancer;
BRCA	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg05347473	chr6:146136440	FBXO30	0.59	10.94	0.4	1.19e-25	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs113835537	0.529	rs11227515	chr11:66287383	C/T	cg24851651	chr11:66362959	CCS	0.42	8.02	0.3	5.18e-15	Airway imaging phenotypes;
BRCA	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg13256891	chr4:100009986	ADH5	0.5	9.49	0.35	4.46e-20	Smoking initiation;
BRCA	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24549020	chr5:56110836	MAP3K1	0.55	11.19	0.4	1.12e-26	Initial pursuit acceleration;
BRCA	cis	rs4268898	0.552	rs11125455	chr2:24374557	C/G	cg26838691	chr2:24397539	C2orf84	0.39	7.92	0.3	1.03e-14	Asthma;
BRCA	cis	rs600806	0.850	rs10858085	chr1:109914983	A/G	cg20591472	chr1:110008990	SYPL2	0.32	7.94	0.3	9.24e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg05863683	chr7:1912471	MAD1L1	0.36	8.19	0.31	1.41e-15	Schizophrenia;
BRCA	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-9.54	-0.35	2.95e-20	Reticulocyte count;
BRCA	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.54	0.35	2.91e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.55	-0.39	4.16e-24	Mean corpuscular volume;
BRCA	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg10556349	chr10:835070	NA	0.64	8.74	0.33	1.98e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs11971779	0.527	rs4379397	chr7:139043385	G/A	cg07862535	chr7:139043722	LUC7L2	0.38	10.37	0.38	2.13e-23	Diisocyanate-induced asthma;
BRCA	trans	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg21659725	chr3:3221576	CRBN	-0.46	-8.68	-0.32	3.25e-17	Menarche (age at onset);
BRCA	cis	rs6484504	0.576	rs158136	chr11:31220712	C/T	cg06552810	chr11:31128660	NA	-0.39	-8.69	-0.33	3.06e-17	Red blood cell count;
BRCA	cis	rs17253792	0.915	rs75862063	chr14:56177769	G/T	cg01858014	chr14:56050164	KTN1	-0.67	-8.24	-0.31	9.82e-16	Putamen volume;
BRCA	trans	rs8073060	0.586	rs4796104	chr17:34046832	T/C	cg19694781	chr19:47549865	TMEM160	1.07	20.64	0.63	6.34e-73	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs965469	1.000	rs2236108	chr20:3286331	A/C	cg25506879	chr20:3388711	C20orf194	-0.51	-10.2	-0.37	9.87e-23	IFN-related cytopenia;
BRCA	cis	rs2742234	0.541	rs11238481	chr10:43719286	A/G	cg15436174	chr10:43711423	RASGEF1A	0.53	10.6	0.39	2.8e-24	Hirschsprung disease;
BRCA	cis	rs6834538	1.000	rs2171280	chr4:113472637	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	-0.39	-8.97	-0.33	3.33e-18	Free thyroxine concentration;
BRCA	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg17366294	chr4:99064904	C4orf37	0.46	10.84	0.39	3.02e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6430585	0.536	rs3213892	chr2:136552517	G/A	cg07169764	chr2:136633963	MCM6	1.27	30.26	0.77	1.84e-125	Corneal structure;
BRCA	cis	rs7766436	0.767	rs6909752	chr6:22612629	G/A	cg13666174	chr6:22585274	NA	-0.36	-9.18	-0.34	6.07e-19	Coronary artery disease;
BRCA	cis	rs7249921	0.833	rs73044054	chr19:35666661	C/A	cg15419183	chr19:35660584	FXYD5	0.46	10.42	0.38	1.32e-23	Platelet count;
BRCA	cis	rs877282	0.891	rs12767043	chr10:797943	C/T	cg17470449	chr10:769945	NA	0.5	8.63	0.32	4.9e-17	Uric acid levels;
BRCA	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.56	-0.32	8.45e-17	Menopause (age at onset);
BRCA	cis	rs9287719	0.649	rs6730247	chr2:10725888	G/C	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	5.17e-19	Prostate cancer;
BRCA	trans	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg09719594	chr16:21412588	NA	-0.33	-7.96	-0.3	7.79e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg02820040	chr2:241836501	C2orf54	-0.46	-9.05	-0.34	1.76e-18	Urinary metabolites;
BRCA	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	19.72	0.62	5.39e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10193935	0.901	rs13393459	chr2:42463124	C/T	cg27598129	chr2:42591480	NA	-0.97	-14.84	-0.51	5.2e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg15145296	chr3:125709740	NA	-0.54	-9.49	-0.35	4.36e-20	Blood pressure (smoking interaction);
BRCA	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	9.04	0.34	1.83e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7677751	0.747	rs1800809	chr4:55093914	A/G	cg17187183	chr4:55093834	PDGFRA	0.44	9.03	0.34	2.03e-18	Corneal astigmatism;
BRCA	cis	rs62458065	0.513	rs787216	chr7:32578891	G/A	cg20159608	chr7:32802032	NA	-0.5	-9.64	-0.36	1.25e-20	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.59	-13.56	-0.47	5.28e-37	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6714710	0.580	rs57804205	chr2:98454472	G/A	cg26665480	chr2:98280029	ACTR1B	0.58	13.62	0.47	2.86e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	16.53	0.55	2.32e-51	Colorectal cancer;
BRCA	trans	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg02030672	chr11:45687055	CHST1	0.52	11.51	0.41	5.49e-28	Obesity-related traits;
BRCA	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg14196790	chr5:131705035	SLC22A5	0.32	8.42	0.32	2.56e-16	Breast cancer;
BRCA	cis	rs12493885	0.505	rs357489	chr3:153884517	A/T	cg12800244	chr3:153838788	SGEF	0.45	9.17	0.34	6.37e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs7851660	0.506	rs1912996	chr9:100598261	G/T	cg13688889	chr9:100608707	NA	-0.49	-9.94	-0.37	9.38e-22	Strep throat;
BRCA	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-15.83	-0.53	7.33e-48	Total cholesterol levels;
BRCA	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg08885076	chr2:99613938	TSGA10	0.43	10.31	0.38	3.72e-23	Chronic sinus infection;
BRCA	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg00074818	chr8:8560427	CLDN23	0.39	8.56	0.32	8.11e-17	Obesity-related traits;
BRCA	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg05347473	chr6:146136440	FBXO30	0.42	8.45	0.32	2.02e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg00105475	chr2:10696890	NA	0.44	10.4	0.38	1.66e-23	Prostate cancer;
BRCA	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.66	0.39	1.63e-24	Tonsillectomy;
BRCA	trans	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg01620082	chr3:125678407	NA	-0.7	-8.74	-0.33	2e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11586313	0.571	rs11583382	chr1:152874096	G/A	cg07796016	chr1:152779584	LCE1C	-0.4	-7.95	-0.3	8.58e-15	Vitamin D levels;
BRCA	trans	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.26	0.31	8.23e-16	Mean corpuscular volume;
BRCA	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg04455712	chr21:45112962	RRP1B	0.42	11.02	0.4	5.4e-26	Mean corpuscular volume;
BRCA	trans	rs11976180	1.000	rs2961126	chr7:143762736	A/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.26	-0.31	8.66e-16	Obesity-related traits;
BRCA	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-13.29	-0.47	8.99e-36	Migraine;Coronary artery disease;
BRCA	cis	rs7707921	0.752	rs6882565	chr5:81356421	G/A	cg15871215	chr5:81402204	ATG10	-0.36	-8.34	-0.31	4.48e-16	Breast cancer;
BRCA	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg13010199	chr12:38710504	ALG10B	0.49	9.39	0.35	1.02e-19	Morning vs. evening chronotype;
BRCA	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.93	0.46	3.84e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg02951883	chr7:2050386	MAD1L1	-0.49	-11.43	-0.41	1.14e-27	Schizophrenia;
BRCA	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg17063962	chr7:91808500	NA	0.52	12.41	0.44	7.57e-32	Breast cancer;
BRCA	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.22	-0.49	4.63e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs10465746	0.747	rs1952066	chr1:84436456	T/C	cg10977910	chr1:84465055	TTLL7	0.57	11.92	0.43	1.01e-29	Obesity-related traits;
BRCA	cis	rs3784262	0.669	rs12914455	chr15:58312096	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.4	-0.38	1.67e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg11663144	chr21:46675770	NA	-0.49	-9.81	-0.36	3.05e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11890956	chr21:40555474	PSMG1	-0.61	-13.62	-0.47	2.86e-37	Menarche (age at onset);
BRCA	cis	rs3099143	0.908	rs6495222	chr15:77180015	A/C	cg21673338	chr15:77095150	SCAPER	0.52	9.44	0.35	6.69e-20	Recalcitrant atopic dermatitis;
BRCA	cis	rs9790314	0.690	rs7614375	chr3:160851331	A/T	cg03342759	chr3:160939853	NMD3	-0.54	-11.37	-0.41	2.03e-27	Morning vs. evening chronotype;
BRCA	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.85	-0.33	8.62e-18	Mood instability;
BRCA	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg09065629	chr16:1709722	CRAMP1L	0.37	8.63	0.32	4.81e-17	Coronary artery disease;
BRCA	cis	rs3784262	0.904	rs3784263	chr15:58253062	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.43	-11.73	-0.42	6.42e-29	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	trans	rs1459104	0.925	rs34245100	chr11:55211191	G/A	cg15704280	chr7:45808275	SEPT13	0.67	8.34	0.31	4.59e-16	Body mass index;
BRCA	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg21918786	chr6:109611834	NA	-0.48	-13.78	-0.48	5.02e-38	Reticulocyte fraction of red cells;
BRCA	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg03146154	chr1:46216737	IPP	0.54	12.05	0.43	2.86e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg18252515	chr7:66147081	NA	-1.04	-15.47	-0.52	4.14e-46	Diabetic kidney disease;
BRCA	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	17.57	0.57	1.1e-56	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg23762105	chr12:34175262	ALG10	0.36	8.31	0.31	5.78e-16	Morning vs. evening chronotype;
BRCA	cis	rs1403694	0.669	rs10440056	chr3:186433822	C/T	cg12454167	chr3:186435060	KNG1	0.29	7.92	0.3	1.04e-14	Blood protein levels;
BRCA	cis	rs72781680	0.799	rs2712084	chr2:24003051	A/G	cg08917208	chr2:24149416	ATAD2B	0.59	9.76	0.36	4.49e-21	Lymphocyte counts;
BRCA	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg25554036	chr4:6271136	WFS1	0.43	10.0	0.37	5.77e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7523050	0.643	rs35860016	chr1:109404639	C/T	cg08274380	chr1:109419600	GPSM2	0.98	14.02	0.49	3.82e-39	Fat distribution (HIV);
BRCA	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg11663144	chr21:46675770	NA	-0.61	-14.27	-0.49	2.52e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08219700	chr8:58056026	NA	0.54	8.78	0.33	1.44e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03264133	chr6:25882463	NA	-0.54	-11.42	-0.41	1.27e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg26893861	chr17:41843967	DUSP3	0.65	12.81	0.45	1.35e-33	Triglycerides;
BRCA	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg26384229	chr12:38710491	ALG10B	-0.44	-10.05	-0.37	3.66e-22	Bladder cancer;
BRCA	cis	rs12760731	0.720	rs7548163	chr1:178306695	G/A	cg00404053	chr1:178313656	RASAL2	0.62	8.57	0.32	7.67e-17	Obesity-related traits;
BRCA	cis	rs897984	0.806	rs1046276	chr16:30914626	A/G	cg00531865	chr16:30841666	NA	0.38	9.15	0.34	7.41e-19	Dementia with Lewy bodies;
BRCA	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg13393036	chr8:95962371	TP53INP1	-0.3	-8.06	-0.3	3.68e-15	Type 2 diabetes;
BRCA	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12756686	chr19:29218302	NA	0.57	10.98	0.4	8.46e-26	Methadone dose in opioid dependence;
BRCA	cis	rs6460942	1.000	rs75333414	chr7:12303829	T/A	cg06484146	chr7:12443880	VWDE	-0.55	-8.1	-0.31	2.72e-15	Coronary artery disease;
BRCA	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.37	-8.25	-0.31	9.03e-16	Axial length;
BRCA	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg27279351	chr12:120934652	DYNLL1	0.56	13.39	0.47	3.26e-36	High light scatter reticulocyte count;
BRCA	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg01324343	chr3:183735012	ABCC5	0.83	21.19	0.64	6.89e-76	Anterior chamber depth;
BRCA	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	17.33	0.57	1.92e-55	Hip circumference adjusted for BMI;
BRCA	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg04362960	chr10:104952993	NT5C2	0.94	14.64	0.5	4.47e-42	Arsenic metabolism;
BRCA	cis	rs2594989	0.708	rs2594997	chr3:11365739	A/T	cg01796438	chr3:11312864	ATG7	-0.55	-8.22	-0.31	1.16e-15	Circulating chemerin levels;
BRCA	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.08e-57	Colorectal cancer;
BRCA	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.68	0.39	1.32e-24	IgG glycosylation;
BRCA	cis	rs490234	0.586	rs12553548	chr9:128155261	T/G	cg14078157	chr9:128172775	NA	-0.34	-8.12	-0.31	2.41e-15	Mean arterial pressure;
BRCA	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	13.87	0.48	2.01e-38	Coronary artery disease;
BRCA	cis	rs4363385	0.747	rs2075739	chr1:152975495	G/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.32	-0.31	5.23e-16	Inflammatory skin disease;
BRCA	cis	rs9287719	0.649	rs10803725	chr2:10732346	T/C	cg00105475	chr2:10696890	NA	0.41	9.23	0.34	3.83e-19	Prostate cancer;
BRCA	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg08807101	chr21:30365312	RNF160	0.41	8.97	0.33	3.16e-18	Pancreatic cancer;
BRCA	cis	rs10911363	0.659	rs2275676	chr1:183430822	C/G	cg09173681	chr1:183549694	NCF2	-0.49	-10.49	-0.38	7.25e-24	Systemic lupus erythematosus;
BRCA	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg21475434	chr5:93447410	FAM172A	0.69	8.72	0.33	2.43e-17	Diabetic retinopathy;
BRCA	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg06623918	chr6:96969491	KIAA0776	0.89	25.79	0.71	4.53e-101	Headache;
BRCA	cis	rs7172677	0.737	rs12914536	chr15:75437715	C/T	cg14664628	chr15:75095509	CSK	-0.36	-7.81	-0.3	2.34e-14	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg23260525	chr10:116636907	FAM160B1	0.31	8.34	0.31	4.65e-16	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg20307385	chr11:47447363	PSMC3	-0.41	-9.55	-0.35	2.8e-20	Subjective well-being;
BRCA	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg20607287	chr7:12443886	VWDE	-0.59	-8.47	-0.32	1.66e-16	Coronary artery disease;
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg23708337	chr7:1209742	NA	0.47	9.06	0.34	1.55e-18	Longevity;Endometriosis;
BRCA	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg02187348	chr16:89574699	SPG7	0.5	11.87	0.43	1.61e-29	Multiple myeloma (IgH translocation);
BRCA	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	19.65	0.61	1.3e-67	Platelet count;
BRCA	cis	rs9487051	0.743	rs388526	chr6:109543425	C/G	cg01475377	chr6:109611718	NA	-0.42	-9.79	-0.36	3.63e-21	Reticulocyte fraction of red cells;
BRCA	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg22972055	chr7:872293	UNC84A	0.38	8.3	0.31	6.12e-16	Cerebrospinal P-tau181p levels;
BRCA	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg20362242	chr5:692897	TPPP	0.54	8.72	0.33	2.42e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg07148914	chr20:33460835	GGT7	-0.41	-8.96	-0.33	3.52e-18	Height;
BRCA	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18876405	chr7:65276391	NA	0.56	13.33	0.47	6.11e-36	Aortic root size;
BRCA	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg26395211	chr5:140044315	WDR55	0.37	8.53	0.32	1.08e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg25358565	chr5:93447407	FAM172A	-0.68	-11.56	-0.42	3.23e-28	Diabetic retinopathy;
BRCA	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	cis	rs738322	0.753	rs5756968	chr22:38595240	C/T	cg25457927	chr22:38595422	NA	0.5	21.42	0.65	3.85e-77	Cutaneous nevi;
BRCA	trans	rs1997103	0.954	rs4947505	chr7:55409448	T/C	cg20935933	chr6:143382018	AIG1	0.61	11.73	0.42	6.24e-29	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg01802117	chr1:53393560	SCP2	-0.4	-9.0	-0.34	2.55e-18	Monocyte count;
BRCA	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg13852791	chr20:30311386	BCL2L1	0.79	15.28	0.52	3.74e-45	Mean corpuscular hemoglobin;
BRCA	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.85	0.36	2.13e-21	Lung cancer in ever smokers;
BRCA	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg26384229	chr12:38710491	ALG10B	-0.43	-9.98	-0.37	6.52e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.89	-0.3	1.36e-14	Aortic root size;
BRCA	cis	rs9290065	0.519	rs2376475	chr3:160708942	C/T	cg03342759	chr3:160939853	NMD3	-0.5	-10.16	-0.37	1.36e-22	Kawasaki disease;
BRCA	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg07636037	chr3:49044803	WDR6	0.94	27.28	0.73	2.99e-109	Parkinson's disease;
BRCA	cis	rs10857712	0.687	rs11101742	chr10:135224372	C/G	cg01444801	chr10:135216882	MTG1	-0.33	-8.32	-0.31	5.37e-16	Systemic lupus erythematosus;
BRCA	cis	rs68170813	0.559	rs6971774	chr7:106834139	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-8.2	-0.31	1.28e-15	Coronary artery disease;
BRCA	trans	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	20.79	0.64	1.05e-73	Exhaled nitric oxide output;
BRCA	cis	rs13394619	0.875	rs9287734	chr2:11724475	A/G	cg07314298	chr2:11723111	GREB1	-0.55	-12.25	-0.44	3.74e-31	Endometriosis;
BRCA	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg22800045	chr5:56110881	MAP3K1	0.7	13.07	0.46	9.58e-35	Initial pursuit acceleration;
BRCA	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg13628971	chr7:2884303	GNA12	0.53	12.04	0.43	3.12e-30	Height;
BRCA	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg20701182	chr2:24300061	SF3B14	0.66	9.47	0.35	5.4e-20	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.87	0.3	1.5e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg08392591	chr16:89556376	ANKRD11	0.49	11.77	0.42	4.26e-29	Multiple myeloma (IgH translocation);
BRCA	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg24296786	chr1:45957014	TESK2	0.64	15.79	0.53	1.16e-47	High light scatter reticulocyte count;
BRCA	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg18252515	chr7:66147081	NA	-0.79	-11.11	-0.4	2.35e-26	Diabetic kidney disease;
BRCA	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	14.94	0.51	1.75e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7975161	0.630	rs7978101	chr12:104630510	A/G	cg25273343	chr12:104657179	TXNRD1	-0.59	-9.88	-0.36	1.59e-21	Toenail selenium levels;
BRCA	trans	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.49	0.32	1.41e-16	Mean corpuscular volume;
BRCA	cis	rs365132	0.875	rs353479	chr5:176372593	C/T	cg16309518	chr5:176445507	NA	-0.39	-9.48	-0.35	4.82e-20	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg18806716	chr10:30721971	MAP3K8	-0.42	-9.98	-0.37	6.6e-22	Inflammatory bowel disease;
BRCA	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.09	-0.3	3.04e-15	Prostate cancer;
BRCA	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg17366294	chr4:99064904	C4orf37	0.42	9.77	0.36	4.27e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg22875332	chr1:76189707	ACADM	-0.53	-10.27	-0.38	5.49e-23	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10985070	0.507	rs12551347	chr9:123936594	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	8.62	0.32	5.26e-17	Rheumatoid arthritis;
BRCA	cis	rs11711311	0.712	rs6795099	chr3:113338782	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.38	-8.32	-0.31	5.42e-16	IgG glycosylation;
BRCA	cis	rs7523050	0.643	rs7551142	chr1:109399710	G/T	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs2860975	0.875	rs2211272	chr10:96765905	G/A	cg09036531	chr10:96991505	NA	-0.38	-8.18	-0.31	1.5e-15	Immune response to smallpox vaccine (IL-6);
BRCA	cis	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.36	-0.31	3.89e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg08392591	chr16:89556376	ANKRD11	0.35	8.2	0.31	1.33e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg18964960	chr10:1102726	WDR37	0.65	8.71	0.33	2.69e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-10.68	-0.39	1.35e-24	IgG glycosylation;
BRCA	cis	rs68170813	0.559	rs76859341	chr7:107070146	C/G	cg02696742	chr7:106810147	HBP1	-0.48	-8.04	-0.3	4.52e-15	Coronary artery disease;
BRCA	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg04362960	chr10:104952993	NT5C2	0.43	9.86	0.36	1.89e-21	Arsenic metabolism;
BRCA	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg24829409	chr8:58192753	C8orf71	-0.45	-8.63	-0.32	5.04e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg01528321	chr10:82214614	TSPAN14	0.81	17.21	0.56	8.09e-55	Post bronchodilator FEV1;
BRCA	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg06138931	chr13:21896616	NA	0.56	10.52	0.38	5.72e-24	White matter hyperintensity burden;
BRCA	trans	rs3741489	1.000	rs3741489	chr12:133417802	A/G	cg24132527	chr5:140019269	TMCO6	1.08	12.68	0.45	5e-33	Cognitive function;
BRCA	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.55	13.56	0.47	5.59e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4662945	0.525	rs10174479	chr2:130296287	A/C	cg05903289	chr2:130345205	NA	-0.33	-8.3	-0.31	6.3e-16	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg24044776	chr19:53454761	ZNF816A	-0.35	-7.86	-0.3	1.58e-14	Psoriasis;
BRCA	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24549020	chr5:56110836	MAP3K1	0.64	13.06	0.46	9.94e-35	Initial pursuit acceleration;
BRCA	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18876405	chr7:65276391	NA	-0.63	-15.42	-0.52	7.67e-46	Aortic root size;
BRCA	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.51	8.77	0.33	1.64e-17	Mean platelet volume;
BRCA	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg18512352	chr11:47633146	NA	-0.37	-9.1	-0.34	1.1e-18	Subjective well-being;
BRCA	cis	rs4947534	1	rs4947534	chr7:56079094	T/C	cg09872392	chr7:56161020	PHKG1	-0.41	-9.39	-0.35	1.02e-19	Amino acid levels;Blood metabolite levels;
BRCA	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-16.05	-0.54	5.71e-49	Heart rate;
BRCA	cis	rs2625529	0.938	rs4776579	chr15:72132608	C/T	cg16672083	chr15:72433130	SENP8	-0.73	-16.4	-0.54	1e-50	Red blood cell count;
BRCA	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-9.6	-0.36	1.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	trans	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg25214090	chr10:38739885	LOC399744	0.46	10.53	0.38	4.99e-24	Corneal astigmatism;
BRCA	trans	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg17675199	chr6:35436792	RPL10A	0.29	7.85	0.3	1.8e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg00383909	chr3:49044727	WDR6	0.98	15.72	0.53	2.59e-47	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg06212747	chr3:49208901	KLHDC8B	0.59	8.28	0.31	7.36e-16	Menarche (age at onset);
BRCA	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25427524	chr10:38739819	LOC399744	-0.69	-16.69	-0.55	3.49e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-8.2	-0.31	1.36e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12667521	chr19:29218732	NA	0.47	8.76	0.33	1.79e-17	Methadone dose in opioid dependence;
BRCA	cis	rs4908760	0.864	rs12136766	chr1:8663821	C/T	cg20416874	chr1:8611966	RERE	-0.27	-7.83	-0.3	2.09e-14	Vitiligo;
BRCA	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11890956	chr21:40555474	PSMG1	-0.85	-21.99	-0.66	3.23e-80	Cognitive function;
BRCA	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg17366294	chr4:99064904	C4orf37	0.41	9.74	0.36	5.38e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg15691649	chr6:25882328	NA	-0.43	-8.37	-0.31	3.7e-16	Uric acid levels;
BRCA	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13126279	chr21:47581558	C21orf56	-0.5	-10.88	-0.4	2.15e-25	Testicular germ cell tumor;
BRCA	cis	rs4423214	0.879	rs1630498	chr11:71150785	A/C	cg05163923	chr11:71159392	DHCR7	-0.57	-11.67	-0.42	1.14e-28	Vitamin D levels;
BRCA	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg15242686	chr22:24348715	GSTTP1	0.38	9.36	0.35	1.37e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg11812906	chr14:75593930	NEK9	0.67	15.72	0.53	2.55e-47	Height;
BRCA	trans	rs11976180	1.000	rs6464574	chr7:143748257	G/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.53	-9.35	-0.35	1.45e-19	Obesity-related traits;
BRCA	trans	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg23533926	chr12:111358616	MYL2	-0.39	-8.08	-0.3	3.13e-15	Extrinsic epigenetic age acceleration;
BRCA	trans	rs1997103	1.000	rs4947504	chr7:55409428	T/C	cg20935933	chr6:143382018	AIG1	0.58	11.17	0.4	1.32e-26	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-14.26	-0.49	3e-40	Platelet count;
BRCA	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg11764359	chr7:65958608	NA	0.67	15.2	0.52	9.47e-45	Aortic root size;
BRCA	cis	rs28830936	1.000	rs17734856	chr15:42045160	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.33	-9.27	-0.34	2.72e-19	Diastolic blood pressure;
BRCA	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.9	0.3	1.19e-14	Axial length;
BRCA	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.36	9.89	0.36	1.44e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24531977	chr5:56204891	C5orf35	-0.86	-17.98	-0.58	8.37e-59	Initial pursuit acceleration;
BRCA	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	19.56	0.61	3.82e-67	Alzheimer's disease;
BRCA	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-11.79	-0.42	3.51e-29	Systolic blood pressure;
BRCA	cis	rs4780401	0.609	rs16958588	chr16:11819330	G/A	cg01061890	chr16:11836724	TXNDC11	-0.56	-13.34	-0.47	5.27e-36	Rheumatoid arthritis;
BRCA	cis	rs96067	0.711	rs11263861	chr1:36628033	G/A	cg24686825	chr1:36642396	MAP7D1	-0.4	-8.91	-0.33	5.08e-18	Corneal structure;
BRCA	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.72	-0.55	2.5e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg05868516	chr6:26286170	HIST1H4H	0.5	11.28	0.41	5.07e-27	Educational attainment;
BRCA	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg11266682	chr4:10021025	SLC2A9	0.41	10.84	0.39	3.01e-25	Bone mineral density;
BRCA	cis	rs2274273	0.967	rs67756714	chr14:55589823	G/A	cg04306507	chr14:55594613	LGALS3	0.29	8.02	0.3	5.24e-15	Protein biomarker;
BRCA	cis	rs1994135	0.617	rs10743824	chr12:33733764	C/T	cg06521331	chr12:34319734	NA	-0.42	-8.6	-0.32	6.19e-17	Resting heart rate;
BRCA	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg10523679	chr1:76189770	ACADM	0.78	18.69	0.59	1.61e-62	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs68170813	0.559	rs74898466	chr7:107053998	C/A	cg02696742	chr7:106810147	HBP1	-0.49	-8.19	-0.31	1.46e-15	Coronary artery disease;
BRCA	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg03806693	chr22:41940476	POLR3H	-1.1	-19.77	-0.62	3.23e-68	Vitiligo;
BRCA	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03576123	chr11:487126	PTDSS2	-1.08	-16.7	-0.55	3.22e-52	Body mass index;
BRCA	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03264133	chr6:25882463	NA	-0.51	-10.87	-0.4	2.3e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs6740322	0.748	rs6544634	chr2:43471528	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.76	-14.9	-0.51	2.59e-43	Coronary artery disease;
BRCA	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg01256987	chr12:42539512	GXYLT1	-0.42	-8.16	-0.31	1.75e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg09658497	chr7:2847517	GNA12	-0.41	-8.67	-0.32	3.66e-17	Height;
BRCA	cis	rs698833	0.962	rs698829	chr2:44730846	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	9.7	0.36	7.9e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg20503657	chr10:835505	NA	-0.54	-10.1	-0.37	2.4e-22	Response to angiotensin II receptor blocker therapy;
BRCA	trans	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs1865721	0.804	rs62089468	chr18:73158850	C/T	cg26385618	chr18:73139727	C18orf62	-0.44	-10.58	-0.39	3.31e-24	Intelligence;
BRCA	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg16506815	chr2:162101123	NA	0.72	18.07	0.58	3.01e-59	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-15.36	-0.52	1.57e-45	Parkinson's disease;
BRCA	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg23711669	chr6:146136114	FBXO30	0.71	16.8	0.55	9.7e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg08213375	chr14:104286397	PPP1R13B	0.49	11.09	0.4	2.92e-26	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.03	20.77	0.63	1.34e-73	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18876405	chr7:65276391	NA	0.55	13.29	0.47	8.91e-36	Aortic root size;
BRCA	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-14.07	-0.49	2.32e-39	Morning vs. evening chronotype;
BRCA	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.45	10.68	0.39	1.27e-24	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg06521331	chr12:34319734	NA	-0.44	-8.39	-0.32	3.07e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10189230	0.967	rs12479119	chr2:222354213	C/T	cg14652038	chr2:222343519	EPHA4	0.47	13.13	0.46	4.83e-35	Urate levels in lean individuals;
BRCA	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-11.79	-0.42	3.7e-29	Alzheimer's disease;
BRCA	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.7	0.36	7.31e-21	Lung cancer in ever smokers;
BRCA	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg04450456	chr4:17643702	FAM184B	0.38	11.37	0.41	1.99e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs9944715	1.000	rs4574015	chr18:43802126	T/C	cg01718231	chr17:29326311	RNF135	-0.44	-8.49	-0.32	1.41e-16	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg13119609	chr19:45449297	APOC2	0.48	13.24	0.46	1.5e-35	Blood protein levels;
BRCA	trans	rs867371	0.519	rs1566559	chr15:82524461	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.32	-8.59	-0.32	6.76e-17	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	9.55	0.35	2.77e-20	Tonsillectomy;
BRCA	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.82	0.3	2.21e-14	Aortic root size;
BRCA	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.81	-22.66	-0.67	6.85e-84	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	8.61	0.32	5.83e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.6	-0.67	1.57e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	25.91	0.72	1.01e-101	Chronic sinus infection;
BRCA	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	9.58	0.35	2.12e-20	Bipolar disorder;
BRCA	trans	rs12517041	0.873	rs6886748	chr5:23307271	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.48	-8.57	-0.32	8.03e-17	Calcium levels;
BRCA	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg00024416	chr22:24240387	NA	-0.32	-7.91	-0.3	1.15e-14	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1691799	0.899	rs1168328	chr12:66729250	T/C	cg16791601	chr12:66731901	HELB	-0.7	-19.79	-0.62	2.49e-68	White blood cell count (basophil);
BRCA	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg06917634	chr15:78832804	PSMA4	-0.58	-12.85	-0.45	8.77e-34	Sudden cardiac arrest;
BRCA	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg01884057	chr2:25150051	NA	0.31	8.17	0.31	1.65e-15	Body mass index;
BRCA	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.01	0.34	2.33e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7572733	0.555	rs6745726	chr2:198934080	A/G	cg00792783	chr2:198669748	PLCL1	0.39	8.32	0.31	5.52e-16	Dermatomyositis;
BRCA	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	9.45	0.35	6.29e-20	Tonsillectomy;
BRCA	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg27129171	chr3:47204927	SETD2	-0.61	-14.2	-0.49	5.94e-40	Colorectal cancer;
BRCA	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg07148914	chr20:33460835	GGT7	-0.37	-7.99	-0.3	6.25e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg13010199	chr12:38710504	ALG10B	0.45	9.38	0.35	1.16e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2463822	0.925	rs1881535	chr11:62121623	C/T	cg06239285	chr11:62104954	ASRGL1	0.69	11.52	0.41	4.72e-28	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs1018836	0.847	rs4735226	chr8:91569238	T/A	cg16814680	chr8:91681699	NA	-0.64	-14.22	-0.49	4.45e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg01475377	chr6:109611718	NA	-0.54	-13.98	-0.48	5.8e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs6820391	0.816	rs1567654	chr4:54448177	C/T	cg04173182	chr4:54446035	LNX1	0.51	11.57	0.42	2.97e-28	Cervical artery dissection;
BRCA	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg05347473	chr6:146136440	FBXO30	0.41	7.96	0.3	8.08e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.67	-18.32	-0.59	1.38e-60	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg12444411	chr7:2802554	GNA12	-0.39	-9.36	-0.35	1.36e-19	Height;
BRCA	trans	rs4596713	0.508	rs4745650	chr9:71777892	G/A	cg16512924	chr15:28394682	HERC2	0.45	10.58	0.39	3.12e-24	Headache;
BRCA	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg06060754	chr5:176797920	RGS14	0.58	11.05	0.4	4.27e-26	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg08330972	chr4:2403930	ZFYVE28	-0.33	-8.68	-0.32	3.22e-17	Cognitive function;
BRCA	cis	rs1891275	0.515	rs1986941	chr10:93444343	C/T	cg07889827	chr10:93443413	NA	-0.44	-12.37	-0.44	1.18e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg12311346	chr5:56204834	C5orf35	-0.82	-16.75	-0.55	1.84e-52	Initial pursuit acceleration;
BRCA	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg12140854	chr5:148520817	ABLIM3	0.42	8.91	0.33	5.37e-18	Breast cancer;
BRCA	trans	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	10.03	0.37	4.5e-22	Mean corpuscular volume;
BRCA	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07080220	chr10:102295463	HIF1AN	0.49	11.34	0.41	2.85e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-9.44	-0.35	6.77e-20	Triglycerides;
BRCA	cis	rs6580649	1.000	rs7305954	chr12:48403530	C/T	cg05342945	chr12:48394962	COL2A1	-0.43	-8.87	-0.33	7.28e-18	Lung cancer;
BRCA	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg19622623	chr12:86230825	RASSF9	-0.33	-9.31	-0.35	2.09e-19	Major depressive disorder;
BRCA	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg25036284	chr2:26402008	FAM59B	-0.78	-12.14	-0.43	1.11e-30	Gut microbiome composition (summer);
BRCA	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg22834771	chr12:69754056	YEATS4	-0.42	-10.56	-0.39	3.78e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18404041	chr3:52824283	ITIH1	-0.28	-8.61	-0.32	5.49e-17	Hemoglobin concentration;
BRCA	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.25	0.31	9.38e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.16	0.34	7.11e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	13.09	0.46	7.74e-35	Bone mineral density;
BRCA	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00166722	chr3:10149974	C3orf24	0.66	13.1	0.46	6.48e-35	Alzheimer's disease;
BRCA	cis	rs72848980	0.512	rs61151381	chr10:105370496	C/G	cg00126946	chr10:105363258	SH3PXD2A	0.46	8.88	0.33	6.9e-18	White matter hyperintensity burden;
BRCA	cis	rs9473147	0.543	rs9367279	chr6:47448336	A/G	cg12968598	chr6:47444699	CD2AP	0.44	9.56	0.35	2.48e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg26031613	chr14:104095156	KLC1	-0.44	-8.0	-0.3	6.01e-15	Coronary artery disease;
BRCA	cis	rs6684514	0.961	rs72710222	chr1:156285995	T/C	cg16558208	chr1:156270281	VHLL	0.34	8.11	0.31	2.62e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg24531977	chr5:56204891	C5orf35	-0.41	-8.51	-0.32	1.21e-16	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg07395648	chr5:131743802	NA	0.37	8.15	0.31	1.96e-15	Breast cancer;
BRCA	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg20908204	chr19:46285434	DMPK	-0.29	-8.65	-0.32	4.16e-17	Coronary artery disease;
BRCA	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs2011503	0.739	rs8108659	chr19:19680738	T/A	cg11584989	chr19:19387371	SF4	-0.47	-9.53	-0.35	3.16e-20	Bipolar disorder;
BRCA	cis	rs10504073	0.647	rs11997959	chr8:50014044	C/T	cg00325661	chr8:49890786	NA	0.38	11.26	0.41	5.95e-27	Blood metabolite ratios;
BRCA	cis	rs3925075	1.000	rs3925074	chr16:31347807	G/A	cg02846316	chr16:31340340	ITGAM	0.53	13.26	0.46	1.25e-35	IgA nephropathy;
BRCA	cis	rs34779708	0.966	rs35079558	chr10:35479886	A/G	cg03585969	chr10:35415529	CREM	0.55	11.29	0.41	4.53e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg13736514	chr6:26305472	NA	-0.37	-12.54	-0.44	2.16e-32	Educational attainment;
BRCA	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg08179530	chr6:36648295	CDKN1A	-0.73	-18.36	-0.59	9.16e-61	QRS duration;
BRCA	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg26513180	chr16:89883248	FANCA	-0.57	-13.24	-0.46	1.63e-35	Vitiligo;
BRCA	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03452623	chr4:187889614	NA	-0.31	-10.14	-0.37	1.7e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg07148914	chr20:33460835	GGT7	0.47	9.98	0.37	6.74e-22	Height;
BRCA	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-16.35	-0.54	1.83e-50	Parkinson's disease;
BRCA	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg00071950	chr4:10020882	SLC2A9	0.54	13.22	0.46	1.87e-35	Bone mineral density;
BRCA	cis	rs3125734	0.633	rs4979772	chr10:63967600	C/T	cg19640130	chr10:64028056	RTKN2	0.31	8.97	0.33	3.23e-18	Rheumatoid arthritis;
BRCA	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg18016565	chr1:150552671	MCL1	-0.37	-8.56	-0.32	8.71e-17	Tonsillectomy;
BRCA	cis	rs2191566	0.576	rs370809	chr19:44493830	C/T	cg20607764	chr19:44506953	ZNF230	0.36	7.87	0.3	1.5e-14	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs11608355	0.515	rs11610558	chr12:109925865	C/T	cg05360138	chr12:110035743	NA	0.74	13.54	0.47	6.41e-37	Neuroticism;
BRCA	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg13010199	chr12:38710504	ALG10B	0.5	9.97	0.37	7.65e-22	Bladder cancer;
BRCA	cis	rs2425143	1.000	rs4504072	chr20:34448773	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.54	-0.32	9.92e-17	Blood protein levels;
BRCA	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg24642844	chr7:1081250	C7orf50	-0.89	-16.29	-0.54	3.52e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg04586622	chr2:25135609	ADCY3	-0.45	-11.48	-0.41	7.52e-28	Body mass index;
BRCA	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg23358479	chr7:1110784	C7orf50	-0.48	-8.17	-0.31	1.68e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg08422745	chr4:174089978	GALNT7	-0.67	-13.77	-0.48	6.08e-38	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs2191566	0.576	rs381983	chr19:44494215	C/T	cg20607764	chr19:44506953	ZNF230	-0.38	-8.26	-0.31	8.33e-16	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg25019033	chr10:957182	NA	-0.42	-8.8	-0.33	1.27e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg08085267	chr17:45401833	C17orf57	-0.62	-12.7	-0.45	4.19e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs11229555	0.874	rs7102852	chr11:58358348	G/A	cg15696309	chr11:58395628	NA	-0.53	-11.5	-0.41	5.77e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs312273	0.743	rs10879395	chr12:41340452	C/G	cg17827154	chr12:41323612	CNTN1	-0.43	-11.12	-0.4	2.11e-26	Bipolar disorder;
BRCA	trans	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg26043149	chr18:55253948	FECH	-0.4	-8.52	-0.32	1.14e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.46	-9.34	-0.35	1.62e-19	Tonsillectomy;
BRCA	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg13010199	chr12:38710504	ALG10B	-0.41	-8.63	-0.32	4.86e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg24558204	chr6:135376177	HBS1L	0.46	12.62	0.45	8.89e-33	Red blood cell count;
BRCA	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.23e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9560113	0.959	rs9555803	chr13:112179560	G/T	cg10483660	chr13:112241077	NA	0.31	7.84	0.3	1.91e-14	Menarche (age at onset);
BRCA	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11644478	chr21:40555479	PSMG1	0.86	20.42	0.63	9.86e-72	Cognitive function;
BRCA	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg07606381	chr6:8435919	SLC35B3	-0.58	-12.45	-0.44	4.98e-32	Motion sickness;
BRCA	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg13319975	chr6:146136371	FBXO30	-0.38	-8.76	-0.33	1.7e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	15.68	0.53	4.14e-47	Tonsillectomy;
BRCA	cis	rs8032158	1.000	rs8024944	chr15:56125135	C/A	cg02198044	chr15:56286336	NEDD4	-0.38	-9.04	-0.34	1.8e-18	Keloid;
BRCA	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg05347473	chr6:146136440	FBXO30	0.41	7.93	0.3	9.73e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg21782813	chr7:2030301	MAD1L1	0.32	8.7	0.33	2.75e-17	Schizophrenia;
BRCA	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.67	0.39	1.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11890956	chr21:40555474	PSMG1	-0.86	-22.07	-0.66	1.11e-80	Cognitive function;
BRCA	cis	rs7715806	0.500	rs888788	chr5:74988336	C/T	cg19683494	chr5:74908142	NA	0.53	8.55	0.32	8.75e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg17971929	chr21:40555470	PSMG1	0.79	19.04	0.6	2.41e-64	Cognitive function;
BRCA	cis	rs7246657	0.606	rs2972439	chr19:38212581	T/C	cg18154014	chr19:37997991	ZNF793	-0.49	-9.39	-0.35	1.03e-19	Coronary artery calcification;
BRCA	cis	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg07460842	chr6:66804631	NA	0.85	15.31	0.52	2.76e-45	Exhaled nitric oxide levels;
BRCA	trans	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg26384229	chr12:38710491	ALG10B	0.51	11.03	0.4	4.98e-26	Morning vs. evening chronotype;
BRCA	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.7	-15.91	-0.53	3.09e-48	Multiple sclerosis;
BRCA	cis	rs17401966	0.540	rs4846199	chr1:10283961	A/G	cg03954927	chr1:10346856	KIF1B	0.35	10.61	0.39	2.39e-24	Hepatocellular carcinoma;
BRCA	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg21132104	chr15:45694354	SPATA5L1	0.74	16.96	0.56	1.57e-53	Homoarginine levels;
BRCA	cis	rs2882667	0.931	rs10038799	chr5:138362283	C/T	cg04439458	chr5:138467593	SIL1	-0.33	-8.89	-0.33	6.09e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11644478	chr21:40555479	PSMG1	-0.51	-10.89	-0.4	1.85e-25	Menarche (age at onset);
BRCA	cis	rs2559856	0.967	rs2559863	chr12:102087108	C/T	cg12924262	chr12:102091054	CHPT1	0.42	9.53	0.35	3.32e-20	Blood protein levels;
BRCA	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg17063962	chr7:91808500	NA	-0.53	-12.62	-0.45	9.07e-33	Breast cancer;
BRCA	cis	rs6450176	0.909	rs3776712	chr5:53304179	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.61	-15.01	-0.51	7.93e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-17.4	-0.57	8.12e-56	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7572733	0.534	rs2574832	chr2:198704818	T/G	cg00792783	chr2:198669748	PLCL1	0.47	10.18	0.37	1.16e-22	Dermatomyositis;
BRCA	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg22676075	chr6:135203613	NA	0.44	8.59	0.32	6.47e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs12973672	1.000	rs10405246	chr19:35768949	A/G	cg12095397	chr19:35769544	USF2	0.37	8.3	0.31	5.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.64	0.36	1.23e-20	Morning vs. evening chronotype;
BRCA	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg16586182	chr3:47516702	SCAP	0.56	12.53	0.44	2.25e-32	Colorectal cancer;
BRCA	cis	rs12711979	0.509	rs10187740	chr2:3823965	A/G	cg17052675	chr2:3827356	NA	0.7	23.56	0.68	8.31e-89	Itch intensity from mosquito bite adjusted by bite size;
BRCA	trans	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.76	0.39	6.29e-25	Type 2 diabetes;
BRCA	cis	rs9549260	0.753	rs10507486	chr13:41186501	A/G	cg21288729	chr13:41239152	FOXO1	-0.51	-8.3	-0.31	6.29e-16	Red blood cell count;
BRCA	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg18301423	chr5:131593218	PDLIM4	-0.35	-8.29	-0.31	6.83e-16	Acylcarnitine levels;
BRCA	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-12.35	-0.44	1.38e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs1451375	0.583	rs3779078	chr7:50610918	C/T	cg18232548	chr7:50535776	DDC	0.44	9.27	0.34	2.76e-19	Malaria;
BRCA	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg18252515	chr7:66147081	NA	-0.9	-12.94	-0.46	3.62e-34	Diabetic kidney disease;
BRCA	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg09888468	chr15:81410853	NA	-0.47	-9.7	-0.36	7.48e-21	QT interval (drug interaction);
BRCA	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg21573476	chr21:45109991	RRP1B	-0.42	-11.11	-0.4	2.42e-26	Mean corpuscular volume;
BRCA	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	10.64	0.39	1.95e-24	Aortic root size;
BRCA	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg25703541	chr22:24373054	LOC391322	0.63	12.57	0.45	1.5e-32	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg26384229	chr12:38710491	ALG10B	0.74	16.49	0.55	3.62e-51	Morning vs. evening chronotype;
BRCA	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg11752832	chr7:134001865	SLC35B4	0.55	14.14	0.49	1.13e-39	Mean platelet volume;
BRCA	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg19336497	chr11:14380999	RRAS2	-0.48	-11.87	-0.42	1.69e-29	Sense of smell;
BRCA	cis	rs9296092	0.538	rs112113649	chr6:33524529	A/G	cg13560919	chr6:33536144	NA	-0.85	-18.66	-0.59	2.28e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg20203395	chr5:56204925	C5orf35	-0.5	-10.12	-0.37	1.97e-22	Initial pursuit acceleration;
BRCA	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg22852734	chr6:133119734	C6orf192	0.73	12.18	0.43	7.45e-31	Type 2 diabetes nephropathy;
BRCA	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg11764359	chr7:65958608	NA	-0.59	-9.85	-0.36	2.06e-21	Aortic root size;
BRCA	cis	rs1011018	0.628	rs76600942	chr7:139449942	G/A	cg03224163	chr7:139420300	HIPK2	-0.6	-9.0	-0.34	2.66e-18	Systolic blood pressure;
BRCA	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	25.91	0.72	1.01e-101	Chronic sinus infection;
BRCA	cis	rs208520	0.874	rs208469	chr6:66915891	T/C	cg07460842	chr6:66804631	NA	-0.89	-15.72	-0.53	2.64e-47	Exhaled nitric oxide output;
BRCA	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg21573476	chr21:45109991	RRP1B	-0.34	-8.82	-0.33	1.1e-17	Mean corpuscular volume;
BRCA	cis	rs7809950	0.911	rs7778250	chr7:107224565	C/A	cg23024343	chr7:107201750	COG5	0.42	8.95	0.33	3.94e-18	Coronary artery disease;
BRCA	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg01262667	chr19:19385393	TM6SF2	0.39	8.02	0.3	5.11e-15	Nonalcoholic fatty liver disease;
BRCA	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	8.09	0.3	3e-15	Aortic root size;
BRCA	cis	rs10193935	0.901	rs6733914	chr2:42674741	A/G	cg27598129	chr2:42591480	NA	0.85	14.03	0.49	3.51e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	13.76	0.48	6.16e-38	Platelet count;
BRCA	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg21143896	chr7:2802374	GNA12	-0.33	-8.6	-0.32	6.03e-17	Height;
BRCA	cis	rs7587476	1.000	rs7587476	chr2:215653887	T/C	cg04004882	chr2:215674386	BARD1	-0.58	-11.0	-0.4	6.57e-26	Neuroblastoma;
BRCA	cis	rs9420	0.961	rs7949841	chr11:57524700	G/C	cg19752551	chr11:57585705	CTNND1	-0.51	-12.58	-0.45	1.37e-32	Schizophrenia;
BRCA	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg14683738	chr19:37701593	ZNF585B	0.48	8.28	0.31	7.32e-16	Coronary artery calcification;
BRCA	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg23711669	chr6:146136114	FBXO30	0.72	17.44	0.57	5.23e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1011018	0.628	rs78366882	chr7:139452776	C/A	cg03224163	chr7:139420300	HIPK2	-0.59	-8.91	-0.33	5.15e-18	Systolic blood pressure;
BRCA	trans	rs9944715	0.954	rs9952469	chr18:43812010	T/C	cg01718231	chr17:29326311	RNF135	-0.42	-8.65	-0.32	4.32e-17	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs74181299	0.684	rs10185243	chr2:65355744	G/T	cg05010058	chr2:65284262	CEP68	-0.3	-8.11	-0.31	2.52e-15	Pulse pressure;
BRCA	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg12062639	chr20:23401060	NAPB	0.87	10.46	0.38	9.93e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.64	-0.5	4.62e-42	Chronic sinus infection;
BRCA	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg05623727	chr3:50126028	RBM5	-0.52	-12.5	-0.44	3.12e-32	Body mass index;
BRCA	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg27661571	chr11:113659931	NA	0.65	8.71	0.33	2.53e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg17211192	chr8:82754475	SNX16	0.56	10.24	0.38	7.15e-23	Diastolic blood pressure;
BRCA	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg03929089	chr4:120376271	NA	-0.94	-25.48	-0.71	2.42e-99	Height;
BRCA	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg12483005	chr1:23474871	LUZP1	-0.37	-8.03	-0.3	4.71e-15	Height;
BRCA	cis	rs727479	0.543	rs1143704	chr15:51510702	T/A	cg19946085	chr15:51559439	CYP19A1	-0.29	-8.18	-0.31	1.51e-15	Estradiol levels;
BRCA	cis	rs73086581	1.000	rs6052217	chr20:3970211	A/G	cg02187196	chr20:3869020	PANK2	0.51	9.22	0.34	4.42e-19	Response to antidepressants in depression;
BRCA	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg00717180	chr2:96193071	NA	-0.38	-10.2	-0.37	9.44e-23	HDL cholesterol;
BRCA	trans	rs7200543	1.000	rs4500751	chr16:15140211	C/T	cg24683922	chr1:11983373	KIAA2013	-0.35	-8.24	-0.31	9.86e-16	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg11608241	chr8:8085544	FLJ10661	0.31	8.88	0.33	6.91e-18	Mood instability;
BRCA	trans	rs1991651	0.578	rs11778453	chr8:10489836	C/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-8.5	-0.32	1.38e-16	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
BRCA	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	16.16	0.54	1.72e-49	Hip circumference adjusted for BMI;
BRCA	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg23625390	chr15:77176239	SCAPER	0.39	9.15	0.34	7.8e-19	Blood metabolite levels;
BRCA	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg22705602	chr4:152727874	NA	-0.38	-10.47	-0.38	8.45e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg16339924	chr4:17578868	LAP3	-0.6	-14.6	-0.5	6.84e-42	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4900538	0.855	rs72698602	chr14:102880454	T/C	cg18135206	chr14:102964638	TECPR2	-0.92	-21.74	-0.65	7.08e-79	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg17330251	chr7:94953956	PON1	-0.42	-9.06	-0.34	1.53e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs73242632	1.000	rs28719609	chr4:57881862	T/G	cg20415529	chr4:57845134	POLR2B;C4orf14	0.69	8.27	0.31	8.02e-16	Congenital heart disease (maternal effect);
BRCA	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg06092702	chr1:163392909	NA	-0.33	-8.68	-0.32	3.38e-17	Motion sickness;
BRCA	cis	rs2191566	0.576	rs436790	chr19:44491927	A/G	cg20607764	chr19:44506953	ZNF230	-0.37	-8.01	-0.3	5.53e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg05343316	chr1:45956843	TESK2	0.62	12.56	0.44	1.76e-32	Platelet count;
BRCA	cis	rs7264396	1.000	rs224418	chr20:34142527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-10.97	-0.4	8.81e-26	Total cholesterol levels;
BRCA	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg13010199	chr12:38710504	ALG10B	0.5	10.43	0.38	1.31e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg20607287	chr7:12443886	VWDE	-0.6	-8.53	-0.32	1.04e-16	Coronary artery disease;
BRCA	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg05535760	chr7:792225	HEATR2	-0.73	-11.6	-0.42	2.2e-28	Cerebrospinal P-tau181p levels;
BRCA	cis	rs829883	1.000	rs249839	chr12:98872364	T/C	cg25150519	chr12:98850993	NA	0.58	11.77	0.42	4.47e-29	Colorectal adenoma (advanced);
BRCA	trans	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.31	-8.2	-0.31	1.34e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9283706	0.689	rs12517976	chr5:66321579	G/A	cg11590213	chr5:66331682	MAST4	0.42	8.08	0.3	3.2e-15	Coronary artery disease;
BRCA	cis	rs929596	0.518	rs13401281	chr2:234628679	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-10.52	-0.38	5.58e-24	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs11690935	0.788	rs10201053	chr2:172889558	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.79	-21.9	-0.65	9.9e-80	Schizophrenia;
BRCA	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg23649088	chr2:200775458	C2orf69	-0.61	-7.95	-0.3	8.69e-15	Schizophrenia;
BRCA	cis	rs9473147	0.516	rs2151975	chr6:47515663	T/C	cg12968598	chr6:47444699	CD2AP	0.44	9.76	0.36	4.44e-21	Platelet distribution width;Mean platelet volume;
BRCA	trans	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg25214090	chr10:38739885	LOC399744	-0.46	-10.47	-0.38	8.76e-24	Corneal astigmatism;
BRCA	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg11062466	chr8:58055876	NA	0.5	8.56	0.32	8.24e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.31	-8.15	-0.31	1.87e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.62	-0.32	5.3e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7580658	0.926	rs4662725	chr2:128141320	G/A	cg09760422	chr2:128146352	NA	-0.35	-7.84	-0.3	1.83e-14	Protein C levels;
BRCA	cis	rs6763687	0.585	rs10936710	chr3:171801991	T/C	cg16233210	chr3:171778391	FNDC3B	0.35	7.81	0.3	2.39e-14	Red cell distribution width;
BRCA	trans	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	14.59	0.5	8.38e-42	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs1847202	0.859	rs7634316	chr3:72941452	C/G	cg25664220	chr3:72788482	NA	0.37	8.56	0.32	8.28e-17	Motion sickness;
BRCA	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg12473912	chr3:136751656	NA	0.37	8.26	0.31	8.34e-16	Neuroticism;
BRCA	cis	rs507080	0.922	rs514143	chr11:118558449	G/A	cg09144398	chr11:118550485	TREH	-0.38	-9.09	-0.34	1.23e-18	Serum metabolite levels;
BRCA	trans	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg25214090	chr10:38739885	LOC399744	0.35	7.93	0.3	9.99e-15	Diastolic blood pressure;
BRCA	cis	rs10504073	0.584	rs4873304	chr8:49922733	G/A	cg00325661	chr8:49890786	NA	0.54	15.54	0.52	1.89e-46	Blood metabolite ratios;
BRCA	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg08392591	chr16:89556376	ANKRD11	0.38	8.91	0.33	5.27e-18	Multiple myeloma (IgH translocation);
BRCA	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.66	0.32	3.7e-17	Motion sickness;
BRCA	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg08645402	chr16:4508243	NA	0.35	7.94	0.3	8.83e-15	Schizophrenia;
BRCA	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg07169764	chr2:136633963	MCM6	1.22	23.93	0.69	7.64e-91	Corneal structure;
BRCA	cis	rs11779988	0.545	rs454692	chr8:17789298	T/C	cg01800426	chr8:17659068	MTUS1	-0.4	-8.23	-0.31	1.02e-15	Breast cancer;
BRCA	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg25809561	chr17:30822961	MYO1D	0.4	9.52	0.35	3.4e-20	Schizophrenia;
BRCA	cis	rs9815354	0.767	rs17280980	chr3:41810949	A/T	cg03022575	chr3:42003672	ULK4	0.7	9.61	0.36	1.66e-20	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg25214090	chr10:38739885	LOC399744	0.49	10.75	0.39	7.05e-25	Corneal astigmatism;
BRCA	cis	rs9837602	0.938	rs793457	chr3:99518987	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-10.41	-0.38	1.56e-23	Breast cancer;
BRCA	cis	rs12348691	0.503	rs7849834	chr9:100606188	T/C	cg13688889	chr9:100608707	NA	-0.49	-10.03	-0.37	4.39e-22	Alopecia areata;
BRCA	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg00666640	chr1:248458726	OR2T12	0.34	9.12	0.34	9.72e-19	Common traits (Other);
BRCA	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-14.58	-0.5	8.75e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg01324343	chr3:183735012	ABCC5	0.84	21.36	0.65	8.57e-77	Anterior chamber depth;
BRCA	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	8.44	0.32	2.1e-16	Personality dimensions;
BRCA	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg09467607	chr2:36825704	FEZ2	-0.65	-17.41	-0.57	7.35e-56	Height;
BRCA	cis	rs9296092	0.538	rs62405943	chr6:33517359	A/G	cg13560919	chr6:33536144	NA	-0.85	-18.39	-0.59	6.37e-61	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.31	-0.38	3.67e-23	Gut microbiome composition (summer);
BRCA	cis	rs36051895	0.632	rs11788963	chr9:5120157	C/A	cg02405213	chr9:5042618	JAK2	-0.49	-8.91	-0.33	5.39e-18	Pediatric autoimmune diseases;
BRCA	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06002616	chr8:101225028	SPAG1	-0.34	-8.3	-0.31	6.4e-16	Atrioventricular conduction;
BRCA	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg18357645	chr12:58087776	OS9	0.48	13.8	0.48	4.11e-38	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7953249	0.502	rs1169294	chr12:121426594	G/A	cg02403541	chr12:121454288	C12orf43	0.51	9.46	0.35	5.95e-20	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
BRCA	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-11.06	-0.4	3.81e-26	Lymphocyte counts;
BRCA	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg27398817	chr8:82754497	SNX16	-0.37	-7.86	-0.3	1.58e-14	Diastolic blood pressure;
BRCA	cis	rs4074536	0.796	rs10157905	chr1:116308511	C/T	cg21648376	chr1:116311395	CASQ2	-0.5	-8.91	-0.33	5.16e-18	QRS duration;
BRCA	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.78	0.67	1.59e-84	Chronic sinus infection;
BRCA	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg12311346	chr5:56204834	C5orf35	0.81	16.55	0.55	1.75e-51	Initial pursuit acceleration;
BRCA	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.62	-0.32	5.36e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg18538332	chr22:24372958	LOC391322	-0.56	-14.13	-0.49	1.25e-39	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg20387954	chr3:183756860	HTR3D	0.45	10.11	0.37	2.09e-22	Anterior chamber depth;
BRCA	cis	rs10911363	0.550	rs10911353	chr1:183489203	G/A	cg09173681	chr1:183549694	NCF2	0.53	11.12	0.4	2.31e-26	Systemic lupus erythematosus;
BRCA	cis	rs870825	0.616	rs28673855	chr4:185627416	T/G	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg12661370	chr5:149340060	SLC26A2	0.56	8.36	0.31	3.8e-16	HIV-1 control;
BRCA	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg20701182	chr2:24300061	SF3B14	0.58	9.0	0.34	2.55e-18	Lymphocyte counts;
BRCA	trans	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg02030672	chr11:45687055	CHST1	0.5	11.35	0.41	2.44e-27	Obesity-related traits;
BRCA	cis	rs909002	0.811	rs11575883	chr1:32085485	G/A	cg13919466	chr1:32135498	COL16A1	-0.27	-9.42	-0.35	8.34e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4845875	0.557	rs4846054	chr1:11869230	C/T	cg24844545	chr1:11908347	NPPA	0.34	8.83	0.33	1.04e-17	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs7818345	0.967	rs12679671	chr8:19270831	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.32	8.23	0.31	1.07e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-9.83	-0.36	2.39e-21	Aortic root size;
BRCA	cis	rs870825	0.616	rs55685500	chr4:185614810	G/A	cg20176042	chr4:185552304	CASP3	-0.54	-8.2	-0.31	1.28e-15	Blood protein levels;
BRCA	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24110177	chr3:50126178	RBM5	0.52	15.68	0.53	4e-47	Body mass index;
BRCA	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg12311346	chr5:56204834	C5orf35	-0.38	-7.9	-0.3	1.23e-14	Coronary artery disease;
BRCA	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.56	0.32	8.33e-17	Rheumatoid arthritis;
BRCA	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	19.06	0.6	1.89e-64	Tonsillectomy;
BRCA	cis	rs2303759	0.958	rs1465697	chr19:49837246	C/T	cg22307029	chr19:49891270	CCDC155	0.58	10.14	0.37	1.71e-22	Multiple sclerosis;
BRCA	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-9.98	-0.37	6.66e-22	Fear of minor pain;
BRCA	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.4	-0.35	9.22e-20	Body mass index;
BRCA	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg19628046	chr18:33552617	C18orf21	0.52	9.99	0.37	6.09e-22	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg06627628	chr2:24431161	ITSN2	-0.63	-11.98	-0.43	5.58e-30	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs17253792	0.545	rs12893610	chr14:56016347	C/T	cg01858014	chr14:56050164	KTN1	-0.63	-8.27	-0.31	7.6e-16	Putamen volume;
BRCA	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.84	0.36	2.22e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg05340658	chr4:99064831	C4orf37	0.7	17.43	0.57	5.62e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg18154014	chr19:37997991	ZNF793	0.61	11.43	0.41	1.13e-27	Coronary artery calcification;
BRCA	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.26	8.13	0.31	2.21e-15	Cardiac Troponin-T levels;
BRCA	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.17	0.31	1.62e-15	Menarche (age at onset);
BRCA	cis	rs9309473	1.000	rs6755217	chr2:73641285	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-11.97	-0.43	6.34e-30	Metabolite levels;
BRCA	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg03351412	chr1:154909251	PMVK	0.57	13.04	0.46	1.31e-34	Prostate cancer;
BRCA	cis	rs7072216	0.763	rs6584201	chr10:100170209	T/C	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.71	-0.36	7.24e-21	Metabolite levels;
BRCA	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg25174290	chr11:3078921	CARS	-0.3	-7.97	-0.3	7.18e-15	Calcium levels;
BRCA	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg02297831	chr4:17616191	MED28	0.36	8.43	0.32	2.25e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg11584989	chr19:19387371	SF4	0.63	13.41	0.47	2.68e-36	Bipolar disorder;
BRCA	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-10.39	-0.38	1.86e-23	Resting heart rate;
BRCA	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.35	9.19	0.34	5.44e-19	IgG glycosylation;
BRCA	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.57	0.32	7.85e-17	Personality dimensions;
BRCA	cis	rs743757	1.000	rs2236975	chr3:50483437	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.46	7.88	0.3	1.43e-14	Diastolic blood pressure;
BRCA	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg10729496	chr3:10149963	C3orf24	0.48	9.0	0.34	2.49e-18	Alzheimer's disease;
BRCA	cis	rs11605924	1.000	rs1401419	chr11:45879739	T/C	ch.11.939596F	chr11:45881766	CRY2	-0.47	-10.41	-0.38	1.56e-23	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg00677455	chr12:58241039	CTDSP2	-0.75	-17.07	-0.56	4.33e-54	Multiple sclerosis;
BRCA	cis	rs1997103	1.000	rs2177804	chr7:55410302	G/A	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.81	0.3	2.32e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs615632	0.530	rs10092464	chr8:9804185	C/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.98	-0.3	6.62e-15	Neuroticism;
BRCA	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg11764359	chr7:65958608	NA	0.47	9.13	0.34	8.92e-19	Calcium levels;
BRCA	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg23711669	chr6:146136114	FBXO30	0.71	16.76	0.55	1.49e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.72	10.25	0.38	6.11e-23	Initial pursuit acceleration;
BRCA	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1499972	0.941	rs73168378	chr3:117636234	G/T	cg07612923	chr3:117604196	NA	0.6	8.16	0.31	1.75e-15	Schizophrenia;
BRCA	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg19717773	chr7:2847554	GNA12	-0.42	-9.51	-0.35	3.68e-20	Height;
BRCA	cis	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg07460842	chr6:66804631	NA	0.88	14.14	0.49	1.11e-39	Exhaled nitric oxide output;
BRCA	cis	rs6120849	0.754	rs6120793	chr20:33604407	T/C	cg24642439	chr20:33292090	TP53INP2	0.59	10.19	0.37	1.1e-22	Protein C levels;
BRCA	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg06453172	chr10:134556979	INPP5A	-0.47	-11.15	-0.4	1.71e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg27535305	chr1:53392650	SCP2	-0.47	-11.46	-0.41	9.07e-28	Monocyte count;
BRCA	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg05985134	chr18:33552581	C18orf21	0.65	11.89	0.43	1.34e-29	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02475777	chr4:1388615	CRIPAK	0.67	13.02	0.46	1.61e-34	Longevity;
BRCA	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg00631329	chr6:26305371	NA	-0.42	-12.61	-0.45	1.07e-32	Educational attainment;
BRCA	cis	rs360798	0.512	rs4461246	chr2:63027671	C/T	cg17519650	chr2:63277830	OTX1	-0.39	-8.4	-0.32	2.86e-16	Coronary artery disease;
BRCA	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg04827223	chr11:72435913	ARAP1	-0.73	-18.35	-0.59	1.03e-60	Body mass index;
BRCA	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.65	-15.01	-0.51	7.38e-44	Ulcerative colitis;
BRCA	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg09035930	chr12:129282057	SLC15A4	0.56	16.41	0.54	8.76e-51	Systemic lupus erythematosus;
BRCA	cis	rs847577	0.540	rs3847055	chr7:97680645	A/G	cg21770322	chr7:97807741	LMTK2	-0.38	-8.62	-0.32	5.26e-17	Breast cancer;
BRCA	cis	rs2066819	0.892	rs112931321	chr12:56667894	C/T	cg26734620	chr12:56694298	CS	0.89	10.24	0.38	6.69e-23	Psoriasis vulgaris;
BRCA	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg08917208	chr2:24149416	ATAD2B	0.52	8.28	0.31	7.42e-16	Asthma;
BRCA	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg23587288	chr2:27483067	SLC30A3	-0.38	-8.9	-0.33	5.91e-18	Blood metabolite levels;
BRCA	cis	rs61990749	0.544	rs3759728	chr14:78230159	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.66	10.57	0.39	3.61e-24	Fibroblast growth factor basic levels;
BRCA	cis	rs813218	0.523	rs652026	chr3:99442809	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.41	-9.33	-0.35	1.68e-19	Orofacial clefts;
BRCA	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	11.64	0.42	1.62e-28	Mean platelet volume;
BRCA	cis	rs1003719	0.679	rs2835674	chr21:38581522	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.01	-0.48	4.4e-39	Eye color traits;
BRCA	cis	rs701145	0.585	rs1470664	chr3:153865193	C/T	cg12800244	chr3:153838788	SGEF	0.58	8.24	0.31	9.43e-16	Coronary artery disease;
BRCA	cis	rs3784262	0.669	rs4646555	chr15:58355345	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-10.65	-0.39	1.79e-24	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs2421770	0.530	rs4755396	chr11:35370624	G/A	cg13971030	chr11:35366721	SLC1A2	-0.44	-9.75	-0.36	5.14e-21	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg24562669	chr7:97807699	LMTK2	0.7	21.74	0.65	7.16e-79	Breast cancer;
BRCA	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-9.72	-0.36	6.21e-21	Alzheimer's disease (late onset);
BRCA	trans	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg15704280	chr7:45808275	SEPT13	0.54	8.11	0.31	2.55e-15	Axial length;
BRCA	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg18811423	chr2:55921094	PNPT1	-0.51	-12.59	-0.45	1.23e-32	Metabolic syndrome;
BRCA	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg07537917	chr2:241836409	C2orf54	-0.47	-11.09	-0.4	2.95e-26	Urinary metabolites;
BRCA	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.47	-9.71	-0.36	7.2e-21	Bipolar disorder;
BRCA	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12756686	chr19:29218302	NA	0.59	11.07	0.4	3.69e-26	Methadone dose in opioid dependence;
BRCA	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg14863265	chr7:2801509	GNA12	0.45	9.74	0.36	5.4e-21	Height;
BRCA	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg07917127	chr4:99064746	C4orf37	0.45	8.19	0.31	1.38e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg04450456	chr4:17643702	FAM184B	0.42	12.53	0.44	2.21e-32	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg17845761	chr1:175162550	KIAA0040	-0.27	-10.05	-0.37	3.53e-22	Alcohol dependence;
BRCA	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg15133208	chr4:90757351	SNCA	-0.4	-8.3	-0.31	6e-16	Neuroticism;
BRCA	cis	rs1975991	0.670	rs7641501	chr3:187950157	T/C	cg15417654	chr3:187959138	LPP	0.37	9.75	0.36	5.04e-21	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg02544614	chr20:61657117	NA	0.29	8.22	0.31	1.12e-15	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg15556689	chr8:8085844	FLJ10661	0.35	9.44	0.35	6.74e-20	Retinal vascular caliber;
BRCA	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg16006841	chr5:176797999	RGS14	0.6	11.82	0.42	2.78e-29	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs7640424	0.826	rs7635063	chr3:107818777	C/T	cg09227934	chr3:107805635	CD47	-0.43	-9.58	-0.35	2.16e-20	Body mass index;
BRCA	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg01065977	chr19:18549689	ISYNA1	0.28	8.33	0.31	4.92e-16	Breast cancer;
BRCA	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18404041	chr3:52824283	ITIH1	-0.42	-12.41	-0.44	7.98e-32	Bipolar disorder;
BRCA	cis	rs919433	0.680	rs7582536	chr2:198436103	C/T	cg00792783	chr2:198669748	PLCL1	-0.39	-8.7	-0.33	2.83e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg04414720	chr1:150670196	GOLPH3L	0.36	8.16	0.31	1.82e-15	Melanoma;
BRCA	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-9.7	-0.36	7.6e-21	Total body bone mineral density;
BRCA	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg06970220	chr1:156163860	SLC25A44	0.38	9.35	0.35	1.44e-19	Testicular germ cell tumor;
BRCA	cis	rs1506636	0.927	rs11983604	chr7:123329754	T/G	cg03229431	chr7:123269106	ASB15	-0.62	-14.03	-0.49	3.46e-39	Plateletcrit;Platelet count;
BRCA	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg03146154	chr1:46216737	IPP	0.53	11.75	0.42	5.61e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7809615	0.901	rs11761528	chr7:99118801	C/T	cg12290671	chr7:99195819	NA	-0.52	-8.66	-0.32	3.82e-17	Blood metabolite ratios;
BRCA	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg10495392	chr1:46806563	NSUN4	0.45	8.32	0.31	5.33e-16	Menopause (age at onset);
BRCA	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg25358565	chr5:93447407	FAM172A	1.16	18.42	0.59	4.3e-61	Diabetic retinopathy;
BRCA	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg00106254	chr7:1943704	MAD1L1	0.42	10.22	0.37	7.92e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg22004693	chr7:99632812	ZKSCAN1	0.46	9.72	0.36	6.21e-21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg03711944	chr11:47377212	SPI1	-0.38	-10.38	-0.38	1.89e-23	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg11301795	chr4:187892539	NA	-0.25	-8.13	-0.31	2.31e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8028182	0.609	rs8038760	chr15:75742095	A/C	cg20655648	chr15:75932815	IMP3	0.4	7.81	0.3	2.38e-14	Sudden cardiac arrest;
BRCA	cis	rs72781680	0.715	rs72796332	chr2:24142060	G/A	cg08917208	chr2:24149416	ATAD2B	0.64	10.69	0.39	1.17e-24	Lymphocyte counts;
BRCA	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg26408565	chr15:76604113	ETFA	-0.49	-10.39	-0.38	1.79e-23	Blood metabolite levels;
BRCA	cis	rs243505	0.898	rs243535	chr7:148410123	A/C	cg09806900	chr7:148480153	CUL1	-0.42	-8.54	-0.32	1e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18404041	chr3:52824283	ITIH1	-0.3	-8.96	-0.33	3.45e-18	Bipolar disorder;
BRCA	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14442939	chr10:27389572	ANKRD26	-0.68	-10.91	-0.4	1.61e-25	Breast cancer;
BRCA	trans	rs61931739	0.513	rs1608906	chr12:33894986	T/C	cg26384229	chr12:38710491	ALG10B	0.41	9.41	0.35	8.75e-20	Morning vs. evening chronotype;
BRCA	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05731713	chr7:157510257	PTPRN2	0.39	10.14	0.37	1.62e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.06	-0.34	1.6e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg03929089	chr4:120376271	NA	0.65	12.96	0.46	2.86e-34	Coronary artery disease;
BRCA	cis	rs68170813	0.559	rs12532967	chr7:106937418	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.55	-0.32	8.91e-17	Coronary artery disease;
BRCA	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-8.98	-0.33	3.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg10495392	chr1:46806563	NSUN4	0.44	8.14	0.31	2.15e-15	Menopause (age at onset);
BRCA	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.82	-0.39	3.6e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.77	-0.42	4.5e-29	Response to antipsychotic treatment;
BRCA	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg26597838	chr10:835615	NA	0.95	14.86	0.51	4.14e-43	Eosinophil percentage of granulocytes;
BRCA	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg11057378	chr10:81107060	PPIF	0.36	8.83	0.33	1.02e-17	Height;
BRCA	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.73	11.27	0.41	5.27e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg11764359	chr7:65958608	NA	0.63	10.74	0.39	7.39e-25	Aortic root size;
BRCA	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg05313129	chr8:58192883	C8orf71	-0.45	-9.24	-0.34	3.65e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs6546550	0.901	rs7419837	chr2:70146625	T/C	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.47	-0.41	7.84e-28	Prevalent atrial fibrillation;
BRCA	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.9e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12618769	0.597	rs72819972	chr2:99035113	A/C	cg10123293	chr2:99228465	UNC50	0.4	8.07	0.3	3.59e-15	Bipolar disorder;
BRCA	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	9.01	0.34	2.4e-18	Personality dimensions;
BRCA	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-10.63	-0.39	2.11e-24	Gut microbiome composition (summer);
BRCA	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21659725	chr3:3221576	CRBN	-0.46	-10.23	-0.38	7.8e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg14784868	chr12:69753453	YEATS4	-0.51	-12.31	-0.44	2.09e-31	Blood protein levels;
BRCA	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg03929089	chr4:120376271	NA	0.5	8.32	0.31	5.45e-16	Axial length;
BRCA	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.63	0.59	3.21e-62	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg23285459	chr7:2802560	GNA12	-0.36	-9.05	-0.34	1.76e-18	Height;
BRCA	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg24829409	chr8:58192753	C8orf71	-0.47	-9.0	-0.34	2.61e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg11822812	chr5:140052017	DND1	-0.3	-8.2	-0.31	1.37e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg16339924	chr4:17578868	LAP3	0.63	15.82	0.53	8.24e-48	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.24	0.68	4.47e-87	Chronic sinus infection;
BRCA	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	17.28	0.56	3.32e-55	Hip circumference adjusted for BMI;
BRCA	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	11.66	0.42	1.3e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg22974920	chr21:40686053	BRWD1	-0.39	-8.57	-0.32	7.84e-17	Cognitive function;
BRCA	cis	rs16958440	0.867	rs10083937	chr18:44695602	A/G	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs2625529	0.761	rs16956444	chr15:72271235	C/T	cg16672083	chr15:72433130	SENP8	-0.85	-17.83	-0.58	5.36e-58	Red blood cell count;
BRCA	trans	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.16	0.31	1.83e-15	Corneal astigmatism;
BRCA	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg18016565	chr1:150552671	MCL1	0.35	8.23	0.31	1.08e-15	Tonsillectomy;
BRCA	cis	rs6558530	0.640	rs7844748	chr8:1702343	C/T	cg19131313	chr8:1704013	NA	0.4	8.27	0.31	7.97e-16	Systolic blood pressure;
BRCA	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-8.86	-0.33	7.94e-18	Mean corpuscular volume;
BRCA	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg19920283	chr7:105172520	RINT1	0.59	10.74	0.39	7.65e-25	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7617773	0.746	rs11713476	chr3:48375434	C/T	cg11946769	chr3:48343235	NME6	0.6	12.69	0.45	4.34e-33	Coronary artery disease;
BRCA	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.69	0.5	2.7e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg08917208	chr2:24149416	ATAD2B	1.12	15.97	0.53	1.45e-48	Lymphocyte counts;
BRCA	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.44	-0.41	1.04e-27	Mean corpuscular volume;
BRCA	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.14	-0.34	8.22e-19	Total body bone mineral density;
BRCA	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg26384229	chr12:38710491	ALG10B	0.69	15.98	0.53	1.38e-48	Bladder cancer;
BRCA	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg06145435	chr7:1022769	CYP2W1	0.49	9.06	0.34	1.62e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs16976116	0.855	rs7172289	chr15:55501705	A/G	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg01528321	chr10:82214614	TSPAN14	0.62	14.12	0.49	1.3e-39	Post bronchodilator FEV1;
BRCA	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.02e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15541040	chr2:3486749	NA	-0.47	-10.43	-0.38	1.21e-23	Neurofibrillary tangles;
BRCA	cis	rs793571	0.544	rs1427282	chr15:58914326	C/T	cg05156742	chr15:59063176	FAM63B	0.49	9.81	0.36	2.97e-21	Schizophrenia;
BRCA	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03576123	chr11:487126	PTDSS2	-1.23	-18.77	-0.6	6.43e-63	Body mass index;
BRCA	cis	rs829883	0.659	rs11109528	chr12:98951362	G/A	cg25150519	chr12:98850993	NA	-0.48	-8.61	-0.32	5.63e-17	Colorectal adenoma (advanced);
BRCA	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg21475434	chr5:93447410	FAM172A	0.67	8.4	0.32	3e-16	Diabetic retinopathy;
BRCA	cis	rs1832871	0.672	rs9457343	chr6:158740567	A/G	cg07165851	chr6:158734300	TULP4	0.63	12.61	0.45	9.95e-33	Height;
BRCA	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.59	-12.64	-0.45	7.4e-33	Lymphocyte percentage of white cells;
BRCA	cis	rs12579753	0.917	rs10129029	chr12:82180324	G/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-8.44	-0.32	2.13e-16	Resting heart rate;
BRCA	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.6	12.66	0.45	6.27e-33	Lymphocyte counts;
BRCA	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg22903471	chr2:27725779	GCKR	-0.34	-8.07	-0.3	3.42e-15	Total body bone mineral density;
BRCA	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg06453172	chr10:134556979	INPP5A	-0.53	-11.49	-0.41	6.44e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.94	0.4	1.2e-25	Rheumatoid arthritis;
BRCA	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg12310025	chr6:25882481	NA	-0.43	-9.98	-0.37	6.86e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.07	0.3	3.55e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs754466	0.580	rs10430529	chr10:79582623	C/A	cg17075019	chr10:79541650	NA	-0.82	-20.01	-0.62	1.63e-69	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg10523679	chr1:76189770	ACADM	-0.62	-11.47	-0.41	7.97e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs503734	0.502	rs348864	chr3:100910127	T/G	cg27318481	chr3:100970896	IMPG2	-0.36	-8.69	-0.33	3.04e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg07645718	chr20:61493192	TCFL5	-0.64	-8.78	-0.33	1.53e-17	Obesity-related traits;
BRCA	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg03462622	chr3:195777018	TFRC	-0.38	-8.6	-0.32	6.28e-17	Mean corpuscular volume;
BRCA	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg16339924	chr4:17578868	LAP3	0.6	14.62	0.5	5.83e-42	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg23791538	chr6:167370224	RNASET2	-0.39	-9.53	-0.35	3.14e-20	Crohn's disease;
BRCA	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	19.27	0.61	1.43e-65	Smoking behavior;
BRCA	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg18230493	chr5:56204884	C5orf35	-0.43	-8.61	-0.32	5.77e-17	Coronary artery disease;
BRCA	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.58	-12.14	-0.43	1.13e-30	IgG glycosylation;
BRCA	trans	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg09719594	chr16:21412588	NA	-0.35	-7.98	-0.3	6.83e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg01416388	chr22:39784598	NA	0.39	8.18	0.31	1.48e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg04317338	chr11:64019027	PLCB3	0.5	8.96	0.33	3.64e-18	Mean platelet volume;
BRCA	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg12292205	chr6:26970375	C6orf41	-0.56	-12.39	-0.44	9.28e-32	Schizophrenia;
BRCA	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg27165867	chr14:105738592	BRF1	-0.36	-8.55	-0.32	8.79e-17	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg08917208	chr2:24149416	ATAD2B	0.9	12.66	0.45	6.34e-33	Lymphocyte counts;
BRCA	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg23711669	chr6:146136114	FBXO30	-0.76	-17.6	-0.57	8.28e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1298908	0.639	rs2993763	chr10:82033594	G/A	cg01528321	chr10:82214614	TSPAN14	0.47	10.33	0.38	3.08e-23	Diabetic kidney disease;
BRCA	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18404041	chr3:52824283	ITIH1	-0.29	-8.72	-0.33	2.44e-17	Electroencephalogram traits;
BRCA	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg17330251	chr7:94953956	PON1	-0.42	-8.79	-0.33	1.39e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs7617773	0.746	rs4130995	chr3:48358255	C/T	cg11946769	chr3:48343235	NME6	0.52	11.59	0.42	2.6e-28	Coronary artery disease;
BRCA	cis	rs939658	0.683	rs8038464	chr15:79463036	A/T	cg17916960	chr15:79447300	NA	-0.39	-9.71	-0.36	7.18e-21	Refractive error;
BRCA	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	18.13	0.58	1.36e-59	Alzheimer's disease;
BRCA	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.1	-0.31	2.84e-15	Depression;
BRCA	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg17372223	chr3:52568218	NT5DC2	0.37	9.07	0.34	1.48e-18	Electroencephalogram traits;
BRCA	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.46	-10.46	-0.38	9.76e-24	Height;
BRCA	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg10223061	chr2:219282414	VIL1	-0.27	-7.89	-0.3	1.36e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg00852783	chr1:26633632	UBXN11	-0.46	-7.9	-0.3	1.2e-14	Obesity-related traits;
BRCA	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.42	-9.42	-0.35	8.15e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs9487051	0.834	rs436880	chr6:109553069	C/T	cg21918786	chr6:109611834	NA	-0.33	-8.53	-0.32	1.07e-16	Reticulocyte fraction of red cells;
BRCA	cis	rs7607369	0.714	rs2272190	chr2:219609995	G/C	cg02176678	chr2:219576539	TTLL4	-0.41	-11.01	-0.4	6e-26	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs897080	0.515	rs698763	chr2:44573624	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	10.43	0.38	1.23e-23	Height;
BRCA	trans	rs225245	0.782	rs321601	chr17:33892087	A/C	cg19694781	chr19:47549865	TMEM160	0.34	8.4	0.32	2.85e-16	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs2236918	1.000	rs735943	chr1:242030151	C/T	cg17736920	chr1:242011382	EXO1	-0.42	-9.47	-0.35	5.15e-20	Menopause (age at onset);
BRCA	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg00750074	chr16:89608354	SPG7	-0.39	-10.36	-0.38	2.44e-23	Multiple myeloma (IgH translocation);
BRCA	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg04455712	chr21:45112962	RRP1B	0.41	10.49	0.38	7.32e-24	Mean corpuscular volume;
BRCA	trans	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg26043149	chr18:55253948	FECH	0.4	8.71	0.33	2.66e-17	Bone mineral density;
BRCA	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg16414030	chr3:133502952	NA	0.34	7.89	0.3	1.28e-14	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs10267417	0.603	rs10244374	chr7:19863170	C/T	cg07541023	chr7:19748670	TWISTNB	0.48	8.52	0.32	1.13e-16	Night sleep phenotypes;
BRCA	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.65	-14.27	-0.49	2.52e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg06521331	chr12:34319734	NA	-0.56	-10.12	-0.37	2.01e-22	Morning vs. evening chronotype;
BRCA	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg03609598	chr5:56110824	MAP3K1	-0.47	-8.01	-0.3	5.4e-15	Initial pursuit acceleration;
BRCA	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg26149184	chr10:133730230	NA	0.39	7.88	0.3	1.38e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs13102973	0.640	rs4864245	chr4:135882847	G/C	cg14419869	chr4:135874104	NA	-0.47	-9.22	-0.34	4.29e-19	Subjective well-being;
BRCA	cis	rs6429082	0.818	rs291344	chr1:235663860	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.54	-12.72	-0.45	3.39e-33	Adiposity;
BRCA	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.96	-0.46	2.7200000000000002e-34	Migraine;Coronary artery disease;
BRCA	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg05343316	chr1:45956843	TESK2	0.67	13.45	0.47	1.73e-36	Platelet count;
BRCA	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg18279126	chr7:2041391	MAD1L1	0.4	9.23	0.34	4.04e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13126279	chr21:47581558	C21orf56	-0.5	-10.88	-0.4	2.03e-25	Testicular germ cell tumor;
BRCA	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg16482183	chr6:26056742	HIST1H1C	0.54	11.16	0.4	1.5e-26	Height;
BRCA	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.7	-0.36	7.54e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg15017067	chr4:17643749	FAM184B	0.32	9.44	0.35	6.58e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs67072384	1.000	rs56693670	chr11:72445143	G/T	cg04827223	chr11:72435913	ARAP1	-0.69	-11.3	-0.41	3.91e-27	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
BRCA	trans	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg26384229	chr12:38710491	ALG10B	0.57	12.23	0.44	4.52e-31	Morning vs. evening chronotype;
BRCA	cis	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.29	-0.38	4.53e-23	Morning vs. evening chronotype;
BRCA	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02176678	chr2:219576539	TTLL4	0.46	12.18	0.43	8.14e-31	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg00852783	chr1:26633632	UBXN11	-0.47	-8.21	-0.31	1.22e-15	Obesity-related traits;
BRCA	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.39	-0.38	1.86e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6723226	0.806	rs2249109	chr2:32750879	G/A	cg02381751	chr2:32503542	YIPF4	0.7	15.6	0.53	1.03e-46	Intelligence (multi-trait analysis);
BRCA	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg03161606	chr19:29218774	NA	0.46	8.15	0.31	1.86e-15	Methadone dose in opioid dependence;
BRCA	trans	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg15704280	chr7:45808275	SEPT13	0.59	8.79	0.33	1.39e-17	Axial length;
BRCA	trans	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.42	-0.32	2.51e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	9.74	0.36	5.35e-21	Aortic root size;
BRCA	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-10.73	-0.39	7.93e-25	IgG glycosylation;
BRCA	cis	rs4730250	0.581	rs3779500	chr7:106792704	T/C	cg02696742	chr7:106810147	HBP1	0.57	9.43	0.35	7.51e-20	Osteoarthritis;
BRCA	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg00814883	chr7:100076585	TSC22D4	-0.49	-10.48	-0.38	8.35e-24	Platelet count;
BRCA	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-11.61	-0.42	2.11e-28	Heart rate;
BRCA	trans	rs11165623	0.792	rs9437609	chr1:96977961	A/C	cg10631902	chr5:14652156	NA	-0.5	-15.22	-0.52	6.9e-45	Hip circumference;Waist circumference;
BRCA	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg24069376	chr3:38537580	EXOG	-0.41	-11.84	-0.42	2.16e-29	Electrocardiographic conduction measures;
BRCA	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg10560079	chr2:191398806	TMEM194B	-0.67	-12.33	-0.44	1.79e-31	Diastolic blood pressure;
BRCA	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg09658497	chr7:2847517	GNA12	-0.45	-9.86	-0.36	1.85e-21	Height;
BRCA	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7043114	0.525	rs2274966	chr9:95155563	C/A	cg14631576	chr9:95140430	CENPP	-0.32	-8.07	-0.3	3.54e-15	Height;
BRCA	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.97	0.43	6.11e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs1973993	0.967	rs1555543	chr1:96944797	A/C	cg10631902	chr5:14652156	NA	0.51	16.2	0.54	1.02e-49	Weight;
BRCA	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg00666640	chr1:248458726	OR2T12	0.3	8.42	0.32	2.5e-16	Common traits (Other);
BRCA	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg12310025	chr6:25882481	NA	-0.51	-11.33	-0.41	3.01e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg05313129	chr8:58192883	C8orf71	-0.44	-9.12	-0.34	9.4e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	18.24	0.59	3.9e-60	Platelet count;
BRCA	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg03877680	chr5:178157825	ZNF354A	0.78	14.43	0.5	4.43e-41	Neutrophil percentage of white cells;
BRCA	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	8.43	0.32	2.35e-16	Rheumatoid arthritis;
BRCA	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg26168224	chr5:2018326	NA	-0.51	-11.44	-0.41	1.05e-27	Gut microbiome composition (winter);
BRCA	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg06115741	chr20:33292138	TP53INP2	0.4	8.78	0.33	1.48e-17	Coronary artery disease;
BRCA	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg05221455	chr11:829616	EFCAB4A	-0.36	-8.07	-0.3	3.49e-15	Mean platelet volume;
BRCA	cis	rs9400271	0.609	rs9386783	chr6:109588644	G/T	cg21918786	chr6:109611834	NA	-0.32	-8.09	-0.3	3.08e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg15017067	chr4:17643749	FAM184B	0.26	7.94	0.3	9.33e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2282335	0.507	rs2498421	chr9:71855357	A/G	cg14075627	chr9:71863002	TJP2	0.38	8.85	0.33	8.61e-18	Renal sinus fat;
BRCA	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08564027	chr20:61660810	NA	0.84	22.49	0.66	5.99e-83	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg14440974	chr22:39074834	NA	0.36	8.48	0.32	1.5e-16	Menopause (age at onset);
BRCA	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg17691542	chr6:26056736	HIST1H1C	-0.43	-9.27	-0.34	2.89e-19	Iron status biomarkers;
BRCA	cis	rs733592	0.507	rs7138917	chr12:48455255	G/A	cg24011408	chr12:48396354	COL2A1	-0.44	-9.99	-0.37	6.05e-22	Plateletcrit;
BRCA	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg18252515	chr7:66147081	NA	-1.06	-15.7	-0.53	3.07e-47	Gout;
BRCA	cis	rs13102973	0.965	rs13142779	chr4:135872841	G/T	cg14419869	chr4:135874104	NA	0.51	10.89	0.4	1.92e-25	Subjective well-being;
BRCA	cis	rs2964802	0.505	rs4410623	chr5:10832271	A/C	cg14521931	chr5:10832172	NA	0.59	13.56	0.47	5.41e-37	Major depressive disorder;Recurrent major depressive disorder;
BRCA	cis	rs7927771	0.524	rs11039402	chr11:47826090	A/C	cg20307385	chr11:47447363	PSMC3	0.41	9.4	0.35	9.67e-20	Subjective well-being;
BRCA	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg12310025	chr6:25882481	NA	-0.48	-11.05	-0.4	4.13e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg11645453	chr3:52864694	ITIH4	0.34	8.39	0.31	3.15e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6723226	0.806	rs2710606	chr2:32811909	A/G	cg02381751	chr2:32503542	YIPF4	0.7	14.72	0.5	1.85e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg12310025	chr6:25882481	NA	-0.5	-12.1	-0.43	1.71e-30	Blood metabolite levels;
BRCA	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg17063962	chr7:91808500	NA	-0.53	-12.46	-0.44	4.56e-32	Breast cancer;
BRCA	cis	rs507080	0.883	rs693306	chr11:118558333	A/G	cg08498647	chr11:118550644	TREH	-0.38	-8.26	-0.31	8.53e-16	Serum metabolite levels;
BRCA	cis	rs4727443	0.866	rs2897075	chr7:99630342	C/T	cg22004693	chr7:99632812	ZKSCAN1	0.4	9.04	0.34	1.91e-18	Interstitial lung disease;
BRCA	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg18230493	chr5:56204884	C5orf35	0.4	8.14	0.31	2.06e-15	Coronary artery disease;
BRCA	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg13010199	chr12:38710504	ALG10B	0.49	9.47	0.35	5.13e-20	Morning vs. evening chronotype;
BRCA	cis	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg21775007	chr8:11205619	TDH	-0.49	-9.88	-0.36	1.65e-21	Triglycerides;
BRCA	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	14.3	0.49	1.81e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7408868	1.000	rs10422818	chr19:15285272	A/G	cg14696996	chr19:15285081	NOTCH3	0.85	12.99	0.46	2e-34	Pulse pressure;
BRCA	trans	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.53	-0.32	1.1e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.3	-7.82	-0.3	2.22e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg11814155	chr7:99998594	ZCWPW1	0.46	8.22	0.31	1.16e-15	Platelet count;
BRCA	cis	rs778371	0.723	rs12999865	chr2:233627250	T/C	cg08000102	chr2:233561755	GIGYF2	0.85	21.14	0.64	1.29e-75	Schizophrenia;
BRCA	cis	rs2777491	0.507	rs34040639	chr15:41760807	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.07	-26.66	-0.73	7.94e-106	Ulcerative colitis;
BRCA	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg04450456	chr4:17643702	FAM184B	-0.38	-10.19	-0.37	1.06e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg17724175	chr1:150552817	MCL1	0.25	7.91	0.3	1.15e-14	Melanoma;
BRCA	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg00677455	chr12:58241039	CTDSP2	0.46	11.08	0.4	3.16e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	trans	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg13010199	chr12:38710504	ALG10B	0.4	8.09	0.3	3.05e-15	Morning vs. evening chronotype;
BRCA	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg01017244	chr2:74357527	NA	0.57	13.33	0.47	6.22e-36	Gestational age at birth (maternal effect);
BRCA	cis	rs490234	0.702	rs12553311	chr9:128398996	T/C	cg14078157	chr9:128172775	NA	-0.48	-10.77	-0.39	5.52e-25	Mean arterial pressure;
BRCA	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-10.42	-0.38	1.33e-23	Personality dimensions;
BRCA	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg03146154	chr1:46216737	IPP	0.52	11.5	0.41	6.16e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg05347473	chr6:146136440	FBXO30	-0.41	-7.98	-0.3	7.05e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg13902645	chr11:5959945	NA	-0.57	-11.54	-0.42	4e-28	DNA methylation (variation);
BRCA	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg18230493	chr5:56204884	C5orf35	-0.72	-14.12	-0.49	1.41e-39	Initial pursuit acceleration;
BRCA	cis	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg08807101	chr21:30365312	RNF160	-0.47	-7.97	-0.3	7.37e-15	Cognitive test performance;
BRCA	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18876405	chr7:65276391	NA	0.52	11.65	0.42	1.43e-28	Aortic root size;
BRCA	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg23711669	chr6:146136114	FBXO30	0.77	17.6	0.57	8.16e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg24531977	chr5:56204891	C5orf35	-0.45	-9.33	-0.35	1.76e-19	Breast cancer;Breast cancer (early onset);
BRCA	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg20290983	chr6:43655470	MRPS18A	1.1	40.85	0.85	2.49e-180	IgG glycosylation;
BRCA	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg17691542	chr6:26056736	HIST1H1C	0.49	9.86	0.36	1.87e-21	Height;
BRCA	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg07817648	chr10:79422355	NA	-0.71	-13.18	-0.46	2.81e-35	Bone mineral density;
BRCA	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.06	-0.34	1.53e-18	Total body bone mineral density;
BRCA	cis	rs6709815	0.902	rs13020432	chr2:219668211	C/T	cg02176678	chr2:219576539	TTLL4	-0.36	-9.59	-0.35	1.92e-20	Reticulocyte count;High light scatter reticulocyte count;
BRCA	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg00321850	chr1:175162397	KIAA0040	0.39	10.96	0.4	9.67e-26	Alcohol dependence;
BRCA	cis	rs7617773	0.817	rs3937	chr3:48312402	T/C	cg11946769	chr3:48343235	NME6	0.62	13.44	0.47	1.95e-36	Coronary artery disease;
BRCA	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.77	-0.42	4.23e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg22906224	chr7:99728672	NA	0.43	8.38	0.31	3.49e-16	Coronary artery disease;
BRCA	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg13047869	chr3:10149882	C3orf24	0.57	10.42	0.38	1.43e-23	Alzheimer's disease;
BRCA	cis	rs6684514	1.000	rs12132794	chr1:156281020	C/G	cg16558208	chr1:156270281	VHLL	-0.36	-8.29	-0.31	6.83e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg17143192	chr8:8559678	CLDN23	0.57	11.08	0.4	3.3e-26	Obesity-related traits;
BRCA	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.6	0.39	2.82e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	8.49	0.32	1.49e-16	Platelet count;
BRCA	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg02743256	chr7:2109353	MAD1L1	-0.45	-7.85	-0.3	1.78e-14	Bipolar disorder;
BRCA	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.59	-14.27	-0.49	2.55e-40	Longevity;Endometriosis;
BRCA	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.29	0.31	6.45e-16	Parkinson's disease;
BRCA	cis	rs7809950	1.000	rs2712214	chr7:107188031	G/A	cg23024343	chr7:107201750	COG5	-0.4	-9.3	-0.35	2.14e-19	Coronary artery disease;
BRCA	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg07080220	chr10:102295463	HIF1AN	0.44	9.8	0.36	3.27e-21	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs208520	0.609	rs208436	chr6:66897470	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.59	-11.31	-0.41	3.7e-27	Exhaled nitric oxide output;
BRCA	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.56	-9.55	-0.35	2.62e-20	Schizophrenia;
BRCA	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.44	-8.47	-0.32	1.72e-16	Iron status biomarkers;
BRCA	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg11764359	chr7:65958608	NA	0.58	12.77	0.45	1.92e-33	Aortic root size;
BRCA	cis	rs2806561	0.929	rs2867315	chr1:23541286	C/T	cg19743168	chr1:23544995	NA	-0.47	-11.84	-0.42	2.19e-29	Height;
BRCA	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg15839431	chr19:19639596	YJEFN3	-0.39	-8.48	-0.32	1.5e-16	Bipolar disorder;
BRCA	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg11752832	chr7:134001865	SLC35B4	0.52	13.41	0.47	2.76e-36	Mean platelet volume;
BRCA	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03264133	chr6:25882463	NA	-0.53	-11.13	-0.4	1.93e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11644478	chr21:40555479	PSMG1	-0.52	-10.93	-0.4	1.36e-25	Menarche (age at onset);
BRCA	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.4	-0.41	1.62e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-9.71	-0.36	6.8e-21	Tonsillectomy;
BRCA	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg17507749	chr15:85114479	UBE2QP1	-0.58	-10.76	-0.39	6.41e-25	Schizophrenia;
BRCA	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg04989706	chr14:50066350	PPIL5	-0.47	-9.18	-0.34	5.93e-19	Carotid intima media thickness;
BRCA	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg18761221	chr20:60518478	NA	0.35	8.7	0.33	2.7e-17	Obesity-related traits;
BRCA	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg09184832	chr6:79620586	NA	-0.52	-11.52	-0.41	5.03e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg18252515	chr7:66147081	NA	-1.05	-15.27	-0.52	4.18e-45	Diabetic kidney disease;
BRCA	cis	rs11030122	0.702	rs10835399	chr11:3989182	G/A	cg18678763	chr11:4115507	RRM1	-0.35	-7.91	-0.3	1.1e-14	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs4953318	0.619	rs35744969	chr2:46353140	C/A	cg12428440	chr2:46370979	PRKCE	0.47	10.0	0.37	5.68e-22	Red blood cell count;Hematocrit;Red blood cell traits;
BRCA	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg05623727	chr3:50126028	RBM5	0.42	10.02	0.37	4.59e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs4285028	0.948	rs35415993	chr3:121669236	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.8	-0.39	4.4e-25	Multiple sclerosis;
BRCA	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg13047869	chr3:10149882	C3orf24	0.52	10.84	0.39	2.92e-25	Alzheimer's disease;
BRCA	cis	rs13046373	0.535	rs2832966	chr21:32017177	A/G	cg16431978	chr21:31797932	KRTAP13-3	0.35	9.01	0.34	2.4e-18	HDL cholesterol;
BRCA	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	11.66	0.42	1.28e-28	Mean platelet volume;
BRCA	cis	rs698833	0.962	rs1067386	chr2:44644257	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	9.69	0.36	8.6e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs62380364	0.602	rs591228	chr5:88064809	G/A	cg22951263	chr5:87985283	NA	-0.37	-10.35	-0.38	2.7e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg07741184	chr6:167504864	NA	0.36	10.44	0.38	1.19e-23	Crohn's disease;
BRCA	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg09877947	chr5:131593287	PDLIM4	0.34	8.43	0.32	2.29e-16	Blood metabolite levels;
BRCA	cis	rs17023223	0.537	rs4508058	chr1:119684250	T/C	cg05756136	chr1:119680316	WARS2	-0.41	-7.81	-0.3	2.31e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.67	-0.32	3.47e-17	Total body bone mineral density;
BRCA	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg22920501	chr2:26401640	FAM59B	-0.67	-11.5	-0.41	5.96e-28	Gut microbiome composition (summer);
BRCA	cis	rs4660306	0.961	rs12082256	chr1:45951380	A/G	cg24296786	chr1:45957014	TESK2	0.42	8.41	0.32	2.77e-16	Homocysteine levels;
BRCA	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.39	-7.98	-0.3	6.69e-15	Body mass index;
BRCA	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs4629180	1.000	rs4629180	chr2:102088370	G/A	cg04415270	chr2:102091202	RFX8	-0.33	-8.32	-0.31	5.14e-16	Chronic rhinosinusitis with nasal polyps;
BRCA	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg05775895	chr3:12838266	CAND2	0.36	8.03	0.3	4.82e-15	QRS complex (12-leadsum);
BRCA	cis	rs6429082	0.510	rs2789367	chr1:235506918	G/C	cg26050004	chr1:235667680	B3GALNT2	0.33	7.99	0.3	6.1e-15	Adiposity;
BRCA	cis	rs7246657	0.712	rs4803263	chr19:38066782	G/A	cg23950597	chr19:37808831	NA	-0.5	-8.64	-0.32	4.63e-17	Coronary artery calcification;
BRCA	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.61	0.32	5.85e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg03213289	chr20:61660250	NA	0.61	16.17	0.54	1.49e-49	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg24596788	chr1:163392923	NA	0.39	10.45	0.38	1.07e-23	Motion sickness;
BRCA	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18404041	chr3:52824283	ITIH1	-0.43	-12.74	-0.45	2.68e-33	Bipolar disorder;
BRCA	cis	rs829883	1.000	rs1347956	chr12:98889564	A/G	cg25150519	chr12:98850993	NA	0.59	12.03	0.43	3.29e-30	Colorectal adenoma (advanced);
BRCA	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.05	-34.79	-0.81	1.34e-149	Myeloid white cell count;
BRCA	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg08514558	chr10:81106712	PPIF	0.36	8.71	0.33	2.56e-17	Height;
BRCA	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.39	-10.16	-0.37	1.39e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg01874867	chr7:94954059	PON1	-0.39	-8.02	-0.3	4.93e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg26043149	chr18:55253948	FECH	0.41	8.72	0.33	2.33e-17	Bone mineral density;
BRCA	trans	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	8.92e-15	Corneal astigmatism;
BRCA	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg22920501	chr2:26401640	FAM59B	-0.91	-16.27	-0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg04362960	chr10:104952993	NT5C2	0.48	10.54	0.38	4.79e-24	Arsenic metabolism;
BRCA	cis	rs4423214	0.592	rs3829251	chr11:71194559	G/A	cg05163923	chr11:71159392	DHCR7	-0.46	-8.05	-0.3	3.94e-15	Vitamin D levels;
BRCA	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg22713356	chr15:30763199	NA	1.3	24.11	0.69	7.71e-92	Uric acid levels;
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.52	-11.95	-0.43	7.75e-30	Longevity;Endometriosis;
BRCA	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs897984	0.609	rs1108431	chr16:31054607	C/T	cg02466173	chr16:30829666	NA	-0.45	-9.98	-0.37	6.54e-22	Dementia with Lewy bodies;
BRCA	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg09658497	chr7:2847517	GNA12	-0.41	-8.69	-0.33	3.03e-17	Height;
BRCA	cis	rs7395581	0.879	rs3758673	chr11:47278917	C/T	cg25783544	chr11:47291846	MADD	0.43	9.49	0.35	4.43e-20	HDL cholesterol;
BRCA	cis	rs2282802	0.685	rs6869910	chr5:139629450	T/C	cg26211634	chr5:139558579	C5orf32	0.35	8.19	0.31	1.47e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs654351	0.543	rs622388	chr6:10387117	T/G	cg17959970	chr6:10383164	NA	-0.42	-8.71	-0.33	2.5e-17	Squamous cell lung carcinoma;
BRCA	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.25	-0.38	6.45e-23	Bladder cancer;
BRCA	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.95	0.37	8.62e-22	Bipolar disorder;
BRCA	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11644478	chr21:40555479	PSMG1	0.73	14.51	0.5	1.99e-41	Cognitive function;
BRCA	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg24558204	chr6:135376177	HBS1L	0.46	12.62	0.45	8.89e-33	Red blood cell count;
BRCA	cis	rs72848980	0.512	rs56033495	chr10:105383611	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.43	8.45	0.32	2.01e-16	White matter hyperintensity burden;
BRCA	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg08754478	chr10:133766260	PPP2R2D	0.68	14.55	0.5	1.19e-41	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	22.44	0.66	1.12e-82	Platelet count;
BRCA	cis	rs752010	0.902	rs60743712	chr1:42076629	G/A	cg06885757	chr1:42089581	HIVEP3	0.25	8.92	0.33	4.86e-18	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg18279126	chr7:2041391	MAD1L1	0.38	8.26	0.31	8.52e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.93	-0.3	9.57e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs11051970	0.879	rs2728682	chr12:32580193	G/A	cg24626660	chr12:32551988	NA	0.28	7.97	0.3	7.27e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs9300255	0.679	rs58809476	chr12:123724880	C/T	cg00376283	chr12:123451042	ABCB9	-0.49	-10.17	-0.37	1.31e-22	Neutrophil percentage of white cells;
BRCA	trans	rs7980799	0.905	rs4244866	chr12:33511983	G/C	cg26384229	chr12:38710491	ALG10B	-0.39	-8.14	-0.31	2.04e-15	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs9790314	0.663	rs1599379	chr3:160860665	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-13.14	-0.46	4.25e-35	Morning vs. evening chronotype;
BRCA	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg04267008	chr7:1944627	MAD1L1	-0.52	-10.73	-0.39	7.91e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs4561483	0.801	rs33649	chr16:11979608	G/C	cg08843971	chr16:11963173	GSPT1	-0.53	-12.06	-0.43	2.59e-30	Testicular germ cell tumor;
BRCA	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg22980127	chr19:33182716	NUDT19	0.9	20.58	0.63	1.44e-72	Red blood cell traits;
BRCA	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	13.04	0.46	1.24e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg11814155	chr7:99998594	ZCWPW1	0.49	8.85	0.33	8.6e-18	Platelet count;
BRCA	cis	rs4908768	0.501	rs6577488	chr1:8534529	T/C	cg20416874	chr1:8611966	RERE	-0.29	-8.31	-0.31	5.55e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03517284	chr6:25882590	NA	-0.71	-16.41	-0.54	9.6e-51	Blood metabolite levels;
BRCA	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg11764359	chr7:65958608	NA	-0.63	-11.19	-0.4	1.18e-26	Aortic root size;
BRCA	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18876405	chr7:65276391	NA	-0.56	-13.45	-0.47	1.65e-36	Aortic root size;
BRCA	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	21.43	0.65	3.48e-77	Platelet count;
BRCA	trans	rs1997103	1.000	rs4590393	chr7:55408990	C/T	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg21573476	chr21:45109991	RRP1B	-0.32	-8.42	-0.32	2.53e-16	Mean corpuscular volume;
BRCA	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg17971929	chr21:40555470	PSMG1	0.72	15.84	0.53	6.82e-48	Cognitive function;
BRCA	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg05665937	chr4:1216051	CTBP1	0.37	7.9	0.3	1.25e-14	Obesity-related traits;
BRCA	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg11833968	chr6:79620685	NA	-0.44	-9.67	-0.36	1.01e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg24044776	chr19:53454761	ZNF816A	-0.35	-7.86	-0.3	1.61e-14	Psoriasis;
BRCA	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-11.34	-0.41	2.72e-27	Mean corpuscular volume;
BRCA	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg11502198	chr6:26597334	ABT1	0.49	9.73	0.36	5.8e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.13	0.37	1.8e-22	Mean corpuscular volume;
BRCA	cis	rs9296092	0.522	rs62405955	chr6:33527176	T/C	cg13560919	chr6:33536144	NA	-0.85	-18.69	-0.59	1.6e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs10754283	0.901	rs10922684	chr1:90117934	T/C	cg21401794	chr1:90099060	LRRC8C	0.48	11.79	0.42	3.56e-29	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18876405	chr7:65276391	NA	-0.5	-11.07	-0.4	3.5e-26	Aortic root size;
BRCA	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	7.93e-19	Lymphocyte counts;
BRCA	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg18252515	chr7:66147081	NA	-0.88	-12.62	-0.45	9.18e-33	Diabetic kidney disease;
BRCA	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg08885076	chr2:99613938	TSGA10	0.42	9.8	0.36	3.11e-21	Chronic sinus infection;
BRCA	cis	rs4812048	1.000	rs6070697	chr20:57599402	G/A	cg14073986	chr20:57617431	SLMO2	0.49	7.91	0.3	1.13e-14	Mean platelet volume;
BRCA	cis	rs36051895	0.664	rs10115518	chr9:5094559	T/C	cg02405213	chr9:5042618	JAK2	-0.5	-8.97	-0.33	3.16e-18	Pediatric autoimmune diseases;
BRCA	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.71	0.39	9.9e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg05340658	chr4:99064831	C4orf37	0.57	11.18	0.4	1.25e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.57	-10.5	-0.38	6.94e-24	Renal function-related traits (BUN);
BRCA	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg13319975	chr6:146136371	FBXO30	-0.61	-13.49	-0.47	1.13e-36	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17228212	1.000	rs17228212	chr15:67458639	A/G	cg26876701	chr15:67458665	SMAD3	-0.47	-9.42	-0.35	8.33e-20	Coronary heart disease;
BRCA	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.74	-0.36	5.32e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg20673091	chr1:2541236	MMEL1	0.32	8.41	0.32	2.64e-16	Ulcerative colitis;
BRCA	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-10.25	-0.38	6.17e-23	Heart rate;
BRCA	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.82	0.36	2.79e-21	Bipolar disorder;
BRCA	cis	rs1712517	0.844	rs1163081	chr10:105029840	G/C	cg05636881	chr10:105038444	INA	0.36	8.17	0.31	1.68e-15	Migraine;
BRCA	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.11	-0.34	1.06e-18	Bipolar disorder;
BRCA	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	11.78	0.42	4.18e-29	Personality dimensions;
BRCA	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24229701	chr12:130821962	PIWIL1	0.39	8.89	0.33	6.08e-18	Menopause (age at onset);
BRCA	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg11887960	chr12:57824829	NA	0.55	8.55	0.32	9.38e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7246657	0.653	rs10402050	chr19:37688958	A/T	cg23950597	chr19:37808831	NA	-0.66	-10.13	-0.37	1.89e-22	Coronary artery calcification;
BRCA	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg05347473	chr6:146136440	FBXO30	-0.4	-7.84	-0.3	1.83e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.4	8.39	0.31	3.14e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs730566	1.000	rs4858819	chr3:48478088	C/T	cg07636037	chr3:49044803	WDR6	-0.54	-10.22	-0.37	8.24e-23	Prion diseases;
BRCA	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg01256987	chr12:42539512	GXYLT1	-0.46	-9.16	-0.34	6.77e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg05234568	chr11:5960015	NA	-0.48	-9.35	-0.35	1.49e-19	DNA methylation (variation);
BRCA	cis	rs12200560	0.505	rs2387378	chr6:97077504	C/A	cg06623918	chr6:96969491	KIAA0776	0.53	12.7	0.45	4.04e-33	Coronary heart disease;
BRCA	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg25767906	chr1:53392781	SCP2	-0.38	-8.46	-0.32	1.87e-16	Monocyte count;
BRCA	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-16.69	-0.55	3.76e-52	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	8.24	0.31	9.64e-16	Schizophrenia;
BRCA	cis	rs9287719	0.649	rs9973374	chr2:10716384	C/T	cg00105475	chr2:10696890	NA	0.41	9.15	0.34	7.77e-19	Prostate cancer;
BRCA	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg03146154	chr1:46216737	IPP	0.45	10.06	0.37	3.5e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs35740288	0.539	rs11634553	chr15:86336611	G/A	cg20737812	chr15:86336631	KLHL25	-0.4	-9.88	-0.36	1.63e-21	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg20283391	chr11:68216788	NA	-0.48	-9.32	-0.35	1.88e-19	Total body bone mineral density;
BRCA	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg18230493	chr5:56204884	C5orf35	-0.43	-8.75	-0.33	1.84e-17	Coronary artery disease;
BRCA	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg26608667	chr7:1196370	ZFAND2A	0.42	10.29	0.38	4.23e-23	Longevity;Endometriosis;
BRCA	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg18230493	chr5:56204884	C5orf35	0.59	12.19	0.43	7.16e-31	Initial pursuit acceleration;
BRCA	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg18252515	chr7:66147081	NA	-1.05	-14.82	-0.51	6.25e-43	Diabetic kidney disease;
BRCA	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg06238570	chr21:40685208	BRWD1	-0.45	-8.93	-0.33	4.63e-18	Cognitive function;
BRCA	trans	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	27.48	0.74	2.41e-110	Exhaled nitric oxide output;
BRCA	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg17366294	chr4:99064904	C4orf37	0.45	10.77	0.39	5.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4742903	0.935	rs17237053	chr9:106946359	C/T	cg14250997	chr9:106856677	SMC2	-0.3	-9.18	-0.34	5.7e-19	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs7833986	1.000	rs34404111	chr8:57099190	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.46	8.27	0.31	8.08e-16	Height;
BRCA	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg04166393	chr7:2884313	GNA12	0.57	12.23	0.44	4.82e-31	Height;
BRCA	cis	rs6942756	1.000	rs6949950	chr7:128914818	G/A	cg02491457	chr7:128862824	NA	-0.7	-13.73	-0.48	8.68e-38	White matter hyperintensity burden;
BRCA	cis	rs13033859	0.526	rs12477065	chr2:292753	C/T	cg12623918	chr2:306882	NA	0.38	8.43	0.32	2.22e-16	Mitochondrial DNA levels;
BRCA	cis	rs16854884	0.837	rs4362712	chr3:143801076	G/A	cg06585982	chr3:143692056	C3orf58	0.4	7.98	0.3	6.7e-15	Economic and political preferences (feminism/equality);
BRCA	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg05234568	chr11:5960015	NA	-0.49	-9.72	-0.36	6.44e-21	DNA methylation (variation);
BRCA	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	9.05	0.34	1.66e-18	Platelet count;
BRCA	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-10.82	-0.39	3.48e-25	IgG glycosylation;
BRCA	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.58	0.39	3.22e-24	IgG glycosylation;
BRCA	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.03	-0.54	7.33e-49	Alzheimer's disease (late onset);
BRCA	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg05665937	chr4:1216051	CTBP1	0.38	7.9	0.3	1.22e-14	Obesity-related traits;
BRCA	cis	rs7766436	0.848	rs6903685	chr6:22605813	C/T	cg13666174	chr6:22585274	NA	-0.42	-9.09	-0.34	1.2e-18	Coronary artery disease;
BRCA	cis	rs6714710	0.603	rs17489454	chr2:98407350	C/T	cg26665480	chr2:98280029	ACTR1B	0.57	13.15	0.46	3.98e-35	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg12311346	chr5:56204834	C5orf35	-0.78	-14.9	-0.51	2.57e-43	Initial pursuit acceleration;
BRCA	trans	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.39	-8.48	-0.32	1.52e-16	Mean corpuscular volume;
BRCA	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg14863265	chr7:2801509	GNA12	-0.39	-8.66	-0.32	3.87e-17	Height;
BRCA	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs887829	0.570	rs7608175	chr2:234599089	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.34	8.53	0.32	1.09e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	trans	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg21659725	chr3:3221576	CRBN	-0.45	-9.78	-0.36	3.79e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.98	0.37	6.83e-22	Bladder cancer;
BRCA	cis	rs7523273	0.606	rs1830764	chr1:207917052	G/A	cg22525895	chr1:207977042	MIR29B2	0.47	12.1	0.43	1.7e-30	Schizophrenia;
BRCA	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg16482183	chr6:26056742	HIST1H1C	0.54	11.43	0.41	1.17e-27	Height;
BRCA	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg06064525	chr11:970664	AP2A2	-0.47	-15.55	-0.52	1.73e-46	Alzheimer's disease (late onset);
BRCA	trans	rs783540	0.867	rs11855735	chr15:83296545	A/T	cg18393722	chr15:85113863	UBE2QP1	0.28	8.87	0.33	7.07e-18	Schizophrenia;
BRCA	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25427524	chr10:38739819	LOC399744	-0.7	-16.92	-0.56	2.46e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1420338	0.967	rs1014581	chr7:34164677	T/G	cg01275685	chr7:34179230	BMPER	-0.46	-10.25	-0.38	6.33e-23	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs10193935	0.901	rs62142561	chr2:42477808	G/C	cg27598129	chr2:42591480	NA	-0.95	-14.83	-0.51	5.82e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17641971	0.684	rs7005693	chr8:49987965	A/C	cg00325661	chr8:49890786	NA	0.38	10.73	0.39	8.31e-25	Blood metabolite levels;
BRCA	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg20203395	chr5:56204925	C5orf35	0.42	9.37	0.35	1.26e-19	Initial pursuit acceleration;
BRCA	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg04727924	chr7:799746	HEATR2	-0.55	-10.81	-0.39	3.81e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs829880	1.000	rs829880	chr12:98845331	G/T	cg25150519	chr12:98850993	NA	0.63	14.01	0.48	4.42e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg24060327	chr5:131705240	SLC22A5	0.41	8.08	0.3	3.27e-15	Blood metabolite levels;
BRCA	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg23711669	chr6:146136114	FBXO30	0.71	16.42	0.54	8.37e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	8.97	0.33	3.36e-18	Personality dimensions;
BRCA	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24110177	chr3:50126178	RBM5	0.37	10.12	0.37	1.97e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.89	-0.33	6.32e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg26384229	chr12:38710491	ALG10B	0.76	16.95	0.56	1.8e-53	Bladder cancer;
BRCA	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg00701064	chr4:6280414	WFS1	0.7	18.05	0.58	3.57e-59	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26314531	chr2:26401878	FAM59B	-0.64	-10.91	-0.4	1.59e-25	Gut microbiome composition (summer);
BRCA	cis	rs36051895	0.664	rs3780370	chr9:5095167	A/C	cg02405213	chr9:5042618	JAK2	-0.51	-9.23	-0.34	4.03e-19	Pediatric autoimmune diseases;
BRCA	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg18016565	chr1:150552671	MCL1	-0.35	-8.19	-0.31	1.41e-15	Melanoma;
BRCA	cis	rs9341808	0.718	rs9448898	chr6:80845341	T/A	cg08355045	chr6:80787529	NA	0.37	9.44	0.35	6.76e-20	Sitting height ratio;
BRCA	trans	rs17685	0.849	rs3815455	chr7:75611756	C/T	cg19862616	chr7:65841803	NCRNA00174	0.56	14.11	0.49	1.53e-39	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs73086581	1.000	rs6052220	chr20:3970594	C/T	cg02187196	chr20:3869020	PANK2	0.51	9.69	0.36	8.4e-21	Response to antidepressants in depression;
BRCA	cis	rs758324	0.947	rs253943	chr5:131320730	C/T	cg06307176	chr5:131281290	NA	0.52	10.5	0.38	6.5e-24	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	11.04	0.4	4.6e-26	Platelet count;
BRCA	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg23711669	chr6:146136114	FBXO30	-0.79	-18.87	-0.6	1.77e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg08997352	chr12:9597637	DDX12	-0.56	-11.25	-0.41	6.44e-27	Breast size;
BRCA	cis	rs17253792	0.822	rs10142497	chr14:56047948	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	-0.59	-8.32	-0.31	5.42e-16	Putamen volume;
BRCA	cis	rs17401966	0.540	rs1536262	chr1:10438687	C/T	cg03954927	chr1:10346856	KIF1B	0.34	10.19	0.37	1.09e-22	Hepatocellular carcinoma;
BRCA	cis	rs6977660	0.505	rs9639338	chr7:19869778	T/A	cg07541023	chr7:19748670	TWISTNB	0.47	8.52	0.32	1.11e-16	Thyroid stimulating hormone;
BRCA	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg07636037	chr3:49044803	WDR6	-0.5	-8.3	-0.31	6.25e-16	Menarche (age at onset);
BRCA	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg20933634	chr6:27740509	NA	-0.44	-8.17	-0.31	1.7e-15	Parkinson's disease;
BRCA	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-9.4	-0.35	9.62e-20	Retinal vascular caliber;
BRCA	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg15934090	chr1:100435551	SLC35A3	0.35	7.91	0.3	1.11e-14	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg13175981	chr1:150552382	MCL1	0.41	9.02	0.34	2.14e-18	Tonsillectomy;
BRCA	cis	rs9341808	0.718	rs9359408	chr6:80820132	T/G	cg08355045	chr6:80787529	NA	0.37	9.38	0.35	1.13e-19	Sitting height ratio;
BRCA	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg01849466	chr14:104193079	ZFYVE21	0.43	11.0	0.4	6.62e-26	Schizophrenia;
BRCA	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.96	13.48	0.47	1.21e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9316337	0.902	rs12430301	chr13:21970729	C/T	cg21011702	chr13:21951294	ZDHHC20	-0.31	-8.01	-0.3	5.44e-15	Schizophrenia;
BRCA	cis	rs3820928	0.874	rs10195072	chr2:227794452	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-8.96	-0.33	3.4e-18	Pulmonary function;
BRCA	cis	rs7809950	0.530	rs111865019	chr7:106812246	A/G	cg23024343	chr7:107201750	COG5	-0.42	-8.36	-0.31	4.07e-16	Coronary artery disease;
BRCA	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.27	-7.89	-0.3	1.3e-14	Personality dimensions;
BRCA	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.52	-0.44	2.59e-32	Type 2 diabetes;
BRCA	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg16325326	chr1:53192061	ZYG11B	0.9	24.9	0.7	3.35e-96	Monocyte count;
BRCA	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg22117172	chr7:91764530	CYP51A1	0.24	8.22	0.31	1.13e-15	Breast cancer;
BRCA	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg14664628	chr15:75095509	CSK	-0.52	-12.37	-0.44	1.2e-31	Breast cancer;
BRCA	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg05340658	chr4:99064831	C4orf37	0.63	15.15	0.51	1.51e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.29	-0.38	4.53e-23	Morning vs. evening chronotype;
BRCA	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.48	-0.41	7.18e-28	Platelet count;
BRCA	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.4	-0.32	2.96e-16	Monocyte percentage of white cells;
BRCA	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-11.44	-0.41	1.07e-27	Neuroticism;
BRCA	cis	rs367943	0.637	rs10039956	chr5:113010928	G/A	cg12552261	chr5:112820674	MCC	0.39	8.11	0.31	2.53e-15	Type 2 diabetes;
BRCA	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg16586182	chr3:47516702	SCAP	0.65	15.12	0.51	2.23e-44	Colorectal cancer;
BRCA	cis	rs8016982	0.698	rs8011097	chr14:81702736	T/C	cg01989461	chr14:81687754	GTF2A1	0.61	14.29	0.49	2.22e-40	Schizophrenia;
BRCA	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg00012203	chr2:219082015	ARPC2	-0.72	-16.39	-0.54	1.19e-50	Colorectal cancer;
BRCA	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg06191203	chr2:152266755	RIF1	-0.35	-10.13	-0.37	1.8e-22	Squamous cell lung carcinoma;
BRCA	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.06	-0.56	4.9e-54	Intelligence (multi-trait analysis);
BRCA	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.27	0.38	5.16e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs68170813	0.559	rs3779498	chr7:106923158	C/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.57	-0.32	7.9e-17	Coronary artery disease;
BRCA	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg21138405	chr5:131827807	IRF1	-0.38	-12.61	-0.45	1.03e-32	Asthma (sex interaction);
BRCA	cis	rs3760982	0.585	rs11083724	chr19:44298988	A/G	cg12072164	chr19:44306565	LYPD5	0.37	8.71	0.33	2.57e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs7394190	0.748	rs3843939	chr10:75578948	T/C	cg07699608	chr10:75541558	CHCHD1	0.68	9.91	0.36	1.24e-21	Incident atrial fibrillation;
BRCA	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg08470875	chr2:26401718	FAM59B	0.76	11.85	0.42	2.09e-29	Gut microbiome composition (summer);
BRCA	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg06552810	chr11:31128660	NA	-0.38	-8.86	-0.33	8.13e-18	Red blood cell count;
BRCA	cis	rs6429082	0.633	rs1416473	chr1:235563259	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.54	-12.3	-0.44	2.42e-31	Adiposity;
BRCA	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.62	-13.37	-0.47	3.83e-36	Lymphocyte counts;
BRCA	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg12698349	chr2:225449008	CUL3	0.61	13.03	0.46	1.44e-34	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg15133208	chr4:90757351	SNCA	-0.39	-7.9	-0.3	1.21e-14	Neuroticism;
BRCA	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg00086871	chr4:6988644	TBC1D14	0.77	11.86	0.42	1.9e-29	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg21427119	chr20:30132790	HM13	-0.41	-8.58	-0.32	7.24e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg05868516	chr6:26286170	HIST1H4H	0.41	8.07	0.3	3.49e-15	Educational attainment;
BRCA	cis	rs10129255	0.556	rs6576222	chr14:107184681	G/A	cg07958169	chr14:107095056	NA	-0.39	-8.41	-0.32	2.66e-16	Kawasaki disease;
BRCA	cis	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg20368463	chr18:77673604	PQLC1	-0.51	-12.75	-0.45	2.41e-33	Schizophrenia;
BRCA	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg14675211	chr2:100938903	LONRF2	0.52	11.82	0.42	2.63e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.51	10.65	0.39	1.78e-24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs3767633	0.925	rs10737502	chr1:161792321	G/A	cg09175582	chr1:161736000	ATF6	0.52	8.73	0.33	2.19e-17	IgG glycosylation;
BRCA	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	13.79	0.48	4.73e-38	Lymphocyte counts;
BRCA	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg22535103	chr8:58192502	C8orf71	-0.46	-9.06	-0.34	1.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg11843238	chr5:131593191	PDLIM4	0.38	9.3	0.35	2.17e-19	Acylcarnitine levels;
BRCA	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg05340658	chr4:99064831	C4orf37	0.7	17.43	0.57	5.62e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg13256891	chr4:100009986	ADH5	0.48	8.83	0.33	1.01e-17	Alcohol dependence;
BRCA	cis	rs10463316	0.817	rs6879238	chr5:150820574	G/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.63	-0.32	5e-17	Metabolite levels (Pyroglutamine);
BRCA	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg13319975	chr6:146136371	FBXO30	0.34	7.86	0.3	1.67e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg13319975	chr6:146136371	FBXO30	-0.41	-9.29	-0.34	2.39e-19	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg04842962	chr6:43655489	MRPS18A	0.87	23.31	0.68	1.89e-87	IgG glycosylation;
BRCA	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg09307838	chr4:120376055	NA	-0.62	-13.07	-0.46	8.81e-35	Corneal astigmatism;
BRCA	cis	rs73001065	0.591	rs2285626	chr19:19467545	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	13.58	0.47	4.3e-37	LDL cholesterol;
BRCA	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	20.1	0.62	5.13e-70	Mean corpuscular hemoglobin;
BRCA	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg20908204	chr19:46285434	DMPK	-0.27	-7.99	-0.3	6.54e-15	Coronary artery disease;
BRCA	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg19743168	chr1:23544995	NA	0.35	8.26	0.31	8.24e-16	Height;
BRCA	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg04362960	chr10:104952993	NT5C2	0.45	10.35	0.38	2.67e-23	Arsenic metabolism;
BRCA	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.07	-0.3	3.46e-15	Prostate cancer;
BRCA	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg18305652	chr10:134549665	INPP5A	0.51	13.36	0.47	4.37e-36	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg19773385	chr1:10388646	KIF1B	-0.39	-8.51	-0.32	1.19e-16	Hepatocellular carcinoma;
BRCA	cis	rs672059	1.000	rs672119	chr1:183162506	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.38	8.67	0.32	3.46e-17	Hypertriglyceridemia;
BRCA	cis	rs3768617	0.706	rs8179460	chr1:183056222	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.49	11.32	0.41	3.29e-27	Fuchs's corneal dystrophy;
BRCA	trans	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg26043149	chr18:55253948	FECH	0.36	7.86	0.3	1.65e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg23285459	chr7:2802560	GNA12	-0.32	-8.44	-0.32	2.08e-16	Height;
BRCA	trans	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.35	0.31	4.21e-16	Corneal astigmatism;
BRCA	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.59	-12.34	-0.44	1.56e-31	Lymphocyte counts;
BRCA	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18876405	chr7:65276391	NA	0.55	13.18	0.46	3.03e-35	Aortic root size;
BRCA	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg08805041	chr16:621841	PIGQ	-0.32	-8.82	-0.33	1.11e-17	Height;
BRCA	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg15083037	chr5:83017644	HAPLN1	-0.53	-10.72	-0.39	9.1e-25	Prostate cancer;
BRCA	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg04414720	chr1:150670196	GOLPH3L	0.36	8.07	0.3	3.38e-15	Tonsillectomy;
BRCA	cis	rs7020830	0.898	rs7846747	chr9:37167539	A/C	cg14294708	chr9:37120828	ZCCHC7	1.16	39.52	0.84	9.82e-174	Schizophrenia;
BRCA	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.4	-11.44	-0.41	1.08e-27	Monocyte percentage of white cells;
BRCA	cis	rs897080	0.515	rs1065784	chr2:44660777	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	8.09	0.3	2.93e-15	Height;
BRCA	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg06671706	chr8:8559999	CLDN23	0.43	8.38	0.31	3.48e-16	Obesity-related traits;
BRCA	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12923728	chr3:195709715	SDHAP1	-0.58	-12.42	-0.44	7.35e-32	Pancreatic cancer;
BRCA	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg12935359	chr14:103987150	CKB	0.64	15.01	0.51	7.3e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg13628971	chr7:2884303	GNA12	0.4	8.82	0.33	1.06e-17	Height;
BRCA	cis	rs2731664	0.792	rs335452	chr5:176879671	C/T	cg23176889	chr5:176863531	GRK6	-0.62	-16.86	-0.55	5.01e-53	Intelligence (multi-trait analysis);
BRCA	cis	rs10267417	0.603	rs4543442	chr7:19911140	G/A	cg05791153	chr7:19748676	TWISTNB	0.47	8.98	0.33	3.07e-18	Night sleep phenotypes;
BRCA	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg22705602	chr4:152727874	NA	-0.31	-7.81	-0.3	2.29e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	14.07	0.49	2.42e-39	Lymphocyte counts;
BRCA	cis	rs752010	0.630	rs11210507	chr1:42105488	T/C	cg06885757	chr1:42089581	HIVEP3	0.23	8.36	0.31	3.94e-16	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-10.89	-0.4	1.84e-25	Bone mineral density;
BRCA	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg26597838	chr10:835615	NA	0.93	17.43	0.57	5.99e-56	Eosinophil percentage of granulocytes;
BRCA	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	8.67	0.32	3.6e-17	Tonsillectomy;
BRCA	cis	rs897080	0.589	rs1085448	chr2:44663805	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	8.4	0.32	2.9e-16	Height;
BRCA	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.48	-0.41	7.35e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg03060546	chr3:49711283	APEH	-0.5	-10.14	-0.37	1.74e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	trans	rs8002861	0.641	rs6561148	chr13:44426269	C/T	cg12856521	chr11:46389249	DGKZ	0.4	8.63	0.32	4.82e-17	Leprosy;
BRCA	cis	rs9868809	0.764	rs2633958	chr3:48635432	A/G	cg00383909	chr3:49044727	WDR6	-0.75	-9.37	-0.35	1.28e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg11502198	chr6:26597334	ABT1	0.58	12.57	0.45	1.47e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg17366294	chr4:99064904	C4orf37	0.45	10.81	0.39	3.9e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg21770322	chr7:97807741	LMTK2	0.45	11.89	0.43	1.42e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6580649	0.941	rs72644841	chr12:48411987	A/G	cg05342945	chr12:48394962	COL2A1	0.47	9.25	0.34	3.2e-19	Lung cancer;
BRCA	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg07952391	chr2:88470173	THNSL2	0.67	9.26	0.34	3.04e-19	Plasma clusterin levels;
BRCA	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg08508325	chr11:3079039	CARS	0.28	8.41	0.32	2.73e-16	Calcium levels;
BRCA	cis	rs2625529	0.526	rs8031386	chr15:72508799	C/A	cg16672083	chr15:72433130	SENP8	-0.69	-15.73	-0.53	2.21e-47	Red blood cell count;
BRCA	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg12011299	chr4:100065546	ADH4	0.53	12.95	0.46	3.03e-34	Alcohol dependence;
BRCA	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.3	-7.99	-0.3	6.12e-15	Total body bone mineral density;
BRCA	cis	rs8114671	0.647	rs1415771	chr20:33734493	G/A	cg24642439	chr20:33292090	TP53INP2	0.4	8.6	0.32	5.93e-17	Height;
BRCA	cis	rs733175	0.857	rs3796838	chr4:10011030	C/T	cg00071950	chr4:10020882	SLC2A9	0.4	7.91	0.3	1.14e-14	Psychosis and Alzheimer's disease;
BRCA	cis	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg07460842	chr6:66804631	NA	0.71	11.57	0.42	2.96e-28	Exhaled nitric oxide output;
BRCA	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	14.0	0.48	4.8e-39	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg08085267	chr17:45401833	C17orf57	-0.57	-11.12	-0.4	2.31e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg03713592	chr11:72463424	ARAP1	0.69	12.43	0.44	6.21e-32	Type 2 diabetes;
BRCA	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg20476274	chr7:133979776	SLC35B4	0.69	21.34	0.65	1.01e-76	Mean platelet volume;
BRCA	trans	rs783540	0.592	rs2567632	chr15:83284804	A/G	cg16105309	chr15:79090380	ADAMTS7	0.34	9.46	0.35	5.56e-20	Schizophrenia;
BRCA	cis	rs7639513	0.767	rs2348201	chr3:12711696	A/G	cg23032965	chr3:12705835	RAF1	0.69	15.09	0.51	3.2e-44	Itch intensity from mosquito bite;
BRCA	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.59	11.46	0.41	8.88e-28	Multiple sclerosis;
BRCA	trans	rs4650994	0.544	rs10798613	chr1:178500022	C/T	cg05059571	chr16:84539110	KIAA1609	-0.57	-12.59	-0.45	1.2e-32	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs858239	0.511	rs10256996	chr7:23145295	G/T	cg23682824	chr7:23144976	KLHL7	-0.34	-9.17	-0.34	6.41e-19	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg23762105	chr12:34175262	ALG10	0.38	9.32	0.35	1.79e-19	Morning vs. evening chronotype;
BRCA	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03517284	chr6:25882590	NA	0.48	10.73	0.39	7.9e-25	Blood metabolite levels;
BRCA	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg16506815	chr2:162101123	NA	0.51	10.97	0.4	9.04e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs1865721	0.771	rs8093397	chr18:73136217	C/G	cg26385618	chr18:73139727	C18orf62	-0.43	-10.64	-0.39	1.88e-24	Intelligence;
BRCA	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg08885076	chr2:99613938	TSGA10	0.45	10.46	0.38	9.8599999999999993e-24	Chronic sinus infection;
BRCA	cis	rs7617773	0.743	rs4632568	chr3:48367819	C/T	cg11946769	chr3:48343235	NME6	0.67	13.59	0.47	3.81e-37	Coronary artery disease;
BRCA	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-12.3	-0.44	2.33e-31	Hemoglobin concentration;
BRCA	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.3	-7.82	-0.3	2.2e-14	Total body bone mineral density;
BRCA	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg15212455	chr7:39170539	POU6F2	0.36	7.87	0.3	1.48e-14	IgG glycosylation;
BRCA	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg20607287	chr7:12443886	VWDE	-0.58	-8.24	-0.31	9.93e-16	Coronary artery disease;
BRCA	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg05868516	chr6:26286170	HIST1H4H	0.43	8.27	0.31	7.84e-16	Educational attainment;
BRCA	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.2e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg08999081	chr20:33150536	PIGU	-0.47	-12.95	-0.46	3.13e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.64	14.13	0.49	1.18e-39	Lymphocyte percentage of white cells;
BRCA	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.39	8.31	0.31	5.95e-16	Total cholesterol levels;
BRCA	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg14196790	chr5:131705035	SLC22A5	0.4	10.24	0.38	6.84e-23	Blood metabolite levels;
BRCA	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg23933602	chr10:16859644	RSU1	0.69	16.39	0.54	1.21e-50	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.52	11.32	0.41	3.26e-27	Hemoglobin concentration;
BRCA	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.34	-0.31	4.57e-16	Schizophrenia;
BRCA	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg22875332	chr1:76189707	ACADM	0.66	14.31	0.49	1.74e-40	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4660306	1.000	rs2993259	chr1:46001550	T/C	cg24296786	chr1:45957014	TESK2	0.44	8.86	0.33	8e-18	Homocysteine levels;
BRCA	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg13256891	chr4:100009986	ADH5	0.51	10.52	0.38	5.7e-24	Alcohol dependence;
BRCA	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg06238570	chr21:40685208	BRWD1	-0.41	-8.15	-0.31	1.93e-15	Menarche (age at onset);
BRCA	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-13.88	-0.48	1.75e-38	Morning vs. evening chronotype;
BRCA	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg07636037	chr3:49044803	WDR6	0.43	8.7	0.33	2.85e-17	Resting heart rate;
BRCA	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg05347473	chr6:146136440	FBXO30	-0.43	-8.76	-0.33	1.79e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg02079420	chr8:82753780	SNX16	0.36	8.09	0.3	2.91e-15	Diastolic blood pressure;
BRCA	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg24803719	chr17:45855879	NA	-0.31	-8.1	-0.31	2.77e-15	IgG glycosylation;
BRCA	cis	rs11690935	0.918	rs12692978	chr2:172725981	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.91	-28.21	-0.74	2.5e-114	Schizophrenia;
BRCA	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg05863683	chr7:1912471	MAD1L1	0.43	9.27	0.34	2.87e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-11.17	-0.4	1.37e-26	Colorectal cancer;
BRCA	cis	rs5167	0.504	rs10426750	chr19:45457684	G/C	cg20090143	chr19:45452003	APOC2	0.27	8.05	0.3	4.1e-15	Blood protein levels;
BRCA	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19346786	chr7:2764209	NA	-0.37	-11.05	-0.4	4.19e-26	Height;
BRCA	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg05025164	chr4:1340916	KIAA1530	0.42	9.38	0.35	1.17e-19	Longevity;
BRCA	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg01475735	chr3:40494733	NA	-0.48	-9.82	-0.36	2.74e-21	Renal cell carcinoma;
BRCA	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg03954927	chr1:10346856	KIF1B	0.48	14.88	0.51	3.21e-43	Hepatocellular carcinoma;
BRCA	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.52	11.64	0.42	1.49e-28	Multiple sclerosis;
BRCA	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg02176678	chr2:219576539	TTLL4	0.47	12.64	0.45	7.71e-33	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs6430585	0.527	rs60966546	chr2:136401843	C/T	cg07169764	chr2:136633963	MCM6	0.98	19.34	0.61	6.13e-66	Corneal structure;
BRCA	cis	rs490234	0.651	rs13291556	chr9:128240922	T/C	cg14078157	chr9:128172775	NA	-0.5	-11.12	-0.4	2.21e-26	Mean arterial pressure;
BRCA	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg04546413	chr19:29218101	NA	0.43	8.02	0.3	5.23e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs698833	0.538	rs1067396	chr2:44637738	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	10.4	0.38	1.7e-23	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg23625390	chr15:77176239	SCAPER	0.39	9.59	0.35	1.94e-20	Blood metabolite levels;
BRCA	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg04511125	chr2:88470314	THNSL2	-0.45	-9.2	-0.34	4.88e-19	Response to metformin (IC50);
BRCA	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.34	8.64	0.32	4.46e-17	IgG glycosylation;
BRCA	cis	rs4478858	0.647	rs7524117	chr1:31738416	A/G	cg00250761	chr1:31883323	NA	-0.31	-8.17	-0.31	1.63e-15	Alcohol dependence;
BRCA	cis	rs3741151	0.773	rs73542979	chr11:73127526	G/C	cg17517138	chr11:73019481	ARHGEF17	0.88	12.73	0.45	3.1e-33	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	trans	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-11.56	-0.42	3.36e-28	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10193935	0.786	rs72796504	chr2:42406728	T/C	cg27598129	chr2:42591480	NA	-0.87	-14.06	-0.49	2.62e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.53	-0.61	5.8e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-9.79	-0.36	3.43e-21	Joint mobility (Beighton score);
BRCA	cis	rs73001065	0.591	rs57009615	chr19:19613622	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	16.14	0.54	2.16e-49	LDL cholesterol;
BRCA	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-9.98	-0.37	7.04e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.58	-0.39	3.3e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg13319975	chr6:146136371	FBXO30	-0.35	-7.97	-0.3	7.48e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9359856	0.564	rs34766278	chr6:90397132	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.64	-8.12	-0.31	2.47e-15	Bipolar disorder;
BRCA	cis	rs2425143	0.730	rs6060624	chr20:34413663	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.1	-0.34	1.16e-18	Blood protein levels;
BRCA	trans	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg06606381	chr12:133084897	FBRSL1	0.72	8.07	0.3	3.54e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg21775007	chr8:11205619	TDH	-0.54	-11.48	-0.41	7.32e-28	Triglycerides;
BRCA	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg21535247	chr6:8435926	SLC35B3	0.41	9.45	0.35	6.39e-20	Motion sickness;
BRCA	trans	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.16	0.37	1.42e-22	Mean corpuscular volume;
BRCA	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-10.56	-0.39	4.05e-24	Lymphocyte counts;
BRCA	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-32.47	-0.79	2.47e-137	Height;
BRCA	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg21518248	chr2:162101506	NA	-0.42	-8.63	-0.32	4.71e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs9463078	0.764	rs1935551	chr6:44786035	T/G	cg25276700	chr6:44698697	NA	-0.36	-8.4	-0.32	2.93e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg20991723	chr1:152506922	NA	0.37	8.15	0.31	1.91e-15	Hair morphology;
BRCA	cis	rs13136331	0.532	rs7375788	chr4:88565687	C/T	cg22416721	chr4:88570574	DMP1	-0.59	-13.96	-0.48	7.66e-39	Sitting height ratio;
BRCA	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.81	0.55	8.35e-53	Axial length;
BRCA	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg25019033	chr10:957182	NA	-0.44	-8.3	-0.31	6.33e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-16.28	-0.54	4.31e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg04989706	chr14:50066350	PPIL5	-0.45	-8.46	-0.32	1.87e-16	Carotid intima media thickness;
BRCA	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.93	0.33	4.65e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg07541023	chr7:19748670	TWISTNB	0.6	9.89	0.36	1.43e-21	Thyroid stimulating hormone;
BRCA	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg21699342	chr2:239360505	ASB1	-0.57	-11.31	-0.41	3.56e-27	Multiple system atrophy;
BRCA	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18876405	chr7:65276391	NA	0.71	18.84	0.6	2.68e-63	Calcium levels;
BRCA	cis	rs12618769	0.652	rs4851145	chr2:99222916	A/G	cg10123293	chr2:99228465	UNC50	-0.41	-8.34	-0.31	4.49e-16	Bipolar disorder;
BRCA	cis	rs1011018	0.628	rs4074827	chr7:139415455	G/A	cg03224163	chr7:139420300	HIPK2	-0.54	-8.82	-0.33	1.05e-17	Systolic blood pressure;
BRCA	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg21143896	chr7:2802374	GNA12	-0.35	-8.48	-0.32	1.53e-16	Height;
BRCA	cis	rs7927771	0.524	rs7936948	chr11:47704200	T/G	cg20307385	chr11:47447363	PSMC3	0.42	9.52	0.35	3.42e-20	Subjective well-being;
BRCA	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg21475434	chr5:93447410	FAM172A	0.66	8.53	0.32	1.03e-16	Diabetic retinopathy;
BRCA	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg03526776	chr6:41159608	TREML2	0.38	7.95	0.3	8.77e-15	Alzheimer's disease (late onset);
BRCA	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg23625390	chr15:77176239	SCAPER	-0.54	-13.82	-0.48	3.31e-38	Blood metabolite levels;
BRCA	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs8002861	0.664	rs9533662	chr13:44435988	T/A	cg12856521	chr11:46389249	DGKZ	0.37	8.14	0.31	2.09e-15	Leprosy;
BRCA	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg12863693	chr15:85201151	NMB	0.56	12.03	0.43	3.39e-30	Schizophrenia;
BRCA	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg02544614	chr20:61657117	NA	0.29	8.17	0.31	1.6e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg04553112	chr3:125709451	NA	-0.55	-8.27	-0.31	7.6e-16	Blood pressure (smoking interaction);
BRCA	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg27170947	chr2:26402098	FAM59B	-0.65	-11.21	-0.41	9.48e-27	Gut microbiome composition (summer);
BRCA	cis	rs7572733	0.534	rs7572123	chr2:198769637	A/G	cg00792783	chr2:198669748	PLCL1	0.49	10.43	0.38	1.31e-23	Dermatomyositis;
BRCA	trans	rs208520	0.690	rs851467	chr6:66802721	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-21.01	-0.64	6.5e-75	Exhaled nitric oxide output;
BRCA	cis	rs6032067	0.673	rs13042474	chr20:43893068	G/T	cg06407657	chr20:43937138	MATN4;RBPJL	0.31	8.17	0.31	1.62e-15	Blood protein levels;
BRCA	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-11.36	-0.41	2.25e-27	Gut microbiome composition (summer);
BRCA	cis	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg07460842	chr6:66804631	NA	0.88	14.14	0.49	1.11e-39	Exhaled nitric oxide output;
BRCA	cis	rs7246967	0.673	rs16999519	chr19:22814076	A/G	cg23217946	chr19:22817039	ZNF492	-0.47	-8.49	-0.32	1.4e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs6484504	0.600	rs2616815	chr11:31327316	C/T	cg14844989	chr11:31128820	NA	0.45	9.6	0.36	1.79e-20	Red blood cell count;
BRCA	cis	rs12973672	1.000	rs34832786	chr19:35769518	T/C	cg12095397	chr19:35769544	USF2	0.38	8.38	0.31	3.28e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg17366294	chr4:99064904	C4orf37	-0.45	-10.72	-0.39	8.98e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.32	8.66	0.32	3.87e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs2882667	0.755	rs55650316	chr5:138467292	C/G	cg04439458	chr5:138467593	SIL1	-0.44	-11.08	-0.4	3.21e-26	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-9.05	-0.34	1.65e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.59	12.5	0.44	3.12e-32	Lymphocyte counts;
BRCA	cis	rs2289583	0.642	rs7162941	chr15:75385622	C/T	cg14664628	chr15:75095509	CSK	0.39	8.94	0.33	4.03e-18	Systemic lupus erythematosus;
BRCA	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg03585969	chr10:35415529	CREM	0.49	10.22	0.37	8.41e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6545883	0.931	rs7557230	chr2:61736652	A/T	cg15711740	chr2:61764176	XPO1	-0.56	-14.23	-0.49	3.95e-40	Tuberculosis;
BRCA	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg09307838	chr4:120376055	NA	0.61	12.85	0.45	8.45e-34	Corneal astigmatism;
BRCA	cis	rs4889855	0.614	rs7208670	chr17:78494220	T/G	cg16591659	chr17:78472290	NA	-0.37	-8.19	-0.31	1.43e-15	Fractional excretion of uric acid;
BRCA	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg16482183	chr6:26056742	HIST1H1C	-0.54	-11.35	-0.41	2.47e-27	Height;
BRCA	cis	rs4919694	1.000	rs11191545	chr10:104829793	C/T	cg04362960	chr10:104952993	NT5C2	0.93	15.2	0.52	8.78e-45	Arsenic metabolism;
BRCA	cis	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg07460842	chr6:66804631	NA	-1.14	-36.01	-0.82	5.95e-156	Exhaled nitric oxide output;
BRCA	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-10.63	-0.39	2.11e-24	Gut microbiome composition (summer);
BRCA	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg03425785	chr20:62221387	GMEB2	0.52	8.34	0.31	4.54e-16	Glioblastoma;
BRCA	cis	rs6460942	0.597	rs35317839	chr7:12524397	C/A	cg06484146	chr7:12443880	VWDE	-0.58	-7.8	-0.3	2.45e-14	Coronary artery disease;
BRCA	cis	rs1538970	0.924	rs1494812	chr1:45876999	C/T	cg05343316	chr1:45956843	TESK2	0.63	12.76	0.45	2.21e-33	Platelet count;
BRCA	cis	rs3771570	0.901	rs28433352	chr2:242339656	A/G	cg21155796	chr2:242212141	HDLBP	0.48	8.29	0.31	6.86e-16	Prostate cancer;
BRCA	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	12.0	0.43	4.5e-30	Personality dimensions;
BRCA	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.72	10.13	0.37	1.81e-22	Initial pursuit acceleration;
BRCA	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg14061069	chr19:46274453	DMPK	-0.47	-11.65	-0.42	1.45e-28	Coronary artery disease;
BRCA	cis	rs17601876	0.651	rs12050772	chr15:51544871	T/G	cg19946085	chr15:51559439	CYP19A1	-0.34	-8.89	-0.33	6.19e-18	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs11955398	0.585	rs6887434	chr5:60035420	C/G	cg02684056	chr5:59996105	DEPDC1B	-0.36	-8.49	-0.32	1.47e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg14004847	chr7:1930337	MAD1L1	0.45	9.72	0.36	6.63e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.84	-0.42	2.31e-29	Total cholesterol levels;
BRCA	trans	rs9393777	0.778	rs66841633	chr6:27382386	G/T	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.85	-0.3	1.73e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg00701064	chr4:6280414	WFS1	0.69	17.68	0.57	3.18e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs2011503	0.782	rs35545554	chr19:19715613	A/G	cg11584989	chr19:19387371	SF4	-0.48	-9.85	-0.36	2.04e-21	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg05340658	chr4:99064831	C4orf37	0.65	16.04	0.54	6.49e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	8.16	0.31	1.76e-15	Diabetic retinopathy;
BRCA	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg17366294	chr4:99064904	C4orf37	0.46	10.95	0.4	1.12e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg24296786	chr1:45957014	TESK2	0.59	14.24	0.49	3.59e-40	High light scatter reticulocyte count;
BRCA	trans	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-12.09	-0.43	1.81e-30	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs7903847	0.642	rs11812223	chr10:99158455	T/C	cg20016023	chr10:99160130	RRP12	-0.26	-8.31	-0.31	5.75e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10754283	0.935	rs10801756	chr1:90101832	C/T	cg21401794	chr1:90099060	LRRC8C	0.46	11.11	0.4	2.33e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg14675211	chr2:100938903	LONRF2	0.47	10.81	0.39	3.94e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg12365402	chr11:9010492	NRIP3	0.42	9.24	0.34	3.62e-19	Hemoglobin concentration;
BRCA	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg25358565	chr5:93447407	FAM172A	1.17	19.76	0.62	3.31e-68	Diabetic retinopathy;
BRCA	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg21747090	chr2:27597821	SNX17	-0.37	-7.89	-0.3	1.33e-14	Total body bone mineral density;
BRCA	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg00495681	chr13:53174319	NA	0.42	8.95	0.33	3.76e-18	Lewy body disease;
BRCA	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg24675658	chr1:53192096	ZYG11B	0.63	15.12	0.51	2.25e-44	Monocyte count;
BRCA	cis	rs9296092	0.517	rs9461877	chr6:33516667	C/T	cg13560919	chr6:33536144	NA	-0.83	-16.87	-0.56	4.55e-53	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.53	-11.09	-0.4	2.99e-26	Lymphocyte counts;
BRCA	cis	rs7766436	0.583	rs7757926	chr6:22561611	C/A	cg13666174	chr6:22585274	NA	-0.4	-8.49	-0.32	1.46e-16	Coronary artery disease;
BRCA	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg04025307	chr7:1156635	C7orf50	0.53	13.44	0.47	1.88e-36	Longevity;Endometriosis;
BRCA	trans	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg25214090	chr10:38739885	LOC399744	0.35	7.95	0.3	8.29e-15	Corneal astigmatism;
BRCA	trans	rs8073060	0.586	rs35542792	chr17:33903886	A/G	cg19694781	chr19:47549865	TMEM160	1.0	20.71	0.63	2.65e-73	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg09526685	chr4:187126073	CYP4V2	0.7	9.58	0.35	2.11e-20	Blood protein levels;
BRCA	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19748678	chr4:122722346	EXOSC9	0.74	16.06	0.54	5.03e-49	Type 2 diabetes;
BRCA	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg23649088	chr2:200775458	C2orf69	-0.61	-7.95	-0.3	8.69e-15	Schizophrenia;
BRCA	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-12.54	-0.44	2.13e-32	Chronic sinus infection;
BRCA	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg07148914	chr20:33460835	GGT7	0.38	8.62	0.32	5.21e-17	Height;
BRCA	cis	rs4846580	0.710	rs12407628	chr1:219935453	C/G	cg07216884	chr1:219964455	NA	-0.34	-7.92	-0.3	1.05e-14	Total body bone mineral density;
BRCA	cis	rs3761847	0.622	rs10435888	chr9:123819603	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	8.23	0.31	1.05e-15	Rheumatoid arthritis;
BRCA	cis	rs1829883	1.000	rs1403661	chr5:98777056	T/A	cg08333243	chr5:99726346	NA	-0.37	-8.81	-0.33	1.18e-17	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg10932868	chr11:921992	NA	0.47	12.11	0.43	1.62e-30	Alzheimer's disease (late onset);
BRCA	cis	rs2882667	0.690	rs6421921	chr5:138167270	T/G	cg04439458	chr5:138467593	SIL1	0.31	7.91	0.3	1.17e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg17644776	chr2:200775616	C2orf69	0.45	9.35	0.35	1.51e-19	Osteoporosis;
BRCA	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg17509989	chr5:176798049	RGS14	0.64	12.81	0.45	1.37e-33	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg01579765	chr21:45077557	HSF2BP	-0.44	-12.2	-0.43	6.25e-31	Mean corpuscular volume;
BRCA	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg18402987	chr7:1209562	NA	0.44	8.8	0.33	1.22e-17	Longevity;Endometriosis;
BRCA	cis	rs17601876	0.814	rs2414101	chr15:51562434	A/G	cg19946085	chr15:51559439	CYP19A1	-0.39	-11.7	-0.42	8.33e-29	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs11955398	0.625	rs11739209	chr5:59959767	T/C	cg02684056	chr5:59996105	DEPDC1B	0.37	8.59	0.32	6.44e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs953387	1.000	rs12473760	chr2:136905697	C/A	cg05194412	chr2:137003533	NA	-0.37	-8.55	-0.32	9.32e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.58	-0.32	7.12e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs700651	0.821	rs700666	chr2:198673544	G/A	cg00792783	chr2:198669748	PLCL1	0.47	10.22	0.37	8.54e-23	Intracranial aneurysm;
BRCA	cis	rs4642101	0.765	rs1985428	chr3:12829315	A/G	cg24848339	chr3:12840334	CAND2	-0.41	-10.77	-0.39	5.49e-25	QRS complex (12-leadsum);
BRCA	cis	rs9309473	0.519	rs35421685	chr2:73910138	T/C	cg20560298	chr2:73613845	ALMS1	0.38	10.06	0.37	3.37e-22	Metabolite levels;
BRCA	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg08470875	chr2:26401718	FAM59B	0.76	11.89	0.43	1.33e-29	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.34e-24	Motion sickness;
BRCA	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg10820045	chr2:198174542	NA	-0.43	-10.07	-0.37	2.98e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs4423214	0.592	rs10898223	chr11:71219264	G/A	cg05163923	chr11:71159392	DHCR7	-0.46	-7.91	-0.3	1.15e-14	Vitamin D levels;
BRCA	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.26	0.64	2.92e-76	Lymphocyte percentage of white cells;
BRCA	trans	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg25214090	chr10:38739885	LOC399744	0.46	10.6	0.39	2.72e-24	Corneal astigmatism;
BRCA	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.94	19.3	0.61	9.6e-66	Body mass index;
BRCA	cis	rs6542838	0.644	rs7590596	chr2:99467938	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.36	-8.11	-0.31	2.62e-15	Fear of minor pain;
BRCA	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg17063962	chr7:91808500	NA	0.54	12.71	0.45	3.79e-33	Breast cancer;
BRCA	cis	rs2415984	0.622	rs1761025	chr14:46930439	T/C	cg14871534	chr14:47121158	RPL10L	0.34	8.3	0.31	6.14e-16	Number of children ever born;
BRCA	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg06640241	chr16:89574553	SPG7	0.77	18.25	0.59	3.5e-60	Multiple myeloma (IgH translocation);
BRCA	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg01181863	chr3:195395398	SDHAP2	-0.69	-10.69	-0.39	1.16e-24	Pancreatic cancer;
BRCA	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg20933634	chr6:27740509	NA	0.43	8.77	0.33	1.58e-17	Parkinson's disease;
BRCA	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.08	0.62	6.44e-70	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.13	0.34	8.91e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6499188	0.522	rs10153230	chr16:68671741	C/G	cg02972257	chr16:68554789	NA	-0.44	-8.74	-0.33	2.01e-17	Ulcerative colitis;
BRCA	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg26384229	chr12:38710491	ALG10B	0.85	22.84	0.67	7.26e-85	Heart rate;
BRCA	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg05347473	chr6:146136440	FBXO30	-0.41	-8.05	-0.3	3.92e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	15.5	0.52	3.24e-46	Lymphocyte counts;
BRCA	cis	rs10181042	0.565	rs1177234	chr2:61260063	G/T	cg15711740	chr2:61764176	XPO1	-0.36	-8.53	-0.32	1.05e-16	Crohn's disease;
BRCA	trans	rs208520	0.661	rs207111	chr6:66792513	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.23	-0.64	4.44e-76	Exhaled nitric oxide output;
BRCA	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg05207973	chr5:176823642	SLC34A1	-0.36	-7.87	-0.3	1.53e-14	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg26384229	chr12:38710491	ALG10B	0.66	15.77	0.53	1.4e-47	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7131987	0.676	rs10843407	chr12:29550244	A/G	cg09582351	chr12:29534625	ERGIC2	0.4	9.52	0.35	3.54e-20	QT interval;
BRCA	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg26384229	chr12:38710491	ALG10B	0.55	11.69	0.42	9.73e-29	Morning vs. evening chronotype;
BRCA	cis	rs9790314	0.687	rs1037888	chr3:160775251	A/T	cg04691961	chr3:161091175	C3orf57	-0.4	-8.51	-0.32	1.25e-16	Morning vs. evening chronotype;
BRCA	cis	rs9976767	0.608	rs11909987	chr21:43822402	C/A	cg23042151	chr21:43824109	UBASH3A	-0.28	-8.71	-0.33	2.5e-17	Type 1 diabetes;
BRCA	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg01420254	chr6:26195488	NA	0.55	8.42	0.32	2.54e-16	Gout;Renal underexcretion gout;
BRCA	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2559856	0.967	rs2695290	chr12:102087844	A/G	cg12924262	chr12:102091054	CHPT1	-0.35	-7.84	-0.3	1.89e-14	Blood protein levels;
BRCA	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.36	-0.38	2.27e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg05901451	chr6:126070800	HEY2	-0.39	-9.41	-0.35	9.06e-20	Endometrial cancer;
BRCA	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18876405	chr7:65276391	NA	0.55	13.35	0.47	4.99e-36	Aortic root size;
BRCA	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs12541635	0.966	rs6469028	chr8:107014552	C/T	cg10147462	chr8:107024639	NA	0.36	9.67	0.36	9.96e-21	Age of smoking initiation;
BRCA	cis	rs3125734	0.633	rs1864836	chr10:64028538	C/G	cg09941381	chr10:64027924	RTKN2	-0.29	-8.12	-0.31	2.46e-15	Rheumatoid arthritis;
BRCA	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg00825309	chr19:58991885	ZNF446	-0.58	-12.8	-0.45	1.44e-33	Uric acid clearance;
BRCA	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.48	-0.32	1.6e-16	Total body bone mineral density;
BRCA	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg08917208	chr2:24149416	ATAD2B	0.91	13.38	0.47	3.55e-36	Lymphocyte counts;
BRCA	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	13.63	0.47	2.61e-37	Response to bleomycin (chromatid breaks);
BRCA	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg21433313	chr16:3507492	NAT15	0.46	10.3	0.38	4e-23	Tuberculosis;
BRCA	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.15	-0.31	1.95e-15	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg08917208	chr2:24149416	ATAD2B	0.92	13.6	0.47	3.66e-37	Lymphocyte counts;
BRCA	cis	rs72627509	0.904	rs781663	chr4:57781754	A/G	cg26694713	chr4:57773883	REST	0.5	9.99	0.37	6.27e-22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-16.02	-0.54	8.55e-49	Colorectal cancer;
BRCA	trans	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.36	0.31	3.95e-16	Mean corpuscular volume;
BRCA	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg03433033	chr1:76189801	ACADM	-0.77	-17.79	-0.58	8.21e-58	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7586879	0.789	rs13035239	chr2:25134000	T/A	cg04586622	chr2:25135609	ADCY3	0.4	9.56	0.35	2.57e-20	Body mass index;
BRCA	trans	rs9944715	0.954	rs9675387	chr18:43798023	G/A	cg01718231	chr17:29326311	RNF135	-0.44	-8.63	-0.32	4.97e-17	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg20203395	chr5:56204925	C5orf35	-0.51	-10.4	-0.38	1.64e-23	Initial pursuit acceleration;
BRCA	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-9.56	-0.35	2.58e-20	Schizophrenia;
BRCA	cis	rs9462027	0.628	rs9462015	chr6:34739726	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.96	-0.3	7.8e-15	Systemic lupus erythematosus;
BRCA	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg21775007	chr8:11205619	TDH	0.61	11.88	0.43	1.53e-29	Retinal vascular caliber;
BRCA	trans	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg25206134	chr2:45395956	NA	0.53	8.77	0.33	1.57e-17	Bipolar disorder;
BRCA	cis	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg06521331	chr12:34319734	NA	0.52	9.32	0.35	1.83e-19	Morning vs. evening chronotype;
BRCA	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg27446573	chr6:127587934	RNF146	0.9	21.07	0.64	2.99e-75	Breast cancer;
BRCA	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg22535103	chr8:58192502	C8orf71	-0.63	-13.16	-0.46	3.62e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg25457927	chr22:38595422	NA	-0.32	-11.88	-0.43	1.46e-29	Cutaneous nevi;
BRCA	trans	rs8073060	0.586	rs225280	chr17:33976296	C/T	cg19694781	chr19:47549865	TMEM160	-1.06	-21.42	-0.65	3.91e-77	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.33	10.4	0.38	1.6e-23	Bipolar disorder;
BRCA	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24549020	chr5:56110836	MAP3K1	0.55	11.33	0.41	3.01e-27	Initial pursuit acceleration;
BRCA	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-10.06	-0.37	3.32e-22	Heart rate;
BRCA	cis	rs7178424	0.840	rs4774427	chr15:62217444	T/C	cg00456672	chr15:62358751	C2CD4A	0.4	9.05	0.34	1.71e-18	Height;
BRCA	cis	rs10465746	0.746	rs6663949	chr1:84452853	T/C	cg10977910	chr1:84465055	TTLL7	0.59	12.39	0.44	9.11e-32	Obesity-related traits;
BRCA	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.4	-8.44	-0.32	2.16e-16	Longevity;Endometriosis;
BRCA	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg03146154	chr1:46216737	IPP	0.53	11.75	0.42	5.61e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9290065	0.519	rs7626904	chr3:160672427	C/T	cg03342759	chr3:160939853	NMD3	-0.45	-9.33	-0.35	1.7e-19	Kawasaki disease;
BRCA	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg20503657	chr10:835505	NA	0.63	10.42	0.38	1.35e-23	Eosinophil percentage of granulocytes;
BRCA	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg03342759	chr3:160939853	NMD3	-0.8	-18.98	-0.6	4.9e-64	Parkinson's disease;
BRCA	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg14664628	chr15:75095509	CSK	0.51	10.68	0.39	1.28e-24	Systemic lupus erythematosus;
BRCA	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg17063962	chr7:91808500	NA	0.57	13.52	0.47	8.49e-37	Breast cancer;
BRCA	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg04362960	chr10:104952993	NT5C2	0.44	10.86	0.39	2.48e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-11.87	-0.43	1.62e-29	Diastolic blood pressure;
BRCA	trans	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg25206134	chr2:45395956	NA	0.53	8.37	0.31	3.66e-16	Neuroticism;
BRCA	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg19743168	chr1:23544995	NA	0.35	8.15	0.31	1.89e-15	Height;
BRCA	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	16.99	0.56	1.09e-53	Fuchs's corneal dystrophy;
BRCA	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	8.8	0.33	1.28e-17	Iron status biomarkers;
BRCA	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg13010199	chr12:38710504	ALG10B	0.43	9.11	0.34	1.04e-18	Morning vs. evening chronotype;
BRCA	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg14664628	chr15:75095509	CSK	-0.84	-22.29	-0.66	7.26e-82	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg23018236	chr17:30244563	NA	-0.68	-10.7	-0.39	1.09e-24	Hip circumference adjusted for BMI;
BRCA	cis	rs12200560	0.505	rs211179	chr6:97074103	A/G	cg06623918	chr6:96969491	KIAA0776	0.53	12.64	0.45	7.46e-33	Coronary heart disease;
BRCA	cis	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg05901451	chr6:126070800	HEY2	0.4	9.69	0.36	8.1e-21	Endometrial cancer;
BRCA	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg14456004	chr13:21872349	NA	1.16	25.28	0.71	2.73e-98	White matter hyperintensity burden;
BRCA	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg21573476	chr21:45109991	RRP1B	-0.36	-9.02	-0.34	2.16e-18	Mean corpuscular volume;
BRCA	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21659725	chr3:3221576	CRBN	-0.71	-21.92	-0.66	7.66e-80	Intelligence (multi-trait analysis);
BRCA	cis	rs4494114	1.000	rs9439081	chr1:39343012	A/G	cg25970120	chr1:39325951	RRAGC	-0.37	-7.92	-0.3	1.08e-14	Blood protein levels;
BRCA	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg27432699	chr2:27873401	GPN1	0.43	8.97	0.33	3.28e-18	Oral cavity cancer;
BRCA	cis	rs7267979	0.780	rs2500413	chr20:25241155	T/C	cg08601574	chr20:25228251	PYGB	0.34	8.01	0.3	5.55e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.58	11.31	0.41	3.68e-27	HDL cholesterol;
BRCA	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg05340658	chr4:99064831	C4orf37	0.68	16.51	0.55	2.8e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-8.99	-0.34	2.69e-18	Longevity;Endometriosis;
BRCA	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg08975724	chr8:8085496	FLJ10661	0.5	10.64	0.39	1.89e-24	Mood instability;
BRCA	cis	rs7539409	0.604	rs6689821	chr1:84316605	A/G	cg10977910	chr1:84465055	TTLL7	0.7	10.64	0.39	1.84e-24	Alzheimer's disease;
BRCA	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.07	23.75	0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.39	-0.32	3.1e-16	Colorectal cancer;
BRCA	cis	rs9487051	0.768	rs427960	chr6:109524939	C/T	cg01475377	chr6:109611718	NA	-0.45	-10.88	-0.4	2.02e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg15017067	chr4:17643749	FAM184B	0.32	9.86	0.36	1.96e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11971779	0.680	rs2355786	chr7:139065622	A/C	cg07862535	chr7:139043722	LUC7L2	-0.39	-10.48	-0.38	8.19e-24	Diisocyanate-induced asthma;
BRCA	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg20848291	chr7:100343083	ZAN	-0.6	-12.72	-0.45	3.31e-33	Other erythrocyte phenotypes;
BRCA	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg00750074	chr16:89608354	SPG7	-0.35	-9.21	-0.34	4.49e-19	Multiple myeloma (IgH translocation);
BRCA	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg01689657	chr7:91764605	CYP51A1	0.22	8.16	0.31	1.73e-15	Breast cancer;
BRCA	cis	rs13064411	0.542	rs9877649	chr3:113226874	C/T	cg18753928	chr3:113234510	CCDC52	-0.45	-9.6	-0.35	1.8e-20	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.58	0.39	3.38e-24	Motion sickness;
BRCA	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg00666640	chr1:248458726	OR2T12	0.32	8.94	0.33	4.09e-18	Common traits (Other);
BRCA	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg20587970	chr11:113659929	NA	-1.24	-22.64	-0.67	8.57e-84	Hip circumference adjusted for BMI;
BRCA	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.32	-0.35	1.82e-19	Electroencephalogram traits;
BRCA	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03352830	chr11:487213	PTDSS2	0.87	13.62	0.47	2.74e-37	Body mass index;
BRCA	cis	rs9649213	0.614	rs4236537	chr7:97996593	T/C	cg09267113	chr7:98030324	BAIAP2L1	-0.58	-15.81	-0.53	9.68e-48	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg03923535	chr7:1197113	ZFAND2A	0.4	7.89	0.3	1.31e-14	Longevity;Endometriosis;
BRCA	trans	rs1974653	0.781	rs175166	chr22:20116182	G/T	cg20152630	chr19:46405944	MYPOP	-0.38	-8.65	-0.32	4.32e-17	Schizophrenia;
BRCA	cis	rs6594713	0.819	rs13180522	chr5:112726022	A/G	cg12552261	chr5:112820674	MCC	0.46	8.1	0.31	2.72e-15	Brain cytoarchitecture;
BRCA	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26314531	chr2:26401878	FAM59B	-0.88	-15.59	-0.52	1.14e-46	Gut microbiome composition (summer);
BRCA	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg22907277	chr7:1156413	C7orf50	0.58	8.91	0.33	5.37e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg27478167	chr7:817139	HEATR2	-0.42	-8.97	-0.33	3.21e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg23711669	chr6:146136114	FBXO30	-0.8	-19.34	-0.61	5.67e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg04450456	chr4:17643702	FAM184B	0.36	10.65	0.39	1.75e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg03213289	chr20:61660250	NA	0.63	16.54	0.55	2.05e-51	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg11693508	chr17:37793320	STARD3	0.61	11.37	0.41	2.14e-27	Bipolar disorder;
BRCA	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg23262073	chr20:60523788	NA	-0.54	-12.72	-0.45	3.5e-33	Obesity-related traits;
BRCA	cis	rs7301016	0.947	rs11174517	chr12:62899757	A/G	cg01804193	chr12:63026212	NA	-0.46	-7.91	-0.3	1.12e-14	IgG glycosylation;
BRCA	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg11814155	chr7:99998594	ZCWPW1	0.46	8.24	0.31	9.66e-16	Platelet count;
BRCA	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg06484146	chr7:12443880	VWDE	-0.75	-10.74	-0.39	7.27e-25	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg05340658	chr4:99064831	C4orf37	0.63	15.08	0.51	3.55e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7551345	0.805	rs7525003	chr1:31698455	A/G	cg19084893	chr1:31688959	NA	-0.46	-10.04	-0.37	4.13e-22	Schizophrenia;
BRCA	trans	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.14	0.31	2.14e-15	Mean corpuscular volume;
BRCA	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg03146154	chr1:46216737	IPP	0.52	11.57	0.42	2.93e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg18904891	chr8:8559673	CLDN23	0.64	12.63	0.45	8.69e-33	Obesity-related traits;
BRCA	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs10463316	0.862	rs10071166	chr5:150768795	T/C	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.32	-0.31	5.27e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg14019146	chr3:50243930	SLC38A3	-0.57	-11.74	-0.42	5.8e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs11608355	0.545	rs33997929	chr12:109912064	C/T	cg05360138	chr12:110035743	NA	0.71	13.05	0.46	1.09e-34	Neuroticism;
BRCA	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg16325326	chr1:53192061	ZYG11B	-0.65	-16.18	-0.54	1.39e-49	Monocyte count;
BRCA	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.58	12.78	0.45	1.77e-33	Hemoglobin concentration;
BRCA	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.38	-9.27	-0.34	2.77e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	10.01	0.37	5.17e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg04166393	chr7:2884313	GNA12	0.6	12.01	0.43	4.26e-30	Height;
BRCA	trans	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	11.95	0.43	7.69e-30	Tonsillectomy;
BRCA	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg16743903	chr16:89593216	SPG7	0.33	8.22	0.31	1.11e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.31	-8.41	-0.32	2.59e-16	Lymphocyte counts;
BRCA	cis	rs8028182	0.636	rs12909863	chr15:75825822	G/C	cg20655648	chr15:75932815	IMP3	0.42	8.23	0.31	1.05e-15	Sudden cardiac arrest;
BRCA	cis	rs6973256	0.897	rs10235846	chr7:133328222	G/T	cg07491979	chr7:133331646	EXOC4	-0.37	-8.53	-0.32	1.06e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg03929089	chr4:120376271	NA	-0.5	-8.31	-0.31	5.69e-16	Axial length;
BRCA	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg07169764	chr2:136633963	MCM6	1.08	23.82	0.69	3.23e-90	Corneal structure;
BRCA	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	14.2	0.49	5.56e-40	Platelet count;
BRCA	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.49	0.57	2.77e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg23762105	chr12:34175262	ALG10	-0.38	-9.68	-0.36	8.83e-21	Morning vs. evening chronotype;
BRCA	cis	rs12618769	0.625	rs3769733	chr2:99100716	A/G	cg10123293	chr2:99228465	UNC50	0.43	8.45	0.32	1.96e-16	Bipolar disorder;
BRCA	cis	rs4845875	0.514	rs198392	chr1:11879162	G/A	cg24844545	chr1:11908347	NPPA	-0.31	-7.98	-0.3	6.92e-15	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs6878727	0.665	rs2633530	chr5:123652476	A/G	cg01806427	chr5:123737813	NA	-0.35	-7.84	-0.3	1.83e-14	Breast cancer;
BRCA	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg02016764	chr4:38805732	TLR1	-0.6	-9.19	-0.34	5.47e-19	Breast cancer;
BRCA	cis	rs8022179	0.580	rs8013228	chr14:103842650	A/G	cg12935359	chr14:103987150	CKB	-0.46	-9.28	-0.34	2.67e-19	Monocyte count;
BRCA	cis	rs17092148	1.000	rs2378260	chr20:33374897	G/A	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.26	-0.41	5.82e-27	Neuroticism;
BRCA	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg07395648	chr5:131743802	NA	-0.37	-9.18	-0.34	5.74e-19	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.44	12.98	0.46	2.44e-34	Response to antipsychotic treatment;
BRCA	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg03146154	chr1:46216737	IPP	-0.44	-9.78	-0.36	3.68e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs311392	0.903	rs6993362	chr8:55089220	A/G	cg11783602	chr8:55087084	NA	-0.33	-9.7	-0.36	7.55e-21	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg24562669	chr7:97807699	LMTK2	0.47	12.44	0.44	5.52e-32	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs6964833	1.000	rs17515241	chr7:74132014	C/T	cg07504079	chr7:72649617	NCF1B	0.47	9.28	0.34	2.49e-19	Menarche (age at onset);
BRCA	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg16230307	chr14:35515116	FAM177A1	0.73	15.19	0.52	9.98e-45	Psoriasis;
BRCA	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg05084668	chr3:125655381	ALG1L	-0.46	-8.05	-0.3	4.01e-15	Blood pressure (smoking interaction);
BRCA	cis	rs7567389	0.744	rs6430934	chr2:128000833	T/C	cg09760422	chr2:128146352	NA	-0.41	-8.64	-0.32	4.39e-17	Self-rated health;
BRCA	cis	rs10193935	0.901	rs10175378	chr2:42456267	A/C	cg27598129	chr2:42591480	NA	-0.96	-14.7	-0.5	2.48e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7551345	0.687	rs2377731	chr1:31697471	G/A	cg19084893	chr1:31688959	NA	-0.46	-10.04	-0.37	4.13e-22	Schizophrenia;
BRCA	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg11764359	chr7:65958608	NA	-0.66	-12.14	-0.43	1.21e-30	Aortic root size;
BRCA	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg24296786	chr1:45957014	TESK2	0.59	14.37	0.49	9.24e-41	High light scatter reticulocyte count;
BRCA	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-11.32	-0.41	3.3e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05901451	chr6:126070800	HEY2	-0.46	-11.43	-0.41	1.2e-27	Endometrial cancer;
BRCA	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	10.38	0.38	1.89e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs7633770	0.749	rs6442011	chr3:46685722	C/T	cg11219411	chr3:46661640	NA	0.64	16.69	0.55	3.46e-52	Coronary artery disease;
BRCA	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03264133	chr6:25882463	NA	0.72	16.63	0.55	7.45e-52	Blood metabolite levels;
BRCA	cis	rs9649213	0.727	rs12113294	chr7:97910637	C/G	cg24562669	chr7:97807699	LMTK2	0.33	8.08	0.3	3.14e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg02544614	chr20:61657117	NA	0.28	8.04	0.3	4.48e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06028605	chr16:24865363	SLC5A11	-0.46	-10.07	-0.37	3.22e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs68170813	0.559	rs74774133	chr7:106941449	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-8.96	-0.33	3.61e-18	Coronary artery disease;
BRCA	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg06453172	chr10:134556979	INPP5A	-0.59	-11.66	-0.42	1.34e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-12.26	-0.44	3.55e-31	Hemoglobin concentration;
BRCA	trans	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.53	0.32	1.05e-16	Corneal astigmatism;
BRCA	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-10.36	-0.38	2.34e-23	Alzheimer's disease;
BRCA	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg21770322	chr7:97807741	LMTK2	0.62	17.87	0.58	3.27e-58	Breast cancer;
BRCA	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs12760731	0.565	rs78577576	chr1:178141982	A/G	cg00404053	chr1:178313656	RASAL2	0.64	7.92	0.3	1.02e-14	Obesity-related traits;
BRCA	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg13010199	chr12:38710504	ALG10B	0.36	8.63	0.32	5.05e-17	Morning vs. evening chronotype;
BRCA	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg07080220	chr10:102295463	HIF1AN	0.61	13.93	0.48	1.02e-38	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7178424	0.774	rs13379947	chr15:62184801	A/G	cg00456672	chr15:62358751	C2CD4A	0.4	9.58	0.35	2.17e-20	Height;
BRCA	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg06627628	chr2:24431161	ITSN2	-0.63	-12.27	-0.44	3.02e-31	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg02659138	chr7:134003124	SLC35B4	0.34	10.67	0.39	1.46e-24	Mean platelet volume;
BRCA	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg24838063	chr12:130822603	PIWIL1	-0.54	-12.92	-0.46	4.18e-34	Menopause (age at onset);
BRCA	cis	rs17767294	0.614	rs72850298	chr6:28222556	G/A	cg08851530	chr6:28072375	NA	1.14	10.4	0.38	1.69e-23	Parkinson's disease;
BRCA	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg22834771	chr12:69754056	YEATS4	-0.37	-9.16	-0.34	6.89e-19	Blood protein levels;
BRCA	cis	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05901451	chr6:126070800	HEY2	0.5	12.29	0.44	2.68e-31	Brugada syndrome;
BRCA	cis	rs11601602	0.576	rs4075635	chr11:28511643	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	9.42	0.35	8.07e-20	Obesity-related traits;
BRCA	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg02773041	chr1:40204384	PPIE	0.45	9.63	0.36	1.42e-20	Blood protein levels;
BRCA	cis	rs6545883	0.507	rs12617371	chr2:61569134	A/G	cg15711740	chr2:61764176	XPO1	0.31	7.81	0.3	2.42e-14	Tuberculosis;
BRCA	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg02896835	chr1:92012615	NA	0.64	16.4	0.54	1.03e-50	Breast cancer;
BRCA	cis	rs1050631	0.564	rs681757	chr18:33744766	A/C	cg19453250	chr18:33710783	SLC39A6;ELP2	-0.29	-8.01	-0.3	5.42e-15	Esophageal squamous cell cancer (length of survival);
BRCA	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg03929089	chr4:120376271	NA	0.6	10.37	0.38	2.13e-23	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg13010199	chr12:38710504	ALG10B	0.45	9.32	0.35	1.81e-19	Bladder cancer;
BRCA	cis	rs9811920	0.809	rs4928151	chr3:99767553	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.57	-13.68	-0.48	1.48e-37	Axial length;
BRCA	cis	rs700651	0.789	rs10190226	chr2:198901564	A/G	cg00792783	chr2:198669748	PLCL1	-0.38	-8.56	-0.32	8.1e-17	Intracranial aneurysm;
BRCA	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg08213375	chr14:104286397	PPP1R13B	0.42	9.2	0.34	4.9e-19	Reticulocyte count;
BRCA	cis	rs7520050	0.966	rs10890361	chr1:46346234	A/T	cg03146154	chr1:46216737	IPP	-0.33	-7.92	-0.3	1.08e-14	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg15595755	chr5:1867978	NA	0.36	8.6	0.32	6.23e-17	Cardiovascular disease risk factors;
BRCA	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg04586622	chr2:25135609	ADCY3	0.45	11.28	0.41	5.02e-27	Body mass index;
BRCA	cis	rs67981189	0.593	rs7160958	chr14:71442526	C/A	cg15816911	chr14:71606274	NA	0.36	8.41	0.32	2.67e-16	Schizophrenia;
BRCA	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	8.44	0.32	2.16e-16	Menarche (age at onset);
BRCA	cis	rs2882667	0.690	rs825672	chr5:138095643	A/G	cg04439458	chr5:138467593	SIL1	0.32	7.89	0.3	1.33e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11890956	chr21:40555474	PSMG1	-0.61	-13.73	-0.48	9.03e-38	Menarche (age at onset);
BRCA	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06636551	chr8:101224915	SPAG1	-0.38	-8.58	-0.32	7.08e-17	Atrioventricular conduction;
BRCA	cis	rs12760731	0.720	rs10913540	chr1:178340060	T/C	cg00404053	chr1:178313656	RASAL2	0.63	8.59	0.32	6.71e-17	Obesity-related traits;
BRCA	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg06671706	chr8:8559999	CLDN23	0.46	8.79	0.33	1.43e-17	Obesity-related traits;
BRCA	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg27129171	chr3:47204927	SETD2	0.75	19.33	0.61	6.5e-66	Colorectal cancer;
BRCA	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg24130564	chr14:104152367	KLC1	-0.41	-8.78	-0.33	1.49e-17	Reticulocyte count;
BRCA	trans	rs1493916	0.837	rs1493908	chr18:31411700	G/A	cg15819921	chr19:927150	ARID3A	-0.41	-8.11	-0.31	2.57e-15	Life satisfaction;
BRCA	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg10556349	chr10:835070	NA	0.63	8.66	0.32	3.75e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs10899021	1.000	rs7935426	chr11:74363890	C/T	cg25880958	chr11:74394337	NA	-0.5	-7.89	-0.3	1.29e-14	Response to metformin (IC50);
BRCA	cis	rs6866614	0.627	rs27437	chr5:131436961	A/G	cg14196790	chr5:131705035	SLC22A5	0.33	8.13	0.31	2.16e-15	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs1018836	0.892	rs1476428	chr8:91555603	G/T	cg16814680	chr8:91681699	NA	-0.5	-10.85	-0.39	2.63e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13046373	0.507	rs11088139	chr21:31978884	T/G	cg24082983	chr21:31802169	KRTAP13-4	0.34	8.63	0.32	4.98e-17	HDL cholesterol;
BRCA	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg05340658	chr4:99064831	C4orf37	0.69	17.54	0.57	1.68e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs939658	1.000	rs11072826	chr15:79461516	C/T	cg17916960	chr15:79447300	NA	0.43	10.82	0.39	3.54e-25	Refractive error;
BRCA	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg15017067	chr4:17643749	FAM184B	0.3	9.02	0.34	2.2e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs72928364	1.000	rs10511181	chr3:100689862	T/G	cg10123952	chr3:100791384	NA	0.53	7.9	0.3	1.19e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg20203395	chr5:56204925	C5orf35	-0.39	-8.16	-0.31	1.75e-15	Type 2 diabetes;
BRCA	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.57	13.62	0.47	2.81e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs72772090	0.522	rs55804164	chr5:96003075	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-7.83	-0.3	2.08e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg15017067	chr4:17643749	FAM184B	0.29	8.98	0.33	3.08e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg19000871	chr14:103996768	TRMT61A	-0.35	-8.04	-0.3	4.21e-15	Coronary artery disease;
BRCA	trans	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg26043149	chr18:55253948	FECH	-0.37	-8.13	-0.31	2.23e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.36	0.38	2.4e-23	Motion sickness;
BRCA	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg24110177	chr3:50126178	RBM5	-0.45	-9.77	-0.36	4e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg17063962	chr7:91808500	NA	0.53	11.7	0.42	8.77e-29	Breast cancer;
BRCA	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg00666640	chr1:248458726	OR2T12	0.34	8.81	0.33	1.13e-17	Common traits (Other);
BRCA	cis	rs7707921	0.723	rs226197	chr5:81574925	G/A	cg15871215	chr5:81402204	ATG10	0.36	8.26	0.31	8.53e-16	Breast cancer;
BRCA	cis	rs113835537	0.529	rs11227525	chr11:66308065	T/G	cg24851651	chr11:66362959	CCS	0.48	8.73	0.33	2.15e-17	Airway imaging phenotypes;
BRCA	cis	rs586533	0.881	rs658789	chr11:99501520	A/G	cg22878054	chr11:99397252	CNTN5	0.32	8.11	0.31	2.53e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	11.97	0.43	5.92e-30	Lung cancer in ever smokers;
BRCA	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg15395560	chr15:45543142	SLC28A2	0.29	8.12	0.31	2.49e-15	Uric acid levels;
BRCA	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg00071950	chr4:10020882	SLC2A9	0.4	8.5	0.32	1.34e-16	Blood metabolite levels;
BRCA	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg00631329	chr6:26305371	NA	-0.55	-15.71	-0.53	2.9e-47	Educational attainment;
BRCA	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg19183879	chr15:85880815	NA	-0.32	-7.85	-0.3	1.7e-14	Coronary artery disease;
BRCA	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg03684893	chr10:554711	DIP2C	-0.41	-9.91	-0.37	1.2e-21	Psychosis in Alzheimer's disease;
BRCA	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03517284	chr6:25882590	NA	0.46	10.29	0.38	4.5e-23	Blood metabolite levels;
BRCA	cis	rs4523957	0.928	rs749240	chr17:2186100	A/G	cg16513277	chr17:2031491	SMG6	0.38	8.08	0.3	3.27e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg05347473	chr6:146136440	FBXO30	0.46	9.14	0.34	7.97e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.58	9.6	0.35	1.83e-20	Lung function (FEV1/FVC);
BRCA	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-11.75	-0.42	5.13e-29	Gut microbiome composition (summer);
BRCA	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg16606324	chr3:10149918	C3orf24	0.5	9.0	0.34	2.46e-18	Alzheimer's disease;
BRCA	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg09307838	chr4:120376055	NA	0.61	11.91	0.43	1.15e-29	Corneal astigmatism;
BRCA	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg20476274	chr7:133979776	SLC35B4	0.6	14.94	0.51	1.66e-43	Mean platelet volume;
BRCA	cis	rs17381785	0.545	rs1494947	chr4:14969983	T/G	cg12377275	chr4:15005593	CPEB2	0.72	17.29	0.56	2.94e-55	Urate levels in overweight individuals;
BRCA	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg17143192	chr8:8559678	CLDN23	0.47	9.08	0.34	1.37e-18	Obesity-related traits;
BRCA	cis	rs17095355	1.000	rs3862006	chr10:111750764	A/G	cg00817464	chr10:111662876	XPNPEP1	0.38	9.42	0.35	8.18e-20	Biliary atresia;
BRCA	cis	rs1185460	0.967	rs1177563	chr11:118949083	C/T	cg23280166	chr11:118938394	VPS11	0.44	10.7	0.39	1.12e-24	Coronary artery disease;
BRCA	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg13010199	chr12:38710504	ALG10B	-0.39	-8.62	-0.32	5.09e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.55	8.66	0.32	3.86e-17	HIV-1 control;
BRCA	cis	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg21775007	chr8:11205619	TDH	0.46	9.12	0.34	9.88e-19	Triglycerides;
BRCA	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg15556689	chr8:8085844	FLJ10661	-0.33	-8.29	-0.31	6.52e-16	Retinal vascular caliber;
BRCA	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg16230307	chr14:35515116	FAM177A1	0.73	15.26	0.52	4.67e-45	Psoriasis;
BRCA	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg06623918	chr6:96969491	KIAA0776	0.9	25.97	0.72	4.85e-102	Headache;
BRCA	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg03146154	chr1:46216737	IPP	0.53	11.89	0.43	1.37e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10193935	0.901	rs3088290	chr2:42578143	A/G	cg27598129	chr2:42591480	NA	-0.93	-14.98	-0.51	1.11e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg03689076	chr20:33865952	NA	-0.51	-9.55	-0.35	2.82e-20	Attention deficit hyperactivity disorder;
BRCA	cis	rs7246657	0.722	rs2972458	chr19:38135403	T/C	cg14683738	chr19:37701593	ZNF585B	-0.46	-7.95	-0.3	8.53e-15	Coronary artery calcification;
BRCA	cis	rs68170813	0.559	rs3801963	chr7:106898036	C/T	cg02696742	chr7:106810147	HBP1	-0.47	-8.35	-0.31	4.27e-16	Coronary artery disease;
BRCA	cis	rs16854884	0.657	rs6783089	chr3:143738034	T/C	cg06585982	chr3:143692056	C3orf58	0.43	8.99	0.33	2.87e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg06671706	chr8:8559999	CLDN23	0.41	7.98	0.3	6.85e-15	Obesity-related traits;
BRCA	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg18964960	chr10:1102726	WDR37	-0.48	-8.59	-0.32	6.63e-17	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	13.02	0.46	1.5e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg11693508	chr17:37793320	STARD3	0.52	9.1	0.34	1.12e-18	Neuroticism;
BRCA	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg09307838	chr4:120376055	NA	0.68	14.41	0.5	5.79e-41	Corneal astigmatism;
BRCA	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.54	8.44	0.32	2.2e-16	Renal function-related traits (BUN);
BRCA	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg26384229	chr12:38710491	ALG10B	0.7	15.83	0.53	7.18e-48	Bladder cancer;
BRCA	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21659725	chr3:3221576	CRBN	0.71	21.71	0.65	1.05e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg11062466	chr8:58055876	NA	0.5	8.75	0.33	1.96e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.05	-19.05	-0.6	1.99e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg18811423	chr2:55921094	PNPT1	0.79	27.77	0.74	6.49e-112	Metabolic syndrome;
BRCA	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg26168224	chr5:2018326	NA	0.66	19.13	0.6	8.14e-65	Gut microbiome composition (winter);
BRCA	cis	rs6973256	0.897	rs2430769	chr7:133349149	A/G	cg07491979	chr7:133331646	EXOC4	0.39	9.05	0.34	1.75e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg00409905	chr10:38381863	ZNF37A	-0.51	-10.9	-0.4	1.73e-25	Extrinsic epigenetic age acceleration;
BRCA	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18876405	chr7:65276391	NA	-0.51	-11.49	-0.41	6.61e-28	Aortic root size;
BRCA	cis	rs3820928	0.904	rs2396432	chr2:227765891	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.42	-0.32	2.58e-16	Pulmonary function;
BRCA	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg02659138	chr7:134003124	SLC35B4	0.33	9.39	0.35	1.05e-19	Mean platelet volume;
BRCA	cis	rs4409675	0.576	rs6564	chr1:28212975	A/G	cg23691781	chr1:28212827	C1orf38	-0.32	-10.95	-0.4	1.11e-25	Corneal astigmatism;
BRCA	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg20891283	chr12:69753455	YEATS4	0.56	13.64	0.47	2.38e-37	Blood protein levels;
BRCA	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg21573476	chr21:45109991	RRP1B	-0.47	-11.95	-0.43	7.57e-30	Mean corpuscular volume;
BRCA	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg03146154	chr1:46216737	IPP	0.49	10.79	0.39	4.87e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.76	17.02	0.56	7.81e-54	Lymphocyte counts;
BRCA	cis	rs698813	0.774	rs1085492	chr2:44609371	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	10.09	0.37	2.53e-22	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.63	10.12	0.37	1.92e-22	Renal function-related traits (BUN);
BRCA	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg12927641	chr6:109611667	NA	-0.42	-10.99	-0.4	7.34e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.78	13.12	0.46	5.41e-35	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.84	0.3	1.89e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.76	0.5	1.21e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6977660	0.714	rs10252965	chr7:19822385	A/C	cg05791153	chr7:19748676	TWISTNB	0.57	10.8	0.39	4.43e-25	Thyroid stimulating hormone;
BRCA	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg11502198	chr6:26597334	ABT1	0.48	9.58	0.35	2.08e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6882046	0.513	rs676096	chr5:88035887	C/T	cg22951263	chr5:87985283	NA	-0.38	-10.61	-0.39	2.46e-24	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg26587870	chr6:27730563	NA	0.42	8.97	0.33	3.26e-18	Parkinson's disease;
BRCA	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg03929089	chr4:120376271	NA	-0.72	-15.47	-0.52	4.26e-46	Coronary artery disease;
BRCA	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg22920501	chr2:26401640	FAM59B	0.94	16.22	0.54	8.59e-50	Gut microbiome composition (summer);
BRCA	cis	rs73242632	1.000	rs73242632	chr4:57893770	C/A	cg20415529	chr4:57845134	POLR2B;C4orf14	0.66	7.82	0.3	2.17e-14	Congenital heart disease (maternal effect);
BRCA	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg03146154	chr1:46216737	IPP	0.53	11.89	0.43	1.37e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg01283332	chr5:1856932	NA	-0.32	-7.81	-0.3	2.41e-14	Cardiovascular disease risk factors;
BRCA	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg22800045	chr5:56110881	MAP3K1	0.68	12.93	0.46	3.81e-34	Initial pursuit acceleration;
BRCA	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.07	0.4	3.43e-26	Bipolar disorder;
BRCA	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg03188948	chr7:1209495	NA	0.86	11.78	0.42	3.91e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg21782813	chr7:2030301	MAD1L1	0.33	9.12	0.34	1e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs4474465	1.000	rs7927722	chr11:78210893	T/C	cg27205649	chr11:78285834	NARS2	0.32	9.06	0.34	1.6e-18	Alzheimer's disease (survival time);
BRCA	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg26395211	chr5:140044315	WDR55	0.35	7.92	0.3	1.05e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6087990	0.806	rs4911258	chr20:31369479	G/A	cg13636640	chr20:31349939	DNMT3B	0.62	19.05	0.6	1.98e-64	Ulcerative colitis;
BRCA	cis	rs813218	0.565	rs6805884	chr3:99684808	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.4	-8.53	-0.32	1.06e-16	Orofacial clefts;
BRCA	cis	rs3925075	0.764	rs8044482	chr16:31345752	T/C	cg02846316	chr16:31340340	ITGAM	0.54	13.37	0.47	3.83e-36	IgA nephropathy;
BRCA	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg00031303	chr3:195681400	NA	0.46	8.57	0.32	7.62e-17	Pancreatic cancer;
BRCA	trans	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg26043149	chr18:55253948	FECH	0.39	8.87	0.33	7.45e-18	Bone mineral density;
BRCA	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg09904177	chr6:26538194	HMGN4	0.56	18.18	0.58	7.27e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.31e-23	Motion sickness;
BRCA	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg03188948	chr7:1209495	NA	0.87	11.85	0.42	2.11e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg09904177	chr6:26538194	HMGN4	0.47	14.7	0.5	2.27e-42	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.81	0.3	2.27e-14	Corneal astigmatism;
BRCA	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg04553112	chr3:125709451	NA	-0.53	-8.69	-0.32	3.12e-17	Blood pressure (smoking interaction);
BRCA	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.84	0.45	9.69e-34	Bipolar disorder;
BRCA	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg24324837	chr19:49891574	CCDC155	0.47	8.03	0.3	4.72e-15	Multiple sclerosis;
BRCA	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg05623727	chr3:50126028	RBM5	-0.42	-9.83	-0.36	2.46e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs13046373	0.508	rs1507393	chr21:31992779	A/G	cg16431978	chr21:31797932	KRTAP13-3	0.35	8.89	0.33	6.35e-18	HDL cholesterol;
BRCA	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg26384229	chr12:38710491	ALG10B	0.62	14.74	0.5	1.57e-42	Bladder cancer;
BRCA	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg25173405	chr17:45401733	C17orf57	0.49	9.99	0.37	6.19e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4478858	0.735	rs2889730	chr1:31827159	C/T	cg00250761	chr1:31883323	NA	-0.33	-8.5	-0.32	1.33e-16	Alcohol dependence;
BRCA	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg06494592	chr3:125709126	NA	-0.54	-8.58	-0.32	7.14e-17	Blood pressure (smoking interaction);
BRCA	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg17470723	chr8:74884337	TCEB1	0.41	8.86	0.33	7.66e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg08508325	chr11:3079039	CARS	0.29	8.64	0.32	4.52e-17	Calcium levels;
BRCA	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	13.37	0.47	4.16e-36	Neuroticism;
BRCA	cis	rs2882667	0.964	rs11739351	chr5:138311742	A/G	cg04439458	chr5:138467593	SIL1	-0.35	-9.5	-0.35	4.09e-20	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg12927641	chr6:109611667	NA	0.42	11.01	0.4	5.95e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg04362960	chr10:104952993	NT5C2	-0.44	-10.46	-0.38	9.39e-24	Arsenic metabolism;
BRCA	cis	rs11585357	1.000	rs11585357	chr1:17601165	C/T	cg08277548	chr1:17600880	PADI3	-0.74	-12.12	-0.43	1.41e-30	Hair shape;
BRCA	cis	rs12472274	0.617	rs7568705	chr2:239081808	C/T	cg17459225	chr2:239074497	NA	0.48	10.27	0.38	5.12e-23	Phospholipid levels (plasma);
BRCA	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.37	-0.41	2.08e-27	Gut microbiome composition (summer);
BRCA	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	8.34	0.31	4.52e-16	Schizophrenia;
BRCA	cis	rs897080	0.515	rs786616	chr2:44592975	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	10.8	0.39	4.39e-25	Height;
BRCA	cis	rs6430585	0.527	rs2289959	chr2:136423904	C/T	cg07169764	chr2:136633963	MCM6	0.9	17.5	0.57	2.71e-56	Corneal structure;
BRCA	cis	rs4566357	0.615	rs10178260	chr2:227914458	G/T	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.2	-0.31	1.33e-15	Coronary artery disease;
BRCA	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.8	0.33	1.24e-17	Personality dimensions;
BRCA	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.52	-9.03	-0.34	1.99e-18	Body mass index (adult);
BRCA	trans	rs7200543	1.000	rs7200543	chr16:15129970	C/T	cg24683922	chr1:11983373	KIAA2013	0.36	8.18	0.31	1.5e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg11822812	chr5:140052017	DND1	-0.32	-8.79	-0.33	1.38e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg05294307	chr14:35346193	BAZ1A	-0.62	-10.42	-0.38	1.41e-23	Psoriasis;
BRCA	trans	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg16006841	chr5:176797999	RGS14	0.62	11.96	0.43	6.66e-30	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs3760047	0.609	rs2541639	chr16:205035	C/T	cg25425005	chr16:202905	HBZ	-0.4	-8.65	-0.32	4.21e-17	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06002616	chr8:101225028	SPAG1	-0.34	-8.28	-0.31	7.2e-16	Atrioventricular conduction;
BRCA	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg06784218	chr1:46089804	CCDC17	0.5	12.08	0.43	2.02e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg05347473	chr6:146136440	FBXO30	0.39	7.81	0.3	2.29e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3784262	0.528	rs4646588	chr15:58304313	A/G	cg12031962	chr15:58353849	ALDH1A2	0.34	8.9	0.33	5.94e-18	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	trans	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg19862616	chr7:65841803	NCRNA00174	0.79	24.63	0.7	1.1e-94	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03264133	chr6:25882463	NA	-0.53	-11.47	-0.41	7.9e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg18252515	chr7:66147081	NA	-0.55	-11.26	-0.41	6.1e-27	Corneal structure;
BRCA	trans	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04565464	chr8:145669602	NFKBIL2	0.4	9.93	0.37	1.08e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs9612	1.000	rs346526	chr19:44259565	A/G	cg08581076	chr19:44259116	C19orf61	0.53	9.71	0.36	6.94e-21	Exhaled nitric oxide output;
BRCA	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.93	-0.4	1.32e-25	Mean corpuscular volume;
BRCA	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg25110126	chr1:46999211	NA	-0.63	-11.33	-0.41	3.14e-27	Monobrow;
BRCA	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg23711669	chr6:146136114	FBXO30	0.79	18.88	0.6	1.64e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs72781680	0.898	rs72786270	chr2:24059049	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	13.52	0.47	8.27e-37	Lymphocyte counts;
BRCA	cis	rs4853036	0.951	rs3755391	chr2:70141519	C/T	cg02498382	chr2:70120550	SNRNP27	-0.54	-9.67	-0.36	9.57e-21	Colorectal or endometrial cancer;
BRCA	cis	rs295137	0.799	rs4145969	chr2:201139961	C/T	cg23649088	chr2:200775458	C2orf69	-0.39	-8.15	-0.31	1.87e-15	Asthma (bronchodilator response);
BRCA	cis	rs1865721	0.771	rs62092763	chr18:73128623	T/G	cg26385618	chr18:73139727	C18orf62	-0.43	-10.23	-0.37	7.83e-23	Intelligence;
BRCA	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg00031303	chr3:195681400	NA	0.45	8.53	0.32	1.05e-16	Pancreatic cancer;
BRCA	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-8.48	-0.32	1.59e-16	Personality dimensions;
BRCA	cis	rs1712517	0.873	rs7916056	chr10:104997914	T/C	cg05636881	chr10:105038444	INA	-0.36	-7.89	-0.3	1.36e-14	Migraine;
BRCA	trans	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg25214090	chr10:38739885	LOC399744	0.52	11.32	0.41	3.29e-27	Corneal astigmatism;
BRCA	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.82	-0.36	2.81e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Fuchs's corneal dystrophy;
BRCA	trans	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	27.22	0.73	6.07e-109	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg26695010	chr11:65641043	EFEMP2	0.42	9.31	0.35	2.05e-19	Eosinophil percentage of white cells;
BRCA	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg17366294	chr4:99064904	C4orf37	0.42	9.84	0.36	2.22e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.14	0.37	1.71e-22	Aortic root size;
BRCA	cis	rs71444571	1	rs71444571	chr12:123771015	G/A	cg00376283	chr12:123451042	ABCB9	-0.55	-10.66	-0.39	1.63e-24	Lymphocyte percentage of white cells;
BRCA	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg12927641	chr6:109611667	NA	-0.42	-10.85	-0.39	2.82e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg13319975	chr6:146136371	FBXO30	0.34	7.86	0.3	1.67e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.88	0.43	1.45e-29	Homoarginine levels;
BRCA	cis	rs13161895	0.818	rs114211674	chr5:179484518	A/C	cg02702477	chr5:179499311	RNF130	0.58	10.11	0.37	2.19e-22	LDL cholesterol;
BRCA	cis	rs4588572	0.686	rs2362823	chr5:77693623	A/G	cg11547950	chr5:77652471	NA	0.47	8.45	0.32	2.04e-16	Triglycerides;
BRCA	cis	rs7172677	0.711	rs8027552	chr15:75439393	A/G	cg14664628	chr15:75095509	CSK	-0.36	-7.82	-0.3	2.24e-14	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs17384381	0.634	rs11801146	chr1:85915374	C/T	cg16011679	chr1:85725395	C1orf52	0.5	7.84	0.3	1.85e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg08847533	chr14:75593920	NEK9	0.87	21.77	0.65	4.72e-79	Height;
BRCA	cis	rs59698941	0.550	rs11739194	chr5:132201230	T/C	cg14825688	chr5:132208181	LEAP2	-0.38	-8.79	-0.33	1.36e-17	Apolipoprotein A-IV levels;
BRCA	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.74	-15.76	-0.53	1.68e-47	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg22800045	chr5:56110881	MAP3K1	0.62	11.85	0.42	2.01e-29	Initial pursuit acceleration;
BRCA	cis	rs9611519	0.589	rs8138917	chr22:41412425	T/C	cg03806693	chr22:41940476	POLR3H	-0.4	-7.81	-0.3	2.29e-14	Neuroticism;
BRCA	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-11.45	-0.41	9.65e-28	Neuroticism;
BRCA	cis	rs8014204	0.736	rs2111705	chr14:75261641	G/A	cg06637938	chr14:75390232	RPS6KL1	0.43	8.8	0.33	1.25e-17	Caffeine consumption;
BRCA	cis	rs6450176	1.000	rs3776703	chr5:53305259	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-15.39	-0.52	1.09e-45	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.37	-0.35	1.21e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg24558204	chr6:135376177	HBS1L	0.45	12.45	0.44	5.39e-32	Red blood cell count;
BRCA	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg11752832	chr7:134001865	SLC35B4	0.5	12.85	0.45	8.99e-34	Mean platelet volume;
BRCA	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg24531977	chr5:56204891	C5orf35	-0.41	-8.74	-0.33	2.04e-17	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs4631830	0.683	rs11004409	chr10:51498019	G/C	cg20129853	chr10:51489980	NA	0.32	8.66	0.32	3.98e-17	Prostate-specific antigen levels;
BRCA	trans	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg13565492	chr6:43139072	SRF	-0.87	-16.03	-0.54	7.52e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.81	-0.36	2.98e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.58	-8.24	-0.31	9.87e-16	Schizophrenia;
BRCA	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.54	11.62	0.42	1.88e-28	Lung function (FEV1/FVC);
BRCA	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.47	0.32	1.74e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg16586182	chr3:47516702	SCAP	0.66	15.26	0.52	4.86e-45	Colorectal cancer;
BRCA	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.47	10.54	0.38	4.79e-24	Colorectal cancer;
BRCA	cis	rs34779708	0.966	rs998658	chr10:35408654	A/G	cg03585969	chr10:35415529	CREM	0.44	9.4	0.35	9.55e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg04315214	chr1:2043799	PRKCZ	0.44	11.85	0.42	1.99e-29	Height;
BRCA	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg12062639	chr20:23401060	NAPB	0.96	13.45	0.47	1.64e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs4660306	0.961	rs12145526	chr1:45969036	G/C	cg24296786	chr1:45957014	TESK2	0.43	8.47	0.32	1.66e-16	Homocysteine levels;
BRCA	cis	rs72627509	0.857	rs55762216	chr4:57765731	G/C	cg26694713	chr4:57773883	REST	0.47	8.58	0.32	7.34e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	trans	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.54	0.32	1e-16	Corneal astigmatism;
BRCA	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4727443	0.932	rs7803714	chr7:99585150	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.39	8.75	0.33	1.91e-17	Interstitial lung disease;
BRCA	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	8.28	0.31	7.46e-16	Diabetic retinopathy;
BRCA	cis	rs10851411	0.559	rs56172155	chr15:42882182	C/T	cg21293051	chr15:42870591	STARD9	0.55	8.86	0.33	7.6e-18	Glucose homeostasis traits;
BRCA	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-9.9	-0.36	1.35e-21	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg12011299	chr4:100065546	ADH4	0.5	13.37	0.47	3.94e-36	Alcohol dependence;
BRCA	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.92	23.0	0.67	9.66e-86	Subjective well-being;
BRCA	cis	rs9463078	0.764	rs1854547	chr6:44912366	G/A	cg25276700	chr6:44698697	NA	-0.36	-8.38	-0.31	3.37e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg02153584	chr22:29168773	CCDC117	-0.52	-11.77	-0.42	4.24e-29	Red cell distribution width;
BRCA	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg21535247	chr6:8435926	SLC35B3	0.41	9.31	0.35	2.08e-19	Motion sickness;
BRCA	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg18252515	chr7:66147081	NA	1.07	15.89	0.53	3.53e-48	Diabetic kidney disease;
BRCA	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg04025307	chr7:1156635	C7orf50	0.57	10.07	0.37	2.98e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg19318889	chr4:1322082	MAEA	0.57	11.84	0.42	2.31e-29	Longevity;
BRCA	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg10295955	chr4:187884368	NA	-0.99	-31.64	-0.78	6.55e-133	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg01028140	chr2:1542097	TPO	-0.58	-12.18	-0.43	8e-31	IgG glycosylation;
BRCA	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-12.41	-0.44	7.49e-32	Response to antipsychotic treatment;
BRCA	cis	rs698833	0.819	rs2340810	chr2:44536546	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.51	-10.53	-0.38	5.28e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs600806	0.821	rs3879447	chr1:109891403	C/T	cg20591472	chr1:110008990	SYPL2	0.33	8.19	0.31	1.42e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs870825	0.929	rs72689278	chr4:185593718	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	14.09	0.49	1.87e-39	Blood protein levels;
BRCA	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	10.2	0.37	9.99e-23	Retinal vascular caliber;
BRCA	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg03474202	chr17:45855739	NA	-0.47	-12.59	-0.45	1.28e-32	IgG glycosylation;
BRCA	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.88	-0.36	1.58e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg25767906	chr1:53392781	SCP2	-0.38	-8.61	-0.32	5.89e-17	Monocyte count;
BRCA	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg09877947	chr5:131593287	PDLIM4	0.4	10.33	0.38	3.19e-23	Breast cancer;
BRCA	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.61	15.67	0.53	4.44e-47	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg03060546	chr3:49711283	APEH	-0.61	-8.63	-0.32	4.84e-17	Menarche (age at onset);
BRCA	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.87	-0.39	2.36e-25	Mean corpuscular volume;
BRCA	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg08807101	chr21:30365312	RNF160	0.75	19.8	0.62	2.09e-68	Dental caries;
BRCA	cis	rs9309473	0.950	rs73947808	chr2:73721250	A/C	cg20560298	chr2:73613845	ALMS1	-0.48	-11.53	-0.41	4.49e-28	Metabolite levels;
BRCA	cis	rs708547	0.914	rs58228066	chr4:57735787	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-11.06	-0.4	3.87e-26	Response to bleomycin (chromatid breaks);
BRCA	cis	rs6893300	0.524	rs6601073	chr5:179177271	A/G	cg14593053	chr5:179126677	CANX	-0.47	-12.95	-0.46	3.01e-34	Resting heart rate;
BRCA	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg23262073	chr20:60523788	NA	0.56	13.0	0.46	1.88e-34	Obesity-related traits;
BRCA	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg06618935	chr21:46677482	NA	-0.37	-8.15	-0.31	1.98e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg06521331	chr12:34319734	NA	-0.53	-9.52	-0.35	3.46e-20	Morning vs. evening chronotype;
BRCA	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg19077165	chr18:44547161	KATNAL2	-0.57	-12.39	-0.44	9.42e-32	Personality dimensions;
BRCA	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18876405	chr7:65276391	NA	0.54	12.99	0.46	2.18e-34	Aortic root size;
BRCA	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-11.27	-0.41	5.52e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs13046373	0.535	rs2832966	chr21:32017177	A/G	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.24	0.31	9.41e-16	HDL cholesterol;
BRCA	cis	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.36	-8.24	-0.31	9.96e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05535760	chr7:792225	HEATR2	-0.87	-14.92	-0.51	2.1e-43	Cerebrospinal P-tau181p levels;
BRCA	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.05e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12711979	0.875	rs11686157	chr2:3855020	C/G	cg17052675	chr2:3827356	NA	-0.41	-11.23	-0.41	8.03e-27	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg07080220	chr10:102295463	HIF1AN	0.6	13.97	0.48	6.82e-39	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg08601574	chr20:25228251	PYGB	0.33	7.95	0.3	8.31e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg16586182	chr3:47516702	SCAP	0.52	11.36	0.41	2.2e-27	Colorectal cancer;
BRCA	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg23950597	chr19:37808831	NA	-0.61	-11.22	-0.41	8.27e-27	Coronary artery calcification;
BRCA	cis	rs9487051	0.803	rs410449	chr6:109539853	C/T	cg21918786	chr6:109611834	NA	-0.35	-8.99	-0.33	2.86e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14829155	chr15:31115871	NA	-0.52	-12.2	-0.43	6.11e-31	Huntington's disease progression;
BRCA	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg15017067	chr4:17643749	FAM184B	0.29	8.84	0.33	9.21e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6882046	0.513	rs34318	chr5:88027149	G/A	cg22951263	chr5:87985283	NA	-0.38	-10.68	-0.39	1.27e-24	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg11057378	chr10:81107060	PPIF	0.4	9.46	0.35	5.85e-20	Height;
BRCA	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg10223061	chr2:219282414	VIL1	-0.27	-8.11	-0.31	2.61e-15	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs4596713	0.538	rs6560589	chr9:71749540	A/T	cg16512924	chr15:28394682	HERC2	0.41	9.85	0.36	2.06e-21	Headache;
BRCA	cis	rs6700896	0.931	rs12043644	chr1:66147348	A/G	cg04111102	chr1:66153794	NA	0.34	8.46	0.32	1.89e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18876405	chr7:65276391	NA	-0.51	-11.39	-0.41	1.75e-27	Aortic root size;
BRCA	cis	rs6484504	0.576	rs2447671	chr11:31334323	A/G	cg14844989	chr11:31128820	NA	-0.41	-8.97	-0.33	3.23e-18	Red blood cell count;
BRCA	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg06885757	chr1:42089581	HIVEP3	0.4	12.99	0.46	2.15e-34	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg06521331	chr12:34319734	NA	-0.62	-11.27	-0.41	5.54e-27	Morning vs. evening chronotype;
BRCA	cis	rs243505	0.733	rs9987055	chr7:148501758	G/A	cg09806900	chr7:148480153	CUL1	0.52	10.77	0.39	5.46e-25	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg18402987	chr7:1209562	NA	0.85	12.2	0.43	6.3e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.89	-21.47	-0.65	2.02e-77	Ulcerative colitis;
BRCA	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg07148914	chr20:33460835	GGT7	0.47	9.96	0.37	7.88e-22	Height;
BRCA	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	21.47	0.65	2.08e-77	Mean platelet volume;
BRCA	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg24642439	chr20:33292090	TP53INP2	0.59	10.26	0.38	5.53e-23	Protein C levels;
BRCA	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-11.2	-0.41	1.03e-26	Platelet count;
BRCA	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg12062639	chr20:23401060	NAPB	0.94	13.43	0.47	2.14e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg04842962	chr6:43655489	MRPS18A	1.11	38.52	0.84	9.34e-169	IgG glycosylation;
BRCA	cis	rs507080	0.922	rs525485	chr11:118555754	C/T	cg09144398	chr11:118550485	TREH	-0.37	-8.8	-0.33	1.24e-17	Serum metabolite levels;
BRCA	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg08738300	chr3:44038990	NA	0.46	8.89	0.33	6.4e-18	Coronary artery disease;
BRCA	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.29	0.31	6.45e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2066819	1.000	rs77120931	chr12:56646213	A/C	cg26714650	chr12:56694279	CS	-1.16	-15.39	-0.52	1.09e-45	Psoriasis vulgaris;
BRCA	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg01884057	chr2:25150051	NA	0.35	9.25	0.34	3.24e-19	Body mass index;
BRCA	cis	rs72772090	0.539	rs35898772	chr5:96179685	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-11.43	-0.41	1.14e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg20701182	chr2:24300061	SF3B14	0.67	10.02	0.37	4.78e-22	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg00106254	chr7:1943704	MAD1L1	-0.31	-8.18	-0.31	1.55e-15	Schizophrenia;
BRCA	cis	rs2479724	0.935	rs2025951	chr6:41827193	C/T	cg17623882	chr6:41773611	USP49	0.38	10.36	0.38	2.32e-23	Menarche (age at onset);
BRCA	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg11752832	chr7:134001865	SLC35B4	0.5	11.35	0.41	2.45e-27	Mean platelet volume;
BRCA	cis	rs9341808	0.644	rs62408577	chr6:80942024	T/A	cg08355045	chr6:80787529	NA	-0.32	-7.85	-0.3	1.72e-14	Sitting height ratio;
BRCA	cis	rs67478160	0.595	rs12433109	chr14:104196607	G/A	cg08213375	chr14:104286397	PPP1R13B	0.59	15.24	0.52	5.63e-45	Schizophrenia;
BRCA	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg06627628	chr2:24431161	ITSN2	-0.79	-15.05	-0.51	5.04e-44	Asthma;
BRCA	trans	rs1459104	0.714	rs36018195	chr11:55172856	G/A	cg15704280	chr7:45808275	SEPT13	0.66	8.25	0.31	8.81e-16	Body mass index;
BRCA	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg12386194	chr3:101231763	SENP7	0.4	8.56	0.32	8.25e-17	Colorectal cancer;
BRCA	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08219700	chr8:58056026	NA	0.45	8.17	0.31	1.62e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg01877450	chr7:97915802	BRI3	-0.39	-8.98	-0.33	3.1e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10489202	0.634	rs6427119	chr1:168074145	A/G	cg24449463	chr1:168025552	DCAF6	0.47	14.97	0.51	1.21e-43	Schizophrenia;
BRCA	trans	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg14791747	chr16:20752902	THUMPD1	0.4	9.39	0.35	1.07e-19	Cognitive test performance;
BRCA	cis	rs17688601	0.951	rs17621345	chr7:40875192	A/C	cg05119115	chr7:40866195	C7orf10	-0.55	-10.96	-0.4	9.58e-26	Pancreatic cancer;
BRCA	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.22	-0.31	1.15e-15	Depression;
BRCA	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg24531977	chr5:56204891	C5orf35	0.4	7.98	0.3	6.8e-15	Coronary artery disease;
BRCA	cis	rs9316337	0.843	rs9509683	chr13:21977812	A/G	cg21011702	chr13:21951294	ZDHHC20	-0.3	-7.81	-0.3	2.41e-14	Schizophrenia;
BRCA	cis	rs6545883	1.000	rs778758	chr2:61782161	T/C	cg15711740	chr2:61764176	XPO1	-0.56	-14.15	-0.49	9.36e-40	Tuberculosis;
BRCA	cis	rs11690935	0.885	rs6725388	chr2:172730015	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.83	-25.83	-0.71	2.58e-101	Schizophrenia;
BRCA	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg24531977	chr5:56204891	C5orf35	-0.41	-8.38	-0.31	3.28e-16	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs2380220	0.606	rs7754906	chr6:95992429	C/T	cg15832292	chr6:96025679	MANEA	0.48	8.03	0.3	4.75e-15	Behavioural disinhibition (generation interaction);
BRCA	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg06784218	chr1:46089804	CCDC17	-0.45	-10.8	-0.39	4.54e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.55	-10.12	-0.37	1.93e-22	Renal function-related traits (BUN);
BRCA	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4363385	0.720	rs1611764	chr1:152957887	G/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.75	-0.33	1.83e-17	Inflammatory skin disease;
BRCA	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg18446336	chr7:2847575	GNA12	-0.41	-9.25	-0.34	3.42e-19	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
BRCA	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg01657329	chr11:68192670	LRP5	-0.34	-7.94	-0.3	9.15e-15	Total body bone mineral density;
BRCA	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08109568	chr15:31115862	NA	-0.44	-10.46	-0.38	9.93e-24	Huntington's disease progression;
BRCA	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.0	-0.34	2.59e-18	Total body bone mineral density;
BRCA	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.61e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4363385	0.747	rs4845330	chr1:152981505	A/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.87	-0.36	1.81e-21	Inflammatory skin disease;
BRCA	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg03342759	chr3:160939853	NMD3	-0.54	-11.61	-0.42	2.17e-28	Morning vs. evening chronotype;
BRCA	cis	rs1559088	0.501	rs8100568	chr19:33567565	T/C	cg17764715	chr19:33622953	WDR88	0.52	8.39	0.32	3.01e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs16958440	0.867	rs77348110	chr18:44674167	T/C	cg17192377	chr18:44677553	HDHD2	0.99	13.89	0.48	1.53e-38	Sitting height ratio;
BRCA	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg01689657	chr7:91764605	CYP51A1	0.22	7.9	0.3	1.23e-14	Breast cancer;
BRCA	cis	rs9297145	0.585	rs62473049	chr7:98777685	T/C	cg05967295	chr7:98741636	SMURF1	-0.64	-14.17	-0.49	7.42e-40	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg12193833	chr17:30244370	NA	-0.58	-8.78	-0.33	1.54e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg02527881	chr3:46936655	PTH1R	-0.37	-9.38	-0.35	1.09e-19	Colorectal cancer;
BRCA	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.35	9.11	0.34	1.02e-18	Resting heart rate;
BRCA	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg16606324	chr3:10149918	C3orf24	0.55	10.84	0.39	2.97e-25	Alzheimer's disease;
BRCA	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18404041	chr3:52824283	ITIH1	-0.29	-8.77	-0.33	1.67e-17	Bipolar disorder;
BRCA	cis	rs4662945	0.525	rs10174479	chr2:130296287	A/C	cg05962382	chr2:130345044	NA	-0.33	-8.0	-0.3	5.82e-15	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg12311346	chr5:56204834	C5orf35	-0.78	-15.45	-0.52	5.29e-46	Initial pursuit acceleration;
BRCA	cis	rs7512552	0.839	rs12040949	chr1:150447462	C/T	cg15654264	chr1:150340011	RPRD2	0.43	9.18	0.34	5.69e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg11584989	chr19:19387371	SF4	0.31	7.88	0.3	1.44e-14	Tonsillectomy;
BRCA	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.87	-0.33	7.49e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg08807101	chr21:30365312	RNF160	0.77	20.35	0.63	2.33e-71	Dental caries;
BRCA	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.62	-13.8	-0.48	4.14e-38	Axial length;
BRCA	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg00686598	chr14:53173677	PSMC6	-1.05	-15.17	-0.51	1.28e-44	Alzheimer's disease (late onset);
BRCA	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg03713592	chr11:72463424	ARAP1	0.62	11.08	0.4	3.08e-26	Body mass index;
BRCA	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg27129171	chr3:47204927	SETD2	0.68	15.82	0.53	8.12e-48	Colorectal cancer;
BRCA	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg03711944	chr11:47377212	SPI1	0.42	11.41	0.41	1.45e-27	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.32	0.35	1.93e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.57	0.39	3.5e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs897984	0.609	rs4889609	chr16:31026427	A/G	cg00531865	chr16:30841666	NA	-0.38	-9.1	-0.34	1.14e-18	Dementia with Lewy bodies;
BRCA	cis	rs2625529	0.824	rs7170754	chr15:72218594	G/A	cg16672083	chr15:72433130	SENP8	-0.83	-17.2	-0.56	8.64e-55	Red blood cell count;
BRCA	cis	rs6842047	1.000	rs4862665	chr4:187136142	C/T	cg09526685	chr4:187126073	CYP4V2	-0.64	-9.39	-0.35	1.04e-19	Blood protein levels;
BRCA	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg08738300	chr3:44038990	NA	0.45	8.7	0.33	2.79e-17	Coronary artery disease;
BRCA	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg26384229	chr12:38710491	ALG10B	0.8	19.69	0.61	7.86e-68	Heart rate;
BRCA	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg08992911	chr2:238395768	MLPH	0.55	8.92	0.33	4.83e-18	Prostate cancer;
BRCA	cis	rs7809950	0.635	rs62483629	chr7:106866178	T/C	cg23024343	chr7:107201750	COG5	-0.45	-8.93	-0.33	4.59e-18	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.21e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg17063962	chr7:91808500	NA	0.57	13.47	0.47	1.42e-36	Breast cancer;
BRCA	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg27170947	chr2:26402098	FAM59B	-0.84	-13.57	-0.47	4.83e-37	Gut microbiome composition (summer);
BRCA	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg03146154	chr1:46216737	IPP	0.54	12.05	0.43	2.88e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg21775007	chr8:11205619	TDH	-0.49	-9.48	-0.35	4.89e-20	Triglycerides;
BRCA	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	17.7	0.57	2.46e-57	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7572263	0.724	rs10497896	chr2:209049899	G/C	cg23998903	chr2:209048830	C2orf80	-0.4	-8.39	-0.31	3.15e-16	Glioma;Non-glioblastoma glioma;
BRCA	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.49	-9.43	-0.35	7.35e-20	Body mass index;
BRCA	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg25319279	chr11:5960081	NA	-0.43	-8.25	-0.31	9.22e-16	DNA methylation (variation);
BRCA	cis	rs9443189	0.615	rs618239	chr6:76350038	A/G	cg01950844	chr6:76311363	SENP6	0.83	13.32	0.47	6.61e-36	Prostate cancer;
BRCA	cis	rs7572733	0.515	rs13382697	chr2:198920560	A/C	cg00792783	chr2:198669748	PLCL1	0.4	8.82	0.33	1.05e-17	Dermatomyositis;
BRCA	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg24060327	chr5:131705240	SLC22A5	0.41	8.0	0.3	5.71e-15	Acylcarnitine levels;
BRCA	cis	rs1691799	0.867	rs1168341	chr12:66759080	G/C	cg16791601	chr12:66731901	HELB	-0.66	-18.11	-0.58	1.7e-59	White blood cell count (basophil);
BRCA	cis	rs59698941	0.527	rs1557852	chr5:132181800	G/A	cg14825688	chr5:132208181	LEAP2	-0.37	-8.65	-0.32	4.12e-17	Apolipoprotein A-IV levels;
BRCA	cis	rs11955398	0.546	rs10050803	chr5:60038225	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.34	-7.91	-0.3	1.16e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg11366901	chr6:160182831	ACAT2	0.78	14.93	0.51	1.81e-43	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs2742234	0.955	rs2435384	chr10:43673731	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.43	-8.91	-0.33	5.1e-18	Hirschsprung disease;
BRCA	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.21	0.31	1.25e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.94	0.3	9.1e-15	Corneal astigmatism;
BRCA	cis	rs8054556	0.787	rs3814877	chr16:30042677	G/T	cg06326092	chr16:30034487	C16orf92	0.32	8.0	0.3	6.03e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	14.16	0.49	8.42e-40	Height;
BRCA	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	11.32	0.41	3.3e-27	Height;
BRCA	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg23625390	chr15:77176239	SCAPER	-0.55	-12.87	-0.45	6.85e-34	Blood metabolite levels;
BRCA	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	9.11	0.34	1.05e-18	Platelet count;
BRCA	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-10.35	-0.38	2.55e-23	Heart rate;
BRCA	cis	rs4588572	0.601	rs6867673	chr5:77779125	A/G	cg11547950	chr5:77652471	NA	-0.49	-8.62	-0.32	5.25e-17	Triglycerides;
BRCA	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg05221455	chr11:829616	EFCAB4A	-0.37	-8.16	-0.31	1.73e-15	Mean platelet volume;
BRCA	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.78	0.42	4.11e-29	Tonsillectomy;
BRCA	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg14675211	chr2:100938903	LONRF2	0.47	11.01	0.4	6.24e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg05623727	chr3:50126028	RBM5	-0.49	-12.08	-0.43	2.03e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg07741184	chr6:167504864	NA	0.36	10.42	0.38	1.42e-23	Crohn's disease;
BRCA	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg01256987	chr12:42539512	GXYLT1	-0.46	-9.21	-0.34	4.74e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs2882667	1.000	rs2060222	chr5:138308466	C/T	cg04439458	chr5:138467593	SIL1	-0.37	-9.85	-0.36	2.08e-21	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.46	0.63	5.84e-72	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2816062	0.775	rs2745315	chr1:18897118	G/A	cg18795169	chr1:18902165	NA	-0.93	-27.15	-0.73	1.48e-108	Urate levels in lean individuals;
BRCA	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg00383909	chr3:49044727	WDR6	0.96	15.69	0.53	3.76e-47	Cognitive function;
BRCA	cis	rs4803468	0.904	rs60781668	chr19:41944842	A/T	cg09537434	chr19:41945824	ATP5SL	1.03	25.55	0.71	9.48e-100	Height;
BRCA	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg23625390	chr15:77176239	SCAPER	-0.51	-12.37	-0.44	1.11e-31	Blood metabolite levels;
BRCA	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.32	9.04	0.34	1.88e-18	Response to antipsychotic treatment;
BRCA	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	7.93	0.3	9.86e-15	Glomerular filtration rate;
BRCA	cis	rs28830936	1.000	rs11637341	chr15:41955825	G/T	cg17847044	chr15:42102381	MAPKBP1	-0.34	-9.64	-0.36	1.27e-20	Diastolic blood pressure;
BRCA	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg19748678	chr4:122722346	EXOSC9	0.74	16.02	0.54	8.42e-49	Type 2 diabetes;
BRCA	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	8.8	0.33	1.28e-17	Iron status biomarkers;
BRCA	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg18230493	chr5:56204884	C5orf35	-0.58	-11.53	-0.42	4.37e-28	Type 2 diabetes;
BRCA	cis	rs870825	0.549	rs7656993	chr4:185635159	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.57	0.57	1.07e-56	Blood protein levels;
BRCA	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg03877680	chr5:178157825	ZNF354A	0.84	16.94	0.56	2.01e-53	Neutrophil percentage of white cells;
BRCA	cis	rs17401966	1.000	rs11121552	chr1:10435324	C/A	cg03954927	chr1:10346856	KIF1B	0.46	12.58	0.45	1.39e-32	Hepatocellular carcinoma;
BRCA	cis	rs4988958	0.565	rs12712146	chr2:103008714	C/T	cg03938978	chr2:103052716	IL18RAP	0.29	8.51	0.32	1.21e-16	Asthma (childhood onset);
BRCA	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.67	-13.53	-0.47	7.38e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg24829409	chr8:58192753	C8orf71	-0.59	-12.29	-0.44	2.57e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg05025164	chr4:1340916	KIAA1530	0.4	8.94	0.33	3.99e-18	Longevity;
BRCA	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg17691542	chr6:26056736	HIST1H1C	0.46	8.87	0.33	7.29e-18	Iron status biomarkers;
BRCA	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg11764359	chr7:65958608	NA	0.68	15.21	0.52	8.16e-45	Aortic root size;
BRCA	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.17	-0.4	1.33e-26	Schizophrenia;
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg22907277	chr7:1156413	C7orf50	0.5	10.91	0.4	1.5e-25	Longevity;Endometriosis;
BRCA	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00149659	chr3:10157352	C3orf10	0.69	10.32	0.38	3.26e-23	Alzheimer's disease;
BRCA	cis	rs7124681	0.584	rs11039448	chr11:47918416	G/T	cg20307385	chr11:47447363	PSMC3	-0.41	-9.36	-0.35	1.37e-19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg11584989	chr19:19387371	SF4	0.61	13.9	0.48	1.5e-38	Bipolar disorder;
BRCA	trans	rs4718428	0.924	rs6971897	chr7:66412774	T/A	cg18876405	chr7:65276391	NA	0.45	10.01	0.37	5.43e-22	Corneal structure;
BRCA	cis	rs490234	0.871	rs13288032	chr9:128255582	T/A	cg14078157	chr9:128172775	NA	-0.43	-9.93	-0.37	1.01e-21	Mean arterial pressure;
BRCA	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg17470723	chr8:74884337	TCEB1	0.4	8.62	0.32	5.44e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg18196295	chr10:418757	DIP2C	0.41	9.48	0.35	4.96e-20	Psychosis in Alzheimer's disease;
BRCA	cis	rs7818345	0.967	rs4433156	chr8:19284247	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.3	7.96	0.3	7.89e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs6604026	0.698	rs10874744	chr1:93306317	G/A	cg17283838	chr1:93427260	FAM69A	-0.39	-8.23	-0.31	1.03e-15	Multiple sclerosis;
BRCA	trans	rs208520	0.690	rs207102	chr6:66795671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.23	-0.64	4.44e-76	Exhaled nitric oxide output;
BRCA	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg01324343	chr3:183735012	ABCC5	0.83	20.87	0.64	3.89e-74	Anterior chamber depth;
BRCA	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg26373071	chr5:1325741	CLPTM1L	0.41	9.55	0.35	2.72e-20	Lung cancer;
BRCA	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg12923728	chr3:195709715	SDHAP1	0.38	7.83	0.3	2.01e-14	Mean corpuscular volume;
BRCA	cis	rs11887277	0.507	rs6547254	chr2:27055618	G/A	cg12368169	chr2:27073192	DPYSL5	-0.27	-8.01	-0.3	5.28e-15	Obesity-related traits;
BRCA	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg24812749	chr6:127587940	RNF146	0.86	19.78	0.62	2.55e-68	Breast cancer;
BRCA	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg23711669	chr6:146136114	FBXO30	0.77	17.96	0.58	1.11e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7818345	0.967	rs11204039	chr8:19280442	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.3	8.08	0.3	3.19e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.53	-11.03	-0.4	5.04e-26	Lymphocyte counts;
BRCA	trans	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg26043149	chr18:55253948	FECH	-0.4	-8.99	-0.34	2.68e-18	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs72848980	0.512	rs11191749	chr10:105378840	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.45	8.77	0.33	1.59e-17	White matter hyperintensity burden;
BRCA	cis	rs312273	0.641	rs7311085	chr12:41361565	G/A	cg17827154	chr12:41323612	CNTN1	-0.36	-9.32	-0.35	1.82e-19	Bipolar disorder;
BRCA	cis	rs2880765	0.743	rs11630410	chr15:86004741	T/A	cg10818794	chr15:86012489	AKAP13	-0.3	-8.14	-0.31	2.01e-15	Coronary artery disease;
BRCA	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.21e-47	Alzheimer's disease (late onset);
BRCA	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg19717773	chr7:2847554	GNA12	-0.42	-8.62	-0.32	5.3e-17	Height;
BRCA	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg01092361	chr6:42185687	MRPS10	0.7	13.29	0.47	9.42e-36	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
BRCA	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.47	-11.18	-0.4	1.21e-26	Hemoglobin concentration;
BRCA	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg20283391	chr11:68216788	NA	-0.48	-9.31	-0.35	2.06e-19	Total body bone mineral density;
BRCA	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg21782813	chr7:2030301	MAD1L1	0.38	9.67	0.36	9.77e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	18.11	0.58	1.89e-59	Menopause (age at onset);
BRCA	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg26850624	chr5:429559	AHRR	0.35	8.36	0.31	4.02e-16	Cystic fibrosis severity;
BRCA	cis	rs1506636	1.000	rs659416	chr7:123401764	A/G	cg03229431	chr7:123269106	ASB15	-0.61	-13.64	-0.47	2.2e-37	Plateletcrit;Platelet count;
BRCA	trans	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.91	0.3	1.11e-14	Corneal astigmatism;
BRCA	cis	rs72781680	0.611	rs74661620	chr2:24365260	C/A	cg08917208	chr2:24149416	ATAD2B	0.52	7.82	0.3	2.2e-14	Lymphocyte counts;
BRCA	cis	rs7809950	1.000	rs12668402	chr7:107173020	G/A	cg23024343	chr7:107201750	COG5	-0.39	-9.03	-0.34	2.06e-18	Coronary artery disease;
BRCA	cis	rs9296092	0.538	rs62407565	chr6:33535739	A/G	cg13560919	chr6:33536144	NA	-0.91	-19.57	-0.61	3.68e-67	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg17330251	chr7:94953956	PON1	-0.42	-8.85	-0.33	8.59e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg24558204	chr6:135376177	HBS1L	0.49	13.4	0.47	2.87e-36	Red blood cell count;
BRCA	cis	rs7617773	1.000	rs12496784	chr3:48186267	C/T	cg11946769	chr3:48343235	NME6	-0.4	-8.9	-0.33	5.7e-18	Coronary artery disease;
BRCA	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg02503808	chr4:7069936	GRPEL1	0.79	17.75	0.57	1.26e-57	Monocyte percentage of white cells;
BRCA	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg05340658	chr4:99064831	C4orf37	0.57	11.08	0.4	3.33e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg17691542	chr6:26056736	HIST1H1C	0.47	9.16	0.34	7.15e-19	Iron status biomarkers;
BRCA	cis	rs1506636	1.000	rs619575	chr7:123393460	C/T	cg03229431	chr7:123269106	ASB15	-0.49	-10.61	-0.39	2.57e-24	Plateletcrit;Platelet count;
BRCA	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg22920501	chr2:26401640	FAM59B	-0.63	-11.18	-0.4	1.2e-26	Gut microbiome composition (summer);
BRCA	trans	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg02030672	chr11:45687055	CHST1	-0.4	-9.03	-0.34	2.05e-18	Obesity-related traits;
BRCA	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg09455208	chr3:40491958	NA	-0.32	-7.85	-0.3	1.7e-14	Renal cell carcinoma;
BRCA	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-21.83	-0.65	2.38e-79	Gut microbiome composition (summer);
BRCA	cis	rs311392	0.902	rs448238	chr8:55093655	C/T	cg11783602	chr8:55087084	NA	0.31	9.34	0.35	1.59e-19	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg02733842	chr7:1102375	C7orf50	-0.69	-12.88	-0.45	6.32e-34	Bronchopulmonary dysplasia;
BRCA	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg05340658	chr4:99064831	C4orf37	0.63	15.08	0.51	3.66e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg00666640	chr1:248458726	OR2T12	0.33	8.93	0.33	4.51e-18	Common traits (Other);
BRCA	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg06623918	chr6:96969491	KIAA0776	-0.77	-14.0	-0.48	4.98e-39	Migraine;Coronary artery disease;
BRCA	cis	rs4588572	0.643	rs10043115	chr5:77692019	T/C	cg11547950	chr5:77652471	NA	0.46	8.34	0.31	4.46e-16	Triglycerides;
BRCA	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg05340658	chr4:99064831	C4orf37	0.7	17.39	0.57	9.43e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11644478	chr21:40555479	PSMG1	0.74	15.13	0.51	2.08e-44	Cognitive function;
BRCA	cis	rs6687430	0.526	rs12120962	chr1:10609505	G/A	cg17425144	chr1:10567563	PEX14	0.56	12.96	0.46	2.71e-34	Hand grip strength;
BRCA	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-10.98	-0.4	7.86e-26	Longevity;Endometriosis;
BRCA	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.32	-8.18	-0.31	1.5e-15	Total body bone mineral density;
BRCA	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg00684032	chr4:1343700	KIAA1530	0.31	7.96	0.3	7.64e-15	Obesity-related traits;
BRCA	cis	rs243505	0.528	rs6977453	chr7:148474746	A/G	cg09806900	chr7:148480153	CUL1	0.54	11.03	0.4	5.18e-26	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10046574	0.561	rs9656457	chr7:135202254	T/A	cg27474649	chr7:135195673	CNOT4	0.67	11.09	0.4	3.01e-26	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs27434	0.529	rs34757	chr5:96152588	T/C	cg16492584	chr5:96139282	ERAP1	-0.51	-12.82	-0.45	1.24e-33	Ankylosing spondylitis;
BRCA	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg04450456	chr4:17643702	FAM184B	0.39	11.62	0.42	1.88e-28	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2712184	0.873	rs1548945	chr2:217665788	T/C	cg05032264	chr2:217675019	NA	-0.36	-8.55	-0.32	8.83e-17	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	8.42	0.32	2.43e-16	Tonsillectomy;
BRCA	cis	rs897080	0.515	rs1067337	chr2:44624859	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	9.34	0.35	1.53e-19	Height;
BRCA	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.62	-0.42	1.85e-28	Response to antipsychotic treatment;
BRCA	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg15556689	chr8:8085844	FLJ10661	-0.39	-9.82	-0.36	2.81e-21	Retinal vascular caliber;
BRCA	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.84	0.42	2.32e-29	Tonsillectomy;
BRCA	cis	rs11622475	1.000	rs34964872	chr14:104448435	T/A	cg12183467	chr14:104352244	NA	-0.5	-10.36	-0.38	2.36e-23	Bipolar disorder;
BRCA	trans	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg02951883	chr7:2050386	MAD1L1	-0.62	-15.84	-0.53	6.82e-48	Bipolar disorder and schizophrenia;
BRCA	cis	rs17253792	0.822	rs76555508	chr14:56071868	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.6	8.13	0.31	2.23e-15	Putamen volume;
BRCA	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg05347473	chr6:146136440	FBXO30	-0.39	-7.87	-0.3	1.57e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg12310025	chr6:25882481	NA	-0.42	-9.97	-0.37	7.67e-22	Height;
BRCA	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg21475434	chr5:93447410	FAM172A	0.68	8.62	0.32	5.37e-17	Diabetic retinopathy;
BRCA	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	14.47	0.5	2.93e-41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11890956	chr21:40555474	PSMG1	-0.85	-21.98	-0.66	3.35e-80	Cognitive function;
BRCA	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg06784218	chr1:46089804	CCDC17	0.44	10.66	0.39	1.59e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3820928	0.904	rs60906902	chr2:227760034	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.41	-0.32	2.76e-16	Pulmonary function;
BRCA	trans	rs12517041	1.000	rs4701362	chr5:23300849	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-7.96	-0.3	8.09e-15	Calcium levels;
BRCA	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg15556689	chr8:8085844	FLJ10661	-0.31	-8.22	-0.31	1.1e-15	Joint mobility (Beighton score);
BRCA	cis	rs11608355	0.545	rs2302705	chr12:109898716	C/T	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg26384229	chr12:38710491	ALG10B	-0.46	-10.57	-0.39	3.71e-24	Bladder cancer;
BRCA	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.38	-8.4	-0.32	2.93e-16	Cognitive ability;
BRCA	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg12379764	chr21:47803548	PCNT	-0.38	-8.32	-0.31	5.19e-16	Testicular germ cell tumor;
BRCA	cis	rs6684514	1.000	rs12139321	chr1:156230429	A/G	cg16558208	chr1:156270281	VHLL	0.37	8.24	0.31	9.85e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-10.75	-0.39	6.89e-25	Bone mineral density;
BRCA	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg13010199	chr12:38710504	ALG10B	0.43	9.11	0.34	1.04e-18	Morning vs. evening chronotype;
BRCA	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.94	0.58	1.43e-58	Fuchs's corneal dystrophy;
BRCA	cis	rs2108225	0.837	rs6958729	chr7:107451211	A/G	cg18560240	chr7:107437656	SLC26A3	0.53	11.18	0.4	1.3e-26	Ulcerative colitis;
BRCA	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg24642439	chr20:33292090	TP53INP2	0.71	16.3	0.54	3.23e-50	Coronary artery disease;
BRCA	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg24596788	chr1:163392923	NA	-0.35	-9.4	-0.35	9.75e-20	Motion sickness;
BRCA	cis	rs10779751	0.734	rs1148485	chr1:11148759	G/A	cg08854313	chr1:11322531	MTOR	0.74	14.28	0.49	2.48e-40	Body mass index;
BRCA	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.69	12.84	0.45	9.69e-34	Lung function (FEV1/FVC);
BRCA	cis	rs3820928	0.874	rs2177594	chr2:227836239	C/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.33	-0.31	5.03e-16	Pulmonary function;
BRCA	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Tonsillectomy;
BRCA	cis	rs897080	0.552	rs1067365	chr2:44655398	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	9.35	0.35	1.44e-19	Height;
BRCA	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg23711669	chr6:146136114	FBXO30	0.74	17.77	0.58	1.06e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12474201	0.832	rs6738426	chr2:46986416	A/G	cg06386533	chr2:46925753	SOCS5	0.84	18.19	0.58	7.22e-60	Height;
BRCA	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg06970220	chr1:156163860	SLC25A44	0.39	9.46	0.35	5.77e-20	Testicular germ cell tumor;
BRCA	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg21138405	chr5:131827807	IRF1	-0.37	-11.6	-0.42	2.3e-28	Asthma (sex interaction);
BRCA	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.05e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg17509989	chr5:176798049	RGS14	-0.73	-12.05	-0.43	2.75e-30	Urate levels in lean individuals;
BRCA	cis	rs1595825	0.891	rs2045244	chr2:198506466	C/T	cg19156104	chr2:198669113	PLCL1	-0.46	-8.59	-0.32	6.53e-17	Ulcerative colitis;
BRCA	cis	rs9394152	0.845	rs9394153	chr6:33471630	A/C	cg13560919	chr6:33536144	NA	0.62	12.76	0.45	2.26e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs7903847	0.642	rs10882910	chr10:99138043	G/A	cg08345082	chr10:99160200	RRP12	-0.29	-8.51	-0.32	1.24e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs13046373	0.507	rs2832969	chr21:32019627	A/G	cg22337977	chr21:31811175	KRTAP15-1	0.33	7.88	0.3	1.42e-14	HDL cholesterol;
BRCA	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg24450063	chr1:156163899	SLC25A44	1.12	36.13	0.82	1.49e-156	Testicular germ cell tumor;
BRCA	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg14926445	chr8:58193284	C8orf71	-0.44	-8.74	-0.33	2.01e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg11645453	chr3:52864694	ITIH4	-0.46	-11.58	-0.42	2.79e-28	Schizophrenia;
BRCA	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.59	8.64	0.32	4.37e-17	Initial pursuit acceleration;
BRCA	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	13.17	0.46	3.37e-35	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.5	-9.94	-0.37	9.99e-22	Body mass index;
BRCA	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg04362960	chr10:104952993	NT5C2	0.44	10.78	0.39	5.3e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg21475434	chr5:93447410	FAM172A	0.66	8.66	0.32	3.97e-17	Diabetic retinopathy;
BRCA	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg25801113	chr15:45476975	SHF	0.31	7.93	0.3	9.92e-15	Uric acid levels;
BRCA	cis	rs9868809	0.881	rs13324142	chr3:48669447	C/T	cg00383909	chr3:49044727	WDR6	0.48	7.85	0.3	1.77e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs11229555	0.874	rs11229512	chr11:58286105	T/C	cg15696309	chr11:58395628	NA	-0.53	-11.43	-0.41	1.15e-27	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg01236616	chr12:121019343	POP5	-1.24	-24.95	-0.7	1.93e-96	Type 1 diabetes nephropathy;
BRCA	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg23711669	chr6:146136114	FBXO30	-0.67	-15.75	-0.53	1.92e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg23711669	chr6:146136114	FBXO30	-0.71	-17.19	-0.56	1.03e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg07741184	chr6:167504864	NA	0.33	9.88	0.36	1.64e-21	Primary biliary cholangitis;
BRCA	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.46	0.38	9.36e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs208520	0.661	rs150263	chr6:66777620	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.09	-0.64	2.28e-75	Exhaled nitric oxide output;
BRCA	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg21143896	chr7:2802374	GNA12	-0.35	-8.96	-0.33	3.5e-18	Height;
BRCA	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg22875332	chr1:76189707	ACADM	0.5	9.85	0.36	2.01e-21	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17253792	0.822	rs78261053	chr14:56061784	C/T	cg01858014	chr14:56050164	KTN1	-0.73	-9.19	-0.34	5.56e-19	Putamen volume;
BRCA	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-10.59	-0.39	3.01e-24	Monocyte count;
BRCA	cis	rs13095912	1.000	rs13100229	chr3:185343200	C/T	cg11274856	chr3:185301563	NA	0.33	8.3	0.31	6.37e-16	Systolic blood pressure;
BRCA	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg20019720	chr6:154832845	CNKSR3	0.52	10.31	0.38	3.64e-23	Lipoprotein (a) levels;
BRCA	cis	rs7524258	0.900	rs7544004	chr1:7314529	A/C	cg07173049	chr1:7289937	CAMTA1	0.38	9.7	0.36	7.54e-21	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg18850127	chr7:39170497	POU6F2	0.54	11.91	0.43	1.15e-29	IgG glycosylation;
BRCA	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.94	0.4	1.21e-25	Bipolar disorder;
BRCA	cis	rs17384381	0.953	rs12717763	chr1:85808164	A/T	cg16011679	chr1:85725395	C1orf52	0.54	8.31	0.31	5.69e-16	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg18479299	chr3:125709523	NA	-0.56	-8.79	-0.33	1.41e-17	Blood pressure (smoking interaction);
BRCA	cis	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.57	-0.32	7.97e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg12310025	chr6:25882481	NA	-0.49	-12.1	-0.43	1.65e-30	Blood metabolite levels;
BRCA	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg26395211	chr5:140044315	WDR55	0.38	8.69	0.32	3.11e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.42	9.95	0.37	8.84e-22	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2559856	0.935	rs2559864	chr12:102084710	C/G	cg12213457	chr12:102090980	CHPT1	-0.37	-7.97	-0.3	7.1e-15	Blood protein levels;
BRCA	trans	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.78	-0.36	3.7e-21	Bladder cancer;
BRCA	cis	rs7953249	0.807	rs2393791	chr12:121423956	A/G	cg02403541	chr12:121454288	C12orf43	0.4	7.93	0.3	9.92e-15	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
BRCA	cis	rs17092148	0.836	rs4564863	chr20:33179367	T/C	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.67	-0.39	1.46e-24	Neuroticism;
BRCA	cis	rs752010	0.543	rs7545381	chr1:42044183	T/A	cg06885757	chr1:42089581	HIVEP3	0.22	8.13	0.31	2.17e-15	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg00531865	chr16:30841666	NA	-0.52	-12.13	-0.43	1.29e-30	Multiple myeloma;
BRCA	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg07211511	chr3:129823064	LOC729375	-0.58	-10.64	-0.39	1.84e-24	Blood pressure (smoking interaction);
BRCA	cis	rs778371	0.676	rs921055	chr2:233697337	A/C	cg08000102	chr2:233561755	GIGYF2	-0.78	-16.62	-0.55	8.38e-52	Schizophrenia;
BRCA	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-11.79	-0.42	3.7e-29	Alzheimer's disease;
BRCA	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg27279351	chr12:120934652	DYNLL1	0.51	12.33	0.44	1.68e-31	High light scatter reticulocyte count;
BRCA	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg24110177	chr3:50126178	RBM5	0.47	12.22	0.44	5.19e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg26384229	chr12:38710491	ALG10B	0.43	10.45	0.38	1.1e-23	Heart rate;
BRCA	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg11814155	chr7:99998594	ZCWPW1	0.53	8.98	0.33	2.9e-18	Platelet count;
BRCA	trans	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg04565464	chr8:145669602	NFKBIL2	0.36	7.99	0.3	6.23e-15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg14196790	chr5:131705035	SLC22A5	-0.39	-10.2	-0.37	9.61e-23	Blood metabolite levels;
BRCA	cis	rs7408868	1.000	rs4809030	chr19:15273381	A/G	cg14696996	chr19:15285081	NOTCH3	0.99	14.46	0.5	3.39e-41	Pulse pressure;
BRCA	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	9.81	0.36	2.93e-21	Mood instability;
BRCA	trans	rs9929218	0.817	rs8055912	chr16:68802068	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-13.85	-0.48	2.54e-38	Colorectal cancer;
BRCA	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.67	-16.39	-0.54	1.2e-50	Ulcerative colitis;
BRCA	cis	rs701145	0.537	rs1713832	chr3:153835833	C/T	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.89e-18	Coronary artery disease;
BRCA	cis	rs1351164	0.947	rs57004880	chr2:218272581	A/C	cg15335768	chr2:218268053	DIRC3	-0.34	-8.48	-0.32	1.53e-16	Height;
BRCA	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg03433033	chr1:76189801	ACADM	0.68	13.64	0.47	2.34e-37	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg01802117	chr1:53393560	SCP2	-0.42	-9.48	-0.35	5.06e-20	Monocyte count;
BRCA	cis	rs495337	1.000	rs2235616	chr20:48569127	G/A	cg17835207	chr20:48524531	SPATA2	-0.58	-13.05	-0.46	1.1e-34	Psoriasis;
BRCA	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg05868516	chr6:26286170	HIST1H4H	0.5	11.05	0.4	4.41e-26	Educational attainment;
BRCA	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.57	-14.94	-0.51	1.6e-43	Electrocardiographic conduction measures;
BRCA	cis	rs7809950	0.599	rs2237658	chr7:106837866	T/G	cg23024343	chr7:107201750	COG5	-0.43	-8.8	-0.33	1.3e-17	Coronary artery disease;
BRCA	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg06386533	chr2:46925753	SOCS5	0.43	8.09	0.3	3.03e-15	HDL cholesterol;
BRCA	cis	rs11874712	1.000	rs11082510	chr18:43656620	T/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.01	0.3	5.44e-15	Migraine - clinic-based;
BRCA	cis	rs11828289	0.607	rs76811253	chr11:23222885	G/A	cg20040320	chr11:23191996	NA	-0.53	-7.81	-0.3	2.37e-14	Cancer;
BRCA	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.53	-0.32	1.08e-16	Aortic root size;
BRCA	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg05714579	chr10:131428358	MGMT	-0.5	-11.9	-0.43	1.28e-29	Response to temozolomide;
BRCA	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14829155	chr15:31115871	NA	-0.42	-9.85	-0.36	2.03e-21	Huntington's disease progression;
BRCA	cis	rs6840360	0.593	rs4696106	chr4:152606818	A/G	cg22705602	chr4:152727874	NA	-0.38	-10.3	-0.38	4.15e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-14.36	-0.49	1.02e-40	Morning vs. evening chronotype;
BRCA	cis	rs7617773	0.780	rs77044321	chr3:48349314	C/T	cg11946769	chr3:48343235	NME6	0.69	13.89	0.48	1.68e-38	Coronary artery disease;
BRCA	cis	rs4363385	0.755	rs516198	chr1:153026196	T/C	cg24667326	chr1:152973720	SPRR3	-0.31	-8.28	-0.31	7.43e-16	Inflammatory skin disease;
BRCA	cis	rs4594175	0.926	rs12101170	chr14:51611902	T/C	cg23942311	chr14:51606299	NA	0.32	7.81	0.3	2.41e-14	Cancer;
BRCA	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg23708337	chr7:1209742	NA	0.54	11.6	0.42	2.32e-28	Longevity;Endometriosis;
BRCA	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-16.7	-0.55	3.21e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg06618935	chr21:46677482	NA	-0.37	-7.94	-0.3	9e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg19539972	chr4:7069911	GRPEL1	-0.63	-12.18	-0.43	7.9e-31	Monocyte percentage of white cells;
BRCA	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.49e-23	Motion sickness;
BRCA	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-8.89	-0.33	6.15e-18	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg03676636	chr4:99064102	C4orf37	0.2	7.94	0.3	9.01e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	14.87	0.51	3.5e-43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg00701064	chr4:6280414	WFS1	0.6	15.32	0.52	2.35e-45	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs55883249	1.000	rs55883249	chr2:9741535	C/A	cg23886495	chr2:9695866	ADAM17	0.55	7.95	0.3	8.39e-15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
BRCA	cis	rs10193935	0.901	rs12622153	chr2:42598386	C/A	cg27598129	chr2:42591480	NA	-0.86	-14.41	-0.5	5.89e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs16910800	0.689	rs4491218	chr11:23163977	G/A	cg20040320	chr11:23191996	NA	-0.57	-9.2	-0.34	5.11e-19	Cancer;
BRCA	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg08859206	chr1:53392774	SCP2	0.48	10.51	0.38	6.23e-24	Monocyte count;
BRCA	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg08000102	chr2:233561755	GIGYF2	0.61	13.06	0.46	1.02e-34	Coronary artery disease;
BRCA	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg20283391	chr11:68216788	NA	-0.45	-8.93	-0.33	4.39e-18	Total body bone mineral density;
BRCA	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg03709012	chr19:19516395	GATAD2A	-0.8	-18.33	-0.59	1.2e-60	Tonsillectomy;
BRCA	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg19000871	chr14:103996768	TRMT61A	0.34	7.84	0.3	1.83e-14	Coronary artery disease;
BRCA	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg13319975	chr6:146136371	FBXO30	-0.41	-9.35	-0.35	1.49e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.33	0.59	1.31e-60	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg00409905	chr10:38381863	ZNF37A	0.49	10.62	0.39	2.31e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2066819	0.892	rs117305040	chr12:56657888	A/G	cg26734620	chr12:56694298	CS	0.92	10.64	0.39	1.83e-24	Psoriasis vulgaris;
BRCA	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg13010199	chr12:38710504	ALG10B	0.42	8.48	0.32	1.54e-16	Bladder cancer;
BRCA	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg26384229	chr12:38710491	ALG10B	-0.45	-10.3	-0.38	3.9699999999999997e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6426558	0.537	rs689094	chr1:227308909	G/A	cg10327440	chr1:227177885	CDC42BPA	0.47	9.31	0.35	2.09e-19	Neutrophil percentage of white cells;
BRCA	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.35	8.51	0.32	1.25e-16	Resting heart rate;
BRCA	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg06627628	chr2:24431161	ITSN2	-0.82	-14.83	-0.51	5.87e-43	Asthma;
BRCA	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg12292205	chr6:26970375	C6orf41	-0.8	-19.68	-0.61	9.64e-68	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs3771570	1.000	rs56383420	chr2:242219281	A/G	cg21155796	chr2:242212141	HDLBP	0.62	9.76	0.36	4.48e-21	Prostate cancer;
BRCA	cis	rs10189230	0.643	rs2710503	chr2:222374699	C/G	cg14652038	chr2:222343519	EPHA4	-0.33	-8.03	-0.3	4.57e-15	Urate levels in lean individuals;
BRCA	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg08000102	chr2:233561755	GIGYF2	0.64	14.45	0.5	3.91e-41	Coronary artery disease;
BRCA	cis	rs4787491	0.729	rs4788213	chr16:30034524	T/C	cg06326092	chr16:30034487	C16orf92	0.38	9.93	0.37	1.07e-21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs11252926	0.732	rs10904541	chr10:744008	A/G	cg08603382	chr10:743973	NA	-0.53	-10.28	-0.38	4.93e-23	Psychosis in Alzheimer's disease;
BRCA	cis	rs1420338	0.867	rs7795950	chr7:34161715	A/G	cg01275685	chr7:34179230	BMPER	-0.46	-10.19	-0.37	1.03e-22	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg00105475	chr2:10696890	NA	-0.43	-10.04	-0.37	4.11e-22	Prostate cancer;
BRCA	cis	rs66887589	0.934	rs2715016	chr4:120452356	T/C	cg09307838	chr4:120376055	NA	-0.43	-8.74	-0.33	2.13e-17	Diastolic blood pressure;
BRCA	cis	rs11229555	0.645	rs11229427	chr11:58180275	A/C	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg14926445	chr8:58193284	C8orf71	-0.44	-8.46	-0.32	1.77e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6684428	0.610	rs12120132	chr1:56322054	G/A	cg11651538	chr1:56320950	NA	-0.44	-7.81	-0.3	2.39e-14	Airflow obstruction;
BRCA	cis	rs4988958	0.527	rs3771155	chr2:103037826	A/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.33	0.31	5.08e-16	Asthma (childhood onset);
BRCA	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	11.17	0.4	1.41e-26	Platelet count;
BRCA	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.94	0.33	4.23e-18	Motion sickness;
BRCA	cis	rs2066819	1.000	rs75754909	chr12:56726349	A/G	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg12641515	chr19:46296257	DMWD	-0.56	-12.56	-0.45	1.64e-32	Coronary artery disease;
BRCA	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg03146154	chr1:46216737	IPP	0.45	10.01	0.37	5.27e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17384381	1.000	rs12138852	chr1:85878208	C/T	cg16011679	chr1:85725395	C1orf52	0.52	8.08	0.3	3.13e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	12.02	0.43	3.94e-30	Tonsillectomy;
BRCA	cis	rs17253792	0.822	rs76918910	chr14:56058762	T/C	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg07460842	chr6:66804631	NA	0.88	14.18	0.49	7.35e-40	Exhaled nitric oxide output;
BRCA	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs910873	0.505	rs2378249	chr20:33218090	G/A	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.41	-0.38	1.57e-23	Melanoma;
BRCA	cis	rs12760731	0.565	rs57247289	chr1:178090138	G/A	cg00404053	chr1:178313656	RASAL2	0.62	7.92	0.3	1.09e-14	Obesity-related traits;
BRCA	trans	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg25214090	chr10:38739885	LOC399744	0.45	10.3	0.38	4.19e-23	Corneal astigmatism;
BRCA	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg27446573	chr6:127587934	RNF146	0.88	20.81	0.64	8.36e-74	Breast cancer;
BRCA	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.89	-0.33	6.32e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs778371	0.697	rs2344611	chr2:233581937	A/G	cg08000102	chr2:233561755	GIGYF2	0.78	17.01	0.56	8.2e-54	Schizophrenia;
BRCA	cis	rs7833986	0.501	rs2719259	chr8:56941630	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.67	13.11	0.46	5.97e-35	Height;
BRCA	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg06640241	chr16:89574553	SPG7	0.85	21.33	0.64	1.17e-76	Multiple myeloma (IgH translocation);
BRCA	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg09035930	chr12:129282057	SLC15A4	0.49	13.77	0.48	5.5e-38	Systemic lupus erythematosus;
BRCA	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.84	-0.33	9.56e-18	Total body bone mineral density;
BRCA	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg20607798	chr8:58055168	NA	0.47	8.09	0.3	3.07e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg16006841	chr5:176797999	RGS14	-0.89	-17.17	-0.56	1.23e-54	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	11.72	0.42	7.07e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg23018236	chr17:30244563	NA	-0.62	-10.14	-0.37	1.72e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.64	-0.39	1.88e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs11471957	1	rs11471957	chr20:57598332	C/CAA	cg14073986	chr20:57617431	SLMO2	0.5	8.25	0.31	9.06e-16	Platelet count;Mean platelet volume;
BRCA	trans	rs34421088	0.576	rs2572432	chr8:11101723	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-8.16	-0.31	1.84e-15	Neuroticism;
BRCA	cis	rs7903847	0.642	rs11189178	chr10:99143272	T/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.67	-0.32	3.61e-17	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs1459104	1.000	rs2903534	chr11:55054044	A/G	cg15704280	chr7:45808275	SEPT13	0.7	8.71	0.33	2.57e-17	Body mass index;
BRCA	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg08999081	chr20:33150536	PIGU	0.47	13.11	0.46	6.3e-35	Glomerular filtration rate (creatinine);
BRCA	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg20283391	chr11:68216788	NA	-0.48	-9.33	-0.35	1.65e-19	Total body bone mineral density;
BRCA	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg05347473	chr6:146136440	FBXO30	0.4	8.0	0.3	5.87e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18876405	chr7:65276391	NA	0.7	18.57	0.59	6.72e-62	Calcium levels;
BRCA	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg15432903	chr11:17409602	KCNJ11	0.71	15.42	0.52	8.06e-46	Type 2 diabetes;
BRCA	trans	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg25214090	chr10:38739885	LOC399744	0.45	10.36	0.38	2.45e-23	Corneal astigmatism;
BRCA	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.58	-13.96	-0.48	7.69e-39	Longevity;Endometriosis;
BRCA	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	23.11	0.67	2.5e-86	Platelet count;
BRCA	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg10560079	chr2:191398806	TMEM194B	-0.36	-8.01	-0.3	5.4e-15	Pulse pressure;
BRCA	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg12062639	chr20:23401060	NAPB	0.96	13.42	0.47	2.43e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	trans	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg26043149	chr18:55253948	FECH	0.38	8.22	0.31	1.15e-15	Bone mineral density;
BRCA	cis	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg07460842	chr6:66804631	NA	0.87	14.42	0.5	5.11e-41	Exhaled nitric oxide output;
BRCA	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-16.99	-0.56	1.06e-53	Chronic sinus infection;
BRCA	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg25554036	chr4:6271136	WFS1	0.41	9.44	0.35	6.67e-20	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg13073564	chr4:8508604	NA	0.46	12.29	0.44	2.61e-31	Response to antineoplastic agents;
BRCA	trans	rs11039798	1.000	rs7924372	chr11:48556319	T/A	cg15704280	chr7:45808275	SEPT13	0.68	8.19	0.31	1.44e-15	Axial length;
BRCA	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-16.92	-0.56	2.36e-53	Intelligence (multi-trait analysis);
BRCA	cis	rs4865169	0.691	rs1056364	chr4:57889677	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.31	-7.97	-0.3	7.54e-15	Breast cancer;
BRCA	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg14061069	chr19:46274453	DMPK	-0.49	-12.06	-0.43	2.67e-30	Coronary artery disease;
BRCA	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg10578991	chr7:12443926	VWDE	-0.52	-7.94	-0.3	9.11e-15	Coronary artery disease;
BRCA	cis	rs11191205	0.644	rs12354716	chr10:103386775	C/A	cg15320455	chr10:103880129	LDB1	0.46	7.85	0.3	1.72e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg26384229	chr12:38710491	ALG10B	0.52	11.12	0.4	2.28e-26	Morning vs. evening chronotype;
BRCA	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg06671706	chr8:8559999	CLDN23	-0.42	-8.14	-0.31	2.05e-15	Obesity-related traits;
BRCA	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.03	-0.43	3.59e-30	Response to antipsychotic treatment;
BRCA	trans	rs11039798	0.841	rs12221667	chr11:48548549	G/T	cg15704280	chr7:45808275	SEPT13	0.68	8.22	0.31	1.12e-15	Axial length;
BRCA	cis	rs9443189	0.570	rs9343316	chr6:76411800	G/A	cg01950844	chr6:76311363	SENP6	0.84	13.57	0.47	5.09e-37	Prostate cancer;
BRCA	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.8e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs78487399	0.908	rs17031088	chr2:43807090	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-8.06	-0.3	3.72e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.03	-0.4	5.24e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg21573476	chr21:45109991	RRP1B	-0.34	-8.61	-0.32	5.7e-17	Mean corpuscular volume;
BRCA	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.6	13.27	0.46	1.17e-35	Hemoglobin concentration;
BRCA	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg13395646	chr4:1353034	KIAA1530	-0.51	-9.17	-0.34	6.26e-19	Obesity-related traits;
BRCA	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.82	-0.33	1.11e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.16	0.56	1.47e-54	Bladder cancer;
BRCA	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.37	-0.41	2.06e-27	Schizophrenia;
BRCA	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.68	-0.5	2.95e-42	Chronic sinus infection;
BRCA	cis	rs11249608	0.789	rs7700958	chr5:178436617	G/A	cg21905437	chr5:178450457	ZNF879	0.48	9.68	0.36	9.38e-21	Pubertal anthropometrics;
BRCA	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg06623918	chr6:96969491	KIAA0776	-0.82	-22.04	-0.66	1.78e-80	Headache;
BRCA	trans	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-12.21	-0.43	5.87e-31	Chronic sinus infection;
BRCA	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.2	0.49	5.86e-40	Motion sickness;
BRCA	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg22532475	chr10:104410764	TRIM8	-0.32	-8.07	-0.3	3.44e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg14664628	chr15:75095509	CSK	-0.84	-22.43	-0.66	1.3e-82	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg22920501	chr2:26401640	FAM59B	0.91	15.61	0.53	9.09e-47	Gut microbiome composition (summer);
BRCA	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00149659	chr3:10157352	C3orf10	-0.65	-9.87	-0.36	1.79e-21	Alzheimer's disease;
BRCA	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg09307838	chr4:120376055	NA	0.58	12.69	0.45	4.73e-33	Corneal astigmatism;
BRCA	cis	rs2070997	0.607	rs3808821	chr9:133712801	G/T	cg11464064	chr9:133710261	ABL1	-0.49	-9.16	-0.34	6.73e-19	Response to amphetamines;
BRCA	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg10523679	chr1:76189770	ACADM	-0.46	-8.91	-0.33	5.27e-18	Daytime sleep phenotypes;
BRCA	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg27572855	chr1:25598939	RHD	-0.44	-12.4	-0.44	8.9e-32	Plateletcrit;Mean corpuscular volume;
BRCA	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg22139774	chr2:100720529	AFF3	-0.29	-8.13	-0.31	2.3e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg15557168	chr22:42548783	NA	-0.31	-8.64	-0.32	4.39e-17	Cognitive function;
BRCA	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg26384229	chr12:38710491	ALG10B	0.73	16.02	0.54	8.33e-49	Bladder cancer;
BRCA	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg02734326	chr4:10020555	SLC2A9	0.36	8.2	0.31	1.31e-15	Bone mineral density;
BRCA	cis	rs17401966	0.838	rs946503	chr1:10308631	C/G	cg03954927	chr1:10346856	KIF1B	-0.4	-12.41	-0.44	7.51e-32	Hepatocellular carcinoma;
BRCA	cis	rs12369179	1.000	rs12369179	chr12:122963550	C/T	cg18578876	chr12:123200353	GPR109B	-1.32	-15.95	-0.53	1.95e-48	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
BRCA	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg08885076	chr2:99613938	TSGA10	-0.35	-8.06	-0.3	3.82e-15	Chronic sinus infection;
BRCA	cis	rs9469578	1.000	rs6942022	chr6:33710284	C/T	cg18708504	chr6:33715942	IP6K3	0.71	10.41	0.38	1.5e-23	Phosphorus levels;
BRCA	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg26384229	chr12:38710491	ALG10B	0.68	14.12	0.49	1.32e-39	Morning vs. evening chronotype;
BRCA	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	8.22	0.31	1.16e-15	Personality dimensions;
BRCA	trans	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.82	-0.3	2.17e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-8.09	-0.3	2.98e-15	Bipolar disorder;
BRCA	cis	rs9309473	0.687	rs6706235	chr2:73613558	C/G	cg20560298	chr2:73613845	ALMS1	-0.52	-14.23	-0.49	4.24e-40	Metabolite levels;
BRCA	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.71	12.05	0.43	2.89e-30	Schizophrenia;
BRCA	trans	rs6479891	1.000	rs59035163	chr10:65292043	C/G	cg14819942	chr15:35414228	NA	0.35	8.41	0.32	2.7e-16	Arthritis (juvenile idiopathic);
BRCA	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.98	-0.48	6.13e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.36	-8.18	-0.31	1.59e-15	Colorectal cancer;
BRCA	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11764359	chr7:65958608	NA	0.62	13.65	0.48	2.09e-37	Calcium levels;
BRCA	cis	rs10924970	0.934	rs4288584	chr1:235436631	C/T	cg26050004	chr1:235667680	B3GALNT2	0.35	8.78	0.33	1.47e-17	Asthma;
BRCA	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	12.12	0.43	1.47e-30	Mean platelet volume;
BRCA	trans	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg26043149	chr18:55253948	FECH	-0.36	-7.98	-0.3	6.76e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs672059	1.000	rs659307	chr1:183163078	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.49	0.32	1.43e-16	Hypertriglyceridemia;
BRCA	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg23711669	chr6:146136114	FBXO30	0.64	14.41	0.5	5.89e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg23950597	chr19:37808831	NA	0.61	11.15	0.4	1.72e-26	Coronary artery calcification;
BRCA	cis	rs34779708	0.897	rs4934529	chr10:35302376	T/A	cg03585969	chr10:35415529	CREM	0.56	11.59	0.42	2.64e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg11766577	chr21:47581405	C21orf56	0.48	10.67	0.39	1.4e-24	Testicular germ cell tumor;
BRCA	cis	rs6840258	1.000	rs56050898	chr4:87945375	A/G	cg08197287	chr4:87952173	AFF1	-0.44	-8.63	-0.32	4.89e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs6788895	1.000	rs76801042	chr3:150482720	A/C	cg09723797	chr3:150481914	SIAH2	0.72	8.6	0.32	6.26e-17	Breast cancer;
BRCA	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.44	9.78	0.36	3.86e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7408868	0.563	rs10423702	chr19:15300069	T/C	cg14696996	chr19:15285081	NOTCH3	0.8	11.92	0.43	1.06e-29	Pulse pressure;
BRCA	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg08917208	chr2:24149416	ATAD2B	0.55	8.62	0.32	5.36e-17	Lymphocyte counts;
BRCA	cis	rs7512552	0.780	rs1260411	chr1:150382088	G/A	cg15654264	chr1:150340011	RPRD2	0.41	8.83	0.33	9.72e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg00814883	chr7:100076585	TSC22D4	-0.5	-10.36	-0.38	2.32e-23	Platelet count;
BRCA	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg15839431	chr19:19639596	YJEFN3	-0.41	-9.15	-0.34	7.81e-19	Bipolar disorder;
BRCA	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg23978390	chr7:1156363	C7orf50	0.41	10.04	0.37	4.07e-22	Longevity;Endometriosis;
BRCA	cis	rs6700896	0.897	rs28480230	chr1:66124075	C/T	cg04111102	chr1:66153794	NA	0.36	8.87	0.33	7.42e-18	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs6484504	0.625	rs6484501	chr11:31373100	G/T	cg26647111	chr11:31128758	NA	0.45	9.59	0.35	1.97e-20	Red blood cell count;
BRCA	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg26031613	chr14:104095156	KLC1	0.62	13.25	0.46	1.43e-35	Body mass index;
BRCA	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07308232	chr7:1071921	C7orf50	-0.5	-10.52	-0.38	5.4e-24	Longevity;Endometriosis;
BRCA	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.86	0.36	1.96e-21	Bipolar disorder;
BRCA	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.58	-14.59	-0.5	8.19e-42	Longevity;Endometriosis;
BRCA	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg10729496	chr3:10149963	C3orf24	0.48	9.0	0.34	2.49e-18	Alzheimer's disease;
BRCA	cis	rs6063312	1.000	rs6063312	chr20:47343059	G/T	cg18078177	chr20:47281410	PREX1	0.65	11.26	0.41	5.84e-27	Tonometry;
BRCA	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg22875332	chr1:76189707	ACADM	0.79	18.87	0.6	1.86e-63	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7833986	0.501	rs2976018	chr8:57014752	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	12.99	0.46	2.13e-34	Height;
BRCA	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24308560	chr3:49941425	MST1R	-0.38	-8.21	-0.31	1.24e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.7	-19.27	-0.61	1.32e-65	Electrocardiographic conduction measures;
BRCA	cis	rs926392	0.896	rs1569538	chr20:37685216	A/G	cg16355469	chr20:37678765	NA	-0.33	-8.33	-0.31	4.93e-16	Dialysis-related mortality;
BRCA	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg10495392	chr1:46806563	NSUN4	0.44	8.13	0.31	2.27e-15	Menopause (age at onset);
BRCA	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg25237894	chr2:233734115	C2orf82	0.4	11.48	0.41	7.19e-28	Coronary artery disease;
BRCA	trans	rs6601327	0.571	rs7838571	chr8:9647796	A/G	cg06636001	chr8:8085503	FLJ10661	0.37	7.88	0.3	1.37e-14	Multiple myeloma (hyperdiploidy);
BRCA	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg00898013	chr13:113819073	PROZ	-0.36	-8.96	-0.33	3.48e-18	Platelet distribution width;
BRCA	cis	rs4363385	0.626	rs11205192	chr1:153062767	C/T	cg07796016	chr1:152779584	LCE1C	-0.37	-7.99	-0.3	6.5e-15	Inflammatory skin disease;
BRCA	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.51	10.09	0.37	2.7e-22	HDL cholesterol;
BRCA	cis	rs56804039	1.000	rs11777086	chr8:8384479	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.03	-0.34	1.94e-18	Cervical cancer;
BRCA	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.37	7.81	0.3	2.34e-14	Insulin-like growth factors;
BRCA	cis	rs4363385	0.620	rs4388644	chr1:152983674	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.15	-0.34	7.26e-19	Inflammatory skin disease;
BRCA	trans	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.39	7.99	0.3	6.26e-15	Menarche (age at onset);
BRCA	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg16586182	chr3:47516702	SCAP	0.56	12.61	0.45	1.06e-32	Colorectal cancer;
BRCA	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.89	0.36	1.53e-21	Bipolar disorder;
BRCA	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.09	0.3	2.91e-15	Tonsillectomy;
BRCA	cis	rs6138458	0.620	rs2151462	chr20:24911823	T/C	cg06937882	chr20:24974362	C20orf3	-0.44	-8.36	-0.31	3.95e-16	Blood protein levels;
BRCA	cis	rs9283706	0.594	rs7717020	chr5:66353322	A/C	cg11590213	chr5:66331682	MAST4	0.41	7.94	0.3	9.42e-15	Coronary artery disease;
BRCA	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg21475434	chr5:93447410	FAM172A	0.7	8.61	0.32	5.52e-17	Diabetic retinopathy;
BRCA	cis	rs1403694	0.695	rs3806689	chr3:186435077	A/G	cg12454167	chr3:186435060	KNG1	0.29	7.9	0.3	1.21e-14	Blood protein levels;
BRCA	cis	rs897080	0.515	rs1067400	chr2:44677647	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.34	0.35	1.58e-19	Height;
BRCA	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg11812906	chr14:75593930	NEK9	0.67	15.45	0.52	5.25e-46	Height;
BRCA	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg04546413	chr19:29218101	NA	0.63	12.26	0.44	3.6e-31	Methadone dose in opioid dependence;
BRCA	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	18.92	0.6	9.84e-64	Alzheimer's disease (late onset);
BRCA	cis	rs9392556	0.829	rs617790	chr6:4115758	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.37	-8.07	-0.3	3.6e-15	Blood metabolite levels;
BRCA	trans	rs9784649	0.882	rs2201296	chr5:24967119	G/A	cg08600765	chr20:34638493	LOC647979	-0.51	-8.4	-0.32	2.79e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9880211	0.752	rs9838884	chr3:136455704	C/T	cg21827317	chr3:136751795	NA	-0.46	-7.89	-0.3	1.33e-14	Body mass index;Height;
BRCA	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18876405	chr7:65276391	NA	-0.5	-11.07	-0.4	3.5e-26	Aortic root size;
BRCA	cis	rs4074536	0.574	rs9887914	chr1:116287975	A/G	cg21648376	chr1:116311395	CASQ2	-0.49	-8.68	-0.32	3.25e-17	QRS duration;
BRCA	cis	rs7577696	0.524	rs12991444	chr2:32265125	G/T	cg02381751	chr2:32503542	YIPF4	-0.41	-7.86	-0.3	1.64e-14	Inflammatory biomarkers;
BRCA	trans	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg25214090	chr10:38739885	LOC399744	0.47	10.62	0.39	2.28e-24	Corneal astigmatism;
BRCA	cis	rs72772090	0.539	rs11746534	chr5:96124807	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.13	-0.43	1.28e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7267979	0.866	rs6138609	chr20:25570985	T/A	cg08601574	chr20:25228251	PYGB	0.36	8.43	0.32	2.21e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg07541023	chr7:19748670	TWISTNB	-0.57	-9.66	-0.36	1.1e-20	Thyroid stimulating hormone;
BRCA	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.97	21.77	0.65	5.16e-79	Lymphocyte percentage of white cells;
BRCA	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-7.96	-0.3	7.64e-15	Ulcerative colitis;
BRCA	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg23711669	chr6:146136114	FBXO30	-0.79	-17.95	-0.58	1.17e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	cis	rs4664304	0.620	rs1397717	chr2:160720444	G/T	cg01092293	chr2:160761427	LY75	0.36	8.51	0.32	1.24e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg05294307	chr14:35346193	BAZ1A	-0.61	-10.39	-0.38	1.73e-23	Psoriasis;
BRCA	cis	rs12291225	0.877	rs2303974	chr11:14264979	G/T	cg19336497	chr11:14380999	RRAS2	-0.36	-8.33	-0.31	4.86e-16	Sense of smell;
BRCA	cis	rs17604090	0.816	rs10248839	chr7:29697253	T/C	cg19413766	chr7:29689036	LOC646762	-0.61	-8.22	-0.31	1.1e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	1e-40	Motion sickness;
BRCA	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg05234568	chr11:5960015	NA	-0.51	-9.93	-0.37	1.04e-21	DNA methylation (variation);
BRCA	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11764359	chr7:65958608	NA	0.78	18.28	0.59	2.24e-60	Aortic root size;
BRCA	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg17328964	chr8:145687451	CYHR1	0.45	9.95	0.37	8.64e-22	Age at first birth;
BRCA	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg06784218	chr1:46089804	CCDC17	-0.45	-10.8	-0.39	4.54e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg15448220	chr1:150897856	SETDB1	0.35	7.86	0.3	1.6e-14	Melanoma;
BRCA	trans	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg17675199	chr6:35436792	RPL10A	-0.3	-8.05	-0.3	4.1e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg03709012	chr19:19516395	GATAD2A	0.82	19.22	0.61	2.52e-65	Tonsillectomy;
BRCA	cis	rs9512730	0.527	rs11619784	chr13:27999643	A/G	cg08193333	chr13:27998609	GTF3A	0.51	9.91	0.36	1.27e-21	Schizophrenia;
BRCA	cis	rs9682041	0.627	rs3772173	chr3:170078232	C/T	cg11886554	chr3:170076028	SKIL	0.48	9.92	0.37	1.1e-21	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs28830936	1.000	rs28754734	chr15:42093152	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.37	-10.09	-0.37	2.56e-22	Diastolic blood pressure;
BRCA	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg06609049	chr19:2785107	THOP1	0.59	12.09	0.43	1.82e-30	Total cholesterol levels;
BRCA	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg09537434	chr19:41945824	ATP5SL	-0.6	-10.96	-0.4	1e-25	Colorectal cancer;
BRCA	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg22535103	chr8:58192502	C8orf71	-0.52	-8.91	-0.33	5.21e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg06191203	chr2:152266755	RIF1	-0.29	-8.45	-0.32	1.96e-16	Lung cancer;
BRCA	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.42	8.81	0.33	1.22e-17	Cognitive ability;
BRCA	cis	rs2108225	0.837	rs6466186	chr7:107446966	G/C	cg18560240	chr7:107437656	SLC26A3	-0.52	-11.13	-0.4	2.06e-26	Ulcerative colitis;
BRCA	cis	rs13102973	0.640	rs34037497	chr4:135833698	C/G	cg14419869	chr4:135874104	NA	0.46	9.18	0.34	5.74e-19	Subjective well-being;
BRCA	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg08085267	chr17:45401833	C17orf57	-0.57	-11.91	-0.43	1.07e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg08601574	chr20:25228251	PYGB	0.35	8.47	0.32	1.63e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg24692254	chr21:30365293	RNF160	-0.5	-10.94	-0.4	1.22e-25	Pancreatic cancer;
BRCA	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg24296786	chr1:45957014	TESK2	-0.56	-13.18	-0.46	2.7900000000000003e-35	High light scatter reticulocyte count;
BRCA	cis	rs895636	0.752	rs4245800	chr2:45189866	G/A	cg16198908	chr2:45192207	NA	0.47	8.84	0.33	9.37e-18	Metabolite levels;Fasting plasma glucose;
BRCA	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg11707556	chr5:10655725	ANKRD33B	0.39	8.02	0.3	4.92e-15	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs11229555	0.598	rs7930623	chr11:58197641	A/G	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg26384229	chr12:38710491	ALG10B	0.66	13.84	0.48	2.82e-38	Morning vs. evening chronotype;
BRCA	cis	rs10463316	0.744	rs6579869	chr5:150763621	G/A	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.4	-0.32	2.96e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg08493051	chr2:3487164	NA	-0.4	-8.26	-0.31	8.35e-16	Neurofibrillary tangles;
BRCA	cis	rs13102973	0.867	rs11722699	chr4:135907871	G/T	cg14419869	chr4:135874104	NA	0.46	9.06	0.34	1.51e-18	Subjective well-being;
BRCA	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08564027	chr20:61660810	NA	0.85	22.96	0.67	1.67e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14829155	chr15:31115871	NA	-0.43	-10.05	-0.37	3.67e-22	Huntington's disease progression;
BRCA	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg04362960	chr10:104952993	NT5C2	0.43	10.45	0.38	1.01e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	14.55	0.5	1.22e-41	Platelet count;
BRCA	cis	rs96067	0.711	rs795047	chr1:36637708	C/T	cg24686825	chr1:36642396	MAP7D1	0.44	9.69	0.36	8.06e-21	Corneal structure;
BRCA	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg24060327	chr5:131705240	SLC22A5	0.65	12.88	0.45	6.76e-34	Breast cancer;
BRCA	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	9.25	0.34	3.44e-19	Platelet count;
BRCA	cis	rs66731853	0.769	rs477679	chr1:20894618	A/G	cg04087271	chr1:20915334	CDA	0.46	9.12	0.34	9.89e-19	Mean corpuscular volume;
BRCA	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-15.01	-0.51	7.7e-44	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg18230493	chr5:56204884	C5orf35	-0.54	-10.57	-0.39	3.5e-24	Type 2 diabetes;
BRCA	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.26	-0.31	8.6e-16	Parkinson's disease;
BRCA	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg20203395	chr5:56204925	C5orf35	-0.51	-10.61	-0.39	2.56e-24	Initial pursuit acceleration;
BRCA	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06636551	chr8:101224915	SPAG1	-0.38	-8.72	-0.33	2.39e-17	Atrioventricular conduction;
BRCA	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg11764359	chr7:65958608	NA	-0.67	-14.97	-0.51	1.15e-43	Aortic root size;
BRCA	cis	rs4629180	1.000	rs6744495	chr2:102099956	T/C	cg04415270	chr2:102091202	RFX8	-0.32	-7.91	-0.3	1.14e-14	Chronic rhinosinusitis with nasal polyps;
BRCA	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg01689657	chr7:91764605	CYP51A1	0.22	8.07	0.3	3.5e-15	Breast cancer;
BRCA	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg23649088	chr2:200775458	C2orf69	-0.55	-7.86	-0.3	1.68e-14	Schizophrenia;
BRCA	cis	rs4319547	0.737	rs11058226	chr12:122938958	A/G	cg23029597	chr12:123009494	RSRC2	-0.41	-8.28	-0.31	7.34e-16	Body mass index;
BRCA	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg27478167	chr7:817139	HEATR2	-0.4	-8.46	-0.32	1.83e-16	Cerebrospinal P-tau181p levels;
BRCA	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg12698349	chr2:225449008	CUL3	0.85	29.73	0.76	1.26e-122	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10819733	chr22:24237672	NA	-0.32	-8.55	-0.32	9.33e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs148734725	1	rs148734725	chr3:49406708	G/A	cg21659725	chr3:3221576	CRBN	-0.45	-10.01	-0.37	5.41e-22	Educational attainment (college completion);
BRCA	cis	rs71636778	0.543	rs36109400	chr1:27247822	G/A	cg12203394	chr1:27248618	NUDC	0.61	9.5	0.35	4.25e-20	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg12927641	chr6:109611667	NA	-0.41	-10.71	-0.39	9.97e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg11366901	chr6:160182831	ACAT2	0.82	16.07	0.54	4.79e-49	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg16386425	chr10:429943	DIP2C	-0.41	-8.59	-0.32	6.73e-17	Psychosis in Alzheimer's disease;
BRCA	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg22676075	chr6:135203613	NA	-0.45	-9.41	-0.35	8.72e-20	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.29	0.56	3.16e-55	Bladder cancer;
BRCA	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.09	0.3	3.03e-15	Cognitive ability;
BRCA	trans	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg01620082	chr3:125678407	NA	-0.75	-9.53	-0.35	3.14e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg17372223	chr3:52568218	NT5DC2	0.34	7.86	0.3	1.68e-14	Electroencephalogram traits;
BRCA	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg25703541	chr22:24373054	LOC391322	-0.67	-15.37	-0.52	1.38e-45	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg06115741	chr20:33292138	TP53INP2	0.49	10.96	0.4	9.75e-26	Coronary artery disease;
BRCA	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.35	8.65	0.32	4.16e-17	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs2637266	0.967	rs12244619	chr10:78352502	C/T	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.29e-14	Pulmonary function;
BRCA	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.36	8.42	0.32	2.57e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg01420254	chr6:26195488	NA	-0.59	-9.21	-0.34	4.74e-19	Gout;Renal underexcretion gout;
BRCA	cis	rs6942756	1.000	rs12111832	chr7:128889025	G/C	cg02491457	chr7:128862824	NA	-0.71	-14.02	-0.49	3.8e-39	White matter hyperintensity burden;
BRCA	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	19.89	0.62	6.82e-69	Platelet count;
BRCA	cis	rs28669119	0.778	rs244752	chr5:88144669	T/C	cg18498987	chr5:88179539	MEF2C	0.45	8.27	0.31	7.96e-16	Schizophrenia;
BRCA	cis	rs6546550	0.901	rs1979214	chr2:70137498	G/C	cg02498382	chr2:70120550	SNRNP27	-0.52	-11.47	-0.41	7.91e-28	Prevalent atrial fibrillation;
BRCA	cis	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg07460842	chr6:66804631	NA	0.99	19.84	0.62	1.25e-68	Exhaled nitric oxide output;
BRCA	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.06	-0.34	1.53e-18	Total body bone mineral density;
BRCA	cis	rs13190036	1.000	rs71601344	chr5:176633493	G/A	cg06733329	chr5:176740039	MXD3	0.46	8.3	0.31	6.26e-16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs9649213	0.574	rs7789440	chr7:97888798	G/T	cg21770322	chr7:97807741	LMTK2	0.44	11.22	0.41	8.32e-27	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs12517041	0.935	rs2099089	chr5:23287372	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.36	-0.31	4.04e-16	Calcium levels;
BRCA	cis	rs6543140	0.964	rs2141781	chr2:103082906	G/A	cg04239558	chr2:103089729	SLC9A4	0.35	9.94	0.37	9.48e-22	Blood protein levels;
BRCA	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg18132916	chr6:79620363	NA	-0.48	-10.69	-0.39	1.23e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13126279	chr21:47581558	C21orf56	-0.48	-10.81	-0.39	3.91e-25	Testicular germ cell tumor;
BRCA	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg04546413	chr19:29218101	NA	0.65	13.29	0.47	9.56e-36	Methadone dose in opioid dependence;
BRCA	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.21	-0.34	4.54e-19	Total body bone mineral density;
BRCA	cis	rs11716531	0.574	rs62256311	chr3:27271505	G/A	cg02860705	chr3:27208620	NA	0.6	11.5	0.41	6.14e-28	Diastolic blood pressure;
BRCA	trans	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04565464	chr8:145669602	NFKBIL2	-0.36	-8.54	-0.32	9.97e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-10.48	-0.38	8.05e-24	Longevity;
BRCA	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg01305625	chr5:131593812	PDLIM4	0.34	8.07	0.3	3.4e-15	Acylcarnitine levels;
BRCA	cis	rs3125734	0.671	rs3852406	chr10:64015162	T/C	cg09941381	chr10:64027924	RTKN2	-0.27	-7.9	-0.3	1.23e-14	Rheumatoid arthritis;
BRCA	cis	rs7552167	0.852	rs10794647	chr1:24509133	C/T	cg01960748	chr1:24522592	NA	-0.62	-10.04	-0.37	4.04e-22	Psoriasis vulgaris;
BRCA	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10802521	chr3:52805072	NEK4	0.33	9.26	0.34	3.07e-19	Electroencephalogram traits;
BRCA	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg12564285	chr5:131593104	PDLIM4	0.34	7.9	0.3	1.22e-14	Breast cancer;
BRCA	cis	rs6882046	0.513	rs651666	chr5:88048767	A/G	cg22951263	chr5:87985283	NA	-0.39	-10.83	-0.39	3.43e-25	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs11677370	0.574	rs10209122	chr2:3871186	C/A	cg17052675	chr2:3827356	NA	-0.51	-12.16	-0.43	9.2e-31	Type 2 diabetes;
BRCA	cis	rs2737618	0.651	rs2248967	chr1:200084893	A/G	cg21825944	chr1:200113062	NR5A2	0.38	9.04	0.34	1.86e-18	Uric acid levels;
BRCA	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg02896835	chr1:92012615	NA	-0.62	-16.57	-0.55	1.53e-51	Breast cancer;
BRCA	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg26384229	chr12:38710491	ALG10B	0.41	9.25	0.34	3.33e-19	Morning vs. evening chronotype;
BRCA	cis	rs965469	1.000	rs77763497	chr20:3250007	A/G	cg25506879	chr20:3388711	C20orf194	-0.55	-10.79	-0.39	4.75e-25	IFN-related cytopenia;
BRCA	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg11266682	chr4:10021025	SLC2A9	0.49	12.82	0.45	1.23e-33	Bone mineral density;
BRCA	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg03477792	chr4:77819574	ANKRD56	0.66	15.67	0.53	4.35e-47	Emphysema distribution in smoking;
BRCA	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg09654669	chr8:57350985	NA	-0.4	-8.67	-0.32	3.62e-17	Obesity-related traits;
BRCA	cis	rs11249608	0.511	rs58827878	chr5:178481936	C/G	cg21905437	chr5:178450457	ZNF879	0.5	9.61	0.36	1.66e-20	Pubertal anthropometrics;
BRCA	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg17845761	chr1:175162550	KIAA0040	0.26	9.65	0.36	1.11e-20	Alcohol dependence;
BRCA	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg00012203	chr2:219082015	ARPC2	-0.5	-9.65	-0.36	1.2e-20	Colorectal cancer;
BRCA	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04004882	chr2:215674386	BARD1	-0.74	-17.74	-0.57	1.57e-57	Neuroblastoma (high-risk);
BRCA	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.89	-0.33	6e-18	Total body bone mineral density;
BRCA	cis	rs2742234	0.541	rs1254958	chr10:43702143	C/T	cg15436174	chr10:43711423	RASGEF1A	0.57	11.53	0.41	4.62e-28	Hirschsprung disease;
BRCA	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg14847009	chr1:175162515	KIAA0040	-0.24	-9.08	-0.34	1.29e-18	Alcohol dependence;
BRCA	cis	rs7178424	1.000	rs8025877	chr15:62377820	A/T	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.26	-0.31	8.22e-16	Height;
BRCA	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg13334819	chr7:99746414	C7orf59	0.4	9.17	0.34	6.33e-19	Coronary artery disease;
BRCA	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg22189786	chr22:42395067	WBP2NL	0.43	8.74	0.33	1.97e-17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg08601574	chr20:25228251	PYGB	0.39	8.98	0.33	2.96e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg13902645	chr11:5959945	NA	-0.56	-11.36	-0.41	2.36e-27	DNA methylation (variation);
BRCA	cis	rs897984	0.511	rs7196726	chr16:31092075	G/A	cg02466173	chr16:30829666	NA	-0.43	-9.61	-0.36	1.58e-20	Dementia with Lewy bodies;
BRCA	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg23708337	chr7:1209742	NA	0.64	8.95	0.33	3.76e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7301016	0.846	rs11174568	chr12:63021157	T/C	cg11441379	chr12:63026424	NA	0.49	8.95	0.33	3.85e-18	IgG glycosylation;
BRCA	cis	rs7264396	0.561	rs6142470	chr20:34570579	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-9.77	-0.36	4.3e-21	Total cholesterol levels;
BRCA	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03264133	chr6:25882463	NA	-0.47	-10.33	-0.38	3.16e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg09307838	chr4:120376055	NA	0.46	8.8	0.33	1.29e-17	Corneal astigmatism;
BRCA	cis	rs11608355	0.545	rs12819142	chr12:109896316	G/T	cg05360138	chr12:110035743	NA	0.65	10.77	0.39	5.72e-25	Neuroticism;
BRCA	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg25237894	chr2:233734115	C2orf82	-0.36	-10.49	-0.38	7.07e-24	Coronary artery disease;
BRCA	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg26384229	chr12:38710491	ALG10B	0.59	13.62	0.47	2.98e-37	Morning vs. evening chronotype;
BRCA	cis	rs7523273	0.606	rs859705	chr1:207959665	A/G	cg22525895	chr1:207977042	MIR29B2	0.5	12.72	0.45	3.46e-33	Schizophrenia;
BRCA	cis	rs6942756	1.000	rs13235749	chr7:128879678	C/G	cg02491457	chr7:128862824	NA	-0.73	-14.9	-0.51	2.65e-43	White matter hyperintensity burden;
BRCA	cis	rs169738	1	rs169738	chr6:33537546	A/G	cg24505687	chr6:33548425	BAK1	0.38	8.4	0.32	2.84e-16	Platelet count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11764359	chr7:65958608	NA	-0.73	-16.06	-0.54	5.07e-49	Aortic root size;
BRCA	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg24101359	chr6:42928495	GNMT	-0.54	-12.79	-0.45	1.67e-33	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6545883	0.965	rs778752	chr2:61776902	C/G	cg15711740	chr2:61764176	XPO1	-0.57	-14.71	-0.5	2.12e-42	Tuberculosis;
BRCA	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.43	-10.06	-0.37	3.35e-22	Lung cancer;
BRCA	cis	rs2015599	0.549	rs7972032	chr12:29444284	G/A	cg09582351	chr12:29534625	ERGIC2	-0.35	-8.23	-0.31	1.05e-15	Mean platelet volume;Platelet count;
BRCA	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.46	9.22	0.34	4.38e-19	Tonsillectomy;
BRCA	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg05340658	chr4:99064831	C4orf37	0.49	10.75	0.39	6.87e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-10.0	-0.37	5.83e-22	Aortic root size;
BRCA	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg04842962	chr6:43655489	MRPS18A	-0.98	-22.41	-0.66	1.7e-82	IgG glycosylation;
BRCA	trans	rs11039798	1.000	rs10769370	chr11:48515430	A/G	cg15704280	chr7:45808275	SEPT13	0.57	8.5	0.32	1.35e-16	Axial length;
BRCA	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00149659	chr3:10157352	C3orf10	0.71	12.54	0.44	2.2e-32	Alzheimer's disease;
BRCA	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg20283391	chr11:68216788	NA	-0.46	-9.22	-0.34	4.1e-19	Total body bone mineral density;
BRCA	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg15212455	chr7:39170539	POU6F2	0.44	9.68	0.36	8.81e-21	IgG glycosylation;
BRCA	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg19628046	chr18:33552617	C18orf21	-0.63	-13.06	-0.46	9.73e-35	Endometriosis;Drug-induced torsades de pointes;
BRCA	trans	rs75804782	0.641	rs56396448	chr2:239335234	C/T	cg01134436	chr17:81009848	B3GNTL1	0.74	9.46	0.35	5.65e-20	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-8.79	-0.33	1.41e-17	Alzheimer's disease (late onset);
BRCA	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.78	21.3	0.64	1.84e-76	Multiple sclerosis;
BRCA	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.47	-0.32	1.67e-16	Monocyte percentage of white cells;
BRCA	cis	rs11734570	0.581	rs55958238	chr4:38604331	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.52	9.57	0.35	2.24e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg04709771	chr16:646395	RAB40C	0.45	11.24	0.41	7.44e-27	Height;
BRCA	cis	rs17401966	1.000	rs7520935	chr1:10354271	G/T	cg03954927	chr1:10346856	KIF1B	0.45	12.96	0.46	2.73e-34	Hepatocellular carcinoma;
BRCA	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg18512352	chr11:47633146	NA	-0.38	-9.26	-0.34	3.03e-19	Subjective well-being;
BRCA	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	11.83	0.42	2.47e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg08601574	chr20:25228251	PYGB	0.36	8.72	0.33	2.4e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.35	8.2	0.31	1.28e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6138458	1.000	rs227621	chr20:24910528	A/C	cg26195577	chr20:24973756	C20orf3	0.98	24.76	0.7	2.17e-95	Blood protein levels;
BRCA	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg06784218	chr1:46089804	CCDC17	-0.45	-10.8	-0.39	4.54e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg20203395	chr5:56204925	C5orf35	0.38	8.62	0.32	5.15e-17	Initial pursuit acceleration;
BRCA	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg21770322	chr7:97807741	LMTK2	0.41	10.97	0.4	8.81e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2425143	1.000	rs11699690	chr20:34271774	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.0	-0.34	2.46e-18	Blood protein levels;
BRCA	cis	rs1865721	1.000	rs8091890	chr18:73197242	T/C	cg26385618	chr18:73139727	C18orf62	-0.39	-8.73	-0.33	2.27e-17	Intelligence;
BRCA	cis	rs7512552	0.839	rs834236	chr1:150362968	C/T	cg15654264	chr1:150340011	RPRD2	0.38	8.4	0.32	2.96e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg14196790	chr5:131705035	SLC22A5	0.4	10.15	0.37	1.51e-22	Blood metabolite levels;
BRCA	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg19920283	chr7:105172520	RINT1	0.58	9.35	0.35	1.42e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg17063962	chr7:91808500	NA	-0.55	-12.64	-0.45	7.58e-33	Breast cancer;
BRCA	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg20307385	chr11:47447363	PSMC3	-0.42	-8.67	-0.32	3.47e-17	Subjective well-being;
BRCA	cis	rs11874712	1.000	rs9945606	chr18:43673325	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.09	0.3	2.98e-15	Migraine - clinic-based;
BRCA	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg17724175	chr1:150552817	MCL1	0.25	8.21	0.31	1.26e-15	Tonsillectomy;
BRCA	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.42e-34	Alzheimer's disease (late onset);
BRCA	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg26608667	chr7:1196370	ZFAND2A	0.44	10.31	0.38	3.79e-23	Longevity;Endometriosis;
BRCA	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07256732	chr16:621771	PIGQ	-0.34	-9.05	-0.34	1.73e-18	Height;
BRCA	cis	rs926392	0.640	rs62202616	chr20:37692775	G/C	cg16355469	chr20:37678765	NA	0.52	11.46	0.41	8.49e-28	Dialysis-related mortality;
BRCA	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg02734326	chr4:10020555	SLC2A9	0.39	8.51	0.32	1.21e-16	Bone mineral density;
BRCA	cis	rs10504073	0.626	rs9298106	chr8:50007508	T/G	cg00325661	chr8:49890786	NA	0.38	11.2	0.4	1.07e-26	Blood metabolite ratios;
BRCA	cis	rs7551345	0.592	rs12087046	chr1:31700412	C/T	cg19084893	chr1:31688959	NA	0.42	9.22	0.34	4.31e-19	Schizophrenia;
BRCA	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg24397884	chr7:158709396	WDR60	-0.99	-25.51	-0.71	1.62e-99	Height;
BRCA	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg09537434	chr19:41945824	ATP5SL	1.01	23.79	0.69	4.72e-90	Height;
BRCA	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg24296786	chr1:45957014	TESK2	-0.63	-15.1	-0.51	2.8e-44	High light scatter reticulocyte count;
BRCA	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg06484146	chr7:12443880	VWDE	-0.72	-10.73	-0.39	8.24e-25	Coronary artery disease;
BRCA	trans	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg25214090	chr10:38739885	LOC399744	0.56	12.85	0.45	9.31e-34	Corneal astigmatism;
BRCA	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg23711669	chr6:146136114	FBXO30	-0.71	-16.8	-0.55	9.37e-53	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6076960	0.684	rs3852947	chr20:6255341	A/G	cg21095983	chr6:86352623	SYNCRIP	0.4	8.92	0.33	4.82e-18	Smooth-surface caries;
BRCA	cis	rs4077515	0.967	rs10781500	chr9:139269338	A/G	cg14019695	chr9:139328340	INPP5E	-0.31	-8.05	-0.3	4.16e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs953387	1.000	rs4954569	chr2:136913375	C/T	cg05194412	chr2:137003533	NA	-0.38	-8.63	-0.32	4.7e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg06115741	chr20:33292138	TP53INP2	-0.45	-10.04	-0.37	4.13e-22	Coronary artery disease;
BRCA	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	trans	rs7830939	0.553	rs10105543	chr8:9323515	C/T	cg15556689	chr8:8085844	FLJ10661	0.33	7.93	0.3	1.01e-14	Neuroticism;
BRCA	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg10523679	chr1:76189770	ACADM	0.88	20.7	0.63	2.98e-73	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg20476274	chr7:133979776	SLC35B4	0.45	11.72	0.42	7.14e-29	Mean platelet volume;
BRCA	cis	rs4074536	0.622	rs10923445	chr1:116320833	T/C	cg21648376	chr1:116311395	CASQ2	-0.54	-9.03	-0.34	1.99e-18	QRS duration;
BRCA	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg14829155	chr15:31115871	NA	-0.43	-10.01	-0.37	5.19e-22	Huntington's disease progression;
BRCA	cis	rs1568889	0.838	rs7952717	chr11:28261658	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.57	0.63	1.47e-72	Bipolar disorder;
BRCA	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	17.07	0.56	4.16e-54	Electrocardiographic conduction measures;
BRCA	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg00105475	chr2:10696890	NA	0.42	9.63	0.36	1.44e-20	Prostate cancer;
BRCA	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg11764359	chr7:65958608	NA	-0.67	-15.11	-0.51	2.51e-44	Aortic root size;
BRCA	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg05793240	chr7:2802953	GNA12	-0.31	-7.95	-0.3	8.63e-15	Height;
BRCA	cis	rs7520050	0.966	rs4545281	chr1:46360054	C/T	cg24296786	chr1:45957014	TESK2	0.41	9.3	0.35	2.13e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2404602	0.552	rs4886823	chr15:76965402	A/G	cg23625390	chr15:77176239	SCAPER	-0.52	-12.2	-0.43	6.41e-31	Blood metabolite levels;
BRCA	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg14349672	chr11:133703707	NA	-0.42	-9.28	-0.34	2.58e-19	Childhood ear infection;
BRCA	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg21782813	chr7:2030301	MAD1L1	0.42	12.04	0.43	3.14e-30	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs365132	0.517	rs3762974	chr5:176328336	G/A	cg16309518	chr5:176445507	NA	0.45	10.57	0.39	3.57e-24	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs12618769	0.597	rs72819987	chr2:99046253	A/G	cg10123293	chr2:99228465	UNC50	0.41	8.3	0.31	6.37e-16	Bipolar disorder;
BRCA	cis	rs7617773	0.746	rs4371540	chr3:48353543	G/A	cg11946769	chr3:48343235	NME6	0.69	13.8	0.48	4.23e-38	Coronary artery disease;
BRCA	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg18225595	chr11:63971243	STIP1	0.53	9.61	0.36	1.61e-20	Mean platelet volume;
BRCA	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg21782813	chr7:2030301	MAD1L1	0.38	9.9	0.36	1.37e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg00757033	chr12:89920650	WDR51B	0.52	10.45	0.38	1.03e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg03213289	chr20:61660250	NA	0.62	16.39	0.54	1.23e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6005807	0.719	rs16986398	chr22:28815629	A/C	cg12565055	chr22:29076175	TTC28	0.43	8.31	0.31	5.83e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs9443645	0.527	rs7756996	chr6:79509367	A/C	cg05283184	chr6:79620031	NA	-0.36	-8.18	-0.31	1.54e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg03060546	chr3:49711283	APEH	-0.53	-10.6	-0.39	2.62e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	22.45	0.66	9.73e-83	Platelet count;
BRCA	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02353165	chr6:42928485	GNMT	0.76	18.46	0.59	2.62e-61	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs11997175	0.583	rs66622174	chr8:33812542	T/G	ch.8.33884649F	chr8:33765107	NA	0.36	8.28	0.31	6.99e-16	Body mass index;
BRCA	trans	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg19862616	chr7:65841803	NCRNA00174	0.82	26.58	0.72	2.01e-105	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4302748	0.862	rs73337008	chr7:36187715	G/T	cg24442661	chr7:36192818	EEPD1	0.47	8.78	0.33	1.48e-17	Platelet count;
BRCA	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23583168	chr7:148888333	NA	-0.96	-25.45	-0.71	3.49e-99	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7766436	0.614	rs55663812	chr6:22562881	G/A	cg13666174	chr6:22585274	NA	-0.41	-8.63	-0.32	4.72e-17	Coronary artery disease;
BRCA	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg25036284	chr2:26402008	FAM59B	-0.63	-10.48	-0.38	8.25e-24	Gut microbiome composition (summer);
BRCA	cis	rs10504073	0.647	rs11785310	chr8:50025035	G/A	cg00325661	chr8:49890786	NA	0.44	12.58	0.45	1.4e-32	Blood metabolite ratios;
BRCA	cis	rs2731664	0.792	rs465670	chr5:176877624	C/T	cg23176889	chr5:176863531	GRK6	-0.62	-16.79	-0.55	1.1e-52	Intelligence (multi-trait analysis);
BRCA	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg17470723	chr8:74884337	TCEB1	0.41	8.64	0.32	4.43e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg13010199	chr12:38710504	ALG10B	0.45	9.25	0.34	3.44e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg02187348	chr16:89574699	SPG7	0.35	8.22	0.31	1.13e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg24531977	chr5:56204891	C5orf35	-0.41	-8.41	-0.32	2.73e-16	Coronary artery disease;
BRCA	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg21995147	chr19:1064017	ABCA7	-0.38	-8.19	-0.31	1.41e-15	Alzheimer's disease (late onset);
BRCA	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg06784218	chr1:46089804	CCDC17	0.46	10.93	0.4	1.34e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.48	-0.35	4.76e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-8.52	-0.32	1.1e-16	Schizophrenia;
BRCA	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg16606324	chr3:10149918	C3orf24	0.58	11.66	0.42	1.3e-28	Alzheimer's disease;
BRCA	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg23229984	chr5:148520753	ABLIM3	0.35	8.86	0.33	7.66e-18	Breast cancer;
BRCA	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg17366294	chr4:99064904	C4orf37	-0.45	-10.55	-0.39	4.21e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg11952622	chr19:58962976	ZNF324B	0.41	8.22	0.31	1.13e-15	Uric acid clearance;
BRCA	cis	rs7714584	1.000	rs11741861	chr5:150277909	C/T	cg22134413	chr5:150180641	NA	-0.84	-11.35	-0.41	2.6e-27	Crohn's disease;
BRCA	trans	rs6479891	1.000	rs4746138	chr10:65241741	A/G	cg14819942	chr15:35414228	NA	0.34	8.56	0.32	8.39e-17	Arthritis (juvenile idiopathic);
BRCA	trans	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg13565492	chr6:43139072	SRF	-0.88	-15.78	-0.53	1.31e-47	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg25457927	chr22:38595422	NA	-0.32	-12.03	-0.43	3.61e-30	Cutaneous nevi;
BRCA	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18876405	chr7:65276391	NA	-0.55	-13.02	-0.46	1.6e-34	Aortic root size;
BRCA	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg12564285	chr5:131593104	PDLIM4	-0.35	-7.9	-0.3	1.18e-14	Breast cancer;
BRCA	cis	rs4363385	0.720	rs11205150	chr1:152959266	C/T	cg24667326	chr1:152973720	SPRR3	-0.35	-9.75	-0.36	5.12e-21	Inflammatory skin disease;
BRCA	cis	rs13102973	0.640	rs11722290	chr4:135832268	C/T	cg14419869	chr4:135874104	NA	0.46	9.33	0.35	1.67e-19	Subjective well-being;
BRCA	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-11.79	-0.42	3.69e-29	Gut microbiome composition (summer);
BRCA	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg18357526	chr6:26021779	HIST1H4A	0.49	8.67	0.32	3.59e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	9.16	0.34	6.71e-19	Systemic lupus erythematosus;
BRCA	cis	rs882300	0.967	rs12691876	chr2:136963794	A/G	cg05194412	chr2:137003533	NA	-0.38	-8.17	-0.31	1.67e-15	Multiple sclerosis;Electrocardiographic traits;
BRCA	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg17143192	chr8:8559678	CLDN23	-0.61	-12.65	-0.45	7.03e-33	Obesity-related traits;
BRCA	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg18252515	chr7:66147081	NA	1.03	15.25	0.52	5.04e-45	Diabetic kidney disease;
BRCA	trans	rs61931739	0.529	rs1525900	chr12:33976652	T/G	cg26384229	chr12:38710491	ALG10B	0.4	9.05	0.34	1.69e-18	Morning vs. evening chronotype;
BRCA	cis	rs17253792	0.822	rs75763956	chr14:56071176	A/G	cg01858014	chr14:56050164	KTN1	-0.78	-11.08	-0.4	3.31e-26	Putamen volume;
BRCA	cis	rs877282	0.947	rs7904978	chr10:768078	C/T	cg17470449	chr10:769945	NA	0.49	8.47	0.32	1.72e-16	Uric acid levels;
BRCA	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg20302533	chr7:39170763	POU6F2	0.38	8.05	0.3	4.18e-15	IgG glycosylation;
BRCA	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg08132940	chr7:1081526	C7orf50	-0.48	-7.95	-0.3	8.72e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.4	-8.29	-0.31	6.49e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs870825	0.616	rs61653735	chr4:185630025	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	17.28	0.56	3.69e-55	Blood protein levels;
BRCA	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg07741184	chr6:167504864	NA	0.29	8.36	0.31	3.96e-16	Crohn's disease;
BRCA	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg13660082	chr14:53194042	PSMC6	-0.57	-8.76	-0.33	1.76e-17	Alzheimer's disease (late onset);
BRCA	cis	rs7131987	0.650	rs10843377	chr12:29437053	C/G	cg09582351	chr12:29534625	ERGIC2	0.46	10.71	0.39	9.54e-25	QT interval;
BRCA	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg26384229	chr12:38710491	ALG10B	-0.44	-10.17	-0.37	1.28e-22	Heart rate;
BRCA	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg13256891	chr4:100009986	ADH5	0.52	9.71	0.36	6.81e-21	Alcohol dependence;
BRCA	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11644478	chr21:40555479	PSMG1	-0.5	-10.7	-0.39	1.05e-24	Menarche (age at onset);
BRCA	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	12.18	0.43	7.98e-31	Coronary artery disease;
BRCA	cis	rs1371614	0.611	rs3843322	chr2:27131849	G/T	cg12368169	chr2:27073192	DPYSL5	0.28	8.35	0.31	4.32e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg04450456	chr4:17643702	FAM184B	0.37	10.88	0.4	2.04e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg03342759	chr3:160939853	NMD3	-0.62	-13.44	-0.47	1.89e-36	Morning vs. evening chronotype;
BRCA	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg11833968	chr6:79620685	NA	-0.46	-10.4	-0.38	1.72e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg12292205	chr6:26970375	C6orf41	0.78	18.73	0.6	1.04e-62	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7903847	0.642	rs2297667	chr10:99145492	A/T	cg08345082	chr10:99160200	RRP12	-0.29	-8.49	-0.32	1.44e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg24642439	chr20:33292090	TP53INP2	-0.44	-8.46	-0.32	1.89e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.17	0.31	1.63e-15	Menopause (age at onset);
BRCA	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg24812749	chr6:127587940	RNF146	0.72	14.79	0.51	8.42e-43	Breast cancer;
BRCA	cis	rs2658782	0.694	rs3019221	chr11:93079700	C/G	cg15737290	chr11:93063684	CCDC67	0.48	9.99	0.37	6.31e-22	Pulmonary function decline;
BRCA	cis	rs4664304	0.739	rs2162500	chr2:160708645	C/G	cg01092293	chr2:160761427	LY75	0.39	9.32	0.35	1.87e-19	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11890956	chr21:40555474	PSMG1	1.06	31.69	0.78	3.73e-133	Cognitive function;
BRCA	cis	rs2425143	1.000	rs11167275	chr20:34340275	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.08	-0.34	1.29e-18	Blood protein levels;
BRCA	cis	rs6977660	0.714	rs4719586	chr7:19825548	T/C	cg05791153	chr7:19748676	TWISTNB	0.58	10.92	0.4	1.41e-25	Thyroid stimulating hormone;
BRCA	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.26	0.34	3.1e-19	Tonsillectomy;
BRCA	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg03585969	chr10:35415529	CREM	0.56	11.46	0.41	9.11e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg08885076	chr2:99613938	TSGA10	0.42	9.88	0.36	1.61e-21	Chronic sinus infection;
BRCA	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg17971929	chr21:40555470	PSMG1	-0.49	-10.69	-0.39	1.23e-24	Menarche (age at onset);
BRCA	cis	rs1113500	0.933	rs3909076	chr1:108631760	T/C	cg06207961	chr1:108661230	NA	0.46	11.07	0.4	3.59e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs754466	0.957	rs61854183	chr10:79698077	T/C	cg17075019	chr10:79541650	NA	-0.65	-12.13	-0.43	1.22e-30	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.78	0.33	1.48e-17	Motion sickness;
BRCA	cis	rs1371614	0.531	rs77562583	chr2:27151643	G/A	cg00617064	chr2:27272375	NA	-0.31	-8.14	-0.31	2.09e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg01802117	chr1:53393560	SCP2	-0.35	-8.16	-0.31	1.78e-15	Monocyte count;
BRCA	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.57	-0.47	4.99e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg21573476	chr21:45109991	RRP1B	-0.35	-9.08	-0.34	1.36e-18	Mean corpuscular volume;
BRCA	trans	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg06521331	chr12:34319734	NA	-0.47	-8.52	-0.32	1.11e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg21395723	chr22:39101663	GTPBP1	-0.38	-8.08	-0.3	3.25e-15	Menopause (age at onset);
BRCA	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9649213	0.614	rs4729432	chr7:97947055	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.58	-15.67	-0.53	4.36e-47	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9473147	0.747	rs9395288	chr6:47598125	C/T	cg12968598	chr6:47444699	CD2AP	0.39	7.86	0.3	1.59e-14	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg04756594	chr16:24857601	SLC5A11	0.35	8.29	0.31	6.49e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	12.17	0.43	8.33e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7122539	0.839	rs6591223	chr11:66609289	C/T	cg24851651	chr11:66362959	CCS	0.4	8.37	0.31	3.55e-16	HIV-1 susceptibility;
BRCA	trans	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.46	0.32	1.88e-16	Mean corpuscular volume;
BRCA	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg05552183	chr6:42928497	GNMT	0.7	15.86	0.53	5.03e-48	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg04450456	chr4:17643702	FAM184B	-0.34	-9.83	-0.36	2.58e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs858239	0.537	rs6955115	chr7:23227144	A/G	cg23682824	chr7:23144976	KLHL7	0.35	8.86	0.33	7.81e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs926392	0.666	rs56877916	chr20:37696192	A/T	cg16355469	chr20:37678765	NA	0.48	11.36	0.41	2.28e-27	Dialysis-related mortality;
BRCA	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-9.56	-0.35	2.59e-20	Blood metabolite levels;
BRCA	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg11764359	chr7:65958608	NA	0.75	17.49	0.57	2.93e-56	Aortic root size;
BRCA	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	14.38	0.49	8.14e-41	Colorectal cancer;
BRCA	cis	rs7646881	0.812	rs73017536	chr3:158460602	C/T	cg19483011	chr3:158453295	NA	-0.46	-8.05	-0.3	4.08e-15	Tetralogy of Fallot;
BRCA	trans	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg26384229	chr12:38710491	ALG10B	0.43	10.26	0.38	5.53e-23	Morning vs. evening chronotype;
BRCA	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg01849466	chr14:104193079	ZFYVE21	0.43	10.95	0.4	1.12e-25	Schizophrenia;
BRCA	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg11764359	chr7:65958608	NA	-0.64	-11.45	-0.41	9.95e-28	Aortic root size;
BRCA	cis	rs858239	0.932	rs1728313	chr7:23271031	A/C	cg23682824	chr7:23144976	KLHL7	0.34	8.77	0.33	1.65e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.2	0.68	7.62e-87	Chronic sinus infection;
BRCA	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg10523679	chr1:76189770	ACADM	0.72	15.04	0.51	5.56e-44	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg02734326	chr4:10020555	SLC2A9	0.35	7.84	0.3	1.83e-14	Bone mineral density;
BRCA	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg07828340	chr4:882639	GAK	0.79	11.5	0.41	6.1e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg08601574	chr20:25228251	PYGB	-0.33	-7.86	-0.3	1.58e-14	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg06238570	chr21:40685208	BRWD1	-0.41	-8.3	-0.31	6.11e-16	Cognitive function;
BRCA	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg06671706	chr8:8559999	CLDN23	0.43	8.43	0.32	2.38e-16	Obesity-related traits;
BRCA	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.35	-0.38	2.49e-23	IgG glycosylation;
BRCA	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	11.66	0.42	1.24e-28	Schizophrenia;
BRCA	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg01877450	chr7:97915802	BRI3	-0.38	-8.82	-0.33	1.11e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg13256891	chr4:100009986	ADH5	0.54	9.97	0.37	7.58e-22	Smoking initiation;
BRCA	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg09682330	chr6:28411287	ZSCAN23	-0.37	-7.82	-0.3	2.15e-14	Pubertal anthropometrics;
BRCA	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg25208724	chr1:156163844	SLC25A44	1.07	35.59	0.82	9.17e-154	Testicular germ cell tumor;
BRCA	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg27129171	chr3:47204927	SETD2	-0.74	-17.51	-0.57	2.34e-56	Colorectal cancer;
BRCA	cis	rs6484504	0.600	rs7122895	chr11:31346620	G/C	cg06552810	chr11:31128660	NA	0.4	8.66	0.32	3.75e-17	Red blood cell count;
BRCA	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg06671706	chr8:8559999	CLDN23	0.41	8.11	0.31	2.67e-15	Obesity-related traits;
BRCA	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg21699342	chr2:239360505	ASB1	0.5	11.52	0.41	5.08e-28	Multiple system atrophy;
BRCA	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26314531	chr2:26401878	FAM59B	0.95	16.58	0.55	1.33e-51	Gut microbiome composition (summer);
BRCA	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.9	0.62	6.05e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	12.51	0.44	2.84e-32	Platelet count;
BRCA	cis	rs6120849	0.754	rs17319032	chr20:33643296	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	10.31	0.38	3.78e-23	Protein C levels;
BRCA	cis	rs4268898	0.552	rs35331966	chr2:24367828	C/T	cg06627628	chr2:24431161	ITSN2	0.4	8.51	0.32	1.24e-16	Asthma;
BRCA	cis	rs7178424	1.000	rs7178540	chr15:62380132	A/G	cg00456672	chr15:62358751	C2CD4A	0.35	8.27	0.31	7.8e-16	Height;
BRCA	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.81	0.39	3.9e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs847577	0.540	rs3847055	chr7:97680645	A/G	cg18676790	chr7:97680731	NA	-0.37	-8.25	-0.31	9.09e-16	Breast cancer;
BRCA	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08048268	chr3:133502702	NA	-0.34	-8.47	-0.32	1.72e-16	Iron status biomarkers;
BRCA	cis	rs34891900	0.507	rs2008085	chr22:18204316	T/G	cg19898043	chr22:18121309	BCL2L13	0.45	9.65	0.36	1.18e-20	Sum neutrophil eosinophil counts;
BRCA	cis	rs10504073	0.584	rs4873306	chr8:49950369	T/C	cg00325661	chr8:49890786	NA	0.45	13.07	0.46	9.48e-35	Blood metabolite ratios;
BRCA	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7043114	0.525	rs4744136	chr9:95275024	A/G	cg14631576	chr9:95140430	CENPP	0.32	8.02	0.3	5e-15	Height;
BRCA	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg16586182	chr3:47516702	SCAP	-0.56	-12.53	-0.44	2.37e-32	Colorectal cancer;
BRCA	cis	rs7927771	0.524	rs7110300	chr11:47848442	T/G	cg20307385	chr11:47447363	PSMC3	0.41	9.4	0.35	9.67e-20	Subjective well-being;
BRCA	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11644478	chr21:40555479	PSMG1	-0.67	-14.49	-0.5	2.42e-41	Cognitive function;
BRCA	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg05340658	chr4:99064831	C4orf37	0.49	10.75	0.39	6.87e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg07460842	chr6:66804631	NA	-1.02	-20.23	-0.62	1.1e-70	Exhaled nitric oxide output;
BRCA	cis	rs208520	0.661	rs851466	chr6:66840476	A/G	cg07460842	chr6:66804631	NA	-1.02	-20.15	-0.62	2.95e-70	Exhaled nitric oxide output;
BRCA	cis	rs78761021	0.867	rs17676067	chr17:9791375	C/T	cg26853458	chr17:9805074	RCVRN	-0.43	-8.62	-0.32	5.19e-17	Type 2 diabetes;
BRCA	cis	rs9649465	1.000	rs10270877	chr7:123327860	T/C	cg04330084	chr7:123175371	IQUB	-0.3	-8.38	-0.31	3.26e-16	Migraine;
BRCA	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg08213375	chr14:104286397	PPP1R13B	0.65	18.58	0.59	5.9e-62	Schizophrenia;
BRCA	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg24692254	chr21:30365293	RNF160	-0.46	-9.8	-0.36	3.22e-21	Cognitive test performance;
BRCA	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	0.39	8.47	0.32	1.66e-16	IgG glycosylation;
BRCA	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg13010199	chr12:38710504	ALG10B	0.48	9.19	0.34	5.33e-19	Morning vs. evening chronotype;
BRCA	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	13.11	0.46	6.14e-35	Migraine;Coronary artery disease;
BRCA	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg04025307	chr7:1156635	C7orf50	0.59	13.67	0.48	1.69e-37	Longevity;Endometriosis;
BRCA	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24308560	chr3:49941425	MST1R	-0.39	-8.11	-0.31	2.57e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg12165864	chr7:66369176	NA	-0.43	-9.66	-0.36	1.08e-20	Corneal structure;
BRCA	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-9.89	-0.36	1.43e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg22920501	chr2:26401640	FAM59B	-0.66	-11.43	-0.41	1.19e-27	Gut microbiome composition (summer);
BRCA	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg03146154	chr1:46216737	IPP	0.47	10.52	0.38	5.5e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg02659138	chr7:134003124	SLC35B4	0.33	10.38	0.38	1.94e-23	Mean platelet volume;
BRCA	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg15395560	chr15:45543142	SLC28A2	0.3	8.3	0.31	6.2e-16	Uric acid levels;
BRCA	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-12.56	-0.44	1.75e-32	Personality dimensions;
BRCA	cis	rs7572733	0.555	rs10202569	chr2:198934726	C/G	cg00792783	chr2:198669748	PLCL1	0.39	8.31	0.31	5.7e-16	Dermatomyositis;
BRCA	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-10.86	-0.39	2.44e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs10242455	0.702	rs45448997	chr7:99041598	G/C	cg09045935	chr12:6379348	NA	0.84	8.26	0.31	8.16e-16	Blood metabolite levels;
BRCA	cis	rs2637266	0.905	rs1978925	chr10:78399879	C/T	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg25208724	chr1:156163844	SLC25A44	0.85	16.28	0.54	4.24e-50	Testicular germ cell tumor;
BRCA	cis	rs9462846	0.919	rs9471966	chr6:42891022	G/A	cg05552183	chr6:42928497	GNMT	0.43	8.06	0.3	3.76e-15	Blood protein levels;
BRCA	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06108461	chr20:60628389	TAF4	-0.99	-22.33	-0.66	4.6e-82	Body mass index;
BRCA	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs7523050	0.643	rs34096625	chr1:109401101	G/A	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs4363385	0.720	rs1338179	chr1:152981548	T/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.36	-0.31	3.79e-16	Inflammatory skin disease;
BRCA	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg26384229	chr12:38710491	ALG10B	0.75	16.82	0.55	7.58e-53	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.96	0.4	1.03e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.37	-7.92	-0.3	1.07e-14	Longevity;Endometriosis;
BRCA	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.77	-0.45	2.1e-33	Type 2 diabetes;
BRCA	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg23788917	chr6:8435910	SLC35B3	-0.48	-10.42	-0.38	1.43e-23	Motion sickness;
BRCA	cis	rs10789491	0.767	rs1816730	chr1:47207346	T/C	cg15501359	chr1:47185051	KIAA0494	0.69	17.09	0.56	3.45e-54	Response to hepatitis C treatment;
BRCA	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg10734432	chr8:145180544	NA	-0.54	-9.05	-0.34	1.7e-18	Blood metabolite levels;
BRCA	trans	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg15556689	chr8:8085844	FLJ10661	0.35	8.38	0.31	3.45e-16	Neuroticism;
BRCA	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg18252515	chr7:66147081	NA	1.04	15.68	0.53	4.14e-47	Diabetic kidney disease;
BRCA	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg14675211	chr2:100938903	LONRF2	0.47	10.86	0.39	2.44e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg12386194	chr3:101231763	SENP7	0.66	12.92	0.46	4.2e-34	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg24531977	chr5:56204891	C5orf35	-0.54	-11.43	-0.41	1.22e-27	Coronary artery disease;
BRCA	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03264133	chr6:25882463	NA	-0.42	-9.74	-0.36	5.23e-21	Height;
BRCA	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg12560992	chr17:57184187	TRIM37	0.69	18.8	0.6	4.41e-63	Intelligence (multi-trait analysis);
BRCA	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg14061069	chr19:46274453	DMPK	-0.48	-11.89	-0.43	1.3e-29	Coronary artery disease;
BRCA	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg27432699	chr2:27873401	GPN1	0.43	9.24	0.34	3.65e-19	Oral cavity cancer;
BRCA	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg21770322	chr7:97807741	LMTK2	0.45	11.74	0.42	5.96e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-10.46	-0.38	9.96e-24	IgG glycosylation;
BRCA	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg18876405	chr7:65276391	NA	-0.52	-11.7	-0.42	8.87e-29	Aortic root size;
BRCA	cis	rs7927771	0.524	rs61895760	chr11:47794538	G/C	cg20307385	chr11:47447363	PSMC3	0.42	9.56	0.35	2.48e-20	Subjective well-being;
BRCA	cis	rs2991971	0.776	rs12139364	chr1:45890155	T/C	cg24296786	chr1:45957014	TESK2	0.57	13.13	0.46	4.95e-35	High light scatter reticulocyte count;
BRCA	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg01819863	chr10:32635814	EPC1	1.14	20.19	0.62	1.67e-70	Sexual dysfunction (female);
BRCA	cis	rs7301826	0.966	rs10734980	chr12:131294626	T/C	cg11011512	chr12:131303247	STX2	0.42	10.89	0.4	1.91e-25	Plasma plasminogen activator levels;
BRCA	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg06784218	chr1:46089804	CCDC17	-0.45	-10.74	-0.39	7.65e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6121246	0.559	rs6060962	chr20:30397847	A/G	cg13852791	chr20:30311386	BCL2L1	0.95	23.04	0.67	5.81e-86	Mean corpuscular hemoglobin;
BRCA	cis	rs35995292	0.500	rs6945239	chr7:38932208	C/T	cg19327137	chr7:38886074	VPS41	0.38	12.67	0.45	5.76e-33	Subjective well-being (multi-trait analysis);
BRCA	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08109568	chr15:31115862	NA	-0.45	-10.37	-0.38	2.15e-23	Huntington's disease progression;
BRCA	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg15997130	chr1:24165203	NA	0.44	11.49	0.41	6.34e-28	Immature fraction of reticulocytes;
BRCA	trans	rs2270927	0.834	rs4496693	chr5:75576729	T/C	cg13563193	chr19:33072644	PDCD5	0.8	11.43	0.41	1.2e-27	Mean corpuscular volume;
BRCA	cis	rs7312774	0.609	rs2374656	chr12:107380411	A/C	cg16260113	chr12:107380972	MTERFD3	0.82	9.01	0.34	2.38e-18	Severe influenza A (H1N1) infection;
BRCA	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg23505145	chr19:12996616	KLF1	0.54	12.32	0.44	1.86e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05025164	chr4:1340916	KIAA1530	-0.71	-14.66	-0.5	3.62e-42	Longevity;
BRCA	cis	rs11887277	0.708	rs12474330	chr2:27063260	G/A	cg12368169	chr2:27073192	DPYSL5	-0.33	-10.0	-0.37	5.81e-22	Obesity-related traits;
BRCA	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg25486957	chr4:152246857	NA	-0.36	-7.9	-0.3	1.26e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	10.67	0.39	1.36e-24	Motion sickness;
BRCA	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg21475434	chr5:93447410	FAM172A	0.64	8.35	0.31	4.13e-16	Diabetic retinopathy;
BRCA	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	19.83	0.62	1.55e-68	Smoking behavior;
BRCA	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg05863683	chr7:1912471	MAD1L1	0.36	8.27	0.31	7.83e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	17.04	0.56	5.63e-54	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	trans	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.45	-0.35	6.17e-20	Bladder cancer;
BRCA	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg02012338	chr4:187126139	CYP4V2	-0.87	-10.08	-0.37	2.87e-22	Blood protein levels;
BRCA	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg21385522	chr1:16154831	NA	-0.45	-9.76	-0.36	4.37e-21	Systolic blood pressure;
BRCA	cis	rs7617773	0.778	rs11707997	chr3:48377875	A/G	cg11946769	chr3:48343235	NME6	0.67	13.48	0.47	1.23e-36	Coronary artery disease;
BRCA	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg08807101	chr21:30365312	RNF160	-0.6	-15.29	-0.52	3.43e-45	Dental caries;
BRCA	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg12641515	chr19:46296257	DMWD	-0.41	-8.59	-0.32	6.85e-17	Coronary artery disease;
BRCA	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg17971929	chr21:40555470	PSMG1	-0.49	-10.84	-0.39	3.12e-25	Menarche (age at onset);
BRCA	trans	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-7.95	-0.3	8.62e-15	Menarche (age at onset);
BRCA	trans	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg02030672	chr11:45687055	CHST1	0.39	8.31	0.31	5.55e-16	Obesity-related traits;
BRCA	trans	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-9.58	-0.35	2.11e-20	Monocyte count;
BRCA	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.79	-0.33	1.39e-17	Breast cancer;
BRCA	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.47	-0.38	8.63e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg24060327	chr5:131705240	SLC22A5	-0.6	-11.09	-0.4	2.89e-26	Breast cancer;
BRCA	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07930192	chr7:1003750	NA	0.39	8.26	0.31	8.12e-16	Longevity;Endometriosis;
BRCA	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg10978503	chr1:24200527	CNR2	-0.43	-11.25	-0.41	6.68e-27	Immature fraction of reticulocytes;
BRCA	cis	rs12611088	0.541	rs2599445	chr19:44005025	C/G	cg15012607	chr19:44012195	ETHE1	-0.33	-8.48	-0.32	1.52e-16	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg10523679	chr1:76189770	ACADM	0.72	12.38	0.44	1.03e-31	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg05340658	chr4:99064831	C4orf37	0.56	10.95	0.4	1.11e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs929596	0.561	rs7564935	chr2:234645186	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.4	-10.09	-0.37	2.53e-22	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg02016764	chr4:38805732	TLR1	-0.6	-9.19	-0.34	5.47e-19	Breast cancer;
BRCA	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	21.71	0.65	1.04e-78	Smoking behavior;
BRCA	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-12.48	-0.44	3.84e-32	Longevity;
BRCA	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg23422044	chr7:1970798	MAD1L1	-0.59	-11.0	-0.4	6.6900000000000006e-26	Neuroticism;
BRCA	cis	rs7131987	0.650	rs7973786	chr12:29462744	C/T	cg09582351	chr12:29534625	ERGIC2	-0.46	-10.63	-0.39	1.99e-24	QT interval;
BRCA	cis	rs1878931	0.559	rs2106863	chr16:3391330	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.64	13.55	0.47	5.9e-37	Body mass index (adult);
BRCA	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg16586182	chr3:47516702	SCAP	-0.55	-12.19	-0.43	6.92e-31	Colorectal cancer;
BRCA	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg15790184	chr11:494944	RNH1	0.64	9.95	0.37	8.42e-22	Body mass index;
BRCA	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg10523679	chr1:76189770	ACADM	0.67	13.38	0.47	3.54e-36	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.44	9.52	0.35	3.49e-20	Hemoglobin concentration;
BRCA	cis	rs2835872	0.758	rs7278101	chr21:39035873	T/C	cg06728970	chr21:39037746	KCNJ6	-0.41	-11.42	-0.41	1.23e-27	Electroencephalographic traits in alcoholism;
BRCA	cis	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg05901451	chr6:126070800	HEY2	-0.39	-9.41	-0.35	9.06e-20	Endometrial cancer;
BRCA	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg17063962	chr7:91808500	NA	-0.56	-12.61	-0.45	1.06e-32	Breast cancer;
BRCA	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-13.91	-0.48	1.28e-38	Blood metabolite levels;
BRCA	cis	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg03060546	chr3:49711283	APEH	0.46	9.59	0.35	1.95e-20	Resting heart rate;
BRCA	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-13.47	-0.47	1.45e-36	Migraine;Coronary artery disease;
BRCA	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg08917208	chr2:24149416	ATAD2B	0.55	8.36	0.31	4.01e-16	Lymphocyte counts;
BRCA	cis	rs6763687	0.856	rs13089972	chr3:171798694	T/A	cg16233210	chr3:171778391	FNDC3B	0.41	9.67	0.36	9.76e-21	Red cell distribution width;
BRCA	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.98	14.32	0.49	1.55e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	12.86	0.45	8.26e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg17802220	chr15:77601643	NA	-0.46	-10.12	-0.37	1.95e-22	Type 2 diabetes;
BRCA	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg12463550	chr7:65579703	CRCP	-0.37	-7.94	-0.3	9.28e-15	Aortic root size;
BRCA	cis	rs11112613	0.713	rs12316204	chr12:105944244	G/A	cg03607813	chr12:105948248	NA	0.6	10.99	0.4	7.33e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.45	-10.53	-0.38	4.91e-24	Urate levels in overweight individuals;
BRCA	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg12386194	chr3:101231763	SENP7	0.46	9.65	0.36	1.17e-20	Colorectal cancer;
BRCA	cis	rs7520050	0.966	rs2275426	chr1:46487552	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.84	0.36	2.35e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg24308560	chr3:49941425	MST1R	-0.37	-7.88	-0.3	1.42e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg02153584	chr22:29168773	CCDC117	0.53	11.05	0.4	4.09e-26	Lymphocyte counts;
BRCA	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.21	-0.34	4.63e-19	Bipolar disorder;
BRCA	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg21252483	chr19:49399788	TULP2	-0.4	-9.06	-0.34	1.52e-18	Red cell distribution width;
BRCA	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg20503657	chr10:835505	NA	1.3	21.72	0.65	9.26e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs9581857	0.547	rs9581881	chr13:28106637	A/G	cg22138327	chr13:27999177	GTF3A	0.58	8.22	0.31	1.1e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
BRCA	trans	rs9951602	0.512	rs6506872	chr18:76649695	T/C	cg02800362	chr5:177631904	HNRNPAB	0.77	18.04	0.58	4.16e-59	Obesity-related traits;
BRCA	trans	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg23505145	chr19:12996616	KLF1	0.55	12.05	0.43	2.84e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg00814883	chr7:100076585	TSC22D4	-0.51	-11.56	-0.42	3.32e-28	Platelet count;
BRCA	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.57	0.55	1.44e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs72781680	0.611	rs74661620	chr2:24365260	C/A	cg20701182	chr2:24300061	SF3B14	0.71	13.15	0.46	3.99e-35	Lymphocyte counts;
BRCA	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg12011299	chr4:100065546	ADH4	0.48	10.87	0.4	2.26e-25	Smoking initiation;
BRCA	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07636037	chr3:49044803	WDR6	-0.77	-15.58	-0.52	1.28e-46	Menarche (age at onset);
BRCA	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18876405	chr7:65276391	NA	0.62	15.23	0.52	6.79e-45	Aortic root size;
BRCA	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg18479299	chr3:125709523	NA	-0.54	-8.34	-0.31	4.59e-16	Blood pressure (smoking interaction);
BRCA	trans	rs10242455	0.557	rs45492501	chr7:99047030	T/A	cg09045935	chr12:6379348	NA	0.83	8.28	0.31	7.06e-16	Blood metabolite levels;
BRCA	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg08888203	chr3:10149979	C3orf24	0.58	12.09	0.43	1.95e-30	Alzheimer's disease;
BRCA	cis	rs8010715	0.848	rs927494	chr14:24600390	A/T	cg23112188	chr14:24563095	PCK2	-0.33	-8.45	-0.32	2.03e-16	IgG glycosylation;
BRCA	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg12310025	chr6:25882481	NA	-0.7	-17.89	-0.58	2.52e-58	Blood metabolite levels;
BRCA	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg13319975	chr6:146136371	FBXO30	-0.41	-9.39	-0.35	1e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg03060546	chr3:49711283	APEH	-0.52	-10.8	-0.39	4.3e-25	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.48	-0.32	1.6e-16	Glomerular filtration rate (creatinine);
BRCA	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg15934090	chr1:100435551	SLC35A3	0.37	8.61	0.32	5.61e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg04362960	chr10:104952993	NT5C2	0.46	10.64	0.39	1.8e-24	Arsenic metabolism;
BRCA	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg08085267	chr17:45401833	C17orf57	0.63	13.31	0.47	7.52e-36	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg27211696	chr2:191398769	TMEM194B	0.52	11.89	0.43	1.39e-29	Pulse pressure;
BRCA	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24531977	chr5:56204891	C5orf35	-0.89	-17.64	-0.57	5.04e-57	Initial pursuit acceleration;
BRCA	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg23711669	chr6:146136114	FBXO30	-0.7	-16.89	-0.56	3.45e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2425143	0.730	rs6579259	chr20:34462550	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.08	-0.3	3.21e-15	Blood protein levels;
BRCA	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg26597838	chr10:835615	NA	-0.51	-9.14	-0.34	8.07e-19	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs7246657	0.722	rs10409605	chr19:38123137	T/G	cg18154014	chr19:37997991	ZNF793	0.5	9.59	0.35	1.99e-20	Coronary artery calcification;
BRCA	cis	rs2066819	1.000	rs79101914	chr12:56729739	A/G	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs2012796	0.956	rs6574646	chr14:81819809	A/G	cg02996355	chr14:81879375	NA	0.49	9.81	0.36	2.94e-21	Night sleep phenotypes;
BRCA	trans	rs1973993	0.691	rs1980683	chr1:96890379	A/G	cg10631902	chr5:14652156	NA	0.56	19.32	0.61	7.58e-66	Weight;
BRCA	cis	rs6594713	0.684	rs1816062	chr5:112856023	A/C	cg12552261	chr5:112820674	MCC	0.5	7.91	0.3	1.16e-14	Brain cytoarchitecture;
BRCA	cis	rs7301826	0.934	rs10773826	chr12:131321174	C/G	cg11011512	chr12:131303247	STX2	0.42	10.56	0.39	3.84e-24	Plasma plasminogen activator levels;
BRCA	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg15556689	chr8:8085844	FLJ10661	-0.37	-9.96	-0.37	8.04e-22	Mood instability;
BRCA	cis	rs13102973	0.614	rs7693794	chr4:135886753	C/G	cg14419869	chr4:135874104	NA	-0.5	-9.78	-0.36	3.91e-21	Subjective well-being;
BRCA	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.42	-10.87	-0.4	2.26e-25	Schizophrenia;
BRCA	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg24060327	chr5:131705240	SLC22A5	0.45	8.92	0.33	4.69e-18	Blood metabolite levels;
BRCA	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg16339924	chr4:17578868	LAP3	0.57	13.78	0.48	5.32e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10802521	chr3:52805072	NEK4	-0.29	-7.97	-0.3	7.55e-15	Bipolar disorder;
BRCA	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg25767906	chr1:53392781	SCP2	-0.39	-8.79	-0.33	1.41e-17	Monocyte count;
BRCA	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg22800045	chr5:56110881	MAP3K1	0.65	12.37	0.44	1.2e-31	Initial pursuit acceleration;
BRCA	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-14.09	-0.49	1.9e-39	Personality dimensions;
BRCA	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.75	-0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs2066819	1.000	rs2306694	chr12:56680636	C/T	cg26734620	chr12:56694298	CS	-0.87	-10.24	-0.38	6.61e-23	Psoriasis vulgaris;
BRCA	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg05985134	chr18:33552581	C18orf21	0.62	11.86	0.42	1.8e-29	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs16976116	0.901	rs56328329	chr15:55502977	A/T	cg11288833	chr15:55489084	RSL24D1	0.47	10.57	0.39	3.46e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg23649088	chr2:200775458	C2orf69	-0.73	-16.68	-0.55	4.05e-52	Osteoporosis;
BRCA	cis	rs11295209	1	rs11295209	chr4:120480233	TA/T	cg09307838	chr4:120376055	NA	-0.43	-9.08	-0.34	1.29e-18	Plateletcrit;
BRCA	cis	rs9462846	0.959	rs6937172	chr6:42884375	A/T	cg05552183	chr6:42928497	GNMT	0.48	8.34	0.31	4.6e-16	Blood protein levels;
BRCA	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg22546130	chr22:19950026	COMT	0.29	9.06	0.34	1.54e-18	Blood metabolite levels;
BRCA	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg23601416	chr22:19950040	COMT	0.38	12.0	0.43	4.5e-30	Blood metabolite levels;
BRCA	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.18e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg18252515	chr7:66147081	NA	-0.86	-12.36	-0.44	1.31e-31	Diabetic kidney disease;
BRCA	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.33	-9.25	-0.34	3.36e-19	Intelligence (multi-trait analysis);
BRCA	trans	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg06521331	chr12:34319734	NA	0.43	8.26	0.31	8.33e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4930561	0.714	rs10896300	chr11:67953772	C/T	cg04465784	chr11:67976953	SUV420H1	0.26	8.63	0.32	4.98e-17	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg17063962	chr7:91808500	NA	-0.52	-11.75	-0.42	5.13e-29	Breast cancer;
BRCA	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg23933602	chr10:16859644	RSU1	0.7	16.39	0.54	1.21e-50	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11890956	chr21:40555474	PSMG1	1.06	29.9	0.76	1.51e-123	Cognitive function;
BRCA	cis	rs4812048	0.901	rs151354	chr20:57606971	A/G	cg14073986	chr20:57617431	SLMO2	0.46	8.72	0.33	2.46e-17	Mean platelet volume;
BRCA	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg11663144	chr21:46675770	NA	-0.59	-14.01	-0.48	4.47e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9649213	0.727	rs12113294	chr7:97910637	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.36	9.53	0.35	3.13e-20	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg21918786	chr6:109611834	NA	-0.49	-14.14	-0.49	1.03e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg02996355	chr14:81879375	NA	0.53	10.83	0.39	3.18e-25	Night sleep phenotypes;
BRCA	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg18016565	chr1:150552671	MCL1	-0.41	-9.43	-0.35	7.2e-20	Tonsillectomy;
BRCA	cis	rs2742234	0.541	rs10899778	chr10:43718509	G/C	cg02780029	chr10:43622663	RET	0.35	7.86	0.3	1.67e-14	Hirschsprung disease;
BRCA	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg06784218	chr1:46089804	CCDC17	-0.53	-12.86	-0.45	8.4e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-8.94	-0.33	4.28e-18	Bladder cancer;
BRCA	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg02951883	chr7:2050386	MAD1L1	-0.49	-10.82	-0.39	3.55e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg08807101	chr21:30365312	RNF160	-0.44	-7.82	-0.3	2.25e-14	Cognitive test performance;
BRCA	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg05082376	chr22:42548792	NA	-0.31	-7.86	-0.3	1.59e-14	Cognitive function;
BRCA	cis	rs1829883	1.000	rs1523381	chr5:98773754	T/C	cg08333243	chr5:99726346	NA	-0.36	-8.56	-0.32	8.5e-17	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg21132104	chr15:45694354	SPATA5L1	0.7	15.36	0.52	1.52e-45	Homoarginine levels;
BRCA	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg23711669	chr6:146136114	FBXO30	0.71	16.82	0.55	7.91e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg15017067	chr4:17643749	FAM184B	0.29	8.8	0.33	1.32e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg16680214	chr1:154839983	KCNN3	-0.45	-12.46	-0.44	4.89e-32	Prostate cancer;
BRCA	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg24675658	chr1:53192096	ZYG11B	-0.68	-15.32	-0.52	2.46e-45	Monocyte count;
BRCA	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg04518342	chr5:131593106	PDLIM4	0.37	9.25	0.34	3.29e-19	Breast cancer;
BRCA	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg08645402	chr16:4508243	NA	-0.37	-8.85	-0.33	8.59e-18	Schizophrenia;
BRCA	cis	rs7553864	0.636	rs7543740	chr1:87609026	C/T	cg17420885	chr1:87600446	LOC339524	-0.44	-9.06	-0.34	1.52e-18	Smoking behavior;
BRCA	cis	rs78707713	0.560	rs55668536	chr10:71242655	A/G	cg12610070	chr10:71211762	TSPAN15	-0.33	-10.35	-0.38	2.6e-23	Venous thromboembolism;
BRCA	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg08999081	chr20:33150536	PIGU	-0.47	-12.84	-0.45	9.74e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg21535247	chr6:8435926	SLC35B3	-0.38	-8.55	-0.32	8.8e-17	Motion sickness;
BRCA	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.45	-0.41	9.82e-28	Personality dimensions;
BRCA	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.16	-17.75	-0.57	1.34e-57	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg11502198	chr6:26597334	ABT1	0.48	9.53	0.35	3.21e-20	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	trans	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	trans	rs141342723	1	rs141342723	chr6:27622084	T/C	cg01620082	chr3:125678407	NA	-0.91	-10.26	-0.38	5.96e-23	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs698833	0.886	rs2289463	chr2:44565447	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	10.6	0.39	2.66e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg00981070	chr1:2046702	PRKCZ	0.3	7.88	0.3	1.38e-14	Height;
BRCA	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg18225595	chr11:63971243	STIP1	0.54	9.91	0.37	1.23e-21	Mean platelet volume;
BRCA	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00166722	chr3:10149974	C3orf24	0.58	11.74	0.42	5.71e-29	Alzheimer's disease;
BRCA	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg03733263	chr8:22462867	KIAA1967	1.0	21.1	0.64	2.03e-75	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs600231	0.542	rs10896009	chr11:65246054	A/G	cg01292856	chr11:65242576	NA	-0.61	-14.31	-0.49	1.68e-40	Bone mineral density;
BRCA	cis	rs813218	0.584	rs11711935	chr3:99808804	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.39	8.71	0.33	2.64e-17	Orofacial clefts;
BRCA	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11890956	chr21:40555474	PSMG1	1.09	33.73	0.8	5.05e-144	Cognitive function;
BRCA	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg17807903	chr1:86174739	ZNHIT6	0.42	10.4	0.38	1.65e-23	Urate levels in overweight individuals;
BRCA	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg19052272	chr2:3704530	ALLC	-0.49	-10.69	-0.39	1.2e-24	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg05985134	chr18:33552581	C18orf21	0.64	12.16	0.43	9.75e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg26597838	chr10:835615	NA	0.69	11.03	0.4	5.08e-26	Eosinophil percentage of granulocytes;
BRCA	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg25457927	chr22:38595422	NA	-0.41	-15.41	-0.52	8.48e-46	Cutaneous nevi;
BRCA	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg04362960	chr10:104952993	NT5C2	0.44	9.92	0.37	1.15e-21	Arsenic metabolism;
BRCA	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg20573242	chr4:122745356	CCNA2	0.49	10.96	0.4	9.98e-26	Type 2 diabetes;
BRCA	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg23708337	chr7:1209742	NA	0.55	9.34	0.35	1.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9682041	0.877	rs10755126	chr3:170071694	C/G	cg11886554	chr3:170076028	SKIL	-0.52	-10.65	-0.39	1.75e-24	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg24879335	chr3:133465180	TF	0.25	7.81	0.3	2.42e-14	Iron status biomarkers;
BRCA	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.77	-0.42	4.5e-29	Response to antipsychotic treatment;
BRCA	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg26384229	chr12:38710491	ALG10B	0.59	13.62	0.47	2.98e-37	Morning vs. evening chronotype;
BRCA	trans	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg17675199	chr6:35436792	RPL10A	-0.29	-7.82	-0.3	2.21e-14	Intelligence (multi-trait analysis);
BRCA	trans	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg06521331	chr12:34319734	NA	-0.53	-10.08	-0.37	2.83e-22	Bladder cancer;
BRCA	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg07541023	chr7:19748670	TWISTNB	0.57	9.71	0.36	6.69e-21	Thyroid stimulating hormone;
BRCA	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg24812749	chr6:127587940	RNF146	0.85	19.76	0.62	3.28e-68	Breast cancer;
BRCA	cis	rs2580764	0.678	rs2588521	chr2:55203931	C/G	cg09592903	chr2:55203963	RTN4	0.43	10.97	0.4	9.07e-26	Mean platelet volume;
BRCA	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg09877947	chr5:131593287	PDLIM4	-0.41	-10.3	-0.38	3.88e-23	Breast cancer;
BRCA	cis	rs10754283	0.967	rs6428561	chr1:90102619	G/A	cg21401794	chr1:90099060	LRRC8C	0.46	11.11	0.4	2.33e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg12365402	chr11:9010492	NRIP3	-0.37	-8.02	-0.3	5.04e-15	Hematocrit;
BRCA	cis	rs6728642	0.908	rs10203833	chr2:98017363	G/A	cg26665480	chr2:98280029	ACTR1B	-0.53	-8.8	-0.33	1.3e-17	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg02175503	chr12:58329896	NA	-0.58	-13.43	-0.47	2.1e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03517284	chr6:25882590	NA	-0.51	-10.82	-0.39	3.55e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg12219531	chr12:120966889	COQ5	0.55	11.61	0.42	2.02e-28	High light scatter reticulocyte count;
BRCA	cis	rs4481887	0.679	rs4466692	chr1:248423174	C/G	cg00666640	chr1:248458726	OR2T12	0.28	7.87	0.3	1.53e-14	Common traits (Other);
BRCA	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg03676636	chr4:99064102	C4orf37	0.21	8.03	0.3	4.61e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs911119	0.866	rs6048920	chr20:23576844	A/G	cg16589663	chr20:23618590	CST3	0.4	7.9	0.3	1.25e-14	Chronic kidney disease;
BRCA	cis	rs250677	0.958	rs17109282	chr5:148416677	A/G	cg18129178	chr5:148520854	ABLIM3	0.58	11.82	0.42	2.68e-29	Breast cancer;
BRCA	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg14196790	chr5:131705035	SLC22A5	0.38	9.26	0.34	2.98e-19	Blood metabolite levels;
BRCA	trans	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg25214090	chr10:38739885	LOC399744	0.55	12.08	0.43	2.18e-30	Corneal astigmatism;
BRCA	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18402987	chr7:1209562	NA	0.65	14.25	0.49	3.34e-40	Longevity;Endometriosis;
BRCA	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg11789530	chr4:8429930	ACOX3	-0.6	-14.98	-0.51	1.03e-43	Response to antineoplastic agents;
BRCA	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	13.19	0.46	2.52e-35	Lymphocyte percentage of white cells;
BRCA	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg22713356	chr15:30763199	NA	1.1	22.04	0.66	1.71e-80	Uric acid levels;
BRCA	cis	rs4363385	0.747	rs4568784	chr1:152972694	G/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.22	-0.31	1.11e-15	Inflammatory skin disease;
BRCA	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-12.66	-0.45	5.89e-33	Developmental language disorder (linguistic errors);
BRCA	cis	rs28830936	1.000	rs17677991	chr15:42032383	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.37	-11.36	-0.41	2.25e-27	Diastolic blood pressure;
BRCA	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg04267008	chr7:1944627	MAD1L1	-0.39	-8.32	-0.31	5.24e-16	Schizophrenia;
BRCA	cis	rs7737355	0.898	rs3775999	chr5:130970090	T/C	cg06307176	chr5:131281290	NA	0.53	9.9	0.36	1.35e-21	Life satisfaction;
BRCA	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg20469991	chr17:27169893	C17orf63	-0.45	-8.8	-0.33	1.31e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg11833968	chr6:79620685	NA	-0.44	-9.89	-0.36	1.48e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9815354	0.812	rs73069203	chr3:41938767	T/C	cg03022575	chr3:42003672	ULK4	0.68	9.48	0.35	4.71e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg24558204	chr6:135376177	HBS1L	0.44	12.17	0.43	8.77e-31	Red blood cell count;
BRCA	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg17366294	chr4:99064904	C4orf37	0.41	9.74	0.36	5.2e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3815700	1.000	rs7260624	chr19:33096562	A/G	cg02997394	chr19:33096574	ANKRD27	0.7	12.01	0.43	4.15e-30	Eosinophilic esophagitis;
BRCA	cis	rs68092024	0.704	rs793487	chr3:99495422	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-10.49	-0.38	7.01e-24	Cleft lip with or without cleft palate;
BRCA	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg21475434	chr5:93447410	FAM172A	-0.68	-9.0	-0.34	2.6e-18	Diabetic retinopathy;
BRCA	cis	rs6132905	0.520	rs2422823	chr20:2646333	C/A	cg01629329	chr20:2633258	NOP56;MIR1292	0.4	7.89	0.3	1.33e-14	Mumps;
BRCA	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg23625390	chr15:77176239	SCAPER	-0.53	-13.12	-0.46	5.26e-35	Blood metabolite levels;
BRCA	cis	rs9296092	0.538	rs9296094	chr6:33520064	A/G	cg13560919	chr6:33536144	NA	-0.85	-17.72	-0.57	1.88e-57	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg13010199	chr12:38710504	ALG10B	0.5	10.3	0.38	4.14e-23	Bladder cancer;
BRCA	cis	rs9796	0.621	rs537244	chr15:41469313	G/T	cg18705301	chr15:41695430	NDUFAF1	0.37	7.92	0.3	1.03e-14	Menopause (age at onset);
BRCA	cis	rs6782228	0.675	rs56141228	chr3:128386042	C/T	cg16766828	chr3:128327626	NA	-0.43	-9.49	-0.35	4.55e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs13102973	0.965	rs28769289	chr4:135878230	T/C	cg14419869	chr4:135874104	NA	-0.59	-13.01	-0.46	1.7e-34	Subjective well-being;
BRCA	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	13.86	0.48	2.19e-38	Coronary artery disease;
BRCA	cis	rs775227	0.574	rs60131925	chr3:113034768	T/C	cg18753928	chr3:113234510	CCDC52	-0.54	-9.2	-0.34	4.83e-19	Dental caries;
BRCA	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg11941060	chr3:133502564	NA	-0.49	-11.8	-0.42	3.32e-29	Iron status biomarkers;
BRCA	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg15556689	chr8:8085844	FLJ10661	0.37	8.66	0.32	3.97e-17	Retinal vascular caliber;
BRCA	trans	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.37	0.38	2.16e-23	Mean corpuscular volume;
BRCA	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22455342	chr2:225449267	CUL3	0.64	16.8	0.55	1.01e-52	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg01236616	chr12:121019343	POP5	1.24	27.13	0.73	1.9e-108	Type 1 diabetes nephropathy;
BRCA	cis	rs7903847	0.642	rs2275089	chr10:99141205	A/G	cg20016023	chr10:99160130	RRP12	-0.27	-8.62	-0.32	5.46e-17	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg25214090	chr10:38739885	LOC399744	0.52	11.52	0.41	4.81e-28	Corneal astigmatism;
BRCA	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg24163568	chr5:669837	TPPP	0.35	9.65	0.36	1.19e-20	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
BRCA	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg23933602	chr10:16859644	RSU1	0.56	11.1	0.4	2.61e-26	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.08	-0.3	3.26e-15	Total body bone mineral density;
BRCA	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03517284	chr6:25882590	NA	0.39	9.12	0.34	9.82e-19	Blood metabolite levels;
BRCA	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg14926445	chr8:58193284	C8orf71	-0.47	-8.92	-0.33	4.83e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg03585969	chr10:35415529	CREM	0.56	11.6	0.42	2.21e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg18357645	chr12:58087776	OS9	0.46	13.24	0.46	1.63e-35	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	15.12	0.51	2.33e-44	Platelet count;
BRCA	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg14019146	chr3:50243930	SLC38A3	-0.4	-9.79	-0.36	3.63e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg06238570	chr21:40685208	BRWD1	-0.43	-8.67	-0.32	3.51e-17	Cognitive function;
BRCA	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00290607	chr11:67383545	NA	0.52	11.7	0.42	8.65e-29	Mean corpuscular volume;
BRCA	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg27170947	chr2:26402098	FAM59B	-0.66	-11.29	-0.41	4.62e-27	Gut microbiome composition (summer);
BRCA	cis	rs17095355	1.000	rs921351	chr10:111704715	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.39	-10.15	-0.37	1.5e-22	Biliary atresia;
BRCA	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg09307838	chr4:120376055	NA	0.72	15.28	0.52	3.69e-45	Corneal astigmatism;
BRCA	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg02951883	chr7:2050386	MAD1L1	0.39	9.4	0.35	9.2e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs11920090	0.858	rs11717435	chr3:170691812	G/A	cg09710316	chr3:170744871	SLC2A2	0.51	8.2	0.31	1.35e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs870825	0.616	rs12498890	chr4:185636096	C/G	cg04058563	chr4:185651563	MLF1IP	-0.79	-17.59	-0.57	9.04e-57	Blood protein levels;
BRCA	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg04989706	chr14:50066350	PPIL5	-0.47	-8.74	-0.33	2.03e-17	Carotid intima media thickness;
BRCA	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg01475377	chr6:109611718	NA	-0.56	-15.13	-0.51	1.98e-44	Reticulocyte fraction of red cells;
BRCA	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg26384229	chr12:38710491	ALG10B	0.69	16.25	0.54	6.24e-50	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg26384229	chr12:38710491	ALG10B	0.48	11.06	0.4	3.81e-26	Morning vs. evening chronotype;
BRCA	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	11.9	0.43	1.27e-29	Lung cancer in ever smokers;
BRCA	trans	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.39	0.32	3.21e-16	Aortic root size;
BRCA	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg23711669	chr6:146136114	FBXO30	0.84	20.31	0.63	3.87e-71	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.49	-0.32	1.4e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs208520	0.837	rs208498	chr6:66931560	G/A	cg07460842	chr6:66804631	NA	-0.81	-14.56	-0.5	1.15e-41	Exhaled nitric oxide output;
BRCA	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.44	0.38	1.1e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg22972055	chr7:872293	UNC84A	0.37	8.29	0.31	6.45e-16	Cerebrospinal P-tau181p levels;
BRCA	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.29	0.49	2.05e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs225245	0.541	rs321613	chr17:33881718	G/A	cg19694781	chr19:47549865	TMEM160	-0.41	-9.28	-0.34	2.6e-19	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg07138768	chr7:917805	C7orf20	0.28	8.21	0.31	1.19e-15	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs11984145	1.000	rs11982889	chr7:38838948	C/T	cg19327137	chr7:38886074	VPS41	0.44	8.39	0.32	3.1e-16	Cognitive performance;
BRCA	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.12	0.43	1.37e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6433895	0.961	rs11891215	chr2:182010027	A/G	cg00481216	chr2:181971175	NA	0.38	8.75	0.33	1.9e-17	Lymphocyte counts;
BRCA	cis	rs72634258	0.554	rs34305100	chr1:7913029	A/G	cg26816564	chr1:7831052	VAMP3	0.55	10.49	0.38	7.55e-24	Inflammatory bowel disease;
BRCA	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg18016565	chr1:150552671	MCL1	-0.43	-9.93	-0.37	1.08e-21	Tonsillectomy;
BRCA	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg24130564	chr14:104152367	KLC1	-0.41	-8.81	-0.33	1.19e-17	Reticulocyte count;
BRCA	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg02734326	chr4:10020555	SLC2A9	0.37	8.16	0.31	1.78e-15	Bone mineral density;
BRCA	trans	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.09	0.3	2.99e-15	Corneal astigmatism;
BRCA	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg15556689	chr8:8085844	FLJ10661	-0.32	-8.16	-0.31	1.82e-15	Neuroticism;
BRCA	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg27165867	chr14:105738592	BRF1	-0.35	-8.3	-0.31	6.1e-16	Mean platelet volume;Platelet distribution width;
BRCA	trans	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	7.81	0.3	2.34e-14	Corneal astigmatism;
BRCA	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.56	-0.32	8.25e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg08885076	chr2:99613938	TSGA10	0.45	10.58	0.39	3.18e-24	Chronic sinus infection;
BRCA	cis	rs644148	0.704	rs2686761	chr19:44989752	T/C	cg15540054	chr19:45004280	ZNF180	-0.5	-9.78	-0.36	3.87e-21	Personality dimensions;
BRCA	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.69	14.59	0.5	7.58e-42	Lymphocyte counts;
BRCA	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	9.99	0.37	6.37e-22	Aortic root size;
BRCA	cis	rs4919087	0.810	rs1572437	chr10:99029278	A/G	cg25902810	chr10:99078978	FRAT1	0.42	9.13	0.34	8.71e-19	Monocyte count;
BRCA	cis	rs887829	0.641	rs7586110	chr2:234590527	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-8.53	-0.32	1.09e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs11945232	1.000	rs4314250	chr4:88340969	A/G	cg23841344	chr4:88312519	HSD17B11	0.47	9.16	0.34	7.14e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs2816062	0.965	rs2816061	chr1:18903819	A/G	cg18795169	chr1:18902165	NA	0.87	23.24	0.68	4.47e-87	Urate levels in lean individuals;
BRCA	cis	rs7582720	0.943	rs114372659	chr2:203715514	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	12.51	0.44	2.8e-32	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs586533	0.846	rs1690817	chr11:99496812	A/G	cg22878054	chr11:99397252	CNTN5	0.31	7.81	0.3	2.39e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs919433	0.680	rs6434934	chr2:198437386	C/G	cg00792783	chr2:198669748	PLCL1	0.35	8.18	0.31	1.53e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	11.31	0.41	3.67e-27	Platelet count;
BRCA	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg24110177	chr3:50126178	RBM5	0.46	11.93	0.43	8.77e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg10932868	chr11:921992	NA	0.48	12.14	0.43	1.13e-30	Alzheimer's disease (late onset);
BRCA	cis	rs495337	0.760	rs6067270	chr20:48537254	T/C	cg17835207	chr20:48524531	SPATA2	-0.69	-16.83	-0.55	7.01e-53	Psoriasis;
BRCA	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg13334819	chr7:99746414	C7orf59	-0.34	-7.96	-0.3	7.71e-15	Coronary artery disease;
BRCA	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg21132104	chr15:45694354	SPATA5L1	0.75	16.78	0.55	1.22e-52	Homoarginine levels;
BRCA	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg10978503	chr1:24200527	CNR2	0.45	11.62	0.42	1.96e-28	Immature fraction of reticulocytes;
BRCA	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg25019033	chr10:957182	NA	-0.42	-8.9	-0.33	5.57e-18	Eosinophil percentage of granulocytes;
BRCA	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg21427119	chr20:30132790	HM13	-0.42	-8.82	-0.33	1.05e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg09307838	chr4:120376055	NA	0.63	13.65	0.48	2.17e-37	Corneal astigmatism;
BRCA	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg20607798	chr8:58055168	NA	0.54	8.35	0.31	4.37e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18876405	chr7:65276391	NA	-0.62	-15.42	-0.52	7.35e-46	Aortic root size;
BRCA	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg19077165	chr18:44547161	KATNAL2	0.58	12.99	0.46	2.03e-34	Personality dimensions;
BRCA	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg18765753	chr7:1198926	ZFAND2A	0.36	7.92	0.3	1.08e-14	Longevity;Endometriosis;
BRCA	cis	rs113835537	0.559	rs11227497	chr11:66269464	T/C	cg24851651	chr11:66362959	CCS	0.44	8.39	0.32	3.05e-16	Airway imaging phenotypes;
BRCA	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.44	0.38	1.1e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg24531977	chr5:56204891	C5orf35	-0.54	-11.4	-0.41	1.49e-27	Coronary artery disease;
BRCA	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg05025164	chr4:1340916	KIAA1530	0.39	8.54	0.32	9.95e-17	Longevity;
BRCA	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg18867708	chr6:26865862	GUSBL1	-0.41	-7.85	-0.3	1.79e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs13102973	0.899	rs10212820	chr4:135899842	G/T	cg14419869	chr4:135874104	NA	-0.52	-10.64	-0.39	1.89e-24	Subjective well-being;
BRCA	cis	rs698833	0.926	rs1085449	chr2:44653432	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	10.02	0.37	4.63e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg05283184	chr6:79620031	NA	-0.43	-11.06	-0.4	3.83e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9653442	0.609	rs10209110	chr2:100672692	C/T	cg22139774	chr2:100720529	AFF3	-0.29	-8.06	-0.3	3.85e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs2806561	0.964	rs683052	chr1:23514953	T/C	cg19743168	chr1:23544995	NA	0.43	10.59	0.39	2.92e-24	Height;
BRCA	cis	rs3815700	1.000	rs8109885	chr19:33095557	A/G	cg02997394	chr19:33096574	ANKRD27	0.69	11.39	0.41	1.69e-27	Eosinophilic esophagitis;
BRCA	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.06	-26.3	-0.72	7.48e-104	Ulcerative colitis;
BRCA	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg20991723	chr1:152506922	NA	0.37	8.29	0.31	6.61e-16	Hair morphology;
BRCA	cis	rs2652834	0.851	rs16946416	chr15:63356721	A/T	cg05507819	chr15:63340323	TPM1	-0.54	-9.24	-0.34	3.7e-19	HDL cholesterol;
BRCA	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg18016565	chr1:150552671	MCL1	0.35	8.22	0.31	1.13e-15	Tonsillectomy;
BRCA	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg03060546	chr3:49711283	APEH	-0.52	-7.88	-0.3	1.4e-14	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
BRCA	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.85	-0.3	1.72e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg01528321	chr10:82214614	TSPAN14	-1.07	-20.35	-0.63	2.25e-71	Post bronchodilator FEV1;
BRCA	trans	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.61	10.82	0.39	3.51e-25	Type 2 diabetes;
BRCA	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg09307838	chr4:120376055	NA	0.64	14.08	0.49	1.96e-39	Corneal astigmatism;
BRCA	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.15	-0.31	1.89e-15	Total body bone mineral density;
BRCA	trans	rs11039798	0.764	rs4357721	chr11:48354907	G/A	cg15704280	chr7:45808275	SEPT13	-0.56	-8.55	-0.32	9.4e-17	Axial length;
BRCA	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg08603382	chr10:743973	NA	-0.45	-8.35	-0.31	4.28e-16	Psychosis in Alzheimer's disease;
BRCA	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg04362960	chr10:104952993	NT5C2	0.41	10.03	0.37	4.49e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	trans	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg25214090	chr10:38739885	LOC399744	0.38	8.7	0.33	2.9e-17	Diastolic blood pressure;
BRCA	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.53	-16.9	-0.56	3.11e-53	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.58	12.62	0.45	9.35e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg08470875	chr2:26401718	FAM59B	-0.51	-8.17	-0.31	1.62e-15	Gut microbiome composition (summer);
BRCA	cis	rs9381107	0.932	rs9380624	chr6:9418725	A/C	cg14735645	chr6:9486422	NA	-0.47	-8.22	-0.31	1.11e-15	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.89	-0.33	6.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2742234	0.955	rs2075913	chr10:43622368	T/A	cg15436174	chr10:43711423	RASGEF1A	-0.41	-8.64	-0.32	4.48e-17	Hirschsprung disease;
BRCA	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg25237894	chr2:233734115	C2orf82	0.39	11.33	0.41	3.13e-27	Coronary artery disease;
BRCA	cis	rs7903847	0.642	rs7088410	chr10:99135539	G/T	cg08345082	chr10:99160200	RRP12	-0.29	-8.6	-0.32	6.17e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7512552	0.839	rs2873669	chr1:150426224	C/T	cg15654264	chr1:150340011	RPRD2	-0.42	-9.03	-0.34	2.02e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs6942756	0.713	rs691807	chr7:129076203	G/C	cg02491457	chr7:128862824	NA	-0.53	-10.76	-0.39	6.52e-25	White matter hyperintensity burden;
BRCA	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg12927641	chr6:109611667	NA	-0.42	-10.9	-0.4	1.8e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg00666640	chr1:248458726	OR2T12	0.34	8.88	0.33	6.87e-18	Common traits (Other);
BRCA	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg09314803	chr17:79180344	AZI1	-0.36	-9.1	-0.34	1.1e-18	Frontotemporal dementia;
BRCA	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-9.54	-0.35	3.04e-20	Alzheimer's disease (late onset);
BRCA	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.45	-0.32	1.98e-16	Menopause (age at onset);
BRCA	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.51	-14.94	-0.51	1.72e-43	Lung cancer;
BRCA	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25427524	chr10:38739819	LOC399744	-0.74	-18.27	-0.59	2.48e-60	Extrinsic epigenetic age acceleration;
BRCA	cis	rs758324	0.947	rs173812	chr5:131319460	A/G	cg06307176	chr5:131281290	NA	-0.5	-9.92	-0.37	1.11e-21	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs6138458	0.816	rs2151463	chr20:24911819	A/C	cg06937882	chr20:24974362	C20orf3	-0.44	-8.36	-0.31	3.95e-16	Blood protein levels;
BRCA	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg12292205	chr6:26970375	C6orf41	0.56	12.47	0.44	4.11e-32	Schizophrenia;
BRCA	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg27279351	chr12:120934652	DYNLL1	0.56	13.13	0.46	4.75e-35	High light scatter reticulocyte count;
BRCA	cis	rs4880487	0.888	rs72760998	chr10:1251203	T/C	cg03183215	chr10:1252341	ADARB2	-0.42	-8.41	-0.32	2.77e-16	Migraine;
BRCA	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1113500	0.748	rs1781048	chr1:108555050	A/T	cg06207961	chr1:108661230	NA	0.34	7.99	0.3	6.29e-15	Growth-regulated protein alpha levels;
BRCA	cis	rs7553864	0.667	rs7512650	chr1:87609076	T/C	cg17420885	chr1:87600446	LOC339524	-0.44	-9.1	-0.34	1.16e-18	Smoking behavior;
BRCA	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg21045802	chr8:109455806	TTC35	0.35	8.03	0.3	4.64e-15	Dupuytren's disease;
BRCA	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.8	13.46	0.47	1.5e-36	Schizophrenia;
BRCA	cis	rs911119	0.954	rs2424582	chr20:23622550	A/G	cg16589663	chr20:23618590	CST3	0.41	7.82	0.3	2.27e-14	Chronic kidney disease;
BRCA	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg21226059	chr5:178986404	RUFY1	-0.5	-14.36	-0.49	9.44e-41	Lung cancer;
BRCA	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg22563815	chr15:78856949	CHRNA5	0.34	7.88	0.3	1.41e-14	Sudden cardiac arrest;
BRCA	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg08999081	chr20:33150536	PIGU	0.38	9.67	0.36	9.62e-21	Coronary artery disease;
BRCA	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg08975724	chr8:8085496	FLJ10661	-0.4	-8.82	-0.33	1.1e-17	Joint mobility (Beighton score);
BRCA	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg22875332	chr1:76189707	ACADM	0.66	11.78	0.42	3.81e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1691799	0.867	rs1168330	chr12:66763167	C/T	cg16791601	chr12:66731901	HELB	0.64	16.5	0.55	3.45e-51	White blood cell count (basophil);
BRCA	trans	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg18876405	chr7:65276391	NA	0.44	8.55	0.32	8.86e-17	Corneal structure;
BRCA	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	trans	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg25482853	chr8:67687455	SGK3	0.79	13.58	0.47	4.15e-37	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7246657	0.525	rs10405238	chr19:37488055	T/G	cg18154014	chr19:37997991	ZNF793	0.49	8.38	0.31	3.31e-16	Coronary artery calcification;
BRCA	trans	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg13565492	chr6:43139072	SRF	-0.81	-12.58	-0.45	1.34e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg25208724	chr1:156163844	SLC25A44	0.85	17.0	0.56	9.78e-54	Testicular germ cell tumor;
BRCA	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.76	0.39	6.24e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg22920501	chr2:26401640	FAM59B	-0.67	-11.56	-0.42	3.5e-28	Gut microbiome composition (summer);
BRCA	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg15352829	chr14:105391018	PLD4	-0.38	-12.42	-0.44	6.89e-32	Rheumatoid arthritis;
BRCA	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.44	0.38	1.15e-23	Motion sickness;
BRCA	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.48	0.47	1.21e-36	Colorectal cancer;
BRCA	cis	rs12200560	0.505	rs211164	chr6:97068140	G/T	cg06623918	chr6:96969491	KIAA0776	0.51	11.93	0.43	9.45e-30	Coronary heart disease;
BRCA	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg23711669	chr6:146136114	FBXO30	0.7	16.17	0.54	1.41e-49	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.82	-0.33	1.13e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg03864215	chr11:17408437	KCNJ11	-0.27	-8.09	-0.3	3.02e-15	Type 2 diabetes;
BRCA	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg20203395	chr5:56204925	C5orf35	-0.51	-10.2	-0.37	9.48e-23	Initial pursuit acceleration;
BRCA	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg00983440	chr10:79422392	NA	-0.53	-10.15	-0.37	1.57e-22	Bone mineral density;
BRCA	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg23978390	chr7:1156363	C7orf50	0.39	7.89	0.3	1.34e-14	Bronchopulmonary dysplasia;
BRCA	cis	rs9462027	0.606	rs2395606	chr6:34778486	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.84	-0.3	1.96e-14	Systemic lupus erythematosus;
BRCA	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg06636001	chr8:8085503	FLJ10661	0.5	10.38	0.38	2.01e-23	Neuroticism;
BRCA	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg21573476	chr21:45109991	RRP1B	-0.49	-12.43	-0.44	6.48e-32	Mean corpuscular volume;
BRCA	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	13.32	0.47	6.82e-36	Mean platelet volume;
BRCA	cis	rs9309473	0.632	rs11885217	chr2:73553208	A/G	cg20560298	chr2:73613845	ALMS1	-0.43	-11.25	-0.41	6.44e-27	Metabolite levels;
BRCA	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.47	-10.17	-0.37	1.32e-22	Longevity;Endometriosis;
BRCA	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg13319975	chr6:146136371	FBXO30	-0.41	-9.39	-0.35	1e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg11845111	chr2:191398756	TMEM194B	0.76	14.08	0.49	2.15e-39	Diastolic blood pressure;
BRCA	cis	rs9463078	0.764	rs6904015	chr6:44785502	G/A	cg25276700	chr6:44698697	NA	-0.36	-8.29	-0.31	6.5e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs12468557	0.527	rs12694205	chr2:211499367	A/G	cg07063745	chr2:211341572	LANCL1;CPS1	-0.36	-8.05	-0.3	4.12e-15	Body mass index in asthmatics;
BRCA	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg09537434	chr19:41945824	ATP5SL	1.02	24.51	0.7	4.84e-94	Height;
BRCA	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.58	-0.32	7.34e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	11.67	0.42	1.2e-28	Hip circumference adjusted for BMI;
BRCA	cis	rs751728	0.664	rs12196293	chr6:33749151	A/G	cg25922239	chr6:33757077	LEMD2	0.51	12.87	0.45	6.89e-34	Crohn's disease;
BRCA	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg01448562	chr3:133502909	NA	0.37	8.98	0.33	2.91e-18	Iron status biomarkers (transferrin levels);
BRCA	trans	rs800082	0.501	rs10935507	chr3:144214631	A/T	cg24215973	chr2:240111563	HDAC4	0.35	8.36	0.31	3.86e-16	Smoking behavior;
BRCA	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18404041	chr3:52824283	ITIH1	-0.42	-12.57	-0.45	1.54e-32	Bipolar disorder;
BRCA	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg18132916	chr6:79620363	NA	-0.45	-10.17	-0.37	1.25e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg26031613	chr14:104095156	KLC1	-0.54	-9.56	-0.35	2.54e-20	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg01483505	chr11:975446	AP2A2	0.33	9.05	0.34	1.7e-18	Alzheimer's disease (late onset);
BRCA	cis	rs10503871	0.594	rs10954994	chr8:30306419	C/A	cg26383811	chr8:30366931	RBPMS	0.3	7.98	0.3	6.6e-15	Metabolite levels  (X-11787);
BRCA	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg20790798	chr5:1857306	NA	-0.39	-9.1	-0.34	1.12e-18	Cardiovascular disease risk factors;
BRCA	cis	rs6977660	0.714	rs4719586	chr7:19825548	T/C	cg07541023	chr7:19748670	TWISTNB	0.55	9.56	0.35	2.41e-20	Thyroid stimulating hormone;
BRCA	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.45	7.94	0.3	9.02e-15	Height;
BRCA	cis	rs7555523	0.887	rs7518099	chr1:165736880	C/T	cg24409356	chr1:165738333	TMCO1	0.51	8.37	0.31	3.65e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.79	0.42	3.64e-29	Tonsillectomy;
BRCA	trans	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.81	0.3	2.3e-14	Corneal astigmatism;
BRCA	cis	rs7301826	0.967	rs4759792	chr12:131296631	G/A	cg11011512	chr12:131303247	STX2	0.43	10.95	0.4	1.07e-25	Plasma plasminogen activator levels;
BRCA	cis	rs1499972	0.941	rs55864156	chr3:117664968	C/G	cg07612923	chr3:117604196	NA	0.6	8.2	0.31	1.35e-15	Schizophrenia;
BRCA	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg06784218	chr1:46089804	CCDC17	0.5	11.81	0.42	2.86e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg06784218	chr1:46089804	CCDC17	0.5	12.03	0.43	3.38e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs12517041	1.000	rs7737479	chr5:23288235	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.07	-0.3	3.42e-15	Calcium levels;
BRCA	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg00666640	chr1:248458726	OR2T12	0.31	8.7	0.33	2.8e-17	Common traits (Other);
BRCA	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg13385794	chr1:248469461	NA	0.28	7.81	0.3	2.28e-14	Common traits (Other);
BRCA	cis	rs6842047	1.000	rs4862665	chr4:187136142	C/T	cg23442198	chr4:187126114	CYP4V2	-0.55	-8.18	-0.31	1.58e-15	Blood protein levels;
BRCA	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg23533926	chr12:111358616	MYL2	-0.41	-8.59	-0.32	6.77e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg04691961	chr3:161091175	C3orf57	-0.46	-10.85	-0.39	2.66e-25	Morning vs. evening chronotype;
BRCA	cis	rs4423214	0.840	rs1792229	chr11:71179395	A/G	cg05163923	chr11:71159392	DHCR7	-0.56	-11.41	-0.41	1.41e-27	Vitamin D levels;
BRCA	cis	rs12367572	0.641	rs7964973	chr12:45402893	T/C	cg04608330	chr12:45269318	NELL2	-0.45	-9.96	-0.37	8.29e-22	Gut microbiome composition (summer);
BRCA	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg00666640	chr1:248458726	OR2T12	-0.34	-9.36	-0.35	1.31e-19	Common traits (Other);
BRCA	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg22705602	chr4:152727874	NA	-0.32	-8.15	-0.31	1.93e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.43	10.23	0.38	7.73e-23	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9986765	1.000	rs9986765	chr7:142835239	C/T	cg15652212	chr7:142981776	TMEM139	-0.56	-9.43	-0.35	7.26e-20	Cancer;Dermatomyositis;
BRCA	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg25767906	chr1:53392781	SCP2	0.49	10.56	0.39	4.03e-24	Monocyte count;
BRCA	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg03146154	chr1:46216737	IPP	-0.44	-9.53	-0.35	3.21e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9470366	0.509	rs4714001	chr6:36638175	G/A	cg08179530	chr6:36648295	CDKN1A	-0.62	-14.56	-0.5	1.16e-41	QRS duration;
BRCA	cis	rs877282	0.945	rs12767287	chr10:787310	A/G	cg17470449	chr10:769945	NA	0.47	8.19	0.31	1.39e-15	Uric acid levels;
BRCA	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg13010199	chr12:38710504	ALG10B	0.47	9.35	0.35	1.49e-19	Morning vs. evening chronotype;
BRCA	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg09307838	chr4:120376055	NA	0.75	16.17	0.54	1.48e-49	Corneal astigmatism;
BRCA	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg03709012	chr19:19516395	GATAD2A	-0.75	-16.71	-0.55	2.78e-52	Tonsillectomy;
BRCA	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg01324343	chr3:183735012	ABCC5	0.85	21.55	0.65	8.03e-78	Anterior chamber depth;
BRCA	cis	rs208520	0.837	rs208471	chr6:66916749	A/C	cg07460842	chr6:66804631	NA	-0.89	-15.64	-0.53	6.62e-47	Exhaled nitric oxide output;
BRCA	cis	rs2422052	1.000	rs2422052	chr2:118651764	G/C	cg22545206	chr2:118617499	NA	0.45	11.25	0.41	6.64e-27	Mosquito bite size;
BRCA	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg14004847	chr7:1930337	MAD1L1	-0.47	-8.87	-0.33	7.53e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg16482183	chr6:26056742	HIST1H1C	0.56	11.91	0.43	1.15e-29	Height;
BRCA	cis	rs9341808	0.754	rs1015158	chr6:80945745	C/T	cg08355045	chr6:80787529	NA	0.39	9.95	0.37	8.77e-22	Sitting height ratio;
BRCA	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg17063962	chr7:91808500	NA	0.57	13.55	0.47	6.1e-37	Breast cancer;
BRCA	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg23505145	chr19:12996616	KLF1	0.56	12.82	0.45	1.19e-33	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1210638	0.706	rs2518798	chr22:18970403	T/C	cg06148736	chr22:18985691	NA	0.34	8.69	0.32	3.14e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
BRCA	cis	rs1190552	0.706	rs2146426	chr14:102995068	A/G	cg18135206	chr14:102964638	TECPR2	0.42	7.94	0.3	8.89e-15	Blood protein levels;
BRCA	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg21784768	chr11:537496	LRRC56	-0.64	-8.28	-0.31	7.08e-16	Body mass index;
BRCA	trans	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.42	-9.6	-0.36	1.79e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.31	-8.0	-0.3	5.69e-15	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg18154014	chr19:37997991	ZNF793	0.61	11.39	0.41	1.77e-27	Coronary artery calcification;
BRCA	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26314531	chr2:26401878	FAM59B	0.96	16.57	0.55	1.37e-51	Gut microbiome composition (summer);
BRCA	cis	rs1018836	0.923	rs4735268	chr8:91629715	C/T	cg16814680	chr8:91681699	NA	-0.53	-11.34	-0.41	2.83e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs17401966	0.558	rs4846218	chr1:10452040	G/T	cg03954927	chr1:10346856	KIF1B	0.35	10.7	0.39	1.09e-24	Hepatocellular carcinoma;
BRCA	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.87	0.33	7.42e-18	Ovarian reserve;
BRCA	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg27366882	chr3:133540807	NA	-0.33	-8.09	-0.3	2.92e-15	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg13334819	chr7:99746414	C7orf59	0.39	9.01	0.34	2.32e-18	Coronary artery disease;
BRCA	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg19622623	chr12:86230825	RASSF9	-0.28	-7.98	-0.3	6.57e-15	Major depressive disorder;
BRCA	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.07	-27.83	-0.74	3.01e-112	Ulcerative colitis;
BRCA	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg09163369	chr1:210001066	C1orf107	0.53	10.86	0.39	2.44e-25	Orofacial clefts;
BRCA	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg21427119	chr20:30132790	HM13	-0.43	-9.03	-0.34	2e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg09537434	chr19:41945824	ATP5SL	-1.0	-23.91	-0.69	9.81e-91	Height;
BRCA	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg17143192	chr8:8559678	CLDN23	0.55	10.58	0.39	3.37e-24	Obesity-related traits;
BRCA	cis	rs7561273	0.609	rs3795953	chr2:24345707	C/G	cg04809136	chr2:24300158	SF3B14	-0.4	-8.94	-0.33	4.13e-18	Quantitative traits;
BRCA	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg17063962	chr7:91808500	NA	0.5	11.16	0.4	1.52e-26	Breast cancer;
BRCA	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg03146154	chr1:46216737	IPP	0.54	11.96	0.43	6.78e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs858239	0.867	rs10250602	chr7:23303701	T/C	cg23682824	chr7:23144976	KLHL7	0.35	8.79	0.33	1.41e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg11822372	chr1:151115635	SEMA6C	0.55	10.81	0.39	3.81e-25	Childhood ear infection;
BRCA	cis	rs17253792	0.822	rs8009608	chr14:56062590	C/T	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg03585969	chr10:35415529	CREM	0.56	11.55	0.42	3.74e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.34	-0.35	1.6e-19	Alzheimer's disease (late onset);
BRCA	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg11584989	chr19:19387371	SF4	-0.66	-13.23	-0.46	1.77e-35	Bipolar disorder;
BRCA	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg08000102	chr2:233561755	GIGYF2	-0.63	-13.56	-0.47	5.55e-37	Coronary artery disease;
BRCA	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg15557168	chr22:42548783	NA	-0.32	-8.81	-0.33	1.18e-17	Cognitive function;
BRCA	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg24642844	chr7:1081250	C7orf50	-0.89	-16.21	-0.54	9.83e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6570726	0.526	rs9403699	chr6:145730685	G/T	cg23711669	chr6:146136114	FBXO30	0.46	9.92	0.37	1.14e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg04944784	chr2:26401820	FAM59B	0.99	16.67	0.55	4.32e-52	Gut microbiome composition (summer);
BRCA	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.25	8.02	0.3	5.21e-15	Cardiac Troponin-T levels;
BRCA	cis	rs7572733	0.534	rs700680	chr2:198707950	A/T	cg00792783	chr2:198669748	PLCL1	-0.47	-10.25	-0.38	6.04e-23	Dermatomyositis;
BRCA	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg24596788	chr1:163392923	NA	-0.4	-10.68	-0.39	1.28e-24	Motion sickness;
BRCA	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg24692254	chr21:30365293	RNF160	-0.47	-10.64	-0.39	1.83e-24	Pancreatic cancer;
BRCA	trans	rs17685	0.515	rs111240556	chr7:75600863	T/C	cg19862616	chr7:65841803	NCRNA00174	0.36	8.64	0.32	4.57e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg21905437	chr5:178450457	ZNF879	0.51	10.72	0.39	8.79e-25	Pubertal anthropometrics;
BRCA	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg07169764	chr2:136633963	MCM6	1.02	19.09	0.6	1.32e-64	Corneal structure;
BRCA	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-13.27	-0.46	1.09e-35	Response to antipsychotic treatment;
BRCA	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08219700	chr8:58056026	NA	0.45	8.18	0.31	1.52e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.3	8.04	0.3	4.32e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg23711669	chr6:146136114	FBXO30	0.64	14.88	0.51	3.31e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg07308232	chr7:1071921	C7orf50	-0.44	-9.28	-0.34	2.62e-19	Longevity;Endometriosis;
BRCA	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg06484146	chr7:12443880	VWDE	-0.71	-10.81	-0.39	4.05e-25	Coronary artery disease;
BRCA	cis	rs4363385	0.720	rs1415968	chr1:152970219	C/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.42	-0.35	8.42e-20	Inflammatory skin disease;
BRCA	cis	rs7633857	0.537	rs9813700	chr3:160683279	G/T	cg03342759	chr3:160939853	NMD3	-0.45	-9.21	-0.34	4.77e-19	Educational attainment (years of education);
BRCA	cis	rs921968	0.565	rs6436072	chr2:219598095	C/T	cg02176678	chr2:219576539	TTLL4	-0.4	-11.0	-0.4	6.73e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg24130564	chr14:104152367	KLC1	0.36	8.15	0.31	1.91e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs3772130	0.962	rs11706783	chr3:121534322	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.91	0.4	1.63e-25	Cognitive performance;
BRCA	trans	rs8073060	0.586	rs188959	chr17:34021307	C/A	cg19694781	chr19:47549865	TMEM160	-1.07	-21.69	-0.65	1.28e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg09307838	chr4:120376055	NA	0.72	14.24	0.49	3.81e-40	Corneal astigmatism;
BRCA	cis	rs10267417	0.603	rs12333603	chr7:19907821	C/G	cg05791153	chr7:19748676	TWISTNB	-0.47	-9.28	-0.34	2.65e-19	Night sleep phenotypes;
BRCA	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg26031613	chr14:104095156	KLC1	0.43	8.51	0.32	1.22e-16	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg23788917	chr6:8435910	SLC35B3	0.47	10.25	0.38	6.41e-23	Motion sickness;
BRCA	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg22974920	chr21:40686053	BRWD1	-0.36	-8.02	-0.3	5.17e-15	Menarche (age at onset);
BRCA	cis	rs9341808	0.754	rs9341811	chr6:80982701	G/A	cg08355045	chr6:80787529	NA	0.36	9.19	0.34	5.48e-19	Sitting height ratio;
BRCA	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg21475434	chr5:93447410	FAM172A	0.66	8.42	0.32	2.47e-16	Diabetic retinopathy;
BRCA	trans	rs1997103	1.000	rs6949244	chr7:55411301	C/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7903847	0.619	rs10882912	chr10:99138077	C/T	cg08345082	chr10:99160200	RRP12	-0.29	-8.51	-0.32	1.24e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	13.95	0.48	8.76e-39	Coronary artery disease;
BRCA	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg05340658	chr4:99064831	C4orf37	0.45	10.39	0.38	1.79e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26314531	chr2:26401878	FAM59B	0.88	15.31	0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs360798	0.553	rs11682530	chr2:63073194	C/T	cg17519650	chr2:63277830	OTX1	-0.39	-8.6	-0.32	6.04e-17	Coronary artery disease;
BRCA	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.45	-9.0	-0.34	2.49e-18	Tonsillectomy;
BRCA	trans	rs8073060	0.533	rs178736	chr17:33928158	G/T	cg19694781	chr19:47549865	TMEM160	-1.05	-21.6	-0.65	4.24e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	trans	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg26384229	chr12:38710491	ALG10B	0.42	10.18	0.37	1.19e-22	Morning vs. evening chronotype;
BRCA	cis	rs5167	0.504	rs3760627	chr19:45457180	T/C	cg13119609	chr19:45449297	APOC2	0.47	12.99	0.46	2.17e-34	Blood protein levels;
BRCA	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.19	-0.31	1.42e-15	Total body bone mineral density;
BRCA	cis	rs7809950	0.906	rs2253269	chr7:107201114	C/T	cg23024343	chr7:107201750	COG5	-0.38	-8.88	-0.33	6.83e-18	Coronary artery disease;
BRCA	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg11502198	chr6:26597334	ABT1	0.56	12.0	0.43	4.68e-30	Intelligence (multi-trait analysis);
BRCA	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.77	-0.48	5.65e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg05729581	chr11:3078854	CARS	-0.37	-9.08	-0.34	1.3e-18	Longevity;
BRCA	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg13906792	chr15:75199810	C15orf17	0.34	8.07	0.3	3.59e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
BRCA	cis	rs1044826	0.518	rs295488	chr3:139239323	C/T	cg00490450	chr3:139108681	COPB2	0.51	9.92	0.37	1.17e-21	Obesity-related traits;
BRCA	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg27446573	chr6:127587934	RNF146	0.89	20.41	0.63	1.17e-71	Breast cancer;
BRCA	cis	rs495337	0.736	rs6020073	chr20:48448280	A/G	cg17835207	chr20:48524531	SPATA2	0.49	10.66	0.39	1.5e-24	Psoriasis;
BRCA	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	26.4	0.72	1.95e-104	Chronic sinus infection;
BRCA	cis	rs4911253	0.527	rs853859	chr20:31402269	A/G	cg13636640	chr20:31349939	DNMT3B	0.46	10.78	0.39	5.11e-25	Lymphocyte counts;
BRCA	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg14440974	chr22:39074834	NA	-0.4	-9.17	-0.34	6.33e-19	Menopause (age at onset);
BRCA	cis	rs10929956	0.760	rs2729704	chr2:160707866	T/A	cg14819504	chr2:160761413	LY75	-0.34	-8.43	-0.32	2.26e-16	Crohn's disease-related phenotypes;
BRCA	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg01256987	chr12:42539512	GXYLT1	-0.69	-16.56	-0.55	1.6e-51	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg20307385	chr11:47447363	PSMC3	0.85	25.32	0.71	1.69e-98	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs9463078	0.715	rs1557143	chr6:44756415	T/C	cg25276700	chr6:44698697	NA	0.39	8.92	0.33	5.02e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs10242455	0.702	rs7794068	chr7:99146873	A/T	cg18809830	chr7:99032528	PTCD1	-0.58	-8.58	-0.32	7.15e-17	Blood metabolite levels;
BRCA	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14294708	chr9:37120828	ZCCHC7	1.17	41.38	0.85	6.41e-183	Schizophrenia;
BRCA	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-14.26	-0.49	3e-40	Platelet count;
BRCA	trans	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg26043149	chr18:55253948	FECH	0.42	9.09	0.34	1.22e-18	Bone mineral density;
BRCA	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg26384229	chr12:38710491	ALG10B	-0.58	-14.82	-0.51	6.12e-43	Heart rate;
BRCA	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg01324343	chr3:183735012	ABCC5	0.8	17.69	0.57	2.57e-57	Anterior chamber depth;
BRCA	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23583168	chr7:148888333	NA	-0.82	-18.75	-0.6	8.07e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg06521331	chr12:34319734	NA	-0.46	-8.5	-0.32	1.34e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-9.18	-0.34	5.74e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg03342759	chr3:160939853	NMD3	-0.67	-15.69	-0.53	3.5e-47	Morning vs. evening chronotype;
BRCA	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	14.13	0.49	1.25e-39	Lymphocyte counts;
BRCA	cis	rs698833	0.886	rs6721675	chr2:44566027	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	10.47	0.38	9.14e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	9.28	0.34	2.65e-19	Tonsillectomy;
BRCA	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg03354898	chr7:1950403	MAD1L1	-0.49	-10.65	-0.39	1.65e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.4	8.71	0.33	2.68e-17	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	26.82	0.73	9.73e-107	Chronic sinus infection;
BRCA	trans	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	15.87	0.53	4.53e-48	Exhaled nitric oxide levels;
BRCA	cis	rs7833986	0.501	rs72651502	chr8:56875533	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	12.32	0.44	2e-31	Height;
BRCA	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.28e-23	Prostate cancer;
BRCA	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.76	0.62	3.56e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg03060546	chr3:49711283	APEH	-0.51	-10.06	-0.37	3.4e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg27446573	chr6:127587934	RNF146	0.81	15.69	0.53	3.75e-47	Breast cancer;
BRCA	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg12365402	chr11:9010492	NRIP3	-0.37	-8.43	-0.32	2.23e-16	Hemoglobin concentration;
BRCA	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg05347473	chr6:146136440	FBXO30	0.41	8.01	0.3	5.36e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg21605333	chr4:119757512	SEC24D	1.31	12.88	0.45	6.22e-34	Cannabis dependence symptom count;
BRCA	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.94	-0.51	1.6e-43	Total cholesterol levels;
BRCA	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg03146154	chr1:46216737	IPP	0.44	9.95	0.37	8.9e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7715811	0.913	rs1910091	chr5:13781535	G/A	cg07548982	chr5:13769939	DNAH5	-0.4	-8.82	-0.33	1.08e-17	Subclinical atherosclerosis traits (other);
BRCA	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	10.11	0.37	2.24e-22	Eosinophil percentage of white cells;
BRCA	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg10523679	chr1:76189770	ACADM	0.88	20.66	0.63	5.02e-73	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.9	-30.07	-0.77	1.89e-124	Schizophrenia;
BRCA	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg01420254	chr6:26195488	NA	0.57	8.89	0.33	6e-18	Gout;Renal underexcretion gout;
BRCA	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg12140854	chr5:148520817	ABLIM3	-0.43	-9.19	-0.34	5.38e-19	Breast cancer;
BRCA	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.43	-0.32	2.33e-16	Breast cancer;
BRCA	cis	rs311392	0.902	rs1511147	chr8:55091227	C/T	cg11783602	chr8:55087084	NA	-0.32	-9.43	-0.35	7.39e-20	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg05347473	chr6:146136440	FBXO30	-0.6	-11.51	-0.41	5.38e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07308232	chr7:1071921	C7orf50	-0.43	-8.85	-0.33	8.21e-18	Longevity;Endometriosis;
BRCA	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg07169764	chr2:136633963	MCM6	1.01	21.03	0.64	5.41e-75	Corneal structure;
BRCA	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg22800045	chr5:56110881	MAP3K1	0.64	12.19	0.43	6.84e-31	Initial pursuit acceleration;
BRCA	cis	rs8016982	0.662	rs1951616	chr14:81671752	T/C	cg01989461	chr14:81687754	GTF2A1	0.47	8.5	0.32	1.34e-16	Schizophrenia;
BRCA	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg01448562	chr3:133502909	NA	-0.64	-15.18	-0.51	1.09e-44	Iron status biomarkers;
BRCA	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg23711669	chr6:146136114	FBXO30	-0.67	-15.72	-0.53	2.69e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.747	rs1611760	chr1:152957573	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.79	-0.33	1.42e-17	Inflammatory skin disease;
BRCA	cis	rs11229555	0.645	rs4594017	chr11:58194788	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg08132940	chr7:1081526	C7orf50	-0.46	-8.29	-0.31	6.84e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	13.42	0.47	2.48e-36	Lymphocyte counts;
BRCA	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg18252515	chr7:66147081	NA	-0.83	-12.01	-0.43	4.26e-30	Diabetic kidney disease;
BRCA	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.43	0.5	4.82e-41	Personality dimensions;
BRCA	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg14664628	chr15:75095509	CSK	-0.53	-12.48	-0.44	3.67e-32	Breast cancer;
BRCA	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00166722	chr3:10149974	C3orf24	0.65	12.98	0.46	2.38e-34	Alzheimer's disease;
BRCA	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg13902645	chr11:5959945	NA	-0.47	-10.42	-0.38	1.42e-23	DNA methylation (variation);
BRCA	cis	rs922182	0.617	rs11852732	chr15:64239907	G/A	cg24729988	chr15:64271149	DAPK2	0.49	10.74	0.39	7.31e-25	Blood protein levels;
BRCA	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg01420254	chr6:26195488	NA	0.56	8.72	0.33	2.43e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg26384229	chr12:38710491	ALG10B	0.51	12.78	0.45	1.76e-33	Morning vs. evening chronotype;
BRCA	cis	rs11888559	0.655	rs4675309	chr2:203879503	A/G	cg24605529	chr2:203879461	NBEAL1	0.45	8.53	0.32	1.05e-16	Height;
BRCA	cis	rs13161895	1.000	rs34882290	chr5:179463836	C/A	cg02702477	chr5:179499311	RNF130	0.46	8.51	0.32	1.24e-16	LDL cholesterol;
BRCA	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg08888203	chr3:10149979	C3orf24	0.56	11.7	0.42	9.05e-29	Alzheimer's disease;
BRCA	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg24675658	chr1:53192096	ZYG11B	-0.53	-11.41	-0.41	1.38e-27	Monocyte count;
BRCA	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.9	0.56	2.97e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg21573476	chr21:45109991	RRP1B	0.35	9.25	0.34	3.21e-19	Mean corpuscular volume;
BRCA	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg08888203	chr3:10149979	C3orf24	0.61	13.19	0.46	2.57e-35	Alzheimer's disease;
BRCA	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg18252515	chr7:66147081	NA	-1.06	-15.7	-0.53	3.07e-47	Gout;
BRCA	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.75e-16	Menopause (age at onset);
BRCA	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg05623727	chr3:50126028	RBM5	0.48	11.24	0.41	6.93e-27	Body mass index;
BRCA	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg00290607	chr11:67383545	NA	-0.51	-10.92	-0.4	1.41e-25	Mean corpuscular volume;
BRCA	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg16586182	chr3:47516702	SCAP	0.59	13.26	0.46	1.32e-35	Colorectal cancer;
BRCA	cis	rs2230307	0.656	rs11166389	chr1:100466279	G/A	cg24955406	chr1:100503596	HIAT1	0.54	9.42	0.35	8.29e-20	Carotid intima media thickness;
BRCA	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg03585969	chr10:35415529	CREM	0.56	11.44	0.41	1.04e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg03929089	chr4:120376271	NA	0.47	7.92	0.3	1.09e-14	Axial length;
BRCA	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg13010199	chr12:38710504	ALG10B	0.52	11.02	0.4	5.69e-26	Heart rate;
BRCA	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg02493740	chr2:85810744	VAMP5	-0.51	-10.55	-0.39	4.25e-24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs778371	1.000	rs778370	chr2:233743363	C/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-17.24	-0.56	5.72e-55	Schizophrenia;
BRCA	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg11062466	chr8:58055876	NA	0.42	7.92	0.3	1.02e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs4742903	0.967	rs10512325	chr9:106861191	C/T	cg14250997	chr9:106856677	SMC2	0.34	10.67	0.39	1.48e-24	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg08085267	chr17:45401833	C17orf57	0.67	15.02	0.51	7.02e-44	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg15556689	chr8:8085844	FLJ10661	0.4	10.45	0.38	1.07e-23	Neuroticism;
BRCA	cis	rs72772090	0.522	rs17399215	chr5:96016280	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-8.12	-0.31	2.41e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg27490568	chr2:178487706	NA	0.51	8.58	0.32	7.29e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg24069376	chr3:38537580	EXOG	0.41	11.94	0.43	8.01e-30	Electrocardiographic conduction measures;
BRCA	cis	rs870825	0.616	rs6852082	chr4:185645783	T/C	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.0	-0.46	1.92e-34	Migraine;Coronary artery disease;
BRCA	trans	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg07211511	chr3:129823064	LOC729375	-1.05	-18.4	-0.59	5.22e-61	Blood pressure (smoking interaction);
BRCA	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-9.62	-0.36	1.56e-20	Fear of minor pain;
BRCA	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.67	-13.78	-0.48	5.21e-38	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs12458462	0.812	rs34583578	chr18:77491070	C/T	cg11879182	chr18:77439856	CTDP1	0.63	13.12	0.46	5.44e-35	Monocyte count;
BRCA	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.38	0.35	1.14e-19	Tonsillectomy;
BRCA	cis	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-9.53	-0.35	3.16e-20	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg22105103	chr4:187893119	NA	0.38	11.91	0.43	1.11e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg06627628	chr2:24431161	ITSN2	-0.51	-8.28	-0.31	7.01e-16	Lymphocyte counts;
BRCA	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg07636037	chr3:49044803	WDR6	0.4	8.15	0.31	1.98e-15	Resting heart rate;
BRCA	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg14683738	chr19:37701593	ZNF585B	0.45	8.05	0.3	3.98e-15	Coronary artery calcification;
BRCA	cis	rs208520	0.690	rs207114	chr6:66791703	C/T	cg07460842	chr6:66804631	NA	-1.02	-19.91	-0.62	5.24e-69	Exhaled nitric oxide output;
BRCA	cis	rs2882667	0.690	rs13178601	chr5:138267377	G/A	cg04439458	chr5:138467593	SIL1	-0.31	-7.82	-0.3	2.21e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7818345	1.000	rs6984145	chr8:19294111	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.31	7.94	0.3	8.95e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs9837602	0.576	rs506186	chr3:99442753	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.52	-9.57	-0.35	2.39e-20	Breast cancer;
BRCA	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg13770153	chr20:60521292	NA	-0.45	-10.57	-0.39	3.7e-24	Body mass index;
BRCA	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg09307838	chr4:120376055	NA	0.59	12.31	0.44	2.18e-31	Corneal astigmatism;
BRCA	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg22705602	chr4:152727874	NA	-0.37	-10.25	-0.38	6.35e-23	Intelligence (multi-trait analysis);
BRCA	trans	rs2840044	1.000	rs225304	chr17:33921857	G/T	cg19694781	chr19:47549865	TMEM160	-0.45	-10.51	-0.38	6.2e-24	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs17401966	0.558	rs12128374	chr1:10426417	G/A	cg03954927	chr1:10346856	KIF1B	0.34	10.19	0.37	1.12e-22	Hepatocellular carcinoma;
BRCA	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.07	0.46	9.57e-35	Bipolar disorder;
BRCA	cis	rs4787491	0.729	rs4788212	chr16:30034469	G/T	cg06326092	chr16:30034487	C16orf92	-0.38	-9.71	-0.36	6.87e-21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.47	9.55	0.35	2.75e-20	Colorectal cancer;
BRCA	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg24296786	chr1:45957014	TESK2	0.59	14.42	0.5	5.24e-41	High light scatter reticulocyte count;
BRCA	cis	rs7020830	0.867	rs1472169	chr9:37209396	C/T	cg14294708	chr9:37120828	ZCCHC7	1.14	37.66	0.83	2.28e-164	Schizophrenia;
BRCA	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg08885076	chr2:99613938	TSGA10	0.43	10.07	0.37	3.12e-22	Chronic sinus infection;
BRCA	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg14863265	chr7:2801509	GNA12	-0.45	-9.96	-0.37	8.01e-22	Height;
BRCA	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg23950597	chr19:37808831	NA	-0.65	-11.1	-0.4	2.75e-26	Coronary artery calcification;
BRCA	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg09035930	chr12:129282057	SLC15A4	0.58	17.23	0.56	6.42e-55	Systemic lupus erythematosus;
BRCA	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg06212747	chr3:49208901	KLHDC8B	0.5	10.34	0.38	2.91e-23	Parkinson's disease;
BRCA	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg03609598	chr5:56110824	MAP3K1	-0.47	-8.33	-0.31	4.97e-16	Initial pursuit acceleration;
BRCA	cis	rs367943	1.000	rs168366	chr5:112818587	C/T	cg12552261	chr5:112820674	MCC	0.55	12.13	0.43	1.31e-30	Type 2 diabetes;
BRCA	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg00106254	chr7:1943704	MAD1L1	-0.41	-11.15	-0.4	1.65e-26	Bipolar disorder and schizophrenia;
BRCA	trans	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg06521331	chr12:34319734	NA	-0.46	-8.56	-0.32	8.34e-17	Bladder cancer;
BRCA	cis	rs495337	0.766	rs6122835	chr20:48452498	T/C	cg17835207	chr20:48524531	SPATA2	0.5	10.92	0.4	1.46e-25	Psoriasis;
BRCA	cis	rs2637030	0.542	rs429384	chr5:52908205	A/G	cg06476337	chr5:52856530	NDUFS4	0.38	8.76	0.33	1.76e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs727479	0.502	rs4774583	chr15:51505993	A/G	cg19946085	chr15:51559439	CYP19A1	-0.3	-8.29	-0.31	6.62e-16	Estradiol levels;
BRCA	trans	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg21775007	chr8:11205619	TDH	-0.39	-8.23	-0.31	1.08e-15	Joint mobility (Beighton score);
BRCA	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	13.06	0.46	9.8e-35	Menarche (age at onset);
BRCA	cis	rs2797160	1.000	rs78602343	chr6:126019768	T/C	cg05901451	chr6:126070800	HEY2	0.4	9.77	0.36	4.03e-21	Endometrial cancer;
BRCA	cis	rs2115536	0.730	rs4238512	chr15:80183898	A/C	cg02196730	chr15:80188777	MTHFS	-0.36	-8.21	-0.31	1.23e-15	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
BRCA	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg17971929	chr21:40555470	PSMG1	0.8	18.58	0.59	6.1e-62	Cognitive function;
BRCA	cis	rs10208940	0.843	rs7608248	chr2:68851403	C/T	cg12452813	chr2:68675892	NA	0.49	8.81	0.33	1.16e-17	Urate levels in lean individuals;
BRCA	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs7246657	0.722	rs2927742	chr19:38133618	T/C	cg23950597	chr19:37808831	NA	0.52	8.87	0.33	7.37e-18	Coronary artery calcification;
BRCA	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg26608667	chr7:1196370	ZFAND2A	0.43	10.18	0.37	1.22e-22	Longevity;Endometriosis;
BRCA	cis	rs1784581	1.000	rs1784581	chr6:162401127	A/C	cg17173639	chr6:162384350	PARK2	-0.44	-10.32	-0.38	3.29e-23	Itch intensity from mosquito bite;
BRCA	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg20503657	chr10:835505	NA	1.09	18.0	0.58	6.98e-59	Eosinophil percentage of granulocytes;
BRCA	trans	rs8073060	0.586	rs6505486	chr17:33996776	G/A	cg19694781	chr19:47549865	TMEM160	-1.05	-21.57	-0.65	6.35e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.74	-16.42	-0.54	7.87e-51	Lymphocyte counts;
BRCA	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.73	16.28	0.54	4.04e-50	Lymphocyte counts;
BRCA	trans	rs4714291	0.963	rs761801	chr6:39997176	G/A	cg02267698	chr19:7991119	CTXN1	0.4	7.94	0.3	8.84e-15	Strep throat;
BRCA	cis	rs9297145	0.761	rs12534399	chr7:98746401	A/G	cg05967295	chr7:98741636	SMURF1	0.94	17.18	0.56	1.18e-54	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs9868809	0.881	rs3821876	chr3:48668394	G/T	cg00383909	chr3:49044727	WDR6	0.55	8.31	0.31	5.79e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg24642439	chr20:33292090	TP53INP2	0.42	8.32	0.31	5.35e-16	Height;
BRCA	cis	rs2859741	0.528	rs2359647	chr1:37483054	A/T	cg09363841	chr1:37513479	NA	-0.51	-10.91	-0.4	1.61e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg20283391	chr11:68216788	NA	-0.39	-8.1	-0.31	2.74e-15	Total body bone mineral density;
BRCA	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg03929089	chr4:120376271	NA	0.65	12.64	0.45	7.38e-33	Coronary artery disease;
BRCA	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	14.21	0.49	5.12e-40	Personality dimensions;
BRCA	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg21132104	chr15:45694354	SPATA5L1	0.75	16.95	0.56	1.66e-53	Homoarginine levels;
BRCA	cis	rs10046574	0.731	rs10458299	chr7:135052348	C/T	cg27474649	chr7:135195673	CNOT4	0.59	7.9	0.3	1.19e-14	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg06521331	chr12:34319734	NA	-0.56	-10.15	-0.37	1.52e-22	Morning vs. evening chronotype;
BRCA	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg05347473	chr6:146136440	FBXO30	0.41	8.07	0.3	3.41e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26314531	chr2:26401878	FAM59B	-0.62	-10.94	-0.4	1.16e-25	Gut microbiome composition (summer);
BRCA	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg00012203	chr2:219082015	ARPC2	-0.47	-8.98	-0.33	2.9e-18	Colorectal cancer;
BRCA	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg01802117	chr1:53393560	SCP2	-0.4	-9.01	-0.34	2.28e-18	Monocyte count;
BRCA	cis	rs6005807	0.668	rs60065194	chr22:28993756	A/G	cg12565055	chr22:29076175	TTC28	0.5	9.38	0.35	1.17e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg26408565	chr15:76604113	ETFA	-0.36	-7.89	-0.3	1.28e-14	Blood metabolite levels;
BRCA	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.74	0.33	2e-17	Tonsillectomy;
BRCA	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.34	7.81	0.3	2.31e-14	Tonsillectomy;
BRCA	cis	rs7766436	0.885	rs765782	chr6:22592216	A/G	cg13666174	chr6:22585274	NA	-0.48	-11.44	-0.41	1.03e-27	Coronary artery disease;
BRCA	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg13628971	chr7:2884303	GNA12	0.6	13.53	0.47	7.58e-37	Height;
BRCA	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.46	-0.35	5.89e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg02556042	chr12:117471086	NA	0.58	10.13	0.37	1.85e-22	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg18446336	chr7:2847575	GNA12	-0.35	-8.25	-0.31	9.06e-16	Height;
BRCA	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.46	9.25	0.34	3.33e-19	Tonsillectomy;
BRCA	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg05985134	chr18:33552581	C18orf21	0.69	12.55	0.44	1.92e-32	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg03188948	chr7:1209495	NA	0.55	10.18	0.37	1.19e-22	Longevity;Endometriosis;
BRCA	cis	rs2014572	0.967	rs11667407	chr19:57763122	C/T	cg24459738	chr19:57751996	ZNF805	-0.37	-8.71	-0.33	2.59e-17	Hyperactive-impulsive symptoms;
BRCA	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg27366882	chr3:133540807	NA	-0.32	-7.99	-0.3	6.48e-15	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg20368463	chr18:77673604	PQLC1	-0.34	-8.08	-0.3	3.36e-15	Schizophrenia;
BRCA	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-12.2	-0.43	6.44e-31	Alzheimer's disease;
BRCA	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg18811423	chr2:55921094	PNPT1	0.76	25.28	0.71	2.82e-98	Metabolic syndrome;
BRCA	cis	rs2505998	0.912	rs2505994	chr10:43568887	C/T	cg15436174	chr10:43711423	RASGEF1A	0.41	7.82	0.3	2.25e-14	Hirschsprung disease;
BRCA	cis	rs8005677	1.000	rs4982712	chr14:23403728	A/G	cg01529538	chr14:23388837	RBM23	0.41	11.08	0.4	3.13e-26	Cognitive ability (multi-trait analysis);
BRCA	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg01689657	chr7:91764605	CYP51A1	0.22	7.92	0.3	1.09e-14	Breast cancer;
BRCA	cis	rs1691799	0.899	rs1168358	chr12:66748664	A/G	cg16791601	chr12:66731901	HELB	-0.62	-16.39	-0.54	1.16e-50	White blood cell count (basophil);
BRCA	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg16329650	chr2:213403929	ERBB4	0.67	19.46	0.61	1.4e-66	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.43	-9.66	-0.36	1.03e-20	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9788721	0.836	rs17484524	chr15:78772676	A/G	cg18825076	chr15:78729989	IREB2	-0.45	-8.75	-0.33	1.87e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.0	-12.4	-0.44	8.88e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs752010	0.631	rs1073197	chr1:42059822	C/T	cg06885757	chr1:42089581	HIVEP3	-0.4	-13.09	-0.46	7.3e-35	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-9.4	-0.35	9.23e-20	Chronic sinus infection;
BRCA	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	12.0	0.43	4.77e-30	Lung cancer in ever smokers;
BRCA	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-13.87	-0.48	1.98e-38	Platelet count;
BRCA	cis	rs7756236	0.538	rs6936598	chr6:36626096	T/C	cg08179530	chr6:36648295	CDKN1A	0.37	7.9	0.3	1.24e-14	QRS duration;
BRCA	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-20.03	-0.62	1.28e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.21	-0.49	5.13e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs3849570	0.925	rs13091492	chr3:81891476	A/G	cg07356753	chr3:81810745	GBE1	-0.41	-9.96	-0.37	7.99e-22	Waist circumference;Body mass index;
BRCA	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg11812906	chr14:75593930	NEK9	-0.62	-14.38	-0.49	8.19e-41	Height;
BRCA	cis	rs6745190	0.575	rs7569991	chr2:181975252	T/G	cg00481216	chr2:181971175	NA	0.4	9.45	0.35	6.15e-20	White blood cell count;
BRCA	cis	rs9811920	0.809	rs1384062	chr3:99597928	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.57	13.87	0.48	1.9e-38	Axial length;
BRCA	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg02403541	chr12:121454288	C12orf43	0.53	9.96	0.37	7.72e-22	N-glycan levels;
BRCA	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg11941060	chr3:133502564	NA	-0.51	-12.3	-0.44	2.31e-31	Iron status biomarkers;
BRCA	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg03934865	chr2:198174659	NA	-0.37	-8.16	-0.31	1.78e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg17644776	chr2:200775616	C2orf69	-0.45	-9.38	-0.35	1.17e-19	Osteoporosis;
BRCA	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg23422044	chr7:1970798	MAD1L1	-0.55	-10.37	-0.38	2.21e-23	Bipolar disorder;
BRCA	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11764359	chr7:65958608	NA	0.74	16.3	0.54	3.24e-50	Aortic root size;
BRCA	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg03709012	chr19:19516395	GATAD2A	0.81	18.96	0.6	6.13e-64	Tonsillectomy;
BRCA	cis	rs793571	0.544	rs11638244	chr15:58907151	A/T	cg05156742	chr15:59063176	FAM63B	0.48	9.71	0.36	6.74e-21	Schizophrenia;
BRCA	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg17848003	chr1:3704513	LRRC47	0.24	7.82	0.3	2.17e-14	Red cell distribution width;
BRCA	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg21132104	chr15:45694354	SPATA5L1	0.71	15.3	0.52	2.88e-45	Homoarginine levels;
BRCA	cis	rs752010	0.543	rs1570355	chr1:42042317	C/T	cg06885757	chr1:42089581	HIVEP3	0.23	8.68	0.32	3.29e-17	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg17063962	chr7:91808500	NA	0.54	12.83	0.45	1.06e-33	Breast cancer;
BRCA	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg20701182	chr2:24300061	SF3B14	0.59	9.13	0.34	8.97e-19	Lymphocyte counts;
BRCA	cis	rs701145	0.585	rs1527799	chr3:153811226	A/G	cg17054900	chr3:154042577	DHX36	0.53	8.92	0.33	4.83e-18	Coronary artery disease;
BRCA	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-14.24	-0.49	3.78e-40	Platelet count;
BRCA	cis	rs6835098	0.924	rs12639929	chr4:174156538	C/T	cg08422745	chr4:174089978	GALNT7	-0.81	-15.62	-0.53	8.05e-47	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	trans	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.81	26.35	0.72	3.8e-104	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.57	-11.98	-0.43	5.39e-30	Lung cancer;
BRCA	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08645402	chr16:4508243	NA	0.39	8.99	0.33	2.86e-18	Schizophrenia;
BRCA	cis	rs7635838	0.619	rs346087	chr3:11274354	A/G	cg00170343	chr3:11313890	ATG7	0.43	8.44	0.32	2.09e-16	HDL cholesterol;
BRCA	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg24812749	chr6:127587940	RNF146	0.87	20.07	0.62	7.99e-70	Breast cancer;
BRCA	cis	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg20368463	chr18:77673604	PQLC1	-0.34	-8.08	-0.3	3.36e-15	Schizophrenia;
BRCA	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg21064579	chr19:49206444	FUT2	0.32	8.02	0.3	4.92e-15	Dietary macronutrient intake;
BRCA	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.89	-17.62	-0.57	6.1e-57	Body mass index;
BRCA	trans	rs8073060	0.586	rs226087	chr17:34017652	T/C	cg19694781	chr19:47549865	TMEM160	-1.07	-21.69	-0.65	1.28e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs6433895	0.677	rs35076700	chr2:181999324	C/T	cg00481216	chr2:181971175	NA	0.46	8.68	0.32	3.35e-17	Lymphocyte counts;
BRCA	cis	rs7737355	0.947	rs244733	chr5:130822778	T/C	cg06307176	chr5:131281290	NA	0.53	10.43	0.38	1.26e-23	Life satisfaction;
BRCA	cis	rs6060717	0.536	rs6060666	chr20:34478954	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.08	-0.3	3.21e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	ch.11.42038R	chr11:967971	AP2A2	0.46	14.07	0.49	2.37e-39	Alzheimer's disease (late onset);
BRCA	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11890956	chr21:40555474	PSMG1	0.99	23.8	0.69	3.96e-90	Cognitive function;
BRCA	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg15704280	chr7:45808275	SEPT13	0.52	8.96	0.33	3.4e-18	Axial length;
BRCA	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.09	0.3	2.91e-15	Tonsillectomy;
BRCA	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg22920501	chr2:26401640	FAM59B	0.85	15.69	0.53	3.6e-47	Gut microbiome composition (summer);
BRCA	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg23933602	chr10:16859644	RSU1	0.98	29.51	0.76	2e-121	Platelet distribution width;
BRCA	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg07080220	chr10:102295463	HIF1AN	0.65	15.51	0.52	2.69e-46	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg09904177	chr6:26538194	HMGN4	0.55	17.65	0.57	4.4e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg10223061	chr2:219282414	VIL1	-0.27	-8.12	-0.31	2.37e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.64	-0.5	4.67e-42	Chronic sinus infection;
BRCA	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg26647111	chr11:31128758	NA	-0.45	-9.83	-0.36	2.5e-21	Red blood cell count;
BRCA	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg13736514	chr6:26305472	NA	-0.35	-11.82	-0.42	2.62e-29	Educational attainment;
BRCA	cis	rs2625529	0.824	rs4776581	chr15:72207071	G/A	cg16672083	chr15:72433130	SENP8	-0.83	-17.19	-0.56	9.91e-55	Red blood cell count;
BRCA	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.17	0.31	1.63e-15	Breast cancer;
BRCA	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg12483005	chr1:23474871	LUZP1	0.46	10.35	0.38	2.53e-23	Height;
BRCA	cis	rs12367572	0.663	rs1857926	chr12:45344524	C/T	cg04608330	chr12:45269318	NELL2	-0.43	-9.48	-0.35	4.82e-20	Gut microbiome composition (summer);
BRCA	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg03477792	chr4:77819574	ANKRD56	0.66	15.7	0.53	3.38e-47	Emphysema distribution in smoking;
BRCA	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.81	0.36	3.04e-21	Morning vs. evening chronotype;
BRCA	cis	rs7586879	0.789	rs36029941	chr2:25127801	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.46	0.35	5.74e-20	Body mass index;
BRCA	cis	rs6088813	1.000	rs6088820	chr20:33987298	T/C	cg14752227	chr20:34000481	UQCC	-0.39	-8.4	-0.32	2.84e-16	Height;
BRCA	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg04025307	chr7:1156635	C7orf50	0.43	9.51	0.35	3.91e-20	Longevity;Endometriosis;
BRCA	cis	rs4302748	0.818	rs1882064	chr7:36188616	G/A	cg24442661	chr7:36192818	EEPD1	0.47	8.81	0.33	1.19e-17	Platelet count;
BRCA	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg06784218	chr1:46089804	CCDC17	0.5	11.98	0.43	5.89e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10129255	0.500	rs7157975	chr14:107212287	G/A	cg07958169	chr14:107095056	NA	-0.38	-8.27	-0.31	8.06e-16	Kawasaki disease;
BRCA	cis	rs10056811	0.510	rs10058171	chr5:74407991	C/T	cg19683494	chr5:74908142	NA	0.56	8.5	0.32	1.38e-16	Coronary artery disease;
BRCA	cis	rs7851660	0.933	rs12341377	chr9:100610382	C/G	cg13688889	chr9:100608707	NA	-0.36	-8.7	-0.33	2.81e-17	Strep throat;
BRCA	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg22139774	chr2:100720529	AFF3	-0.3	-8.6	-0.32	5.97e-17	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg06640241	chr16:89574553	SPG7	0.83	20.76	0.63	1.52e-73	Multiple myeloma (IgH translocation);
BRCA	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg14983838	chr19:29218262	NA	0.54	10.11	0.37	2.21e-22	Methadone dose in opioid dependence;
BRCA	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg21770322	chr7:97807741	LMTK2	-0.44	-11.53	-0.42	4.46e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11622475	1.000	rs2236246	chr14:104379206	A/C	cg12183467	chr14:104352244	NA	0.46	9.67	0.36	9.7e-21	Bipolar disorder;
BRCA	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg12365402	chr11:9010492	NRIP3	-0.4	-9.38	-0.35	1.12e-19	Hemoglobin concentration;
BRCA	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg08601574	chr20:25228251	PYGB	-0.34	-8.25	-0.31	9.18e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs1997103	1.000	rs6966183	chr7:55407546	A/C	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg14675211	chr2:100938903	LONRF2	0.43	9.54	0.35	2.99e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg21724239	chr8:58056113	NA	0.57	9.24	0.34	3.58e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs11025559	1.000	rs11025559	chr11:20443875	A/G	cg19653624	chr11:20408972	PRMT3	0.38	8.12	0.31	2.38e-15	Pursuit maintenance gain;
BRCA	cis	rs1577917	0.958	rs12660846	chr6:86573809	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.43	-0.41	1.14e-27	Response to antipsychotic treatment;
BRCA	cis	rs9487051	0.708	rs378447	chr6:109526823	G/A	cg01475377	chr6:109611718	NA	-0.41	-10.27	-0.38	5.22e-23	Reticulocyte fraction of red cells;
BRCA	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg02951883	chr7:2050386	MAD1L1	-0.52	-11.42	-0.41	1.32e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs1997103	0.705	rs56301138	chr7:55396555	G/T	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.72e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00802000	chr16:706648	WDR90	-0.39	-9.1	-0.34	1.14e-18	Height;
BRCA	cis	rs3750965	0.959	rs2253658	chr11:68856804	C/G	cg06818126	chr11:68850279	TPCN2	-0.36	-8.43	-0.32	2.26e-16	Hair color;
BRCA	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg24642844	chr7:1081250	C7orf50	-0.52	-11.55	-0.42	3.66e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-10.14	-0.37	1.7e-22	Schizophrenia;
BRCA	cis	rs2425143	1.000	rs6060642	chr20:34449840	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.56	-0.32	8.47e-17	Blood protein levels;
BRCA	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg00071950	chr4:10020882	SLC2A9	0.53	13.2	0.46	2.34e-35	Bone mineral density;
BRCA	cis	rs13190036	1.000	rs34832871	chr5:176655929	A/G	cg06733329	chr5:176740039	MXD3	0.45	8.2	0.31	1.33e-15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg24308560	chr3:49941425	MST1R	-0.39	-8.19	-0.31	1.45e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.68	-0.32	3.36e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25427524	chr10:38739819	LOC399744	-0.73	-18.16	-0.58	1.03e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg13770153	chr20:60521292	NA	-0.46	-10.99	-0.4	7.66e-26	Body mass index;
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg03923535	chr7:1197113	ZFAND2A	0.43	8.58	0.32	7.16e-17	Longevity;Endometriosis;
BRCA	cis	rs7631605	1.000	rs4647277	chr3:37058509	A/G	cg15934958	chr3:37212084	LRRFIP2	0.39	9.07	0.34	1.5e-18	Cerebrospinal P-tau181p levels;
BRCA	trans	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg09658497	chr7:2847517	GNA12	-0.41	-8.56	-0.32	8.71e-17	Height;
BRCA	cis	rs72772090	0.539	rs11740375	chr5:96112897	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-11.61	-0.42	2.09e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-18.54	-0.59	9.69e-62	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6782228	0.606	rs6439135	chr3:128358633	G/A	cg16766828	chr3:128327626	NA	-0.43	-9.64	-0.36	1.26e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg18154014	chr19:37997991	ZNF793	0.61	11.42	0.41	1.34e-27	Coronary artery calcification;
BRCA	cis	rs17253792	0.822	rs75995456	chr14:56073194	A/G	cg01858014	chr14:56050164	KTN1	-0.74	-9.1	-0.34	1.12e-18	Putamen volume;
BRCA	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg08859206	chr1:53392774	SCP2	0.42	8.31	0.31	5.65e-16	Monocyte count;
BRCA	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg22705602	chr4:152727874	NA	-0.33	-8.26	-0.31	8.67e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg00540400	chr15:79124168	NA	0.27	7.81	0.3	2.44e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	5.1e-16	Tonsillectomy;
BRCA	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg27432699	chr2:27873401	GPN1	-0.53	-11.24	-0.41	7.05e-27	Oral cavity cancer;
BRCA	cis	rs7000551	0.606	rs7844699	chr8:22248920	G/T	cg12081754	chr8:22256438	SLC39A14	-0.64	-13.23	-0.46	1.67e-35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg09184832	chr6:79620586	NA	-0.52	-11.42	-0.41	1.3e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	11.52	0.41	5.17e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2766692	1.000	rs2766692	chr14:100684192	C/T	cg14866419	chr14:100704911	YY1	0.43	8.91	0.33	5.15e-18	Electroencephalographic traits in alcoholism;
BRCA	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg24558204	chr6:135376177	HBS1L	0.59	15.99	0.53	1.14e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.67	0.42	1.12e-28	Homoarginine levels;
BRCA	cis	rs1691799	0.899	rs1168317	chr12:66746225	C/T	cg16791601	chr12:66731901	HELB	-0.69	-19.72	-0.62	5.51e-68	White blood cell count (basophil);
BRCA	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	13.45	0.47	1.67e-36	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg18230493	chr5:56204884	C5orf35	-0.74	-14.72	-0.5	1.98e-42	Initial pursuit acceleration;
BRCA	cis	rs6120849	0.754	rs11167253	chr20:33614449	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	10.29	0.38	4.57e-23	Protein C levels;
BRCA	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-9.45	-0.35	6.26e-20	Joint mobility (Beighton score);
BRCA	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.69	0.42	9.8e-29	Homoarginine levels;
BRCA	cis	rs208520	0.690	rs207118	chr6:66788948	T/A	cg07460842	chr6:66804631	NA	-1.02	-20.41	-0.63	1.11e-71	Exhaled nitric oxide output;
BRCA	cis	rs631288	0.557	rs894470	chr1:146671947	A/G	cg25205988	chr1:146714368	CHD1L	0.82	8.08	0.3	3.13e-15	PR interval in Tripanosoma cruzi seropositivity;
BRCA	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.55	-0.39	4.39e-24	Mean corpuscular volume;
BRCA	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg12310025	chr6:25882481	NA	0.72	17.43	0.57	5.62e-56	Blood metabolite levels;
BRCA	cis	rs919433	0.617	rs4850807	chr2:198575975	G/A	cg00792783	chr2:198669748	PLCL1	-0.44	-9.67	-0.36	9.55e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs250677	0.522	rs10477400	chr5:148359598	T/C	cg18129178	chr5:148520854	ABLIM3	0.54	10.46	0.38	9.85e-24	Breast cancer;
BRCA	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg18301423	chr5:131593218	PDLIM4	0.35	8.78	0.33	1.52e-17	Acylcarnitine levels;
BRCA	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg00012203	chr2:219082015	ARPC2	0.64	14.31	0.49	1.64e-40	Colorectal cancer;
BRCA	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-23.15	-0.68	1.44e-86	Headache;
BRCA	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg17366294	chr4:99064904	C4orf37	0.45	10.66	0.39	1.58e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11605924	0.868	rs34043764	chr11:45837457	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.45	-9.65	-0.36	1.13e-20	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs490234	0.615	rs2819625	chr9:128156648	A/G	cg14078157	chr9:128172775	NA	-0.35	-7.82	-0.3	2.26e-14	Mean arterial pressure;
BRCA	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg06064525	chr11:970664	AP2A2	-0.28	-8.21	-0.31	1.24e-15	Alzheimer's disease (late onset);
BRCA	cis	rs10789491	1.000	rs618505	chr1:47144532	T/C	cg15501359	chr1:47185051	KIAA0494	0.65	18.1	0.58	1.93e-59	Response to hepatitis C treatment;
BRCA	trans	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.6	0.32	6.06e-17	Mean corpuscular volume;
BRCA	cis	rs6484504	0.532	rs7121949	chr11:31288160	G/T	cg06552810	chr11:31128660	NA	-0.39	-8.76	-0.33	1.77e-17	Red blood cell count;
BRCA	cis	rs528301	0.833	rs578584	chr2:45143175	A/T	cg02372786	chr2:45167549	SIX3	0.48	11.18	0.4	1.26e-26	Alcohol and nicotine co-dependence;
BRCA	cis	rs600806	0.850	rs1880670	chr1:109941133	C/T	cg20591472	chr1:110008990	SYPL2	0.33	8.22	0.31	1.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.15	0.34	7.63e-19	Tonsillectomy;
BRCA	cis	rs17023223	0.553	rs56234947	chr1:119707744	G/A	cg05756136	chr1:119680316	WARS2	-0.42	-8.06	-0.3	3.75e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg21475434	chr5:93447410	FAM172A	0.67	8.97	0.33	3.29e-18	Diabetic retinopathy;
BRCA	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.46	-10.45	-0.38	1.09e-23	Urate levels in overweight individuals;
BRCA	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg03954927	chr1:10346856	KIF1B	-0.45	-12.9	-0.45	5.21e-34	Hepatocellular carcinoma;
BRCA	cis	rs9837602	1.000	rs1021103	chr3:99603230	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.44	0.41	1.05e-27	Breast cancer;
BRCA	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg22029157	chr1:209979665	IRF6	0.55	12.16	0.43	9.7e-31	Cleft lip with or without cleft palate;
BRCA	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	12.96	0.46	2.93e-34	Lymphocyte percentage of white cells;
BRCA	cis	rs7191439	0.589	rs11076699	chr16:88756812	A/C	cg02389323	chr16:88786976	FAM38A	-0.61	-8.1	-0.31	2.73e-15	Plateletcrit;
BRCA	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg03929089	chr4:120376271	NA	0.65	12.8	0.45	1.46e-33	Coronary artery disease;
BRCA	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	9.24	0.34	3.62e-19	Personality dimensions;
BRCA	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg19812747	chr11:111475976	SIK2	0.45	8.23	0.31	1.09e-15	Primary sclerosing cholangitis;
BRCA	cis	rs67981189	0.593	rs7143595	chr14:71522001	A/T	cg15816911	chr14:71606274	NA	0.36	8.32	0.31	5.3e-16	Schizophrenia;
BRCA	cis	rs4074536	0.714	rs12023881	chr1:116304301	G/T	cg21648376	chr1:116311395	CASQ2	-0.49	-8.67	-0.32	3.54e-17	QRS duration;
BRCA	cis	rs6543140	0.964	rs13390895	chr2:103075499	G/A	cg04239558	chr2:103089729	SLC9A4	0.34	9.56	0.35	2.4e-20	Blood protein levels;
BRCA	cis	rs7523273	0.606	rs1970530	chr1:207924066	G/A	cg22525895	chr1:207977042	MIR29B2	0.48	12.18	0.43	7.55e-31	Schizophrenia;
BRCA	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg11168104	chr5:1857477	NA	-0.33	-8.71	-0.33	2.6e-17	Cardiovascular disease risk factors;
BRCA	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg09658497	chr7:2847517	GNA12	-0.43	-8.85	-0.33	8.31e-18	Height;
BRCA	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-8.8	-0.33	1.3e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg04166393	chr7:2884313	GNA12	0.41	8.52	0.32	1.15e-16	Height;
BRCA	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11644478	chr21:40555479	PSMG1	-0.83	-18.96	-0.6	6.27e-64	Cognitive function;
BRCA	cis	rs12200560	0.505	rs9400167	chr6:97077192	G/T	cg06623918	chr6:96969491	KIAA0776	0.53	12.7	0.45	4.04e-33	Coronary heart disease;
BRCA	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg06064525	chr11:970664	AP2A2	-0.49	-16.27	-0.54	4.64e-50	Alzheimer's disease (late onset);
BRCA	trans	rs1459104	1.000	rs35882309	chr11:55237464	G/A	cg15704280	chr7:45808275	SEPT13	0.67	8.35	0.31	4.13e-16	Body mass index;
BRCA	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg21045802	chr8:109455806	TTC35	0.34	7.83	0.3	2.1e-14	Dupuytren's disease;
BRCA	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg18402987	chr7:1209562	NA	0.66	11.24	0.41	7.04e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg11707556	chr5:10655725	ANKRD33B	0.4	8.79	0.33	1.33e-17	Coronary artery disease;
BRCA	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg17063962	chr7:91808500	NA	-0.55	-12.69	-0.45	4.37e-33	Breast cancer;
BRCA	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs1451375	0.617	rs10277662	chr7:50594836	C/T	cg18232548	chr7:50535776	DDC	0.44	9.29	0.34	2.44e-19	Malaria;
BRCA	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.06	0.74	1.58e-113	Chronic sinus infection;
BRCA	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg06784218	chr1:46089804	CCDC17	-0.45	-10.73	-0.39	7.88e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg12165864	chr7:66369176	NA	0.41	9.43	0.35	7.58e-20	Corneal structure;
BRCA	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11764359	chr7:65958608	NA	-0.75	-16.67	-0.55	4.55e-52	Aortic root size;
BRCA	cis	rs1784581	1.000	rs1618170	chr6:162400337	C/T	cg17173639	chr6:162384350	PARK2	-0.43	-10.1	-0.37	2.33e-22	Itch intensity from mosquito bite;
BRCA	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	12.74	0.45	2.81e-33	Mean platelet volume;
BRCA	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17830980	chr10:43048298	ZNF37B	0.57	13.98	0.48	5.97e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg24130564	chr14:104152367	KLC1	-0.41	-8.73	-0.33	2.17e-17	Reticulocyte count;
BRCA	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg24558204	chr6:135376177	HBS1L	0.47	12.88	0.45	6.62e-34	Red blood cell count;
BRCA	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg00750074	chr16:89608354	SPG7	-0.38	-10.05	-0.37	3.72e-22	Multiple myeloma (IgH translocation);
BRCA	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.46	-0.77	1.51e-126	Schizophrenia;
BRCA	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg21605333	chr4:119757512	SEC24D	1.33	13.92	0.48	1.18e-38	Cannabis dependence symptom count;
BRCA	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg07636037	chr3:49044803	WDR6	-0.58	-8.06	-0.3	3.81e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs10193935	0.901	rs3755304	chr2:42589921	A/G	cg27598129	chr2:42591480	NA	0.84	13.53	0.47	7.76e-37	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg04362960	chr10:104952993	NT5C2	0.46	10.7	0.39	1.13e-24	Arsenic metabolism;
BRCA	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg27446573	chr6:127587934	RNF146	0.67	15.13	0.51	2.02e-44	Breast cancer;
BRCA	cis	rs12612619	0.732	rs11897106	chr2:27196299	A/G	cg00617064	chr2:27272375	NA	0.31	8.34	0.31	4.65e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.8	0.33	1.28e-17	Iron status biomarkers;
BRCA	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg08601574	chr20:25228251	PYGB	-0.39	-9.05	-0.34	1.77e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11644478	chr21:40555479	PSMG1	0.83	19.11	0.6	1.01e-64	Cognitive function;
BRCA	cis	rs11229555	0.609	rs12291791	chr11:58186290	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.71	-0.36	7.23e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg04317338	chr11:64019027	PLCB3	0.56	9.72	0.36	6.35e-21	Mean platelet volume;
BRCA	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03264133	chr6:25882463	NA	0.49	11.06	0.4	3.9e-26	Blood metabolite levels;
BRCA	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg25174290	chr11:3078921	CARS	-0.44	-13.64	-0.47	2.19e-37	Longevity;
BRCA	cis	rs965469	1.000	rs6051705	chr20:3253143	G/A	cg25506879	chr20:3388711	C20orf194	-0.55	-10.79	-0.39	4.75e-25	IFN-related cytopenia;
BRCA	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.38	-9.68	-0.36	9.31e-21	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs7727544	0.508	rs10900804	chr5:131401845	C/T	cg14196790	chr5:131705035	SLC22A5	0.38	9.31	0.35	2.07e-19	Blood metabolite levels;
BRCA	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg01448562	chr3:133502909	NA	-0.6	-14.43	-0.5	4.46e-41	Iron status biomarkers;
BRCA	cis	rs1904096	0.506	rs6823404	chr4:95197520	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.15	-0.37	1.51e-22	Type 2 diabetes;
BRCA	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg25036284	chr2:26402008	FAM59B	-0.77	-12.17	-0.43	8.78e-31	Gut microbiome composition (summer);
BRCA	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.39	-8.33	-0.31	4.78e-16	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg07636037	chr3:49044803	WDR6	0.57	9.26	0.34	3e-19	Menarche (age at onset);
BRCA	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg04981885	chr1:160991156	F11R	-0.63	-11.62	-0.42	1.94e-28	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg05775895	chr3:12838266	CAND2	0.38	8.49	0.32	1.44e-16	QRS complex (12-leadsum);
BRCA	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg04896959	chr15:78267971	NA	-0.42	-9.94	-0.37	9.23e-22	Coronary artery disease or large artery stroke;
BRCA	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg18105134	chr13:113819100	PROZ	-0.61	-13.99	-0.48	5.45e-39	Platelet distribution width;
BRCA	cis	rs778371	0.697	rs4973564	chr2:233718440	A/G	cg08000102	chr2:233561755	GIGYF2	-0.85	-20.72	-0.63	2.32e-73	Schizophrenia;
BRCA	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg14500267	chr11:67383377	NA	0.4	8.55	0.32	9.37e-17	Mean corpuscular volume;
BRCA	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-14.26	-0.49	2.95e-40	Chronic sinus infection;
BRCA	trans	rs78049276	0.688	rs1878406	chr4:148393664	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.45	-7.81	-0.3	2.42e-14	Pulse pressure;
BRCA	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg04450456	chr4:17643702	FAM184B	0.37	11.09	0.4	3.01e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg23840854	chr1:161414152	NA	0.74	9.86	0.36	1.87e-21	Rheumatoid arthritis;
BRCA	cis	rs9462846	0.959	rs6937172	chr6:42884375	A/T	cg02353165	chr6:42928485	GNMT	0.54	9.71	0.36	7.04e-21	Blood protein levels;
BRCA	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.45	0.55	5.92e-51	Colorectal cancer;
BRCA	trans	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs28830936	0.966	rs17733613	chr15:41917585	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.32	-9.0	-0.34	2.66e-18	Diastolic blood pressure;
BRCA	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg04546413	chr19:29218101	NA	0.58	9.9	0.36	1.34e-21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg12011299	chr4:100065546	ADH4	0.47	10.65	0.39	1.7e-24	Alcohol dependence;
BRCA	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg12935359	chr14:103987150	CKB	0.61	14.08	0.49	1.99e-39	Intelligence (multi-trait analysis);
BRCA	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21659725	chr3:3221576	CRBN	0.72	22.39	0.66	1.95e-82	Intelligence (multi-trait analysis);
BRCA	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-10.28	-0.38	4.86e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg23711669	chr6:146136114	FBXO30	0.65	15.41	0.52	8.21e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg21433313	chr16:3507492	NAT15	-0.4	-8.7	-0.33	2.87e-17	Tuberculosis;
BRCA	cis	rs113835537	0.529	rs11227495	chr11:66263243	C/T	cg24851651	chr11:66362959	CCS	0.45	8.36	0.31	3.93e-16	Airway imaging phenotypes;
BRCA	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs2018683	0.707	rs4722878	chr7:28973031	C/T	cg19402173	chr7:128379420	CALU	-0.42	-9.88	-0.36	1.63e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg08999081	chr20:33150536	PIGU	0.45	12.54	0.44	2.02e-32	Glomerular filtration rate (creatinine);
BRCA	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg23533926	chr12:111358616	MYL2	-0.43	-8.95	-0.33	3.88e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg15017067	chr4:17643749	FAM184B	0.31	9.56	0.35	2.54e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.61	-12.93	-0.46	4.08e-34	Personality dimensions;
BRCA	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	12.79	0.45	1.62e-33	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg18451016	chr1:38461880	NA	0.49	11.49	0.41	6.34e-28	Coronary artery disease;
BRCA	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg23887609	chr12:130822674	PIWIL1	0.49	10.69	0.39	1.22e-24	Menopause (age at onset);
BRCA	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg20476274	chr7:133979776	SLC35B4	0.51	11.82	0.42	2.78e-29	Mean platelet volume;
BRCA	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.95e-32	Developmental language disorder (linguistic errors);
BRCA	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg08975724	chr8:8085496	FLJ10661	0.43	8.05	0.3	3.95e-15	Retinal vascular caliber;
BRCA	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg21775007	chr8:11205619	TDH	0.58	13.28	0.47	1.02e-35	Retinal vascular caliber;
BRCA	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg12373951	chr3:133503437	NA	0.44	10.19	0.37	1.11e-22	Iron status biomarkers;
BRCA	cis	rs733592	0.723	rs10875766	chr12:48593580	G/C	cg24011408	chr12:48396354	COL2A1	0.39	8.11	0.31	2.58e-15	Plateletcrit;
BRCA	cis	rs4908768	0.501	rs4908761	chr1:8552219	G/A	cg20416874	chr1:8611966	RERE	-0.27	-7.81	-0.3	2.43e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg13047869	chr3:10149882	C3orf24	0.57	10.37	0.38	2.19e-23	Alzheimer's disease;
BRCA	cis	rs73086581	1.000	rs73086588	chr20:3982224	A/T	cg02187196	chr20:3869020	PANK2	0.53	9.37	0.35	1.23e-19	Response to antidepressants in depression;
BRCA	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg16339924	chr4:17578868	LAP3	0.56	13.86	0.48	2.31e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs870825	0.655	rs10013685	chr4:185617785	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	16.77	0.55	1.36e-52	Blood protein levels;
BRCA	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg08888203	chr3:10149979	C3orf24	0.57	12.08	0.43	2.15e-30	Alzheimer's disease;
BRCA	cis	rs9318086	0.712	rs1886970	chr13:24440498	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.33	9.6	0.35	1.85e-20	Myopia (pathological);
BRCA	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg12062639	chr20:23401060	NAPB	0.89	10.64	0.39	1.94e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	trans	rs8073060	0.544	rs225246	chr17:33944773	T/C	cg19694781	chr19:47549865	TMEM160	-1.06	-21.52	-0.65	1.07e-77	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs12618769	0.597	rs6753515	chr2:99128965	T/A	cg10123293	chr2:99228465	UNC50	0.41	8.33	0.31	4.95e-16	Bipolar disorder;
BRCA	cis	rs13095912	0.962	rs1568664	chr3:185312231	T/C	cg11274856	chr3:185301563	NA	0.36	9.05	0.34	1.74e-18	Systolic blood pressure;
BRCA	cis	rs7617773	0.780	rs35411187	chr3:48360017	C/G	cg11946769	chr3:48343235	NME6	0.7	14.13	0.49	1.21e-39	Coronary artery disease;
BRCA	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg08392591	chr16:89556376	ANKRD11	-0.43	-10.52	-0.38	5.51e-24	Multiple myeloma (IgH translocation);
BRCA	cis	rs1451375	1.000	rs921450	chr7:50623260	A/G	cg18232548	chr7:50535776	DDC	-0.42	-9.96	-0.37	8.35e-22	Malaria;
BRCA	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03264133	chr6:25882463	NA	-0.54	-12.39	-0.44	9.07e-32	Blood metabolite levels;
BRCA	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg11843238	chr5:131593191	PDLIM4	0.33	8.72	0.33	2.34e-17	Breast cancer;
BRCA	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg24562669	chr7:97807699	LMTK2	0.45	12.08	0.43	2.16e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg18904891	chr8:8559673	CLDN23	0.62	12.42	0.44	7.03e-32	Obesity-related traits;
BRCA	cis	rs965469	0.779	rs8117749	chr20:3386692	A/C	cg25506879	chr20:3388711	C20orf194	-0.45	-8.78	-0.33	1.51e-17	IFN-related cytopenia;
BRCA	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03264133	chr6:25882463	NA	-0.48	-10.77	-0.39	5.48e-25	Blood metabolite levels;
BRCA	cis	rs2070433	1.000	rs2839306	chr21:47954219	G/T	cg12379764	chr21:47803548	PCNT	-0.48	-8.9	-0.33	5.87e-18	Lymphocyte counts;
BRCA	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg20607798	chr8:58055168	NA	0.46	7.92	0.3	1.08e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs3772130	1.000	rs13087578	chr3:121369207	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	8.97	0.33	3.29e-18	Cognitive performance;
BRCA	cis	rs9309473	0.607	rs6546826	chr2:73599808	A/G	cg20560298	chr2:73613845	ALMS1	0.47	12.79	0.45	1.69e-33	Metabolite levels;
BRCA	cis	rs7092929	0.941	rs1890583	chr10:3590269	T/C	cg14308648	chr10:3568949	NA	0.44	8.01	0.3	5.47e-15	Coronary artery calcification;
BRCA	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	12.07	0.43	2.31e-30	Multiple sclerosis;
BRCA	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg16339924	chr4:17578868	LAP3	0.56	13.89	0.48	1.62e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13064411	0.735	rs13098166	chr3:113210038	A/G	cg18753928	chr3:113234510	CCDC52	-0.59	-12.52	-0.44	2.53e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs1595825	0.838	rs6742343	chr2:198666752	C/T	cg19156104	chr2:198669113	PLCL1	-0.48	-8.58	-0.32	7.39e-17	Ulcerative colitis;
BRCA	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg04267008	chr7:1944627	MAD1L1	-0.41	-9.11	-0.34	1.04e-18	Schizophrenia;
BRCA	cis	rs9837602	0.882	rs6807176	chr3:99760864	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	10.3	0.38	3.87e-23	Breast cancer;
BRCA	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg05340658	chr4:99064831	C4orf37	0.68	16.86	0.55	4.76e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg06521331	chr12:34319734	NA	-0.56	-10.14	-0.37	1.7e-22	Morning vs. evening chronotype;
BRCA	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg18765753	chr7:1198926	ZFAND2A	-0.42	-8.68	-0.32	3.18e-17	Bronchopulmonary dysplasia;
BRCA	cis	rs2816062	0.735	rs2816054	chr1:18896431	C/T	cg18795169	chr1:18902165	NA	-0.98	-29.92	-0.76	1.28e-123	Urate levels in lean individuals;
BRCA	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg18132916	chr6:79620363	NA	-0.47	-10.74	-0.39	7.41e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs9811920	0.535	rs792831	chr3:99473720	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-9.99	-0.37	6.28e-22	Axial length;
BRCA	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg06917634	chr15:78832804	PSMA4	-0.58	-12.85	-0.45	8.77e-34	Sudden cardiac arrest;
BRCA	cis	rs12579753	0.917	rs2401003	chr12:82215192	G/A	cg07988820	chr12:82153109	PPFIA2	-0.49	-8.33	-0.31	4.84e-16	Resting heart rate;
BRCA	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg04455712	chr21:45112962	RRP1B	0.44	11.01	0.4	6.38e-26	Mean corpuscular volume;
BRCA	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.5	0.5	2.14e-41	Personality dimensions;
BRCA	cis	rs6433857	0.657	rs10209994	chr2:181514955	A/C	cg23363182	chr2:181467187	NA	-0.45	-9.49	-0.35	4.64e-20	Body mass index;
BRCA	trans	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg14791747	chr16:20752902	THUMPD1	0.41	9.83	0.36	2.53e-21	Cognitive test performance;
BRCA	cis	rs68170813	0.559	rs6964798	chr7:106933013	C/G	cg02696742	chr7:106810147	HBP1	-0.53	-8.68	-0.32	3.31e-17	Coronary artery disease;
BRCA	cis	rs6429082	0.807	rs4659857	chr1:235581411	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.55	-13.7	-0.48	1.16e-37	Adiposity;
BRCA	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.84e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-7.89	-0.3	1.29e-14	Menopause (age at onset);
BRCA	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg15485101	chr11:133734466	NA	0.41	10.11	0.37	2.08e-22	Childhood ear infection;
BRCA	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19748678	chr4:122722346	EXOSC9	0.74	16.12	0.54	2.75e-49	Type 2 diabetes;
BRCA	cis	rs490234	0.676	rs4838264	chr9:128225561	T/C	cg14078157	chr9:128172775	NA	-0.5	-11.14	-0.4	1.81e-26	Mean arterial pressure;
BRCA	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg04851639	chr8:1020857	NA	-0.36	-10.11	-0.37	2.23e-22	Schizophrenia;
BRCA	cis	rs6426558	0.537	rs6685823	chr1:227270835	A/G	cg10327440	chr1:227177885	CDC42BPA	0.48	9.56	0.35	2.52e-20	Neutrophil percentage of white cells;
BRCA	cis	rs1018836	0.923	rs10956748	chr8:91621537	T/A	cg16814680	chr8:91681699	NA	-0.6	-12.89	-0.45	6.02e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs847649	0.732	rs56269620	chr7:102489456	A/G	cg18108683	chr7:102477205	FBXL13	-0.53	-13.49	-0.47	1.1e-36	Morning vs. evening chronotype;
BRCA	cis	rs68170813	0.559	rs7793594	chr7:106891829	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.44	-0.32	2.05e-16	Coronary artery disease;
BRCA	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg10253484	chr15:75165896	SCAMP2	-0.5	-9.63	-0.36	1.35e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs16958440	0.867	rs79078752	chr18:44667462	A/G	cg17192377	chr18:44677553	HDHD2	0.99	13.87	0.48	1.94e-38	Sitting height ratio;
BRCA	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg08061076	chr7:1943177	MAD1L1	0.35	8.01	0.3	5.57e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg27170947	chr2:26402098	FAM59B	-0.65	-11.14	-0.4	1.76e-26	Gut microbiome composition (summer);
BRCA	cis	rs887829	0.588	rs6715325	chr2:234635241	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.35	-9.24	-0.34	3.52e-19	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs6433895	0.809	rs35323141	chr2:181996558	C/G	cg00481216	chr2:181971175	NA	0.41	9.43	0.35	7.22e-20	Lymphocyte counts;
BRCA	cis	rs3771570	1.000	rs56363214	chr2:242227157	A/G	cg21155796	chr2:242212141	HDLBP	0.59	9.34	0.35	1.52e-19	Prostate cancer;
BRCA	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg07169764	chr2:136633963	MCM6	1.06	20.03	0.62	1.27e-69	Corneal structure;
BRCA	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08564027	chr20:61660810	NA	0.82	21.9	0.65	9.93e-80	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg21573476	chr21:45109991	RRP1B	-0.33	-8.69	-0.32	3.15e-17	Mean corpuscular volume;
BRCA	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg08859206	chr1:53392774	SCP2	-0.63	-13.88	-0.48	1.74e-38	Monocyte count;
BRCA	cis	rs9831754	0.906	rs4680929	chr3:78387591	T/A	cg06138941	chr3:78371609	NA	-0.76	-16.44	-0.55	6.71e-51	Calcium levels;
BRCA	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	ch.11.42038R	chr11:967971	AP2A2	0.52	16.68	0.55	4.17e-52	Alzheimer's disease (late onset);
BRCA	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg16339924	chr4:17578868	LAP3	0.76	19.13	0.6	8.22e-65	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9976767	0.637	rs2156309	chr21:43824529	G/A	cg23042151	chr21:43824109	UBASH3A	-0.27	-8.6	-0.32	6.12e-17	Type 1 diabetes;
BRCA	cis	rs4865169	0.623	rs6838975	chr4:57739816	G/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.33	-7.81	-0.3	2.33e-14	Breast cancer;
BRCA	cis	rs6546550	0.835	rs3752781	chr2:70124316	T/A	cg02498382	chr2:70120550	SNRNP27	-0.52	-11.31	-0.41	3.74e-27	Prevalent atrial fibrillation;
BRCA	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg08668359	chr10:1443807	ADARB2	-0.45	-8.4	-0.32	2.82e-16	Radiation response;
BRCA	cis	rs897080	0.515	rs696595	chr2:44682692	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	9.2	0.34	4.95e-19	Height;
BRCA	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.84	0.36	2.36e-21	Bipolar disorder;
BRCA	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg17971929	chr21:40555470	PSMG1	-0.47	-10.42	-0.38	1.38e-23	Menarche (age at onset);
BRCA	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4853036	1.000	rs35002543	chr2:70091299	A/G	cg02498382	chr2:70120550	SNRNP27	-0.5	-9.07	-0.34	1.49e-18	Colorectal or endometrial cancer;
BRCA	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg09307838	chr4:120376055	NA	-0.49	-9.2	-0.34	5.12e-19	Corneal astigmatism;
BRCA	cis	rs11718455	0.767	rs6771202	chr3:43990087	A/T	cg08738300	chr3:44038990	NA	0.48	8.96	0.33	3.48e-18	Coronary artery disease;
BRCA	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg17158414	chr2:27665306	KRTCAP3	0.31	7.84	0.3	1.89e-14	Total body bone mineral density;
BRCA	cis	rs6840258	1.000	rs17701999	chr4:87955544	C/T	cg08197287	chr4:87952173	AFF1	-0.44	-8.95	-0.33	3.86e-18	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg06115741	chr20:33292138	TP53INP2	0.49	10.74	0.39	7.34e-25	Coronary artery disease;
BRCA	trans	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg00938859	chr5:1591904	SDHAP3	0.67	9.14	0.34	8.3e-19	Breast cancer;
BRCA	cis	rs4363385	0.818	rs451939	chr1:153006877	C/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg25356066	chr3:128598488	ACAD9	0.37	8.57	0.32	7.54e-17	IgG glycosylation;
BRCA	cis	rs1568889	1.000	rs11602768	chr11:28351786	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	13.2	0.46	2.45e-35	Bipolar disorder;
BRCA	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-11.2	-0.41	1e-26	Alzheimer's disease;
BRCA	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg02248941	chr16:2239361	CASKIN1	0.62	15.27	0.52	4.3e-45	Height;
BRCA	cis	rs1506636	1.000	rs676755	chr7:123439082	A/G	cg03229431	chr7:123269106	ASB15	-0.56	-12.44	-0.44	6.02e-32	Plateletcrit;Platelet count;
BRCA	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg22920501	chr2:26401640	FAM59B	0.79	11.46	0.41	8.77e-28	Gut microbiome composition (summer);
BRCA	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg23711669	chr6:146136114	FBXO30	0.79	19.46	0.61	1.38e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg01448562	chr3:133502909	NA	0.62	15.05	0.51	4.7e-44	Iron status biomarkers;
BRCA	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg24130564	chr14:104152367	KLC1	-0.41	-8.68	-0.32	3.26e-17	Reticulocyte count;
BRCA	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg10223061	chr2:219282414	VIL1	0.3	8.36	0.31	3.92e-16	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg07169764	chr2:136633963	MCM6	1.08	23.95	0.69	5.98e-91	Corneal structure;
BRCA	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg24803719	chr17:45855879	NA	-0.33	-8.71	-0.33	2.68e-17	IgG glycosylation;
BRCA	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14442939	chr10:27389572	ANKRD26	0.64	10.93	0.4	1.33e-25	Breast cancer;
BRCA	cis	rs477692	0.507	rs7080570	chr10:131455328	C/T	cg05714579	chr10:131428358	MGMT	-0.39	-8.75	-0.33	1.96e-17	Response to temozolomide;
BRCA	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg01448562	chr3:133502909	NA	-0.75	-19.5	-0.61	8.07e-67	Iron status biomarkers;
BRCA	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg20701182	chr2:24300061	SF3B14	0.58	9.09	0.34	1.25e-18	Lymphocyte counts;
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg25703541	chr22:24373054	LOC391322	0.93	24.82	0.7	1.02e-95	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4727443	0.866	rs13238380	chr7:99629061	C/T	cg22004693	chr7:99632812	ZKSCAN1	0.4	9.05	0.34	1.7e-18	Interstitial lung disease;
BRCA	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg27661571	chr11:113659931	NA	-0.83	-12.08	-0.43	2.16e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg07148914	chr20:33460835	GGT7	0.41	9.16	0.34	7.04e-19	Height;
BRCA	cis	rs6761276	0.649	rs3811057	chr2:113831188	C/A	cg12858261	chr2:113808755	IL1F8	0.43	8.53	0.32	1.1e-16	Protein quantitative trait loci;
BRCA	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.34	9.18	0.34	5.69e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg23625390	chr15:77176239	SCAPER	-0.57	-14.08	-0.49	2.07e-39	Blood metabolite levels;
BRCA	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg06766960	chr11:133703094	NA	0.44	10.18	0.37	1.21e-22	Childhood ear infection;
BRCA	cis	rs7178375	0.607	rs7171212	chr15:31207711	C/T	cg15020726	chr15:31196382	MTMR15	0.5	7.84	0.3	1.9e-14	Hypertriglyceridemia;
BRCA	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	26.73	0.73	3.22e-106	Chronic sinus infection;
BRCA	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg20503657	chr10:835505	NA	0.83	14.86	0.51	3.99e-43	Eosinophil percentage of granulocytes;
BRCA	trans	rs7746199	0.673	rs72847313	chr6:27730082	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.85	-0.33	8.51e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.15	-0.49	9.24e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg13852791	chr20:30311386	BCL2L1	0.83	16.13	0.54	2.32e-49	Mean corpuscular hemoglobin;
BRCA	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg09307838	chr4:120376055	NA	0.65	13.19	0.46	2.55e-35	Corneal astigmatism;
BRCA	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	11.22	0.41	8.98e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10129255	0.500	rs6576226	chr14:107186374	G/A	cg07958169	chr14:107095056	NA	-0.4	-8.67	-0.32	3.43e-17	Kawasaki disease;
BRCA	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg21856205	chr7:94953877	PON1	-0.37	-7.97	-0.3	7.26e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6484504	0.625	rs10835766	chr11:31374329	C/A	cg06552810	chr11:31128660	NA	0.38	8.69	0.32	3.14e-17	Red blood cell count;
BRCA	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg24642439	chr20:33292090	TP53INP2	0.61	13.64	0.47	2.22e-37	Coronary artery disease;
BRCA	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.87	-0.33	7.13e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	8.74	0.33	2.06e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg03676636	chr4:99064102	C4orf37	0.21	7.98	0.3	6.8e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21659725	chr3:3221576	CRBN	-0.48	-10.32	-0.38	3.26e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg21770322	chr7:97807741	LMTK2	0.42	11.31	0.41	3.74e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.48	9.61	0.36	1.64e-20	Tonsillectomy;
BRCA	cis	rs897080	0.515	rs1067321	chr2:44631312	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.76	0.33	1.68e-17	Height;
BRCA	trans	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg25214090	chr10:38739885	LOC399744	0.47	11.01	0.4	6.46e-26	Corneal astigmatism;
BRCA	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg21573476	chr21:45109991	RRP1B	-0.37	-9.68	-0.36	9e-21	Mean corpuscular volume;
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg07308232	chr7:1071921	C7orf50	-0.44	-9.58	-0.35	2.17e-20	Longevity;Endometriosis;
BRCA	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg06970220	chr1:156163860	SLC25A44	0.39	9.58	0.35	2.19e-20	Testicular germ cell tumor;
BRCA	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg24060327	chr5:131705240	SLC22A5	-0.48	-10.17	-0.37	1.28e-22	Blood metabolite levels;
BRCA	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg02773041	chr1:40204384	PPIE	0.45	9.74	0.36	5.51e-21	Blood protein levels;
BRCA	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg03808351	chr9:123631620	PHF19	0.39	7.87	0.3	1.53e-14	Rheumatoid arthritis;
BRCA	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg07148914	chr20:33460835	GGT7	0.4	8.88	0.33	6.55e-18	Height;
BRCA	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg23029597	chr12:123009494	RSRC2	-0.66	-12.03	-0.43	3.32e-30	Body mass index;
BRCA	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg26384229	chr12:38710491	ALG10B	0.83	22.45	0.66	9.57e-83	Heart rate;
BRCA	cis	rs6977660	0.619	rs10231972	chr7:19789354	C/G	cg05791153	chr7:19748676	TWISTNB	0.47	9.43	0.35	7.67e-20	Thyroid stimulating hormone;
BRCA	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg14675211	chr2:100938903	LONRF2	0.52	11.7	0.42	9.01e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-15.95	-0.53	1.75e-48	Heart rate;
BRCA	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg08422745	chr4:174089978	GALNT7	0.78	16.14	0.54	2.09e-49	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08564027	chr20:61660810	NA	0.85	23.01	0.67	7.95e-86	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg26384229	chr12:38710491	ALG10B	0.6	13.57	0.47	4.75e-37	Morning vs. evening chronotype;
BRCA	cis	rs758324	0.947	rs28537859	chr5:131237277	C/G	cg06307176	chr5:131281290	NA	-0.53	-10.21	-0.37	8.61e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs1865721	0.804	rs3826652	chr18:73142153	C/T	cg26385618	chr18:73139727	C18orf62	0.39	10.0	0.37	5.85e-22	Intelligence;
BRCA	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg08992911	chr2:238395768	MLPH	-0.37	-8.2	-0.31	1.35e-15	Prostate cancer;
BRCA	cis	rs528301	0.555	rs340514	chr2:45189011	C/T	cg02372786	chr2:45167549	SIX3	-0.43	-9.47	-0.35	5.54e-20	Alcohol and nicotine co-dependence;
BRCA	cis	rs12541635	1.000	rs1540420	chr8:107088426	C/T	cg10147462	chr8:107024639	NA	-0.3	-8.36	-0.31	4e-16	Age of smoking initiation;
BRCA	trans	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.46	-9.16	-0.34	6.83e-19	Mean corpuscular volume;
BRCA	cis	rs350251	0.868	rs350278	chr16:12232402	T/C	cg06014057	chr16:12226852	SNX29	0.29	7.93	0.3	9.65e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg02951883	chr7:2050386	MAD1L1	-0.49	-10.78	-0.39	5.03e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg16405210	chr4:1374714	KIAA1530	-0.91	-22.72	-0.67	3.2e-84	Longevity;
BRCA	cis	rs778371	0.697	rs2344613	chr2:233603065	C/G	cg08000102	chr2:233561755	GIGYF2	0.78	17.25	0.56	5.08e-55	Schizophrenia;
BRCA	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.4	8.02	0.3	4.95e-15	Tonsillectomy;
BRCA	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg07945448	chr16:4304224	NA	0.48	9.89	0.36	1.46e-21	Prostate-specific antigen levels;
BRCA	cis	rs58235267	0.553	rs11890276	chr2:63366191	C/T	cg17519650	chr2:63277830	OTX1	0.43	9.18	0.34	5.68e-19	Prostate-specific antigen levels (conditioned on lead SNPs);
BRCA	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg01256987	chr12:42539512	GXYLT1	-0.42	-8.23	-0.31	1.04e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs12618769	0.625	rs3769717	chr2:99124817	G/A	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs4853036	0.597	rs1048165	chr2:70131964	A/C	cg02498382	chr2:70120550	SNRNP27	-0.53	-9.52	-0.35	3.52e-20	Colorectal or endometrial cancer;
BRCA	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.15	0.31	1.97e-15	Breast cancer;
BRCA	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg01448562	chr3:133502909	NA	-0.39	-8.93	-0.33	4.53e-18	Iron status biomarkers;
BRCA	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg01256987	chr12:42539512	GXYLT1	-0.57	-11.71	-0.42	7.85e-29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg03188948	chr7:1209495	NA	0.84	11.6	0.42	2.4e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg22920501	chr2:26401640	FAM59B	0.72	12.28	0.44	2.87e-31	Gut microbiome composition (summer);
BRCA	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg06623918	chr6:96969491	KIAA0776	-0.92	-27.15	-0.73	1.64e-108	Headache;
BRCA	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.64	-17.7	-0.57	2.43e-57	Schizophrenia;
BRCA	cis	rs9309711	0.772	rs9309715	chr2:3492318	C/G	cg10845886	chr2:3471009	TTC15	0.74	15.5	0.52	2.99e-46	Neurofibrillary tangles;
BRCA	cis	rs1595825	0.891	rs7587716	chr2:198630667	G/T	cg19156104	chr2:198669113	PLCL1	-0.44	-8.33	-0.31	4.87e-16	Ulcerative colitis;
BRCA	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg05340658	chr4:99064831	C4orf37	-0.43	-9.8	-0.36	3.27e-21	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7561273	0.586	rs9309225	chr2:24292863	T/C	cg04809136	chr2:24300158	SF3B14	-0.4	-9.28	-0.34	2.62e-19	Quantitative traits;
BRCA	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg04317338	chr11:64019027	PLCB3	0.55	9.52	0.35	3.59e-20	Mean platelet volume;
BRCA	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg09307838	chr4:120376055	NA	0.69	14.11	0.49	1.45e-39	Corneal astigmatism;
BRCA	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg05340658	chr4:99064831	C4orf37	0.45	10.14	0.37	1.62e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg15934090	chr1:100435551	SLC35A3	0.36	8.39	0.32	3.12e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg21747090	chr2:27597821	SNX17	-0.44	-9.52	-0.35	3.51e-20	Total body bone mineral density;
BRCA	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg13852791	chr20:30311386	BCL2L1	0.89	20.27	0.63	6.31e-71	Subcortical brain region volumes;Putamen volume;
BRCA	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.78	0.62	2.8e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	ch.11.42038R	chr11:967971	AP2A2	0.52	16.55	0.55	1.84e-51	Alzheimer's disease (late onset);
BRCA	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg04455712	chr21:45112962	RRP1B	0.44	11.66	0.42	1.29e-28	Mean corpuscular volume;
BRCA	cis	rs4302748	0.862	rs11971724	chr7:36184708	T/C	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg26446133	chr18:72167187	CNDP2	-0.53	-12.61	-0.45	1.08e-32	Refractive error;
BRCA	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg11584989	chr19:19387371	SF4	0.64	13.59	0.47	3.82e-37	Bipolar disorder;
BRCA	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg00409905	chr10:38381863	ZNF37A	0.52	11.12	0.4	2.24e-26	Extrinsic epigenetic age acceleration;
BRCA	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21659725	chr3:3221576	CRBN	0.45	11.31	0.41	3.64e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs7809950	0.678	rs79902674	chr7:106866498	A/C	cg23024343	chr7:107201750	COG5	-0.44	-8.84	-0.33	9.51e-18	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg21535247	chr6:8435926	SLC35B3	-0.4	-9.04	-0.34	1.82e-18	Motion sickness;
BRCA	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg04267008	chr7:1944627	MAD1L1	-0.51	-11.11	-0.4	2.45e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	17.72	0.57	1.83e-57	Electrocardiographic conduction measures;
BRCA	trans	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg21659725	chr3:3221576	CRBN	-0.46	-9.91	-0.36	1.27e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg11062466	chr8:58055876	NA	0.5	8.75	0.33	1.83e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4742903	0.904	rs10991167	chr9:106974382	C/T	cg14250997	chr9:106856677	SMC2	-0.3	-9.39	-0.35	1.02e-19	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs7809950	0.954	rs2894466	chr7:107242909	G/A	cg23024343	chr7:107201750	COG5	0.42	9.18	0.34	5.8e-19	Coronary artery disease;
BRCA	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg05279229	chr7:1896384	MAD1L1	-0.41	-7.85	-0.3	1.73e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg04705435	chr11:17411270	KCNJ11	0.38	8.17	0.31	1.71e-15	Type 2 diabetes;
BRCA	cis	rs5167	0.504	rs7246900	chr19:45454236	G/A	cg13119609	chr19:45449297	APOC2	0.47	12.99	0.46	2e-34	Blood protein levels;
BRCA	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg13010199	chr12:38710504	ALG10B	0.42	8.83	0.33	9.68e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7727544	0.582	rs2301579	chr5:131553340	C/A	cg14196790	chr5:131705035	SLC22A5	0.35	8.98	0.33	3.07e-18	Blood metabolite levels;
BRCA	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg12444411	chr7:2802554	GNA12	-0.35	-8.37	-0.31	3.56e-16	Height;
BRCA	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.01	0.3	5.39e-15	Breast cancer;
BRCA	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg01939980	chr4:1354348	KIAA1530	0.36	9.9	0.36	1.32e-21	Longevity;
BRCA	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg19920283	chr7:105172520	RINT1	0.61	9.53	0.35	3.16e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-8.3	-0.31	6.13e-16	Monocyte percentage of white cells;
BRCA	cis	rs17253792	0.822	rs78522049	chr14:56071203	A/C	cg01858014	chr14:56050164	KTN1	-0.78	-11.08	-0.4	3.12e-26	Putamen volume;
BRCA	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11764359	chr7:65958608	NA	-0.79	-19.5	-0.61	8.84e-67	Aortic root size;
BRCA	trans	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	8.55e-21	Bladder cancer;
BRCA	cis	rs1904096	0.506	rs4558832	chr4:95148042	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.1	-0.37	2.47e-22	Type 2 diabetes;
BRCA	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg26384229	chr12:38710491	ALG10B	0.57	13.16	0.46	3.66e-35	Morning vs. evening chronotype;
BRCA	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg04450456	chr4:17643702	FAM184B	0.42	12.73	0.45	3.07e-33	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs41005	0.967	rs193928	chr2:8107899	T/C	cg03155496	chr2:8117019	LOC339788	0.56	14.78	0.5	1e-42	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs600806	0.778	rs1525916	chr1:110010949	A/G	cg20591472	chr1:110008990	SYPL2	0.31	7.91	0.3	1.1e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg01877450	chr7:97915802	BRI3	-0.38	-8.49	-0.32	1.47e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg01689657	chr7:91764605	CYP51A1	0.23	8.09	0.3	2.92e-15	Breast cancer;
BRCA	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.49	-0.32	1.46e-16	Breast cancer;
BRCA	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg13628971	chr7:2884303	GNA12	0.55	12.38	0.44	1.07e-31	Height;
BRCA	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg04362960	chr10:104952993	NT5C2	-0.44	-9.95	-0.37	8.45e-22	Arsenic metabolism;
BRCA	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.36	-8.14	-0.31	2.08e-15	High light scatter reticulocyte count;
BRCA	cis	rs7524258	0.835	rs7521425	chr1:7306543	C/T	cg07173049	chr1:7289937	CAMTA1	0.41	9.9	0.36	1.41e-21	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg11789530	chr4:8429930	ACOX3	0.59	14.87	0.51	3.54e-43	Response to antineoplastic agents;
BRCA	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07636037	chr3:49044803	WDR6	-0.71	-15.29	-0.52	3.47e-45	Menarche (age at onset);
BRCA	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg02659138	chr7:134003124	SLC35B4	0.36	11.23	0.41	7.6e-27	Mean platelet volume;
BRCA	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg08917208	chr2:24149416	ATAD2B	0.55	8.44	0.32	2.15e-16	Lymphocyte counts;
BRCA	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg13073564	chr4:8508604	NA	0.45	12.28	0.44	2.8e-31	Response to antineoplastic agents;
BRCA	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg12011299	chr4:100065546	ADH4	-0.49	-11.63	-0.42	1.76e-28	Alcohol dependence;
BRCA	cis	rs4363385	0.720	rs1415968	chr1:152970219	C/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.88	-0.33	6.69e-18	Inflammatory skin disease;
BRCA	trans	rs6479891	1.000	rs61853336	chr10:64899875	G/A	cg14819942	chr15:35414228	NA	0.35	8.58	0.32	7.14e-17	Arthritis (juvenile idiopathic);
BRCA	trans	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg06636001	chr8:8085503	FLJ10661	0.42	8.57	0.32	7.71e-17	Neuroticism;
BRCA	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg00852783	chr1:26633632	UBXN11	0.5	10.82	0.39	3.46e-25	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4845875	0.564	rs2151655	chr1:11845518	G/C	cg24844545	chr1:11908347	NPPA	0.36	8.42	0.32	2.49e-16	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg21573476	chr21:45109991	RRP1B	0.37	9.36	0.35	1.39e-19	Mean corpuscular volume;
BRCA	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg01324343	chr3:183735012	ABCC5	0.77	19.16	0.6	5.28e-65	Anterior chamber depth;
BRCA	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	10.5	0.38	6.54e-24	Rheumatoid arthritis;
BRCA	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	12.02	0.43	3.77e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg21475434	chr5:93447410	FAM172A	0.67	8.62	0.32	5.45e-17	Diabetic retinopathy;
BRCA	cis	rs1044826	0.553	rs295469	chr3:139212900	G/A	cg00490450	chr3:139108681	COPB2	0.43	8.28	0.31	7.14e-16	Obesity-related traits;
BRCA	cis	rs4363385	0.791	rs4041401	chr1:152985629	A/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.42	-0.32	2.39e-16	Inflammatory skin disease;
BRCA	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg16325326	chr1:53192061	ZYG11B	0.53	11.66	0.42	1.34e-28	Monocyte count;
BRCA	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.46	-9.29	-0.35	2.3e-19	Menarche (age at onset);
BRCA	cis	rs2625529	0.818	rs16956241	chr15:72111688	G/T	cg16672083	chr15:72433130	SENP8	-0.8	-16.28	-0.54	4.18e-50	Red blood cell count;
BRCA	cis	rs7178424	0.742	rs12911564	chr15:62211976	G/A	cg00456672	chr15:62358751	C2CD4A	0.38	9.35	0.35	1.5e-19	Height;
BRCA	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.72	0.42	7.23e-29	Tonsillectomy;
BRCA	cis	rs4664304	0.620	rs11675122	chr2:160713446	C/A	cg14819504	chr2:160761413	LY75	0.34	8.26	0.31	8.28e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg15212455	chr7:39170539	POU6F2	0.39	8.6	0.32	6.16e-17	IgG glycosylation;
BRCA	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg20203395	chr5:56204925	C5orf35	0.63	12.44	0.44	5.79e-32	Initial pursuit acceleration;
BRCA	cis	rs7520050	0.966	rs61102033	chr1:46382441	G/T	cg24296786	chr1:45957014	TESK2	0.43	9.74	0.36	5.25e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7567389	0.740	rs4536600	chr2:128002572	A/G	cg09760422	chr2:128146352	NA	0.39	8.5	0.32	1.3e-16	Self-rated health;
BRCA	cis	rs6066835	1.000	rs6125439	chr20:47314634	G/A	cg18078177	chr20:47281410	PREX1	0.69	8.04	0.3	4.27e-15	Multiple myeloma;
BRCA	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg04362960	chr10:104952993	NT5C2	0.46	10.7	0.39	1.08e-24	Arsenic metabolism;
BRCA	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg22875332	chr1:76189707	ACADM	0.57	9.68	0.36	9.28e-21	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs11039798	1.000	rs10838918	chr11:48507449	A/G	cg15704280	chr7:45808275	SEPT13	0.57	8.44	0.32	2.16e-16	Axial length;
BRCA	cis	rs10189230	0.967	rs12613015	chr2:222356119	G/A	cg14652038	chr2:222343519	EPHA4	0.47	13.06	0.46	9.99e-35	Urate levels in lean individuals;
BRCA	trans	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg26043149	chr18:55253948	FECH	1.04	21.65	0.65	2.17e-78	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs6809651	0.524	rs4686730	chr3:185805993	C/T	cg00760338	chr3:185826511	ETV5	-0.49	-10.03	-0.37	4.36e-22	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
BRCA	cis	rs1997103	0.906	rs4618644	chr7:55402037	T/G	cg17469321	chr7:55412551	NA	0.51	9.72	0.36	6.37e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg07917127	chr4:99064746	C4orf37	0.42	8.01	0.3	5.26e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg03676636	chr4:99064102	C4orf37	0.21	7.97	0.3	7.55e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg22705602	chr4:152727874	NA	-0.32	-8.0	-0.3	5.82e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg15556689	chr8:8085844	FLJ10661	-0.36	-9.84	-0.36	2.27e-21	Mood instability;
BRCA	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.21	-0.34	4.57e-19	Alzheimer's disease (late onset);
BRCA	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.67	-16.03	-0.54	7.19e-49	Ulcerative colitis;
BRCA	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	18.86	0.6	2.15e-63	Alzheimer's disease;
BRCA	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.88	0.33	6.7e-18	Platelet count;
BRCA	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg05457628	chr5:178986728	RUFY1	-0.53	-13.46	-0.47	1.59e-36	Lung cancer;
BRCA	trans	rs2018683	0.649	rs221171	chr7:29006139	C/G	cg19402173	chr7:128379420	CALU	0.37	8.03	0.3	4.59e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs6901250	0.788	rs591794	chr6:117089018	G/A	cg12892004	chr6:117198278	RFX6	0.46	10.66	0.39	1.57e-24	C-reactive protein levels;
BRCA	cis	rs490234	0.966	rs530628	chr9:128325934	C/G	cg14078157	chr9:128172775	NA	-0.33	-8.0	-0.3	5.82e-15	Mean arterial pressure;
BRCA	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg05340658	chr4:99064831	C4orf37	0.53	8.75	0.33	1.91e-17	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg23029597	chr12:123009494	RSRC2	-0.63	-12.61	-0.45	1.06e-32	Body mass index;
BRCA	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10802521	chr3:52805072	NEK4	-0.34	-9.36	-0.35	1.29e-19	Bipolar disorder;
BRCA	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg23649088	chr2:200775458	C2orf69	0.6	9.09	0.34	1.21e-18	Schizophrenia;
BRCA	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg06671706	chr8:8559999	CLDN23	0.45	8.77	0.33	1.57e-17	Obesity-related traits;
BRCA	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.46	8.02	0.3	4.98e-15	Mean platelet volume;
BRCA	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg18252515	chr7:66147081	NA	-0.84	-12.12	-0.43	1.34e-30	Diabetic kidney disease;
BRCA	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.02	-0.34	2.13e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs12541635	0.966	rs56352125	chr8:107041831	G/T	cg10147462	chr8:107024639	NA	0.37	9.72	0.36	6.3e-21	Age of smoking initiation;
BRCA	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	10.39	0.38	1.88e-23	Bone mineral density;
BRCA	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg00701064	chr4:6280414	WFS1	0.68	17.68	0.57	3.11e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg10818794	chr15:86012489	AKAP13	0.4	10.88	0.4	2.13e-25	Coronary artery disease;
BRCA	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg12379764	chr21:47803548	PCNT	-0.37	-7.84	-0.3	1.84e-14	Testicular germ cell tumor;
BRCA	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.03	-0.34	1.94e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg25358565	chr5:93447407	FAM172A	-0.46	-8.28	-0.31	7.35e-16	Diabetic retinopathy;
BRCA	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg18230493	chr5:56204884	C5orf35	-0.56	-11.87	-0.43	1.66e-29	Coronary artery disease;
BRCA	trans	rs4650994	0.525	rs4650997	chr1:178530744	T/A	cg05059571	chr16:84539110	KIAA1609	-0.57	-12.54	-0.44	1.99e-32	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg18230493	chr5:56204884	C5orf35	-0.55	-11.74	-0.42	6.1e-29	Coronary artery disease;
BRCA	cis	rs6066825	0.605	rs761273	chr20:47315488	A/G	cg18078177	chr20:47281410	PREX1	0.41	10.15	0.37	1.57e-22	Colorectal cancer;
BRCA	trans	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg05926928	chr17:57297772	GDPD1	0.42	8.22	0.31	1.13e-15	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
BRCA	cis	rs9309473	0.606	rs78941213	chr2:73885137	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.91	-0.3	1.18e-14	Metabolite levels;
BRCA	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-14.06	-0.49	2.43e-39	Platelet count;
BRCA	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg11502198	chr6:26597334	ABT1	0.61	11.56	0.42	3.36e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05901451	chr6:126070800	HEY2	0.4	9.68	0.36	9.01e-21	Endometrial cancer;
BRCA	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.57	0.35	2.33e-20	Morning vs. evening chronotype;
BRCA	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg13256891	chr4:100009986	ADH5	0.52	9.74	0.36	5.31e-21	Smoking initiation;
BRCA	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-8.13	-0.31	2.3e-15	Blood pressure (smoking interaction);
BRCA	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg00071950	chr4:10020882	SLC2A9	0.55	13.19	0.46	2.62e-35	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7598759	0.548	rs1823328	chr2:232355184	G/A	cg19187155	chr2:232395269	NMUR1	0.7	16.77	0.55	1.42e-52	Noise-induced hearing loss;
BRCA	trans	rs7980799	0.935	rs10844580	chr12:33553867	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-8.18	-0.31	1.51e-15	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.94	14.53	0.5	1.5e-41	Body mass index;
BRCA	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg00898013	chr13:113819073	PROZ	-0.35	-8.92	-0.33	4.96e-18	Platelet distribution width;
BRCA	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg24692254	chr21:30365293	RNF160	0.46	10.19	0.37	1.07e-22	Cognitive test performance;
BRCA	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg26597838	chr10:835615	NA	1.29	21.15	0.64	1.22e-75	Eosinophil percentage of granulocytes;
BRCA	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.29	-0.35	2.31e-19	Electroencephalogram traits;
BRCA	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg17788362	chr6:86352627	SYNCRIP	0.39	7.94	0.3	9.07e-15	Smooth-surface caries;
BRCA	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.25	-0.44	3.71e-31	Alzheimer's disease;
BRCA	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg12011299	chr4:100065546	ADH4	0.48	10.87	0.4	2.26e-25	Smoking initiation;
BRCA	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.64	9.67	0.36	9.73e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs28374715	0.662	rs691907	chr15:41474657	C/G	cg18705301	chr15:41695430	NDUFAF1	0.78	16.62	0.55	7.6900000000000007e-52	Ulcerative colitis;
BRCA	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg02659138	chr7:134003124	SLC35B4	0.34	10.79	0.39	4.94e-25	Mean platelet volume;
BRCA	trans	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg14791747	chr16:20752902	THUMPD1	0.4	9.31	0.35	2.11e-19	Cognitive test performance;
BRCA	cis	rs9309473	0.948	rs11884776	chr2:73746923	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-10.92	-0.4	1.43e-25	Metabolite levels;
BRCA	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg09654669	chr8:57350985	NA	-0.38	-8.34	-0.31	4.55e-16	Obesity-related traits;
BRCA	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg16006841	chr5:176797999	RGS14	0.58	11.57	0.42	3.09e-28	Hemoglobin concentration;Hematocrit;
BRCA	trans	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg26043149	chr18:55253948	FECH	-0.41	-9.06	-0.34	1.52e-18	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg12573674	chr2:1569213	NA	-0.49	-9.56	-0.35	2.53e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg03342759	chr3:160939853	NMD3	-0.79	-18.47	-0.59	2.41e-61	Morning vs. evening chronotype;
BRCA	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg15557168	chr22:42548783	NA	-0.31	-8.58	-0.32	7.15e-17	Cognitive function;
BRCA	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg14664628	chr15:75095509	CSK	-0.59	-14.47	-0.5	3.03e-41	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-8.51	-0.32	1.29e-16	Mood instability;
BRCA	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25427524	chr10:38739819	LOC399744	-0.69	-16.76	-0.55	1.62e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1829883	0.835	rs2460664	chr5:98802442	C/T	cg08333243	chr5:99726346	NA	-0.35	-7.81	-0.3	2.39e-14	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs4074536	0.574	rs10754354	chr1:116292402	A/G	cg21648376	chr1:116311395	CASQ2	-0.49	-8.63	-0.32	4.94e-17	QRS duration;
BRCA	trans	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg06521331	chr12:34319734	NA	-0.52	-9.45	-0.35	6.17e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs701145	0.585	rs1624917	chr3:153827300	T/A	cg12800244	chr3:153838788	SGEF	0.63	7.87	0.3	1.47e-14	Coronary artery disease;
BRCA	cis	rs7598759	0.712	rs6727372	chr2:232331906	T/G	cg19187155	chr2:232395269	NMUR1	0.37	7.83	0.3	2.08e-14	Noise-induced hearing loss;
BRCA	trans	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg26043149	chr18:55253948	FECH	-0.37	-8.14	-0.31	2e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg05623727	chr3:50126028	RBM5	0.44	10.43	0.38	1.22e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.47	9.63	0.36	1.39e-20	Menarche (age at onset);
BRCA	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	9.9	0.36	1.38e-21	Aortic root size;
BRCA	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg09537434	chr19:41945824	ATP5SL	-0.96	-23.21	-0.68	6.54e-87	Height;
BRCA	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg00686598	chr14:53173677	PSMC6	1.25	16.37	0.54	1.43e-50	Alzheimer's disease (late onset);
BRCA	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg22800045	chr5:56110881	MAP3K1	0.67	12.89	0.45	5.7e-34	Initial pursuit acceleration;
BRCA	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg11845111	chr2:191398756	TMEM194B	0.41	9.23	0.34	3.9e-19	Pulse pressure;
BRCA	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.68e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg01304814	chr3:48885189	PRKAR2A	0.7	7.91	0.3	1.13e-14	Cognitive function;
BRCA	trans	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17712092	chr4:129076599	LARP1B	0.56	13.38	0.47	3.54e-36	Breast cancer;
BRCA	cis	rs919433	0.679	rs10203581	chr2:198515900	G/A	cg00792783	chr2:198669748	PLCL1	0.4	9.0	0.34	2.59e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs3936840	0.565	rs8006911	chr14:102975265	A/G	cg18135206	chr14:102964638	TECPR2	0.53	10.87	0.39	2.34e-25	Plateletcrit;
BRCA	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg05083358	chr7:2394359	EIF3B	-0.51	-8.0	-0.3	5.66e-15	Multiple sclerosis;
BRCA	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg22601191	chr20:60968625	CABLES2	0.34	8.61	0.32	5.52e-17	Colorectal cancer;
BRCA	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg13852791	chr20:30311386	BCL2L1	0.79	14.87	0.51	3.55e-43	Mean corpuscular hemoglobin;
BRCA	cis	rs724568	0.546	rs10188512	chr2:67940962	C/T	cg14046302	chr2:67939758	NA	-0.39	-10.68	-0.39	1.3e-24	Major depressive disorder (broad);
BRCA	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg19000871	chr14:103996768	TRMT61A	0.47	10.55	0.39	4.13e-24	Coronary artery disease;
BRCA	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	18.07	0.58	2.92e-59	Platelet count;
BRCA	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg19336497	chr11:14380999	RRAS2	-0.44	-11.75	-0.42	5.16e-29	Vitamin D levels;
BRCA	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	10.27	0.38	5.32e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.87	0.36	1.75e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg23711669	chr6:146136114	FBXO30	0.71	16.36	0.54	1.66e-50	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6942407	0.546	rs765968	chr7:86794724	G/A	cg02420886	chr7:86849541	C7orf23	0.52	7.81	0.3	2.31e-14	Food allergy;
BRCA	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.05	-0.34	1.65e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg27170947	chr2:26402098	FAM59B	-0.7	-11.84	-0.42	2.14e-29	Gut microbiome composition (summer);
BRCA	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	16.44	0.55	6.19e-51	Lymphocyte counts;
BRCA	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg18402987	chr7:1209562	NA	0.84	12.05	0.43	2.92e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg17063962	chr7:91808500	NA	0.53	12.48	0.44	3.84e-32	Breast cancer;
BRCA	cis	rs9807989	0.507	rs2287033	chr2:103011237	C/T	cg03938978	chr2:103052716	IL18RAP	-0.29	-8.4	-0.32	2.89e-16	Asthma;
BRCA	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg25811766	chr13:21894605	NA	0.59	9.22	0.34	4.15e-19	White matter hyperintensity burden;
BRCA	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg13770153	chr20:60521292	NA	-0.42	-9.35	-0.35	1.43e-19	Body mass index;
BRCA	cis	rs17401966	0.838	rs11579365	chr1:10470846	G/T	cg19773385	chr1:10388646	KIF1B	-0.37	-7.98	-0.3	6.94e-15	Hepatocellular carcinoma;
BRCA	cis	rs7572733	0.534	rs700667	chr2:198677508	T/C	cg00792783	chr2:198669748	PLCL1	0.47	10.22	0.37	8.54e-23	Dermatomyositis;
BRCA	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg01884057	chr2:25150051	NA	0.31	8.31	0.31	5.61e-16	Body mass index in non-asthmatics;
BRCA	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.16e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg06212747	chr3:49208901	KLHDC8B	0.42	8.19	0.31	1.4e-15	Parkinson's disease;
BRCA	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg24006582	chr15:45444508	DUOX1	-0.56	-11.72	-0.42	7.49e-29	Uric acid levels;
BRCA	cis	rs6840258	1.000	rs55787557	chr4:87950825	A/G	cg08197287	chr4:87952173	AFF1	-0.44	-8.8	-0.33	1.25e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs13046373	0.535	rs13051135	chr21:32005278	G/A	cg16812893	chr21:31813075	KRTAP15-1	0.38	9.55	0.35	2.76e-20	HDL cholesterol;
BRCA	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	12.18	0.43	7.79e-31	Personality dimensions;
BRCA	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg02221750	chr19:17393354	ANKLE1	-0.66	-12.83	-0.45	1.07e-33	Systemic lupus erythematosus;
BRCA	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg05347473	chr6:146136440	FBXO30	0.4	8.11	0.31	2.64e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs877529	0.967	rs139400	chr22:39545396	C/T	cg18708252	chr22:39545030	CBX7	-0.31	-7.93	-0.3	9.74e-15	Multiple myeloma;
BRCA	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.54	8.35	0.31	4.1e-16	Schizophrenia;
BRCA	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-11.39	-0.41	1.64e-27	Mood instability;
BRCA	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.46	9.25	0.34	3.3e-19	Tonsillectomy;
BRCA	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg19748678	chr4:122722346	EXOSC9	0.65	14.23	0.49	4.05e-40	Type 2 diabetes;
BRCA	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.52	-10.31	-0.38	3.56e-23	Body mass index;
BRCA	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18876405	chr7:65276391	NA	0.62	15.21	0.52	8.2e-45	Aortic root size;
BRCA	cis	rs7617773	0.817	rs11928691	chr3:48286765	C/T	cg11946769	chr3:48343235	NME6	0.55	12.13	0.43	1.34e-30	Coronary artery disease;
BRCA	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.2	-0.37	9.64e-23	IgG glycosylation;
BRCA	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg22004693	chr7:99632812	ZKSCAN1	0.53	11.49	0.41	6.53e-28	Lung function (FEV1/FVC);
BRCA	cis	rs12493885	0.697	rs11710478	chr3:153777037	A/C	cg17054900	chr3:154042577	DHX36	-0.5	-8.64	-0.32	4.44e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg24812749	chr6:127587940	RNF146	0.88	20.59	0.63	1.27e-72	Breast cancer;
BRCA	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg02175503	chr12:58329896	NA	0.61	14.45	0.5	3.63e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg12386194	chr3:101231763	SENP7	0.44	8.99	0.34	2.72e-18	Colorectal cancer;
BRCA	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg26384229	chr12:38710491	ALG10B	0.81	20.39	0.63	1.5e-71	Heart rate;
BRCA	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg02556042	chr12:117471086	NA	-0.58	-9.81	-0.36	2.97e-21	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs4919694	0.572	rs72846714	chr10:104878454	G/A	cg04362960	chr10:104952993	NT5C2	0.73	12.72	0.45	3.27e-33	Arsenic metabolism;
BRCA	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18876405	chr7:65276391	NA	0.51	11.56	0.42	3.27e-28	Aortic root size;
BRCA	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg23711669	chr6:146136114	FBXO30	0.71	17.04	0.56	6.13e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg07460842	chr6:66804631	NA	0.97	19.45	0.61	1.52e-66	Exhaled nitric oxide output;
BRCA	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg05552183	chr6:42928497	GNMT	0.8	19.34	0.61	6.32e-66	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg25767906	chr1:53392781	SCP2	-0.37	-8.24	-0.31	9.99e-16	Monocyte count;
BRCA	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs11608355	0.515	rs56244055	chr12:109936211	G/A	cg05360138	chr12:110035743	NA	0.72	13.3	0.47	8.56e-36	Neuroticism;
BRCA	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-11.69	-0.42	9.71e-29	Gut microbiome composition (summer);
BRCA	cis	rs4363385	0.747	rs4568784	chr1:152972694	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-9.24	-0.34	3.72e-19	Inflammatory skin disease;
BRCA	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg25173405	chr17:45401733	C17orf57	0.49	9.94	0.37	9.42e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg07952391	chr2:88470173	THNSL2	-0.4	-8.02	-0.3	5.12e-15	Response to metformin (IC50);
BRCA	cis	rs921968	0.619	rs1554623	chr2:219606177	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-11.16	-0.4	1.59e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.59	-0.52	1.17e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs1003719	1.000	rs1003719	chr21:38491095	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.12	0.49	1.38e-39	Eye color traits;
BRCA	cis	rs6429082	0.967	rs704710	chr1:235621026	A/G	cg26050004	chr1:235667680	B3GALNT2	0.39	9.58	0.35	2.08e-20	Adiposity;
BRCA	cis	rs2522056	1.000	rs1003533	chr5:131755651	C/T	cg24060327	chr5:131705240	SLC22A5	0.5	8.73	0.33	2.21e-17	Lymphocyte counts;Fibrinogen;
BRCA	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Tonsillectomy;
BRCA	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg15556689	chr8:8085844	FLJ10661	0.37	8.74	0.33	2.04e-17	Retinal vascular caliber;
BRCA	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg07423050	chr13:99094983	FARP1	0.5	12.35	0.44	1.46e-31	Neuroticism;
BRCA	trans	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg25214090	chr10:38739885	LOC399744	0.44	10.01	0.37	5.38e-22	Corneal astigmatism;
BRCA	trans	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg19862616	chr7:65841803	NCRNA00174	0.82	26.58	0.72	2.01e-105	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg18964960	chr10:1102726	WDR37	0.53	8.9	0.33	5.93e-18	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg24829409	chr8:58192753	C8orf71	-0.48	-9.25	-0.34	3.23e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg18252515	chr7:66147081	NA	-0.8	-11.18	-0.4	1.23e-26	Diabetic kidney disease;
BRCA	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg23711669	chr6:146136114	FBXO30	0.77	17.59	0.57	8.37e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00166722	chr3:10149974	C3orf24	0.65	13.07	0.46	8.76e-35	Alzheimer's disease;
BRCA	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.74	0.65	7.41e-79	Lymphocyte percentage of white cells;
BRCA	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg05340658	chr4:99064831	C4orf37	0.62	14.72	0.5	1.88e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.66	-0.32	3.74e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg26043149	chr18:55253948	FECH	-0.37	-8.2	-0.31	1.35e-15	Bone mineral density;
BRCA	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg05714579	chr10:131428358	MGMT	0.57	14.08	0.49	2.03e-39	Response to temozolomide;
BRCA	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg14784868	chr12:69753453	YEATS4	0.68	19.81	0.62	1.79e-68	Blood protein levels;
BRCA	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg03342759	chr3:160939853	NMD3	-0.8	-18.87	-0.6	1.83e-63	Parkinson's disease;
BRCA	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg23029597	chr12:123009494	RSRC2	0.59	11.42	0.41	1.35e-27	Body mass index;
BRCA	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg20203395	chr5:56204925	C5orf35	0.41	9.18	0.34	5.91e-19	Initial pursuit acceleration;
BRCA	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg26516362	chr5:178986906	RUFY1	0.44	12.47	0.44	4.14e-32	Lung cancer;
BRCA	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg13854012	chr2:162103682	NA	-0.39	-8.68	-0.32	3.33e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs870825	0.616	rs4264873	chr4:185624336	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg24006582	chr15:45444508	DUOX1	0.54	10.62	0.39	2.17e-24	Uric acid levels;
BRCA	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.95	0.33	3.68e-18	Motion sickness;
BRCA	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg03146154	chr1:46216737	IPP	0.51	11.12	0.4	2.18e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4800452	0.956	rs4239436	chr18:20731930	A/G	cg26136497	chr18:20735537	CABLES1	-0.48	-11.55	-0.42	3.66e-28	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-14.37	-0.49	8.98e-41	Total cholesterol levels;
BRCA	cis	rs332507	0.830	rs13069961	chr3:124358715	A/G	cg05980111	chr3:124395277	KALRN	0.36	8.23	0.31	1.09e-15	Plateletcrit;
BRCA	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-9.66	-0.36	1.07e-20	Schizophrenia;
BRCA	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg11584989	chr19:19387371	SF4	-0.59	-13.22	-0.46	1.98e-35	Bipolar disorder;
BRCA	trans	rs236907	0.812	rs55732843	chr1:171796962	A/G	cg13482142	chr2:234261155	NA	0.51	8.03	0.3	4.68e-15	Mean platelet volume;
BRCA	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg01262667	chr19:19385393	TM6SF2	0.42	10.87	0.39	2.35e-25	Tonsillectomy;
BRCA	cis	rs34779708	0.733	rs4244997	chr10:35547254	T/C	cg03585969	chr10:35415529	CREM	0.44	9.1	0.34	1.17e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg14863265	chr7:2801509	GNA12	-0.42	-9.69	-0.36	8.48e-21	Height;
BRCA	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.49	-9.1	-0.34	1.09e-18	Gut microbiome composition (summer);
BRCA	cis	rs2742540	0.505	rs2742493	chr11:8967592	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.31	7.9	0.3	1.24e-14	Hematocrit;
BRCA	cis	rs367943	0.698	rs728915	chr5:112995748	C/T	cg12552261	chr5:112820674	MCC	0.45	9.45	0.35	6.4e-20	Type 2 diabetes;
BRCA	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22496380	chr5:211416	CCDC127	-1.0	-14.08	-0.49	1.99e-39	Breast cancer;
BRCA	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	17.01	0.56	8.73e-54	Hypertriglyceridemia;
BRCA	cis	rs6580649	0.941	rs4760618	chr12:48434767	G/A	cg24011408	chr12:48396354	COL2A1	-0.48	-7.93	-0.3	9.92e-15	Lung cancer;
BRCA	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg23422044	chr7:1970798	MAD1L1	-0.56	-9.6	-0.35	1.85e-20	Neuroticism;
BRCA	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.72	-13.8	-0.48	4.19e-38	Alzheimer's disease;
BRCA	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.93	-0.33	4.38e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg08601574	chr20:25228251	PYGB	-0.35	-8.36	-0.31	3.88e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg18230493	chr5:56204884	C5orf35	-0.74	-14.73	-0.5	1.73e-42	Initial pursuit acceleration;
BRCA	cis	rs9533799	1.000	rs2282064	chr13:44805870	G/A	cg19190762	chr13:44806055	NA	0.4	8.77	0.33	1.56e-17	Amyotrophic lateral sclerosis;
BRCA	cis	rs2066819	0.786	rs116934693	chr12:56696545	T/G	cg26714650	chr12:56694279	CS	-1.18	-15.46	-0.52	5.14e-46	Psoriasis vulgaris;
BRCA	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg04450456	chr4:17643702	FAM184B	0.31	9.08	0.34	1.37e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg18357645	chr12:58087776	OS9	0.49	13.85	0.48	2.58e-38	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg16482183	chr6:26056742	HIST1H1C	0.45	8.74	0.33	2.11e-17	Iron status biomarkers;
BRCA	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	12.53	0.44	2.22e-32	Calcium levels;
BRCA	cis	rs922182	0.556	rs10851734	chr15:64216247	C/T	cg24729988	chr15:64271149	DAPK2	-0.45	-9.35	-0.35	1.43e-19	Blood protein levels;
BRCA	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02018176	chr4:1364513	KIAA1530	0.4	8.29	0.31	6.87e-16	Longevity;
BRCA	cis	rs4853036	0.723	rs2312557	chr2:70090243	G/A	cg02498382	chr2:70120550	SNRNP27	-0.54	-8.76	-0.33	1.77e-17	Colorectal or endometrial cancer;
BRCA	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.72	-10.3	-0.38	4.11e-23	Initial pursuit acceleration;
BRCA	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg16339924	chr4:17578868	LAP3	0.63	15.73	0.53	2.26e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9880211	1.000	rs17364492	chr3:136204437	G/T	cg21827317	chr3:136751795	NA	0.42	7.82	0.3	2.2e-14	Body mass index;Height;
BRCA	cis	rs6834538	0.965	rs1580476	chr4:113493365	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.38	8.41	0.32	2.66e-16	Free thyroxine concentration;
BRCA	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg25019033	chr10:957182	NA	-0.41	-7.82	-0.3	2.16e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg12310025	chr6:25882481	NA	0.44	9.7	0.36	7.52e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg11814155	chr7:99998594	ZCWPW1	0.46	8.22	0.31	1.16e-15	Platelet count;
BRCA	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg23625390	chr15:77176239	SCAPER	-0.52	-12.72	-0.45	3.52e-33	Blood metabolite levels;
BRCA	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.69	0.5	2.56e-42	Colorectal cancer;
BRCA	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03264133	chr6:25882463	NA	0.43	10.21	0.37	9.03e-23	Blood metabolite levels;
BRCA	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.46	-9.39	-0.35	1e-19	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs6138458	1.000	rs227631	chr20:24913653	A/G	cg26195577	chr20:24973756	C20orf3	0.98	24.67	0.7	6.47e-95	Blood protein levels;
BRCA	cis	rs62458065	0.513	rs787220	chr7:32581139	C/G	cg20159608	chr7:32802032	NA	-0.5	-9.64	-0.36	1.25e-20	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg23029597	chr12:123009494	RSRC2	-0.64	-12.64	-0.45	7.38e-33	Body mass index;
BRCA	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg10729496	chr3:10149963	C3orf24	0.48	9.11	0.34	1.02e-18	Alzheimer's disease;
BRCA	cis	rs4363385	0.747	rs1415970	chr1:152965741	G/C	cg25856811	chr1:152973957	SPRR3	-0.35	-9.44	-0.35	7.12e-20	Inflammatory skin disease;
BRCA	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg23711669	chr6:146136114	FBXO30	0.63	14.06	0.49	2.66e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg26384229	chr12:38710491	ALG10B	-0.47	-11.05	-0.4	4.34e-26	Morning vs. evening chronotype;
BRCA	cis	rs2387326	0.717	rs12261194	chr10:129944464	T/C	cg16087940	chr10:129947807	NA	-0.45	-8.01	-0.3	5.47e-15	Select biomarker traits;
BRCA	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.41	-0.32	2.59e-16	Monocyte percentage of white cells;
BRCA	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	10.01	0.37	5.17e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4363385	0.747	rs1999886	chr1:152955522	T/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.29	-0.34	2.43e-19	Inflammatory skin disease;
BRCA	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg14186256	chr22:23484241	RTDR1	0.8	24.94	0.7	2.24e-96	Bone mineral density;
BRCA	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.43	8.2	0.31	1.33e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg05340658	chr4:99064831	C4orf37	0.55	10.81	0.39	3.79e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs67981189	0.865	rs2810071	chr14:71387648	A/G	cg15816911	chr14:71606274	NA	-0.37	-8.28	-0.31	7.17e-16	Schizophrenia;
BRCA	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg00745463	chr17:30367425	LRRC37B	-0.54	-8.89	-0.33	6.17e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg08807101	chr21:30365312	RNF160	0.53	13.2	0.46	2.43e-35	Dental caries;
BRCA	cis	rs362296	0.661	rs3095079	chr4:3265414	A/G	cg06533319	chr4:3265114	C4orf44	-0.29	-7.83	-0.3	2e-14	Parental longevity (mother's age at death);
BRCA	cis	rs10193935	0.901	rs2374429	chr2:42677888	A/G	cg27598129	chr2:42591480	NA	-0.81	-13.87	-0.48	1.89e-38	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.06	-0.3	3.79e-15	Depression;
BRCA	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	16.96	0.56	1.6e-53	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg16482183	chr6:26056742	HIST1H1C	0.65	13.49	0.47	1.08e-36	Height;
BRCA	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg07080220	chr10:102295463	HIF1AN	0.57	13.04	0.46	1.19e-34	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26314531	chr2:26401878	FAM59B	-0.88	-15.31	-0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg20290983	chr6:43655470	MRPS18A	1.12	41.25	0.85	2.53e-182	IgG glycosylation;
BRCA	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.33	8.44	0.32	2.15e-16	IgG glycosylation;
BRCA	cis	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg09307838	chr4:120376055	NA	0.46	9.57	0.35	2.25e-20	Diastolic blood pressure;
BRCA	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg24069376	chr3:38537580	EXOG	0.42	12.17	0.43	8.73e-31	Electrocardiographic conduction measures;
BRCA	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg16606324	chr3:10149918	C3orf24	0.56	11.15	0.4	1.74e-26	Alzheimer's disease;
BRCA	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.52	12.6	0.45	1.14e-32	Chronic sinus infection;
BRCA	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg15212455	chr7:39170539	POU6F2	0.36	7.87	0.3	1.48e-14	IgG glycosylation;
BRCA	cis	rs9487051	0.768	rs463916	chr6:109520538	A/G	cg21918786	chr6:109611834	NA	-0.34	-9.15	-0.34	7.44e-19	Reticulocyte fraction of red cells;
BRCA	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21659725	chr3:3221576	CRBN	-0.48	-10.56	-0.39	3.87e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg24060327	chr5:131705240	SLC22A5	-0.6	-11.6	-0.42	2.24e-28	Acylcarnitine levels;
BRCA	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg01256987	chr12:42539512	GXYLT1	-0.55	-11.05	-0.4	4.45e-26	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg09658497	chr7:2847517	GNA12	-0.39	-8.37	-0.31	3.78e-16	Height;
BRCA	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg17366294	chr4:99064904	C4orf37	0.44	10.4	0.38	1.6e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs739496	0.542	rs7399113	chr12:111792848	G/A	cg10833066	chr12:111807467	FAM109A	0.35	8.1	0.31	2.77e-15	Platelet count;
BRCA	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg22431228	chr1:16359049	CLCNKA	-0.45	-9.26	-0.34	2.96e-19	Dilated cardiomyopathy;
BRCA	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg09904177	chr6:26538194	HMGN4	0.46	12.7	0.45	4.02e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs1113500	0.897	rs10785832	chr1:108638899	G/A	cg06207961	chr1:108661230	NA	0.44	10.82	0.39	3.75e-25	Growth-regulated protein alpha levels;
BRCA	cis	rs290268	0.874	rs290995	chr9:93559477	C/A	cg02608019	chr9:93564028	SYK	0.55	12.28	0.44	2.92e-31	Platelet count;
BRCA	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg12310025	chr6:25882481	NA	0.4	9.06	0.34	1.62e-18	Blood metabolite levels;
BRCA	cis	rs427394	0.659	rs175594	chr5:6729885	T/G	cg10857441	chr5:6722123	POLS	-0.31	-9.91	-0.37	1.23e-21	Menopause (age at onset);
BRCA	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg12826209	chr6:26865740	GUSBL1	0.73	7.8	0.3	2.44e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs13088645	0.683	rs9790169	chr3:134151959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-11.98	-0.43	5.41e-30	Coronary artery disease;
BRCA	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg24110177	chr3:50126178	RBM5	0.52	15.17	0.51	1.34e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs12618769	0.652	rs3203856	chr2:99226021	C/T	cg10123293	chr2:99228465	UNC50	0.44	8.7	0.33	2.71e-17	Bipolar disorder;
BRCA	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg23533926	chr12:111358616	MYL2	-0.44	-9.18	-0.34	5.78e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs59698941	0.550	rs11748737	chr5:132201070	C/T	cg14825688	chr5:132208181	LEAP2	-0.38	-8.79	-0.33	1.36e-17	Apolipoprotein A-IV levels;
BRCA	cis	rs10739663	0.520	rs3122935	chr9:128154203	A/G	cg14078157	chr9:128172775	NA	0.42	10.05	0.37	3.67e-22	Resting heart rate;
BRCA	trans	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.82	0.33	1.06e-17	Mean corpuscular volume;
BRCA	cis	rs6484504	0.532	rs1475558	chr11:31263428	A/G	cg26647111	chr11:31128758	NA	-0.4	-8.97	-0.33	3.14e-18	Red blood cell count;
BRCA	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg23649088	chr2:200775458	C2orf69	0.62	10.74	0.39	7.2e-25	Schizophrenia;
BRCA	cis	rs7640424	0.620	rs17231503	chr3:107817299	C/T	cg09227934	chr3:107805635	CD47	-0.43	-8.3	-0.31	6.39e-16	Body mass index;
BRCA	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg01819863	chr10:32635814	EPC1	1.09	19.55	0.61	4.83e-67	Sexual dysfunction (female);
BRCA	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg03433033	chr1:76189801	ACADM	-0.47	-8.93	-0.33	4.61e-18	Daytime sleep phenotypes;
BRCA	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg08601574	chr20:25228251	PYGB	0.35	8.49	0.32	1.39e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6815814	0.851	rs11466645	chr4:38778203	A/T	cg06935464	chr4:38784597	TLR10	0.47	7.83	0.3	2e-14	Breast cancer;
BRCA	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg09417038	chr21:47716443	C21orf57	-0.32	-7.98	-0.3	6.57e-15	Testicular germ cell tumor;
BRCA	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg12483005	chr1:23474871	LUZP1	0.37	7.96	0.3	7.82e-15	Height;
BRCA	cis	rs13272623	0.502	rs268601	chr8:71518548	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.47	-9.94	-0.37	9.3e-22	IgG glycosylation;
BRCA	cis	rs7580658	0.509	rs12477653	chr2:127952081	C/T	cg16751203	chr2:127950803	CYP27C1	0.28	8.19	0.31	1.44e-15	Protein C levels;
BRCA	cis	rs698833	0.926	rs698835	chr2:44737089	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	9.73	0.36	5.71e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs72627509	0.951	rs72627508	chr4:57831564	C/G	cg26694713	chr4:57773883	REST	0.45	8.03	0.3	4.56e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg19622623	chr12:86230825	RASSF9	-0.29	-8.29	-0.31	6.91e-16	Major depressive disorder;
BRCA	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg18758796	chr5:131593413	PDLIM4	0.37	9.02	0.34	2.19e-18	Acylcarnitine levels;
BRCA	cis	rs6910061	1.000	rs10080950	chr6:11116467	T/G	cg27233058	chr6:11094804	LOC221710	0.53	9.43	0.35	7.64e-20	Diabetic kidney disease;
BRCA	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg25358565	chr5:93447407	FAM172A	-0.65	-11.2	-0.41	1.04e-26	Diabetic retinopathy;
BRCA	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg17420585	chr12:42539391	GXYLT1	-0.38	-8.02	-0.3	5.08e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs6543140	0.964	rs7561351	chr2:103077780	A/G	cg04239558	chr2:103089729	SLC9A4	0.34	9.6	0.36	1.72e-20	Blood protein levels;
BRCA	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg05793240	chr7:2802953	GNA12	-0.34	-8.7	-0.33	2.82e-17	Height;
BRCA	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg22907277	chr7:1156413	C7orf50	0.65	12.75	0.45	2.52e-33	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1451375	1.000	rs1451374	chr7:50622653	G/A	cg18232548	chr7:50535776	DDC	0.44	10.19	0.37	1.09e-22	Malaria;
BRCA	cis	rs243505	0.528	rs740951	chr7:148470160	C/A	cg09806900	chr7:148480153	CUL1	0.54	11.32	0.41	3.41e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg25801113	chr15:45476975	SHF	-0.33	-8.31	-0.31	5.63e-16	Uric acid levels;
BRCA	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03713592	chr11:72463424	ARAP1	-0.72	-10.76	-0.39	6.39e-25	Type 2 diabetes;
BRCA	trans	rs1325195	0.881	rs2791941	chr1:179112435	G/A	cg11624085	chr17:8464688	MYH10	0.26	8.14	0.31	2e-15	IgE grass sensitization;
BRCA	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg09065629	chr16:1709722	CRAMP1L	0.35	8.1	0.31	2.84e-15	Coronary artery disease;
BRCA	cis	rs775227	0.574	rs34049435	chr3:113099499	C/T	cg18753928	chr3:113234510	CCDC52	-0.58	-9.5	-0.35	4.02e-20	Dental caries;
BRCA	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg18131467	chr2:239335373	ASB1	0.96	35.03	0.81	7.62e-151	Multiple system atrophy;
BRCA	cis	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg06521331	chr12:34319734	NA	-0.63	-12.16	-0.43	9.6e-31	Morning vs. evening chronotype;
BRCA	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.3	8.01	0.3	5.61e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg21427119	chr20:30132790	HM13	-0.43	-8.94	-0.33	4.11e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs9463078	0.547	rs116177834	chr6:44738548	C/A	cg25276700	chr6:44698697	NA	0.35	8.05	0.3	4.19e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg25124228	chr12:125621409	AACS	-0.43	-8.9	-0.33	5.94e-18	Post bronchodilator FEV1/FVC ratio;
BRCA	trans	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg26384229	chr12:38710491	ALG10B	0.52	11.2	0.41	1e-26	Morning vs. evening chronotype;
BRCA	trans	rs2008242	0.593	rs985222	chr4:5229884	A/G	cg26099876	chr8:141644609	EIF2C2	-0.38	-9.59	-0.35	2.01e-20	Electrocardiographic conduction measures;
BRCA	cis	rs727479	0.502	rs28757202	chr15:51503881	T/A	cg19946085	chr15:51559439	CYP19A1	-0.3	-8.4	-0.32	2.97e-16	Estradiol levels;
BRCA	cis	rs11677370	0.561	rs4849990	chr2:3819558	A/G	cg17052675	chr2:3827356	NA	-0.57	-13.92	-0.48	1.14e-38	Type 2 diabetes;
BRCA	cis	rs2070433	0.948	rs2839304	chr21:47952650	C/G	cg12379764	chr21:47803548	PCNT	-0.53	-9.83	-0.36	2.46e-21	Lymphocyte counts;
BRCA	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg09436375	chr6:42928200	GNMT	-0.3	-11.01	-0.4	6.3e-26	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs10911363	0.615	rs12024309	chr1:183419981	A/G	cg09173681	chr1:183549694	NCF2	-0.52	-10.99	-0.4	7.23e-26	Systemic lupus erythematosus;
BRCA	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg08601574	chr20:25228251	PYGB	-0.34	-8.24	-0.31	9.76e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg17691542	chr6:26056736	HIST1H1C	0.47	9.55	0.35	2.61e-20	Height;
BRCA	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg13319975	chr6:146136371	FBXO30	-0.44	-10.11	-0.37	2.1e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg00083206	chr6:110721305	DDO	-0.4	-9.67	-0.36	1.01e-20	Platelet distribution width;
BRCA	cis	rs965469	0.947	rs56689368	chr20:3332921	G/A	cg25506879	chr20:3388711	C20orf194	-0.53	-10.5	-0.38	6.58e-24	IFN-related cytopenia;
BRCA	cis	rs10193935	0.786	rs13416119	chr2:42462930	A/G	cg27598129	chr2:42591480	NA	-1.03	-11.7	-0.42	8.5e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg08601574	chr20:25228251	PYGB	0.34	8.27	0.31	7.69e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.47	-12.84	-0.45	9.97e-34	Total body bone mineral density;
BRCA	cis	rs220324	0.688	rs11701681	chr21:43564274	A/G	cg09727148	chr21:43560719	UMODL1	0.43	7.88	0.3	1.38e-14	Idiopathic osteonecrosis of the femoral head;
BRCA	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13126279	chr21:47581558	C21orf56	-0.5	-10.88	-0.4	2.03e-25	Testicular germ cell tumor;
BRCA	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-16.18	-0.54	1.37e-49	Alzheimer's disease (late onset);
BRCA	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg19336497	chr11:14380999	RRAS2	0.3	8.04	0.3	4.29e-15	Mitochondrial DNA levels;
BRCA	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.39	8.46	0.32	1.82e-16	Aortic root size;
BRCA	trans	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg25214090	chr10:38739885	LOC399744	0.54	12.25	0.44	3.83e-31	Corneal astigmatism;
BRCA	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.39	2.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.59	12.32	0.44	1.96e-31	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.48	9.55	0.35	2.73e-20	Iron status biomarkers;
BRCA	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13126279	chr21:47581558	C21orf56	-0.4	-8.44	-0.32	2.1e-16	Testicular germ cell tumor;
BRCA	trans	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg06521331	chr12:34319734	NA	-0.43	-7.82	-0.3	2.16e-14	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg10223061	chr2:219282414	VIL1	-0.27	-8.01	-0.3	5.56e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg03146154	chr1:46216737	IPP	0.53	11.75	0.42	5.61e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg08999081	chr20:33150536	PIGU	-0.45	-12.33	-0.44	1.72e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-8.11	-0.31	2.51e-15	Tonsillectomy;
BRCA	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg00074818	chr8:8560427	CLDN23	0.38	8.3	0.31	6.14e-16	Obesity-related traits;
BRCA	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg23533926	chr12:111358616	MYL2	-0.43	-8.89	-0.33	6.36e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1371614	0.531	rs77562583	chr2:27151643	G/A	cg12368169	chr2:27073192	DPYSL5	0.28	8.24	0.31	9.55e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs9658691	0.607	rs9325604	chr10:90775756	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.56	-8.17	-0.31	1.7e-15	Mosquito bite size;
BRCA	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg04518342	chr5:131593106	PDLIM4	0.33	8.21	0.31	1.21e-15	Blood metabolite levels;
BRCA	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg19622623	chr12:86230825	RASSF9	-0.33	-9.28	-0.34	2.49e-19	Major depressive disorder;
BRCA	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg27121462	chr16:89883253	FANCA	-0.44	-9.84	-0.36	2.25e-21	Vitiligo;
BRCA	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg10295955	chr4:187884368	NA	-0.99	-32.04	-0.79	4.48e-135	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg13010199	chr12:38710504	ALG10B	0.44	8.87	0.33	7.18e-18	Bladder cancer;
BRCA	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg10295955	chr4:187884368	NA	-0.99	-31.64	-0.78	6.55e-133	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg08601574	chr20:25228251	PYGB	0.34	8.04	0.3	4.28e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg12698349	chr2:225449008	CUL3	0.84	29.39	0.76	8.89e-121	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg22508957	chr16:3507546	NAT15	-0.55	-9.01	-0.34	2.41e-18	Tuberculosis;
BRCA	cis	rs12541635	0.967	rs13256474	chr8:107086419	T/C	cg10147462	chr8:107024639	NA	-0.3	-8.25	-0.31	9.29e-16	Age of smoking initiation;
BRCA	cis	rs7249921	0.833	rs59975720	chr19:35660954	G/A	cg15419183	chr19:35660584	FXYD5	0.45	10.04	0.37	3.97e-22	Platelet count;
BRCA	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg26031613	chr14:104095156	KLC1	0.44	8.77	0.33	1.57e-17	Schizophrenia;
BRCA	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg13010199	chr12:38710504	ALG10B	0.56	12.22	0.44	5.11e-31	Heart rate;
BRCA	cis	rs752010	0.875	rs11210501	chr1:42091634	T/C	cg06885757	chr1:42089581	HIVEP3	0.24	8.66	0.32	3.9e-17	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs708547	0.647	rs1718839	chr4:57827206	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.37	9.51	0.35	3.67e-20	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg23625390	chr15:77176239	SCAPER	-0.54	-13.65	-0.48	1.99e-37	Blood metabolite levels;
BRCA	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.69	-12.98	-0.46	2.21e-34	Alzheimer's disease;
BRCA	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.62	-0.32	5.38e-17	Monocyte percentage of white cells;
BRCA	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.64	-18.4	-0.59	5.36e-61	Schizophrenia;
BRCA	cis	rs17604090	0.529	rs2392128	chr7:29711139	A/G	cg19413766	chr7:29689036	LOC646762	0.56	9.08	0.34	1.36e-18	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11764359	chr7:65958608	NA	0.62	13.64	0.47	2.29e-37	Calcium levels;
BRCA	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg25482853	chr8:67687455	SGK3	0.79	13.2	0.46	2.48e-35	Obesity-related traits;
BRCA	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg26695010	chr11:65641043	EFEMP2	0.38	8.45	0.32	2.04e-16	Eosinophil percentage of white cells;
BRCA	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg06159980	chr1:16340746	HSPB7	-0.38	-8.8	-0.33	1.27e-17	Dilated cardiomyopathy;
BRCA	cis	rs17601876	0.807	rs12910259	chr15:51555049	G/A	cg19946085	chr15:51559439	CYP19A1	-0.38	-11.11	-0.4	2.54e-26	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18876405	chr7:65276391	NA	-0.49	-10.77	-0.39	5.79e-25	Aortic root size;
BRCA	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.38	-8.86	-0.33	7.8e-18	Tonsillectomy;
BRCA	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg24060327	chr5:131705240	SLC22A5	-0.63	-12.27	-0.44	3.2e-31	Breast cancer;
BRCA	trans	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06636551	chr8:101224915	SPAG1	-0.38	-8.66	-0.32	3.83e-17	Atrioventricular conduction;
BRCA	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg27588902	chr6:42928151	GNMT	-0.31	-10.16	-0.37	1.45e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-14.11	-0.49	1.48e-39	Monocyte count;
BRCA	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18876405	chr7:65276391	NA	0.63	15.45	0.52	5.37e-46	Aortic root size;
BRCA	cis	rs16866061	1.000	rs1568750	chr2:225342597	A/T	cg12698349	chr2:225449008	CUL3	0.77	21.11	0.64	1.92e-75	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg07636037	chr3:49044803	WDR6	0.56	9.16	0.34	7.19e-19	Menarche (age at onset);
BRCA	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.46	9.25	0.34	3.33e-19	Tonsillectomy;
BRCA	cis	rs6684514	0.885	rs12036837	chr1:156283895	A/C	cg16558208	chr1:156270281	VHLL	0.34	7.87	0.3	1.5e-14	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg22713356	chr15:30763199	NA	1.25	20.77	0.63	1.25e-73	Uric acid levels;
BRCA	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg04414720	chr1:150670196	GOLPH3L	0.35	7.84	0.3	1.88e-14	Tonsillectomy;
BRCA	cis	rs477692	0.792	rs12762024	chr10:131441055	G/C	cg05714579	chr10:131428358	MGMT	-0.55	-13.28	-0.47	9.78e-36	Response to temozolomide;
BRCA	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	10.89	0.4	1.93e-25	Rheumatoid arthritis;
BRCA	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg03929089	chr4:120376271	NA	-0.69	-13.56	-0.47	5.16e-37	Coronary artery disease;
BRCA	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg17971929	chr21:40555470	PSMG1	-0.47	-10.15	-0.37	1.59e-22	Menarche (age at onset);
BRCA	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg01028140	chr2:1542097	TPO	-0.8	-15.82	-0.53	8.12e-48	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg02082929	chr2:109068933	GCC2	0.41	12.17	0.43	8.42e-31	Mean platelet volume;
BRCA	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg23711669	chr6:146136114	FBXO30	-0.72	-16.98	-0.56	1.25e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.72	0.39	9.15e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg15432903	chr11:17409602	KCNJ11	0.72	15.82	0.53	7.83e-48	Type 2 diabetes;
BRCA	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	12.1	0.43	1.72e-30	Mean platelet volume;
BRCA	cis	rs4853036	0.904	rs12713683	chr2:70156321	G/A	cg02498382	chr2:70120550	SNRNP27	-0.55	-10.77	-0.39	5.74e-25	Colorectal or endometrial cancer;
BRCA	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	12.98	0.46	2.41e-34	Personality dimensions;
BRCA	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg21724239	chr8:58056113	NA	0.57	9.3	0.35	2.24e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs9296092	0.560	rs62407569	chr6:33538865	A/G	cg13560919	chr6:33536144	NA	-0.86	-17.74	-0.57	1.44e-57	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs7737355	0.947	rs6596027	chr5:130879547	A/G	cg06307176	chr5:131281290	NA	0.53	10.55	0.39	4.12e-24	Life satisfaction;
BRCA	cis	rs7617773	0.780	rs13082859	chr3:48344675	C/T	cg11946769	chr3:48343235	NME6	0.68	13.86	0.48	2.24e-38	Coronary artery disease;
BRCA	cis	rs9400271	0.632	rs9384706	chr6:109601504	C/T	cg01475377	chr6:109611718	NA	-0.43	-10.2	-0.37	1.01e-22	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg08807101	chr21:30365312	RNF160	-0.44	-9.33	-0.35	1.66e-19	Dental caries;
BRCA	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg14675211	chr2:100938903	LONRF2	0.52	11.54	0.42	4.07e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs10045504	0.502	rs72746032	chr5:38743982	T/C	cg15396434	chr5:38725168	NA	-0.57	-11.06	-0.4	3.91e-26	Night sleep phenotypes;
BRCA	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.54	13.39	0.47	3.11e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.61	-0.32	5.73e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg19077165	chr18:44547161	KATNAL2	0.39	8.38	0.31	3.39e-16	Personality dimensions;
BRCA	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	13.46	0.47	1.53e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10463316	0.894	rs3846712	chr5:150759813	C/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.08	-0.3	3.31e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.43	-0.32	2.27e-16	Monocyte percentage of white cells;
BRCA	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg03709012	chr19:19516395	GATAD2A	-0.79	-18.04	-0.58	4.11e-59	Tonsillectomy;
BRCA	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.36	0.35	1.33e-19	Menopause (age at onset);
BRCA	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg23442198	chr4:187126114	CYP4V2	0.92	10.72	0.39	8.98e-25	Blood protein levels;
BRCA	cis	rs921968	0.565	rs7562426	chr2:219605118	G/A	cg02176678	chr2:219576539	TTLL4	-0.41	-11.01	-0.4	6.11e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.5	11.12	0.4	2.24e-26	Multiple sclerosis;
BRCA	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg05623727	chr3:50126028	RBM5	-0.42	-10.06	-0.37	3.32e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2282802	0.685	rs12717951	chr5:139589309	A/G	cg26211634	chr5:139558579	C5orf32	0.33	8.05	0.3	3.98e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10128251	0.847	rs12777965	chr10:5724297	T/C	cg24097872	chr10:5724021	NA	-0.57	-12.34	-0.44	1.59e-31	Childhood ear infection;
BRCA	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	7.15e-19	Alzheimer's disease (late onset);
BRCA	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg05535760	chr7:792225	HEATR2	0.74	13.47	0.47	1.33e-36	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14294708	chr9:37120828	ZCCHC7	1.06	32.19	0.79	7.47e-136	Schizophrenia;
BRCA	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg27588902	chr6:42928151	GNMT	-0.3	-10.06	-0.37	3.51e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22307029	chr19:49891270	CCDC155	0.55	9.96	0.37	8.16e-22	Multiple sclerosis;
BRCA	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg23711669	chr6:146136114	FBXO30	-0.78	-18.77	-0.6	5.83e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	5.1e-16	Tonsillectomy;
BRCA	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg08392591	chr16:89556376	ANKRD11	0.46	10.83	0.39	3.22e-25	Multiple myeloma (IgH translocation);
BRCA	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg03929089	chr4:120376271	NA	-0.47	-9.04	-0.34	1.9e-18	HDL cholesterol;
BRCA	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14240646	chr10:27532245	ACBD5	-0.62	-9.64	-0.36	1.26e-20	Breast cancer;
BRCA	cis	rs12472274	0.646	rs2305171	chr2:239097140	G/A	cg17459225	chr2:239074497	NA	0.57	9.71	0.36	7.16e-21	Phospholipid levels (plasma);
BRCA	trans	rs3960554	0.674	rs112742093	chr7:75800597	T/C	cg19862616	chr7:65841803	NCRNA00174	0.6	11.82	0.42	2.76e-29	Eotaxin levels;
BRCA	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg05084668	chr3:125655381	ALG1L	-0.47	-7.98	-0.3	6.69e-15	Blood pressure (smoking interaction);
BRCA	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	13.0	0.46	1.8e-34	Response to antipsychotic treatment;
BRCA	cis	rs27434	0.583	rs151908	chr5:96156494	A/G	cg16492584	chr5:96139282	ERAP1	-0.51	-12.73	-0.45	3.03e-33	Ankylosing spondylitis;
BRCA	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg15557168	chr22:42548783	NA	-0.31	-8.66	-0.32	3.9e-17	Cognitive function;
BRCA	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg25173405	chr17:45401733	C17orf57	-0.44	-8.93	-0.33	4.61e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs10193935	0.901	rs72800020	chr2:42655615	A/G	cg27598129	chr2:42591480	NA	-0.87	-14.35	-0.49	1.13e-40	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.12	0.4	2.21e-26	Bipolar disorder;
BRCA	cis	rs67460515	0.500	rs9812507	chr3:160723393	G/A	cg03342759	chr3:160939853	NMD3	-0.6	-11.99	-0.43	5.24e-30	Parkinson's disease;
BRCA	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.34	-0.41	2.65e-27	Colorectal cancer;
BRCA	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg15017067	chr4:17643749	FAM184B	0.32	9.92	0.37	1.16e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1669338	0.588	rs3846135	chr3:3195574	C/T	cg16797762	chr3:3221439	CRBN	-0.58	-9.11	-0.34	1.06e-18	White matter integrity;
BRCA	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg01028140	chr2:1542097	TPO	-0.71	-14.05	-0.49	2.86e-39	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg03060546	chr3:49711283	APEH	-0.48	-9.63	-0.36	1.42e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9487051	0.768	rs1269172	chr6:109522080	G/C	cg21918786	chr6:109611834	NA	-0.35	-9.24	-0.34	3.73e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.48	8.53	0.32	1.09e-16	Body mass index (adult);
BRCA	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24308560	chr3:49941425	MST1R	-0.4	-8.6	-0.32	6.08e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs4662945	0.525	rs28819474	chr2:130264623	T/C	cg05903289	chr2:130345205	NA	-0.32	-8.08	-0.3	3.34e-15	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg06212747	chr3:49208901	KLHDC8B	0.54	11.64	0.42	1.55e-28	Menarche (age at onset);
BRCA	cis	rs9815354	0.812	rs73071242	chr3:41993011	T/C	cg03022575	chr3:42003672	ULK4	0.7	9.76	0.36	4.45e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs9318086	0.712	rs9510916	chr13:24442789	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.32	8.96	0.33	3.57e-18	Myopia (pathological);
BRCA	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg26597838	chr10:835615	NA	0.95	14.56	0.5	1.14e-41	Eosinophil percentage of granulocytes;
BRCA	trans	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg25214090	chr10:38739885	LOC399744	0.49	11.47	0.41	7.92e-28	Corneal astigmatism;
BRCA	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg11301795	chr4:187892539	NA	-0.3	-10.15	-0.37	1.54e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg27347728	chr4:17578864	LAP3	0.43	8.08	0.3	3.13e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7395581	0.918	rs1055510	chr11:47292237	A/G	cg25783544	chr11:47291846	MADD	0.43	9.78	0.36	3.68e-21	HDL cholesterol;
BRCA	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.67	0.36	9.68e-21	Bipolar disorder;
BRCA	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg18252515	chr7:66147081	NA	-1.06	-15.58	-0.52	1.26e-46	Diabetic kidney disease;
BRCA	cis	rs2625529	0.938	rs8747	chr15:72115541	C/A	cg16672083	chr15:72433130	SENP8	-0.81	-16.58	-0.55	1.25e-51	Red blood cell count;
BRCA	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg02176678	chr2:219576539	TTLL4	-0.47	-12.25	-0.44	4e-31	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg13010199	chr12:38710504	ALG10B	0.58	12.89	0.45	6.06e-34	Heart rate;
BRCA	trans	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.37	0.38	2.12e-23	Mean corpuscular volume;
BRCA	cis	rs738321	0.762	rs5995543	chr22:38579026	G/A	cg25457927	chr22:38595422	NA	-0.39	-13.0	-0.46	1.85e-34	Breast cancer;
BRCA	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg04034577	chr2:241836375	C2orf54	-0.55	-13.58	-0.47	4.49e-37	Urinary metabolites;
BRCA	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg12310025	chr6:25882481	NA	-0.59	-12.72	-0.45	3.21e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg14061069	chr19:46274453	DMPK	-0.47	-11.82	-0.42	2.58e-29	Coronary artery disease;
BRCA	cis	rs1568889	1.000	rs7934085	chr11:28369660	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.69	0.5	2.53e-42	Bipolar disorder;
BRCA	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg16339924	chr4:17578868	LAP3	0.63	15.75	0.53	1.78e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.88	0.3	1.4e-14	Endometrial cancer;
BRCA	cis	rs10838687	1.000	rs10838687	chr11:47312892	T/G	cg25783544	chr11:47291846	MADD	0.42	8.49	0.32	1.48e-16	Proinsulin levels;
BRCA	cis	rs1127311	0.846	rs61811388	chr1:154581231	G/C	cg17218026	chr1:154582156	ADAR	0.29	8.59	0.32	6.52e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
BRCA	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02475777	chr4:1388615	CRIPAK	0.56	11.13	0.4	1.96e-26	Longevity;
BRCA	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg08847533	chr14:75593920	NEK9	-0.86	-21.94	-0.66	5.69e-80	Height;
BRCA	cis	rs4363385	0.747	rs1415961	chr1:152973464	G/A	cg24667326	chr1:152973720	SPRR3	-0.35	-9.57	-0.35	2.23e-20	Inflammatory skin disease;
BRCA	cis	rs17095355	1.000	rs7905306	chr10:111712902	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.39	-10.1	-0.37	2.37e-22	Biliary atresia;
BRCA	cis	rs870825	0.616	rs9715644	chr4:185632965	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	17.4	0.57	8.32e-56	Blood protein levels;
BRCA	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg05283184	chr6:79620031	NA	-0.43	-10.91	-0.4	1.61e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18876405	chr7:65276391	NA	0.61	15.12	0.51	2.26e-44	Aortic root size;
BRCA	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg09184832	chr6:79620586	NA	-0.5	-10.82	-0.39	3.49e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg21427119	chr20:30132790	HM13	-0.42	-8.85	-0.33	8.37e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.4	8.02	0.3	5.01e-15	Ulcerative colitis;Inflammatory bowel disease;
BRCA	trans	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-18.36	-0.59	9.01e-61	Exhaled nitric oxide output;
BRCA	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.45	0.35	6.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg05340658	chr4:99064831	C4orf37	0.62	14.71	0.5	2.04e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	11.32	0.41	3.19e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg16586182	chr3:47516702	SCAP	-0.53	-11.64	-0.42	1.57e-28	Colorectal cancer;
BRCA	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-11.95	-0.43	7.41e-30	Mood instability;
BRCA	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-13.8	-0.48	4.28e-38	Morning vs. evening chronotype;
BRCA	cis	rs17601876	0.843	rs6493494	chr15:51549835	G/A	cg19946085	chr15:51559439	CYP19A1	-0.37	-10.71	-0.39	1e-24	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs7520050	0.966	rs6675726	chr1:46560643	A/G	cg24296786	chr1:45957014	TESK2	0.41	9.14	0.34	8.37e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg11833968	chr6:79620685	NA	-0.4	-8.9	-0.33	5.7e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	10.58	0.39	3.23e-24	Aortic root size;
BRCA	trans	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg25214090	chr10:38739885	LOC399744	-0.55	-11.96	-0.43	6.58e-30	Corneal astigmatism;
BRCA	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg00990874	chr7:1149470	C7orf50	-0.6	-11.81	-0.42	3.11e-29	Bronchopulmonary dysplasia;
BRCA	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11644478	chr21:40555479	PSMG1	-0.66	-14.18	-0.49	7.33e-40	Cognitive function;
BRCA	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg15595755	chr5:1867978	NA	0.35	8.35	0.31	4.19e-16	Cardiovascular disease risk factors;
BRCA	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg15017067	chr4:17643749	FAM184B	0.26	7.87	0.3	1.5e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg26647111	chr11:31128758	NA	0.45	9.8	0.36	3.31e-21	Bone mineral density (spine);
BRCA	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg04455712	chr21:45112962	RRP1B	0.38	9.8	0.36	3.3e-21	Mean corpuscular volume;
BRCA	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg13010199	chr12:38710504	ALG10B	0.49	9.64	0.36	1.23e-20	Morning vs. evening chronotype;
BRCA	cis	rs16854884	0.632	rs1466941	chr3:143670131	A/G	cg06585982	chr3:143692056	C3orf58	0.44	9.04	0.34	1.81e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs1355223	0.545	rs12278318	chr11:34876507	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-9.48	-0.35	4.85e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg25174290	chr11:3078921	CARS	-0.3	-7.84	-0.3	1.86e-14	Calcium levels;
BRCA	trans	rs12310956	0.510	rs10129020	chr12:33858936	T/G	cg26384229	chr12:38710491	ALG10B	0.39	8.84	0.33	9.52e-18	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg27170947	chr2:26402098	FAM59B	0.88	16.3	0.54	3.17e-50	Gut microbiome composition (summer);
BRCA	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.56	11.16	0.4	1.5e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9463078	0.845	rs1023090	chr6:45012381	T/C	cg25276700	chr6:44698697	NA	-0.35	-7.98	-0.3	6.6e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.44	-8.4	-0.32	2.82e-16	Renal function-related traits (BUN);
BRCA	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.12	0.4	2.21e-26	Bipolar disorder;
BRCA	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06544989	chr22:39130855	UNC84B	0.37	8.46	0.32	1.77e-16	Menopause (age at onset);
BRCA	cis	rs6446731	0.517	rs2071668	chr4:3269905	A/G	cg08886695	chr4:3369023	RGS12	0.37	9.87	0.36	1.82e-21	Mean platelet volume;
BRCA	trans	rs6601327	0.602	rs7829463	chr8:9649691	C/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-8.33	-0.31	5.04e-16	Multiple myeloma (hyperdiploidy);
BRCA	cis	rs3806933	0.500	rs10491423	chr5:110453977	C/A	cg04022379	chr5:110408740	TSLP	0.47	10.11	0.37	2.11e-22	Eosinophilic esophagitis;
BRCA	cis	rs11112613	0.595	rs871219	chr12:105938519	C/A	cg03607813	chr12:105948248	NA	0.59	9.92	0.37	1.12e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg10819733	chr22:24237672	NA	-0.29	-7.94	-0.3	9.15e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg13175981	chr1:150552382	MCL1	0.48	10.65	0.39	1.71e-24	Tonsillectomy;
BRCA	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg22491629	chr6:157744540	C6orf35	-0.65	-11.56	-0.42	3.36e-28	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg25019033	chr10:957182	NA	-0.41	-7.99	-0.3	6.33e-15	Eosinophil percentage of granulocytes;
BRCA	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg03929089	chr4:120376271	NA	-0.45	-8.44	-0.32	2.2e-16	Height;
BRCA	cis	rs17095355	1.000	rs734165	chr10:111697789	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.4	-8.68	-0.32	3.22e-17	Biliary atresia;
BRCA	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg15704280	chr7:45808275	SEPT13	-0.57	-9.66	-0.36	1.04e-20	Axial length;
BRCA	cis	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg06521331	chr12:34319734	NA	-0.58	-11.47	-0.41	7.88e-28	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg13010199	chr12:38710504	ALG10B	0.47	8.99	0.34	2.82e-18	Morning vs. evening chronotype;
BRCA	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg03342759	chr3:160939853	NMD3	-0.63	-13.25	-0.46	1.38e-35	Morning vs. evening chronotype;
BRCA	trans	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg19894588	chr14:64061835	NA	0.34	8.43	0.32	2.33e-16	Glioblastoma;Glioma;
BRCA	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08564027	chr20:61660810	NA	0.84	22.84	0.67	7.41e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6840360	0.593	rs1366907	chr4:152682749	T/C	cg22705602	chr4:152727874	NA	-0.38	-10.39	-0.38	1.81e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18876405	chr7:65276391	NA	-0.5	-11.07	-0.4	3.5e-26	Aortic root size;
BRCA	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.79	-0.33	1.36e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18876405	chr7:65276391	NA	-0.62	-15.43	-0.52	6.52e-46	Aortic root size;
BRCA	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.48	9.07	0.34	1.4e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-9.08	-0.34	1.35e-18	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2463822	0.858	rs2513077	chr11:62105925	A/G	cg06239285	chr11:62104954	ASRGL1	-0.69	-11.7	-0.42	9.08e-29	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs9400271	0.632	rs949881	chr6:109586240	A/G	cg01475377	chr6:109611718	NA	-0.44	-10.66	-0.39	1.57e-24	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-12.18	-0.43	7.81e-31	Schizophrenia;
BRCA	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.11	-40.97	-0.85	6.13e-181	Myeloid white cell count;
BRCA	cis	rs12468557	0.527	rs12694206	chr2:211499394	T/A	cg07063745	chr2:211341572	LANCL1;CPS1	-0.36	-8.05	-0.3	4.12e-15	Body mass index in asthmatics;
BRCA	cis	rs9420	0.884	rs644883	chr11:57663522	C/G	cg19752551	chr11:57585705	CTNND1	0.48	12.38	0.44	1.04e-31	Schizophrenia;
BRCA	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	15.99	0.53	1.19e-48	Platelet count;
BRCA	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-9.09	-0.34	1.19e-18	Triglycerides;
BRCA	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg26149184	chr10:133730230	NA	0.38	7.97	0.3	7.44e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08564027	chr20:61660810	NA	0.85	22.96	0.67	1.66e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24308560	chr3:49941425	MST1R	-0.39	-8.3	-0.31	6.26e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg26149184	chr10:133730230	NA	0.41	8.28	0.31	7.31e-16	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg07148914	chr20:33460835	GGT7	-0.44	-9.44	-0.35	7.01e-20	Height;
BRCA	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg08213375	chr14:104286397	PPP1R13B	0.64	17.63	0.57	5.71e-57	Schizophrenia;
BRCA	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg27661571	chr11:113659931	NA	0.57	8.08	0.3	3.21e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs36051895	0.588	rs12340895	chr9:5076691	C/G	cg02405213	chr9:5042618	JAK2	0.52	9.48	0.35	4.87e-20	Pediatric autoimmune diseases;
BRCA	cis	rs9649213	0.593	rs6967576	chr7:98016373	A/G	cg01877450	chr7:97915802	BRI3	0.36	8.41	0.32	2.73e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg15212455	chr7:39170539	POU6F2	0.36	7.87	0.3	1.48e-14	IgG glycosylation;
BRCA	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg18200150	chr17:30822561	MYO1D	0.35	8.91	0.33	5.16e-18	Schizophrenia;
BRCA	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg10818794	chr15:86012489	AKAP13	-0.31	-8.68	-0.32	3.27e-17	Coronary artery disease;
BRCA	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg25319279	chr11:5960081	NA	0.41	8.18	0.31	1.55e-15	DNA methylation (variation);
BRCA	cis	rs9462027	0.628	rs10947532	chr6:34780315	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.84	-0.3	1.96e-14	Systemic lupus erythematosus;
BRCA	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg15017067	chr4:17643749	FAM184B	-0.27	-8.17	-0.31	1.7e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg27129171	chr3:47204927	SETD2	-0.68	-16.16	-0.54	1.74e-49	Colorectal cancer;
BRCA	cis	rs9649465	0.934	rs34030532	chr7:123274992	A/G	cg04330084	chr7:123175371	IQUB	-0.33	-8.98	-0.33	3.04e-18	Migraine;
BRCA	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg26395211	chr5:140044315	WDR55	0.37	8.58	0.32	7.32e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23978390	chr7:1156363	C7orf50	0.51	11.97	0.43	6.04e-30	Longevity;Endometriosis;
BRCA	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg20701182	chr2:24300061	SF3B14	0.71	13.07	0.46	9.61e-35	Lymphocyte counts;
BRCA	trans	rs2018683	0.707	rs10279610	chr7:28975696	C/G	cg19402173	chr7:128379420	CALU	0.41	9.87	0.36	1.74e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg08859206	chr1:53392774	SCP2	-0.49	-9.64	-0.36	1.24e-20	Monocyte count;
BRCA	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.51	10.04	0.37	4.16e-22	Birth weight;
BRCA	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg04455712	chr21:45112962	RRP1B	0.42	11.0	0.4	6.95e-26	Mean corpuscular volume;
BRCA	trans	rs1941687	0.505	rs8091920	chr18:31303557	C/G	cg27147174	chr7:100797783	AP1S1	-0.41	-8.38	-0.31	3.37e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.57	-12.2	-0.43	6.44e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11229555	0.645	rs7930547	chr11:58197616	A/C	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg01191920	chr7:158217561	PTPRN2	-0.36	-8.43	-0.32	2.32e-16	Obesity-related traits;
BRCA	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20887711	chr4:1340912	KIAA1530	-0.6	-12.95	-0.46	3.14e-34	Obesity-related traits;
BRCA	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg13319975	chr6:146136371	FBXO30	0.34	8.0	0.3	5.98e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs813218	0.625	rs793484	chr3:99491508	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-9.86	-0.36	1.97e-21	Orofacial clefts;
BRCA	cis	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	11.55	0.42	3.57e-28	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg02544614	chr20:61657117	NA	0.29	8.07	0.3	3.48e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg08061076	chr7:1943177	MAD1L1	-0.36	-8.22	-0.31	1.17e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg24562669	chr7:97807699	LMTK2	0.47	12.62	0.45	8.93e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	12.26	0.44	3.63e-31	Calcium levels;
BRCA	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg06453172	chr10:134556979	INPP5A	-0.58	-11.54	-0.42	3.98e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg01689657	chr7:91764605	CYP51A1	-0.26	-9.19	-0.34	5.33e-19	Breast cancer;
BRCA	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg04374321	chr14:90722782	PSMC1	0.72	18.59	0.59	5.19e-62	Mortality in heart failure;
BRCA	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs7590368	1.000	rs55968911	chr2:10961840	C/T	cg15705551	chr2:10952987	PDIA6	0.44	8.09	0.3	3.12e-15	Educational attainment (years of education);
BRCA	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.18	0.49	7.18e-40	Motion sickness;
BRCA	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	12.81	0.45	1.39e-33	Lung cancer in ever smokers;
BRCA	cis	rs17604090	0.793	rs17150667	chr7:29689338	G/T	cg19413766	chr7:29689036	LOC646762	-0.51	-8.2	-0.31	1.33e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs829883	0.659	rs12366950	chr12:98947900	T/C	cg25150519	chr12:98850993	NA	-0.49	-8.67	-0.32	3.56e-17	Colorectal adenoma (advanced);
BRCA	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.45	-11.56	-0.42	3.3e-28	Schizophrenia;
BRCA	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg19622623	chr12:86230825	RASSF9	-0.32	-8.97	-0.33	3.31e-18	Major depressive disorder;
BRCA	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg15017067	chr4:17643749	FAM184B	0.3	9.09	0.34	1.23e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg11993925	chr19:44307056	LYPD5	0.37	8.95	0.33	3.73e-18	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg21782813	chr7:2030301	MAD1L1	0.36	9.11	0.34	1.06e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg24675658	chr1:53192096	ZYG11B	-0.66	-14.3	-0.49	1.81e-40	Monocyte count;
BRCA	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	18.52	0.59	1.22e-61	Platelet count;
BRCA	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.37	0.38	2.09e-23	Motion sickness;
BRCA	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg16743903	chr16:89593216	SPG7	-0.32	-7.94	-0.3	8.98e-15	Multiple myeloma (IgH translocation);
BRCA	trans	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg26384229	chr12:38710491	ALG10B	0.45	10.22	0.37	8.55e-23	Morning vs. evening chronotype;
BRCA	cis	rs2066819	1.000	rs75754909	chr12:56726349	A/G	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs12200560	0.505	rs172425	chr6:97075299	A/T	cg06623918	chr6:96969491	KIAA0776	0.53	12.75	0.45	2.46e-33	Coronary heart disease;
BRCA	trans	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg13010199	chr12:38710504	ALG10B	0.43	7.95	0.3	8.65e-15	Resting heart rate;
BRCA	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg02592271	chr2:27665507	KRTCAP3	0.31	7.92	0.3	1.03e-14	Total body bone mineral density;
BRCA	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg26384229	chr12:38710491	ALG10B	0.66	15.09	0.51	3.26e-44	Bladder cancer;
BRCA	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg11812906	chr14:75593930	NEK9	-0.68	-15.85	-0.53	5.71e-48	Height;
BRCA	cis	rs4924935	0.781	rs2472694	chr17:18848498	A/G	cg26378065	chr17:18585709	ZNF286B	0.45	8.15	0.31	1.91e-15	Pancreatic cancer;
BRCA	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11644478	chr21:40555479	PSMG1	-0.83	-18.8	-0.6	4.12e-63	Cognitive function;
BRCA	trans	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg25214090	chr10:38739885	LOC399744	0.47	10.65	0.39	1.73e-24	Corneal astigmatism;
BRCA	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg18016565	chr1:150552671	MCL1	-0.41	-9.43	-0.35	7.2e-20	Tonsillectomy;
BRCA	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg12310025	chr6:25882481	NA	-0.75	-18.47	-0.59	2.43e-61	Blood metabolite levels;
BRCA	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg19257562	chr1:2043853	PRKCZ	0.38	10.51	0.38	6.28e-24	Height;
BRCA	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg07395648	chr5:131743802	NA	0.38	9.52	0.35	3.48e-20	Blood metabolite levels;
BRCA	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21659725	chr3:3221576	CRBN	-0.47	-11.9	-0.43	1.24e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg07917127	chr4:99064746	C4orf37	0.42	7.97	0.3	7.51e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.01	-0.48	4.2e-39	Extrinsic epigenetic age acceleration;
BRCA	trans	rs10242455	0.702	rs3528	chr7:99055940	T/C	cg09045935	chr12:6379348	NA	0.89	9.35	0.35	1.41e-19	Blood metabolite levels;
BRCA	trans	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg19862616	chr7:65841803	NCRNA00174	0.83	27.27	0.73	3.26e-109	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg16482183	chr6:26056742	HIST1H1C	0.55	11.74	0.42	5.81e-29	Height;
BRCA	cis	rs507080	0.663	rs7926970	chr11:118559881	T/G	cg09144398	chr11:118550485	TREH	-0.38	-8.96	-0.33	3.57e-18	Serum metabolite levels;
BRCA	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.79	-0.45	1.57e-33	Bipolar disorder;
BRCA	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg02503808	chr4:7069936	GRPEL1	0.81	17.8	0.58	6.91e-58	Monocyte percentage of white cells;
BRCA	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg14004847	chr7:1930337	MAD1L1	-0.4	-7.98	-0.3	6.57e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg00106254	chr7:1943704	MAD1L1	-0.37	-9.0	-0.34	2.64e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	14.99	0.51	9.36e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg08601574	chr20:25228251	PYGB	0.4	9.47	0.35	5.42e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs8114671	0.527	rs3736802	chr20:33604042	T/C	cg24642439	chr20:33292090	TP53INP2	-0.44	-9.73	-0.36	5.86e-21	Height;
BRCA	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg13770153	chr20:60521292	NA	-0.4	-9.44	-0.35	6.82e-20	Body mass index;
BRCA	cis	rs10924970	0.934	rs3856241	chr1:235429692	G/A	cg26050004	chr1:235667680	B3GALNT2	0.34	8.45	0.32	1.9e-16	Asthma;
BRCA	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg04166393	chr7:2884313	GNA12	0.4	8.59	0.32	6.59e-17	Height;
BRCA	trans	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg23762105	chr12:34175262	ALG10	0.35	8.25	0.31	9.16e-16	Morning vs. evening chronotype;
BRCA	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-9.5	-0.35	3.98e-20	Aortic root size;
BRCA	trans	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg21659725	chr3:3221576	CRBN	0.48	8.04	0.3	4.35e-15	Menarche (age at onset);
BRCA	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg08807101	chr21:30365312	RNF160	0.5	11.08	0.4	3.31e-26	Cognitive test performance;
BRCA	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg26384229	chr12:38710491	ALG10B	0.41	9.2	0.34	5.01e-19	Morning vs. evening chronotype;
BRCA	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg08222618	chr4:941054	TMEM175	0.36	7.81	0.3	2.33e-14	Sjögren's syndrome;
BRCA	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18404041	chr3:52824283	ITIH1	-0.42	-12.47	-0.44	4.3e-32	Bipolar disorder;
BRCA	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg15017067	chr4:17643749	FAM184B	-0.26	-7.9	-0.3	1.22e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.37	-7.81	-0.3	2.43e-14	Body mass index;
BRCA	cis	rs922182	0.595	rs7176387	chr15:64219108	A/G	cg24729988	chr15:64271149	DAPK2	-0.46	-9.56	-0.35	2.49e-20	Blood protein levels;
BRCA	trans	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg21659725	chr3:3221576	CRBN	-0.48	-8.65	-0.32	4.23e-17	Menarche (age at onset);
BRCA	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg24692254	chr21:30365293	RNF160	0.77	21.21	0.64	5.42e-76	Dental caries;
BRCA	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg26384229	chr12:38710491	ALG10B	0.63	15.09	0.51	2.97e-44	Bladder cancer;
BRCA	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Tonsillectomy;
BRCA	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg02544614	chr20:61657117	NA	0.29	8.09	0.3	3e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg07148914	chr20:33460835	GGT7	0.43	8.78	0.33	1.44e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs7617773	0.780	rs13066758	chr3:48343877	G/A	cg11946769	chr3:48343235	NME6	0.69	13.87	0.48	2.01e-38	Coronary artery disease;
BRCA	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg22139774	chr2:100720529	AFF3	-0.29	-8.27	-0.31	7.82e-16	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg24642439	chr20:33292090	TP53INP2	-0.43	-9.17	-0.34	6.32e-19	Height;
BRCA	trans	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg25214090	chr10:38739885	LOC399744	0.56	12.39	0.44	9.8e-32	Corneal astigmatism;
BRCA	cis	rs2806561	0.704	rs6680974	chr1:23376233	A/G	cg19743168	chr1:23544995	NA	0.35	8.04	0.3	4.5e-15	Height;
BRCA	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08109568	chr15:31115862	NA	-0.51	-12.59	-0.45	1.31e-32	Huntington's disease progression;
BRCA	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg04944784	chr2:26401820	FAM59B	-0.69	-11.41	-0.41	1.37e-27	Gut microbiome composition (summer);
BRCA	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.65	0.39	1.68e-24	Bipolar disorder;
BRCA	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg25809561	chr17:30822961	MYO1D	0.4	9.5	0.35	4.06e-20	Schizophrenia;
BRCA	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg04691961	chr3:161091175	C3orf57	-0.58	-14.99	-0.51	9.31e-44	Morning vs. evening chronotype;
BRCA	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	9.87	0.36	1.77e-21	Tonsillectomy;
BRCA	cis	rs3125734	0.671	rs3852406	chr10:64015162	T/C	cg19640130	chr10:64028056	RTKN2	-0.29	-8.46	-0.32	1.84e-16	Rheumatoid arthritis;
BRCA	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14240646	chr10:27532245	ACBD5	0.74	9.4	0.35	9.27e-20	Breast cancer;
BRCA	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg24675658	chr1:53192096	ZYG11B	0.66	14.4	0.5	6.21e-41	Monocyte count;
BRCA	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg05283184	chr6:79620031	NA	-0.38	-9.57	-0.35	2.21e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg03354898	chr7:1950403	MAD1L1	-0.56	-12.57	-0.45	1.58e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg24459738	chr19:57751996	ZNF805	0.4	9.58	0.35	2.08e-20	Hyperactive-impulsive symptoms;
BRCA	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg12365402	chr11:9010492	NRIP3	0.41	9.25	0.34	3.33e-19	Hemoglobin concentration;
BRCA	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg23649088	chr2:200775458	C2orf69	0.61	9.06	0.34	1.54e-18	Schizophrenia;
BRCA	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg01420254	chr6:26195488	NA	0.57	8.81	0.33	1.15e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24229701	chr12:130821962	PIWIL1	0.39	8.93	0.33	4.4e-18	Menopause (age at onset);
BRCA	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg24069376	chr3:38537580	EXOG	0.33	9.4	0.35	9.8e-20	Electrocardiographic conduction measures;
BRCA	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg21854759	chr1:92012499	NA	-0.42	-9.8	-0.36	3.14e-21	Breast cancer;
BRCA	cis	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-8.8	-0.33	1.31e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs17401966	0.522	rs946504	chr1:10308597	T/C	cg03954927	chr1:10346856	KIF1B	0.34	10.46	0.38	9.71e-24	Hepatocellular carcinoma;
BRCA	cis	rs1691799	0.867	rs1168297	chr12:66735644	T/C	cg16791601	chr12:66731901	HELB	-0.65	-17.57	-0.57	1.16e-56	White blood cell count (basophil);
BRCA	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg24829409	chr8:58192753	C8orf71	-0.48	-9.14	-0.34	7.94e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.47	8.65	0.32	4.02e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4363385	0.818	rs419721	chr1:153006902	C/T	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg17211192	chr8:82754475	SNX16	-0.61	-11.94	-0.43	8.29e-30	Diastolic blood pressure;
BRCA	cis	rs503734	0.502	rs348876	chr3:100930989	A/G	cg27318481	chr3:100970896	IMPG2	-0.36	-8.61	-0.32	5.81e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11112613	0.762	rs66754070	chr12:105949779	G/A	cg03607813	chr12:105948248	NA	0.6	11.29	0.41	4.64e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	trans	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg19862616	chr7:65841803	NCRNA00174	0.81	25.25	0.71	4.33e-98	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg25036284	chr2:26402008	FAM59B	-0.89	-15.1	-0.51	2.72e-44	Gut microbiome composition (summer);
BRCA	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.56	-0.32	8.58e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21385522	chr1:16154831	NA	-0.88	-16.46	-0.55	4.99e-51	Dilated cardiomyopathy;
BRCA	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg22029157	chr1:209979665	IRF6	0.41	8.06	0.3	3.66e-15	Cleft lip with or without cleft palate;
BRCA	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.46	-10.33	-0.38	2.99e-23	Reticulocyte count;
BRCA	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg00012203	chr2:219082015	ARPC2	0.49	9.53	0.35	3.12e-20	Colorectal cancer;
BRCA	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg02297831	chr4:17616191	MED28	-0.34	-8.0	-0.3	5.95e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00934597	chr7:893267	UNC84A	-0.51	-11.19	-0.4	1.13e-26	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.01	-0.46	1.66e-34	Migraine;Coronary artery disease;
BRCA	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg26384229	chr12:38710491	ALG10B	0.67	14.37	0.49	9.24e-41	Heart rate;
BRCA	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg26597838	chr10:835615	NA	1.31	21.35	0.65	9.17e-77	Eosinophil percentage of granulocytes;
BRCA	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	10.92	0.4	1.46e-25	Bipolar disorder;
BRCA	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.28	-0.41	4.78e-27	Gut microbiome composition (summer);
BRCA	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg01939980	chr4:1354348	KIAA1530	0.39	10.81	0.39	4.01e-25	Longevity;
BRCA	cis	rs6728642	0.808	rs113319086	chr2:97633267	G/C	cg26665480	chr2:98280029	ACTR1B	-0.67	-7.86	-0.3	1.65e-14	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.95	-0.3	8.63e-15	Aortic root size;
BRCA	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg00814883	chr7:100076585	TSC22D4	-0.49	-10.26	-0.38	5.9e-23	Platelet count;
BRCA	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg10818794	chr15:86012489	AKAP13	-0.3	-8.44	-0.32	2.07e-16	Coronary artery disease;
BRCA	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18876405	chr7:65276391	NA	0.48	10.79	0.39	4.88e-25	Aortic root size;
BRCA	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg24977027	chr2:88469347	THNSL2	0.47	8.17	0.31	1.59e-15	Plasma clusterin levels;
BRCA	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg03585969	chr10:35415529	CREM	0.56	11.58	0.42	2.9e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.06e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg07080220	chr10:102295463	HIF1AN	0.56	11.9	0.43	1.27e-29	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs8014204	0.781	rs10143492	chr14:75212114	G/C	cg06637938	chr14:75390232	RPS6KL1	0.45	9.33	0.35	1.66e-19	Caffeine consumption;
BRCA	cis	rs6484504	0.576	rs2616792	chr11:31324298	T/G	cg26647111	chr11:31128758	NA	0.44	9.59	0.35	1.8899999999999998e-20	Red blood cell count;
BRCA	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.62	9.12	0.34	9.81e-19	Initial pursuit acceleration;
BRCA	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.95	0.4	1.07e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7524258	0.868	rs11120885	chr1:7306755	C/G	cg07173049	chr1:7289937	CAMTA1	0.41	9.97	0.37	7.37e-22	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.01	-22.16	-0.66	3.76e-81	Gut microbiome composition (summer);
BRCA	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.69	13.61	0.47	3.32e-37	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg26384229	chr12:38710491	ALG10B	0.67	14.24	0.49	3.8e-40	Morning vs. evening chronotype;
BRCA	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg05234568	chr11:5960015	NA	-0.49	-9.65	-0.36	1.15e-20	DNA methylation (variation);
BRCA	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg03923535	chr7:1197113	ZFAND2A	0.48	9.63	0.36	1.34e-20	Longevity;Endometriosis;
BRCA	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6545883	0.791	rs4672445	chr2:61655008	T/C	cg15711740	chr2:61764176	XPO1	0.56	14.37	0.49	8.46e-41	Tuberculosis;
BRCA	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	13.73	0.48	8.61e-38	Coronary artery disease;
BRCA	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-9.57	-0.35	2.2e-20	Tonsillectomy;
BRCA	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	10.92	0.4	1.4e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg06521331	chr12:34319734	NA	0.46	8.91	0.33	5.31e-18	Morning vs. evening chronotype;
BRCA	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.52	-10.77	-0.39	5.93e-25	Chronic sinus infection;
BRCA	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg26384229	chr12:38710491	ALG10B	0.68	14.12	0.49	1.38e-39	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg04705435	chr11:17411270	KCNJ11	0.43	9.32	0.35	1.89e-19	Type 2 diabetes;
BRCA	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg17063962	chr7:91808500	NA	-0.56	-12.82	-0.45	1.23e-33	Breast cancer;
BRCA	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg24812749	chr6:127587940	RNF146	0.68	15.41	0.52	8.21e-46	Breast cancer;
BRCA	trans	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg25042112	chr7:64838748	ZNF92	-0.45	-8.23	-0.31	1.03e-15	Pain;
BRCA	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg16482183	chr6:26056742	HIST1H1C	0.56	11.86	0.42	1.79e-29	Height;
BRCA	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg18132916	chr6:79620363	NA	-0.48	-10.89	-0.4	1.89e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.43	0.35	7.23e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-12.17	-0.43	8.6e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.53	-0.35	3.1e-20	Total body bone mineral density;
BRCA	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.75	-13.16	-0.46	3.72e-35	Platelet count;
BRCA	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-9.23	-0.34	3.82e-19	Menopause (age at onset);
BRCA	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.4	-0.32	2.97e-16	Colorectal cancer;
BRCA	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg19622623	chr12:86230825	RASSF9	-0.35	-9.69	-0.36	8.31e-21	Major depressive disorder;
BRCA	cis	rs2742234	0.759	rs12241923	chr10:43713047	T/C	cg02780029	chr10:43622663	RET	0.32	7.97	0.3	7.44e-15	Hirschsprung disease;
BRCA	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02176678	chr2:219576539	TTLL4	0.5	12.72	0.45	3.34e-33	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg26874164	chr19:58962979	ZNF324B	0.44	9.29	0.35	2.3e-19	Uric acid clearance;
BRCA	cis	rs1113500	0.702	rs11185262	chr1:108639742	C/T	cg06207961	chr1:108661230	NA	0.45	10.95	0.4	1.11e-25	Growth-regulated protein alpha levels;
BRCA	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg16405210	chr4:1374714	KIAA1530	0.87	19.83	0.62	1.54e-68	Longevity;
BRCA	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg03060546	chr3:49711283	APEH	-0.57	-8.86	-0.33	7.59e-18	Menarche (age at onset);
BRCA	cis	rs701145	0.585	rs1727947	chr3:153879467	C/T	cg17054900	chr3:154042577	DHX36	0.49	8.55	0.32	8.93e-17	Coronary artery disease;
BRCA	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg14926445	chr8:58193284	C8orf71	-0.44	-8.44	-0.32	2.14e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	13.42	0.47	2.36e-36	Mean platelet volume;
BRCA	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg21573476	chr21:45109991	RRP1B	-0.34	-9.13	-0.34	8.86e-19	Mean corpuscular volume;
BRCA	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg07988820	chr12:82153109	PPFIA2	-0.66	-10.68	-0.39	1.32e-24	Resting heart rate;
BRCA	cis	rs10779751	1.000	rs1135172	chr1:11301714	C/T	cg08854313	chr1:11322531	MTOR	-0.8	-16.7	-0.55	3.11e-52	Body mass index;
BRCA	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.59	9.16	0.34	7.02e-19	Renal function-related traits (BUN);
BRCA	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg02012338	chr4:187126139	CYP4V2	-0.84	-9.98	-0.37	6.55e-22	Blood protein levels;
BRCA	trans	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg25206134	chr2:45395956	NA	0.49	7.86	0.3	1.67e-14	Neuroticism;
BRCA	cis	rs7814319	0.966	rs10112328	chr8:97254372	C/T	cg20787634	chr8:97240163	UQCRB	0.46	10.14	0.37	1.65e-22	Lung function (FVC);
BRCA	cis	rs2286885	0.896	rs62578061	chr9:129248219	C/T	cg15282417	chr9:129245246	FAM125B	0.3	7.86	0.3	1.7e-14	Intraocular pressure;
BRCA	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-12.28	-0.44	2.95e-31	Tonsillectomy;
BRCA	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	20.41	0.63	1.11e-71	Smoking behavior;
BRCA	cis	rs11112613	0.713	rs17037317	chr12:105952058	T/C	cg03607813	chr12:105948248	NA	0.55	10.43	0.38	1.25e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg01324343	chr3:183735012	ABCC5	0.85	21.49	0.65	1.68e-77	Anterior chamber depth;
BRCA	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg14019146	chr3:50243930	SLC38A3	-0.58	-11.97	-0.43	6.2e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg21361702	chr7:150065534	REPIN1	0.51	10.44	0.38	1.13e-23	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.52	-0.32	1.14e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs6066825	0.644	rs2092492	chr20:47338650	A/G	cg18078177	chr20:47281410	PREX1	0.39	9.51	0.35	3.76e-20	Colorectal cancer;
BRCA	cis	rs27434	0.607	rs34750	chr5:96142806	G/C	cg16492584	chr5:96139282	ERAP1	-0.5	-13.01	-0.46	1.76e-34	Ankylosing spondylitis;
BRCA	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.42	-8.66	-0.32	3.83e-17	Eosinophil percentage of white cells;
BRCA	cis	rs939658	0.967	rs11629665	chr15:79457133	C/T	cg17916960	chr15:79447300	NA	0.38	9.5	0.35	4.02e-20	Refractive error;
BRCA	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg24829409	chr8:58192753	C8orf71	-0.59	-12.09	-0.43	1.86e-30	Developmental language disorder (linguistic errors);
BRCA	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.23	0.41	7.56e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11890956	chr21:40555474	PSMG1	1.04	29.27	0.76	3.97e-120	Cognitive function;
BRCA	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.42	9.1	0.34	1.14e-18	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7945718	0.875	rs9888179	chr11:12782601	G/T	cg25843174	chr11:12811716	TEAD1	0.22	8.7	0.33	2.87e-17	Educational attainment (years of education);
BRCA	trans	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg25214090	chr10:38739885	LOC399744	0.51	11.31	0.41	3.77e-27	Corneal astigmatism;
BRCA	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06022373	chr22:39101656	GTPBP1	0.73	18.11	0.58	1.89e-59	Menopause (age at onset);
BRCA	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg09307838	chr4:120376055	NA	0.75	16.17	0.54	1.48e-49	Corneal astigmatism;
BRCA	cis	rs4845875	0.563	rs10864540	chr1:11838099	A/G	cg24844545	chr1:11908347	NPPA	0.37	8.68	0.32	3.35e-17	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg26384229	chr12:38710491	ALG10B	-0.42	-9.88	-0.36	1.6e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg14675211	chr2:100938903	LONRF2	0.49	11.2	0.4	1.09e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.36	-0.38	2.43e-23	Mean corpuscular volume;
BRCA	cis	rs3739998	0.527	rs4749524	chr10:30332618	G/C	cg12786570	chr10:30316432	KIAA1462	0.49	9.69	0.36	8.39e-21	Coronary heart disease;
BRCA	cis	rs16944613	0.541	rs7183319	chr15:91095032	A/T	cg26821196	chr15:91095069	CRTC3	0.45	8.63	0.32	4.85e-17	Colorectal cancer;
BRCA	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg06627628	chr2:24431161	ITSN2	-0.57	-11.12	-0.4	2.24e-26	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs943466	1.000	rs7755323	chr6:33761159	A/G	cg25922239	chr6:33757077	LEMD2	-0.37	-8.35	-0.31	4.17e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	trans	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg13565492	chr6:43139072	SRF	-0.79	-8.14	-0.31	2.15e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-8.7	-0.33	2.89e-17	Monocyte percentage of white cells;
BRCA	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg11632617	chr15:75315747	PPCDC	0.4	8.7	0.33	2.89e-17	Blood trace element (Zn levels);
BRCA	cis	rs737008	0.960	rs949429	chr16:11376029	C/T	cg00044050	chr16:11439710	C16orf75	-0.36	-7.95	-0.3	8.64e-15	Obesity-related traits;
BRCA	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-18.12	-0.58	1.55e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg21045802	chr8:109455806	TTC35	0.35	8.02	0.3	5.19e-15	Dupuytren's disease;
BRCA	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg12311346	chr5:56204834	C5orf35	0.56	11.8	0.42	3.3600000000000003e-29	Initial pursuit acceleration;
BRCA	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg08213375	chr14:104286397	PPP1R13B	0.52	10.77	0.39	5.51e-25	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11764359	chr7:65958608	NA	-0.79	-19.09	-0.6	1.29e-64	Aortic root size;
BRCA	cis	rs34779708	0.931	rs6481935	chr10:35342959	C/T	cg03585969	chr10:35415529	CREM	0.46	9.52	0.35	3.37e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10802521	chr3:52805072	NEK4	-0.34	-9.33	-0.35	1.73e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7572733	0.534	rs700682	chr2:198712310	C/A	cg00792783	chr2:198669748	PLCL1	0.47	10.11	0.37	2.17e-22	Dermatomyositis;
BRCA	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg20203395	chr5:56204925	C5orf35	-0.5	-10.11	-0.37	2.13e-22	Initial pursuit acceleration;
BRCA	cis	rs1595825	0.838	rs57437055	chr2:198782617	A/C	cg19156104	chr2:198669113	PLCL1	-0.41	-7.84	-0.3	1.89e-14	Ulcerative colitis;
BRCA	cis	rs12760731	0.720	rs12026110	chr1:178410984	G/A	cg00404053	chr1:178313656	RASAL2	0.61	7.92	0.3	1.09e-14	Obesity-related traits;
BRCA	cis	rs708547	0.874	rs1713984	chr4:57886493	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.48	10.69	0.39	1.17e-24	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2073300	1.000	rs6106669	chr20:23460328	C/T	cg12062639	chr20:23401060	NAPB	0.6	8.67	0.32	3.63e-17	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs11690935	0.550	rs62183769	chr2:172838074	A/C	cg13550731	chr2:172543902	DYNC1I2	0.5	12.07	0.43	2.43e-30	Schizophrenia;
BRCA	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg12444411	chr7:2802554	GNA12	-0.38	-9.45	-0.35	6.34e-20	Height;
BRCA	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg24631222	chr15:78858424	CHRNA5	0.45	8.94	0.33	4.3e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.31	7.92	0.3	1.03e-14	IgG glycosylation;
BRCA	cis	rs57590327	0.503	rs13079104	chr3:81886039	A/T	cg07356753	chr3:81810745	GBE1	-0.45	-10.54	-0.38	4.61e-24	Extraversion;
BRCA	cis	rs7903847	0.642	rs9887991	chr10:99159634	T/C	cg20016023	chr10:99160130	RRP12	-0.26	-8.45	-0.32	1.91e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.65	9.8	0.36	3.27e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg19676328	chr12:49525230	TUBA1B	-0.51	-11.75	-0.42	5.34e-29	Total cholesterol levels;
BRCA	cis	rs2073300	1.000	rs115730610	chr20:23442621	G/A	cg12062639	chr20:23401060	NAPB	0.87	10.4	0.38	1.58e-23	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs10465746	0.653	rs11163877	chr1:84441848	T/A	cg10977910	chr1:84465055	TTLL7	0.57	12.06	0.43	2.46e-30	Obesity-related traits;
BRCA	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-7.88	-0.3	1.41e-14	Menopause (age at onset);
BRCA	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg17143192	chr8:8559678	CLDN23	0.57	12.35	0.44	1.48e-31	Obesity-related traits;
BRCA	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg07537917	chr2:241836409	C2orf54	-0.45	-9.99	-0.37	5.99e-22	Urinary metabolites;
BRCA	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11764359	chr7:65958608	NA	-0.76	-16.82	-0.55	7.85e-53	Aortic root size;
BRCA	cis	rs7633857	0.532	rs1580254	chr3:160767278	C/T	cg03342759	chr3:160939853	NMD3	-0.58	-12.22	-0.44	5.13e-31	Educational attainment (years of education);
BRCA	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.05e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-10.27	-0.38	5.1e-23	Heart rate;
BRCA	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11764359	chr7:65958608	NA	0.61	13.43	0.47	2.03e-36	Aortic root size;
BRCA	cis	rs9880211	0.898	rs6770476	chr3:136073920	C/T	cg21827317	chr3:136751795	NA	-0.41	-8.34	-0.31	4.7e-16	Body mass index;Height;
BRCA	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.38	0.49	8.02e-41	Motion sickness;
BRCA	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.04	0.4	4.7e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs9944715	0.954	rs8093407	chr18:43849464	A/G	cg01718231	chr17:29326311	RNF135	-0.45	-8.93	-0.33	4.67e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg13256891	chr4:100009986	ADH5	0.38	8.18	0.31	1.49e-15	Alcohol dependence;
BRCA	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.42	8.06	0.3	3.66e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg26384229	chr12:38710491	ALG10B	0.77	16.47	0.55	4.85e-51	Bladder cancer;
BRCA	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg15737290	chr11:93063684	CCDC67	0.5	9.71	0.36	7.03e-21	Pulmonary function decline;
BRCA	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg18230493	chr5:56204884	C5orf35	-0.73	-13.75	-0.48	7.45e-38	Initial pursuit acceleration;
BRCA	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg03354898	chr7:1950403	MAD1L1	-0.4	-8.38	-0.31	3.31e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg23625390	chr15:77176239	SCAPER	-0.5	-12.18	-0.43	7.72e-31	Blood metabolite levels;
BRCA	cis	rs12210905	0.688	rs12193557	chr6:27435944	T/C	cg08851530	chr6:28072375	NA	0.81	7.97	0.3	7.05e-15	Hip circumference adjusted for BMI;
BRCA	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.45	-10.06	-0.37	3.43e-22	Height;
BRCA	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg25110126	chr1:46999211	NA	0.74	13.93	0.48	1.1e-38	Monobrow;
BRCA	cis	rs34779708	0.733	rs4934740	chr10:35547141	C/T	cg03585969	chr10:35415529	CREM	0.44	9.1	0.34	1.17e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-8.98	-0.33	2.96e-18	Alzheimer's disease (late onset);
BRCA	trans	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg21659725	chr3:3221576	CRBN	-0.48	-8.96	-0.33	3.51e-18	Menarche (age at onset);
BRCA	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg05295671	chr13:79234353	RNF219	0.59	10.56	0.39	3.83e-24	Large artery stroke;
BRCA	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg16606324	chr3:10149918	C3orf24	0.57	10.04	0.37	3.9e-22	Alzheimer's disease;
BRCA	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.3	-0.49	1.94e-40	Eye color traits;
BRCA	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg11814155	chr7:99998594	ZCWPW1	0.56	9.42	0.35	7.84e-20	Platelet count;
BRCA	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg08601574	chr20:25228251	PYGB	0.35	8.45	0.32	1.89e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	9.08	0.34	1.34e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-8.55	-0.32	8.89e-17	Monocyte percentage of white cells;
BRCA	cis	rs78487399	0.808	rs13414619	chr2:43699406	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-7.99	-0.3	6.25e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg17971929	chr21:40555470	PSMG1	-0.47	-10.15	-0.37	1.59e-22	Menarche (age at onset);
BRCA	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg12483005	chr1:23474871	LUZP1	0.44	9.88	0.36	1.57e-21	Height;
BRCA	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg05283184	chr6:79620031	NA	-0.42	-10.75	-0.39	6.97e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg13567636	chr1:160991154	F11R	-0.48	-9.36	-0.35	1.35e-19	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg19257562	chr1:2043853	PRKCZ	-0.35	-9.21	-0.34	4.6e-19	Height;
BRCA	trans	rs4714291	0.832	rs1923462	chr6:39976100	T/C	cg02267698	chr19:7991119	CTXN1	-0.46	-9.35	-0.35	1.49e-19	Strep throat;
BRCA	cis	rs4363385	0.693	rs2339487	chr1:152983528	C/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.31	-0.31	5.54e-16	Inflammatory skin disease;
BRCA	cis	rs3784262	0.527	rs1441815	chr15:58274229	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-8.52	-0.32	1.16e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg18512352	chr11:47633146	NA	-0.35	-8.4	-0.32	2.8e-16	Subjective well-being;
BRCA	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12893428	chr3:195717962	SDHAP1	0.34	8.38	0.31	3.49e-16	Pancreatic cancer;
BRCA	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.81	0.33	1.2e-17	Motion sickness;
BRCA	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.16	0.31	1.85e-15	Total cholesterol levels;
BRCA	trans	rs7939886	0.920	rs1905069	chr11:55887135	T/C	cg15704280	chr7:45808275	SEPT13	0.61	7.94	0.3	9.12e-15	Myopia (pathological);
BRCA	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg22139774	chr2:100720529	AFF3	-0.29	-8.11	-0.31	2.56e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03517284	chr6:25882590	NA	-0.39	-8.18	-0.31	1.48e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg20224285	chr3:52813920	ITIH1	0.33	8.17	0.31	1.67e-15	Bipolar disorder;
BRCA	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15664640	chr17:80829946	TBCD	-0.69	-19.39	-0.61	3.09e-66	Breast cancer;
BRCA	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg14844989	chr11:31128820	NA	-0.45	-9.65	-0.36	1.18e-20	Red blood cell count;
BRCA	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg26031613	chr14:104095156	KLC1	-0.45	-8.81	-0.33	1.17e-17	Schizophrenia;
BRCA	trans	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.36	-8.25	-0.31	9.03e-16	Endometrial cancer;
BRCA	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.19e-40	Motion sickness;
BRCA	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.55	8.25	0.31	9.28e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	9.13	0.34	8.58e-19	Personality dimensions;
BRCA	trans	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg26384229	chr12:38710491	ALG10B	0.4	9.29	0.34	2.43e-19	Morning vs. evening chronotype;
BRCA	cis	rs144658219	1	rs144658219	chr7:80296965	G/GTACTTGAT	cg21369886	chr7:80305251	CD36	-0.39	-9.38	-0.35	1.16e-19	Red blood cell count;
BRCA	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg00074818	chr8:8560427	CLDN23	0.38	8.37	0.31	3.69e-16	Obesity-related traits;
BRCA	cis	rs72634258	0.554	rs12745962	chr1:7919825	C/T	cg00042356	chr1:8021962	PARK7	0.53	8.31	0.31	5.8e-16	Inflammatory bowel disease;
BRCA	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg22920501	chr2:26401640	FAM59B	-0.82	-13.04	-0.46	1.23e-34	Gut microbiome composition (summer);
BRCA	cis	rs113835537	0.529	rs57207756	chr11:66270360	C/T	cg24851651	chr11:66362959	CCS	0.51	8.83	0.33	9.85e-18	Airway imaging phenotypes;
BRCA	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg22906224	chr7:99728672	NA	-0.43	-8.04	-0.3	4.29e-15	Coronary artery disease;
BRCA	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	11.64	0.42	1.61e-28	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg19628046	chr18:33552617	C18orf21	0.58	11.87	0.43	1.66e-29	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs1451375	0.617	rs880029	chr7:50569927	G/C	cg18232548	chr7:50535776	DDC	-0.42	-9.0	-0.34	2.62e-18	Malaria;
BRCA	cis	rs2249625	0.761	rs2496500	chr6:72884438	G/C	cg18830697	chr6:72922368	RIMS1	-0.37	-7.86	-0.3	1.63e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg11764359	chr7:65958608	NA	-0.77	-17.78	-0.58	9.23e-58	Aortic root size;
BRCA	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg21573476	chr21:45109991	RRP1B	-0.36	-9.17	-0.34	6.35e-19	Mean corpuscular volume;
BRCA	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg22834771	chr12:69754056	YEATS4	-0.36	-8.77	-0.33	1.57e-17	Blood protein levels;
BRCA	trans	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg07211511	chr3:129823064	LOC729375	-0.62	-10.85	-0.39	2.79e-25	Blood pressure (smoking interaction);
BRCA	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg13319975	chr6:146136371	FBXO30	-0.37	-8.44	-0.32	2.2e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06108461	chr20:60628389	TAF4	-1.01	-22.73	-0.67	2.96e-84	Body mass index;
BRCA	cis	rs6840360	0.571	rs12650655	chr4:152556075	G/A	cg22705602	chr4:152727874	NA	-0.33	-8.49	-0.32	1.47e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg21017887	chr14:105400489	NA	0.65	17.46	0.57	4.36e-56	Rheumatoid arthritis;
BRCA	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg14784868	chr12:69753453	YEATS4	0.68	19.79	0.62	2.25e-68	Blood protein levels;
BRCA	cis	rs897080	0.515	rs698795	chr2:44689326	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	9.44	0.35	6.83e-20	Height;
BRCA	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	8.42	0.32	2.54e-16	Neuroticism;
BRCA	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg19920283	chr7:105172520	RINT1	0.58	9.39	0.35	1.02e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg03161606	chr19:29218774	NA	0.46	8.12	0.31	2.49e-15	Methadone dose in opioid dependence;
BRCA	cis	rs708547	1.000	rs10003229	chr4:57809598	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.47	-10.64	-0.39	1.87e-24	Response to bleomycin (chromatid breaks);
BRCA	trans	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	8.92e-15	Corneal astigmatism;
BRCA	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-15.9	-0.53	3.24e-48	Total cholesterol levels;
BRCA	cis	rs2625529	0.652	rs8023788	chr15:72459847	A/G	cg16672083	chr15:72433130	SENP8	0.66	16.15	0.54	1.76e-49	Red blood cell count;
BRCA	cis	rs867371	1.000	rs11855089	chr15:82447265	T/C	cg00614314	chr15:82944287	LOC80154	0.43	9.11	0.34	1.05e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg01236616	chr12:121019343	POP5	-1.17	-26.13	-0.72	6.5e-103	Type 1 diabetes nephropathy;
BRCA	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg18154014	chr19:37997991	ZNF793	0.48	9.41	0.35	8.49e-20	Coronary artery calcification;
BRCA	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	11.83	0.42	2.57e-29	Schizophrenia;
BRCA	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg25173405	chr17:45401733	C17orf57	-0.51	-10.35	-0.38	2.53e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6684514	1.000	rs2273833	chr1:156233189	C/T	cg16558208	chr1:156270281	VHLL	0.37	8.16	0.31	1.82e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	10.14	0.37	1.73e-22	Retinal vascular caliber;
BRCA	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg04586622	chr2:25135609	ADCY3	0.43	10.7	0.39	1.13e-24	Body mass index;
BRCA	trans	rs66573146	1.000	rs6838042	chr4:6973049	G/T	cg07817883	chr1:32538562	TMEM39B	1.41	17.47	0.57	3.73e-56	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs965469	0.779	rs3746630	chr20:3320902	C/T	cg25506879	chr20:3388711	C20orf194	-0.44	-8.82	-0.33	1.11e-17	IFN-related cytopenia;
BRCA	cis	rs7172677	0.737	rs8027604	chr15:75447773	C/T	cg14664628	chr15:75095509	CSK	-0.42	-9.02	-0.34	2.13e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.62	14.1	0.49	1.62e-39	Platelet count;
BRCA	cis	rs4631830	0.832	rs10825652	chr10:51510761	G/A	cg20129853	chr10:51489980	NA	0.29	7.99	0.3	6.29e-15	Prostate-specific antigen levels;
BRCA	cis	rs7737355	0.947	rs6895586	chr5:130588008	C/A	cg06307176	chr5:131281290	NA	0.45	8.8	0.33	1.3e-17	Life satisfaction;
BRCA	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg16006841	chr5:176797999	RGS14	0.61	11.88	0.43	1.57e-29	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.95	0.56	1.71e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11231017	0.507	rs10897267	chr11:62157418	C/T	cg23876832	chr11:62092739	NA	0.33	8.23	0.31	1.02e-15	HIV-1 viral setpoint;
BRCA	cis	rs7809950	0.678	rs2237659	chr7:106847492	G/T	cg23024343	chr7:107201750	COG5	0.43	8.55	0.32	9.33e-17	Coronary artery disease;
BRCA	cis	rs4974559	0.947	rs10000012	chr4:1357325	C/G	cg02980000	chr4:1222292	CTBP1	-0.69	-11.84	-0.42	2.26e-29	Systolic blood pressure;
BRCA	cis	rs2904967	0.852	rs488289	chr11:65039264	T/C	cg09225861	chr11:65069680	NA	0.39	8.07	0.3	3.62e-15	Mean corpuscular volume;
BRCA	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg05621596	chr22:47072043	GRAMD4	-0.47	-10.03	-0.37	4.55e-22	Urate levels in obese individuals;
BRCA	cis	rs2882667	0.690	rs891996	chr5:138267816	A/G	cg04439458	chr5:138467593	SIL1	-0.31	-7.91	-0.3	1.16e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg25237894	chr2:233734115	C2orf82	0.4	11.39	0.41	1.76e-27	Coronary artery disease;
BRCA	cis	rs3768617	0.624	rs34105373	chr1:183098387	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.46	10.37	0.38	2.14e-23	Fuchs's corneal dystrophy;
BRCA	cis	rs2797160	1.000	rs61299898	chr6:126007651	G/C	cg05901451	chr6:126070800	HEY2	0.39	9.4	0.35	9.72e-20	Endometrial cancer;
BRCA	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg25554036	chr4:6271136	WFS1	0.42	9.99	0.37	6.36e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg23422044	chr7:1970798	MAD1L1	-0.55	-9.48	-0.35	5.07e-20	Neuroticism;
BRCA	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg00031303	chr3:195681400	NA	0.5	9.65	0.36	1.15e-20	Pancreatic cancer;
BRCA	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg08999081	chr20:33150536	PIGU	-0.46	-12.49	-0.44	3.35e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.27	-0.54	4.82e-50	Alzheimer's disease (late onset);
BRCA	cis	rs9986765	1.000	rs9986765	chr7:142835239	C/T	cg21852589	chr7:142981689	TMEM139	-0.55	-9.55	-0.35	2.6e-20	Cancer;Dermatomyositis;
BRCA	cis	rs4363385	0.747	rs6668696	chr1:152964910	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.21	-0.34	4.48e-19	Inflammatory skin disease;
BRCA	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg16576597	chr16:28551801	NUPR1	0.35	8.86	0.33	8.13e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs13046373	0.535	rs2832966	chr21:32017177	A/G	cg22337977	chr21:31811175	KRTAP15-1	0.33	8.0	0.3	5.92e-15	HDL cholesterol;
BRCA	cis	rs4889609	0.834	rs72785520	chr16:31070778	C/T	cg00531865	chr16:30841666	NA	-0.36	-8.45	-0.32	2.04e-16	Response to metformin (IC50);
BRCA	cis	rs10751667	0.600	rs11246377	chr11:999796	G/T	ch.11.42038R	chr11:967971	AP2A2	0.47	14.47	0.5	2.93e-41	Alzheimer's disease (late onset);
BRCA	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg20818283	chr2:191399100	TMEM194B	-0.39	-9.16	-0.34	7.23e-19	Pulse pressure;
BRCA	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.09	0.49	1.88e-39	Eye color traits;
BRCA	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg06784218	chr1:46089804	CCDC17	-0.48	-11.53	-0.42	4.46e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs58235267	0.544	rs12478556	chr2:63341711	T/A	cg17519650	chr2:63277830	OTX1	0.38	8.14	0.31	2.03e-15	Prostate-specific antigen levels (conditioned on lead SNPs);
BRCA	cis	rs6435862	0.593	rs34732883	chr2:215674371	C/T	cg04004882	chr2:215674386	BARD1	-0.75	-17.8	-0.58	7.67e-58	Neuroblastoma (high-risk);
BRCA	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg08847533	chr14:75593920	NEK9	-0.88	-22.68	-0.67	5.28e-84	Height;
BRCA	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg24450063	chr1:156163899	SLC25A44	0.93	17.99	0.58	7.3e-59	Testicular germ cell tumor;
BRCA	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02353165	chr6:42928485	GNMT	0.75	18.09	0.58	2.25e-59	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18876405	chr7:65276391	NA	-0.62	-15.19	-0.52	1.02e-44	Aortic root size;
BRCA	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.96	-0.3	7.72e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	11.21	0.41	9.07e-27	Height;
BRCA	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg07169764	chr2:136633963	MCM6	1.22	23.96	0.69	5.42e-91	Corneal structure;
BRCA	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg26384229	chr12:38710491	ALG10B	0.42	9.36	0.35	1.34e-19	Morning vs. evening chronotype;
BRCA	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg26248373	chr2:1572462	NA	-0.57	-12.92	-0.46	4.13e-34	Placebo response in major depressive disorder (% change in symptom score);
BRCA	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.39	-10.12	-0.37	2e-22	Intelligence (multi-trait analysis);
BRCA	trans	rs12310956	0.510	rs10743832	chr12:33884146	A/C	cg26384229	chr12:38710491	ALG10B	0.42	9.46	0.35	5.83e-20	Morning vs. evening chronotype;
BRCA	cis	rs6740322	0.895	rs28456986	chr2:43553321	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-12.26	-0.44	3.38e-31	Coronary artery disease;
BRCA	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.3	0.49	1.82e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.52	-10.15	-0.37	1.49e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9875589	0.915	rs13097822	chr3:13969396	T/A	cg19554555	chr3:13937349	NA	0.4	8.36	0.31	4.01e-16	Ovarian reserve;
BRCA	cis	rs3820928	0.845	rs7570869	chr2:227878818	A/C	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.1	-0.31	2.75e-15	Pulmonary function;
BRCA	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg26384229	chr12:38710491	ALG10B	-0.62	-14.81	-0.51	6.86e-43	Bladder cancer;
BRCA	cis	rs13161895	1.000	rs34603792	chr5:179459287	A/G	cg02702477	chr5:179499311	RNF130	0.45	8.45	0.32	2.01e-16	LDL cholesterol;
BRCA	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg23649088	chr2:200775458	C2orf69	-0.62	-10.49	-0.38	7.56e-24	Schizophrenia;
BRCA	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg00339695	chr16:24857497	SLC5A11	0.52	11.01	0.4	5.92e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg15145296	chr3:125709740	NA	-0.55	-8.7	-0.33	2.73e-17	Blood pressure (smoking interaction);
BRCA	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg14458575	chr2:238380390	NA	0.54	8.08	0.3	3.34e-15	Prostate cancer;
BRCA	cis	rs752010	0.905	rs10890150	chr1:42095603	A/C	cg06885757	chr1:42089581	HIVEP3	0.29	10.21	0.37	8.87e-23	Lupus nephritis in systemic lupus erythematosus;
BRCA	trans	rs4650994	0.967	rs6681043	chr1:178525957	A/G	cg05059571	chr16:84539110	KIAA1609	-0.42	-9.48	-0.35	5.01e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs2859741	0.528	rs59729868	chr1:37493710	G/A	cg09363841	chr1:37513479	NA	-0.51	-11.1	-0.4	2.62e-26	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs965469	1.000	rs6051724	chr20:3279338	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-10.24	-0.38	6.8e-23	IFN-related cytopenia;
BRCA	cis	rs75804782	0.641	rs41264155	chr2:239342096	G/A	cg18131467	chr2:239335373	ASB1	-0.62	-7.85	-0.3	1.8e-14	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs6815814	0.950	rs5743795	chr4:38832495	C/T	cg02016764	chr4:38805732	TLR1	-0.52	-8.09	-0.3	2.92e-15	Breast cancer;
BRCA	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg03585969	chr10:35415529	CREM	0.56	11.5	0.41	5.98e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs312274	0.674	rs10879340	chr12:41295126	A/C	cg17827154	chr12:41323612	CNTN1	-0.43	-10.77	-0.39	5.48e-25	Metabolite levels  (X-11787);
BRCA	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg06238570	chr21:40685208	BRWD1	-0.39	-7.97	-0.3	7.54e-15	Menarche (age at onset);
BRCA	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg04518342	chr5:131593106	PDLIM4	0.42	10.1	0.37	2.41e-22	Acylcarnitine levels;
BRCA	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11890956	chr21:40555474	PSMG1	0.66	15.39	0.52	1.11e-45	Cognitive function;
BRCA	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11890956	chr21:40555474	PSMG1	1.06	30.07	0.77	1.88e-124	Cognitive function;
BRCA	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	20.81	0.64	8.17e-74	Platelet count;
BRCA	cis	rs708547	0.735	rs1277280	chr4:57866872	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-10.53	-0.38	5.32e-24	Response to bleomycin (chromatid breaks);
BRCA	cis	rs7903847	0.642	rs2275090	chr10:99148151	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.51	-0.32	1.28e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-8.34	-0.31	4.66e-16	Hepatocellular carcinoma;
BRCA	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg25208724	chr1:156163844	SLC25A44	0.89	17.93	0.58	1.52e-58	Testicular germ cell tumor;
BRCA	cis	rs17601876	0.814	rs749292	chr15:51558731	A/G	cg19946085	chr15:51559439	CYP19A1	0.38	11.61	0.42	2.11e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs3740540	0.530	rs2362505	chr10:126290739	T/G	cg04949429	chr10:126290192	LHPP	0.44	12.32	0.44	1.96e-31	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg06784218	chr1:46089804	CCDC17	-0.46	-10.5	-0.38	6.66e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03264133	chr6:25882463	NA	-0.7	-16.67	-0.55	4.49e-52	Blood metabolite levels;
BRCA	trans	rs1973993	0.967	rs10875017	chr1:96949526	C/T	cg10631902	chr5:14652156	NA	0.52	16.32	0.54	2.52e-50	Weight;
BRCA	cis	rs965469	1.000	rs2236089	chr20:3257194	C/A	cg25506879	chr20:3388711	C20orf194	-0.56	-10.94	-0.4	1.18e-25	IFN-related cytopenia;
BRCA	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg25036284	chr2:26402008	FAM59B	-0.64	-10.67	-0.39	1.37e-24	Gut microbiome composition (summer);
BRCA	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg22963979	chr7:1858916	MAD1L1	-0.37	-7.84	-0.3	1.91e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12292205	chr6:26970375	C6orf41	-0.48	-8.13	-0.31	2.3e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs11585357	0.895	rs72633823	chr1:17630779	G/A	cg19159961	chr1:17633534	PADI4	0.58	9.18	0.34	6.01e-19	Hair shape;
BRCA	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03517284	chr6:25882590	NA	-0.35	-7.92	-0.3	1.05e-14	Height;
BRCA	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg13010199	chr12:38710504	ALG10B	0.37	7.84	0.3	1.91e-14	Heart rate;
BRCA	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg11814155	chr7:99998594	ZCWPW1	0.59	10.15	0.37	1.52e-22	Platelet count;
BRCA	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg08859206	chr1:53392774	SCP2	-0.63	-13.9	-0.48	1.46e-38	Monocyte count;
BRCA	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg25482853	chr8:67687455	SGK3	-0.88	-14.36	-0.49	1.02e-40	Obesity-related traits;
BRCA	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-12.77	-0.45	1.94e-33	Bipolar disorder;
BRCA	trans	rs11088226	0.681	rs2833902	chr21:33940458	A/G	cg09050820	chr6:167586206	TCP10L2	0.78	13.22	0.46	1.92e-35	Gastritis;
BRCA	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.14e-19	Total body bone mineral density;
BRCA	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg24692254	chr21:30365293	RNF160	-0.79	-22.1	-0.66	7.51e-81	Dental caries;
BRCA	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg20387954	chr3:183756860	HTR3D	0.45	10.14	0.37	1.6e-22	Anterior chamber depth;
BRCA	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg26838691	chr2:24397539	C2orf84	-0.49	-8.85	-0.33	8.53e-18	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg08179530	chr6:36648295	CDKN1A	0.67	15.97	0.53	1.41e-48	QRS duration;
BRCA	cis	rs1975974	0.872	rs17052344	chr17:21717543	A/G	cg18423549	chr17:21743878	NA	0.53	11.68	0.42	1.04e-28	Psoriasis;
BRCA	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg14784868	chr12:69753453	YEATS4	0.68	19.79	0.62	2.42e-68	Blood protein levels;
BRCA	cis	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg06521331	chr12:34319734	NA	-0.55	-9.86	-0.36	1.89e-21	Morning vs. evening chronotype;
BRCA	cis	rs1997103	1.000	rs6949222	chr7:55411264	C/T	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs1371614	0.632	rs1992311	chr2:27159341	G/A	cg00617064	chr2:27272375	NA	-0.3	-7.93	-0.3	1.02e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg03676636	chr4:99064102	C4orf37	0.2	7.83	0.3	2.1e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg24812749	chr6:127587940	RNF146	0.88	20.75	0.63	1.58e-73	Breast cancer;
BRCA	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg18196295	chr10:418757	DIP2C	-0.41	-9.58	-0.35	2.19e-20	Psychosis in Alzheimer's disease;
BRCA	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg00717180	chr2:96193071	NA	0.32	8.73	0.33	2.16e-17	Coronary artery disease;
BRCA	cis	rs7572733	0.534	rs58374969	chr2:198764363	C/T	cg00792783	chr2:198669748	PLCL1	0.49	10.42	0.38	1.37e-23	Dermatomyositis;
BRCA	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	9.21	0.34	4.81e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg04990556	chr1:26633338	UBXN11	0.56	9.15	0.34	7.48e-19	Obesity-related traits;
BRCA	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg13319975	chr6:146136371	FBXO30	-0.34	-7.96	-0.3	7.78e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg01448562	chr3:133502909	NA	0.39	9.01	0.34	2.41e-18	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	13.74	0.48	7.57e-38	Schizophrenia;
BRCA	cis	rs2625529	0.618	rs6494992	chr15:72420750	G/C	cg16672083	chr15:72433130	SENP8	0.65	15.56	0.52	1.55e-46	Red blood cell count;
BRCA	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg22713356	chr15:30763199	NA	1.3	24.75	0.7	2.51e-95	Uric acid levels;
BRCA	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.43	-0.38	1.25e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg00666640	chr1:248458726	OR2T12	0.35	8.85	0.33	8.41e-18	Common traits (Other);
BRCA	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg17971929	chr21:40555470	PSMG1	0.6	13.8	0.48	4.36e-38	Cognitive function;
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg18402987	chr7:1209562	NA	0.52	9.97	0.37	7.17e-22	Longevity;Endometriosis;
BRCA	cis	rs1371614	0.632	rs3739085	chr2:27163044	T/C	cg00617064	chr2:27272375	NA	-0.31	-8.1	-0.31	2.76e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg09021430	chr5:549028	NA	-0.66	-16.91	-0.56	2.82e-53	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg03806693	chr22:41940476	POLR3H	-0.56	-9.75	-0.36	4.8e-21	Neuroticism;
BRCA	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg14298792	chr15:30685198	CHRFAM7A	-0.4	-7.87	-0.3	1.5e-14	Huntington's disease progression;
BRCA	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg27170947	chr2:26402098	FAM59B	-0.64	-11.34	-0.41	2.73e-27	Gut microbiome composition (summer);
BRCA	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.13	-0.43	1.25e-30	Alzheimer's disease;
BRCA	cis	rs11585357	0.895	rs877552	chr1:17631236	C/T	cg19159961	chr1:17633534	PADI4	0.58	9.59	0.35	1.93e-20	Hair shape;
BRCA	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg11843238	chr5:131593191	PDLIM4	-0.35	-9.17	-0.34	6.36e-19	Breast cancer;
BRCA	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg08847533	chr14:75593920	NEK9	-0.88	-22.39	-0.66	1.97e-82	Height;
BRCA	cis	rs7572733	0.515	rs11887138	chr2:198805838	T/A	cg00792783	chr2:198669748	PLCL1	0.45	9.89	0.36	1.43e-21	Dermatomyositis;
BRCA	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg16482183	chr6:26056742	HIST1H1C	0.46	8.87	0.33	7.32e-18	Iron status biomarkers;
BRCA	cis	rs4363385	0.791	rs10788855	chr1:153002359	A/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.32	-0.31	5.19e-16	Inflammatory skin disease;
BRCA	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10819733	chr22:24237672	NA	-0.3	-8.25	-0.31	9.11e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg16989086	chr20:62203971	PRIC285	0.53	8.97	0.33	3.29e-18	Glioblastoma;
BRCA	cis	rs17490626	0.568	rs12413525	chr10:71211721	C/A	cg12610070	chr10:71211762	TSPAN15	-0.33	-11.77	-0.42	4.44e-29	Thrombosis;
BRCA	cis	rs7677751	0.806	rs4864863	chr4:55100831	A/G	cg17187183	chr4:55093834	PDGFRA	0.43	8.84	0.33	9.59e-18	Corneal astigmatism;
BRCA	cis	rs112908525	1	rs112908525	chr7:80305278	T/TGAGGGTTGA	cg21369886	chr7:80305251	CD36	-0.4	-9.74	-0.36	5.44e-21	Mean corpuscular volume;
BRCA	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	9.31	0.35	1.94e-19	Multiple sclerosis;
BRCA	cis	rs7394190	0.748	rs3088070	chr10:75530013	C/T	cg07699608	chr10:75541558	CHCHD1	0.65	9.64	0.36	1.26e-20	Incident atrial fibrillation;
BRCA	cis	rs16910800	0.731	rs56067480	chr11:23190184	C/T	cg20040320	chr11:23191996	NA	-0.59	-10.23	-0.38	7.61e-23	Cancer;
BRCA	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	10.07	0.37	3.05e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg17063962	chr7:91808500	NA	-0.51	-11.89	-0.43	1.32e-29	Breast cancer;
BRCA	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11644478	chr21:40555479	PSMG1	0.85	19.38	0.61	3.87e-66	Cognitive function;
BRCA	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg01305625	chr5:131593812	PDLIM4	0.34	8.07	0.3	3.4e-15	Acylcarnitine levels;
BRCA	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	11.01	0.4	5.99e-26	Monocyte percentage of white cells;
BRCA	cis	rs34891900	0.507	rs738133	chr22:18205557	C/T	cg19898043	chr22:18121309	BCL2L13	0.46	9.66	0.36	1.03e-20	Sum neutrophil eosinophil counts;
BRCA	cis	rs775227	0.574	rs60279293	chr3:113096087	T/G	cg18753928	chr3:113234510	CCDC52	-0.55	-9.3	-0.35	2.28e-19	Dental caries;
BRCA	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.74e-18	Motion sickness;
BRCA	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg11161846	chr1:160990452	F11R	-0.54	-13.22	-0.46	1.86e-35	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg00106254	chr7:1943704	MAD1L1	-0.31	-7.94	-0.3	9.14e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05901451	chr6:126070800	HEY2	-0.45	-10.78	-0.39	5.43e-25	Endometrial cancer;
BRCA	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg04450456	chr4:17643702	FAM184B	0.41	12.15	0.43	1.06e-30	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8032158	1.000	rs7176225	chr15:56126857	G/A	cg02198044	chr15:56286336	NEDD4	-0.38	-9.05	-0.34	1.76e-18	Keloid;
BRCA	cis	rs12618769	0.625	rs72819982	chr2:99043337	A/G	cg10123293	chr2:99228465	UNC50	0.4	8.03	0.3	4.87e-15	Bipolar disorder;
BRCA	cis	rs7586879	0.789	rs13404163	chr2:25126616	A/G	cg04586622	chr2:25135609	ADCY3	0.4	9.48	0.35	4.86e-20	Body mass index;
BRCA	cis	rs10463316	0.894	rs6579864	chr5:150762181	G/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.22	-0.31	1.12e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs490234	0.683	rs9409281	chr9:128159171	C/G	cg14078157	chr9:128172775	NA	-0.36	-8.42	-0.32	2.43e-16	Mean arterial pressure;
BRCA	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg21535247	chr6:8435926	SLC35B3	0.41	9.27	0.34	2.9e-19	Motion sickness;
BRCA	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg20607798	chr8:58055168	NA	0.63	9.54	0.35	2.86e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg04025307	chr7:1156635	C7orf50	0.53	13.44	0.47	1.88e-36	Longevity;Endometriosis;
BRCA	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg02403541	chr12:121454288	C12orf43	0.44	8.64	0.32	4.35e-17	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
BRCA	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg18512352	chr11:47633146	NA	-0.33	-7.88	-0.3	1.39e-14	Subjective well-being;
BRCA	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	15.87	0.53	4.82e-48	Platelet count;
BRCA	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	26.38	0.72	2.76e-104	Chronic sinus infection;
BRCA	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg11845111	chr2:191398756	TMEM194B	-0.76	-13.92	-0.48	1.2e-38	Diastolic blood pressure;
BRCA	cis	rs778371	0.647	rs974321	chr2:233638351	G/A	cg08000102	chr2:233561755	GIGYF2	0.78	16.67	0.55	4.54e-52	Schizophrenia;
BRCA	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg14343924	chr8:8086146	FLJ10661	0.4	8.26	0.31	8.36e-16	Mood instability;
BRCA	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.25	-9.34	-0.35	1.58e-19	Schizophrenia;
BRCA	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg21782813	chr7:2030301	MAD1L1	0.39	11.4	0.41	1.55e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.66e-15	Menopause (age at onset);
BRCA	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg25801113	chr15:45476975	SHF	-0.33	-8.3	-0.31	6.21e-16	Uric acid levels;
BRCA	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.91	-31.34	-0.78	2.69e-131	Schizophrenia;
BRCA	cis	rs7945718	0.775	rs10500759	chr11:12822588	A/G	cg25843174	chr11:12811716	TEAD1	-0.23	-8.81	-0.33	1.18e-17	Educational attainment (years of education);
BRCA	cis	rs698833	0.620	rs1067354	chr2:44663675	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	8.4	0.32	2.9e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	trans	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg06521331	chr12:34319734	NA	-0.46	-8.52	-0.32	1.1e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.23	-0.38	7.32e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9790314	0.730	rs4856705	chr3:161100219	T/G	cg04691961	chr3:161091175	C3orf57	-0.4	-9.39	-0.35	1.04e-19	Morning vs. evening chronotype;
BRCA	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg03433033	chr1:76189801	ACADM	0.69	12.93	0.46	3.86e-34	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.52	7.97	0.3	7.39e-15	HIV-1 control;
BRCA	cis	rs6987853	0.736	rs2923446	chr8:42404177	G/A	cg09913449	chr8:42400586	C8orf40	0.4	9.11	0.34	1.07e-18	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.08	-0.4	3.36e-26	Extrinsic epigenetic age acceleration;
BRCA	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-9.65	-0.36	1.14e-20	Axial length;
BRCA	cis	rs250677	0.522	rs919731	chr5:148352150	T/C	cg12140854	chr5:148520817	ABLIM3	0.41	8.46	0.32	1.83e-16	Breast cancer;
BRCA	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg24642439	chr20:33292090	TP53INP2	0.71	15.79	0.53	1.16e-47	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg25358565	chr5:93447407	FAM172A	-0.66	-11.57	-0.42	3.15e-28	Diabetic retinopathy;
BRCA	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg03188948	chr7:1209495	NA	0.82	11.41	0.41	1.43e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.52	11.21	0.41	9.32e-27	Colorectal cancer;
BRCA	cis	rs7580658	0.545	rs59318157	chr2:127950074	G/C	cg16751203	chr2:127950803	CYP27C1	0.29	8.07	0.3	3.55e-15	Protein C levels;
BRCA	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	11.67	0.42	1.12e-28	Schizophrenia;
BRCA	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg06238570	chr21:40685208	BRWD1	-0.42	-8.65	-0.32	4.03e-17	Cognitive function;
BRCA	cis	rs524281	0.861	rs4013917	chr11:65926185	A/G	cg16950941	chr11:66035639	RAB1B	-0.37	-7.84	-0.3	1.91e-14	Electroencephalogram traits;
BRCA	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg26168224	chr5:2018326	NA	0.48	11.03	0.4	5e-26	Gut microbiome composition (winter);
BRCA	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg20307385	chr11:47447363	PSMC3	0.43	9.67	0.36	9.81e-21	Subjective well-being;
BRCA	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.43	-0.41	1.22e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg11833968	chr6:79620685	NA	-0.42	-9.55	-0.35	2.74e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.31	-0.31	5.58e-16	Bipolar disorder;
BRCA	cis	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.29	-0.38	4.28e-23	Morning vs. evening chronotype;
BRCA	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg08000102	chr2:233561755	GIGYF2	-0.46	-9.99	-0.37	6.34e-22	Coronary artery disease;
BRCA	cis	rs58804349	0.685	rs11239855	chr10:43483879	A/G	cg08461752	chr10:43522343	NA	0.64	10.83	0.39	3.18e-25	Pediatric bone mineral content (radius);
BRCA	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg26384229	chr12:38710491	ALG10B	0.66	15.31	0.52	2.75e-45	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg17420585	chr12:42539391	GXYLT1	-0.49	-10.6	-0.39	2.61e-24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs4363385	0.818	rs1415969	chr1:153006448	G/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.49	-0.32	1.4e-16	Inflammatory skin disease;
BRCA	cis	rs7819412	0.502	rs11777918	chr8:11036919	A/G	cg21775007	chr8:11205619	TDH	0.43	8.42	0.32	2.42e-16	Triglycerides;
BRCA	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs370915	0.542	rs1425953	chr4:187833652	A/C	cg19519643	chr4:187840862	NA	-0.36	-8.5	-0.32	1.34e-16	Gout;
BRCA	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg05623727	chr3:50126028	RBM5	0.46	8.85	0.33	8.54e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs13046373	0.534	rs9305426	chr21:31964916	A/C	cg22337977	chr21:31811175	KRTAP15-1	0.34	7.94	0.3	9.15e-15	HDL cholesterol;
BRCA	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.63	10.18	0.37	1.16e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg26384229	chr12:38710491	ALG10B	0.77	17.67	0.57	3.37e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg00277334	chr10:82204260	NA	-0.43	-8.51	-0.32	1.2e-16	Post bronchodilator FEV1;
BRCA	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg17971929	chr21:40555470	PSMG1	-0.49	-10.73	-0.39	8.27e-25	Menarche (age at onset);
BRCA	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg01324343	chr3:183735012	ABCC5	0.79	19.65	0.61	1.32e-67	Anterior chamber depth;
BRCA	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg11764359	chr7:65958608	NA	0.68	15.24	0.52	5.79e-45	Aortic root size;
BRCA	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg09307838	chr4:120376055	NA	0.64	13.94	0.48	9.61e-39	Corneal astigmatism;
BRCA	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg10523679	chr1:76189770	ACADM	0.67	11.98	0.43	5.52e-30	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs8032158	1.000	rs2288344	chr15:56122347	T/G	cg02198044	chr15:56286336	NEDD4	-0.38	-9.08	-0.34	1.36e-18	Keloid;
BRCA	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.35	-0.35	1.46e-19	Bipolar disorder;
BRCA	cis	rs4074536	0.536	rs6687862	chr1:116289728	T/C	cg21648376	chr1:116311395	CASQ2	-0.49	-8.71	-0.33	2.5e-17	QRS duration;
BRCA	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.32	-9.63	-0.36	1.43e-20	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg27433088	chr4:174089019	GALNT7	0.33	8.78	0.33	1.54e-17	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg16576597	chr16:28551801	NUPR1	0.3	8.37	0.31	3.53e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.14	0.31	2.06e-15	Cognitive ability;
BRCA	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg18876405	chr7:65276391	NA	0.51	7.97	0.3	7.08e-15	Diabetic kidney disease;
BRCA	cis	rs1420338	0.839	rs918036	chr7:34181859	A/G	cg01275685	chr7:34179230	BMPER	-0.51	-11.35	-0.41	2.45e-27	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	trans	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg26384229	chr12:38710491	ALG10B	0.51	10.95	0.4	1.1e-25	Morning vs. evening chronotype;
BRCA	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg25173405	chr17:45401733	C17orf57	-0.47	-9.71	-0.36	7e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.81	0.36	2.92e-21	Bipolar disorder;
BRCA	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.22	-0.34	4.29e-19	Neuroticism;
BRCA	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg11843238	chr5:131593191	PDLIM4	0.36	7.88	0.3	1.39e-14	Acylcarnitine levels;
BRCA	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg11502198	chr6:26597334	ABT1	0.52	9.96	0.37	7.94e-22	Intelligence (multi-trait analysis);
BRCA	trans	rs208520	0.690	rs864314	chr6:66814830	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.13	-38.83	-0.84	2.83e-170	Exhaled nitric oxide output;
BRCA	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg11812906	chr14:75593930	NEK9	-0.61	-14.13	-0.49	1.21e-39	Height;
BRCA	cis	rs7011049	1.000	rs11993171	chr8:53832898	C/A	cg26025543	chr8:53854495	NA	0.55	9.94	0.37	9.57e-22	Systolic blood pressure;
BRCA	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00166722	chr3:10149974	C3orf24	0.66	13.26	0.46	1.33e-35	Alzheimer's disease;
BRCA	cis	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg06521331	chr12:34319734	NA	-0.56	-10.19	-0.37	1.06e-22	Morning vs. evening chronotype;
BRCA	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg26149184	chr10:133730230	NA	0.42	8.25	0.31	8.92e-16	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg17971929	chr21:40555470	PSMG1	0.8	19.27	0.61	1.36e-65	Cognitive function;
BRCA	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg12011299	chr4:100065546	ADH4	-0.5	-11.53	-0.41	4.55e-28	Alcohol dependence;
BRCA	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.04	15.68	0.53	3.87e-47	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg21775007	chr8:11205619	TDH	0.62	11.99	0.43	5.23e-30	Retinal vascular caliber;
BRCA	cis	rs9790314	0.695	rs7637086	chr3:160836822	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-11.33	-0.41	3.02e-27	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg05896524	chr21:47604654	C21orf56	0.5	9.69	0.36	8.36e-21	Testicular germ cell tumor;
BRCA	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg19418458	chr7:158789849	NA	-0.41	-9.26	-0.34	2.94e-19	Facial morphology (factor 20);
BRCA	cis	rs12210905	0.688	rs114157955	chr6:27329878	C/T	cg08851530	chr6:28072375	NA	0.91	8.7	0.33	2.7e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs858239	0.600	rs7776644	chr7:23119307	C/T	cg23682824	chr7:23144976	KLHL7	0.44	11.45	0.41	9.84e-28	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.48	-8.67	-0.32	3.53e-17	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.89e-18	Motion sickness;
BRCA	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg18132916	chr6:79620363	NA	-0.39	-8.09	-0.3	3.05e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg23033748	chr14:75592666	NEK9	-0.43	-10.61	-0.39	2.43e-24	Height;
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-10.7	-0.39	1.09e-24	Longevity;Endometriosis;
BRCA	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.29	0.31	6.9e-16	Parkinson's disease;
BRCA	cis	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-9.57	-0.35	2.2e-20	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs12541635	0.677	rs6469032	chr8:107057509	A/T	cg10147462	chr8:107024639	NA	0.41	10.89	0.4	1.89e-25	Age of smoking initiation;
BRCA	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg14863265	chr7:2801509	GNA12	-0.46	-10.07	-0.37	3.06e-22	Height;
BRCA	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg24060327	chr5:131705240	SLC22A5	0.46	9.44	0.35	7.06e-20	Blood metabolite levels;
BRCA	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.29	-0.38	4.59e-23	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6723226	0.772	rs2366894	chr2:32713706	A/T	cg02381751	chr2:32503542	YIPF4	0.69	15.25	0.52	5.11e-45	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg05283184	chr6:79620031	NA	-0.43	-11.03	-0.4	4.97e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-8.7	-0.33	2.78e-17	Monocyte percentage of white cells;
BRCA	cis	rs7617773	0.780	rs35297395	chr3:48342882	C/T	cg11946769	chr3:48343235	NME6	0.68	13.79	0.48	4.87e-38	Coronary artery disease;
BRCA	cis	rs3916	0.911	rs7313271	chr12:121152667	C/T	cg21892295	chr12:121157589	UNC119B	-0.38	-9.78	-0.36	3.69e-21	Urinary metabolites (H-NMR features);
BRCA	cis	rs66887589	0.934	rs4834792	chr4:120555696	T/A	cg09307838	chr4:120376055	NA	-0.44	-9.14	-0.34	8.1e-19	Diastolic blood pressure;
BRCA	trans	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.9	-0.36	1.38e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg22117172	chr7:91764530	CYP51A1	0.23	7.99	0.3	6.46e-15	Breast cancer;
BRCA	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg13010199	chr12:38710504	ALG10B	0.5	10.33	0.38	2.96e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.35	0.49	1.13e-40	Motion sickness;
BRCA	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.23	0.31	1.07e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg07460842	chr6:66804631	NA	-1.0	-20.11	-0.62	4.5e-70	Exhaled nitric oxide output;
BRCA	cis	rs11718455	0.960	rs13082990	chr3:44005172	T/C	cg08738300	chr3:44038990	NA	0.47	8.85	0.33	8.52e-18	Coronary artery disease;
BRCA	cis	rs10499694	1.000	rs10499694	chr7:50614173	A/G	cg18232548	chr7:50535776	DDC	-0.36	-9.01	-0.34	2.34e-18	Body mass index;
BRCA	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg10876282	chr6:28092338	ZSCAN16	0.41	7.95	0.3	8.43e-15	Parkinson's disease;
BRCA	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg09904177	chr6:26538194	HMGN4	0.47	14.72	0.5	1.88e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.78	-0.42	3.93e-29	Bipolar disorder;
BRCA	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08048268	chr3:133502702	NA	0.43	11.22	0.41	8.37e-27	Iron status biomarkers;
BRCA	cis	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg06521331	chr12:34319734	NA	-0.52	-10.22	-0.37	8.04e-23	Morning vs. evening chronotype;
BRCA	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.81	-0.33	1.15e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg17425144	chr1:10567563	PEX14	0.56	14.31	0.49	1.75e-40	Breast cancer;
BRCA	cis	rs9462027	0.628	rs7756405	chr6:34722659	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.99	-0.3	6.37e-15	Systemic lupus erythematosus;
BRCA	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	14.11	0.49	1.47e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1799922	0.684	rs339095	chr7:128406047	C/G	cg02354431	chr7:128423266	NA	0.31	7.97	0.3	7.46e-15	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
BRCA	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	14.42	0.5	5.25e-41	Motion sickness;
BRCA	cis	rs9463078	0.665	rs9472339	chr6:44711791	A/G	cg25276700	chr6:44698697	NA	0.37	8.57	0.32	7.53e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	trans	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.35	-7.88	-0.3	1.41e-14	Endometrial cancer;
BRCA	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11764359	chr7:65958608	NA	0.74	16.65	0.55	5.68e-52	Aortic root size;
BRCA	trans	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg26043149	chr18:55253948	FECH	1.02	25.1	0.7	2.66e-97	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg21132104	chr15:45694354	SPATA5L1	0.74	16.77	0.55	1.47e-52	Homoarginine levels;
BRCA	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-9.67	-0.36	9.63e-21	Mean corpuscular volume;
BRCA	cis	rs7560272	0.501	rs11126417	chr2:73974315	A/G	cg20560298	chr2:73613845	ALMS1	-0.34	-8.57	-0.32	7.58e-17	Schizophrenia;
BRCA	trans	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg14791747	chr16:20752902	THUMPD1	0.4	9.67	0.36	1.01e-20	Cognitive test performance;
BRCA	cis	rs2742234	1.000	rs1864399	chr10:43610455	T/C	cg02780029	chr10:43622663	RET	-0.42	-10.36	-0.38	2.39e-23	Hirschsprung disease;
BRCA	cis	rs62380364	0.542	rs2247885	chr5:88047999	T/C	cg22951263	chr5:87985283	NA	-0.39	-10.82	-0.39	3.58e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-9.25	-0.34	3.25e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	22.78	0.67	1.57e-84	Chronic sinus infection;
BRCA	cis	rs12611088	0.602	rs6509092	chr19:44022305	A/T	cg15012607	chr19:44012195	ETHE1	-0.35	-9.02	-0.34	2.09e-18	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg22189786	chr22:42395067	WBP2NL	0.41	8.11	0.31	2.64e-15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	19.69	0.61	7.86e-68	Platelet count;
BRCA	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	11.77	0.42	4.61e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.94	20.94	0.64	1.61e-74	IgG glycosylation;
BRCA	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg18154014	chr19:37997991	ZNF793	0.62	11.66	0.42	1.31e-28	Coronary artery calcification;
BRCA	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-9.02	-0.34	2.09e-18	Blood metabolite levels;
BRCA	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg03733263	chr8:22462867	KIAA1967	1.04	24.53	0.7	3.77e-94	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.36	-8.38	-0.31	3.41e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg01448562	chr3:133502909	NA	-0.62	-14.61	-0.5	6.43e-42	Iron status biomarkers;
BRCA	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-8.79	-0.33	1.43e-17	IgG glycosylation;
BRCA	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg21535247	chr6:8435926	SLC35B3	0.41	9.38	0.35	1.09e-19	Motion sickness;
BRCA	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-9.69	-0.36	8.4e-21	Menopause (age at onset);
BRCA	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg24642439	chr20:33292090	TP53INP2	0.43	9.11	0.34	1.03e-18	Height;
BRCA	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg03433033	chr1:76189801	ACADM	-0.59	-11.61	-0.42	2.08e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs909002	0.819	rs2292989	chr1:32135773	A/G	cg13919466	chr1:32135498	COL16A1	0.25	8.57	0.32	7.93e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg03717367	chr9:139980219	LOC100289341;MAN1B1	-0.39	-9.27	-0.34	2.75e-19	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg04362960	chr10:104952993	NT5C2	0.44	8.67	0.32	3.47e-17	Arsenic metabolism;
BRCA	cis	rs1113500	0.933	rs11185260	chr1:108635079	A/T	cg06207961	chr1:108661230	NA	-0.44	-10.73	-0.39	8.23e-25	Growth-regulated protein alpha levels;
BRCA	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg06671706	chr8:8559999	CLDN23	0.43	8.34	0.31	4.64e-16	Obesity-related traits;
BRCA	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.08	-0.4	3.12e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg09904177	chr6:26538194	HMGN4	0.55	17.8	0.58	7.39e-58	Intelligence (multi-trait analysis);
BRCA	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg00631329	chr6:26305371	NA	-0.43	-12.91	-0.45	4.96e-34	Educational attainment;
BRCA	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg05896524	chr21:47604654	C21orf56	-0.5	-9.8	-0.36	3.31e-21	Testicular germ cell tumor;
BRCA	cis	rs2880765	0.835	rs900573	chr15:86037993	G/T	cg10818794	chr15:86012489	AKAP13	0.3	8.53	0.32	1.04e-16	Coronary artery disease;
BRCA	cis	rs72799341	1.000	rs1458201	chr16:30916129	G/A	cg02466173	chr16:30829666	NA	-0.48	-9.0	-0.34	2.62e-18	Diastolic blood pressure;
BRCA	cis	rs7178424	1.000	rs7177711	chr15:62379971	A/G	cg00456672	chr15:62358751	C2CD4A	-0.34	-8.13	-0.31	2.25e-15	Height;
BRCA	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg01529538	chr14:23388837	RBM23	0.41	11.12	0.4	2.25e-26	Cognitive ability (multi-trait analysis);
BRCA	cis	rs7572733	0.576	rs1368989	chr2:198937082	T/C	cg00792783	chr2:198669748	PLCL1	0.36	7.91	0.3	1.15e-14	Dermatomyositis;
BRCA	cis	rs9837602	1.000	rs35669453	chr3:99766063	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.18	0.4	1.29e-26	Breast cancer;
BRCA	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.89	0.3	1.33e-14	Axial length;
BRCA	cis	rs7903847	0.642	rs7909345	chr10:99150794	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.78	-0.33	1.53e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-7.85	-0.3	1.77e-14	Axial length;
BRCA	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	9.75	0.36	4.75e-21	Tonsillectomy;
BRCA	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg09184832	chr6:79620586	NA	-0.5	-11.22	-0.41	8.91e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18876405	chr7:65276391	NA	0.55	13.17	0.46	3.21e-35	Aortic root size;
BRCA	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg11764359	chr7:65958608	NA	-0.63	-13.48	-0.47	1.2e-36	Aortic root size;
BRCA	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg22535103	chr8:58192502	C8orf71	-0.61	-13.17	-0.46	3.08e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.33	-0.38	3.1e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg26384229	chr12:38710491	ALG10B	0.76	17.01	0.56	8.48e-54	Morning vs. evening chronotype;
BRCA	cis	rs9341808	0.935	rs1535825	chr6:80938586	C/T	cg08355045	chr6:80787529	NA	-0.34	-8.82	-0.33	1.05e-17	Sitting height ratio;
BRCA	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.7	0.33	2.82e-17	Iron status biomarkers;
BRCA	cis	rs6121246	0.609	rs2149281	chr20:30417918	G/A	cg13852791	chr20:30311386	BCL2L1	0.88	20.0	0.62	1.72e-69	Mean corpuscular hemoglobin;
BRCA	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg17063962	chr7:91808500	NA	0.52	12.35	0.44	1.39e-31	Breast cancer;
BRCA	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg23950597	chr19:37808831	NA	-0.75	-13.13	-0.46	4.8e-35	Coronary artery calcification;
BRCA	cis	rs701145	0.585	rs959376	chr3:153866707	A/T	cg17054900	chr3:154042577	DHX36	0.44	8.24	0.31	9.99e-16	Coronary artery disease;
BRCA	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.72	-0.33	2.47e-17	Alzheimer's disease (late onset);
BRCA	trans	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg21659725	chr3:3221576	CRBN	-0.47	-8.66	-0.32	3.84e-17	Menarche (age at onset);
BRCA	cis	rs62229266	0.771	rs62230790	chr21:37388911	A/G	cg12218747	chr21:37451666	NA	-0.34	-8.01	-0.3	5.59e-15	Mitral valve prolapse;
BRCA	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-10.6	-0.39	2.78e-24	Daytime sleep phenotypes;
BRCA	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg18357645	chr12:58087776	OS9	-0.34	-8.24	-0.31	9.51e-16	Multiple sclerosis;
BRCA	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg03433033	chr1:76189801	ACADM	0.68	12.54	0.44	2.14e-32	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.21	-0.43	6e-31	Total cholesterol levels;
BRCA	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg00495681	chr13:53174319	NA	0.41	8.61	0.32	5.48e-17	Lewy body disease;
BRCA	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	12.93	0.46	3.7e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4690686	0.500	rs4690429	chr4:177263983	G/A	cg17059388	chr4:177262070	NA	0.51	10.68	0.39	1.34e-24	Essential tremor;
BRCA	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg23283495	chr1:209979779	IRF6	0.38	8.88	0.33	6.55e-18	Cleft lip with or without cleft palate;
BRCA	trans	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg19862616	chr7:65841803	NCRNA00174	0.83	27.61	0.74	4.43e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg27170947	chr2:26402098	FAM59B	-0.98	-17.25	-0.56	4.73e-55	Gut microbiome composition (summer);
BRCA	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg10556349	chr10:835070	NA	0.59	8.31	0.31	5.59e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	25.65	0.71	2.54e-100	Chronic sinus infection;
BRCA	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	20.34	0.63	2.86e-71	Electrocardiographic conduction measures;
BRCA	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg12310025	chr6:25882481	NA	-0.54	-13.07	-0.46	9.5e-35	Blood metabolite levels;
BRCA	cis	rs68170813	0.559	rs113211438	chr7:106969198	G/A	cg02696742	chr7:106810147	HBP1	-0.55	-8.92	-0.33	4.99e-18	Coronary artery disease;
BRCA	trans	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg15704280	chr7:45808275	SEPT13	0.54	8.19	0.31	1.43e-15	Intraocular pressure;
BRCA	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg18230493	chr5:56204884	C5orf35	-0.62	-13.37	-0.47	4.03e-36	Initial pursuit acceleration;
BRCA	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.79	0.33	1.39e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg06623918	chr6:96969491	KIAA0776	0.9	25.54	0.71	1.14e-99	Headache;
BRCA	cis	rs9715521	0.645	rs13134207	chr4:59848379	G/T	cg11281224	chr4:60001000	NA	-0.35	-7.88	-0.3	1.43e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg08807101	chr21:30365312	RNF160	0.56	11.89	0.43	1.41e-29	Selective IgA deficiency;
BRCA	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg22105103	chr4:187893119	NA	0.42	13.5	0.47	1e-36	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg23711669	chr6:146136114	FBXO30	-0.69	-16.63	-0.55	7.2e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg18402987	chr7:1209562	NA	0.82	11.85	0.42	1.95e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg15704280	chr7:45808275	SEPT13	-0.53	-10.33	-0.38	2.95e-23	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg21064579	chr19:49206444	FUT2	0.37	9.34	0.35	1.62e-19	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
BRCA	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg24747557	chr10:131355152	MGMT	0.37	9.32	0.35	1.87e-19	Response to temozolomide;
BRCA	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg05340658	chr4:99064831	C4orf37	0.51	8.3	0.31	6.19e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg06627628	chr2:24431161	ITSN2	-0.83	-15.41	-0.52	8.37e-46	Asthma;
BRCA	cis	rs6545883	0.503	rs1665272	chr2:61379286	A/C	cg15711740	chr2:61764176	XPO1	-0.44	-11.03	-0.4	5.28e-26	Tuberculosis;
BRCA	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg25036284	chr2:26402008	FAM59B	0.94	15.84	0.53	6.66e-48	Gut microbiome composition (summer);
BRCA	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg24848339	chr3:12840334	CAND2	0.43	11.4	0.41	1.51e-27	QRS complex (12-leadsum);
BRCA	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-9.43	-0.35	7.63e-20	Intelligence (multi-trait analysis);
BRCA	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg27661571	chr11:113659931	NA	-0.73	-11.22	-0.41	8.28e-27	Hip circumference adjusted for BMI;
BRCA	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg10523679	chr1:76189770	ACADM	0.7	12.24	0.44	4.12e-31	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg06784218	chr1:46089804	CCDC17	-0.53	-12.82	-0.45	1.24e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg03342759	chr3:160939853	NMD3	-0.63	-13.4	-0.47	2.93e-36	Morning vs. evening chronotype;
BRCA	cis	rs6815814	0.950	rs5743580	chr4:38804405	C/T	cg06935464	chr4:38784597	TLR10	0.51	8.49	0.32	1.46e-16	Breast cancer;
BRCA	trans	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.62	13.87	0.48	2.06e-38	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg23895963	chr12:117471115	NA	-0.53	-9.36	-0.35	1.38e-19	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg25664220	chr3:72788482	NA	-0.54	-11.64	-0.42	1.6e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg12698349	chr2:225449008	CUL3	0.6	13.3	0.47	8.71e-36	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	cg01483505	chr11:975446	AP2A2	0.3	7.96	0.3	7.96e-15	Alzheimer's disease (late onset);
BRCA	cis	rs11971779	0.680	rs6467846	chr7:139079385	G/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	trans	rs1459104	1.000	rs12575696	chr11:55057235	C/T	cg15704280	chr7:45808275	SEPT13	0.69	8.63	0.32	4.7e-17	Body mass index;
BRCA	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.33	-9.98	-0.37	6.82e-22	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg25358565	chr5:93447407	FAM172A	1.03	16.45	0.55	6.03e-51	Diabetic retinopathy;
BRCA	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg04691961	chr3:161091175	C3orf57	-0.51	-12.81	-0.45	1.33e-33	Morning vs. evening chronotype;
BRCA	cis	rs3768617	0.677	rs12739316	chr1:183052080	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.48	11.18	0.4	1.27e-26	Fuchs's corneal dystrophy;
BRCA	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg14458575	chr2:238380390	NA	0.58	12.91	0.45	4.67e-34	Prostate cancer;
BRCA	cis	rs67981189	0.896	rs8012728	chr14:71447948	T/C	cg15816911	chr14:71606274	NA	0.35	7.83	0.3	2.02e-14	Schizophrenia;
BRCA	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg23260525	chr10:116636907	FAM160B1	0.32	8.34	0.31	4.62e-16	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs701145	0.556	rs355779	chr3:153977253	T/C	cg16511985	chr3:153974050	SGEF	0.46	10.63	0.39	2e-24	Coronary artery disease;
BRCA	cis	rs7551345	0.653	rs2889713	chr1:31697751	A/G	cg19084893	chr1:31688959	NA	-0.46	-10.04	-0.37	4.13e-22	Schizophrenia;
BRCA	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.45	8.62	0.32	5.21e-17	Cognitive ability;
BRCA	cis	rs4478858	0.684	rs16865957	chr1:31753353	G/A	cg00250761	chr1:31883323	NA	-0.32	-8.33	-0.31	4.93e-16	Alcohol dependence;
BRCA	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg06060754	chr5:176797920	RGS14	-0.66	-10.42	-0.38	1.43e-23	Urate levels in lean individuals;
BRCA	cis	rs4901869	0.902	rs2162491	chr14:59296247	C/T	cg02291164	chr14:59296302	NA	0.32	8.75	0.33	1.83e-17	Panic disorder;
BRCA	cis	rs708547	0.647	rs781666	chr4:57830981	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.38	9.55	0.35	2.61e-20	Response to bleomycin (chromatid breaks);
BRCA	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	9.05	0.34	1.65e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg10224037	chr5:178157518	ZNF354A	0.79	18.21	0.58	5.28e-60	Neutrophil percentage of white cells;
BRCA	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.73	-0.33	2.14e-17	Height;
BRCA	cis	rs9443189	0.615	rs602873	chr6:76323818	T/A	cg01950844	chr6:76311363	SENP6	0.85	13.82	0.48	3.24e-38	Prostate cancer;
BRCA	cis	rs208520	0.874	rs208515	chr6:66945749	A/G	cg07460842	chr6:66804631	NA	-0.89	-15.83	-0.53	7.13e-48	Exhaled nitric oxide output;
BRCA	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-15.46	-0.52	5.06e-46	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.14	-0.4	1.77e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg03954927	chr1:10346856	KIF1B	0.45	12.47	0.44	4.43e-32	Hepatocellular carcinoma;
BRCA	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg12365402	chr11:9010492	NRIP3	0.4	9.37	0.35	1.18e-19	Hemoglobin concentration;
BRCA	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.38	-0.31	3.34e-16	Colorectal cancer;
BRCA	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg15556689	chr8:8085844	FLJ10661	-0.33	-8.81	-0.33	1.19e-17	Joint mobility (Beighton score);
BRCA	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg08085267	chr17:45401833	C17orf57	-0.67	-14.89	-0.51	3e-43	Multiple sclerosis;Ankylosing spondylitis;
BRCA	cis	rs10504073	0.545	rs4406405	chr8:49957261	G/C	cg00325661	chr8:49890786	NA	0.49	14.07	0.49	2.32e-39	Blood metabolite ratios;
BRCA	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg01528321	chr10:82214614	TSPAN14	0.79	16.67	0.55	4.64e-52	Post bronchodilator FEV1;
BRCA	cis	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg00852783	chr1:26633632	UBXN11	-0.46	-8.09	-0.3	2.9e-15	Obesity-related traits;
BRCA	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg23708337	chr7:1209742	NA	0.63	8.84	0.33	8.9e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg13256891	chr4:100009986	ADH5	0.4	8.45	0.32	1.94e-16	Alcohol dependence;
BRCA	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg26395211	chr5:140044315	WDR55	0.38	8.62	0.32	5.29e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9811920	0.732	rs7613864	chr3:99602470	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.57	13.87	0.48	1.9e-38	Axial length;
BRCA	trans	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.38	7.96	0.3	7.64e-15	Menarche (age at onset);
BRCA	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg02466173	chr16:30829666	NA	0.49	11.26	0.41	5.97e-27	Dementia with Lewy bodies;
BRCA	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.3	-0.35	2.21e-19	Electroencephalogram traits;
BRCA	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	10.01	0.37	5.23e-22	Tonsillectomy;
BRCA	trans	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg06521331	chr12:34319734	NA	-0.53	-9.61	-0.36	1.57e-20	Bladder cancer;
BRCA	trans	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.92	-0.3	1.02e-14	Corneal astigmatism;
BRCA	cis	rs17023223	0.537	rs4590715	chr1:119750201	C/T	cg05756136	chr1:119680316	WARS2	-0.42	-7.86	-0.3	1.59e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg09307838	chr4:120376055	NA	0.72	15.24	0.52	5.6e-45	Corneal astigmatism;
BRCA	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg11366901	chr6:160182831	ACAT2	0.78	14.93	0.51	1.95e-43	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg06521331	chr12:34319734	NA	-0.56	-10.0	-0.37	5.64e-22	Morning vs. evening chronotype;
BRCA	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg15704280	chr7:45808275	SEPT13	0.62	10.42	0.38	1.41e-23	Axial length;
BRCA	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.84	0.36	2.34e-21	Bipolar disorder;
BRCA	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg06623918	chr6:96969491	KIAA0776	0.9	25.49	0.71	1.97e-99	Headache;
BRCA	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg20607798	chr8:58055168	NA	0.47	8.07	0.3	3.41e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12410462	0.901	rs16847844	chr1:227638110	A/G	cg23173402	chr1:227635558	NA	0.44	8.16	0.31	1.81e-15	Major depressive disorder;
BRCA	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg05714579	chr10:131428358	MGMT	0.5	11.03	0.4	4.95e-26	Response to temozolomide;
BRCA	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg16586182	chr3:47516702	SCAP	0.6	14.02	0.49	3.9e-39	Colorectal cancer;
BRCA	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg20476274	chr7:133979776	SLC35B4	0.5	11.77	0.42	4.24e-29	Mean platelet volume;
BRCA	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg05340658	chr4:99064831	C4orf37	0.45	10.39	0.38	1.79e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05901451	chr6:126070800	HEY2	-0.43	-10.85	-0.39	2.62e-25	Endometrial cancer;
BRCA	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.05	21.9	0.65	9.95e-80	Gut microbiome composition (summer);
BRCA	cis	rs7523273	0.568	rs1318653	chr1:208014922	C/T	cg22525895	chr1:207977042	MIR29B2	0.4	8.23	0.31	1.05e-15	Schizophrenia;
BRCA	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.86e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg23711669	chr6:146136114	FBXO30	-0.68	-15.76	-0.53	1.54e-47	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-16.69	-0.55	3.62e-52	Intelligence (multi-trait analysis);
BRCA	cis	rs7575217	0.697	rs2582930	chr2:101721369	T/A	cg23907051	chr2:101730305	TBC1D8	-0.2	-7.9	-0.3	1.22e-14	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg19743168	chr1:23544995	NA	0.46	11.45	0.41	9.37e-28	Height;
BRCA	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg15083037	chr5:83017644	HAPLN1	-0.51	-10.12	-0.37	2.02e-22	Prostate cancer;
BRCA	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg24596788	chr1:163392923	NA	-0.37	-9.9	-0.36	1.3e-21	Motion sickness;
BRCA	cis	rs2559856	1.000	rs2559857	chr12:102089399	A/C	cg12213457	chr12:102090980	CHPT1	-0.36	-7.81	-0.3	2.32e-14	Blood protein levels;
BRCA	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg17971929	chr21:40555470	PSMG1	0.77	18.05	0.58	3.77e-59	Cognitive function;
BRCA	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg17987982	chr7:158820591	NA	-0.43	-8.15	-0.31	1.87e-15	Facial morphology (factor 20);
BRCA	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17261708	chr5:176794207	RGS14	-0.39	-8.44	-0.32	2.08e-16	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg26752888	chr8:11627280	NEIL2	0.43	9.03	0.34	1.94e-18	Myopia (pathological);
BRCA	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg04727924	chr7:799746	HEATR2	-0.55	-10.82	-0.39	3.66e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg06484146	chr7:12443880	VWDE	-0.78	-11.09	-0.4	3.03e-26	Coronary artery disease;
BRCA	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg05868516	chr6:26286170	HIST1H4H	0.5	11.3	0.41	4e-27	Educational attainment;
BRCA	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg24558204	chr6:135376177	HBS1L	0.46	12.62	0.45	9.12e-33	Red blood cell count;
BRCA	cis	rs6725517	0.737	rs7576788	chr2:25083310	A/G	cg04586622	chr2:25135609	ADCY3	0.39	10.08	0.37	2.9e-22	Breast cancer;
BRCA	cis	rs929596	1.000	rs929596	chr2:234674476	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-11.0	-0.4	7.05e-26	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs644148	0.933	rs565819	chr19:44967714	A/G	cg15540054	chr19:45004280	ZNF180	0.56	11.87	0.43	1.6e-29	Personality dimensions;
BRCA	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11890956	chr21:40555474	PSMG1	-0.61	-13.62	-0.47	2.88e-37	Menarche (age at onset);
BRCA	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg11814155	chr7:99998594	ZCWPW1	0.46	8.22	0.31	1.16e-15	Platelet count;
BRCA	cis	rs7512552	0.839	rs11581351	chr1:150440200	G/C	cg15654264	chr1:150340011	RPRD2	0.4	8.55	0.32	8.74e-17	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7737355	0.812	rs6868007	chr5:130824810	T/C	cg06307176	chr5:131281290	NA	0.48	10.48	0.38	7.88e-24	Life satisfaction;
BRCA	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg00071950	chr4:10020882	SLC2A9	-0.49	-11.74	-0.42	5.81e-29	Bone mineral density;
BRCA	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg01028140	chr2:1542097	TPO	-0.56	-11.48	-0.41	7.52e-28	IgG glycosylation;
BRCA	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.81	-0.33	1.21e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg25237894	chr2:233734115	C2orf82	0.4	11.39	0.41	1.76e-27	Coronary artery disease;
BRCA	cis	rs10754283	0.756	rs17441836	chr1:90135433	C/T	cg21401794	chr1:90099060	LRRC8C	0.41	9.4	0.35	9.66e-20	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg17691542	chr6:26056736	HIST1H1C	0.47	9.59	0.35	1.92e-20	Height;
BRCA	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-14.95	-0.51	1.48e-43	Coronary artery disease;
BRCA	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg12923728	chr3:195709715	SDHAP1	-0.53	-9.17	-0.34	6.47e-19	Pancreatic cancer;
BRCA	trans	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg06521331	chr12:34319734	NA	-0.52	-9.81	-0.36	2.88e-21	Bladder cancer;
BRCA	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg27165867	chr14:105738592	BRF1	-0.35	-8.18	-0.31	1.54e-15	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs68170813	0.559	rs11769861	chr7:106979559	T/C	cg02696742	chr7:106810147	HBP1	-0.55	-8.79	-0.33	1.4e-17	Coronary artery disease;
BRCA	cis	rs7640424	0.784	rs68044584	chr3:107845395	A/G	cg09227934	chr3:107805635	CD47	-0.43	-8.95	-0.33	3.9e-18	Body mass index;
BRCA	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg03146154	chr1:46216737	IPP	0.47	10.52	0.38	5.5e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg21918786	chr6:109611834	NA	-0.49	-14.14	-0.49	1.13e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg18230493	chr5:56204884	C5orf35	-0.75	-14.2	-0.49	5.87e-40	Initial pursuit acceleration;
BRCA	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg03433033	chr1:76189801	ACADM	-0.6	-12.15	-0.43	1.08e-30	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg01620082	chr3:125678407	NA	-0.64	-8.56	-0.32	8.69e-17	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs12517041	0.935	rs35858834	chr5:23325233	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-8.2	-0.31	1.29e-15	Calcium levels;
BRCA	cis	rs7927771	0.832	rs1542321	chr11:47379615	G/A	cg20307385	chr11:47447363	PSMC3	0.41	8.57	0.32	7.7e-17	Subjective well-being;
BRCA	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.43	-0.38	1.25e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07343612	chr16:622815	PIGQ	-0.68	-22.83	-0.67	8.65e-85	Height;
BRCA	cis	rs17253792	0.822	rs10135426	chr14:56054644	A/G	cg01858014	chr14:56050164	KTN1	-0.73	-10.81	-0.39	3.79e-25	Putamen volume;
BRCA	cis	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg07460842	chr6:66804631	NA	0.88	14.14	0.49	1.11e-39	Exhaled nitric oxide output;
BRCA	cis	rs870825	0.616	rs28582728	chr4:185646920	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg19920283	chr7:105172520	RINT1	0.61	9.53	0.35	3.16e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs708547	0.647	rs1626594	chr4:57878254	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.38	9.82	0.36	2.67e-21	Response to bleomycin (chromatid breaks);
BRCA	trans	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg26384229	chr12:38710491	ALG10B	0.51	10.95	0.4	1.13e-25	Morning vs. evening chronotype;
BRCA	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg04362960	chr10:104952993	NT5C2	0.46	10.74	0.39	7.57e-25	Arsenic metabolism;
BRCA	cis	rs2882667	0.690	rs825769	chr5:138115355	G/A	cg04439458	chr5:138467593	SIL1	0.31	7.87	0.3	1.47e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-23.3	-0.68	2.16e-87	Primary sclerosing cholangitis;
BRCA	cis	rs2882667	0.898	rs2351465	chr5:138363851	A/C	cg04439458	chr5:138467593	SIL1	-0.32	-8.87	-0.33	7.33e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg11766577	chr21:47581405	C21orf56	-0.44	-9.72	-0.36	6.44e-21	Testicular germ cell tumor;
BRCA	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.8599999999999993e-24	Motion sickness;
BRCA	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg18252515	chr7:66147081	NA	-0.83	-12.11	-0.43	1.49e-30	Diabetic kidney disease;
BRCA	cis	rs12369179	0.737	rs116896792	chr12:122948907	T/C	cg18578876	chr12:123200353	GPR109B	-1.35	-15.69	-0.53	3.67e-47	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
BRCA	cis	rs16854884	0.657	rs62269895	chr3:143749085	C/G	cg06585982	chr3:143692056	C3orf58	0.42	8.93	0.33	4.52e-18	Economic and political preferences (feminism/equality);
BRCA	trans	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	8.55e-21	Bladder cancer;
BRCA	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg13047869	chr3:10149882	C3orf24	-0.55	-10.19	-0.37	1.04e-22	Alzheimer's disease;
BRCA	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.56	-10.48	-0.38	7.86e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg02544614	chr20:61657117	NA	0.28	7.82	0.3	2.14e-14	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.84	0.33	8.92e-18	Iron status biomarkers;
BRCA	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.81	0.33	1.18e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6005807	0.719	rs9625512	chr22:29020756	G/C	cg12565055	chr22:29076175	TTC28	0.49	9.36	0.35	1.35e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs6723226	0.750	rs762019	chr2:32688601	A/C	cg02381751	chr2:32503542	YIPF4	0.48	10.23	0.38	7.52e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg10495392	chr1:46806563	NSUN4	0.44	8.11	0.31	2.59e-15	Menopause (age at onset);
BRCA	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg18402987	chr7:1209562	NA	0.84	11.92	0.43	9.85e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg15352829	chr14:105391018	PLD4	-0.41	-13.03	-0.46	1.44e-34	Rheumatoid arthritis;
BRCA	cis	rs4889855	0.505	rs7501740	chr17:78610345	A/G	cg16591659	chr17:78472290	NA	-0.31	-8.0	-0.3	6.06e-15	Fractional excretion of uric acid;
BRCA	cis	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg06521331	chr12:34319734	NA	-0.55	-10.7	-0.39	1.04e-24	Morning vs. evening chronotype;
BRCA	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg21918786	chr6:109611834	NA	-0.48	-13.79	-0.48	4.72e-38	Reticulocyte fraction of red cells;
BRCA	cis	rs17253792	0.908	rs74354306	chr14:56065778	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.98	0.3	7e-15	Putamen volume;
BRCA	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11644478	chr21:40555479	PSMG1	0.84	19.08	0.6	1.43e-64	Cognitive function;
BRCA	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.99	-0.34	2.81e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg11266682	chr4:10021025	SLC2A9	0.48	12.86	0.45	8.27e-34	Bone mineral density;
BRCA	cis	rs9649465	1.000	rs56396297	chr7:123350535	T/C	cg04330084	chr7:123175371	IQUB	-0.3	-8.35	-0.31	4.35e-16	Migraine;
BRCA	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg12386194	chr3:101231763	SENP7	0.46	9.77	0.36	4.14e-21	Colorectal cancer;
BRCA	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12667521	chr19:29218732	NA	0.47	8.66	0.32	3.79e-17	Methadone dose in opioid dependence;
BRCA	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.48	-10.82	-0.39	3.59e-25	Longevity;Endometriosis;
BRCA	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg05714579	chr10:131428358	MGMT	0.59	14.69	0.5	2.65e-42	Response to temozolomide;
BRCA	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg12386194	chr3:101231763	SENP7	0.46	9.7	0.36	7.74e-21	Colorectal cancer;
BRCA	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg03676636	chr4:99064102	C4orf37	0.2	7.81	0.3	2.43e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg25405998	chr7:65216604	CCT6P1	0.41	8.37	0.31	3.65e-16	Calcium levels;
BRCA	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg27165867	chr14:105738592	BRF1	-0.36	-8.35	-0.31	4.09e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.11	0.37	2.23e-22	Aortic root size;
BRCA	cis	rs4285028	0.948	rs34158925	chr3:121678465	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.82	-0.39	3.64e-25	Multiple sclerosis;
BRCA	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg24846343	chr22:24311635	DDTL	0.56	14.85	0.51	4.73e-43	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg13010199	chr12:38710504	ALG10B	0.51	9.97	0.37	7.62e-22	Bladder cancer;
BRCA	cis	rs6580649	1.000	rs6580649	chr12:48410517	A/G	cg05342945	chr12:48394962	COL2A1	-0.44	-8.42	-0.32	2.52e-16	Lung cancer;
BRCA	cis	rs9837602	1.000	rs2291495	chr3:99782227	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.21	0.41	9.77e-27	Breast cancer;
BRCA	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	19.82	0.62	1.71e-68	Platelet count;
BRCA	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg00012203	chr2:219082015	ARPC2	-0.48	-9.38	-0.35	1.17e-19	Colorectal cancer;
BRCA	cis	rs332507	0.789	rs10755078	chr3:124378412	A/G	cg05980111	chr3:124395277	KALRN	0.37	8.44	0.32	2.16e-16	Plateletcrit;
BRCA	cis	rs1371614	0.589	rs502751	chr2:27111650	C/T	cg12368169	chr2:27073192	DPYSL5	-0.3	-9.04	-0.34	1.89e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs13046373	0.507	rs11088139	chr21:31978884	T/G	cg06468780	chr21:31798236	KRTAP13-3	0.36	9.0	0.34	2.61e-18	HDL cholesterol;
BRCA	cis	rs10899021	1.000	rs11236190	chr11:74366755	G/T	cg25880958	chr11:74394337	NA	-0.69	-9.07	-0.34	1.42e-18	Response to metformin (IC50);
BRCA	cis	rs9308433	0.529	rs3767842	chr1:214498306	C/T	cg06198575	chr1:214491504	SMYD2	0.56	12.24	0.44	4.43e-31	IgG glycosylation;
BRCA	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg11271282	chr2:238384023	NA	0.43	7.88	0.3	1.39e-14	Prostate cancer;
BRCA	cis	rs2016266	0.819	rs10747662	chr12:53669821	A/T	cg26875137	chr12:53738046	NA	0.38	9.52	0.35	3.59e-20	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	17.42	0.57	6.31e-56	Smoking behavior;
BRCA	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.35	-9.78	-0.36	3.81e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg05985134	chr18:33552581	C18orf21	0.67	12.75	0.45	2.36e-33	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg11262906	chr1:85462892	MCOLN2	-0.52	-10.05	-0.37	3.7e-22	Serum sulfate level;
BRCA	cis	rs11051970	0.879	rs2651363	chr12:32587550	G/T	cg24626660	chr12:32551988	NA	-0.29	-8.43	-0.32	2.27e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	trans	rs800082	0.668	rs9876975	chr3:144292255	G/A	cg24215973	chr2:240111563	HDAC4	-0.43	-10.32	-0.38	3.26e-23	Smoking behavior;
BRCA	cis	rs12618769	0.597	rs11888595	chr2:99084708	T/G	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg01475377	chr6:109611718	NA	-0.59	-16.05	-0.54	5.8e-49	Reticulocyte fraction of red cells;
BRCA	trans	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg26043149	chr18:55253948	FECH	-0.37	-8.28	-0.31	7.35e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg08807101	chr21:30365312	RNF160	-0.57	-14.01	-0.48	4.23e-39	Dental caries;
BRCA	cis	rs6121246	0.559	rs6058462	chr20:30367674	C/T	cg13852791	chr20:30311386	BCL2L1	0.84	18.2	0.58	6.18e-60	Mean corpuscular hemoglobin;
BRCA	cis	rs10129255	0.500	rs8004923	chr14:107194164	A/G	cg07958169	chr14:107095056	NA	-0.38	-8.3	-0.31	6.17e-16	Kawasaki disease;
BRCA	cis	rs7631605	0.905	rs11720064	chr3:37101519	G/T	cg15934958	chr3:37212084	LRRFIP2	0.46	10.44	0.38	1.18e-23	Cerebrospinal P-tau181p levels;
BRCA	cis	rs965469	0.947	rs6037578	chr20:3345911	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-10.54	-0.38	4.61e-24	IFN-related cytopenia;
BRCA	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg08807101	chr21:30365312	RNF160	0.36	8.11	0.31	2.69e-15	Pancreatic cancer;
BRCA	cis	rs858239	0.670	rs3807452	chr7:23162081	C/T	cg23682824	chr7:23144976	KLHL7	-0.39	-9.8	-0.36	3.09e-21	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg21782813	chr7:2030301	MAD1L1	0.38	9.92	0.37	1.14e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg20701182	chr2:24300061	SF3B14	0.6	9.39	0.35	1.02e-19	Lymphocyte counts;
BRCA	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.68	-0.42	1.08e-28	Gut microbiome composition (summer);
BRCA	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg23018236	chr17:30244563	NA	-0.66	-10.6	-0.39	2.65e-24	Hip circumference adjusted for BMI;
BRCA	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.06	-0.43	2.48e-30	Developmental language disorder (linguistic errors);
BRCA	cis	rs4363385	0.818	rs12029168	chr1:152987993	G/A	cg24667326	chr1:152973720	SPRR3	-0.31	-8.53	-0.32	1.09e-16	Inflammatory skin disease;
BRCA	cis	rs9469578	0.901	rs57303110	chr6:33706159	G/A	cg18708504	chr6:33715942	IP6K3	0.72	10.29	0.38	4.21e-23	Phosphorus levels;
BRCA	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg06935464	chr4:38784597	TLR10	0.51	8.25	0.31	9.26e-16	Breast cancer;
BRCA	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.59	0.5	8.24e-42	Motion sickness;
BRCA	cis	rs1997103	0.954	rs6593222	chr7:55372932	A/C	cg17469321	chr7:55412551	NA	0.49	9.21	0.34	4.66e-19	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg09904177	chr6:26538194	HMGN4	0.56	18.25	0.59	3.23e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.08	-0.4	3.36e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26314531	chr2:26401878	FAM59B	-0.63	-10.82	-0.39	3.74e-25	Gut microbiome composition (summer);
BRCA	cis	rs775227	0.574	rs13068107	chr3:113029530	A/C	cg18753928	chr3:113234510	CCDC52	-0.53	-9.17	-0.34	6.43e-19	Dental caries;
BRCA	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg24692254	chr21:30365293	RNF160	-0.48	-10.24	-0.38	6.79e-23	Cognitive test performance;
BRCA	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg20587970	chr11:113659929	NA	-1.2	-22.13	-0.66	5.45e-81	Hip circumference adjusted for BMI;
BRCA	cis	rs9296092	0.538	rs75082458	chr6:33524792	C/T	cg13560919	chr6:33536144	NA	-0.85	-17.71	-0.57	2.21e-57	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24549020	chr5:56110836	MAP3K1	0.66	13.46	0.47	1.47e-36	Initial pursuit acceleration;
BRCA	cis	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg07460842	chr6:66804631	NA	0.88	14.2	0.49	5.86e-40	Exhaled nitric oxide output;
BRCA	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23583168	chr7:148888333	NA	-0.71	-15.78	-0.53	1.33e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10193935	0.892	rs6744964	chr2:42441088	A/G	cg27598129	chr2:42591480	NA	-0.92	-15.04	-0.51	5.67e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6723226	0.721	rs3769600	chr2:32616879	G/A	cg02381751	chr2:32503542	YIPF4	-0.48	-10.56	-0.39	3.89e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg20607798	chr8:58055168	NA	0.48	8.43	0.32	2.29e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg23625390	chr15:77176239	SCAPER	-0.55	-13.58	-0.47	4.26e-37	Blood metabolite levels;
BRCA	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.23e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.22e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10150615	chr22:24372951	LOC391322	-0.46	-10.63	-0.39	2.06e-24	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs236907	0.679	rs12750330	chr1:171803556	G/A	cg13482142	chr2:234261155	NA	0.51	8.06	0.3	3.67e-15	Mean platelet volume;
BRCA	cis	rs6714710	0.603	rs78006955	chr2:98455510	G/C	cg26665480	chr2:98280029	ACTR1B	0.58	13.62	0.47	2.86e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg23719950	chr11:63933701	MACROD1	-0.53	-9.06	-0.34	1.56e-18	Mean platelet volume;
BRCA	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.73	-0.42	6.52e-29	Response to antipsychotic treatment;
BRCA	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg23625390	chr15:77176239	SCAPER	0.51	12.74	0.45	2.75e-33	Blood metabolite levels;
BRCA	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	13.55	0.47	5.79e-37	Colorectal cancer;
BRCA	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-10.59	-0.39	3.03e-24	Gut microbiome composition (summer);
BRCA	cis	rs3767633	0.925	rs4579731	chr1:161766859	G/A	cg09175582	chr1:161736000	ATF6	0.49	8.08	0.3	3.16e-15	IgG glycosylation;
BRCA	cis	rs9837602	0.592	rs1711557	chr3:99425669	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.96	-0.33	3.45e-18	Breast cancer;
BRCA	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-13.95	-0.48	8.1e-39	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.05	0.4	4.42e-26	Bipolar disorder;
BRCA	cis	rs2066819	1.000	rs58852079	chr12:56706922	A/C	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg12193833	chr17:30244370	NA	-0.55	-8.65	-0.32	4.25e-17	Hip circumference adjusted for BMI;
BRCA	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg22713356	chr15:30763199	NA	1.25	20.77	0.63	1.25e-73	Uric acid levels;
BRCA	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	16.95	0.56	1.64e-53	Platelet count;
BRCA	cis	rs3772130	0.583	rs6767409	chr3:121564989	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	14.38	0.49	7.63e-41	Cognitive performance;
BRCA	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg26248373	chr2:1572462	NA	-0.62	-14.12	-0.49	1.37e-39	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9649465	0.967	rs9641717	chr7:123350060	C/T	cg04330084	chr7:123175371	IQUB	-0.3	-8.29	-0.31	6.61e-16	Migraine;
BRCA	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg22875332	chr1:76189707	ACADM	0.55	11.65	0.42	1.37e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg03433033	chr1:76189801	ACADM	-0.49	-10.49	-0.38	7.15e-24	Daytime sleep phenotypes;
BRCA	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg08422745	chr4:174089978	GALNT7	-0.77	-15.71	-0.53	2.9e-47	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs1003719	0.680	rs7276569	chr21:38578207	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.73	-0.5	1.77e-42	Eye color traits;
BRCA	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg13902645	chr11:5959945	NA	-0.53	-11.03	-0.4	5.35e-26	DNA methylation (variation);
BRCA	cis	rs9462027	0.628	rs9462010	chr6:34716605	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.96	-0.3	7.83e-15	Systemic lupus erythematosus;
BRCA	cis	rs4363385	0.818	rs11205166	chr1:152988627	C/G	cg25856811	chr1:152973957	SPRR3	-0.31	-8.3	-0.31	6.32e-16	Inflammatory skin disease;
BRCA	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-13.96	-0.48	7.58e-39	Platelet count;
BRCA	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg20307385	chr11:47447363	PSMC3	-0.44	-9.09	-0.34	1.22e-18	Subjective well-being;
BRCA	cis	rs6138458	0.626	rs6050259	chr20:25011423	A/G	cg26195577	chr20:24973756	C20orf3	0.61	14.68	0.5	2.99e-42	Blood protein levels;
BRCA	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg27446573	chr6:127587934	RNF146	0.86	19.7	0.61	7.62e-68	Breast cancer;
BRCA	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg06238570	chr21:40685208	BRWD1	-0.4	-8.21	-0.31	1.27e-15	Menarche (age at onset);
BRCA	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg03188948	chr7:1209495	NA	0.47	9.62	0.36	1.56e-20	Longevity;Endometriosis;
BRCA	cis	rs7586879	0.789	rs13382979	chr2:25131736	G/A	cg01884057	chr2:25150051	NA	0.31	7.89	0.3	1.32e-14	Body mass index;
BRCA	cis	rs919433	0.783	rs55725278	chr2:198238223	C/T	cg00792783	chr2:198669748	PLCL1	0.35	7.83	0.3	1.98e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.24	8.42	0.32	2.44e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg14675211	chr2:100938903	LONRF2	0.48	11.13	0.4	2.09e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg14458575	chr2:238380390	NA	0.78	17.5	0.57	2.69e-56	Prostate cancer;
BRCA	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg08859206	chr1:53392774	SCP2	0.48	10.78	0.39	5.03e-25	Monocyte count;
BRCA	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-10.24	-0.38	7.17e-23	Blood metabolite levels;
BRCA	trans	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg25214090	chr10:38739885	LOC399744	0.57	12.97	0.46	2.47e-34	Corneal astigmatism;
BRCA	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg08999081	chr20:33150536	PIGU	0.37	9.44	0.35	6.93e-20	Coronary artery disease;
BRCA	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg04842962	chr6:43655489	MRPS18A	-0.83	-21.01	-0.64	6.46e-75	IgG glycosylation;
BRCA	cis	rs6005807	0.719	rs9625524	chr22:29052951	C/T	cg12565055	chr22:29076175	TTC28	0.48	9.46	0.35	6.01e-20	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg26384229	chr12:38710491	ALG10B	-0.57	-13.92	-0.48	1.21e-38	Morning vs. evening chronotype;
BRCA	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11644478	chr21:40555479	PSMG1	-0.54	-11.63	-0.42	1.73e-28	Menarche (age at onset);
BRCA	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg17971929	chr21:40555470	PSMG1	0.79	18.76	0.6	6.99e-63	Cognitive function;
BRCA	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg08422745	chr4:174089978	GALNT7	-0.81	-17.84	-0.58	4.44e-58	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg23933602	chr10:16859644	RSU1	0.56	9.02	0.34	2.13e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg10223061	chr2:219282414	VIL1	0.3	8.78	0.33	1.52e-17	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs16854884	0.657	rs35085196	chr3:143712210	C/T	cg06585982	chr3:143692056	C3orf58	0.44	9.03	0.34	2.09e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg22800045	chr5:56110881	MAP3K1	-0.46	-9.1	-0.34	1.17e-18	Initial pursuit acceleration;
BRCA	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.71	0.55	2.93e-52	Colorectal cancer;
BRCA	cis	rs2652822	0.525	rs17828874	chr15:63516266	C/G	cg02713581	chr15:63449717	RPS27L	-0.42	-8.3	-0.31	6.02e-16	Metabolic traits;
BRCA	trans	rs61931739	0.892	rs73309466	chr12:34093146	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-8.94	-0.33	4.03e-18	Morning vs. evening chronotype;
BRCA	cis	rs2835872	0.758	rs8134288	chr21:39036989	T/C	cg06728970	chr21:39037746	KCNJ6	0.45	12.93	0.46	3.95e-34	Electroencephalographic traits in alcoholism;
BRCA	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07636037	chr3:49044803	WDR6	-0.74	-16.07	-0.54	4.89e-49	Menarche (age at onset);
BRCA	cis	rs7944584	0.632	rs749067	chr11:47318157	T/C	cg03711944	chr11:47377212	SPI1	-0.35	-7.98	-0.3	6.58e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg07537917	chr2:241836409	C2orf54	-0.48	-11.38	-0.41	1.94e-27	Urinary metabolites;
BRCA	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg04756594	chr16:24857601	SLC5A11	0.34	8.51	0.32	1.21e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-16.62	-0.55	7.91e-52	Alzheimer's disease (late onset);
BRCA	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-19.6	-0.61	2.49e-67	Systemic lupus erythematosus;
BRCA	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg22961513	chr11:14280813	SPON1	0.3	7.83	0.3	2.08e-14	Mitochondrial DNA levels;
BRCA	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00149659	chr3:10157352	C3orf10	0.71	12.33	0.44	1.69e-31	Alzheimer's disease;
BRCA	cis	rs858239	0.601	rs4140959	chr7:23170776	C/T	cg23682824	chr7:23144976	KLHL7	0.45	11.9	0.43	1.19e-29	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs490234	0.702	rs4838275	chr9:128352785	C/T	cg14078157	chr9:128172775	NA	-0.52	-11.44	-0.41	1.08e-27	Mean arterial pressure;
BRCA	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg05234568	chr11:5960015	NA	-0.43	-8.64	-0.32	4.6e-17	DNA methylation (variation);
BRCA	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12826209	chr6:26865740	GUSBL1	-0.55	-9.86	-0.36	1.86e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1029738	0.659	rs1608553	chr7:22896231	G/C	cg15401507	chr7:22894281	NA	-0.41	-9.38	-0.35	1.15e-19	Fibrinogen levels;
BRCA	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	17.76	0.57	1.21e-57	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs10992471	0.603	rs10992342	chr9:95212068	C/T	cg14631576	chr9:95140430	CENPP	-0.38	-9.38	-0.35	1.18e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs7107174	0.901	rs10899496	chr11:78123831	A/G	cg27205649	chr11:78285834	NARS2	-0.29	-8.51	-0.32	1.23e-16	Testicular germ cell tumor;
BRCA	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg01448562	chr3:133502909	NA	-0.63	-14.87	-0.51	3.7e-43	Iron status biomarkers;
BRCA	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg06784218	chr1:46089804	CCDC17	-0.53	-12.89	-0.45	5.96e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg04733989	chr22:42467013	NAGA	0.37	8.2	0.31	1.32e-15	Schizophrenia;
BRCA	cis	rs4780401	0.609	rs11639945	chr16:11824056	T/G	cg01061890	chr16:11836724	TXNDC11	-0.55	-12.8	-0.45	1.54e-33	Rheumatoid arthritis;
BRCA	cis	rs1865721	1.000	rs72977890	chr18:73198776	C/A	cg26385618	chr18:73139727	C18orf62	-0.38	-8.56	-0.32	8.24e-17	Intelligence;
BRCA	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg21143896	chr7:2802374	GNA12	-0.36	-8.68	-0.32	3.25e-17	Height;
BRCA	trans	rs783540	0.967	rs1269134	chr15:83282628	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.29	-8.9	-0.33	5.59e-18	Schizophrenia;
BRCA	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg21138405	chr5:131827807	IRF1	0.4	12.97	0.46	2.5e-34	Asthma (sex interaction);
BRCA	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg11814155	chr7:99998594	ZCWPW1	0.54	8.93	0.33	4.49e-18	Platelet count;
BRCA	cis	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg04990556	chr1:26633338	UBXN11	0.55	9.24	0.34	3.56e-19	Obesity-related traits;
BRCA	cis	rs2637030	0.515	rs2130744	chr5:52896723	C/T	cg06476337	chr5:52856530	NDUFS4	0.38	8.62	0.32	5.24e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg03354898	chr7:1950403	MAD1L1	-0.39	-8.17	-0.31	1.69e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-16.17	-0.54	1.56e-49	Extrinsic epigenetic age acceleration;
BRCA	cis	rs11971779	0.625	rs10260850	chr7:139003602	G/T	cg07862535	chr7:139043722	LUC7L2	0.31	8.19	0.31	1.46e-15	Diisocyanate-induced asthma;
BRCA	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg11879182	chr18:77439856	CTDP1	0.63	13.39	0.47	3.34e-36	Monocyte count;
BRCA	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg00684032	chr4:1343700	KIAA1530	0.31	7.84	0.3	1.89e-14	Obesity-related traits;
BRCA	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg23602478	chr1:26503979	CNKSR1	0.23	8.01	0.3	5.44e-15	Height;
BRCA	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.58	9.93	0.37	1.03e-21	Gut microbiome composition (summer);
BRCA	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.31	-8.07	-0.3	3.49e-15	Response to antipsychotic treatment;
BRCA	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.29	9.85	0.36	2.15e-21	Bipolar disorder;
BRCA	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-9.95	-0.37	8.79e-22	Alzheimer's disease (late onset);
BRCA	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg01884057	chr2:25150051	NA	0.34	9.22	0.34	4.2e-19	Body mass index;
BRCA	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg21724239	chr8:58056113	NA	0.58	9.46	0.35	6.03e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs7560272	0.538	rs4852972	chr2:73916672	C/T	cg20560298	chr2:73613845	ALMS1	0.36	9.26	0.34	3.06e-19	Schizophrenia;
BRCA	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg24692254	chr21:30365293	RNF160	-0.63	-16.57	-0.55	1.49e-51	Dental caries;
BRCA	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.52	-0.32	1.19e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs16958440	0.867	rs79712753	chr18:44676727	C/A	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.48	0.32	1.51e-16	Cognitive ability;
BRCA	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg05623727	chr3:50126028	RBM5	0.45	8.59	0.32	6.59e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg02753203	chr1:228287806	NA	-0.6	-12.84	-0.45	1.01e-33	Diastolic blood pressure;
BRCA	trans	rs4650994	0.525	rs2493848	chr1:178547838	T/A	cg05059571	chr16:84539110	KIAA1609	0.54	12.45	0.44	5.11e-32	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-9.03	-0.34	1.93e-18	Alzheimer's disease (late onset);
BRCA	cis	rs1568889	1.000	rs7951681	chr11:28273894	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	14.13	0.49	1.18e-39	Bipolar disorder;
BRCA	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.9	0.3	1.19e-14	Axial length;
BRCA	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg08213375	chr14:104286397	PPP1R13B	0.52	10.97	0.4	8.87e-26	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-19.86	-0.62	1e-68	Systemic lupus erythematosus;
BRCA	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg13010199	chr12:38710504	ALG10B	0.36	8.42	0.32	2.47e-16	Morning vs. evening chronotype;
BRCA	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg16339924	chr4:17578868	LAP3	0.64	15.76	0.53	1.69e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9814567	0.964	rs10935113	chr3:134173091	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-17.14	-0.56	1.9e-54	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg26031613	chr14:104095156	KLC1	0.45	8.17	0.31	1.63e-15	Coronary artery disease;
BRCA	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-13.88	-0.48	1.77e-38	Blood metabolite levels;
BRCA	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg16586182	chr3:47516702	SCAP	0.56	12.61	0.45	1.06e-32	Colorectal cancer;
BRCA	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06544989	chr22:39130855	UNC84B	0.38	8.6	0.32	6.13e-17	Menopause (age at onset);
BRCA	cis	rs11690935	0.632	rs6737308	chr2:172872042	G/A	cg13550731	chr2:172543902	DYNC1I2	0.52	12.68	0.45	5.09e-33	Schizophrenia;
BRCA	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg24154853	chr7:158122151	PTPRN2	0.35	8.44	0.32	2.1e-16	Calcium levels;
BRCA	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.6	-13.39	-0.47	3.21e-36	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg11764359	chr7:65958608	NA	0.68	15.01	0.51	7.32e-44	Aortic root size;
BRCA	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg07741184	chr6:167504864	NA	0.29	8.37	0.31	3.57e-16	Crohn's disease;
BRCA	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.46	-13.82	-0.48	3.56e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs783540	1.000	rs783540	chr15:83254708	C/T	cg18393722	chr15:85113863	UBE2QP1	0.26	8.24	0.31	9.98e-16	Schizophrenia;
BRCA	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg22117172	chr7:91764530	CYP51A1	0.23	7.84	0.3	1.88e-14	Breast cancer;
BRCA	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.72	-0.33	2.36e-17	Total body bone mineral density;
BRCA	trans	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	13.92	0.48	1.14e-38	Hip circumference adjusted for BMI;
BRCA	cis	rs67981189	0.634	rs221900	chr14:71604354	C/T	cg15816911	chr14:71606274	NA	0.42	9.08	0.34	1.32e-18	Schizophrenia;
BRCA	cis	rs9649465	0.935	rs3807636	chr7:123368488	G/A	cg04330084	chr7:123175371	IQUB	-0.33	-8.98	-0.33	2.93e-18	Migraine;
BRCA	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	0.4	8.87	0.33	7.46e-18	IgG glycosylation;
BRCA	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg05340658	chr4:99064831	C4orf37	0.62	14.93	0.51	1.92e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg09307838	chr4:120376055	NA	0.61	12.23	0.44	4.63e-31	Corneal astigmatism;
BRCA	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg23649088	chr2:200775458	C2orf69	0.62	10.73	0.39	8.46e-25	Schizophrenia;
BRCA	cis	rs1371614	0.655	rs4665927	chr2:27149366	A/T	cg00617064	chr2:27272375	NA	0.31	8.19	0.31	1.48e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-8.06	-0.3	3.7e-15	Obesity-related traits;
BRCA	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg25358565	chr5:93447407	FAM172A	1.17	18.51	0.59	1.52e-61	Diabetic retinopathy;
BRCA	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg11764359	chr7:65958608	NA	0.66	11.88	0.43	1.43e-29	Aortic root size;
BRCA	cis	rs897984	0.609	rs35468353	chr16:31056433	A/G	cg02466173	chr16:30829666	NA	-0.42	-9.36	-0.35	1.39e-19	Dementia with Lewy bodies;
BRCA	trans	rs4819388	0.915	rs7278940	chr21:45648992	C/T	cg17383793	chr5:52405638	MOCS2	-0.48	-11.03	-0.4	5e-26	Celiac disease;
BRCA	cis	rs8058578	0.832	rs35969813	chr16:30714417	T/C	cg00531865	chr16:30841666	NA	-0.51	-11.42	-0.41	1.33e-27	Multiple myeloma;
BRCA	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg14829155	chr15:31115871	NA	0.41	9.94	0.37	9.24e-22	Huntington's disease progression;
BRCA	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.4	8.4	0.32	2.87e-16	Total cholesterol levels;
BRCA	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	11.89	0.43	1.38e-29	Mean platelet volume;
BRCA	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg14993813	chr1:46806288	NSUN4	-0.45	-8.31	-0.31	5.63e-16	Menopause (age at onset);
BRCA	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-10.01	-0.37	5.17e-22	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-8.01	-0.3	5.55e-15	Response to antipsychotic treatment;
BRCA	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.06	-0.43	2.49e-30	Alzheimer's disease;
BRCA	cis	rs7927771	0.524	rs12226431	chr11:47805856	G/A	cg20307385	chr11:47447363	PSMC3	0.42	9.57	0.35	2.28e-20	Subjective well-being;
BRCA	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg23625390	chr15:77176239	SCAPER	-0.51	-12.15	-0.43	1.0500000000000001e-30	Blood metabolite levels;
BRCA	cis	rs10267417	0.535	rs6960579	chr7:19869364	A/G	cg05791153	chr7:19748676	TWISTNB	0.51	9.75	0.36	5.1e-21	Night sleep phenotypes;
BRCA	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg15432903	chr11:17409602	KCNJ11	0.71	15.59	0.52	1.15e-46	Type 2 diabetes;
BRCA	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.53	-0.35	3.1e-20	Total body bone mineral density;
BRCA	cis	rs600806	0.778	rs12145677	chr1:110023610	G/A	cg20591472	chr1:110008990	SYPL2	-0.32	-8.21	-0.31	1.2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg04362960	chr10:104952993	NT5C2	0.44	10.81	0.39	4.09e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg18196295	chr10:418757	DIP2C	-0.47	-11.08	-0.4	3.17e-26	Psychosis in Alzheimer's disease;
BRCA	cis	rs6460942	1.000	rs7808819	chr7:12297440	C/T	cg06484146	chr7:12443880	VWDE	-0.65	-8.92	-0.33	5.04e-18	Coronary artery disease;
BRCA	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg24642439	chr20:33292090	TP53INP2	0.71	16.46	0.55	5.15e-51	Coronary artery disease;
BRCA	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.39	7.94	0.3	9.23e-15	Personality dimensions;
BRCA	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.33	-10.72	-0.39	9.2e-25	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg09021430	chr5:549028	NA	-0.69	-14.55	-0.5	1.3e-41	Lung disease severity in cystic fibrosis;
BRCA	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg00012203	chr2:219082015	ARPC2	-0.41	-8.04	-0.3	4.32e-15	Ulcerative colitis;
BRCA	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg20007245	chr22:24372913	LOC391322	-0.55	-12.18	-0.43	7.42e-31	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.87	-0.3	1.53e-14	Electroencephalogram traits;
BRCA	cis	rs66887589	0.967	rs2892869	chr4:120521297	T/C	cg09307838	chr4:120376055	NA	-0.44	-9.16	-0.34	7.02e-19	Diastolic blood pressure;
BRCA	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg23711669	chr6:146136114	FBXO30	0.71	17.21	0.56	7.67e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg18538332	chr22:24372958	LOC391322	0.58	14.6	0.5	7.36e-42	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs17685	0.753	rs869806	chr7:75688623	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-8.72	-0.33	2.34e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg04455712	chr21:45112962	RRP1B	0.38	9.76	0.36	4.61e-21	Mean corpuscular volume;
BRCA	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	12.14	0.43	1.11e-30	Lymphocyte counts;
BRCA	cis	rs2422052	0.505	rs7569755	chr2:118648261	G/A	cg22545206	chr2:118617499	NA	-0.37	-7.96	-0.3	7.96e-15	Mosquito bite size;
BRCA	cis	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.57	-0.32	7.97e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs10754283	0.967	rs7552896	chr1:90103194	A/G	cg21401794	chr1:90099060	LRRC8C	0.49	11.63	0.42	1.79e-28	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg03146154	chr1:46216737	IPP	0.53	11.89	0.43	1.37e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg14926445	chr8:58193284	C8orf71	-0.46	-8.88	-0.33	6.81e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.43	-0.61	1.94e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08564027	chr20:61660810	NA	0.84	22.84	0.67	7.41e-85	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.21	-0.56	7.85e-55	Blood protein levels;
BRCA	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg00106254	chr7:1943704	MAD1L1	-0.43	-10.79	-0.39	4.91e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs7631605	0.935	rs9831084	chr3:37025661	T/C	cg15934958	chr3:37212084	LRRFIP2	0.4	9.17	0.34	6.33e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1577917	0.917	rs4707226	chr6:86527828	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.48	-0.41	7.11e-28	Response to antipsychotic treatment;
BRCA	cis	rs7264396	0.561	rs2050930	chr20:34579397	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-9.46	-0.35	6.02e-20	Total cholesterol levels;
BRCA	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg18252515	chr7:66147081	NA	-1.04	-15.52	-0.52	2.55e-46	Diabetic kidney disease;
BRCA	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg14631576	chr9:95140430	CENPP	-0.37	-8.97	-0.33	3.26e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg21827317	chr3:136751795	NA	0.45	9.84	0.36	2.22e-21	Neuroticism;
BRCA	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-9.12	-0.34	9.31e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg11693508	chr17:37793320	STARD3	0.48	10.42	0.38	1.35e-23	Bipolar disorder;
BRCA	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg13319975	chr6:146136371	FBXO30	0.43	9.87	0.36	1.78e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg13319975	chr6:146136371	FBXO30	0.61	13.76	0.48	6.68e-38	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	8.99	0.34	2.73e-18	Motion sickness;
BRCA	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg21770322	chr7:97807741	LMTK2	0.45	11.78	0.42	3.98e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9487051	0.734	rs56214745	chr6:109536748	G/T	cg01475377	chr6:109611718	NA	-0.43	-10.77	-0.39	5.94e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.3	7.99	0.3	6.38e-15	Monocyte percentage of white cells;
BRCA	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg06784218	chr1:46089804	CCDC17	0.5	12.0	0.43	4.75e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg22535103	chr8:58192502	C8orf71	-0.43	-8.72	-0.33	2.42e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6840360	0.533	rs4696295	chr4:152717430	T/C	cg22705602	chr4:152727874	NA	0.39	10.43	0.38	1.24e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg22920501	chr2:26401640	FAM59B	0.9	16.26	0.54	5.15e-50	Gut microbiome composition (summer);
BRCA	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg13902645	chr11:5959945	NA	-0.55	-11.61	-0.42	2.06e-28	DNA methylation (variation);
BRCA	cis	rs6763687	0.892	rs4894798	chr3:171795514	T/C	cg16233210	chr3:171778391	FNDC3B	0.42	9.77	0.36	4.13e-21	Red cell distribution width;
BRCA	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16405210	chr4:1374714	KIAA1530	-0.54	-12.83	-0.45	1.05e-33	Longevity;
BRCA	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11644478	chr21:40555479	PSMG1	0.53	11.55	0.42	3.65e-28	Cognitive function;
BRCA	trans	rs1459104	1.000	rs66510003	chr11:55160196	G/A	cg15704280	chr7:45808275	SEPT13	0.63	8.0	0.3	5.74e-15	Body mass index;
BRCA	cis	rs2901460	0.509	rs12465313	chr2:62078301	G/A	cg02183531	chr2:62113199	CCT4	-0.47	-9.27	-0.34	2.72e-19	Mean corpuscular volume;
BRCA	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg26195577	chr20:24973756	C20orf3	1.03	28.97	0.75	1.65e-118	Blood protein levels;
BRCA	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg05025164	chr4:1340916	KIAA1530	0.37	8.13	0.31	2.24e-15	Longevity;
BRCA	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg06212747	chr3:49208901	KLHDC8B	0.46	9.34	0.35	1.53e-19	Parkinson's disease;
BRCA	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg21782813	chr7:2030301	MAD1L1	0.3	7.94	0.3	8.89e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg18154014	chr19:37997991	ZNF793	0.5	9.78	0.36	3.69e-21	Coronary artery calcification;
BRCA	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg18964960	chr10:1102726	WDR37	-0.47	-9.01	-0.34	2.46e-18	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs7851660	0.967	rs13288000	chr9:100608980	A/G	cg13688889	chr9:100608707	NA	-0.37	-8.88	-0.33	6.84e-18	Strep throat;
BRCA	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	14.33	0.49	1.3e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg20887711	chr4:1340912	KIAA1530	0.42	10.21	0.37	9.14e-23	Longevity;
BRCA	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-13.85	-0.48	2.58e-38	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs6545883	0.868	rs7608483	chr2:61836235	A/C	cg15711740	chr2:61764176	XPO1	-0.55	-13.86	-0.48	2.21e-38	Tuberculosis;
BRCA	cis	rs9487051	0.702	rs670414	chr6:109529912	A/G	cg01475377	chr6:109611718	NA	0.43	10.44	0.38	1.17e-23	Reticulocyte fraction of red cells;
BRCA	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg25036284	chr2:26402008	FAM59B	0.95	15.98	0.53	1.27e-48	Gut microbiome composition (summer);
BRCA	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.59	-0.32	6.45e-17	Glomerular filtration rate (creatinine);
BRCA	trans	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-10.34	-0.38	2.75e-23	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg23711669	chr6:146136114	FBXO30	0.79	18.81	0.6	3.79e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9682041	0.696	rs6786542	chr3:170105378	C/T	cg11886554	chr3:170076028	SKIL	0.51	10.05	0.37	3.75e-22	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs8023845	1.000	rs62019997	chr15:40443476	T/C	cg20259534	chr15:40453036	BUB1B	0.58	8.47	0.32	1.72e-16	Chronic lymphocytic leukemia;
BRCA	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg17420585	chr12:42539391	GXYLT1	-0.6	-14.89	-0.51	2.85e-43	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg24154853	chr7:158122151	PTPRN2	0.35	8.16	0.31	1.73e-15	Calcium levels;
BRCA	cis	rs524281	0.692	rs2302884	chr11:65824084	C/T	cg16950941	chr11:66035639	RAB1B	-0.41	-8.94	-0.33	4.28e-18	Electroencephalogram traits;
BRCA	cis	rs2625529	0.652	rs2899775	chr15:72268354	C/T	cg16672083	chr15:72433130	SENP8	0.68	16.32	0.54	2.58e-50	Red blood cell count;
BRCA	trans	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg25042112	chr7:64838748	ZNF92	-0.45	-8.34	-0.31	4.45e-16	Pain;
BRCA	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg00757033	chr12:89920650	WDR51B	0.52	10.44	0.38	1.13e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7394190	0.748	rs78790589	chr10:75539598	G/A	cg07699608	chr10:75541558	CHCHD1	0.71	10.37	0.38	2.13e-23	Incident atrial fibrillation;
BRCA	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.83	0.39	3.42e-25	Bipolar disorder;
BRCA	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg18301423	chr5:131593218	PDLIM4	0.31	7.96	0.3	7.71e-15	Breast cancer;
BRCA	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.17e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13082711	0.911	rs11719386	chr3:27505636	G/C	cg02860705	chr3:27208620	NA	0.59	11.06	0.4	3.95e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg03351412	chr1:154909251	PMVK	0.61	14.04	0.49	3.04e-39	Prostate cancer;
BRCA	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.71	0.33	2.65e-17	Tonsillectomy;
BRCA	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09307838	chr4:120376055	NA	0.76	16.93	0.56	2.2e-53	Corneal astigmatism;
BRCA	cis	rs4889609	0.834	rs72785520	chr16:31070778	C/T	cg02466173	chr16:30829666	NA	-0.43	-9.67	-0.36	9.42e-21	Response to metformin (IC50);
BRCA	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg18758796	chr5:131593413	PDLIM4	0.34	8.85	0.33	8.33e-18	Breast cancer;
BRCA	cis	rs6665290	0.558	rs1319103	chr1:227219314	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.74	-16.81	-0.55	8.96e-53	Myeloid white cell count;
BRCA	cis	rs9487051	0.743	rs388526	chr6:109543425	C/G	cg21918786	chr6:109611834	NA	-0.35	-8.61	-0.32	5.78e-17	Reticulocyte fraction of red cells;
BRCA	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-9.97	-0.37	7.2e-22	Joint mobility (Beighton score);
BRCA	cis	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg06521331	chr12:34319734	NA	-0.56	-10.12	-0.37	2.01e-22	Morning vs. evening chronotype;
BRCA	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg23422044	chr7:1970798	MAD1L1	-0.45	-9.44	-0.35	6.86e-20	Neuroticism;
BRCA	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.02	-0.34	2.13e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg09307838	chr4:120376055	NA	0.74	16.17	0.54	1.53e-49	Corneal astigmatism;
BRCA	cis	rs7165102	1.000	rs8027260	chr15:65955172	A/C	cg03382306	chr15:66097959	NA	0.36	9.79	0.36	3.6e-21	Mean corpuscular hemoglobin;
BRCA	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg26408565	chr15:76604113	ETFA	-0.38	-8.24	-0.31	1.01e-15	Blood metabolite levels;
BRCA	cis	rs9487051	0.768	rs9480910	chr6:109521707	T/C	cg01475377	chr6:109611718	NA	-0.45	-11.4	-0.41	1.58e-27	Reticulocyte fraction of red cells;
BRCA	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg11247378	chr22:39784982	NA	-0.56	-12.98	-0.46	2.31e-34	Intelligence (multi-trait analysis);
BRCA	trans	rs4714291	0.963	rs1743973	chr6:40094549	T/G	cg02267698	chr19:7991119	CTXN1	0.41	7.95	0.3	8.35e-15	Strep throat;
BRCA	cis	rs10499694	0.967	rs7786398	chr7:50612906	G/A	cg18232548	chr7:50535776	DDC	-0.35	-8.54	-0.32	9.48e-17	Body mass index;
BRCA	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg03711944	chr11:47377212	SPI1	-0.38	-9.04	-0.34	1.88e-18	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.06	-0.3	3.88e-15	Menopause (age at onset);
BRCA	trans	rs7980799	0.682	rs7311794	chr12:33635630	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-10.21	-0.37	8.62e-23	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg23000734	chr10:126850823	CTBP2	-0.36	-9.14	-0.34	8.15e-19	Menarche (age at onset);
BRCA	cis	rs2882667	0.505	rs6596465	chr5:138483026	A/G	cg04439458	chr5:138467593	SIL1	0.31	8.46	0.32	1.8e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg16989086	chr20:62203971	PRIC285	0.53	8.97	0.33	3.29e-18	Glioma;Non-glioblastoma glioma;Glioblastoma;
BRCA	cis	rs6546550	0.935	rs3214007	chr2:70098808	A/G	cg02498382	chr2:70120550	SNRNP27	-0.5	-10.55	-0.39	4.3e-24	Prevalent atrial fibrillation;
BRCA	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg26597838	chr10:835615	NA	-0.43	-8.22	-0.31	1.18e-15	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg06115741	chr20:33292138	TP53INP2	-0.4	-8.8	-0.33	1.25e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.43	-7.94	-0.3	9.35e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg20476274	chr7:133979776	SLC35B4	0.65	19.4	0.61	2.78e-66	Mean platelet volume;
BRCA	cis	rs7809950	0.678	rs7803151	chr7:106934246	G/A	cg23024343	chr7:107201750	COG5	-0.47	-9.27	-0.34	2.91e-19	Coronary artery disease;
BRCA	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg08885076	chr2:99613938	TSGA10	0.44	10.4	0.38	1.62e-23	Chronic sinus infection;
BRCA	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg05872129	chr22:39784769	NA	-0.57	-13.12	-0.46	5.51e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg24296786	chr1:45957014	TESK2	0.65	16.04	0.54	6.96e-49	High light scatter reticulocyte count;
BRCA	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg00531865	chr16:30841666	NA	-0.5	-11.11	-0.4	2.38e-26	Multiple myeloma;
BRCA	cis	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.4	1.46e-26	Morning vs. evening chronotype;
BRCA	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg05535760	chr7:792225	HEATR2	0.72	13.22	0.46	1.9e-35	Cerebrospinal P-tau181p levels;
BRCA	cis	rs208520	0.690	rs207094	chr6:66799009	G/A	cg07460842	chr6:66804631	NA	-1.0	-20.02	-0.62	1.44e-69	Exhaled nitric oxide output;
BRCA	trans	rs28595532	0.557	rs4359977	chr4:119314055	T/C	cg26518628	chr1:97050305	NA	-0.61	-10.44	-0.38	1.18e-23	Cannabis dependence symptom count;
BRCA	cis	rs1975991	0.711	rs6778034	chr3:187963710	A/G	cg15417654	chr3:187959138	LPP	0.36	9.45	0.35	6.48e-20	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg13770153	chr20:60521292	NA	-0.42	-9.48	-0.35	5.05e-20	Body mass index;
BRCA	trans	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg26384229	chr12:38710491	ALG10B	0.56	12.16	0.43	9.7e-31	Morning vs. evening chronotype;
BRCA	cis	rs501916	0.634	rs603569	chr15:48058929	G/A	cg16110827	chr15:48056943	SEMA6D	-0.41	-9.09	-0.34	1.21e-18	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg15556689	chr8:8085844	FLJ10661	-0.36	-9.6	-0.36	1.73e-20	Joint mobility (Beighton score);
BRCA	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg25019033	chr10:957182	NA	-0.43	-8.89	-0.33	6.11e-18	Eosinophil percentage of granulocytes;
BRCA	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00166722	chr3:10149974	C3orf24	0.62	11.1	0.4	2.62e-26	Alzheimer's disease;
BRCA	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg18132916	chr6:79620363	NA	-0.5	-11.86	-0.42	1.85e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg04691961	chr3:161091175	C3orf57	0.58	13.95	0.48	7.96e-39	Morning vs. evening chronotype;
BRCA	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg06238570	chr21:40685208	BRWD1	-0.41	-8.36	-0.31	3.95e-16	Menarche (age at onset);
BRCA	trans	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs5167	0.504	rs3760628	chr19:45457225	G/A	cg09555818	chr19:45449301	APOC2	0.47	12.12	0.43	1.44e-30	Blood protein levels;
BRCA	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg21775979	chr11:780331	NA	-0.36	-7.95	-0.3	8.62e-15	Breast cancer;
BRCA	cis	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg07460842	chr6:66804631	NA	0.77	14.02	0.48	4.08e-39	Exhaled nitric oxide levels;
BRCA	cis	rs67460515	0.500	rs6806015	chr3:160724766	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-11.86	-0.42	1.74e-29	Parkinson's disease;
BRCA	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg24209194	chr3:40518798	ZNF619	-0.39	-7.91	-0.3	1.13e-14	Renal cell carcinoma;
BRCA	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	18.99	0.6	4.13e-64	Electrocardiographic conduction measures;
BRCA	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg03433033	chr1:76189801	ACADM	0.76	17.54	0.57	1.62e-56	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg15017067	chr4:17643749	FAM184B	0.26	7.87	0.3	1.53e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg02574844	chr11:5959923	NA	-0.4	-7.84	-0.3	1.88e-14	DNA methylation (variation);
BRCA	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-11.48	-0.41	7.07e-28	Neuroticism;
BRCA	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg07148914	chr20:33460835	GGT7	-0.41	-8.96	-0.33	3.4e-18	Height;
BRCA	cis	rs7975161	0.640	rs10735394	chr12:104687142	C/A	cg25273343	chr12:104657179	TXNRD1	-0.5	-9.98	-0.37	7.05e-22	Toenail selenium levels;
BRCA	cis	rs6740322	0.895	rs6710656	chr2:43566941	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-12.43	-0.44	6.17e-32	Coronary artery disease;
BRCA	trans	rs9951602	0.512	rs4798995	chr18:76654344	T/G	cg02800362	chr5:177631904	HNRNPAB	0.78	18.3	0.59	1.73e-60	Obesity-related traits;
BRCA	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.51	0.63	3.48e-72	Electrocardiographic conduction measures;
BRCA	cis	rs13223928	0.666	rs9986825	chr7:3151177	C/T	cg19214707	chr7:3157722	NA	0.4	9.34	0.35	1.53e-19	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
BRCA	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.8	-0.33	1.23e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg25214090	chr10:38739885	LOC399744	0.53	12.0	0.43	4.63e-30	Corneal astigmatism;
BRCA	cis	rs9487051	0.768	rs9398188	chr6:109526615	G/A	cg01475377	chr6:109611718	NA	-0.41	-10.29	-0.38	4.49e-23	Reticulocyte fraction of red cells;
BRCA	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg03146154	chr1:46216737	IPP	-0.5	-11.07	-0.4	3.54e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.51	0.38	6.38e-24	Motion sickness;
BRCA	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg03188948	chr7:1209495	NA	0.85	8.57	0.32	7.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg14675211	chr2:100938903	LONRF2	0.52	11.96	0.43	7.15e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs9942416	0.650	rs2640646	chr5:74977458	A/T	cg19683494	chr5:74908142	NA	-0.47	-8.72	-0.33	2.42e-17	Age-related disease endophenotypes;
BRCA	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg00071950	chr4:10020882	SLC2A9	-0.42	-9.51	-0.35	3.96e-20	Bone mineral density;
BRCA	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg18225595	chr11:63971243	STIP1	0.51	9.38	0.35	1.11e-19	Mean platelet volume;
BRCA	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg09307838	chr4:120376055	NA	0.6	11.16	0.4	1.57e-26	Corneal astigmatism;
BRCA	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg22189786	chr22:42395067	WBP2NL	0.43	8.59	0.32	6.7e-17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg05340658	chr4:99064831	C4orf37	0.62	14.93	0.51	1.86e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7737355	0.898	rs3775998	chr5:130979332	A/G	cg06307176	chr5:131281290	NA	0.52	10.28	0.38	4.63e-23	Life satisfaction;
BRCA	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg00321850	chr1:175162397	KIAA0040	-0.41	-11.44	-0.41	1.08e-27	Alcohol dependence;
BRCA	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.32	-7.83	-0.3	1.99e-14	Hematocrit;
BRCA	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg18252515	chr7:66147081	NA	-0.9	-12.9	-0.45	5.33e-34	Diabetic kidney disease;
BRCA	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg08885076	chr2:99613938	TSGA10	0.45	10.46	0.38	9.8599999999999993e-24	Chronic sinus infection;
BRCA	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg04362960	chr10:104952993	NT5C2	0.43	10.25	0.38	6.27e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	8.41	0.32	2.74e-16	Axial length;
BRCA	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	8.75	0.33	1.87e-17	Mean platelet volume;
BRCA	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-10.3	-0.38	4e-23	Reticulocyte count;
BRCA	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg18876405	chr7:65276391	NA	-0.54	-12.07	-0.43	2.41e-30	Calcium levels;
BRCA	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg21770322	chr7:97807741	LMTK2	0.43	11.37	0.41	2.12e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg22907277	chr7:1156413	C7orf50	-0.48	-10.53	-0.38	4.9299999999999996e-24	Longevity;Endometriosis;
BRCA	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg24060327	chr5:131705240	SLC22A5	-0.64	-12.48	-0.44	3.78e-32	Breast cancer;
BRCA	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg04842962	chr6:43655489	MRPS18A	1.12	38.86	0.84	1.86e-170	IgG glycosylation;
BRCA	cis	rs34779708	0.966	rs2045915	chr10:35418616	G/C	cg03585969	chr10:35415529	CREM	0.44	9.13	0.34	8.93e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1997103	1.000	rs10278894	chr7:55404748	A/G	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.92e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg15145296	chr3:125709740	NA	-0.57	-9.29	-0.34	2.42e-19	Blood pressure (smoking interaction);
BRCA	cis	rs6450176	0.904	rs4351101	chr5:53300591	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-15.14	-0.51	1.8e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs1975991	0.538	rs9863680	chr3:187959089	C/G	cg15417654	chr3:187959138	LPP	-0.31	-8.1	-0.31	2.71e-15	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-17.96	-0.58	1.02e-58	Chronic sinus infection;
BRCA	cis	rs41005	0.967	rs17433703	chr2:8115300	A/G	cg03155496	chr2:8117019	LOC339788	0.61	17.68	0.57	2.99e-57	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.41	-0.32	2.64e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1710278	0.967	rs1710288	chr10:127741286	C/G	cg22975853	chr10:127789788	ADAM12	0.31	8.17	0.31	1.61e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
BRCA	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.76	0.36	4.41e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg06784218	chr1:46089804	CCDC17	0.46	10.91	0.4	1.53e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg02569458	chr12:86230093	RASSF9	0.32	7.87	0.3	1.5e-14	Major depressive disorder;
BRCA	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-8.21	-0.31	1.19e-15	Response to antipsychotic treatment;
BRCA	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-12.84	-0.45	1.03e-33	Chronic sinus infection;
BRCA	cis	rs754466	0.958	rs11002341	chr10:79701363	A/C	cg17075019	chr10:79541650	NA	-0.64	-12.18	-0.43	7.71e-31	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.2e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.51	10.34	0.38	2.77e-23	Height;
BRCA	cis	rs9649465	1.000	rs13230338	chr7:123373622	T/C	cg04330084	chr7:123175371	IQUB	-0.33	-9.0	-0.34	2.52e-18	Migraine;
BRCA	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-11.69	-0.42	9.51e-29	Bipolar disorder and schizophrenia;
BRCA	cis	rs7714584	1.000	rs12656600	chr5:150311872	A/G	cg22134413	chr5:150180641	NA	0.73	10.73	0.39	8.61e-25	Crohn's disease;
BRCA	cis	rs2625529	0.556	rs55679065	chr15:72433395	C/T	cg16672083	chr15:72433130	SENP8	0.68	16.91	0.56	2.89e-53	Red blood cell count;
BRCA	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg25036284	chr2:26402008	FAM59B	0.94	14.23	0.49	4.14e-40	Gut microbiome composition (summer);
BRCA	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg16482183	chr6:26056742	HIST1H1C	0.51	10.41	0.38	1.45e-23	Height;
BRCA	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.81	-0.36	2.89e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs34779708	0.742	rs35912711	chr10:35312996	T/C	cg03585969	chr10:35415529	CREM	0.49	10.25	0.38	6.46e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg00825309	chr19:58991885	ZNF446	-0.59	-12.82	-0.45	1.15e-33	Uric acid clearance;
BRCA	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg13628971	chr7:2884303	GNA12	0.44	9.28	0.34	2.62e-19	Height;
BRCA	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg19077165	chr18:44547161	KATNAL2	0.37	7.98	0.3	7.04e-15	Personality dimensions;
BRCA	cis	rs6546550	0.935	rs4853027	chr2:70039224	A/G	cg02498382	chr2:70120550	SNRNP27	0.48	10.09	0.37	2.5e-22	Prevalent atrial fibrillation;
BRCA	cis	rs7590720	0.959	rs2372684	chr2:216884764	C/A	cg12620499	chr2:216877984	MREG	0.81	22.26	0.66	1.1e-81	Alcohol dependence;
BRCA	trans	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg07817883	chr1:32538562	TMEM39B	-0.44	-8.3	-0.31	6.42e-16	Monocyte percentage of white cells;
BRCA	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg24642844	chr7:1081250	C7orf50	-0.88	-16.14	-0.54	2.03e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	11.84	0.42	2.3e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10746514	0.833	rs867844	chr1:232266278	A/T	cg09506761	chr1:232265262	NA	0.42	8.8	0.33	1.32e-17	Response to statin therapy;
BRCA	cis	rs10267417	0.535	rs6946403	chr7:19861549	C/T	cg07541023	chr7:19748670	TWISTNB	0.49	8.97	0.33	3.22e-18	Night sleep phenotypes;
BRCA	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.5	-0.32	1.38e-16	Monocyte percentage of white cells;
BRCA	cis	rs6484504	0.600	rs2616815	chr11:31327316	C/T	cg06552810	chr11:31128660	NA	0.39	8.53	0.32	1.07e-16	Red blood cell count;
BRCA	trans	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg25214090	chr10:38739885	LOC399744	0.48	10.66	0.39	1.53e-24	Corneal astigmatism;
BRCA	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.51	0.55	2.86e-51	Alzheimer's disease (late onset);
BRCA	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03517284	chr6:25882590	NA	-0.34	-7.89	-0.3	1.34e-14	Height;
BRCA	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg15128208	chr22:42549153	NA	0.48	7.82	0.3	2.15e-14	Birth weight;
BRCA	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08045932	chr20:61659980	NA	0.5	11.51	0.41	5.25e-28	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg07211511	chr3:129823064	LOC729375	-0.63	-11.1	-0.4	2.72e-26	Blood pressure (smoking interaction);
BRCA	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg21475434	chr5:93447410	FAM172A	0.69	8.65	0.32	4.2e-17	Diabetic retinopathy;
BRCA	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg13319975	chr6:146136371	FBXO30	-0.35	-8.16	-0.31	1.83e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9283706	0.641	rs6414805	chr5:66322600	T/C	cg11590213	chr5:66331682	MAST4	0.42	8.09	0.3	3.09e-15	Coronary artery disease;
BRCA	cis	rs8010715	0.816	rs6573565	chr14:24594733	A/G	cg23112188	chr14:24563095	PCK2	0.34	8.4	0.32	2.98e-16	IgG glycosylation;
BRCA	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.75	-12.94	-0.46	3.67e-34	Platelet count;
BRCA	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg21573476	chr21:45109991	RRP1B	-0.37	-8.8	-0.33	1.25e-17	Mean corpuscular volume;
BRCA	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg14004847	chr7:1930337	MAD1L1	0.45	9.81	0.36	3.03e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.42	-8.46	-0.32	1.89e-16	Eosinophil percentage of white cells;
BRCA	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg08400316	chr16:204221	HBZ	0.76	16.49	0.55	3.72e-51	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg01420254	chr6:26195488	NA	0.61	9.22	0.34	4.28e-19	Gout;Renal underexcretion gout;
BRCA	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13012494	chr21:47604986	C21orf56	-0.44	-9.1	-0.34	1.15e-18	Testicular germ cell tumor;
BRCA	cis	rs6543140	0.929	rs6742530	chr2:103082280	G/A	cg04239558	chr2:103089729	SLC9A4	0.35	9.74	0.36	5.21e-21	Blood protein levels;
BRCA	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg00750074	chr16:89608354	SPG7	-0.42	-11.61	-0.42	2.13e-28	Multiple myeloma (IgH translocation);
BRCA	trans	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg05863683	chr7:1912471	MAD1L1	-0.44	-9.57	-0.35	2.34e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs73242632	1.000	rs10002090	chr4:57859592	T/C	cg20415529	chr4:57845134	POLR2B;C4orf14	0.7	8.49	0.32	1.49e-16	Congenital heart disease (maternal effect);
BRCA	cis	rs6733011	0.578	rs1581250	chr2:99500750	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.37	-8.56	-0.32	8.41e-17	Bipolar disorder;
BRCA	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-14.36	-0.49	9.48e-41	Morning vs. evening chronotype;
BRCA	cis	rs495337	0.736	rs483508	chr20:48499609	C/T	cg17835207	chr20:48524531	SPATA2	-0.54	-12.01	-0.43	4.03e-30	Psoriasis;
BRCA	trans	rs656319	0.564	rs11776035	chr8:10071527	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.74	-0.33	2.08e-17	Myopia (pathological);
BRCA	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg18129178	chr5:148520854	ABLIM3	-0.58	-11.93	-0.43	9.28e-30	Breast cancer;
BRCA	cis	rs490234	0.702	rs4838279	chr9:128411726	G/A	cg14078157	chr9:128172775	NA	-0.51	-11.3	-0.41	3.88e-27	Mean arterial pressure;
BRCA	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg05623727	chr3:50126028	RBM5	-0.42	-10.04	-0.37	3.92e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.96	0.37	8.41e-22	Bipolar disorder;
BRCA	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg11843238	chr5:131593191	PDLIM4	0.35	9.12	0.34	9.57e-19	Breast cancer;
BRCA	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg01528321	chr10:82214614	TSPAN14	0.67	14.14	0.49	1.03e-39	Post bronchodilator FEV1;
BRCA	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.62	-16.34	-0.54	2.1e-50	Hypertriglyceridemia;
BRCA	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg09307838	chr4:120376055	NA	-0.49	-9.26	-0.34	3.11e-19	Corneal astigmatism;
BRCA	cis	rs7020830	0.825	rs10973248	chr9:37197768	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	41.16	0.85	7e-182	Schizophrenia;
BRCA	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg08085267	chr17:45401833	C17orf57	-0.58	-12.06	-0.43	2.66e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg08999081	chr20:33150536	PIGU	0.49	13.78	0.48	5.24e-38	Coronary artery disease;
BRCA	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg24399712	chr22:39784796	NA	-0.47	-10.42	-0.38	1.33e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	14.8	0.51	7.89e-43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-11.29	-0.41	4.46e-27	IgG glycosylation;
BRCA	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg20891283	chr12:69753455	YEATS4	-0.83	-28.36	-0.75	3.84e-115	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg06618935	chr21:46677482	NA	-0.37	-7.99	-0.3	6.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg07211511	chr3:129823064	LOC729375	-0.62	-10.82	-0.39	3.47e-25	Blood pressure (smoking interaction);
BRCA	cis	rs36051895	0.695	rs2183137	chr9:5026293	A/G	cg02405213	chr9:5042618	JAK2	-0.5	-9.11	-0.34	1.08e-18	Pediatric autoimmune diseases;
BRCA	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05901451	chr6:126070800	HEY2	-0.53	-13.46	-0.47	1.6e-36	Brugada syndrome;
BRCA	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.24	-0.31	9.46e-16	Aortic root size;
BRCA	cis	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg07460842	chr6:66804631	NA	0.84	15.17	0.51	1.22e-44	Exhaled nitric oxide levels;
BRCA	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg15605315	chr1:45957053	TESK2	0.47	9.9	0.36	1.33e-21	High light scatter reticulocyte count;
BRCA	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	8.34	0.31	4.41e-16	Mean platelet volume;
BRCA	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg18270830	chr10:32634957	EPC1	0.58	10.04	0.37	4.01e-22	Sexual dysfunction (female);
BRCA	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.08e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs11249608	0.636	rs13359572	chr5:178449276	T/C	cg21905437	chr5:178450457	ZNF879	0.51	10.66	0.39	1.59e-24	Pubertal anthropometrics;
BRCA	trans	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg17675199	chr6:35436792	RPL10A	0.3	7.89	0.3	1.31e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.693	rs6668311	chr1:152964586	A/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.57	-0.35	2.28e-20	Inflammatory skin disease;
BRCA	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02176678	chr2:219576539	TTLL4	-0.5	-12.76	-0.45	2.32e-33	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs367943	0.901	rs463167	chr5:112799369	C/A	cg12552261	chr5:112820674	MCC	-0.55	-12.22	-0.44	4.98e-31	Type 2 diabetes;
BRCA	cis	rs3857067	0.806	rs17302300	chr4:95109177	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.39	-0.35	1.02e-19	QT interval;
BRCA	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg05207973	chr5:176823642	SLC34A1	-0.35	-8.23	-0.31	1.06e-15	Urinary electrolytes (magnesium/calcium ratio);
BRCA	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.74	16.29	0.54	3.92e-50	Cognitive ability;
BRCA	cis	rs273218	1.000	rs273217	chr5:53380938	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.42	8.68	0.32	3.36e-17	Migraine;
BRCA	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg24829409	chr8:58192753	C8orf71	-0.5	-8.23	-0.31	1.06e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-8.7	-0.33	2.74e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7091068	0.671	rs620890	chr10:95405424	G/A	cg20715218	chr10:95462985	C10orf4	-0.47	-8.44	-0.32	2.05e-16	Urinary tract infection frequency;
BRCA	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg15595755	chr5:1867978	NA	0.36	8.6	0.32	6.23e-17	Cardiovascular disease risk factors;
BRCA	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg24747557	chr10:131355152	MGMT	-0.35	-8.53	-0.32	1.1e-16	Response to temozolomide;
BRCA	cis	rs6840360	0.593	rs6857073	chr4:152689274	A/G	cg22705602	chr4:152727874	NA	0.39	10.2	0.37	1.01e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs13064411	0.696	rs7622740	chr3:113206771	G/A	cg18753928	chr3:113234510	CCDC52	-0.58	-12.0	-0.43	4.67e-30	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs4787491	0.729	rs4238960	chr16:30038648	G/C	cg06326092	chr16:30034487	C16orf92	0.38	9.62	0.36	1.47e-20	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg11062466	chr8:58055876	NA	0.57	9.5	0.35	4.18e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.93	13.64	0.47	2.27e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2249625	0.564	rs2463734	chr6:72882558	C/T	cg18830697	chr6:72922368	RIMS1	-0.63	-14.36	-0.49	9.82e-41	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg22963979	chr7:1858916	MAD1L1	-0.37	-8.01	-0.3	5.36e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.05	-0.37	3.78e-22	Mean corpuscular volume;
BRCA	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg11764359	chr7:65958608	NA	0.63	11.25	0.41	6.34e-27	Aortic root size;
BRCA	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21659725	chr3:3221576	CRBN	-0.35	-8.7	-0.33	2.74e-17	Body mass index;
BRCA	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.42	-8.35	-0.31	4.25e-16	Body mass index;
BRCA	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg22920501	chr2:26401640	FAM59B	-0.82	-13.65	-0.48	2.16e-37	Gut microbiome composition (summer);
BRCA	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-10.45	-0.38	1.07e-23	Neuroticism;
BRCA	cis	rs6138458	0.961	rs11700073	chr20:24975215	C/G	cg26195577	chr20:24973756	C20orf3	1.02	28.56	0.75	2.91e-116	Blood protein levels;
BRCA	trans	rs61931739	0.533	rs7970871	chr12:33917301	G/A	cg26384229	chr12:38710491	ALG10B	0.4	8.98	0.33	3.05e-18	Morning vs. evening chronotype;
BRCA	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	11.02	0.4	5.47e-26	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg06671706	chr8:8559999	CLDN23	0.45	8.74	0.33	2.11e-17	Obesity-related traits;
BRCA	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg14196790	chr5:131705035	SLC22A5	0.3	7.87	0.3	1.56e-14	Breast cancer;
BRCA	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg23895963	chr12:117471115	NA	0.5	9.14	0.34	8e-19	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg22875332	chr1:76189707	ACADM	-0.71	-15.45	-0.52	5.21e-46	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg11584989	chr19:19387371	SF4	-0.65	-14.01	-0.48	4.3e-39	Bipolar disorder;
BRCA	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	11.42	0.41	1.26e-27	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	4.15e-15	Alzheimer's disease (late onset);
BRCA	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-13.63	-0.47	2.63e-37	Response to antipsychotic treatment;
BRCA	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg00071950	chr4:10020882	SLC2A9	0.53	13.41	0.47	2.6e-36	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg05535760	chr7:792225	HEATR2	-0.72	-11.51	-0.41	5.51e-28	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg12292205	chr6:26970375	C6orf41	0.58	12.99	0.46	2.15e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg12591125	chr7:1885375	MAD1L1	0.49	8.64	0.32	4.52e-17	Bipolar disorder;
BRCA	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.53	-8.46	-0.32	1.77e-16	Schizophrenia;
BRCA	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	11.89	0.43	1.4e-29	Bipolar disorder and schizophrenia;
BRCA	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg22963979	chr7:1858916	MAD1L1	-0.38	-8.03	-0.3	4.63e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg03342759	chr3:160939853	NMD3	-0.64	-13.47	-0.47	1.36e-36	Morning vs. evening chronotype;
BRCA	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg23711669	chr6:146136114	FBXO30	0.65	14.84	0.51	4.91e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs881375	0.967	rs3761849	chr9:123690957	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	8.85	0.33	8.38e-18	Rheumatoid arthritis;
BRCA	cis	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-9.76	-0.36	4.42e-21	Mean corpuscular volume;
BRCA	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.94	0.3	8.88e-15	Depression;
BRCA	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00149659	chr3:10157352	C3orf10	0.72	12.57	0.45	1.49e-32	Alzheimer's disease;
BRCA	cis	rs4363385	0.747	rs3964619	chr1:152972811	A/C	cg24667326	chr1:152973720	SPRR3	-0.35	-9.52	-0.35	3.44e-20	Inflammatory skin disease;
BRCA	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg10495392	chr1:46806563	NSUN4	0.45	8.12	0.31	2.49e-15	Menopause (age at onset);
BRCA	cis	rs6910061	1.000	rs5027679	chr6:11118871	A/G	cg27233058	chr6:11094804	LOC221710	-0.52	-9.11	-0.34	1.01e-18	Diabetic kidney disease;
BRCA	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.61	0.32	5.85e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg07461501	chr17:79650226	HGS;ARL16	0.4	10.23	0.38	7.26e-23	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7246760	0.867	rs16981648	chr19:9804424	A/C	cg16876255	chr19:9731953	ZNF561	0.63	7.83	0.3	1.98e-14	Pursuit maintenance gain;
BRCA	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.72	0.65	9.17e-79	Lymphocyte percentage of white cells;
BRCA	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg12564285	chr5:131593104	PDLIM4	0.32	8.23	0.31	1.09e-15	Blood metabolite levels;
BRCA	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.57	11.98	0.43	5.5e-30	Monocyte percentage of white cells;
BRCA	cis	rs6120849	0.707	rs3746444	chr20:33578251	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	10.04	0.37	4.04e-22	Protein C levels;
BRCA	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	13.38	0.47	3.55e-36	Lymphocyte counts;
BRCA	cis	rs3862030	0.720	rs3740415	chr10:104232716	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.14	-0.43	1.18e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs858239	0.636	rs7808488	chr7:23221870	T/C	cg23682824	chr7:23144976	KLHL7	0.32	8.18	0.31	1.56e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg05729581	chr11:3078854	CARS	-0.35	-8.51	-0.32	1.22e-16	Longevity;
BRCA	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18404041	chr3:52824283	ITIH1	-0.36	-11.18	-0.4	1.23e-26	Electroencephalogram traits;
BRCA	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg00757033	chr12:89920650	WDR51B	0.54	11.16	0.4	1.56e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	trans	rs783540	0.934	rs803747	chr15:83258096	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.27	-8.44	-0.32	2.05e-16	Schizophrenia;
BRCA	trans	rs6964833	0.935	rs35735900	chr7:74066227	T/C	cg07504079	chr7:72649617	NCF1B	-0.47	-9.17	-0.34	6.61e-19	Menarche (age at onset);
BRCA	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg23711669	chr6:146136114	FBXO30	-0.77	-17.91	-0.58	1.88e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-8.3	-0.31	6.2e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg00105475	chr2:10696890	NA	0.44	10.25	0.38	6.03e-23	Prostate cancer;
BRCA	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-12.59	-0.45	1.23e-32	Bone mineral density;
BRCA	trans	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg25214090	chr10:38739885	LOC399744	0.52	11.49	0.41	6.72e-28	Corneal astigmatism;
BRCA	cis	rs7095944	0.614	rs11245354	chr10:126450125	C/A	cg08799069	chr10:126477246	METTL10	-0.4	-10.16	-0.37	1.43e-22	Asthma;
BRCA	cis	rs2882667	0.690	rs6873425	chr5:138155245	G/A	cg04439458	chr5:138467593	SIL1	0.32	8.14	0.31	2.11e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg25036284	chr2:26402008	FAM59B	-0.9	-15.23	-0.52	6.86e-45	Gut microbiome composition (summer);
BRCA	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.36	9.16	0.34	6.73e-19	Resting heart rate;
BRCA	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg11833968	chr6:79620685	NA	-0.45	-10.02	-0.37	4.82e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg05623727	chr3:50126028	RBM5	-0.49	-12.16	-0.43	9.5e-31	Body mass index;
BRCA	cis	rs701145	0.585	rs357477	chr3:153892717	A/G	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.9e-18	Coronary artery disease;
BRCA	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.35	9.13	0.34	8.77e-19	Resting heart rate;
BRCA	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg21395723	chr22:39101663	GTPBP1	0.39	8.33	0.31	4.9e-16	Menopause (age at onset);
BRCA	cis	rs8170	0.603	rs10259	chr19:17430915	G/A	cg02455703	chr19:17412272	ABHD8	-0.35	-7.85	-0.3	1.71e-14	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
BRCA	cis	rs13631	0.928	rs9411308	chr9:140000115	C/T	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.38	8.87	0.33	7.32e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6684514	0.961	rs10908497	chr1:156274740	G/A	cg16558208	chr1:156270281	VHLL	0.36	8.42	0.32	2.48e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.76	12.59	0.45	1.2e-32	Schizophrenia;
BRCA	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg01689657	chr7:91764605	CYP51A1	-0.23	-8.33	-0.31	5.08e-16	Breast cancer;
BRCA	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg08885076	chr2:99613938	TSGA10	-0.59	-13.08	-0.46	8e-35	Chronic sinus infection;
BRCA	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg01262667	chr19:19385393	TM6SF2	-0.42	-10.79	-0.39	4.77e-25	Tonsillectomy;
BRCA	trans	rs1997103	1.000	rs10263552	chr7:55404747	C/T	cg20935933	chr6:143382018	AIG1	0.6	11.63	0.42	1.73e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9300255	0.602	rs2851435	chr12:123712416	G/A	cg00376283	chr12:123451042	ABCB9	0.49	10.09	0.37	2.64e-22	Neutrophil percentage of white cells;
BRCA	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg22974920	chr21:40686053	BRWD1	-0.39	-8.57	-0.32	8.01e-17	Cognitive function;
BRCA	cis	rs1371614	0.635	rs877273	chr2:27140022	C/T	cg12368169	chr2:27073192	DPYSL5	-0.3	-8.85	-0.33	8.5e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg02659138	chr7:134003124	SLC35B4	0.38	11.37	0.41	2.02e-27	Mean platelet volume;
BRCA	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg11279151	chr3:101281821	RG9MTD1	0.38	8.63	0.32	4.79e-17	Colorectal cancer;
BRCA	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg11266682	chr4:10021025	SLC2A9	0.46	12.3	0.44	2.43e-31	Bone mineral density;
BRCA	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18876405	chr7:65276391	NA	-0.5	-11.18	-0.4	1.29e-26	Aortic root size;
BRCA	cis	rs7617773	0.780	rs11716848	chr3:48378500	G/A	cg11946769	chr3:48343235	NME6	0.67	13.46	0.47	1.62e-36	Coronary artery disease;
BRCA	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg13271783	chr10:134563150	INPP5A	-0.48	-9.63	-0.36	1.38e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs12220238	0.908	rs10824124	chr10:75997360	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.49	7.99	0.3	6.44e-15	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18876405	chr7:65276391	NA	-0.55	-13.25	-0.46	1.36e-35	Aortic root size;
BRCA	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs6960043	0.818	rs10267273	chr7:15053589	A/G	cg19272540	chr7:15055459	NA	-0.23	-8.11	-0.31	2.64e-15	Type 2 diabetes;
BRCA	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg16606324	chr3:10149918	C3orf24	0.54	10.48	0.38	8.25e-24	Alzheimer's disease;
BRCA	trans	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.78	-0.36	3.7e-21	Bladder cancer;
BRCA	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.7	0.36	7.46e-21	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg09658497	chr7:2847517	GNA12	-0.41	-8.69	-0.33	3.04e-17	Height;
BRCA	cis	rs36051895	0.594	rs7029244	chr9:5180961	A/C	cg02405213	chr9:5042618	JAK2	-0.48	-9.39	-0.35	1.04e-19	Pediatric autoimmune diseases;
BRCA	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg08601574	chr20:25228251	PYGB	-0.39	-9.05	-0.34	1.77e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7246657	0.722	rs2927739	chr19:38149330	C/A	cg18154014	chr19:37997991	ZNF793	-0.49	-9.15	-0.34	7.26e-19	Coronary artery calcification;
BRCA	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg20701182	chr2:24300061	SF3B14	0.62	8.86	0.33	8.1e-18	Lymphocyte counts;
BRCA	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg23533926	chr12:111358616	MYL2	0.41	8.64	0.32	4.59e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.81	-0.36	2.99e-21	Schizophrenia;
BRCA	cis	rs11997175	0.846	rs11776207	chr8:33765126	G/T	ch.8.33884649F	chr8:33765107	NA	-0.42	-9.71	-0.36	7.1e-21	Body mass index;
BRCA	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg10523679	chr1:76189770	ACADM	0.67	12.47	0.44	4.11e-32	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.19	-0.37	1.12e-22	Morning vs. evening chronotype;
BRCA	cis	rs17253792	0.822	rs10483650	chr14:56145312	A/G	cg01858014	chr14:56050164	KTN1	-0.75	-9.37	-0.35	1.25e-19	Putamen volume;
BRCA	cis	rs11971779	0.680	rs4728465	chr7:139069061	G/A	cg07862535	chr7:139043722	LUC7L2	0.41	11.16	0.4	1.46e-26	Diisocyanate-induced asthma;
BRCA	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg17971929	chr21:40555470	PSMG1	0.77	18.02	0.58	5.08e-59	Cognitive function;
BRCA	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg22906224	chr7:99728672	NA	-0.43	-8.04	-0.3	4.29e-15	Coronary artery disease;
BRCA	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg23231163	chr10:75533350	FUT11	-0.34	-8.83	-0.33	9.85e-18	Inflammatory bowel disease;
BRCA	cis	rs7818345	0.967	rs11787230	chr8:19280982	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.04	0.3	4.28e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	trans	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.92	0.3	1.05e-14	Endometrial cancer;
BRCA	cis	rs58804349	0.581	rs12221397	chr10:43239833	A/G	cg08461752	chr10:43522343	NA	0.66	9.43	0.35	7.57e-20	Pediatric bone mineral content (radius);
BRCA	cis	rs2559856	0.935	rs7970952	chr12:102081577	C/T	cg12213457	chr12:102090980	CHPT1	-0.37	-8.05	-0.3	4.16e-15	Blood protein levels;
BRCA	cis	rs2505998	0.843	rs2435344	chr10:43585874	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.42	-8.39	-0.32	3.06e-16	Hirschsprung disease;
BRCA	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg10729496	chr3:10149963	C3orf24	0.41	7.88	0.3	1.44e-14	Alzheimer's disease;
BRCA	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg12373951	chr3:133503437	NA	-0.32	-8.12	-0.31	2.35e-15	Iron status biomarkers (transferrin levels);
BRCA	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg20476274	chr7:133979776	SLC35B4	0.68	20.42	0.63	9.97e-72	Mean platelet volume;
BRCA	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg12463550	chr7:65579703	CRCP	0.37	7.93	0.3	9.93e-15	Aortic root size;
BRCA	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg17063962	chr7:91808500	NA	0.52	12.37	0.44	1.15e-31	Breast cancer;
BRCA	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.74	11.17	0.4	1.41e-26	Platelet count;
BRCA	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg05347473	chr6:146136440	FBXO30	0.41	8.05	0.3	4.05e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg14343924	chr8:8086146	FLJ10661	0.39	8.19	0.31	1.4e-15	Mood instability;
BRCA	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg01849466	chr14:104193079	ZFYVE21	0.47	10.6	0.39	2.59e-24	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg23711669	chr6:146136114	FBXO30	0.79	18.77	0.6	6.37e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7590368	1.000	rs72779469	chr2:10963764	C/G	cg15705551	chr2:10952987	PDIA6	0.43	8.05	0.3	3.97e-15	Educational attainment (years of education);
BRCA	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg12011299	chr4:100065546	ADH4	0.42	10.53	0.38	4.9e-24	Alcohol dependence;
BRCA	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.08e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg27446573	chr6:127587934	RNF146	0.9	21.07	0.64	2.99e-75	Breast cancer;
BRCA	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg13256891	chr4:100009986	ADH5	0.52	9.77	0.36	4.15e-21	Alcohol dependence;
BRCA	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg27147174	chr7:100797783	AP1S1	-0.52	-10.53	-0.38	5.27e-24	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg02551604	chr5:131831745	NA	-0.4	-14.95	-0.51	1.56e-43	Asthma (sex interaction);
BRCA	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg01028140	chr2:1542097	TPO	-0.62	-11.87	-0.43	1.67e-29	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg14926445	chr8:58193284	C8orf71	-0.42	-8.19	-0.31	1.43e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7246760	0.867	rs55800282	chr19:9833530	A/G	cg16876255	chr19:9731953	ZNF561	0.64	7.92	0.3	1.07e-14	Pursuit maintenance gain;
BRCA	trans	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg15556689	chr8:8085844	FLJ10661	0.37	8.93	0.33	4.6e-18	Systemic lupus erythematosus;
BRCA	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.52	0.38	5.68e-24	Motion sickness;
BRCA	trans	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg26043149	chr18:55253948	FECH	0.39	8.92	0.33	4.71e-18	Bone mineral density;
BRCA	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.5	-14.02	-0.49	3.9e-39	Lung cancer;
BRCA	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs17401966	0.838	rs1538557	chr1:10297230	T/C	cg03954927	chr1:10346856	KIF1B	0.44	13.95	0.48	8.64e-39	Hepatocellular carcinoma;
BRCA	cis	rs1941023	0.503	rs894591	chr11:60132647	T/C	cg08716584	chr11:60157161	MS4A7	-0.43	-9.92	-0.37	1.13e-21	Congenital heart disease (maternal effect);
BRCA	cis	rs12618769	0.625	rs72819984	chr2:99044762	G/C	cg10123293	chr2:99228465	UNC50	0.4	8.17	0.31	1.71e-15	Bipolar disorder;
BRCA	cis	rs16867321	0.950	rs9677293	chr2:181499459	C/G	cg23363182	chr2:181467187	NA	-0.44	-8.39	-0.31	3.16e-16	Obesity;
BRCA	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg23711669	chr6:146136114	FBXO30	-0.66	-15.17	-0.51	1.22e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg08508325	chr11:3079039	CARS	0.27	8.26	0.31	8.3e-16	Calcium levels;
BRCA	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg17366294	chr4:99064904	C4orf37	0.45	10.74	0.39	7.86e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1538970	0.884	rs781232	chr1:45890399	C/T	cg05343316	chr1:45956843	TESK2	-0.55	-11.39	-0.41	1.69e-27	Platelet count;
BRCA	trans	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-7.86	-0.3	1.65e-14	Menarche (age at onset);
BRCA	cis	rs11971779	0.638	rs77668044	chr7:139111085	T/A	cg07862535	chr7:139043722	LUC7L2	0.51	11.99	0.43	5.25e-30	Diisocyanate-induced asthma;
BRCA	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg10560079	chr2:191398806	TMEM194B	0.39	8.58	0.32	7.06e-17	Pulse pressure;
BRCA	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg18132916	chr6:79620363	NA	-0.5	-11.48	-0.41	7.25e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg19748678	chr4:122722346	EXOSC9	0.64	13.82	0.48	3.26e-38	Type 2 diabetes;
BRCA	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	18.13	0.58	1.36e-59	Alzheimer's disease;
BRCA	cis	rs6066835	1.000	rs73138221	chr20:47349525	T/C	cg18078177	chr20:47281410	PREX1	0.72	8.47	0.32	1.72e-16	Multiple myeloma;
BRCA	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg16230307	chr14:35515116	FAM177A1	0.74	15.31	0.52	2.52e-45	Psoriasis;
BRCA	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg22713356	chr15:30763199	NA	1.32	24.9	0.7	3.56e-96	Uric acid levels;
BRCA	cis	rs2797160	1.000	rs4897153	chr6:126003403	A/G	cg05901451	chr6:126070800	HEY2	-0.39	-9.42	-0.35	7.86e-20	Endometrial cancer;
BRCA	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg24675658	chr1:53192096	ZYG11B	0.72	16.81	0.55	9.31e-53	Monocyte count;
BRCA	cis	rs7582720	1.000	rs72936326	chr2:204054141	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	12.22	0.44	5.16e-31	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs4711336	0.967	rs4711338	chr6:33660188	T/C	cg14003231	chr6:33640908	ITPR3	0.32	7.87	0.3	1.53e-14	Height;
BRCA	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg03433033	chr1:76189801	ACADM	0.76	17.3	0.56	2.91e-55	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs730775	0.505	rs324137	chr6:44273546	G/T	cg21130236	chr6:44246755	TMEM151B	0.29	8.38	0.31	3.36e-16	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs400736	0.535	rs4418631	chr1:8174197	A/G	cg25007680	chr1:8021821	PARK7	0.36	8.96	0.33	3.67e-18	Response to antidepressants and depression;
BRCA	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg05985134	chr18:33552581	C18orf21	0.64	12.46	0.44	4.72e-32	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg13319975	chr6:146136371	FBXO30	-0.39	-8.93	-0.33	4.47e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg14196790	chr5:131705035	SLC22A5	-0.41	-10.1	-0.37	2.35e-22	Breast cancer;Mosquito bite size;
BRCA	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg21573476	chr21:45109991	RRP1B	-0.37	-9.52	-0.35	3.37e-20	Mean corpuscular volume;
BRCA	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg25019033	chr10:957182	NA	-0.41	-7.89	-0.3	1.3e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg16586182	chr3:47516702	SCAP	-0.53	-11.71	-0.42	7.64e-29	Colorectal cancer;
BRCA	cis	rs9469890	0.604	rs11758471	chr6:34503517	A/C	cg17674042	chr6:34482479	PACSIN1	-0.33	-8.56	-0.32	8.1e-17	Pubertal anthropometrics;Coronary artery disease;
BRCA	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg10523679	chr1:76189770	ACADM	0.72	12.55	0.44	1.88e-32	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2637030	0.515	rs449160	chr5:53005969	A/G	cg06476337	chr5:52856530	NDUFS4	0.37	8.47	0.32	1.63e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	trans	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg01620082	chr3:125678407	NA	-0.62	-8.23	-0.31	1.05e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1538970	0.962	rs3219472	chr1:45804050	A/G	cg05343316	chr1:45956843	TESK2	-0.49	-9.25	-0.34	3.35e-19	Platelet count;
BRCA	trans	rs8073060	0.586	rs117573546	chr17:33909588	G/A	cg19694781	chr19:47549865	TMEM160	1.05	21.57	0.65	5.93e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg18132916	chr6:79620363	NA	-0.38	-7.81	-0.3	2.32e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs74181299	0.892	rs2540945	chr2:65289825	A/G	cg05010058	chr2:65284262	CEP68	0.3	8.43	0.32	2.34e-16	Pulse pressure;
BRCA	cis	rs7737355	1.000	rs12517604	chr5:130748500	T/C	cg06307176	chr5:131281290	NA	-0.5	-9.87	-0.36	1.8e-21	Life satisfaction;
BRCA	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.63	13.95	0.48	8.64e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4363385	0.747	rs4319267	chr1:152972699	T/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.52	-0.35	3.44e-20	Inflammatory skin disease;
BRCA	cis	rs17253792	0.915	rs28375514	chr14:56179941	G/A	cg01858014	chr14:56050164	KTN1	-0.67	-8.51	-0.32	1.22e-16	Putamen volume;
BRCA	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05025164	chr4:1340916	KIAA1530	0.76	15.5	0.52	3.12e-46	Longevity;
BRCA	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg15103426	chr22:29168792	CCDC117	0.52	12.3	0.44	2.39e-31	Lymphocyte counts;
BRCA	cis	rs8017423	0.647	rs4904677	chr14:90819245	C/T	cg04374321	chr14:90722782	PSMC1	-0.5	-11.92	-0.43	9.86e-30	Mortality in heart failure;
BRCA	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg13319975	chr6:146136371	FBXO30	-0.4	-9.14	-0.34	8.3e-19	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg25517755	chr10:38738941	LOC399744	-0.37	-7.87	-0.3	1.53e-14	Corneal astigmatism;
BRCA	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.37	0.38	2.24e-23	Motion sickness;
BRCA	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg11645453	chr3:52864694	ITIH4	-0.35	-9.42	-0.35	8.1e-20	Body mass index;
BRCA	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg18270830	chr10:32634957	EPC1	0.58	10.07	0.37	3.08e-22	Sexual dysfunction (female);
BRCA	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg17971929	chr21:40555470	PSMG1	0.78	18.39	0.59	6.48e-61	Cognitive function;
BRCA	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11644478	chr21:40555479	PSMG1	-0.7	-15.79	-0.53	1.2e-47	Cognitive function;
BRCA	cis	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05901451	chr6:126070800	HEY2	-0.43	-10.17	-0.37	1.3e-22	Endometrial cancer;
BRCA	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg19678392	chr7:94953810	PON1	-0.42	-8.67	-0.32	3.47e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg06627628	chr2:24431161	ITSN2	-0.5	-8.08	-0.3	3.35e-15	Lymphocyte counts;
BRCA	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	18.43	0.59	3.66e-61	Platelet count;
BRCA	cis	rs4631830	0.720	rs11004415	chr10:51498181	G/A	cg20129853	chr10:51489980	NA	0.32	8.66	0.32	3.98e-17	Prostate-specific antigen levels;
BRCA	cis	rs34734847	0.871	rs2239760	chr12:121163518	C/A	cg21892295	chr12:121157589	UNC119B	-0.42	-12.8	-0.45	1.45e-33	Mean corpuscular volume;
BRCA	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.75	0.42	5.51e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg01528321	chr10:82214614	TSPAN14	0.85	18.93	0.6	8.63e-64	Post bronchodilator FEV1;
BRCA	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14294708	chr9:37120828	ZCCHC7	1.16	40.86	0.85	2.1e-180	Schizophrenia;
BRCA	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00149659	chr3:10157352	C3orf10	0.77	13.17	0.46	3.36e-35	Alzheimer's disease;
BRCA	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg05347473	chr6:146136440	FBXO30	-0.41	-8.38	-0.31	3.45e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs858239	0.600	rs1468592	chr7:23140647	C/T	cg23682824	chr7:23144976	KLHL7	-0.45	-12.17	-0.43	8.74e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg01475377	chr6:109611718	NA	-0.61	-17.05	-0.56	5.07e-54	Reticulocyte fraction of red cells;
BRCA	cis	rs7131987	0.903	rs11050153	chr12:29405148	T/C	cg09582351	chr12:29534625	ERGIC2	-0.4	-9.46	-0.35	5.71e-20	QT interval;
BRCA	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.86	0.36	1.84e-21	Bipolar disorder;
BRCA	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg03433033	chr1:76189801	ACADM	-0.42	-7.89	-0.3	1.32e-14	Daytime sleep phenotypes;
BRCA	cis	rs6450176	1.000	rs3776702	chr5:53305419	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-15.39	-0.52	1.09e-45	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg04511125	chr2:88470314	THNSL2	-0.72	-14.76	-0.5	1.24e-42	Response to metformin (IC50);
BRCA	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg22834771	chr12:69754056	YEATS4	-0.37	-9.05	-0.34	1.68e-18	Blood protein levels;
BRCA	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs11955398	0.542	rs2085413	chr5:60025379	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.38	-9.16	-0.34	6.96e-19	Intelligence (multi-trait analysis);
BRCA	trans	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg13565492	chr6:43139072	SRF	-0.85	-15.37	-0.52	1.31e-45	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-12.63	-0.45	8.28e-33	Response to antipsychotic treatment;
BRCA	cis	rs7903847	0.642	rs11189178	chr10:99143272	T/G	cg20016023	chr10:99160130	RRP12	-0.27	-8.61	-0.32	5.6e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	0.39	8.3	0.31	6.42e-16	Longevity;Endometriosis;
BRCA	cis	rs1882538	0.538	rs7783217	chr7:133104117	C/G	cg10665199	chr7:133106180	EXOC4	-0.45	-9.63	-0.36	1.42e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg01262667	chr19:19385393	TM6SF2	0.37	9.48	0.35	4.71e-20	Tonsillectomy;
BRCA	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg02753203	chr1:228287806	NA	-0.6	-13.03	-0.46	1.4e-34	Diastolic blood pressure;
BRCA	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg05340658	chr4:99064831	C4orf37	-0.43	-9.8	-0.36	3.27e-21	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg02659138	chr7:134003124	SLC35B4	0.32	9.78	0.36	3.74e-21	Mean platelet volume;
BRCA	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.21	-0.34	4.43e-19	Total body bone mineral density;
BRCA	cis	rs7572263	0.724	rs11676550	chr2:209053775	T/C	cg23998903	chr2:209048830	C2orf80	-0.41	-8.45	-0.32	2.01e-16	Glioma;Non-glioblastoma glioma;
BRCA	cis	rs3768617	0.811	rs4396114	chr1:183007441	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	9.47	0.35	5.11e-20	Fuchs's corneal dystrophy;
BRCA	cis	rs4880487	0.888	rs10794731	chr10:1251905	T/A	cg03183215	chr10:1252341	ADARB2	-0.38	-8.54	-0.32	1.01e-16	Migraine;
BRCA	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg22974920	chr21:40686053	BRWD1	-0.39	-8.72	-0.33	2.41e-17	Cognitive function;
BRCA	cis	rs877529	0.967	rs139406	chr22:39551798	T/C	cg18708252	chr22:39545030	CBX7	-0.32	-8.19	-0.31	1.44e-15	Multiple myeloma;
BRCA	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg08807101	chr21:30365312	RNF160	0.75	19.73	0.62	5.22e-68	Dental caries;
BRCA	trans	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.11	0.37	2.09e-22	Mean corpuscular volume;
BRCA	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg13010199	chr12:38710504	ALG10B	0.45	9.22	0.34	4.16e-19	Bladder cancer;
BRCA	trans	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.28	0.38	4.65e-23	Mean corpuscular volume;
BRCA	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	19.88	0.62	8.13e-69	Platelet count;
BRCA	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03517284	chr6:25882590	NA	-0.44	-9.48	-0.35	4.93e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-10.41	-0.38	1.5e-23	Schizophrenia;
BRCA	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg06784218	chr1:46089804	CCDC17	0.52	12.36	0.44	1.3e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.75	-0.55	1.78e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7635838	0.619	rs347614	chr3:11276399	T/C	cg00170343	chr3:11313890	ATG7	0.42	8.07	0.3	3.44e-15	HDL cholesterol;
BRCA	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg00757033	chr12:89920650	WDR51B	0.53	10.71	0.39	1.02e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.73	0.55	2.36e-52	Colorectal cancer;
BRCA	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg11645453	chr3:52864694	ITIH4	0.49	11.98	0.43	5.43e-30	Schizophrenia;
BRCA	trans	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg01620082	chr3:125678407	NA	-0.68	-8.38	-0.31	3.47e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg23708337	chr7:1209742	NA	0.48	8.14	0.31	2.11e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg17063962	chr7:91808500	NA	-0.53	-12.12	-0.43	1.47e-30	Breast cancer;
BRCA	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg08742575	chr21:47604166	C21orf56	0.41	8.01	0.3	5.51e-15	Testicular germ cell tumor;
BRCA	cis	rs2559856	1.000	rs2695296	chr12:102085487	T/C	cg12924262	chr12:102091054	CHPT1	0.36	8.17	0.31	1.66e-15	Blood protein levels;
BRCA	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg18016565	chr1:150552671	MCL1	-0.4	-9.18	-0.34	5.95e-19	Tonsillectomy;
BRCA	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg00012203	chr2:219082015	ARPC2	-0.57	-12.03	-0.43	3.43e-30	Colorectal cancer;
BRCA	cis	rs6450176	0.857	rs1541680	chr5:53304725	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-15.55	-0.52	1.79e-46	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03517284	chr6:25882590	NA	-0.41	-8.79	-0.33	1.38e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg18270830	chr10:32634957	EPC1	0.61	10.46	0.38	9.64e-24	Sexual dysfunction (female);
BRCA	cis	rs6987853	0.814	rs2923447	chr8:42439848	G/T	cg09913449	chr8:42400586	C8orf40	0.37	7.8	0.3	2.44e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4880487	0.888	rs7074199	chr10:1251022	C/T	cg03183215	chr10:1252341	ADARB2	-0.38	-8.54	-0.32	1.01e-16	Migraine;
BRCA	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg25767906	chr1:53392781	SCP2	-0.46	-10.31	-0.38	3.68e-23	Monocyte count;
BRCA	cis	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg06521331	chr12:34319734	NA	0.53	10.32	0.38	3.44e-23	Morning vs. evening chronotype;
BRCA	cis	rs1832871	0.616	rs55675950	chr6:158773994	T/A	cg07165851	chr6:158734300	TULP4	0.64	12.73	0.45	2.92e-33	Height;
BRCA	cis	rs9810890	1.000	rs73196974	chr3:128449006	A/C	cg15033153	chr3:128514015	RAB7A	0.7	8.08	0.3	3.34e-15	Dental caries;
BRCA	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.52	-10.97	-0.4	9.19e-26	Lymphocyte counts;
BRCA	cis	rs4664304	0.649	rs12692570	chr2:160726599	C/T	cg01092293	chr2:160761427	LY75	0.34	8.18	0.31	1.52e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.69	14.64	0.5	4.77e-42	Lymphocyte counts;
BRCA	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg27661571	chr11:113659931	NA	-0.7	-10.88	-0.4	2e-25	Hip circumference adjusted for BMI;
BRCA	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.49	9.7	0.36	7.59e-21	Iron status biomarkers;
BRCA	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg05985134	chr18:33552581	C18orf21	0.65	12.32	0.44	1.91e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg06766960	chr11:133703094	NA	0.48	10.35	0.38	2.55e-23	Childhood ear infection;
BRCA	cis	rs6688613	0.694	rs12062326	chr1:166820186	G/A	ch.1.3259774R	chr1:166827647	TADA1	0.42	8.62	0.32	5.39e-17	Refractive astigmatism;
BRCA	cis	rs13064411	0.518	rs1471883	chr3:113211828	C/T	cg18753928	chr3:113234510	CCDC52	-0.4	-9.15	-0.34	7.81e-19	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs9463078	0.838	rs9357470	chr6:45065613	C/T	cg25276700	chr6:44698697	NA	-0.36	-8.19	-0.31	1.45e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6121246	0.559	rs6119650	chr20:30258480	C/A	cg21427119	chr20:30132790	HM13	-0.37	-8.4	-0.32	2.96e-16	Mean corpuscular hemoglobin;
BRCA	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.92	-18.43	-0.59	3.59e-61	Alzheimer's disease;
BRCA	cis	rs9649465	1.000	rs7805759	chr7:123318696	C/A	cg04330084	chr7:123175371	IQUB	-0.3	-8.38	-0.31	3.26e-16	Migraine;
BRCA	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00166722	chr3:10149974	C3orf24	0.56	11.54	0.42	4.1e-28	Alzheimer's disease;
BRCA	cis	rs11229555	0.645	rs12285111	chr11:58208385	T/G	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11644478	chr21:40555479	PSMG1	0.83	19.13	0.6	7.5e-65	Cognitive function;
BRCA	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11890956	chr21:40555474	PSMG1	1.06	30.49	0.77	1.02e-126	Cognitive function;
BRCA	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg02733842	chr7:1102375	C7orf50	-0.64	-12.06	-0.43	2.55e-30	Bronchopulmonary dysplasia;
BRCA	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg27170947	chr2:26402098	FAM59B	-0.98	-17.45	-0.57	4.66e-56	Gut microbiome composition (summer);
BRCA	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12310025	chr6:25882481	NA	0.53	11.63	0.42	1.72e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs6977660	0.714	rs6943204	chr7:19818671	A/G	cg07541023	chr7:19748670	TWISTNB	0.47	8.63	0.32	4.92e-17	Thyroid stimulating hormone;
BRCA	cis	rs4363385	0.747	rs1415961	chr1:152973464	G/A	cg25856811	chr1:152973957	SPRR3	-0.34	-9.06	-0.34	1.61e-18	Inflammatory skin disease;
BRCA	trans	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg25214090	chr10:38739885	LOC399744	-0.48	-10.46	-0.38	9.21e-24	Corneal astigmatism;
BRCA	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-9.57	-0.35	2.21e-20	Chronic sinus infection;
BRCA	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg23711669	chr6:146136114	FBXO30	0.75	17.36	0.57	1.37e-55	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6964833	1.000	rs34324835	chr7:74132305	T/A	cg07504079	chr7:72649617	NCF1B	-0.5	-9.82	-0.36	2.82e-21	Menarche (age at onset);
BRCA	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10802521	chr3:52805072	NEK4	-0.31	-7.91	-0.3	1.1e-14	Bipolar disorder;
BRCA	cis	rs7766436	0.885	rs13220769	chr6:22596464	T/A	cg13666174	chr6:22585274	NA	-0.49	-11.46	-0.41	9.02e-28	Coronary artery disease;
BRCA	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-9.54	-0.35	2.85e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg17330251	chr7:94953956	PON1	-0.4	-8.25	-0.31	9.27e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg00701064	chr4:6280414	WFS1	0.68	17.68	0.57	3.11e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	trans	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg15704280	chr7:45808275	SEPT13	0.59	8.8	0.33	1.26e-17	Axial length;
BRCA	cis	rs4074536	0.585	rs10923447	chr1:116323567	C/A	cg21648376	chr1:116311395	CASQ2	-0.53	-8.81	-0.33	1.22e-17	QRS duration;
BRCA	cis	rs1997103	1.000	rs9642578	chr7:55400320	A/G	cg17469321	chr7:55412551	NA	0.51	9.78	0.36	3.77e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg09455208	chr3:40491958	NA	0.34	7.91	0.3	1.11e-14	Renal cell carcinoma;
BRCA	cis	rs1163251	0.902	rs639216	chr1:120217414	C/T	cg19096424	chr1:120255104	PHGDH	0.44	9.73	0.36	5.98e-21	Blood metabolite levels;
BRCA	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg16586182	chr3:47516702	SCAP	0.49	10.86	0.39	2.43e-25	Colorectal cancer;
BRCA	cis	rs10216189	0.967	rs4724700	chr7:5526789	A/G	cg05318486	chr7:5553423	FBXL18	-0.36	-8.28	-0.31	7.13e-16	Relative hand skill in reading disability;
BRCA	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03923535	chr7:1197113	ZFAND2A	0.5	11.01	0.4	5.92e-26	Longevity;Endometriosis;
BRCA	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg06197492	chr11:2016605	H19	0.41	8.85	0.33	8.37e-18	DNA methylation (parent-of-origin);DNA methylation (variation);
BRCA	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06108461	chr20:60628389	TAF4	-0.99	-22.28	-0.66	7.76e-82	Body mass index;
BRCA	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg13047869	chr3:10149882	C3orf24	0.55	10.3	0.38	4.02e-23	Alzheimer's disease;
BRCA	cis	rs1003719	0.788	rs1155785	chr21:38447939	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.25	0.49	3.26e-40	Eye color traits;
BRCA	cis	rs1468333	1.000	rs7735635	chr5:137508336	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	-0.45	-8.75	-0.33	1.96e-17	Resting heart rate;
BRCA	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg22705602	chr4:152727874	NA	-0.38	-10.46	-0.38	9.24e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs2019216	0.521	rs6565386	chr17:21901755	A/G	cg14492302	chr17:21911362	FLJ36000	-0.24	-7.83	-0.3	2.09e-14	Pelvic organ prolapse;
BRCA	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg17971929	chr21:40555470	PSMG1	-0.48	-10.5	-0.38	6.57e-24	Menarche (age at onset);
BRCA	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg06713675	chr4:122721982	EXOSC9	-0.5	-11.9	-0.43	1.28e-29	Type 2 diabetes;
BRCA	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg23708337	chr7:1209742	NA	0.64	8.93	0.33	4.47e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg22764044	chr5:178986830	RUFY1	0.46	12.38	0.44	1.03e-31	Lung cancer;
BRCA	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg03342759	chr3:160939853	NMD3	-0.8	-18.89	-0.6	1.45e-63	Parkinson's disease;
BRCA	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg05457628	chr5:178986728	RUFY1	0.5	11.84	0.42	2.31e-29	Lung cancer;
BRCA	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg06784218	chr1:46089804	CCDC17	0.51	12.25	0.44	3.85e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17818399	0.501	rs13413254	chr2:46802934	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.46	9.44	0.35	6.83e-20	Height;
BRCA	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg11764359	chr7:65958608	NA	-0.61	-13.07	-0.46	8.94e-35	Aortic root size;
BRCA	cis	rs586533	0.881	rs674682	chr11:99506883	A/C	cg22878054	chr11:99397252	CNTN5	-0.31	-7.82	-0.3	2.27e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg18252515	chr7:66147081	NA	-1.08	-16.09	-0.54	3.78e-49	Diabetic kidney disease;
BRCA	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	13.98	0.48	6.28e-39	Breast cancer;
BRCA	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.68	-0.42	1.04e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg08508325	chr11:3079039	CARS	0.4	14.06	0.49	2.57e-39	Longevity;
BRCA	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.28e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.39	7.82	0.3	2.23e-14	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	8.69	0.32	3.14e-17	Rheumatoid arthritis;
BRCA	cis	rs897984	0.572	rs4889526	chr16:31030344	C/A	cg00531865	chr16:30841666	NA	-0.38	-9.11	-0.34	1.02e-18	Dementia with Lewy bodies;
BRCA	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg01448562	chr3:133502909	NA	-0.36	-8.29	-0.31	6.66e-16	Iron status biomarkers;
BRCA	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg08888203	chr3:10149979	C3orf24	0.59	12.75	0.45	2.55e-33	Alzheimer's disease;
BRCA	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-9.05	-0.34	1.64e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.05	16.15	0.54	1.81e-49	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18876405	chr7:65276391	NA	0.55	13.31	0.47	7.72e-36	Aortic root size;
BRCA	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg14675211	chr2:100938903	LONRF2	-0.42	-9.65	-0.36	1.2e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	11.13	0.4	2.01e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg02503808	chr4:7069936	GRPEL1	-0.82	-15.54	-0.52	2.08e-46	Monocyte percentage of white cells;
BRCA	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg10495392	chr1:46806563	NSUN4	0.43	8.01	0.3	5.64e-15	Menopause (age at onset);
BRCA	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	11.37	0.41	2.05e-27	Retinal vascular caliber;
BRCA	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg18755752	chr8:142205143	DENND3	-0.46	-11.15	-0.4	1.66e-26	Immature fraction of reticulocytes;
BRCA	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg08807101	chr21:30365312	RNF160	-0.57	-13.87	-0.48	1.98e-38	Dental caries;
BRCA	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg15556689	chr8:8085844	FLJ10661	0.38	10.23	0.38	7.45e-23	Neuroticism;
BRCA	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg01475735	chr3:40494733	NA	-0.45	-8.0	-0.3	5.76e-15	Renal cell carcinoma;
BRCA	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg09537434	chr19:41945824	ATP5SL	1.01	24.62	0.7	1.24e-94	Height;
BRCA	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg01324343	chr3:183735012	ABCC5	0.65	15.21	0.52	8.52e-45	Anterior chamber depth;
BRCA	cis	rs11888559	0.511	rs1351826	chr2:203850508	G/A	cg24605529	chr2:203879461	NBEAL1	0.45	8.43	0.32	2.37e-16	Height;
BRCA	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg24642439	chr20:33292090	TP53INP2	0.52	11.44	0.41	1.06e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs975210	0.556	rs2291986	chr15:70368432	C/T	cg01666796	chr15:70364327	TLE3	0.41	7.86	0.3	1.67e-14	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.55	-0.32	9.03e-17	Aortic root size;
BRCA	trans	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg25517755	chr10:38738941	LOC399744	-0.37	-7.82	-0.3	2.22e-14	Corneal astigmatism;
BRCA	cis	rs36051895	0.632	rs10974969	chr9:5125336	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-9.01	-0.34	2.4e-18	Pediatric autoimmune diseases;
BRCA	cis	rs72781680	0.716	rs17045975	chr2:24099611	A/T	cg08917208	chr2:24149416	ATAD2B	-0.6	-10.41	-0.38	1.49e-23	Lymphocyte counts;
BRCA	cis	rs16867321	0.614	rs10204086	chr2:181449668	G/T	cg23363182	chr2:181467187	NA	-0.48	-10.62	-0.39	2.17e-24	Obesity;
BRCA	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	9.75	0.36	5.02e-21	Rheumatoid arthritis;
BRCA	trans	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg26043149	chr18:55253948	FECH	0.4	8.88	0.33	6.73e-18	Bone mineral density;
BRCA	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg04362960	chr10:104952993	NT5C2	0.44	10.71	0.39	1.02e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	-0.45	-8.95	-0.33	3.78e-18	Tonsillectomy;
BRCA	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg06618935	chr21:46677482	NA	-0.36	-7.98	-0.3	6.96e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9467773	0.626	rs6936006	chr6:26350565	A/G	cg09904177	chr6:26538194	HMGN4	-0.31	-8.36	-0.31	3.94e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.49	10.2	0.37	1.01e-22	Height;
BRCA	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg11279151	chr3:101281821	RG9MTD1	0.49	10.01	0.37	5.26e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg15432903	chr11:17409602	KCNJ11	0.79	17.69	0.57	2.84e-57	Type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg05340658	chr4:99064831	C4orf37	0.68	16.87	0.56	4.31e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg06784218	chr1:46089804	CCDC17	-0.43	-10.13	-0.37	1.82e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg15448220	chr1:150897856	SETDB1	0.35	7.9	0.3	1.26e-14	Melanoma;
BRCA	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	12.68	0.45	5.16e-33	Mean platelet volume;
BRCA	cis	rs9788682	0.747	rs2656071	chr15:78745343	A/T	cg24631222	chr15:78858424	CHRNA5	-0.51	-10.08	-0.37	2.86e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	trans	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg25214090	chr10:38739885	LOC399744	0.45	10.28	0.38	4.83e-23	Corneal astigmatism;
BRCA	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg01884057	chr2:25150051	NA	0.29	7.83	0.3	2.1e-14	Body mass index in non-asthmatics;
BRCA	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.35	0.57	1.6e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12292205	chr6:26970375	C6orf41	-0.47	-7.97	-0.3	7.21e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg07636037	chr3:49044803	WDR6	0.39	8.02	0.3	5.04e-15	Resting heart rate;
BRCA	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.55e-18	Motion sickness;
BRCA	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg09035930	chr12:129282057	SLC15A4	0.47	12.33	0.44	1.69e-31	Systemic lupus erythematosus;
BRCA	cis	rs12545109	0.879	rs893234	chr8:57363885	G/A	cg09654669	chr8:57350985	NA	-0.45	-8.57	-0.32	7.87e-17	Obesity-related traits;
BRCA	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.34	-0.38	2.9e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg26195577	chr20:24973756	C20orf3	1.02	26.56	0.72	2.74e-105	Blood protein levels;
BRCA	cis	rs1863824	0.625	rs10887599	chr10:88168780	G/A	cg07322936	chr10:88137208	NA	-0.45	-8.89	-0.33	6.16e-18	Schizophrenia;
BRCA	cis	rs36051895	0.632	rs7022901	chr9:5177680	C/G	cg02405213	chr9:5042618	JAK2	-0.46	-8.77	-0.33	1.66e-17	Pediatric autoimmune diseases;
BRCA	cis	rs4629710	0.545	rs11154621	chr6:131547341	A/G	cg12606694	chr6:131520996	AKAP7	0.43	9.25	0.34	3.42e-19	Multiple myeloma (IgH translocation);
BRCA	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-12.06	-0.43	2.62e-30	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg08470875	chr2:26401718	FAM59B	-0.77	-12.04	-0.43	2.96e-30	Gut microbiome composition (summer);
BRCA	cis	rs758324	0.947	rs1875177	chr5:131202625	T/C	cg06307176	chr5:131281290	NA	0.53	10.18	0.37	1.15e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg13319975	chr6:146136371	FBXO30	0.41	9.25	0.34	3.38e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg27129171	chr3:47204927	SETD2	0.72	17.72	0.57	1.95e-57	Colorectal cancer;
BRCA	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg20891283	chr12:69753455	YEATS4	0.48	12.49	0.44	3.43e-32	Blood protein levels;
BRCA	cis	rs3087591	1.000	rs2854332	chr17:29712378	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.44	-8.86	-0.33	8.16e-18	Hip circumference;
BRCA	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.67	-9.72	-0.36	6.19e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7809950	0.954	rs2520243	chr7:107136973	T/C	cg23024343	chr7:107201750	COG5	-0.4	-9.17	-0.34	6.53e-19	Coronary artery disease;
BRCA	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg13010199	chr12:38710504	ALG10B	-0.39	-8.83	-0.33	1.04e-17	Morning vs. evening chronotype;
BRCA	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg00750074	chr16:89608354	SPG7	0.33	8.97	0.33	3.2e-18	Multiple myeloma (IgH translocation);
BRCA	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-8.09	-0.3	2.97e-15	Obesity-related traits;
BRCA	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24531977	chr5:56204891	C5orf35	-0.81	-16.77	-0.55	1.38e-52	Initial pursuit acceleration;
BRCA	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26314531	chr2:26401878	FAM59B	0.75	10.54	0.38	4.46e-24	Gut microbiome composition (summer);
BRCA	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg21252483	chr19:49399788	TULP2	-0.51	-10.86	-0.39	2.46e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg19274703	chr22:41806451	NA	-0.34	-7.88	-0.3	1.44e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.09	0.4	2.92e-26	Bipolar disorder;
BRCA	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg17757837	chr7:157058334	UBE3C	-0.72	-17.81	-0.58	6.54e-58	Body mass index;
BRCA	cis	rs13315871	1.000	rs11717423	chr3:58330177	C/G	cg20936604	chr3:58311152	NA	-0.62	-7.99	-0.3	6.31e-15	Cholesterol, total;
BRCA	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	6.83e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg11366901	chr6:160182831	ACAT2	0.85	16.58	0.55	1.28e-51	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs16854884	0.657	rs6440210	chr3:143705763	A/G	cg06585982	chr3:143692056	C3orf58	0.42	8.8	0.33	1.31e-17	Economic and political preferences (feminism/equality);
BRCA	cis	rs2120243	0.874	rs1840680	chr3:157156029	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.44	9.88	0.36	1.56e-21	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.57	-0.32	7.75e-17	Total body bone mineral density;
BRCA	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg27478167	chr7:817139	HEATR2	-0.54	-10.91	-0.4	1.6e-25	Cerebrospinal P-tau181p levels;
BRCA	trans	rs9944715	0.954	rs1808946	chr18:43854860	A/G	cg01718231	chr17:29326311	RNF135	-0.44	-8.61	-0.32	5.89e-17	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs2835872	0.758	rs1787395	chr21:39036478	A/C	cg06728970	chr21:39037746	KCNJ6	0.45	12.83	0.45	1.14e-33	Electroencephalographic traits in alcoholism;
BRCA	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg06108461	chr20:60628389	TAF4	-0.68	-14.14	-0.49	1.12e-39	Body mass index;
BRCA	cis	rs7617773	0.780	rs71323395	chr3:48374077	G/A	cg11946769	chr3:48343235	NME6	0.67	13.43	0.47	2.05e-36	Coronary artery disease;
BRCA	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26384229	chr12:38710491	ALG10B	0.74	16.62	0.55	8.14e-52	Morning vs. evening chronotype;
BRCA	cis	rs6087990	0.735	rs2424906	chr20:31359109	A/G	cg13636640	chr20:31349939	DNMT3B	0.65	19.13	0.6	8.13e-65	Ulcerative colitis;
BRCA	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg16482183	chr6:26056742	HIST1H1C	0.49	9.66	0.36	1.1e-20	Iron status biomarkers;
BRCA	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.35	-0.35	1.41e-19	Total body bone mineral density;
BRCA	cis	rs3916	0.955	rs35525135	chr12:121140064	T/C	cg21892295	chr12:121157589	UNC119B	-0.38	-9.77	-0.36	4.08e-21	Urinary metabolites (H-NMR features);
BRCA	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg26384229	chr12:38710491	ALG10B	0.74	17.23	0.56	6.66e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17023223	0.537	rs55836852	chr1:119725401	G/A	cg05756136	chr1:119680316	WARS2	-0.42	-8.05	-0.3	3.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs2549794	0.537	rs34755	chr5:96151760	A/C	cg16492584	chr5:96139282	ERAP1	0.32	8.58	0.32	7.14e-17	Crohn's disease;
BRCA	cis	rs4363385	0.818	rs12029168	chr1:152987993	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.3	-0.31	6.23e-16	Inflammatory skin disease;
BRCA	cis	rs847851	0.612	rs7768189	chr6:34742450	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.94	-0.3	9.15e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg04166393	chr7:2884313	GNA12	0.47	8.99	0.33	2.85e-18	Height;
BRCA	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21582582	chr3:182698605	DCUN1D1	0.37	9.86	0.36	1.95e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7301826	0.651	rs10734981	chr12:131297895	C/G	cg11011512	chr12:131303247	STX2	0.51	13.62	0.47	3e-37	Plasma plasminogen activator levels;
BRCA	cis	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg07460842	chr6:66804631	NA	1.04	29.65	0.76	3.53e-122	Exhaled nitric oxide output;
BRCA	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg14458575	chr2:238380390	NA	0.74	16.51	0.55	2.84e-51	Prostate cancer;
BRCA	cis	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg21775007	chr8:11205619	TDH	0.39	8.41	0.32	2.65e-16	Retinal vascular caliber;
BRCA	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg01689657	chr7:91764605	CYP51A1	0.21	7.87	0.3	1.48e-14	Breast cancer;
BRCA	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg25237894	chr2:233734115	C2orf82	-0.41	-11.81	-0.42	3.12e-29	Coronary artery disease;
BRCA	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-13.91	-0.48	1.33e-38	Platelet count;
BRCA	cis	rs7617773	0.784	rs11715799	chr3:48255220	A/G	cg11946769	chr3:48343235	NME6	0.68	13.8	0.48	4.34e-38	Coronary artery disease;
BRCA	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg11887960	chr12:57824829	NA	0.53	8.26	0.31	8.2e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9790314	0.613	rs2121718	chr3:160603511	C/T	cg03342759	chr3:160939853	NMD3	0.43	8.31	0.31	5.94e-16	Morning vs. evening chronotype;
BRCA	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.53	11.46	0.41	9.13e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs11088226	1.000	rs11701091	chr21:33920244	T/A	cg09050820	chr6:167586206	TCP10L2	0.49	8.05	0.3	4.01e-15	Gastritis;
BRCA	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.28	0.49	2.26e-40	Motion sickness;
BRCA	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg15395560	chr15:45543142	SLC28A2	0.29	8.27	0.31	7.69e-16	Uric acid levels;
BRCA	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-9.8	-0.36	3.31e-21	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.15	-0.34	7.38e-19	Total body bone mineral density;
BRCA	trans	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg05926928	chr17:57297772	GDPD1	-0.85	-12.34	-0.44	1.65e-31	Opioid sensitivity;
BRCA	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg08807892	chr2:162101083	NA	0.72	16.49	0.55	3.72e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg22349387	chr12:9600060	DDX12	-0.38	-8.84	-0.33	9.44e-18	Breast size;
BRCA	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg08085267	chr17:45401833	C17orf57	0.59	12.23	0.44	4.69e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs921968	0.565	rs6436084	chr2:219639782	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-10.93	-0.4	1.27e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4853036	0.904	rs7578366	chr2:70135695	C/T	cg02498382	chr2:70120550	SNRNP27	-0.52	-10.26	-0.38	6.01e-23	Colorectal or endometrial cancer;
BRCA	cis	rs9427116	0.502	rs7531982	chr1:154596122	A/T	cg17218026	chr1:154582156	ADAR	0.28	8.44	0.32	2.14e-16	Blood protein levels;
BRCA	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	8.63	0.32	4.69e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg24690094	chr11:67383802	NA	-0.54	-11.47	-0.41	7.96e-28	Mean corpuscular volume;
BRCA	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg13010199	chr12:38710504	ALG10B	0.45	9.32	0.35	1.92e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00152838	chr16:24741724	TNRC6A	-0.36	-7.95	-0.3	8.47e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs11971779	0.680	rs6949599	chr7:139054188	A/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.24	0.38	6.65e-23	Diisocyanate-induced asthma;
BRCA	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	10.39	0.38	1.73e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs4919694	0.572	rs12262258	chr10:104900272	G/A	cg04362960	chr10:104952993	NT5C2	0.72	12.66	0.45	6.05e-33	Arsenic metabolism;
BRCA	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.43	10.06	0.37	3.29e-22	Platelet count;
BRCA	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-10.69	-0.39	1.14e-24	Hemoglobin concentration;
BRCA	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg18904891	chr8:8559673	CLDN23	0.59	11.51	0.41	5.28e-28	Obesity-related traits;
BRCA	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg10876282	chr6:28092338	ZSCAN16	0.42	8.37	0.31	3.58e-16	Cardiac Troponin-T levels;
BRCA	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.75	-0.33	1.95e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg24642439	chr20:33292090	TP53INP2	-0.43	-8.65	-0.32	4.3e-17	Height;
BRCA	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg05340658	chr4:99064831	C4orf37	0.65	15.96	0.53	1.74e-48	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg05294307	chr14:35346193	BAZ1A	-0.58	-10.3	-0.38	3.98e-23	Psoriasis;
BRCA	cis	rs6460942	0.545	rs17448114	chr7:12524458	G/C	cg06484146	chr7:12443880	VWDE	-0.6	-7.85	-0.3	1.8e-14	Coronary artery disease;
BRCA	cis	rs12210905	0.688	rs12215386	chr6:27406877	G/T	cg08851530	chr6:28072375	NA	0.81	7.89	0.3	1.3e-14	Hip circumference adjusted for BMI;
BRCA	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg02297831	chr4:17616191	MED28	0.4	8.62	0.32	5.2e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3771570	1.000	rs73018141	chr2:242221570	G/A	cg21155796	chr2:242212141	HDLBP	0.62	9.72	0.36	6.59e-21	Prostate cancer;
BRCA	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.13e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg14784868	chr12:69753453	YEATS4	-0.43	-10.98	-0.4	8.12e-26	Blood protein levels;
BRCA	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	14.29	0.49	2.14e-40	Hip circumference adjusted for BMI;
BRCA	trans	rs148734725	1	rs148734725	chr3:49406708	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.37	-9.24	-0.34	3.75e-19	Educational attainment (college completion);
BRCA	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg25358565	chr5:93447407	FAM172A	1.2	18.62	0.59	3.58e-62	Diabetic retinopathy;
BRCA	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg10818794	chr15:86012489	AKAP13	-0.31	-8.68	-0.32	3.36e-17	Coronary artery disease;
BRCA	trans	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.96	0.4	9.84e-26	Type 2 diabetes;
BRCA	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.79	17.47	0.57	3.69e-56	Cognitive ability;
BRCA	cis	rs9816226	1.000	rs73052033	chr3:185828465	T/C	cg00760338	chr3:185826511	ETV5	-0.53	-8.2	-0.31	1.32e-15	Obesity;Body mass index;
BRCA	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg22875332	chr1:76189707	ACADM	0.68	14.41	0.5	5.9e-41	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg09307838	chr4:120376055	NA	-0.67	-13.63	-0.47	2.7e-37	Corneal astigmatism;
BRCA	cis	rs6750795	0.746	rs1667301	chr2:232423717	C/T	cg19187155	chr2:232395269	NMUR1	0.78	19.94	0.62	3.73e-69	Height;
BRCA	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg05342682	chr7:94953680	PON1	-0.34	-8.35	-0.31	4.34e-16	Paraoxonase activity;
BRCA	trans	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	7.99	0.3	6.55e-15	Mean corpuscular volume;
BRCA	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-15.08	-0.51	3.49e-44	Total cholesterol levels;
BRCA	cis	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg21775007	chr8:11205619	TDH	-0.44	-8.72	-0.33	2.42e-17	Triglycerides;
BRCA	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg18132916	chr6:79620363	NA	-0.46	-10.43	-0.38	1.25e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-8.97	-0.33	3.21e-18	Chronic sinus infection;
BRCA	cis	rs2742234	0.955	rs2075910	chr10:43614230	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.43	-9.14	-0.34	7.94e-19	Hirschsprung disease;
BRCA	cis	rs2742417	0.603	rs2673055	chr3:45772772	G/A	cg04837898	chr3:45731254	SACM1L	-0.38	-7.82	-0.3	2.24e-14	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg15242686	chr22:24348715	GSTTP1	0.5	12.83	0.45	1.1e-33	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg22705602	chr4:152727874	NA	-0.32	-8.29	-0.31	6.81e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs11785693	0.862	rs17435612	chr8:4987896	C/T	cg26367366	chr8:4980734	NA	-0.6	-10.98	-0.4	7.83e-26	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs919433	0.680	rs2605039	chr2:198362851	C/A	cg00792783	chr2:198669748	PLCL1	0.4	8.9	0.33	5.81e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.71	-15.36	-0.52	1.56e-45	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	trans	rs8073060	0.586	rs225250	chr17:33941963	A/G	cg19694781	chr19:47549865	TMEM160	-1.04	-21.68	-0.65	1.59e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg24642439	chr20:33292090	TP53INP2	0.53	11.6	0.42	2.23e-28	Glomerular filtration rate (creatinine);
BRCA	trans	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.35	-7.83	-0.3	1.98e-14	Endometrial cancer;
BRCA	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg07148914	chr20:33460835	GGT7	0.47	10.01	0.37	5.42e-22	Height;
BRCA	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21659725	chr3:3221576	CRBN	-0.71	-21.61	-0.65	3.66e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg21573476	chr21:45109991	RRP1B	0.35	9.24	0.34	3.61e-19	Mean corpuscular volume;
BRCA	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg10167378	chr1:228756711	NA	0.65	10.15	0.37	1.47e-22	Chronic lymphocytic leukemia;
BRCA	cis	rs4722166	0.532	rs6963866	chr7:22757341	C/T	cg05472934	chr7:22766657	IL6	0.41	10.1	0.37	2.42e-22	Lung cancer;
BRCA	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	18.13	0.58	1.36e-59	Alzheimer's disease;
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.41	-8.12	-0.31	2.48e-15	Longevity;Endometriosis;
BRCA	cis	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.54	-0.32	9.97e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs939658	0.805	rs11638004	chr15:79425765	A/C	cg17916960	chr15:79447300	NA	-0.46	-11.42	-0.41	1.29e-27	Refractive error;
BRCA	cis	rs68170813	0.559	rs79026644	chr7:107031803	A/G	cg02696742	chr7:106810147	HBP1	-0.54	-8.78	-0.33	1.49e-17	Coronary artery disease;
BRCA	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.4	-8.5	-0.32	1.38e-16	Aortic root size;
BRCA	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	10.63	0.39	2.15e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs13190036	0.901	rs28715668	chr5:176699268	T/C	cg06733329	chr5:176740039	MXD3	-0.47	-8.46	-0.32	1.83e-16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-8.86	-0.33	7.65e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.05	-0.34	1.66e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg06191203	chr2:152266755	RIF1	-0.4	-10.34	-0.38	2.74e-23	Lung cancer;
BRCA	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.46	-0.32	1.78e-16	Height;
BRCA	cis	rs7903847	0.642	rs10882923	chr10:99159018	G/A	cg20016023	chr10:99160130	RRP12	-0.26	-8.43	-0.32	2.23e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg24692254	chr21:30365293	RNF160	-0.43	-9.64	-0.36	1.28e-20	Pancreatic cancer;
BRCA	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.64	14.13	0.49	1.18e-39	Lymphocyte percentage of white cells;
BRCA	cis	rs17253792	1.000	rs28616134	chr14:56178802	G/A	cg01858014	chr14:56050164	KTN1	-0.67	-8.51	-0.32	1.22e-16	Putamen volume;
BRCA	cis	rs6942756	1.000	rs2402945	chr7:128956256	C/A	cg02491457	chr7:128862824	NA	-0.71	-14.0	-0.48	5.08e-39	White matter hyperintensity burden;
BRCA	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03264133	chr6:25882463	NA	-0.75	-16.33	-0.54	2.34e-50	Intelligence (multi-trait analysis);
BRCA	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	10.35	0.38	2.67e-23	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6121246	0.559	rs6121172	chr20:30296095	A/C	cg13852791	chr20:30311386	BCL2L1	0.96	23.38	0.68	7.83e-88	Mean corpuscular hemoglobin;
BRCA	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg18230493	chr5:56204884	C5orf35	-0.74	-14.06	-0.49	2.68e-39	Initial pursuit acceleration;
BRCA	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	13.42	0.47	2.29e-36	Platelet count;
BRCA	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg14004847	chr7:1930337	MAD1L1	-0.49	-9.67	-0.36	9.97e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg04518342	chr5:131593106	PDLIM4	0.35	8.85	0.33	8.43e-18	Breast cancer;
BRCA	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.66	9.92	0.37	1.18e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10754283	0.901	rs10922683	chr1:90116068	G/A	cg21401794	chr1:90099060	LRRC8C	0.51	12.24	0.44	4.28e-31	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs1163251	0.902	rs483360	chr1:120200606	C/T	cg19096424	chr1:120255104	PHGDH	-0.43	-9.58	-0.35	2.18e-20	Blood metabolite levels;
BRCA	cis	rs80130819	0.515	rs1793917	chr12:48384944	A/T	cg05342945	chr12:48394962	COL2A1	-0.5	-9.67	-0.36	9.91e-21	Prostate cancer;
BRCA	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg09184832	chr6:79620586	NA	-0.48	-10.46	-0.38	9.7e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs2637266	0.935	rs2579774	chr10:78402253	T/C	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	11.11	0.4	2.5e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg15819921	chr19:927150	ARID3A	-0.52	-10.09	-0.37	2.52e-22	Life satisfaction;
BRCA	cis	rs30380	0.632	rs27640	chr5:96127905	T/C	cg16492584	chr5:96139282	ERAP1	-0.46	-11.0	-0.4	7.09e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.39	-0.32	3.1e-16	Total body bone mineral density;
BRCA	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-10.02	-0.37	4.67e-22	Alzheimer's disease (late onset);
BRCA	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg08885076	chr2:99613938	TSGA10	-0.61	-13.37	-0.47	3.79e-36	Chronic sinus infection;
BRCA	cis	rs10129255	0.518	rs8009594	chr14:107185733	G/T	cg07958169	chr14:107095056	NA	-0.39	-8.46	-0.32	1.84e-16	Kawasaki disease;
BRCA	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00166722	chr3:10149974	C3orf24	0.65	12.85	0.45	9.06e-34	Alzheimer's disease;
BRCA	cis	rs895636	0.848	rs2840037	chr2:45189872	G/A	cg16198908	chr2:45192207	NA	0.47	8.84	0.33	9.37e-18	Metabolite levels;Fasting plasma glucose;
BRCA	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24531977	chr5:56204891	C5orf35	-0.72	-16.11	-0.54	2.79e-49	Initial pursuit acceleration;
BRCA	cis	rs2625529	0.526	rs62022789	chr15:72564492	C/T	cg16672083	chr15:72433130	SENP8	0.61	14.42	0.5	5.17e-41	Red blood cell count;
BRCA	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg23711669	chr6:146136114	FBXO30	-0.71	-16.78	-0.55	1.24e-52	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg26384229	chr12:38710491	ALG10B	0.68	14.16	0.49	8.91e-40	Morning vs. evening chronotype;
BRCA	cis	rs1595825	0.891	rs78198610	chr2:198522769	T/C	cg19156104	chr2:198669113	PLCL1	-0.42	-8.15	-0.31	1.91e-15	Ulcerative colitis;
BRCA	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg24829409	chr8:58192753	C8orf71	-0.49	-9.25	-0.34	3.45e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs78456975	0.739	rs28913003	chr2:1519620	A/T	cg26248373	chr2:1572462	NA	-0.52	-10.58	-0.39	3.38e-24	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9309711	0.922	rs13385119	chr2:3484521	G/A	cg10845886	chr2:3471009	TTC15	-0.81	-17.78	-0.58	9.5e-58	Neurofibrillary tangles;
BRCA	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg04842962	chr6:43655489	MRPS18A	1.11	39.06	0.84	1.91e-171	IgG glycosylation;
BRCA	cis	rs912057	1.000	rs1294407	chr6:6738103	C/G	cg06612196	chr6:6737390	NA	0.45	9.84	0.36	2.28e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg26116260	chr4:7069785	GRPEL1	0.92	23.27	0.68	3.35e-87	Monocyte percentage of white cells;
BRCA	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg10253484	chr15:75165896	SCAMP2	-0.54	-10.05	-0.37	3.75e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.02	0.58	5.02e-59	Fuchs's corneal dystrophy;
BRCA	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg18402987	chr7:1209562	NA	0.84	11.92	0.43	9.85e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	20.19	0.62	1.73e-70	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2425143	1.000	rs56052651	chr20:34344084	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.18	-0.34	5.86e-19	Blood protein levels;
BRCA	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg18230493	chr5:56204884	C5orf35	0.61	13.01	0.46	1.73e-34	Initial pursuit acceleration;
BRCA	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg21573476	chr21:45109991	RRP1B	-0.35	-9.12	-0.34	9.42e-19	Mean corpuscular volume;
BRCA	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.54	0.57	1.68e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg12011299	chr4:100065546	ADH4	0.52	15.33	0.52	2.03e-45	HDL cholesterol;HDL cholesterol levels;
BRCA	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg24642439	chr20:33292090	TP53INP2	0.72	16.61	0.55	8.91e-52	Coronary artery disease;
BRCA	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.53	-0.61	5.54e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2637266	1.000	rs12260492	chr10:78365242	C/A	cg18941641	chr10:78392320	NA	0.35	7.82	0.3	2.18e-14	Pulmonary function;
BRCA	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg25427524	chr10:38739819	LOC399744	-0.67	-13.56	-0.47	5.32e-37	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4742903	0.967	rs10820605	chr9:106881402	C/T	cg14250997	chr9:106856677	SMC2	0.35	11.22	0.41	8.7e-27	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs75804782	0.641	rs11904390	chr2:239344663	T/A	cg18131467	chr2:239335373	ASB1	-0.62	-8.16	-0.31	1.79e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs9880211	0.948	rs1604793	chr3:136181070	G/C	cg21827317	chr3:136751795	NA	-0.47	-8.36	-0.31	3.78e-16	Body mass index;Height;
BRCA	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg13319975	chr6:146136371	FBXO30	0.41	9.33	0.35	1.67e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.97	0.56	1.3e-53	Hypertriglyceridemia;
BRCA	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg20503657	chr10:835505	NA	0.95	14.77	0.5	1.14e-42	Eosinophil percentage of granulocytes;
BRCA	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00908189	chr16:619842	PIGQ	0.7	17.69	0.57	2.66e-57	Height;
BRCA	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg16423285	chr20:60520624	NA	-0.42	-8.06	-0.3	3.74e-15	Body mass index;
BRCA	cis	rs6728642	0.908	rs11901495	chr2:98017804	A/G	cg26665480	chr2:98280029	ACTR1B	0.52	8.8	0.33	1.23e-17	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11890956	chr21:40555474	PSMG1	-0.86	-22.26	-0.66	1.04e-81	Cognitive function;
BRCA	cis	rs17253792	0.822	rs8013831	chr14:56172898	G/A	cg01858014	chr14:56050164	KTN1	-0.58	-9.01	-0.34	2.31e-18	Putamen volume;
BRCA	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg17509989	chr5:176798049	RGS14	-0.73	-12.07	-0.43	2.32e-30	Urate levels in lean individuals;
BRCA	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg17063962	chr7:91808500	NA	-0.57	-13.48	-0.47	1.2e-36	Breast cancer;
BRCA	cis	rs9359856	0.564	rs55722352	chr6:90365853	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.64	-8.54	-0.32	9.91e-17	Bipolar disorder;
BRCA	cis	rs6546537	0.714	rs17036759	chr2:69767029	C/T	cg10773587	chr2:69614142	GFPT1	-0.42	-9.28	-0.34	2.69e-19	Serum thyroid-stimulating hormone levels;
BRCA	trans	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg15704280	chr7:45808275	SEPT13	0.52	7.94	0.3	9.14e-15	Intraocular pressure;
BRCA	cis	rs3849570	0.961	rs3772896	chr3:81751968	C/T	cg07356753	chr3:81810745	GBE1	-0.47	-11.51	-0.41	5.69e-28	Waist circumference;Body mass index;
BRCA	cis	rs9309711	0.961	rs11675119	chr2:3476422	C/A	cg10845886	chr2:3471009	TTC15	-0.76	-16.3	-0.54	3.21e-50	Neurofibrillary tangles;
BRCA	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg17420585	chr12:42539391	GXYLT1	-0.38	-7.97	-0.3	7.37e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs6580649	0.941	rs1968071	chr12:48489357	A/G	cg05342945	chr12:48394962	COL2A1	0.4	7.9	0.3	1.26e-14	Lung cancer;
BRCA	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg11764359	chr7:65958608	NA	-0.62	-13.14	-0.46	4.35e-35	Aortic root size;
BRCA	cis	rs2279817	1.000	rs10888048	chr1:18019742	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.55	16.39	0.54	1.17e-50	Neuroticism;
BRCA	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg04455712	chr21:45112962	RRP1B	0.38	9.81	0.36	2.99e-21	Mean corpuscular volume;
BRCA	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg13906792	chr15:75199810	C15orf17	0.34	8.04	0.3	4.4e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
BRCA	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg16414030	chr3:133502952	NA	-0.47	-11.12	-0.4	2.13e-26	Iron status biomarkers;
BRCA	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg25767906	chr1:53392781	SCP2	-0.38	-8.57	-0.32	7.55e-17	Monocyte count;
BRCA	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg26597838	chr10:835615	NA	1.03	17.78	0.58	8.92e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs2415984	0.622	rs61993305	chr14:46950955	C/T	cg14871534	chr14:47121158	RPL10L	-0.33	-8.17	-0.31	1.68e-15	Number of children ever born;
BRCA	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg12863693	chr15:85201151	NMB	-0.33	-8.0	-0.3	6.03e-15	P wave terminal force;
BRCA	cis	rs17095355	0.688	rs1349348	chr10:111794554	T/C	cg00817464	chr10:111662876	XPNPEP1	0.38	9.26	0.34	3.12e-19	Biliary atresia;
BRCA	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg21747090	chr2:27597821	SNX17	-0.43	-9.43	-0.35	7.24e-20	Total body bone mineral density;
BRCA	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.21e-14	Parkinson's disease;
BRCA	trans	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg26384229	chr12:38710491	ALG10B	0.56	12.16	0.43	9.7e-31	Morning vs. evening chronotype;
BRCA	cis	rs701145	0.585	rs1534386	chr3:153819035	C/G	cg17054900	chr3:154042577	DHX36	0.53	9.04	0.34	1.88e-18	Coronary artery disease;
BRCA	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18876405	chr7:65276391	NA	0.5	11.2	0.4	1.09e-26	Aortic root size;
BRCA	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg01256987	chr12:42539512	GXYLT1	0.39	7.86	0.3	1.67e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7789940	1.000	rs7789940	chr7:75951230	A/G	cg10167463	chr7:75959203	YWHAG	-0.45	-8.89	-0.33	6.23e-18	Multiple sclerosis;
BRCA	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg21475434	chr5:93447410	FAM172A	0.62	8.35	0.31	4.16e-16	Diabetic retinopathy;
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.46	-10.63	-0.39	2.04e-24	Longevity;Endometriosis;
BRCA	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg15556689	chr8:8085844	FLJ10661	0.5	13.97	0.48	6.93e-39	Mood instability;
BRCA	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg08807101	chr21:30365312	RNF160	-0.54	-12.95	-0.46	3.25e-34	Dental caries;
BRCA	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg20503657	chr10:835505	NA	0.99	17.46	0.57	4.23e-56	Eosinophil percentage of granulocytes;
BRCA	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg12927641	chr6:109611667	NA	-0.41	-10.85	-0.39	2.65e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg27279351	chr12:120934652	DYNLL1	0.58	13.28	0.47	1.02e-35	High light scatter reticulocyte count;
BRCA	trans	rs7939886	0.920	rs11231794	chr11:55765776	T/C	cg15704280	chr7:45808275	SEPT13	0.62	7.92	0.3	1.03e-14	Myopia (pathological);
BRCA	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19748678	chr4:122722346	EXOSC9	0.72	15.5	0.52	3.26e-46	Type 2 diabetes;
BRCA	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg27170947	chr2:26402098	FAM59B	-0.66	-11.32	-0.41	3.36e-27	Gut microbiome composition (summer);
BRCA	cis	rs2882667	0.858	rs7724108	chr5:138410922	A/G	cg04439458	chr5:138467593	SIL1	0.45	11.39	0.41	1.76e-27	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg25767906	chr1:53392781	SCP2	-0.43	-9.87	-0.36	1.78e-21	Monocyte count;
BRCA	cis	rs17023223	0.537	rs12081327	chr1:119686358	A/G	cg05756136	chr1:119680316	WARS2	-0.41	-7.88	-0.3	1.41e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs11734570	0.581	rs73811716	chr4:38590773	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.58	11.39	0.41	1.72e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg04827223	chr11:72435913	ARAP1	-0.59	-15.43	-0.52	6.78e-46	Body mass index;
BRCA	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg12935359	chr14:103987150	CKB	0.52	12.67	0.45	5.61e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg09307838	chr4:120376055	NA	0.74	15.84	0.53	6.39e-48	Corneal astigmatism;
BRCA	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg02196655	chr2:10830764	NOL10	-0.3	-7.99	-0.3	6.12e-15	Prostate cancer;
BRCA	trans	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg26384229	chr12:38710491	ALG10B	0.43	10.31	0.38	3.53e-23	Morning vs. evening chronotype;
BRCA	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg24110177	chr3:50126178	RBM5	0.47	12.23	0.44	4.5e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26314531	chr2:26401878	FAM59B	-0.98	-16.87	-0.56	4.52e-53	Gut microbiome composition (summer);
BRCA	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg15448220	chr1:150897856	SETDB1	0.36	8.04	0.3	4.43e-15	Melanoma;
BRCA	trans	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg06521331	chr12:34319734	NA	-0.45	-8.84	-0.33	9.08e-18	Bladder cancer;
BRCA	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg08824895	chr13:115047677	UPF3A	0.49	9.78	0.36	3.93e-21	Schizophrenia;
BRCA	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00149659	chr3:10157352	C3orf10	0.79	13.72	0.48	9.42e-38	Alzheimer's disease;
BRCA	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg01877450	chr7:97915802	BRI3	-0.39	-8.72	-0.33	2.36e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg02544614	chr20:61657117	NA	0.29	7.96	0.3	7.77e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg07905965	chr19:39260460	NA	0.49	11.23	0.41	7.51e-27	Heart rate;
BRCA	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg07917127	chr4:99064746	C4orf37	0.44	8.1	0.31	2.86e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10267417	0.535	rs6946403	chr7:19861549	C/T	cg05791153	chr7:19748676	TWISTNB	0.48	9.51	0.35	3.77e-20	Night sleep phenotypes;
BRCA	cis	rs7582720	1.000	rs72936309	chr2:204040296	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	12.25	0.44	3.99e-31	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs4728302	0.869	rs10253633	chr7:133590869	A/G	cg07491979	chr7:133331646	EXOC4	0.36	7.81	0.3	2.32e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18404041	chr3:52824283	ITIH1	-0.42	-12.32	-0.44	1.93e-31	Bipolar disorder;
BRCA	trans	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.05	0.3	3.95e-15	Corneal astigmatism;
BRCA	cis	rs7809950	0.953	rs2237670	chr7:107131485	A/G	cg23024343	chr7:107201750	COG5	-0.41	-9.54	-0.35	2.86e-20	Coronary artery disease;
BRCA	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg08885076	chr2:99613938	TSGA10	0.45	10.61	0.39	2.51e-24	Chronic sinus infection;
BRCA	cis	rs2463822	1.000	rs2513749	chr11:62105391	C/T	cg06239285	chr11:62104954	ASRGL1	0.67	11.47	0.41	7.9e-28	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg11366901	chr6:160182831	ACAT2	0.83	15.91	0.53	3.09e-48	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg24558204	chr6:135376177	HBS1L	0.44	11.85	0.42	2.03e-29	Red blood cell count;
BRCA	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	23.0	0.67	8.99e-86	Platelet count;
BRCA	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg04317338	chr11:64019027	PLCB3	0.55	9.51	0.35	3.77e-20	Mean platelet volume;
BRCA	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg26597838	chr10:835615	NA	1.03	18.35	0.59	1e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg21535247	chr6:8435926	SLC35B3	0.42	9.61	0.36	1.67e-20	Motion sickness;
BRCA	cis	rs62380364	0.626	rs618741	chr5:88064012	C/T	cg22951263	chr5:87985283	NA	-0.37	-10.32	-0.38	3.37e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg19052272	chr2:3704530	ALLC	-0.46	-10.37	-0.38	2.13e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs12618769	0.543	rs4851132	chr2:99042782	T/C	cg10123293	chr2:99228465	UNC50	0.4	8.17	0.31	1.71e-15	Bipolar disorder;
BRCA	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg26384229	chr12:38710491	ALG10B	0.66	14.23	0.49	4.08e-40	Morning vs. evening chronotype;
BRCA	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg06636001	chr8:8085503	FLJ10661	-0.38	-7.98	-0.3	6.83e-15	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
BRCA	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg08999081	chr20:33150536	PIGU	0.45	12.08	0.43	2.18e-30	Coronary artery disease;
BRCA	cis	rs6460942	1.000	rs79659770	chr7:12326371	T/C	cg06484146	chr7:12443880	VWDE	-0.62	-8.57	-0.32	7.55e-17	Coronary artery disease;
BRCA	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg08859206	chr1:53392774	SCP2	-0.44	-8.7	-0.33	2.75e-17	Monocyte count;
BRCA	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07308232	chr7:1071921	C7orf50	-0.5	-10.52	-0.38	5.4e-24	Longevity;Endometriosis;
BRCA	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09256448	chr16:638327	NA	0.3	7.99	0.3	6.54e-15	Height;
BRCA	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg03433033	chr1:76189801	ACADM	-0.46	-9.0	-0.34	2.61e-18	Daytime sleep phenotypes;
BRCA	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg07917127	chr4:99064746	C4orf37	0.44	8.1	0.31	2.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs965469	1.000	rs6139064	chr20:3277050	G/T	cg25506879	chr20:3388711	C20orf194	-0.51	-10.26	-0.38	5.58e-23	IFN-related cytopenia;
BRCA	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg11812906	chr14:75593930	NEK9	-0.55	-12.5	-0.44	3.09e-32	Height;
BRCA	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg17971929	chr21:40555470	PSMG1	0.75	15.77	0.53	1.46e-47	Cognitive function;
BRCA	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-15.94	-0.53	2.15e-48	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg27170947	chr2:26402098	FAM59B	0.97	17.09	0.56	3.41e-54	Gut microbiome composition (summer);
BRCA	cis	rs6763687	0.930	rs4894797	chr3:171783546	G/A	cg16233210	chr3:171778391	FNDC3B	0.5	11.67	0.42	1.19e-28	Red cell distribution width;
BRCA	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24531977	chr5:56204891	C5orf35	-0.88	-18.13	-0.58	1.46e-59	Initial pursuit acceleration;
BRCA	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg16850897	chr7:100343110	ZAN	-0.58	-11.26	-0.41	5.76e-27	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs35123781	0.696	rs7703195	chr5:139071632	G/A	cg10513866	chr5:139070639	NA	0.45	9.79	0.36	3.46e-21	Schizophrenia;
BRCA	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-7.89	-0.3	1.36e-14	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.29	-0.31	6.59e-16	Breast cancer;
BRCA	cis	rs6743226	0.870	rs12624197	chr2:242254737	G/C	cg10021735	chr2:242295487	FARP2	0.37	10.13	0.37	1.79e-22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs4363385	0.747	rs1415959	chr1:152973690	C/T	cg25856811	chr1:152973957	SPRR3	0.34	9.32	0.35	1.9e-19	Inflammatory skin disease;
BRCA	cis	rs897080	0.515	rs1067349	chr2:44670369	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	9.37	0.35	1.26e-19	Height;
BRCA	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13012494	chr21:47604986	C21orf56	-0.41	-8.54	-0.32	9.55e-17	Testicular germ cell tumor;
BRCA	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg08000102	chr2:233561755	GIGYF2	-0.64	-14.0	-0.48	5.16e-39	Coronary artery disease;
BRCA	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg11663144	chr21:46675770	NA	-0.6	-13.84	-0.48	2.6e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg27129171	chr3:47204927	SETD2	0.74	18.94	0.6	8.23e-64	Colorectal cancer;
BRCA	cis	rs4809760	0.669	rs6020069	chr20:48438572	T/C	cg17835207	chr20:48524531	SPATA2	0.37	8.26	0.31	8.23e-16	Gut microbiota (beta diversity);
BRCA	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.36	-9.27	-0.34	2.77e-19	IgG glycosylation;
BRCA	cis	rs10193935	0.901	rs6544529	chr2:42510652	A/T	cg27598129	chr2:42591480	NA	-0.94	-14.78	-0.5	9.39e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg26587870	chr6:27730563	NA	-0.41	-8.83	-0.33	9.71e-18	Parkinson's disease;
BRCA	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg14004847	chr7:1930337	MAD1L1	-0.44	-8.69	-0.33	3.01e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs6723226	0.708	rs2754513	chr2:32782763	G/A	cg02381751	chr2:32503542	YIPF4	0.66	14.13	0.49	1.15e-39	Intelligence (multi-trait analysis);
BRCA	cis	rs12210905	0.688	rs72843191	chr6:27383301	G/C	cg08851530	chr6:28072375	NA	0.81	7.97	0.3	7.49e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs6429082	0.714	rs704719	chr1:235667170	G/A	cg26050004	chr1:235667680	B3GALNT2	0.56	13.11	0.46	6.21e-35	Adiposity;
BRCA	cis	rs6669008	1.000	rs55912359	chr1:114167099	C/T	cg26035817	chr1:114414802	PTPN22	0.35	8.35	0.31	4.17e-16	Bacteremia;
BRCA	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg24596788	chr1:163392923	NA	-0.37	-9.83	-0.36	2.52e-21	Motion sickness;
BRCA	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg04025307	chr7:1156635	C7orf50	0.56	13.0	0.46	1.98e-34	Longevity;Endometriosis;
BRCA	cis	rs7937840	0.501	rs4963459	chr11:61877137	G/A	cg01969543	chr11:61895209	INCENP	-0.39	-8.59	-0.32	6.79e-17	Breast cancer;
BRCA	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg25665528	chr16:2260870	C16orf79	-0.33	-8.19	-0.31	1.38e-15	Height;
BRCA	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg04989706	chr14:50066350	PPIL5	0.48	9.33	0.35	1.67e-19	Carotid intima media thickness;
BRCA	cis	rs11828289	0.660	rs17306433	chr11:23223034	C/G	cg20040320	chr11:23191996	NA	-0.53	-7.81	-0.3	2.41e-14	Cancer;
BRCA	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.13	-0.31	2.25e-15	Depression;
BRCA	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg20503657	chr10:835505	NA	1.05	18.38	0.59	6.64e-61	Eosinophil percentage of granulocytes;
BRCA	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg05729581	chr11:3078854	CARS	-0.35	-8.65	-0.32	4.15e-17	Longevity;
BRCA	cis	rs34779708	0.966	rs10508816	chr10:35459976	G/A	cg03585969	chr10:35415529	CREM	0.45	9.42	0.35	7.93e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg11752832	chr7:134001865	SLC35B4	0.46	11.61	0.42	2.1e-28	Mean platelet volume;
BRCA	cis	rs1468333	1.000	rs4552585	chr5:137533159	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.43	8.49	0.32	1.5e-16	Resting heart rate;
BRCA	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.73	16.4	0.54	1.09e-50	Lymphocyte counts;
BRCA	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg25173405	chr17:45401733	C17orf57	0.5	10.43	0.38	1.23e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg13770153	chr20:60521292	NA	-0.34	-7.84	-0.3	1.89e-14	Body mass index;
BRCA	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg02176678	chr2:219576539	TTLL4	0.39	10.54	0.38	4.57e-24	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg01579765	chr21:45077557	HSF2BP	-0.44	-11.79	-0.42	3.75e-29	Mean corpuscular volume;
BRCA	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg02951883	chr7:2050386	MAD1L1	-0.45	-10.58	-0.39	3.19e-24	Schizophrenia;
BRCA	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg09065629	chr16:1709722	CRAMP1L	0.37	8.76	0.33	1.73e-17	Coronary artery disease;
BRCA	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11764359	chr7:65958608	NA	0.8	19.21	0.6	3.07e-65	Aortic root size;
BRCA	cis	rs4664304	0.620	rs55664214	chr2:160708059	C/T	cg14819504	chr2:160761413	LY75	-0.32	-7.85	-0.3	1.74e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg12011299	chr4:100065546	ADH4	0.48	10.87	0.4	2.26e-25	Smoking initiation;
BRCA	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg06159980	chr1:16340746	HSPB7	-0.4	-9.03	-0.34	2e-18	Systolic blood pressure;
BRCA	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg26838691	chr2:24397539	C2orf84	-0.53	-9.45	-0.35	6.19e-20	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs8114671	0.967	rs2065978	chr20:33767291	C/T	cg07148914	chr20:33460835	GGT7	0.39	8.28	0.31	7.4e-16	Height;
BRCA	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg27170947	chr2:26402098	FAM59B	0.97	16.89	0.56	3.52e-53	Gut microbiome composition (summer);
BRCA	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg23422044	chr7:1970798	MAD1L1	-0.46	-10.25	-0.38	6.55e-23	Neuroticism;
BRCA	trans	rs61931739	1.000	rs12427279	chr12:34025898	T/G	cg26384229	chr12:38710491	ALG10B	-0.43	-9.65	-0.36	1.17e-20	Morning vs. evening chronotype;
BRCA	cis	rs2629751	0.512	rs2723845	chr12:104446721	T/C	cg14987745	chr12:104360022	TDG	-0.48	-9.1	-0.34	1.14e-18	Hepatitis C induced liver fibrosis;
BRCA	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.1	0.31	2.83e-15	Parkinson's disease;
BRCA	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg13114125	chr14:105738426	BRF1	-0.54	-11.46	-0.41	8.79e-28	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs870825	0.860	rs72689277	chr4:185593699	G/A	cg04058563	chr4:185651563	MLF1IP	0.84	14.09	0.49	1.87e-39	Blood protein levels;
BRCA	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg06713675	chr4:122721982	EXOSC9	-0.49	-11.74	-0.42	5.79e-29	Type 2 diabetes;
BRCA	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg16099169	chr2:106886729	NA	-0.59	-10.55	-0.39	4.11e-24	Facial morphology (factor 23);
BRCA	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg03585969	chr10:35415529	CREM	0.49	10.38	0.38	2.0500000000000001e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.49	0.41	6.46e-28	Bipolar disorder;
BRCA	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg05340658	chr4:99064831	C4orf37	0.69	17.49	0.57	2.77e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	12.74	0.45	2.81e-33	Mean platelet volume;
BRCA	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.6	0.32	6e-17	Rheumatoid arthritis;
BRCA	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg23950597	chr19:37808831	NA	-0.61	-11.49	-0.41	6.73e-28	Coronary artery calcification;
BRCA	cis	rs9462027	0.628	rs2038839	chr6:34777791	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.89	-0.3	1.33e-14	Systemic lupus erythematosus;
BRCA	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg15595755	chr5:1867978	NA	0.37	8.76	0.33	1.78e-17	Cardiovascular disease risk factors;
BRCA	cis	rs36051895	0.632	rs62541944	chr9:5159318	G/T	cg02405213	chr9:5042618	JAK2	-0.48	-8.85	-0.33	8.36e-18	Pediatric autoimmune diseases;
BRCA	cis	rs9790314	0.628	rs4342141	chr3:160783922	T/C	cg03342759	chr3:160939853	NMD3	-0.52	-10.7	-0.39	1.13e-24	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg25214090	chr10:38739885	LOC399744	0.53	12.06	0.43	2.49e-30	Corneal astigmatism;
BRCA	trans	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg25214090	chr10:38739885	LOC399744	0.51	11.52	0.41	4.81e-28	Corneal astigmatism;
BRCA	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg26816564	chr1:7831052	VAMP3	0.73	13.01	0.46	1.72e-34	Inflammatory bowel disease;
BRCA	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.38	0.31	3.26e-16	Aortic root size;
BRCA	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg18811423	chr2:55921094	PNPT1	0.71	22.36	0.66	3.16e-82	Metabolic syndrome;
BRCA	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg15704280	chr7:45808275	SEPT13	-0.46	-8.93	-0.33	4.59e-18	Height;
BRCA	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg11663144	chr21:46675770	NA	-0.6	-13.84	-0.48	2.6e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9596863	0.898	rs9316655	chr13:54319640	A/G	ch.13.53330881F	chr13:54432880	NA	0.45	7.82	0.3	2.23e-14	Epilepsy and lamotrigine-induced maculopapular eruptions;
BRCA	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg06713675	chr4:122721982	EXOSC9	-0.53	-12.46	-0.44	4.65e-32	Type 2 diabetes;
BRCA	cis	rs11051970	0.553	rs325419	chr12:32572460	A/G	cg02745156	chr12:32552066	NA	0.23	7.92	0.3	1.05e-14	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs1003719	0.788	rs60447195	chr21:38448600	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.25	0.49	3.26e-40	Eye color traits;
BRCA	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg22535103	chr8:58192502	C8orf71	-0.42	-8.56	-0.32	8.18e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-16.87	-0.56	4.43e-53	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.87	0.39	2.32e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.48	8.75	0.33	1.9e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg13319975	chr6:146136371	FBXO30	-0.39	-8.92	-0.33	4.73e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	11.73	0.42	6.48e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs11231017	0.507	rs9633995	chr11:62071215	A/C	cg23876832	chr11:62092739	NA	0.32	8.08	0.3	3.18e-15	HIV-1 viral setpoint;
BRCA	cis	rs78456975	0.622	rs11888851	chr2:1518254	C/G	cg26248373	chr2:1572462	NA	-0.38	-7.91	-0.3	1.13e-14	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.02	14.88	0.51	3.4e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg24562669	chr7:97807699	LMTK2	0.62	18.68	0.59	1.78e-62	Breast cancer;
BRCA	trans	rs629535	0.590	rs55988608	chr8:70133619	A/G	cg21567404	chr3:27674614	NA	-0.97	-18.03	-0.58	4.74e-59	Dupuytren's disease;
BRCA	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg21535247	chr6:8435926	SLC35B3	0.4	8.96	0.33	3.57e-18	Motion sickness;
BRCA	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	11.84	0.42	2.33e-29	Lung cancer in ever smokers;
BRCA	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg24450063	chr1:156163899	SLC25A44	0.94	18.44	0.59	3.44e-61	Testicular germ cell tumor;
BRCA	cis	rs3917254	0.543	rs11123911	chr2:102761538	C/T	cg22835712	chr2:102737379	NA	-0.49	-8.93	-0.33	4.54e-18	Blood protein levels;
BRCA	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg04450456	chr4:17643702	FAM184B	-0.38	-11.28	-0.41	4.71e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02176678	chr2:219576539	TTLL4	-0.52	-13.21	-0.46	2.23e-35	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg06627628	chr2:24431161	ITSN2	-0.45	-9.48	-0.35	4.72e-20	Asthma;
BRCA	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg04117972	chr1:227635322	NA	0.49	8.9	0.33	5.78e-18	Major depressive disorder;
BRCA	cis	rs7737355	1.000	rs798415	chr5:130693723	T/G	cg06307176	chr5:131281290	NA	-0.47	-9.04	-0.34	1.79e-18	Life satisfaction;
BRCA	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg18132916	chr6:79620363	NA	-0.48	-10.88	-0.4	2.04e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs1499972	0.941	rs62263115	chr3:117622116	G/A	cg07612923	chr3:117604196	NA	0.58	7.92	0.3	1.04e-14	Schizophrenia;
BRCA	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07080220	chr10:102295463	HIF1AN	0.49	11.34	0.41	2.85e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg20991723	chr1:152506922	NA	0.38	8.67	0.32	3.48e-17	Hair morphology;
BRCA	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.5	0.35	3.97e-20	Morning vs. evening chronotype;
BRCA	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg23711669	chr6:146136114	FBXO30	0.72	14.81	0.51	7.21e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10819733	chr22:24237672	NA	-0.3	-8.2	-0.31	1.3e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs365132	0.875	rs2962842	chr5:176338955	A/G	cg16309518	chr5:176445507	NA	-0.41	-10.06	-0.37	3.47e-22	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg21475434	chr5:93447410	FAM172A	0.67	8.72	0.33	2.4e-17	Diabetic retinopathy;
BRCA	cis	rs13082711	0.554	rs6804440	chr3:27398150	C/T	cg02860705	chr3:27208620	NA	0.66	11.52	0.41	4.97e-28	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs6005807	0.719	rs9620810	chr22:29053727	T/C	cg12565055	chr22:29076175	TTC28	0.5	9.47	0.35	5.27e-20	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg04025307	chr7:1156635	C7orf50	0.57	13.92	0.48	1.14e-38	Longevity;Endometriosis;
BRCA	trans	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg26043149	chr18:55253948	FECH	-0.4	-8.77	-0.33	1.66e-17	Bone mineral density;
BRCA	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg19077165	chr18:44547161	KATNAL2	-0.62	-13.83	-0.48	3.03e-38	Personality dimensions;
BRCA	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg08885076	chr2:99613938	TSGA10	0.45	10.61	0.39	2.51e-24	Chronic sinus infection;
BRCA	cis	rs11984145	1.000	rs17171466	chr7:38835926	A/G	cg19327137	chr7:38886074	VPS41	0.47	8.56	0.32	8.37e-17	Cognitive performance;
BRCA	trans	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg07817883	chr1:32538562	TMEM39B	-0.46	-8.8	-0.33	1.31e-17	Monocyte percentage of white cells;
BRCA	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg20387954	chr3:183756860	HTR3D	0.45	10.05	0.37	3.66e-22	Anterior chamber depth;
BRCA	cis	rs524281	0.861	rs11227411	chr11:65879478	C/T	cg16950941	chr11:66035639	RAB1B	-0.38	-8.12	-0.31	2.4e-15	Electroencephalogram traits;
BRCA	cis	rs6745190	0.575	rs6706397	chr2:181971800	T/G	cg00481216	chr2:181971175	NA	0.38	8.98	0.33	2.95e-18	White blood cell count;
BRCA	cis	rs4240897	1.000	rs4240897	chr1:12042755	A/G	cg13216073	chr1:12042593	MFN2	-0.45	-10.71	-0.39	1.02e-24	Tuberculosis;
BRCA	cis	rs1468333	0.694	rs7719684	chr5:137614085	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.38	7.94	0.3	9.06e-15	Resting heart rate;
BRCA	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg25036284	chr2:26402008	FAM59B	-0.97	-16.2	-0.54	1.09e-49	Gut microbiome composition (summer);
BRCA	cis	rs9815354	0.680	rs73073242	chr3:42015335	G/A	cg03022575	chr3:42003672	ULK4	0.75	9.65	0.36	1.17e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-10.24	-0.38	7.17e-23	Blood metabolite levels;
BRCA	trans	rs7939886	0.920	rs11534518	chr11:55808146	C/T	cg15704280	chr7:45808275	SEPT13	0.61	7.82	0.3	2.14e-14	Myopia (pathological);
BRCA	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.07e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg01292856	chr11:65242576	NA	0.32	8.14	0.31	2.13e-15	Bone mineral density;
BRCA	cis	rs3125734	0.719	rs3852410	chr10:64037563	A/G	cg19640130	chr10:64028056	RTKN2	0.3	8.35	0.31	4.31e-16	Rheumatoid arthritis;
BRCA	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg10556349	chr10:835070	NA	0.75	10.1	0.37	2.41e-22	Eosinophil percentage of granulocytes;
BRCA	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.46	-0.32	1.88e-16	Total body bone mineral density;
BRCA	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23583168	chr7:148888333	NA	-0.84	-19.69	-0.61	7.7e-68	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg11764359	chr7:65958608	NA	0.56	12.09	0.43	1.85e-30	Aortic root size;
BRCA	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg26587870	chr6:27730563	NA	-0.37	-7.85	-0.3	1.75e-14	Parkinson's disease;
BRCA	cis	rs17641971	0.684	rs4873093	chr8:49974740	G/T	cg00325661	chr8:49890786	NA	0.38	10.58	0.39	3.29e-24	Blood metabolite levels;
BRCA	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg01689657	chr7:91764605	CYP51A1	0.21	7.85	0.3	1.74e-14	Breast cancer;
BRCA	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg14019146	chr3:50243930	SLC38A3	0.36	8.96	0.33	3.53e-18	Body mass index;
BRCA	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg18225595	chr11:63971243	STIP1	0.52	9.46	0.35	6.01e-20	Mean platelet volume;
BRCA	cis	rs7590720	0.731	rs1864253	chr2:216878008	C/G	cg12620499	chr2:216877984	MREG	0.84	27.36	0.73	1.13e-109	Alcohol dependence;
BRCA	trans	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.11	0.31	2.51e-15	Endometrial cancer;
BRCA	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg06115741	chr20:33292138	TP53INP2	0.51	11.48	0.41	7.45e-28	Coronary artery disease;
BRCA	cis	rs76419734	0.510	rs4699198	chr4:106645771	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.57	12.65	0.45	7.2e-33	Post bronchodilator FEV1;
BRCA	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.33	0.35	1.73e-19	Morning vs. evening chronotype;
BRCA	cis	rs2882667	0.690	rs11953339	chr5:138259542	T/A	cg04439458	chr5:138467593	SIL1	-0.35	-8.61	-0.32	5.84e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05025164	chr4:1340916	KIAA1530	0.78	15.63	0.53	7.41e-47	Longevity;
BRCA	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg18305652	chr10:134549665	INPP5A	0.48	12.74	0.45	2.88e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg12826209	chr6:26865740	GUSBL1	0.63	8.28	0.31	7.24e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg03396347	chr1:1875803	NA	0.47	12.04	0.43	3.12e-30	Body mass index;
BRCA	trans	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg25214090	chr10:38739885	LOC399744	0.47	10.99	0.4	7.28e-26	Corneal astigmatism;
BRCA	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg03354898	chr7:1950403	MAD1L1	-0.48	-9.66	-0.36	1.06e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg25237894	chr2:233734115	C2orf82	0.4	11.52	0.41	4.8e-28	Coronary artery disease;
BRCA	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg19678392	chr7:94953810	PON1	-0.6	-14.88	-0.51	3.2e-43	Paraoxonase activity;
BRCA	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.96	14.55	0.5	1.18e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6546550	0.935	rs7563062	chr2:70050725	G/A	cg02498382	chr2:70120550	SNRNP27	-0.48	-10.09	-0.37	2.7e-22	Prevalent atrial fibrillation;
BRCA	cis	rs12760731	0.565	rs12036491	chr1:178163651	C/A	cg00404053	chr1:178313656	RASAL2	0.64	7.85	0.3	1.75e-14	Obesity-related traits;
BRCA	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg04944784	chr2:26401820	FAM59B	-0.95	-16.17	-0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs6540556	0.859	rs11119340	chr1:209940560	A/T	cg05527609	chr1:210001259	C1orf107	0.46	8.54	0.32	1.01e-16	Red blood cell count;
BRCA	cis	rs870825	0.616	rs61539306	chr4:185650276	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	17.79	0.58	7.74e-58	Blood protein levels;
BRCA	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg24675658	chr1:53192096	ZYG11B	-0.65	-14.23	-0.49	3.9e-40	Monocyte count;
BRCA	cis	rs9463078	0.764	rs1576382	chr6:44957553	G/A	cg25276700	chr6:44698697	NA	-0.37	-8.54	-0.32	9.76e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	trans	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg21775007	chr8:11205619	TDH	-0.38	-8.35	-0.31	4.16e-16	Mood instability;
BRCA	cis	rs2016266	0.819	rs4758965	chr12:53662735	C/T	cg26875137	chr12:53738046	NA	0.36	9.8	0.36	3.14e-21	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs6565180	0.962	rs6565183	chr16:30382755	T/C	cg17640201	chr16:30407289	ZNF48	-0.8	-21.01	-0.64	6.72e-75	Tonsillectomy;
BRCA	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg20203395	chr5:56204925	C5orf35	-0.5	-10.15	-0.37	1.54e-22	Initial pursuit acceleration;
BRCA	trans	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs911119	1.000	rs35488434	chr20:23620401	T/C	cg16589663	chr20:23618590	CST3	0.47	8.81	0.33	1.2e-17	Chronic kidney disease;
BRCA	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08704250	chr15:31115839	NA	-0.36	-8.94	-0.33	4.28e-18	Huntington's disease progression;
BRCA	cis	rs9790314	0.690	rs7651087	chr3:160821929	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-11.46	-0.41	8.46e-28	Morning vs. evening chronotype;
BRCA	cis	rs13046373	0.508	rs13048637	chr21:31999055	T/G	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.25	0.31	8.99e-16	HDL cholesterol;
BRCA	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg26384229	chr12:38710491	ALG10B	0.39	8.65	0.32	4.08e-17	Morning vs. evening chronotype;
BRCA	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg16325326	chr1:53192061	ZYG11B	0.52	11.12	0.4	2.12e-26	Monocyte count;
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg03923535	chr7:1197113	ZFAND2A	0.46	9.31	0.35	2.09e-19	Longevity;Endometriosis;
BRCA	trans	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg17712092	chr4:129076599	LARP1B	-0.5	-10.94	-0.4	1.19e-25	Breast cancer;
BRCA	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg23711669	chr6:146136114	FBXO30	0.7	16.66	0.55	5.09e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg17063962	chr7:91808500	NA	0.55	12.72	0.45	3.22e-33	Breast cancer;
BRCA	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg08847533	chr14:75593920	NEK9	-0.8	-19.77	-0.62	3.04e-68	Height;
BRCA	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	7.97	0.3	7.19e-15	Breast cancer;
BRCA	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg27170947	chr2:26402098	FAM59B	0.83	11.63	0.42	1.8e-28	Gut microbiome composition (summer);
BRCA	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg06784218	chr1:46089804	CCDC17	0.45	10.81	0.39	3.92e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg14196790	chr5:131705035	SLC22A5	0.4	10.16	0.37	1.41e-22	Blood metabolite levels;
BRCA	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg21535247	chr6:8435926	SLC35B3	0.42	9.61	0.36	1.65e-20	Motion sickness;
BRCA	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-9.56	-0.35	2.58e-20	Schizophrenia;
BRCA	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg08000102	chr2:233561755	GIGYF2	-0.62	-13.57	-0.47	4.77e-37	Coronary artery disease;
BRCA	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-9.54	-0.35	3.04e-20	Alzheimer's disease (late onset);
BRCA	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg04362960	chr10:104952993	NT5C2	0.44	9.99	0.37	6.05e-22	Arsenic metabolism;
BRCA	cis	rs9811920	0.809	rs6802817	chr3:99779264	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.55	-13.16	-0.46	3.47e-35	Axial length;
BRCA	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg17063962	chr7:91808500	NA	0.59	13.96	0.48	7.47e-39	Breast cancer;
BRCA	cis	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg07988820	chr12:82153109	PPFIA2	-0.59	-9.69	-0.36	8.49e-21	Resting heart rate;
BRCA	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg04455712	chr21:45112962	RRP1B	0.43	11.01	0.4	6.41e-26	Mean corpuscular volume;
BRCA	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg04944784	chr2:26401820	FAM59B	-1.01	-16.45	-0.55	5.57e-51	Gut microbiome composition (summer);
BRCA	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.3	8.21	0.31	1.22e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.83	0.3	2.07e-14	Corneal astigmatism;
BRCA	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg03474202	chr17:45855739	NA	-0.47	-12.49	-0.44	3.33e-32	IgG glycosylation;
BRCA	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-16.03	-0.54	7.47e-49	Alzheimer's disease (late onset);
BRCA	cis	rs919433	0.588	rs11690163	chr2:198527507	A/T	cg00792783	chr2:198669748	PLCL1	0.39	9.03	0.34	2.08e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg23205692	chr1:25664452	TMEM50A	0.44	10.94	0.4	1.24e-25	Erythrocyte sedimentation rate;
BRCA	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg12483005	chr1:23474871	LUZP1	-0.47	-10.43	-0.38	1.26e-23	Height;
BRCA	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg05294307	chr14:35346193	BAZ1A	-0.58	-10.21	-0.37	8.65e-23	Psoriasis;
BRCA	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg18357645	chr12:58087776	OS9	-0.33	-8.39	-0.32	3.05e-16	Multiple sclerosis;
BRCA	trans	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.19	0.31	1.39e-15	Corneal astigmatism;
BRCA	trans	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg16011800	chr17:1958478	HIC1	-0.56	-9.02	-0.34	2.13e-18	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs6580649	0.883	rs7967762	chr12:48420214	C/T	cg24011408	chr12:48396354	COL2A1	-0.48	-8.06	-0.3	3.77e-15	Lung cancer;
BRCA	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg04691961	chr3:161091175	C3orf57	-0.59	-14.33	-0.49	1.38e-40	Morning vs. evening chronotype;
BRCA	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03517284	chr6:25882590	NA	-0.45	-9.23	-0.34	3.9e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11764359	chr7:65958608	NA	0.8	19.28	0.61	1.17e-65	Aortic root size;
BRCA	cis	rs3739998	0.647	rs7920686	chr10:30317838	A/G	cg12786570	chr10:30316432	KIAA1462	0.43	9.4	0.35	9.39e-20	Coronary heart disease;
BRCA	cis	rs3125734	0.633	rs7088891	chr10:64034019	G/T	cg19640130	chr10:64028056	RTKN2	-0.32	-8.87	-0.33	7.33e-18	Rheumatoid arthritis;
BRCA	trans	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg07211511	chr3:129823064	LOC729375	-0.63	-11.03	-0.4	4.99e-26	Blood pressure (smoking interaction);
BRCA	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg13902645	chr11:5959945	NA	-0.56	-11.47	-0.41	7.69e-28	DNA methylation (variation);
BRCA	cis	rs7927771	0.542	rs3886262	chr11:47817010	T/G	cg20307385	chr11:47447363	PSMC3	0.41	9.4	0.35	9.36e-20	Subjective well-being;
BRCA	trans	rs6561151	0.957	rs3764147	chr13:44457925	C/T	cg17145862	chr1:211918768	LPGAT1	-0.41	-8.41	-0.32	2.71e-16	Crohn's disease;
BRCA	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg01620082	chr3:125678407	NA	-0.84	-9.78	-0.36	3.96e-21	Depression;
BRCA	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg11247378	chr22:39784982	NA	0.64	14.52	0.5	1.69e-41	Intelligence (multi-trait analysis);
BRCA	trans	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg13565492	chr6:43139072	SRF	-0.81	-12.57	-0.45	1.62e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg08807101	chr21:30365312	RNF160	-0.47	-8.01	-0.3	5.52e-15	Cognitive test performance;
BRCA	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg25767906	chr1:53392781	SCP2	-0.39	-8.79	-0.33	1.41e-17	Monocyte count;
BRCA	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg25358565	chr5:93447407	FAM172A	1.19	18.82	0.6	3.54e-63	Diabetic retinopathy;
BRCA	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg06623918	chr6:96969491	KIAA0776	0.74	12.19	0.43	6.85e-31	Migraine;Coronary artery disease;
BRCA	cis	rs5753618	0.504	rs9609297	chr22:31893731	G/T	cg02404636	chr22:31891804	SFI1	0.45	9.05	0.34	1.64e-18	Colorectal cancer;
BRCA	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg06784218	chr1:46089804	CCDC17	0.46	10.9	0.4	1.78e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg22875332	chr1:76189707	ACADM	0.61	11.64	0.42	1.57e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6484504	0.512	rs2774402	chr11:31312897	G/C	cg26647111	chr11:31128758	NA	0.43	9.54	0.35	2.94e-20	Red blood cell count;
BRCA	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.22e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6743226	0.811	rs10933537	chr2:242154930	C/G	cg10021735	chr2:242295487	FARP2	-0.32	-8.86	-0.33	7.95e-18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs12986413	0.651	rs2238612	chr19:2149694	C/T	cg09261902	chr19:2140048	AP3D1	-0.39	-9.89	-0.36	1.5e-21	Height;
BRCA	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg03923535	chr7:1197113	ZFAND2A	0.46	9.36	0.35	1.36e-19	Longevity;Endometriosis;
BRCA	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg22491629	chr6:157744540	C6orf35	-0.61	-11.89	-0.43	1.36e-29	Hemostatic factors and hematological phenotypes;
BRCA	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.18	-0.56	1.12e-54	Intelligence (multi-trait analysis);
BRCA	cis	rs28374715	0.617	rs28626792	chr15:41562218	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.56	-12.13	-0.43	1.23e-30	Ulcerative colitis;
BRCA	cis	rs6598955	0.543	rs17163720	chr1:26549399	A/G	cg04990556	chr1:26633338	UBXN11	-0.69	-12.02	-0.43	3.65e-30	Obesity-related traits;
BRCA	cis	rs6540556	0.723	rs3766618	chr1:209895437	G/T	cg05527609	chr1:210001259	C1orf107	-0.52	-8.68	-0.32	3.24e-17	Red blood cell count;
BRCA	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg09658497	chr7:2847517	GNA12	0.44	9.36	0.35	1.28e-19	Height;
BRCA	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg20673091	chr1:2541236	MMEL1	-0.46	-11.88	-0.43	1.56e-29	Ulcerative colitis;
BRCA	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24531977	chr5:56204891	C5orf35	-0.79	-16.28	-0.54	4.15e-50	Initial pursuit acceleration;
BRCA	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg04025307	chr7:1156635	C7orf50	-0.42	-7.98	-0.3	7.04e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg04944784	chr2:26401820	FAM59B	0.82	11.32	0.41	3.33e-27	Gut microbiome composition (summer);
BRCA	cis	rs1712517	0.740	rs11191643	chr10:105057561	C/G	cg05636881	chr10:105038444	INA	0.36	8.09	0.3	2.93e-15	Migraine;
BRCA	cis	rs6545883	0.859	rs13004855	chr2:61505072	C/T	cg15711740	chr2:61764176	XPO1	0.49	11.97	0.43	6.11e-30	Tuberculosis;
BRCA	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg08807101	chr21:30365312	RNF160	0.57	12.45	0.44	5.37e-32	Selective IgA deficiency;
BRCA	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg08355456	chr11:67383691	NA	0.41	8.54	0.32	9.87e-17	Mean corpuscular volume;
BRCA	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.38	-8.5	-0.32	1.3e-16	HDL cholesterol;
BRCA	cis	rs9296092	0.500	rs9469504	chr6:33527243	G/A	cg13560919	chr6:33536144	NA	-0.85	-18.69	-0.59	1.6e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg24101359	chr6:42928495	GNMT	0.62	15.16	0.51	1.5e-44	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg12444411	chr7:2802554	GNA12	-0.3	-7.82	-0.3	2.2e-14	Height;
BRCA	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-11.3	-0.41	4e-27	IgG glycosylation;
BRCA	cis	rs1832871	0.599	rs7752547	chr6:158751163	C/T	cg07215822	chr6:158701037	NA	0.46	9.31	0.35	1.95e-19	Height;
BRCA	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg22764044	chr5:178986830	RUFY1	0.48	13.19	0.46	2.52e-35	Lung cancer;
BRCA	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg09163369	chr1:210001066	C1orf107	0.63	11.94	0.43	8.75e-30	Orofacial clefts;
BRCA	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg00677455	chr12:58241039	CTDSP2	0.54	12.39	0.44	9.89e-32	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg25214090	chr10:38739885	LOC399744	0.46	10.29	0.38	4.47e-23	Corneal astigmatism;
BRCA	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	20.06	0.62	8.66e-70	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg07148914	chr20:33460835	GGT7	-0.43	-9.17	-0.34	6.56e-19	Height;
BRCA	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14240646	chr10:27532245	ACBD5	-0.63	-9.65	-0.36	1.19e-20	Breast cancer;
BRCA	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg24829409	chr8:58192753	C8orf71	-0.48	-9.25	-0.34	3.23e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.42	9.02	0.34	2.22e-18	Hemoglobin concentration;
BRCA	cis	rs4363385	0.747	rs6689609	chr1:152967588	G/A	cg21543102	chr1:152974771	SPRR3	-0.3	-8.61	-0.32	5.54e-17	Inflammatory skin disease;
BRCA	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg21573476	chr21:45109991	RRP1B	-0.4	-10.82	-0.39	3.57e-25	Mean corpuscular volume;
BRCA	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg03923535	chr7:1197113	ZFAND2A	0.52	11.05	0.4	4.27e-26	Longevity;Endometriosis;
BRCA	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.11	-0.34	1.09e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg08975724	chr8:8085496	FLJ10661	0.44	8.9	0.33	5.59e-18	Neuroticism;
BRCA	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg00717180	chr2:96193071	NA	0.31	8.68	0.32	3.39e-17	Height;
BRCA	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg00071950	chr4:10020882	SLC2A9	0.59	14.53	0.5	1.53e-41	Bone mineral density;
BRCA	trans	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg06521331	chr12:34319734	NA	-0.44	-8.35	-0.31	4.37e-16	Bladder cancer;
BRCA	cis	rs7593730	0.537	rs1457231	chr2:161101562	C/T	cg22609984	chr2:161126801	NA	0.38	8.2	0.31	1.28e-15	Type 2 diabetes;
BRCA	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg12615879	chr12:58013172	SLC26A10	-0.33	-9.21	-0.34	4.74e-19	Multiple sclerosis;
BRCA	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg20587970	chr11:113659929	NA	-1.26	-22.92	-0.67	2.71e-85	Hip circumference adjusted for BMI;
BRCA	cis	rs760805	0.965	rs4648883	chr1:25261203	T/C	cg22509179	chr1:25234806	RUNX3	-0.57	-14.58	-0.5	9e-42	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22509189	chr2:225307070	NA	0.47	10.09	0.37	2.57e-22	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg13319975	chr6:146136371	FBXO30	-0.37	-8.44	-0.32	2.09e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10193935	0.892	rs12612372	chr2:42414035	A/G	cg27598129	chr2:42591480	NA	-0.94	-15.03	-0.51	6.18e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg18032046	chr6:28092343	ZSCAN16	0.48	7.82	0.3	2.26e-14	Depression;
BRCA	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg13319975	chr6:146136371	FBXO30	0.43	9.74	0.36	5.39e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17401966	0.838	rs34636442	chr1:10427459	T/G	cg03954927	chr1:10346856	KIF1B	0.43	13.54	0.47	6.56e-37	Hepatocellular carcinoma;
BRCA	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg06618935	chr21:46677482	NA	-0.36	-8.25	-0.31	9.14e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg25801113	chr15:45476975	SHF	0.31	8.05	0.3	4.16e-15	Uric acid levels;
BRCA	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg11707556	chr5:10655725	ANKRD33B	0.48	11.12	0.4	2.23e-26	Height;
BRCA	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	18.9	0.6	1.21e-63	Smoking behavior;
BRCA	cis	rs74181299	0.620	rs6546123	chr2:65303582	T/C	cg05010058	chr2:65284262	CEP68	-0.29	-7.99	-0.3	6.43e-15	Pulse pressure;
BRCA	cis	rs495337	0.736	rs599195	chr20:48464795	A/T	cg17835207	chr20:48524531	SPATA2	-0.48	-10.11	-0.37	2.13e-22	Psoriasis;
BRCA	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg04362960	chr10:104952993	NT5C2	0.43	10.39	0.38	1.88e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs897080	0.515	rs1067356	chr2:44663072	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	8.16	0.31	1.77e-15	Height;
BRCA	cis	rs4948102	0.551	rs4275190	chr7:56104388	C/T	cg09872392	chr7:56161020	PHKG1	-0.47	-11.65	-0.42	1.47e-28	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg05457628	chr5:178986728	RUFY1	0.4	9.14	0.34	8.06e-19	Lung cancer;
BRCA	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	11.17	0.4	1.34e-26	Birth weight;
BRCA	cis	rs13315871	0.929	rs71311854	chr3:58319159	G/A	cg20936604	chr3:58311152	NA	-0.65	-8.24	-0.31	9.48e-16	Cholesterol, total;
BRCA	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg12219531	chr12:120966889	COQ5	0.54	11.06	0.4	4.06e-26	High light scatter reticulocyte count;
BRCA	trans	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-14.12	-0.49	1.27e-39	Brugada syndrome;
BRCA	cis	rs7124681	0.584	rs1471712	chr11:47912150	G/A	cg20307385	chr11:47447363	PSMC3	-0.41	-9.35	-0.35	1.45e-19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs7246657	0.722	rs10417576	chr19:38119212	A/C	cg18154014	chr19:37997991	ZNF793	0.5	9.59	0.35	1.99e-20	Coronary artery calcification;
BRCA	cis	rs30380	1.000	rs30187	chr5:96124330	T/C	cg16492584	chr5:96139282	ERAP1	-0.31	-7.98	-0.3	6.64e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg02466173	chr16:30829666	NA	-0.52	-11.18	-0.4	1.29e-26	Multiple myeloma;
BRCA	cis	rs3784262	0.669	rs6493981	chr15:58352923	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.2	-0.37	9.78e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs1421811	0.606	rs10057069	chr5:32716589	A/G	cg16267343	chr5:32710456	NPR3	0.57	10.82	0.39	3.47e-25	Blood pressure;
BRCA	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-10.6	-0.39	2.8e-24	Putamen volume;
BRCA	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg02079420	chr8:82753780	SNX16	0.32	8.64	0.32	4.49e-17	Diastolic blood pressure;
BRCA	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg22875332	chr1:76189707	ACADM	0.62	14.13	0.49	1.26e-39	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs17685	0.712	rs869805	chr7:75688596	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	28.34	0.75	4.9e-115	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.12	-0.31	2.49e-15	Parkinson's disease;
BRCA	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg25427524	chr10:38739819	LOC399744	-0.51	-8.81	-0.33	1.14e-17	Obesity (extreme);
BRCA	cis	rs7149337	0.805	rs4350491	chr14:51675798	A/G	cg23942311	chr14:51606299	NA	0.41	11.5	0.41	6.11e-28	Cancer;
BRCA	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg22705602	chr4:152727874	NA	-0.36	-9.86	-0.36	2e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs6434928	1	rs6434928	chr2:198304577	G/A	cg00792783	chr2:198669748	PLCL1	0.38	8.58	0.32	7.16e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs72772090	0.522	rs17086504	chr5:96011023	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-8.18	-0.31	1.53e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg12292205	chr6:26970375	C6orf41	0.64	14.57	0.5	9.93e-42	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs3820928	0.874	rs13403281	chr2:227880769	G/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.54	-0.32	9.58e-17	Pulmonary function;
BRCA	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	25.48	0.71	2.27e-99	Platelet count;
BRCA	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg17691542	chr6:26056736	HIST1H1C	0.67	13.67	0.48	1.6e-37	Height;
BRCA	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg04362960	chr10:104952993	NT5C2	0.44	10.77	0.39	5.46e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	trans	rs587242	0.955	rs12566597	chr1:96978626	A/G	cg10631902	chr5:14652156	NA	-0.43	-10.65	-0.39	1.79e-24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
BRCA	cis	rs733175	0.951	rs6846692	chr4:10031133	C/G	cg00071950	chr4:10020882	SLC2A9	0.42	8.03	0.3	4.61e-15	Psychosis and Alzheimer's disease;
BRCA	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.58	0.32	7.26e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg13010199	chr12:38710504	ALG10B	0.56	12.36	0.44	1.25e-31	Heart rate;
BRCA	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg23285459	chr7:2802560	GNA12	0.35	8.98	0.33	2.92e-18	Height;
BRCA	trans	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg26043149	chr18:55253948	FECH	-0.37	-8.12	-0.31	2.34e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg11693508	chr17:37793320	STARD3	0.68	12.95	0.46	3.06e-34	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg05340658	chr4:99064831	C4orf37	0.69	17.39	0.57	9.41e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg19784903	chr17:45786737	TBKBP1	-0.37	-8.69	-0.33	2.94e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg00277334	chr10:82204260	NA	-0.85	-24.93	-0.7	2.31e-96	Post bronchodilator FEV1;
BRCA	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-10.66	-0.39	1.56e-24	Gut microbiome composition (summer);
BRCA	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg03060546	chr3:49711283	APEH	0.51	10.71	0.39	1.02e-24	Resting heart rate;
BRCA	cis	rs9815354	0.812	rs73071203	chr3:41977464	A/C	cg03022575	chr3:42003672	ULK4	0.7	9.67	0.36	9.51e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	trans	rs4596713	0.538	rs4592105	chr9:71754305	T/G	cg16512924	chr15:28394682	HERC2	0.42	9.84	0.36	2.36e-21	Headache;
BRCA	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.38	-9.21	-0.34	4.67e-19	Cognitive function;
BRCA	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg21475434	chr5:93447410	FAM172A	0.68	8.62	0.32	5.18e-17	Diabetic retinopathy;
BRCA	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg06784218	chr1:46089804	CCDC17	0.49	11.81	0.42	3.11e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9815354	0.812	rs17218264	chr3:41975847	C/T	cg03022575	chr3:42003672	ULK4	-0.69	-9.67	-0.36	9.84e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24308560	chr3:49941425	MST1R	-0.4	-8.6	-0.32	6.08e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.75	0.55	1.71e-52	Hypertriglyceridemia;
BRCA	cis	rs7635838	0.654	rs347585	chr3:11286220	C/T	cg00170343	chr3:11313890	ATG7	0.42	8.05	0.3	4.02e-15	HDL cholesterol;
BRCA	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg13010199	chr12:38710504	ALG10B	0.44	9.21	0.34	4.54e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg05340658	chr4:99064831	C4orf37	0.46	10.63	0.39	2.06e-24	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs495337	0.721	rs6125822	chr20:48548766	T/G	cg17835207	chr20:48524531	SPATA2	-0.69	-16.8	-0.55	1.04e-52	Psoriasis;
BRCA	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg18479299	chr3:125709523	NA	-0.51	-8.31	-0.31	5.66e-16	Blood pressure (smoking interaction);
BRCA	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg12927641	chr6:109611667	NA	-0.42	-10.81	-0.39	4.04e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	14.17	0.49	8.1e-40	Alzheimer's disease;
BRCA	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg11887960	chr12:57824829	NA	0.52	8.12	0.31	2.32e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs3784262	0.643	rs2453280	chr15:58368379	C/T	cg12031962	chr15:58353849	ALDH1A2	0.32	8.14	0.31	2.07e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg03396347	chr1:1875803	NA	-0.43	-10.92	-0.4	1.38e-25	Body mass index;
BRCA	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-8.93	-0.33	4.67e-18	Monocyte percentage of white cells;
BRCA	trans	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	16.05	0.54	5.8e-49	Exhaled nitric oxide levels;
BRCA	trans	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg06521331	chr12:34319734	NA	-0.49	-9.17	-0.34	6.51e-19	Bladder cancer;
BRCA	cis	rs10193935	1.000	rs57883795	chr2:42387926	C/T	cg27598129	chr2:42591480	NA	-1.0	-15.03	-0.51	6.31e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg04362960	chr10:104952993	NT5C2	0.43	10.47	0.38	8.76e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs1499972	0.941	rs55958116	chr3:117672772	C/T	cg07612923	chr3:117604196	NA	0.6	8.2	0.31	1.35e-15	Schizophrenia;
BRCA	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg22963979	chr7:1858916	MAD1L1	-0.45	-9.05	-0.34	1.65e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg06453172	chr10:134556979	INPP5A	-0.55	-11.59	-0.42	2.56e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg13256891	chr4:100009986	ADH5	0.55	10.28	0.38	4.94e-23	Smoking initiation;
BRCA	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg26384229	chr12:38710491	ALG10B	0.7	16.24	0.54	6.39e-50	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs11229555	0.874	rs11229505	chr11:58274155	T/C	cg15696309	chr11:58395628	NA	-0.53	-11.49	-0.41	6.8e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.67	10.46	0.38	9.82e-24	Schizophrenia;
BRCA	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.02	-0.49	3.77e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.17	0.74	4.21e-114	Chronic sinus infection;
BRCA	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg03060546	chr3:49711283	APEH	-0.51	-10.16	-0.37	1.44e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg25405998	chr7:65216604	CCT6P1	0.43	9.03	0.34	1.95e-18	Calcium levels;
BRCA	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg13010199	chr12:38710504	ALG10B	0.49	9.53	0.35	3.12e-20	Morning vs. evening chronotype;
BRCA	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-9.74	-0.36	5.28e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs6815814	0.904	rs3924113	chr4:38796255	G/T	cg02016764	chr4:38805732	TLR1	-0.63	-9.61	-0.36	1.63e-20	Breast cancer;
BRCA	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11905131	chr22:24372483	LOC391322	0.53	11.83	0.42	2.39e-29	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg04166393	chr7:2884313	GNA12	-0.48	-9.0	-0.34	2.49e-18	Height;
BRCA	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg04013166	chr16:89971882	TCF25	0.52	9.49	0.35	4.47e-20	Skin colour saturation;
BRCA	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.49	-0.32	1.43e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg19077165	chr18:44547161	KATNAL2	0.38	8.22	0.31	1.14e-15	Personality dimensions;
BRCA	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.63	10.75	0.39	6.8e-25	Lung function (FEV1/FVC);
BRCA	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.62	0.36	1.54e-20	Menopause (age at onset);
BRCA	cis	rs870825	0.616	rs28618216	chr4:185648998	T/C	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs7395581	0.918	rs1375688	chr11:47327217	G/A	cg25783544	chr11:47291846	MADD	0.43	9.64	0.36	1.23e-20	HDL cholesterol;
BRCA	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg18230493	chr5:56204884	C5orf35	-0.71	-13.57	-0.47	4.81e-37	Initial pursuit acceleration;
BRCA	cis	rs7301826	0.627	rs73162873	chr12:131296013	A/G	cg11011512	chr12:131303247	STX2	0.52	13.62	0.47	2.92e-37	Plasma plasminogen activator levels;
BRCA	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.71	15.49	0.52	3.32e-46	Lymphocyte counts;
BRCA	cis	rs758324	0.898	rs11958749	chr5:131166014	T/C	cg06307176	chr5:131281290	NA	0.56	11.84	0.42	2.26e-29	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs9649213	0.614	rs3944111	chr7:98005766	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.58	-15.88	-0.53	4.07e-48	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg01324343	chr3:183735012	ABCC5	0.8	19.97	0.62	2.76e-69	Anterior chamber depth;
BRCA	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-11.61	-0.42	2.17e-28	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg12292205	chr6:26970375	C6orf41	-0.64	-9.99	-0.37	6.45e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg14784868	chr12:69753453	YEATS4	0.66	19.09	0.6	1.27e-64	Blood protein levels;
BRCA	trans	rs4698048	0.506	rs6833292	chr4:10272429	C/T	cg26043149	chr18:55253948	FECH	-0.47	-10.9	-0.4	1.66e-25	Skin aging (microtopography measurement);
BRCA	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg09307838	chr4:120376055	NA	0.64	13.8	0.48	4.15e-38	Corneal astigmatism;
BRCA	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg24642439	chr20:33292090	TP53INP2	0.45	9.82	0.36	2.75e-21	Height;
BRCA	cis	rs757081	0.667	rs476890	chr11:17209962	A/G	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.68	-0.32	3.16e-17	Systolic blood pressure;
BRCA	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg06784218	chr1:46089804	CCDC17	-0.44	-10.5	-0.38	6.67e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg18512352	chr11:47633146	NA	-0.35	-8.35	-0.31	4.17e-16	Subjective well-being;
BRCA	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg12698349	chr2:225449008	CUL3	0.6	13.23	0.46	1.76e-35	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00149659	chr3:10157352	C3orf10	0.8	13.78	0.48	5.12e-38	Alzheimer's disease;
BRCA	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.34	-0.38	2.73e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg17063962	chr7:91808500	NA	0.53	12.67	0.45	5.63e-33	Breast cancer;
BRCA	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg17691542	chr6:26056736	HIST1H1C	0.43	9.27	0.34	2.89e-19	Iron status biomarkers;
BRCA	cis	rs4566357	0.787	rs12475134	chr2:227880511	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-8.81	-0.33	1.16e-17	Coronary artery disease;
BRCA	cis	rs17601876	0.651	rs12908960	chr15:51545860	G/A	cg19946085	chr15:51559439	CYP19A1	-0.33	-8.7	-0.33	2.71e-17	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg03315344	chr16:75512273	CHST6	0.54	12.66	0.45	6.32e-33	Dupuytren's disease;
BRCA	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg07988820	chr12:82153109	PPFIA2	-0.68	-11.8	-0.42	3.32e-29	Resting heart rate;
BRCA	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg11645453	chr3:52864694	ITIH4	-0.35	-9.17	-0.34	6.66e-19	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg26384229	chr12:38710491	ALG10B	-0.72	-15.65	-0.53	5.53e-47	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg21747090	chr2:27597821	SNX17	-0.45	-9.81	-0.36	3.05e-21	Total body bone mineral density;
BRCA	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg02079420	chr8:82753780	SNX16	-0.36	-7.92	-0.3	1.05e-14	Diastolic blood pressure;
BRCA	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg17971929	chr21:40555470	PSMG1	-0.6	-13.11	-0.46	6.05e-35	Cognitive function;
BRCA	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.55	9.31	0.35	2.06e-19	Renal function-related traits (BUN);
BRCA	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.21	-0.31	1.19e-15	Total body bone mineral density;
BRCA	cis	rs7737355	0.947	rs11242081	chr5:130908135	T/C	cg06307176	chr5:131281290	NA	0.53	10.4	0.38	1.64e-23	Life satisfaction;
BRCA	trans	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg25214090	chr10:38739885	LOC399744	0.53	11.71	0.42	7.51e-29	Corneal astigmatism;
BRCA	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.39	8.02	0.3	4.99e-15	Tonsillectomy;
BRCA	cis	rs4478858	0.735	rs6681286	chr1:31799384	G/C	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg24562669	chr7:97807699	LMTK2	0.45	12.03	0.43	3.31e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	9.47	0.35	5.33e-20	Tonsillectomy;
BRCA	cis	rs6782228	0.606	rs2712404	chr3:128332679	C/T	cg16766828	chr3:128327626	NA	0.4	8.88	0.33	6.96e-18	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.43	-0.32	2.27e-16	Monocyte percentage of white cells;
BRCA	cis	rs11051970	0.704	rs7312698	chr12:32554695	G/T	cg02745156	chr12:32552066	NA	0.25	8.47	0.32	1.68e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.12	0.4	2.24e-26	Bipolar disorder;
BRCA	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg06784218	chr1:46089804	CCDC17	0.45	10.81	0.39	3.85e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs708547	0.957	rs781667	chr4:57798469	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.47	10.83	0.39	3.17e-25	Response to bleomycin (chromatid breaks);
BRCA	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg24110177	chr3:50126178	RBM5	-0.51	-14.42	-0.5	4.93e-41	Body mass index;
BRCA	cis	rs9790314	0.663	rs55888276	chr3:160651406	A/G	cg03342759	chr3:160939853	NMD3	0.44	8.54	0.32	9.71e-17	Morning vs. evening chronotype;
BRCA	cis	rs11779988	0.545	rs431961	chr8:17786204	T/G	cg01800426	chr8:17659068	MTUS1	-0.4	-8.41	-0.32	2.77e-16	Breast cancer;
BRCA	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg16339924	chr4:17578868	LAP3	0.67	17.11	0.56	2.65e-54	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg05347473	chr6:146136440	FBXO30	-0.4	-7.91	-0.3	1.14e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg04450456	chr4:17643702	FAM184B	0.37	9.91	0.36	1.28e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg03188948	chr7:1209495	NA	0.57	10.82	0.39	3.57e-25	Longevity;Endometriosis;
BRCA	cis	rs28735056	0.967	rs56328473	chr18:77636101	C/T	cg20368463	chr18:77673604	PQLC1	-0.35	-8.06	-0.3	3.67e-15	Schizophrenia;
BRCA	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg22029157	chr1:209979665	IRF6	-0.4	-7.84	-0.3	1.83e-14	Cleft lip with or without cleft palate;
BRCA	trans	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.49	9.42	0.35	8.36e-20	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs365132	1.000	rs365132	chr5:176378574	G/T	cg16309518	chr5:176445507	NA	-0.52	-13.42	-0.47	2.36e-36	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12986413	0.624	rs2159213	chr19:2136102	T/C	cg09261902	chr19:2140048	AP3D1	0.41	10.81	0.39	4.02e-25	Height;
BRCA	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.43	-0.32	2.27e-16	Monocyte percentage of white cells;
BRCA	cis	rs3818285	0.544	rs9787456	chr10:111711822	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.41	-10.23	-0.38	7.66e-23	Superior crus of antihelix expression;
BRCA	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg09307838	chr4:120376055	NA	0.64	14.0	0.48	4.78e-39	Corneal astigmatism;
BRCA	cis	rs312274	0.550	rs11179040	chr12:41311370	T/G	cg17827154	chr12:41323612	CNTN1	-0.42	-10.5	-0.38	6.95e-24	Metabolite levels  (X-11787);
BRCA	cis	rs9341808	0.754	rs10806185	chr6:80954511	G/A	cg08355045	chr6:80787529	NA	0.39	9.86	0.36	1.97e-21	Sitting height ratio;
BRCA	cis	rs427394	0.802	rs274721	chr5:6719164	C/T	cg10857441	chr5:6722123	POLS	-0.33	-10.96	-0.4	1.03e-25	Menopause (age at onset);
BRCA	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg01528321	chr10:82214614	TSPAN14	0.67	14.22	0.49	4.49e-40	Post bronchodilator FEV1;
BRCA	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg10756475	chr4:1757242	NA	0.39	8.9	0.33	5.88e-18	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.45	8.44	0.32	2.12e-16	Multiple sclerosis;
BRCA	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg13256891	chr4:100009986	ADH5	-0.53	-9.91	-0.37	1.23e-21	Alcohol dependence;
BRCA	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg21770322	chr7:97807741	LMTK2	-0.43	-11.32	-0.41	3.23e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs524281	0.861	rs11227409	chr11:65870938	A/G	cg16950941	chr11:66035639	RAB1B	-0.38	-8.05	-0.3	4.15e-15	Electroencephalogram traits;
BRCA	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg01324343	chr3:183735012	ABCC5	0.67	15.74	0.53	1.94e-47	Anterior chamber depth;
BRCA	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.15e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9649465	1.000	rs608447	chr7:123395983	A/G	cg04330084	chr7:123175371	IQUB	0.31	8.41	0.32	2.62e-16	Migraine;
BRCA	cis	rs1506636	1.000	rs60689684	chr7:123370403	C/T	cg03229431	chr7:123269106	ASB15	0.63	13.06	0.46	1.06e-34	Plateletcrit;Platelet count;
BRCA	cis	rs4363385	0.597	rs55667413	chr1:152976849	G/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.31	-0.31	5.57e-16	Inflammatory skin disease;
BRCA	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-10.1	-0.37	2.37e-22	Body mass index;
BRCA	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg25427524	chr10:38739819	LOC399744	0.57	10.84	0.39	2.95e-25	Obesity (extreme);
BRCA	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18876405	chr7:65276391	NA	0.5	11.2	0.41	1.06e-26	Aortic root size;
BRCA	cis	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg06521331	chr12:34319734	NA	-0.43	-8.03	-0.3	4.55e-15	Resting heart rate;
BRCA	cis	rs2882667	0.858	rs11242447	chr5:138426173	T/C	cg04439458	chr5:138467593	SIL1	-0.43	-10.73	-0.39	8.6e-25	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg11833968	chr6:79620685	NA	-0.43	-9.59	-0.35	1.8899999999999998e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg26384229	chr12:38710491	ALG10B	-0.44	-10.15	-0.37	1.47e-22	Bladder cancer;
BRCA	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg22920501	chr2:26401640	FAM59B	-0.66	-11.48	-0.41	7.08e-28	Gut microbiome composition (summer);
BRCA	cis	rs868036	1.000	rs7168156	chr15:68102933	T/C	cg05925327	chr15:68127851	NA	-0.31	-7.9	-0.3	1.23e-14	Restless legs syndrome;
BRCA	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14019695	chr9:139328340	INPP5E	-0.42	-11.51	-0.41	5.19e-28	Monocyte percentage of white cells;
BRCA	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.05	29.57	0.76	9.6e-122	Cognitive ability;
BRCA	cis	rs10838687	0.736	rs2633083	chr11:47249420	T/C	cg25783544	chr11:47291846	MADD	-0.42	-7.92	-0.3	1.09e-14	Proinsulin levels;
BRCA	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6942756	0.806	rs2718096	chr7:128951000	A/G	cg02491457	chr7:128862824	NA	0.56	12.05	0.43	2.92e-30	White matter hyperintensity burden;
BRCA	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg05340658	chr4:99064831	C4orf37	-0.48	-11.15	-0.4	1.67e-26	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg05340658	chr4:99064831	C4orf37	0.56	11.14	0.4	1.86e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	12.67	0.45	5.85e-33	Ileal carcinoids;
BRCA	trans	rs78049276	0.688	rs56024659	chr4:148378604	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.47	-8.47	-0.32	1.65e-16	Pulse pressure;
BRCA	cis	rs6484504	0.576	rs158144	chr11:31211795	A/C	cg26647111	chr11:31128758	NA	-0.44	-9.58	-0.35	2.07e-20	Red blood cell count;
BRCA	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg05863683	chr7:1912471	MAD1L1	-0.37	-8.16	-0.31	1.83e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg00173435	chr12:106696525	TCP11L2	-0.55	-9.71	-0.36	7.11e-21	Tourette syndrome;
BRCA	cis	rs10751667	0.560	rs10902267	chr11:1007831	T/C	cg20946044	chr11:1010712	AP2A2	-0.37	-7.95	-0.3	8.63e-15	Alzheimer's disease (late onset);
BRCA	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-18.12	-0.58	1.55e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06221963	chr1:154839813	KCNN3	-0.56	-15.63	-0.53	7.06e-47	Prostate cancer;
BRCA	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.62	9.95	0.37	8.65e-22	Renal function-related traits (BUN);
BRCA	trans	rs4714291	0.963	rs12194361	chr6:40116264	T/G	cg02267698	chr19:7991119	CTXN1	-0.42	-8.14	-0.31	2.03e-15	Strep throat;
BRCA	cis	rs7903847	0.620	rs11189165	chr10:99123457	A/G	cg08345082	chr10:99160200	RRP12	-0.28	-8.04	-0.3	4.38e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg15448220	chr1:150897856	SETDB1	0.35	7.94	0.3	9.17e-15	Melanoma;
BRCA	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs3845702	0.673	rs12468986	chr2:180862320	T/G	cg01881094	chr2:180872142	CWC22	1.01	17.22	0.56	6.97e-55	Schizophrenia;
BRCA	cis	rs2637266	0.935	rs2579775	chr10:78401677	G/A	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	trans	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-7.81	-0.3	2.3e-14	Menarche (age at onset);
BRCA	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg24642439	chr20:33292090	TP53INP2	0.42	8.44	0.32	2.13e-16	Height;
BRCA	cis	rs1832871	0.655	rs6920121	chr6:158678504	C/T	cg07165851	chr6:158734300	TULP4	-0.62	-12.74	-0.45	2.62e-33	Height;
BRCA	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg08000102	chr2:233561755	GIGYF2	0.63	13.78	0.48	4.93e-38	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	2.03e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs62458065	0.640	rs10271491	chr7:32530665	C/A	cg20159608	chr7:32802032	NA	-0.45	-8.2	-0.31	1.37e-15	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg18196295	chr10:418757	DIP2C	0.4	9.18	0.34	6.02e-19	Psychosis in Alzheimer's disease;
BRCA	cis	rs12545109	0.800	rs1437278	chr8:57357024	T/C	cg09654669	chr8:57350985	NA	-0.43	-8.11	-0.31	2.64e-15	Obesity-related traits;
BRCA	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg07211511	chr3:129823064	LOC729375	-1.05	-18.49	-0.59	1.78e-61	Blood pressure (smoking interaction);
BRCA	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg03060546	chr3:49711283	APEH	0.58	10.07	0.37	2.95e-22	Menarche (age at onset);
BRCA	cis	rs2204008	0.743	rs11495614	chr12:38156358	C/T	cg26384229	chr12:38710491	ALG10B	0.73	15.58	0.52	1.26e-46	Bladder cancer;
BRCA	cis	rs67981189	0.896	rs917065	chr14:71397846	G/A	cg15816911	chr14:71606274	NA	-0.37	-8.23	-0.31	1.04e-15	Schizophrenia;
BRCA	cis	rs7572733	0.534	rs1589162	chr2:198782692	A/G	cg00792783	chr2:198669748	PLCL1	0.46	9.87	0.36	1.82e-21	Dermatomyositis;
BRCA	cis	rs6782228	0.675	rs4443194	chr3:128383446	T/A	cg16766828	chr3:128327626	NA	-0.44	-9.67	-0.36	9.88e-21	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg07636037	chr3:49044803	WDR6	0.97	29.54	0.76	1.35e-121	Parkinson's disease;
BRCA	trans	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg04565464	chr8:145669602	NFKBIL2	0.45	10.76	0.39	6.42e-25	Schizophrenia;
BRCA	cis	rs7127129	0.503	rs1131715	chr11:70053487	C/T	cg06159181	chr11:70072977	NA	-0.32	-7.84	-0.3	1.83e-14	Aortic root size;
BRCA	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg23933602	chr10:16859644	RSU1	-0.97	-32.14	-0.79	1.42e-135	Platelet distribution width;
BRCA	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18357526	chr6:26021779	HIST1H4A	0.47	8.72	0.33	2.35e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg14926445	chr8:58193284	C8orf71	-0.44	-8.41	-0.32	2.72e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26314531	chr2:26401878	FAM59B	0.69	11.55	0.42	3.74e-28	Gut microbiome composition (summer);
BRCA	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg25427524	chr10:38739819	LOC399744	-0.66	-13.56	-0.47	5.38e-37	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg27600084	chr12:12264075	NA	0.39	8.82	0.33	1.05e-17	Breast size;
BRCA	cis	rs4566357	0.595	rs1320406	chr2:227920474	C/T	cg05526886	chr2:227700861	RHBDD1	-0.39	-7.9	-0.3	1.25e-14	Coronary artery disease;
BRCA	cis	rs713587	0.563	rs7591460	chr2:25103967	A/C	cg04586622	chr2:25135609	ADCY3	0.45	11.54	0.42	4.22e-28	Body mass index in non-asthmatics;
BRCA	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg21918786	chr6:109611834	NA	-0.49	-14.04	-0.49	3.1e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs4728302	0.608	rs10254118	chr7:133158353	T/A	cg10665199	chr7:133106180	EXOC4	0.47	10.09	0.37	2.51e-22	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg20476274	chr7:133979776	SLC35B4	0.7	21.43	0.65	3.66e-77	Mean platelet volume;
BRCA	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg22535103	chr8:58192502	C8orf71	-0.44	-8.87	-0.33	7.16e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.49	0.5	2.37e-41	Motion sickness;
BRCA	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.49e-34	Alzheimer's disease (late onset);
BRCA	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.33	0.54	2.37e-50	Hypertriglyceridemia;
BRCA	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.33	9.25	0.34	3.24e-19	Response to antipsychotic treatment;
BRCA	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg10857441	chr5:6722123	POLS	-0.31	-9.76	-0.36	4.63e-21	Menopause (age at onset);
BRCA	trans	rs4819388	0.650	rs8127114	chr21:45644504	T/C	cg17383793	chr5:52405638	MOCS2	0.48	10.65	0.39	1.7e-24	Celiac disease;
BRCA	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg15242686	chr22:24348715	GSTTP1	0.37	9.01	0.34	2.27e-18	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.62	14.35	0.49	1.09e-40	Platelet count;
BRCA	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg19077165	chr18:44547161	KATNAL2	0.54	11.71	0.42	7.7e-29	Personality dimensions;
BRCA	cis	rs6142102	0.602	rs4911402	chr20:32667645	A/G	cg24642439	chr20:33292090	TP53INP2	0.39	7.82	0.3	2.24e-14	Skin pigmentation;
BRCA	trans	rs28735056	0.903	rs56185453	chr18:77638297	A/G	cg05926928	chr17:57297772	GDPD1	-0.52	-10.55	-0.39	4.12e-24	Schizophrenia;
BRCA	cis	rs1451375	0.669	rs4469404	chr7:50647062	C/T	cg18232548	chr7:50535776	DDC	-0.38	-8.75	-0.33	1.87e-17	Malaria;
BRCA	cis	rs6484504	0.600	rs2616815	chr11:31327316	C/T	cg26647111	chr11:31128758	NA	0.45	9.65	0.36	1.18e-20	Red blood cell count;
BRCA	trans	rs2018683	0.624	rs1006521	chr7:28996220	G/A	cg19402173	chr7:128379420	CALU	-0.47	-11.2	-0.41	9.97e-27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg00071950	chr4:10020882	SLC2A9	0.65	16.24	0.54	6.46e-50	Bone mineral density;
BRCA	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg24812749	chr6:127587940	RNF146	0.89	20.97	0.64	1.08e-74	Breast cancer;
BRCA	cis	rs427394	0.796	rs274683	chr5:6747950	T/A	cg10857441	chr5:6722123	POLS	-0.29	-9.36	-0.35	1.32e-19	Menopause (age at onset);
BRCA	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg23791538	chr6:167370224	RNASET2	-0.48	-11.84	-0.42	2.13e-29	Crohn's disease;
BRCA	cis	rs7586879	0.828	rs10195271	chr2:25108650	A/C	cg04586622	chr2:25135609	ADCY3	-0.4	-9.59	-0.35	1.9e-20	Body mass index;
BRCA	cis	rs10227331	0.617	rs55977076	chr7:157301739	A/G	cg04156418	chr7:157293606	NA	0.32	9.06	0.34	1.51e-18	Inattentive symptoms;
BRCA	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg09877947	chr5:131593287	PDLIM4	-0.37	-8.11	-0.31	2.51e-15	Breast cancer;
BRCA	cis	rs877529	1.000	rs139388	chr22:39531732	C/G	cg12193277	chr22:39547181	CBX7	0.46	12.76	0.45	2.24e-33	Multiple myeloma;
BRCA	cis	rs870825	0.616	rs41278579	chr4:185622402	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	16.4	0.54	1.05e-50	Blood protein levels;
BRCA	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg14820908	chr5:178986412	RUFY1	0.5	13.33	0.47	5.9e-36	Lung cancer;
BRCA	cis	rs360798	0.512	rs34104251	chr2:62995183	A/G	cg17519650	chr2:63277830	OTX1	-0.36	-7.95	-0.3	8.79e-15	Coronary artery disease;
BRCA	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	14.81	0.51	7.16e-43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3771570	0.901	rs4675944	chr2:242430170	C/T	cg21155796	chr2:242212141	HDLBP	0.53	8.74	0.33	2.04e-17	Prostate cancer;
BRCA	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	9.26	0.34	3.05e-19	Tonsillectomy;
BRCA	cis	rs6878727	0.626	rs183164	chr5:123670448	A/G	cg01806427	chr5:123737813	NA	-0.37	-8.43	-0.32	2.21e-16	Breast cancer;
BRCA	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.71	-0.33	2.55e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.59	-0.42	2.6e-28	Personality dimensions;
BRCA	cis	rs2267137	0.903	rs715494	chr22:29782433	G/T	cg07256473	chr22:29710276	RASL10A	-0.34	-8.14	-0.31	2.12e-15	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg15934090	chr1:100435551	SLC35A3	0.36	8.43	0.32	2.38e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg03060546	chr3:49711283	APEH	0.59	10.23	0.37	7.84e-23	Menarche (age at onset);
BRCA	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.62	-13.09	-0.46	7.81e-35	Lung cancer;
BRCA	cis	rs7616215	0.519	rs2133664	chr3:46101774	T/A	cg08033130	chr3:45983597	CXCR6;FYCO1	0.3	8.03	0.3	4.63e-15	Behcet's disease;
BRCA	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg17143192	chr8:8559678	CLDN23	0.52	10.05	0.37	3.82e-22	Obesity-related traits;
BRCA	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06544989	chr22:39130855	UNC84B	0.35	7.98	0.3	6.85e-15	Menopause (age at onset);
BRCA	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.55	8.21	0.31	1.24e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	12.33	0.44	1.81e-31	Platelet count;
BRCA	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg21573476	chr21:45109991	RRP1B	-0.37	-9.42	-0.35	8.28e-20	Mean corpuscular volume;
BRCA	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.6	-0.35	1.82e-20	Alzheimer's disease;
BRCA	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11764359	chr7:65958608	NA	0.74	16.0	0.53	1.01e-48	Aortic root size;
BRCA	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg05283184	chr6:79620031	NA	-0.43	-10.91	-0.4	1.56e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg23711669	chr6:146136114	FBXO30	-0.78	-18.65	-0.59	2.56e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06558623	chr16:89946397	TCF25	0.65	11.86	0.42	1.76e-29	Skin colour saturation;
BRCA	cis	rs3845702	0.736	rs72962575	chr2:180862133	C/G	cg01881094	chr2:180872142	CWC22	1.01	17.22	0.56	6.97e-55	Schizophrenia;
BRCA	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg13010199	chr12:38710504	ALG10B	0.52	10.88	0.4	2.06e-25	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg09455208	chr3:40491958	NA	0.4	9.57	0.35	2.32e-20	Renal cell carcinoma;
BRCA	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg15133208	chr4:90757351	SNCA	-0.38	-7.85	-0.3	1.73e-14	Neuroticism;
BRCA	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.36	9.34	0.35	1.58e-19	IgG glycosylation;
BRCA	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg26384229	chr12:38710491	ALG10B	0.43	9.53	0.35	3.15e-20	Morning vs. evening chronotype;
BRCA	cis	rs8005677	1.000	rs1956880	chr14:23394007	A/G	cg01529538	chr14:23388837	RBM23	0.42	11.39	0.41	1.73e-27	Cognitive ability (multi-trait analysis);
BRCA	cis	rs7582720	1.000	rs72936332	chr2:204056678	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	12.22	0.44	5.16e-31	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg23708337	chr7:1209742	NA	0.6	8.29	0.31	6.64e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg15123519	chr2:136567270	LCT	-0.32	-8.0	-0.3	5.69e-15	Mosquito bite size;
BRCA	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.46	-8.69	-0.33	3.03e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg13010199	chr12:38710504	ALG10B	0.59	12.95	0.46	3.28e-34	Heart rate;
BRCA	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.52	-11.78	-0.42	3.89e-29	Longevity;Endometriosis;
BRCA	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg08999081	chr20:33150536	PIGU	0.35	8.92	0.33	5.02e-18	Coronary artery disease;
BRCA	cis	rs965469	0.619	rs6037565	chr20:3330308	T/C	cg25506879	chr20:3388711	C20orf194	-0.43	-8.74	-0.33	2.11e-17	IFN-related cytopenia;
BRCA	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg19622623	chr12:86230825	RASSF9	0.33	9.44	0.35	6.68e-20	Major depressive disorder;
BRCA	cis	rs897984	0.553	rs2335013	chr16:30877346	T/G	cg02466173	chr16:30829666	NA	0.45	9.19	0.34	5.24e-19	Dementia with Lewy bodies;
BRCA	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	19.25	0.61	1.87e-65	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	10.65	0.39	1.7e-24	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg18876405	chr7:65276391	NA	0.44	8.58	0.32	7.45e-17	Corneal structure;
BRCA	cis	rs698833	0.561	rs698820	chr2:44716323	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	8.17	0.31	1.62e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg20307385	chr11:47447363	PSMC3	0.83	20.76	0.63	1.48e-73	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg00666640	chr1:248458726	OR2T12	0.3	8.42	0.32	2.5e-16	Common traits (Other);
BRCA	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.75	12.18	0.43	7.6e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7633770	0.735	rs4683271	chr3:46684823	A/G	cg11219411	chr3:46661640	NA	-0.56	-13.39	-0.47	3.32e-36	Coronary artery disease;
BRCA	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg14784868	chr12:69753453	YEATS4	0.68	19.91	0.62	5.54e-69	Blood protein levels;
BRCA	cis	rs7572733	0.534	rs1983359	chr2:198805098	C/T	cg00792783	chr2:198669748	PLCL1	0.45	9.94	0.37	9.5e-22	Dermatomyositis;
BRCA	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg20203395	chr5:56204925	C5orf35	-0.49	-9.91	-0.36	1.25e-21	Initial pursuit acceleration;
BRCA	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg22834771	chr12:69754056	YEATS4	0.39	9.88	0.36	1.63e-21	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg15556689	chr8:8085844	FLJ10661	0.36	9.54	0.35	2.83e-20	Joint mobility (Beighton score);
BRCA	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.23e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs9796	0.621	rs28737302	chr15:41469943	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.36	-7.84	-0.3	1.89e-14	Menopause (age at onset);
BRCA	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg14683738	chr19:37701593	ZNF585B	0.44	7.9	0.3	1.22e-14	Coronary artery calcification;
BRCA	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	16.11	0.54	2.99e-49	Fuchs's corneal dystrophy;
BRCA	cis	rs4919694	1.000	rs35159404	chr10:104805610	C/A	cg04362960	chr10:104952993	NT5C2	0.94	14.4	0.5	6.33e-41	Arsenic metabolism;
BRCA	cis	rs2479724	0.846	rs2488338	chr6:41808351	A/G	cg17623882	chr6:41773611	USP49	-0.34	-9.17	-0.34	6.64e-19	Menarche (age at onset);
BRCA	trans	rs8002861	0.935	rs1819595	chr13:44429716	T/A	cg17145862	chr1:211918768	LPGAT1	0.68	17.84	0.58	4.56e-58	Leprosy;
BRCA	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18404041	chr3:52824283	ITIH1	-0.43	-12.98	-0.46	2.29e-34	Bipolar disorder;
BRCA	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24549020	chr5:56110836	MAP3K1	0.6	12.27	0.44	3.19e-31	Initial pursuit acceleration;
BRCA	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg00666640	chr1:248458726	OR2T12	0.33	9.04	0.34	1.79e-18	Common traits (Other);
BRCA	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg12573674	chr2:1569213	NA	-0.5	-9.47	-0.35	5.24e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.45	0.55	5.6e-51	Colorectal cancer;
BRCA	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg25358565	chr5:93447407	FAM172A	1.17	18.51	0.59	1.49e-61	Diabetic retinopathy;
BRCA	cis	rs3845702	1.000	rs3768839	chr2:180835992	G/A	cg01881094	chr2:180872142	CWC22	-0.66	-12.6	-0.45	1.17e-32	Schizophrenia;
BRCA	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.55	-9.69	-0.36	8.18e-21	Body mass index (adult);
BRCA	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.68	-12.11	-0.43	1.6e-30	Lung cancer in ever smokers;
BRCA	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg20628663	chr10:43360327	NA	-0.7	-13.59	-0.47	4.08e-37	Blood protein levels;
BRCA	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg09904177	chr6:26538194	HMGN4	0.55	17.67	0.57	3.26e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg08085267	chr17:45401833	C17orf57	0.57	11.76	0.42	4.79e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg23029597	chr12:123009494	RSRC2	-0.6	-11.54	-0.42	4.25e-28	Body mass index;
BRCA	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg04034577	chr2:241836375	C2orf54	-0.57	-14.0	-0.48	4.88e-39	Urinary metabolites;
BRCA	trans	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg15556689	chr8:8085844	FLJ10661	-0.33	-8.42	-0.32	2.39e-16	Triglycerides;
BRCA	cis	rs7945718	0.806	rs7480572	chr11:12787048	T/C	cg25843174	chr11:12811716	TEAD1	0.23	9.06	0.34	1.6e-18	Educational attainment (years of education);
BRCA	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg16386425	chr10:429943	DIP2C	0.42	8.35	0.31	4.21e-16	Psychosis in Alzheimer's disease;
BRCA	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	26.42	0.72	1.58e-104	Chronic sinus infection;
BRCA	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg13256891	chr4:100009986	ADH5	-0.53	-9.87	-0.36	1.82e-21	Alcohol dependence;
BRCA	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs9942416	0.660	rs4704231	chr5:74986576	G/A	cg19683494	chr5:74908142	NA	0.48	9.0	0.34	2.47e-18	Age-related disease endophenotypes;
BRCA	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg23173402	chr1:227635558	NA	0.5	9.18	0.34	5.68e-19	Major depressive disorder;
BRCA	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg24578937	chr1:2090814	PRKCZ	0.33	10.48	0.38	7.83e-24	Height;
BRCA	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg13119609	chr19:45449297	APOC2	0.47	13.08	0.46	8.51e-35	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg12444411	chr7:2802554	GNA12	-0.36	-8.98	-0.33	2.9e-18	Height;
BRCA	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6684428	1.000	rs12141666	chr1:56370556	T/C	cg11651538	chr1:56320950	NA	-0.46	-7.81	-0.3	2.32e-14	Airflow obstruction;
BRCA	cis	rs6977660	0.714	rs4719587	chr7:19828174	C/G	cg05791153	chr7:19748676	TWISTNB	0.54	10.12	0.37	2.02e-22	Thyroid stimulating hormone;
BRCA	cis	rs698833	0.828	rs1067341	chr2:44623687	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	9.47	0.35	5.17e-20	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg16482183	chr6:26056742	HIST1H1C	0.49	9.66	0.36	1.1e-20	Iron status biomarkers;
BRCA	cis	rs4742903	1.000	rs7350148	chr9:106883085	T/G	cg21169611	chr9:106856078	SMC2	0.35	9.08	0.34	1.29e-18	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg07741184	chr6:167504864	NA	0.31	9.33	0.35	1.73e-19	Crohn's disease;
BRCA	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg02017074	chr12:117425053	FBXW8	0.55	10.24	0.38	7.15e-23	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.92	14.07	0.49	2.34e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg06085985	chr11:830527	EFCAB4A	-0.41	-9.24	-0.34	3.48e-19	Mean platelet volume;
BRCA	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg18225595	chr11:63971243	STIP1	0.51	9.46	0.35	5.83e-20	Mean platelet volume;
BRCA	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg03188948	chr7:1209495	NA	0.45	8.3	0.31	6.08e-16	Longevity;Endometriosis;
BRCA	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg01017244	chr2:74357527	NA	0.57	13.23	0.46	1.78e-35	Gestational age at birth (maternal effect);
BRCA	trans	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg13565492	chr6:43139072	SRF	-0.56	-10.06	-0.37	3.24e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg17712092	chr4:129076599	LARP1B	-0.5	-10.89	-0.4	1.83e-25	Breast cancer;
BRCA	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg19077165	chr18:44547161	KATNAL2	-0.58	-12.87	-0.45	7e-34	Personality dimensions;
BRCA	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg19653624	chr11:20408972	PRMT3	-0.44	-10.13	-0.37	1.83e-22	Pursuit maintenance gain;
BRCA	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg24692254	chr21:30365293	RNF160	-0.62	-15.86	-0.53	5.2e-48	Dental caries;
BRCA	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	trans	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.48	-10.12	-0.37	1.93e-22	Mean corpuscular volume;
BRCA	cis	rs7077164	1.000	rs1227769	chr10:71586296	C/T	cg07630274	chr10:71583235	COL13A1	-0.25	-8.06	-0.3	3.72e-15	Non-alcoholic fatty liver disease histology (lobular);
BRCA	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.68	-0.42	1.08e-28	Gut microbiome composition (summer);
BRCA	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg03342759	chr3:160939853	NMD3	-0.53	-11.24	-0.41	7.01e-27	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.13	-0.34	8.58e-19	Total body bone mineral density;
BRCA	trans	rs1973993	0.934	rs588660	chr1:96886604	G/A	cg10631902	chr5:14652156	NA	0.51	15.88	0.53	4.3e-48	Weight;
BRCA	cis	rs10992471	0.528	rs10992347	chr9:95220633	C/A	cg14631576	chr9:95140430	CENPP	-0.35	-8.85	-0.33	8.49e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs8017423	1.000	rs769044	chr14:90671138	A/G	cg04374321	chr14:90722782	PSMC1	0.71	18.69	0.59	1.6e-62	Mortality in heart failure;
BRCA	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.48	0.38	8.25e-24	Motion sickness;
BRCA	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg07080220	chr10:102295463	HIF1AN	0.56	13.14	0.46	4.42e-35	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg06521331	chr12:34319734	NA	-0.47	-8.75	-0.33	1.86e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9341808	0.690	rs9448909	chr6:80909031	G/A	cg08355045	chr6:80787529	NA	0.39	9.95	0.37	8.61e-22	Sitting height ratio;
BRCA	cis	rs3771570	1.000	rs62193205	chr2:242316512	C/T	cg21155796	chr2:242212141	HDLBP	0.6	9.2	0.34	5.1e-19	Prostate cancer;
BRCA	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23978390	chr7:1156363	C7orf50	0.48	11.54	0.42	4.16e-28	Longevity;Endometriosis;
BRCA	cis	rs9290065	0.519	rs6763532	chr3:160701816	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-9.95	-0.37	9.17e-22	Kawasaki disease;
BRCA	cis	rs7524258	0.903	rs4908449	chr1:7292700	T/C	cg07173049	chr1:7289937	CAMTA1	0.55	13.56	0.47	5.59e-37	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs698833	0.886	rs2304770	chr2:44569328	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	11.41	0.41	1.37e-27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.49	-0.44	3.53e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs10465746	0.725	rs4907185	chr1:84336047	T/C	cg10977910	chr1:84465055	TTLL7	0.61	13.16	0.46	3.51e-35	Obesity-related traits;
BRCA	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg23033748	chr14:75592666	NEK9	0.44	10.51	0.38	5.92e-24	Height;
BRCA	cis	rs1003719	0.715	rs35199609	chr21:38510262	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.19	-0.49	6.3e-40	Eye color traits;
BRCA	cis	rs698833	0.892	rs698831	chr2:44731117	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	9.61	0.36	1.63e-20	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.13	0.56	2.16e-54	Fuchs's corneal dystrophy;
BRCA	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg01262667	chr19:19385393	TM6SF2	0.42	11.18	0.4	1.31e-26	Tonsillectomy;
BRCA	cis	rs16866061	1.000	rs11688397	chr2:225393173	C/T	cg12698349	chr2:225449008	CUL3	0.78	21.23	0.64	4.3e-76	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg25036284	chr2:26402008	FAM59B	-0.64	-10.67	-0.39	1.39e-24	Gut microbiome composition (summer);
BRCA	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg27129171	chr3:47204927	SETD2	0.65	14.27	0.49	2.61e-40	Birth weight;
BRCA	cis	rs897080	0.552	rs1067388	chr2:44642482	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.45	0.35	6.32e-20	Height;
BRCA	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.36	-9.13	-0.34	8.95e-19	Total body bone mineral density;
BRCA	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.53	-0.35	3.1e-20	Total body bone mineral density;
BRCA	cis	rs2742417	0.603	rs2673032	chr3:45756927	C/T	cg04837898	chr3:45731254	SACM1L	-0.4	-8.15	-0.31	1.87e-15	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs3892630	0.878	rs8112955	chr19:33191192	C/T	cg22980127	chr19:33182716	NUDT19	0.9	18.06	0.58	3.08e-59	Red blood cell traits;
BRCA	cis	rs9341808	1.000	rs1359239	chr6:80956146	G/A	cg08355045	chr6:80787529	NA	0.35	9.21	0.34	4.55e-19	Sitting height ratio;
BRCA	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.42e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.9	0.36	1.36e-21	Bipolar disorder;
BRCA	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg21535247	chr6:8435926	SLC35B3	0.41	9.45	0.35	6.39e-20	Motion sickness;
BRCA	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg16606324	chr3:10149918	C3orf24	0.58	10.26	0.38	5.81e-23	Alzheimer's disease;
BRCA	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg00106254	chr7:1943704	MAD1L1	-0.34	-8.45	-0.32	2.01e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.33	8.44	0.32	2.16e-16	IgG glycosylation;
BRCA	cis	rs9533799	0.966	rs7999368	chr13:44807184	G/A	cg19190762	chr13:44806055	NA	0.41	9.02	0.34	2.17e-18	Amyotrophic lateral sclerosis;
BRCA	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg16405210	chr4:1374714	KIAA1530	0.36	8.01	0.3	5.34e-15	Obesity-related traits;
BRCA	cis	rs2764980	1.000	rs2814925	chr10:3284061	A/G	cg18054281	chr10:3284093	NA	-0.31	-7.89	-0.3	1.33e-14	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	0.31	8.0	0.3	6e-15	Total body bone mineral density;
BRCA	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11764359	chr7:65958608	NA	0.62	13.59	0.47	4.03e-37	Aortic root size;
BRCA	cis	rs7043114	0.507	rs6479420	chr9:95116406	T/C	cg14631576	chr9:95140430	CENPP	-0.34	-8.29	-0.31	6.8e-16	Height;
BRCA	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg08742575	chr21:47604166	C21orf56	0.39	7.88	0.3	1.4e-14	Testicular germ cell tumor;
BRCA	cis	rs965469	0.779	rs6037515	chr20:3233091	C/A	cg25506879	chr20:3388711	C20orf194	-0.43	-8.68	-0.32	3.38e-17	IFN-related cytopenia;
BRCA	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-9.96	-0.37	8.41e-22	Personality dimensions;
BRCA	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg23533926	chr12:111358616	MYL2	-0.44	-9.18	-0.34	5.78e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg08917208	chr2:24149416	ATAD2B	0.56	8.64	0.32	4.38e-17	Lymphocyte counts;
BRCA	trans	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg26043149	chr18:55253948	FECH	-0.37	-8.14	-0.31	2.06e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg20848291	chr7:100343083	ZAN	-0.59	-11.31	-0.41	3.79e-27	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.47	7.95	0.3	8.55e-15	Height;
BRCA	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg25554036	chr4:6271136	WFS1	0.39	9.3	0.35	2.22e-19	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.05	-0.34	1.65e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg03342759	chr3:160939853	NMD3	-0.67	-14.7	-0.5	2.31e-42	Morning vs. evening chronotype;
BRCA	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg08132940	chr7:1081526	C7orf50	-0.6	-8.99	-0.34	2.69e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg03433033	chr1:76189801	ACADM	0.71	13.81	0.48	3.58e-38	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs743757	0.762	rs12491425	chr3:50575312	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.34	-8.08	-0.3	3.18e-15	Diastolic blood pressure;
BRCA	cis	rs12618769	0.597	rs4850876	chr2:99112069	C/T	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.05	0.3	3.98e-15	Breast cancer;
BRCA	cis	rs4948102	0.642	rs4948104	chr7:56142519	A/G	cg09872392	chr7:56161020	PHKG1	-0.5	-12.53	-0.44	2.34e-32	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg16339924	chr4:17578868	LAP3	0.6	14.48	0.5	2.65e-41	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2554380	0.943	rs2585049	chr15:84352873	A/C	cg14598478	chr15:84363061	ADAMTSL3	0.32	8.1	0.31	2.7e-15	Height;
BRCA	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg07395648	chr5:131743802	NA	-0.36	-7.99	-0.3	6.09e-15	Breast cancer;
BRCA	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg00677455	chr12:58241039	CTDSP2	-0.35	-7.96	-0.3	7.8e-15	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg07636037	chr3:49044803	WDR6	0.97	29.45	0.76	4.14e-121	Parkinson's disease;
BRCA	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg04607235	chr12:12878440	APOLD1	-0.56	-8.96	-0.33	3.42e-18	Systemic lupus erythematosus;
BRCA	cis	rs9487051	0.735	rs351756	chr6:109538773	A/G	cg01475377	chr6:109611718	NA	0.45	11.18	0.4	1.22e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-12.49	-0.44	3.46e-32	Bipolar disorder;
BRCA	cis	rs6840360	0.533	rs13119490	chr4:152713412	A/G	cg22705602	chr4:152727874	NA	0.4	10.57	0.39	3.45e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs365132	0.875	rs353496	chr5:176429898	T/C	cg16309518	chr5:176445507	NA	-0.4	-9.73	-0.36	5.73e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs6426558	0.537	rs2718193	chr1:227404672	C/G	cg10327440	chr1:227177885	CDC42BPA	0.43	8.41	0.32	2.74e-16	Neutrophil percentage of white cells;
BRCA	cis	rs666930	1.000	rs666930	chr1:120258970	A/G	cg19096424	chr1:120255104	PHGDH	0.37	8.77	0.33	1.64e-17	Breast cancer;
BRCA	cis	rs7512552	0.839	rs1260459	chr1:150348253	T/G	cg15654264	chr1:150340011	RPRD2	0.38	8.44	0.32	2.06e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg12373951	chr3:133503437	NA	0.33	7.9	0.3	1.21e-14	Iron status biomarkers;
BRCA	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg14664628	chr15:75095509	CSK	-0.59	-14.53	-0.5	1.59e-41	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	8.86	0.33	7.98e-18	Iron status biomarkers;
BRCA	cis	rs55883249	0.957	rs62119431	chr2:9750461	G/A	cg23886495	chr2:9695866	ADAM17	0.55	7.86	0.3	1.59e-14	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
BRCA	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg05283184	chr6:79620031	NA	-0.36	-8.35	-0.31	4.12e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg25358565	chr5:93447407	FAM172A	1.2	19.24	0.61	2.01e-65	Diabetic retinopathy;
BRCA	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24531977	chr5:56204891	C5orf35	0.71	15.67	0.53	4.4e-47	Initial pursuit acceleration;
BRCA	cis	rs1355223	0.506	rs1828299	chr11:34870418	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-9.38	-0.35	1.1e-19	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs3768617	0.811	rs10911233	chr1:183052585	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.46	10.14	0.37	1.61e-22	Fuchs's corneal dystrophy;
BRCA	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg20578329	chr17:80767326	TBCD	-0.57	-9.18	-0.34	6.04e-19	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
BRCA	trans	rs1997103	0.871	rs1997100	chr7:55399656	C/G	cg20935933	chr6:143382018	AIG1	0.6	11.52	0.41	4.77e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.55e-18	Motion sickness;
BRCA	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.38	-0.31	3.3e-16	Breast cancer;
BRCA	trans	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg06521331	chr12:34319734	NA	-0.46	-8.53	-0.32	1.08e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-13.51	-0.47	8.94e-37	Bipolar disorder and schizophrenia;
BRCA	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg10253484	chr15:75165896	SCAMP2	0.47	8.53	0.32	1.07e-16	Systemic lupus erythematosus;
BRCA	trans	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.66	-0.36	1.07e-20	Bladder cancer;
BRCA	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.79	0.42	3.73e-29	Homoarginine levels;
BRCA	cis	rs10267417	0.603	rs10233354	chr7:19895372	C/T	cg07541023	chr7:19748670	TWISTNB	0.46	8.32	0.31	5.3e-16	Night sleep phenotypes;
BRCA	cis	rs1371614	0.589	rs4665919	chr2:27115304	T/C	cg12368169	chr2:27073192	DPYSL5	-0.29	-8.41	-0.32	2.61e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-11.73	-0.42	6.35e-29	Monocyte count;
BRCA	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg26408565	chr15:76604113	ETFA	-0.36	-7.8	-0.3	2.44e-14	Blood metabolite levels;
BRCA	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg06784218	chr1:46089804	CCDC17	0.46	10.93	0.4	1.34e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3771570	0.786	rs62186396	chr2:242221219	A/G	cg21155796	chr2:242212141	HDLBP	0.62	9.75	0.36	4.91e-21	Prostate cancer;
BRCA	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg20503657	chr10:835505	NA	0.9	13.79	0.48	4.67e-38	Eosinophil percentage of granulocytes;
BRCA	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-7.88	-0.3	1.42e-14	Axial length;
BRCA	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg11887960	chr12:57824829	NA	0.52	8.12	0.31	2.34e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg21905437	chr5:178450457	ZNF879	0.51	10.64	0.39	1.95e-24	Pubertal anthropometrics;
BRCA	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18876405	chr7:65276391	NA	-0.51	-11.69	-0.42	9.89e-29	Aortic root size;
BRCA	trans	rs8002861	0.810	rs9533664	chr13:44440527	T/C	cg17145862	chr1:211918768	LPGAT1	0.63	16.32	0.54	2.68e-50	Leprosy;
BRCA	cis	rs17490626	0.533	rs12771890	chr10:71189483	T/A	cg12610070	chr10:71211762	TSPAN15	-0.33	-10.47	-0.38	8.7e-24	Thrombosis;
BRCA	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg07606381	chr6:8435919	SLC35B3	0.66	14.38	0.49	8.22e-41	Motion sickness;
BRCA	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg22800045	chr5:56110881	MAP3K1	-0.47	-9.34	-0.35	1.54e-19	Initial pursuit acceleration;
BRCA	cis	rs8032158	0.963	rs11071231	chr15:56159118	A/C	cg02198044	chr15:56286336	NEDD4	-0.37	-8.93	-0.33	4.47e-18	Keloid;
BRCA	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	18.6	0.59	4.85e-62	Platelet count;
BRCA	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14240646	chr10:27532245	ACBD5	-0.62	-9.58	-0.35	2.13e-20	Breast cancer;
BRCA	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg13393036	chr8:95962371	TP53INP1	0.31	8.33	0.31	5.05e-16	Type 2 diabetes;
BRCA	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg01528321	chr10:82214614	TSPAN14	-1.09	-23.48	-0.68	2.22e-88	Post bronchodilator FEV1;
BRCA	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.36	0.44	1.23e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg11502198	chr6:26597334	ABT1	-0.54	-11.52	-0.41	4.99e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	15.56	0.52	1.59e-46	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg05714579	chr10:131428358	MGMT	-0.52	-11.75	-0.42	5.53e-29	Response to temozolomide;
BRCA	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06636551	chr8:101224915	SPAG1	-0.38	-8.72	-0.33	2.39e-17	Atrioventricular conduction;
BRCA	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg26384229	chr12:38710491	ALG10B	0.48	11.69	0.42	9.48e-29	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.6	0.55	9.67e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-8.87	-0.33	7.39e-18	Monocyte percentage of white cells;
BRCA	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg19784903	chr17:45786737	TBKBP1	-0.35	-8.17	-0.31	1.62e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg07080220	chr10:102295463	HIF1AN	0.62	13.42	0.47	2.41e-36	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.85	-14.92	-0.51	2.05e-43	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg26384229	chr12:38710491	ALG10B	0.46	11.66	0.42	1.3e-28	Morning vs. evening chronotype;
BRCA	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg00701064	chr4:6280414	WFS1	0.68	17.7	0.57	2.54e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg02524346	chr8:600233	NA	-0.78	-8.82	-0.33	1.09e-17	IgG glycosylation;
BRCA	cis	rs4363385	0.818	rs3795382	chr1:153004853	C/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.59	-0.32	6.84e-17	Inflammatory skin disease;
BRCA	cis	rs12545109	0.800	rs2609978	chr8:57394467	T/C	cg09654669	chr8:57350985	NA	-0.42	-8.03	-0.3	4.6e-15	Obesity-related traits;
BRCA	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg03342759	chr3:160939853	NMD3	-0.7	-14.09	-0.49	1.85e-39	Parkinson's disease;
BRCA	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg15395560	chr15:45543142	SLC28A2	0.3	8.3	0.31	6.2e-16	Uric acid levels;
BRCA	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg26031613	chr14:104095156	KLC1	-0.65	-14.04	-0.49	3.08e-39	Body mass index;
BRCA	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg15395560	chr15:45543142	SLC28A2	0.29	8.21	0.31	1.22e-15	Uric acid levels;
BRCA	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg19257562	chr1:2043853	PRKCZ	0.36	9.87	0.36	1.73e-21	Height;
BRCA	trans	rs2018683	0.834	rs733485	chr7:29026685	C/A	cg19402173	chr7:128379420	CALU	-0.49	-12.16	-0.43	9.52e-31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg03462622	chr3:195777018	TFRC	-0.39	-8.9	-0.33	5.87e-18	Mean corpuscular volume;
BRCA	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00166722	chr3:10149974	C3orf24	0.65	12.78	0.45	1.74e-33	Alzheimer's disease;
BRCA	cis	rs738322	0.600	rs6001030	chr22:38555904	T/G	cg20207973	chr22:38506712	BAIAP2L2	0.35	8.48	0.32	1.59e-16	Cutaneous nevi;
BRCA	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.55	-0.42	3.66e-28	Platelet count;
BRCA	cis	rs4919087	0.962	rs10748691	chr10:98983955	C/T	cg25902810	chr10:99078978	FRAT1	0.41	8.77	0.33	1.68e-17	Monocyte count;
BRCA	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg24562669	chr7:97807699	LMTK2	-0.52	-14.61	-0.5	6.13e-42	Breast cancer;
BRCA	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.8	-0.33	1.32e-17	Mood instability;
BRCA	cis	rs16958440	0.867	rs28578518	chr18:44687548	A/C	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs72772090	0.539	rs11743410	chr5:96124453	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.13	-0.43	1.28e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs679087	0.932	rs7312697	chr12:29933069	T/C	cg14258853	chr12:29935411	TMTC1	0.35	8.05	0.3	3.96e-15	Schizophrenia;
BRCA	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg21143896	chr7:2802374	GNA12	-0.32	-8.12	-0.31	2.49e-15	Height;
BRCA	cis	rs62380364	0.565	rs13158247	chr5:88030670	C/T	cg22951263	chr5:87985283	NA	-0.38	-10.62	-0.39	2.35e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg20607798	chr8:58055168	NA	0.48	8.38	0.31	3.26e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg26248373	chr2:1572462	NA	-0.63	-14.95	-0.51	1.49e-43	IgG glycosylation;
BRCA	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg00717180	chr2:96193071	NA	-0.31	-8.5	-0.32	1.32e-16	Coronary artery disease;
BRCA	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg13010199	chr12:38710504	ALG10B	0.5	10.53	0.38	4.99e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg10495392	chr1:46806563	NSUN4	0.44	8.11	0.31	2.59e-15	Menopause (age at onset);
BRCA	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26384229	chr12:38710491	ALG10B	0.74	16.62	0.55	8.14e-52	Morning vs. evening chronotype;
BRCA	cis	rs752010	1.000	rs2077172	chr1:42093340	A/G	cg06885757	chr1:42089581	HIVEP3	0.27	9.66	0.36	1.11e-20	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs7617773	0.709	rs4404473	chr3:48353626	A/G	cg11946769	chr3:48343235	NME6	0.68	13.33	0.47	6.26e-36	Coronary artery disease;
BRCA	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg23649088	chr2:200775458	C2orf69	0.55	10.25	0.38	6.28e-23	Schizophrenia;
BRCA	cis	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg07460842	chr6:66804631	NA	1.0	19.98	0.62	2.21e-69	Exhaled nitric oxide output;
BRCA	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg23788917	chr6:8435910	SLC35B3	-0.43	-9.26	-0.34	2.96e-19	Motion sickness;
BRCA	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg17425144	chr1:10567563	PEX14	0.57	14.19	0.49	6.61e-40	Breast cancer;
BRCA	trans	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-19.39	-0.61	3.14e-66	Exhaled nitric oxide output;
BRCA	cis	rs11191270	1.000	rs4919626	chr10:104079818	T/C	cg15320455	chr10:103880129	LDB1	0.49	8.0	0.3	5.96e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg21659725	chr3:3221576	CRBN	-0.45	-9.61	-0.36	1.65e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg12927641	chr6:109611667	NA	-0.38	-9.38	-0.35	1.13e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs7766436	0.553	rs55936918	chr6:22610269	A/T	cg13666174	chr6:22585274	NA	-0.44	-7.99	-0.3	6.39e-15	Coronary artery disease;
BRCA	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.15	-0.31	1.96e-15	Depression;
BRCA	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg04317338	chr11:64019027	PLCB3	0.54	9.19	0.34	5.59e-19	Mean platelet volume;
BRCA	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.81	0.67	1.05e-84	Chronic sinus infection;
BRCA	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.48	-0.35	4.99e-20	Bipolar disorder and schizophrenia;
BRCA	trans	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.78	-0.33	1.44e-17	Depression;
BRCA	cis	rs2742234	0.910	rs2505511	chr10:43641029	T/A	cg02780029	chr10:43622663	RET	-0.38	-9.34	-0.35	1.51e-19	Hirschsprung disease;
BRCA	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg06623918	chr6:96969491	KIAA0776	0.74	12.97	0.46	2.61e-34	Migraine;Coronary artery disease;
BRCA	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg21045802	chr8:109455806	TTC35	0.35	8.06	0.3	3.69e-15	Dupuytren's disease;
BRCA	cis	rs1371614	0.589	rs3739086	chr2:27165202	T/C	cg00617064	chr2:27272375	NA	0.32	8.57	0.32	7.69e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.27	-0.31	8e-16	Bipolar disorder;
BRCA	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.53	-0.35	3.1e-20	Total body bone mineral density;
BRCA	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg03709012	chr19:19516395	GATAD2A	0.81	18.99	0.6	4.17e-64	Tonsillectomy;
BRCA	cis	rs965469	0.779	rs2236103	chr20:3276821	A/G	cg25506879	chr20:3388711	C20orf194	0.44	8.9	0.33	5.93e-18	IFN-related cytopenia;
BRCA	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg04013166	chr16:89971882	TCF25	0.44	8.59	0.32	6.46e-17	Skin colour saturation;
BRCA	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg15934090	chr1:100435551	SLC35A3	0.35	7.93	0.3	1.01e-14	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg02891314	chr5:179741120	GFPT2	-0.67	-13.55	-0.47	6.29e-37	Height;
BRCA	cis	rs35123781	1.000	rs601728	chr5:139057076	T/C	cg05227215	chr5:139057496	CXXC5	0.35	8.47	0.32	1.64e-16	Schizophrenia;
BRCA	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg09754948	chr16:28834200	ATXN2L	0.47	9.09	0.34	1.23e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs503734	0.502	rs2660803	chr3:100914035	A/G	cg27318481	chr3:100970896	IMPG2	-0.37	-8.51	-0.32	1.28e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg22535103	chr8:58192502	C8orf71	-0.61	-13.17	-0.46	3.08e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.37	-0.35	1.24e-19	Menopause (age at onset);
BRCA	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg08847533	chr14:75593920	NEK9	-0.8	-19.53	-0.61	5.85e-67	Height;
BRCA	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.45	10.45	0.38	1.06e-23	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	10.23	0.38	7.56e-23	Height;
BRCA	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-8.87	-0.33	7.47e-18	Morning vs. evening chronotype;
BRCA	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg22349387	chr12:9600060	DDX12	-0.42	-9.54	-0.35	2.94e-20	Breast size;
BRCA	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg25237894	chr2:233734115	C2orf82	-0.36	-10.15	-0.37	1.48e-22	Coronary artery disease;
BRCA	trans	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg25214090	chr10:38739885	LOC399744	0.35	8.12	0.31	2.32e-15	Diastolic blood pressure;
BRCA	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-9.37	-0.35	1.2e-19	Fear of minor pain;
BRCA	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg06618935	chr21:46677482	NA	-0.37	-8.08	-0.3	3.29e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.9	0.56	3.04e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg06784218	chr1:46089804	CCDC17	0.52	12.53	0.44	2.36e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7520050	0.966	rs61783200	chr1:46297403	T/C	cg24296786	chr1:45957014	TESK2	0.44	9.9	0.36	1.38e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4742903	1.000	rs7350148	chr9:106883085	T/G	cg14250997	chr9:106856677	SMC2	0.35	10.88	0.4	2.12e-25	High-grade serous ovarian cancer;Breast cancer;
BRCA	trans	rs4650994	0.935	rs12039531	chr1:178515612	G/A	cg05059571	chr16:84539110	KIAA1609	-0.43	-9.77	-0.36	4.27e-21	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.37	7.82	0.3	2.17e-14	Total cholesterol levels;
BRCA	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg06784218	chr1:46089804	CCDC17	0.46	10.58	0.39	3.39e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs4596713	0.568	rs7850547	chr9:71747208	G/A	cg16512924	chr15:28394682	HERC2	0.39	9.42	0.35	8.29e-20	Headache;
BRCA	trans	rs71537559	1	rs71537559	chr6:27309779	G/C	cg01620082	chr3:125678407	NA	-0.74	-8.96	-0.33	3.45e-18	Squamous cell lung carcinoma;
BRCA	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg00024416	chr22:24240387	NA	-0.48	-11.22	-0.41	8.87e-27	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	trans	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg26384229	chr12:38710491	ALG10B	0.4	8.58	0.32	7.38e-17	Resting heart rate;
BRCA	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg17063962	chr7:91808500	NA	-0.53	-12.53	-0.44	2.43e-32	Breast cancer;
BRCA	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg20891283	chr12:69753455	YEATS4	0.84	28.6	0.75	1.77e-116	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg24803719	chr17:45855879	NA	-0.32	-8.4	-0.32	2.95e-16	IgG glycosylation;
BRCA	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg11845111	chr2:191398756	TMEM194B	-0.71	-13.93	-0.48	1.05e-38	Diastolic blood pressure;
BRCA	cis	rs7551345	0.653	rs7513301	chr1:31698473	C/T	cg19084893	chr1:31688959	NA	-0.46	-10.04	-0.37	4.13e-22	Schizophrenia;
BRCA	cis	rs36051895	0.632	rs62541958	chr9:5175621	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-8.72	-0.33	2.39e-17	Pediatric autoimmune diseases;
BRCA	cis	rs7301826	0.651	rs2037789	chr12:131288292	C/T	cg11011512	chr12:131303247	STX2	-0.51	-13.5	-0.47	1.05e-36	Plasma plasminogen activator levels;
BRCA	cis	rs4363385	0.818	rs529077	chr1:153012149	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg18252515	chr7:66147081	NA	0.84	12.14	0.43	1.2e-30	Diabetic kidney disease;
BRCA	cis	rs4423214	0.840	rs1792235	chr11:71181473	C/T	cg05163923	chr11:71159392	DHCR7	-0.57	-11.58	-0.42	2.84e-28	Vitamin D levels;
BRCA	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.55	-0.39	4.32e-24	Bipolar disorder;
BRCA	trans	rs61931739	0.612	rs1906136	chr12:33905293	C/T	cg26384229	chr12:38710491	ALG10B	0.41	9.26	0.34	3.06e-19	Morning vs. evening chronotype;
BRCA	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.87	0.56	4.51e-53	Colorectal cancer;
BRCA	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg23711669	chr6:146136114	FBXO30	0.73	17.14	0.56	1.74e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg24812749	chr6:127587940	RNF146	0.68	15.55	0.52	1.82e-46	Breast cancer;
BRCA	cis	rs9790314	0.687	rs1037888	chr3:160775251	A/T	cg03342759	chr3:160939853	NMD3	-0.51	-9.81	-0.36	2.95e-21	Morning vs. evening chronotype;
BRCA	cis	rs752010	0.695	rs11210509	chr1:42109311	A/G	cg06885757	chr1:42089581	HIVEP3	0.23	8.41	0.32	2.71e-16	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs9394159	0.583	rs4713650	chr6:33616828	C/T	cg14003231	chr6:33640908	ITPR3	-0.4	-10.04	-0.37	4.14e-22	Graves' disease;
BRCA	cis	rs4595586	0.566	rs7307174	chr12:39368862	A/G	cg26384229	chr12:38710491	ALG10B	0.37	8.18	0.31	1.58e-15	Morning vs. evening chronotype;
BRCA	cis	rs67981189	0.766	rs2526852	chr14:71416167	T/C	cg15816911	chr14:71606274	NA	-0.36	-8.02	-0.3	5.17e-15	Schizophrenia;
BRCA	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg05340658	chr4:99064831	C4orf37	-0.43	-9.79	-0.36	3.64e-21	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.71	12.4	0.44	8.82e-32	Renal function-related traits (BUN);
BRCA	cis	rs3762637	1.000	rs16845530	chr3:122142447	T/C	cg24169773	chr3:122142474	KPNA1	-0.43	-8.26	-0.31	8.17e-16	LDL cholesterol levels;
BRCA	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	21.77	0.65	5.22e-79	Platelet count;
BRCA	trans	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg13565492	chr6:43139072	SRF	-0.79	-10.92	-0.4	1.41e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.64	0.32	4.61e-17	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.88	-0.33	6.98e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg06784218	chr1:46089804	CCDC17	0.46	10.93	0.4	1.34e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	16.37	0.54	1.4e-50	Platelet count;
BRCA	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-13.18	-0.46	3.06e-35	Platelet count;
BRCA	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg16482183	chr6:26056742	HIST1H1C	0.49	9.66	0.36	1.1e-20	Iron status biomarkers;
BRCA	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg05623727	chr3:50126028	RBM5	-0.42	-9.88	-0.36	1.61e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	11.65	0.42	1.48e-28	Schizophrenia;
BRCA	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg11608241	chr8:8085544	FLJ10661	0.28	7.86	0.3	1.63e-14	Mood instability;
BRCA	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-9.95	-0.37	8.91e-22	Alzheimer's disease (late onset);
BRCA	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg16339924	chr4:17578868	LAP3	0.63	15.92	0.53	2.55e-48	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9815354	1.000	rs1994157	chr3:41897482	G/A	cg03022575	chr3:42003672	ULK4	0.49	7.99	0.3	6.4e-15	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg20701182	chr2:24300061	SF3B14	0.67	9.76	0.36	4.51e-21	Lymphocyte counts;
BRCA	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg26384229	chr12:38710491	ALG10B	0.69	16.22	0.54	8.24e-50	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6545883	0.929	rs778155	chr2:61647901	A/G	cg15711740	chr2:61764176	XPO1	0.53	12.83	0.45	1.13e-33	Tuberculosis;
BRCA	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg19717773	chr7:2847554	GNA12	-0.48	-11.37	-0.41	2.06e-27	Height;
BRCA	trans	rs4714291	0.698	rs9296321	chr6:40118352	C/T	cg02267698	chr19:7991119	CTXN1	-0.45	-9.28	-0.34	2.66e-19	Strep throat;
BRCA	cis	rs7408868	0.908	rs10416865	chr19:15277601	T/C	cg14696996	chr19:15285081	NOTCH3	1.01	14.77	0.5	1.08e-42	Pulse pressure;
BRCA	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-13.99	-0.48	5.67e-39	Bipolar disorder and schizophrenia;
BRCA	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg09307838	chr4:120376055	NA	0.64	14.05	0.49	2.77e-39	Corneal astigmatism;
BRCA	cis	rs4680	1.000	rs165656	chr22:19948863	C/G	cg23601416	chr22:19950040	COMT	-0.28	-9.59	-0.35	1.99e-20	Blood metabolite levels;
BRCA	cis	rs6580649	0.941	rs7957764	chr12:48429701	C/T	cg24011408	chr12:48396354	COL2A1	-0.49	-8.02	-0.3	5.13e-15	Lung cancer;
BRCA	cis	rs7294478	1.000	rs7294478	chr12:7266805	A/G	cg01074767	chr12:7262137	C1RL;LOC283314	-0.28	-7.96	-0.3	7.85e-15	Neuritic plaque;
BRCA	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.41	-0.32	2.6e-16	Colorectal cancer;
BRCA	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg00677455	chr12:58241039	CTDSP2	0.79	17.66	0.57	4.05e-57	Multiple sclerosis;
BRCA	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05535760	chr7:792225	HEATR2	0.87	14.93	0.51	1.94e-43	Cerebrospinal P-tau181p levels;
BRCA	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.49	8.61	0.32	5.8e-17	Mean platelet volume;
BRCA	cis	rs600806	0.751	rs7551176	chr1:109961965	C/T	cg20591472	chr1:110008990	SYPL2	0.32	7.89	0.3	1.35e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs3740540	0.507	rs897293	chr10:126290050	T/G	cg04949429	chr10:126290192	LHPP	0.43	12.19	0.43	7.03e-31	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs1974653	0.781	rs175164	chr22:20115562	C/T	cg20152630	chr19:46405944	MYPOP	0.35	8.08	0.3	3.31e-15	Schizophrenia;
BRCA	cis	rs7247513	0.964	rs12979795	chr19:12717847	C/T	cg01871581	chr19:12707946	ZNF490	0.68	16.21	0.54	9.87e-50	Bipolar disorder;
BRCA	cis	rs6700896	0.931	rs1938490	chr1:66132800	T/A	cg04111102	chr1:66153794	NA	0.36	8.82	0.33	1.08e-17	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg13010199	chr12:38710504	ALG10B	0.47	8.99	0.34	2.84e-18	Morning vs. evening chronotype;
BRCA	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.22	-0.34	4.2e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg18016565	chr1:150552671	MCL1	-0.37	-8.58	-0.32	7.01e-17	Tonsillectomy;
BRCA	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg12311346	chr5:56204834	C5orf35	-0.82	-16.93	-0.56	2.26e-53	Initial pursuit acceleration;
BRCA	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg26384229	chr12:38710491	ALG10B	0.65	15.45	0.52	5.28e-46	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg08601574	chr20:25228251	PYGB	0.37	8.82	0.33	1.07e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs3820928	1.000	rs1346618	chr2:227771988	C/T	cg11843606	chr2:227700838	RHBDD1	0.39	8.53	0.32	1.04e-16	Pulmonary function;
BRCA	cis	rs4363385	0.693	rs6668311	chr1:152964586	A/G	cg21543102	chr1:152974771	SPRR3	-0.31	-8.85	-0.33	8.26e-18	Inflammatory skin disease;
BRCA	cis	rs2882667	0.858	rs11959803	chr5:138451315	G/A	cg04439458	chr5:138467593	SIL1	-0.43	-10.76	-0.39	6.08e-25	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-14.12	-0.49	1.33e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg11812906	chr14:75593930	NEK9	-0.67	-14.95	-0.51	1.48e-43	Height;
BRCA	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.0	-0.46	1.92e-34	Migraine;Coronary artery disease;
BRCA	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg26395211	chr5:140044315	WDR55	0.38	8.57	0.32	7.73e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05901451	chr6:126070800	HEY2	0.4	9.72	0.36	6.35e-21	Endometrial cancer;
BRCA	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.53	-11.02	-0.4	5.67e-26	Lymphocyte counts;
BRCA	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg04851639	chr8:1020857	NA	-0.4	-11.44	-0.41	1.09e-27	Schizophrenia;
BRCA	cis	rs13053817	1.000	rs2106107	chr22:29835987	A/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	0.5	9.76	0.36	4.73e-21	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs7677751	0.806	rs7673027	chr4:55096180	T/A	cg17187183	chr4:55093834	PDGFRA	0.44	9.14	0.34	8.19e-19	Corneal astigmatism;
BRCA	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-7.81	-0.3	2.39e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg04166393	chr7:2884313	GNA12	0.49	9.24	0.34	3.74e-19	Height;
BRCA	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg21918786	chr6:109611834	NA	-0.44	-11.83	-0.42	2.49e-29	Reticulocyte fraction of red cells;
BRCA	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg22907277	chr7:1156413	C7orf50	0.58	8.91	0.33	5.37e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg08888203	chr3:10149979	C3orf24	0.68	14.49	0.5	2.36e-41	Alzheimer's disease;
BRCA	cis	rs11051970	0.679	rs2733696	chr12:32554635	A/G	cg24626660	chr12:32551988	NA	0.32	9.4	0.35	9.19e-20	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg11952622	chr19:58962976	ZNF324B	0.43	8.75	0.33	1.92e-17	Uric acid clearance;
BRCA	cis	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.69	-0.33	3.09e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11764359	chr7:65958608	NA	-0.8	-19.34	-0.61	5.76e-66	Aortic root size;
BRCA	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg01475377	chr6:109611718	NA	-0.58	-16.27	-0.54	4.86e-50	Reticulocyte fraction of red cells;
BRCA	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg14683738	chr19:37701593	ZNF585B	0.44	7.9	0.3	1.23e-14	Coronary artery calcification;
BRCA	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.09	-0.34	1.27e-18	Total body bone mineral density;
BRCA	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg17691542	chr6:26056736	HIST1H1C	0.53	11.44	0.41	1.05e-27	Height;
BRCA	cis	rs11971779	0.648	rs9656512	chr7:139054046	A/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.23	0.38	7.66e-23	Diisocyanate-induced asthma;
BRCA	cis	rs724568	0.527	rs1430768	chr2:67929165	A/G	cg14046302	chr2:67939758	NA	-0.38	-10.22	-0.37	8.27e-23	Major depressive disorder (broad);
BRCA	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg11366901	chr6:160182831	ACAT2	0.78	15.03	0.51	5.93e-44	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.76	-0.5	1.19e-42	Chronic sinus infection;
BRCA	cis	rs9948	0.655	rs17119562	chr2:97381844	G/C	cg20312557	chr2:97357134	FER1L5	-0.59	-7.97	-0.3	7.54e-15	Erectile dysfunction and prostate cancer treatment;
BRCA	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg17135325	chr3:160939158	NMD3	0.42	8.05	0.3	4.02e-15	Parkinson's disease;
BRCA	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.83	-0.42	2.37e-29	Bipolar disorder;
BRCA	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.79	-0.42	3.6e-29	Bipolar disorder;
BRCA	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	9.06	0.34	1.6e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg26384229	chr12:38710491	ALG10B	0.68	14.37	0.49	9.31e-41	Morning vs. evening chronotype;
BRCA	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.33	7.96	0.3	8.13e-15	Hematocrit;
BRCA	cis	rs651907	1.000	rs651907	chr3:101600724	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.34	8.87	0.33	7.42e-18	Colorectal cancer;
BRCA	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg08888203	chr3:10149979	C3orf24	-0.68	-14.27	-0.49	2.67e-40	Alzheimer's disease;
BRCA	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg22920501	chr2:26401640	FAM59B	-0.67	-11.5	-0.41	5.96e-28	Gut microbiome composition (summer);
BRCA	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg00677455	chr12:58241039	CTDSP2	0.63	15.89	0.53	3.52e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.34	-0.35	1.54e-19	Schizophrenia;
BRCA	cis	rs4948102	0.961	rs7776550	chr7:56092391	T/C	cg09872392	chr7:56161020	PHKG1	-0.42	-9.71	-0.36	6.84e-21	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs8114671	0.647	rs1124511	chr20:33736697	A/C	cg24642439	chr20:33292090	TP53INP2	0.41	8.86	0.33	7.58e-18	Height;
BRCA	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs7640424	0.649	rs13093976	chr3:107864963	A/C	cg09227934	chr3:107805635	CD47	0.37	7.94	0.3	9.07e-15	Body mass index;
BRCA	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg04842962	chr6:43655489	MRPS18A	-1.1	-35.79	-0.82	8.43e-155	IgG glycosylation;
BRCA	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg27147174	chr7:100797783	AP1S1	-0.57	-11.47	-0.41	7.74e-28	Life satisfaction;
BRCA	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.18	-0.31	1.49e-15	Depression;
BRCA	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg03146154	chr1:46216737	IPP	-0.43	-9.42	-0.35	8.22e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg25817165	chr18:72167213	CNDP2	-0.77	-19.52	-0.61	6.25e-67	Refractive error;
BRCA	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg17135325	chr3:160939158	NMD3	0.4	7.93	0.3	9.61e-15	Morning vs. evening chronotype;
BRCA	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg04705435	chr11:17411270	KCNJ11	0.48	10.33	0.38	3.13e-23	Type 2 diabetes;
BRCA	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg01877450	chr7:97915802	BRI3	-0.36	-8.2	-0.31	1.34e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.73	-15.92	-0.53	2.77e-48	Cognitive ability;
BRCA	cis	rs867371	1.000	rs1501372	chr15:82468455	C/T	cg00614314	chr15:82944287	LOC80154	0.43	9.04	0.34	1.81e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs16867321	0.588	rs2368175	chr2:181493763	G/C	cg23363182	chr2:181467187	NA	-0.49	-10.98	-0.4	8.5e-26	Obesity;
BRCA	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg00814883	chr7:100076585	TSC22D4	-0.49	-9.61	-0.36	1.69e-20	Platelet count;
BRCA	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg17063962	chr7:91808500	NA	-0.53	-12.46	-0.44	4.56e-32	Breast cancer;
BRCA	cis	rs28374715	0.662	rs28382348	chr15:41487934	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.87	-18.15	-0.58	1.07e-59	Ulcerative colitis;
BRCA	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg14784868	chr12:69753453	YEATS4	0.77	25.08	0.7	3.64e-97	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg00106254	chr7:1943704	MAD1L1	-0.41	-10.09	-0.37	2.52e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-12.55	-0.44	1.94e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15541040	chr2:3486749	NA	-0.42	-9.13	-0.34	9.26e-19	Neurofibrillary tangles;
BRCA	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.95	0.4	1.12e-25	Rheumatoid arthritis;
BRCA	cis	rs4845875	0.602	rs2001584	chr1:11841351	G/A	cg24844545	chr1:11908347	NPPA	0.33	8.21	0.31	1.21e-15	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg05639522	chr1:247681581	NA	0.47	10.47	0.38	8.46e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg07884673	chr3:53033167	SFMBT1	0.86	9.98	0.37	6.83e-22	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs35123781	1.000	rs601324	chr5:139057179	C/G	cg05227215	chr5:139057496	CXXC5	0.35	8.42	0.32	2.46e-16	Schizophrenia;
BRCA	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg19920283	chr7:105172520	RINT1	0.59	9.46	0.35	5.64e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg12463550	chr7:65579703	CRCP	-0.38	-8.06	-0.3	3.67e-15	Aortic root size;
BRCA	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg14019146	chr3:50243930	SLC38A3	-0.42	-10.28	-0.38	4.84e-23	Body mass index;
BRCA	cis	rs27434	0.821	rs28337	chr5:96125314	A/T	cg16492584	chr5:96139282	ERAP1	-0.46	-10.92	-0.4	1.46e-25	Ankylosing spondylitis;
BRCA	cis	rs4302748	0.817	rs11773129	chr7:36186670	C/T	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs7927771	0.800	rs11039200	chr11:47379646	A/C	cg20307385	chr11:47447363	PSMC3	-0.43	-8.44	-0.32	2.05e-16	Subjective well-being;
BRCA	trans	rs7395662	0.929	rs11039903	chr11:48679705	G/T	cg00717180	chr2:96193071	NA	-0.29	-8.09	-0.3	3.04e-15	HDL cholesterol;
BRCA	cis	rs6834538	0.597	rs6822451	chr4:113463265	G/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.43	10.39	0.38	1.82e-23	Free thyroxine concentration;
BRCA	cis	rs290268	0.647	rs1333637	chr9:93557066	C/T	cg02608019	chr9:93564028	SYK	-0.49	-10.9	-0.4	1.74e-25	Platelet count;
BRCA	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg08470875	chr2:26401718	FAM59B	0.67	11.05	0.4	4.38e-26	Gut microbiome composition (summer);
BRCA	cis	rs7554547	0.667	rs4846072	chr1:11950391	T/C	cg13216073	chr1:12042593	MFN2	0.38	7.87	0.3	1.52e-14	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.01	15.72	0.53	2.65e-47	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg13073564	chr4:8508604	NA	0.39	10.94	0.4	1.17e-25	Response to antineoplastic agents;
BRCA	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg09537434	chr19:41945824	ATP5SL	-1.0	-23.92	-0.69	8.58e-91	Height;
BRCA	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	8.74	0.33	1.98e-17	Iron status biomarkers;
BRCA	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-18.45	-0.59	2.85e-61	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.06	0.37	3.32e-22	Aortic root size;
BRCA	cis	rs2066819	1.000	rs76466034	chr12:56719450	G/A	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg11663144	chr21:46675770	NA	-0.46	-9.3	-0.35	2.14e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4728302	0.869	rs10156088	chr7:133592544	G/A	cg07491979	chr7:133331646	EXOC4	0.36	7.89	0.3	1.31e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg04034577	chr2:241836375	C2orf54	-0.5	-12.62	-0.45	9.24e-33	Urinary metabolites;
BRCA	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-8.52	-0.32	1.1e-16	Schizophrenia;
BRCA	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg17052675	chr2:3827356	NA	-0.46	-13.47	-0.47	1.4e-36	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg17971929	chr21:40555470	PSMG1	-0.45	-9.41	-0.35	9.01e-20	Menarche (age at onset);
BRCA	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg19077165	chr18:44547161	KATNAL2	-0.5	-10.57	-0.39	3.39e-24	Personality dimensions;
BRCA	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-10.78	-0.39	5.23e-25	IgG glycosylation;
BRCA	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-12.08	-0.43	2e-30	Response to antipsychotic treatment;
BRCA	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg07741184	chr6:167504864	NA	0.29	8.07	0.3	3.58e-15	Crohn's disease;
BRCA	cis	rs7631605	0.608	rs11715128	chr3:37440674	A/T	cg15934958	chr3:37212084	LRRFIP2	0.37	7.89	0.3	1.28e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg00852783	chr1:26633632	UBXN11	0.51	11.02	0.4	5.81e-26	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg11843238	chr5:131593191	PDLIM4	0.31	7.89	0.3	1.35e-14	Blood metabolite levels;
BRCA	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg26384229	chr12:38710491	ALG10B	0.83	22.36	0.66	2.87e-82	Heart rate;
BRCA	cis	rs2764208	0.576	rs6457791	chr6:34759954	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.99	-0.3	6.33e-15	Systemic lupus erythematosus;
BRCA	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg00701064	chr4:6280414	WFS1	0.68	17.68	0.57	3.11e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs586533	0.881	rs599609	chr11:99505610	T/C	cg22878054	chr11:99397252	CNTN5	0.32	8.12	0.31	2.44e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg06212747	chr3:49208901	KLHDC8B	0.52	10.76	0.39	6.11e-25	Parkinson's disease;
BRCA	cis	rs10463316	0.894	rs7727770	chr5:150767116	G/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.32	-0.31	5.17e-16	Metabolite levels (Pyroglutamine);
BRCA	trans	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	8.51	0.32	1.22e-16	Mean corpuscular volume;
BRCA	cis	rs2276314	0.947	rs16967319	chr18:33573525	A/G	cg05985134	chr18:33552581	C18orf21	0.67	12.17	0.43	8.16e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg16109817	chr1:16162209	FLJ37453	-0.3	-8.25	-0.31	8.85e-16	Systolic blood pressure;
BRCA	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18404041	chr3:52824283	ITIH1	-0.43	-12.84	-0.45	9.92e-34	Bipolar disorder;
BRCA	cis	rs6750047	0.719	rs4670232	chr2:38272033	C/G	cg07380506	chr2:38303506	CYP1B1	0.43	9.61	0.36	1.61e-20	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs3820928	0.874	rs10933163	chr2:227815286	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-9.06	-0.34	1.6e-18	Pulmonary function;
BRCA	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg16230307	chr14:35515116	FAM177A1	0.73	15.06	0.51	4.55e-44	Psoriasis;
BRCA	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.54	-9.77	-0.36	4.2e-21	Body mass index;
BRCA	cis	rs4728302	0.869	rs2042455	chr7:133580545	A/G	cg07491979	chr7:133331646	EXOC4	0.36	7.81	0.3	2.28e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg17063962	chr7:91808500	NA	0.53	11.77	0.42	4.53e-29	Breast cancer;
BRCA	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07308232	chr7:1071921	C7orf50	-0.4	-8.18	-0.31	1.5e-15	Longevity;Endometriosis;
BRCA	trans	rs1941687	0.764	rs1493915	chr18:31377582	G/T	cg27147174	chr7:100797783	AP1S1	-0.38	-7.82	-0.3	2.26e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs9359856	0.510	rs4235839	chr6:90472410	A/G	cg13799429	chr6:90582589	CASP8AP2	0.72	11.06	0.4	3.84e-26	Bipolar disorder;
BRCA	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg04586622	chr2:25135609	ADCY3	0.47	11.64	0.42	1.54e-28	Body mass index;
BRCA	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg22907277	chr7:1156413	C7orf50	0.51	11.46	0.41	9.19e-28	Longevity;Endometriosis;
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg09177884	chr7:1199841	ZFAND2A	0.51	10.97	0.4	9e-26	Longevity;Endometriosis;
BRCA	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg00531865	chr16:30841666	NA	0.39	9.38	0.35	1.17e-19	Dementia with Lewy bodies;
BRCA	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg00012203	chr2:219082015	ARPC2	-0.49	-9.05	-0.34	1.67e-18	Colorectal cancer;
BRCA	cis	rs7809950	1.000	rs2250414	chr7:107140987	T/G	cg23024343	chr7:107201750	COG5	-0.39	-9.09	-0.34	1.25e-18	Coronary artery disease;
BRCA	cis	rs919433	0.963	rs12617117	chr2:198155170	T/A	cg00792783	chr2:198669748	PLCL1	-0.38	-8.0	-0.3	5.75e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg01324343	chr3:183735012	ABCC5	0.81	20.24	0.62	9.63e-71	Anterior chamber depth;
BRCA	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg19920283	chr7:105172520	RINT1	0.59	9.22	0.34	4.15e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg20908204	chr19:46285434	DMPK	0.27	8.19	0.31	1.38e-15	Coronary artery disease;
BRCA	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.98	0.43	5.89e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10463316	0.604	rs28744577	chr5:150768983	A/T	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.34	-0.31	4.68e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.84	0.33	8.98e-18	Personality dimensions;
BRCA	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.75	16.65	0.55	5.51e-52	Lymphocyte counts;
BRCA	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg15704280	chr7:45808275	SEPT13	-0.77	-17.33	-0.57	1.84e-55	Coronary artery disease;
BRCA	trans	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg26384229	chr12:38710491	ALG10B	0.51	10.96	0.4	1.02e-25	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	11.25	0.41	6.32e-27	Schizophrenia;
BRCA	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	10.56	0.39	3.72e-24	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg20469991	chr17:27169893	C17orf63	-0.43	-8.5	-0.32	1.31e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21659725	chr3:3221576	CRBN	-0.48	-10.19	-0.37	1.06e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg13319975	chr6:146136371	FBXO30	-0.41	-9.61	-0.36	1.63e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg13010199	chr12:38710504	ALG10B	0.5	9.85	0.36	2.1e-21	Bladder cancer;
BRCA	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg04691961	chr3:161091175	C3orf57	-0.59	-14.26	-0.49	3e-40	Morning vs. evening chronotype;
BRCA	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.17	-0.31	1.68e-15	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg11502198	chr6:26597334	ABT1	0.55	11.74	0.42	6.04e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg26116260	chr4:7069785	GRPEL1	0.94	27.86	0.74	1.94e-112	Monocyte percentage of white cells;
BRCA	cis	rs72772090	0.539	rs11747896	chr5:96113397	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.57	12.3	0.44	2.33e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg11941060	chr3:133502564	NA	-0.5	-11.82	-0.42	2.71e-29	Iron status biomarkers;
BRCA	trans	rs12310956	0.510	rs4931758	chr12:33871870	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.94	0.37	9.33e-22	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg22920501	chr2:26401640	FAM59B	0.95	16.82	0.55	7.55e-53	Gut microbiome composition (summer);
BRCA	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg22705602	chr4:152727874	NA	-0.32	-8.17	-0.31	1.6e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.22	0.34	4.35e-19	Tonsillectomy;
BRCA	cis	rs400736	0.930	rs370812	chr1:8075894	C/T	cg25007680	chr1:8021821	PARK7	0.48	12.05	0.43	2.87e-30	Response to antidepressants and depression;
BRCA	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.57	-0.32	7.75e-17	Total body bone mineral density;
BRCA	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.32	-0.38	3.3e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18876405	chr7:65276391	NA	0.51	11.55	0.42	3.6e-28	Aortic root size;
BRCA	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg06784218	chr1:46089804	CCDC17	-0.45	-10.62	-0.39	2.3e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg02297831	chr4:17616191	MED28	0.36	8.51	0.32	1.21e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9469890	0.604	rs11756280	chr6:34503439	T/C	cg17674042	chr6:34482479	PACSIN1	-0.33	-8.56	-0.32	8.1e-17	Pubertal anthropometrics;Coronary artery disease;
BRCA	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg15556689	chr8:8085844	FLJ10661	-0.33	-8.56	-0.32	8.12e-17	Joint mobility (Beighton score);
BRCA	cis	rs73001065	0.818	rs58847337	chr19:19726022	G/A	cg03709012	chr19:19516395	GATAD2A	0.75	9.37	0.35	1.18e-19	LDL cholesterol;
BRCA	trans	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg13565492	chr6:43139072	SRF	-0.79	-11.12	-0.4	2.25e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg10523679	chr1:76189770	ACADM	-0.5	-9.69	-0.36	8.41e-21	Daytime sleep phenotypes;
BRCA	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06544989	chr22:39130855	UNC84B	-0.37	-9.61	-0.36	1.58e-20	Menopause (age at onset);
BRCA	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg13047869	chr3:10149882	C3orf24	-0.53	-11.45	-0.41	9.7e-28	Alzheimer's disease;
BRCA	cis	rs13053817	0.898	rs7291001	chr22:29857859	C/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.48	-9.25	-0.34	3.35e-19	Carotid atherosclerosis in HIV infection;
BRCA	trans	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg07211511	chr3:129823064	LOC729375	-0.96	-13.67	-0.48	1.64e-37	Blood pressure (smoking interaction);
BRCA	cis	rs4919087	0.962	rs10882891	chr10:99059645	C/A	cg25902810	chr10:99078978	FRAT1	0.5	10.79	0.39	4.96e-25	Monocyte count;
BRCA	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg18446336	chr7:2847575	GNA12	-0.35	-8.24	-0.31	9.82e-16	Height;
BRCA	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg19336497	chr11:14380999	RRAS2	-0.48	-11.8	-0.42	3.33e-29	Sense of smell;
BRCA	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg16482183	chr6:26056742	HIST1H1C	0.53	11.23	0.41	8.17e-27	Height;
BRCA	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg07080220	chr10:102295463	HIF1AN	0.58	13.5	0.47	9.99e-37	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg03647239	chr10:116582469	FAM160B1	0.36	7.95	0.3	8.65e-15	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg08742575	chr21:47604166	C21orf56	-0.4	-7.82	-0.3	2.26e-14	Testicular germ cell tumor;
BRCA	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.34	-0.38	2.72e-23	Schizophrenia;
BRCA	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.9	-30.68	-0.77	9.51e-128	Chronic sinus infection;
BRCA	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.09	-0.3	2.94e-15	Aortic root size;
BRCA	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-9.54	-0.35	2.94e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg27624424	chr6:160112604	SOD2	-0.4	-8.47	-0.32	1.64e-16	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg25036284	chr2:26402008	FAM59B	-0.63	-10.62	-0.39	2.29e-24	Gut microbiome composition (summer);
BRCA	trans	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.98	29.42	0.76	6.09e-121	Colorectal cancer;
BRCA	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12756686	chr19:29218302	NA	-0.5	-8.81	-0.33	1.2e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.38	8.37	0.31	3.68e-16	Multiple sclerosis;
BRCA	cis	rs3824867	0.920	rs4282946	chr11:47456202	G/A	cg20307385	chr11:47447363	PSMC3	0.51	11.55	0.42	3.81e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg21475434	chr5:93447410	FAM172A	0.67	8.73	0.33	2.25e-17	Diabetic retinopathy;
BRCA	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.35	-8.87	-0.33	7.57e-18	Menopause (age at onset);
BRCA	cis	rs4363385	0.747	rs4845507	chr1:152968414	T/G	cg21543102	chr1:152974771	SPRR3	-0.3	-8.3	-0.31	6.13e-16	Inflammatory skin disease;
BRCA	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg09307838	chr4:120376055	NA	0.6	13.01	0.46	1.7e-34	Corneal astigmatism;
BRCA	cis	rs4363385	0.693	rs368076	chr1:153046514	A/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.04	-0.3	4.26e-15	Inflammatory skin disease;
BRCA	cis	rs1050631	0.564	rs684890	chr18:33744677	T/C	cg19453250	chr18:33710783	SLC39A6;ELP2	-0.29	-7.92	-0.3	1.07e-14	Esophageal squamous cell cancer (length of survival);
BRCA	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg26384229	chr12:38710491	ALG10B	-0.44	-10.19	-0.37	1.06e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05901451	chr6:126070800	HEY2	-0.39	-9.48	-0.35	4.8e-20	Endometrial cancer;
BRCA	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.83	-0.39	3.35e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-9.93	-0.37	1.06e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-8.76	-0.33	1.75e-17	Monocyte percentage of white cells;
BRCA	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg23625390	chr15:77176239	SCAPER	0.54	13.95	0.48	8.6e-39	Blood metabolite levels;
BRCA	cis	rs965469	1.000	rs965469	chr20:3381549	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-10.36	-0.38	2.44e-23	IFN-related cytopenia;
BRCA	cis	rs7072216	0.763	rs6584205	chr10:100173806	C/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.68	-0.36	8.8e-21	Metabolite levels;
BRCA	cis	rs490234	0.702	rs10120000	chr9:128288428	C/T	cg14078157	chr9:128172775	NA	-0.49	-11.12	-0.4	2.17e-26	Mean arterial pressure;
BRCA	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg09904177	chr6:26538194	HMGN4	0.56	18.25	0.59	3.23e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg20801007	chr11:830320	EFCAB4A	-0.49	-10.62	-0.39	2.3e-24	Mean platelet volume;
BRCA	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21659725	chr3:3221576	CRBN	-0.5	-12.81	-0.45	1.31e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg07169764	chr2:136633963	MCM6	1.23	26.49	0.72	6.67e-105	Corneal structure;
BRCA	cis	rs17092148	1.000	rs910871	chr20:33333208	C/A	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.31	-0.41	3.74e-27	Neuroticism;
BRCA	cis	rs912057	0.671	rs1294425	chr6:6744292	G/A	cg06612196	chr6:6737390	NA	0.46	10.85	0.39	2.81e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs6977660	0.714	rs4721827	chr7:19825655	A/G	cg07541023	chr7:19748670	TWISTNB	0.55	9.61	0.36	1.58e-20	Thyroid stimulating hormone;
BRCA	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-14.28	-0.49	2.45e-40	Bipolar disorder and schizophrenia;
BRCA	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg04455712	chr21:45112962	RRP1B	0.39	10.38	0.38	1.91e-23	Mean corpuscular volume;
BRCA	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg01262667	chr19:19385393	TM6SF2	0.41	10.61	0.39	2.51e-24	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.94e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs701145	0.585	rs357476	chr3:153892844	A/G	cg17054900	chr3:154042577	DHX36	-0.55	-9.39	-0.35	1.01e-19	Coronary artery disease;
BRCA	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg23625390	chr15:77176239	SCAPER	0.43	10.59	0.39	3.03e-24	Blood metabolite levels;
BRCA	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg09455208	chr3:40491958	NA	0.41	9.77	0.36	4.28e-21	Renal cell carcinoma;
BRCA	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Tonsillectomy;
BRCA	trans	rs11088226	0.846	rs2833884	chr21:33923075	A/G	cg09050820	chr6:167586206	TCP10L2	0.57	10.65	0.39	1.65e-24	Gastritis;
BRCA	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg05791153	chr7:19748676	TWISTNB	0.66	11.55	0.42	3.79e-28	Thyroid stimulating hormone;
BRCA	trans	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg23505145	chr19:12996616	KLF1	0.55	12.4	0.44	8.22e-32	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg03929089	chr4:120376271	NA	-0.9	-22.93	-0.67	2.36e-85	Coronary artery disease;
BRCA	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg11887960	chr12:57824829	NA	0.55	8.55	0.32	8.82e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs10129255	0.500	rs988133	chr14:107184963	A/G	cg07958169	chr14:107095056	NA	-0.4	-8.62	-0.32	5.2e-17	Kawasaki disease;
BRCA	trans	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg01620082	chr3:125678407	NA	-0.83	-10.07	-0.37	2.97e-22	Depression;
BRCA	cis	rs11229555	0.645	rs12295551	chr11:58188983	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg05457628	chr5:178986728	RUFY1	0.41	8.57	0.32	7.48e-17	Lung cancer;
BRCA	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg02574844	chr11:5959923	NA	-0.39	-7.85	-0.3	1.72e-14	DNA methylation (variation);
BRCA	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg21775007	chr8:11205619	TDH	-0.63	-14.16	-0.49	8.54e-40	Retinal vascular caliber;
BRCA	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.09e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7512552	0.839	rs7523428	chr1:150430472	G/A	cg15654264	chr1:150340011	RPRD2	0.4	8.56	0.32	8.26e-17	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs78707713	0.841	rs12242391	chr10:71201504	C/T	cg12610070	chr10:71211762	TSPAN15	-0.32	-8.32	-0.31	5.38e-16	Venous thromboembolism;
BRCA	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg18512352	chr11:47633146	NA	-0.34	-8.21	-0.31	1.2e-15	Subjective well-being;
BRCA	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.37	8.35	0.31	4.1e-16	Coronary artery disease;
BRCA	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13126279	chr21:47581558	C21orf56	-0.44	-9.81	-0.36	2.99e-21	Testicular germ cell tumor;
BRCA	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg15432903	chr11:17409602	KCNJ11	0.81	17.65	0.57	4.13e-57	Type 2 diabetes;
BRCA	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg24829409	chr8:58192753	C8orf71	-0.47	-9.09	-0.34	1.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11890956	chr21:40555474	PSMG1	-0.82	-19.71	-0.61	6.59e-68	Cognitive function;
BRCA	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg21644426	chr2:191273491	MFSD6	0.44	11.23	0.41	7.76e-27	Pulse pressure;
BRCA	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg02659138	chr7:134003124	SLC35B4	0.34	10.62	0.39	2.22e-24	Mean platelet volume;
BRCA	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.4	-8.42	-0.32	2.44e-16	Ulcerative colitis;
BRCA	cis	rs672059	1.000	rs483783	chr1:183162152	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.38	8.81	0.33	1.13e-17	Hypertriglyceridemia;
BRCA	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg06784218	chr1:46089804	CCDC17	-0.45	-10.73	-0.39	7.88e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg04998671	chr14:104000505	TRMT61A	-0.42	-9.03	-0.34	2.02e-18	Coronary artery disease;
BRCA	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.56	10.66	0.39	1.63e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.24	-0.38	6.9e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7809950	0.678	rs7788330	chr7:106985648	G/T	cg23024343	chr7:107201750	COG5	-0.48	-9.6	-0.36	1.7e-20	Coronary artery disease;
BRCA	trans	rs208520	0.874	rs208512	chr6:66943869	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-15.32	-0.52	2.46e-45	Exhaled nitric oxide output;
BRCA	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg20307385	chr11:47447363	PSMC3	-0.4	-9.51	-0.35	3.69e-20	Subjective well-being;
BRCA	cis	rs7246657	0.508	rs10419845	chr19:37491192	G/T	cg23950597	chr19:37808831	NA	-0.58	-8.34	-0.31	4.44e-16	Coronary artery calcification;
BRCA	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg01191920	chr7:158217561	PTPRN2	-0.46	-11.09	-0.4	2.83e-26	Obesity-related traits;
BRCA	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg08017756	chr2:100939284	LONRF2	-0.3	-7.91	-0.3	1.15e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs877282	0.898	rs12359731	chr10:759497	A/G	cg17470449	chr10:769945	NA	0.46	8.11	0.31	2.69e-15	Uric acid levels;
BRCA	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg17691542	chr6:26056736	HIST1H1C	0.55	11.62	0.42	1.82e-28	Height;
BRCA	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	14.46	0.5	3.41e-41	Personality dimensions;
BRCA	cis	rs701145	0.585	rs2060622	chr3:153833862	A/T	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.89e-18	Coronary artery disease;
BRCA	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg08888203	chr3:10149979	C3orf24	0.56	11.7	0.42	9.05e-29	Alzheimer's disease;
BRCA	cis	rs7246967	0.611	rs66866654	chr19:22813739	A/G	cg23217946	chr19:22817039	ZNF492	0.47	8.43	0.32	2.22e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-12.56	-0.44	1.79e-32	Bipolar disorder;
BRCA	cis	rs2066819	1.000	rs2306693	chr12:56680531	T/C	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs7646881	0.812	rs73015644	chr3:158447744	C/T	cg19483011	chr3:158453295	NA	-0.5	-8.58	-0.32	7.34e-17	Tetralogy of Fallot;
BRCA	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	ch.11.42038R	chr11:967971	AP2A2	0.52	16.65	0.55	5.42e-52	Alzheimer's disease (late onset);
BRCA	cis	rs6545883	0.929	rs6545877	chr2:61741947	T/C	cg15711740	chr2:61764176	XPO1	-0.55	-14.21	-0.49	5.23e-40	Tuberculosis;
BRCA	trans	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg23762105	chr12:34175262	ALG10	0.34	8.0	0.3	5.92e-15	Morning vs. evening chronotype;
BRCA	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.43e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg24069376	chr3:38537580	EXOG	0.34	9.34	0.35	1.56e-19	Electrocardiographic conduction measures;
BRCA	cis	rs17601876	0.545	rs61018102	chr15:51533530	G/C	cg19946085	chr15:51559439	CYP19A1	-0.3	-8.17	-0.31	1.64e-15	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg00409905	chr10:38381863	ZNF37A	0.49	10.62	0.39	2.31e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg06115741	chr20:33292138	TP53INP2	-0.37	-8.27	-0.31	8.04e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs10782582	0.609	rs11161848	chr1:76367722	A/G	cg03433033	chr1:76189801	ACADM	-0.39	-7.85	-0.3	1.74e-14	Daytime sleep phenotypes;
BRCA	cis	rs870825	0.929	rs72689261	chr4:185590897	C/A	cg04058563	chr4:185651563	MLF1IP	0.69	11.83	0.42	2.39e-29	Blood protein levels;
BRCA	cis	rs12986413	0.846	rs12609327	chr19:2183000	A/C	cg09261902	chr19:2140048	AP3D1	0.37	9.41	0.35	8.88e-20	Height;
BRCA	cis	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg06521331	chr12:34319734	NA	-0.61	-11.16	-0.4	1.47e-26	Morning vs. evening chronotype;
BRCA	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-9.34	-0.35	1.5700000000000001e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.42	-0.41	1.24e-27	Gut microbiome composition (summer);
BRCA	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	13.11	0.46	5.97e-35	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg07211511	chr3:129823064	LOC729375	-0.62	-10.94	-0.4	1.23e-25	Blood pressure (smoking interaction);
BRCA	cis	rs10492096	0.947	rs11064227	chr12:6598043	A/G	cg13857086	chr12:6580257	VAMP1	0.42	8.33	0.31	4.86e-16	Hip geometry;
BRCA	trans	rs208520	0.690	rs207118	chr6:66788948	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.23	-0.64	4.44e-76	Exhaled nitric oxide output;
BRCA	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg22903471	chr2:27725779	GCKR	-0.36	-8.88	-0.33	6.67e-18	Total body bone mineral density;
BRCA	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg18252515	chr7:66147081	NA	0.76	10.89	0.4	1.97e-25	Diabetic kidney disease;
BRCA	cis	rs72627509	0.904	rs12645070	chr4:57770106	G/A	cg26694713	chr4:57773883	REST	0.46	8.6	0.32	6.25e-17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg14186256	chr22:23484241	RTDR1	0.78	24.58	0.7	2.12e-94	Bone mineral density;
BRCA	cis	rs2599510	0.783	rs2038534	chr2:32659489	G/A	cg02381751	chr2:32503542	YIPF4	0.43	8.41	0.32	2.75e-16	Interleukin-18 levels;
BRCA	trans	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg26384229	chr12:38710491	ALG10B	0.43	10.55	0.39	4.07e-24	Morning vs. evening chronotype;
BRCA	trans	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg20935933	chr6:143382018	AIG1	0.61	11.7	0.42	8.67e-29	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-10.31	-0.38	3.61e-23	Mean corpuscular volume;
BRCA	cis	rs10501293	0.956	rs10768918	chr11:43134481	C/T	cg03447554	chr11:43094025	NA	-0.47	-8.65	-0.32	4.08e-17	Cognitive performance;
BRCA	cis	rs13082711	0.522	rs653886	chr3:27343549	C/T	cg02860705	chr3:27208620	NA	0.42	8.84	0.33	9.21e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs4595586	0.679	rs7955725	chr12:39322903	C/T	cg26384229	chr12:38710491	ALG10B	0.39	8.88	0.33	6.66e-18	Morning vs. evening chronotype;
BRCA	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.07	16.17	0.54	1.54e-49	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11644478	chr21:40555479	PSMG1	-0.52	-10.88	-0.4	2.07e-25	Menarche (age at onset);
BRCA	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-8.76	-0.33	1.77e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs208520	0.874	rs208517	chr6:66947040	G/T	cg07460842	chr6:66804631	NA	-0.89	-15.83	-0.53	7.13e-48	Exhaled nitric oxide output;
BRCA	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	9.92	0.37	1.1e-21	Lung cancer in ever smokers;
BRCA	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg22633769	chr20:60982531	CABLES2	0.43	7.95	0.3	8.7e-15	Colorectal cancer;
BRCA	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg03146154	chr1:46216737	IPP	-0.5	-11.16	-0.4	1.55e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg11833968	chr6:79620685	NA	-0.42	-9.52	-0.35	3.55e-20	Intelligence (multi-trait analysis);
BRCA	trans	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg19862616	chr7:65841803	NCRNA00174	0.84	27.31	0.73	1.94e-109	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	7.15e-19	Alzheimer's disease (late onset);
BRCA	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs8017423	0.630	rs12589687	chr14:90819570	C/G	cg04374321	chr14:90722782	PSMC1	-0.5	-11.93	-0.43	8.85e-30	Mortality in heart failure;
BRCA	cis	rs7766436	0.648	rs6908475	chr6:22572798	A/G	cg13666174	chr6:22585274	NA	-0.39	-9.83	-0.36	2.39e-21	Coronary artery disease;
BRCA	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg25173405	chr17:45401733	C17orf57	0.55	11.83	0.42	2.47e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg25174290	chr11:3078921	CARS	0.44	13.73	0.48	8.43e-38	Longevity;
BRCA	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	13.08	0.46	8.02e-35	Bone mineral density;
BRCA	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	8.54	0.32	9.65e-17	Schizophrenia;
BRCA	trans	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg07211511	chr3:129823064	LOC729375	-0.58	-11.02	-0.4	5.39e-26	Blood pressure (smoking interaction);
BRCA	cis	rs2882667	0.690	rs6596455	chr5:138167105	T/C	cg04439458	chr5:138467593	SIL1	0.34	8.47	0.32	1.73e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg00958927	chr1:175162553	KIAA0040	-0.21	-7.85	-0.3	1.71e-14	Alcohol dependence;
BRCA	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-16.81	-0.55	9.16e-53	Axial length;
BRCA	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	7.82	0.3	2.18e-14	Platelet count;
BRCA	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.64	0.55	6.41e-52	Colorectal cancer;
BRCA	trans	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg06521331	chr12:34319734	NA	-0.51	-9.36	-0.35	1.32e-19	Bladder cancer;
BRCA	cis	rs9790314	0.715	rs9290065	chr3:160776964	A/G	cg04691961	chr3:161091175	C3orf57	0.41	8.69	0.33	3.09e-17	Morning vs. evening chronotype;
BRCA	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg06115741	chr20:33292138	TP53INP2	0.39	8.73	0.33	2.22e-17	Glomerular filtration rate (creatinine);
BRCA	trans	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-34.85	-0.81	6.59e-150	Exhaled nitric oxide output;
BRCA	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg11822812	chr5:140052017	DND1	-0.3	-8.32	-0.31	5.16e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4363385	0.818	rs574649	chr1:153008471	G/A	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg00631329	chr6:26305371	NA	-0.43	-12.88	-0.45	6.66e-34	Educational attainment;
BRCA	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg08601574	chr20:25228251	PYGB	0.39	9.5	0.35	4.08e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04267008	chr7:1944627	MAD1L1	-0.57	-11.87	-0.43	1.65e-29	Bipolar disorder and schizophrenia;
BRCA	cis	rs250677	0.687	rs250679	chr5:148434952	A/T	cg12140854	chr5:148520817	ABLIM3	0.42	8.85	0.33	8.75e-18	Breast cancer;
BRCA	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg26373071	chr5:1325741	CLPTM1L	0.45	10.62	0.39	2.25e-24	Lung cancer;
BRCA	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-15.97	-0.53	1.41e-48	Chronic sinus infection;
BRCA	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg12379764	chr21:47803548	PCNT	-0.37	-7.86	-0.3	1.61e-14	Testicular germ cell tumor;
BRCA	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15320075	chr8:145703422	NA	-0.42	-9.12	-0.34	9.49e-19	Age at first birth;
BRCA	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.19e-47	Alzheimer's disease (late onset);
BRCA	cis	rs7524258	0.835	rs7543228	chr1:7306538	G/C	cg07173049	chr1:7289937	CAMTA1	0.41	10.1	0.37	2.32e-22	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg25817165	chr18:72167213	CNDP2	-0.73	-14.18	-0.49	6.77e-40	Refractive error;
BRCA	cis	rs6905628	1	rs6905628	chr6:90344869	C/G	cg23505970	chr6:90529759	MDN1	0.47	8.21	0.31	1.2e-15	Coronary artery disease;
BRCA	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.89	0.36	1.54e-21	Bladder cancer;
BRCA	cis	rs10242455	0.702	rs112475236	chr7:99044679	A/G	cg18809830	chr7:99032528	PTCD1	-0.59	-8.57	-0.32	7.81e-17	Blood metabolite levels;
BRCA	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg06713675	chr4:122721982	EXOSC9	-0.41	-10.28	-0.38	4.8e-23	Type 2 diabetes;
BRCA	cis	rs273218	1.000	rs168861	chr5:53377310	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.39	8.13	0.31	2.22e-15	Migraine;
BRCA	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.51	-10.6	-0.39	2.68e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1165668	0.816	rs1866072	chr12:104310706	C/G	cg21863207	chr12:104234989	NT5DC3	0.39	8.05	0.3	4.1e-15	Coronary heart disease (SNP X SNP interaction);
BRCA	cis	rs6545883	0.894	rs6545845	chr2:61437044	G/C	cg15711740	chr2:61764176	XPO1	0.52	13.12	0.46	5.26e-35	Tuberculosis;
BRCA	trans	rs61332075	0.518	rs72994950	chr2:239422993	T/C	cg01134436	chr17:81009848	B3GNTL1	0.7	9.0	0.34	2.56e-18	Lung function (FEV1/FVC);
BRCA	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg10729496	chr3:10149963	C3orf24	0.47	7.84	0.3	1.9e-14	Alzheimer's disease;
BRCA	trans	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17712092	chr4:129076599	LARP1B	-0.53	-12.8	-0.45	1.48e-33	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24110177	chr3:50126178	RBM5	-0.37	-9.96	-0.37	7.85e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.68	-0.42	1.1e-28	Electroencephalogram traits;
BRCA	cis	rs10911363	0.592	rs2702177	chr1:183450622	G/C	cg09173681	chr1:183549694	NCF2	0.49	10.7	0.39	1.05e-24	Systemic lupus erythematosus;
BRCA	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.54	-11.04	-0.4	4.88e-26	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.84	0.33	9.42e-18	Motion sickness;
BRCA	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg11789530	chr4:8429930	ACOX3	0.58	13.76	0.48	6.38e-38	Response to antineoplastic agents;
BRCA	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.93	0.56	2.07e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4363385	0.818	rs441229	chr1:153015059	A/C	cg24667326	chr1:152973720	SPRR3	-0.32	-8.83	-0.33	1.04e-17	Inflammatory skin disease;
BRCA	cis	rs7572733	0.515	rs1356542	chr2:198835702	G/T	cg00792783	chr2:198669748	PLCL1	0.45	9.85	0.36	2.05e-21	Dermatomyositis;
BRCA	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg16339924	chr4:17578868	LAP3	0.64	16.0	0.53	1.01e-48	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg27489772	chr12:121021490	NA	0.44	7.95	0.3	8.79e-15	Type 1 diabetes nephropathy;
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.6	-14.29	-0.49	2.12e-40	Longevity;Endometriosis;
BRCA	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg05347473	chr6:146136440	FBXO30	-0.4	-7.91	-0.3	1.14e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg06238570	chr21:40685208	BRWD1	0.41	8.4	0.32	2.96e-16	Cognitive function;
BRCA	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg20887711	chr4:1340912	KIAA1530	0.74	16.36	0.54	1.59e-50	Longevity;
BRCA	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	12.3	0.44	2.42e-31	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	-0.45	-9.08	-0.34	1.28e-18	Resistin levels;
BRCA	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.97	-0.37	7.54e-22	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10465746	0.901	rs17475760	chr1:84398435	A/T	cg10977910	chr1:84465055	TTLL7	0.49	9.8	0.36	3.17e-21	Obesity-related traits;
BRCA	trans	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg21167628	chr1:45308625	PTCH2	-0.32	-7.95	-0.3	8.45e-15	Facial morphology (factor 20);
BRCA	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg10523679	chr1:76189770	ACADM	-0.44	-8.37	-0.31	3.71e-16	Daytime sleep phenotypes;
BRCA	cis	rs13046373	0.535	rs1395775	chr21:32025065	G/A	cg16431978	chr21:31797932	KRTAP13-3	0.36	9.05	0.34	1.71e-18	HDL cholesterol;
BRCA	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg10560079	chr2:191398806	TMEM194B	0.37	8.24	0.31	9.67e-16	Pulse pressure;
BRCA	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	17.92	0.58	1.72e-58	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs6433895	1.000	rs12999974	chr2:182019537	G/A	cg00481216	chr2:181971175	NA	0.4	9.18	0.34	5.9e-19	Lymphocyte counts;
BRCA	cis	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs17604090	1.000	rs10272065	chr7:29694236	A/T	cg19413766	chr7:29689036	LOC646762	-0.59	-7.95	-0.3	8.38e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg09307838	chr4:120376055	NA	0.77	17.16	0.56	1.49e-54	Corneal astigmatism;
BRCA	cis	rs2070997	0.527	rs3847192	chr9:133724916	T/G	cg11464064	chr9:133710261	ABL1	0.6	9.66	0.36	1.1e-20	Response to amphetamines;
BRCA	trans	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.67	-0.36	9.61e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg25517755	chr10:38738941	LOC399744	-0.38	-8.0	-0.3	5.81e-15	Corneal astigmatism;
BRCA	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg09021430	chr5:549028	NA	-0.65	-13.67	-0.48	1.7e-37	Lung disease severity in cystic fibrosis;
BRCA	cis	rs4588572	0.643	rs1560195	chr5:77701913	A/G	cg11547950	chr5:77652471	NA	0.46	8.37	0.31	3.71e-16	Triglycerides;
BRCA	cis	rs1050631	0.564	rs8098627	chr18:33721636	T/G	cg19453250	chr18:33710783	SLC39A6;ELP2	-0.29	-7.94	-0.3	9.24e-15	Esophageal squamous cell cancer (length of survival);
BRCA	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.41	0.5	5.45e-41	Motion sickness;
BRCA	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg04691961	chr3:161091175	C3orf57	-0.44	-10.69	-0.39	1.18e-24	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.818	rs561143	chr1:153010734	C/T	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs775227	0.574	rs13083453	chr3:113096943	G/A	cg18753928	chr3:113234510	CCDC52	-0.58	-9.53	-0.35	3.24e-20	Dental caries;
BRCA	cis	rs9443189	0.526	rs9359132	chr6:76289553	G/A	cg01950844	chr6:76311363	SENP6	0.84	13.79	0.48	4.58e-38	Prostate cancer;
BRCA	cis	rs9316337	0.933	rs1409071	chr13:21962773	C/T	cg21011702	chr13:21951294	ZDHHC20	0.32	8.44	0.32	2.1e-16	Schizophrenia;
BRCA	cis	rs6714710	0.603	rs11690687	chr2:98461821	C/T	cg26665480	chr2:98280029	ACTR1B	0.55	12.92	0.46	4.45e-34	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs12618769	0.652	rs13402379	chr2:99209314	G/A	cg10123293	chr2:99228465	UNC50	0.42	8.67	0.32	3.58e-17	Bipolar disorder;
BRCA	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg24642439	chr20:33292090	TP53INP2	0.42	9.16	0.34	6.94e-19	Height;
BRCA	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg09904177	chr6:26538194	HMGN4	0.46	12.69	0.45	4.59e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg17971929	chr21:40555470	PSMG1	-0.61	-13.5	-0.47	1.03e-36	Cognitive function;
BRCA	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.53	-0.35	3.1e-20	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs12517041	1.000	rs16892325	chr5:23283742	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.24	-0.31	9.5e-16	Calcium levels;
BRCA	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg17063962	chr7:91808500	NA	0.53	12.49	0.44	3.35e-32	Breast cancer;
BRCA	cis	rs11920090	0.789	rs11711206	chr3:170732945	A/G	cg09710316	chr3:170744871	SLC2A2	0.56	9.53	0.35	3.18e-20	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.44	-10.1	-0.37	2.44e-22	Longevity;Endometriosis;
BRCA	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg00686598	chr14:53173677	PSMC6	1.15	15.86	0.53	5.01e-48	Alzheimer's disease (late onset);
BRCA	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg11742103	chr11:62369870	EML3;MTA2	-0.5	-10.78	-0.39	5.03e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03713592	chr11:72463424	ARAP1	0.8	11.92	0.43	1.05e-29	Type 2 diabetes;
BRCA	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg26384229	chr12:38710491	ALG10B	0.69	16.12	0.54	2.66e-49	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg00990874	chr7:1149470	C7orf50	-0.52	-9.49	-0.35	4.33e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg21772509	chr8:41503840	NKX6-3	0.48	11.25	0.41	6.69e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
BRCA	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08645402	chr16:4508243	NA	0.41	9.82	0.36	2.76e-21	Schizophrenia;
BRCA	cis	rs6546550	0.901	rs6754896	chr2:70138170	T/C	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.62	-0.42	1.93e-28	Prevalent atrial fibrillation;
BRCA	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg15556689	chr8:8085844	FLJ10661	-0.31	-8.15	-0.31	1.86e-15	Joint mobility (Beighton score);
BRCA	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg13736514	chr6:26305472	NA	-0.28	-9.34	-0.35	1.52e-19	Educational attainment;
BRCA	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.45	-0.61	1.55e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg00071950	chr4:10020882	SLC2A9	-0.41	-8.88	-0.33	6.7e-18	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs6910061	0.830	rs9468404	chr6:11092858	C/A	cg27233058	chr6:11094804	LOC221710	0.5	8.43	0.32	2.36e-16	Diabetic kidney disease;
BRCA	cis	rs2066819	1.000	rs2371454	chr12:56647243	A/G	cg26714650	chr12:56694279	CS	1.18	15.55	0.52	1.84e-46	Psoriasis vulgaris;
BRCA	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00149659	chr3:10157352	C3orf10	-1.05	-18.06	-0.58	3.29e-59	Alzheimer's disease;
BRCA	trans	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg26384229	chr12:38710491	ALG10B	0.49	10.01	0.37	4.99e-22	Resting heart rate;
BRCA	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.25	8.01	0.3	5.6e-15	Cardiac Troponin-T levels;
BRCA	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	8.85	0.33	8.6e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs12908161	0.515	rs12907646	chr15:85403496	G/A	cg12863693	chr15:85201151	NMB	0.44	8.03	0.3	4.77e-15	Schizophrenia;
BRCA	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg06784218	chr1:46089804	CCDC17	0.46	10.8	0.39	4.41e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1868673	1.000	rs4681619	chr3:150160253	G/A	cg04908077	chr3:150187338	NA	-0.33	-9.0	-0.34	2.56e-18	Waist circumference;
BRCA	cis	rs4953076	0.573	rs6726680	chr2:44406686	C/G	cg04920474	chr2:44395004	PPM1B	0.51	10.38	0.38	1.93e-23	Height;
BRCA	cis	rs7633770	0.841	rs11709936	chr3:46680483	C/G	cg11219411	chr3:46661640	NA	0.69	18.71	0.6	1.21e-62	Coronary artery disease;
BRCA	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg22713356	chr15:30763199	NA	1.3	24.11	0.69	7.71e-92	Uric acid levels;
BRCA	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg08645402	chr16:4508243	NA	0.44	10.11	0.37	2.15e-22	Schizophrenia;
BRCA	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg17971929	chr21:40555470	PSMG1	0.81	19.92	0.62	4.86e-69	Cognitive function;
BRCA	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg23711669	chr6:146136114	FBXO30	-0.69	-16.63	-0.55	6.96e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7520050	0.966	rs10890361	chr1:46346234	A/T	cg24296786	chr1:45957014	TESK2	0.36	8.42	0.32	2.4e-16	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22307029	chr19:49891270	CCDC155	0.57	9.77	0.36	4.09e-21	Multiple sclerosis;
BRCA	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg19196401	chr6:110721138	DDO	-0.41	-10.23	-0.38	7.46e-23	Platelet distribution width;
BRCA	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg00012203	chr2:219082015	ARPC2	0.51	10.35	0.38	2.63e-23	Colorectal cancer;
BRCA	cis	rs9487051	0.646	rs4548045	chr6:109576135	C/T	cg01475377	chr6:109611718	NA	-0.41	-8.13	-0.31	2.21e-15	Reticulocyte fraction of red cells;
BRCA	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg04450456	chr4:17643702	FAM184B	0.41	11.95	0.43	7.41e-30	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg21143896	chr7:2802374	GNA12	0.34	8.76	0.33	1.71e-17	Height;
BRCA	cis	rs7408868	1.000	rs757475	chr19:15273749	C/T	cg14696996	chr19:15285081	NOTCH3	0.99	14.46	0.5	3.39e-41	Pulse pressure;
BRCA	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.75	-0.55	1.78e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.35	0.49	1.13e-40	Motion sickness;
BRCA	cis	rs36051895	0.623	rs3780382	chr9:5232299	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-8.9	-0.33	5.88e-18	Pediatric autoimmune diseases;
BRCA	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg13334819	chr7:99746414	C7orf59	0.34	7.94	0.3	9.32e-15	Coronary artery disease;
BRCA	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg16482183	chr6:26056742	HIST1H1C	0.49	9.66	0.36	1.1e-20	Iron status biomarkers;
BRCA	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg00383909	chr3:49044727	WDR6	0.97	15.71	0.53	2.72e-47	Cognitive function;
BRCA	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg11843238	chr5:131593191	PDLIM4	0.36	7.91	0.3	1.17e-14	Breast cancer;
BRCA	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24549020	chr5:56110836	MAP3K1	0.52	10.52	0.38	5.72e-24	Initial pursuit acceleration;
BRCA	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09263875	chr16:632152	PIGQ	0.73	21.12	0.64	1.65e-75	Height;
BRCA	trans	rs526821	0.574	rs11230156	chr11:55334809	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.91	-0.3	1.11e-14	Pediatric bone mineral density (spine);
BRCA	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.79	0.55	1.14e-52	Hypertriglyceridemia;
BRCA	cis	rs700651	0.856	rs9288280	chr2:198744324	A/G	cg00792783	chr2:198669748	PLCL1	0.46	10.14	0.37	1.66e-22	Intracranial aneurysm;
BRCA	cis	rs2901460	0.527	rs10167456	chr2:62112839	G/A	cg02183531	chr2:62113199	CCT4	-0.45	-9.17	-0.34	6.51e-19	Mean corpuscular volume;
BRCA	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg06212747	chr3:49208901	KLHDC8B	0.54	11.79	0.42	3.7e-29	Menarche (age at onset);
BRCA	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg25801113	chr15:45476975	SHF	-0.33	-8.3	-0.31	6.21e-16	Uric acid levels;
BRCA	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg12386194	chr3:101231763	SENP7	-0.45	-9.61	-0.36	1.6e-20	Colorectal cancer;
BRCA	trans	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.06	0.3	3.79e-15	Corneal astigmatism;
BRCA	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg00757033	chr12:89920650	WDR51B	0.53	10.57	0.39	3.7e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.56	10.89	0.4	1.95e-25	Birth weight;
BRCA	cis	rs6594713	0.717	rs10065790	chr5:112911165	C/T	cg12552261	chr5:112820674	MCC	0.48	8.22	0.31	1.18e-15	Brain cytoarchitecture;
BRCA	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg27129171	chr3:47204927	SETD2	0.57	10.36	0.38	2.27e-23	Birth weight;
BRCA	cis	rs490234	0.683	rs2841326	chr9:128161768	G/A	cg14078157	chr9:128172775	NA	-0.36	-8.53	-0.32	1.05e-16	Mean arterial pressure;
BRCA	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg01939980	chr4:1354348	KIAA1530	0.31	8.71	0.33	2.69e-17	Longevity;
BRCA	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg15556689	chr8:8085844	FLJ10661	-0.32	-8.39	-0.32	3.22e-16	Neuroticism;
BRCA	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg21475434	chr5:93447410	FAM172A	0.68	8.86	0.33	7.78e-18	Diabetic retinopathy;
BRCA	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg16405210	chr4:1374714	KIAA1530	0.94	23.7	0.68	1.41e-89	Longevity;
BRCA	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg25019033	chr10:957182	NA	-0.41	-8.63	-0.32	4.83e-17	Eosinophil percentage of granulocytes;
BRCA	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21659725	chr3:3221576	CRBN	-0.45	-11.07	-0.4	3.57e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.63	0.39	2.12e-24	Aortic root size;
BRCA	cis	rs2882667	0.861	rs13176902	chr5:138393329	T/C	cg04439458	chr5:138467593	SIL1	-0.33	-9.01	-0.34	2.31e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs877282	0.853	rs12779017	chr10:763619	T/C	cg17470449	chr10:769945	NA	0.47	7.92	0.3	1.08e-14	Uric acid levels;
BRCA	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	12.84	0.45	9.76e-34	Menarche (age at onset);
BRCA	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg25817165	chr18:72167213	CNDP2	-0.77	-19.53	-0.61	5.84e-67	Refractive error;
BRCA	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.94	-0.37	9.36e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg21280719	chr6:42927975	GNMT	-0.32	-13.8	-0.48	4.05e-38	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4820318	1	rs4820318	chr22:38570313	G/A	cg25457927	chr22:38595422	NA	-0.35	-12.65	-0.45	6.86e-33	Breast cancer;
BRCA	cis	rs9296092	0.538	rs62407567	chr6:33537213	A/G	cg13560919	chr6:33536144	NA	-0.87	-16.36	-0.54	1.61e-50	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs7980687	0.550	rs1727324	chr12:123698603	A/T	cg00376283	chr12:123451042	ABCB9	0.55	10.54	0.38	4.47e-24	Height;Educational attainment;Head circumference (infant);
BRCA	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg01256987	chr12:42539512	GXYLT1	-0.46	-9.22	-0.34	4.42e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs225245	0.687	rs321614	chr17:33881734	A/G	cg08516792	chr17:33866067	SLFN12L	0.35	7.9	0.3	1.25e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg08470875	chr2:26401718	FAM59B	0.71	11.35	0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg11062466	chr8:58055876	NA	0.5	8.74	0.33	2.04e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4302748	0.862	rs57007022	chr7:36187369	C/T	cg24442661	chr7:36192818	EEPD1	0.46	8.8	0.33	1.27e-17	Platelet count;
BRCA	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.22	-0.31	1.15e-15	Depression;
BRCA	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11890956	chr21:40555474	PSMG1	1.05	29.86	0.76	2.64e-123	Cognitive function;
BRCA	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg08470875	chr2:26401718	FAM59B	0.49	8.09	0.3	3.04e-15	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-8.59	-0.32	6.42e-17	Schizophrenia;
BRCA	cis	rs28374715	0.578	rs17730888	chr15:41637547	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.06	-25.89	-0.72	1.3e-101	Ulcerative colitis;
BRCA	cis	rs6977660	0.505	rs9639338	chr7:19869778	T/A	cg05791153	chr7:19748676	TWISTNB	0.49	9.41	0.35	8.92e-20	Thyroid stimulating hormone;
BRCA	cis	rs7646881	1.000	rs59217052	chr3:158452456	C/T	cg19483011	chr3:158453295	NA	-0.49	-9.32	-0.35	1.81e-19	Tetralogy of Fallot;
BRCA	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg14675211	chr2:100938903	LONRF2	0.52	11.62	0.42	1.92e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg05526886	chr2:227700861	RHBDD1	-0.41	-8.55	-0.32	9.19e-17	Pulmonary function;
BRCA	trans	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg06521331	chr12:34319734	NA	-0.45	-8.39	-0.32	3.03e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg04546413	chr19:29218101	NA	0.64	12.31	0.44	2.04e-31	Methadone dose in opioid dependence;
BRCA	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg20203395	chr5:56204925	C5orf35	-0.49	-10.52	-0.38	5.5e-24	Initial pursuit acceleration;
BRCA	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg07169764	chr2:136633963	MCM6	1.22	23.89	0.69	1.27e-90	Corneal structure;
BRCA	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg14196790	chr5:131705035	SLC22A5	-0.5	-13.76	-0.48	6.66e-38	Blood metabolite levels;
BRCA	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg04842962	chr6:43655489	MRPS18A	1.12	38.52	0.84	1.01e-168	IgG glycosylation;
BRCA	cis	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg24692254	chr21:30365293	RNF160	-0.44	-7.89	-0.3	1.3e-14	Cognitive test performance;
BRCA	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-18.07	-0.58	3e-59	Chronic sinus infection;
BRCA	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	14.46	0.5	3.43e-41	Alzheimer's disease;
BRCA	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	trans	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg13565492	chr6:43139072	SRF	-0.73	-13.47	-0.47	1.35e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg04565464	chr8:145669602	NFKBIL2	-0.36	-8.97	-0.33	3.31e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.34	7.83	0.3	2e-14	Multiple sclerosis;
BRCA	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.5	-0.44	3.1e-32	Type 2 diabetes;
BRCA	cis	rs9837602	0.748	rs9875878	chr3:99884509	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	8.57	0.32	7.74e-17	Breast cancer;
BRCA	cis	rs4727443	0.691	rs6975827	chr7:99585798	C/G	cg22004693	chr7:99632812	ZKSCAN1	-0.38	-8.51	-0.32	1.24e-16	Interstitial lung disease;
BRCA	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-9.74	-0.36	5.51e-21	Alzheimer's disease (late onset);
BRCA	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg05294307	chr14:35346193	BAZ1A	-0.6	-11.71	-0.42	8.13e-29	Psoriasis;
BRCA	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-14.21	-0.49	5.18e-40	Monocyte count;
BRCA	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg23029597	chr12:123009494	RSRC2	-0.6	-11.69	-0.42	9.17e-29	Body mass index;
BRCA	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg16262614	chr3:133464971	TF	0.25	8.02	0.3	5.02e-15	Iron status biomarkers (transferrin levels);
BRCA	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg06784218	chr1:46089804	CCDC17	0.44	10.51	0.38	5.97e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg13010199	chr12:38710504	ALG10B	0.4	8.34	0.31	4.52e-16	Bladder cancer;
BRCA	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg20203395	chr5:56204925	C5orf35	0.43	9.56	0.35	2.43e-20	Initial pursuit acceleration;
BRCA	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg06618935	chr21:46677482	NA	-0.36	-8.0	-0.3	5.66e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg10518572	chr11:65560635	OVOL1	-0.28	-8.1	-0.31	2.71e-15	Acne (severe);
BRCA	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	8.8	0.33	1.28e-17	Iron status biomarkers;
BRCA	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg12365402	chr11:9010492	NRIP3	0.43	9.5	0.35	4.24e-20	Hemoglobin concentration;
BRCA	cis	rs524281	0.692	rs2302884	chr11:65824084	C/T	cg14036092	chr11:66035641	RAB1B	-0.41	-8.98	-0.33	2.89e-18	Electroencephalogram traits;
BRCA	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg18252515	chr7:66147081	NA	1.05	15.84	0.53	6.5e-48	Diabetic kidney disease;
BRCA	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg18404041	chr3:52824283	ITIH1	-0.3	-7.82	-0.3	2.26e-14	Schizophrenia;
BRCA	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-9.53	-0.35	3.25e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11905131	chr22:24372483	LOC391322	-0.54	-11.91	-0.43	1.07e-29	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.33	0.35	1.73e-19	Morning vs. evening chronotype;
BRCA	cis	rs9807989	0.507	rs10439410	chr2:102990788	A/C	cg03938978	chr2:103052716	IL18RAP	-0.29	-8.45	-0.32	1.9e-16	Asthma;
BRCA	cis	rs6142102	0.961	rs2284386	chr20:32644396	G/A	cg24642439	chr20:33292090	TP53INP2	0.41	8.01	0.3	5.34e-15	Skin pigmentation;
BRCA	trans	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg25206134	chr2:45395956	NA	-0.53	-8.88	-0.33	6.74e-18	Bipolar disorder;
BRCA	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg16586182	chr3:47516702	SCAP	0.56	12.68	0.45	5.17e-33	Colorectal cancer;
BRCA	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg00080972	chr5:178986291	RUFY1	0.53	14.71	0.5	2.12e-42	Lung cancer;
BRCA	cis	rs10465746	0.747	rs10493741	chr1:84388118	G/C	cg10977910	chr1:84465055	TTLL7	0.58	11.96	0.43	6.85e-30	Obesity-related traits;
BRCA	cis	rs1371614	0.502	rs4572551	chr2:27194013	T/C	cg00617064	chr2:27272375	NA	-0.33	-8.62	-0.32	5.09e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg04756594	chr16:24857601	SLC5A11	-0.53	-12.2	-0.43	6.31e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg11584989	chr19:19387371	SF4	0.64	13.48	0.47	1.26e-36	Bipolar disorder;
BRCA	cis	rs829883	0.902	rs829884	chr12:98879500	C/G	cg25150519	chr12:98850993	NA	0.58	11.77	0.42	4.21e-29	Colorectal adenoma (advanced);
BRCA	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-12.98	-0.46	2.27e-34	Response to antipsychotic treatment;
BRCA	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18876405	chr7:65276391	NA	-0.62	-15.48	-0.52	4.02e-46	Aortic root size;
BRCA	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg16325326	chr1:53192061	ZYG11B	0.7	16.97	0.56	1.39e-53	Monocyte count;
BRCA	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg23711669	chr6:146136114	FBXO30	-0.68	-15.6	-0.53	9.68e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg05283184	chr6:79620031	NA	-0.43	-11.0	-0.4	6.5e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg01304814	chr3:48885189	PRKAR2A	0.67	7.82	0.3	2.15e-14	Cognitive function;
BRCA	cis	rs9649213	0.586	rs55648546	chr7:97960800	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.59	-15.77	-0.53	1.53e-47	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg04450456	chr4:17643702	FAM184B	0.33	9.65	0.36	1.15e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6028335	0.674	rs66513266	chr20:37597410	G/T	cg16355469	chr20:37678765	NA	0.46	8.2	0.31	1.29e-15	Alcohol and nicotine co-dependence;
BRCA	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg10792982	chr14:105748885	BRF1	0.44	10.4	0.38	1.7e-23	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs921968	0.565	rs7594046	chr2:219624170	A/G	cg02176678	chr2:219576539	TTLL4	0.41	11.04	0.4	4.83e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.27	-0.38	5.25e-23	Morning vs. evening chronotype;
BRCA	cis	rs7011049	1.000	rs11995106	chr8:53834768	C/T	cg26025543	chr8:53854495	NA	0.54	9.86	0.36	1.85e-21	Systolic blood pressure;
BRCA	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.56	-13.3	-0.47	8.33e-36	Longevity;Endometriosis;
BRCA	trans	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg26043149	chr18:55253948	FECH	0.43	9.34	0.35	1.58e-19	Bone mineral density;
BRCA	cis	rs7584330	0.740	rs7586312	chr2:238439389	G/A	cg14458575	chr2:238380390	NA	0.39	8.62	0.32	5.43e-17	Prostate cancer;
BRCA	cis	rs7904985	0.924	rs2217223	chr10:88111630	A/G	cg07322936	chr10:88137208	NA	0.49	10.34	0.38	2.86e-23	Barrett's esophagus;
BRCA	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg23992470	chr4:843637	GAK	0.55	8.19	0.31	1.42e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg06547715	chr2:218990976	CXCR2	0.32	7.96	0.3	7.76e-15	Ulcerative colitis;
BRCA	cis	rs2629540	0.889	rs10901808	chr10:126399159	A/C	cg08799069	chr10:126477246	METTL10	0.45	9.15	0.34	7.66e-19	Cocaine dependence;
BRCA	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-13.45	-0.47	1.65e-36	Morning vs. evening chronotype;
BRCA	cis	rs4478858	0.735	rs10798843	chr1:31797094	A/G	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg03354898	chr7:1950403	MAD1L1	-0.45	-8.81	-0.33	1.18e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg08885076	chr2:99613938	TSGA10	0.44	10.13	0.37	1.76e-22	Chronic sinus infection;
BRCA	cis	rs4588572	0.570	rs6453389	chr5:77727003	T/G	cg11547950	chr5:77652471	NA	-0.44	-8.41	-0.32	2.75e-16	Triglycerides;
BRCA	cis	rs7631605	0.625	rs11718848	chr3:37366459	C/A	cg15934958	chr3:37212084	LRRFIP2	0.38	8.11	0.31	2.61e-15	Cerebrospinal P-tau181p levels;
BRCA	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg25024717	chr12:54324583	NA	-0.3	-7.96	-0.3	7.92e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
BRCA	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.37	0.38	2.23e-23	Motion sickness;
BRCA	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg11764359	chr7:65958608	NA	0.63	13.68	0.48	1.54e-37	Aortic root size;
BRCA	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg27588902	chr6:42928151	GNMT	-0.3	-10.13	-0.37	1.77e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg01448562	chr3:133502909	NA	-0.63	-15.06	-0.51	4.14e-44	Iron status biomarkers;
BRCA	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	14.31	0.49	1.79e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg14664628	chr15:75095509	CSK	-0.95	-29.16	-0.76	1.67e-119	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg21918786	chr6:109611834	NA	-0.49	-14.13	-0.49	1.19e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs7677751	0.806	rs4864858	chr4:55089953	T/A	cg17187183	chr4:55093834	PDGFRA	0.44	9.17	0.34	6.18e-19	Corneal astigmatism;
BRCA	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08645402	chr16:4508243	NA	0.47	10.77	0.39	5.59e-25	Schizophrenia;
BRCA	cis	rs507080	0.922	rs638805	chr11:118558889	G/T	cg09144398	chr11:118550485	TREH	-0.37	-8.96	-0.33	3.5e-18	Serum metabolite levels;
BRCA	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	trans	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07923666	chr12:49932857	KCNH3	-0.39	-7.84	-0.3	1.88e-14	Resting heart rate;
BRCA	trans	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg21659725	chr3:3221576	CRBN	-0.49	-8.5	-0.32	1.31e-16	Menarche (age at onset);
BRCA	cis	rs7809950	1.000	rs2520260	chr7:107172794	A/G	cg23024343	chr7:107201750	COG5	-0.39	-9.03	-0.34	2.06e-18	Coronary artery disease;
BRCA	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26314531	chr2:26401878	FAM59B	0.93	14.99	0.51	9.06e-44	Gut microbiome composition (summer);
BRCA	trans	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	19.86	0.62	9.99e-69	Exhaled nitric oxide output;
BRCA	cis	rs36051895	0.695	rs10974915	chr9:5016818	A/G	cg02405213	chr9:5042618	JAK2	-0.45	-8.4	-0.32	2.83e-16	Pediatric autoimmune diseases;
BRCA	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-15.54	-0.52	1.92e-46	Systemic lupus erythematosus;
BRCA	cis	rs10463316	0.894	rs7719630	chr5:150760961	C/T	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.24	-0.31	1.01e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg18252515	chr7:66147081	NA	-0.84	-12.14	-0.43	1.2e-30	Diabetic kidney disease;
BRCA	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	15.95	0.53	1.88e-48	Fuchs's corneal dystrophy;
BRCA	cis	rs3857067	0.806	rs7654565	chr4:95112939	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.49	-0.35	4.67e-20	QT interval;
BRCA	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg10932868	chr11:921992	NA	0.49	12.63	0.45	8.38e-33	Alzheimer's disease (late onset);
BRCA	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg20387954	chr3:183756860	HTR3D	0.45	10.14	0.37	1.6e-22	Anterior chamber depth;
BRCA	cis	rs6460942	0.597	rs13245635	chr7:12526454	T/A	cg06484146	chr7:12443880	VWDE	-0.6	-7.85	-0.3	1.8e-14	Coronary artery disease;
BRCA	cis	rs6484504	0.600	rs7122895	chr11:31346620	G/C	cg26647111	chr11:31128758	NA	0.45	9.71	0.36	7.27e-21	Red blood cell count;
BRCA	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg21573476	chr21:45109991	RRP1B	-0.36	-9.19	-0.34	5.66e-19	Mean corpuscular volume;
BRCA	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg20476274	chr7:133979776	SLC35B4	0.63	18.07	0.58	3.03e-59	Mean platelet volume;
BRCA	cis	rs758324	0.947	rs924434	chr5:131143369	A/C	cg06307176	chr5:131281290	NA	0.54	10.78	0.39	5.26e-25	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg17691542	chr6:26056736	HIST1H1C	0.47	9.74	0.36	5.38e-21	Height;
BRCA	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg02175503	chr12:58329896	NA	0.61	14.45	0.5	3.63e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.82	-13.59	-0.47	4.07e-37	Platelet count;
BRCA	cis	rs922182	0.617	rs28737203	chr15:64241169	C/T	cg24729988	chr15:64271149	DAPK2	0.49	10.72	0.39	9.37e-25	Blood protein levels;
BRCA	trans	rs12517041	1.000	rs1428620	chr5:23283138	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.32	-0.31	5.27e-16	Calcium levels;
BRCA	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg27170947	chr2:26402098	FAM59B	0.77	11.01	0.4	6.14e-26	Gut microbiome composition (summer);
BRCA	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg04267008	chr7:1944627	MAD1L1	-0.45	-9.79	-0.36	3.44e-21	Schizophrenia;
BRCA	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg24747557	chr10:131355152	MGMT	-0.4	-10.04	-0.37	3.98e-22	Response to temozolomide;
BRCA	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg18357645	chr12:58087776	OS9	0.46	13.11	0.46	6.25e-35	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg20203395	chr5:56204925	C5orf35	-0.52	-10.59	-0.39	2.92e-24	Initial pursuit acceleration;
BRCA	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg19901468	chr14:105411992	AHNAK2	-0.51	-12.48	-0.44	3.82e-32	Rheumatoid arthritis;
BRCA	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24229701	chr12:130821962	PIWIL1	0.39	8.89	0.33	6.08e-18	Menopause (age at onset);
BRCA	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	12.1	0.43	1.72e-30	Mean platelet volume;
BRCA	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg20701182	chr2:24300061	SF3B14	0.69	13.13	0.46	4.96e-35	Lymphocyte counts;
BRCA	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg20790798	chr5:1857306	NA	-0.37	-8.88	-0.33	6.68e-18	Cardiovascular disease risk factors;
BRCA	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg00147160	chr1:26503991	CNKSR1	0.29	9.39	0.35	1e-19	Height;
BRCA	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.89e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22307029	chr19:49891270	CCDC155	0.56	10.41	0.38	1.53e-23	Multiple sclerosis;
BRCA	trans	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg06521331	chr12:34319734	NA	0.46	9.09	0.34	1.22e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-8.0	-0.3	5.87e-15	Longevity;Endometriosis;
BRCA	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg16322792	chr1:120165303	ZNF697	0.58	15.43	0.52	6.54e-46	Systemic lupus erythematosus;
BRCA	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg16405210	chr4:1374714	KIAA1530	-0.91	-20.96	-0.64	1.29e-74	Longevity;
BRCA	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg23533926	chr12:111358616	MYL2	-0.41	-8.58	-0.32	7.18e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg21475434	chr5:93447410	FAM172A	0.69	8.65	0.32	4.2e-17	Diabetic retinopathy;
BRCA	trans	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg06521331	chr12:34319734	NA	-0.47	-8.73	-0.33	2.28e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg07169764	chr2:136633963	MCM6	1.32	32.61	0.79	4.13e-138	Corneal structure;
BRCA	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	14.26	0.49	2.84e-40	Calcium levels;
BRCA	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg14683738	chr19:37701593	ZNF585B	0.44	7.89	0.3	1.3e-14	Coronary artery calcification;
BRCA	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg08000102	chr2:233561755	GIGYF2	0.56	12.05	0.43	2.81e-30	Coronary artery disease;
BRCA	cis	rs7927771	0.524	rs7939420	chr11:47723938	A/G	cg20307385	chr11:47447363	PSMC3	-0.39	-9.01	-0.34	2.44e-18	Subjective well-being;
BRCA	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg02659138	chr7:134003124	SLC35B4	0.35	9.98	0.37	6.79e-22	Mean platelet volume;
BRCA	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg19077165	chr18:44547161	KATNAL2	0.37	7.81	0.3	2.39e-14	Personality dimensions;
BRCA	cis	rs8010715	0.816	rs11574503	chr14:24601318	C/G	cg23112188	chr14:24563095	PCK2	0.32	8.06	0.3	3.82e-15	IgG glycosylation;
BRCA	cis	rs2880765	0.835	rs12708553	chr15:86046833	C/G	cg10818794	chr15:86012489	AKAP13	0.3	8.38	0.31	3.47e-16	Coronary artery disease;
BRCA	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.62	8.73	0.33	2.29e-17	Schizophrenia;
BRCA	trans	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg23762105	chr12:34175262	ALG10	0.35	8.05	0.3	3.92e-15	Morning vs. evening chronotype;
BRCA	cis	rs921968	0.565	rs13408427	chr2:219628389	C/T	cg02176678	chr2:219576539	TTLL4	-0.42	-11.2	-0.41	1e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg09436375	chr6:42928200	GNMT	-0.29	-10.93	-0.4	1.36e-25	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs11674184	0.659	rs59129126	chr2:11728388	T/C	cg07314298	chr2:11723111	GREB1	-0.8	-19.77	-0.62	2.91e-68	Endometriosis;
BRCA	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg20701182	chr2:24300061	SF3B14	0.71	13.24	0.46	1.62e-35	Lymphocyte counts;
BRCA	cis	rs7264396	0.836	rs6058276	chr20:34187728	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-12.05	-0.43	2.88e-30	Total cholesterol levels;
BRCA	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg03954927	chr1:10346856	KIF1B	0.43	13.7	0.48	1.21e-37	Hepatocellular carcinoma;
BRCA	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg03342759	chr3:160939853	NMD3	-0.63	-14.06	-0.49	2.6e-39	Morning vs. evening chronotype;
BRCA	cis	rs12760731	0.720	rs71628282	chr1:178449993	C/G	cg00404053	chr1:178313656	RASAL2	0.69	8.6	0.32	6.18e-17	Obesity-related traits;
BRCA	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg26384229	chr12:38710491	ALG10B	0.7	15.72	0.53	2.55e-47	Bladder cancer;
BRCA	cis	rs897080	0.552	rs1067378	chr2:44648047	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	9.68	0.36	8.88e-21	Height;
BRCA	cis	rs977987	0.806	rs2865531	chr16:75390316	T/A	cg03315344	chr16:75512273	CHST6	0.53	12.64	0.45	7.21e-33	Dupuytren's disease;
BRCA	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	12.26	0.44	3.52e-31	Obesity-related traits;
BRCA	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-9.95	-0.37	8.92e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg03585969	chr10:35415529	CREM	0.55	11.23	0.41	7.64e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	14.33	0.49	1.4e-40	Ileal carcinoids;
BRCA	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg21905437	chr5:178450457	ZNF879	-0.51	-10.6	-0.39	2.61e-24	Pubertal anthropometrics;
BRCA	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg03425785	chr20:62221387	GMEB2	0.51	8.17	0.31	1.6e-15	Glioblastoma;
BRCA	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg00147160	chr1:26503991	CNKSR1	0.28	9.24	0.34	3.71e-19	Height;
BRCA	cis	rs7395581	0.959	rs326222	chr11:47259668	A/G	cg25783544	chr11:47291846	MADD	-0.38	-8.31	-0.31	5.84e-16	HDL cholesterol;
BRCA	cis	rs1215050	0.791	rs11729826	chr4:98657190	G/T	cg05340658	chr4:99064831	C4orf37	-0.44	-9.97	-0.37	7.4e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21659725	chr3:3221576	CRBN	0.5	11.29	0.41	4.35e-27	Resting heart rate;
BRCA	cis	rs2066819	1.000	rs79436528	chr12:56686997	C/T	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs6545883	0.929	rs2264100	chr2:61670829	G/A	cg15711740	chr2:61764176	XPO1	-0.56	-14.22	-0.49	4.62e-40	Tuberculosis;
BRCA	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg24692254	chr21:30365293	RNF160	0.49	10.84	0.39	3e-25	Pancreatic cancer;
BRCA	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.64	-13.69	-0.48	1.4e-37	Lymphocyte counts;
BRCA	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg01689657	chr7:91764605	CYP51A1	0.24	8.77	0.33	1.56e-17	Breast cancer;
BRCA	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg24006582	chr15:45444508	DUOX1	0.56	11.12	0.4	2.28e-26	Uric acid levels;
BRCA	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg10729496	chr3:10149963	C3orf24	0.49	9.34	0.35	1.5700000000000001e-19	Alzheimer's disease;
BRCA	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg02551604	chr5:131831745	NA	0.39	14.32	0.49	1.46e-40	Asthma (sex interaction);
BRCA	cis	rs17095355	1.000	rs72828241	chr10:111744704	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.43	-9.14	-0.34	8.28e-19	Biliary atresia;
BRCA	cis	rs490234	0.841	rs536861	chr9:128313444	A/C	cg14078157	chr9:128172775	NA	0.34	8.11	0.31	2.66e-15	Mean arterial pressure;
BRCA	cis	rs1371614	0.545	rs13035643	chr2:27173341	G/A	cg00617064	chr2:27272375	NA	0.31	8.07	0.3	3.62e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs6484504	0.576	rs2616792	chr11:31324298	T/G	cg14844989	chr11:31128820	NA	0.45	9.52	0.35	3.5e-20	Red blood cell count;
BRCA	cis	rs4730250	0.707	rs257387	chr7:106808480	G/A	cg02696742	chr7:106810147	HBP1	-0.61	-9.62	-0.36	1.49e-20	Osteoarthritis;
BRCA	trans	rs1422110	0.513	rs1363264	chr5:85450380	G/C	cg01787110	chr1:109008453	NBPF6	0.37	8.16	0.31	1.76e-15	Attention function in attention deficit hyperactive disorder;
BRCA	trans	rs12517041	1.000	rs34069672	chr5:23281789	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.33	-0.31	4.92e-16	Calcium levels;
BRCA	trans	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.36	-8.13	-0.31	2.25e-15	Corneal astigmatism;
BRCA	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg23992470	chr4:843637	GAK	0.48	8.12	0.31	2.32e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg05347473	chr6:146136440	FBXO30	0.44	8.7	0.33	2.8e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	22.12	0.66	5.79e-81	Platelet count;
BRCA	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg24130564	chr14:104152367	KLC1	-0.39	-8.79	-0.33	1.33e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg00321850	chr1:175162397	KIAA0040	-0.41	-11.47	-0.41	8.16e-28	Alcohol dependence;
BRCA	cis	rs72615157	0.539	rs2261360	chr7:99692993	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.53	11.04	0.4	4.49e-26	Lung function (FEV1/FVC);
BRCA	cis	rs11608355	0.705	rs6663	chr12:109886603	G/A	cg05360138	chr12:110035743	NA	0.45	8.55	0.32	8.76e-17	Neuroticism;
BRCA	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg08213375	chr14:104286397	PPP1R13B	0.65	18.39	0.59	5.96e-61	Schizophrenia;
BRCA	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg23262073	chr20:60523788	NA	0.4	8.6	0.32	6.05e-17	Body mass index;
BRCA	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg04691961	chr3:161091175	C3orf57	-0.58	-14.01	-0.48	4.43e-39	Morning vs. evening chronotype;
BRCA	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg03433033	chr1:76189801	ACADM	0.7	13.81	0.48	3.94e-38	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	19.33	0.61	6.67e-66	Smoking behavior;
BRCA	cis	rs1003719	0.628	rs2252402	chr21:38520720	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	11.01	0.4	6.36e-26	Eye color traits;
BRCA	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg04586622	chr2:25135609	ADCY3	0.43	10.7	0.39	1.13e-24	Body mass index;
BRCA	trans	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg06521331	chr12:34319734	NA	0.44	8.74	0.33	2.07e-17	Bladder cancer;
BRCA	cis	rs208520	0.874	rs208456	chr6:66907942	A/G	cg07460842	chr6:66804631	NA	-0.89	-15.26	-0.52	4.77e-45	Exhaled nitric oxide output;
BRCA	cis	rs17401966	0.838	rs2105212	chr1:10281012	T/C	cg03954927	chr1:10346856	KIF1B	0.41	12.97	0.46	2.59e-34	Hepatocellular carcinoma;
BRCA	trans	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	8.92e-15	Corneal astigmatism;
BRCA	cis	rs2425143	1.000	rs6058311	chr20:34321895	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.0	-0.34	2.6e-18	Blood protein levels;
BRCA	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.51	-0.44	2.97e-32	Bipolar disorder;
BRCA	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.76	16.9	0.56	2.89e-53	Lymphocyte counts;
BRCA	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.25	-0.31	9.2e-16	Axial length;
BRCA	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg13319975	chr6:146136371	FBXO30	-0.41	-9.39	-0.35	1.01e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4642101	0.855	rs9836128	chr3:12845426	G/C	cg24848339	chr3:12840334	CAND2	0.41	10.56	0.39	3.86e-24	QRS complex (12-leadsum);
BRCA	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.24	-0.41	6.91e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs501916	0.634	rs61333299	chr15:48066806	G/A	cg16110827	chr15:48056943	SEMA6D	-0.42	-8.67	-0.32	3.56e-17	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs72792276	0.818	rs3805610	chr5:127487719	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	9.29	0.35	2.34e-19	Red cell distribution width;
BRCA	cis	rs7851660	0.967	rs7043885	chr9:100596439	C/T	cg13688889	chr9:100608707	NA	-0.37	-8.78	-0.33	1.52e-17	Strep throat;
BRCA	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg19784903	chr17:45786737	TBKBP1	0.33	7.97	0.3	7.06e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1997103	1.000	rs9642580	chr7:55400359	G/A	cg17469321	chr7:55412551	NA	0.49	9.25	0.34	3.45e-19	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs11051970	0.838	rs2651369	chr12:32552769	C/G	cg02745156	chr12:32552066	NA	0.29	9.28	0.34	2.64e-19	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11764359	chr7:65958608	NA	0.75	16.57	0.55	1.37e-51	Aortic root size;
BRCA	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg04450456	chr4:17643702	FAM184B	0.32	9.34	0.35	1.5700000000000001e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg19901468	chr14:105411992	AHNAK2	-0.51	-12.43	-0.44	6.12e-32	Rheumatoid arthritis;
BRCA	trans	rs9784649	0.760	rs17403440	chr5:25054004	C/T	cg11038491	chr20:34638489	LOC647979	-0.5	-9.62	-0.36	1.48e-20	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs12220238	0.818	rs10824082	chr10:75904080	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.5	8.22	0.31	1.11e-15	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg06627628	chr2:24431161	ITSN2	-0.56	-9.13	-0.34	8.8e-19	Lymphocyte counts;
BRCA	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg27279351	chr12:120934652	DYNLL1	0.56	13.4	0.47	2.91e-36	High light scatter reticulocyte count;
BRCA	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18876405	chr7:65276391	NA	0.54	12.64	0.45	7.84e-33	Aortic root size;
BRCA	trans	rs6076960	0.684	rs3909041	chr20:6249598	C/G	cg17788362	chr6:86352627	SYNCRIP	0.4	7.85	0.3	1.82e-14	Smooth-surface caries;
BRCA	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.83	-0.39	3.18e-25	Personality dimensions;
BRCA	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.61	13.42	0.47	2.47e-36	Hemoglobin concentration;
BRCA	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg01262667	chr19:19385393	TM6SF2	-0.42	-10.65	-0.39	1.71e-24	Tonsillectomy;
BRCA	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg06115741	chr20:33292138	TP53INP2	0.44	9.64	0.36	1.29e-20	Coronary artery disease;
BRCA	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.79	0.42	3.64e-29	Tonsillectomy;
BRCA	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg25427524	chr10:38739819	LOC399744	0.59	11.0	0.4	6.67e-26	Obesity (extreme);
BRCA	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg05457628	chr5:178986728	RUFY1	-0.57	-14.53	-0.5	1.6e-41	Lung cancer;
BRCA	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg04166393	chr7:2884313	GNA12	0.63	13.58	0.47	4.3e-37	Height;
BRCA	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg01475377	chr6:109611718	NA	-0.51	-12.98	-0.46	2.34e-34	Reticulocyte fraction of red cells;
BRCA	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.99	0.3	6.41e-15	Depression;
BRCA	cis	rs6450176	0.625	rs3776725	chr5:53290138	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-15.14	-0.51	1.74e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	trans	rs12543645	0.598	rs17767186	chr8:10277494	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	8.88	0.33	6.78e-18	Schizophrenia;
BRCA	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg12483005	chr1:23474871	LUZP1	0.37	7.93	0.3	1.01e-14	Height;
BRCA	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg00106254	chr7:1943704	MAD1L1	-0.44	-11.68	-0.42	1.06e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.56	-0.32	8.25e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg05926928	chr17:57297772	GDPD1	0.4	8.02	0.3	5.02e-15	Schizophrenia;
BRCA	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg10932868	chr11:921992	NA	0.49	12.59	0.45	1.21e-32	Alzheimer's disease (late onset);
BRCA	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg05863683	chr7:1912471	MAD1L1	0.4	8.53	0.32	1.04e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg03676636	chr4:99064102	C4orf37	0.2	7.93	0.3	9.65e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	13.53	0.47	7.03e-37	Platelet count;
BRCA	cis	rs4594175	0.962	rs7157823	chr14:51633170	C/T	cg23942311	chr14:51606299	NA	0.33	8.32	0.31	5.22e-16	Cancer;
BRCA	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.53	7.89	0.3	1.35e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg15208524	chr1:10270712	KIF1B	0.37	8.24	0.31	9.770000000000001e-16	Hepatocellular carcinoma;
BRCA	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg20476274	chr7:133979776	SLC35B4	0.6	14.74	0.5	1.56e-42	Mean platelet volume;
BRCA	trans	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg26043149	chr18:55253948	FECH	-0.37	-8.23	-0.31	1.09e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg00504896	chr12:9437009	LOC642846	-0.46	-10.17	-0.37	1.25e-22	Breast size;
BRCA	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.05	0.4	4.16e-26	Rheumatoid arthritis;
BRCA	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg06064525	chr11:970664	AP2A2	-0.48	-16.24	-0.54	6.84e-50	Alzheimer's disease (late onset);
BRCA	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg08847533	chr14:75593920	NEK9	0.83	20.57	0.63	1.56e-72	Height;
BRCA	cis	rs17384381	0.859	rs12130591	chr1:85904985	C/T	cg16011679	chr1:85725395	C1orf52	0.51	7.98	0.3	6.81e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs877282	1.000	rs112522746	chr10:772288	T/C	cg17470449	chr10:769945	NA	0.5	9.35	0.35	1.44e-19	Uric acid levels;
BRCA	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg15704280	chr7:45808275	SEPT13	-0.48	-9.84	-0.36	2.28e-21	HDL cholesterol;
BRCA	trans	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg06606381	chr12:133084897	FBRSL1	-0.85	-8.79	-0.33	1.33e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg09307838	chr4:120376055	NA	0.64	13.92	0.48	1.13e-38	Corneal astigmatism;
BRCA	cis	rs8030485	0.728	rs4778886	chr15:79389019	T/C	cg17916960	chr15:79447300	NA	0.34	7.85	0.3	1.72e-14	Left ventricle wall thickness;
BRCA	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg26898376	chr11:64110657	CCDC88B	0.36	7.86	0.3	1.62e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-15.89	-0.53	3.7e-48	Total cholesterol levels;
BRCA	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg15485101	chr11:133734466	NA	0.41	9.66	0.36	1.11e-20	Childhood ear infection;
BRCA	trans	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg25214090	chr10:38739885	LOC399744	0.45	10.11	0.37	2.1e-22	Corneal astigmatism;
BRCA	cis	rs11779988	0.545	rs398806	chr8:17786226	T/C	cg01800426	chr8:17659068	MTUS1	-0.4	-8.41	-0.32	2.65e-16	Breast cancer;
BRCA	trans	rs3960554	0.569	rs1894761	chr7:75876754	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.48	-11.02	-0.4	5.44e-26	Eotaxin levels;
BRCA	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12923728	chr3:195709715	SDHAP1	-0.59	-12.56	-0.45	1.67e-32	Pancreatic cancer;
BRCA	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00908189	chr16:619842	PIGQ	0.68	16.82	0.55	8.26e-53	Height;
BRCA	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	13.02	0.46	1.48e-34	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-9.48	-0.35	4.72e-20	Response to bleomycin (chromatid breaks);
BRCA	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg19336497	chr11:14380999	RRAS2	-0.48	-11.99	-0.43	4.92e-30	Sense of smell;
BRCA	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg12219531	chr12:120966889	COQ5	0.55	11.42	0.41	1.25e-27	High light scatter reticulocyte count;
BRCA	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg25019033	chr10:957182	NA	-0.42	-8.07	-0.3	3.47e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg13010199	chr12:38710504	ALG10B	0.51	9.97	0.37	7.62e-22	Bladder cancer;
BRCA	trans	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg05926928	chr17:57297772	GDPD1	-0.42	-8.65	-0.32	4.02e-17	Schizophrenia;
BRCA	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.81	0.39	4.03e-25	Bipolar disorder;
BRCA	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18404041	chr3:52824283	ITIH1	-0.38	-11.34	-0.41	2.88e-27	Electroencephalogram traits;
BRCA	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.66	0.36	1.07e-20	Bipolar disorder;
BRCA	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18876405	chr7:65276391	NA	0.56	13.33	0.47	6.11e-36	Aortic root size;
BRCA	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.36	9.34	0.35	1.58e-19	IgG glycosylation;
BRCA	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg10556349	chr10:835070	NA	0.61	8.43	0.32	2.32e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg26384229	chr12:38710491	ALG10B	0.7	15.83	0.53	7.18e-48	Bladder cancer;
BRCA	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.68	-0.32	3.18e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg18016565	chr1:150552671	MCL1	0.36	8.55	0.32	9.09e-17	Tonsillectomy;
BRCA	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg04166393	chr7:2884313	GNA12	0.46	8.54	0.32	9.8e-17	Height;
BRCA	cis	rs2797160	1.000	rs1739363	chr6:126020980	G/A	cg05901451	chr6:126070800	HEY2	0.39	9.51	0.35	3.87e-20	Endometrial cancer;
BRCA	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg01689657	chr7:91764605	CYP51A1	0.21	7.85	0.3	1.74e-14	Breast cancer;
BRCA	cis	rs3784262	0.669	rs4646602	chr15:58294757	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.04	-0.37	4.14e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	18.04	0.58	4e-59	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg02659138	chr7:134003124	SLC35B4	0.37	10.87	0.4	2.21e-25	Mean platelet volume;
BRCA	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg23950597	chr19:37808831	NA	-0.61	-11.4	-0.41	1.5e-27	Coronary artery calcification;
BRCA	cis	rs6952809	0.590	rs1468337	chr7:2432211	C/T	cg23289794	chr7:2394357	EIF3B	-0.53	-10.45	-0.38	1.05e-23	Multiple sclerosis;
BRCA	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg00631329	chr6:26305371	NA	-0.43	-12.72	-0.45	3.24e-33	Educational attainment;
BRCA	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg27535305	chr1:53392650	SCP2	-0.37	-9.27	-0.34	2.78e-19	Monocyte count;
BRCA	cis	rs17095355	1.000	rs12254785	chr10:111699607	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.39	-10.26	-0.38	5.76e-23	Biliary atresia;
BRCA	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.2	-0.34	5.21e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg21918786	chr6:109611834	NA	-0.5	-14.01	-0.48	4.55e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg13010199	chr12:38710504	ALG10B	0.51	10.16	0.37	1.4e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg01475377	chr6:109611718	NA	-0.51	-12.88	-0.45	6.46e-34	Reticulocyte fraction of red cells;
BRCA	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg08999081	chr20:33150536	PIGU	-0.48	-13.41	-0.47	2.64e-36	Glomerular filtration rate (creatinine);
BRCA	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg08213375	chr14:104286397	PPP1R13B	0.63	17.42	0.57	6.31e-56	Schizophrenia;
BRCA	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg20283391	chr11:68216788	NA	-0.49	-9.52	-0.35	3.55e-20	Total body bone mineral density;
BRCA	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg15997130	chr1:24165203	NA	0.46	11.75	0.42	5.29e-29	Immature fraction of reticulocytes;
BRCA	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg02297831	chr4:17616191	MED28	0.38	8.52	0.32	1.12e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg17691542	chr6:26056736	HIST1H1C	0.48	9.55	0.35	2.75e-20	Iron status biomarkers;
BRCA	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg26384229	chr12:38710491	ALG10B	0.67	14.21	0.49	5.23e-40	Morning vs. evening chronotype;
BRCA	cis	rs2882667	0.858	rs13174479	chr5:138444170	G/A	cg04439458	chr5:138467593	SIL1	-0.41	-10.51	-0.38	6.31e-24	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs72634258	0.786	rs7524424	chr1:8173369	A/G	cg00042356	chr1:8021962	PARK7	0.46	8.27	0.31	7.83e-16	Inflammatory bowel disease;
BRCA	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg27170947	chr2:26402098	FAM59B	0.98	17.0	0.56	8.96e-54	Gut microbiome composition (summer);
BRCA	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg17372223	chr3:52568218	NT5DC2	0.36	8.61	0.32	5.58e-17	Electroencephalogram traits;
BRCA	cis	rs36051895	0.603	rs1590804	chr9:5177573	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-9.06	-0.34	1.52e-18	Pediatric autoimmune diseases;
BRCA	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg06784218	chr1:46089804	CCDC17	-0.45	-10.84	-0.39	2.92e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.73	-0.39	8.05e-25	Retinal vascular caliber;
BRCA	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg06627628	chr2:24431161	ITSN2	0.44	9.11	0.34	1.07e-18	Asthma;
BRCA	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	11.99	0.43	5.33e-30	Mean platelet volume;
BRCA	trans	rs3857536	0.813	rs6455090	chr6:66948909	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.82	-0.3	2.17e-14	Blood trace element (Cu levels);
BRCA	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg05343316	chr1:45956843	TESK2	0.7	13.86	0.48	2.25e-38	Platelet count;
BRCA	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg23750338	chr8:142222470	SLC45A4	0.51	12.52	0.44	2.45e-32	Immature fraction of reticulocytes;
BRCA	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg09184832	chr6:79620586	NA	-0.43	-8.45	-0.32	2.03e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg12444411	chr7:2802554	GNA12	-0.32	-8.34	-0.31	4.74e-16	Height;
BRCA	cis	rs9790314	0.715	rs898681	chr3:160773098	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-10.04	-0.37	3.9e-22	Morning vs. evening chronotype;
BRCA	cis	rs4930561	0.677	rs7946212	chr11:67982187	T/A	cg04465784	chr11:67976953	SUV420H1	-0.27	-8.56	-0.32	8.27e-17	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs9287719	0.578	rs10168852	chr2:10746323	C/A	cg00105475	chr2:10696890	NA	0.48	10.55	0.39	4.24e-24	Prostate cancer;
BRCA	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	18.95	0.6	7.1e-64	Fuchs's corneal dystrophy;
BRCA	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg05985134	chr18:33552581	C18orf21	0.61	10.84	0.39	2.87e-25	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	10.71	0.39	1.02e-24	Bipolar disorder;
BRCA	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg04691961	chr3:161091175	C3orf57	-0.59	-14.13	-0.49	1.19e-39	Morning vs. evening chronotype;
BRCA	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.42	-10.5	-0.38	6.96e-24	Schizophrenia;
BRCA	cis	rs62229266	0.804	rs11088331	chr21:37421872	T/C	cg12218747	chr21:37451666	NA	-0.33	-7.94	-0.3	9.32e-15	Mitral valve prolapse;
BRCA	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg22875332	chr1:76189707	ACADM	0.66	15.7	0.53	3.07e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs897080	0.553	rs1067338	chr2:44624708	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	10.32	0.38	3.38e-23	Height;
BRCA	cis	rs911119	0.955	rs6036474	chr20:23604414	G/A	cg16589663	chr20:23618590	CST3	0.43	8.19	0.31	1.42e-15	Chronic kidney disease;
BRCA	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg05527609	chr1:210001259	C1orf107	0.74	17.08	0.56	3.49e-54	Orofacial clefts;
BRCA	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg06627628	chr2:24431161	ITSN2	-0.84	-15.51	-0.52	2.91e-46	Asthma;
BRCA	cis	rs6433895	1.000	rs34714467	chr2:182017987	G/A	cg00481216	chr2:181971175	NA	0.39	8.91	0.33	5.34e-18	Lymphocyte counts;
BRCA	cis	rs701145	0.640	rs357497	chr3:153943068	C/A	cg17054900	chr3:154042577	DHX36	0.58	9.73	0.36	5.84e-21	Coronary artery disease;
BRCA	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.74	0.36	5.38e-21	Morning vs. evening chronotype;
BRCA	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24531977	chr5:56204891	C5orf35	-0.86	-18.37	-0.59	7.75e-61	Initial pursuit acceleration;
BRCA	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg06627628	chr2:24431161	ITSN2	-0.55	-9.0	-0.34	2.59e-18	Lymphocyte counts;
BRCA	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg07080220	chr10:102295463	HIF1AN	0.62	14.64	0.5	4.63e-42	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	21.05	0.64	4.24e-75	Lymphocyte percentage of white cells;
BRCA	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg07169764	chr2:136633963	MCM6	1.23	26.19	0.72	2.99e-103	Corneal structure;
BRCA	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	17.47	0.57	3.6e-56	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-13.02	-0.46	1.59e-34	Obesity-related traits;
BRCA	cis	rs10189230	0.967	rs11692482	chr2:222352405	C/T	cg14652038	chr2:222343519	EPHA4	0.47	13.11	0.46	6.05e-35	Urate levels in lean individuals;
BRCA	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg25405998	chr7:65216604	CCT6P1	-0.42	-8.85	-0.33	8.36e-18	Calcium levels;
BRCA	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08048268	chr3:133502702	NA	0.32	8.33	0.31	4.77e-16	Iron status biomarkers;
BRCA	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg13256891	chr4:100009986	ADH5	0.5	10.35	0.38	2.51e-23	Alcohol dependence;
BRCA	cis	rs877282	1.000	rs7100358	chr10:773681	G/A	cg17470449	chr10:769945	NA	0.49	9.36	0.35	1.37e-19	Uric acid levels;
BRCA	trans	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg09719594	chr16:21412588	NA	-0.32	-7.82	-0.3	2.19e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg03676636	chr4:99064102	C4orf37	0.24	8.18	0.31	1.53e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6709815	0.841	rs12694442	chr2:219663599	T/C	cg02176678	chr2:219576539	TTLL4	-0.38	-10.18	-0.37	1.18e-22	Reticulocyte count;High light scatter reticulocyte count;
BRCA	cis	rs11608355	0.545	rs12819658	chr12:109907670	A/T	cg05360138	chr12:110035743	NA	0.71	13.15	0.46	4.04e-35	Neuroticism;
BRCA	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.22	0.34	4.35e-19	Tonsillectomy;
BRCA	cis	rs4642101	0.535	rs55692304	chr3:12840057	C/T	cg24848339	chr3:12840334	CAND2	0.52	14.13	0.49	1.18e-39	QRS complex (12-leadsum);
BRCA	cis	rs858239	0.799	rs10279941	chr7:23370508	C/G	cg23682824	chr7:23144976	KLHL7	0.33	8.17	0.31	1.62e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg12923728	chr3:195709715	SDHAP1	-0.53	-7.94	-0.3	9.15e-15	Lung disease severity in cystic fibrosis;
BRCA	trans	rs1941687	0.505	rs12605642	chr18:31313965	G/T	cg27147174	chr7:100797783	AP1S1	-0.4	-7.89	-0.3	1.36e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	trans	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg06521331	chr12:34319734	NA	-0.54	-10.29	-0.38	4.42e-23	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.58e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1400816	0.702	rs1515812	chr2:172558047	G/A	cg13550731	chr2:172543902	DYNC1I2	0.54	8.48	0.32	1.56e-16	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.14e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2710642	0.962	rs4671051	chr2:63032696	A/T	cg17519650	chr2:63277830	OTX1	-0.39	-8.58	-0.32	7.06e-17	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs4974559	0.947	rs28540746	chr4:1352954	G/A	cg02980000	chr4:1222292	CTBP1	0.76	12.75	0.45	2.41e-33	Systolic blood pressure;
BRCA	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00802000	chr16:706648	WDR90	-0.41	-9.55	-0.35	2.61e-20	Height;
BRCA	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-10.29	-0.38	4.51e-23	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg11822812	chr5:140052017	DND1	0.29	8.01	0.3	5.26e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08048268	chr3:133502702	NA	-0.32	-8.14	-0.31	2.12e-15	Iron status biomarkers;
BRCA	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg24642439	chr20:33292090	TP53INP2	0.72	16.61	0.55	8.91e-52	Coronary artery disease;
BRCA	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg07636037	chr3:49044803	WDR6	0.97	28.37	0.75	3.38e-115	Parkinson's disease;
BRCA	cis	rs11608355	0.515	rs7971160	chr12:109946751	T/A	cg05360138	chr12:110035743	NA	0.74	13.64	0.47	2.36e-37	Neuroticism;
BRCA	cis	rs9300255	0.722	rs1060105	chr12:123806219	C/T	cg00376283	chr12:123451042	ABCB9	-0.52	-10.32	-0.38	3.45e-23	Neutrophil percentage of white cells;
BRCA	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg04455712	chr21:45112962	RRP1B	0.41	10.73	0.39	8.24e-25	Mean corpuscular volume;
BRCA	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.29	0.44	2.59e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg13319975	chr6:146136371	FBXO30	0.42	8.46	0.32	1.86e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg18132916	chr6:79620363	NA	-0.49	-11.14	-0.4	1.87e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg08999081	chr20:33150536	PIGU	0.35	8.78	0.33	1.48e-17	Coronary artery disease;
BRCA	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg26031613	chr14:104095156	KLC1	-0.53	-9.49	-0.35	4.66e-20	Reticulocyte count;
BRCA	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg10729496	chr3:10149963	C3orf24	0.48	9.11	0.34	1.02e-18	Alzheimer's disease;
BRCA	cis	rs7474896	0.559	rs1208560	chr10:38221618	A/T	cg25427524	chr10:38739819	LOC399744	0.52	9.66	0.36	1.05e-20	Obesity (extreme);
BRCA	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg05347473	chr6:146136440	FBXO30	0.42	8.45	0.32	2.03e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs738321	0.757	rs5750546	chr22:38542499	C/T	cg25457927	chr22:38595422	NA	-0.36	-12.62	-0.45	9.02e-33	Breast cancer;
BRCA	cis	rs7715806	0.500	rs17649350	chr5:75006156	C/T	cg19683494	chr5:74908142	NA	-0.53	-8.73	-0.33	2.22e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg02951883	chr7:2050386	MAD1L1	-0.49	-11.46	-0.41	8.97e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs68170813	0.523	rs111590023	chr7:107055323	T/C	cg02696742	chr7:106810147	HBP1	-0.46	-8.03	-0.3	4.77e-15	Coronary artery disease;
BRCA	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg10224037	chr5:178157518	ZNF354A	0.76	15.87	0.53	4.64e-48	Neutrophil percentage of white cells;
BRCA	cis	rs6028335	0.674	rs3829696	chr20:37634704	C/T	cg16355469	chr20:37678765	NA	-0.44	-8.16	-0.31	1.78e-15	Alcohol and nicotine co-dependence;
BRCA	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg02527881	chr3:46936655	PTH1R	0.36	8.66	0.32	3.73e-17	Colorectal cancer;
BRCA	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg20573242	chr4:122745356	CCNA2	0.49	10.94	0.4	1.23e-25	Type 2 diabetes;
BRCA	cis	rs9649465	1.000	rs10215466	chr7:123326044	G/T	cg04330084	chr7:123175371	IQUB	-0.3	-8.38	-0.31	3.26e-16	Migraine;
BRCA	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg26031613	chr14:104095156	KLC1	0.55	9.86	0.36	1.88e-21	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2637030	0.559	rs372135	chr5:52944948	T/C	cg06476337	chr5:52856530	NDUFS4	0.37	8.5	0.32	1.36e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs4690686	0.500	rs11728314	chr4:177268373	G/A	cg17059388	chr4:177262070	NA	0.51	10.65	0.39	1.7e-24	Essential tremor;
BRCA	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg26528668	chr16:1614120	IFT140	0.38	8.45	0.32	1.99e-16	Coronary artery disease;
BRCA	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg06784218	chr1:46089804	CCDC17	0.49	11.55	0.42	3.77e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg17425144	chr1:10567563	PEX14	0.55	13.76	0.48	6.67e-38	Prostate cancer;
BRCA	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-15.88	-0.53	4.21e-48	Migraine;Coronary artery disease;
BRCA	cis	rs1953600	0.837	rs3098105	chr10:81953266	C/T	cg04850286	chr10:81895943	PLAC9	0.32	9.0	0.34	2.57e-18	Sarcoidosis;
BRCA	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg11812906	chr14:75593930	NEK9	-0.63	-14.3	-0.49	1.84e-40	Height;
BRCA	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.52	0.38	5.61e-24	Motion sickness;
BRCA	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg12011299	chr4:100065546	ADH4	-0.5	-11.33	-0.41	3.03e-27	Alcohol dependence;
BRCA	cis	rs867371	0.820	rs12443224	chr15:82495610	C/T	cg00614314	chr15:82944287	LOC80154	0.38	7.96	0.3	7.71e-15	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg04234412	chr22:24373322	LOC391322	0.57	12.35	0.44	1.37e-31	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	cis	rs6426558	0.537	rs1320494	chr1:227241300	A/T	cg10327440	chr1:227177885	CDC42BPA	0.49	9.75	0.36	5.15e-21	Neutrophil percentage of white cells;
BRCA	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	13.3	0.47	8.12e-36	Schizophrenia;
BRCA	cis	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg06521331	chr12:34319734	NA	-0.63	-11.49	-0.41	6.35e-28	Morning vs. evening chronotype;
BRCA	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.96	0.3	7.63e-15	Depression;
BRCA	cis	rs9790314	0.747	rs1841526	chr3:160834682	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-9.88	-0.36	1.65e-21	Morning vs. evening chronotype;
BRCA	cis	rs4566357	0.595	rs6707159	chr2:227909339	T/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-9.65	-0.36	1.13e-20	Coronary artery disease;
BRCA	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg23711669	chr6:146136114	FBXO30	-0.79	-18.94	-0.6	8.14e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg03342759	chr3:160939853	NMD3	-0.81	-19.09	-0.6	1.33e-64	Parkinson's disease;
BRCA	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.66e-15	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg11663144	chr21:46675770	NA	-0.61	-14.24	-0.49	3.81e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg12379764	chr21:47803548	PCNT	-0.37	-7.86	-0.3	1.61e-14	Testicular germ cell tumor;
BRCA	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg12373951	chr3:133503437	NA	-0.44	-10.57	-0.39	3.54e-24	Iron status biomarkers;
BRCA	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg13114125	chr14:105738426	BRF1	-0.5	-10.4	-0.38	1.64e-23	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg21770322	chr7:97807741	LMTK2	0.5	14.15	0.49	9.55e-40	Breast cancer;
BRCA	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-9.43	-0.35	7.23e-20	Response to bleomycin (chromatid breaks);
BRCA	cis	rs9649465	0.967	rs12534834	chr7:123307079	T/C	cg04330084	chr7:123175371	IQUB	-0.3	-8.34	-0.31	4.53e-16	Migraine;
BRCA	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg23711669	chr6:146136114	FBXO30	-0.81	-19.89	-0.62	6.69e-69	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg17971929	chr21:40555470	PSMG1	-0.63	-14.39	-0.49	7.3e-41	Cognitive function;
BRCA	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg12011299	chr4:100065546	ADH4	0.48	10.94	0.4	1.21e-25	Smoking initiation;
BRCA	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg08514558	chr10:81106712	PPIF	0.37	8.99	0.34	2.78e-18	Height;
BRCA	cis	rs16910800	0.731	rs16910759	chr11:23192131	C/G	cg20040320	chr11:23191996	NA	-0.58	-10.0	-0.37	5.63e-22	Cancer;
BRCA	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg05347473	chr6:146136440	FBXO30	-0.4	-7.9	-0.3	1.2e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-8.72	-0.33	2.36e-17	Schizophrenia;
BRCA	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.2	-0.31	1.37e-15	Total body bone mineral density;
BRCA	cis	rs36051895	0.632	rs7850484	chr9:5147817	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-9.6	-0.36	1.72e-20	Pediatric autoimmune diseases;
BRCA	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg23649088	chr2:200775458	C2orf69	0.47	8.06	0.3	3.74e-15	Schizophrenia;
BRCA	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.59	-0.39	2.95e-24	Bipolar disorder;
BRCA	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg15448220	chr1:150897856	SETDB1	0.37	8.32	0.31	5.23e-16	Melanoma;
BRCA	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.71	0.39	1.02e-24	Bipolar disorder;
BRCA	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg04362960	chr10:104952993	NT5C2	0.43	10.46	0.38	9.81e-24	Arsenic metabolism;
BRCA	trans	rs10411161	0.702	rs11878586	chr19:52388576	A/G	cg22319618	chr22:45562946	NUP50	-0.42	-8.02	-0.3	4.89e-15	Breast cancer;
BRCA	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg09035930	chr12:129282057	SLC15A4	0.57	16.85	0.55	5.49e-53	Systemic lupus erythematosus;
BRCA	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg16339924	chr4:17578868	LAP3	0.74	18.77	0.6	6.15e-63	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg26850624	chr5:429559	AHRR	0.34	7.96	0.3	7.62e-15	Cystic fibrosis severity;
BRCA	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg08222618	chr4:941054	TMEM175	0.41	9.43	0.35	7.27e-20	Sjögren's syndrome;
BRCA	cis	rs7520050	0.966	rs785503	chr1:46595868	T/C	cg24296786	chr1:45957014	TESK2	0.41	9.12	0.34	1e-18	Red blood cell count;Reticulocyte count;
BRCA	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg18758796	chr5:131593413	PDLIM4	0.43	11.3	0.41	3.86e-27	Acylcarnitine levels;
BRCA	cis	rs4423214	0.879	rs1792277	chr11:71138918	C/T	cg05163923	chr11:71159392	DHCR7	-0.55	-11.06	-0.4	3.76e-26	Vitamin D levels;
BRCA	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg03929089	chr4:120376271	NA	0.65	12.72	0.45	3.44e-33	Coronary artery disease;
BRCA	cis	rs6542838	0.611	rs7423519	chr2:99518319	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.38	-8.44	-0.32	2.06e-16	Fear of minor pain;
BRCA	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg15412446	chr2:106886593	NA	0.6	12.12	0.43	1.4e-30	Facial morphology (factor 23);
BRCA	cis	rs12472274	0.941	rs12616232	chr2:239080093	C/T	cg17459225	chr2:239074497	NA	0.62	12.59	0.45	1.27e-32	Phospholipid levels (plasma);
BRCA	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg03929089	chr4:120376271	NA	-0.43	-8.07	-0.3	3.6e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.4	-9.03	-0.34	2.08e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg17063962	chr7:91808500	NA	0.57	13.6	0.47	3.52e-37	Breast cancer;
BRCA	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg05234568	chr11:5960015	NA	-0.43	-8.89	-0.33	6.25e-18	DNA methylation (variation);
BRCA	cis	rs5771069	0.931	rs5771222	chr22:50445704	C/T	cg03721641	chr22:50451245	IL17REL	-0.31	-9.88	-0.36	1.58e-21	Ulcerative colitis;
BRCA	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg11608241	chr8:8085544	FLJ10661	0.32	7.91	0.3	1.17e-14	Red cell distribution width;
BRCA	trans	rs7200543	1.000	rs34614532	chr16:15132908	T/C	cg24683922	chr1:11983373	KIAA2013	-0.39	-8.72	-0.33	2.32e-17	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg04518342	chr5:131593106	PDLIM4	0.37	9.47	0.35	5.4e-20	Breast cancer;
BRCA	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg18402987	chr7:1209562	NA	0.66	11.21	0.41	9.4e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg06108461	chr20:60628389	TAF4	-0.71	-14.74	-0.5	1.52e-42	Body mass index;
BRCA	cis	rs870825	0.929	rs72689255	chr4:185590141	T/C	cg20176042	chr4:185552304	CASP3	-0.62	-8.51	-0.32	1.27e-16	Blood protein levels;
BRCA	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	9.41	0.35	8.83e-20	Lung cancer in ever smokers;
BRCA	cis	rs13046373	0.534	rs9305426	chr21:31964916	A/C	cg24082983	chr21:31802169	KRTAP13-4	0.35	8.65	0.32	4.12e-17	HDL cholesterol;
BRCA	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.38	8.18	0.31	1.49e-15	Cognitive ability;
BRCA	cis	rs4900538	0.819	rs72698595	chr14:102863099	G/A	cg18135206	chr14:102964638	TECPR2	-0.9	-20.78	-0.63	1.22e-73	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs7945718	0.967	rs10765989	chr11:12769397	A/G	cg25843174	chr11:12811716	TEAD1	-0.22	-8.69	-0.33	3e-17	Educational attainment (years of education);
BRCA	cis	rs1832871	0.619	rs262826	chr6:158680567	C/T	cg07215822	chr6:158701037	NA	-0.5	-10.53	-0.38	4.88e-24	Height;
BRCA	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08280861	chr8:58055591	NA	0.53	8.49	0.32	1.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg11764359	chr7:65958608	NA	0.63	10.91	0.4	1.5e-25	Aortic root size;
BRCA	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	18.12	0.58	1.61e-59	Alzheimer's disease;
BRCA	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00166722	chr3:10149974	C3orf24	0.65	13.07	0.46	8.76e-35	Alzheimer's disease;
BRCA	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg11584989	chr19:19387371	SF4	0.63	13.76	0.48	6.11e-38	Bipolar disorder;
BRCA	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24549020	chr5:56110836	MAP3K1	0.67	13.55	0.47	6.19e-37	Initial pursuit acceleration;
BRCA	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg08645402	chr16:4508243	NA	0.4	9.17	0.34	6.25e-19	Schizophrenia;
BRCA	cis	rs1883415	0.534	rs2760145	chr6:24478813	T/C	cg20631270	chr6:24437470	GPLD1	0.4	8.16	0.31	1.78e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg24296786	chr1:45957014	TESK2	0.43	8.6	0.32	5.99e-17	Homocysteine levels;
BRCA	trans	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg15704280	chr7:45808275	SEPT13	0.59	8.84	0.33	9.53e-18	Axial length;
BRCA	cis	rs6691722	0.503	rs1142057	chr1:24706292	C/T	cg18323236	chr1:24743029	NIPAL3	-0.29	-7.92	-0.3	1.06e-14	Response to interferon beta in multiple sclerosis;
BRCA	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg26031613	chr14:104095156	KLC1	-0.43	-8.5	-0.32	1.29e-16	Schizophrenia;
BRCA	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.96	-0.33	3.49e-18	Monocyte percentage of white cells;
BRCA	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg04004882	chr2:215674386	BARD1	0.67	12.38	0.44	1.05e-31	Neuroblastoma;
BRCA	cis	rs2882667	0.654	rs6863054	chr5:138188855	C/T	cg04439458	chr5:138467593	SIL1	0.31	7.94	0.3	8.82e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	13.82	0.48	3.55e-38	Hip circumference adjusted for BMI;
BRCA	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg26031613	chr14:104095156	KLC1	0.74	16.27	0.54	4.7e-50	Body mass index;
BRCA	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg13852791	chr20:30311386	BCL2L1	-0.83	-17.72	-0.57	1.86e-57	Mean corpuscular hemoglobin;
BRCA	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg20933634	chr6:27740509	NA	0.45	9.0	0.34	2.5e-18	Parkinson's disease;
BRCA	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.78e-21	Total body bone mineral density;
BRCA	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg04013093	chr6:42928303	GNMT	-0.29	-8.93	-0.33	4.33e-18	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg05729581	chr11:3078854	CARS	-0.34	-8.46	-0.32	1.76e-16	Longevity;
BRCA	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg06784218	chr1:46089804	CCDC17	-0.5	-11.63	-0.42	1.74e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9394152	0.845	rs7747216	chr6:33476718	A/G	cg13560919	chr6:33536144	NA	-0.62	-12.95	-0.46	3.09e-34	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs9381107	0.932	rs16892227	chr6:9425046	A/G	cg14735645	chr6:9486422	NA	-0.47	-8.18	-0.31	1.52e-15	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg21132104	chr15:45694354	SPATA5L1	0.74	16.96	0.56	1.57e-53	Homoarginine levels;
BRCA	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	9.65	0.36	1.21e-20	Lung cancer in ever smokers;
BRCA	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	14.55	0.5	1.24e-41	Motion sickness;
BRCA	cis	rs11971779	0.680	rs10271297	chr7:139052310	A/T	cg07862535	chr7:139043722	LUC7L2	0.37	10.08	0.37	2.71e-22	Diisocyanate-induced asthma;
BRCA	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	14.64	0.5	4.38e-42	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg18279126	chr7:2041391	MAD1L1	0.38	8.51	0.32	1.21e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg09307838	chr4:120376055	NA	-0.69	-13.6	-0.47	3.66e-37	Corneal astigmatism;
BRCA	cis	rs12545109	0.879	rs2609994	chr8:57365844	A/G	cg09654669	chr8:57350985	NA	-0.46	-8.66	-0.32	3.82e-17	Obesity-related traits;
BRCA	trans	rs6600671	0.966	rs6600664	chr1:121222436	G/A	cg17023122	chr1:144479586	NA	0.35	8.04	0.3	4.29e-15	Hip geometry;
BRCA	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.35	0.57	1.61e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9986765	1.000	rs73452570	chr7:142817482	T/A	cg21852589	chr7:142981689	TMEM139	0.55	9.52	0.35	3.4e-20	Cancer;Dermatomyositis;
BRCA	cis	rs17253792	0.822	rs75936910	chr14:56149351	T/C	cg01858014	chr14:56050164	KTN1	-0.75	-9.37	-0.35	1.25e-19	Putamen volume;
BRCA	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg13271783	chr10:134563150	INPP5A	-0.5	-9.26	-0.34	3.01e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg12386194	chr3:101231763	SENP7	0.45	9.37	0.35	1.18e-19	Colorectal cancer;
BRCA	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg05340658	chr4:99064831	C4orf37	-0.55	-10.48	-0.38	8.06e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg23625390	chr15:77176239	SCAPER	-0.51	-11.94	-0.43	8.44e-30	Blood metabolite levels;
BRCA	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-9.69	-0.36	8.2e-21	Fear of minor pain;
BRCA	cis	rs12493885	0.818	rs73158491	chr3:153764112	T/C	cg17054900	chr3:154042577	DHX36	-0.5	-8.54	-0.32	9.6e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg11812906	chr14:75593930	NEK9	-0.62	-14.25	-0.49	3.28e-40	Height;
BRCA	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg20476274	chr7:133979776	SLC35B4	-0.48	-11.0	-0.4	7.04e-26	Mean platelet volume;
BRCA	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg20573242	chr4:122745356	CCNA2	0.49	10.79	0.39	4.65e-25	Type 2 diabetes;
BRCA	cis	rs911119	0.955	rs6114201	chr20:23607231	T/A	cg16589663	chr20:23618590	CST3	0.4	8.2	0.31	1.34e-15	Chronic kidney disease;
BRCA	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg06484146	chr7:12443880	VWDE	-0.71	-10.81	-0.39	4.05e-25	Coronary artery disease;
BRCA	cis	rs7520050	0.966	rs10789475	chr1:46304177	C/G	cg24296786	chr1:45957014	TESK2	0.41	9.34	0.35	1.53e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.69e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg22535103	chr8:58192502	C8orf71	-0.46	-9.03	-0.34	1.97e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg05340658	chr4:99064831	C4orf37	0.56	10.76	0.39	6.41e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg13319975	chr6:146136371	FBXO30	-0.4	-9.0	-0.34	2.52e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg19678392	chr7:94953810	PON1	-0.41	-8.51	-0.32	1.27e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg16606324	chr3:10149918	C3orf24	0.56	11.01	0.4	5.91e-26	Alzheimer's disease;
BRCA	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg27432699	chr2:27873401	GPN1	0.43	9.19	0.34	5.65e-19	Oral cavity cancer;
BRCA	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg03388025	chr16:89894329	SPIRE2	-0.29	-9.66	-0.36	1.03e-20	Vitiligo;
BRCA	trans	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg06636001	chr8:8085503	FLJ10661	0.41	8.22	0.31	1.17e-15	Retinal vascular caliber;
BRCA	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg18904891	chr8:8559673	CLDN23	0.61	12.07	0.43	2.35e-30	Obesity-related traits;
BRCA	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg15017067	chr4:17643749	FAM184B	-0.28	-8.5	-0.32	1.38e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	11.52	0.41	4.72e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.93	0.33	4.51e-18	Motion sickness;
BRCA	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg01181863	chr3:195395398	SDHAP2	-0.6	-10.99	-0.4	7.22e-26	Pancreatic cancer;
BRCA	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg14926445	chr8:58193284	C8orf71	-0.43	-8.2	-0.31	1.33e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1691799	0.899	rs1168357	chr12:66749879	T/C	cg16791601	chr12:66731901	HELB	-0.68	-18.93	-0.6	8.89e-64	White blood cell count (basophil);
BRCA	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg15605315	chr1:45957053	TESK2	-0.46	-9.26	-0.34	2.97e-19	High light scatter reticulocyte count;
BRCA	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg11663144	chr21:46675770	NA	-0.62	-14.32	-0.49	1.53e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs13046373	0.508	rs1911572	chr21:32031648	A/G	cg14062083	chr21:31802829	KRTAP13-4	-0.36	-9.85	-0.36	2.09e-21	HDL cholesterol;
BRCA	cis	rs4730250	0.707	rs61014091	chr7:106810107	A/C	cg02696742	chr7:106810147	HBP1	-0.57	-9.95	-0.37	8.9e-22	Osteoarthritis;
BRCA	cis	rs2625529	0.761	rs972029	chr15:72172986	C/T	cg16672083	chr15:72433130	SENP8	-0.76	-16.55	-0.55	1.83e-51	Red blood cell count;
BRCA	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg00631329	chr6:26305371	NA	-0.4	-12.05	-0.43	2.68e-30	Educational attainment;
BRCA	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.43	-8.85	-0.33	8.37e-18	Tonsillectomy;
BRCA	cis	rs4919087	0.892	rs2065861	chr10:99004608	C/T	cg25902810	chr10:99078978	FRAT1	0.43	9.15	0.34	7.7e-19	Monocyte count;
BRCA	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg14675211	chr2:100938903	LONRF2	0.52	11.65	0.42	1.44e-28	Intelligence (multi-trait analysis);
BRCA	trans	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.9	24.74	0.7	2.71e-95	Colorectal cancer;
BRCA	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-8.41	-0.32	2.69e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2019216	0.967	rs1606426	chr17:21927959	A/G	cg22648282	chr17:21454238	C17orf51	-0.36	-8.2	-0.31	1.33e-15	Pelvic organ prolapse;
BRCA	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg17366294	chr4:99064904	C4orf37	0.41	9.69	0.36	8.24e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg03146154	chr1:46216737	IPP	-0.5	-11.01	-0.4	6.25e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs7980799	0.967	rs7971226	chr12:33586881	C/T	cg26384229	chr12:38710491	ALG10B	0.42	8.78	0.33	1.51e-17	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg23711669	chr6:146136114	FBXO30	0.66	13.22	0.46	1.96e-35	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg26149184	chr10:133730230	NA	0.41	8.45	0.32	1.97e-16	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg18132916	chr6:79620363	NA	-0.49	-11.15	-0.4	1.64e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg12935359	chr14:103987150	CKB	0.65	15.14	0.51	1.84e-44	Intelligence (multi-trait analysis);
BRCA	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg13010199	chr12:38710504	ALG10B	0.48	9.46	0.35	5.66e-20	Morning vs. evening chronotype;
BRCA	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg04317338	chr11:64019027	PLCB3	0.53	9.41	0.35	9.07e-20	Attention deficit hyperactivity disorder;
BRCA	cis	rs12541635	0.966	rs11786829	chr8:107023752	C/G	cg10147462	chr8:107024639	NA	0.37	10.33	0.38	3e-23	Age of smoking initiation;
BRCA	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg26850624	chr5:429559	AHRR	0.33	7.97	0.3	7.54e-15	Cystic fibrosis severity;
BRCA	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg26597838	chr10:835615	NA	0.9	15.15	0.51	1.61e-44	Eosinophil percentage of granulocytes;
BRCA	trans	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg26043149	chr18:55253948	FECH	0.38	8.21	0.31	1.26e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg02030672	chr11:45687055	CHST1	0.52	11.77	0.42	4.23e-29	Obesity-related traits;
BRCA	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg17063962	chr7:91808500	NA	0.54	12.39	0.44	9.73e-32	Breast cancer;
BRCA	trans	rs9397585	0.599	rs685826	chr6:153411255	C/T	cg17727855	chr9:108007124	SLC44A1	0.46	8.4	0.32	2.93e-16	Body mass index;
BRCA	cis	rs2559856	1.000	rs2695291	chr12:102087543	G/A	cg12924262	chr12:102091054	CHPT1	0.4	9.26	0.34	3.02e-19	Blood protein levels;
BRCA	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-10.96	-0.4	9.57e-26	Personality dimensions;
BRCA	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg05340658	chr4:99064831	C4orf37	0.68	16.67	0.55	4.69e-52	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.13	0.31	2.29e-15	Corneal astigmatism;
BRCA	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.54	-11.38	-0.41	1.92e-27	Lymphocyte counts;
BRCA	cis	rs2147904	0.934	rs783625	chr1:42365548	C/T	cg16685388	chr1:42384056	HIVEP3	0.31	8.8	0.33	1.32e-17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
BRCA	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg06970220	chr1:156163860	SLC25A44	0.39	9.45	0.35	6.04e-20	Testicular germ cell tumor;
BRCA	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg27478167	chr7:817139	HEATR2	0.5	9.63	0.36	1.4e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-11.25	-0.41	6.27e-27	Chronic sinus infection;
BRCA	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.14e-19	Total body bone mineral density;
BRCA	trans	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg21659725	chr3:3221576	CRBN	0.34	7.99	0.3	6.52e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.41	0.38	1.45e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg14403583	chr14:105418241	AHNAK2	-0.38	-8.97	-0.33	3.29e-18	Rheumatoid arthritis;
BRCA	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg09307838	chr4:120376055	NA	-0.59	-12.9	-0.45	5.16e-34	Corneal astigmatism;
BRCA	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.63	-0.32	4.78e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs290268	0.874	rs290991	chr9:93561450	A/C	cg02608019	chr9:93564028	SYK	-0.54	-11.9	-0.43	1.26e-29	Platelet count;
BRCA	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg25019033	chr10:957182	NA	-0.42	-8.68	-0.32	3.24e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs6121246	0.583	rs28815498	chr20:30351560	T/C	cg13852791	chr20:30311386	BCL2L1	0.96	23.37	0.68	8.7e-88	Mean corpuscular hemoglobin;
BRCA	cis	rs7631605	0.935	rs2286939	chr3:37062040	T/C	cg15934958	chr3:37212084	LRRFIP2	0.41	9.63	0.36	1.42e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg07148914	chr20:33460835	GGT7	0.38	8.55	0.32	8.73e-17	Height;
BRCA	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.43	8.89	0.33	6.34e-18	Cognitive ability;
BRCA	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg16339924	chr4:17578868	LAP3	0.59	14.49	0.5	2.43e-41	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg01304814	chr3:48885189	PRKAR2A	0.77	7.94	0.3	8.96e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.51	-11.62	-0.42	1.85e-28	Longevity;Endometriosis;
BRCA	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.5	11.06	0.4	3.84e-26	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs6834538	0.597	rs4833414	chr4:113469913	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.43	10.37	0.38	2.14e-23	Free thyroxine concentration;
BRCA	cis	rs11874712	0.931	rs8095608	chr18:43678911	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.33	7.92	0.3	1.02e-14	Migraine - clinic-based;
BRCA	cis	rs858239	0.570	rs10235467	chr7:23148808	C/T	cg23682824	chr7:23144976	KLHL7	0.42	11.08	0.4	3.14e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs367943	1.000	rs191553	chr5:112823659	A/G	cg12552261	chr5:112820674	MCC	-0.55	-12.07	-0.43	2.28e-30	Type 2 diabetes;
BRCA	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.71	-0.33	2.62e-17	Total body bone mineral density;
BRCA	cis	rs6545883	0.929	rs2421203	chr2:61669248	C/A	cg15711740	chr2:61764176	XPO1	-0.55	-14.13	-0.49	1.17e-39	Tuberculosis;
BRCA	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg04511125	chr2:88470314	THNSL2	0.95	13.69	0.48	1.31e-37	Plasma clusterin levels;
BRCA	cis	rs12541635	0.677	rs7819501	chr8:107006962	C/T	cg10147462	chr8:107024639	NA	-0.39	-10.29	-0.38	4.22e-23	Age of smoking initiation;
BRCA	cis	rs6973256	0.829	rs17167199	chr7:133333292	C/T	cg07491979	chr7:133331646	EXOC4	-0.39	-8.76	-0.33	1.73e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg25206134	chr2:45395956	NA	0.53	8.77	0.33	1.57e-17	Bipolar disorder;
BRCA	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg11843238	chr5:131593191	PDLIM4	0.35	9.07	0.34	1.42e-18	Breast cancer;
BRCA	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg11822812	chr5:140052017	DND1	-0.31	-8.4	-0.32	2.79e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9815354	0.812	rs73071222	chr3:41986896	C/T	cg03022575	chr3:42003672	ULK4	0.7	9.76	0.36	4.45e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2625529	0.617	rs2929509	chr15:72239272	T/C	cg16672083	chr15:72433130	SENP8	0.66	15.66	0.53	4.97e-47	Red blood cell count;
BRCA	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.75e-16	Menopause (age at onset);
BRCA	cis	rs9463078	0.874	rs9357478	chr6:45196708	A/G	cg25276700	chr6:44698697	NA	-0.36	-8.09	-0.3	2.98e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.13e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg11366901	chr6:160182831	ACAT2	0.83	15.91	0.53	3.09e-48	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs3771570	0.892	rs55751610	chr2:242346057	C/T	cg21155796	chr2:242212141	HDLBP	0.61	9.26	0.34	3.11e-19	Prostate cancer;
BRCA	cis	rs7617773	0.779	rs1045482	chr3:48312229	A/G	cg11946769	chr3:48343235	NME6	0.51	11.63	0.42	1.7e-28	Coronary artery disease;
BRCA	cis	rs2652834	0.851	rs4238372	chr15:63351488	G/A	cg05507819	chr15:63340323	TPM1	0.53	9.22	0.34	4.21e-19	HDL cholesterol;
BRCA	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg02659138	chr7:134003124	SLC35B4	0.36	10.19	0.37	1.07e-22	Mean platelet volume;
BRCA	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg21252483	chr19:49399788	TULP2	-0.52	-11.28	-0.41	4.76e-27	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg09307838	chr4:120376055	NA	0.6	11.15	0.4	1.65e-26	Corneal astigmatism;
BRCA	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	13.98	0.48	5.77e-39	Colorectal cancer;
BRCA	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg25358565	chr5:93447407	FAM172A	-0.64	-11.4	-0.41	1.61e-27	Diabetic retinopathy;
BRCA	cis	rs7246657	0.654	rs10407568	chr19:38123009	A/T	cg18154014	chr19:37997991	ZNF793	0.5	9.55	0.35	2.62e-20	Coronary artery calcification;
BRCA	cis	rs27434	0.583	rs26653	chr5:96139250	C/G	cg16492584	chr5:96139282	ERAP1	-0.51	-13.24	-0.46	1.49e-35	Ankylosing spondylitis;
BRCA	cis	rs11984145	1.000	rs16879966	chr7:38843256	C/G	cg19327137	chr7:38886074	VPS41	-0.5	-9.26	-0.34	3.17e-19	Cognitive performance;
BRCA	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.55	-12.43	-0.44	6.65e-32	Bipolar disorder and schizophrenia;
BRCA	trans	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg25214090	chr10:38739885	LOC399744	0.52	11.71	0.42	7.85e-29	Corneal astigmatism;
BRCA	cis	rs10496034	0.850	rs75903234	chr2:55217518	T/C	cg16098955	chr2:55172992	EML6	0.52	8.6	0.32	6e-17	Refractive astigmatism;
BRCA	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg08017756	chr2:100939284	LONRF2	-0.3	-7.82	-0.3	2.17e-14	Intelligence (multi-trait analysis);
BRCA	trans	rs208520	1.000	rs208523	chr6:66954195	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-14.55	-0.5	1.17e-41	Exhaled nitric oxide output;
BRCA	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg03929089	chr4:120376271	NA	0.61	10.52	0.38	5.41e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg12923728	chr3:195709715	SDHAP1	0.38	7.88	0.3	1.45e-14	Mean corpuscular volume;
BRCA	cis	rs8016982	0.698	rs12590764	chr14:81704417	G/A	cg01989461	chr14:81687754	GTF2A1	0.6	14.22	0.49	4.63e-40	Schizophrenia;
BRCA	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg04756594	chr16:24857601	SLC5A11	-0.51	-11.74	-0.42	6.07e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg23625390	chr15:77176239	SCAPER	-0.56	-14.04	-0.49	3.19e-39	Blood metabolite levels;
BRCA	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg01657329	chr11:68192670	LRP5	0.36	8.13	0.31	2.27e-15	Bone mineral density (spine);
BRCA	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg14784868	chr12:69753453	YEATS4	-0.77	-25.25	-0.71	4.04e-98	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg22705602	chr4:152727874	NA	-0.32	-8.0	-0.3	6.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg25358565	chr5:93447407	FAM172A	1.22	19.71	0.61	6.2e-68	Diabetic retinopathy;
BRCA	cis	rs7178424	0.935	rs12900645	chr15:62286208	A/G	cg00456672	chr15:62358751	C2CD4A	-0.38	-8.71	-0.33	2.66e-17	Height;
BRCA	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-11.42	-0.41	1.33e-27	Bipolar disorder and schizophrenia;
BRCA	trans	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg19862616	chr7:65841803	NCRNA00174	0.79	25.62	0.71	4.05e-100	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg21433313	chr16:3507492	NAT15	-0.59	-8.09	-0.3	2.95e-15	Tuberculosis;
BRCA	cis	rs4478858	0.684	rs7528066	chr1:31749092	C/G	cg00250761	chr1:31883323	NA	-0.32	-8.33	-0.31	4.93e-16	Alcohol dependence;
BRCA	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02176678	chr2:219576539	TTLL4	0.47	12.16	0.43	9.04e-31	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg18357645	chr12:58087776	OS9	-0.31	-7.95	-0.3	8.74e-15	Multiple sclerosis;
BRCA	cis	rs34779708	0.931	rs35317849	chr10:35285721	C/A	cg03585969	chr10:35415529	CREM	0.56	11.49	0.41	6.62e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7072216	0.763	rs6584200	chr10:100170037	A/G	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.71	-0.36	7.24e-21	Metabolite levels;
BRCA	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-10.61	-0.39	2.5300000000000002e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs738321	0.757	rs6001020	chr22:38538246	C/G	cg25457927	chr22:38595422	NA	-0.36	-12.14	-0.43	1.15e-30	Breast cancer;
BRCA	cis	rs4730250	0.707	rs10253291	chr7:106786550	C/A	cg02696742	chr7:106810147	HBP1	0.57	9.42	0.35	8.1e-20	Osteoarthritis;
BRCA	cis	rs1712517	0.838	rs1891293	chr10:105001797	C/T	cg05636881	chr10:105038444	INA	-0.39	-8.82	-0.33	1.09e-17	Migraine;
BRCA	trans	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg25042112	chr7:64838748	ZNF92	-0.45	-8.34	-0.31	4.45e-16	Pain;
BRCA	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg03934865	chr2:198174659	NA	-0.38	-8.31	-0.31	5.76e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06108461	chr20:60628389	TAF4	0.72	15.22	0.52	7.64e-45	Body mass index;
BRCA	cis	rs4363385	0.755	rs516198	chr1:153026196	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.5	-0.32	1.34e-16	Inflammatory skin disease;
BRCA	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg21143896	chr7:2802374	GNA12	-0.35	-8.93	-0.33	4.34e-18	Height;
BRCA	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	11.79	0.42	3.74e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	13.0	0.46	1.94e-34	Colorectal cancer;
BRCA	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg27478167	chr7:817139	HEATR2	0.54	10.51	0.38	6.25e-24	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg02176678	chr2:219576539	TTLL4	-0.48	-12.9	-0.45	5.31e-34	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg26587870	chr6:27730563	NA	-0.41	-8.73	-0.33	2.21e-17	Parkinson's disease;
BRCA	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	16.89	0.56	3.28e-53	Alzheimer's disease;
BRCA	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.43	-0.61	2e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg12463550	chr7:65579703	CRCP	-0.37	-7.86	-0.3	1.58e-14	Aortic root size;
BRCA	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg11657440	chr19:46296263	DMWD	-0.55	-12.98	-0.46	2.33e-34	Coronary artery disease;
BRCA	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg00857998	chr1:205179979	DSTYK	0.42	8.11	0.31	2.62e-15	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg15737290	chr11:93063684	CCDC67	0.53	10.17	0.37	1.24e-22	Pulmonary function decline;
BRCA	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg18154014	chr19:37997991	ZNF793	0.62	11.61	0.42	1.98e-28	Coronary artery calcification;
BRCA	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg09035930	chr12:129282057	SLC15A4	-0.49	-13.85	-0.48	2.34e-38	Systemic lupus erythematosus;
BRCA	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg19920283	chr7:105172520	RINT1	0.58	10.4	0.38	1.63e-23	Bipolar disorder (body mass index interaction);
BRCA	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg12935359	chr14:103987150	CKB	-0.61	-13.84	-0.48	2.63e-38	Intelligence (multi-trait analysis);
BRCA	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg12935359	chr14:103987150	CKB	-0.59	-13.91	-0.48	1.32e-38	Body mass index;
BRCA	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg12444411	chr7:2802554	GNA12	-0.37	-9.06	-0.34	1.6e-18	Height;
BRCA	cis	rs2408955	0.522	rs4760679	chr12:48461635	G/T	cg24011408	chr12:48396354	COL2A1	-0.4	-7.93	-0.3	9.88e-15	Glycated hemoglobin levels;
BRCA	trans	rs629535	0.814	rs558511	chr8:70069908	C/A	cg21567404	chr3:27674614	NA	1.01	20.96	0.64	1.2e-74	Dupuytren's disease;
BRCA	cis	rs6484504	0.576	rs208103	chr11:31167400	A/G	cg26647111	chr11:31128758	NA	-0.44	-9.64	-0.36	1.31e-20	Red blood cell count;
BRCA	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg15017067	chr4:17643749	FAM184B	0.35	10.83	0.39	3.2e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9443645	0.527	rs1413969	chr6:79790982	A/G	cg05283184	chr6:79620031	NA	-0.36	-8.42	-0.32	2.41e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg25036284	chr2:26402008	FAM59B	0.89	15.6	0.53	1.03e-46	Gut microbiome composition (summer);
BRCA	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg13319975	chr6:146136371	FBXO30	-0.42	-9.42	-0.35	7.89e-20	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg16141378	chr3:129829833	LOC729375	-0.34	-8.22	-0.31	1.16e-15	Mood instability;
BRCA	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg08470875	chr2:26401718	FAM59B	0.76	11.94	0.43	8.04e-30	Gut microbiome composition (summer);
BRCA	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg12564285	chr5:131593104	PDLIM4	0.42	10.22	0.37	8.51e-23	Acylcarnitine levels;
BRCA	trans	rs4650994	1.000	rs4511075	chr1:178518636	G/A	cg05059571	chr16:84539110	KIAA1609	-0.43	-9.77	-0.36	4.34e-21	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg23649088	chr2:200775458	C2orf69	0.71	15.21	0.52	7.94e-45	Osteoporosis;
BRCA	cis	rs1018836	0.923	rs4734266	chr8:91628147	C/T	cg16814680	chr8:91681699	NA	-0.6	-12.75	-0.45	2.37e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg14196790	chr5:131705035	SLC22A5	0.4	10.0	0.37	5.54e-22	Blood metabolite levels;
BRCA	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg00983440	chr10:79422392	NA	-0.57	-10.88	-0.4	2e-25	Bone mineral density;
BRCA	cis	rs600806	0.713	rs11102984	chr1:109997373	T/C	cg20591472	chr1:110008990	SYPL2	0.33	8.3	0.31	6.14e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg25809561	chr17:30822961	MYO1D	0.37	8.64	0.32	4.49e-17	Schizophrenia;
BRCA	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg03923535	chr7:1197113	ZFAND2A	0.4	8.0	0.3	6.02e-15	Longevity;Endometriosis;
BRCA	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg08917208	chr2:24149416	ATAD2B	1.05	14.36	0.49	9.8e-41	Lymphocyte counts;
BRCA	trans	rs1547374	0.694	rs225349	chr21:43776890	C/T	cg09521743	chr10:75415752	SYNPO2L	0.43	8.81	0.33	1.19e-17	Pancreatic cancer;
BRCA	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	16.12	0.54	2.55e-49	Bone mineral density;
BRCA	cis	rs68170813	0.562	rs17429825	chr7:107050731	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.12	-0.31	2.49e-15	Coronary artery disease;
BRCA	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg04989706	chr14:50066350	PPIL5	-0.48	-9.01	-0.34	2.38e-18	Carotid intima media thickness;
BRCA	cis	rs4363385	0.818	rs558363	chr1:153010431	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg11693508	chr17:37793320	STARD3	0.57	10.81	0.39	4.14e-25	Bipolar disorder;
BRCA	cis	rs4900538	0.819	rs72700604	chr14:102882307	G/A	cg18135206	chr14:102964638	TECPR2	-0.93	-22.04	-0.66	1.58e-80	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg16482183	chr6:26056742	HIST1H1C	0.41	8.78	0.33	1.51e-17	Iron status biomarkers;
BRCA	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg11502198	chr6:26597334	ABT1	0.47	9.46	0.35	5.99e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg05234568	chr11:5960015	NA	0.56	12.16	0.43	9.75e-31	DNA methylation (variation);
BRCA	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11890956	chr21:40555474	PSMG1	-0.65	-14.76	-0.5	1.21e-42	Menarche (age at onset);
BRCA	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg13770153	chr20:60521292	NA	-0.4	-9.28	-0.34	2.5e-19	Body mass index;
BRCA	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg05985134	chr18:33552581	C18orf21	0.64	11.51	0.41	5.2e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.06	-0.34	1.62e-18	Menopause (age at onset);
BRCA	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.04	-24.43	-0.7	1.28e-93	Ulcerative colitis;
BRCA	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7246657	0.679	rs12461113	chr19:38083188	G/A	cg23950597	chr19:37808831	NA	-0.5	-8.64	-0.32	4.63e-17	Coronary artery calcification;
BRCA	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg24642844	chr7:1081250	C7orf50	-0.89	-15.97	-0.53	1.45e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg15017067	chr4:17643749	FAM184B	0.31	9.41	0.35	8.83e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6138458	1.000	rs2387361	chr20:24899905	C/T	cg06937882	chr20:24974362	C20orf3	0.44	8.35	0.31	4.34e-16	Blood protein levels;
BRCA	cis	rs1506636	1.000	rs635072	chr7:123403255	G/A	cg03229431	chr7:123269106	ASB15	0.61	13.76	0.48	6.43e-38	Plateletcrit;Platelet count;
BRCA	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-10.54	-0.38	4.52e-24	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.49	9.27	0.34	2.83e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.48e-23	Motion sickness;
BRCA	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-15.75	-0.53	1.79e-47	Chronic sinus infection;
BRCA	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.23	-0.31	1.05e-15	Bipolar disorder;
BRCA	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	12.35	0.44	1.4e-31	Platelet count;
BRCA	cis	rs4664304	0.658	rs2667015	chr2:160868586	T/C	cg01092293	chr2:160761427	LY75	-0.36	-8.66	-0.32	3.83e-17	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg21475434	chr5:93447410	FAM172A	0.66	8.65	0.32	4.01e-17	Diabetic retinopathy;
BRCA	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg26384229	chr12:38710491	ALG10B	0.71	16.34	0.54	2.18e-50	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs8002861	0.713	rs7339417	chr13:44413496	A/T	cg12856521	chr11:46389249	DGKZ	0.37	8.07	0.3	3.5e-15	Leprosy;
BRCA	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg04756594	chr16:24857601	SLC5A11	0.53	12.17	0.43	8.7e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.82	11.26	0.41	5.85e-27	Initial pursuit acceleration;
BRCA	cis	rs3806933	0.522	rs13186912	chr5:110456704	A/T	cg04022379	chr5:110408740	TSLP	-0.47	-9.93	-0.37	1.03e-21	Eosinophilic esophagitis;
BRCA	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.66	-0.57	3.68e-57	Chronic sinus infection;
BRCA	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg15145296	chr3:125709740	NA	-0.54	-8.93	-0.33	4.68e-18	Blood pressure (smoking interaction);
BRCA	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg14664628	chr15:75095509	CSK	-0.74	-18.23	-0.58	4.43e-60	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs6424115	0.644	rs2267960	chr1:24068544	T/C	cg15997130	chr1:24165203	NA	0.36	8.72	0.33	2.43e-17	Immature fraction of reticulocytes;
BRCA	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg17063962	chr7:91808500	NA	-0.51	-11.82	-0.42	2.74e-29	Breast cancer;
BRCA	cis	rs897984	0.542	rs35713203	chr16:31090407	G/C	cg02466173	chr16:30829666	NA	-0.41	-8.86	-0.33	7.98e-18	Dementia with Lewy bodies;
BRCA	cis	rs6594713	0.717	rs2914198	chr5:112950253	C/G	cg12552261	chr5:112820674	MCC	-0.48	-8.02	-0.3	4.93e-15	Brain cytoarchitecture;
BRCA	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00908189	chr16:619842	PIGQ	0.7	17.9	0.58	2.18e-58	Height;
BRCA	trans	rs9951602	0.512	rs77157626	chr18:76644771	C/T	cg02800362	chr5:177631904	HNRNPAB	0.76	17.47	0.57	3.5e-56	Obesity-related traits;
BRCA	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg20476274	chr7:133979776	SLC35B4	0.52	12.67	0.45	5.76e-33	Mean platelet volume;
BRCA	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg05347473	chr6:146136440	FBXO30	-0.43	-8.49	-0.32	1.42e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg03877680	chr5:178157825	ZNF354A	0.82	15.94	0.53	2.16e-48	Neutrophil percentage of white cells;
BRCA	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg04362960	chr10:104952993	NT5C2	0.41	10.14	0.37	1.62e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg04944784	chr2:26401820	FAM59B	-0.96	-16.37	-0.54	1.41e-50	Gut microbiome composition (summer);
BRCA	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg00684032	chr4:1343700	KIAA1530	0.32	8.38	0.31	3.46e-16	Obesity-related traits;
BRCA	cis	rs1941023	0.584	rs2233253	chr11:60157166	C/T	cg08716584	chr11:60157161	MS4A7	-0.44	-10.63	-0.39	2.13e-24	Congenital heart disease (maternal effect);
BRCA	cis	rs1691799	0.867	rs1027400	chr12:66760922	A/T	cg16791601	chr12:66731901	HELB	-0.64	-17.34	-0.57	1.78e-55	White blood cell count (basophil);
BRCA	cis	rs4478858	0.647	rs10798835	chr1:31709055	T/C	cg00250761	chr1:31883323	NA	-0.31	-8.11	-0.31	2.64e-15	Alcohol dependence;
BRCA	trans	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17712092	chr4:129076599	LARP1B	0.62	14.79	0.5	8.45e-43	Eosinophil percentage of white cells;
BRCA	cis	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg21573476	chr21:45109991	RRP1B	-0.39	-10.28	-0.38	4.86e-23	Mean corpuscular volume;
BRCA	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg04362960	chr10:104952993	NT5C2	0.42	10.03	0.37	4.46e-22	Arsenic metabolism;
BRCA	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg01475377	chr6:109611718	NA	-0.59	-16.46	-0.55	5.05e-51	Reticulocyte fraction of red cells;
BRCA	cis	rs6840258	0.547	rs4693795	chr4:87868056	G/A	cg08197287	chr4:87952173	AFF1	-0.45	-8.15	-0.31	1.89e-15	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg09163369	chr1:210001066	C1orf107	0.48	9.05	0.34	1.69e-18	Orofacial clefts;
BRCA	cis	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg09307838	chr4:120376055	NA	0.47	9.76	0.36	4.59e-21	Diastolic blood pressure;
BRCA	cis	rs4363385	0.720	rs6680624	chr1:152983872	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.28	-0.31	7.23e-16	Inflammatory skin disease;
BRCA	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg25801113	chr15:45476975	SHF	-0.34	-8.27	-0.31	7.79e-16	Uric acid levels;
BRCA	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg14517863	chr17:44321492	NA	0.37	7.82	0.3	2.2e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
BRCA	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg18404041	chr3:52824283	ITIH1	-0.35	-9.55	-0.35	2.66e-20	Bipolar disorder;
BRCA	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg09307838	chr4:120376055	NA	0.69	14.05	0.49	2.88e-39	Corneal astigmatism;
BRCA	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	19.84	0.62	1.36e-68	Electrocardiographic conduction measures;
BRCA	trans	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg07817883	chr1:32538562	TMEM39B	0.92	13.93	0.48	1.04e-38	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	11.84	0.42	2.28e-29	Schizophrenia;
BRCA	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg06212747	chr3:49208901	KLHDC8B	0.47	9.49	0.35	4.44e-20	Parkinson's disease;
BRCA	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19723775	chr5:179050963	HNRNPH1	-0.38	-9.16	-0.34	6.87e-19	Lung cancer;
BRCA	cis	rs8038465	0.615	rs11072430	chr15:73981701	A/G	cg15420318	chr15:73925796	NPTN	-0.38	-8.55	-0.32	8.77e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg21775007	chr8:11205619	TDH	-0.39	-8.35	-0.31	4.34e-16	Neuroticism;
BRCA	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.74e-16	Menopause (age at onset);
BRCA	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg00105475	chr2:10696890	NA	0.44	10.26	0.38	5.78e-23	Prostate cancer;
BRCA	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg05025164	chr4:1340916	KIAA1530	0.36	7.9	0.3	1.2e-14	Longevity;
BRCA	cis	rs897984	0.542	rs73530203	chr16:31099859	G/A	cg02466173	chr16:30829666	NA	-0.41	-8.79	-0.33	1.4e-17	Dementia with Lewy bodies;
BRCA	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg23029597	chr12:123009494	RSRC2	-0.55	-11.27	-0.41	5.15e-27	Body mass index;
BRCA	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg13798912	chr7:905769	UNC84A	-0.49	-7.9	-0.3	1.18e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-10.27	-0.38	5.35e-23	Alzheimer's disease (late onset);
BRCA	cis	rs4478858	0.735	rs6685728	chr1:31802550	T/C	cg00250761	chr1:31883323	NA	-0.33	-8.54	-0.32	9.96e-17	Alcohol dependence;
BRCA	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg00409905	chr10:38381863	ZNF37A	-0.48	-10.16	-0.37	1.43e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg11764359	chr7:65958608	NA	-0.62	-13.28	-0.47	1e-35	Aortic root size;
BRCA	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg17971929	chr21:40555470	PSMG1	0.78	18.39	0.59	6.43e-61	Cognitive function;
BRCA	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg13880726	chr7:1868755	MAD1L1	0.53	9.87	0.36	1.72e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg06627628	chr2:24431161	ITSN2	-0.84	-15.13	-0.51	1.98e-44	Asthma;
BRCA	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.53	-0.41	4.66e-28	Personality dimensions;
BRCA	cis	rs4363385	0.782	rs10788857	chr1:153024941	T/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.5	-0.32	1.38e-16	Inflammatory skin disease;
BRCA	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg24531977	chr5:56204891	C5orf35	0.65	13.86	0.48	2.27e-38	Initial pursuit acceleration;
BRCA	trans	rs2018683	0.649	rs12536605	chr7:28970500	C/T	cg19402173	chr7:128379420	CALU	-0.42	-10.02	-0.37	4.85e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg07988820	chr12:82153109	PPFIA2	-0.65	-11.16	-0.4	1.45e-26	Resting heart rate;
BRCA	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.51	-10.8	-0.39	4.42e-25	Colorectal cancer;
BRCA	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18404041	chr3:52824283	ITIH1	-0.29	-8.54	-0.32	1e-16	Electroencephalogram traits;
BRCA	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	11.69	0.42	9.95e-29	Schizophrenia;
BRCA	cis	rs6840258	0.941	rs72667757	chr4:87946994	C/A	cg08197287	chr4:87952173	AFF1	-0.44	-7.86	-0.3	1.68e-14	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs829883	0.621	rs11109516	chr12:98921035	G/A	cg25150519	chr12:98850993	NA	-0.51	-9.29	-0.34	2.48e-19	Colorectal adenoma (advanced);
BRCA	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg03711944	chr11:47377212	SPI1	-0.38	-9.04	-0.34	1.88e-18	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.74	16.29	0.54	3.92e-50	Cognitive ability;
BRCA	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg12310025	chr6:25882481	NA	-0.54	-12.83	-0.45	1.04e-33	Blood metabolite levels;
BRCA	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg18876405	chr7:65276391	NA	0.55	12.26	0.44	3.43e-31	Calcium levels;
BRCA	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg13736514	chr6:26305472	NA	-0.35	-11.95	-0.43	7.59e-30	Educational attainment;
BRCA	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg25204440	chr1:209979598	IRF6	0.41	8.41	0.32	2.69e-16	Cleft lip with or without cleft palate;
BRCA	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg00071950	chr4:10020882	SLC2A9	0.64	15.96	0.53	1.61e-48	Bone mineral density;
BRCA	cis	rs6840258	0.660	rs17012216	chr4:87889437	G/T	cg08197287	chr4:87952173	AFF1	-0.46	-8.4	-0.32	2.8e-16	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg01028140	chr2:1542097	TPO	-0.57	-11.62	-0.42	1.91e-28	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg03711944	chr11:47377212	SPI1	-0.42	-11.45	-0.41	9.25e-28	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs1904096	0.506	rs10028613	chr4:95223698	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-8.42	-0.32	2.47e-16	Type 2 diabetes;
BRCA	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg25036284	chr2:26402008	FAM59B	-0.61	-10.35	-0.38	2.47e-23	Gut microbiome composition (summer);
BRCA	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.8	-0.36	3.19e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg14036092	chr11:66035641	RAB1B	0.39	10.24	0.38	6.7e-23	Gout;
BRCA	cis	rs9309473	1.000	rs6736866	chr2:73661986	C/G	cg20560298	chr2:73613845	ALMS1	-0.49	-12.19	-0.43	7.35e-31	Metabolite levels;
BRCA	cis	rs7020830	0.830	rs17487601	chr9:37213641	G/A	cg14294708	chr9:37120828	ZCCHC7	1.16	39.03	0.84	2.8000000000000002e-171	Schizophrenia;
BRCA	cis	rs12949688	0.967	rs9905938	chr17:55824351	G/A	cg12582317	chr17:55822272	NA	0.32	7.83	0.3	2.04e-14	Schizophrenia;
BRCA	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg04546413	chr19:29218101	NA	0.64	12.32	0.44	1.96e-31	Methadone dose in opioid dependence;
BRCA	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg15704280	chr7:45808275	SEPT13	-0.53	-10.25	-0.38	6.4e-23	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs2016266	0.859	rs10783575	chr12:53742885	C/T	cg26875137	chr12:53738046	NA	-0.42	-10.91	-0.4	1.59e-25	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15506890	chr2:3487001	NA	0.58	13.15	0.46	4.09e-35	Neurofibrillary tangles;
BRCA	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg23711669	chr6:146136114	FBXO30	0.64	14.63	0.5	4.95e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3845702	0.733	rs12693217	chr2:180841914	T/G	cg01881094	chr2:180872142	CWC22	-1.02	-17.11	-0.56	2.7e-54	Schizophrenia;
BRCA	trans	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg07461501	chr17:79650226	HGS;ARL16	0.63	14.27	0.49	2.62e-40	Obesity-related traits;
BRCA	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg25036284	chr2:26402008	FAM59B	-0.95	-15.98	-0.53	1.27e-48	Gut microbiome composition (summer);
BRCA	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-11.38	-0.41	1.87e-27	Bone mineral density;
BRCA	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg04455712	chr21:45112962	RRP1B	0.42	10.66	0.39	1.6e-24	Mean corpuscular volume;
BRCA	cis	rs8114671	0.967	rs1415774	chr20:33765616	C/T	cg07148914	chr20:33460835	GGT7	-0.39	-8.34	-0.31	4.6e-16	Height;
BRCA	cis	rs7833986	0.501	rs2953898	chr8:56980803	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	13.23	0.46	1.72e-35	Height;
BRCA	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg26384229	chr12:38710491	ALG10B	0.66	15.19	0.52	1.03e-44	Bladder cancer;
BRCA	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.13	0.46	4.84e-35	Bipolar disorder;
BRCA	cis	rs11229555	0.645	rs12273638	chr11:58186335	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.52	-0.35	3.53e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3087591	1.000	rs2854331	chr17:29711728	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.43	-8.69	-0.33	3.01e-17	Hip circumference;
BRCA	cis	rs829883	0.664	rs829876	chr12:98842138	A/G	cg25150519	chr12:98850993	NA	0.67	16.41	0.54	8.83e-51	Colorectal adenoma (advanced);
BRCA	cis	rs2108225	0.714	rs929393	chr7:107437048	C/T	cg18560240	chr7:107437656	SLC26A3	-0.57	-12.5	-0.44	3.26e-32	Ulcerative colitis;
BRCA	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg26516362	chr5:178986906	RUFY1	-0.34	-9.26	-0.34	3.02e-19	Lung cancer;
BRCA	cis	rs6815814	0.861	rs12233670	chr4:38787216	C/T	cg06935464	chr4:38784597	TLR10	0.49	10.18	0.37	1.21e-22	Breast cancer;
BRCA	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg03342759	chr3:160939853	NMD3	-0.65	-13.83	-0.48	3.01e-38	Morning vs. evening chronotype;
BRCA	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03517284	chr6:25882590	NA	0.48	10.71	0.39	1e-24	Blood metabolite levels;
BRCA	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg11764359	chr7:65958608	NA	0.63	10.7	0.39	1.06e-24	Aortic root size;
BRCA	cis	rs813218	0.523	rs1711554	chr3:99428998	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-8.88	-0.33	6.53e-18	Orofacial clefts;
BRCA	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.76	16.8	0.55	1.03e-52	Cognitive ability;
BRCA	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-15.68	-0.53	4.25e-47	Height;
BRCA	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	18.28	0.59	2.45e-60	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs919433	0.679	rs6741314	chr2:198526088	G/A	cg00792783	chr2:198669748	PLCL1	0.39	9.03	0.34	2.08e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	trans	rs61931739	0.500	rs11836207	chr12:34315177	G/A	cg26384229	chr12:38710491	ALG10B	0.43	9.37	0.35	1.19e-19	Morning vs. evening chronotype;
BRCA	cis	rs1577917	0.958	rs2324839	chr6:86536942	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.54	-0.42	4.21e-28	Response to antipsychotic treatment;
BRCA	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg16339924	chr4:17578868	LAP3	0.59	14.31	0.49	1.8e-40	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg13256891	chr4:100009986	ADH5	0.52	9.69	0.36	8.6e-21	Alcohol dependence;
BRCA	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg14004847	chr7:1930337	MAD1L1	-0.44	-8.46	-0.32	1.8e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	4.98e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg27572855	chr1:25598939	RHD	0.47	13.33	0.47	5.88e-36	Erythrocyte sedimentation rate;
BRCA	cis	rs4478858	0.735	rs11582342	chr1:31810681	A/G	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs6782228	0.606	rs7613073	chr3:128388503	T/G	cg16766828	chr3:128327626	NA	-0.43	-9.46	-0.35	5.76e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11890956	chr21:40555474	PSMG1	-0.62	-14.07	-0.49	2.25e-39	Menarche (age at onset);
BRCA	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18876405	chr7:65276391	NA	-0.62	-15.35	-0.52	1.68e-45	Aortic root size;
BRCA	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg12463550	chr7:65579703	CRCP	-0.37	-8.01	-0.3	5.4e-15	Aortic root size;
BRCA	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg10523679	chr1:76189770	ACADM	0.58	10.52	0.38	5.54e-24	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg26769984	chr7:1090371	C7orf50	0.47	10.04	0.37	3.96e-22	Bronchopulmonary dysplasia;
BRCA	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.22	0.37	8.56e-23	Aortic root size;
BRCA	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg18132916	chr6:79620363	NA	-0.47	-10.68	-0.39	1.29e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg25919922	chr13:100150906	NA	-0.69	-12.5	-0.44	3.24e-32	Obesity-related traits;
BRCA	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg02038168	chr22:39784481	NA	-0.39	-7.82	-0.3	2.19e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.11	0.31	2.58e-15	Breast cancer;
BRCA	cis	rs7123876	0.504	rs1157343	chr11:72429141	A/G	cg03713592	chr11:72463424	ARAP1	-0.47	-9.19	-0.34	5.48e-19	Body mass index;
BRCA	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg04756594	chr16:24857601	SLC5A11	0.34	8.44	0.32	2.06e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.99	0.33	2.88e-18	Tonsillectomy;
BRCA	trans	rs62103177	0.565	rs473119	chr18:77849459	T/G	cg05926928	chr17:57297772	GDPD1	-0.78	-10.93	-0.4	1.25e-25	Opioid sensitivity;
BRCA	trans	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg07211511	chr3:129823064	LOC729375	-0.63	-11.17	-0.4	1.39e-26	Blood pressure (smoking interaction);
BRCA	cis	rs36051895	0.623	rs62541543	chr9:5042082	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-9.14	-0.34	7.9e-19	Pediatric autoimmune diseases;
BRCA	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg27284194	chr4:1044797	NA	0.44	9.49	0.35	4.63e-20	Recombination rate (males);
BRCA	cis	rs9815354	0.638	rs73069277	chr3:41967521	C/T	cg03022575	chr3:42003672	ULK4	0.72	9.93	0.37	1.03e-21	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs3960554	0.867	rs10239209	chr7:75804085	G/A	cg19862616	chr7:65841803	NCRNA00174	0.59	12.29	0.44	2.69e-31	Eotaxin levels;
BRCA	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg00814883	chr7:100076585	TSC22D4	-0.49	-9.38	-0.35	1.14e-19	Platelet count;
BRCA	trans	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.37	-9.07	-0.34	1.45e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg24558204	chr6:135376177	HBS1L	-0.58	-15.94	-0.53	1.99e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18402987	chr7:1209562	NA	0.53	10.2	0.37	9.98e-23	Longevity;Endometriosis;
BRCA	cis	rs754466	0.606	rs11002310	chr10:79596030	A/C	cg17075019	chr10:79541650	NA	-0.8	-20.37	-0.63	1.93e-71	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg02297831	chr4:17616191	MED28	0.37	8.76	0.33	1.7e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2463822	0.925	rs12292586	chr11:62156312	C/T	cg06239285	chr11:62104954	ASRGL1	-0.64	-9.18	-0.34	5.72e-19	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg08601574	chr20:25228251	PYGB	0.37	8.79	0.33	1.41e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg22907277	chr7:1156413	C7orf50	0.6	9.15	0.34	7.54e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.06	-25.8	-0.71	4.21e-101	Ulcerative colitis;
BRCA	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.08	-0.43	2.06e-30	Total cholesterol levels;
BRCA	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg04691961	chr3:161091175	C3orf57	-0.59	-14.06	-0.49	2.61e-39	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	1.01e-40	Motion sickness;
BRCA	cis	rs9487051	0.698	rs11153168	chr6:109629420	A/T	cg21918786	chr6:109611834	NA	-0.36	-8.73	-0.33	2.16e-17	Reticulocyte fraction of red cells;
BRCA	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg03146154	chr1:46216737	IPP	0.46	10.38	0.38	2.03e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.27	-0.31	7.52e-16	Total body bone mineral density;
BRCA	cis	rs2046867	0.818	rs6792109	chr3:72867091	C/T	cg25664220	chr3:72788482	NA	-0.54	-11.68	-0.42	1.02e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg11189052	chr15:85197271	WDR73	-0.34	-8.23	-0.31	1.04e-15	P wave terminal force;
BRCA	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26314531	chr2:26401878	FAM59B	0.96	16.52	0.55	2.62e-51	Gut microbiome composition (summer);
BRCA	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.17	-0.34	6.4e-19	Menopause (age at onset);
BRCA	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg24558204	chr6:135376177	HBS1L	0.45	12.32	0.44	1.88e-31	Red blood cell count;
BRCA	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.11	0.37	2.18e-22	Calcium levels;
BRCA	cis	rs12989701	1.000	rs6710467	chr2:127889932	C/T	cg08168897	chr2:127865431	BIN1	0.6	10.78	0.39	5.02e-25	Alzheimer's disease (late onset);
BRCA	trans	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg16141378	chr3:129829833	LOC729375	-0.33	-8.06	-0.3	3.79e-15	Mood instability;
BRCA	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg12310025	chr6:25882481	NA	0.52	12.31	0.44	2.12e-31	Blood metabolite levels;
BRCA	cis	rs57590327	0.508	rs4622918	chr3:81965382	A/G	cg07356753	chr3:81810745	GBE1	-0.37	-8.75	-0.33	1.82e-17	Extraversion;
BRCA	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg26031613	chr14:104095156	KLC1	-0.43	-8.42	-0.32	2.41e-16	Schizophrenia;
BRCA	cis	rs10208940	1.000	rs10208940	chr2:68733389	C/T	cg12452813	chr2:68675892	NA	-0.46	-8.21	-0.31	1.21e-15	Urate levels in lean individuals;
BRCA	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	15.81	0.53	9.36e-48	Hip circumference adjusted for BMI;
BRCA	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg27170947	chr2:26402098	FAM59B	-0.65	-11.21	-0.41	9.48e-27	Gut microbiome composition (summer);
BRCA	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg02931644	chr1:25747376	RHCE	0.4	10.77	0.39	5.89e-25	Erythrocyte sedimentation rate;
BRCA	cis	rs7894051	0.717	rs4838741	chr10:135206873	C/T	cg05676341	chr10:135206831	MTG1	0.57	8.84	0.33	9.01e-18	Lifespan;
BRCA	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg06115741	chr20:33292138	TP53INP2	0.48	10.6	0.39	2.68e-24	Coronary artery disease;
BRCA	cis	rs752010	0.841	rs17363834	chr1:42076607	C/T	cg06885757	chr1:42089581	HIVEP3	0.23	8.53	0.32	1.09e-16	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg11845111	chr2:191398756	TMEM194B	0.43	9.7	0.36	7.86e-21	Pulse pressure;
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07308232	chr7:1071921	C7orf50	0.45	9.34	0.35	1.6e-19	Longevity;Endometriosis;
BRCA	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg05863683	chr7:1912471	MAD1L1	0.42	9.06	0.34	1.59e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg22800045	chr5:56110881	MAP3K1	-0.42	-8.4	-0.32	2.87e-16	Initial pursuit acceleration;
BRCA	cis	rs9463078	0.683	rs227848	chr6:44698499	G/A	cg25276700	chr6:44698697	NA	0.36	7.82	0.3	2.19e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	trans	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.39	0.49	6.85e-41	Exhaled nitric oxide output;
BRCA	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg03146154	chr1:46216737	IPP	-0.45	-10.0	-0.37	5.46e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-9.05	-0.34	1.65e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9811920	0.683	rs813218	chr3:99592596	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	10.91	0.4	1.5e-25	Axial length;
BRCA	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24308560	chr3:49941425	MST1R	-0.4	-8.56	-0.32	8.62e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg17385448	chr1:15911702	AGMAT	0.37	7.86	0.3	1.68e-14	Systolic blood pressure;
BRCA	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg06671706	chr8:8559999	CLDN23	0.45	8.77	0.33	1.57e-17	Obesity-related traits;
BRCA	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11644478	chr21:40555479	PSMG1	0.58	8.86	0.33	7.92e-18	Cognitive function;
BRCA	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg18479299	chr3:125709523	NA	-0.54	-8.33	-0.31	4.84e-16	Blood pressure (smoking interaction);
BRCA	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg08999081	chr20:33150536	PIGU	0.36	9.13	0.34	8.57e-19	Coronary artery disease;
BRCA	cis	rs17604090	0.628	rs875263	chr7:29711066	T/C	cg19413766	chr7:29689036	LOC646762	-0.57	-9.12	-0.34	1e-18	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs477692	0.569	rs871028	chr10:131293478	C/T	cg05714579	chr10:131428358	MGMT	-0.46	-10.41	-0.38	1.5e-23	Response to temozolomide;
BRCA	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-10.2	-0.37	9.73e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg19784903	chr17:45786737	TBKBP1	-0.34	-8.1	-0.31	2.87e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.35	-9.15	-0.34	7.27e-19	Total body bone mineral density;
BRCA	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-9.56	-0.35	2.45e-20	Chronic sinus infection;
BRCA	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg04691961	chr3:161091175	C3orf57	0.59	14.44	0.5	4.09e-41	Morning vs. evening chronotype;
BRCA	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.59	9.35	0.35	1.51e-19	Renal function-related traits (BUN);
BRCA	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg02743256	chr7:2109353	MAD1L1	-0.47	-8.31	-0.31	5.75e-16	Neuroticism;
BRCA	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	15.49	0.52	3.47e-46	Colorectal cancer;
BRCA	cis	rs738321	0.701	rs4821754	chr22:38581503	A/G	cg25457927	chr22:38595422	NA	0.38	12.47	0.44	4.06e-32	Breast cancer;
BRCA	cis	rs6942756	1.000	rs73472312	chr7:128925217	T/C	cg02491457	chr7:128862824	NA	-0.71	-13.89	-0.48	1.61e-38	White matter hyperintensity burden;
BRCA	cis	rs870825	0.616	rs72703531	chr4:185611092	C/T	cg20176042	chr4:185552304	CASP3	-0.54	-8.22	-0.31	1.1e-15	Blood protein levels;
BRCA	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg04709771	chr16:646395	RAB40C	0.42	10.6	0.39	2.78e-24	Height;
BRCA	cis	rs7587476	0.954	rs3768708	chr2:215645046	C/T	cg04004882	chr2:215674386	BARD1	-0.57	-11.23	-0.41	8.22e-27	Neuroblastoma;
BRCA	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg00717180	chr2:96193071	NA	-0.41	-11.35	-0.41	2.48e-27	HDL cholesterol;
BRCA	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.92	0.4	1.46e-25	Bipolar disorder;
BRCA	cis	rs600806	0.888	rs10745352	chr1:109871787	T/C	cg20591472	chr1:110008990	SYPL2	0.33	8.16	0.31	1.75e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg26149184	chr10:133730230	NA	0.41	8.15	0.31	1.85e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs68170813	0.559	rs77671232	chr7:106939202	A/G	cg02696742	chr7:106810147	HBP1	-0.48	-8.49	-0.32	1.39e-16	Coronary artery disease;
BRCA	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.52	-0.41	4.78e-28	Gut microbiome composition (summer);
BRCA	cis	rs753274	0.650	rs7257738	chr19:14418921	G/C	cg25450033	chr19:14444658	NA	0.33	7.84	0.3	1.93e-14	Tumor necrosis factor beta levels;
BRCA	cis	rs701145	0.878	rs442480	chr3:153992952	T/A	cg17054900	chr3:154042577	DHX36	0.68	11.79	0.42	3.71e-29	Coronary artery disease;
BRCA	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg17691542	chr6:26056736	HIST1H1C	0.47	9.74	0.36	5.38e-21	Height;
BRCA	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.96e-21	Total body bone mineral density;
BRCA	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg04362960	chr10:104952993	NT5C2	0.41	9.78	0.36	3.85e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg11502198	chr6:26597334	ABT1	0.49	9.73	0.36	5.8e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg10729496	chr3:10149963	C3orf24	0.47	8.84	0.33	8.98e-18	Alzheimer's disease;
BRCA	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	9.84	0.36	2.28e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg04287289	chr16:89883240	FANCA	-0.73	-18.1	-0.58	2e-59	Vitiligo;
BRCA	cis	rs9309473	1.000	rs9309473	chr2:73743982	A/G	cg20560298	chr2:73613845	ALMS1	-0.43	-10.65	-0.39	1.64e-24	Metabolite levels;
BRCA	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg12698349	chr2:225449008	CUL3	0.61	13.07	0.46	8.9e-35	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs9361491	0.543	rs1507153	chr6:79484386	C/A	cg09184832	chr6:79620586	NA	-0.4	-7.96	-0.3	7.86e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10851411	0.697	rs17766258	chr15:42785137	A/G	cg21293051	chr15:42870591	STARD9	-0.53	-8.71	-0.33	2.68e-17	Glucose homeostasis traits;
BRCA	cis	rs701145	0.537	rs1713855	chr3:153847833	T/C	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.82e-18	Coronary artery disease;
BRCA	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26314531	chr2:26401878	FAM59B	-0.9	-15.64	-0.53	6.69e-47	Gut microbiome composition (summer);
BRCA	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg14664628	chr15:75095509	CSK	-0.74	-18.05	-0.58	3.45e-59	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs10924970	1.000	rs10924870	chr1:235359782	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.34	-8.43	-0.32	2.22e-16	Asthma;
BRCA	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg01191920	chr7:158217561	PTPRN2	0.46	11.02	0.4	5.44e-26	Obesity-related traits;
BRCA	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg23978390	chr7:1156363	C7orf50	0.4	8.13	0.31	2.16e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06028605	chr16:24865363	SLC5A11	0.43	9.63	0.36	1.34e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9560113	0.959	rs9555802	chr13:112179504	T/C	cg10483660	chr13:112241077	NA	0.31	7.84	0.3	1.91e-14	Menarche (age at onset);
BRCA	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.13	-0.34	8.85e-19	Bipolar disorder;
BRCA	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg13010199	chr12:38710504	ALG10B	-0.34	-8.0	-0.3	5.67e-15	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.84e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6743226	0.934	rs6704615	chr2:242228733	A/G	cg10021735	chr2:242295487	FARP2	-0.36	-9.91	-0.37	1.24e-21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg05535760	chr7:792225	HEATR2	0.71	13.37	0.47	4.01e-36	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.74e-16	Menopause (age at onset);
BRCA	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.46	-13.97	-0.48	6.96e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg03433033	chr1:76189801	ACADM	-0.4	-8.17	-0.31	1.68e-15	Daytime sleep phenotypes;
BRCA	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg13047869	chr3:10149882	C3orf24	0.59	12.11	0.43	1.62e-30	Alzheimer's disease;
BRCA	trans	rs208520	0.586	rs208442	chr6:66900618	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.59	-11.28	-0.41	5.03e-27	Exhaled nitric oxide output;
BRCA	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17691542	chr6:26056736	HIST1H1C	0.98	19.58	0.61	3.18e-67	Iron status biomarkers;
BRCA	cis	rs7617773	0.817	rs3731555	chr3:48206102	G/A	cg11946769	chr3:48343235	NME6	0.67	14.0	0.48	4.67e-39	Coronary artery disease;
BRCA	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg20587970	chr11:113659929	NA	-1.21	-21.96	-0.66	4.49e-80	Hip circumference adjusted for BMI;
BRCA	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg26818010	chr10:134567672	INPP5A	-0.72	-15.21	-0.52	7.79e-45	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg08859206	chr1:53392774	SCP2	-0.41	-8.64	-0.32	4.41e-17	Monocyte count;
BRCA	cis	rs897984	0.542	rs7199949	chr16:31096164	G/C	cg02466173	chr16:30829666	NA	-0.44	-9.79	-0.36	3.39e-21	Dementia with Lewy bodies;
BRCA	cis	rs10789491	1.000	rs11211342	chr1:47163098	T/C	cg15501359	chr1:47185051	KIAA0494	0.65	18.21	0.58	5.39e-60	Response to hepatitis C treatment;
BRCA	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg00106254	chr7:1943704	MAD1L1	-0.38	-9.33	-0.35	1.76e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs72772090	0.539	rs72775809	chr5:96183556	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-11.44	-0.41	1.02e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg08807101	chr21:30365312	RNF160	0.74	19.41	0.61	2.47e-66	Dental caries;
BRCA	cis	rs2742234	0.541	rs7096500	chr10:43712095	C/T	cg02780029	chr10:43622663	RET	0.35	7.84	0.3	1.89e-14	Hirschsprung disease;
BRCA	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg24531977	chr5:56204891	C5orf35	-0.41	-8.34	-0.31	4.42e-16	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs914187	0.840	rs914186	chr21:42619657	A/G	cg21268422	chr21:42620091	BACE2	-0.55	-11.39	-0.41	1.74e-27	Body mass index;
BRCA	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg00290607	chr11:67383545	NA	-0.53	-11.49	-0.41	6.85e-28	Mean corpuscular volume;
BRCA	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg03806693	chr22:41940476	POLR3H	-0.99	-19.34	-0.61	6.08e-66	Vitiligo;
BRCA	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg06212747	chr3:49208901	KLHDC8B	0.47	9.59	0.35	1.93e-20	Parkinson's disease;
BRCA	cis	rs679087	1.000	rs302321	chr12:29928388	A/C	cg14258853	chr12:29935411	TMTC1	0.42	8.99	0.34	2.69e-18	Schizophrenia;
BRCA	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg26874164	chr19:58962979	ZNF324B	0.52	11.16	0.4	1.48e-26	Uric acid clearance;
BRCA	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg20607798	chr8:58055168	NA	0.53	8.34	0.31	4.56e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs629535	0.551	rs62513429	chr8:70149995	A/C	cg21567404	chr3:27674614	NA	-0.97	-17.72	-0.57	1.98e-57	Dupuytren's disease;
BRCA	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg00409905	chr10:38381863	ZNF37A	-0.47	-9.72	-0.36	6.42e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6435161	1.000	rs1039968	chr2:203557151	T/C	cg18429434	chr2:203499731	FAM117B	-0.43	-8.58	-0.32	6.92e-17	Total cholesterol levels;
BRCA	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.1	0.46	6.97e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.32	-0.31	5.51e-16	Aortic root size;
BRCA	cis	rs7246657	0.722	rs2972438	chr19:38210847	A/G	cg23950597	chr19:37808831	NA	-0.48	-8.22	-0.31	1.17e-15	Coronary artery calcification;
BRCA	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg00852783	chr1:26633632	UBXN11	0.49	10.64	0.39	1.86e-24	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7927771	0.524	rs1563820	chr11:47833398	A/T	cg20307385	chr11:47447363	PSMC3	-0.4	-9.5	-0.35	4.26e-20	Subjective well-being;
BRCA	cis	rs6743226	0.840	rs6747036	chr2:242227054	T/C	cg10021735	chr2:242295487	FARP2	0.36	9.96	0.37	8.2e-22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg03146154	chr1:46216737	IPP	0.53	11.8	0.42	3.42e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.21	-0.34	4.59e-19	Menopause (age at onset);
BRCA	cis	rs3784262	0.565	rs4646607	chr15:58285388	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.31	-0.35	2.06e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs6750047	0.605	rs59501228	chr2:38261972	A/C	cg07380506	chr2:38303506	CYP1B1	-0.49	-10.63	-0.39	2.1e-24	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg09184832	chr6:79620586	NA	-0.5	-11.16	-0.4	1.48e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-15.59	-0.52	1.17e-46	Chronic sinus infection;
BRCA	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21659725	chr3:3221576	CRBN	0.71	22.21	0.66	2.04e-81	Intelligence (multi-trait analysis);
BRCA	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	19.47	0.61	1.19e-66	Smoking behavior;
BRCA	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg12437481	chr16:420112	MRPL28	0.48	11.32	0.41	3.48e-27	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18404041	chr3:52824283	ITIH1	-0.42	-12.32	-0.44	1.93e-31	Bipolar disorder;
BRCA	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg26031613	chr14:104095156	KLC1	-0.43	-8.52	-0.32	1.12e-16	Schizophrenia;
BRCA	cis	rs4478858	0.602	rs6425723	chr1:31715204	T/C	cg00250761	chr1:31883323	NA	-0.31	-8.07	-0.3	3.51e-15	Alcohol dependence;
BRCA	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg00701064	chr4:6280414	WFS1	0.63	12.17	0.43	8.81e-31	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg01877450	chr7:97915802	BRI3	-0.39	-8.99	-0.33	2.83e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg19336497	chr11:14380999	RRAS2	-0.48	-11.83	-0.42	2.47e-29	Sense of smell;
BRCA	cis	rs6834538	1.000	rs6816676	chr4:113483843	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.39	8.91	0.33	5.09e-18	Free thyroxine concentration;
BRCA	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg08470875	chr2:26401718	FAM59B	-0.71	-11.53	-0.41	4.62e-28	Gut microbiome composition (summer);
BRCA	cis	rs9394841	0.692	rs9394834	chr6:41806793	G/A	cg08135965	chr6:41755394	TOMM6	0.47	7.82	0.3	2.15e-14	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg01065977	chr19:18549689	ISYNA1	-0.26	-7.83	-0.3	1.99e-14	Breast cancer;
BRCA	cis	rs311392	0.902	rs411839	chr8:55092189	T/C	cg11783602	chr8:55087084	NA	-0.32	-9.11	-0.34	1.03e-18	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg08601574	chr20:25228251	PYGB	0.36	8.4	0.32	2.89e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10802521	chr3:52805072	NEK4	-0.33	-8.48	-0.32	1.61e-16	Bipolar disorder;
BRCA	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg22907277	chr7:1156413	C7orf50	0.57	11.5	0.41	5.9e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg27490568	chr2:178487706	NA	0.5	8.4	0.32	2.91e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs34779708	0.702	rs4244995	chr10:35547175	A/G	cg03585969	chr10:35415529	CREM	0.44	9.1	0.34	1.17e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9462027	0.628	rs6921363	chr6:34770820	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.83	-0.3	2.04e-14	Systemic lupus erythematosus;
BRCA	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg12756686	chr19:29218302	NA	0.46	8.07	0.3	3.39e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg15704280	chr7:45808275	SEPT13	0.58	9.84	0.36	2.29e-21	Axial length;
BRCA	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg27279351	chr12:120934652	DYNLL1	0.51	12.4	0.44	8.27e-32	High light scatter reticulocyte count;
BRCA	cis	rs4662945	0.525	rs28625431	chr2:130303333	A/G	cg05962382	chr2:130345044	NA	-0.33	-8.0	-0.3	5.74e-15	Response to cytidine analogues (gemcitabine);
BRCA	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-16.87	-0.56	4.27e-53	Colorectal cancer;
BRCA	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg25358565	chr5:93447407	FAM172A	1.16	19.49	0.61	9.49e-67	Diabetic retinopathy;
BRCA	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.5	8.75	0.33	1.89e-17	Body mass index (adult);
BRCA	cis	rs7246657	0.722	rs10406379	chr19:38036725	G/A	cg23950597	chr19:37808831	NA	-0.51	-8.65	-0.32	4.11e-17	Coronary artery calcification;
BRCA	cis	rs61990749	0.686	rs11159288	chr14:78216972	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.64	10.04	0.37	3.96e-22	Fibroblast growth factor basic levels;
BRCA	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg09417038	chr21:47716443	C21orf57	-0.33	-8.25	-0.31	8.72e-16	Testicular germ cell tumor;
BRCA	cis	rs7927771	0.507	rs11039432	chr11:47873327	G/A	cg20307385	chr11:47447363	PSMC3	0.42	9.47	0.35	5.25e-20	Subjective well-being;
BRCA	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg01324343	chr3:183735012	ABCC5	0.83	20.87	0.64	3.74e-74	Anterior chamber depth;
BRCA	cis	rs877282	0.945	rs34367686	chr10:791868	G/C	cg17470449	chr10:769945	NA	0.51	8.62	0.32	5.29e-17	Uric acid levels;
BRCA	cis	rs4363385	0.747	rs4314835	chr1:152984901	C/T	cg24667326	chr1:152973720	SPRR3	-0.36	-10.03	-0.37	4.19e-22	Inflammatory skin disease;
BRCA	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg09754948	chr16:28834200	ATXN2L	0.46	9.19	0.34	5.45e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs11997175	0.766	rs4442096	chr8:33691039	T/C	ch.8.33884649F	chr8:33765107	NA	0.35	8.19	0.31	1.39e-15	Body mass index;
BRCA	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg26597838	chr10:835615	NA	1.03	17.3	0.56	2.73e-55	Eosinophil percentage of granulocytes;
BRCA	trans	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg25482853	chr8:67687455	SGK3	0.79	13.97	0.48	7.1e-39	Ulcerative colitis;
BRCA	cis	rs1030877	1.000	rs2576743	chr2:105901337	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.72	17.89	0.58	2.49e-58	Obesity-related traits;
BRCA	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg08847533	chr14:75593920	NEK9	-0.8	-19.76	-0.62	3.6e-68	Height;
BRCA	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	12.74	0.45	2.73e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg06671706	chr8:8559999	CLDN23	0.45	8.77	0.33	1.57e-17	Obesity-related traits;
BRCA	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg22705602	chr4:152727874	NA	-0.32	-8.3	-0.31	6.2e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs4714291	0.855	rs1743971	chr6:40095927	A/C	cg02267698	chr19:7991119	CTXN1	0.42	8.13	0.31	2.22e-15	Strep throat;
BRCA	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	3.94e-15	Alzheimer's disease (late onset);
BRCA	cis	rs9487051	0.698	rs11153168	chr6:109629420	A/T	cg01475377	chr6:109611718	NA	-0.45	-10.24	-0.38	6.74e-23	Reticulocyte fraction of red cells;
BRCA	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg24829409	chr8:58192753	C8orf71	-0.47	-9.0	-0.34	2.61e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs16958440	0.867	rs2117373	chr18:44671834	C/T	cg17192377	chr18:44677553	HDHD2	0.88	13.01	0.46	1.74e-34	Sitting height ratio;
BRCA	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg21770322	chr7:97807741	LMTK2	0.41	10.86	0.39	2.39e-25	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg09184832	chr6:79620586	NA	-0.53	-11.65	-0.42	1.43e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg21782813	chr7:2030301	MAD1L1	0.33	9.08	0.34	1.3e-18	Schizophrenia;
BRCA	cis	rs9739070	1	rs9739070	chr12:123771032	A/G	cg00376283	chr12:123451042	ABCB9	0.49	10.91	0.4	1.52e-25	Allergy;
BRCA	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-18.07	-0.58	3e-59	Chronic sinus infection;
BRCA	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.85	-0.33	8.26e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9359856	0.564	rs56281344	chr6:90445393	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.71	-8.58	-0.32	7.04e-17	Bipolar disorder;
BRCA	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg21143896	chr7:2802374	GNA12	-0.36	-8.99	-0.33	2.87e-18	Height;
BRCA	cis	rs67460515	0.529	rs6795586	chr3:160897701	A/C	cg03342759	chr3:160939853	NMD3	-0.5	-10.14	-0.37	1.73e-22	Parkinson's disease;
BRCA	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg18964960	chr10:1102726	WDR37	0.63	8.71	0.33	2.65e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.68	0.39	1.28e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7737355	1.000	rs27873	chr5:130731151	T/C	cg06307176	chr5:131281290	NA	-0.44	-9.33	-0.35	1.69e-19	Life satisfaction;
BRCA	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.86	-0.3	1.59e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg06671706	chr8:8559999	CLDN23	0.44	8.46	0.32	1.88e-16	Obesity-related traits;
BRCA	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg26031613	chr14:104095156	KLC1	-0.42	-8.39	-0.32	3.01e-16	Schizophrenia;
BRCA	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.75	0.62	3.7e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs1975991	0.686	rs6777135	chr3:187947668	G/A	cg15417654	chr3:187959138	LPP	0.36	9.2	0.34	4.86e-19	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg05294307	chr14:35346193	BAZ1A	0.59	10.59	0.39	2.86e-24	Psoriasis;
BRCA	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg13010199	chr12:38710504	ALG10B	-0.42	-9.71	-0.36	6.68e-21	Morning vs. evening chronotype;
BRCA	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg01420254	chr6:26195488	NA	0.52	8.29	0.31	6.57e-16	Gout;Renal underexcretion gout;
BRCA	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	11.13	0.4	1.99e-26	Height;
BRCA	cis	rs9290065	0.538	rs9840600	chr3:160769101	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-11.3	-0.41	4.08e-27	Kawasaki disease;
BRCA	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg13010199	chr12:38710504	ALG10B	0.43	9.1	0.34	1.09e-18	Morning vs. evening chronotype;
BRCA	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.42	-8.37	-0.31	3.65e-16	Monocyte percentage of white cells;
BRCA	trans	rs2262909	0.889	rs61268244	chr19:22310130	C/T	cg17074339	chr11:11642133	GALNTL4	0.45	8.89	0.33	6.28e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg08132940	chr7:1081526	C7orf50	-0.6	-8.99	-0.34	2.69e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7020830	1.000	rs7020830	chr9:37085184	A/T	cg14294708	chr9:37120828	ZCCHC7	1.09	33.86	0.8	1.04e-144	Schizophrenia;
BRCA	trans	rs783540	0.967	rs55972423	chr15:83258954	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.27	-8.36	-0.31	3.85e-16	Schizophrenia;
BRCA	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg01528321	chr10:82214614	TSPAN14	0.91	20.04	0.62	1.1e-69	Post bronchodilator FEV1;
BRCA	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg13010199	chr12:38710504	ALG10B	0.42	8.74	0.33	2.02e-17	Bladder cancer;
BRCA	cis	rs11112613	0.713	rs12321309	chr12:105943263	T/G	cg03607813	chr12:105948248	NA	0.6	10.01	0.37	5e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-11.94	-0.43	7.99e-30	Gut microbiome composition (summer);
BRCA	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.49	10.92	0.4	1.39e-25	Cognitive ability;
BRCA	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03188948	chr7:1209495	NA	0.63	12.91	0.45	4.99e-34	Longevity;Endometriosis;
BRCA	cis	rs1568889	0.938	rs11601602	chr11:28233768	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	13.29	0.47	8.77e-36	Bipolar disorder;
BRCA	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg22764044	chr5:178986830	RUFY1	0.51	14.1	0.49	1.75e-39	Lung cancer;
BRCA	cis	rs2290159	0.800	rs6766666	chr3:12690855	A/C	cg23032965	chr3:12705835	RAF1	-0.51	-9.05	-0.34	1.72e-18	Cholesterol, total;
BRCA	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg26816564	chr1:7831052	VAMP3	0.69	12.73	0.45	3.12e-33	Inflammatory bowel disease;
BRCA	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg00105475	chr2:10696890	NA	0.44	10.25	0.38	6.03e-23	Prostate cancer;
BRCA	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg19748678	chr4:122722346	EXOSC9	0.72	15.43	0.52	7.08e-46	Type 2 diabetes;
BRCA	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.57	9.81	0.36	3e-21	Gut microbiome composition (summer);
BRCA	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg13271783	chr10:134563150	INPP5A	-0.5	-9.36	-0.35	1.28e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg17294928	chr15:75287854	SCAMP5	-0.64	-13.96	-0.48	7.87e-39	Blood trace element (Zn levels);
BRCA	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.92	-0.33	5.05e-18	Alzheimer's disease (late onset);
BRCA	cis	rs10911363	0.615	rs9286848	chr1:183426249	C/G	cg09173681	chr1:183549694	NCF2	-0.53	-11.04	-0.4	4.78e-26	Systemic lupus erythematosus;
BRCA	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg15208524	chr1:10270712	KIF1B	0.38	7.86	0.3	1.68e-14	Hepatocellular carcinoma;
BRCA	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg01689657	chr7:91764605	CYP51A1	0.25	8.58	0.32	6.97e-17	Breast cancer;
BRCA	cis	rs4363385	0.747	rs4845330	chr1:152981505	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.1	-0.34	1.15e-18	Inflammatory skin disease;
BRCA	cis	rs12711979	0.509	rs10178286	chr2:3823821	A/G	cg17052675	chr2:3827356	NA	0.69	22.71	0.67	3.67e-84	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg04362960	chr10:104952993	NT5C2	0.46	10.7	0.39	1.08e-24	Arsenic metabolism;
BRCA	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.96	21.03	0.64	5.43e-75	Lymphocyte percentage of white cells;
BRCA	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg04691961	chr3:161091175	C3orf57	-0.62	-15.42	-0.52	7.54e-46	Morning vs. evening chronotype;
BRCA	cis	rs7523273	0.626	rs2466572	chr1:207934487	A/C	cg22525895	chr1:207977042	MIR29B2	0.4	8.44	0.32	2.19e-16	Schizophrenia;
BRCA	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg25036284	chr2:26402008	FAM59B	-0.63	-10.68	-0.39	1.29e-24	Gut microbiome composition (summer);
BRCA	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg07506560	chr2:240697449	NA	-0.38	-7.98	-0.3	6.78e-15	Obesity-related traits;
BRCA	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07343612	chr16:622815	PIGQ	-0.69	-23.48	-0.68	2.32e-88	Height;
BRCA	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg18252515	chr7:66147081	NA	-0.9	-12.9	-0.45	5.17e-34	Diabetic kidney disease;
BRCA	cis	rs524281	0.861	rs10791858	chr11:65978396	A/G	cg16950941	chr11:66035639	RAB1B	-0.38	-8.11	-0.31	2.58e-15	Electroencephalogram traits;
BRCA	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18876405	chr7:65276391	NA	-0.62	-15.43	-0.52	6.52e-46	Aortic root size;
BRCA	cis	rs2880765	0.835	rs730372	chr15:86038193	G/T	cg10818794	chr15:86012489	AKAP13	0.31	8.56	0.32	8.67e-17	Coronary artery disease;
BRCA	trans	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg00938859	chr5:1591904	SDHAP3	0.66	9.06	0.34	1.58e-18	Breast cancer;
BRCA	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg11366901	chr6:160182831	ACAT2	-0.72	-14.37	-0.49	9.34e-41	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6028335	0.674	rs12625983	chr20:37603936	C/T	cg16355469	chr20:37678765	NA	-0.48	-8.77	-0.33	1.55e-17	Alcohol and nicotine co-dependence;
BRCA	cis	rs78707713	0.531	rs12411720	chr10:71192471	T/G	cg12610070	chr10:71211762	TSPAN15	-0.32	-10.99	-0.4	7.26e-26	Venous thromboembolism;
BRCA	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg00277334	chr10:82204260	NA	-0.43	-8.48	-0.32	1.53e-16	Post bronchodilator FEV1;
BRCA	cis	rs2415984	0.622	rs1761029	chr14:46934764	T/C	cg14871534	chr14:47121158	RPL10L	0.32	7.94	0.3	9.45e-15	Number of children ever born;
BRCA	cis	rs4671400	0.516	rs62152277	chr2:61503404	C/T	cg15711740	chr2:61764176	XPO1	0.44	8.8	0.33	1.28e-17	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg23649088	chr2:200775458	C2orf69	0.55	7.98	0.3	6.93e-15	Schizophrenia;
BRCA	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.41	8.43	0.32	2.35e-16	Alzheimer's disease (late onset);
BRCA	cis	rs939658	0.728	rs12904323	chr15:79412583	A/C	cg17916960	chr15:79447300	NA	-0.42	-9.81	-0.36	2.9e-21	Refractive error;
BRCA	cis	rs12541635	0.966	rs7819043	chr8:106989783	T/C	cg10147462	chr8:107024639	NA	0.37	9.94	0.37	9.35e-22	Age of smoking initiation;
BRCA	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg04553112	chr3:125709451	NA	-0.56	-8.53	-0.32	1.02e-16	Blood pressure (smoking interaction);
BRCA	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg12311346	chr5:56204834	C5orf35	-0.49	-10.11	-0.37	2.12e-22	Coronary artery disease;
BRCA	cis	rs6064559	0.685	rs1042523	chr20:56137807	A/G	cg16101800	chr20:56136569	PCK1	-0.48	-12.56	-0.44	1.71e-32	Hemoglobin concentration;
BRCA	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12379764	chr21:47803548	PCNT	0.37	7.94	0.3	9.18e-15	Testicular germ cell tumor;
BRCA	cis	rs2191566	0.576	rs405763	chr19:44493547	A/G	cg20607764	chr19:44506953	ZNF230	0.36	7.87	0.3	1.5e-14	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs2637266	1.000	rs2130795	chr10:78333892	C/G	cg18941641	chr10:78392320	NA	0.34	7.83	0.3	2.04e-14	Pulmonary function;
BRCA	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.43	12.35	0.44	1.37e-31	Response to antipsychotic treatment;
BRCA	cis	rs708547	0.914	rs2412760	chr4:57735192	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-11.03	-0.4	4.92e-26	Response to bleomycin (chromatid breaks);
BRCA	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg19336497	chr11:14380999	RRAS2	-0.48	-11.95	-0.43	7.75e-30	Sense of smell;
BRCA	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.94e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.81	-0.33	1.2e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24549020	chr5:56110836	MAP3K1	0.42	8.95	0.33	3.92e-18	Initial pursuit acceleration;
BRCA	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg20203395	chr5:56204925	C5orf35	-0.51	-10.4	-0.38	1.64e-23	Initial pursuit acceleration;
BRCA	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg18806716	chr10:30721971	MAP3K8	-0.46	-10.81	-0.39	4.01e-25	Inflammatory bowel disease;
BRCA	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg24812749	chr6:127587940	RNF146	0.87	19.8	0.62	2.14e-68	Breast cancer;
BRCA	cis	rs1018836	0.923	rs13262354	chr8:91635731	G/A	cg16814680	chr8:91681699	NA	-0.58	-12.37	-0.44	1.21e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg25358565	chr5:93447407	FAM172A	1.21	17.99	0.58	7.17e-59	Diabetic retinopathy;
BRCA	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.94e-24	Motion sickness;
BRCA	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg15704280	chr7:45808275	SEPT13	0.75	15.99	0.53	1.23e-48	Coronary artery disease;
BRCA	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg03453431	chr7:157225567	NA	-0.48	-9.78	-0.36	3.87e-21	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg12463550	chr7:65579703	CRCP	-0.38	-8.29	-0.31	6.75e-16	Aortic root size;
BRCA	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-9.06	-0.34	1.55e-18	Alzheimer's disease (late onset);
BRCA	cis	rs13046373	0.535	rs1961167	chr21:32030310	T/C	cg16812893	chr21:31813075	KRTAP15-1	0.38	9.28	0.34	2.53e-19	HDL cholesterol;
BRCA	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg00631329	chr6:26305371	NA	-0.55	-15.66	-0.53	5.07e-47	Educational attainment;
BRCA	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg08807101	chr21:30365312	RNF160	-0.42	-8.91	-0.33	5.43e-18	Pancreatic cancer;
BRCA	cis	rs11971779	0.648	rs59791374	chr7:139116962	C/T	cg07862535	chr7:139043722	LUC7L2	0.4	10.61	0.39	2.5300000000000002e-24	Diisocyanate-induced asthma;
BRCA	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg21918786	chr6:109611834	NA	-0.44	-11.87	-0.42	1.69e-29	Reticulocyte fraction of red cells;
BRCA	cis	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg21775007	chr8:11205619	TDH	0.38	8.12	0.31	2.44e-15	Neuroticism;
BRCA	cis	rs10504073	0.647	rs4873317	chr8:50021111	C/T	cg00325661	chr8:49890786	NA	0.44	12.52	0.44	2.54e-32	Blood metabolite ratios;
BRCA	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg12620499	chr2:216877984	MREG	0.82	24.97	0.7	1.52e-96	Alcohol dependence;
BRCA	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06558623	chr16:89946397	TCF25	0.65	11.86	0.42	1.81e-29	Skin colour saturation;
BRCA	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg12310025	chr6:25882481	NA	0.72	17.85	0.58	4.14e-58	Blood metabolite levels;
BRCA	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02176678	chr2:219576539	TTLL4	-0.5	-12.74	-0.45	2.64e-33	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg08738300	chr3:44038990	NA	0.44	8.54	0.32	9.8e-17	Coronary artery disease;
BRCA	cis	rs68170813	0.641	rs79328953	chr7:106901557	C/T	cg02696742	chr7:106810147	HBP1	-0.5	-8.86	-0.33	7.78e-18	Coronary artery disease;
BRCA	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg08000102	chr2:233561755	GIGYF2	0.64	13.93	0.48	1.03e-38	Coronary artery disease;
BRCA	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg03060546	chr3:49711283	APEH	-0.61	-12.3	-0.44	2.28e-31	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.78	-0.36	3.92e-21	IgG glycosylation;
BRCA	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg20387954	chr3:183756860	HTR3D	0.45	10.19	0.37	1.05e-22	Anterior chamber depth;
BRCA	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg02931644	chr1:25747376	RHCE	0.43	11.66	0.42	1.23e-28	Erythrocyte sedimentation rate;
BRCA	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg08213375	chr14:104286397	PPP1R13B	0.64	18.2	0.58	5.6899999999999994e-60	Schizophrenia;
BRCA	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg13119609	chr19:45449297	APOC2	0.46	12.71	0.45	3.79e-33	Blood protein levels;
BRCA	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.5	-11.33	-0.41	3.11e-27	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	trans	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-10.75	-0.39	6.63e-25	Morning vs. evening chronotype;
BRCA	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg09021430	chr5:549028	NA	-0.65	-16.14	-0.54	2e-49	Obesity-related traits;
BRCA	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg11789530	chr4:8429930	ACOX3	0.59	14.62	0.5	5.43e-42	Response to antineoplastic agents;
BRCA	cis	rs62158211	0.955	rs7556815	chr2:114085785	G/A	cg17784749	chr2:114082611	LOC440839	0.56	9.54	0.35	2.88e-20	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
BRCA	cis	rs4730250	0.669	rs6466160	chr7:106793175	T/A	cg02696742	chr7:106810147	HBP1	0.57	9.43	0.35	7.51e-20	Osteoarthritis;
BRCA	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.62	0.39	2.17e-24	Bladder cancer;
BRCA	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg12373951	chr3:133503437	NA	0.44	10.22	0.37	8.02e-23	Iron status biomarkers;
BRCA	trans	rs8073060	0.586	rs225298	chr17:33923946	T/G	cg19694781	chr19:47549865	TMEM160	-1.04	-22.12	-0.66	5.97e-81	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg21479132	chr6:26055353	NA	0.57	7.97	0.3	7.48e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg17063962	chr7:91808500	NA	0.52	12.38	0.44	1.01e-31	Breast cancer;
BRCA	cis	rs2274471	0.645	rs3780375	chr9:5109431	G/A	cg03390472	chr9:5043263	JAK2	-0.46	-8.67	-0.32	3.54e-17	Crohn's disease;
BRCA	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg07169764	chr2:136633963	MCM6	1.01	22.6	0.67	1.49e-83	Corneal structure;
BRCA	trans	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg07211511	chr3:129823064	LOC729375	-0.62	-11.18	-0.4	1.21e-26	Blood pressure (smoking interaction);
BRCA	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.55	10.31	0.38	3.74e-23	Alzheimer's disease;
BRCA	cis	rs7149337	0.773	rs3007067	chr14:51596420	G/A	cg23942311	chr14:51606299	NA	0.45	12.86	0.45	8.31e-34	Cancer;
BRCA	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.42	-8.38	-0.31	3.41e-16	Monocyte percentage of white cells;
BRCA	cis	rs1595825	0.891	rs59617443	chr2:198653204	C/A	cg19156104	chr2:198669113	PLCL1	-0.42	-7.97	-0.3	7.13e-15	Ulcerative colitis;
BRCA	cis	rs2425143	1.000	rs113203744	chr20:34253656	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.8	-0.33	1.31e-17	Blood protein levels;
BRCA	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg24812749	chr6:127587940	RNF146	0.9	20.92	0.64	2.01e-74	Breast cancer;
BRCA	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg09754948	chr16:28834200	ATXN2L	0.46	9.16	0.34	7.18e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs2797160	1.000	rs2747725	chr6:126012397	A/C	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.03	0.3	4.65e-15	Endometrial cancer;
BRCA	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.49	12.39	0.44	9.06e-32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs812925	0.537	rs778146	chr2:61606475	A/G	cg15711740	chr2:61764176	XPO1	0.32	7.9	0.3	1.22e-14	Immature fraction of reticulocytes;
BRCA	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg21361702	chr7:150065534	REPIN1	0.49	10.07	0.37	3.03e-22	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg08738300	chr3:44038990	NA	0.45	8.65	0.32	4.03e-17	Coronary artery disease;
BRCA	cis	rs11030122	0.632	rs11030599	chr11:4031677	A/G	cg18678763	chr11:4115507	RRM1	-0.35	-8.24	-0.31	9.61e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs1997103	1.000	rs4590393	chr7:55408990	C/T	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7818345	0.967	rs4921638	chr8:19274793	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.3	7.84	0.3	1.91e-14	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg25319279	chr11:5960081	NA	-0.43	-8.4	-0.32	3e-16	DNA methylation (variation);
BRCA	cis	rs7572733	0.534	rs700683	chr2:198712332	G/A	cg00792783	chr2:198669748	PLCL1	0.47	10.11	0.37	2.17e-22	Dermatomyositis;
BRCA	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26384229	chr12:38710491	ALG10B	-0.74	-16.47	-0.55	4.44e-51	Morning vs. evening chronotype;
BRCA	cis	rs6060717	0.536	rs6060664	chr20:34478884	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.08	-0.3	3.21e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg00666640	chr1:248458726	OR2T12	0.33	8.99	0.34	2.75e-18	Common traits (Other);
BRCA	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	20.07	0.62	7.34e-70	Platelet count;
BRCA	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.56	-0.52	1.63e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg26608667	chr7:1196370	ZFAND2A	0.37	8.3	0.31	6.3e-16	Longevity;Endometriosis;
BRCA	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg08999081	chr20:33150536	PIGU	0.47	13.11	0.46	6.3e-35	Glomerular filtration rate (creatinine);
BRCA	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg22834771	chr12:69754056	YEATS4	-0.43	-10.63	-0.39	2.04e-24	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg03929089	chr4:120376271	NA	-0.68	-13.31	-0.47	7.52e-36	Coronary artery disease;
BRCA	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg02880119	chr16:3481970	NA	0.44	7.97	0.3	7.41e-15	Body mass index (adult);
BRCA	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg16049864	chr8:95962084	TP53INP1	-0.4	-9.57	-0.35	2.32e-20	Type 2 diabetes;
BRCA	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00166722	chr3:10149974	C3orf24	0.56	10.0	0.37	5.5e-22	Alzheimer's disease;
BRCA	trans	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.88	0.3	1.4e-14	Endometrial cancer;
BRCA	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg05340658	chr4:99064831	C4orf37	0.68	16.96	0.56	1.53e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-15.27	-0.52	4.23e-45	Obesity-related traits;
BRCA	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.24	-0.34	3.54e-19	Menopause (age at onset);
BRCA	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg07395648	chr5:131743802	NA	-0.39	-9.66	-0.36	1.04e-20	Blood metabolite levels;
BRCA	cis	rs13095912	0.743	rs13076556	chr3:185339575	A/G	cg11274856	chr3:185301563	NA	0.54	12.88	0.45	6.28e-34	Systolic blood pressure;
BRCA	cis	rs4363385	0.720	rs1415967	chr1:152965585	C/T	cg21543102	chr1:152974771	SPRR3	-0.3	-8.62	-0.32	5.38e-17	Inflammatory skin disease;
BRCA	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs3845702	1.000	rs10497555	chr2:180864967	A/G	cg01881094	chr2:180872142	CWC22	0.63	12.47	0.44	4.15e-32	Schizophrenia;
BRCA	cis	rs4730250	0.554	rs112665932	chr7:106916121	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-8.05	-0.3	4.17e-15	Osteoarthritis;
BRCA	cis	rs7020830	0.894	rs12337316	chr9:37148105	G/A	cg14294708	chr9:37120828	ZCCHC7	1.05	31.27	0.78	6.68e-131	Schizophrenia;
BRCA	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.22	-0.31	1.13e-15	Depression;
BRCA	cis	rs13046373	0.507	rs2832969	chr21:32019627	A/G	cg16431978	chr21:31797932	KRTAP13-3	0.36	9.13	0.34	8.98e-19	HDL cholesterol;
BRCA	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	13.73	0.48	9.11e-38	Lymphocyte counts;
BRCA	cis	rs4730250	0.707	rs257386	chr7:106807783	C/G	cg02696742	chr7:106810147	HBP1	-0.61	-9.6	-0.36	1.75e-20	Osteoarthritis;
BRCA	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg03929089	chr4:120376271	NA	-0.49	-9.11	-0.34	1.04e-18	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg14926445	chr8:58193284	C8orf71	-0.44	-8.41	-0.32	2.59e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg23711669	chr6:146136114	FBXO30	0.64	14.63	0.5	4.89e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-12.84	-0.45	1.02e-33	Mood instability;
BRCA	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg13010199	chr12:38710504	ALG10B	0.39	8.94	0.33	4.09e-18	Morning vs. evening chronotype;
BRCA	cis	rs77972916	0.611	rs10495899	chr2:43602304	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-10.84	-0.39	2.9e-25	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg08493051	chr2:3487164	NA	-0.43	-9.22	-0.34	4.1e-19	Neurofibrillary tangles;
BRCA	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.63	-16.96	-0.56	1.57e-53	Colorectal cancer;
BRCA	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs4974559	0.690	rs28641665	chr4:1288781	G/T	cg02980000	chr4:1222292	CTBP1	0.81	13.37	0.47	3.94e-36	Systolic blood pressure;
BRCA	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg18512352	chr11:47633146	NA	-0.34	-8.32	-0.31	5.4e-16	Subjective well-being;
BRCA	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.12	-0.34	9.78e-19	Total body bone mineral density;
BRCA	trans	rs9784649	0.891	rs57762467	chr5:25025700	C/T	cg08600765	chr20:34638493	LOC647979	-0.53	-7.91	-0.3	1.1e-14	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7617773	0.780	rs34749846	chr3:48347168	T/G	cg11946769	chr3:48343235	NME6	0.68	13.86	0.48	2.24e-38	Coronary artery disease;
BRCA	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.75	0.62	3.7e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg06917634	chr15:78832804	PSMA4	0.66	13.76	0.48	6.64e-38	Sudden cardiac arrest;
BRCA	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg20283391	chr11:68216788	NA	-0.44	-8.96	-0.33	3.47e-18	Total body bone mineral density;
BRCA	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.41	-0.41	1.4e-27	Gut microbiome composition (summer);
BRCA	trans	rs1493916	0.777	rs1845385	chr18:31318336	T/C	cg27147174	chr7:100797783	AP1S1	-0.41	-8.04	-0.3	4.47e-15	Life satisfaction;
BRCA	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.43	0.35	7.76e-20	Tonsillectomy;
BRCA	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg06212747	chr3:49208901	KLHDC8B	0.49	10.29	0.38	4.3e-23	Parkinson's disease;
BRCA	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.94	0.3	8.9e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg05084668	chr3:125655381	ALG1L	-0.47	-8.13	-0.31	2.3e-15	Blood pressure (smoking interaction);
BRCA	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg02187348	chr16:89574699	SPG7	0.38	9.05	0.34	1.73e-18	Multiple myeloma (IgH translocation);
BRCA	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.03	-0.3	4.72e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg17845761	chr1:175162550	KIAA0040	0.26	10.08	0.37	2.92e-22	Alcohol dependence;
BRCA	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-11.74	-0.42	5.76e-29	Hemoglobin concentration;
BRCA	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg26384229	chr12:38710491	ALG10B	-0.43	-10.06	-0.37	3.32e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.61	13.04	0.46	1.24e-34	Lymphocyte counts;
BRCA	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg00383909	chr3:49044727	WDR6	0.98	15.74	0.53	2.1e-47	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg11764359	chr7:65958608	NA	0.66	11.84	0.42	2.3e-29	Aortic root size;
BRCA	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg11812906	chr14:75593930	NEK9	-0.6	-13.7	-0.48	1.18e-37	Height;
BRCA	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg12219531	chr12:120966889	COQ5	0.54	11.39	0.41	1.72e-27	High light scatter reticulocyte count;
BRCA	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg02176678	chr2:219576539	TTLL4	-0.47	-12.65	-0.45	7.19e-33	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs17253792	0.822	rs76164147	chr14:56140369	T/C	cg01858014	chr14:56050164	KTN1	-0.75	-9.37	-0.35	1.25e-19	Putamen volume;
BRCA	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg21918786	chr6:109611834	NA	0.46	13.29	0.47	9.25e-36	Reticulocyte fraction of red cells;
BRCA	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg18512352	chr11:47633146	NA	-0.34	-8.11	-0.31	2.52e-15	Subjective well-being;
BRCA	trans	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg21775007	chr8:11205619	TDH	0.41	8.58	0.32	7.06e-17	Mood instability;
BRCA	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg07636037	chr3:49044803	WDR6	0.5	8.25	0.31	9.35e-16	Menarche (age at onset);
BRCA	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg08917208	chr2:24149416	ATAD2B	0.94	14.13	0.49	1.25e-39	Lymphocyte counts;
BRCA	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg17470723	chr8:74884337	TCEB1	-0.37	-8.17	-0.31	1.65e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg21747090	chr2:27597821	SNX17	-0.44	-9.33	-0.35	1.73e-19	Total body bone mineral density;
BRCA	trans	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg15704280	chr7:45808275	SEPT13	0.54	8.19	0.31	1.43e-15	Intraocular pressure;
BRCA	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg09184832	chr6:79620586	NA	-0.47	-10.37	-0.38	2.19e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg25358565	chr5:93447407	FAM172A	1.22	18.61	0.59	4.26e-62	Diabetic retinopathy;
BRCA	trans	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg26043149	chr18:55253948	FECH	-0.41	-9.0	-0.34	2.53e-18	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg26384229	chr12:38710491	ALG10B	-0.84	-22.69	-0.67	4.86e-84	Heart rate;
BRCA	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg09877947	chr5:131593287	PDLIM4	0.36	7.84	0.3	1.94e-14	Blood metabolite levels;
BRCA	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-8.21	-0.31	1.2e-15	Tonsillectomy;
BRCA	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.38	0.59	6.86e-61	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7903847	0.596	rs10882934	chr10:99170995	T/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.62	-0.32	5.25e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg26818010	chr10:134567672	INPP5A	-0.78	-15.37	-0.52	1.39e-45	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg13256891	chr4:100009986	ADH5	0.39	9.0	0.34	2.66e-18	Alcohol dependence;
BRCA	cis	rs17253792	0.822	rs13379340	chr14:56050346	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.61	8.47	0.32	1.68e-16	Putamen volume;
BRCA	cis	rs1371614	0.569	rs486582	chr2:27104131	C/T	cg12368169	chr2:27073192	DPYSL5	0.31	9.58	0.35	2.14e-20	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg00530320	chr1:46809349	NSUN4	0.45	8.97	0.33	3.37e-18	Menopause (age at onset);
BRCA	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg08061076	chr7:1943177	MAD1L1	-0.35	-7.86	-0.3	1.63e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs10046574	0.831	rs113826521	chr7:135167999	T/C	cg27474649	chr7:135195673	CNOT4	0.61	8.87	0.33	7.2e-18	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.51	-0.35	3.86e-20	Total body bone mineral density;
BRCA	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg04166393	chr7:2884313	GNA12	0.43	9.33	0.35	1.72e-19	Height;
BRCA	cis	rs977987	0.806	rs1895490	chr16:75392806	G/A	cg03315344	chr16:75512273	CHST6	0.52	12.42	0.44	7.37e-32	Dupuytren's disease;
BRCA	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	trans	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg07211511	chr3:129823064	LOC729375	-0.63	-11.03	-0.4	4.99e-26	Blood pressure (smoking interaction);
BRCA	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.93	16.85	0.55	5.43e-53	Body mass index;
BRCA	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg01028140	chr2:1542097	TPO	-0.72	-14.13	-0.49	1.2e-39	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg04944784	chr2:26401820	FAM59B	1.01	16.65	0.55	5.91e-52	Gut microbiome composition (summer);
BRCA	trans	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-21.35	-0.65	9.92e-77	Exhaled nitric oxide output;
BRCA	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.85e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg03709012	chr19:19516395	GATAD2A	1.08	21.04	0.64	4.43e-75	Nonalcoholic fatty liver disease;
BRCA	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg01689657	chr7:91764605	CYP51A1	0.21	7.82	0.3	2.14e-14	Breast cancer;
BRCA	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg05340658	chr4:99064831	C4orf37	0.51	9.66	0.36	1.03e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-13.77	-0.48	5.7800000000000005e-38	Migraine;Coronary artery disease;
BRCA	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs757081	0.671	rs214070	chr11:17305317	T/A	cg15432903	chr11:17409602	KCNJ11	-0.49	-8.59	-0.32	6.68e-17	Systolic blood pressure;
BRCA	cis	rs7402982	0.934	rs6598539	chr15:99204483	T/C	cg03437748	chr15:99193247	IGF1R	0.71	17.33	0.57	1.91e-55	Birth weight;
BRCA	cis	rs9487051	0.646	rs13203365	chr6:109614810	G/T	cg01475377	chr6:109611718	NA	-0.38	-8.16	-0.31	1.77e-15	Reticulocyte fraction of red cells;
BRCA	cis	rs4363385	0.747	rs1015995	chr1:152976114	G/C	cg25856811	chr1:152973957	SPRR3	-0.35	-9.29	-0.34	2.4e-19	Inflammatory skin disease;
BRCA	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg07741184	chr6:167504864	NA	-0.27	-7.84	-0.3	1.92e-14	Primary biliary cholangitis;
BRCA	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg15704280	chr7:45808275	SEPT13	0.68	13.92	0.48	1.19e-38	Coronary artery disease;
BRCA	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg12698349	chr2:225449008	CUL3	0.61	13.1	0.46	6.76e-35	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg09307838	chr4:120376055	NA	0.7	14.06	0.49	2.51e-39	Corneal astigmatism;
BRCA	cis	rs9287719	0.649	rs6721857	chr2:10721210	C/T	cg00105475	chr2:10696890	NA	-0.4	-8.89	-0.33	6.1e-18	Prostate cancer;
BRCA	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.01	0.58	5.98e-59	Fuchs's corneal dystrophy;
BRCA	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08045932	chr20:61659980	NA	0.5	11.43	0.41	1.2100000000000001e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs870825	0.655	rs10033035	chr4:185630880	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	17.14	0.56	1.9e-54	Blood protein levels;
BRCA	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg14349672	chr11:133703707	NA	-0.43	-9.53	-0.35	3.29e-20	Childhood ear infection;
BRCA	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg02475777	chr4:1388615	CRIPAK	0.38	8.81	0.33	1.14e-17	Longevity;
BRCA	cis	rs2070997	0.667	rs72765063	chr9:133717391	G/A	cg11464064	chr9:133710261	ABL1	0.55	9.92	0.37	1.14e-21	Response to amphetamines;
BRCA	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg09184832	chr6:79620586	NA	-0.43	-8.6	-0.32	6.25e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg08917208	chr2:24149416	ATAD2B	1.07	14.55	0.5	1.27e-41	Lymphocyte counts;
BRCA	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.46	-9.16	-0.34	7.1e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg11879182	chr18:77439856	CTDP1	0.64	13.74	0.48	7.85e-38	Monocyte count;
BRCA	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.86	-0.33	7.92e-18	Breast cancer;
BRCA	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg25457927	chr22:38595422	NA	-0.33	-12.52	-0.44	2.53e-32	Cutaneous nevi;
BRCA	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg17330251	chr7:94953956	PON1	-0.39	-7.88	-0.3	1.37e-14	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9381107	0.932	rs9394703	chr6:9455062	C/T	cg14735645	chr6:9486422	NA	0.45	7.95	0.3	8.22e-15	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs6570726	0.526	rs4896805	chr6:145735429	C/A	cg23711669	chr6:146136114	FBXO30	-0.45	-9.69	-0.36	8.5e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6714710	0.603	rs2278700	chr2:98427382	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	13.62	0.47	2.86e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs10193935	1.000	rs13419669	chr2:42387254	T/C	cg27598129	chr2:42591480	NA	-0.87	-14.49	-0.5	2.46e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6546550	0.935	rs10865380	chr2:70091246	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-9.39	-0.35	1.04e-19	Prevalent atrial fibrillation;
BRCA	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg00106254	chr7:1943704	MAD1L1	-0.33	-8.31	-0.31	5.88e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-13.45	-0.47	1.75e-36	Morning vs. evening chronotype;
BRCA	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg08601574	chr20:25228251	PYGB	-0.34	-8.25	-0.31	9.18e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4302748	0.862	rs61003864	chr7:36189798	T/C	cg24442661	chr7:36192818	EEPD1	0.48	9.09	0.34	1.24e-18	Platelet count;
BRCA	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	13.44	0.47	1.85e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg11941060	chr3:133502564	NA	-0.5	-12.04	-0.43	3.04e-30	Iron status biomarkers;
BRCA	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg04166393	chr7:2884313	GNA12	0.41	8.68	0.32	3.35e-17	Height;
BRCA	trans	rs7939886	0.920	rs12417606	chr11:55750479	C/T	cg15704280	chr7:45808275	SEPT13	0.62	7.94	0.3	9.08e-15	Myopia (pathological);
BRCA	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg15704280	chr7:45808275	SEPT13	-0.93	-26.3	-0.72	7.17e-104	Height;
BRCA	cis	rs9837602	0.938	rs28503408	chr3:99794842	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	10.46	0.38	9.25e-24	Breast cancer;
BRCA	cis	rs6750047	0.546	rs1367696	chr2:38286914	C/T	cg07380506	chr2:38303506	CYP1B1	0.47	11.24	0.41	7.39e-27	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg05340658	chr4:99064831	C4orf37	0.68	16.78	0.55	1.25e-52	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg25517755	chr10:38738941	LOC399744	-0.39	-8.1	-0.31	2.74e-15	Corneal astigmatism;
BRCA	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg06238570	chr21:40685208	BRWD1	-0.43	-8.41	-0.32	2.67e-16	Cognitive function;
BRCA	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27286337	chr10:134555280	INPP5A	-0.75	-12.4	-0.44	8.43e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	12.02	0.43	3.79e-30	Multiple sclerosis;
BRCA	cis	rs1043763	0.826	rs3741452	chr12:122628429	A/T	cg14400030	chr12:122498111	BCL7A	-0.66	-13.64	-0.47	2.24e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
BRCA	cis	rs4566357	0.615	rs10174591	chr2:227913140	G/A	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.08	-0.3	3.32e-15	Coronary artery disease;
BRCA	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-9.43	-0.35	7.18e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6546550	0.933	rs1454498	chr2:70149225	C/A	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.47	-0.41	7.89e-28	Prevalent atrial fibrillation;
BRCA	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-12.6	-0.45	1.15e-32	Response to antipsychotic treatment;
BRCA	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg15145296	chr3:125709740	NA	-0.55	-8.81	-0.33	1.13e-17	Blood pressure (smoking interaction);
BRCA	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg23791538	chr6:167370224	RNASET2	-0.37	-9.14	-0.34	8.39e-19	Crohn's disease;
BRCA	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.51	10.46	0.38	1e-23	Hemoglobin concentration;
BRCA	trans	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs867371	1.000	rs1174543	chr15:82448073	C/T	cg00614314	chr15:82944287	LOC80154	-0.43	-9.14	-0.34	8.44e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg24642439	chr20:33292090	TP53INP2	-0.52	-11.23	-0.41	7.97e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg03354898	chr7:1950403	MAD1L1	0.44	8.95	0.33	3.74e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27286337	chr10:134555280	INPP5A	0.8	13.19	0.46	2.56e-35	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg23762105	chr12:34175262	ALG10	0.37	8.57	0.32	7.7e-17	Morning vs. evening chronotype;
BRCA	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg03929089	chr4:120376271	NA	0.65	12.61	0.45	1.01e-32	Coronary artery disease;
BRCA	cis	rs10504073	0.584	rs56074306	chr8:49940282	C/T	cg00325661	chr8:49890786	NA	0.49	14.21	0.49	5.09e-40	Blood metabolite ratios;
BRCA	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.62	10.19	0.37	1.03e-22	Renal function-related traits (BUN);
BRCA	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg24692254	chr21:30365293	RNF160	0.44	9.94	0.37	9.45e-22	Pancreatic cancer;
BRCA	cis	rs4908760	0.965	rs301814	chr1:8510577	T/C	cg20416874	chr1:8611966	RERE	-0.28	-8.0	-0.3	5.87e-15	Vitiligo;
BRCA	cis	rs427394	0.582	rs274662	chr5:6704860	G/A	cg10857441	chr5:6722123	POLS	-0.3	-9.42	-0.35	8.22e-20	Menopause (age at onset);
BRCA	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg24812749	chr6:127587940	RNF146	0.67	15.05	0.51	4.9e-44	Breast cancer;
BRCA	cis	rs11945232	1.000	rs6854710	chr4:88334640	A/G	cg23841344	chr4:88312519	HSD17B11	-0.48	-9.53	-0.35	3.18e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12826209	chr6:26865740	GUSBL1	0.58	10.3	0.38	3.9699999999999997e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg12011299	chr4:100065546	ADH4	0.46	10.39	0.38	1.85e-23	Alcohol dependence;
BRCA	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg17470723	chr8:74884337	TCEB1	0.39	8.51	0.32	1.25e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg11663144	chr21:46675770	NA	-0.59	-14.05	-0.49	2.86e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4363385	0.747	rs4845333	chr1:152982877	G/T	cg25856811	chr1:152973957	SPRR3	-0.34	-9.1	-0.34	1.15e-18	Inflammatory skin disease;
BRCA	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg08885076	chr2:99613938	TSGA10	-0.56	-12.54	-0.44	2.01e-32	Chronic sinus infection;
BRCA	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.45	-10.54	-0.38	4.83e-24	Urate levels in overweight individuals;
BRCA	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg07395648	chr5:131743802	NA	-0.37	-7.95	-0.3	8.72e-15	Breast cancer;
BRCA	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg03425785	chr20:62221387	GMEB2	0.51	8.23	0.31	1.07e-15	Glioblastoma;
BRCA	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.61	-13.87	-0.48	1.89e-38	Ulcerative colitis;
BRCA	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.79e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg27446573	chr6:127587934	RNF146	0.85	19.78	0.62	2.75e-68	Breast cancer;
BRCA	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg25036284	chr2:26402008	FAM59B	-0.64	-10.63	-0.39	2.11e-24	Gut microbiome composition (summer);
BRCA	trans	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-14.73	-0.5	1.7e-42	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10411936	0.682	rs6512113	chr19:16598269	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.47	9.71	0.36	7.15e-21	White blood cell count;Multiple sclerosis;
BRCA	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10046574	0.831	rs78220593	chr7:135166787	T/C	cg27474649	chr7:135195673	CNOT4	0.61	8.89	0.33	6.04e-18	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-9.72	-0.36	6.27e-21	Schizophrenia;
BRCA	trans	rs12310956	0.510	rs1386936	chr12:33875369	G/A	cg26384229	chr12:38710491	ALG10B	0.39	9.22	0.34	4.24e-19	Morning vs. evening chronotype;
BRCA	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.56	9.1	0.34	1.17e-18	Alzheimer's disease;
BRCA	cis	rs72627509	0.857	rs781658	chr4:57779567	G/A	cg26694713	chr4:57773883	REST	0.5	10.03	0.37	4.39e-22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.49	-12.86	-0.45	7.69e-34	Schizophrenia;
BRCA	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg23358479	chr7:1110784	C7orf50	-0.49	-8.2	-0.31	1.27e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.94	13.95	0.48	8.85e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs397969	0.646	rs6813	chr17:19808445	C/T	cg13482628	chr17:19912719	NA	-0.36	-7.84	-0.3	1.93e-14	Platelet count;
BRCA	cis	rs10754283	0.967	rs2390763	chr1:90105688	A/G	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.2e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg18854424	chr1:2615690	NA	0.32	8.05	0.3	4.04e-15	Ulcerative colitis;
BRCA	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-21.65	-0.65	2.32e-78	Gut microbiome composition (summer);
BRCA	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg25738037	chr1:168025549	DCAF6	0.28	8.08	0.3	3.29e-15	Schizophrenia;
BRCA	cis	rs7248779	1.000	rs7248779	chr19:2403564	G/T	cg22729335	chr19:2427816	TIMM13	-0.58	-12.16	-0.43	9.91e-31	Cortisol levels (saliva);
BRCA	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg04450456	chr4:17643702	FAM184B	-0.31	-9.18	-0.34	5.69e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg13047869	chr3:10149882	C3orf24	-0.6	-12.72	-0.45	3.33e-33	Alzheimer's disease;
BRCA	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.36	-8.31	-0.31	5.73e-16	Fear of minor pain;
BRCA	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.18	0.68	1e-86	Chronic sinus infection;
BRCA	trans	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.85	0.3	1.76e-14	Corneal astigmatism;
BRCA	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg17507749	chr15:85114479	UBE2QP1	0.56	10.59	0.39	3.04e-24	Schizophrenia;
BRCA	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg20891283	chr12:69753455	YEATS4	0.48	12.6	0.45	1.09e-32	Blood protein levels;
BRCA	trans	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.37	-9.03	-0.34	1.96e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg22800045	chr5:56110881	MAP3K1	0.56	10.53	0.38	5.3e-24	Initial pursuit acceleration;
BRCA	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	15.61	0.53	9.41e-47	Colorectal cancer;
BRCA	cis	rs2013441	1.000	rs17686798	chr17:20029170	A/C	cg13482628	chr17:19912719	NA	-0.37	-8.16	-0.31	1.72e-15	Obesity-related traits;
BRCA	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg18252515	chr7:66147081	NA	-0.88	-12.19	-0.43	6.77e-31	Diabetic kidney disease;
BRCA	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg05283184	chr6:79620031	NA	-0.41	-10.51	-0.38	6.1e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg15640734	chr5:494837	SLC9A3	-0.42	-8.2	-0.31	1.33e-15	Cystic fibrosis severity;
BRCA	cis	rs7633857	0.537	rs1580253	chr3:160767150	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-10.69	-0.39	1.16e-24	Educational attainment (years of education);
BRCA	cis	rs7011049	1.000	rs72643586	chr8:53847859	A/T	cg26025543	chr8:53854495	NA	0.55	9.57	0.35	2.31e-20	Systolic blood pressure;
BRCA	cis	rs6882046	0.513	rs647983	chr5:88048071	T/C	cg22951263	chr5:87985283	NA	-0.38	-10.74	-0.39	7.32e-25	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23583168	chr7:148888333	NA	-0.83	-18.82	-0.6	3.25e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	17.55	0.57	1.49e-56	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg07741184	chr6:167504864	NA	0.32	9.77	0.36	4.04e-21	Crohn's disease;
BRCA	cis	rs2455799	0.573	rs2255248	chr3:15754849	A/G	cg16303742	chr3:15540471	COLQ	0.34	8.15	0.31	1.9e-15	Mean platelet volume;
BRCA	cis	rs2882667	0.690	rs288007	chr5:138230628	C/T	cg04439458	chr5:138467593	SIL1	-0.34	-8.43	-0.32	2.3e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg12311346	chr5:56204834	C5orf35	-0.81	-16.08	-0.54	4.04e-49	Initial pursuit acceleration;
BRCA	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.39	0.49	6.83e-41	Motion sickness;
BRCA	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg06623918	chr6:96969491	KIAA0776	-0.92	-27.27	-0.73	3.36e-109	Headache;
BRCA	cis	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg23422044	chr7:1970798	MAD1L1	-0.49	-10.09	-0.37	2.49e-22	Bipolar disorder;
BRCA	cis	rs10789491	1.000	rs1258061	chr1:47105000	G/A	cg15501359	chr1:47185051	KIAA0494	-0.65	-17.84	-0.58	4.36e-58	Response to hepatitis C treatment;
BRCA	cis	rs9361491	0.510	rs1507151	chr6:79483246	T/C	cg05283184	chr6:79620031	NA	-0.35	-8.0	-0.3	5.95e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-10.01	-0.37	5.17e-22	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10193935	1.000	rs12612527	chr2:42392099	T/C	cg27598129	chr2:42591480	NA	-0.98	-14.69	-0.5	2.66e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10416265	0.516	rs1270252	chr19:33623604	G/A	cg17764715	chr19:33622953	WDR88	-0.51	-8.13	-0.31	2.22e-15	Bone properties (heel);
BRCA	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg00684032	chr4:1343700	KIAA1530	0.32	7.88	0.3	1.42e-14	Obesity-related traits;
BRCA	trans	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.32	0.31	5.29e-16	Mean corpuscular volume;
BRCA	cis	rs7851660	0.967	rs7847126	chr9:100600635	A/C	cg13688889	chr9:100608707	NA	-0.36	-8.64	-0.32	4.6e-17	Strep throat;
BRCA	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg26608667	chr7:1196370	ZFAND2A	0.42	9.24	0.34	3.62e-19	Longevity;Endometriosis;
BRCA	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10802521	chr3:52805072	NEK4	-0.33	-8.41	-0.32	2.72e-16	Bipolar disorder;
BRCA	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-11.96	-0.43	6.6e-30	Alzheimer's disease;
BRCA	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg00106254	chr7:1943704	MAD1L1	-0.39	-9.11	-0.34	1.02e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs6942756	0.531	rs9649531	chr7:128927659	T/C	cg02491457	chr7:128862824	NA	0.44	9.19	0.34	5.67e-19	White matter hyperintensity burden;
BRCA	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg13319975	chr6:146136371	FBXO30	-0.44	-10.14	-0.37	1.67e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg13880726	chr7:1868755	MAD1L1	0.52	9.81	0.36	2.93e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07308232	chr7:1071921	C7orf50	-0.49	-10.26	-0.38	5.79e-23	Longevity;Endometriosis;
BRCA	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-10.89	-0.4	1.86e-25	Schizophrenia;
BRCA	cis	rs1843834	1.000	rs1565072	chr2:225545245	C/T	cg22455342	chr2:225449267	CUL3	-0.38	-9.2	-0.34	5.15e-19	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.7	-0.33	2.85e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg25237894	chr2:233734115	C2orf82	0.38	10.92	0.4	1.47e-25	Coronary artery disease;
BRCA	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg05775895	chr3:12838266	CAND2	0.35	7.97	0.3	7.22e-15	QRS complex (12-leadsum);
BRCA	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg24692254	chr21:30365293	RNF160	0.79	22.17	0.66	3.3e-81	Dental caries;
BRCA	cis	rs2835872	0.758	rs1709821	chr21:39035622	T/C	cg06728970	chr21:39037746	KCNJ6	0.45	12.84	0.45	9.59e-34	Electroencephalographic traits in alcoholism;
BRCA	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.34	9.52	0.35	3.35e-20	Response to antipsychotic treatment;
BRCA	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg06618935	chr21:46677482	NA	-0.36	-8.13	-0.31	2.26e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg10523679	chr1:76189770	ACADM	0.76	15.67	0.53	4.33e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.49	9.28	0.34	2.51e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg09658497	chr7:2847517	GNA12	-0.39	-7.93	-0.3	9.76e-15	Height;
BRCA	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg00684032	chr4:1343700	KIAA1530	0.33	8.31	0.31	5.59e-16	Obesity-related traits;
BRCA	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg02187348	chr16:89574699	SPG7	0.4	9.25	0.34	3.24e-19	Multiple myeloma (IgH translocation);
BRCA	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg13319975	chr6:146136371	FBXO30	-0.41	-9.27	-0.34	2.9e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg25124228	chr12:125621409	AACS	-0.54	-10.81	-0.39	3.82e-25	Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs3784262	0.692	rs4646581	chr15:58307898	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.08	-0.37	2.74e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs4953076	0.573	rs13008237	chr2:44404902	A/G	cg04920474	chr2:44395004	PPM1B	0.48	10.18	0.37	1.15e-22	Height;
BRCA	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg07080220	chr10:102295463	HIF1AN	0.55	12.45	0.44	5.37e-32	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.4	-9.0	-0.34	2.53e-18	Longevity;Endometriosis;
BRCA	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.62	0.75	1.49e-116	Chronic sinus infection;
BRCA	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-9.39	-0.35	1e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.85	-0.36	2.02e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-10.0	-0.37	5.74e-22	Alzheimer's disease (late onset);
BRCA	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg11952622	chr19:58962976	ZNF324B	0.46	9.58	0.35	2.18e-20	Uric acid clearance;
BRCA	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg09307838	chr4:120376055	NA	0.56	11.44	0.41	1.1e-27	Corneal astigmatism;
BRCA	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg21770322	chr7:97807741	LMTK2	0.44	11.76	0.42	4.66e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11191205	0.644	rs10883667	chr10:103384849	A/T	cg15320455	chr10:103880129	LDB1	0.46	7.88	0.3	1.41e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.34	0.38	2.73e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg12140854	chr5:148520817	ABLIM3	-0.43	-8.95	-0.33	3.71e-18	Breast cancer;
BRCA	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	23.75	0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg18252515	chr7:66147081	NA	-1.06	-16.01	-0.54	9.39e-49	Gout;
BRCA	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.77	-0.36	4.24e-21	IgG glycosylation;
BRCA	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg23711669	chr6:146136114	FBXO30	-0.7	-16.89	-0.56	3.45e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg05340658	chr4:99064831	C4orf37	0.57	11.0	0.4	6.93e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg00850481	chr1:228891306	NA	0.36	7.93	0.3	9.96e-15	Chronic lymphocytic leukemia;
BRCA	cis	rs68170813	0.559	rs75203426	chr7:107017589	G/C	cg02696742	chr7:106810147	HBP1	-0.55	-8.74	-0.33	2.05e-17	Coronary artery disease;
BRCA	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03352830	chr11:487213	PTDSS2	-0.87	-13.59	-0.47	3.99e-37	Body mass index;
BRCA	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.37	10.22	0.37	8.54e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg24296786	chr1:45957014	TESK2	0.43	8.66	0.32	3.96e-17	Homocysteine levels;
BRCA	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg00277334	chr10:82204260	NA	-0.84	-23.82	-0.69	2.94e-90	Post bronchodilator FEV1;
BRCA	cis	rs4919694	1.000	rs77969925	chr10:104649357	C/T	cg04362960	chr10:104952993	NT5C2	0.9	14.59	0.5	8.3e-42	Arsenic metabolism;
BRCA	cis	rs36051895	0.623	rs2146041	chr9:5262911	A/G	cg02405213	chr9:5042618	JAK2	-0.48	-8.91	-0.33	5.49e-18	Pediatric autoimmune diseases;
BRCA	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg12444411	chr7:2802554	GNA12	0.35	8.7	0.33	2.83e-17	Height;
BRCA	cis	rs4819852	1.000	rs1034565	chr22:19984211	A/G	cg07821417	chr22:19972146	ARVCF	-0.45	-10.46	-0.38	9.83e-24	Pulse pressure;
BRCA	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg22920501	chr2:26401640	FAM59B	-0.9	-15.98	-0.53	1.37e-48	Gut microbiome composition (summer);
BRCA	trans	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.63	-0.36	1.33e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.09e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg18154014	chr19:37997991	ZNF793	-0.63	-11.9	-0.43	1.19e-29	Coronary artery calcification;
BRCA	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18876405	chr7:65276391	NA	-0.49	-11.05	-0.4	4.13e-26	Aortic root size;
BRCA	cis	rs67460515	0.527	rs34221255	chr3:160854123	T/C	cg03342759	chr3:160939853	NMD3	-0.63	-13.08	-0.46	8.04e-35	Parkinson's disease;
BRCA	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg12923728	chr3:195709715	SDHAP1	0.38	7.83	0.3	2.01e-14	Mean corpuscular volume;
BRCA	cis	rs7809950	1.000	rs3801948	chr7:107238447	A/T	cg23024343	chr7:107201750	COG5	-0.4	-9.13	-0.34	8.92e-19	Coronary artery disease;
BRCA	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11644478	chr21:40555479	PSMG1	0.84	18.75	0.6	8.13e-63	Cognitive function;
BRCA	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg26384229	chr12:38710491	ALG10B	0.66	14.44	0.5	3.92e-41	Bladder cancer;
BRCA	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24531977	chr5:56204891	C5orf35	1.07	22.49	0.66	5.77e-83	Initial pursuit acceleration;
BRCA	cis	rs73001065	0.901	rs73002956	chr19:19578743	A/G	cg03709012	chr19:19516395	GATAD2A	0.9	9.6	0.36	1.72e-20	LDL cholesterol;
BRCA	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.21	0.46	2.22e-35	Bipolar disorder;
BRCA	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg06238570	chr21:40685208	BRWD1	-0.44	-8.56	-0.32	8.23e-17	Cognitive function;
BRCA	cis	rs3784262	0.669	rs12912093	chr15:58332583	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.85	-0.36	2.07e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs4363385	0.782	rs2152993	chr1:152991695	C/A	cg25856811	chr1:152973957	SPRR3	-0.31	-8.34	-0.31	4.69e-16	Inflammatory skin disease;
BRCA	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg21918786	chr6:109611834	NA	-0.45	-12.24	-0.44	4.08e-31	Reticulocyte fraction of red cells;
BRCA	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg00080972	chr5:178986291	RUFY1	0.39	9.27	0.34	2.88e-19	Lung cancer;
BRCA	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.52	-0.52	2.52e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9828933	0.752	rs73117082	chr3:63947565	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.75	-11.9	-0.43	1.27e-29	Type 2 diabetes;
BRCA	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg15556689	chr8:8085844	FLJ10661	-0.38	-10.48	-0.38	8.2e-24	Neuroticism;
BRCA	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg27165867	chr14:105738592	BRF1	0.38	8.81	0.33	1.2e-17	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.9	0.3	1.19e-14	Axial length;
BRCA	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg25801113	chr15:45476975	SHF	0.31	8.03	0.3	4.63e-15	Uric acid levels;
BRCA	cis	rs11984145	1.000	rs73121384	chr7:38865187	T/C	cg19327137	chr7:38886074	VPS41	0.5	7.91	0.3	1.15e-14	Cognitive performance;
BRCA	cis	rs6060717	0.536	rs11699899	chr20:34525646	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.03	-0.3	4.56e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg27432699	chr2:27873401	GPN1	0.47	9.92	0.37	1.17e-21	Oral cavity cancer;
BRCA	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg06618935	chr21:46677482	NA	-0.37	-8.04	-0.3	4.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg22907277	chr7:1156413	C7orf50	0.48	11.63	0.42	1.76e-28	Longevity;Endometriosis;
BRCA	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg13628971	chr7:2884303	GNA12	0.4	8.72	0.33	2.45e-17	Height;
BRCA	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg07636037	chr3:49044803	WDR6	0.97	27.43	0.74	4.56e-110	Parkinson's disease;
BRCA	cis	rs6138458	0.847	rs56312312	chr20:24959386	C/A	cg26195577	chr20:24973756	C20orf3	0.98	21.49	0.65	1.56e-77	Blood protein levels;
BRCA	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.38	-0.31	3.37e-16	Monocyte percentage of white cells;
BRCA	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg02176678	chr2:219576539	TTLL4	0.42	11.0	0.4	6.79e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2130392	0.924	rs873687	chr4:185638853	G/A	cg21366198	chr4:185655624	MLF1IP	0.35	8.02	0.3	5.05e-15	Kawasaki disease;
BRCA	cis	rs1003719	0.715	rs2835653	chr21:38558636	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.49	-0.5	2.46e-41	Eye color traits;
BRCA	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.38	8.3	0.31	6.41e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1595825	0.891	rs16823385	chr2:198602101	G/A	cg19156104	chr2:198669113	PLCL1	-0.47	-8.25	-0.31	8.74e-16	Ulcerative colitis;
BRCA	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg23887609	chr12:130822674	PIWIL1	0.43	9.33	0.35	1.71e-19	Menopause (age at onset);
BRCA	cis	rs12995491	0.933	rs12995212	chr2:88527184	C/T	cg04511125	chr2:88470314	THNSL2	-0.45	-8.77	-0.33	1.64e-17	Response to metformin (IC50);
BRCA	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg00677455	chr12:58241039	CTDSP2	0.77	18.71	0.59	1.29e-62	Multiple sclerosis;
BRCA	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg06618935	chr21:46677482	NA	-0.37	-8.11	-0.31	2.68e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs870825	0.616	rs28459754	chr4:185636280	C/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.32	0.57	2.07e-55	Blood protein levels;
BRCA	cis	rs13046373	0.535	rs13051135	chr21:32005278	G/A	cg22337977	chr21:31811175	KRTAP15-1	0.33	7.93	0.3	9.69e-15	HDL cholesterol;
BRCA	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg18252515	chr7:66147081	NA	1.04	15.68	0.53	4.14e-47	Diabetic kidney disease;
BRCA	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg22800045	chr5:56110881	MAP3K1	0.66	12.33	0.44	1.69e-31	Initial pursuit acceleration;
BRCA	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.64	-0.32	4.6e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs4363385	0.747	rs4240868	chr1:152981599	G/A	cg25856811	chr1:152973957	SPRR3	-0.34	-9.1	-0.34	1.11e-18	Inflammatory skin disease;
BRCA	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg13271783	chr10:134563150	INPP5A	-0.5	-9.57	-0.35	2.28e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg24642439	chr20:33292090	TP53INP2	0.6	13.29	0.47	8.92e-36	Coronary artery disease;
BRCA	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg27129171	chr3:47204927	SETD2	0.71	17.26	0.56	4.46e-55	Colorectal cancer;
BRCA	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg09307838	chr4:120376055	NA	0.63	13.21	0.46	2.1e-35	Corneal astigmatism;
BRCA	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	14.11	0.49	1.48e-39	Hip circumference adjusted for BMI;
BRCA	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg15839431	chr19:19639596	YJEFN3	-0.41	-9.02	-0.34	2.19e-18	Bipolar disorder;
BRCA	cis	rs4631830	0.720	rs11004415	chr10:51498181	G/A	cg16070123	chr10:51489643	NA	0.35	7.85	0.3	1.73e-14	Prostate-specific antigen levels;
BRCA	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg15017067	chr4:17643749	FAM184B	0.32	10.0	0.37	5.88e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs654950	0.776	rs2759252	chr1:42021854	G/A	cg06885757	chr1:42089581	HIVEP3	-0.32	-10.75	-0.39	6.91e-25	Airway imaging phenotypes;
BRCA	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.88	0.56	3.66e-53	Colorectal cancer;
BRCA	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.92	-0.37	1.1e-21	Recombination measurement;
BRCA	trans	rs1997103	1.000	rs6950311	chr7:55400990	G/A	cg20935933	chr6:143382018	AIG1	0.6	11.42	0.41	1.32e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg27535305	chr1:53392650	SCP2	0.39	9.17	0.34	6.67e-19	Monocyte count;
BRCA	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg22491629	chr6:157744540	C6orf35	-0.65	-11.68	-0.42	1.06e-28	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg01448562	chr3:133502909	NA	0.6	14.59	0.5	7.88e-42	Iron status biomarkers;
BRCA	cis	rs9560113	0.959	rs4771756	chr13:112176083	T/G	cg10483660	chr13:112241077	NA	0.32	7.93	0.3	9.77e-15	Menarche (age at onset);
BRCA	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.13	0.31	2.28e-15	Total cholesterol levels;
BRCA	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.67	-0.42	1.13e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs1570989	0.543	rs6458035	chr6:12015296	A/G	cg17804551	chr6:12015979	HIVEP1	0.4	9.56	0.35	2.44e-20	Alcohol and nicotine co-dependence;
BRCA	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-17.82	-0.58	5.97e-58	Morning vs. evening chronotype;
BRCA	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg09307838	chr4:120376055	NA	0.69	13.77	0.48	5.85e-38	Corneal astigmatism;
BRCA	cis	rs9682041	0.696	rs11917147	chr3:170088448	C/T	cg11886554	chr3:170076028	SKIL	0.51	10.19	0.37	1.03e-22	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg13852791	chr20:30311386	BCL2L1	0.79	15.29	0.52	3.19e-45	Mean corpuscular hemoglobin;
BRCA	trans	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg07211511	chr3:129823064	LOC729375	-0.6	-11.53	-0.41	4.5e-28	Blood pressure (smoking interaction);
BRCA	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg23933602	chr10:16859644	RSU1	0.63	11.74	0.42	5.94e-29	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-10.0	-0.37	5.69e-22	Bladder cancer;
BRCA	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg04450456	chr4:17643702	FAM184B	0.36	10.39	0.38	1.81e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg09455208	chr3:40491958	NA	0.53	11.94	0.43	8.23e-30	Renal cell carcinoma;
BRCA	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	15.12	0.51	2.34e-44	Platelet count;
BRCA	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg24803719	chr17:45855879	NA	-0.31	-8.29	-0.31	6.67e-16	IgG glycosylation;
BRCA	cis	rs7520050	0.931	rs785472	chr1:46518288	T/A	cg24296786	chr1:45957014	TESK2	0.41	9.22	0.34	4.28e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.8	0.39	4.53e-25	Rheumatoid arthritis;
BRCA	cis	rs870825	0.616	rs28672716	chr4:185647345	G/A	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.2	-18.94	-0.6	8.07e-64	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7246967	0.673	rs34676724	chr19:22918473	A/C	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.71	-0.57	2.11e-57	Chronic sinus infection;
BRCA	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24397884	chr7:158709396	WDR60	-0.97	-24.82	-0.7	9.75e-96	Height;
BRCA	cis	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg07460842	chr6:66804631	NA	0.6	10.41	0.38	1.57e-23	Type 2 diabetes;
BRCA	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg21475434	chr5:93447410	FAM172A	0.68	8.8	0.33	1.26e-17	Diabetic retinopathy;
BRCA	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08219700	chr8:58056026	NA	0.45	8.31	0.31	5.83e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg06159980	chr1:16340746	HSPB7	0.4	8.46	0.32	1.85e-16	Dilated cardiomyopathy;
BRCA	cis	rs250677	0.522	rs12523526	chr5:148349107	A/C	cg18129178	chr5:148520854	ABLIM3	0.54	10.29	0.38	4.51e-23	Breast cancer;
BRCA	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg17063962	chr7:91808500	NA	-0.52	-12.28	-0.44	2.98e-31	Breast cancer;
BRCA	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00152838	chr16:24741724	TNRC6A	-0.35	-7.88	-0.3	1.47e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9341808	0.727	rs1324120	chr6:80976125	G/C	cg08355045	chr6:80787529	NA	0.37	9.55	0.35	2.77e-20	Sitting height ratio;
BRCA	cis	rs6545883	0.895	rs6545871	chr2:61692203	G/T	cg15711740	chr2:61764176	XPO1	-0.57	-14.37	-0.49	9e-41	Tuberculosis;
BRCA	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg24692254	chr21:30365293	RNF160	-0.48	-10.45	-0.38	1.04e-23	Pancreatic cancer;
BRCA	cis	rs9392556	0.829	rs693953	chr6:4120565	A/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.38	-8.2	-0.31	1.37e-15	Blood metabolite levels;
BRCA	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg08645402	chr16:4508243	NA	-0.38	-8.27	-0.31	7.81e-16	Schizophrenia;
BRCA	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.51	-9.24	-0.34	3.62e-19	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs12618769	0.597	rs3754888	chr2:99090674	T/C	cg10123293	chr2:99228465	UNC50	0.42	8.37	0.31	3.7e-16	Bipolar disorder;
BRCA	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg10729496	chr3:10149963	C3orf24	0.48	8.98	0.33	3.08e-18	Alzheimer's disease;
BRCA	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-10.82	-0.39	3.75e-25	Morning vs. evening chronotype;
BRCA	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg05623727	chr3:50126028	RBM5	-0.42	-10.06	-0.37	3.36e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-14.7	-0.5	2.47e-42	Bladder cancer;
BRCA	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.47	-9.66	-0.36	1.03e-20	Body mass index;
BRCA	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.25	0.34	3.27e-19	Tonsillectomy;
BRCA	trans	rs9951602	0.512	rs9946138	chr18:76654608	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	18.28	0.59	2.2e-60	Obesity-related traits;
BRCA	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06221963	chr1:154839813	KCNN3	-0.55	-15.17	-0.51	1.23e-44	Prostate cancer;
BRCA	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg05294307	chr14:35346193	BAZ1A	-0.62	-10.51	-0.38	6.36e-24	Psoriasis;
BRCA	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	1e-20	Total body bone mineral density;
BRCA	cis	rs644148	0.738	rs2686768	chr19:44995990	C/T	cg15540054	chr19:45004280	ZNF180	-0.41	-8.41	-0.32	2.62e-16	Personality dimensions;
BRCA	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-12.59	-0.45	1.26e-32	Personality dimensions;
BRCA	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg27129171	chr3:47204927	SETD2	-0.65	-14.25	-0.49	3.45e-40	Colorectal cancer;
BRCA	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	11.7	0.42	8.37e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18876405	chr7:65276391	NA	0.51	11.55	0.42	3.58e-28	Aortic root size;
BRCA	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18876405	chr7:65276391	NA	0.58	13.64	0.47	2.35e-37	Aortic root size;
BRCA	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg23711669	chr6:146136114	FBXO30	-0.79	-19.16	-0.6	5.32e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg16606324	chr3:10149918	C3orf24	0.57	10.03	0.37	4.25e-22	Alzheimer's disease;
BRCA	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg24060327	chr5:131705240	SLC22A5	-0.56	-9.25	-0.34	3.45e-19	Lymphocyte counts;Fibrinogen;
BRCA	cis	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.28	-0.34	2.62e-19	Resting heart rate;
BRCA	cis	rs2731664	0.740	rs2731670	chr5:176848019	G/T	cg23176889	chr5:176863531	GRK6	0.52	13.64	0.47	2.22e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23583168	chr7:148888333	NA	-0.95	-25.37	-0.71	9.16e-99	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg11764359	chr7:65958608	NA	0.78	18.21	0.58	5.34e-60	Aortic root size;
BRCA	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg21775007	chr8:11205619	TDH	-0.59	-11.5	-0.41	5.8e-28	Retinal vascular caliber;
BRCA	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg13852791	chr20:30311386	BCL2L1	0.86	16.68	0.55	4.04e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs13161895	0.818	rs78282770	chr5:179483686	T/A	cg02702477	chr5:179499311	RNF130	0.57	9.99	0.37	6.47e-22	LDL cholesterol;
BRCA	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg21770322	chr7:97807741	LMTK2	0.58	16.99	0.56	1.12e-53	Breast cancer;
BRCA	cis	rs11893307	0.536	rs6719798	chr2:191677664	C/T	cg05765582	chr2:191677683	NA	0.44	7.92	0.3	1.09e-14	Mean platelet volume;
BRCA	trans	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg26043149	chr18:55253948	FECH	0.42	9.14	0.34	8.39e-19	Bone mineral density;
BRCA	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg27541892	chr1:1571801	CDK11B	0.38	8.47	0.32	1.71e-16	Body mass index;
BRCA	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg00750074	chr16:89608354	SPG7	-0.41	-10.96	-0.4	1e-25	Multiple myeloma (IgH translocation);
BRCA	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg17971929	chr21:40555470	PSMG1	0.77	18.18	0.58	7.78e-60	Cognitive function;
BRCA	cis	rs858239	0.601	rs28673077	chr7:23250854	C/T	cg23682824	chr7:23144976	KLHL7	0.35	8.61	0.32	5.6e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	19.46	0.61	1.39e-66	Alzheimer's disease;
BRCA	cis	rs9297145	0.565	rs941001	chr7:98735185	A/T	cg05967295	chr7:98741636	SMURF1	-0.62	-13.39	-0.47	3.23e-36	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs36051895	0.695	rs4527935	chr9:5016455	A/T	cg02405213	chr9:5042618	JAK2	-0.49	-8.7	-0.33	2.77e-17	Pediatric autoimmune diseases;
BRCA	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg22920501	chr2:26401640	FAM59B	-0.65	-11.32	-0.41	3.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg02038168	chr22:39784481	NA	0.43	8.24	0.31	9.9e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.747	rs2339494	chr1:152975143	G/C	cg24667326	chr1:152973720	SPRR3	-0.35	-9.59	-0.35	1.92e-20	Inflammatory skin disease;
BRCA	cis	rs10504073	0.605	rs62507176	chr8:49930321	G/A	cg00325661	chr8:49890786	NA	0.54	15.54	0.52	1.89e-46	Blood metabolite ratios;
BRCA	cis	rs7072216	0.726	rs4474372	chr10:100164571	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-8.5	-0.32	1.3e-16	Metabolite levels;
BRCA	cis	rs1003719	0.715	rs2835649	chr21:38552230	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.26	0.49	2.85e-40	Eye color traits;
BRCA	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg11266682	chr4:10021025	SLC2A9	0.41	10.86	0.39	2.47e-25	Bone mineral density;
BRCA	cis	rs4363385	0.747	rs1933383	chr1:152963468	C/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.2	-0.31	1.31e-15	Inflammatory skin disease;
BRCA	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg26031613	chr14:104095156	KLC1	0.75	16.33	0.54	2.24e-50	Body mass index;
BRCA	cis	rs6752107	0.935	rs10929325	chr2:234151031	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	10.81	0.39	4.12e-25	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg07636037	chr3:49044803	WDR6	-0.57	-7.86	-0.3	1.61e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12826209	chr6:26865740	GUSBL1	0.58	10.3	0.38	3.9699999999999997e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg02951883	chr7:2050386	MAD1L1	-0.56	-13.44	-0.47	1.83e-36	Bipolar disorder and schizophrenia;
BRCA	cis	rs2386661	0.591	rs11255051	chr10:5653450	A/G	cg17085576	chr10:5658249	NA	-0.36	-8.88	-0.33	6.51e-18	Breast cancer;
BRCA	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg23625390	chr15:77176239	SCAPER	-0.53	-12.57	-0.45	1.61e-32	Blood metabolite levels;
BRCA	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg26597838	chr10:835615	NA	0.95	14.42	0.5	5.19e-41	Eosinophil percentage of granulocytes;
BRCA	cis	rs586533	0.846	rs646067	chr11:99497122	T/C	cg22878054	chr11:99397252	CNTN5	0.32	8.02	0.3	5.08e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-13.3	-0.47	8.1e-36	Morning vs. evening chronotype;
BRCA	cis	rs586533	0.881	rs12806028	chr11:99512171	C/A	cg22878054	chr11:99397252	CNTN5	0.31	7.84	0.3	1.85e-14	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg23505145	chr19:12996616	KLF1	0.56	12.68	0.45	5.18e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6565180	1.000	rs68051857	chr16:30360011	A/G	cg17640201	chr16:30407289	ZNF48	-0.78	-20.01	-0.62	1.64e-69	Tonsillectomy;
BRCA	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg05340658	chr4:99064831	C4orf37	0.45	10.37	0.38	2.18e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg16558253	chr16:72132732	DHX38	-0.39	-9.52	-0.35	3.6e-20	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg09307838	chr4:120376055	NA	0.76	17.1	0.56	2.9e-54	Corneal astigmatism;
BRCA	cis	rs7395581	0.959	rs59663860	chr11:47276350	G/C	cg25783544	chr11:47291846	MADD	0.43	9.49	0.35	4.43e-20	HDL cholesterol;
BRCA	trans	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg09719594	chr16:21412588	NA	-0.35	-8.36	-0.31	3.87e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg05552183	chr6:42928497	GNMT	0.7	15.77	0.53	1.43e-47	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs12517041	1.000	rs71611220	chr5:23281005	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.27	-0.31	7.76e-16	Calcium levels;
BRCA	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.56	8.71	0.33	2.68e-17	HIV-1 control;
BRCA	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg11833968	chr6:79620685	NA	-0.45	-10.03	-0.37	4.43e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg02733842	chr7:1102375	C7orf50	0.72	12.81	0.45	1.4e-33	Bronchopulmonary dysplasia;
BRCA	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.87	-0.33	7.27e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg20790798	chr5:1857306	NA	-0.39	-9.18	-0.34	5.76e-19	Cardiovascular disease risk factors;
BRCA	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	cg06064525	chr11:970664	AP2A2	-0.27	-7.85	-0.3	1.76e-14	Alzheimer's disease (late onset);
BRCA	trans	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg25214090	chr10:38739885	LOC399744	0.43	10.0	0.37	5.45e-22	Corneal astigmatism;
BRCA	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg05665937	chr4:1216051	CTBP1	0.44	8.86	0.33	7.93e-18	Obesity-related traits;
BRCA	trans	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg26384229	chr12:38710491	ALG10B	0.44	10.72	0.39	8.67e-25	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.82	0.3	2.22e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg05313129	chr8:58192883	C8orf71	-0.48	-9.83	-0.36	2.58e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg25237894	chr2:233734115	C2orf82	0.4	11.43	0.41	1.15e-27	Coronary artery disease;
BRCA	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	16.49	0.55	3.83e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.46	-11.53	-0.42	4.43e-28	Longevity;Endometriosis;
BRCA	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg04166393	chr7:2884313	GNA12	0.47	8.97	0.33	3.31e-18	Height;
BRCA	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.2	-0.41	1.07e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg13770153	chr20:60521292	NA	-0.38	-9.03	-0.34	2.07e-18	Body mass index;
BRCA	cis	rs698813	0.604	rs768007	chr2:44487486	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	7.93	0.3	1.01e-14	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg06627628	chr2:24431161	ITSN2	-0.71	-13.31	-0.47	7.78e-36	Asthma;
BRCA	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg05623727	chr3:50126028	RBM5	0.51	12.87	0.45	6.91e-34	Body mass index;
BRCA	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11764359	chr7:65958608	NA	0.81	19.52	0.61	6.65e-67	Aortic root size;
BRCA	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg17063962	chr7:91808500	NA	-0.5	-11.74	-0.42	5.93e-29	Breast cancer;
BRCA	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg26384229	chr12:38710491	ALG10B	0.58	13.55	0.47	5.8e-37	Bladder cancer;
BRCA	trans	rs3858145	0.588	rs115455464	chr10:70038498	T/C	cg04882175	chr6:131122610	NA	-0.35	-8.35	-0.31	4.33e-16	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
BRCA	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg01579765	chr21:45077557	HSF2BP	-0.47	-13.2	-0.46	2.38e-35	Mean corpuscular volume;
BRCA	trans	rs7746199	0.736	rs34543938	chr6:27624640	A/G	cg01620082	chr3:125678407	NA	-0.91	-10.26	-0.38	5.96e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg18357645	chr12:58087776	OS9	0.48	13.63	0.47	2.49e-37	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg27284194	chr4:1044797	NA	0.44	9.35	0.35	1.5e-19	Recombination rate (males);
BRCA	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg24642844	chr7:1081250	C7orf50	-0.91	-16.39	-0.54	1.21e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg25036284	chr2:26402008	FAM59B	0.95	15.98	0.53	1.27e-48	Gut microbiome composition (summer);
BRCA	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-8.22	-0.31	1.13e-15	Mood instability;
BRCA	cis	rs9790314	0.663	rs13098884	chr3:160687386	A/G	cg03342759	chr3:160939853	NMD3	0.45	8.76	0.33	1.72e-17	Morning vs. evening chronotype;
BRCA	trans	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.24	0.38	7.13e-23	Mean corpuscular volume;
BRCA	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.31	-0.35	2.02e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs9463078	0.715	rs1891411	chr6:44760903	G/C	cg25276700	chr6:44698697	NA	0.38	8.82	0.33	1.06e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	11.1	0.4	2.7e-26	Height;
BRCA	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.09	0.3	2.92e-15	Tonsillectomy;
BRCA	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg24977027	chr2:88469347	THNSL2	-0.56	-9.37	-0.35	1.24e-19	Plasma clusterin levels;
BRCA	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19748678	chr4:122722346	EXOSC9	0.74	16.01	0.54	9.39e-49	Type 2 diabetes;
BRCA	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg17143192	chr8:8559678	CLDN23	0.55	10.77	0.39	5.9e-25	Obesity-related traits;
BRCA	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	9.87	0.36	1.77e-21	Tonsillectomy;
BRCA	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg18850127	chr7:39170497	POU6F2	0.39	8.26	0.31	8.58e-16	IgG glycosylation;
BRCA	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg02176678	chr2:219576539	TTLL4	0.39	10.46	0.38	9.28e-24	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.99	0.56	1.02e-53	Hypertriglyceridemia;
BRCA	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg21770322	chr7:97807741	LMTK2	0.43	11.4	0.41	1.55e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.1	-0.31	2.87e-15	Bipolar disorder;
BRCA	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg22800045	chr5:56110881	MAP3K1	0.62	11.8	0.42	3.17e-29	Initial pursuit acceleration;
BRCA	cis	rs12618769	0.652	rs7585747	chr2:99219071	T/C	cg10123293	chr2:99228465	UNC50	0.42	8.49	0.32	1.44e-16	Bipolar disorder;
BRCA	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-12.68	-0.45	4.8e-33	Response to antipsychotic treatment;
BRCA	cis	rs13095912	1.000	rs13072759	chr3:185326391	G/A	cg11274856	chr3:185301563	NA	0.36	8.84	0.33	9.31e-18	Systolic blood pressure;
BRCA	cis	rs7246657	0.722	rs10409605	chr19:38123137	T/G	cg23950597	chr19:37808831	NA	-0.49	-8.51	-0.32	1.28e-16	Coronary artery calcification;
BRCA	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4891159	0.790	rs9950025	chr18:74113596	C/G	cg24786174	chr18:74118243	ZNF516	0.74	18.66	0.59	2.39e-62	Longevity;
BRCA	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg26384229	chr12:38710491	ALG10B	0.69	15.68	0.53	4.01e-47	Bladder cancer;
BRCA	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg13256891	chr4:100009986	ADH5	-0.54	-9.95	-0.37	8.56e-22	Alcohol dependence;
BRCA	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg17063962	chr7:91808500	NA	-0.53	-11.96	-0.43	6.84e-30	Breast cancer;
BRCA	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg26384229	chr12:38710491	ALG10B	0.83	22.45	0.66	9.57e-83	Heart rate;
BRCA	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg24692254	chr21:30365293	RNF160	-0.62	-15.86	-0.53	5.18e-48	Dental caries;
BRCA	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-12.5	-0.44	3.27e-32	Response to antipsychotic treatment;
BRCA	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg23950597	chr19:37808831	NA	0.74	13.03	0.46	1.37e-34	Coronary artery calcification;
BRCA	cis	rs7945718	0.875	rs6486057	chr11:12810338	T/A	cg25843174	chr11:12811716	TEAD1	0.23	8.73	0.33	2.16e-17	Educational attainment (years of education);
BRCA	trans	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg25206134	chr2:45395956	NA	0.49	7.82	0.3	2.14e-14	Neuroticism;
BRCA	cis	rs12611088	0.541	rs2682579	chr19:44012609	T/C	cg15012607	chr19:44012195	ETHE1	-0.35	-9.17	-0.34	6.41e-19	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-9.84	-0.36	2.22e-21	Schizophrenia;
BRCA	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.28	0.44	2.75e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg22676075	chr6:135203613	NA	0.44	8.6	0.32	6.06e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.8	-0.42	3.39e-29	Colorectal cancer;
BRCA	cis	rs7020830	0.894	rs13300951	chr9:37146627	A/G	cg14294708	chr9:37120828	ZCCHC7	1.18	42.36	0.86	1.03e-187	Schizophrenia;
BRCA	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.74	0.55	2.09e-52	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6484504	0.625	rs672396	chr11:31386165	A/G	cg26647111	chr11:31128758	NA	0.43	9.53	0.35	3.18e-20	Red blood cell count;
BRCA	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg16405210	chr4:1374714	KIAA1530	-0.92	-22.73	-0.67	3e-84	Longevity;
BRCA	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg26149184	chr10:133730230	NA	0.38	7.82	0.3	2.14e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16405210	chr4:1374714	KIAA1530	-0.58	-13.26	-0.46	1.21e-35	Longevity;
BRCA	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg15605315	chr1:45957053	TESK2	0.49	9.95	0.37	9.04e-22	High light scatter reticulocyte count;
BRCA	cis	rs17164103	0.505	rs10500136	chr7:143014244	C/T	cg22531018	chr7:142981779	TMEM139	-0.72	-14.48	-0.5	2.55e-41	Cancer;
BRCA	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-9.0	-0.34	2.53e-18	Alzheimer's disease (late onset);
BRCA	cis	rs243505	0.762	rs10241408	chr7:148481488	G/A	cg09806900	chr7:148480153	CUL1	0.52	11.0	0.4	7.09e-26	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.33	-8.07	-0.3	3.42e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg15395560	chr15:45543142	SLC28A2	0.3	8.32	0.31	5.52e-16	Uric acid levels;
BRCA	cis	rs5167	0.504	rs7259679	chr19:45457306	C/T	cg09555818	chr19:45449301	APOC2	0.46	11.94	0.43	8.27e-30	Blood protein levels;
BRCA	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.14	-0.43	1.13e-30	Response to antipsychotic treatment;
BRCA	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg26031613	chr14:104095156	KLC1	0.75	16.51	0.55	2.81e-51	Body mass index;
BRCA	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21659725	chr3:3221576	CRBN	0.34	7.88	0.3	1.41e-14	Body mass index;
BRCA	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07308232	chr7:1071921	C7orf50	-0.44	-9.18	-0.34	6.09e-19	Longevity;Endometriosis;
BRCA	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg16586182	chr3:47516702	SCAP	0.64	15.05	0.51	4.68e-44	Colorectal cancer;
BRCA	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.17	0.74	4.21e-114	Chronic sinus infection;
BRCA	cis	rs17401966	1.000	rs58549151	chr1:10314657	A/C	cg03954927	chr1:10346856	KIF1B	0.45	12.8	0.45	1.41e-33	Hepatocellular carcinoma;
BRCA	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg00717180	chr2:96193071	NA	0.3	8.25	0.31	8.96e-16	Height;
BRCA	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-7.92	-0.3	1.02e-14	Total body bone mineral density;
BRCA	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg18132916	chr6:79620363	NA	-0.45	-10.17	-0.37	1.25e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg26838691	chr2:24397539	C2orf84	-0.39	-7.91	-0.3	1.18e-14	Asthma;
BRCA	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg08999081	chr20:33150536	PIGU	0.49	14.02	0.48	4e-39	Coronary artery disease;
BRCA	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.78	-0.36	3.82e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2742234	0.541	rs11238476	chr10:43711436	G/T	cg15436174	chr10:43711423	RASGEF1A	0.56	10.95	0.4	1.13e-25	Hirschsprung disease;
BRCA	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg20203395	chr5:56204925	C5orf35	0.41	9.17	0.34	6.66e-19	Initial pursuit acceleration;
BRCA	cis	rs10193935	1.000	rs13399869	chr2:42386041	C/G	cg27598129	chr2:42591480	NA	-0.87	-14.49	-0.5	2.26e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs495337	0.736	rs6095681	chr20:48451129	A/T	cg17835207	chr20:48524531	SPATA2	0.53	12.11	0.43	1.53e-30	Psoriasis;
BRCA	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg16262614	chr3:133464971	TF	0.24	7.88	0.3	1.37e-14	Iron status biomarkers (transferrin levels);
BRCA	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg24848339	chr3:12840334	CAND2	0.5	13.33	0.47	6.34e-36	QRS complex (12-leadsum);
BRCA	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg25554036	chr4:6271136	WFS1	-0.45	-9.96	-0.37	8.25e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg24812749	chr6:127587940	RNF146	0.86	20.21	0.62	1.41e-70	Breast cancer;
BRCA	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-8.55	-0.32	9.09e-17	Bladder cancer;
BRCA	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg08807892	chr2:162101083	NA	0.72	16.47	0.55	4.43e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg11707556	chr5:10655725	ANKRD33B	0.4	8.55	0.32	9.24e-17	Coronary artery disease;
BRCA	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg19622623	chr12:86230825	RASSF9	-0.33	-9.28	-0.34	2.49e-19	Major depressive disorder;
BRCA	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg22963979	chr7:1858916	MAD1L1	-0.4	-8.46	-0.32	1.77e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs7020830	0.898	rs506981	chr9:37351348	A/T	cg14294708	chr9:37120828	ZCCHC7	-1.0	-28.86	-0.75	7e-118	Schizophrenia;
BRCA	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12292205	chr6:26970375	C6orf41	-0.49	-8.27	-0.31	7.96e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg11833968	chr6:79620685	NA	-0.43	-9.6	-0.35	1.8e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	12.32	0.44	2e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs11051970	0.659	rs1809913	chr12:32591626	A/G	cg02745156	chr12:32552066	NA	0.27	8.15	0.31	1.96e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	trans	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg25214090	chr10:38739885	LOC399744	0.55	12.78	0.45	1.87e-33	Corneal astigmatism;
BRCA	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.43	-10.19	-0.37	1.05e-22	Lymphocyte counts;
BRCA	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg23719950	chr11:63933701	MACROD1	-0.59	-9.61	-0.36	1.65e-20	Mean platelet volume;
BRCA	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg21770322	chr7:97807741	LMTK2	-0.41	-10.84	-0.39	2.99e-25	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7945718	0.875	rs9888181	chr11:12782781	G/A	cg25843174	chr11:12811716	TEAD1	0.24	9.28	0.34	2.52e-19	Educational attainment (years of education);
BRCA	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg05623727	chr3:50126028	RBM5	-0.52	-12.7	-0.45	3.93e-33	Body mass index;
BRCA	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Tonsillectomy;
BRCA	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg09307838	chr4:120376055	NA	0.75	16.21	0.54	9.31e-50	Corneal astigmatism;
BRCA	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg22974920	chr21:40686053	BRWD1	0.35	8.0	0.3	5.7e-15	Menarche (age at onset);
BRCA	trans	rs9944715	1.000	rs8099202	chr18:43834634	G/T	cg01718231	chr17:29326311	RNF135	0.4	7.89	0.3	1.31e-14	Red cell distribution width;Mean corpuscular volume;
BRCA	trans	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.05	0.3	4.12e-15	Corneal astigmatism;
BRCA	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg04450456	chr4:17643702	FAM184B	0.36	10.45	0.38	1.05e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs751728	0.687	rs9357164	chr6:33761021	T/C	cg25922239	chr6:33757077	LEMD2	0.49	12.31	0.44	2.1e-31	Crohn's disease;
BRCA	cis	rs6426558	0.559	rs485234	chr1:227317747	A/G	cg10327440	chr1:227177885	CDC42BPA	0.47	9.33	0.35	1.73e-19	Neutrophil percentage of white cells;
BRCA	cis	rs11690935	0.959	rs4668412	chr2:172619770	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.37	-0.77	4.35e-126	Schizophrenia;
BRCA	trans	rs1478897	0.804	rs9329246	chr8:11392880	A/G	cg06636001	chr8:8085503	FLJ10661	0.43	8.73	0.33	2.17e-17	Systemic lupus erythematosus;
BRCA	cis	rs9473147	0.543	rs1004173	chr6:47445017	C/T	cg12968598	chr6:47444699	CD2AP	0.46	9.79	0.36	3.38e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs12611088	0.571	rs2305375	chr19:44013260	C/T	cg15012607	chr19:44012195	ETHE1	-0.33	-8.6	-0.32	5.93e-17	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg23711669	chr6:146136114	FBXO30	-0.72	-16.33	-0.54	2.24e-50	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg20573242	chr4:122745356	CCNA2	0.38	8.7	0.33	2.83e-17	Type 2 diabetes;
BRCA	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg13010199	chr12:38710504	ALG10B	0.42	9.0	0.34	2.56e-18	Morning vs. evening chronotype;
BRCA	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg09307838	chr4:120376055	NA	-0.53	-11.02	-0.4	5.48e-26	Corneal astigmatism;
BRCA	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11764359	chr7:65958608	NA	-0.77	-17.06	-0.56	4.76e-54	Aortic root size;
BRCA	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg17063962	chr7:91808500	NA	0.53	12.51	0.44	2.79e-32	Breast cancer;
BRCA	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-9.0	-0.34	2.61e-18	Aortic root size;
BRCA	trans	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-20.03	-0.62	1.27e-69	Exhaled nitric oxide output;
BRCA	cis	rs939658	0.805	rs6495374	chr15:79434031	C/T	cg17916960	chr15:79447300	NA	-0.42	-10.59	-0.39	2.86e-24	Refractive error;
BRCA	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03517284	chr6:25882590	NA	-0.5	-11.34	-0.41	2.87e-27	Blood metabolite levels;
BRCA	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg23711669	chr6:146136114	FBXO30	0.74	15.93	0.53	2.41e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-11.37	-0.41	2.14e-27	Resting heart rate;
BRCA	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14829155	chr15:31115871	NA	-0.43	-9.85	-0.36	2.15e-21	Huntington's disease progression;
BRCA	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg02659138	chr7:134003124	SLC35B4	0.33	10.14	0.37	1.73e-22	Mean platelet volume;
BRCA	cis	rs7640424	0.819	rs34937412	chr3:107829484	G/C	cg09227934	chr3:107805635	CD47	-0.41	-8.71	-0.33	2.68e-17	Body mass index;
BRCA	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg21017887	chr14:105400489	NA	0.66	17.49	0.57	2.82e-56	Rheumatoid arthritis;
BRCA	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	17.21	0.56	7.98e-55	Colorectal cancer;
BRCA	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg13073564	chr4:8508604	NA	0.32	8.67	0.32	3.69e-17	Response to antineoplastic agents;
BRCA	cis	rs9473147	0.516	rs9395286	chr6:47575332	T/C	cg12968598	chr6:47444699	CD2AP	0.44	9.56	0.35	2.56e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.42	9.68	0.36	8.97e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs698833	0.828	rs3738984	chr2:44531484	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.52	-10.8	-0.39	4.35e-25	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs8114671	0.967	rs6060285	chr20:33770487	G/T	cg07148914	chr20:33460835	GGT7	0.38	8.01	0.3	5.27e-15	Height;
BRCA	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg06784218	chr1:46089804	CCDC17	-0.44	-10.51	-0.38	6.02e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg00750074	chr16:89608354	SPG7	-0.43	-11.62	-0.42	1.87e-28	Multiple myeloma (IgH translocation);
BRCA	cis	rs911119	0.954	rs2405367	chr20:23622880	A/G	cg16589663	chr20:23618590	CST3	-0.41	-7.84	-0.3	1.87e-14	Chronic kidney disease;
BRCA	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg22920501	chr2:26401640	FAM59B	-0.67	-11.56	-0.42	3.38e-28	Gut microbiome composition (summer);
BRCA	trans	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.28e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg19077165	chr18:44547161	KATNAL2	0.44	9.0	0.34	2.6e-18	Educational attainment;
BRCA	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	9.96	0.37	7.85e-22	Tonsillectomy;
BRCA	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.02	-0.3	4.98e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.52	-11.38	-0.41	1.97e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs3857536	0.813	rs2040594	chr6:66943966	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.99	-0.3	6.42e-15	Blood trace element (Cu levels);
BRCA	trans	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.9	0.3	1.22e-14	Corneal astigmatism;
BRCA	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg01191920	chr7:158217561	PTPRN2	-0.47	-11.13	-0.4	2.07e-26	Obesity-related traits;
BRCA	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03452623	chr4:187889614	NA	-0.31	-10.02	-0.37	4.75e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.66	-15.94	-0.53	1.99e-48	Ulcerative colitis;
BRCA	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg25358565	chr5:93447407	FAM172A	1.21	18.91	0.6	1.11e-63	Diabetic retinopathy;
BRCA	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.87	-0.48	1.9e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-22.14	-0.66	4.72e-81	Chronic sinus infection;
BRCA	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	12.84	0.45	1.03e-33	Height;
BRCA	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg19508488	chr2:152266495	RIF1	0.52	10.51	0.38	6.02e-24	Lung cancer;
BRCA	cis	rs4302748	0.862	rs4723481	chr7:36180023	A/G	cg24442661	chr7:36192818	EEPD1	0.45	8.63	0.32	4.88e-17	Platelet count;
BRCA	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg25801113	chr15:45476975	SHF	0.31	7.84	0.3	1.93e-14	Uric acid levels;
BRCA	cis	rs2346177	0.875	rs2881327	chr2:46641955	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	8.53	0.32	1.1e-16	HDL cholesterol;
BRCA	cis	rs2882667	0.898	rs10058347	chr5:138361358	G/A	cg04439458	chr5:138467593	SIL1	-0.33	-8.84	-0.33	9.39e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg03433033	chr1:76189801	ACADM	0.75	17.23	0.56	6.15e-55	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11764359	chr7:65958608	NA	0.79	18.98	0.6	4.56e-64	Aortic root size;
BRCA	cis	rs11608355	0.515	rs11611012	chr12:109945203	G/A	cg05360138	chr12:110035743	NA	0.69	10.75	0.39	6.84e-25	Neuroticism;
BRCA	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg08888203	chr3:10149979	C3orf24	0.66	14.05	0.49	2.73e-39	Alzheimer's disease;
BRCA	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs6005807	0.563	rs7288792	chr22:29015603	C/T	cg12565055	chr22:29076175	TTC28	0.49	9.33	0.35	1.65e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg12292205	chr6:26970375	C6orf41	-0.56	-12.39	-0.44	9.28e-32	Schizophrenia;
BRCA	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25427524	chr10:38739819	LOC399744	-0.7	-16.96	-0.56	1.56e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11252926	0.797	rs61837235	chr10:489363	G/A	cg18196295	chr10:418757	DIP2C	-0.52	-10.65	-0.39	1.64e-24	Psychosis in Alzheimer's disease;
BRCA	cis	rs2421770	0.530	rs7945809	chr11:35369253	G/A	cg13971030	chr11:35366721	SLC1A2	-0.43	-9.61	-0.36	1.65e-20	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs7178424	0.967	rs11635980	chr15:62370516	T/A	cg00456672	chr15:62358751	C2CD4A	-0.42	-9.49	-0.35	4.67e-20	Height;
BRCA	cis	rs9560113	0.919	rs11069896	chr13:112178887	C/T	cg10483660	chr13:112241077	NA	0.31	7.84	0.3	1.94e-14	Menarche (age at onset);
BRCA	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.35	-0.35	1.46e-19	Bipolar disorder;
BRCA	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg02640540	chr1:67518911	SLC35D1	-0.51	-11.27	-0.41	5.22e-27	Lymphocyte percentage of white cells;
BRCA	cis	rs208520	0.661	rs150263	chr6:66777620	T/C	cg07460842	chr6:66804631	NA	-1.02	-20.25	-0.63	8.29e-71	Exhaled nitric oxide output;
BRCA	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg02544614	chr20:61657117	NA	0.28	7.9	0.3	1.21e-14	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.47	-11.17	-0.4	1.42e-26	IgG glycosylation;
BRCA	cis	rs6882046	0.513	rs35148765	chr5:88046158	C/A	cg22951263	chr5:87985283	NA	-0.38	-10.73	-0.39	7.9e-25	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08280861	chr8:58055591	NA	0.57	8.92	0.33	4.93e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.3	-7.95	-0.3	8.36e-15	Total body bone mineral density;
BRCA	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg00757033	chr12:89920650	WDR51B	0.53	10.7	0.39	1.13e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg07828340	chr4:882639	GAK	1.05	14.37	0.49	8.71e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg03060546	chr3:49711283	APEH	0.6	10.31	0.38	3.56e-23	Menarche (age at onset);
BRCA	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg13628971	chr7:2884303	GNA12	0.4	8.78	0.33	1.44e-17	Height;
BRCA	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04267008	chr7:1944627	MAD1L1	0.59	12.42	0.44	7.36e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg23992470	chr4:843637	GAK	0.49	8.16	0.31	1.72e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.63	-0.53	6.99e-47	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg19628046	chr18:33552617	C18orf21	0.55	10.73	0.39	7.94e-25	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.61	-13.1	-0.46	6.7e-35	Lymphocyte counts;
BRCA	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg07211511	chr3:129823064	LOC729375	-0.82	-15.38	-0.52	1.23e-45	Blood pressure (smoking interaction);
BRCA	cis	rs10501293	0.662	rs7929773	chr11:42999551	C/G	cg03447554	chr11:43094025	NA	-0.41	-7.88	-0.3	1.39e-14	Cognitive performance;
BRCA	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.9	-0.33	5.54e-18	Total body bone mineral density;
BRCA	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg09998033	chr7:158218633	PTPRN2	-0.41	-9.66	-0.36	1.07e-20	Obesity-related traits;
BRCA	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	7.99	0.3	6.27e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3857536	0.740	rs4710572	chr6:66890361	C/A	cg07460842	chr6:66804631	NA	-0.46	-8.85	-0.33	8.46e-18	Blood trace element (Cu levels);
BRCA	cis	rs7903847	0.667	rs7096801	chr10:99140969	T/C	cg20016023	chr10:99160130	RRP12	-0.27	-8.62	-0.32	5.46e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.2	-0.41	1.02e-26	Mean corpuscular volume;
BRCA	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.43	0.35	7.69e-20	Morning vs. evening chronotype;
BRCA	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg06784218	chr1:46089804	CCDC17	0.5	12.02	0.43	3.96e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg11812906	chr14:75593930	NEK9	-0.61	-14.04	-0.49	3.14e-39	Height;
BRCA	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg13047869	chr3:10149882	C3orf24	0.52	11.01	0.4	6.24e-26	Alzheimer's disease;
BRCA	cis	rs13161895	1.000	rs35973843	chr5:179466502	T/C	cg02702477	chr5:179499311	RNF130	0.46	8.53	0.32	1.03e-16	LDL cholesterol;
BRCA	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg26384229	chr12:38710491	ALG10B	0.8	19.69	0.61	7.9e-68	Heart rate;
BRCA	cis	rs10501293	0.917	rs9645617	chr11:43105620	G/A	cg03447554	chr11:43094025	NA	-0.45	-8.49	-0.32	1.49e-16	Cognitive performance;
BRCA	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.43	8.63	0.32	4.86e-17	Huntington's disease progression;
BRCA	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg26031613	chr14:104095156	KLC1	0.73	15.89	0.53	3.64e-48	Body mass index;
BRCA	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg16339924	chr4:17578868	LAP3	-0.57	-13.27	-0.46	1.09e-35	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg12193833	chr17:30244370	NA	-0.58	-8.74	-0.33	2.11e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg19077165	chr18:44547161	KATNAL2	-0.38	-8.27	-0.31	7.83e-16	Educational attainment;
BRCA	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg12573674	chr2:1569213	NA	-0.51	-9.48	-0.35	4.98e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11644478	chr21:40555479	PSMG1	-0.67	-15.22	-0.52	7.43e-45	Cognitive function;
BRCA	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-9.95	-0.37	8.93e-22	Aortic root size;
BRCA	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg08859206	chr1:53392774	SCP2	-0.52	-11.34	-0.41	2.72e-27	Monocyte count;
BRCA	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg06784218	chr1:46089804	CCDC17	0.45	10.8	0.39	4.54e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1003719	0.762	rs9975361	chr21:38450025	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.25	0.49	3.28e-40	Eye color traits;
BRCA	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg03146154	chr1:46216737	IPP	0.48	10.66	0.39	1.52e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	14.83	0.51	5.53e-43	Smoking behavior;
BRCA	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	18.08	0.58	2.44e-59	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9394841	0.667	rs9471653	chr6:41755410	C/G	cg08135965	chr6:41755394	TOMM6	0.5	8.1	0.31	2.87e-15	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg04414720	chr1:150670196	GOLPH3L	0.35	8.07	0.3	3.52e-15	Tonsillectomy;
BRCA	trans	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.3	0.38	3.91e-23	Mean corpuscular volume;
BRCA	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06022373	chr22:39101656	GTPBP1	0.74	16.95	0.56	1.62e-53	Menopause (age at onset);
BRCA	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg01304814	chr3:48885189	PRKAR2A	0.56	7.82	0.3	2.25e-14	Cognitive function;
BRCA	cis	rs12220238	1.000	rs10824125	chr10:75997498	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.49	8.0	0.3	5.7e-15	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.49	0.38	7.52e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.59e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg01283332	chr5:1856932	NA	-0.37	-8.9	-0.33	5.7e-18	Cardiovascular disease risk factors;
BRCA	cis	rs11690935	0.851	rs7581072	chr2:172859849	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.79	-22.99	-0.67	1.04e-85	Schizophrenia;
BRCA	trans	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg25214090	chr10:38739885	LOC399744	0.45	9.99	0.37	6.45e-22	Corneal astigmatism;
BRCA	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.56	10.66	0.39	1.52e-24	HDL cholesterol;
BRCA	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-17.7	-0.57	2.38e-57	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs34779708	0.733	rs7086715	chr10:35541840	A/G	cg03585969	chr10:35415529	CREM	0.45	9.18	0.34	5.96e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4466137	0.953	rs7735476	chr5:83015140	G/C	cg15083037	chr5:83017644	HAPLN1	-0.55	-10.95	-0.4	1.09e-25	Prostate cancer;
BRCA	cis	rs4478858	0.684	rs7521463	chr1:31761936	T/A	cg00250761	chr1:31883323	NA	-0.31	-8.17	-0.31	1.63e-15	Alcohol dependence;
BRCA	cis	rs3857067	0.806	rs7669168	chr4:95104881	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.24	-0.34	3.55e-19	QT interval;
BRCA	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg15704280	chr7:45808275	SEPT13	0.52	8.85	0.33	8.42e-18	Axial length;
BRCA	trans	rs7395662	0.819	rs11039913	chr11:48692081	G/A	cg00717180	chr2:96193071	NA	-0.28	-7.9	-0.3	1.26e-14	HDL cholesterol;
BRCA	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.37	-8.81	-0.33	1.2e-17	Tonsillectomy;
BRCA	trans	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg26384229	chr12:38710491	ALG10B	0.7	15.83	0.53	7.18e-48	Bladder cancer;
BRCA	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.49e-15	Tonsillectomy;
BRCA	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	13.59	0.47	3.9e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg19717773	chr7:2847554	GNA12	-0.45	-9.83	-0.36	2.38e-21	Height;
BRCA	cis	rs61160187	0.503	rs248911	chr5:59847538	T/C	cg02684056	chr5:59996105	DEPDC1B	0.35	8.46	0.32	1.76e-16	Educational attainment (years of education);Educational attainment (college completion);
BRCA	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-9.14	-0.34	8.43e-19	Morning vs. evening chronotype;
BRCA	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-10.06	-0.37	3.39e-22	Heart rate;
BRCA	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.39	8.88	0.33	6.64e-18	Eosinophil percentage of white cells;
BRCA	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg09904177	chr6:26538194	HMGN4	0.56	18.45	0.59	3.08e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg03342759	chr3:160939853	NMD3	-0.56	-11.93	-0.43	9.38e-30	Morning vs. evening chronotype;
BRCA	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.5	0.44	3.09e-32	Electroencephalogram traits;
BRCA	trans	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg26384229	chr12:38710491	ALG10B	0.4	8.6	0.32	6.3e-17	Resting heart rate;
BRCA	cis	rs1018836	0.923	rs9693182	chr8:91621876	T/C	cg16814680	chr8:91681699	NA	-0.6	-12.8	-0.45	1.46e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	trans	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg25214090	chr10:38739885	LOC399744	0.5	11.62	0.42	1.85e-28	Corneal astigmatism;
BRCA	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg05793240	chr7:2802953	GNA12	-0.33	-8.58	-0.32	7.06e-17	Height;
BRCA	cis	rs965469	0.895	rs6051839	chr20:3391191	C/T	cg25506879	chr20:3388711	C20orf194	0.54	10.71	0.39	1e-24	IFN-related cytopenia;
BRCA	cis	rs9287719	0.624	rs10187659	chr2:10726960	C/T	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	5.17e-19	Prostate cancer;
BRCA	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs778371	0.958	rs2675968	chr2:233736244	A/G	cg08000102	chr2:233561755	GIGYF2	0.77	17.17	0.56	1.27e-54	Schizophrenia;
BRCA	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg11814155	chr7:99998594	ZCWPW1	0.49	8.85	0.33	8.6e-18	Platelet count;
BRCA	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg18252515	chr7:66147081	NA	-0.82	-11.96	-0.43	7e-30	Diabetic kidney disease;
BRCA	cis	rs6426558	0.537	rs10799381	chr1:227239746	G/T	cg10327440	chr1:227177885	CDC42BPA	0.49	9.71	0.36	6.74e-21	Neutrophil percentage of white cells;
BRCA	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg17063962	chr7:91808500	NA	0.61	14.46	0.5	3.48e-41	Breast cancer;
BRCA	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg26446133	chr18:72167187	CNDP2	-0.73	-12.98	-0.46	2.35e-34	Refractive error;
BRCA	cis	rs3857536	0.704	rs4710570	chr6:66890244	A/G	cg07460842	chr6:66804631	NA	-0.46	-8.86	-0.33	8.01e-18	Blood trace element (Cu levels);
BRCA	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg14863265	chr7:2801509	GNA12	-0.43	-9.31	-0.35	1.96e-19	Height;
BRCA	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg03342759	chr3:160939853	NMD3	-0.54	-11.72	-0.42	7.11e-29	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg25214090	chr10:38739885	LOC399744	0.53	11.71	0.42	7.51e-29	Corneal astigmatism;
BRCA	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.17	-0.31	1.67e-15	Depression;
BRCA	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg18402987	chr7:1209562	NA	0.72	12.6	0.45	1.16e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg08885076	chr2:99613938	TSGA10	0.41	9.63	0.36	1.4e-20	Chronic sinus infection;
BRCA	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg03433033	chr1:76189801	ACADM	0.62	11.52	0.41	5.05e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.67	10.46	0.38	9.82e-24	Schizophrenia;
BRCA	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg09307838	chr4:120376055	NA	0.64	14.0	0.48	4.78e-39	Corneal astigmatism;
BRCA	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.32	-0.38	3.48e-23	Psoriasis;
BRCA	cis	rs7635838	0.654	rs164101	chr3:11281082	G/A	cg00170343	chr3:11313890	ATG7	0.45	8.67	0.32	3.51e-17	HDL cholesterol;
BRCA	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg00071950	chr4:10020882	SLC2A9	0.65	16.37	0.54	1.48e-50	Bone mineral density;
BRCA	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	7.15e-19	Alzheimer's disease (late onset);
BRCA	cis	rs2992756	0.663	rs1360919	chr1:18805844	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.41	-8.39	-0.32	3.03e-16	Breast cancer;
BRCA	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg16482183	chr6:26056742	HIST1H1C	0.45	8.76	0.33	1.81e-17	Iron status biomarkers;
BRCA	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-10.45	-0.38	1.06e-23	Reticulocyte count;
BRCA	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	14.77	0.5	1.09e-42	Platelet count;
BRCA	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg23711669	chr6:146136114	FBXO30	0.79	18.97	0.6	5.75e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	12.35	0.44	1.39e-31	Hip circumference adjusted for BMI;
BRCA	trans	rs2270927	0.510	rs6453213	chr5:75579518	A/G	cg13563193	chr19:33072644	PDCD5	0.88	11.25	0.41	6.55e-27	Mean corpuscular volume;
BRCA	cis	rs2070433	0.539	rs1008548	chr21:47959692	G/A	cg12379764	chr21:47803548	PCNT	0.59	12.08	0.43	2.15e-30	Lymphocyte counts;
BRCA	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	10.89	0.4	1.95e-25	Height;
BRCA	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.9	-0.33	5.58e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg13319975	chr6:146136371	FBXO30	0.43	10.13	0.37	1.8e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg08085267	chr17:45401833	C17orf57	-0.69	-15.2	-0.52	9.32e-45	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.77	0.39	5.6e-25	Bipolar disorder;
BRCA	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.07	-0.4	3.38e-26	Schizophrenia;
BRCA	cis	rs6545883	0.868	rs2441381	chr2:61798829	C/T	cg15711740	chr2:61764176	XPO1	-0.54	-13.45	-0.47	1.64e-36	Tuberculosis;
BRCA	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg13319975	chr6:146136371	FBXO30	-0.34	-8.03	-0.3	4.85e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg15704280	chr7:45808275	SEPT13	0.52	8.91	0.33	5.21e-18	Axial length;
BRCA	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg18753928	chr3:113234510	CCDC52	-0.5	-9.42	-0.35	8.42e-20	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs4285028	0.747	rs7648340	chr3:121426188	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-13.97	-0.48	6.66e-39	Multiple sclerosis;
BRCA	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.19	0.34	5.39e-19	Tonsillectomy;
BRCA	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg22105103	chr4:187893119	NA	0.34	11.01	0.4	5.96e-26	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg06115741	chr20:33292138	TP53INP2	0.36	8.29	0.31	6.45e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs965469	1.000	rs2236092	chr20:3258188	G/C	cg25506879	chr20:3388711	C20orf194	-0.55	-10.79	-0.39	4.55e-25	IFN-related cytopenia;
BRCA	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg05868516	chr6:26286170	HIST1H4H	0.5	11.25	0.41	6.6e-27	Educational attainment;
BRCA	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg26384229	chr12:38710491	ALG10B	0.51	13.55	0.47	5.99e-37	Morning vs. evening chronotype;
BRCA	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg05279229	chr7:1896384	MAD1L1	-0.4	-7.98	-0.3	6.89e-15	Schizophrenia;
BRCA	trans	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg20935933	chr6:143382018	AIG1	0.6	11.57	0.42	3.18e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs11088226	0.681	rs4547609	chr21:33953542	G/A	cg09050820	chr6:167586206	TCP10L2	0.86	14.75	0.5	1.41e-42	Gastritis;
BRCA	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg16506815	chr2:162101123	NA	0.41	8.64	0.32	4.55e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	13.86	0.48	2.1e-38	Multiple sclerosis;
BRCA	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg13010199	chr12:38710504	ALG10B	-0.35	-8.41	-0.32	2.64e-16	Morning vs. evening chronotype;
BRCA	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg16482183	chr6:26056742	HIST1H1C	0.46	8.88	0.33	6.81e-18	Iron status biomarkers;
BRCA	cis	rs17767294	0.708	rs72848754	chr6:27878458	T/A	cg08851530	chr6:28072375	NA	0.92	8.91	0.33	5.15e-18	Parkinson's disease;
BRCA	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg17143192	chr8:8559678	CLDN23	0.54	10.38	0.38	1.95e-23	Obesity-related traits;
BRCA	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03264133	chr6:25882463	NA	-0.55	-12.86	-0.45	7.7e-34	Blood metabolite levels;
BRCA	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg18806716	chr10:30721971	MAP3K8	-0.42	-10.09	-0.37	2.53e-22	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	8.05	0.3	4e-15	Menarche (age at onset);
BRCA	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18876405	chr7:65276391	NA	0.48	10.77	0.39	5.54e-25	Aortic root size;
BRCA	cis	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.75	-0.33	1.96e-17	Resting heart rate;
BRCA	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg09640425	chr7:158790006	NA	-0.37	-7.81	-0.3	2.34e-14	Facial morphology (factor 20);
BRCA	cis	rs10501293	0.956	rs12361827	chr11:43137261	T/C	cg03447554	chr11:43094025	NA	-0.46	-8.05	-0.3	4.16e-15	Cognitive performance;
BRCA	cis	rs17384381	0.953	rs12120551	chr1:85810903	T/C	cg16011679	chr1:85725395	C1orf52	0.53	7.99	0.3	6.48e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-9.4	-0.35	9.47e-20	Menopause (age at onset);
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg00024416	chr22:24240387	NA	-0.33	-8.24	-0.31	9.87e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7809950	0.953	rs2253271	chr7:107201252	G/C	cg23024343	chr7:107201750	COG5	-0.38	-8.82	-0.33	1.11e-17	Coronary artery disease;
BRCA	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg20503657	chr10:835505	NA	0.86	15.72	0.53	2.53e-47	Eosinophil percentage of granulocytes;
BRCA	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg26384229	chr12:38710491	ALG10B	0.58	13.16	0.46	3.41e-35	Morning vs. evening chronotype;
BRCA	cis	rs7917772	0.604	rs11191358	chr10:104399250	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.38	-10.18	-0.37	1.18e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9287719	0.639	rs2357649	chr2:10696788	C/T	cg00105475	chr2:10696890	NA	-0.54	-13.32	-0.47	6.72e-36	Prostate cancer;
BRCA	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg26248373	chr2:1572462	NA	-0.47	-9.29	-0.34	2.48e-19	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs2387326	0.717	rs10829340	chr10:129943941	G/T	cg16087940	chr10:129947807	NA	-0.45	-8.01	-0.3	5.47e-15	Select biomarker traits;
BRCA	trans	rs60843830	0.550	rs300751	chr2:209063	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.39	8.42	0.32	2.41e-16	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg17366294	chr4:99064904	C4orf37	0.54	11.67	0.42	1.15e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2276314	0.600	rs28729782	chr18:33590529	A/G	cg05985134	chr18:33552581	C18orf21	0.42	7.88	0.3	1.38e-14	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs7707921	0.881	rs112355050	chr5:81386035	C/T	cg15871215	chr5:81402204	ATG10	-0.39	-8.22	-0.31	1.17e-15	Breast cancer;
BRCA	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg11822812	chr5:140052017	DND1	-0.31	-8.4	-0.32	2.85e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6867032	1.000	rs4254943	chr5:2009878	C/T	cg26168224	chr5:2018326	NA	0.63	16.88	0.56	3.83e-53	Gut microbiome composition (winter);
BRCA	cis	rs6546550	0.901	rs6716937	chr2:70127229	G/A	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.62	-0.42	1.89e-28	Prevalent atrial fibrillation;
BRCA	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18876405	chr7:65276391	NA	-0.5	-11.04	-0.4	4.78e-26	Aortic root size;
BRCA	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg02951883	chr7:2050386	MAD1L1	0.51	11.56	0.42	3.23e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg23649088	chr2:200775458	C2orf69	-0.48	-8.06	-0.3	3.74e-15	Schizophrenia;
BRCA	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg00530320	chr1:46809349	NSUN4	0.49	9.76	0.36	4.52e-21	Menopause (age at onset);
BRCA	cis	rs11622475	1.000	rs7143682	chr14:104413455	C/T	cg12183467	chr14:104352244	NA	-0.52	-10.76	-0.39	6.39e-25	Bipolar disorder;
BRCA	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg24562669	chr7:97807699	LMTK2	0.45	12.03	0.43	3.38e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7131987	0.834	rs11050167	chr12:29426387	C/T	cg09582351	chr12:29534625	ERGIC2	-0.5	-11.31	-0.41	3.63e-27	QT interval;
BRCA	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	10.64	0.39	1.86e-24	Retinal vascular caliber;
BRCA	cis	rs6495367	0.898	rs2049176	chr15:79392548	A/C	cg17916960	chr15:79447300	NA	0.39	9.38	0.35	1.18e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6580649	0.943	rs1990029	chr12:48407987	C/T	cg24011408	chr12:48396354	COL2A1	0.53	8.65	0.32	4.18e-17	Lung cancer;
BRCA	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg26384229	chr12:38710491	ALG10B	0.74	17.02	0.56	7.3e-54	Bladder cancer;
BRCA	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg05313129	chr8:58192883	C8orf71	-0.36	-8.11	-0.31	2.67e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg08000102	chr2:233561755	GIGYF2	0.62	13.66	0.48	1.78e-37	Coronary artery disease;
BRCA	cis	rs2279817	0.818	rs867984	chr1:17982559	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.49	-11.23	-0.41	8.05e-27	Neuroticism;
BRCA	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg13319975	chr6:146136371	FBXO30	0.42	9.47	0.35	5.14e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.71	-0.57	2.04e-57	Chronic sinus infection;
BRCA	cis	rs754466	0.651	rs10824582	chr10:79603688	T/C	cg17075019	chr10:79541650	NA	-0.74	-17.7	-0.57	2.44e-57	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg25517755	chr10:38738941	LOC399744	-0.37	-7.86	-0.3	1.66e-14	Corneal astigmatism;
BRCA	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg23933602	chr10:16859644	RSU1	0.54	8.62	0.32	5.13e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg11764359	chr7:65958608	NA	0.64	10.9	0.4	1.8e-25	Aortic root size;
BRCA	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	11.87	0.43	1.61e-29	Lung cancer in ever smokers;
BRCA	cis	rs5753618	0.583	rs5753639	chr22:31870400	A/G	cg02404636	chr22:31891804	SFI1	-0.41	-9.25	-0.34	3.39e-19	Colorectal cancer;
BRCA	cis	rs6847149	0.929	rs6839680	chr4:110765496	A/G	cg07850274	chr4:110748770	RRH	-0.44	-8.59	-0.32	6.86e-17	Exercise treadmill test traits;
BRCA	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg12564285	chr5:131593104	PDLIM4	0.34	7.9	0.3	1.22e-14	Breast cancer;
BRCA	cis	rs897080	0.515	rs1067398	chr2:44678882	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.53	0.35	3.35e-20	Height;
BRCA	cis	rs6121246	0.559	rs1062794	chr20:30381758	G/C	cg21427119	chr20:30132790	HM13	-0.34	-7.82	-0.3	2.19e-14	Mean corpuscular hemoglobin;
BRCA	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg17063962	chr7:91808500	NA	0.53	12.11	0.43	1.56e-30	Breast cancer;
BRCA	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg20203395	chr5:56204925	C5orf35	-0.49	-10.12	-0.37	2.06e-22	Initial pursuit acceleration;
BRCA	cis	rs2731664	0.792	rs1130857	chr5:176863519	G/C	cg23176889	chr5:176863531	GRK6	-0.61	-16.6	-0.55	1.04e-51	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg17971929	chr21:40555470	PSMG1	0.8	18.6	0.59	4.88e-62	Cognitive function;
BRCA	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg13902645	chr11:5959945	NA	-0.48	-10.15	-0.37	1.59e-22	DNA methylation (variation);
BRCA	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.08	0.49	2.02e-39	Motion sickness;
BRCA	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg13256891	chr4:100009986	ADH5	-0.39	-9.24	-0.34	3.48e-19	Alcohol dependence;
BRCA	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-13.71	-0.48	1.11e-37	Migraine;Coronary artery disease;
BRCA	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg20476274	chr7:133979776	SLC35B4	0.7	21.43	0.65	3.4e-77	Mean platelet volume;
BRCA	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg09060608	chr5:178986726	RUFY1	-0.55	-14.03	-0.49	3.52e-39	Lung cancer;
BRCA	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg26116260	chr4:7069785	GRPEL1	-0.89	-19.09	-0.6	1.19e-64	Monocyte percentage of white cells;
BRCA	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg27284194	chr4:1044797	NA	0.69	15.96	0.53	1.66e-48	Recombination rate (males);
BRCA	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	9.13	0.34	8.92e-19	Systemic lupus erythematosus;
BRCA	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg18230493	chr5:56204884	C5orf35	-0.73	-14.77	-0.5	1.05e-42	Initial pursuit acceleration;
BRCA	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg24692254	chr21:30365293	RNF160	0.47	10.47	0.38	9.11e-24	Pancreatic cancer;
BRCA	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg12310025	chr6:25882481	NA	-0.55	-13.08	-0.46	8.48e-35	Blood metabolite levels;
BRCA	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg06784218	chr1:46089804	CCDC17	0.45	10.67	0.39	1.38e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg26597838	chr10:835615	NA	1.0	17.7	0.57	2.54e-57	Eosinophil percentage of granulocytes;
BRCA	cis	rs1997103	1.000	rs11238364	chr7:55407632	G/T	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4853036	0.951	rs6738783	chr2:70120608	A/G	cg02498382	chr2:70120550	SNRNP27	-0.56	-10.16	-0.37	1.4e-22	Colorectal or endometrial cancer;
BRCA	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.87	0.36	1.78e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11955398	0.585	rs4447941	chr5:60022211	A/G	cg02684056	chr5:59996105	DEPDC1B	-0.38	-9.13	-0.34	8.56e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg07741184	chr6:167504864	NA	0.33	9.87	0.36	1.79e-21	Primary biliary cholangitis;
BRCA	cis	rs4363385	0.747	rs946098	chr1:152975038	A/C	cg25856811	chr1:152973957	SPRR3	-0.34	-9.07	-0.34	1.48e-18	Inflammatory skin disease;
BRCA	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-9.0	-0.34	2.53e-18	Alzheimer's disease (late onset);
BRCA	cis	rs6750047	0.747	rs2116229	chr2:38270490	G/T	cg07380506	chr2:38303506	CYP1B1	0.43	9.65	0.36	1.16e-20	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.56	-0.32	8.43e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4561483	0.801	rs33640	chr16:11986874	C/T	cg08843971	chr16:11963173	GSPT1	-0.53	-12.06	-0.43	2.5e-30	Testicular germ cell tumor;
BRCA	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg08888203	chr3:10149979	C3orf24	0.6	12.32	0.44	1.92e-31	Alzheimer's disease;
BRCA	cis	rs6604026	0.671	rs6697543	chr1:93312295	C/A	cg17283838	chr1:93427260	FAM69A	-0.39	-8.14	-0.31	2.07e-15	Multiple sclerosis;
BRCA	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg10862848	chr6:42927986	GNMT	0.38	15.57	0.52	1.4e-46	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg00277334	chr10:82204260	NA	-0.85	-24.58	-0.7	2.14e-94	Post bronchodilator FEV1;
BRCA	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg13880726	chr7:1868755	MAD1L1	0.53	10.48	0.38	8.16e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg24848339	chr3:12840334	CAND2	0.48	12.7	0.45	4.22e-33	QRS complex (12-leadsum);
BRCA	cis	rs490234	0.812	rs10121109	chr9:128455206	C/A	cg14078157	chr9:128172775	NA	-0.43	-9.68	-0.36	9.03e-21	Mean arterial pressure;
BRCA	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9400271	0.632	rs9372205	chr6:109588401	A/T	cg21918786	chr6:109611834	NA	-0.32	-8.1	-0.31	2.73e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.6	-0.32	6.38e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg03354898	chr7:1950403	MAD1L1	-0.39	-8.44	-0.32	2.07e-16	Schizophrenia;
BRCA	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg15556689	chr8:8085844	FLJ10661	0.38	10.7	0.39	1.11e-24	Mood instability;
BRCA	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-14.87	-0.51	3.65e-43	Total cholesterol levels;
BRCA	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg12564285	chr5:131593104	PDLIM4	0.43	11.04	0.4	4.77e-26	Acylcarnitine levels;
BRCA	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg18132916	chr6:79620363	NA	-0.39	-7.83	-0.3	2.07e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.49	-0.32	1.4e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs208520	1.000	rs208520	chr6:66952828	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-13.59	-0.47	3.96e-37	Exhaled nitric oxide output;
BRCA	trans	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg15556689	chr8:8085844	FLJ10661	0.34	9.11	0.34	1.04e-18	Retinal vascular caliber;
BRCA	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg05552183	chr6:42928497	GNMT	0.8	19.52	0.61	6.96e-67	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg12062639	chr20:23401060	NAPB	0.8	11.49	0.41	6.31e-28	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.41	-0.32	2.72e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg06238570	chr21:40685208	BRWD1	0.44	9.0	0.34	2.62e-18	Cognitive function;
BRCA	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.66	-9.71	-0.36	7.17e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs3849570	1.000	rs13088000	chr3:81839404	T/C	cg07356753	chr3:81810745	GBE1	-0.48	-11.52	-0.41	4.74e-28	Waist circumference;Body mass index;
BRCA	trans	rs6076960	0.682	rs6054065	chr20:6267920	G/A	cg21095983	chr6:86352623	SYNCRIP	0.37	8.37	0.31	3.56e-16	Smooth-surface caries;
BRCA	cis	rs2882667	0.654	rs884470	chr5:138155925	A/G	cg04439458	chr5:138467593	SIL1	0.32	8.09	0.3	3.06e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs72772090	0.539	rs72773932	chr5:96118148	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.18	-0.43	7.64e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg10223061	chr2:219282414	VIL1	-0.27	-8.1	-0.31	2.71e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6005807	0.719	rs12167434	chr22:29040821	C/T	cg12565055	chr22:29076175	TTC28	0.5	9.36	0.35	1.32e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26314531	chr2:26401878	FAM59B	-0.89	-15.65	-0.53	5.44e-47	Gut microbiome composition (summer);
BRCA	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg19052272	chr2:3704530	ALLC	-0.45	-10.09	-0.37	2.64e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg04553112	chr3:125709451	NA	-0.55	-8.44	-0.32	2.1e-16	Blood pressure (smoking interaction);
BRCA	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.86	-18.97	-0.6	5.27e-64	Cognitive ability;
BRCA	cis	rs7851660	1.000	rs7851660	chr9:100610759	C/A	cg13688889	chr9:100608707	NA	-0.36	-8.69	-0.32	3.12e-17	Strep throat;
BRCA	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg21427119	chr20:30132790	HM13	-0.44	-9.12	-0.34	9.32e-19	Mean corpuscular hemoglobin;
BRCA	cis	rs6087990	0.806	rs910084	chr20:31379665	C/T	cg13636640	chr20:31349939	DNMT3B	0.58	17.36	0.57	1.35e-55	Ulcerative colitis;
BRCA	trans	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	16.05	0.54	5.75e-49	Exhaled nitric oxide levels;
BRCA	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg16049864	chr8:95962084	TP53INP1	0.48	10.68	0.39	1.33e-24	Type 2 diabetes;
BRCA	cis	rs795544	0.580	rs7709692	chr5:13789420	T/C	cg07548982	chr5:13769939	DNAH5	-0.4	-8.41	-0.32	2.62e-16	Corneal astigmatism;
BRCA	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg27478167	chr7:817139	HEATR2	-0.44	-9.41	-0.35	8.63e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg15839431	chr19:19639596	YJEFN3	0.35	8.19	0.31	1.42e-15	Bipolar disorder;
BRCA	cis	rs4742903	0.509	rs10991124	chr9:106917475	A/T	cg14250997	chr9:106856677	SMC2	0.27	8.17	0.31	1.64e-15	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg00383909	chr3:49044727	WDR6	0.58	11.06	0.4	4.06e-26	Cognitive function;
BRCA	cis	rs877282	0.533	rs10904565	chr10:819991	G/T	cg15764593	chr10:829463	NA	-0.63	-10.29	-0.38	4.47e-23	Uric acid levels;
BRCA	cis	rs2014572	0.967	rs7248000	chr19:57762139	C/T	cg24459738	chr19:57751996	ZNF805	-0.38	-8.86	-0.33	7.95e-18	Hyperactive-impulsive symptoms;
BRCA	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg05985134	chr18:33552581	C18orf21	0.65	11.68	0.42	1.01e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs6495367	0.966	rs745029	chr15:79381779	C/T	cg17916960	chr15:79447300	NA	0.38	8.95	0.33	3.86e-18	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg13010199	chr12:38710504	ALG10B	0.49	9.51	0.35	3.84e-20	Morning vs. evening chronotype;
BRCA	cis	rs7818345	1.000	rs7835461	chr8:19307051	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.07	0.3	3.58e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22509189	chr2:225307070	NA	-0.46	-9.91	-0.37	1.21e-21	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg06627628	chr2:24431161	ITSN2	0.41	8.45	0.32	1.93e-16	Asthma;
BRCA	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.21	-0.34	4.78e-19	Menopause (age at onset);
BRCA	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg15704280	chr7:45808275	SEPT13	0.53	8.97	0.33	3.33e-18	Axial length;
BRCA	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg18402987	chr7:1209562	NA	0.43	8.17	0.31	1.65e-15	Longevity;Endometriosis;
BRCA	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.13	-0.34	9.13e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg23696834	chr6:42928345	GNMT	-0.26	-7.86	-0.3	1.65e-14	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4727443	0.899	rs6954978	chr7:99582212	A/G	cg22004693	chr7:99632812	ZKSCAN1	0.37	8.31	0.31	5.67e-16	Interstitial lung disease;
BRCA	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.69	-16.07	-0.54	4.42e-49	Axial length;
BRCA	cis	rs2387326	0.717	rs10829343	chr10:129944496	T/C	cg16087940	chr10:129947807	NA	-0.46	-8.1	-0.31	2.82e-15	Select biomarker traits;
BRCA	cis	rs360798	0.512	rs6739804	chr2:63269604	T/C	cg17519650	chr2:63277830	OTX1	0.47	10.47	0.38	8.94e-24	Coronary artery disease;
BRCA	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg06060754	chr5:176797920	RGS14	0.79	14.16	0.49	8.75e-40	Urinary electrolytes (magnesium/calcium ratio);
BRCA	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg03146154	chr1:46216737	IPP	0.46	10.32	0.38	3.49e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg24642844	chr7:1081250	C7orf50	-0.61	-12.29	-0.44	2.51e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs870825	0.872	rs12507711	chr4:185571776	C/T	cg04058563	chr4:185651563	MLF1IP	0.68	11.86	0.42	1.8e-29	Blood protein levels;
BRCA	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg13385794	chr1:248469461	NA	0.28	8.01	0.3	5.61e-15	Common traits (Other);
BRCA	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg24130564	chr14:104152367	KLC1	0.35	7.95	0.3	8.76e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7598759	0.679	rs6437019	chr2:232327707	T/C	cg19187155	chr2:232395269	NMUR1	0.37	7.92	0.3	1.04e-14	Noise-induced hearing loss;
BRCA	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11905131	chr22:24372483	LOC391322	-0.53	-12.13	-0.43	1.25e-30	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.61	-0.32	5.91e-17	Monocyte percentage of white cells;
BRCA	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.58	9.55	0.35	2.75e-20	Lung function (FEV1/FVC);
BRCA	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg12379764	chr21:47803548	PCNT	-0.39	-8.46	-0.32	1.79e-16	Testicular germ cell tumor;
BRCA	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.49	0.65	1.55e-77	Lymphocyte percentage of white cells;
BRCA	cis	rs6087990	0.735	rs2424915	chr20:31378448	C/T	cg13636640	chr20:31349939	DNMT3B	0.56	16.24	0.54	6.62e-50	Ulcerative colitis;
BRCA	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg05347473	chr6:146136440	FBXO30	0.42	8.39	0.32	3.02e-16	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs36096196	0.891	rs12081179	chr1:2251119	A/G	cg18313694	chr15:45480185	SHF	0.46	8.83	0.33	1.01e-17	Coronary artery disease;
BRCA	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg11833968	chr6:79620685	NA	-0.41	-9.26	-0.34	3.12e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg06808227	chr14:105710500	BRF1	-0.8	-15.89	-0.53	3.55e-48	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg06453172	chr10:134556979	INPP5A	-0.61	-11.94	-0.43	7.95e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg16339924	chr4:17578868	LAP3	0.62	15.38	0.52	1.21e-45	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13126279	chr21:47581558	C21orf56	0.5	10.89	0.4	1.89e-25	Testicular germ cell tumor;
BRCA	cis	rs7617773	0.817	rs745116	chr3:48272536	T/G	cg11946769	chr3:48343235	NME6	0.62	13.5	0.47	1e-36	Coronary artery disease;
BRCA	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg19622623	chr12:86230825	RASSF9	-0.33	-9.32	-0.35	1.83e-19	Major depressive disorder;
BRCA	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.63	-13.5	-0.47	1.03e-36	Lung cancer;
BRCA	trans	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg11693508	chr17:37793320	STARD3	0.6	11.05	0.4	4.11e-26	Bipolar disorder;
BRCA	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-9.99	-0.37	6.44e-22	Aortic root size;
BRCA	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg07148914	chr20:33460835	GGT7	-0.44	-8.87	-0.33	7.41e-18	Glomerular filtration rate (creatinine);
BRCA	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-11.48	-0.41	6.92e-28	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	trans	rs3857536	0.813	rs7743965	chr6:66941346	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.3	0.54	3.15e-50	Colorectal cancer;
BRCA	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.54e-19	Morning vs. evening chronotype;
BRCA	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg11502198	chr6:26597334	ABT1	0.48	9.62	0.36	1.45e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg16339924	chr4:17578868	LAP3	0.57	14.0	0.48	5.14e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg14440974	chr22:39074834	NA	-0.38	-9.13	-0.34	8.96e-19	Menopause (age at onset);
BRCA	trans	rs1422110	0.681	rs35625401	chr5:85465408	G/A	cg01787110	chr1:109008453	NBPF6	0.46	9.2	0.34	4.92e-19	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg17747265	chr1:1875780	NA	0.37	9.42	0.35	8.15e-20	Body mass index;
BRCA	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.96	0.4	1.01e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg26384229	chr12:38710491	ALG10B	0.6	13.83	0.48	3.13e-38	Morning vs. evening chronotype;
BRCA	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg14558114	chr2:88469736	THNSL2	-0.41	-8.96	-0.33	3.62e-18	Response to metformin (IC50);
BRCA	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg21782813	chr7:2030301	MAD1L1	0.42	12.03	0.43	3.28e-30	Bipolar disorder and schizophrenia;
BRCA	cis	rs2120243	0.874	rs7616177	chr3:157153208	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	9.55	0.35	2.66e-20	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs897080	0.552	rs1068714	chr2:44634063	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.39	0.35	1.04e-19	Height;
BRCA	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg26248373	chr2:1572462	NA	-0.52	-10.2	-0.37	9.55e-23	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg07460842	chr6:66804631	NA	-0.54	-9.86	-0.36	1.92e-21	Blood trace element (Cu levels);
BRCA	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.18e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6120849	0.950	rs6088732	chr20:33744134	A/G	cg24642439	chr20:33292090	TP53INP2	-0.47	-8.45	-0.32	1.98e-16	Protein C levels;
BRCA	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg20908204	chr19:46285434	DMPK	-0.27	-7.92	-0.3	1.07e-14	Coronary artery disease;
BRCA	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg10818794	chr15:86012489	AKAP13	-0.31	-8.66	-0.32	3.96e-17	Coronary artery disease;
BRCA	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg03477792	chr4:77819574	ANKRD56	0.64	15.41	0.52	8.45e-46	Emphysema distribution in smoking;
BRCA	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg13256891	chr4:100009986	ADH5	0.47	9.06	0.34	1.52e-18	Alcohol dependence;
BRCA	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg01939980	chr4:1354348	KIAA1530	0.38	10.28	0.38	5.02e-23	Longevity;
BRCA	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg00686598	chr14:53173677	PSMC6	1.25	16.37	0.54	1.43e-50	Alzheimer's disease (late onset);
BRCA	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg05535760	chr7:792225	HEATR2	0.73	13.12	0.46	5.7e-35	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1371614	0.635	rs6706127	chr2:27140741	C/T	cg00617064	chr2:27272375	NA	0.3	7.88	0.3	1.41e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg13397359	chr6:42928475	GNMT	0.82	22.36	0.66	3.02e-82	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs198389	0.589	rs12404124	chr1:11873869	A/C	cg24844545	chr1:11908347	NPPA	-0.33	-8.79	-0.33	1.36e-17	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
BRCA	cis	rs2249625	0.523	rs2496552	chr6:72853042	T/C	cg18830697	chr6:72922368	RIMS1	-0.51	-11.32	-0.41	3.36e-27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg05347473	chr6:146136440	FBXO30	-0.41	-8.06	-0.3	3.75e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7638995	0.878	rs17005384	chr3:69181552	A/G	cg26574240	chr3:69171822	LMOD3	0.44	8.26	0.31	8.45e-16	Alzheimer's disease (late onset);
BRCA	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg00631329	chr6:26305371	NA	-0.51	-13.56	-0.47	5.18e-37	Mosquito bite size;
BRCA	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.71	16.82	0.55	7.74e-53	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg22307297	chr20:60903441	LAMA5	0.34	9.35	0.35	1.42e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg26536863	chr7:158807979	LOC154822	0.35	8.04	0.3	4.49e-15	Facial morphology (factor 20);
BRCA	cis	rs6088813	1.000	rs6142360	chr20:33960486	T/C	cg14752227	chr20:34000481	UQCC	-0.39	-7.96	-0.3	7.9e-15	Height;
BRCA	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg02659138	chr7:134003124	SLC35B4	0.32	9.49	0.35	4.53e-20	Mean platelet volume;
BRCA	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-10.45	-0.38	1.09e-23	Schizophrenia;
BRCA	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg13073564	chr4:8508604	NA	0.39	10.48	0.38	8.21e-24	Response to antineoplastic agents;
BRCA	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg22875332	chr1:76189707	ACADM	0.79	19.31	0.61	8.43e-66	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg22920501	chr2:26401640	FAM59B	0.96	16.92	0.56	2.42e-53	Gut microbiome composition (summer);
BRCA	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg20991723	chr1:152506922	NA	0.37	8.23	0.31	1.06e-15	Hair morphology;
BRCA	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg01206211	chr2:36825736	FEZ2	-0.4	-9.87	-0.36	1.83e-21	Height;
BRCA	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg13010199	chr12:38710504	ALG10B	-0.47	-9.43	-0.35	7.25e-20	Morning vs. evening chronotype;
BRCA	cis	rs7246657	0.663	rs4803276	chr19:38072330	C/A	cg18154014	chr19:37997991	ZNF793	0.49	9.24	0.34	3.49e-19	Coronary artery calcification;
BRCA	cis	rs2625529	0.824	rs35167572	chr15:72378960	A/G	cg16672083	chr15:72433130	SENP8	-0.84	-17.56	-0.57	1.29e-56	Red blood cell count;
BRCA	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg05863683	chr7:1912471	MAD1L1	0.34	7.86	0.3	1.63e-14	Schizophrenia;
BRCA	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg25036284	chr2:26402008	FAM59B	-0.64	-10.63	-0.39	2.11e-24	Gut microbiome composition (summer);
BRCA	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.57	-12.68	-0.45	5.12e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.37	0.57	1.19e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	8.22	0.31	1.18e-15	Personality dimensions;
BRCA	cis	rs9341808	0.754	rs10733162	chr6:81023389	G/A	cg08355045	chr6:80787529	NA	0.36	9.25	0.34	3.37e-19	Sitting height ratio;
BRCA	cis	rs7789940	0.904	rs7459185	chr7:75934640	C/G	cg10167463	chr7:75959203	YWHAG	0.39	7.94	0.3	9.29e-15	Multiple sclerosis;
BRCA	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	19.2	0.6	3.37e-65	Platelet count;
BRCA	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg25237894	chr2:233734115	C2orf82	0.31	8.82	0.33	1.06e-17	Coronary artery disease;
BRCA	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.57	-0.39	3.69e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg12193833	chr17:30244370	NA	-0.54	-8.61	-0.32	5.56e-17	Hip circumference adjusted for BMI;
BRCA	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	10.61	0.39	2.44e-24	Retinal vascular caliber;
BRCA	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.06e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg04518342	chr5:131593106	PDLIM4	0.4	9.08	0.34	1.35e-18	Acylcarnitine levels;
BRCA	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.56	8.23	0.31	1.01e-15	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg06627628	chr2:24431161	ITSN2	-0.65	-12.6	-0.45	1.1e-32	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-12.11	-0.43	1.62e-30	Mood instability;
BRCA	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.59	9.97	0.37	7.44e-22	Lung function (FEV1/FVC);
BRCA	cis	rs10465746	0.846	rs9700285	chr1:84336685	G/A	cg10977910	chr1:84465055	TTLL7	0.5	10.0	0.37	5.83e-22	Obesity-related traits;
BRCA	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg07741184	chr6:167504864	NA	-0.32	-9.55	-0.35	2.64e-20	Primary biliary cholangitis;
BRCA	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.02e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs698833	0.852	rs4953089	chr2:44565024	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	10.76	0.39	6.5e-25	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg18811423	chr2:55921094	PNPT1	0.71	22.36	0.66	3.18e-82	Metabolic syndrome;
BRCA	cis	rs60843830	0.661	rs11674477	chr2:105822	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.46	8.17	0.31	1.61e-15	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.69	-15.4	-0.52	1.02e-45	Breast cancer;
BRCA	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg03146154	chr1:46216737	IPP	0.46	10.12	0.37	2e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06108461	chr20:60628389	TAF4	-0.69	-14.26	-0.49	2.84e-40	Body mass index;
BRCA	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg05340658	chr4:99064831	C4orf37	0.61	14.44	0.5	3.99e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs55883249	1.000	rs10495571	chr2:9736066	A/G	cg23886495	chr2:9695866	ADAM17	0.54	8.01	0.3	5.55e-15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
BRCA	cis	rs4363385	0.818	rs406350	chr1:153007492	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs698813	0.604	rs7606004	chr2:44479983	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	8.42	0.32	2.39e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs8028182	0.549	rs56395816	chr15:75664571	A/T	cg25207952	chr15:75499952	C15orf39	-0.32	-7.9	-0.3	1.21e-14	Sudden cardiac arrest;
BRCA	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg03060546	chr3:49711283	APEH	0.47	10.04	0.37	4.06e-22	Resting heart rate;
BRCA	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg06212747	chr3:49208901	KLHDC8B	0.47	9.65	0.36	1.14e-20	Parkinson's disease;
BRCA	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg06637938	chr14:75390232	RPS6KL1	0.58	11.55	0.42	3.86e-28	Caffeine consumption;
BRCA	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg12365402	chr11:9010492	NRIP3	-0.38	-7.96	-0.3	7.78e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg24812749	chr6:127587940	RNF146	0.89	20.79	0.64	9.64e-74	Breast cancer;
BRCA	trans	rs2018683	0.707	rs2057957	chr7:28974626	A/C	cg19402173	chr7:128379420	CALU	0.42	9.97	0.37	7.63e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg23029597	chr12:123009494	RSRC2	-0.49	-9.92	-0.37	1.17e-21	Body mass index;
BRCA	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg08000102	chr2:233561755	GIGYF2	-0.45	-9.73	-0.36	5.74e-21	Coronary artery disease;
BRCA	cis	rs12618769	0.597	rs10199199	chr2:99061834	T/C	cg10123293	chr2:99228465	UNC50	0.42	8.42	0.32	2.51e-16	Bipolar disorder;
BRCA	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg02659138	chr7:134003124	SLC35B4	0.33	10.34	0.38	2.74e-23	Mean platelet volume;
BRCA	cis	rs701145	0.585	rs1727948	chr3:153876929	G/T	cg17054900	chr3:154042577	DHX36	0.55	9.41	0.35	9.09e-20	Coronary artery disease;
BRCA	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg23711669	chr6:146136114	FBXO30	0.73	16.63	0.55	7.47e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9649213	0.559	rs56997921	chr7:98009224	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.58	-15.91	-0.53	2.83e-48	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9400271	0.632	rs9487020	chr6:109587672	A/G	cg21918786	chr6:109611834	NA	-0.32	-8.02	-0.3	5.08e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	trans	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	10.55	0.39	4.36e-24	Motion sickness;
BRCA	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12826209	chr6:26865740	GUSBL1	0.58	10.33	0.38	3.1e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs3741798	1.000	rs61922028	chr12:12487096	A/C	cg08615371	chr12:12503544	MANSC1	1.07	15.38	0.52	1.25e-45	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg12310025	chr6:25882481	NA	-0.55	-13.41	-0.47	2.52e-36	Blood metabolite levels;
BRCA	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg08885076	chr2:99613938	TSGA10	-0.59	-13.08	-0.46	8e-35	Chronic sinus infection;
BRCA	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg04944784	chr2:26401820	FAM59B	-0.95	-16.86	-0.55	5.15e-53	Gut microbiome composition (summer);
BRCA	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg08017756	chr2:100939284	LONRF2	-0.31	-7.97	-0.3	7.58e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg05283184	chr6:79620031	NA	-0.37	-8.57	-0.32	7.53e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs2249625	0.874	rs1852705	chr6:72875512	G/T	cg18830697	chr6:72922368	RIMS1	-0.38	-8.2	-0.31	1.33e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs34779708	0.931	rs2148482	chr10:35348910	A/G	cg03585969	chr10:35415529	CREM	0.49	10.27	0.38	5.13e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15506890	chr2:3487001	NA	-0.57	-12.88	-0.45	6.43e-34	Neurofibrillary tangles;
BRCA	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.98	-0.53	1.27e-48	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg05863683	chr7:1912471	MAD1L1	0.41	8.61	0.32	5.91e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs78487399	0.908	rs6731636	chr2:43843046	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-8.16	-0.31	1.74e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg10518572	chr11:65560635	OVOL1	-0.28	-8.11	-0.31	2.52e-15	Acne (severe);
BRCA	cis	rs495337	0.736	rs527892	chr20:48477454	A/C	cg17835207	chr20:48524531	SPATA2	-0.5	-11.06	-0.4	3.87e-26	Psoriasis;
BRCA	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.32	0.35	1.82e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-10.28	-0.38	4.63e-23	Schizophrenia;
BRCA	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	7.83	0.3	2.1e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg24642439	chr20:33292090	TP53INP2	0.4	7.87	0.3	1.52e-14	Height;
BRCA	cis	rs6901250	0.851	rs607372	chr6:117155929	A/G	cg12892004	chr6:117198278	RFX6	-0.49	-11.42	-0.41	1.24e-27	C-reactive protein levels;
BRCA	cis	rs13136331	0.684	rs7677103	chr4:88721279	C/G	cg22416721	chr4:88570574	DMP1	0.39	8.38	0.31	3.3e-16	Sitting height ratio;
BRCA	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11890956	chr21:40555474	PSMG1	-0.61	-13.62	-0.47	2.88e-37	Menarche (age at onset);
BRCA	cis	rs12200560	0.505	rs211177	chr6:97074088	C/T	cg06623918	chr6:96969491	KIAA0776	0.53	12.64	0.45	7.46e-33	Coronary heart disease;
BRCA	cis	rs36051895	0.632	rs7029084	chr9:5174638	T/C	cg02405213	chr9:5042618	JAK2	-0.46	-8.86	-0.33	7.68e-18	Pediatric autoimmune diseases;
BRCA	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg00074818	chr8:8560427	CLDN23	0.38	8.41	0.32	2.69e-16	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg05340658	chr4:99064831	C4orf37	0.67	16.82	0.55	8.18e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg04455712	chr21:45112962	RRP1B	0.45	11.21	0.41	9.07e-27	Mean corpuscular volume;
BRCA	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg16606324	chr3:10149918	C3orf24	0.5	10.1	0.37	2.28e-22	Alzheimer's disease;
BRCA	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg18225595	chr11:63971243	STIP1	-0.4	-9.88	-0.36	1.67e-21	Platelet count;
BRCA	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	14.98	0.51	1.08e-43	Mean corpuscular hemoglobin;
BRCA	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg25554036	chr4:6271136	WFS1	0.39	9.65	0.36	1.13e-20	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12667521	chr19:29218732	NA	0.46	8.79	0.33	1.33e-17	Methadone dose in opioid dependence;
BRCA	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-7.96	-0.3	8.15e-15	Total body bone mineral density;
BRCA	cis	rs35995292	0.534	rs2392607	chr7:38930380	G/A	cg19327137	chr7:38886074	VPS41	0.38	12.75	0.45	2.57e-33	Subjective well-being (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.12e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg23285459	chr7:2802560	GNA12	-0.34	-8.34	-0.31	4.6e-16	Height;
BRCA	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.42	-7.93	-0.3	9.52e-15	Tuberculosis;
BRCA	cis	rs17253792	0.915	rs76952651	chr14:56188994	G/A	cg01858014	chr14:56050164	KTN1	-0.68	-8.45	-0.32	2.02e-16	Putamen volume;
BRCA	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg11843238	chr5:131593191	PDLIM4	0.38	9.34	0.35	1.56e-19	Acylcarnitine levels;
BRCA	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg10729496	chr3:10149963	C3orf24	0.41	7.81	0.3	2.4e-14	Alzheimer's disease;
BRCA	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg05868516	chr6:26286170	HIST1H4H	-0.49	-10.71	-0.39	9.68e-25	Educational attainment;
BRCA	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg24112000	chr20:60950667	NA	-0.58	-12.47	-0.44	4.11e-32	Colorectal cancer;
BRCA	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg21782813	chr7:2030301	MAD1L1	-0.38	-10.4	-0.38	1.72e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs11190604	0.767	rs11190519	chr10:102175133	C/T	cg07080220	chr10:102295463	HIF1AN	0.49	10.04	0.37	4.17e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2742234	0.541	rs10899779	chr10:43723976	C/T	cg02780029	chr10:43622663	RET	0.35	7.9	0.3	1.26e-14	Hirschsprung disease;
BRCA	cis	rs490234	0.702	rs7864945	chr9:128373469	C/T	cg14078157	chr9:128172775	NA	-0.53	-11.64	-0.42	1.49e-28	Mean arterial pressure;
BRCA	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg12386194	chr3:101231763	SENP7	0.46	9.76	0.36	4.43e-21	Colorectal cancer;
BRCA	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg17366294	chr4:99064904	C4orf37	-0.44	-10.37	-0.38	2.22e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.92	-17.02	-0.56	7.2e-54	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.01	17.7	0.57	2.47e-57	Gut microbiome composition (summer);
BRCA	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg11608241	chr8:8085544	FLJ10661	0.28	8.13	0.31	2.29e-15	Neuroticism;
BRCA	cis	rs34779708	0.801	rs34592588	chr10:35540134	A/G	cg03585969	chr10:35415529	CREM	0.45	9.22	0.34	4.14e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7586879	1.000	rs10207698	chr2:25117672	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.34	0.35	1.63e-19	Body mass index;
BRCA	cis	rs13046373	0.535	rs2226377	chr21:32031915	T/C	cg06468780	chr21:31798236	KRTAP13-3	0.35	8.47	0.32	1.74e-16	HDL cholesterol;
BRCA	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-16.92	-0.56	2.46e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.83	12.84	0.45	9.76e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg05347473	chr6:146136440	FBXO30	0.39	8.06	0.3	3.89e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11890956	chr21:40555474	PSMG1	0.66	15.41	0.52	8.84e-46	Cognitive function;
BRCA	trans	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg26043149	chr18:55253948	FECH	-0.37	-8.18	-0.31	1.49e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg11584989	chr19:19387371	SF4	0.63	13.52	0.47	7.85e-37	Bipolar disorder;
BRCA	cis	rs4594175	0.926	rs4318127	chr14:51624897	G/C	cg23942311	chr14:51606299	NA	0.33	8.45	0.32	2e-16	Cancer;
BRCA	cis	rs6977660	0.714	rs4719587	chr7:19828174	C/G	cg07541023	chr7:19748670	TWISTNB	0.52	9.04	0.34	1.93e-18	Thyroid stimulating hormone;
BRCA	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-13.87	-0.48	1.98e-38	Blood metabolite levels;
BRCA	cis	rs9633740	1.000	rs10749609	chr10:82249752	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	18.38	0.59	6.97e-61	Post bronchodilator FEV1;
BRCA	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg22974920	chr21:40686053	BRWD1	-0.38	-8.7	-0.33	2.86e-17	Cognitive function;
BRCA	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.21	-0.34	4.63e-19	Bipolar disorder;
BRCA	cis	rs2191566	1.000	rs390369	chr19:44506984	C/T	cg20607764	chr19:44506953	ZNF230	0.49	10.92	0.4	1.39e-25	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9644630	0.870	rs10888165	chr8:19358961	T/C	cg01280390	chr8:19363452	CSGALNACT1	0.38	8.67	0.32	3.53e-17	Oropharynx cancer;
BRCA	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg11301795	chr4:187892539	NA	0.3	9.66	0.36	1.06e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg04317338	chr11:64019027	PLCB3	-0.54	-9.11	-0.34	1.05e-18	Mean platelet volume;
BRCA	cis	rs72772090	0.710	rs17479052	chr5:96065636	A/G	cg24982541	chr5:96078678	CAST	-0.46	-7.95	-0.3	8.51e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11644478	chr21:40555479	PSMG1	0.74	15.01	0.51	8.03e-44	Cognitive function;
BRCA	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg26587870	chr6:27730563	NA	-0.45	-8.03	-0.3	4.73e-15	Lung cancer in ever smokers;
BRCA	cis	rs6435161	0.919	rs72930744	chr2:203597269	C/T	cg18429434	chr2:203499731	FAM117B	-0.46	-9.02	-0.34	2.1e-18	Total cholesterol levels;
BRCA	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg20587970	chr11:113659929	NA	-0.82	-15.39	-0.52	1.13e-45	Hip circumference adjusted for BMI;
BRCA	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg15133208	chr4:90757351	SNCA	-0.38	-8.03	-0.3	4.61e-15	Neuroticism;
BRCA	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg22800045	chr5:56110881	MAP3K1	-0.68	-12.98	-0.46	2.27e-34	Initial pursuit acceleration;
BRCA	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg12292205	chr6:26970375	C6orf41	-0.8	-19.61	-0.61	2.16e-67	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg04455712	chr21:45112962	RRP1B	0.39	9.92	0.37	1.1e-21	Mean corpuscular volume;
BRCA	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg01483505	chr11:975446	AP2A2	-0.32	-8.88	-0.33	6.53e-18	Alzheimer's disease (late onset);
BRCA	cis	rs17164103	0.505	rs10500136	chr7:143014244	C/T	cg21852589	chr7:142981689	TMEM139	-0.69	-14.14	-0.49	1.11e-39	Cancer;
BRCA	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg07169764	chr2:136633963	MCM6	0.98	19.48	0.61	1.11e-66	Mosquito bite size;
BRCA	cis	rs12545109	0.836	rs2196586	chr8:57347126	C/T	cg09654669	chr8:57350985	NA	0.38	7.96	0.3	7.92e-15	Obesity-related traits;
BRCA	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg21770322	chr7:97807741	LMTK2	-0.49	-12.12	-0.43	1.4e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02176678	chr2:219576539	TTLL4	0.45	11.62	0.42	1.97e-28	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs7980799	0.935	rs1905427	chr12:33534368	T/C	cg26384229	chr12:38710491	ALG10B	-0.4	-8.33	-0.31	5.1e-16	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs191220855	1	rs191220855	chr2:200778130	A/G	cg23649088	chr2:200775458	C2orf69	-0.67	-9.6	-0.36	1.76e-20	Chickenpox;
BRCA	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg19784903	chr17:45786737	TBKBP1	-0.35	-8.24	-0.31	9.99e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs17401966	0.627	rs35859381	chr1:10466040	G/A	cg03954927	chr1:10346856	KIF1B	0.44	13.28	0.47	1.03e-35	Hepatocellular carcinoma;
BRCA	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.37	-0.41	2.06e-27	Schizophrenia;
BRCA	cis	rs7640424	0.819	rs34154497	chr3:107824222	T/C	cg09227934	chr3:107805635	CD47	-0.4	-8.41	-0.32	2.69e-16	Body mass index;
BRCA	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg16230307	chr14:35515116	FAM177A1	0.62	13.96	0.48	7.67e-39	Psoriasis;
BRCA	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg12310025	chr6:25882481	NA	0.51	11.99	0.43	4.85e-30	Blood metabolite levels;
BRCA	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	18.63	0.59	3.29e-62	Nonalcoholic fatty liver disease;
BRCA	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.52	-0.32	1.18e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs877282	0.583	rs7072970	chr10:822757	G/A	cg22713356	chr15:30763199	NA	1.01	15.85	0.53	6.01e-48	Uric acid levels;
BRCA	cis	rs9341808	0.718	rs35447745	chr6:80816748	T/C	cg08355045	chr6:80787529	NA	0.37	9.37	0.35	1.27e-19	Sitting height ratio;
BRCA	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg05340658	chr4:99064831	C4orf37	0.69	17.49	0.57	2.8e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.34	-0.38	2.72e-23	Schizophrenia;
BRCA	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg00083206	chr6:110721305	DDO	0.36	8.58	0.32	7.37e-17	Platelet distribution width;
BRCA	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg03934865	chr2:198174659	NA	-0.38	-8.22	-0.31	1.14e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4679121	0.642	rs76826102	chr3:126185964	C/T	cg01106040	chr3:126194903	ZXDC	-0.7	-8.04	-0.3	4.5e-15	Pursuit maintenance gain;
BRCA	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.89	16.77	0.55	1.47e-52	Lymphocyte percentage of white cells;
BRCA	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg05340658	chr4:99064831	C4orf37	0.61	14.56	0.5	1.14e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg23711669	chr6:146136114	FBXO30	0.63	14.68	0.5	2.93e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg13319975	chr6:146136371	FBXO30	-0.42	-9.81	-0.36	2.95e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.31	0.38	3.57e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg24562669	chr7:97807699	LMTK2	0.44	11.81	0.42	2.92e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	7.91	0.3	1.11e-14	Tonsillectomy;
BRCA	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05901451	chr6:126070800	HEY2	-0.55	-14.83	-0.51	5.6e-43	Brugada syndrome;
BRCA	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg24060327	chr5:131705240	SLC22A5	-0.63	-12.25	-0.44	3.84e-31	Breast cancer;
BRCA	trans	rs4714291	0.802	rs1474870	chr6:39980359	C/T	cg02267698	chr19:7991119	CTXN1	0.43	8.9	0.33	5.75e-18	Strep throat;
BRCA	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-11.64	-0.42	1.62e-28	Alzheimer's disease;
BRCA	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg26138937	chr11:71823887	C11orf51	-1.01	-9.91	-0.36	1.27e-21	Severe influenza A (H1N1) infection;
BRCA	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg08017756	chr2:100939284	LONRF2	-0.3	-7.91	-0.3	1.15e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg18132916	chr6:79620363	NA	-0.44	-9.97	-0.37	7.3e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9290065	0.519	rs10936216	chr3:160698314	G/C	cg03342759	chr3:160939853	NMD3	-0.49	-10.06	-0.37	3.49e-22	Kawasaki disease;
BRCA	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg13770153	chr20:60521292	NA	-0.43	-9.38	-0.35	1.15e-19	Body mass index;
BRCA	cis	rs6834538	0.965	rs4834294	chr4:113529020	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.39	8.47	0.32	1.7e-16	Free thyroxine concentration;
BRCA	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs6060717	0.536	rs7271036	chr20:34467215	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.59	8.08	0.3	3.21e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg26195577	chr20:24973756	C20orf3	1.03	28.97	0.75	1.65e-118	Blood protein levels;
BRCA	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg08000102	chr2:233561755	GIGYF2	-0.77	-17.07	-0.56	4.13e-54	Schizophrenia;
BRCA	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.44	-9.98	-0.37	6.79e-22	Personality dimensions;
BRCA	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg12648201	chr2:27665141	KRTCAP3	-0.37	-9.09	-0.34	1.24e-18	Total body bone mineral density;
BRCA	cis	rs10911363	0.509	rs10911339	chr1:183442097	C/T	cg09173681	chr1:183549694	NCF2	0.59	12.18	0.43	7.93e-31	Systemic lupus erythematosus;
BRCA	cis	rs735860	0.737	rs2397139	chr6:53150804	C/G	cg10236188	chr6:53219634	NA	-0.38	-8.21	-0.31	1.23e-15	Glaucoma;
BRCA	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg10932868	chr11:921992	NA	-0.48	-12.28	-0.44	2.84e-31	Alzheimer's disease (late onset);
BRCA	cis	rs11608355	0.515	rs4766476	chr12:109934700	A/G	cg05360138	chr12:110035743	NA	0.74	13.68	0.48	1.56e-37	Neuroticism;
BRCA	trans	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg26043149	chr18:55253948	FECH	-0.36	-7.87	-0.3	1.51e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10465746	0.714	rs12141272	chr1:84434517	C/T	cg10977910	chr1:84465055	TTLL7	0.57	11.98	0.43	5.5e-30	Obesity-related traits;
BRCA	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27286337	chr10:134555280	INPP5A	-0.64	-10.94	-0.4	1.16e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg15997130	chr1:24165203	NA	0.49	12.96	0.46	2.96e-34	Immature fraction of reticulocytes;
BRCA	cis	rs7833986	0.534	rs72653924	chr8:56906088	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	12.57	0.45	1.6e-32	Height;
BRCA	cis	rs7246657	0.722	rs12979640	chr19:38179156	T/C	cg14683738	chr19:37701593	ZNF585B	-0.5	-8.74	-0.33	2.08e-17	Coronary artery calcification;
BRCA	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg12908607	chr1:44402522	ARTN	-0.41	-9.98	-0.37	6.52e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg27600084	chr12:12264075	NA	0.39	9.17	0.34	6.34e-19	Breast size;
BRCA	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg13010199	chr12:38710504	ALG10B	0.48	9.45	0.35	6.55e-20	Morning vs. evening chronotype;
BRCA	cis	rs752010	0.619	rs10736421	chr1:42106230	G/A	cg06885757	chr1:42089581	HIVEP3	0.33	11.0	0.4	6.94e-26	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs2652834	1.000	rs2729783	chr15:63403316	C/T	cg05507819	chr15:63340323	TPM1	0.47	8.59	0.32	6.55e-17	HDL cholesterol;
BRCA	cis	rs11690935	0.851	rs10201430	chr2:172813241	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.75	-22.26	-0.66	1.02e-81	Schizophrenia;
BRCA	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.78	0.5	9.3e-43	Colorectal cancer;
BRCA	cis	rs6121246	0.559	rs6058352	chr20:30269179	T/C	cg13852791	chr20:30311386	BCL2L1	0.96	23.31	0.68	1.8e-87	Mean corpuscular hemoglobin;
BRCA	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg13877915	chr19:58951672	ZNF132	0.4	9.38	0.35	1.13e-19	Uric acid clearance;
BRCA	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08704250	chr15:31115839	NA	-0.36	-9.13	-0.34	9e-19	Huntington's disease progression;
BRCA	cis	rs9341808	0.628	rs9294172	chr6:80918561	G/A	cg08355045	chr6:80787529	NA	0.32	7.92	0.3	1.05e-14	Sitting height ratio;
BRCA	cis	rs34779708	0.733	rs7914560	chr10:35548099	G/A	cg03585969	chr10:35415529	CREM	0.44	9.1	0.34	1.17e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg04414720	chr1:150670196	GOLPH3L	0.35	7.84	0.3	1.88e-14	Tonsillectomy;
BRCA	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg24562669	chr7:97807699	LMTK2	0.43	11.48	0.41	7.55e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6745190	0.575	rs6706696	chr2:181981055	C/T	cg00481216	chr2:181971175	NA	0.4	9.53	0.35	3.22e-20	White blood cell count;
BRCA	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18876405	chr7:65276391	NA	0.62	15.35	0.52	1.74e-45	Aortic root size;
BRCA	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg21475434	chr5:93447410	FAM172A	0.7	8.74	0.33	2.03e-17	Diabetic retinopathy;
BRCA	cis	rs7809950	0.954	rs2520247	chr7:107143946	A/T	cg23024343	chr7:107201750	COG5	-0.39	-9.13	-0.34	8.89e-19	Coronary artery disease;
BRCA	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg26384229	chr12:38710491	ALG10B	0.6	15.33	0.52	2.21e-45	Morning vs. evening chronotype;
BRCA	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg10523679	chr1:76189770	ACADM	-0.76	-16.11	-0.54	2.86e-49	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg00383909	chr3:49044727	WDR6	0.76	12.7	0.45	4.07e-33	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-9.7	-0.36	7.9e-21	Total body bone mineral density;
BRCA	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg27211696	chr2:191398769	TMEM194B	-0.45	-10.34	-0.38	2.89e-23	Pulse pressure;
BRCA	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.72	0.55	2.61e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg09060608	chr5:178986726	RUFY1	0.55	12.7	0.45	3.94e-33	Lung cancer;
BRCA	cis	rs6120849	0.901	rs6088739	chr20:33748724	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	8.61	0.32	5.6e-17	Protein C levels;
BRCA	cis	rs1577917	0.958	rs6454487	chr6:86446868	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.43	11.73	0.42	6.31e-29	Response to antipsychotic treatment;
BRCA	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg23625390	chr15:77176239	SCAPER	-0.56	-12.86	-0.45	8.39e-34	Blood metabolite levels;
BRCA	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg14784868	chr12:69753453	YEATS4	0.51	12.47	0.44	4.34e-32	Blood protein levels;
BRCA	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg27284194	chr4:1044797	NA	0.43	9.3	0.35	2.12e-19	Recombination rate (males);
BRCA	trans	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-8.37	-0.31	3.65e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs507080	0.922	rs561845	chr11:118558827	A/G	cg08498647	chr11:118550644	TREH	-0.38	-8.26	-0.31	8.53e-16	Serum metabolite levels;
BRCA	cis	rs16867321	0.950	rs4667223	chr2:181498302	C/G	cg23363182	chr2:181467187	NA	-0.44	-8.26	-0.31	8.35e-16	Obesity;
BRCA	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg03060546	chr3:49711283	APEH	-0.51	-10.51	-0.38	6.34e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg02297831	chr4:17616191	MED28	0.36	8.61	0.32	5.52e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg12386194	chr3:101231763	SENP7	0.45	9.45	0.35	6.18e-20	Colorectal cancer;
BRCA	trans	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.75	13.64	0.47	2.38e-37	Exhaled nitric oxide levels;
BRCA	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg18402987	chr7:1209562	NA	0.85	12.22	0.44	5.38e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg16586182	chr3:47516702	SCAP	-0.56	-12.85	-0.45	8.73e-34	Colorectal cancer;
BRCA	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03934478	chr11:495069	RNH1	0.79	11.76	0.42	5.06e-29	Body mass index;
BRCA	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg05347473	chr6:146136440	FBXO30	-0.6	-11.46	-0.41	8.44e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7903847	0.642	rs1537645	chr10:99149914	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.77	-0.33	1.63e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs812925	0.537	rs778153	chr2:61608652	A/G	cg15711740	chr2:61764176	XPO1	0.32	7.85	0.3	1.74e-14	Immature fraction of reticulocytes;
BRCA	cis	rs4363385	0.720	rs1134220	chr1:152976306	T/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.75	-0.36	4.91e-21	Inflammatory skin disease;
BRCA	cis	rs812925	0.533	rs35507645	chr2:61396766	A/G	cg15711740	chr2:61764176	XPO1	-0.32	-7.85	-0.3	1.72e-14	Immature fraction of reticulocytes;
BRCA	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg05535760	chr7:792225	HEATR2	0.77	13.59	0.47	3.77e-37	Cerebrospinal P-tau181p levels;
BRCA	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg24829409	chr8:58192753	C8orf71	0.45	8.71	0.33	2.68e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9942416	0.660	rs66493518	chr5:74990125	G/C	cg19683494	chr5:74908142	NA	0.48	9.04	0.34	1.78e-18	Age-related disease endophenotypes;
BRCA	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg05623727	chr3:50126028	RBM5	0.44	10.43	0.38	1.22e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg18850127	chr7:39170497	POU6F2	0.41	8.4	0.32	2.96e-16	IgG glycosylation;
BRCA	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.8e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.32	0.38	3.25e-23	Motion sickness;
BRCA	cis	rs847577	0.715	rs4729402	chr7:97707731	A/G	cg21770322	chr7:97807741	LMTK2	0.44	11.96	0.43	6.53e-30	Breast cancer;
BRCA	cis	rs9658691	0.607	rs9658766	chr10:90771612	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.55	-8.04	-0.3	4.34e-15	Mosquito bite size;
BRCA	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg21770322	chr7:97807741	LMTK2	0.42	11.25	0.41	6.77e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7072216	0.763	rs2274243	chr10:100175267	T/C	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.68	-0.36	8.8e-21	Metabolite levels;
BRCA	cis	rs6977660	1.000	rs57916046	chr7:19800542	T/C	cg07541023	chr7:19748670	TWISTNB	0.48	8.63	0.32	4.78e-17	Thyroid stimulating hormone;
BRCA	trans	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg07211511	chr3:129823064	LOC729375	-0.61	-10.74	-0.39	7.24e-25	Blood pressure (smoking interaction);
BRCA	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg24558204	chr6:135376177	HBS1L	0.45	12.3	0.44	2.41e-31	Red blood cell count;
BRCA	cis	rs216205	0.547	rs2641431	chr17:2030507	C/G	cg16513277	chr17:2031491	SMG6	-0.5	-8.89	-0.33	6.11e-18	Mitral valve prolapse;
BRCA	trans	rs12439619	0.810	rs28876157	chr15:82509049	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-7.93	-0.3	9.59e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7131987	0.675	rs1436322	chr12:29554805	A/G	cg09582351	chr12:29534625	ERGIC2	0.34	8.11	0.31	2.58e-15	QT interval;
BRCA	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.39	8.4	0.32	2.99e-16	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00149659	chr3:10157352	C3orf10	0.74	12.96	0.46	2.94e-34	Alzheimer's disease;
BRCA	cis	rs1476670	0.710	rs2477616	chr1:44504809	G/A	cg09470012	chr1:44509516	NA	0.44	9.33	0.35	1.71e-19	Eotaxin levels;
BRCA	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg23711669	chr6:146136114	FBXO30	-0.71	-17.19	-0.56	1.03e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg17724175	chr1:150552817	MCL1	-0.24	-7.86	-0.3	1.6e-14	Melanoma;
BRCA	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14240646	chr10:27532245	ACBD5	-0.72	-9.31	-0.35	2.1e-19	Breast cancer;
BRCA	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg03585969	chr10:35415529	CREM	0.56	11.58	0.42	2.9e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg13628971	chr7:2884303	GNA12	0.4	9.04	0.34	1.8e-18	Height;
BRCA	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg02951883	chr7:2050386	MAD1L1	0.51	13.22	0.46	1.87e-35	Bipolar disorder and schizophrenia;
BRCA	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg26446133	chr18:72167187	CNDP2	-0.79	-19.95	-0.62	3.38e-69	Refractive error;
BRCA	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	9.9	0.36	1.35e-21	Calcium levels;
BRCA	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	11.12	0.4	2.17e-26	HDL cholesterol;
BRCA	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.47	-0.38	9.03e-24	Mean corpuscular volume;
BRCA	cis	rs17270561	0.636	rs3922681	chr6:25698481	C/T	cg17691542	chr6:26056736	HIST1H1C	0.47	8.96	0.33	3.56e-18	Iron status biomarkers;
BRCA	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg18230493	chr5:56204884	C5orf35	-0.71	-13.93	-0.48	1.01e-38	Initial pursuit acceleration;
BRCA	cis	rs858239	0.537	rs6942981	chr7:23231548	C/T	cg23682824	chr7:23144976	KLHL7	0.35	8.85	0.33	8.39e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs758324	0.891	rs491624	chr5:131270222	A/T	cg06307176	chr5:131281290	NA	-0.53	-10.18	-0.37	1.17e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs11231017	0.501	rs11231053	chr11:62133220	G/A	cg23876832	chr11:62092739	NA	0.32	8.21	0.31	1.23e-15	HIV-1 viral setpoint;
BRCA	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.63	0.39	2.13e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg12564285	chr5:131593104	PDLIM4	0.43	11.25	0.41	6.39e-27	Acylcarnitine levels;
BRCA	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg26384229	chr12:38710491	ALG10B	0.74	17.24	0.56	5.67e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg18850127	chr7:39170497	POU6F2	0.48	10.35	0.38	2.51e-23	IgG glycosylation;
BRCA	cis	rs147120681	1	rs147120681	chr1:101239293	CT/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.42	-9.61	-0.36	1.67e-20	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03264133	chr6:25882463	NA	-0.56	-11.5	-0.41	5.82e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs10129255	0.536	rs10142951	chr14:107190574	A/G	cg07958169	chr14:107095056	NA	-0.4	-8.54	-0.32	9.55e-17	Kawasaki disease;
BRCA	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg00666640	chr1:248458726	OR2T12	0.32	8.83	0.33	9.7e-18	Common traits (Other);
BRCA	trans	rs2562456	0.917	rs6511256	chr19:21693315	G/T	cg25042112	chr7:64838748	ZNF92	0.46	8.58	0.32	7.29e-17	Pain;
BRCA	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg06623918	chr6:96969491	KIAA0776	0.74	12.97	0.46	2.61e-34	Migraine;Coronary artery disease;
BRCA	cis	rs2882667	0.898	rs3828600	chr5:138386859	G/T	cg04439458	chr5:138467593	SIL1	-0.35	-9.67	-0.36	1.02e-20	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg09877947	chr5:131593287	PDLIM4	-0.45	-10.61	-0.39	2.41e-24	Acylcarnitine levels;
BRCA	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg23796481	chr11:64053134	BAD;GPR137	0.5	10.52	0.38	5.41e-24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg00080972	chr5:178986291	RUFY1	0.38	8.98	0.33	2.99e-18	Lung cancer;
BRCA	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg24060327	chr5:131705240	SLC22A5	0.5	10.38	0.38	1.9e-23	Blood metabolite levels;
BRCA	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg05863683	chr7:1912471	MAD1L1	-0.41	-9.25	-0.34	3.33e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg24675658	chr1:53192096	ZYG11B	0.55	12.37	0.44	1.11e-31	Monocyte count;
BRCA	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg05519781	chr21:40033154	ERG	0.44	9.34	0.35	1.61e-19	Coronary artery disease;
BRCA	cis	rs870825	0.550	rs35981185	chr4:185639720	A/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.43	0.57	5.93e-56	Blood protein levels;
BRCA	cis	rs1555322	0.530	rs2425042	chr20:33865895	G/A	cg03689076	chr20:33865952	NA	0.48	8.56	0.32	8.38e-17	Attention deficit hyperactivity disorder;
BRCA	trans	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-13.86	-0.48	2.11e-38	Brugada syndrome;
BRCA	cis	rs7524258	0.868	rs6693725	chr1:7307810	G/T	cg07173049	chr1:7289937	CAMTA1	0.42	10.28	0.38	4.87e-23	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg20991723	chr1:152506922	NA	0.38	8.67	0.32	3.48e-17	Hair morphology;
BRCA	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.66	-0.61	1.21e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.94	0.33	4.23e-18	Motion sickness;
BRCA	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.95	0.4	1.07e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs701145	0.585	rs357465	chr3:153903095	T/A	cg17054900	chr3:154042577	DHX36	0.58	9.66	0.36	1.04e-20	Coronary artery disease;
BRCA	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.98	-0.3	6.85e-15	Bipolar disorder;
BRCA	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg06636001	chr8:8085503	FLJ10661	0.56	10.47	0.38	8.57e-24	Retinal vascular caliber;
BRCA	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.49	-0.32	1.4e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11585357	0.895	rs2501795	chr1:17633499	A/G	cg19159961	chr1:17633534	PADI4	0.6	10.58	0.39	3.16e-24	Hair shape;
BRCA	cis	rs7944584	0.879	rs11039182	chr11:47346723	T/C	cg03711944	chr11:47377212	SPI1	-0.39	-8.42	-0.32	2.52e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs965469	0.779	rs6133039	chr20:3385006	C/T	cg25506879	chr20:3388711	C20orf194	-0.44	-8.78	-0.33	1.55e-17	IFN-related cytopenia;
BRCA	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg06784218	chr1:46089804	CCDC17	0.45	10.91	0.4	1.54e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg08888203	chr3:10149979	C3orf24	0.59	8.98	0.33	2.96e-18	Alzheimer's disease;
BRCA	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26314531	chr2:26401878	FAM59B	-0.9	-15.64	-0.53	6.69e-47	Gut microbiome composition (summer);
BRCA	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg22307297	chr20:60903441	LAMA5	0.34	9.2	0.34	4.93e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg07080220	chr10:102295463	HIF1AN	0.62	13.27	0.46	1.08e-35	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs55882075	0.722	rs10903245	chr5:179133608	T/C	cg14593053	chr5:179126677	CANX	0.48	12.69	0.45	4.38e-33	Monocyte percentage of white cells;
BRCA	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.66	-9.54	-0.35	2.84e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs9463078	0.547	rs9472362	chr6:44751285	C/A	cg25276700	chr6:44698697	NA	0.34	7.91	0.3	1.16e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.08e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg11189052	chr15:85197271	WDR73	-0.39	-9.39	-0.35	1.04e-19	P wave terminal force;
BRCA	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg21280719	chr6:42927975	GNMT	-0.31	-13.05	-0.46	1.17e-34	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg03929089	chr4:120376271	NA	0.6	10.37	0.38	2.13e-23	Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-13.07	-0.46	9e-35	Obesity-related traits;
BRCA	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg02773041	chr1:40204384	PPIE	0.44	9.55	0.35	2.79e-20	Blood protein levels;
BRCA	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg06618935	chr21:46677482	NA	-0.38	-8.46	-0.32	1.87e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4889855	0.505	rs8082303	chr17:78605012	A/G	cg16591659	chr17:78472290	NA	-0.31	-7.88	-0.3	1.38e-14	Fractional excretion of uric acid;
BRCA	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11764359	chr7:65958608	NA	0.75	16.63	0.55	7.35e-52	Aortic root size;
BRCA	cis	rs12541635	1.000	rs11992752	chr8:107083122	G/A	cg10147462	chr8:107024639	NA	-0.31	-8.42	-0.32	2.47e-16	Age of smoking initiation;
BRCA	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	12.06	0.43	2.62e-30	Rheumatoid arthritis;
BRCA	cis	rs72772090	0.539	rs72775810	chr5:96185307	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-11.44	-0.41	1.02e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21659725	chr3:3221576	CRBN	0.71	21.67	0.65	1.79e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs4908768	0.501	rs35865480	chr1:8603777	C/T	cg20416874	chr1:8611966	RERE	-0.29	-8.25	-0.31	8.99e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs3820928	1.000	rs4673173	chr2:227769493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-8.95	-0.33	3.93e-18	Pulmonary function;
BRCA	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg12751644	chr20:60527061	NA	-0.33	-7.83	-0.3	2.09e-14	Body mass index;
BRCA	cis	rs10754283	0.967	rs7546410	chr1:90109815	C/T	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.31e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs6088813	0.961	rs2425063	chr20:33924273	C/A	cg14752227	chr20:34000481	UQCC	0.41	8.59	0.32	6.4e-17	Height;
BRCA	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg22903471	chr2:27725779	GCKR	-0.38	-9.22	-0.34	4.36e-19	Total body bone mineral density;
BRCA	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	8.08	0.3	3.33e-15	Platelet count;
BRCA	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg18402987	chr7:1209562	NA	0.42	8.11	0.31	2.65e-15	Longevity;Endometriosis;
BRCA	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg12549451	chr6:135224345	NA	-0.36	-8.63	-0.32	4.69e-17	Red blood cell count;
BRCA	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg20019720	chr6:154832845	CNKSR3	0.52	10.31	0.38	3.64e-23	Lipoprotein (a) levels;
BRCA	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg02503808	chr4:7069936	GRPEL1	0.8	18.43	0.59	3.81e-61	Monocyte percentage of white cells;
BRCA	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.99	-0.37	6.04e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18876405	chr7:65276391	NA	0.5	11.2	0.4	1.09e-26	Aortic root size;
BRCA	cis	rs4845875	0.626	rs2004445	chr1:11841366	C/T	cg24844545	chr1:11908347	NPPA	0.33	8.25	0.31	9.01e-16	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.29	-0.35	2.32e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg06521331	chr12:34319734	NA	-0.44	-8.18	-0.31	1.54e-15	Resting heart rate;
BRCA	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	11.15	0.4	1.72e-26	Platelet count;
BRCA	cis	rs7833986	0.501	rs72653917	chr8:56892844	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.67	12.45	0.44	5.19e-32	Height;
BRCA	cis	rs2882667	0.858	rs11951899	chr5:138374310	A/G	cg04439458	chr5:138467593	SIL1	-0.43	-10.36	-0.38	2.28e-23	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-9.48	-0.35	4.96e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10465746	0.780	rs7551787	chr1:84419297	A/G	cg10977910	chr1:84465055	TTLL7	0.53	11.16	0.4	1.5e-26	Obesity-related traits;
BRCA	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg06618935	chr21:46677482	NA	-0.36	-8.06	-0.3	3.7e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg06138931	chr13:21896616	NA	0.54	8.96	0.33	3.54e-18	White matter hyperintensity burden;
BRCA	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.24	-8.47	-0.32	1.65e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7193541	0.684	rs4888262	chr16:74670458	C/T	cg01733217	chr16:74700730	RFWD3	0.92	32.44	0.79	3.54e-137	Multiple myeloma;
BRCA	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-11.45	-0.41	9.33e-28	Gut microbiome composition (summer);
BRCA	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg26384229	chr12:38710491	ALG10B	0.57	12.85	0.45	9.02e-34	Morning vs. evening chronotype;
BRCA	cis	rs367943	1.000	rs348960	chr5:112820651	C/A	cg12552261	chr5:112820674	MCC	0.55	12.04	0.43	3.23e-30	Type 2 diabetes;
BRCA	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg02196655	chr2:10830764	NOL10	-0.29	-7.84	-0.3	1.94e-14	Prostate cancer;
BRCA	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg08470875	chr2:26401718	FAM59B	-0.5	-8.09	-0.3	3.09e-15	Gut microbiome composition (summer);
BRCA	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2904967	0.852	rs668735	chr11:65045725	G/T	cg09225861	chr11:65069680	NA	0.39	8.07	0.3	3.62e-15	Mean corpuscular volume;
BRCA	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg21573476	chr21:45109991	RRP1B	-0.36	-9.22	-0.34	4.22e-19	Mean corpuscular volume;
BRCA	cis	rs11874712	0.933	rs8097521	chr18:43666952	C/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.18	0.31	1.57e-15	Migraine - clinic-based;
BRCA	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg27170947	chr2:26402098	FAM59B	0.97	16.91	0.56	2.72e-53	Gut microbiome composition (summer);
BRCA	cis	rs10493773	0.862	rs12075929	chr1:86248138	A/C	cg17807903	chr1:86174739	ZNHIT6	0.46	10.27	0.38	5.07e-23	Urate levels in overweight individuals;
BRCA	cis	rs6580649	1.000	rs6580647	chr12:48403229	G/T	cg24011408	chr12:48396354	COL2A1	-0.52	-9.13	-0.34	8.75e-19	Lung cancer;
BRCA	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg16586182	chr3:47516702	SCAP	0.61	13.43	0.47	2.11e-36	Colorectal cancer;
BRCA	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg00105475	chr2:10696890	NA	0.42	9.6	0.36	1.74e-20	Prostate cancer;
BRCA	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.74	14.45	0.5	3.72e-41	Lung function (FEV1/FVC);
BRCA	cis	rs13394619	0.565	rs12478958	chr2:11748037	A/G	cg07314298	chr2:11723111	GREB1	-0.4	-9.34	-0.35	1.54e-19	Endometriosis;
BRCA	cis	rs9287719	0.649	rs10803724	chr2:10732323	C/T	cg00105475	chr2:10696890	NA	0.41	9.23	0.34	3.83e-19	Prostate cancer;
BRCA	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg23711669	chr6:146136114	FBXO30	0.78	19.15	0.6	6.21e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg22307297	chr20:60903441	LAMA5	0.33	9.44	0.35	6.88e-20	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs812925	0.519	rs1186706	chr2:61673394	G/T	cg15711740	chr2:61764176	XPO1	-0.34	-8.34	-0.31	4.49e-16	Immature fraction of reticulocytes;
BRCA	cis	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg06521331	chr12:34319734	NA	-0.62	-11.17	-0.4	1.35e-26	Morning vs. evening chronotype;
BRCA	cis	rs1163251	0.837	rs2764886	chr1:120241771	C/T	cg19096424	chr1:120255104	PHGDH	0.45	10.3	0.38	4.15e-23	Blood metabolite levels;
BRCA	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg03433033	chr1:76189801	ACADM	0.89	23.79	0.69	4.28e-90	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg19748678	chr4:122722346	EXOSC9	0.65	14.01	0.48	4.39e-39	Type 2 diabetes;
BRCA	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg08738300	chr3:44038990	NA	0.45	8.88	0.33	6.83e-18	Coronary artery disease;
BRCA	cis	rs6076065	0.548	rs1112819	chr20:23323987	A/G	cg11657817	chr20:23433608	CST11	0.33	8.09	0.3	3.04e-15	Facial morphology (factor 15, philtrum width);
BRCA	cis	rs61990749	0.597	rs1549119	chr14:78219812	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.66	10.57	0.39	3.61e-24	Fibroblast growth factor basic levels;
BRCA	trans	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.69	-16.67	-0.55	4.25e-52	Obesity-related traits;
BRCA	cis	rs870825	0.929	rs72689269	chr4:185592085	T/C	cg04058563	chr4:185651563	MLF1IP	0.68	11.7	0.42	8.45e-29	Blood protein levels;
BRCA	cis	rs4268898	0.552	rs12620938	chr2:24367122	C/A	cg06627628	chr2:24431161	ITSN2	0.4	8.51	0.32	1.24e-16	Asthma;
BRCA	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.64	9.99	0.37	6.08e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs11088226	1.000	rs2833888	chr21:33927560	A/G	cg09050820	chr6:167586206	TCP10L2	0.49	8.22	0.31	1.1e-15	Gastritis;
BRCA	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg01420254	chr6:26195488	NA	0.58	9.03	0.34	2.08e-18	Gout;Renal underexcretion gout;
BRCA	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-8.89	-0.33	6.28e-18	Schizophrenia;
BRCA	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg04546413	chr19:29218101	NA	0.45	8.25	0.31	9.32e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg05347473	chr6:146136440	FBXO30	0.4	7.94	0.3	9.43e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg01420254	chr6:26195488	NA	0.53	8.54	0.32	9.95e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg08213375	chr14:104286397	PPP1R13B	0.63	17.27	0.56	3.87e-55	Schizophrenia;
BRCA	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg18904891	chr8:8559673	CLDN23	-0.67	-14.11	-0.49	1.55e-39	Obesity-related traits;
BRCA	cis	rs698813	0.674	rs6544753	chr2:44501895	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	8.12	0.31	2.44e-15	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19346786	chr7:2764209	NA	0.3	8.87	0.33	7.46e-18	Height;
BRCA	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.54	0.38	4.56e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03264133	chr6:25882463	NA	0.72	16.67	0.55	4.42e-52	Blood metabolite levels;
BRCA	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg10518572	chr11:65560635	OVOL1	-0.28	-8.1	-0.31	2.86e-15	Acne (severe);
BRCA	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg01304814	chr3:48885189	PRKAR2A	0.71	7.88	0.3	1.4e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs4363385	0.747	rs3964619	chr1:152972811	A/C	cg25856811	chr1:152973957	SPRR3	-0.34	-9.02	-0.34	2.12e-18	Inflammatory skin disease;
BRCA	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg04374321	chr14:90722782	PSMC1	-0.5	-11.99	-0.43	5.23e-30	Mortality in heart failure;
BRCA	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg18964960	chr10:1102726	WDR37	0.65	8.85	0.33	8.82e-18	Eosinophil percentage of granulocytes;
BRCA	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg04414720	chr1:150670196	GOLPH3L	0.35	7.84	0.3	1.88e-14	Tonsillectomy;
BRCA	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg04511125	chr2:88470314	THNSL2	-0.45	-9.13	-0.34	8.61e-19	Response to metformin (IC50);
BRCA	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg16325326	chr1:53192061	ZYG11B	-0.94	-26.17	-0.72	3.62e-103	Monocyte count;
BRCA	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg12011299	chr4:100065546	ADH4	0.48	11.21	0.41	9.8e-27	Smoking initiation;
BRCA	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg17385448	chr1:15911702	AGMAT	0.41	9.33	0.35	1.73e-19	Systolic blood pressure;
BRCA	cis	rs701145	0.585	rs1713813	chr3:153873643	T/G	cg17054900	chr3:154042577	DHX36	0.55	9.29	0.35	2.32e-19	Coronary artery disease;
BRCA	cis	rs1865721	0.804	rs59187673	chr18:73143964	A/G	cg26385618	chr18:73139727	C18orf62	-0.43	-10.46	-0.38	9.32e-24	Intelligence;
BRCA	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg02880119	chr16:3481970	NA	0.43	7.97	0.3	7.36e-15	Body mass index (adult);
BRCA	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.11	0.31	2.61e-15	Menarche (age at onset);
BRCA	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.51	11.09	0.4	3e-26	Colorectal cancer;
BRCA	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg08000102	chr2:233561755	GIGYF2	0.64	14.27	0.49	2.56e-40	Coronary artery disease;
BRCA	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg22875332	chr1:76189707	ACADM	0.61	11.74	0.42	5.97e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg04166393	chr7:2884313	GNA12	0.6	11.93	0.43	9.21e-30	Height;
BRCA	cis	rs858239	0.738	rs7807879	chr7:23260588	G/T	cg23682824	chr7:23144976	KLHL7	0.36	9.26	0.34	3.01e-19	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2249625	0.545	rs2496487	chr6:72875226	G/C	cg18830697	chr6:72922368	RIMS1	-0.64	-14.66	-0.5	3.57e-42	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs9341808	0.591	rs6454147	chr6:80916328	G/A	cg08355045	chr6:80787529	NA	0.32	7.95	0.3	8.27e-15	Sitting height ratio;
BRCA	cis	rs2425143	1.000	rs73905926	chr20:34251982	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.8	-0.33	1.31e-17	Blood protein levels;
BRCA	trans	rs931812	1.000	rs4734494	chr8:101917721	T/C	cg20993868	chr7:22813445	NA	0.47	13.13	0.46	4.68e-35	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs6782228	0.606	rs2712381	chr3:128338600	A/C	cg16766828	chr3:128327626	NA	-0.42	-9.54	-0.35	2.9e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg00814883	chr7:100076585	TSC22D4	-0.51	-11.49	-0.41	6.47e-28	Platelet count;
BRCA	cis	rs6910061	0.830	rs6906360	chr6:11118427	C/T	cg27233058	chr6:11094804	LOC221710	0.48	8.36	0.31	4.02e-16	Diabetic kidney disease;
BRCA	trans	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg14791747	chr16:20752902	THUMPD1	0.4	9.42	0.35	8.16e-20	Cognitive test performance;
BRCA	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06108461	chr20:60628389	TAF4	0.62	12.9	0.45	5.2e-34	Body mass index;
BRCA	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg18129178	chr5:148520854	ABLIM3	-0.59	-12.3	-0.44	2.44e-31	Breast cancer;
BRCA	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	2.03e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7903847	0.642	rs6584127	chr10:99142948	A/C	cg08345082	chr10:99160200	RRP12	-0.29	-8.37	-0.31	3.54e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs11229555	0.645	rs4579945	chr11:58190873	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7737355	0.947	rs6882552	chr5:130841493	A/G	cg06307176	chr5:131281290	NA	0.54	10.64	0.39	1.89e-24	Life satisfaction;
BRCA	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg01579765	chr21:45077557	HSF2BP	0.41	10.14	0.37	1.69e-22	Mean corpuscular volume;
BRCA	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg23625390	chr15:77176239	SCAPER	0.43	10.75	0.39	6.84e-25	Blood metabolite levels;
BRCA	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg21573476	chr21:45109991	RRP1B	-0.38	-10.44	-0.38	1.18e-23	Mean corpuscular volume;
BRCA	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg16482183	chr6:26056742	HIST1H1C	0.41	8.78	0.33	1.49e-17	Iron status biomarkers;
BRCA	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14442939	chr10:27389572	ANKRD26	0.53	9.29	0.34	2.37e-19	Breast cancer;
BRCA	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg00031303	chr3:195681400	NA	0.45	8.54	0.32	9.64e-17	Pancreatic cancer;
BRCA	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg13160058	chr8:26243215	BNIP3L	0.43	11.08	0.4	3.36e-26	Red cell distribution width;
BRCA	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg09877947	chr5:131593287	PDLIM4	0.44	10.06	0.37	3.32e-22	Acylcarnitine levels;
BRCA	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg20891283	chr12:69753455	YEATS4	0.73	21.66	0.65	1.94e-78	Blood protein levels;
BRCA	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg24006582	chr15:45444508	DUOX1	0.56	11.26	0.41	6.01e-27	Uric acid levels;
BRCA	cis	rs9309473	1.000	rs7598419	chr2:73798223	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-11.51	-0.41	5.54e-28	Metabolite levels;
BRCA	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg01620082	chr3:125678407	NA	-0.75	-9.59	-0.35	1.86e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1371614	0.635	rs9309559	chr2:27141515	G/T	cg12368169	chr2:27073192	DPYSL5	0.28	8.42	0.32	2.57e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg07169764	chr2:136633963	MCM6	1.23	23.98	0.69	3.98e-91	Corneal structure;
BRCA	trans	rs208520	0.955	rs208538	chr6:66964492	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.78	-13.59	-0.47	3.96e-37	Exhaled nitric oxide output;
BRCA	cis	rs2637266	1.000	rs7896379	chr10:78366247	C/T	cg18941641	chr10:78392320	NA	0.35	7.82	0.3	2.18e-14	Pulmonary function;
BRCA	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg13010199	chr12:38710504	ALG10B	-0.54	-12.01	-0.43	4.15e-30	Heart rate;
BRCA	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-10.14	-0.37	1.7e-22	Schizophrenia;
BRCA	cis	rs2075165	0.901	rs10908492	chr1:156224795	C/T	cg20302342	chr1:156215951	PAQR6	0.33	7.85	0.3	1.73e-14	Tonsillectomy;
BRCA	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg12927641	chr6:109611667	NA	-0.37	-9.11	-0.34	1.05e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs4363385	0.747	rs4478766	chr1:152984906	G/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.35	-0.31	4.16e-16	Inflammatory skin disease;
BRCA	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.48	-9.77	-0.36	4.14e-21	Tonsillectomy;
BRCA	cis	rs1595825	0.838	rs16823400	chr2:198603229	A/G	cg19156104	chr2:198669113	PLCL1	-0.41	-7.83	-0.3	2.02e-14	Ulcerative colitis;
BRCA	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg17136484	chr7:158649327	WDR60	0.41	8.73	0.33	2.13e-17	Height;
BRCA	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg12310025	chr6:25882481	NA	0.42	9.47	0.35	5.4e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs701145	0.556	rs355764	chr3:154013480	A/T	cg16511985	chr3:153974050	SGEF	0.49	11.14	0.4	1.91e-26	Coronary artery disease;
BRCA	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg09754948	chr16:28834200	ATXN2L	0.46	8.45	0.32	2.02e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.34	9.31	0.35	2.03e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg16405210	chr4:1374714	KIAA1530	-0.45	-10.44	-0.38	1.17e-23	Longevity;
BRCA	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg24631222	chr15:78858424	CHRNA5	0.49	9.5	0.35	4.08e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs36051895	0.589	rs16922786	chr9:5200714	A/G	cg02405213	chr9:5042618	JAK2	-0.44	-8.46	-0.32	1.85e-16	Pediatric autoimmune diseases;
BRCA	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.48	-9.77	-0.36	4.23e-21	Bronchopulmonary dysplasia;
BRCA	cis	rs11608355	0.545	rs56144717	chr12:109902304	T/C	cg05360138	chr12:110035743	NA	0.71	13.03	0.46	1.38e-34	Neuroticism;
BRCA	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.11	0.37	2.23e-22	Aortic root size;
BRCA	cis	rs17401966	0.838	rs4475756	chr1:10387788	A/G	cg03954927	chr1:10346856	KIF1B	0.43	14.06	0.49	2.49e-39	Hepatocellular carcinoma;
BRCA	cis	rs13046373	0.508	rs13048637	chr21:31999055	T/G	cg06468780	chr21:31798236	KRTAP13-3	0.33	8.07	0.3	3.5e-15	HDL cholesterol;
BRCA	cis	rs1997103	1.000	rs4628219	chr7:55410449	A/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg01256987	chr12:42539512	GXYLT1	-0.7	-16.89	-0.56	3.35e-53	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11890956	chr21:40555474	PSMG1	-0.6	-13.36	-0.47	4.21e-36	Menarche (age at onset);
BRCA	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg24642439	chr20:33292090	TP53INP2	0.54	11.6	0.42	2.25e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg02733842	chr7:1102375	C7orf50	-0.6	-10.6	-0.39	2.67e-24	Bronchopulmonary dysplasia;
BRCA	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg17143192	chr8:8559678	CLDN23	0.55	10.5	0.38	6.52e-24	Obesity-related traits;
BRCA	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg17788362	chr6:86352627	SYNCRIP	0.44	8.6	0.32	6.09e-17	Smooth-surface caries;
BRCA	cis	rs7631605	0.935	rs9819025	chr3:37073287	T/G	cg15934958	chr3:37212084	LRRFIP2	0.41	9.54	0.35	3e-20	Cerebrospinal P-tau181p levels;
BRCA	trans	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.22	0.31	1.12e-15	Corneal astigmatism;
BRCA	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg10253484	chr15:75165896	SCAMP2	-0.51	-9.75	-0.36	5.09e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg18964960	chr10:1102726	WDR37	0.6	8.02	0.3	5.2e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.55	13.19	0.46	2.56e-35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs912057	0.671	rs1294420	chr6:6742752	C/T	cg06612196	chr6:6737390	NA	0.46	10.82	0.39	3.65e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg10057126	chr4:77819792	ANKRD56	0.65	15.21	0.52	8.53e-45	Emphysema distribution in smoking;
BRCA	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg26031613	chr14:104095156	KLC1	0.44	8.74	0.33	1.98e-17	Schizophrenia;
BRCA	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-17.91	-0.58	1.96e-58	Chronic sinus infection;
BRCA	cis	rs1555322	0.530	rs2425043	chr20:33868702	T/C	cg03689076	chr20:33865952	NA	0.44	8.1	0.31	2.74e-15	Attention deficit hyperactivity disorder;
BRCA	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg09307838	chr4:120376055	NA	0.66	14.3	0.49	1.9e-40	Corneal astigmatism;
BRCA	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg25173405	chr17:45401733	C17orf57	0.45	9.27	0.34	2.71e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7560272	0.501	rs6750494	chr2:73946496	G/A	cg20560298	chr2:73613845	ALMS1	0.33	8.53	0.32	1.06e-16	Schizophrenia;
BRCA	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg19508488	chr2:152266495	RIF1	0.49	10.6	0.39	2.68e-24	Lung cancer;
BRCA	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18876405	chr7:65276391	NA	-0.5	-11.07	-0.4	3.5e-26	Aortic root size;
BRCA	trans	rs1493916	0.837	rs2123333	chr18:31410730	G/A	cg15819921	chr19:927150	ARID3A	-0.41	-8.11	-0.31	2.57e-15	Life satisfaction;
BRCA	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg18252515	chr7:66147081	NA	-1.04	-15.22	-0.52	7.66e-45	Diabetic kidney disease;
BRCA	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg03433033	chr1:76189801	ACADM	0.75	16.21	0.54	9.49e-50	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg00383909	chr3:49044727	WDR6	0.93	14.32	0.49	1.6e-40	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs9788721	0.836	rs17484235	chr15:78761414	C/G	cg18825076	chr15:78729989	IREB2	-0.45	-8.73	-0.33	2.13e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg13047869	chr3:10149882	C3orf24	0.55	10.19	0.37	1.03e-22	Alzheimer's disease;
BRCA	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg12927641	chr6:109611667	NA	-0.42	-10.81	-0.39	4.04e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg11822812	chr5:140052017	DND1	0.33	9.13	0.34	9.26e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs11828289	0.660	rs17306426	chr11:23222079	G/T	cg20040320	chr11:23191996	NA	0.55	7.91	0.3	1.1e-14	Cancer;
BRCA	cis	rs11608355	0.545	rs11615949	chr12:109894347	G/A	cg05360138	chr12:110035743	NA	0.71	13.1	0.46	6.6e-35	Neuroticism;
BRCA	cis	rs4363385	0.818	rs9659389	chr1:152989844	T/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.32	-0.31	5.13e-16	Inflammatory skin disease;
BRCA	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23583168	chr7:148888333	NA	-0.84	-19.08	-0.6	1.46e-64	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	16.48	0.55	4.05e-51	Lymphocyte counts;
BRCA	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-9.06	-0.34	1.58e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.68	-0.32	3.33e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	13.89	0.48	1.53e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg14926445	chr8:58193284	C8orf71	-0.44	-8.38	-0.31	3.41e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.5	-0.32	1.36e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08109568	chr15:31115862	NA	-0.45	-10.64	-0.39	1.84e-24	Huntington's disease progression;
BRCA	cis	rs4930561	0.714	rs7122250	chr11:67946472	T/C	cg04465784	chr11:67976953	SUV420H1	-0.26	-8.59	-0.32	6.39e-17	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs929596	0.597	rs10173355	chr2:234597321	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.4	-9.67	-0.36	9.65e-21	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.96	-0.46	2.97e-34	Migraine;Coronary artery disease;
BRCA	trans	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg01620082	chr3:125678407	NA	-0.83	-9.45	-0.35	6.18e-20	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg15556689	chr8:8085844	FLJ10661	-0.33	-8.61	-0.32	5.79e-17	Myopia (pathological);
BRCA	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg25427524	chr10:38739819	LOC399744	-0.54	-9.45	-0.35	6.5e-20	Obesity (extreme);
BRCA	cis	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg00852783	chr1:26633632	UBXN11	-0.45	-7.93	-0.3	1.02e-14	Obesity-related traits;
BRCA	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg27129171	chr3:47204927	SETD2	-0.72	-17.31	-0.56	2.57e-55	Colorectal cancer;
BRCA	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg13010199	chr12:38710504	ALG10B	-0.49	-9.89	-0.36	1.5e-21	Bladder cancer;
BRCA	cis	rs4302748	0.862	rs57133121	chr7:36182859	G/T	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg11764359	chr7:65958608	NA	0.65	11.2	0.41	1.03e-26	Aortic root size;
BRCA	cis	rs4974559	0.895	rs12646130	chr4:1330530	G/C	cg02980000	chr4:1222292	CTBP1	0.77	12.67	0.45	5.56e-33	Systolic blood pressure;
BRCA	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10802521	chr3:52805072	NEK4	0.3	7.85	0.3	1.79e-14	Bipolar disorder;
BRCA	cis	rs7523273	0.606	rs2488252	chr1:207938228	C/T	cg22525895	chr1:207977042	MIR29B2	0.47	12.04	0.43	3.08e-30	Schizophrenia;
BRCA	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	9.97	0.37	7.69e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs870825	0.929	rs1405939	chr4:185591444	C/T	cg04058563	chr4:185651563	MLF1IP	0.65	11.19	0.4	1.1e-26	Blood protein levels;
BRCA	trans	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg26043149	chr18:55253948	FECH	-0.38	-8.32	-0.31	5.17e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg08132940	chr7:1081526	C7orf50	-0.44	-7.84	-0.3	1.95e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg21427119	chr20:30132790	HM13	-0.43	-9.03	-0.34	2e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg00105475	chr2:10696890	NA	-0.45	-10.46	-0.38	9.29e-24	Prostate cancer;
BRCA	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg21918786	chr6:109611834	NA	-0.49	-14.06	-0.49	2.61e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11890956	chr21:40555474	PSMG1	-0.54	-10.95	-0.4	1.05e-25	Menarche (age at onset);
BRCA	cis	rs4363385	0.747	rs9919227	chr1:152970867	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-8.98	-0.33	3.11e-18	Inflammatory skin disease;
BRCA	cis	rs7809950	1.000	rs6976607	chr7:107223401	A/C	cg23024343	chr7:107201750	COG5	0.42	9.02	0.34	2.24e-18	Coronary artery disease;
BRCA	cis	rs701145	0.730	rs2666192	chr3:154004009	T/C	cg17054900	chr3:154042577	DHX36	0.68	11.79	0.42	3.71e-29	Coronary artery disease;
BRCA	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg00376283	chr12:123451042	ABCB9	0.48	10.9	0.4	1.68e-25	Neutrophil percentage of white cells;
BRCA	trans	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg25214090	chr10:38739885	LOC399744	0.35	8.04	0.3	4.34e-15	Diastolic blood pressure;
BRCA	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg03188948	chr7:1209495	NA	0.85	8.62	0.32	5.18e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg25358565	chr5:93447407	FAM172A	-0.67	-11.77	-0.42	4.23e-29	Diabetic retinopathy;
BRCA	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.78	-0.33	1.51e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-18.2	-0.58	5.86e-60	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg20891558	chr2:74357851	NA	0.36	7.84	0.3	1.87e-14	Gestational age at birth (maternal effect);
BRCA	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg08999081	chr20:33150536	PIGU	-0.33	-7.83	-0.3	2.11e-14	Glomerular filtration rate (creatinine);
BRCA	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	4.04e-15	Alzheimer's disease (late onset);
BRCA	trans	rs6479891	0.915	rs2616628	chr10:65219957	G/C	cg14819942	chr15:35414228	NA	0.35	8.59	0.32	6.62e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg24531977	chr5:56204891	C5orf35	0.41	8.15	0.31	1.88e-15	Coronary artery disease;
BRCA	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg08807101	chr21:30365312	RNF160	0.45	9.43	0.35	7.53e-20	Cognitive test performance;
BRCA	cis	rs2652834	0.851	rs7170462	chr15:63345622	A/G	cg05507819	chr15:63340323	TPM1	0.52	9.16	0.34	7.04e-19	HDL cholesterol;
BRCA	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg22875332	chr1:76189707	ACADM	0.66	15.65	0.53	5.95e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg03146154	chr1:46216737	IPP	-0.51	-11.2	-0.41	1.06e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.63	9.69	0.36	8.49e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs17741873	0.836	rs10824039	chr10:75602849	G/A	cg07699608	chr10:75541558	CHCHD1	0.56	8.76	0.33	1.79e-17	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg23708337	chr7:1209742	NA	0.63	8.85	0.33	8.71e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg20307385	chr11:47447363	PSMC3	0.76	16.91	0.56	2.84e-53	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs16866061	1.000	rs2047134	chr2:225347713	A/C	cg12698349	chr2:225449008	CUL3	0.76	20.26	0.63	7.31e-71	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs2559856	0.904	rs2695283	chr12:102089391	G/C	cg12924262	chr12:102091054	CHPT1	0.38	8.65	0.32	4.28e-17	Blood protein levels;
BRCA	cis	rs534126	0.744	rs10248147	chr7:142941023	C/G	cg22531018	chr7:142981779	TMEM139	-0.47	-10.75	-0.39	7.07e-25	Cancer;
BRCA	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg23033748	chr14:75592666	NEK9	0.43	10.17	0.37	1.26e-22	Height;
BRCA	trans	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg07211511	chr3:129823064	LOC729375	-0.96	-13.57	-0.47	5.09e-37	Blood pressure (smoking interaction);
BRCA	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg00071950	chr4:10020882	SLC2A9	0.63	16.17	0.54	1.49e-49	Bone mineral density;
BRCA	cis	rs2346177	0.811	rs4953373	chr2:46652145	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.38	7.95	0.3	8.24e-15	HDL cholesterol;
BRCA	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	19.97	0.62	2.63e-69	Platelet count;
BRCA	cis	rs1832871	0.711	rs9459954	chr6:158709345	G/T	cg07215822	chr6:158701037	NA	-0.51	-8.21	-0.31	1.22e-15	Height;
BRCA	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00149659	chr3:10157352	C3orf10	1.07	18.11	0.58	1.87e-59	Alzheimer's disease;
BRCA	cis	rs72772090	0.539	rs3335	chr5:96115070	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.16	-0.43	9.57e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg21724239	chr8:58056113	NA	0.57	9.25	0.34	3.22e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg06784218	chr1:46089804	CCDC17	0.45	10.7	0.39	1.08e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.71	0.33	2.58e-17	Personality dimensions;
BRCA	cis	rs7301826	0.557	rs7953184	chr12:131284852	T/G	cg11011512	chr12:131303247	STX2	-0.48	-12.52	-0.44	2.48e-32	Plasma plasminogen activator levels;
BRCA	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg01483505	chr11:975446	AP2A2	0.33	8.98	0.33	2.93e-18	Alzheimer's disease (late onset);
BRCA	cis	rs2629540	0.889	rs4962402	chr10:126459114	T/G	cg08799069	chr10:126477246	METTL10	-0.53	-11.66	-0.42	1.29e-28	Cocaine dependence;
BRCA	cis	rs1035144	0.506	rs7150858	chr14:81280425	T/C	cg06600135	chr14:81408086	NA	-0.39	-9.24	-0.34	3.66e-19	Male sexual orientation;
BRCA	cis	rs6910061	0.830	rs36021520	chr6:11106122	C/T	cg27233058	chr6:11094804	LOC221710	0.5	8.44	0.32	2.19e-16	Diabetic kidney disease;
BRCA	trans	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg26384229	chr12:38710491	ALG10B	0.44	10.55	0.39	4.3e-24	Morning vs. evening chronotype;
BRCA	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg16405210	chr4:1374714	KIAA1530	-0.45	-10.41	-0.38	1.48e-23	Longevity;
BRCA	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg09904177	chr6:26538194	HMGN4	0.47	15.0	0.51	8.32e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg24812749	chr6:127587940	RNF146	0.88	20.75	0.63	1.58e-73	Breast cancer;
BRCA	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	12.86	0.45	7.71e-34	Electrocardiographic conduction measures;
BRCA	cis	rs3125734	0.633	rs4561099	chr10:64041163	T/C	cg19640130	chr10:64028056	RTKN2	-0.32	-9.15	-0.34	7.85e-19	Rheumatoid arthritis;
BRCA	trans	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg06606381	chr12:133084897	FBRSL1	-0.89	-9.35	-0.35	1.42e-19	Depression;
BRCA	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg08885076	chr2:99613938	TSGA10	-0.53	-12.25	-0.44	3.9e-31	Chronic sinus infection;
BRCA	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.64	-0.32	4.59e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	9.01	0.34	2.36e-18	Tonsillectomy;
BRCA	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg13628971	chr7:2884303	GNA12	0.47	9.42	0.35	7.9e-20	Height;
BRCA	cis	rs654950	0.806	rs1815257	chr1:42041479	A/C	cg06885757	chr1:42089581	HIVEP3	-0.3	-10.33	-0.38	3.09e-23	Airway imaging phenotypes;
BRCA	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg16339924	chr4:17578868	LAP3	0.67	17.11	0.56	2.65e-54	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.48	10.53	0.38	5.12e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10992471	0.603	rs747628	chr9:95289532	A/T	cg14631576	chr9:95140430	CENPP	-0.34	-8.34	-0.31	4.67e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg06808227	chr14:105710500	BRF1	-0.79	-16.08	-0.54	3.99e-49	Mean platelet volume;Platelet distribution width;
BRCA	trans	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg04565464	chr8:145669602	NFKBIL2	-0.37	-9.16	-0.34	7.06e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs6942756	0.876	rs822039	chr7:129065774	A/G	cg02491457	chr7:128862824	NA	-0.57	-11.84	-0.42	2.31e-29	White matter hyperintensity burden;
BRCA	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg23649088	chr2:200775458	C2orf69	0.49	10.1	0.37	2.33e-22	Osteoporosis;
BRCA	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.21	0.49	5.09e-40	Motion sickness;
BRCA	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26314531	chr2:26401878	FAM59B	-0.47	-8.54	-0.32	9.5e-17	Gut microbiome composition (summer);
BRCA	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg25703541	chr22:24373054	LOC391322	-0.66	-15.21	-0.52	8.21e-45	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg16590910	chr6:42928470	GNMT	0.43	9.61	0.36	1.65e-20	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6580649	0.943	rs1990029	chr12:48407987	C/T	cg05342945	chr12:48394962	COL2A1	-0.5	-9.65	-0.36	1.18e-20	Lung cancer;
BRCA	cis	rs13102973	0.640	rs11737779	chr4:135831516	C/T	cg14419869	chr4:135874104	NA	0.47	9.64	0.36	1.24e-20	Subjective well-being;
BRCA	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.67	14.42	0.5	5.39e-41	Lymphocyte counts;
BRCA	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg16339924	chr4:17578868	LAP3	-0.61	-14.95	-0.51	1.57e-43	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg08470875	chr2:26401718	FAM59B	-0.5	-8.17	-0.31	1.65e-15	Gut microbiome composition (summer);
BRCA	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18876405	chr7:65276391	NA	-0.55	-12.97	-0.46	2.6e-34	Aortic root size;
BRCA	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg15556689	chr8:8085844	FLJ10661	0.37	8.71	0.33	2.68e-17	Retinal vascular caliber;
BRCA	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg26384229	chr12:38710491	ALG10B	0.44	10.6	0.39	2.77e-24	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg04842962	chr6:43655489	MRPS18A	1.13	39.06	0.84	1.82e-171	IgG glycosylation;
BRCA	cis	rs701145	0.585	rs1727882	chr3:153837246	C/T	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.82e-18	Coronary artery disease;
BRCA	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	16.82	0.55	7.99e-53	Bone mineral density;
BRCA	trans	rs853679	0.546	rs2232426	chr6:28360659	G/C	cg06606381	chr12:133084897	FBRSL1	-0.9	-8.84	-0.33	9.38e-18	Depression;
BRCA	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg26597838	chr10:835615	NA	0.98	17.29	0.56	2.96e-55	Eosinophil percentage of granulocytes;
BRCA	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11890956	chr21:40555474	PSMG1	1.06	30.01	0.76	3.96e-124	Cognitive function;
BRCA	cis	rs2742234	0.541	rs60845448	chr10:43721462	C/T	cg02780029	chr10:43622663	RET	0.35	7.86	0.3	1.69e-14	Hirschsprung disease;
BRCA	cis	rs17253792	0.822	rs77197405	chr14:56159662	T/A	cg01858014	chr14:56050164	KTN1	-0.76	-9.61	-0.36	1.57e-20	Putamen volume;
BRCA	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg16386425	chr10:429943	DIP2C	-0.41	-8.83	-0.33	1e-17	Psychosis in Alzheimer's disease;
BRCA	cis	rs13223928	0.621	rs4722438	chr7:3155813	A/G	cg19214707	chr7:3157722	NA	0.44	11.03	0.4	5.12e-26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
BRCA	cis	rs9308433	0.569	rs1353718	chr1:214459652	A/T	cg06198575	chr1:214491504	SMYD2	0.51	10.67	0.39	1.44e-24	IgG glycosylation;
BRCA	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.07	0.49	2.42e-39	Motion sickness;
BRCA	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.08e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs427394	0.659	rs274693	chr5:6734162	G/A	cg10857441	chr5:6722123	POLS	-0.31	-9.87	-0.36	1.72e-21	Menopause (age at onset);
BRCA	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.98	-0.48	6.13e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg00012203	chr2:219082015	ARPC2	0.64	13.27	0.46	1.12e-35	Colorectal cancer;
BRCA	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg25554036	chr4:6271136	WFS1	0.38	9.32	0.35	1.84e-19	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg00012203	chr2:219082015	ARPC2	-0.48	-9.21	-0.34	4.58e-19	Colorectal cancer;
BRCA	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.33	10.64	0.39	1.94e-24	Bipolar disorder;
BRCA	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg12386194	chr3:101231763	SENP7	0.44	9.52	0.35	3.43e-20	Colorectal cancer;
BRCA	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.35	-9.15	-0.34	7.76e-19	Total body bone mineral density;
BRCA	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07636037	chr3:49044803	WDR6	-0.75	-16.03	-0.54	7.41e-49	Menarche (age at onset);
BRCA	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg18279126	chr7:2041391	MAD1L1	0.37	8.0	0.3	5.76e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg00666640	chr1:248458726	OR2T12	0.3	8.58	0.32	7.32e-17	Common traits (Other);
BRCA	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg05340658	chr4:99064831	C4orf37	0.67	15.74	0.53	2.01e-47	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1371614	0.635	rs12612619	chr2:27137671	C/T	cg12368169	chr2:27073192	DPYSL5	-0.31	-9.16	-0.34	7.14e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg26384229	chr12:38710491	ALG10B	0.75	16.96	0.56	1.52e-53	Bladder cancer;
BRCA	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.54	9.96	0.37	8.26e-22	Height;
BRCA	cis	rs28595532	0.582	rs71608361	chr4:119224081	T/C	cg21605333	chr4:119757512	SEC24D	0.81	8.48	0.32	1.58e-16	Cannabis dependence symptom count;
BRCA	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.22	0.34	4.4e-19	Tonsillectomy;
BRCA	cis	rs7640424	0.929	rs17828045	chr3:107821546	A/C	cg09227934	chr3:107805635	CD47	-0.4	-8.34	-0.31	4.46e-16	Body mass index;
BRCA	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg03585969	chr10:35415529	CREM	0.48	10.03	0.37	4.24e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6815814	0.851	rs17582893	chr4:38886420	G/A	cg02016764	chr4:38805732	TLR1	-0.53	-8.49	-0.32	1.41e-16	Breast cancer;
BRCA	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg04450456	chr4:17643702	FAM184B	0.38	11.4	0.41	1.55e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg25206134	chr2:45395956	NA	0.52	8.4	0.32	3e-16	Neuroticism;
BRCA	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.15	-0.43	1.1e-30	Total cholesterol levels;
BRCA	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg04455712	chr21:45112962	RRP1B	0.4	10.16	0.37	1.36e-22	Mean corpuscular volume;
BRCA	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.32	0.61	7.31e-66	Alzheimer's disease;
BRCA	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg13010199	chr12:38710504	ALG10B	0.45	9.4	0.35	9.42e-20	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs3857536	0.785	rs1935895	chr6:66936606	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs7246967	0.673	rs2361260	chr19:22914144	C/T	cg23217946	chr19:22817039	ZNF492	-0.5	-9.13	-0.34	9.02e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg11814155	chr7:99998594	ZCWPW1	0.48	8.81	0.33	1.22e-17	Platelet count;
BRCA	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg09184832	chr6:79620586	NA	-0.41	-8.2	-0.31	1.35e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs586533	0.881	rs657055	chr11:99500087	G/A	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.52	12.99	0.46	2.13e-34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	18.24	0.59	3.67e-60	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg10556349	chr10:835070	NA	0.6	8.41	0.32	2.75e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg09455208	chr3:40491958	NA	0.41	9.75	0.36	5.14e-21	Renal cell carcinoma;
BRCA	cis	rs644148	0.781	rs630469	chr19:44970167	T/C	cg15540054	chr19:45004280	ZNF180	-0.57	-12.05	-0.43	2.76e-30	Personality dimensions;
BRCA	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	10.07	0.37	3.2e-22	Aortic root size;
BRCA	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg25554036	chr4:6271136	WFS1	0.44	10.48	0.38	7.8e-24	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg18200150	chr17:30822561	MYO1D	0.34	8.74	0.33	2.12e-17	Schizophrenia;
BRCA	cis	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg09307838	chr4:120376055	NA	0.47	9.76	0.36	4.59e-21	Diastolic blood pressure;
BRCA	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs12310956	0.510	rs7301767	chr12:33886529	A/T	cg26384229	chr12:38710491	ALG10B	0.39	9.19	0.34	5.51e-19	Morning vs. evening chronotype;
BRCA	cis	rs427394	0.582	rs4701751	chr5:6704137	C/T	cg10857441	chr5:6722123	POLS	-0.3	-9.23	-0.34	3.91e-19	Menopause (age at onset);
BRCA	trans	rs4650994	1.000	rs10798617	chr1:178515806	T/C	cg05059571	chr16:84539110	KIAA1609	-0.42	-9.6	-0.36	1.71e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21659725	chr3:3221576	CRBN	-0.45	-9.45	-0.35	6.06e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4077515	0.967	rs3812558	chr9:139269135	A/G	cg14019695	chr9:139328340	INPP5E	0.31	7.89	0.3	1.3e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.18	-0.34	5.91e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg16386425	chr10:429943	DIP2C	0.39	8.14	0.31	2.11e-15	Psychosis in Alzheimer's disease;
BRCA	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg05347473	chr6:146136440	FBXO30	-0.6	-11.33	-0.41	3.05e-27	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg06552810	chr11:31128660	NA	-0.4	-8.92	-0.33	4.82e-18	Red blood cell count;
BRCA	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg03954927	chr1:10346856	KIF1B	0.43	13.7	0.48	1.21e-37	Hepatocellular carcinoma;
BRCA	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	10.62	0.39	2.24e-24	Motion sickness;
BRCA	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg02175503	chr12:58329896	NA	-0.38	-8.21	-0.31	1.21e-15	Multiple sclerosis;
BRCA	cis	rs6005807	0.719	rs9625521	chr22:29039953	T/G	cg12565055	chr22:29076175	TTC28	0.5	9.36	0.35	1.32e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg05863683	chr7:1912471	MAD1L1	0.38	8.34	0.31	4.67e-16	Schizophrenia;
BRCA	cis	rs8177179	0.570	rs4441652	chr3:133439450	A/G	cg24879335	chr3:133465180	TF	0.28	8.33	0.31	4.86e-16	Iron status biomarkers (transferrin levels);
BRCA	cis	rs17741873	0.779	rs17631000	chr10:75602500	C/T	cg07699608	chr10:75541558	CHCHD1	-0.51	-8.03	-0.3	4.62e-15	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-8.13	-0.31	2.2e-15	Obesity-related traits;
BRCA	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg17366294	chr4:99064904	C4orf37	0.43	9.94	0.37	9.93e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs965469	0.947	rs1854834	chr20:3376619	C/T	cg25506879	chr20:3388711	C20orf194	-0.54	-10.44	-0.38	1.12e-23	IFN-related cytopenia;
BRCA	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg13902645	chr11:5959945	NA	-0.54	-10.92	-0.4	1.4e-25	DNA methylation (variation);
BRCA	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg17971929	chr21:40555470	PSMG1	0.77	17.94	0.58	1.35e-58	Cognitive function;
BRCA	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs4948102	0.924	rs13240915	chr7:56090752	G/C	cg09872392	chr7:56161020	PHKG1	-0.4	-9.29	-0.34	2.42e-19	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.38	-0.31	3.32e-16	Breast cancer;
BRCA	cis	rs73086581	1.000	rs73088416	chr20:3995276	A/G	cg02187196	chr20:3869020	PANK2	0.54	9.43	0.35	7.47e-20	Response to antidepressants in depression;
BRCA	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg13010199	chr12:38710504	ALG10B	0.55	11.92	0.43	1e-29	Heart rate;
BRCA	cis	rs4363385	0.747	rs1413848	chr1:152970210	C/T	cg21543102	chr1:152974771	SPRR3	-0.28	-8.01	-0.3	5.65e-15	Inflammatory skin disease;
BRCA	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg02711726	chr17:80685570	FN3KRP	0.68	16.67	0.55	4.3e-52	Glycated hemoglobin levels;
BRCA	cis	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg07460842	chr6:66804631	NA	0.62	11.44	0.41	1.1e-27	Type 2 diabetes;
BRCA	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg04518342	chr5:131593106	PDLIM4	0.38	8.78	0.33	1.48e-17	Acylcarnitine levels;
BRCA	cis	rs11622475	1.000	rs1187448	chr14:104406627	C/T	cg12183467	chr14:104352244	NA	-0.48	-10.24	-0.38	6.99e-23	Bipolar disorder;
BRCA	cis	rs13064411	0.696	rs6768648	chr3:113234141	C/G	cg18753928	chr3:113234510	CCDC52	-0.59	-12.37	-0.44	1.15e-31	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs68170813	0.559	rs12535081	chr7:106979291	C/T	cg02696742	chr7:106810147	HBP1	-0.55	-8.69	-0.33	2.97e-17	Coronary artery disease;
BRCA	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	15.11	0.51	2.4e-44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.92	0.56	2.52e-53	Hypertriglyceridemia;
BRCA	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg26384229	chr12:38710491	ALG10B	0.73	16.78	0.55	1.32e-52	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg25358565	chr5:93447407	FAM172A	-0.62	-10.92	-0.4	1.47e-25	Diabetic retinopathy;
BRCA	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg18811423	chr2:55921094	PNPT1	0.72	22.21	0.66	2.03e-81	Metabolic syndrome;
BRCA	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg01475377	chr6:109611718	NA	-0.59	-16.46	-0.55	5.04e-51	Reticulocyte fraction of red cells;
BRCA	cis	rs12541635	0.932	rs1835267	chr8:107044435	C/T	cg10147462	chr8:107024639	NA	0.37	9.69	0.36	8.27e-21	Age of smoking initiation;
BRCA	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00684032	chr4:1343700	KIAA1530	0.51	12.28	0.44	3.01e-31	Obesity-related traits;
BRCA	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg24642439	chr20:33292090	TP53INP2	0.61	13.64	0.47	2.22e-37	Coronary artery disease;
BRCA	cis	rs595982	0.517	rs10404905	chr19:49406175	A/T	cg21252483	chr19:49399788	TULP2	0.27	8.48	0.32	1.57e-16	Red cell distribution width;
BRCA	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg06784218	chr1:46089804	CCDC17	0.51	12.48	0.44	4.02e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs68170813	0.559	rs12537342	chr7:106943563	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.64	-0.32	4.46e-17	Coronary artery disease;
BRCA	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg25358565	chr5:93447407	FAM172A	1.16	18.69	0.59	1.7e-62	Diabetic retinopathy;
BRCA	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg18230493	chr5:56204884	C5orf35	0.6	12.85	0.45	8.8e-34	Initial pursuit acceleration;
BRCA	cis	rs10267417	0.603	rs9638768	chr7:19869522	C/T	cg05791153	chr7:19748676	TWISTNB	-0.45	-8.42	-0.32	2.56e-16	Night sleep phenotypes;
BRCA	cis	rs2425143	1.000	rs60646509	chr20:34303409	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.96	-0.33	3.53e-18	Blood protein levels;
BRCA	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg13010199	chr12:38710504	ALG10B	0.49	9.53	0.35	3.12e-20	Morning vs. evening chronotype;
BRCA	cis	rs7727544	0.582	rs10052046	chr5:131544466	G/T	cg14196790	chr5:131705035	SLC22A5	0.36	9.15	0.34	7.58e-19	Blood metabolite levels;
BRCA	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg22906224	chr7:99728672	NA	0.44	8.46	0.32	1.87e-16	Coronary artery disease;
BRCA	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.94	-0.33	4.31e-18	Mood instability;
BRCA	cis	rs13046373	0.508	rs2253516	chr21:31993317	C/T	cg14062083	chr21:31802829	KRTAP13-4	0.34	9.14	0.34	8.23e-19	HDL cholesterol;
BRCA	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.86	-0.36	1.89e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg19318889	chr4:1322082	MAEA	-0.48	-10.05	-0.37	3.77e-22	Obesity-related traits;
BRCA	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.18	-0.49	7.04e-40	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2625529	0.652	rs2929518	chr15:72332748	A/C	cg16672083	chr15:72433130	SENP8	0.67	16.21	0.54	9.08e-50	Red blood cell count;
BRCA	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.67	15.55	0.52	1.82e-46	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.51	-14.7	-0.5	2.43e-42	Lung cancer;
BRCA	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg04546413	chr19:29218101	NA	0.61	12.5	0.44	3.15e-32	Methadone dose in opioid dependence;
BRCA	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.03e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.4	1.46e-26	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	8.36	0.31	3.97e-16	Schizophrenia;
BRCA	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-9.9	-0.36	1.32e-21	Bone mineral density;
BRCA	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg14675211	chr2:100938903	LONRF2	0.43	9.86	0.36	1.89e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg18758796	chr5:131593413	PDLIM4	0.36	9.34	0.35	1.63e-19	Breast cancer;
BRCA	cis	rs7043114	0.525	rs2025388	chr9:95128740	T/C	cg14631576	chr9:95140430	CENPP	-0.34	-8.39	-0.31	3.16e-16	Height;
BRCA	cis	rs6484504	0.553	rs413067	chr11:31223497	T/C	cg06552810	chr11:31128660	NA	-0.39	-8.65	-0.32	4.19e-17	Red blood cell count;
BRCA	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg26031613	chr14:104095156	KLC1	-0.42	-8.54	-0.32	1e-16	Schizophrenia;
BRCA	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg06618935	chr21:46677482	NA	-0.35	-8.02	-0.3	5.04e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg06521331	chr12:34319734	NA	-0.59	-10.7	-0.39	1.13e-24	Morning vs. evening chronotype;
BRCA	cis	rs1371614	0.679	rs4441421	chr2:27142091	G/A	cg00617064	chr2:27272375	NA	-0.3	-7.86	-0.3	1.6e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs9682041	0.808	rs9875109	chr3:170064776	A/G	cg11886554	chr3:170076028	SKIL	-0.49	-9.78	-0.36	3.78e-21	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	trans	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg25214090	chr10:38739885	LOC399744	0.46	10.44	0.38	1.13e-23	Corneal astigmatism;
BRCA	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg06453172	chr10:134556979	INPP5A	-0.47	-10.36	-0.38	2.43e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.02	15.31	0.52	2.64e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4845570	1.000	rs11585294	chr1:151769887	A/C	cg07092448	chr1:151763213	TDRKH	-0.95	-16.17	-0.54	1.54e-49	Coronary artery disease;
BRCA	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg20573242	chr4:122745356	CCNA2	0.49	10.86	0.39	2.41e-25	Type 2 diabetes;
BRCA	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg12386194	chr3:101231763	SENP7	0.45	9.6	0.35	1.79e-20	Colorectal cancer;
BRCA	cis	rs12618769	0.656	rs56091613	chr2:99103761	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs1209950	0.866	rs1734588	chr21:40180889	A/G	cg01359822	chr21:40176597	ETS2	0.35	8.59	0.32	6.89e-17	Non-small cell lung cancer (survival);
BRCA	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg06784218	chr1:46089804	CCDC17	0.49	11.66	0.42	1.26e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504073	0.565	rs974780	chr8:49930976	G/A	cg00325661	chr8:49890786	NA	0.54	15.54	0.52	1.89e-46	Blood metabolite ratios;
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg22907277	chr7:1156413	C7orf50	0.53	11.52	0.41	5.09e-28	Longevity;Endometriosis;
BRCA	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08219700	chr8:58056026	NA	0.47	8.61	0.32	5.68e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs10193935	1.000	rs10193935	chr2:42419829	C/T	cg27598129	chr2:42591480	NA	-0.87	-14.24	-0.49	3.5e-40	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.35	-0.35	1.45e-19	Bipolar disorder;
BRCA	cis	rs4363385	0.818	rs10888524	chr1:153000125	A/G	cg24667326	chr1:152973720	SPRR3	-0.33	-9.01	-0.34	2.29e-18	Inflammatory skin disease;
BRCA	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg24642439	chr20:33292090	TP53INP2	-0.44	-8.82	-0.33	1.12e-17	Height;
BRCA	cis	rs2882667	0.690	rs6860780	chr5:138160056	A/G	cg04439458	chr5:138467593	SIL1	0.31	7.82	0.3	2.23e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg08999081	chr20:33150536	PIGU	-0.44	-12.06	-0.43	2.68e-30	Glomerular filtration rate (creatinine);
BRCA	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg08000102	chr2:233561755	GIGYF2	0.64	14.75	0.5	1.43e-42	Coronary artery disease;
BRCA	cis	rs12210905	0.610	rs12204953	chr6:27396737	G/A	cg08851530	chr6:28072375	NA	0.81	7.94	0.3	8.95e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg22903471	chr2:27725779	GCKR	-0.35	-8.4	-0.32	2.79e-16	Menopause (age at onset);
BRCA	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg15839431	chr19:19639596	YJEFN3	-0.43	-9.16	-0.34	6.76e-19	Bipolar disorder;
BRCA	cis	rs708547	0.915	rs28605409	chr4:57766261	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.47	10.87	0.39	2.33e-25	Response to bleomycin (chromatid breaks);
BRCA	trans	rs1973993	0.689	rs17131755	chr1:96886167	G/A	cg10631902	chr5:14652156	NA	-0.45	-12.52	-0.44	2.49e-32	Weight;
BRCA	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11890956	chr21:40555474	PSMG1	-0.62	-13.75	-0.48	6.99e-38	Menarche (age at onset);
BRCA	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg10932868	chr11:921992	NA	0.39	9.52	0.35	3.6e-20	Alzheimer's disease (late onset);
BRCA	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.56	-0.52	1.55e-46	Chronic sinus infection;
BRCA	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	11.06	0.4	3.79e-26	Retinal vascular caliber;
BRCA	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-13.22	-0.46	1.85e-35	Platelet count;
BRCA	cis	rs758324	0.947	rs1500115	chr5:131216427	G/T	cg06307176	chr5:131281290	NA	0.52	10.01	0.37	5.18e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	trans	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg26043149	chr18:55253948	FECH	0.4	8.77	0.33	1.59e-17	Bone mineral density;
BRCA	cis	rs2320614	0.967	rs12500406	chr4:164034998	C/A	cg15586945	chr4:164088095	NAF1	-0.4	-8.08	-0.3	3.35e-15	Lung adenocarcinoma;
BRCA	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg26769984	chr7:1090371	C7orf50	0.43	9.13	0.34	8.76e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg11833968	chr6:79620685	NA	-0.44	-9.76	-0.36	4.58e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg06238570	chr21:40685208	BRWD1	-0.39	-7.86	-0.3	1.69e-14	Menarche (age at onset);
BRCA	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.56	-13.83	-0.48	2.95e-38	Longevity;Endometriosis;
BRCA	cis	rs754466	0.651	rs11813532	chr10:79637991	T/C	cg17075019	chr10:79541650	NA	-0.73	-17.61	-0.57	7.05e-57	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-13.8	-0.48	4.04e-38	Morning vs. evening chronotype;
BRCA	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg11764359	chr7:65958608	NA	-0.66	-12.12	-0.43	1.34e-30	Aortic root size;
BRCA	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg01528321	chr10:82214614	TSPAN14	0.81	17.1	0.56	2.94e-54	Post bronchodilator FEV1;
BRCA	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg13010199	chr12:38710504	ALG10B	0.59	12.95	0.46	3.28e-34	Heart rate;
BRCA	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg21132104	chr15:45694354	SPATA5L1	0.7	15.45	0.52	5.52e-46	Homoarginine levels;
BRCA	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg20307385	chr11:47447363	PSMC3	0.42	9.56	0.35	2.42e-20	Subjective well-being;
BRCA	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg11301795	chr4:187892539	NA	-0.26	-9.01	-0.34	2.44e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg00701064	chr4:6280414	WFS1	0.68	17.68	0.57	3.11e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	11.12	0.4	2.13e-26	Rheumatoid arthritis;
BRCA	cis	rs3845702	0.736	rs6433821	chr2:180837806	T/A	cg01881094	chr2:180872142	CWC22	-1.04	-18.5	-0.59	1.71e-61	Schizophrenia;
BRCA	cis	rs6087990	0.735	rs2424913	chr20:31374259	C/T	cg13636640	chr20:31349939	DNMT3B	0.55	15.54	0.52	2e-46	Ulcerative colitis;
BRCA	cis	rs6910061	0.830	rs13203123	chr6:11103491	T/C	cg27233058	chr6:11094804	LOC221710	0.5	8.48	0.32	1.6e-16	Diabetic kidney disease;
BRCA	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg04691961	chr3:161091175	C3orf57	-0.39	-8.15	-0.31	1.92e-15	Parkinson's disease;
BRCA	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg18402987	chr7:1209562	NA	0.83	11.81	0.42	2.85e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg01256987	chr12:42539512	GXYLT1	-0.4	-8.01	-0.3	5.61e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.41	0.5	5.45e-41	Motion sickness;
BRCA	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg21747090	chr2:27597821	SNX17	-0.43	-9.43	-0.35	7.24e-20	Total body bone mineral density;
BRCA	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.02	-0.49	4.14e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg25427524	chr10:38739819	LOC399744	-0.55	-10.1	-0.37	2.31e-22	Obesity (extreme);
BRCA	cis	rs7560272	0.538	rs3980695	chr2:73939552	A/G	cg20560298	chr2:73613845	ALMS1	0.35	8.92	0.33	4.77e-18	Schizophrenia;
BRCA	cis	rs1113500	0.787	rs473704	chr1:108637310	T/C	cg06207961	chr1:108661230	NA	-0.36	-8.85	-0.33	8.71e-18	Growth-regulated protein alpha levels;
BRCA	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg25173405	chr17:45401733	C17orf57	-0.52	-10.88	-0.4	2.1e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg22467129	chr15:76604101	ETFA	-0.48	-10.49	-0.38	7.16e-24	Blood metabolite levels;
BRCA	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg06159980	chr1:16340746	HSPB7	-0.38	-7.85	-0.3	1.81e-14	Dilated cardiomyopathy;
BRCA	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06221963	chr1:154839813	KCNN3	-0.59	-16.62	-0.55	8.53e-52	Prostate cancer;
BRCA	trans	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	20.55	0.63	2.12e-72	Exhaled nitric oxide output;
BRCA	cis	rs3772130	1.000	rs35988617	chr3:121432902	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	9.65	0.36	1.16e-20	Cognitive performance;
BRCA	cis	rs4268898	1.000	rs10195436	chr2:24436112	C/T	cg06627628	chr2:24431161	ITSN2	0.49	10.07	0.37	3.11e-22	Asthma;
BRCA	trans	rs1422110	0.543	rs888804	chr5:85411181	G/A	cg01787110	chr1:109008453	NBPF6	0.48	10.61	0.39	2.51e-24	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg21782813	chr7:2030301	MAD1L1	0.33	8.95	0.33	3.96e-18	Schizophrenia;
BRCA	cis	rs7617773	0.780	rs3731550	chr3:48206583	A/C	cg11946769	chr3:48343235	NME6	0.68	13.82	0.48	3.24e-38	Coronary artery disease;
BRCA	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg06766960	chr11:133703094	NA	0.53	11.42	0.41	1.31e-27	Childhood ear infection;
BRCA	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg08917208	chr2:24149416	ATAD2B	0.7	11.5	0.41	5.72e-28	Lymphocyte counts;
BRCA	trans	rs2018683	0.870	rs13232487	chr7:28985119	C/A	cg19402173	chr7:128379420	CALU	-0.49	-12.41	-0.44	7.87e-32	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs4845570	0.831	rs11588634	chr1:151780686	T/A	cg07092448	chr1:151763213	TDRKH	-0.77	-12.7	-0.45	4.15e-33	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00149659	chr3:10157352	C3orf10	0.8	14.11	0.49	1.53e-39	Alzheimer's disease;
BRCA	cis	rs11605275	1.000	rs78249104	chr11:20027680	G/T	cg14835545	chr11:20032148	NAV2	-0.63	-8.98	-0.33	2.91e-18	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	8.09	0.3	3.08e-15	Aortic root size;
BRCA	cis	rs490234	0.676	rs13299008	chr9:128213966	T/G	cg14078157	chr9:128172775	NA	-0.53	-11.39	-0.41	1.76e-27	Mean arterial pressure;
BRCA	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.72	15.72	0.53	2.63e-47	Hip circumference adjusted for BMI;
BRCA	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg26818010	chr10:134567672	INPP5A	-0.69	-14.44	-0.5	4.23e-41	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg24558204	chr6:135376177	HBS1L	0.59	15.94	0.53	1.98e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg08999081	chr20:33150536	PIGU	0.32	7.97	0.3	7.11e-15	Coronary artery disease;
BRCA	cis	rs4595586	0.545	rs4142846	chr12:39395140	C/T	cg26384229	chr12:38710491	ALG10B	0.37	8.15	0.31	1.87e-15	Morning vs. evening chronotype;
BRCA	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.43	-9.28	-0.34	2.5e-19	Iron status biomarkers;
BRCA	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08564027	chr20:61660810	NA	0.85	22.97	0.67	1.42e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg12826209	chr6:26865740	GUSBL1	0.56	9.23	0.34	3.92e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18876405	chr7:65276391	NA	0.62	15.24	0.52	5.52e-45	Aortic root size;
BRCA	cis	rs13046373	0.507	rs2832959	chr21:31982934	C/T	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.54	0.35	3.04e-20	HDL cholesterol;
BRCA	cis	rs7904985	0.961	rs12355013	chr10:88114538	A/G	cg07322936	chr10:88137208	NA	0.39	7.97	0.3	7.16e-15	Barrett's esophagus;
BRCA	cis	rs11955398	0.716	rs1379117	chr5:59942309	T/C	cg02684056	chr5:59996105	DEPDC1B	0.38	9.13	0.34	8.69e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs528301	0.613	rs4953143	chr2:45124291	C/G	cg02372786	chr2:45167549	SIX3	0.43	9.35	0.35	1.46e-19	Alcohol and nicotine co-dependence;
BRCA	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg12311346	chr5:56204834	C5orf35	0.44	8.78	0.33	1.53e-17	Coronary artery disease;
BRCA	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg00012203	chr2:219082015	ARPC2	-0.45	-8.75	-0.33	1.86e-17	Colorectal cancer;
BRCA	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.21	-0.34	4.69e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg18200150	chr17:30822561	MYO1D	0.35	8.91	0.33	5.17e-18	Schizophrenia;
BRCA	cis	rs698833	0.892	rs1067363	chr2:44658401	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	9.87	0.36	1.78e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs10162002	1.000	rs10162002	chr13:24042510	G/A	cg00158254	chr13:24040743	NA	0.57	9.34	0.35	1.51e-19	Hypothyroidism;
BRCA	cis	rs2070433	0.500	rs9306156	chr21:47960493	T/C	cg12379764	chr21:47803548	PCNT	0.46	10.29	0.38	4.32e-23	Lymphocyte counts;
BRCA	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-11.19	-0.4	1.19e-26	Gut microbiome composition (summer);
BRCA	cis	rs7851660	0.933	rs894673	chr9:100612270	A/T	cg13688889	chr9:100608707	NA	-0.36	-8.7	-0.33	2.81e-17	Strep throat;
BRCA	cis	rs7246657	0.525	rs10401417	chr19:37467540	C/T	cg23950597	chr19:37808831	NA	-0.59	-9.39	-0.35	1.06e-19	Coronary artery calcification;
BRCA	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg14675211	chr2:100938903	LONRF2	0.47	10.74	0.39	7.85e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg25042112	chr7:64838748	ZNF92	0.46	8.51	0.32	1.27e-16	Pain;
BRCA	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-12.3	-0.44	2.33e-31	Hemoglobin concentration;
BRCA	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg05347473	chr6:146136440	FBXO30	0.42	8.27	0.31	7.91e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	8.48	0.32	1.57e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2742234	0.541	rs60845448	chr10:43721462	C/T	cg15436174	chr10:43711423	RASGEF1A	0.53	10.6	0.39	2.8e-24	Hirschsprung disease;
BRCA	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg12927641	chr6:109611667	NA	-0.41	-10.56	-0.39	3.79e-24	Reticulocyte fraction of red cells;
BRCA	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg12311346	chr5:56204834	C5orf35	-0.47	-9.81	-0.36	2.83e-21	Coronary artery disease;
BRCA	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg12927641	chr6:109611667	NA	-0.4	-10.39	-0.38	1.88e-23	Reticulocyte fraction of red cells;
BRCA	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg03560586	chr2:239334908	ASB1	-0.41	-7.87	-0.3	1.55e-14	Multiple system atrophy;
BRCA	cis	rs7254114	0.578	rs7246614	chr19:11310538	C/T	cg02815516	chr19:11306319	KANK2	-0.35	-10.02	-0.37	4.8e-22	Immature fraction of reticulocytes;
BRCA	cis	rs6060717	0.536	rs6058364	chr20:34507890	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.12	-0.31	2.41e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg06484146	chr7:12443880	VWDE	-0.62	-8.57	-0.32	7.55e-17	Coronary artery disease;
BRCA	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg27279351	chr12:120934652	DYNLL1	0.57	13.5	0.47	1.05e-36	High light scatter reticulocyte count;
BRCA	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg17211192	chr8:82754475	SNX16	-0.56	-10.57	-0.39	3.54e-24	Diastolic blood pressure;
BRCA	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg22903471	chr2:27725779	GCKR	-0.34	-8.13	-0.31	2.25e-15	Total body bone mineral density;
BRCA	cis	rs10992471	0.528	rs7037194	chr9:95216745	G/A	cg14631576	chr9:95140430	CENPP	-0.35	-8.69	-0.33	3.04e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs6813479	0.594	rs1031711	chr4:137737358	A/C	cg16185213	chr4:137733633	NA	0.4	9.46	0.35	5.86e-20	Longevity;
BRCA	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg11812906	chr14:75593930	NEK9	-0.63	-14.62	-0.5	5.46e-42	Height;
BRCA	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-13.52	-0.47	8.46e-37	Bipolar disorder and schizophrenia;
BRCA	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg05347473	chr6:146136440	FBXO30	0.4	7.94	0.3	9.34e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg18252515	chr7:66147081	NA	-1.06	-15.57	-0.52	1.48e-46	Diabetic kidney disease;
BRCA	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg11502198	chr6:26597334	ABT1	0.58	12.52	0.44	2.58e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg17971929	chr21:40555470	PSMG1	0.72	15.88	0.53	4.35e-48	Cognitive function;
BRCA	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12379764	chr21:47803548	PCNT	0.37	7.82	0.3	2.2e-14	Testicular germ cell tumor;
BRCA	cis	rs1400816	1.000	rs1400816	chr2:172680678	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.52	-7.86	-0.3	1.68e-14	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs2637030	0.559	rs370594	chr5:52955554	C/T	cg06476337	chr5:52856530	NDUFS4	0.35	7.92	0.3	1.03e-14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25427524	chr10:38739819	LOC399744	-0.73	-18.18	-0.58	7.43e-60	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg08000102	chr2:233561755	GIGYF2	-0.62	-13.45	-0.47	1.7e-36	Coronary artery disease;
BRCA	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.6	-0.67	1.57e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.64	0.42	1.55e-28	Homoarginine levels;
BRCA	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg09307838	chr4:120376055	NA	0.67	13.39	0.47	3.26e-36	Corneal astigmatism;
BRCA	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg06917634	chr15:78832804	PSMA4	-0.58	-12.45	-0.44	5.35e-32	Sudden cardiac arrest;
BRCA	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg00684032	chr4:1343700	KIAA1530	0.32	7.96	0.3	7.86e-15	Obesity-related traits;
BRCA	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg19628046	chr18:33552617	C18orf21	0.56	11.62	0.42	1.89e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs9308433	0.529	rs904321	chr1:214506550	G/C	cg06198575	chr1:214491504	SMYD2	0.58	12.6	0.45	1.17e-32	IgG glycosylation;
BRCA	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg15556689	chr8:8085844	FLJ10661	-0.36	-9.67	-0.36	1.01e-20	Joint mobility (Beighton score);
BRCA	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.88	-0.36	1.65e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs7560272	0.538	rs11126415	chr2:73936500	C/T	cg20560298	chr2:73613845	ALMS1	0.34	8.96	0.33	3.56e-18	Schizophrenia;
BRCA	trans	rs12406019	0.510	rs2025614	chr1:78618151	G/A	cg20826526	chr3:156266748	SSR3	-0.38	-8.14	-0.31	2.01e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg22920501	chr2:26401640	FAM59B	-0.65	-11.32	-0.41	3.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg15501526	chr10:2543763	NA	0.55	12.88	0.45	6.66e-34	Age-related hearing impairment;
BRCA	cis	rs1577917	1.000	rs4707239	chr6:86610717	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.43	-0.41	1.22e-27	Response to antipsychotic treatment;
BRCA	trans	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg09436375	chr6:42928200	GNMT	-0.3	-10.86	-0.39	2.5e-25	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg02773041	chr1:40204384	PPIE	0.46	9.66	0.36	1.06e-20	Blood protein levels;
BRCA	cis	rs6782228	0.606	rs2811500	chr3:128366256	C/T	cg16766828	chr3:128327626	NA	-0.43	-9.67	-0.36	9.86e-21	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs4900538	0.855	rs12587464	chr14:102886561	G/C	cg18135206	chr14:102964638	TECPR2	-0.89	-20.89	-0.64	2.86e-74	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	trans	rs1941687	0.563	rs1586987	chr18:31338661	A/G	cg27147174	chr7:100797783	AP1S1	-0.42	-8.59	-0.32	6.4e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg16339924	chr4:17578868	LAP3	0.63	15.68	0.53	4.2e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08045932	chr20:61659980	NA	0.5	11.51	0.41	5.25e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs775227	0.574	rs16861158	chr3:113261709	G/T	cg18753928	chr3:113234510	CCDC52	-0.57	-9.58	-0.35	2.02e-20	Dental caries;
BRCA	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg21427119	chr20:30132790	HM13	-0.35	-8.04	-0.3	4.25e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs7178424	1.000	rs8038932	chr15:62364257	T/C	cg00456672	chr15:62358751	C2CD4A	-0.34	-8.18	-0.31	1.49e-15	Height;
BRCA	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg03954927	chr1:10346856	KIF1B	0.48	15.23	0.52	6.45e-45	Hepatocellular carcinoma;
BRCA	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.12	-0.34	1e-18	Bipolar disorder;
BRCA	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.49	0.44	3.42e-32	Bipolar disorder;
BRCA	trans	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.47	-8.75	-0.33	1.82e-17	Monocyte count;
BRCA	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	0.37	7.84	0.3	1.85e-14	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.57	10.25	0.38	6.18e-23	Gut microbiome composition (summer);
BRCA	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg13393036	chr8:95962371	TP53INP1	-0.3	-8.07	-0.3	3.54e-15	Type 2 diabetes;
BRCA	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg27661571	chr11:113659931	NA	-0.76	-11.7	-0.42	8.85e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg04733989	chr22:42467013	NAGA	0.58	13.01	0.46	1.7e-34	Schizophrenia;
BRCA	cis	rs1421811	0.606	rs62369523	chr5:32713365	T/G	cg16267343	chr5:32710456	NPR3	0.7	12.91	0.45	4.86e-34	Blood pressure;
BRCA	cis	rs4566357	0.615	rs4675139	chr2:227908527	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.37	-0.35	1.23e-19	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.84e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs36051895	0.659	rs10974944	chr9:5070831	C/G	cg02405213	chr9:5042618	JAK2	-0.51	-9.23	-0.34	3.82e-19	Pediatric autoimmune diseases;
BRCA	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	8.78	0.33	1.45e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg07636037	chr3:49044803	WDR6	-0.6	-8.95	-0.33	3.94e-18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7727544	0.582	rs6896703	chr5:131521295	C/G	cg14196790	chr5:131705035	SLC22A5	-0.38	-9.34	-0.35	1.61e-19	Blood metabolite levels;
BRCA	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg00990874	chr7:1149470	C7orf50	-0.57	-10.56	-0.39	3.87e-24	Bronchopulmonary dysplasia;
BRCA	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg04944784	chr2:26401820	FAM59B	-0.94	-17.09	-0.56	3.34e-54	Gut microbiome composition (summer);
BRCA	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg09555818	chr19:45449301	APOC2	0.47	12.21	0.43	5.72e-31	Blood protein levels;
BRCA	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg10295955	chr4:187884368	NA	0.95	29.09	0.75	4.11e-119	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07080220	chr10:102295463	HIF1AN	0.58	13.7	0.48	1.27e-37	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg11530693	chr1:120165357	ZNF697	0.62	14.94	0.51	1.68e-43	Systemic lupus erythematosus;
BRCA	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.39	-0.38	1.72e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg00074818	chr8:8560427	CLDN23	0.36	8.07	0.3	3.47e-15	Obesity-related traits;
BRCA	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg26587870	chr6:27730563	NA	-0.37	-7.89	-0.3	1.34e-14	Parkinson's disease;
BRCA	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.16	0.31	1.82e-15	Total cholesterol levels;
BRCA	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.71	-0.33	2.55e-17	Colorectal cancer;
BRCA	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg09307838	chr4:120376055	NA	0.48	10.22	0.37	8e-23	Diastolic blood pressure;
BRCA	cis	rs6700896	0.931	rs79050868	chr1:66120916	G/A	cg04111102	chr1:66153794	NA	0.36	8.86	0.33	7.9e-18	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3981351	0.528	rs12768908	chr10:115443894	C/T	cg24846397	chr10:115438155	CASP7	-0.35	-8.28	-0.31	7.15e-16	Obesity-related traits;
BRCA	trans	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg25214090	chr10:38739885	LOC399744	0.37	8.53	0.32	1.09e-16	Diastolic blood pressure;
BRCA	cis	rs6484504	0.576	rs158140	chr11:31212971	T/C	cg06552810	chr11:31128660	NA	-0.39	-8.69	-0.33	3.06e-17	Red blood cell count;
BRCA	cis	rs9807989	0.507	rs2110659	chr2:103043867	G/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.38	0.31	3.39e-16	Asthma;
BRCA	cis	rs2016266	0.826	rs61928079	chr12:53741468	T/C	cg26875137	chr12:53738046	NA	-0.44	-9.7	-0.36	7.59e-21	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-9.5	-0.35	4.21e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	trans	rs1422110	0.616	rs1862230	chr5:85444868	C/T	cg01787110	chr1:109008453	NBPF6	-0.41	-8.47	-0.32	1.7e-16	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs6066835	1.000	rs6066835	chr20:47355009	A/G	cg18078177	chr20:47281410	PREX1	0.64	8.87	0.33	7.57e-18	Multiple myeloma;
BRCA	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg24642439	chr20:33292090	TP53INP2	0.42	8.71	0.33	2.52e-17	Height;
BRCA	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg18850127	chr7:39170497	POU6F2	0.43	8.87	0.33	7.22e-18	IgG glycosylation;
BRCA	cis	rs3772130	0.962	rs4413346	chr3:121486310	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.61	0.39	2.56e-24	Cognitive performance;
BRCA	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg11584989	chr19:19387371	SF4	0.62	13.0	0.46	1.89e-34	Bipolar disorder;
BRCA	cis	rs10411936	0.720	rs4808513	chr19:16580498	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.45	9.62	0.36	1.48e-20	White blood cell count;Multiple sclerosis;
BRCA	cis	rs758324	0.898	rs510434	chr5:131292503	C/T	cg06307176	chr5:131281290	NA	-0.54	-10.43	-0.38	1.24e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg13010199	chr12:38710504	ALG10B	0.45	8.94	0.33	4.06e-18	Morning vs. evening chronotype;
BRCA	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg07371521	chr5:154026371	NA	0.42	8.13	0.31	2.25e-15	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg27170947	chr2:26402098	FAM59B	-0.81	-15.26	-0.52	4.63e-45	Gut microbiome composition (summer);
BRCA	cis	rs9290065	0.519	rs6774203	chr3:160705217	G/T	cg03342759	chr3:160939853	NMD3	-0.46	-9.48	-0.35	5.04e-20	Kawasaki disease;
BRCA	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg00071950	chr4:10020882	SLC2A9	0.43	9.94	0.37	9.89e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs8073060	0.559	rs17550632	chr17:33890883	G/C	cg19694781	chr19:47549865	TMEM160	1.06	21.79	0.65	3.65e-79	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg18252515	chr7:66147081	NA	-0.8	-11.18	-0.4	1.23e-26	Diabetic kidney disease;
BRCA	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.67	-0.32	3.43e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg01579765	chr21:45077557	HSF2BP	0.41	10.63	0.39	2.09e-24	Mean corpuscular volume;
BRCA	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg05623727	chr3:50126028	RBM5	-0.42	-10.06	-0.37	3.32e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	10.67	0.39	1.36e-24	Motion sickness;
BRCA	cis	rs400736	1.000	rs400736	chr1:8078309	T/C	cg25007680	chr1:8021821	PARK7	0.47	11.89	0.43	1.43e-29	Response to antidepressants and depression;
BRCA	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg25036284	chr2:26402008	FAM59B	-0.95	-15.47	-0.52	4.27e-46	Gut microbiome composition (summer);
BRCA	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg13010199	chr12:38710504	ALG10B	0.49	10.46	0.38	9.44e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg17802220	chr15:77601643	NA	-0.43	-9.93	-0.37	1.09e-21	Type 2 diabetes;
BRCA	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg25237894	chr2:233734115	C2orf82	-0.44	-13.92	-0.48	1.12e-38	Coronary artery disease;
BRCA	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg22535103	chr8:58192502	C8orf71	-0.6	-13.08	-0.46	8.35e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg00701064	chr4:6280414	WFS1	-0.66	-18.11	-0.58	1.69e-59	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-14.07	-0.49	2.4e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	trans	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg06521331	chr12:34319734	NA	-0.47	-8.68	-0.32	3.27e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs600626	0.636	rs11236516	chr11:75451668	C/T	cg24262691	chr11:75473276	NA	-0.47	-7.98	-0.3	6.96e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
BRCA	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg21918786	chr6:109611834	NA	-0.46	-12.7	-0.45	4.21e-33	Reticulocyte fraction of red cells;
BRCA	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12292205	chr6:26970375	C6orf41	-0.51	-8.68	-0.32	3.16e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs11229555	1.000	rs12808544	chr11:58373221	C/A	cg15696309	chr11:58395628	NA	-0.53	-11.58	-0.42	2.85e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg07211511	chr3:129823064	LOC729375	-0.62	-10.91	-0.4	1.56e-25	Blood pressure (smoking interaction);
BRCA	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg00666640	chr1:248458726	OR2T12	0.34	8.76	0.33	1.75e-17	Common traits (Other);
BRCA	cis	rs72781680	0.716	rs2712071	chr2:23990419	A/G	cg08917208	chr2:24149416	ATAD2B	0.65	10.56	0.39	3.94e-24	Lymphocyte counts;
BRCA	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg23625390	chr15:77176239	SCAPER	-0.55	-13.76	-0.48	6.34e-38	Blood metabolite levels;
BRCA	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg04362960	chr10:104952993	NT5C2	0.43	10.36	0.38	2.42e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-13.52	-0.47	7.84e-37	Mood instability;
BRCA	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs4363385	0.747	rs4323653	chr1:152983359	T/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.33	-0.31	5.08e-16	Inflammatory skin disease;
BRCA	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg15432903	chr11:17409602	KCNJ11	0.72	15.86	0.53	5.11e-48	Type 2 diabetes;
BRCA	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg00495681	chr13:53174319	NA	0.38	7.9	0.3	1.2e-14	Lewy body disease;
BRCA	cis	rs2629540	0.924	rs1545910	chr10:126428145	G/C	cg08799069	chr10:126477246	METTL10	-0.52	-11.24	-0.41	7.09e-27	Cocaine dependence;
BRCA	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg24562669	chr7:97807699	LMTK2	0.44	11.82	0.42	2.74e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2625529	0.878	rs2929511	chr15:72231682	C/T	cg16672083	chr15:72433130	SENP8	0.67	16.11	0.54	3.05e-49	Red blood cell count;
BRCA	cis	rs490234	0.841	rs950534	chr9:128225881	C/G	cg14078157	chr9:128172775	NA	-0.34	-8.16	-0.31	1.78e-15	Mean arterial pressure;
BRCA	cis	rs4948102	0.731	rs6593292	chr7:56043037	G/C	cg09872392	chr7:56161020	PHKG1	-0.4	-9.07	-0.34	1.42e-18	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg08888203	chr3:10149979	C3orf24	0.67	14.48	0.5	2.56e-41	Alzheimer's disease;
BRCA	cis	rs757081	0.667	rs3950680	chr11:17138666	G/A	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.63	-0.32	4.78e-17	Systolic blood pressure;
BRCA	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg23625390	chr15:77176239	SCAPER	0.39	9.15	0.34	7.8e-19	Blood metabolite levels;
BRCA	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg12386194	chr3:101231763	SENP7	-0.46	-9.67	-0.36	9.84e-21	Colorectal cancer;
BRCA	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.86	-0.39	2.59e-25	Bipolar disorder;
BRCA	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg24642844	chr7:1081250	C7orf50	-0.89	-16.21	-0.54	9.83e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11644478	chr21:40555479	PSMG1	-0.66	-14.2	-0.49	5.77e-40	Cognitive function;
BRCA	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs7737355	0.898	rs6864413	chr5:130637868	G/T	cg06307176	chr5:131281290	NA	0.46	8.87	0.33	7.29e-18	Life satisfaction;
BRCA	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg04267008	chr7:1944627	MAD1L1	-0.51	-11.71	-0.42	8.08e-29	Bipolar disorder and schizophrenia;
BRCA	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.34	-11.69	-0.42	9.3e-29	Systemic lupus erythematosus;
BRCA	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg16414030	chr3:133502952	NA	-0.49	-11.52	-0.41	4.73e-28	Iron status biomarkers;
BRCA	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg13880726	chr7:1868755	MAD1L1	0.52	10.27	0.38	5.32e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs12618769	0.652	rs17034171	chr2:99221095	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.49	0.32	1.44e-16	Bipolar disorder;
BRCA	cis	rs17095355	1.000	rs17126902	chr10:111710381	A/G	cg00817464	chr10:111662876	XPNPEP1	0.39	9.45	0.35	6.16e-20	Biliary atresia;
BRCA	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg27572855	chr1:25598939	RHD	0.52	15.25	0.52	5.13e-45	Erythrocyte sedimentation rate;
BRCA	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg04025307	chr7:1156635	C7orf50	0.59	9.31	0.35	2e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	12.71	0.45	3.8e-33	Hip circumference adjusted for BMI;
BRCA	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg24642439	chr20:33292090	TP53INP2	0.42	8.84	0.33	9.58e-18	Height;
BRCA	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.6	-0.32	5.96e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg26043149	chr18:55253948	FECH	1.15	27.71	0.74	1.32e-111	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	8.29	0.31	6.45e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg22764044	chr5:178986830	RUFY1	0.5	13.69	0.48	1.38e-37	Lung cancer;
BRCA	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00149659	chr3:10157352	C3orf10	0.79	13.76	0.48	6.55e-38	Alzheimer's disease;
BRCA	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg26384229	chr12:38710491	ALG10B	0.67	14.1	0.49	1.68e-39	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.588	rs6660878	chr1:153027068	A/G	cg25856811	chr1:152973957	SPRR3	-0.31	-7.84	-0.3	1.86e-14	Inflammatory skin disease;
BRCA	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg14829155	chr15:31115871	NA	0.41	9.97	0.37	7.62e-22	Huntington's disease progression;
BRCA	cis	rs11229555	0.645	rs12274866	chr11:58177129	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9831754	0.526	rs6548551	chr3:78342292	C/T	cg06138941	chr3:78371609	NA	0.41	9.89	0.36	1.44e-21	Calcium levels;
BRCA	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg20701182	chr2:24300061	SF3B14	0.69	13.04	0.46	1.21e-34	Lymphocyte counts;
BRCA	cis	rs1829883	0.898	rs2461990	chr5:98793519	G/A	cg08333243	chr5:99726346	NA	-0.35	-8.01	-0.3	5.27e-15	Hemostatic factors and hematological phenotypes;
BRCA	trans	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg21659725	chr3:3221576	CRBN	0.47	8.67	0.32	3.45e-17	Menarche (age at onset);
BRCA	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.57	-0.42	3.14e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg11366901	chr6:160182831	ACAT2	0.82	15.22	0.52	7.19e-45	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.32	-8.15	-0.31	1.96e-15	Total body bone mineral density;
BRCA	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg22800045	chr5:56110881	MAP3K1	0.66	12.36	0.44	1.22e-31	Initial pursuit acceleration;
BRCA	cis	rs7178424	1.000	rs8026008	chr15:62377805	C/T	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.26	-0.31	8.22e-16	Height;
BRCA	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg20476274	chr7:133979776	SLC35B4	0.66	19.45	0.61	1.48e-66	Mean platelet volume;
BRCA	trans	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg21775007	chr8:11205619	TDH	0.41	8.51	0.32	1.23e-16	Mood instability;
BRCA	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg11645453	chr3:52864694	ITIH4	0.48	11.4	0.41	1.52e-27	Schizophrenia;
BRCA	cis	rs11955398	0.604	rs1445852	chr5:59891304	C/T	cg02684056	chr5:59996105	DEPDC1B	0.35	8.4	0.32	2.86e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg22852734	chr6:133119734	C6orf192	-0.78	-13.38	-0.47	3.7e-36	Type 2 diabetes nephropathy;
BRCA	trans	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg26384229	chr12:38710491	ALG10B	0.57	12.15	0.43	1.03e-30	Morning vs. evening chronotype;
BRCA	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.62	-0.36	1.5e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.45	9.86	0.36	1.91e-21	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg20176042	chr4:185552304	CASP3	-0.52	-7.92	-0.3	1.03e-14	Blood protein levels;
BRCA	cis	rs1800795	0.553	rs1524099	chr7:22781657	G/A	cg05472934	chr7:22766657	IL6	0.35	7.86	0.3	1.67e-14	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
BRCA	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-17.95	-0.58	1.25e-58	Morning vs. evening chronotype;
BRCA	trans	rs6598955	0.671	rs12354062	chr1:26608761	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-13.49	-0.47	1.08e-36	Obesity-related traits;
BRCA	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg07636037	chr3:49044803	WDR6	0.96	28.71	0.75	4.39e-117	Parkinson's disease;
BRCA	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg13047869	chr3:10149882	C3orf24	0.6	12.77	0.45	1.93e-33	Alzheimer's disease;
BRCA	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.74	11.42	0.41	1.31e-27	Gut microbiome composition (summer);
BRCA	cis	rs600806	0.778	rs2140923	chr1:110004990	C/T	cg20591472	chr1:110008990	SYPL2	0.33	8.45	0.32	2.04e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.38	-9.16	-0.34	7.18e-19	Bipolar disorder;
BRCA	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.63	10.79	0.39	4.65e-25	Lung function (FEV1/FVC);
BRCA	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	14.13	0.49	1.15e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg00677455	chr12:58241039	CTDSP2	0.63	15.43	0.52	6.76e-46	Multiple sclerosis;
BRCA	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg07080220	chr10:102295463	HIF1AN	0.64	14.78	0.5	9.46e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.33	8.47	0.32	1.63e-16	Depression;
BRCA	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg23283495	chr1:209979779	IRF6	0.38	9.15	0.34	7.58e-19	Cleft lip with or without cleft palate;
BRCA	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg16230307	chr14:35515116	FAM177A1	0.46	9.34	0.35	1.6e-19	Psoriasis;
BRCA	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg08493051	chr2:3487164	NA	-0.43	-9.25	-0.34	3.35e-19	Neurofibrillary tangles;
BRCA	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.55	-14.72	-0.5	1.98e-42	Colorectal cancer;
BRCA	cis	rs9815354	0.761	rs73083326	chr3:41927150	G/T	cg03022575	chr3:42003672	ULK4	0.69	9.49	0.35	4.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7072216	0.763	rs942803	chr10:100168631	G/T	cg26618903	chr10:100175079	PYROXD2	-0.32	-9.36	-0.35	1.39e-19	Metabolite levels;
BRCA	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg21798802	chr22:38057573	PDXP	0.31	8.62	0.32	5.36e-17	Fat distribution (HIV);
BRCA	trans	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg27600084	chr12:12264075	NA	0.36	8.39	0.32	3.19e-16	Breast size;
BRCA	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg21475434	chr5:93447410	FAM172A	0.69	8.84	0.33	9.14e-18	Diabetic retinopathy;
BRCA	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg22764044	chr5:178986830	RUFY1	0.45	11.38	0.41	1.82e-27	Lung cancer;
BRCA	cis	rs4363385	0.818	rs4845522	chr1:153011099	C/T	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg09307838	chr4:120376055	NA	0.69	13.97	0.48	6.93e-39	Corneal astigmatism;
BRCA	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	11.21	0.41	9.51e-27	Monocyte percentage of white cells;
BRCA	cis	rs55882075	0.583	rs9637934	chr5:179114025	G/C	cg14593053	chr5:179126677	CANX	0.38	9.51	0.35	3.7e-20	Monocyte percentage of white cells;
BRCA	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg02734326	chr4:10020555	SLC2A9	0.39	8.34	0.31	4.56e-16	Bone mineral density;
BRCA	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg17971929	chr21:40555470	PSMG1	-0.61	-13.29	-0.47	9.34e-36	Cognitive function;
BRCA	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg16482183	chr6:26056742	HIST1H1C	0.49	9.7	0.36	7.51e-21	Iron status biomarkers;
BRCA	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg03585969	chr10:35415529	CREM	-0.49	-10.25	-0.38	6.56e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg04450456	chr4:17643702	FAM184B	0.38	11.32	0.41	3.31e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg22875332	chr1:76189707	ACADM	0.65	14.03	0.49	3.48e-39	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg02659138	chr7:134003124	SLC35B4	-0.36	-10.85	-0.39	2.62e-25	Mean platelet volume;
BRCA	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg17330251	chr7:94953956	PON1	-0.4	-8.24	-0.31	9.5e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs7572733	0.515	rs6752458	chr2:198835106	G/T	cg00792783	chr2:198669748	PLCL1	0.45	9.89	0.36	1.49e-21	Dermatomyositis;
BRCA	trans	rs8002861	0.870	rs9525855	chr13:44431660	A/G	cg17145862	chr1:211918768	LPGAT1	0.63	16.2	0.54	1.07e-49	Leprosy;
BRCA	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.04	21.58	0.65	5.52e-78	Gut microbiome composition (summer);
BRCA	trans	rs6479891	1.000	rs10740117	chr10:65098277	G/A	cg14819942	chr15:35414228	NA	-0.34	-8.48	-0.32	1.54e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.54	-0.32	9.97e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7254114	0.578	rs4804574	chr19:11317482	G/A	cg06870470	chr19:11315767	DOCK6	0.4	9.44	0.35	6.9e-20	Immature fraction of reticulocytes;
BRCA	cis	rs9790314	0.613	rs6799160	chr3:160634889	A/G	cg03342759	chr3:160939853	NMD3	0.43	8.29	0.31	6.76e-16	Morning vs. evening chronotype;
BRCA	cis	rs11945232	1.000	rs28609242	chr4:88342497	T/C	cg23841344	chr4:88312519	HSD17B11	-0.48	-9.49	-0.35	4.54e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg23649088	chr2:200775458	C2orf69	0.62	10.69	0.39	1.16e-24	Schizophrenia;
BRCA	cis	rs5167	0.504	rs7259679	chr19:45457306	C/T	cg13119609	chr19:45449297	APOC2	0.46	12.83	0.45	1.04e-33	Blood protein levels;
BRCA	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07343612	chr16:622815	PIGQ	-0.68	-22.3	-0.66	6.78e-82	Height;
BRCA	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	13.87	0.48	2.09e-38	Mood instability;
BRCA	cis	rs72781680	0.821	rs111571980	chr2:24201695	C/G	cg08917208	chr2:24149416	ATAD2B	0.61	10.39	0.38	1.73e-23	Lymphocyte counts;
BRCA	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs4664304	0.620	rs11675085	chr2:160713352	C/G	cg18514922	chr2:160761262	LY75	0.34	7.97	0.3	7.22e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs28735056	0.935	rs537962	chr18:77592660	C/G	cg20368463	chr18:77673604	PQLC1	0.35	8.41	0.32	2.75e-16	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.29	0.38	4.48e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg00684032	chr4:1343700	KIAA1530	-0.34	-8.86	-0.33	7.7e-18	Obesity-related traits;
BRCA	cis	rs9341808	0.754	rs3805885	chr6:80996751	C/G	cg08355045	chr6:80787529	NA	-0.35	-8.96	-0.33	3.65e-18	Sitting height ratio;
BRCA	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg00701064	chr4:6280414	WFS1	0.71	19.5	0.61	7.91e-67	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	trans	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg09872104	chr7:134855509	C7orf49	0.77	9.66	0.36	1.08e-20	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg09021430	chr5:549028	NA	-0.67	-15.05	-0.51	4.83e-44	Lung disease severity in cystic fibrosis;
BRCA	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg03161606	chr19:29218774	NA	0.46	8.11	0.31	2.58e-15	Methadone dose in opioid dependence;
BRCA	cis	rs9560113	0.959	rs9560108	chr13:112180303	A/C	cg10483660	chr13:112241077	NA	0.31	7.84	0.3	1.91e-14	Menarche (age at onset);
BRCA	cis	rs13136331	0.680	rs4440183	chr4:88653805	C/T	cg22416721	chr4:88570574	DMP1	-0.57	-13.48	-0.47	1.2e-36	Sitting height ratio;
BRCA	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg08422745	chr4:174089978	GALNT7	0.79	18.33	0.59	1.24e-60	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg27347728	chr4:17578864	LAP3	0.43	8.25	0.31	9.07e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4722404	0.592	rs7791687	chr7:3119643	G/A	cg19214707	chr7:3157722	NA	-0.37	-8.04	-0.3	4.38e-15	Atopic dermatitis;
BRCA	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg08313168	chr12:7315531	NA	0.48	7.94	0.3	8.93e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs507080	0.885	rs533144	chr11:118559247	C/A	cg09144398	chr11:118550485	TREH	-0.36	-8.78	-0.33	1.47e-17	Serum metabolite levels;
BRCA	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg15997130	chr1:24165203	NA	-0.45	-10.18	-0.37	1.16e-22	Immature fraction of reticulocytes;
BRCA	cis	rs7633857	0.512	rs1868109	chr3:160682500	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-11.63	-0.42	1.77e-28	Educational attainment (years of education);
BRCA	trans	rs7980799	0.935	rs1905408	chr12:33516963	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-8.5	-0.32	1.35e-16	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18357526	chr6:26021779	HIST1H4A	0.46	8.51	0.32	1.24e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs16910800	0.689	rs7101825	chr11:23164951	C/G	cg20040320	chr11:23191996	NA	0.48	8.34	0.31	4.46e-16	Cancer;
BRCA	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-7.93	-0.3	9.68e-15	Homocysteine levels;
BRCA	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg24829409	chr8:58192753	C8orf71	-0.49	-9.25	-0.34	3.45e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg13010199	chr12:38710504	ALG10B	0.52	10.87	0.4	2.24e-25	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2336384	0.929	rs2236056	chr1:12056440	C/T	cg13216073	chr1:12042593	MFN2	0.49	10.53	0.38	4.98e-24	Platelet count;
BRCA	trans	rs61931739	1.000	rs12311881	chr12:34036100	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-9.4	-0.35	9.2e-20	Morning vs. evening chronotype;
BRCA	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg03929089	chr4:120376271	NA	0.61	10.56	0.39	3.97e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg26597838	chr10:835615	NA	1.3	21.86	0.65	1.6e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06544989	chr22:39130855	UNC84B	0.35	8.37	0.31	3.56e-16	Menopause (age at onset);
BRCA	cis	rs295140	0.585	rs4233996	chr2:201131228	A/T	cg23649088	chr2:200775458	C2orf69	-0.38	-8.14	-0.31	2.07e-15	QT interval;
BRCA	trans	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg26384229	chr12:38710491	ALG10B	0.4	9.36	0.35	1.37e-19	Morning vs. evening chronotype;
BRCA	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg03711944	chr11:47377212	SPI1	-0.41	-10.91	-0.4	1.61e-25	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	10.42	0.38	1.35e-23	Aortic root size;
BRCA	cis	rs2120243	0.845	rs2316710	chr3:157150180	G/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	9.51	0.35	3.96e-20	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03517284	chr6:25882590	NA	-0.51	-11.52	-0.41	5.1e-28	Blood metabolite levels;
BRCA	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg26384229	chr12:38710491	ALG10B	-0.48	-11.23	-0.41	7.66e-27	Morning vs. evening chronotype;
BRCA	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg18512352	chr11:47633146	NA	-0.37	-8.99	-0.33	2.85e-18	Subjective well-being;
BRCA	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg24803719	chr17:45855879	NA	-0.32	-8.51	-0.32	1.26e-16	IgG glycosylation;
BRCA	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg06784218	chr1:46089804	CCDC17	-0.43	-10.13	-0.37	1.82e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg08493051	chr2:3487164	NA	-0.43	-9.15	-0.34	7.42e-19	Neurofibrillary tangles;
BRCA	cis	rs9469578	0.792	rs79297236	chr6:33713930	T/C	cg18708504	chr6:33715942	IP6K3	0.7	10.18	0.37	1.12e-22	Phosphorus levels;
BRCA	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02353165	chr6:42928485	GNMT	0.78	18.86	0.6	2.17e-63	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1784581	0.802	rs2156747	chr6:162430000	C/G	cg17173639	chr6:162384350	PARK2	-0.37	-8.92	-0.33	4.71e-18	Itch intensity from mosquito bite;
BRCA	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg10729496	chr3:10149963	C3orf24	0.48	9.07	0.34	1.5e-18	Alzheimer's disease;
BRCA	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg24069376	chr3:38537580	EXOG	0.34	9.36	0.35	1.35e-19	Electrocardiographic conduction measures;
BRCA	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs61935443	0.666	rs73218073	chr12:95314346	A/G	cg21533806	chr12:95267307	NA	0.45	8.01	0.3	5.54e-15	Schizophrenia;
BRCA	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg16405210	chr4:1374714	KIAA1530	0.65	13.59	0.47	3.78e-37	Obesity-related traits;
BRCA	cis	rs4363385	0.818	rs57311099	chr1:153005597	A/C	cg21543102	chr1:152974771	SPRR3	-0.28	-7.81	-0.3	2.39e-14	Inflammatory skin disease;
BRCA	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	ch.11.42038R	chr11:967971	AP2A2	0.52	16.55	0.55	1.84e-51	Alzheimer's disease (late onset);
BRCA	trans	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-10.25	-0.38	6.04e-23	Morning vs. evening chronotype;
BRCA	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11890956	chr21:40555474	PSMG1	1.03	27.92	0.74	9.19e-113	Cognitive function;
BRCA	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg01877450	chr7:97915802	BRI3	-0.36	-8.2	-0.31	1.28e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg20203395	chr5:56204925	C5orf35	-0.52	-10.53	-0.38	4.88e-24	Type 2 diabetes;
BRCA	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	13.2	0.46	2.26e-35	Schizophrenia;
BRCA	cis	rs10779751	0.770	rs2275527	chr1:11190646	A/G	cg08854313	chr1:11322531	MTOR	0.7	13.97	0.48	7.06e-39	Body mass index;
BRCA	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25427524	chr10:38739819	LOC399744	-0.71	-17.44	-0.57	5.3e-56	Extrinsic epigenetic age acceleration;
BRCA	cis	rs5771069	0.931	rs137864	chr22:50446988	C/T	cg03721641	chr22:50451245	IL17REL	0.32	9.91	0.36	1.24e-21	Ulcerative colitis;
BRCA	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg08999081	chr20:33150536	PIGU	0.44	11.76	0.42	4.8e-29	Coronary artery disease;
BRCA	trans	rs9929218	1.000	rs7186084	chr16:68816260	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	12.2	0.43	6.3e-31	Colorectal cancer;
BRCA	trans	rs1997103	1.000	rs9642580	chr7:55400359	G/A	cg20935933	chr6:143382018	AIG1	0.6	11.48	0.41	7.49e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4919087	1.000	rs7076523	chr10:99089296	T/C	cg25902810	chr10:99078978	FRAT1	-0.45	-9.49	-0.35	4.54e-20	Monocyte count;
BRCA	cis	rs1577917	0.883	rs6454505	chr6:86592362	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.32	-8.34	-0.31	4.55e-16	Response to antipsychotic treatment;
BRCA	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg10523679	chr1:76189770	ACADM	0.69	11.75	0.42	5.22e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.29	-0.35	2.32e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg23711669	chr6:146136114	FBXO30	-0.71	-17.19	-0.56	9.59e-55	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg03146154	chr1:46216737	IPP	0.45	9.92	0.37	1.1e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2108225	1.000	rs989960	chr7:107445727	C/T	cg18560240	chr7:107437656	SLC26A3	-0.53	-10.66	-0.39	1.57e-24	Ulcerative colitis;
BRCA	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg21573476	chr21:45109991	RRP1B	-0.49	-12.84	-0.45	9.49e-34	Mean corpuscular volume;
BRCA	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg27478167	chr7:817139	HEATR2	-0.42	-8.72	-0.33	2.49e-17	Cerebrospinal P-tau181p levels;
BRCA	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.48	-11.91	-0.43	1.1e-29	Coronary artery disease;
BRCA	cis	rs7945718	0.967	rs7927470	chr11:12748899	A/T	cg25843174	chr11:12811716	TEAD1	0.23	8.47	0.32	1.72e-16	Educational attainment (years of education);
BRCA	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg19773385	chr1:10388646	KIF1B	-0.38	-7.99	-0.3	6.17e-15	Hepatocellular carcinoma;
BRCA	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg21427119	chr20:30132790	HM13	-0.36	-8.27	-0.31	7.77e-16	Mean corpuscular hemoglobin;
BRCA	cis	rs701145	0.643	rs7647694	chr3:153851535	C/G	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.22e-14	Coronary artery disease;
BRCA	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg22676075	chr6:135203613	NA	0.44	8.7	0.33	2.91e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg24848339	chr3:12840334	CAND2	0.43	11.43	0.41	1.19e-27	QRS complex (12-leadsum);
BRCA	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg00277334	chr10:82204260	NA	-0.43	-8.47	-0.32	1.74e-16	Post bronchodilator FEV1;
BRCA	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg23788917	chr6:8435910	SLC35B3	0.47	10.13	0.37	1.84e-22	Motion sickness;
BRCA	cis	rs4363385	0.747	rs3806219	chr1:152972522	C/T	cg21543102	chr1:152974771	SPRR3	0.29	8.27	0.31	7.84e-16	Inflammatory skin disease;
BRCA	cis	rs9487051	0.737	rs1260593	chr6:109521400	C/T	cg01475377	chr6:109611718	NA	-0.45	-11.4	-0.41	1.58e-27	Reticulocyte fraction of red cells;
BRCA	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg05347473	chr6:146136440	FBXO30	-0.43	-8.7	-0.33	2.88e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg12549451	chr6:135224345	NA	-0.36	-8.32	-0.31	5.18e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg25036284	chr2:26402008	FAM59B	0.9	14.79	0.5	9.2e-43	Gut microbiome composition (summer);
BRCA	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg19052272	chr2:3704530	ALLC	-0.45	-10.16	-0.37	1.44e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg03354898	chr7:1950403	MAD1L1	-0.4	-8.32	-0.31	5.49e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg03342759	chr3:160939853	NMD3	-0.81	-17.91	-0.58	2.06e-58	Parkinson's disease;
BRCA	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg01884057	chr2:25150051	NA	0.34	9.04	0.34	1.88e-18	Body mass index;
BRCA	trans	rs8073060	0.614	rs225279	chr17:33974214	A/G	cg19694781	chr19:47549865	TMEM160	-1.05	-20.96	-0.64	1.16e-74	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs10463316	0.817	rs13355052	chr5:150802003	A/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.62	-0.32	5.19e-17	Metabolite levels (Pyroglutamine);
BRCA	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg00745463	chr17:30367425	LRRC37B	-0.54	-8.89	-0.33	6.17e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	ch.11.42038R	chr11:967971	AP2A2	0.47	14.38	0.49	8.06e-41	Alzheimer's disease (late onset);
BRCA	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.06	-25.8	-0.71	4.21e-101	Ulcerative colitis;
BRCA	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg12011299	chr4:100065546	ADH4	0.41	10.68	0.39	1.35e-24	Alcohol dependence;
BRCA	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg06145435	chr7:1022769	CYP2W1	0.49	9.08	0.34	1.39e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.63	-0.42	1.77e-28	Platelet count;
BRCA	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	cis	rs7766436	0.885	rs12662891	chr6:22575096	C/T	cg13666174	chr6:22585274	NA	-0.48	-11.13	-0.4	2.06e-26	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg26395211	chr5:140044315	WDR55	0.35	7.97	0.3	7.14e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg09065629	chr16:1709722	CRAMP1L	0.36	8.49	0.32	1.45e-16	Coronary artery disease;
BRCA	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-11.56	-0.42	3.28e-28	Lymphocyte counts;
BRCA	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	13.12	0.46	5.72e-35	Lymphocyte percentage of white cells;
BRCA	cis	rs35123781	1.000	rs599946	chr5:139057461	A/G	cg05227215	chr5:139057496	CXXC5	0.35	8.43	0.32	2.31e-16	Schizophrenia;
BRCA	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.36	-7.81	-0.3	2.33e-14	Total cholesterol levels;
BRCA	cis	rs11051970	0.636	rs2733704	chr12:32567858	C/T	cg02745156	chr12:32552066	NA	0.25	8.23	0.31	1.07e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs4671400	0.543	rs10178135	chr2:61485267	T/C	cg15711740	chr2:61764176	XPO1	0.42	9.05	0.34	1.67e-18	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs4561483	0.831	rs2075158	chr16:11945231	T/C	cg08843971	chr16:11963173	GSPT1	0.43	8.84	0.33	8.89e-18	Testicular germ cell tumor;
BRCA	trans	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg15556689	chr8:8085844	FLJ10661	-0.33	-7.86	-0.3	1.66e-14	Neuroticism;
BRCA	cis	rs1997103	1.000	rs10228182	chr7:55406695	A/T	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2463822	0.925	rs6863	chr11:62160725	G/T	cg06239285	chr11:62104954	ASRGL1	-0.63	-8.79	-0.33	1.38e-17	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg26528668	chr16:1614120	IFT140	0.39	8.73	0.33	2.26e-17	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08219700	chr8:58056026	NA	0.57	9.48	0.35	4.72e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-15.48	-0.52	3.69e-46	Parkinson's disease;
BRCA	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg19539972	chr4:7069911	GRPEL1	0.69	16.91	0.56	2.78e-53	Monocyte percentage of white cells;
BRCA	cis	rs9533799	1.000	rs11620543	chr13:44798371	G/A	cg19190762	chr13:44806055	NA	0.4	8.66	0.32	3.7e-17	Amyotrophic lateral sclerosis;
BRCA	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.39	2.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-8.98	-0.33	3.08e-18	Alzheimer's disease (late onset);
BRCA	cis	rs4631830	0.720	rs11599333	chr10:51499655	A/C	cg16070123	chr10:51489643	NA	0.35	7.86	0.3	1.69e-14	Prostate-specific antigen levels;
BRCA	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg25767906	chr1:53392781	SCP2	-0.39	-8.04	-0.3	4.25e-15	Monocyte count;
BRCA	cis	rs887829	0.569	rs4663965	chr2:234650604	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.6	-0.32	6.05e-17	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs3099143	1.000	rs4541044	chr15:77173193	C/T	cg21673338	chr15:77095150	SCAPER	0.52	9.44	0.35	6.69e-20	Recalcitrant atopic dermatitis;
BRCA	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg18963800	chr10:38644991	HSD17B7P2	-0.44	-8.78	-0.33	1.46e-17	Breast cancer;
BRCA	cis	rs3820928	1.000	rs6752707	chr2:227766822	C/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.63	-0.32	4.82e-17	Pulmonary function;
BRCA	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21385522	chr1:16154831	NA	0.6	11.54	0.42	4.01e-28	Dilated cardiomyopathy;
BRCA	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg22875332	chr1:76189707	ACADM	-0.48	-9.13	-0.34	9.22e-19	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg27446573	chr6:127587934	RNF146	0.9	21.49	0.65	1.64e-77	Breast cancer;
BRCA	cis	rs6840258	0.660	rs17012200	chr4:87884646	C/G	cg08197287	chr4:87952173	AFF1	0.47	8.61	0.32	5.6e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs11229555	1.000	rs2276153	chr11:58407740	C/G	cg15696309	chr11:58395628	NA	-0.52	-11.43	-0.41	1.2e-27	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg06108461	chr20:60628389	TAF4	-0.79	-16.99	-0.56	1.11e-53	Body mass index;
BRCA	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg06609049	chr19:2785107	THOP1	0.57	11.89	0.43	1.31e-29	Total cholesterol levels;
BRCA	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg02544614	chr20:61657117	NA	0.28	7.92	0.3	1.03e-14	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	14.55	0.5	1.22e-41	Motion sickness;
BRCA	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg14004847	chr7:1930337	MAD1L1	0.45	9.13	0.34	8.94e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg17063962	chr7:91808500	NA	0.53	12.53	0.44	2.32e-32	Breast cancer;
BRCA	cis	rs10267417	0.603	rs4721836	chr7:19910497	A/G	cg05791153	chr7:19748676	TWISTNB	0.46	9.01	0.34	2.29e-18	Night sleep phenotypes;
BRCA	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg16482183	chr6:26056742	HIST1H1C	0.74	12.96	0.46	2.9e-34	Iron status biomarkers;
BRCA	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg12011299	chr4:100065546	ADH4	0.49	10.97	0.4	8.73e-26	Smoking initiation;
BRCA	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg01028140	chr2:1542097	TPO	-0.61	-11.67	-0.42	1.16e-28	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg07148914	chr20:33460835	GGT7	-0.37	-7.96	-0.3	8.05e-15	Glomerular filtration rate (creatinine);
BRCA	trans	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04565464	chr8:145669602	NFKBIL2	0.41	9.35	0.35	1.51e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11644478	chr21:40555479	PSMG1	0.73	14.48	0.5	2.74e-41	Cognitive function;
BRCA	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg23625390	chr15:77176239	SCAPER	0.35	7.97	0.3	7.23e-15	Blood metabolite levels;
BRCA	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-9.22	-0.34	4.28e-19	Renal function-related traits (BUN);
BRCA	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg25817165	chr18:72167213	CNDP2	-0.77	-19.62	-0.61	1.84e-67	Refractive error;
BRCA	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg04025307	chr7:1156635	C7orf50	0.37	8.32	0.31	5.45e-16	Longevity;Endometriosis;
BRCA	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg07080220	chr10:102295463	HIF1AN	0.65	15.51	0.52	2.69e-46	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg20476274	chr7:133979776	SLC35B4	0.7	21.33	0.64	1.25e-76	Mean platelet volume;
BRCA	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18876405	chr7:65276391	NA	-0.51	-11.47	-0.41	7.75e-28	Aortic root size;
BRCA	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg08132940	chr7:1081526	C7orf50	-0.6	-8.74	-0.33	2.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg02659138	chr7:134003124	SLC35B4	0.33	10.13	0.37	1.75e-22	Mean platelet volume;
BRCA	trans	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg23762105	chr12:34175262	ALG10	0.35	7.88	0.3	1.43e-14	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08219700	chr8:58056026	NA	0.46	8.19	0.31	1.44e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg17211192	chr8:82754475	SNX16	-0.5	-10.75	-0.39	7.13e-25	Diastolic blood pressure;
BRCA	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-15.83	-0.53	7.67e-48	Chronic sinus infection;
BRCA	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-9.48	-0.35	4.7e-20	Bone mineral density;
BRCA	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg18252515	chr7:66147081	NA	-1.06	-15.28	-0.52	3.86e-45	Diabetic kidney disease;
BRCA	cis	rs897080	0.515	rs1067404	chr2:44675823	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.53	-9.27	-0.34	2.9e-19	Height;
BRCA	trans	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg05926928	chr17:57297772	GDPD1	-0.51	-10.22	-0.37	8.25e-23	Schizophrenia;
BRCA	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg13319975	chr6:146136371	FBXO30	-0.4	-9.22	-0.34	4.27e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.86e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4478858	0.735	rs4949393	chr1:31851875	G/A	cg00250761	chr1:31883323	NA	-0.32	-8.44	-0.32	2.18e-16	Alcohol dependence;
BRCA	cis	rs4363385	0.747	rs946097	chr1:152974732	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.24	-0.31	1.01e-15	Inflammatory skin disease;
BRCA	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-10.56	-0.39	3.98e-24	Lymphocyte counts;
BRCA	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg02176678	chr2:219576539	TTLL4	0.4	10.88	0.4	2.09e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg07952391	chr2:88470173	THNSL2	0.64	8.61	0.32	5.56e-17	Plasma clusterin levels;
BRCA	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg17173187	chr15:85201210	NMB	0.43	9.17	0.34	6.42e-19	Schizophrenia;
BRCA	cis	rs4363385	0.747	rs4240866	chr1:152954875	T/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.29	-0.34	2.43e-19	Inflammatory skin disease;
BRCA	cis	rs807669	0.524	rs11089258	chr22:19162276	C/T	cg02655711	chr22:19163373	SLC25A1	0.5	11.94	0.43	8.72e-30	Metabolite levels;
BRCA	cis	rs4499344	0.604	rs259245	chr19:33145106	A/G	cg22980127	chr19:33182716	NUDT19	-0.4	-7.91	-0.3	1.17e-14	Mean platelet volume;
BRCA	cis	rs17253792	0.822	rs78323463	chr14:56045451	T/G	cg01858014	chr14:56050164	KTN1	-0.73	-9.45	-0.35	6.29e-20	Putamen volume;
BRCA	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg12935359	chr14:103987150	CKB	-0.58	-13.9	-0.48	1.46e-38	Body mass index;
BRCA	cis	rs7178424	0.811	rs12899801	chr15:62246864	G/A	cg00456672	chr15:62358751	C2CD4A	0.35	8.58	0.32	7.08e-17	Height;
BRCA	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg06917634	chr15:78832804	PSMA4	0.67	13.89	0.48	1.53e-38	Sudden cardiac arrest;
BRCA	cis	rs9039	1.000	rs9039	chr16:9205363	A/G	cg08831531	chr16:9218945	NA	-0.62	-13.57	-0.47	4.61e-37	Menopause (age at onset);
BRCA	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg14004847	chr7:1930337	MAD1L1	-0.39	-8.0	-0.3	6.01e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.29	-8.27	-0.31	8e-16	Monocyte percentage of white cells;
BRCA	cis	rs4363385	0.818	rs4845335	chr1:152993955	G/A	cg24667326	chr1:152973720	SPRR3	-0.31	-8.37	-0.31	3.71e-16	Inflammatory skin disease;
BRCA	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	8.16	0.31	1.81e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg26384229	chr12:38710491	ALG10B	0.39	8.56	0.32	8.7e-17	Resting heart rate;
BRCA	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg20587970	chr11:113659929	NA	0.82	13.88	0.48	1.85e-38	Hip circumference adjusted for BMI;
BRCA	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08048268	chr3:133502702	NA	-0.43	-11.15	-0.4	1.72e-26	Iron status biomarkers;
BRCA	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg03711944	chr11:47377212	SPI1	-0.34	-9.07	-0.34	1.42e-18	Neuroticism;
BRCA	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg08470875	chr2:26401718	FAM59B	0.76	11.41	0.41	1.47e-27	Gut microbiome composition (summer);
BRCA	cis	rs9815354	0.812	rs73081392	chr3:41923009	G/A	cg03022575	chr3:42003672	ULK4	0.71	9.74	0.36	5.4e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg05729581	chr11:3078854	CARS	-0.35	-8.63	-0.32	5.02e-17	Longevity;
BRCA	cis	rs11229555	0.645	rs12289985	chr11:58185436	C/G	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18876405	chr7:65276391	NA	-0.51	-11.75	-0.42	5.48e-29	Aortic root size;
BRCA	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg00074818	chr8:8560427	CLDN23	0.38	8.26	0.31	8.19e-16	Obesity-related traits;
BRCA	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4965272	0.830	rs11637820	chr15:100560239	C/T	cg27344315	chr15:100560801	ADAMTS17	-0.41	-8.99	-0.33	2.83e-18	Gastroesophageal reflux disease;
BRCA	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg10011062	chr15:43941034	CATSPER2	-0.53	-7.81	-0.3	2.27e-14	Lung cancer in ever smokers;
BRCA	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.67	-0.45	5.66e-33	Bipolar disorder;
BRCA	cis	rs700651	0.821	rs4850812	chr2:198743655	G/T	cg00792783	chr2:198669748	PLCL1	-0.47	-10.14	-0.37	1.7e-22	Intracranial aneurysm;
BRCA	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg08601574	chr20:25228251	PYGB	-0.39	-8.95	-0.33	3.74e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2859741	0.587	rs580029	chr1:37471609	C/A	cg09363841	chr1:37513479	NA	-0.46	-9.61	-0.36	1.67e-20	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25427524	chr10:38739819	LOC399744	-0.69	-16.69	-0.55	3.49e-52	Extrinsic epigenetic age acceleration;
BRCA	trans	rs7980799	0.682	rs10844611	chr12:33603544	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-10.58	-0.39	3.34e-24	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg05283184	chr6:79620031	NA	-0.35	-8.21	-0.31	1.27e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg07636037	chr3:49044803	WDR6	0.97	28.46	0.75	1.02e-115	Parkinson's disease;
BRCA	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.69	0.42	9.4e-29	Tonsillectomy;
BRCA	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg17689763	chr4:710664	PCGF3	-0.59	-13.36	-0.47	4.53e-36	White blood cell count;
BRCA	cis	rs9323205	0.577	rs9672038	chr14:51724856	A/G	cg23942311	chr14:51606299	NA	-0.38	-9.41	-0.35	8.8e-20	Cancer;
BRCA	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg01305625	chr5:131593812	PDLIM4	-0.36	-8.72	-0.33	2.36e-17	Acylcarnitine levels;
BRCA	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg01528321	chr10:82214614	TSPAN14	0.73	16.46	0.55	5.31e-51	Post bronchodilator FEV1;
BRCA	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26314531	chr2:26401878	FAM59B	-0.83	-13.24	-0.46	1.6e-35	Gut microbiome composition (summer);
BRCA	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.79	0.33	1.43e-17	Iron status biomarkers;
BRCA	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg03146154	chr1:46216737	IPP	0.46	10.03	0.37	4.21e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg23625390	chr15:77176239	SCAPER	0.42	10.33	0.38	3.04e-23	Blood metabolite levels;
BRCA	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.49	-9.46	-0.35	5.83e-20	Body mass index;
BRCA	cis	rs9462027	0.583	rs11755420	chr6:34760956	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.88	-0.3	1.44e-14	Systemic lupus erythematosus;
BRCA	cis	rs867371	0.929	rs1045508	chr15:82449906	A/C	cg00614314	chr15:82944287	LOC80154	-0.43	-9.26	-0.34	3.04e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	17.67	0.57	3.29e-57	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.34	-0.38	2.72e-23	Schizophrenia;
BRCA	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg16586182	chr3:47516702	SCAP	0.61	14.11	0.49	1.55e-39	Colorectal cancer;
BRCA	cis	rs10496034	1.000	rs17046514	chr2:55185862	C/T	cg16098955	chr2:55172992	EML6	0.51	9.07	0.34	1.5e-18	Refractive astigmatism;
BRCA	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg06623918	chr6:96969491	KIAA0776	0.74	12.19	0.43	6.85e-31	Migraine;Coronary artery disease;
BRCA	cis	rs4363385	0.747	rs4240866	chr1:152954875	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.79	-0.33	1.42e-17	Inflammatory skin disease;
BRCA	cis	rs870825	0.655	rs2310104	chr4:185619967	A/G	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg02931644	chr1:25747376	RHCE	0.41	11.33	0.41	2.97e-27	Erythrocyte sedimentation rate;
BRCA	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg21960279	chr19:17905606	B3GNT3	0.49	11.23	0.41	8.09e-27	Tumor biomarkers;
BRCA	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg23887609	chr12:130822674	PIWIL1	0.42	9.22	0.34	4.35e-19	Menopause (age at onset);
BRCA	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg04025307	chr7:1156635	C7orf50	0.61	15.39	0.52	1.12e-45	Longevity;Endometriosis;
BRCA	cis	rs6976053	0.541	rs314359	chr7:100411278	T/C	cg03098644	chr7:100410630	EPHB4	-0.44	-8.9	-0.33	5.89e-18	Plasminogen activator inhibitor type 1 levels (PAI-1);
BRCA	cis	rs698833	0.892	rs1067322	chr2:44630107	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	10.68	0.39	1.32e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg06636001	chr8:8085503	FLJ10661	0.48	10.44	0.38	1.2e-23	Neuroticism;
BRCA	cis	rs6120849	0.754	rs6088691	chr20:33633758	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	10.31	0.38	3.78e-23	Protein C levels;
BRCA	cis	rs11711311	0.712	rs3773684	chr3:113334488	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.4	8.55	0.32	9.22e-17	IgG glycosylation;
BRCA	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	13.05	0.46	1.17e-34	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs4853036	0.672	rs1840340	chr2:70025457	C/T	cg02498382	chr2:70120550	SNRNP27	0.41	7.89	0.3	1.34e-14	Colorectal or endometrial cancer;
BRCA	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg25110126	chr1:46999211	NA	0.71	13.09	0.46	7.48e-35	Monobrow;
BRCA	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg02659138	chr7:134003124	SLC35B4	0.35	10.06	0.37	3.25e-22	Mean platelet volume;
BRCA	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg03060546	chr3:49711283	APEH	0.47	10.13	0.37	1.84e-22	Resting heart rate;
BRCA	trans	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg26043149	chr18:55253948	FECH	0.42	8.99	0.34	2.84e-18	Bone mineral density;
BRCA	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg01939980	chr4:1354348	KIAA1530	0.3	8.02	0.3	5.12e-15	Obesity-related traits;
BRCA	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg14458575	chr2:238380390	NA	0.76	16.87	0.56	4.4e-53	Prostate cancer;
BRCA	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg03425785	chr20:62221387	GMEB2	0.51	8.27	0.31	7.88e-16	Glioblastoma;
BRCA	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.31	7.96	0.3	7.79e-15	IgG glycosylation;
BRCA	cis	rs3824867	0.879	rs10769267	chr11:47460098	C/T	cg20307385	chr11:47447363	PSMC3	0.51	11.52	0.41	4.99e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg08885076	chr2:99613938	TSGA10	0.46	10.71	0.39	9.63e-25	Chronic sinus infection;
BRCA	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.51	0.41	5.66e-28	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg18016565	chr1:150552671	MCL1	0.34	7.88	0.3	1.39e-14	Melanoma;
BRCA	cis	rs870825	0.698	rs28412823	chr4:185638829	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.46	0.57	3.99e-56	Blood protein levels;
BRCA	trans	rs11976180	1.000	rs11975942	chr7:143740580	T/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.49	-8.85	-0.33	8.5e-18	Obesity-related traits;
BRCA	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.49	-0.35	4.4e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	13.48	0.47	1.32e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8028182	0.636	rs28783769	chr15:75849009	C/A	cg20655648	chr15:75932815	IMP3	0.45	8.79	0.33	1.41e-17	Sudden cardiac arrest;
BRCA	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg16325326	chr1:53192061	ZYG11B	-0.71	-18.48	-0.59	2.16e-61	Monocyte count;
BRCA	trans	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg26043149	chr18:55253948	FECH	-0.37	-8.25	-0.31	8.96e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg16339924	chr4:17578868	LAP3	0.63	15.74	0.53	2.01e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg11663144	chr21:46675770	NA	-0.62	-14.66	-0.5	3.53e-42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg19847866	chr10:1019161	NA	0.52	10.66	0.39	1.52e-24	Response to angiotensin II receptor blocker therapy;
BRCA	trans	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg25214090	chr10:38739885	LOC399744	0.53	11.06	0.4	3.92e-26	Corneal astigmatism;
BRCA	cis	rs6820391	1.000	rs17660253	chr4:54414365	G/T	cg04173182	chr4:54446035	LNX1	0.4	8.03	0.3	4.64e-15	Cervical artery dissection;
BRCA	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg00530320	chr1:46809349	NSUN4	0.49	9.76	0.36	4.52e-21	Menopause (age at onset);
BRCA	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg09307838	chr4:120376055	NA	0.73	15.87	0.53	4.5e-48	Corneal astigmatism;
BRCA	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.62	9.84	0.36	2.35e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg23625390	chr15:77176239	SCAPER	-0.58	-14.84	-0.51	4.95e-43	Blood metabolite levels;
BRCA	trans	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg26384229	chr12:38710491	ALG10B	0.47	10.36	0.38	2.37e-23	Morning vs. evening chronotype;
BRCA	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg22906224	chr7:99728672	NA	0.44	8.6	0.32	6.33e-17	Coronary artery disease;
BRCA	cis	rs6435161	1.000	rs7568438	chr2:203547106	C/T	cg18429434	chr2:203499731	FAM117B	-0.45	-8.94	-0.33	4.07e-18	Total cholesterol levels;
BRCA	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg00012203	chr2:219082015	ARPC2	-0.48	-9.18	-0.34	5.88e-19	Colorectal cancer;
BRCA	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg17470723	chr8:74884337	TCEB1	0.4	8.62	0.32	5.44e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.42	-0.38	1.39e-23	Aortic root size;
BRCA	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg17724175	chr1:150552817	MCL1	0.27	8.96	0.33	3.51e-18	Tonsillectomy;
BRCA	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg10011062	chr15:43941034	CATSPER2	-0.54	-7.94	-0.3	9.19e-15	Lung cancer in ever smokers;
BRCA	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg23029597	chr12:123009494	RSRC2	-0.59	-11.45	-0.41	9.35e-28	Body mass index;
BRCA	cis	rs2637030	0.502	rs1844698	chr5:52970339	G/A	cg06476337	chr5:52856530	NDUFS4	0.35	7.96	0.3	8.08e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08859206	chr1:53392774	SCP2	-0.61	-13.6	-0.47	3.57e-37	Monocyte count;
BRCA	cis	rs17253792	0.822	rs8006705	chr14:56171283	C/T	cg01858014	chr14:56050164	KTN1	-0.57	-8.77	-0.33	1.58e-17	Putamen volume;
BRCA	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg23933602	chr10:16859644	RSU1	0.55	8.93	0.33	4.38e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg02196655	chr2:10830764	NOL10	0.3	7.99	0.3	6.55e-15	Prostate cancer;
BRCA	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg03929089	chr4:120376271	NA	0.71	14.67	0.5	3.26e-42	Coronary artery disease;
BRCA	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg05714579	chr10:131428358	MGMT	0.56	13.43	0.47	2.03e-36	Response to temozolomide;
BRCA	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.25e-23	Motion sickness;
BRCA	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg19920283	chr7:105172520	RINT1	0.59	9.54	0.35	2.83e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2992756	0.663	rs2992755	chr1:18807897	C/G	cg14356550	chr1:18808102	KLHDC7A	-0.42	-8.9	-0.33	5.65e-18	Breast cancer;
BRCA	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg22638593	chr5:131593259	PDLIM4	0.32	7.97	0.3	7.08e-15	Acylcarnitine levels;
BRCA	cis	rs1403694	0.695	rs13095338	chr3:186435583	T/C	cg12454167	chr3:186435060	KNG1	0.3	8.02	0.3	5.09e-15	Blood protein levels;
BRCA	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg24101359	chr6:42928495	GNMT	0.54	12.66	0.45	5.91e-33	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-9.19	-0.34	5.28e-19	Renal function-related traits (BUN);
BRCA	cis	rs198389	0.617	rs503040	chr1:11890695	C/T	cg24844545	chr1:11908347	NPPA	-0.32	-8.31	-0.31	5.77e-16	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
BRCA	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.89e-18	Motion sickness;
BRCA	cis	rs1829883	0.931	rs7720138	chr5:98879849	G/C	cg08333243	chr5:99726346	NA	0.37	8.8	0.33	1.29e-17	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.55	-13.34	-0.47	5.47e-36	Longevity;Endometriosis;
BRCA	cis	rs1113500	0.897	rs2336127	chr1:108640870	G/A	cg06207961	chr1:108661230	NA	0.46	11.13	0.4	1.97e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs427394	0.659	rs274678	chr5:6752385	A/G	cg10857441	chr5:6722123	POLS	0.31	9.91	0.36	1.3e-21	Menopause (age at onset);
BRCA	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	11.64	0.42	1.58e-28	Hip circumference adjusted for BMI;
BRCA	cis	rs897080	0.552	rs1067384	chr2:44644554	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	9.56	0.35	2.51e-20	Height;
BRCA	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.33	-0.44	1.69e-31	Chronic sinus infection;
BRCA	cis	rs6426558	0.621	rs7521639	chr1:227223736	T/C	cg10327440	chr1:227177885	CDC42BPA	0.75	17.16	0.56	1.43e-54	Neutrophil percentage of white cells;
BRCA	cis	rs12545109	0.765	rs2576594	chr8:57412126	T/G	cg09654669	chr8:57350985	NA	-0.41	-7.9	-0.3	1.21e-14	Obesity-related traits;
BRCA	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10802521	chr3:52805072	NEK4	-0.31	-7.9	-0.3	1.26e-14	Bipolar disorder;
BRCA	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11890956	chr21:40555474	PSMG1	0.95	21.62	0.65	3.42e-78	Cognitive function;
BRCA	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg05714579	chr10:131428358	MGMT	0.59	14.4	0.49	6.55e-41	Response to temozolomide;
BRCA	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg00277334	chr10:82204260	NA	-0.45	-9.56	-0.35	2.56e-20	Post bronchodilator FEV1;
BRCA	cis	rs6087990	0.701	rs1997797	chr20:31387954	C/G	cg13636640	chr20:31349939	DNMT3B	0.6	16.64	0.55	6.56e-52	Ulcerative colitis;
BRCA	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg08132940	chr7:1081526	C7orf50	-0.49	-7.89	-0.3	1.36e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg13256891	chr4:100009986	ADH5	0.54	10.14	0.37	1.65e-22	Smoking initiation;
BRCA	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg10820045	chr2:198174542	NA	-0.42	-9.62	-0.36	1.47e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs4308124	0.708	rs6747657	chr2:112003163	C/T	cg04571233	chr2:111982156	NA	-0.45	-9.99	-0.37	6.43e-22	Vitiligo;
BRCA	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.51	8.49	0.32	1.43e-16	Renal function-related traits (BUN);
BRCA	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.66	-0.61	1.12e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg23505145	chr19:12996616	KLF1	-0.5	-11.52	-0.41	4.77e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7903847	0.642	rs3814553	chr10:99155984	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-8.72	-0.33	2.41e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg13770153	chr20:60521292	NA	-0.44	-9.92	-0.37	1.12e-21	Body mass index;
BRCA	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg11707556	chr5:10655725	ANKRD33B	0.39	9.36	0.35	1.29e-19	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.19	0.49	6.41e-40	Motion sickness;
BRCA	trans	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07923666	chr12:49932857	KCNH3	-0.4	-8.1	-0.31	2.77e-15	Resting heart rate;
BRCA	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg06784218	chr1:46089804	CCDC17	-0.42	-9.71	-0.36	7.19e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.66	-15.18	-0.51	1.13e-44	Mean platelet volume;
BRCA	cis	rs7246657	0.722	rs2909093	chr19:38199462	T/C	cg14683738	chr19:37701593	ZNF585B	-0.48	-8.03	-0.3	4.74e-15	Coronary artery calcification;
BRCA	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11890956	chr21:40555474	PSMG1	-0.61	-13.7	-0.48	1.26e-37	Menarche (age at onset);
BRCA	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg23301140	chr18:77439876	CTDP1	0.34	7.81	0.3	2.38e-14	Monocyte count;
BRCA	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg01304814	chr3:48885189	PRKAR2A	0.63	7.84	0.3	1.91e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs7523050	0.730	rs7519107	chr1:109399367	A/C	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.89	19.92	0.62	4.83e-69	Cognitive ability;
BRCA	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg24101359	chr6:42928495	GNMT	0.53	12.54	0.44	2.16e-32	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg24642844	chr7:1081250	C7orf50	-0.89	-16.0	-0.53	1.07e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg13010199	chr12:38710504	ALG10B	0.53	10.79	0.39	4.56e-25	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10899021	1.000	rs11236201	chr11:74375633	A/G	cg25880958	chr11:74394337	NA	-0.72	-9.39	-0.35	1.03e-19	Response to metformin (IC50);
BRCA	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08045932	chr20:61659980	NA	0.49	11.18	0.4	1.31e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg11266682	chr4:10021025	SLC2A9	0.45	12.09	0.43	1.91e-30	Bone mineral density;
BRCA	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	11.26	0.41	6.07e-27	Hip circumference adjusted for BMI;
BRCA	cis	rs965469	1.000	rs2236104	chr20:3277602	C/A	cg25506879	chr20:3388711	C20orf194	-0.54	-10.44	-0.38	1.13e-23	IFN-related cytopenia;
BRCA	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg13010199	chr12:38710504	ALG10B	0.49	9.51	0.35	3.76e-20	Morning vs. evening chronotype;
BRCA	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg09537434	chr19:41945824	ATP5SL	-1.0	-25.23	-0.71	5.23e-98	Height;
BRCA	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24308560	chr3:49941425	MST1R	0.4	8.43	0.32	2.21e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4664304	0.620	rs3951216	chr2:160711045	G/C	cg01092293	chr2:160761427	LY75	0.33	7.95	0.3	8.35e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs559928	1.000	rs72926050	chr11:64143574	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	9.65	0.36	1.21e-20	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs400736	0.671	rs2472862	chr1:7991203	G/A	cg25007680	chr1:8021821	PARK7	-0.42	-10.51	-0.38	6.25e-24	Response to antidepressants and depression;
BRCA	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg25019033	chr10:957182	NA	-0.42	-8.82	-0.33	1.05e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-9.54	-0.35	3.04e-20	Alzheimer's disease (late onset);
BRCA	trans	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg00078996	chr12:132293329	NA	-0.45	-11.33	-0.41	2.9e-27	Migraine;
BRCA	cis	rs654128	0.640	rs339333	chr6:117211809	T/G	cg12892004	chr6:117198278	RFX6	-0.45	-8.23	-0.31	1.05e-15	Telomere length;
BRCA	cis	rs1451375	1.000	rs1966839	chr7:50627101	T/C	cg18232548	chr7:50535776	DDC	0.43	10.14	0.37	1.62e-22	Malaria;
BRCA	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg15698299	chr3:52233019	ALAS1	-0.4	-9.31	-0.35	1.99e-19	Electroencephalogram traits;
BRCA	cis	rs68170813	0.559	rs12537733	chr7:106965447	A/T	cg02696742	chr7:106810147	HBP1	-0.52	-9.01	-0.34	2.45e-18	Coronary artery disease;
BRCA	cis	rs2882667	0.964	rs2288824	chr5:138298396	C/T	cg04439458	chr5:138467593	SIL1	-0.35	-9.27	-0.34	2.72e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.99	0.3	6.15e-15	Depression;
BRCA	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	11.38	0.41	1.8e-27	Personality dimensions;
BRCA	cis	rs12760731	0.565	rs12028024	chr1:178087423	G/T	cg00404053	chr1:178313656	RASAL2	0.67	8.02	0.3	5.06e-15	Obesity-related traits;
BRCA	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg00106254	chr7:1943704	MAD1L1	-0.45	-11.79	-0.42	3.69e-29	Bipolar disorder and schizophrenia;
BRCA	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg25358565	chr5:93447407	FAM172A	1.16	18.43	0.59	3.76e-61	Diabetic retinopathy;
BRCA	cis	rs7188861	0.768	rs441349	chr16:11371759	C/T	cg01510278	chr16:11456238	NA	0.42	8.21	0.31	1.2e-15	HDL cholesterol;
BRCA	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11890956	chr21:40555474	PSMG1	-0.6	-13.49	-0.47	1.12e-36	Menarche (age at onset);
BRCA	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg25208724	chr1:156163844	SLC25A44	1.04	34.06	0.8	9.05e-146	Testicular germ cell tumor;
BRCA	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg16024904	chr19:17905718	B3GNT3	0.4	8.26	0.31	8.2e-16	Tumor biomarkers;
BRCA	cis	rs4074536	0.622	rs114150777	chr1:116322834	A/C	cg21648376	chr1:116311395	CASQ2	-0.53	-8.81	-0.33	1.22e-17	QRS duration;
BRCA	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg06238570	chr21:40685208	BRWD1	-0.41	-8.42	-0.32	2.55e-16	Menarche (age at onset);
BRCA	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg00290607	chr11:67383545	NA	-0.53	-11.49	-0.41	6.59e-28	Mean corpuscular volume;
BRCA	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg13319975	chr6:146136371	FBXO30	0.43	10.01	0.37	5.33e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12618769	0.652	rs3754875	chr2:99202747	C/G	cg10123293	chr2:99228465	UNC50	0.43	8.51	0.32	1.2e-16	Bipolar disorder;
BRCA	cis	rs4530754	0.691	rs171777	chr5:123053647	C/T	cg27365991	chr5:123036376	NA	-0.48	-11.26	-0.41	6.08e-27	LDL cholesterol;Total cholesterol levels;Cholesterol, total;LDL cholesterol levels;
BRCA	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	8.98e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg24069376	chr3:38537580	EXOG	0.34	9.41	0.35	8.96e-20	Electrocardiographic conduction measures;
BRCA	trans	rs931812	0.691	rs884488	chr8:101898523	C/G	cg20993868	chr7:22813445	NA	0.43	12.56	0.44	1.69e-32	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg18016565	chr1:150552671	MCL1	0.35	7.96	0.3	7.62e-15	Melanoma;
BRCA	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg18811423	chr2:55921094	PNPT1	0.72	22.98	0.67	1.28e-85	Metabolic syndrome;
BRCA	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg17507749	chr15:85114479	UBE2QP1	0.54	9.23	0.34	3.98e-19	Schizophrenia;
BRCA	trans	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	20.37	0.63	1.92e-71	Exhaled nitric oxide output;
BRCA	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg05985134	chr18:33552581	C18orf21	0.64	11.6	0.42	2.2e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg06494592	chr3:125709126	NA	-0.54	-8.41	-0.32	2.67e-16	Blood pressure (smoking interaction);
BRCA	cis	rs1451375	0.617	rs11772714	chr7:50542843	G/A	cg18232548	chr7:50535776	DDC	-0.42	-8.84	-0.33	9.24e-18	Malaria;
BRCA	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg01528321	chr10:82214614	TSPAN14	-0.82	-18.17	-0.58	8.4e-60	Post bronchodilator FEV1;
BRCA	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-11.89	-0.43	1.3e-29	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs1505368	0.789	rs13419353	chr2:213271459	A/T	cg16329650	chr2:213403929	ERBB4	-0.32	-7.96	-0.3	7.65e-15	Symmetrical dimethylarginine levels;
BRCA	trans	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg18876405	chr7:65276391	NA	-0.41	-7.86	-0.3	1.69e-14	Corneal structure;
BRCA	cis	rs6700896	0.864	rs56274111	chr1:66128511	A/C	cg04111102	chr1:66153794	NA	0.36	8.82	0.33	1.08e-17	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg23422044	chr7:1970798	MAD1L1	-0.56	-9.65	-0.36	1.15e-20	Neuroticism;
BRCA	cis	rs13102973	0.863	rs13103492	chr4:135907685	A/C	cg14419869	chr4:135874104	NA	0.45	8.99	0.34	2.73e-18	Subjective well-being;
BRCA	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg23283495	chr1:209979779	IRF6	0.38	8.88	0.33	6.55e-18	Cleft lip with or without cleft palate;
BRCA	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg03342759	chr3:160939853	NMD3	-0.53	-11.24	-0.41	7.45e-27	Kawasaki disease;
BRCA	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-9.09	-0.34	1.21e-18	Mood instability;
BRCA	cis	rs11191205	0.644	rs10883664	chr10:103368208	C/T	cg15320455	chr10:103880129	LDB1	0.48	8.15	0.31	1.92e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg25214090	chr10:38739885	LOC399744	0.53	10.84	0.39	3.02e-25	Corneal astigmatism;
BRCA	trans	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.36	-0.35	1.32e-19	Bladder cancer;
BRCA	trans	rs4650994	0.525	rs10913567	chr1:178511941	A/C	cg05059571	chr16:84539110	KIAA1609	-0.58	-13.13	-0.46	5.07e-35	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg03146154	chr1:46216737	IPP	0.46	10.12	0.37	2e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg13565492	chr6:43139072	SRF	-0.79	-11.0	-0.4	6.8e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg25319279	chr11:5960081	NA	-0.4	-8.88	-0.33	6.81e-18	DNA methylation (variation);
BRCA	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.67	10.4	0.38	1.6e-23	Schizophrenia;
BRCA	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	21.33	0.64	1.16e-76	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-9.32	-0.35	1.86e-19	Colorectal cancer;
BRCA	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.0	-12.71	-0.45	3.62e-33	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4409675	0.619	rs12070173	chr1:28231955	G/C	cg23691781	chr1:28212827	C1orf38	0.32	10.71	0.39	9.82e-25	Corneal astigmatism;
BRCA	cis	rs9470366	0.816	rs4331968	chr6:36623243	A/T	cg08179530	chr6:36648295	CDKN1A	0.5	10.31	0.38	3.65e-23	QRS duration;
BRCA	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg16606324	chr3:10149918	C3orf24	0.56	9.97	0.37	7.35e-22	Alzheimer's disease;
BRCA	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg00677455	chr12:58241039	CTDSP2	0.63	14.19	0.49	6.18e-40	Multiple sclerosis;
BRCA	cis	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg06521331	chr12:34319734	NA	0.53	10.32	0.38	3.44e-23	Morning vs. evening chronotype;
BRCA	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg07080220	chr10:102295463	HIF1AN	0.48	10.21	0.37	8.66e-23	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg15704280	chr7:45808275	SEPT13	0.6	8.83	0.33	9.87e-18	Axial length;
BRCA	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg10523679	chr1:76189770	ACADM	-0.47	-9.13	-0.34	9.04e-19	Daytime sleep phenotypes;
BRCA	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg01874867	chr7:94954059	PON1	-0.4	-8.28	-0.31	7.03e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg25214090	chr10:38739885	LOC399744	0.55	12.51	0.44	2.82e-32	Corneal astigmatism;
BRCA	cis	rs7011049	1.000	rs28867471	chr8:53838179	C/T	cg26025543	chr8:53854495	NA	0.53	9.48	0.35	4.84e-20	Systolic blood pressure;
BRCA	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg12062639	chr20:23401060	NAPB	0.94	13.32	0.47	6.43e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg00530320	chr1:46809349	NSUN4	0.49	9.67	0.36	9.57e-21	Menopause (age at onset);
BRCA	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg08885076	chr2:99613938	TSGA10	0.44	10.21	0.37	8.7e-23	Chronic sinus infection;
BRCA	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg26408565	chr15:76604113	ETFA	0.51	11.53	0.41	4.52e-28	Blood metabolite levels;
BRCA	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.48	10.06	0.37	3.4e-22	Lymphocyte percentage of white cells;
BRCA	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	10.82	0.39	3.76e-25	Multiple sclerosis;
BRCA	trans	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	11.89	0.43	1.3e-29	Exhaled nitric oxide output;
BRCA	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21659725	chr3:3221576	CRBN	-0.33	-7.87	-0.3	1.48e-14	Body mass index;
BRCA	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg09455208	chr3:40491958	NA	-0.48	-11.89	-0.43	1.39e-29	Renal cell carcinoma;
BRCA	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.87	-0.33	7.2e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg21770322	chr7:97807741	LMTK2	0.43	11.28	0.41	4.71e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9323205	0.954	rs4258524	chr14:51638739	A/T	cg23942311	chr14:51606299	NA	-0.39	-9.08	-0.34	1.35e-18	Cancer;
BRCA	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs4363385	0.747	rs946101	chr1:152972032	C/T	cg24667326	chr1:152973720	SPRR3	0.34	9.59	0.35	1.87e-20	Inflammatory skin disease;
BRCA	cis	rs67460515	0.500	rs964533	chr3:160749019	C/A	cg03342759	chr3:160939853	NMD3	-0.57	-11.31	-0.41	3.61e-27	Parkinson's disease;
BRCA	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg02017074	chr12:117425053	FBXW8	0.6	11.29	0.41	4.56e-27	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg26384229	chr12:38710491	ALG10B	0.48	11.47	0.41	8.25e-28	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg16482183	chr6:26056742	HIST1H1C	0.66	13.39	0.47	3.11e-36	Height;
BRCA	cis	rs7914558	0.505	rs12260436	chr10:104741114	A/C	cg04362960	chr10:104952993	NT5C2	0.46	10.22	0.37	8.08e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11764359	chr7:65958608	NA	0.75	16.82	0.55	8.27e-53	Aortic root size;
BRCA	trans	rs2840044	1.000	rs9900378	chr17:33911302	C/T	cg19694781	chr19:47549865	TMEM160	0.45	10.47	0.38	8.73e-24	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs2625529	0.775	rs4777466	chr15:72136872	C/T	cg16672083	chr15:72433130	SENP8	-0.67	-15.85	-0.53	5.53e-48	Red blood cell count;
BRCA	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.44	0.63	8.2e-72	Chronic sinus infection;
BRCA	cis	rs7095944	0.584	rs10901814	chr10:126431281	G/C	cg08799069	chr10:126477246	METTL10	-0.38	-9.01	-0.34	2.36e-18	Asthma;
BRCA	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.46	-0.32	1.88e-16	Total body bone mineral density;
BRCA	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg00409905	chr10:38381863	ZNF37A	0.44	8.88	0.33	6.52e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg02574844	chr11:5959923	NA	-0.43	-8.05	-0.3	4.1e-15	DNA methylation (variation);
BRCA	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.89	-0.33	6.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs782590	0.721	rs1084525	chr2:55929430	C/T	cg18811423	chr2:55921094	PNPT1	0.77	25.92	0.72	8.56e-102	Metabolic syndrome;
BRCA	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg13010199	chr12:38710504	ALG10B	0.49	9.57	0.35	2.32e-20	Morning vs. evening chronotype;
BRCA	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.36	0.31	3.81e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.48	0.38	8.25e-24	Motion sickness;
BRCA	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg22467129	chr15:76604101	ETFA	-0.54	-12.73	-0.45	3.05e-33	Blood metabolite levels;
BRCA	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg05623727	chr3:50126028	RBM5	-0.38	-8.68	-0.32	3.18e-17	Menarche (age at onset);
BRCA	cis	rs877282	0.838	rs11253408	chr10:796374	T/C	cg17470449	chr10:769945	NA	0.51	8.71	0.33	2.54e-17	Uric acid levels;
BRCA	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg09307838	chr4:120376055	NA	0.6	11.86	0.42	1.77e-29	Corneal astigmatism;
BRCA	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg13628971	chr7:2884303	GNA12	0.46	9.14	0.34	7.93e-19	Height;
BRCA	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.55	-0.32	8.82e-17	Total body bone mineral density;
BRCA	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg10295955	chr4:187884368	NA	-0.76	-20.75	-0.63	1.69e-73	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07636037	chr3:49044803	WDR6	-0.74	-16.07	-0.54	4.89e-49	Menarche (age at onset);
BRCA	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg13010199	chr12:38710504	ALG10B	0.48	9.36	0.35	1.31e-19	Morning vs. evening chronotype;
BRCA	cis	rs6820391	0.816	rs4418038	chr4:54446302	A/G	cg04173182	chr4:54446035	LNX1	0.52	11.64	0.42	1.62e-28	Cervical artery dissection;
BRCA	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg13010199	chr12:38710504	ALG10B	0.43	9.14	0.34	7.97e-19	Morning vs. evening chronotype;
BRCA	cis	rs7560272	0.501	rs12615807	chr2:73947583	T/C	cg20560298	chr2:73613845	ALMS1	0.33	8.44	0.32	2.13e-16	Schizophrenia;
BRCA	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.23	0.68	5.59e-87	Chronic sinus infection;
BRCA	cis	rs3820928	1.000	rs12615988	chr2:227769000	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.89	-0.33	6.22e-18	Pulmonary function;
BRCA	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg25214090	chr10:38739885	LOC399744	0.43	10.02	0.37	4.62e-22	Corneal astigmatism;
BRCA	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg24812749	chr6:127587940	RNF146	0.75	16.47	0.55	4.43e-51	Breast cancer;
BRCA	cis	rs113835537	0.529	rs11227503	chr11:66275242	G/C	cg24851651	chr11:66362959	CCS	0.44	8.3	0.31	6.33e-16	Airway imaging phenotypes;
BRCA	trans	rs6479891	0.908	rs7078456	chr10:65269479	C/T	cg14819942	chr15:35414228	NA	-0.33	-8.33	-0.31	4.85e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg08917208	chr2:24149416	ATAD2B	0.51	8.06	0.3	3.89e-15	Asthma;
BRCA	cis	rs631288	0.793	rs1530337	chr1:146683319	C/A	cg25205988	chr1:146714368	CHD1L	0.82	8.01	0.3	5.33e-15	PR interval in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.65e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg24879335	chr3:133465180	TF	0.32	10.62	0.39	2.24e-24	Iron status biomarkers (transferrin levels);
BRCA	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17712092	chr4:129076599	LARP1B	0.57	13.98	0.48	6.28e-39	Eosinophil percentage of white cells;
BRCA	cis	rs8114671	0.967	rs4911472	chr20:33775377	T/A	cg07148914	chr20:33460835	GGT7	0.37	7.92	0.3	1.09e-14	Height;
BRCA	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-12.58	-0.45	1.33e-32	Bipolar disorder;
BRCA	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.95	0.33	3.72e-18	Motion sickness;
BRCA	trans	rs526821	0.595	rs608964	chr11:55339266	G/A	cg15704280	chr7:45808275	SEPT13	-0.43	-8.12	-0.31	2.47e-15	Pediatric bone mineral density (spine);
BRCA	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg07817648	chr10:79422355	NA	-0.68	-12.54	-0.44	2e-32	Bone mineral density;
BRCA	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg03808351	chr9:123631620	PHF19	-0.55	-8.26	-0.31	8.19e-16	Birth weight;
BRCA	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.41	0.35	8.46e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.46	-9.83	-0.36	2.47e-21	Bipolar disorder;
BRCA	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.52	9.21	0.34	4.65e-19	Mean platelet volume;
BRCA	cis	rs312273	0.806	rs12296676	chr12:41348067	T/G	cg17827154	chr12:41323612	CNTN1	-0.41	-10.81	-0.39	3.94e-25	Bipolar disorder;
BRCA	cis	rs7020830	0.522	rs10814509	chr9:37111057	A/G	cg14294708	chr9:37120828	ZCCHC7	0.8	18.84	0.6	2.54e-63	Schizophrenia;
BRCA	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	13.45	0.47	1.71e-36	Bone mineral density;
BRCA	cis	rs1468333	0.929	rs2107682	chr5:137543135	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.43	8.32	0.31	5.43e-16	Resting heart rate;
BRCA	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg23033748	chr14:75592666	NEK9	-0.43	-10.12	-0.37	1.97e-22	Height;
BRCA	trans	rs629535	0.773	rs489206	chr8:70064883	T/C	cg21567404	chr3:27674614	NA	1.01	20.79	0.64	9.62e-74	Dupuytren's disease;
BRCA	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24549020	chr5:56110836	MAP3K1	0.64	13.25	0.46	1.38e-35	Initial pursuit acceleration;
BRCA	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	12.1	0.43	1.79e-30	Mean platelet volume;
BRCA	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg26248373	chr2:1572462	NA	-0.58	-13.04	-0.46	1.26e-34	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.57	0.35	2.33e-20	Bipolar disorder;
BRCA	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg23033748	chr14:75592666	NEK9	-0.38	-9.2	-0.34	5.22e-19	Height;
BRCA	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg25817165	chr18:72167213	CNDP2	-0.72	-12.76	-0.45	2.25e-33	Refractive error;
BRCA	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg03585969	chr10:35415529	CREM	0.56	11.54	0.42	3.91e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg27535305	chr1:53392650	SCP2	-0.46	-11.44	-0.41	1.08e-27	Monocyte count;
BRCA	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.46	13.43	0.47	2.22e-36	Response to antipsychotic treatment;
BRCA	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg07080220	chr10:102295463	HIF1AN	0.6	13.28	0.47	1.03e-35	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg05283184	chr6:79620031	NA	-0.43	-11.03	-0.4	4.97e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg17063962	chr7:91808500	NA	0.53	12.43	0.44	6.26e-32	Breast cancer;
BRCA	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg12908607	chr1:44402522	ARTN	-0.34	-8.21	-0.31	1.27e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg23711669	chr6:146136114	FBXO30	0.65	14.97	0.51	1.22e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg21479132	chr6:26055353	NA	0.57	7.97	0.3	7.48e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9462846	0.959	rs9462845	chr6:42860958	A/G	cg02353165	chr6:42928485	GNMT	0.49	8.64	0.32	4.47e-17	Blood protein levels;
BRCA	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.44	0.35	6.85e-20	Tonsillectomy;
BRCA	cis	rs3820928	1.000	rs4675119	chr2:227774635	A/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.53	-0.32	1.09e-16	Pulmonary function;
BRCA	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg04398451	chr17:18023971	MYO15A	-0.7	-15.31	-0.52	2.77e-45	Total body bone mineral density;
BRCA	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.87	0.3	1.55e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.56	-0.32	8.45e-17	Total body bone mineral density;
BRCA	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg27129171	chr3:47204927	SETD2	-0.52	-10.72	-0.39	9.04e-25	Birth weight;
BRCA	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg01689657	chr7:91764605	CYP51A1	0.22	7.92	0.3	1.09e-14	Breast cancer;
BRCA	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg24829409	chr8:58192753	C8orf71	-0.47	-9.08	-0.34	1.32e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg04362960	chr10:104952993	NT5C2	0.48	10.54	0.38	4.79e-24	Arsenic metabolism;
BRCA	trans	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg06521331	chr12:34319734	NA	-0.57	-10.55	-0.39	4.08e-24	Morning vs. evening chronotype;
BRCA	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03517284	chr6:25882590	NA	0.46	9.54	0.35	3.05e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg17168535	chr8:21777572	XPO7	0.59	13.91	0.48	1.23e-38	Mean corpuscular volume;
BRCA	cis	rs6910061	0.789	rs9461490	chr6:11119471	G/A	cg27233058	chr6:11094804	LOC221710	0.51	8.64	0.32	4.59e-17	Diabetic kidney disease;
BRCA	cis	rs4713675	0.584	rs4711339	chr6:33667199	A/G	cg14003231	chr6:33640908	ITPR3	0.33	8.19	0.31	1.42e-15	Plateletcrit;
BRCA	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00166722	chr3:10149974	C3orf24	0.57	11.15	0.4	1.6e-26	Alzheimer's disease;
BRCA	cis	rs9443189	0.570	rs504446	chr6:76326939	T/C	cg01950844	chr6:76311363	SENP6	0.85	13.76	0.48	6.17e-38	Prostate cancer;
BRCA	cis	rs3106136	0.527	rs2664894	chr4:95153831	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.08	-0.37	2.85e-22	Capecitabine sensitivity;
BRCA	cis	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg07460842	chr6:66804631	NA	-0.96	-19.18	-0.6	4.27e-65	Exhaled nitric oxide output;
BRCA	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg01874867	chr7:94954059	PON1	-0.39	-7.97	-0.3	7.31e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg18270830	chr10:32634957	EPC1	0.6	10.28	0.38	4.83e-23	Sexual dysfunction (female);
BRCA	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.5	10.28	0.38	4.78e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg23711669	chr6:146136114	FBXO30	0.7	16.34	0.54	2.13e-50	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg10518543	chr12:38710700	ALG10B	0.36	7.94	0.3	9.43e-15	Morning vs. evening chronotype;
BRCA	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.17	0.31	1.67e-15	Uric acid levels;
BRCA	cis	rs73086581	0.945	rs6052219	chr20:3970307	A/G	cg02187196	chr20:3869020	PANK2	0.51	9.22	0.34	4.42e-19	Response to antidepressants in depression;
BRCA	cis	rs6426558	0.559	rs2813947	chr1:227459413	G/T	cg10327440	chr1:227177885	CDC42BPA	0.49	9.67	0.36	9.78e-21	Neutrophil percentage of white cells;
BRCA	trans	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg06521331	chr12:34319734	NA	-0.52	-9.41	-0.35	8.45e-20	Bladder cancer;
BRCA	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg18876405	chr7:65276391	NA	-0.5	-11.16	-0.4	1.46e-26	Aortic root size;
BRCA	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg26384229	chr12:38710491	ALG10B	0.66	15.77	0.53	1.46e-47	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg07414643	chr4:187882934	NA	0.23	7.86	0.3	1.59e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	15.22	0.52	7.08e-45	Systolic blood pressure;
BRCA	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.52	-0.41	4.86e-28	Mean corpuscular volume;
BRCA	trans	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg26043149	chr18:55253948	FECH	1.11	23.73	0.68	9.8e-90	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-12.49	-0.44	3.4e-32	Chronic sinus infection;
BRCA	trans	rs867371	0.502	rs2047679	chr15:82531881	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.31	-8.29	-0.31	6.79e-16	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.4	1.46e-26	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.53	-8.98	-0.33	3.13e-18	Schizophrenia;
BRCA	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg11993925	chr19:44307056	LYPD5	0.37	8.92	0.33	4.75e-18	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs2882667	0.861	rs10075541	chr5:138390318	C/T	cg04439458	chr5:138467593	SIL1	-0.33	-9.07	-0.34	1.51e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1468333	1.000	rs2906128	chr5:137550054	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.43	8.56	0.32	8.09e-17	Resting heart rate;
BRCA	cis	rs6834538	0.597	rs1486865	chr4:113465651	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.43	10.38	0.38	1.94e-23	Free thyroxine concentration;
BRCA	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.62	-0.36	1.52e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs11608355	0.545	rs1073780	chr12:109895143	T/C	cg05360138	chr12:110035743	NA	0.65	10.77	0.39	5.72e-25	Neuroticism;
BRCA	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg23289794	chr7:2394357	EIF3B	-0.45	-9.36	-0.35	1.31e-19	Multiple sclerosis;
BRCA	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg03733263	chr8:22462867	KIAA1967	0.97	23.17	0.68	1.16e-86	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg18252515	chr7:66147081	NA	1.06	15.97	0.53	1.49e-48	Diabetic kidney disease;
BRCA	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08045932	chr20:61659980	NA	0.45	10.39	0.38	1.81e-23	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg03146154	chr1:46216737	IPP	-0.43	-9.38	-0.35	1.09e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg22961513	chr11:14280813	SPON1	0.31	7.96	0.3	7.63e-15	Mitochondrial DNA levels;
BRCA	cis	rs4389656	0.857	rs2279657	chr5:6737571	A/G	cg10857441	chr5:6722123	POLS	-0.25	-7.82	-0.3	2.23e-14	Coronary artery disease;
BRCA	cis	rs9341808	0.718	rs6910201	chr6:80904938	G/C	cg08355045	chr6:80787529	NA	0.39	9.96	0.37	7.9e-22	Sitting height ratio;
BRCA	cis	rs3806933	0.522	rs11241100	chr5:110460958	C/T	cg04022379	chr5:110408740	TSLP	0.48	10.15	0.37	1.55e-22	Eosinophilic esophagitis;
BRCA	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg11266682	chr4:10021025	SLC2A9	0.45	11.99	0.43	4.9e-30	Bone mineral density;
BRCA	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg06623918	chr6:96969491	KIAA0776	0.73	12.97	0.46	2.56e-34	Migraine;Coronary artery disease;
BRCA	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg06238570	chr21:40685208	BRWD1	-0.42	-8.62	-0.32	5.25e-17	Menarche (age at onset);
BRCA	cis	rs7172677	0.737	rs11855234	chr15:75446834	C/A	cg14664628	chr15:75095509	CSK	-0.41	-8.87	-0.33	7.47e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg08807101	chr21:30365312	RNF160	-0.59	-15.16	-0.51	1.39e-44	Dental caries;
BRCA	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg21132104	chr15:45694354	SPATA5L1	0.76	17.26	0.56	4.5e-55	Homoarginine levels;
BRCA	cis	rs6815814	0.904	rs73236628	chr4:38825443	C/T	cg02016764	chr4:38805732	TLR1	-0.56	-8.5	-0.32	1.34e-16	Breast cancer;
BRCA	cis	rs7178424	1.000	rs17205407	chr15:62372827	A/G	cg00456672	chr15:62358751	C2CD4A	0.37	8.83	0.33	1.03e-17	Height;
BRCA	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.45	-0.32	1.98e-16	Total body bone mineral density;
BRCA	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg22920501	chr2:26401640	FAM59B	-0.91	-16.27	-0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.82	-0.3	2.16e-14	Aortic root size;
BRCA	trans	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg04702396	chr17:15466718	FAM18B2	-0.37	-7.82	-0.3	2.26e-14	Educational attainment (years of education);
BRCA	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	15.99	0.53	1.23e-48	Coronary artery disease;
BRCA	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg25036284	chr2:26402008	FAM59B	-0.89	-15.63	-0.53	7.3e-47	Gut microbiome composition (summer);
BRCA	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg14186256	chr22:23484241	RTDR1	0.79	24.29	0.69	8.25e-93	Bone mineral density;
BRCA	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg00074818	chr8:8560427	CLDN23	-0.39	-8.49	-0.32	1.46e-16	Obesity-related traits;
BRCA	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg25237894	chr2:233734115	C2orf82	-0.41	-11.83	-0.42	2.37e-29	Coronary artery disease;
BRCA	cis	rs12431939	1.000	rs7140375	chr14:51637242	T/G	cg23942311	chr14:51606299	NA	-0.42	-8.2	-0.31	1.27e-15	Cancer;
BRCA	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.62	9.66	0.36	1.08e-20	Lung function (FEV1/FVC);
BRCA	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg10523679	chr1:76189770	ACADM	0.76	16.01	0.54	9.23e-49	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18876405	chr7:65276391	NA	0.5	11.2	0.4	1.09e-26	Aortic root size;
BRCA	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.17	0.31	1.62e-15	Axial length;
BRCA	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg24812749	chr6:127587940	RNF146	0.68	15.58	0.52	1.2e-46	Breast cancer;
BRCA	cis	rs4423214	0.879	rs1790330	chr11:71147825	C/T	cg05163923	chr11:71159392	DHCR7	-0.54	-10.94	-0.4	1.22e-25	Vitamin D levels;
BRCA	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg22676075	chr6:135203613	NA	0.45	8.66	0.32	3.86e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs17092148	0.887	rs4302281	chr20:33171645	C/T	cg16810054	chr20:33298113	TP53INP2	0.46	10.59	0.39	2.99e-24	Neuroticism;
BRCA	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg21143896	chr7:2802374	GNA12	-0.33	-8.6	-0.32	6.35e-17	Height;
BRCA	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24110177	chr3:50126178	RBM5	0.4	10.99	0.4	7.56e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs6684514	1.000	rs12024813	chr1:156224529	C/A	cg16558208	chr1:156270281	VHLL	0.36	8.02	0.3	4.92e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg07828340	chr4:882639	GAK	1.01	14.02	0.49	3.76e-39	Intelligence (multi-trait analysis);
BRCA	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg24558204	chr6:135376177	HBS1L	0.45	12.41	0.44	8.13e-32	Red blood cell count;
BRCA	cis	rs2737618	0.722	rs2816978	chr1:200078773	A/G	cg21825944	chr1:200113062	NR5A2	-0.4	-9.01	-0.34	2.28e-18	Uric acid levels;
BRCA	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.72	-0.33	2.47e-17	Alzheimer's disease (late onset);
BRCA	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg21475434	chr5:93447410	FAM172A	0.66	8.46	0.32	1.89e-16	Diabetic retinopathy;
BRCA	cis	rs6430585	0.527	rs1438303	chr2:136429857	C/T	cg07169764	chr2:136633963	MCM6	1.0	19.48	0.61	1.1e-66	Corneal structure;
BRCA	cis	rs7124681	0.584	rs7950674	chr11:47871017	T/C	cg20307385	chr11:47447363	PSMC3	0.41	9.47	0.35	5.45e-20	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg18252515	chr7:66147081	NA	-0.56	-11.21	-0.41	9.36e-27	Corneal structure;
BRCA	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.61	-12.77	-0.45	2.03e-33	Lymphocyte counts;
BRCA	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24838063	chr12:130822603	PIWIL1	0.69	16.86	0.55	4.75e-53	Menopause (age at onset);
BRCA	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.42	11.44	0.41	1.1e-27	Response to bleomycin (chromatid breaks);
BRCA	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.43	11.68	0.42	1.07e-28	Response to bleomycin (chromatid breaks);
BRCA	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.47	-11.16	-0.4	1.49e-26	IgG glycosylation;
BRCA	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg11941060	chr3:133502564	NA	-0.35	-8.01	-0.3	5.44e-15	Iron status biomarkers;
BRCA	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-9.81	-0.36	3.01e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7560272	0.538	rs7370393	chr2:73925636	A/C	cg20560298	chr2:73613845	ALMS1	0.35	8.97	0.33	3.39e-18	Schizophrenia;
BRCA	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-9.98	-0.37	7.03e-22	Neuroticism;
BRCA	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg09307838	chr4:120376055	NA	0.67	12.42	0.44	6.73e-32	Corneal astigmatism;
BRCA	cis	rs6700896	0.897	rs1938494	chr1:66117691	G/T	cg04111102	chr1:66153794	NA	0.34	8.42	0.32	2.57e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-8.41	-0.32	2.67e-16	Monocyte percentage of white cells;
BRCA	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	9.36	0.35	1.3e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg27170947	chr2:26402098	FAM59B	-0.78	-12.58	-0.45	1.36e-32	Gut microbiome composition (summer);
BRCA	cis	rs11585357	0.895	rs72633823	chr1:17630779	G/A	cg08277548	chr1:17600880	PADI3	-0.75	-12.26	-0.44	3.67e-31	Hair shape;
BRCA	cis	rs57590327	0.503	rs17019299	chr3:81851643	A/G	cg07356753	chr3:81810745	GBE1	-0.42	-9.79	-0.36	3.46e-21	Extraversion;
BRCA	cis	rs36051895	0.659	rs3780367	chr9:5068755	T/G	cg02405213	chr9:5042618	JAK2	-0.5	-9.09	-0.34	1.22e-18	Pediatric autoimmune diseases;
BRCA	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	trans	rs783540	0.900	rs55924160	chr15:83282196	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.29	-9.09	-0.34	1.23e-18	Schizophrenia;
BRCA	cis	rs7124681	0.584	rs12226590	chr11:47571808	T/C	cg20307385	chr11:47447363	PSMC3	0.47	10.57	0.39	3.44e-24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs9790314	0.695	rs7630763	chr3:160864865	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-13.03	-0.46	1.37e-34	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg13319975	chr6:146136371	FBXO30	0.45	10.43	0.38	1.24e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg23649088	chr2:200775458	C2orf69	-0.7	-15.24	-0.52	5.71e-45	Osteoporosis;
BRCA	cis	rs6121246	0.559	rs6060857	chr20:30300222	A/G	cg21427119	chr20:30132790	HM13	-0.35	-7.9	-0.3	1.18e-14	Mean corpuscular hemoglobin;
BRCA	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg12311346	chr5:56204834	C5orf35	-0.46	-9.34	-0.35	1.64e-19	Coronary artery disease;
BRCA	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-9.85	-0.36	2.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg25237894	chr2:233734115	C2orf82	-0.41	-11.81	-0.42	3.12e-29	Coronary artery disease;
BRCA	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	20.11	0.62	4.61e-70	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs17253792	0.731	rs79483151	chr14:56048851	C/T	cg01858014	chr14:56050164	KTN1	-0.73	-9.45	-0.35	6.29e-20	Putamen volume;
BRCA	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-13.39	-0.47	3.23e-36	Chronic sinus infection;
BRCA	cis	rs2625529	0.938	rs4777464	chr15:72131763	C/T	cg16672083	chr15:72433130	SENP8	-0.75	-16.73	-0.55	2.2e-52	Red blood cell count;
BRCA	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg09307838	chr4:120376055	NA	-0.49	-9.2	-0.34	5.14e-19	Corneal astigmatism;
BRCA	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.35	0.59	9.88e-61	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs919433	0.680	rs6434930	chr2:198369370	A/G	cg00792783	chr2:198669748	PLCL1	0.39	8.97	0.33	3.14e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs1400816	0.850	rs3821096	chr2:172664020	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.54	-8.33	-0.31	4.99e-16	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg19717773	chr7:2847554	GNA12	-0.43	-9.71	-0.36	7.11e-21	Height;
BRCA	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg08601574	chr20:25228251	PYGB	-0.35	-8.63	-0.32	4.82e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg15839431	chr19:19639596	YJEFN3	0.4	8.84	0.33	9.43e-18	Bipolar disorder;
BRCA	trans	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	20.27	0.63	6.67e-71	Exhaled nitric oxide output;
BRCA	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg18964960	chr10:1102726	WDR37	-0.51	-9.13	-0.34	8.55e-19	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg05863683	chr7:1912471	MAD1L1	0.38	8.36	0.31	3.94e-16	Schizophrenia;
BRCA	cis	rs4363385	0.510	rs7531076	chr1:153039167	G/T	cg25856811	chr1:152973957	SPRR3	-0.31	-7.85	-0.3	1.8e-14	Inflammatory skin disease;
BRCA	cis	rs2249625	0.545	rs2496505	chr6:72891063	C/G	cg18830697	chr6:72922368	RIMS1	-0.64	-14.27	-0.49	2.63e-40	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg09307838	chr4:120376055	NA	0.73	15.59	0.53	1.08e-46	Corneal astigmatism;
BRCA	cis	rs6761276	0.649	rs3827763	chr2:113831289	C/T	cg12858261	chr2:113808755	IL1F8	-0.43	-8.74	-0.33	2.08e-17	Protein quantitative trait loci;
BRCA	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg18230493	chr5:56204884	C5orf35	-0.74	-14.4	-0.49	6.67e-41	Initial pursuit acceleration;
BRCA	cis	rs13046373	0.535	rs2832964	chr21:32014012	A/C	cg24082983	chr21:31802169	KRTAP13-4	0.32	8.16	0.31	1.83e-15	HDL cholesterol;
BRCA	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg17807903	chr1:86174739	ZNHIT6	-0.59	-15.84	-0.53	6.88e-48	Urate levels in overweight individuals;
BRCA	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	11.66	0.42	1.3e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg13770153	chr20:60521292	NA	-0.42	-9.45	-0.35	6.5e-20	Body mass index;
BRCA	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.36	-8.39	-0.32	3.01e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg08997352	chr12:9597637	DDX12	-0.61	-12.41	-0.44	7.65e-32	Breast size;
BRCA	trans	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg23762105	chr12:34175262	ALG10	0.35	8.11	0.31	2.55e-15	Morning vs. evening chronotype;
BRCA	cis	rs6546550	0.743	rs6546548	chr2:70017022	A/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-7.99	-0.3	6.14e-15	Prevalent atrial fibrillation;
BRCA	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg15017067	chr4:17643749	FAM184B	0.3	9.05	0.34	1.68e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1267303	0.716	rs942255	chr1:46989792	C/T	cg25110126	chr1:46999211	NA	0.58	10.34	0.38	2.89e-23	Monobrow;
BRCA	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	20.0	0.62	1.89e-69	Platelet count;
BRCA	trans	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg25214090	chr10:38739885	LOC399744	0.55	12.47	0.44	4.27e-32	Corneal astigmatism;
BRCA	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg05535760	chr7:792225	HEATR2	0.73	13.44	0.47	2e-36	Cerebrospinal P-tau181p levels;
BRCA	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11764359	chr7:65958608	NA	-0.76	-17.3	-0.56	2.89e-55	Aortic root size;
BRCA	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.27	8.81	0.33	1.15e-17	Electroencephalogram traits;
BRCA	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg12292205	chr6:26970375	C6orf41	0.64	14.22	0.49	4.44e-40	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg05665937	chr4:1216051	CTBP1	0.53	11.57	0.42	3.02e-28	Obesity-related traits;
BRCA	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg05347473	chr6:146136440	FBXO30	0.59	11.0	0.4	6.53e-26	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs909002	0.849	rs6664789	chr1:32072406	C/G	cg13919466	chr1:32135498	COL16A1	-0.25	-8.36	-0.31	3.9e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg25214090	chr10:38739885	LOC399744	0.5	11.47	0.41	7.99e-28	Corneal astigmatism;
BRCA	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg07988820	chr12:82153109	PPFIA2	-0.62	-10.1	-0.37	2.44e-22	Resting heart rate;
BRCA	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg05347473	chr6:146136440	FBXO30	0.43	8.57	0.32	7.57e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg22834771	chr12:69754056	YEATS4	-0.37	-9.16	-0.34	6.89e-19	Blood protein levels;
BRCA	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	19.62	0.61	1.9e-67	Platelet count;
BRCA	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg24562669	chr7:97807699	LMTK2	0.43	11.46	0.41	9.17e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg06917634	chr15:78832804	PSMA4	-0.75	-17.67	-0.57	3.59e-57	Sudden cardiac arrest;
BRCA	cis	rs11971779	0.818	rs12056045	chr7:139025430	C/G	cg07862535	chr7:139043722	LUC7L2	0.53	12.74	0.45	2.72e-33	Diisocyanate-induced asthma;
BRCA	cis	rs4853036	0.857	rs1048139	chr2:70131791	T/A	cg02498382	chr2:70120550	SNRNP27	-0.53	-9.59	-0.35	1.95e-20	Colorectal or endometrial cancer;
BRCA	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-10.28	-0.38	4.8e-23	HDL cholesterol;
BRCA	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg27170947	chr2:26402098	FAM59B	0.96	16.79	0.55	1.13e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.8	-0.42	3.24e-29	Response to antipsychotic treatment;
BRCA	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg26061582	chr7:22766209	IL6	0.42	9.5	0.35	4.25e-20	Lung cancer;
BRCA	cis	rs6088813	1.000	rs6088815	chr20:33976474	G/C	cg14752227	chr20:34000481	UQCC	-0.39	-8.37	-0.31	3.73e-16	Height;
BRCA	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.98	0.43	5.89e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10193935	0.901	rs6713242	chr2:42470794	C/T	cg27598129	chr2:42591480	NA	-0.97	-13.27	-0.46	1.11e-35	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg24920358	chr1:40204285	PPIE	-0.35	-8.17	-0.31	1.69e-15	Blood protein levels;
BRCA	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg17691542	chr6:26056736	HIST1H1C	0.61	12.39	0.44	9.21e-32	Height;
BRCA	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg08514558	chr10:81106712	PPIF	0.36	8.66	0.32	3.94e-17	Height;
BRCA	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11890956	chr21:40555474	PSMG1	-0.63	-14.44	-0.5	4.01e-41	Menarche (age at onset);
BRCA	cis	rs11971779	0.616	rs7784192	chr7:139039649	T/C	cg07862535	chr7:139043722	LUC7L2	0.38	10.3	0.38	4.17e-23	Diisocyanate-induced asthma;
BRCA	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg24110177	chr3:50126178	RBM5	-0.44	-9.59	-0.35	2.02e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs11608355	0.515	rs12826754	chr12:109923244	A/G	cg05360138	chr12:110035743	NA	0.74	13.54	0.47	6.41e-37	Neuroticism;
BRCA	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg08085267	chr17:45401833	C17orf57	-0.58	-11.87	-0.42	1.72e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs11690935	0.959	rs7586207	chr2:172671094	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.9	-29.11	-0.76	3.11e-119	Schizophrenia;
BRCA	cis	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg07460842	chr6:66804631	NA	0.77	14.02	0.48	4.08e-39	Exhaled nitric oxide levels;
BRCA	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg16486109	chr11:613632	IRF7	0.42	8.83	0.33	1.01e-17	Systemic lupus erythematosus;
BRCA	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11644478	chr21:40555479	PSMG1	-0.5	-10.46	-0.38	1e-23	Menarche (age at onset);
BRCA	cis	rs7593730	0.537	rs10803762	chr2:161105876	G/A	cg22609984	chr2:161126801	NA	0.39	8.48	0.32	1.55e-16	Type 2 diabetes;
BRCA	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg11764359	chr7:65958608	NA	0.65	11.9	0.43	1.21e-29	Aortic root size;
BRCA	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg10523679	chr1:76189770	ACADM	0.7	12.72	0.45	3.51e-33	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2108225	1.000	rs2108226	chr7:107453279	A/C	cg18560240	chr7:107437656	SLC26A3	-0.49	-9.91	-0.36	1.25e-21	Ulcerative colitis;
BRCA	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg04827223	chr11:72435913	ARAP1	-0.73	-18.35	-0.59	1.03e-60	Body mass index;
BRCA	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg14926445	chr8:58193284	C8orf71	-0.46	-8.88	-0.33	6.81e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg23649088	chr2:200775458	C2orf69	0.63	10.95	0.4	1.08e-25	Schizophrenia;
BRCA	cis	rs922692	0.744	rs2277545	chr15:79083591	T/C	cg04896959	chr15:78267971	NA	0.37	8.65	0.32	4.25e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs10129255	0.500	rs1024350	chr14:107141122	C/T	cg07958169	chr14:107095056	NA	-0.37	-7.93	-0.3	9.52e-15	Kawasaki disease;
BRCA	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03517284	chr6:25882590	NA	-0.52	-12.05	-0.43	2.95e-30	Blood metabolite levels;
BRCA	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg22713356	chr15:30763199	NA	1.3	24.75	0.7	2.51e-95	Uric acid levels;
BRCA	cis	rs4363385	0.765	rs1094409	chr1:153021040	T/A	cg24667326	chr1:152973720	SPRR3	-0.31	-8.42	-0.32	2.54e-16	Inflammatory skin disease;
BRCA	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg05863683	chr7:1912471	MAD1L1	0.4	8.58	0.32	7e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs7091068	0.522	rs10882323	chr10:95483280	T/C	cg20715218	chr10:95462985	C10orf4	0.48	9.13	0.34	8.67e-19	Urinary tract infection frequency;
BRCA	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	16.41	0.54	9.01e-51	Platelet count;
BRCA	cis	rs2304206	0.614	rs12104272	chr19:50148052	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.6	-11.68	-0.42	1.02e-28	Vitiligo;
BRCA	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.62	-0.32	5.3e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs858239	0.600	rs6967419	chr7:23136310	C/T	cg23682824	chr7:23144976	KLHL7	0.45	11.89	0.43	1.36e-29	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4363385	0.693	rs4845331	chr1:152982623	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.1	-0.34	1.15e-18	Inflammatory skin disease;
BRCA	trans	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-14.16	-0.49	8.49e-40	Exhaled nitric oxide output;
BRCA	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg26384229	chr12:38710491	ALG10B	0.51	12.78	0.45	1.76e-33	Heart rate;
BRCA	cis	rs4423214	0.625	rs78685409	chr11:71137383	T/C	cg05163923	chr11:71159392	DHCR7	-0.56	-11.19	-0.4	1.1e-26	Vitamin D levels;
BRCA	cis	rs3820928	0.845	rs13415319	chr2:227878936	G/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.78	-0.33	1.54e-17	Pulmonary function;
BRCA	cis	rs10924970	0.934	rs2891026	chr1:235429907	A/C	cg26050004	chr1:235667680	B3GALNT2	0.33	8.14	0.31	2.08e-15	Asthma;
BRCA	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg21573476	chr21:45109991	RRP1B	-0.35	-8.92	-0.33	4.7e-18	Mean corpuscular volume;
BRCA	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg00701064	chr4:6280414	WFS1	0.67	18.42	0.59	4.34e-61	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22509189	chr2:225307070	NA	-0.46	-9.89	-0.36	1.5e-21	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs10493773	1.000	rs2274738	chr1:86119898	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.44	-9.15	-0.34	7.77e-19	Urate levels in overweight individuals;
BRCA	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg00666640	chr1:248458726	OR2T12	0.32	8.76	0.33	1.73e-17	Common traits (Other);
BRCA	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg26384229	chr12:38710491	ALG10B	0.58	13.39	0.47	3.38e-36	Morning vs. evening chronotype;
BRCA	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.55	12.26	0.44	3.34e-31	Colorectal cancer;
BRCA	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg13271783	chr10:134563150	INPP5A	-0.49	-10.03	-0.37	4.42e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg25358565	chr5:93447407	FAM172A	-1.15	-18.02	-0.58	5.22e-59	Diabetic retinopathy;
BRCA	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg20476274	chr7:133979776	SLC35B4	0.55	13.31	0.47	7.47e-36	Mean platelet volume;
BRCA	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg07148914	chr20:33460835	GGT7	0.37	8.41	0.32	2.59e-16	Height;
BRCA	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg01420254	chr6:26195488	NA	0.55	8.51	0.32	1.23e-16	Gout;Renal underexcretion gout;
BRCA	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg10295955	chr4:187884368	NA	-0.96	-28.43	-0.75	1.47e-115	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg22907277	chr7:1156413	C7orf50	0.51	11.16	0.4	1.51e-26	Longevity;Endometriosis;
BRCA	cis	rs16958440	0.867	rs74845165	chr18:44690852	T/C	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg23033748	chr14:75592666	NEK9	-0.36	-8.43	-0.32	2.36e-16	Height;
BRCA	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg25457927	chr22:38595422	NA	-0.31	-11.75	-0.42	5.26e-29	Cutaneous nevi;
BRCA	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg08975724	chr8:8085496	FLJ10661	0.39	8.1	0.31	2.87e-15	Retinal vascular caliber;
BRCA	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg09877947	chr5:131593287	PDLIM4	0.4	10.15	0.37	1.5e-22	Breast cancer;
BRCA	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg16339924	chr4:17578868	LAP3	0.71	16.83	0.55	6.93e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3917254	0.543	rs12470623	chr2:102744015	A/T	cg22835712	chr2:102737379	NA	-0.53	-9.33	-0.35	1.72e-19	Blood protein levels;
BRCA	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-15.75	-0.53	1.79e-47	Chronic sinus infection;
BRCA	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg01262667	chr19:19385393	TM6SF2	0.42	10.97	0.4	9.28e-26	Tonsillectomy;
BRCA	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-13.89	-0.48	1.61e-38	Response to antipsychotic treatment;
BRCA	trans	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg00938859	chr5:1591904	SDHAP3	0.69	9.4	0.35	9.53e-20	Breast cancer;
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11905131	chr22:24372483	LOC391322	0.57	12.89	0.45	6.06e-34	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg00173435	chr12:106696525	TCP11L2	-0.54	-8.12	-0.31	2.4e-15	Tourette syndrome;
BRCA	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-22.22	-0.66	1.81e-81	Body mass index;
BRCA	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg15704280	chr7:45808275	SEPT13	0.73	15.2	0.52	9.16e-45	Height;
BRCA	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg15704280	chr7:45808275	SEPT13	0.7	14.4	0.49	6.33e-41	Coronary artery disease;
BRCA	cis	rs965469	0.779	rs6051785	chr20:3339199	C/T	cg25506879	chr20:3388711	C20orf194	-0.44	-8.85	-0.33	8.26e-18	IFN-related cytopenia;
BRCA	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg26384229	chr12:38710491	ALG10B	-0.49	-12.4	-0.44	8.84e-32	Morning vs. evening chronotype;
BRCA	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg06970220	chr1:156163860	SLC25A44	0.38	9.1	0.34	1.17e-18	Testicular germ cell tumor;
BRCA	cis	rs9341808	0.718	rs10943699	chr6:80940541	G/A	cg08355045	chr6:80787529	NA	0.39	9.94	0.37	9.33e-22	Sitting height ratio;
BRCA	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.79	-14.38	-0.49	7.94e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg18196295	chr10:418757	DIP2C	0.49	11.82	0.42	2.79e-29	Psychosis in Alzheimer's disease;
BRCA	cis	rs10463316	0.784	rs906678	chr5:150779040	T/C	cg03212797	chr5:150827313	SLC36A1	-0.39	-7.83	-0.3	2.09e-14	Metabolite levels (Pyroglutamine);
BRCA	cis	rs11191270	0.554	rs11191253	chr10:104066507	A/T	cg15320455	chr10:103880129	LDB1	0.73	10.7	0.39	1.05e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7639513	0.767	rs9861271	chr3:12707620	A/C	cg23032965	chr3:12705835	RAF1	0.7	15.4	0.52	1e-45	Itch intensity from mosquito bite;
BRCA	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg00166722	chr3:10149974	C3orf24	0.64	11.17	0.4	1.42e-26	Alzheimer's disease;
BRCA	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg00106254	chr7:1943704	MAD1L1	-0.46	-12.41	-0.44	7.79e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs10751667	0.621	rs7396049	chr11:1001561	G/A	cg06064525	chr11:970664	AP2A2	-0.27	-8.02	-0.3	4.98e-15	Alzheimer's disease (late onset);
BRCA	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg17509989	chr5:176798049	RGS14	-0.8	-15.76	-0.53	1.61e-47	Urinary electrolytes (magnesium/calcium ratio);
BRCA	cis	rs80130819	0.515	rs1793915	chr12:48386577	G/T	cg05342945	chr12:48394962	COL2A1	-0.48	-9.53	-0.35	3.12e-20	Prostate cancer;
BRCA	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg19743168	chr1:23544995	NA	-0.34	-8.08	-0.3	3.17e-15	Height;
BRCA	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg10818794	chr15:86012489	AKAP13	-0.3	-8.51	-0.32	1.21e-16	Coronary artery disease;
BRCA	cis	rs9287719	0.649	rs12476554	chr2:10727747	A/G	cg00105475	chr2:10696890	NA	0.41	9.18	0.34	5.83e-19	Prostate cancer;
BRCA	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg08807101	chr21:30365312	RNF160	0.74	18.8	0.6	4.35e-63	Dental caries;
BRCA	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06544989	chr22:39130855	UNC84B	-0.39	-10.08	-0.37	2.85e-22	Menopause (age at onset);
BRCA	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.8e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg15017067	chr4:17643749	FAM184B	-0.28	-8.21	-0.31	1.25e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1997103	1.000	rs10270618	chr7:55396712	T/A	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.72e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.61	13.59	0.47	4.07e-37	Eosinophil percentage of white cells;
BRCA	trans	rs526821	0.553	rs510095	chr11:55289154	T/C	cg15704280	chr7:45808275	SEPT13	-0.42	-7.89	-0.3	1.35e-14	Pediatric bone mineral density (spine);
BRCA	trans	rs7980799	0.649	rs2084391	chr12:33655419	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-9.62	-0.36	1.48e-20	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg02743256	chr7:2109353	MAD1L1	-0.44	-8.25	-0.31	8.98e-16	Neuroticism;
BRCA	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg21427119	chr20:30132790	HM13	-0.35	-7.92	-0.3	1.09e-14	Mean corpuscular hemoglobin;
BRCA	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	trans	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg18876405	chr7:65276391	NA	0.43	8.39	0.32	3.04e-16	Corneal structure;
BRCA	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg11764359	chr7:65958608	NA	-0.68	-15.38	-0.52	1.14e-45	Aortic root size;
BRCA	cis	rs2652822	0.967	rs4775633	chr15:63437746	G/A	cg02713581	chr15:63449717	RPS27L	0.49	9.89	0.36	1.45e-21	Metabolic traits;
BRCA	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg03146154	chr1:46216737	IPP	0.45	9.72	0.36	6.45e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.77	12.53	0.44	2.37e-32	Platelet count;
BRCA	cis	rs10492096	1.000	rs11064210	chr12:6576721	C/T	cg13857086	chr12:6580257	VAMP1	0.42	8.08	0.3	3.18e-15	Hip geometry;
BRCA	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.99	22.65	0.67	8.12e-84	Lymphocyte percentage of white cells;
BRCA	trans	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg01620082	chr3:125678407	NA	-0.62	-8.23	-0.31	1.08e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs13064411	0.542	rs9874747	chr3:113221258	G/A	cg18753928	chr3:113234510	CCDC52	-0.47	-10.11	-0.37	2.15e-22	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg00012203	chr2:219082015	ARPC2	-0.48	-9.32	-0.35	1.92e-19	Colorectal cancer;
BRCA	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.53	11.17	0.4	1.44e-26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg11663144	chr21:46675770	NA	-0.64	-15.28	-0.52	3.72e-45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.29	0.38	4.28e-23	Motion sickness;
BRCA	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	8.21	0.31	1.22e-15	Diabetic retinopathy;
BRCA	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.34	-9.6	-0.35	1.84e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg13628971	chr7:2884303	GNA12	0.44	8.74	0.33	2.03e-17	Height;
BRCA	trans	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.26	0.31	8.38e-16	Corneal astigmatism;
BRCA	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg24879335	chr3:133465180	TF	0.33	11.07	0.4	3.67e-26	Iron status biomarkers (transferrin levels);
BRCA	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg11833968	chr6:79620685	NA	-0.43	-9.8	-0.36	3.26e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs17023223	0.537	rs12097967	chr1:119702913	A/G	cg05756136	chr1:119680316	WARS2	-0.42	-7.99	-0.3	6.09e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg14926445	chr8:58193284	C8orf71	-0.47	-8.92	-0.33	4.83e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.41	0.5	5.45e-41	Motion sickness;
BRCA	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg21252483	chr19:49399788	TULP2	-0.5	-10.99	-0.4	7.77e-26	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs56804039	1.000	rs6986470	chr8:8381430	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-9.29	-0.35	2.32e-19	Cervical cancer;
BRCA	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg05623727	chr3:50126028	RBM5	0.49	11.81	0.42	3.01e-29	Body mass index;
BRCA	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg20701182	chr2:24300061	SF3B14	0.55	8.19	0.31	1.38e-15	Lymphocyte counts;
BRCA	cis	rs6005807	0.640	rs7289534	chr22:29016057	C/T	cg12565055	chr22:29076175	TTC28	0.49	9.33	0.35	1.65e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg25214090	chr10:38739885	LOC399744	0.54	12.5	0.44	3.02e-32	Corneal astigmatism;
BRCA	trans	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg06521331	chr12:34319734	NA	-0.48	-8.72	-0.33	2.44e-17	Bladder cancer;
BRCA	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10465746	0.746	rs6699501	chr1:84389993	A/G	cg10977910	chr1:84465055	TTLL7	0.58	12.06	0.43	2.56e-30	Obesity-related traits;
BRCA	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg18154014	chr19:37997991	ZNF793	0.62	11.73	0.42	6.45e-29	Coronary artery calcification;
BRCA	trans	rs11775334	0.599	rs11774836	chr8:10062543	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-8.32	-0.31	5.41e-16	Hypertension;
BRCA	cis	rs6545883	0.860	rs6749226	chr2:61509783	G/A	cg15711740	chr2:61764176	XPO1	0.49	12.08	0.43	2.07e-30	Tuberculosis;
BRCA	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg09184832	chr6:79620586	NA	-0.53	-11.71	-0.42	7.74e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	ch.11.42038R	chr11:967971	AP2A2	0.52	16.55	0.55	1.84e-51	Alzheimer's disease (late onset);
BRCA	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.36	8.14	0.31	2.08e-15	Tonsillectomy;
BRCA	cis	rs3820928	0.874	rs4234062	chr2:227819050	C/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.88	-0.33	6.91e-18	Pulmonary function;
BRCA	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg04362960	chr10:104952993	NT5C2	0.45	10.36	0.38	2.38e-23	Arsenic metabolism;
BRCA	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-13.41	-0.47	2.55e-36	Response to antipsychotic treatment;
BRCA	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-18.7	-0.59	1.36e-62	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs870825	0.860	rs2705899	chr4:185596219	A/G	cg04058563	chr4:185651563	MLF1IP	0.67	11.95	0.43	7.77e-30	Blood protein levels;
BRCA	cis	rs2066819	1.000	rs74496027	chr12:56726340	C/T	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg15017067	chr4:17643749	FAM184B	0.29	8.38	0.31	3.28e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg13010199	chr12:38710504	ALG10B	0.35	8.26	0.31	8.26e-16	Morning vs. evening chronotype;
BRCA	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg02079420	chr8:82753780	SNX16	-0.31	-8.53	-0.32	1.09e-16	Diastolic blood pressure;
BRCA	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.68	0.32	3.25e-17	Rheumatoid arthritis;
BRCA	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-11.48	-0.41	7.48e-28	Personality dimensions;
BRCA	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg23018236	chr17:30244563	NA	-0.64	-10.31	-0.38	3.67e-23	Hip circumference adjusted for BMI;
BRCA	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg16384552	chr7:74938386	SPDYE8P	0.45	9.56	0.35	2.53e-20	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg12311346	chr5:56204834	C5orf35	-0.81	-16.05	-0.54	5.76e-49	Initial pursuit acceleration;
BRCA	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg23029597	chr12:123009494	RSRC2	-0.56	-11.26	-0.41	5.89e-27	Body mass index;
BRCA	cis	rs250677	0.524	rs250665	chr5:148454394	A/C	cg18129178	chr5:148520854	ABLIM3	-0.49	-10.53	-0.38	5.1e-24	Breast cancer;
BRCA	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.48	0.44	3.94e-32	Electroencephalogram traits;
BRCA	trans	rs11976180	1.000	rs1320893	chr7:143752112	A/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.82	-0.33	1.08e-17	Obesity-related traits;
BRCA	cis	rs11605924	0.935	rs6485645	chr11:45862353	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.46	-9.97	-0.37	7.15e-22	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg05623727	chr3:50126028	RBM5	-0.42	-9.98	-0.37	7e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg04166393	chr7:2884313	GNA12	0.51	10.03	0.37	4.2e-22	Height;
BRCA	cis	rs3772130	0.961	rs1573819	chr3:121469646	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	9.61	0.36	1.58e-20	Cognitive performance;
BRCA	trans	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.44	-9.31	-0.35	2.07e-19	Mean corpuscular volume;
BRCA	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg17211192	chr8:82754475	SNX16	-0.52	-11.94	-0.43	8.29e-30	Diastolic blood pressure;
BRCA	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg16590910	chr6:42928470	GNMT	0.37	8.11	0.31	2.58e-15	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs877282	1.000	rs12763443	chr10:771941	G/A	cg17470449	chr10:769945	NA	0.53	9.27	0.34	2.81e-19	Uric acid levels;
BRCA	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.96	-0.3	8.07e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	8.48	0.32	1.53e-16	Rheumatoid arthritis;
BRCA	cis	rs4478858	0.698	rs6669381	chr1:31833506	A/G	cg00250761	chr1:31883323	NA	-0.33	-8.45	-0.32	2.03e-16	Alcohol dependence;
BRCA	cis	rs10267417	0.603	rs10229973	chr7:19894778	G/A	cg07541023	chr7:19748670	TWISTNB	0.46	8.32	0.31	5.3e-16	Night sleep phenotypes;
BRCA	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.42	-10.14	-0.37	1.6400000000000001e-22	Longevity;Endometriosis;
BRCA	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg07169764	chr2:136633963	MCM6	1.0	20.29	0.63	4.98e-71	Corneal structure;
BRCA	cis	rs2637266	0.935	rs7477361	chr10:78393586	G/A	cg18941641	chr10:78392320	NA	0.35	8.0	0.3	5.69e-15	Pulmonary function;
BRCA	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg15412446	chr2:106886593	NA	-0.53	-9.33	-0.35	1.73e-19	Facial morphology (factor 23);
BRCA	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg18252515	chr7:66147081	NA	-0.54	-10.94	-0.4	1.15e-25	Corneal structure;
BRCA	cis	rs35661897	0.920	rs12478549	chr2:227329662	T/A	cg03426602	chr2:227312417	NA	-0.51	-8.28	-0.31	7.12e-16	Urinary tract infection frequency;
BRCA	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	9.12	0.34	9.79e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg05084668	chr3:125655381	ALG1L	-0.47	-8.09	-0.3	2.91e-15	Blood pressure (smoking interaction);
BRCA	cis	rs877529	0.625	rs714016	chr22:39532554	G/T	cg12193277	chr22:39547181	CBX7	-0.36	-8.42	-0.32	2.56e-16	Multiple myeloma;
BRCA	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg26677194	chr12:130822605	PIWIL1	0.6	14.33	0.49	1.31e-40	Menopause (age at onset);
BRCA	cis	rs13046373	0.508	rs13048637	chr21:31999055	T/G	cg14062083	chr21:31802829	KRTAP13-4	0.34	9.17	0.34	6.55e-19	HDL cholesterol;
BRCA	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg23978390	chr7:1156363	C7orf50	0.39	9.26	0.34	3.01e-19	Longevity;Endometriosis;
BRCA	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-16.19	-0.54	1.18e-49	Total cholesterol levels;
BRCA	trans	rs7939886	0.920	rs7940563	chr11:55875133	C/T	cg15704280	chr7:45808275	SEPT13	0.61	7.93	0.3	1.01e-14	Myopia (pathological);
BRCA	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.05	-0.3	3.95e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs367943	1.000	rs348957	chr5:112821178	C/T	cg12552261	chr5:112820674	MCC	0.55	12.1	0.43	1.66e-30	Type 2 diabetes;
BRCA	cis	rs16858210	0.607	rs59321941	chr3:183571024	A/G	cg25686905	chr3:183603175	PARL	-0.4	-8.56	-0.32	8.57e-17	Menopause (age at onset);
BRCA	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg06552810	chr11:31128660	NA	-0.4	-8.88	-0.33	6.83e-18	Red blood cell count;
BRCA	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg10523679	chr1:76189770	ACADM	0.6	10.6	0.39	2.79e-24	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg17971929	chr21:40555470	PSMG1	-0.62	-13.88	-0.48	1.73e-38	Cognitive function;
BRCA	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg17971929	chr21:40555470	PSMG1	0.71	14.7	0.5	2.31e-42	Cognitive function;
BRCA	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg26031613	chr14:104095156	KLC1	-0.54	-9.77	-0.36	3.99e-21	Reticulocyte count;
BRCA	trans	rs7178375	1.000	rs7178533	chr15:31215976	C/G	cg04373760	chr16:53404718	NA	0.46	8.5	0.32	1.29e-16	Hypertriglyceridemia;
BRCA	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg09877947	chr5:131593287	PDLIM4	0.47	11.5	0.41	6.11e-28	Acylcarnitine levels;
BRCA	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg11814155	chr7:99998594	ZCWPW1	0.42	7.95	0.3	8.26e-15	Platelet count;
BRCA	trans	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.16	0.37	1.43e-22	Mean corpuscular volume;
BRCA	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.47	7.84	0.3	1.9e-14	Renal function-related traits (BUN);
BRCA	cis	rs9790314	0.613	rs13086250	chr3:160631965	G/A	cg03342759	chr3:160939853	NMD3	0.44	8.8	0.33	1.25e-17	Morning vs. evening chronotype;
BRCA	cis	rs6546550	0.904	rs3771537	chr2:70038792	A/C	cg02498382	chr2:70120550	SNRNP27	-0.4	-8.64	-0.32	4.62e-17	Prevalent atrial fibrillation;
BRCA	cis	rs2387326	0.680	rs954650	chr10:129941513	C/A	cg16087940	chr10:129947807	NA	-0.46	-7.99	-0.3	6.51e-15	Select biomarker traits;
BRCA	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.35	0.49	1.11e-40	Motion sickness;
BRCA	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.13	-0.34	9.19e-19	Bipolar disorder;
BRCA	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg00277334	chr10:82204260	NA	-0.84	-23.85	-0.69	2e-90	Post bronchodilator FEV1;
BRCA	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg14558114	chr2:88469736	THNSL2	-0.41	-9.08	-0.34	1.39e-18	Response to metformin (IC50);
BRCA	cis	rs752010	0.756	rs943374	chr1:42056194	A/G	cg06885757	chr1:42089581	HIVEP3	0.23	8.42	0.32	2.41e-16	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.17	0.56	1.25e-54	Bladder cancer;
BRCA	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg23533926	chr12:111358616	MYL2	-0.43	-8.95	-0.33	3.88e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.49	-10.94	-0.4	1.22e-25	Rheumatoid arthritis;
BRCA	cis	rs9368481	0.524	rs9393768	chr6:26885619	A/G	cg18867708	chr6:26865862	GUSBL1	0.42	8.36	0.31	4.03e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.55	-12.96	-0.46	2.77e-34	Longevity;Endometriosis;
BRCA	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg11764359	chr7:65958608	NA	0.67	15.14	0.51	1.7e-44	Aortic root size;
BRCA	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg02269571	chr22:50332266	NA	0.53	7.92	0.3	1.09e-14	Schizophrenia;
BRCA	cis	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05901451	chr6:126070800	HEY2	0.46	11.53	0.41	4.7e-28	Endometrial cancer;
BRCA	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg14863265	chr7:2801509	GNA12	-0.5	-10.78	-0.39	5.22e-25	Height;
BRCA	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.58	-0.45	1.41e-32	Type 2 diabetes;
BRCA	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.41	-0.32	2.73e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg12379764	chr21:47803548	PCNT	-0.38	-8.1	-0.31	2.86e-15	Testicular germ cell tumor;
BRCA	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-12.6	-0.45	1.15e-32	Alzheimer's disease;
BRCA	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg16482183	chr6:26056742	HIST1H1C	0.55	11.42	0.41	1.27e-27	Height;
BRCA	cis	rs6942756	0.956	rs7792317	chr7:128963971	G/A	cg02491457	chr7:128862824	NA	-0.71	-14.09	-0.49	1.8e-39	White matter hyperintensity burden;
BRCA	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg00074818	chr8:8560427	CLDN23	0.37	8.16	0.31	1.77e-15	Obesity-related traits;
BRCA	cis	rs1570989	0.571	rs6916066	chr6:12016009	G/C	cg17804551	chr6:12015979	HIVEP1	0.41	9.9	0.36	1.32e-21	Alcohol and nicotine co-dependence;
BRCA	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg06064525	chr11:970664	AP2A2	-0.5	-17.02	-0.56	7.5e-54	Alzheimer's disease (late onset);
BRCA	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg23505145	chr19:12996616	KLF1	0.56	12.69	0.45	4.46e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg04450456	chr4:17643702	FAM184B	-0.32	-9.11	-0.34	1.09e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	12.86	0.45	8.26e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11677370	0.574	rs11686118	chr2:3854938	C/T	cg17052675	chr2:3827356	NA	-0.51	-11.96	-0.43	6.77e-30	Type 2 diabetes;
BRCA	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg17330251	chr7:94953956	PON1	-0.42	-8.64	-0.32	4.63e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs6479891	1.000	rs12413730	chr10:64964148	C/T	cg14819942	chr15:35414228	NA	0.35	8.65	0.32	4.26e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg26395211	chr5:140044315	WDR55	0.37	8.6	0.32	6e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.59	14.24	0.49	3.79e-40	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg25319279	chr11:5960081	NA	0.42	8.2	0.31	1.35e-15	DNA methylation (variation);
BRCA	cis	rs6700896	0.931	rs2154384	chr1:66108517	C/T	cg04111102	chr1:66153794	NA	0.34	8.41	0.32	2.71e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs911119	0.913	rs13037490	chr20:23583725	T/C	cg16589663	chr20:23618590	CST3	0.46	8.28	0.31	7.17e-16	Chronic kidney disease;
BRCA	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.77	-0.33	1.66e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs68170813	0.559	rs60255281	chr7:106963913	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.92	-0.33	5.05e-18	Coronary artery disease;
BRCA	trans	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg18876405	chr7:65276391	NA	0.45	10.02	0.37	4.6e-22	Corneal structure;
BRCA	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg22105103	chr4:187893119	NA	0.41	13.39	0.47	3.27e-36	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg01324343	chr3:183735012	ABCC5	0.8	20.01	0.62	1.52e-69	Anterior chamber depth;
BRCA	cis	rs243505	0.559	rs734003	chr7:148505498	T/G	cg09806900	chr7:148480153	CUL1	0.53	10.94	0.4	1.2e-25	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	13.38	0.47	3.49e-36	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg18402987	chr7:1209562	NA	0.42	7.97	0.3	7.26e-15	Longevity;Endometriosis;
BRCA	cis	rs1997103	0.954	rs940880	chr7:55392619	C/G	cg17469321	chr7:55412551	NA	0.51	9.76	0.36	4.44e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2066819	1.000	rs75265219	chr12:56640341	G/A	cg26734620	chr12:56694298	CS	0.86	9.88	0.36	1.64e-21	Psoriasis vulgaris;
BRCA	cis	rs9487051	0.621	rs351726	chr6:109548304	C/T	cg01475377	chr6:109611718	NA	-0.39	-7.84	-0.3	1.9e-14	Reticulocyte fraction of red cells;
BRCA	cis	rs56159542	1	rs56159542	chr19:19682971	T/C	cg11584989	chr19:19387371	SF4	-0.48	-9.77	-0.36	4.24e-21	Attention deficit hyperactivity disorder symptom score;
BRCA	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.81	11.72	0.42	6.92e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg06640241	chr16:89574553	SPG7	0.87	22.42	0.66	1.46e-82	Multiple myeloma (IgH translocation);
BRCA	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg20735989	chr4:730612	PCGF3	-0.4	-8.91	-0.33	5.29e-18	White blood cell count;
BRCA	trans	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg26384229	chr12:38710491	ALG10B	0.44	10.57	0.39	3.48e-24	Morning vs. evening chronotype;
BRCA	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg23533926	chr12:111358616	MYL2	-0.43	-9.0	-0.34	2.62e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7737355	0.947	rs40400	chr5:130831365	C/T	cg06307176	chr5:131281290	NA	-0.52	-10.5	-0.38	6.84e-24	Life satisfaction;
BRCA	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	1.02e-40	Motion sickness;
BRCA	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg12311346	chr5:56204834	C5orf35	-0.82	-16.25	-0.54	5.79e-50	Initial pursuit acceleration;
BRCA	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg16230307	chr14:35515116	FAM177A1	0.62	13.87	0.48	1.94e-38	Psoriasis;
BRCA	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg13880726	chr7:1868755	MAD1L1	0.39	8.01	0.3	5.64e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs1843834	0.755	rs10197382	chr2:225574650	T/C	cg22455342	chr2:225449267	CUL3	0.34	8.11	0.31	2.67e-15	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg19920283	chr7:105172520	RINT1	0.57	8.99	0.34	2.79e-18	Bipolar disorder (body mass index interaction);
BRCA	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg27129171	chr3:47204927	SETD2	0.71	17.18	0.56	1.13e-54	Colorectal cancer;
BRCA	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg24578937	chr1:2090814	PRKCZ	0.35	10.73	0.39	8.57e-25	Height;
BRCA	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg25358565	chr5:93447407	FAM172A	1.22	18.72	0.6	1.12e-62	Diabetic retinopathy;
BRCA	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg01324343	chr3:183735012	ABCC5	0.86	21.62	0.65	3.05e-78	Anterior chamber depth;
BRCA	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs68170813	0.559	rs1548523	chr7:106944408	G/A	cg02696742	chr7:106810147	HBP1	-0.52	-8.51	-0.32	1.23e-16	Coronary artery disease;
BRCA	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg26384229	chr12:38710491	ALG10B	0.66	13.84	0.48	2.82e-38	Morning vs. evening chronotype;
BRCA	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.49	0.38	7.33e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7560272	0.501	rs10191988	chr2:73947787	A/G	cg20560298	chr2:73613845	ALMS1	0.33	8.32	0.31	5.25e-16	Schizophrenia;
BRCA	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg17120908	chr11:65337727	SSSCA1	0.53	9.74	0.36	5.51e-21	Bone mineral density;
BRCA	cis	rs1865721	0.771	rs7235563	chr18:73139335	C/G	cg26385618	chr18:73139727	C18orf62	-0.43	-10.74	-0.39	7.34e-25	Intelligence;
BRCA	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg13877915	chr19:58951672	ZNF132	0.46	10.88	0.4	2.08e-25	Uric acid clearance;
BRCA	cis	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg24692254	chr21:30365293	RNF160	-0.46	-8.13	-0.31	2.31e-15	Cognitive test performance;
BRCA	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12310025	chr6:25882481	NA	-0.54	-11.75	-0.42	5.2e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg02951883	chr7:2050386	MAD1L1	-0.51	-11.1	-0.4	2.63e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs72928364	0.860	rs34281790	chr3:100790767	G/A	cg10123952	chr3:100791384	NA	0.59	8.51	0.32	1.2e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg27446573	chr6:127587934	RNF146	0.89	20.42	0.63	1e-71	Breast cancer;
BRCA	cis	rs2625529	0.824	rs7183749	chr15:72377278	G/A	cg16672083	chr15:72433130	SENP8	-0.84	-17.65	-0.57	4.28e-57	Red blood cell count;
BRCA	trans	rs3960554	0.673	rs112680895	chr7:75623520	G/A	cg19862616	chr7:65841803	NCRNA00174	0.57	11.19	0.4	1.14e-26	Eotaxin levels;
BRCA	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	14.13	0.49	1.18e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg11822812	chr5:140052017	DND1	-0.32	-8.98	-0.33	2.94e-18	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg11663144	chr21:46675770	NA	-0.62	-14.32	-0.49	1.53e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg18811423	chr2:55921094	PNPT1	0.7	22.61	0.67	1.32e-83	Metabolic syndrome;
BRCA	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg17971929	chr21:40555470	PSMG1	0.47	10.3	0.38	3.92e-23	Menarche (age at onset);
BRCA	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg08999081	chr20:33150536	PIGU	0.35	8.75	0.33	1.84e-17	Coronary artery disease;
BRCA	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg08601574	chr20:25228251	PYGB	-0.38	-9.05	-0.34	1.76e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg14019695	chr9:139328340	INPP5E	-0.31	-8.0	-0.3	5.73e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs17818399	0.890	rs34752561	chr2:46850150	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.55	9.76	0.36	4.36e-21	Height;
BRCA	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg20476274	chr7:133979776	SLC35B4	0.66	19.6	0.61	2.4e-67	Mean platelet volume;
BRCA	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg04166393	chr7:2884313	GNA12	0.58	12.47	0.44	4.04e-32	Height;
BRCA	cis	rs4891159	0.790	rs72975925	chr18:74143902	G/A	cg24786174	chr18:74118243	ZNF516	-0.77	-17.92	-0.58	1.72e-58	Longevity;
BRCA	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg01017244	chr2:74357527	NA	0.56	13.2	0.46	2.49e-35	Gestational age at birth (maternal effect);
BRCA	trans	rs11039798	1.000	rs12281162	chr11:48650491	T/C	cg15704280	chr7:45808275	SEPT13	0.51	7.81	0.3	2.33e-14	Axial length;
BRCA	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg24450063	chr1:156163899	SLC25A44	0.97	28.51	0.75	5.78e-116	Testicular germ cell tumor;
BRCA	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg00983440	chr10:79422392	NA	0.52	10.26	0.38	5.99e-23	Bone mineral density;
BRCA	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg05973401	chr12:123451056	ABCB9	0.41	9.14	0.34	8.18e-19	Platelet count;
BRCA	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg03354898	chr7:1950403	MAD1L1	-0.45	-9.61	-0.36	1.7e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs6788895	1.000	rs16862842	chr3:150484844	A/G	cg09723797	chr3:150481914	SIAH2	0.7	8.65	0.32	4.16e-17	Breast cancer;
BRCA	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-16.3	-0.54	3.38e-50	Alzheimer's disease (late onset);
BRCA	cis	rs2286885	1.000	rs2286885	chr9:129246487	A/C	cg15282417	chr9:129245246	FAM125B	0.31	7.95	0.3	8.18e-15	Intraocular pressure;
BRCA	cis	rs400736	0.562	rs12129505	chr1:8171734	T/C	cg25007680	chr1:8021821	PARK7	-0.36	-8.59	-0.32	6.83e-17	Response to antidepressants and depression;
BRCA	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-9.33	-0.35	1.72e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg08888203	chr3:10149979	C3orf24	0.56	11.7	0.42	9.05e-29	Alzheimer's disease;
BRCA	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg23711669	chr6:146136114	FBXO30	0.72	17.59	0.57	8.45e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg24578937	chr1:2090814	PRKCZ	0.33	10.47	0.38	8.79e-24	Height;
BRCA	cis	rs887829	0.641	rs10167119	chr2:234589312	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-8.53	-0.32	1.09e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	trans	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.36	0.38	2.29e-23	Mean corpuscular volume;
BRCA	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg11663144	chr21:46675770	NA	-0.48	-9.62	-0.36	1.54e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg02551604	chr5:131831745	NA	-0.4	-15.17	-0.51	1.21e-44	Asthma (sex interaction);
BRCA	cis	rs1190552	1.000	rs1190552	chr14:102911907	A/G	cg18135206	chr14:102964638	TECPR2	-0.42	-7.84	-0.3	1.87e-14	Blood protein levels;
BRCA	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg13114125	chr14:105738426	BRF1	-0.48	-10.41	-0.38	1.53e-23	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg25237894	chr2:233734115	C2orf82	0.39	11.1	0.4	2.76e-26	Coronary artery disease;
BRCA	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21659725	chr3:3221576	CRBN	0.46	11.55	0.42	3.81e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg20219911	chr3:52813652	ITIH1	0.29	8.13	0.31	2.16e-15	Cognitive function;
BRCA	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg00530320	chr1:46809349	NSUN4	0.47	9.18	0.34	6.13e-19	Menopause (age at onset);
BRCA	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-8.68	-0.32	3.2e-17	Renal function-related traits (BUN);
BRCA	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.57	8.96	0.33	3.68e-18	Lung function (FEV1/FVC);
BRCA	cis	rs7246967	0.673	rs62120125	chr19:22955099	T/A	cg23217946	chr19:22817039	ZNF492	0.5	9.11	0.34	1.04e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg03585969	chr10:35415529	CREM	0.56	11.55	0.42	3.82e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11608355	0.576	rs1477117	chr12:109888779	A/G	cg05360138	chr12:110035743	NA	-0.64	-10.69	-0.39	1.15e-24	Neuroticism;
BRCA	cis	rs9394841	0.692	rs35085306	chr6:41856002	A/G	cg08135965	chr6:41755394	TOMM6	0.52	8.56	0.32	8.08e-17	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg01528321	chr10:82214614	TSPAN14	0.63	14.18	0.49	7.14e-40	Post bronchodilator FEV1;
BRCA	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg23442198	chr4:187126114	CYP4V2	0.95	11.42	0.41	1.23e-27	Blood protein levels;
BRCA	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg19318889	chr4:1322082	MAEA	0.48	10.35	0.38	2.65e-23	Longevity;
BRCA	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06634786	chr22:41940651	POLR3H	-0.63	-10.86	-0.39	2.43e-25	Vitiligo;
BRCA	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.39	0.49	7.08e-41	Motion sickness;
BRCA	cis	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg05084668	chr3:125655381	ALG1L	0.72	12.98	0.46	2.35e-34	Blood pressure (smoking interaction);
BRCA	cis	rs1420338	1.000	rs4723351	chr7:34155813	T/G	cg01275685	chr7:34179230	BMPER	-0.47	-10.37	-0.38	2.09e-23	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg20307385	chr11:47447363	PSMC3	0.76	16.68	0.55	4e-52	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg05985134	chr18:33552581	C18orf21	0.68	12.65	0.45	6.79e-33	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12756686	chr19:29218302	NA	0.57	11.08	0.4	3.26e-26	Methadone dose in opioid dependence;
BRCA	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg22800045	chr5:56110881	MAP3K1	0.46	9.1	0.34	1.14e-18	Initial pursuit acceleration;
BRCA	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.06	15.87	0.53	4.42e-48	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7395581	0.918	rs10838693	chr11:47350553	G/C	cg25783544	chr11:47291846	MADD	0.38	8.44	0.32	2.14e-16	HDL cholesterol;
BRCA	cis	rs2505998	0.833	rs752977	chr10:43588381	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.43	-8.45	-0.32	2.02e-16	Hirschsprung disease;
BRCA	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg24692254	chr21:30365293	RNF160	0.61	13.1	0.46	7.02e-35	Selective IgA deficiency;
BRCA	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg26384229	chr12:38710491	ALG10B	0.77	17.53	0.57	1.92e-56	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg17366294	chr4:99064904	C4orf37	0.41	9.62	0.36	1.46e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10802521	chr3:52805072	NEK4	-0.31	-8.39	-0.31	3.15e-16	Bipolar disorder;
BRCA	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00166722	chr3:10149974	C3orf24	0.64	12.76	0.45	2.3e-33	Alzheimer's disease;
BRCA	cis	rs73001065	0.551	rs56397647	chr19:19642795	C/T	cg03709012	chr19:19516395	GATAD2A	0.98	14.64	0.5	4.83e-42	LDL cholesterol;
BRCA	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg20203395	chr5:56204925	C5orf35	0.61	12.0	0.43	4.47e-30	Initial pursuit acceleration;
BRCA	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg05347473	chr6:146136440	FBXO30	-0.43	-8.74	-0.33	2.02e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6750047	0.546	rs985257	chr2:38283228	A/T	cg07380506	chr2:38303506	CYP1B1	-0.54	-11.55	-0.42	3.85e-28	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg24450063	chr1:156163899	SLC25A44	1.12	36.13	0.82	1.49e-156	Testicular germ cell tumor;
BRCA	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg23711669	chr6:146136114	FBXO30	-0.72	-15.96	-0.53	1.63e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	14.6	0.5	6.9e-42	Platelet count;
BRCA	cis	rs72772090	0.539	rs11750464	chr5:96113031	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.57	11.87	0.43	1.6800000000000001e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24549020	chr5:56110836	MAP3K1	0.6	12.19	0.43	7.39e-31	Initial pursuit acceleration;
BRCA	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.6	-14.35	-0.49	1.1e-40	Longevity;Endometriosis;
BRCA	trans	rs4596713	0.568	rs7850573	chr9:71747260	C/T	cg16512924	chr15:28394682	HERC2	0.39	9.31	0.35	2.07e-19	Headache;
BRCA	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg01256987	chr12:42539512	GXYLT1	-0.41	-8.22	-0.31	1.13e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg18154014	chr19:37997991	ZNF793	0.61	11.09	0.4	3.01e-26	Coronary artery calcification;
BRCA	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.63	0.36	1.43e-20	Menopause (age at onset);
BRCA	cis	rs11608355	0.515	rs12831026	chr12:109903651	C/T	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg24562669	chr7:97807699	LMTK2	0.46	12.24	0.44	4.08e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.34	0.35	1.56e-19	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs6545883	0.524	rs12713435	chr2:61499789	C/T	cg15711740	chr2:61764176	XPO1	0.33	8.09	0.3	3.06e-15	Tuberculosis;
BRCA	cis	rs34891900	0.507	rs2535679	chr22:18202850	A/G	cg19898043	chr22:18121309	BCL2L13	0.45	9.65	0.36	1.18e-20	Sum neutrophil eosinophil counts;
BRCA	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg25237894	chr2:233734115	C2orf82	0.41	12.03	0.43	3.29e-30	Coronary artery disease;
BRCA	cis	rs312273	0.563	rs4768319	chr12:41299039	A/C	cg17827154	chr12:41323612	CNTN1	-0.35	-8.49	-0.32	1.41e-16	Bipolar disorder;
BRCA	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.5	-9.71	-0.36	7.16e-21	Body mass index;
BRCA	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.35	7.91	0.3	1.12e-14	Coronary artery disease;
BRCA	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-10.83	-0.39	3.37e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.28e-17	Iron status biomarkers;
BRCA	trans	rs9951602	0.512	rs9946123	chr18:76654557	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	18.28	0.59	2.2e-60	Obesity-related traits;
BRCA	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg04990556	chr1:26633338	UBXN11	0.54	8.98	0.33	2.89e-18	Obesity-related traits;
BRCA	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg12444411	chr7:2802554	GNA12	-0.33	-8.26	-0.31	8.29e-16	Height;
BRCA	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg26384229	chr12:38710491	ALG10B	0.74	17.22	0.56	7.02e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10769966	0.515	rs2568069	chr11:8977707	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.33	8.42	0.32	2.5e-16	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7131987	0.630	rs1006409	chr12:29435675	A/G	cg09582351	chr12:29534625	ERGIC2	-0.34	-8.37	-0.31	3.63e-16	QT interval;
BRCA	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg04455712	chr21:45112962	RRP1B	0.39	10.44	0.38	1.15e-23	Mean corpuscular volume;
BRCA	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	10.9	0.4	1.78e-25	Rheumatoid arthritis;
BRCA	trans	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg06521331	chr12:34319734	NA	-0.46	-8.48	-0.32	1.58e-16	Bladder cancer;
BRCA	trans	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg25214090	chr10:38739885	LOC399744	0.55	12.2	0.43	6.09e-31	Corneal astigmatism;
BRCA	cis	rs75804782	0.641	rs11885523	chr2:239344263	G/A	cg18131467	chr2:239335373	ASB1	-0.62	-8.16	-0.31	1.79e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg11764359	chr7:65958608	NA	-0.64	-11.32	-0.41	3.39e-27	Aortic root size;
BRCA	cis	rs4953318	0.704	rs10495927	chr2:46352499	A/G	cg12428440	chr2:46370979	PRKCE	0.42	9.68	0.36	9.25e-21	Red blood cell count;Hematocrit;Red blood cell traits;
BRCA	cis	rs9400271	0.632	rs9400262	chr6:109591433	T/C	cg01475377	chr6:109611718	NA	-0.44	-10.39	-0.38	1.79e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs9296095	0.796	rs3846855	chr6:33555877	G/A	cg14003231	chr6:33640908	ITPR3	0.45	9.11	0.34	1.02e-18	Platelet count;
BRCA	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg26597838	chr10:835615	NA	0.98	16.98	0.56	1.18e-53	Eosinophil percentage of granulocytes;
BRCA	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-12.6	-0.45	1.15e-32	Alzheimer's disease;
BRCA	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg12311346	chr5:56204834	C5orf35	0.61	12.59	0.45	1.29e-32	Initial pursuit acceleration;
BRCA	cis	rs2745967	0.740	rs2796252	chr1:208067308	C/A	cg09788693	chr1:208063733	CD34	0.37	7.84	0.3	1.86e-14	Resting heart rate;
BRCA	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4713675	0.565	rs9469566	chr6:33667605	G/T	cg14003231	chr6:33640908	ITPR3	0.35	8.84	0.33	9.09e-18	Plateletcrit;
BRCA	cis	rs2797160	1.000	rs2747714	chr6:126007620	A/G	cg05901451	chr6:126070800	HEY2	0.39	9.54	0.35	2.89e-20	Endometrial cancer;
BRCA	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg26587870	chr6:27730563	NA	-0.52	-8.02	-0.3	5.04e-15	Breast cancer;
BRCA	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg08501292	chr6:25962987	TRIM38	0.57	7.81	0.3	2.35e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg15595755	chr5:1867978	NA	0.35	8.01	0.3	5.3e-15	Cardiovascular disease risk factors;
BRCA	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.46	-0.32	1.85e-16	Monocyte percentage of white cells;
BRCA	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg24069376	chr3:38537580	EXOG	0.32	9.2	0.34	5.18e-19	Electrocardiographic conduction measures;
BRCA	cis	rs8016982	0.633	rs4363794	chr14:81674327	C/A	cg01989461	chr14:81687754	GTF2A1	0.62	14.6	0.5	7.12e-42	Schizophrenia;
BRCA	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg00071950	chr4:10020882	SLC2A9	0.62	14.61	0.5	6.27e-42	Bone mineral density;
BRCA	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg14004847	chr7:1930337	MAD1L1	-0.42	-7.94	-0.3	8.94e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs6032067	0.561	rs2743317	chr20:43936931	C/T	cg06407657	chr20:43937138	MATN4;RBPJL	0.31	8.47	0.32	1.65e-16	Blood protein levels;
BRCA	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.13e-54	Bladder cancer;
BRCA	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg20387954	chr3:183756860	HTR3D	0.4	9.02	0.34	2.26e-18	Anterior chamber depth;
BRCA	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg24848339	chr3:12840334	CAND2	0.43	11.41	0.41	1.43e-27	QRS complex (12-leadsum);
BRCA	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.66	18.77	0.6	5.93e-63	Schizophrenia;
BRCA	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.39	-8.94	-0.33	4.03e-18	Longevity;Endometriosis;
BRCA	cis	rs1904096	0.506	rs6841121	chr4:95222995	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-10.18	-0.37	1.22e-22	Type 2 diabetes;
BRCA	cis	rs10463316	0.817	rs2112419	chr5:150797804	T/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.58	-0.32	7.32e-17	Metabolite levels (Pyroglutamine);
BRCA	cis	rs7301826	0.651	rs7299281	chr12:131303132	G/A	cg11011512	chr12:131303247	STX2	-0.45	-11.27	-0.41	5.41e-27	Plasma plasminogen activator levels;
BRCA	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	15.31	0.52	2.67e-45	Colorectal cancer;
BRCA	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07308232	chr7:1071921	C7orf50	-0.42	-8.45	-0.32	1.9e-16	Longevity;Endometriosis;
BRCA	cis	rs4780401	0.609	rs4781141	chr16:11808769	A/C	cg01061890	chr16:11836724	TXNDC11	-0.55	-13.08	-0.46	8.08e-35	Rheumatoid arthritis;
BRCA	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg24110177	chr3:50126178	RBM5	-0.47	-11.71	-0.42	7.98e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07308232	chr7:1071921	C7orf50	-0.5	-10.49	-0.38	7.27e-24	Longevity;Endometriosis;
BRCA	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg01262667	chr19:19385393	TM6SF2	-0.42	-10.9	-0.4	1.66e-25	Tonsillectomy;
BRCA	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg22972055	chr7:872293	UNC84A	0.39	8.09	0.3	3.04e-15	Cerebrospinal P-tau181p levels;
BRCA	cis	rs78663649	0.908	rs79083128	chr19:16556222	G/C	cg05286348	chr19:16641544	CHERP	-0.68	-8.9	-0.33	5.75e-18	White blood cell count;
BRCA	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg25427524	chr10:38739819	LOC399744	-0.52	-9.22	-0.34	4.17e-19	Obesity (extreme);
BRCA	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07636037	chr3:49044803	WDR6	0.73	15.74	0.53	2.09e-47	Menarche (age at onset);
BRCA	trans	rs7395662	0.782	rs66468703	chr11:48738773	T/C	cg00717180	chr2:96193071	NA	-0.32	-8.77	-0.33	1.61e-17	HDL cholesterol;
BRCA	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg20701182	chr2:24300061	SF3B14	0.56	8.63	0.32	5.01e-17	Lymphocyte counts;
BRCA	cis	rs7903847	0.620	rs2297988	chr10:99118382	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.36	-0.31	3.83e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg19678392	chr7:94953810	PON1	-0.4	-8.68	-0.32	3.22e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25427524	chr10:38739819	LOC399744	-0.55	-12.51	-0.44	2.71e-32	Extrinsic epigenetic age acceleration;
BRCA	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	10.7	0.39	1.06e-24	Rheumatoid arthritis;
BRCA	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.8	-0.36	3.32e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs965469	0.779	rs6051780	chr20:3334167	A/C	cg25506879	chr20:3388711	C20orf194	-0.44	-8.81	-0.33	1.21e-17	IFN-related cytopenia;
BRCA	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg13010199	chr12:38710504	ALG10B	0.5	10.11	0.37	2.19e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg12365402	chr11:9010492	NRIP3	-0.44	-10.44	-0.38	1.15e-23	Hemoglobin concentration;
BRCA	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.4	-8.0	-0.3	6e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg02733842	chr7:1102375	C7orf50	-0.73	-12.55	-0.44	1.89e-32	Bronchopulmonary dysplasia;
BRCA	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg14675211	chr2:100938903	LONRF2	0.51	11.82	0.42	2.75e-29	Intelligence (multi-trait analysis);
BRCA	trans	rs35110281	0.600	rs914198	chr21:45117456	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	8.83	0.33	9.62e-18	Mean corpuscular volume;
BRCA	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg21395723	chr22:39101663	GTPBP1	0.38	8.32	0.31	5.17e-16	Menopause (age at onset);
BRCA	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	13.36	0.47	4.56e-36	Height;
BRCA	cis	rs7903847	0.642	rs1048442	chr10:99160152	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.83	-0.33	9.93e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6956675	0.830	rs4585626	chr7:62671592	C/G	cg27518014	chr7:62859535	LOC100287834	-0.44	-7.94	-0.3	9.23e-15	Obesity-related traits;
BRCA	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.46	-0.77	1.51e-126	Schizophrenia;
BRCA	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00166722	chr3:10149974	C3orf24	0.55	10.74	0.39	7.48e-25	Alzheimer's disease;
BRCA	cis	rs62458065	0.513	rs9655340	chr7:32535920	A/G	cg20159608	chr7:32802032	NA	0.5	9.59	0.35	2e-20	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-7.92	-0.3	1.05e-14	Total body bone mineral density;
BRCA	cis	rs7903847	0.642	rs6584128	chr10:99171926	G/T	cg08345082	chr10:99160200	RRP12	0.29	8.33	0.31	5.05e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg17691542	chr6:26056736	HIST1H1C	0.43	9.27	0.34	2.89e-19	Iron status biomarkers;
BRCA	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg05347473	chr6:146136440	FBXO30	0.39	8.0	0.3	5.83e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg24069376	chr3:38537580	EXOG	0.4	11.52	0.41	4.93e-28	Electrocardiographic conduction measures;
BRCA	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg11822812	chr5:140052017	DND1	-0.29	-7.9	-0.3	1.18e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg04989706	chr14:50066350	PPIL5	-0.49	-9.97	-0.37	7.31e-22	Carotid intima media thickness;
BRCA	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg11843238	chr5:131593191	PDLIM4	0.35	7.94	0.3	9.21e-15	Breast cancer;
BRCA	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg25358565	chr5:93447407	FAM172A	1.18	18.56	0.59	7.72e-62	Diabetic retinopathy;
BRCA	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg06191203	chr2:152266755	RIF1	-0.28	-8.14	-0.31	2.12e-15	Lung cancer;
BRCA	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg08755490	chr11:65554678	OVOL1	0.55	11.5	0.41	5.88e-28	Acne (severe);
BRCA	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg22906224	chr7:99728672	NA	-0.49	-9.38	-0.35	1.1e-19	Coronary artery disease;
BRCA	trans	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg19894588	chr14:64061835	NA	0.37	8.95	0.33	3.8e-18	Glioblastoma;Glioma;
BRCA	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg23711669	chr6:146136114	FBXO30	-0.75	-17.24	-0.56	5.62e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg03342759	chr3:160939853	NMD3	-0.8	-18.89	-0.6	1.45e-63	Parkinson's disease;
BRCA	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11890956	chr21:40555474	PSMG1	1.09	32.69	0.79	1.56e-138	Cognitive function;
BRCA	cis	rs34779708	0.931	rs12268745	chr10:35305989	C/G	cg03585969	chr10:35415529	CREM	0.49	10.34	0.38	2.81e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7246657	0.663	rs4803276	chr19:38072330	C/A	cg14683738	chr19:37701593	ZNF585B	0.46	7.81	0.3	2.31e-14	Coronary artery calcification;
BRCA	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	9.44	0.35	6.78e-20	Eosinophil percentage of white cells;
BRCA	cis	rs9427116	0.502	rs6699825	chr1:154582970	A/G	cg17218026	chr1:154582156	ADAR	0.28	8.68	0.32	3.27e-17	Blood protein levels;
BRCA	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.56	0.35	2.42e-20	Morning vs. evening chronotype;
BRCA	cis	rs1113500	0.932	rs1343205	chr1:108597873	C/G	cg06207961	chr1:108661230	NA	0.43	10.49	0.38	7.19e-24	Growth-regulated protein alpha levels;
BRCA	cis	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg04990556	chr1:26633338	UBXN11	0.54	9.04	0.34	1.84e-18	Obesity-related traits;
BRCA	cis	rs6120849	0.754	rs6120828	chr20:33674460	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	10.0	0.37	5.54e-22	Protein C levels;
BRCA	cis	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.29	-0.31	6.8e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg19920283	chr7:105172520	RINT1	0.58	9.39	0.35	1e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg23958373	chr8:599963	NA	-0.71	-8.22	-0.31	1.1e-15	IgG glycosylation;
BRCA	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg06784218	chr1:46089804	CCDC17	0.46	10.93	0.4	1.34e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg25214090	chr10:38739885	LOC399744	0.52	11.78	0.42	4.01e-29	Corneal astigmatism;
BRCA	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg14847009	chr1:175162515	KIAA0040	0.25	9.44	0.35	7.06e-20	Alcohol dependence;
BRCA	cis	rs16867321	0.950	rs1919148	chr2:181501758	G/A	cg23363182	chr2:181467187	NA	-0.44	-8.37	-0.31	3.75e-16	Obesity;
BRCA	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg03146154	chr1:46216737	IPP	0.52	11.59	0.42	2.58e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2816062	1.000	rs2816062	chr1:18903902	G/A	cg18795169	chr1:18902165	NA	-0.88	-23.19	-0.68	9.21e-87	Urate levels in lean individuals;
BRCA	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg08999081	chr20:33150536	PIGU	0.39	10.76	0.39	6.12e-25	Glomerular filtration rate (creatinine);
BRCA	cis	rs733175	0.857	rs3796835	chr4:10011530	C/T	cg00071950	chr4:10020882	SLC2A9	0.43	8.08	0.3	3.23e-15	Psychosis and Alzheimer's disease;
BRCA	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.39	8.56	0.32	8.4e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg11645453	chr3:52864694	ITIH4	-0.44	-10.54	-0.38	4.48e-24	Schizophrenia;
BRCA	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	19.52	0.61	6.96e-67	Platelet count;
BRCA	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg12826209	chr6:26865740	GUSBL1	0.63	8.27	0.31	7.87e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-8.36	-0.31	3.96e-16	Monocyte percentage of white cells;
BRCA	cis	rs7809950	1.000	rs2395883	chr7:107089670	T/C	cg23024343	chr7:107201750	COG5	-0.41	-9.45	-0.35	6.3e-20	Coronary artery disease;
BRCA	trans	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.92	0.3	1.05e-14	Endometrial cancer;
BRCA	cis	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.66	0.32	3.82e-17	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.33	-7.93	-0.3	1.01e-14	Personality dimensions;
BRCA	cis	rs57590327	0.503	rs13075250	chr3:81907952	T/C	cg07356753	chr3:81810745	GBE1	-0.45	-10.33	-0.38	3.06e-23	Extraversion;
BRCA	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-11.12	-0.4	2.22e-26	Glomerular filtration rate (creatinine);
BRCA	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg05347473	chr6:146136440	FBXO30	0.42	8.12	0.31	2.45e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.15	-0.31	1.93e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.49	-0.32	1.4e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11644478	chr21:40555479	PSMG1	-0.44	-8.71	-0.33	2.52e-17	Menarche (age at onset);
BRCA	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg21856205	chr7:94953877	PON1	-0.38	-8.3	-0.31	6.42e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	9.21	0.34	4.81e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	17.25	0.56	5.25e-55	Hip circumference adjusted for BMI;
BRCA	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.93	-32.47	-0.79	2.36e-137	Schizophrenia;
BRCA	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.56	-0.44	1.79e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs72781680	0.799	rs2551332	chr2:23988950	T/C	cg08917208	chr2:24149416	ATAD2B	0.65	10.43	0.38	1.31e-23	Lymphocyte counts;
BRCA	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg13114125	chr14:105738426	BRF1	-0.48	-11.1	-0.4	2.66e-26	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	14.45	0.5	3.56e-41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg05082376	chr22:42548792	NA	-0.31	-7.86	-0.3	1.67e-14	Cognitive function;
BRCA	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	19.89	0.62	7.35e-69	Platelet count;
BRCA	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg06212747	chr3:49208901	KLHDC8B	0.5	7.92	0.3	1.08e-14	Menarche (age at onset);
BRCA	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg27165867	chr14:105738592	BRF1	-0.36	-8.4	-0.32	2.83e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg21535247	chr6:8435926	SLC35B3	0.41	9.36	0.35	1.35e-19	Motion sickness;
BRCA	cis	rs7587476	0.906	rs17487792	chr2:215643500	A/G	cg04004882	chr2:215674386	BARD1	-0.59	-10.25	-0.38	6.46e-23	Neuroblastoma;
BRCA	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	12.88	0.45	6.41e-34	Bipolar disorder;
BRCA	cis	rs9837602	1.000	rs7620228	chr3:99790332	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.14	0.4	1.91e-26	Breast cancer;
BRCA	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.16	0.31	1.78e-15	Breast cancer;
BRCA	trans	rs12517041	1.000	rs35670742	chr5:23281811	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.9	-0.3	1.19e-14	Calcium levels;
BRCA	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11890956	chr21:40555474	PSMG1	-0.82	-19.65	-0.61	1.39e-67	Cognitive function;
BRCA	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs1568889	0.838	rs7933991	chr11:28059761	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.38	0.63	1.74e-71	Bipolar disorder;
BRCA	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06108461	chr20:60628389	TAF4	-0.73	-15.3	-0.52	3e-45	Body mass index;
BRCA	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	11.29	0.41	4.64e-27	Platelet count;
BRCA	cis	rs6785206	0.892	rs6439143	chr3:128425132	C/T	cg16766828	chr3:128327626	NA	-0.65	-9.94	-0.37	9.29e-22	Lymphocyte percentage of white cells;
BRCA	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-19.61	-0.61	2.28e-67	Electrocardiographic conduction measures;
BRCA	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg12564285	chr5:131593104	PDLIM4	0.36	8.06	0.3	3.85e-15	Breast cancer;
BRCA	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.64	-14.06	-0.49	2.66e-39	Lung cancer;
BRCA	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.03	-0.34	1.98e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg02820040	chr2:241836501	C2orf54	-0.53	-10.26	-0.38	5.85e-23	Urinary metabolites;
BRCA	cis	rs10089	0.953	rs6887674	chr5:127531183	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	13.87	0.48	1.97e-38	Ileal carcinoids;
BRCA	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.02	0.48	4.03e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.7	16.38	0.54	1.26e-50	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg20587970	chr11:113659929	NA	-1.2	-22.15	-0.66	4.31e-81	Hip circumference adjusted for BMI;
BRCA	cis	rs7147624	1.000	rs7160390	chr14:66052460	G/A	cg03016385	chr14:66212404	NA	-0.58	-8.82	-0.33	1.1e-17	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg08999081	chr20:33150536	PIGU	0.37	9.37	0.35	1.26e-19	Coronary artery disease;
BRCA	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg26031613	chr14:104095156	KLC1	-0.43	-8.65	-0.32	4.05e-17	Schizophrenia;
BRCA	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg06937882	chr20:24974362	C20orf3	-0.47	-8.97	-0.33	3.24e-18	Blood protein levels;
BRCA	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg24558204	chr6:135376177	HBS1L	0.45	12.29	0.44	2.69e-31	Red blood cell count;
BRCA	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg18132916	chr6:79620363	NA	-0.44	-9.78	-0.36	3.72e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg24296786	chr1:45957014	TESK2	0.43	8.89	0.33	6.39e-18	Homocysteine levels;
BRCA	trans	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg13565492	chr6:43139072	SRF	-0.79	-10.84	-0.39	2.99e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs72928364	0.858	rs66598219	chr3:100779435	T/C	cg10123952	chr3:100791384	NA	0.58	8.47	0.32	1.63e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg06521331	chr12:34319734	NA	-0.58	-11.59	-0.42	2.46e-28	Morning vs. evening chronotype;
BRCA	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-13.71	-0.48	1.06e-37	Schizophrenia;
BRCA	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	11.75	0.42	5.51e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.24e-23	Motion sickness;
BRCA	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg03929089	chr4:120376271	NA	-0.65	-12.84	-0.45	9.51e-34	Coronary artery disease;
BRCA	cis	rs6586163	0.509	rs2031610	chr10:90754487	T/C	cg03111039	chr10:90751583	FAS;ACTA2	0.58	13.45	0.47	1.64e-36	Chronic lymphocytic leukemia;
BRCA	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg03060546	chr3:49711283	APEH	-0.58	-11.84	-0.42	2.29e-29	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs1555322	0.530	rs2250205	chr20:33867924	C/T	cg03689076	chr20:33865952	NA	0.45	8.26	0.31	8.62e-16	Attention deficit hyperactivity disorder;
BRCA	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.58	-12.08	-0.43	2.18e-30	Lymphocyte counts;
BRCA	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg20283391	chr11:68216788	NA	-0.47	-9.21	-0.34	4.55e-19	Total body bone mineral density;
BRCA	cis	rs34779708	0.931	rs34304999	chr10:35365705	C/T	cg03585969	chr10:35415529	CREM	0.56	11.53	0.42	4.31e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg00717180	chr2:96193071	NA	-0.35	-9.85	-0.36	2.05e-21	Coronary artery disease;
BRCA	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg09654669	chr8:57350985	NA	-0.4	-8.62	-0.32	5.06e-17	Obesity-related traits;
BRCA	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg05985134	chr18:33552581	C18orf21	0.64	11.57	0.42	2.93e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg24562669	chr7:97807699	LMTK2	0.45	12.04	0.43	3.16e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.56	11.83	0.42	2.43e-29	Monocyte percentage of white cells;
BRCA	cis	rs7172677	0.737	rs12910348	chr15:75437642	A/G	cg14664628	chr15:75095509	CSK	-0.39	-8.08	-0.3	3.19e-15	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg18479299	chr3:125709523	NA	-0.5	-8.32	-0.31	5.17e-16	Blood pressure (smoking interaction);
BRCA	cis	rs12493885	0.872	rs9840371	chr3:153796829	C/T	cg17054900	chr3:154042577	DHX36	0.53	9.19	0.34	5.62e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg18196295	chr10:418757	DIP2C	-0.46	-9.44	-0.35	6.74e-20	Psychosis in Alzheimer's disease;
BRCA	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg02030672	chr11:45687055	CHST1	0.37	8.2	0.31	1.31e-15	Obesity-related traits;
BRCA	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg04469686	chr1:162760199	HSD17B7	-0.42	-8.01	-0.3	5.33e-15	Breast cancer;
BRCA	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg07080220	chr10:102295463	HIF1AN	0.44	9.78	0.36	3.69e-21	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg06521331	chr12:34319734	NA	-0.51	-9.28	-0.34	2.52e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.83	0.51	5.42e-43	Colorectal cancer;
BRCA	cis	rs6882046	0.513	rs616391	chr5:88038845	C/T	cg22951263	chr5:87985283	NA	-0.38	-10.6	-0.39	2.82e-24	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs394563	0.601	rs439495	chr6:149793224	A/G	cg11245181	chr6:149772854	ZC3H12D	0.27	7.95	0.3	8.76e-15	Dupuytren's disease;
BRCA	cis	rs36051895	0.659	rs57204002	chr9:5062610	T/C	cg02405213	chr9:5042618	JAK2	-0.46	-8.62	-0.32	5.13e-17	Pediatric autoimmune diseases;
BRCA	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg21252483	chr19:49399788	TULP2	-0.42	-9.55	-0.35	2.64e-20	Red cell distribution width;
BRCA	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg11584989	chr19:19387371	SF4	0.47	10.53	0.38	5.01e-24	Bipolar disorder;
BRCA	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg24130564	chr14:104152367	KLC1	0.36	8.15	0.31	1.91e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg04833646	chr19:10679720	CDKN2D	-0.99	-22.76	-0.67	2.08e-84	Red cell distribution width;
BRCA	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg20887711	chr4:1340912	KIAA1530	0.72	15.98	0.53	1.27e-48	Longevity;
BRCA	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg24642844	chr7:1081250	C7orf50	-0.83	-15.69	-0.53	3.75e-47	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg21775007	chr8:11205619	TDH	0.43	8.94	0.33	4.05e-18	Retinal vascular caliber;
BRCA	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg22920501	chr2:26401640	FAM59B	0.95	16.82	0.55	7.55e-53	Gut microbiome composition (summer);
BRCA	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	9.1e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg13047869	chr3:10149882	C3orf24	-0.59	-12.45	-0.44	5.44e-32	Alzheimer's disease;
BRCA	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg14196790	chr5:131705035	SLC22A5	0.33	8.63	0.32	4.73e-17	Lung function (FEV1/FVC);
BRCA	cis	rs9831754	0.906	rs2102601	chr3:78410536	G/A	cg06138941	chr3:78371609	NA	-0.74	-16.24	-0.54	6.3e-50	Calcium levels;
BRCA	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg03709012	chr19:19516395	GATAD2A	-0.74	-16.54	-0.55	2.13e-51	Tonsillectomy;
BRCA	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11764359	chr7:65958608	NA	-0.74	-16.3	-0.54	3.5e-50	Aortic root size;
BRCA	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg02733842	chr7:1102375	C7orf50	-0.72	-12.42	-0.44	7.02e-32	Bronchopulmonary dysplasia;
BRCA	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02475777	chr4:1388615	CRIPAK	0.67	13.04	0.46	1.26e-34	Longevity;
BRCA	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg07636037	chr3:49044803	WDR6	-0.5	-8.36	-0.31	3.89e-16	Menarche (age at onset);
BRCA	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg11752832	chr7:134001865	SLC35B4	0.52	13.53	0.47	7.65e-37	Mean platelet volume;
BRCA	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg05340658	chr4:99064831	C4orf37	0.63	15.45	0.52	5.32e-46	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7520050	0.931	rs11576305	chr1:46460046	C/T	cg24296786	chr1:45957014	TESK2	0.44	9.81	0.36	2.95e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg00012203	chr2:219082015	ARPC2	-0.6	-12.59	-0.45	1.26e-32	Colorectal cancer;
BRCA	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19748678	chr4:122722346	EXOSC9	0.53	11.72	0.42	7.14e-29	Type 2 diabetes;
BRCA	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg06623918	chr6:96969491	KIAA0776	0.89	25.79	0.71	4.53e-101	Headache;
BRCA	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg06784218	chr1:46089804	CCDC17	0.45	10.84	0.39	2.92e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg27170947	chr2:26402098	FAM59B	0.92	16.52	0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs9467773	0.626	rs6935803	chr6:26350495	A/G	cg09904177	chr6:26538194	HMGN4	-0.31	-8.36	-0.31	3.94e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs367615	0.506	rs2963013	chr5:108775811	C/T	cg17395555	chr5:108820864	NA	-0.41	-12.71	-0.45	3.68e-33	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.87e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9487051	0.646	rs9487049	chr6:109615905	A/T	cg01475377	chr6:109611718	NA	-0.4	-8.7	-0.33	2.72e-17	Reticulocyte fraction of red cells;
BRCA	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg08888203	chr3:10149979	C3orf24	0.56	11.55	0.42	3.8e-28	Alzheimer's disease;
BRCA	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg14675211	chr2:100938903	LONRF2	0.44	9.73	0.36	5.87e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7301826	0.610	rs7957899	chr12:131279076	T/C	cg11011512	chr12:131303247	STX2	0.5	13.34	0.47	5.45e-36	Plasma plasminogen activator levels;
BRCA	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg13628971	chr7:2884303	GNA12	0.4	8.84	0.33	9.18e-18	Height;
BRCA	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.53	0.35	3.12e-20	Morning vs. evening chronotype;
BRCA	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	19.67	0.61	1.03e-67	Platelet count;
BRCA	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg18252515	chr7:66147081	NA	-0.84	-12.26	-0.44	3.6e-31	Diabetic kidney disease;
BRCA	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg08470875	chr2:26401718	FAM59B	-0.71	-11.54	-0.42	4.1e-28	Gut microbiome composition (summer);
BRCA	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg16482183	chr6:26056742	HIST1H1C	0.41	8.8	0.33	1.32e-17	Iron status biomarkers;
BRCA	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg07080220	chr10:102295463	HIF1AN	0.65	15.26	0.52	4.46e-45	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg12935359	chr14:103987150	CKB	-0.59	-14.08	-0.49	2.04e-39	Body mass index;
BRCA	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg20701182	chr2:24300061	SF3B14	0.68	12.57	0.45	1.53e-32	Lymphocyte counts;
BRCA	trans	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	8.92e-15	Corneal astigmatism;
BRCA	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg22535103	chr8:58192502	C8orf71	-0.6	-13.19	-0.46	2.71e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs939658	0.805	rs2177056	chr15:79441489	T/C	cg17916960	chr15:79447300	NA	-0.43	-10.98	-0.4	8.11e-26	Refractive error;
BRCA	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg08470875	chr2:26401718	FAM59B	0.76	11.94	0.43	8.04e-30	Gut microbiome composition (summer);
BRCA	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg10932868	chr11:921992	NA	0.47	12.09	0.43	1.93e-30	Alzheimer's disease (late onset);
BRCA	cis	rs34779708	0.931	rs4934702	chr10:35323074	T/C	cg03585969	chr10:35415529	CREM	0.49	10.22	0.37	8.28e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg07080220	chr10:102295463	HIF1AN	0.61	14.33	0.49	1.36e-40	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.85	-0.42	2.09e-29	Gut microbiome composition (summer);
BRCA	cis	rs1113500	0.862	rs11185264	chr1:108640506	T/C	cg06207961	chr1:108661230	NA	0.45	10.77	0.39	5.48e-25	Growth-regulated protein alpha levels;
BRCA	cis	rs9394841	0.667	rs9394831	chr6:41753084	C/T	cg08135965	chr6:41755394	TOMM6	0.5	8.13	0.31	2.18e-15	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	trans	rs7980799	0.935	rs7312012	chr12:33517984	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-8.5	-0.32	1.35e-16	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg25173405	chr17:45401733	C17orf57	0.49	9.93	0.37	1e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18876405	chr7:65276391	NA	-0.51	-11.54	-0.42	3.95e-28	Aortic root size;
BRCA	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-11.99	-0.43	4.87e-30	Morning vs. evening chronotype;
BRCA	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg03462622	chr3:195777018	TFRC	-0.38	-8.63	-0.32	4.83e-17	Mean corpuscular volume;
BRCA	cis	rs586533	0.837	rs630095	chr11:99503356	T/C	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.31	2.76e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3824867	0.920	rs7130693	chr11:47452321	T/C	cg20307385	chr11:47447363	PSMC3	-0.51	-11.48	-0.41	6.99e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs2415984	0.622	rs7156444	chr14:46933296	C/G	cg14871534	chr14:47121158	RPL10L	-0.37	-8.82	-0.33	1.12e-17	Number of children ever born;
BRCA	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.45	-10.9	-0.4	1.77e-25	IgG glycosylation;
BRCA	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11890956	chr21:40555474	PSMG1	1.06	30.4	0.77	3.01e-126	Cognitive function;
BRCA	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.74	-0.33	2e-17	Neuroticism;
BRCA	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg20503657	chr10:835505	NA	1.05	18.77	0.6	5.82e-63	Eosinophil percentage of granulocytes;
BRCA	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.92	-18.06	-0.58	3.42e-59	Alzheimer's disease;
BRCA	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg13319975	chr6:146136371	FBXO30	-0.4	-9.11	-0.34	1.06e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg08999081	chr20:33150536	PIGU	0.43	11.53	0.41	4.5e-28	Coronary artery disease;
BRCA	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg13319975	chr6:146136371	FBXO30	-0.59	-13.1	-0.46	6.95e-35	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23583168	chr7:148888333	NA	-0.96	-25.96	-0.72	5.37e-102	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg15704280	chr7:45808275	SEPT13	0.52	7.83	0.3	1.97e-14	Intraocular pressure;
BRCA	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg17063962	chr7:91808500	NA	0.51	11.61	0.42	2.16e-28	Breast cancer;
BRCA	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg14004847	chr7:1930337	MAD1L1	-0.41	-7.97	-0.3	7.42e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg06521331	chr12:34319734	NA	-0.65	-12.01	-0.43	3.99e-30	Morning vs. evening chronotype;
BRCA	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg16339924	chr4:17578868	LAP3	0.6	14.63	0.5	4.92e-42	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg24069376	chr3:38537580	EXOG	0.32	8.83	0.33	1e-17	Electrocardiographic conduction measures;
BRCA	trans	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg25214090	chr10:38739885	LOC399744	0.44	9.47	0.35	5.39e-20	Corneal astigmatism;
BRCA	cis	rs6430585	0.702	rs73958637	chr2:136546927	C/T	cg07169764	chr2:136633963	MCM6	1.28	30.68	0.77	8.99e-128	Corneal structure;
BRCA	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.33	0.68	1.52e-87	Chronic sinus infection;
BRCA	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	18.85	0.6	2.47e-63	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg08470875	chr2:26401718	FAM59B	-0.58	-9.84	-0.36	2.37e-21	Gut microbiome composition (summer);
BRCA	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg20991723	chr1:152506922	NA	0.39	8.93	0.33	4.56e-18	Hair morphology;
BRCA	cis	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg19338460	chr6:170058176	WDR27	-0.48	-7.87	-0.3	1.55e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs6032067	0.673	rs36019441	chr20:43892401	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	0.34	8.17	0.31	1.6e-15	Blood protein levels;
BRCA	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg18904891	chr8:8559673	CLDN23	0.58	11.59	0.42	2.49e-28	Obesity-related traits;
BRCA	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg26516362	chr5:178986906	RUFY1	0.39	10.11	0.37	2.08e-22	Lung cancer;
BRCA	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.53	-11.93	-0.43	9.31e-30	Personality dimensions;
BRCA	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.31	-0.38	3.59e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	19.77	0.62	3.21e-68	Platelet count;
BRCA	cis	rs6429082	0.791	rs291394	chr1:235651682	A/G	cg26050004	chr1:235667680	B3GALNT2	0.57	13.54	0.47	6.94e-37	Adiposity;
BRCA	cis	rs7760949	0.889	rs9475807	chr6:13934597	T/C	cg27413430	chr6:13925136	RNF182	0.46	9.24	0.34	3.66e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg21798802	chr22:38057573	PDXP	0.5	13.34	0.47	5.58e-36	Fat distribution (HIV);
BRCA	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg27446573	chr6:127587934	RNF146	0.67	15.25	0.52	5.03e-45	Breast cancer;
BRCA	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg17063962	chr7:91808500	NA	0.53	12.45	0.44	5.16e-32	Breast cancer;
BRCA	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg16339924	chr4:17578868	LAP3	0.76	18.27	0.59	2.49e-60	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	19.36	0.61	4.72e-66	Platelet count;
BRCA	cis	rs7020830	0.928	rs11544336	chr9:37089150	A/G	cg14294708	chr9:37120828	ZCCHC7	1.16	40.51	0.85	1.2e-178	Schizophrenia;
BRCA	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg20701182	chr2:24300061	SF3B14	0.71	12.98	0.46	2.33e-34	Lymphocyte counts;
BRCA	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg14631576	chr9:95140430	CENPP	-0.37	-9.04	-0.34	1.92e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg22508957	chr16:3507546	NAT15	-0.52	-7.85	-0.3	1.82e-14	Tuberculosis;
BRCA	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg09359103	chr1:154839909	KCNN3	-0.56	-14.55	-0.5	1.26e-41	Prostate cancer;
BRCA	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	19.99	0.62	2.04e-69	Platelet count;
BRCA	cis	rs11955398	0.716	rs2061250	chr5:59917678	C/A	cg02684056	chr5:59996105	DEPDC1B	0.39	9.35	0.35	1.49e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs68170813	0.605	rs10464620	chr7:107135653	A/G	cg02696742	chr7:106810147	HBP1	0.5	7.87	0.3	1.48e-14	Coronary artery disease;
BRCA	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg01292856	chr11:65242576	NA	-0.36	-9.25	-0.34	3.24e-19	Bone mineral density;
BRCA	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg26248373	chr2:1572462	NA	-0.67	-15.83	-0.53	7.21e-48	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs3125734	0.633	rs10821968	chr10:63993905	C/T	cg09941381	chr10:64027924	RTKN2	0.28	8.21	0.31	1.25e-15	Rheumatoid arthritis;
BRCA	trans	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg25214090	chr10:38739885	LOC399744	0.52	11.72	0.42	7.25e-29	Corneal astigmatism;
BRCA	cis	rs921968	0.565	rs6436073	chr2:219618237	A/C	cg02176678	chr2:219576539	TTLL4	-0.42	-11.25	-0.41	6.19e-27	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00149659	chr3:10157352	C3orf10	0.84	14.7	0.5	2.39e-42	Alzheimer's disease;
BRCA	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg12744634	chr1:26560303	CCDC21	0.33	8.92	0.33	4.74e-18	Obesity-related traits;
BRCA	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.58	-0.45	1.41e-32	Type 2 diabetes;
BRCA	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg16576597	chr16:28551801	NUPR1	0.35	9.46	0.35	5.9e-20	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	trans	rs877282	0.755	rs1769242	chr10:787896	T/C	cg22713356	chr15:30763199	NA	1.1	21.99	0.66	3.3e-80	Uric acid levels;
BRCA	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg26408565	chr15:76604113	ETFA	-0.48	-10.43	-0.38	1.26e-23	Blood metabolite levels;
BRCA	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	12.43	0.44	6.38e-32	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg22875332	chr1:76189707	ACADM	0.7	15.04	0.51	5.42e-44	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs13046373	0.535	rs2832966	chr21:32017177	A/G	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.28	0.34	2.66e-19	HDL cholesterol;
BRCA	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg21535247	chr6:8435926	SLC35B3	0.42	9.48	0.35	4.81e-20	Motion sickness;
BRCA	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.55	-0.32	9.19e-17	Monocyte percentage of white cells;
BRCA	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10189230	0.967	rs7573758	chr2:222357326	G/T	cg14652038	chr2:222343519	EPHA4	0.47	13.22	0.46	1.94e-35	Urate levels in lean individuals;
BRCA	cis	rs250677	0.522	rs10050928	chr5:148353463	C/A	cg18129178	chr5:148520854	ABLIM3	0.54	10.26	0.38	5.53e-23	Breast cancer;
BRCA	cis	rs6745190	0.557	rs13011738	chr2:181985742	A/G	cg00481216	chr2:181971175	NA	0.46	8.72	0.33	2.36e-17	White blood cell count;
BRCA	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg20701182	chr2:24300061	SF3B14	0.59	9.29	0.35	2.35e-19	Lymphocyte counts;
BRCA	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.65	-9.78	-0.36	3.92e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs858239	0.600	rs7799422	chr7:23128413	G/A	cg23682824	chr7:23144976	KLHL7	0.45	11.82	0.42	2.6e-29	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs858239	0.669	rs6461688	chr7:23116615	G/A	cg23682824	chr7:23144976	KLHL7	0.34	8.78	0.33	1.49e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs3771570	1.000	rs55645375	chr2:242269024	A/G	cg21155796	chr2:242212141	HDLBP	0.6	9.3	0.35	2.25e-19	Prostate cancer;
BRCA	cis	rs71227278	1	rs71227278	chr12:54358047	C/CTTAA	cg26079753	chr12:54355528	NA	-0.43	-11.1	-0.4	2.68e-26	Urinary tract infection frequency;
BRCA	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg15605315	chr1:45957053	TESK2	-0.41	-8.32	-0.31	5.18e-16	Red blood cell count;Reticulocyte count;
BRCA	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.18	-0.56	1.12e-54	Intelligence (multi-trait analysis);
BRCA	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg23422044	chr7:1970798	MAD1L1	-0.44	-9.39	-0.35	1.04e-19	Neuroticism;
BRCA	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg08508325	chr11:3079039	CARS	0.44	16.38	0.54	1.36e-50	Longevity;
BRCA	cis	rs6772849	0.896	rs61112519	chr3:128338176	T/A	cg16766828	chr3:128327626	NA	-0.39	-8.65	-0.32	4.17e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs3820928	1.000	rs3820927	chr2:227779191	C/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.49	-0.32	1.39e-16	Pulmonary function;
BRCA	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg04811098	chr7:155088454	INSIG1	0.39	10.26	0.38	5.76e-23	Stem cell growth factor beta levels;
BRCA	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg06784218	chr1:46089804	CCDC17	-0.45	-10.87	-0.4	2.17e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11958404	0.789	rs72818145	chr5:157476552	G/C	cg05962755	chr5:157440814	NA	0.54	9.55	0.35	2.72e-20	IgG glycosylation;
BRCA	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg17063962	chr7:91808500	NA	0.55	13.04	0.46	1.21e-34	Breast cancer;
BRCA	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg17971929	chr21:40555470	PSMG1	0.77	18.02	0.58	4.98e-59	Cognitive function;
BRCA	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg19508488	chr2:152266495	RIF1	0.47	9.13	0.34	9.09e-19	Squamous cell lung carcinoma;
BRCA	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg03585969	chr10:35415529	CREM	0.56	11.54	0.42	3.91e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs35740288	0.539	rs34362339	chr15:86337628	C/T	cg20737812	chr15:86336631	KLHL25	-0.4	-9.78	-0.36	3.73e-21	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-23.71	-0.68	1.3e-89	Height;
BRCA	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg16606324	chr3:10149918	C3orf24	-0.55	-10.84	-0.39	2.92e-25	Alzheimer's disease;
BRCA	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.62	10.03	0.37	4.52e-22	Renal function-related traits (BUN);
BRCA	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg21775007	chr8:11205619	TDH	0.65	15.72	0.53	2.43e-47	Retinal vascular caliber;
BRCA	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.18	0.34	6e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg26384229	chr12:38710491	ALG10B	0.76	16.98	0.56	1.17e-53	Bladder cancer;
BRCA	cis	rs912057	0.601	rs1294405	chr6:6737591	A/G	cg06612196	chr6:6737390	NA	0.55	13.23	0.46	1.65e-35	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.02	-0.34	2.13e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9811920	0.928	rs2130369	chr3:99873317	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	11.2	0.41	1.04e-26	Axial length;
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.63	-15.39	-0.52	1.1e-45	Longevity;Endometriosis;
BRCA	cis	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg21775007	chr8:11205619	TDH	0.72	16.75	0.55	1.76e-52	Retinal vascular caliber;
BRCA	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg22800045	chr5:56110881	MAP3K1	0.63	12.36	0.44	1.26e-31	Initial pursuit acceleration;
BRCA	trans	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.26	0.31	8.38e-16	Corneal astigmatism;
BRCA	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg20503657	chr10:835505	NA	-1.03	-17.82	-0.58	5.89e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg12564285	chr5:131593104	PDLIM4	0.43	11.04	0.4	4.77e-26	Acylcarnitine levels;
BRCA	cis	rs11231017	0.507	rs2178258	chr11:62069893	C/T	cg23876832	chr11:62092739	NA	0.32	8.18	0.31	1.59e-15	HIV-1 viral setpoint;
BRCA	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-11.73	-0.42	6.41e-29	Mood instability;
BRCA	trans	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-10.06	-0.37	3.25e-22	Monocyte count;
BRCA	trans	rs9409565	0.826	rs4744338	chr9:97158965	C/T	cg05679027	chr9:99775184	HIATL2	0.42	9.43	0.35	7.65e-20	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg00530320	chr1:46809349	NSUN4	0.48	9.74	0.36	5.54e-21	Menopause (age at onset);
BRCA	trans	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg07211511	chr3:129823064	LOC729375	-0.62	-11.05	-0.4	4.24e-26	Blood pressure (smoking interaction);
BRCA	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	10.34	0.38	2.87e-23	Height;
BRCA	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg13010199	chr12:38710504	ALG10B	0.53	11.07	0.4	3.38e-26	Heart rate;
BRCA	cis	rs332507	0.830	rs3821532	chr3:124402618	G/T	cg05980111	chr3:124395277	KALRN	0.38	8.75	0.33	1.89e-17	Plateletcrit;
BRCA	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg20848291	chr7:100343083	ZAN	-0.58	-10.69	-0.39	1.19e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg14926445	chr8:58193284	C8orf71	-0.44	-8.47	-0.32	1.74e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg22875332	chr1:76189707	ACADM	0.66	15.71	0.53	3e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs868036	1.000	rs4776377	chr15:68103387	T/C	cg05925327	chr15:68127851	NA	-0.31	-7.9	-0.3	1.23e-14	Restless legs syndrome;
BRCA	cis	rs3125734	0.719	rs10821972	chr10:64043735	G/A	cg19640130	chr10:64028056	RTKN2	-0.3	-8.2	-0.31	1.34e-15	Rheumatoid arthritis;
BRCA	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg18446336	chr7:2847575	GNA12	-0.35	-8.16	-0.31	1.73e-15	Height;
BRCA	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg26597838	chr10:835615	NA	1.02	15.64	0.53	6.11e-47	Eosinophil percentage of granulocytes;
BRCA	cis	rs34779708	0.733	rs59287215	chr10:35543994	C/T	cg03585969	chr10:35415529	CREM	0.45	9.11	0.34	1.01e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs250677	1.000	rs36079	chr5:148430504	G/A	cg18129178	chr5:148520854	ABLIM3	-0.56	-11.25	-0.41	6.28e-27	Breast cancer;
BRCA	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg26031613	chr14:104095156	KLC1	-0.43	-8.42	-0.32	2.55e-16	Schizophrenia;
BRCA	cis	rs6088813	1.000	rs6142358	chr20:33960308	A/G	cg14752227	chr20:34000481	UQCC	0.41	8.82	0.33	1.05e-17	Height;
BRCA	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg06784218	chr1:46089804	CCDC17	0.52	12.53	0.44	2.36e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg00953403	chr17:74099816	EXOC7	-0.45	-8.22	-0.31	1.14e-15	Psychosis in Alzheimer's disease;
BRCA	cis	rs2964802	0.505	rs4314375	chr5:10803435	C/T	cg14521931	chr5:10832172	NA	0.58	12.97	0.46	2.6e-34	Major depressive disorder;Recurrent major depressive disorder;
BRCA	cis	rs4363385	0.720	rs9325996	chr1:152965347	A/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.51	-0.35	3.95e-20	Inflammatory skin disease;
BRCA	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	13.21	0.46	2.15e-35	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg05294307	chr14:35346193	BAZ1A	-0.55	-9.8	-0.36	3.16e-21	Psoriasis;
BRCA	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12667521	chr19:29218732	NA	0.47	8.75	0.33	1.93e-17	Methadone dose in opioid dependence;
BRCA	cis	rs858239	0.539	rs870476	chr7:23193271	C/T	cg23682824	chr7:23144976	KLHL7	0.41	10.9	0.4	1.67e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6840258	1.000	rs17604480	chr4:87970127	C/A	cg08197287	chr4:87952173	AFF1	-0.45	-8.98	-0.33	2.93e-18	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs9443189	0.570	rs775075	chr6:76380035	A/C	cg01950844	chr6:76311363	SENP6	-0.84	-13.48	-0.47	1.32e-36	Prostate cancer;
BRCA	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg11645453	chr3:52864694	ITIH4	-0.37	-9.7	-0.36	7.37e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg00105475	chr2:10696890	NA	-0.45	-10.41	-0.38	1.55e-23	Prostate cancer;
BRCA	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg11530693	chr1:120165357	ZNF697	0.62	14.94	0.51	1.68e-43	Systemic lupus erythematosus;
BRCA	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg25319279	chr11:5960081	NA	-0.42	-8.41	-0.32	2.67e-16	DNA methylation (variation);
BRCA	cis	rs12986413	0.619	rs1859954	chr19:2145481	G/T	cg09261902	chr19:2140048	AP3D1	-0.37	-9.77	-0.36	4.33e-21	Height;
BRCA	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg10932868	chr11:921992	NA	0.39	9.29	0.35	2.31e-19	Alzheimer's disease (late onset);
BRCA	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg27661571	chr11:113659931	NA	0.53	8.44	0.32	2.2e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs2230307	0.706	rs564562	chr1:100471566	T/C	cg24955406	chr1:100503596	HIAT1	0.54	9.43	0.35	7.66e-20	Carotid intima media thickness;
BRCA	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg13010199	chr12:38710504	ALG10B	-0.4	-9.14	-0.34	8.46e-19	Morning vs. evening chronotype;
BRCA	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11890956	chr21:40555474	PSMG1	-0.87	-23.0	-0.67	9.6e-86	Cognitive function;
BRCA	cis	rs909002	0.925	rs7524405	chr1:32108579	A/C	cg13919466	chr1:32135498	COL16A1	0.23	7.96	0.3	7.67e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4948102	0.731	rs7800001	chr7:56072010	T/C	cg09872392	chr7:56161020	PHKG1	-0.37	-8.32	-0.31	5.44e-16	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg26769984	chr7:1090371	C7orf50	0.49	8.78	0.33	1.49e-17	Bronchopulmonary dysplasia;
BRCA	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.96	-0.37	8.34e-22	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18876405	chr7:65276391	NA	-0.51	-11.63	-0.42	1.67e-28	Aortic root size;
BRCA	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg11663144	chr21:46675770	NA	-0.56	-13.19	-0.46	2.72e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg00825309	chr19:58991885	ZNF446	-0.64	-14.4	-0.5	6.13e-41	Uric acid clearance;
BRCA	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg03188948	chr7:1209495	NA	0.78	11.27	0.41	5.59e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.52	-10.14	-0.37	1.7e-22	Body mass index;
BRCA	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg26031613	chr14:104095156	KLC1	-0.42	-8.35	-0.31	4.22e-16	Schizophrenia;
BRCA	cis	rs1829883	0.898	rs2460684	chr5:98776329	C/T	cg08333243	chr5:99726346	NA	-0.35	-7.98	-0.3	6.56e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-8.94	-0.33	4.08e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg09021430	chr5:549028	NA	-0.68	-14.14	-0.49	1.07e-39	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7607369	0.617	rs12987009	chr2:219658170	A/T	cg02176678	chr2:219576539	TTLL4	-0.47	-12.26	-0.44	3.34e-31	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19717773	chr7:2847554	GNA12	-0.42	-8.53	-0.32	1.04e-16	Height;
BRCA	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.45	-0.41	1.01e-27	Mean corpuscular volume;
BRCA	cis	rs9400271	0.632	rs6930698	chr6:109590304	A/G	cg21918786	chr6:109611834	NA	-0.32	-8.05	-0.3	4.14e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg13880726	chr7:1868755	MAD1L1	-0.43	-8.14	-0.31	2.09e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7944584	0.552	rs12361415	chr11:47474146	T/G	cg03711944	chr11:47377212	SPI1	-0.44	-10.1	-0.37	2.28e-22	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg22974920	chr21:40686053	BRWD1	-0.35	-7.91	-0.3	1.11e-14	Menarche (age at onset);
BRCA	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg19622623	chr12:86230825	RASSF9	-0.33	-9.17	-0.34	6.19e-19	Major depressive disorder;
BRCA	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg00814883	chr7:100076585	TSC22D4	-0.49	-10.26	-0.38	5.9e-23	Platelet count;
BRCA	cis	rs877529	0.625	rs714016	chr22:39532554	G/T	cg18708252	chr22:39545030	CBX7	0.38	9.01	0.34	2.45e-18	Multiple myeloma;
BRCA	cis	rs4845570	1.000	rs3790514	chr1:151744168	T/C	cg07092448	chr1:151763213	TDRKH	-0.88	-17.0	-0.56	9.09e-54	Coronary artery disease;
BRCA	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg11833968	chr6:79620685	NA	-0.43	-9.58	-0.35	2.12e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg13271783	chr10:134563150	INPP5A	-0.47	-9.95	-0.37	8.73e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg26647111	chr11:31128758	NA	-0.43	-9.17	-0.34	6.54e-19	Red blood cell count;
BRCA	trans	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg26043149	chr18:55253948	FECH	-0.37	-8.25	-0.31	8.96e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg11301795	chr4:187892539	NA	0.3	9.7	0.36	7.88e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4302748	0.862	rs11772280	chr7:36186110	C/T	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs4891159	0.756	rs3892540	chr18:74118058	C/T	cg24786174	chr18:74118243	ZNF516	-0.78	-18.93	-0.6	8.67e-64	Longevity;
BRCA	cis	rs9790314	0.589	rs1447618	chr3:160610438	C/T	cg03342759	chr3:160939853	NMD3	0.44	8.73	0.33	2.29e-17	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.818	rs1415969	chr1:153006448	G/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.28	-0.34	2.53e-19	Inflammatory skin disease;
BRCA	cis	rs7191700	0.578	rs243327	chr16:11353304	C/T	cg00044050	chr16:11439710	C16orf75	-0.38	-8.89	-0.33	6.17e-18	Multiple sclerosis;
BRCA	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg26597838	chr10:835615	NA	-0.51	-9.68	-0.36	9.19e-21	Response to angiotensin II receptor blocker therapy;
BRCA	trans	rs7395662	0.853	rs10838885	chr11:48398806	A/G	cg00717180	chr2:96193071	NA	-0.28	-7.82	-0.3	2.17e-14	HDL cholesterol;
BRCA	trans	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg26043149	chr18:55253948	FECH	1.08	22.94	0.67	2.05e-85	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.93	0.33	4.51e-18	Motion sickness;
BRCA	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.38	9.14	0.34	8.45e-19	Platelet count;
BRCA	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11764359	chr7:65958608	NA	-0.76	-16.7	-0.55	3.01e-52	Aortic root size;
BRCA	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.61	-0.32	5.51e-17	Total body bone mineral density;
BRCA	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.91	20.35	0.63	2.29e-71	Cognitive ability;
BRCA	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg25358565	chr5:93447407	FAM172A	1.2	18.7	0.59	1.46e-62	Diabetic retinopathy;
BRCA	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg24562669	chr7:97807699	LMTK2	0.46	12.25	0.44	3.78e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs877282	0.898	rs11253343	chr10:765117	C/T	cg17470449	chr10:769945	NA	0.47	7.96	0.3	8.16e-15	Uric acid levels;
BRCA	trans	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg25214090	chr10:38739885	LOC399744	0.53	11.79	0.42	3.47e-29	Corneal astigmatism;
BRCA	trans	rs3857536	0.730	rs7761295	chr6:66932532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.08	-0.3	3.22e-15	Blood trace element (Cu levels);
BRCA	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg22980127	chr19:33182716	NUDT19	0.9	17.65	0.57	4.12e-57	Red blood cell traits;
BRCA	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11764359	chr7:65958608	NA	-0.76	-17.22	-0.56	7.4e-55	Aortic root size;
BRCA	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.23	-0.68	4.97e-87	Gut microbiome composition (summer);
BRCA	cis	rs7523273	0.565	rs1998538	chr1:207886487	C/T	cg22525895	chr1:207977042	MIR29B2	-0.33	-7.82	-0.3	2.24e-14	Schizophrenia;
BRCA	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg01416388	chr22:39784598	NA	-0.38	-7.95	-0.3	8.4e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.5	9.94	0.37	1e-21	Height;
BRCA	cis	rs847577	0.572	rs847573	chr7:97681761	C/T	cg21770322	chr7:97807741	LMTK2	-0.4	-9.48	-0.35	4.96e-20	Breast cancer;
BRCA	cis	rs999943	1.000	rs999943	chr6:33624733	A/G	cg14003231	chr6:33640908	ITPR3	0.5	12.3	0.44	2.26e-31	Obesity (extreme);
BRCA	cis	rs9467773	0.572	rs9467737	chr6:26381630	T/C	cg09904177	chr6:26538194	HMGN4	-0.34	-8.84	-0.33	9.15e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg22705602	chr4:152727874	NA	-0.32	-8.35	-0.31	4.37e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2599510	0.693	rs2754514	chr2:32788836	T/A	cg02381751	chr2:32503542	YIPF4	0.49	10.14	0.37	1.66e-22	Interleukin-18 levels;
BRCA	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg04546413	chr19:29218101	NA	0.47	9.71	0.36	6.99e-21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg23260525	chr10:116636907	FAM160B1	0.3	7.9	0.3	1.18e-14	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs7809950	1.000	rs2066735	chr7:107188719	G/T	cg23024343	chr7:107201750	COG5	-0.42	-9.67	-0.36	1.01e-20	Coronary artery disease;
BRCA	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg06618935	chr21:46677482	NA	-0.35	-7.85	-0.3	1.82e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs2262909	0.962	rs56369285	chr19:22267185	T/C	cg17074339	chr11:11642133	GALNTL4	0.43	8.31	0.31	5.77e-16	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs490234	0.841	rs477813	chr9:128416874	C/T	cg14078157	chr9:128172775	NA	0.35	8.38	0.31	3.36e-16	Mean arterial pressure;
BRCA	cis	rs698813	0.851	rs786413	chr2:44702758	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	8.75	0.33	1.87e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-8.99	-0.34	2.74e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg00750074	chr16:89608354	SPG7	-0.37	-10.01	-0.37	5.44e-22	Multiple myeloma (IgH translocation);
BRCA	cis	rs8038465	0.592	rs58443257	chr15:73930707	A/T	cg15420318	chr15:73925796	NPTN	0.41	8.83	0.33	1.04e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg24562669	chr7:97807699	LMTK2	0.45	12.04	0.43	3.01e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	13.73	0.48	9.02e-38	Lymphocyte counts;
BRCA	cis	rs250677	0.522	rs2217638	chr5:148364355	A/G	cg12140854	chr5:148520817	ABLIM3	0.41	8.41	0.32	2.64e-16	Breast cancer;
BRCA	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg03395511	chr6:291903	DUSP22	0.55	11.2	0.41	1.06e-26	Menopause (age at onset);
BRCA	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg04317338	chr11:64019027	PLCB3	0.54	9.5	0.35	4.12e-20	Mean platelet volume;
BRCA	cis	rs4409675	0.576	rs2295367	chr1:28224312	C/T	cg23691781	chr1:28212827	C1orf38	0.34	11.21	0.41	9.29e-27	Corneal astigmatism;
BRCA	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	10.03	0.37	4.23e-22	Bipolar disorder;
BRCA	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg15782153	chr7:917662	C7orf20	0.4	9.74	0.36	5.26e-21	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs12367572	0.620	rs2643140	chr12:45418311	C/T	cg04608330	chr12:45269318	NELL2	-0.38	-7.88	-0.3	1.42e-14	Gut microbiome composition (summer);
BRCA	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg02187348	chr16:89574699	SPG7	0.37	8.56	0.32	8.72e-17	Multiple myeloma (IgH translocation);
BRCA	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.76	-0.5	1.19e-42	Chronic sinus infection;
BRCA	cis	rs72781680	0.716	rs6731314	chr2:24048338	C/T	cg08917208	chr2:24149416	ATAD2B	-0.59	-10.08	-0.37	2.87e-22	Lymphocyte counts;
BRCA	trans	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg25214090	chr10:38739885	LOC399744	0.55	12.23	0.44	4.59e-31	Corneal astigmatism;
BRCA	trans	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg06521331	chr12:34319734	NA	-0.51	-9.31	-0.35	2.03e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg04234412	chr22:24373322	LOC391322	0.62	15.17	0.51	1.32e-44	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg18016565	chr1:150552671	MCL1	0.34	7.9	0.3	1.25e-14	Melanoma;
BRCA	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03264133	chr6:25882463	NA	0.39	8.45	0.32	2.01e-16	Blood metabolite levels;
BRCA	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg03146154	chr1:46216737	IPP	0.52	11.73	0.42	6.24e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.39	9.98	0.37	6.67e-22	IgG glycosylation;
BRCA	cis	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05901451	chr6:126070800	HEY2	-0.39	-9.47	-0.35	5.54e-20	Endometrial cancer;
BRCA	trans	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg21659725	chr3:3221576	CRBN	-0.48	-8.4	-0.32	2.91e-16	Menarche (age at onset);
BRCA	cis	rs2637266	0.935	rs2579727	chr10:78395497	A/C	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs758324	0.947	rs559971	chr5:131316164	A/G	cg06307176	chr5:131281290	NA	0.5	9.84	0.36	2.25e-21	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.0	22.58	0.67	1.81e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg23018236	chr17:30244563	NA	-0.66	-9.97	-0.37	7.61e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs2599510	0.811	rs2754523	chr2:32837110	A/G	cg02381751	chr2:32503542	YIPF4	0.42	8.34	0.31	4.61e-16	Interleukin-18 levels;
BRCA	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.67	0.42	1.12e-28	Homoarginine levels;
BRCA	cis	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg06521331	chr12:34319734	NA	-0.57	-11.25	-0.41	6.58e-27	Morning vs. evening chronotype;
BRCA	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	13.89	0.48	1.56e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg23711669	chr6:146136114	FBXO30	0.75	17.26	0.56	4.26e-55	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg23505145	chr19:12996616	KLF1	0.56	12.64	0.45	7.56e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24549020	chr5:56110836	MAP3K1	0.6	12.38	0.44	1.05e-31	Initial pursuit acceleration;
BRCA	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg22676075	chr6:135203613	NA	0.46	8.99	0.34	2.72e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs3741151	0.773	rs73544711	chr11:73164870	T/A	cg17517138	chr11:73019481	ARHGEF17	0.89	12.53	0.44	2.35e-32	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-10.63	-0.39	2.11e-24	Gut microbiome composition (summer);
BRCA	cis	rs9560113	1.000	rs4773386	chr13:112180896	C/G	cg10483660	chr13:112241077	NA	0.32	7.98	0.3	6.88e-15	Menarche (age at onset);
BRCA	trans	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg18876405	chr7:65276391	NA	0.47	10.17	0.37	1.29e-22	Corneal structure;
BRCA	cis	rs7586879	1.000	rs6736711	chr2:25116456	C/T	cg01884057	chr2:25150051	NA	0.33	8.24	0.31	9.61e-16	Body mass index;
BRCA	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg22903657	chr4:1355424	KIAA1530	-0.36	-8.06	-0.3	3.74e-15	Obesity-related traits;
BRCA	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	11.68	0.42	1.04e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg11663144	chr21:46675770	NA	-0.47	-11.24	-0.41	7.12e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs311392	0.867	rs434952	chr8:55091998	C/T	cg11783602	chr8:55087084	NA	-0.31	-9.07	-0.34	1.49e-18	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg25036284	chr2:26402008	FAM59B	-0.89	-15.33	-0.52	2.09e-45	Gut microbiome composition (summer);
BRCA	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg03060546	chr3:49711283	APEH	-0.51	-10.04	-0.37	3.84e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.14	-0.37	1.63e-22	Heart rate;
BRCA	cis	rs12220238	1.000	rs10824128	chr10:76007903	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.49	8.03	0.3	4.84e-15	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg02196655	chr2:10830764	NOL10	-0.3	-8.05	-0.3	4.13e-15	Prostate cancer;
BRCA	trans	rs3942852	0.955	rs1532754	chr11:48115279	A/T	cg15704280	chr7:45808275	SEPT13	-0.48	-8.44	-0.32	2.15e-16	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.94	-0.46	3.55e-34	Migraine;Coronary artery disease;
BRCA	cis	rs10189230	0.967	rs1367241	chr2:222353413	G/A	cg14652038	chr2:222343519	EPHA4	0.47	13.02	0.46	1.53e-34	Urate levels in lean individuals;
BRCA	trans	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg11693508	chr17:37793320	STARD3	0.5	8.73	0.33	2.25e-17	Neuroticism;
BRCA	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.22	7.89	0.3	1.34e-14	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	13.36	0.47	4.29e-36	Exhaled nitric oxide output;
BRCA	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-9.83	-0.36	2.47e-21	Tonsillectomy;
BRCA	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg22920501	chr2:26401640	FAM59B	-0.92	-17.62	-0.57	6.42e-57	Gut microbiome composition (summer);
BRCA	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg23285459	chr7:2802560	GNA12	-0.35	-8.41	-0.32	2.67e-16	Height;
BRCA	cis	rs6942756	1.000	rs56026912	chr7:128913937	A/G	cg02491457	chr7:128862824	NA	-0.7	-13.6	-0.47	3.59e-37	White matter hyperintensity burden;
BRCA	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg11887960	chr12:57824829	NA	0.5	8.33	0.31	5e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-32.4	-0.79	5.77e-137	Schizophrenia;
BRCA	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02176678	chr2:219576539	TTLL4	0.47	12.32	0.44	1.88e-31	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg27661571	chr11:113659931	NA	-0.7	-10.89	-0.4	1.93e-25	Hip circumference adjusted for BMI;
BRCA	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.82e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.37	8.37	0.31	3.64e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03264133	chr6:25882463	NA	-0.53	-11.93	-0.43	9.61e-30	Blood metabolite levels;
BRCA	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.43	-0.38	1.25e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg03146154	chr1:46216737	IPP	0.45	9.99	0.37	6.25e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg18252515	chr7:66147081	NA	-0.86	-12.42	-0.44	7.02e-32	Diabetic kidney disease;
BRCA	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg09469691	chr10:81107165	PPIF	0.42	9.05	0.34	1.64e-18	Height;
BRCA	cis	rs864745	0.653	rs1635853	chr7:28189549	A/C	cg22892036	chr7:28189139	JAZF1	0.5	11.25	0.41	6.7e-27	Crohn's disease;Type 2 diabetes;
BRCA	cis	rs757081	0.867	rs2521999	chr11:17333183	G/A	cg15432903	chr11:17409602	KCNJ11	-0.54	-9.64	-0.36	1.27e-20	Systolic blood pressure;
BRCA	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg01802117	chr1:53393560	SCP2	-0.36	-8.19	-0.31	1.39e-15	Monocyte count;
BRCA	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	14.29	0.49	2.11e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg07080220	chr10:102295463	HIF1AN	0.59	13.65	0.48	2.09e-37	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26314531	chr2:26401878	FAM59B	-0.72	-11.88	-0.43	1.44e-29	Gut microbiome composition (summer);
BRCA	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg10932868	chr11:921992	NA	0.5	12.71	0.45	3.63e-33	Alzheimer's disease (late onset);
BRCA	cis	rs13394619	0.936	rs9789414	chr2:11724684	A/G	cg07314298	chr2:11723111	GREB1	-0.56	-12.44	-0.44	5.56e-32	Endometriosis;
BRCA	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24110177	chr3:50126178	RBM5	0.4	11.09	0.4	3.02e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg26384229	chr12:38710491	ALG10B	0.76	17.28	0.56	3.49e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg05340658	chr4:99064831	C4orf37	0.44	10.13	0.37	1.74e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.7e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7727544	0.505	rs721121	chr5:131406433	T/G	cg14196790	chr5:131705035	SLC22A5	0.36	9.11	0.34	1.07e-18	Blood metabolite levels;
BRCA	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg05313129	chr8:58192883	C8orf71	-0.48	-9.85	-0.36	2.01e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg23887609	chr12:130822674	PIWIL1	0.42	9.05	0.34	1.76e-18	Menopause (age at onset);
BRCA	cis	rs4566357	0.615	rs4675140	chr2:227908665	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-9.5	-0.35	4.04e-20	Coronary artery disease;
BRCA	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg00106254	chr7:1943704	MAD1L1	-0.38	-9.86	-0.36	1.98e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs977987	0.806	rs4887818	chr16:75361995	T/C	cg03315344	chr16:75512273	CHST6	0.53	12.24	0.44	4.48e-31	Dupuytren's disease;
BRCA	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-13.53	-0.47	7.3e-37	Chronic sinus infection;
BRCA	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.16	0.4	1.49e-26	Electroencephalogram traits;
BRCA	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg23649088	chr2:200775458	C2orf69	0.49	10.09	0.37	2.57e-22	Osteoporosis;
BRCA	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg02551604	chr5:131831745	NA	-0.39	-14.62	-0.5	5.71e-42	Asthma (sex interaction);
BRCA	cis	rs965469	1.000	rs6037538	chr20:3282978	T/C	cg25506879	chr20:3388711	C20orf194	-0.5	-9.84	-0.36	2.33e-21	IFN-related cytopenia;
BRCA	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg26536863	chr7:158807979	LOC154822	0.37	8.62	0.32	5.39e-17	Facial morphology (factor 20);
BRCA	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg04455712	chr21:45112962	RRP1B	0.38	9.79	0.36	3.5e-21	Mean corpuscular volume;
BRCA	cis	rs11605275	1.000	rs78687006	chr11:20032176	G/A	cg14835545	chr11:20032148	NAV2	-0.59	-9.36	-0.35	1.28e-19	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg26528668	chr16:1614120	IFT140	0.37	8.35	0.31	4.16e-16	Coronary artery disease;
BRCA	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg06064525	chr11:970664	AP2A2	-0.32	-9.15	-0.34	7.28e-19	Alzheimer's disease (late onset);
BRCA	trans	rs3960554	0.800	rs80002395	chr7:75814902	C/T	cg19862616	chr7:65841803	NCRNA00174	0.58	11.91	0.43	1.15e-29	Eotaxin levels;
BRCA	cis	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg24692254	chr21:30365293	RNF160	-0.45	-8.03	-0.3	4.85e-15	Cognitive test performance;
BRCA	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg08645402	chr16:4508243	NA	0.39	8.42	0.32	2.53e-16	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.82	0.55	8.18e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6429082	0.702	rs10802797	chr1:235705673	A/G	cg26050004	chr1:235667680	B3GALNT2	0.45	10.64	0.39	1.95e-24	Adiposity;
BRCA	cis	rs9463078	0.605	rs4711799	chr6:44765780	A/T	cg25276700	chr6:44698697	NA	0.37	8.65	0.32	4.1e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.65	12.94	0.46	3.43e-34	Lymphocyte counts;
BRCA	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.01	-0.3	5.32e-15	Extrinsic epigenetic age acceleration;
BRCA	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	5.91e-52	Morning vs. evening chronotype;
BRCA	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg09256448	chr16:638327	NA	0.3	7.88	0.3	1.42e-14	Height;
BRCA	cis	rs2354432	0.607	rs6683243	chr1:146733422	A/T	cg25205988	chr1:146714368	CHD1L	-0.95	-11.76	-0.42	5e-29	Mitochondrial DNA levels;
BRCA	trans	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg26384229	chr12:38710491	ALG10B	0.44	10.59	0.39	2.89e-24	Morning vs. evening chronotype;
BRCA	trans	rs11088226	1.000	rs11088226	chr21:33925531	C/G	cg09050820	chr6:167586206	TCP10L2	0.49	8.52	0.32	1.17e-16	Gastritis;
BRCA	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg08422745	chr4:174089978	GALNT7	-0.58	-11.99	-0.43	5.12e-30	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg13334819	chr7:99746414	C7orf59	0.39	8.96	0.33	3.49e-18	Coronary artery disease;
BRCA	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18404041	chr3:52824283	ITIH1	-0.5	-16.06	-0.54	4.97e-49	Bipolar disorder;
BRCA	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg26248373	chr2:1572462	NA	-0.45	-8.58	-0.32	7.23e-17	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg17366294	chr4:99064904	C4orf37	0.45	10.64	0.39	1.81e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.14	-0.4	1.81e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg11845111	chr2:191398756	TMEM194B	-0.81	-13.88	-0.48	1.73e-38	Diastolic blood pressure;
BRCA	cis	rs6450176	0.909	rs6898870	chr5:53293107	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.59	-13.85	-0.48	2.33e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-12.6	-0.45	1.15e-32	Response to antipsychotic treatment;
BRCA	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	7.97	0.3	7.13e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs9790314	0.747	rs9990115	chr3:160838412	C/G	cg04691961	chr3:161091175	C3orf57	-0.46	-9.88	-0.36	1.65e-21	Morning vs. evening chronotype;
BRCA	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg22601191	chr20:60968625	CABLES2	0.33	8.37	0.31	3.64e-16	Colorectal cancer;
BRCA	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg08975724	chr8:8085496	FLJ10661	0.44	8.56	0.32	8.57e-17	Retinal vascular caliber;
BRCA	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg06784218	chr1:46089804	CCDC17	-0.54	-13.26	-0.46	1.22e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg21138405	chr5:131827807	IRF1	0.32	10.35	0.38	2.5e-23	Breast cancer;Mosquito bite size;
BRCA	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg05347473	chr6:146136440	FBXO30	-0.61	-12.02	-0.43	3.63e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg23978390	chr7:1156363	C7orf50	0.4	7.84	0.3	1.91e-14	Bronchopulmonary dysplasia;
BRCA	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-9.0	-0.34	2.61e-18	Aortic root size;
BRCA	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg08885076	chr2:99613938	TSGA10	0.45	10.64	0.39	1.8e-24	Chronic sinus infection;
BRCA	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.04	21.1	0.64	2.26e-75	Gut microbiome composition (summer);
BRCA	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg03806693	chr22:41940476	POLR3H	0.9	15.34	0.52	1.91e-45	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg05863683	chr7:1912471	MAD1L1	0.4	8.44	0.32	2.1e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg07952391	chr2:88470173	THNSL2	0.67	9.09	0.34	1.27e-18	Plasma clusterin levels;
BRCA	cis	rs6842047	0.520	rs4253425	chr4:187205929	T/C	cg14349977	chr4:187219430	NA	-0.6	-7.9	-0.3	1.25e-14	Blood protein levels;
BRCA	trans	rs526821	0.553	rs519637	chr11:55295935	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.37	-8.18	-0.31	1.53e-15	Pediatric bone mineral density (spine);
BRCA	cis	rs10992471	0.603	rs1535755	chr9:95202031	G/T	cg14631576	chr9:95140430	CENPP	-0.39	-9.31	-0.35	2.09e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs1882538	0.538	rs7803848	chr7:133108547	C/T	cg10665199	chr7:133106180	EXOC4	0.43	9.18	0.34	6.06e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg26587870	chr6:27730563	NA	-0.51	-7.98	-0.3	6.71e-15	Breast cancer;
BRCA	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.6	12.56	0.45	1.65e-32	Personality dimensions;
BRCA	cis	rs754466	0.651	rs10824584	chr10:79625947	G/A	cg17075019	chr10:79541650	NA	-0.73	-17.59	-0.57	8.49e-57	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg24675658	chr1:53192096	ZYG11B	-0.66	-14.4	-0.5	6.14e-41	Monocyte count;
BRCA	cis	rs7092929	0.883	rs705459	chr10:3615477	T/C	cg14308648	chr10:3568949	NA	0.46	8.43	0.32	2.37e-16	Coronary artery calcification;
BRCA	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.07e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2522056	1.000	rs2706381	chr5:131810619	C/T	cg24060327	chr5:131705240	SLC22A5	0.46	8.01	0.3	5.4e-15	Lymphocyte counts;Fibrinogen;
BRCA	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.52	-0.61	6.85e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11764359	chr7:65958608	NA	-0.76	-16.74	-0.55	1.98e-52	Aortic root size;
BRCA	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg23018236	chr17:30244563	NA	-0.64	-10.29	-0.38	4.42e-23	Hip circumference adjusted for BMI;
BRCA	cis	rs7264396	0.563	rs6058296	chr20:34269225	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.69	-0.39	1.23e-24	Total cholesterol levels;
BRCA	cis	rs17401966	0.964	rs6674843	chr1:10458378	A/T	cg03954927	chr1:10346856	KIF1B	0.41	11.14	0.4	1.87e-26	Hepatocellular carcinoma;
BRCA	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg26384229	chr12:38710491	ALG10B	0.68	15.78	0.53	1.36e-47	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-19.08	-0.6	1.43e-64	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg11764359	chr7:65958608	NA	0.68	15.14	0.51	1.77e-44	Aortic root size;
BRCA	cis	rs208520	0.779	rs208451	chr6:66906155	G/A	cg07460842	chr6:66804631	NA	-0.89	-15.26	-0.52	4.77e-45	Exhaled nitric oxide output;
BRCA	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06028605	chr16:24865363	SLC5A11	-0.45	-10.1	-0.37	2.28e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg25319279	chr11:5960081	NA	-0.39	-8.16	-0.31	1.79e-15	DNA methylation (variation);
BRCA	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg09307838	chr4:120376055	NA	0.68	13.34	0.47	5.48e-36	Corneal astigmatism;
BRCA	cis	rs6594499	0.872	rs6881147	chr5:110451936	G/C	cg04022379	chr5:110408740	TSLP	0.35	7.92	0.3	1.09e-14	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7756236	0.521	rs9462209	chr6:36628042	T/G	cg08179530	chr6:36648295	CDKN1A	0.37	7.95	0.3	8.38e-15	QRS duration;
BRCA	cis	rs2479724	0.776	rs12523672	chr6:41749692	T/G	cg17623882	chr6:41773611	USP49	0.32	8.56	0.32	8.48e-17	Menarche (age at onset);
BRCA	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-12.2	-0.43	6.19e-31	Platelet count;
BRCA	trans	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg25214090	chr10:38739885	LOC399744	0.51	11.78	0.42	4.18e-29	Corneal astigmatism;
BRCA	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.67	15.53	0.52	2.17e-46	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs16866061	1.000	rs72974267	chr2:225454209	T/C	cg12698349	chr2:225449008	CUL3	0.77	20.78	0.63	1.21e-73	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg00106254	chr7:1943704	MAD1L1	-0.39	-9.6	-0.36	1.72e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.46	8.76	0.33	1.76e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08109568	chr15:31115862	NA	0.41	10.02	0.37	4.66e-22	Huntington's disease progression;
BRCA	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg12311346	chr5:56204834	C5orf35	-0.82	-16.25	-0.54	5.79e-50	Initial pursuit acceleration;
BRCA	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg10560079	chr2:191398806	TMEM194B	-0.76	-12.98	-0.46	2.24e-34	Diastolic blood pressure;
BRCA	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18404041	chr3:52824283	ITIH1	-0.42	-12.4	-0.44	8.87e-32	Bipolar disorder;
BRCA	cis	rs7766436	0.885	rs10946567	chr6:22581302	T/C	cg13666174	chr6:22585274	NA	-0.49	-11.6	-0.42	2.25e-28	Coronary artery disease;
BRCA	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg23533926	chr12:111358616	MYL2	0.41	8.62	0.32	5.12e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg23306229	chr2:178417860	TTC30B	-0.46	-7.88	-0.3	1.4e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs1904096	0.506	rs7439869	chr4:95173779	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.41	-8.51	-0.32	1.26e-16	Type 2 diabetes;
BRCA	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.82	-0.36	2.68e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg01283332	chr5:1856932	NA	-0.35	-8.55	-0.32	9.33e-17	Cardiovascular disease risk factors;
BRCA	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21659725	chr3:3221576	CRBN	0.51	12.26	0.44	3.67e-31	Resting heart rate;
BRCA	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg15673110	chr2:32581747	BIRC6	0.35	8.01	0.3	5.58e-15	Mosquito bite size;
BRCA	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg03954927	chr1:10346856	KIF1B	0.45	13.16	0.46	3.76e-35	Hepatocellular carcinoma;
BRCA	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg04691961	chr3:161091175	C3orf57	-0.59	-14.32	-0.49	1.53e-40	Morning vs. evening chronotype;
BRCA	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06634786	chr22:41940651	POLR3H	0.57	10.31	0.38	3.6e-23	Vitiligo;
BRCA	cis	rs911119	0.818	rs67862677	chr20:23591086	A/C	cg16589663	chr20:23618590	CST3	0.43	8.16	0.31	1.76e-15	Chronic kidney disease;
BRCA	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	8.66	0.32	3.86e-17	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.02e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6545883	1.000	rs778763	chr2:61785639	C/G	cg15711740	chr2:61764176	XPO1	-0.56	-14.18	-0.49	6.66e-40	Tuberculosis;
BRCA	cis	rs11971779	0.680	rs10229249	chr7:139052510	A/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.24	0.38	6.65e-23	Diisocyanate-induced asthma;
BRCA	cis	rs600806	0.850	rs3879452	chr1:109929237	G/A	cg20591472	chr1:110008990	SYPL2	0.33	8.22	0.31	1.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg16482183	chr6:26056742	HIST1H1C	0.65	13.47	0.47	1.41e-36	Height;
BRCA	cis	rs12431939	0.947	rs68180359	chr14:51672027	G/A	cg23942311	chr14:51606299	NA	-0.44	-8.09	-0.3	2.92e-15	Cancer;
BRCA	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	16.37	0.54	1.48e-50	Smoking behavior;
BRCA	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-9.25	-0.34	3.37e-19	Bipolar disorder;
BRCA	cis	rs701145	0.556	rs355787	chr3:153994502	T/C	cg12800244	chr3:153838788	SGEF	0.44	8.91	0.33	5.1e-18	Coronary artery disease;
BRCA	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25427524	chr10:38739819	LOC399744	0.69	16.75	0.55	1.84e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs8114671	0.647	rs6060267	chr20:33734012	A/G	cg24642439	chr20:33292090	TP53INP2	0.4	8.6	0.32	5.93e-17	Height;
BRCA	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg24558204	chr6:135376177	HBS1L	0.45	12.34	0.44	1.6e-31	Red blood cell count;
BRCA	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09256448	chr16:638327	NA	0.3	7.81	0.3	2.43e-14	Height;
BRCA	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg00684032	chr4:1343700	KIAA1530	-0.3	-7.86	-0.3	1.68e-14	Obesity-related traits;
BRCA	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg03342759	chr3:160939853	NMD3	-0.55	-12.07	-0.43	2.26e-30	Morning vs. evening chronotype;
BRCA	cis	rs701145	0.585	rs1470663	chr3:153870883	A/G	cg17054900	chr3:154042577	DHX36	0.55	9.29	0.35	2.32e-19	Coronary artery disease;
BRCA	cis	rs9462027	0.628	rs9469889	chr6:34763900	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.88	-0.3	1.44e-14	Systemic lupus erythematosus;
BRCA	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.04	-0.34	1.8e-18	Total body bone mineral density;
BRCA	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg03146154	chr1:46216737	IPP	-0.47	-10.32	-0.38	3.43e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg06521331	chr12:34319734	NA	-0.55	-9.94	-0.37	9.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg01849466	chr14:104193079	ZFYVE21	0.43	11.06	0.4	3.72e-26	Schizophrenia;
BRCA	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg04450456	chr4:17643702	FAM184B	0.35	9.64	0.36	1.22e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9420	0.961	rs12804972	chr11:57463767	T/C	cg19752551	chr11:57585705	CTNND1	-0.51	-12.52	-0.44	2.44e-32	Schizophrenia;
BRCA	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg26384229	chr12:38710491	ALG10B	0.42	9.44	0.35	6.82e-20	Morning vs. evening chronotype;
BRCA	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	19.7	0.61	6.89e-68	Platelet count;
BRCA	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg21045802	chr8:109455806	TTC35	0.35	8.02	0.3	5.19e-15	Dupuytren's disease;
BRCA	cis	rs965469	0.901	rs7270135	chr20:3247922	T/C	cg25506879	chr20:3388711	C20orf194	-0.55	-10.73	-0.39	7.94e-25	IFN-related cytopenia;
BRCA	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11890956	chr21:40555474	PSMG1	0.94	22.75	0.67	2.32e-84	Cognitive function;
BRCA	cis	rs36051895	0.632	rs10974983	chr9:5149657	G/T	cg02405213	chr9:5042618	JAK2	-0.46	-8.58	-0.32	7.2e-17	Pediatric autoimmune diseases;
BRCA	cis	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg06521331	chr12:34319734	NA	-0.57	-11.13	-0.4	2.03e-26	Morning vs. evening chronotype;
BRCA	cis	rs4664304	0.802	rs1511224	chr2:160750861	C/T	cg01092293	chr2:160761427	LY75	-0.34	-7.87	-0.3	1.57e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg01256987	chr12:42539512	GXYLT1	-0.4	-7.86	-0.3	1.59e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg13271783	chr10:134563150	INPP5A	-0.44	-9.18	-0.34	6.01e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-9.95	-0.37	9.11e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24531977	chr5:56204891	C5orf35	-0.81	-16.77	-0.55	1.38e-52	Initial pursuit acceleration;
BRCA	cis	rs7020830	0.867	rs7852593	chr9:37332380	A/T	cg14294708	chr9:37120828	ZCCHC7	1.14	37.96	0.83	6.2e-166	Schizophrenia;
BRCA	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.85	0.51	4.51e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.77	21.35	0.65	1e-76	Multiple sclerosis;
BRCA	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg03929089	chr4:120376271	NA	-0.48	-9.09	-0.34	1.28e-18	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg01324343	chr3:183735012	ABCC5	-0.75	-15.99	-0.53	1.2e-48	Anterior chamber depth;
BRCA	trans	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg09719594	chr16:21412588	NA	-0.32	-7.92	-0.3	1.05e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11764359	chr7:65958608	NA	0.76	16.79	0.55	1.17e-52	Aortic root size;
BRCA	trans	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg19862616	chr7:65841803	NCRNA00174	0.83	27.56	0.74	8.71e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9880211	0.706	rs67382287	chr3:136380459	C/T	cg21827317	chr3:136751795	NA	-0.45	-8.03	-0.3	4.75e-15	Body mass index;Height;
BRCA	cis	rs96067	0.805	rs1033890	chr1:36608414	C/T	cg24686825	chr1:36642396	MAP7D1	-0.5	-8.93	-0.33	4.6e-18	Corneal structure;
BRCA	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg21772509	chr8:41503840	NKX6-3	0.49	11.36	0.41	2.27e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
BRCA	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg13628971	chr7:2884303	GNA12	0.4	9.16	0.34	6.76e-19	Height;
BRCA	cis	rs6942756	1.000	rs9640854	chr7:128884057	A/T	cg02491457	chr7:128862824	NA	-0.72	-13.95	-0.48	8.27e-39	White matter hyperintensity burden;
BRCA	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg06191203	chr2:152266755	RIF1	0.36	10.75	0.39	7.06e-25	Lung cancer;
BRCA	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg11663144	chr21:46675770	NA	-0.52	-12.11	-0.43	1.57e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg08017756	chr2:100939284	LONRF2	0.31	8.01	0.3	5.51e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.818	rs572821	chr1:153008276	G/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-8.8	-0.33	1.3e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Tonsillectomy;
BRCA	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg03433033	chr1:76189801	ACADM	0.57	11.59	0.42	2.44e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg11266682	chr4:10021025	SLC2A9	0.41	11.02	0.4	5.59e-26	Bone mineral density;
BRCA	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.57	13.79	0.48	4.61e-38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg21775007	chr8:11205619	TDH	-0.53	-11.52	-0.41	5.11e-28	Retinal vascular caliber;
BRCA	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg23277830	chr1:3704460	LRRC47	0.26	7.97	0.3	7.22e-15	Red cell distribution width;
BRCA	cis	rs6598955	0.543	rs6690461	chr1:26543097	T/A	cg04990556	chr1:26633338	UBXN11	0.71	11.98	0.43	5.76e-30	Obesity-related traits;
BRCA	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg04553112	chr3:125709451	NA	-0.56	-8.44	-0.32	2.07e-16	Blood pressure (smoking interaction);
BRCA	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.0	0.51	8.96e-44	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.97	-0.33	3.23e-18	Coronary artery disease;
BRCA	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg11189052	chr15:85197271	WDR73	-0.33	-7.81	-0.3	2.35e-14	P wave terminal force;
BRCA	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.48	-0.38	8.16e-24	Aortic root size;
BRCA	cis	rs4780401	0.782	rs933573	chr16:11793395	A/G	cg01061890	chr16:11836724	TXNDC11	0.36	7.96	0.3	7.65e-15	Rheumatoid arthritis;
BRCA	cis	rs1997103	1.000	rs1997102	chr7:55399322	A/C	cg17469321	chr7:55412551	NA	-0.5	-9.29	-0.34	2.46e-19	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg00420348	chr11:830190	EFCAB4A	-0.49	-10.58	-0.39	3.16e-24	Mean platelet volume;
BRCA	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg18154014	chr19:37997991	ZNF793	0.48	9.57	0.35	2.23e-20	Coronary artery calcification;
BRCA	cis	rs8114671	0.773	rs3746438	chr20:33584289	C/T	cg07148914	chr20:33460835	GGT7	-0.38	-8.12	-0.31	2.47e-15	Height;
BRCA	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg23533926	chr12:111358616	MYL2	-0.41	-8.59	-0.32	6.78e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6840360	0.593	rs1429558	chr4:152685406	A/T	cg22705602	chr4:152727874	NA	-0.38	-10.39	-0.38	1.81e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04267008	chr7:1944627	MAD1L1	-0.51	-11.52	-0.41	4.77e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18404041	chr3:52824283	ITIH1	0.43	12.04	0.43	3.23e-30	Bipolar disorder;
BRCA	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg13770153	chr20:60521292	NA	-0.38	-9.01	-0.34	2.37e-18	Body mass index;
BRCA	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.51e-36	High light scatter reticulocyte count;
BRCA	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg10523679	chr1:76189770	ACADM	0.91	26.56	0.72	2.59e-105	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg18252515	chr7:66147081	NA	-0.88	-12.64	-0.45	7.81e-33	Diabetic kidney disease;
BRCA	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg23533926	chr12:111358616	MYL2	-0.41	-8.59	-0.32	6.69e-17	Extrinsic epigenetic age acceleration;
BRCA	trans	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg16141378	chr3:129829833	LOC729375	-0.32	-8.1	-0.31	2.8e-15	Mood instability;
BRCA	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg01528321	chr10:82214614	TSPAN14	0.68	14.62	0.5	5.85e-42	Post bronchodilator FEV1;
BRCA	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg24562669	chr7:97807699	LMTK2	0.44	11.81	0.42	2.89e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	trans	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.9	-0.33	5.82e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg19847866	chr10:1019161	NA	-0.52	-10.64	-0.39	1.9e-24	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs2882667	0.858	rs10900856	chr5:138417746	C/T	cg04439458	chr5:138467593	SIL1	0.44	11.11	0.4	2.43e-26	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg17971929	chr21:40555470	PSMG1	0.78	18.39	0.59	6.48e-61	Cognitive function;
BRCA	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg23950597	chr19:37808831	NA	-0.62	-11.33	-0.41	2.99e-27	Coronary artery calcification;
BRCA	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg03585969	chr10:35415529	CREM	0.55	11.37	0.41	2.17e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg22906224	chr7:99728672	NA	0.45	8.65	0.32	4.11e-17	Coronary artery disease;
BRCA	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg13385521	chr17:29058706	SUZ12P	0.77	12.06	0.43	2.56e-30	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg08313168	chr12:7315531	NA	0.5	8.09	0.3	2.95e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.29	9.53	0.35	3.08e-20	Bipolar disorder;
BRCA	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-7.81	-0.3	2.39e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.59	9.68	0.36	8.68e-21	Renal function-related traits (BUN);
BRCA	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg07414643	chr4:187882934	NA	0.28	9.65	0.36	1.2e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg14664628	chr15:75095509	CSK	0.5	10.62	0.39	2.23e-24	Systemic lupus erythematosus;
BRCA	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.84	0.6	2.52e-63	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	12.85	0.45	8.5e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.64	0.55	6.41e-52	Colorectal cancer;
BRCA	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg05985134	chr18:33552581	C18orf21	0.71	13.62	0.47	2.99e-37	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg04756594	chr16:24857601	SLC5A11	0.34	8.35	0.31	4.09e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs912057	0.965	rs1294415	chr6:6740633	G/A	cg06612196	chr6:6737390	NA	0.44	9.48	0.35	5.04e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg21782813	chr7:2030301	MAD1L1	0.3	7.86	0.3	1.58e-14	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs9951602	0.512	rs58352488	chr18:76651113	T/A	cg02800362	chr5:177631904	HNRNPAB	0.77	18.01	0.58	5.8e-59	Obesity-related traits;
BRCA	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	18.21	0.58	5.62e-60	Electrocardiographic conduction measures;
BRCA	cis	rs12367572	0.965	rs1506678	chr12:45249492	A/G	cg04608330	chr12:45269318	NELL2	-0.62	-14.07	-0.49	2.23e-39	Gut microbiome composition (summer);
BRCA	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-11.38	-0.41	1.89e-27	Alzheimer's disease;
BRCA	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11644478	chr21:40555479	PSMG1	0.85	19.83	0.62	1.53e-68	Cognitive function;
BRCA	trans	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.33	-8.78	-0.33	1.47e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05901451	chr6:126070800	HEY2	-0.39	-9.53	-0.35	3.35e-20	Endometrial cancer;
BRCA	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.57	10.18	0.37	1.13e-22	Gut microbiome composition (summer);
BRCA	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg13010199	chr12:38710504	ALG10B	-0.36	-7.95	-0.3	8.19e-15	Morning vs. evening chronotype;
BRCA	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg01528321	chr10:82214614	TSPAN14	0.62	14.12	0.49	1.3e-39	Post bronchodilator FEV1;
BRCA	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	12.01	0.43	4.02e-30	Rheumatoid arthritis;
BRCA	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg24006582	chr15:45444508	DUOX1	-0.55	-11.51	-0.41	5.45e-28	Uric acid levels;
BRCA	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg11952622	chr19:58962976	ZNF324B	0.43	8.7	0.33	2.77e-17	Uric acid clearance;
BRCA	cis	rs4423214	0.840	rs1790328	chr11:71148038	G/A	cg05163923	chr11:71159392	DHCR7	-0.54	-10.94	-0.4	1.22e-25	Vitamin D levels;
BRCA	cis	rs9462027	0.651	rs34493158	chr6:34753339	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.04	-0.3	4.28e-15	Systemic lupus erythematosus;
BRCA	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg07636037	chr3:49044803	WDR6	0.97	28.28	0.75	1.07e-114	Parkinson's disease;
BRCA	cis	rs3820928	0.839	rs35068645	chr2:227844265	T/C	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.33	-0.31	4.85e-16	Pulmonary function;
BRCA	trans	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.05	0.3	4.02e-15	Mean corpuscular volume;
BRCA	cis	rs738322	0.533	rs5756934	chr22:38547279	G/A	cg20207973	chr22:38506712	BAIAP2L2	0.35	8.57	0.32	7.5e-17	Cutaneous nevi;
BRCA	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg05729581	chr11:3078854	CARS	-0.36	-8.8	-0.33	1.31e-17	Longevity;
BRCA	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19346786	chr7:2764209	NA	0.35	10.64	0.39	1.94e-24	Height;
BRCA	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg07148914	chr20:33460835	GGT7	0.38	8.63	0.32	4.77e-17	Height;
BRCA	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	16.69	0.55	3.59e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	13.48	0.47	1.27e-36	Colorectal cancer;
BRCA	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02475777	chr4:1388615	CRIPAK	-0.48	-9.49	-0.35	4.57e-20	Obesity-related traits;
BRCA	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg18876405	chr7:65276391	NA	0.47	10.57	0.39	3.65e-24	Aortic root size;
BRCA	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg09888468	chr15:81410853	NA	-0.46	-7.94	-0.3	9.02e-15	QT interval (drug interaction);
BRCA	cis	rs1865721	0.958	rs57073257	chr18:73172316	A/G	cg26385618	chr18:73139727	C18orf62	-0.39	-9.03	-0.34	1.94e-18	Intelligence;
BRCA	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-13.16	-0.46	3.63e-35	Chronic sinus infection;
BRCA	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg16405210	chr4:1374714	KIAA1530	0.67	13.87	0.48	1.95e-38	Obesity-related traits;
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg03923535	chr7:1197113	ZFAND2A	0.48	9.44	0.35	6.7e-20	Longevity;Endometriosis;
BRCA	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.21	0.68	7.15e-87	Chronic sinus infection;
BRCA	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg06627628	chr2:24431161	ITSN2	-0.85	-15.66	-0.53	5.08e-47	Asthma;
BRCA	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.39	-8.16	-0.31	1.77e-15	Alzheimer's disease (late onset);
BRCA	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg11764359	chr7:65958608	NA	0.67	14.95	0.51	1.49e-43	Aortic root size;
BRCA	cis	rs17253792	0.822	rs76557162	chr14:56064701	A/G	cg01858014	chr14:56050164	KTN1	-0.77	-10.93	-0.4	1.3e-25	Putamen volume;
BRCA	cis	rs36051895	0.695	rs59384377	chr9:5005034	A/T	cg02405213	chr9:5042618	JAK2	-0.51	-9.1	-0.34	1.16e-18	Pediatric autoimmune diseases;
BRCA	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.89	0.33	6.31e-18	Tonsillectomy;
BRCA	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-13.28	-0.46	1.06e-35	Response to antipsychotic treatment;
BRCA	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	8.02e-19	Lymphocyte counts;
BRCA	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.78	-0.36	3.82e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.69	-11.12	-0.4	2.28e-26	Red cell distribution width;
BRCA	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.47	0.5	2.98e-41	Colorectal cancer;
BRCA	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg24631222	chr15:78858424	CHRNA5	0.49	9.54	0.35	2.94e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg02574844	chr11:5959923	NA	-0.39	-8.17	-0.31	1.61e-15	DNA methylation (variation);
BRCA	cis	rs12579753	0.917	rs7972839	chr12:82178920	C/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-8.17	-0.31	1.67e-15	Resting heart rate;
BRCA	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-9.85	-0.36	2.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7301016	0.846	rs11174568	chr12:63021157	T/C	cg01804193	chr12:63026212	NA	0.47	8.41	0.32	2.73e-16	IgG glycosylation;
BRCA	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg00814883	chr7:100076585	TSC22D4	-0.47	-10.43	-0.38	1.3e-23	Platelet count;
BRCA	cis	rs757081	0.667	rs34724588	chr11:17137581	T/C	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.62	-0.32	5.29e-17	Systolic blood pressure;
BRCA	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10267417	0.603	rs4721829	chr7:19873199	A/G	cg07541023	chr7:19748670	TWISTNB	0.47	8.45	0.32	2.01e-16	Night sleep phenotypes;
BRCA	cis	rs7602441	0.521	rs1434985	chr2:14767916	C/T	cg06545361	chr2:14773388	FAM84A	0.62	8.46	0.32	1.77e-16	Visceral adipose tissue adjusted for BMI;
BRCA	cis	rs9837602	0.938	rs1017968	chr3:99787011	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.33	0.41	2.91e-27	Breast cancer;
BRCA	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg07395648	chr5:131743802	NA	0.37	8.71	0.33	2.51e-17	Breast cancer;Mosquito bite size;
BRCA	cis	rs13046373	0.535	rs2832970	chr21:32020767	T/C	cg16431978	chr21:31797932	KRTAP13-3	0.35	8.98	0.33	3.03e-18	HDL cholesterol;
BRCA	cis	rs7020830	0.825	rs13297152	chr9:37075623	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	35.4	0.81	9.39e-153	Schizophrenia;
BRCA	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg04756594	chr16:24857601	SLC5A11	-0.36	-8.69	-0.32	3.14e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6450176	1.000	rs3776716	chr5:53298923	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.62	-15.07	-0.51	3.71e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	trans	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-11.92	-0.43	1.04e-29	Morning vs. evening chronotype;
BRCA	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg25767906	chr1:53392781	SCP2	0.38	8.71	0.33	2.68e-17	Monocyte count;
BRCA	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg27535305	chr1:53392650	SCP2	-0.5	-12.2	-0.43	6.56e-31	Monocyte count;
BRCA	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg06784218	chr1:46089804	CCDC17	-0.49	-11.61	-0.42	2.08e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs13046373	0.535	rs1961491	chr21:31973685	C/T	cg16431978	chr21:31797932	KRTAP13-3	0.37	9.22	0.34	4.39e-19	HDL cholesterol;
BRCA	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg24296786	chr1:45957014	TESK2	0.58	14.22	0.49	4.48e-40	High light scatter reticulocyte count;
BRCA	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg06108461	chr20:60628389	TAF4	-0.82	-17.59	-0.57	8.54e-57	Body mass index;
BRCA	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg17691542	chr6:26056736	HIST1H1C	0.51	10.46	0.38	9.53e-24	Height;
BRCA	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg12444411	chr7:2802554	GNA12	-0.35	-8.48	-0.32	1.6e-16	Height;
BRCA	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	10.87	0.39	2.36e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg16606324	chr3:10149918	C3orf24	0.48	9.47	0.35	5.5e-20	Alzheimer's disease;
BRCA	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg17366294	chr4:99064904	C4orf37	0.42	9.72	0.36	6.33e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg27170947	chr2:26402098	FAM59B	-0.64	-10.93	-0.4	1.29e-25	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg22920501	chr2:26401640	FAM59B	-0.67	-11.56	-0.42	3.5e-28	Gut microbiome composition (summer);
BRCA	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg05868516	chr6:26286170	HIST1H4H	0.42	8.17	0.31	1.6e-15	Educational attainment;
BRCA	cis	rs9296092	0.517	rs56069946	chr6:33511136	G/A	cg13560919	chr6:33536144	NA	-0.86	-16.21	-0.54	9.71e-50	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs6910061	0.957	rs58680949	chr6:11103062	G/C	cg27233058	chr6:11094804	LOC221710	0.52	9.32	0.35	1.82e-19	Diabetic kidney disease;
BRCA	cis	rs586533	0.846	rs687007	chr11:99511801	A/G	cg22878054	chr11:99397252	CNTN5	0.31	7.88	0.3	1.44e-14	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg01620082	chr3:125678407	NA	-0.69	-8.59	-0.32	6.67e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.57	-10.18	-0.37	1.13e-22	Gut microbiome composition (summer);
BRCA	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.57	8.41	0.32	2.63e-16	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24531977	chr5:56204891	C5orf35	0.67	14.6	0.5	7.34e-42	Initial pursuit acceleration;
BRCA	cis	rs9341808	0.690	rs9343970	chr6:80881289	C/G	cg08355045	chr6:80787529	NA	0.38	9.71	0.36	7.25e-21	Sitting height ratio;
BRCA	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	8.63	0.32	4.98e-17	Personality dimensions;
BRCA	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg20573242	chr4:122745356	CCNA2	0.43	9.92	0.37	1.18e-21	Type 2 diabetes;
BRCA	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10802521	chr3:52805072	NEK4	-0.3	-8.0	-0.3	5.78e-15	Electroencephalogram traits;
BRCA	trans	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.23	0.31	1.06e-15	Mean corpuscular volume;
BRCA	cis	rs4845875	0.530	rs4846048	chr1:11846252	A/G	cg24844545	chr1:11908347	NPPA	-0.36	-8.58	-0.32	7.06e-17	Midregional pro atrial natriuretic peptide levels;
BRCA	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg15704280	chr7:45808275	SEPT13	0.63	11.24	0.41	6.97e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.82	18.86	0.6	2.17e-63	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.23	-0.31	1.06e-15	Bipolar disorder;
BRCA	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.07	-0.3	3.48e-15	Prostate cancer;
BRCA	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg02551604	chr5:131831745	NA	-0.4	-14.94	-0.51	1.6e-43	Asthma (sex interaction);
BRCA	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg24130564	chr14:104152367	KLC1	-0.34	-7.92	-0.3	1.02e-14	Body mass index;
BRCA	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-16.12	-0.54	2.63e-49	Extrinsic epigenetic age acceleration;
BRCA	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.31	-8.04	-0.3	4.32e-15	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg20503657	chr10:835505	NA	1.3	21.17	0.64	8.88e-76	Eosinophil percentage of granulocytes;
BRCA	cis	rs10045504	0.502	rs10512692	chr5:38762993	G/A	cg15396434	chr5:38725168	NA	-0.53	-10.19	-0.37	1.09e-22	Night sleep phenotypes;
BRCA	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg25110126	chr1:46999211	NA	0.72	13.57	0.47	4.84e-37	Monobrow;
BRCA	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg12219531	chr12:120966889	COQ5	0.56	11.7	0.42	8.42e-29	High light scatter reticulocyte count;
BRCA	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	ch.11.42038R	chr11:967971	AP2A2	0.46	13.79	0.48	4.83e-38	Alzheimer's disease (late onset);
BRCA	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg26061582	chr7:22766209	IL6	0.42	9.44	0.35	6.71e-20	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
BRCA	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg12641515	chr19:46296257	DMWD	0.69	16.87	0.56	4.48e-53	Coronary artery disease;
BRCA	cis	rs6460942	0.597	rs17545416	chr7:12525944	A/T	cg06484146	chr7:12443880	VWDE	-0.6	-7.85	-0.3	1.8e-14	Coronary artery disease;
BRCA	cis	rs4919087	1.000	rs10882898	chr10:99087330	G/A	cg25902810	chr10:99078978	FRAT1	-0.45	-9.37	-0.35	1.2e-19	Monocyte count;
BRCA	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18876405	chr7:65276391	NA	-0.55	-13.3	-0.47	8.39e-36	Aortic root size;
BRCA	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00149659	chr3:10157352	C3orf10	0.76	12.99	0.46	2.1e-34	Alzheimer's disease;
BRCA	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg19678392	chr7:94953810	PON1	-0.42	-8.58	-0.32	7.29e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6815814	0.950	rs5743595	chr4:38802644	A/G	cg02016764	chr4:38805732	TLR1	-0.63	-10.03	-0.37	4.28e-22	Breast cancer;
BRCA	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg17749961	chr2:30669863	LCLAT1	1.12	14.83	0.51	5.9e-43	Midgestational circulating levels of PBDEs (fetal genetic effect);
BRCA	cis	rs701145	0.938	rs355776	chr3:154035626	A/T	cg17054900	chr3:154042577	DHX36	0.68	11.88	0.43	1.56e-29	Coronary artery disease;
BRCA	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg17366294	chr4:99064904	C4orf37	0.47	8.16	0.31	1.79e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7246657	0.722	rs10409605	chr19:38123137	T/G	cg14683738	chr19:37701593	ZNF585B	0.47	8.11	0.31	2.51e-15	Coronary artery calcification;
BRCA	cis	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg06521331	chr12:34319734	NA	0.53	9.81	0.36	2.93e-21	Morning vs. evening chronotype;
BRCA	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.99	-0.46	2.13e-34	Facial morphology (factor 17, height of vermillion upper lip);
BRCA	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg21385522	chr1:16154831	NA	-0.85	-15.3	-0.52	3.03e-45	Dilated cardiomyopathy;
BRCA	cis	rs78487399	0.908	rs76765584	chr2:43808034	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-7.9	-0.3	1.22e-14	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18876405	chr7:65276391	NA	-0.5	-11.04	-0.4	4.74e-26	Aortic root size;
BRCA	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15541040	chr2:3486749	NA	-0.46	-10.23	-0.38	7.58e-23	Neurofibrillary tangles;
BRCA	trans	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg17675199	chr6:35436792	RPL10A	-0.3	-7.92	-0.3	1.05e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg14683738	chr19:37701593	ZNF585B	0.45	8.02	0.3	4.94e-15	Coronary artery calcification;
BRCA	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg11266682	chr4:10021025	SLC2A9	0.47	12.68	0.45	5e-33	Bone mineral density;
BRCA	cis	rs9462027	0.628	rs2764197	chr6:34705055	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.87	-0.3	1.55e-14	Systemic lupus erythematosus;
BRCA	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-8.76	-0.33	1.71e-17	Response to antipsychotic treatment;
BRCA	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg23711669	chr6:146136114	FBXO30	0.69	16.02	0.54	8.15e-49	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg00666640	chr1:248458726	OR2T12	0.34	9.09	0.34	1.23e-18	Common traits (Other);
BRCA	cis	rs911119	1.000	rs3088162	chr20:23607752	C/A	cg16589663	chr20:23618590	CST3	0.46	8.91	0.33	5.45e-18	Chronic kidney disease;
BRCA	cis	rs17092148	0.945	rs6060042	chr20:33361721	A/G	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.3	-0.41	4.05e-27	Neuroticism;
BRCA	cis	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg06521331	chr12:34319734	NA	-0.63	-12.2	-0.43	6.34e-31	Morning vs. evening chronotype;
BRCA	cis	rs847577	0.575	rs41278842	chr7:97815999	A/G	cg24562669	chr7:97807699	LMTK2	-0.49	-13.0	-0.46	1.94e-34	Breast cancer;
BRCA	cis	rs312274	0.569	rs10879356	chr12:41312365	A/T	cg17827154	chr12:41323612	CNTN1	-0.42	-10.63	-0.39	2.04e-24	Metabolite levels  (X-11787);
BRCA	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06221963	chr1:154839813	KCNN3	-0.57	-16.22	-0.54	8.16e-50	Prostate cancer;
BRCA	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.42	-9.13	-0.34	8.69e-19	Longevity;Endometriosis;
BRCA	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg27535305	chr1:53392650	SCP2	0.49	11.32	0.41	3.5e-27	Monocyte count;
BRCA	cis	rs9612	0.948	rs12609056	chr19:44258702	G/T	cg08581076	chr19:44259116	C19orf61	0.53	9.34	0.35	1.59e-19	Exhaled nitric oxide output;
BRCA	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg06917634	chr15:78832804	PSMA4	0.76	17.82	0.58	5.48e-58	Sudden cardiac arrest;
BRCA	cis	rs9392556	0.829	rs634698	chr6:4114247	T/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.38	-8.13	-0.31	2.28e-15	Blood metabolite levels;
BRCA	cis	rs4363385	0.818	rs2651413	chr1:153012068	T/A	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg05340658	chr4:99064831	C4orf37	0.61	14.67	0.5	3.23e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs220324	0.688	rs9980786	chr21:43562535	C/T	cg09727148	chr21:43560719	UMODL1	0.48	8.4	0.32	2.81e-16	Idiopathic osteonecrosis of the femoral head;
BRCA	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07343612	chr16:622815	PIGQ	-0.65	-21.24	-0.64	3.63e-76	Height;
BRCA	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03517284	chr6:25882590	NA	-0.37	-7.89	-0.3	1.35e-14	Intelligence (multi-trait analysis);
BRCA	trans	rs3960554	0.808	rs61303167	chr7:75671175	G/T	cg19862616	chr7:65841803	NCRNA00174	0.59	12.53	0.44	2.26e-32	Eotaxin levels;
BRCA	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg10523679	chr1:76189770	ACADM	-0.48	-9.2	-0.34	5.21e-19	Daytime sleep phenotypes;
BRCA	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg00105475	chr2:10696890	NA	0.44	10.21	0.37	9.03e-23	Prostate cancer;
BRCA	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg04362960	chr10:104952993	NT5C2	-0.92	-14.57	-0.5	9.68e-42	Arsenic metabolism;
BRCA	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg00105475	chr2:10696890	NA	-0.45	-10.4	-0.38	1.61e-23	Prostate cancer;
BRCA	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg05340658	chr4:99064831	C4orf37	0.61	14.49	0.5	2.44e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs59724122	0.542	rs28633173	chr8:27446980	A/G	cg01579299	chr8:27450062	NA	0.47	8.91	0.33	5.46e-18	Bipolar disorder lithium response (categorical) or schizophrenia;
BRCA	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg00383909	chr3:49044727	WDR6	0.53	9.44	0.35	6.62e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg26384229	chr12:38710491	ALG10B	0.44	10.09	0.37	2.68e-22	Heart rate;
BRCA	cis	rs1113500	0.897	rs11185263	chr1:108639804	C/G	cg06207961	chr1:108661230	NA	0.43	11.02	0.4	5.69e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg14458575	chr2:238380390	NA	0.75	16.29	0.54	3.59e-50	Prostate cancer;
BRCA	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs757081	0.702	rs522619	chr11:17204448	A/G	cg15432903	chr11:17409602	KCNJ11	-0.45	-8.51	-0.32	1.23e-16	Systolic blood pressure;
BRCA	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.55	-0.39	4.16e-24	Mean corpuscular volume;
BRCA	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg22676075	chr6:135203613	NA	0.44	8.7	0.33	2.91e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	8.27	0.31	7.99e-16	Mean platelet volume;
BRCA	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg20701182	chr2:24300061	SF3B14	0.58	9.05	0.34	1.73e-18	Lymphocyte counts;
BRCA	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	15.12	0.51	2.22e-44	Colorectal cancer;
BRCA	cis	rs6545883	0.929	rs6705235	chr2:61713580	G/C	cg15711740	chr2:61764176	XPO1	-0.55	-14.0	-0.48	5.14e-39	Tuberculosis;
BRCA	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg03146154	chr1:46216737	IPP	0.49	10.66	0.39	1.61e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg10224037	chr5:178157518	ZNF354A	0.75	15.63	0.53	7.51e-47	Neutrophil percentage of white cells;
BRCA	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg01689657	chr7:91764605	CYP51A1	0.21	7.83	0.3	2.04e-14	Breast cancer;
BRCA	cis	rs7737355	0.947	rs42264	chr5:130810028	T/G	cg06307176	chr5:131281290	NA	0.53	10.41	0.38	1.45e-23	Life satisfaction;
BRCA	cis	rs1568889	1.000	rs1568889	chr11:28009463	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	13.23	0.46	1.69e-35	Bipolar disorder;
BRCA	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg03188948	chr7:1209495	NA	0.61	12.08	0.43	2e-30	Longevity;Endometriosis;
BRCA	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18402987	chr7:1209562	NA	0.64	13.99	0.48	5.5e-39	Longevity;Endometriosis;
BRCA	cis	rs586533	0.881	rs611253	chr11:99505250	A/G	cg22878054	chr11:99397252	CNTN5	0.32	8.12	0.31	2.44e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg12483005	chr1:23474871	LUZP1	0.46	10.22	0.37	8.4e-23	Height;
BRCA	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg17420585	chr12:42539391	GXYLT1	-0.38	-7.96	-0.3	8.03e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg21573476	chr21:45109991	RRP1B	-0.4	-10.48	-0.38	7.94e-24	Mean corpuscular volume;
BRCA	cis	rs7586879	1.000	rs7603153	chr2:25116966	T/C	cg04586622	chr2:25135609	ADCY3	0.4	9.4	0.35	9.69e-20	Body mass index;
BRCA	trans	rs6600671	1.000	rs11249350	chr1:121178446	C/T	cg17023122	chr1:144479586	NA	0.33	7.85	0.3	1.71e-14	Hip geometry;
BRCA	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg05283184	chr6:79620031	NA	0.34	8.51	0.32	1.2e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg24562669	chr7:97807699	LMTK2	0.47	12.78	0.45	1.9e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg18225595	chr11:63971243	STIP1	0.5	8.89	0.33	6.02e-18	Mean platelet volume;
BRCA	cis	rs4363385	0.747	rs2339491	chr1:152985322	T/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.29	-0.31	6.7e-16	Inflammatory skin disease;
BRCA	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg17136484	chr7:158649327	WDR60	0.38	8.13	0.31	2.29e-15	Height;
BRCA	cis	rs1669338	0.588	rs3931974	chr3:3186894	A/G	cg16797762	chr3:3221439	CRBN	0.55	8.65	0.32	4.02e-17	White matter integrity;
BRCA	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg00012203	chr2:219082015	ARPC2	-0.51	-10.46	-0.38	9.84e-24	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.65	16.6	0.55	9.95e-52	Colorectal cancer;
BRCA	cis	rs6908034	0.660	rs12525506	chr6:19794234	G/T	cg02682789	chr6:19804855	NA	0.76	9.23	0.34	4.06e-19	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
BRCA	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.81	0.55	8.35e-53	Axial length;
BRCA	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg04362960	chr10:104952993	NT5C2	0.45	10.43	0.38	1.31e-23	Arsenic metabolism;
BRCA	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.82	0.39	3.53e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg04851639	chr8:1020857	NA	-0.35	-9.53	-0.35	3.3e-20	Schizophrenia;
BRCA	cis	rs7395581	0.918	rs326214	chr11:47298360	G/A	cg25783544	chr11:47291846	MADD	-0.39	-8.78	-0.33	1.48e-17	HDL cholesterol;
BRCA	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.81e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg23978390	chr7:1156363	C7orf50	0.41	8.07	0.3	3.52e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg04025307	chr7:1156635	C7orf50	0.58	9.14	0.34	8.42e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12292205	chr6:26970375	C6orf41	-0.48	-8.07	-0.3	3.56e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25427524	chr10:38739819	LOC399744	-0.66	-16.24	-0.54	6.88e-50	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17767294	0.708	rs79956881	chr6:28030150	T/C	cg08851530	chr6:28072375	NA	1.18	10.76	0.39	6.47e-25	Parkinson's disease;
BRCA	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg08601574	chr20:25228251	PYGB	0.42	9.84	0.36	2.31e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg08132940	chr7:1081526	C7orf50	-0.53	-8.29	-0.31	6.8e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6594499	0.843	rs1993465	chr5:110433098	A/G	cg04022379	chr5:110408740	TSLP	0.35	7.88	0.3	1.44e-14	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg03894339	chr8:19674705	INTS10	0.43	8.21	0.31	1.18e-15	Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs11165623	0.564	rs12752866	chr1:97000181	T/C	cg10631902	chr5:14652156	NA	-0.43	-12.14	-0.43	1.11e-30	Hip circumference;Waist circumference;
BRCA	cis	rs1267303	0.537	rs59935547	chr1:47001423	A/G	cg25110126	chr1:46999211	NA	0.56	10.72	0.39	9.03e-25	Monobrow;
BRCA	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg17366294	chr4:99064904	C4orf37	0.45	10.74	0.39	7.86e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg18230493	chr5:56204884	C5orf35	-0.62	-13.19	-0.46	2.68e-35	Initial pursuit acceleration;
BRCA	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg02734326	chr4:10020555	SLC2A9	0.36	7.81	0.3	2.37e-14	Bone mineral density;
BRCA	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg11814155	chr7:99998594	ZCWPW1	0.43	8.1	0.31	2.75e-15	Platelet count;
BRCA	trans	rs6011368	0.840	rs6062361	chr20:62904542	C/T	cg13869341	chr1:15865	WASH5P	-0.41	-9.31	-0.35	2.09e-19	Clozapine-induced cytotoxicity;
BRCA	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg24596788	chr1:163392923	NA	-0.34	-8.97	-0.33	3.26e-18	Motion sickness;
BRCA	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg05340658	chr4:99064831	C4orf37	0.63	15.01	0.51	7.95e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg08213375	chr14:104286397	PPP1R13B	0.64	18.3	0.59	1.85e-60	Schizophrenia;
BRCA	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.71	-0.33	2.6e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs912057	0.932	rs1294404	chr6:6735022	G/A	cg06612196	chr6:6737390	NA	0.46	9.94	0.37	9.34e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg15017067	chr4:17643749	FAM184B	0.34	10.56	0.39	3.74e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7572733	0.534	rs4550664	chr2:198691405	C/T	cg00792783	chr2:198669748	PLCL1	0.47	10.14	0.37	1.65e-22	Dermatomyositis;
BRCA	cis	rs6840360	0.533	rs1397683	chr4:152715916	T/C	cg22705602	chr4:152727874	NA	0.4	10.58	0.39	3.36e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs4631830	0.863	rs57263518	chr10:51519154	A/G	cg20129853	chr10:51489980	NA	-0.29	-7.93	-0.3	1.01e-14	Prostate-specific antigen levels;
BRCA	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.41	10.55	0.39	4.26e-24	IgG glycosylation;
BRCA	cis	rs2880765	0.714	rs6497187	chr15:86011350	A/G	cg10818794	chr15:86012489	AKAP13	-0.31	-8.39	-0.31	3.16e-16	Coronary artery disease;
BRCA	cis	rs4919087	0.962	rs3740522	chr10:99019144	C/T	cg25902810	chr10:99078978	FRAT1	0.44	9.23	0.34	3.76e-19	Monocyte count;
BRCA	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg08508325	chr11:3079039	CARS	0.29	8.98	0.33	2.93e-18	Calcium levels;
BRCA	cis	rs990171	0.506	rs2041748	chr2:102756295	A/G	cg22835712	chr2:102737379	NA	0.6	11.3	0.41	3.97e-27	Lymphocyte counts;
BRCA	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg06108461	chr20:60628389	TAF4	-0.64	-13.18	-0.46	2.7900000000000003e-35	Body mass index;
BRCA	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11644478	chr21:40555479	PSMG1	0.5	10.74	0.39	7.39e-25	Menarche (age at onset);
BRCA	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08280861	chr8:58055591	NA	0.53	8.59	0.32	6.62e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg15017067	chr4:17643749	FAM184B	0.32	9.79	0.36	3.53e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg23708337	chr7:1209742	NA	0.6	8.31	0.31	5.89e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg17366294	chr4:99064904	C4orf37	0.42	9.92	0.37	1.13e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg08601574	chr20:25228251	PYGB	0.34	8.15	0.31	1.86e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02187348	chr16:89574699	SPG7	0.5	11.97	0.43	6.11e-30	Multiple myeloma (IgH translocation);
BRCA	trans	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.95	0.3	8.6e-15	Corneal astigmatism;
BRCA	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg26168224	chr5:2018326	NA	0.63	17.48	0.57	3.28e-56	Gut microbiome composition (winter);
BRCA	cis	rs34779708	0.733	rs3853672	chr10:35549606	A/C	cg03585969	chr10:35415529	CREM	0.43	8.64	0.32	4.64e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.37	0.35	1.18e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg06521331	chr12:34319734	NA	-0.62	-11.15	-0.4	1.68e-26	Morning vs. evening chronotype;
BRCA	cis	rs9296092	0.538	rs9461875	chr6:33516644	C/T	cg13560919	chr6:33536144	NA	-0.83	-16.87	-0.56	4.55e-53	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg12935359	chr14:103987150	CKB	0.64	15.0	0.51	8.63e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.63	13.66	0.48	1.83e-37	Lymphocyte percentage of white cells;
BRCA	trans	rs208520	0.837	rs208498	chr6:66931560	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.81	-15.18	-0.51	1.12e-44	Exhaled nitric oxide output;
BRCA	cis	rs6834538	0.597	rs9307383	chr4:113529834	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.42	9.75	0.36	4.99e-21	Free thyroxine concentration;
BRCA	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg01483505	chr11:975446	AP2A2	0.31	8.3	0.31	6.1e-16	Alzheimer's disease (late onset);
BRCA	cis	rs74181299	0.819	rs2252867	chr2:65296280	T/C	cg05010058	chr2:65284262	CEP68	0.3	8.35	0.31	4.15e-16	Pulse pressure;
BRCA	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13095912	1.000	rs13072061	chr3:185326023	G/T	cg11274856	chr3:185301563	NA	0.34	8.56	0.32	8.33e-17	Systolic blood pressure;
BRCA	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.36	0.38	2.39e-23	Motion sickness;
BRCA	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg17127132	chr2:85788382	GGCX	0.35	8.0	0.3	5.72e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg13010199	chr12:38710504	ALG10B	-0.37	-8.41	-0.32	2.59e-16	Morning vs. evening chronotype;
BRCA	cis	rs7149337	1.000	rs4261445	chr14:51723540	G/A	cg23942311	chr14:51606299	NA	0.36	9.76	0.36	4.47e-21	Cancer;
BRCA	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg04117972	chr1:227635322	NA	0.52	9.21	0.34	4.5e-19	Major depressive disorder;
BRCA	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg20290983	chr6:43655470	MRPS18A	1.06	35.82	0.82	5.79e-155	IgG glycosylation;
BRCA	cis	rs4664304	0.658	rs2667008	chr2:160865095	C/T	cg14819504	chr2:160761413	LY75	-0.33	-8.08	-0.3	3.25e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.49	-0.32	1.47e-16	Total body bone mineral density;
BRCA	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-18.12	-0.58	1.55e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg07636037	chr3:49044803	WDR6	0.99	29.87	0.76	2.35e-123	Parkinson's disease;
BRCA	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg26608667	chr7:1196370	ZFAND2A	0.44	10.69	0.39	1.17e-24	Longevity;Endometriosis;
BRCA	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg08885076	chr2:99613938	TSGA10	0.42	9.88	0.36	1.61e-21	Chronic sinus infection;
BRCA	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-8.81	-0.33	1.15e-17	Monocyte percentage of white cells;
BRCA	cis	rs7020830	0.830	rs12554976	chr9:37244505	G/T	cg14294708	chr9:37120828	ZCCHC7	1.13	36.23	0.82	4.69e-157	Schizophrenia;
BRCA	cis	rs6433895	1.000	rs7592486	chr2:182013263	A/G	cg00481216	chr2:181971175	NA	0.37	8.72	0.33	2.49e-17	Lymphocyte counts;
BRCA	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg18904891	chr8:8559673	CLDN23	0.64	12.54	0.44	2.06e-32	Obesity-related traits;
BRCA	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg25358565	chr5:93447407	FAM172A	1.17	18.19	0.58	6.98e-60	Diabetic retinopathy;
BRCA	trans	rs9409565	0.826	rs9409767	chr9:97228524	T/C	cg05679027	chr9:99775184	HIATL2	-0.43	-9.59	-0.35	1.8899999999999998e-20	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg21918786	chr6:109611834	NA	-0.49	-13.85	-0.48	2.47e-38	Reticulocyte fraction of red cells;
BRCA	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg09307838	chr4:120376055	NA	0.75	16.17	0.54	1.48e-49	Corneal astigmatism;
BRCA	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.78	21.34	0.65	1.05e-76	Multiple sclerosis;
BRCA	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg04546413	chr19:29218101	NA	0.64	12.28	0.44	2.81e-31	Methadone dose in opioid dependence;
BRCA	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg09658497	chr7:2847517	GNA12	-0.4	-8.54	-0.32	1.01e-16	Height;
BRCA	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg11812906	chr14:75593930	NEK9	0.66	15.33	0.52	2.05e-45	Height;
BRCA	trans	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.62	-0.36	1.55e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs250677	0.522	rs6872172	chr5:148359529	G/C	cg18129178	chr5:148520854	ABLIM3	0.54	10.41	0.38	1.57e-23	Breast cancer;
BRCA	cis	rs870825	0.616	rs6825561	chr4:185615532	A/T	cg04058563	chr4:185651563	MLF1IP	0.78	17.17	0.56	1.32e-54	Blood protein levels;
BRCA	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg12483005	chr1:23474871	LUZP1	0.47	10.36	0.38	2.36e-23	Height;
BRCA	cis	rs12579753	0.917	rs10862375	chr12:82254809	C/G	cg07988820	chr12:82153109	PPFIA2	0.49	8.3	0.31	6.04e-16	Resting heart rate;
BRCA	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg12698349	chr2:225449008	CUL3	0.75	17.89	0.58	2.44e-58	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg23711669	chr6:146136114	FBXO30	0.66	15.61	0.53	9.32e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg03264133	chr6:25882463	NA	-0.34	-7.86	-0.3	1.61e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.05	15.93	0.53	2.27e-48	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg24558204	chr6:135376177	HBS1L	0.49	13.38	0.47	3.61e-36	Red blood cell count;
BRCA	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg04727924	chr7:799746	HEATR2	-0.53	-9.88	-0.36	1.6e-21	Cerebrospinal P-tau181p levels;
BRCA	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg00717180	chr2:96193071	NA	-0.4	-11.13	-0.4	2.1e-26	HDL cholesterol;
BRCA	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg13852791	chr20:30311386	BCL2L1	0.87	19.45	0.61	1.48e-66	Mean corpuscular hemoglobin;
BRCA	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-14.16	-0.49	8.73e-40	Migraine;Coronary artery disease;
BRCA	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21545522	chr1:205238299	TMCC2	0.37	8.24	0.31	9.57e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26314531	chr2:26401878	FAM59B	0.88	15.47	0.52	4.57e-46	Gut microbiome composition (summer);
BRCA	cis	rs4711336	1.000	rs4711337	chr6:33659987	T/C	cg14003231	chr6:33640908	ITPR3	0.32	7.88	0.3	1.41e-14	Height;
BRCA	cis	rs9649465	0.934	rs718781	chr7:123313573	T/C	cg04330084	chr7:123175371	IQUB	-0.3	-8.34	-0.31	4.53e-16	Migraine;
BRCA	cis	rs5753618	0.504	rs5753659	chr22:31893613	A/G	cg02404636	chr22:31891804	SFI1	0.43	8.81	0.33	1.21e-17	Colorectal cancer;
BRCA	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.55	-12.35	-0.44	1.44e-31	Longevity;Endometriosis;
BRCA	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg15997130	chr1:24165203	NA	0.49	12.86	0.45	7.62e-34	Immature fraction of reticulocytes;
BRCA	trans	rs2262909	1.000	rs2359821	chr19:22208314	C/T	cg17074339	chr11:11642133	GALNTL4	-0.41	-7.86	-0.3	1.64e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.27	0.34	2.88e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9359856	0.510	rs4053618	chr6:90459454	G/A	cg13799429	chr6:90582589	CASP8AP2	0.72	10.96	0.4	9.94e-26	Bipolar disorder;
BRCA	cis	rs4953076	0.533	rs1551315	chr2:44407618	G/A	cg04920474	chr2:44395004	PPM1B	0.51	10.57	0.39	3.42e-24	Height;
BRCA	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg13334819	chr7:99746414	C7orf59	-0.42	-9.93	-0.37	1.08e-21	Coronary artery disease;
BRCA	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg02734326	chr4:10020555	SLC2A9	0.38	8.31	0.31	5.94e-16	Bone mineral density;
BRCA	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg15212455	chr7:39170539	POU6F2	0.45	9.94	0.37	9.44e-22	IgG glycosylation;
BRCA	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.52	11.43	0.41	1.16e-27	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg08085267	chr17:45401833	C17orf57	-0.59	-12.19	-0.43	7.29e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg08807101	chr21:30365312	RNF160	-0.46	-8.15	-0.31	1.85e-15	Cognitive test performance;
BRCA	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24549020	chr5:56110836	MAP3K1	0.65	13.23	0.46	1.79e-35	Initial pursuit acceleration;
BRCA	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.33	0.49	1.33e-40	Colorectal cancer;
BRCA	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg06623918	chr6:96969491	KIAA0776	0.74	13.11	0.46	5.89e-35	Migraine;Coronary artery disease;
BRCA	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg22009923	chr11:832065	CD151	-0.48	-10.32	-0.38	3.37e-23	Mean platelet volume;
BRCA	cis	rs4363385	0.747	rs9919276	chr1:152968654	A/T	cg24667326	chr1:152973720	SPRR3	-0.33	-8.98	-0.33	3.03e-18	Inflammatory skin disease;
BRCA	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg05283184	chr6:79620031	NA	-0.4	-10.25	-0.38	6.42e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4285028	0.898	rs4305455	chr3:121619774	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.62	-11.28	-0.41	4.74e-27	Multiple sclerosis;
BRCA	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg03477792	chr4:77819574	ANKRD56	0.66	15.67	0.53	4.35e-47	Emphysema distribution in smoking;
BRCA	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg02038168	chr22:39784481	NA	-0.42	-8.73	-0.33	2.24e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs34891900	0.507	rs5992088	chr22:18135912	C/T	cg19898043	chr22:18121309	BCL2L13	-0.43	-8.36	-0.31	3.9e-16	Sum neutrophil eosinophil counts;
BRCA	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg11789530	chr4:8429930	ACOX3	0.69	18.11	0.58	1.73e-59	Response to antineoplastic agents;
BRCA	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.02	-0.49	3.77e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg25036284	chr2:26402008	FAM59B	0.88	15.06	0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs921968	0.528	rs35695178	chr2:219589164	C/T	cg02176678	chr2:219576539	TTLL4	-0.4	-10.97	-0.4	9.26e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg01802117	chr1:53393560	SCP2	0.36	8.48	0.32	1.54e-16	Monocyte count;
BRCA	cis	rs2422052	0.527	rs12466517	chr2:118830391	C/A	cg22545206	chr2:118617499	NA	-0.33	-8.01	-0.3	5.3e-15	Mosquito bite size;
BRCA	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.59	-12.31	-0.44	2.07e-31	Lymphocyte counts;
BRCA	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg20887711	chr4:1340912	KIAA1530	0.4	8.82	0.33	1.05e-17	Obesity-related traits;
BRCA	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-11.33	-0.41	3.05e-27	Multiple sclerosis;Ankylosing spondylitis;
BRCA	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg20476274	chr7:133979776	SLC35B4	0.67	19.69	0.61	8.42e-68	Mean platelet volume;
BRCA	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg02659138	chr7:134003124	SLC35B4	0.32	10.0	0.37	5.94e-22	Mean platelet volume;
BRCA	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-12.63	-0.45	8.57e-33	Response to antipsychotic treatment;
BRCA	trans	rs961253	0.501	rs6054183	chr20:6354161	T/C	cg21095983	chr6:86352623	SYNCRIP	0.39	7.97	0.3	7.23e-15	Colorectal cancer;
BRCA	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	14.05	0.49	2.93e-39	Lymphocyte counts;
BRCA	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg12011299	chr4:100065546	ADH4	0.45	10.43	0.38	1.22e-23	Alcohol dependence;
BRCA	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg24130564	chr14:104152367	KLC1	-0.39	-8.8	-0.33	1.28e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg17330251	chr7:94953956	PON1	-0.4	-8.3	-0.31	6.29e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs11051970	0.879	rs2088806	chr12:32592125	C/T	cg02745156	chr12:32552066	NA	0.27	8.87	0.33	7.3e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	trans	rs629535	0.911	rs627382	chr8:70014081	C/T	cg21567404	chr3:27674614	NA	-0.98	-20.59	-0.63	1.24e-72	Dupuytren's disease;
BRCA	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg08847533	chr14:75593920	NEK9	-0.78	-18.54	-0.59	9.57e-62	Height;
BRCA	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.35	-0.41	2.61e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg25486957	chr4:152246857	NA	-0.36	-7.95	-0.3	8.18e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg06784218	chr1:46089804	CCDC17	-0.48	-11.48	-0.41	7.5e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11051970	0.879	rs2243815	chr12:32576158	C/T	cg02745156	chr12:32552066	NA	0.27	8.99	0.33	2.86e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg07080220	chr10:102295463	HIF1AN	0.6	13.95	0.48	8.71e-39	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	8.41	0.32	2.62e-16	Tonsillectomy;
BRCA	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg06494592	chr3:125709126	NA	-0.53	-8.31	-0.31	5.63e-16	Blood pressure (smoking interaction);
BRCA	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg06636001	chr8:8085503	FLJ10661	0.69	16.69	0.55	3.49e-52	Mood instability;
BRCA	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.74	0.67	2.6e-84	Chronic sinus infection;
BRCA	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.65	17.01	0.56	8.71e-54	Hypertriglyceridemia;
BRCA	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	trans	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	9.32	0.35	1.92e-19	Mean corpuscular volume;
BRCA	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-12.35	-0.44	1.44e-31	Gut microbiome composition (summer);
BRCA	trans	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg02030672	chr11:45687055	CHST1	-0.41	-9.29	-0.34	2.48e-19	Obesity-related traits;
BRCA	cis	rs3936840	0.548	rs1190545	chr14:102904179	G/C	cg18135206	chr14:102964638	TECPR2	-0.47	-9.27	-0.34	2.76e-19	Plateletcrit;
BRCA	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg01028140	chr2:1542097	TPO	-0.57	-11.62	-0.42	1.89e-28	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg00106254	chr7:1943704	MAD1L1	0.38	10.31	0.38	3.81e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs1003719	0.680	rs2835668	chr21:38580151	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.51	-0.5	1.83e-41	Eye color traits;
BRCA	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.23	-0.54	7.7e-50	Alzheimer's disease (late onset);
BRCA	cis	rs2637266	1.000	rs2395410	chr10:78381767	C/T	cg18941641	chr10:78392320	NA	0.35	7.84	0.3	1.85e-14	Pulmonary function;
BRCA	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	10.75	0.39	7.11e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg06784218	chr1:46089804	CCDC17	0.51	12.25	0.44	3.85e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21582582	chr3:182698605	DCUN1D1	0.36	9.52	0.35	3.53e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs250677	0.524	rs250665	chr5:148454394	A/C	cg12140854	chr5:148520817	ABLIM3	-0.37	-8.41	-0.32	2.6e-16	Breast cancer;
BRCA	cis	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg07460842	chr6:66804631	NA	-0.97	-19.12	-0.6	8.49e-65	Exhaled nitric oxide output;
BRCA	cis	rs9790314	0.663	rs7630674	chr3:160813597	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-10.73	-0.39	8.47e-25	Morning vs. evening chronotype;
BRCA	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg09904177	chr6:26538194	HMGN4	0.47	15.0	0.51	8.32e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg22535103	chr8:58192502	C8orf71	-0.49	-9.53	-0.35	3.18e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg12573674	chr2:1569213	NA	-0.47	-9.26	-0.34	3.18e-19	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.0	23.01	0.67	8.16e-86	Lymphocyte percentage of white cells;
BRCA	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg04362960	chr10:104952993	NT5C2	0.48	10.1	0.37	2.46e-22	Arsenic metabolism;
BRCA	cis	rs73242632	1.000	rs3775083	chr4:57868186	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	0.69	8.27	0.31	8.02e-16	Congenital heart disease (maternal effect);
BRCA	cis	rs6694270	0.913	rs11261069	chr1:19117300	C/G	cg26220594	chr1:19110978	NA	-0.43	-8.31	-0.31	5.65e-16	Drug-induced liver injury (nitrofurantoin);
BRCA	cis	rs6120849	0.754	rs6120819	chr20:33653038	T/C	cg24642439	chr20:33292090	TP53INP2	0.59	10.03	0.37	4.23e-22	Protein C levels;
BRCA	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg16576597	chr16:28551801	NUPR1	0.27	7.88	0.3	1.42e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	12.32	0.44	2e-31	Lung cancer in ever smokers;
BRCA	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg11833968	chr6:79620685	NA	-0.45	-9.83	-0.36	2.46e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg17830980	chr10:43048298	ZNF37B	-0.54	-13.02	-0.46	1.52e-34	Extrinsic epigenetic age acceleration;
BRCA	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-10.06	-0.37	3.2800000000000002e-22	Retinal vascular caliber;
BRCA	cis	rs858239	0.601	rs764533	chr7:23153875	C/T	cg23682824	chr7:23144976	KLHL7	0.42	10.79	0.39	4.58e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7301826	1.000	rs4759787	chr12:131290180	A/C	cg11011512	chr12:131303247	STX2	0.42	10.83	0.39	3.21e-25	Plasma plasminogen activator levels;
BRCA	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg04315214	chr1:2043799	PRKCZ	-0.48	-12.73	-0.45	3.12e-33	Height;
BRCA	cis	rs6120849	0.754	rs6120813	chr20:33642112	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	10.31	0.38	3.78e-23	Protein C levels;
BRCA	cis	rs3824867	0.920	rs80241400	chr11:47453828	T/C	cg20307385	chr11:47447363	PSMC3	-0.51	-11.43	-0.41	1.22e-27	Mean corpuscular hemoglobin;
BRCA	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg01528321	chr10:82214614	TSPAN14	0.62	13.83	0.48	3.07e-38	Post bronchodilator FEV1;
BRCA	cis	rs849141	0.890	rs860263	chr7:28182346	A/G	cg22892036	chr7:28189139	JAZF1	0.47	8.4	0.32	2.84e-16	Height;Hip circumference adjusted for BMI;
BRCA	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg22875332	chr1:76189707	ACADM	0.61	11.56	0.42	3.21e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs922182	0.617	rs13329183	chr15:64240809	A/G	cg24729988	chr15:64271149	DAPK2	0.49	10.65	0.39	1.69e-24	Blood protein levels;
BRCA	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg19920283	chr7:105172520	RINT1	0.59	9.4	0.35	9.51e-20	Bipolar disorder (body mass index interaction);
BRCA	trans	rs1997103	1.000	rs6976824	chr7:55396115	A/C	cg20935933	chr6:143382018	AIG1	0.58	10.91	0.4	1.57e-25	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg09555818	chr19:45449301	APOC2	0.47	12.21	0.43	5.76e-31	Blood protein levels;
BRCA	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg08132940	chr7:1081526	C7orf50	-0.54	-8.41	-0.32	2.68e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3772130	0.583	rs12695415	chr3:121398853	C/T	cg20356878	chr3:121714668	ILDR1	0.38	8.6	0.32	6.17e-17	Cognitive performance;
BRCA	cis	rs586533	0.881	rs638688	chr11:99504511	A/T	cg22878054	chr11:99397252	CNTN5	0.32	8.12	0.31	2.44e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19346786	chr7:2764209	NA	-0.31	-9.05	-0.34	1.67e-18	Height;
BRCA	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	14.13	0.49	1.18e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.56	0.35	2.42e-20	Morning vs. evening chronotype;
BRCA	cis	rs2066819	1.000	rs76466034	chr12:56719450	G/A	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg07537917	chr2:241836409	C2orf54	-0.48	-11.19	-0.4	1.18e-26	Urinary metabolites;
BRCA	cis	rs11249608	0.548	rs62393076	chr5:178450646	C/G	cg21905437	chr5:178450457	ZNF879	0.55	11.44	0.41	1.07e-27	Pubertal anthropometrics;
BRCA	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18404041	chr3:52824283	ITIH1	0.38	11.77	0.42	4.43e-29	Electroencephalogram traits;
BRCA	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg07148914	chr20:33460835	GGT7	-0.37	-7.97	-0.3	7.47e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs11112613	0.762	rs73184078	chr12:105950017	A/G	cg03607813	chr12:105948248	NA	0.6	11.21	0.41	9.41e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-16.23	-0.54	7.7e-50	Alzheimer's disease (late onset);
BRCA	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.8e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg17063962	chr7:91808500	NA	-0.6	-13.95	-0.48	8.4e-39	Breast cancer;
BRCA	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg27211696	chr2:191398769	TMEM194B	-0.46	-10.72	-0.39	9.22e-25	Pulse pressure;
BRCA	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg12292205	chr6:26970375	C6orf41	-0.65	-10.04	-0.37	3.89e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg18402987	chr7:1209562	NA	0.43	8.18	0.31	1.55e-15	Longevity;Endometriosis;
BRCA	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg04450456	chr4:17643702	FAM184B	0.37	9.89	0.36	1.5e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg03806693	chr22:41940476	POLR3H	1.1	19.5	0.61	8.78e-67	Vitiligo;
BRCA	cis	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg07460842	chr6:66804631	NA	-0.92	-18.3	-0.59	1.86e-60	Exhaled nitric oxide output;
BRCA	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg05623727	chr3:50126028	RBM5	-0.49	-12.12	-0.43	1.44e-30	Body mass index;
BRCA	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.26	0.34	3.15e-19	Tonsillectomy;
BRCA	cis	rs2425143	1.000	rs17093027	chr20:34319118	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.96	-0.33	3.53e-18	Blood protein levels;
BRCA	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg22713356	chr15:30763199	NA	1.25	20.77	0.63	1.25e-73	Uric acid levels;
BRCA	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.36	-8.71	-0.33	2.6e-17	Personality dimensions;
BRCA	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg09307838	chr4:120376055	NA	0.76	16.77	0.55	1.42e-52	Corneal astigmatism;
BRCA	cis	rs1035144	0.505	rs10145099	chr14:81456694	C/T	cg06600135	chr14:81408086	NA	-0.46	-10.76	-0.39	6.18e-25	Male sexual orientation;
BRCA	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg24879335	chr3:133465180	TF	0.33	11.08	0.4	3.25e-26	Iron status biomarkers (transferrin levels);
BRCA	trans	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg26043149	chr18:55253948	FECH	1.18	27.27	0.73	3.37e-109	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.57	0.32	7.65e-17	Tonsillectomy;
BRCA	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg11502198	chr6:26597334	ABT1	0.47	9.47	0.35	5.19e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2016266	0.929	rs11170495	chr12:53665202	G/A	cg26875137	chr12:53738046	NA	0.36	9.64	0.36	1.22e-20	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.36	12.42	0.44	6.9e-32	Bipolar disorder;
BRCA	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg12373951	chr3:133503437	NA	0.45	10.6	0.39	2.67e-24	Iron status biomarkers;
BRCA	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	7.97	0.3	7.15e-15	Menarche (age at onset);
BRCA	cis	rs10499694	0.933	rs12718583	chr7:50582631	T/C	cg18232548	chr7:50535776	DDC	-0.39	-9.31	-0.35	2.06e-19	Body mass index;
BRCA	cis	rs735860	0.712	rs2294864	chr6:53140928	T/A	cg10236188	chr6:53219634	NA	-0.39	-8.25	-0.31	9.29e-16	Glaucoma;
BRCA	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg18016565	chr1:150552671	MCL1	0.37	8.51	0.32	1.21e-16	Urate levels;
BRCA	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11764359	chr7:65958608	NA	0.8	19.49	0.61	9.4e-67	Aortic root size;
BRCA	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg04234412	chr22:24373322	LOC391322	-0.44	-8.88	-0.33	6.5e-18	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18876405	chr7:65276391	NA	0.48	10.83	0.39	3.43e-25	Aortic root size;
BRCA	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg26587870	chr6:27730563	NA	-0.38	-8.36	-0.31	3.99e-16	Parkinson's disease;
BRCA	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg01448562	chr3:133502909	NA	-0.62	-14.59	-0.5	7.79e-42	Iron status biomarkers;
BRCA	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-12.1	-0.43	1.65e-30	Gut microbiome composition (summer);
BRCA	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg26022315	chr17:47021804	SNF8	0.3	7.93	0.3	9.5e-15	Type 2 diabetes;
BRCA	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.3	8.39	0.31	3.15e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg20283391	chr11:68216788	NA	-0.46	-9.07	-0.34	1.48e-18	Total body bone mineral density;
BRCA	cis	rs6542838	0.611	rs1878589	chr2:99517979	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.38	-8.55	-0.32	8.94e-17	Fear of minor pain;
BRCA	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.01	-0.3	5.36e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs490234	0.783	rs13283793	chr9:128441641	C/T	cg14078157	chr9:128172775	NA	-0.35	-8.24	-0.31	1e-15	Mean arterial pressure;
BRCA	trans	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg25214090	chr10:38739885	LOC399744	0.46	10.62	0.39	2.31e-24	Corneal astigmatism;
BRCA	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg12365402	chr11:9010492	NRIP3	-0.44	-10.32	-0.38	3.41e-23	Hemoglobin concentration;
BRCA	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg01528321	chr10:82214614	TSPAN14	0.92	20.04	0.62	1.07e-69	Post bronchodilator FEV1;
BRCA	cis	rs752010	0.523	rs10890158	chr1:42117985	C/T	cg06885757	chr1:42089581	HIVEP3	0.28	9.75	0.36	4.91e-21	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg08470875	chr2:26401718	FAM59B	0.73	11.91	0.43	1.08e-29	Gut microbiome composition (summer);
BRCA	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	8.25	0.31	9.33e-16	Schizophrenia;
BRCA	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg00677455	chr12:58241039	CTDSP2	0.69	15.93	0.53	2.39e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.818	rs557553	chr1:153010370	T/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.05e-17	Inflammatory skin disease;
BRCA	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.86	-0.33	7.87e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	10.34	0.38	2.87e-23	Height;
BRCA	cis	rs6840258	1.000	rs6840258	chr4:87973668	C/T	cg08197287	chr4:87952173	AFF1	-0.45	-9.13	-0.34	9.08e-19	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg12011299	chr4:100065546	ADH4	0.42	10.63	0.39	2.05e-24	Alcohol dependence;
BRCA	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-9.14	-0.34	8.37e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs727479	0.502	rs12148604	chr15:51501404	A/G	cg19946085	chr15:51559439	CYP19A1	0.29	8.13	0.31	2.31e-15	Estradiol levels;
BRCA	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg00701064	chr4:6280414	WFS1	0.68	17.68	0.57	3.11e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg06115741	chr20:33292138	TP53INP2	0.5	11.29	0.41	4.34e-27	Coronary artery disease;
BRCA	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg15605315	chr1:45957053	TESK2	-0.5	-10.03	-0.37	4.24e-22	High light scatter reticulocyte count;
BRCA	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg18230493	chr5:56204884	C5orf35	-0.39	-8.0	-0.3	5.96e-15	Coronary artery disease;
BRCA	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.36	0.44	1.23e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg03585969	chr10:35415529	CREM	0.49	10.31	0.38	3.76e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11644478	chr21:40555479	PSMG1	0.82	18.68	0.59	1.91e-62	Cognitive function;
BRCA	cis	rs36051895	0.659	rs10283730	chr9:5073289	G/A	cg02405213	chr9:5042618	JAK2	-0.53	-9.42	-0.35	8.04e-20	Pediatric autoimmune diseases;
BRCA	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00339695	chr16:24857497	SLC5A11	0.35	8.41	0.32	2.64e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2171564	0.557	rs9831780	chr3:112442083	G/A	cg06685282	chr3:112453648	NA	0.52	11.68	0.42	1.05e-28	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26314531	chr2:26401878	FAM59B	-0.88	-15.45	-0.52	5.59e-46	Gut microbiome composition (summer);
BRCA	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.17	0.31	1.68e-15	Depression;
BRCA	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.47	8.32	0.31	5.31e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.32	-0.35	1.89e-19	Bladder cancer;
BRCA	trans	rs61931739	0.635	rs10743837	chr12:33982162	A/G	cg26384229	chr12:38710491	ALG10B	0.4	8.95	0.33	3.69e-18	Morning vs. evening chronotype;
BRCA	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg23625390	chr15:77176239	SCAPER	-0.54	-12.8	-0.45	1.52e-33	Blood metabolite levels;
BRCA	cis	rs9986765	1.000	rs73452567	chr7:142816043	T/G	cg21852589	chr7:142981689	TMEM139	0.63	10.18	0.37	1.14e-22	Cancer;Dermatomyositis;
BRCA	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg13319975	chr6:146136371	FBXO30	0.59	13.19	0.46	2.58e-35	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg10811474	chr19:8428787	ANGPTL4	-0.33	-8.35	-0.31	4.15e-16	HDL cholesterol;
BRCA	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg12011299	chr4:100065546	ADH4	0.44	11.37	0.41	2.07e-27	Alcohol dependence;
BRCA	cis	rs7659604	0.540	rs4833769	chr4:122672970	A/C	cg19671926	chr4:122722719	EXOSC9	-0.42	-9.01	-0.34	2.35e-18	Type 2 diabetes;
BRCA	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg16339924	chr4:17578868	LAP3	0.76	19.09	0.6	1.26e-64	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg17971929	chr21:40555470	PSMG1	0.81	19.45	0.61	1.49e-66	Cognitive function;
BRCA	cis	rs1005224	0.654	rs8005753	chr14:76136086	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.35	-8.22	-0.31	1.11e-15	Large artery stroke;
BRCA	cis	rs11608355	0.545	rs35590455	chr12:109893514	A/G	cg05360138	chr12:110035743	NA	0.71	13.18	0.46	2.85e-35	Neuroticism;
BRCA	trans	rs4650994	0.525	rs4993304	chr1:178535144	A/G	cg05059571	chr16:84539110	KIAA1609	-0.58	-12.8	-0.45	1.47e-33	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg12292205	chr6:26970375	C6orf41	0.58	13.04	0.46	1.2e-34	Schizophrenia;
BRCA	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg14403583	chr14:105418241	AHNAK2	-0.38	-8.97	-0.33	3.29e-18	Rheumatoid arthritis;
BRCA	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg14675211	chr2:100938903	LONRF2	0.48	11.09	0.4	2.83e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.38	-0.41	1.84e-27	Gut microbiome composition (summer);
BRCA	cis	rs7586879	0.789	rs13382979	chr2:25131736	G/A	cg04586622	chr2:25135609	ADCY3	0.4	9.46	0.35	5.57e-20	Body mass index;
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03923535	chr7:1197113	ZFAND2A	0.46	10.3	0.38	3.9e-23	Longevity;Endometriosis;
BRCA	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	10.71	0.39	9.47e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg15704280	chr7:45808275	SEPT13	-0.84	-19.11	-0.6	9.63e-65	Height;
BRCA	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg09877947	chr5:131593287	PDLIM4	0.39	9.79	0.36	3.46e-21	Breast cancer;
BRCA	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg12386194	chr3:101231763	SENP7	0.46	9.86	0.36	1.99e-21	Colorectal cancer;
BRCA	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg14863265	chr7:2801509	GNA12	-0.44	-9.52	-0.35	3.41e-20	Height;
BRCA	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg25208724	chr1:156163844	SLC25A44	1.07	35.23	0.81	7.01e-152	Testicular germ cell tumor;
BRCA	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg09307838	chr4:120376055	NA	0.6	12.96	0.46	2.83e-34	Educational attainment;
BRCA	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.63	-13.23	-0.46	1.75e-35	Hip circumference adjusted for BMI;
BRCA	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-10.27	-0.38	5.26e-23	Heart rate;
BRCA	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.08	-27.37	-0.73	9.73e-110	Ulcerative colitis;
BRCA	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14442939	chr10:27389572	ANKRD26	-0.68	-10.91	-0.4	1.61e-25	Breast cancer;
BRCA	cis	rs3784262	0.709	rs4080	chr15:58201341	C/G	cg12031962	chr15:58353849	ALDH1A2	0.34	9.22	0.34	4.38e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg24110177	chr3:50126178	RBM5	-0.44	-9.79	-0.36	3.61e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2505998	1.000	rs2435362	chr10:43578779	A/C	cg15436174	chr10:43711423	RASGEF1A	-0.42	-8.38	-0.31	3.45e-16	Hirschsprung disease;
BRCA	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.68	-15.8	-0.53	1.05e-47	Axial length;
BRCA	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg06784218	chr1:46089804	CCDC17	0.45	10.8	0.39	4.19e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08045932	chr20:61659980	NA	0.5	11.43	0.41	1.2100000000000001e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs738322	0.600	rs6001035	chr22:38562425	A/G	cg20207973	chr22:38506712	BAIAP2L2	0.32	7.9	0.3	1.19e-14	Cutaneous nevi;
BRCA	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.72	-0.45	3.4e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg14863265	chr7:2801509	GNA12	-0.46	-9.65	-0.36	1.14e-20	Height;
BRCA	cis	rs897984	0.568	rs8063565	chr16:30883965	G/C	cg02466173	chr16:30829666	NA	0.46	9.11	0.34	1.01e-18	Dementia with Lewy bodies;
BRCA	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	19.23	0.61	2.31e-65	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs6604026	0.666	rs11164830	chr1:93356823	C/A	cg17283838	chr1:93427260	FAM69A	-0.4	-8.22	-0.31	1.14e-15	Multiple sclerosis;
BRCA	cis	rs7635838	0.684	rs346079	chr3:11328139	G/A	cg00170343	chr3:11313890	ATG7	0.41	8.52	0.32	1.14e-16	HDL cholesterol;
BRCA	cis	rs2559856	1.000	rs2695288	chr12:102088112	T/C	cg12924262	chr12:102091054	CHPT1	0.38	8.67	0.32	3.54e-17	Blood protein levels;
BRCA	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg15049968	chr18:44337910	ST8SIA5	-0.27	-7.81	-0.3	2.35e-14	Personality dimensions;
BRCA	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg21747090	chr2:27597821	SNX17	-0.4	-8.8	-0.33	1.24e-17	Total body bone mineral density;
BRCA	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24838063	chr12:130822603	PIWIL1	0.68	16.73	0.55	2.13e-52	Menopause (age at onset);
BRCA	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.56	-0.32	8.43e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2797160	1.000	rs1739352	chr6:126005310	T/C	cg05901451	chr6:126070800	HEY2	-0.39	-9.49	-0.35	4.46e-20	Endometrial cancer;
BRCA	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-13.3	-0.47	8.71e-36	Migraine;Coronary artery disease;
BRCA	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg08917208	chr2:24149416	ATAD2B	0.52	8.23	0.31	1.05e-15	Asthma;
BRCA	cis	rs9633740	1.000	rs10748526	chr10:82273079	T/C	cg00277334	chr10:82204260	NA	-0.42	-7.86	-0.3	1.69e-14	Post bronchodilator FEV1;
BRCA	cis	rs7246657	0.722	rs2972447	chr19:38129736	C/T	cg18154014	chr19:37997991	ZNF793	-0.49	-9.24	-0.34	3.72e-19	Coronary artery calcification;
BRCA	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.66	-0.61	1.21e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.2	0.49	5.86e-40	Motion sickness;
BRCA	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	18.83	0.6	3.04e-63	Platelet count;
BRCA	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg04727924	chr7:799746	HEATR2	-0.55	-10.89	-0.4	1.96e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs367943	0.556	rs7709820	chr5:112991327	G/A	cg12552261	chr5:112820674	MCC	0.37	8.13	0.31	2.3e-15	Type 2 diabetes;
BRCA	cis	rs365132	1.000	rs353478	chr5:176370988	T/C	cg16309518	chr5:176445507	NA	-0.53	-13.62	-0.47	2.88e-37	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.3	-7.85	-0.3	1.75e-14	Total body bone mineral density;
BRCA	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg24812749	chr6:127587940	RNF146	0.7	15.39	0.52	1.13e-45	Breast cancer;
BRCA	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg07274523	chr3:49395745	GPX1	0.46	7.84	0.3	1.84e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9811920	0.683	rs16841874	chr3:99720564	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-11.04	-0.4	4.66e-26	Axial length;
BRCA	cis	rs4285028	0.948	rs2332033	chr3:121699548	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.57	-10.55	-0.39	4.29e-24	Multiple sclerosis;
BRCA	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.4	0.38	1.71e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg21573476	chr21:45109991	RRP1B	-0.33	-8.45	-0.32	1.98e-16	Mean corpuscular volume;
BRCA	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-16.16	-0.54	1.65e-49	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg04414720	chr1:150670196	GOLPH3L	0.35	7.84	0.3	1.88e-14	Tonsillectomy;
BRCA	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg22920501	chr2:26401640	FAM59B	-0.66	-11.46	-0.41	8.67e-28	Gut microbiome composition (summer);
BRCA	cis	rs4662945	0.603	rs13002385	chr2:130276865	T/C	cg05962382	chr2:130345044	NA	-0.36	-8.51	-0.32	1.23e-16	Response to cytidine analogues (gemcitabine);
BRCA	trans	rs1997103	1.000	rs6958022	chr7:55397389	G/A	cg20935933	chr6:143382018	AIG1	0.6	11.52	0.41	4.77e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2481665	0.772	rs12730782	chr1:62537265	A/G	cg18591186	chr1:62594603	INADL	-0.56	-12.24	-0.44	4.27e-31	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg20368463	chr18:77673604	PQLC1	-0.51	-12.76	-0.45	2.15e-33	Schizophrenia;
BRCA	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg17691542	chr6:26056736	HIST1H1C	0.44	9.44	0.35	6.79e-20	Iron status biomarkers;
BRCA	cis	rs858239	0.508	rs2390754	chr7:23190494	A/G	cg23682824	chr7:23144976	KLHL7	0.37	9.8	0.36	3.27e-21	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4074536	0.622	rs6668528	chr1:116314321	G/A	cg21648376	chr1:116311395	CASQ2	-0.55	-9.02	-0.34	2.21e-18	QRS duration;
BRCA	cis	rs12760731	0.565	rs7536856	chr1:178057927	A/G	cg00404053	chr1:178313656	RASAL2	0.64	8.06	0.3	3.66e-15	Obesity-related traits;
BRCA	cis	rs67366981	1.000	rs17105547	chr14:77698358	G/A	cg22824376	chr14:77648248	TMEM63C	0.62	9.1	0.34	1.15e-18	Obsessive-compulsive symptoms;
BRCA	cis	rs6815814	0.950	rs73236618	chr4:38794041	T/C	cg02016764	chr4:38805732	TLR1	-0.6	-9.11	-0.34	1.06e-18	Breast cancer;
BRCA	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg06636001	chr8:8085503	FLJ10661	0.54	10.16	0.37	1.42e-22	Retinal vascular caliber;
BRCA	cis	rs8014204	0.762	rs973879	chr14:75297727	T/C	cg06637938	chr14:75390232	RPS6KL1	0.42	8.81	0.33	1.15e-17	Caffeine consumption;
BRCA	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg01448562	chr3:133502909	NA	-0.39	-9.01	-0.34	2.38e-18	Iron status biomarkers;
BRCA	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg23719950	chr11:63933701	MACROD1	-0.58	-9.62	-0.36	1.45e-20	Mean platelet volume;
BRCA	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg12310025	chr6:25882481	NA	-0.54	-13.09	-0.46	7.43e-35	Blood metabolite levels;
BRCA	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-9.92	-0.37	1.1e-21	Neuroticism;
BRCA	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg21699342	chr2:239360505	ASB1	0.47	11.85	0.42	1.95e-29	Multiple system atrophy;
BRCA	cis	rs11690935	0.595	rs788170	chr2:172919958	T/C	cg13550731	chr2:172543902	DYNC1I2	0.56	14.18	0.49	7.11e-40	Schizophrenia;
BRCA	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg15083037	chr5:83017644	HAPLN1	-0.43	-8.05	-0.3	4.08e-15	Prostate cancer;
BRCA	cis	rs7903847	0.620	rs10882903	chr10:99115584	A/T	cg20016023	chr10:99160130	RRP12	-0.25	-7.85	-0.3	1.79e-14	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11764359	chr7:65958608	NA	-0.8	-19.59	-0.61	2.9e-67	Aortic root size;
BRCA	cis	rs2964802	0.505	rs7737359	chr5:10832104	A/G	cg14521931	chr5:10832172	NA	-0.47	-10.17	-0.37	1.24e-22	Major depressive disorder;Recurrent major depressive disorder;
BRCA	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg08885076	chr2:99613938	TSGA10	0.44	10.21	0.37	9.27e-23	Chronic sinus infection;
BRCA	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg26587870	chr6:27730563	NA	-0.39	-8.3	-0.31	6.14e-16	Parkinson's disease;
BRCA	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	14.13	0.49	1.18e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7903847	0.642	rs9887991	chr10:99159634	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.88	-0.33	6.73e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs17401966	0.964	rs17400510	chr1:10290421	T/C	cg03954927	chr1:10346856	KIF1B	0.44	12.99	0.46	2.1e-34	Hepatocellular carcinoma;
BRCA	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	18.46	0.59	2.64e-61	Alzheimer's disease;
BRCA	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg26248373	chr2:1572462	NA	-0.59	-12.84	-0.45	9.74e-34	IgG glycosylation;
BRCA	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.78	-11.2	-0.41	1.05e-26	Schizophrenia;
BRCA	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg05340658	chr4:99064831	C4orf37	-0.44	-9.94	-0.37	9.52e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4900538	0.927	rs8005804	chr14:102957803	A/G	cg18135206	chr14:102964638	TECPR2	1.05	29.71	0.76	1.64e-122	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg02297831	chr4:17616191	MED28	0.35	7.93	0.3	9.66e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg21775007	chr8:11205619	TDH	-0.45	-8.48	-0.32	1.6e-16	Triglycerides;
BRCA	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg26043149	chr18:55253948	FECH	1.1	23.27	0.68	3.3e-87	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs208520	0.837	rs208488	chr6:66926902	C/T	cg07460842	chr6:66804631	NA	-0.9	-15.72	-0.53	2.51e-47	Exhaled nitric oxide output;
BRCA	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	8.27	0.31	7.99e-16	Mean platelet volume;
BRCA	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg24642844	chr7:1081250	C7orf50	-0.69	-13.08	-0.46	8.25e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg00106254	chr7:1943704	MAD1L1	-0.45	-11.94	-0.43	7.97e-30	Bipolar disorder and schizophrenia;
BRCA	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg26384229	chr12:38710491	ALG10B	0.67	14.35	0.49	1.15e-40	Morning vs. evening chronotype;
BRCA	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg03146154	chr1:46216737	IPP	-0.5	-11.0	-0.4	6.76e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.71	-0.33	2.67e-17	Extrinsic epigenetic age acceleration;
BRCA	trans	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg26384229	chr12:38710491	ALG10B	0.43	10.31	0.38	3.53e-23	Morning vs. evening chronotype;
BRCA	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg23018236	chr17:30244563	NA	-0.69	-10.69	-0.39	1.19e-24	Hip circumference adjusted for BMI;
BRCA	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg11058730	chr11:34937778	PDHX;APIP	0.42	7.99	0.3	6.15e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs4478858	0.684	rs10798838	chr1:31719450	G/A	cg00250761	chr1:31883323	NA	-0.31	-8.0	-0.3	6.03e-15	Alcohol dependence;
BRCA	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.96	21.04	0.64	4.62e-75	Lymphocyte percentage of white cells;
BRCA	cis	rs7572263	0.652	rs34575089	chr2:209047368	G/A	cg23998903	chr2:209048830	C2orf80	-0.38	-8.33	-0.31	5.03e-16	Glioma;Non-glioblastoma glioma;
BRCA	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg21132104	chr15:45694354	SPATA5L1	0.75	17.27	0.56	4.02e-55	Homoarginine levels;
BRCA	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg08917208	chr2:24149416	ATAD2B	1.05	14.38	0.49	7.78e-41	Lymphocyte counts;
BRCA	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg26587870	chr6:27730563	NA	-0.42	-9.05	-0.34	1.75e-18	Parkinson's disease;
BRCA	cis	rs4253311	0.544	rs4253236	chr4:187148071	T/C	cg24794857	chr4:187113578	CYP4V2	0.39	8.05	0.3	4.15e-15	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
BRCA	cis	rs9473147	0.516	rs2171089	chr6:47515811	A/G	cg12968598	chr6:47444699	CD2AP	0.47	9.95	0.37	9.13e-22	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs926392	0.640	rs1007913	chr20:37693592	G/A	cg16355469	chr20:37678765	NA	0.48	11.24	0.41	7.27e-27	Dialysis-related mortality;
BRCA	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg01475377	chr6:109611718	NA	-0.6	-16.73	-0.55	2.36e-52	Reticulocyte fraction of red cells;
BRCA	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg23711669	chr6:146136114	FBXO30	0.8	19.43	0.61	2.07e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg23711669	chr6:146136114	FBXO30	0.72	16.53	0.55	2.42e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03517284	chr6:25882590	NA	-0.38	-8.31	-0.31	5.91e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs7746199	0.611	rs17750747	chr6:27730334	T/C	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.85	-0.33	8.51e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs495337	0.760	rs2769977	chr20:48527464	T/C	cg17835207	chr20:48524531	SPATA2	-0.68	-16.81	-0.55	9.28e-53	Psoriasis;
BRCA	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07636037	chr3:49044803	WDR6	0.88	21.18	0.64	7.59e-76	Menarche (age at onset);
BRCA	cis	rs1468333	0.824	rs10952	chr5:137588340	T/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.41	7.88	0.3	1.43e-14	Resting heart rate;
BRCA	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-8.92	-0.33	4.97e-18	Triglycerides;
BRCA	cis	rs897984	0.645	rs58726213	chr16:31044683	A/G	cg02466173	chr16:30829666	NA	-0.42	-9.47	-0.35	5.39e-20	Dementia with Lewy bodies;
BRCA	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg24110177	chr3:50126178	RBM5	-0.51	-14.44	-0.5	3.99e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg23625390	chr15:77176239	SCAPER	-0.55	-12.83	-0.45	1.1e-33	Blood metabolite levels;
BRCA	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg17971929	chr21:40555470	PSMG1	0.79	18.57	0.59	6.58e-62	Cognitive function;
BRCA	cis	rs7520050	0.966	rs4660910	chr1:46548402	G/T	cg24296786	chr1:45957014	TESK2	0.41	9.19	0.34	5.42e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.17	-0.31	1.59e-15	Bipolar disorder;
BRCA	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03517284	chr6:25882590	NA	0.47	10.45	0.38	1.04e-23	Blood metabolite levels;
BRCA	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg12923728	chr3:195709715	SDHAP1	-0.6	-13.08	-0.46	8.62e-35	Pancreatic cancer;
BRCA	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-11.25	-0.41	6.33e-27	Mean corpuscular volume;
BRCA	cis	rs11051970	0.659	rs904917	chr12:32591302	G/A	cg02745156	chr12:32552066	NA	0.27	8.08	0.3	3.34e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg09184832	chr6:79620586	NA	-0.49	-10.98	-0.4	8.39e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2354432	0.607	rs894469	chr1:146672906	C/T	cg25205988	chr1:146714368	CHD1L	0.84	10.87	0.4	2.19e-25	Mitochondrial DNA levels;
BRCA	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.48	-11.87	-0.43	1.65e-29	Height;
BRCA	cis	rs12472274	0.529	rs11677996	chr2:239118007	A/G	cg17459225	chr2:239074497	NA	0.59	10.41	0.38	1.47e-23	Phospholipid levels (plasma);
BRCA	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg26384229	chr12:38710491	ALG10B	0.85	22.52	0.67	3.94e-83	Heart rate;
BRCA	cis	rs829880	0.570	rs4488248	chr12:98853688	G/C	cg25150519	chr12:98850993	NA	0.65	14.91	0.51	2.27e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg07741184	chr6:167504864	NA	0.28	8.16	0.31	1.82e-15	Crohn's disease;
BRCA	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19717773	chr7:2847554	GNA12	-0.41	-7.85	-0.3	1.71e-14	Height;
BRCA	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg09469691	chr10:81107165	PPIF	0.45	9.77	0.36	4.01e-21	Height;
BRCA	trans	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg26384229	chr12:38710491	ALG10B	0.49	10.53	0.38	5.07e-24	Resting heart rate;
BRCA	cis	rs3824867	0.881	rs4752829	chr11:47396654	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-10.76	-0.39	6.46e-25	Mean corpuscular hemoglobin;
BRCA	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg20933634	chr6:27740509	NA	0.49	9.82	0.36	2.62e-21	Parkinson's disease;
BRCA	cis	rs6433895	1.000	rs35543145	chr2:182018115	A/G	cg00481216	chr2:181971175	NA	0.39	8.91	0.33	5.34e-18	Lymphocyte counts;
BRCA	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.54	0.57	1.68e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.62	-0.32	5.36e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg18252515	chr7:66147081	NA	-0.9	-12.91	-0.45	4.98e-34	Diabetic kidney disease;
BRCA	trans	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.27	0.31	7.93e-16	Corneal astigmatism;
BRCA	cis	rs701145	0.585	rs1960241	chr3:153858398	T/C	cg12800244	chr3:153838788	SGEF	0.62	7.83	0.3	2.1e-14	Coronary artery disease;
BRCA	cis	rs3784262	0.669	rs1063666	chr15:58246602	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.35	-9.61	-0.36	1.62e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs9462846	1.000	rs9471941	chr6:42857827	C/T	cg02353165	chr6:42928485	GNMT	-0.47	-7.86	-0.3	1.63e-14	Blood protein levels;
BRCA	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.47	-0.32	1.73e-16	Total body bone mineral density;
BRCA	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg26516362	chr5:178986906	RUFY1	-0.45	-13.45	-0.47	1.73e-36	Lung cancer;
BRCA	cis	rs6460942	0.915	rs7803051	chr7:12306904	A/T	cg10578991	chr7:12443926	VWDE	-0.44	-8.08	-0.3	3.35e-15	Coronary artery disease;
BRCA	cis	rs7258465	0.965	rs10409003	chr19:18543054	C/T	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.76	-0.33	1.71e-17	Breast cancer;
BRCA	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.41	-9.98	-0.37	6.5600000000000005e-22	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.35	7.93	0.3	9.51e-15	Coronary artery disease;
BRCA	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.33	0.35	1.77e-19	Menopause (age at onset);
BRCA	cis	rs1577917	0.687	rs1470531	chr6:86507369	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-12.11	-0.43	1.52e-30	Response to antipsychotic treatment;
BRCA	cis	rs6121246	0.559	rs6060933	chr20:30351903	C/T	cg21427119	chr20:30132790	HM13	-0.36	-8.12	-0.31	2.35e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.76	16.82	0.55	7.78e-53	Lymphocyte counts;
BRCA	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg16339924	chr4:17578868	LAP3	-0.56	-13.56	-0.47	5.61e-37	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs2797160	1.000	rs1739352	chr6:126005310	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.35	-7.83	-0.3	2.01e-14	Endometrial cancer;
BRCA	cis	rs77956314	0.818	rs12296869	chr12:117431203	G/A	cg02017074	chr12:117425053	FBXW8	-0.57	-8.95	-0.33	3.93e-18	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs754466	0.724	rs11002318	chr10:79633807	G/A	cg17075019	chr10:79541650	NA	-0.75	-18.04	-0.58	4.08e-59	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24549020	chr5:56110836	MAP3K1	-0.4	-8.41	-0.32	2.78e-16	Initial pursuit acceleration;
BRCA	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26314531	chr2:26401878	FAM59B	-0.9	-15.7	-0.53	3.05e-47	Gut microbiome composition (summer);
BRCA	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg01877450	chr7:97915802	BRI3	-0.37	-8.5	-0.32	1.31e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00149659	chr3:10157352	C3orf10	1.07	18.1	0.58	2.08e-59	Alzheimer's disease;
BRCA	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg03954927	chr1:10346856	KIF1B	0.47	14.07	0.49	2.34e-39	Hepatocellular carcinoma;
BRCA	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00166722	chr3:10149974	C3orf24	0.65	13.07	0.46	8.76e-35	Alzheimer's disease;
BRCA	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg22508957	chr16:3507546	NAT15	-0.57	-8.33	-0.31	4.75e-16	Tuberculosis;
BRCA	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg01483505	chr11:975446	AP2A2	-0.3	-8.05	-0.3	4.11e-15	Alzheimer's disease (late onset);
BRCA	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg09367891	chr1:107599246	PRMT6	-0.43	-8.24	-0.31	9.74e-16	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06108461	chr20:60628389	TAF4	-0.99	-22.33	-0.66	4.6e-82	Body mass index;
BRCA	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs7072216	0.763	rs7923729	chr10:100169465	C/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.71	-0.36	7.24e-21	Metabolite levels;
BRCA	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg00531865	chr16:30841666	NA	-0.52	-12.2	-0.43	6.47e-31	Multiple myeloma;
BRCA	trans	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg26043149	chr18:55253948	FECH	-0.37	-8.25	-0.31	8.96e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg08807101	chr21:30365312	RNF160	0.74	19.41	0.61	2.47e-66	Dental caries;
BRCA	trans	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.49	-0.35	4.61e-20	Bladder cancer;
BRCA	cis	rs9970334	0.596	rs709209	chr1:6278414	A/G	cg15892785	chr1:6309343	GPR153	-0.42	-9.34	-0.35	1.63e-19	Resting heart rate;
BRCA	cis	rs10949834	0.652	rs2269082	chr7:73519875	A/G	cg07137043	chr7:73588983	EIF4H	-0.53	-8.64	-0.32	4.61e-17	Verbal memory performance (residualized delayed recall change);
BRCA	cis	rs751728	0.626	rs57150921	chr6:33737518	T/C	cg25922239	chr6:33757077	LEMD2	0.52	13.2	0.46	2.44e-35	Crohn's disease;
BRCA	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.43	0.35	7.24e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18252515	chr7:66147081	NA	-0.35	-7.83	-0.3	2.04e-14	Aortic root size;
BRCA	cis	rs9649213	0.614	rs10953254	chr7:97914305	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.6	-14.83	-0.51	5.62e-43	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21659725	chr3:3221576	CRBN	0.71	22.09	0.66	8.94e-81	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18876405	chr7:65276391	NA	0.5	11.2	0.4	1.09e-26	Aortic root size;
BRCA	cis	rs3768617	0.811	rs12563494	chr1:183039698	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.46	9.94	0.37	9.49e-22	Fuchs's corneal dystrophy;
BRCA	cis	rs7191700	0.673	rs12325495	chr16:11418328	C/T	cg00044050	chr16:11439710	C16orf75	0.47	11.34	0.41	2.84e-27	Multiple sclerosis;
BRCA	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.86	-0.48	2.11e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg04025307	chr7:1156635	C7orf50	0.46	9.19	0.34	5.33e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg08601574	chr20:25228251	PYGB	-0.36	-8.59	-0.32	6.58e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg08470875	chr2:26401718	FAM59B	-0.54	-8.48	-0.32	1.58e-16	Gut microbiome composition (summer);
BRCA	cis	rs6700896	0.931	rs12035753	chr1:66116691	T/G	cg04111102	chr1:66153794	NA	0.34	8.42	0.32	2.57e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-12.22	-0.44	5.2e-31	Gut microbiome composition (summer);
BRCA	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg10223061	chr2:219282414	VIL1	-0.28	-7.99	-0.3	6.23e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2131877	0.554	rs2131876	chr3:194854788	C/T	cg13868855	chr3:194833887	C3orf21	-0.35	-8.35	-0.31	4.37e-16	Non-small cell lung cancer;
BRCA	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.84	-14.8	-0.51	7.83e-43	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg01529538	chr14:23388837	RBM23	0.42	11.48	0.41	7.01e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs2766692	1.000	rs4905941	chr14:100725438	A/G	cg14866419	chr14:100704911	YY1	0.44	9.44	0.35	6.57e-20	Electroencephalographic traits in alcoholism;
BRCA	trans	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg25214090	chr10:38739885	LOC399744	0.46	10.49	0.38	7.18e-24	Educational attainment;
BRCA	cis	rs2637266	0.935	rs7909808	chr10:78392318	A/G	cg18941641	chr10:78392320	NA	0.35	8.17	0.31	1.65e-15	Pulmonary function;
BRCA	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.75	-17.23	-0.56	6.35e-55	Primary sclerosing cholangitis;
BRCA	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg06671706	chr8:8559999	CLDN23	0.44	8.43	0.32	2.36e-16	Obesity-related traits;
BRCA	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg14196790	chr5:131705035	SLC22A5	0.33	8.69	0.33	3.08e-17	Breast cancer;
BRCA	cis	rs11605924	0.901	rs11607883	chr11:45839709	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.45	-9.83	-0.36	2.47e-21	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12923728	chr3:195709715	SDHAP1	-0.58	-12.41	-0.44	7.61e-32	Pancreatic cancer;
BRCA	trans	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.61	10.88	0.4	2.09e-25	Type 2 diabetes;
BRCA	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg24069376	chr3:38537580	EXOG	0.38	10.89	0.4	1.84e-25	Electrocardiographic conduction measures;
BRCA	cis	rs1975991	0.686	rs9824010	chr3:187961924	T/G	cg15417654	chr3:187959138	LPP	0.35	9.07	0.34	1.47e-18	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03264133	chr6:25882463	NA	-0.51	-10.67	-0.39	1.42e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.02	0.48	4.03e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs870825	0.655	rs28604350	chr4:185638723	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.04e-56	Blood protein levels;
BRCA	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-11.42	-0.41	1.28e-27	Morning vs. evening chronotype;
BRCA	cis	rs7551345	0.805	rs10914332	chr1:31699002	A/G	cg19084893	chr1:31688959	NA	-0.44	-8.61	-0.32	5.72e-17	Schizophrenia;
BRCA	cis	rs243505	1.000	rs243512	chr7:148430062	C/T	cg09806900	chr7:148480153	CUL1	-0.4	-8.27	-0.31	8.07e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg13010199	chr12:38710504	ALG10B	0.43	9.12	0.34	9.85e-19	Morning vs. evening chronotype;
BRCA	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg11657440	chr19:46296263	DMWD	-0.44	-9.62	-0.36	1.49e-20	Coronary artery disease;
BRCA	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg00990874	chr7:1149470	C7orf50	-0.6	-10.65	-0.39	1.72e-24	Bronchopulmonary dysplasia;
BRCA	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg15485101	chr11:133734466	NA	0.38	10.19	0.37	1.08e-22	Childhood ear infection;
BRCA	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.6	0.35	1.81e-20	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg25214090	chr10:38739885	LOC399744	0.45	10.66	0.39	1.59e-24	Corneal astigmatism;
BRCA	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-9.58	-0.35	2.04e-20	Mean corpuscular volume;
BRCA	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg16606324	chr3:10149918	C3orf24	0.49	9.76	0.36	4.36e-21	Alzheimer's disease;
BRCA	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.37	0.49	8.67e-41	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.6	0.42	2.29e-28	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg27170947	chr2:26402098	FAM59B	-1.0	-17.53	-0.57	1.76e-56	Gut microbiome composition (summer);
BRCA	cis	rs495337	0.760	rs13040201	chr20:48536349	T/C	cg17835207	chr20:48524531	SPATA2	-0.69	-16.83	-0.55	7.01e-53	Psoriasis;
BRCA	cis	rs4908760	0.965	rs10864353	chr1:8549716	A/G	cg20416874	chr1:8611966	RERE	-0.29	-8.27	-0.31	7.84e-16	Vitiligo;
BRCA	cis	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.42	-0.32	2.51e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	12.87	0.45	7.06e-34	Coronary artery disease;
BRCA	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg03929089	chr4:120376271	NA	0.58	9.33	0.35	1.73e-19	Axial length;
BRCA	cis	rs7945705	0.846	rs4929912	chr11:8816695	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-9.92	-0.37	1.17e-21	Hemoglobin concentration;
BRCA	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg14847009	chr1:175162515	KIAA0040	-0.28	-10.43	-0.38	1.23e-23	Diastolic blood pressure;
BRCA	cis	rs10851411	0.697	rs62022316	chr15:42770362	T/C	cg21293051	chr15:42870591	STARD9	0.52	8.43	0.32	2.25e-16	Glucose homeostasis traits;
BRCA	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	22.12	0.66	5.79e-81	Platelet count;
BRCA	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.39	13.42	0.47	2.44e-36	Bipolar disorder;
BRCA	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.69	-15.74	-0.53	2.09e-47	Axial length;
BRCA	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg14675211	chr2:100938903	LONRF2	0.52	11.53	0.41	4.56e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.77	-0.36	4.2e-21	Alcohol dependence;
BRCA	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg22907277	chr7:1156413	C7orf50	0.48	11.63	0.42	1.76e-28	Longevity;Endometriosis;
BRCA	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg01028140	chr2:1542097	TPO	-0.81	-15.95	-0.53	1.81e-48	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg03060546	chr3:49711283	APEH	-0.61	-12.35	-0.44	1.43e-31	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs8114671	0.967	rs2069952	chr20:33763951	C/T	cg07148914	chr20:33460835	GGT7	0.38	8.03	0.3	4.77e-15	Height;
BRCA	cis	rs1003719	0.788	rs4572679	chr21:38453227	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.07	0.49	2.27e-39	Eye color traits;
BRCA	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg05535760	chr7:792225	HEATR2	-0.67	-11.21	-0.41	9.41e-27	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11644478	chr21:40555479	PSMG1	0.84	19.13	0.6	7.75e-65	Cognitive function;
BRCA	cis	rs208520	0.837	rs208489	chr6:66927584	G/A	cg07460842	chr6:66804631	NA	-0.9	-15.72	-0.53	2.51e-47	Exhaled nitric oxide output;
BRCA	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg10523679	chr1:76189770	ACADM	0.73	12.57	0.45	1.59e-32	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11955398	0.604	rs11951950	chr5:59876940	C/G	cg02684056	chr5:59996105	DEPDC1B	0.35	8.33	0.31	5.12e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17712092	chr4:129076599	LARP1B	0.49	11.86	0.42	1.75e-29	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg11764359	chr7:65958608	NA	-0.68	-15.05	-0.51	4.69e-44	Aortic root size;
BRCA	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg06145435	chr7:1022769	CYP2W1	-0.41	-7.92	-0.3	1.02e-14	Bronchopulmonary dysplasia;
BRCA	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg00071950	chr4:10020882	SLC2A9	0.64	15.79	0.53	1.16e-47	Bone mineral density;
BRCA	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.46	-10.51	-0.38	6.12e-24	IgG glycosylation;
BRCA	cis	rs4423214	0.840	rs1792315	chr11:71165547	C/T	cg05163923	chr11:71159392	DHCR7	-0.55	-11.13	-0.4	2.09e-26	Vitamin D levels;
BRCA	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.89	-0.33	6.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.48	-10.88	-0.4	2.14e-25	Longevity;Endometriosis;
BRCA	cis	rs11920090	0.932	rs10513685	chr3:170724390	A/G	cg09710316	chr3:170744871	SLC2A2	-0.42	-8.4	-0.32	2.79e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs72799341	1.000	rs72799341	chr16:30936743	G/A	cg02466173	chr16:30829666	NA	-0.47	-8.69	-0.32	3.11e-17	Diastolic blood pressure;
BRCA	cis	rs6005807	0.719	rs9625522	chr22:29045212	C/A	cg12565055	chr22:29076175	TTC28	0.49	9.28	0.34	2.68e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg04691961	chr3:161091175	C3orf57	-0.41	-10.07	-0.37	3.16e-22	Morning vs. evening chronotype;
BRCA	cis	rs73001065	0.551	rs79954596	chr19:19548643	T/G	cg03709012	chr19:19516395	GATAD2A	1.02	15.45	0.52	5.66e-46	LDL cholesterol;
BRCA	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg11645453	chr3:52864694	ITIH4	0.49	11.98	0.43	5.43e-30	Schizophrenia;
BRCA	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.48	0.32	1.52e-16	Platelet count;
BRCA	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg18225595	chr11:63971243	STIP1	0.55	13.82	0.48	3.47e-38	Platelet count;
BRCA	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg18252515	chr7:66147081	NA	-0.82	-11.95	-0.43	7.52e-30	Diabetic kidney disease;
BRCA	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.02	0.4	5.41e-26	Rheumatoid arthritis;
BRCA	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg04691961	chr3:161091175	C3orf57	-0.59	-14.41	-0.5	5.86e-41	Morning vs. evening chronotype;
BRCA	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg13010199	chr12:38710504	ALG10B	0.51	9.97	0.37	7.46e-22	Bladder cancer;
BRCA	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg09021430	chr5:549028	NA	-0.7	-16.01	-0.54	9.52e-49	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.64	13.58	0.47	4.41e-37	Lymphocyte counts;
BRCA	cis	rs9527	0.590	rs7073323	chr10:104797423	A/C	cg04362960	chr10:104952993	NT5C2	0.42	9.56	0.35	2.45e-20	Arsenic metabolism;
BRCA	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg12373951	chr3:133503437	NA	0.53	12.26	0.44	3.44e-31	Iron status biomarkers;
BRCA	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg23033748	chr14:75592666	NEK9	-0.33	-7.94	-0.3	9.21e-15	Height;
BRCA	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14240646	chr10:27532245	ACBD5	-0.66	-10.35	-0.38	2.64e-23	Breast cancer;
BRCA	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg08999081	chr20:33150536	PIGU	-0.44	-12.23	-0.44	4.57e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	9.24	0.34	3.63e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.38	0.49	8.21e-41	Motion sickness;
BRCA	trans	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg25042112	chr7:64838748	ZNF92	0.45	8.32	0.31	5.25e-16	Pain;
BRCA	trans	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.5	11.8	0.42	3.25e-29	Brugada syndrome;
BRCA	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11764359	chr7:65958608	NA	-0.7	-14.79	-0.51	8.77e-43	Aortic root size;
BRCA	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg00814883	chr7:100076585	TSC22D4	-0.53	-11.45	-0.41	1e-27	Platelet count;
BRCA	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg00666640	chr1:248458726	OR2T12	0.3	8.42	0.32	2.5e-16	Common traits (Other);
BRCA	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	13.88	0.48	1.69e-38	Motion sickness;
BRCA	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	21.02	0.64	6.08e-75	Platelet count;
BRCA	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg20607798	chr8:58055168	NA	0.59	8.96	0.33	3.59e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	11.77	0.42	4.22e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7903847	0.642	rs61863819	chr10:99142400	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.34	-0.31	4.51e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg14582100	chr15:45693742	SPATA5L1	0.37	11.87	0.42	1.69e-29	Homoarginine levels;
BRCA	cis	rs7264396	0.563	rs11698796	chr20:34248134	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.78	-0.39	5.32e-25	Total cholesterol levels;
BRCA	cis	rs9420	0.528	rs7117896	chr11:57388551	G/A	cg19752551	chr11:57585705	CTNND1	-0.37	-9.27	-0.34	2.84e-19	Schizophrenia;
BRCA	cis	rs12472274	0.646	rs11677736	chr2:239087198	A/T	cg17459225	chr2:239074497	NA	0.6	11.14	0.4	1.83e-26	Phospholipid levels (plasma);
BRCA	cis	rs1707322	0.638	rs1416706	chr1:46602844	G/A	cg06784218	chr1:46089804	CCDC17	-0.39	-8.73	-0.33	2.2e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg05340658	chr4:99064831	C4orf37	0.45	10.41	0.38	1.45e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.04e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7827545	1.000	rs6578234	chr8:135566363	A/G	cg17885191	chr8:135476712	NA	0.44	8.51	0.32	1.27e-16	Hypertension (SNP x SNP interaction);
BRCA	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg26384229	chr12:38710491	ALG10B	-0.41	-9.43	-0.35	7.55e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg22105103	chr4:187893119	NA	0.38	11.85	0.42	2.08e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26314531	chr2:26401878	FAM59B	-0.88	-15.45	-0.52	5.59e-46	Gut microbiome composition (summer);
BRCA	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg04455712	chr21:45112962	RRP1B	-0.45	-11.04	-0.4	4.73e-26	Mean corpuscular volume;
BRCA	cis	rs7246967	0.673	rs73022713	chr19:22876222	G/C	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg20503657	chr10:835505	NA	1.3	21.62	0.65	3.08e-78	Eosinophil percentage of granulocytes;
BRCA	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg25358565	chr5:93447407	FAM172A	1.19	18.82	0.6	3.54e-63	Diabetic retinopathy;
BRCA	cis	rs7246657	0.722	rs2909093	chr19:38199462	T/C	cg18154014	chr19:37997991	ZNF793	-0.51	-9.61	-0.36	1.69e-20	Coronary artery calcification;
BRCA	cis	rs701145	0.585	rs357473	chr3:153895147	C/T	cg17054900	chr3:154042577	DHX36	0.57	9.49	0.35	4.51e-20	Coronary artery disease;
BRCA	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg20219911	chr3:52813652	ITIH1	0.3	8.31	0.31	5.6e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6694270	0.529	rs4076925	chr1:19113026	C/T	cg19637330	chr1:19110922	NA	0.46	8.31	0.31	5.87e-16	Drug-induced liver injury (nitrofurantoin);
BRCA	trans	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg23762105	chr12:34175262	ALG10	-0.36	-9.01	-0.34	2.34e-18	Morning vs. evening chronotype;
BRCA	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg08805041	chr16:621841	PIGQ	-0.32	-8.83	-0.33	1.01e-17	Height;
BRCA	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg19622623	chr12:86230825	RASSF9	0.33	9.43	0.35	7.68e-20	Major depressive disorder;
BRCA	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg03929089	chr4:120376271	NA	-0.79	-17.06	-0.56	4.75e-54	Height;
BRCA	cis	rs73086581	0.947	rs55794220	chr20:3956402	C/T	cg02187196	chr20:3869020	PANK2	0.53	9.55	0.35	2.71e-20	Response to antidepressants in depression;
BRCA	trans	rs3857536	0.785	rs6455089	chr6:66944733	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.84	-0.3	1.89e-14	Blood trace element (Cu levels);
BRCA	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1493916	0.837	rs8088362	chr18:31413016	A/G	cg27147174	chr7:100797783	AP1S1	-0.42	-8.5	-0.32	1.37e-16	Life satisfaction;
BRCA	cis	rs11229555	0.609	rs12273635	chr11:58186327	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.71	-0.36	7.23e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.53	0.35	3.31e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.78	15.22	0.52	7.53e-45	HIV-1 control;
BRCA	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-11.25	-0.41	6.59e-27	Neuroticism;
BRCA	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg17691542	chr6:26056736	HIST1H1C	0.56	12.12	0.43	1.46e-30	Height;
BRCA	cis	rs11997175	0.740	rs6991071	chr8:33814103	G/A	ch.8.33884649F	chr8:33765107	NA	0.42	10.22	0.37	8.56e-23	Body mass index;
BRCA	trans	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg26043149	chr18:55253948	FECH	0.4	8.7	0.33	2.79e-17	Bone mineral density;
BRCA	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg04025307	chr7:1156635	C7orf50	0.48	8.33	0.31	5.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg03954927	chr1:10346856	KIF1B	-0.45	-12.85	-0.45	8.82e-34	Hepatocellular carcinoma;
BRCA	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg01475735	chr3:40494733	NA	0.48	9.85	0.36	2.02e-21	Renal cell carcinoma;
BRCA	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg16606324	chr3:10149918	C3orf24	0.49	9.81	0.36	2.97e-21	Alzheimer's disease;
BRCA	cis	rs870825	0.616	rs4437299	chr4:185643223	T/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.2	0.56	9.11e-55	Blood protein levels;
BRCA	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg03929089	chr4:120376271	NA	-0.45	-8.31	-0.31	5.66e-16	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs4363385	0.720	rs883810	chr1:152941345	T/C	cg25856811	chr1:152973957	SPRR3	-0.31	-8.02	-0.3	5.14e-15	Inflammatory skin disease;
BRCA	cis	rs2637266	1.000	rs7073355	chr10:78354419	G/A	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg20607287	chr7:12443886	VWDE	-0.58	-8.44	-0.32	2.17e-16	Coronary artery disease;
BRCA	cis	rs738322	0.718	rs2899297	chr22:38594668	A/G	cg25457927	chr22:38595422	NA	-0.5	-21.46	-0.65	2.33e-77	Cutaneous nevi;
BRCA	cis	rs6545883	0.965	rs10186325	chr2:61757721	G/T	cg15711740	chr2:61764176	XPO1	-0.53	-13.72	-0.48	9.74e-38	Tuberculosis;
BRCA	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg05347473	chr6:146136440	FBXO30	0.4	8.11	0.31	2.64e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg17063962	chr7:91808500	NA	0.55	13.04	0.46	1.24e-34	Breast cancer;
BRCA	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14240646	chr10:27532245	ACBD5	-0.62	-9.65	-0.36	1.21e-20	Breast cancer;
BRCA	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03264133	chr6:25882463	NA	0.41	8.8	0.33	1.26e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg21475434	chr5:93447410	FAM172A	0.7	9.3	0.35	2.22e-19	Diabetic retinopathy;
BRCA	trans	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg17470723	chr8:74884337	TCEB1	0.4	8.68	0.32	3.36e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg11062466	chr8:58055876	NA	-0.48	-8.42	-0.32	2.55e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg16989086	chr20:62203971	PRIC285	0.54	9.07	0.34	1.41e-18	Glioblastoma;
BRCA	cis	rs4363385	0.747	rs2339496	chr1:152970719	C/T	cg21543102	chr1:152974771	SPRR3	-0.3	-8.52	-0.32	1.18e-16	Inflammatory skin disease;
BRCA	trans	rs6076960	0.598	rs3905168	chr20:6226752	C/T	cg17788362	chr6:86352627	SYNCRIP	0.4	8.09	0.3	3.03e-15	Smooth-surface caries;
BRCA	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg13802316	chr11:70253460	CTTN	-0.56	-8.37	-0.31	3.65e-16	Coronary artery disease;
BRCA	cis	rs9828933	0.752	rs28675788	chr3:63942188	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.75	-11.7	-0.42	8.89e-29	Type 2 diabetes;
BRCA	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg17366294	chr4:99064904	C4orf37	0.52	11.54	0.42	4.23e-28	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg20290983	chr6:43655470	MRPS18A	0.8	20.54	0.63	2.25e-72	IgG glycosylation;
BRCA	cis	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg06521331	chr12:34319734	NA	-0.63	-12.48	-0.44	3.99e-32	Morning vs. evening chronotype;
BRCA	cis	rs57590327	0.503	rs2049415	chr3:81901887	A/T	cg07356753	chr3:81810745	GBE1	-0.44	-10.06	-0.37	3.41e-22	Extraversion;
BRCA	cis	rs4919087	0.926	rs7072078	chr10:99026509	G/A	cg25902810	chr10:99078978	FRAT1	0.38	8.12	0.31	2.49e-15	Monocyte count;
BRCA	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg18252515	chr7:66147081	NA	-0.91	-13.01	-0.46	1.68e-34	Diabetic kidney disease;
BRCA	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg14092571	chr14:90743983	NA	-0.34	-8.12	-0.31	2.36e-15	Mortality in heart failure;
BRCA	cis	rs6460942	0.597	rs4719315	chr7:12528634	A/G	cg06484146	chr7:12443880	VWDE	-0.58	-7.8	-0.3	2.45e-14	Coronary artery disease;
BRCA	cis	rs7851660	0.967	rs4743134	chr9:100598568	C/A	cg13688889	chr9:100608707	NA	-0.36	-8.61	-0.32	5.84e-17	Strep throat;
BRCA	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg21161173	chr5:140098174	VTRNA1-2	0.31	7.83	0.3	2e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9790314	0.663	rs7630674	chr3:160813597	G/A	cg04691961	chr3:161091175	C3orf57	-0.36	-8.07	-0.3	3.39e-15	Morning vs. evening chronotype;
BRCA	cis	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg08807101	chr21:30365312	RNF160	-0.47	-8.07	-0.3	3.56e-15	Cognitive test performance;
BRCA	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg12292205	chr6:26970375	C6orf41	-0.71	-16.7	-0.55	3.2e-52	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.55	-0.32	8.89e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg14664628	chr15:75095509	CSK	-0.89	-24.26	-0.69	1.12e-92	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs600806	0.815	rs10858089	chr1:109926828	T/C	cg20591472	chr1:110008990	SYPL2	0.33	8.22	0.31	1.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs243505	0.559	rs1558420	chr7:148480114	G/T	cg09806900	chr7:148480153	CUL1	0.55	11.29	0.41	4.44e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	8.65e-21	Menopause (age at onset);
BRCA	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg03188948	chr7:1209495	NA	0.49	9.04	0.34	1.9e-18	Longevity;Endometriosis;
BRCA	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.68	-0.32	3.33e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.33	8.68	0.32	3.23e-17	IgG glycosylation;
BRCA	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg26384229	chr12:38710491	ALG10B	0.49	12.32	0.44	1.99e-31	Morning vs. evening chronotype;
BRCA	cis	rs698833	0.624	rs7564087	chr2:44693647	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	9.19	0.34	5.54e-19	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg23711669	chr6:146136114	FBXO30	-0.69	-16.01	-0.54	8.99e-49	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg18758796	chr5:131593413	PDLIM4	0.35	9.29	0.34	2.43e-19	Breast cancer;
BRCA	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg12927641	chr6:109611667	NA	0.42	11.14	0.4	1.87e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg17847044	chr15:42102381	MAPKBP1	0.46	17.15	0.56	1.64e-54	Diastolic blood pressure;
BRCA	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-11.93	-0.43	9.38e-30	Morning vs. evening chronotype;
BRCA	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg24812749	chr6:127587940	RNF146	0.69	15.59	0.53	1.08e-46	Breast cancer;
BRCA	cis	rs752010	0.934	rs11210503	chr1:42101134	A/G	cg06885757	chr1:42089581	HIVEP3	0.24	8.72	0.33	2.35e-17	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg26587870	chr6:27730563	NA	-0.52	-8.04	-0.3	4.31e-15	Breast cancer;
BRCA	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg03188948	chr7:1209495	NA	0.74	12.12	0.43	1.47e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.95	-0.3	8.35e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	12.11	0.43	1.57e-30	Response to bleomycin (chromatid breaks);
BRCA	cis	rs6066825	0.555	rs717709	chr20:47305959	G/A	cg18078177	chr20:47281410	PREX1	0.39	9.66	0.36	1.09e-20	Colorectal cancer;
BRCA	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.53	-11.3	-0.41	4.04e-27	IgG glycosylation;
BRCA	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg05283184	chr6:79620031	NA	-0.42	-11.16	-0.4	1.45e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-12.03	-0.43	3.45e-30	Chronic sinus infection;
BRCA	cis	rs698833	0.926	rs786622	chr2:44606598	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	10.9	0.4	1.7e-25	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs2880765	0.743	rs4551990	chr15:86015287	A/C	cg10818794	chr15:86012489	AKAP13	-0.31	-8.46	-0.32	1.84e-16	Coronary artery disease;
BRCA	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg21132104	chr15:45694354	SPATA5L1	0.71	15.58	0.52	1.28e-46	Homoarginine levels;
BRCA	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg10523679	chr1:76189770	ACADM	0.7	12.24	0.44	4.12e-31	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg24558204	chr6:135376177	HBS1L	0.45	12.41	0.44	8.13e-32	Red blood cell count;
BRCA	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.98	-21.52	-0.65	1.07e-77	Lymphocyte percentage of white cells;
BRCA	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg21770322	chr7:97807741	LMTK2	0.44	11.54	0.42	3.92e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.86	-0.3	1.7e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs534126	0.778	rs10256011	chr7:142936243	G/A	cg22531018	chr7:142981779	TMEM139	0.48	10.84	0.39	3.02e-25	Cancer;
BRCA	cis	rs6120849	0.754	rs6088686	chr20:33623437	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	10.31	0.38	3.78e-23	Protein C levels;
BRCA	cis	rs7945718	0.967	rs4415740	chr11:12783911	C/T	cg25843174	chr11:12811716	TEAD1	0.23	8.81	0.33	1.2e-17	Educational attainment (years of education);
BRCA	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg16230307	chr14:35515116	FAM177A1	0.73	15.28	0.52	3.85e-45	Psoriasis;
BRCA	cis	rs7945718	0.934	rs10831905	chr11:12776467	C/T	cg25843174	chr11:12811716	TEAD1	-0.24	-8.97	-0.33	3.34e-18	Educational attainment (years of education);
BRCA	trans	rs4650994	1.000	rs4650994	chr1:178515312	A/G	cg05059571	chr16:84539110	KIAA1609	0.41	9.44	0.35	6.88e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg16006841	chr5:176797999	RGS14	-0.69	-11.1	-0.4	2.59e-26	Urate levels in lean individuals;
BRCA	trans	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg13565492	chr6:43139072	SRF	-0.79	-10.95	-0.4	1.07e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4285028	0.747	rs11923248	chr3:121566498	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.89	-15.88	-0.53	4.04e-48	Multiple sclerosis;
BRCA	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg16339924	chr4:17578868	LAP3	0.58	14.02	0.49	3.9e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg19077165	chr18:44547161	KATNAL2	-0.6	-13.52	-0.47	7.93e-37	Personality dimensions;
BRCA	cis	rs4919087	1.000	rs11189132	chr10:99086195	G/C	cg25902810	chr10:99078978	FRAT1	-0.45	-9.49	-0.35	4.33e-20	Monocyte count;
BRCA	cis	rs9487051	0.735	rs351754	chr6:109537553	A/G	cg21918786	chr6:109611834	NA	0.36	9.61	0.36	1.68e-20	Reticulocyte fraction of red cells;
BRCA	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg04842962	chr6:43655489	MRPS18A	1.12	39.16	0.84	5.65e-172	IgG glycosylation;
BRCA	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-8.99	-0.34	2.75e-18	Alzheimer's disease (late onset);
BRCA	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11764359	chr7:65958608	NA	-0.76	-16.82	-0.55	7.85e-53	Aortic root size;
BRCA	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg12011299	chr4:100065546	ADH4	0.51	11.77	0.42	4.27e-29	Alcohol dependence;
BRCA	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg00074818	chr8:8560427	CLDN23	-0.36	-7.83	-0.3	2.1e-14	Obesity-related traits;
BRCA	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.74	16.31	0.54	2.85e-50	Cognitive ability;
BRCA	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg24060327	chr5:131705240	SLC22A5	-0.59	-10.85	-0.39	2.79e-25	Breast cancer;
BRCA	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg17724175	chr1:150552817	MCL1	0.26	8.54	0.32	9.94e-17	Tonsillectomy;
BRCA	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	13.38	0.47	3.55e-36	Lymphocyte counts;
BRCA	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18876405	chr7:65276391	NA	0.47	10.73	0.39	8.55e-25	Aortic root size;
BRCA	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-9.44	-0.35	6.8e-20	Longevity;Endometriosis;
BRCA	trans	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg25214090	chr10:38739885	LOC399744	0.37	8.58	0.32	7.01e-17	Diastolic blood pressure;
BRCA	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg26818010	chr10:134567672	INPP5A	-0.77	-15.31	-0.52	2.62e-45	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg26384229	chr12:38710491	ALG10B	0.7	16.01	0.53	9.85e-49	Bladder cancer;
BRCA	cis	rs4073582	0.576	rs556595	chr11:66058082	T/G	cg14036092	chr11:66035641	RAB1B	0.37	9.65	0.36	1.15e-20	Gout;
BRCA	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05535760	chr7:792225	HEATR2	0.87	14.89	0.51	2.79e-43	Cerebrospinal P-tau181p levels;
BRCA	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg03433033	chr1:76189801	ACADM	-0.41	-8.24	-0.31	9.93e-16	Daytime sleep phenotypes;
BRCA	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg25173405	chr17:45401733	C17orf57	-0.54	-11.12	-0.4	2.26e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	13.91	0.48	1.32e-38	Personality dimensions;
BRCA	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg00074818	chr8:8560427	CLDN23	0.38	8.26	0.31	8.4e-16	Obesity-related traits;
BRCA	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-14.81	-0.51	6.91e-43	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg13010199	chr12:38710504	ALG10B	0.41	8.91	0.33	5.14e-18	Morning vs. evening chronotype;
BRCA	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12756686	chr19:29218302	NA	0.57	11.01	0.4	6.44e-26	Methadone dose in opioid dependence;
BRCA	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.89	0.45	6.08e-34	Bipolar disorder;
BRCA	cis	rs9986765	1.000	rs4565384	chr7:142811564	C/A	cg21852589	chr7:142981689	TMEM139	0.57	9.68	0.36	8.95e-21	Cancer;Dermatomyositis;
BRCA	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.38	-8.43	-0.32	2.26e-16	Tonsillectomy;
BRCA	cis	rs7246657	0.722	rs2909102	chr19:38167364	C/T	cg14683738	chr19:37701593	ZNF585B	-0.47	-7.96	-0.3	7.99e-15	Coronary artery calcification;
BRCA	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg06784218	chr1:46089804	CCDC17	0.51	12.3	0.44	2.3e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg10523679	chr1:76189770	ACADM	0.77	15.94	0.53	2.03e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg13736514	chr6:26305472	NA	-0.34	-11.71	-0.42	8.23e-29	Educational attainment;
BRCA	cis	rs752010	0.967	rs6681441	chr1:42098321	G/A	cg06885757	chr1:42089581	HIVEP3	0.23	8.33	0.31	4.94e-16	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs7587476	0.505	rs777323	chr2:215738485	A/G	cg04004882	chr2:215674386	BARD1	-0.53	-9.63	-0.36	1.35e-20	Neuroblastoma;
BRCA	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg24562669	chr7:97807699	LMTK2	0.46	12.25	0.44	4e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs312273	0.658	rs1372544	chr12:41353559	T/C	cg17827154	chr12:41323612	CNTN1	-0.39	-10.0	-0.37	5.71e-22	Bipolar disorder;
BRCA	cis	rs2617583	0.530	rs10060889	chr5:1456803	A/G	cg07148919	chr5:1466943	LPCAT1	-0.37	-7.89	-0.3	1.31e-14	Breast cancer;
BRCA	cis	rs705471	0.762	rs555978	chr10:3662558	G/A	cg14308648	chr10:3568949	NA	0.39	10.09	0.37	2.61e-22	Capecitabine sensitivity;
BRCA	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg05283184	chr6:79620031	NA	-0.44	-11.15	-0.4	1.62e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-9.17	-0.34	6.23e-19	Tonsillectomy;
BRCA	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.45	0.35	6.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg01620082	chr3:125678407	NA	-0.92	-10.33	-0.38	2.97e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs8073060	0.586	rs9649	chr17:34050934	C/T	cg19694781	chr19:47549865	TMEM160	1.07	20.64	0.63	6.34e-73	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	trans	rs4650994	1.000	rs10913571	chr1:178526648	A/T	cg05059571	chr16:84539110	KIAA1609	-0.41	-9.22	-0.34	4.12e-19	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg20891283	chr12:69753455	YEATS4	0.73	21.68	0.65	1.5e-78	Blood protein levels;
BRCA	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg00409905	chr10:38381863	ZNF37A	0.48	9.36	0.35	1.31e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6977660	0.714	rs728156	chr7:19826309	G/C	cg05791153	chr7:19748676	TWISTNB	0.58	10.92	0.4	1.41e-25	Thyroid stimulating hormone;
BRCA	cis	rs16854884	0.657	rs2099543	chr3:143742164	C/T	cg06585982	chr3:143692056	C3orf58	0.42	8.93	0.33	4.41e-18	Economic and political preferences (feminism/equality);
BRCA	trans	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	16.56	0.55	1.59e-51	Colorectal cancer;
BRCA	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08048268	chr3:133502702	NA	-0.32	-8.11	-0.31	2.66e-15	Iron status biomarkers;
BRCA	cis	rs7586879	0.828	rs13387053	chr2:25103025	G/A	cg04586622	chr2:25135609	ADCY3	0.4	9.48	0.35	4.77e-20	Body mass index;
BRCA	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.37	0.35	1.19e-19	Morning vs. evening chronotype;
BRCA	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg09035930	chr12:129282057	SLC15A4	0.56	16.77	0.55	1.35e-52	Systemic lupus erythematosus;
BRCA	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-10.91	-0.4	1.54e-25	Morning vs. evening chronotype;
BRCA	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg00990874	chr7:1149470	C7orf50	-0.59	-11.87	-0.42	1.7e-29	Bronchopulmonary dysplasia;
BRCA	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.62	-0.32	5.3e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg20701182	chr2:24300061	SF3B14	0.6	8.68	0.32	3.21e-17	Lymphocyte counts;
BRCA	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg08132940	chr7:1081526	C7orf50	-0.57	-8.67	-0.32	3.65e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26314531	chr2:26401878	FAM59B	-0.79	-12.72	-0.45	3.52e-33	Gut microbiome composition (summer);
BRCA	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg26597838	chr10:835615	NA	1.02	18.05	0.58	3.74e-59	Eosinophil percentage of granulocytes;
BRCA	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg27129171	chr3:47204927	SETD2	-0.73	-17.74	-0.57	1.55e-57	Colorectal cancer;
BRCA	cis	rs12474201	0.928	rs1109380	chr2:46924490	G/T	cg06386533	chr2:46925753	SOCS5	0.87	19.2	0.6	3.39e-65	Height;
BRCA	cis	rs243505	0.898	rs243544	chr7:148402710	T/A	cg09806900	chr7:148480153	CUL1	-0.4	-8.18	-0.31	1.56e-15	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs919433	0.679	rs1902249	chr2:198521356	T/C	cg00792783	chr2:198669748	PLCL1	0.39	9.02	0.34	2.24e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg03709012	chr19:19516395	GATAD2A	-0.75	-16.72	-0.55	2.46e-52	Tonsillectomy;
BRCA	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg23505145	chr19:12996616	KLF1	0.56	12.69	0.45	4.46e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg01114163	chr5:1856713	NA	-0.35	-7.84	-0.3	1.92e-14	Cardiovascular disease risk factors;
BRCA	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-9.66	-0.36	1.1e-20	Bipolar disorder;
BRCA	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg00898013	chr13:113819073	PROZ	-0.38	-9.45	-0.35	6.55e-20	Platelet distribution width;
BRCA	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17509989	chr5:176798049	RGS14	-0.9	-17.3	-0.56	2.86e-55	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs7903847	0.667	rs7096801	chr10:99140969	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.66	-0.32	3.88e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10754283	0.901	rs4520403	chr1:90112840	T/G	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.31e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg05340658	chr4:99064831	C4orf37	0.69	17.37	0.57	1.19e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg20848291	chr7:100343083	ZAN	-0.6	-12.31	-0.44	2.13e-31	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg07741184	chr6:167504864	NA	0.33	9.88	0.36	1.64e-21	Primary biliary cholangitis;
BRCA	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg05552183	chr6:42928497	GNMT	0.68	15.48	0.52	4.03e-46	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg25237894	chr2:233734115	C2orf82	0.4	11.42	0.41	1.32e-27	Coronary artery disease;
BRCA	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-12.47	-0.44	4.25e-32	Platelet count;
BRCA	trans	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	8.59	0.32	6.63e-17	Mean corpuscular volume;
BRCA	cis	rs829883	0.659	rs12366275	chr12:98920276	G/C	cg25150519	chr12:98850993	NA	-0.52	-9.44	-0.35	6.93e-20	Colorectal adenoma (advanced);
BRCA	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg19196401	chr6:110721138	DDO	0.37	9.23	0.34	3.81e-19	Platelet distribution width;
BRCA	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg04691961	chr3:161091175	C3orf57	-0.52	-12.94	-0.46	3.68e-34	Morning vs. evening chronotype;
BRCA	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.31	-0.31	5.79e-16	Bipolar disorder;
BRCA	cis	rs2249625	0.564	rs2496496	chr6:72884053	A/G	cg18830697	chr6:72922368	RIMS1	-0.63	-14.36	-0.49	9.82e-41	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.65	13.36	0.47	4.3e-36	Lymphocyte counts;
BRCA	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg06191203	chr2:152266755	RIF1	-0.28	-8.11	-0.31	2.57e-15	Lung cancer;
BRCA	cis	rs953387	0.910	rs7568884	chr2:136928320	A/G	cg05194412	chr2:137003533	NA	0.35	8.11	0.31	2.51e-15	Arthritis (juvenile idiopathic);
BRCA	cis	rs10046574	0.831	rs10227931	chr7:135084601	C/T	cg27474649	chr7:135195673	CNOT4	0.58	8.3	0.31	6.41e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19626725	chr5:178986131	RUFY1	0.36	11.04	0.4	4.54e-26	Lung cancer;
BRCA	trans	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg25214090	chr10:38739885	LOC399744	0.48	10.62	0.39	2.18e-24	Corneal astigmatism;
BRCA	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.05	29.88	0.76	2.12e-123	Cognitive ability;
BRCA	cis	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-10.39	-0.38	1.77e-23	Resting heart rate;
BRCA	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg01324343	chr3:183735012	ABCC5	0.83	20.89	0.64	3.1e-74	Anterior chamber depth;
BRCA	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg03146154	chr1:46216737	IPP	0.54	12.19	0.43	7.22e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	10.77	0.39	5.84e-25	Neuroticism;
BRCA	cis	rs6700896	0.931	rs1892534	chr1:66105944	C/T	cg04111102	chr1:66153794	NA	0.32	8.03	0.3	4.77e-15	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11764359	chr7:65958608	NA	0.79	19.31	0.61	8.49e-66	Aortic root size;
BRCA	cis	rs858239	0.899	rs1881203	chr7:23292808	T/C	cg23682824	chr7:23144976	KLHL7	0.33	8.45	0.32	1.96e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg01529538	chr14:23388837	RBM23	0.42	11.48	0.41	7.01e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs2880765	0.835	rs6497206	chr15:86029225	A/G	cg10818794	chr15:86012489	AKAP13	-0.31	-8.68	-0.32	3.23e-17	Coronary artery disease;
BRCA	cis	rs75920871	0.660	rs12271161	chr11:116979911	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.54	-9.86	-0.36	1.92e-21	Subjective well-being;
BRCA	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg13047869	chr3:10149882	C3orf24	0.55	10.3	0.38	4.02e-23	Alzheimer's disease;
BRCA	cis	rs1505368	0.836	rs10201067	chr2:213284411	A/G	cg20637307	chr2:213403960	ERBB4	-0.4	-9.6	-0.36	1.72e-20	Symmetrical dimethylarginine levels;
BRCA	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg02733842	chr7:1102375	C7orf50	-0.64	-11.97	-0.43	6.34e-30	Bronchopulmonary dysplasia;
BRCA	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg22800045	chr5:56110881	MAP3K1	0.69	12.96	0.46	2.81e-34	Initial pursuit acceleration;
BRCA	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg21427119	chr20:30132790	HM13	-0.35	-7.92	-0.3	1.08e-14	Mean corpuscular hemoglobin;
BRCA	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg04025307	chr7:1156635	C7orf50	0.58	9.0	0.34	2.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.73	-15.78	-0.53	1.26e-47	Primary sclerosing cholangitis;
BRCA	cis	rs6484504	0.576	rs208090	chr11:31190992	T/C	cg06552810	chr11:31128660	NA	-0.39	-8.6	-0.32	6.15e-17	Red blood cell count;
BRCA	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg26384229	chr12:38710491	ALG10B	0.68	14.16	0.49	8.91e-40	Morning vs. evening chronotype;
BRCA	cis	rs4629710	0.592	rs13195700	chr6:131585299	C/T	cg12606694	chr6:131520996	AKAP7	0.54	11.53	0.41	4.64e-28	Multiple myeloma (IgH translocation);
BRCA	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg27170947	chr2:26402098	FAM59B	0.94	17.46	0.57	4e-56	Gut microbiome composition (summer);
BRCA	cis	rs4363385	0.693	rs2339487	chr1:152983528	C/T	cg24667326	chr1:152973720	SPRR3	-0.35	-9.74	-0.36	5.18e-21	Inflammatory skin disease;
BRCA	cis	rs2425143	1.000	rs11699793	chr20:34271574	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.88	-0.33	6.56e-18	Blood protein levels;
BRCA	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	11.23	0.41	7.91e-27	Monocyte percentage of white cells;
BRCA	trans	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17712092	chr4:129076599	LARP1B	0.5	12.17	0.43	8.8e-31	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs672059	0.966	rs689375	chr1:183160973	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.56	0.32	8.46e-17	Hypertriglyceridemia;
BRCA	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg26384229	chr12:38710491	ALG10B	0.74	17.05	0.56	5.56e-54	Bladder cancer;
BRCA	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg04013093	chr6:42928303	GNMT	-0.28	-8.79	-0.33	1.4e-17	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24531977	chr5:56204891	C5orf35	-0.89	-18.88	-0.6	1.64e-63	Initial pursuit acceleration;
BRCA	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.68	0.61	9.04e-68	Alzheimer's disease;
BRCA	cis	rs3806701	0.619	rs6442008	chr3:46645753	C/T	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.44	-8.53	-0.32	1.08e-16	Blood protein levels;
BRCA	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.69	0.42	9.8e-29	Homoarginine levels;
BRCA	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg22713356	chr15:30763199	NA	-1.1	-21.66	-0.65	1.86e-78	Uric acid levels;
BRCA	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg13010199	chr12:38710504	ALG10B	0.49	9.62	0.36	1.5e-20	Morning vs. evening chronotype;
BRCA	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg04586622	chr2:25135609	ADCY3	0.46	11.66	0.42	1.26e-28	Body mass index;
BRCA	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-15.45	-0.52	5.35e-46	Total cholesterol levels;
BRCA	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg27170947	chr2:26402098	FAM59B	-0.47	-8.55	-0.32	8.99e-17	Gut microbiome composition (summer);
BRCA	cis	rs72634258	0.796	rs6703955	chr1:8165975	C/G	cg00042356	chr1:8021962	PARK7	-0.54	-9.27	-0.34	2.84e-19	Inflammatory bowel disease;
BRCA	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.31	-0.35	2.06e-19	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.01	22.16	0.66	3.76e-81	Gut microbiome composition (summer);
BRCA	cis	rs6745190	0.557	rs13031518	chr2:181991759	A/G	cg00481216	chr2:181971175	NA	0.47	8.89	0.33	6.33e-18	White blood cell count;
BRCA	cis	rs73001065	0.636	rs56241616	chr19:19506092	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	15.4	0.52	9.25e-46	LDL cholesterol;
BRCA	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.35	7.92	0.3	1.07e-14	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg04455712	chr21:45112962	RRP1B	0.41	11.06	0.4	3.77e-26	Mean corpuscular volume;
BRCA	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg24296786	chr1:45957014	TESK2	0.6	14.53	0.5	1.52e-41	High light scatter reticulocyte count;
BRCA	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg24692254	chr21:30365293	RNF160	0.74	20.32	0.63	3.42e-71	Dental caries;
BRCA	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.33	-0.35	1.7e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg09307838	chr4:120376055	NA	0.75	16.17	0.54	1.48e-49	Corneal astigmatism;
BRCA	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.6	11.79	0.42	3.56e-29	Multiple sclerosis;
BRCA	cis	rs41005	1.000	rs41003	chr2:8111772	A/C	cg03155496	chr2:8117019	LOC339788	0.57	15.33	0.52	2.21e-45	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg21248554	chr2:27665150	KRTCAP3	-0.35	-8.95	-0.33	3.93e-18	Total body bone mineral density;
BRCA	trans	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg00953403	chr17:74099816	EXOC7	-0.45	-8.07	-0.3	3.37e-15	Psychosis in Alzheimer's disease;
BRCA	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg24846343	chr22:24311635	DDTL	-0.56	-14.35	-0.49	1.08e-40	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2046867	0.862	rs2322612	chr3:72830058	A/G	cg25664220	chr3:72788482	NA	-0.46	-10.07	-0.37	3.19e-22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	trans	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg25206134	chr2:45395956	NA	-0.52	-8.89	-0.33	6.41e-18	Bipolar disorder;
BRCA	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg16606324	chr3:10149918	C3orf24	-0.5	-10.14	-0.37	1.61e-22	Alzheimer's disease;
BRCA	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.39	9.04	0.34	1.8e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs13046373	0.508	rs1012969	chr21:31996108	G/A	cg06468780	chr21:31798236	KRTAP13-3	0.33	8.26	0.31	8.39e-16	HDL cholesterol;
BRCA	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg09367891	chr1:107599246	PRMT6	0.55	10.1	0.37	2.42e-22	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg27446573	chr6:127587934	RNF146	0.89	20.51	0.63	3.45e-72	Breast cancer;
BRCA	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	trans	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg15704280	chr7:45808275	SEPT13	0.6	8.88	0.33	6.87e-18	Axial length;
BRCA	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	11.61	0.42	1.98e-28	Rheumatoid arthritis;
BRCA	cis	rs1506636	0.646	rs805778	chr7:123214655	C/T	cg03229431	chr7:123269106	ASB15	-0.59	-12.65	-0.45	6.73e-33	Plateletcrit;Platelet count;
BRCA	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg23978390	chr7:1156363	C7orf50	-0.38	-8.52	-0.32	1.16e-16	Longevity;Endometriosis;
BRCA	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg23625390	chr15:77176239	SCAPER	-0.54	-13.65	-0.48	1.99e-37	Blood metabolite levels;
BRCA	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg18252515	chr7:66147081	NA	0.91	13.47	0.47	1.37e-36	Diabetic kidney disease;
BRCA	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg08000102	chr2:233561755	GIGYF2	0.61	13.21	0.46	2.16e-35	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg24829409	chr8:58192753	C8orf71	-0.47	-8.1	-0.31	2.77e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg23950597	chr19:37808831	NA	-0.62	-11.37	-0.41	2.02e-27	Coronary artery calcification;
BRCA	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg26408565	chr15:76604113	ETFA	-0.48	-10.29	-0.38	4.59e-23	Blood metabolite levels;
BRCA	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg10729496	chr3:10149963	C3orf24	-0.43	-8.54	-0.32	9.47e-17	Alzheimer's disease;
BRCA	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg23649088	chr2:200775458	C2orf69	0.61	10.58	0.39	3.19e-24	Schizophrenia;
BRCA	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg03146154	chr1:46216737	IPP	0.45	9.99	0.37	6.35e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	8.52	0.32	1.15e-16	Rheumatoid arthritis;
BRCA	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.67	-16.23	-0.54	7.33e-50	Ulcerative colitis;
BRCA	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg01877450	chr7:97915802	BRI3	-0.39	-8.63	-0.32	4.77e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8017423	0.647	rs12895269	chr14:90822430	T/C	cg04374321	chr14:90722782	PSMC1	-0.49	-11.86	-0.42	1.75e-29	Mortality in heart failure;
BRCA	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	trans	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-20.99	-0.64	8.24e-75	Exhaled nitric oxide output;
BRCA	trans	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg26043149	chr18:55253948	FECH	0.39	8.33	0.31	5.05e-16	Bone mineral density;
BRCA	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-12.01	-0.43	4.2000000000000004e-30	Schizophrenia;
BRCA	cis	rs858239	0.601	rs6980224	chr7:23149137	C/T	cg23682824	chr7:23144976	KLHL7	0.42	11.17	0.4	1.44e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg23711669	chr6:146136114	FBXO30	-0.62	-14.03	-0.49	3.49e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.99	26.3	0.72	7.42e-104	Body mass index (adult);
BRCA	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg17063962	chr7:91808500	NA	0.53	12.07	0.43	2.32e-30	Breast cancer;
BRCA	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg02556042	chr12:117471086	NA	0.55	10.0	0.37	5.74e-22	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg06784218	chr1:46089804	CCDC17	0.51	12.22	0.44	5.44e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg26769984	chr7:1090371	C7orf50	0.48	9.1	0.34	1.12e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs10046574	0.731	rs10270842	chr7:135163062	A/G	cg27474649	chr7:135195673	CNOT4	0.52	8.06	0.3	3.88e-15	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	10.98	0.4	8.2e-26	Lung cancer in ever smokers;
BRCA	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg22491629	chr6:157744540	C6orf35	-0.68	-12.22	-0.44	5.38e-31	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg07636037	chr3:49044803	WDR6	0.52	8.53	0.32	1.04e-16	Menarche (age at onset);
BRCA	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg21775007	chr8:11205619	TDH	0.63	13.99	0.48	5.56e-39	Retinal vascular caliber;
BRCA	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.57	-0.32	7.75e-17	Total body bone mineral density;
BRCA	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg26384229	chr12:38710491	ALG10B	0.49	12.68	0.45	5.13e-33	Heart rate;
BRCA	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24110177	chr3:50126178	RBM5	-0.36	-9.71	-0.36	6.98e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	25.44	0.71	4.05e-99	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg24154853	chr7:158122151	PTPRN2	0.35	8.16	0.31	1.74e-15	Calcium levels;
BRCA	cis	rs11971779	0.648	rs7799165	chr7:139084957	G/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.35e-23	Diisocyanate-induced asthma;
BRCA	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-11.28	-0.41	4.76e-27	Bone mineral density;
BRCA	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg27535305	chr1:53392650	SCP2	-0.32	-7.99	-0.3	6.16e-15	Monocyte count;
BRCA	trans	rs9944715	1.000	rs9944836	chr18:43831380	C/T	cg01718231	chr17:29326311	RNF135	0.45	9.09	0.34	1.21e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	trans	rs783540	1.000	rs1267657	chr15:83215251	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.26	-8.0	-0.3	5.84e-15	Schizophrenia;
BRCA	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.3	8.35	0.31	4.34e-16	Monocyte percentage of white cells;
BRCA	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg23505145	chr19:12996616	KLF1	0.54	12.33	0.44	1.69e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.71	0.33	2.61e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg21659725	chr3:3221576	CRBN	-0.45	-9.95	-0.37	8.66e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg11266682	chr4:10021025	SLC2A9	0.47	12.09	0.43	1.85e-30	Bone mineral density;
BRCA	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19717773	chr7:2847554	GNA12	-0.38	-8.01	-0.3	5.41e-15	Height;
BRCA	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg21573476	chr21:45109991	RRP1B	-0.33	-8.48	-0.32	1.56e-16	Mean corpuscular volume;
BRCA	cis	rs12474201	0.928	rs7594523	chr2:46935791	G/C	cg06386533	chr2:46925753	SOCS5	0.81	18.08	0.58	2.55e-59	Height;
BRCA	cis	rs7246657	0.722	rs2972447	chr19:38129736	C/T	cg14683738	chr19:37701593	ZNF585B	-0.46	-7.84	-0.3	1.96e-14	Coronary artery calcification;
BRCA	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg21535247	chr6:8435926	SLC35B3	0.4	8.96	0.33	3.57e-18	Motion sickness;
BRCA	trans	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg25206134	chr2:45395956	NA	0.53	8.82	0.33	1.05e-17	Bipolar disorder;
BRCA	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg25019033	chr10:957182	NA	-0.43	-8.97	-0.33	3.13e-18	Eosinophil percentage of granulocytes;
BRCA	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg24578937	chr1:2090814	PRKCZ	0.36	11.31	0.41	3.73e-27	Height;
BRCA	cis	rs12618769	0.652	rs3754877	chr2:99184019	A/G	cg10123293	chr2:99228465	UNC50	0.44	8.49	0.32	1.49e-16	Bipolar disorder;
BRCA	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.32	-0.44	1.93e-31	Bipolar disorder;
BRCA	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	9.52	0.35	3.59e-20	Aortic root size;
BRCA	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg05347473	chr6:146136440	FBXO30	0.41	8.07	0.3	3.38e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg04756594	chr16:24857601	SLC5A11	0.35	8.61	0.32	5.72e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7617773	0.817	rs6791930	chr3:48329900	A/G	cg11946769	chr3:48343235	NME6	0.63	13.53	0.47	7.1e-37	Coronary artery disease;
BRCA	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg09877947	chr5:131593287	PDLIM4	0.38	9.78	0.36	3.94e-21	Breast cancer;
BRCA	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg25173405	chr17:45401733	C17orf57	-0.56	-12.11	-0.43	1.54e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg22105103	chr4:187893119	NA	0.41	13.36	0.47	4.33e-36	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.747	rs4845504	chr1:152960043	G/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.4	-0.32	2.95e-16	Inflammatory skin disease;
BRCA	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg12310025	chr6:25882481	NA	-0.51	-11.31	-0.41	3.65e-27	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg25214090	chr10:38739885	LOC399744	0.55	12.09	0.43	1.97e-30	Corneal astigmatism;
BRCA	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-14.62	-0.5	5.59e-42	Coronary artery disease;
BRCA	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	18.83	0.6	3.15e-63	Multiple sclerosis;
BRCA	cis	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg06521331	chr12:34319734	NA	0.56	10.01	0.37	5.41e-22	Morning vs. evening chronotype;
BRCA	cis	rs11025559	0.773	rs10833334	chr11:20498640	T/C	cg19653624	chr11:20408972	PRMT3	-0.45	-9.88	-0.36	1.58e-21	Pursuit maintenance gain;
BRCA	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg07636037	chr3:49044803	WDR6	0.5	8.23	0.31	1.02e-15	Menarche (age at onset);
BRCA	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24549020	chr5:56110836	MAP3K1	0.55	10.98	0.4	7.84e-26	Initial pursuit acceleration;
BRCA	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg02551604	chr5:131831745	NA	-0.39	-13.57	-0.47	4.73e-37	Asthma (sex interaction);
BRCA	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg10729496	chr3:10149963	C3orf24	0.49	9.17	0.34	6.54e-19	Alzheimer's disease;
BRCA	trans	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg07211511	chr3:129823064	LOC729375	-0.61	-10.87	-0.4	2.29e-25	Blood pressure (smoking interaction);
BRCA	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19346786	chr7:2764209	NA	-0.31	-8.98	-0.33	3.11e-18	Height;
BRCA	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05901451	chr6:126070800	HEY2	-0.55	-14.89	-0.51	2.88e-43	Brugada syndrome;
BRCA	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.2	0.37	9.45e-23	Aortic root size;
BRCA	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg13397359	chr6:42928475	GNMT	0.66	16.08	0.54	4.1e-49	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg20891283	chr12:69753455	YEATS4	0.84	28.33	0.75	5.71e-115	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7799006	0.929	rs6951493	chr7:2257612	G/A	cg08027265	chr7:2291960	NA	-0.4	-10.04	-0.37	4.17e-22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs4363385	0.747	rs1577964	chr1:152961784	C/A	cg24667326	chr1:152973720	SPRR3	-0.33	-8.98	-0.33	3.06e-18	Inflammatory skin disease;
BRCA	cis	rs724568	0.565	rs13405830	chr2:67952260	A/G	cg14046302	chr2:67939758	NA	-0.37	-9.81	-0.36	3.07e-21	Major depressive disorder (broad);
BRCA	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg21770322	chr7:97807741	LMTK2	0.44	11.54	0.42	4.02e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.23	-0.41	7.51e-27	Colorectal cancer;
BRCA	trans	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg25206134	chr2:45395956	NA	0.53	8.37	0.31	3.66e-16	Neuroticism;
BRCA	cis	rs919433	0.680	rs787983	chr2:198345797	C/T	cg00792783	chr2:198669748	PLCL1	0.35	8.11	0.31	2.56e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs13102973	0.640	rs4608865	chr4:135885434	G/A	cg14419869	chr4:135874104	NA	-0.5	-9.84	-0.36	2.33e-21	Subjective well-being;
BRCA	cis	rs7254827	0.737	rs34563036	chr19:17154195	C/T	cg19418318	chr19:17219073	MYO9B	-0.48	-10.13	-0.37	1.86e-22	Mean platelet volume;
BRCA	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-9.95	-0.37	8.92e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg08999081	chr20:33150536	PIGU	0.49	13.7	0.48	1.19e-37	Coronary artery disease;
BRCA	cis	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-10.14	-0.37	1.63e-22	Endometrial cancer;
BRCA	cis	rs754466	0.561	rs11002343	chr10:79705871	G/A	cg17075019	chr10:79541650	NA	-0.54	-7.98	-0.3	6.56e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg22153463	chr1:85462885	MCOLN2	-0.57	-9.99	-0.37	5.94e-22	Serum sulfate level;
BRCA	trans	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg06521331	chr12:34319734	NA	0.43	8.41	0.32	2.77e-16	Morning vs. evening chronotype;
BRCA	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg18132916	chr6:79620363	NA	-0.48	-10.89	-0.4	1.89e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.43	10.44	0.38	1.14e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg05084668	chr3:125655381	ALG1L	-0.82	-11.53	-0.41	4.52e-28	Blood pressure (smoking interaction);
BRCA	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg09877947	chr5:131593287	PDLIM4	0.49	12.48	0.44	3.8e-32	Acylcarnitine levels;
BRCA	cis	rs2625529	0.761	rs3743224	chr15:72466799	C/T	cg16672083	chr15:72433130	SENP8	-0.83	-17.56	-0.57	1.25e-56	Red blood cell count;
BRCA	cis	rs11051970	0.879	rs2733682	chr12:32574608	G/A	cg24626660	chr12:32551988	NA	0.29	8.15	0.31	1.91e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg13047869	chr3:10149882	C3orf24	0.6	12.65	0.45	6.87e-33	Alzheimer's disease;
BRCA	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.5	-9.71	-0.36	7.16e-21	Body mass index;
BRCA	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.94	0.3	8.91e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg07148914	chr20:33460835	GGT7	-0.42	-9.03	-0.34	1.99e-18	Height;
BRCA	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11644478	chr21:40555479	PSMG1	-0.67	-14.44	-0.5	4.36e-41	Cognitive function;
BRCA	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg04362960	chr10:104952993	NT5C2	0.42	9.74	0.36	5.38e-21	Arsenic metabolism;
BRCA	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg04727924	chr7:799746	HEATR2	-0.55	-10.87	-0.4	2.25e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg03213289	chr20:61660250	NA	0.62	16.39	0.54	1.23e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg18357645	chr12:58087776	OS9	0.33	8.06	0.3	3.89e-15	Multiple sclerosis;
BRCA	cis	rs68092024	0.731	rs792841	chr3:99471308	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-10.67	-0.39	1.43e-24	Cleft lip with or without cleft palate;
BRCA	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg13256891	chr4:100009986	ADH5	0.51	10.53	0.38	5.08e-24	Alcohol dependence;
BRCA	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg14675211	chr2:100938903	LONRF2	0.5	11.42	0.41	1.35e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg06238570	chr21:40685208	BRWD1	0.44	8.91	0.33	5.37e-18	Cognitive function;
BRCA	cis	rs13064411	0.696	rs2399479	chr3:113227050	G/A	cg18753928	chr3:113234510	CCDC52	-0.58	-11.79	-0.42	3.58e-29	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.21	-0.34	4.57e-19	Alzheimer's disease (late onset);
BRCA	cis	rs2652822	1.000	rs1126308	chr15:63429086	G/T	cg02713581	chr15:63449717	RPS27L	-0.46	-9.5	-0.35	4.11e-20	Metabolic traits;
BRCA	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg24006582	chr15:45444508	DUOX1	0.56	11.26	0.41	6.01e-27	Uric acid levels;
BRCA	cis	rs1865721	1.000	rs11659761	chr18:73186974	A/G	cg26385618	chr18:73139727	C18orf62	-0.39	-8.85	-0.33	8.71e-18	Intelligence;
BRCA	cis	rs7677751	0.806	rs60806423	chr4:55086816	C/T	cg17187183	chr4:55093834	PDGFRA	0.45	8.95	0.33	3.96e-18	Corneal astigmatism;
BRCA	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg07952391	chr2:88470173	THNSL2	0.58	8.09	0.3	3.09e-15	Plasma clusterin levels;
BRCA	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.87	0.4	2.26e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6450176	1.000	rs7735253	chr5:53297611	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-15.18	-0.51	1.2e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	8.23	0.31	1.04e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg21535247	chr6:8435926	SLC35B3	0.41	9.45	0.35	6.39e-20	Motion sickness;
BRCA	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.79	0.42	3.68e-29	Homoarginine levels;
BRCA	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg14186256	chr22:23484241	RTDR1	0.77	23.32	0.68	1.77e-87	Bone mineral density;
BRCA	trans	rs1493916	0.837	rs4992177	chr18:31407020	C/T	cg15819921	chr19:927150	ARID3A	-0.41	-8.07	-0.3	3.37e-15	Life satisfaction;
BRCA	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18876405	chr7:65276391	NA	0.62	15.47	0.52	4.15e-46	Aortic root size;
BRCA	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg00071950	chr4:10020882	SLC2A9	-0.43	-10.11	-0.37	2.14e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12200560	0.505	rs211162	chr6:97067344	G/A	cg06623918	chr6:96969491	KIAA0776	0.51	12.09	0.43	1.99e-30	Coronary heart disease;
BRCA	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg11789530	chr4:8429930	ACOX3	0.66	16.29	0.54	3.73e-50	Response to antineoplastic agents;
BRCA	trans	rs10411161	0.702	rs7251755	chr19:52388948	G/A	cg22319618	chr22:45562946	NUP50	-0.42	-8.02	-0.3	4.89e-15	Breast cancer;
BRCA	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg01483505	chr11:975446	AP2A2	0.32	8.43	0.32	2.36e-16	Alzheimer's disease (late onset);
BRCA	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg24812749	chr6:127587940	RNF146	0.65	14.65	0.5	4.28e-42	Breast cancer;
BRCA	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.17	-0.4	1.33e-26	Schizophrenia;
BRCA	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.23e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07080220	chr10:102295463	HIF1AN	0.49	11.31	0.41	3.76e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs10465746	0.780	rs2389649	chr1:84379449	C/T	cg10977910	chr1:84465055	TTLL7	0.55	11.51	0.41	5.39e-28	Obesity-related traits;
BRCA	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.06	-0.3	3.81e-15	Prostate cancer;
BRCA	cis	rs12541635	0.677	rs1006480	chr8:106975524	T/C	cg10147462	chr8:107024639	NA	0.39	10.48	0.38	7.74e-24	Age of smoking initiation;
BRCA	cis	rs11231017	0.507	rs9633987	chr11:62071249	C/T	cg23876832	chr11:62092739	NA	0.32	8.09	0.3	2.91e-15	HIV-1 viral setpoint;
BRCA	cis	rs3772130	1.000	rs11714406	chr3:121372513	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	9.33	0.35	1.74e-19	Cognitive performance;
BRCA	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg17971929	chr21:40555470	PSMG1	0.51	11.61	0.42	2.02e-28	Cognitive function;
BRCA	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02475777	chr4:1388615	CRIPAK	-0.51	-9.87	-0.36	1.73e-21	Obesity-related traits;
BRCA	trans	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-15.22	-0.52	7.28e-45	Obesity-related traits;
BRCA	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg18867708	chr6:26865862	GUSBL1	0.42	8.26	0.31	8.26e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs312274	0.569	rs4638361	chr12:41319355	A/G	cg17827154	chr12:41323612	CNTN1	-0.42	-10.47	-0.38	8.73e-24	Metabolite levels  (X-11787);
BRCA	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg20991723	chr1:152506922	NA	0.39	9.08	0.34	1.36e-18	Hair morphology;
BRCA	cis	rs7809950	0.817	rs2253833	chr7:107205669	A/G	cg23024343	chr7:107201750	COG5	0.48	9.93	0.37	1.06e-21	Coronary artery disease;
BRCA	cis	rs2629540	0.847	rs10901811	chr10:126417914	G/A	cg08799069	chr10:126477246	METTL10	0.44	9.04	0.34	1.91e-18	Cocaine dependence;
BRCA	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg03060546	chr3:49711283	APEH	-0.57	-11.1	-0.4	2.76e-26	Educational attainment;
BRCA	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10802521	chr3:52805072	NEK4	-0.33	-8.9	-0.33	5.54e-18	Bipolar disorder;
BRCA	cis	rs789294	1	rs789294	chr3:154057741	C/G	cg17054900	chr3:154042577	DHX36	0.68	11.88	0.43	1.56e-29	Coronary artery disease;
BRCA	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg26384229	chr12:38710491	ALG10B	0.85	22.52	0.67	3.94e-83	Heart rate;
BRCA	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg12310025	chr6:25882481	NA	0.43	10.8	0.39	4.17e-25	Blood metabolite levels;
BRCA	cis	rs17401966	1.000	rs11121533	chr1:10292888	G/C	cg03954927	chr1:10346856	KIF1B	0.44	13.05	0.46	1.08e-34	Hepatocellular carcinoma;
BRCA	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg14789911	chr21:47582049	C21orf56	-0.38	-7.99	-0.3	6.29e-15	Testicular germ cell tumor;
BRCA	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.5	0.44	3.09e-32	Electroencephalogram traits;
BRCA	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg21782813	chr7:2030301	MAD1L1	-0.36	-9.73	-0.36	5.88e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs11971779	0.941	rs7800795	chr7:139080348	A/G	cg07862535	chr7:139043722	LUC7L2	0.53	12.87	0.45	7.08e-34	Diisocyanate-induced asthma;
BRCA	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg26384229	chr12:38710491	ALG10B	0.67	15.18	0.51	1.13e-44	Bladder cancer;
BRCA	cis	rs9560113	1.000	rs11620313	chr13:112179363	G/A	cg10483660	chr13:112241077	NA	0.31	7.84	0.3	1.91e-14	Menarche (age at onset);
BRCA	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.04	0.58	4.21e-59	Colorectal cancer;
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18402987	chr7:1209562	NA	0.65	14.81	0.51	6.9e-43	Longevity;Endometriosis;
BRCA	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg25427524	chr10:38739819	LOC399744	0.58	13.06	0.46	1.01e-34	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs12474201	0.928	rs17822019	chr2:46934505	T/C	cg06386533	chr2:46925753	SOCS5	0.87	18.92	0.6	1.02e-63	Height;
BRCA	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-12.04	-0.43	3.09e-30	Response to antipsychotic treatment;
BRCA	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	17.19	0.56	1.06e-54	Hip circumference adjusted for BMI;
BRCA	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg11833968	chr6:79620685	NA	-0.43	-9.55	-0.35	2.75e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg23711669	chr6:146136114	FBXO30	0.66	14.94	0.51	1.6700000000000001e-43	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg15704280	chr7:45808275	SEPT13	0.6	10.71	0.39	9.62e-25	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg18232548	chr7:50535776	DDC	-0.51	-12.79	-0.45	1.57e-33	Response to zileuton treatment in asthma (FEV1 change interaction);
BRCA	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg10578991	chr7:12443926	VWDE	-0.57	-8.08	-0.3	3.31e-15	Coronary artery disease;
BRCA	cis	rs6426558	0.502	rs10916080	chr1:227232040	A/G	cg10327440	chr1:227177885	CDC42BPA	0.48	9.49	0.35	4.49e-20	Neutrophil percentage of white cells;
BRCA	cis	rs367943	0.965	rs644154	chr5:112799080	G/T	cg12552261	chr5:112820674	MCC	-0.55	-12.1	-0.43	1.81e-30	Type 2 diabetes;
BRCA	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg27347728	chr4:17578864	LAP3	0.44	8.54	0.32	1.01e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12618769	0.597	rs72821943	chr2:99141640	T/C	cg10123293	chr2:99228465	UNC50	0.41	8.24	0.31	9.93e-16	Bipolar disorder;
BRCA	trans	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg06521331	chr12:34319734	NA	0.5	9.63	0.36	1.34e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg08085267	chr17:45401833	C17orf57	0.66	14.35	0.49	1.11e-40	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.44	-8.88	-0.33	6.8e-18	Tonsillectomy;
BRCA	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.73	-14.83	-0.51	5.57e-43	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.22	-0.54	8.78e-50	Alzheimer's disease (late onset);
BRCA	cis	rs1400816	0.702	rs58565148	chr2:172535396	C/T	cg13550731	chr2:172543902	DYNC1I2	0.54	8.48	0.32	1.56e-16	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.81	-0.33	1.2e-17	Mood instability;
BRCA	trans	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg02030672	chr11:45687055	CHST1	0.38	8.67	0.32	3.64e-17	Obesity-related traits;
BRCA	cis	rs7649275	0.882	rs755886	chr3:53791948	A/T	cg21503701	chr3:53781065	CACNA1D	0.45	8.06	0.3	3.86e-15	Trans fatty acid levels;
BRCA	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg06238570	chr21:40685208	BRWD1	-0.41	-8.32	-0.31	5.38e-16	Cognitive function;
BRCA	cis	rs524281	0.817	rs7115081	chr11:65853541	A/G	cg16950941	chr11:66035639	RAB1B	-0.38	-8.05	-0.3	4.15e-15	Electroencephalogram traits;
BRCA	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg08508325	chr11:3079039	CARS	0.28	8.49	0.32	1.5e-16	Calcium levels;
BRCA	cis	rs9815354	0.812	rs4299460	chr3:41952445	A/C	cg03022575	chr3:42003672	ULK4	0.69	9.62	0.36	1.44e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.31	8.97	0.33	3.33e-18	Bipolar disorder;
BRCA	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg05313129	chr8:58192883	C8orf71	-0.48	-9.84	-0.36	2.23e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11644478	chr21:40555479	PSMG1	-0.68	-14.83	-0.51	5.69e-43	Cognitive function;
BRCA	cis	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg09307838	chr4:120376055	NA	0.44	9.15	0.34	7.81e-19	Diastolic blood pressure;
BRCA	cis	rs10463316	0.817	rs11167545	chr5:150778076	C/T	cg03212797	chr5:150827313	SLC36A1	-0.4	-7.89	-0.3	1.3e-14	Metabolite levels (Pyroglutamine);
BRCA	cis	rs6087990	0.899	rs6058893	chr20:31392777	C/T	cg13636640	chr20:31349939	DNMT3B	0.68	21.15	0.64	1.08e-75	Ulcerative colitis;
BRCA	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.62	0.55	8.44e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	11.73	0.42	6.59e-29	Tonsillectomy;
BRCA	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg12463550	chr7:65579703	CRCP	-0.37	-8.02	-0.3	5.18e-15	Aortic root size;
BRCA	cis	rs7805747	1.000	rs10480299	chr7:151405818	A/G	cg17611936	chr7:151411526	PRKAG2	0.4	7.87	0.3	1.55e-14	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
BRCA	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg22903471	chr2:27725779	GCKR	-0.36	-8.73	-0.33	2.29e-17	Total body bone mineral density;
BRCA	trans	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg09719594	chr16:21412588	NA	-0.32	-8.0	-0.3	6.07e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.79e-21	Bladder cancer;
BRCA	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg06238570	chr21:40685208	BRWD1	-0.41	-8.21	-0.31	1.26e-15	Menarche (age at onset);
BRCA	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg03342759	chr3:160939853	NMD3	-0.72	-14.78	-0.5	1.01e-42	Parkinson's disease;
BRCA	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.57	12.55	0.44	1.93e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg13880726	chr7:1868755	MAD1L1	0.43	8.49	0.32	1.47e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg07460842	chr6:66804631	NA	0.99	19.82	0.62	1.59e-68	Exhaled nitric oxide output;
BRCA	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg23711669	chr6:146136114	FBXO30	0.79	18.22	0.58	4.92e-60	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3784262	0.669	rs17820990	chr15:58349568	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-10.57	-0.39	3.69e-24	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.88	-0.36	1.65e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg02475777	chr4:1388615	CRIPAK	0.38	8.33	0.31	5.12e-16	Longevity;
BRCA	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg11752832	chr7:134001865	SLC35B4	0.5	12.69	0.45	4.42e-33	Mean platelet volume;
BRCA	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg20503657	chr10:835505	NA	-0.54	-9.89	-0.36	1.42e-21	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg11764359	chr7:65958608	NA	0.66	12.01	0.43	4.34e-30	Aortic root size;
BRCA	cis	rs7809950	0.678	rs17153981	chr7:106922106	A/G	cg23024343	chr7:107201750	COG5	-0.46	-9.15	-0.34	7.64e-19	Coronary artery disease;
BRCA	cis	rs1403694	0.695	rs5029970	chr3:186434491	T/C	cg12454167	chr3:186435060	KNG1	0.29	7.94	0.3	8.96e-15	Blood protein levels;
BRCA	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg00495681	chr13:53174319	NA	0.41	8.66	0.32	3.93e-17	Lewy body disease;
BRCA	cis	rs752010	0.871	rs10789405	chr1:42101962	C/T	cg06885757	chr1:42089581	HIVEP3	0.25	8.92	0.33	4.78e-18	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.44	-9.03	-0.34	2.06e-18	IgG glycosylation;
BRCA	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg20636351	chr8:55087400	NA	-0.29	-7.95	-0.3	8.33e-15	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg21770322	chr7:97807741	LMTK2	0.44	11.77	0.42	4.58e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6733011	0.519	rs12990579	chr2:99457447	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.36	-7.81	-0.3	2.29e-14	Bipolar disorder;
BRCA	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg15432903	chr11:17409602	KCNJ11	0.79	17.2	0.56	9.29e-55	Type 2 diabetes;
BRCA	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7975161	0.630	rs4129598	chr12:104620638	T/C	cg25273343	chr12:104657179	TXNRD1	-0.61	-10.34	-0.38	2.74e-23	Toenail selenium levels;
BRCA	cis	rs208520	0.690	rs866452	chr6:66849936	A/T	cg07460842	chr6:66804631	NA	-1.0	-20.23	-0.62	1.01e-70	Exhaled nitric oxide output;
BRCA	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-14.82	-0.51	6.35e-43	Parkinson's disease;
BRCA	cis	rs965469	1.000	rs6051708	chr20:3262493	A/G	cg25506879	chr20:3388711	C20orf194	-0.48	-9.03	-0.34	2.04e-18	IFN-related cytopenia;
BRCA	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg21775007	chr8:11205619	TDH	-0.6	-12.42	-0.44	7.3e-32	Retinal vascular caliber;
BRCA	cis	rs72634258	0.503	rs34177663	chr1:7833228	A/G	cg26816564	chr1:7831052	VAMP3	0.73	12.95	0.46	3.1e-34	Inflammatory bowel disease;
BRCA	cis	rs7178424	1.000	rs7178945	chr15:62379814	T/C	cg00456672	chr15:62358751	C2CD4A	-0.34	-8.15	-0.31	1.87e-15	Height;
BRCA	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg26116260	chr4:7069785	GRPEL1	-0.95	-26.48	-0.72	7.5e-105	Monocyte percentage of white cells;
BRCA	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg17063962	chr7:91808500	NA	0.53	12.58	0.45	1.43e-32	Breast cancer;
BRCA	cis	rs12986413	1.000	rs11882273	chr19:2173836	T/C	cg09261902	chr19:2140048	AP3D1	0.38	9.94	0.37	9.61e-22	Height;
BRCA	trans	rs11088226	0.681	rs74779447	chr21:33929013	G/A	cg09050820	chr6:167586206	TCP10L2	0.79	13.98	0.48	6.21e-39	Gastritis;
BRCA	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg04034577	chr2:241836375	C2orf54	-0.5	-12.59	-0.45	1.21e-32	Urinary metabolites;
BRCA	cis	rs4589502	1.000	rs79390908	chr15:67130924	C/T	cg09911534	chr15:67153556	NA	-0.81	-10.09	-0.37	2.57e-22	Lung cancer (smoking interaction);
BRCA	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg26384229	chr12:38710491	ALG10B	0.72	15.5	0.52	2.97e-46	Bladder cancer;
BRCA	trans	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.84	-27.72	-0.74	1.21e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7246657	0.722	rs2909100	chr19:38212680	C/T	cg18154014	chr19:37997991	ZNF793	-0.49	-9.39	-0.35	1.03e-19	Coronary artery calcification;
BRCA	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.69	-15.4	-0.52	1.02e-45	Breast cancer;
BRCA	cis	rs9815354	0.812	rs59138513	chr3:41908611	T/G	cg03022575	chr3:42003672	ULK4	0.69	9.49	0.35	4.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg26752888	chr8:11627280	NEIL2	-0.76	-15.74	-0.53	2.08e-47	Alcohol dependence;Nicotine use;
BRCA	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.41	9.18	0.34	5.89e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9329289	0.510	rs12359941	chr10:2547015	G/A	cg15501526	chr10:2543763	NA	0.46	10.7	0.39	1.06e-24	Age-related hearing impairment;
BRCA	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	20.65	0.63	5.7e-73	Electrocardiographic conduction measures;
BRCA	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg14829155	chr15:31115871	NA	-0.42	-10.21	-0.37	9.21e-23	Huntington's disease progression;
BRCA	trans	rs3857536	0.813	rs6903411	chr6:66938288	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs9337951	0.595	rs2478835	chr10:30317949	C/T	cg00730780	chr10:30316187	KIAA1462	-0.47	-9.79	-0.36	3.63e-21	Pulse pressure;Coronary artery disease;
BRCA	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10802521	chr3:52805072	NEK4	-0.29	-7.96	-0.3	7.6e-15	Bipolar disorder;
BRCA	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg11663144	chr21:46675770	NA	-0.62	-14.32	-0.49	1.53e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg01689657	chr7:91764605	CYP51A1	0.23	7.96	0.3	8e-15	Breast cancer;
BRCA	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg08888203	chr3:10149979	C3orf24	0.65	11.96	0.43	6.52e-30	Alzheimer's disease;
BRCA	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-8.8	-0.33	1.3e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-14.01	-0.48	4.34e-39	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg25358565	chr5:93447407	FAM172A	1.2	19.89	0.62	7.04e-69	Diabetic retinopathy;
BRCA	cis	rs17092148	1.000	rs7271289	chr20:33397303	C/T	cg16810054	chr20:33298113	TP53INP2	0.49	11.17	0.4	1.35e-26	Neuroticism;
BRCA	cis	rs977987	0.806	rs17696696	chr16:75393352	G/T	cg03315344	chr16:75512273	CHST6	-0.52	-12.41	-0.44	7.93e-32	Dupuytren's disease;
BRCA	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	10.01	0.37	5.17e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg13010199	chr12:38710504	ALG10B	0.57	12.57	0.45	1.55e-32	Heart rate;
BRCA	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.81	0.39	3.95e-25	Bipolar disorder;
BRCA	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg21775007	chr8:11205619	TDH	-0.38	-7.95	-0.3	8.72e-15	Neuroticism;
BRCA	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg13010199	chr12:38710504	ALG10B	0.42	8.65	0.32	4.32e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg21573476	chr21:45109991	RRP1B	-0.36	-9.25	-0.34	3.21e-19	Mean corpuscular volume;
BRCA	cis	rs41005	1.000	rs798450	chr2:8107093	C/T	cg03155496	chr2:8117019	LOC339788	0.56	14.89	0.51	3.02e-43	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg20701182	chr2:24300061	SF3B14	0.68	9.83	0.36	2.55e-21	Lymphocyte counts;
BRCA	cis	rs870825	0.550	rs57301026	chr4:185646505	C/G	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-8.53	-0.32	1.07e-16	Longevity;Endometriosis;
BRCA	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg12826209	chr6:26865740	GUSBL1	0.56	9.23	0.34	3.92e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg06697600	chr4:7070879	GRPEL1	-0.55	-11.27	-0.41	5.42e-27	Monocyte percentage of white cells;
BRCA	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg14582100	chr15:45693742	SPATA5L1	0.37	12.16	0.43	9.5e-31	Homoarginine levels;
BRCA	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg27446573	chr6:127587934	RNF146	-0.93	-21.58	-0.65	5.23e-78	Breast cancer;
BRCA	cis	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg09526685	chr4:187126073	CYP4V2	0.73	9.93	0.37	1.03e-21	Blood protein levels;
BRCA	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg12310025	chr6:25882481	NA	-0.81	-21.07	-0.64	3.01e-75	Urate levels;
BRCA	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2422052	0.614	rs13033724	chr2:118644670	C/T	cg22545206	chr2:118617499	NA	0.38	9.25	0.34	3.2e-19	Mosquito bite size;
BRCA	cis	rs751728	0.664	rs2296744	chr6:33740382	G/A	cg25922239	chr6:33757077	LEMD2	0.49	11.93	0.43	8.9e-30	Crohn's disease;
BRCA	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg13854012	chr2:162103682	NA	-0.39	-8.69	-0.33	2.94e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg00277334	chr10:82204260	NA	0.52	11.16	0.4	1.52e-26	Post bronchodilator FEV1;
BRCA	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg06784218	chr1:46089804	CCDC17	0.45	10.83	0.39	3.23e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg00814883	chr7:100076585	TSC22D4	-0.54	-10.51	-0.38	6.04e-24	Platelet count;
BRCA	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg08859206	chr1:53392774	SCP2	0.45	10.04	0.37	4.12e-22	Monocyte count;
BRCA	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg22800045	chr5:56110881	MAP3K1	0.51	9.9	0.36	1.36e-21	Type 2 diabetes;
BRCA	cis	rs7178424	0.742	rs1981917	chr15:62171906	A/G	cg00456672	chr15:62358751	C2CD4A	-0.37	-8.9	-0.33	5.84e-18	Height;
BRCA	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg10523679	chr1:76189770	ACADM	0.76	15.9	0.53	3.47e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9790314	0.535	rs4679922	chr3:160642984	T/C	cg03342759	chr3:160939853	NMD3	0.43	8.31	0.31	5.73e-16	Morning vs. evening chronotype;
BRCA	cis	rs9296092	0.500	rs9461885	chr6:33521069	G/T	cg13560919	chr6:33536144	NA	-0.85	-18.66	-0.59	2.26e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	trans	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg23762105	chr12:34175262	ALG10	-0.36	-9.01	-0.34	2.34e-18	Morning vs. evening chronotype;
BRCA	cis	rs1198430	1.000	rs1198434	chr1:23758134	A/G	cg19827787	chr1:23763612	ASAP3	0.35	9.24	0.34	3.5e-19	Total cholesterol levels;
BRCA	trans	rs9397585	0.599	rs685826	chr6:153411255	C/T	cg25263898	chr1:36774223	C1orf113	-0.45	-8.56	-0.32	8.48e-17	Body mass index;
BRCA	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg18225595	chr11:63971243	STIP1	0.43	10.93	0.4	1.34e-25	Platelet count;
BRCA	cis	rs7552167	0.925	rs7546025	chr1:24510252	T/C	cg01960748	chr1:24522592	NA	-0.61	-10.03	-0.37	4.54e-22	Psoriasis vulgaris;
BRCA	cis	rs7254827	0.868	rs62127865	chr19:17210164	A/G	cg19418318	chr19:17219073	MYO9B	-0.51	-10.4	-0.38	1.69e-23	Mean platelet volume;
BRCA	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg08601574	chr20:25228251	PYGB	0.35	8.48	0.32	1.51e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.53	0.32	1.05e-16	Corneal astigmatism;
BRCA	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.03	0.3	4.61e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.81	0.33	1.19e-17	Motion sickness;
BRCA	cis	rs36052053	0.908	rs34780834	chr6:109624766	C/A	cg12927641	chr6:109611667	NA	-0.5	-7.84	-0.3	1.95e-14	Red cell distribution width;
BRCA	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.85	-0.33	8.34e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg12160578	chr15:63334699	TPM1	0.43	8.9	0.33	5.53e-18	Platelet count;
BRCA	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg18301423	chr5:131593218	PDLIM4	0.33	7.85	0.3	1.79e-14	Acylcarnitine levels;
BRCA	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg05714579	chr10:131428358	MGMT	-0.5	-11.02	-0.4	5.4e-26	Response to temozolomide;
BRCA	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.84	0.36	2.3e-21	Bipolar disorder;
BRCA	cis	rs4147929	0.532	rs757232	chr19:1075979	C/T	cg12082025	chr19:1064218	ABCA7	0.4	7.83	0.3	1.98e-14	Alzheimer's disease (late onset);
BRCA	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg21918786	chr6:109611834	NA	0.5	14.56	0.5	1.1e-41	Reticulocyte fraction of red cells;
BRCA	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-11.27	-0.41	5.52e-27	Gut microbiome composition (summer);
BRCA	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg12011299	chr4:100065546	ADH4	0.42	10.92	0.4	1.5e-25	Alcohol dependence;
BRCA	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg11301795	chr4:187892539	NA	-0.27	-8.71	-0.33	2.5e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg15839431	chr19:19639596	YJEFN3	0.36	8.21	0.31	1.19e-15	Bipolar disorder;
BRCA	cis	rs2882667	0.690	rs288024	chr5:138223792	A/G	cg04439458	chr5:138467593	SIL1	-0.34	-8.36	-0.31	4.08e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.44	-0.32	2.2e-16	Height;
BRCA	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg13334819	chr7:99746414	C7orf59	0.34	8.05	0.3	4.16e-15	Coronary artery disease;
BRCA	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg20701182	chr2:24300061	SF3B14	0.56	8.63	0.32	4.99e-17	Lymphocyte counts;
BRCA	cis	rs7786808	0.776	rs11983316	chr7:158209742	A/G	cg01191920	chr7:158217561	PTPRN2	-0.37	-8.63	-0.32	4.91e-17	Obesity-related traits;
BRCA	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg27398817	chr8:82754497	SNX16	0.49	9.26	0.34	2.97e-19	Diastolic blood pressure;
BRCA	cis	rs1005224	0.819	rs10147492	chr14:76155309	T/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.35	-8.23	-0.31	1.01e-15	Large artery stroke;
BRCA	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg05340658	chr4:99064831	C4orf37	0.67	16.59	0.55	1.2e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1113500	0.933	rs1414674	chr1:108625947	A/G	cg06207961	chr1:108661230	NA	0.46	11.24	0.41	6.97e-27	Growth-regulated protein alpha levels;
BRCA	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.58	13.6	0.47	3.39e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.41	9.8	0.36	3.31e-21	Menarche (age at onset);
BRCA	cis	rs7927771	0.524	rs1563821	chr11:47756568	C/T	cg20307385	chr11:47447363	PSMC3	0.42	9.57	0.35	2.28e-20	Subjective well-being;
BRCA	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg01620082	chr3:125678407	NA	-0.84	-9.88	-0.36	1.61e-21	Depression;
BRCA	cis	rs4594175	0.926	rs4349056	chr14:51625819	A/G	cg23942311	chr14:51606299	NA	0.33	8.26	0.31	8.09e-16	Cancer;
BRCA	cis	rs4302748	0.818	rs61387197	chr7:36184016	T/A	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg08132940	chr7:1081526	C7orf50	-0.59	-8.77	-0.33	1.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05901451	chr6:126070800	HEY2	-0.54	-14.14	-0.49	1.1e-39	Brugada syndrome;
BRCA	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg12386194	chr3:101231763	SENP7	0.39	8.37	0.31	3.7e-16	Colorectal cancer;
BRCA	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg02951883	chr7:2050386	MAD1L1	0.49	10.78	0.39	5.25e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs9649465	1.000	rs13230294	chr7:123380821	T/C	cg04330084	chr7:123175371	IQUB	-0.32	-8.81	-0.33	1.17e-17	Migraine;
BRCA	cis	rs6545883	0.894	rs2694632	chr2:61558682	T/C	cg15711740	chr2:61764176	XPO1	0.52	13.42	0.47	2.33e-36	Tuberculosis;
BRCA	trans	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.37	9.74	0.36	5.51e-21	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg26378065	chr17:18585709	ZNF286B	-0.36	-8.03	-0.3	4.86e-15	Educational attainment (years of education);
BRCA	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg25036284	chr2:26402008	FAM59B	-0.78	-12.16	-0.43	9.02e-31	Gut microbiome composition (summer);
BRCA	cis	rs11955398	0.585	rs930864	chr5:60021688	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.38	-9.13	-0.34	8.56e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.86e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg06115741	chr20:33292138	TP53INP2	0.5	10.41	0.38	1.45e-23	Coronary artery disease;
BRCA	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg23033748	chr14:75592666	NEK9	-0.42	-10.19	-0.37	1.04e-22	Height;
BRCA	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg03929089	chr4:120376271	NA	0.69	13.58	0.47	4.17e-37	Coronary artery disease;
BRCA	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.92	0.33	4.74e-18	Tonsillectomy;
BRCA	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg26384229	chr12:38710491	ALG10B	0.58	13.31	0.47	7.62e-36	Heart rate;
BRCA	cis	rs17092148	0.652	rs76324086	chr20:33079392	T/G	cg16810054	chr20:33298113	TP53INP2	0.45	9.96	0.37	8.01e-22	Neuroticism;
BRCA	cis	rs965469	0.532	rs6115865	chr20:3359303	A/G	cg25506879	chr20:3388711	C20orf194	0.4	8.66	0.32	3.85e-17	IFN-related cytopenia;
BRCA	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00149659	chr3:10157352	C3orf10	0.8	13.68	0.48	1.56e-37	Alzheimer's disease;
BRCA	cis	rs400736	0.930	rs408320	chr1:8085328	T/C	cg25007680	chr1:8021821	PARK7	0.47	11.85	0.42	2.06e-29	Response to antidepressants and depression;
BRCA	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg17063962	chr7:91808500	NA	0.53	12.5	0.44	3.23e-32	Breast cancer;
BRCA	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.6	0.55	9.67e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1215050	0.791	rs1585088	chr4:98675071	C/A	cg05340658	chr4:99064831	C4orf37	-0.44	-10.07	-0.37	3.12e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7715806	0.500	rs17563995	chr5:75007556	A/G	cg19683494	chr5:74908142	NA	0.5	8.06	0.3	3.72e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17095355	0.818	rs6584970	chr10:111847820	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.33	-8.06	-0.3	3.66e-15	Biliary atresia;
BRCA	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg23533926	chr12:111358616	MYL2	-0.41	-8.59	-0.32	6.69e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-9.78	-0.36	3.77e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs7011049	1.000	rs72643588	chr8:53849335	C/T	cg26025543	chr8:53854495	NA	0.53	9.06	0.34	1.59e-18	Systolic blood pressure;
BRCA	cis	rs4944092	0.960	rs10400322	chr11:75910913	C/T	cg04588336	chr11:75916460	WNT11	0.51	12.16	0.43	9.66e-31	PR interval;
BRCA	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg00012203	chr2:219082015	ARPC2	-0.51	-10.46	-0.38	9.84e-24	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg26384229	chr12:38710491	ALG10B	0.68	14.16	0.49	8.6e-40	Morning vs. evening chronotype;
BRCA	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg20387954	chr3:183756860	HTR3D	0.43	9.76	0.36	4.69e-21	Anterior chamber depth;
BRCA	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs9790314	0.747	rs7650703	chr3:160851639	T/C	cg03342759	chr3:160939853	NMD3	-0.54	-10.51	-0.38	5.95e-24	Morning vs. evening chronotype;
BRCA	cis	rs5167	0.504	rs7259679	chr19:45457306	C/T	cg20090143	chr19:45452003	APOC2	0.27	7.88	0.3	1.37e-14	Blood protein levels;
BRCA	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg22117172	chr7:91764530	CYP51A1	0.23	7.96	0.3	7.8e-15	Breast cancer;
BRCA	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00149659	chr3:10157352	C3orf10	0.66	10.19	0.37	1.05e-22	Alzheimer's disease;
BRCA	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg08392591	chr16:89556376	ANKRD11	0.48	11.41	0.41	1.36e-27	Multiple myeloma (IgH translocation);
BRCA	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10802521	chr3:52805072	NEK4	-0.34	-9.3	-0.35	2.15e-19	Electroencephalogram traits;
BRCA	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg04362960	chr10:104952993	NT5C2	0.42	10.17	0.37	1.25e-22	Arsenic metabolism;
BRCA	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg17063962	chr7:91808500	NA	0.52	12.33	0.44	1.72e-31	Breast cancer;
BRCA	cis	rs477692	0.618	rs7080419	chr10:131455235	A/G	cg05714579	chr10:131428358	MGMT	0.41	8.68	0.32	3.37e-17	Response to temozolomide;
BRCA	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.46	11.04	0.4	4.87e-26	IgG glycosylation;
BRCA	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg26597838	chr10:835615	NA	0.83	15.11	0.51	2.46e-44	Eosinophil percentage of granulocytes;
BRCA	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11764359	chr7:65958608	NA	0.8	19.51	0.61	7.33e-67	Aortic root size;
BRCA	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg23711669	chr6:146136114	FBXO30	0.8	18.97	0.6	5.73e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg27446573	chr6:127587934	RNF146	0.9	21.32	0.64	1.39e-76	Breast cancer;
BRCA	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg10792982	chr14:105748885	BRF1	0.48	11.1	0.4	2.74e-26	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs4891159	0.790	rs8085133	chr18:74144083	A/C	cg24786174	chr18:74118243	ZNF516	-0.79	-21.83	-0.65	2.22e-79	Longevity;
BRCA	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.7	0.33	2.72e-17	Iron status biomarkers;
BRCA	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg15103426	chr22:29168792	CCDC117	0.51	11.96	0.43	7.15e-30	Lymphocyte counts;
BRCA	cis	rs3820928	0.874	rs1996998	chr2:227840294	C/A	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.27	-0.31	7.79e-16	Pulmonary function;
BRCA	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg24562669	chr7:97807699	LMTK2	0.45	12.28	0.44	2.88e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg16606324	chr3:10149918	C3orf24	0.57	10.04	0.37	3.9e-22	Alzheimer's disease;
BRCA	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg04511125	chr2:88470314	THNSL2	0.94	13.56	0.47	5.22e-37	Plasma clusterin levels;
BRCA	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-10.76	-0.39	5.99e-25	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg01877450	chr7:97915802	BRI3	-0.39	-8.85	-0.33	8.4e-18	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.93	-0.3	9.81e-15	Corneal astigmatism;
BRCA	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg01448562	chr3:133502909	NA	-0.6	-14.18	-0.49	7.03e-40	Iron status biomarkers;
BRCA	cis	rs887829	0.570	rs11680450	chr2:234597483	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.29	-0.31	6.48e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs7131987	1.000	rs7131987	chr12:29406488	G/T	cg09582351	chr12:29534625	ERGIC2	-0.4	-9.46	-0.35	5.71e-20	QT interval;
BRCA	cis	rs30380	0.506	rs469735	chr5:96130014	T/C	cg16492584	chr5:96139282	ERAP1	-0.46	-10.61	-0.39	2.37e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg05347473	chr6:146136440	FBXO30	0.43	8.63	0.32	4.97e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg22834771	chr12:69754056	YEATS4	-0.37	-8.68	-0.32	3.22e-17	Blood protein levels;
BRCA	trans	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.45	-8.53	-0.32	1.02e-16	Monocyte count;
BRCA	cis	rs12760731	0.720	rs10913535	chr1:178302914	C/A	cg00404053	chr1:178313656	RASAL2	0.62	8.57	0.32	7.67e-17	Obesity-related traits;
BRCA	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.33	-0.44	1.69e-31	Chronic sinus infection;
BRCA	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg13385521	chr17:29058706	SUZ12P	0.77	12.06	0.43	2.56e-30	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg03354898	chr7:1950403	MAD1L1	0.38	8.57	0.32	8.07e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs4780401	0.609	rs35902600	chr16:11800848	C/T	cg01061890	chr16:11836724	TXNDC11	-0.56	-13.16	-0.46	3.54e-35	Rheumatoid arthritis;
BRCA	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg05714579	chr10:131428358	MGMT	0.59	14.69	0.5	2.65e-42	Response to temozolomide;
BRCA	cis	rs4588572	0.643	rs10474554	chr5:77799158	C/T	cg11547950	chr5:77652471	NA	-0.51	-8.77	-0.33	1.64e-17	Triglycerides;
BRCA	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg20991723	chr1:152506922	NA	0.39	8.75	0.33	1.95e-17	Hair morphology;
BRCA	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26314531	chr2:26401878	FAM59B	0.96	16.34	0.54	2.18e-50	Gut microbiome composition (summer);
BRCA	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.85e-29	Chronic sinus infection;
BRCA	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07930192	chr7:1003750	NA	0.48	10.42	0.38	1.42e-23	Longevity;Endometriosis;
BRCA	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg17366294	chr4:99064904	C4orf37	0.42	9.83	0.36	2.52e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg21770322	chr7:97807741	LMTK2	0.41	10.97	0.4	8.81e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07256732	chr16:621771	PIGQ	-0.36	-9.53	-0.35	3.11e-20	Height;
BRCA	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg24112000	chr20:60950667	NA	0.48	9.52	0.35	3.51e-20	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs72634258	0.796	rs4369247	chr1:8168993	C/T	cg00042356	chr1:8021962	PARK7	-0.5	-8.77	-0.33	1.61e-17	Inflammatory bowel disease;
BRCA	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg04607235	chr12:12878440	APOLD1	-0.69	-10.73	-0.39	8.18e-25	Systemic lupus erythematosus;
BRCA	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.13	0.4	2.05e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg03146154	chr1:46216737	IPP	-0.49	-10.7	-0.39	1.05e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7011049	1.000	rs10958336	chr8:53841318	G/A	cg26025543	chr8:53854495	NA	0.53	9.13	0.34	8.77e-19	Systolic blood pressure;
BRCA	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-12.5	-0.44	2.99e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg24110177	chr3:50126178	RBM5	0.52	14.77	0.5	1.16e-42	Body mass index;
BRCA	cis	rs362296	0.597	rs3129320	chr4:3265130	G/C	cg06533319	chr4:3265114	C4orf44	0.31	8.39	0.32	3.07e-16	Parental longevity (mother's age at death);
BRCA	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg25838465	chr1:92012736	NA	0.46	9.07	0.34	1.46e-18	Eosinophil percentage of white cells;
BRCA	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg21475434	chr5:93447410	FAM172A	0.67	8.4	0.32	3e-16	Diabetic retinopathy;
BRCA	cis	rs17253792	0.822	rs79398217	chr14:56067350	C/T	cg01858014	chr14:56050164	KTN1	-0.73	-9.19	-0.34	5.56e-19	Putamen volume;
BRCA	cis	rs7766436	0.961	rs6922960	chr6:22570189	T/C	cg13666174	chr6:22585274	NA	-0.43	-10.17	-0.37	1.28e-22	Coronary artery disease;
BRCA	cis	rs2625529	0.824	rs12916694	chr15:72298140	C/T	cg16672083	chr15:72433130	SENP8	-0.85	-17.53	-0.57	1.89e-56	Red blood cell count;
BRCA	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg08999081	chr20:33150536	PIGU	-0.33	-8.46	-0.32	1.82e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg03954927	chr1:10346856	KIF1B	0.44	13.98	0.48	6.18e-39	Hepatocellular carcinoma;
BRCA	cis	rs11605275	1.000	rs74809393	chr11:20031520	C/A	cg14835545	chr11:20032148	NAV2	-0.59	-9.32	-0.35	1.87e-19	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21659725	chr3:3221576	CRBN	-0.46	-9.72	-0.36	6.29e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12826209	chr6:26865740	GUSBL1	0.6	10.47	0.38	8.57e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs2108225	0.872	rs7792139	chr7:107445433	G/A	cg18560240	chr7:107437656	SLC26A3	-0.53	-11.05	-0.4	4.14e-26	Ulcerative colitis;
BRCA	cis	rs7715806	0.500	rs17563610	chr5:74981322	A/T	cg19683494	chr5:74908142	NA	0.54	8.6	0.32	6.21e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	12.82	0.45	1.19e-33	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg08999081	chr20:33150536	PIGU	0.36	9.14	0.34	7.9e-19	Coronary artery disease;
BRCA	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg26597838	chr10:835615	NA	1.3	22.1	0.66	8.2e-81	Eosinophil percentage of granulocytes;
BRCA	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg18230493	chr5:56204884	C5orf35	-0.56	-12.03	-0.43	3.38e-30	Coronary artery disease;
BRCA	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-16.76	-0.55	1.52e-52	Bipolar disorder;
BRCA	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg23533926	chr12:111358616	MYL2	-0.43	-9.08	-0.34	1.35e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg14784868	chr12:69753453	YEATS4	0.79	25.23	0.71	5.18e-98	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg25237894	chr2:233734115	C2orf82	0.39	11.3	0.41	4.04e-27	Coronary artery disease;
BRCA	cis	rs754466	1.000	rs12220328	chr10:79681482	G/C	cg17075019	chr10:79541650	NA	-0.57	-11.08	-0.4	3.2e-26	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs1493916	0.837	rs1027332	chr18:31410097	A/C	cg27147174	chr7:100797783	AP1S1	-0.42	-8.48	-0.32	1.55e-16	Life satisfaction;
BRCA	cis	rs9487051	0.768	rs463503	chr6:109525757	T/C	cg21918786	chr6:109611834	NA	-0.34	-8.97	-0.33	3.36e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	11.26	0.41	5.92e-27	Coronary artery disease;
BRCA	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26314531	chr2:26401878	FAM59B	0.94	14.17	0.49	7.9e-40	Gut microbiome composition (summer);
BRCA	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.35	-0.35	1.42e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.48	-9.06	-0.34	1.56e-18	Gut microbiome composition (summer);
BRCA	trans	rs783540	0.609	rs803686	chr15:83219340	G/A	cg16105309	chr15:79090380	ADAMTS7	0.34	9.24	0.34	3.54e-19	Schizophrenia;
BRCA	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg08885076	chr2:99613938	TSGA10	0.45	10.6	0.39	2.7e-24	Chronic sinus infection;
BRCA	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg27029518	chr18:72166324	CNDP2	-0.31	-8.77	-0.33	1.55e-17	Refractive error;
BRCA	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg22705602	chr4:152727874	NA	-0.33	-8.02	-0.3	5.22e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs926392	0.666	rs35166252	chr20:37695601	C/T	cg16355469	chr20:37678765	NA	0.48	11.36	0.41	2.28e-27	Dialysis-related mortality;
BRCA	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg10556349	chr10:835070	NA	0.59	8.09	0.3	2.95e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.52	-0.61	6.57e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-14.16	-0.49	8.73e-40	Migraine;Coronary artery disease;
BRCA	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg06064525	chr11:970664	AP2A2	-0.48	-16.23	-0.54	7.7e-50	Alzheimer's disease (late onset);
BRCA	cis	rs4280164	0.887	rs11158634	chr14:24776457	C/G	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.46	-7.91	-0.3	1.15e-14	Parent of origin effect on language impairment (paternal);
BRCA	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.53	-11.04	-0.4	4.79e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs312274	0.674	rs4420356	chr12:41210532	A/G	cg17827154	chr12:41323612	CNTN1	0.34	8.2	0.31	1.31e-15	Metabolite levels  (X-11787);
BRCA	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg08885076	chr2:99613938	TSGA10	-0.6	-13.45	-0.47	1.74e-36	Chronic sinus infection;
BRCA	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg11764359	chr7:65958608	NA	0.57	11.92	0.43	1e-29	Calcium levels;
BRCA	cis	rs13315871	0.858	rs78946071	chr3:58318523	G/T	cg20936604	chr3:58311152	NA	-0.66	-8.48	-0.32	1.5e-16	Cholesterol, total;
BRCA	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg12444411	chr7:2802554	GNA12	-0.39	-9.63	-0.36	1.43e-20	Height;
BRCA	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg06784218	chr1:46089804	CCDC17	0.5	12.08	0.43	2.02e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	10.74	0.39	7.32e-25	Platelet count;
BRCA	cis	rs2625529	0.529	rs7183055	chr15:72377048	C/T	cg16672083	chr15:72433130	SENP8	0.67	16.21	0.54	9.1e-50	Red blood cell count;
BRCA	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18876405	chr7:65276391	NA	-0.63	-15.65	-0.53	5.63e-47	Aortic root size;
BRCA	cis	rs1506636	0.646	rs805776	chr7:123212561	T/C	cg03229431	chr7:123269106	ASB15	-0.59	-12.49	-0.44	3.52e-32	Plateletcrit;Platelet count;
BRCA	cis	rs4268898	0.760	rs11125535	chr2:24528114	T/C	cg06627628	chr2:24431161	ITSN2	0.4	8.54	0.32	9.87e-17	Asthma;
BRCA	cis	rs1712517	1.000	rs3123794	chr10:105033742	A/G	cg05636881	chr10:105038444	INA	0.37	8.63	0.32	4.76e-17	Migraine;
BRCA	cis	rs10992471	0.580	rs10992304	chr9:95085365	G/A	cg14631576	chr9:95140430	CENPP	-0.4	-9.7	-0.36	7.6e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg00105475	chr2:10696890	NA	0.44	10.32	0.38	3.4e-23	Prostate cancer;
BRCA	cis	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.73	-0.36	5.73e-21	Morning vs. evening chronotype;
BRCA	cis	rs13046373	0.535	rs1961167	chr21:32030310	T/C	cg14062083	chr21:31802829	KRTAP13-4	0.33	8.8	0.33	1.25e-17	HDL cholesterol;
BRCA	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg05519781	chr21:40033154	ERG	0.46	9.86	0.36	1.9e-21	Coronary artery disease;
BRCA	cis	rs778371	0.723	rs12993791	chr2:233690082	C/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-16.65	-0.55	5.95e-52	Schizophrenia;
BRCA	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg06640241	chr16:89574553	SPG7	-0.55	-11.7	-0.42	8.79e-29	Multiple myeloma (IgH translocation);
BRCA	cis	rs9815354	0.597	rs80066790	chr3:42000843	A/G	cg03022575	chr3:42003672	ULK4	0.62	9.08	0.34	1.34e-18	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg16586182	chr3:47516702	SCAP	0.66	14.94	0.51	1.64e-43	Colorectal cancer;
BRCA	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.27	-0.49	2.62e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	trans	rs7980799	0.840	rs7315695	chr12:33551841	G/C	cg26384229	chr12:38710491	ALG10B	-0.4	-8.18	-0.31	1.49e-15	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.06	0.54	4.96e-49	Fuchs's corneal dystrophy;
BRCA	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg12011299	chr4:100065546	ADH4	0.49	10.95	0.4	1.12e-25	Smoking initiation;
BRCA	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg23358479	chr7:1110784	C7orf50	-0.48	-8.17	-0.31	1.68e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-12.03	-0.43	3.51e-30	Alzheimer's disease;
BRCA	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg16576597	chr16:28551801	NUPR1	-0.33	-8.85	-0.33	8.75e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg15017067	chr4:17643749	FAM184B	0.29	8.82	0.33	1.06e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg11764359	chr7:65958608	NA	-0.67	-14.9	-0.51	2.48e-43	Aortic root size;
BRCA	cis	rs11997175	0.583	rs56045827	chr8:33787015	G/A	ch.8.33884649F	chr8:33765107	NA	0.37	8.33	0.31	4.86e-16	Body mass index;
BRCA	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-11.95	-0.43	7.82e-30	Chronic sinus infection;
BRCA	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	8.89	0.33	6.16e-18	Personality dimensions;
BRCA	cis	rs17601876	0.786	rs2414100	chr15:51562420	T/A	cg19946085	chr15:51559439	CYP19A1	-0.39	-11.74	-0.42	5.67e-29	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18876405	chr7:65276391	NA	0.55	13.22	0.46	1.98e-35	Aortic root size;
BRCA	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg21784768	chr11:537496	LRRC56	-0.67	-8.48	-0.32	1.57e-16	Body mass index;
BRCA	cis	rs72772090	0.539	rs72775817	chr5:96190709	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-11.04	-0.4	4.51e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg10560079	chr2:191398806	TMEM194B	0.4	8.85	0.33	8.88e-18	Pulse pressure;
BRCA	cis	rs11229555	0.598	rs1893902	chr11:58190747	A/G	cg15696309	chr11:58395628	NA	-0.45	-9.73	-0.36	6.06e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg18270830	chr10:32634957	EPC1	0.58	10.03	0.37	4.37e-22	Sexual dysfunction (female);
BRCA	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.15	-0.31	1.9e-15	Depression;
BRCA	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26314531	chr2:26401878	FAM59B	-0.83	-15.43	-0.52	6.8e-46	Gut microbiome composition (summer);
BRCA	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg07636037	chr3:49044803	WDR6	-0.77	-15.46	-0.52	4.7e-46	Menarche (age at onset);
BRCA	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06544989	chr22:39130855	UNC84B	0.38	8.74	0.33	2.04e-17	Menopause (age at onset);
BRCA	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg13334819	chr7:99746414	C7orf59	-0.45	-10.58	-0.39	3.16e-24	Coronary artery disease;
BRCA	cis	rs7524258	0.903	rs6577424	chr1:7292417	C/T	cg07173049	chr1:7289937	CAMTA1	-0.54	-13.37	-0.47	4.15e-36	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.51	-0.35	3.85e-20	Tonsillectomy;
BRCA	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs10411161	0.702	rs11879319	chr19:52389592	C/T	cg22319618	chr22:45562946	NUP50	-0.42	-8.05	-0.3	4.13e-15	Breast cancer;
BRCA	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	10.53	0.38	4.95e-24	Retinal vascular caliber;
BRCA	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03264133	chr6:25882463	NA	-0.69	-16.33	-0.54	2.38e-50	Blood metabolite levels;
BRCA	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.85	0.45	8.83e-34	Bipolar disorder;
BRCA	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg05714579	chr10:131428358	MGMT	0.59	14.74	0.5	1.52e-42	Response to temozolomide;
BRCA	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg13319975	chr6:146136371	FBXO30	-0.34	-7.94	-0.3	9.24e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg19508488	chr2:152266495	RIF1	0.52	10.01	0.37	5.44e-22	Lung cancer;
BRCA	cis	rs727479	0.502	rs2304463	chr15:51508120	A/C	cg19946085	chr15:51559439	CYP19A1	-0.3	-8.47	-0.32	1.72e-16	Estradiol levels;
BRCA	trans	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg23762105	chr12:34175262	ALG10	0.37	8.59	0.32	6.53e-17	Morning vs. evening chronotype;
BRCA	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26818010	chr10:134567672	INPP5A	-0.63	-13.71	-0.48	1.1e-37	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg13047869	chr3:10149882	C3orf24	0.54	10.17	0.37	1.25e-22	Alzheimer's disease;
BRCA	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg04944784	chr2:26401820	FAM59B	-0.9	-16.33	-0.54	2.3e-50	Gut microbiome composition (summer);
BRCA	cis	rs708547	0.874	rs1713984	chr4:57886493	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.54	-9.19	-0.34	5.61e-19	Response to bleomycin (chromatid breaks);
BRCA	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg05340658	chr4:99064831	C4orf37	0.45	10.39	0.38	1.79e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	8.64	0.32	4.48e-17	Neuroticism;
BRCA	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.36	-8.2	-0.31	1.34e-15	Longevity;Endometriosis;
BRCA	cis	rs6844506	1.000	rs6844506	chr4:185217148	C/T	cg12654155	chr4:185238627	NA	-0.45	-8.42	-0.32	2.54e-16	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
BRCA	cis	rs7707921	0.522	rs12374541	chr5:81491408	A/G	cg15871215	chr5:81402204	ATG10	0.35	8.82	0.33	1.1e-17	Breast cancer;
BRCA	cis	rs6878727	0.665	rs149628	chr5:123676213	C/T	cg01806427	chr5:123737813	NA	-0.36	-8.06	-0.3	3.85e-15	Breast cancer;
BRCA	cis	rs7818345	1.000	rs11991105	chr8:19290655	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.3	7.85	0.3	1.72e-14	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs870825	0.616	rs6552810	chr4:185644143	G/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.2	0.56	9.11e-55	Blood protein levels;
BRCA	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg18479299	chr3:125709523	NA	-0.52	-8.77	-0.33	1.68e-17	Blood pressure (smoking interaction);
BRCA	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	11.45	0.41	9.68e-28	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs698833	0.926	rs1085485	chr2:44616728	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	9.1	0.34	1.11e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs2304069	1.000	rs7737689	chr5:149396159	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.59	13.09	0.46	7.74e-35	HIV-1 control;
BRCA	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg04362960	chr10:104952993	NT5C2	0.43	10.55	0.39	4.27e-24	Reticulocyte count;
BRCA	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg24060327	chr5:131705240	SLC22A5	0.5	10.5	0.38	6.56e-24	Blood metabolite levels;
BRCA	cis	rs11971779	0.553	rs7799742	chr7:139051878	C/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.22	0.37	8.22e-23	Diisocyanate-induced asthma;
BRCA	cis	rs7075426	0.512	rs9633738	chr10:88183796	T/A	cg07322936	chr10:88137208	NA	-0.42	-8.19	-0.31	1.45e-15	Migraine without aura;
BRCA	trans	rs11976180	1.000	rs2961134	chr7:143771062	A/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.42	-7.89	-0.3	1.35e-14	Obesity-related traits;
BRCA	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg05025164	chr4:1340916	KIAA1530	0.4	9.06	0.34	1.62e-18	Longevity;
BRCA	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg20848291	chr7:100343083	ZAN	-0.59	-11.44	-0.41	1.11e-27	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11644478	chr21:40555479	PSMG1	-0.5	-10.65	-0.39	1.66e-24	Menarche (age at onset);
BRCA	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg16386425	chr10:429943	DIP2C	0.4	8.01	0.3	5.57e-15	Psychosis in Alzheimer's disease;
BRCA	trans	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	14.76	0.5	1.27e-42	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg03954927	chr1:10346856	KIF1B	0.48	15.31	0.52	2.52e-45	Hepatocellular carcinoma;
BRCA	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg07308232	chr7:1071921	C7orf50	-0.39	-8.35	-0.31	4.16e-16	Longevity;Endometriosis;
BRCA	cis	rs11608355	0.672	rs9943689	chr12:109890339	G/A	cg05360138	chr12:110035743	NA	0.46	8.35	0.31	4.36e-16	Neuroticism;
BRCA	cis	rs965469	1.000	rs6051831	chr20:3373712	G/T	cg25506879	chr20:3388711	C20orf194	0.49	9.8	0.36	3.3e-21	IFN-related cytopenia;
BRCA	cis	rs56399783	0.614	rs11765492	chr7:2771642	G/A	cg23627948	chr7:2760692	NA	0.51	8.47	0.32	1.64e-16	Childhood ear infection;
BRCA	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.08	-0.43	2.06e-30	Blood protein levels;
BRCA	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg13628971	chr7:2884303	GNA12	0.37	8.36	0.31	3.98e-16	Height;
BRCA	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg08975724	chr8:8085496	FLJ10661	0.37	8.08	0.3	3.33e-15	Neuroticism;
BRCA	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-21.91	-0.66	8.14e-80	Gut microbiome composition (summer);
BRCA	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.3	-7.82	-0.3	2.17e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.37	-0.35	1.21e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2282802	0.685	rs11745502	chr5:139558808	G/A	cg26211634	chr5:139558579	C5orf32	-0.33	-7.98	-0.3	6.85e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs17023223	0.537	rs61806983	chr1:119731524	G/C	cg05756136	chr1:119680316	WARS2	-0.42	-8.16	-0.31	1.8e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.72e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg03929089	chr4:120376271	NA	-0.44	-8.25	-0.31	9.12e-16	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg25204440	chr1:209979598	IRF6	0.42	8.44	0.32	2.13e-16	Cleft lip with or without cleft palate;
BRCA	cis	rs2108225	1.000	rs6466191	chr7:107453511	A/T	cg18560240	chr7:107437656	SLC26A3	-0.52	-10.37	-0.38	2.15e-23	Ulcerative colitis;
BRCA	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14829155	chr15:31115871	NA	-0.43	-10.14	-0.37	1.74e-22	Huntington's disease progression;
BRCA	cis	rs858239	0.932	rs858272	chr7:23276785	A/G	cg23682824	chr7:23144976	KLHL7	0.39	9.66	0.36	1.06e-20	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg06618935	chr21:46677482	NA	-0.37	-8.23	-0.31	1.04e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg23625390	chr15:77176239	SCAPER	-0.49	-10.68	-0.39	1.25e-24	Blood metabolite levels;
BRCA	cis	rs16866061	0.517	rs7594223	chr2:225472985	T/C	cg12698349	chr2:225449008	CUL3	0.45	10.93	0.4	1.34e-25	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs28830936	1.000	rs4924575	chr15:42096926	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.37	-10.12	-0.37	2.05e-22	Diastolic blood pressure;
BRCA	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	12.81	0.45	1.33e-33	Lung cancer in ever smokers;
BRCA	cis	rs400736	0.894	rs172811	chr1:8039949	A/G	cg25007680	chr1:8021821	PARK7	0.48	12.06	0.43	2.54e-30	Response to antidepressants and depression;
BRCA	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.59	9.55	0.35	2.66e-20	Renal function-related traits (BUN);
BRCA	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	17.64	0.57	4.76e-57	Electrocardiographic conduction measures;
BRCA	cis	rs7677751	0.767	rs6832597	chr4:55076237	C/A	cg17187183	chr4:55093834	PDGFRA	0.4	8.21	0.31	1.26e-15	Corneal astigmatism;
BRCA	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg04756594	chr16:24857601	SLC5A11	0.48	10.08	0.37	2.94e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg22875332	chr1:76189707	ACADM	0.63	13.07	0.46	9.1e-35	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg21535247	chr6:8435926	SLC35B3	0.41	9.15	0.34	7.49e-19	Motion sickness;
BRCA	cis	rs10046574	0.831	rs28399231	chr7:135093154	G/A	cg27474649	chr7:135195673	CNOT4	0.59	8.27	0.31	8e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.71	11.91	0.43	1.07e-29	Schizophrenia;
BRCA	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg22800045	chr5:56110881	MAP3K1	0.55	10.53	0.38	5.14e-24	Initial pursuit acceleration;
BRCA	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg01802117	chr1:53393560	SCP2	0.34	8.0	0.3	5.66e-15	Monocyte count;
BRCA	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg17691542	chr6:26056736	HIST1H1C	0.61	12.35	0.44	1.37e-31	Iron status biomarkers;
BRCA	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	13.46	0.47	1.5e-36	Lymphocyte counts;
BRCA	cis	rs7707921	0.767	rs862244	chr5:81586801	G/A	cg15871215	chr5:81402204	ATG10	0.35	8.29	0.31	6.7e-16	Breast cancer;
BRCA	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-10.83	-0.39	3.33e-25	Longevity;
BRCA	cis	rs6604026	0.740	rs7536563	chr1:93349046	A/G	cg17283838	chr1:93427260	FAM69A	-0.4	-8.31	-0.31	5.64e-16	Multiple sclerosis;
BRCA	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg11752832	chr7:134001865	SLC35B4	0.52	13.55	0.47	6.19e-37	Mean platelet volume;
BRCA	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.45	0.55	5.92e-51	Colorectal cancer;
BRCA	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg15839431	chr19:19639596	YJEFN3	0.41	9.13	0.34	9.05e-19	Bipolar disorder;
BRCA	cis	rs6580649	0.941	rs7957764	chr12:48429701	C/T	cg05342945	chr12:48394962	COL2A1	0.42	8.06	0.3	3.85e-15	Lung cancer;
BRCA	trans	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.16	0.31	1.83e-15	Corneal astigmatism;
BRCA	cis	rs10949834	0.504	rs12539781	chr7:73568425	C/T	cg07137043	chr7:73588983	EIF4H	-0.63	-10.42	-0.38	1.37e-23	Verbal memory performance (residualized delayed recall change);
BRCA	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg10818794	chr15:86012489	AKAP13	-0.3	-8.48	-0.32	1.57e-16	Coronary artery disease;
BRCA	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.74	-15.78	-0.53	1.27e-47	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg22906224	chr7:99728672	NA	0.5	9.47	0.35	5.42e-20	Coronary artery disease;
BRCA	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.44	0.35	6.82e-20	Morning vs. evening chronotype;
BRCA	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg06494592	chr3:125709126	NA	-0.51	-7.9	-0.3	1.18e-14	Blood pressure (smoking interaction);
BRCA	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.73	-0.33	2.15e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg06521331	chr12:34319734	NA	-0.52	-9.25	-0.34	3.25e-19	Bladder cancer;
BRCA	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	25.91	0.72	1.01e-101	Chronic sinus infection;
BRCA	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg00101154	chr16:420108	MRPL28	-0.43	-9.36	-0.35	1.34e-19	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg21132104	chr15:45694354	SPATA5L1	0.73	16.07	0.54	4.83e-49	Homoarginine levels;
BRCA	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg20701182	chr2:24300061	SF3B14	0.71	13.25	0.46	1.44e-35	Lymphocyte counts;
BRCA	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg04025307	chr7:1156635	C7orf50	0.59	9.36	0.35	1.33e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.29e-40	Motion sickness;
BRCA	trans	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg02030672	chr11:45687055	CHST1	-0.41	-9.1	-0.34	1.17e-18	Obesity-related traits;
BRCA	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg13175981	chr1:150552382	MCL1	0.53	11.66	0.42	1.25e-28	Tonsillectomy;
BRCA	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.38	-8.05	-0.3	4.15e-15	Personality dimensions;
BRCA	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	16.24	0.54	6.81e-50	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.58	0.55	1.29e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg06191203	chr2:152266755	RIF1	-0.42	-12.09	-0.43	1.95e-30	Lung cancer;
BRCA	cis	rs6981523	0.500	rs4412337	chr8:11072020	C/T	cg21775007	chr8:11205619	TDH	0.48	9.16	0.34	6.76e-19	Neuroticism;
BRCA	cis	rs11608355	0.545	rs2302706	chr12:109894028	A/G	cg05360138	chr12:110035743	NA	0.71	13.18	0.46	2.85e-35	Neuroticism;
BRCA	cis	rs16854884	0.657	rs1979910	chr3:143710268	A/C	cg06585982	chr3:143692056	C3orf58	0.44	9.07	0.34	1.39e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.29	-0.38	4.53e-23	Morning vs. evening chronotype;
BRCA	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg12373951	chr3:133503437	NA	0.34	8.03	0.3	4.6e-15	Iron status biomarkers;
BRCA	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08280861	chr8:58055591	NA	0.56	8.78	0.33	1.49e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-10.21	-0.37	8.89e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7246657	0.550	rs9941475	chr19:38064517	C/T	cg23950597	chr19:37808831	NA	-0.5	-8.64	-0.32	4.63e-17	Coronary artery calcification;
BRCA	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg16606324	chr3:10149918	C3orf24	0.56	11.08	0.4	3.11e-26	Alzheimer's disease;
BRCA	cis	rs6840360	0.593	rs4696286	chr4:152606547	G/A	cg22705602	chr4:152727874	NA	-0.37	-10.08	-0.37	2.74e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg22705602	chr4:152727874	NA	-0.33	-8.02	-0.3	5.22e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6687430	0.526	rs7555790	chr1:10613167	A/G	cg17425144	chr1:10567563	PEX14	-0.57	-13.44	-0.47	1.96e-36	Hand grip strength;
BRCA	cis	rs7766436	0.848	rs16901663	chr6:22598054	T/C	cg13666174	chr6:22585274	NA	-0.44	-9.56	-0.35	2.43e-20	Coronary artery disease;
BRCA	cis	rs208520	1.000	rs208537	chr6:66963544	A/G	cg07460842	chr6:66804631	NA	-0.86	-14.3	-0.49	1.93e-40	Exhaled nitric oxide output;
BRCA	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	9.89	0.36	1.53e-21	Lung cancer in ever smokers;
BRCA	cis	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.28	-0.34	2.62e-19	Resting heart rate;
BRCA	cis	rs11955398	0.625	rs11745077	chr5:59955716	C/T	cg02684056	chr5:59996105	DEPDC1B	0.38	8.86	0.33	8.04e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg02079420	chr8:82753780	SNX16	-0.36	-7.92	-0.3	1.05e-14	Diastolic blood pressure;
BRCA	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-15.04	-0.51	5.54e-44	Chronic sinus infection;
BRCA	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg19717773	chr7:2847554	GNA12	-0.48	-11.12	-0.4	2.22e-26	Height;
BRCA	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg17211192	chr8:82754475	SNX16	0.57	10.31	0.38	3.8e-23	Diastolic blood pressure;
BRCA	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-12.92	-0.46	4.19e-34	Morning vs. evening chronotype;
BRCA	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg16325326	chr1:53192061	ZYG11B	-0.69	-17.39	-0.57	9.4e-56	Monocyte count;
BRCA	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg24562669	chr7:97807699	LMTK2	0.44	11.94	0.43	8.34e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.76	-0.5	1.19e-42	Chronic sinus infection;
BRCA	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.52	-9.14	-0.34	8.51e-19	Schizophrenia;
BRCA	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg03560586	chr2:239334908	ASB1	-0.52	-11.48	-0.41	7.11e-28	Multiple system atrophy;
BRCA	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21659725	chr3:3221576	CRBN	-0.71	-21.61	-0.65	3.69e-78	Intelligence (multi-trait analysis);
BRCA	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	8.24	0.31	9.92e-16	Neuroticism;
BRCA	trans	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-7.98	-0.3	6.61e-15	Menarche (age at onset);
BRCA	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.79	-0.42	3.58e-29	Bipolar disorder;
BRCA	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg23950597	chr19:37808831	NA	-0.62	-10.94	-0.4	1.13e-25	Coronary artery calcification;
BRCA	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg19743168	chr1:23544995	NA	0.47	11.73	0.42	6.8e-29	Height;
BRCA	cis	rs3739998	0.647	rs7920682	chr10:30317826	C/T	cg12786570	chr10:30316432	KIAA1462	-0.43	-9.29	-0.34	2.39e-19	Coronary heart disease;
BRCA	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26314531	chr2:26401878	FAM59B	-0.64	-11.13	-0.4	2.02e-26	Gut microbiome composition (summer);
BRCA	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg26395211	chr5:140044315	WDR55	0.37	8.61	0.32	5.86e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg13770153	chr20:60521292	NA	0.37	8.84	0.33	9.03e-18	Body mass index;
BRCA	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg23950597	chr19:37808831	NA	-0.72	-12.54	-0.44	2e-32	Coronary artery calcification;
BRCA	cis	rs10411936	0.692	rs62118141	chr19:16602808	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.45	9.52	0.35	3.42e-20	White blood cell count;Multiple sclerosis;
BRCA	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg08847533	chr14:75593920	NEK9	-0.88	-22.45	-0.66	9.64e-83	Height;
BRCA	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.37	-7.92	-0.3	1.06e-14	Longevity;Endometriosis;
BRCA	cis	rs757081	0.667	rs569780	chr11:17206745	C/T	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.58	-0.32	7.23e-17	Systolic blood pressure;
BRCA	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg09436375	chr6:42928200	GNMT	-0.28	-10.56	-0.39	3.82e-24	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1468333	1.000	rs423258	chr5:137475787	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.45	8.66	0.32	3.83e-17	Resting heart rate;
BRCA	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg09307838	chr4:120376055	NA	0.74	15.98	0.53	1.38e-48	Corneal astigmatism;
BRCA	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	13.11	0.46	5.99e-35	Bone mineral density;
BRCA	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg06060754	chr5:176797920	RGS14	0.59	11.11	0.4	2.32e-26	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs11874712	1.000	rs11082509	chr18:43655010	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.01	0.3	5.44e-15	Migraine - clinic-based;
BRCA	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.58	9.79	0.36	3.53e-21	Gut microbiome composition (summer);
BRCA	cis	rs4285028	0.699	rs73855465	chr3:121574219	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.73	-13.4	-0.47	2.99e-36	Multiple sclerosis;
BRCA	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg15556689	chr8:8085844	FLJ10661	0.39	10.34	0.38	2.72e-23	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg20887711	chr4:1340912	KIAA1530	0.72	16.1	0.54	3.33e-49	Longevity;
BRCA	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg19000871	chr14:103996768	TRMT61A	0.47	10.48	0.38	8.35e-24	Coronary artery disease;
BRCA	cis	rs17601876	0.814	rs28674681	chr15:51559917	A/C	cg19946085	chr15:51559439	CYP19A1	-0.39	-11.87	-0.42	1.74e-29	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg10253484	chr15:75165896	SCAMP2	-0.54	-11.03	-0.4	5.11e-26	Breast cancer;
BRCA	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg17845761	chr1:175162550	KIAA0040	-0.25	-9.38	-0.35	1.14e-19	Alcohol dependence;
BRCA	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg18351406	chr4:77819688	ANKRD56	0.61	13.39	0.47	3.13e-36	Emphysema distribution in smoking;
BRCA	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg03433033	chr1:76189801	ACADM	-0.42	-8.44	-0.32	2.17e-16	Daytime sleep phenotypes;
BRCA	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	14.14	0.49	1.08e-39	Alzheimer's disease;
BRCA	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg11843238	chr5:131593191	PDLIM4	0.35	7.99	0.3	6.49e-15	Breast cancer;
BRCA	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg26248373	chr2:1572462	NA	-0.52	-10.26	-0.38	6e-23	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.56	8.42	0.32	2.44e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg17330251	chr7:94953956	PON1	-0.41	-8.7	-0.33	2.84e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12292205	chr6:26970375	C6orf41	-0.46	-7.87	-0.3	1.51e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg03433033	chr1:76189801	ACADM	-0.51	-10.05	-0.37	3.79e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2051211	1.000	rs17037804	chr3:38559215	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.47	-9.72	-0.36	6.34e-21	QRS duration;
BRCA	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26314531	chr2:26401878	FAM59B	0.96	16.33	0.54	2.39e-50	Gut microbiome composition (summer);
BRCA	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg00321850	chr1:175162397	KIAA0040	0.41	11.2	0.4	1.07e-26	Alcohol dependence;
BRCA	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg23750338	chr8:142222470	SLC45A4	0.51	12.48	0.44	3.85e-32	Immature fraction of reticulocytes;
BRCA	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.44	-9.49	-0.35	4.49e-20	Lung cancer in ever smokers;
BRCA	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg09904177	chr6:26538194	HMGN4	0.44	12.79	0.45	1.65e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg17063962	chr7:91808500	NA	-0.51	-11.93	-0.43	9.32e-30	Breast cancer;
BRCA	cis	rs7149337	1.000	rs4901103	chr14:51746873	C/T	cg23942311	chr14:51606299	NA	0.36	9.62	0.36	1.5e-20	Cancer;
BRCA	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg09904177	chr6:26538194	HMGN4	0.48	13.8	0.48	4.36e-38	Intelligence (multi-trait analysis);
BRCA	cis	rs9986765	0.867	rs1994498	chr7:142816448	C/T	cg22531018	chr7:142981779	TMEM139	0.59	9.8	0.36	3.28e-21	Cancer;Dermatomyositis;
BRCA	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.81	-0.36	2.89e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg14689365	chr7:158441557	NCAPG2	0.43	8.93	0.33	4.55e-18	Height;
BRCA	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg08807101	chr21:30365312	RNF160	-0.44	-9.33	-0.35	1.66e-19	Dental caries;
BRCA	cis	rs11971779	0.680	rs6467843	chr7:139070523	A/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	trans	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg06521331	chr12:34319734	NA	-0.5	-8.76	-0.33	1.78e-17	Bladder cancer;
BRCA	cis	rs9549260	0.753	rs9549238	chr13:41179321	G/A	cg21288729	chr13:41239152	FOXO1	0.54	8.68	0.32	3.38e-17	Red blood cell count;
BRCA	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-10.3	-0.38	3.93e-23	Morning vs. evening chronotype;
BRCA	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg21918786	chr6:109611834	NA	-0.45	-12.05	-0.43	2.77e-30	Reticulocyte fraction of red cells;
BRCA	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24229701	chr12:130821962	PIWIL1	0.39	8.89	0.33	6.08e-18	Menopause (age at onset);
BRCA	trans	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	8.92e-15	Corneal astigmatism;
BRCA	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg02297831	chr4:17616191	MED28	0.37	8.55	0.32	9.21e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6942756	0.747	rs692432	chr7:129113287	G/A	cg02491457	chr7:128862824	NA	-0.55	-11.37	-0.41	2.05e-27	White matter hyperintensity burden;
BRCA	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg23933602	chr10:16859644	RSU1	0.96	28.61	0.75	1.68e-116	Platelet distribution width;
BRCA	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	10.14	0.37	1.65e-22	Tonsillectomy;
BRCA	cis	rs813218	0.523	rs669676	chr3:99448852	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-9.01	-0.34	2.33e-18	Orofacial clefts;
BRCA	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-13.85	-0.48	2.44e-38	Personality dimensions;
BRCA	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	13.63	0.47	2.65e-37	Colorectal cancer;
BRCA	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg26597838	chr10:835615	NA	0.97	17.03	0.56	6.77e-54	Eosinophil percentage of granulocytes;
BRCA	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg09085632	chr11:111637200	PPP2R1B	0.73	16.08	0.54	4.39e-49	Primary sclerosing cholangitis;
BRCA	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg18252515	chr7:66147081	NA	-1.04	-15.52	-0.52	2.55e-46	Diabetic kidney disease;
BRCA	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg06212747	chr3:49208901	KLHDC8B	0.49	10.2	0.37	1.02e-22	Parkinson's disease;
BRCA	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg14036092	chr11:66035641	RAB1B	0.39	10.15	0.37	1.5e-22	Gout;
BRCA	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg03146154	chr1:46216737	IPP	0.52	11.61	0.42	2.16e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg06159980	chr1:16340746	HSPB7	-0.38	-8.84	-0.33	9.14e-18	Systolic blood pressure;
BRCA	trans	rs783540	0.656	rs783524	chr15:83284144	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.32	-8.77	-0.33	1.66e-17	Schizophrenia;
BRCA	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg00106254	chr7:1943704	MAD1L1	-0.32	-8.02	-0.3	4.96e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.98	-0.46	2.26e-34	Migraine;Coronary artery disease;
BRCA	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg16322792	chr1:120165303	ZNF697	0.58	15.24	0.52	5.78e-45	Systemic lupus erythematosus;
BRCA	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg06484146	chr7:12443880	VWDE	-0.78	-11.1	-0.4	2.74e-26	Coronary artery disease;
BRCA	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg04545296	chr12:48745243	ZNF641	0.24	7.92	0.3	1.06e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11890956	chr21:40555474	PSMG1	-0.6	-13.22	-0.46	1.9e-35	Menarche (age at onset);
BRCA	cis	rs7715811	1.000	rs9688222	chr5:13760906	C/A	cg07548982	chr5:13769939	DNAH5	-0.38	-8.35	-0.31	4.39e-16	Subclinical atherosclerosis traits (other);
BRCA	cis	rs10128251	0.962	rs10752281	chr10:5711220	C/T	cg24097872	chr10:5724021	NA	-0.52	-11.62	-0.42	1.81e-28	Childhood ear infection;
BRCA	cis	rs775227	0.574	rs13086266	chr3:113083535	T/A	cg18753928	chr3:113234510	CCDC52	-0.59	-9.18	-0.34	6.12e-19	Dental caries;
BRCA	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.77	-0.33	1.68e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18402987	chr7:1209562	NA	0.58	11.39	0.41	1.76e-27	Longevity;Endometriosis;
BRCA	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg05623727	chr3:50126028	RBM5	-0.37	-8.66	-0.32	3.94e-17	Menarche (age at onset);
BRCA	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.32	-8.02	-0.3	5.11e-15	Menopause (age at onset);
BRCA	trans	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg26043149	chr18:55253948	FECH	-0.42	-8.74	-0.33	2.09e-17	Bone mineral density;
BRCA	cis	rs654128	0.640	rs339339	chr6:117214866	A/C	cg12892004	chr6:117198278	RFX6	-0.44	-8.02	-0.3	4.96e-15	Telomere length;
BRCA	cis	rs8028182	0.636	rs4886707	chr15:75755467	C/T	cg20655648	chr15:75932815	IMP3	0.42	8.39	0.31	3.15e-16	Sudden cardiac arrest;
BRCA	cis	rs10754283	0.967	rs7528433	chr1:90114071	T/C	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.24e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.71	-16.69	-0.55	3.42e-52	Axial length;
BRCA	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg12311346	chr5:56204834	C5orf35	-0.62	-13.0	-0.46	1.9e-34	Initial pursuit acceleration;
BRCA	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg25036284	chr2:26402008	FAM59B	0.88	15.06	0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.04e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs6088813	1.000	rs6087705	chr20:34001250	C/T	cg14752227	chr20:34000481	UQCC	-0.38	-8.06	-0.3	3.7e-15	Height;
BRCA	trans	rs8002861	0.641	rs2028813	chr13:44422126	G/T	cg17145862	chr1:211918768	LPGAT1	0.47	10.5	0.38	6.61e-24	Leprosy;
BRCA	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg24596788	chr1:163392923	NA	-0.36	-9.3	-0.35	2.22e-19	Motion sickness;
BRCA	cis	rs775227	0.574	rs79709668	chr3:113161265	G/A	cg18753928	chr3:113234510	CCDC52	-0.53	-8.83	-0.33	9.94e-18	Dental caries;
BRCA	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00149659	chr3:10157352	C3orf10	0.8	13.77	0.48	5.57e-38	Alzheimer's disease;
BRCA	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg07414643	chr4:187882934	NA	0.28	9.61	0.36	1.64e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.47	0.35	5.28e-20	Menopause (age at onset);
BRCA	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18876405	chr7:65276391	NA	-0.58	-13.8	-0.48	3.98e-38	Aortic root size;
BRCA	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.38	0.57	1.12e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg03146154	chr1:46216737	IPP	0.52	11.73	0.42	6.32e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.5	-11.42	-0.41	1.32e-27	Electroencephalogram traits;
BRCA	cis	rs1577917	1.000	rs2166663	chr6:86593896	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-10.97	-0.4	9.25e-26	Response to antipsychotic treatment;
BRCA	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21385522	chr1:16154831	NA	0.56	10.36	0.38	2.45e-23	Dilated cardiomyopathy;
BRCA	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg03146154	chr1:46216737	IPP	0.46	10.2	0.37	9.95e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.3	8.39	0.31	3.13e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-14.46	-0.5	3.47e-41	Monocyte count;
BRCA	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg08992911	chr2:238395768	MLPH	0.59	10.3	0.38	3.98e-23	Prostate cancer;
BRCA	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg07606381	chr6:8435919	SLC35B3	-0.57	-12.19	-0.43	7.19e-31	Motion sickness;
BRCA	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18876405	chr7:65276391	NA	-0.48	-10.46	-0.38	9.72e-24	Aortic root size;
BRCA	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg22907277	chr7:1156413	C7orf50	0.6	11.75	0.42	5.5e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg13271783	chr10:134563150	INPP5A	-0.5	-9.45	-0.35	6.18e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg06618935	chr21:46677482	NA	-0.37	-8.08	-0.3	3.29e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg24558204	chr6:135376177	HBS1L	0.57	15.19	0.52	1.01e-44	Red blood cell count;
BRCA	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.83	-0.58	5.25e-58	Chronic sinus infection;
BRCA	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg23978390	chr7:1156363	C7orf50	0.48	11.42	0.41	1.31e-27	Longevity;Endometriosis;
BRCA	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	8.06	0.3	3.8e-15	Schizophrenia;
BRCA	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg22920501	chr2:26401640	FAM59B	-0.65	-11.69	-0.42	9.3e-29	Gut microbiome composition (summer);
BRCA	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.82	-0.36	2.65e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg02951883	chr7:2050386	MAD1L1	-0.58	-15.11	-0.51	2.42e-44	Bipolar disorder and schizophrenia;
BRCA	cis	rs8005677	0.962	rs11157931	chr14:23403193	A/C	cg01529538	chr14:23388837	RBM23	0.41	10.91	0.4	1.58e-25	Cognitive ability (multi-trait analysis);
BRCA	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23978390	chr7:1156363	C7orf50	0.37	8.9	0.33	5.64e-18	Longevity;Endometriosis;
BRCA	cis	rs7577696	0.597	rs6756085	chr2:32336522	A/G	cg02381751	chr2:32503542	YIPF4	-0.42	-7.83	-0.3	2.06e-14	Inflammatory biomarkers;
BRCA	cis	rs11229555	0.645	rs12269928	chr11:58184358	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.78	12.96	0.46	2.88e-34	Platelet count;
BRCA	cis	rs6580649	0.941	rs4760618	chr12:48434767	G/A	cg05342945	chr12:48394962	COL2A1	0.42	8.12	0.31	2.33e-15	Lung cancer;
BRCA	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg18705301	chr15:41695430	NDUFAF1	1.07	27.94	0.74	7.36e-113	Ulcerative colitis;
BRCA	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.93	0.3	9.65e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs965469	0.724	rs6051818	chr20:3362033	T/C	cg25506879	chr20:3388711	C20orf194	-0.45	-9.08	-0.34	1.37e-18	IFN-related cytopenia;
BRCA	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	9.57	0.35	2.39e-20	Parkinson's disease;
BRCA	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg17830980	chr10:43048298	ZNF37B	-0.55	-13.28	-0.47	1.08e-35	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg26408565	chr15:76604113	ETFA	-0.47	-10.27	-0.38	5.06e-23	Blood metabolite levels;
BRCA	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	7.83	0.3	2.08e-14	Menarche (age at onset);
BRCA	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-19.18	-0.6	4.14e-65	Systemic lupus erythematosus;
BRCA	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg10932868	chr11:921992	NA	0.49	12.63	0.45	7.98e-33	Alzheimer's disease (late onset);
BRCA	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg24450063	chr1:156163899	SLC25A44	0.89	17.49	0.57	2.83e-56	Testicular germ cell tumor;
BRCA	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg09754948	chr16:28834200	ATXN2L	0.46	8.65	0.32	4.12e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg11887960	chr12:57824829	NA	0.55	8.57	0.32	7.74e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-13.16	-0.46	3.75e-35	Lymphocyte counts;
BRCA	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.73	-0.33	2.15e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg00684032	chr4:1343700	KIAA1530	0.36	8.64	0.32	4.56e-17	Obesity-related traits;
BRCA	trans	rs11976180	1.000	rs2961120	chr7:143756585	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.48	-8.8	-0.33	1.23e-17	Obesity-related traits;
BRCA	trans	rs1493916	0.837	rs4997493	chr18:31407302	C/T	cg15819921	chr19:927150	ARID3A	-0.41	-8.07	-0.3	3.37e-15	Life satisfaction;
BRCA	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg19052272	chr2:3704530	ALLC	-0.46	-10.42	-0.38	1.36e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11644478	chr21:40555479	PSMG1	-0.68	-15.35	-0.52	1.74e-45	Cognitive function;
BRCA	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg09537434	chr19:41945824	ATP5SL	-0.98	-24.01	-0.69	2.89e-91	Height;
BRCA	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg05985134	chr18:33552581	C18orf21	0.64	12.21	0.43	5.7e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	trans	rs1493916	0.748	rs2040203	chr18:31307420	G/T	cg15819921	chr19:927150	ARID3A	-0.42	-8.27	-0.31	7.78e-16	Life satisfaction;
BRCA	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg16584676	chr17:46985605	UBE2Z	0.37	8.69	0.33	2.92e-17	Type 2 diabetes;
BRCA	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.51	0.38	6.01e-24	Motion sickness;
BRCA	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg23711669	chr6:146136114	FBXO30	-0.76	-17.27	-0.56	3.75e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9942416	0.660	rs1817869	chr5:74989037	T/C	cg19683494	chr5:74908142	NA	0.48	9.01	0.34	2.33e-18	Age-related disease endophenotypes;
BRCA	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-7.91	-0.3	1.15e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9810890	1.000	rs77303548	chr3:128454766	C/T	cg15033153	chr3:128514015	RAB7A	0.7	8.08	0.3	3.34e-15	Dental caries;
BRCA	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg10560079	chr2:191398806	TMEM194B	-0.75	-12.85	-0.45	8.91e-34	Diastolic blood pressure;
BRCA	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg15103426	chr22:29168792	CCDC117	-0.5	-11.15	-0.4	1.6e-26	Lymphocyte counts;
BRCA	cis	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07988820	chr12:82153109	PPFIA2	-0.67	-10.7	-0.39	1.13e-24	Resting heart rate;
BRCA	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	26.38	0.72	2.76e-104	Chronic sinus infection;
BRCA	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg03474202	chr17:45855739	NA	-0.48	-12.65	-0.45	6.85e-33	IgG glycosylation;
BRCA	cis	rs6714710	0.603	rs35255677	chr2:98567820	G/A	cg26665480	chr2:98280029	ACTR1B	0.59	13.62	0.47	2.91e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	trans	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg25214090	chr10:38739885	LOC399744	0.53	11.69	0.42	9.28e-29	Corneal astigmatism;
BRCA	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg21747090	chr2:27597821	SNX17	-0.37	-7.89	-0.3	1.33e-14	Total body bone mineral density;
BRCA	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg18402987	chr7:1209562	NA	0.87	9.15	0.34	7.77e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg14349672	chr11:133703707	NA	-0.41	-9.13	-0.34	9.09e-19	Childhood ear infection;
BRCA	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg21545522	chr1:205238299	TMCC2	0.4	8.36	0.31	3.85e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg06627628	chr2:24431161	ITSN2	-0.54	-8.84	-0.33	9.14e-18	Lymphocyte counts;
BRCA	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg22906224	chr7:99728672	NA	-0.44	-8.5	-0.32	1.29e-16	Coronary artery disease;
BRCA	cis	rs4664304	0.620	rs2357691	chr2:160725139	A/G	cg14819504	chr2:160761413	LY75	-0.34	-8.26	-0.31	8.61e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs3925075	0.934	rs9673522	chr16:31347648	T/C	cg02846316	chr16:31340340	ITGAM	0.54	13.29	0.47	9.24e-36	IgA nephropathy;
BRCA	trans	rs1459104	0.636	rs559362	chr11:55275456	T/G	cg03929089	chr4:120376271	NA	0.52	8.07	0.3	3.4e-15	Body mass index;
BRCA	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.51	-11.55	-0.42	3.88e-28	Personality dimensions;
BRCA	trans	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg06521331	chr12:34319734	NA	-0.54	-10.31	-0.38	3.61e-23	Bladder cancer;
BRCA	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg24578937	chr1:2090814	PRKCZ	0.38	11.78	0.42	4.16e-29	Height;
BRCA	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg18305652	chr10:134549665	INPP5A	0.51	13.12	0.46	5.49e-35	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg06766960	chr11:133703094	NA	-0.61	-13.29	-0.47	9.15e-36	Childhood ear infection;
BRCA	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	10.75	0.39	7.03e-25	Height;
BRCA	cis	rs12220238	1.000	rs10824090	chr10:75923446	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.48	7.94	0.3	8.87e-15	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg08999081	chr20:33150536	PIGU	0.44	12.26	0.44	3.36e-31	Glomerular filtration rate (creatinine);
BRCA	trans	rs11039798	1.000	rs11039798	chr11:48540223	G/A	cg15704280	chr7:45808275	SEPT13	0.69	8.18	0.31	1.56e-15	Axial length;
BRCA	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg08355456	chr11:67383691	NA	-0.4	-8.71	-0.33	2.51e-17	Mean corpuscular volume;
BRCA	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.78	0.36	3.95e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs8028182	0.636	rs4886715	chr15:75831449	C/T	cg20655648	chr15:75932815	IMP3	0.42	8.26	0.31	8.3e-16	Sudden cardiac arrest;
BRCA	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.63	15.06	0.51	4.14e-44	Chronic sinus infection;
BRCA	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.22e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3820928	0.934	rs4675117	chr2:227769794	A/G	cg11843606	chr2:227700838	RHBDD1	0.41	8.19	0.31	1.44e-15	Pulmonary function;
BRCA	cis	rs1555322	0.530	rs2425042	chr20:33865895	G/A	cg17927777	chr20:33865990	NA	0.47	8.75	0.33	1.88e-17	Attention deficit hyperactivity disorder;
BRCA	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg21045802	chr8:109455806	TTC35	0.39	9.04	0.34	1.84e-18	Dupuytren's disease;
BRCA	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05890377	chr2:74357713	NA	-0.42	-9.26	-0.34	3.12e-19	Gestational age at birth (maternal effect);
BRCA	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg16586182	chr3:47516702	SCAP	0.64	14.83	0.51	5.65e-43	Colorectal cancer;
BRCA	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-13.52	-0.47	8.46e-37	Bipolar disorder and schizophrenia;
BRCA	cis	rs7617773	0.851	rs6775179	chr3:48313418	T/C	cg11946769	chr3:48343235	NME6	0.62	13.51	0.47	9.11e-37	Coronary artery disease;
BRCA	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg02659138	chr7:134003124	SLC35B4	0.33	10.41	0.38	1.46e-23	Mean platelet volume;
BRCA	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg26384229	chr12:38710491	ALG10B	-0.49	-12.02	-0.43	3.64e-30	Morning vs. evening chronotype;
BRCA	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg00908766	chr1:109817496	CELSR2	0.62	19.41	0.61	2.54e-66	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
BRCA	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.57	-12.78	-0.45	1.8e-33	Longevity;Endometriosis;
BRCA	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11764359	chr7:65958608	NA	0.76	16.82	0.55	7.85e-53	Aortic root size;
BRCA	cis	rs9296092	0.538	rs62407564	chr6:33534010	C/T	cg13560919	chr6:33536144	NA	-0.91	-19.42	-0.61	2.12e-66	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg18016565	chr1:150552671	MCL1	0.35	8.23	0.31	1.08e-15	Tonsillectomy;
BRCA	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg16339924	chr4:17578868	LAP3	0.57	13.96	0.48	7.43e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg02734326	chr4:10020555	SLC2A9	0.38	8.22	0.31	1.17e-15	Bone mineral density;
BRCA	cis	rs2415984	0.622	rs61993294	chr14:46932466	C/G	cg14871534	chr14:47121158	RPL10L	-0.38	-9.04	-0.34	1.84e-18	Number of children ever born;
BRCA	cis	rs7011049	0.908	rs72640860	chr8:53840500	G/A	cg26025543	chr8:53854495	NA	0.56	9.66	0.36	1.11e-20	Systolic blood pressure;
BRCA	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg24558204	chr6:135376177	HBS1L	0.47	12.77	0.45	2.04e-33	Red blood cell count;
BRCA	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg13010199	chr12:38710504	ALG10B	0.52	10.87	0.4	2.24e-25	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1568889	1.000	rs7949057	chr11:28255053	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.67	0.5	3.17e-42	Bipolar disorder;
BRCA	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-14.89	-0.51	2.92e-43	Chronic sinus infection;
BRCA	cis	rs6840258	0.941	rs7665282	chr4:87900850	C/T	cg08197287	chr4:87952173	AFF1	-0.44	-8.28	-0.31	7.47e-16	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg08807101	chr21:30365312	RNF160	-0.57	-13.87	-0.48	1.98e-38	Dental caries;
BRCA	cis	rs698813	0.573	rs6544750	chr2:44490780	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	8.62	0.32	5.46e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	10.95	0.4	1.04e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg16414030	chr3:133502952	NA	0.4	8.98	0.33	2.94e-18	Iron status biomarkers;
BRCA	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.89	-0.33	6.32e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6740322	0.895	rs10196095	chr2:43571885	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-12.09	-0.43	1.9e-30	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9815354	0.812	rs56983571	chr3:41994473	T/C	cg03022575	chr3:42003672	ULK4	0.7	9.76	0.36	4.45e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg14863265	chr7:2801509	GNA12	-0.46	-10.08	-0.37	2.91e-22	Height;
BRCA	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg06636001	chr8:8085503	FLJ10661	0.43	8.74	0.33	2.03e-17	Morning vs. evening chronotype;
BRCA	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg01689657	chr7:91764605	CYP51A1	0.21	7.86	0.3	1.61e-14	Breast cancer;
BRCA	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg20703242	chr1:230279135	GALNT2	0.47	10.36	0.38	2.4e-23	Coronary artery disease;
BRCA	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	trans	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.13	0.31	2.28e-15	Corneal astigmatism;
BRCA	cis	rs758324	0.947	rs4705838	chr5:131150593	G/T	cg06307176	chr5:131281290	NA	0.54	10.32	0.38	3.37e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg25174290	chr11:3078921	CARS	-0.38	-11.23	-0.41	8.15e-27	Longevity;
BRCA	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg11764359	chr7:65958608	NA	0.63	14.3	0.49	1.81e-40	Aortic root size;
BRCA	cis	rs9649465	0.561	rs2429620	chr7:123430012	A/G	cg03229431	chr7:123269106	ASB15	0.41	9.48	0.35	5.1e-20	Migraine;
BRCA	trans	rs8002861	0.810	rs7334812	chr13:44445538	C/T	cg17145862	chr1:211918768	LPGAT1	0.65	16.59	0.55	1.19e-51	Leprosy;
BRCA	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg17063962	chr7:91808500	NA	-0.54	-12.92	-0.46	4.26e-34	Breast cancer;
BRCA	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03517284	chr6:25882590	NA	-0.36	-8.42	-0.32	2.42e-16	Height;
BRCA	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504073	0.647	rs6997703	chr8:49998364	T/C	cg00325661	chr8:49890786	NA	0.44	12.44	0.44	5.56e-32	Blood metabolite ratios;
BRCA	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.51	-9.67	-0.36	1.01e-20	Aortic root size;
BRCA	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.45	8.41	0.32	2.62e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg13010199	chr12:38710504	ALG10B	0.51	10.46	0.38	9.29e-24	Bladder cancer;
BRCA	cis	rs2115536	0.730	rs12898642	chr15:80182050	T/C	cg02196730	chr15:80188777	MTHFS	0.38	8.62	0.32	5.44e-17	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
BRCA	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg20307385	chr11:47447363	PSMC3	-0.42	-8.76	-0.33	1.72e-17	Subjective well-being;
BRCA	cis	rs12425451	0.544	rs28623776	chr12:3147631	C/T	cg05389053	chr12:3131226	TEAD4	-0.44	-8.35	-0.31	4.21e-16	Narcolepsy with cataplexy;
BRCA	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg20701182	chr2:24300061	SF3B14	0.56	8.61	0.32	5.89e-17	Lymphocyte counts;
BRCA	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg19257562	chr1:2043853	PRKCZ	-0.34	-9.65	-0.36	1.17e-20	Height;
BRCA	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg01849466	chr14:104193079	ZFYVE21	0.41	10.46	0.38	9.34e-24	Schizophrenia;
BRCA	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.2e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs853679	0.607	rs67998226	chr6:28238059	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.76	-0.33	1.75e-17	Depression;
BRCA	cis	rs17253792	0.908	rs9972177	chr14:56073206	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-10.8	-0.39	4.21e-25	Putamen volume;
BRCA	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg05418105	chr22:50981406	NA	0.43	8.36	0.31	3.9e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg25767906	chr1:53392781	SCP2	-0.49	-10.67	-0.39	1.42e-24	Monocyte count;
BRCA	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	11.2	0.41	1.05e-26	Multiple sclerosis;
BRCA	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg26031613	chr14:104095156	KLC1	0.53	10.47	0.38	9.02e-24	Schizophrenia;
BRCA	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg08859206	chr1:53392774	SCP2	-0.51	-11.13	-0.4	2.08e-26	Monocyte count;
BRCA	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg06070324	chr15:75322058	PPCDC	0.39	8.14	0.31	2.12e-15	Blood trace element (Zn levels);
BRCA	trans	rs459571	0.920	rs460154	chr9:136909309	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-13.76	-0.48	6.14e-38	Platelet distribution width;
BRCA	cis	rs868036	1.000	rs3784719	chr15:68098180	C/T	cg08079166	chr15:68083412	MAP2K5	0.35	9.44	0.35	7.13e-20	Restless legs syndrome;
BRCA	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00149659	chr3:10157352	C3orf10	0.8	13.73	0.48	9.11e-38	Alzheimer's disease;
BRCA	cis	rs7945705	0.846	rs11042055	chr11:8756856	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.52	10.79	0.39	4.56e-25	Hemoglobin concentration;
BRCA	trans	rs526821	0.574	rs11230156	chr11:55334809	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-7.98	-0.3	7.04e-15	Pediatric bone mineral density (spine);
BRCA	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg15704280	chr7:45808275	SEPT13	-0.7	-14.08	-0.49	2.08e-39	Coronary artery disease;
BRCA	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.22e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg24692254	chr21:30365293	RNF160	-0.59	-14.83	-0.51	5.77e-43	Dental caries;
BRCA	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg20203395	chr5:56204925	C5orf35	0.41	9.18	0.34	5.91e-19	Initial pursuit acceleration;
BRCA	cis	rs1113500	0.933	rs10785834	chr1:108639101	A/C	cg06207961	chr1:108661230	NA	0.44	10.79	0.39	4.68e-25	Growth-regulated protein alpha levels;
BRCA	cis	rs10484885	0.680	rs72921943	chr6:90581542	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.88	-17.0	-0.56	9.97e-54	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg11822812	chr5:140052017	DND1	-0.3	-8.31	-0.31	5.89e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs67981189	0.896	rs7146591	chr14:71438228	C/T	cg15816911	chr14:71606274	NA	-0.36	-8.03	-0.3	4.81e-15	Schizophrenia;
BRCA	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg21385522	chr1:16154831	NA	0.47	8.45	0.32	1.9e-16	Dilated cardiomyopathy;
BRCA	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg03146154	chr1:46216737	IPP	-0.44	-9.64	-0.36	1.27e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs965469	0.895	rs6037595	chr20:3401128	T/G	cg25506879	chr20:3388711	C20orf194	-0.53	-10.05	-0.37	3.59e-22	IFN-related cytopenia;
BRCA	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21659725	chr3:3221576	CRBN	0.36	8.5	0.32	1.33e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	16.14	0.54	2.01e-49	Homoarginine levels;
BRCA	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg10223061	chr2:219282414	VIL1	0.3	8.69	0.33	3.04e-17	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg03146154	chr1:46216737	IPP	0.49	10.62	0.39	2.29e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg11707556	chr5:10655725	ANKRD33B	0.4	8.87	0.33	7.33e-18	Coronary artery disease;
BRCA	cis	rs6942756	0.806	rs6967464	chr7:128909727	T/C	cg02491457	chr7:128862824	NA	0.57	12.0	0.43	4.73e-30	White matter hyperintensity burden;
BRCA	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg24558204	chr6:135376177	HBS1L	0.44	12.2	0.43	6.19e-31	Reticulocyte count;High light scatter reticulocyte count;
BRCA	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg18811423	chr2:55921094	PNPT1	-0.64	-19.11	-0.6	9.57e-65	Metabolic syndrome;
BRCA	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg26248373	chr2:1572462	NA	-0.67	-15.88	-0.53	4e-48	IgG glycosylation;
BRCA	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.35	-8.32	-0.31	5.4e-16	Menarche (age at onset);
BRCA	cis	rs36051895	0.695	rs7043489	chr9:5023604	A/C	cg02405213	chr9:5042618	JAK2	-0.44	-8.23	-0.31	1.09e-15	Pediatric autoimmune diseases;
BRCA	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.52	0.55	2.47e-51	Colorectal cancer;
BRCA	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg11764359	chr7:65958608	NA	-0.63	-11.16	-0.4	1.5e-26	Aortic root size;
BRCA	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg21782813	chr7:2030301	MAD1L1	0.39	10.22	0.37	8.22e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs1788820	0.917	rs1652349	chr18:21142734	A/T	cg14672496	chr18:21087552	C18orf8	0.34	8.19	0.31	1.43e-15	Body mass index;
BRCA	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg20487152	chr13:99095054	FARP1	-0.4	-11.67	-0.42	1.2e-28	Neuroticism;
BRCA	trans	rs7200543	0.961	rs3803573	chr16:15138413	C/T	cg24683922	chr1:11983373	KIAA2013	-0.35	-7.83	-0.3	2e-14	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg00852783	chr1:26633632	UBXN11	-0.46	-8.09	-0.3	2.9e-15	Obesity-related traits;
BRCA	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg06238570	chr21:40685208	BRWD1	-0.4	-8.06	-0.3	3.77e-15	Menarche (age at onset);
BRCA	cis	rs13046373	0.535	rs35909098	chr21:32021649	C/T	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.33	0.31	5.05e-16	HDL cholesterol;
BRCA	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg21573476	chr21:45109991	RRP1B	-0.42	-11.25	-0.41	6.46e-27	Mean corpuscular volume;
BRCA	cis	rs10929956	0.760	rs2729704	chr2:160707866	T/A	cg01092293	chr2:160761427	LY75	-0.36	-8.52	-0.32	1.12e-16	Crohn's disease-related phenotypes;
BRCA	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg12386194	chr3:101231763	SENP7	0.46	9.66	0.36	1.05e-20	Colorectal cancer;
BRCA	trans	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.13	-38.27	-0.83	1.82e-167	Exhaled nitric oxide output;
BRCA	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.89	-0.33	6.18e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4466137	0.953	rs7735476	chr5:83015140	G/C	cg16102102	chr5:83017553	HAPLN1	-0.92	-18.52	-0.59	1.23e-61	Prostate cancer;
BRCA	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg13319975	chr6:146136371	FBXO30	-0.36	-8.16	-0.31	1.73e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-9.32	-0.35	1.88e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg24846343	chr22:24311635	DDTL	0.57	15.01	0.51	7.46e-44	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4908760	0.931	rs1463049	chr1:8597108	A/T	cg20416874	chr1:8611966	RERE	-0.28	-8.1	-0.31	2.86e-15	Vitiligo;
BRCA	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.65	-14.24	-0.49	3.5e-40	Ileal carcinoids;
BRCA	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg04989706	chr14:50066350	PPIL5	-0.47	-9.26	-0.34	3.13e-19	Carotid intima media thickness;
BRCA	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg03452623	chr4:187889614	NA	-0.32	-10.71	-0.39	1.04e-24	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg00701064	chr4:6280414	WFS1	0.67	17.55	0.57	1.46e-56	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg01262667	chr19:19385393	TM6SF2	0.42	10.88	0.4	2.04e-25	Tonsillectomy;
BRCA	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11644478	chr21:40555479	PSMG1	-0.46	-9.91	-0.37	1.2e-21	Cognitive function;
BRCA	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg18230493	chr5:56204884	C5orf35	-0.72	-14.07	-0.49	2.27e-39	Initial pursuit acceleration;
BRCA	cis	rs2835872	0.733	rs2850124	chr21:39036763	T/A	cg06728970	chr21:39037746	KCNJ6	0.43	12.38	0.44	1.1e-31	Electroencephalographic traits in alcoholism;
BRCA	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg04362960	chr10:104952993	NT5C2	0.44	9.27	0.34	2.92e-19	Arsenic metabolism;
BRCA	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg05347473	chr6:146136440	FBXO30	0.39	7.94	0.3	9.39e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs495337	0.760	rs6122845	chr20:48546274	G/A	cg17835207	chr20:48524531	SPATA2	-0.69	-16.8	-0.55	1.04e-52	Psoriasis;
BRCA	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.46	8.5	0.32	1.35e-16	Multiple sclerosis;
BRCA	cis	rs365132	0.875	rs4490607	chr5:176349386	T/C	cg16309518	chr5:176445507	NA	-0.39	-9.61	-0.36	1.59e-20	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg23711669	chr6:146136114	FBXO30	0.63	14.42	0.5	4.94e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9290065	0.519	rs2121721	chr3:160685788	A/G	cg03342759	chr3:160939853	NMD3	-0.46	-9.36	-0.35	1.38e-19	Kawasaki disease;
BRCA	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg05025164	chr4:1340916	KIAA1530	0.4	8.97	0.33	3.39e-18	Longevity;
BRCA	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg05863683	chr7:1912471	MAD1L1	-0.35	-8.41	-0.32	2.65e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg11833968	chr6:79620685	NA	-0.41	-9.05	-0.34	1.78e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg21573476	chr21:45109991	RRP1B	-0.4	-10.68	-0.39	1.32e-24	Mean corpuscular volume;
BRCA	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg12483005	chr1:23474871	LUZP1	0.48	10.46	0.38	9.57e-24	Height;
BRCA	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg06159980	chr1:16340746	HSPB7	-0.38	-8.83	-0.33	1.01e-17	Dilated cardiomyopathy;
BRCA	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg13126279	chr21:47581558	C21orf56	-0.38	-8.27	-0.31	7.59e-16	Testicular germ cell tumor;
BRCA	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg18512352	chr11:47633146	NA	-0.35	-8.37	-0.31	3.64e-16	Subjective well-being;
BRCA	cis	rs2742234	0.541	rs11238483	chr10:43728780	A/G	cg15436174	chr10:43711423	RASGEF1A	0.53	10.62	0.39	2.29e-24	Hirschsprung disease;
BRCA	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-10.16	-0.37	1.35e-22	Bone mineral density;
BRCA	cis	rs17641971	0.684	rs11990854	chr8:49992048	T/C	cg00325661	chr8:49890786	NA	0.39	10.81	0.39	4.14e-25	Blood metabolite levels;
BRCA	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg12310025	chr6:25882481	NA	-0.56	-12.34	-0.44	1.55e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg08085267	chr17:45401833	C17orf57	0.63	12.98	0.46	2.39e-34	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg24324837	chr19:49891574	CCDC155	0.42	7.86	0.3	1.68e-14	Multiple sclerosis;
BRCA	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg11584989	chr19:19387371	SF4	0.3	7.85	0.3	1.71e-14	Tonsillectomy;
BRCA	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.54	-0.32	1.01e-16	Total body bone mineral density;
BRCA	cis	rs9463078	0.764	rs9369516	chr6:44833598	C/T	cg25276700	chr6:44698697	NA	-0.36	-8.31	-0.31	5.82e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg27129171	chr3:47204927	SETD2	0.71	16.99	0.56	1.03e-53	Colorectal cancer;
BRCA	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg20387954	chr3:183756860	HTR3D	0.47	10.45	0.38	1.01e-23	Anterior chamber depth;
BRCA	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg08645402	chr16:4508243	NA	0.43	9.95	0.37	8.82e-22	Schizophrenia;
BRCA	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.05	-15.64	-0.53	6.17e-47	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.96	26.43	0.72	1.42e-104	Birth weight;
BRCA	cis	rs10248839	0.518	rs1317741	chr7:29711149	T/C	cg19413766	chr7:29689036	LOC646762	-0.56	-8.92	-0.33	4.87e-18	Facial emotion recognition (angry faces);
BRCA	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg11502198	chr6:26597334	ABT1	0.49	9.73	0.36	5.8e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg08888203	chr3:10149979	C3orf24	0.65	13.64	0.47	2.35e-37	Alzheimer's disease;
BRCA	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg09462578	chr12:12878428	APOLD1	-0.58	-10.4	-0.38	1.66e-23	Systemic lupus erythematosus;
BRCA	cis	rs758324	0.783	rs253941	chr5:131320293	C/T	cg06307176	chr5:131281290	NA	-0.52	-10.41	-0.38	1.44e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.45	-9.35	-0.35	1.4e-19	Eosinophil percentage of white cells;
BRCA	trans	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04565464	chr8:145669602	NFKBIL2	0.38	8.93	0.33	4.59e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs3820928	0.839	rs4675123	chr2:227800205	T/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.6	-0.32	6.39e-17	Pulmonary function;
BRCA	trans	rs12517041	1.000	rs28472703	chr5:23281381	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.32	-0.31	5.27e-16	Calcium levels;
BRCA	cis	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	8.73	0.33	2.25e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg25358565	chr5:93447407	FAM172A	1.16	18.42	0.59	4.3e-61	Diabetic retinopathy;
BRCA	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg14019146	chr3:50243930	SLC38A3	-0.55	-11.37	-0.41	2.14e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.45	9.42	0.35	7.78e-20	Ulcerative colitis;
BRCA	cis	rs60843830	0.508	rs300750	chr2:208794	T/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.42	8.27	0.31	7.62e-16	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg04025307	chr7:1156635	C7orf50	0.59	9.31	0.35	2e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.74	-0.77	4.42e-128	Schizophrenia;
BRCA	cis	rs877282	0.945	rs11253391	chr10:788752	G/A	cg17470449	chr10:769945	NA	0.51	8.62	0.32	5.29e-17	Uric acid levels;
BRCA	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg04511125	chr2:88470314	THNSL2	-0.52	-10.77	-0.39	5.85e-25	Response to metformin (IC50);
BRCA	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.62	-0.32	5.12e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7408868	1.000	rs8107180	chr19:15275430	T/C	cg14696996	chr19:15285081	NOTCH3	0.99	14.46	0.5	3.39e-41	Pulse pressure;
BRCA	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg12219531	chr12:120966889	COQ5	0.53	11.14	0.4	1.81e-26	High light scatter reticulocyte count;
BRCA	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg19628046	chr18:33552617	C18orf21	0.6	12.38	0.44	1.01e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg22920501	chr2:26401640	FAM59B	-0.66	-11.52	-0.41	4.74e-28	Gut microbiome composition (summer);
BRCA	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg14675211	chr2:100938903	LONRF2	0.42	9.4	0.35	9.93e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg08645402	chr16:4508243	NA	0.37	8.86	0.33	7.67e-18	Schizophrenia;
BRCA	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg17366294	chr4:99064904	C4orf37	0.5	11.06	0.4	3.81e-26	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg25214090	chr10:38739885	LOC399744	0.42	9.76	0.36	4.41e-21	Educational attainment;
BRCA	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg06484146	chr7:12443880	VWDE	-0.66	-10.22	-0.37	8.22e-23	Coronary artery disease;
BRCA	cis	rs9469578	0.892	rs6929527	chr6:33707976	G/T	cg18708504	chr6:33715942	IP6K3	0.72	10.42	0.38	1.43e-23	Phosphorus levels;
BRCA	cis	rs9815354	0.812	rs73081321	chr3:41890231	G/A	cg03022575	chr3:42003672	ULK4	0.71	9.71	0.36	7.25e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg24399712	chr22:39784796	NA	-0.58	-13.74	-0.48	8.09e-38	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg08493051	chr2:3487164	NA	-0.43	-9.1	-0.34	1.09e-18	Neurofibrillary tangles;
BRCA	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg04362960	chr10:104952993	NT5C2	0.46	10.64	0.39	1.87e-24	Arsenic metabolism;
BRCA	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg14784868	chr12:69753453	YEATS4	0.51	11.52	0.41	4.96e-28	Response to diuretic therapy;
BRCA	cis	rs6545883	0.718	rs3771260	chr2:61762384	G/T	cg15711740	chr2:61764176	XPO1	-0.54	-13.87	-0.48	1.93e-38	Tuberculosis;
BRCA	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg10011062	chr15:43941034	CATSPER2	-0.52	-7.83	-0.3	2.1e-14	Lung cancer in ever smokers;
BRCA	cis	rs3925075	0.515	rs4459557	chr16:31361643	G/C	cg02846316	chr16:31340340	ITGAM	0.43	9.39	0.35	1.01e-19	IgA nephropathy;
BRCA	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg00898013	chr13:113819073	PROZ	0.45	10.22	0.37	8.21e-23	Platelet distribution width;
BRCA	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg17330251	chr7:94953956	PON1	-0.42	-8.58	-0.32	7.32e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs10267417	0.603	rs10260797	chr7:19890181	A/G	cg05791153	chr7:19748676	TWISTNB	0.47	9.14	0.34	7.94e-19	Night sleep phenotypes;
BRCA	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11764359	chr7:65958608	NA	0.76	17.1	0.56	2.94e-54	Aortic root size;
BRCA	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.64	-14.92	-0.51	2.13e-43	Mean platelet volume;
BRCA	trans	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg26384229	chr12:38710491	ALG10B	0.44	10.35	0.38	2.51e-23	Morning vs. evening chronotype;
BRCA	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg16482183	chr6:26056742	HIST1H1C	0.41	8.78	0.33	1.49e-17	Iron status biomarkers;
BRCA	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg01028140	chr2:1542097	TPO	-0.61	-12.61	-0.45	9.79e-33	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg01256987	chr12:42539512	GXYLT1	-0.42	-8.49	-0.32	1.49e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg26384229	chr12:38710491	ALG10B	0.82	21.86	0.65	1.51e-79	Heart rate;
BRCA	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg26168224	chr5:2018326	NA	0.64	17.71	0.57	2.02e-57	Gut microbiome composition (winter);
BRCA	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.68	-13.76	-0.48	6.61e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg25214090	chr10:38739885	LOC399744	0.53	11.97	0.43	6.48e-30	Corneal astigmatism;
BRCA	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg18132916	chr6:79620363	NA	-0.46	-10.66	-0.39	1.57e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs1712517	0.740	rs11191663	chr10:105118462	C/T	cg05636881	chr10:105038444	INA	0.36	7.96	0.3	7.99e-15	Migraine;
BRCA	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	16.63	0.55	7.04e-52	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg16482183	chr6:26056742	HIST1H1C	0.54	11.49	0.41	6.87e-28	Height;
BRCA	cis	rs9815354	1.000	rs9874513	chr3:41909508	G/A	cg03022575	chr3:42003672	ULK4	0.51	8.31	0.31	5.54e-16	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00339695	chr16:24857497	SLC5A11	0.36	8.5	0.32	1.38e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.42	-0.35	7.95e-20	Alzheimer's disease;
BRCA	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	11.63	0.42	1.71e-28	Rheumatoid arthritis;
BRCA	cis	rs6813479	0.562	rs2634900	chr4:137733596	C/A	cg16185213	chr4:137733633	NA	0.39	9.13	0.34	9.07e-19	Longevity;
BRCA	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21659725	chr3:3221576	CRBN	-0.43	-10.38	-0.38	1.93e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg21138405	chr5:131827807	IRF1	0.39	12.9	0.45	5.51e-34	Asthma (sex interaction);
BRCA	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08219700	chr8:58056026	NA	0.44	7.94	0.3	8.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs68170813	0.641	rs77397573	chr7:107006892	G/A	cg02696742	chr7:106810147	HBP1	-0.55	-8.61	-0.32	5.89e-17	Coronary artery disease;
BRCA	cis	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-8.09	-0.3	3.11e-15	Obesity-related traits;
BRCA	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg02734326	chr4:10020555	SLC2A9	0.39	8.28	0.31	7.31e-16	Bone mineral density;
BRCA	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg15704280	chr7:45808275	SEPT13	0.74	17.82	0.58	6.03e-58	Height;
BRCA	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg05535760	chr7:792225	HEATR2	-0.74	-11.7	-0.42	8.3e-29	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.91	-0.3	1.13e-14	Prostate cancer;
BRCA	cis	rs10046574	0.561	rs10214966	chr7:135196642	A/G	cg27474649	chr7:135195673	CNOT4	0.67	10.95	0.4	1.07e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.46	0.32	1.76e-16	Menopause (age at onset);
BRCA	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg16576597	chr16:28551801	NUPR1	0.29	8.21	0.31	1.2e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg13319975	chr6:146136371	FBXO30	0.41	9.3	0.35	2.13e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg23173402	chr1:227635558	NA	0.51	9.3	0.35	2.21e-19	Major depressive disorder;
BRCA	trans	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg25214090	chr10:38739885	LOC399744	0.56	12.85	0.45	9.31e-34	Corneal astigmatism;
BRCA	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.53	-0.38	4.99e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg11789530	chr4:8429930	ACOX3	-0.55	-12.51	-0.44	2.96e-32	Response to antineoplastic agents;
BRCA	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg22105103	chr4:187893119	NA	0.38	11.86	0.42	1.75e-29	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs629535	0.862	rs654604	chr8:70048939	C/A	cg21567404	chr3:27674614	NA	1.0	21.1	0.64	2.04e-75	Dupuytren's disease;
BRCA	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg12310025	chr6:25882481	NA	-0.51	-12.16	-0.43	9.04e-31	Blood metabolite levels;
BRCA	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg07541023	chr7:19748670	TWISTNB	0.58	9.87	0.36	1.71e-21	Thyroid stimulating hormone;
BRCA	cis	rs4889855	0.530	rs12603265	chr17:78618637	A/G	cg16591659	chr17:78472290	NA	-0.32	-8.26	-0.31	8.41e-16	Fractional excretion of uric acid;
BRCA	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-10.36	-0.38	2.38e-23	Renal function-related traits (BUN);
BRCA	trans	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg09719594	chr16:21412588	NA	-0.32	-7.82	-0.3	2.19e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg01475377	chr6:109611718	NA	0.59	16.33	0.54	2.24e-50	Reticulocyte fraction of red cells;
BRCA	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-13.56	-0.47	5.25e-37	Gut microbiome composition (summer);
BRCA	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg16339924	chr4:17578868	LAP3	0.62	15.45	0.52	5.68e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8016982	0.651	rs9806027	chr14:81668707	G/C	cg01989461	chr14:81687754	GTF2A1	0.61	14.3	0.49	1.99e-40	Schizophrenia;
BRCA	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-11.17	-0.4	1.33e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9287719	0.614	rs10929681	chr2:10723283	C/T	cg00105475	chr2:10696890	NA	0.41	9.17	0.34	6.17e-19	Prostate cancer;
BRCA	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.46	9.03	0.34	2.07e-18	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs17641971	0.684	rs11785391	chr8:49930203	G/T	cg00325661	chr8:49890786	NA	0.39	10.64	0.39	1.89e-24	Blood metabolite levels;
BRCA	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.34	-0.41	2.79e-27	Colorectal cancer;
BRCA	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg04944784	chr2:26401820	FAM59B	0.95	16.58	0.55	1.26e-51	Gut microbiome composition (summer);
BRCA	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25427524	chr10:38739819	LOC399744	0.66	16.08	0.54	4.08e-49	Extrinsic epigenetic age acceleration;
BRCA	cis	rs73001065	0.818	rs73004975	chr19:19727152	A/G	cg03709012	chr19:19516395	GATAD2A	0.77	9.61	0.36	1.64e-20	LDL cholesterol;
BRCA	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.76	-0.42	4.75e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg13010199	chr12:38710504	ALG10B	0.58	12.72	0.45	3.48e-33	Heart rate;
BRCA	cis	rs6684514	1.000	rs2241106	chr1:156218910	C/G	cg16558208	chr1:156270281	VHLL	0.36	7.94	0.3	9.43e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.85	0.33	8.53e-18	Parkinson's disease;
BRCA	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg18850127	chr7:39170497	POU6F2	0.49	10.83	0.39	3.36e-25	IgG glycosylation;
BRCA	cis	rs6121246	0.512	rs6060938	chr20:30363645	T/C	cg13852791	chr20:30311386	BCL2L1	0.96	23.37	0.68	8.7e-88	Mean corpuscular hemoglobin;
BRCA	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg27432699	chr2:27873401	GPN1	-0.5	-10.51	-0.38	6.25e-24	Oral cavity cancer;
BRCA	trans	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg06521331	chr12:34319734	NA	-0.45	-8.34	-0.31	4.46e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2637266	0.935	rs2579720	chr10:78399918	T/C	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg04851639	chr8:1020857	NA	-0.34	-10.07	-0.37	3.08e-22	Schizophrenia;
BRCA	trans	rs877282	0.838	rs11253408	chr10:796374	T/C	cg22713356	chr15:30763199	NA	1.41	28.52	0.75	5.26e-116	Uric acid levels;
BRCA	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg07080220	chr10:102295463	HIF1AN	-0.59	-14.16	-0.49	8.25e-40	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg06784218	chr1:46089804	CCDC17	0.46	10.89	0.4	1.93e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg08807101	chr21:30365312	RNF160	-0.55	-12.57	-0.45	1.55e-32	Cognitive test performance;
BRCA	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-11.56	-0.42	3.3e-28	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.59	0.32	6.61e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs72792276	1.000	rs56657382	chr5:127387338	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	9.41	0.35	8.67e-20	Red cell distribution width;
BRCA	cis	rs4919087	1.000	rs12221430	chr10:99061386	C/G	cg25902810	chr10:99078978	FRAT1	0.5	10.83	0.39	3.3e-25	Monocyte count;
BRCA	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg24562669	chr7:97807699	LMTK2	0.62	18.43	0.59	3.57e-61	Breast cancer;
BRCA	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg06917634	chr15:78832804	PSMA4	0.6	11.71	0.42	8.24e-29	Sudden cardiac arrest;
BRCA	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg21385522	chr1:16154831	NA	0.48	10.29	0.38	4.37e-23	Systolic blood pressure;
BRCA	cis	rs4891159	0.790	rs7234653	chr18:74111988	C/T	cg24786174	chr18:74118243	ZNF516	-0.74	-18.41	-0.59	4.58e-61	Longevity;
BRCA	cis	rs6684514	1.000	rs12027103	chr1:156244856	G/A	cg16558208	chr1:156270281	VHLL	0.35	7.95	0.3	8.56e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg05347473	chr6:146136440	FBXO30	0.42	8.06	0.3	3.83e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg11584989	chr19:19387371	SF4	0.63	13.46	0.47	1.53e-36	Bipolar disorder;
BRCA	trans	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg15704280	chr7:45808275	SEPT13	0.54	8.19	0.31	1.43e-15	Axial length;
BRCA	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg14004847	chr7:1930337	MAD1L1	0.46	10.02	0.37	4.71e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-10.21	-0.37	8.85e-23	Morning vs. evening chronotype;
BRCA	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg00666640	chr1:248458726	OR2T12	0.32	8.59	0.32	6.44e-17	Common traits (Other);
BRCA	cis	rs4478858	0.839	rs10798834	chr1:31708977	G/A	cg00250761	chr1:31883323	NA	-0.32	-8.48	-0.32	1.59e-16	Alcohol dependence;
BRCA	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.64	-0.32	4.63e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg05283184	chr6:79620031	NA	-0.42	-11.06	-0.4	3.85e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg12463550	chr7:65579703	CRCP	-0.37	-7.82	-0.3	2.19e-14	Aortic root size;
BRCA	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg08514558	chr10:81106712	PPIF	0.35	8.46	0.32	1.86e-16	Height;
BRCA	cis	rs11051970	0.877	rs2651360	chr12:32588920	C/T	cg02745156	chr12:32552066	NA	0.27	8.89	0.33	6.07e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs6066835	1.000	rs6066820	chr20:47318444	T/C	cg18078177	chr20:47281410	PREX1	0.69	8.21	0.31	1.25e-15	Multiple myeloma;
BRCA	trans	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg17675199	chr6:35436792	RPL10A	-0.29	-7.82	-0.3	2.26e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg20701182	chr2:24300061	SF3B14	0.68	9.84	0.36	2.37e-21	Lymphocyte counts;
BRCA	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.09	0.3	3.1e-15	Menarche (age at onset);
BRCA	cis	rs11051970	0.877	rs2728671	chr12:32589715	T/A	cg02745156	chr12:32552066	NA	0.27	8.87	0.33	7.25e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	8.56	0.32	8.44e-17	Rheumatoid arthritis;
BRCA	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg13770153	chr20:60521292	NA	-0.46	-10.99	-0.4	7.66e-26	Body mass index;
BRCA	cis	rs1113500	0.787	rs10881501	chr1:108641745	C/T	cg06207961	chr1:108661230	NA	0.36	9.05	0.34	1.78e-18	Growth-regulated protein alpha levels;
BRCA	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg06627628	chr2:24431161	ITSN2	-0.56	-8.87	-0.33	7.52e-18	Lymphocyte counts;
BRCA	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg20503657	chr10:835505	NA	1.05	18.42	0.59	4.49e-61	Eosinophil percentage of granulocytes;
BRCA	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg23505145	chr19:12996616	KLF1	0.56	12.76	0.45	2.12e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg15017067	chr4:17643749	FAM184B	0.35	10.99	0.4	7.64e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg05623727	chr3:50126028	RBM5	-0.42	-10.02	-0.37	4.73e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	25.18	0.71	9.98e-98	Platelet count;
BRCA	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg05874882	chr4:1763078	NA	0.47	8.44	0.32	2.16e-16	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs6545883	0.929	rs12713436	chr2:61691260	T/C	cg15711740	chr2:61764176	XPO1	-0.56	-14.29	-0.49	2.03e-40	Tuberculosis;
BRCA	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.12	0.31	2.37e-15	Uric acid levels;
BRCA	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg16586182	chr3:47516702	SCAP	-0.43	-8.62	-0.32	5.18e-17	Birth weight;
BRCA	cis	rs7091068	0.518	rs1543580	chr10:95446811	C/T	cg20715218	chr10:95462985	C10orf4	0.47	9.94	0.37	9.77e-22	Urinary tract infection frequency;
BRCA	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg11693508	chr17:37793320	STARD3	0.67	12.21	0.43	5.71e-31	Bipolar disorder;
BRCA	cis	rs8038465	0.592	rs1542580	chr15:73935834	C/G	cg15420318	chr15:73925796	NPTN	0.42	9.33	0.35	1.65e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg10057126	chr4:77819792	ANKRD56	0.67	15.27	0.52	4.03e-45	Emphysema distribution in smoking;
BRCA	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg22535103	chr8:58192502	C8orf71	-0.46	-9.07	-0.34	1.5e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.59	-0.32	6.69e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	18.11	0.58	1.82e-59	Platelet count;
BRCA	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg24450063	chr1:156163899	SLC25A44	0.92	17.94	0.58	1.34e-58	Testicular germ cell tumor;
BRCA	cis	rs977987	0.806	rs11865004	chr16:75395777	C/T	cg03315344	chr16:75512273	CHST6	0.53	12.57	0.45	1.61e-32	Dupuytren's disease;
BRCA	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg08085267	chr17:45401833	C17orf57	-0.5	-9.57	-0.35	2.2e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs12541635	0.701	rs2029878	chr8:107025283	A/G	cg10147462	chr8:107024639	NA	0.37	9.85	0.36	2.13e-21	Age of smoking initiation;
BRCA	cis	rs4853036	0.629	rs13428251	chr2:70014561	G/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.03	-0.3	4.87e-15	Colorectal or endometrial cancer;
BRCA	trans	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg07211511	chr3:129823064	LOC729375	-1.05	-18.4	-0.59	5.22e-61	Blood pressure (smoking interaction);
BRCA	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg24558204	chr6:135376177	HBS1L	0.45	12.48	0.44	3.7e-32	Red blood cell count;
BRCA	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04824913	chr4:887549	GAK	0.71	12.93	0.46	3.76e-34	Systemic sclerosis;
BRCA	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg04166393	chr7:2884313	GNA12	0.4	8.57	0.32	7.85e-17	Height;
BRCA	trans	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg21659725	chr3:3221576	CRBN	-0.47	-8.66	-0.32	3.84e-17	Menarche (age at onset);
BRCA	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg23505145	chr19:12996616	KLF1	0.54	12.36	0.44	1.31e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1975991	0.597	rs9863463	chr3:187955779	T/G	cg15417654	chr3:187959138	LPP	0.36	9.23	0.34	4.01e-19	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg26195577	chr20:24973756	C20orf3	1.03	28.97	0.75	1.65e-118	Blood protein levels;
BRCA	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg11266682	chr4:10021025	SLC2A9	0.34	8.62	0.32	5.35e-17	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs501916	0.761	rs79925748	chr15:48046412	G/C	cg16110827	chr15:48056943	SEMA6D	-0.39	-8.25	-0.31	9.27e-16	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs881375	0.967	rs1548783	chr9:123658639	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	9.77	0.36	4e-21	Rheumatoid arthritis;
BRCA	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg09307838	chr4:120376055	NA	0.75	16.14	0.54	2.07e-49	Corneal astigmatism;
BRCA	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg17143192	chr8:8559678	CLDN23	0.49	9.45	0.35	6.1e-20	Obesity-related traits;
BRCA	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11890956	chr21:40555474	PSMG1	-1.03	-28.54	-0.75	3.91e-116	Cognitive function;
BRCA	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg24112000	chr20:60950667	NA	-0.47	-9.26	-0.34	3.11e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg12311346	chr5:56204834	C5orf35	0.62	12.95	0.46	3.14e-34	Initial pursuit acceleration;
BRCA	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg13628971	chr7:2884303	GNA12	0.47	9.57	0.35	2.32e-20	Height;
BRCA	cis	rs870825	0.929	rs72689273	chr4:185592750	C/T	cg04058563	chr4:185651563	MLF1IP	0.68	11.6	0.42	2.33e-28	Blood protein levels;
BRCA	cis	rs7586879	0.765	rs10171663	chr2:25086431	T/C	cg04586622	chr2:25135609	ADCY3	0.37	8.94	0.33	4.26e-18	Body mass index;
BRCA	cis	rs9815354	0.812	rs17218504	chr3:41987278	A/G	cg03022575	chr3:42003672	ULK4	0.7	9.76	0.36	4.45e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg27432699	chr2:27873401	GPN1	0.44	9.31	0.35	2.04e-19	Oral cavity cancer;
BRCA	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.64	0.55	6.17e-52	Colorectal cancer;
BRCA	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.31	0.35	1.95e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2276314	0.947	rs16967319	chr18:33573525	A/G	cg19628046	chr18:33552617	C18orf21	0.58	11.53	0.42	4.47e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.45	7.92	0.3	1.02e-14	Body mass index (adult);
BRCA	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg06115741	chr20:33292138	TP53INP2	0.49	11.02	0.4	5.73e-26	Coronary artery disease;
BRCA	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.35	-0.41	2.61e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg01802117	chr1:53393560	SCP2	-0.36	-8.31	-0.31	5.97e-16	Monocyte count;
BRCA	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg13010199	chr12:38710504	ALG10B	0.4	8.56	0.32	8.67e-17	Bladder cancer;
BRCA	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	8.96	0.33	3.46e-18	Tonsillectomy;
BRCA	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05926928	chr17:57297772	GDPD1	1.21	15.95	0.53	1.8e-48	Opioid sensitivity;
BRCA	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.62	0.55	8.25e-52	Alzheimer's disease (late onset);
BRCA	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07636037	chr3:49044803	WDR6	0.75	16.49	0.55	3.8e-51	Menarche (age at onset);
BRCA	cis	rs4690686	0.500	rs7683662	chr4:177272004	A/T	cg17059388	chr4:177262070	NA	0.54	11.33	0.41	2.94e-27	Essential tremor;
BRCA	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg15448220	chr1:150897856	SETDB1	0.35	7.88	0.3	1.38e-14	Melanoma;
BRCA	cis	rs68170813	0.521	rs61673847	chr7:106892431	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.33	-0.31	4.77e-16	Coronary artery disease;
BRCA	trans	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg13565492	chr6:43139072	SRF	-0.89	-16.16	-0.54	1.65e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7254827	0.522	rs1077795	chr19:17222584	A/G	cg19418318	chr19:17219073	MYO9B	-0.39	-8.92	-0.33	4.98e-18	Mean platelet volume;
BRCA	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	17.12	0.56	2.3e-54	Electrocardiographic conduction measures;
BRCA	cis	rs708547	0.874	rs7674167	chr4:57721477	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.46	-10.41	-0.38	1.54e-23	Response to bleomycin (chromatid breaks);
BRCA	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.03	0.3	4.61e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7927771	0.524	rs7932703	chr11:47769936	A/C	cg20307385	chr11:47447363	PSMC3	0.42	9.56	0.35	2.48e-20	Subjective well-being;
BRCA	cis	rs72781680	0.821	rs72781644	chr2:24209348	T/C	cg08917208	chr2:24149416	ATAD2B	0.61	10.44	0.38	1.16e-23	Lymphocyte counts;
BRCA	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg08807892	chr2:162101083	NA	-0.48	-9.73	-0.36	5.93e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg24692254	chr21:30365293	RNF160	-0.72	-19.08	-0.6	1.43e-64	Dental caries;
BRCA	trans	rs4714291	0.722	rs9296320	chr6:40118298	C/G	cg02267698	chr19:7991119	CTXN1	0.43	8.99	0.34	2.77e-18	Strep throat;
BRCA	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg24920358	chr1:40204285	PPIE	0.34	7.93	0.3	9.95e-15	Blood protein levels;
BRCA	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg23029597	chr12:123009494	RSRC2	-0.59	-11.38	-0.41	1.9e-27	Body mass index;
BRCA	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.49	10.76	0.39	6.31e-25	Hemoglobin concentration;
BRCA	cis	rs7809950	0.954	rs2520241	chr7:107135443	A/G	cg23024343	chr7:107201750	COG5	-0.42	-9.6	-0.36	1.77e-20	Coronary artery disease;
BRCA	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg10729496	chr3:10149963	C3orf24	0.49	9.01	0.34	2.35e-18	Alzheimer's disease;
BRCA	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg05347473	chr6:146136440	FBXO30	-0.45	-8.89	-0.33	6.29e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg04025307	chr7:1156635	C7orf50	0.51	9.86	0.36	1.96e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs754466	0.651	rs2004382	chr10:79650351	G/C	cg17075019	chr10:79541650	NA	-0.71	-16.21	-0.54	9.51e-50	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg22764044	chr5:178986830	RUFY1	0.44	10.88	0.4	2e-25	Lung cancer;
BRCA	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg08601574	chr20:25228251	PYGB	-0.34	-8.25	-0.31	9.18e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4363385	0.782	rs394859	chr1:153025704	T/C	cg24667326	chr1:152973720	SPRR3	-0.31	-8.27	-0.31	7.56e-16	Inflammatory skin disease;
BRCA	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg24110177	chr3:50126178	RBM5	-0.51	-14.45	-0.5	3.53e-41	Body mass index;
BRCA	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg15595755	chr5:1867978	NA	0.37	8.67	0.32	3.5e-17	Cardiovascular disease risk factors;
BRCA	cis	rs9283706	0.608	rs10065036	chr5:66338084	G/A	cg11590213	chr5:66331682	MAST4	0.37	7.88	0.3	1.4e-14	Coronary artery disease;
BRCA	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg03161606	chr19:29218774	NA	0.46	8.11	0.31	2.56e-15	Methadone dose in opioid dependence;
BRCA	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.66e-18	Motion sickness;
BRCA	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg08508325	chr11:3079039	CARS	-0.41	-14.33	-0.49	1.42e-40	Longevity;
BRCA	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.95	0.6	7.28e-64	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg16102102	chr5:83017553	HAPLN1	-0.92	-17.63	-0.57	5.25e-57	Prostate cancer;
BRCA	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg08470875	chr2:26401718	FAM59B	0.58	9.17	0.34	6.58e-19	Gut microbiome composition (summer);
BRCA	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.66	10.75	0.39	6.91e-25	Renal function-related traits (BUN);
BRCA	cis	rs6066825	0.555	rs4810849	chr20:47289944	C/T	cg18078177	chr20:47281410	PREX1	0.4	10.04	0.37	4.18e-22	Colorectal cancer;
BRCA	cis	rs1371614	0.632	rs6759548	chr2:27161060	A/G	cg00617064	chr2:27272375	NA	-0.3	-8.1	-0.31	2.8e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21659725	chr3:3221576	CRBN	-0.46	-9.85	-0.36	2.17e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs870825	0.616	rs2130393	chr4:185642335	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	16.78	0.55	1.26e-52	Blood protein levels;
BRCA	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg10223061	chr2:219282414	VIL1	-0.26	-7.81	-0.3	2.38e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24549020	chr5:56110836	MAP3K1	0.38	8.15	0.31	1.94e-15	Coronary artery disease;
BRCA	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.47	-0.41	8e-28	Mean corpuscular volume;
BRCA	cis	rs2742234	0.504	rs7093409	chr10:43740067	A/G	cg15436174	chr10:43711423	RASGEF1A	0.5	10.08	0.37	2.95e-22	Hirschsprung disease;
BRCA	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg25664220	chr3:72788482	NA	-0.55	-11.73	-0.42	6.4e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12200560	0.505	rs1334318	chr6:97079610	A/G	cg06623918	chr6:96969491	KIAA0776	-0.46	-10.61	-0.39	2.51e-24	Coronary heart disease;
BRCA	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg15395560	chr15:45543142	SLC28A2	0.3	8.45	0.32	2.02e-16	Uric acid levels;
BRCA	cis	rs2540552	0.600	rs35432547	chr7:91200238	G/A	cg15143024	chr7:91199642	NA	-0.47	-11.77	-0.42	4.28e-29	IgG glycosylation;
BRCA	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1800795	0.599	rs1546762	chr7:22757503	C/T	cg05472934	chr7:22766657	IL6	0.42	10.54	0.38	4.6e-24	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
BRCA	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg00651523	chr6:28411279	ZSCAN23	-0.36	-7.82	-0.3	2.21e-14	Pubertal anthropometrics;
BRCA	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.62	15.93	0.53	2.21e-48	Colorectal cancer;
BRCA	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg03188948	chr7:1209495	NA	0.63	12.83	0.45	1.05e-33	Longevity;Endometriosis;
BRCA	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg24642439	chr20:33292090	TP53INP2	0.42	8.45	0.32	2.03e-16	Height;
BRCA	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	12.77	0.45	1.97e-33	Response to antipsychotic treatment;
BRCA	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg15556689	chr8:8085844	FLJ10661	-0.36	-8.16	-0.31	1.72e-15	Obesity-related traits;
BRCA	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg08888203	chr3:10149979	C3orf24	0.65	11.96	0.43	6.86e-30	Alzheimer's disease;
BRCA	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg01689657	chr7:91764605	CYP51A1	0.24	8.48	0.32	1.59e-16	Breast cancer;
BRCA	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.29	8.0	0.3	5.7e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11644478	chr21:40555479	PSMG1	-0.68	-15.3	-0.52	3e-45	Cognitive function;
BRCA	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg09307838	chr4:120376055	NA	0.76	16.36	0.54	1.61e-50	Corneal astigmatism;
BRCA	cis	rs7127900	0.583	rs11043140	chr11:2233951	T/C	cg25635251	chr11:2234043	NA	0.46	12.55	0.44	1.97e-32	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
BRCA	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24110177	chr3:50126178	RBM5	0.52	15.68	0.53	4e-47	Body mass index;
BRCA	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg17845761	chr1:175162550	KIAA0040	-0.25	-9.66	-0.36	1.05e-20	Alcohol dependence;
BRCA	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg10523679	chr1:76189770	ACADM	0.76	15.51	0.52	2.79e-46	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10465746	0.935	rs12758441	chr1:84352034	A/G	cg10977910	chr1:84465055	TTLL7	0.51	10.31	0.38	3.81e-23	Obesity-related traits;
BRCA	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg15704280	chr7:45808275	SEPT13	-0.55	-10.6	-0.39	2.7e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg25237894	chr2:233734115	C2orf82	0.4	11.42	0.41	1.28e-27	Coronary artery disease;
BRCA	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg23711669	chr6:146136114	FBXO30	0.73	17.14	0.56	1.74e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6750047	0.585	rs62136319	chr2:38272950	G/A	cg07380506	chr2:38303506	CYP1B1	0.48	10.54	0.38	4.65e-24	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs7191700	0.578	rs243324	chr16:11354970	A/G	cg00044050	chr16:11439710	C16orf75	0.38	8.99	0.34	2.79e-18	Multiple sclerosis;
BRCA	cis	rs7020830	0.898	rs6476617	chr9:37200103	G/A	cg14294708	chr9:37120828	ZCCHC7	1.09	34.18	0.8	2.16e-146	Schizophrenia;
BRCA	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg20628663	chr10:43360327	NA	-0.71	-13.74	-0.48	8.06e-38	Blood protein levels;
BRCA	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg08888203	chr3:10149979	C3orf24	0.66	14.05	0.49	2.73e-39	Alzheimer's disease;
BRCA	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-8.84	-0.33	9.55e-18	IgG glycosylation;
BRCA	cis	rs73001065	0.901	rs739846	chr19:19419071	G/A	cg03709012	chr19:19516395	GATAD2A	0.8	9.42	0.35	7.76e-20	LDL cholesterol;
BRCA	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg00321850	chr1:175162397	KIAA0040	0.44	12.39	0.44	9.15e-32	Alcohol dependence;
BRCA	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg22920501	chr2:26401640	FAM59B	0.91	16.27	0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg06627628	chr2:24431161	ITSN2	-0.57	-9.12	-0.34	9.96e-19	Lymphocyte counts;
BRCA	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.77	-0.36	4.32e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs887829	0.570	rs45615240	chr2:234599296	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.34	-0.31	4.62e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg01028140	chr2:1542097	TPO	-0.58	-11.82	-0.42	2.77e-29	IgG glycosylation;
BRCA	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg05347473	chr6:146136440	FBXO30	-0.39	-7.9	-0.3	1.18e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7178424	1.000	rs4775458	chr15:62375036	T/G	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.3	-0.31	6.42e-16	Height;
BRCA	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	12.86	0.45	7.88e-34	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.8	0.33	1.25e-17	Platelet count;
BRCA	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg06937882	chr20:24974362	C20orf3	-0.47	-8.97	-0.33	3.28e-18	Blood protein levels;
BRCA	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg18132916	chr6:79620363	NA	-0.48	-10.91	-0.4	1.59e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg16989086	chr20:62203971	PRIC285	0.52	8.74	0.33	2.05e-17	Glioblastoma;
BRCA	cis	rs9443645	0.527	rs1413968	chr6:79791042	A/G	cg09184832	chr6:79620586	NA	-0.44	-8.83	-0.33	9.68e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg03213289	chr20:61660250	NA	0.61	16.2	0.54	1e-49	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7577696	0.597	rs212690	chr2:32437631	C/G	cg02381751	chr2:32503542	YIPF4	0.48	8.74	0.33	2.08e-17	Inflammatory biomarkers;
BRCA	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg18876405	chr7:65276391	NA	-0.57	-13.21	-0.46	2.12e-35	Aortic root size;
BRCA	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.58	0.55	1.23e-51	Hypertriglyceridemia;
BRCA	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-15.13	-0.51	1.93e-44	Body mass index;
BRCA	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg05340658	chr4:99064831	C4orf37	0.68	17.08	0.56	3.57e-54	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9409565	0.762	rs55877910	chr9:97234213	G/C	cg05679027	chr9:99775184	HIATL2	-0.43	-9.4	-0.35	9.79e-20	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs2797160	1.000	rs2797161	chr6:126010789	A/G	cg05901451	chr6:126070800	HEY2	0.4	9.79	0.36	3.51e-21	Endometrial cancer;
BRCA	cis	rs877282	0.685	rs56234340	chr10:781339	A/G	cg17470449	chr10:769945	NA	0.43	7.91	0.3	1.1e-14	Uric acid levels;
BRCA	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-11.34	-0.41	2.7e-27	Resting heart rate;
BRCA	cis	rs11696845	0.649	rs6031782	chr20:43383832	A/G	cg25301532	chr20:43378953	KCNK15	-0.43	-10.26	-0.38	5.8e-23	Obesity-related traits;
BRCA	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg21143896	chr7:2802374	GNA12	-0.34	-8.64	-0.32	4.34e-17	Height;
BRCA	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg18252515	chr7:66147081	NA	-0.8	-11.18	-0.4	1.23e-26	Diabetic kidney disease;
BRCA	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg03146154	chr1:46216737	IPP	0.53	11.89	0.43	1.37e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg18230493	chr5:56204884	C5orf35	-0.74	-14.51	-0.5	1.97e-41	Initial pursuit acceleration;
BRCA	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.4	-0.41	1.59e-27	Coronary artery disease;
BRCA	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.92	-0.33	4.95e-18	Bipolar disorder;
BRCA	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg00031303	chr3:195681400	NA	-0.48	-8.99	-0.33	2.85e-18	Pancreatic cancer;
BRCA	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-13.44	-0.47	1.88e-36	Migraine;Coronary artery disease;
BRCA	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	8.7	0.33	2.75e-17	Platelet count;
BRCA	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg08917208	chr2:24149416	ATAD2B	0.93	13.77	0.48	5.51e-38	Lymphocyte counts;
BRCA	cis	rs13046373	0.535	rs8129571	chr21:31980646	G/A	cg22337977	chr21:31811175	KRTAP15-1	0.35	8.31	0.31	5.68e-16	HDL cholesterol;
BRCA	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg11887960	chr12:57824829	NA	0.55	8.57	0.32	7.74e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7809950	0.954	rs12673675	chr7:107113220	T/C	cg23024343	chr7:107201750	COG5	-0.42	-9.63	-0.36	1.32e-20	Coronary artery disease;
BRCA	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00152838	chr16:24741724	TNRC6A	-0.35	-7.82	-0.3	2.16e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.4	8.97	0.33	3.13e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg15934090	chr1:100435551	SLC35A3	0.35	8.11	0.31	2.66e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg00147160	chr1:26503991	CNKSR1	-0.28	-9.22	-0.34	4.1e-19	Height;
BRCA	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	20.15	0.62	2.72e-70	Smoking behavior;
BRCA	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.67	0.36	9.78e-21	Morning vs. evening chronotype;
BRCA	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg06212747	chr3:49208901	KLHDC8B	0.51	10.51	0.38	6.26e-24	Parkinson's disease;
BRCA	cis	rs56399783	0.901	rs17300022	chr7:2808517	C/T	cg19731401	chr7:2775893	GNA12	-0.54	-8.67	-0.32	3.68e-17	Childhood ear infection;
BRCA	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.57	0.39	3.41e-24	Tonsillectomy;
BRCA	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg01324343	chr3:183735012	ABCC5	0.7	17.12	0.56	2.33e-54	Anterior chamber depth;
BRCA	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg27432699	chr2:27873401	GPN1	0.46	9.71	0.36	6.83e-21	Oral cavity cancer;
BRCA	trans	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	8.55e-21	Bladder cancer;
BRCA	cis	rs6700896	0.931	rs10443261	chr1:66129121	T/C	cg04111102	chr1:66153794	NA	0.36	8.82	0.33	1.08e-17	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs9682041	0.696	rs6774380	chr3:170091644	T/A	cg11886554	chr3:170076028	SKIL	0.51	10.24	0.38	7.03e-23	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg20887711	chr4:1340912	KIAA1530	0.72	15.68	0.53	4.26e-47	Longevity;
BRCA	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg20908204	chr19:46285434	DMPK	-0.28	-8.29	-0.31	6.63e-16	Coronary artery disease;
BRCA	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23583168	chr7:148888333	NA	-0.86	-20.1	-0.62	5.34e-70	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.09	0.34	1.21e-18	Tonsillectomy;
BRCA	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg06532163	chr17:45867833	NA	0.39	7.94	0.3	9.3e-15	IgG glycosylation;
BRCA	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.49	10.87	0.39	2.35e-25	IgG glycosylation;
BRCA	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg22907277	chr7:1156413	C7orf50	0.6	11.51	0.41	5.69e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg08601574	chr20:25228251	PYGB	0.36	8.79	0.33	1.35e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.37	-8.86	-0.33	8.05e-18	Longevity;Endometriosis;
BRCA	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.22	0.34	4.12e-19	Tonsillectomy;
BRCA	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg07395648	chr5:131743802	NA	0.56	14.98	0.51	1.07e-43	Blood metabolite levels;
BRCA	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg12863693	chr15:85201151	NMB	0.56	11.91	0.43	1.16e-29	Schizophrenia;
BRCA	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg13047869	chr3:10149882	C3orf24	-0.59	-12.51	-0.44	2.94e-32	Alzheimer's disease;
BRCA	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg01657329	chr11:68192670	LRP5	0.36	7.86	0.3	1.61e-14	Bone mineral density (spine);
BRCA	cis	rs55665837	1.000	rs12288873	chr11:14450465	C/T	cg19336497	chr11:14380999	RRAS2	-0.36	-9.47	-0.35	5.22e-20	Vitamin D levels;
BRCA	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.4	-0.61	2.69e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg01689657	chr7:91764605	CYP51A1	-0.22	-7.87	-0.3	1.57e-14	Breast cancer;
BRCA	cis	rs965469	1.000	rs6139068	chr20:3284393	G/A	cg25506879	chr20:3388711	C20orf194	-0.54	-10.55	-0.39	4.29e-24	IFN-related cytopenia;
BRCA	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg08999081	chr20:33150536	PIGU	0.5	14.04	0.49	3.21e-39	Coronary artery disease;
BRCA	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg24692254	chr21:30365293	RNF160	-0.6	-15.15	-0.51	1.56e-44	Dental caries;
BRCA	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg07741184	chr6:167504864	NA	0.26	7.81	0.3	2.35e-14	Crohn's disease;
BRCA	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg09035930	chr12:129282057	SLC15A4	0.55	16.19	0.54	1.17e-49	Systemic lupus erythematosus;
BRCA	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.57	-0.32	7.75e-17	Total body bone mineral density;
BRCA	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg09654669	chr8:57350985	NA	-0.38	-8.34	-0.31	4.55e-16	Obesity-related traits;
BRCA	cis	rs7408868	0.908	rs62113794	chr19:15277337	C/A	cg14696996	chr19:15285081	NOTCH3	1.02	14.48	0.5	2.56e-41	Pulse pressure;
BRCA	cis	rs6893300	0.524	rs10516146	chr5:179166974	A/G	cg14593053	chr5:179126677	CANX	0.49	13.42	0.47	2.3e-36	Resting heart rate;
BRCA	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.81	-0.33	1.22e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-11.29	-0.41	4.54e-27	Morning vs. evening chronotype;
BRCA	cis	rs243505	0.762	rs2007404	chr7:148487395	A/G	cg09806900	chr7:148480153	CUL1	0.52	11.17	0.4	1.36e-26	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.53	11.68	0.42	1.1e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.45	8.48	0.32	1.59e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7772486	0.875	rs2777482	chr6:146320341	A/C	cg23711669	chr6:146136114	FBXO30	0.59	12.88	0.45	6.27e-34	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg14343924	chr8:8086146	FLJ10661	0.43	7.98	0.3	6.82e-15	Red cell distribution width;
BRCA	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg26408565	chr15:76604113	ETFA	-0.46	-9.82	-0.36	2.74e-21	Blood metabolite levels;
BRCA	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg01420254	chr6:26195488	NA	0.59	9.16	0.34	6.84e-19	Gout;Renal underexcretion gout;
BRCA	cis	rs198389	0.589	rs198391	chr1:11876417	C/T	cg24844545	chr1:11908347	NPPA	0.33	8.76	0.33	1.78e-17	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
BRCA	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg06115741	chr20:33292138	TP53INP2	0.39	8.74	0.33	1.99e-17	Coronary artery disease;
BRCA	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg09904177	chr6:26538194	HMGN4	0.47	14.71	0.5	2.02e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg25036284	chr2:26402008	FAM59B	0.83	11.73	0.42	6.48e-29	Gut microbiome composition (summer);
BRCA	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11644478	chr21:40555479	PSMG1	-0.66	-14.01	-0.48	4.46e-39	Cognitive function;
BRCA	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg16606324	chr3:10149918	C3orf24	0.58	11.5	0.41	6.09e-28	Alzheimer's disease;
BRCA	cis	rs11920090	0.858	rs16855591	chr3:170693708	A/G	cg09710316	chr3:170744871	SLC2A2	0.51	8.06	0.3	3.75e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs2629540	0.882	rs10901813	chr10:126429875	G/A	cg08799069	chr10:126477246	METTL10	-0.53	-11.34	-0.41	2.78e-27	Cocaine dependence;
BRCA	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	8.07	0.3	3.59e-15	Diabetic retinopathy;
BRCA	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg18132916	chr6:79620363	NA	-0.48	-10.76	-0.39	6.37e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg16099169	chr2:106886729	NA	0.77	15.98	0.53	1.28e-48	Facial morphology (factor 23);
BRCA	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg05868516	chr6:26286170	HIST1H4H	0.39	8.39	0.31	3.19e-16	Educational attainment;
BRCA	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg22800045	chr5:56110881	MAP3K1	0.64	12.05	0.43	2.94e-30	Initial pursuit acceleration;
BRCA	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg22920501	chr2:26401640	FAM59B	-0.66	-11.39	-0.41	1.74e-27	Gut microbiome composition (summer);
BRCA	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-10.95	-0.4	1.1e-25	Uric acid levels;
BRCA	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg01483505	chr11:975446	AP2A2	0.33	9.01	0.34	2.41e-18	Alzheimer's disease (late onset);
BRCA	cis	rs9309473	1.000	rs7594511	chr2:73681639	A/G	cg20560298	chr2:73613845	ALMS1	-0.43	-10.57	-0.39	3.44e-24	Metabolite levels;
BRCA	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg08999081	chr20:33150536	PIGU	0.47	13.06	0.46	1.04e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg14004847	chr7:1930337	MAD1L1	-0.42	-9.12	-0.34	9.98e-19	Schizophrenia;
BRCA	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg08999081	chr20:33150536	PIGU	0.45	12.12	0.43	1.44e-30	Coronary artery disease;
BRCA	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg21770322	chr7:97807741	LMTK2	0.44	11.55	0.42	3.81e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10735851	1	rs10735851	chr12:53743064	G/A	cg26875137	chr12:53738046	NA	0.42	11.05	0.4	4.24e-26	Total body bone mineral density;
BRCA	cis	rs6120849	0.754	rs6120812	chr20:33629427	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	10.31	0.38	3.78e-23	Protein C levels;
BRCA	cis	rs3771570	1.000	rs62193207	chr2:242318501	G/C	cg21155796	chr2:242212141	HDLBP	0.6	9.19	0.34	5.62e-19	Prostate cancer;
BRCA	cis	rs12545109	0.800	rs1996105	chr8:57413123	A/G	cg09654669	chr8:57350985	NA	-0.41	-7.94	-0.3	9.17e-15	Obesity-related traits;
BRCA	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg03433033	chr1:76189801	ACADM	-0.47	-9.8	-0.36	3.13e-21	Daytime sleep phenotypes;
BRCA	cis	rs4285028	0.603	rs79312528	chr3:121608997	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-13.25	-0.46	1.38e-35	Multiple sclerosis;
BRCA	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg22875332	chr1:76189707	ACADM	-0.52	-10.16	-0.37	1.37e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11764359	chr7:65958608	NA	0.77	17.35	0.57	1.46e-55	Aortic root size;
BRCA	trans	rs6479891	0.915	rs10761744	chr10:65101026	C/G	cg14819942	chr15:35414228	NA	-0.34	-8.59	-0.32	6.8e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg03060546	chr3:49711283	APEH	-0.53	-10.58	-0.39	3.33e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg13902645	chr11:5959945	NA	-0.4	-8.54	-0.32	1e-16	DNA methylation (variation);
BRCA	trans	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg21775007	chr8:11205619	TDH	-0.37	-7.81	-0.3	2.43e-14	Joint mobility (Beighton score);
BRCA	cis	rs2204008	0.743	rs11495614	chr12:38156358	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.32	0.35	1.92e-19	Bladder cancer;
BRCA	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg18811423	chr2:55921094	PNPT1	0.76	25.28	0.71	2.82e-98	Metabolic syndrome;
BRCA	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.37	-12.22	-0.44	5.31e-31	Homoarginine levels;
BRCA	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg07395648	chr5:131743802	NA	0.37	9.35	0.35	1.4e-19	Blood metabolite levels;
BRCA	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-8.8	-0.33	1.26e-17	Alzheimer's disease (late onset);
BRCA	trans	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg06521331	chr12:34319734	NA	-0.52	-9.99	-0.37	6.29e-22	Bladder cancer;
BRCA	cis	rs365132	0.967	rs353471	chr5:176363429	T/C	cg16309518	chr5:176445507	NA	-0.52	-13.47	-0.47	1.45e-36	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg08601574	chr20:25228251	PYGB	0.34	8.15	0.31	1.86e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg09877947	chr5:131593287	PDLIM4	0.41	10.37	0.38	2.21e-23	Breast cancer;
BRCA	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg16482183	chr6:26056742	HIST1H1C	0.55	11.45	0.41	9.94e-28	Height;
BRCA	cis	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg21775007	chr8:11205619	TDH	-0.49	-9.62	-0.36	1.45e-20	Neuroticism;
BRCA	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.6	0.32	6.11e-17	Rheumatoid arthritis;
BRCA	cis	rs7927771	0.507	rs1483988	chr11:47899030	C/T	cg20307385	chr11:47447363	PSMC3	0.43	9.53	0.35	3.15e-20	Subjective well-being;
BRCA	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg01475377	chr6:109611718	NA	-0.52	-13.05	-0.46	1.17e-34	Reticulocyte fraction of red cells;
BRCA	cis	rs6545883	0.929	rs2593625	chr2:61668769	C/T	cg15711740	chr2:61764176	XPO1	-0.56	-14.31	-0.49	1.67e-40	Tuberculosis;
BRCA	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg08975724	chr8:8085496	FLJ10661	0.43	8.13	0.31	2.19e-15	Retinal vascular caliber;
BRCA	cis	rs9300255	0.602	rs1569068	chr12:123632276	A/G	cg00376283	chr12:123451042	ABCB9	-0.46	-10.05	-0.37	3.67e-22	Neutrophil percentage of white cells;
BRCA	cis	rs7809950	1.000	rs2520265	chr7:107181231	A/G	cg23024343	chr7:107201750	COG5	-0.4	-9.05	-0.34	1.65e-18	Coronary artery disease;
BRCA	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg00631329	chr6:26305371	NA	-0.46	-13.06	-0.46	9.65e-35	Educational attainment;
BRCA	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.04	-0.37	4.16e-22	IgG glycosylation;
BRCA	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg04518342	chr5:131593106	PDLIM4	0.34	8.3	0.31	6.34e-16	Blood metabolite levels;
BRCA	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11890956	chr21:40555474	PSMG1	-0.52	-10.89	-0.4	1.91e-25	Menarche (age at onset);
BRCA	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.4	8.72	0.33	2.31e-17	HDL cholesterol;
BRCA	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg23933602	chr10:16859644	RSU1	0.92	26.79	0.73	1.39e-106	Platelet distribution width;
BRCA	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg06115741	chr20:33292138	TP53INP2	0.36	7.98	0.3	6.59e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs4290604	0.748	rs4549025	chr2:238052911	C/T	cg23555395	chr2:238036564	NA	0.51	8.28	0.31	7.02e-16	Asthma;
BRCA	cis	rs4642101	0.680	rs7626609	chr3:12806080	A/G	cg24848339	chr3:12840334	CAND2	-0.41	-10.82	-0.39	3.68e-25	QRS complex (12-leadsum);
BRCA	cis	rs3768617	0.966	rs6669796	chr1:183082825	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.47	10.33	0.38	3.14e-23	Fuchs's corneal dystrophy;
BRCA	cis	rs870825	1.000	rs870821	chr4:185587377	T/C	cg04058563	chr4:185651563	MLF1IP	0.67	12.18	0.43	7.78e-31	Blood protein levels;
BRCA	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg03954927	chr1:10346856	KIF1B	0.47	13.89	0.48	1.59e-38	Hepatocellular carcinoma;
BRCA	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	14.31	0.49	1.63e-40	Alzheimer's disease;
BRCA	cis	rs5753618	0.583	rs5749279	chr22:31854209	A/G	cg02404636	chr22:31891804	SFI1	0.39	8.76	0.33	1.71e-17	Colorectal cancer;
BRCA	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg02659138	chr7:134003124	SLC35B4	0.34	10.79	0.39	4.94e-25	Mean platelet volume;
BRCA	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.47	0.41	8.15e-28	Homoarginine levels;
BRCA	cis	rs62458065	0.640	rs28587905	chr7:32533054	C/T	cg20159608	chr7:32802032	NA	-0.47	-8.42	-0.32	2.47e-16	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg02659138	chr7:134003124	SLC35B4	0.36	10.36	0.38	2.37e-23	Mean platelet volume;
BRCA	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.94e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1499972	0.941	rs55734908	chr3:117613268	A/T	cg07612923	chr3:117604196	NA	0.59	8.01	0.3	5.48e-15	Schizophrenia;
BRCA	cis	rs7072216	0.763	rs7091709	chr10:100167605	G/A	cg26618903	chr10:100175079	PYROXD2	-0.31	-9.03	-0.34	2.08e-18	Metabolite levels;
BRCA	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.13	0.34	8.54e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	12.84	0.45	1.01e-33	Menarche (age at onset);
BRCA	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg24558204	chr6:135376177	HBS1L	0.45	12.33	0.44	1.66e-31	Red blood cell count;
BRCA	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	13.11	0.46	5.97e-35	Bone mineral density;
BRCA	cis	rs3125734	0.633	rs4979754	chr10:64048959	G/A	cg19640130	chr10:64028056	RTKN2	-0.35	-9.76	-0.36	4.64e-21	Rheumatoid arthritis;
BRCA	cis	rs12540874	0.542	rs4947582	chr7:50566090	C/T	cg18232548	chr7:50535776	DDC	-0.5	-12.55	-0.44	1.93e-32	Systemic sclerosis;
BRCA	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg03609598	chr5:56110824	MAP3K1	-0.46	-8.11	-0.31	2.53e-15	Initial pursuit acceleration;
BRCA	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.84	0.36	2.36e-21	Bipolar disorder;
BRCA	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg11812906	chr14:75593930	NEK9	-0.59	-13.33	-0.47	6.23e-36	Height;
BRCA	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.25	-0.41	6.69e-27	Schizophrenia;
BRCA	cis	rs10465746	0.967	rs12118434	chr1:84328629	C/T	cg10977910	chr1:84465055	TTLL7	0.51	10.41	0.38	1.45e-23	Obesity-related traits;
BRCA	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg08999081	chr20:33150536	PIGU	0.5	14.23	0.49	4.29e-40	Coronary artery disease;
BRCA	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg17143192	chr8:8559678	CLDN23	0.5	9.8	0.36	3.2e-21	Obesity-related traits;
BRCA	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg16989086	chr20:62203971	PRIC285	0.53	9.0	0.34	2.63e-18	Glioblastoma;
BRCA	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.59	-10.36	-0.38	2.36e-23	Gut microbiome composition (summer);
BRCA	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg20224285	chr3:52813920	ITIH1	0.32	8.02	0.3	4.98e-15	Bipolar disorder;
BRCA	cis	rs11971779	0.688	rs8137	chr7:139104461	A/C	cg07862535	chr7:139043722	LUC7L2	-0.38	-10.21	-0.37	8.75e-23	Diisocyanate-induced asthma;
BRCA	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.1	-0.31	2.73e-15	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg03676636	chr4:99064102	C4orf37	0.2	7.94	0.3	8.91e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg13047869	chr3:10149882	C3orf24	0.6	12.67	0.45	5.42e-33	Alzheimer's disease;
BRCA	cis	rs6700896	0.931	rs2154382	chr1:66131681	C/T	cg04111102	chr1:66153794	NA	0.36	8.82	0.33	1.08e-17	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg08885076	chr2:99613938	TSGA10	0.46	10.83	0.39	3.42e-25	Chronic sinus infection;
BRCA	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg14863265	chr7:2801509	GNA12	-0.42	-9.61	-0.36	1.63e-20	Height;
BRCA	cis	rs17253792	0.822	rs79024594	chr14:56092997	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-12.97	-0.46	2.59e-34	Mood instability;
BRCA	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg18230493	chr5:56204884	C5orf35	-0.67	-13.33	-0.47	6.06e-36	Initial pursuit acceleration;
BRCA	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg11266682	chr4:10021025	SLC2A9	0.48	12.72	0.45	3.27e-33	Bone mineral density;
BRCA	trans	rs4650994	0.524	rs2761465	chr1:178579404	G/T	cg05059571	chr16:84539110	KIAA1609	0.57	12.47	0.44	4.05e-32	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.52	-0.52	2.52e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg05347473	chr6:146136440	FBXO30	0.41	8.06	0.3	3.74e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg02297831	chr4:17616191	MED28	0.36	8.36	0.31	3.79e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9381107	0.932	rs13219694	chr6:9422441	T/G	cg14735645	chr6:9486422	NA	-0.47	-8.17	-0.31	1.65e-15	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg01114163	chr5:1856713	NA	-0.36	-8.08	-0.3	3.36e-15	Cardiovascular disease risk factors;
BRCA	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00149659	chr3:10157352	C3orf10	0.73	10.74	0.39	7.58e-25	Alzheimer's disease;
BRCA	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg10556349	chr10:835070	NA	0.63	8.74	0.33	2.06e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs7737355	1.000	rs2158428	chr5:130751481	T/A	cg06307176	chr5:131281290	NA	-0.51	-10.06	-0.37	3.24e-22	Life satisfaction;
BRCA	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.51	0.35	3.74e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg06521331	chr12:34319734	NA	-0.54	-9.58	-0.35	2.16e-20	Morning vs. evening chronotype;
BRCA	cis	rs4819852	1.000	rs1034566	chr22:19984277	C/T	cg07821417	chr22:19972146	ARVCF	0.48	10.8	0.39	4.51e-25	Pulse pressure;
BRCA	cis	rs17253792	0.822	rs17746106	chr14:56069168	C/T	cg01858014	chr14:56050164	KTN1	-0.59	-9.53	-0.35	3.28e-20	Putamen volume;
BRCA	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg14835575	chr10:16859367	RSU1	0.61	12.46	0.44	4.7e-32	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg11266682	chr4:10021025	SLC2A9	-0.42	-11.14	-0.4	1.82e-26	Bone mineral density;
BRCA	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.45	0.41	9.48e-28	Rheumatoid arthritis;
BRCA	cis	rs9790314	0.632	rs55672403	chr3:160681026	C/A	cg03342759	chr3:160939853	NMD3	0.45	8.71	0.33	2.5e-17	Morning vs. evening chronotype;
BRCA	trans	rs3857536	0.842	rs2188590	chr6:66939534	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs9283706	0.689	rs10041705	chr5:66317222	C/T	cg11590213	chr5:66331682	MAST4	-0.41	-7.89	-0.3	1.31e-14	Coronary artery disease;
BRCA	cis	rs2859741	0.546	rs3934329	chr1:37504523	C/T	cg09363841	chr1:37513479	NA	-0.52	-11.17	-0.4	1.35e-26	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.29	8.34	0.31	4.5e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs28735056	0.904	rs72980087	chr18:77632194	G/A	cg20368463	chr18:77673604	PQLC1	-0.34	-8.0	-0.3	5.75e-15	Schizophrenia;
BRCA	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg00105475	chr2:10696890	NA	-0.43	-10.26	-0.38	5.74e-23	Prostate cancer;
BRCA	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg27572855	chr1:25598939	RHD	0.45	12.93	0.46	3.79e-34	Erythrocyte sedimentation rate;
BRCA	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg24692254	chr21:30365293	RNF160	-0.59	-15.06	-0.51	4.31e-44	Dental caries;
BRCA	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg23711669	chr6:146136114	FBXO30	-0.7	-16.55	-0.55	1.88e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.747	rs9919333	chr1:152968744	G/T	cg25856811	chr1:152973957	SPRR3	-0.34	-8.98	-0.33	3.11e-18	Inflammatory skin disease;
BRCA	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	19.23	0.61	2.41e-65	Electrocardiographic conduction measures;
BRCA	cis	rs7945718	0.967	rs11826129	chr11:12768883	G/A	cg25843174	chr11:12811716	TEAD1	0.23	8.65	0.32	4.09e-17	Educational attainment (years of education);
BRCA	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg03213289	chr20:61660250	NA	0.61	16.28	0.54	4.1e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg10729496	chr3:10149963	C3orf24	0.49	9.12	0.34	9.81e-19	Alzheimer's disease;
BRCA	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06108461	chr20:60628389	TAF4	-0.86	-15.77	-0.53	1.47e-47	Body mass index;
BRCA	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.33e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.79	-19.22	-0.61	2.53e-65	Multiple sclerosis;
BRCA	cis	rs7737355	0.947	rs7720339	chr5:130837134	T/C	cg06307176	chr5:131281290	NA	0.54	10.64	0.39	1.94e-24	Life satisfaction;
BRCA	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg05283184	chr6:79620031	NA	-0.42	-10.85	-0.39	2.67e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg17971929	chr21:40555470	PSMG1	-0.44	-9.22	-0.34	4.18e-19	Menarche (age at onset);
BRCA	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg16405210	chr4:1374714	KIAA1530	-0.38	-8.27	-0.31	7.56e-16	Obesity-related traits;
BRCA	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg26587870	chr6:27730563	NA	-0.4	-8.59	-0.32	6.5e-17	Parkinson's disease;
BRCA	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23583168	chr7:148888333	NA	-0.85	-19.99	-0.62	2.15e-69	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg09184832	chr6:79620586	NA	-0.48	-10.46	-0.38	9.77e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg00383909	chr3:49044727	WDR6	0.97	13.43	0.47	2.23e-36	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg06238570	chr21:40685208	BRWD1	-0.46	-9.05	-0.34	1.73e-18	Cognitive function;
BRCA	cis	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg06521331	chr12:34319734	NA	-0.56	-10.84	-0.39	2.95e-25	Morning vs. evening chronotype;
BRCA	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg14343924	chr8:8086146	FLJ10661	-0.38	-7.9	-0.3	1.23e-14	Monocyte count;
BRCA	cis	rs7092929	0.574	rs7074352	chr10:3538749	G/T	cg14308648	chr10:3568949	NA	0.42	9.67	0.36	9.64e-21	Coronary artery calcification;
BRCA	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	12.02	0.43	3.94e-30	Tonsillectomy;
BRCA	cis	rs9649465	0.561	rs609953	chr7:123422444	T/A	cg03229431	chr7:123269106	ASB15	0.43	9.68	0.36	9.34e-21	Migraine;
BRCA	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.58	-0.35	2.17e-20	Tonsillectomy;
BRCA	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg27661571	chr11:113659931	NA	0.65	8.71	0.33	2.53e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg13010199	chr12:38710504	ALG10B	0.5	10.56	0.39	4.03e-24	Bladder cancer;
BRCA	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg24531977	chr5:56204891	C5orf35	-0.66	-13.23	-0.46	1.79e-35	Type 2 diabetes;
BRCA	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.96	0.58	1.14e-58	Fuchs's corneal dystrophy;
BRCA	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg17971929	chr21:40555470	PSMG1	-0.62	-14.48	-0.5	2.58e-41	Cognitive function;
BRCA	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	19.67	0.61	1.1e-67	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg05025164	chr4:1340916	KIAA1530	0.77	15.38	0.52	1.16e-45	Longevity;
BRCA	trans	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg14791747	chr16:20752902	THUMPD1	0.4	9.35	0.35	1.51e-19	Cognitive test performance;
BRCA	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.26	0.38	5.83e-23	Bladder cancer;
BRCA	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg11752832	chr7:134001865	SLC35B4	0.48	11.98	0.43	5.36e-30	Mean platelet volume;
BRCA	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg18225595	chr11:63971243	STIP1	0.41	10.06	0.37	3.44e-22	Platelet count;
BRCA	cis	rs11677370	0.603	rs10174064	chr2:3849806	C/T	cg17052675	chr2:3827356	NA	-0.52	-12.85	-0.45	8.97e-34	Type 2 diabetes;
BRCA	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg02773041	chr1:40204384	PPIE	0.45	9.7	0.36	7.64e-21	Blood protein levels;
BRCA	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg05535760	chr7:792225	HEATR2	-0.79	-14.09	-0.49	1.86e-39	Cerebrospinal P-tau181p levels;
BRCA	trans	rs2270927	0.790	rs4566770	chr5:75576313	A/G	cg13563193	chr19:33072644	PDCD5	-0.72	-11.08	-0.4	3.28e-26	Mean corpuscular volume;
BRCA	cis	rs9612	1.000	rs2277745	chr19:44259077	C/T	cg08581076	chr19:44259116	C19orf61	0.59	10.44	0.38	1.18e-23	Exhaled nitric oxide output;
BRCA	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg04719120	chr6:96025338	MANEA	0.51	7.81	0.3	2.29e-14	Behavioural disinhibition (generation interaction);
BRCA	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs7091068	0.518	rs1572772	chr10:95432862	A/G	cg20715218	chr10:95462985	C10orf4	-0.44	-9.33	-0.35	1.69e-19	Urinary tract infection frequency;
BRCA	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg00071950	chr4:10020882	SLC2A9	0.65	16.48	0.55	4.18e-51	Bone mineral density;
BRCA	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.31	0.31	5.74e-16	Rheumatoid arthritis;
BRCA	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg26384229	chr12:38710491	ALG10B	0.67	15.99	0.53	1.15e-48	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg22875332	chr1:76189707	ACADM	0.69	14.76	0.5	1.23e-42	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	12.29	0.44	2.59e-31	Coronary artery disease;
BRCA	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg07148914	chr20:33460835	GGT7	0.43	9.28	0.34	2.66e-19	Height;
BRCA	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg11752832	chr7:134001865	SLC35B4	0.53	13.77	0.48	5.7800000000000005e-38	Mean platelet volume;
BRCA	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.45	-0.52	5.26e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.38	-0.44	1.06e-31	Type 2 diabetes;
BRCA	cis	rs4800452	0.956	rs4239437	chr18:20732224	A/G	cg26136497	chr18:20735537	CABLES1	-0.47	-11.63	-0.42	1.72e-28	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6088813	1.000	rs1540927	chr20:33931344	A/G	cg14752227	chr20:34000481	UQCC	-0.39	-8.46	-0.32	1.83e-16	Height;
BRCA	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg01262667	chr19:19385393	TM6SF2	0.4	10.46	0.38	9.53e-24	Tonsillectomy;
BRCA	cis	rs12220238	1.000	rs10824076	chr10:75886956	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.49	8.06	0.3	3.65e-15	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.39	0.49	7.17e-41	Motion sickness;
BRCA	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg17971929	chr21:40555470	PSMG1	0.76	16.54	0.55	2.08e-51	Cognitive function;
BRCA	cis	rs7246657	0.722	rs10402671	chr19:38117086	C/T	cg18154014	chr19:37997991	ZNF793	0.5	9.59	0.35	1.99e-20	Coronary artery calcification;
BRCA	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg06636001	chr8:8085503	FLJ10661	0.65	14.92	0.51	2.04e-43	Mood instability;
BRCA	cis	rs6901250	0.851	rs7760125	chr6:117123391	A/C	cg12892004	chr6:117198278	RFX6	0.49	11.44	0.41	1.03e-27	C-reactive protein levels;
BRCA	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg08470875	chr2:26401718	FAM59B	-0.68	-10.67	-0.39	1.44e-24	Gut microbiome composition (summer);
BRCA	trans	rs1973993	0.689	rs17115225	chr1:96884330	C/T	cg10631902	chr5:14652156	NA	-0.45	-12.52	-0.44	2.49e-32	Weight;
BRCA	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	11.48	0.41	7.08e-28	Monocyte percentage of white cells;
BRCA	cis	rs1788820	0.843	rs1788821	chr18:21120869	A/G	cg14672496	chr18:21087552	C18orf8	0.35	8.43	0.32	2.34e-16	Body mass index;
BRCA	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg03462622	chr3:195777018	TFRC	-0.38	-8.63	-0.32	4.86e-17	Mean corpuscular volume;
BRCA	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg26384229	chr12:38710491	ALG10B	-0.58	-15.11	-0.51	2.36e-44	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-8.03	-0.3	4.53e-15	Corneal astigmatism;
BRCA	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg14683738	chr19:37701593	ZNF585B	0.45	8.03	0.3	4.85e-15	Coronary artery calcification;
BRCA	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	12.67	0.45	5.53e-33	Mean platelet volume;
BRCA	cis	rs2797160	0.967	rs28629380	chr6:126004197	A/G	cg05901451	chr6:126070800	HEY2	-0.38	-9.17	-0.34	6.55e-19	Endometrial cancer;
BRCA	cis	rs6988985	0.678	rs7831617	chr8:144002283	G/T	cg01972576	chr8:143916273	GML	0.34	9.89	0.36	1.43e-21	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
BRCA	cis	rs61990749	0.544	rs7151211	chr14:78151901	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.63	-9.65	-0.36	1.13e-20	Fibroblast growth factor basic levels;
BRCA	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.74	-0.33	2.11e-17	Colorectal cancer;
BRCA	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02353165	chr6:42928485	GNMT	0.76	18.87	0.6	1.91e-63	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-8.26	-0.31	8.17e-16	Neuroticism;
BRCA	cis	rs6973256	0.897	rs2483507	chr7:133339546	C/T	cg07491979	chr7:133331646	EXOC4	-0.39	-9.05	-0.34	1.69e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg13334819	chr7:99746414	C7orf59	0.34	7.92	0.3	1.06e-14	Coronary artery disease;
BRCA	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-11.31	-0.41	3.69e-27	Gut microbiome composition (summer);
BRCA	trans	rs12310956	0.510	rs10844690	chr12:33854752	C/A	cg26384229	chr12:38710491	ALG10B	0.39	9.04	0.34	1.89e-18	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg26384229	chr12:38710491	ALG10B	0.68	14.37	0.49	9.31e-41	Morning vs. evening chronotype;
BRCA	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg05985134	chr18:33552581	C18orf21	-0.7	-13.55	-0.47	5.95e-37	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg00599163	chr2:162100495	NA	0.28	8.96	0.33	3.42e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.31	-0.38	3.63e-23	Gut microbiome composition (summer);
BRCA	cis	rs1577917	0.545	rs7755958	chr6:86488511	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.34	9.25	0.34	3.44e-19	Response to antipsychotic treatment;
BRCA	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg14019146	chr3:50243930	SLC38A3	0.36	8.96	0.33	3.53e-18	Body mass index;
BRCA	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg07636037	chr3:49044803	WDR6	0.94	26.36	0.72	3.23e-104	Parkinson's disease;
BRCA	trans	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg21659725	chr3:3221576	CRBN	0.36	8.52	0.32	1.17e-16	Menarche (age at onset);
BRCA	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg18016565	chr1:150552671	MCL1	0.35	8.23	0.31	1.08e-15	Tonsillectomy;
BRCA	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	19.7	0.61	7.2e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.96	26.59	0.72	1.94e-105	Birth weight;
BRCA	cis	rs7729447	0.813	rs10941022	chr5:32691416	C/T	cg16267343	chr5:32710456	NPR3	0.43	8.92	0.33	4.69e-18	Blood pressure;
BRCA	cis	rs4932217	0.579	rs150302	chr15:89946789	C/G	cg25932290	chr15:89939252	LOC254559	-0.28	-8.85	-0.33	8.24e-18	Height;
BRCA	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg12564285	chr5:131593104	PDLIM4	-0.34	-7.86	-0.3	1.66e-14	Breast cancer;
BRCA	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.83	12.71	0.45	3.9e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg17063962	chr7:91808500	NA	-0.56	-12.76	-0.45	2.13e-33	Breast cancer;
BRCA	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg17063962	chr7:91808500	NA	-0.57	-13.36	-0.47	4.6e-36	Breast cancer;
BRCA	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg14631576	chr9:95140430	CENPP	-0.37	-9.02	-0.34	2.22e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg05340658	chr4:99064831	C4orf37	0.69	17.4	0.57	8.22e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg21045802	chr8:109455806	TTC35	0.35	8.03	0.3	4.64e-15	Dupuytren's disease;
BRCA	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg04362960	chr10:104952993	NT5C2	0.45	10.32	0.38	3.52e-23	Arsenic metabolism;
BRCA	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg26031613	chr14:104095156	KLC1	-0.42	-8.32	-0.31	5.33e-16	Schizophrenia;
BRCA	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg21433313	chr16:3507492	NAT15	0.47	10.44	0.38	1.12e-23	Tuberculosis;
BRCA	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg07384165	chr1:10488281	NA	0.4	8.59	0.32	6.46e-17	Prostate cancer;
BRCA	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg04450456	chr4:17643702	FAM184B	0.42	12.53	0.44	2.21e-32	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg06064525	chr11:970664	AP2A2	-0.33	-9.81	-0.36	2.86e-21	Alzheimer's disease (late onset);
BRCA	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg20628663	chr10:43360327	NA	-0.7	-13.62	-0.47	2.75e-37	Blood protein levels;
BRCA	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg03585969	chr10:35415529	CREM	0.5	10.48	0.38	7.81e-24	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10193935	0.818	rs10221927	chr2:42546680	A/C	cg27598129	chr2:42591480	NA	-0.9	-14.5	-0.5	2.09e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg06092702	chr1:163392909	NA	-0.32	-8.48	-0.32	1.57e-16	Motion sickness;
BRCA	cis	rs250677	0.522	rs4705302	chr5:148354962	G/C	cg18129178	chr5:148520854	ABLIM3	0.54	10.48	0.38	8.11e-24	Breast cancer;
BRCA	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg01528321	chr10:82214614	TSPAN14	0.62	14.12	0.49	1.3e-39	Post bronchodilator FEV1;
BRCA	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg04586622	chr2:25135609	ADCY3	0.46	11.53	0.41	4.52e-28	Body mass index;
BRCA	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11644478	chr21:40555479	PSMG1	0.85	19.54	0.61	5.15e-67	Cognitive function;
BRCA	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.64	-0.32	4.48e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs503734	0.521	rs348881	chr3:100970920	A/C	cg27318481	chr3:100970896	IMPG2	-0.41	-9.98	-0.37	6.83e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.44	-8.23	-0.31	1.07e-15	Mean corpuscular volume;
BRCA	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg18132916	chr6:79620363	NA	-0.49	-11.13	-0.4	1.93e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg08888203	chr3:10149979	C3orf24	-0.54	-9.99	-0.37	6.25e-22	Alzheimer's disease;
BRCA	cis	rs13223928	0.651	rs4722426	chr7:3150697	C/T	cg19214707	chr7:3157722	NA	0.44	11.08	0.4	3.14e-26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
BRCA	cis	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg07460842	chr6:66804631	NA	-1.0	-27.09	-0.73	3.19e-108	Exhaled nitric oxide output;
BRCA	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.66	0.42	1.31e-28	Homoarginine levels;
BRCA	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg26384229	chr12:38710491	ALG10B	0.7	15.94	0.53	2.16e-48	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs13053817	0.904	rs13053624	chr22:29838203	A/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.5	-9.83	-0.36	2.57e-21	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg21427119	chr20:30132790	HM13	-0.41	-8.69	-0.33	2.96e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs6121246	0.609	rs6060983	chr20:30420924	T/C	cg13852791	chr20:30311386	BCL2L1	0.86	18.96	0.6	6.11e-64	Mean corpuscular hemoglobin;
BRCA	cis	rs10193935	0.792	rs222472	chr2:42662911	C/T	cg27598129	chr2:42591480	NA	-0.71	-12.05	-0.43	2.91e-30	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg08514558	chr10:81106712	PPIF	0.38	8.69	0.33	2.93e-17	Height;
BRCA	cis	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg06521331	chr12:34319734	NA	-0.64	-11.81	-0.42	2.95e-29	Morning vs. evening chronotype;
BRCA	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg18479299	chr3:125709523	NA	-0.53	-8.22	-0.31	1.15e-15	Blood pressure (smoking interaction);
BRCA	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg18479299	chr3:125709523	NA	-0.51	-8.62	-0.32	5.34e-17	Blood pressure (smoking interaction);
BRCA	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg09307838	chr4:120376055	NA	0.59	12.89	0.45	5.65e-34	Educational attainment;
BRCA	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.49	-0.61	9.03e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1451375	0.669	rs10274172	chr7:50637575	G/A	cg18232548	chr7:50535776	DDC	-0.38	-8.82	-0.33	1.04e-17	Malaria;
BRCA	cis	rs10463316	0.817	rs12653378	chr5:150802366	A/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.62	-0.32	5.06e-17	Metabolite levels (Pyroglutamine);
BRCA	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg12011299	chr4:100065546	ADH4	0.48	11.06	0.4	3.79e-26	Alcohol dependence;
BRCA	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg17420585	chr12:42539391	GXYLT1	-0.38	-7.99	-0.3	6.3e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.39	-8.78	-0.33	1.48e-17	Colorectal cancer;
BRCA	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14442939	chr10:27389572	ANKRD26	-0.68	-10.76	-0.39	6.52e-25	Breast cancer;
BRCA	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg08999081	chr20:33150536	PIGU	0.47	12.96	0.46	3e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs4664304	0.620	rs11675085	chr2:160713352	C/G	cg14819504	chr2:160761413	LY75	0.34	8.5	0.32	1.38e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.6	-14.76	-0.5	1.18e-42	Longevity;Endometriosis;
BRCA	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg17063962	chr7:91808500	NA	0.49	11.14	0.4	1.8e-26	Breast cancer;
BRCA	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg11812906	chr14:75593930	NEK9	-0.59	-13.45	-0.47	1.79e-36	Height;
BRCA	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg11657440	chr19:46296263	DMWD	-0.59	-14.09	-0.49	1.88e-39	Coronary artery disease;
BRCA	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg10820045	chr2:198174542	NA	-0.45	-10.59	-0.39	3.03e-24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg20368463	chr18:77673604	PQLC1	-0.34	-7.94	-0.3	9.45e-15	Schizophrenia;
BRCA	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00166722	chr3:10149974	C3orf24	0.64	11.32	0.41	3.47e-27	Alzheimer's disease;
BRCA	cis	rs2637030	0.559	rs2636991	chr5:52943067	T/G	cg06476337	chr5:52856530	NDUFS4	0.37	8.54	0.32	9.77e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs11971779	0.680	rs6978680	chr7:139112048	A/G	cg07862535	chr7:139043722	LUC7L2	-0.38	-10.2	-0.37	9.55e-23	Diisocyanate-induced asthma;
BRCA	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg23229984	chr5:148520753	ABLIM3	0.35	8.13	0.31	2.18e-15	Breast cancer;
BRCA	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg12379764	chr21:47803548	PCNT	-0.41	-9.15	-0.34	7.55e-19	Testicular germ cell tumor;
BRCA	cis	rs758324	0.947	rs2404778	chr5:131172886	T/C	cg06307176	chr5:131281290	NA	0.56	11.7	0.42	8.56e-29	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg06197492	chr11:2016605	H19	0.41	8.44	0.32	2.2e-16	DNA methylation (parent-of-origin);DNA methylation (variation);
BRCA	cis	rs72772090	0.908	rs11750510	chr5:96042095	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.53	-11.54	-0.42	4.05e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg20283391	chr11:68216788	NA	-0.46	-9.22	-0.34	4.1e-19	Total body bone mineral density;
BRCA	cis	rs68170813	0.559	rs4730229	chr7:106925353	A/G	cg02696742	chr7:106810147	HBP1	-0.53	-8.57	-0.32	7.9e-17	Coronary artery disease;
BRCA	cis	rs28374715	0.662	rs10851403	chr15:41466087	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.84	-17.53	-0.57	1.92e-56	Ulcerative colitis;
BRCA	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg00321850	chr1:175162397	KIAA0040	-0.41	-11.41	-0.41	1.46e-27	Alcohol dependence;
BRCA	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg27170947	chr2:26402098	FAM59B	-0.93	-17.28	-0.56	3.64e-55	Gut microbiome composition (summer);
BRCA	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg27490568	chr2:178487706	NA	0.49	8.21	0.31	1.26e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg16584290	chr5:462447	EXOC3	0.52	14.37	0.49	9.25e-41	Cystic fibrosis severity;
BRCA	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.6	0.32	5.94e-17	Rheumatoid arthritis;
BRCA	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	10.97	0.4	8.58e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg23029597	chr12:123009494	RSRC2	-0.49	-9.92	-0.37	1.17e-21	Body mass index;
BRCA	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg00677455	chr12:58241039	CTDSP2	0.47	11.06	0.4	4e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs13095912	1.000	rs13095912	chr3:185302098	G/A	cg11274856	chr3:185301563	NA	0.36	9.0	0.34	2.59e-18	Systolic blood pressure;
BRCA	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg10224037	chr5:178157518	ZNF354A	0.79	18.14	0.58	1.26e-59	Neutrophil percentage of white cells;
BRCA	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg27165867	chr14:105738592	BRF1	-0.35	-8.28	-0.31	6.96e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg02503808	chr4:7069936	GRPEL1	-0.78	-14.35	-0.49	1.05e-40	Monocyte percentage of white cells;
BRCA	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.47	9.4	0.35	9.18e-20	Multiple sclerosis;
BRCA	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg20203395	chr5:56204925	C5orf35	-0.51	-10.63	-0.39	2.13e-24	Initial pursuit acceleration;
BRCA	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.07	-0.56	4.09e-54	Intelligence (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg24562669	chr7:97807699	LMTK2	0.46	12.33	0.44	1.82e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	19.97	0.62	2.45e-69	Platelet count;
BRCA	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg17063962	chr7:91808500	NA	-0.56	-12.78	-0.45	1.77e-33	Breast cancer;
BRCA	cis	rs6032067	0.598	rs2741500	chr20:43944958	G/T	cg06407657	chr20:43937138	MATN4;RBPJL	0.31	8.34	0.31	4.5e-16	Blood protein levels;
BRCA	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg18806716	chr10:30721971	MAP3K8	-0.46	-10.74	-0.39	7.46e-25	Itch intensity from mosquito bite;
BRCA	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.2	-0.6	3.27e-65	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11644478	chr21:40555479	PSMG1	-0.5	-10.51	-0.38	6.37e-24	Menarche (age at onset);
BRCA	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg06212747	chr3:49208901	KLHDC8B	0.48	9.75	0.36	4.9e-21	Parkinson's disease;
BRCA	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.63	-13.28	-0.47	9.89e-36	Lymphocyte counts;
BRCA	cis	rs4722166	0.532	rs4719711	chr7:22755688	A/G	cg05472934	chr7:22766657	IL6	-0.39	-9.74	-0.36	5.33e-21	Lung cancer;
BRCA	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg13010199	chr12:38710504	ALG10B	0.52	10.58	0.39	3.24e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24531977	chr5:56204891	C5orf35	-0.88	-18.09	-0.58	2.35e-59	Initial pursuit acceleration;
BRCA	cis	rs4900538	0.855	rs9788420	chr14:102839338	A/G	cg18135206	chr14:102964638	TECPR2	-0.93	-21.9	-0.65	1e-79	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	12.39	0.44	9.47e-32	Monocyte percentage of white cells;
BRCA	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg17830980	chr10:43048298	ZNF37B	-0.55	-13.31	-0.47	7.8e-36	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg00631329	chr6:26305371	NA	-0.41	-11.24	-0.41	7.3e-27	Educational attainment;
BRCA	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg22676075	chr6:135203613	NA	0.4	8.2	0.31	1.31e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg21856205	chr7:94953877	PON1	0.38	8.42	0.32	2.56e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg08859206	chr1:53392774	SCP2	-0.42	-8.5	-0.32	1.29e-16	Monocyte count;
BRCA	trans	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg06521331	chr12:34319734	NA	-0.43	-7.87	-0.3	1.56e-14	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-9.4	-0.35	9.47e-20	Menopause (age at onset);
BRCA	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg17143192	chr8:8559678	CLDN23	0.54	10.32	0.38	3.24e-23	Obesity-related traits;
BRCA	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg18305652	chr10:134549665	INPP5A	0.5	13.13	0.46	5.03e-35	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg00666640	chr1:248458726	OR2T12	0.3	8.42	0.32	2.5e-16	Common traits (Other);
BRCA	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.84	-0.39	3.08e-25	Bone mineral density;
BRCA	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg26384229	chr12:38710491	ALG10B	0.54	13.72	0.48	1.01e-37	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg10523679	chr1:76189770	ACADM	-0.45	-8.78	-0.33	1.49e-17	Daytime sleep phenotypes;
BRCA	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	13.73	0.48	8.4e-38	Lymphocyte counts;
BRCA	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24549020	chr5:56110836	MAP3K1	0.59	12.21	0.44	5.52e-31	Initial pursuit acceleration;
BRCA	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg25767906	chr1:53392781	SCP2	0.35	8.21	0.31	1.23e-15	Monocyte count;
BRCA	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg26384229	chr12:38710491	ALG10B	0.77	17.43	0.57	5.93e-56	Bladder cancer;
BRCA	cis	rs10416265	0.528	rs10420258	chr19:33602757	C/T	cg17764715	chr19:33622953	WDR88	0.49	7.95	0.3	8.21e-15	Bone properties (heel);
BRCA	cis	rs7945718	0.967	rs7930077	chr11:12778769	C/T	cg25843174	chr11:12811716	TEAD1	0.22	8.6	0.32	5.97e-17	Educational attainment (years of education);
BRCA	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg11814155	chr7:99998594	ZCWPW1	0.56	9.49	0.35	4.41e-20	Platelet count;
BRCA	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-9.79	-0.36	3.39e-21	Gut microbiome composition (summer);
BRCA	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	10.78	0.39	5.34e-25	Monocyte percentage of white cells;
BRCA	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg26384229	chr12:38710491	ALG10B	0.75	16.35	0.54	1.76e-50	Morning vs. evening chronotype;
BRCA	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg09307838	chr4:120376055	NA	0.67	13.49	0.47	1.12e-36	Corneal astigmatism;
BRCA	trans	rs747782	0.527	rs7129364	chr11:48150576	G/A	cg15704280	chr7:45808275	SEPT13	0.58	8.07	0.3	3.45e-15	Intraocular pressure;
BRCA	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg08888203	chr3:10149979	C3orf24	0.55	11.7	0.42	8.97e-29	Alzheimer's disease;
BRCA	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg24069376	chr3:38537580	EXOG	0.41	11.91	0.43	1.12e-29	Electrocardiographic conduction measures;
BRCA	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.39	8.65	0.32	4.22e-17	Multiple sclerosis;
BRCA	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg03477792	chr4:77819574	ANKRD56	0.65	15.66	0.53	4.98e-47	Emphysema distribution in smoking;
BRCA	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-8.34	-0.31	4.72e-16	Joint mobility (Beighton score);
BRCA	cis	rs3125734	0.534	rs10821973	chr10:64052337	G/A	cg19640130	chr10:64028056	RTKN2	-0.33	-9.05	-0.34	1.74e-18	Rheumatoid arthritis;
BRCA	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg01689657	chr7:91764605	CYP51A1	0.22	8.01	0.3	5.35e-15	Breast cancer;
BRCA	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg23950597	chr19:37808831	NA	-0.62	-11.34	-0.41	2.68e-27	Coronary artery calcification;
BRCA	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg22875332	chr1:76189707	ACADM	0.57	10.34	0.38	2.81e-23	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.48	8.78	0.33	1.48e-17	Breast cancer;
BRCA	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg21132104	chr15:45694354	SPATA5L1	0.74	16.48	0.55	4.21e-51	Homoarginine levels;
BRCA	cis	rs4919694	0.808	rs80020194	chr10:105035954	A/G	cg04362960	chr10:104952993	NT5C2	0.82	10.97	0.4	9.18e-26	Arsenic metabolism;
BRCA	cis	rs698833	0.892	rs786408	chr2:44733156	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	9.95	0.37	8.75e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg27170947	chr2:26402098	FAM59B	0.93	17.03	0.56	6.61e-54	Gut microbiome composition (summer);
BRCA	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.93	0.46	3.84e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs13082711	0.554	rs1494422	chr3:27375190	T/C	cg02860705	chr3:27208620	NA	-0.56	-10.68	-0.39	1.28e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs4764124	0.646	rs10846062	chr12:14965781	T/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.5	11.62	0.42	1.84e-28	Pubertal anthropometrics;
BRCA	cis	rs12986413	0.651	rs2238610	chr19:2146852	T/C	cg09261902	chr19:2140048	AP3D1	0.43	11.05	0.4	4.35e-26	Height;
BRCA	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg16482183	chr6:26056742	HIST1H1C	0.43	8.46	0.32	1.89e-16	Iron status biomarkers;
BRCA	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg26647111	chr11:31128758	NA	-0.45	-9.78	-0.36	3.99e-21	Red blood cell count;
BRCA	trans	rs11088226	0.681	rs2833906	chr21:33945521	G/T	cg09050820	chr6:167586206	TCP10L2	0.81	14.76	0.5	1.25e-42	Gastritis;
BRCA	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.3	-0.31	6.42e-16	Bipolar disorder;
BRCA	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.54	-11.33	-0.41	3.02e-27	Lymphocyte counts;
BRCA	cis	rs68092024	0.704	rs704575	chr3:99486075	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-10.53	-0.38	5.12e-24	Cleft lip with or without cleft palate;
BRCA	trans	rs6479891	1.000	rs9415692	chr10:65115152	G/A	cg14819942	chr15:35414228	NA	0.34	8.35	0.31	4.37e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.57	-12.67	-0.45	5.43e-33	Platelet count;
BRCA	cis	rs1997103	1.000	rs6950311	chr7:55400990	G/A	cg17469321	chr7:55412551	NA	0.51	9.72	0.36	6.37e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4363385	0.747	rs4845333	chr1:152982877	G/T	cg24667326	chr1:152973720	SPRR3	-0.35	-9.87	-0.36	1.81e-21	Inflammatory skin disease;
BRCA	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg12483005	chr1:23474871	LUZP1	-0.38	-8.29	-0.31	6.93e-16	Height;
BRCA	trans	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg25214090	chr10:38739885	LOC399744	-0.41	-9.27	-0.34	2.8e-19	Corneal astigmatism;
BRCA	cis	rs6545883	0.831	rs2592356	chr2:61810428	G/C	cg15711740	chr2:61764176	XPO1	-0.56	-14.36	-0.49	1.03e-40	Tuberculosis;
BRCA	cis	rs10504073	0.647	rs10957357	chr8:49988587	C/A	cg00325661	chr8:49890786	NA	0.42	11.96	0.43	6.72e-30	Blood metabolite ratios;
BRCA	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.31	-0.44	2.18e-31	Chronic sinus infection;
BRCA	cis	rs290268	0.817	rs291006	chr9:93540244	A/C	cg02608019	chr9:93564028	SYK	0.48	10.08	0.37	2.89e-22	Platelet count;
BRCA	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg23711669	chr6:146136114	FBXO30	-0.8	-19.34	-0.61	5.67e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4589502	1.000	rs2414925	chr15:67129986	A/G	cg09911534	chr15:67153556	NA	-0.73	-9.7	-0.36	7.57e-21	Lung cancer (smoking interaction);
BRCA	cis	rs2070997	0.816	rs6597642	chr9:133725767	C/T	cg11464064	chr9:133710261	ABL1	0.53	8.76	0.33	1.75e-17	Response to amphetamines;
BRCA	trans	rs4714291	0.832	rs1524087	chr6:40057504	A/G	cg02267698	chr19:7991119	CTXN1	-0.45	-9.29	-0.34	2.42e-19	Strep throat;
BRCA	cis	rs887829	0.569	rs4663963	chr2:234650193	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.32	-8.39	-0.31	3.14e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs146671954	1	rs146671954	chr9:136934203	G/A	cg13789015	chr9:136890014	NCRNA00094	0.57	8.92	0.33	4.73e-18	Red cell distribution width;
BRCA	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg02153584	chr22:29168773	CCDC117	-0.52	-10.83	-0.39	3.18e-25	Lymphocyte counts;
BRCA	cis	rs7572733	0.534	rs4369854	chr2:198800630	T/C	cg00792783	chr2:198669748	PLCL1	0.45	9.89	0.36	1.53e-21	Dermatomyositis;
BRCA	cis	rs9790314	0.613	rs13092102	chr3:160598093	C/G	cg03342759	chr3:160939853	NMD3	0.44	8.37	0.31	3.55e-16	Morning vs. evening chronotype;
BRCA	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	8.83	0.33	1.02e-17	Personality dimensions;
BRCA	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	9.22	0.34	4.11e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-10.58	-0.39	3.14e-24	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2016266	0.819	rs7397757	chr12:53652684	A/G	cg26875137	chr12:53738046	NA	-0.37	-9.19	-0.34	5.33e-19	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg06627628	chr2:24431161	ITSN2	0.56	9.02	0.34	2.15e-18	Lymphocyte counts;
BRCA	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg05340658	chr4:99064831	C4orf37	0.64	14.74	0.5	1.47e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg00106254	chr7:1943704	MAD1L1	-0.38	-9.81	-0.36	2.97e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg14186256	chr22:23484241	RTDR1	0.78	23.89	0.69	1.32e-90	Bone mineral density;
BRCA	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg18252515	chr7:66147081	NA	1.06	16.03	0.54	7.81e-49	Diabetic kidney disease;
BRCA	trans	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.02	0.3	5.03e-15	Corneal astigmatism;
BRCA	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07080220	chr10:102295463	HIF1AN	0.51	11.66	0.42	1.3e-28	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg04673462	chr1:38461896	NA	0.45	10.37	0.38	2.21e-23	Coronary artery disease;
BRCA	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg18132916	chr6:79620363	NA	-0.4	-8.14	-0.31	2.11e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6484504	0.532	rs7121949	chr11:31288160	G/T	cg26647111	chr11:31128758	NA	-0.45	-9.77	-0.36	4.28e-21	Red blood cell count;
BRCA	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg14186256	chr22:23484241	RTDR1	0.76	22.49	0.66	6.07e-83	Bone mineral density;
BRCA	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg13010199	chr12:38710504	ALG10B	0.48	9.23	0.34	3.94e-19	Morning vs. evening chronotype;
BRCA	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg08807101	chr21:30365312	RNF160	-0.6	-15.37	-0.52	1.35e-45	Dental caries;
BRCA	cis	rs17001868	0.568	rs9611328	chr22:40791972	C/T	cg07138101	chr22:40742427	ADSL	0.54	9.8	0.36	3.18e-21	Mammographic density (dense area);
BRCA	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg02551604	chr5:131831745	NA	-0.39	-14.62	-0.5	5.71e-42	Asthma (sex interaction);
BRCA	cis	rs312273	0.573	rs11179173	chr12:41346762	A/G	cg17827154	chr12:41323612	CNTN1	-0.42	-10.71	-0.39	1.01e-24	Bipolar disorder;
BRCA	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.48	9.51	0.35	3.76e-20	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg13010199	chr12:38710504	ALG10B	0.53	10.73	0.39	8.42e-25	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18404041	chr3:52824283	ITIH1	-0.42	-12.42	-0.44	7.09e-32	Bipolar disorder;
BRCA	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg20203395	chr5:56204925	C5orf35	0.35	7.93	0.3	1.01e-14	Coronary artery disease;
BRCA	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs34779708	0.931	rs10437420	chr10:35335044	A/C	cg03585969	chr10:35415529	CREM	-0.44	-9.29	-0.35	2.35e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03452623	chr4:187889614	NA	-0.34	-11.64	-0.42	1.53e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7809950	1.000	rs2107713	chr7:107232369	C/T	cg23024343	chr7:107201750	COG5	-0.37	-8.23	-0.31	1.05e-15	Coronary artery disease;
BRCA	cis	rs867371	1.000	rs2867579	chr15:82475384	G/C	cg00614314	chr15:82944287	LOC80154	0.43	9.09	0.34	1.21e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs34779708	0.733	rs7070778	chr10:35541688	T/C	cg03585969	chr10:35415529	CREM	0.45	9.16	0.34	6.72e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg23711669	chr6:146136114	FBXO30	0.63	14.29	0.49	2.19e-40	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.23	-0.41	7.69e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs495337	0.760	rs2769978	chr20:48527423	A/G	cg17835207	chr20:48524531	SPATA2	-0.69	-17.45	-0.57	4.93e-56	Psoriasis;
BRCA	cis	rs1557765	0.527	rs4756887	chr11:17394597	T/G	cg04705435	chr11:17411270	KCNJ11	0.34	7.88	0.3	1.38e-14	Body mass index;Social communication problems;
BRCA	cis	rs68170813	0.559	rs2395880	chr7:107074264	A/G	cg02696742	chr7:106810147	HBP1	-0.45	-7.87	-0.3	1.52e-14	Coronary artery disease;
BRCA	cis	rs1577917	1.000	rs12204015	chr6:86598334	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.77	-0.42	4.47e-29	Response to antipsychotic treatment;
BRCA	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg22974920	chr21:40686053	BRWD1	-0.41	-9.03	-0.34	1.96e-18	Cognitive function;
BRCA	cis	rs6484504	0.576	rs158140	chr11:31212971	T/C	cg14844989	chr11:31128820	NA	-0.45	-9.62	-0.36	1.51e-20	Red blood cell count;
BRCA	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg11764359	chr7:65958608	NA	-0.78	-17.94	-0.58	1.29e-58	Aortic root size;
BRCA	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg11645453	chr3:52864694	ITIH4	0.49	11.8	0.42	3.4e-29	Schizophrenia;
BRCA	cis	rs12986413	0.967	rs1074047	chr19:2158748	A/G	cg09261902	chr19:2140048	AP3D1	0.4	10.5	0.38	6.59e-24	Height;
BRCA	cis	rs400736	0.602	rs7553544	chr1:8165719	C/T	cg25007680	chr1:8021821	PARK7	-0.36	-8.19	-0.31	1.4e-15	Response to antidepressants and depression;
BRCA	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg00814883	chr7:100076585	TSC22D4	-0.51	-11.67	-0.42	1.17e-28	Platelet count;
BRCA	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.62	9.88	0.36	1.66e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs870825	0.655	rs7683556	chr4:185632019	T/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.4	0.57	8.32e-56	Blood protein levels;
BRCA	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg00677455	chr12:58241039	CTDSP2	0.71	16.12	0.54	2.69e-49	Intelligence (multi-trait analysis);
BRCA	cis	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg06521331	chr12:34319734	NA	-0.62	-11.12	-0.4	2.15e-26	Morning vs. evening chronotype;
BRCA	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg20891283	chr12:69753455	YEATS4	0.55	11.06	0.4	3.83e-26	Response to diuretic therapy;
BRCA	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-11.91	-0.43	1.11e-29	Monocyte percentage of white cells;
BRCA	cis	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg07460842	chr6:66804631	NA	0.88	14.2	0.49	5.86e-40	Exhaled nitric oxide output;
BRCA	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg17063962	chr7:91808500	NA	0.59	14.06	0.49	2.62e-39	Breast cancer;
BRCA	cis	rs11955398	0.604	rs4700379	chr5:59872392	G/A	cg02684056	chr5:59996105	DEPDC1B	0.35	8.28	0.31	7.48e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1113500	0.933	rs3893034	chr1:108632178	G/A	cg06207961	chr1:108661230	NA	0.46	11.07	0.4	3.59e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg04851639	chr8:1020857	NA	-0.39	-11.11	-0.4	2.53e-26	Schizophrenia;
BRCA	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-13.27	-0.46	1.11e-35	Platelet count;
BRCA	cis	rs7640424	0.589	rs7612356	chr3:107811037	C/G	cg09227934	chr3:107805635	CD47	-0.43	-8.11	-0.31	2.68e-15	Body mass index;
BRCA	cis	rs9468199	0.505	rs72847381	chr6:27873931	G/A	cg08851530	chr6:28072375	NA	0.8	8.24	0.31	1.01e-15	Parkinson's disease;
BRCA	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg02733842	chr7:1102375	C7orf50	-0.86	-14.76	-0.5	1.23e-42	Bronchopulmonary dysplasia;
BRCA	cis	rs7927771	0.524	rs2869024	chr11:47674101	G/A	cg20307385	chr11:47447363	PSMC3	-0.42	-9.49	-0.35	4.68e-20	Subjective well-being;
BRCA	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.35	0.38	2.69e-23	Motion sickness;
BRCA	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg08975724	chr8:8085496	FLJ10661	0.52	11.32	0.41	3.47e-27	Mood instability;
BRCA	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg19077165	chr18:44547161	KATNAL2	0.55	12.2	0.43	6.37e-31	Personality dimensions;
BRCA	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.58	10.28	0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs1371614	0.545	rs3769138	chr2:27169540	G/T	cg00617064	chr2:27272375	NA	-0.31	-8.1	-0.31	2.75e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg13047869	chr3:10149882	C3orf24	0.6	12.07	0.43	2.33e-30	Alzheimer's disease;
BRCA	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg05623727	chr3:50126028	RBM5	0.43	10.07	0.37	3.18e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg05283184	chr6:79620031	NA	-0.39	-9.75	-0.36	4.96e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7903847	0.642	rs11189191	chr10:99148796	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.25	-0.31	9.03e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg11166453	chr1:247681781	NA	0.45	9.92	0.37	1.19e-21	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs17741873	0.836	rs17631059	chr10:75625558	G/C	cg07699608	chr10:75541558	CHCHD1	0.55	8.4	0.32	2.78e-16	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.52	-0.32	1.16e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9443645	0.527	rs1413969	chr6:79790982	A/G	cg09184832	chr6:79620586	NA	-0.44	-8.83	-0.33	9.68e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.89	-0.33	6.26e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg14847009	chr1:175162515	KIAA0040	-0.25	-9.31	-0.35	1.99e-19	Alcohol dependence;
BRCA	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg11645453	chr3:52864694	ITIH4	0.46	10.75	0.39	6.58e-25	Schizophrenia;
BRCA	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.32	8.7	0.33	2.88e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg05967295	chr7:98741636	SMURF1	-0.98	-18.54	-0.59	1.05e-61	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg06671706	chr8:8559999	CLDN23	0.44	8.45	0.32	1.94e-16	Obesity-related traits;
BRCA	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg22117172	chr7:91764530	CYP51A1	0.24	8.37	0.31	3.74e-16	Breast cancer;
BRCA	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-14.96	-0.51	1.4e-43	Menarche (age at onset);
BRCA	cis	rs78707713	0.512	rs35793747	chr10:71182165	A/G	cg12610070	chr10:71211762	TSPAN15	-0.32	-10.05	-0.37	3.76e-22	Venous thromboembolism;
BRCA	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03452623	chr4:187889614	NA	0.33	10.88	0.4	2.02e-25	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg10523679	chr1:76189770	ACADM	-0.61	-11.66	-0.42	1.34e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg21770322	chr7:97807741	LMTK2	-0.47	-12.9	-0.45	5.46e-34	Breast cancer;
BRCA	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg07828340	chr4:882639	GAK	1.04	12.43	0.44	6.32e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg05623727	chr3:50126028	RBM5	-0.38	-8.28	-0.31	7.29e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	19.35	0.61	5.21e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg24747557	chr10:131355152	MGMT	-0.37	-8.84	-0.33	8.93e-18	Response to temozolomide;
BRCA	trans	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.48	9.36	0.35	1.35e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.38	-0.31	3.49e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.35	-7.88	-0.3	1.42e-14	Colorectal cancer;
BRCA	trans	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg25214090	chr10:38739885	LOC399744	0.51	10.46	0.38	9.9899999999999993e-24	Corneal astigmatism;
BRCA	cis	rs4478858	0.698	rs11802155	chr1:31805012	T/C	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs4818225	0.804	rs9975388	chr21:42626362	C/A	cg21268422	chr21:42620091	BACE2	0.46	8.73	0.33	2.24e-17	Educational attainment;
BRCA	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg13770153	chr20:60521292	NA	-0.78	-19.39	-0.61	3.4e-66	Obesity-related traits;
BRCA	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg19784903	chr17:45786737	TBKBP1	0.34	8.09	0.3	3.05e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.31	-7.85	-0.3	1.78e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs72480748	0.509	rs3865457	chr19:41398969	C/T	cg09508736	chr19:41385865	CYP2A7	-0.45	-9.44	-0.35	6.86e-20	Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
BRCA	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg08917208	chr2:24149416	ATAD2B	0.94	14.07	0.49	2.2e-39	Lymphocyte counts;
BRCA	cis	rs12474201	0.775	rs7584870	chr2:46973400	A/T	cg06386533	chr2:46925753	SOCS5	0.69	15.24	0.52	6.13e-45	Height;
BRCA	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.82	0.36	2.67e-21	Bipolar disorder;
BRCA	trans	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04565464	chr8:145669602	NFKBIL2	0.41	9.36	0.35	1.31e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs1595825	0.891	rs16866980	chr2:198513009	A/C	cg19156104	chr2:198669113	PLCL1	-0.43	-8.19	-0.31	1.41e-15	Ulcerative colitis;
BRCA	cis	rs7394190	0.748	rs11000775	chr10:75539010	T/C	cg07699608	chr10:75541558	CHCHD1	0.61	9.3	0.35	2.28e-19	Incident atrial fibrillation;
BRCA	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg08508325	chr11:3079039	CARS	0.28	8.63	0.32	5.01e-17	Calcium levels;
BRCA	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg27661571	chr11:113659931	NA	-0.7	-10.88	-0.4	2e-25	Hip circumference adjusted for BMI;
BRCA	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.49	-9.25	-0.34	3.32e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg26031613	chr14:104095156	KLC1	-0.48	-9.52	-0.35	3.54e-20	Schizophrenia;
BRCA	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg11845111	chr2:191398756	TMEM194B	-0.78	-14.78	-0.5	1.01e-42	Diastolic blood pressure;
BRCA	trans	rs2270927	0.510	rs6453214	chr5:75584423	A/G	cg13563193	chr19:33072644	PDCD5	0.86	10.09	0.37	2.51e-22	Mean corpuscular volume;
BRCA	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg21064579	chr19:49206444	FUT2	0.37	9.12	0.34	9.49e-19	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
BRCA	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-11.52	-0.41	4.89e-28	Personality dimensions;
BRCA	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg16339924	chr4:17578868	LAP3	-0.58	-13.53	-0.47	7.28e-37	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.34	-7.87	-0.3	1.48e-14	Colorectal cancer;
BRCA	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-8.68	-0.32	3.21e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg03060546	chr3:49711283	APEH	-0.54	-10.99	-0.4	7.38e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg13798780	chr7:105162888	PUS7	0.45	7.9	0.3	1.21e-14	Bipolar disorder (body mass index interaction);
BRCA	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg26769984	chr7:1090371	C7orf50	0.64	11.44	0.41	1.08e-27	Bronchopulmonary dysplasia;
BRCA	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg05347473	chr6:146136440	FBXO30	0.41	7.97	0.3	7.53e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9287719	0.649	rs12104950	chr2:10732105	G/A	cg00105475	chr2:10696890	NA	0.41	9.23	0.34	3.83e-19	Prostate cancer;
BRCA	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg16405210	chr4:1374714	KIAA1530	-0.93	-21.48	-0.65	1.86e-77	Longevity;
BRCA	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg08392591	chr16:89556376	ANKRD11	0.47	11.17	0.4	1.32e-26	Multiple myeloma (IgH translocation);
BRCA	cis	rs10654220	1	rs10654220	chr12:123703422	A/AGTT	cg00376283	chr12:123451042	ABCB9	0.51	9.98	0.37	6.87e-22	Platelet count;
BRCA	cis	rs6740322	0.748	rs13432574	chr2:43544328	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-12.54	-0.44	2.19e-32	Coronary artery disease;
BRCA	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	8.31	0.31	5.64e-16	Bipolar disorder;
BRCA	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	9.99	0.37	6.26e-22	Iron status biomarkers;
BRCA	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.42	8.41	0.32	2.6e-16	Tonsillectomy;
BRCA	cis	rs17401966	0.838	rs12127604	chr1:10352800	T/G	cg03954927	chr1:10346856	KIF1B	0.43	13.7	0.48	1.24e-37	Hepatocellular carcinoma;
BRCA	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18876405	chr7:65276391	NA	0.5	11.1	0.4	2.63e-26	Aortic root size;
BRCA	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg08975724	chr8:8085496	FLJ10661	0.46	10.04	0.37	4.02e-22	Mood instability;
BRCA	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg13628971	chr7:2884303	GNA12	0.37	7.98	0.3	6.87e-15	Height;
BRCA	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg09904177	chr6:26538194	HMGN4	-0.43	-13.65	-0.48	2.01e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs17095355	0.892	rs7085888	chr10:111713930	A/G	cg00817464	chr10:111662876	XPNPEP1	0.34	8.48	0.32	1.62e-16	Biliary atresia;
BRCA	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-7.98	-0.3	6.61e-15	Total body bone mineral density;
BRCA	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg08601574	chr20:25228251	PYGB	-0.34	-8.12	-0.31	2.42e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	12.72	0.45	3.26e-33	Mean platelet volume;
BRCA	cis	rs13102973	0.965	rs4864240	chr4:135856737	T/C	cg14419869	chr4:135874104	NA	-0.59	-13.08	-0.46	8.68e-35	Subjective well-being;
BRCA	cis	rs11971779	0.680	rs6962366	chr7:139043867	G/A	cg07862535	chr7:139043722	LUC7L2	0.38	10.37	0.38	2.13e-23	Diisocyanate-induced asthma;
BRCA	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg11663144	chr21:46675770	NA	-0.54	-12.7	-0.45	4.17e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	17.94	0.58	1.42e-58	Platelet count;
BRCA	cis	rs6545883	0.894	rs778143	chr2:61581890	A/C	cg15711740	chr2:61764176	XPO1	-0.5	-12.07	-0.43	2.43e-30	Tuberculosis;
BRCA	cis	rs2479724	0.868	rs2249703	chr6:41814760	A/G	cg17623882	chr6:41773611	USP49	-0.36	-9.76	-0.36	4.53e-21	Menarche (age at onset);
BRCA	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.4	0.47	2.88e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs62229266	0.804	rs998383	chr21:37445739	C/G	cg12218747	chr21:37451666	NA	-0.38	-8.9	-0.33	5.83e-18	Mitral valve prolapse;
BRCA	cis	rs427394	0.664	rs274697	chr5:6731477	A/C	cg10857441	chr5:6722123	POLS	-0.32	-10.9	-0.4	1.66e-25	Menopause (age at onset);
BRCA	trans	rs2270927	0.510	rs2358712	chr5:75580687	A/G	cg13563193	chr19:33072644	PDCD5	0.86	10.12	0.37	2.01e-22	Mean corpuscular volume;
BRCA	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg27170947	chr2:26402098	FAM59B	-0.81	-13.08	-0.46	7.88e-35	Gut microbiome composition (summer);
BRCA	cis	rs6910061	1.000	rs9468436	chr6:11112626	C/G	cg27233058	chr6:11094804	LOC221710	0.53	9.51	0.35	3.79e-20	Diabetic kidney disease;
BRCA	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg12000995	chr2:27665139	KRTCAP3	0.34	8.54	0.32	9.62e-17	Total body bone mineral density;
BRCA	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.4	-8.45	-0.32	1.92e-16	Ulcerative colitis;
BRCA	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg11887960	chr12:57824829	NA	0.51	8.34	0.31	4.57e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs7560272	0.538	rs4241257	chr2:73938607	T/C	cg20560298	chr2:73613845	ALMS1	0.33	8.58	0.32	7.16e-17	Schizophrenia;
BRCA	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg24558204	chr6:135376177	HBS1L	0.45	12.4	0.44	8.41e-32	Red blood cell count;
BRCA	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26314531	chr2:26401878	FAM59B	-0.66	-11.2	-0.4	1.08e-26	Gut microbiome composition (summer);
BRCA	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg05714579	chr10:131428358	MGMT	0.51	11.09	0.4	2.81e-26	Response to temozolomide;
BRCA	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21659725	chr3:3221576	CRBN	-0.49	-10.57	-0.39	3.56e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12756686	chr19:29218302	NA	0.38	8.04	0.3	4.42e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg07917127	chr4:99064746	C4orf37	0.39	7.85	0.3	1.79e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.65	-11.59	-0.42	2.59e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg04691961	chr3:161091175	C3orf57	-0.39	-9.12	-0.34	1e-18	Morning vs. evening chronotype;
BRCA	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg02297831	chr4:17616191	MED28	0.36	8.52	0.32	1.17e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11644478	chr21:40555479	PSMG1	-0.5	-10.7	-0.39	1.04e-24	Menarche (age at onset);
BRCA	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.59	12.23	0.44	4.51e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg21017887	chr14:105400489	NA	-0.63	-16.17	-0.54	1.51e-49	Rheumatoid arthritis;
BRCA	cis	rs1883415	0.534	rs2760149	chr6:24477848	C/T	cg20631270	chr6:24437470	GPLD1	0.4	8.17	0.31	1.6e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10267417	0.535	rs10242331	chr7:19923552	T/C	cg05791153	chr7:19748676	TWISTNB	0.43	7.95	0.3	8.6e-15	Night sleep phenotypes;
BRCA	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.06e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-12.6	-0.45	1.13e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs2415984	0.622	rs2817568	chr14:46940986	C/G	cg14871534	chr14:47121158	RPL10L	0.32	8.08	0.3	3.18e-15	Number of children ever born;
BRCA	cis	rs250677	0.522	rs1007400	chr5:148382635	C/T	cg12140854	chr5:148520817	ABLIM3	0.42	8.55	0.32	9.35e-17	Breast cancer;
BRCA	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24531977	chr5:56204891	C5orf35	0.87	18.56	0.59	8.17e-62	Initial pursuit acceleration;
BRCA	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg21427119	chr20:30132790	HM13	-0.42	-8.92	-0.33	4.92e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-8.8	-0.33	1.3e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg12419862	chr22:24373484	LOC391322	0.62	13.26	0.46	1.29e-35	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg04398451	chr17:18023971	MYO15A	-0.66	-14.46	-0.5	3.37e-41	Total body bone mineral density;
BRCA	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg01483505	chr11:975446	AP2A2	0.34	9.09	0.34	1.28e-18	Alzheimer's disease (late onset);
BRCA	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.97	21.48	0.65	1.77e-77	Lymphocyte percentage of white cells;
BRCA	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.33	0.68	1.52e-87	Chronic sinus infection;
BRCA	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg20607798	chr8:58055168	NA	0.65	10.01	0.37	5.05e-22	Developmental language disorder (linguistic errors);
BRCA	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg22875332	chr1:76189707	ACADM	0.66	13.85	0.48	2.36e-38	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs7980799	0.649	rs11052736	chr12:33669583	T/C	cg26384229	chr12:38710491	ALG10B	0.52	10.89	0.4	1.81e-25	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg03146154	chr1:46216737	IPP	0.45	9.95	0.37	8.9e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7903847	0.642	rs10882910	chr10:99138043	G/A	cg20016023	chr10:99160130	RRP12	-0.27	-8.59	-0.32	6.67e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2455799	0.573	rs924753	chr3:15706124	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-9.19	-0.34	5.57e-19	Mean platelet volume;
BRCA	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.24	0.49	3.5e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg14664628	chr15:75095509	CSK	0.94	28.94	0.75	2.65e-118	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg12011299	chr4:100065546	ADH4	-0.52	-11.93	-0.43	8.89e-30	Alcohol dependence;
BRCA	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-9.56	-0.35	2.58e-20	Schizophrenia;
BRCA	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg08807101	chr21:30365312	RNF160	-0.45	-7.9	-0.3	1.22e-14	Cognitive test performance;
BRCA	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg20573242	chr4:122745356	CCNA2	0.49	10.99	0.4	7.79e-26	Type 2 diabetes;
BRCA	cis	rs7178424	1.000	rs34096515	chr15:62379449	T/C	cg00456672	chr15:62358751	C2CD4A	-0.34	-8.22	-0.31	1.11e-15	Height;
BRCA	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-11.02	-0.4	5.55e-26	Total cholesterol levels;
BRCA	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg07080220	chr10:102295463	HIF1AN	0.63	14.98	0.51	1.08e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25427524	chr10:38739819	LOC399744	-0.69	-16.76	-0.55	1.62e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg05347473	chr6:146136440	FBXO30	-0.39	-7.87	-0.3	1.57e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs943466	0.956	rs1075379	chr6:33737800	T/C	cg25922239	chr6:33757077	LEMD2	-0.38	-8.29	-0.31	6.5e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg13319975	chr6:146136371	FBXO30	-0.4	-9.11	-0.34	1.04e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg08601574	chr20:25228251	PYGB	-0.39	-9.0	-0.34	2.64e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg06784218	chr1:46089804	CCDC17	0.5	12.02	0.43	3.88e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.72	0.36	6.36e-21	Menopause (age at onset);
BRCA	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08219700	chr8:58056026	NA	0.44	7.94	0.3	8.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2712184	0.687	rs62180470	chr2:217645451	A/G	cg05032264	chr2:217675019	NA	0.34	8.06	0.3	3.8e-15	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs4363385	0.818	rs2152994	chr1:152991060	C/T	cg24667326	chr1:152973720	SPRR3	0.3	8.49	0.32	1.45e-16	Inflammatory skin disease;
BRCA	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg16339924	chr4:17578868	LAP3	0.56	13.86	0.48	2.31e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs858239	0.539	rs3950345	chr7:23191114	T/C	cg23682824	chr7:23144976	KLHL7	0.41	10.94	0.4	1.21e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg26446133	chr18:72167187	CNDP2	-0.75	-14.45	-0.5	3.78e-41	Refractive error;
BRCA	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-9.27	-0.34	2.92e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs870825	0.655	rs2017101	chr4:185637381	G/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.32	0.57	2.07e-55	Blood protein levels;
BRCA	trans	rs1997103	1.000	rs2140915	chr7:55410699	G/C	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg22903471	chr2:27725779	GCKR	-0.37	-9.03	-0.34	1.96e-18	Total body bone mineral density;
BRCA	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.56	-0.52	1.55e-46	Chronic sinus infection;
BRCA	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg17063962	chr7:91808500	NA	0.54	12.84	0.45	9.87e-34	Breast cancer;
BRCA	cis	rs12711979	0.509	rs10195596	chr2:3824222	T/G	cg17052675	chr2:3827356	NA	-0.7	-23.65	-0.68	2.6e-89	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg08601574	chr20:25228251	PYGB	-0.34	-8.12	-0.31	2.45e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs7939886	0.841	rs11231800	chr11:55770930	A/G	cg03929089	chr4:120376271	NA	0.69	8.01	0.3	5.46e-15	Myopia (pathological);
BRCA	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06108461	chr20:60628389	TAF4	-0.72	-15.25	-0.52	4.92e-45	Body mass index;
BRCA	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11890956	chr21:40555474	PSMG1	0.97	22.36	0.66	3.2e-82	Cognitive function;
BRCA	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg09184832	chr6:79620586	NA	-0.48	-10.63	-0.39	2.12e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg10664184	chr19:17420304	DDA1	0.36	10.24	0.38	6.85e-23	Systemic lupus erythematosus;
BRCA	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg04414720	chr1:150670196	GOLPH3L	0.36	7.96	0.3	7.96e-15	Tonsillectomy;
BRCA	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.67	0.42	1.12e-28	Homoarginine levels;
BRCA	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00166722	chr3:10149974	C3orf24	0.57	11.34	0.41	2.89e-27	Alzheimer's disease;
BRCA	cis	rs7264396	0.561	rs6060753	chr20:34598430	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-9.42	-0.35	7.86e-20	Total cholesterol levels;
BRCA	trans	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg15704280	chr7:45808275	SEPT13	0.6	8.88	0.33	6.87e-18	Axial length;
BRCA	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg00631329	chr6:26305371	NA	-0.42	-12.61	-0.45	1.07e-32	Educational attainment;
BRCA	cis	rs6815814	0.950	rs5743556	chr4:38806851	A/G	cg06935464	chr4:38784597	TLR10	0.51	8.42	0.32	2.52e-16	Breast cancer;
BRCA	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18876405	chr7:65276391	NA	-0.56	-13.35	-0.47	5.16e-36	Aortic root size;
BRCA	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg07080220	chr10:102295463	HIF1AN	0.64	14.96	0.51	1.32e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs11585357	0.947	rs6666990	chr1:17611520	G/A	cg19159961	chr1:17633534	PADI4	-0.49	-8.76	-0.33	1.69e-17	Hair shape;
BRCA	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg15819921	chr19:927150	ARID3A	0.45	8.51	0.32	1.22e-16	Life satisfaction;
BRCA	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg01657329	chr11:68192670	LRP5	-0.39	-9.78	-0.36	3.82e-21	Total body bone mineral density;
BRCA	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg25554036	chr4:6271136	WFS1	0.42	10.16	0.37	1.36e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7586879	0.828	rs9631062	chr2:25110084	C/T	cg04586622	chr2:25135609	ADCY3	0.39	9.36	0.35	1.37e-19	Body mass index;
BRCA	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg22920501	chr2:26401640	FAM59B	-0.9	-16.11	-0.54	3.04e-49	Gut microbiome composition (summer);
BRCA	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg07169764	chr2:136633963	MCM6	1.28	29.33	0.76	2.04e-120	Corneal structure;
BRCA	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg09904177	chr6:26538194	HMGN4	0.55	17.61	0.57	7.14e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs4588572	0.643	rs1864173	chr5:77691158	C/T	cg11547950	chr5:77652471	NA	0.44	7.81	0.3	2.35e-14	Triglycerides;
BRCA	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg11693508	chr17:37793320	STARD3	0.61	11.25	0.41	6.75e-27	Bipolar disorder;
BRCA	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg20362242	chr5:692897	TPPP	0.53	8.0	0.3	5.8e-15	Lung disease severity in cystic fibrosis;
BRCA	trans	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg26043149	chr18:55253948	FECH	0.43	9.29	0.34	2.32e-19	Bone mineral density;
BRCA	cis	rs7833986	0.501	rs72653967	chr8:56999432	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	12.99	0.46	2.13e-34	Height;
BRCA	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03517284	chr6:25882590	NA	0.69	16.0	0.53	1.06e-48	Blood metabolite levels;
BRCA	cis	rs9880211	0.752	rs9847427	chr3:136351550	C/A	cg21827317	chr3:136751795	NA	-0.45	-7.93	-0.3	1.01e-14	Body mass index;Height;
BRCA	cis	rs6973256	0.828	rs12707117	chr7:133429058	G/A	cg07491979	chr7:133331646	EXOC4	0.36	8.36	0.31	3.8e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg09307838	chr4:120376055	NA	0.69	13.84	0.48	2.79e-38	Corneal astigmatism;
BRCA	cis	rs2425143	1.000	rs8115150	chr20:34397189	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.53	-0.32	1.09e-16	Blood protein levels;
BRCA	cis	rs11971779	0.793	rs9632774	chr7:139137562	C/T	cg07862535	chr7:139043722	LUC7L2	0.37	9.11	0.34	1.03e-18	Diisocyanate-induced asthma;
BRCA	cis	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg06521331	chr12:34319734	NA	-0.62	-12.2	-0.43	6.08e-31	Morning vs. evening chronotype;
BRCA	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg19418458	chr7:158789849	NA	-0.41	-9.29	-0.34	2.44e-19	Facial morphology (factor 20);
BRCA	cis	rs11051970	0.879	rs1500874	chr12:32589407	G/A	cg02745156	chr12:32552066	NA	0.27	8.86	0.33	7.83e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs11971779	0.938	rs11981688	chr7:139088895	A/G	cg07862535	chr7:139043722	LUC7L2	0.51	12.72	0.45	3.24e-33	Diisocyanate-induced asthma;
BRCA	trans	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg06521331	chr12:34319734	NA	-0.51	-9.24	-0.34	3.5e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg12311346	chr5:56204834	C5orf35	-0.56	-11.82	-0.42	2.74e-29	Coronary artery disease;
BRCA	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg07741184	chr6:167504864	NA	-0.28	-8.36	-0.31	3.78e-16	Rheumatoid arthritis;
BRCA	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg07169764	chr2:136633963	MCM6	-0.95	-20.19	-0.62	1.78e-70	Corneal structure;
BRCA	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg18225595	chr11:63971243	STIP1	0.52	13.01	0.46	1.67e-34	Platelet count;
BRCA	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg10523679	chr1:76189770	ACADM	-0.46	-8.73	-0.33	2.29e-17	Daytime sleep phenotypes;
BRCA	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg06623918	chr6:96969491	KIAA0776	-0.92	-26.72	-0.73	3.64e-106	Headache;
BRCA	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26314531	chr2:26401878	FAM59B	-0.69	-11.53	-0.41	4.68e-28	Gut microbiome composition (summer);
BRCA	cis	rs2505998	0.833	rs2742243	chr10:43601749	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.39	-7.98	-0.3	6.97e-15	Hirschsprung disease;
BRCA	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.45	10.36	0.38	2.35e-23	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg12756686	chr19:29218302	NA	0.46	8.16	0.31	1.79e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg11301795	chr4:187892539	NA	-0.26	-8.5	-0.32	1.33e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg09367891	chr1:107599246	PRMT6	-0.55	-9.93	-0.37	1.01e-21	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg18225595	chr11:63971243	STIP1	0.53	9.6	0.36	1.73e-20	Mean platelet volume;
BRCA	cis	rs9612	1.000	rs28446957	chr19:44246600	T/A	cg08581076	chr19:44259116	C19orf61	0.53	9.19	0.34	5.46e-19	Exhaled nitric oxide output;
BRCA	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg03676636	chr4:99064102	C4orf37	0.23	7.88	0.3	1.38e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg14004847	chr7:1930337	MAD1L1	-0.45	-8.56	-0.32	8.67e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg00339695	chr16:24857497	SLC5A11	0.48	9.72	0.36	6.25e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs3820928	0.874	rs13393902	chr2:227880554	A/G	cg11843606	chr2:227700838	RHBDD1	-0.36	-8.03	-0.3	4.57e-15	Pulmonary function;
BRCA	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg06784218	chr1:46089804	CCDC17	0.46	11.02	0.4	5.46e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.75	-0.33	1.82e-17	Neuroticism;
BRCA	cis	rs9986765	1.000	rs9986765	chr7:142835239	C/T	cg22531018	chr7:142981779	TMEM139	-0.57	-9.72	-0.36	6.41e-21	Cancer;Dermatomyositis;
BRCA	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg09307838	chr4:120376055	NA	-0.63	-13.7	-0.48	1.22e-37	Corneal astigmatism;
BRCA	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	12.22	0.44	5.35e-31	Response to bleomycin (chromatid breaks);
BRCA	cis	rs6450176	0.638	rs3822497	chr5:53299693	C/G	cg22592108	chr5:53304441	ARL15	0.31	7.83	0.3	2.04e-14	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	trans	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg06521331	chr12:34319734	NA	-0.5	-9.14	-0.34	8.28e-19	Bladder cancer;
BRCA	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg13319975	chr6:146136371	FBXO30	-0.38	-8.37	-0.31	3.77e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.16	-0.4	1.56e-26	Schizophrenia;
BRCA	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg13319975	chr6:146136371	FBXO30	0.62	14.38	0.49	8.08e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg02176678	chr2:219576539	TTLL4	0.4	10.88	0.4	2.09e-25	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg03929089	chr4:120376271	NA	-0.47	-9.04	-0.34	1.9e-18	HDL cholesterol;
BRCA	cis	rs9487051	0.768	rs458185	chr6:109524074	A/G	cg01475377	chr6:109611718	NA	-0.44	-11.24	-0.41	7.33e-27	Reticulocyte fraction of red cells;
BRCA	cis	rs6669008	1.000	rs1891969	chr1:114185855	C/A	cg26035817	chr1:114414802	PTPN22	0.35	8.57	0.32	7.83e-17	Bacteremia;
BRCA	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg08888203	chr3:10149979	C3orf24	0.68	14.48	0.5	2.55e-41	Alzheimer's disease;
BRCA	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24531977	chr5:56204891	C5orf35	-0.8	-16.12	-0.54	2.66e-49	Initial pursuit acceleration;
BRCA	trans	rs2797160	1.000	rs1739378	chr6:126012262	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.91	0.3	1.11e-14	Endometrial cancer;
BRCA	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg23711669	chr6:146136114	FBXO30	0.69	16.02	0.54	7.97e-49	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg00750074	chr16:89608354	SPG7	-0.38	-10.25	-0.38	6.4e-23	Multiple myeloma (IgH translocation);
BRCA	cis	rs7178424	0.869	rs3784634	chr15:62259637	C/T	cg00456672	chr15:62358751	C2CD4A	0.42	9.42	0.35	7.78e-20	Height;
BRCA	trans	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg21659725	chr3:3221576	CRBN	-0.46	-9.86	-0.36	1.94e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2882667	0.858	rs11959851	chr5:138421405	C/G	cg04439458	chr5:138467593	SIL1	-0.39	-10.51	-0.38	5.9e-24	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs586533	0.881	rs593946	chr11:99498370	C/A	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.9e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2274273	1.000	rs7160110	chr14:55594635	A/G	cg04306507	chr14:55594613	LGALS3	0.33	9.14	0.34	8.1e-19	Protein biomarker;
BRCA	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.18	0.54	1.35e-49	Fuchs's corneal dystrophy;
BRCA	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg12011299	chr4:100065546	ADH4	0.53	12.86	0.45	7.62e-34	Alcohol dependence;
BRCA	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.37	0.31	3.62e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg24692254	chr21:30365293	RNF160	-0.6	-15.11	-0.51	2.49e-44	Dental caries;
BRCA	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg08885076	chr2:99613938	TSGA10	0.43	10.31	0.38	3.72e-23	Chronic sinus infection;
BRCA	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.37e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs919433	0.617	rs4850436	chr2:198541398	C/T	cg00792783	chr2:198669748	PLCL1	-0.43	-9.53	-0.35	3.25e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg15485101	chr11:133734466	NA	0.4	9.77	0.36	4.32e-21	Childhood ear infection;
BRCA	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg21770322	chr7:97807741	LMTK2	0.61	17.63	0.57	5.22e-57	Breast cancer;
BRCA	cis	rs2479724	0.905	rs2251274	chr6:41839438	T/G	cg17623882	chr6:41773611	USP49	-0.38	-10.28	-0.38	4.85e-23	Menarche (age at onset);
BRCA	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	9.97	0.37	7.69e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2625529	0.824	rs11072339	chr15:72247190	C/T	cg16672083	chr15:72433130	SENP8	-0.84	-17.27	-0.56	3.79e-55	Red blood cell count;
BRCA	cis	rs7818345	0.967	rs11784873	chr8:19281113	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.25	0.31	8.78e-16	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs12493885	0.818	rs73160504	chr3:153773384	C/T	cg17054900	chr3:154042577	DHX36	-0.5	-8.65	-0.32	4.07e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg24450063	chr1:156163899	SLC25A44	1.09	34.22	0.8	1.34e-146	Testicular germ cell tumor;
BRCA	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg23978390	chr7:1156363	C7orf50	0.39	7.97	0.3	7.14e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg26587870	chr6:27730563	NA	-0.51	-7.91	-0.3	1.12e-14	Breast cancer;
BRCA	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg00376283	chr12:123451042	ABCB9	0.45	9.82	0.36	2.69e-21	Height;Educational attainment;Head circumference (infant);
BRCA	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg21770322	chr7:97807741	LMTK2	0.41	10.7	0.39	1.11e-24	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	10.41	0.38	1.45e-23	Height;
BRCA	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg21918786	chr6:109611834	NA	-0.49	-14.13	-0.49	1.18e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg16586182	chr3:47516702	SCAP	-0.57	-12.47	-0.44	4.09e-32	Colorectal cancer;
BRCA	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-9.44	-0.35	7.1e-20	Menopause (age at onset);
BRCA	cis	rs9290065	0.585	rs716779	chr3:160645428	G/A	cg03342759	chr3:160939853	NMD3	0.41	8.41	0.32	2.64e-16	Kawasaki disease;
BRCA	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg23029597	chr12:123009494	RSRC2	-0.47	-9.8	-0.36	3.23e-21	Body mass index;
BRCA	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg00071950	chr4:10020882	SLC2A9	0.55	13.35	0.47	5.05e-36	Bone mineral density;
BRCA	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg12661370	chr5:149340060	SLC26A2	0.58	10.25	0.38	6.37e-23	HIV-1 control;
BRCA	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg18016565	chr1:150552671	MCL1	0.35	8.2	0.31	1.3e-15	Tonsillectomy;
BRCA	trans	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.64	-0.32	4.36e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg11645453	chr3:52864694	ITIH4	0.47	11.31	0.41	3.56e-27	Schizophrenia;
BRCA	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.46	-0.77	1.51e-126	Schizophrenia;
BRCA	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg22875332	chr1:76189707	ACADM	0.56	10.06	0.37	3.37e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Tonsillectomy;
BRCA	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg18131467	chr2:239335373	ASB1	0.94	32.28	0.79	2.42e-136	Multiple system atrophy;
BRCA	cis	rs13046373	0.535	rs2832957	chr21:31973140	C/T	cg16812893	chr21:31813075	KRTAP15-1	0.39	9.7	0.36	7.75e-21	HDL cholesterol;
BRCA	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg09654669	chr8:57350985	NA	-0.4	-8.81	-0.33	1.15e-17	Obesity-related traits;
BRCA	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.1	-0.34	1.15e-18	Menopause (age at onset);
BRCA	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.01	0.34	2.33e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.64e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg13010199	chr12:38710504	ALG10B	0.39	7.91	0.3	1.13e-14	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg19717773	chr7:2847554	GNA12	-0.43	-9.63	-0.36	1.43e-20	Height;
BRCA	cis	rs11887277	0.741	rs12471783	chr2:27039919	A/G	cg12368169	chr2:27073192	DPYSL5	-0.29	-8.17	-0.31	1.62e-15	Obesity-related traits;
BRCA	cis	rs939658	0.683	rs1560895	chr15:79468082	A/G	cg17916960	chr15:79447300	NA	-0.39	-9.58	-0.35	2.18e-20	Refractive error;
BRCA	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg25358565	chr5:93447407	FAM172A	1.22	18.67	0.59	2.2e-62	Diabetic retinopathy;
BRCA	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.55	10.13	0.37	1.87e-22	Body mass index (adult);
BRCA	trans	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.26	0.31	8.38e-16	Corneal astigmatism;
BRCA	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg18402987	chr7:1209562	NA	0.85	12.22	0.44	5.38e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg25237894	chr2:233734115	C2orf82	0.39	11.04	0.4	4.74e-26	Coronary artery disease;
BRCA	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-12.32	-0.44	1.95e-31	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7301016	0.846	rs17732089	chr12:63023658	A/G	cg01804193	chr12:63026212	NA	-0.47	-8.24	-0.31	1.01e-15	IgG glycosylation;
BRCA	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg06627628	chr2:24431161	ITSN2	0.73	13.87	0.48	1.93e-38	Asthma;
BRCA	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg15605315	chr1:45957053	TESK2	0.46	9.44	0.35	6.61e-20	High light scatter reticulocyte count;
BRCA	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg13256891	chr4:100009986	ADH5	0.53	9.77	0.36	4.33e-21	Smoking initiation;
BRCA	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg11764359	chr7:65958608	NA	0.67	15.15	0.51	1.68e-44	Aortic root size;
BRCA	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg11814155	chr7:99998594	ZCWPW1	0.47	8.41	0.32	2.78e-16	Platelet count;
BRCA	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg11395062	chr17:14139857	CDRT15	-0.49	-10.93	-0.4	1.25e-25	Temperament;
BRCA	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg11993925	chr19:44307056	LYPD5	0.37	8.77	0.33	1.6e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg17971929	chr21:40555470	PSMG1	-0.49	-10.84	-0.39	3.1e-25	Menarche (age at onset);
BRCA	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg22105103	chr4:187893119	NA	0.33	10.72	0.39	8.67e-25	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs477692	0.569	rs1762418	chr10:131303353	G/A	cg05714579	chr10:131428358	MGMT	0.46	10.25	0.38	6.21e-23	Response to temozolomide;
BRCA	cis	rs7833986	0.501	rs2719257	chr8:56940173	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.73	13.99	0.48	5.27e-39	Height;
BRCA	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.18	0.62	1.96e-70	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg11764359	chr7:65958608	NA	-0.65	-11.72	-0.42	7.28e-29	Aortic root size;
BRCA	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg08807101	chr21:30365312	RNF160	-0.57	-13.92	-0.48	1.12e-38	Dental caries;
BRCA	cis	rs897080	0.552	rs1067318	chr2:44634509	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.39	0.35	1.04e-19	Height;
BRCA	cis	rs4853036	0.951	rs13011127	chr2:70040147	T/C	cg02498382	chr2:70120550	SNRNP27	-0.48	-8.8	-0.33	1.23e-17	Colorectal or endometrial cancer;
BRCA	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg14530993	chr4:882597	GAK	0.51	8.58	0.32	7.04e-17	Parkinson's disease;
BRCA	cis	rs62458065	0.513	rs7788809	chr7:32552622	T/A	cg20159608	chr7:32802032	NA	-0.49	-9.4	-0.35	9.82e-20	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	14.11	0.49	1.48e-39	Hip circumference adjusted for BMI;
BRCA	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg17063962	chr7:91808500	NA	0.52	11.47	0.41	7.99e-28	Breast cancer;
BRCA	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg24905316	chr10:135186343	ECHS1	0.62	9.58	0.35	2.12e-20	Lifespan;
BRCA	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg13319975	chr6:146136371	FBXO30	-0.4	-9.14	-0.34	8.3e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05901451	chr6:126070800	HEY2	0.4	9.72	0.36	6.35e-21	Endometrial cancer;
BRCA	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.41	8.09	0.3	2.94e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs28595532	0.546	rs17516389	chr4:119239267	T/C	cg21605333	chr4:119757512	SEC24D	0.82	8.61	0.32	5.8e-17	Cannabis dependence symptom count;
BRCA	cis	rs738322	0.775	rs4375	chr22:38539041	T/C	cg25457927	chr22:38595422	NA	-0.33	-12.16	-0.43	9.55e-31	Cutaneous nevi;
BRCA	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11890956	chr21:40555474	PSMG1	-0.85	-21.97	-0.66	4.2e-80	Cognitive function;
BRCA	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg18806716	chr10:30721971	MAP3K8	-0.44	-10.0	-0.37	5.51e-22	Inflammatory bowel disease;
BRCA	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22455342	chr2:225449267	CUL3	0.66	17.09	0.56	3.17e-54	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11890956	chr21:40555474	PSMG1	0.82	13.11	0.46	6.33e-35	Cognitive function;
BRCA	trans	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg01620082	chr3:125678407	NA	-0.62	-8.23	-0.31	1.08e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7818345	0.845	rs11782540	chr8:19268251	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.35	8.97	0.33	3.25e-18	Language performance in older adults (adjusted for episodic memory);
BRCA	trans	rs1422110	0.515	rs1155791	chr5:85417582	A/C	cg01787110	chr1:109008453	NBPF6	0.49	10.72	0.39	9.06e-25	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg19077165	chr18:44547161	KATNAL2	-0.51	-10.92	-0.4	1.37e-25	Personality dimensions;
BRCA	cis	rs490234	0.812	rs12341150	chr9:128340770	C/T	cg14078157	chr9:128172775	NA	-0.48	-10.97	-0.4	8.89e-26	Mean arterial pressure;
BRCA	cis	rs586533	0.846	rs1690809	chr11:99512037	C/T	cg22878054	chr11:99397252	CNTN5	0.31	7.84	0.3	1.85e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg20991723	chr1:152506922	NA	0.39	8.71	0.33	2.6e-17	Hair morphology;
BRCA	cis	rs9986765	1.000	rs4565384	chr7:142811564	C/A	cg22531018	chr7:142981779	TMEM139	0.59	9.76	0.36	4.54e-21	Cancer;Dermatomyositis;
BRCA	cis	rs10463316	0.894	rs4099171	chr5:150766623	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.32	-0.31	5.17e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs9790314	0.779	rs1599374	chr3:160891727	G/A	cg04691961	chr3:161091175	C3orf57	-0.5	-11.05	-0.4	4.13e-26	Morning vs. evening chronotype;
BRCA	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg03676636	chr4:99064102	C4orf37	0.24	8.56	0.32	8.42e-17	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs758324	0.704	rs31480	chr5:131396332	C/T	cg06307176	chr5:131281290	NA	-0.46	-8.78	-0.33	1.53e-17	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs2742417	0.603	rs2064062	chr3:45761115	G/C	cg04837898	chr3:45731254	SACM1L	-0.39	-8.07	-0.3	3.51e-15	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg12935359	chr14:103987150	CKB	-0.59	-13.47	-0.47	1.42e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-13.83	-0.48	3.01e-38	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg25214090	chr10:38739885	LOC399744	0.53	11.77	0.42	4.25e-29	Corneal astigmatism;
BRCA	cis	rs4074536	0.536	rs12140557	chr1:116291066	G/A	cg21648376	chr1:116311395	CASQ2	-0.49	-8.57	-0.32	7.66e-17	QRS duration;
BRCA	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	trans	rs877282	0.583	rs12358255	chr10:828626	C/T	cg22713356	chr15:30763199	NA	0.89	14.51	0.5	1.86e-41	Uric acid levels;
BRCA	cis	rs7631605	0.905	rs6550445	chr3:37066369	T/C	cg15934958	chr3:37212084	LRRFIP2	0.42	9.68	0.36	9.27e-21	Cerebrospinal P-tau181p levels;
BRCA	trans	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.84	-27.72	-0.74	1.21e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg17211192	chr8:82754475	SNX16	0.49	11.13	0.4	1.94e-26	Diastolic blood pressure;
BRCA	cis	rs4268898	1.000	rs6746005	chr2:24434345	G/A	cg06627628	chr2:24431161	ITSN2	0.5	10.36	0.38	2.4e-23	Asthma;
BRCA	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg16586182	chr3:47516702	SCAP	0.63	13.82	0.48	3.36e-38	Colorectal cancer;
BRCA	trans	rs208520	0.690	rs207094	chr6:66799009	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-21.01	-0.64	6.5e-75	Exhaled nitric oxide output;
BRCA	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24110177	chr3:50126178	RBM5	-0.37	-9.9	-0.36	1.38e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg01884057	chr2:25150051	NA	0.34	8.99	0.34	2.76e-18	Body mass index;
BRCA	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.38e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg12927641	chr6:109611667	NA	-0.41	-10.85	-0.39	2.65e-25	Reticulocyte fraction of red cells;
BRCA	trans	rs6479891	1.000	rs7895348	chr10:65109541	C/A	cg14819942	chr15:35414228	NA	-0.33	-8.18	-0.31	1.57e-15	Arthritis (juvenile idiopathic);
BRCA	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg15252951	chr6:33757062	LEMD2	0.4	10.33	0.38	3.17e-23	Crohn's disease;
BRCA	trans	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg25214090	chr10:38739885	LOC399744	0.56	12.39	0.44	9.8e-32	Corneal astigmatism;
BRCA	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11644478	chr21:40555479	PSMG1	-0.51	-10.9	-0.4	1.66e-25	Menarche (age at onset);
BRCA	trans	rs1941687	0.583	rs8091977	chr18:31359414	T/C	cg15819921	chr19:927150	ARID3A	-0.4	-7.84	-0.3	1.94e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs9309711	0.770	rs13409323	chr2:3488184	C/T	cg10845886	chr2:3471009	TTC15	-0.71	-14.59	-0.5	8.34e-42	Neurofibrillary tangles;
BRCA	cis	rs13161895	1.000	rs34027780	chr5:179478891	C/A	cg02702477	chr5:179499311	RNF130	0.46	8.65	0.32	4.17e-17	LDL cholesterol;
BRCA	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg24812749	chr6:127587940	RNF146	0.8	15.62	0.53	7.74e-47	Breast cancer;
BRCA	cis	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg06521331	chr12:34319734	NA	-0.65	-11.99	-0.43	5.28e-30	Morning vs. evening chronotype;
BRCA	cis	rs113835537	0.529	rs11227499	chr11:66272824	A/G	cg24851651	chr11:66362959	CCS	0.39	8.0	0.3	6.07e-15	Airway imaging phenotypes;
BRCA	cis	rs2637266	1.000	rs10824431	chr10:78356622	C/A	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg02403541	chr12:121454288	C12orf43	0.64	12.29	0.44	2.52e-31	N-glycan levels;
BRCA	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg04450456	chr4:17643702	FAM184B	-0.36	-10.44	-0.38	1.14e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg06521331	chr12:34319734	NA	0.46	9.08	0.34	1.38e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6750047	0.756	rs4670233	chr2:38272342	A/G	cg07380506	chr2:38303506	CYP1B1	0.41	9.31	0.35	1.98e-19	Cutaneous malignant melanoma;Melanoma;
BRCA	trans	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg01620082	chr3:125678407	NA	-0.59	-8.24	-0.31	1.01e-15	Depression;
BRCA	cis	rs7903847	0.642	rs7074511	chr10:99140177	G/A	cg08345082	chr10:99160200	RRP12	-0.29	-8.53	-0.32	1.03e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs367943	0.712	rs1366393	chr5:112729472	A/G	cg12552261	chr5:112820674	MCC	0.36	7.86	0.3	1.69e-14	Type 2 diabetes;
BRCA	cis	rs9287719	0.649	rs12473957	chr2:10717714	C/G	cg00105475	chr2:10696890	NA	-0.41	-9.01	-0.34	2.44e-18	Prostate cancer;
BRCA	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg11822812	chr5:140052017	DND1	-0.29	-8.06	-0.3	3.83e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg22508957	chr16:3507546	NAT15	-0.58	-8.65	-0.32	4.2e-17	Tuberculosis;
BRCA	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg07080220	chr10:102295463	HIF1AN	0.51	10.54	0.38	4.47e-24	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg04166393	chr7:2884313	GNA12	0.63	13.63	0.47	2.69e-37	Height;
BRCA	cis	rs17095355	1.000	rs9988702	chr10:111703389	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.99	-0.37	6.01e-22	Biliary atresia;
BRCA	cis	rs77633900	0.614	rs280014	chr15:76986890	A/G	cg21673338	chr15:77095150	SCAPER	-0.54	-9.98	-0.37	6.81e-22	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg22834771	chr12:69754056	YEATS4	-0.42	-10.43	-0.38	1.27e-23	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs644148	0.785	rs118112019	chr19:44965091	T/G	cg15540054	chr19:45004280	ZNF180	0.47	9.22	0.34	4.36e-19	Personality dimensions;
BRCA	cis	rs1468333	0.964	rs10479180	chr5:137581901	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.41	7.96	0.3	8.04e-15	Resting heart rate;
BRCA	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	10.58	0.39	3.17e-24	Height;
BRCA	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	6.69e-19	Alzheimer's disease (late onset);
BRCA	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg17105886	chr17:28927953	LRRC37B2	0.59	7.86	0.3	1.6e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.01	-21.96	-0.66	4.55e-80	Gut microbiome composition (summer);
BRCA	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg22705602	chr4:152727874	NA	-0.32	-8.24	-0.31	9.68e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg16606324	chr3:10149918	C3orf24	0.52	10.03	0.37	4.4e-22	Alzheimer's disease;
BRCA	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg04455712	chr21:45112962	RRP1B	0.42	10.71	0.39	1.02e-24	Mean corpuscular volume;
BRCA	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg17063962	chr7:91808500	NA	0.52	12.33	0.44	1.72e-31	Breast cancer;
BRCA	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08564027	chr20:61660810	NA	0.84	22.84	0.67	7.41e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg26647111	chr11:31128758	NA	-0.45	-9.82	-0.36	2.73e-21	Bone mineral density (spine);
BRCA	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-9.05	-0.34	1.65e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs8028182	0.636	rs12708519	chr15:75803200	T/C	cg20655648	chr15:75932815	IMP3	0.42	8.06	0.3	3.87e-15	Sudden cardiac arrest;
BRCA	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg09877947	chr5:131593287	PDLIM4	0.34	7.98	0.3	6.71e-15	Blood metabolite levels;
BRCA	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.46	-11.12	-0.4	2.32e-26	IgG glycosylation;
BRCA	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg27535305	chr1:53392650	SCP2	-0.37	-9.26	-0.34	3.07e-19	Monocyte count;
BRCA	trans	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.99	0.3	6.37e-15	Corneal astigmatism;
BRCA	trans	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	8.92e-15	Corneal astigmatism;
BRCA	trans	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.89	-0.36	1.51e-21	Triglycerides;
BRCA	cis	rs2629540	0.889	rs17624662	chr10:126408146	A/C	cg08799069	chr10:126477246	METTL10	0.46	9.35	0.35	1.4e-19	Cocaine dependence;
BRCA	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.62	0.39	2.16e-24	Tonsillectomy;
BRCA	cis	rs1003719	0.715	rs8130643	chr21:38551715	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.49	-0.5	2.46e-41	Eye color traits;
BRCA	cis	rs13136331	0.568	rs13103299	chr4:88590012	T/C	cg22416721	chr4:88570574	DMP1	0.61	14.33	0.49	1.43e-40	Sitting height ratio;
BRCA	cis	rs7586879	0.789	rs7560156	chr2:25124794	T/C	cg04586622	chr2:25135609	ADCY3	0.4	9.56	0.35	2.4e-20	Body mass index;
BRCA	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg17691542	chr6:26056736	HIST1H1C	0.48	9.67	0.36	9.7e-21	Iron status biomarkers;
BRCA	cis	rs7903847	0.642	rs11189175	chr10:99139609	T/C	cg20016023	chr10:99160130	RRP12	-0.27	-8.64	-0.32	4.4e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg14403583	chr14:105418241	AHNAK2	-0.37	-8.61	-0.32	5.6e-17	Rheumatoid arthritis;
BRCA	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg08888203	chr3:10149979	C3orf24	0.56	11.7	0.42	9.05e-29	Alzheimer's disease;
BRCA	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.87	0.36	1.75e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg05865280	chr17:75406074	SEPT9	0.46	12.64	0.45	7.59e-33	Airflow obstruction;
BRCA	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.01	-0.3	5.27e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10504073	0.565	rs35282337	chr8:49920994	G/A	cg00325661	chr8:49890786	NA	0.51	15.04	0.51	5.21e-44	Blood metabolite ratios;
BRCA	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-14.3	-0.49	1.94e-40	Response to antipsychotic treatment;
BRCA	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.27	-0.41	5.39e-27	Coronary artery disease;
BRCA	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.48	0.35	4.92e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg27446573	chr6:127587934	RNF146	0.89	20.5	0.63	3.86e-72	Breast cancer;
BRCA	cis	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg07460842	chr6:66804631	NA	0.73	12.71	0.45	3.88e-33	Exhaled nitric oxide levels;
BRCA	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-9.4	-0.35	9.79e-20	Personality dimensions;
BRCA	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg12641515	chr19:46296257	DMWD	0.71	17.61	0.57	7.39e-57	Coronary artery disease;
BRCA	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.68	11.24	0.41	7.45e-27	Lung function (FEV1/FVC);
BRCA	trans	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg26043149	chr18:55253948	FECH	0.41	8.91	0.33	5.1e-18	Bone mineral density;
BRCA	cis	rs1505368	0.505	rs1394781	chr2:213248822	C/T	cg20637307	chr2:213403960	ERBB4	-0.36	-8.41	-0.32	2.67e-16	Symmetrical dimethylarginine levels;
BRCA	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-10.23	-0.38	7.77e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs3741151	0.773	rs17244602	chr11:73219907	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.71	-10.65	-0.39	1.74e-24	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs503734	0.502	rs348880	chr3:100981426	A/G	cg27318481	chr3:100970896	IMPG2	-0.41	-9.83	-0.36	2.42e-21	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3812049	0.784	rs7734927	chr5:127453735	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	10.56	0.39	3.82e-24	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg06618935	chr21:46677482	NA	-0.38	-8.39	-0.32	3.11e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6546550	0.935	rs1056482	chr2:70108256	A/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-9.28	-0.34	2.67e-19	Prevalent atrial fibrillation;
BRCA	cis	rs73242632	1.000	rs73242623	chr4:57840543	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.69	8.28	0.31	7.48e-16	Congenital heart disease (maternal effect);
BRCA	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg21132104	chr15:45694354	SPATA5L1	0.74	16.82	0.55	7.77e-53	Homoarginine levels;
BRCA	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg25281562	chr12:121454272	C12orf43	0.36	9.45	0.35	6.07e-20	N-glycan levels;
BRCA	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg25237894	chr2:233734115	C2orf82	0.4	11.47	0.41	8.37e-28	Coronary artery disease;
BRCA	cis	rs7011049	1.000	rs117708010	chr8:53844026	G/A	cg26025543	chr8:53854495	NA	0.56	9.66	0.36	1.11e-20	Systolic blood pressure;
BRCA	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg08601574	chr20:25228251	PYGB	-0.34	-8.24	-0.31	9.57e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg03342759	chr3:160939853	NMD3	-0.67	-15.68	-0.53	3.83e-47	Morning vs. evening chronotype;
BRCA	cis	rs870825	0.616	rs2130394	chr4:185642577	C/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.14	0.56	1.74e-54	Blood protein levels;
BRCA	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg08355456	chr11:67383691	NA	0.41	8.53	0.32	1.04e-16	Mean corpuscular volume;
BRCA	cis	rs61990749	0.597	rs176952	chr14:78180736	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.64	10.06	0.37	3.36e-22	Fibroblast growth factor basic levels;
BRCA	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg22638593	chr5:131593259	PDLIM4	0.3	7.88	0.3	1.41e-14	Breast cancer;
BRCA	cis	rs7408868	1.000	rs10420466	chr19:15261371	G/T	cg14696996	chr19:15285081	NOTCH3	0.96	14.34	0.49	1.17e-40	Pulse pressure;
BRCA	cis	rs929596	0.517	rs3806592	chr2:234625936	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-10.99	-0.4	7.33e-26	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg04455712	chr21:45112962	RRP1B	0.41	11.08	0.4	3.32e-26	Mean corpuscular volume;
BRCA	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg26384229	chr12:38710491	ALG10B	0.74	17.6	0.57	7.83e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.49	-8.83	-0.33	1.02e-17	Renal function-related traits (BUN);
BRCA	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-7.81	-0.3	2.39e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs208520	0.837	rs208509	chr6:66941706	A/G	cg07460842	chr6:66804631	NA	-0.82	-14.66	-0.5	3.59e-42	Exhaled nitric oxide output;
BRCA	trans	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg14791747	chr16:20752902	THUMPD1	0.32	8.81	0.33	1.16e-17	Cognitive test performance;
BRCA	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg13010199	chr12:38710504	ALG10B	0.5	9.82	0.36	2.62e-21	Morning vs. evening chronotype;
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg07308232	chr7:1071921	C7orf50	-0.46	-9.5	-0.35	4.25e-20	Longevity;Endometriosis;
BRCA	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	16.95	0.56	1.65e-53	Platelet count;
BRCA	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg06238570	chr21:40685208	BRWD1	-0.43	-8.46	-0.32	1.8e-16	Cognitive function;
BRCA	cis	rs4853036	0.951	rs10496175	chr2:70153848	A/G	cg02498382	chr2:70120550	SNRNP27	-0.51	-9.24	-0.34	3.75e-19	Colorectal or endometrial cancer;
BRCA	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg23649088	chr2:200775458	C2orf69	0.72	16.16	0.54	1.72e-49	Osteoporosis;
BRCA	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg10820045	chr2:198174542	NA	0.4	9.27	0.34	2.7e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg20307385	chr11:47447363	PSMC3	-0.41	-9.68	-0.36	9.19e-21	Subjective well-being;
BRCA	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg03806693	chr22:41940476	POLR3H	1.06	20.43	0.63	8.87e-72	Vitiligo;
BRCA	cis	rs4780401	0.728	rs8057398	chr16:11780629	G/T	cg01061890	chr16:11836724	TXNDC11	-0.41	-8.85	-0.33	8.57e-18	Rheumatoid arthritis;
BRCA	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg11366901	chr6:160182831	ACAT2	0.78	15.21	0.52	8.47e-45	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs61931739	0.853	rs7133716	chr12:34041847	G/C	cg26384229	chr12:38710491	ALG10B	-0.42	-9.38	-0.35	1.09e-19	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg09658497	chr7:2847517	GNA12	-0.41	-8.62	-0.32	5.06e-17	Height;
BRCA	trans	rs11165623	0.564	rs6673207	chr1:96999259	C/G	cg10631902	chr5:14652156	NA	-0.43	-12.24	-0.44	4.16e-31	Hip circumference;Waist circumference;
BRCA	cis	rs2549794	0.511	rs27645	chr5:96163439	A/C	cg16492584	chr5:96139282	ERAP1	-0.3	-7.88	-0.3	1.45e-14	Crohn's disease;
BRCA	cis	rs9653442	0.712	rs6749757	chr2:100730111	A/C	cg22139774	chr2:100720529	AFF3	0.29	8.29	0.31	6.63e-16	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs6977660	0.943	rs12668201	chr7:19831610	A/C	cg05791153	chr7:19748676	TWISTNB	-0.39	-8.14	-0.31	2.05e-15	Thyroid stimulating hormone;
BRCA	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg15128208	chr22:42549153	NA	0.31	8.05	0.3	4.2e-15	Cognitive function;
BRCA	cis	rs4561483	0.832	rs171656	chr16:11953167	C/T	cg08843971	chr16:11963173	GSPT1	-0.51	-11.42	-0.41	1.34e-27	Testicular germ cell tumor;
BRCA	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-9.28	-0.34	2.65e-19	Alzheimer's disease;
BRCA	cis	rs7684253	0.565	rs13130605	chr4:57810071	G/A	cg11939399	chr4:57773300	REST	0.29	7.92	0.3	1.05e-14	Migraine;
BRCA	cis	rs12760731	0.720	rs2175254	chr1:178319105	G/A	cg00404053	chr1:178313656	RASAL2	0.69	8.7	0.33	2.83e-17	Obesity-related traits;
BRCA	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg16482183	chr6:26056742	HIST1H1C	0.74	14.54	0.5	1.42e-41	Iron status biomarkers;
BRCA	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.8	-0.42	3.16e-29	Mean corpuscular volume;
BRCA	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg03342759	chr3:160939853	NMD3	-0.72	-17.97	-0.58	9.09e-59	Morning vs. evening chronotype;
BRCA	cis	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg00852783	chr1:26633632	UBXN11	-0.49	-8.25	-0.31	8.77e-16	Obesity-related traits;
BRCA	cis	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-8.85	-0.33	8.3e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06108461	chr20:60628389	TAF4	-0.99	-22.17	-0.66	3.29e-81	Body mass index;
BRCA	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg10523679	chr1:76189770	ACADM	0.58	11.0	0.4	6.66e-26	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4853036	0.629	rs34704699	chr2:70014710	G/A	cg02498382	chr2:70120550	SNRNP27	-0.46	-8.04	-0.3	4.29e-15	Colorectal or endometrial cancer;
BRCA	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.64	11.49	0.41	6.63e-28	Total cholesterol levels;
BRCA	cis	rs1506403	0.685	rs10281506	chr7:142823928	C/T	cg22531018	chr7:142981779	TMEM139	0.43	8.37	0.31	3.67e-16	Cancer;
BRCA	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg08601574	chr20:25228251	PYGB	-0.34	-8.18	-0.31	1.58e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-8.89	-0.33	6.2e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg06360820	chr2:242988706	NA	-0.88	-15.52	-0.52	2.57e-46	Obesity-related traits;
BRCA	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg11814155	chr7:99998594	ZCWPW1	0.43	8.28	0.31	6.98e-16	Platelet count;
BRCA	trans	rs1493916	0.748	rs1845386	chr18:31318256	C/G	cg27147174	chr7:100797783	AP1S1	-0.43	-8.27	-0.31	8.05e-16	Life satisfaction;
BRCA	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg20203395	chr5:56204925	C5orf35	-0.49	-10.35	-0.38	2.6e-23	Initial pursuit acceleration;
BRCA	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	10.46	0.38	9.53e-24	Height;
BRCA	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg01324343	chr3:183735012	ABCC5	0.83	21.02	0.64	6.06e-75	Anterior chamber depth;
BRCA	cis	rs922692	0.744	rs12899147	chr15:79079512	A/G	cg04896959	chr15:78267971	NA	0.37	8.68	0.32	3.17e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg16325326	chr1:53192061	ZYG11B	-0.91	-24.95	-0.7	1.81e-96	Monocyte count;
BRCA	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	12.67	0.45	5.57e-33	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.42	9.43	0.35	7.5599999999999994e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.12	-0.31	2.47e-15	Gut microbiome composition (summer);
BRCA	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg03877680	chr5:178157825	ZNF354A	0.61	10.16	0.37	1.43e-22	Neutrophil percentage of white cells;
BRCA	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.97	-0.3	7.21e-15	Depression;
BRCA	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18404041	chr3:52824283	ITIH1	-0.43	-12.84	-0.45	9.96e-34	Bipolar disorder;
BRCA	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg00409905	chr10:38381863	ZNF37A	-0.48	-10.21	-0.37	8.94e-23	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg08601574	chr20:25228251	PYGB	0.36	8.73	0.33	2.23e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg20701182	chr2:24300061	SF3B14	0.57	8.97	0.33	3.37e-18	Lymphocyte counts;
BRCA	cis	rs17253792	0.822	rs10142757	chr14:56074211	C/A	cg01858014	chr14:56050164	KTN1	-0.77	-10.52	-0.38	5.49e-24	Putamen volume;
BRCA	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24308560	chr3:49941425	MST1R	0.39	8.51	0.32	1.25e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg14926445	chr8:58193284	C8orf71	-0.42	-8.13	-0.31	2.17e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.64	13.62	0.47	2.82e-37	Lymphocyte counts;
BRCA	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg18850127	chr7:39170497	POU6F2	0.55	12.14	0.43	1.16e-30	IgG glycosylation;
BRCA	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg18154014	chr19:37997991	ZNF793	0.63	12.15	0.43	1.04e-30	Coronary artery calcification;
BRCA	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	8.98e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg21475434	chr5:93447410	FAM172A	0.69	8.73	0.33	2.15e-17	Diabetic retinopathy;
BRCA	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg05340658	chr4:99064831	C4orf37	0.45	10.41	0.38	1.48e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg11833968	chr6:79620685	NA	-0.4	-8.78	-0.33	1.55e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs9951602	0.512	rs6506868	chr18:76642559	C/G	cg02800362	chr5:177631904	HNRNPAB	0.76	17.47	0.57	3.91e-56	Obesity-related traits;
BRCA	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg24562669	chr7:97807699	LMTK2	0.45	12.28	0.44	2.88e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg20933634	chr6:27740509	NA	0.44	8.43	0.32	2.24e-16	Parkinson's disease;
BRCA	cis	rs9462027	0.628	rs1998702	chr6:34741917	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.03	-0.3	4.79e-15	Systemic lupus erythematosus;
BRCA	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-10.59	-0.39	3.03e-24	Gut microbiome composition (summer);
BRCA	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-9.02	-0.34	2.17e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg00277334	chr10:82204260	NA	-0.44	-8.59	-0.32	6.6e-17	Post bronchodilator FEV1;
BRCA	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg23625390	chr15:77176239	SCAPER	-0.53	-12.7	-0.45	4.29e-33	Blood metabolite levels;
BRCA	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg14689365	chr7:158441557	NCAPG2	-0.42	-8.37	-0.31	3.68e-16	Height;
BRCA	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.18	-0.43	7.96e-31	Total cholesterol levels;
BRCA	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23583168	chr7:148888333	NA	-0.76	-17.63	-0.57	5.59e-57	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs12618769	0.652	rs11896729	chr2:99225645	T/C	cg10123293	chr2:99228465	UNC50	0.41	8.36	0.31	3.98e-16	Bipolar disorder;
BRCA	cis	rs2354432	0.607	rs6677679	chr1:146803630	C/T	cg25205988	chr1:146714368	CHD1L	-0.91	-13.1	-0.46	6.75e-35	Mitochondrial DNA levels;
BRCA	cis	rs6594713	0.756	rs10053341	chr5:112784007	G/T	cg12552261	chr5:112820674	MCC	0.47	8.13	0.31	2.29e-15	Brain cytoarchitecture;
BRCA	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.34	-7.86	-0.3	1.67e-14	High light scatter reticulocyte count;
BRCA	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg18850127	chr7:39170497	POU6F2	0.39	8.26	0.31	8.58e-16	IgG glycosylation;
BRCA	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg00814883	chr7:100076585	TSC22D4	-0.52	-11.86	-0.42	1.78e-29	Platelet count;
BRCA	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg17845761	chr1:175162550	KIAA0040	-0.26	-10.08	-0.37	2.83e-22	Alcohol dependence;
BRCA	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg03877680	chr5:178157825	ZNF354A	0.84	16.83	0.55	6.89e-53	Neutrophil percentage of white cells;
BRCA	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg24812749	chr6:127587940	RNF146	0.87	20.03	0.62	1.31e-69	Breast cancer;
BRCA	cis	rs2421770	0.530	rs3847622	chr11:35368700	A/G	cg13971030	chr11:35366721	SLC1A2	0.44	9.83	0.36	2.57e-21	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	17.04	0.56	6.06e-54	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs28595532	0.557	rs12498329	chr4:119311524	C/T	cg26518628	chr1:97050305	NA	-0.58	-10.62	-0.39	2.18e-24	Cannabis dependence symptom count;
BRCA	cis	rs3125734	0.633	rs10821968	chr10:63993905	C/T	cg19640130	chr10:64028056	RTKN2	0.33	9.74	0.36	5.17e-21	Rheumatoid arthritis;
BRCA	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg10876282	chr6:28092338	ZSCAN16	0.4	7.91	0.3	1.17e-14	Parkinson's disease;
BRCA	cis	rs7119038	0.509	rs11216960	chr11:118577873	G/A	cg19308663	chr11:118741387	NA	0.38	8.53	0.32	1.1e-16	Sjögren's syndrome;
BRCA	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg14675211	chr2:100938903	LONRF2	0.52	11.66	0.42	1.32e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg12365402	chr11:9010492	NRIP3	0.39	7.99	0.3	6.36e-15	Hemoglobin concentration;
BRCA	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg14847009	chr1:175162515	KIAA0040	-0.25	-9.45	-0.35	6.06e-20	Alcohol dependence;
BRCA	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg12935359	chr14:103987150	CKB	-0.52	-12.64	-0.45	7.23e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg03954927	chr1:10346856	KIF1B	0.44	13.98	0.48	6.18e-39	Hepatocellular carcinoma;
BRCA	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg05340658	chr4:99064831	C4orf37	0.59	12.67	0.45	5.43e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs34734847	0.965	rs2005455	chr12:121128699	A/G	cg21892295	chr12:121157589	UNC119B	-0.41	-12.48	-0.44	3.79e-32	Mean corpuscular volume;
BRCA	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg15017067	chr4:17643749	FAM184B	0.26	7.86	0.3	1.61e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg13628971	chr7:2884303	GNA12	0.41	9.21	0.34	4.76e-19	Height;
BRCA	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg00074818	chr8:8560427	CLDN23	0.39	8.51	0.32	1.23e-16	Obesity-related traits;
BRCA	cis	rs11971779	0.711	rs6961204	chr7:139047399	T/G	cg07862535	chr7:139043722	LUC7L2	0.47	11.91	0.43	1.16e-29	Diisocyanate-induced asthma;
BRCA	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02353165	chr6:42928485	GNMT	0.94	27.25	0.73	4.33e-109	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg22563815	chr15:78856949	CHRNA5	-0.36	-8.5	-0.32	1.34e-16	Sudden cardiac arrest;
BRCA	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs17253792	0.915	rs28537145	chr14:56179119	G/A	cg01858014	chr14:56050164	KTN1	-0.66	-8.39	-0.31	3.19e-16	Putamen volume;
BRCA	cis	rs9831754	1.000	rs3946823	chr3:78353052	G/A	cg06138941	chr3:78371609	NA	-0.81	-17.6	-0.57	7.74e-57	Calcium levels;
BRCA	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg07169764	chr2:136633963	MCM6	1.23	26.19	0.72	2.99e-103	Corneal structure;
BRCA	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg18132916	chr6:79620363	NA	-0.48	-10.95	-0.4	1.09e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg08422745	chr4:174089978	GALNT7	-0.79	-16.77	-0.55	1.33e-52	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg01262667	chr19:19385393	TM6SF2	-0.42	-10.88	-0.4	1.99e-25	Tonsillectomy;
BRCA	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg09307838	chr4:120376055	NA	0.72	15.68	0.53	3.89e-47	Corneal astigmatism;
BRCA	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg12311346	chr5:56204834	C5orf35	-0.39	-7.94	-0.3	9.41e-15	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg08601574	chr20:25228251	PYGB	0.37	8.59	0.32	6.76e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.55	-9.94	-0.37	9.63e-22	Body mass index (adult);
BRCA	cis	rs11955398	0.501	rs4235480	chr5:60032371	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.41	-9.5	-0.35	4.27e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.77	0.58	1.01e-57	Colorectal cancer;
BRCA	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.39	-8.55	-0.32	9.05e-17	HDL cholesterol;
BRCA	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-22.19	-0.66	2.46e-81	Heart rate;
BRCA	trans	rs3857536	0.776	rs9363560	chr6:66949686	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	2.02e-14	Blood trace element (Cu levels);
BRCA	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11644478	chr21:40555479	PSMG1	-0.67	-15.09	-0.51	3.07e-44	Cognitive function;
BRCA	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg15145296	chr3:125709740	NA	-0.55	-8.65	-0.32	4.23e-17	Blood pressure (smoking interaction);
BRCA	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.56	8.97	0.33	3.3e-18	Renal function-related traits (BUN);
BRCA	cis	rs2354432	0.660	rs10751415	chr1:146830785	T/A	cg25205988	chr1:146714368	CHD1L	0.88	12.52	0.44	2.69e-32	Mitochondrial DNA levels;
BRCA	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg04166393	chr7:2884313	GNA12	0.47	9.49	0.35	4.43e-20	Height;
BRCA	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg11584989	chr19:19387371	SF4	0.63	13.5	0.47	1e-36	Bipolar disorder;
BRCA	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg23711669	chr6:146136114	FBXO30	0.79	18.81	0.6	3.73e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg03188948	chr7:1209495	NA	0.44	8.77	0.33	1.56e-17	Longevity;Endometriosis;
BRCA	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg01689657	chr7:91764605	CYP51A1	0.25	8.85	0.33	8.51e-18	Breast cancer;
BRCA	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg12365402	chr11:9010492	NRIP3	-0.37	-8.4	-0.32	2.97e-16	Hemoglobin concentration;
BRCA	cis	rs2742234	0.541	rs10899779	chr10:43723976	C/T	cg15436174	chr10:43711423	RASGEF1A	0.54	10.68	0.39	1.35e-24	Hirschsprung disease;
BRCA	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg18404041	chr3:52824283	ITIH1	-0.47	-14.1	-0.49	1.62e-39	Bipolar disorder;
BRCA	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg03433033	chr1:76189801	ACADM	0.68	13.06	0.46	1.06e-34	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg03709012	chr19:19516395	GATAD2A	0.91	17.82	0.58	5.64e-58	Nonalcoholic fatty liver disease;
BRCA	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg25110126	chr1:46999211	NA	-0.62	-11.38	-0.41	1.92e-27	Monobrow;
BRCA	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-8.1	-0.31	2.84e-15	Blood pressure (smoking interaction);
BRCA	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg20503657	chr10:835505	NA	1.03	18.33	0.59	1.26e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg04414720	chr1:150670196	GOLPH3L	0.35	7.84	0.3	1.88e-14	Tonsillectomy;
BRCA	cis	rs858239	0.601	rs10263110	chr7:23160551	G/A	cg23682824	chr7:23144976	KLHL7	0.42	11.09	0.4	2.96e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	18.82	0.6	3.34e-63	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg03676636	chr4:99064102	C4orf37	0.21	7.94	0.3	9.23e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7903847	0.642	rs11189196	chr10:99155079	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.55	-0.32	9.17e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs35762459	1	rs35762459	chr11:8844653	T/TA	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-9.82	-0.36	2.65e-21	Immature fraction of reticulocytes;
BRCA	cis	rs13046373	0.535	rs35909098	chr21:32021649	C/T	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.51	0.35	3.87e-20	HDL cholesterol;
BRCA	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg17691542	chr6:26056736	HIST1H1C	0.48	10.13	0.37	1.84e-22	Height;
BRCA	cis	rs858239	0.601	rs1558313	chr7:23156079	G/A	cg23682824	chr7:23144976	KLHL7	0.42	11.09	0.4	2.96e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs68170813	0.559	rs76167266	chr7:106900664	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.65	-0.32	4.02e-17	Coronary artery disease;
BRCA	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg01256987	chr12:42539512	GXYLT1	-0.44	-8.57	-0.32	8.02e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg06212747	chr3:49208901	KLHDC8B	0.47	9.4	0.35	9.73e-20	Parkinson's disease;
BRCA	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg21782813	chr7:2030301	MAD1L1	0.42	11.22	0.41	8.65e-27	Bipolar disorder and schizophrenia;
BRCA	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg15704280	chr7:45808275	SEPT13	-0.48	-9.75	-0.36	4.87e-21	Coronary artery disease;
BRCA	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-9.16	-0.34	6.97e-19	Schizophrenia;
BRCA	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg08859206	chr1:53392774	SCP2	-0.46	-9.46	-0.35	5.66e-20	Monocyte count;
BRCA	cis	rs13315871	0.929	rs1045115	chr3:58305199	C/T	cg20936604	chr3:58311152	NA	-0.62	-8.26	-0.31	8.45e-16	Cholesterol, total;
BRCA	cis	rs6835098	0.509	rs2332655	chr4:174093002	A/G	cg08422745	chr4:174089978	GALNT7	0.53	11.38	0.41	1.87e-27	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg23708337	chr7:1209742	NA	0.6	8.31	0.31	5.89e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg12062639	chr20:23401060	NAPB	0.96	13.45	0.47	1.64e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	8.54	0.32	9.95e-17	Electroencephalogram traits;
BRCA	cis	rs11690935	0.851	rs10930502	chr2:172890588	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.79	-22.17	-0.66	3.35e-81	Schizophrenia;
BRCA	trans	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg21659725	chr3:3221576	CRBN	0.48	8.7	0.33	2.83e-17	Menarche (age at onset);
BRCA	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg22903471	chr2:27725779	GCKR	-0.38	-9.15	-0.34	7.82e-19	Total body bone mineral density;
BRCA	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg26384229	chr12:38710491	ALG10B	0.73	16.25	0.54	5.95e-50	Morning vs. evening chronotype;
BRCA	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg04450456	chr4:17643702	FAM184B	0.35	10.13	0.37	1.8e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg21918786	chr6:109611834	NA	-0.49	-13.96	-0.48	7.5e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg27170947	chr2:26402098	FAM59B	-0.94	-16.9	-0.56	3.15e-53	Gut microbiome composition (summer);
BRCA	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg19539972	chr4:7069911	GRPEL1	0.66	16.03	0.54	7.73e-49	Monocyte percentage of white cells;
BRCA	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg05234568	chr11:5960015	NA	-0.46	-9.22	-0.34	4.34e-19	DNA methylation (variation);
BRCA	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg14186256	chr22:23484241	RTDR1	0.75	22.46	0.66	8.1e-83	Bone mineral density;
BRCA	cis	rs17401966	1.000	rs1339458	chr1:10328338	C/T	cg15208524	chr1:10270712	KIF1B	0.36	7.85	0.3	1.72e-14	Hepatocellular carcinoma;
BRCA	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg11764359	chr7:65958608	NA	0.68	15.06	0.51	4.35e-44	Aortic root size;
BRCA	trans	rs12517041	0.935	rs10053181	chr5:23293265	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg23505145	chr19:12996616	KLF1	0.54	12.19	0.43	7.29e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg11952622	chr19:58962976	ZNF324B	0.46	9.52	0.35	3.51e-20	Uric acid clearance;
BRCA	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg19628046	chr18:33552617	C18orf21	0.53	10.63	0.39	2.08e-24	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs877282	0.945	rs71491311	chr10:791747	G/A	cg17470449	chr10:769945	NA	0.51	8.58	0.32	7.24e-17	Uric acid levels;
BRCA	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg05535760	chr7:792225	HEATR2	0.72	13.11	0.46	5.99e-35	Cerebrospinal P-tau181p levels;
BRCA	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg20503657	chr10:835505	NA	1.03	18.41	0.59	4.71e-61	Eosinophil percentage of granulocytes;
BRCA	cis	rs55788414	0.932	rs12102728	chr16:81181436	C/T	cg06400318	chr16:81190750	PKD1L2	-0.51	-8.81	-0.33	1.15e-17	Left ventricular obstructive tract defect (maternal effect);
BRCA	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-11.2	-0.41	1.04e-26	Bone mineral density;
BRCA	cis	rs4629710	0.545	rs2077490	chr6:131554184	C/T	cg12606694	chr6:131520996	AKAP7	0.43	9.29	0.34	2.47e-19	Multiple myeloma (IgH translocation);
BRCA	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg11266682	chr4:10021025	SLC2A9	0.45	11.99	0.43	4.9e-30	Bone mineral density;
BRCA	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg06238570	chr21:40685208	BRWD1	-0.47	-9.26	-0.34	3.12e-19	Cognitive function;
BRCA	cis	rs7246657	0.722	rs8110865	chr19:38047387	G/A	cg23950597	chr19:37808831	NA	-0.5	-8.62	-0.32	5.36e-17	Coronary artery calcification;
BRCA	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg27432699	chr2:27873401	GPN1	0.46	9.7	0.36	7.89e-21	Oral cavity cancer;
BRCA	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg00631329	chr6:26305371	NA	-0.46	-13.06	-0.46	9.65e-35	Educational attainment;
BRCA	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg00106254	chr7:1943704	MAD1L1	-0.33	-8.29	-0.31	6.78e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg12463550	chr7:65579703	CRCP	-0.36	-7.87	-0.3	1.53e-14	Aortic root size;
BRCA	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg18850127	chr7:39170497	POU6F2	0.43	9.67	0.36	9.44e-21	IgG glycosylation;
BRCA	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg26384229	chr12:38710491	ALG10B	0.41	9.24	0.34	3.61e-19	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg21535247	chr6:8435926	SLC35B3	-0.37	-8.22	-0.31	1.1e-15	Motion sickness;
BRCA	cis	rs6740322	0.895	rs6738717	chr2:43573670	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-12.11	-0.43	1.54e-30	Coronary artery disease;
BRCA	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05926928	chr17:57297772	GDPD1	1.2	16.07	0.54	4.61e-49	Opioid sensitivity;
BRCA	trans	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-14.69	-0.5	2.65e-42	Platelet distribution width;
BRCA	cis	rs524281	0.861	rs11227415	chr11:65885459	C/T	cg16950941	chr11:66035639	RAB1B	0.39	8.48	0.32	1.6e-16	Electroencephalogram traits;
BRCA	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg12863693	chr15:85201151	NMB	-0.34	-8.08	-0.3	3.17e-15	P wave terminal force;
BRCA	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg18131467	chr2:239335373	ASB1	0.95	34.27	0.8	7.02e-147	Multiple system atrophy;
BRCA	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.22e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1568889	1.000	rs7933332	chr11:28036392	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.84	0.51	5.04e-43	Bipolar disorder;
BRCA	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg08999081	chr20:33150536	PIGU	0.47	13.03	0.46	1.35e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18876405	chr7:65276391	NA	-0.7	-18.11	-0.58	1.82e-59	Aortic root size;
BRCA	cis	rs10267417	0.535	rs6960579	chr7:19869364	A/G	cg07541023	chr7:19748670	TWISTNB	0.51	9.17	0.34	6.47e-19	Night sleep phenotypes;
BRCA	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-8.73	-0.33	2.13e-17	Morning vs. evening chronotype;
BRCA	cis	rs7301826	1.000	rs10848205	chr12:131280714	A/G	cg11011512	chr12:131303247	STX2	0.39	9.66	0.36	1.09e-20	Plasma plasminogen activator levels;
BRCA	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11764359	chr7:65958608	NA	-0.8	-19.46	-0.61	1.39e-66	Aortic root size;
BRCA	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg01283332	chr5:1856932	NA	-0.32	-7.85	-0.3	1.8e-14	Cardiovascular disease risk factors;
BRCA	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.93	0.46	3.84e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6684514	0.961	rs12048077	chr1:156299916	T/A	cg16558208	chr1:156270281	VHLL	0.35	8.08	0.3	3.34e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg21366198	chr4:185655624	MLF1IP	-0.42	-10.23	-0.38	7.34e-23	Kawasaki disease;
BRCA	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.56	11.91	0.43	1.11e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg21138405	chr5:131827807	IRF1	0.36	8.6	0.32	6.16e-17	Asthma (sex interaction);
BRCA	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg12310025	chr6:25882481	NA	-0.44	-10.84	-0.39	3.12e-25	Blood metabolite levels;
BRCA	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg13010199	chr12:38710504	ALG10B	0.53	11.65	0.42	1.36e-28	Heart rate;
BRCA	cis	rs13102973	0.864	rs7435952	chr4:135900983	C/T	cg14419869	chr4:135874104	NA	0.47	9.42	0.35	7.94e-20	Subjective well-being;
BRCA	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg05868516	chr6:26286170	HIST1H4H	-0.48	-10.77	-0.39	5.93e-25	Educational attainment;
BRCA	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg17143192	chr8:8559678	CLDN23	-0.47	-8.59	-0.32	6.78e-17	Obesity-related traits;
BRCA	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg24829409	chr8:58192753	C8orf71	-0.47	-9.08	-0.34	1.35e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.44	11.94	0.43	8.47e-30	Response to bleomycin (chromatid breaks);
BRCA	cis	rs7523273	0.606	rs2724380	chr1:207949682	C/T	cg22525895	chr1:207977042	MIR29B2	0.47	12.02	0.43	3.87e-30	Schizophrenia;
BRCA	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg02659138	chr7:134003124	SLC35B4	-0.33	-9.62	-0.36	1.45e-20	Mean platelet volume;
BRCA	cis	rs8028182	0.636	rs11637068	chr15:75743002	G/A	cg20655648	chr15:75932815	IMP3	0.4	7.86	0.3	1.69e-14	Sudden cardiac arrest;
BRCA	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg12564285	chr5:131593104	PDLIM4	0.37	9.79	0.36	3.66e-21	Breast cancer;
BRCA	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg11502198	chr6:26597334	ABT1	0.48	9.45	0.35	6.1e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg24296786	chr1:45957014	TESK2	-0.46	-10.65	-0.39	1.7e-24	Red blood cell count;Reticulocyte count;
BRCA	trans	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg21659725	chr3:3221576	CRBN	-0.47	-8.55	-0.32	9.32e-17	Menarche (age at onset);
BRCA	cis	rs965469	0.779	rs6051771	chr20:3328271	A/G	cg25506879	chr20:3388711	C20orf194	-0.43	-8.74	-0.33	2.11e-17	IFN-related cytopenia;
BRCA	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.55	10.88	0.4	2.04e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs10193935	1.000	rs10190326	chr2:42388262	A/C	cg27598129	chr2:42591480	NA	0.87	14.58	0.5	8.85e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg12373951	chr3:133503437	NA	0.44	10.49	0.38	7.27e-24	Iron status biomarkers;
BRCA	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg04944784	chr2:26401820	FAM59B	-0.95	-16.17	-0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg08859206	chr1:53392774	SCP2	0.46	10.21	0.37	8.87e-23	Monocyte count;
BRCA	trans	rs526821	0.595	rs517627	chr11:55356489	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-8.08	-0.3	3.19e-15	Pediatric bone mineral density (spine);
BRCA	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	11.44	0.41	1.02e-27	Tonsillectomy;
BRCA	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg17987982	chr7:158820591	NA	-0.43	-8.14	-0.31	2.08e-15	Facial morphology (factor 20);
BRCA	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.3	-0.38	4.09e-23	Psoriasis;
BRCA	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-12.39	-0.44	9.69e-32	Hemoglobin concentration;
BRCA	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg01256987	chr12:42539512	GXYLT1	-0.42	-8.16	-0.31	1.85e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs13082711	0.595	rs4973762	chr3:27364789	A/T	cg02860705	chr3:27208620	NA	0.71	13.37	0.47	3.98e-36	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs10924970	0.967	rs1933246	chr1:235391446	T/C	cg26050004	chr1:235667680	B3GALNT2	0.35	8.76	0.33	1.8e-17	Asthma;
BRCA	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg27147174	chr7:100797783	AP1S1	-0.58	-11.79	-0.42	3.49e-29	Life satisfaction;
BRCA	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg11645453	chr3:52864694	ITIH4	0.37	9.9	0.36	1.4e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs367943	1.000	rs1057827	chr5:112823768	T/C	cg12552261	chr5:112820674	MCC	0.55	12.07	0.43	2.28e-30	Type 2 diabetes;
BRCA	cis	rs6728642	0.808	rs114192053	chr2:97871906	G/A	cg26665480	chr2:98280029	ACTR1B	-0.66	-7.93	-0.3	9.55e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs17253792	0.822	rs10133962	chr14:56066088	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg13397359	chr6:42928475	GNMT	0.66	15.79	0.53	1.12e-47	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs77972916	0.536	rs7589361	chr2:43589328	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-10.17	-0.37	1.29e-22	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	9.18	0.34	5.9e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg19508488	chr2:152266495	RIF1	0.38	8.28	0.31	6.97e-16	Lung cancer;
BRCA	cis	rs858239	0.632	rs7811903	chr7:23119056	A/G	cg23682824	chr7:23144976	KLHL7	0.45	11.82	0.42	2.63e-29	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg24675658	chr1:53192096	ZYG11B	0.68	14.71	0.5	2.16e-42	Monocyte count;
BRCA	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg04944784	chr2:26401820	FAM59B	0.95	16.17	0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg27147174	chr7:100797783	AP1S1	-0.52	-10.57	-0.39	3.69e-24	Life satisfaction;
BRCA	cis	rs11997175	0.624	rs12677772	chr8:33772521	T/C	ch.8.33884649F	chr8:33765107	NA	0.45	10.62	0.39	2.22e-24	Body mass index;
BRCA	cis	rs400736	0.602	rs4573544	chr1:8165247	C/T	cg25007680	chr1:8021821	PARK7	-0.35	-8.75	-0.33	1.9e-17	Response to antidepressants and depression;
BRCA	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.01	0.3	5.36e-15	Breast cancer;
BRCA	trans	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg26384229	chr12:38710491	ALG10B	0.44	10.53	0.38	5.07e-24	Morning vs. evening chronotype;
BRCA	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg17063962	chr7:91808500	NA	0.54	12.64	0.45	7.91e-33	Breast cancer;
BRCA	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg20476274	chr7:133979776	SLC35B4	-0.59	-15.49	-0.52	3.57e-46	Mean platelet volume;
BRCA	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg07917127	chr4:99064746	C4orf37	0.42	7.97	0.3	7.51e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg11266682	chr4:10021025	SLC2A9	-0.38	-10.01	-0.37	5.43e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-9.64	-0.36	1.23e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.51	0.32	1.26e-16	Cognitive ability;
BRCA	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg02951883	chr7:2050386	MAD1L1	-0.57	-13.07	-0.46	8.81e-35	Bipolar disorder and schizophrenia;
BRCA	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg18132916	chr6:79620363	NA	-0.49	-11.1	-0.4	2.67e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg13736514	chr6:26305472	NA	-0.35	-11.59	-0.42	2.44e-28	Educational attainment;
BRCA	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg02187348	chr16:89574699	SPG7	0.44	10.33	0.38	3.02e-23	Multiple myeloma (IgH translocation);
BRCA	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg03733263	chr8:22462867	KIAA1967	1.03	24.94	0.7	2.14e-96	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12292205	chr6:26970375	C6orf41	0.46	8.02	0.3	5.25e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg24296786	chr1:45957014	TESK2	-0.46	-10.6	-0.39	2.74e-24	Red blood cell count;Reticulocyte count;
BRCA	cis	rs16910800	0.731	rs56768542	chr11:23191946	A/G	cg20040320	chr11:23191996	NA	-0.59	-10.19	-0.37	1.11e-22	Cancer;
BRCA	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg25358565	chr5:93447407	FAM172A	1.2	17.51	0.57	2.23e-56	Diabetic retinopathy;
BRCA	cis	rs858239	0.899	rs10085838	chr7:23298415	C/A	cg23682824	chr7:23144976	KLHL7	0.33	8.28	0.31	7.34e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg16230307	chr14:35515116	FAM177A1	0.78	15.56	0.52	1.6e-46	Psoriasis;
BRCA	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg16606324	chr3:10149918	C3orf24	0.46	8.17	0.31	1.69e-15	Alzheimer's disease;
BRCA	cis	rs13046373	0.508	rs2253516	chr21:31993317	C/T	cg06468780	chr21:31798236	KRTAP13-3	0.33	8.13	0.31	2.24e-15	HDL cholesterol;
BRCA	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg18402987	chr7:1209562	NA	0.82	11.83	0.42	2.38e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	cg06064525	chr11:970664	AP2A2	-0.29	-8.49	-0.32	1.47e-16	Alzheimer's disease (late onset);
BRCA	cis	rs2398668	0.570	rs4721548	chr7:2330496	A/G	cg08027265	chr7:2291960	NA	-0.31	-7.9	-0.3	1.25e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	20.07	0.62	7.34e-70	Platelet count;
BRCA	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	16.3	0.54	3.13e-50	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg00071950	chr4:10020882	SLC2A9	0.56	13.87	0.48	1.9e-38	Bone mineral density;
BRCA	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg08885076	chr2:99613938	TSGA10	0.45	10.64	0.39	1.8e-24	Chronic sinus infection;
BRCA	cis	rs7737355	0.947	rs4705894	chr5:131079288	A/G	cg06307176	chr5:131281290	NA	0.51	10.09	0.37	2.52e-22	Life satisfaction;
BRCA	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	24.67	0.7	6.7e-95	Platelet count;
BRCA	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03517284	chr6:25882590	NA	-0.51	-11.54	-0.42	4.09e-28	Blood metabolite levels;
BRCA	cis	rs10504073	0.647	rs341807	chr8:50032676	C/T	cg00325661	chr8:49890786	NA	0.38	10.94	0.4	1.21e-25	Blood metabolite ratios;
BRCA	cis	rs6028335	0.674	rs67379757	chr20:37671051	C/G	cg16355469	chr20:37678765	NA	0.51	9.04	0.34	1.86e-18	Alcohol and nicotine co-dependence;
BRCA	cis	rs870825	0.616	rs6833858	chr4:185639961	C/T	cg04058563	chr4:185651563	MLF1IP	0.8	18.17	0.58	8.56e-60	Blood protein levels;
BRCA	cis	rs7264396	0.887	rs11698935	chr20:34075015	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-7.87	-0.3	1.5e-14	Total cholesterol levels;
BRCA	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.79	-12.49	-0.44	3.49e-32	Platelet count;
BRCA	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg18351406	chr4:77819688	ANKRD56	0.61	13.3	0.47	7.98e-36	Emphysema distribution in smoking;
BRCA	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26314531	chr2:26401878	FAM59B	0.65	11.21	0.41	9.87e-27	Gut microbiome composition (summer);
BRCA	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg00147160	chr1:26503991	CNKSR1	0.29	9.39	0.35	1e-19	Height;
BRCA	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg08917208	chr2:24149416	ATAD2B	1.1	15.51	0.52	2.65e-46	Lymphocyte counts;
BRCA	cis	rs877529	0.625	rs713841	chr22:39529029	A/G	cg18708252	chr22:39545030	CBX7	-0.37	-8.75	-0.33	1.89e-17	Multiple myeloma;
BRCA	cis	rs7818345	1.000	rs11204041	chr8:19291371	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.06	0.3	3.7e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg19623624	chr10:135278901	LOC619207	-0.43	-10.19	-0.37	1.1e-22	Systemic lupus erythematosus;
BRCA	cis	rs4728302	0.838	rs10225454	chr7:133591535	G/C	cg07491979	chr7:133331646	EXOC4	0.36	7.82	0.3	2.17e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.54	8.13	0.31	2.19e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7586879	0.964	rs4077679	chr2:25122852	T/C	cg04586622	chr2:25135609	ADCY3	0.4	9.23	0.34	3.91e-19	Body mass index;
BRCA	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg14847009	chr1:175162515	KIAA0040	0.24	8.84	0.33	9.36e-18	Alcohol dependence;
BRCA	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg17691542	chr6:26056736	HIST1H1C	0.5	10.4	0.38	1.67e-23	Height;
BRCA	cis	rs4566357	0.615	rs3769645	chr2:227913717	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-8.92	-0.33	4.81e-18	Coronary artery disease;
BRCA	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg08999081	chr20:33150536	PIGU	0.44	12.5	0.44	3.03e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg19622623	chr12:86230825	RASSF9	-0.34	-9.49	-0.35	4.41e-20	Major depressive disorder;
BRCA	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg03188948	chr7:1209495	NA	0.6	11.35	0.41	2.54e-27	Longevity;Endometriosis;
BRCA	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg24324837	chr19:49891574	CCDC155	0.52	9.38	0.35	1.09e-19	Multiple sclerosis;
BRCA	cis	rs7587476	0.784	rs13026390	chr2:215687075	C/T	cg04004882	chr2:215674386	BARD1	-0.61	-11.2	-0.41	9.99e-27	Neuroblastoma;
BRCA	cis	rs9309711	0.961	rs11675119	chr2:3476422	C/A	cg16153549	chr2:3496821	NA	-0.38	-8.63	-0.32	4.86e-17	Neurofibrillary tangles;
BRCA	cis	rs858239	0.570	rs6968242	chr7:23167411	T/G	cg23682824	chr7:23144976	KLHL7	0.45	12.03	0.43	3.48e-30	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg16141378	chr3:129829833	LOC729375	-0.32	-7.98	-0.3	6.59e-15	Mood instability;
BRCA	trans	rs7980799	0.649	rs11052732	chr12:33657801	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-11.01	-0.4	5.92e-26	Heart rate;Heart rate variability traits (RMSSD);
BRCA	trans	rs1997103	1.000	rs6977292	chr7:55396335	T/C	cg20935933	chr6:143382018	AIG1	0.6	11.52	0.41	4.77e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg23992470	chr4:843637	GAK	0.53	8.43	0.32	2.28e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7408868	1.000	rs7408868	chr19:15285679	G/C	cg14696996	chr19:15285081	NOTCH3	0.94	13.72	0.48	1.02e-37	Pulse pressure;
BRCA	cis	rs11690935	0.550	rs6730085	chr2:172864845	C/A	cg13550731	chr2:172543902	DYNC1I2	0.49	12.15	0.43	1.02e-30	Schizophrenia;
BRCA	cis	rs9309473	0.519	rs2421574	chr2:73908767	C/G	cg20560298	chr2:73613845	ALMS1	0.38	9.93	0.37	1.01e-21	Metabolite levels;
BRCA	cis	rs4308124	0.708	rs10179596	chr2:111970380	G/A	cg04571233	chr2:111982156	NA	-0.45	-9.58	-0.35	2.04e-20	Vitiligo;
BRCA	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg09877947	chr5:131593287	PDLIM4	0.39	10.02	0.37	4.92e-22	Breast cancer;
BRCA	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.09	-0.3	3.04e-15	Prostate cancer;
BRCA	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg13073564	chr4:8508604	NA	-0.39	-10.61	-0.39	2.43e-24	Response to antineoplastic agents;
BRCA	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.59	-0.77	2.82e-127	Schizophrenia;
BRCA	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.45	-10.05	-0.37	3.62e-22	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	10.62	0.39	2.29e-24	Motion sickness;
BRCA	cis	rs6545883	0.791	rs2600665	chr2:61405795	G/T	cg15711740	chr2:61764176	XPO1	-0.5	-12.32	-0.44	1.96e-31	Tuberculosis;
BRCA	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg18904891	chr8:8559673	CLDN23	0.65	13.1	0.46	6.52e-35	Obesity-related traits;
BRCA	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg16482183	chr6:26056742	HIST1H1C	0.5	10.38	0.38	1.99e-23	Height;
BRCA	cis	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg06521331	chr12:34319734	NA	-0.61	-11.11	-0.4	2.37e-26	Morning vs. evening chronotype;
BRCA	cis	rs77741769	0.571	rs3861797	chr12:121255334	T/C	cg02419362	chr12:121203948	SPPL3	0.33	7.83	0.3	1.98e-14	Mean corpuscular volume;
BRCA	cis	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg06521331	chr12:34319734	NA	-0.57	-11.27	-0.41	5.32e-27	Morning vs. evening chronotype;
BRCA	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg26838691	chr2:24397539	C2orf84	0.48	8.76	0.33	1.78e-17	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24110177	chr3:50126178	RBM5	0.52	15.68	0.53	4e-47	Body mass index;
BRCA	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg13256891	chr4:100009986	ADH5	0.52	9.67	0.36	1e-20	Alcohol dependence;
BRCA	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg00814883	chr7:100076585	TSC22D4	-0.49	-10.28	-0.38	4.61e-23	Platelet count;
BRCA	cis	rs7577696	0.539	rs2280972	chr2:32377961	C/T	cg02381751	chr2:32503542	YIPF4	-0.48	-8.44	-0.32	2.09e-16	Inflammatory biomarkers;
BRCA	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-7.85	-0.3	1.82e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4706831	0.647	rs627240	chr6:80985885	C/A	cg08355045	chr6:80787529	NA	-0.31	-8.08	-0.3	3.24e-15	Joint mobility (Beighton score);
BRCA	cis	rs752010	0.619	rs6702659	chr1:42112236	T/C	cg06885757	chr1:42089581	HIVEP3	0.32	10.6	0.39	2.77e-24	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs1559088	0.501	rs35492529	chr19:33597495	C/G	cg17764715	chr19:33622953	WDR88	0.5	8.06	0.3	3.71e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.5	0.63	3.81e-72	Chronic sinus infection;
BRCA	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg23978390	chr7:1156363	C7orf50	0.4	8.13	0.31	2.2e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg20908204	chr19:46285434	DMPK	-0.29	-8.57	-0.32	7.99e-17	Coronary artery disease;
BRCA	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	11.03	0.4	4.9e-26	Bipolar disorder;
BRCA	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg10224037	chr5:178157518	ZNF354A	0.73	15.57	0.52	1.36e-46	Neutrophil percentage of white cells;
BRCA	cis	rs36051895	0.626	rs3780368	chr9:5093188	G/C	cg02405213	chr9:5042618	JAK2	-0.5	-9.04	-0.34	1.78e-18	Pediatric autoimmune diseases;
BRCA	cis	rs2742417	0.624	rs2673030	chr3:45757900	T/G	cg04837898	chr3:45731254	SACM1L	-0.4	-8.15	-0.31	1.87e-15	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg00677455	chr12:58241039	CTDSP2	0.49	10.24	0.38	7.18e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.39	0.35	1e-19	Tonsillectomy;
BRCA	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.43	-10.94	-0.4	1.14e-25	Schizophrenia;
BRCA	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.85	18.9	0.6	1.31e-63	Smoking behavior;
BRCA	cis	rs10746514	0.813	rs9724918	chr1:232248087	C/T	cg09506761	chr1:232265262	NA	0.48	10.38	0.38	1.95e-23	Response to statin therapy;
BRCA	cis	rs13064411	0.696	rs9836396	chr3:113184282	T/C	cg18753928	chr3:113234510	CCDC52	-0.54	-11.21	-0.41	9.33e-27	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg09555818	chr19:45449301	APOC2	0.47	12.49	0.44	3.52e-32	Blood protein levels;
BRCA	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11890956	chr21:40555474	PSMG1	1.04	29.91	0.76	1.32e-123	Cognitive function;
BRCA	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg06453172	chr10:134556979	INPP5A	-0.6	-11.82	-0.42	2.81e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs9951602	0.512	rs4799246	chr18:76653417	A/G	cg02800362	chr5:177631904	HNRNPAB	0.77	18.16	0.58	9.86e-60	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.52e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs738322	0.600	rs6001035	chr22:38562425	A/G	cg25457927	chr22:38595422	NA	-0.34	-12.44	-0.44	5.79e-32	Cutaneous nevi;
BRCA	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg12927641	chr6:109611667	NA	0.42	10.96	0.4	9.53e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg26536863	chr7:158807979	LOC154822	0.36	8.4	0.32	3e-16	Facial morphology (factor 20);
BRCA	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg05340658	chr4:99064831	C4orf37	-0.55	-10.96	-0.4	9.82e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg24631222	chr15:78858424	CHRNA5	-0.51	-10.13	-0.37	1.87e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg19717773	chr7:2847554	GNA12	-0.43	-9.75	-0.36	4.86e-21	Height;
BRCA	cis	rs9811920	0.809	rs1387647	chr3:99826942	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.52	12.37	0.44	1.18e-31	Axial length;
BRCA	cis	rs7766436	0.885	rs5010014	chr6:22587299	A/G	cg13666174	chr6:22585274	NA	-0.49	-11.6	-0.42	2.25e-28	Coronary artery disease;
BRCA	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24308560	chr3:49941425	MST1R	-0.4	-8.57	-0.32	7.82e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg24812749	chr6:127587940	RNF146	0.69	15.63	0.53	7.31e-47	Breast cancer;
BRCA	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg12310025	chr6:25882481	NA	0.52	12.44	0.44	5.51e-32	Blood metabolite levels;
BRCA	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg21573476	chr21:45109991	RRP1B	-0.31	-8.08	-0.3	3.3e-15	Mean corpuscular volume;
BRCA	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.31	-8.04	-0.3	4.33e-15	Response to antipsychotic treatment;
BRCA	cis	rs2455601	0.638	rs2248245	chr11:8988350	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-7.93	-0.3	9.71e-15	Schizophrenia;
BRCA	cis	rs3771570	1.000	rs60209440	chr2:242260340	G/C	cg21155796	chr2:242212141	HDLBP	0.6	9.38	0.35	1.09e-19	Prostate cancer;
BRCA	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg25482853	chr8:67687455	SGK3	1.06	17.06	0.56	4.86e-54	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg26384229	chr12:38710491	ALG10B	0.74	17.28	0.56	3.44e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg08422745	chr4:174089978	GALNT7	0.76	14.55	0.5	1.27e-41	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg00757033	chr12:89920650	WDR51B	0.54	11.07	0.4	3.49e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg10523679	chr1:76189770	ACADM	0.78	18.6	0.59	4.97e-62	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg22535103	chr8:58192502	C8orf71	-0.61	-13.39	-0.47	3.29e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg25036284	chr2:26402008	FAM59B	-0.83	-14.94	-0.51	1.6e-43	Gut microbiome composition (summer);
BRCA	cis	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05901451	chr6:126070800	HEY2	0.4	9.72	0.36	6.35e-21	Endometrial cancer;
BRCA	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.64	10.52	0.38	5.7e-24	Renal function-related traits (BUN);
BRCA	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-13.88	-0.48	1.77e-38	Blood metabolite levels;
BRCA	trans	rs4650994	1.000	rs4650995	chr1:178517316	C/T	cg05059571	chr16:84539110	KIAA1609	-0.42	-9.6	-0.36	1.71e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg04025307	chr7:1156635	C7orf50	0.46	8.93	0.33	4.45e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18876405	chr7:65276391	NA	0.56	13.33	0.47	6.11e-36	Aortic root size;
BRCA	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.66	10.84	0.39	2.92e-25	Renal function-related traits (BUN);
BRCA	cis	rs12612619	0.659	rs12997235	chr2:27229079	A/C	cg00617064	chr2:27272375	NA	0.31	8.02	0.3	5.1e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs4953318	0.694	rs3768747	chr2:46352058	G/T	cg12428440	chr2:46370979	PRKCE	-0.41	-9.54	-0.35	2.99e-20	Red blood cell count;Hematocrit;Red blood cell traits;
BRCA	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.57	-0.47	4.99e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.29	7.85	0.3	1.81e-14	Monocyte percentage of white cells;
BRCA	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg23285459	chr7:2802560	GNA12	-0.34	-8.6	-0.32	6.27e-17	Height;
BRCA	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg04998671	chr14:104000505	TRMT61A	0.41	9.34	0.35	1.54e-19	Coronary artery disease;
BRCA	cis	rs6426558	0.537	rs648877	chr1:227283614	A/G	cg10327440	chr1:227177885	CDC42BPA	0.48	9.48	0.35	5.08e-20	Neutrophil percentage of white cells;
BRCA	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg21226059	chr5:178986404	RUFY1	0.5	13.8	0.48	4.34e-38	Lung cancer;
BRCA	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg03342759	chr3:160939853	NMD3	-0.62	-13.12	-0.46	5.46e-35	Morning vs. evening chronotype;
BRCA	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg10523679	chr1:76189770	ACADM	0.76	15.66	0.53	5.17e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg24812749	chr6:127587940	RNF146	0.79	15.37	0.52	1.4e-45	Breast cancer;
BRCA	cis	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg07460842	chr6:66804631	NA	0.64	13.82	0.48	3.46e-38	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs4074536	0.625	rs3827737	chr1:116312824	C/T	cg21648376	chr1:116311395	CASQ2	-0.53	-8.51	-0.32	1.23e-16	QRS duration;
BRCA	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-11.92	-0.43	9.74e-30	Tonsillectomy;
BRCA	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg18016565	chr1:150552671	MCL1	0.35	8.41	0.32	2.67e-16	Tonsillectomy;
BRCA	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.12	0.31	2.39e-15	Total cholesterol levels;
BRCA	cis	rs7918232	0.662	rs10741125	chr10:27288925	G/A	cg14240646	chr10:27532245	ACBD5	-0.61	-10.08	-0.37	2.78e-22	Breast cancer;
BRCA	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg03709012	chr19:19516395	GATAD2A	0.8	18.21	0.58	5.59e-60	Tonsillectomy;
BRCA	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg10223061	chr2:219282414	VIL1	-0.27	-8.12	-0.31	2.37e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg09021430	chr5:549028	NA	-0.68	-14.24	-0.49	3.68e-40	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg04362960	chr10:104952993	NT5C2	0.46	10.73	0.39	8.24e-25	Arsenic metabolism;
BRCA	cis	rs6429082	0.791	rs61836205	chr1:235638753	C/G	cg26050004	chr1:235667680	B3GALNT2	0.57	13.44	0.47	1.95e-36	Adiposity;
BRCA	cis	rs501916	0.605	rs11070612	chr15:48073174	C/G	cg16110827	chr15:48056943	SEMA6D	-0.41	-8.76	-0.33	1.72e-17	Inflammatory bowel disease;Ulcerative colitis;
BRCA	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg26384229	chr12:38710491	ALG10B	0.75	16.82	0.55	8.24e-53	Morning vs. evening chronotype;
BRCA	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg02659138	chr7:134003124	SLC35B4	0.31	9.7	0.36	7.37e-21	Mean platelet volume;
BRCA	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.48	8.78	0.33	1.52e-17	Breast cancer;
BRCA	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg14019146	chr3:50243930	SLC38A3	-0.44	-10.61	-0.39	2.5300000000000002e-24	Body mass index;
BRCA	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	12.91	0.45	4.77e-34	Lung cancer in ever smokers;
BRCA	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg12292205	chr6:26970375	C6orf41	0.64	14.68	0.5	2.89e-42	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08704250	chr15:31115839	NA	-0.36	-8.82	-0.33	1.05e-17	Huntington's disease progression;
BRCA	cis	rs10129255	0.500	rs6576229	chr14:107186773	G/A	cg07958169	chr14:107095056	NA	-0.4	-8.67	-0.32	3.43e-17	Kawasaki disease;
BRCA	cis	rs4268898	0.552	rs4665663	chr2:24372139	G/C	cg06627628	chr2:24431161	ITSN2	0.41	8.66	0.32	3.8e-17	Asthma;
BRCA	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12756686	chr19:29218302	NA	0.53	9.14	0.34	8.46e-19	Methadone dose in opioid dependence;
BRCA	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg03342759	chr3:160939853	NMD3	-0.62	-12.99	-0.46	2e-34	Morning vs. evening chronotype;
BRCA	cis	rs7903847	0.642	rs11189180	chr10:99143529	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.66	-0.32	3.7e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.24	0.49	3.5e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.24	0.34	3.64e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12493885	0.818	rs61791543	chr3:153766797	C/G	cg17054900	chr3:154042577	DHX36	-0.49	-8.46	-0.32	1.89e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg04362960	chr10:104952993	NT5C2	0.44	10.01	0.37	5.06e-22	Arsenic metabolism;
BRCA	trans	rs1997103	1.000	rs2177802	chr7:55410789	G/A	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs897080	0.515	rs1085486	chr2:44617324	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	10.06	0.37	3.23e-22	Height;
BRCA	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg04166393	chr7:2884313	GNA12	0.46	8.94	0.33	4.09e-18	Height;
BRCA	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg17063962	chr7:91808500	NA	0.54	12.83	0.45	1.06e-33	Breast cancer;
BRCA	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg15704280	chr7:45808275	SEPT13	0.52	8.96	0.33	3.48e-18	Axial length;
BRCA	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg12419862	chr22:24373484	LOC391322	-0.52	-9.73	-0.36	5.8e-21	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21659725	chr3:3221576	CRBN	0.49	12.38	0.44	1.09e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg23711669	chr6:146136114	FBXO30	0.77	17.6	0.57	8.16e-57	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.42	0.32	2.47e-16	Corneal astigmatism;
BRCA	cis	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg24110177	chr3:50126178	RBM5	-0.37	-9.93	-0.37	1.06e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs72627509	0.857	rs2227901	chr4:57798189	A/G	cg26694713	chr4:57773883	REST	-0.51	-9.91	-0.36	1.25e-21	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	trans	rs1973993	0.691	rs1989141	chr1:96898520	C/T	cg10631902	chr5:14652156	NA	0.59	21.2	0.64	6.24e-76	Weight;
BRCA	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg18402987	chr7:1209562	NA	0.82	11.85	0.42	1.95e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg06115741	chr20:33292138	TP53INP2	0.5	11.12	0.4	2.28e-26	Coronary artery disease;
BRCA	cis	rs6714710	0.603	rs13023980	chr2:98502987	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	13.44	0.47	1.82e-36	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg27170947	chr2:26402098	FAM59B	-0.95	-16.86	-0.55	5.15e-53	Gut microbiome composition (summer);
BRCA	cis	rs11955398	0.501	rs4700387	chr5:60036751	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.37	-8.35	-0.31	4.29e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.15	-0.31	1.86e-15	Total body bone mineral density;
BRCA	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.27	0.49	2.73e-40	Motion sickness;
BRCA	cis	rs778371	0.834	rs778364	chr2:233777859	A/G	cg08000102	chr2:233561755	GIGYF2	0.51	9.72	0.36	6.27e-21	Schizophrenia;
BRCA	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00475322	chr7:917719	C7orf20	0.45	11.65	0.42	1.36e-28	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs7560272	0.588	rs4852965	chr2:73911169	T/C	cg20560298	chr2:73613845	ALMS1	0.38	10.07	0.37	3.2e-22	Schizophrenia;
BRCA	trans	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg25214090	chr10:38739885	LOC399744	0.45	10.4	0.38	1.72e-23	Corneal astigmatism;
BRCA	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-12.54	-0.44	2.18e-32	Personality dimensions;
BRCA	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11764359	chr7:65958608	NA	-0.75	-16.63	-0.55	7.22e-52	Aortic root size;
BRCA	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg23033748	chr14:75592666	NEK9	-0.37	-8.57	-0.32	7.59e-17	Height;
BRCA	trans	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg25214090	chr10:38739885	LOC399744	0.54	12.21	0.43	5.69e-31	Corneal astigmatism;
BRCA	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg01304814	chr3:48885189	PRKAR2A	0.75	7.89	0.3	1.36e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7727544	0.548	rs2069616	chr5:131408077	A/G	cg14196790	chr5:131705035	SLC22A5	0.35	8.77	0.33	1.61e-17	Blood metabolite levels;
BRCA	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg13334819	chr7:99746414	C7orf59	0.34	8.05	0.3	4.16e-15	Coronary artery disease;
BRCA	cis	rs8114671	0.935	rs6060282	chr20:33767066	C/T	cg07148914	chr20:33460835	GGT7	0.39	8.28	0.31	7.4e-16	Height;
BRCA	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg26384229	chr12:38710491	ALG10B	0.54	11.37	0.41	2.1e-27	Morning vs. evening chronotype;
BRCA	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg16339924	chr4:17578868	LAP3	0.66	16.9	0.56	3.1e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg08601574	chr20:25228251	PYGB	0.34	8.36	0.31	3.94e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg03954927	chr1:10346856	KIF1B	0.43	12.76	0.45	2.22e-33	Hepatocellular carcinoma;
BRCA	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg02880119	chr16:3481970	NA	0.48	8.65	0.32	4.15e-17	Body mass index (adult);
BRCA	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-15.95	-0.53	1.8e-48	Alzheimer's disease (late onset);
BRCA	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg12310025	chr6:25882481	NA	0.49	10.84	0.39	2.98e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs17685	0.753	rs10476	chr7:75696420	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	8.41	0.32	2.58e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg24829409	chr8:58192753	C8orf71	-0.59	-12.09	-0.43	1.86e-30	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg23711669	chr6:146136114	FBXO30	0.75	16.92	0.56	2.5e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg23018236	chr17:30244563	NA	-0.52	-9.47	-0.35	5.47e-20	Hip circumference adjusted for BMI;
BRCA	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg19683494	chr5:74908142	NA	0.48	8.32	0.31	5.4e-16	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
BRCA	trans	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg23762105	chr12:34175262	ALG10	0.36	8.45	0.32	2.02e-16	Morning vs. evening chronotype;
BRCA	cis	rs7903847	0.602	rs7916665	chr10:99157573	T/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.46	-0.32	1.77e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.76	-0.5	1.19e-42	Chronic sinus infection;
BRCA	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.39	8.25	0.31	9.01e-16	Total cholesterol levels;
BRCA	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.57	9.69	0.36	8.1899999999999992e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs700651	0.789	rs10184395	chr2:198894285	G/A	cg00792783	chr2:198669748	PLCL1	0.38	8.71	0.33	2.5e-17	Intracranial aneurysm;
BRCA	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg06697600	chr4:7070879	GRPEL1	-0.55	-10.95	-0.4	1.08e-25	Monocyte percentage of white cells;
BRCA	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg03609598	chr5:56110824	MAP3K1	-0.48	-7.96	-0.3	7.6e-15	Initial pursuit acceleration;
BRCA	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.59	7.87	0.3	1.47e-14	Diabetic retinopathy;
BRCA	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg02297831	chr4:17616191	MED28	0.35	8.29	0.31	6.6e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.75	15.41	0.52	8.18e-46	Smoking behavior;
BRCA	cis	rs2997447	0.655	rs12094933	chr1:26374779	T/C	cg19633962	chr1:26362018	EXTL1	-0.53	-9.45	-0.35	6.24e-20	QRS complex (12-leadsum);
BRCA	cis	rs6910061	0.830	rs6456830	chr6:11093298	G/A	cg27233058	chr6:11094804	LOC221710	0.5	8.43	0.32	2.33e-16	Diabetic kidney disease;
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.41	-8.24	-0.31	1.01e-15	Longevity;Endometriosis;
BRCA	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg24829409	chr8:58192753	C8orf71	-0.48	-9.25	-0.34	3.23e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs7246657	0.653	rs10414983	chr19:37665732	T/C	cg23950597	chr19:37808831	NA	-0.66	-10.28	-0.38	4.82e-23	Coronary artery calcification;
BRCA	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg00990874	chr7:1149470	C7orf50	-0.63	-13.42	-0.47	2.38e-36	Bronchopulmonary dysplasia;
BRCA	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg12365402	chr11:9010492	NRIP3	-0.43	-9.2	-0.34	5.11e-19	Hemoglobin concentration;
BRCA	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg26647111	chr11:31128758	NA	-0.45	-9.87	-0.36	1.72e-21	Red blood cell count;
BRCA	cis	rs9400271	0.632	rs6899616	chr6:109584885	A/G	cg01475377	chr6:109611718	NA	-0.44	-10.44	-0.38	1.1e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg05623727	chr3:50126028	RBM5	-0.49	-12.16	-0.43	9.5e-31	Body mass index;
BRCA	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg07395648	chr5:131743802	NA	-0.37	-9.14	-0.34	7.96e-19	Blood metabolite levels;
BRCA	cis	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.43	-9.8	-0.36	3.11e-21	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.06	0.3	3.83e-15	Corneal astigmatism;
BRCA	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg20607287	chr7:12443886	VWDE	-0.51	-8.04	-0.3	4.52e-15	Coronary artery disease;
BRCA	cis	rs4363385	0.782	rs2152993	chr1:152991695	C/A	cg24667326	chr1:152973720	SPRR3	-0.32	-8.88	-0.33	6.73e-18	Inflammatory skin disease;
BRCA	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg23788917	chr6:8435910	SLC35B3	0.49	10.73	0.39	8.29e-25	Motion sickness;
BRCA	trans	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg21659725	chr3:3221576	CRBN	-0.45	-9.78	-0.36	3.79e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg13319975	chr6:146136371	FBXO30	0.58	12.6	0.45	1.15e-32	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.36	-8.38	-0.31	3.41e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2901460	0.509	rs17573253	chr2:62101915	C/T	cg02183531	chr2:62113199	CCT4	0.45	9.14	0.34	8.38e-19	Mean corpuscular volume;
BRCA	cis	rs724568	0.546	rs10188512	chr2:67940962	C/T	cg17945962	chr2:67939740	NA	-0.39	-10.58	-0.39	3.13e-24	Major depressive disorder (broad);
BRCA	trans	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg13395646	chr4:1353034	KIAA1530	-0.51	-9.1	-0.34	1.09e-18	Obesity-related traits;
BRCA	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.81	0.6	3.96e-63	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs1882538	0.564	rs10488164	chr7:133106199	A/G	cg10665199	chr7:133106180	EXOC4	0.47	10.33	0.38	3.21e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg20818283	chr2:191399100	TMEM194B	-0.39	-9.08	-0.34	1.33e-18	Pulse pressure;
BRCA	cis	rs7267979	1.000	rs2500424	chr20:25391969	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.07	-0.3	3.6e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg10223061	chr2:219282414	VIL1	-0.27	-8.08	-0.3	3.13e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg24101359	chr6:42928495	GNMT	0.55	12.63	0.45	8.46e-33	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg00339695	chr16:24857497	SLC5A11	0.54	11.57	0.42	3.12e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs887829	0.569	rs4663333	chr2:234655303	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.32	-8.29	-0.31	6.77e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg18230493	chr5:56204884	C5orf35	-0.73	-14.66	-0.5	3.79e-42	Initial pursuit acceleration;
BRCA	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs17401966	0.838	rs12738317	chr1:10419663	C/T	cg03954927	chr1:10346856	KIF1B	0.43	13.57	0.47	4.97e-37	Hepatocellular carcinoma;
BRCA	cis	rs701145	0.585	rs6440935	chr3:153816976	A/T	cg17054900	chr3:154042577	DHX36	0.53	9.04	0.34	1.88e-18	Coronary artery disease;
BRCA	cis	rs17401966	0.558	rs6541090	chr1:10402842	A/G	cg03954927	chr1:10346856	KIF1B	0.34	10.34	0.38	2.83e-23	Hepatocellular carcinoma;
BRCA	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg13047869	chr3:10149882	C3orf24	0.6	12.77	0.45	1.99e-33	Alzheimer's disease;
BRCA	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg19748678	chr4:122722346	EXOSC9	-0.55	-10.58	-0.39	3.26e-24	Type 2 diabetes;
BRCA	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05901451	chr6:126070800	HEY2	-0.53	-14.02	-0.49	3.81e-39	Brugada syndrome;
BRCA	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg00074818	chr8:8560427	CLDN23	0.38	8.35	0.31	4.17e-16	Obesity-related traits;
BRCA	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	9.45	0.35	6.23e-20	Lung cancer in ever smokers;
BRCA	cis	rs4302748	0.862	rs11772400	chr7:36186371	G/C	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs6782228	0.606	rs2712417	chr3:128345179	A/G	cg16766828	chr3:128327626	NA	-0.42	-9.51	-0.35	3.95e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.3	0.35	2.21e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1691799	0.899	rs1168301	chr12:66736771	C/T	cg16791601	chr12:66731901	HELB	-0.63	-16.85	-0.55	5.7e-53	White blood cell count (basophil);
BRCA	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg01528321	chr10:82214614	TSPAN14	0.69	14.59	0.5	7.96e-42	Post bronchodilator FEV1;
BRCA	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03517284	chr6:25882590	NA	-0.47	-10.71	-0.39	9.52e-25	Blood metabolite levels;
BRCA	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.07	-0.37	3.01e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.91e-24	Motion sickness;
BRCA	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11644478	chr21:40555479	PSMG1	0.76	15.53	0.52	2.29e-46	Cognitive function;
BRCA	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs629535	0.862	rs662725	chr8:70029616	C/T	cg21567404	chr3:27674614	NA	1.0	20.96	0.64	1.17e-74	Dupuytren's disease;
BRCA	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg23933602	chr10:16859644	RSU1	0.54	8.76	0.33	1.77e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs10992471	0.528	rs10117627	chr9:95203953	G/A	cg14631576	chr9:95140430	CENPP	-0.34	-8.48	-0.32	1.51e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg10932868	chr11:921992	NA	0.49	12.38	0.44	1.09e-31	Alzheimer's disease (late onset);
BRCA	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg15782153	chr7:917662	C7orf20	0.4	9.42	0.35	7.84e-20	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.41	8.41	0.32	2.66e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9503598	0.636	rs6596977	chr6:3466254	G/A	cg00476032	chr6:3446245	SLC22A23	0.38	9.29	0.34	2.47e-19	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	trans	rs7980799	0.682	rs1351682	chr12:33598775	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-10.62	-0.39	2.29e-24	Heart rate;Heart rate variability traits (RMSSD);
BRCA	trans	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.3	0.31	6e-16	Corneal astigmatism;
BRCA	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg24812749	chr6:127587940	RNF146	0.8	15.44	0.52	6.04e-46	Breast cancer;
BRCA	cis	rs4268898	0.760	rs7597919	chr2:24563646	A/G	cg06627628	chr2:24431161	ITSN2	0.4	8.55	0.32	9.25e-17	Asthma;
BRCA	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.02	-0.3	5.22e-15	Depression;
BRCA	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg26384229	chr12:38710491	ALG10B	0.59	13.61	0.47	3.04e-37	Morning vs. evening chronotype;
BRCA	cis	rs1832871	0.711	rs9459954	chr6:158709345	G/T	cg07165851	chr6:158734300	TULP4	0.63	13.03	0.46	1.37e-34	Height;
BRCA	cis	rs4363385	0.818	rs10788852	chr1:153000491	C/G	cg24667326	chr1:152973720	SPRR3	-0.33	-9.0	-0.34	2.49e-18	Inflammatory skin disease;
BRCA	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.41	-9.62	-0.36	1.48e-20	Longevity;Endometriosis;
BRCA	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg05347473	chr6:146136440	FBXO30	-0.41	-8.12	-0.31	2.36e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-12.09	-0.43	1.86e-30	Mood instability;
BRCA	cis	rs7729447	0.813	rs4867470	chr5:32692536	C/A	cg16267343	chr5:32710456	NPR3	0.44	9.19	0.34	5.38e-19	Blood pressure;
BRCA	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg09184832	chr6:79620586	NA	-0.53	-11.74	-0.42	5.65e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs6728642	0.908	rs7588921	chr2:98021001	C/T	cg26665480	chr2:98280029	ACTR1B	-0.55	-8.32	-0.31	5.48e-16	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs13082711	0.911	rs73046191	chr3:27454398	T/A	cg02860705	chr3:27208620	NA	0.53	10.65	0.39	1.65e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg12573674	chr2:1569213	NA	-0.48	-9.47	-0.35	5.23e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg01529538	chr14:23388837	RBM23	0.42	11.23	0.41	7.61e-27	Cognitive ability (multi-trait analysis);
BRCA	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg03188948	chr7:1209495	NA	0.87	11.85	0.42	2.11e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg19729930	chr2:74357872	NA	0.59	14.48	0.5	2.66e-41	Gestational age at birth (maternal effect);
BRCA	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.74	0.67	2.6e-84	Chronic sinus infection;
BRCA	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg11833968	chr6:79620685	NA	-0.4	-8.9	-0.33	5.7e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg26528668	chr16:1614120	IFT140	0.37	8.6	0.32	6.11e-17	Coronary artery disease;
BRCA	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18876405	chr7:65276391	NA	-0.57	-13.53	-0.47	7.72e-37	Aortic root size;
BRCA	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.37	0.35	1.25e-19	Morning vs. evening chronotype;
BRCA	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg26874164	chr19:58962979	ZNF324B	0.47	10.05	0.37	3.67e-22	Uric acid clearance;
BRCA	cis	rs7927771	0.524	rs11039345	chr11:47720228	A/G	cg20307385	chr11:47447363	PSMC3	0.42	9.45	0.35	6.42e-20	Subjective well-being;
BRCA	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.06	0.49	2.58e-39	Motion sickness;
BRCA	cis	rs4566357	0.615	rs12474622	chr2:227912793	A/G	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.08	-0.3	3.32e-15	Coronary artery disease;
BRCA	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg03354898	chr7:1950403	MAD1L1	-0.4	-8.43	-0.32	2.26e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.63	0.32	4.73e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10267417	0.603	rs34087364	chr7:19860293	A/C	cg05791153	chr7:19748676	TWISTNB	0.5	9.53	0.35	3.2e-20	Night sleep phenotypes;
BRCA	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg08470875	chr2:26401718	FAM59B	0.76	11.99	0.43	5.11e-30	Gut microbiome composition (summer);
BRCA	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg04450456	chr4:17643702	FAM184B	0.37	10.91	0.4	1.54e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg13010199	chr12:38710504	ALG10B	-0.39	-8.9	-0.33	5.76e-18	Morning vs. evening chronotype;
BRCA	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	11.36	0.41	2.35e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.51e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg09184832	chr6:79620586	NA	-0.48	-10.52	-0.38	5.72e-24	Intelligence (multi-trait analysis);
BRCA	trans	rs2018683	0.584	rs4722880	chr7:28999197	C/T	cg19402173	chr7:128379420	CALU	-0.49	-11.79	-0.42	3.45e-29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs12611088	0.571	rs7252955	chr19:44021766	A/T	cg15012607	chr19:44012195	ETHE1	-0.35	-9.13	-0.34	8.66e-19	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg22875332	chr1:76189707	ACADM	0.68	14.4	0.5	6.06e-41	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7617773	0.817	rs11707606	chr3:48237087	A/C	cg11946769	chr3:48343235	NME6	0.68	14.11	0.49	1.58e-39	Coronary artery disease;
BRCA	cis	rs36051895	0.632	rs11791281	chr9:5172540	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-9.57	-0.35	2.24e-20	Pediatric autoimmune diseases;
BRCA	cis	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg07460842	chr6:66804631	NA	0.92	18.29	0.59	2.09e-60	Exhaled nitric oxide output;
BRCA	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	14.63	0.5	5.31e-42	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg05347473	chr6:146136440	FBXO30	0.43	8.76	0.33	1.7e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6723226	0.721	rs10172510	chr2:32620888	A/G	cg02381751	chr2:32503542	YIPF4	0.46	10.03	0.37	4.36e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg13114125	chr14:105738426	BRF1	-0.46	-10.04	-0.37	4.16e-22	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.29	0.31	6.45e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg16339924	chr4:17578868	LAP3	0.57	13.93	0.48	1.08e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2625529	0.824	rs7170461	chr15:72218599	C/A	cg16672083	chr15:72433130	SENP8	-0.83	-17.2	-0.56	8.64e-55	Red blood cell count;
BRCA	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg22508957	chr16:3507546	NAT15	0.47	11.54	0.42	4.05e-28	Tuberculosis;
BRCA	cis	rs528301	0.833	rs340498	chr2:45135885	A/C	cg02372786	chr2:45167549	SIX3	-0.45	-10.86	-0.39	2.41e-25	Alcohol and nicotine co-dependence;
BRCA	trans	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.69	-16.68	-0.55	3.79e-52	Obesity-related traits;
BRCA	cis	rs1595825	0.891	rs73056823	chr2:198769788	T/C	cg19156104	chr2:198669113	PLCL1	-0.41	-7.82	-0.3	2.17e-14	Ulcerative colitis;
BRCA	cis	rs10193935	0.901	rs17029344	chr2:42444287	T/C	cg27598129	chr2:42591480	NA	-0.94	-15.2	-0.52	8.77e-45	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg22467129	chr15:76604101	ETFA	-0.39	-8.79	-0.33	1.34e-17	Blood metabolite levels;
BRCA	trans	rs6479891	1.000	rs9414780	chr10:65001433	G/T	cg14819942	chr15:35414228	NA	0.35	8.64	0.32	4.39e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.59	-10.84	-0.39	2.98e-25	Renal function-related traits (BUN);
BRCA	cis	rs77633900	0.614	rs280012	chr15:76974854	G/T	cg21673338	chr15:77095150	SCAPER	-0.53	-9.74	-0.36	5.55e-21	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg08999081	chr20:33150536	PIGU	-0.47	-12.95	-0.46	3.13e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs3784262	0.669	rs3742960	chr15:58248088	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.21	-0.37	9.27e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs17092148	1.000	rs60789653	chr20:33447162	G/A	cg16810054	chr20:33298113	TP53INP2	0.47	10.3	0.38	3.91e-23	Neuroticism;
BRCA	cis	rs2562152	0.706	rs216598	chr16:108585	T/C	cg02949481	chr16:131562	MPG	0.58	9.32	0.35	1.8e-19	Glioblastoma;
BRCA	cis	rs9394152	0.845	rs9366823	chr6:33471059	C/T	cg13560919	chr6:33536144	NA	0.62	12.76	0.45	2.26e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg08470875	chr2:26401718	FAM59B	-0.64	-9.57	-0.35	2.34e-20	Gut microbiome composition (summer);
BRCA	trans	rs12517041	1.000	rs1820748	chr5:23323355	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.95	-0.3	8.47e-15	Calcium levels;
BRCA	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg15832292	chr6:96025679	MANEA	0.51	8.67	0.32	3.66e-17	Behavioural disinhibition (generation interaction);
BRCA	cis	rs6543140	0.572	rs17027173	chr2:103057043	G/A	cg04239558	chr2:103089729	SLC9A4	0.33	7.97	0.3	7.05e-15	Blood protein levels;
BRCA	cis	rs12545109	0.837	rs1437277	chr8:57356734	T/C	cg09654669	chr8:57350985	NA	-0.43	-8.14	-0.31	2.01e-15	Obesity-related traits;
BRCA	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg15103426	chr22:29168792	CCDC117	0.52	12.36	0.44	1.34e-31	Lymphocyte counts;
BRCA	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg20607798	chr8:58055168	NA	0.47	8.02	0.3	5.03e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg05472934	chr7:22766657	IL6	0.61	15.55	0.52	1.79e-46	Lung cancer;
BRCA	cis	rs72772090	0.539	rs114006288	chr5:96118004	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.18	-0.43	7.64e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg24642439	chr20:33292090	TP53INP2	-0.43	-8.65	-0.32	4.21e-17	Height;
BRCA	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg21573476	chr21:45109991	RRP1B	-0.36	-9.06	-0.34	1.56e-18	Mean corpuscular volume;
BRCA	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00166722	chr3:10149974	C3orf24	0.67	13.38	0.47	3.6e-36	Alzheimer's disease;
BRCA	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg07636037	chr3:49044803	WDR6	-0.6	-8.69	-0.33	2.99e-17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg18154014	chr19:37997991	ZNF793	0.56	10.74	0.39	7.29e-25	Coronary artery calcification;
BRCA	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg19628046	chr18:33552617	C18orf21	0.56	11.05	0.4	4.43e-26	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs7560272	0.538	rs2012574	chr2:73928366	G/C	cg20560298	chr2:73613845	ALMS1	0.35	8.96	0.33	3.41e-18	Schizophrenia;
BRCA	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg22705602	chr4:152727874	NA	-0.38	-10.5	-0.38	6.91e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg06618935	chr21:46677482	NA	-0.38	-8.49	-0.32	1.48e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg08888203	chr3:10149979	C3orf24	0.56	11.7	0.42	9.05e-29	Alzheimer's disease;
BRCA	cis	rs10465746	0.570	rs1886769	chr1:84471134	C/A	cg10977910	chr1:84465055	TTLL7	0.54	11.17	0.4	1.37e-26	Obesity-related traits;
BRCA	cis	rs10838687	0.932	rs4752973	chr11:47269159	T/C	cg25783544	chr11:47291846	MADD	0.43	8.38	0.31	3.44e-16	Proinsulin levels;
BRCA	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg06212747	chr3:49208901	KLHDC8B	0.48	9.83	0.36	2.56e-21	Parkinson's disease;
BRCA	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	7.93e-19	Lymphocyte counts;
BRCA	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg21475434	chr5:93447410	FAM172A	0.68	8.8	0.33	1.26e-17	Diabetic retinopathy;
BRCA	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg05313129	chr8:58192883	C8orf71	-0.48	-9.85	-0.36	2.12e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg11584989	chr19:19387371	SF4	0.55	12.27	0.44	3.08e-31	Bipolar disorder;
BRCA	trans	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg25214090	chr10:38739885	LOC399744	0.57	13.01	0.46	1.79e-34	Corneal astigmatism;
BRCA	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg24558204	chr6:135376177	HBS1L	0.45	12.35	0.44	1.45e-31	Red blood cell count;
BRCA	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg08601574	chr20:25228251	PYGB	-0.39	-9.01	-0.34	2.34e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-9.78	-0.36	3.77e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg06238570	chr21:40685208	BRWD1	-0.39	-7.94	-0.3	9.01e-15	Menarche (age at onset);
BRCA	cis	rs17604090	0.793	rs66956566	chr7:29688702	A/G	cg19413766	chr7:29689036	LOC646762	-0.5	-8.12	-0.31	2.43e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs3784262	0.527	rs4646557	chr15:58354697	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-9.99	-0.37	6.16e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg03676636	chr4:99064102	C4orf37	0.23	8.2	0.31	1.31e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05901451	chr6:126070800	HEY2	-0.56	-15.2	-0.52	9.59e-45	Brugada syndrome;
BRCA	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg16606324	chr3:10149918	C3orf24	0.57	10.13	0.37	1.86e-22	Alzheimer's disease;
BRCA	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg13385521	chr17:29058706	SUZ12P	-0.75	-11.68	-0.42	1.05e-28	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs6840258	1.000	rs56395939	chr4:87963633	T/G	cg08197287	chr4:87952173	AFF1	-0.47	-9.25	-0.34	3.45e-19	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs3925075	1.000	rs9673405	chr16:31347599	A/C	cg02846316	chr16:31340340	ITGAM	0.53	13.04	0.46	1.2e-34	IgA nephropathy;
BRCA	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	cg20946044	chr11:1010712	AP2A2	-0.37	-7.94	-0.3	9.33e-15	Alzheimer's disease (late onset);
BRCA	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg21535247	chr6:8435926	SLC35B3	0.41	9.36	0.35	1.36e-19	Motion sickness;
BRCA	cis	rs724568	0.509	rs10203976	chr2:67941638	T/G	cg17945962	chr2:67939740	NA	-0.39	-10.56	-0.39	3.9e-24	Major depressive disorder (broad);
BRCA	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24549020	chr5:56110836	MAP3K1	0.64	13.06	0.46	9.94e-35	Initial pursuit acceleration;
BRCA	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	8.14	0.31	2.1e-15	Diabetic retinopathy;
BRCA	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg21724239	chr8:58056113	NA	0.57	9.29	0.34	2.48e-19	Developmental language disorder (linguistic errors);
BRCA	trans	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg25206134	chr2:45395956	NA	-0.53	-9.1	-0.34	1.16e-18	Bipolar disorder;
BRCA	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg19183879	chr15:85880815	NA	-0.32	-7.85	-0.3	1.7e-14	Coronary artery disease;
BRCA	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg11645453	chr3:52864694	ITIH4	0.45	11.26	0.41	5.99e-27	Schizophrenia;
BRCA	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg11301795	chr4:187892539	NA	-0.26	-8.71	-0.33	2.57e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.3	-0.31	6.42e-16	Bipolar disorder;
BRCA	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	12.44	0.44	6e-32	Electrocardiographic conduction measures;
BRCA	cis	rs1163251	0.837	rs595283	chr1:120247887	C/G	cg19096424	chr1:120255104	PHGDH	-0.46	-10.58	-0.39	3.24e-24	Blood metabolite levels;
BRCA	cis	rs9420	0.925	rs10896636	chr11:57448032	C/G	cg19752551	chr11:57585705	CTNND1	-0.5	-12.23	-0.44	4.91e-31	Schizophrenia;
BRCA	cis	rs7254114	0.578	rs12980863	chr19:11309871	C/T	cg02815516	chr19:11306319	KANK2	-0.34	-10.18	-0.37	1.14e-22	Immature fraction of reticulocytes;
BRCA	trans	rs8073060	0.614	rs72829932	chr17:34055935	A/G	cg19694781	chr19:47549865	TMEM160	1.02	19.12	0.6	9e-65	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg12463550	chr7:65579703	CRCP	0.37	7.92	0.3	1.03e-14	Aortic root size;
BRCA	cis	rs17095355	0.818	rs12571549	chr10:111770013	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.41	-9.32	-0.35	1.86e-19	Biliary atresia;
BRCA	cis	rs4660306	0.961	rs4660864	chr1:45966582	C/T	cg24296786	chr1:45957014	TESK2	0.41	8.24	0.31	9.85e-16	Homocysteine levels;
BRCA	trans	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	10.02	0.37	4.87e-22	Mean corpuscular volume;
BRCA	cis	rs922692	0.715	rs2277546	chr15:79083376	C/A	cg04896959	chr15:78267971	NA	0.37	8.66	0.32	3.84e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg08822215	chr16:89438651	ANKRD11	-0.47	-10.61	-0.39	2.4e-24	Multiple myeloma (IgH translocation);
BRCA	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	11.25	0.41	6.58e-27	Platelet count;
BRCA	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg24747557	chr10:131355152	MGMT	0.33	8.36	0.31	3.93e-16	Response to temozolomide;
BRCA	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg08422745	chr4:174089978	GALNT7	0.81	15.23	0.52	6.2e-45	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	17.6	0.57	8e-57	Electrocardiographic conduction measures;
BRCA	trans	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	11.68	0.42	1.01e-28	Exhaled nitric oxide output;
BRCA	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg07636037	chr3:49044803	WDR6	0.98	29.1	0.75	3.3e-119	Parkinson's disease;
BRCA	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11764359	chr7:65958608	NA	-0.75	-16.67	-0.55	4.55e-52	Aortic root size;
BRCA	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg11941060	chr3:133502564	NA	0.34	7.98	0.3	6.92e-15	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.71	-15.26	-0.52	4.88e-45	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg20283391	chr11:68216788	NA	-0.45	-9.08	-0.34	1.36e-18	Total body bone mineral density;
BRCA	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg04607235	chr12:12878440	APOLD1	0.69	10.71	0.39	9.63e-25	Systemic lupus erythematosus;
BRCA	cis	rs3862030	0.720	rs7341995	chr10:104223831	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-13.01	-0.46	1.63e-34	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs13136331	0.532	rs2615492	chr4:88569491	A/G	cg22416721	chr4:88570574	DMP1	-0.6	-14.85	-0.51	4.7e-43	Sitting height ratio;
BRCA	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg02734326	chr4:10020555	SLC2A9	0.41	8.96	0.33	3.56e-18	Bone mineral density;
BRCA	cis	rs380904	0.552	rs10099003	chr8:144645460	C/T	cg13399544	chr8:144649678	C8orf73	-0.34	-7.85	-0.3	1.82e-14	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.62	-13.59	-0.47	3.95e-37	Lung cancer;
BRCA	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg03060546	chr3:49711283	APEH	0.6	10.21	0.37	8.9e-23	Menarche (age at onset);
BRCA	cis	rs3125734	0.582	rs7904465	chr10:64002393	G/A	cg09941381	chr10:64027924	RTKN2	-0.28	-7.94	-0.3	8.91e-15	Rheumatoid arthritis;
BRCA	cis	rs2637030	0.559	rs256095	chr5:52972669	C/T	cg06476337	chr5:52856530	NDUFS4	-0.35	-7.83	-0.3	2.05e-14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg22906224	chr7:99728672	NA	0.49	9.22	0.34	4.41e-19	Coronary artery disease;
BRCA	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg16576597	chr16:28551801	NUPR1	0.3	8.44	0.32	2.14e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs8014204	0.762	rs7144654	chr14:75298637	A/G	cg06637938	chr14:75390232	RPS6KL1	0.42	8.69	0.32	3.15e-17	Caffeine consumption;
BRCA	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg24531977	chr5:56204891	C5orf35	-0.43	-8.91	-0.33	5.37e-18	Coronary artery disease;
BRCA	cis	rs12620999	0.774	rs6711726	chr2:238101795	C/T	cg23555395	chr2:238036564	NA	-0.37	-8.62	-0.32	5.07e-17	Systemic lupus erythematosus;
BRCA	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	20.92	0.64	1.93e-74	Smoking behavior;
BRCA	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11890956	chr21:40555474	PSMG1	-0.86	-22.18	-0.66	2.73e-81	Cognitive function;
BRCA	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.42	-8.16	-0.31	1.76e-15	Iron status biomarkers;
BRCA	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg20587970	chr11:113659929	NA	-1.35	-24.74	-0.7	2.76e-95	Hip circumference adjusted for BMI;
BRCA	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg24578937	chr1:2090814	PRKCZ	0.57	17.81	0.58	6.82e-58	Height;
BRCA	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	8.44	0.32	2.05e-16	Axial length;
BRCA	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06544989	chr22:39130855	UNC84B	-0.35	-8.43	-0.32	2.36e-16	Menopause (age at onset);
BRCA	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.52	-0.32	1.18e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg26384229	chr12:38710491	ALG10B	0.69	15.68	0.53	4.01e-47	Bladder cancer;
BRCA	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg16950941	chr11:66035639	RAB1B	0.45	11.83	0.42	2.5e-29	Gout;
BRCA	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg11279151	chr3:101281821	RG9MTD1	0.5	10.77	0.39	5.89e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	10.47	0.38	8.48e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg25214090	chr10:38739885	LOC399744	0.56	12.83	0.45	1.08e-33	Corneal astigmatism;
BRCA	trans	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg25214090	chr10:38739885	LOC399744	0.54	10.99	0.4	7.59e-26	Corneal astigmatism;
BRCA	cis	rs701145	0.585	rs938989	chr3:153788222	A/G	cg17054900	chr3:154042577	DHX36	0.56	8.24	0.31	9.8e-16	Coronary artery disease;
BRCA	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg11663144	chr21:46675770	NA	-0.6	-13.84	-0.48	2.6e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-9.65	-0.36	1.14e-20	Axial length;
BRCA	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg23711669	chr6:146136114	FBXO30	0.72	17.38	0.57	1.09e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg00012203	chr2:219082015	ARPC2	0.59	12.31	0.44	2.23e-31	Colorectal cancer;
BRCA	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg25457927	chr22:38595422	NA	-0.31	-11.83	-0.42	2.46e-29	Cutaneous nevi;
BRCA	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg00012203	chr2:219082015	ARPC2	-0.57	-12.11	-0.43	1.56e-30	Colorectal cancer;
BRCA	cis	rs4728302	0.869	rs10224683	chr7:133590937	A/G	cg07491979	chr7:133331646	EXOC4	-0.36	-7.87	-0.3	1.58e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23248424	chr5:179741104	GFPT2	0.64	13.59	0.47	3.96e-37	Height;
BRCA	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg22875332	chr1:76189707	ACADM	0.69	14.93	0.51	1.77e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2835872	0.758	rs1787396	chr21:39036487	A/C	cg06728970	chr21:39037746	KCNJ6	0.45	12.83	0.45	1.14e-33	Electroencephalographic traits in alcoholism;
BRCA	cis	rs735539	0.645	rs1052209	chr13:21216850	C/T	cg27499820	chr13:21296301	IL17D	0.44	8.44	0.32	2.19e-16	Dental caries;
BRCA	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	11.34	0.41	2.88e-27	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.39	-7.9	-0.3	1.2e-14	Response to fenofibrate (adiponectin levels);
BRCA	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg10932868	chr11:921992	NA	0.48	12.32	0.44	1.92e-31	Alzheimer's disease (late onset);
BRCA	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg00166722	chr3:10149974	C3orf24	0.64	11.27	0.41	5.44e-27	Alzheimer's disease;
BRCA	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24531977	chr5:56204891	C5orf35	-0.88	-19.08	-0.6	1.37e-64	Initial pursuit acceleration;
BRCA	cis	rs9815354	0.812	rs73071239	chr3:41992610	C/A	cg03022575	chr3:42003672	ULK4	0.7	9.76	0.36	4.45e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg02734326	chr4:10020555	SLC2A9	0.35	7.87	0.3	1.47e-14	Bone mineral density;
BRCA	trans	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-9.01	-0.34	2.31e-18	Retinal vascular caliber;
BRCA	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg18132916	chr6:79620363	NA	-0.47	-10.73	-0.39	8.25e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs870825	0.616	rs28497285	chr4:185629169	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg07917127	chr4:99064746	C4orf37	0.44	8.1	0.31	2.86e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg13010199	chr12:38710504	ALG10B	0.51	10.61	0.39	2.57e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6700896	0.898	rs1938495	chr1:66106469	A/G	cg04111102	chr1:66153794	NA	0.34	8.45	0.32	1.97e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18876405	chr7:65276391	NA	0.55	13.14	0.46	4.51e-35	Aortic root size;
BRCA	trans	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-15.49	-0.52	3.38e-46	Obesity-related traits;
BRCA	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg04398451	chr17:18023971	MYO15A	0.45	9.19	0.34	5.51e-19	Body mass index;
BRCA	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.69	14.46	0.5	3.43e-41	Total cholesterol levels;
BRCA	cis	rs67981189	0.634	rs2526875	chr14:71378360	G/C	cg15816911	chr14:71606274	NA	-0.37	-8.45	-0.32	2.03e-16	Schizophrenia;
BRCA	cis	rs2070433	0.539	rs56157650	chr21:47957959	T/C	cg12379764	chr21:47803548	PCNT	0.59	12.56	0.44	1.77e-32	Lymphocyte counts;
BRCA	cis	rs72792276	1.000	rs78529289	chr5:127405378	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	10.37	0.38	2.21e-23	Red cell distribution width;
BRCA	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg04362960	chr10:104952993	NT5C2	0.45	10.43	0.38	1.29e-23	Arsenic metabolism;
BRCA	cis	rs3820928	0.874	rs4675131	chr2:227836742	T/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.37	-0.31	3.68e-16	Pulmonary function;
BRCA	cis	rs6138458	1.000	rs7268095	chr20:24972333	C/T	cg26195577	chr20:24973756	C20orf3	1.03	28.97	0.75	1.68e-118	Blood protein levels;
BRCA	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg01884057	chr2:25150051	NA	0.35	9.26	0.34	3.07e-19	Body mass index;
BRCA	cis	rs965469	1.000	rs6051790	chr20:3342994	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-10.52	-0.38	5.66e-24	IFN-related cytopenia;
BRCA	cis	rs483180	0.855	rs562038	chr1:120254545	G/C	cg19096424	chr1:120255104	PHGDH	0.62	13.28	0.47	9.88e-36	Macular telangiectasia type 2;
BRCA	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg13073564	chr4:8508604	NA	-0.44	-11.99	-0.43	4.87e-30	Response to antineoplastic agents;
BRCA	cis	rs9341808	0.718	rs1324123	chr6:80932894	G/A	cg08355045	chr6:80787529	NA	0.39	9.98	0.37	6.98e-22	Sitting height ratio;
BRCA	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg21699342	chr2:239360505	ASB1	0.5	11.52	0.41	5.08e-28	Multiple system atrophy;
BRCA	cis	rs733592	0.929	rs4760678	chr12:48461581	T/C	cg24011408	chr12:48396354	COL2A1	-0.46	-9.79	-0.36	3.39e-21	Plateletcrit;
BRCA	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-13.59	-0.47	3.99e-37	Developmental language disorder (linguistic errors);
BRCA	trans	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg25214090	chr10:38739885	LOC399744	0.35	7.92	0.3	1.04e-14	Diastolic blood pressure;
BRCA	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg04025307	chr7:1156635	C7orf50	0.59	9.23	0.34	4.08e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24549020	chr5:56110836	MAP3K1	0.6	12.16	0.43	9.47e-31	Initial pursuit acceleration;
BRCA	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.57	0.45	1.51e-32	Bipolar disorder;
BRCA	trans	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.85	0.3	1.76e-14	Endometrial cancer;
BRCA	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg03354898	chr7:1950403	MAD1L1	-0.39	-8.19	-0.31	1.38e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg04688828	chr8:143858612	LYNX1	-0.38	-8.14	-0.31	2.1e-15	Urinary tract infection frequency;
BRCA	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg12826209	chr6:26865740	GUSBL1	0.56	9.25	0.34	3.28e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg16325326	chr1:53192061	ZYG11B	-0.73	-19.03	-0.6	2.63e-64	Monocyte count;
BRCA	cis	rs7635838	0.617	rs346076	chr3:11292682	A/G	cg00170343	chr3:11313890	ATG7	-0.47	-9.82	-0.36	2.79e-21	HDL cholesterol;
BRCA	trans	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg16011800	chr17:1958478	HIC1	-0.51	-8.48	-0.32	1.5e-16	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs6484504	0.576	rs158136	chr11:31220712	C/T	cg26647111	chr11:31128758	NA	-0.44	-9.67	-0.36	9.59e-21	Red blood cell count;
BRCA	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg20607287	chr7:12443886	VWDE	-0.51	-8.17	-0.31	1.69e-15	Coronary artery disease;
BRCA	trans	rs877282	0.583	rs112372193	chr10:826602	A/G	cg22713356	chr15:30763199	NA	0.95	15.33	0.52	2.01e-45	Uric acid levels;
BRCA	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08048268	chr3:133502702	NA	-0.33	-8.26	-0.31	8.58e-16	Iron status biomarkers;
BRCA	cis	rs679087	1.000	rs302315	chr12:29919054	G/C	cg14258853	chr12:29935411	TMTC1	-0.43	-9.05	-0.34	1.71e-18	Schizophrenia;
BRCA	cis	rs7903847	0.642	rs10882911	chr10:99138064	A/C	cg20016023	chr10:99160130	RRP12	-0.27	-8.59	-0.32	6.67e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg23625390	chr15:77176239	SCAPER	-0.54	-13.61	-0.47	3.16e-37	Blood metabolite levels;
BRCA	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.26	-0.34	3.15e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-12.1	-0.43	1.71e-30	Response to antipsychotic treatment;
BRCA	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.66	0.32	3.82e-17	Rheumatoid arthritis;
BRCA	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg12311346	chr5:56204834	C5orf35	0.77	15.15	0.51	1.52e-44	Initial pursuit acceleration;
BRCA	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg09624528	chr10:1369823	ADARB2	0.44	8.63	0.32	5.05e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs939658	1.000	rs8027411	chr15:79461029	G/T	cg17916960	chr15:79447300	NA	0.39	9.95	0.37	8.63e-22	Refractive error;
BRCA	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg11822812	chr5:140052017	DND1	-0.32	-8.74	-0.33	2.05e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10802521	chr3:52805072	NEK4	-0.31	-7.91	-0.3	1.14e-14	Bipolar disorder;
BRCA	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.36	7.86	0.3	1.66e-14	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg09469691	chr10:81107165	PPIF	0.52	10.69	0.39	1.24e-24	Height;
BRCA	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.97	0.3	7.09e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.56	-0.32	8.09e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg19257562	chr1:2043853	PRKCZ	-0.33	-8.73	-0.33	2.19e-17	Height;
BRCA	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg09469691	chr10:81107165	PPIF	-0.52	-11.05	-0.4	4.45e-26	Height;
BRCA	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.55	7.82	0.3	2.12e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9942416	0.617	rs72633979	chr5:74990178	A/T	cg19683494	chr5:74908142	NA	0.48	8.92	0.33	4.95e-18	Age-related disease endophenotypes;
BRCA	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	19.41	0.61	2.56e-66	Electrocardiographic conduction measures;
BRCA	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg20290983	chr6:43655470	MRPS18A	1.11	40.57	0.85	5.58e-179	IgG glycosylation;
BRCA	trans	rs2018683	0.523	rs886834	chr7:29021336	G/A	cg19402173	chr7:128379420	CALU	-0.38	-8.4	-0.32	2.9e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg02951883	chr7:2050386	MAD1L1	-0.51	-11.94	-0.43	8.45e-30	Schizophrenia;
BRCA	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18876405	chr7:65276391	NA	0.62	15.37	0.52	1.28e-45	Aortic root size;
BRCA	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg23788917	chr6:8435910	SLC35B3	-0.48	-10.44	-0.38	1.12e-23	Motion sickness;
BRCA	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg08000102	chr2:233561755	GIGYF2	0.61	13.48	0.47	1.29e-36	Coronary artery disease;
BRCA	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg23711669	chr6:146136114	FBXO30	0.73	17.3	0.56	2.77e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.48	10.57	0.39	3.7e-24	IgG glycosylation;
BRCA	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg04989706	chr14:50066350	PPIL5	-0.47	-9.12	-0.34	9.4e-19	Carotid intima media thickness;
BRCA	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg23625390	chr15:77176239	SCAPER	-0.55	-13.9	-0.48	1.44e-38	Blood metabolite levels;
BRCA	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg05347473	chr6:146136440	FBXO30	0.43	8.79	0.33	1.43e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-10.41	-0.38	1.49e-23	Reticulocyte count;
BRCA	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg24812749	chr6:127587940	RNF146	0.87	20.04	0.62	1.06e-69	Breast cancer;
BRCA	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg14004847	chr7:1930337	MAD1L1	-0.47	-9.05	-0.34	1.76e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg12373951	chr3:133503437	NA	0.53	12.57	0.45	1.51e-32	Iron status biomarkers;
BRCA	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg12386194	chr3:101231763	SENP7	0.45	9.53	0.35	3.33e-20	Colorectal cancer;
BRCA	cis	rs870825	0.929	rs10003354	chr4:185589782	G/A	cg04058563	chr4:185651563	MLF1IP	0.68	11.54	0.42	4.01e-28	Blood protein levels;
BRCA	trans	rs8073060	0.544	rs225287	chr17:33929487	G/T	cg19694781	chr19:47549865	TMEM160	-1.01	-20.68	-0.63	4.01e-73	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs7809950	1.000	rs2712215	chr7:107188207	A/G	cg23024343	chr7:107201750	COG5	-0.4	-9.3	-0.35	2.14e-19	Coronary artery disease;
BRCA	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg24296786	chr1:45957014	TESK2	-0.39	-8.13	-0.31	2.17e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg25358565	chr5:93447407	FAM172A	0.69	11.87	0.42	1.73e-29	Diabetic retinopathy;
BRCA	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg23505145	chr19:12996616	KLF1	0.54	12.33	0.44	1.69e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72627509	0.680	rs66790703	chr4:57773908	G/A	cg26694713	chr4:57773883	REST	0.5	10.03	0.37	4.39e-22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg02269571	chr22:50332266	NA	-0.55	-7.84	-0.3	1.94e-14	Schizophrenia;
BRCA	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg26373071	chr5:1325741	CLPTM1L	0.48	11.46	0.41	8.71e-28	Lung cancer;
BRCA	cis	rs72848980	0.512	rs12359556	chr10:105390677	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.43	8.37	0.31	3.62e-16	White matter hyperintensity burden;
BRCA	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs16854884	0.683	rs2053211	chr3:143774592	C/T	cg06585982	chr3:143692056	C3orf58	-0.47	-9.1	-0.34	1.17e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs57590327	0.503	rs7426937	chr3:81881360	T/C	cg07356753	chr3:81810745	GBE1	-0.41	-9.6	-0.35	1.85e-20	Extraversion;
BRCA	cis	rs250677	0.522	rs10040798	chr5:148367324	A/G	cg18129178	chr5:148520854	ABLIM3	0.53	10.25	0.38	6.53e-23	Breast cancer;
BRCA	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg02004499	chr7:4244250	SDK1	0.43	9.16	0.34	6.81e-19	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
BRCA	cis	rs4663866	1.000	rs4663865	chr2:239145960	C/T	cg16914508	chr2:239161102	PER2	-0.61	-8.88	-0.33	6.53e-18	Irritable bowel syndrome;
BRCA	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg23505145	chr19:12996616	KLF1	0.56	12.65	0.45	6.93e-33	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.53	0.32	1.05e-16	Corneal astigmatism;
BRCA	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.66	-15.24	-0.52	5.84e-45	Systemic lupus erythematosus;
BRCA	cis	rs752010	0.806	rs4457567	chr1:42091407	C/T	cg06885757	chr1:42089581	HIVEP3	0.28	10.28	0.38	4.88e-23	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg00105475	chr2:10696890	NA	0.43	10.19	0.37	1.04e-22	Prostate cancer;
BRCA	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.56	8.4	0.32	2.9e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.53	0.32	1.05e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	17.77	0.58	1.04e-57	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7131987	0.903	rs67150462	chr12:29393325	T/C	cg09582351	chr12:29534625	ERGIC2	-0.41	-9.68	-0.36	8.65e-21	QT interval;
BRCA	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-9.51	-0.35	3.69e-20	Fear of minor pain;
BRCA	cis	rs7572733	0.515	rs13408411	chr2:198825462	G/A	cg00792783	chr2:198669748	PLCL1	0.45	9.89	0.36	1.47e-21	Dermatomyositis;
BRCA	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg08000102	chr2:233561755	GIGYF2	-0.63	-13.61	-0.47	3.18e-37	Coronary artery disease;
BRCA	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg13047869	chr3:10149882	C3orf24	0.56	10.35	0.38	2.51e-23	Alzheimer's disease;
BRCA	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg24675658	chr1:53192096	ZYG11B	0.52	11.58	0.42	2.65e-28	Monocyte count;
BRCA	cis	rs9837602	1.000	rs71313585	chr3:99770696	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.18	0.4	1.31e-26	Breast cancer;
BRCA	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg19784903	chr17:45786737	TBKBP1	0.33	7.85	0.3	1.75e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7408868	0.908	rs62113793	chr19:15277336	G/A	cg14696996	chr19:15285081	NOTCH3	1.02	14.48	0.5	2.56e-41	Pulse pressure;
BRCA	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27286337	chr10:134555280	INPP5A	0.8	12.94	0.46	3.49e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	11.65	0.42	1.42e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.1	0.56	2.86e-54	Bladder cancer;
BRCA	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg11941060	chr3:133502564	NA	-0.51	-12.17	-0.43	8.96e-31	Iron status biomarkers;
BRCA	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.47	-13.04	-0.46	1.22e-34	Lung cancer;
BRCA	cis	rs1185460	1.000	rs7127212	chr11:118953202	A/G	cg23280166	chr11:118938394	VPS11	-0.36	-8.57	-0.32	7.69e-17	Coronary artery disease;
BRCA	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg02403541	chr12:121454288	C12orf43	0.53	10.08	0.37	2.74e-22	N-glycan levels;
BRCA	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg01262667	chr19:19385393	TM6SF2	0.41	10.5	0.38	6.5e-24	Tonsillectomy;
BRCA	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	17.01	0.56	8.75e-54	Alzheimer's disease;
BRCA	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.5	-9.47	-0.35	5.48e-20	Lung cancer in ever smokers;
BRCA	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24110177	chr3:50126178	RBM5	-0.41	-11.17	-0.4	1.39e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg21724239	chr8:58056113	NA	0.51	8.76	0.33	1.71e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06022373	chr22:39101656	GTPBP1	-0.74	-16.62	-0.55	8.19e-52	Menopause (age at onset);
BRCA	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	11.68	0.42	1.02e-28	Rheumatoid arthritis;
BRCA	cis	rs2479724	0.846	rs1536702	chr6:41869950	T/A	cg17623882	chr6:41773611	USP49	-0.35	-9.47	-0.35	5.16e-20	Menarche (age at onset);
BRCA	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg05340658	chr4:99064831	C4orf37	0.63	15.04	0.51	5.65e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg08805041	chr16:621841	PIGQ	-0.31	-8.52	-0.32	1.14e-16	Height;
BRCA	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-9.32	-0.35	1.92e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg26838691	chr2:24397539	C2orf84	0.4	8.08	0.3	3.3e-15	Asthma;
BRCA	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	14.12	0.49	1.31e-39	Alzheimer's disease;
BRCA	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.86	-0.36	1.91e-21	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg23762105	chr12:34175262	ALG10	0.37	8.53	0.32	1.1e-16	Morning vs. evening chronotype;
BRCA	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg04691961	chr3:161091175	C3orf57	-0.59	-14.36	-0.49	9.48e-41	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.52	-0.61	6.85e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.84	-17.25	-0.56	4.93e-55	Alzheimer's disease;
BRCA	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.49	9.66	0.36	1.1e-20	Iron status biomarkers;
BRCA	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg16506815	chr2:162101123	NA	-0.45	-8.65	-0.32	4.23e-17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
BRCA	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg17158414	chr2:27665306	KRTCAP3	0.31	8.11	0.31	2.6e-15	Total body bone mineral density;
BRCA	cis	rs13046373	0.535	rs2832964	chr21:32014012	A/C	cg06468780	chr21:31798236	KRTAP13-3	0.34	8.46	0.32	1.85e-16	HDL cholesterol;
BRCA	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg05863683	chr7:1912471	MAD1L1	-0.35	-8.23	-0.31	1.06e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg24846343	chr22:24311635	DDTL	0.5	12.17	0.43	8.22e-31	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs78487399	0.908	rs6725688	chr2:43846553	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-8.03	-0.3	4.55e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg09904177	chr6:26538194	HMGN4	0.56	18.25	0.59	3.23e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-15.12	-0.51	2.13e-44	Morning vs. evening chronotype;
BRCA	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg23649088	chr2:200775458	C2orf69	0.6	8.87	0.33	7.04e-18	Schizophrenia;
BRCA	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg04450456	chr4:17643702	FAM184B	0.37	10.73	0.39	8.05e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg08508325	chr11:3079039	CARS	0.28	8.43	0.32	2.22e-16	Calcium levels;
BRCA	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg19257562	chr1:2043853	PRKCZ	-0.33	-8.86	-0.33	7.64e-18	Height;
BRCA	cis	rs1420338	0.933	rs1362460	chr7:34147964	C/T	cg01275685	chr7:34179230	BMPER	-0.52	-11.68	-0.42	1.03e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-8.79	-0.33	1.43e-17	IgG glycosylation;
BRCA	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg21775007	chr8:11205619	TDH	-0.4	-8.51	-0.32	1.23e-16	Neuroticism;
BRCA	cis	rs7188861	0.861	rs7197188	chr16:11443424	C/A	cg01510278	chr16:11456238	NA	-0.38	-8.13	-0.31	2.23e-15	HDL cholesterol;
BRCA	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg22980127	chr19:33182716	NUDT19	0.9	17.65	0.57	4.12e-57	Red blood cell traits;
BRCA	trans	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.76	0.39	6.29e-25	Type 2 diabetes;
BRCA	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.64	0.55	6.17e-52	Colorectal cancer;
BRCA	cis	rs12618769	0.597	rs11884553	chr2:99131206	T/C	cg10123293	chr2:99228465	UNC50	0.41	8.24	0.31	9.93e-16	Bipolar disorder;
BRCA	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.5e-36	High light scatter reticulocyte count;
BRCA	cis	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg00852783	chr1:26633632	UBXN11	0.43	8.06	0.3	3.69e-15	Obesity-related traits;
BRCA	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg25237894	chr2:233734115	C2orf82	0.39	10.98	0.4	8.04e-26	Coronary artery disease;
BRCA	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg22431228	chr1:16359049	CLCNKA	-0.45	-9.27	-0.34	2.91e-19	Dilated cardiomyopathy;
BRCA	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg06484146	chr7:12443880	VWDE	-0.75	-10.63	-0.39	2.15e-24	Coronary artery disease;
BRCA	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg26597838	chr10:835615	NA	1.3	21.81	0.65	2.87e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.21	0.41	9.55e-27	Bipolar disorder;
BRCA	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg13047869	chr3:10149882	C3orf24	0.52	11.01	0.4	6.24e-26	Alzheimer's disease;
BRCA	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg10381502	chr11:71823885	C11orf51	-0.9	-9.4	-0.35	9.44e-20	Severe influenza A (H1N1) infection;
BRCA	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg18811423	chr2:55921094	PNPT1	0.71	22.4	0.66	1.91e-82	Metabolic syndrome;
BRCA	cis	rs4988958	0.584	rs7589142	chr2:103024660	T/C	cg03938978	chr2:103052716	IL18RAP	0.29	8.51	0.32	1.25e-16	Asthma (childhood onset);
BRCA	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg08213375	chr14:104286397	PPP1R13B	0.65	18.25	0.59	3.25e-60	Schizophrenia;
BRCA	cis	rs752010	0.806	rs4641303	chr1:42091310	A/G	cg06885757	chr1:42089581	HIVEP3	0.28	10.28	0.38	4.88e-23	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs910873	0.505	rs6059969	chr20:33245284	T/C	cg16810054	chr20:33298113	TP53INP2	-0.48	-10.4	-0.38	1.62e-23	Melanoma;
BRCA	cis	rs2882667	0.690	rs11954103	chr5:138269148	G/A	cg04439458	chr5:138467593	SIL1	-0.37	-8.66	-0.32	3.75e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg14004847	chr7:1930337	MAD1L1	0.43	8.86	0.33	8.16e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs7777754	0.734	rs4947709	chr7:50672907	A/G	cg18232548	chr7:50535776	DDC	-0.34	-8.09	-0.3	3.04e-15	Response to zileuton treatment in asthma (FEV1 change interaction);
BRCA	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	12.97	0.46	2.61e-34	Migraine;Coronary artery disease;
BRCA	trans	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg06521331	chr12:34319734	NA	-0.51	-9.62	-0.36	1.47e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2286885	0.965	rs10987301	chr9:129250688	T/C	cg15282417	chr9:129245246	FAM125B	-0.31	-7.95	-0.3	8.77e-15	Intraocular pressure;
BRCA	cis	rs11622475	0.677	rs7145372	chr14:104359121	A/G	cg12183467	chr14:104352244	NA	0.45	9.8	0.36	3.1e-21	Bipolar disorder;
BRCA	cis	rs477692	0.685	rs3852507	chr10:131399616	G/T	cg05714579	chr10:131428358	MGMT	-0.54	-12.83	-0.45	1.11e-33	Response to temozolomide;
BRCA	cis	rs7394190	0.688	rs76033784	chr10:75535970	A/G	cg07699608	chr10:75541558	CHCHD1	0.65	9.64	0.36	1.26e-20	Incident atrial fibrillation;
BRCA	cis	rs17095355	1.000	rs731793	chr10:111716667	C/G	cg00817464	chr10:111662876	XPNPEP1	0.38	9.95	0.37	9.12e-22	Biliary atresia;
BRCA	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg18154014	chr19:37997991	ZNF793	0.62	11.64	0.42	1.49e-28	Coronary artery calcification;
BRCA	trans	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg25214090	chr10:38739885	LOC399744	0.56	12.39	0.44	9.8e-32	Corneal astigmatism;
BRCA	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg12310025	chr6:25882481	NA	0.72	17.85	0.58	4.14e-58	Blood metabolite levels;
BRCA	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg21535247	chr6:8435926	SLC35B3	-0.39	-8.85	-0.33	8.3e-18	Motion sickness;
BRCA	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg20701182	chr2:24300061	SF3B14	0.56	8.65	0.32	4.24e-17	Lymphocyte counts;
BRCA	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg14847009	chr1:175162515	KIAA0040	0.26	9.98	0.37	6.73e-22	Alcohol dependence;
BRCA	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg18016565	chr1:150552671	MCL1	-0.45	-10.08	-0.37	2.91e-22	Tonsillectomy;
BRCA	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg05340658	chr4:99064831	C4orf37	0.62	14.71	0.5	2.04e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.84	-0.33	9.56e-18	Total body bone mineral density;
BRCA	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.45	-10.68	-0.39	1.34e-24	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg04511125	chr2:88470314	THNSL2	-0.45	-9.09	-0.34	1.26e-18	Response to metformin (IC50);
BRCA	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg08888203	chr3:10149979	C3orf24	0.68	14.5	0.5	2.22e-41	Alzheimer's disease;
BRCA	cis	rs4566357	0.557	rs6707158	chr2:227911269	A/G	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.12	-0.31	2.34e-15	Coronary artery disease;
BRCA	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg25358565	chr5:93447407	FAM172A	1.18	18.56	0.59	7.72e-62	Diabetic retinopathy;
BRCA	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.66	-0.42	1.31e-28	Bipolar disorder;
BRCA	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg27170947	chr2:26402098	FAM59B	-0.85	-15.96	-0.53	1.7e-48	Gut microbiome composition (summer);
BRCA	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.84	0.39	2.92e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.77	21.03	0.64	5.28e-75	Multiple sclerosis;
BRCA	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg11833968	chr6:79620685	NA	-0.4	-8.59	-0.32	6.68e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs72634258	0.554	rs35307738	chr1:7919839	C/G	cg26816564	chr1:7831052	VAMP3	0.54	10.53	0.38	5.3e-24	Inflammatory bowel disease;
BRCA	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg24803719	chr17:45855879	NA	-0.31	-8.1	-0.31	2.77e-15	IgG glycosylation;
BRCA	cis	rs4924935	0.770	rs4924946	chr17:18846525	A/T	cg26306683	chr17:18585705	ZNF286B	-0.31	-8.39	-0.32	3.08e-16	Pancreatic cancer;
BRCA	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11764359	chr7:65958608	NA	0.74	16.3	0.54	3.24e-50	Aortic root size;
BRCA	cis	rs4631830	0.832	rs2611513	chr10:51515457	A/G	cg20129853	chr10:51489980	NA	0.28	7.87	0.3	1.53e-14	Prostate-specific antigen levels;
BRCA	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.77e-24	Motion sickness;
BRCA	cis	rs2882667	0.898	rs6863347	chr5:138361135	C/T	cg04439458	chr5:138467593	SIL1	-0.32	-8.71	-0.33	2.51e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1784581	0.674	rs1784592	chr6:162387365	T/A	cg17173639	chr6:162384350	PARK2	-0.38	-9.08	-0.34	1.33e-18	Itch intensity from mosquito bite;
BRCA	cis	rs7246657	0.722	rs2972430	chr19:38182111	C/T	cg14683738	chr19:37701593	ZNF585B	-0.47	-8.04	-0.3	4.29e-15	Coronary artery calcification;
BRCA	cis	rs72772090	0.539	rs67140788	chr5:96116286	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.19	-0.43	7.23e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs1451375	0.657	rs12672526	chr7:50657695	C/T	cg18232548	chr7:50535776	DDC	0.41	9.36	0.35	1.38e-19	Malaria;
BRCA	trans	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.93	-0.3	9.66e-15	Corneal astigmatism;
BRCA	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg21856205	chr7:94953877	PON1	-0.37	-7.93	-0.3	9.6e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg22834771	chr12:69754056	YEATS4	-0.41	-10.28	-0.38	4.7e-23	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg18252515	chr7:66147081	NA	-0.82	-11.88	-0.43	1.52e-29	Diabetic kidney disease;
BRCA	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg24562669	chr7:97807699	LMTK2	0.46	12.19	0.43	7.37e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-10.06	-0.37	3.46e-22	Mean corpuscular volume;
BRCA	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.03	0.3	4.75e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9790314	0.669	rs7630768	chr3:160864879	T/A	cg03342759	chr3:160939853	NMD3	-0.59	-13.03	-0.46	1.37e-34	Morning vs. evening chronotype;
BRCA	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	17.06	0.56	4.73e-54	Nonalcoholic fatty liver disease;
BRCA	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.06	-0.43	2.49e-30	Alzheimer's disease;
BRCA	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg22875332	chr1:76189707	ACADM	-0.46	-8.86	-0.33	8.17e-18	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg02079420	chr8:82753780	SNX16	0.31	7.94	0.3	9.08e-15	Diastolic blood pressure;
BRCA	cis	rs921968	0.565	rs6436069	chr2:219597185	T/C	cg02176678	chr2:219576539	TTLL4	-0.41	-11.07	-0.4	3.48e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.85	0.36	2.07e-21	Bipolar disorder;
BRCA	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11890956	chr21:40555474	PSMG1	1.09	33.17	0.8	4.71e-141	Cognitive function;
BRCA	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg03929089	chr4:120376271	NA	-0.53	-8.82	-0.33	1.09e-17	Axial length;
BRCA	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg05552183	chr6:42928497	GNMT	0.67	14.93	0.51	1.77e-43	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18404041	chr3:52824283	ITIH1	-0.38	-11.4	-0.41	1.57e-27	Electroencephalogram traits;
BRCA	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg13319975	chr6:146136371	FBXO30	-0.61	-13.94	-0.48	9.12e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg08392591	chr16:89556376	ANKRD11	0.51	12.45	0.44	5.39e-32	Multiple myeloma (IgH translocation);
BRCA	cis	rs1691799	0.899	rs1168322	chr12:66743769	C/T	cg16791601	chr12:66731901	HELB	-0.69	-19.67	-0.61	1.03e-67	White blood cell count (basophil);
BRCA	cis	rs117623576	0.941	rs211422	chr10:32398589	A/G	cg03047570	chr10:32398778	NA	0.62	9.32	0.35	1.87e-19	Anti-saccade response;
BRCA	cis	rs7095944	0.614	rs10901816	chr10:126440395	G/A	cg08799069	chr10:126477246	METTL10	-0.4	-9.49	-0.35	4.41e-20	Asthma;
BRCA	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg08997352	chr12:9597637	DDX12	-0.54	-10.43	-0.38	1.25e-23	Breast size;
BRCA	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.04	0.3	4.52e-15	Melanoma;
BRCA	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg12573674	chr2:1569213	NA	-0.51	-9.66	-0.36	1.09e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11644478	chr21:40555479	PSMG1	-0.51	-10.76	-0.39	6.25e-25	Menarche (age at onset);
BRCA	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.38	-10.09	-0.37	2.52e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs977987	0.806	rs7185640	chr16:75394399	A/G	cg03315344	chr16:75512273	CHST6	0.52	12.41	0.44	8.12e-32	Dupuytren's disease;
BRCA	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26314531	chr2:26401878	FAM59B	-0.66	-11.2	-0.4	1.08e-26	Gut microbiome composition (summer);
BRCA	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg21427119	chr20:30132790	HM13	-0.42	-8.76	-0.33	1.72e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg03954927	chr1:10346856	KIF1B	-0.48	-15.06	-0.51	4.47e-44	Hepatocellular carcinoma;
BRCA	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12826209	chr6:26865740	GUSBL1	0.6	10.56	0.39	4e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg00857998	chr1:205179979	DSTYK	0.43	8.2	0.31	1.36e-15	Mean corpuscular volume;Mean platelet volume;
BRCA	trans	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17712092	chr4:129076599	LARP1B	0.62	14.8	0.51	7.63e-43	Eosinophil percentage of white cells;
BRCA	cis	rs10044254	0.614	rs4273604	chr5:15732604	A/C	cg07238450	chr5:15720153	FBXL7	-0.38	-7.91	-0.3	1.12e-14	Asthma (corticosteroid response);
BRCA	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg23649088	chr2:200775458	C2orf69	-0.63	-12.39	-0.44	9.68e-32	Osteoporosis;
BRCA	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg23029597	chr12:123009494	RSRC2	-0.6	-11.78	-0.42	3.83e-29	Body mass index;
BRCA	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg10820045	chr2:198174542	NA	-0.42	-9.61	-0.36	1.65e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs55665837	1.000	rs12804549	chr11:14437758	A/T	cg19336497	chr11:14380999	RRAS2	-0.37	-9.66	-0.36	1.03e-20	Vitamin D levels;
BRCA	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg23503501	chr22:45809793	SMC1B;RIBC2	-0.55	-7.99	-0.3	6.09e-15	Tonsillectomy;
BRCA	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg14993813	chr1:46806288	NSUN4	-0.47	-9.04	-0.34	1.91e-18	Menopause (age at onset);
BRCA	cis	rs1020064	0.636	rs2679876	chr2:105938107	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.41	7.93	0.3	1.02e-14	AIDS;
BRCA	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg06636001	chr8:8085503	FLJ10661	0.59	12.67	0.45	5.51e-33	Retinal vascular caliber;
BRCA	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	16.64	0.55	6.06e-52	Colorectal cancer;
BRCA	cis	rs6545883	0.929	rs2463100	chr2:61659199	C/G	cg15711740	chr2:61764176	XPO1	-0.52	-11.64	-0.42	1.49e-28	Tuberculosis;
BRCA	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg18446336	chr7:2847575	GNA12	-0.35	-8.22	-0.31	1.15e-15	Height;
BRCA	cis	rs8014204	0.762	rs2359237	chr14:75245002	G/A	cg06637938	chr14:75390232	RPS6KL1	0.43	8.83	0.33	1.02e-17	Caffeine consumption;
BRCA	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg03929089	chr4:120376271	NA	-0.47	-9.04	-0.34	1.9e-18	HDL cholesterol;
BRCA	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03713592	chr11:72463424	ARAP1	0.78	11.7	0.42	8.97e-29	Type 2 diabetes;
BRCA	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23583168	chr7:148888333	NA	-0.86	-20.07	-0.62	7.29e-70	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg05279229	chr7:1896384	MAD1L1	-0.4	-8.02	-0.3	5.03e-15	Schizophrenia;
BRCA	trans	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-15.7	-0.53	3.33e-47	Obesity-related traits;
BRCA	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18876405	chr7:65276391	NA	0.54	12.94	0.46	3.55e-34	Aortic root size;
BRCA	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg03264133	chr6:25882463	NA	-0.36	-7.97	-0.3	7.37e-15	Height;
BRCA	trans	rs6479891	1.000	rs9414799	chr10:65129602	T/C	cg14819942	chr15:35414228	NA	0.35	8.49	0.32	1.4e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg13852791	chr20:30311386	BCL2L1	-0.83	-16.31	-0.54	2.9e-50	Mean corpuscular hemoglobin;
BRCA	cis	rs7178424	0.935	rs1344601	chr15:62259066	A/T	cg00456672	chr15:62358751	C2CD4A	0.38	8.54	0.32	9.52e-17	Height;
BRCA	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg19539972	chr4:7069911	GRPEL1	0.7	15.77	0.53	1.45e-47	Monocyte percentage of white cells;
BRCA	cis	rs4642101	0.824	rs3889514	chr3:12844072	T/C	cg24848339	chr3:12840334	CAND2	0.41	10.53	0.38	4.9299999999999996e-24	QRS complex (12-leadsum);
BRCA	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00908189	chr16:619842	PIGQ	0.71	18.56	0.59	8.33e-62	Height;
BRCA	cis	rs3772130	0.583	rs11710169	chr3:121426655	A/G	cg20356878	chr3:121714668	ILDR1	0.37	8.27	0.31	7.94e-16	Cognitive performance;
BRCA	cis	rs679087	0.932	rs10843506	chr12:29930883	G/A	cg14258853	chr12:29935411	TMTC1	0.36	8.26	0.31	8.17e-16	Schizophrenia;
BRCA	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg15017067	chr4:17643749	FAM184B	0.34	10.74	0.39	7.64e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7945718	0.967	rs4757945	chr11:12808718	A/G	cg25843174	chr11:12811716	TEAD1	-0.22	-8.36	-0.31	3.78e-16	Educational attainment (years of education);
BRCA	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg02640540	chr1:67518911	SLC35D1	0.38	8.19	0.31	1.47e-15	Lymphocyte percentage of white cells;
BRCA	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg25358565	chr5:93447407	FAM172A	1.25	19.02	0.6	2.98e-64	Diabetic retinopathy;
BRCA	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	11.64	0.42	1.61e-28	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs10463316	0.862	rs11740475	chr5:150777997	A/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.43	-0.32	2.33e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs12612619	0.704	rs6742004	chr2:27309659	A/C	cg00617064	chr2:27272375	NA	-0.34	-8.89	-0.33	6.31e-18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	11.1	0.4	2.54e-26	Mood instability;
BRCA	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-8.55	-0.32	8.95e-17	Chronic sinus infection;
BRCA	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg12935359	chr14:103987150	CKB	0.61	14.18	0.49	6.76e-40	Intelligence (multi-trait analysis);
BRCA	cis	rs921968	0.565	rs3821035	chr2:219620223	T/G	cg02176678	chr2:219576539	TTLL4	-0.41	-11.06	-0.4	3.87e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.6	-14.61	-0.5	6.47e-42	Longevity;Endometriosis;
BRCA	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg08754654	chr5:154026448	NA	0.42	10.06	0.37	3.5e-22	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg01324343	chr3:183735012	ABCC5	-0.66	-15.37	-0.52	1.31e-45	Anterior chamber depth;
BRCA	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg03146154	chr1:46216737	IPP	0.45	10.01	0.37	5.26e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg14993813	chr1:46806288	NSUN4	-0.46	-8.66	-0.32	3.91e-17	Menopause (age at onset);
BRCA	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	11.67	0.42	1.12e-28	Systemic lupus erythematosus;
BRCA	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg01114163	chr5:1856713	NA	-0.35	-7.88	-0.3	1.37e-14	Cardiovascular disease risk factors;
BRCA	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	10.78	0.39	5.08e-25	Bipolar disorder;
BRCA	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg10523679	chr1:76189770	ACADM	-0.71	-12.17	-0.43	8.91e-31	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg07741184	chr6:167504864	NA	0.33	9.8	0.36	3.32e-21	Primary biliary cholangitis;
BRCA	cis	rs6782228	0.675	rs2253151	chr3:128330137	T/C	cg16766828	chr3:128327626	NA	-0.41	-9.09	-0.34	1.22e-18	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-14.89	-0.51	2.92e-43	Chronic sinus infection;
BRCA	cis	rs6723226	0.699	rs376914	chr2:32508393	G/C	cg02381751	chr2:32503542	YIPF4	0.67	14.26	0.49	2.92e-40	Intelligence (multi-trait analysis);
BRCA	cis	rs7617773	0.815	rs7624450	chr3:48350375	A/G	cg11946769	chr3:48343235	NME6	0.69	14.01	0.48	4.54e-39	Coronary artery disease;
BRCA	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg00071950	chr4:10020882	SLC2A9	0.66	16.76	0.55	1.6e-52	Bone mineral density;
BRCA	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg06238570	chr21:40685208	BRWD1	-0.4	-8.17	-0.31	1.62e-15	Cognitive function;
BRCA	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg06627628	chr2:24431161	ITSN2	0.69	13.54	0.47	6.44e-37	Asthma;
BRCA	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg26673648	chr5:177209285	NA	0.39	8.89	0.33	6.24e-18	Methadone dose in opioid dependence;
BRCA	cis	rs1499972	0.941	rs62264763	chr3:117637305	G/A	cg07612923	chr3:117604196	NA	0.6	8.16	0.31	1.75e-15	Schizophrenia;
BRCA	trans	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg25214090	chr10:38739885	LOC399744	-0.46	-10.43	-0.38	1.22e-23	Corneal astigmatism;
BRCA	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	9.42	0.35	7.87e-20	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-15.49	-0.52	3.5e-46	Bipolar disorder and schizophrenia;
BRCA	cis	rs914187	0.548	rs2837992	chr21:42620520	A/G	cg21268422	chr21:42620091	BACE2	0.47	9.42	0.35	7.95e-20	Body mass index;
BRCA	cis	rs2933343	0.533	rs13086121	chr3:128704290	A/T	cg11901034	chr3:128598214	ACAD9	-0.34	-7.92	-0.3	1.08e-14	IgG glycosylation;
BRCA	cis	rs651907	0.640	rs771574	chr3:101620682	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.37	7.82	0.3	2.15e-14	Colorectal cancer;
BRCA	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg05343316	chr1:45956843	TESK2	0.55	11.24	0.41	7.05e-27	Platelet count;
BRCA	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg09359103	chr1:154839909	KCNN3	-0.58	-15.61	-0.53	8.9e-47	Prostate cancer;
BRCA	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs7520050	0.966	rs10890354	chr1:46305347	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.9	0.36	1.4e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg20673091	chr1:2541236	MMEL1	0.32	8.31	0.31	5.6e-16	Ulcerative colitis;
BRCA	cis	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg05901451	chr6:126070800	HEY2	0.4	9.65	0.36	1.2e-20	Endometrial cancer;
BRCA	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.53e-23	Motion sickness;
BRCA	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg13334819	chr7:99746414	C7orf59	-0.39	-9.49	-0.35	4.67e-20	Coronary artery disease;
BRCA	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.76	-0.42	4.98e-29	Alcohol dependence;
BRCA	cis	rs7811528	0.520	rs2286690	chr7:2695617	A/G	cg11411865	chr7:2701802	TTYH3	-0.49	-8.97	-0.33	3.35e-18	Schizophrenia;
BRCA	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg13385521	chr17:29058706	SUZ12P	0.62	8.49	0.32	1.49e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.8e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs6740322	0.895	rs9309097	chr2:43554397	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-12.28	-0.44	2.87e-31	Coronary artery disease;
BRCA	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg26597838	chr10:835615	NA	1.01	17.96	0.58	1.05e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg03342759	chr3:160939853	NMD3	-0.72	-17.97	-0.58	9.09e-59	Morning vs. evening chronotype;
BRCA	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg10523679	chr1:76189770	ACADM	-0.46	-8.92	-0.33	5.05e-18	Daytime sleep phenotypes;
BRCA	cis	rs36051895	0.664	rs3780369	chr9:5095095	A/C	cg02405213	chr9:5042618	JAK2	-0.51	-9.16	-0.34	7.19e-19	Pediatric autoimmune diseases;
BRCA	cis	rs2625529	0.701	rs12911154	chr15:72212653	G/A	cg16672083	chr15:72433130	SENP8	-0.84	-17.27	-0.56	4.16e-55	Red blood cell count;
BRCA	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06544989	chr22:39130855	UNC84B	-0.37	-8.3	-0.31	6.1e-16	Menopause (age at onset);
BRCA	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg12564285	chr5:131593104	PDLIM4	0.39	9.64	0.36	1.24e-20	Acylcarnitine levels;
BRCA	cis	rs6910061	0.830	rs13190922	chr6:11125002	T/C	cg27233058	chr6:11094804	LOC221710	0.51	8.73	0.33	2.24e-17	Diabetic kidney disease;
BRCA	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg08885076	chr2:99613938	TSGA10	-0.56	-12.54	-0.44	2.01e-32	Chronic sinus infection;
BRCA	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg14266287	chr2:239334506	ASB1	-0.34	-8.15	-0.31	1.87e-15	Multiple system atrophy;
BRCA	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg00677455	chr12:58241039	CTDSP2	0.63	14.34	0.49	1.22e-40	Multiple sclerosis;
BRCA	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg24692254	chr21:30365293	RNF160	-0.74	-19.71	-0.61	6.03e-68	Dental caries;
BRCA	cis	rs778371	0.723	rs10210953	chr2:233698830	G/A	cg08000102	chr2:233561755	GIGYF2	-0.83	-20.3	-0.63	4.66e-71	Schizophrenia;
BRCA	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg16339924	chr4:17578868	LAP3	0.56	13.89	0.48	1.65e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg04025307	chr7:1156635	C7orf50	0.47	9.16	0.34	7.1e-19	Bronchopulmonary dysplasia;
BRCA	trans	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	8.28	0.31	7.26e-16	Mean corpuscular volume;
BRCA	trans	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg06521331	chr12:34319734	NA	-0.46	-8.54	-0.32	9.43e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg22117172	chr7:91764530	CYP51A1	0.24	8.08	0.3	3.21e-15	Breast cancer;
BRCA	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg08422745	chr4:174089978	GALNT7	-0.8	-18.39	-0.59	6.24e-61	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs2580764	0.566	rs2968794	chr2:55290651	C/G	cg09592903	chr2:55203963	RTN4	-0.36	-9.33	-0.35	1.67e-19	Mean platelet volume;
BRCA	cis	rs877282	0.947	rs957642	chr10:773966	C/T	cg17470449	chr10:769945	NA	0.51	9.67	0.36	9.84e-21	Uric acid levels;
BRCA	cis	rs113835537	0.597	rs11227523	chr11:66305938	C/T	cg24851651	chr11:66362959	CCS	0.47	8.84	0.33	9.15e-18	Airway imaging phenotypes;
BRCA	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.33	8.77	0.33	1.58e-17	Ovarian reserve;
BRCA	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.5	-9.71	-0.36	7.16e-21	Body mass index;
BRCA	cis	rs6545883	0.965	rs11887205	chr2:61774473	T/G	cg15711740	chr2:61764176	XPO1	-0.57	-14.38	-0.49	8.34e-41	Tuberculosis;
BRCA	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg01262667	chr19:19385393	TM6SF2	0.4	10.49	0.38	7.51e-24	Tonsillectomy;
BRCA	cis	rs6973256	0.897	rs4731970	chr7:133326602	C/T	cg07491979	chr7:133331646	EXOC4	-0.39	-8.85	-0.33	8.79e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6433895	1.000	rs6759865	chr2:182017385	A/G	cg00481216	chr2:181971175	NA	0.39	8.91	0.33	5.34e-18	Lymphocyte counts;
BRCA	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00908189	chr16:619842	PIGQ	0.71	18.45	0.59	2.82e-61	Height;
BRCA	cis	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg07929629	chr2:241523174	NA	0.54	11.59	0.42	2.64e-28	Bipolar disorder;
BRCA	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg13385794	chr1:248469461	NA	-0.27	-8.14	-0.31	2.06e-15	Common traits (Other);
BRCA	cis	rs4664304	0.620	rs12692568	chr2:160718440	T/C	cg14819504	chr2:160761413	LY75	0.34	8.36	0.31	3.88e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg08085267	chr17:45401833	C17orf57	-0.67	-14.99	-0.51	9.59e-44	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.77	-0.55	1.45e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg24642439	chr20:33292090	TP53INP2	0.43	9.12	0.34	9.85e-19	Height;
BRCA	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg00071950	chr4:10020882	SLC2A9	-0.48	-11.57	-0.42	3.03e-28	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg22105103	chr4:187893119	NA	0.37	11.84	0.42	2.26e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10392	0.850	rs725322	chr20:37563352	C/T	cg16355469	chr20:37678765	NA	0.47	8.04	0.3	4.35e-15	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
BRCA	cis	rs9649465	1.000	rs10215473	chr7:123380681	C/G	cg04330084	chr7:123175371	IQUB	-0.3	-8.27	-0.31	7.73e-16	Migraine;
BRCA	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg19156104	chr2:198669113	PLCL1	-0.44	-8.13	-0.31	2.26e-15	Ulcerative colitis;
BRCA	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg06636001	chr8:8085503	FLJ10661	0.58	12.24	0.44	4.42e-31	Neuroticism;
BRCA	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	19.48	0.61	1.02e-66	Electrocardiographic conduction measures;
BRCA	cis	rs9682041	0.660	rs13089074	chr3:170113481	G/A	cg11886554	chr3:170076028	SKIL	0.51	10.13	0.37	1.76e-22	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs7191700	0.511	rs8058983	chr16:11360849	A/G	cg00044050	chr16:11439710	C16orf75	-0.42	-9.78	-0.36	3.92e-21	Multiple sclerosis;
BRCA	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg06191203	chr2:152266755	RIF1	0.31	9.06	0.34	1.61e-18	Lung cancer;
BRCA	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg13736514	chr6:26305472	NA	-0.37	-11.91	-0.43	1.09e-29	Educational attainment;
BRCA	trans	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg25214090	chr10:38739885	LOC399744	0.56	12.83	0.45	1.04e-33	Corneal astigmatism;
BRCA	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg25208724	chr1:156163844	SLC25A44	1.07	35.26	0.81	4.84e-152	Testicular germ cell tumor;
BRCA	cis	rs7631605	0.935	rs2241031	chr3:37090274	C/T	cg15934958	chr3:37212084	LRRFIP2	0.41	9.54	0.35	3.08e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03517284	chr6:25882590	NA	-0.46	-9.64	-0.36	1.22e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg20476274	chr7:133979776	SLC35B4	0.66	19.45	0.61	1.61e-66	Mean platelet volume;
BRCA	cis	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.19	-0.4	1.14e-26	Morning vs. evening chronotype;
BRCA	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg11752832	chr7:134001865	SLC35B4	0.44	9.62	0.36	1.53e-20	Mean platelet volume;
BRCA	cis	rs708547	1.000	rs2412770	chr4:57794660	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.49	-8.37	-0.31	3.68e-16	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2742417	0.565	rs2673031	chr3:45756986	A/G	cg04837898	chr3:45731254	SACM1L	-0.4	-8.15	-0.31	1.87e-15	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg14582100	chr15:45693742	SPATA5L1	0.36	11.72	0.42	7.51e-29	Homoarginine levels;
BRCA	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	16.75	0.55	1.79e-52	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	11.99	0.43	5.16e-30	Platelet count;
BRCA	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00166722	chr3:10149974	C3orf24	0.65	12.8	0.45	1.54e-33	Alzheimer's disease;
BRCA	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00149659	chr3:10157352	C3orf10	1.07	18.1	0.58	2.08e-59	Alzheimer's disease;
BRCA	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg23533926	chr12:111358616	MYL2	-0.44	-9.18	-0.34	5.78e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg17063962	chr7:91808500	NA	0.54	12.41	0.44	7.41e-32	Breast cancer;
BRCA	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg22431228	chr1:16359049	CLCNKA	-0.43	-9.53	-0.35	3.09e-20	Dilated cardiomyopathy;
BRCA	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg23719950	chr11:63933701	MACROD1	-0.58	-9.62	-0.36	1.48e-20	Mean platelet volume;
BRCA	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg13880726	chr7:1868755	MAD1L1	0.41	7.94	0.3	9.03e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg17136484	chr7:158649327	WDR60	0.4	8.62	0.32	5.38e-17	Height;
BRCA	cis	rs36051895	0.632	rs10118789	chr9:5141178	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-9.11	-0.34	1.08e-18	Pediatric autoimmune diseases;
BRCA	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg22431228	chr1:16359049	CLCNKA	-0.44	-9.82	-0.36	2.63e-21	Dilated cardiomyopathy;
BRCA	cis	rs4389656	0.767	rs369769	chr5:6720712	T/C	cg10857441	chr5:6722123	POLS	-0.25	-7.82	-0.3	2.22e-14	Coronary artery disease;
BRCA	cis	rs9986765	1.000	rs76467433	chr7:142824852	C/T	cg21852589	chr7:142981689	TMEM139	0.62	10.13	0.37	1.75e-22	Cancer;Dermatomyositis;
BRCA	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.39	-8.24	-0.31	9.86e-16	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs870825	0.616	rs2696037	chr4:185610940	C/T	cg04058563	chr4:185651563	MLF1IP	-0.67	-12.72	-0.45	3.24e-33	Blood protein levels;
BRCA	cis	rs2637030	0.559	rs2637027	chr5:52980471	G/A	cg06476337	chr5:52856530	NDUFS4	0.36	8.27	0.31	7.87e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg00080972	chr5:178986291	RUFY1	0.41	10.68	0.39	1.33e-24	Lung cancer;
BRCA	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	ch.11.42038R	chr11:967971	AP2A2	0.5	15.89	0.53	3.78e-48	Alzheimer's disease (late onset);
BRCA	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.14	-0.4	1.81e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4742903	0.967	rs2417485	chr9:106867106	A/C	cg21169611	chr9:106856078	SMC2	0.36	9.55	0.35	2.75e-20	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs10992471	0.603	rs12336415	chr9:95195458	G/T	cg14631576	chr9:95140430	CENPP	-0.39	-9.32	-0.35	1.83e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs3857536	0.740	rs9354392	chr6:66894555	G/T	cg07460842	chr6:66804631	NA	-0.45	-8.74	-0.33	2.05e-17	Blood trace element (Cu levels);
BRCA	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg27661571	chr11:113659931	NA	-0.8	-12.01	-0.43	4.07e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg15556689	chr8:8085844	FLJ10661	0.49	13.87	0.48	2.01e-38	Mood instability;
BRCA	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg23029597	chr12:123009494	RSRC2	-0.46	-9.42	-0.35	8.37e-20	Body mass index;
BRCA	cis	rs7560272	0.538	rs7599453	chr2:73937901	T/G	cg20560298	chr2:73613845	ALMS1	0.35	8.99	0.34	2.67e-18	Schizophrenia;
BRCA	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg09469691	chr10:81107165	PPIF	0.52	11.07	0.4	3.68e-26	Height;
BRCA	trans	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg13565492	chr6:43139072	SRF	-0.69	-10.06	-0.37	3.5e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg14683738	chr19:37701593	ZNF585B	0.45	8.02	0.3	4.94e-15	Coronary artery calcification;
BRCA	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg21782813	chr7:2030301	MAD1L1	0.34	9.05	0.34	1.75e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg21724239	chr8:58056113	NA	0.58	9.4	0.35	9.72e-20	Developmental language disorder (linguistic errors);
BRCA	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg13010199	chr12:38710504	ALG10B	0.49	9.56	0.35	2.56e-20	Morning vs. evening chronotype;
BRCA	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.0	-0.3	6.08e-15	Prostate cancer;
BRCA	cis	rs897984	0.762	rs2054213	chr16:30971810	A/G	cg02466173	chr16:30829666	NA	0.49	11.07	0.4	3.6e-26	Dementia with Lewy bodies;
BRCA	trans	rs587242	0.910	rs56339673	chr1:97000555	C/T	cg10631902	chr5:14652156	NA	0.34	8.4	0.32	2.83e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
BRCA	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg24829409	chr8:58192753	C8orf71	-0.47	-9.01	-0.34	2.38e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.05	0.49	2.87e-39	Motion sickness;
BRCA	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg06115741	chr20:33292138	TP53INP2	-0.36	-8.1	-0.31	2.74e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.63	14.05	0.49	2.79e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg11887960	chr12:57824829	NA	0.53	8.26	0.31	8.2e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2617583	0.967	rs2550947	chr5:1450506	T/C	cg07151155	chr5:1473589	LPCAT1	-0.42	-9.14	-0.34	8.43e-19	Breast cancer;
BRCA	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	19.69	0.61	8.42e-68	Mean platelet volume;
BRCA	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg16850897	chr7:100343110	ZAN	0.38	8.41	0.32	2.68e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	9.33	0.35	1.68e-19	Platelet count;
BRCA	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg21138405	chr5:131827807	IRF1	-0.38	-11.78	-0.42	3.84e-29	Asthma (sex interaction);
BRCA	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg26384229	chr12:38710491	ALG10B	0.68	14.54	0.5	1.35e-41	Morning vs. evening chronotype;
BRCA	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.33	0.38	3.11e-23	Bipolar disorder;
BRCA	cis	rs13064411	0.518	rs6438160	chr3:113217591	A/C	cg18753928	chr3:113234510	CCDC52	-0.41	-9.18	-0.34	6.13e-19	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	trans	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.93	-0.3	9.81e-15	Corneal astigmatism;
BRCA	cis	rs1506636	0.708	rs7788702	chr7:123237421	C/T	cg03229431	chr7:123269106	ASB15	0.6	13.16	0.46	3.52e-35	Plateletcrit;Platelet count;
BRCA	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24397884	chr7:158709396	WDR60	-0.98	-24.72	-0.7	3.33e-95	Height;
BRCA	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25427524	chr10:38739819	LOC399744	-0.7	-16.88	-0.56	4.06e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg11584989	chr19:19387371	SF4	-0.59	-13.38	-0.47	3.44e-36	Bipolar disorder;
BRCA	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-14.62	-0.5	5.66e-42	Total cholesterol levels;
BRCA	cis	rs2625529	0.526	rs7179942	chr15:72563074	C/G	cg16672083	chr15:72433130	SENP8	0.61	14.51	0.5	1.95e-41	Red blood cell count;
BRCA	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg08000102	chr2:233561755	GIGYF2	0.64	13.9	0.48	1.5e-38	Coronary artery disease;
BRCA	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08109568	chr15:31115862	NA	-0.43	-10.16	-0.37	1.44e-22	Huntington's disease progression;
BRCA	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-7.86	-0.3	1.67e-14	Developmental language disorder (linguistic errors);
BRCA	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg03929089	chr4:120376271	NA	0.65	12.83	0.45	1.07e-33	Coronary artery disease;
BRCA	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg21017887	chr14:105400489	NA	0.59	14.76	0.5	1.2e-42	Rheumatoid arthritis;
BRCA	cis	rs858239	1.000	rs156407	chr7:23315639	G/A	cg23682824	chr7:23144976	KLHL7	0.4	9.83	0.36	2.39e-21	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg04990556	chr1:26633338	UBXN11	0.55	8.62	0.32	5.06e-17	Obesity-related traits;
BRCA	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg00717180	chr2:96193071	NA	-0.41	-11.31	-0.41	3.64e-27	HDL cholesterol;
BRCA	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.86	-0.33	7.7e-18	Coronary artery disease;
BRCA	trans	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg06521331	chr12:34319734	NA	-0.54	-9.73	-0.36	5.76e-21	Morning vs. evening chronotype;
BRCA	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24308560	chr3:49941425	MST1R	0.39	8.51	0.32	1.25e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg06238570	chr21:40685208	BRWD1	-0.4	-8.11	-0.31	2.53e-15	Menarche (age at onset);
BRCA	cis	rs2066819	1.000	rs17118409	chr12:56630764	G/A	cg26734620	chr12:56694298	CS	0.86	9.88	0.36	1.64e-21	Psoriasis vulgaris;
BRCA	cis	rs7395581	0.918	rs3781622	chr11:47348702	T/C	cg25783544	chr11:47291846	MADD	0.41	9.23	0.34	3.87e-19	HDL cholesterol;
BRCA	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg20203395	chr5:56204925	C5orf35	-0.5	-10.38	-0.38	1.93e-23	Initial pursuit acceleration;
BRCA	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg01483505	chr11:975446	AP2A2	0.31	8.13	0.31	2.26e-15	Alzheimer's disease (late onset);
BRCA	cis	rs9790314	0.664	rs723757	chr3:160645435	C/T	cg03342759	chr3:160939853	NMD3	0.43	8.24	0.31	9.7e-16	Morning vs. evening chronotype;
BRCA	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	12.02	0.43	3.78e-30	Multiple sclerosis;
BRCA	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21659725	chr3:3221576	CRBN	-0.36	-8.74	-0.33	1.99e-17	Body mass index;
BRCA	cis	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg20368463	chr18:77673604	PQLC1	-0.51	-12.54	-0.44	2.2e-32	Schizophrenia;
BRCA	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg27446573	chr6:127587934	RNF146	0.86	20.0	0.62	1.76e-69	Breast cancer;
BRCA	trans	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg17675199	chr6:35436792	RPL10A	-0.3	-8.0	-0.3	5.78e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs3770081	1.000	rs2241435	chr2:86360916	C/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.58	-7.95	-0.3	8.54e-15	Facial emotion recognition (sad faces);
BRCA	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg13010199	chr12:38710504	ALG10B	0.49	9.5	0.35	4.29e-20	Morning vs. evening chronotype;
BRCA	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg04851639	chr8:1020857	NA	-0.3	-8.43	-0.32	2.26e-16	Schizophrenia;
BRCA	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	10.65	0.39	1.64e-24	Rheumatoid arthritis;
BRCA	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg18404041	chr3:52824283	ITIH1	-0.35	-9.22	-0.34	4.43e-19	Schizophrenia;
BRCA	trans	rs783540	0.835	rs8030185	chr15:83391537	G/A	cg18393722	chr15:85113863	UBE2QP1	0.27	8.3	0.31	5.99e-16	Schizophrenia;
BRCA	cis	rs10501293	1.000	rs4755698	chr11:43123536	G/T	cg03447554	chr11:43094025	NA	-0.47	-8.57	-0.32	7.95e-17	Cognitive performance;
BRCA	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg02743256	chr7:2109353	MAD1L1	-0.45	-8.05	-0.3	4.16e-15	Neuroticism;
BRCA	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg02403541	chr12:121454288	C12orf43	0.59	12.8	0.45	1.51e-33	Subjective well-being;Cardiovascular disease risk factors;
BRCA	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg22508957	chr16:3507546	NAT15	0.43	9.71	0.36	6.71e-21	Tuberculosis;
BRCA	trans	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg14011486	chr1:26737247	LIN28	0.48	8.03	0.3	4.68e-15	Atrial fibrillation;
BRCA	cis	rs586533	0.846	rs1003122	chr11:99496892	A/G	cg22878054	chr11:99397252	CNTN5	0.31	7.81	0.3	2.39e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs72627509	0.951	rs72606404	chr4:57841213	G/C	cg26694713	chr4:57773883	REST	0.45	8.16	0.31	1.82e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs754466	0.874	rs55910200	chr10:79665173	T/C	cg17075019	chr10:79541650	NA	-0.68	-12.98	-0.46	2.33e-34	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs847649	0.692	rs7800548	chr7:102481842	C/T	cg18108683	chr7:102477205	FBXL13	0.55	14.21	0.49	4.87e-40	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg25214090	chr10:38739885	LOC399744	-0.58	-12.65	-0.45	7.2e-33	Corneal astigmatism;
BRCA	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg26031613	chr14:104095156	KLC1	-0.42	-8.33	-0.31	4.82e-16	Schizophrenia;
BRCA	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg11822812	chr5:140052017	DND1	-0.29	-8.17	-0.31	1.6e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12756686	chr19:29218302	NA	0.57	10.93	0.4	1.36e-25	Methadone dose in opioid dependence;
BRCA	cis	rs34779708	0.733	rs16935945	chr10:35540320	A/C	cg03585969	chr10:35415529	CREM	0.45	9.19	0.34	5.29e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg09658497	chr7:2847517	GNA12	-0.45	-9.94	-0.37	1e-21	Height;
BRCA	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11644478	chr21:40555479	PSMG1	0.85	19.28	0.61	1.18e-65	Cognitive function;
BRCA	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg04842962	chr6:43655489	MRPS18A	1.12	38.54	0.84	7.46e-169	IgG glycosylation;
BRCA	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg13010199	chr12:38710504	ALG10B	0.48	9.37	0.35	1.2e-19	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.49	0.38	7.25e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.54e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg06484146	chr7:12443880	VWDE	-0.7	-9.7	-0.36	7.38e-21	Coronary artery disease;
BRCA	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg08645402	chr16:4508243	NA	0.4	9.33	0.35	1.78e-19	Schizophrenia;
BRCA	cis	rs1403694	0.695	rs1050274	chr3:186435370	G/A	cg12454167	chr3:186435060	KNG1	0.29	7.9	0.3	1.23e-14	Blood protein levels;
BRCA	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg10523679	chr1:76189770	ACADM	-0.78	-16.42	-0.54	8.12e-51	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1451375	0.698	rs68143668	chr7:50638110	C/T	cg18232548	chr7:50535776	DDC	0.38	9.14	0.34	8.18e-19	Malaria;
BRCA	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.33	-0.31	4.95e-16	Aortic root size;
BRCA	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg21770322	chr7:97807741	LMTK2	0.65	19.7	0.61	7.01e-68	Breast cancer;
BRCA	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg03684893	chr10:554711	DIP2C	-0.43	-10.39	-0.38	1.73e-23	Psychosis in Alzheimer's disease;
BRCA	cis	rs3820928	0.874	rs6717168	chr2:227901342	C/T	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.35	-0.31	4.31e-16	Pulmonary function;
BRCA	cis	rs6484504	0.625	rs796341	chr11:31414151	G/A	cg14844989	chr11:31128820	NA	0.44	9.38	0.35	1.16e-19	Red blood cell count;
BRCA	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg26384229	chr12:38710491	ALG10B	0.68	15.91	0.53	2.84e-48	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.29	8.34	0.31	4.5e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg24812749	chr6:127587940	RNF146	0.68	15.55	0.52	1.82e-46	Breast cancer;
BRCA	trans	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.46	9.01	0.34	2.3e-18	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg00677455	chr12:58241039	CTDSP2	0.45	10.73	0.39	8.25e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg15839431	chr19:19639596	YJEFN3	0.41	9.09	0.34	1.26e-18	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg17366294	chr4:99064904	C4orf37	0.43	10.08	0.37	2.77e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.06	-0.43	2.49e-30	Alzheimer's disease;
BRCA	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg01028140	chr2:1542097	TPO	-0.7	-13.25	-0.46	1.46e-35	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg25036284	chr2:26402008	FAM59B	-0.65	-10.18	-0.37	1.16e-22	Gut microbiome composition (summer);
BRCA	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg11822812	chr5:140052017	DND1	-0.31	-8.58	-0.32	7.33e-17	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.2	-0.56	9.32e-55	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.667	rs78426057	chr1:152964528	T/C	cg21543102	chr1:152974771	SPRR3	-0.3	-8.49	-0.32	1.44e-16	Inflammatory skin disease;
BRCA	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18876405	chr7:65276391	NA	0.7	18.56	0.59	7.85e-62	Calcium levels;
BRCA	cis	rs6456156	0.526	rs1854853	chr6:167533062	A/G	cg07741184	chr6:167504864	NA	-0.28	-8.34	-0.31	4.56e-16	Primary biliary cholangitis;
BRCA	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg01877450	chr7:97915802	BRI3	-0.37	-8.57	-0.32	7.96e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	29.51	0.76	2.06e-121	Chronic sinus infection;
BRCA	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg18357645	chr12:58087776	OS9	0.44	12.47	0.44	4.44e-32	Celiac disease or Rheumatoid arthritis;
BRCA	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg16141378	chr3:129829833	LOC729375	0.33	7.83	0.3	1.98e-14	Mood instability;
BRCA	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.69	-15.43	-0.52	6.69e-46	Breast cancer;
BRCA	cis	rs6942756	0.806	rs10248810	chr7:128993806	G/A	cg02491457	chr7:128862824	NA	-0.58	-12.04	-0.43	3.07e-30	White matter hyperintensity burden;
BRCA	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg08045932	chr20:61659980	NA	0.49	11.18	0.4	1.22e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg09307838	chr4:120376055	NA	0.44	9.12	0.34	9.32e-19	Diastolic blood pressure;
BRCA	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg16950941	chr11:66035639	RAB1B	0.46	12.3	0.44	2.24e-31	Gout;
BRCA	cis	rs1499972	0.941	rs62263123	chr3:117632263	G/A	cg07612923	chr3:117604196	NA	0.6	8.15	0.31	1.97e-15	Schizophrenia;
BRCA	trans	rs6479891	1.000	rs2616629	chr10:65213816	T/C	cg14819942	chr15:35414228	NA	0.35	8.55	0.32	8.78e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.43	-0.38	1.21e-23	Psoriasis;
BRCA	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg23711669	chr6:146136114	FBXO30	0.78	18.73	0.6	1.03e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3106136	0.527	rs10016806	chr4:95158495	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.14	-0.37	1.72e-22	Capecitabine sensitivity;
BRCA	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg07636037	chr3:49044803	WDR6	0.98	29.26	0.76	4.4e-120	Parkinson's disease;
BRCA	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg10560079	chr2:191398806	TMEM194B	-0.68	-12.88	-0.45	6.29e-34	Diastolic blood pressure;
BRCA	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg00277334	chr10:82204260	NA	-0.44	-8.32	-0.31	5.36e-16	Post bronchodilator FEV1;
BRCA	cis	rs7809799	0.850	rs10248890	chr7:98752384	A/G	cg05967295	chr7:98741636	SMURF1	-0.78	-7.83	-0.3	2.1e-14	Ulcerative colitis;
BRCA	cis	rs7572733	0.534	rs1401095	chr2:198779867	C/T	cg00792783	chr2:198669748	PLCL1	-0.48	-10.32	-0.38	3.35e-23	Dermatomyositis;
BRCA	cis	rs4631830	0.720	rs12763717	chr10:51500874	C/G	cg16070123	chr10:51489643	NA	0.35	7.81	0.3	2.28e-14	Prostate-specific antigen levels;
BRCA	trans	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg17712092	chr4:129076599	LARP1B	-0.44	-9.33	-0.35	1.76e-19	DNA methylation (variation);
BRCA	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg18404041	chr3:52824283	ITIH1	-0.36	-9.36	-0.35	1.29e-19	Schizophrenia;
BRCA	cis	rs13315871	1.000	rs75828026	chr3:58346736	C/T	cg20936604	chr3:58311152	NA	-0.63	-8.07	-0.3	3.46e-15	Cholesterol, total;
BRCA	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg04025307	chr7:1156635	C7orf50	0.58	9.08	0.34	1.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11229555	1.000	rs7102510	chr11:58371283	T/G	cg15696309	chr11:58395628	NA	-0.53	-11.58	-0.42	2.85e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg26043149	chr18:55253948	FECH	-0.36	-7.92	-0.3	1.05e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7945718	0.934	rs11022478	chr11:12741104	T/C	cg25843174	chr11:12811716	TEAD1	0.21	7.86	0.3	1.61e-14	Educational attainment (years of education);
BRCA	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	18.05	0.58	3.74e-59	Platelet count;
BRCA	trans	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg26043149	chr18:55253948	FECH	0.42	8.99	0.34	2.84e-18	Bone mineral density;
BRCA	cis	rs4671400	0.571	rs6738482	chr2:61494901	A/G	cg15711740	chr2:61764176	XPO1	0.42	8.83	0.33	1.03e-17	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.24	-20.65	-0.63	5.99e-73	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	13.19	0.46	2.73e-35	Eosinophil percentage of white cells;
BRCA	cis	rs2479724	0.935	rs7753507	chr6:41784094	C/T	cg17623882	chr6:41773611	USP49	0.37	10.32	0.38	3.39e-23	Menarche (age at onset);
BRCA	cis	rs12367572	0.965	rs10748405	chr12:45321341	C/G	cg04608330	chr12:45269318	NELL2	-0.61	-13.46	-0.47	1.62e-36	Gut microbiome composition (summer);
BRCA	cis	rs7560272	0.501	rs12624267	chr2:73986931	C/T	cg20560298	chr2:73613845	ALMS1	0.34	8.74	0.33	1.98e-17	Schizophrenia;
BRCA	cis	rs870825	0.655	rs1527870	chr4:185616631	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.17	0.56	1.32e-54	Blood protein levels;
BRCA	cis	rs4074536	0.622	rs10737736	chr1:116315536	G/A	cg21648376	chr1:116311395	CASQ2	-0.55	-9.08	-0.34	1.37e-18	QRS duration;
BRCA	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg00579200	chr11:133705235	NA	-0.37	-7.82	-0.3	2.23e-14	Childhood ear infection;
BRCA	cis	rs911119	1.000	rs1064039	chr20:23618427	C/T	cg16589663	chr20:23618590	CST3	0.47	8.83	0.33	9.75e-18	Chronic kidney disease;
BRCA	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.92	-0.33	4.83e-18	Monocyte percentage of white cells;
BRCA	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg12193833	chr17:30244370	NA	-0.61	-9.2	-0.34	4.97e-19	Hip circumference adjusted for BMI;
BRCA	cis	rs12618769	0.597	rs72819965	chr2:99023719	G/C	cg10123293	chr2:99228465	UNC50	0.44	8.76	0.33	1.81e-17	Bipolar disorder;
BRCA	cis	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg07460842	chr6:66804631	NA	0.87	15.64	0.53	6.69e-47	Exhaled nitric oxide levels;
BRCA	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg26384229	chr12:38710491	ALG10B	0.56	11.67	0.42	1.12e-28	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08219700	chr8:58056026	NA	0.44	7.92	0.3	1.08e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg14019146	chr3:50243930	SLC38A3	0.41	10.05	0.37	3.63e-22	Body mass index;
BRCA	cis	rs9463078	0.774	rs10948222	chr6:45244415	T/C	cg25276700	chr6:44698697	NA	-0.35	-7.9	-0.3	1.2e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs1941023	0.584	rs2233252	chr11:60157107	T/G	cg08716584	chr11:60157161	MS4A7	-0.44	-10.63	-0.39	2.13e-24	Congenital heart disease (maternal effect);
BRCA	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg18198730	chr1:247681584	NA	0.5	11.33	0.41	3.1e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg25358565	chr5:93447407	FAM172A	1.25	19.09	0.6	1.28e-64	Diabetic retinopathy;
BRCA	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg01292856	chr11:65242576	NA	0.36	9.24	0.34	3.66e-19	Bone mineral density;
BRCA	cis	rs7524258	0.900	rs12035586	chr1:7273020	C/T	cg07173049	chr1:7289937	CAMTA1	-0.37	-8.79	-0.33	1.41e-17	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg13256891	chr4:100009986	ADH5	0.5	9.39	0.35	1.05e-19	Alcohol dependence;
BRCA	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02176678	chr2:219576539	TTLL4	0.46	11.91	0.43	1.07e-29	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg11764359	chr7:65958608	NA	0.68	15.5	0.52	3.05e-46	Aortic root size;
BRCA	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	12.82	0.45	1.27e-33	Lung cancer in ever smokers;
BRCA	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.86e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg26395211	chr5:140044315	WDR55	0.35	7.84	0.3	1.86e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-8.16	-0.31	1.74e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs36051895	0.632	rs12336875	chr9:5138404	C/A	cg02405213	chr9:5042618	JAK2	-0.42	-8.1	-0.31	2.76e-15	Pediatric autoimmune diseases;
BRCA	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	10.07	0.37	3e-22	Neuroticism;
BRCA	cis	rs701145	0.556	rs191651	chr3:153973887	T/G	cg12800244	chr3:153838788	SGEF	0.43	8.54	0.32	1.01e-16	Coronary artery disease;
BRCA	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg23711669	chr6:146136114	FBXO30	0.65	14.9	0.51	2.65e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg18132916	chr6:79620363	NA	-0.46	-10.16	-0.37	1.42e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg26395211	chr5:140044315	WDR55	0.36	8.01	0.3	5.3e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	14.87	0.51	3.65e-43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9790314	0.638	rs13064176	chr3:160644181	A/T	cg03342759	chr3:160939853	NMD3	-0.45	-8.62	-0.32	5.12e-17	Morning vs. evening chronotype;
BRCA	cis	rs10504073	0.669	rs11779189	chr8:50030592	C/G	cg00325661	chr8:49890786	NA	-0.37	-10.9	-0.4	1.75e-25	Blood metabolite ratios;
BRCA	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg03585969	chr10:35415529	CREM	0.56	11.51	0.41	5.36e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg26818010	chr10:134567672	INPP5A	-0.63	-13.42	-0.47	2.27e-36	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs1997103	0.954	rs940880	chr7:55392619	C/G	cg20935933	chr6:143382018	AIG1	0.6	11.57	0.42	3.12e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg09307838	chr4:120376055	NA	-0.54	-11.3	-0.41	3.99e-27	Corneal astigmatism;
BRCA	trans	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.33	8.5	0.32	1.3e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	9.05	0.34	1.66e-18	Platelet count;
BRCA	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs34779708	0.733	rs4444023	chr10:35548354	G/A	cg03585969	chr10:35415529	CREM	0.44	9.1	0.34	1.17e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20891558	chr2:74357851	NA	0.48	11.69	0.42	9.69e-29	Gestational age at birth (maternal effect);
BRCA	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg09065629	chr16:1709722	CRAMP1L	0.37	8.47	0.32	1.63e-16	Coronary artery disease;
BRCA	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	8.7	0.33	2.75e-17	Platelet count;
BRCA	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg26384229	chr12:38710491	ALG10B	0.77	17.53	0.57	1.92e-56	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg21775007	chr8:11205619	TDH	-0.37	-7.95	-0.3	8.58e-15	Joint mobility (Beighton score);
BRCA	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.42	-8.93	-0.33	4.58e-18	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg18252515	chr7:66147081	NA	-0.98	-13.86	-0.48	2.29e-38	Diabetic kidney disease;
BRCA	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg06671706	chr8:8559999	CLDN23	0.44	8.46	0.32	1.85e-16	Obesity-related traits;
BRCA	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg13010199	chr12:38710504	ALG10B	0.44	8.82	0.33	1.11e-17	Bladder cancer;
BRCA	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg09307838	chr4:120376055	NA	0.47	8.97	0.33	3.33e-18	Corneal astigmatism;
BRCA	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg14631576	chr9:95140430	CENPP	-0.37	-8.96	-0.33	3.55e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00908189	chr16:619842	PIGQ	0.7	17.52	0.57	1.96e-56	Height;
BRCA	cis	rs870825	0.616	rs4443323	chr4:185629805	C/A	cg20176042	chr4:185552304	CASP3	-0.53	-8.12	-0.31	2.38e-15	Blood protein levels;
BRCA	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	5.04e-21	Alcohol dependence;
BRCA	cis	rs1865721	0.848	rs12966327	chr18:73208445	C/T	cg26385618	chr18:73139727	C18orf62	-0.36	-8.06	-0.3	3.84e-15	Intelligence;
BRCA	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg26384229	chr12:38710491	ALG10B	0.83	22.45	0.66	9.57e-83	Heart rate;
BRCA	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg24642439	chr20:33292090	TP53INP2	0.68	15.58	0.52	1.32e-46	Coronary artery disease;
BRCA	trans	rs3960554	0.610	rs10265696	chr7:75766712	G/A	cg19862616	chr7:65841803	NCRNA00174	0.59	12.29	0.44	2.64e-31	Eotaxin levels;
BRCA	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.46	-0.61	1.35e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.68	-17.18	-0.56	1.15e-54	Multiple sclerosis;
BRCA	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.51	-9.67	-0.36	1.01e-20	Aortic root size;
BRCA	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11644478	chr21:40555479	PSMG1	0.89	21.0	0.64	7.43e-75	Cognitive function;
BRCA	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg14683738	chr19:37701593	ZNF585B	0.47	8.07	0.3	3.43e-15	Coronary artery calcification;
BRCA	cis	rs10193935	0.901	rs59890734	chr2:42595662	G/A	cg27598129	chr2:42591480	NA	-0.97	-15.46	-0.52	5.13e-46	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.25	-8.46	-0.32	1.83e-16	Systemic lupus erythematosus;
BRCA	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-10.58	-0.39	3.33e-24	Systolic blood pressure;
BRCA	cis	rs1568889	1.000	rs61889054	chr11:28333000	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.6	11.44	0.41	1.02e-27	Bipolar disorder;
BRCA	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg22676075	chr6:135203613	NA	0.44	8.6	0.32	6.06e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg03929089	chr4:120376271	NA	0.49	8.21	0.31	1.24e-15	Axial length;
BRCA	cis	rs17253792	0.822	rs10137340	chr14:56050989	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.61	8.65	0.32	4.02e-17	Putamen volume;
BRCA	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-9.26	-0.34	3.02e-19	Systolic blood pressure;
BRCA	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg26597838	chr10:835615	NA	0.88	13.49	0.47	1.1e-36	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg25358565	chr5:93447407	FAM172A	1.19	18.01	0.58	6.22e-59	Diabetic retinopathy;
BRCA	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg26384229	chr12:38710491	ALG10B	0.74	17.23	0.56	6.19e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg07460842	chr6:66804631	NA	0.99	19.85	0.62	1.08e-68	Exhaled nitric oxide output;
BRCA	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg17888033	chr8:143858414	LYNX1	-0.34	-8.22	-0.31	1.17e-15	Urinary tract infection frequency;
BRCA	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg06238570	chr21:40685208	BRWD1	-0.46	-8.95	-0.33	3.71e-18	Cognitive function;
BRCA	cis	rs6920965	0.545	rs2326242	chr6:126174859	A/C	cg05901451	chr6:126070800	HEY2	-0.35	-8.46	-0.32	1.76e-16	High light scatter reticulocyte count;
BRCA	cis	rs9612	1.000	rs346534	chr19:44250831	A/G	cg08581076	chr19:44259116	C19orf61	0.53	9.56	0.35	2.53e-20	Exhaled nitric oxide output;
BRCA	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg04896959	chr15:78267971	NA	0.36	8.48	0.32	1.55e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg20090143	chr19:45452003	APOC2	0.27	8.1	0.31	2.69e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg11822812	chr5:140052017	DND1	-0.32	-8.68	-0.32	3.31e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs752010	0.619	rs6703992	chr1:42115888	G/A	cg06885757	chr1:42089581	HIVEP3	0.32	10.53	0.38	5.02e-24	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14240646	chr10:27532245	ACBD5	-0.74	-9.4	-0.35	9.27e-20	Breast cancer;
BRCA	cis	rs9400271	0.632	rs9374069	chr6:109586334	A/G	cg21918786	chr6:109611834	NA	-0.31	-7.86	-0.3	1.64e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1997103	0.911	rs6949931	chr7:55391081	T/C	cg20935933	chr6:143382018	AIG1	0.61	11.57	0.42	3.17e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg00106254	chr7:1943704	MAD1L1	-0.38	-9.25	-0.34	3.45e-19	Schizophrenia;
BRCA	cis	rs7593730	0.666	rs10929973	chr2:161119907	A/G	cg22609984	chr2:161126801	NA	0.43	9.28	0.34	2.51e-19	Type 2 diabetes;
BRCA	cis	rs6545883	0.965	rs6545872	chr2:61724568	G/A	cg15711740	chr2:61764176	XPO1	-0.55	-13.97	-0.48	6.42e-39	Tuberculosis;
BRCA	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg04450456	chr4:17643702	FAM184B	0.41	12.04	0.43	3.16e-30	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10129255	0.500	rs9324092	chr14:107139823	A/G	cg07958169	chr14:107095056	NA	0.42	9.04	0.34	1.85e-18	Kawasaki disease;
BRCA	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11764359	chr7:65958608	NA	-0.75	-17.02	-0.56	7.54e-54	Aortic root size;
BRCA	cis	rs9467773	0.595	rs2237236	chr6:26451553	A/G	cg09904177	chr6:26538194	HMGN4	-0.36	-9.54	-0.35	2.89e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.37	-9.6	-0.35	1.82e-20	Schizophrenia;
BRCA	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg17135325	chr3:160939158	NMD3	0.44	8.41	0.32	2.59e-16	Parkinson's disease;
BRCA	cis	rs9341808	0.683	rs9359409	chr6:80826897	C/G	cg08355045	chr6:80787529	NA	0.37	9.37	0.35	1.24e-19	Sitting height ratio;
BRCA	cis	rs4948102	0.655	rs4947533	chr7:56071282	T/C	cg09872392	chr7:56161020	PHKG1	-0.39	-8.86	-0.33	8.09e-18	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg14092988	chr3:52407081	DNAH1	0.38	8.77	0.33	1.61e-17	Bipolar disorder;
BRCA	cis	rs9649465	0.551	rs10255400	chr7:123388036	G/A	cg03229431	chr7:123269106	ASB15	-0.55	-12.45	-0.44	5.11e-32	Migraine;
BRCA	cis	rs6484504	0.600	rs942272	chr11:31364368	C/T	cg26647111	chr11:31128758	NA	0.45	9.59	0.35	1.97e-20	Red blood cell count;
BRCA	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg18132916	chr6:79620363	NA	-0.48	-10.89	-0.4	1.93e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg00701064	chr4:6280414	WFS1	-0.65	-17.23	-0.56	6.59e-55	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg10057126	chr4:77819792	ANKRD56	0.66	14.86	0.51	3.87e-43	Emphysema distribution in smoking;
BRCA	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg00981070	chr1:2046702	PRKCZ	-0.29	-7.81	-0.3	2.32e-14	Height;
BRCA	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18876405	chr7:65276391	NA	-0.51	-11.78	-0.42	4.09e-29	Aortic root size;
BRCA	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg22800045	chr5:56110881	MAP3K1	-0.41	-8.24	-0.31	9.93e-16	Coronary artery disease;
BRCA	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06002616	chr8:101225028	SPAG1	-0.34	-8.28	-0.31	7.37e-16	Atrioventricular conduction;
BRCA	cis	rs10465746	0.935	rs11163878	chr1:84442654	G/A	cg10977910	chr1:84465055	TTLL7	0.52	10.55	0.39	4.28e-24	Obesity-related traits;
BRCA	cis	rs2073300	1.000	rs17830565	chr20:23444805	G/A	cg12062639	chr20:23401060	NAPB	0.89	10.63	0.39	2.06e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs724568	0.546	rs1549778	chr2:67951297	G/T	cg14046302	chr2:67939758	NA	-0.39	-10.38	-0.38	1.99e-23	Major depressive disorder (broad);
BRCA	cis	rs6429082	0.608	rs4469707	chr1:235570634	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.53	-12.2	-0.43	6.3e-31	Adiposity;
BRCA	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg14820908	chr5:178986412	RUFY1	0.48	11.77	0.42	4.39e-29	Lung cancer;
BRCA	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.72	-0.39	9.03e-25	Tonsillectomy;
BRCA	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg21280719	chr6:42927975	GNMT	0.25	9.46	0.35	5.56e-20	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
BRCA	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.21	0.49	5.09e-40	Motion sickness;
BRCA	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.39	-10.15	-0.37	1.46e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.06	-0.3	3.74e-15	Prostate cancer;
BRCA	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg00012203	chr2:219082015	ARPC2	0.48	9.21	0.34	4.56e-19	Colorectal cancer;
BRCA	cis	rs1953600	0.729	rs2819872	chr10:81906269	A/G	cg04850286	chr10:81895943	PLAC9	0.33	10.18	0.37	1.15e-22	Sarcoidosis;
BRCA	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg04691961	chr3:161091175	C3orf57	-0.58	-14.02	-0.49	3.77e-39	Morning vs. evening chronotype;
BRCA	cis	rs490234	0.812	rs13300639	chr9:128407298	A/G	cg14078157	chr9:128172775	NA	-0.47	-10.43	-0.38	1.22e-23	Mean arterial pressure;
BRCA	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg15212455	chr7:39170539	POU6F2	0.39	8.59	0.32	6.7e-17	IgG glycosylation;
BRCA	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg05863683	chr7:1912471	MAD1L1	0.4	8.49	0.32	1.47e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs9512730	0.527	rs11619784	chr13:27999643	A/G	cg04070771	chr13:27998621	GTF3A	0.44	8.37	0.31	3.66e-16	Schizophrenia;
BRCA	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg14675211	chr2:100938903	LONRF2	0.44	9.68	0.36	9.17e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs877282	0.898	rs34490091	chr10:765800	A/C	cg22713356	chr15:30763199	NA	1.3	24.11	0.69	7.71e-92	Uric acid levels;
BRCA	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg14004847	chr7:1930337	MAD1L1	-0.47	-8.95	-0.33	3.73e-18	Bipolar disorder and schizophrenia;
BRCA	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg15934090	chr1:100435551	SLC35A3	0.35	8.15	0.31	1.91e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg26384229	chr12:38710491	ALG10B	0.64	17.08	0.56	3.92e-54	Heart rate;
BRCA	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg20307385	chr11:47447363	PSMC3	0.8	19.04	0.6	2.3e-64	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg17971929	chr21:40555470	PSMG1	0.74	15.9	0.53	3.36e-48	Cognitive function;
BRCA	cis	rs1190552	0.846	rs12883789	chr14:102954621	G/A	cg18135206	chr14:102964638	TECPR2	0.45	8.88	0.33	6.6e-18	Blood protein levels;
BRCA	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-11.15	-0.4	1.71e-26	Mood instability;
BRCA	trans	rs931812	0.895	rs4734493	chr8:101902169	C/T	cg20993868	chr7:22813445	NA	-0.52	-15.22	-0.52	7.6e-45	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs4478858	0.684	rs4949372	chr1:31738857	G/A	cg00250761	chr1:31883323	NA	-0.32	-8.33	-0.31	4.93e-16	Alcohol dependence;
BRCA	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg26384229	chr12:38710491	ALG10B	0.74	17.56	0.57	1.3e-56	Bladder cancer;
BRCA	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	9.48	0.35	5.03e-20	Tonsillectomy;
BRCA	cis	rs4664304	0.620	rs10186586	chr2:160715334	T/C	cg14819504	chr2:160761413	LY75	0.34	8.48	0.32	1.59e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	17.26	0.56	4.69e-55	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs13046373	0.507	rs11088139	chr21:31978884	T/G	cg16431978	chr21:31797932	KRTAP13-3	0.36	9.22	0.34	4.27e-19	HDL cholesterol;
BRCA	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-9.71	-0.36	6.91e-21	Tonsillectomy;
BRCA	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-15.47	-0.52	4.4e-46	Total cholesterol levels;
BRCA	cis	rs117623576	0.680	rs12269122	chr10:32367864	C/T	cg03047570	chr10:32398778	NA	-0.5	-7.9	-0.3	1.25e-14	Anti-saccade response;
BRCA	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.47	9.62	0.36	1.55e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.58	-0.32	7.12e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-10.86	-0.39	2.48e-25	Bipolar disorder and schizophrenia;
BRCA	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-16.96	-0.56	1.56e-53	Intelligence (multi-trait analysis);
BRCA	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg20290983	chr6:43655470	MRPS18A	1.09	37.56	0.83	7e-164	IgG glycosylation;
BRCA	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg06671706	chr8:8559999	CLDN23	0.43	8.42	0.32	2.42e-16	Obesity-related traits;
BRCA	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.52	-0.32	1.15e-16	Aortic root size;
BRCA	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-11.19	-0.4	1.17e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg20203395	chr5:56204925	C5orf35	0.41	9.14	0.34	7.89e-19	Initial pursuit acceleration;
BRCA	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg05985134	chr18:33552581	C18orf21	-0.65	-12.6	-0.45	1.18e-32	Endometriosis;Drug-induced torsades de pointes;
BRCA	trans	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg25214090	chr10:38739885	LOC399744	0.42	9.71	0.36	6.98e-21	Corneal astigmatism;
BRCA	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-8.06	-0.3	3.9e-15	Tonsillectomy;
BRCA	cis	rs593982	0.920	rs487264	chr11:65481465	A/C	cg08755490	chr11:65554678	OVOL1	1.22	18.09	0.58	2.4e-59	Atopic dermatitis;
BRCA	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00149659	chr3:10157352	C3orf10	0.75	13.37	0.47	4.08e-36	Alzheimer's disease;
BRCA	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg03474202	chr17:45855739	NA	0.46	12.11	0.43	1.48e-30	IgG glycosylation;
BRCA	trans	rs2262909	0.925	rs56073035	chr19:22276298	C/G	cg17074339	chr11:11642133	GALNTL4	0.44	8.6	0.32	5.92e-17	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs990171	0.607	rs3917245	chr2:102775155	G/A	cg22835712	chr2:102737379	NA	0.53	9.2	0.34	5.15e-19	Lymphocyte counts;
BRCA	cis	rs62158211	1.000	rs1807282	chr2:114110036	A/T	cg17784749	chr2:114082611	LOC440839	0.52	9.07	0.34	1.44e-18	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
BRCA	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	18.0	0.58	6.64e-59	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.09	0.4	2.92e-26	Bipolar disorder;
BRCA	cis	rs829880	0.789	rs1096146	chr12:98850966	A/G	cg25150519	chr12:98850993	NA	0.63	14.04	0.49	3.33e-39	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg25482853	chr8:67687455	SGK3	1.0	17.42	0.57	6.34e-56	Lung disease severity in cystic fibrosis;
BRCA	cis	rs4363385	0.693	rs2339487	chr1:152983528	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-9.08	-0.34	1.38e-18	Inflammatory skin disease;
BRCA	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg23888215	chr10:79422304	NA	-0.56	-10.56	-0.39	3.9e-24	Bone mineral density;
BRCA	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg24812749	chr6:127587940	RNF146	0.86	20.25	0.63	7.96e-71	Breast cancer;
BRCA	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg22713356	chr15:30763199	NA	1.3	24.75	0.7	2.51e-95	Uric acid levels;
BRCA	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg01420254	chr6:26195488	NA	0.55	8.54	0.32	9.51e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18854424	chr1:2615690	NA	-0.35	-8.46	-0.32	1.87e-16	Ulcerative colitis;
BRCA	cis	rs477692	0.905	rs514963	chr10:131419707	C/T	cg05714579	chr10:131428358	MGMT	0.56	13.71	0.48	1.05e-37	Response to temozolomide;
BRCA	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-9.94	-0.37	9.93e-22	Renal function-related traits (BUN);
BRCA	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.37	-0.52	1.39e-45	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg24642439	chr20:33292090	TP53INP2	0.7	15.82	0.53	7.88e-48	Coronary artery disease;
BRCA	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13126279	chr21:47581558	C21orf56	-0.48	-10.83	-0.39	3.37e-25	Testicular germ cell tumor;
BRCA	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.53	12.39	0.44	9.04e-32	Electrocardiographic conduction measures;
BRCA	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.59	-8.63	-0.32	5.03e-17	Schizophrenia;
BRCA	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11764359	chr7:65958608	NA	-0.75	-16.59	-0.55	1.12e-51	Aortic root size;
BRCA	trans	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg06521331	chr12:34319734	NA	-0.45	-8.62	-0.32	5.4e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11644478	chr21:40555479	PSMG1	-0.66	-14.26	-0.49	2.92e-40	Cognitive function;
BRCA	cis	rs4730250	0.707	rs3729877	chr7:106787065	T/G	cg02696742	chr7:106810147	HBP1	0.58	9.5	0.35	3.97e-20	Osteoarthritis;
BRCA	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg05623727	chr3:50126028	RBM5	-0.48	-11.64	-0.42	1.63e-28	Body mass index;
BRCA	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg00666640	chr1:248458726	OR2T12	0.3	8.42	0.32	2.5e-16	Common traits (Other);
BRCA	cis	rs2016266	0.964	rs1609474	chr12:53676814	C/T	cg26875137	chr12:53738046	NA	-0.36	-9.63	-0.36	1.41e-20	Bone mineral density (spine);Bone mineral density;
BRCA	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg26384229	chr12:38710491	ALG10B	0.66	13.95	0.48	8.57e-39	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.34	-8.38	-0.31	3.48e-16	Personality dimensions;
BRCA	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg16339924	chr4:17578868	LAP3	0.66	15.54	0.52	1.99e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg13010199	chr12:38710504	ALG10B	0.51	10.15	0.37	1.53e-22	Bladder cancer;
BRCA	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg03354898	chr7:1950403	MAD1L1	-0.4	-8.5	-0.32	1.32e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs939658	0.805	rs12902831	chr15:79433171	G/A	cg17916960	chr15:79447300	NA	-0.42	-10.65	-0.39	1.75e-24	Refractive error;
BRCA	cis	rs7973719	0.833	rs7962563	chr12:7353514	G/A	cg07052231	chr12:7363540	PEX5	0.36	8.18	0.31	1.54e-15	IgG glycosylation;
BRCA	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg05985134	chr18:33552581	C18orf21	0.64	11.51	0.41	5.2e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs4478858	0.735	rs3806255	chr1:31791578	A/G	cg00250761	chr1:31883323	NA	-0.33	-8.54	-0.32	9.88e-17	Alcohol dependence;
BRCA	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg13175981	chr1:150552382	MCL1	0.41	9.18	0.34	5.73e-19	Tonsillectomy;
BRCA	cis	rs2668423	0.922	rs3826942	chr19:1360575	A/G	cg02639931	chr19:1387894	NDUFS7	0.63	13.9	0.48	1.37e-38	Nonalcoholic fatty liver disease;
BRCA	cis	rs3925075	0.966	rs7195915	chr16:31344455	A/G	cg02846316	chr16:31340340	ITGAM	0.54	13.33	0.47	5.89e-36	IgA nephropathy;
BRCA	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg08888203	chr3:10149979	C3orf24	0.63	13.81	0.48	3.82e-38	Alzheimer's disease;
BRCA	cis	rs965469	0.545	rs6051845	chr20:3402792	A/G	cg25506879	chr20:3388711	C20orf194	-0.44	-9.32	-0.35	1.79e-19	IFN-related cytopenia;
BRCA	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg27478167	chr7:817139	HEATR2	-0.41	-8.69	-0.33	3.03e-17	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.59	-12.31	-0.44	2.1e-31	Lymphocyte counts;
BRCA	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg24829409	chr8:58192753	C8orf71	-0.61	-12.57	-0.45	1.5e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03517284	chr6:25882590	NA	0.53	12.22	0.44	5.47e-31	Blood metabolite levels;
BRCA	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg00717180	chr2:96193071	NA	-0.38	-10.34	-0.38	2.9e-23	HDL cholesterol;
BRCA	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.49	-0.32	1.46e-16	Monocyte percentage of white cells;
BRCA	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg14440974	chr22:39074834	NA	-0.35	-8.04	-0.3	4.35e-15	Menopause (age at onset);
BRCA	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg20203395	chr5:56204925	C5orf35	-0.6	-11.91	-0.43	1.1e-29	Initial pursuit acceleration;
BRCA	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-11.95	-0.43	7.75e-30	Personality dimensions;
BRCA	cis	rs2274273	1.000	rs7142704	chr14:55630603	C/A	cg04306507	chr14:55594613	LGALS3	0.32	8.85	0.33	8.49e-18	Protein biomarker;
BRCA	cis	rs2191566	0.576	rs381888	chr19:44493005	C/T	cg20607764	chr19:44506953	ZNF230	0.36	7.85	0.3	1.81e-14	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.65	0.39	1.76e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg11946769	chr3:48343235	NME6	0.68	14.02	0.48	4.16e-39	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg05340658	chr4:99064831	C4orf37	0.68	17.16	0.56	1.43e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg20701182	chr2:24300061	SF3B14	0.71	13.61	0.47	3.21e-37	Lymphocyte counts;
BRCA	cis	rs751728	0.664	rs943474	chr6:33749834	G/C	cg25922239	chr6:33757077	LEMD2	0.5	12.69	0.45	4.58e-33	Crohn's disease;
BRCA	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00149659	chr3:10157352	C3orf10	0.71	12.54	0.44	2.2e-32	Alzheimer's disease;
BRCA	trans	rs629535	0.767	rs72654073	chr8:70081231	G/A	cg21567404	chr3:27674614	NA	-1.02	-21.45	-0.65	2.82e-77	Dupuytren's disease;
BRCA	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.05e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72781680	0.821	rs11894756	chr2:24170214	A/G	cg08917208	chr2:24149416	ATAD2B	-0.64	-10.86	-0.39	2.59e-25	Lymphocyte counts;
BRCA	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg23708337	chr7:1209742	NA	0.5	8.61	0.32	5.65e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg14675211	chr2:100938903	LONRF2	0.52	11.96	0.43	7.15e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.64	0.36	1.23e-20	Menopause (age at onset);
BRCA	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg04989706	chr14:50066350	PPIL5	-0.47	-9.27	-0.34	2.81e-19	Carotid intima media thickness;
BRCA	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg22601191	chr20:60968625	CABLES2	0.43	10.01	0.37	5.2e-22	Colorectal cancer;
BRCA	trans	rs12517041	1.000	rs115818285	chr5:23291449	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.45	-8.13	-0.31	2.16e-15	Calcium levels;
BRCA	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg20587970	chr11:113659929	NA	-1.2	-21.73	-0.65	8.56e-79	Hip circumference adjusted for BMI;
BRCA	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg04025307	chr7:1156635	C7orf50	0.58	9.08	0.34	1.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1035144	0.546	rs2215981	chr14:81444967	G/A	cg06600135	chr14:81408086	NA	-0.48	-11.07	-0.4	3.59e-26	Male sexual orientation;
BRCA	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-14.6	-0.5	7.34e-42	Total cholesterol levels;
BRCA	trans	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.42	9.44	0.35	7.13e-20	Brugada syndrome;
BRCA	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg03433033	chr1:76189801	ACADM	0.7	13.27	0.46	1.13e-35	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg08859206	chr1:53392774	SCP2	0.48	10.61	0.39	2.5e-24	Monocyte count;
BRCA	cis	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg24692254	chr21:30365293	RNF160	-0.46	-7.96	-0.3	7.6e-15	Cognitive test performance;
BRCA	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg21138405	chr5:131827807	IRF1	0.4	12.97	0.46	2.5e-34	Asthma (sex interaction);
BRCA	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg04607235	chr12:12878440	APOLD1	-0.69	-10.67	-0.39	1.38e-24	Systemic lupus erythematosus;
BRCA	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	13.84	0.48	2.6e-38	Colorectal cancer;
BRCA	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.39	-8.39	-0.32	3.03e-16	IgG glycosylation;
BRCA	cis	rs1467026	0.563	rs12629928	chr3:12811796	C/T	cg24848339	chr3:12840334	CAND2	0.4	10.04	0.37	3.96e-22	P wave duration;
BRCA	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.52	8.26	0.31	8.48e-16	Renal function-related traits (BUN);
BRCA	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg24747557	chr10:131355152	MGMT	0.37	8.54	0.32	9.79e-17	Response to temozolomide;
BRCA	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	27.91	0.74	1.14e-112	Chronic sinus infection;
BRCA	cis	rs11718455	0.961	rs3846068	chr3:44029835	G/A	cg08738300	chr3:44038990	NA	0.46	8.81	0.33	1.17e-17	Coronary artery disease;
BRCA	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg20387954	chr3:183756860	HTR3D	0.57	12.4	0.44	8.74e-32	Anterior chamber depth;
BRCA	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.43	-10.81	-0.39	3.99e-25	Schizophrenia;
BRCA	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg26384229	chr12:38710491	ALG10B	0.69	16.31	0.54	2.86e-50	Bladder cancer;
BRCA	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-11.96	-0.43	6.63e-30	Response to antipsychotic treatment;
BRCA	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	trans	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg26043149	chr18:55253948	FECH	0.38	8.24	0.31	9.49e-16	Bone mineral density;
BRCA	cis	rs3820928	0.935	rs113195824	chr2:227769139	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.89	-0.33	6.38e-18	Pulmonary function;
BRCA	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.91	-0.33	5.36e-18	Hip circumference adjusted for BMI;
BRCA	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg27661571	chr11:113659931	NA	-0.81	-12.12	-0.43	1.41e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg24692254	chr21:30365293	RNF160	-0.46	-10.16	-0.37	1.36e-22	Dental caries;
BRCA	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg20701182	chr2:24300061	SF3B14	0.6	9.39	0.35	1.02e-19	Lymphocyte counts;
BRCA	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg20283391	chr11:68216788	NA	-0.48	-9.43	-0.35	7.5e-20	Total body bone mineral density;
BRCA	cis	rs4664304	0.620	rs2048437	chr2:160712065	C/T	cg18514922	chr2:160761262	LY75	0.34	7.97	0.3	7.22e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6782228	0.606	rs58977394	chr3:128337917	C/T	cg16766828	chr3:128327626	NA	-0.42	-9.53	-0.35	3.22e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg07395648	chr5:131743802	NA	0.35	7.94	0.3	9.19e-15	Breast cancer;
BRCA	cis	rs12200560	0.505	rs2015196	chr6:97075331	G/C	cg06623918	chr6:96969491	KIAA0776	0.53	12.75	0.45	2.46e-33	Coronary heart disease;
BRCA	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.78	0.39	5.07e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs17253792	0.818	rs78393484	chr14:56065802	T/C	cg01858014	chr14:56050164	KTN1	-0.73	-9.19	-0.34	5.56e-19	Putamen volume;
BRCA	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06028605	chr16:24865363	SLC5A11	-0.43	-8.83	-0.33	9.71e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg13073564	chr4:8508604	NA	-0.36	-9.62	-0.36	1.47e-20	Response to antineoplastic agents;
BRCA	cis	rs3125734	0.633	rs1864836	chr10:64028538	C/G	cg19640130	chr10:64028056	RTKN2	-0.35	-9.76	-0.36	4.38e-21	Rheumatoid arthritis;
BRCA	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.78	-0.36	3.67e-21	Retinal vascular caliber;
BRCA	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14240646	chr10:27532245	ACBD5	-0.63	-10.02	-0.37	4.98e-22	Breast cancer;
BRCA	cis	rs778371	0.723	rs1022329	chr2:233591239	T/C	cg08000102	chr2:233561755	GIGYF2	0.85	20.92	0.64	2.05e-74	Schizophrenia;
BRCA	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24531977	chr5:56204891	C5orf35	-0.88	-17.68	-0.57	3.01e-57	Initial pursuit acceleration;
BRCA	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg08888203	chr3:10149979	C3orf24	0.65	13.74	0.48	7.58e-38	Alzheimer's disease;
BRCA	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg06060754	chr5:176797920	RGS14	-0.56	-10.82	-0.39	3.7e-25	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14298792	chr15:30685198	CHRFAM7A	-0.42	-7.83	-0.3	2.05e-14	Huntington's disease progression;
BRCA	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg24060327	chr5:131705240	SLC22A5	-0.62	-11.78	-0.42	4.1e-29	Breast cancer;
BRCA	cis	rs28374715	0.617	rs16971735	chr15:41563970	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.57	-12.37	-0.44	1.13e-31	Ulcerative colitis;
BRCA	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	12.25	0.44	4.05e-31	Lung cancer in ever smokers;
BRCA	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg00898013	chr13:113819073	PROZ	-0.36	-8.64	-0.32	4.44e-17	Platelet distribution width;
BRCA	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg04362960	chr10:104952993	NT5C2	0.46	10.74	0.39	7.57e-25	Arsenic metabolism;
BRCA	cis	rs3824867	0.920	rs7105122	chr11:47449544	A/G	cg20307385	chr11:47447363	PSMC3	0.48	10.74	0.39	7.8e-25	Mean corpuscular hemoglobin;
BRCA	cis	rs4594175	0.926	rs7160948	chr14:51612537	T/A	cg23942311	chr14:51606299	NA	0.32	7.81	0.3	2.41e-14	Cancer;
BRCA	trans	rs1973993	0.745	rs6686016	chr1:96948002	G/A	cg10631902	chr5:14652156	NA	-0.49	-14.5	-0.5	2.26e-41	Weight;
BRCA	trans	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg01620082	chr3:125678407	NA	-0.92	-10.32	-0.38	3.23e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs3762637	0.882	rs72958418	chr3:122160373	G/C	cg24169773	chr3:122142474	KPNA1	-0.43	-8.05	-0.3	3.93e-15	LDL cholesterol levels;
BRCA	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21659725	chr3:3221576	CRBN	-0.71	-21.92	-0.66	7.71e-80	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg06784218	chr1:46089804	CCDC17	0.51	12.22	0.44	5.2e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg23708337	chr7:1209742	NA	0.69	10.7	0.39	1.1e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg26384229	chr12:38710491	ALG10B	0.48	11.53	0.41	4.56e-28	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs6479891	1.000	rs61853589	chr10:65187111	T/A	cg14819942	chr15:35414228	NA	0.35	8.58	0.32	7.31e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg14926445	chr8:58193284	C8orf71	-0.47	-8.92	-0.33	4.83e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs3784262	0.528	rs8027188	chr15:58334799	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-9.93	-0.37	1.03e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03452623	chr4:187889614	NA	-0.33	-11.0	-0.4	6.68e-26	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9649465	0.967	rs3779261	chr7:123315174	A/G	cg04330084	chr7:123175371	IQUB	-0.3	-8.29	-0.31	6.93e-16	Migraine;
BRCA	cis	rs9309711	0.772	rs9752251	chr2:3489869	C/T	cg10845886	chr2:3471009	TTC15	-0.77	-16.34	-0.54	2.14e-50	Neurofibrillary tangles;
BRCA	cis	rs7927771	0.524	rs10838784	chr11:47882341	G/A	cg20307385	chr11:47447363	PSMC3	0.41	9.32	0.35	1.89e-19	Subjective well-being;
BRCA	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg05564831	chr3:52568323	NT5DC2	0.36	8.44	0.32	2.17e-16	Electroencephalogram traits;
BRCA	trans	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.28	-0.34	2.54e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg04607235	chr12:12878440	APOLD1	0.51	10.97	0.4	8.97e-26	Birth weight;
BRCA	cis	rs9649465	0.967	rs12706546	chr7:123353414	G/A	cg04330084	chr7:123175371	IQUB	-0.33	-9.0	-0.34	2.54e-18	Migraine;
BRCA	cis	rs9837602	1.000	rs28714363	chr3:99752068	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.16	0.4	1.52e-26	Breast cancer;
BRCA	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg08807101	chr21:30365312	RNF160	0.44	9.5	0.35	4.27e-20	Pancreatic cancer;
BRCA	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.0	22.49	0.66	5.85e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-12.71	-0.45	3.79e-33	Response to antipsychotic treatment;
BRCA	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21659725	chr3:3221576	CRBN	0.33	8.08	0.3	3.32e-15	Body mass index;
BRCA	cis	rs9309473	0.607	rs4641966	chr2:73590806	G/A	cg20560298	chr2:73613845	ALMS1	-0.42	-11.03	-0.4	5.15e-26	Metabolite levels;
BRCA	cis	rs10838687	0.867	rs2957873	chr11:47249294	G/A	cg25783544	chr11:47291846	MADD	-0.42	-8.38	-0.31	3.39e-16	Proinsulin levels;
BRCA	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg05347473	chr6:146136440	FBXO30	0.38	7.81	0.3	2.43e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg05347473	chr6:146136440	FBXO30	0.39	7.94	0.3	9e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-19.13	-0.6	7.5e-65	Systemic lupus erythematosus;
BRCA	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-19.31	-0.61	8.57e-66	Electrocardiographic conduction measures;
BRCA	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg25237894	chr2:233734115	C2orf82	-0.45	-14.33	-0.49	1.34e-40	Coronary artery disease;
BRCA	trans	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg26384229	chr12:38710491	ALG10B	0.55	12.04	0.43	3.26e-30	Morning vs. evening chronotype;
BRCA	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.37	-0.31	3.62e-16	Obesity-related traits;
BRCA	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg21573476	chr21:45109991	RRP1B	0.42	11.28	0.41	4.81e-27	Mean corpuscular volume;
BRCA	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	cg01483505	chr11:975446	AP2A2	0.31	8.41	0.32	2.68e-16	Alzheimer's disease (late onset);
BRCA	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.5	-10.13	-0.37	1.88e-22	Systemic lupus erythematosus;
BRCA	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg03934865	chr2:198174659	NA	-0.38	-8.23	-0.31	1.03e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	trans	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg23762105	chr12:34175262	ALG10	-0.38	-9.72	-0.36	6.49e-21	Morning vs. evening chronotype;
BRCA	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg06618935	chr21:46677482	NA	-0.37	-8.09	-0.3	2.96e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-10.38	-0.38	1.96e-23	Schizophrenia;
BRCA	cis	rs6191	0.838	rs6877893	chr5:142727193	C/T	cg08845721	chr5:142780693	NR3C1	-0.33	-7.81	-0.3	2.42e-14	Night sleep phenotypes;
BRCA	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg11833968	chr6:79620685	NA	-0.44	-9.71	-0.36	7.09e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg11663144	chr21:46675770	NA	-0.47	-11.04	-0.4	4.77e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg08807101	chr21:30365312	RNF160	-0.53	-13.09	-0.46	7.1e-35	Dental caries;
BRCA	cis	rs921968	0.643	rs1344645	chr2:219538019	A/C	cg02176678	chr2:219576539	TTLL4	0.39	10.11	0.37	2.25e-22	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs12210905	0.688	rs12189640	chr6:27474657	T/C	cg08851530	chr6:28072375	NA	0.81	8.01	0.3	5.53e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs218264	0.592	rs35978703	chr4:55368882	C/T	cg17105814	chr4:55365203	NA	-0.39	-8.19	-0.31	1.42e-15	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	8.7	0.33	2.75e-17	Platelet count;
BRCA	trans	rs4650994	0.544	rs4132058	chr1:178505557	A/C	cg05059571	chr16:84539110	KIAA1609	-0.49	-11.12	-0.4	2.23e-26	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs2425143	1.000	rs6060557	chr20:34270266	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.0	-0.34	2.46e-18	Blood protein levels;
BRCA	cis	rs4812048	0.649	rs6070705	chr20:57625231	A/C	cg14073986	chr20:57617431	SLMO2	0.77	11.9	0.43	1.22e-29	Mean platelet volume;
BRCA	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	22.42	0.66	1.41e-82	Platelet count;
BRCA	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.44	10.32	0.38	3.3e-23	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs12618769	0.625	rs113342082	chr2:99034198	G/A	cg10123293	chr2:99228465	UNC50	0.4	7.83	0.3	2.07e-14	Bipolar disorder;
BRCA	cis	rs7011049	0.908	rs79560601	chr8:53853614	C/T	cg26025543	chr8:53854495	NA	0.53	9.03	0.34	2.06e-18	Systolic blood pressure;
BRCA	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg03585969	chr10:35415529	CREM	0.56	11.5	0.41	5.98e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg14784868	chr12:69753453	YEATS4	0.47	9.31	0.35	2.01e-19	Response to diuretic therapy;
BRCA	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21659725	chr3:3221576	CRBN	-0.71	-21.92	-0.66	7.66e-80	Intelligence (multi-trait analysis);
BRCA	cis	rs7301826	0.651	rs7295705	chr12:131301885	C/T	cg11011512	chr12:131303247	STX2	0.51	13.6	0.47	3.41e-37	Plasma plasminogen activator levels;
BRCA	cis	rs4074536	0.574	rs10127797	chr1:116287305	C/T	cg21648376	chr1:116311395	CASQ2	-0.48	-8.43	-0.32	2.24e-16	QRS duration;
BRCA	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg08000102	chr2:233561755	GIGYF2	0.74	15.78	0.53	1.33e-47	Schizophrenia;
BRCA	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.63	0.32	4.92e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2742234	0.541	rs11528481	chr10:43737767	C/A	cg02780029	chr10:43622663	RET	0.36	8.05	0.3	3.97e-15	Hirschsprung disease;
BRCA	cis	rs6701037	0.522	rs12094153	chr1:175094025	G/A	cg00321850	chr1:175162397	KIAA0040	-0.32	-8.18	-0.31	1.58e-15	Alcohol dependence;
BRCA	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg07884673	chr3:53033167	SFMBT1	0.88	10.31	0.38	3.62e-23	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs2882667	0.659	rs10056014	chr5:138256018	T/A	cg04439458	chr5:138467593	SIL1	-0.31	-7.87	-0.3	1.58e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00166722	chr3:10149974	C3orf24	0.65	11.23	0.41	7.83e-27	Alzheimer's disease;
BRCA	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg20818283	chr2:191399100	TMEM194B	0.43	9.81	0.36	2.92e-21	Pulse pressure;
BRCA	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg23029597	chr12:123009494	RSRC2	-0.6	-11.64	-0.42	1.58e-28	Body mass index;
BRCA	cis	rs2011503	0.509	rs884480	chr19:19773923	G/A	cg11584989	chr19:19387371	SF4	0.4	8.0	0.3	5.73e-15	Bipolar disorder;
BRCA	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg01305625	chr5:131593812	PDLIM4	0.37	9.14	0.34	7.87e-19	Acylcarnitine levels;
BRCA	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11644478	chr21:40555479	PSMG1	0.84	19.08	0.6	1.35e-64	Cognitive function;
BRCA	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg25664220	chr3:72788482	NA	-0.55	-11.66	-0.42	1.29e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11190604	0.767	rs11190520	chr10:102175309	T/C	cg07080220	chr10:102295463	HIF1AN	0.5	10.18	0.37	1.13e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg03264133	chr6:25882463	NA	-0.36	-7.92	-0.3	1.07e-14	Height;
BRCA	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg03709012	chr19:19516395	GATAD2A	0.78	18.2	0.58	5.89e-60	Tonsillectomy;
BRCA	cis	rs698833	0.501	rs10194161	chr2:44507213	A/G	cg04920474	chr2:44395004	PPM1B	-0.4	-9.39	-0.35	1.04e-19	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg04944784	chr2:26401820	FAM59B	-0.95	-16.58	-0.55	1.26e-51	Gut microbiome composition (summer);
BRCA	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg18132916	chr6:79620363	NA	-0.44	-9.8	-0.36	3.27e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08219700	chr8:58056026	NA	0.62	9.98	0.37	6.99e-22	Developmental language disorder (linguistic errors);
BRCA	cis	rs7945718	0.875	rs7924501	chr11:12813870	A/G	cg25843174	chr11:12811716	TEAD1	0.22	8.55	0.32	8.78e-17	Educational attainment (years of education);
BRCA	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-9.71	-0.36	6.85e-21	Height;
BRCA	cis	rs752010	0.746	rs10749837	chr1:42089471	T/C	cg06885757	chr1:42089581	HIVEP3	0.3	10.98	0.4	8.48e-26	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg24879335	chr3:133465180	TF	0.33	11.1	0.4	2.62e-26	Iron status biomarkers (transferrin levels);
BRCA	cis	rs1865721	0.804	rs7243462	chr18:73147998	A/T	cg26385618	chr18:73139727	C18orf62	-0.44	-10.63	-0.39	2.1e-24	Intelligence;
BRCA	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.9	0.3	1.19e-14	Axial length;
BRCA	cis	rs965469	0.779	rs6051740	chr20:3301165	T/C	cg25506879	chr20:3388711	C20orf194	-0.44	-8.73	-0.33	2.27e-17	IFN-related cytopenia;
BRCA	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg12564285	chr5:131593104	PDLIM4	0.35	9.48	0.35	4.85e-20	Breast cancer;
BRCA	trans	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs698833	0.886	rs1056865	chr2:44546741	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	9.22	0.34	4.25e-19	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	trans	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.16	0.31	1.84e-15	Mean corpuscular volume;
BRCA	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	19.83	0.62	1.39e-68	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg20307385	chr11:47447363	PSMC3	-0.82	-23.01	-0.67	8.25e-86	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs3772130	0.923	rs34865234	chr3:121560995	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.56	9.8	0.36	3.28e-21	Cognitive performance;
BRCA	cis	rs9790314	0.690	rs7617204	chr3:160821969	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-11.73	-0.42	6.58e-29	Morning vs. evening chronotype;
BRCA	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg08508325	chr11:3079039	CARS	-0.44	-16.22	-0.54	8.11e-50	Longevity;
BRCA	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11890956	chr21:40555474	PSMG1	-0.61	-13.72	-0.48	9.35e-38	Menarche (age at onset);
BRCA	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.61	-0.39	2.5e-24	Bipolar disorder;
BRCA	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg18811423	chr2:55921094	PNPT1	0.73	23.5	0.68	1.76e-88	Metabolic syndrome;
BRCA	cis	rs7520050	0.843	rs1707334	chr1:46605728	A/C	cg24296786	chr1:45957014	TESK2	0.38	8.4	0.32	2.93e-16	Red blood cell count;Reticulocyte count;
BRCA	cis	rs28493229	0.522	rs2233152	chr19:41281016	C/T	cg21869046	chr19:41225005	ITPKC	0.39	10.21	0.37	8.59e-23	Kawasaki disease;
BRCA	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	1.98e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg23950597	chr19:37808831	NA	0.61	11.24	0.41	6.93e-27	Coronary artery calcification;
BRCA	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg17971929	chr21:40555470	PSMG1	0.62	14.4	0.49	6.43e-41	Cognitive function;
BRCA	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg26677194	chr12:130822605	PIWIL1	-0.48	-11.55	-0.42	3.74e-28	Menopause (age at onset);
BRCA	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg03060546	chr3:49711283	APEH	-0.54	-10.99	-0.4	7.4e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6028335	0.610	rs3752291	chr20:37570404	G/T	cg16355469	chr20:37678765	NA	0.45	8.14	0.31	2e-15	Alcohol and nicotine co-dependence;
BRCA	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg21775007	chr8:11205619	TDH	-0.56	-11.53	-0.41	4.62e-28	Retinal vascular caliber;
BRCA	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg04944784	chr2:26401820	FAM59B	0.95	16.58	0.55	1.26e-51	Gut microbiome composition (summer);
BRCA	cis	rs35110281	0.600	rs914198	chr21:45117456	A/C	cg01579765	chr21:45077557	HSF2BP	-0.44	-11.72	-0.42	6.85e-29	Mean corpuscular volume;
BRCA	cis	rs877282	0.891	rs11253393	chr10:788824	G/T	cg17470449	chr10:769945	NA	0.51	8.62	0.32	5.29e-17	Uric acid levels;
BRCA	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg05665937	chr4:1216051	CTBP1	0.38	7.9	0.3	1.22e-14	Obesity-related traits;
BRCA	cis	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg07460842	chr6:66804631	NA	-1.14	-36.07	-0.82	3.01e-156	Exhaled nitric oxide output;
BRCA	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg21573476	chr21:45109991	RRP1B	-0.4	-10.66	-0.39	1.56e-24	Mean corpuscular volume;
BRCA	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg25767906	chr1:53392781	SCP2	0.35	7.98	0.3	6.94e-15	Monocyte count;
BRCA	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.61	-0.36	1.63e-20	Schizophrenia;
BRCA	cis	rs17401966	0.965	rs12751375	chr1:10291874	C/G	cg15208524	chr1:10270712	KIF1B	0.39	8.39	0.31	3.18e-16	Hepatocellular carcinoma;
BRCA	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg13010199	chr12:38710504	ALG10B	0.49	9.56	0.35	2.42e-20	Morning vs. evening chronotype;
BRCA	cis	rs9420	0.961	rs1647405	chr11:57477889	C/T	cg19752551	chr11:57585705	CTNND1	-0.42	-10.79	-0.39	4.62e-25	Schizophrenia;
BRCA	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg01262667	chr19:19385393	TM6SF2	0.41	8.94	0.33	4.01e-18	Nonalcoholic fatty liver disease;
BRCA	cis	rs55665837	1.000	rs12295723	chr11:14450201	T/C	cg19336497	chr11:14380999	RRAS2	-0.36	-9.47	-0.35	5.33e-20	Vitamin D levels;
BRCA	cis	rs9807989	0.507	rs2293224	chr2:103035779	T/C	cg03938978	chr2:103052716	IL18RAP	0.29	8.35	0.31	4.32e-16	Asthma;
BRCA	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg20203395	chr5:56204925	C5orf35	-0.43	-9.66	-0.36	1.04e-20	Initial pursuit acceleration;
BRCA	cis	rs9487051	0.768	rs458740	chr6:109525527	C/T	cg01475377	chr6:109611718	NA	-0.44	-10.99	-0.4	7.28e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg06627628	chr2:24431161	ITSN2	-0.82	-14.69	-0.5	2.71e-42	Asthma;
BRCA	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08219700	chr8:58056026	NA	0.46	8.36	0.31	3.92e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	12.73	0.45	3.03e-33	Bone mineral density;
BRCA	cis	rs939658	1.000	rs4778935	chr15:79453282	T/C	cg17916960	chr15:79447300	NA	0.39	9.73	0.36	6.11e-21	Refractive error;
BRCA	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20891558	chr2:74357851	NA	0.48	11.65	0.42	1.36e-28	Gestational age at birth (maternal effect);
BRCA	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.2	0.68	7.62e-87	Chronic sinus infection;
BRCA	cis	rs2463822	0.687	rs118012228	chr11:62155914	G/A	cg06239285	chr11:62104954	ASRGL1	-0.68	-9.15	-0.34	7.5e-19	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg07917127	chr4:99064746	C4orf37	-0.43	-8.04	-0.3	4.43e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1878931	0.559	rs1968055	chr16:3392053	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.63	13.66	0.48	1.77e-37	Body mass index (adult);
BRCA	cis	rs2279817	1.000	rs10788681	chr1:18019524	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.56	16.5	0.55	3.44e-51	Neuroticism;
BRCA	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg18252515	chr7:66147081	NA	-0.84	-12.21	-0.43	5.66e-31	Diabetic kidney disease;
BRCA	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02475777	chr4:1388615	CRIPAK	0.54	10.91	0.4	1.58e-25	Longevity;
BRCA	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg18357645	chr12:58087776	OS9	-0.33	-7.99	-0.3	6.21e-15	Multiple sclerosis;
BRCA	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.08	-0.43	2.05e-30	Total cholesterol levels;
BRCA	cis	rs1874326	0.545	rs2353348	chr7:138111275	T/C	cg18008034	chr7:138118925	NA	-0.45	-9.35	-0.35	1.47e-19	Quantitative traits;
BRCA	cis	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg09307838	chr4:120376055	NA	0.47	9.73	0.36	5.63e-21	Corneal astigmatism;
BRCA	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21659725	chr3:3221576	CRBN	-0.71	-21.75	-0.65	6.15e-79	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.96	0.3	7.99e-15	Corneal astigmatism;
BRCA	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-9.47	-0.35	5.43e-20	Joint mobility (Beighton score);
BRCA	cis	rs6088813	0.890	rs6088817	chr20:33984976	T/C	cg14752227	chr20:34000481	UQCC	-0.43	-9.08	-0.34	1.39e-18	Height;
BRCA	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg07080220	chr10:102295463	HIF1AN	0.44	9.78	0.36	3.69e-21	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.66	-0.61	1.21e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs12618769	0.597	rs7585939	chr2:99219206	T/A	cg10123293	chr2:99228465	UNC50	0.42	8.49	0.32	1.44e-16	Bipolar disorder;
BRCA	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg21395723	chr22:39101663	GTPBP1	-0.38	-8.45	-0.32	2.03e-16	Menopause (age at onset);
BRCA	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg22105103	chr4:187893119	NA	0.37	11.84	0.42	2.26e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25427524	chr10:38739819	LOC399744	-0.7	-16.87	-0.56	4.23e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.94	13.91	0.48	1.23e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.64	-0.68	3.1e-89	Gut microbiome composition (summer);
BRCA	cis	rs11711311	0.712	rs3773684	chr3:113334488	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.33	-8.23	-0.31	1.02e-15	IgG glycosylation;
BRCA	cis	rs311392	0.871	rs402088	chr8:55092805	A/G	cg11783602	chr8:55087084	NA	-0.31	-9.07	-0.34	1.49e-18	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg19318889	chr4:1322082	MAEA	0.58	12.04	0.43	3.16e-30	Longevity;
BRCA	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg03709012	chr19:19516395	GATAD2A	1.07	21.12	0.64	1.62e-75	Nonalcoholic fatty liver disease;
BRCA	cis	rs6546550	0.694	rs12467361	chr2:70019127	G/A	cg02498382	chr2:70120550	SNRNP27	-0.4	-8.09	-0.3	3.03e-15	Prevalent atrial fibrillation;
BRCA	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg05340658	chr4:99064831	C4orf37	0.67	16.8	0.55	9.98e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1113500	0.933	rs745795	chr1:108629345	C/T	cg06207961	chr1:108661230	NA	0.45	11.05	0.4	4.25e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg00701064	chr4:6280414	WFS1	0.66	18.03	0.58	4.57e-59	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg21798802	chr22:38057573	PDXP	-0.48	-13.18	-0.46	2.98e-35	Fat distribution (HIV);
BRCA	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26314531	chr2:26401878	FAM59B	0.88	15.31	0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs9790314	0.723	rs12631850	chr3:160883062	C/T	cg03342759	chr3:160939853	NMD3	0.57	13.03	0.46	1.35e-34	Morning vs. evening chronotype;
BRCA	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg18811423	chr2:55921094	PNPT1	0.77	26.88	0.73	4.57e-107	Metabolic syndrome;
BRCA	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03713592	chr11:72463424	ARAP1	0.76	11.5	0.41	5.72e-28	Type 2 diabetes;
BRCA	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg06784218	chr1:46089804	CCDC17	0.45	10.8	0.39	4.19e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11651000	0.947	rs11657376	chr17:45835984	A/T	cg03474202	chr17:45855739	NA	-0.43	-7.83	-0.3	2.06e-14	IgG glycosylation;
BRCA	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.55	0.39	4.3e-24	Motion sickness;
BRCA	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg06784218	chr1:46089804	CCDC17	0.45	10.79	0.39	4.55e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9309473	0.687	rs11126399	chr2:73613341	G/A	cg20560298	chr2:73613845	ALMS1	-0.51	-13.67	-0.48	1.69e-37	Metabolite levels;
BRCA	cis	rs1451375	0.572	rs3807558	chr7:50571022	A/G	cg18232548	chr7:50535776	DDC	-0.41	-8.79	-0.33	1.4e-17	Malaria;
BRCA	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19723775	chr5:179050963	HNRNPH1	0.36	8.54	0.32	9.75e-17	Lung cancer;
BRCA	cis	rs9463078	0.774	rs3923353	chr6:45256482	C/G	cg25276700	chr6:44698697	NA	-0.35	-7.9	-0.3	1.25e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	trans	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg21659725	chr3:3221576	CRBN	-0.47	-8.44	-0.32	2.17e-16	Menarche (age at onset);
BRCA	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg09184832	chr6:79620586	NA	-0.52	-11.37	-0.41	2e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.17	-0.31	1.65e-15	Total body bone mineral density;
BRCA	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg12292205	chr6:26970375	C6orf41	-0.57	-12.69	-0.45	4.35e-33	Schizophrenia;
BRCA	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg21475434	chr5:93447410	FAM172A	0.67	8.85	0.33	8.58e-18	Diabetic retinopathy;
BRCA	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg13319975	chr6:146136371	FBXO30	0.41	9.17	0.34	6.47e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg20607287	chr7:12443886	VWDE	-0.56	-7.85	-0.3	1.77e-14	Coronary artery disease;
BRCA	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg14631576	chr9:95140430	CENPP	0.35	8.47	0.32	1.72e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg05343316	chr1:45956843	TESK2	0.7	14.57	0.5	1.02e-41	Platelet count;
BRCA	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg27170947	chr2:26402098	FAM59B	0.92	16.52	0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg02551604	chr5:131831745	NA	-0.39	-14.62	-0.5	5.71e-42	Asthma (sex interaction);
BRCA	cis	rs6565180	1.000	rs8049108	chr16:30376486	A/G	cg17640201	chr16:30407289	ZNF48	-0.77	-20.31	-0.63	3.79e-71	Tonsillectomy;
BRCA	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg04691961	chr3:161091175	C3orf57	-0.37	-7.92	-0.3	1.05e-14	Parkinson's disease;
BRCA	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg18811423	chr2:55921094	PNPT1	-0.51	-13.19	-0.46	2.6e-35	Metabolic syndrome;
BRCA	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg13010199	chr12:38710504	ALG10B	0.44	8.84	0.33	9.41e-18	Bladder cancer;
BRCA	cis	rs10504073	0.647	rs10435574	chr8:49996028	G/A	cg00325661	chr8:49890786	NA	0.44	12.49	0.44	3.6e-32	Blood metabolite ratios;
BRCA	cis	rs4478858	0.735	rs11436	chr1:31837320	T/C	cg00250761	chr1:31883323	NA	-0.32	-8.4	-0.32	2.9e-16	Alcohol dependence;
BRCA	cis	rs1669338	0.588	rs55959448	chr3:3204000	C/T	cg16797762	chr3:3221439	CRBN	-0.66	-9.85	-0.36	2.03e-21	White matter integrity;
BRCA	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg14186256	chr22:23484241	RTDR1	0.69	17.5	0.57	2.64e-56	Bone mineral density;
BRCA	trans	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.91	-0.3	1.14e-14	Corneal astigmatism;
BRCA	cis	rs9815354	1.000	rs73081353	chr3:41906448	T/A	cg03022575	chr3:42003672	ULK4	0.51	8.31	0.31	5.54e-16	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs9341808	0.718	rs9448886	chr6:80825901	C/T	cg08355045	chr6:80787529	NA	0.37	9.37	0.35	1.24e-19	Sitting height ratio;
BRCA	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	12.98	0.46	2.34e-34	Migraine;Coronary artery disease;
BRCA	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	10.52	0.38	5.84e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs7572733	0.534	rs11890137	chr2:198816662	G/A	cg00792783	chr2:198669748	PLCL1	0.45	9.81	0.36	2.86e-21	Dermatomyositis;
BRCA	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg22920501	chr2:26401640	FAM59B	0.96	16.89	0.56	3.51e-53	Gut microbiome composition (summer);
BRCA	cis	rs6840360	0.615	rs6535816	chr4:152614264	T/C	cg22705602	chr4:152727874	NA	-0.37	-9.93	-0.37	1.05e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7760949	0.889	rs9382688	chr6:13926746	A/T	cg27413430	chr6:13925136	RNF182	0.47	9.25	0.34	3.32e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.06	0.34	1.52e-18	Platelet count;
BRCA	cis	rs9427116	0.502	rs3766922	chr1:154577055	A/C	cg17218026	chr1:154582156	ADAR	0.27	8.17	0.31	1.66e-15	Blood protein levels;
BRCA	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg24829409	chr8:58192753	C8orf71	-0.51	-8.32	-0.31	5.35e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg17143192	chr8:8559678	CLDN23	0.55	10.63	0.39	2.04e-24	Obesity-related traits;
BRCA	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg22974920	chr21:40686053	BRWD1	-0.4	-8.88	-0.33	6.85e-18	Cognitive function;
BRCA	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg03060546	chr3:49711283	APEH	0.48	10.34	0.38	2.7e-23	Resting heart rate;
BRCA	cis	rs10411936	0.712	rs8103521	chr19:16589750	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.47	9.82	0.36	2.61e-21	White blood cell count;Multiple sclerosis;
BRCA	cis	rs17092148	1.000	rs2425004	chr20:33405956	G/T	cg16810054	chr20:33298113	TP53INP2	0.49	11.09	0.4	2.95e-26	Neuroticism;
BRCA	cis	rs4423214	0.840	rs1540127	chr11:71179038	G/A	cg05163923	chr11:71159392	DHCR7	-0.57	-11.6	-0.42	2.31e-28	Vitamin D levels;
BRCA	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.58	9.27	0.34	2.75e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg19077165	chr18:44547161	KATNAL2	0.39	8.15	0.31	1.86e-15	Personality dimensions;
BRCA	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg26031613	chr14:104095156	KLC1	-0.43	-8.5	-0.32	1.38e-16	Schizophrenia;
BRCA	trans	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-15.49	-0.52	3.38e-46	Obesity-related traits;
BRCA	cis	rs400736	0.930	rs225100	chr1:8066914	C/T	cg25007680	chr1:8021821	PARK7	-0.47	-12.07	-0.43	2.23e-30	Response to antidepressants and depression;
BRCA	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-11.27	-0.41	5.27e-27	Gut microbiome composition (summer);
BRCA	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg04586622	chr2:25135609	ADCY3	0.41	10.22	0.37	8.4e-23	Body mass index in non-asthmatics;
BRCA	trans	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.88	0.4	2.1e-25	Type 2 diabetes;
BRCA	cis	rs7301826	0.651	rs10744484	chr12:131298506	T/G	cg11011512	chr12:131303247	STX2	0.51	13.62	0.47	3e-37	Plasma plasminogen activator levels;
BRCA	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg18811423	chr2:55921094	PNPT1	-0.52	-12.82	-0.45	1.19e-33	Metabolic syndrome;
BRCA	trans	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg23762105	chr12:34175262	ALG10	-0.38	-9.68	-0.36	9.08e-21	Morning vs. evening chronotype;
BRCA	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg13798912	chr7:905769	UNC84A	-0.5	-7.96	-0.3	7.8e-15	Cerebrospinal P-tau181p levels;
BRCA	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg02176678	chr2:219576539	TTLL4	0.39	10.47	0.38	8.85e-24	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs12681288	0.963	rs7822955	chr8:1029090	C/T	cg04851639	chr8:1020857	NA	0.32	9.68	0.36	8.67e-21	Schizophrenia;
BRCA	cis	rs17604090	0.557	rs10279965	chr7:29717082	C/G	cg19413766	chr7:29689036	LOC646762	-0.56	-9.01	-0.34	2.35e-18	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.17	0.31	1.67e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs17021463	0.966	rs10856908	chr4:95222755	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.26	-0.38	5.58e-23	Testicular germ cell tumor;
BRCA	cis	rs7975161	0.608	rs10861169	chr12:104610640	C/T	cg25273343	chr12:104657179	TXNRD1	-0.38	-8.99	-0.34	2.7e-18	Toenail selenium levels;
BRCA	trans	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg26384229	chr12:38710491	ALG10B	0.44	10.71	0.39	9.92e-25	Morning vs. evening chronotype;
BRCA	trans	rs1325195	0.770	rs965401	chr1:179133221	T/A	cg11624085	chr17:8464688	MYH10	0.26	7.83	0.3	2.08e-14	IgE grass sensitization;
BRCA	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg26838691	chr2:24397539	C2orf84	-0.48	-8.65	-0.32	4.29e-17	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg02773041	chr1:40204384	PPIE	0.45	9.73	0.36	6.04e-21	Blood protein levels;
BRCA	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg00383909	chr3:49044727	WDR6	0.6	10.99	0.4	7.23e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9308433	0.553	rs9308435	chr1:214500166	C/T	cg06198575	chr1:214491504	SMYD2	0.54	11.85	0.42	2.11e-29	IgG glycosylation;
BRCA	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg20587970	chr11:113659929	NA	-1.35	-24.74	-0.7	2.76e-95	Hip circumference adjusted for BMI;
BRCA	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.52	-8.8	-0.33	1.25e-17	Body mass index (adult);
BRCA	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg14004847	chr7:1930337	MAD1L1	0.43	8.86	0.33	8.16e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.93	-0.33	4.55e-18	Breast cancer;
BRCA	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg17509989	chr5:176798049	RGS14	0.63	12.66	0.45	6.41e-33	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs4919087	1.000	rs4919089	chr10:99087905	G/A	cg25902810	chr10:99078978	FRAT1	-0.45	-9.36	-0.35	1.32e-19	Monocyte count;
BRCA	cis	rs78707713	0.512	rs12412776	chr10:71179502	G/A	cg12610070	chr10:71211762	TSPAN15	-0.31	-9.3	-0.35	2.18e-19	Venous thromboembolism;
BRCA	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg11645453	chr3:52864694	ITIH4	0.42	9.66	0.36	1.09e-20	Schizophrenia;
BRCA	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.1	31.43	0.78	8.72e-132	Cognitive ability;
BRCA	cis	rs1832871	0.644	rs56180963	chr6:158773990	G/A	cg07165851	chr6:158734300	TULP4	0.64	12.73	0.45	2.92e-33	Height;
BRCA	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg03954927	chr1:10346856	KIF1B	0.46	13.06	0.46	1.04e-34	Hepatocellular carcinoma;
BRCA	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.3	-0.31	6.42e-16	Bipolar disorder;
BRCA	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg02527881	chr3:46936655	PTH1R	-0.36	-8.69	-0.32	3.11e-17	Colorectal cancer;
BRCA	trans	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.0	0.3	5.71e-15	Corneal astigmatism;
BRCA	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.94	-0.46	3.55e-34	Migraine;Coronary artery disease;
BRCA	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg14196790	chr5:131705035	SLC22A5	0.42	10.15	0.37	1.47e-22	Breast cancer;Mosquito bite size;
BRCA	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg12311346	chr5:56204834	C5orf35	-0.8	-15.86	-0.53	5.36e-48	Initial pursuit acceleration;
BRCA	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.32	-8.89	-0.33	6.1e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg26384229	chr12:38710491	ALG10B	0.84	22.66	0.67	6.72e-84	Heart rate;
BRCA	cis	rs4423214	0.840	rs1790339	chr11:71182761	C/A	cg05163923	chr11:71159392	DHCR7	-0.56	-11.33	-0.41	3.01e-27	Vitamin D levels;
BRCA	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06028605	chr16:24865363	SLC5A11	0.4	8.07	0.3	3.6e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg08917208	chr2:24149416	ATAD2B	0.92	13.65	0.48	2.16e-37	Lymphocyte counts;
BRCA	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg00757033	chr12:89920650	WDR51B	0.52	10.53	0.38	5.03e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs2629540	0.737	rs10901821	chr10:126480556	T/C	cg08799069	chr10:126477246	METTL10	-0.44	-10.02	-0.37	4.79e-22	Cocaine dependence;
BRCA	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg11707556	chr5:10655725	ANKRD33B	0.4	8.83	0.33	1.02e-17	Coronary artery disease;
BRCA	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg21573476	chr21:45109991	RRP1B	-0.41	-11.3	-0.41	4.15e-27	Mean corpuscular volume;
BRCA	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg05729581	chr11:3078854	CARS	0.36	8.86	0.33	7.64e-18	Longevity;
BRCA	cis	rs6429082	0.818	rs291391	chr1:235649955	A/G	cg26050004	chr1:235667680	B3GALNT2	0.57	14.17	0.49	7.96e-40	Adiposity;
BRCA	cis	rs1109501	0.881	rs28566795	chr4:71343532	C/T	cg22786090	chr4:71381880	NA	0.36	7.85	0.3	1.8e-14	Alcoholism (heaviness of drinking);
BRCA	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg20818283	chr2:191399100	TMEM194B	0.38	8.94	0.33	4.06e-18	Pulse pressure;
BRCA	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.28e-23	Prostate cancer;
BRCA	trans	rs6479891	1.000	rs9414793	chr10:65075109	G/A	cg14819942	chr15:35414228	NA	-0.34	-8.45	-0.32	2.02e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs4302748	0.862	rs11981777	chr7:36184753	G/A	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-10.1	-0.37	2.4e-22	Gut microbiome composition (summer);
BRCA	cis	rs3770081	1.000	rs17027011	chr2:86406556	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.58	-8.04	-0.3	4.4e-15	Facial emotion recognition (sad faces);
BRCA	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg13736514	chr6:26305472	NA	-0.37	-12.07	-0.43	2.4e-30	Educational attainment;
BRCA	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg06558623	chr16:89946397	TCF25	0.58	10.55	0.39	4.34e-24	Skin colour saturation;
BRCA	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-16.11	-0.54	2.87e-49	Chronic sinus infection;
BRCA	trans	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-7.95	-0.3	8.62e-15	Menarche (age at onset);
BRCA	cis	rs250677	0.522	rs4705301	chr5:148354902	C/G	cg18129178	chr5:148520854	ABLIM3	-0.55	-10.48	-0.38	7.77e-24	Breast cancer;
BRCA	cis	rs9612	1.000	rs346545	chr19:44256386	T/C	cg08581076	chr19:44259116	C19orf61	0.52	9.64	0.36	1.31e-20	Exhaled nitric oxide output;
BRCA	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.4	-0.32	2.8e-16	Monocyte percentage of white cells;
BRCA	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg15704280	chr7:45808275	SEPT13	-0.5	-9.53	-0.35	3.27e-20	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs4920343	0.890	rs4920531	chr1:19095746	A/G	cg19637330	chr1:19110922	NA	-0.39	-7.95	-0.3	8.72e-15	Knee osteoarthritis;
BRCA	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11890956	chr21:40555474	PSMG1	1.06	31.86	0.78	4.18e-134	Cognitive function;
BRCA	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg19628046	chr18:33552617	C18orf21	0.56	11.04	0.4	4.47e-26	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg23711669	chr6:146136114	FBXO30	0.72	14.83	0.51	5.9e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2742234	1.000	rs1864395	chr10:43655697	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.42	-9.01	-0.34	2.43e-18	Hirschsprung disease;
BRCA	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.12	-0.31	2.49e-15	Depression;
BRCA	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg13319975	chr6:146136371	FBXO30	-0.41	-9.39	-0.35	1e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg24642439	chr20:33292090	TP53INP2	0.53	11.48	0.41	7.58e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.52	-14.85	-0.51	4.34e-43	Lung cancer;
BRCA	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.28e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs311392	0.966	rs454975	chr8:55087514	T/C	cg11783602	chr8:55087084	NA	-0.33	-9.59	-0.35	1.94e-20	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg10820045	chr2:198174542	NA	-0.42	-9.61	-0.36	1.6e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	trans	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.49	9.51	0.35	3.7799999999999997e-20	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.98	0.43	5.89e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg16339924	chr4:17578868	LAP3	-0.53	-12.7	-0.45	4.26e-33	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg26597838	chr10:835615	NA	1.29	21.57	0.65	6.19e-78	Eosinophil percentage of granulocytes;
BRCA	cis	rs7975161	0.521	rs4447242	chr12:104720708	T/G	cg25273343	chr12:104657179	TXNRD1	-0.56	-8.98	-0.33	2.92e-18	Toenail selenium levels;
BRCA	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.07	-27.53	-0.74	1.32e-110	Ulcerative colitis;
BRCA	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg06627628	chr2:24431161	ITSN2	-0.5	-8.26	-0.31	8.39e-16	Lymphocyte counts;
BRCA	cis	rs1499972	0.941	rs817507	chr3:117681065	A/C	cg07612923	chr3:117604196	NA	-0.6	-8.19	-0.31	1.48e-15	Schizophrenia;
BRCA	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg04691961	chr3:161091175	C3orf57	-0.41	-10.07	-0.37	3.14e-22	Morning vs. evening chronotype;
BRCA	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg15485101	chr11:133734466	NA	0.39	9.6	0.36	1.78e-20	Childhood ear infection;
BRCA	cis	rs2742417	0.603	rs2742457	chr3:45767487	G/A	cg04837898	chr3:45731254	SACM1L	-0.41	-8.14	-0.31	2e-15	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.74	-0.39	7.55e-25	Tonsillectomy;
BRCA	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg12011299	chr4:100065546	ADH4	0.53	12.95	0.46	3.03e-34	Alcohol dependence;
BRCA	cis	rs16976116	0.851	rs13380400	chr15:55490518	A/G	cg11288833	chr15:55489084	RSL24D1	0.47	10.58	0.39	3.25e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8030485	0.716	rs12899109	chr15:79410970	T/C	cg17916960	chr15:79447300	NA	0.34	7.9	0.3	1.27e-14	Left ventricle wall thickness;
BRCA	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.67	-0.42	1.16e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs10129255	0.518	rs2006284	chr14:107132201	G/A	cg07958169	chr14:107095056	NA	-0.38	-8.14	-0.31	2.09e-15	Kawasaki disease;
BRCA	cis	rs6815814	0.904	rs73236629	chr4:38825449	G/T	cg02016764	chr4:38805732	TLR1	-0.54	-8.08	-0.3	3.26e-15	Breast cancer;
BRCA	cis	rs3781663	0.500	rs10160730	chr11:70021687	T/C	cg06393558	chr11:69982916	ANO1	-0.39	-8.96	-0.33	3.55e-18	Survival in rectal cancer;
BRCA	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg08470875	chr2:26401718	FAM59B	-0.51	-8.53	-0.32	1.09e-16	Gut microbiome composition (summer);
BRCA	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg20891558	chr2:74357851	NA	0.57	11.88	0.43	1.51e-29	Gestational age at birth (maternal effect);
BRCA	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg12756686	chr19:29218302	NA	0.46	8.1	0.31	2.77e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg05340658	chr4:99064831	C4orf37	0.67	16.63	0.55	7.2e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.21	0.37	9.15e-23	Aortic root size;
BRCA	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg07884673	chr3:53033167	SFMBT1	0.86	9.98	0.37	6.83e-22	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12516959	chr21:47718080	NA	0.41	9.37	0.35	1.21e-19	Testicular germ cell tumor;
BRCA	cis	rs4595586	0.655	rs7958206	chr12:39329294	G/A	cg26384229	chr12:38710491	ALG10B	0.39	8.75	0.33	1.91e-17	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg23711669	chr6:146136114	FBXO30	-0.77	-17.92	-0.58	1.72e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7267979	0.932	rs6132848	chr20:25561645	C/T	cg08601574	chr20:25228251	PYGB	0.36	8.43	0.32	2.22e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4728302	0.838	rs755664	chr7:133596671	C/G	cg07491979	chr7:133331646	EXOC4	0.36	7.83	0.3	1.99e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg14440974	chr22:39074834	NA	0.35	8.38	0.31	3.5e-16	Menopause (age at onset);
BRCA	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg15605315	chr1:45957053	TESK2	0.49	10.16	0.37	1.45e-22	High light scatter reticulocyte count;
BRCA	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg00757033	chr12:89920650	WDR51B	0.54	11.01	0.4	6.42e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg26597838	chr10:835615	NA	0.81	14.74	0.5	1.52e-42	Eosinophil percentage of granulocytes;
BRCA	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg06784218	chr1:46089804	CCDC17	0.51	12.48	0.44	4.02e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3820928	0.874	rs13419455	chr2:227850465	C/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.59	-0.32	6.69e-17	Pulmonary function;
BRCA	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg23442198	chr4:187126114	CYP4V2	0.83	9.68	0.36	8.88e-21	Activated partial thromboplastin time;
BRCA	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg26384229	chr12:38710491	ALG10B	0.72	16.37	0.54	1.53e-50	Morning vs. evening chronotype;
BRCA	cis	rs9296092	0.500	rs4376348	chr6:33521097	A/G	cg13560919	chr6:33536144	NA	-0.85	-17.72	-0.57	1.88e-57	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg21475434	chr5:93447410	FAM172A	0.65	8.65	0.32	4e-17	Diabetic retinopathy;
BRCA	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg25665528	chr16:2260870	C16orf79	-0.36	-9.14	-0.34	8.03e-19	Height;
BRCA	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.55	9.62	0.36	1.51e-20	Body mass index (adult);
BRCA	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11644478	chr21:40555479	PSMG1	-0.42	-8.4	-0.32	2.83e-16	Menarche (age at onset);
BRCA	cis	rs795484	0.610	rs2936839	chr12:118580315	T/C	cg16572268	chr12:118583242	PEBP1	-0.36	-9.32	-0.35	1.88e-19	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
BRCA	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.9	-0.3	1.19e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs1595825	0.786	rs77218291	chr2:198565011	A/G	cg19156104	chr2:198669113	PLCL1	-0.46	-8.38	-0.31	3.45e-16	Ulcerative colitis;
BRCA	cis	rs6745190	0.575	rs7566146	chr2:181974086	T/C	cg00481216	chr2:181971175	NA	0.4	9.43	0.35	7.52e-20	White blood cell count;
BRCA	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg11812906	chr14:75593930	NEK9	-0.63	-14.31	-0.49	1.64e-40	Height;
BRCA	cis	rs12545109	0.643	rs1119707	chr8:57411548	T/C	cg09654669	chr8:57350985	NA	-0.41	-7.94	-0.3	9.17e-15	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9811920	0.715	rs6776886	chr3:99906270	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.39	9.06	0.34	1.57e-18	Axial length;
BRCA	cis	rs7520050	0.807	rs28378621	chr1:46189554	T/C	cg24296786	chr1:45957014	TESK2	-0.47	-10.72	-0.39	8.89e-25	Red blood cell count;Reticulocyte count;
BRCA	cis	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.19	-0.4	1.1e-26	Morning vs. evening chronotype;
BRCA	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg23018236	chr17:30244563	NA	0.55	8.28	0.31	7.06e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs7975161	0.580	rs4246270	chr12:104728530	G/A	cg25273343	chr12:104657179	TXNRD1	-0.56	-8.98	-0.33	2.92e-18	Toenail selenium levels;
BRCA	trans	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg06521331	chr12:34319734	NA	-0.53	-10.19	-0.37	1.08e-22	Bladder cancer;
BRCA	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.52	-11.6	-0.42	2.35e-28	Multiple sclerosis;
BRCA	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.23	0.34	3.82e-19	Tonsillectomy;
BRCA	cis	rs4363385	0.791	rs489323	chr1:153006047	G/A	cg21543102	chr1:152974771	SPRR3	-0.28	-7.81	-0.3	2.39e-14	Inflammatory skin disease;
BRCA	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg18252515	chr7:66147081	NA	-1.06	-15.83	-0.53	7.57e-48	Diabetic kidney disease;
BRCA	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.23	-20.55	-0.63	1.94e-72	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs312273	0.582	rs312279	chr12:41256200	T/C	cg17827154	chr12:41323612	CNTN1	-0.34	-8.06	-0.3	3.69e-15	Bipolar disorder;
BRCA	cis	rs3818285	0.544	rs7899805	chr10:111671177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.36	-9.72	-0.36	6.27e-21	Superior crus of antihelix expression;
BRCA	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg15017067	chr4:17643749	FAM184B	0.31	9.45	0.35	6.05e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg00666640	chr1:248458726	OR2T12	0.32	8.76	0.33	1.69e-17	Common traits (Other);
BRCA	cis	rs11718455	0.960	rs3843373	chr3:44011053	C/T	cg08738300	chr3:44038990	NA	-0.45	-8.56	-0.32	8.63e-17	Coronary artery disease;
BRCA	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg03585969	chr10:35415529	CREM	0.49	10.29	0.38	4.56e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.37e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs8014204	0.762	rs12891131	chr14:75240090	A/G	cg06637938	chr14:75390232	RPS6KL1	0.42	8.69	0.33	2.99e-17	Caffeine consumption;
BRCA	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg13402656	chr8:1511478	DLGAP2	-0.58	-14.92	-0.51	1.96e-43	Lung cancer;
BRCA	trans	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.36	7.98	0.3	6.72e-15	Endometrial cancer;
BRCA	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.36	-0.41	2.36e-27	Colorectal cancer;
BRCA	cis	rs6815814	0.898	rs5743562	chr4:38806096	T/C	cg06935464	chr4:38784597	TLR10	0.51	8.49	0.32	1.46e-16	Breast cancer;
BRCA	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.34	-0.31	4.74e-16	Aortic root size;
BRCA	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.1	0.4	2.73e-26	Bipolar disorder;
BRCA	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.8	0.39	4.51e-25	Rheumatoid arthritis;
BRCA	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg26605046	chr4:2439731	NA	-0.44	-10.15	-0.37	1.48e-22	Cognitive function;
BRCA	trans	rs11039798	0.844	rs7126949	chr11:48972166	A/G	cg15704280	chr7:45808275	SEPT13	0.6	8.93	0.33	4.6e-18	Axial length;
BRCA	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg25767906	chr1:53392781	SCP2	-0.47	-10.34	-0.38	2.85e-23	Monocyte count;
BRCA	cis	rs2479724	0.840	rs6925777	chr6:41750822	C/T	cg17623882	chr6:41773611	USP49	0.37	10.12	0.37	2.03e-22	Menarche (age at onset);
BRCA	cis	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.92	-0.3	1.02e-14	Corneal astigmatism;
BRCA	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12292205	chr6:26970375	C6orf41	-0.47	-7.97	-0.3	7.21e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg00631329	chr6:26305371	NA	-0.55	-15.55	-0.52	1.68e-46	Educational attainment;
BRCA	cis	rs2652834	1.000	rs68088462	chr15:63397617	T/C	cg05507819	chr15:63340323	TPM1	0.45	8.06	0.3	3.77e-15	HDL cholesterol;
BRCA	trans	rs7241530	0.623	rs2411417	chr18:75917469	G/A	cg25697769	chr22:39097335	JOSD1	0.37	8.06	0.3	3.78e-15	Educational attainment (years of education);
BRCA	cis	rs312273	0.685	rs391052	chr12:41378240	G/A	cg17827154	chr12:41323612	CNTN1	-0.39	-10.2	-0.37	1.01e-22	Bipolar disorder;
BRCA	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11764359	chr7:65958608	NA	-0.73	-16.04	-0.54	6.41e-49	Aortic root size;
BRCA	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg26149184	chr10:133730230	NA	0.4	8.2	0.31	1.37e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg14004847	chr7:1930337	MAD1L1	-0.47	-9.63	-0.36	1.36e-20	Bipolar disorder and schizophrenia;
BRCA	trans	rs1493916	0.905	rs34165207	chr18:31400153	G/A	cg27147174	chr7:100797783	AP1S1	-0.53	-10.37	-0.38	2.13e-23	Life satisfaction;
BRCA	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg15790184	chr11:494944	RNH1	-0.66	-10.26	-0.38	5.73e-23	Body mass index;
BRCA	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg11764359	chr7:65958608	NA	-0.62	-13.35	-0.47	4.8e-36	Aortic root size;
BRCA	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.14	-0.31	2.1e-15	Depression;
BRCA	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg23950597	chr19:37808831	NA	-0.62	-11.45	-0.41	9.99e-28	Coronary artery calcification;
BRCA	cis	rs9790314	0.747	rs4616689	chr3:160856269	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-9.94	-0.37	9.5e-22	Morning vs. evening chronotype;
BRCA	trans	rs1493916	0.748	rs1845386	chr18:31318256	C/G	cg15819921	chr19:927150	ARID3A	-0.44	-8.23	-0.31	1.02e-15	Life satisfaction;
BRCA	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg03477792	chr4:77819574	ANKRD56	0.62	15.03	0.51	5.77e-44	Emphysema distribution in smoking;
BRCA	trans	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg06437703	chr8:37914619	EIF4EBP1	0.31	7.88	0.3	1.44e-14	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs870825	0.616	rs28608669	chr4:185632890	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	16.91	0.56	2.63e-53	Blood protein levels;
BRCA	cis	rs4588572	0.643	rs10044028	chr5:77794750	C/T	cg11547950	chr5:77652471	NA	0.5	9.15	0.34	7.51e-19	Triglycerides;
BRCA	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg22705602	chr4:152727874	NA	-0.32	-8.06	-0.3	3.75e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs965469	0.779	rs6139071	chr20:3299054	A/G	cg25506879	chr20:3388711	C20orf194	-0.46	-9.19	-0.34	5.58e-19	IFN-related cytopenia;
BRCA	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.14	-0.31	2.1e-15	Depression;
BRCA	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.42	-8.52	-0.32	1.18e-16	Lung cancer in ever smokers;
BRCA	cis	rs3767633	0.925	rs4656339	chr1:161915387	A/T	cg09175582	chr1:161736000	ATF6	0.5	8.69	0.32	3.15e-17	IgG glycosylation;
BRCA	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg16339924	chr4:17578868	LAP3	0.56	13.9	0.48	1.42e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2386661	0.516	rs61832676	chr10:5646337	G/A	cg17085576	chr10:5658249	NA	-0.33	-8.1	-0.31	2.83e-15	Breast cancer;
BRCA	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	10.08	0.37	2.74e-22	Bipolar disorder;
BRCA	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg01689657	chr7:91764605	CYP51A1	0.23	8.36	0.31	3.95e-16	Breast cancer;
BRCA	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18876405	chr7:65276391	NA	0.71	18.71	0.59	1.32e-62	Calcium levels;
BRCA	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07080220	chr10:102295463	HIF1AN	0.49	11.32	0.41	3.25e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs17253792	0.822	rs8018142	chr14:56173288	C/T	cg01858014	chr14:56050164	KTN1	-0.57	-8.93	-0.33	4.51e-18	Putamen volume;
BRCA	cis	rs79390637	1	rs79390637	chr11:47456867	C/A	cg20307385	chr11:47447363	PSMC3	0.51	11.55	0.42	3.81e-28	Intraocular pressure;
BRCA	cis	rs503734	0.502	rs348885	chr3:100976219	C/G	cg27318481	chr3:100970896	IMPG2	-0.41	-9.82	-0.36	2.65e-21	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs812925	0.502	rs778150	chr2:61608372	C/T	cg15711740	chr2:61764176	XPO1	0.32	7.86	0.3	1.64e-14	Immature fraction of reticulocytes;
BRCA	trans	rs9650657	0.771	rs6601513	chr8:10594843	A/G	cg06636001	chr8:8085503	FLJ10661	-0.39	-8.1	-0.31	2.77e-15	Neuroticism;
BRCA	trans	rs1200821	0.535	rs1938417	chr10:37687520	A/C	cg25427524	chr10:38739819	LOC399744	0.39	8.27	0.31	7.61e-16	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.69	-16.08	-0.54	3.95e-49	Axial length;
BRCA	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg14582100	chr15:45693742	SPATA5L1	0.34	10.15	0.37	1.55e-22	Homoarginine levels;
BRCA	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02353165	chr6:42928485	GNMT	0.89	24.06	0.69	1.53e-91	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs698813	0.604	rs4953077	chr2:44481207	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	7.91	0.3	1.15e-14	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs2304069	0.614	rs216140	chr5:149443298	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.35	8.54	0.32	9.57e-17	HIV-1 control;
BRCA	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg03128534	chr1:43423976	SLC2A1	0.62	15.04	0.51	5.73e-44	Red cell distribution width;
BRCA	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.08	0.34	1.39e-18	Tonsillectomy;
BRCA	cis	rs12760731	0.720	rs10913557	chr1:178442190	C/T	cg00404053	chr1:178313656	RASAL2	0.61	7.96	0.3	8.08e-15	Obesity-related traits;
BRCA	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-9.82	-0.36	2.6e-21	Gut microbiome composition (summer);
BRCA	cis	rs7927771	0.524	rs10838769	chr11:47825333	A/G	cg20307385	chr11:47447363	PSMC3	-0.4	-9.5	-0.35	4.09e-20	Subjective well-being;
BRCA	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg07917127	chr4:99064746	C4orf37	0.41	7.85	0.3	1.7e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg13647721	chr17:30228624	UTP6	0.5	8.7	0.33	2.89e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg12311346	chr5:56204834	C5orf35	-0.77	-15.54	-0.52	2.06e-46	Initial pursuit acceleration;
BRCA	cis	rs490234	0.805	rs562004	chr9:128321771	T/C	cg14078157	chr9:128172775	NA	0.34	7.98	0.3	6.71e-15	Mean arterial pressure;
BRCA	trans	rs7939886	0.920	rs10501343	chr11:55759573	G/T	cg15704280	chr7:45808275	SEPT13	0.62	7.94	0.3	9.08e-15	Myopia (pathological);
BRCA	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.31	-8.21	-0.31	1.25e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23583168	chr7:148888333	NA	-0.88	-20.81	-0.64	7.98e-74	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7523273	0.606	rs10449303	chr1:207961058	A/G	cg22525895	chr1:207977042	MIR29B2	-0.53	-13.42	-0.47	2.28e-36	Schizophrenia;
BRCA	cis	rs7572263	0.724	rs34082227	chr2:209055449	G/T	cg23998903	chr2:209048830	C2orf80	-0.42	-8.55	-0.32	9.21e-17	Glioma;Non-glioblastoma glioma;
BRCA	cis	rs3760982	0.585	rs68073292	chr19:44291401	T/C	cg12072164	chr19:44306565	LYPD5	0.37	8.67	0.32	3.5e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26314531	chr2:26401878	FAM59B	0.94	16.39	0.54	1.24e-50	Gut microbiome composition (summer);
BRCA	cis	rs6484504	0.600	rs366758	chr11:31222499	A/C	cg06552810	chr11:31128660	NA	-0.39	-8.69	-0.33	3.06e-17	Red blood cell count;
BRCA	cis	rs36051895	0.559	rs72701682	chr9:5208025	A/G	cg02405213	chr9:5042618	JAK2	-0.46	-8.18	-0.31	1.58e-15	Pediatric autoimmune diseases;
BRCA	cis	rs9649465	0.522	rs662705	chr7:123431594	A/C	cg03229431	chr7:123269106	ASB15	0.41	9.35	0.35	1.4e-19	Migraine;
BRCA	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26168224	chr5:2018326	NA	-0.63	-17.86	-0.58	3.39e-58	Gut microbiome composition (winter);
BRCA	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	25.72	0.71	1.05e-100	Chronic sinus infection;
BRCA	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19717773	chr7:2847554	GNA12	-0.46	-9.84	-0.36	2.19e-21	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
BRCA	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg12444411	chr7:2802554	GNA12	-0.38	-9.35	-0.35	1.47e-19	Height;
BRCA	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.55	0.39	4.3e-24	Motion sickness;
BRCA	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg15501526	chr10:2543763	NA	0.58	14.06	0.49	2.46e-39	Age-related hearing impairment;
BRCA	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg24977027	chr2:88469347	THNSL2	0.56	9.44	0.35	6.66e-20	Plasma clusterin levels;
BRCA	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg03433033	chr1:76189801	ACADM	0.76	17.39	0.57	9.72e-56	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00166722	chr3:10149974	C3orf24	0.65	12.75	0.45	2.35e-33	Alzheimer's disease;
BRCA	cis	rs9341808	0.754	rs3812126	chr6:80952701	A/G	cg08355045	chr6:80787529	NA	-0.38	-9.96	-0.37	8.06e-22	Sitting height ratio;
BRCA	cis	rs7577696	0.554	rs35978916	chr2:32400635	T/C	cg02381751	chr2:32503542	YIPF4	-0.48	-8.79	-0.33	1.34e-17	Inflammatory biomarkers;
BRCA	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg23649088	chr2:200775458	C2orf69	0.61	10.58	0.39	3.19e-24	Schizophrenia;
BRCA	cis	rs13161895	1.000	rs4389651	chr5:179460968	T/A	cg02702477	chr5:179499311	RNF130	0.45	8.45	0.32	2.01e-16	LDL cholesterol;
BRCA	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg03585969	chr10:35415529	CREM	0.5	10.46	0.38	9.82e-24	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.42	-10.68	-0.39	1.34e-24	Schizophrenia;
BRCA	cis	rs6087771	0.851	rs6087775	chr20:30325765	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	18.23	0.58	4.23e-60	Subcortical brain region volumes;Putamen volume;
BRCA	trans	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg26043149	chr18:55253948	FECH	-0.37	-8.25	-0.31	8.96e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10463316	0.823	rs7700340	chr5:150776320	C/T	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.18	-0.31	1.54e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg11645453	chr3:52864694	ITIH4	-0.37	-9.78	-0.36	3.69e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg23719950	chr11:63933701	MACROD1	-0.53	-8.53	-0.32	1.08e-16	Mean platelet volume;
BRCA	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.37	8.0	0.3	5.67e-15	Platelet count;
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg18402987	chr7:1209562	NA	0.51	9.49	0.35	4.43e-20	Longevity;Endometriosis;
BRCA	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg09307838	chr4:120376055	NA	0.73	15.6	0.53	9.59e-47	Corneal astigmatism;
BRCA	cis	rs11971779	0.838	rs11764161	chr7:139115198	T/C	cg07862535	chr7:139043722	LUC7L2	0.44	11.35	0.41	2.6e-27	Diisocyanate-induced asthma;
BRCA	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg20587970	chr11:113659929	NA	-1.21	-22.23	-0.66	1.6e-81	Hip circumference adjusted for BMI;
BRCA	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg01304814	chr3:48885189	PRKAR2A	0.57	8.01	0.3	5.25e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-10.5	-0.38	6.85e-24	Personality dimensions;
BRCA	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg12310025	chr6:25882481	NA	-0.37	-8.64	-0.32	4.38e-17	Height;
BRCA	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg03342759	chr3:160939853	NMD3	-0.71	-14.55	-0.5	1.21e-41	Parkinson's disease;
BRCA	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25427524	chr10:38739819	LOC399744	0.58	13.28	0.47	9.93e-36	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg04450456	chr4:17643702	FAM184B	0.39	11.62	0.42	1.95e-28	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.34	0.75	4.7e-115	Chronic sinus infection;
BRCA	cis	rs8064299	0.967	rs7420	chr17:72765215	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.39	-11.13	-0.4	2.04e-26	Monocyte count;
BRCA	cis	rs2629540	0.847	rs12247543	chr10:126419743	G/C	cg08799069	chr10:126477246	METTL10	0.44	8.98	0.33	2.97e-18	Cocaine dependence;
BRCA	cis	rs6087990	1.000	rs6087990	chr20:31349908	T/C	cg13636640	chr20:31349939	DNMT3B	0.8	27.46	0.74	3.23e-110	Ulcerative colitis;
BRCA	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.92	0.4	1.43e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1003719	0.788	rs1155787	chr21:38448069	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.25	0.49	3.26e-40	Eye color traits;
BRCA	cis	rs2282802	0.685	rs2436391	chr5:139557385	C/T	cg26211634	chr5:139558579	C5orf32	-0.33	-7.98	-0.3	6.85e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg21427119	chr20:30132790	HM13	-0.43	-9.04	-0.34	1.81e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg17971929	chr21:40555470	PSMG1	-0.45	-9.27	-0.34	2.88e-19	Menarche (age at onset);
BRCA	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	cis	rs12210905	0.688	rs12195783	chr6:27444345	A/G	cg08851530	chr6:28072375	NA	0.78	7.84	0.3	1.88e-14	Hip circumference adjusted for BMI;
BRCA	cis	rs1691799	0.867	rs2172881	chr12:66766039	C/G	cg16791601	chr12:66731901	HELB	-0.63	-16.97	-0.56	1.41e-53	White blood cell count (basophil);
BRCA	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.46	-9.88	-0.36	1.6e-21	Cognitive ability;
BRCA	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg11663144	chr21:46675770	NA	-0.59	-13.74	-0.48	8.29e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg14061069	chr19:46274453	DMPK	-0.41	-9.46	-0.35	5.86e-20	Coronary artery disease;
BRCA	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg03354898	chr7:1950403	MAD1L1	-0.49	-10.17	-0.37	1.26e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-12.45	-0.44	5.12e-32	Personality dimensions;
BRCA	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21659725	chr3:3221576	CRBN	-0.71	-21.71	-0.65	1.04e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs4268898	1.000	rs2303294	chr2:24432620	A/G	cg06627628	chr2:24431161	ITSN2	0.5	10.44	0.38	1.14e-23	Asthma;
BRCA	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08280861	chr8:58055591	NA	0.53	8.68	0.32	3.27e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg15997130	chr1:24165203	NA	0.49	13.34	0.47	5.3e-36	Immature fraction of reticulocytes;
BRCA	trans	rs783540	0.542	rs62009945	chr15:83299956	T/A	cg16105309	chr15:79090380	ADAMTS7	0.34	8.56	0.32	8.65e-17	Schizophrenia;
BRCA	cis	rs17253792	0.822	rs77182097	chr14:56136695	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-9.37	-0.35	1.25e-19	Putamen volume;
BRCA	cis	rs887829	0.569	rs2008595	chr2:234637192	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.32	-8.35	-0.31	4.3e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg06484146	chr7:12443880	VWDE	-0.76	-10.67	-0.39	1.43e-24	Coronary artery disease;
BRCA	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg23033748	chr14:75592666	NEK9	0.43	10.25	0.38	6.35e-23	Height;
BRCA	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.53	-0.35	3.1e-20	Total body bone mineral density;
BRCA	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg23029597	chr12:123009494	RSRC2	-0.46	-9.32	-0.35	1.84e-19	Body mass index;
BRCA	trans	rs11976180	1.000	rs2961117	chr7:143755253	C/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.43	-7.87	-0.3	1.49e-14	Obesity-related traits;
BRCA	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs10924970	0.967	rs2382616	chr1:235454237	C/T	cg26050004	chr1:235667680	B3GALNT2	0.35	8.55	0.32	9.19e-17	Asthma;
BRCA	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg24812749	chr6:127587940	RNF146	0.88	20.75	0.63	1.58e-73	Breast cancer;
BRCA	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg06627628	chr2:24431161	ITSN2	0.56	8.95	0.33	3.81e-18	Lymphocyte counts;
BRCA	cis	rs3771570	1.000	rs6752050	chr2:242228780	T/C	cg21155796	chr2:242212141	HDLBP	0.58	8.85	0.33	8.46e-18	Prostate cancer;
BRCA	cis	rs4908768	0.501	rs11121201	chr1:8632791	A/T	cg20416874	chr1:8611966	RERE	-0.28	-8.17	-0.31	1.65e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg00666640	chr1:248458726	OR2T12	0.33	8.93	0.33	4.51e-18	Common traits (Other);
BRCA	trans	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg06521331	chr12:34319734	NA	-0.49	-9.03	-0.34	2.06e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg00321850	chr1:175162397	KIAA0040	-0.41	-11.19	-0.4	1.17e-26	Alcohol dependence;
BRCA	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg16099169	chr2:106886729	NA	-0.59	-9.98	-0.37	6.66e-22	Facial morphology (factor 23);
BRCA	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg27398817	chr8:82754497	SNX16	0.37	8.54	0.32	1e-16	Diastolic blood pressure;
BRCA	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg22496339	chr2:162101262	NA	0.58	13.04	0.46	1.21e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs12949688	0.967	rs8081251	chr17:55824033	A/G	cg12582317	chr17:55822272	NA	0.32	7.95	0.3	8.73e-15	Schizophrenia;
BRCA	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.81	14.49	0.5	2.43e-41	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.6	0.39	2.83e-24	Motion sickness;
BRCA	cis	rs9473147	0.516	rs1485780	chr6:47556630	A/C	cg12968598	chr6:47444699	CD2AP	0.44	9.62	0.36	1.56e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg09163369	chr1:210001066	C1orf107	-0.59	-10.54	-0.38	4.57e-24	Orofacial clefts;
BRCA	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	trans	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-18.04	-0.58	4.06e-59	Exhaled nitric oxide output;
BRCA	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg21518248	chr2:162101506	NA	-0.47	-9.09	-0.34	1.21e-18	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
BRCA	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg18876405	chr7:65276391	NA	0.55	12.5	0.44	3.25e-32	Calcium levels;
BRCA	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	8.66	0.32	3.85e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.95	0.56	1.76e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg05754148	chr16:3507555	NAT15	0.53	7.9	0.3	1.23e-14	Tuberculosis;
BRCA	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-9.85	-0.36	2.07e-21	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg12310025	chr6:25882481	NA	0.71	17.27	0.56	4.13e-55	Blood metabolite levels;
BRCA	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg25173405	chr17:45401733	C17orf57	0.48	10.29	0.38	4.57e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	14.78	0.5	9.58e-43	Platelet count;
BRCA	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg08975724	chr8:8085496	FLJ10661	0.43	7.95	0.3	8.66e-15	Retinal vascular caliber;
BRCA	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg26116260	chr4:7069785	GRPEL1	0.95	27.92	0.74	9.28e-113	Monocyte percentage of white cells;
BRCA	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.48	9.71	0.36	7.14e-21	Systemic lupus erythematosus;
BRCA	cis	rs1355223	0.506	rs7130678	chr11:34869181	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-9.76	-0.36	4.49e-21	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg18154014	chr19:37997991	ZNF793	0.48	9.5	0.35	4.15e-20	Coronary artery calcification;
BRCA	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg05347473	chr6:146136440	FBXO30	0.41	8.12	0.31	2.44e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg05347473	chr6:146136440	FBXO30	0.4	7.94	0.3	9.18e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	17.14	0.56	1.86e-54	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg24558204	chr6:135376177	HBS1L	0.45	12.26	0.44	3.46e-31	Red blood cell count;
BRCA	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg17509989	chr5:176798049	RGS14	0.64	12.74	0.45	2.72e-33	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg07810366	chr2:100720526	AFF3	-0.3	-7.86	-0.3	1.64e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg03609598	chr5:56110824	MAP3K1	-0.47	-8.11	-0.31	2.54e-15	Initial pursuit acceleration;
BRCA	trans	rs1493916	0.837	rs9945976	chr18:31409314	C/T	cg27147174	chr7:100797783	AP1S1	-0.42	-8.48	-0.32	1.55e-16	Life satisfaction;
BRCA	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.16	-0.4	1.51e-26	Response to antipsychotic treatment;
BRCA	cis	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg06521331	chr12:34319734	NA	-0.63	-12.18	-0.43	7.88e-31	Morning vs. evening chronotype;
BRCA	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg08917208	chr2:24149416	ATAD2B	0.52	8.28	0.31	7.42e-16	Asthma;
BRCA	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.6	-0.67	1.57e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	ch.11.42038R	chr11:967971	AP2A2	0.58	19.0	0.6	3.69e-64	Alzheimer's disease (late onset);
BRCA	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07308232	chr7:1071921	C7orf50	-0.51	-10.72	-0.39	9.32e-25	Longevity;Endometriosis;
BRCA	cis	rs12022452	0.506	rs11208363	chr1:41010454	A/G	cg25568243	chr1:40974465	DEM1	0.45	8.28	0.31	7.06e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg16339924	chr4:17578868	LAP3	0.62	15.36	0.52	1.59e-45	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg23711669	chr6:146136114	FBXO30	0.65	14.73	0.5	1.63e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.69	-0.36	8.48e-21	Alcohol dependence;
BRCA	cis	rs17270561	0.609	rs4711093	chr6:25687895	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	8.87	0.33	7.32e-18	Iron status biomarkers;
BRCA	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg08822215	chr16:89438651	ANKRD11	0.45	9.66	0.36	1.06e-20	Multiple myeloma (IgH translocation);
BRCA	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg05665937	chr4:1216051	CTBP1	0.52	10.85	0.39	2.76e-25	Obesity-related traits;
BRCA	cis	rs9287719	0.614	rs12622053	chr2:10722140	T/C	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	5.17e-19	Prostate cancer;
BRCA	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg04944784	chr2:26401820	FAM59B	-0.64	-10.6	-0.39	2.66e-24	Gut microbiome composition (summer);
BRCA	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18357526	chr6:26021779	HIST1H4A	0.48	8.85	0.33	8.74e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg15839431	chr19:19639596	YJEFN3	0.35	8.05	0.3	4.14e-15	Bipolar disorder;
BRCA	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg23625390	chr15:77176239	SCAPER	0.42	10.41	0.38	1.45e-23	Blood metabolite levels;
BRCA	cis	rs243505	0.898	rs243540	chr7:148403312	A/G	cg09806900	chr7:148480153	CUL1	-0.42	-8.33	-0.31	4.81e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs250677	0.522	rs10050928	chr5:148353463	C/A	cg12140854	chr5:148520817	ABLIM3	0.41	8.24	0.31	9.66e-16	Breast cancer;
BRCA	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05901451	chr6:126070800	HEY2	-0.55	-14.18	-0.49	7.14e-40	Brugada syndrome;
BRCA	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg21475434	chr5:93447410	FAM172A	0.66	8.55	0.32	9.24e-17	Diabetic retinopathy;
BRCA	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg21280719	chr6:42927975	GNMT	0.26	8.56	0.32	8.23e-17	Blood protein levels;
BRCA	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-8.62	-0.32	5.14e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs754466	1.000	rs754466	chr10:79680434	A/T	cg17075019	chr10:79541650	NA	-0.54	-11.06	-0.4	3.91e-26	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg06191203	chr2:152266755	RIF1	-0.33	-9.44	-0.35	6.57e-20	Squamous cell lung carcinoma;
BRCA	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg24130564	chr14:104152367	KLC1	0.36	8.2	0.31	1.33e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9403521	1.000	rs117303301	chr6:143999003	C/T	cg18240653	chr6:144019428	PHACTR2	-0.41	-8.18	-0.31	1.5e-15	Obesity-related traits;
BRCA	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.92	-0.51	2.06e-43	Total cholesterol levels;
BRCA	cis	rs4919087	0.962	rs10882889	chr10:99045890	A/G	cg25902810	chr10:99078978	FRAT1	0.45	9.4	0.35	9.69e-20	Monocyte count;
BRCA	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg05535760	chr7:792225	HEATR2	-0.73	-11.6	-0.42	2.2e-28	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg11584989	chr19:19387371	SF4	0.62	12.97	0.46	2.52e-34	Bipolar disorder;
BRCA	trans	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.12	0.31	2.33e-15	Corneal astigmatism;
BRCA	cis	rs7640424	0.628	rs7628325	chr3:107816314	G/A	cg09227934	chr3:107805635	CD47	-0.44	-8.22	-0.31	1.1e-15	Body mass index;
BRCA	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg00277334	chr10:82204260	NA	-0.58	-13.26	-0.46	1.31e-35	Post bronchodilator FEV1;
BRCA	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg20290983	chr6:43655470	MRPS18A	1.12	41.98	0.86	7.04e-186	IgG glycosylation;
BRCA	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.57	-0.61	3.59e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4535700	0.501	rs9642405	chr7:55978166	C/T	cg09872392	chr7:56161020	PHKG1	0.35	8.07	0.3	3.51e-15	Macular telangiectasia type 2;
BRCA	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg05347473	chr6:146136440	FBXO30	0.41	8.05	0.3	3.96e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12986413	1.000	rs12983458	chr19:2168612	A/G	cg09261902	chr19:2140048	AP3D1	0.39	10.31	0.38	3.74e-23	Height;
BRCA	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg11266682	chr4:10021025	SLC2A9	0.48	12.68	0.45	4.85e-33	Bone mineral density;
BRCA	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.99	-0.3	6.24e-15	Bipolar disorder;
BRCA	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg22920501	chr2:26401640	FAM59B	0.74	10.71	0.39	1.01e-24	Gut microbiome composition (summer);
BRCA	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg12483005	chr1:23474871	LUZP1	0.44	9.81	0.36	2.84e-21	Height;
BRCA	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg02734326	chr4:10020555	SLC2A9	0.38	8.18	0.31	1.56e-15	Bone mineral density;
BRCA	cis	rs6484504	0.532	rs2616799	chr11:31319044	T/C	cg06552810	chr11:31128660	NA	0.4	8.89	0.33	6.19e-18	Red blood cell count;
BRCA	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.28	-0.38	5.01e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg11890956	chr21:40555474	PSMG1	-0.61	-13.47	-0.47	1.34e-36	Menarche (age at onset);
BRCA	cis	rs4363385	0.818	rs557553	chr1:153010370	T/G	cg24667326	chr1:152973720	SPRR3	-0.33	-9.17	-0.34	6.49e-19	Inflammatory skin disease;
BRCA	cis	rs7246657	0.653	rs4805208	chr19:37674259	G/A	cg18154014	chr19:37997991	ZNF793	0.54	9.05	0.34	1.73e-18	Coronary artery calcification;
BRCA	cis	rs6545883	0.826	rs777593	chr2:61419103	C/A	cg15711740	chr2:61764176	XPO1	-0.53	-12.94	-0.46	3.57e-34	Tuberculosis;
BRCA	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg20701182	chr2:24300061	SF3B14	0.56	8.61	0.32	5.89e-17	Lymphocyte counts;
BRCA	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg20607798	chr8:58055168	NA	0.47	8.02	0.3	5.03e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.17	0.49	7.64e-40	Motion sickness;
BRCA	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg19274703	chr22:41806451	NA	-0.37	-8.4	-0.32	2.99e-16	Vitiligo;
BRCA	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03264133	chr6:25882463	NA	-0.51	-10.64	-0.39	1.86e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	0.624	rs10172926	chr2:10733254	A/C	cg00105475	chr2:10696890	NA	0.41	9.23	0.34	3.83e-19	Prostate cancer;
BRCA	cis	rs9868809	0.881	rs7620853	chr3:48666503	G/A	cg00383909	chr3:49044727	WDR6	0.52	7.92	0.3	1.08e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg16850897	chr7:100343110	ZAN	-0.57	-11.11	-0.4	2.51e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.71	-0.36	6.84e-21	IgG glycosylation;
BRCA	cis	rs9815354	0.812	rs113528686	chr3:41951547	T/C	cg03022575	chr3:42003672	ULK4	0.69	9.62	0.36	1.44e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2904967	0.866	rs526502	chr11:65026590	T/C	cg09225861	chr11:65069680	NA	-0.39	-8.07	-0.3	3.62e-15	Mean corpuscular volume;
BRCA	cis	rs2625529	0.652	rs2957361	chr15:72345218	G/A	cg16672083	chr15:72433130	SENP8	0.65	15.48	0.52	4.12e-46	Red blood cell count;
BRCA	cis	rs10189230	0.967	rs12993766	chr2:222350321	C/T	cg14652038	chr2:222343519	EPHA4	0.48	13.26	0.46	1.28e-35	Urate levels in lean individuals;
BRCA	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg22875332	chr1:76189707	ACADM	0.7	14.97	0.51	1.26e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg21475434	chr5:93447410	FAM172A	0.68	9.2	0.34	5.14e-19	Diabetic retinopathy;
BRCA	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg08601574	chr20:25228251	PYGB	0.36	8.58	0.32	7.39e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg01689657	chr7:91764605	CYP51A1	0.21	7.85	0.3	1.74e-14	Breast cancer;
BRCA	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.43	-9.97	-0.37	7.13e-22	Lymphocyte counts;
BRCA	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.94	-0.43	7.97e-30	Response to antipsychotic treatment;
BRCA	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.39	-8.19	-0.31	1.42e-15	Body mass index;
BRCA	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05901451	chr6:126070800	HEY2	-0.55	-15.0	-0.51	8.26e-44	Brugada syndrome;
BRCA	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.17	-0.43	8.62e-31	Alzheimer's disease;
BRCA	cis	rs8054556	0.647	rs11863174	chr16:30019375	A/C	cg06326092	chr16:30034487	C16orf92	0.31	7.98	0.3	6.58e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6484504	0.576	rs208066	chr11:31156206	C/G	cg14844989	chr11:31128820	NA	-0.43	-9.05	-0.34	1.7e-18	Red blood cell count;
BRCA	cis	rs593982	0.843	rs680948	chr11:65472394	C/G	cg08755490	chr11:65554678	OVOL1	1.14	16.68	0.55	4.1e-52	Atopic dermatitis;
BRCA	cis	rs13046373	0.535	rs35909098	chr21:32021649	C/T	cg22337977	chr21:31811175	KRTAP15-1	0.33	7.92	0.3	1.04e-14	HDL cholesterol;
BRCA	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.52	11.16	0.4	1.5e-26	Colorectal cancer;
BRCA	cis	rs534126	0.778	rs6464540	chr7:142954903	G/A	cg22531018	chr7:142981779	TMEM139	0.48	10.82	0.39	3.44e-25	Cancer;
BRCA	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg02176678	chr2:219576539	TTLL4	0.43	11.56	0.42	3.34e-28	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.78	0.33	1.48e-17	Motion sickness;
BRCA	cis	rs9470366	0.883	rs9462210	chr6:36628953	G/A	cg08179530	chr6:36648295	CDKN1A	0.49	9.76	0.36	4.41e-21	QRS duration;
BRCA	cis	rs12618769	0.652	rs76525766	chr2:99221088	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.49	0.32	1.44e-16	Bipolar disorder;
BRCA	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg22875332	chr1:76189707	ACADM	0.81	19.69	0.61	7.96e-68	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10788264	0.518	rs1028632	chr10:124044657	C/G	cg09507567	chr10:124027408	NA	0.38	7.83	0.3	2.07e-14	Total body bone mineral density;
BRCA	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg08470875	chr2:26401718	FAM59B	-0.5	-8.06	-0.3	3.87e-15	Gut microbiome composition (summer);
BRCA	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.67	-0.32	3.58e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg21479132	chr6:26055353	NA	0.59	8.31	0.31	5.6e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg25358565	chr5:93447407	FAM172A	1.25	19.46	0.61	1.36e-66	Diabetic retinopathy;
BRCA	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg24768116	chr2:27665128	KRTCAP3	0.34	8.52	0.32	1.14e-16	Total body bone mineral density;
BRCA	cis	rs10924970	0.967	rs12741262	chr1:235406849	T/C	cg26050004	chr1:235667680	B3GALNT2	0.35	8.75	0.33	1.82e-17	Asthma;
BRCA	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg15145296	chr3:125709740	NA	-0.49	-8.53	-0.32	1.07e-16	Blood pressure (smoking interaction);
BRCA	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	17.82	0.58	5.88e-58	Platelet count;
BRCA	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20887711	chr4:1340912	KIAA1530	-0.58	-12.78	-0.45	1.77e-33	Obesity-related traits;
BRCA	cis	rs1401999	0.898	rs6443928	chr3:183729487	C/T	cg01324343	chr3:183735012	ABCC5	0.8	20.0	0.62	1.84e-69	Anterior chamber depth;
BRCA	cis	rs1198872	0.503	rs1627163	chr2:10954844	A/G	cg15705551	chr2:10952987	PDIA6	0.45	9.34	0.35	1.64e-19	Cardiac Troponin-T levels;
BRCA	trans	rs10242455	0.702	rs73397499	chr7:99039627	T/C	cg09045935	chr12:6379348	NA	0.86	8.35	0.31	4.08e-16	Blood metabolite levels;
BRCA	cis	rs11255291	1.000	rs7917456	chr10:7732323	A/G	cg26051552	chr10:7670683	ITIH5	0.36	7.83	0.3	2.07e-14	Ovarian reserve;
BRCA	trans	rs853679	0.599	rs156743	chr6:27967089	T/C	cg01620082	chr3:125678407	NA	-0.53	-8.07	-0.3	3.39e-15	Depression;
BRCA	cis	rs12541635	0.677	rs11781234	chr8:107012342	G/T	cg10147462	chr8:107024639	NA	0.39	10.61	0.39	2.5e-24	Age of smoking initiation;
BRCA	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg10862848	chr6:42927986	GNMT	-0.36	-14.43	-0.5	4.61e-41	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	10.46	0.38	9.9899999999999993e-24	Calcium levels;
BRCA	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	cis	rs9308433	0.505	rs958304	chr1:214474241	C/T	cg06198575	chr1:214491504	SMYD2	0.59	12.69	0.45	4.73e-33	IgG glycosylation;
BRCA	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg27490568	chr2:178487706	NA	0.43	7.93	0.3	1.01e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg22920501	chr2:26401640	FAM59B	0.91	15.61	0.53	9.09e-47	Gut microbiome composition (summer);
BRCA	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg11584989	chr19:19387371	SF4	0.64	13.48	0.47	1.25e-36	Bipolar disorder;
BRCA	cis	rs2336384	1.000	rs873457	chr1:12046334	C/G	cg13216073	chr1:12042593	MFN2	0.43	9.51	0.35	3.86e-20	Platelet count;
BRCA	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06634786	chr22:41940651	POLR3H	0.58	9.62	0.36	1.49e-20	Vitiligo;
BRCA	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg04944784	chr2:26401820	FAM59B	-0.75	-13.02	-0.46	1.51e-34	Gut microbiome composition (summer);
BRCA	cis	rs10779751	0.770	rs2258621	chr1:11141187	C/G	cg08854313	chr1:11322531	MTOR	0.74	14.86	0.51	3.98e-43	Body mass index;
BRCA	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg07741184	chr6:167504864	NA	0.33	9.82	0.36	2.83e-21	Primary biliary cholangitis;
BRCA	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg19920283	chr7:105172520	RINT1	0.58	9.35	0.35	1.42e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg08601574	chr20:25228251	PYGB	-0.35	-8.55	-0.32	9.04e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1975991	0.765	rs4686940	chr3:187957193	T/C	cg15417654	chr3:187959138	LPP	0.36	9.34	0.35	1.59e-19	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.27	-0.41	5.37e-27	Schizophrenia;
BRCA	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	10.39	0.38	1.8e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs11190604	1.000	rs76683169	chr10:102358397	A/T	cg07080220	chr10:102295463	HIF1AN	0.61	11.91	0.43	1.08e-29	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg00409905	chr10:38381863	ZNF37A	0.48	9.87	0.36	1.77e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4285028	0.747	rs7153	chr3:121383297	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-13.85	-0.48	2.53e-38	Multiple sclerosis;
BRCA	cis	rs12618769	0.597	rs4069739	chr2:99049528	G/C	cg10123293	chr2:99228465	UNC50	0.4	7.95	0.3	8.52e-15	Bipolar disorder;
BRCA	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg17330251	chr7:94953956	PON1	-0.41	-8.48	-0.32	1.51e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg21782813	chr7:2030301	MAD1L1	0.39	10.18	0.37	1.22e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg05347473	chr6:146136440	FBXO30	0.4	7.91	0.3	1.16e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs858239	0.600	rs2003555	chr7:23122915	C/T	cg23682824	chr7:23144976	KLHL7	0.45	11.82	0.42	2.65e-29	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg09877947	chr5:131593287	PDLIM4	0.42	9.88	0.36	1.55e-21	Acylcarnitine levels;
BRCA	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg18016565	chr1:150552671	MCL1	0.35	8.03	0.3	4.85e-15	Melanoma;
BRCA	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-12.78	-0.45	1.85e-33	Developmental language disorder (linguistic errors);
BRCA	cis	rs965469	0.779	rs6051710	chr20:3264661	T/C	cg25506879	chr20:3388711	C20orf194	-0.44	-8.77	-0.33	1.65e-17	IFN-related cytopenia;
BRCA	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg23711669	chr6:146136114	FBXO30	-0.71	-16.94	-0.56	2e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg18230493	chr5:56204884	C5orf35	0.74	14.59	0.5	8.41e-42	Initial pursuit acceleration;
BRCA	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.65	0.39	1.73e-24	Motion sickness;
BRCA	trans	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg25214090	chr10:38739885	LOC399744	-0.47	-10.43	-0.38	1.25e-23	Corneal astigmatism;
BRCA	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg07636037	chr3:49044803	WDR6	0.82	21.8	0.65	3.56e-79	Menarche (age at onset);
BRCA	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-15.71	-0.53	2.97e-47	Electrocardiographic conduction measures;
BRCA	cis	rs701145	0.537	rs1713831	chr3:153836299	T/C	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.89e-18	Coronary artery disease;
BRCA	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg25809561	chr17:30822961	MYO1D	-0.38	-8.97	-0.33	3.33e-18	Schizophrenia;
BRCA	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg26587870	chr6:27730563	NA	-0.52	-7.99	-0.3	6.27e-15	Depression;
BRCA	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.27e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7246967	0.673	rs9677019	chr19:22912659	T/C	cg23217946	chr19:22817039	ZNF492	0.5	9.16	0.34	6.71e-19	Bronchopulmonary dysplasia;
BRCA	trans	rs1459104	0.759	rs7939392	chr11:55257285	C/T	cg15704280	chr7:45808275	SEPT13	0.55	8.98	0.33	2.93e-18	Body mass index;
BRCA	cis	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg04990556	chr1:26633338	UBXN11	0.55	8.9	0.33	5.93e-18	Obesity-related traits;
BRCA	cis	rs10242455	0.702	rs17854665	chr7:99050039	G/A	cg18809830	chr7:99032528	PTCD1	-0.61	-8.86	-0.33	7.76e-18	Blood metabolite levels;
BRCA	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.72e-18	Alzheimer's disease (late onset);
BRCA	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11764359	chr7:65958608	NA	-0.72	-15.42	-0.52	7.91e-46	Aortic root size;
BRCA	cis	rs8028182	0.537	rs4371118	chr15:75898890	C/G	cg20655648	chr15:75932815	IMP3	0.46	8.86	0.33	8.2e-18	Sudden cardiac arrest;
BRCA	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg12483005	chr1:23474871	LUZP1	0.46	10.27	0.38	5.48e-23	Height;
BRCA	cis	rs11700980	0.636	rs73190119	chr21:30303685	C/A	cg24692254	chr21:30365293	RNF160	-0.47	-8.07	-0.3	3.43e-15	QRS complex (12-leadsum);
BRCA	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg16049864	chr8:95962084	TP53INP1	-0.46	-11.19	-0.4	1.19e-26	Type 2 diabetes;
BRCA	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg12311346	chr5:56204834	C5orf35	-0.79	-15.4	-0.52	9.6e-46	Initial pursuit acceleration;
BRCA	cis	rs68170813	0.559	rs59782202	chr7:107032766	G/T	cg02696742	chr7:106810147	HBP1	-0.51	-8.45	-0.32	1.95e-16	Coronary artery disease;
BRCA	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18404041	chr3:52824283	ITIH1	-0.43	-12.64	-0.45	7.89e-33	Bipolar disorder;
BRCA	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg24747557	chr10:131355152	MGMT	-0.37	-8.96	-0.33	3.56e-18	Response to temozolomide;
BRCA	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg01483505	chr11:975446	AP2A2	0.34	9.33	0.35	1.78e-19	Alzheimer's disease (late onset);
BRCA	cis	rs3820928	0.904	rs2195487	chr2:227759720	G/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.53	-0.32	1.04e-16	Pulmonary function;
BRCA	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg23788917	chr6:8435910	SLC35B3	-0.65	-12.06	-0.43	2.49e-30	Motion sickness;
BRCA	cis	rs1568889	1.000	rs9783375	chr11:28033667	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	12.64	0.45	7.4e-33	Bipolar disorder;
BRCA	cis	rs4742903	0.527	rs7350223	chr9:106885332	A/G	cg14250997	chr9:106856677	SMC2	0.29	8.57	0.32	7.68e-17	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg01262667	chr19:19385393	TM6SF2	0.42	10.97	0.4	9.28e-26	Tonsillectomy;
BRCA	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg26384229	chr12:38710491	ALG10B	0.67	13.98	0.48	6.25e-39	Morning vs. evening chronotype;
BRCA	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg11887960	chr12:57824829	NA	0.52	8.15	0.31	1.89e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg00677455	chr12:58241039	CTDSP2	0.63	14.18	0.49	7.02e-40	Multiple sclerosis;
BRCA	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg08470875	chr2:26401718	FAM59B	0.71	11.35	0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs13102973	0.932	rs11099305	chr4:135895569	C/G	cg14419869	chr4:135874104	NA	0.52	10.97	0.4	9.3e-26	Subjective well-being;
BRCA	cis	rs7560272	0.538	rs17434634	chr2:73922926	T/A	cg20560298	chr2:73613845	ALMS1	0.35	9.04	0.34	1.8e-18	Schizophrenia;
BRCA	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11764359	chr7:65958608	NA	0.81	19.67	0.61	1.05e-67	Aortic root size;
BRCA	cis	rs7246657	0.507	rs8107654	chr19:37453534	C/T	cg23950597	chr19:37808831	NA	-0.6	-8.62	-0.32	5.33e-17	Coronary artery calcification;
BRCA	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg15017067	chr4:17643749	FAM184B	0.35	10.83	0.39	3.2e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg08213375	chr14:104286397	PPP1R13B	0.64	18.18	0.58	7.35e-60	Schizophrenia;
BRCA	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg15934090	chr1:100435551	SLC35A3	0.36	8.43	0.32	2.38e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72772090	0.710	rs11739280	chr5:96074147	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.58	12.65	0.45	6.98e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs9463078	0.739	rs1293457	chr6:44758098	T/C	cg25276700	chr6:44698697	NA	0.38	8.92	0.33	4.79e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg27432699	chr2:27873401	GPN1	0.46	9.71	0.36	7.18e-21	Oral cavity cancer;
BRCA	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg10253484	chr15:75165896	SCAMP2	-0.55	-11.44	-0.41	1.06e-27	Breast cancer;
BRCA	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg11502198	chr6:26597334	ABT1	0.61	11.56	0.42	3.24e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg13736514	chr6:26305472	NA	-0.41	-12.26	-0.44	3.58e-31	Mosquito bite size;
BRCA	cis	rs887829	0.569	rs10179091	chr2:234657983	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.3	-7.95	-0.3	8.2e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.52	-0.61	6.62e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg11764359	chr7:65958608	NA	0.68	15.21	0.52	8.16e-45	Aortic root size;
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.56	-12.7	-0.45	4.04e-33	Longevity;Endometriosis;
BRCA	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.46	9.25	0.34	3.33e-19	Tonsillectomy;
BRCA	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg00106254	chr7:1943704	MAD1L1	-0.38	-9.12	-0.34	1e-18	Bipolar disorder and schizophrenia;
BRCA	trans	rs11088226	0.681	rs2409456	chr21:33929374	G/A	cg09050820	chr6:167586206	TCP10L2	0.76	13.65	0.48	2.14e-37	Gastritis;
BRCA	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg23533926	chr12:111358616	MYL2	-0.42	-8.71	-0.33	2.6e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6138458	1.000	rs4273288	chr20:24900873	G/A	cg26195577	chr20:24973756	C20orf3	-0.98	-24.76	-0.7	2.17e-95	Blood protein levels;
BRCA	cis	rs17095355	0.818	rs12572438	chr10:111769236	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.45	-9.74	-0.36	5.35e-21	Biliary atresia;
BRCA	trans	rs3857536	0.813	rs6931701	chr6:66940905	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg06623918	chr6:96969491	KIAA0776	0.74	12.19	0.43	6.85e-31	Migraine;Coronary artery disease;
BRCA	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-12.13	-0.43	1.31e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg22800045	chr5:56110881	MAP3K1	-0.51	-8.5	-0.32	1.32e-16	Initial pursuit acceleration;
BRCA	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg08601574	chr20:25228251	PYGB	-0.34	-8.25	-0.31	9.18e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7246657	0.722	rs2287229	chr19:38188652	G/A	cg18154014	chr19:37997991	ZNF793	-0.51	-9.64	-0.36	1.27e-20	Coronary artery calcification;
BRCA	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg02275930	chr1:2372054	NA	-0.42	-9.97	-0.37	7.43e-22	Non-obstructive azoospermia;
BRCA	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.54	-13.26	-0.46	1.27e-35	Urate levels in overweight individuals;
BRCA	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-10.73	-0.39	8.53e-25	Gut microbiome composition (summer);
BRCA	cis	rs6840360	0.533	rs13139327	chr4:152728590	A/C	cg22705602	chr4:152727874	NA	-0.39	-10.57	-0.39	3.52e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7520050	0.966	rs1707340	chr1:46514942	T/C	cg24296786	chr1:45957014	TESK2	0.41	9.22	0.34	4.28e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg03433033	chr1:76189801	ACADM	0.73	18.63	0.59	3.43e-62	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6598955	0.543	rs60676610	chr1:26543421	G/C	cg04990556	chr1:26633338	UBXN11	0.7	11.96	0.43	6.68e-30	Obesity-related traits;
BRCA	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00802000	chr16:706648	WDR90	-0.41	-9.69	-0.36	8.16e-21	Height;
BRCA	cis	rs4363385	0.818	rs426360	chr1:153014710	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.62	-0.32	5.11e-17	Inflammatory skin disease;
BRCA	cis	rs6878727	0.707	rs7717536	chr5:123718821	C/T	cg01806427	chr5:123737813	NA	0.39	9.04	0.34	1.85e-18	Breast cancer;
BRCA	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg24101359	chr6:42928495	GNMT	0.62	14.99	0.51	9.23e-44	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs35740288	0.929	rs11556865	chr15:86303180	C/G	cg20737812	chr15:86336631	KLHL25	-0.33	-8.09	-0.3	2.99e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs6121246	0.559	rs6060915	chr20:30330306	A/G	cg13852791	chr20:30311386	BCL2L1	0.93	22.13	0.66	5.66e-81	Mean corpuscular hemoglobin;
BRCA	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg24675658	chr1:53192096	ZYG11B	0.68	14.68	0.5	2.81e-42	Monocyte count;
BRCA	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg16325326	chr1:53192061	ZYG11B	0.73	18.75	0.6	7.85e-63	Monocyte count;
BRCA	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg20290983	chr6:43655470	MRPS18A	1.1	40.87	0.85	2e-180	IgG glycosylation;
BRCA	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg04414720	chr1:150670196	GOLPH3L	0.36	8.21	0.31	1.2e-15	Tonsillectomy;
BRCA	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4819852	1.000	rs2073743	chr22:19989612	C/G	cg07821417	chr22:19972146	ARVCF	0.49	10.4	0.38	1.67e-23	Pulse pressure;
BRCA	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.35	-0.38	2.66e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	9.98	0.37	7.04e-22	Aortic root size;
BRCA	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg16230307	chr14:35515116	FAM177A1	0.72	14.91	0.51	2.41e-43	Psoriasis;
BRCA	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg05552183	chr6:42928497	GNMT	0.8	19.33	0.61	6.54e-66	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg23708337	chr7:1209742	NA	0.6	13.68	0.48	1.45e-37	Longevity;Endometriosis;
BRCA	cis	rs9986765	0.881	rs73452602	chr7:142828331	A/T	cg21852589	chr7:142981689	TMEM139	0.56	9.65	0.36	1.12e-20	Cancer;Dermatomyositis;
BRCA	cis	rs7264396	0.563	rs6060558	chr20:34271092	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.81	-0.39	3.84e-25	Total cholesterol levels;
BRCA	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg26384229	chr12:38710491	ALG10B	-0.63	-16.51	-0.55	2.96e-51	Heart rate;
BRCA	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-7.81	-0.3	2.39e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9837602	1.000	rs2291494	chr3:99781805	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.21	0.41	9.77e-27	Breast cancer;
BRCA	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.14	0.34	7.92e-19	Platelet count;
BRCA	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg00105475	chr2:10696890	NA	0.44	10.41	0.38	1.56e-23	Prostate cancer;
BRCA	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg21366198	chr4:185655624	MLF1IP	0.38	9.38	0.35	1.1e-19	Kawasaki disease;
BRCA	cis	rs6745190	0.575	rs62178846	chr2:181973399	G/A	cg00481216	chr2:181971175	NA	0.4	9.41	0.35	8.62e-20	White blood cell count;
BRCA	cis	rs752010	0.875	rs11210502	chr1:42093712	A/C	cg06885757	chr1:42089581	HIVEP3	0.3	10.65	0.39	1.77e-24	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	11.2	0.4	1.07e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1595825	0.891	rs75373125	chr2:198657044	G/A	cg19156104	chr2:198669113	PLCL1	-0.49	-8.43	-0.32	2.34e-16	Ulcerative colitis;
BRCA	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.42	9.37	0.35	1.2e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg03060546	chr3:49711283	APEH	-0.49	-9.87	-0.36	1.79e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg11663144	chr21:46675770	NA	-0.64	-15.28	-0.52	3.72e-45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg09307838	chr4:120376055	NA	0.69	14.08	0.49	2.13e-39	Corneal astigmatism;
BRCA	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	11.34	0.41	2.83e-27	Personality dimensions;
BRCA	cis	rs10267417	0.535	rs6956976	chr7:19869168	G/A	cg05791153	chr7:19748676	TWISTNB	0.5	9.54	0.35	3.01e-20	Night sleep phenotypes;
BRCA	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg12310025	chr6:25882481	NA	0.4	9.17	0.34	6.68e-19	Blood metabolite levels;
BRCA	cis	rs6963495	0.818	rs6943132	chr7:105166776	C/T	cg19920283	chr7:105172520	RINT1	0.59	8.45	0.32	2.02e-16	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.38	-0.31	3.45e-16	Bipolar disorder;
BRCA	cis	rs4074536	0.622	rs10802001	chr1:116315610	A/T	cg21648376	chr1:116311395	CASQ2	-0.54	-8.98	-0.33	3.02e-18	QRS duration;
BRCA	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02176678	chr2:219576539	TTLL4	0.46	11.93	0.43	8.95e-30	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg21138405	chr5:131827807	IRF1	0.4	13.0	0.46	1.85e-34	Asthma (sex interaction);
BRCA	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	10.1	0.37	2.44e-22	Retinal vascular caliber;
BRCA	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14442939	chr10:27389572	ANKRD26	0.72	14.17	0.49	8.17e-40	Breast cancer;
BRCA	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	12.98	0.46	2.2e-34	Menarche (age at onset);
BRCA	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-13.7	-0.48	1.19e-37	Migraine;Coronary artery disease;
BRCA	cis	rs3925075	0.584	rs12600286	chr16:31360679	G/C	cg02846316	chr16:31340340	ITGAM	0.5	11.87	0.42	1.72e-29	IgA nephropathy;
BRCA	cis	rs4664304	0.658	rs2667012	chr2:160867553	G/T	cg01092293	chr2:160761427	LY75	-0.36	-8.75	-0.33	1.85e-17	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs17401966	1.000	rs12129035	chr1:10291166	G/A	cg15208524	chr1:10270712	KIF1B	0.37	8.24	0.31	9.770000000000001e-16	Hepatocellular carcinoma;
BRCA	cis	rs1538970	0.961	rs7553318	chr1:45843086	A/G	cg05343316	chr1:45956843	TESK2	0.58	11.89	0.43	1.38e-29	Platelet count;
BRCA	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg23708337	chr7:1209742	NA	0.64	9.98	0.37	7.05e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4664304	0.620	rs2357691	chr2:160725139	A/G	cg01092293	chr2:160761427	LY75	-0.35	-8.23	-0.31	1.08e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg00254258	chr1:3105189	PRDM16	-0.48	-11.15	-0.4	1.67e-26	Migraine;
BRCA	cis	rs7246657	0.722	rs1531549	chr19:38088009	T/C	cg18154014	chr19:37997991	ZNF793	0.48	9.15	0.34	7.66e-19	Coronary artery calcification;
BRCA	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21659725	chr3:3221576	CRBN	0.48	12.09	0.43	1.86e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs17095355	0.901	rs10884919	chr10:111757791	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.38	-9.67	-0.36	9.59e-21	Biliary atresia;
BRCA	cis	rs11249608	0.789	rs7706393	chr5:178437737	G/T	cg21905437	chr5:178450457	ZNF879	-0.44	-9.16	-0.34	6.75e-19	Pubertal anthropometrics;
BRCA	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.61	11.39	0.41	1.65e-27	IgG glycosylation;
BRCA	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg11168104	chr5:1857477	NA	-0.32	-8.45	-0.32	1.93e-16	Cardiovascular disease risk factors;
BRCA	cis	rs977987	0.735	rs166013	chr16:75434146	C/T	cg03315344	chr16:75512273	CHST6	-0.55	-12.68	-0.45	4.85e-33	Dupuytren's disease;
BRCA	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg15017067	chr4:17643749	FAM184B	0.28	8.6	0.32	6.13e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg11941060	chr3:133502564	NA	-0.41	-9.02	-0.34	2.17e-18	Iron status biomarkers;
BRCA	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg10560079	chr2:191398806	TMEM194B	0.71	12.52	0.44	2.48e-32	Diastolic blood pressure;
BRCA	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg19773385	chr1:10388646	KIF1B	-0.36	-7.97	-0.3	7.53e-15	Hepatocellular carcinoma;
BRCA	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg00071950	chr4:10020882	SLC2A9	0.5	11.65	0.42	1.43e-28	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.62	12.83	0.45	1.14e-33	Monocyte percentage of white cells;
BRCA	cis	rs12618769	0.597	rs17502889	chr2:99031745	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.17	0.31	1.68e-15	Bipolar disorder;
BRCA	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg22467129	chr15:76604101	ETFA	-0.5	-10.82	-0.39	3.63e-25	Blood metabolite levels;
BRCA	cis	rs9811920	0.535	rs1610509	chr3:99474327	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.42	9.9	0.36	1.32e-21	Axial length;
BRCA	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	12.53	0.44	2.42e-32	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs507080	0.922	rs546890	chr11:118557198	T/C	cg09144398	chr11:118550485	TREH	-0.37	-8.96	-0.33	3.5e-18	Serum metabolite levels;
BRCA	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-9.35	-0.35	1.45e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	16.3	0.54	3.31e-50	Smoking behavior;
BRCA	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg22920501	chr2:26401640	FAM59B	-0.95	-16.82	-0.55	7.55e-53	Gut microbiome composition (summer);
BRCA	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg16479474	chr6:28041457	NA	0.43	7.93	0.3	9.63e-15	Parkinson's disease;
BRCA	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg09060608	chr5:178986726	RUFY1	-0.58	-14.89	-0.51	2.94e-43	Lung cancer;
BRCA	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg20607287	chr7:12443886	VWDE	-0.5	-8.6	-0.32	6.03e-17	Coronary artery disease;
BRCA	cis	rs727479	0.502	rs7167936	chr15:51499545	A/G	cg19946085	chr15:51559439	CYP19A1	-0.3	-8.26	-0.31	8.13e-16	Estradiol levels;
BRCA	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg19773385	chr1:10388646	KIF1B	-0.38	-8.27	-0.31	7.87e-16	Hepatocellular carcinoma;
BRCA	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-7.95	-0.3	8.57e-15	Ulcerative colitis;
BRCA	cis	rs12472274	0.646	rs10929269	chr2:239097423	A/G	cg17459225	chr2:239074497	NA	0.59	10.52	0.38	5.65e-24	Phospholipid levels (plasma);
BRCA	cis	rs4074536	0.622	rs3827736	chr1:116313263	C/G	cg21648376	chr1:116311395	CASQ2	-0.52	-8.67	-0.32	3.55e-17	QRS duration;
BRCA	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg08508325	chr11:3079039	CARS	-0.41	-14.23	-0.49	4.11e-40	Longevity;
BRCA	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg10523679	chr1:76189770	ACADM	0.69	11.95	0.43	7.32e-30	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg23933602	chr10:16859644	RSU1	0.94	28.08	0.74	1.27e-113	Platelet distribution width;
BRCA	cis	rs7246657	0.524	rs10411251	chr19:37428755	C/T	cg18154014	chr19:37997991	ZNF793	0.49	8.75	0.33	1.88e-17	Coronary artery calcification;
BRCA	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg13010199	chr12:38710504	ALG10B	0.5	9.86	0.36	1.88e-21	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg22920501	chr2:26401640	FAM59B	0.9	16.44	0.55	6.44e-51	Gut microbiome composition (summer);
BRCA	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg19628046	chr18:33552617	C18orf21	-0.55	-11.36	-0.41	2.27e-27	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs12612619	0.732	rs7560595	chr2:27229372	C/G	cg00617064	chr2:27272375	NA	-0.33	-8.71	-0.33	2.66e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.42	8.91	0.33	5.19e-18	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-11.36	-0.41	2.25e-27	Gut microbiome composition (summer);
BRCA	cis	rs243505	0.965	rs243503	chr7:148436106	G/C	cg09806900	chr7:148480153	CUL1	-0.43	-8.69	-0.33	3.05e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs812925	0.537	rs2463097	chr2:61614301	G/C	cg15711740	chr2:61764176	XPO1	0.32	8.02	0.3	4.89e-15	Immature fraction of reticulocytes;
BRCA	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg18154014	chr19:37997991	ZNF793	0.54	10.44	0.38	1.11e-23	Coronary artery calcification;
BRCA	cis	rs55788414	0.505	rs7190949	chr16:81189583	C/T	cg06400318	chr16:81190750	PKD1L2	0.56	11.47	0.41	8.22e-28	Left ventricular obstructive tract defect (maternal effect);
BRCA	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.84	0.39	3.02e-25	Bipolar disorder;
BRCA	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18404041	chr3:52824283	ITIH1	-0.48	-14.44	-0.5	4.03e-41	Bipolar disorder;
BRCA	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg14004847	chr7:1930337	MAD1L1	-0.45	-9.13	-0.34	8.86e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs829883	0.714	rs249847	chr12:98867716	C/T	cg25150519	chr12:98850993	NA	0.68	16.69	0.55	3.52e-52	Colorectal adenoma (advanced);
BRCA	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg09469691	chr10:81107165	PPIF	0.53	11.06	0.4	3.99e-26	Height;
BRCA	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg11833968	chr6:79620685	NA	-0.42	-9.28	-0.34	2.68e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs8032158	1.000	rs66462353	chr15:56186767	T/C	cg02198044	chr15:56286336	NEDD4	-0.38	-9.26	-0.34	3.1e-19	Keloid;
BRCA	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg03146154	chr1:46216737	IPP	0.54	12.14	0.43	1.17e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs919433	0.680	rs6710530	chr2:198277551	G/A	cg00792783	chr2:198669748	PLCL1	0.38	8.45	0.32	1.91e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg03934865	chr2:198174659	NA	-0.39	-8.29	-0.31	6.66e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6745190	0.575	rs11678264	chr2:181976494	T/C	cg00481216	chr2:181971175	NA	0.4	9.45	0.35	6.15e-20	White blood cell count;
BRCA	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs16976116	0.901	rs1061875	chr15:55496278	C/T	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg00686598	chr14:53173677	PSMC6	1.15	15.36	0.52	1.45e-45	Alzheimer's disease (late onset);
BRCA	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.87e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.37	-7.92	-0.3	1.09e-14	Mean corpuscular volume;
BRCA	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.63	0.55	7.2e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6426558	0.537	rs4351610	chr1:227325245	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.47	-9.3	-0.35	2.13e-19	Neutrophil percentage of white cells;
BRCA	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg02951883	chr7:2050386	MAD1L1	-0.5	-12.29	-0.44	2.6e-31	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.88	0.3	1.37e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg16576597	chr16:28551801	NUPR1	0.3	8.26	0.31	8.25e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg23978390	chr7:1156363	C7orf50	0.4	9.13	0.34	8.78e-19	Longevity;Endometriosis;
BRCA	cis	rs8114671	0.967	rs1415773	chr20:33765585	G/A	cg07148914	chr20:33460835	GGT7	0.39	8.28	0.31	7.4e-16	Height;
BRCA	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.83	0.3	1.98e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10754283	0.967	rs7519971	chr1:90108743	G/A	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.31e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.47	-13.19	-0.46	2.58e-35	Lung cancer;
BRCA	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg06640241	chr16:89574553	SPG7	-0.51	-11.13	-0.4	2.04e-26	Multiple myeloma (IgH translocation);
BRCA	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	7.98	0.3	6.6e-15	Tonsillectomy;
BRCA	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg00383909	chr3:49044727	WDR6	0.98	15.72	0.53	2.59e-47	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg21479132	chr6:26055353	NA	0.55	7.9	0.3	1.19e-14	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg26384229	chr12:38710491	ALG10B	0.51	11.26	0.41	5.83e-27	Morning vs. evening chronotype;
BRCA	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	12.02	0.43	3.77e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7903847	0.642	rs11189183	chr10:99144321	A/G	cg20016023	chr10:99160130	RRP12	-0.27	-8.6	-0.32	6.17e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg18357645	chr12:58087776	OS9	0.42	11.95	0.43	7.61e-30	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg04989706	chr14:50066350	PPIL5	-0.47	-9.03	-0.34	2.02e-18	Carotid intima media thickness;
BRCA	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg04727924	chr7:799746	HEATR2	-0.55	-10.8	-0.39	4.25e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11890956	chr21:40555474	PSMG1	1.03	29.72	0.76	1.41e-122	Cognitive function;
BRCA	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg04362960	chr10:104952993	NT5C2	0.45	10.09	0.37	2.55e-22	Arsenic metabolism;
BRCA	trans	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg06521331	chr12:34319734	NA	-0.47	-8.77	-0.33	1.59e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs654351	0.572	rs813274	chr6:10387731	C/T	cg04978078	chr6:10383147	NA	-0.44	-8.58	-0.32	7.38e-17	Squamous cell lung carcinoma;
BRCA	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg12935359	chr14:103987150	CKB	-0.59	-14.12	-0.49	1.39e-39	Body mass index;
BRCA	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg24675658	chr1:53192096	ZYG11B	0.68	14.64	0.5	4.53e-42	Monocyte count;
BRCA	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.76	0.62	3.43e-68	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg21782813	chr7:2030301	MAD1L1	0.36	10.26	0.38	5.73e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.67	-13.54	-0.47	6.81e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.61	0.32	5.79e-17	Personality dimensions;
BRCA	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10150615	chr22:24372951	LOC391322	0.43	9.47	0.35	5.46e-20	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg04166393	chr7:2884313	GNA12	-0.41	-9.04	-0.34	1.79e-18	Plateletcrit;
BRCA	cis	rs13394619	0.875	rs7576826	chr2:11723021	C/T	cg07314298	chr2:11723111	GREB1	-0.56	-12.21	-0.43	5.69e-31	Endometriosis;
BRCA	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg18225595	chr11:63971243	STIP1	0.58	13.78	0.48	4.96e-38	Platelet count;
BRCA	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg23711669	chr6:146136114	FBXO30	-0.68	-15.81	-0.53	8.7e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6137287	0.668	rs6047258	chr20:21098277	A/C	cg04219410	chr20:21106687	PLK1S1	0.35	8.19	0.31	1.41e-15	Height;
BRCA	trans	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg01620082	chr3:125678407	NA	-0.56	-8.06	-0.3	3.9e-15	Depression;
BRCA	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg27170947	chr2:26402098	FAM59B	0.92	16.84	0.55	6.2e-53	Gut microbiome composition (summer);
BRCA	cis	rs877282	0.898	rs71489279	chr10:760510	T/C	cg17470449	chr10:769945	NA	0.47	8.07	0.3	3.41e-15	Uric acid levels;
BRCA	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg08470875	chr2:26401718	FAM59B	0.72	10.14	0.37	1.67e-22	Gut microbiome composition (summer);
BRCA	cis	rs929596	0.583	rs77070100	chr2:234587847	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.35	-8.94	-0.33	4.02e-18	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.11	0.34	1.07e-18	Tonsillectomy;
BRCA	cis	rs10789491	1.000	rs7547522	chr1:47179918	C/G	cg15501359	chr1:47185051	KIAA0494	0.65	18.17	0.58	8.75e-60	Response to hepatitis C treatment;
BRCA	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg14863265	chr7:2801509	GNA12	-0.37	-8.43	-0.32	2.3e-16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
BRCA	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg04450456	chr4:17643702	FAM184B	0.38	10.19	0.37	1.11e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7246657	0.722	rs1564206	chr19:38040076	C/T	cg18154014	chr19:37997991	ZNF793	0.48	9.11	0.34	1.03e-18	Coronary artery calcification;
BRCA	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	8.49	0.32	1.4e-16	Electroencephalogram traits;
BRCA	cis	rs57590327	0.504	rs13065281	chr3:81693550	G/A	cg07356753	chr3:81810745	GBE1	-0.43	-9.83	-0.36	2.4e-21	Extraversion;
BRCA	cis	rs868036	1.000	rs6494696	chr15:68103206	C/G	cg05925327	chr15:68127851	NA	0.31	7.84	0.3	1.92e-14	Restless legs syndrome;
BRCA	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg20703242	chr1:230279135	GALNT2	0.46	10.24	0.38	6.78e-23	Coronary artery disease;
BRCA	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	9.1e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6450176	1.000	rs12654393	chr5:53302620	A/C	ch.5.1024479R	chr5:53302184	ARL15	0.65	15.95	0.53	1.95e-48	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05901451	chr6:126070800	HEY2	-0.56	-14.96	-0.51	1.32e-43	Brugada syndrome;
BRCA	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg03146154	chr1:46216737	IPP	0.45	10.11	0.37	2.08e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg11812906	chr14:75593930	NEK9	-0.62	-14.16	-0.49	8.75e-40	Height;
BRCA	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg18811423	chr2:55921094	PNPT1	-0.6	-16.91	-0.56	2.63e-53	Metabolic syndrome;
BRCA	cis	rs7617773	0.817	rs34225441	chr3:48308891	T/A	cg11946769	chr3:48343235	NME6	0.68	13.71	0.48	1.09e-37	Coronary artery disease;
BRCA	cis	rs9420	0.961	rs7936998	chr11:57639017	G/A	cg19752551	chr11:57585705	CTNND1	-0.51	-12.53	-0.44	2.21e-32	Schizophrenia;
BRCA	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg04315214	chr1:2043799	PRKCZ	-0.48	-13.39	-0.47	3.23e-36	Height;
BRCA	cis	rs9487051	0.738	rs171272	chr6:109530094	T/C	cg01475377	chr6:109611718	NA	-0.42	-10.46	-0.38	9.29e-24	Reticulocyte fraction of red cells;
BRCA	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg05868516	chr6:26286170	HIST1H4H	0.51	11.24	0.41	7.44e-27	Educational attainment;
BRCA	cis	rs7809950	1.000	rs2712200	chr7:107142435	G/T	cg23024343	chr7:107201750	COG5	-0.4	-9.12	-0.34	9.56e-19	Coronary artery disease;
BRCA	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg11301795	chr4:187892539	NA	-0.28	-9.46	-0.35	5.83e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg06521331	chr12:34319734	NA	-0.56	-10.12	-0.37	2.03e-22	Morning vs. evening chronotype;
BRCA	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg18154014	chr19:37997991	ZNF793	0.62	11.63	0.42	1.75e-28	Coronary artery calcification;
BRCA	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.57	11.13	0.4	1.98e-26	HDL cholesterol;
BRCA	cis	rs6750047	0.566	rs1157185	chr2:38285735	C/T	cg07380506	chr2:38303506	CYP1B1	0.44	10.68	0.39	1.31e-24	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs6484504	0.576	rs208091	chr11:31190099	G/C	cg06552810	chr11:31128660	NA	-0.39	-8.58	-0.32	7.04e-17	Red blood cell count;
BRCA	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.71	-11.43	-0.41	1.2100000000000001e-27	Red cell distribution width;
BRCA	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09307838	chr4:120376055	NA	0.77	17.17	0.56	1.25e-54	Corneal astigmatism;
BRCA	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg11752832	chr7:134001865	SLC35B4	0.55	14.14	0.49	1.12e-39	Mean platelet volume;
BRCA	cis	rs3784262	0.669	rs4646592	chr15:58302557	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-9.99	-0.37	5.97e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7631605	0.905	rs9876116	chr3:37083740	A/G	cg15934958	chr3:37212084	LRRFIP2	0.4	9.33	0.35	1.67e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.72	11.84	0.42	2.3e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2637266	0.935	rs2579719	chr10:78400026	A/G	cg18941641	chr10:78392320	NA	0.36	8.27	0.31	7.61e-16	Pulmonary function;
BRCA	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg26384229	chr12:38710491	ALG10B	0.45	10.28	0.38	4.99e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs965469	0.895	rs6051840	chr20:3391483	C/T	cg25506879	chr20:3388711	C20orf194	0.57	11.5	0.41	6.19e-28	IFN-related cytopenia;
BRCA	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-13.56	-0.47	5.25e-37	Gut microbiome composition (summer);
BRCA	cis	rs4363385	0.818	rs436621	chr1:153005492	A/G	cg21543102	chr1:152974771	SPRR3	-0.28	-7.81	-0.3	2.39e-14	Inflammatory skin disease;
BRCA	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg08470875	chr2:26401718	FAM59B	0.72	11.26	0.41	6.14e-27	Gut microbiome composition (summer);
BRCA	cis	rs4363385	0.818	rs1334850	chr1:153004519	G/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.59	-0.32	6.5e-17	Inflammatory skin disease;
BRCA	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg16339924	chr4:17578868	LAP3	0.6	14.63	0.5	5.01e-42	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.79	-0.36	3.41e-21	Schizophrenia;
BRCA	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg01475735	chr3:40494733	NA	0.47	9.88	0.36	1.65e-21	Renal cell carcinoma;
BRCA	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg11608241	chr8:8085544	FLJ10661	0.28	7.83	0.3	2.08e-14	Neuroticism;
BRCA	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	13.72	0.48	1.02e-37	Height;
BRCA	trans	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg07211511	chr3:129823064	LOC729375	-0.62	-11.46	-0.41	8.62e-28	Blood pressure (smoking interaction);
BRCA	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.51	-10.61	-0.39	2.38e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1776421	0.760	rs61768413	chr1:53904746	C/T	cg10892335	chr1:53966318	NA	0.49	7.92	0.3	1.04e-14	PR interval in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg23173402	chr1:227635558	NA	0.5	9.15	0.34	7.32e-19	Major depressive disorder;
BRCA	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12516959	chr21:47718080	NA	-0.35	-8.59	-0.32	6.62e-17	Testicular germ cell tumor;
BRCA	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg03709012	chr19:19516395	GATAD2A	1.07	20.84	0.64	5.14e-74	Nonalcoholic fatty liver disease;
BRCA	cis	rs7560272	0.501	rs12713793	chr2:73956114	T/C	cg20560298	chr2:73613845	ALMS1	0.33	8.6	0.32	6.02e-17	Schizophrenia;
BRCA	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg25237894	chr2:233734115	C2orf82	0.38	10.95	0.4	1.06e-25	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24308560	chr3:49941425	MST1R	-0.4	-8.52	-0.32	1.17e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.43	-0.41	1.22e-27	Schizophrenia;
BRCA	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.92	0.37	1.11e-21	Bipolar disorder;
BRCA	cis	rs55882075	0.936	rs34646062	chr5:179186318	A/G	cg14593053	chr5:179126677	CANX	-0.4	-10.25	-0.38	6.02e-23	Monocyte percentage of white cells;
BRCA	cis	rs796364	0.616	rs2140486	chr2:200690102	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	8.34	0.31	4.49e-16	Schizophrenia;
BRCA	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg18016565	chr1:150552671	MCL1	-0.47	-10.65	-0.39	1.79e-24	Tonsillectomy;
BRCA	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg26597838	chr10:835615	NA	0.98	17.29	0.56	3.06e-55	Eosinophil percentage of granulocytes;
BRCA	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg13319975	chr6:146136371	FBXO30	0.39	9.01	0.34	2.4e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg13010199	chr12:38710504	ALG10B	0.54	11.78	0.42	3.98e-29	Heart rate;
BRCA	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg06636001	chr8:8085503	FLJ10661	0.49	10.6	0.39	2.82e-24	Retinal vascular caliber;
BRCA	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg01475377	chr6:109611718	NA	-0.51	-12.85	-0.45	8.96e-34	Reticulocyte fraction of red cells;
BRCA	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg01181863	chr3:195395398	SDHAP2	-0.47	-8.23	-0.31	1.09e-15	Pancreatic cancer;
BRCA	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.62	10.2	0.37	9.79e-23	Renal function-related traits (BUN);
BRCA	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1011018	0.628	rs10254826	chr7:139433480	T/C	cg03224163	chr7:139420300	HIPK2	-0.54	-9.14	-0.34	8.03e-19	Systolic blood pressure;
BRCA	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg20476274	chr7:133979776	SLC35B4	0.7	21.43	0.65	3.5e-77	Mean platelet volume;
BRCA	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.48	0.35	4.85e-20	Morning vs. evening chronotype;
BRCA	cis	rs1451375	0.583	rs11575320	chr7:50605298	A/G	cg18232548	chr7:50535776	DDC	-0.43	-8.99	-0.33	2.88e-18	Malaria;
BRCA	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg13010199	chr12:38710504	ALG10B	0.44	8.48	0.32	1.53e-16	Heart rate;
BRCA	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg11764359	chr7:65958608	NA	-0.62	-13.32	-0.47	7.04e-36	Aortic root size;
BRCA	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg14582100	chr15:45693742	SPATA5L1	0.37	11.92	0.43	1e-29	Homoarginine levels;
BRCA	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.22	-0.31	1.14e-15	Height;
BRCA	trans	rs11976180	1.000	rs1540894	chr7:143767676	T/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.47	-8.65	-0.32	4.07e-17	Obesity-related traits;
BRCA	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg17063962	chr7:91808500	NA	0.51	11.28	0.41	5.02e-27	Breast cancer;
BRCA	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs7809950	0.861	rs10264412	chr7:107183877	G/A	cg23024343	chr7:107201750	COG5	-0.49	-10.03	-0.37	4.26e-22	Coronary artery disease;
BRCA	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	13.19	0.46	2.5e-35	Schizophrenia;
BRCA	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg17971929	chr21:40555470	PSMG1	-0.49	-10.72	-0.39	8.75e-25	Menarche (age at onset);
BRCA	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg13393036	chr8:95962371	TP53INP1	0.34	8.25	0.31	8.77e-16	Type 2 diabetes;
BRCA	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg08917208	chr2:24149416	ATAD2B	0.94	14.13	0.49	1.25e-39	Lymphocyte counts;
BRCA	cis	rs10746514	0.931	rs11582890	chr1:232251218	C/T	cg09506761	chr1:232265262	NA	0.4	8.07	0.3	3.5e-15	Response to statin therapy;
BRCA	cis	rs9682041	0.932	rs1525362	chr3:170070702	C/T	cg11886554	chr3:170076028	SKIL	0.69	12.88	0.45	6.52e-34	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg19077165	chr18:44547161	KATNAL2	0.55	12.48	0.44	3.7e-32	Personality dimensions;
BRCA	cis	rs10492096	0.947	rs10849483	chr12:6635374	G/A	cg13857086	chr12:6580257	VAMP1	0.43	8.26	0.31	8.61e-16	Hip geometry;
BRCA	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-10.83	-0.39	3.42e-25	Uric acid levels;
BRCA	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg12310025	chr6:25882481	NA	-0.38	-8.79	-0.33	1.34e-17	Height;
BRCA	cis	rs9463078	0.665	rs227849	chr6:44698708	C/T	cg25276700	chr6:44698697	NA	0.4	9.47	0.35	5.48e-20	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.32	-10.32	-0.38	3.51e-23	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg03342759	chr3:160939853	NMD3	-0.79	-18.75	-0.6	7.85e-63	Parkinson's disease;
BRCA	cis	rs713587	0.806	rs6737082	chr2:25138040	A/C	cg04586622	chr2:25135609	ADCY3	0.39	9.63	0.36	1.35e-20	Body mass index in non-asthmatics;
BRCA	cis	rs3925075	0.833	rs11641202	chr16:31330161	A/G	cg02846316	chr16:31340340	ITGAM	0.51	12.34	0.44	1.52e-31	IgA nephropathy;
BRCA	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	11.32	0.41	3.45e-27	Monocyte percentage of white cells;
BRCA	cis	rs17799476	0.938	rs72808770	chr2:46361322	G/A	cg12428440	chr2:46370979	PRKCE	0.5	8.54	0.32	1e-16	Hemoglobin concentration;Hematocrit;
BRCA	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg07211511	chr3:129823064	LOC729375	-1.06	-21.77	-0.65	4.72e-79	Blood pressure (smoking interaction);
BRCA	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg14675211	chr2:100938903	LONRF2	0.52	11.96	0.43	7.15e-30	Intelligence (multi-trait analysis);
BRCA	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg15934090	chr1:100435551	SLC35A3	0.35	8.1	0.31	2.75e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26314531	chr2:26401878	FAM59B	0.92	14.25	0.49	3.25e-40	Gut microbiome composition (summer);
BRCA	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg15997130	chr1:24165203	NA	-0.45	-11.65	-0.42	1.36e-28	Immature fraction of reticulocytes;
BRCA	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg26195577	chr20:24973756	C20orf3	1.03	28.96	0.75	1.94e-118	Blood protein levels;
BRCA	cis	rs1499972	0.941	rs62264816	chr3:117666232	C/G	cg07612923	chr3:117604196	NA	0.6	8.2	0.31	1.35e-15	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.19e-40	Motion sickness;
BRCA	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg20848291	chr7:100343083	ZAN	0.37	8.33	0.31	4.83e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-9.95	-0.37	8.92e-22	Joint mobility (Beighton score);
BRCA	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.2	-0.34	4.95e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs2463822	1.000	rs11231050	chr11:62131660	C/G	cg06239285	chr11:62104954	ASRGL1	-0.62	-9.32	-0.35	1.82e-19	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.19e-40	Motion sickness;
BRCA	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg26384229	chr12:38710491	ALG10B	0.75	17.2	0.56	8.9e-55	Bladder cancer;
BRCA	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg03709012	chr19:19516395	GATAD2A	0.69	14.66	0.5	3.55e-42	Tonsillectomy;
BRCA	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg24633833	chr3:10029261	TMEM111	0.41	7.83	0.3	2.03e-14	Alzheimer's disease;
BRCA	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg00012203	chr2:219082015	ARPC2	0.6	12.54	0.44	2.11e-32	Colorectal cancer;
BRCA	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg09307838	chr4:120376055	NA	0.68	13.99	0.48	5.74e-39	Corneal astigmatism;
BRCA	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg05072774	chr3:49840536	C3orf54	0.36	7.85	0.3	1.79e-14	Resting heart rate;
BRCA	cis	rs17490626	0.568	rs12413529	chr10:71211644	G/T	cg12610070	chr10:71211762	TSPAN15	-0.33	-11.77	-0.42	4.44e-29	Thrombosis;
BRCA	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08109568	chr15:31115862	NA	0.52	13.36	0.47	4.58e-36	Huntington's disease progression;
BRCA	cis	rs490234	0.586	rs3122934	chr9:128154100	C/G	cg14078157	chr9:128172775	NA	0.35	7.86	0.3	1.7e-14	Mean arterial pressure;
BRCA	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg00814883	chr7:100076585	TSC22D4	-0.47	-10.51	-0.38	6e-24	Platelet count;
BRCA	cis	rs7973719	0.833	rs7970916	chr12:7357746	T/C	cg07052231	chr12:7363540	PEX5	0.36	8.17	0.31	1.66e-15	IgG glycosylation;
BRCA	cis	rs2354432	0.607	rs894471	chr1:146687913	A/G	cg25205988	chr1:146714368	CHD1L	-0.78	-10.16	-0.37	1.39e-22	Mitochondrial DNA levels;
BRCA	cis	rs2882667	0.690	rs9327829	chr5:138261671	A/G	cg04439458	chr5:138467593	SIL1	0.33	8.24	0.31	9.82e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs11608355	0.515	rs6606727	chr12:109941450	T/A	cg05360138	chr12:110035743	NA	0.74	13.68	0.48	1.56e-37	Neuroticism;
BRCA	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg06784218	chr1:46089804	CCDC17	0.51	12.17	0.43	8.34e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg22963979	chr7:1858916	MAD1L1	-0.47	-9.4	-0.35	9.23e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg24562669	chr7:97807699	LMTK2	0.47	12.39	0.44	9.53e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12986413	0.651	rs2238609	chr19:2146629	C/T	cg09261902	chr19:2140048	AP3D1	0.43	11.07	0.4	3.52e-26	Height;
BRCA	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg07741184	chr6:167504864	NA	0.33	9.87	0.36	1.8e-21	Primary biliary cholangitis;
BRCA	cis	rs7727544	0.526	rs4705908	chr5:131347520	G/A	cg14196790	chr5:131705035	SLC22A5	0.33	8.3	0.31	6.4e-16	Blood metabolite levels;
BRCA	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.66	13.42	0.47	2.36e-36	Lymphocyte counts;
BRCA	cis	rs10463316	0.817	rs13359941	chr5:150802118	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.62	-0.32	5.19e-17	Metabolite levels (Pyroglutamine);
BRCA	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24549020	chr5:56110836	MAP3K1	0.66	13.27	0.46	1.13e-35	Initial pursuit acceleration;
BRCA	cis	rs870825	0.616	rs1401361	chr4:185643742	G/C	cg04058563	chr4:185651563	MLF1IP	0.76	17.01	0.56	8.69e-54	Blood protein levels;
BRCA	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg06484146	chr7:12443880	VWDE	-0.63	-8.62	-0.32	5.18e-17	Coronary artery disease;
BRCA	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg13010199	chr12:38710504	ALG10B	0.43	9.12	0.34	9.85e-19	Morning vs. evening chronotype;
BRCA	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg12641515	chr19:46296257	DMWD	-0.53	-11.54	-0.42	3.92e-28	Coronary artery disease;
BRCA	trans	rs9951602	0.512	rs9955812	chr18:76650954	T/A	cg02800362	chr5:177631904	HNRNPAB	0.77	18.01	0.58	5.8e-59	Obesity-related traits;
BRCA	cis	rs965469	1.000	rs6037579	chr20:3347980	G/A	cg25506879	chr20:3388711	C20orf194	-0.55	-10.57	-0.39	3.46e-24	IFN-related cytopenia;
BRCA	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg26597838	chr10:835615	NA	1.07	17.92	0.58	1.78e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg22907277	chr7:1156413	C7orf50	0.46	10.47	0.38	8.61e-24	Longevity;Endometriosis;
BRCA	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg12311346	chr5:56204834	C5orf35	-0.78	-14.91	-0.51	2.36e-43	Initial pursuit acceleration;
BRCA	cis	rs13315871	0.929	rs9871725	chr3:58292525	T/G	cg20936604	chr3:58311152	NA	-0.67	-8.64	-0.32	4.35e-17	Cholesterol, total;
BRCA	trans	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg23762105	chr12:34175262	ALG10	-0.36	-9.08	-0.34	1.36e-18	Morning vs. evening chronotype;
BRCA	cis	rs9811920	0.690	rs7623587	chr3:99906751	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.38	8.88	0.33	6.54e-18	Axial length;
BRCA	trans	rs8073060	0.586	rs7213804	chr17:34010931	T/G	cg19694781	chr19:47549865	TMEM160	-1.06	-21.56	-0.65	7.18e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs965469	1.000	rs2236106	chr20:3278410	A/C	cg25506879	chr20:3388711	C20orf194	-0.51	-10.24	-0.38	6.8e-23	IFN-related cytopenia;
BRCA	trans	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg25042112	chr7:64838748	ZNF92	0.45	8.36	0.31	3.91e-16	Pain;
BRCA	cis	rs1971762	0.583	rs10876485	chr12:54087648	C/T	cg23533419	chr12:54090519	NA	0.31	7.86	0.3	1.63e-14	Height;
BRCA	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg00325661	chr8:49890786	NA	0.34	8.96	0.33	3.58e-18	Sudden cardiac arrest;
BRCA	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23583168	chr7:148888333	NA	-0.89	-23.38	-0.68	7.44e-88	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg19862616	chr7:65841803	NCRNA00174	0.85	27.57	0.74	7.42e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-11.19	-0.4	1.19e-26	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg05340658	chr4:99064831	C4orf37	0.7	17.28	0.56	3.4e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg26893861	chr17:41843967	DUSP3	-0.63	-11.9	-0.43	1.28e-29	Triglycerides;
BRCA	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg20933634	chr6:27740509	NA	0.48	9.61	0.36	1.64e-20	Parkinson's disease;
BRCA	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg02353165	chr6:42928485	GNMT	-0.72	-13.29	-0.47	9.38e-36	Blood protein levels;
BRCA	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg24747557	chr10:131355152	MGMT	-0.36	-8.81	-0.33	1.19e-17	Response to temozolomide;
BRCA	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg25358565	chr5:93447407	FAM172A	1.19	18.71	0.59	1.27e-62	Diabetic retinopathy;
BRCA	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-11.35	-0.41	2.48e-27	Chronic sinus infection;
BRCA	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg23719950	chr11:63933701	MACROD1	-0.59	-9.71	-0.36	6.84e-21	Mean platelet volume;
BRCA	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24549020	chr5:56110836	MAP3K1	0.59	12.16	0.43	9.22e-31	Initial pursuit acceleration;
BRCA	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg18252515	chr7:66147081	NA	-1.04	-15.46	-0.52	5.05e-46	Diabetic kidney disease;
BRCA	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08048268	chr3:133502702	NA	-0.42	-10.77	-0.39	5.91e-25	Iron status biomarkers;
BRCA	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg03433033	chr1:76189801	ACADM	-0.47	-9.86	-0.36	1.94e-21	Daytime sleep phenotypes;
BRCA	cis	rs3917254	0.570	rs2310187	chr2:102750428	G/T	cg22835712	chr2:102737379	NA	-0.58	-10.62	-0.39	2.31e-24	Blood protein levels;
BRCA	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg12310025	chr6:25882481	NA	0.41	9.36	0.35	1.34e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg03213289	chr20:61660250	NA	0.61	16.28	0.54	4.14e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg23711669	chr6:146136114	FBXO30	0.71	17.21	0.56	7.67e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.46	-10.99	-0.4	7.55e-26	IgG glycosylation;
BRCA	cis	rs13102973	0.965	rs7656209	chr4:135875550	G/A	cg14419869	chr4:135874104	NA	0.51	10.88	0.4	2.04e-25	Subjective well-being;
BRCA	trans	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-10.09	-0.37	2.67e-22	Mood instability;
BRCA	cis	rs757278	0.608	rs6977789	chr7:117342771	A/G	cg10524701	chr7:117356490	CTTNBP2	0.42	7.81	0.3	2.32e-14	Response to methotrexate in juvenile idiopathic arthritis;
BRCA	trans	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg02030672	chr11:45687055	CHST1	-0.38	-7.98	-0.3	6.81e-15	Obesity-related traits;
BRCA	trans	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg25042112	chr7:64838748	ZNF92	-0.45	-8.34	-0.31	4.45e-16	Pain;
BRCA	cis	rs713587	0.520	rs483428	chr2:25305136	A/G	cg01884057	chr2:25150051	NA	0.32	8.18	0.31	1.54e-15	Body mass index in non-asthmatics;
BRCA	cis	rs12579753	0.917	rs11115058	chr12:82263427	T/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-8.0	-0.3	5.67e-15	Resting heart rate;
BRCA	trans	rs7200543	1.000	rs16966947	chr16:15141045	T/C	cg24683922	chr1:11983373	KIAA2013	-0.35	-7.89	-0.3	1.29e-14	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg23033748	chr14:75592666	NEK9	-0.41	-9.99	-0.37	6.3e-22	Height;
BRCA	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg02297831	chr4:17616191	MED28	-0.35	-7.9	-0.3	1.26e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7707921	0.881	rs112413913	chr5:81359709	A/G	cg15871215	chr5:81402204	ATG10	-0.39	-8.2	-0.31	1.33e-15	Breast cancer;
BRCA	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.19	-0.34	5.31e-19	Menopause (age at onset);
BRCA	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg17211192	chr8:82754475	SNX16	0.6	11.81	0.42	2.98e-29	Diastolic blood pressure;
BRCA	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg11161846	chr1:160990452	F11R	-0.54	-13.22	-0.46	1.86e-35	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	14.5	0.5	2.19e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg00666640	chr1:248458726	OR2T12	0.33	9.04	0.34	1.9e-18	Common traits (Other);
BRCA	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg23625390	chr15:77176239	SCAPER	-0.5	-11.84	-0.42	2.14e-29	Blood metabolite levels;
BRCA	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg16325326	chr1:53192061	ZYG11B	0.86	25.41	0.71	5.81e-99	Monocyte count;
BRCA	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg18225595	chr11:63971243	STIP1	0.52	9.85	0.36	2.05e-21	Mean platelet volume;
BRCA	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.82	0.33	1.1e-17	Motion sickness;
BRCA	trans	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg06766960	chr11:133703094	NA	-0.62	-13.06	-0.46	1.02e-34	Childhood ear infection;
BRCA	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg03146154	chr1:46216737	IPP	0.46	10.2	0.37	9.95e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11191205	0.865	rs11191161	chr10:103726528	C/T	cg15320455	chr10:103880129	LDB1	-0.57	-9.03	-0.34	2.02e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7264396	0.563	rs6060560	chr20:34278890	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.83	-0.39	3.28e-25	Total cholesterol levels;
BRCA	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg08754654	chr5:154026448	NA	0.4	9.78	0.36	3.76e-21	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg27129171	chr3:47204927	SETD2	0.6	11.15	0.4	1.72e-26	Birth weight;
BRCA	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.97	-0.37	7.54e-22	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg20476274	chr7:133979776	SLC35B4	0.63	17.86	0.58	3.52e-58	Mean platelet volume;
BRCA	cis	rs2742234	0.541	rs1317214	chr10:43733531	C/G	cg15436174	chr10:43711423	RASGEF1A	0.52	10.42	0.38	1.32e-23	Hirschsprung disease;
BRCA	cis	rs701145	0.537	rs1713855	chr3:153847833	T/C	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.22e-14	Coronary artery disease;
BRCA	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg21132104	chr15:45694354	SPATA5L1	0.74	15.79	0.53	1.16e-47	Homoarginine levels;
BRCA	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg00409905	chr10:38381863	ZNF37A	-0.43	-9.04	-0.34	1.91e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg21064579	chr19:49206444	FUT2	0.38	9.42	0.35	8.19e-20	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
BRCA	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg20701182	chr2:24300061	SF3B14	0.56	8.63	0.32	4.99e-17	Lymphocyte counts;
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.4	-7.82	-0.3	2.13e-14	Longevity;Endometriosis;
BRCA	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg03188948	chr7:1209495	NA	0.82	11.39	0.41	1.8e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg07952391	chr2:88470173	THNSL2	-0.52	-10.09	-0.37	2.51e-22	Response to metformin (IC50);
BRCA	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.55	17.85	0.58	3.83e-58	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg25214090	chr10:38739885	LOC399744	-0.46	-9.84	-0.36	2.35e-21	Corneal astigmatism;
BRCA	cis	rs1371614	0.635	rs34803465	chr2:27138285	G/A	cg12368169	chr2:27073192	DPYSL5	-0.31	-9.15	-0.34	7.45e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg07148914	chr20:33460835	GGT7	0.38	8.57	0.32	7.57e-17	Height;
BRCA	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg15145296	chr3:125709740	NA	-0.53	-8.38	-0.31	3.25e-16	Blood pressure (smoking interaction);
BRCA	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.63	18.06	0.58	3.25e-59	Schizophrenia;
BRCA	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg20818283	chr2:191399100	TMEM194B	0.43	9.72	0.36	6.35e-21	Pulse pressure;
BRCA	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg13256891	chr4:100009986	ADH5	0.53	9.77	0.36	4.33e-21	Smoking initiation;
BRCA	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg12756686	chr19:29218302	NA	-0.47	-8.5	-0.32	1.36e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs68170813	0.523	rs7781947	chr7:106902219	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.48	-0.32	1.59e-16	Coronary artery disease;
BRCA	cis	rs870825	0.616	rs2141257	chr4:185609463	C/T	cg04058563	chr4:185651563	MLF1IP	-0.82	-15.53	-0.52	2.11e-46	Blood protein levels;
BRCA	trans	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.75	-0.39	6.9e-25	Retinal vascular caliber;
BRCA	cis	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.69	-0.33	3.09e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs10492096	1.000	rs11064218	chr12:6586261	C/T	cg13857086	chr12:6580257	VAMP1	0.45	8.63	0.32	4.81e-17	Hip geometry;
BRCA	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg11663144	chr21:46675770	NA	-0.6	-13.94	-0.48	9.31e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg08885076	chr2:99613938	TSGA10	0.46	10.93	0.4	1.36e-25	Chronic sinus infection;
BRCA	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg26893861	chr17:41843967	DUSP3	0.88	22.21	0.66	2.09e-81	Triglycerides;
BRCA	cis	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg08601574	chr20:25228251	PYGB	0.34	8.23	0.31	1.02e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-13.35	-0.47	5.07e-36	Chronic sinus infection;
BRCA	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-11.09	-0.4	2.88e-26	Longevity;
BRCA	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg16339924	chr4:17578868	LAP3	0.66	16.95	0.56	1.68e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9394841	0.692	rs9381094	chr6:41800629	T/C	cg08135965	chr6:41755394	TOMM6	0.47	7.82	0.3	2.15e-14	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs6446731	0.517	rs2798221	chr4:3270488	T/C	cg08886695	chr4:3369023	RGS12	0.37	9.68	0.36	9.04e-21	Mean platelet volume;
BRCA	trans	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	26.58	0.72	2.01e-105	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.03	-0.54	7.47e-49	Alzheimer's disease (late onset);
BRCA	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg09436375	chr6:42928200	GNMT	0.31	11.28	0.41	4.86e-27	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.73	-17.26	-0.56	4.2e-55	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs208520	0.837	rs208467	chr6:66914837	T/C	cg07460842	chr6:66804631	NA	-0.89	-15.72	-0.53	2.64e-47	Exhaled nitric oxide output;
BRCA	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg10523679	chr1:76189770	ACADM	0.77	18.74	0.6	8.51e-63	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg10729496	chr3:10149963	C3orf24	0.47	7.84	0.3	1.9e-14	Alzheimer's disease;
BRCA	cis	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg20368463	chr18:77673604	PQLC1	0.46	11.64	0.42	1.63e-28	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
BRCA	cis	rs9814567	0.806	rs9857242	chr3:134316378	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.35	8.2	0.31	1.35e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg23711669	chr6:146136114	FBXO30	0.73	16.71	0.55	2.91e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs208520	0.690	rs851468	chr6:66825875	G/A	cg07460842	chr6:66804631	NA	-1.01	-19.81	-0.62	1.93e-68	Exhaled nitric oxide output;
BRCA	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	7.87	0.3	1.53e-14	Diabetic retinopathy;
BRCA	trans	rs4714291	0.832	rs3008839	chr6:40052660	G/A	cg02267698	chr19:7991119	CTXN1	-0.44	-8.9	-0.33	5.9e-18	Strep throat;
BRCA	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.69	-0.33	2.99e-17	Glomerular filtration rate (creatinine);
BRCA	trans	rs4596713	0.538	rs11145484	chr9:71769857	G/C	cg16512924	chr15:28394682	HERC2	0.44	10.45	0.38	1.04e-23	Headache;
BRCA	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg12927641	chr6:109611667	NA	-0.42	-10.95	-0.4	1.11e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.74	10.14	0.37	1.73e-22	Initial pursuit acceleration;
BRCA	cis	rs965469	0.857	rs6037523	chr20:3249463	A/T	cg25506879	chr20:3388711	C20orf194	-0.44	-8.72	-0.33	2.4e-17	IFN-related cytopenia;
BRCA	cis	rs7737355	0.947	rs251014	chr5:131029463	A/G	cg06307176	chr5:131281290	NA	0.52	10.22	0.37	8.02e-23	Life satisfaction;
BRCA	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.97	-0.33	3.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg07460842	chr6:66804631	NA	0.6	10.2	0.37	1.01e-22	Type 2 diabetes;
BRCA	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg01236616	chr12:121019343	POP5	1.24	27.07	0.73	4.13e-108	Type 1 diabetes nephropathy;
BRCA	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg05025164	chr4:1340916	KIAA1530	0.38	8.18	0.31	1.58e-15	Longevity;
BRCA	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg11062466	chr8:58055876	NA	0.41	7.92	0.3	1.04e-14	Developmental language disorder (linguistic errors);
BRCA	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	10.25	0.38	6.3e-23	Retinal vascular caliber;
BRCA	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg21605333	chr4:119757512	SEC24D	1.23	12.24	0.44	4.48e-31	Cannabis dependence symptom count;
BRCA	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg01884057	chr2:25150051	NA	0.31	8.09	0.3	3.08e-15	Body mass index;
BRCA	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24110177	chr3:50126178	RBM5	-0.52	-15.02	-0.51	6.94e-44	Body mass index;
BRCA	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg07741184	chr6:167504864	NA	0.33	9.9	0.36	1.41e-21	Primary biliary cholangitis;
BRCA	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.72	11.84	0.42	2.3e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	8.5	0.32	1.32e-16	Schizophrenia;
BRCA	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.83e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg26384229	chr12:38710491	ALG10B	-0.74	-16.88	-0.56	3.78e-53	Bladder cancer;
BRCA	cis	rs427394	0.802	rs274720	chr5:6719933	A/G	cg10857441	chr5:6722123	POLS	-0.33	-10.96	-0.4	1.03e-25	Menopause (age at onset);
BRCA	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.98	0.43	5.89e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	19.11	0.6	9.47e-65	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg04025307	chr7:1156635	C7orf50	0.72	18.68	0.59	1.78e-62	Longevity;Endometriosis;
BRCA	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg04117972	chr1:227635322	NA	0.58	9.97	0.37	7.71e-22	Major depressive disorder;
BRCA	cis	rs12200560	0.505	rs984519	chr6:97076223	A/G	cg06623918	chr6:96969491	KIAA0776	-0.51	-12.39	-0.44	9.32e-32	Coronary heart disease;
BRCA	cis	rs4268898	0.795	rs12470303	chr2:24619883	C/T	cg06627628	chr2:24431161	ITSN2	-0.41	-8.56	-0.32	8.32e-17	Asthma;
BRCA	cis	rs7617773	0.780	rs34946886	chr3:48338487	A/G	cg11946769	chr3:48343235	NME6	0.68	14.05	0.49	2.93e-39	Coronary artery disease;
BRCA	cis	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.4	9.03	0.34	2.05e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg13770153	chr20:60521292	NA	0.58	12.47	0.44	4.18e-32	Body mass index;
BRCA	cis	rs9837602	0.935	rs9860290	chr3:99839106	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.56	9.69	0.36	8.35e-21	Breast cancer;
BRCA	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg17143192	chr8:8559678	CLDN23	0.56	10.87	0.4	2.2e-25	Obesity-related traits;
BRCA	trans	rs4714291	0.802	rs911818	chr6:39988816	C/A	cg02267698	chr19:7991119	CTXN1	-0.46	-9.43	-0.35	7.69e-20	Strep throat;
BRCA	cis	rs7927771	0.507	rs10838759	chr11:47785347	T/C	cg20307385	chr11:47447363	PSMC3	0.42	9.54	0.35	2.88e-20	Subjective well-being;
BRCA	cis	rs10193935	0.579	rs62142594	chr2:42524531	G/A	cg27598129	chr2:42591480	NA	-1.07	-11.92	-0.43	1.01e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg00852783	chr1:26633632	UBXN11	-0.47	-8.52	-0.32	1.15e-16	Obesity-related traits;
BRCA	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.21	-0.34	4.59e-19	Menopause (age at onset);
BRCA	trans	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17712092	chr4:129076599	LARP1B	0.54	13.09	0.46	7.47e-35	Eosinophil percentage of white cells;
BRCA	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.45	-11.39	-0.41	1.77e-27	Height;
BRCA	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg01262667	chr19:19385393	TM6SF2	-0.42	-10.95	-0.4	1.04e-25	Tonsillectomy;
BRCA	trans	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg01620082	chr3:125678407	NA	-0.99	-11.42	-0.41	1.23e-27	Depression;
BRCA	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg21518248	chr2:162101506	NA	0.48	9.69	0.36	7.99e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs11997175	0.545	rs7818001	chr8:33807682	G/T	ch.8.33884649F	chr8:33765107	NA	0.36	8.52	0.32	1.15e-16	Body mass index;
BRCA	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg22508957	chr16:3507546	NAT15	-0.58	-8.77	-0.33	1.65e-17	Tuberculosis;
BRCA	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg22875332	chr1:76189707	ACADM	-0.69	-15.05	-0.51	4.97e-44	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.87	0.36	1.72e-21	Lung cancer in ever smokers;
BRCA	cis	rs1420338	0.869	rs1362452	chr7:34170519	G/A	cg01275685	chr7:34179230	BMPER	-0.5	-11.29	-0.41	4.42e-27	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg23711669	chr6:146136114	FBXO30	-0.71	-16.08	-0.54	4.02e-49	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	9.1e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg06623918	chr6:96969491	KIAA0776	0.74	12.19	0.43	6.85e-31	Migraine;Coronary artery disease;
BRCA	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg14019146	chr3:50243930	SLC38A3	0.37	9.1	0.34	1.12e-18	Menarche (age at onset);
BRCA	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	7.93	0.3	9.65e-15	Breast cancer;
BRCA	cis	rs11984145	1.000	rs28680843	chr7:38869571	C/T	cg19327137	chr7:38886074	VPS41	0.49	8.55	0.32	9.39e-17	Cognitive performance;
BRCA	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.38	0.49	7.88e-41	Motion sickness;
BRCA	cis	rs62229266	0.804	rs2835231	chr21:37390598	C/T	cg12218747	chr21:37451666	NA	-0.34	-7.85	-0.3	1.8e-14	Mitral valve prolapse;
BRCA	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg01483505	chr11:975446	AP2A2	0.34	9.28	0.34	2.49e-19	Alzheimer's disease (late onset);
BRCA	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.35	0.35	1.49e-19	Tonsillectomy;
BRCA	trans	rs970548	0.738	rs61854124	chr10:46077158	T/C	cg20477318	chr10:51623047	TIMM23	0.44	7.91	0.3	1.14e-14	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
BRCA	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg04414720	chr1:150670196	GOLPH3L	0.36	8.21	0.31	1.27e-15	Melanoma;
BRCA	cis	rs965469	1.000	rs6051838	chr20:3389012	A/C	cg25506879	chr20:3388711	C20orf194	-0.54	-10.81	-0.39	4.03e-25	IFN-related cytopenia;
BRCA	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg01819863	chr10:32635814	EPC1	1.15	20.1	0.62	5.42e-70	Sexual dysfunction (female);
BRCA	cis	rs6484504	0.625	rs796341	chr11:31414151	G/A	cg06552810	chr11:31128660	NA	0.39	8.52	0.32	1.15e-16	Red blood cell count;
BRCA	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs495337	1.000	rs6067293	chr20:48581741	T/C	cg17835207	chr20:48524531	SPATA2	-0.61	-14.07	-0.49	2.21e-39	Psoriasis;
BRCA	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg25767906	chr1:53392781	SCP2	0.52	11.09	0.4	3.01e-26	Monocyte count;
BRCA	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg12756686	chr19:29218302	NA	0.47	8.32	0.31	5.17e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg23442198	chr4:187126114	CYP4V2	0.61	8.41	0.32	2.69e-16	Blood protein levels;
BRCA	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.64	-15.85	-0.53	5.85e-48	Longevity;Endometriosis;
BRCA	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg05347473	chr6:146136440	FBXO30	0.62	12.07	0.43	2.26e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	9.02e-21	Menopause (age at onset);
BRCA	cis	rs2012796	0.957	rs7151434	chr14:81819468	A/G	cg02996355	chr14:81879375	NA	0.43	8.61	0.32	5.54e-17	Night sleep phenotypes;
BRCA	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.74e-18	Motion sickness;
BRCA	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg26597838	chr10:835615	NA	1.01	15.79	0.53	1.1e-47	Eosinophil percentage of granulocytes;
BRCA	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg17063962	chr7:91808500	NA	0.52	12.33	0.44	1.72e-31	Breast cancer;
BRCA	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg12310025	chr6:25882481	NA	-0.7	-17.53	-0.57	1.72e-56	Blood metabolite levels;
BRCA	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg27029518	chr18:72166324	CNDP2	-0.31	-8.67	-0.32	3.67e-17	Refractive error;
BRCA	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg00701064	chr4:6280414	WFS1	0.71	19.54	0.61	5.18e-67	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs965469	0.779	rs2236114	chr20:3296040	A/G	cg25506879	chr20:3388711	C20orf194	-0.43	-8.77	-0.33	1.66e-17	IFN-related cytopenia;
BRCA	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg14440974	chr22:39074834	NA	-0.39	-9.14	-0.34	8.25e-19	Menopause (age at onset);
BRCA	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg01689657	chr7:91764605	CYP51A1	0.24	8.58	0.32	7.31e-17	Breast cancer;
BRCA	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg23711669	chr6:146136114	FBXO30	0.64	14.88	0.51	3.31e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg13256891	chr4:100009986	ADH5	0.53	9.77	0.36	4.33e-21	Smoking initiation;
BRCA	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg18196295	chr10:418757	DIP2C	0.45	10.59	0.39	3.09e-24	Psychosis in Alzheimer's disease;
BRCA	cis	rs2239547	0.522	rs9846976	chr3:53007995	T/C	cg11645453	chr3:52864694	ITIH4	0.42	10.6	0.39	2.68e-24	Schizophrenia;
BRCA	cis	rs10789491	1.000	rs35861275	chr1:47171909	A/C	cg15501359	chr1:47185051	KIAA0494	-0.65	-16.05	-0.54	5.82e-49	Response to hepatitis C treatment;
BRCA	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg23708337	chr7:1209742	NA	0.5	9.77	0.36	4.14e-21	Longevity;Endometriosis;
BRCA	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg10729496	chr3:10149963	C3orf24	-0.46	-7.93	-0.3	9.74e-15	Alzheimer's disease;
BRCA	cis	rs12474201	0.507	rs6714451	chr2:47017743	G/C	cg06386533	chr2:46925753	SOCS5	0.39	7.87	0.3	1.47e-14	Height;
BRCA	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg24044776	chr19:53454761	ZNF816A	-0.41	-9.31	-0.35	2.09e-19	Psoriasis;
BRCA	cis	rs3917254	0.596	rs13001315	chr2:102763210	G/A	cg22835712	chr2:102737379	NA	-0.52	-8.8	-0.33	1.27e-17	Blood protein levels;
BRCA	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg16339924	chr4:17578868	LAP3	0.6	14.62	0.5	5.83e-42	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg09754948	chr16:28834200	ATXN2L	0.46	9.18	0.34	6.07e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.45	0.55	5.92e-51	Colorectal cancer;
BRCA	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg06026331	chr20:60912101	LAMA5	-0.54	-10.66	-0.39	1.57e-24	Colorectal cancer;
BRCA	trans	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg25214090	chr10:38739885	LOC399744	0.53	11.98	0.43	5.76e-30	Corneal astigmatism;
BRCA	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00166722	chr3:10149974	C3orf24	-0.61	-12.85	-0.45	8.82e-34	Alzheimer's disease;
BRCA	trans	rs12310956	0.532	rs2087270	chr12:33850109	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.43	0.35	7.23e-20	Morning vs. evening chronotype;
BRCA	cis	rs7523050	0.643	rs35438081	chr1:109402831	G/T	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg07395648	chr5:131743802	NA	-0.36	-7.9	-0.3	1.2e-14	Breast cancer;
BRCA	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg04317338	chr11:64019027	PLCB3	0.53	9.25	0.34	3.32e-19	Mean platelet volume;
BRCA	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg03342759	chr3:160939853	NMD3	-0.64	-13.48	-0.47	1.2e-36	Morning vs. evening chronotype;
BRCA	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg03146154	chr1:46216737	IPP	-0.51	-11.08	-0.4	3.11e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg19761014	chr17:28927070	LRRC37B2	0.49	7.93	0.3	9.65e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg04362960	chr10:104952993	NT5C2	0.41	10.03	0.37	4.23e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11764359	chr7:65958608	NA	0.78	17.51	0.57	2.41e-56	Aortic root size;
BRCA	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg18305652	chr10:134549665	INPP5A	0.49	11.42	0.41	1.28e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg26677194	chr12:130822605	PIWIL1	0.6	14.33	0.49	1.31e-40	Menopause (age at onset);
BRCA	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.33	-9.93	-0.37	1.05e-21	Bipolar disorder;
BRCA	cis	rs490234	0.783	rs10119855	chr9:128271123	A/T	cg14078157	chr9:128172775	NA	-0.48	-10.97	-0.4	8.85e-26	Mean arterial pressure;
BRCA	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg25767906	chr1:53392781	SCP2	-0.37	-8.54	-0.32	9.64e-17	Monocyte count;
BRCA	trans	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg25214090	chr10:38739885	LOC399744	0.37	8.52	0.32	1.19e-16	Diastolic blood pressure;
BRCA	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg01028140	chr2:1542097	TPO	-0.77	-15.31	-0.52	2.73e-45	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	11.91	0.43	1.13e-29	Height;
BRCA	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	8.26	0.31	8.51e-16	Schizophrenia;
BRCA	cis	rs77861329	1.000	rs893056	chr3:52109564	G/A	cg08692210	chr3:52188851	WDR51A	0.66	9.64	0.36	1.26e-20	Macrophage inflammatory protein 1b levels;
BRCA	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg16606324	chr3:10149918	C3orf24	0.56	11.2	0.4	1.08e-26	Alzheimer's disease;
BRCA	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12756686	chr19:29218302	NA	0.58	11.74	0.42	6.06e-29	Methadone dose in opioid dependence;
BRCA	cis	rs56399783	0.901	rs55767077	chr7:2774608	C/T	cg23627948	chr7:2760692	NA	0.51	8.23	0.31	1.03e-15	Childhood ear infection;
BRCA	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11890956	chr21:40555474	PSMG1	1.04	29.45	0.76	4.5e-121	Cognitive function;
BRCA	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg07606381	chr6:8435919	SLC35B3	0.66	14.56	0.5	1.08e-41	Motion sickness;
BRCA	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg26384229	chr12:38710491	ALG10B	0.42	9.4	0.35	9.92e-20	Morning vs. evening chronotype;
BRCA	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg05868516	chr6:26286170	HIST1H4H	0.49	10.88	0.4	2e-25	Educational attainment;
BRCA	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.39	0.38	1.75e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg03213289	chr20:61660250	NA	0.61	15.72	0.53	2.47e-47	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg17420585	chr12:42539391	GXYLT1	-0.38	-8.06	-0.3	3.77e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg03477792	chr4:77819574	ANKRD56	0.66	15.8	0.53	9.93e-48	Emphysema distribution in smoking;
BRCA	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-15.45	-0.52	5.35e-46	Total cholesterol levels;
BRCA	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg16339924	chr4:17578868	LAP3	0.57	14.01	0.48	4.4e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.54	-10.13	-0.37	1.81e-22	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg12444411	chr7:2802554	GNA12	-0.36	-8.89	-0.33	6.21e-18	Height;
BRCA	cis	rs12612619	0.579	rs4552148	chr2:27080513	A/T	cg12368169	chr2:27073192	DPYSL5	-0.33	-10.16	-0.37	1.36e-22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs4642101	0.824	rs9820977	chr3:12842932	G/A	cg24848339	chr3:12840334	CAND2	0.41	10.56	0.39	3.85e-24	QRS complex (12-leadsum);
BRCA	cis	rs6580649	0.941	rs72644847	chr12:48516093	C/A	cg24011408	chr12:48396354	COL2A1	-0.49	-7.93	-0.3	9.64e-15	Lung cancer;
BRCA	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg11752832	chr7:134001865	SLC35B4	0.47	11.78	0.42	3.97e-29	Mean platelet volume;
BRCA	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg15556689	chr8:8085844	FLJ10661	-0.36	-9.69	-0.36	8.1e-21	Joint mobility (Beighton score);
BRCA	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg04362960	chr10:104952993	NT5C2	0.42	10.22	0.37	8.37e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg25817165	chr18:72167213	CNDP2	-0.77	-19.64	-0.61	1.55e-67	Refractive error;
BRCA	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg13393036	chr8:95962371	TP53INP1	-0.34	-9.32	-0.35	1.91e-19	Type 2 diabetes;
BRCA	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg04455712	chr21:45112962	RRP1B	0.38	9.68	0.36	9.36e-21	Mean corpuscular volume;
BRCA	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg13271783	chr10:134563150	INPP5A	-0.5	-9.51	-0.35	3.8e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9462027	0.628	rs2814967	chr6:34712838	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.81	-0.3	2.37e-14	Systemic lupus erythematosus;
BRCA	cis	rs7945705	0.875	rs11042059	chr11:8795080	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.5	10.46	0.38	9.94e-24	Hemoglobin concentration;
BRCA	trans	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg21659725	chr3:3221576	CRBN	0.48	8.7	0.33	2.83e-17	Menarche (age at onset);
BRCA	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg03354898	chr7:1950403	MAD1L1	0.47	9.87	0.36	1.8e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.54	-11.79	-0.42	3.55e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	9.92	0.37	1.09e-21	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs57590327	0.503	rs12152272	chr3:81911684	G/A	cg07356753	chr3:81810745	GBE1	-0.45	-10.51	-0.38	6.33e-24	Extraversion;
BRCA	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.77	16.24	0.54	6.44e-50	Smoking behavior;
BRCA	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11890956	chr21:40555474	PSMG1	-0.84	-22.0	-0.66	2.88e-80	Cognitive function;
BRCA	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg21132104	chr15:45694354	SPATA5L1	0.74	16.3	0.54	3.4e-50	Homoarginine levels;
BRCA	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25427524	chr10:38739819	LOC399744	-0.74	-18.27	-0.59	2.53e-60	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9296092	0.538	rs62405953	chr6:33524760	C/T	cg13560919	chr6:33536144	NA	-0.86	-18.74	-0.6	8.89e-63	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	trans	rs9951602	0.512	rs8097996	chr18:76648035	A/G	cg02800362	chr5:177631904	HNRNPAB	0.77	17.82	0.58	6.06e-58	Obesity-related traits;
BRCA	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg20283391	chr11:68216788	NA	-0.47	-9.12	-0.34	9.66e-19	Total body bone mineral density;
BRCA	cis	rs17092148	0.887	rs2068474	chr20:33231079	A/G	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.39	-0.38	1.73e-23	Neuroticism;
BRCA	trans	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg25042112	chr7:64838748	ZNF92	0.45	8.29	0.31	6.69e-16	Pain;
BRCA	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs10193935	0.901	rs72798529	chr2:42537471	C/T	cg27598129	chr2:42591480	NA	-0.95	-14.87	-0.51	3.75e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10746514	0.804	rs1854822	chr1:232262270	G/C	cg09506761	chr1:232265262	NA	-0.42	-8.66	-0.32	3.86e-17	Response to statin therapy;
BRCA	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg19678392	chr7:94953810	PON1	-0.41	-8.6	-0.32	6.16e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg09537434	chr19:41945824	ATP5SL	-0.99	-23.25	-0.68	4.24e-87	Height;
BRCA	cis	rs7975161	0.671	rs4475991	chr12:104596756	A/G	cg25273343	chr12:104657179	TXNRD1	0.38	9.15	0.34	7.33e-19	Toenail selenium levels;
BRCA	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg11062466	chr8:58055876	NA	0.41	8.04	0.3	4.43e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg22974920	chr21:40686053	BRWD1	-0.4	-8.77	-0.33	1.57e-17	Cognitive function;
BRCA	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg12432903	chr7:1882776	MAD1L1	0.44	7.94	0.3	8.89e-15	Bipolar disorder;
BRCA	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg20503657	chr10:835505	NA	1.06	18.21	0.58	5.52e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs7301826	0.610	rs4759791	chr12:131296495	A/G	cg11011512	chr12:131303247	STX2	0.51	13.62	0.47	3e-37	Plasma plasminogen activator levels;
BRCA	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-11.79	-0.42	3.69e-29	Gut microbiome composition (summer);
BRCA	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg26384229	chr12:38710491	ALG10B	0.41	9.02	0.34	2.15e-18	Morning vs. evening chronotype;
BRCA	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.6	-12.71	-0.45	3.81e-33	Lymphocyte counts;
BRCA	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg09021430	chr5:549028	NA	-0.64	-16.44	-0.55	6.66e-51	Ulcerative colitis;
BRCA	cis	rs600806	0.683	rs10857788	chr1:110012289	G/A	cg20591472	chr1:110008990	SYPL2	0.31	7.85	0.3	1.77e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.77	12.63	0.45	8.45e-33	Platelet count;
BRCA	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg04944784	chr2:26401820	FAM59B	-0.74	-12.11	-0.43	1.62e-30	Gut microbiome composition (summer);
BRCA	cis	rs7944584	0.655	rs11039183	chr11:47346940	G/A	cg20307385	chr11:47447363	PSMC3	0.59	12.51	0.44	2.74e-32	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs4363385	0.647	rs4845513	chr1:152998066	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.45	-0.32	1.9e-16	Inflammatory skin disease;
BRCA	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	11.95	0.43	7.31e-30	Mean platelet volume;
BRCA	cis	rs7737355	1.000	rs76753180	chr5:130763701	A/T	cg06307176	chr5:131281290	NA	-0.51	-9.78	-0.36	3.71e-21	Life satisfaction;
BRCA	cis	rs12618769	0.652	rs11537554	chr2:99216531	A/G	cg10123293	chr2:99228465	UNC50	0.44	8.69	0.32	3.15e-17	Bipolar disorder;
BRCA	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg02196655	chr2:10830764	NOL10	0.29	7.82	0.3	2.12e-14	Prostate cancer;
BRCA	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg13699009	chr12:122356056	WDR66	-0.37	-8.47	-0.32	1.68e-16	Mean corpuscular volume;
BRCA	cis	rs6840258	1.000	rs72667753	chr4:87941012	C/T	cg08197287	chr4:87952173	AFF1	-0.42	-8.31	-0.31	5.54e-16	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08045932	chr20:61659980	NA	0.49	11.17	0.4	1.35e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg13736514	chr6:26305472	NA	-0.35	-11.91	-0.43	1.16e-29	Educational attainment;
BRCA	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.1	0.37	2.42e-22	Bladder cancer;
BRCA	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg09060608	chr5:178986726	RUFY1	0.47	11.3	0.41	4.12e-27	Lung cancer;
BRCA	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	19.98	0.62	2.34e-69	Platelet count;
BRCA	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg21951975	chr1:209979733	IRF6	0.38	8.96	0.33	3.49e-18	Cleft lip with or without cleft palate;
BRCA	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.55	-0.52	1.7e-46	Chronic sinus infection;
BRCA	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.85e-29	Chronic sinus infection;
BRCA	cis	rs909002	0.849	rs2271933	chr1:32092525	C/T	cg13919466	chr1:32135498	COL16A1	0.27	9.46	0.35	5.88e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.57	13.62	0.47	2.81e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	10.18	0.37	1.21e-22	Retinal vascular caliber;
BRCA	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.43	-8.12	-0.31	2.38e-15	Tonsillectomy;
BRCA	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg26248373	chr2:1572462	NA	-0.65	-15.81	-0.53	9.41e-48	IgG glycosylation;
BRCA	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg26384229	chr12:38710491	ALG10B	0.67	15.12	0.51	2.21e-44	Morning vs. evening chronotype;
BRCA	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg00531865	chr16:30841666	NA	-0.58	-14.88	-0.51	3.26e-43	Dementia with Lewy bodies;
BRCA	cis	rs4074536	0.740	rs11578967	chr1:116301670	T/G	cg21648376	chr1:116311395	CASQ2	-0.46	-8.18	-0.31	1.58e-15	QRS duration;
BRCA	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg04267008	chr7:1944627	MAD1L1	0.4	8.94	0.33	4.06e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg16339924	chr4:17578868	LAP3	-0.62	-15.27	-0.52	4.02e-45	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.73	16.4	0.54	9.88e-51	Lymphocyte counts;
BRCA	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.5	0.32	1.32e-16	Cognitive ability;
BRCA	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg05340658	chr4:99064831	C4orf37	0.62	14.69	0.5	2.65e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.47	-10.93	-0.4	1.36e-25	Urate levels in overweight individuals;
BRCA	trans	rs61931739	0.635	rs1825746	chr12:33939984	C/T	cg26384229	chr12:38710491	ALG10B	0.4	9.0	0.34	2.52e-18	Morning vs. evening chronotype;
BRCA	trans	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg26043149	chr18:55253948	FECH	-0.4	-8.85	-0.33	8.36e-18	Bone mineral density;
BRCA	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg26818010	chr10:134567672	INPP5A	-0.77	-15.68	-0.53	3.83e-47	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	9.7	0.36	7.5e-21	Personality dimensions;
BRCA	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg09537434	chr19:41945824	ATP5SL	-0.99	-23.25	-0.68	4.24e-87	Height;
BRCA	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.22	-0.31	1.15e-15	Depression;
BRCA	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg04944784	chr2:26401820	FAM59B	-1.0	-16.79	-0.55	1.16e-52	Gut microbiome composition (summer);
BRCA	cis	rs495337	0.721	rs554263	chr20:48513893	G/C	cg17835207	chr20:48524531	SPATA2	-0.68	-16.2	-0.54	1.08e-49	Psoriasis;
BRCA	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg08885076	chr2:99613938	TSGA10	0.46	10.69	0.39	1.19e-24	Chronic sinus infection;
BRCA	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg02297831	chr4:17616191	MED28	0.36	8.43	0.32	2.24e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg00757033	chr12:89920650	WDR51B	0.53	10.74	0.39	7.86e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg18811423	chr2:55921094	PNPT1	0.69	22.01	0.66	2.57e-80	Metabolic syndrome;
BRCA	cis	rs2625529	0.590	rs2856929	chr15:72496762	T/C	cg16672083	chr15:72433130	SENP8	-0.82	-17.26	-0.56	4.5e-55	Red blood cell count;
BRCA	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg12923728	chr3:195709715	SDHAP1	0.38	7.83	0.3	2.01e-14	Mean corpuscular volume;
BRCA	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg03929089	chr4:120376271	NA	-0.81	-18.81	-0.6	3.73e-63	Height;
BRCA	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg10011062	chr15:43941034	CATSPER2	-0.57	-8.57	-0.32	8.04e-17	Lung cancer in ever smokers;
BRCA	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18876405	chr7:65276391	NA	0.56	13.15	0.46	3.81e-35	Aortic root size;
BRCA	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg04944784	chr2:26401820	FAM59B	-0.95	-16.17	-0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-11.33	-0.41	3.18e-27	Gut microbiome composition (summer);
BRCA	trans	rs1200821	0.535	rs1208789	chr10:37722472	A/G	cg25427524	chr10:38739819	LOC399744	-0.41	-8.81	-0.33	1.18e-17	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7586879	0.828	rs11675013	chr2:25107208	G/A	cg04586622	chr2:25135609	ADCY3	0.39	9.5	0.35	4.06e-20	Body mass index;
BRCA	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg14829155	chr15:31115871	NA	-0.43	-9.74	-0.36	5.24e-21	Huntington's disease progression;
BRCA	cis	rs6987853	0.966	rs2084709	chr8:42423190	A/G	cg09913449	chr8:42400586	C8orf40	0.37	7.97	0.3	7.52e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg24531977	chr5:56204891	C5orf35	0.42	8.6	0.32	6.32e-17	Coronary artery disease;
BRCA	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-13.69	-0.48	1.3e-37	Morning vs. evening chronotype;
BRCA	cis	rs7737355	0.773	rs32103	chr5:131030961	T/C	cg06307176	chr5:131281290	NA	0.53	10.58	0.39	3.15e-24	Life satisfaction;
BRCA	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg25427524	chr10:38739819	LOC399744	-0.53	-9.35	-0.35	1.51e-19	Obesity (extreme);
BRCA	cis	rs600806	0.888	rs12046539	chr1:109875415	C/T	cg20591472	chr1:110008990	SYPL2	0.32	7.94	0.3	9.19e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg24130564	chr14:104152367	KLC1	0.37	8.28	0.31	7.04e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg19346786	chr7:2764209	NA	-0.33	-9.89	-0.36	1.53e-21	Height;
BRCA	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg24296786	chr1:45957014	TESK2	-0.46	-10.54	-0.38	4.68e-24	Red blood cell count;Reticulocyte count;
BRCA	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg08847533	chr14:75593920	NEK9	-0.83	-20.8	-0.64	9.42e-74	Height;
BRCA	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6594499	0.564	rs12518884	chr5:110452223	A/G	cg04022379	chr5:110408740	TSLP	0.4	9.17	0.34	6.44e-19	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs17253792	0.822	rs76267907	chr14:56066969	C/A	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs4664304	0.620	rs11675085	chr2:160713352	C/G	cg02280532	chr2:160761244	LY75	0.35	7.85	0.3	1.81e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2859741	0.528	rs3753776	chr1:37480144	C/T	cg09363841	chr1:37513479	NA	-0.51	-10.92	-0.4	1.48e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg18252515	chr7:66147081	NA	-0.85	-12.24	-0.44	4.45e-31	Diabetic kidney disease;
BRCA	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg15704280	chr7:45808275	SEPT13	0.7	14.28	0.49	2.29e-40	Coronary artery disease;
BRCA	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg12365402	chr11:9010492	NRIP3	-0.41	-9.62	-0.36	1.44e-20	Hemoglobin concentration;
BRCA	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg03354898	chr7:1950403	MAD1L1	-0.4	-8.99	-0.33	2.85e-18	Schizophrenia;
BRCA	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg18196295	chr10:418757	DIP2C	0.49	11.86	0.42	1.87e-29	Psychosis in Alzheimer's disease;
BRCA	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg21573476	chr21:45109991	RRP1B	-0.35	-9.31	-0.35	2e-19	Mean corpuscular volume;
BRCA	cis	rs6700896	0.931	rs1805096	chr1:66102257	C/T	cg04111102	chr1:66153794	NA	0.34	8.35	0.31	4.08e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg07051648	chr19:49177693	NTN5;SEC1	-0.42	-8.02	-0.3	5.01e-15	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
BRCA	cis	rs28374715	0.609	rs8043237	chr15:41514298	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.83	-17.14	-0.56	1.73e-54	Ulcerative colitis;
BRCA	cis	rs6809651	0.524	rs56940353	chr3:185798296	T/C	cg00760338	chr3:185826511	ETV5	-0.49	-9.66	-0.36	1.11e-20	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
BRCA	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg19622623	chr12:86230825	RASSF9	-0.33	-9.23	-0.34	3.96e-19	Major depressive disorder;
BRCA	cis	rs1005224	0.853	rs61980778	chr14:76151532	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	0.35	8.26	0.31	8.29e-16	Large artery stroke;
BRCA	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02353165	chr6:42928485	GNMT	-0.6	-14.32	-0.49	1.45e-40	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg09904177	chr6:26538194	HMGN4	-0.46	-13.26	-0.46	1.2e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-11.92	-0.43	9.82e-30	Tonsillectomy;
BRCA	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-8.99	-0.33	2.86e-18	Educational attainment;
BRCA	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg23711669	chr6:146136114	FBXO30	0.72	17.35	0.57	1.59e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg23711669	chr6:146136114	FBXO30	0.77	17.96	0.58	1.11e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg10523679	chr1:76189770	ACADM	0.77	15.95	0.53	1.95e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg13319975	chr6:146136371	FBXO30	0.34	8.03	0.3	4.59e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.3	-0.44	2.28e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg03433033	chr1:76189801	ACADM	-0.47	-8.96	-0.33	3.6e-18	Daytime sleep phenotypes;
BRCA	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg22920501	chr2:26401640	FAM59B	-0.67	-11.53	-0.42	4.47e-28	Gut microbiome composition (summer);
BRCA	cis	rs9649465	0.967	rs2299986	chr7:123369539	T/C	cg04330084	chr7:123175371	IQUB	-0.31	-8.44	-0.32	2.13e-16	Migraine;
BRCA	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg20387954	chr3:183756860	HTR3D	0.43	9.85	0.36	2.07e-21	Anterior chamber depth;
BRCA	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg18402987	chr7:1209562	NA	0.52	9.0	0.34	2.55e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10170846	0.924	rs3768973	chr2:223436402	C/T	cg25565276	chr2:223520875	FARSB	0.5	13.21	0.46	2.02e-35	Schizophrenia (inflammation and infection response interaction);
BRCA	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg19678392	chr7:94953810	PON1	-0.43	-9.01	-0.34	2.41e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg01483505	chr11:975446	AP2A2	-0.33	-9.0	-0.34	2.57e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7524258	0.868	rs8179413	chr1:7267729	T/G	cg07173049	chr1:7289937	CAMTA1	0.53	12.93	0.46	3.98e-34	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg03146154	chr1:46216737	IPP	0.51	11.28	0.41	4.89e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08045932	chr20:61659980	NA	0.49	11.08	0.4	3.09e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg05985134	chr18:33552581	C18orf21	0.68	12.91	0.45	4.77e-34	Endometriosis;Drug-induced torsades de pointes;
BRCA	trans	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg26043149	chr18:55253948	FECH	0.43	9.22	0.34	4.29e-19	Bone mineral density;
BRCA	cis	rs2882667	0.898	rs2043272	chr5:138390631	A/C	cg04439458	chr5:138467593	SIL1	-0.34	-9.41	-0.35	8.73e-20	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3845702	0.668	rs3856415	chr2:180807367	G/A	cg01881094	chr2:180872142	CWC22	-1.03	-18.02	-0.58	5.24e-59	Schizophrenia;
BRCA	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.09	0.34	1.22e-18	Tonsillectomy;
BRCA	cis	rs3925075	0.531	rs9673519	chr16:31347557	T/C	cg02846316	chr16:31340340	ITGAM	0.42	8.56	0.32	8.58e-17	IgA nephropathy;
BRCA	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg08999081	chr20:33150536	PIGU	0.36	9.29	0.35	2.35e-19	Coronary artery disease;
BRCA	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg14458575	chr2:238380390	NA	0.48	10.84	0.39	3.1e-25	Prostate cancer;
BRCA	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg00495681	chr13:53174319	NA	0.39	8.04	0.3	4.21e-15	Lewy body disease;
BRCA	cis	rs1451375	0.572	rs11575463	chr7:50547173	A/G	cg18232548	chr7:50535776	DDC	-0.42	-8.91	-0.33	5.42e-18	Malaria;
BRCA	trans	rs4650994	0.544	rs2811306	chr1:178599248	C/G	cg05059571	chr16:84539110	KIAA1609	0.56	12.23	0.44	4.88e-31	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs9297145	0.724	rs62473013	chr7:98762418	G/T	cg05967295	chr7:98741636	SMURF1	0.96	18.17	0.58	8.37e-60	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg08917208	chr2:24149416	ATAD2B	1.1	15.51	0.52	2.65e-46	Lymphocyte counts;
BRCA	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg10174797	chr19:8464628	RAB11B	0.36	9.17	0.34	6.2e-19	HDL cholesterol;
BRCA	cis	rs6910061	1.000	rs34846077	chr6:11096561	G/A	cg27233058	chr6:11094804	LOC221710	0.52	9.3	0.35	2.15e-19	Diabetic kidney disease;
BRCA	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg15704280	chr7:45808275	SEPT13	-0.54	-10.84	-0.39	2.98e-25	HDL cholesterol;
BRCA	cis	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg04990556	chr1:26633338	UBXN11	0.55	9.24	0.34	3.56e-19	Obesity-related traits;
BRCA	cis	rs6484504	0.625	rs4922859	chr11:31382517	A/G	cg06552810	chr11:31128660	NA	0.38	8.6	0.32	6.04e-17	Red blood cell count;
BRCA	cis	rs1568889	0.838	rs7121937	chr11:28359858	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	19.52	0.61	6.57e-67	Bipolar disorder;
BRCA	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.77	0.33	1.61e-17	Iron status biomarkers;
BRCA	cis	rs6088813	1.000	rs6088825	chr20:33995972	C/T	cg14752227	chr20:34000481	UQCC	-0.42	-8.92	-0.33	4.73e-18	Height;
BRCA	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.56	12.29	0.44	2.7e-31	Hemoglobin concentration;
BRCA	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-15.25	-0.52	5.13e-45	Parkinson's disease;
BRCA	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg17971929	chr21:40555470	PSMG1	0.8	18.71	0.59	1.3e-62	Cognitive function;
BRCA	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg26384229	chr12:38710491	ALG10B	0.58	13.87	0.48	1.94e-38	Bladder cancer;
BRCA	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg06115741	chr20:33292138	TP53INP2	0.52	11.55	0.42	3.81e-28	Coronary artery disease;
BRCA	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg21775007	chr8:11205619	TDH	-0.56	-11.32	-0.41	3.43e-27	Retinal vascular caliber;
BRCA	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.88	0.56	3.66e-53	Colorectal cancer;
BRCA	cis	rs4908768	0.539	rs7537982	chr1:8644007	C/T	cg20416874	chr1:8611966	RERE	-0.29	-8.39	-0.31	3.21e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs9469578	1.000	rs9469582	chr6:33715939	A/G	cg18708504	chr6:33715942	IP6K3	0.68	9.99	0.37	6.43e-22	Phosphorus levels;
BRCA	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-10.01	-0.37	5.31e-22	Monocyte percentage of white cells;
BRCA	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg01877450	chr7:97915802	BRI3	-0.37	-8.33	-0.31	4.86e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg13256891	chr4:100009986	ADH5	0.38	8.06	0.3	3.84e-15	Alcohol dependence;
BRCA	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg10495392	chr1:46806563	NSUN4	0.44	8.11	0.31	2.59e-15	Menopause (age at onset);
BRCA	cis	rs7560272	0.538	rs13006448	chr2:73924424	G/T	cg20560298	chr2:73613845	ALMS1	0.35	9.03	0.34	1.99e-18	Schizophrenia;
BRCA	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-9.25	-0.34	3.45e-19	Bipolar disorder;
BRCA	cis	rs1557765	0.527	rs11024272	chr11:17395760	T/C	cg15432903	chr11:17409602	KCNJ11	0.4	8.55	0.32	9.28e-17	Body mass index;Social communication problems;
BRCA	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg08508325	chr11:3079039	CARS	0.28	8.49	0.32	1.5e-16	Calcium levels;
BRCA	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg20503657	chr10:835505	NA	1.04	18.21	0.58	5.16e-60	Eosinophil percentage of granulocytes;
BRCA	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg15556689	chr8:8085844	FLJ10661	0.37	8.73	0.33	2.22e-17	Retinal vascular caliber;
BRCA	cis	rs1351164	0.591	rs9752576	chr2:218269445	G/A	cg15335768	chr2:218268053	DIRC3	-0.38	-9.17	-0.34	6.66e-19	Height;
BRCA	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.62	-0.32	5.12e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg26031613	chr14:104095156	KLC1	0.97	25.72	0.71	1.06e-100	Body mass index;
BRCA	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg01579765	chr21:45077557	HSF2BP	-0.45	-12.77	-0.45	2.01e-33	Mean corpuscular volume;
BRCA	cis	rs17095355	1.000	rs12267704	chr10:111722008	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.82	-0.36	2.69e-21	Biliary atresia;
BRCA	cis	rs10267417	0.603	rs28770193	chr7:19860804	A/T	cg07541023	chr7:19748670	TWISTNB	0.47	8.73	0.33	2.23e-17	Night sleep phenotypes;
BRCA	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg05535760	chr7:792225	HEATR2	0.72	13.3	0.47	8.12e-36	Cerebrospinal P-tau181p levels;
BRCA	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.7	0.42	9.02e-29	Tonsillectomy;
BRCA	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg13798780	chr7:105162888	PUS7	0.45	7.9	0.3	1.21e-14	Bipolar disorder (body mass index interaction);
BRCA	cis	rs6433857	0.657	rs2368177	chr2:181501242	T/C	cg23363182	chr2:181467187	NA	-0.45	-9.73	-0.36	6.11e-21	Body mass index;
BRCA	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg18225595	chr11:63971243	STIP1	0.41	10.06	0.37	3.44e-22	Platelet count;
BRCA	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.56	10.07	0.37	3.2e-22	Gut microbiome composition (summer);
BRCA	trans	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	27.77	0.74	5.91e-112	Exhaled nitric oxide output;
BRCA	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg27094323	chr7:1216898	NA	-0.36	-8.19	-0.31	1.45e-15	Longevity;Endometriosis;
BRCA	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg27432699	chr2:27873401	GPN1	0.46	9.46	0.35	5.92e-20	Oral cavity cancer;
BRCA	cis	rs1967309	0.604	rs8061182	chr16:4070333	A/G	cg00061520	chr16:4070371	ADCY9	0.37	8.0	0.3	5.69e-15	Response to Dalcetrapib treatment in acute coronary syndrome;
BRCA	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg20607798	chr8:58055168	NA	0.47	8.02	0.3	5.03e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg06271696	chr7:157225062	NA	-0.39	-10.3	-0.38	4.15e-23	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	trans	rs61931739	0.635	rs3937819	chr12:33942715	A/G	cg26384229	chr12:38710491	ALG10B	0.4	8.97	0.33	3.18e-18	Morning vs. evening chronotype;
BRCA	cis	rs2274273	0.774	rs17128440	chr14:55861912	C/T	cg04306507	chr14:55594613	LGALS3	0.3	8.25	0.31	9.21e-16	Protein biomarker;
BRCA	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg24812749	chr6:127587940	RNF146	0.87	19.88	0.62	7.86e-69	Breast cancer;
BRCA	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg27165867	chr14:105738592	BRF1	-0.36	-8.37	-0.31	3.53e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7246657	0.551	rs11084873	chr19:37583910	A/G	cg23950597	chr19:37808831	NA	-0.64	-9.66	-0.36	1.04e-20	Coronary artery calcification;
BRCA	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.57	11.33	0.41	3.18e-27	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	7.81	0.3	2.3e-14	Menarche (age at onset);
BRCA	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg14789911	chr21:47582049	C21orf56	-0.37	-7.98	-0.3	6.78e-15	Testicular germ cell tumor;
BRCA	cis	rs3771570	1.000	rs56156035	chr2:242205955	T/A	cg21155796	chr2:242212141	HDLBP	0.62	9.76	0.36	4.52e-21	Prostate cancer;
BRCA	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.77	0.39	5.85e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs870825	0.616	rs1401358	chr4:185640057	C/T	cg04058563	chr4:185651563	MLF1IP	0.74	16.93	0.56	2.21e-53	Blood protein levels;
BRCA	cis	rs6546550	0.713	rs6718517	chr2:70018462	T/C	cg02498382	chr2:70120550	SNRNP27	-0.4	-8.24	-0.31	9.62e-16	Prevalent atrial fibrillation;
BRCA	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11890956	chr21:40555474	PSMG1	0.94	21.62	0.65	3.15e-78	Cognitive function;
BRCA	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg27129171	chr3:47204927	SETD2	-0.59	-13.62	-0.47	2.83e-37	Colorectal cancer;
BRCA	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18876405	chr7:65276391	NA	-0.51	-11.75	-0.42	5.48e-29	Aortic root size;
BRCA	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg24642439	chr20:33292090	TP53INP2	0.46	8.8	0.33	1.27e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	11.12	0.4	2.15e-26	Height;
BRCA	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.45	8.64	0.32	4.51e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	9.08	0.34	1.35e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg03808351	chr9:123631620	PHF19	0.43	7.85	0.3	1.72e-14	Rheumatoid arthritis;
BRCA	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.02e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2742234	0.518	rs1254967	chr10:43690391	G/A	cg15436174	chr10:43711423	RASGEF1A	0.57	11.47	0.41	7.89e-28	Hirschsprung disease;
BRCA	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.95	0.33	3.68e-18	Motion sickness;
BRCA	cis	rs1568889	1.000	rs7937117	chr11:28370038	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.69	0.5	2.53e-42	Bipolar disorder;
BRCA	cis	rs35740288	0.685	rs12899481	chr15:86308970	C/T	cg20737812	chr15:86336631	KLHL25	-0.33	-8.05	-0.3	4.19e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	trans	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg25214090	chr10:38739885	LOC399744	0.45	10.3	0.38	4.19e-23	Corneal astigmatism;
BRCA	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.45	-8.13	-0.31	2.22e-15	Menarche (age at onset);
BRCA	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.85	-17.16	-0.56	1.5e-54	Alzheimer's disease;
BRCA	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-13.43	-0.47	2.14e-36	Hemoglobin concentration;
BRCA	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-8.59	-0.32	6.46e-17	Monocyte percentage of white cells;
BRCA	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00166722	chr3:10149974	C3orf24	0.55	11.13	0.4	1.93e-26	Alzheimer's disease;
BRCA	trans	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-14.22	-0.49	4.75e-40	Obesity-related traits;
BRCA	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03517284	chr6:25882590	NA	-0.49	-10.19	-0.37	1.1e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg17757837	chr7:157058334	UBE3C	0.56	12.55	0.44	1.9e-32	Body mass index;
BRCA	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg20573242	chr4:122745356	CCNA2	0.48	10.84	0.39	2.96e-25	Type 2 diabetes;
BRCA	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg11833968	chr6:79620685	NA	-0.44	-9.95	-0.37	8.48e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2522056	1.000	rs2106854	chr5:131769174	C/T	cg24060327	chr5:131705240	SLC22A5	0.44	7.81	0.3	2.33e-14	Lymphocyte counts;Fibrinogen;
BRCA	cis	rs490234	0.812	rs2900229	chr9:128466312	A/G	cg14078157	chr9:128172775	NA	-0.36	-8.2	-0.31	1.29e-15	Mean arterial pressure;
BRCA	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.14	-0.4	1.77e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.96	26.35	0.72	3.76e-104	Birth weight;
BRCA	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.65	0.39	1.77e-24	Bipolar disorder;
BRCA	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg18446336	chr7:2847575	GNA12	-0.36	-8.35	-0.31	4.19e-16	Height;
BRCA	cis	rs7590720	1.000	rs1991533	chr2:216908910	T/C	cg12620499	chr2:216877984	MREG	0.79	21.44	0.65	3.09e-77	Alcohol dependence;
BRCA	trans	rs2262909	0.962	rs11669110	chr19:22296485	A/G	cg17074339	chr11:11642133	GALNTL4	0.44	8.62	0.32	5.06e-17	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg10818794	chr15:86012489	AKAP13	-0.31	-8.61	-0.32	5.47e-17	Coronary artery disease;
BRCA	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26314531	chr2:26401878	FAM59B	-0.62	-10.82	-0.39	3.45e-25	Gut microbiome composition (summer);
BRCA	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg18132916	chr6:79620363	NA	-0.47	-10.74	-0.39	7.41e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg12444411	chr7:2802554	GNA12	-0.35	-8.74	-0.33	2.07e-17	Height;
BRCA	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg22974920	chr21:40686053	BRWD1	-0.4	-8.91	-0.33	5.4e-18	Cognitive function;
BRCA	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg00666640	chr1:248458726	OR2T12	0.32	8.94	0.33	4.09e-18	Common traits (Other);
BRCA	cis	rs35740288	0.787	rs11637768	chr15:86223410	C/T	cg20737812	chr15:86336631	KLHL25	-0.32	-7.87	-0.3	1.58e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-10.19	-0.37	1.09e-22	Heart rate;
BRCA	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg27535305	chr1:53392650	SCP2	0.4	9.84	0.36	2.22e-21	Monocyte count;
BRCA	cis	rs7903847	0.667	rs11189181	chr10:99144154	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.34	-0.31	4.51e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs17270561	0.636	rs3922681	chr6:25698481	C/T	cg16482183	chr6:26056742	HIST1H1C	0.45	8.56	0.32	8.24e-17	Iron status biomarkers;
BRCA	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg13010199	chr12:38710504	ALG10B	0.5	9.7	0.36	7.46e-21	Morning vs. evening chronotype;
BRCA	cis	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg23422044	chr7:1970798	MAD1L1	-0.43	-8.79	-0.33	1.41e-17	Neuroticism;
BRCA	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg08470875	chr2:26401718	FAM59B	-0.63	-9.47	-0.35	5.17e-20	Gut microbiome composition (summer);
BRCA	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg25703541	chr22:24373054	LOC391322	-0.69	-16.0	-0.53	1.09e-48	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6546550	0.935	rs11673826	chr2:70041033	G/A	cg02498382	chr2:70120550	SNRNP27	-0.41	-8.79	-0.33	1.4e-17	Prevalent atrial fibrillation;
BRCA	trans	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04565464	chr8:145669602	NFKBIL2	0.36	8.81	0.33	1.16e-17	Bipolar disorder and schizophrenia;
BRCA	trans	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg07461501	chr17:79650226	HGS;ARL16	0.4	10.09	0.37	2.5e-22	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg00599163	chr2:162100495	NA	0.27	8.83	0.33	9.71e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	trans	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg01620082	chr3:125678407	NA	-0.98	-11.11	-0.4	2.38e-26	Depression;
BRCA	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26314531	chr2:26401878	FAM59B	-0.92	-14.35	-0.49	1.07e-40	Gut microbiome composition (summer);
BRCA	cis	rs7301826	0.651	rs10773824	chr12:131298851	G/A	cg11011512	chr12:131303247	STX2	0.49	12.98	0.46	2.3e-34	Plasma plasminogen activator levels;
BRCA	cis	rs9612	0.718	rs346522	chr19:44262545	C/T	cg08581076	chr19:44259116	C19orf61	-0.45	-8.2	-0.31	1.33e-15	Exhaled nitric oxide output;
BRCA	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg21475434	chr5:93447410	FAM172A	0.69	8.65	0.32	4.07e-17	Diabetic retinopathy;
BRCA	trans	rs6582618	1	rs6582618	chr12:38726137	A/G	cg23762105	chr12:34175262	ALG10	-0.37	-9.41	-0.35	9.01e-20	Morning vs. evening chronotype;
BRCA	cis	rs7640424	0.649	rs17233248	chr3:107899513	T/C	cg09227934	chr3:107805635	CD47	-0.38	-7.9	-0.3	1.27e-14	Body mass index;
BRCA	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg16482183	chr6:26056742	HIST1H1C	0.45	8.76	0.33	1.81e-17	Iron status biomarkers;
BRCA	cis	rs12949688	0.934	rs12449409	chr17:55822467	G/A	cg12582317	chr17:55822272	NA	0.32	7.93	0.3	9.97e-15	Schizophrenia;
BRCA	cis	rs72781680	0.611	rs6720131	chr2:24364736	C/T	cg20701182	chr2:24300061	SF3B14	0.71	13.18	0.46	2.85e-35	Lymphocyte counts;
BRCA	cis	rs7020830	0.516	rs36047049	chr9:37375472	G/T	cg14294708	chr9:37120828	ZCCHC7	0.89	16.76	0.55	1.5e-52	Schizophrenia;
BRCA	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.49	-0.61	9.03e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg24006582	chr15:45444508	DUOX1	-0.56	-11.58	-0.42	2.68e-28	Uric acid levels;
BRCA	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg08213375	chr14:104286397	PPP1R13B	0.64	18.34	0.59	1.12e-60	Schizophrenia;
BRCA	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.0	22.78	0.67	1.56e-84	Lymphocyte percentage of white cells;
BRCA	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.31	-8.05	-0.3	4.07e-15	Response to antipsychotic treatment;
BRCA	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.62	-13.08	-0.46	7.84e-35	Lung cancer;
BRCA	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg12564285	chr5:131593104	PDLIM4	-0.37	-9.73	-0.36	5.66e-21	Breast cancer;
BRCA	cis	rs950173	1.000	rs950173	chr2:172570419	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.72	-10.24	-0.38	6.94e-23	Hippocampal volume;
BRCA	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg23711669	chr6:146136114	FBXO30	0.63	14.05	0.49	2.88e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg00106254	chr7:1943704	MAD1L1	-0.45	-12.24	-0.44	4.18e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.54e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg05025164	chr4:1340916	KIAA1530	0.39	8.84	0.33	9.58e-18	Longevity;
BRCA	cis	rs652260	1.000	rs590394	chr19:7902505	C/T	cg26014689	chr19:7917955	EVI5L	-0.51	-11.69	-0.42	9.84e-29	Menarche (age at onset);
BRCA	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.29	-8.08	-0.3	3.31e-15	Lymphocyte counts;
BRCA	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.11	-0.37	2.19e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.86	14.36	0.49	9.42e-41	Platelet count;
BRCA	cis	rs7246657	0.722	rs10410588	chr19:38042410	C/G	cg18154014	chr19:37997991	ZNF793	0.48	9.08	0.34	1.32e-18	Coronary artery calcification;
BRCA	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg20848291	chr7:100343083	ZAN	0.38	8.31	0.31	5.79e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs7587476	0.501	rs11888027	chr2:215639612	A/C	cg04004882	chr2:215674386	BARD1	-0.42	-8.89	-0.33	6.38e-18	Neuroblastoma;
BRCA	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg24130564	chr14:104152367	KLC1	0.36	8.0	0.3	5.9e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg19539972	chr4:7069911	GRPEL1	0.72	16.98	0.56	1.19e-53	Monocyte percentage of white cells;
BRCA	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg13877915	chr19:58951672	ZNF132	0.46	10.84	0.39	3.05e-25	Uric acid clearance;
BRCA	cis	rs6088813	0.961	rs6060373	chr20:33914208	C/T	cg14752227	chr20:34000481	UQCC	-0.39	-8.43	-0.32	2.34e-16	Height;
BRCA	cis	rs1635	0.655	rs16893975	chr6:28302278	C/T	cg15743358	chr6:28303923	ZNF323	0.69	8.09	0.3	3.03e-15	Schizophrenia;
BRCA	cis	rs7789940	0.904	rs12531348	chr7:75937191	G/C	cg10167463	chr7:75959203	YWHAG	-0.43	-8.42	-0.32	2.55e-16	Multiple sclerosis;
BRCA	cis	rs6684514	1.000	rs10908496	chr1:156264000	G/A	cg16558208	chr1:156270281	VHLL	0.36	8.43	0.32	2.35e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg08999081	chr20:33150536	PIGU	-0.32	-8.41	-0.32	2.77e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg06521331	chr12:34319734	NA	-0.59	-11.48	-0.41	7.48e-28	Morning vs. evening chronotype;
BRCA	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs3925075	1.000	rs12923297	chr16:31360944	T/C	cg02846316	chr16:31340340	ITGAM	0.53	12.97	0.46	2.69e-34	IgA nephropathy;
BRCA	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg00666640	chr1:248458726	OR2T12	0.33	8.66	0.32	3.96e-17	Common traits (Other);
BRCA	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg21132104	chr15:45694354	SPATA5L1	0.71	15.77	0.53	1.45e-47	Homoarginine levels;
BRCA	cis	rs867371	1.000	rs6495642	chr15:82457497	G/C	cg00614314	chr15:82944287	LOC80154	0.44	9.14	0.34	8.41e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg18196295	chr10:418757	DIP2C	-0.49	-11.06	-0.4	3.81e-26	Psychosis in Alzheimer's disease;
BRCA	cis	rs35995292	0.534	rs28460817	chr7:38921917	T/C	cg19327137	chr7:38886074	VPS41	0.38	12.76	0.45	2.2e-33	Subjective well-being (multi-trait analysis);
BRCA	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg12193833	chr17:30244370	NA	-0.58	-8.9	-0.33	5.51e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg27170947	chr2:26402098	FAM59B	0.97	16.87	0.56	4.19e-53	Gut microbiome composition (summer);
BRCA	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg06115741	chr20:33292138	TP53INP2	0.39	8.47	0.32	1.68e-16	Coronary artery disease;
BRCA	cis	rs9463078	0.625	rs12190136	chr6:44767072	A/G	cg25276700	chr6:44698697	NA	-0.35	-8.26	-0.31	8.43e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.7	-12.12	-0.43	1.4e-30	Platelet count;
BRCA	cis	rs4664304	0.710	rs9636280	chr2:160717852	C/T	cg01092293	chr2:160761427	LY75	-0.4	-9.64	-0.36	1.27e-20	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs3857067	0.806	rs6817795	chr4:95127716	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.57	-0.35	2.22e-20	QT interval;
BRCA	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg17145862	chr1:211918768	LPGAT1	-0.58	-12.7	-0.45	4.13e-33	Leprosy;
BRCA	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.06	-0.43	2.49e-30	Alzheimer's disease;
BRCA	cis	rs2880765	0.835	rs4526974	chr15:86024284	C/T	cg10818794	chr15:86012489	AKAP13	-0.31	-8.59	-0.32	6.71e-17	Coronary artery disease;
BRCA	cis	rs1568889	0.838	rs10835304	chr11:28296529	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	19.47	0.61	1.2e-66	Bipolar disorder;
BRCA	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.75	-22.0	-0.66	2.64e-80	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg13852791	chr20:30311386	BCL2L1	0.85	16.41	0.54	9.49e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg09307838	chr4:120376055	NA	0.59	12.95	0.46	3.11e-34	Corneal astigmatism;
BRCA	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.1	0.34	1.12e-18	Tonsillectomy;
BRCA	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg22875332	chr1:76189707	ACADM	-0.53	-10.08	-0.37	2.94e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17095355	1.000	rs12570145	chr10:111712913	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.44	-9.57	-0.35	2.2e-20	Biliary atresia;
BRCA	trans	rs2262909	1.000	rs2017962	chr19:22208751	T/C	cg17074339	chr11:11642133	GALNTL4	-0.41	-7.86	-0.3	1.64e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4308124	0.708	rs10178095	chr2:111972516	C/T	cg04571233	chr2:111982156	NA	-0.45	-9.58	-0.35	2.12e-20	Vitiligo;
BRCA	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg23796481	chr11:64053134	BAD;GPR137	-0.51	-10.59	-0.39	2.84e-24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs10911363	0.659	rs7518244	chr1:183434807	C/T	cg09173681	chr1:183549694	NCF2	-0.53	-11.12	-0.4	2.21e-26	Systemic lupus erythematosus;
BRCA	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg11764359	chr7:65958608	NA	-0.62	-13.27	-0.46	1.09e-35	Aortic root size;
BRCA	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.43	-0.32	2.31e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg16606324	chr3:10149918	C3orf24	0.53	10.53	0.38	5.16e-24	Alzheimer's disease;
BRCA	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg18225595	chr11:63971243	STIP1	0.45	10.88	0.4	2.06e-25	Platelet count;
BRCA	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03517284	chr6:25882590	NA	-0.37	-8.2	-0.31	1.34e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs36051895	0.632	rs62541899	chr9:5143291	C/T	cg02405213	chr9:5042618	JAK2	-0.49	-8.93	-0.33	4.54e-18	Pediatric autoimmune diseases;
BRCA	cis	rs17034641	0.744	rs2053797	chr2:46370892	C/T	cg12428440	chr2:46370979	PRKCE	0.47	8.51	0.32	1.2e-16	Hemoglobin;Hematocrit;
BRCA	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg06145435	chr7:1022769	CYP2W1	0.49	9.02	0.34	2.23e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg13770153	chr20:60521292	NA	-0.44	-9.81	-0.36	3.02e-21	Body mass index;
BRCA	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg26116260	chr4:7069785	GRPEL1	0.93	26.3	0.72	6.74e-104	Monocyte percentage of white cells;
BRCA	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg05793240	chr7:2802953	GNA12	-0.29	-7.87	-0.3	1.49e-14	Height;
BRCA	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg14019146	chr3:50243930	SLC38A3	-0.4	-9.81	-0.36	2.96e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg12591125	chr7:1885375	MAD1L1	0.43	8.74	0.33	2.12e-17	Bipolar disorder;
BRCA	cis	rs524281	0.773	rs11227413	chr11:65883696	G/A	cg16950941	chr11:66035639	RAB1B	-0.39	-8.23	-0.31	1.02e-15	Electroencephalogram traits;
BRCA	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg10932868	chr11:921992	NA	0.47	12.11	0.43	1.62e-30	Alzheimer's disease (late onset);
BRCA	cis	rs4363385	0.818	rs10788856	chr1:153011517	G/C	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	trans	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg01620082	chr3:125678407	NA	-0.71	-8.61	-0.32	5.56e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9649465	1.000	rs10238422	chr7:123353708	G/C	cg04330084	chr7:123175371	IQUB	-0.31	-8.45	-0.32	1.95e-16	Migraine;
BRCA	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg24812749	chr6:127587940	RNF146	0.87	20.07	0.62	7.99e-70	Breast cancer;
BRCA	cis	rs7095944	0.644	rs4962694	chr10:126436717	G/T	cg08799069	chr10:126477246	METTL10	-0.4	-9.49	-0.35	4.41e-20	Asthma;
BRCA	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg09359103	chr1:154839909	KCNN3	-0.6	-15.79	-0.53	1.09e-47	Prostate cancer;
BRCA	cis	rs9400271	0.632	rs9384705	chr6:109588244	T/C	cg01475377	chr6:109611718	NA	-0.43	-10.27	-0.38	5.14e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs17428076	0.556	rs12692976	chr2:172684403	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.51	-12.66	-0.45	6.2e-33	Myopia;
BRCA	cis	rs7789940	0.904	rs73140040	chr7:75936240	C/T	cg10167463	chr7:75959203	YWHAG	-0.42	-8.3	-0.31	6.02e-16	Multiple sclerosis;
BRCA	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg10729496	chr3:10149963	C3orf24	-0.51	-9.57	-0.35	2.28e-20	Alzheimer's disease;
BRCA	cis	rs698813	0.851	rs2592199	chr2:44710169	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	8.77	0.33	1.65e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	13.86	0.48	2.16e-38	Personality dimensions;
BRCA	cis	rs2387326	0.717	rs77277629	chr10:129944462	C/T	cg16087940	chr10:129947807	NA	-0.51	-8.29	-0.31	6.83e-16	Select biomarker traits;
BRCA	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg03425785	chr20:62221387	GMEB2	0.51	8.26	0.31	8.42e-16	Glioblastoma;
BRCA	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg26587870	chr6:27730563	NA	-0.52	-8.02	-0.3	5.04e-15	Breast cancer;
BRCA	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg20607287	chr7:12443886	VWDE	-0.59	-8.31	-0.31	5.68e-16	Coronary artery disease;
BRCA	cis	rs7512552	0.839	rs1260421	chr1:150357780	G/A	cg15654264	chr1:150340011	RPRD2	0.44	9.44	0.35	6.94e-20	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.62	12.87	0.45	7.41e-34	Lymphocyte counts;
BRCA	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg18904891	chr8:8559673	CLDN23	-0.62	-12.13	-0.43	1.3e-30	Obesity-related traits;
BRCA	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24110177	chr3:50126178	RBM5	-0.36	-9.79	-0.36	3.4e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg12311346	chr5:56204834	C5orf35	-0.73	-13.46	-0.47	1.56e-36	Initial pursuit acceleration;
BRCA	cis	rs6545883	0.929	rs1186711	chr2:61688505	T/C	cg15711740	chr2:61764176	XPO1	-0.56	-13.36	-0.47	4.21e-36	Tuberculosis;
BRCA	cis	rs2070433	0.539	rs2839314	chr21:47961067	A/G	cg12379764	chr21:47803548	PCNT	0.57	12.08	0.43	2.19e-30	Lymphocyte counts;
BRCA	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg04013093	chr6:42928303	GNMT	-0.29	-8.9	-0.33	5.85e-18	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.48	-9.83	-0.36	2.49e-21	Tonsillectomy;
BRCA	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg18230493	chr5:56204884	C5orf35	0.58	12.41	0.44	8.1e-32	Initial pursuit acceleration;
BRCA	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg20283391	chr11:68216788	NA	-0.48	-9.36	-0.35	1.35e-19	Total body bone mineral density;
BRCA	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg11822812	chr5:140052017	DND1	-0.3	-8.41	-0.32	2.7e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4588572	0.644	rs1159930	chr5:77768943	C/T	cg11547950	chr5:77652471	NA	0.44	8.56	0.32	8.24e-17	Triglycerides;
BRCA	cis	rs6942756	0.774	rs891545	chr7:128866616	A/C	cg02491457	chr7:128862824	NA	0.59	12.67	0.45	5.8e-33	White matter hyperintensity burden;
BRCA	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	11.08	0.4	3.17e-26	Rheumatoid arthritis;
BRCA	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.51	0.35	3.8e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24549020	chr5:56110836	MAP3K1	0.55	10.98	0.4	7.84e-26	Initial pursuit acceleration;
BRCA	cis	rs17767294	0.708	rs72848786	chr6:27980017	G/A	cg08851530	chr6:28072375	NA	1.13	10.5	0.38	6.89e-24	Parkinson's disease;
BRCA	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg10057126	chr4:77819792	ANKRD56	0.65	15.2	0.52	8.87e-45	Emphysema distribution in smoking;
BRCA	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg17509989	chr5:176798049	RGS14	0.64	12.86	0.45	8.13e-34	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs10045504	0.502	rs72746043	chr5:38757226	T/C	cg15396434	chr5:38725168	NA	-0.57	-10.71	-0.39	9.92e-25	Night sleep phenotypes;
BRCA	trans	rs3942852	0.910	rs10742831	chr11:48119691	G/A	cg15704280	chr7:45808275	SEPT13	-0.46	-8.12	-0.31	2.45e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6433895	0.710	rs11692625	chr2:182015484	C/T	cg00481216	chr2:181971175	NA	0.43	8.05	0.3	4.14e-15	Lymphocyte counts;
BRCA	cis	rs12220238	1.000	rs10824084	chr10:75911415	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.5	8.09	0.3	3.05e-15	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg02475777	chr4:1388615	CRIPAK	0.41	9.3	0.35	2.17e-19	Longevity;
BRCA	trans	rs2018683	0.523	rs4513881	chr7:29025410	C/T	cg19402173	chr7:128379420	CALU	0.4	8.96	0.33	3.62e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.08	-0.43	2.05e-30	Total cholesterol levels;
BRCA	cis	rs2901460	0.509	rs6721488	chr2:62071562	A/T	cg02183531	chr2:62113199	CCT4	-0.46	-9.14	-0.34	7.99e-19	Mean corpuscular volume;
BRCA	cis	rs4302748	0.862	rs11974973	chr7:36184850	A/T	cg24442661	chr7:36192818	EEPD1	-0.45	-8.6	-0.32	6.24e-17	Platelet count;
BRCA	cis	rs2580764	0.565	rs2044291	chr2:55247954	A/G	cg09592903	chr2:55203963	RTN4	-0.4	-10.33	-0.38	3.03e-23	Mean platelet volume;
BRCA	cis	rs2882667	0.628	rs13173618	chr5:138139780	T/G	cg04439458	chr5:138467593	SIL1	-0.42	-9.32	-0.35	1.85e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs524281	0.861	rs11227410	chr11:65873396	G/C	cg16950941	chr11:66035639	RAB1B	-0.38	-8.05	-0.3	4.15e-15	Electroencephalogram traits;
BRCA	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11890956	chr21:40555474	PSMG1	0.85	22.02	0.66	2.17e-80	Cognitive function;
BRCA	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.46	-13.78	-0.48	5.21e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.47	-10.9	-0.4	1.67e-25	Height;
BRCA	cis	rs887829	0.570	rs6736743	chr2:234595950	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.32	-8.28	-0.31	7e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs9341808	0.754	rs6916405	chr6:81024188	C/T	cg08355045	chr6:80787529	NA	0.36	9.26	0.34	3e-19	Sitting height ratio;
BRCA	cis	rs12995491	1.000	rs12995491	chr2:88527414	C/T	cg04511125	chr2:88470314	THNSL2	0.45	9.35	0.35	1.4e-19	Response to metformin (IC50);
BRCA	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.24	-0.31	9.86e-16	Aortic root size;
BRCA	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.55	7.86	0.3	1.65e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg16606324	chr3:10149918	C3orf24	0.56	10.97	0.4	9.02e-26	Alzheimer's disease;
BRCA	trans	rs587242	0.955	rs12739556	chr1:96977901	C/T	cg10631902	chr5:14652156	NA	0.44	10.72	0.39	8.96e-25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
BRCA	cis	rs9462027	0.628	rs9462019	chr6:34748730	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.94	-0.3	9.2e-15	Systemic lupus erythematosus;
BRCA	cis	rs34891900	0.507	rs9605364	chr22:18127437	G/A	cg19898043	chr22:18121309	BCL2L13	0.45	8.93	0.33	4.6e-18	Sum neutrophil eosinophil counts;
BRCA	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-11.07	-0.4	3.66e-26	Longevity;
BRCA	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg20090143	chr19:45452003	APOC2	0.27	8.04	0.3	4.46e-15	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	1.98e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg01420254	chr6:26195488	NA	0.59	9.16	0.34	6.84e-19	Gout;Renal underexcretion gout;
BRCA	cis	rs1595825	0.786	rs75415672	chr2:198535679	G/A	cg19156104	chr2:198669113	PLCL1	-0.44	-8.36	-0.31	3.9e-16	Ulcerative colitis;
BRCA	cis	rs8016982	0.657	rs8021125	chr14:81704787	C/T	cg01989461	chr14:81687754	GTF2A1	-0.59	-14.06	-0.49	2.56e-39	Schizophrenia;
BRCA	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18876405	chr7:65276391	NA	-0.5	-11.07	-0.4	3.5e-26	Aortic root size;
BRCA	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00166722	chr3:10149974	C3orf24	0.65	12.84	0.45	9.71e-34	Alzheimer's disease;
BRCA	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg17063962	chr7:91808500	NA	-0.51	-11.61	-0.42	2.13e-28	Breast cancer;
BRCA	cis	rs1941023	0.503	rs4939350	chr11:60136243	C/G	cg08716584	chr11:60157161	MS4A7	-0.44	-10.25	-0.38	6.36e-23	Congenital heart disease (maternal effect);
BRCA	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg13877915	chr19:58951672	ZNF132	0.45	10.35	0.38	2.6e-23	Uric acid clearance;
BRCA	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg11843238	chr5:131593191	PDLIM4	0.35	7.83	0.3	2e-14	Breast cancer;
BRCA	cis	rs1691799	0.899	rs1168310	chr12:66726355	A/G	cg16791601	chr12:66731901	HELB	0.63	16.64	0.55	6.11e-52	White blood cell count (basophil);
BRCA	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg20019720	chr6:154832845	CNKSR3	0.56	13.06	0.46	1.06e-34	Lipoprotein (a) levels;
BRCA	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg08601574	chr20:25228251	PYGB	-0.34	-8.19	-0.31	1.4e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg22153463	chr1:85462885	MCOLN2	-0.62	-11.15	-0.4	1.63e-26	Serum sulfate level;
BRCA	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg26116260	chr4:7069785	GRPEL1	0.9	22.98	0.67	1.27e-85	Monocyte percentage of white cells;
BRCA	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg09307838	chr4:120376055	NA	0.63	13.63	0.47	2.45e-37	Corneal astigmatism;
BRCA	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	17.97	0.58	9.44e-59	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs9560113	1.000	rs9555805	chr13:112179765	C/T	cg10483660	chr13:112241077	NA	0.31	7.84	0.3	1.91e-14	Menarche (age at onset);
BRCA	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg23887609	chr12:130822674	PIWIL1	0.42	9.14	0.34	8.42e-19	Menopause (age at onset);
BRCA	trans	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.48	-10.78	-0.39	5.19e-25	Brugada syndrome;
BRCA	trans	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg16011800	chr17:1958478	HIC1	0.5	8.16	0.31	1.74e-15	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs8028182	0.636	rs8029112	chr15:75808972	T/C	cg20655648	chr15:75932815	IMP3	0.42	8.06	0.3	3.87e-15	Sudden cardiac arrest;
BRCA	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg22563815	chr15:78856949	CHRNA5	-0.36	-8.48	-0.32	1.52e-16	Sudden cardiac arrest;
BRCA	cis	rs4474465	0.646	rs10751297	chr11:78278567	C/T	cg27205649	chr11:78285834	NARS2	0.4	13.69	0.48	1.37e-37	Alzheimer's disease (survival time);
BRCA	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg09904177	chr6:26538194	HMGN4	0.53	15.82	0.53	8.05e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs939658	0.805	rs36068099	chr15:79438598	G/C	cg17916960	chr15:79447300	NA	-0.43	-11.02	-0.4	5.66e-26	Refractive error;
BRCA	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	11.24	0.41	7.36e-27	Multiple sclerosis;
BRCA	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg22535103	chr8:58192502	C8orf71	-0.46	-8.09	-0.3	3.08e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs78707713	0.560	rs12784882	chr10:71230334	C/G	cg12610070	chr10:71211762	TSPAN15	-0.33	-10.03	-0.37	4.34e-22	Venous thromboembolism;
BRCA	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.49	-0.32	1.47e-16	Monocyte percentage of white cells;
BRCA	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.54	-0.32	9.62e-17	Total body bone mineral density;
BRCA	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg24101359	chr6:42928495	GNMT	0.54	12.83	0.45	1.04e-33	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.41	0.32	2.59e-16	Corneal astigmatism;
BRCA	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg06115741	chr20:33292138	TP53INP2	0.5	10.91	0.4	1.59e-25	Coronary artery disease;
BRCA	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg00666640	chr1:248458726	OR2T12	0.3	8.38	0.31	3.3e-16	Common traits (Other);
BRCA	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg24110177	chr3:50126178	RBM5	-0.53	-15.91	-0.53	2.93e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs12410462	0.901	rs16847844	chr1:227638110	A/G	cg04117972	chr1:227635322	NA	0.44	8.07	0.3	3.62e-15	Major depressive disorder;
BRCA	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg14019146	chr3:50243930	SLC38A3	-0.53	-13.03	-0.46	1.33e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	20.88	0.64	3.37e-74	Nonalcoholic fatty liver disease;
BRCA	cis	rs10046574	0.831	rs77819442	chr7:135072552	C/T	cg27474649	chr7:135195673	CNOT4	0.59	7.93	0.3	9.85e-15	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg16586182	chr3:47516702	SCAP	-0.55	-12.44	-0.44	5.89e-32	Colorectal cancer;
BRCA	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg23711669	chr6:146136114	FBXO30	-0.78	-17.76	-0.57	1.16e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg10223061	chr2:219282414	VIL1	-0.27	-8.08	-0.3	3.13e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg11663144	chr21:46675770	NA	-0.57	-13.58	-0.47	4.45e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11984145	1.000	rs73121381	chr7:38864327	A/G	cg19327137	chr7:38886074	VPS41	0.5	9.14	0.34	8.08e-19	Cognitive performance;
BRCA	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-15.27	-0.52	4.04e-45	Parkinson's disease;
BRCA	cis	rs6484504	0.600	rs10835763	chr11:31345574	G/A	cg14844989	chr11:31128820	NA	0.45	9.63	0.36	1.33e-20	Red blood cell count;
BRCA	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg00757033	chr12:89920650	WDR51B	0.48	9.31	0.35	1.97e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg20637307	chr2:213403960	ERBB4	0.49	10.43	0.38	1.23e-23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg08601574	chr20:25228251	PYGB	-0.35	-8.51	-0.32	1.24e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg05343316	chr1:45956843	TESK2	0.69	14.37	0.49	9.34e-41	Platelet count;
BRCA	cis	rs3771570	0.901	rs3821285	chr2:242421314	A/G	cg21155796	chr2:242212141	HDLBP	-0.49	-8.63	-0.32	4.83e-17	Prostate cancer;
BRCA	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08045932	chr20:61659980	NA	0.5	11.51	0.41	5.25e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg11663144	chr21:46675770	NA	-0.5	-10.2	-0.37	9.97e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg27411982	chr8:10470053	RP1L1	-0.32	-8.13	-0.31	2.22e-15	Neuroticism;
BRCA	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03188948	chr7:1209495	NA	0.62	12.87	0.45	7.41e-34	Longevity;Endometriosis;
BRCA	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg19318889	chr4:1322082	MAEA	0.48	10.21	0.37	8.9e-23	Longevity;
BRCA	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg23131131	chr22:24373011	LOC391322	-0.48	-11.44	-0.41	1.06e-27	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2625529	0.529	rs1552133	chr15:72232897	T/A	cg16672083	chr15:72433130	SENP8	0.67	15.81	0.53	9.1e-48	Red blood cell count;
BRCA	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg26116260	chr4:7069785	GRPEL1	-0.85	-16.84	-0.55	6e-53	Monocyte percentage of white cells;
BRCA	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg10729496	chr3:10149963	C3orf24	0.48	9.07	0.34	1.41e-18	Alzheimer's disease;
BRCA	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg21017887	chr14:105400489	NA	0.66	17.48	0.57	3.47e-56	Rheumatoid arthritis;
BRCA	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg18446336	chr7:2847575	GNA12	-0.35	-8.26	-0.31	8.65e-16	Height;
BRCA	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	13.82	0.48	3.34e-38	Lymphocyte counts;
BRCA	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg02544614	chr20:61657117	NA	0.29	8.22	0.31	1.12e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.25	0.34	3.23e-19	Tonsillectomy;
BRCA	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg20887711	chr4:1340912	KIAA1530	0.59	13.12	0.46	5.67e-35	Longevity;
BRCA	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	26.42	0.72	1.58e-104	Chronic sinus infection;
BRCA	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg17971929	chr21:40555470	PSMG1	0.74	15.7	0.53	3.07e-47	Cognitive function;
BRCA	cis	rs72781680	0.611	rs6720131	chr2:24364736	C/T	cg06627628	chr2:24431161	ITSN2	-0.53	-8.38	-0.31	3.3e-16	Lymphocyte counts;
BRCA	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg26031613	chr14:104095156	KLC1	-0.42	-8.37	-0.31	3.52e-16	Schizophrenia;
BRCA	cis	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg06521331	chr12:34319734	NA	-0.61	-11.18	-0.4	1.2e-26	Morning vs. evening chronotype;
BRCA	cis	rs11605275	1.000	rs11604179	chr11:20024759	G/A	cg14835545	chr11:20032148	NAV2	-0.67	-9.25	-0.34	3.21e-19	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs17818399	0.815	rs17768138	chr2:46868217	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.44	7.81	0.3	2.4e-14	Height;
BRCA	cis	rs7727544	0.582	rs3805683	chr5:131535125	T/G	cg14196790	chr5:131705035	SLC22A5	0.37	9.1	0.34	1.18e-18	Blood metabolite levels;
BRCA	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg04450456	chr4:17643702	FAM184B	-0.36	-9.37	-0.35	1.21e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1451375	0.652	rs7803788	chr7:50625898	A/G	cg18232548	chr7:50535776	DDC	-0.38	-8.05	-0.3	4.1e-15	Malaria;
BRCA	cis	rs6060717	0.536	rs11697024	chr20:34546500	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.01	-0.3	5.63e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg25358565	chr5:93447407	FAM172A	0.69	11.87	0.42	1.73e-29	Diabetic retinopathy;
BRCA	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg11584989	chr19:19387371	SF4	0.64	13.48	0.47	1.25e-36	Bipolar disorder;
BRCA	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	11.83	0.42	2.57e-29	Schizophrenia;
BRCA	cis	rs2066819	1.000	rs116849218	chr12:56683975	C/T	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	trans	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg13565492	chr6:43139072	SRF	-0.79	-11.0	-0.4	6.8e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-10.48	-0.38	8.13e-24	Monocyte percentage of white cells;
BRCA	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg12258179	chr19:49232187	RASIP1	-0.32	-7.81	-0.3	2.36e-14	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
BRCA	cis	rs1971762	0.522	rs10747680	chr12:54077776	T/G	cg23533419	chr12:54090519	NA	-0.33	-8.3	-0.31	6.05e-16	Height;
BRCA	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg20628663	chr10:43360327	NA	0.71	13.83	0.48	3.04e-38	Blood protein levels;
BRCA	cis	rs34779708	0.966	rs17591857	chr10:35499043	A/G	cg03585969	chr10:35415529	CREM	-0.49	-10.39	-0.38	1.84e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg13852791	chr20:30311386	BCL2L1	0.79	15.2	0.52	9.18e-45	Mean corpuscular volume;
BRCA	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg07262247	chr5:131593730	PDLIM4	0.36	8.04	0.3	4.4e-15	Acylcarnitine levels;
BRCA	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg23033748	chr14:75592666	NEK9	-0.34	-8.11	-0.31	2.64e-15	Height;
BRCA	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.92	0.4	1.38e-25	Bipolar disorder;
BRCA	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg05347473	chr6:146136440	FBXO30	-0.42	-8.24	-0.31	9.99e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg25358565	chr5:93447407	FAM172A	1.22	18.6	0.59	4.89e-62	Diabetic retinopathy;
BRCA	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg15017067	chr4:17643749	FAM184B	0.29	9.0	0.34	2.56e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4629710	0.568	rs9492880	chr6:131565962	G/T	cg12606694	chr6:131520996	AKAP7	0.49	10.43	0.38	1.21e-23	Multiple myeloma (IgH translocation);
BRCA	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg02153584	chr22:29168773	CCDC117	0.54	11.1	0.4	2.68e-26	Lymphocyte counts;
BRCA	cis	rs35123781	1.000	rs682164	chr5:139058589	A/G	cg05227215	chr5:139057496	CXXC5	0.34	8.33	0.31	5e-16	Schizophrenia;
BRCA	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	11.13	0.4	1.93e-26	Platelet count;
BRCA	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg03585969	chr10:35415529	CREM	0.49	10.31	0.38	3.73e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.97	21.49	0.65	1.62e-77	Lymphocyte percentage of white cells;
BRCA	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00166722	chr3:10149974	C3orf24	0.56	11.16	0.4	1.5e-26	Alzheimer's disease;
BRCA	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	16.12	0.54	2.49e-49	Platelet count;
BRCA	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg13256891	chr4:100009986	ADH5	0.53	9.79	0.36	3.62e-21	Smoking initiation;
BRCA	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13732083	chr21:47605072	C21orf56	-0.39	-7.93	-0.3	9.86e-15	Testicular germ cell tumor;
BRCA	cis	rs939658	0.805	rs35484723	chr15:79441032	A/G	cg17916960	chr15:79447300	NA	-0.43	-10.96	-0.4	9.69e-26	Refractive error;
BRCA	cis	rs6684514	1.000	rs11264462	chr1:156241728	G/A	cg16558208	chr1:156270281	VHLL	0.36	8.03	0.3	4.59e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg24069376	chr3:38537580	EXOG	0.32	8.93	0.33	4.53e-18	Electrocardiographic conduction measures;
BRCA	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg14675211	chr2:100938903	LONRF2	0.52	11.82	0.42	2.63e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs6772849	0.930	rs12630379	chr3:128370204	G/C	cg16766828	chr3:128327626	NA	-0.4	-8.86	-0.33	7.7e-18	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs858239	0.601	rs7805206	chr7:23160210	C/T	cg23682824	chr7:23144976	KLHL7	0.38	10.2	0.37	9.44e-23	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg19336497	chr11:14380999	RRAS2	-0.48	-11.94	-0.43	8.6e-30	Sense of smell;
BRCA	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg08807101	chr21:30365312	RNF160	0.4	8.52	0.32	1.14e-16	Cognitive test performance;
BRCA	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg24977027	chr2:88469347	THNSL2	0.56	9.38	0.35	1.12e-19	Plasma clusterin levels;
BRCA	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg18230493	chr5:56204884	C5orf35	-0.43	-8.77	-0.33	1.61e-17	Coronary artery disease;
BRCA	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23583168	chr7:148888333	NA	-0.79	-18.98	-0.6	4.88e-64	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7246657	0.722	rs2909098	chr19:38204248	G/A	cg14683738	chr19:37701593	ZNF585B	-0.47	-8.04	-0.3	4.51e-15	Coronary artery calcification;
BRCA	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	16.54	0.55	2.16e-51	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.75	-13.3	-0.47	8.56e-36	Gut microbiome composition (summer);
BRCA	cis	rs1003719	0.715	rs2252893	chr21:38507572	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.19	-0.49	6.29e-40	Eye color traits;
BRCA	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg24130564	chr14:104152367	KLC1	-0.34	-7.91	-0.3	1.17e-14	Body mass index;
BRCA	cis	rs11030122	0.673	rs4910590	chr11:4018619	C/T	cg18678763	chr11:4115507	RRM1	-0.35	-7.85	-0.3	1.81e-14	Mean platelet volume;Platelet distribution width;
BRCA	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg15704280	chr7:45808275	SEPT13	0.69	13.07	0.46	8.79e-35	Coronary artery disease;
BRCA	cis	rs1011018	0.628	rs73158616	chr7:139438551	T/C	cg03224163	chr7:139420300	HIPK2	-0.52	-9.03	-0.34	1.96e-18	Systolic blood pressure;
BRCA	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.44	-8.88	-0.33	6.8e-18	Tonsillectomy;
BRCA	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg21045802	chr8:109455806	TTC35	0.38	8.01	0.3	5.38e-15	Dupuytren's disease;
BRCA	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg24829409	chr8:58192753	C8orf71	-0.44	-8.67	-0.32	3.52e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg08917208	chr2:24149416	ATAD2B	1.12	15.82	0.53	7.88e-48	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg03676636	chr4:99064102	C4orf37	0.21	8.05	0.3	4.14e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg05340658	chr4:99064831	C4orf37	0.66	16.1	0.54	3.26e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.5	0.63	3.81e-72	Chronic sinus infection;
BRCA	cis	rs4363385	0.818	rs6661791	chr1:152994113	G/A	cg24667326	chr1:152973720	SPRR3	-0.32	-8.88	-0.33	6.73e-18	Inflammatory skin disease;
BRCA	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	11.65	0.42	1.39e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg11608241	chr8:8085544	FLJ10661	0.33	9.19	0.34	5.32e-19	Parkinson's disease;
BRCA	cis	rs13102973	0.965	rs6838419	chr4:135875682	T/C	cg14419869	chr4:135874104	NA	-0.59	-13.02	-0.46	1.53e-34	Subjective well-being;
BRCA	trans	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.27	0.31	7.5e-16	Mean corpuscular volume;
BRCA	cis	rs3784262	0.669	rs1061278	chr15:58246029	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.18	-0.37	1.15e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs2712184	0.967	rs11892032	chr2:217668981	G/A	cg05032264	chr2:217675019	NA	-0.43	-10.73	-0.39	8.15e-25	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs1468333	1.000	rs2967784	chr5:137539239	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.43	8.56	0.32	8.09e-17	Resting heart rate;
BRCA	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg23788917	chr6:8435910	SLC35B3	0.47	10.31	0.38	3.56e-23	Motion sickness;
BRCA	trans	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg09719594	chr16:21412588	NA	-0.32	-8.0	-0.3	6.07e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg09021430	chr5:549028	NA	-0.64	-15.17	-0.51	1.26e-44	Obesity-related traits;
BRCA	cis	rs71520386	0.530	rs10256628	chr7:22883259	G/C	cg04907244	chr7:22894795	SNORD93	0.37	7.92	0.3	1.03e-14	Fibrinogen levels;
BRCA	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.9e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg20701182	chr2:24300061	SF3B14	0.57	8.95	0.33	3.98e-18	Lymphocyte counts;
BRCA	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-10.56	-0.39	3.93e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-11.7	-0.42	9.09e-29	Gut microbiome composition (summer);
BRCA	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-8.15	-0.31	1.92e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.73	0.33	2.2e-17	Personality dimensions;
BRCA	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg14196790	chr5:131705035	SLC22A5	0.4	10.49	0.38	7.4e-24	Blood metabolite levels;
BRCA	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg17971929	chr21:40555470	PSMG1	-0.47	-10.28	-0.38	4.88e-23	Menarche (age at onset);
BRCA	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg18131467	chr2:239335373	ASB1	0.96	35.03	0.81	7.62e-151	Multiple system atrophy;
BRCA	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg18230493	chr5:56204884	C5orf35	-0.68	-13.49	-0.47	1.11e-36	Initial pursuit acceleration;
BRCA	trans	rs57046232	0.552	rs6054184	chr20:6354592	A/G	cg21095983	chr6:86352623	SYNCRIP	0.38	7.96	0.3	7.97e-15	Colorectal cancer;
BRCA	cis	rs2346177	0.875	rs2166745	chr2:46646879	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.39	8.05	0.3	3.94e-15	HDL cholesterol;
BRCA	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg01475735	chr3:40494733	NA	0.45	9.27	0.34	2.84e-19	Renal cell carcinoma;
BRCA	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.77	0.33	1.61e-17	Iron status biomarkers;
BRCA	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg21782813	chr7:2030301	MAD1L1	0.43	11.51	0.41	5.65e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-10.68	-0.39	1.34e-24	Mean corpuscular volume;
BRCA	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.72	16.99	0.56	1.03e-53	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs6977660	1.000	rs7812001	chr7:19803323	A/G	cg07541023	chr7:19748670	TWISTNB	-0.44	-8.16	-0.31	1.85e-15	Thyroid stimulating hormone;
BRCA	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12667521	chr19:29218732	NA	0.47	7.92	0.3	1.07e-14	Methadone dose in opioid dependence;
BRCA	cis	rs9309711	0.961	rs11692184	chr2:3480710	C/T	cg16153549	chr2:3496821	NA	-0.38	-9.03	-0.34	1.95e-18	Neurofibrillary tangles;
BRCA	cis	rs534126	0.736	rs10239488	chr7:142949599	C/G	cg22531018	chr7:142981779	TMEM139	0.48	10.82	0.39	3.44e-25	Cancer;
BRCA	cis	rs12474201	0.925	rs17822294	chr2:46960004	G/A	cg06386533	chr2:46925753	SOCS5	0.86	18.92	0.6	9.79e-64	Height;
BRCA	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg24006582	chr15:45444508	DUOX1	-0.56	-11.55	-0.42	3.82e-28	Uric acid levels;
BRCA	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-9.25	-0.34	3.45e-19	Bipolar disorder;
BRCA	cis	rs13136331	0.840	rs6857696	chr4:88701522	C/T	cg22416721	chr4:88570574	DMP1	0.49	10.84	0.39	2.97e-25	Sitting height ratio;
BRCA	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg08213375	chr14:104286397	PPP1R13B	0.61	16.09	0.54	3.93e-49	Schizophrenia;
BRCA	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.67	0.55	4.58e-52	Morning vs. evening chronotype;
BRCA	cis	rs7590720	0.819	rs1344694	chr2:216893637	T/G	cg12620499	chr2:216877984	MREG	0.82	24.71	0.7	4.09e-95	Alcohol dependence;
BRCA	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-13.12	-0.46	5.29e-35	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2880765	0.743	rs8028240	chr15:86013248	A/G	cg10818794	chr15:86012489	AKAP13	-0.3	-8.27	-0.31	8.06e-16	Coronary artery disease;
BRCA	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	20.1	0.62	5.33e-70	Smoking behavior;
BRCA	trans	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg25214090	chr10:38739885	LOC399744	0.53	11.71	0.42	7.51e-29	Corneal astigmatism;
BRCA	trans	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	10.54	0.38	4.6e-24	Retinal vascular caliber;
BRCA	cis	rs36051895	0.659	rs7036476	chr9:5063664	T/C	cg02405213	chr9:5042618	JAK2	-0.5	-9.51	-0.35	3.77e-20	Pediatric autoimmune diseases;
BRCA	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg24829409	chr8:58192753	C8orf71	-0.45	-8.69	-0.33	2.99e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11890956	chr21:40555474	PSMG1	0.66	15.42	0.52	7.75e-46	Cognitive function;
BRCA	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg00666640	chr1:248458726	OR2T12	0.31	8.73	0.33	2.19e-17	Common traits (Other);
BRCA	cis	rs12493885	0.818	rs1713817	chr3:153872345	A/G	cg17054900	chr3:154042577	DHX36	0.41	8.02	0.3	4.89e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg15556689	chr8:8085844	FLJ10661	0.33	8.8	0.33	1.26e-17	Neuroticism;
BRCA	cis	rs9649465	0.967	rs12531955	chr7:123377066	G/A	cg04330084	chr7:123175371	IQUB	-0.33	-8.88	-0.33	6.76e-18	Migraine;
BRCA	trans	rs877282	0.945	rs12767287	chr10:787310	A/G	cg22713356	chr15:30763199	NA	1.36	27.32	0.73	1.82e-109	Uric acid levels;
BRCA	cis	rs7715811	1.000	rs7715811	chr5:13769974	C/T	cg07548982	chr5:13769939	DNAH5	-0.39	-8.83	-0.33	9.9e-18	Subclinical atherosclerosis traits (other);
BRCA	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg01324343	chr3:183735012	ABCC5	0.65	15.21	0.52	8.32e-45	Anterior chamber depth;
BRCA	trans	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg06521331	chr12:34319734	NA	-0.48	-9.0	-0.34	2.54e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.35	8.2	0.31	1.28e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs9951602	0.512	rs12455591	chr18:76656028	A/G	cg02800362	chr5:177631904	HNRNPAB	0.77	17.83	0.58	5.16e-58	Obesity-related traits;
BRCA	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.08	-0.34	1.33e-18	Neuroticism;
BRCA	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-18.97	-0.6	5.62e-64	Chronic sinus infection;
BRCA	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03517284	chr6:25882590	NA	-0.51	-11.54	-0.42	4.09e-28	Blood metabolite levels;
BRCA	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.85	20.83	0.64	6.07e-74	Birth weight;
BRCA	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg25754956	chr12:51612065	POU6F1	0.84	17.1	0.56	3.08e-54	Cisplatin-induced ototoxicity;
BRCA	cis	rs16866061	1.000	rs4674916	chr2:225365635	C/A	cg12698349	chr2:225449008	CUL3	0.78	21.64	0.65	2.43e-78	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg00074818	chr8:8560427	CLDN23	0.38	8.44	0.32	2.08e-16	Obesity-related traits;
BRCA	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg07828340	chr4:882639	GAK	0.47	8.1	0.31	2.83e-15	Parkinson's disease;
BRCA	cis	rs1577917	1.000	rs9647603	chr6:86639341	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.39	-0.41	1.77e-27	Response to antipsychotic treatment;
BRCA	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg12373951	chr3:133503437	NA	0.47	10.97	0.4	8.9e-26	Iron status biomarkers;
BRCA	cis	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg06521331	chr12:34319734	NA	-0.51	-10.17	-0.37	1.25e-22	Morning vs. evening chronotype;
BRCA	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg11764359	chr7:65958608	NA	-0.68	-15.19	-0.52	1.04e-44	Aortic root size;
BRCA	cis	rs7586879	1.000	rs10175064	chr2:25117537	T/C	cg04586622	chr2:25135609	ADCY3	0.4	9.34	0.35	1.63e-19	Body mass index;
BRCA	trans	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	14.6	0.5	7.14e-42	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg12698349	chr2:225449008	CUL3	-0.62	-13.51	-0.47	9.24e-37	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.07	0.37	3.16e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7766436	0.614	rs16886471	chr6:22567379	C/T	cg13666174	chr6:22585274	NA	-0.41	-8.66	-0.32	3.86e-17	Coronary artery disease;
BRCA	cis	rs2629540	1.000	rs2629540	chr10:126426148	G/C	cg08799069	chr10:126477246	METTL10	0.51	9.74	0.36	5.45e-21	Cocaine dependence;
BRCA	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.35	0.38	2.69e-23	Motion sickness;
BRCA	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg18016565	chr1:150552671	MCL1	0.36	8.2	0.31	1.28e-15	Melanoma;
BRCA	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg13119609	chr19:45449297	APOC2	0.47	13.08	0.46	8.51e-35	Blood protein levels;
BRCA	cis	rs2559856	0.935	rs7970952	chr12:102081577	C/T	cg12924262	chr12:102091054	CHPT1	0.36	8.12	0.31	2.42e-15	Blood protein levels;
BRCA	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg04362960	chr10:104952993	NT5C2	0.46	10.74	0.39	7.57e-25	Arsenic metabolism;
BRCA	cis	rs1941023	0.584	rs7935082	chr11:60155000	T/C	cg08716584	chr11:60157161	MS4A7	-0.43	-10.46	-0.38	9.28e-24	Congenital heart disease (maternal effect);
BRCA	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg02891314	chr5:179741120	GFPT2	-0.67	-13.48	-0.47	1.23e-36	Height;
BRCA	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg10932868	chr11:921992	NA	0.39	9.35	0.35	1.48e-19	Alzheimer's disease (late onset);
BRCA	cis	rs1595825	0.891	rs4491721	chr2:198521407	C/G	cg19156104	chr2:198669113	PLCL1	-0.42	-8.15	-0.31	1.91e-15	Ulcerative colitis;
BRCA	cis	rs2652834	1.000	rs2729782	chr15:63403354	G/C	cg05507819	chr15:63340323	TPM1	0.45	8.26	0.31	8.19e-16	HDL cholesterol;
BRCA	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.24	8.24	0.31	9.94e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg18016565	chr1:150552671	MCL1	-0.41	-9.39	-0.35	1.07e-19	Blood protein levels;
BRCA	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg22189786	chr22:42395067	WBP2NL	-0.42	-8.3	-0.31	6.05e-16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg02153584	chr22:29168773	CCDC117	0.46	8.16	0.31	1.73e-15	Lymphocyte counts;
BRCA	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg05791153	chr7:19748676	TWISTNB	0.57	10.38	0.38	2.03e-23	Thyroid stimulating hormone;
BRCA	cis	rs1577917	1.000	rs117907570	chr6:86601283	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.4	-10.93	-0.4	1.32e-25	Response to antipsychotic treatment;
BRCA	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.25	-0.44	3.84e-31	Response to antipsychotic treatment;
BRCA	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg05868516	chr6:26286170	HIST1H4H	0.5	11.25	0.41	6.6e-27	Educational attainment;
BRCA	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg09877947	chr5:131593287	PDLIM4	-0.48	-12.25	-0.44	3.88e-31	Acylcarnitine levels;
BRCA	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.44	8.02	0.3	4.93e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-9.2	-0.34	5.1e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2625529	0.526	rs6494997	chr15:72560642	C/T	cg16672083	chr15:72433130	SENP8	0.61	14.64	0.5	4.47e-42	Red blood cell count;
BRCA	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg24692254	chr21:30365293	RNF160	-0.62	-15.86	-0.53	5.22e-48	Dental caries;
BRCA	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg21770322	chr7:97807741	LMTK2	0.43	11.34	0.41	2.83e-27	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	27.65	0.74	2.75e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11764359	chr7:65958608	NA	-0.8	-19.57	-0.61	3.39e-67	Aortic root size;
BRCA	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg23708337	chr7:1209742	NA	0.63	8.84	0.33	8.9e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg08975724	chr8:8085496	FLJ10661	0.42	9.36	0.35	1.32e-19	Mood instability;
BRCA	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg20307385	chr11:47447363	PSMC3	-0.42	-9.65	-0.36	1.16e-20	Subjective well-being;
BRCA	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-11.35	-0.41	2.6e-27	Alzheimer's disease;
BRCA	trans	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg25214090	chr10:38739885	LOC399744	0.54	12.23	0.44	4.84e-31	Corneal astigmatism;
BRCA	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg02527881	chr3:46936655	PTH1R	-0.38	-9.28	-0.34	2.51e-19	Colorectal cancer;
BRCA	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg03060546	chr3:49711283	APEH	0.52	10.85	0.39	2.8e-25	Resting heart rate;
BRCA	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg26408565	chr15:76604113	ETFA	-0.48	-10.3	-0.38	3.92e-23	Blood metabolite levels;
BRCA	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg15556689	chr8:8085844	FLJ10661	-0.34	-8.92	-0.33	4.94e-18	Neuroticism;
BRCA	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg22875332	chr1:76189707	ACADM	0.7	15.05	0.51	4.65e-44	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg20587970	chr11:113659929	NA	-1.19	-21.91	-0.65	9e-80	Hip circumference adjusted for BMI;
BRCA	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	12.39	0.44	9.22e-32	Lung cancer in ever smokers;
BRCA	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg06159980	chr1:16340746	HSPB7	-0.38	-8.74	-0.33	1.98e-17	Dilated cardiomyopathy;
BRCA	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.61	9.23	0.34	4.03e-19	Lung function (FEV1/FVC);
BRCA	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg19784903	chr17:45786737	TBKBP1	-0.46	-11.16	-0.4	1.52e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg09904177	chr6:26538194	HMGN4	0.56	18.19	0.58	6.45e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg20991723	chr1:152506922	NA	0.37	8.32	0.31	5.36e-16	Hair morphology;
BRCA	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00152838	chr16:24741724	TNRC6A	-0.36	-7.98	-0.3	6.88e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg07080220	chr10:102295463	HIF1AN	0.61	14.37	0.49	8.44e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6973256	0.897	rs2991242	chr7:133336459	A/T	cg07491979	chr7:133331646	EXOC4	-0.39	-8.87	-0.33	7.24e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg06784218	chr1:46089804	CCDC17	0.49	11.68	0.42	1.08e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg06064525	chr11:970664	AP2A2	0.32	9.43	0.35	7.33e-20	Alzheimer's disease (late onset);
BRCA	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.49	-0.41	6.45e-28	Platelet count;
BRCA	cis	rs752010	0.811	rs10749836	chr1:42086860	G/C	cg06885757	chr1:42089581	HIVEP3	0.24	8.65	0.32	4.31e-17	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg09915433	chr19:53449742	NA	-0.77	-18.64	-0.59	2.83e-62	Psoriasis;
BRCA	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-10.6	-0.39	2.74e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg17366294	chr4:99064904	C4orf37	0.46	10.95	0.4	1.07e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg24069376	chr3:38537580	EXOG	0.4	11.33	0.41	3.12e-27	Electrocardiographic conduction measures;
BRCA	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.51	0.44	2.88e-32	Electroencephalogram traits;
BRCA	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg27489772	chr12:121021490	NA	0.45	8.03	0.3	4.74e-15	Type 1 diabetes nephropathy;
BRCA	cis	rs3820928	1.000	rs4675115	chr2:227769123	C/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.31	-0.31	5.7e-16	Pulmonary function;
BRCA	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg04025307	chr7:1156635	C7orf50	0.47	9.31	0.35	2.06e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.78e-21	Total body bone mineral density;
BRCA	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg16482183	chr6:26056742	HIST1H1C	0.96	19.06	0.6	1.77e-64	Iron status biomarkers;
BRCA	cis	rs12618769	0.652	rs3820941	chr2:99233781	C/T	cg10123293	chr2:99228465	UNC50	0.42	8.17	0.31	1.66e-15	Bipolar disorder;
BRCA	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg03188948	chr7:1209495	NA	0.48	9.89	0.36	1.53e-21	Longevity;Endometriosis;
BRCA	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.74	10.24	0.38	6.77e-23	Initial pursuit acceleration;
BRCA	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg26384229	chr12:38710491	ALG10B	-0.45	-10.91	-0.4	1.54e-25	Morning vs. evening chronotype;
BRCA	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11764359	chr7:65958608	NA	0.62	13.55	0.47	6.08e-37	Calcium levels;
BRCA	cis	rs2710642	0.815	rs6545971	chr2:63074986	A/T	cg17519650	chr2:63277830	OTX1	0.39	8.6	0.32	6.25e-17	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs17253792	0.598	rs71413578	chr14:56018651	T/C	cg01858014	chr14:56050164	KTN1	-0.61	-7.94	-0.3	9.14e-15	Putamen volume;
BRCA	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg26031613	chr14:104095156	KLC1	-0.61	-13.24	-0.46	1.53e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.83e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7520050	0.933	rs11211203	chr1:46315592	A/G	cg24296786	chr1:45957014	TESK2	0.44	9.9	0.36	1.37e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg03676636	chr4:99064102	C4orf37	0.2	7.82	0.3	2.12e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg25214090	chr10:38739885	LOC399744	-0.42	-9.77	-0.36	4.06e-21	Corneal astigmatism;
BRCA	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg04058563	chr4:185651563	MLF1IP	0.37	8.89	0.33	5.99e-18	Kawasaki disease;
BRCA	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg14784868	chr12:69753453	YEATS4	0.66	18.61	0.59	4.31e-62	Blood protein levels;
BRCA	cis	rs7301016	0.846	rs11174571	chr12:63022329	C/T	cg11441379	chr12:63026424	NA	0.49	8.95	0.33	3.98e-18	IgG glycosylation;
BRCA	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg01028140	chr2:1542097	TPO	-0.58	-11.89	-0.43	1.35e-29	IgG glycosylation;
BRCA	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg03711944	chr11:47377212	SPI1	-0.42	-11.33	-0.41	2.93e-27	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg22705602	chr4:152727874	NA	-0.32	-8.0	-0.3	5.82e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg14983838	chr19:29218262	NA	0.54	10.07	0.37	2.97e-22	Methadone dose in opioid dependence;
BRCA	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg00857998	chr1:205179979	DSTYK	0.44	8.36	0.31	3.95e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs10465746	0.780	rs11163867	chr1:84384847	C/T	cg10977910	chr1:84465055	TTLL7	0.58	12.09	0.43	1.92e-30	Obesity-related traits;
BRCA	cis	rs12617721	0.681	rs10190015	chr2:99018717	A/G	cg10123293	chr2:99228465	UNC50	0.49	8.99	0.33	2.87e-18	Bipolar disorder with mood-incongruent psychosis;
BRCA	trans	rs12517041	0.872	rs78861527	chr5:23283534	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.9	-0.3	1.19e-14	Calcium levels;
BRCA	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg19678392	chr7:94953810	PON1	-0.41	-8.52	-0.32	1.17e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.39	-8.48	-0.32	1.51e-16	IgG glycosylation;
BRCA	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg03433033	chr1:76189801	ACADM	-0.48	-10.2	-0.37	9.42e-23	Daytime sleep phenotypes;
BRCA	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03264133	chr6:25882463	NA	-0.49	-11.01	-0.4	6.3e-26	Blood metabolite levels;
BRCA	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.19	0.31	1.44e-15	Menarche (age at onset);
BRCA	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00166722	chr3:10149974	C3orf24	0.57	10.99	0.4	7.79e-26	Alzheimer's disease;
BRCA	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg02403541	chr12:121454288	C12orf43	0.64	12.1	0.43	1.76e-30	N-glycan levels;
BRCA	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg03342759	chr3:160939853	NMD3	-0.81	-19.0	-0.6	3.77e-64	Parkinson's disease;
BRCA	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg08917208	chr2:24149416	ATAD2B	0.93	13.78	0.48	5.46e-38	Lymphocyte counts;
BRCA	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg25173405	chr17:45401733	C17orf57	0.51	10.74	0.39	7.58e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg01620082	chr3:125678407	NA	-0.91	-10.37	-0.38	2.19e-23	Depression;
BRCA	cis	rs61935443	0.832	rs11107771	chr12:95276844	A/G	cg21533806	chr12:95267307	NA	0.46	8.92	0.33	4.94e-18	Schizophrenia;
BRCA	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.36	0.35	1.31e-19	Morning vs. evening chronotype;
BRCA	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg23625390	chr15:77176239	SCAPER	0.35	7.98	0.3	6.93e-15	Blood metabolite levels;
BRCA	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg21475434	chr5:93447410	FAM172A	0.64	8.55	0.32	9.13e-17	Diabetic retinopathy;
BRCA	cis	rs17641971	0.684	rs7835336	chr8:49957895	A/G	cg00325661	chr8:49890786	NA	0.38	10.51	0.38	6.06e-24	Blood metabolite levels;
BRCA	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs10501293	1.000	rs2114087	chr11:43133002	G/C	cg03447554	chr11:43094025	NA	-0.47	-8.76	-0.33	1.71e-17	Cognitive performance;
BRCA	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg20933634	chr6:27740509	NA	0.47	8.87	0.33	7.41e-18	Parkinson's disease;
BRCA	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.66	-0.32	3.86e-17	Alzheimer's disease (late onset);
BRCA	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg16680214	chr1:154839983	KCNN3	-0.43	-12.06	-0.43	2.56e-30	Prostate cancer;
BRCA	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	14.73	0.5	1.65e-42	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg08601574	chr20:25228251	PYGB	0.4	9.21	0.34	4.79e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs30380	1.000	rs469758	chr5:96121715	C/T	cg16492584	chr5:96139282	ERAP1	-0.31	-7.88	-0.3	1.46e-14	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg04944784	chr2:26401820	FAM59B	-0.85	-13.17	-0.46	3.18e-35	Gut microbiome composition (summer);
BRCA	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg17063962	chr7:91808500	NA	-0.55	-12.72	-0.45	3.49e-33	Breast cancer;
BRCA	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg06453172	chr10:134556979	INPP5A	-0.6	-11.86	-0.42	1.78e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21385522	chr1:16154831	NA	-0.52	-10.22	-0.37	8.51e-23	Dilated cardiomyopathy;
BRCA	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18876405	chr7:65276391	NA	0.48	10.74	0.39	7.45e-25	Aortic root size;
BRCA	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.18	-0.4	1.22e-26	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg17366294	chr4:99064904	C4orf37	0.44	10.48	0.38	7.72e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7737355	0.947	rs1422871	chr5:130942481	G/A	cg06307176	chr5:131281290	NA	0.54	10.56	0.39	3.96e-24	Life satisfaction;
BRCA	cis	rs754466	0.580	rs1344966	chr10:79534527	T/C	cg17075019	chr10:79541650	NA	-0.84	-20.92	-0.64	1.99e-74	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs3849570	0.732	rs11715625	chr3:81875938	A/T	cg07356753	chr3:81810745	GBE1	-0.4	-9.64	-0.36	1.29e-20	Waist circumference;Body mass index;
BRCA	cis	rs7737355	0.812	rs40991	chr5:131000654	C/A	cg06307176	chr5:131281290	NA	0.53	10.41	0.38	1.51e-23	Life satisfaction;
BRCA	cis	rs6429082	0.818	rs291381	chr1:235641924	A/G	cg26050004	chr1:235667680	B3GALNT2	0.57	14.15	0.49	9.77e-40	Adiposity;
BRCA	cis	rs55883249	0.957	rs62119393	chr2:9718247	C/T	cg23886495	chr2:9695866	ADAM17	0.56	8.19	0.31	1.45e-15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
BRCA	trans	rs9944715	0.954	rs6507677	chr18:43762557	T/C	cg01718231	chr17:29326311	RNF135	0.47	9.46	0.35	5.62e-20	Red cell distribution width;Mean corpuscular volume;
BRCA	trans	rs853679	0.546	rs2232426	chr6:28360659	G/C	cg01620082	chr3:125678407	NA	-0.97	-11.01	-0.4	6.21e-26	Depression;
BRCA	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg08601574	chr20:25228251	PYGB	-0.39	-9.0	-0.34	2.64e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	28.21	0.74	2.43e-114	Chronic sinus infection;
BRCA	cis	rs208520	0.955	rs208532	chr6:66961280	T/A	cg07460842	chr6:66804631	NA	-0.86	-14.32	-0.49	1.47e-40	Exhaled nitric oxide output;
BRCA	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg06618935	chr21:46677482	NA	0.38	8.49	0.32	1.43e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg23711669	chr6:146136114	FBXO30	0.63	14.65	0.5	4.04e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9296092	0.538	rs7761268	chr6:33519300	C/T	cg13560919	chr6:33536144	NA	-0.85	-18.62	-0.59	3.9e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-12.09	-0.43	1.86e-30	Developmental language disorder (linguistic errors);
BRCA	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.59	12.08	0.43	2.1000000000000002e-30	Body mass index (adult);
BRCA	cis	rs1829883	1.000	rs2461971	chr5:98777650	A/G	cg08333243	chr5:99726346	NA	-0.37	-8.81	-0.33	1.18e-17	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg01858014	chr14:56050164	KTN1	-0.79	-11.43	-0.41	1.15e-27	Putamen volume;
BRCA	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg08470875	chr2:26401718	FAM59B	0.71	11.35	0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg03929089	chr4:120376271	NA	0.5	8.33	0.31	5.1e-16	Axial length;
BRCA	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10802521	chr3:52805072	NEK4	-0.31	-8.18	-0.31	1.57e-15	Bipolar disorder;
BRCA	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg21644426	chr2:191273491	MFSD6	-0.43	-11.02	-0.4	5.42e-26	Pulse pressure;
BRCA	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg08085267	chr17:45401833	C17orf57	-0.63	-13.56	-0.47	5.45e-37	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg16482183	chr6:26056742	HIST1H1C	0.41	8.78	0.33	1.49e-17	Iron status biomarkers;
BRCA	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	13.98	0.48	6.3e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg25767906	chr1:53392781	SCP2	-0.47	-10.37	-0.38	2.22e-23	Monocyte count;
BRCA	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg08992911	chr2:238395768	MLPH	0.6	10.16	0.37	1.38e-22	Prostate cancer;
BRCA	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg00677455	chr12:58241039	CTDSP2	0.74	18.02	0.58	5.5e-59	Multiple sclerosis;
BRCA	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.46	-13.66	-0.48	1.87e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg01939980	chr4:1354348	KIAA1530	0.39	10.93	0.4	1.34e-25	Longevity;
BRCA	cis	rs4478858	0.647	rs4949380	chr1:31764160	A/G	cg00250761	chr1:31883323	NA	-0.32	-8.33	-0.31	4.93e-16	Alcohol dependence;
BRCA	cis	rs6772849	0.896	rs9816260	chr3:128352083	A/T	cg16766828	chr3:128327626	NA	-0.39	-8.71	-0.33	2.64e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs6426558	0.537	rs7512409	chr1:227484038	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.47	-9.43	-0.35	7.73e-20	Neutrophil percentage of white cells;
BRCA	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.65	-16.85	-0.55	5.56e-53	Hypertriglyceridemia;
BRCA	trans	rs4596713	0.538	rs10781440	chr9:71762766	A/G	cg16512924	chr15:28394682	HERC2	-0.42	-9.86	-0.36	1.94e-21	Headache;
BRCA	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-14.06	-0.49	2.7e-39	Blood metabolite levels;
BRCA	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg26248373	chr2:1572462	NA	-0.51	-9.5	-0.35	4.05e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg06766960	chr11:133703094	NA	0.51	10.0	0.37	5.75e-22	Childhood ear infection;
BRCA	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg26384229	chr12:38710491	ALG10B	0.64	14.93	0.51	1.8e-43	Bladder cancer;
BRCA	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg26373071	chr5:1325741	CLPTM1L	0.49	12.09	0.43	1.98e-30	Lung cancer;
BRCA	cis	rs2625529	0.641	rs11852789	chr15:72265494	G/C	cg16672083	chr15:72433130	SENP8	-0.85	-17.56	-0.57	1.2e-56	Red blood cell count;
BRCA	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.14e-19	Total body bone mineral density;
BRCA	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg11905131	chr22:24372483	LOC391322	-0.45	-9.78	-0.36	3.71e-21	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1030877	0.515	rs3828300	chr2:105901107	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.62	-11.14	-0.4	1.88e-26	Obesity-related traits;
BRCA	cis	rs897080	0.552	rs698793	chr2:44685685	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	9.2	0.34	4.85e-19	Height;
BRCA	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.01	0.3	5.63e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7527798	0.614	rs1830762	chr1:207874272	A/G	cg21110645	chr1:207815933	NA	0.28	8.18	0.31	1.59e-15	Erythrocyte sedimentation rate;
BRCA	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg03146154	chr1:46216737	IPP	-0.5	-11.2	-0.41	9.99e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg07636037	chr3:49044803	WDR6	0.97	29.41	0.76	6.97e-121	Parkinson's disease;
BRCA	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg15212455	chr7:39170539	POU6F2	0.48	10.62	0.39	2.16e-24	IgG glycosylation;
BRCA	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	12.02	0.43	3.79e-30	Multiple sclerosis;
BRCA	cis	rs700651	0.752	rs7592556	chr2:198891021	G/A	cg00792783	chr2:198669748	PLCL1	0.43	9.56	0.35	2.43e-20	Intracranial aneurysm;
BRCA	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg21918786	chr6:109611834	NA	-0.44	-11.95	-0.43	7.9e-30	Reticulocyte fraction of red cells;
BRCA	cis	rs9341808	0.683	rs7771449	chr6:80919977	C/T	cg08355045	chr6:80787529	NA	0.39	9.83	0.36	2.45e-21	Sitting height ratio;
BRCA	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg18904891	chr8:8559673	CLDN23	0.61	12.14	0.43	1.19e-30	Obesity-related traits;
BRCA	trans	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg06521331	chr12:34319734	NA	-0.47	-8.35	-0.31	4.12e-16	Bladder cancer;
BRCA	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg14349672	chr11:133703707	NA	-0.42	-9.17	-0.34	6.16e-19	Childhood ear infection;
BRCA	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.6	-12.42	-0.44	6.85e-32	Lung cancer;
BRCA	trans	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg13565492	chr6:43139072	SRF	-0.7	-9.93	-0.37	1.09e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10465746	0.658	rs980418	chr1:84365653	T/G	cg10977910	chr1:84465055	TTLL7	0.59	12.66	0.45	6.17e-33	Obesity-related traits;
BRCA	cis	rs13223928	0.536	rs12700594	chr7:3156701	G/A	cg19214707	chr7:3157722	NA	0.45	11.32	0.41	3.46e-27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
BRCA	trans	rs6479891	0.818	rs9415700	chr10:65145565	C/T	cg14819942	chr15:35414228	NA	0.36	8.77	0.33	1.57e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-9.3	-0.35	2.13e-19	Colorectal cancer;
BRCA	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg17691542	chr6:26056736	HIST1H1C	0.48	9.84	0.36	2.36e-21	Height;
BRCA	cis	rs2249625	0.844	rs1830339	chr6:72877600	G/A	cg18830697	chr6:72922368	RIMS1	-0.38	-8.18	-0.31	1.49e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	trans	rs208520	0.690	rs207082	chr6:66773796	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.08	-0.64	2.77e-75	Exhaled nitric oxide output;
BRCA	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg18904891	chr8:8559673	CLDN23	0.65	12.91	0.45	4.83e-34	Obesity-related traits;
BRCA	cis	rs9381107	0.932	rs34030781	chr6:9451449	C/T	cg14735645	chr6:9486422	NA	-0.45	-7.92	-0.3	1.09e-14	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg14186256	chr22:23484241	RTDR1	0.74	21.07	0.64	3.24e-75	Bone mineral density;
BRCA	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg19622623	chr12:86230825	RASSF9	-0.29	-8.14	-0.31	2.01e-15	Major depressive disorder;
BRCA	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg04455712	chr21:45112962	RRP1B	0.4	10.28	0.38	4.82e-23	Mean corpuscular volume;
BRCA	cis	rs12617721	0.874	rs3754890	chr2:99088624	C/T	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder with mood-incongruent psychosis;
BRCA	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.29	-0.41	4.4e-27	Schizophrenia;
BRCA	cis	rs250677	0.522	rs1432798	chr5:148383345	C/G	cg18129178	chr5:148520854	ABLIM3	-0.49	-9.71	-0.36	6.89e-21	Breast cancer;
BRCA	trans	rs629535	0.773	rs630235	chr8:70033529	T/G	cg21567404	chr3:27674614	NA	1.0	20.78	0.64	1.15e-73	Dupuytren's disease;
BRCA	trans	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.95	-0.37	8.7e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs509477	0.962	rs562412	chr18:32576305	T/C	cg23791764	chr18:32556832	MAPRE2	-0.35	-8.26	-0.31	8.55e-16	Cerebrospinal fluid AB1-42 levels;
BRCA	cis	rs4974559	0.690	rs28515563	chr4:1315123	G/A	cg02980000	chr4:1222292	CTBP1	0.81	13.29	0.47	9.29e-36	Systolic blood pressure;
BRCA	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg16482183	chr6:26056742	HIST1H1C	0.45	8.79	0.33	1.39e-17	Iron status biomarkers;
BRCA	cis	rs7072216	0.770	rs1739	chr10:100176339	A/G	cg26618903	chr10:100175079	PYROXD2	-0.27	-8.06	-0.3	3.65e-15	Metabolite levels;
BRCA	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.51	-0.38	5.89e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg03433033	chr1:76189801	ACADM	-0.42	-8.55	-0.32	9.23e-17	Daytime sleep phenotypes;
BRCA	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg21782813	chr7:2030301	MAD1L1	0.39	10.87	0.39	2.32e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg13175981	chr1:150552382	MCL1	0.53	11.77	0.42	4.36e-29	Tonsillectomy;
BRCA	cis	rs75557865	1	rs75557865	chr3:121652141	G/A	cg20356878	chr3:121714668	ILDR1	0.43	10.08	0.37	2.81e-22	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg18016565	chr1:150552671	MCL1	0.36	8.68	0.32	3.35e-17	Urate levels;
BRCA	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg20891558	chr2:74357851	NA	0.51	12.13	0.43	1.26e-30	Gestational age at birth (maternal effect);
BRCA	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg13010199	chr12:38710504	ALG10B	0.45	9.49	0.35	4.33e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14294708	chr9:37120828	ZCCHC7	1.17	41.64	0.85	3.28e-184	Schizophrenia;
BRCA	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg08738300	chr3:44038990	NA	0.44	8.5	0.32	1.31e-16	Coronary artery disease;
BRCA	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg14582100	chr15:45693742	SPATA5L1	0.37	11.81	0.42	3.07e-29	Homoarginine levels;
BRCA	cis	rs7598759	0.712	rs6740474	chr2:232331831	A/G	cg19187155	chr2:232395269	NMUR1	0.37	7.83	0.3	2.1e-14	Noise-induced hearing loss;
BRCA	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg24296786	chr1:45957014	TESK2	-0.56	-13.15	-0.46	3.9e-35	High light scatter reticulocyte count;
BRCA	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	22.79	0.67	1.39e-84	Chronic sinus infection;
BRCA	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg05863683	chr7:1912471	MAD1L1	0.44	9.89	0.36	1.45e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs17092148	0.887	rs6142199	chr20:33162298	G/C	cg16810054	chr20:33298113	TP53INP2	-0.44	-10.21	-0.37	8.76e-23	Neuroticism;
BRCA	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-9.14	-0.34	8.22e-19	IgG glycosylation;
BRCA	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg11766577	chr21:47581405	C21orf56	0.49	10.68	0.39	1.3e-24	Testicular germ cell tumor;
BRCA	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.08e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg21770322	chr7:97807741	LMTK2	-0.45	-12.37	-0.44	1.16e-31	Breast cancer;
BRCA	cis	rs17401966	1.000	rs1049887	chr1:10460485	T/C	cg03954927	chr1:10346856	KIF1B	0.45	11.97	0.43	6.06e-30	Hepatocellular carcinoma;
BRCA	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg10876282	chr6:28092338	ZSCAN16	0.42	8.3	0.31	6.43e-16	Cardiac Troponin-T levels;
BRCA	cis	rs2041840	0.538	rs6708524	chr2:37572687	C/T	cg25727520	chr2:37576821	QPCT	-0.28	-7.91	-0.3	1.17e-14	Chronic lymphocytic leukemia;
BRCA	cis	rs9287719	0.686	rs10174605	chr2:10725232	G/A	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	5.17e-19	Prostate cancer;
BRCA	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-10.9	-0.4	1.71e-25	Hemoglobin concentration;
BRCA	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg15704280	chr7:45808275	SEPT13	-0.53	-10.26	-0.38	5.58e-23	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs4478858	0.735	rs12134484	chr1:31823741	G/A	cg00250761	chr1:31883323	NA	-0.32	-8.47	-0.32	1.7e-16	Alcohol dependence;
BRCA	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11905131	chr22:24372483	LOC391322	-0.53	-12.12	-0.43	1.47e-30	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.29	0.31	6.45e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg10729496	chr3:10149963	C3orf24	0.49	9.26	0.34	3.05e-19	Alzheimer's disease;
BRCA	cis	rs12711979	0.509	rs10200764	chr2:3827772	C/G	cg17052675	chr2:3827356	NA	-0.71	-24.21	-0.69	2.14e-92	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23708337	chr7:1209742	NA	0.55	11.82	0.42	2.78e-29	Longevity;Endometriosis;
BRCA	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	18.8	0.6	4.4e-63	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11644478	chr21:40555479	PSMG1	-0.48	-10.03	-0.37	4.5e-22	Menarche (age at onset);
BRCA	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.23	7.96	0.3	8.14e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6121246	0.559	rs12479491	chr20:30265450	T/C	cg13852791	chr20:30311386	BCL2L1	0.96	23.14	0.68	1.63e-86	Mean corpuscular hemoglobin;
BRCA	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg23131131	chr22:24373011	LOC391322	-0.45	-10.36	-0.38	2.26e-23	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg08807101	chr21:30365312	RNF160	-0.38	-8.13	-0.31	2.19e-15	Pancreatic cancer;
BRCA	cis	rs10501293	0.917	rs10768914	chr11:43102263	G/A	cg03447554	chr11:43094025	NA	-0.44	-8.43	-0.32	2.33e-16	Cognitive performance;
BRCA	cis	rs698833	0.780	rs2005203	chr2:44541725	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	10.09	0.37	2.67e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-8.16	-0.31	1.77e-15	Coronary artery disease;
BRCA	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg05665937	chr4:1216051	CTBP1	0.41	8.57	0.32	7.56e-17	Obesity-related traits;
BRCA	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.51	0.38	6.01e-24	Motion sickness;
BRCA	cis	rs7539409	0.915	rs761404	chr1:84226766	G/T	cg10977910	chr1:84465055	TTLL7	-0.61	-8.0	-0.3	5.72e-15	Alzheimer's disease;
BRCA	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg22705602	chr4:152727874	NA	-0.31	-8.06	-0.3	3.68e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg21143896	chr7:2802374	GNA12	-0.34	-8.6	-0.32	6.03e-17	Height;
BRCA	cis	rs10501293	0.543	rs4272772	chr11:42989183	T/C	cg03447554	chr11:43094025	NA	0.42	7.96	0.3	7.83e-15	Cognitive performance;
BRCA	cis	rs1904096	0.506	rs114312933	chr4:95216802	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-10.45	-0.38	1.02e-23	Type 2 diabetes;
BRCA	cis	rs13102973	0.965	rs13131455	chr4:135883112	A/C	cg14419869	chr4:135874104	NA	-0.51	-10.74	-0.39	7.45e-25	Subjective well-being;
BRCA	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg09469691	chr10:81107165	PPIF	0.51	10.61	0.39	2.45e-24	Height;
BRCA	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg11502198	chr6:26597334	ABT1	0.49	9.52	0.35	3.45e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg12591125	chr7:1885375	MAD1L1	0.43	8.83	0.33	1.02e-17	Bipolar disorder;
BRCA	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg24692254	chr21:30365293	RNF160	0.79	22.1	0.66	7.47e-81	Dental caries;
BRCA	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg26395211	chr5:140044315	WDR55	0.37	8.43	0.32	2.36e-16	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg15704280	chr7:45808275	SEPT13	-0.7	-14.25	-0.49	3.26e-40	Coronary artery disease;
BRCA	cis	rs4363385	0.818	rs946095	chr1:153006470	T/C	cg21543102	chr1:152974771	SPRR3	-0.28	-7.84	-0.3	1.86e-14	Inflammatory skin disease;
BRCA	cis	rs9463078	0.774	rs12199720	chr6:45307443	C/T	cg25276700	chr6:44698697	NA	0.36	8.2	0.31	1.32e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg13334819	chr7:99746414	C7orf59	-0.43	-9.98	-0.37	6.64e-22	Coronary artery disease;
BRCA	cis	rs6120849	0.707	rs752075	chr20:33591591	C/A	cg24642439	chr20:33292090	TP53INP2	0.58	10.12	0.37	1.91e-22	Protein C levels;
BRCA	cis	rs1555322	0.530	rs2250205	chr20:33867924	C/T	cg17927777	chr20:33865990	NA	0.42	8.04	0.3	4.36e-15	Attention deficit hyperactivity disorder;
BRCA	cis	rs701145	0.585	rs1713828	chr3:153838553	C/T	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.82e-18	Coronary artery disease;
BRCA	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24308560	chr3:49941425	MST1R	-0.4	-8.59	-0.32	6.72e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	9.3	0.35	2.18e-19	Rheumatoid arthritis;
BRCA	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg24558204	chr6:135376177	HBS1L	0.57	15.35	0.52	1.74e-45	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-12.8	-0.45	1.47e-33	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.52	-0.32	1.15e-16	Aortic root size;
BRCA	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg20573242	chr4:122745356	CCNA2	0.49	10.99	0.4	7.79e-26	Type 2 diabetes;
BRCA	cis	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg05901451	chr6:126070800	HEY2	0.39	9.47	0.35	5.21e-20	Endometrial cancer;
BRCA	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg12564285	chr5:131593104	PDLIM4	0.37	10.07	0.37	3.15e-22	Breast cancer;
BRCA	cis	rs7737355	0.947	rs10067982	chr5:130835940	C/G	cg06307176	chr5:131281290	NA	0.53	10.26	0.38	5.52e-23	Life satisfaction;
BRCA	cis	rs877282	1.000	rs877282	chr10:771532	G/A	cg17470449	chr10:769945	NA	0.49	8.68	0.32	3.22e-17	Uric acid levels;
BRCA	cis	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	9.49	0.35	4.65e-20	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg24250549	chr1:154909240	PMVK	-0.61	-14.61	-0.5	6.36e-42	Prostate cancer;
BRCA	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg00631329	chr6:26305371	NA	-0.44	-13.0	-0.46	1.8e-34	Educational attainment;
BRCA	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg26384229	chr12:38710491	ALG10B	0.69	16.21	0.54	9.67e-50	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg15017067	chr4:17643749	FAM184B	0.31	9.64	0.36	1.27e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.43	-9.57	-0.35	2.38e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs13082711	0.911	rs7650165	chr3:27462440	C/T	cg02860705	chr3:27208620	NA	0.54	10.73	0.39	8.49e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.5	11.94	0.43	8.09e-30	Response to bleomycin (chromatid breaks);
BRCA	cis	rs4594175	0.926	rs116372620	chr14:51599682	T/C	cg23942311	chr14:51606299	NA	0.34	8.47	0.32	1.74e-16	Cancer;
BRCA	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg17135325	chr3:160939158	NMD3	0.41	7.93	0.3	9.66e-15	Parkinson's disease;
BRCA	trans	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg26043149	chr18:55253948	FECH	0.56	12.2	0.43	6.54e-31	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs4642101	0.824	rs9835677	chr3:12845158	G/A	cg24848339	chr3:12840334	CAND2	0.41	10.56	0.39	3.86e-24	QRS complex (12-leadsum);
BRCA	cis	rs7523050	0.643	rs12736534	chr1:109399934	T/C	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs13064411	0.735	rs9875025	chr3:113147552	T/C	cg18753928	chr3:113234510	CCDC52	-0.44	-8.77	-0.33	1.64e-17	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg10932868	chr11:921992	NA	0.5	12.8	0.45	1.55e-33	Alzheimer's disease (late onset);
BRCA	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg10169327	chr19:45448959	APOC2	0.31	7.81	0.3	2.28e-14	Blood protein levels;
BRCA	cis	rs4409675	0.576	rs2815707	chr1:28238880	T/C	cg23691781	chr1:28212827	C1orf38	0.32	10.63	0.39	2.04e-24	Corneal astigmatism;
BRCA	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.38	-0.31	3.45e-16	Bipolar disorder;
BRCA	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg03146154	chr1:46216737	IPP	0.51	11.19	0.4	1.09e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg11707556	chr5:10655725	ANKRD33B	0.39	9.23	0.34	3.79e-19	Height;
BRCA	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.35	-8.03	-0.3	4.68e-15	Bipolar disorder;
BRCA	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg08470875	chr2:26401718	FAM59B	-0.76	-12.08	-0.43	2.19e-30	Gut microbiome composition (summer);
BRCA	trans	rs4650994	0.525	rs10913574	chr1:178536482	G/C	cg05059571	chr16:84539110	KIAA1609	-0.54	-12.12	-0.43	1.43e-30	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg24531977	chr5:56204891	C5orf35	-0.41	-8.47	-0.32	1.73e-16	Coronary artery disease;
BRCA	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg19729930	chr2:74357872	NA	0.72	15.09	0.51	3.04e-44	Gestational age at birth (maternal effect);
BRCA	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg03709012	chr19:19516395	GATAD2A	-0.75	-17.01	-0.56	8.07e-54	Tonsillectomy;
BRCA	cis	rs5771242	0.518	rs6010216	chr22:50679471	C/T	cg16473166	chr22:50639996	SELO	0.72	13.46	0.47	1.48e-36	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
BRCA	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg06627628	chr2:24431161	ITSN2	0.78	15.01	0.51	7.53e-44	Asthma;
BRCA	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg27129171	chr3:47204927	SETD2	0.73	17.82	0.58	5.81e-58	Colorectal cancer;
BRCA	cis	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg05901451	chr6:126070800	HEY2	0.39	9.5	0.35	4.27e-20	Endometrial cancer;
BRCA	cis	rs3125734	0.633	rs3852412	chr10:64050288	C/T	cg19640130	chr10:64028056	RTKN2	-0.32	-8.91	-0.33	5.37e-18	Rheumatoid arthritis;
BRCA	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	14.11	0.49	1.47e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs55882075	0.967	rs59666900	chr5:179147641	C/T	cg14593053	chr5:179126677	CANX	0.4	10.09	0.37	2.62e-22	Monocyte percentage of white cells;
BRCA	cis	rs870825	0.616	rs6844588	chr4:185644517	T/G	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg06212747	chr3:49208901	KLHDC8B	0.5	10.33	0.38	3.05e-23	Parkinson's disease;
BRCA	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg25110126	chr1:46999211	NA	0.67	12.79	0.45	1.7e-33	Monobrow;
BRCA	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg18512352	chr11:47633146	NA	-0.33	-7.93	-0.3	1.01e-14	Subjective well-being;
BRCA	cis	rs2712184	0.756	rs2712161	chr2:217662384	G/A	cg05032264	chr2:217675019	NA	-0.35	-8.66	-0.32	3.84e-17	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs6087990	0.835	rs4911106	chr20:31331330	A/G	cg13636640	chr20:31349939	DNMT3B	0.71	21.42	0.65	4.07e-77	Ulcerative colitis;
BRCA	cis	rs3824867	0.920	rs9919526	chr11:47451623	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-10.94	-0.4	1.16e-25	Mean corpuscular hemoglobin;
BRCA	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg21770322	chr7:97807741	LMTK2	0.42	11.16	0.4	1.55e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03517284	chr6:25882590	NA	0.39	8.12	0.31	2.47e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	12.87	0.45	7.21e-34	Lymphocyte counts;
BRCA	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg01262667	chr19:19385393	TM6SF2	0.41	10.73	0.39	8.34e-25	Tonsillectomy;
BRCA	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg15704280	chr7:45808275	SEPT13	0.69	14.18	0.49	6.74e-40	Coronary artery disease;
BRCA	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg00383909	chr3:49044727	WDR6	0.98	15.72	0.53	2.59e-47	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg18811423	chr2:55921094	PNPT1	0.54	14.41	0.5	5.96e-41	Metabolic syndrome;
BRCA	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03264133	chr6:25882463	NA	-0.49	-10.62	-0.39	2.26e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7927771	0.524	rs10458915	chr11:47864392	T/A	cg20307385	chr11:47447363	PSMC3	0.42	9.49	0.35	4.65e-20	Subjective well-being;
BRCA	cis	rs7809950	0.953	rs2520263	chr7:107179119	T/C	cg23024343	chr7:107201750	COG5	-0.41	-9.36	-0.35	1.29e-19	Coronary artery disease;
BRCA	cis	rs9875589	0.509	rs2731332	chr3:14110083	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.97	0.33	3.29e-18	Ovarian reserve;
BRCA	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg05729581	chr11:3078854	CARS	-0.36	-8.72	-0.33	2.42e-17	Longevity;
BRCA	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg08601574	chr20:25228251	PYGB	0.38	9.31	0.35	2e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg08601574	chr20:25228251	PYGB	-0.39	-9.12	-0.34	9.78e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6750047	0.719	rs1583171	chr2:38270107	G/A	cg07380506	chr2:38303506	CYP1B1	0.42	9.61	0.36	1.62e-20	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.35	-8.99	-0.34	2.69e-18	Total body bone mineral density;
BRCA	cis	rs17401966	1.000	rs1339458	chr1:10328338	C/T	cg03954927	chr1:10346856	KIF1B	0.45	13.12	0.46	5.4e-35	Hepatocellular carcinoma;
BRCA	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg26769984	chr7:1090371	C7orf50	0.48	9.1	0.34	1.16e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs1451375	0.959	rs6962356	chr7:50621941	T/C	cg18232548	chr7:50535776	DDC	0.39	9.55	0.35	2.81e-20	Malaria;
BRCA	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg08999081	chr20:33150536	PIGU	0.37	9.32	0.35	1.93e-19	Coronary artery disease;
BRCA	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg10932868	chr11:921992	NA	0.49	12.63	0.45	8.39e-33	Alzheimer's disease (late onset);
BRCA	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg11271282	chr2:238384023	NA	0.45	8.35	0.31	4.16e-16	Prostate cancer;
BRCA	cis	rs698833	0.926	rs1067347	chr2:44672165	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.45	-9.03	-0.34	2.08e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-24.14	-0.69	5.6e-92	Gut microbiome composition (summer);
BRCA	cis	rs7580658	0.545	rs885275	chr2:127951095	T/C	cg16751203	chr2:127950803	CYP27C1	0.28	7.98	0.3	6.69e-15	Protein C levels;
BRCA	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg23711669	chr6:146136114	FBXO30	0.74	17.37	0.57	1.2e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-9.06	-0.34	1.55e-18	Alzheimer's disease (late onset);
BRCA	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg11764359	chr7:65958608	NA	0.65	11.14	0.4	1.9e-26	Aortic root size;
BRCA	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg04025307	chr7:1156635	C7orf50	0.59	9.31	0.35	2e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg06521331	chr12:34319734	NA	-0.48	-9.24	-0.34	3.75e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg08470875	chr2:26401718	FAM59B	0.59	7.94	0.3	9.38e-15	Gut microbiome composition (summer);
BRCA	cis	rs1451375	0.785	rs10278338	chr7:50630270	C/T	cg18232548	chr7:50535776	DDC	0.41	9.79	0.36	3.36e-21	Malaria;
BRCA	trans	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg23762105	chr12:34175262	ALG10	0.35	7.87	0.3	1.49e-14	Morning vs. evening chronotype;
BRCA	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg00757033	chr12:89920650	WDR51B	-0.51	-10.5	-0.38	6.95e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg21226059	chr5:178986404	RUFY1	0.36	8.35	0.31	4.27e-16	Lung cancer;
BRCA	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg11502198	chr6:26597334	ABT1	-0.57	-11.97	-0.43	6.16e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.54	-16.88	-0.56	4.08e-53	Total body bone mineral density;
BRCA	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg14019146	chr3:50243930	SLC38A3	0.44	10.53	0.38	5.05e-24	Body mass index;
BRCA	trans	rs9951602	0.512	rs9946120	chr18:76654548	A/T	cg02800362	chr5:177631904	HNRNPAB	0.78	18.28	0.59	2.2e-60	Obesity-related traits;
BRCA	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg00814883	chr7:100076585	TSC22D4	-0.49	-10.26	-0.38	5.9e-23	Platelet count;
BRCA	cis	rs6878727	0.638	rs170345	chr5:123674517	G/A	cg01806427	chr5:123737813	NA	-0.36	-8.15	-0.31	1.97e-15	Breast cancer;
BRCA	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.42	-7.91	-0.3	1.15e-14	Gut microbiome composition (summer);
BRCA	cis	rs698813	0.851	rs698812	chr2:44703714	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	8.89	0.33	6.18e-18	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.9	0.3	1.19e-14	Axial length;
BRCA	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg15432903	chr11:17409602	KCNJ11	0.7	15.36	0.52	1.55e-45	Type 2 diabetes;
BRCA	cis	rs4742903	0.967	rs7048372	chr9:106859738	T/C	cg21169611	chr9:106856078	SMC2	0.35	9.25	0.34	3.19e-19	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.48e-23	Motion sickness;
BRCA	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18876405	chr7:65276391	NA	0.61	15.02	0.51	6.93e-44	Aortic root size;
BRCA	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg09307838	chr4:120376055	NA	0.67	13.87	0.48	2.09e-38	Corneal astigmatism;
BRCA	cis	rs9828933	0.752	rs13434089	chr3:63948566	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.72	11.99	0.43	5.24e-30	Type 2 diabetes;
BRCA	trans	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg25042112	chr7:64838748	ZNF92	-0.45	-8.23	-0.31	1.03e-15	Pain;
BRCA	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg13736514	chr6:26305472	NA	-0.46	-14.79	-0.5	8.88e-43	Educational attainment;
BRCA	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg18301423	chr5:131593218	PDLIM4	-0.34	-8.7	-0.33	2.88e-17	Breast cancer;
BRCA	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg23711669	chr6:146136114	FBXO30	0.72	17.44	0.57	5.49e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg09904177	chr6:26538194	HMGN4	0.47	14.88	0.51	3.21e-43	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	3.97e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg06784218	chr1:46089804	CCDC17	0.51	12.22	0.44	5.44e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.31	-7.85	-0.3	1.74e-14	Total body bone mineral density;
BRCA	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg12011299	chr4:100065546	ADH4	0.48	10.81	0.39	4e-25	Smoking initiation;
BRCA	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02176678	chr2:219576539	TTLL4	0.46	12.15	0.43	1.04e-30	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg03060546	chr3:49711283	APEH	-0.51	-10.52	-0.38	5.42e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.36	-8.03	-0.3	4.78e-15	Mean platelet volume;
BRCA	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg19628046	chr18:33552617	C18orf21	0.51	10.55	0.39	4.3e-24	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg22920501	chr2:26401640	FAM59B	0.94	16.23	0.54	7.34e-50	Gut microbiome composition (summer);
BRCA	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg22705602	chr4:152727874	NA	-0.32	-8.24	-0.31	9.68e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11764359	chr7:65958608	NA	0.77	17.35	0.57	1.46e-55	Aortic root size;
BRCA	cis	rs6137287	0.668	rs6082329	chr20:21100138	G/T	cg04219410	chr20:21106687	PLK1S1	-0.34	-8.04	-0.3	4.5e-15	Height;
BRCA	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	11.13	0.4	2e-26	Height;
BRCA	cis	rs2066819	1.000	rs2371454	chr12:56647243	A/G	cg26734620	chr12:56694298	CS	-0.88	-10.11	-0.37	2.09e-22	Psoriasis vulgaris;
BRCA	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.6	13.34	0.47	5.62e-36	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg24154853	chr7:158122151	PTPRN2	0.35	8.17	0.31	1.61e-15	Calcium levels;
BRCA	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg04166393	chr7:2884313	GNA12	0.48	10.24	0.38	6.76e-23	Height;
BRCA	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg13319975	chr6:146136371	FBXO30	0.41	9.29	0.34	2.42e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-15.1	-0.51	2.66e-44	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg25817165	chr18:72167213	CNDP2	-0.72	-12.7	-0.45	4.06e-33	Refractive error;
BRCA	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg24130564	chr14:104152367	KLC1	-0.41	-8.77	-0.33	1.58e-17	Reticulocyte count;
BRCA	cis	rs870825	0.929	rs72689260	chr4:185590656	G/T	cg04058563	chr4:185651563	MLF1IP	0.69	11.83	0.42	2.39e-29	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.63	0.39	2.13e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs629535	0.590	rs62513427	chr8:70138891	A/T	cg21567404	chr3:27674614	NA	-0.96	-17.45	-0.57	4.53e-56	Dupuytren's disease;
BRCA	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg12379764	chr21:47803548	PCNT	-0.37	-8.05	-0.3	4.13e-15	Testicular germ cell tumor;
BRCA	cis	rs3741151	0.892	rs2027763	chr11:73035799	A/G	cg17517138	chr11:73019481	ARHGEF17	0.57	9.0	0.34	2.5e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg05340658	chr4:99064831	C4orf37	0.45	10.38	0.38	1.92e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10089	0.552	rs59430737	chr5:127557568	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	9.45	0.35	6.04e-20	Ileal carcinoids;
BRCA	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.43	0.57	5.74e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg10729496	chr3:10149963	C3orf24	0.42	8.19	0.31	1.48e-15	Alzheimer's disease;
BRCA	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg20701182	chr2:24300061	SF3B14	0.71	13.46	0.47	1.49e-36	Lymphocyte counts;
BRCA	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg06623918	chr6:96969491	KIAA0776	0.9	25.74	0.71	9.02e-101	Headache;
BRCA	cis	rs7927771	0.524	rs7122182	chr11:47843133	A/C	cg20307385	chr11:47447363	PSMC3	-0.41	-9.53	-0.35	3.2e-20	Subjective well-being;
BRCA	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.25	-0.31	9.39e-16	Depression;
BRCA	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg10523679	chr1:76189770	ACADM	0.67	12.47	0.44	4.11e-32	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg03929089	chr4:120376271	NA	0.56	9.47	0.35	5.26e-20	Axial length;
BRCA	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg15934090	chr1:100435551	SLC35A3	0.35	8.12	0.31	2.4e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg11833968	chr6:79620685	NA	-0.43	-9.55	-0.35	2.69e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.1	-0.31	2.79e-15	Total body bone mineral density;
BRCA	cis	rs27434	0.583	rs28129	chr5:96155518	G/A	cg16492584	chr5:96139282	ERAP1	-0.51	-12.82	-0.45	1.22e-33	Ankylosing spondylitis;
BRCA	cis	rs858239	0.508	rs10242104	chr7:23220450	C/T	cg23682824	chr7:23144976	KLHL7	0.36	9.05	0.34	1.64e-18	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs637571	0.584	rs594689	chr11:65635559	G/A	cg17712092	chr4:129076599	LARP1B	-0.59	-13.71	-0.48	1.05e-37	Eosinophil percentage of white cells;
BRCA	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg18806716	chr10:30721971	MAP3K8	-0.58	-14.19	-0.49	6.54e-40	Inflammatory bowel disease;
BRCA	cis	rs6580649	0.943	rs1859444	chr12:48399403	T/C	cg24011408	chr12:48396354	COL2A1	0.54	9.25	0.34	3.23e-19	Lung cancer;
BRCA	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg05526886	chr2:227700861	RHBDD1	-0.41	-8.54	-0.32	9.82e-17	Pulmonary function;
BRCA	cis	rs61935443	0.666	rs11107781	chr12:95301086	T/A	cg21533806	chr12:95267307	NA	0.47	8.18	0.31	1.57e-15	Schizophrenia;
BRCA	cis	rs4930561	0.714	rs7950452	chr11:67962407	C/A	cg16338278	chr11:67432957	ALDH3B2	0.44	8.97	0.33	3.37e-18	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg27588902	chr6:42928151	GNMT	-0.3	-10.1	-0.37	2.28e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	1.9e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05535760	chr7:792225	HEATR2	0.84	14.56	0.5	1.1e-41	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg18252515	chr7:66147081	NA	-0.84	-12.14	-0.43	1.2e-30	Diabetic kidney disease;
BRCA	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.83	0.58	4.89e-58	Fuchs's corneal dystrophy;
BRCA	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg06238570	chr21:40685208	BRWD1	-0.4	-8.14	-0.31	2.02e-15	Menarche (age at onset);
BRCA	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg20701182	chr2:24300061	SF3B14	0.55	8.6	0.32	6.09e-17	Lymphocyte counts;
BRCA	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00149659	chr3:10157352	C3orf10	1.06	17.88	0.58	2.77e-58	Alzheimer's disease;
BRCA	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg18252515	chr7:66147081	NA	-1.07	-15.7	-0.53	3.09e-47	Diabetic kidney disease;
BRCA	cis	rs4908768	0.501	rs6577502	chr1:8615577	T/C	cg20416874	chr1:8611966	RERE	-0.29	-8.43	-0.32	2.38e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs7833986	0.534	rs17759244	chr8:57033768	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	12.82	0.45	1.2e-33	Height;
BRCA	cis	rs3820928	0.869	rs2396436	chr2:227795464	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.84	-0.33	8.99e-18	Pulmonary function;
BRCA	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18402987	chr7:1209562	NA	0.6	12.9	0.45	5.41e-34	Longevity;Endometriosis;
BRCA	cis	rs9470366	1.000	rs9470366	chr6:36625562	C/T	cg08179530	chr6:36648295	CDKN1A	0.46	8.93	0.33	4.59e-18	QRS duration;
BRCA	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg03060546	chr3:49711283	APEH	-0.58	-11.9	-0.43	1.23e-29	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.77	-0.42	4.25e-29	Platelet count;
BRCA	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg00800038	chr16:89945340	TCF25	-0.7	-10.62	-0.39	2.23e-24	Skin colour saturation;
BRCA	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg24399712	chr22:39784796	NA	0.59	12.77	0.45	1.98e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs11690935	0.877	rs72890834	chr2:172835802	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.89	-27.13	-0.73	1.94e-108	Schizophrenia;
BRCA	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg22029157	chr1:209979665	IRF6	0.55	11.21	0.41	9.49e-27	Cleft lip with or without cleft palate;
BRCA	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-10.12	-0.37	2e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg03733263	chr8:22462867	KIAA1967	0.69	15.6	0.53	9.83e-47	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg25358565	chr5:93447407	FAM172A	1.18	19.93	0.62	4.39e-69	Diabetic retinopathy;
BRCA	cis	rs1018836	0.812	rs10808619	chr8:91622916	A/T	cg16814680	chr8:91681699	NA	-0.61	-13.64	-0.47	2.41e-37	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg22705602	chr4:152727874	NA	-0.32	-8.22	-0.31	1.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg06784218	chr1:46089804	CCDC17	0.44	10.65	0.39	1.76e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9467773	0.566	rs66972160	chr6:26359306	T/C	cg09904177	chr6:26538194	HMGN4	-0.32	-8.72	-0.33	2.41e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs7178375	1.000	rs4779797	chr15:31208425	C/T	cg04373760	chr16:53404718	NA	-0.47	-9.06	-0.34	1.61e-18	Hypertriglyceridemia;
BRCA	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.35	-9.78	-0.36	3.81e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg21143896	chr7:2802374	GNA12	0.34	8.77	0.33	1.59e-17	Height;
BRCA	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg00071950	chr4:10020882	SLC2A9	0.65	16.24	0.54	6.46e-50	Bone mineral density;
BRCA	trans	rs3857536	0.813	rs9360190	chr6:66942302	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.12	-0.31	2.36e-15	Blood trace element (Cu levels);
BRCA	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg01874867	chr7:94954059	PON1	-0.37	-8.14	-0.31	2.13e-15	Paraoxonase activity;
BRCA	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	12.1	0.43	1.76e-30	Mean platelet volume;
BRCA	cis	rs4363385	0.720	rs1984197	chr1:152962915	C/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.69	-0.33	3.09e-17	Inflammatory skin disease;
BRCA	cis	rs3820928	0.874	rs10176882	chr2:227896432	A/T	cg11843606	chr2:227700838	RHBDD1	-0.36	-7.9	-0.3	1.19e-14	Pulmonary function;
BRCA	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg14349672	chr11:133703707	NA	-0.4	-9.22	-0.34	4.33e-19	Childhood ear infection;
BRCA	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg05347473	chr6:146136440	FBXO30	-0.41	-7.95	-0.3	8.44e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2412459	1.000	rs6492925	chr15:40304170	T/G	cg10636054	chr15:40330586	SRP14	0.53	8.62	0.32	5.25e-17	Response to haloperidol in psychosis;
BRCA	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.39	-0.52	1.04e-45	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg06627628	chr2:24431161	ITSN2	-0.78	-14.63	-0.5	5.26e-42	Asthma;
BRCA	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg14675211	chr2:100938903	LONRF2	0.46	10.71	0.39	1.04e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs965469	1.000	rs6051722	chr20:3274435	A/G	cg25506879	chr20:3388711	C20orf194	-0.54	-10.42	-0.38	1.34e-23	IFN-related cytopenia;
BRCA	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg05347473	chr6:146136440	FBXO30	-0.44	-8.67	-0.32	3.53e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg03684893	chr10:554711	DIP2C	-0.38	-9.15	-0.34	7.41e-19	Psychosis in Alzheimer's disease;
BRCA	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg06618935	chr21:46677482	NA	-0.37	-7.94	-0.3	9e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg16482183	chr6:26056742	HIST1H1C	0.45	8.76	0.33	1.81e-17	Iron status biomarkers;
BRCA	cis	rs6815814	0.950	rs67206233	chr4:38807853	T/C	cg02016764	chr4:38805732	TLR1	-0.6	-9.49	-0.35	4.33e-20	Breast cancer;
BRCA	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg24829409	chr8:58192753	C8orf71	-0.51	-8.34	-0.31	4.71e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg05084668	chr3:125655381	ALG1L	0.85	11.82	0.42	2.65e-29	Blood pressure (smoking interaction);
BRCA	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg20503657	chr10:835505	NA	1.3	21.49	0.65	1.74e-77	Eosinophil percentage of granulocytes;
BRCA	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg15782153	chr7:917662	C7orf20	0.43	10.38	0.38	2.06e-23	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg18301423	chr5:131593218	PDLIM4	0.33	8.59	0.32	6.77e-17	Breast cancer;
BRCA	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg21475434	chr5:93447410	FAM172A	0.72	9.14	0.34	8.25e-19	Diabetic retinopathy;
BRCA	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26314531	chr2:26401878	FAM59B	-0.62	-10.9	-0.4	1.69e-25	Gut microbiome composition (summer);
BRCA	cis	rs877529	0.967	rs6001455	chr22:39547962	C/T	cg12193277	chr22:39547181	CBX7	0.46	12.55	0.44	1.91e-32	Multiple myeloma;
BRCA	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg07395648	chr5:131743802	NA	0.37	8.71	0.33	2.51e-17	Breast cancer;Mosquito bite size;
BRCA	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg23625390	chr15:77176239	SCAPER	0.42	10.41	0.38	1.46e-23	Blood metabolite levels;
BRCA	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg03433033	chr1:76189801	ACADM	0.76	17.39	0.57	9.72e-56	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9815354	0.638	rs17218866	chr3:42017634	T/C	cg03022575	chr3:42003672	ULK4	0.75	9.65	0.36	1.17e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs17818399	0.620	rs1598517	chr2:46857401	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.42	8.29	0.31	6.5e-16	Height;
BRCA	trans	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.36	0.38	2.43e-23	Mean corpuscular volume;
BRCA	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg16576597	chr16:28551801	NUPR1	0.3	8.28	0.31	7.23e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11890956	chr21:40555474	PSMG1	1.04	29.41	0.76	7.29e-121	Cognitive function;
BRCA	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg25664220	chr3:72788482	NA	-0.55	-11.72	-0.42	7.07e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12618769	0.597	rs7593615	chr2:99030598	C/A	cg10123293	chr2:99228465	UNC50	0.4	8.1	0.31	2.75e-15	Bipolar disorder;
BRCA	trans	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-7.81	-0.3	2.3e-14	Menarche (age at onset);
BRCA	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg22713356	chr15:30763199	NA	1.17	23.7	0.68	1.43e-89	Uric acid levels;
BRCA	cis	rs2806561	0.929	rs627304	chr1:23537555	A/G	cg19743168	chr1:23544995	NA	0.45	11.13	0.4	1.94e-26	Height;
BRCA	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg05472934	chr7:22766657	IL6	0.5	12.89	0.45	5.98e-34	Lung cancer;
BRCA	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg05347473	chr6:146136440	FBXO30	-0.41	-8.06	-0.3	3.75e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs72772090	0.539	rs11739020	chr5:96113838	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.57	12.47	0.44	4.15e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg03585969	chr10:35415529	CREM	0.49	10.27	0.38	5.1e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg22920501	chr2:26401640	FAM59B	-0.66	-11.49	-0.41	6.36e-28	Gut microbiome composition (summer);
BRCA	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg14403583	chr14:105418241	AHNAK2	-0.38	-8.97	-0.33	3.39e-18	Rheumatoid arthritis;
BRCA	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg04553112	chr3:125709451	NA	-0.54	-8.12	-0.31	2.34e-15	Blood pressure (smoking interaction);
BRCA	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.77	-0.36	4.24e-21	IgG glycosylation;
BRCA	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg07537917	chr2:241836409	C2orf54	-0.49	-11.59	-0.42	2.41e-28	Urinary metabolites;
BRCA	trans	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.46	-8.69	-0.33	3e-17	Monocyte count;
BRCA	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg24060327	chr5:131705240	SLC22A5	-0.42	-7.9	-0.3	1.2e-14	Acylcarnitine levels;
BRCA	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.11	0.49	1.54e-39	Motion sickness;
BRCA	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg25486957	chr4:152246857	NA	-0.35	-7.81	-0.3	2.37e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg06784218	chr1:46089804	CCDC17	0.49	11.66	0.42	1.25e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg23505145	chr19:12996616	KLF1	0.56	12.69	0.45	4.46e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg20503657	chr10:835505	NA	0.92	14.47	0.5	3.1e-41	Eosinophil percentage of granulocytes;
BRCA	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.55	-0.35	2.8e-20	Tonsillectomy;
BRCA	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg17366294	chr4:99064904	C4orf37	0.51	11.46	0.41	8.52e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8016982	1.000	rs12147118	chr14:81652975	A/C	cg01989461	chr14:81687754	GTF2A1	-0.48	-10.1	-0.37	2.37e-22	Schizophrenia;
BRCA	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.97	-0.33	3.26e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs858239	0.670	rs6967526	chr7:23159241	C/A	cg23682824	chr7:23144976	KLHL7	0.41	10.35	0.38	2.67e-23	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg24642844	chr7:1081250	C7orf50	-0.73	-13.66	-0.48	1.91e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg08501292	chr6:25962987	TRIM38	0.59	8.02	0.3	4.97e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.57	-0.42	2.98e-28	Morning vs. evening chronotype;
BRCA	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg00277334	chr10:82204260	NA	-0.43	-8.47	-0.32	1.74e-16	Post bronchodilator FEV1;
BRCA	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg20307385	chr11:47447363	PSMC3	-0.86	-26.13	-0.72	5.92e-103	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg02659138	chr7:134003124	SLC35B4	0.32	10.09	0.37	2.59e-22	Mean platelet volume;
BRCA	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7131987	0.903	rs7308125	chr12:29425211	T/C	cg09582351	chr12:29534625	ERGIC2	-0.49	-11.87	-0.43	1.61e-29	QT interval;
BRCA	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg26248373	chr2:1572462	NA	-0.49	-9.83	-0.36	2.52e-21	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	16.6	0.55	9.75e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs534126	0.778	rs6464540	chr7:142954903	G/A	cg15652212	chr7:142981776	TMEM139	0.46	10.44	0.38	1.12e-23	Cancer;
BRCA	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg08470875	chr2:26401718	FAM59B	-0.72	-12.37	-0.44	1.15e-31	Gut microbiome composition (summer);
BRCA	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg16099169	chr2:106886729	NA	-0.59	-10.55	-0.39	4.11e-24	Facial morphology (factor 23);
BRCA	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg10932868	chr11:921992	NA	0.5	12.8	0.45	1.55e-33	Alzheimer's disease (late onset);
BRCA	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg12292205	chr6:26970375	C6orf41	0.57	12.66	0.45	6.35e-33	Schizophrenia;
BRCA	cis	rs754466	0.651	rs56138814	chr10:79625795	T/C	cg17075019	chr10:79541650	NA	-0.73	-17.59	-0.57	8.49e-57	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2421770	0.530	rs11033084	chr11:35367408	T/G	cg13971030	chr11:35366721	SLC1A2	-0.43	-9.57	-0.35	2.38e-20	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs72627123	0.500	rs67852564	chr14:74559920	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.54	9.25	0.34	3.44e-19	Morning vs. evening chronotype;
BRCA	cis	rs1568889	1.000	rs16917689	chr11:28064466	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	14.62	0.5	5.52e-42	Bipolar disorder;
BRCA	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg22834771	chr12:69754056	YEATS4	-0.42	-10.46	-0.38	9.51e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg24006582	chr15:45444508	DUOX1	-0.56	-11.55	-0.42	3.82e-28	Uric acid levels;
BRCA	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg12463550	chr7:65579703	CRCP	0.38	8.2	0.31	1.34e-15	Aortic root size;
BRCA	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg22467129	chr15:76604101	ETFA	-0.42	-9.37	-0.35	1.26e-19	Blood metabolite levels;
BRCA	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg21724239	chr8:58056113	NA	0.51	8.73	0.33	2.22e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg21724239	chr8:58056113	NA	-0.6	-9.75	-0.36	5.04e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg18758796	chr5:131593413	PDLIM4	-0.37	-9.37	-0.35	1.24e-19	Acylcarnitine levels;
BRCA	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg14675211	chr2:100938903	LONRF2	0.52	12.14	0.43	1.12e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	11.84	0.42	2.28e-29	Height;
BRCA	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg25173405	chr17:45401733	C17orf57	-0.56	-12.25	-0.44	3.76e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg16339924	chr4:17578868	LAP3	0.63	15.75	0.53	1.72e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg05343316	chr1:45956843	TESK2	-0.58	-11.89	-0.43	1.4e-29	Platelet count;
BRCA	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	ch.11.42038R	chr11:967971	AP2A2	0.52	16.65	0.55	5.42e-52	Alzheimer's disease (late onset);
BRCA	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-9.77	-0.36	4.14e-21	Tonsillectomy;
BRCA	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg04553112	chr3:125709451	NA	-0.55	-8.34	-0.31	4.41e-16	Blood pressure (smoking interaction);
BRCA	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg22431228	chr1:16359049	CLCNKA	-0.43	-9.64	-0.36	1.27e-20	Dilated cardiomyopathy;
BRCA	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg23422044	chr7:1970798	MAD1L1	-0.43	-9.3	-0.35	2.21e-19	Neuroticism;
BRCA	trans	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg26043149	chr18:55253948	FECH	0.39	8.78	0.33	1.46e-17	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17712092	chr4:129076599	LARP1B	0.49	11.95	0.43	7.36e-30	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg24642439	chr20:33292090	TP53INP2	0.52	11.43	0.41	1.14e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg06623918	chr6:96969491	KIAA0776	0.9	25.43	0.71	4.24e-99	Headache;
BRCA	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.43	-9.52	-0.35	3.42e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-11.23	-0.41	7.66e-27	Morning vs. evening chronotype;
BRCA	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg01448562	chr3:133502909	NA	-0.44	-9.85	-0.36	2.02e-21	Iron status biomarkers;
BRCA	cis	rs2997447	0.655	rs1317709	chr1:26384690	A/C	cg19633962	chr1:26362018	EXTL1	-0.51	-9.6	-0.35	1.84e-20	QRS complex (12-leadsum);
BRCA	cis	rs34779708	0.931	rs12767414	chr10:35390193	C/T	cg03585969	chr10:35415529	CREM	0.45	9.53	0.35	3.33e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg04450456	chr4:17643702	FAM184B	-0.35	-9.62	-0.36	1.5e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12348691	0.503	rs7848950	chr9:100612774	T/C	cg13688889	chr9:100608707	NA	-0.49	-9.91	-0.36	1.27e-21	Alopecia areata;
BRCA	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg18964960	chr10:1102726	WDR37	0.63	8.71	0.33	2.65e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs600550	0.528	rs7108307	chr11:59844861	G/T	cg02771260	chr11:59836817	MS4A3	0.54	11.86	0.42	1.91e-29	Lipoprotein-associated phospholipase A2 activity and mass;
BRCA	cis	rs6484504	0.625	rs672396	chr11:31386165	A/G	cg14844989	chr11:31128820	NA	0.44	9.65	0.36	1.14e-20	Red blood cell count;
BRCA	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg11301795	chr4:187892539	NA	0.32	10.5	0.38	6.74e-24	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg25173405	chr17:45401733	C17orf57	-0.57	-12.4	-0.44	8.44e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg08470875	chr2:26401718	FAM59B	0.76	11.99	0.43	4.93e-30	Gut microbiome composition (summer);
BRCA	cis	rs1784581	0.802	rs9365359	chr6:162423945	C/A	cg17173639	chr6:162384350	PARK2	0.38	9.09	0.34	1.18e-18	Itch intensity from mosquito bite;
BRCA	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg07741184	chr6:167504864	NA	0.33	9.82	0.36	2.83e-21	Primary biliary cholangitis;
BRCA	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg07741184	chr6:167504864	NA	0.32	9.21	0.34	4.6e-19	Primary biliary cholangitis;
BRCA	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg07636037	chr3:49044803	WDR6	0.82	22.19	0.66	2.51e-81	Menarche (age at onset);
BRCA	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-18.54	-0.59	9.69e-62	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.82	0.3	2.21e-14	Aortic root size;
BRCA	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg08085267	chr17:45401833	C17orf57	-0.69	-15.3	-0.52	2.9e-45	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg15017067	chr4:17643749	FAM184B	0.29	8.38	0.31	3.27e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg22974920	chr21:40686053	BRWD1	0.4	9.1	0.34	1.11e-18	Cognitive function;
BRCA	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.6	0.39	2.83e-24	Motion sickness;
BRCA	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg06494592	chr3:125709126	NA	-0.51	-8.69	-0.32	3.12e-17	Blood pressure (smoking interaction);
BRCA	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg11814155	chr7:99998594	ZCWPW1	0.47	8.36	0.31	3.8e-16	Platelet count;
BRCA	trans	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg06521331	chr12:34319734	NA	-0.46	-8.54	-0.32	9.43e-17	Bladder cancer;
BRCA	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg05623727	chr3:50126028	RBM5	0.42	10.1	0.37	2.46e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg03585969	chr10:35415529	CREM	0.56	11.55	0.42	3.74e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6545883	0.929	rs3821222	chr2:61713526	C/G	cg15711740	chr2:61764176	XPO1	-0.54	-13.74	-0.48	7.77e-38	Tuberculosis;
BRCA	cis	rs4800452	0.826	rs4800149	chr18:20744254	A/C	cg26136497	chr18:20735537	CABLES1	0.41	9.91	0.36	1.28e-21	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.77e-24	Motion sickness;
BRCA	cis	rs6910061	1.000	rs9468446	chr6:11118718	C/T	cg27233058	chr6:11094804	LOC221710	0.52	9.32	0.35	1.8e-19	Diabetic kidney disease;
BRCA	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg23711669	chr6:146136114	FBXO30	-0.74	-15.52	-0.52	2.51e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg01256987	chr12:42539512	GXYLT1	-0.45	-9.1	-0.34	1.1e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs12541635	0.934	rs4734893	chr8:106990275	T/G	cg10147462	chr8:107024639	NA	0.38	10.14	0.37	1.66e-22	Age of smoking initiation;
BRCA	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg14664628	chr15:75095509	CSK	-0.9	-24.52	-0.7	4.55e-94	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs10754283	0.934	rs10754284	chr1:90113702	A/C	cg21401794	chr1:90099060	LRRC8C	0.46	11.06	0.4	4.04e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs9790314	0.747	rs1841526	chr3:160834682	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-10.33	-0.38	2.95e-23	Morning vs. evening chronotype;
BRCA	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg14835575	chr10:16859367	RSU1	0.66	14.49	0.5	2.46e-41	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg23649088	chr2:200775458	C2orf69	0.51	10.12	0.37	2.07e-22	Osteoporosis;
BRCA	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg15557168	chr22:42548783	NA	0.3	8.38	0.31	3.24e-16	Cognitive function;
BRCA	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg03433033	chr1:76189801	ACADM	0.73	18.72	0.6	1.19e-62	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.99	0.3	6.41e-15	Depression;
BRCA	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.58	9.23	0.34	3.94e-19	Renal function-related traits (BUN);
BRCA	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg11262906	chr1:85462892	MCOLN2	0.48	9.36	0.35	1.3e-19	Serum sulfate level;
BRCA	cis	rs870825	0.616	rs4519838	chr4:185628457	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	16.98	0.56	1.17e-53	Blood protein levels;
BRCA	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg04450456	chr4:17643702	FAM184B	0.38	10.21	0.37	9.28e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg06521331	chr12:34319734	NA	-0.65	-11.92	-0.43	1.01e-29	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.5	0.5	2.03e-41	Motion sickness;
BRCA	trans	rs4714291	0.963	rs4714292	chr6:40003679	A/C	cg02267698	chr19:7991119	CTXN1	0.41	8.09	0.3	2.98e-15	Strep throat;
BRCA	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg11366901	chr6:160182831	ACAT2	0.76	14.89	0.51	2.96e-43	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7809950	1.000	rs7786801	chr7:107085889	C/T	cg23024343	chr7:107201750	COG5	-0.4	-9.25	-0.34	3.2e-19	Coronary artery disease;
BRCA	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg15704280	chr7:45808275	SEPT13	0.83	20.17	0.62	2.09e-70	Coronary artery disease;
BRCA	cis	rs12711979	0.765	rs7559345	chr2:3818523	G/A	cg17052675	chr2:3827356	NA	-0.48	-14.1	-0.49	1.76e-39	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs7809950	1.000	rs3801954	chr7:107117048	C/T	cg23024343	chr7:107201750	COG5	-0.42	-9.9	-0.36	1.39e-21	Coronary artery disease;
BRCA	trans	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg26384229	chr12:38710491	ALG10B	0.51	11.26	0.41	5.83e-27	Morning vs. evening chronotype;
BRCA	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg18806716	chr10:30721971	MAP3K8	-0.61	-14.25	-0.49	3.12e-40	Inflammatory bowel disease;
BRCA	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg15017067	chr4:17643749	FAM184B	0.28	8.46	0.32	1.88e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03352830	chr11:487213	PTDSS2	0.85	12.68	0.45	5.03e-33	Body mass index;
BRCA	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg13319975	chr6:146136371	FBXO30	0.62	14.55	0.5	1.28e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg20503657	chr10:835505	NA	1.05	18.16	0.58	9.5e-60	Eosinophil percentage of granulocytes;
BRCA	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg26384229	chr12:38710491	ALG10B	0.74	16.31	0.54	2.94e-50	Morning vs. evening chronotype;
BRCA	cis	rs13046373	0.507	rs2832959	chr21:31982934	C/T	cg16812893	chr21:31813075	KRTAP15-1	0.39	9.86	0.36	1.86e-21	HDL cholesterol;
BRCA	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	9.14	0.34	8.5e-19	Systemic lupus erythematosus;
BRCA	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg22535103	chr8:58192502	C8orf71	-0.49	-8.67	-0.32	3.61e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.28	-0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs7249921	0.802	rs35746990	chr19:35666857	C/T	cg15419183	chr19:35660584	FXYD5	0.46	10.59	0.39	2.95e-24	Platelet count;
BRCA	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg11584989	chr19:19387371	SF4	0.5	11.21	0.41	9.48e-27	Bipolar disorder;
BRCA	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.69	-11.14	-0.4	1.8e-26	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs77861329	0.748	rs9851576	chr3:52091254	C/T	cg08692210	chr3:52188851	WDR51A	-0.45	-8.77	-0.33	1.67e-17	Macrophage inflammatory protein 1b levels;
BRCA	cis	rs2904967	0.929	rs592050	chr11:65030189	C/G	cg09225861	chr11:65069680	NA	0.39	8.07	0.3	3.62e-15	Mean corpuscular volume;
BRCA	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-12.92	-0.46	4.11e-34	Chronic sinus infection;
BRCA	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.07	23.75	0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg20503657	chr10:835505	NA	1.3	21.76	0.65	5.72e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg16482183	chr6:26056742	HIST1H1C	0.42	9.06	0.34	1.54e-18	Iron status biomarkers;
BRCA	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg17063962	chr7:91808500	NA	0.61	14.52	0.5	1.72e-41	Breast cancer;
BRCA	cis	rs9811920	0.809	rs35422475	chr3:99711545	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.57	-13.93	-0.48	1.1e-38	Axial length;
BRCA	cis	rs9296092	0.521	rs9461886	chr6:33526770	T/C	cg13560919	chr6:33536144	NA	-0.85	-18.69	-0.59	1.6e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg06784218	chr1:46089804	CCDC17	-0.52	-12.68	-0.45	4.88e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.31	-0.38	3.71e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs36051895	0.664	rs12344629	chr9:5109208	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-8.55	-0.32	8.8e-17	Pediatric autoimmune diseases;
BRCA	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.6	9.12	0.34	9.76e-19	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs11976180	1.000	rs4726669	chr7:143758191	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.43	-8.03	-0.3	4.82e-15	Obesity-related traits;
BRCA	trans	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg25214090	chr10:38739885	LOC399744	0.48	10.66	0.39	1.53e-24	Corneal astigmatism;
BRCA	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.59	12.83	0.45	1.09e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs921968	0.565	rs6436070	chr2:219597960	A/G	cg02176678	chr2:219576539	TTLL4	-0.41	-11.07	-0.4	3.46e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg08501292	chr6:25962987	TRIM38	0.59	8.02	0.3	4.97e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs698813	0.763	rs786615	chr2:44590608	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	11.26	0.41	5.7e-27	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs17818399	0.926	rs13032670	chr2:46830794	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.55	10.01	0.37	5.37e-22	Height;
BRCA	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg19743168	chr1:23544995	NA	0.35	8.15	0.31	1.89e-15	Height;
BRCA	trans	rs8073060	0.586	rs225256	chr17:33955756	C/T	cg19694781	chr19:47549865	TMEM160	-1.06	-21.33	-0.64	1.25e-76	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	trans	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.33	-8.79	-0.33	1.33e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg20933634	chr6:27740509	NA	0.47	8.87	0.33	7.41e-18	Parkinson's disease;
BRCA	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg00677455	chr12:58241039	CTDSP2	0.58	13.73	0.48	8.85e-38	Multiple sclerosis;
BRCA	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg22467129	chr15:76604101	ETFA	-0.4	-8.91	-0.33	5.48e-18	Blood metabolite levels;
BRCA	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg02551604	chr5:131831745	NA	-0.39	-14.68	-0.5	2.84e-42	Asthma (sex interaction);
BRCA	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg00106254	chr7:1943704	MAD1L1	-0.32	-8.17	-0.31	1.68e-15	Schizophrenia;
BRCA	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg11833968	chr6:79620685	NA	-0.45	-10.3	-0.38	4.07e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg08888203	chr3:10149979	C3orf24	0.63	11.82	0.42	2.73e-29	Alzheimer's disease;
BRCA	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg11845111	chr2:191398756	TMEM194B	-0.76	-13.92	-0.48	1.2e-38	Diastolic blood pressure;
BRCA	cis	rs9942416	0.660	rs17563686	chr5:74984818	A/T	cg19683494	chr5:74908142	NA	0.48	9.0	0.34	2.64e-18	Age-related disease endophenotypes;
BRCA	cis	rs7551345	0.653	rs7546080	chr1:31696977	G/A	cg19084893	chr1:31688959	NA	-0.46	-10.04	-0.37	4.13e-22	Schizophrenia;
BRCA	trans	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-8.24	-0.31	9.44e-16	Menarche (age at onset);
BRCA	cis	rs80033912	0.640	rs6785832	chr3:49224316	C/T	cg07636037	chr3:49044803	WDR6	0.49	9.64	0.36	1.31e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.5	10.49	0.38	7.65e-24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	16.22	0.54	8.48e-50	Intelligence (multi-trait analysis);
BRCA	cis	rs11958404	0.932	rs111802867	chr5:157424971	G/A	cg05962755	chr5:157440814	NA	0.58	10.55	0.39	4.36e-24	IgG glycosylation;
BRCA	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg00701064	chr4:6280414	WFS1	0.68	17.58	0.57	9.78e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs10779751	1.000	rs2253213	chr1:11265785	A/G	cg08854313	chr1:11322531	MTOR	0.78	15.8	0.53	1.07e-47	Body mass index;
BRCA	cis	rs1198430	1.000	rs1198430	chr1:23755513	C/T	cg19827787	chr1:23763612	ASAP3	-0.33	-8.8	-0.33	1.29e-17	Total cholesterol levels;
BRCA	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.3	0.38	3.95e-23	Bladder cancer;
BRCA	cis	rs2274273	1.000	rs1009977	chr14:55603002	T/G	cg04306507	chr14:55594613	LGALS3	0.32	8.96	0.33	3.65e-18	Protein biomarker;
BRCA	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.13	-0.4	1.98e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg22875332	chr1:76189707	ACADM	0.61	10.5	0.38	6.95e-24	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	9.19	0.34	5.41e-19	Mean platelet volume;
BRCA	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg13010199	chr12:38710504	ALG10B	0.5	10.45	0.38	1.07e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs965469	0.779	rs6051772	chr20:3328654	C/G	cg25506879	chr20:3388711	C20orf194	-0.43	-8.74	-0.33	2.11e-17	IFN-related cytopenia;
BRCA	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg08213375	chr14:104286397	PPP1R13B	0.62	17.8	0.58	7.48e-58	Schizophrenia;
BRCA	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg03433033	chr1:76189801	ACADM	0.75	16.94	0.56	1.86e-53	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg25036284	chr2:26402008	FAM59B	-0.64	-10.64	-0.39	1.96e-24	Gut microbiome composition (summer);
BRCA	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.72	-0.33	2.45e-17	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2882667	0.690	rs700624	chr5:138099021	C/G	cg04439458	chr5:138467593	SIL1	0.31	7.85	0.3	1.74e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4308124	0.708	rs7585313	chr2:111975203	A/G	cg04571233	chr2:111982156	NA	-0.45	-9.65	-0.36	1.16e-20	Vitiligo;
BRCA	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg24562669	chr7:97807699	LMTK2	0.44	11.77	0.42	4.24e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7520050	0.902	rs1355642	chr1:46598903	A/G	cg24296786	chr1:45957014	TESK2	0.39	8.52	0.32	1.14e-16	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26314531	chr2:26401878	FAM59B	-0.79	-12.64	-0.45	7.76e-33	Gut microbiome composition (summer);
BRCA	cis	rs17604090	0.878	rs4457221	chr7:29701774	C/T	cg19413766	chr7:29689036	LOC646762	-0.61	-8.23	-0.31	1.07e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10189230	0.935	rs3755029	chr2:222345820	T/C	cg14652038	chr2:222343519	EPHA4	0.49	13.22	0.46	1.92e-35	Urate levels in lean individuals;
BRCA	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg08888203	chr3:10149979	C3orf24	0.58	11.86	0.42	1.8e-29	Alzheimer's disease;
BRCA	cis	rs9560113	1.000	rs9555812	chr13:112181535	A/G	cg10483660	chr13:112241077	NA	0.32	7.97	0.3	7.17e-15	Menarche (age at onset);
BRCA	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg17366294	chr4:99064904	C4orf37	0.43	9.95	0.37	9.17e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.44	-8.47	-0.32	1.68e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg04691961	chr3:161091175	C3orf57	0.6	14.75	0.5	1.31e-42	Morning vs. evening chronotype;
BRCA	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg15556689	chr8:8085844	FLJ10661	0.37	9.06	0.34	1.56e-18	Retinal vascular caliber;
BRCA	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg10862848	chr6:42927986	GNMT	0.24	8.94	0.33	4.06e-18	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
BRCA	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg04166393	chr7:2884313	GNA12	0.38	8.09	0.3	3.03e-15	Height;
BRCA	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg26769984	chr7:1090371	C7orf50	0.48	9.68	0.36	8.91e-21	Bronchopulmonary dysplasia;
BRCA	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-9.66	-0.36	1.04e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg25457927	chr22:38595422	NA	-0.32	-11.64	-0.42	1.54e-28	Cutaneous nevi;
BRCA	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg08885076	chr2:99613938	TSGA10	0.45	10.61	0.39	2.51e-24	Chronic sinus infection;
BRCA	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg02176678	chr2:219576539	TTLL4	0.4	10.88	0.4	2.13e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg06521331	chr12:34319734	NA	-0.61	-11.11	-0.4	2.37e-26	Morning vs. evening chronotype;
BRCA	cis	rs3767633	0.925	rs2499856	chr1:161926637	C/T	cg09175582	chr1:161736000	ATF6	-0.49	-8.56	-0.32	8.19e-17	IgG glycosylation;
BRCA	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg06238570	chr21:40685208	BRWD1	-0.39	-8.03	-0.3	4.7e-15	Menarche (age at onset);
BRCA	cis	rs6543140	0.964	rs10200081	chr2:103091556	T/C	cg04239558	chr2:103089729	SLC9A4	0.36	9.97	0.37	7.38e-22	Blood protein levels;
BRCA	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg27129171	chr3:47204927	SETD2	-0.68	-16.02	-0.54	8.5e-49	Colorectal cancer;
BRCA	cis	rs9487051	0.768	rs427960	chr6:109524939	C/T	cg21918786	chr6:109611834	NA	-0.35	-8.93	-0.33	4.33e-18	Reticulocyte fraction of red cells;
BRCA	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.0	-0.48	4.88e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26314531	chr2:26401878	FAM59B	0.68	11.42	0.41	1.26e-27	Gut microbiome composition (summer);
BRCA	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.66e-15	Menopause (age at onset);
BRCA	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-9.98	-0.37	6.6e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg11693508	chr17:37793320	STARD3	0.6	11.18	0.4	1.21e-26	Bipolar disorder;
BRCA	trans	rs7178375	1.000	rs12907055	chr15:31204294	C/G	cg04373760	chr16:53404718	NA	0.47	8.81	0.33	1.2e-17	Hypertriglyceridemia;
BRCA	cis	rs4664304	0.620	rs2048437	chr2:160712065	C/T	cg14819504	chr2:160761413	LY75	0.34	8.5	0.32	1.38e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.52	-0.32	1.13e-16	Monocyte percentage of white cells;
BRCA	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-7.88	-0.3	1.39e-14	Colorectal cancer;
BRCA	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg23711669	chr6:146136114	FBXO30	0.64	14.53	0.5	1.48e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7903847	0.642	rs11189177	chr10:99141663	C/T	cg08345082	chr10:99160200	RRP12	-0.3	-8.66	-0.32	3.88e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg12564285	chr5:131593104	PDLIM4	0.35	8.0	0.3	6.03e-15	Breast cancer;
BRCA	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.95	0.58	1.27e-58	Fuchs's corneal dystrophy;
BRCA	cis	rs27434	0.660	rs26493	chr5:96155318	C/T	cg16492584	chr5:96139282	ERAP1	-0.42	-8.3	-0.31	6.27e-16	Ankylosing spondylitis;
BRCA	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg02466173	chr16:30829666	NA	-0.51	-11.16	-0.4	1.53e-26	Multiple myeloma;
BRCA	cis	rs2625529	0.627	rs1037680	chr15:72514319	T/C	cg16672083	chr15:72433130	SENP8	-0.81	-17.23	-0.56	6.67e-55	Red blood cell count;
BRCA	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg18811423	chr2:55921094	PNPT1	0.7	22.52	0.67	3.82e-83	Metabolic syndrome;
BRCA	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg06145435	chr7:1022769	CYP2W1	0.47	8.93	0.33	4.57e-18	Bronchopulmonary dysplasia;
BRCA	trans	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg14791747	chr16:20752902	THUMPD1	0.4	9.79	0.36	3.61e-21	Cognitive test performance;
BRCA	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg04362960	chr10:104952993	NT5C2	0.43	10.09	0.37	2.49e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs10193935	0.901	rs10170082	chr2:42623452	T/C	cg27598129	chr2:42591480	NA	-0.8	-13.51	-0.47	9.41e-37	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs68170813	0.559	rs79564258	chr7:107059803	C/A	cg02696742	chr7:106810147	HBP1	-0.5	-8.07	-0.3	3.5e-15	Coronary artery disease;
BRCA	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg20503657	chr10:835505	NA	-0.45	-8.66	-0.32	3.87e-17	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.5	-0.32	1.32e-16	Breast cancer;
BRCA	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg06494592	chr3:125709126	NA	-0.53	-8.64	-0.32	4.66e-17	Blood pressure (smoking interaction);
BRCA	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg25174290	chr11:3078921	CARS	0.44	13.11	0.46	6.26e-35	Longevity;
BRCA	cis	rs12618769	0.597	rs17032870	chr2:99132786	C/T	cg10123293	chr2:99228465	UNC50	0.41	8.24	0.31	9.93e-16	Bipolar disorder;
BRCA	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg12463550	chr7:65579703	CRCP	-0.37	-7.84	-0.3	1.88e-14	Aortic root size;
BRCA	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg25019033	chr10:957182	NA	-0.41	-7.9	-0.3	1.24e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg13628971	chr7:2884303	GNA12	-0.39	-8.99	-0.34	2.69e-18	Height;
BRCA	cis	rs62380364	0.602	rs589544	chr5:88064462	T/C	cg22951263	chr5:87985283	NA	-0.38	-10.39	-0.38	1.87e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg00745463	chr17:30367425	LRRC37B	0.49	8.37	0.31	3.54e-16	Hip circumference adjusted for BMI;
BRCA	trans	rs75804782	0.641	rs56134361	chr2:239318905	A/G	cg01134436	chr17:81009848	B3GNTL1	0.77	9.69	0.36	8.3e-21	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs55665837	1.000	rs11023214	chr11:14436259	G/C	cg19336497	chr11:14380999	RRAS2	-0.36	-9.49	-0.35	4.37e-20	Vitamin D levels;
BRCA	cis	rs13046373	0.505	rs2832934	chr21:31899760	A/G	cg16431978	chr21:31797932	KRTAP13-3	0.39	9.71	0.36	6.88e-21	HDL cholesterol;
BRCA	cis	rs2663905	0.664	rs2460855	chr15:81361729	G/T	cg09888468	chr15:81410853	NA	-0.42	-8.87	-0.33	7.34e-18	QT interval (drug interaction);
BRCA	cis	rs586533	0.813	rs1790263	chr11:99495583	T/G	cg22878054	chr11:99397252	CNTN5	0.31	7.86	0.3	1.65e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2464469	0.654	rs2067062	chr15:58341954	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-7.93	-0.3	1e-14	Barrett's esophagus  or Esophageal adenocarcinoma;
BRCA	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg17294928	chr15:75287854	SCAMP5	-0.75	-16.42	-0.54	7.94e-51	Blood trace element (Zn levels);
BRCA	trans	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-8.35	-0.31	4.36e-16	Triglycerides;
BRCA	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg04944784	chr2:26401820	FAM59B	0.99	14.55	0.5	1.22e-41	Gut microbiome composition (summer);
BRCA	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg05707623	chr12:122985044	ZCCHC8	0.49	9.42	0.35	7.86e-20	Body mass index;
BRCA	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg02734326	chr4:10020555	SLC2A9	0.35	7.81	0.3	2.41e-14	Bone mineral density;
BRCA	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg00530320	chr1:46809349	NSUN4	0.48	9.7	0.36	7.66e-21	Menopause (age at onset);
BRCA	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg03060546	chr3:49711283	APEH	-0.59	-10.21	-0.37	9.07e-23	Menarche (age at onset);
BRCA	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg11584989	chr19:19387371	SF4	0.64	13.59	0.47	3.98e-37	Bipolar disorder;
BRCA	cis	rs897080	0.515	rs1067368	chr2:44654889	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	9.28	0.34	2.67e-19	Height;
BRCA	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.62	0.42	1.93e-28	Homoarginine levels;
BRCA	cis	rs4363385	0.747	rs1415962	chr1:152958731	T/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.41	-0.32	2.62e-16	Inflammatory skin disease;
BRCA	cis	rs887829	0.570	rs6724485	chr2:234592816	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.32	-8.31	-0.31	5.65e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25427524	chr10:38739819	LOC399744	-0.7	-16.95	-0.56	1.63e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg18252515	chr7:66147081	NA	-1.05	-15.27	-0.52	4.18e-45	Diabetic kidney disease;
BRCA	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg24633833	chr3:10029261	TMEM111	0.41	7.81	0.3	2.39e-14	Alzheimer's disease;
BRCA	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	12.37	0.44	1.18e-31	Mean corpuscular hemoglobin;
BRCA	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg20701182	chr2:24300061	SF3B14	0.68	12.76	0.45	2.28e-33	Lymphocyte counts;
BRCA	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg13385794	chr1:248469461	NA	0.27	7.87	0.3	1.5e-14	Common traits (Other);
BRCA	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.34	0.49	1.26e-40	Personality dimensions;
BRCA	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-10.44	-0.38	1.17e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg22349387	chr12:9600060	DDX12	-0.39	-9.04	-0.34	1.86e-18	Breast size;
BRCA	cis	rs4891159	0.790	rs4891161	chr18:74142683	A/G	cg24786174	chr18:74118243	ZNF516	-0.79	-21.73	-0.65	7.8e-79	Longevity;
BRCA	cis	rs6684514	1.000	rs10908498	chr1:156278175	T/C	cg16558208	chr1:156270281	VHLL	0.34	8.07	0.3	3.48e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg00071950	chr4:10020882	SLC2A9	0.51	12.6	0.45	1.12e-32	Bone mineral density;
BRCA	cis	rs13046373	0.535	rs7276743	chr21:31984545	C/T	cg16431978	chr21:31797932	KRTAP13-3	0.35	8.58	0.32	7.07e-17	HDL cholesterol;
BRCA	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	11.14	0.4	1.91e-26	Multiple sclerosis;
BRCA	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg00745463	chr17:30367425	LRRC37B	-0.54	-8.89	-0.33	6.17e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg27489772	chr12:121021490	NA	0.44	7.95	0.3	8.41e-15	Type 1 diabetes nephropathy;
BRCA	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg12310025	chr6:25882481	NA	-0.43	-9.73	-0.36	5.93e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg06784218	chr1:46089804	CCDC17	0.45	10.77	0.39	5.56e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7809950	0.723	rs2237662	chr7:106874065	C/G	cg23024343	chr7:107201750	COG5	-0.47	-9.35	-0.35	1.47e-19	Coronary artery disease;
BRCA	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-12.15	-0.43	1.04e-30	Alzheimer's disease;
BRCA	cis	rs7833986	0.534	rs2976022	chr8:57007843	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	12.99	0.46	2.13e-34	Height;
BRCA	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg22633769	chr20:60982531	CABLES2	0.44	7.92	0.3	1.02e-14	Colorectal cancer;
BRCA	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg24675658	chr1:53192096	ZYG11B	-0.61	-14.03	-0.49	3.37e-39	Monocyte count;
BRCA	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg18252515	chr7:66147081	NA	-0.91	-12.95	-0.46	3.02e-34	Diabetic kidney disease;
BRCA	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.72	-0.48	9.54e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	16.54	0.55	2.03e-51	Bone mineral density;
BRCA	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.06	-18.86	-0.6	1.99e-63	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	14.55	0.5	1.24e-41	Motion sickness;
BRCA	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18876405	chr7:65276391	NA	0.56	13.31	0.47	7.25e-36	Aortic root size;
BRCA	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg20908204	chr19:46285434	DMPK	-0.28	-8.05	-0.3	4.02e-15	Coronary artery disease;
BRCA	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18876405	chr7:65276391	NA	-0.7	-18.32	-0.59	1.36e-60	Aortic root size;
BRCA	cis	rs858239	0.601	rs1981665	chr7:23167969	T/C	cg23682824	chr7:23144976	KLHL7	0.45	12.05	0.43	2.72e-30	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg00074818	chr8:8560427	CLDN23	0.38	8.29	0.31	6.81e-16	Obesity-related traits;
BRCA	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg05347473	chr6:146136440	FBXO30	0.59	11.21	0.41	9.86e-27	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	20.28	0.63	5.89e-71	Platelet count;
BRCA	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg21724239	chr8:58056113	NA	0.47	8.31	0.31	5.8e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7646881	0.812	rs61696028	chr3:158455703	A/C	cg19483011	chr3:158453295	NA	-0.47	-8.26	-0.31	8.52e-16	Tetralogy of Fallot;
BRCA	cis	rs911119	0.913	rs67483168	chr20:23581312	T/C	cg16589663	chr20:23618590	CST3	0.45	8.12	0.31	2.35e-15	Chronic kidney disease;
BRCA	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg02820040	chr2:241836501	C2orf54	-0.59	-11.74	-0.42	5.92e-29	Urinary metabolites;
BRCA	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	12.97	0.46	2.45e-34	Personality dimensions;
BRCA	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg13852791	chr20:30311386	BCL2L1	0.76	13.89	0.48	1.58e-38	Mean corpuscular hemoglobin;
BRCA	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11644478	chr21:40555479	PSMG1	0.77	16.75	0.55	1.81e-52	Cognitive function;
BRCA	cis	rs11690935	0.550	rs6718013	chr2:172869185	A/G	cg13550731	chr2:172543902	DYNC1I2	0.5	12.22	0.44	5.17e-31	Schizophrenia;
BRCA	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg00106254	chr7:1943704	MAD1L1	-0.35	-8.76	-0.33	1.71e-17	Schizophrenia;
BRCA	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg14983838	chr19:29218262	NA	0.55	10.78	0.39	5.09e-25	Methadone dose in opioid dependence;
BRCA	trans	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg04565464	chr8:145669602	NFKBIL2	0.39	8.84	0.33	9.04e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.34	-0.41	2.64e-27	Gut microbiome composition (summer);
BRCA	cis	rs2882667	0.722	rs4835649	chr5:138146223	T/C	cg04439458	chr5:138467593	SIL1	0.31	7.9	0.3	1.22e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg21475434	chr5:93447410	FAM172A	0.73	8.81	0.33	1.18e-17	Diabetic retinopathy;
BRCA	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg20503657	chr10:835505	NA	1.01	17.77	0.58	1.09e-57	Eosinophil percentage of granulocytes;
BRCA	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg08508325	chr11:3079039	CARS	0.34	11.51	0.41	5.31e-28	Longevity;
BRCA	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg04034577	chr2:241836375	C2orf54	-0.62	-16.03	-0.54	7.27e-49	Urinary metabolites;
BRCA	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.6	-0.32	6.14e-17	Total body bone mineral density;
BRCA	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg22800045	chr5:56110881	MAP3K1	0.63	12.17	0.43	8.2e-31	Initial pursuit acceleration;
BRCA	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18876405	chr7:65276391	NA	-0.62	-15.37	-0.52	1.41e-45	Aortic root size;
BRCA	cis	rs9487051	0.768	rs463916	chr6:109520538	A/G	cg01475377	chr6:109611718	NA	-0.45	-11.31	-0.41	3.73e-27	Reticulocyte fraction of red cells;
BRCA	cis	rs4664304	0.620	rs10929958	chr2:160720538	A/G	cg18514922	chr2:160761262	LY75	0.33	7.89	0.3	1.29e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6138458	1.000	rs227631	chr20:24913653	A/G	cg06937882	chr20:24974362	C20orf3	-0.44	-8.41	-0.32	2.76e-16	Blood protein levels;
BRCA	cis	rs6910061	0.830	rs7762961	chr6:11109669	A/G	cg27233058	chr6:11094804	LOC221710	-0.47	-8.36	-0.31	4.06e-16	Diabetic kidney disease;
BRCA	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	8.83e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs367615	0.879	rs56689485	chr5:108879828	A/T	cg17395555	chr5:108820864	NA	0.37	9.39	0.35	1.03e-19	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg25358565	chr5:93447407	FAM172A	-1.08	-16.94	-0.56	1.92e-53	Diabetic retinopathy;
BRCA	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.17	-0.31	1.62e-15	Gut microbiome composition (summer);
BRCA	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg05283184	chr6:79620031	NA	-0.41	-10.3	-0.38	4.01e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg21782813	chr7:2030301	MAD1L1	0.42	11.08	0.4	3.09e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-12.62	-0.45	9.22e-33	Alzheimer's disease;
BRCA	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg03474202	chr17:45855739	NA	-0.48	-12.66	-0.45	6.03e-33	IgG glycosylation;
BRCA	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg13256891	chr4:100009986	ADH5	0.53	9.77	0.36	4.33e-21	Smoking initiation;
BRCA	trans	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg25214090	chr10:38739885	LOC399744	0.52	11.63	0.42	1.72e-28	Corneal astigmatism;
BRCA	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg21545522	chr1:205238299	TMCC2	0.4	8.3	0.31	6.2e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg26597838	chr10:835615	NA	0.98	17.29	0.56	2.96e-55	Eosinophil percentage of granulocytes;
BRCA	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11644478	chr21:40555479	PSMG1	0.85	19.85	0.62	1.1e-68	Cognitive function;
BRCA	cis	rs6545883	0.929	rs10193666	chr2:61629408	C/T	cg15711740	chr2:61764176	XPO1	0.54	13.51	0.47	9.33e-37	Tuberculosis;
BRCA	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg04362960	chr10:104952993	NT5C2	0.43	10.29	0.38	4.49e-23	Arsenic metabolism;
BRCA	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg27661571	chr11:113659931	NA	-0.7	-10.89	-0.4	1.93e-25	Hip circumference adjusted for BMI;
BRCA	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.69	11.76	0.42	4.78e-29	Inflammatory bowel disease;
BRCA	cis	rs2505998	0.833	rs2505536	chr10:43592204	A/T	cg15436174	chr10:43711423	RASGEF1A	0.42	8.18	0.31	1.55e-15	Hirschsprung disease;
BRCA	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg18357645	chr12:58087776	OS9	0.47	13.47	0.47	1.43e-36	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25427524	chr10:38739819	LOC399744	0.59	13.33	0.47	6.1e-36	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg16339924	chr4:17578868	LAP3	0.57	13.67	0.48	1.67e-37	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.66	-9.58	-0.35	2.1e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg26116260	chr4:7069785	GRPEL1	0.95	28.11	0.74	9e-114	Monocyte percentage of white cells;
BRCA	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.53	11.22	0.41	8.32e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.22	-0.31	1.14e-15	Height;
BRCA	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg10295955	chr4:187884368	NA	-0.99	-31.94	-0.78	1.62e-134	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg08885076	chr2:99613938	TSGA10	0.45	10.54	0.38	4.78e-24	Chronic sinus infection;
BRCA	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00908189	chr16:619842	PIGQ	0.69	18.09	0.58	2.15e-59	Height;
BRCA	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg13770153	chr20:60521292	NA	-0.46	-11.06	-0.4	3.73e-26	Body mass index;
BRCA	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg08885076	chr2:99613938	TSGA10	-0.48	-9.21	-0.34	4.79e-19	Chronic sinus infection;
BRCA	cis	rs778371	0.723	rs13001052	chr2:233683984	C/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-16.9	-0.56	2.92e-53	Schizophrenia;
BRCA	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21659725	chr3:3221576	CRBN	-0.49	-12.65	-0.45	7.15e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg09462578	chr12:12878428	APOLD1	0.55	12.13	0.43	1.32e-30	Pulse pressure;
BRCA	trans	rs4650994	1.000	rs10798615	chr1:178513895	T/G	cg05059571	chr16:84539110	KIAA1609	-0.43	-9.66	-0.36	1.06e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	trans	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg12575136	chr18:32820987	ZNF397	0.4	9.73	0.36	5.96e-21	White blood cell count;
BRCA	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.46	-9.52	-0.35	3.6e-20	Body mass index;
BRCA	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	7.97	0.3	7.54e-15	Menarche (age at onset);
BRCA	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.45	0.35	6.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg23442198	chr4:187126114	CYP4V2	-0.94	-11.4	-0.41	1.51e-27	Blood protein levels;
BRCA	cis	rs3824867	0.676	rs7104366	chr11:47462115	G/A	cg20307385	chr11:47447363	PSMC3	0.51	11.52	0.41	4.99e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs7246657	0.722	rs2909100	chr19:38212680	C/T	cg23950597	chr19:37808831	NA	0.5	8.62	0.32	5.24e-17	Coronary artery calcification;
BRCA	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg06046430	chr4:77819534	ANKRD56	0.56	12.58	0.45	1.35e-32	Emphysema distribution in smoking;
BRCA	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg16141378	chr3:129829833	LOC729375	0.39	9.34	0.35	1.59e-19	Neuroticism;
BRCA	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg21143896	chr7:2802374	GNA12	-0.36	-9.11	-0.34	1.06e-18	Height;
BRCA	cis	rs6594713	0.819	rs10061462	chr5:112726205	A/T	cg12552261	chr5:112820674	MCC	0.44	7.95	0.3	8.43e-15	Brain cytoarchitecture;
BRCA	cis	rs495337	0.760	rs11696437	chr20:48548318	C/T	cg17835207	chr20:48524531	SPATA2	-0.69	-16.8	-0.55	1.04e-52	Psoriasis;
BRCA	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg23533926	chr12:111358616	MYL2	-0.42	-8.73	-0.33	2.26e-17	Extrinsic epigenetic age acceleration;
BRCA	trans	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg19862616	chr7:65841803	NCRNA00174	0.86	28.34	0.75	4.75e-115	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs912057	0.671	rs1294417	chr6:6741932	T/C	cg06612196	chr6:6737390	NA	0.46	10.67	0.39	1.42e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg21775007	chr8:11205619	TDH	0.55	10.88	0.4	2.04e-25	Retinal vascular caliber;
BRCA	cis	rs3824867	0.804	rs12419342	chr11:47468545	C/T	cg20307385	chr11:47447363	PSMC3	0.52	11.66	0.42	1.3e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg18252515	chr7:66147081	NA	-0.97	-13.78	-0.48	5.39e-38	Diabetic kidney disease;
BRCA	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg18301423	chr5:131593218	PDLIM4	0.32	8.27	0.31	7.94e-16	Breast cancer;
BRCA	trans	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg26043149	chr18:55253948	FECH	0.4	8.69	0.33	3.1e-17	Bone mineral density;
BRCA	trans	rs1459104	1.000	rs12577585	chr11:55302603	G/A	cg15704280	chr7:45808275	SEPT13	0.64	8.12	0.31	2.47e-15	Body mass index;
BRCA	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg03146154	chr1:46216737	IPP	0.49	10.87	0.39	2.35e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg04362960	chr10:104952993	NT5C2	0.43	10.36	0.38	2.38e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg14631576	chr9:95140430	CENPP	-0.37	-8.99	-0.34	2.81e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg15704280	chr7:45808275	SEPT13	0.69	13.9	0.48	1.38e-38	Coronary artery disease;
BRCA	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg07741184	chr6:167504864	NA	0.33	9.99	0.37	6.31e-22	Primary biliary cholangitis;
BRCA	cis	rs1997103	0.911	rs9642575	chr7:55399090	C/T	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.72e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg03709012	chr19:19516395	GATAD2A	0.82	18.95	0.6	6.56e-64	Tonsillectomy;
BRCA	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg06115741	chr20:33292138	TP53INP2	0.35	7.86	0.3	1.63e-14	Glomerular filtration rate (creatinine);
BRCA	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg03161606	chr19:29218774	NA	0.44	8.0	0.3	5.98e-15	Methadone dose in opioid dependence;
BRCA	cis	rs1003719	0.715	rs9981715	chr21:38499610	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.19	-0.49	6.28e-40	Eye color traits;
BRCA	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg24692254	chr21:30365293	RNF160	-0.66	-17.89	-0.58	2.54e-58	Dental caries;
BRCA	trans	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-14.12	-0.49	1.27e-39	Brugada syndrome;
BRCA	cis	rs6594499	0.542	rs4530809	chr5:110462230	A/G	cg04022379	chr5:110408740	TSLP	0.37	8.39	0.32	3.11e-16	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00166722	chr3:10149974	C3orf24	0.61	12.33	0.44	1.79e-31	Alzheimer's disease;
BRCA	cis	rs1975991	0.711	rs2378394	chr3:187964383	T/G	cg15417654	chr3:187959138	LPP	0.35	9.03	0.34	1.96e-18	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg19847866	chr10:1019161	NA	0.55	12.0	0.43	4.72e-30	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg17063962	chr7:91808500	NA	-0.55	-12.71	-0.45	3.76e-33	Breast cancer;
BRCA	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg18758796	chr5:131593413	PDLIM4	0.36	8.61	0.32	5.72e-17	Acylcarnitine levels;
BRCA	cis	rs13082711	0.513	rs66472045	chr3:27242887	G/A	cg02860705	chr3:27208620	NA	0.54	10.99	0.4	7.33e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs6433895	0.736	rs11893772	chr2:181989311	C/T	cg00481216	chr2:181971175	NA	0.43	9.05	0.34	1.73e-18	Lymphocyte counts;
BRCA	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.06	0.74	1.58e-113	Chronic sinus infection;
BRCA	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg04362960	chr10:104952993	NT5C2	0.45	10.31	0.38	3.81e-23	Arsenic metabolism;
BRCA	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00149659	chr3:10157352	C3orf10	0.8	14.11	0.49	1.53e-39	Alzheimer's disease;
BRCA	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg05234568	chr11:5960015	NA	-0.43	-8.83	-0.33	1.01e-17	DNA methylation (variation);
BRCA	cis	rs7520050	0.966	rs6669522	chr1:46397941	A/G	cg24296786	chr1:45957014	TESK2	0.44	9.88	0.36	1.61e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05901451	chr6:126070800	HEY2	-0.71	-19.69	-0.61	8.13e-68	Brugada syndrome;
BRCA	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg16850897	chr7:100343110	ZAN	0.38	8.56	0.32	8.64e-17	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	18.27	0.59	2.5e-60	Platelet count;
BRCA	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.86	13.54	0.47	6.44e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06022373	chr22:39101656	GTPBP1	-0.73	-18.27	-0.59	2.61e-60	Menopause (age at onset);
BRCA	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg19508488	chr2:152266495	RIF1	0.44	9.21	0.34	4.58e-19	Squamous cell lung carcinoma;
BRCA	cis	rs2108225	0.900	rs2395930	chr7:107451677	T/C	cg18560240	chr7:107437656	SLC26A3	-0.53	-11.29	-0.41	4.41e-27	Ulcerative colitis;
BRCA	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.57	-0.32	7.8e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-9.7	-0.36	7.56e-21	Monocyte percentage of white cells;
BRCA	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.98	-0.33	3.05e-18	Obesity-related traits;
BRCA	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	19.41	0.61	2.45e-66	Platelet count;
BRCA	cis	rs9837602	0.592	rs694429	chr3:99459669	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.54	-9.84	-0.36	2.31e-21	Breast cancer;
BRCA	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg19318889	chr4:1322082	MAEA	0.49	10.4	0.38	1.62e-23	Longevity;
BRCA	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.48e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9649213	1.000	rs9649213	chr7:98021211	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.41	-11.15	-0.4	1.67e-26	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg11707556	chr5:10655725	ANKRD33B	0.43	9.66	0.36	1.05e-20	Coronary artery disease;
BRCA	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg17063962	chr7:91808500	NA	-0.55	-12.77	-0.45	1.94e-33	Breast cancer;
BRCA	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg23711669	chr6:146136114	FBXO30	0.71	16.55	0.55	1.83e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1190552	0.894	rs1190546	chr14:102904966	A/G	cg18135206	chr14:102964638	TECPR2	-0.43	-8.29	-0.31	6.82e-16	Blood protein levels;
BRCA	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg12564285	chr5:131593104	PDLIM4	0.35	8.0	0.3	6.03e-15	Acylcarnitine levels;
BRCA	cis	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg07460842	chr6:66804631	NA	0.59	10.37	0.38	2.24e-23	Type 2 diabetes;
BRCA	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg11584989	chr19:19387371	SF4	0.64	13.51	0.47	8.71e-37	Bipolar disorder;
BRCA	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.37	7.91	0.3	1.11e-14	Osteoporosis;
BRCA	trans	rs9929218	0.954	rs7186333	chr16:68815838	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-13.31	-0.47	7.84e-36	Colorectal cancer;
BRCA	cis	rs365132	0.846	rs353470	chr5:176444861	C/T	cg16309518	chr5:176445507	NA	-0.4	-9.71	-0.36	6.81e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg08917208	chr2:24149416	ATAD2B	0.53	8.27	0.31	7.97e-16	Asthma;
BRCA	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg10495392	chr1:46806563	NSUN4	0.45	8.49	0.32	1.44e-16	Menopause (age at onset);
BRCA	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg06627628	chr2:24431161	ITSN2	-0.65	-12.46	-0.44	4.49e-32	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-17.81	-0.58	6.55e-58	Chronic sinus infection;
BRCA	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg17063962	chr7:91808500	NA	0.57	12.75	0.45	2.57e-33	Breast cancer;
BRCA	trans	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	8.37	0.31	3.6e-16	Mean corpuscular volume;
BRCA	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg06623918	chr6:96969491	KIAA0776	0.73	12.97	0.46	2.56e-34	Migraine;Coronary artery disease;
BRCA	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg11812906	chr14:75593930	NEK9	0.6	13.75	0.48	7.07e-38	Height;
BRCA	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg13073564	chr4:8508604	NA	-0.39	-10.61	-0.39	2.57e-24	Response to antineoplastic agents;
BRCA	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg06547715	chr2:218990976	CXCR2	0.32	7.94	0.3	9.19e-15	Ulcerative colitis;
BRCA	trans	rs208520	0.874	rs208469	chr6:66915891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.48	-0.55	3.88e-51	Exhaled nitric oxide output;
BRCA	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg26597838	chr10:835615	NA	0.5	8.71	0.33	2.68e-17	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg15017067	chr4:17643749	FAM184B	0.26	7.87	0.3	1.53e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs16866061	1.000	rs3768886	chr2:225450161	G/C	cg12698349	chr2:225449008	CUL3	0.77	20.74	0.63	1.84e-73	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs7165102	1.000	rs17809330	chr15:65889250	C/T	cg03382306	chr15:66097959	NA	0.35	9.25	0.34	3.42e-19	Mean corpuscular hemoglobin;
BRCA	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.5	0.32	1.34e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-13.55	-0.47	5.85e-37	Migraine;Coronary artery disease;
BRCA	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg06784218	chr1:46089804	CCDC17	0.49	11.54	0.42	4.04e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11920090	0.720	rs60354090	chr3:170740217	C/T	cg09710316	chr3:170744871	SLC2A2	0.64	10.46	0.38	9.42e-24	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg23992470	chr4:843637	GAK	-0.53	-8.44	-0.32	2.06e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg08888203	chr3:10149979	C3orf24	0.65	11.93	0.43	8.91e-30	Alzheimer's disease;
BRCA	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg17063962	chr7:91808500	NA	0.58	13.45	0.47	1.71e-36	Breast cancer;
BRCA	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg19077165	chr18:44547161	KATNAL2	-0.4	-8.41	-0.32	2.69e-16	Educational attainment;
BRCA	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg00814883	chr7:100076585	TSC22D4	-0.49	-9.64	-0.36	1.26e-20	Platelet count;
BRCA	trans	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg17830980	chr10:43048298	ZNF37B	0.35	7.91	0.3	1.17e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg16606324	chr3:10149918	C3orf24	0.55	10.79	0.39	4.78e-25	Alzheimer's disease;
BRCA	cis	rs1451375	1.000	rs2329341	chr7:50620275	A/C	cg18232548	chr7:50535776	DDC	0.44	10.2	0.37	9.99e-23	Malaria;
BRCA	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg07606381	chr6:8435919	SLC35B3	0.63	13.66	0.48	1.79e-37	Motion sickness;
BRCA	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.3	-0.31	6.3e-16	Aortic root size;
BRCA	cis	rs858239	0.600	rs10235786	chr7:23139940	T/C	cg23682824	chr7:23144976	KLHL7	0.44	11.73	0.42	6.34e-29	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.85	-0.33	8.51e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg11663144	chr21:46675770	NA	-0.61	-13.91	-0.48	1.22e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	9.91	0.37	1.21e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg14036092	chr11:66035641	RAB1B	0.37	10.09	0.37	2.57e-22	Gout;
BRCA	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg06627628	chr2:24431161	ITSN2	-0.52	-10.4	-0.38	1.6e-23	Asthma;
BRCA	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg14019146	chr3:50243930	SLC38A3	0.53	13.72	0.48	9.62e-38	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg04455712	chr21:45112962	RRP1B	-0.41	-10.87	-0.39	2.32e-25	Mean corpuscular volume;
BRCA	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg26384229	chr12:38710491	ALG10B	-0.43	-9.98	-0.37	6.74e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6433895	1.000	rs55954384	chr2:182017630	A/G	cg00481216	chr2:181971175	NA	0.39	8.91	0.33	5.34e-18	Lymphocyte counts;
BRCA	trans	rs2262909	0.962	rs73021832	chr19:22316144	G/C	cg17074339	chr11:11642133	GALNTL4	0.45	8.71	0.33	2.58e-17	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg00666640	chr1:248458726	OR2T12	0.33	8.99	0.34	2.75e-18	Common traits (Other);
BRCA	cis	rs9287719	0.601	rs1861299	chr2:10763757	C/G	cg00105475	chr2:10696890	NA	0.47	10.32	0.38	3.26e-23	Prostate cancer;
BRCA	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg11166453	chr1:247681781	NA	0.41	9.21	0.34	4.64e-19	Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs208520	0.690	rs851464	chr6:66839802	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-21.02	-0.64	6.06e-75	Exhaled nitric oxide output;
BRCA	cis	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg06521331	chr12:34319734	NA	-0.63	-11.51	-0.41	5.2e-28	Morning vs. evening chronotype;
BRCA	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.4	0.47	2.88e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs4650994	0.525	rs2224811	chr1:178544323	C/T	cg05059571	chr16:84539110	KIAA1609	0.57	12.7	0.45	4.3e-33	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.84	-0.3	1.9e-14	Depression;
BRCA	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg27446573	chr6:127587934	RNF146	0.8	15.81	0.53	9.67e-48	Breast cancer;
BRCA	trans	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg00953403	chr17:74099816	EXOC7	-0.5	-9.11	-0.34	1.05e-18	Psychosis in Alzheimer's disease;
BRCA	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg11645453	chr3:52864694	ITIH4	-0.38	-10.07	-0.37	3.01e-22	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07636037	chr3:49044803	WDR6	-0.72	-15.49	-0.52	3.34e-46	Menarche (age at onset);
BRCA	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg01874867	chr7:94954059	PON1	-0.38	-7.85	-0.3	1.74e-14	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs7011049	1.000	rs72643576	chr8:53845016	A/T	cg26025543	chr8:53854495	NA	0.53	9.13	0.34	8.77e-19	Systolic blood pressure;
BRCA	trans	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg25042112	chr7:64838748	ZNF92	-0.45	-8.34	-0.31	4.45e-16	Pain;
BRCA	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg23625390	chr15:77176239	SCAPER	-0.49	-12.69	-0.45	4.69e-33	Blood metabolite levels;
BRCA	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	11.44	0.41	1.11e-27	Personality dimensions;
BRCA	cis	rs4711336	1.000	rs764754	chr6:33658310	C/T	cg14003231	chr6:33640908	ITPR3	0.32	7.86	0.3	1.69e-14	Height;
BRCA	cis	rs4363385	0.818	rs1750309	chr1:153013630	G/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.38	-0.31	3.4e-16	Inflammatory skin disease;
BRCA	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg17971929	chr21:40555470	PSMG1	0.77	17.92	0.58	1.83e-58	Cognitive function;
BRCA	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg13010199	chr12:38710504	ALG10B	0.54	11.48	0.41	7.19e-28	Heart rate;
BRCA	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.49	-0.32	1.48e-16	Monocyte percentage of white cells;
BRCA	trans	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-7.86	-0.3	1.65e-14	Menarche (age at onset);
BRCA	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg12573674	chr2:1569213	NA	-0.63	-14.05	-0.49	2.77e-39	IgG glycosylation;
BRCA	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg05347473	chr6:146136440	FBXO30	0.4	7.87	0.3	1.52e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg23711669	chr6:146136114	FBXO30	0.76	17.46	0.57	3.96e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.02	-0.37	4.72e-22	IgG glycosylation;
BRCA	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg19773385	chr1:10388646	KIF1B	-0.35	-7.81	-0.3	2.31e-14	Hepatocellular carcinoma;
BRCA	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg18252515	chr7:66147081	NA	-0.84	-12.12	-0.43	1.34e-30	Diabetic kidney disease;
BRCA	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg13395646	chr4:1353034	KIAA1530	-0.51	-9.16	-0.34	7.21e-19	Obesity-related traits;
BRCA	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.42	0.54	8.08e-51	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.48	-0.32	1.51e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.74	16.08	0.54	4.26e-49	Cognitive ability;
BRCA	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg03711944	chr11:47377212	SPI1	-0.41	-9.49	-0.35	4.42e-20	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg16576597	chr16:28551801	NUPR1	0.31	8.5	0.32	1.32e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.21	0.31	1.26e-15	Aortic root size;
BRCA	cis	rs365132	0.875	rs2456178	chr5:176413570	C/G	cg16309518	chr5:176445507	NA	-0.52	-13.35	-0.47	4.77e-36	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg24296786	chr1:45957014	TESK2	0.64	15.85	0.53	5.88e-48	High light scatter reticulocyte count;
BRCA	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	13.76	0.48	6.16e-38	Platelet count;
BRCA	cis	rs61990749	0.544	rs176979	chr14:78198072	A/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.44	7.97	0.3	7.37e-15	Fibroblast growth factor basic levels;
BRCA	cis	rs57590327	0.503	rs12638997	chr3:81844912	A/G	cg07356753	chr3:81810745	GBE1	-0.45	-10.53	-0.38	4.97e-24	Extraversion;
BRCA	cis	rs3772130	0.962	rs9822949	chr3:121541239	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.97	0.4	9.17e-26	Cognitive performance;
BRCA	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg27165867	chr14:105738592	BRF1	-0.37	-8.61	-0.32	5.47e-17	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg09469691	chr10:81107165	PPIF	0.44	9.56	0.35	2.41e-20	Height;
BRCA	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg20701182	chr2:24300061	SF3B14	0.57	9.01	0.34	2.39e-18	Lymphocyte counts;
BRCA	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg08807101	chr21:30365312	RNF160	0.37	8.33	0.31	4.75e-16	Pancreatic cancer;
BRCA	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg02073558	chr3:44770973	ZNF501	0.5	10.44	0.38	1.18e-23	Depressive symptoms;
BRCA	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.5	0.32	1.32e-16	Cognitive ability;
BRCA	cis	rs679087	1.000	rs679087	chr12:29917265	C/A	cg14258853	chr12:29935411	TMTC1	-0.42	-8.85	-0.33	8.36e-18	Schizophrenia;
BRCA	cis	rs16854884	0.633	rs6779321	chr3:143736676	T/C	cg06585982	chr3:143692056	C3orf58	0.43	8.99	0.33	2.87e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg05340658	chr4:99064831	C4orf37	0.67	16.51	0.55	2.9e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.5	0.63	3.81e-72	Chronic sinus infection;
BRCA	cis	rs7572733	0.534	rs700685	chr2:198715972	A/G	cg00792783	chr2:198669748	PLCL1	0.46	10.16	0.37	1.39e-22	Dermatomyositis;
BRCA	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg20673091	chr1:2541236	MMEL1	0.35	9.23	0.34	3.78e-19	Ulcerative colitis;
BRCA	cis	rs12618769	0.597	rs72821907	chr2:99085296	A/G	cg10123293	chr2:99228465	UNC50	0.41	8.05	0.3	4.12e-15	Bipolar disorder;
BRCA	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.07	-26.3	-0.72	7.28e-104	Ulcerative colitis;
BRCA	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg23649088	chr2:200775458	C2orf69	-0.61	-7.95	-0.3	8.69e-15	Schizophrenia;
BRCA	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.54	8.27	0.31	7.51e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.69	0.5	2.55e-42	Personality dimensions;
BRCA	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg17135325	chr3:160939158	NMD3	0.39	7.82	0.3	2.14e-14	Parkinson's disease;
BRCA	cis	rs644148	0.770	rs2571113	chr19:44999814	A/G	cg15540054	chr19:45004280	ZNF180	-0.57	-12.28	-0.44	2.9e-31	Personality dimensions;
BRCA	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg18016565	chr1:150552671	MCL1	-0.45	-9.97	-0.37	7.39e-22	Tonsillectomy;
BRCA	cis	rs9790314	0.747	rs7619011	chr3:160855676	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-10.41	-0.38	1.53e-23	Morning vs. evening chronotype;
BRCA	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg00484396	chr16:3507460	NAT15	0.43	9.04	0.34	1.86e-18	Tuberculosis;
BRCA	cis	rs4891159	0.757	rs11665018	chr18:74123589	C/T	cg24786174	chr18:74118243	ZNF516	-0.78	-18.93	-0.6	9.23e-64	Longevity;
BRCA	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-14.81	-0.51	7.04e-43	Hemoglobin concentration;
BRCA	cis	rs9815354	0.812	rs113300894	chr3:41984243	G/C	cg03022575	chr3:42003672	ULK4	0.73	9.9	0.36	1.36e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg03433033	chr1:76189801	ACADM	-0.57	-11.41	-0.41	1.46e-27	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs3099143	1.000	rs1913001	chr15:77179408	A/C	cg21673338	chr15:77095150	SCAPER	0.52	9.14	0.34	7.87e-19	Recalcitrant atopic dermatitis;
BRCA	cis	rs953387	0.910	rs72976292	chr2:136929107	T/A	cg05194412	chr2:137003533	NA	-0.35	-8.02	-0.3	4.98e-15	Arthritis (juvenile idiopathic);
BRCA	cis	rs9788721	0.836	rs17483721	chr15:78733731	C/T	cg18825076	chr15:78729989	IREB2	0.38	7.92	0.3	1.03e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg00757033	chr12:89920650	WDR51B	0.42	8.8	0.33	1.25e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg23285459	chr7:2802560	GNA12	-0.37	-9.33	-0.35	1.75e-19	Height;
BRCA	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	9.82	0.36	2.8e-21	Monocyte percentage of white cells;
BRCA	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg12935359	chr14:103987150	CKB	0.65	15.04	0.51	5.37e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg22764044	chr5:178986830	RUFY1	0.46	12.35	0.44	1.46e-31	Lung cancer;
BRCA	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.16	0.31	1.76e-15	Menopause (age at onset);
BRCA	cis	rs858239	0.600	rs10237755	chr7:23131564	A/G	cg23682824	chr7:23144976	KLHL7	0.45	12.23	0.44	4.63e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7809950	1.000	rs987391	chr7:107100794	C/G	cg23024343	chr7:107201750	COG5	-0.4	-9.3	-0.35	2.24e-19	Coronary artery disease;
BRCA	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg03954927	chr1:10346856	KIF1B	0.43	13.74	0.48	8.33e-38	Hepatocellular carcinoma;
BRCA	trans	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg06521331	chr12:34319734	NA	-0.49	-9.07	-0.34	1.51e-18	Bladder cancer;
BRCA	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg04851639	chr8:1020857	NA	0.39	11.25	0.41	6.21e-27	Schizophrenia;
BRCA	cis	rs807669	0.525	rs9605955	chr22:19181557	C/T	cg02655711	chr22:19163373	SLC25A1	0.45	10.3	0.38	3.9e-23	Metabolite levels;
BRCA	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg11266682	chr4:10021025	SLC2A9	0.46	12.57	0.45	1.57e-32	Bone mineral density;
BRCA	cis	rs13064411	0.696	rs13325046	chr3:113104444	C/T	cg18753928	chr3:113234510	CCDC52	-0.52	-9.43	-0.35	7.25e-20	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg16414030	chr3:133502952	NA	-0.54	-12.95	-0.46	3.25e-34	Iron status biomarkers;
BRCA	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11764359	chr7:65958608	NA	-0.8	-19.34	-0.61	5.76e-66	Aortic root size;
BRCA	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg16339924	chr4:17578868	LAP3	0.58	14.15	0.49	9.29e-40	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13046373	0.535	rs7281489	chr21:31978125	C/T	cg24082983	chr21:31802169	KRTAP13-4	0.35	8.99	0.34	2.79e-18	HDL cholesterol;
BRCA	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26314531	chr2:26401878	FAM59B	-0.66	-11.2	-0.4	1.08e-26	Gut microbiome composition (summer);
BRCA	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.34	-0.35	1.55e-19	Menopause (age at onset);
BRCA	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg13175981	chr1:150552382	MCL1	0.42	9.4	0.35	9.95e-20	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.92	0.37	1.13e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6430585	0.527	rs1900306	chr2:136416533	G/A	cg07169764	chr2:136633963	MCM6	1.13	21.95	0.66	5.05e-80	Corneal structure;
BRCA	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg25036284	chr2:26402008	FAM59B	-0.64	-10.63	-0.39	2.11e-24	Gut microbiome composition (summer);
BRCA	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg25036284	chr2:26402008	FAM59B	-0.67	-10.99	-0.4	7.66e-26	Gut microbiome composition (summer);
BRCA	cis	rs1050631	0.564	rs12185396	chr18:33738496	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.38	7.9	0.3	1.2e-14	Esophageal squamous cell cancer (length of survival);
BRCA	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg13256891	chr4:100009986	ADH5	0.5	10.35	0.38	2.51e-23	Alcohol dependence;
BRCA	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg25817165	chr18:72167213	CNDP2	-0.75	-14.62	-0.5	5.74e-42	Refractive error;
BRCA	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	4.08e-15	Alzheimer's disease (late onset);
BRCA	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg13010199	chr12:38710504	ALG10B	0.43	10.2	0.37	9.44e-23	Heart rate;
BRCA	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.27e-23	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs629535	0.699	rs539956	chr8:70033647	G/A	cg21567404	chr3:27674614	NA	1.0	21.04	0.64	4.79e-75	Dupuytren's disease;
BRCA	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg24675658	chr1:53192096	ZYG11B	-0.51	-11.25	-0.41	6.66e-27	Monocyte count;
BRCA	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg06191203	chr2:152266755	RIF1	-0.42	-11.96	-0.43	7.13e-30	Lung cancer;
BRCA	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg05340658	chr4:99064831	C4orf37	0.48	11.11	0.4	2.54e-26	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.65	-13.59	-0.47	3.79e-37	Lymphocyte counts;
BRCA	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg05665937	chr4:1216051	CTBP1	0.37	7.82	0.3	2.2e-14	Obesity-related traits;
BRCA	cis	rs7254114	0.578	rs4804574	chr19:11317482	G/A	cg02815516	chr19:11306319	KANK2	0.34	9.89	0.36	1.45e-21	Immature fraction of reticulocytes;
BRCA	cis	rs3820928	0.810	rs10175929	chr2:227858609	T/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.42	-0.32	2.41e-16	Pulmonary function;
BRCA	cis	rs34779708	1.000	rs34779708	chr10:35466185	T/G	cg03585969	chr10:35415529	CREM	0.49	10.4	0.38	1.68e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg00102166	chr1:43425337	SLC2A1	-0.51	-8.87	-0.33	7.3e-18	Monocyte count;
BRCA	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg11584989	chr19:19387371	SF4	0.62	13.0	0.46	1.89e-34	Bipolar disorder;
BRCA	trans	rs3960554	0.932	rs4728597	chr7:75821062	C/T	cg19862616	chr7:65841803	NCRNA00174	0.59	11.55	0.42	3.67e-28	Eotaxin levels;
BRCA	cis	rs6963495	0.556	rs711427	chr7:105161755	T/G	cg19920283	chr7:105172520	RINT1	0.44	9.16	0.34	6.84e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg13385794	chr1:248469461	NA	0.27	7.97	0.3	7.54e-15	Common traits (Other);
BRCA	cis	rs10789491	1.000	rs1890473	chr1:47149794	C/T	cg15501359	chr1:47185051	KIAA0494	0.62	17.31	0.57	2.41e-55	Response to hepatitis C treatment;
BRCA	cis	rs7580658	0.545	rs885276	chr2:127950904	A/T	cg16751203	chr2:127950803	CYP27C1	0.29	8.32	0.31	5.28e-16	Protein C levels;
BRCA	cis	rs1468333	1.000	rs17171770	chr5:137514815	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.44	8.73	0.33	2.15e-17	Resting heart rate;
BRCA	cis	rs701145	0.585	rs357494	chr3:153937753	G/A	cg17054900	chr3:154042577	DHX36	0.57	9.59	0.35	1.96e-20	Coronary artery disease;
BRCA	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg03146154	chr1:46216737	IPP	0.54	12.03	0.43	3.34e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-7.85	-0.3	1.82e-14	Colorectal cancer;
BRCA	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg04455712	chr21:45112962	RRP1B	0.37	9.45	0.35	6.3e-20	Mean corpuscular volume;
BRCA	cis	rs11690935	0.921	rs7355523	chr2:172744421	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.89	-27.64	-0.74	3.21e-111	Schizophrenia;
BRCA	cis	rs11696845	0.787	rs6017408	chr20:43363529	A/G	cg25301532	chr20:43378953	KCNK15	0.33	7.96	0.3	7.8e-15	Obesity-related traits;
BRCA	cis	rs6138458	1.000	rs227630	chr20:24913584	A/G	cg26195577	chr20:24973756	C20orf3	0.98	24.67	0.7	6.47e-95	Blood protein levels;
BRCA	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg08807101	chr21:30365312	RNF160	-0.44	-9.45	-0.35	6.49e-20	Pancreatic cancer;
BRCA	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg06238570	chr21:40685208	BRWD1	-0.4	-8.08	-0.3	3.14e-15	Menarche (age at onset);
BRCA	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.66	-0.61	1.21e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs897080	0.514	rs1067376	chr2:44648361	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.41	0.35	9.08e-20	Height;
BRCA	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg06784218	chr1:46089804	CCDC17	0.54	12.73	0.45	2.89e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1011018	0.554	rs56124209	chr7:139463275	C/G	cg03224163	chr7:139420300	HIPK2	-0.59	-8.83	-0.33	1.01e-17	Systolic blood pressure;
BRCA	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg22535103	chr8:58192502	C8orf71	-0.47	-9.24	-0.34	3.68e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs11679564	0.714	rs4670638	chr2:37164911	C/G	cg14987922	chr2:37194071	STRN	0.4	8.57	0.32	8.05e-17	Immature fraction of reticulocytes;
BRCA	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg09555818	chr19:45449301	APOC2	0.47	12.22	0.44	5.19e-31	Blood protein levels;
BRCA	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg26516362	chr5:178986906	RUFY1	0.37	10.35	0.38	2.62e-23	Lung cancer;
BRCA	trans	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.99	-31.25	-0.78	7.75e-131	Colorectal cancer;
BRCA	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg04013093	chr6:42928303	GNMT	-0.29	-8.84	-0.33	9.55e-18	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg00105475	chr2:10696890	NA	0.44	10.21	0.37	9.17e-23	Prostate cancer;
BRCA	trans	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg25214090	chr10:38739885	LOC399744	0.46	10.6	0.39	2.72e-24	Corneal astigmatism;
BRCA	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg23625390	chr15:77176239	SCAPER	-0.56	-13.0	-0.46	1.98e-34	Blood metabolite levels;
BRCA	cis	rs919433	0.680	rs7568250	chr2:198409611	G/A	cg00792783	chr2:198669748	PLCL1	0.39	8.61	0.32	5.66e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg19920283	chr7:105172520	RINT1	0.58	9.39	0.35	1.07e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.56	-0.32	8.42e-17	Total body bone mineral density;
BRCA	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg20607798	chr8:58055168	NA	0.46	8.13	0.31	2.32e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg00339695	chr16:24857497	SLC5A11	-0.52	-11.1	-0.4	2.61e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-9.84	-0.36	2.37e-21	Bone mineral density;
BRCA	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	11.34	0.41	2.69e-27	Coronary artery disease;
BRCA	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg19628046	chr18:33552617	C18orf21	0.63	12.99	0.46	2.07e-34	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.88	13.89	0.48	1.53e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs11229555	0.645	rs11229429	chr11:58180872	G/A	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg06484146	chr7:12443880	VWDE	-0.76	-10.58	-0.39	3.2e-24	Coronary artery disease;
BRCA	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-12.13	-0.43	1.3e-30	Personality dimensions;
BRCA	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.42	-10.83	-0.39	3.19e-25	Schizophrenia;
BRCA	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg22920501	chr2:26401640	FAM59B	-0.91	-16.27	-0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	trans	rs3857536	0.740	rs7766407	chr6:66885658	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.49	-9.77	-0.36	4.07e-21	Blood trace element (Cu levels);
BRCA	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg15145296	chr3:125709740	NA	-0.54	-8.57	-0.32	7.5e-17	Blood pressure (smoking interaction);
BRCA	cis	rs4588572	0.643	rs11744479	chr5:77729220	T/G	cg11547950	chr5:77652471	NA	-0.46	-8.11	-0.31	2.58e-15	Triglycerides;
BRCA	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg11814155	chr7:99998594	ZCWPW1	0.51	9.1	0.34	1.16e-18	Platelet count;
BRCA	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg01528321	chr10:82214614	TSPAN14	0.65	14.66	0.5	3.84e-42	Post bronchodilator FEV1;
BRCA	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	15.43	0.52	6.96e-46	Colorectal cancer;
BRCA	cis	rs6121246	0.559	rs6119652	chr20:30259445	C/G	cg21427119	chr20:30132790	HM13	-0.36	-8.17	-0.31	1.71e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4911259	0.552	rs13038017	chr20:31467551	T/C	cg13636640	chr20:31349939	DNMT3B	-0.45	-11.95	-0.43	7.56e-30	Inflammatory bowel disease;
BRCA	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg03188948	chr7:1209495	NA	0.55	9.32	0.35	1.91e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg03929089	chr4:120376271	NA	0.5	8.22	0.31	1.18e-15	Axial length;
BRCA	cis	rs12618769	0.681	rs72823792	chr2:99215142	G/A	cg10123293	chr2:99228465	UNC50	0.42	8.53	0.32	1.07e-16	Bipolar disorder;
BRCA	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg15782153	chr7:917662	C7orf20	0.43	10.38	0.38	1.95e-23	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs698813	0.756	rs2592196	chr2:44605522	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.93	0.37	1.02e-21	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg18252515	chr7:66147081	NA	-1.07	-15.86	-0.53	5.14e-48	Gout;
BRCA	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg07080220	chr10:102295463	HIF1AN	0.6	14.26	0.49	3.07e-40	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs939658	0.805	rs11635757	chr15:79432737	T/C	cg17916960	chr15:79447300	NA	-0.44	-11.18	-0.4	1.28e-26	Refractive error;
BRCA	cis	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg06521331	chr12:34319734	NA	-0.52	-10.32	-0.38	3.33e-23	Morning vs. evening chronotype;
BRCA	cis	rs10046574	0.561	rs10215176	chr7:135198589	A/G	cg27474649	chr7:135195673	CNOT4	0.67	10.95	0.4	1.07e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-11.34	-0.41	2.89e-27	Systolic blood pressure;
BRCA	trans	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg06521331	chr12:34319734	NA	0.44	8.75	0.33	1.96e-17	Bladder cancer;
BRCA	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg13010199	chr12:38710504	ALG10B	0.5	10.43	0.38	1.31e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg24829409	chr8:58192753	C8orf71	-0.47	-8.94	-0.33	4.23e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7100689	0.524	rs7902460	chr10:82199263	T/A	cg01528321	chr10:82214614	TSPAN14	0.73	16.66	0.55	5.29e-52	Post bronchodilator FEV1;
BRCA	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23583168	chr7:148888333	NA	-0.85	-19.78	-0.62	2.74e-68	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7944584	0.837	rs11039149	chr11:47276675	A/G	cg20307385	chr11:47447363	PSMC3	0.63	11.91	0.43	1.1e-29	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs524281	0.861	rs11607393	chr11:65875149	C/A	cg16950941	chr11:66035639	RAB1B	-0.39	-8.16	-0.31	1.8e-15	Electroencephalogram traits;
BRCA	cis	rs897984	0.542	rs3751855	chr16:31091209	T/C	cg02466173	chr16:30829666	NA	-0.44	-9.77	-0.36	4.18e-21	Dementia with Lewy bodies;
BRCA	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg07587117	chr16:2239488	CASKIN1	0.37	8.07	0.3	3.5e-15	Height;
BRCA	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.05	-19.05	-0.6	1.99e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	11.29	0.41	4.32e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3820928	0.874	rs12105952	chr2:227864521	G/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.44	-0.32	2.21e-16	Pulmonary function;
BRCA	cis	rs55665837	1.000	rs10832271	chr11:14466919	C/G	cg19336497	chr11:14380999	RRAS2	-0.37	-9.77	-0.36	4.22e-21	Vitamin D levels;
BRCA	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg27170947	chr2:26402098	FAM59B	0.95	16.36	0.54	1.59e-50	Gut microbiome composition (summer);
BRCA	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.65	-18.77	-0.6	6.24e-63	Schizophrenia;
BRCA	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.42	-0.38	1.34e-23	Extrinsic epigenetic age acceleration;
BRCA	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg25019033	chr10:957182	NA	-0.42	-8.74	-0.33	2.01e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.79	0.42	3.68e-29	Homoarginine levels;
BRCA	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg24450063	chr1:156163899	SLC25A44	1.1	34.38	0.81	1.92e-147	Testicular germ cell tumor;
BRCA	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.7	14.01	0.48	4.45e-39	Total cholesterol levels;
BRCA	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg11764359	chr7:65958608	NA	0.67	14.95	0.51	1.51e-43	Aortic root size;
BRCA	cis	rs7677751	0.767	rs11133315	chr4:55082158	G/A	cg17187183	chr4:55093834	PDGFRA	0.45	9.0	0.34	2.65e-18	Corneal astigmatism;
BRCA	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg05347473	chr6:146136440	FBXO30	-0.44	-8.81	-0.33	1.17e-17	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs747782	0.527	rs2279822	chr11:48146114	C/T	cg15704280	chr7:45808275	SEPT13	0.58	8.16	0.31	1.75e-15	Intraocular pressure;
BRCA	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.78	0.36	3.89e-21	Lung cancer in ever smokers;
BRCA	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg20701182	chr2:24300061	SF3B14	0.58	9.05	0.34	1.77e-18	Lymphocyte counts;
BRCA	cis	rs9297145	1.000	rs10953280	chr7:98763405	A/G	cg05967295	chr7:98741636	SMURF1	-0.88	-20.87	-0.64	3.56e-74	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg08470875	chr2:26401718	FAM59B	-0.68	-11.53	-0.41	4.61e-28	Gut microbiome composition (summer);
BRCA	cis	rs2629540	0.847	rs12762597	chr10:126387043	G/A	cg08799069	chr10:126477246	METTL10	0.45	9.13	0.34	9e-19	Cocaine dependence;
BRCA	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg03929089	chr4:120376271	NA	-0.48	-9.03	-0.34	2.02e-18	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.5	-0.32	1.38e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg24110177	chr3:50126178	RBM5	-0.51	-14.18	-0.49	7.09e-40	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg20607798	chr8:58055168	NA	0.46	8.08	0.3	3.19e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9837602	0.938	rs9873709	chr3:99711687	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	10.6	0.39	2.68e-24	Breast cancer;
BRCA	cis	rs6120849	0.901	rs6088738	chr20:33747331	A/G	cg24642439	chr20:33292090	TP53INP2	-0.47	-8.62	-0.32	5.22e-17	Protein C levels;
BRCA	cis	rs61990749	0.544	rs1477259	chr14:78256138	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	9.29	0.34	2.41e-19	Fibroblast growth factor basic levels;
BRCA	cis	rs6430585	0.583	rs3769013	chr2:136556182	C/T	cg07169764	chr2:136633963	MCM6	1.22	28.11	0.74	8.76e-114	Corneal structure;
BRCA	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg03585969	chr10:35415529	CREM	0.56	11.55	0.42	3.74e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg26043149	chr18:55253948	FECH	-0.36	-8.06	-0.3	3.82e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	11.85	0.42	2.03e-29	Lung cancer in ever smokers;
BRCA	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.61	-0.42	2.03e-28	Mean corpuscular volume;
BRCA	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-8.9	-0.33	5.68e-18	Monocyte percentage of white cells;
BRCA	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs17685	0.535	rs41299460	chr7:75600951	G/A	cg19862616	chr7:65841803	NCRNA00174	0.38	9.09	0.34	1.25e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9318086	0.648	rs7331047	chr13:24467342	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.3	8.44	0.32	2.13e-16	Myopia (pathological);
BRCA	trans	rs4650994	0.544	rs2811314	chr1:178619183	C/T	cg05059571	chr16:84539110	KIAA1609	0.53	11.88	0.43	1.45e-29	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs36051895	0.625	rs12340333	chr9:5176215	C/G	cg02405213	chr9:5042618	JAK2	-0.46	-8.9	-0.33	5.92e-18	Pediatric autoimmune diseases;
BRCA	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	18.27	0.59	2.7e-60	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.77	-0.33	1.65e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg09359103	chr1:154839909	KCNN3	-0.56	-14.71	-0.5	2.03e-42	Prostate cancer;
BRCA	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.58	7.84	0.3	1.92e-14	Putamen volume;
BRCA	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.75	11.73	0.42	6.29e-29	Gut microbiome composition (summer);
BRCA	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg26384229	chr12:38710491	ALG10B	-0.44	-10.05	-0.37	3.71e-22	Bladder cancer;
BRCA	cis	rs9487051	0.676	rs9320278	chr6:109562589	T/C	cg21918786	chr6:109611834	NA	-0.31	-7.97	-0.3	7.24e-15	Reticulocyte fraction of red cells;
BRCA	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg09359103	chr1:154839909	KCNN3	-0.59	-15.31	-0.52	2.79e-45	Prostate cancer;
BRCA	cis	rs7264396	0.561	rs6060741	chr20:34571484	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.54	10.06	0.37	3.37e-22	Total cholesterol levels;
BRCA	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg06636001	chr8:8085503	FLJ10661	0.45	8.9	0.33	5.83e-18	Monocyte count;
BRCA	cis	rs919433	0.680	rs2244271	chr2:198286581	C/T	cg00792783	chr2:198669748	PLCL1	0.39	8.66	0.32	3.9e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg00814883	chr7:100076585	TSC22D4	-0.55	-10.74	-0.39	7.84e-25	Platelet count;
BRCA	trans	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg26043149	chr18:55253948	FECH	0.41	8.88	0.33	6.69e-18	Bone mineral density;
BRCA	cis	rs6893300	0.785	rs7704520	chr5:179191054	G/A	cg14593053	chr5:179126677	CANX	-0.36	-8.09	-0.3	2.9e-15	Resting heart rate;
BRCA	cis	rs113835537	0.627	rs11227534	chr11:66336171	C/A	cg24851651	chr11:66362959	CCS	0.43	8.17	0.31	1.65e-15	Airway imaging phenotypes;
BRCA	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-10.54	-0.38	4.82e-24	Bladder cancer;
BRCA	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg00666640	chr1:248458726	OR2T12	0.34	9.11	0.34	1.03e-18	Common traits (Other);
BRCA	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg04362960	chr10:104952993	NT5C2	0.45	10.36	0.38	2.38e-23	Arsenic metabolism;
BRCA	cis	rs6484504	0.625	rs1535741	chr11:31375072	T/C	cg06552810	chr11:31128660	NA	0.38	8.53	0.32	1.06e-16	Red blood cell count;
BRCA	cis	rs4363385	0.818	rs529077	chr1:153012149	T/C	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	trans	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-11.86	-0.42	1.78e-29	Brugada syndrome;
BRCA	cis	rs72781680	0.821	rs17038360	chr2:24095798	A/G	cg08917208	chr2:24149416	ATAD2B	0.61	10.4	0.38	1.59e-23	Lymphocyte counts;
BRCA	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg08885076	chr2:99613938	TSGA10	-0.49	-9.45	-0.35	6.45e-20	Chronic sinus infection;
BRCA	cis	rs919433	0.680	rs2565163	chr2:198354414	T/C	cg00792783	chr2:198669748	PLCL1	0.39	8.67	0.32	3.56e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg18357645	chr12:58087776	OS9	-0.36	-9.43	-0.35	7.16e-20	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.99	14.92	0.51	2.08e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg03146154	chr1:46216737	IPP	0.54	12.02	0.43	3.81e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21659725	chr3:3221576	CRBN	0.51	12.1	0.43	1.72e-30	Resting heart rate;
BRCA	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-9.96	-0.37	7.78e-22	Aortic root size;
BRCA	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg06212747	chr3:49208901	KLHDC8B	0.68	14.76	0.5	1.25e-42	Subjective well-being (multi-trait analysis);Menarche (age at onset);
BRCA	cis	rs10046574	0.634	rs77474267	chr7:135098679	G/A	cg27474649	chr7:135195673	CNOT4	0.58	8.33	0.31	5.1e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg12826209	chr6:26865740	GUSBL1	0.56	9.19	0.34	5.36e-19	Intelligence (multi-trait analysis);
BRCA	trans	rs1974653	0.781	rs9606245	chr22:20084681	G/A	cg20152630	chr19:46405944	MYPOP	0.38	8.48	0.32	1.6e-16	Schizophrenia;
BRCA	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18876405	chr7:65276391	NA	0.51	11.4	0.41	1.57e-27	Aortic root size;
BRCA	cis	rs36051895	0.632	rs62541916	chr9:5151904	C/A	cg02405213	chr9:5042618	JAK2	-0.44	-8.57	-0.32	7.72e-17	Pediatric autoimmune diseases;
BRCA	cis	rs6910233	0.793	rs210133	chr6:33536797	C/G	cg13560919	chr6:33536144	NA	0.37	7.88	0.3	1.45e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg26818010	chr10:134567672	INPP5A	-0.63	-13.42	-0.47	2.27e-36	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg25124228	chr12:125621409	AACS	0.43	8.31	0.31	5.95e-16	Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	17.97	0.58	9.63e-59	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2658782	0.951	rs2608214	chr11:93148665	C/T	cg15737290	chr11:93063684	CCDC67	0.47	9.51	0.35	3.92e-20	Pulmonary function decline;
BRCA	cis	rs7945718	0.810	rs7930282	chr11:12835941	C/T	cg25843174	chr11:12811716	TEAD1	0.21	8.22	0.31	1.17e-15	Educational attainment (years of education);
BRCA	cis	rs4919087	1.000	rs61863767	chr10:99084426	C/T	cg25902810	chr10:99078978	FRAT1	0.51	10.82	0.39	3.53e-25	Monocyte count;
BRCA	cis	rs3820928	0.900	rs6754155	chr2:227784961	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-8.87	-0.33	7.05e-18	Pulmonary function;
BRCA	cis	rs6558530	0.692	rs6558525	chr8:1702523	A/G	cg19131313	chr8:1704013	NA	-0.39	-7.82	-0.3	2.16e-14	Systolic blood pressure;
BRCA	cis	rs7665147	1	rs7665147	chr4:57767327	T/A	cg26694713	chr4:57773883	REST	0.5	10.07	0.37	3.21e-22	Platelet count;
BRCA	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.58	-11.84	-0.42	2.2e-29	Body mass index (adult);
BRCA	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	14.37	0.49	8.53e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17401966	0.931	rs34225619	chr1:10371987	C/T	cg15208524	chr1:10270712	KIF1B	0.37	8.11	0.31	2.57e-15	Hepatocellular carcinoma;
BRCA	cis	rs3820928	0.874	rs6740108	chr2:227889559	G/T	cg11843606	chr2:227700838	RHBDD1	0.35	7.81	0.3	2.4e-14	Pulmonary function;
BRCA	cis	rs68170813	0.559	rs74387778	chr7:106963213	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.47	-0.32	1.7e-16	Coronary artery disease;
BRCA	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg01420254	chr6:26195488	NA	0.57	8.81	0.33	1.15e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg13119609	chr19:45449297	APOC2	0.48	13.24	0.46	1.5e-35	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs17384381	1.000	rs12140935	chr1:85855716	G/A	cg16011679	chr1:85725395	C1orf52	0.53	8.18	0.31	1.56e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6594713	0.570	rs35926701	chr5:112898969	A/G	cg12552261	chr5:112820674	MCC	0.5	7.91	0.3	1.13e-14	Brain cytoarchitecture;
BRCA	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg03929089	chr4:120376271	NA	-0.43	-8.02	-0.3	5.16e-15	Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.03	0.3	4.79e-15	Corneal astigmatism;
BRCA	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-9.1	-0.34	1.11e-18	Schizophrenia;
BRCA	cis	rs752010	0.545	rs6600379	chr1:42053497	T/C	cg06885757	chr1:42089581	HIVEP3	0.22	8.0	0.3	6.07e-15	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-8.75	-0.33	1.94e-17	Monocyte percentage of white cells;
BRCA	cis	rs7953508	0.506	rs10777530	chr12:93961110	C/T	cg18151635	chr12:93972918	NA	-0.46	-9.12	-0.34	9.46e-19	Pubertal anthropometrics;
BRCA	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24838063	chr12:130822603	PIWIL1	0.68	16.73	0.55	2.13e-52	Menopause (age at onset);
BRCA	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg11663144	chr21:46675770	NA	-0.47	-9.54	-0.35	2.88e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg09307838	chr4:120376055	NA	-0.53	-11.23	-0.41	7.88e-27	Corneal astigmatism;
BRCA	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15506890	chr2:3487001	NA	0.47	10.07	0.37	3.21e-22	Neurofibrillary tangles;
BRCA	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03517284	chr6:25882590	NA	-0.47	-10.66	-0.39	1.57e-24	Blood metabolite levels;
BRCA	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg03929089	chr4:120376271	NA	-0.74	-16.12	-0.54	2.68e-49	Coronary artery disease;
BRCA	cis	rs739496	0.542	rs10219736	chr12:111788402	C/T	cg10833066	chr12:111807467	FAM109A	0.34	8.11	0.31	2.52e-15	Platelet count;
BRCA	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg01483505	chr11:975446	AP2A2	0.3	8.07	0.3	3.51e-15	Alzheimer's disease (late onset);
BRCA	cis	rs7580658	0.545	rs13001184	chr2:127952206	A/G	cg16751203	chr2:127950803	CYP27C1	0.28	8.19	0.31	1.44e-15	Protein C levels;
BRCA	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg08601574	chr20:25228251	PYGB	-0.34	-8.37	-0.31	3.55e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg11905131	chr22:24372483	LOC391322	0.45	8.9	0.33	5.51e-18	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	cis	rs7560272	0.538	rs2001436	chr2:73928965	A/T	cg20560298	chr2:73613845	ALMS1	0.35	9.0	0.34	2.64e-18	Schizophrenia;
BRCA	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg04518342	chr5:131593106	PDLIM4	0.38	9.56	0.35	2.46e-20	Breast cancer;
BRCA	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.64	0.32	4.52e-17	Rheumatoid arthritis;
BRCA	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg08392591	chr16:89556376	ANKRD11	-0.48	-12.02	-0.43	3.87e-30	Multiple myeloma (IgH translocation);
BRCA	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg02734326	chr4:10020555	SLC2A9	0.4	8.72	0.33	2.41e-17	Bone mineral density;
BRCA	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-9.07	-0.34	1.49e-18	Schizophrenia;
BRCA	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg08917208	chr2:24149416	ATAD2B	1.05	14.36	0.49	9.8e-41	Lymphocyte counts;
BRCA	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg17691542	chr6:26056736	HIST1H1C	0.48	9.55	0.35	2.75e-20	Iron status biomarkers;
BRCA	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg11822812	chr5:140052017	DND1	0.29	7.93	0.3	9.56e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs778371	0.723	rs12105766	chr2:233617647	A/G	cg08000102	chr2:233561755	GIGYF2	0.82	19.07	0.6	1.55e-64	Schizophrenia;
BRCA	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg20469991	chr17:27169893	C17orf63	-0.47	-9.28	-0.34	2.6e-19	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs870825	0.932	rs10034861	chr4:185577450	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	12.9	0.45	5.51e-34	Blood protein levels;
BRCA	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg20933634	chr6:27740509	NA	0.42	8.2	0.31	1.34e-15	Parkinson's disease;
BRCA	cis	rs13046373	0.535	rs9977510	chr21:32027920	A/G	cg14062083	chr21:31802829	KRTAP13-4	0.33	8.85	0.33	8.46e-18	HDL cholesterol;
BRCA	cis	rs3768617	0.966	rs10911253	chr1:183086190	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.46	10.37	0.38	2.24e-23	Fuchs's corneal dystrophy;
BRCA	trans	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg26043149	chr18:55253948	FECH	-0.4	-8.47	-0.32	1.75e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6087990	0.806	rs4911257	chr20:31359574	T/C	cg13636640	chr20:31349939	DNMT3B	0.6	18.32	0.59	1.44e-60	Ulcerative colitis;
BRCA	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.4	7.83	0.3	2.05e-14	Lung disease severity in cystic fibrosis;
BRCA	cis	rs870825	0.616	rs2310108	chr4:185639475	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	17.43	0.57	5.93e-56	Blood protein levels;
BRCA	cis	rs7766436	0.614	rs12660581	chr6:22564435	C/T	cg13666174	chr6:22585274	NA	-0.41	-8.66	-0.32	3.86e-17	Coronary artery disease;
BRCA	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg11608241	chr8:8085544	FLJ10661	0.28	8.1	0.31	2.86e-15	Mood instability;
BRCA	cis	rs11229555	1.000	rs3168135	chr11:58386177	G/A	cg15696309	chr11:58395628	NA	-0.53	-11.58	-0.42	2.85e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg23887609	chr12:130822674	PIWIL1	0.43	9.33	0.35	1.71e-19	Menopause (age at onset);
BRCA	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg16230307	chr14:35515116	FAM177A1	0.76	15.31	0.52	2.65e-45	Psoriasis;
BRCA	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.48	0.5	2.79e-41	Motion sickness;
BRCA	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg00990874	chr7:1149470	C7orf50	-0.63	-13.23	-0.46	1.71e-35	Bronchopulmonary dysplasia;
BRCA	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg05872129	chr22:39784769	NA	-0.57	-13.37	-0.47	4e-36	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs28374715	0.662	rs16971558	chr15:41458619	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.77	-15.67	-0.53	4.54e-47	Ulcerative colitis;
BRCA	cis	rs7737355	0.947	rs3776030	chr5:130776738	A/G	cg06307176	chr5:131281290	NA	-0.55	-10.99	-0.4	7.78e-26	Life satisfaction;
BRCA	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.67	-0.32	3.58e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg01528321	chr10:82214614	TSPAN14	0.82	17.42	0.57	6.76e-56	Post bronchodilator FEV1;
BRCA	trans	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg09719594	chr16:21412588	NA	-0.36	-8.52	-0.32	1.12e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-11.38	-0.41	1.97e-27	Colorectal cancer;
BRCA	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg09904177	chr6:26538194	HMGN4	0.47	14.7	0.5	2.42e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg12564285	chr5:131593104	PDLIM4	0.35	8.0	0.3	5.92e-15	Blood metabolite levels;
BRCA	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.66	-17.75	-0.57	1.3e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg00540400	chr15:79124168	NA	-0.28	-7.91	-0.3	1.12e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg23018236	chr17:30244563	NA	-0.66	-10.06	-0.37	3.49e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs11051970	0.614	rs2728684	chr12:32575665	C/A	cg02745156	chr12:32552066	NA	0.27	8.28	0.31	6.98e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg01689657	chr7:91764605	CYP51A1	0.23	8.3	0.31	6.23e-16	Breast cancer;
BRCA	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg08917208	chr2:24149416	ATAD2B	0.93	13.78	0.48	5.46e-38	Lymphocyte counts;
BRCA	cis	rs1451375	0.698	rs1813214	chr7:50637525	A/G	cg18232548	chr7:50535776	DDC	0.4	9.26	0.34	3.07e-19	Malaria;
BRCA	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg11279151	chr3:101281821	RG9MTD1	0.5	9.41	0.35	9e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg04990556	chr1:26633338	UBXN11	-0.48	-9.6	-0.36	1.77e-20	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg18351406	chr4:77819688	ANKRD56	0.56	12.35	0.44	1.48e-31	Emphysema distribution in smoking;
BRCA	cis	rs897984	0.609	rs17839567	chr16:31057945	A/G	cg00531865	chr16:30841666	NA	-0.38	-9.13	-0.34	8.86e-19	Dementia with Lewy bodies;
BRCA	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg13319975	chr6:146136371	FBXO30	-0.4	-9.12	-0.34	1e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg22676075	chr6:135203613	NA	0.47	9.07	0.34	1.44e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.28e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11088226	0.581	rs2236430	chr21:33973408	A/G	cg09050820	chr6:167586206	TCP10L2	-0.56	-11.21	-0.41	9.31e-27	Gastritis;
BRCA	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12292205	chr6:26970375	C6orf41	-0.47	-7.97	-0.3	7.21e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4302748	0.862	rs12533280	chr7:36171953	C/T	cg24442661	chr7:36192818	EEPD1	0.43	8.13	0.31	2.29e-15	Platelet count;
BRCA	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg06115741	chr20:33292138	TP53INP2	0.51	11.44	0.41	1.11e-27	Coronary artery disease;
BRCA	trans	rs1941687	0.563	rs9953034	chr18:31335294	A/G	cg15819921	chr19:927150	ARID3A	-0.44	-8.48	-0.32	1.56e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs7560272	0.501	rs12713790	chr2:73945611	C/T	cg20560298	chr2:73613845	ALMS1	0.33	8.4	0.32	2.84e-16	Schizophrenia;
BRCA	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg14820908	chr5:178986412	RUFY1	0.44	11.2	0.4	1.07e-26	Lung cancer;
BRCA	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg20200200	chr1:18807388	KLHDC7A	-0.45	-11.37	-0.41	2.02e-27	Breast cancer;
BRCA	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.53	11.89	0.43	1.4e-29	Colorectal cancer;
BRCA	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg26838691	chr2:24397539	C2orf84	-0.48	-8.64	-0.32	4.35e-17	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs7766436	0.767	rs6456497	chr6:22603559	G/A	cg13666174	chr6:22585274	NA	-0.36	-9.42	-0.35	8.31e-20	Coronary artery disease;
BRCA	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg10820045	chr2:198174542	NA	-0.4	-9.66	-0.36	1.1e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-8.91	-0.33	5.22e-18	Alzheimer's disease (late onset);
BRCA	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.16	0.31	1.77e-15	Tonsillectomy;
BRCA	cis	rs4363385	0.818	rs472076	chr1:153013742	G/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.54	-0.32	9.7e-17	Inflammatory skin disease;
BRCA	cis	rs7301826	0.651	rs7956851	chr12:131319099	C/T	cg11011512	chr12:131303247	STX2	0.48	12.34	0.44	1.52e-31	Plasma plasminogen activator levels;
BRCA	cis	rs7707921	0.541	rs10066167	chr5:81495445	C/T	cg15871215	chr5:81402204	ATG10	0.35	8.82	0.33	1.1e-17	Breast cancer;
BRCA	trans	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg15556689	chr8:8085844	FLJ10661	0.32	8.46	0.32	1.84e-16	Retinal vascular caliber;
BRCA	cis	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg09307838	chr4:120376055	NA	0.52	10.3	0.38	4.1000000000000003e-23	Corneal astigmatism;
BRCA	trans	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg26043149	chr18:55253948	FECH	0.47	9.94	0.37	9.37e-22	Bone mineral density;
BRCA	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14442939	chr10:27389572	ANKRD26	0.66	11.01	0.4	6.05e-26	Breast cancer;
BRCA	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-10.39	-0.38	1.86e-23	Resting heart rate;
BRCA	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg27170947	chr2:26402098	FAM59B	-0.66	-11.27	-0.41	5.17e-27	Gut microbiome composition (summer);
BRCA	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.69	12.05	0.43	2.72e-30	Renal function-related traits (BUN);
BRCA	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.36	-0.38	2.44e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs877529	0.967	rs139385	chr22:39530132	C/A	cg18708252	chr22:39545030	CBX7	-0.31	-7.9	-0.3	1.18e-14	Multiple myeloma;
BRCA	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-7.83	-0.3	2.07e-14	Colorectal cancer;
BRCA	trans	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.85	-0.3	1.79e-14	Corneal astigmatism;
BRCA	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.58	-0.32	7.04e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs16854884	0.770	rs951865	chr3:143812677	G/A	cg06585982	chr3:143692056	C3orf58	0.42	8.1	0.31	2.88e-15	Economic and political preferences (feminism/equality);
BRCA	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	9.88	0.36	1.55e-21	Aortic root size;
BRCA	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg03342759	chr3:160939853	NMD3	-0.66	-14.31	-0.49	1.77e-40	Morning vs. evening chronotype;
BRCA	cis	rs7633770	0.841	rs6442010	chr3:46669500	A/T	cg11219411	chr3:46661640	NA	0.69	18.91	0.6	1.19e-63	Coronary artery disease;
BRCA	cis	rs600806	0.778	rs2787015	chr1:110009434	A/C	cg20591472	chr1:110008990	SYPL2	0.31	7.89	0.3	1.31e-14	Intelligence (multi-trait analysis);
BRCA	trans	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-11.71	-0.42	8.2e-29	Migraine;
BRCA	trans	rs11088226	0.598	rs79634586	chr21:33959363	A/G	cg09050820	chr6:167586206	TCP10L2	0.85	14.35	0.49	1.1e-40	Gastritis;
BRCA	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg20387954	chr3:183756860	HTR3D	0.45	10.09	0.37	2.67e-22	Anterior chamber depth;
BRCA	cis	rs7172677	0.737	rs8027604	chr15:75447773	C/T	cg10253484	chr15:75165896	SCAMP2	-0.42	-8.04	-0.3	4.51e-15	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-11.92	-0.43	1.06e-29	Bipolar disorder;
BRCA	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg21475434	chr5:93447410	FAM172A	0.66	8.47	0.32	1.62e-16	Diabetic retinopathy;
BRCA	cis	rs2425143	0.818	rs12481545	chr20:34407698	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-7.84	-0.3	1.85e-14	Blood protein levels;
BRCA	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg09462578	chr12:12878428	APOLD1	-0.62	-11.13	-0.4	1.94e-26	Systemic lupus erythematosus;
BRCA	cis	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg06521331	chr12:34319734	NA	-0.51	-10.12	-0.37	1.98e-22	Morning vs. evening chronotype;
BRCA	cis	rs3740540	0.761	rs34042290	chr10:126286806	G/A	cg04949429	chr10:126290192	LHPP	-0.39	-8.27	-0.31	7.58e-16	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg25457927	chr22:38595422	NA	0.43	16.95	0.56	1.68e-53	Cutaneous nevi;
BRCA	cis	rs990171	0.607	rs2192752	chr2:102769373	A/C	cg22835712	chr2:102737379	NA	-0.55	-9.57	-0.35	2.27e-20	Lymphocyte counts;
BRCA	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg08601574	chr20:25228251	PYGB	0.39	9.45	0.35	6.06e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg04756594	chr16:24857601	SLC5A11	0.55	12.32	0.44	1.89e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg18904891	chr8:8559673	CLDN23	0.6	11.68	0.42	1.02e-28	Obesity-related traits;
BRCA	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg05535760	chr7:792225	HEATR2	0.72	11.7	0.42	8.51e-29	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg05283184	chr6:79620031	NA	0.43	11.15	0.4	1.61e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg20387954	chr3:183756860	HTR3D	0.45	10.21	0.37	8.78e-23	Anterior chamber depth;
BRCA	cis	rs17095355	1.000	rs11194917	chr10:111692552	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.76	-0.36	4.45e-21	Biliary atresia;
BRCA	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg17063962	chr7:91808500	NA	-0.51	-11.86	-0.42	1.89e-29	Breast cancer;
BRCA	cis	rs9487051	0.676	rs13211313	chr6:109562074	G/C	cg21918786	chr6:109611834	NA	-0.32	-8.25	-0.31	9.15e-16	Reticulocyte fraction of red cells;
BRCA	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.76	-0.36	4.67e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs311392	0.966	rs425548	chr8:55087468	C/T	cg11783602	chr8:55087084	NA	-0.33	-9.59	-0.35	1.94e-20	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10802521	chr3:52805072	NEK4	0.31	8.4	0.32	2.87e-16	Electroencephalogram traits;
BRCA	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11890956	chr21:40555474	PSMG1	-0.82	-19.71	-0.61	6.73e-68	Cognitive function;
BRCA	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg22920501	chr2:26401640	FAM59B	0.91	16.27	0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg19010396	chr19:19431384	KIAA0892;SF4	-0.45	-8.93	-0.33	4.44e-18	Tonsillectomy;
BRCA	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg24675658	chr1:53192096	ZYG11B	-0.51	-11.25	-0.41	6.58e-27	Monocyte count;
BRCA	cis	rs17490626	0.568	rs12260685	chr10:71215799	C/T	cg12610070	chr10:71211762	TSPAN15	-0.33	-11.48	-0.41	7.61e-28	Thrombosis;
BRCA	trans	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg25214090	chr10:38739885	LOC399744	0.55	12.56	0.44	1.66e-32	Corneal astigmatism;
BRCA	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.73	10.0	0.37	5.6e-22	Initial pursuit acceleration;
BRCA	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg20703242	chr1:230279135	GALNT2	0.47	10.4	0.38	1.61e-23	Coronary artery disease;
BRCA	cis	rs16958440	1.000	rs75800624	chr18:44633605	G/C	cg17192377	chr18:44677553	HDHD2	0.67	9.75	0.36	4.96e-21	Sitting height ratio;
BRCA	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.46	0.55	5.3e-51	Alzheimer's disease (late onset);
BRCA	cis	rs17253792	0.545	rs3742570	chr14:56016434	A/C	cg01858014	chr14:56050164	KTN1	-0.61	-7.95	-0.3	8.3e-15	Putamen volume;
BRCA	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg15698299	chr3:52233019	ALAS1	-0.39	-9.25	-0.34	3.27e-19	Electroencephalogram traits;
BRCA	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	22.91	0.67	2.83e-85	Platelet count;
BRCA	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg06026331	chr20:60912101	LAMA5	0.68	13.59	0.47	3.86e-37	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs939658	0.935	rs4778651	chr15:79447810	G/A	cg17916960	chr15:79447300	NA	-0.42	-10.15	-0.37	1.47e-22	Refractive error;
BRCA	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.57	0.67	2.25e-83	Chronic sinus infection;
BRCA	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg14019146	chr3:50243930	SLC38A3	-0.39	-9.32	-0.35	1.88e-19	Menarche (age at onset);
BRCA	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.17	0.31	1.67e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg03954927	chr1:10346856	KIF1B	0.45	12.84	0.45	9.75e-34	Hepatocellular carcinoma;
BRCA	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg04166393	chr7:2884313	GNA12	0.41	8.66	0.32	3.9e-17	Height;
BRCA	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg23750338	chr8:142222470	SLC45A4	0.53	12.77	0.45	1.94e-33	Immature fraction of reticulocytes;
BRCA	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg02753203	chr1:228287806	NA	-0.58	-12.34	-0.44	1.64e-31	Diastolic blood pressure;
BRCA	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.8	-0.42	3.24e-29	Response to antipsychotic treatment;
BRCA	cis	rs4285028	0.948	rs2877560	chr3:121699238	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.85	-0.39	2.68e-25	Multiple sclerosis;
BRCA	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	18.04	0.58	3.93e-59	Mean corpuscular hemoglobin;
BRCA	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg21535247	chr6:8435926	SLC35B3	-0.41	-9.45	-0.35	6.14e-20	Motion sickness;
BRCA	cis	rs4281086	0.541	rs10094938	chr8:10395326	A/C	cg01072821	chr8:10382165	T-SP1	-0.29	-8.12	-0.31	2.39e-15	Obesity-related traits;
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg04025307	chr7:1156635	C7orf50	0.72	17.73	0.57	1.64e-57	Longevity;Endometriosis;
BRCA	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg12386194	chr3:101231763	SENP7	-0.39	-8.37	-0.31	3.75e-16	Colorectal cancer;
BRCA	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg13010199	chr12:38710504	ALG10B	0.55	12.08	0.43	2.07e-30	Heart rate;
BRCA	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	14.6	0.5	6.9e-42	Platelet count;
BRCA	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg00277334	chr10:82204260	NA	-0.48	-10.26	-0.38	5.96e-23	Post bronchodilator FEV1;
BRCA	cis	rs965469	0.779	rs6051830	chr20:3373397	T/C	cg25506879	chr20:3388711	C20orf194	-0.46	-9.06	-0.34	1.55e-18	IFN-related cytopenia;
BRCA	cis	rs877282	0.583	rs11253425	chr10:815173	G/A	cg15764593	chr10:829463	NA	-0.61	-10.02	-0.37	4.78e-22	Uric acid levels;
BRCA	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg18305652	chr10:134549665	INPP5A	0.49	12.04	0.43	3.15e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.45	9.24	0.34	3.66e-19	Schizophrenia;
BRCA	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-14.89	-0.51	2.92e-43	Chronic sinus infection;
BRCA	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg11266682	chr4:10021025	SLC2A9	0.38	9.7	0.36	7.62e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg09165964	chr15:75287851	SCAMP5	-0.85	-20.27	-0.63	6.12e-71	Blood trace element (Zn levels);
BRCA	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg03146154	chr1:46216737	IPP	0.46	10.2	0.37	1.01e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg05896524	chr21:47604654	C21orf56	0.51	10.46	0.38	9.19e-24	Testicular germ cell tumor;
BRCA	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11890956	chr21:40555474	PSMG1	1.04	29.38	0.76	1.05e-120	Cognitive function;
BRCA	cis	rs11718455	0.767	rs13076333	chr3:43955070	G/A	cg08738300	chr3:44038990	NA	0.5	8.69	0.33	2.95e-17	Coronary artery disease;
BRCA	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg13175981	chr1:150552382	MCL1	0.41	9.01	0.34	2.37e-18	Tonsillectomy;
BRCA	cis	rs6028335	0.674	rs3752301	chr20:37654024	T/G	cg16355469	chr20:37678765	NA	0.49	8.62	0.32	5.07e-17	Alcohol and nicotine co-dependence;
BRCA	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.17	-0.43	8.86e-31	Total cholesterol levels;
BRCA	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg04450456	chr4:17643702	FAM184B	0.39	11.62	0.42	1.95e-28	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs700651	0.789	rs10497812	chr2:198911245	A/G	cg00792783	chr2:198669748	PLCL1	-0.42	-9.06	-0.34	1.56e-18	Intracranial aneurysm;
BRCA	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg08859206	chr1:53392774	SCP2	0.45	9.28	0.34	2.53e-19	Monocyte count;
BRCA	cis	rs36051895	0.659	rs12348771	chr9:5083634	T/C	cg02405213	chr9:5042618	JAK2	-0.55	-9.62	-0.36	1.52e-20	Pediatric autoimmune diseases;
BRCA	cis	rs11252926	0.617	rs11253319	chr10:722732	C/T	cg18196295	chr10:418757	DIP2C	-0.39	-7.85	-0.3	1.71e-14	Psychosis in Alzheimer's disease;
BRCA	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.13	0.31	2.23e-15	Tonsillectomy;
BRCA	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg05283184	chr6:79620031	NA	-0.42	-10.86	-0.39	2.46e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs600806	0.888	rs10858084	chr1:109882250	T/A	cg20591472	chr1:110008990	SYPL2	0.32	8.14	0.31	2.05e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg25036284	chr2:26402008	FAM59B	0.95	13.98	0.48	6.16e-39	Gut microbiome composition (summer);
BRCA	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23583168	chr7:148888333	NA	-0.79	-18.48	-0.59	2.1e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs13064411	0.696	rs6766615	chr3:113219342	T/C	cg18753928	chr3:113234510	CCDC52	-0.59	-12.53	-0.44	2.23e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg10556349	chr10:835070	NA	0.74	10.02	0.37	4.76e-22	Eosinophil percentage of granulocytes;
BRCA	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg08213375	chr14:104286397	PPP1R13B	0.65	18.33	0.59	1.2e-60	Schizophrenia;
BRCA	cis	rs10899021	0.512	rs2186955	chr11:74375475	C/T	cg25880958	chr11:74394337	NA	0.4	8.51	0.32	1.26e-16	Response to metformin (IC50);
BRCA	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26314531	chr2:26401878	FAM59B	-0.62	-10.91	-0.4	1.57e-25	Gut microbiome composition (summer);
BRCA	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg14675211	chr2:100938903	LONRF2	0.52	11.56	0.42	3.33e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg24675658	chr1:53192096	ZYG11B	-0.65	-14.37	-0.49	8.77e-41	Monocyte count;
BRCA	cis	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg07460842	chr6:66804631	NA	0.87	15.61	0.53	8.61e-47	Exhaled nitric oxide levels;
BRCA	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.55	-0.32	9.19e-17	Monocyte percentage of white cells;
BRCA	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	21.02	0.64	5.49e-75	Smoking behavior;
BRCA	cis	rs41005	0.597	rs62104919	chr2:8101999	C/T	cg03155496	chr2:8117019	LOC339788	-0.5	-11.91	-0.43	1.13e-29	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg00666640	chr1:248458726	OR2T12	0.32	8.77	0.33	1.63e-17	Common traits (Other);
BRCA	cis	rs10463316	0.894	rs6579862	chr5:150761717	T/G	cg03212797	chr5:150827313	SLC36A1	-0.4	-7.93	-0.3	1.01e-14	Metabolite levels (Pyroglutamine);
BRCA	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg04455712	chr21:45112962	RRP1B	0.38	9.85	0.36	2.03e-21	Mean corpuscular volume;
BRCA	cis	rs13046373	0.507	rs2832969	chr21:32019627	A/G	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.33	0.31	4.81e-16	HDL cholesterol;
BRCA	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg04553112	chr3:125709451	NA	-0.56	-8.57	-0.32	7.58e-17	Blood pressure (smoking interaction);
BRCA	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg12935359	chr14:103987150	CKB	0.64	14.72	0.5	1.86e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg17330251	chr7:94953956	PON1	-0.42	-8.8	-0.33	1.27e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg05234568	chr11:5960015	NA	-0.46	-9.19	-0.34	5.61e-19	DNA methylation (variation);
BRCA	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21659725	chr3:3221576	CRBN	-0.71	-21.59	-0.65	4.63e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs2806561	0.715	rs10753550	chr1:23322471	C/G	cg19743168	chr1:23544995	NA	-0.41	-9.82	-0.36	2.67e-21	Height;
BRCA	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg17366294	chr4:99064904	C4orf37	0.45	10.44	0.38	1.15e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg00504896	chr12:9437009	LOC642846	-0.45	-9.99	-0.37	6.13e-22	Breast size;
BRCA	cis	rs812925	0.571	rs3087898	chr2:61765074	G/A	cg15711740	chr2:61764176	XPO1	-0.42	-9.89	-0.36	1.46e-21	Immature fraction of reticulocytes;
BRCA	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.17	-0.49	7.4e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs1595825	0.891	rs77029420	chr2:198651492	G/A	cg19156104	chr2:198669113	PLCL1	-0.49	-8.43	-0.32	2.34e-16	Ulcerative colitis;
BRCA	cis	rs8017423	0.630	rs4900038	chr14:90821677	A/G	cg04374321	chr14:90722782	PSMC1	-0.49	-11.96	-0.43	6.75e-30	Mortality in heart failure;
BRCA	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.71	15.63	0.53	7.39e-47	Lymphocyte counts;
BRCA	cis	rs7572263	0.724	rs6710543	chr2:209050447	G/A	cg23998903	chr2:209048830	C2orf80	-0.42	-8.68	-0.32	3.16e-17	Glioma;Non-glioblastoma glioma;
BRCA	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg04362960	chr10:104952993	NT5C2	0.46	10.74	0.39	7.4e-25	Arsenic metabolism;
BRCA	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg00101154	chr16:420108	MRPL28	-0.58	-11.67	-0.42	1.22e-28	Bone mineral density (spine);Bone mineral density;
BRCA	trans	rs9951602	0.512	rs1599636	chr18:76643916	G/A	cg02800362	chr5:177631904	HNRNPAB	0.75	17.49	0.57	2.96e-56	Obesity-related traits;
BRCA	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg20476274	chr7:133979776	SLC35B4	0.65	19.57	0.61	3.71e-67	Mean platelet volume;
BRCA	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-19.62	-0.61	1.91e-67	Systemic lupus erythematosus;
BRCA	cis	rs600806	0.778	rs2115787	chr1:110003840	T/G	cg20591472	chr1:110008990	SYPL2	0.31	7.88	0.3	1.42e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11764359	chr7:65958608	NA	-0.73	-15.99	-0.53	1.18e-48	Aortic root size;
BRCA	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	21.28	0.64	2.17e-76	Platelet count;
BRCA	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg05347473	chr6:146136440	FBXO30	-0.39	-7.87	-0.3	1.57e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1451375	0.698	rs56766899	chr7:50648938	T/C	cg18232548	chr7:50535776	DDC	0.39	9.19	0.34	5.5e-19	Malaria;
BRCA	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06627557	chr7:32535165	LSM5;AVL9	1.13	34.93	0.81	2.54e-150	Cognitive ability;
BRCA	trans	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-17.64	-0.57	5.01e-57	Colorectal cancer;
BRCA	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg10057126	chr4:77819792	ANKRD56	0.66	15.36	0.52	1.46e-45	Emphysema distribution in smoking;
BRCA	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg05313129	chr8:58192883	C8orf71	-0.4	-8.33	-0.31	4.96e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg16576597	chr16:28551801	NUPR1	0.35	9.46	0.35	5.9e-20	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg09307838	chr4:120376055	NA	0.75	16.06	0.54	5.37e-49	Corneal astigmatism;
BRCA	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.57	-0.32	7.75e-17	Total body bone mineral density;
BRCA	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg18016565	chr1:150552671	MCL1	-0.37	-8.52	-0.32	1.15e-16	Blood protein levels;
BRCA	cis	rs2637030	0.586	rs1552649	chr5:52870476	A/T	cg06476337	chr5:52856530	NDUFS4	0.35	7.91	0.3	1.15e-14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs4566357	0.615	rs2396445	chr2:227917726	C/G	cg05526886	chr2:227700861	RHBDD1	-0.4	-8.21	-0.31	1.2e-15	Coronary artery disease;
BRCA	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg08508325	chr11:3079039	CARS	0.28	8.49	0.32	1.5e-16	Calcium levels;
BRCA	cis	rs9790314	0.687	rs62280331	chr3:160682092	C/A	cg03342759	chr3:160939853	NMD3	0.45	8.62	0.32	5.14e-17	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg26384229	chr12:38710491	ALG10B	0.58	13.16	0.46	3.41e-35	Morning vs. evening chronotype;
BRCA	cis	rs61990749	0.544	rs176962	chr14:78185510	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	9.6	0.36	1.75e-20	Fibroblast growth factor basic levels;
BRCA	cis	rs1865721	0.839	rs59718187	chr18:73144032	C/T	cg26385618	chr18:73139727	C18orf62	-0.43	-10.46	-0.38	9.32e-24	Intelligence;
BRCA	cis	rs1868673	1.000	rs6770424	chr3:150174304	A/G	cg04908077	chr3:150187338	NA	-0.32	-8.6	-0.32	6.39e-17	Waist circumference;
BRCA	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06028605	chr16:24865363	SLC5A11	0.4	8.23	0.31	1.03e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02475777	chr4:1388615	CRIPAK	0.56	11.22	0.41	8.48e-27	Longevity;
BRCA	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00149659	chr3:10157352	C3orf10	0.79	13.62	0.47	2.94e-37	Alzheimer's disease;
BRCA	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.17	-0.31	1.63e-15	Height;
BRCA	cis	rs4663866	0.901	rs34040298	chr2:239191607	T/C	cg16914508	chr2:239161102	PER2	0.67	9.27	0.34	2.84e-19	Irritable bowel syndrome;
BRCA	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg25237894	chr2:233734115	C2orf82	-0.41	-11.92	-0.43	9.93e-30	Coronary artery disease;
BRCA	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg26384229	chr12:38710491	ALG10B	0.55	14.52	0.5	1.64e-41	Morning vs. evening chronotype;
BRCA	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.38	-8.97	-0.33	3.19e-18	Platelet count;
BRCA	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg01420254	chr6:26195488	NA	0.56	8.86	0.33	7.89e-18	Gout;Renal underexcretion gout;
BRCA	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg09658497	chr7:2847517	GNA12	-0.41	-8.65	-0.32	4.17e-17	Height;
BRCA	cis	rs73086581	1.000	rs17287486	chr20:3946267	T/C	cg02187196	chr20:3869020	PANK2	0.54	9.62	0.36	1.48e-20	Response to antidepressants in depression;
BRCA	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.8	0.62	2.24e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg25457927	chr22:38595422	NA	-0.32	-11.89	-0.43	1.39e-29	Cutaneous nevi;
BRCA	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg02297831	chr4:17616191	MED28	0.38	8.47	0.32	1.62e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.41	8.53	0.32	1.05e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg06494592	chr3:125709126	NA	-0.52	-8.14	-0.31	2.08e-15	Blood pressure (smoking interaction);
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg03923535	chr7:1197113	ZFAND2A	0.41	8.47	0.32	1.62e-16	Longevity;Endometriosis;
BRCA	trans	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.26	0.31	8.38e-16	Corneal astigmatism;
BRCA	cis	rs1451375	0.657	rs7802148	chr7:50648284	T/C	cg18232548	chr7:50535776	DDC	0.39	9.19	0.34	5.5e-19	Malaria;
BRCA	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg16141378	chr3:129829833	LOC729375	-0.32	-8.41	-0.32	2.71e-16	Mood instability;
BRCA	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg16325326	chr1:53192061	ZYG11B	0.82	22.22	0.66	1.71e-81	Monocyte count;
BRCA	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03517284	chr6:25882590	NA	0.47	10.68	0.39	1.36e-24	Blood metabolite levels;
BRCA	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg08847533	chr14:75593920	NEK9	-0.81	-19.85	-0.62	1.11e-68	Height;
BRCA	cis	rs4074536	0.536	rs10733096	chr1:116290280	T/C	cg21648376	chr1:116311395	CASQ2	-0.49	-8.71	-0.33	2.5e-17	QRS duration;
BRCA	trans	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg00938859	chr5:1591904	SDHAP3	0.63	8.84	0.33	9.45e-18	Breast cancer;
BRCA	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg05714579	chr10:131428358	MGMT	-0.78	-20.49	-0.63	4.01e-72	Response to temozolomide;
BRCA	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.57	11.42	0.41	1.23e-27	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs312273	0.693	rs1442192	chr12:41336447	A/G	cg17827154	chr12:41323612	CNTN1	-0.39	-10.11	-0.37	2.11e-22	Bipolar disorder;
BRCA	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10046574	0.561	rs13438700	chr7:135207626	C/A	cg27474649	chr7:135195673	CNOT4	0.65	10.84	0.39	2.91e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg12935359	chr14:103987150	CKB	0.55	13.32	0.47	6.69e-36	Body mass index;
BRCA	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg17135325	chr3:160939158	NMD3	0.42	7.97	0.3	7.58e-15	Parkinson's disease;
BRCA	cis	rs7945718	1.000	rs7945719	chr11:12748820	A/C	cg25843174	chr11:12811716	TEAD1	0.23	8.52	0.32	1.19e-16	Educational attainment (years of education);
BRCA	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-11.55	-0.42	3.53e-28	Schizophrenia;
BRCA	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg18301423	chr5:131593218	PDLIM4	0.33	8.68	0.32	3.32e-17	Breast cancer;
BRCA	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22590775	chr19:49891494	CCDC155	0.49	8.68	0.32	3.4e-17	Multiple sclerosis;
BRCA	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg14004847	chr7:1930337	MAD1L1	0.48	10.28	0.38	4.72e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg05347473	chr6:146136440	FBXO30	0.45	8.99	0.33	2.86e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg13798912	chr7:905769	UNC84A	-0.49	-7.85	-0.3	1.7e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg25358565	chr5:93447407	FAM172A	0.62	11.18	0.4	1.26e-26	Diabetic retinopathy;
BRCA	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg13852791	chr20:30311386	BCL2L1	0.84	16.37	0.54	1.51e-50	Mean corpuscular hemoglobin;
BRCA	cis	rs1712517	0.844	rs1163074	chr10:105021762	C/T	cg05636881	chr10:105038444	INA	0.34	7.88	0.3	1.4e-14	Migraine;
BRCA	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg18225595	chr11:63971243	STIP1	0.51	9.39	0.35	1.01e-19	Mean platelet volume;
BRCA	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.39	8.09	0.3	3.01e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.48	-8.66	-0.32	3.91e-17	Schizophrenia;
BRCA	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.74	0.39	7.82e-25	Tonsillectomy;
BRCA	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg03213289	chr20:61660250	NA	0.63	16.54	0.55	2.05e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-10.1	-0.37	2.41e-22	Schizophrenia;
BRCA	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.21	0.46	2.22e-35	Bipolar disorder;
BRCA	cis	rs9341808	0.718	rs2322630	chr6:80841033	A/G	cg08355045	chr6:80787529	NA	0.38	9.55	0.35	2.61e-20	Sitting height ratio;
BRCA	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg23649088	chr2:200775458	C2orf69	0.57	8.22	0.31	1.13e-15	Schizophrenia;
BRCA	cis	rs1577917	0.958	rs34994386	chr6:86524135	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.69	-0.42	1e-28	Response to antipsychotic treatment;
BRCA	cis	rs977987	0.806	rs2903033	chr16:75389606	T/A	cg03315344	chr16:75512273	CHST6	0.51	11.87	0.43	1.6800000000000001e-29	Dupuytren's disease;
BRCA	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg02569458	chr12:86230093	RASSF9	0.32	7.87	0.3	1.5e-14	Major depressive disorder;
BRCA	cis	rs877529	0.967	rs139410	chr22:39552597	A/G	cg12193277	chr22:39547181	CBX7	0.47	12.88	0.45	6.39e-34	Multiple myeloma;
BRCA	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-8.51	-0.32	1.19e-16	Hepatocellular carcinoma;
BRCA	cis	rs2712184	0.756	rs2541395	chr2:217647675	C/T	cg05032264	chr2:217675019	NA	-0.39	-9.34	-0.35	1.62e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg26384229	chr12:38710491	ALG10B	-0.42	-9.26	-0.34	3.18e-19	Morning vs. evening chronotype;
BRCA	cis	rs965469	0.895	rs6051844	chr20:3402674	G/T	cg25506879	chr20:3388711	C20orf194	0.53	11.03	0.4	5.23e-26	IFN-related cytopenia;
BRCA	cis	rs11696845	0.666	rs6103849	chr20:43365687	C/T	cg25301532	chr20:43378953	KCNK15	-0.39	-9.1	-0.34	1.18e-18	Obesity-related traits;
BRCA	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg17063962	chr7:91808500	NA	0.55	12.59	0.45	1.25e-32	Breast cancer;
BRCA	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg05283184	chr6:79620031	NA	-0.41	-10.33	-0.38	3.03e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-9.16	-0.34	7.04e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	9.93	0.37	1.03e-21	Tonsillectomy;
BRCA	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg24558204	chr6:135376177	HBS1L	0.45	12.24	0.44	4.37e-31	Red blood cell count;
BRCA	trans	rs9929218	1.000	rs2113200	chr16:68814948	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-14.21	-0.49	5.03e-40	Colorectal cancer;
BRCA	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg25206134	chr2:45395956	NA	0.53	8.84	0.33	9.05e-18	Bipolar disorder;
BRCA	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg23711669	chr6:146136114	FBXO30	0.74	16.8	0.55	9.38e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg12310025	chr6:25882481	NA	-0.42	-10.48	-0.38	7.77e-24	Height;
BRCA	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg09307838	chr4:120376055	NA	0.73	16.01	0.53	9.75e-49	Corneal astigmatism;
BRCA	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg11833968	chr6:79620685	NA	-0.43	-9.65	-0.36	1.14e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.79	-14.35	-0.49	1.1e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3772130	0.962	rs11715951	chr3:121522968	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.84	0.39	2.87e-25	Cognitive performance;
BRCA	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg26597838	chr10:835615	NA	0.6	10.39	0.38	1.87e-23	Eosinophil percentage of granulocytes;
BRCA	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.32	-7.94	-0.3	8.96e-15	Personality dimensions;
BRCA	trans	rs4596713	0.508	rs7467352	chr9:71766081	G/A	cg16512924	chr15:28394682	HERC2	0.44	10.41	0.38	1.53e-23	Headache;
BRCA	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg14683738	chr19:37701593	ZNF585B	0.44	7.93	0.3	1e-14	Coronary artery calcification;
BRCA	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg18305652	chr10:134549665	INPP5A	0.5	11.47	0.41	8.08e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg06238570	chr21:40685208	BRWD1	0.41	8.23	0.31	1.07e-15	Cognitive function;
BRCA	cis	rs8030485	0.756	rs2102999	chr15:79410710	C/T	cg17916960	chr15:79447300	NA	-0.36	-8.33	-0.31	4.96e-16	Left ventricle wall thickness;
BRCA	trans	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.82	-26.79	-0.73	1.5e-106	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg25358565	chr5:93447407	FAM172A	1.15	18.02	0.58	5.09e-59	Diabetic retinopathy;
BRCA	cis	rs2354432	0.607	rs72692962	chr1:146802674	C/A	cg25205988	chr1:146714368	CHD1L	-0.91	-13.1	-0.46	6.75e-35	Mitochondrial DNA levels;
BRCA	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.51	-0.41	5.51e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs11955398	0.625	rs286154	chr5:59926911	C/T	cg02684056	chr5:59996105	DEPDC1B	0.33	7.85	0.3	1.78e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs558133	1.000	rs558133	chr5:78425188	G/T	cg25119155	chr5:78426943	BHMT	0.49	12.39	0.44	9.56e-32	Blood and toenail selenium levels;
BRCA	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg05623727	chr3:50126028	RBM5	0.48	11.34	0.41	2.82e-27	Body mass index;
BRCA	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	10.5	0.38	6.99e-24	Iron status biomarkers;
BRCA	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg21475434	chr5:93447410	FAM172A	0.68	9.19	0.34	5.49e-19	Diabetic retinopathy;
BRCA	cis	rs17253792	0.915	rs75296402	chr14:56182491	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-8.53	-0.32	1.07e-16	Putamen volume;
BRCA	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg25208724	chr1:156163844	SLC25A44	1.03	32.52	0.79	1.27e-137	Testicular germ cell tumor;
BRCA	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg23033748	chr14:75592666	NEK9	0.34	8.02	0.3	5e-15	Height;
BRCA	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg00857998	chr1:205179979	DSTYK	0.42	8.11	0.31	2.63e-15	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.48	10.23	0.38	7.34e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs36051895	0.664	rs884132	chr9:5114522	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-8.65	-0.32	4.21e-17	Pediatric autoimmune diseases;
BRCA	cis	rs11229555	0.598	rs11229426	chr11:58180063	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg18404041	chr3:52824283	ITIH1	-0.34	-9.09	-0.34	1.25e-18	Schizophrenia;
BRCA	cis	rs7715811	1.000	rs2173980	chr5:13767116	A/T	cg07548982	chr5:13769939	DNAH5	-0.41	-9.05	-0.34	1.75e-18	Subclinical atherosclerosis traits (other);
BRCA	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.52	0.59	1.22e-61	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg01028140	chr2:1542097	TPO	-0.81	-16.01	-0.53	9.7e-49	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.56	-0.47	5.53e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg13010199	chr12:38710504	ALG10B	-0.43	-9.97	-0.37	7.63e-22	Heart rate;
BRCA	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.01	14.77	0.5	1.1e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1635	0.655	rs59598126	chr6:28303600	A/C	cg15743358	chr6:28303923	ZNF323	-0.75	-8.56	-0.32	8.52e-17	Schizophrenia;
BRCA	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	11.0	0.4	6.75e-26	Bipolar disorder;
BRCA	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.59	12.07	0.43	2.26e-30	Body mass index (adult);
BRCA	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	14.04	0.49	3.05e-39	Mood instability;
BRCA	trans	rs2562456	0.920	rs2650784	chr19:21666597	T/C	cg25042112	chr7:64838748	ZNF92	0.42	8.35	0.31	4.13e-16	Pain;
BRCA	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg23260525	chr10:116636907	FAM160B1	0.3	7.95	0.3	8.56e-15	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg21605333	chr4:119757512	SEC24D	1.34	14.02	0.48	4.03e-39	Cannabis dependence symptom count;
BRCA	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.85	-0.36	2.06e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-8.96	-0.33	3.5e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08219700	chr8:58056026	NA	0.45	8.16	0.31	1.77e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.71	0.55	2.93e-52	Colorectal cancer;
BRCA	cis	rs4363385	0.510	rs6689066	chr1:153045154	T/C	cg25856811	chr1:152973957	SPRR3	-0.32	-7.83	-0.3	2.11e-14	Inflammatory skin disease;
BRCA	cis	rs28493229	0.708	rs4803352	chr19:41159193	C/T	cg21869046	chr19:41225005	ITPKC	-0.3	-8.79	-0.33	1.33e-17	Kawasaki disease;
BRCA	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg05343316	chr1:45956843	TESK2	0.69	13.95	0.48	8.72e-39	Platelet count;
BRCA	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg15017067	chr4:17643749	FAM184B	0.3	9.1	0.34	1.17e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg22974920	chr21:40686053	BRWD1	-0.4	-8.65	-0.32	4.15e-17	Cognitive function;
BRCA	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg08645402	chr16:4508243	NA	0.4	8.53	0.32	1.03e-16	Schizophrenia;
BRCA	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg27432699	chr2:27873401	GPN1	0.44	9.28	0.34	2.52e-19	Oral cavity cancer;
BRCA	cis	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg06521331	chr12:34319734	NA	-0.52	-10.17	-0.37	1.3e-22	Morning vs. evening chronotype;
BRCA	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6910061	0.830	rs6456869	chr6:11115348	G/A	cg27233058	chr6:11094804	LOC221710	0.5	8.51	0.32	1.21e-16	Diabetic kidney disease;
BRCA	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg21475434	chr5:93447410	FAM172A	0.67	8.48	0.32	1.51e-16	Diabetic retinopathy;
BRCA	trans	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg13565492	chr6:43139072	SRF	-0.89	-16.02	-0.54	8.45e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg24812749	chr6:127587940	RNF146	0.75	16.7	0.55	3.14e-52	Breast cancer;
BRCA	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg08999081	chr20:33150536	PIGU	0.44	12.51	0.44	2.96e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-8.93	-0.33	4.67e-18	Schizophrenia;
BRCA	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg01884057	chr2:25150051	NA	0.34	9.22	0.34	4.21e-19	Body mass index;
BRCA	cis	rs7072216	0.727	rs3750603	chr10:100175536	A/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.7	-0.36	7.5e-21	Metabolite levels;
BRCA	cis	rs10046574	0.731	rs6961685	chr7:135115985	T/C	cg27474649	chr7:135195673	CNOT4	0.61	8.62	0.32	5.25e-17	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg23018236	chr17:30244563	NA	-0.68	-10.71	-0.39	1.02e-24	Hip circumference adjusted for BMI;
BRCA	cis	rs524281	0.814	rs10896098	chr11:65968416	G/A	cg16950941	chr11:66035639	RAB1B	-0.38	-8.03	-0.3	4.85e-15	Electroencephalogram traits;
BRCA	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.2	-0.31	1.31e-15	Height;
BRCA	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg03676636	chr4:99064102	C4orf37	-0.23	-8.05	-0.3	4.13e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg14835575	chr10:16859367	RSU1	0.6	12.49	0.44	3.5e-32	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg19913688	chr11:428466	ANO9	0.71	10.26	0.38	5.56e-23	Body mass index;
BRCA	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg26587870	chr6:27730563	NA	-0.71	-9.62	-0.36	1.5e-20	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4285028	0.948	rs1920309	chr3:121665479	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.94	-0.4	1.2e-25	Multiple sclerosis;
BRCA	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg09998033	chr7:158218633	PTPRN2	0.34	8.31	0.31	5.96e-16	Obesity-related traits;
BRCA	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg00071950	chr4:10020882	SLC2A9	0.44	10.34	0.38	2.77e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs897984	0.542	rs8061047	chr16:31068960	T/C	cg00531865	chr16:30841666	NA	-0.36	-8.45	-0.32	2.03e-16	Dementia with Lewy bodies;
BRCA	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg14196790	chr5:131705035	SLC22A5	0.42	10.24	0.38	6.61e-23	Breast cancer;Mosquito bite size;
BRCA	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg20891283	chr12:69753455	YEATS4	-0.55	-13.41	-0.47	2.75e-36	Blood protein levels;
BRCA	cis	rs887829	0.569	rs3821242	chr2:234637803	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.72	-0.33	2.41e-17	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24229701	chr12:130821962	PIWIL1	0.38	8.33	0.31	4.81e-16	Menopause (age at onset);
BRCA	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg26874164	chr19:58962979	ZNF324B	0.45	9.57	0.35	2.37e-20	Uric acid clearance;
BRCA	cis	rs7598759	0.712	rs10933372	chr2:232332325	G/A	cg19187155	chr2:232395269	NMUR1	0.37	7.83	0.3	2.1e-14	Noise-induced hearing loss;
BRCA	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.15	-0.49	1.01e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs13064411	0.627	rs9872168	chr3:113233132	A/C	cg18753928	chr3:113234510	CCDC52	-0.58	-12.11	-0.43	1.62e-30	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18404041	chr3:52824283	ITIH1	-0.5	-16.05	-0.54	5.8e-49	Bipolar disorder;
BRCA	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg18904891	chr8:8559673	CLDN23	0.58	11.36	0.41	2.2e-27	Obesity-related traits;
BRCA	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg17691542	chr6:26056736	HIST1H1C	0.46	8.79	0.33	1.4e-17	Iron status biomarkers;
BRCA	cis	rs66731853	0.769	rs657624	chr1:20888348	C/T	cg04087271	chr1:20915334	CDA	-0.45	-9.51	-0.35	3.93e-20	Mean corpuscular volume;
BRCA	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg25124228	chr12:125621409	AACS	0.44	8.88	0.33	6.71e-18	Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg16850897	chr7:100343110	ZAN	0.38	8.56	0.32	8.64e-17	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	trans	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	14.82	0.51	6.39e-43	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg23711669	chr6:146136114	FBXO30	0.7	16.2	0.54	9.95e-50	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10267417	0.603	rs10241914	chr7:19932429	C/T	cg05791153	chr7:19748676	TWISTNB	0.43	8.09	0.3	3.01e-15	Night sleep phenotypes;
BRCA	cis	rs754466	0.580	rs11002289	chr10:79532580	G/A	cg17075019	chr10:79541650	NA	-0.83	-20.3	-0.63	4.5e-71	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2302729	0.545	rs10161275	chr12:2771018	A/G	cg19945202	chr12:2788847	CACNA1C	-0.44	-10.02	-0.37	4.87e-22	Sleep quality;
BRCA	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.5	-0.32	1.34e-16	Monocyte percentage of white cells;
BRCA	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg18252515	chr7:66147081	NA	-1.07	-15.92	-0.53	2.69e-48	Diabetic kidney disease;
BRCA	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg04455712	chr21:45112962	RRP1B	0.41	10.57	0.39	3.56e-24	Mean corpuscular volume;
BRCA	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	8.45	0.32	1.93e-16	Menarche (age at onset);
BRCA	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg09307838	chr4:120376055	NA	0.64	14.08	0.49	1.96e-39	Corneal astigmatism;
BRCA	cis	rs4948102	0.667	rs7811270	chr7:56139990	A/G	cg09872392	chr7:56161020	PHKG1	-0.51	-12.71	-0.45	3.54e-33	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.79	-0.42	3.6e-29	Bipolar disorder;
BRCA	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg03146154	chr1:46216737	IPP	0.53	11.78	0.42	3.81e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6580649	0.941	rs1635529	chr12:48395102	T/G	cg05342945	chr12:48394962	COL2A1	-0.53	-10.43	-0.38	1.31e-23	Lung cancer;
BRCA	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg18538332	chr22:24372958	LOC391322	-0.41	-9.73	-0.36	6.09e-21	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs13418410	0.539	rs11677468	chr2:33839053	T/C	cg04131969	chr2:33951647	MYADML	-0.5	-10.16	-0.37	1.35e-22	Non-response to antidepressants and depression;
BRCA	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg21518248	chr2:162101506	NA	-0.47	-9.05	-0.34	1.71e-18	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
BRCA	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg14196790	chr5:131705035	SLC22A5	0.44	11.34	0.41	2.77e-27	Blood metabolite levels;
BRCA	cis	rs17384381	0.953	rs3768223	chr1:85809183	T/C	cg16011679	chr1:85725395	C1orf52	0.52	7.94	0.3	8.83e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7607369	0.719	rs12613545	chr2:219623504	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-11.06	-0.4	3.87e-26	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-15.92	-0.53	2.7e-48	Colorectal cancer;
BRCA	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg20891283	chr12:69753455	YEATS4	0.7	19.14	0.6	7.06e-65	Blood protein levels;
BRCA	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	13.4	0.47	2.76e-36	Platelet count;
BRCA	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg09065629	chr16:1709722	CRAMP1L	0.35	8.02	0.3	5.16e-15	Coronary artery disease;
BRCA	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg01483505	chr11:975446	AP2A2	0.34	9.12	0.34	9.66e-19	Alzheimer's disease (late onset);
BRCA	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.48	0.32	1.51e-16	Cognitive ability;
BRCA	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg15428835	chr7:75027521	TRIM73;TRIM74	-0.31	-8.21	-0.31	1.25e-15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs600231	0.542	rs11227196	chr11:65234922	G/A	cg01292856	chr11:65242576	NA	0.66	14.89	0.51	2.96e-43	Bone mineral density;
BRCA	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg02153584	chr22:29168773	CCDC117	-0.5	-10.22	-0.37	8.2000000000000006e-23	Lymphocyte counts;
BRCA	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24110177	chr3:50126178	RBM5	-0.35	-9.44	-0.35	6.9e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.78	20.91	0.64	2.19e-74	Chronic sinus infection;
BRCA	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg13010199	chr12:38710504	ALG10B	0.48	9.32	0.35	1.82e-19	Morning vs. evening chronotype;
BRCA	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg24675658	chr1:53192096	ZYG11B	-0.52	-11.44	-0.41	1.07e-27	Monocyte count;
BRCA	trans	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg02030672	chr11:45687055	CHST1	-0.43	-9.49	-0.35	4.35e-20	Obesity-related traits;
BRCA	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg00012203	chr2:219082015	ARPC2	0.6	12.39	0.44	9.4e-32	Colorectal cancer;
BRCA	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.33	0.35	1.73e-19	Morning vs. evening chronotype;
BRCA	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	8.6	0.32	6.33e-17	Neuroticism;
BRCA	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg24829409	chr8:58192753	C8orf71	-0.49	-9.25	-0.34	3.45e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs6545883	0.931	rs11125885	chr2:61755728	G/C	cg15711740	chr2:61764176	XPO1	-0.55	-14.14	-0.49	1.11e-39	Tuberculosis;
BRCA	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg13047869	chr3:10149882	C3orf24	0.57	10.42	0.38	1.43e-23	Alzheimer's disease;
BRCA	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	10.63	0.39	2.12e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg26384229	chr12:38710491	ALG10B	0.76	16.73	0.55	2.22e-52	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.38	-8.87	-0.33	7.4e-18	Longevity;Endometriosis;
BRCA	cis	rs17253792	0.822	rs78826571	chr14:56048906	G/A	cg01858014	chr14:56050164	KTN1	-0.73	-9.45	-0.35	6.29e-20	Putamen volume;
BRCA	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21659725	chr3:3221576	CRBN	-0.49	-10.32	-0.38	3.47e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg15839431	chr19:19639596	YJEFN3	-0.4	-8.71	-0.33	2.56e-17	Bipolar disorder;
BRCA	cis	rs4409675	0.576	rs10794507	chr1:28216072	T/C	cg23691781	chr1:28212827	C1orf38	0.32	10.77	0.39	5.68e-25	Corneal astigmatism;
BRCA	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	11.8	0.42	3.25e-29	Tonsillectomy;
BRCA	trans	rs61931739	0.963	rs59195137	chr12:34091838	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-9.05	-0.34	1.66e-18	Morning vs. evening chronotype;
BRCA	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.37	8.19	0.31	1.38e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg26248373	chr2:1572462	NA	-0.5	-10.18	-0.37	1.13e-22	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg13256891	chr4:100009986	ADH5	-0.47	-9.03	-0.34	1.93e-18	Alcohol dependence;
BRCA	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg15017067	chr4:17643749	FAM184B	0.34	9.7	0.36	7.5e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs5756813	0.661	rs2285178	chr22:38205989	T/C	cg19894588	chr14:64061835	NA	-0.55	-11.55	-0.42	3.67e-28	Optic cup area;Vertical cup-disc ratio;
BRCA	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg15704280	chr7:45808275	SEPT13	0.51	8.9	0.33	5.58e-18	Axial length;
BRCA	trans	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg25214090	chr10:38739885	LOC399744	0.5	10.65	0.39	1.68e-24	Corneal astigmatism;
BRCA	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg11812906	chr14:75593930	NEK9	-0.69	-16.07	-0.54	4.73e-49	Height;
BRCA	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg07741184	chr6:167504864	NA	-0.29	-8.54	-0.32	9.84e-17	Primary biliary cholangitis;
BRCA	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg03342759	chr3:160939853	NMD3	-0.7	-14.53	-0.5	1.52e-41	Parkinson's disease;
BRCA	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg26597838	chr10:835615	NA	0.6	10.37	0.38	2.12e-23	Eosinophil percentage of granulocytes;
BRCA	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg17971929	chr21:40555470	PSMG1	-0.62	-14.4	-0.49	6.73e-41	Cognitive function;
BRCA	trans	rs4596713	0.568	rs10114342	chr9:71746005	A/G	cg16512924	chr15:28394682	HERC2	0.4	9.53	0.35	3.27e-20	Headache;
BRCA	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00149659	chr3:10157352	C3orf10	0.99	13.6	0.47	3.58e-37	Alzheimer's disease;
BRCA	cis	rs2625529	0.652	rs2415128	chr15:72191073	T/C	cg16672083	chr15:72433130	SENP8	0.7	16.89	0.56	3.26e-53	Red blood cell count;
BRCA	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-7.97	-0.3	7.2e-15	Ulcerative colitis;
BRCA	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg08470875	chr2:26401718	FAM59B	-0.58	-9.2	-0.34	4.82e-19	Gut microbiome composition (summer);
BRCA	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.85	-0.42	2.07e-29	Response to antipsychotic treatment;
BRCA	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	19.72	0.62	5.57e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg05347473	chr6:146136440	FBXO30	-0.43	-8.45	-0.32	1.92e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2425143	1.000	rs56116518	chr20:34286251	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.84	-0.33	9.09e-18	Blood protein levels;
BRCA	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg22800045	chr5:56110881	MAP3K1	0.65	12.34	0.44	1.62e-31	Initial pursuit acceleration;
BRCA	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg23708337	chr7:1209742	NA	0.51	8.43	0.32	2.28e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.56	8.88	0.33	6.58e-18	Renal function-related traits (BUN);
BRCA	cis	rs7301826	0.651	rs4759517	chr12:131283698	G/A	cg11011512	chr12:131303247	STX2	0.51	13.22	0.46	1.87e-35	Plasma plasminogen activator levels;
BRCA	cis	rs13064411	0.627	rs9825827	chr3:113182231	T/C	cg18753928	chr3:113234510	CCDC52	-0.54	-11.21	-0.41	9.33e-27	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs6977660	0.619	rs10263780	chr7:19778086	A/G	cg05791153	chr7:19748676	TWISTNB	-0.58	-11.27	-0.41	5.14e-27	Thyroid stimulating hormone;
BRCA	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.03	-18.48	-0.59	2e-61	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs28493229	0.708	rs111410535	chr19:41158441	C/T	cg21869046	chr19:41225005	ITPKC	0.32	9.17	0.34	6.31e-19	Kawasaki disease;
BRCA	trans	rs12517041	0.935	rs16892409	chr5:23324350	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-8.11	-0.31	2.55e-15	Calcium levels;
BRCA	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg22903471	chr2:27725779	GCKR	-0.36	-8.61	-0.32	5.79e-17	Total body bone mineral density;
BRCA	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1325195	0.881	rs2816185	chr1:179117740	C/T	cg11624085	chr17:8464688	MYH10	0.26	8.09	0.3	3.1e-15	IgE grass sensitization;
BRCA	cis	rs4566357	0.557	rs6707158	chr2:227911269	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.48	-0.35	4.75e-20	Coronary artery disease;
BRCA	cis	rs4664304	0.620	rs11895141	chr2:160716449	T/A	cg18514922	chr2:160761262	LY75	0.33	7.89	0.3	1.29e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg13334819	chr7:99746414	C7orf59	0.35	8.13	0.31	2.27e-15	Coronary artery disease;
BRCA	cis	rs9487051	0.768	rs351752	chr6:109536034	C/A	cg21918786	chr6:109611834	NA	-0.34	-8.99	-0.34	2.7e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs6987853	0.787	rs2923448	chr8:42406008	G/A	cg09913449	chr8:42400586	C8orf40	0.42	9.39	0.35	1.07e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.29	-8.02	-0.3	5.04e-15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1865721	0.771	rs72975988	chr18:73128289	T/G	cg26385618	chr18:73139727	C18orf62	-0.43	-10.23	-0.37	7.83e-23	Intelligence;
BRCA	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.42	-8.19	-0.31	1.45e-15	Eosinophil percentage of white cells;
BRCA	cis	rs9649465	0.967	rs1506642	chr7:123390058	A/G	cg04330084	chr7:123175371	IQUB	-0.32	-8.74	-0.33	2.02e-17	Migraine;
BRCA	cis	rs895636	1.000	rs895636	chr2:45188353	A/G	cg16198908	chr2:45192207	NA	-0.43	-8.49	-0.32	1.42e-16	Metabolite levels;Fasting plasma glucose;
BRCA	cis	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg21775007	chr8:11205619	TDH	-0.49	-9.93	-0.37	1.01e-21	Retinal vascular caliber;
BRCA	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs1577917	0.839	rs1447159	chr6:86609249	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.34	-8.97	-0.33	3.31e-18	Response to antipsychotic treatment;
BRCA	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg17691542	chr6:26056736	HIST1H1C	0.49	9.29	0.35	2.34e-19	Iron status biomarkers;
BRCA	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	7.9	0.3	1.26e-14	Tonsillectomy;
BRCA	cis	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg27411982	chr8:10470053	RP1L1	0.37	8.39	0.31	3.15e-16	Neuroticism;
BRCA	trans	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg25214090	chr10:38739885	LOC399744	-0.54	-11.67	-0.42	1.15e-28	Corneal astigmatism;
BRCA	cis	rs10924970	0.967	rs12731177	chr1:235463173	T/G	cg26050004	chr1:235667680	B3GALNT2	0.35	8.6	0.32	5.95e-17	Asthma;
BRCA	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg19678392	chr7:94953810	PON1	-0.42	-8.82	-0.33	1.11e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg20503657	chr10:835505	NA	0.89	13.51	0.47	9.13e-37	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg08213375	chr14:104286397	PPP1R13B	0.65	18.68	0.59	1.87e-62	Schizophrenia;
BRCA	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg26597838	chr10:835615	NA	1.01	17.83	0.58	5.39e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00166722	chr3:10149974	C3orf24	0.67	13.44	0.47	1.83e-36	Alzheimer's disease;
BRCA	cis	rs796364	0.715	rs77089299	chr2:201116853	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.65	-8.34	-0.31	4.54e-16	Schizophrenia;
BRCA	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg11057378	chr10:81107060	PPIF	0.37	9.21	0.34	4.48e-19	Height;
BRCA	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg22676075	chr6:135203613	NA	-0.43	-8.45	-0.32	1.96e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs7677751	0.806	rs4864857	chr4:55089814	T/C	cg17187183	chr4:55093834	PDGFRA	0.45	8.88	0.33	6.85e-18	Corneal astigmatism;
BRCA	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg02733842	chr7:1102375	C7orf50	-0.71	-12.35	-0.44	1.4e-31	Bronchopulmonary dysplasia;
BRCA	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg00106254	chr7:1943704	MAD1L1	-0.42	-10.67	-0.39	1.46e-24	Bipolar disorder and schizophrenia;
BRCA	trans	rs853679	0.599	rs149943	chr6:28002388	G/A	cg01620082	chr3:125678407	NA	-0.53	-8.0	-0.3	5.96e-15	Depression;
BRCA	cis	rs4948102	0.767	rs4948096	chr7:56053118	C/T	cg09872392	chr7:56161020	PHKG1	-0.4	-9.15	-0.34	7.4e-19	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg06784218	chr1:46089804	CCDC17	0.45	10.52	0.38	5.64e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	25.76	0.71	6.98e-101	Platelet count;
BRCA	trans	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg26384229	chr12:38710491	ALG10B	0.5	10.79	0.39	4.7e-25	Morning vs. evening chronotype;
BRCA	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg11663144	chr21:46675770	NA	-0.64	-15.38	-0.52	1.24e-45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg20503657	chr10:835505	NA	0.61	10.55	0.39	4.26e-24	Eosinophil percentage of granulocytes;
BRCA	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.6	9.67	0.36	9.88e-21	Renal function-related traits (BUN);
BRCA	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg08742575	chr21:47604166	C21orf56	0.4	8.09	0.3	2.98e-15	Testicular germ cell tumor;
BRCA	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg05340658	chr4:99064831	C4orf37	0.55	10.7	0.39	1.04e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13046373	0.535	rs9977510	chr21:32027920	A/G	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.09	0.3	3.12e-15	HDL cholesterol;
BRCA	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.81e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2882667	0.690	rs10463975	chr5:138263249	G/A	cg04439458	chr5:138467593	SIL1	-0.36	-8.55	-0.32	8.77e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs6479891	1.000	rs12414796	chr10:65303087	G/A	cg14819942	chr15:35414228	NA	0.35	8.44	0.32	2.16e-16	Arthritis (juvenile idiopathic);
BRCA	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg26384229	chr12:38710491	ALG10B	0.66	13.92	0.48	1.2e-38	Morning vs. evening chronotype;
BRCA	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	13.21	0.46	2.03e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.35e-15	Prostate cancer;
BRCA	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.86	0.3	1.62e-14	Parkinson's disease;
BRCA	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg11062466	chr8:58055876	NA	0.41	7.88	0.3	1.46e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.36	-9.16	-0.34	6.8e-19	Total body bone mineral density;
BRCA	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg04450456	chr4:17643702	FAM184B	0.33	9.66	0.36	1.07e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4730250	0.554	rs17428504	chr7:106914944	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-8.1	-0.31	2.72e-15	Osteoarthritis;
BRCA	cis	rs13064411	0.735	rs2614191	chr3:113269201	C/T	cg18753928	chr3:113234510	CCDC52	-0.5	-10.21	-0.37	8.7e-23	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs9467160	0.651	rs9393557	chr6:24453195	C/G	cg20631270	chr6:24437470	GPLD1	0.43	8.56	0.32	8.24e-17	Liver enzyme levels;
BRCA	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg17691542	chr6:26056736	HIST1H1C	0.51	10.46	0.38	9.53e-24	Height;
BRCA	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg07636037	chr3:49044803	WDR6	0.5	8.24	0.31	9.95e-16	Menarche (age at onset);
BRCA	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg14664628	chr15:75095509	CSK	0.39	8.73	0.33	2.2e-17	Systemic lupus erythematosus;
BRCA	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg21644426	chr2:191273491	MFSD6	0.44	11.03	0.4	5.24e-26	Pulse pressure;
BRCA	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.56	-11.99	-0.43	5.06e-30	Menarche (age at onset);
BRCA	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.2	0.37	1.01e-22	Aortic root size;
BRCA	cis	rs858239	0.600	rs7785842	chr7:23141706	T/A	cg23682824	chr7:23144976	KLHL7	0.45	12.24	0.44	4.33e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs61990749	0.597	rs11623088	chr14:78137735	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.64	-10.09	-0.37	2.67e-22	Fibroblast growth factor basic levels;
BRCA	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg24069376	chr3:38537580	EXOG	-0.42	-12.05	-0.43	2.72e-30	Electrocardiographic conduction measures;
BRCA	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-8.5	-0.32	1.33e-16	Obesity-related traits;
BRCA	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg23029597	chr12:123009494	RSRC2	-0.59	-12.44	-0.44	5.67e-32	Body mass index;
BRCA	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg02403541	chr12:121454288	C12orf43	0.64	12.05	0.43	2.96e-30	N-glycan levels;
BRCA	cis	rs9487051	0.735	rs459956	chr6:109524760	A/G	cg01475377	chr6:109611718	NA	-0.44	-11.1	-0.4	2.62e-26	Reticulocyte fraction of red cells;
BRCA	trans	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg26384229	chr12:38710491	ALG10B	-0.51	-10.79	-0.39	4.88e-25	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.52	-0.32	1.11e-16	Monocyte percentage of white cells;
BRCA	cis	rs965469	1.000	rs6051709	chr20:3263685	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-10.2	-0.37	9.47e-23	IFN-related cytopenia;
BRCA	cis	rs943466	1.000	rs6940353	chr6:33752550	G/A	cg25922239	chr6:33757077	LEMD2	-0.38	-7.82	-0.3	2.19e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs2742234	0.541	rs10899782	chr10:43736361	A/T	cg02780029	chr10:43622663	RET	0.36	7.96	0.3	7.91e-15	Hirschsprung disease;
BRCA	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg03433033	chr1:76189801	ACADM	0.89	23.77	0.69	5.4e-90	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs2736340	0.539	rs9644687	chr8:11323025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-8.51	-0.32	1.28e-16	Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;Systemic lupus erythematosus;Kawasaki disease;Systemic lupus erythematosus or rheumatoid arthritis;
BRCA	cis	rs2455799	0.573	rs2470546	chr3:15733897	T/C	cg16303742	chr3:15540471	COLQ	-0.38	-9.13	-0.34	8.98e-19	Mean platelet volume;
BRCA	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	20.35	0.63	2.32e-71	Platelet count;
BRCA	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg26384229	chr12:38710491	ALG10B	0.68	14.34	0.49	1.23e-40	Morning vs. evening chronotype;
BRCA	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg14675211	chr2:100938903	LONRF2	0.52	11.96	0.43	7.15e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.79	10.83	0.39	3.39e-25	Initial pursuit acceleration;
BRCA	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.79	0.36	3.39e-21	Bipolar disorder;
BRCA	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-10.04	-0.37	4.08e-22	Bladder cancer;
BRCA	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg26893861	chr17:41843967	DUSP3	-1.06	-30.39	-0.77	3.64e-126	Triglycerides;
BRCA	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg16049864	chr8:95962084	TP53INP1	0.48	10.7	0.39	1.13e-24	Type 2 diabetes;
BRCA	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.45	-0.38	1.05e-23	Aortic root size;
BRCA	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg13010199	chr12:38710504	ALG10B	0.48	9.26	0.34	3.1e-19	Morning vs. evening chronotype;
BRCA	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03264133	chr6:25882463	NA	0.7	15.98	0.53	1.32e-48	Blood metabolite levels;
BRCA	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.71	0.42	7.88e-29	Homoarginine levels;
BRCA	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs12618769	0.597	rs3769740	chr2:99069208	A/G	cg10123293	chr2:99228465	UNC50	-0.41	-8.36	-0.31	3.91e-16	Bipolar disorder;
BRCA	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg11833968	chr6:79620685	NA	-0.4	-8.77	-0.33	1.55e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs11083475	0.607	rs6508816	chr19:39267783	G/A	cg07905965	chr19:39260460	NA	0.47	10.37	0.38	2.15e-23	Heart rate;
BRCA	cis	rs9487051	0.621	rs830552	chr6:109549914	A/G	cg01475377	chr6:109611718	NA	-0.39	-7.84	-0.3	1.9e-14	Reticulocyte fraction of red cells;
BRCA	trans	rs3858145	0.588	rs61854831	chr10:70035837	C/T	cg04882175	chr6:131122610	NA	-0.35	-8.35	-0.31	4.33e-16	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
BRCA	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg13010199	chr12:38710504	ALG10B	0.42	9.03	0.34	2.05e-18	Morning vs. evening chronotype;
BRCA	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg09624528	chr10:1369823	ADARB2	0.41	8.47	0.32	1.67e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg06115741	chr20:33292138	TP53INP2	-0.36	-7.9	-0.3	1.25e-14	Glomerular filtration rate (creatinine);
BRCA	cis	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.33	-0.31	5.04e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg18270830	chr10:32634957	EPC1	0.56	9.72	0.36	6.35e-21	Sexual dysfunction (female);
BRCA	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg17211192	chr8:82754475	SNX16	-0.58	-11.25	-0.41	6.3100000000000004e-27	Diastolic blood pressure;
BRCA	cis	rs34779708	0.897	rs12830	chr10:35302705	C/T	cg03585969	chr10:35415529	CREM	0.56	11.59	0.42	2.64e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg26587870	chr6:27730563	NA	-0.49	-7.84	-0.3	1.94e-14	Breast cancer;
BRCA	cis	rs7301826	0.610	rs4759789	chr12:131296380	A/C	cg11011512	chr12:131303247	STX2	0.51	13.52	0.47	8.46e-37	Plasma plasminogen activator levels;
BRCA	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg26384229	chr12:38710491	ALG10B	-0.69	-14.91	-0.51	2.35e-43	Morning vs. evening chronotype;
BRCA	cis	rs28830936	1.000	rs2577960	chr15:42028354	C/A	cg17847044	chr15:42102381	MAPKBP1	0.33	9.38	0.35	1.15e-19	Diastolic blood pressure;
BRCA	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg22907277	chr7:1156413	C7orf50	0.46	10.55	0.39	4.08e-24	Longevity;Endometriosis;
BRCA	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg14926445	chr8:58193284	C8orf71	-0.46	-8.76	-0.33	1.78e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.25	0.49	3.12e-40	Eye color traits;
BRCA	cis	rs68170813	0.559	rs75154004	chr7:106903326	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.48	-0.32	1.59e-16	Coronary artery disease;
BRCA	cis	rs2016266	0.819	rs6580942	chr12:53662624	C/A	cg26875137	chr12:53738046	NA	0.39	9.08	0.34	1.33e-18	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs73086581	0.891	rs55871214	chr20:3965706	A/C	cg02187196	chr20:3869020	PANK2	0.53	9.48	0.35	4.73e-20	Response to antidepressants in depression;
BRCA	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	12.68	0.45	5.22e-33	Hip circumference adjusted for BMI;
BRCA	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg19156104	chr2:198669113	PLCL1	-0.41	-7.95	-0.3	8.41e-15	Ulcerative colitis;
BRCA	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg19729930	chr2:74357872	NA	0.59	14.26	0.49	3.04e-40	Gestational age at birth (maternal effect);
BRCA	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg02880119	chr16:3481970	NA	0.43	7.86	0.3	1.63e-14	Body mass index (adult);
BRCA	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg17135325	chr3:160939158	NMD3	0.43	8.19	0.31	1.41e-15	Parkinson's disease;
BRCA	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	trans	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg07817883	chr1:32538562	TMEM39B	0.52	8.53	0.32	1.03e-16	Monocyte percentage of white cells;
BRCA	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg11266682	chr4:10021025	SLC2A9	0.36	9.38	0.35	1.16e-19	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg20573242	chr4:122745356	CCNA2	0.49	10.79	0.39	4.65e-25	Type 2 diabetes;
BRCA	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg14835575	chr10:16859367	RSU1	0.59	11.97	0.43	6.23e-30	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.33	11.23	0.41	7.54e-27	Systemic lupus erythematosus;
BRCA	trans	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs4889855	0.505	rs8076974	chr17:78621817	G/A	cg16591659	chr17:78472290	NA	-0.31	-7.88	-0.3	1.39e-14	Fractional excretion of uric acid;
BRCA	cis	rs1829883	0.866	rs1523391	chr5:98794214	A/C	cg08333243	chr5:99726346	NA	-0.35	-8.03	-0.3	4.62e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-10.25	-0.38	6.09e-23	Aortic root size;
BRCA	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg20307385	chr11:47447363	PSMC3	0.86	25.99	0.72	3.64e-102	Diastolic blood pressure;Systolic blood pressure;
BRCA	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg26384229	chr12:38710491	ALG10B	0.75	16.69	0.55	3.62e-52	Morning vs. evening chronotype;
BRCA	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	17.42	0.57	6.31e-56	Smoking behavior;
BRCA	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg13647721	chr17:30228624	UTP6	0.52	9.34	0.35	1.61e-19	Hip circumference adjusted for BMI;
BRCA	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg25019033	chr10:957182	NA	-0.41	-7.88	-0.3	1.41e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08564027	chr20:61660810	NA	0.85	22.44	0.66	1.17e-82	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12541635	0.966	rs2132471	chr8:107000963	G/A	cg10147462	chr8:107024639	NA	0.37	9.92	0.37	1.18e-21	Age of smoking initiation;
BRCA	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11764359	chr7:65958608	NA	-0.76	-17.43	-0.57	5.6e-56	Aortic root size;
BRCA	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.83	-19.57	-0.61	3.51e-67	Ulcerative colitis;
BRCA	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg14092571	chr14:90743983	NA	-0.34	-8.07	-0.3	3.4e-15	Mortality in heart failure;
BRCA	cis	rs13136331	0.532	rs2615480	chr4:88577573	A/G	cg22416721	chr4:88570574	DMP1	-0.59	-14.33	-0.49	1.43e-40	Sitting height ratio;
BRCA	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg04553112	chr3:125709451	NA	-0.54	-9.0	-0.34	2.48e-18	Blood pressure (smoking interaction);
BRCA	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.09	-38.02	-0.83	3.29e-166	Myeloid white cell count;
BRCA	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg08798685	chr6:27730294	NA	-0.41	-8.03	-0.3	4.78e-15	Parkinson's disease;
BRCA	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg17143192	chr8:8559678	CLDN23	0.57	11.12	0.4	2.3e-26	Obesity-related traits;
BRCA	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg02655711	chr22:19163373	SLC25A1	0.65	16.03	0.54	7.32e-49	Metabolite levels;
BRCA	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-14.33	-0.49	1.34e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	trans	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-15.35	-0.52	1.65e-45	Obesity-related traits;
BRCA	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg24690094	chr11:67383802	NA	0.49	10.57	0.39	3.53e-24	Mean corpuscular volume;
BRCA	trans	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.01	0.3	5.51e-15	Corneal astigmatism;
BRCA	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg24558204	chr6:135376177	HBS1L	0.44	12.22	0.44	5.3e-31	Red blood cell count;
BRCA	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg20587970	chr11:113659929	NA	-1.22	-22.1	-0.66	7.73e-81	Hip circumference adjusted for BMI;
BRCA	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg10556349	chr10:835070	NA	0.73	9.89	0.36	1.48e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg08132940	chr7:1081526	C7orf50	-0.6	-8.74	-0.33	2.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs36051895	0.664	rs3780373	chr9:5098223	T/C	cg02405213	chr9:5042618	JAK2	-0.5	-9.46	-0.35	5.73e-20	Pediatric autoimmune diseases;
BRCA	trans	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg06521331	chr12:34319734	NA	-0.46	-8.52	-0.32	1.16e-16	Bladder cancer;
BRCA	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg22705602	chr4:152727874	NA	-0.33	-8.13	-0.31	2.24e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs12357919	0.542	rs3740471	chr10:105363289	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.49	9.42	0.35	8.21e-20	White matter hyperintensity burden;
BRCA	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg15103426	chr22:29168792	CCDC117	0.47	11.25	0.41	6.33e-27	Red cell distribution width;
BRCA	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-12.3	-0.44	2.25e-31	Total cholesterol levels;
BRCA	cis	rs7560272	0.695	rs10190002	chr2:73794054	C/T	cg20560298	chr2:73613845	ALMS1	-0.42	-11.49	-0.41	6.32e-28	Schizophrenia;
BRCA	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	14.65	0.5	4.09e-42	Personality dimensions;
BRCA	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.72	0.36	6.56e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg15704280	chr7:45808275	SEPT13	0.64	10.67	0.39	1.41e-24	Axial length;
BRCA	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.1	0.34	1.14e-18	Tonsillectomy;
BRCA	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg15133208	chr4:90757351	SNCA	-0.38	-7.84	-0.3	1.85e-14	Neuroticism;
BRCA	cis	rs2629540	0.855	rs12776722	chr10:126469833	G/A	cg08799069	chr10:126477246	METTL10	0.56	11.02	0.4	5.75e-26	Cocaine dependence;
BRCA	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg16386425	chr10:429943	DIP2C	-0.42	-9.06	-0.34	1.59e-18	Psychosis in Alzheimer's disease;
BRCA	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg08000102	chr2:233561755	GIGYF2	0.6	13.13	0.46	4.96e-35	Coronary artery disease;
BRCA	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg01874867	chr7:94954059	PON1	-0.5	-11.36	-0.41	2.34e-27	Paraoxonase activity;
BRCA	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg21535247	chr6:8435926	SLC35B3	0.42	9.49	0.35	4.66e-20	Motion sickness;
BRCA	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg20991723	chr1:152506922	NA	0.38	8.67	0.32	3.47e-17	Hair morphology;
BRCA	cis	rs13102973	0.899	rs13104662	chr4:135904615	C/T	cg14419869	chr4:135874104	NA	0.46	9.16	0.34	7.08e-19	Subjective well-being;
BRCA	cis	rs2992756	0.663	rs2992763	chr1:18804386	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.39	-7.97	-0.3	7.36e-15	Breast cancer;
BRCA	cis	rs2742234	0.554	rs1270015	chr10:43698240	G/T	cg15436174	chr10:43711423	RASGEF1A	0.58	11.76	0.42	5e-29	Hirschsprung disease;
BRCA	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.24	8.21	0.31	1.25e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg05340658	chr4:99064831	C4orf37	0.66	16.18	0.54	1.39e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg25036284	chr2:26402008	FAM59B	0.88	15.06	0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs724568	0.527	rs11126147	chr2:67934313	C/A	cg17945962	chr2:67939740	NA	-0.37	-9.76	-0.36	4.61e-21	Major depressive disorder (broad);
BRCA	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg22903471	chr2:27725779	GCKR	-0.39	-9.77	-0.36	4.3e-21	Total body bone mineral density;
BRCA	cis	rs7095944	0.614	rs7099316	chr10:126469005	G/A	cg08799069	chr10:126477246	METTL10	-0.4	-10.07	-0.37	3.04e-22	Asthma;
BRCA	cis	rs9810890	0.850	rs73196995	chr3:128458070	G/A	cg15033153	chr3:128514015	RAB7A	0.7	8.08	0.3	3.34e-15	Dental caries;
BRCA	cis	rs8028182	0.636	rs7184046	chr15:75866150	G/C	cg20655648	chr15:75932815	IMP3	0.46	8.99	0.33	2.87e-18	Sudden cardiac arrest;
BRCA	cis	rs708547	0.647	rs781668	chr4:57825140	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.42	8.12	0.31	2.46e-15	Response to bleomycin (chromatid breaks);
BRCA	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-10.89	-0.4	1.91e-25	Schizophrenia;
BRCA	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg17971929	chr21:40555470	PSMG1	0.81	19.49	0.61	9.95e-67	Cognitive function;
BRCA	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	13.09	0.46	7.21e-35	Personality dimensions;
BRCA	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.17	0.56	1.26e-54	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.01	0.3	5.51e-15	Corneal astigmatism;
BRCA	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24110177	chr3:50126178	RBM5	0.4	11.12	0.4	2.27e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg05347473	chr6:146136440	FBXO30	-0.41	-7.95	-0.3	8.44e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10992471	0.603	rs7868013	chr9:95240173	G/A	cg14631576	chr9:95140430	CENPP	-0.38	-9.23	-0.34	3.97e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs4588572	0.643	rs1529499	chr5:77721431	T/C	cg11547950	chr5:77652471	NA	-0.47	-8.36	-0.31	4e-16	Triglycerides;
BRCA	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	14.7	0.5	2.41e-42	Motion sickness;
BRCA	trans	rs2840044	1.000	rs10068	chr17:33901965	C/G	cg19694781	chr19:47549865	TMEM160	0.45	10.67	0.39	1.47e-24	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg00531865	chr16:30841666	NA	-0.5	-11.86	-0.42	1.76e-29	Multiple myeloma;
BRCA	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	11.77	0.42	4.25e-29	Height;
BRCA	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg03188948	chr7:1209495	NA	0.83	11.3	0.41	4.03e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg10523679	chr1:76189770	ACADM	-0.92	-26.53	-0.72	4.12e-105	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg24558204	chr6:135376177	HBS1L	0.59	15.88	0.53	4.35e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg26343298	chr8:95960752	TP53INP1	0.29	8.3	0.31	6.37e-16	Type 2 diabetes;
BRCA	trans	rs9929218	0.953	rs28608872	chr16:68802038	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-14.01	-0.48	4.55e-39	Colorectal cancer;
BRCA	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg04025307	chr7:1156635	C7orf50	0.43	9.72	0.36	6.53e-21	Longevity;Endometriosis;
BRCA	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg11814155	chr7:99998594	ZCWPW1	0.44	8.32	0.31	5.27e-16	Platelet count;
BRCA	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg23358479	chr7:1110784	C7orf50	-0.49	-8.33	-0.31	4.8e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.69	14.68	0.5	2.83e-42	Lymphocyte counts;
BRCA	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg15112475	chr7:1198522	ZFAND2A	-0.37	-8.02	-0.3	4.91e-15	Longevity;Endometriosis;
BRCA	cis	rs12618769	0.597	rs17033136	chr2:99149404	C/T	cg10123293	chr2:99228465	UNC50	-0.42	-8.35	-0.31	4.37e-16	Bipolar disorder;
BRCA	cis	rs2354432	0.556	rs72710311	chr1:146698256	A/G	cg25205988	chr1:146714368	CHD1L	-0.91	-11.4	-0.41	1.61e-27	Mitochondrial DNA levels;
BRCA	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg17971929	chr21:40555470	PSMG1	0.79	18.81	0.6	3.73e-63	Cognitive function;
BRCA	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.51	-14.66	-0.5	3.66e-42	Lung cancer;
BRCA	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg08859206	chr1:53392774	SCP2	-0.39	-8.08	-0.3	3.28e-15	Monocyte count;
BRCA	cis	rs7131987	0.903	rs67517901	chr12:29421346	A/G	cg09582351	chr12:29534625	ERGIC2	-0.48	-11.61	-0.42	2.16e-28	QT interval;
BRCA	cis	rs16958440	0.867	rs74346439	chr18:44677467	G/C	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg11645453	chr3:52864694	ITIH4	0.45	10.56	0.39	3.82e-24	Schizophrenia;
BRCA	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00166722	chr3:10149974	C3orf24	0.66	13.42	0.47	2.4e-36	Alzheimer's disease;
BRCA	cis	rs11958404	0.932	rs72816566	chr5:157427613	G/A	cg05962755	chr5:157440814	NA	0.51	9.93	0.37	1.04e-21	IgG glycosylation;
BRCA	cis	rs7737355	0.947	rs6884741	chr5:130894613	A/G	cg06307176	chr5:131281290	NA	0.52	10.06	0.37	3.4e-22	Life satisfaction;
BRCA	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.5	-12.49	-0.44	3.44e-32	Schizophrenia;
BRCA	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg02527881	chr3:46936655	PTH1R	-0.38	-9.34	-0.35	1.59e-19	Colorectal cancer;
BRCA	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg27588902	chr6:42928151	GNMT	0.31	11.19	0.4	1.13e-26	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2288073	0.801	rs72797831	chr2:24366829	G/A	cg06627628	chr2:24431161	ITSN2	-0.57	-10.79	-0.39	4.66e-25	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.35	-8.35	-0.31	4.19e-16	Electroencephalogram traits;
BRCA	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.57	-0.32	7.75e-17	Total body bone mineral density;
BRCA	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.6	0.39	2.68e-24	Motion sickness;
BRCA	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg23708337	chr7:1209742	NA	0.68	10.69	0.39	1.18e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs754466	0.958	rs58916802	chr10:79695870	G/A	cg17075019	chr10:79541650	NA	-0.67	-12.3	-0.44	2.43e-31	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg05347473	chr6:146136440	FBXO30	0.39	7.94	0.3	9e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6714710	0.580	rs1838797	chr2:98454572	G/C	cg26665480	chr2:98280029	ACTR1B	0.58	13.6	0.47	3.4e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs12618769	0.597	rs17504774	chr2:99135627	A/G	cg10123293	chr2:99228465	UNC50	-0.41	-8.09	-0.3	2.98e-15	Bipolar disorder;
BRCA	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg07395648	chr5:131743802	NA	0.4	9.95	0.37	8.89e-22	Blood metabolite levels;
BRCA	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-8.97	-0.33	3.26e-18	IgG glycosylation;
BRCA	cis	rs67981189	0.896	rs1859468	chr14:71402290	C/G	cg15816911	chr14:71606274	NA	-0.37	-8.28	-0.31	7.4e-16	Schizophrenia;
BRCA	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg15704280	chr7:45808275	SEPT13	-0.73	-14.66	-0.5	3.83e-42	Coronary artery disease;
BRCA	cis	rs9283706	0.641	rs1990894	chr5:66331685	C/T	cg11590213	chr5:66331682	MAST4	0.38	8.08	0.3	3.28e-15	Coronary artery disease;
BRCA	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.32	10.19	0.37	1.07e-22	Bipolar disorder;
BRCA	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg21132104	chr15:45694354	SPATA5L1	0.75	16.99	0.56	1.07e-53	Homoarginine levels;
BRCA	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg08601574	chr20:25228251	PYGB	0.36	8.63	0.32	4.9e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.2	-0.31	1.37e-15	Menopause (age at onset);
BRCA	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg18876405	chr7:65276391	NA	-0.49	-10.22	-0.37	7.99e-23	Calcium levels;
BRCA	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg03954927	chr1:10346856	KIF1B	-0.46	-14.45	-0.5	3.6700000000000003e-41	Hepatocellular carcinoma;
BRCA	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg17691542	chr6:26056736	HIST1H1C	0.74	14.51	0.5	1.9e-41	Iron status biomarkers;
BRCA	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg12140854	chr5:148520817	ABLIM3	-0.43	-9.07	-0.34	1.41e-18	Breast cancer;
BRCA	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg02820040	chr2:241836501	C2orf54	-0.53	-10.03	-0.37	4.21e-22	Urinary metabolites;
BRCA	cis	rs870825	0.616	rs28445002	chr4:185648977	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.66	-15.81	-0.53	9.47e-48	Ulcerative colitis;
BRCA	cis	rs2455601	0.638	rs11042148	chr11:9008674	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-8.43	-0.32	2.27e-16	Schizophrenia;
BRCA	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-8.26	-0.31	8.64e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg09307838	chr4:120376055	NA	0.63	13.55	0.47	5.84e-37	Corneal astigmatism;
BRCA	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09263875	chr16:632152	PIGQ	0.71	20.46	0.63	6e-72	Height;
BRCA	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	13.01	0.46	1.73e-34	Hip circumference adjusted for BMI;
BRCA	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg21427119	chr20:30132790	HM13	-0.42	-8.9	-0.33	5.92e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.04	15.74	0.53	1.94e-47	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg11663144	chr21:46675770	NA	-0.49	-9.7	-0.36	7.64e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7633770	0.786	rs4683256	chr3:46683617	T/G	cg11219411	chr3:46661640	NA	0.65	16.96	0.56	1.59e-53	Coronary artery disease;
BRCA	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg18357645	chr12:58087776	OS9	0.46	13.35	0.47	4.74e-36	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg13319975	chr6:146136371	FBXO30	0.43	9.83	0.36	2.57e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.31	-0.56	2.53e-55	Chronic sinus infection;
BRCA	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg24642439	chr20:33292090	TP53INP2	0.41	8.53	0.32	1.04e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-9.97	-0.37	7.4e-22	Bipolar disorder;
BRCA	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.2	0.56	8.77e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11764359	chr7:65958608	NA	-0.77	-17.87	-0.58	3.29e-58	Aortic root size;
BRCA	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	13.79	0.48	4.56e-38	Hip circumference adjusted for BMI;
BRCA	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.7	13.72	0.48	9.58e-38	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg17211192	chr8:82754475	SNX16	-0.53	-12.1	-0.43	1.69e-30	Diastolic blood pressure;
BRCA	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	12.31	0.44	2.21e-31	Monocyte percentage of white cells;
BRCA	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg06191203	chr2:152266755	RIF1	-0.31	-9.05	-0.34	1.67e-18	Lung cancer;
BRCA	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.49	0.5	2.37e-41	Motion sickness;
BRCA	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	8.89	0.33	6.4e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4631830	0.832	rs2843554	chr10:51523861	G/T	cg20129853	chr10:51489980	NA	-0.28	-7.83	-0.3	2.03e-14	Prostate-specific antigen levels;
BRCA	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg02297831	chr4:17616191	MED28	-0.36	-8.55	-0.32	9.3e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg08999081	chr20:33150536	PIGU	0.5	14.14	0.49	1.03e-39	Coronary artery disease;
BRCA	cis	rs13102973	0.965	rs28874134	chr4:135867088	C/A	cg14419869	chr4:135874104	NA	-0.59	-12.99	-0.46	2.06e-34	Subjective well-being;
BRCA	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg01448562	chr3:133502909	NA	0.39	8.92	0.33	4.98e-18	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	18.86	0.6	2.15e-63	Alzheimer's disease;
BRCA	cis	rs35934224	0.831	rs8141610	chr22:19870147	A/G	cg11182965	chr22:19864308	TXNRD2	0.35	7.94	0.3	9.15e-15	Glaucoma (primary open-angle);
BRCA	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg08470875	chr2:26401718	FAM59B	-0.51	-8.3	-0.31	6.38e-16	Gut microbiome composition (summer);
BRCA	cis	rs654128	0.640	rs6914581	chr6:117228916	C/T	cg12892004	chr6:117198278	RFX6	0.43	8.17	0.31	1.61e-15	Telomere length;
BRCA	cis	rs2070433	0.539	rs2070432	chr21:47957332	G/A	cg12379764	chr21:47803548	PCNT	0.6	12.27	0.44	3.25e-31	Lymphocyte counts;
BRCA	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg06159980	chr1:16340746	HSPB7	-0.38	-7.82	-0.3	2.21e-14	Dilated cardiomyopathy;
BRCA	cis	rs10899021	1.000	rs61900636	chr11:74359591	G/T	cg25880958	chr11:74394337	NA	-0.52	-8.11	-0.31	2.67e-15	Response to metformin (IC50);
BRCA	cis	rs7737355	0.947	rs6864173	chr5:130871822	T/C	cg06307176	chr5:131281290	NA	0.53	10.52	0.38	5.56e-24	Life satisfaction;
BRCA	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg22906224	chr7:99728672	NA	-0.42	-7.98	-0.3	6.88e-15	Coronary artery disease;
BRCA	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg23358479	chr7:1110784	C7orf50	-0.47	-7.95	-0.3	8.4e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11644478	chr21:40555479	PSMG1	0.84	19.09	0.6	1.21e-64	Cognitive function;
BRCA	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg04553112	chr3:125709451	NA	-0.58	-9.09	-0.34	1.26e-18	Blood pressure (smoking interaction);
BRCA	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg24642844	chr7:1081250	C7orf50	-0.91	-16.39	-0.54	1.21e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6545883	0.602	rs11125871	chr2:61470126	C/T	cg15711740	chr2:61764176	XPO1	0.44	10.82	0.39	3.55e-25	Tuberculosis;
BRCA	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg08470875	chr2:26401718	FAM59B	-0.77	-12.2	-0.43	6.34e-31	Gut microbiome composition (summer);
BRCA	cis	rs7640424	0.649	rs13091474	chr3:107877134	A/T	cg09227934	chr3:107805635	CD47	-0.37	-7.84	-0.3	1.9e-14	Body mass index;
BRCA	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg11845111	chr2:191398756	TMEM194B	-0.82	-14.54	-0.5	1.44e-41	Diastolic blood pressure;
BRCA	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	14.47	0.5	3e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs698833	0.886	rs698824	chr2:44723123	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	10.07	0.37	3.03e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg00277334	chr10:82204260	NA	-0.42	-8.57	-0.32	7.55e-17	Post bronchodilator FEV1;
BRCA	cis	rs2425143	1.000	rs6058303	chr20:34290281	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.85	-0.33	8.76e-18	Blood protein levels;
BRCA	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg09184832	chr6:79620586	NA	-0.52	-11.42	-0.41	1.3e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg11764359	chr7:65958608	NA	0.62	13.33	0.47	5.9e-36	Aortic root size;
BRCA	cis	rs698833	0.926	rs786419	chr2:44685153	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.42	8.51	0.32	1.28e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs490234	0.812	rs4838268	chr9:128280315	G/T	cg14078157	chr9:128172775	NA	-0.34	-8.02	-0.3	5.06e-15	Mean arterial pressure;
BRCA	cis	rs1113500	0.636	rs3853493	chr1:108637193	G/A	cg06207961	chr1:108661230	NA	0.36	8.93	0.33	4.46e-18	Growth-regulated protein alpha levels;
BRCA	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg15556689	chr8:8085844	FLJ10661	0.36	9.31	0.35	1.98e-19	Retinal vascular caliber;
BRCA	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18876405	chr7:65276391	NA	0.55	13.29	0.47	8.91e-36	Aortic root size;
BRCA	cis	rs11997175	0.583	rs7824990	chr8:33779934	A/G	ch.8.33884649F	chr8:33765107	NA	0.36	8.25	0.31	8.75e-16	Body mass index;
BRCA	cis	rs1371614	0.523	rs12468761	chr2:27183793	G/A	cg00617064	chr2:27272375	NA	0.31	8.04	0.3	4.34e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg10523679	chr1:76189770	ACADM	-0.47	-9.19	-0.34	5.31e-19	Daytime sleep phenotypes;
BRCA	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs6138458	1.000	rs2387362	chr20:24899906	C/T	cg26195577	chr20:24973756	C20orf3	-0.98	-24.65	-0.7	8.06e-95	Blood protein levels;
BRCA	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18876405	chr7:65276391	NA	0.55	13.12	0.46	5.35e-35	Aortic root size;
BRCA	cis	rs4845875	0.530	rs6667720	chr1:11831615	A/G	cg24844545	chr1:11908347	NPPA	-0.36	-8.58	-0.32	7.46e-17	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs4566357	0.615	rs2272202	chr2:227914625	C/T	cg11843606	chr2:227700838	RHBDD1	0.42	9.43	0.35	7.69e-20	Coronary artery disease;
BRCA	trans	rs1459104	0.866	rs12804916	chr11:54831763	G/A	cg15704280	chr7:45808275	SEPT13	0.63	8.26	0.31	8.33e-16	Body mass index;
BRCA	cis	rs30380	0.586	rs28119	chr5:96131733	G/A	cg16492584	chr5:96139282	ERAP1	-0.47	-11.05	-0.4	4.34e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg00990874	chr7:1149470	C7orf50	-0.6	-12.14	-0.43	1.14e-30	Bronchopulmonary dysplasia;
BRCA	cis	rs12541635	0.677	rs2880950	chr8:106983624	C/A	cg10147462	chr8:107024639	NA	0.4	10.77	0.39	5.51e-25	Age of smoking initiation;
BRCA	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg06618935	chr21:46677482	NA	-0.36	-7.95	-0.3	8.52e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03517284	chr6:25882590	NA	-0.5	-11.34	-0.41	2.87e-27	Blood metabolite levels;
BRCA	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg16141378	chr3:129829833	LOC729375	0.32	8.03	0.3	4.72e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
BRCA	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg26395211	chr5:140044315	WDR55	0.37	8.58	0.32	7.32e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7809615	0.901	rs10226310	chr7:99118320	G/A	cg12290671	chr7:99195819	NA	-0.53	-8.93	-0.33	4.48e-18	Blood metabolite ratios;
BRCA	cis	rs9649465	0.934	rs7799354	chr7:123269819	A/G	cg04330084	chr7:123175371	IQUB	-0.32	-8.85	-0.33	8.69e-18	Migraine;
BRCA	cis	rs75229567	0.618	rs77168443	chr12:70208563	G/A	cg10114359	chr12:70132523	RAB3IP	1.18	13.34	0.47	5.5e-36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg17366294	chr4:99064904	C4orf37	0.42	9.82	0.36	2.66e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-16.53	-0.55	2.17e-51	Lymphocyte percentage of white cells;
BRCA	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg11366901	chr6:160182831	ACAT2	0.77	14.95	0.51	1.47e-43	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08859206	chr1:53392774	SCP2	-0.55	-12.16	-0.43	9.37e-31	Monocyte count;
BRCA	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg13114125	chr14:105738426	BRF1	-0.49	-10.39	-0.38	1.8e-23	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg13628971	chr7:2884303	GNA12	0.48	10.65	0.39	1.77e-24	Height;
BRCA	trans	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg14791747	chr16:20752902	THUMPD1	-0.39	-9.29	-0.34	2.41e-19	Cognitive test performance;
BRCA	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg21535247	chr6:8435926	SLC35B3	0.42	9.42	0.35	7.86e-20	Motion sickness;
BRCA	cis	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.5	-0.32	1.31e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg08885076	chr2:99613938	TSGA10	0.42	9.88	0.36	1.6e-21	Chronic sinus infection;
BRCA	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.83	-0.33	1.01e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.83	0.33	9.93e-18	Motion sickness;
BRCA	trans	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	10.2	0.37	9.54e-23	Neuroticism;
BRCA	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg06640241	chr16:89574553	SPG7	0.88	23.1	0.67	2.54e-86	Multiple myeloma (IgH translocation);
BRCA	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.25e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg18200150	chr17:30822561	MYO1D	-0.33	-8.53	-0.32	1.06e-16	Schizophrenia;
BRCA	cis	rs6545883	0.894	rs12615783	chr2:61440947	T/C	cg15711740	chr2:61764176	XPO1	0.5	12.19	0.43	7.15e-31	Tuberculosis;
BRCA	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg08085267	chr17:45401833	C17orf57	0.63	12.86	0.45	7.82e-34	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg18132916	chr6:79620363	NA	-0.46	-10.22	-0.37	8.56e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg17509989	chr5:176798049	RGS14	0.73	11.76	0.42	4.93e-29	Urate levels in lean individuals;
BRCA	trans	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg06636001	chr8:8085503	FLJ10661	0.46	9.62	0.36	1.44e-20	Neuroticism;
BRCA	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.13	0.37	1.79e-22	Cognitive ability;
BRCA	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.47	8.65	0.32	4.02e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10848704	1.000	rs10848704	chr12:2882544	A/G	cg19995117	chr12:2880862	NA	-0.47	-10.77	-0.39	5.54e-25	Quantitative traits;
BRCA	cis	rs909002	0.830	rs10914461	chr1:32113217	G/A	cg13919466	chr1:32135498	COL16A1	-0.26	-8.83	-0.33	9.76e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs4919087	1.000	rs10786329	chr10:99074621	G/A	cg25902810	chr10:99078978	FRAT1	0.52	11.25	0.41	6.34e-27	Monocyte count;
BRCA	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg09754948	chr16:28834200	ATXN2L	0.47	8.98	0.33	2.92e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg11062466	chr8:58055876	NA	0.51	8.92	0.33	4.88e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.77	11.03	0.4	5.15e-26	Initial pursuit acceleration;
BRCA	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-10.1	-0.37	2.39e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs78487399	0.908	rs6715003	chr2:43808659	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-7.98	-0.3	6.71e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs7903847	0.642	rs11189182	chr10:99144186	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.66	-0.32	3.88e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs77633900	0.614	rs2930681	chr15:76995150	G/A	cg21673338	chr15:77095150	SCAPER	-0.54	-9.91	-0.37	1.22e-21	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs9921222	0.786	rs3848365	chr16:374617	C/T	cg00101154	chr16:420108	MRPL28	-0.35	-8.03	-0.3	4.6e-15	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg03711944	chr11:47377212	SPI1	-0.44	-10.36	-0.38	2.41e-23	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg15133208	chr4:90757351	SNCA	-0.43	-8.76	-0.33	1.72e-17	Neuroticism;
BRCA	trans	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg26043149	chr18:55253948	FECH	-0.36	-8.04	-0.3	4.33e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9462027	0.628	rs34141614	chr6:34777031	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.84	-0.3	1.96e-14	Systemic lupus erythematosus;
BRCA	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg02544614	chr20:61657117	NA	0.28	7.95	0.3	8.19e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg23711669	chr6:146136114	FBXO30	0.79	18.88	0.6	1.6e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg21045802	chr8:109455806	TTC35	0.35	7.82	0.3	2.12e-14	Dupuytren's disease;
BRCA	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg18538332	chr22:24372958	LOC391322	0.54	13.12	0.46	5.71e-35	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg18806716	chr10:30721971	MAP3K8	0.59	13.69	0.48	1.33e-37	Inflammatory bowel disease;
BRCA	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg18512352	chr11:47633146	NA	-0.34	-8.32	-0.31	5.4e-16	Subjective well-being;
BRCA	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg06618935	chr21:46677482	NA	-0.36	-8.11	-0.31	2.68e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-15.25	-0.52	5.03e-45	Obesity-related traits;
BRCA	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg08738300	chr3:44038990	NA	0.45	8.61	0.32	5.81e-17	Coronary artery disease;
BRCA	cis	rs3099143	0.908	rs3102716	chr15:77051003	T/G	cg21673338	chr15:77095150	SCAPER	-0.53	-9.72	-0.36	6.45e-21	Recalcitrant atopic dermatitis;
BRCA	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg13010199	chr12:38710504	ALG10B	-0.42	-9.78	-0.36	3.79e-21	Heart rate;
BRCA	trans	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg25214090	chr10:38739885	LOC399744	0.55	12.23	0.44	4.59e-31	Corneal astigmatism;
BRCA	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg20503657	chr10:835505	NA	0.93	16.56	0.55	1.66e-51	Eosinophil percentage of granulocytes;
BRCA	cis	rs7551345	0.653	rs56125362	chr1:31698765	G/A	cg19084893	chr1:31688959	NA	-0.46	-10.04	-0.37	4.17e-22	Schizophrenia;
BRCA	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg14458575	chr2:238380390	NA	0.76	16.63	0.55	6.82e-52	Prostate cancer;
BRCA	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg00321850	chr1:175162397	KIAA0040	-0.41	-11.54	-0.42	3.93e-28	Alcohol dependence;
BRCA	cis	rs7631605	0.875	rs7638620	chr3:37200085	A/G	cg15934958	chr3:37212084	LRRFIP2	0.42	9.76	0.36	4.55e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg17971929	chr21:40555470	PSMG1	-0.62	-13.67	-0.48	1.72e-37	Cognitive function;
BRCA	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg13319975	chr6:146136371	FBXO30	0.34	7.87	0.3	1.47e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2637030	0.559	rs2637024	chr5:52993453	A/G	cg06476337	chr5:52856530	NDUFS4	0.37	8.47	0.32	1.67e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs5771069	0.931	rs137864	chr22:50446988	C/T	cg27068297	chr22:50451975	IL17REL	0.33	7.89	0.3	1.3e-14	Ulcerative colitis;
BRCA	cis	rs6570726	0.526	rs7755237	chr6:145731852	T/C	cg23711669	chr6:146136114	FBXO30	-0.48	-10.56	-0.39	3.9e-24	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2742234	0.541	rs7098236	chr10:43740508	T/C	cg15436174	chr10:43711423	RASGEF1A	0.5	9.97	0.37	7.18e-22	Hirschsprung disease;
BRCA	cis	rs4764124	0.571	rs11830399	chr12:14956932	G/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.5	11.44	0.41	1.05e-27	Pubertal anthropometrics;
BRCA	cis	rs977987	0.806	rs4993970	chr16:75411619	G/A	cg03315344	chr16:75512273	CHST6	0.53	12.62	0.45	9.48e-33	Dupuytren's disease;
BRCA	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg14019146	chr3:50243930	SLC38A3	-0.57	-11.69	-0.42	9.96e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs9290065	0.538	rs6809206	chr3:160755708	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-10.74	-0.39	7.56e-25	Kawasaki disease;
BRCA	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg23625390	chr15:77176239	SCAPER	-0.56	-14.03	-0.49	3.43e-39	Blood metabolite levels;
BRCA	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg27170947	chr2:26402098	FAM59B	0.98	15.28	0.52	3.87e-45	Gut microbiome composition (summer);
BRCA	trans	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.97	0.3	7.32e-15	Corneal astigmatism;
BRCA	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg22705602	chr4:152727874	NA	-0.38	-10.34	-0.38	2.7e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg11502198	chr6:26597334	ABT1	0.56	12.1	0.43	1.75e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs11605275	1.000	rs11605275	chr11:20031865	C/T	cg14835545	chr11:20032148	NAV2	-0.6	-8.96	-0.33	3.54e-18	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg00383909	chr3:49044727	WDR6	0.5	9.67	0.36	9.49e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg23711669	chr6:146136114	FBXO30	-0.79	-18.84	-0.6	2.71e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg26384229	chr12:38710491	ALG10B	0.51	13.57	0.47	4.68e-37	Morning vs. evening chronotype;
BRCA	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07343612	chr16:622815	PIGQ	-0.68	-22.29	-0.66	6.92e-82	Height;
BRCA	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg14664628	chr15:75095509	CSK	-0.95	-29.18	-0.76	1.26e-119	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	trans	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg16141378	chr3:129829833	LOC729375	-0.35	-8.64	-0.32	4.57e-17	Mood instability;
BRCA	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	10.62	0.39	2.34e-24	Personality dimensions;
BRCA	cis	rs67981189	0.896	rs1018977	chr14:71400653	G/T	cg15816911	chr14:71606274	NA	-0.37	-8.23	-0.31	1.04e-15	Schizophrenia;
BRCA	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.38	-0.31	3.28e-16	Colorectal cancer;
BRCA	trans	rs6600671	0.899	rs2319971	chr1:121226982	A/C	cg17023122	chr1:144479586	NA	0.35	7.99	0.3	6.19e-15	Hip geometry;
BRCA	cis	rs250677	0.522	rs919731	chr5:148352150	T/C	cg18129178	chr5:148520854	ABLIM3	0.54	10.52	0.38	5.62e-24	Breast cancer;
BRCA	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg16482183	chr6:26056742	HIST1H1C	0.56	10.98	0.4	7.82e-26	Height;
BRCA	cis	rs2742234	0.910	rs2505505	chr10:43648221	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.43	-9.18	-0.34	5.98e-19	Hirschsprung disease;
BRCA	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.49	0.65	1.55e-77	Lymphocyte percentage of white cells;
BRCA	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.73	0.33	2.16e-17	Personality dimensions;
BRCA	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg09904177	chr6:26538194	HMGN4	0.47	15.02	0.51	7.17e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-8.4	-0.32	2.79e-16	Monocyte percentage of white cells;
BRCA	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-9.48	-0.35	4.75e-20	Schizophrenia;
BRCA	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg03433033	chr1:76189801	ACADM	0.7	13.73	0.48	8.8e-38	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	8.07	0.3	3.57e-15	Diabetic retinopathy;
BRCA	cis	rs4880487	0.888	rs67699390	chr10:1252427	G/A	cg03183215	chr10:1252341	ADARB2	-0.39	-8.8	-0.33	1.32e-17	Migraine;
BRCA	cis	rs9682041	0.877	rs9682908	chr3:170072010	C/T	cg11886554	chr3:170076028	SKIL	0.52	10.71	0.39	1.03e-24	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	trans	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg19862616	chr7:65841803	NCRNA00174	0.79	24.71	0.7	3.87e-95	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg04362960	chr10:104952993	NT5C2	0.46	10.7	0.39	1.08e-24	Arsenic metabolism;
BRCA	cis	rs1832871	0.655	rs6920121	chr6:158678504	C/T	cg07215822	chr6:158701037	NA	0.5	8.01	0.3	5.61e-15	Height;
BRCA	cis	rs9287719	0.639	rs2357650	chr2:10696877	C/T	cg00105475	chr2:10696890	NA	0.55	13.27	0.46	1.18e-35	Prostate cancer;
BRCA	cis	rs1018836	0.923	rs1858674	chr8:91580665	G/T	cg16814680	chr8:91681699	NA	-0.58	-12.38	-0.44	1.09e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg02753203	chr1:228287806	NA	-0.6	-12.95	-0.46	3.31e-34	Diastolic blood pressure;
BRCA	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg06970220	chr1:156163860	SLC25A44	0.39	9.56	0.35	2.54e-20	Testicular germ cell tumor;
BRCA	cis	rs13102973	0.932	rs4130841	chr4:135869673	T/C	cg14419869	chr4:135874104	NA	-0.59	-12.99	-0.46	2.2e-34	Subjective well-being;
BRCA	cis	rs6878727	1.000	rs6878727	chr5:123736406	A/G	cg01806427	chr5:123737813	NA	0.39	8.88	0.33	6.98e-18	Breast cancer;
BRCA	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg20476274	chr7:133979776	SLC35B4	0.65	19.4	0.61	2.78e-66	Mean platelet volume;
BRCA	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg18252515	chr7:66147081	NA	1.04	15.68	0.53	3.96e-47	Diabetic kidney disease;
BRCA	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg08917208	chr2:24149416	ATAD2B	0.51	7.88	0.3	1.37e-14	Lymphocyte counts;
BRCA	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	19.54	0.61	4.85e-67	Platelet count;
BRCA	trans	rs7939886	0.920	rs1586014	chr11:55771540	C/T	cg15704280	chr7:45808275	SEPT13	0.62	7.83	0.3	2.05e-14	Myopia (pathological);
BRCA	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg01028140	chr2:1542097	TPO	-0.79	-15.58	-0.52	1.28e-46	Placebo response in major depressive disorder (% change in symptom score);
BRCA	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg15704280	chr7:45808275	SEPT13	0.51	8.7	0.33	2.89e-17	Axial length;
BRCA	cis	rs4363385	0.818	rs1591736	chr1:152987497	A/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.35	-0.31	4.35e-16	Inflammatory skin disease;
BRCA	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg21770322	chr7:97807741	LMTK2	0.41	10.97	0.4	8.81e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	9.93	0.37	1.08e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs2840044	1.000	rs225251	chr17:33951228	A/C	cg19694781	chr19:47549865	TMEM160	-0.46	-10.73	-0.39	8.11e-25	Response to radiotherapy in cancer (late toxicity);
BRCA	trans	rs4596713	0.538	rs11145460	chr9:71766091	T/G	cg16512924	chr15:28394682	HERC2	0.44	10.41	0.38	1.53e-23	Headache;
BRCA	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4853036	0.723	rs35690619	chr2:70053619	A/T	cg02498382	chr2:70120550	SNRNP27	-0.54	-8.75	-0.33	1.82e-17	Colorectal or endometrial cancer;
BRCA	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.43	0.35	7.36e-20	Morning vs. evening chronotype;
BRCA	trans	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04565464	chr8:145669602	NFKBIL2	0.38	8.93	0.33	4.59e-18	Bipolar disorder and schizophrenia;
BRCA	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	8.73	0.33	2.22e-17	Neuroticism;
BRCA	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg20607798	chr8:58055168	NA	0.48	8.43	0.32	2.29e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10267417	0.603	rs10263119	chr7:19872844	C/G	cg05791153	chr7:19748676	TWISTNB	0.48	9.19	0.34	5.63e-19	Night sleep phenotypes;
BRCA	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg13010199	chr12:38710504	ALG10B	0.53	11.07	0.4	3.38e-26	Heart rate;
BRCA	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg24578937	chr1:2090814	PRKCZ	-0.56	-17.5	-0.57	2.49e-56	Height;
BRCA	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg14092571	chr14:90743983	NA	-0.34	-8.07	-0.3	3.4e-15	Mortality in heart failure;
BRCA	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg25817165	chr18:72167213	CNDP2	-0.76	-14.14	-0.49	1.14e-39	Refractive error;
BRCA	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg20848291	chr7:100343083	ZAN	-0.58	-10.69	-0.39	1.19e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg26608667	chr7:1196370	ZFAND2A	0.37	8.37	0.31	3.65e-16	Longevity;Endometriosis;
BRCA	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg11502198	chr6:26597334	ABT1	0.6	9.21	0.34	4.6e-19	Small cell lung carcinoma;
BRCA	cis	rs6546550	0.901	rs10167142	chr2:70062360	T/C	cg02498382	chr2:70120550	SNRNP27	-0.5	-10.46	-0.38	9.25e-24	Prevalent atrial fibrillation;
BRCA	cis	rs9287719	0.649	rs10190673	chr2:10718618	T/C	cg00105475	chr2:10696890	NA	0.41	9.19	0.34	5.62e-19	Prostate cancer;
BRCA	cis	rs11051970	0.636	rs2733704	chr12:32567858	C/T	cg24626660	chr12:32551988	NA	0.31	9.22	0.34	4.38e-19	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg19920283	chr7:105172520	RINT1	0.59	9.54	0.35	2.83e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs877282	0.945	rs10904556	chr10:789429	A/G	cg17470449	chr10:769945	NA	0.47	8.16	0.31	1.73e-15	Uric acid levels;
BRCA	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.41	-0.38	1.47e-23	Blood protein levels;
BRCA	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	13.97	0.48	6.83e-39	Colorectal cancer;
BRCA	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11890956	chr21:40555474	PSMG1	-0.81	-19.07	-0.6	1.7e-64	Cognitive function;
BRCA	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg05970437	chr19:1864622	KLF16	-0.41	-7.81	-0.3	2.31e-14	Bipolar disorder;
BRCA	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg03354898	chr7:1950403	MAD1L1	-0.41	-8.2	-0.31	1.35e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.12	0.31	2.38e-15	Depression;
BRCA	cis	rs4671400	0.516	rs1809028	chr2:61413723	A/G	cg15711740	chr2:61764176	XPO1	-0.46	-8.79	-0.33	1.43e-17	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg21573476	chr21:45109991	RRP1B	-0.36	-9.09	-0.34	1.25e-18	Mean corpuscular volume;
BRCA	cis	rs495337	1.000	rs615926	chr20:48519258	T/C	cg17835207	chr20:48524531	SPATA2	-0.63	-14.47	-0.5	3.06e-41	Psoriasis;
BRCA	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg01256987	chr12:42539512	GXYLT1	-0.47	-9.25	-0.34	3.27e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-9.64	-0.36	1.23e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.66	-0.36	1.09e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg25173405	chr17:45401733	C17orf57	-0.51	-10.59	-0.39	2.89e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg24631222	chr15:78858424	CHRNA5	-0.5	-10.03	-0.37	4.38e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg17802220	chr15:77601643	NA	-0.47	-10.39	-0.38	1.81e-23	Type 2 diabetes;
BRCA	cis	rs9473147	0.571	rs9369717	chr6:47554468	T/G	cg12968598	chr6:47444699	CD2AP	0.46	9.74	0.36	5.58e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	7e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.34	-9.31	-0.35	1.97e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg09307838	chr4:120376055	NA	0.69	14.38	0.49	7.56e-41	Corneal astigmatism;
BRCA	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-8.0	-0.3	5.76e-15	Tonsillectomy;
BRCA	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg03342759	chr3:160939853	NMD3	0.62	12.54	0.44	1.99e-32	Parkinson's disease;
BRCA	trans	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg25173405	chr17:45401733	C17orf57	-0.52	-10.72	-0.39	8.84e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg09307838	chr4:120376055	NA	0.74	15.99	0.53	1.23e-48	Corneal astigmatism;
BRCA	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-15.75	-0.53	1.79e-47	Chronic sinus infection;
BRCA	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg17420585	chr12:42539391	GXYLT1	-0.49	-10.61	-0.39	2.57e-24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.5	0.57	2.57e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg23033748	chr14:75592666	NEK9	-0.38	-9.26	-0.34	3.02e-19	Height;
BRCA	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.52	-0.32	1.13e-16	Total body bone mineral density;
BRCA	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg13319975	chr6:146136371	FBXO30	-0.36	-8.16	-0.31	1.73e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg11814155	chr7:99998594	ZCWPW1	0.48	8.81	0.33	1.22e-17	Platelet count;
BRCA	trans	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg02030672	chr11:45687055	CHST1	0.39	8.31	0.31	5.86e-16	Obesity-related traits;
BRCA	cis	rs2882667	0.587	rs2174972	chr5:138101918	C/G	cg04439458	chr5:138467593	SIL1	0.31	7.85	0.3	1.74e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg05347473	chr6:146136440	FBXO30	0.39	7.94	0.3	9e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1506636	1.000	rs7779099	chr7:123295964	C/T	cg03229431	chr7:123269106	ASB15	-0.64	-14.3	-0.49	1.95e-40	Plateletcrit;Platelet count;
BRCA	trans	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.64	-13.78	-0.48	5.12e-38	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.66	13.56	0.47	5.14e-37	Lymphocyte counts;
BRCA	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg05623727	chr3:50126028	RBM5	0.42	8.05	0.3	4.06e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7607369	0.559	rs4674339	chr2:219659787	C/G	cg02176678	chr2:219576539	TTLL4	-0.39	-10.42	-0.38	1.35e-23	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-10.09	-0.37	2.56e-22	Neuroticism;
BRCA	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg15704280	chr7:45808275	SEPT13	-0.63	-11.16	-0.4	1.54e-26	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs654950	0.806	rs7550496	chr1:42043834	G/A	cg06885757	chr1:42089581	HIVEP3	0.3	10.2	0.37	9.45e-23	Airway imaging phenotypes;
BRCA	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg04545296	chr12:48745243	ZNF641	0.25	8.3	0.31	6.07e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg04362960	chr10:104952993	NT5C2	0.45	10.43	0.38	1.31e-23	Arsenic metabolism;
BRCA	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg08213375	chr14:104286397	PPP1R13B	0.62	17.71	0.57	2.12e-57	Schizophrenia;
BRCA	cis	rs9790314	0.663	rs17826438	chr3:160640295	C/T	cg03342759	chr3:160939853	NMD3	0.45	8.63	0.32	4.75e-17	Morning vs. evening chronotype;
BRCA	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.52	8.08	0.3	3.17e-15	Schizophrenia;
BRCA	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg23029597	chr12:123009494	RSRC2	-0.47	-9.69	-0.36	8.08e-21	Body mass index;
BRCA	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg24558204	chr6:135376177	HBS1L	0.45	12.18	0.43	7.58e-31	Red blood cell count;
BRCA	cis	rs10851411	0.559	rs62019322	chr15:42897374	T/C	cg21293051	chr15:42870591	STARD9	0.56	9.05	0.34	1.75e-18	Glucose homeostasis traits;
BRCA	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg08601574	chr20:25228251	PYGB	0.38	9.19	0.34	5.5e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg13319975	chr6:146136371	FBXO30	0.44	10.22	0.37	8.16e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg26838691	chr2:24397539	C2orf84	0.41	8.26	0.31	8.67e-16	Asthma;
BRCA	trans	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg06521331	chr12:34319734	NA	-0.56	-9.58	-0.35	2.04e-20	Bladder cancer;
BRCA	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg11663144	chr21:46675770	NA	-0.53	-12.24	-0.44	4.1e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2637266	1.000	rs12783273	chr10:78353221	T/C	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg05283184	chr6:79620031	NA	-0.35	-7.95	-0.3	8.28e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg09754948	chr16:28834200	ATXN2L	0.45	9.03	0.34	2.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg03342759	chr3:160939853	NMD3	-0.74	-15.57	-0.52	1.44e-46	Parkinson's disease;
BRCA	cis	rs113835537	0.529	rs2279865	chr11:66203025	A/C	cg24851651	chr11:66362959	CCS	0.41	7.99	0.3	6.24e-15	Airway imaging phenotypes;
BRCA	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18402987	chr7:1209562	NA	0.53	10.45	0.38	1.08e-23	Longevity;Endometriosis;
BRCA	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg04362960	chr10:104952993	NT5C2	0.43	10.55	0.39	4.27e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23248424	chr5:179741104	GFPT2	-0.62	-12.94	-0.46	3.43e-34	Height;
BRCA	cis	rs1904096	0.506	rs6532476	chr4:95192461	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.26	-0.38	5.74e-23	Type 2 diabetes;
BRCA	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg03684893	chr10:554711	DIP2C	-0.36	-7.98	-0.3	6.75e-15	Psychosis in Alzheimer's disease;
BRCA	cis	rs4363385	0.934	rs1415964	chr1:152955085	T/C	cg25856811	chr1:152973957	SPRR3	-0.32	-7.96	-0.3	7.61e-15	Inflammatory skin disease;
BRCA	cis	rs11120822	0.787	rs11120829	chr1:7123793	A/C	cg20434152	chr1:7120926	CAMTA1	-0.38	-9.45	-0.35	6.23e-20	Stearic acid (18:0) levels;
BRCA	cis	rs34779708	0.931	rs11010077	chr10:35328088	C/T	cg03585969	chr10:35415529	CREM	-0.43	-9.23	-0.34	3.76e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.02e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg23505145	chr19:12996616	KLF1	0.54	12.34	0.44	1.49e-31	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21659725	chr3:3221576	CRBN	0.48	12.1	0.43	1.67e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs754466	1.000	rs12220902	chr10:79682918	C/T	cg17075019	chr10:79541650	NA	-0.57	-11.04	-0.4	4.53e-26	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg10523679	chr1:76189770	ACADM	0.68	12.76	0.45	2.34e-33	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg09307838	chr4:120376055	NA	0.69	14.85	0.51	4.44e-43	Corneal astigmatism;
BRCA	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-11.41	-0.41	1.38e-27	Gut microbiome composition (summer);
BRCA	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg06453172	chr10:134556979	INPP5A	-0.53	-11.49	-0.41	6.44e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7020830	0.931	rs9775431	chr9:37130433	G/A	cg14294708	chr9:37120828	ZCCHC7	1.06	31.7	0.78	2.96e-133	Schizophrenia;
BRCA	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg05347473	chr6:146136440	FBXO30	0.42	8.07	0.3	3.51e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg03477792	chr4:77819574	ANKRD56	0.65	15.44	0.52	5.85e-46	Emphysema distribution in smoking;
BRCA	cis	rs10838687	0.610	rs4647737	chr11:47253244	T/G	cg25783544	chr11:47291846	MADD	0.43	7.97	0.3	7.52e-15	Proinsulin levels;
BRCA	trans	rs6499188	0.522	rs10153230	chr16:68671741	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.47	8.88	0.33	6.45e-18	Ulcerative colitis;
BRCA	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg26597838	chr10:835615	NA	0.9	15.21	0.52	8.03e-45	Eosinophil percentage of granulocytes;
BRCA	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg01528321	chr10:82214614	TSPAN14	0.74	16.68	0.55	3.86e-52	Post bronchodilator FEV1;
BRCA	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.49	-10.53	-0.38	5.07e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg07636037	chr3:49044803	WDR6	-0.6	-8.16	-0.31	1.84e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg08847533	chr14:75593920	NEK9	-0.93	-24.06	-0.69	1.38e-91	Height;
BRCA	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09263875	chr16:632152	PIGQ	0.72	21.49	0.65	1.57e-77	Height;
BRCA	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-15.4	-0.52	9.89e-46	Total cholesterol levels;
BRCA	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg21252483	chr19:49399788	TULP2	-0.4	-9.06	-0.34	1.52e-18	Red cell distribution width;
BRCA	cis	rs4363385	0.818	rs3806223	chr1:153002646	T/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.36	-0.31	3.83e-16	Inflammatory skin disease;
BRCA	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.56	-12.44	-0.44	5.98e-32	Platelet count;
BRCA	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg24069376	chr3:38537580	EXOG	0.34	9.37	0.35	1.24e-19	Electrocardiographic conduction measures;
BRCA	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg13256891	chr4:100009986	ADH5	0.53	9.77	0.36	4.33e-21	Smoking initiation;
BRCA	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg04267008	chr7:1944627	MAD1L1	-0.4	-8.81	-0.33	1.14e-17	Schizophrenia;
BRCA	cis	rs1113500	0.787	rs11185266	chr1:108642664	G/A	cg06207961	chr1:108661230	NA	0.37	8.9	0.33	5.89e-18	Growth-regulated protein alpha levels;
BRCA	cis	rs7254827	0.737	rs16981580	chr19:17173826	T/C	cg19418318	chr19:17219073	MYO9B	-0.48	-10.04	-0.37	3.85e-22	Mean platelet volume;
BRCA	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg13175981	chr1:150552382	MCL1	0.42	9.45	0.35	6.31e-20	Tonsillectomy;
BRCA	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg04944784	chr2:26401820	FAM59B	-1.02	-17.43	-0.57	6.26e-56	Gut microbiome composition (summer);
BRCA	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg05343316	chr1:45956843	TESK2	0.64	13.16	0.46	3.46e-35	Platelet count;
BRCA	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg07537917	chr2:241836409	C2orf54	-0.49	-11.64	-0.42	1.6e-28	Urinary metabolites;
BRCA	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg23649088	chr2:200775458	C2orf69	0.43	9.2	0.34	4.89e-19	Systolic blood pressure;
BRCA	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.07	16.15	0.54	1.79e-49	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg24069376	chr3:38537580	EXOG	0.42	11.99	0.43	5.33e-30	Electrocardiographic conduction measures;
BRCA	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg00757033	chr12:89920650	WDR51B	0.54	11.14	0.4	1.78e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	trans	rs5756813	0.661	rs6000898	chr22:38202399	T/C	cg19894588	chr14:64061835	NA	-0.55	-11.54	-0.42	4.17e-28	Optic cup area;Vertical cup-disc ratio;
BRCA	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg04317338	chr11:64019027	PLCB3	0.56	9.53	0.35	3.13e-20	Mean platelet volume;
BRCA	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.87	-0.33	7.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1568889	0.887	rs7102237	chr11:28344296	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	19.31	0.61	8.49e-66	Bipolar disorder;
BRCA	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg13175981	chr1:150552382	MCL1	0.37	7.94	0.3	9.22e-15	Blood protein levels;
BRCA	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-11.98	-0.43	5.79e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6424115	0.557	rs35904775	chr1:24180623	T/C	cg10978503	chr1:24200527	CNR2	-0.52	-13.74	-0.48	8.06e-38	Immature fraction of reticulocytes;
BRCA	trans	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	19.41	0.61	2.52e-66	Exhaled nitric oxide output;
BRCA	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12310025	chr6:25882481	NA	-0.55	-12.35	-0.44	1.46e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	1.01e-40	Motion sickness;
BRCA	trans	rs75804782	0.521	rs72982598	chr2:239455052	G/A	cg01134436	chr17:81009848	B3GNTL1	0.58	8.17	0.31	1.65e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg23033748	chr14:75592666	NEK9	0.34	8.02	0.3	5e-15	Height;
BRCA	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.82e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg01304814	chr3:48885189	PRKAR2A	0.56	7.91	0.3	1.12e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.87	-0.33	7.1e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs870825	0.616	rs2310110	chr4:185647902	G/A	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs67981189	0.593	rs2240341	chr14:71373580	T/C	cg15816911	chr14:71606274	NA	-0.38	-8.62	-0.32	5.26e-17	Schizophrenia;
BRCA	cis	rs12541635	0.966	rs2345070	chr8:107072027	A/G	cg10147462	chr8:107024639	NA	-0.37	-9.77	-0.36	4.03e-21	Age of smoking initiation;
BRCA	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21659725	chr3:3221576	CRBN	-0.47	-9.68	-0.36	8.71e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7560272	0.695	rs780393	chr2:73701669	T/A	cg20560298	chr2:73613845	ALMS1	0.43	11.64	0.42	1.57e-28	Schizophrenia;
BRCA	trans	rs629535	0.514	rs55653755	chr8:70154383	A/C	cg21567404	chr3:27674614	NA	-0.96	-17.52	-0.57	2.09e-56	Dupuytren's disease;
BRCA	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg21475434	chr5:93447410	FAM172A	0.68	8.61	0.32	5.66e-17	Diabetic retinopathy;
BRCA	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg24848339	chr3:12840334	CAND2	0.45	11.95	0.43	7.32e-30	QRS complex (12-leadsum);
BRCA	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg00409905	chr10:38381863	ZNF37A	-0.48	-10.19	-0.37	1.04e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-9.06	-0.34	1.52e-18	Monocyte percentage of white cells;
BRCA	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg05754148	chr16:3507555	NAT15	0.38	7.96	0.3	8.04e-15	Tuberculosis;
BRCA	trans	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.16	-0.54	1.65e-49	Obesity-related traits;
BRCA	cis	rs858239	0.730	rs858289	chr7:23248158	C/T	cg23682824	chr7:23144976	KLHL7	0.31	7.95	0.3	8.52e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22590775	chr19:49891494	CCDC155	0.45	8.0	0.3	5.81e-15	Multiple sclerosis;
BRCA	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.37e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg17366294	chr4:99064904	C4orf37	0.42	9.72	0.36	6.54e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs16958440	0.867	rs12386076	chr18:44673340	T/C	cg17192377	chr18:44677553	HDHD2	0.99	13.88	0.48	1.7e-38	Sitting height ratio;
BRCA	cis	rs965469	0.779	rs967366	chr20:3266935	T/G	cg25506879	chr20:3388711	C20orf194	-0.44	-8.81	-0.33	1.17e-17	IFN-related cytopenia;
BRCA	cis	rs870825	0.616	rs28563856	chr4:185635581	G/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.14	0.56	1.89e-54	Blood protein levels;
BRCA	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg19622623	chr12:86230825	RASSF9	-0.34	-9.71	-0.36	7.07e-21	Major depressive disorder;
BRCA	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg12744634	chr1:26560303	CCDC21	0.31	8.7	0.33	2.81e-17	Obesity-related traits;
BRCA	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg07148914	chr20:33460835	GGT7	-0.37	-7.99	-0.3	6.25e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs7072216	0.727	rs942809	chr10:100168001	G/A	cg26618903	chr10:100175079	PYROXD2	-0.29	-8.58	-0.32	6.92e-17	Metabolite levels;
BRCA	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg04166393	chr7:2884313	GNA12	0.39	8.45	0.32	1.96e-16	Height;
BRCA	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg22875332	chr1:76189707	ACADM	0.66	15.78	0.53	1.35e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg14983838	chr19:29218262	NA	0.54	10.1	0.37	2.35e-22	Methadone dose in opioid dependence;
BRCA	cis	rs460214	0.539	rs55819392	chr21:40038207	G/A	cg21578987	chr21:40029669	ERG	0.36	8.32	0.31	5.33e-16	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs8170	0.603	rs11086068	chr19:17420165	T/C	cg04749549	chr19:17459798	NA	-0.36	-9.78	-0.36	3.75e-21	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
BRCA	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg25208724	chr1:156163844	SLC25A44	1.03	31.84	0.78	5.35e-134	Testicular germ cell tumor;
BRCA	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg22117172	chr7:91764530	CYP51A1	0.23	7.84	0.3	1.9e-14	Breast cancer;
BRCA	cis	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.08	-0.3	3.2e-15	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	19.81	0.62	1.76e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg02153584	chr22:29168773	CCDC117	0.51	10.74	0.39	7.34e-25	Lymphocyte counts;
BRCA	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.24	-0.31	9.74e-16	Axial length;
BRCA	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg04267008	chr7:1944627	MAD1L1	-0.4	-8.79	-0.33	1.43e-17	Schizophrenia;
BRCA	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.42	-0.38	1.39e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg16576597	chr16:28551801	NUPR1	0.3	8.42	0.32	2.52e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.35e-15	Prostate cancer;
BRCA	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-16.14	-0.54	2.07e-49	Total cholesterol levels;
BRCA	cis	rs12973672	1.000	rs10414846	chr19:35772471	A/G	cg12095397	chr19:35769544	USF2	-0.37	-8.29	-0.31	6.72e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg09021430	chr5:549028	NA	-0.52	-14.83	-0.51	5.54e-43	Obesity-related traits;
BRCA	cis	rs758324	0.947	rs687816	chr5:131262077	C/T	cg06307176	chr5:131281290	NA	-0.53	-10.1	-0.37	2.4e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg12373951	chr3:133503437	NA	0.34	8.03	0.3	4.6e-15	Iron status biomarkers;
BRCA	cis	rs9463078	0.547	rs764397	chr6:44710771	C/A	cg25276700	chr6:44698697	NA	0.36	8.18	0.31	1.56e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg09184832	chr6:79620586	NA	0.52	11.54	0.42	4.23e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-18.33	-0.59	1.34e-60	Extrinsic epigenetic age acceleration;
BRCA	trans	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg06521331	chr12:34319734	NA	-0.51	-9.43	-0.35	7.52e-20	Bladder cancer;
BRCA	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.54	-11.35	-0.41	2.41e-27	Lymphocyte counts;
BRCA	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg09904177	chr6:26538194	HMGN4	0.56	18.25	0.59	3.23e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-23.41	-0.68	5.39e-88	Height;
BRCA	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg10523679	chr1:76189770	ACADM	-0.42	-8.05	-0.3	4.17e-15	Daytime sleep phenotypes;
BRCA	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg24006582	chr15:45444508	DUOX1	-0.55	-11.31	-0.41	3.77e-27	Uric acid levels;
BRCA	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg13770153	chr20:60521292	NA	-0.45	-10.81	-0.39	4.09e-25	Body mass index;
BRCA	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg16179182	chr5:140090404	VTRNA1-1	0.47	10.99	0.4	7.61e-26	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3845702	0.736	rs9288045	chr2:180814194	G/A	cg01881094	chr2:180872142	CWC22	-1.03	-18.42	-0.59	4.48e-61	Schizophrenia;
BRCA	cis	rs708547	0.581	rs10020462	chr4:57825593	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.42	8.21	0.31	1.25e-15	Response to bleomycin (chromatid breaks);
BRCA	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg16586182	chr3:47516702	SCAP	-0.56	-12.79	-0.45	1.59e-33	Colorectal cancer;
BRCA	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg04166393	chr7:2884313	GNA12	-0.44	-8.52	-0.32	1.15e-16	Height;
BRCA	trans	rs6479891	1.000	rs12416113	chr10:64896477	A/T	cg14819942	chr15:35414228	NA	0.34	8.52	0.32	1.19e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs2882667	0.858	rs11741150	chr5:138431457	C/T	cg04439458	chr5:138467593	SIL1	-0.41	-10.18	-0.37	1.13e-22	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-9.56	-0.35	2.58e-20	Schizophrenia;
BRCA	cis	rs2108225	0.967	rs6979054	chr7:107447488	A/C	cg18560240	chr7:107437656	SLC26A3	-0.53	-10.59	-0.39	2.87e-24	Ulcerative colitis;
BRCA	cis	rs7246657	0.653	rs10406612	chr19:37716611	C/T	cg14683738	chr19:37701593	ZNF585B	0.54	8.13	0.31	2.26e-15	Coronary artery calcification;
BRCA	cis	rs77741769	0.571	rs869781	chr12:121340246	T/C	cg02419362	chr12:121203948	SPPL3	0.34	7.96	0.3	7.83e-15	Mean corpuscular volume;
BRCA	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.89	0.4	1.94e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg20503657	chr10:835505	NA	-0.57	-10.44	-0.38	1.16e-23	Eosinophil percentage of granulocytes;
BRCA	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg25358565	chr5:93447407	FAM172A	-0.51	-9.36	-0.35	1.37e-19	Diabetic retinopathy;
BRCA	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg11812906	chr14:75593930	NEK9	-0.63	-14.42	-0.5	4.98e-41	Height;
BRCA	trans	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg21659725	chr3:3221576	CRBN	-0.47	-8.46	-0.32	1.86e-16	Menarche (age at onset);
BRCA	cis	rs1451375	0.617	rs896307	chr7:50569060	T/C	cg18232548	chr7:50535776	DDC	-0.42	-9.06	-0.34	1.59e-18	Malaria;
BRCA	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	8.55	0.32	9.35e-17	Glomerular filtration rate (creatinine);
BRCA	trans	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg26384229	chr12:38710491	ALG10B	0.56	12.16	0.43	9.7e-31	Morning vs. evening chronotype;
BRCA	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.4	9.59	0.35	2.01e-20	Eosinophil percentage of white cells;
BRCA	cis	rs6815814	0.950	rs55830619	chr4:38807364	G/A	cg02016764	chr4:38805732	TLR1	-0.6	-9.57	-0.35	2.39e-20	Breast cancer;
BRCA	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.24	-0.41	7.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.94e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7395581	0.918	rs7124955	chr11:47315274	A/T	cg25783544	chr11:47291846	MADD	0.4	9.03	0.34	1.97e-18	HDL cholesterol;
BRCA	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	13.88	0.48	1.77e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs17601876	0.814	rs12050767	chr15:51557257	T/C	cg19946085	chr15:51559439	CYP19A1	-0.38	-11.4	-0.41	1.55e-27	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg08999081	chr20:33150536	PIGU	-0.44	-12.35	-0.44	1.37e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg01262667	chr19:19385393	TM6SF2	0.41	10.62	0.39	2.25e-24	Tonsillectomy;
BRCA	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg22903471	chr2:27725779	GCKR	-0.39	-9.72	-0.36	6.36e-21	Total body bone mineral density;
BRCA	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg00898013	chr13:113819073	PROZ	-0.37	-8.96	-0.33	3.61e-18	Platelet distribution width;
BRCA	cis	rs2859741	0.967	rs535876	chr1:37484052	C/G	cg09363841	chr1:37513479	NA	-0.64	-16.09	-0.54	3.75e-49	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	trans	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-7.9	-0.3	1.26e-14	Menarche (age at onset);
BRCA	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg19812747	chr11:111475976	SIK2	-0.41	-7.95	-0.3	8.57e-15	Primary sclerosing cholangitis;
BRCA	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg18252515	chr7:66147081	NA	-1.07	-15.67	-0.53	4.69e-47	Diabetic kidney disease;
BRCA	cis	rs6088813	1.000	rs1406947	chr20:33969530	C/T	cg14752227	chr20:34000481	UQCC	-0.42	-8.93	-0.33	4.33e-18	Height;
BRCA	cis	rs12791968	0.649	rs3802785	chr11:44995441	C/T	cg11846598	chr11:44996168	LOC221122	-0.53	-9.15	-0.34	7.85e-19	Inhibitory control;
BRCA	cis	rs7646881	0.953	rs73015657	chr3:158451932	G/A	cg19483011	chr3:158453295	NA	-0.49	-9.34	-0.35	1.61e-19	Tetralogy of Fallot;
BRCA	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg24069376	chr3:38537580	EXOG	0.4	11.4	0.41	1.51e-27	Electrocardiographic conduction measures;
BRCA	cis	rs11605924	0.934	rs7945565	chr11:45878992	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.45	-10.16	-0.37	1.42e-22	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2014572	0.967	rs8100154	chr19:57765432	A/G	cg24459738	chr19:57751996	ZNF805	-0.37	-8.59	-0.32	6.39e-17	Hyperactive-impulsive symptoms;
BRCA	trans	rs629535	0.814	rs614050	chr8:70065642	G/A	cg21567404	chr3:27674614	NA	1.01	20.74	0.63	1.93e-73	Dupuytren's disease;
BRCA	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg04553112	chr3:125709451	NA	-0.54	-8.86	-0.33	8.18e-18	Blood pressure (smoking interaction);
BRCA	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg01448562	chr3:133502909	NA	-0.52	-11.02	-0.4	5.54e-26	Iron status biomarkers;
BRCA	cis	rs73086581	1.000	rs73086597	chr20:3983571	G/A	cg02187196	chr20:3869020	PANK2	0.52	9.36	0.35	1.37e-19	Response to antidepressants in depression;
BRCA	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg16576597	chr16:28551801	NUPR1	0.28	7.93	0.3	9.92e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.8	0.36	3.22e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	8.3	0.31	6.33e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2066819	1.000	rs41363748	chr12:56696056	C/T	cg26714650	chr12:56694279	CS	1.0	13.94	0.48	9.08e-39	Psoriasis vulgaris;
BRCA	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg00105475	chr2:10696890	NA	0.44	10.29	0.38	4.38e-23	Prostate cancer;
BRCA	trans	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg25214090	chr10:38739885	LOC399744	0.53	11.71	0.42	7.51e-29	Corneal astigmatism;
BRCA	cis	rs3772130	0.583	rs28497949	chr3:121448675	T/A	cg20356878	chr3:121714668	ILDR1	0.37	8.32	0.31	5.23e-16	Cognitive performance;
BRCA	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg15017067	chr4:17643749	FAM184B	0.32	9.63	0.36	1.43e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg02659138	chr7:134003124	SLC35B4	-0.4	-12.05	-0.43	2.72e-30	Mean platelet volume;
BRCA	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	13.11	0.46	5.78e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	8.78	0.33	1.53e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.48	9.58	0.35	2.11e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	10.95	0.4	1.11e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg03929089	chr4:120376271	NA	0.49	8.21	0.31	1.24e-15	Axial length;
BRCA	cis	rs2404602	0.735	rs11629888	chr15:76719880	A/T	cg23625390	chr15:77176239	SCAPER	-0.52	-12.1	-0.43	1.76e-30	Blood metabolite levels;
BRCA	cis	rs250677	0.522	rs56309414	chr5:148376026	C/G	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.19	-0.31	1.38e-15	Breast cancer;
BRCA	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6484504	0.652	rs674035	chr11:31399014	G/A	cg26647111	chr11:31128758	NA	0.46	9.89	0.36	1.54e-21	Red blood cell count;
BRCA	cis	rs6120849	1.000	rs6120849	chr20:33730387	C/T	cg24642439	chr20:33292090	TP53INP2	0.54	9.36	0.35	1.29e-19	Protein C levels;
BRCA	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg23711669	chr6:146136114	FBXO30	0.71	17.07	0.56	4.4e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2011503	0.782	rs8113006	chr19:19669441	C/G	cg11584989	chr19:19387371	SF4	-0.49	-9.99	-0.37	6.24e-22	Bipolar disorder;
BRCA	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg12935359	chr14:103987150	CKB	0.58	14.02	0.48	3.98e-39	Body mass index;
BRCA	cis	rs2580764	0.624	rs12713284	chr2:55228861	G/A	cg09592903	chr2:55203963	RTN4	-0.41	-10.35	-0.38	2.69e-23	Mean platelet volume;
BRCA	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg13256891	chr4:100009986	ADH5	-0.52	-9.77	-0.36	4.25e-21	Alcohol dependence;
BRCA	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.76	-0.42	5.03e-29	Bipolar disorder;
BRCA	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.13	0.31	2.19e-15	Tonsillectomy;
BRCA	cis	rs367615	0.704	rs7704824	chr5:108850278	A/G	cg17395555	chr5:108820864	NA	0.34	10.69	0.39	1.18e-24	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg22907277	chr7:1156413	C7orf50	0.59	9.1	0.34	1.11e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10267417	0.603	rs10081258	chr7:19934237	C/G	cg05791153	chr7:19748676	TWISTNB	0.43	8.09	0.3	3.01e-15	Night sleep phenotypes;
BRCA	cis	rs953387	0.910	rs16833170	chr2:136929076	A/G	cg05194412	chr2:137003533	NA	-0.34	-7.98	-0.3	6.88e-15	Arthritis (juvenile idiopathic);
BRCA	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg26647111	chr11:31128758	NA	-0.44	-9.71	-0.36	6.96e-21	Red blood cell count;
BRCA	cis	rs17604090	0.878	rs10262227	chr7:29704073	G/A	cg19413766	chr7:29689036	LOC646762	-0.61	-8.23	-0.31	1.07e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg10057126	chr4:77819792	ANKRD56	0.68	15.42	0.52	7.78e-46	Emphysema distribution in smoking;
BRCA	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10802521	chr3:52805072	NEK4	-0.31	-8.44	-0.32	2.17e-16	Electroencephalogram traits;
BRCA	cis	rs76419734	0.510	rs28450989	chr4:106630007	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.57	12.5	0.44	3.21e-32	Post bronchodilator FEV1;
BRCA	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg07395648	chr5:131743802	NA	-0.39	-9.71	-0.36	7.05e-21	Blood metabolite levels;
BRCA	trans	rs1997103	1.000	rs6948112	chr7:55411302	G/A	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs758324	0.947	rs7725924	chr5:131118165	C/G	cg06307176	chr5:131281290	NA	0.53	10.21	0.37	8.75e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg24130564	chr14:104152367	KLC1	-0.41	-8.78	-0.33	1.52e-17	Reticulocyte count;
BRCA	cis	rs1018836	0.923	rs13277387	chr8:91633713	C/G	cg16814680	chr8:91681699	NA	-0.5	-10.52	-0.38	5.61e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg11247378	chr22:39784982	NA	-0.62	-14.22	-0.49	4.45e-40	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9929218	1.000	rs9928847	chr16:68797893	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-13.82	-0.48	3.34e-38	Colorectal cancer;
BRCA	cis	rs1865721	1.000	rs17284077	chr18:73204128	C/T	cg26385618	chr18:73139727	C18orf62	-0.38	-8.63	-0.32	4.7e-17	Intelligence;
BRCA	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg25019033	chr10:957182	NA	-0.42	-8.05	-0.3	4.14e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs6684514	1.000	rs12117951	chr1:156305286	G/A	cg16558208	chr1:156270281	VHLL	0.37	8.32	0.31	5.29e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg18479299	chr3:125709523	NA	-0.54	-8.33	-0.31	4.84e-16	Blood pressure (smoking interaction);
BRCA	trans	rs800082	0.668	rs6805395	chr3:144292116	T/C	cg24215973	chr2:240111563	HDAC4	-0.43	-10.32	-0.38	3.26e-23	Smoking behavior;
BRCA	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg20476274	chr7:133979776	SLC35B4	0.7	21.39	0.65	5.77e-77	Mean platelet volume;
BRCA	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	12.97	0.46	2.61e-34	Migraine;Coronary artery disease;
BRCA	cis	rs17253792	0.908	rs74354306	chr14:56065778	T/G	cg01858014	chr14:56050164	KTN1	-0.77	-10.93	-0.4	1.3e-25	Putamen volume;
BRCA	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2108225	0.934	rs2301988	chr7:107443833	A/G	cg18560240	chr7:107437656	SLC26A3	0.53	11.16	0.4	1.49e-26	Ulcerative colitis;
BRCA	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg18357645	chr12:58087776	OS9	0.45	13.22	0.46	1.89e-35	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg08917208	chr2:24149416	ATAD2B	0.52	8.28	0.31	7.42e-16	Asthma;
BRCA	cis	rs10501293	1.000	rs10768913	chr11:43060750	T/C	cg03447554	chr11:43094025	NA	0.5	9.15	0.34	7.78e-19	Cognitive performance;
BRCA	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg24069376	chr3:38537580	EXOG	0.33	9.18	0.34	6.07e-19	Electrocardiographic conduction measures;
BRCA	trans	rs1997103	1.000	rs6949222	chr7:55411264	C/T	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg25019033	chr10:957182	NA	-0.41	-7.9	-0.3	1.23e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs4566357	0.615	rs10184991	chr2:227916533	G/A	cg05526886	chr2:227700861	RHBDD1	-0.4	-8.23	-0.31	1.06e-15	Coronary artery disease;
BRCA	cis	rs1568889	1.000	rs10767693	chr11:28093926	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.25	0.63	7.91e-71	Bipolar disorder;
BRCA	cis	rs2901460	0.509	rs10165560	chr2:62059398	A/C	cg02183531	chr2:62113199	CCT4	-0.44	-8.62	-0.32	5.3e-17	Mean corpuscular volume;
BRCA	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg23260525	chr10:116636907	FAM160B1	0.3	8.03	0.3	4.75e-15	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs3818285	0.632	rs536343	chr10:111632879	T/C	cg00817464	chr10:111662876	XPNPEP1	0.45	14.64	0.5	4.8e-42	Superior crus of antihelix expression;
BRCA	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg04546413	chr19:29218101	NA	0.64	12.33	0.44	1.75e-31	Methadone dose in opioid dependence;
BRCA	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg11266682	chr4:10021025	SLC2A9	0.45	12.02	0.43	3.9e-30	Bone mineral density;
BRCA	cis	rs921968	0.528	rs13382651	chr2:219628191	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-10.97	-0.4	8.97e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg26587870	chr6:27730563	NA	-0.45	-8.09	-0.3	3.07e-15	Lung cancer in ever smokers;
BRCA	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg18876405	chr7:65276391	NA	0.68	17.94	0.58	1.33e-58	Aortic root size;
BRCA	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.36e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	trans	rs6076960	0.811	rs6053960	chr20:6176778	T/C	cg21095983	chr6:86352623	SYNCRIP	0.42	10.07	0.37	3.11e-22	Smooth-surface caries;
BRCA	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.13	-0.37	1.86e-22	Mean corpuscular volume;
BRCA	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.58	-0.42	2.73e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs17818399	0.708	rs1531133	chr2:46843631	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.47	9.63	0.36	1.36e-20	Height;
BRCA	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg10523679	chr1:76189770	ACADM	0.76	15.88	0.53	4.12e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17345786	0.520	rs13062677	chr3:101305078	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.36	8.36	0.31	4.07e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4363385	0.747	rs2339491	chr1:152985322	T/C	cg25856811	chr1:152973957	SPRR3	-0.34	-9.15	-0.34	7.8e-19	Inflammatory skin disease;
BRCA	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.68	16.02	0.54	8.33e-49	Axial length;
BRCA	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg05623727	chr3:50126028	RBM5	-0.42	-10.07	-0.37	3.2e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.58	-0.61	3.27e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs4596713	0.538	rs4421408	chr9:71760884	G/T	cg16512924	chr15:28394682	HERC2	0.44	10.38	0.38	2.06e-23	Headache;
BRCA	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg18351406	chr4:77819688	ANKRD56	-0.58	-13.08	-0.46	8.63e-35	Emphysema distribution in smoking;
BRCA	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg24642844	chr7:1081250	C7orf50	-0.9	-16.23	-0.54	7.52e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg01528321	chr10:82214614	TSPAN14	0.81	17.21	0.56	8.09e-55	Post bronchodilator FEV1;
BRCA	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg22974920	chr21:40686053	BRWD1	-0.38	-8.7	-0.33	2.86e-17	Cognitive function;
BRCA	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.2	18.89	0.6	1.41e-63	Hemostatic factors and hematological phenotypes;
BRCA	trans	rs9397585	0.599	rs685826	chr6:153411255	C/T	cg15216925	chr5:179921655	CNOT6	0.48	8.86	0.33	8.09e-18	Body mass index;
BRCA	cis	rs9649465	0.806	rs6971297	chr7:123293342	A/T	cg04330084	chr7:123175371	IQUB	-0.3	-8.21	-0.31	1.25e-15	Migraine;
BRCA	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg00825309	chr19:58991885	ZNF446	-0.58	-12.78	-0.45	1.83e-33	Uric acid clearance;
BRCA	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg14061069	chr19:46274453	DMPK	0.63	17.68	0.57	3.04e-57	Coronary artery disease;
BRCA	cis	rs4780401	0.609	rs12927966	chr16:11814562	C/T	cg01061890	chr16:11836724	TXNDC11	-0.57	-13.35	-0.47	5.15e-36	Rheumatoid arthritis;
BRCA	trans	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg26384229	chr12:38710491	ALG10B	0.52	11.18	0.4	1.28e-26	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg22920501	chr2:26401640	FAM59B	0.83	13.58	0.47	4.15e-37	Gut microbiome composition (summer);
BRCA	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg03433033	chr1:76189801	ACADM	0.74	18.97	0.6	5.66e-64	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.3	7.98	0.3	6.85e-15	Monocyte percentage of white cells;
BRCA	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg11764359	chr7:65958608	NA	0.63	10.76	0.39	6.35e-25	Aortic root size;
BRCA	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.25	-0.44	3.84e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.77	-0.33	1.58e-17	Resting heart rate;
BRCA	cis	rs929596	0.785	rs6714634	chr2:234664765	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.47	12.21	0.43	5.72e-31	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.12	0.49	1.31e-39	Eye color traits;
BRCA	cis	rs9487051	0.768	rs435611	chr6:109527755	C/T	cg01475377	chr6:109611718	NA	-0.42	-10.48	-0.38	7.98e-24	Reticulocyte fraction of red cells;
BRCA	cis	rs7617773	0.780	rs34630841	chr3:48343261	G/A	cg11946769	chr3:48343235	NME6	0.7	14.01	0.48	4.4e-39	Coronary artery disease;
BRCA	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg16339924	chr4:17578868	LAP3	0.57	13.77	0.48	5.56e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg02297831	chr4:17616191	MED28	0.37	8.72	0.33	2.44e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg15556689	chr8:8085844	FLJ10661	0.33	8.25	0.31	9.01e-16	Monocyte count;
BRCA	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-11.96	-0.43	6.52e-30	Developmental language disorder (linguistic errors);
BRCA	cis	rs4478137	0.899	rs10857354	chr4:164239841	A/G	cg06758707	chr4:164254230	NPY1R	0.57	12.45	0.44	5.39e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.52	-0.32	1.11e-16	Monocyte percentage of white cells;
BRCA	cis	rs1020064	0.636	rs1529975	chr2:105929901	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.44	8.43	0.32	2.31e-16	AIDS;
BRCA	cis	rs1371614	0.635	rs12714002	chr2:27134925	C/T	cg12368169	chr2:27073192	DPYSL5	-0.3	-8.71	-0.33	2.68e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg11502198	chr6:26597334	ABT1	0.47	9.37	0.35	1.25e-19	Intelligence (multi-trait analysis);
BRCA	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg15704280	chr7:45808275	SEPT13	0.54	9.13	0.34	8.85e-19	Axial length;
BRCA	cis	rs9341808	0.718	rs9448899	chr6:80845864	G/A	cg08355045	chr6:80787529	NA	0.37	9.44	0.35	6.69e-20	Sitting height ratio;
BRCA	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11764359	chr7:65958608	NA	-0.79	-19.31	-0.61	8.33e-66	Aortic root size;
BRCA	cis	rs4363385	0.747	rs2225919	chr1:152969603	A/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.85	-0.36	2.13e-21	Inflammatory skin disease;
BRCA	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg14092571	chr14:90743983	NA	-0.66	-17.78	-0.58	9.31e-58	Gut microbiota (bacterial taxa);
BRCA	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14169450	chr9:139327907	INPP5E	0.41	9.46	0.35	5.92e-20	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg12193833	chr17:30244370	NA	-0.56	-8.77	-0.33	1.58e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26314531	chr2:26401878	FAM59B	0.88	15.31	0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs7178424	0.742	rs1981916	chr15:62171479	T/C	cg00456672	chr15:62358751	C2CD4A	-0.38	-8.93	-0.33	4.64e-18	Height;
BRCA	cis	rs2637030	0.501	rs375956	chr5:52883715	C/G	cg06476337	chr5:52856530	NDUFS4	0.38	8.62	0.32	5.24e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg23711669	chr6:146136114	FBXO30	0.65	15.41	0.52	8.21e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg05714579	chr10:131428358	MGMT	-0.72	-16.77	-0.55	1.38e-52	Response to temozolomide;
BRCA	cis	rs1577917	1.000	rs791856	chr6:86681841	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.44	11.93	0.43	9.43e-30	Response to antipsychotic treatment;
BRCA	cis	rs2191566	1.000	rs2356549	chr19:44511202	A/T	cg20607764	chr19:44506953	ZNF230	-0.42	-9.5	-0.35	4e-20	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs644148	0.785	rs117048220	chr19:44965555	G/A	cg15540054	chr19:45004280	ZNF180	0.56	11.6	0.42	2.2e-28	Personality dimensions;
BRCA	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg21770322	chr7:97807741	LMTK2	0.42	11.1	0.4	2.64e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg16950941	chr11:66035639	RAB1B	0.44	11.97	0.43	6.29e-30	Gout;
BRCA	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.46	0.55	4.99e-51	Morning vs. evening chronotype;
BRCA	cis	rs1865721	0.804	rs719179	chr18:73146396	A/G	cg26385618	chr18:73139727	C18orf62	-0.45	-10.82	-0.39	3.68e-25	Intelligence;
BRCA	trans	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.88	0.3	1.4e-14	Endometrial cancer;
BRCA	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg13319975	chr6:146136371	FBXO30	0.42	9.65	0.36	1.19e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg21784768	chr11:537496	LRRC56	0.65	8.46	0.32	1.87e-16	Body mass index;
BRCA	cis	rs7903847	0.642	rs7078004	chr10:99140511	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.64	-0.32	4.5e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10046574	0.731	rs10267977	chr7:135159392	G/A	cg27474649	chr7:135195673	CNOT4	0.61	8.89	0.33	6.04e-18	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	trans	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg01620082	chr3:125678407	NA	-0.84	-9.71	-0.36	7.09e-21	Urinary tract infection frequency;
BRCA	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg12386194	chr3:101231763	SENP7	0.59	11.88	0.43	1.54e-29	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21659725	chr3:3221576	CRBN	-0.71	-21.74	-0.65	6.96e-79	Intelligence (multi-trait analysis);
BRCA	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg24130564	chr14:104152367	KLC1	0.35	7.98	0.3	6.97e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg13010199	chr12:38710504	ALG10B	0.46	11.29	0.41	4.41e-27	Morning vs. evening chronotype;
BRCA	cis	rs2625529	0.824	rs4776586	chr15:72430503	C/A	cg16672083	chr15:72433130	SENP8	-0.85	-17.91	-0.58	1.94e-58	Red blood cell count;
BRCA	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg13319975	chr6:146136371	FBXO30	-0.36	-8.3	-0.31	6.2e-16	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg06521331	chr12:34319734	NA	-0.48	-8.78	-0.33	1.47e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6942756	0.774	rs2402944	chr7:128951402	G/T	cg02491457	chr7:128862824	NA	-0.56	-12.01	-0.43	4.11e-30	White matter hyperintensity burden;
BRCA	cis	rs17095355	1.000	rs12263915	chr10:111744664	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.38	-9.64	-0.36	1.26e-20	Biliary atresia;
BRCA	cis	rs4285028	0.948	rs13067270	chr3:121673901	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.82	-0.39	3.64e-25	Multiple sclerosis;
BRCA	cis	rs2463822	1.000	rs2513076	chr11:62103711	A/G	cg06239285	chr11:62104954	ASRGL1	0.68	11.2	0.41	1.03e-26	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg04362960	chr10:104952993	NT5C2	0.88	14.07	0.49	2.25e-39	Arsenic metabolism;
BRCA	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg06046430	chr4:77819534	ANKRD56	0.58	12.65	0.45	6.89e-33	Emphysema distribution in smoking;
BRCA	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg11812906	chr14:75593930	NEK9	-0.61	-14.2	-0.49	5.8e-40	Height;
BRCA	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg12386194	chr3:101231763	SENP7	0.46	9.76	0.36	4.64e-21	Colorectal cancer;
BRCA	cis	rs7020830	0.898	rs997318	chr9:37364094	C/T	cg14294708	chr9:37120828	ZCCHC7	1.13	36.57	0.82	8.6e-159	Schizophrenia;
BRCA	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.94	0.33	4.2e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs490234	0.676	rs4838263	chr9:128225199	G/A	cg14078157	chr9:128172775	NA	-0.5	-11.12	-0.4	2.15e-26	Mean arterial pressure;
BRCA	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg09307838	chr4:120376055	NA	0.5	10.84	0.39	2.97e-25	Diastolic blood pressure;
BRCA	cis	rs112217694	1.000	rs17196218	chr4:104658371	C/T	cg04535008	chr4:104641033	TACR3	-0.82	-8.78	-0.33	1.49e-17	Menarche (age at onset);
BRCA	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.72	0.6	1.16e-62	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs3820928	1.000	rs3731593	chr2:227773924	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-8.92	-0.33	5.06e-18	Pulmonary function;
BRCA	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg02951883	chr7:2050386	MAD1L1	0.61	15.79	0.53	1.15e-47	Bipolar disorder and schizophrenia;
BRCA	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg18154014	chr19:37997991	ZNF793	0.61	11.39	0.41	1.69e-27	Coronary artery calcification;
BRCA	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26314531	chr2:26401878	FAM59B	-0.65	-11.17	-0.4	1.42e-26	Gut microbiome composition (summer);
BRCA	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg19920283	chr7:105172520	RINT1	0.59	9.53	0.35	3.29e-20	Bipolar disorder (body mass index interaction);
BRCA	trans	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg06521331	chr12:34319734	NA	-0.46	-8.54	-0.32	9.43e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs883565	0.718	rs1112438	chr3:39152345	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	0.39	8.46	0.32	1.84e-16	Handedness;
BRCA	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12379764	chr21:47803548	PCNT	0.4	8.86	0.33	7.77e-18	Testicular germ cell tumor;
BRCA	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1868673	0.965	rs6792759	chr3:150138424	C/T	cg04908077	chr3:150187338	NA	-0.33	-8.73	-0.33	2.22e-17	Waist circumference;
BRCA	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg05340658	chr4:99064831	C4orf37	0.69	17.38	0.57	1.03e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-8.73	-0.33	2.24e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6785206	0.527	rs9844706	chr3:128380781	G/A	cg16766828	chr3:128327626	NA	-0.67	-10.84	-0.39	2.97e-25	Lymphocyte percentage of white cells;
BRCA	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg25173405	chr17:45401733	C17orf57	0.54	11.83	0.42	2.41e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg13628971	chr7:2884303	GNA12	0.49	9.9	0.36	1.3e-21	Height;
BRCA	cis	rs953387	0.744	rs115224560	chr2:136896041	T/A	cg05194412	chr2:137003533	NA	-0.38	-8.79	-0.33	1.4e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg07169764	chr2:136633963	MCM6	1.29	29.44	0.76	5.11e-121	Corneal structure;
BRCA	cis	rs10851411	0.697	rs62019315	chr15:42863542	G/C	cg21293051	chr15:42870591	STARD9	0.51	8.77	0.33	1.58e-17	Glucose homeostasis traits;
BRCA	trans	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	20.3	0.63	4.18e-71	Exhaled nitric oxide output;
BRCA	cis	rs1113500	0.730	rs1777456	chr1:108588472	G/A	cg06207961	chr1:108661230	NA	-0.33	-7.81	-0.3	2.33e-14	Growth-regulated protein alpha levels;
BRCA	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.36	-9.36	-0.35	1.38e-19	Total body bone mineral density;
BRCA	cis	rs6484504	0.532	rs7121949	chr11:31288160	G/T	cg14844989	chr11:31128820	NA	-0.45	-9.56	-0.35	2.5e-20	Red blood cell count;
BRCA	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg23711669	chr6:146136114	FBXO30	-0.68	-15.92	-0.53	2.69e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.53	-0.32	1.1e-16	Monocyte percentage of white cells;
BRCA	cis	rs7945718	0.934	rs3993110	chr11:12794530	A/C	cg25843174	chr11:12811716	TEAD1	0.23	8.68	0.32	3.34e-17	Educational attainment (years of education);
BRCA	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.48	9.6	0.35	1.8e-20	Tonsillectomy;
BRCA	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg22963979	chr7:1858916	MAD1L1	-0.44	-9.22	-0.34	4.16e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.09	0.34	1.28e-18	Motion sickness;
BRCA	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg09307838	chr4:120376055	NA	0.63	13.64	0.47	2.32e-37	Corneal astigmatism;
BRCA	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg24110177	chr3:50126178	RBM5	-0.37	-9.94	-0.37	9.84e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-9.06	-0.34	1.57e-18	Schizophrenia;
BRCA	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg09904177	chr6:26538194	HMGN4	0.55	17.65	0.57	4.53e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg19723775	chr5:179050963	HNRNPH1	0.47	10.86	0.39	2.54e-25	Lung cancer;
BRCA	trans	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.97	-0.33	3.19e-18	Depression;
BRCA	cis	rs778371	0.723	rs12619195	chr2:233678326	G/A	cg08000102	chr2:233561755	GIGYF2	-0.85	-21.05	-0.64	3.94e-75	Schizophrenia;
BRCA	cis	rs909002	0.830	rs10914461	chr1:32113217	G/A	cg01639898	chr1:32083012	HCRTR1	0.3	8.95	0.33	3.82e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	15.68	0.53	3.95e-47	Platelet count;
BRCA	cis	rs4566357	0.576	rs3769644	chr2:227917240	C/G	cg05526886	chr2:227700861	RHBDD1	-0.4	-8.23	-0.31	1.06e-15	Coronary artery disease;
BRCA	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg20203395	chr5:56204925	C5orf35	0.41	9.17	0.34	6.66e-19	Initial pursuit acceleration;
BRCA	cis	rs2882667	0.690	rs4835706	chr5:138164726	G/A	cg04439458	chr5:138467593	SIL1	0.31	7.81	0.3	2.28e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg12311346	chr5:56204834	C5orf35	0.62	13.08	0.46	8.22e-35	Initial pursuit acceleration;
BRCA	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-9.51	-0.35	3.93e-20	IgG glycosylation;
BRCA	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg20469991	chr17:27169893	C17orf63	-0.45	-8.77	-0.33	1.66e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	trans	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.26	0.31	8.48e-16	Corneal astigmatism;
BRCA	cis	rs965469	1.000	rs2281500	chr20:3262824	C/T	cg25506879	chr20:3388711	C20orf194	-0.52	-10.27	-0.38	5.09e-23	IFN-related cytopenia;
BRCA	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.24	-0.34	3.68e-19	Bipolar disorder;
BRCA	cis	rs9790314	0.715	rs980975	chr3:160771410	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-8.78	-0.33	1.5e-17	Morning vs. evening chronotype;
BRCA	trans	rs10242455	0.702	rs17854665	chr7:99050039	G/A	cg09045935	chr12:6379348	NA	0.83	8.28	0.31	7.06e-16	Blood metabolite levels;
BRCA	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg14004847	chr7:1930337	MAD1L1	-0.4	-8.33	-0.31	5.01e-16	Schizophrenia;
BRCA	cis	rs858239	1.000	rs156421	chr7:23312487	A/G	cg23682824	chr7:23144976	KLHL7	0.35	8.92	0.33	4.7e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg14530993	chr4:882597	GAK	0.6	9.81	0.36	3.02e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg16339924	chr4:17578868	LAP3	0.66	16.3	0.54	3.13e-50	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg11764359	chr7:65958608	NA	0.62	13.54	0.47	6.51e-37	Aortic root size;
BRCA	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.56	12.19	0.43	6.71e-31	Chronic sinus infection;
BRCA	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg05340658	chr4:99064831	C4orf37	0.68	16.98	0.56	1.21e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg23533926	chr12:111358616	MYL2	-0.42	-8.71	-0.33	2.6e-17	Extrinsic epigenetic age acceleration;
BRCA	trans	rs3857536	0.813	rs1891600	chr6:66941645	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	8.24	0.31	1.01e-15	Menarche (age at onset);
BRCA	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00684032	chr4:1343700	KIAA1530	0.48	11.43	0.41	1.18e-27	Obesity-related traits;
BRCA	cis	rs13418410	0.539	rs1545399	chr2:33843801	A/G	cg04131969	chr2:33951647	MYADML	-0.56	-10.94	-0.4	1.17e-25	Non-response to antidepressants and depression;
BRCA	cis	rs1635	0.655	rs73742535	chr6:28302925	G/A	cg15743358	chr6:28303923	ZNF323	-0.75	-8.56	-0.32	8.52e-17	Schizophrenia;
BRCA	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg15704280	chr7:45808275	SEPT13	-0.48	-9.28	-0.34	2.58e-19	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg04450456	chr4:17643702	FAM184B	0.4	10.87	0.39	2.36e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg13880726	chr7:1868755	MAD1L1	0.5	9.79	0.36	3.55e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg01483505	chr11:975446	AP2A2	0.3	8.1	0.31	2.72e-15	Alzheimer's disease (late onset);
BRCA	trans	rs12310956	0.510	rs11052882	chr12:33890017	T/C	cg26384229	chr12:38710491	ALG10B	0.41	9.44	0.35	6.6e-20	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg11062466	chr8:58055876	NA	0.5	8.88	0.33	6.54e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs470119	1.000	rs470119	chr22:50966914	C/T	cg12969734	chr22:50962224	SCO2	-0.38	-9.24	-0.34	3.56e-19	Mean corpuscular hemoglobin;
BRCA	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg13319975	chr6:146136371	FBXO30	-0.6	-13.45	-0.47	1.66e-36	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs36051895	0.659	rs3780366	chr9:5068596	T/C	cg02405213	chr9:5042618	JAK2	-0.5	-8.99	-0.34	2.79e-18	Pediatric autoimmune diseases;
BRCA	cis	rs7560272	0.538	rs1806683	chr2:73939812	C/T	cg20560298	chr2:73613845	ALMS1	-0.33	-8.46	-0.32	1.88e-16	Schizophrenia;
BRCA	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg23711669	chr6:146136114	FBXO30	0.75	17.25	0.56	4.8e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg16586182	chr3:47516702	SCAP	0.64	13.93	0.48	1.04e-38	Colorectal cancer;
BRCA	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.26	0.41	5.88e-27	Bipolar disorder;
BRCA	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg07395648	chr5:131743802	NA	0.39	8.31	0.31	5.75e-16	Breast cancer;
BRCA	cis	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.33	-0.31	4.98e-16	Obesity-related traits;
BRCA	cis	rs11585357	1.000	rs72646785	chr1:17603472	G/T	cg19159961	chr1:17633534	PADI4	0.56	8.7	0.33	2.8e-17	Hair shape;
BRCA	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg00277334	chr10:82204260	NA	-0.49	-10.46	-0.38	9.98e-24	Post bronchodilator FEV1;
BRCA	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg02733842	chr7:1102375	C7orf50	-0.48	-9.65	-0.36	1.18e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg22105103	chr4:187893119	NA	0.41	13.28	0.47	1.05e-35	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg18252515	chr7:66147081	NA	-0.84	-12.26	-0.44	3.6e-31	Diabetic kidney disease;
BRCA	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg16586182	chr3:47516702	SCAP	-0.55	-12.36	-0.44	1.33e-31	Colorectal cancer;
BRCA	cis	rs13040088	0.580	rs11905041	chr20:61563408	C/T	cg23096297	chr20:61557774	DIDO1	0.68	14.37	0.49	9.35e-41	Menopause (age at onset);
BRCA	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs921968	0.591	rs6717107	chr2:219588697	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-10.97	-0.4	8.94e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-18.07	-0.58	2.78e-59	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.23	0.31	1.07e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18876405	chr7:65276391	NA	-0.56	-13.53	-0.47	7.6e-37	Aortic root size;
BRCA	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg10495392	chr1:46806563	NSUN4	0.44	8.11	0.31	2.59e-15	Menopause (age at onset);
BRCA	cis	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.42	-0.32	2.49e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs17401966	0.597	rs11121555	chr1:10442856	C/T	cg03954927	chr1:10346856	KIF1B	0.37	11.02	0.4	5.53e-26	Hepatocellular carcinoma;
BRCA	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg23933602	chr10:16859644	RSU1	0.56	9.13	0.34	8.73e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg20701182	chr2:24300061	SF3B14	0.58	9.06	0.34	1.57e-18	Lymphocyte counts;
BRCA	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg21535247	chr6:8435926	SLC35B3	0.38	8.39	0.32	3.1e-16	Motion sickness;
BRCA	cis	rs312273	0.530	rs278921	chr12:41377739	A/G	cg17827154	chr12:41323612	CNTN1	-0.36	-9.26	-0.34	3.1e-19	Bipolar disorder;
BRCA	cis	rs7524258	0.900	rs2412151	chr1:7303216	G/C	cg07173049	chr1:7289937	CAMTA1	0.39	9.5	0.35	4e-20	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	trans	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.76	0.39	6.29e-25	Type 2 diabetes;
BRCA	cis	rs11585357	0.947	rs2977304	chr1:17611615	T/C	cg08277548	chr1:17600880	PADI3	0.6	10.95	0.4	1.06e-25	Hair shape;
BRCA	cis	rs965469	0.895	rs6051841	chr20:3392871	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-10.17	-0.37	1.27e-22	IFN-related cytopenia;
BRCA	cis	rs701145	0.585	rs1713839	chr3:153829105	A/G	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.89e-18	Coronary artery disease;
BRCA	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg06784218	chr1:46089804	CCDC17	0.52	12.36	0.44	1.3e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg05340658	chr4:99064831	C4orf37	0.62	14.74	0.5	1.55e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs367943	0.604	rs28519541	chr5:113006931	C/G	cg12552261	chr5:112820674	MCC	0.42	8.37	0.31	3.69e-16	Type 2 diabetes;
BRCA	cis	rs2625529	0.652	rs2278987	chr15:72409769	T/C	cg16672083	chr15:72433130	SENP8	0.66	15.88	0.53	4.17e-48	Red blood cell count;
BRCA	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00166722	chr3:10149974	C3orf24	0.65	13.02	0.46	1.52e-34	Alzheimer's disease;
BRCA	cis	rs10465746	0.545	rs12145516	chr1:84480376	A/G	cg10977910	chr1:84465055	TTLL7	0.52	10.69	0.39	1.23e-24	Obesity-related traits;
BRCA	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.43	-8.73	-0.33	2.23e-17	Response to bleomycin (chromatid breaks);
BRCA	cis	rs13102973	0.640	rs6857995	chr4:135834193	G/A	cg14419869	chr4:135874104	NA	0.48	9.72	0.36	6.15e-21	Subjective well-being;
BRCA	cis	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg24110177	chr3:50126178	RBM5	-0.47	-11.43	-0.41	1.13e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg16325326	chr1:53192061	ZYG11B	0.58	12.68	0.45	5.16e-33	Monocyte count;
BRCA	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg23711669	chr6:146136114	FBXO30	0.79	18.66	0.59	2.27e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.94e-24	Motion sickness;
BRCA	cis	rs367943	0.712	rs255861	chr5:112745327	G/A	cg12552261	chr5:112820674	MCC	0.36	7.87	0.3	1.51e-14	Type 2 diabetes;
BRCA	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg10845886	chr2:3471009	TTC15	-0.53	-11.8	-0.42	3.35e-29	Neurofibrillary tangles;
BRCA	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg19773385	chr1:10388646	KIF1B	-0.38	-8.28	-0.31	6.99e-16	Hepatocellular carcinoma;
BRCA	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg02544614	chr20:61657117	NA	0.28	7.85	0.3	1.8e-14	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10802521	chr3:52805072	NEK4	0.34	9.45	0.35	6.05e-20	Bipolar disorder;
BRCA	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.44	-9.56	-0.35	2.5e-20	Multiple sclerosis;
BRCA	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.52	-10.39	-0.38	1.84e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1691799	0.899	rs1168302	chr12:66737518	C/T	cg16791601	chr12:66731901	HELB	-0.69	-19.41	-0.61	2.66e-66	White blood cell count (basophil);
BRCA	cis	rs7617773	0.780	rs35190747	chr3:48343290	C/T	cg11946769	chr3:48343235	NME6	0.69	13.87	0.48	2.01e-38	Coronary artery disease;
BRCA	cis	rs7246657	0.722	rs2927747	chr19:38159530	C/T	cg23950597	chr19:37808831	NA	0.54	9.08	0.34	1.3e-18	Coronary artery calcification;
BRCA	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg15556689	chr8:8085844	FLJ10661	0.38	8.85	0.33	8.82e-18	Retinal vascular caliber;
BRCA	cis	rs3862030	0.720	rs2025713	chr10:104230156	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.14	-0.43	1.12e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg24596788	chr1:163392923	NA	-0.32	-8.44	-0.32	2.18e-16	Motion sickness;
BRCA	trans	rs7200543	1.000	rs35574015	chr16:15146061	T/C	cg24683922	chr1:11983373	KIAA2013	-0.36	-8.17	-0.31	1.64e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	trans	rs2262909	0.962	rs4932952	chr19:22246788	G/A	cg17074339	chr11:11642133	GALNTL4	0.42	8.14	0.31	2.13e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg05283184	chr6:79620031	NA	-0.36	-8.23	-0.31	1.02e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00149659	chr3:10157352	C3orf10	0.8	14.13	0.49	1.23e-39	Alzheimer's disease;
BRCA	cis	rs9297145	0.916	rs4236540	chr7:98769025	A/C	cg05967295	chr7:98741636	SMURF1	0.88	21.32	0.64	1.41e-76	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg07741184	chr6:167504864	NA	0.33	9.88	0.36	1.64e-21	Primary biliary cholangitis;
BRCA	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg11366901	chr6:160182831	ACAT2	0.78	15.39	0.52	1.14e-45	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs1997103	0.954	rs56030000	chr7:55405750	A/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg17712092	chr4:129076599	LARP1B	-0.48	-10.48	-0.38	8.06e-24	Breast cancer;
BRCA	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg22920501	chr2:26401640	FAM59B	-0.66	-11.54	-0.42	3.93e-28	Gut microbiome composition (summer);
BRCA	cis	rs919433	0.647	rs1979239	chr2:198498316	T/G	cg00792783	chr2:198669748	PLCL1	0.41	9.06	0.34	1.56e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs10129255	0.518	rs10150460	chr14:107133196	C/G	cg07958169	chr14:107095056	NA	0.37	7.87	0.3	1.47e-14	Kawasaki disease;
BRCA	cis	rs9831754	1.000	rs9831754	chr3:78353591	A/C	cg06138941	chr3:78371609	NA	-0.81	-18.01	-0.58	6.22e-59	Calcium levels;
BRCA	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg26597838	chr10:835615	NA	0.88	14.75	0.5	1.43e-42	Eosinophil percentage of granulocytes;
BRCA	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18876405	chr7:65276391	NA	0.56	13.33	0.47	6.11e-36	Aortic root size;
BRCA	cis	rs10193935	0.901	rs17029411	chr2:42479149	G/A	cg27598129	chr2:42591480	NA	-0.65	-10.81	-0.39	4.05e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9311474	0.967	rs610060	chr3:52273421	G/A	cg18404041	chr3:52824283	ITIH1	0.29	8.19	0.31	1.44e-15	Electroencephalogram traits;
BRCA	cis	rs13046373	0.535	rs7281489	chr21:31978125	C/T	cg16812893	chr21:31813075	KRTAP15-1	0.4	10.14	0.37	1.63e-22	HDL cholesterol;
BRCA	trans	rs2736337	0.530	rs2003422	chr8:11303137	G/C	cg06636001	chr8:8085503	FLJ10661	0.45	8.61	0.32	5.57e-17	Rheumatoid arthritis;
BRCA	cis	rs4285028	0.747	rs12496318	chr3:121561500	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.83	15.31	0.52	2.69e-45	Multiple sclerosis;
BRCA	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg06935464	chr4:38784597	TLR10	0.51	8.2	0.31	1.32e-15	Breast cancer;
BRCA	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg22974920	chr21:40686053	BRWD1	-0.36	-8.02	-0.3	5.17e-15	Menarche (age at onset);
BRCA	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg22431228	chr1:16359049	CLCNKA	-0.44	-9.81	-0.36	2.97e-21	Dilated cardiomyopathy;
BRCA	trans	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg25482853	chr8:67687455	SGK3	0.78	13.92	0.48	1.13e-38	Obesity-related traits;
BRCA	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg09184832	chr6:79620586	NA	-0.43	-8.41	-0.32	2.66e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs3740540	0.507	rs2362500	chr10:126290431	T/C	cg04949429	chr10:126290192	LHPP	0.43	12.23	0.44	4.55e-31	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.53	0.5	1.53e-41	Motion sickness;
BRCA	cis	rs4363385	0.818	rs451939	chr1:153006877	C/T	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11890956	chr21:40555474	PSMG1	1.04	29.04	0.75	7.55e-119	Cognitive function;
BRCA	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.37	-8.13	-0.31	2.18e-15	Longevity;Endometriosis;
BRCA	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg24642439	chr20:33292090	TP53INP2	0.54	11.61	0.42	2e-28	Glomerular filtration rate (creatinine);
BRCA	trans	rs4714291	0.832	rs6936016	chr6:40097013	A/G	cg02267698	chr19:7991119	CTXN1	-0.46	-9.48	-0.35	5.06e-20	Strep throat;
BRCA	cis	rs1557765	0.527	rs2018218	chr11:17390855	A/G	cg04705435	chr11:17411270	KCNJ11	0.34	7.94	0.3	9.25e-15	Body mass index;Social communication problems;
BRCA	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg18402987	chr7:1209562	NA	0.83	12.02	0.43	3.93e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg04990556	chr1:26633338	UBXN11	-0.47	-9.28	-0.34	2.69e-19	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg11752832	chr7:134001865	SLC35B4	-0.42	-9.7	-0.36	7.63e-21	Mean platelet volume;
BRCA	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg16179182	chr5:140090404	VTRNA1-1	0.44	10.32	0.38	3.3e-23	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs11165623	0.792	rs6671371	chr1:96977039	A/G	cg10631902	chr5:14652156	NA	-0.5	-15.43	-0.52	6.5e-46	Hip circumference;Waist circumference;
BRCA	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg06784218	chr1:46089804	CCDC17	0.51	12.51	0.44	2.9e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.99	-0.37	6.41e-22	Mean corpuscular volume;
BRCA	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg05347473	chr6:146136440	FBXO30	0.39	7.94	0.3	9.39e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg06766960	chr11:133703094	NA	-0.52	-11.89	-0.43	1.37e-29	Childhood ear infection;
BRCA	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.93	0.4	1.35e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05901451	chr6:126070800	HEY2	-0.56	-14.88	-0.51	3.19e-43	Brugada syndrome;
BRCA	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg09307838	chr4:120376055	NA	0.62	13.22	0.46	1.98e-35	Corneal astigmatism;
BRCA	cis	rs9403521	1.000	rs12528456	chr6:144003706	A/G	cg18240653	chr6:144019428	PHACTR2	-0.4	-8.0	-0.3	5.81e-15	Obesity-related traits;
BRCA	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26314531	chr2:26401878	FAM59B	-0.63	-10.72	-0.39	8.94e-25	Gut microbiome composition (summer);
BRCA	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.11	0.34	1.01e-18	Platelet count;
BRCA	cis	rs10046574	0.831	rs56285116	chr7:135164950	C/T	cg27474649	chr7:135195673	CNOT4	0.61	8.89	0.33	6.04e-18	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg19784903	chr17:45786737	TBKBP1	-0.35	-8.22	-0.31	1.14e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg11789530	chr4:8429930	ACOX3	0.69	18.19	0.58	6.7e-60	Response to antineoplastic agents;
BRCA	cis	rs727479	0.502	rs28757200	chr15:51504061	C/T	cg19946085	chr15:51559439	CYP19A1	-0.3	-8.49	-0.32	1.45e-16	Estradiol levels;
BRCA	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-10.47	-0.38	8.71e-24	IgG glycosylation;
BRCA	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg20503657	chr10:835505	NA	0.73	10.44	0.38	1.1e-23	Eosinophil percentage of granulocytes;
BRCA	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	14.09	0.49	1.82e-39	Lymphocyte percentage of white cells;
BRCA	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.9e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-12.5	-0.44	2.99e-32	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg17971929	chr21:40555470	PSMG1	-0.48	-10.57	-0.39	3.68e-24	Menarche (age at onset);
BRCA	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg04455712	chr21:45112962	RRP1B	0.41	10.56	0.39	3.72e-24	Mean corpuscular volume;
BRCA	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg27170947	chr2:26402098	FAM59B	-0.93	-16.65	-0.55	5.69e-52	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.7	0.33	2.7e-17	Motion sickness;
BRCA	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg11887960	chr12:57824829	NA	0.55	8.54	0.32	9.6e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9283706	0.764	rs17218390	chr5:66280426	A/G	cg11590213	chr5:66331682	MAST4	0.39	8.05	0.3	3.92e-15	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.52e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4566357	0.576	rs6750845	chr2:227911037	T/G	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.12	-0.31	2.34e-15	Coronary artery disease;
BRCA	cis	rs7707921	0.767	rs226202	chr5:81571669	C/T	cg15871215	chr5:81402204	ATG10	0.36	8.24	0.31	1.01e-15	Breast cancer;
BRCA	cis	rs2742234	0.541	rs2742235	chr10:43616325	A/G	cg02780029	chr10:43622663	RET	-0.35	-7.82	-0.3	2.25e-14	Hirschsprung disease;
BRCA	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.78	11.17	0.4	1.33e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.14	-0.4	1.81e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.42	-9.41	-0.35	8.65e-20	Personality dimensions;
BRCA	cis	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.18	-0.4	1.22e-26	Morning vs. evening chronotype;
BRCA	cis	rs4588572	0.643	rs10063742	chr5:77759362	A/G	cg11547950	chr5:77652471	NA	-0.48	-8.41	-0.32	2.77e-16	Triglycerides;
BRCA	cis	rs922182	0.617	rs12324438	chr15:64243436	A/C	cg24729988	chr15:64271149	DAPK2	-0.49	-10.43	-0.38	1.31e-23	Blood protein levels;
BRCA	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-13.29	-0.47	8.77e-36	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg05340658	chr4:99064831	C4orf37	0.5	10.99	0.4	7.37e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.47	-0.32	1.73e-16	Total body bone mineral density;
BRCA	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg15605315	chr1:45957053	TESK2	0.49	10.15	0.37	1.5e-22	High light scatter reticulocyte count;
BRCA	cis	rs6545883	0.894	rs2694634	chr2:61551435	T/C	cg15711740	chr2:61764176	XPO1	0.51	13.12	0.46	5.33e-35	Tuberculosis;
BRCA	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.2	0.31	1.29e-15	Cognitive ability;
BRCA	cis	rs1904096	0.506	rs3113863	chr4:95147827	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-10.04	-0.37	4.03e-22	Type 2 diabetes;
BRCA	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg24558204	chr6:135376177	HBS1L	0.45	12.47	0.44	4.45e-32	Red blood cell count;
BRCA	trans	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg26043149	chr18:55253948	FECH	-0.36	-7.98	-0.3	6.76e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs7746199	0.611	rs17750747	chr6:27730334	T/C	cg01620082	chr3:125678407	NA	-0.92	-10.32	-0.38	3.23e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.5	-11.23	-0.41	8.19e-27	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg18154014	chr19:37997991	ZNF793	0.54	10.46	0.38	9.45e-24	Coronary artery calcification;
BRCA	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg03213289	chr20:61660250	NA	0.63	16.54	0.55	2.05e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	18.91	0.6	1.2e-63	Tonsillectomy;
BRCA	cis	rs4363385	0.747	rs6587716	chr1:152966705	C/T	cg25856811	chr1:152973957	SPRR3	-0.35	-9.37	-0.35	1.23e-19	Inflammatory skin disease;
BRCA	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.76	0.39	6.28e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7809950	0.817	rs2237678	chr7:107203265	T/G	cg23024343	chr7:107201750	COG5	-0.51	-10.22	-0.37	7.95e-23	Coronary artery disease;
BRCA	trans	rs6479891	1.000	rs2466128	chr10:65208321	T/C	cg14819942	chr15:35414228	NA	0.35	8.55	0.32	9.19e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs6120849	0.901	rs13037296	chr20:33749228	T/A	cg24642439	chr20:33292090	TP53INP2	0.48	8.83	0.33	9.82e-18	Protein C levels;
BRCA	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-16.23	-0.54	7.7e-50	Alzheimer's disease (late onset);
BRCA	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg24692254	chr21:30365293	RNF160	0.5	11.27	0.41	5.47e-27	Cognitive test performance;
BRCA	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg00666640	chr1:248458726	OR2T12	0.32	8.77	0.33	1.63e-17	Common traits (Other);
BRCA	cis	rs208520	0.690	rs851467	chr6:66802721	A/G	cg07460842	chr6:66804631	NA	-1.0	-20.02	-0.62	1.44e-69	Exhaled nitric oxide output;
BRCA	cis	rs36051895	0.554	rs7856773	chr9:5204705	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-8.45	-0.32	1.94e-16	Pediatric autoimmune diseases;
BRCA	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg15485101	chr11:133734466	NA	0.39	9.35	0.35	1.44e-19	Childhood ear infection;
BRCA	cis	rs7617773	0.817	rs34728236	chr3:48259108	A/G	cg11946769	chr3:48343235	NME6	0.68	13.84	0.48	2.69e-38	Coronary artery disease;
BRCA	trans	rs7200543	1.000	rs14347	chr16:15133889	T/G	cg24683922	chr1:11983373	KIAA2013	-0.39	-8.91	-0.33	5.47e-18	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg13880726	chr7:1868755	MAD1L1	0.52	9.74	0.36	5.5e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs7523050	0.643	rs35924015	chr1:109404626	T/C	cg08274380	chr1:109419600	GPSM2	0.9	13.16	0.46	3.53e-35	Fat distribution (HIV);
BRCA	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg11301795	chr4:187892539	NA	-0.3	-9.8	-0.36	3.3e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.747	rs10494285	chr1:152982285	G/A	cg25856811	chr1:152973957	SPRR3	-0.34	-9.1	-0.34	1.15e-18	Inflammatory skin disease;
BRCA	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.43	-8.08	-0.3	3.23e-15	Tonsillectomy;
BRCA	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-8.8	-0.33	1.26e-17	Alzheimer's disease (late onset);
BRCA	cis	rs965469	1.000	rs6051712	chr20:3265029	T/A	cg25506879	chr20:3388711	C20orf194	-0.51	-10.22	-0.37	8.01e-23	IFN-related cytopenia;
BRCA	cis	rs9816226	0.590	rs872602	chr3:185826028	A/G	cg00760338	chr3:185826511	ETV5	0.56	12.08	0.43	2.19e-30	Obesity;Body mass index;
BRCA	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg23711669	chr6:146136114	FBXO30	-0.71	-17.1	-0.56	2.85e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg25801113	chr15:45476975	SHF	0.37	9.84	0.36	2.33e-21	Uric acid levels;
BRCA	cis	rs17095355	0.818	rs72828263	chr10:111785703	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.45	-9.71	-0.36	6.71e-21	Biliary atresia;
BRCA	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11890956	chr21:40555474	PSMG1	1.1	34.02	0.8	1.5e-145	Cognitive function;
BRCA	cis	rs16858210	0.520	rs35586421	chr3:183544607	G/A	cg03417191	chr3:183542750	MAP6D1	-0.66	-11.02	-0.4	5.89e-26	Menopause (age at onset);
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg15112475	chr7:1198522	ZFAND2A	-0.59	-13.37	-0.47	3.95e-36	Longevity;Endometriosis;
BRCA	cis	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg09307838	chr4:120376055	NA	0.47	9.76	0.36	4.59e-21	Diastolic blood pressure;
BRCA	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg21535247	chr6:8435926	SLC35B3	0.4	8.92	0.33	4.83e-18	Motion sickness;
BRCA	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg14926445	chr8:58193284	C8orf71	-0.43	-8.4	-0.32	2.93e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg15605315	chr1:45957053	TESK2	0.5	10.12	0.37	1.99e-22	High light scatter reticulocyte count;
BRCA	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.09	-0.34	1.22e-18	Bipolar disorder;
BRCA	cis	rs6815814	0.861	rs10012017	chr4:38784633	G/T	cg06935464	chr4:38784597	TLR10	0.48	9.76	0.36	4.69e-21	Breast cancer;
BRCA	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg27588902	chr6:42928151	GNMT	-0.31	-10.27	-0.38	5.08e-23	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03517284	chr6:25882590	NA	0.37	7.83	0.3	2.04e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs586533	0.752	rs635715	chr11:99495141	G/T	cg22878054	chr11:99397252	CNTN5	0.32	8.03	0.3	4.67e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.69	-0.33	2.99e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg12219531	chr12:120966889	COQ5	0.56	11.7	0.42	8.42e-29	High light scatter reticulocyte count;
BRCA	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg13736514	chr6:26305472	NA	-0.34	-11.49	-0.41	6.69e-28	Educational attainment;
BRCA	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg17366294	chr4:99064904	C4orf37	0.42	9.83	0.36	2.53e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg08807101	chr21:30365312	RNF160	-0.39	-8.45	-0.32	1.94e-16	Pancreatic cancer;
BRCA	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	9.19	0.34	5.32e-19	Rheumatoid arthritis;
BRCA	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	10.99	0.4	7.28e-26	Monocyte percentage of white cells;
BRCA	cis	rs4728302	0.869	rs13221033	chr7:133617487	T/A	cg07491979	chr7:133331646	EXOC4	0.36	7.84	0.3	1.92e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09263875	chr16:632152	PIGQ	0.71	20.51	0.63	3.28e-72	Height;
BRCA	cis	rs9682041	0.627	rs3772172	chr3:170077713	C/T	cg11886554	chr3:170076028	SKIL	-0.5	-10.25	-0.38	6.46e-23	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg21775007	chr8:11205619	TDH	-0.55	-12.02	-0.43	3.69e-30	Retinal vascular caliber;
BRCA	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg00677455	chr12:58241039	CTDSP2	0.77	17.43	0.57	6.09e-56	Multiple sclerosis;
BRCA	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg10818794	chr15:86012489	AKAP13	-0.31	-8.62	-0.32	5.27e-17	Coronary artery disease;
BRCA	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.59	-9.8	-0.36	3.15e-21	Body mass index (adult);
BRCA	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg23625390	chr15:77176239	SCAPER	0.45	11.31	0.41	3.53e-27	Blood metabolite levels;
BRCA	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg00701064	chr4:6280414	WFS1	0.65	14.6	0.5	7.35e-42	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs9807989	0.507	rs1420096	chr2:103010912	C/T	cg03938978	chr2:103052716	IL18RAP	0.29	8.49	0.32	1.5e-16	Asthma;
BRCA	cis	rs9487051	0.768	rs2483913	chr6:109521042	G/A	cg01475377	chr6:109611718	NA	-0.45	-11.31	-0.41	3.73e-27	Reticulocyte fraction of red cells;
BRCA	cis	rs4728302	0.869	rs889826	chr7:133595871	A/G	cg07491979	chr7:133331646	EXOC4	0.36	7.84	0.3	1.88e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.79	-12.65	-0.45	6.65e-33	Platelet count;
BRCA	cis	rs4730250	0.707	rs257377	chr7:106801088	G/T	cg02696742	chr7:106810147	HBP1	-0.62	-9.76	-0.36	4.45e-21	Osteoarthritis;
BRCA	cis	rs4911259	0.552	rs13041458	chr20:31467376	G/T	cg13636640	chr20:31349939	DNMT3B	-0.45	-11.86	-0.42	1.78e-29	Inflammatory bowel disease;
BRCA	cis	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg06360820	chr2:242988706	NA	-0.81	-14.34	-0.49	1.25e-40	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg17366294	chr4:99064904	C4orf37	0.41	9.61	0.36	1.57e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg06618935	chr21:46677482	NA	-0.38	-8.56	-0.32	8.68e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9487051	0.676	rs9386775	chr6:109561779	T/C	cg01475377	chr6:109611718	NA	-0.37	-8.87	-0.33	7.04e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg06494592	chr3:125709126	NA	-0.5	-8.53	-0.32	1.06e-16	Blood pressure (smoking interaction);
BRCA	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg12463550	chr7:65579703	CRCP	-0.37	-8.04	-0.3	4.23e-15	Aortic root size;
BRCA	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg11247378	chr22:39784982	NA	-0.63	-15.67	-0.53	4.38e-47	Intelligence (multi-trait analysis);
BRCA	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg24531977	chr5:56204891	C5orf35	-0.41	-8.21	-0.31	1.21e-15	Coronary artery disease;
BRCA	cis	rs7178424	0.742	rs12916268	chr15:62175642	G/A	cg00456672	chr15:62358751	C2CD4A	-0.37	-8.86	-0.33	8.1e-18	Height;
BRCA	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg25319279	chr11:5960081	NA	0.41	9.06	0.34	1.6e-18	DNA methylation (variation);
BRCA	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.03	0.3	4.61e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	14.6	0.5	6.91e-42	Exhaled nitric oxide output;
BRCA	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-9.24	-0.34	3.54e-19	Menopause (age at onset);
BRCA	cis	rs113835537	0.529	rs117112180	chr11:66293273	A/G	cg24851651	chr11:66362959	CCS	0.52	8.95	0.33	3.84e-18	Airway imaging phenotypes;
BRCA	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg18252515	chr7:66147081	NA	1.06	15.97	0.53	1.49e-48	Diabetic kidney disease;
BRCA	cis	rs35740288	0.545	rs11637283	chr15:86316103	C/T	cg20737812	chr15:86336631	KLHL25	-0.39	-8.41	-0.32	2.76e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg08885076	chr2:99613938	TSGA10	-0.6	-13.45	-0.47	1.67e-36	Chronic sinus infection;
BRCA	cis	rs977987	0.872	rs4888422	chr16:75470576	A/G	cg03315344	chr16:75512273	CHST6	0.51	11.78	0.42	3.83e-29	Dupuytren's disease;
BRCA	cis	rs7020830	0.898	rs13289199	chr9:37278064	A/T	cg14294708	chr9:37120828	ZCCHC7	1.11	35.23	0.81	7.34e-152	Schizophrenia;
BRCA	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg16339924	chr4:17578868	LAP3	0.58	14.07	0.49	2.27e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg10057126	chr4:77819792	ANKRD56	0.67	15.45	0.52	5.51e-46	Emphysema distribution in smoking;
BRCA	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg20607287	chr7:12443886	VWDE	0.51	8.16	0.31	1.74e-15	Coronary artery disease;
BRCA	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg27129171	chr3:47204927	SETD2	0.63	13.38	0.47	3.48e-36	Birth weight;
BRCA	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg18404041	chr3:52824283	ITIH1	-0.35	-9.31	-0.35	1.94e-19	Schizophrenia;
BRCA	cis	rs7684253	0.565	rs13108570	chr4:57807083	G/C	cg11939399	chr4:57773300	REST	0.29	7.97	0.3	7.4e-15	Migraine;
BRCA	trans	rs656319	0.559	rs17689007	chr8:9974824	G/A	cg06636001	chr8:8085503	FLJ10661	-0.39	-8.05	-0.3	3.94e-15	Myopia (pathological);
BRCA	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	8.77	0.33	1.57e-17	Platelet count;
BRCA	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg09307838	chr4:120376055	NA	0.59	12.91	0.45	4.81e-34	Corneal astigmatism;
BRCA	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg14186256	chr22:23484241	RTDR1	0.77	23.57	0.68	7.11e-89	Bone mineral density;
BRCA	cis	rs782590	0.902	rs4672052	chr2:55732018	A/C	cg18811423	chr2:55921094	PNPT1	0.66	19.77	0.62	3.04e-68	Metabolic syndrome;
BRCA	trans	rs7980799	0.653	rs10844613	chr12:33605362	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-10.26	-0.38	5.98e-23	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs2066819	1.000	rs117683816	chr12:56638267	T/C	cg26714650	chr12:56694279	CS	-1.18	-15.33	-0.52	2.13e-45	Psoriasis vulgaris;
BRCA	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg20090143	chr19:45452003	APOC2	0.27	7.91	0.3	1.17e-14	Blood protein levels;
BRCA	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg05729581	chr11:3078854	CARS	0.35	8.64	0.32	4.46e-17	Longevity;
BRCA	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg00420348	chr11:830190	EFCAB4A	-0.5	-10.47	-0.38	8.97e-24	Mean platelet volume;
BRCA	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg07636037	chr3:49044803	WDR6	-0.5	-8.25	-0.31	9.35e-16	Menarche (age at onset);
BRCA	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00166722	chr3:10149974	C3orf24	0.67	13.49	0.47	1.13e-36	Alzheimer's disease;
BRCA	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg04362960	chr10:104952993	NT5C2	0.46	10.02	0.37	4.66e-22	Arsenic metabolism;
BRCA	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	11.37	0.41	2.13e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs62458065	0.513	rs702831	chr7:32579715	C/T	cg20159608	chr7:32802032	NA	-0.5	-9.64	-0.36	1.25e-20	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg05340658	chr4:99064831	C4orf37	0.69	17.5	0.57	2.45e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12760731	0.720	rs67857740	chr1:178402250	A/G	cg00404053	chr1:178313656	RASAL2	0.6	7.86	0.3	1.67e-14	Obesity-related traits;
BRCA	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05890377	chr2:74357713	NA	0.5	12.26	0.44	3.51e-31	Gestational age at birth (maternal effect);
BRCA	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11764359	chr7:65958608	NA	0.77	17.42	0.57	6.69e-56	Aortic root size;
BRCA	cis	rs2742234	0.910	rs2505513	chr10:43633537	C/G	cg02780029	chr10:43622663	RET	-0.39	-9.67	-0.36	1.01e-20	Hirschsprung disease;
BRCA	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg14004847	chr7:1930337	MAD1L1	0.41	8.58	0.32	7.02e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.55	0.55	1.84e-51	Alzheimer's disease (late onset);
BRCA	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg07148914	chr20:33460835	GGT7	0.47	9.98	0.37	7.06e-22	Height;
BRCA	cis	rs1975991	0.538	rs1062148	chr3:187964915	T/C	cg15417654	chr3:187959138	LPP	0.36	9.22	0.34	4.1e-19	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg23958373	chr8:599963	NA	-0.59	-8.7	-0.33	2.91e-17	IgG glycosylation;
BRCA	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-9.11	-0.34	1.08e-18	Eosinophil percentage of white cells;
BRCA	cis	rs208520	0.661	rs207090	chr6:66783963	T/A	cg07460842	chr6:66804631	NA	-1.02	-20.41	-0.63	1.11e-71	Exhaled nitric oxide output;
BRCA	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg07952391	chr2:88470173	THNSL2	0.58	8.08	0.3	3.24e-15	Plasma clusterin levels;
BRCA	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.74e-16	Menopause (age at onset);
BRCA	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	18.99	0.6	4.37e-64	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	11.96	0.43	7.08e-30	Personality dimensions;
BRCA	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	8.88	0.33	6.81e-18	Iron status biomarkers;
BRCA	cis	rs9880211	1.000	rs9812579	chr3:136151250	A/G	cg21827317	chr3:136751795	NA	-0.47	-8.28	-0.31	7.19e-16	Body mass index;Height;
BRCA	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg08888203	chr3:10149979	C3orf24	0.67	13.29	0.47	8.92e-36	Alzheimer's disease;
BRCA	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-9.65	-0.36	1.14e-20	Tonsillectomy;
BRCA	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-9.46	-0.35	5.71e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	11.34	0.41	2.67e-27	Platelet count;
BRCA	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg22508957	chr16:3507546	NAT15	-0.46	-10.71	-0.39	1.01e-24	Tuberculosis;
BRCA	trans	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg04565464	chr8:145669602	NFKBIL2	0.38	8.28	0.31	7.06e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.64	16.52	0.55	2.64e-51	Colorectal cancer;
BRCA	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.67	-0.32	3.66e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg08847533	chr14:75593920	NEK9	0.95	25.2	0.71	7.84e-98	Height;
BRCA	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg18811423	chr2:55921094	PNPT1	0.74	25.09	0.7	3.05e-97	Metabolic syndrome;
BRCA	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg15921436	chr17:44337874	NA	0.57	10.51	0.38	6.09e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
BRCA	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg11502198	chr6:26597334	ABT1	-0.55	-11.78	-0.42	3.94e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg25457927	chr22:38595422	NA	0.43	16.76	0.55	1.59e-52	Cutaneous nevi;
BRCA	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg09184832	chr6:79620586	NA	-0.43	-8.36	-0.31	4.04e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg21770322	chr7:97807741	LMTK2	-0.37	-10.13	-0.37	1.83e-22	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs12517041	1.000	rs10064195	chr5:23278179	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.97	-0.3	7.41e-15	Calcium levels;
BRCA	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg22875332	chr1:76189707	ACADM	-0.64	-11.37	-0.41	2.11e-27	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	14.31	0.49	1.69e-40	Platelet count;
BRCA	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	18.13	0.58	1.36e-59	Alzheimer's disease;
BRCA	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg02734326	chr4:10020555	SLC2A9	0.38	8.22	0.31	1.17e-15	Bone mineral density;
BRCA	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg24829409	chr8:58192753	C8orf71	-0.49	-9.25	-0.34	3.45e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs7246657	0.722	rs16958861	chr19:38124179	G/A	cg23950597	chr19:37808831	NA	-0.48	-8.18	-0.31	1.54e-15	Coronary artery calcification;
BRCA	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg21770322	chr7:97807741	LMTK2	0.42	11.05	0.4	4.43e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10242455	0.702	rs73397499	chr7:99039627	T/C	cg18809830	chr7:99032528	PTCD1	-0.64	-9.09	-0.34	1.18e-18	Blood metabolite levels;
BRCA	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.57	-10.59	-0.39	2.92e-24	Alzheimer's disease;
BRCA	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg06618935	chr21:46677482	NA	-0.37	-8.04	-0.3	4.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.1	-0.43	1.71e-30	Response to antipsychotic treatment;
BRCA	cis	rs12190007	0.508	rs9406321	chr6:169726841	A/T	cg16388071	chr6:169726476	NA	0.5	11.4	0.41	1.54e-27	Obesity-related traits;
BRCA	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.27	-0.31	7.52e-16	Total body bone mineral density;
BRCA	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg16414030	chr3:133502952	NA	-0.54	-12.47	-0.44	4.25e-32	Iron status biomarkers;
BRCA	cis	rs6028335	0.674	rs68173814	chr20:37621180	A/G	cg16355469	chr20:37678765	NA	0.49	8.95	0.33	3.97e-18	Alcohol and nicotine co-dependence;
BRCA	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg20701182	chr2:24300061	SF3B14	0.66	9.47	0.35	5.4e-20	Lymphocyte counts;
BRCA	trans	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg11693508	chr17:37793320	STARD3	0.4	8.26	0.31	8.23e-16	Neuroticism;
BRCA	cis	rs10751667	0.621	rs11246375	chr11:999620	T/C	ch.11.42038R	chr11:967971	AP2A2	0.47	14.32	0.49	1.62e-40	Alzheimer's disease (late onset);
BRCA	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg13010199	chr12:38710504	ALG10B	0.45	9.38	0.35	1.16e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs4780401	0.609	rs8047190	chr16:11807097	T/C	cg01061890	chr16:11836724	TXNDC11	-0.55	-13.07	-0.46	9.28e-35	Rheumatoid arthritis;
BRCA	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18404041	chr3:52824283	ITIH1	-0.41	-12.15	-0.43	1.07e-30	Bipolar disorder;
BRCA	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-17.08	-0.56	3.81e-54	Colorectal cancer;
BRCA	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg05340658	chr4:99064831	C4orf37	0.49	10.79	0.39	4.91e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg25790453	chr13:113633590	MCF2L	-0.33	-7.99	-0.3	6.22e-15	Systolic blood pressure;
BRCA	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg26816564	chr1:7831052	VAMP3	0.73	13.01	0.46	1.72e-34	Inflammatory bowel disease;
BRCA	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	cg01483505	chr11:975446	AP2A2	0.3	8.09	0.3	2.92e-15	Alzheimer's disease (late onset);
BRCA	cis	rs11229555	0.645	rs12294062	chr11:58175603	G/T	cg15696309	chr11:58395628	NA	-0.45	-9.77	-0.36	4.3e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg19847866	chr10:1019161	NA	0.47	10.3	0.38	4.19e-23	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg06627628	chr2:24431161	ITSN2	-0.76	-14.0	-0.48	4.71e-39	Asthma;
BRCA	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg02544614	chr20:61657117	NA	0.29	8.22	0.31	1.12e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg06671706	chr8:8559999	CLDN23	0.43	8.34	0.31	4.4e-16	Obesity-related traits;
BRCA	cis	rs6088813	0.961	rs6060369	chr20:33907161	A/G	cg14752227	chr20:34000481	UQCC	0.4	8.27	0.31	7.54e-16	Height;
BRCA	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg02493740	chr2:85810744	VAMP5	-0.59	-11.93	-0.43	8.76e-30	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg25358565	chr5:93447407	FAM172A	0.65	11.51	0.41	5.53e-28	Diabetic retinopathy;
BRCA	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.25	0.31	9.38e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs28647808	0.881	rs4962139	chr9:136267869	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	-0.74	-11.39	-0.41	1.69e-27	Blood protein levels;
BRCA	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg00277334	chr10:82204260	NA	-0.51	-11.42	-0.41	1.24e-27	Post bronchodilator FEV1;
BRCA	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg01529538	chr14:23388837	RBM23	0.41	10.97	0.4	9.28e-26	Cognitive ability (multi-trait analysis);
BRCA	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg18538332	chr22:24372958	LOC391322	0.51	12.01	0.43	4e-30	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6543140	0.964	rs1523206	chr2:103070175	A/T	cg04239558	chr2:103089729	SLC9A4	0.34	9.56	0.35	2.4e-20	Blood protein levels;
BRCA	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg13010199	chr12:38710504	ALG10B	0.45	9.29	0.35	2.32e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg16576597	chr16:28551801	NUPR1	0.34	9.04	0.34	1.78e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9297145	0.509	rs13222381	chr7:98785024	T/G	cg05967295	chr7:98741636	SMURF1	-0.6	-12.99	-0.46	2.13e-34	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs13046373	0.535	rs2832964	chr21:32014012	A/C	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.45	0.35	6.14e-20	HDL cholesterol;
BRCA	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg11822812	chr5:140052017	DND1	0.29	7.83	0.3	2.04e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg11366901	chr6:160182831	ACAT2	0.81	15.75	0.53	1.83e-47	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.56	0.39	3.81e-24	Tonsillectomy;
BRCA	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg18252515	chr7:66147081	NA	1.04	15.68	0.53	4.14e-47	Diabetic kidney disease;
BRCA	trans	rs2262909	0.849	rs10420483	chr19:22190378	A/G	cg17074339	chr11:11642133	GALNTL4	-0.42	-7.9	-0.3	1.23e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	trans	rs11088226	0.681	rs2833897	chr21:33931792	T/C	cg09050820	chr6:167586206	TCP10L2	0.77	13.28	0.47	1.06e-35	Gastritis;
BRCA	cis	rs6604026	0.524	rs532834	chr1:93468062	A/T	cg17283838	chr1:93427260	FAM69A	0.48	10.43	0.38	1.26e-23	Multiple sclerosis;
BRCA	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg11584989	chr19:19387371	SF4	0.3	7.85	0.3	1.71e-14	Tonsillectomy;
BRCA	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.24	-0.31	9.76e-16	Bipolar disorder;
BRCA	cis	rs4423214	0.879	rs1790345	chr11:71145941	G/A	cg05163923	chr11:71159392	DHCR7	-0.52	-10.5	-0.38	6.85e-24	Vitamin D levels;
BRCA	cis	rs2599510	0.703	rs58852184	chr2:32729763	A/T	cg02381751	chr2:32503542	YIPF4	0.41	8.12	0.31	2.33e-15	Interleukin-18 levels;
BRCA	cis	rs7945718	0.870	rs10765988	chr11:12731218	C/T	cg25843174	chr11:12811716	TEAD1	0.24	8.9	0.33	5.66e-18	Educational attainment (years of education);
BRCA	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.42	-0.32	2.46e-16	Total body bone mineral density;
BRCA	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg13397359	chr6:42928475	GNMT	0.66	16.15	0.54	1.89e-49	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg21605333	chr4:119757512	SEC24D	0.97	10.98	0.4	8.48e-26	Cannabis dependence symptom count;
BRCA	cis	rs35150201	0.529	rs7806221	chr7:135318779	T/C	cg23117316	chr7:135346802	PL-5283	-0.3	-8.49	-0.32	1.43e-16	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
BRCA	cis	rs10411936	0.712	rs3810198	chr19:16601194	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.47	9.7	0.36	7.36e-21	White blood cell count;Multiple sclerosis;
BRCA	cis	rs586533	0.881	rs602718	chr11:99499998	T/C	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg10820045	chr2:198174542	NA	-0.41	-9.63	-0.36	1.36e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs1506636	1.000	rs2402671	chr7:123355483	T/C	cg03229431	chr7:123269106	ASB15	-0.61	-13.96	-0.48	7.91e-39	Plateletcrit;Platelet count;
BRCA	trans	rs12517041	0.935	rs28493622	chr5:23282147	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.32	-0.31	5.27e-16	Calcium levels;
BRCA	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-8.65	-0.32	4.09e-17	Monocyte percentage of white cells;
BRCA	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg03462622	chr3:195777018	TFRC	-0.38	-8.58	-0.32	7.44e-17	Mean corpuscular volume;
BRCA	cis	rs2191566	1.000	rs369106	chr19:44506930	C/T	cg20607764	chr19:44506953	ZNF230	0.49	10.99	0.4	7.48e-26	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg16362232	chr11:430036	ANO9	0.5	8.03	0.3	4.82e-15	Body mass index;
BRCA	cis	rs13394619	0.935	rs6746291	chr2:11728381	T/C	cg07314298	chr2:11723111	GREB1	-0.54	-12.84	-0.45	9.83e-34	Endometriosis;
BRCA	cis	rs919433	0.680	rs7605813	chr2:198375329	C/G	cg00792783	chr2:198669748	PLCL1	0.39	8.73	0.33	2.14e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	trans	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg21659725	chr3:3221576	CRBN	-0.48	-8.97	-0.33	3.38e-18	Menarche (age at onset);
BRCA	cis	rs7903847	0.642	rs7909345	chr10:99150794	T/C	cg20016023	chr10:99160130	RRP12	-0.26	-8.54	-0.32	1.01e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	25.91	0.72	1.01e-101	Chronic sinus infection;
BRCA	cis	rs3784262	1.000	rs9325	chr15:58245986	A/T	cg12031962	chr15:58353849	ALDH1A2	0.48	12.88	0.45	6.53e-34	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg09307838	chr4:120376055	NA	0.7	14.62	0.5	5.68e-42	Corneal astigmatism;
BRCA	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg03709012	chr19:19516395	GATAD2A	-0.79	-17.85	-0.58	3.94e-58	Tonsillectomy;
BRCA	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg10932868	chr11:921992	NA	0.51	13.14	0.46	4.43e-35	Alzheimer's disease (late onset);
BRCA	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg16482183	chr6:26056742	HIST1H1C	0.74	14.73	0.5	1.78e-42	Iron status biomarkers;
BRCA	cis	rs4363385	0.693	rs310102	chr1:153042423	T/C	cg24667326	chr1:152973720	SPRR3	-0.3	-7.95	-0.3	8.53e-15	Inflammatory skin disease;
BRCA	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg21535247	chr6:8435926	SLC35B3	-0.38	-8.61	-0.32	5.8e-17	Motion sickness;
BRCA	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	18.98	0.6	4.6e-64	Platelet count;
BRCA	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg11266682	chr4:10021025	SLC2A9	0.49	12.82	0.45	1.23e-33	Bone mineral density;
BRCA	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg12483005	chr1:23474871	LUZP1	0.49	10.59	0.39	2.89e-24	Height;
BRCA	cis	rs13095912	0.962	rs12374077	chr3:185317674	G/C	cg11274856	chr3:185301563	NA	0.34	8.53	0.32	1.09e-16	Systolic blood pressure;
BRCA	trans	rs75804782	0.641	rs72983853	chr2:239324210	C/T	cg01134436	chr17:81009848	B3GNTL1	0.77	9.68	0.36	8.84e-21	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg07636037	chr3:49044803	WDR6	0.97	28.18	0.74	3.48e-114	Parkinson's disease;
BRCA	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg15839431	chr19:19639596	YJEFN3	-0.41	-9.12	-0.34	9.68e-19	Bipolar disorder;
BRCA	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg13256891	chr4:100009986	ADH5	0.43	8.15	0.31	1.98e-15	Alcohol dependence;
BRCA	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.64	11.6	0.42	2.21e-28	Height;
BRCA	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.96	0.58	1.14e-58	Fuchs's corneal dystrophy;
BRCA	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg18301423	chr5:131593218	PDLIM4	-0.37	-9.54	-0.35	2.91e-20	Acylcarnitine levels;
BRCA	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg21132104	chr15:45694354	SPATA5L1	0.75	16.78	0.55	1.22e-52	Homoarginine levels;
BRCA	cis	rs5850	0.557	rs10270788	chr7:23189000	T/C	cg23682824	chr7:23144976	KLHL7	0.42	10.97	0.4	9.04e-26	Blood protein levels;
BRCA	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg18904891	chr8:8559673	CLDN23	0.65	12.91	0.45	4.83e-34	Obesity-related traits;
BRCA	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg16339924	chr4:17578868	LAP3	0.57	13.8	0.48	4.27e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg06521331	chr12:34319734	NA	-0.56	-10.14	-0.37	1.7e-22	Morning vs. evening chronotype;
BRCA	cis	rs911119	1.000	rs3787499	chr20:23616807	G/A	cg16589663	chr20:23618590	CST3	0.47	8.72	0.33	2.36e-17	Chronic kidney disease;
BRCA	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg07395648	chr5:131743802	NA	0.37	8.71	0.33	2.51e-17	Breast cancer;Mosquito bite size;
BRCA	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg15017067	chr4:17643749	FAM184B	-0.28	-8.49	-0.32	1.46e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3740540	0.530	rs2362506	chr10:126290751	C/G	cg04949429	chr10:126290192	LHPP	0.44	12.32	0.44	2e-31	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg13319975	chr6:146136371	FBXO30	-0.6	-13.43	-0.47	2.05e-36	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg09904177	chr6:26538194	HMGN4	0.46	14.48	0.5	2.64e-41	Intelligence (multi-trait analysis);
BRCA	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21659725	chr3:3221576	CRBN	-0.72	-22.05	-0.66	1.44e-80	Intelligence (multi-trait analysis);
BRCA	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg07828340	chr4:882639	GAK	0.86	10.53	0.38	5.31e-24	Parkinson's disease;
BRCA	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg06937882	chr20:24974362	C20orf3	-0.48	-9.12	-0.34	9.53e-19	Blood protein levels;
BRCA	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	13.24	0.46	1.53e-35	Lung cancer in ever smokers;
BRCA	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg04362960	chr10:104952993	NT5C2	0.42	10.11	0.37	2.12e-22	Arsenic metabolism;
BRCA	cis	rs1997103	1.000	rs6977292	chr7:55396335	T/C	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.72e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg17063962	chr7:91808500	NA	-0.57	-13.48	-0.47	1.2e-36	Breast cancer;
BRCA	cis	rs2425143	1.000	rs2425141	chr20:34350123	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.14	-0.37	1.61e-22	Blood protein levels;
BRCA	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg16850897	chr7:100343110	ZAN	-0.57	-10.58	-0.39	3.17e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.36	0.44	1.23e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs1997103	1.000	rs2177803	chr7:55410773	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3754648	0.525	rs3768924	chr2:237023108	G/C	cg13658143	chr2:237026123	AGAP1	0.48	10.75	0.39	6.58e-25	Craniofacial microsomia;
BRCA	trans	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg06521331	chr12:34319734	NA	-0.47	-8.66	-0.32	3.72e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg04476341	chr5:669733	TPPP	0.39	7.83	0.3	2.02e-14	Lung disease severity in cystic fibrosis;
BRCA	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg12386194	chr3:101231763	SENP7	0.41	8.77	0.33	1.63e-17	Colorectal cancer;
BRCA	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg08601574	chr20:25228251	PYGB	-0.34	-8.25	-0.31	9.18e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	14.55	0.5	1.27e-41	Motion sickness;
BRCA	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.88	16.4	0.54	9.96e-51	Lymphocyte percentage of white cells;
BRCA	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg21918786	chr6:109611834	NA	0.48	13.95	0.48	8.42e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg13736514	chr6:26305472	NA	-0.35	-11.82	-0.42	2.62e-29	Educational attainment;
BRCA	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg09307838	chr4:120376055	NA	-0.49	-9.18	-0.34	5.85e-19	Corneal astigmatism;
BRCA	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg21918786	chr6:109611834	NA	-0.45	-12.1	-0.43	1.77e-30	Reticulocyte fraction of red cells;
BRCA	cis	rs7809950	0.678	rs6949634	chr7:106984684	G/T	cg23024343	chr7:107201750	COG5	-0.46	-9.46	-0.35	5.89e-20	Coronary artery disease;
BRCA	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg26597838	chr10:835615	NA	1.29	21.78	0.65	4.37e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg15832292	chr6:96025679	MANEA	0.56	8.44	0.32	2.06e-16	Behavioural disinhibition (generation interaction);
BRCA	cis	rs9815354	0.812	rs73069292	chr3:41973963	T/C	cg03022575	chr3:42003672	ULK4	0.69	9.67	0.36	1.01e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2637030	0.559	rs1559266	chr5:52851931	C/T	cg06476337	chr5:52856530	NDUFS4	0.36	8.36	0.31	3.91e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg23711669	chr6:146136114	FBXO30	0.69	15.88	0.53	4.3e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.77	0.33	1.58e-17	Tonsillectomy;
BRCA	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.89	0.36	1.54e-21	Lung cancer in ever smokers;
BRCA	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04267008	chr7:1944627	MAD1L1	-0.56	-12.38	-0.44	1.07e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs7851660	0.967	rs1867280	chr9:100616066	G/C	cg13688889	chr9:100608707	NA	-0.36	-8.72	-0.33	2.42e-17	Strep throat;
BRCA	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg23033748	chr14:75592666	NEK9	-0.38	-9.05	-0.34	1.66e-18	Height;
BRCA	trans	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg26043149	chr18:55253948	FECH	-0.36	-8.01	-0.3	5.29e-15	Bone mineral density;
BRCA	cis	rs7575217	0.697	rs6727703	chr2:101698533	G/T	cg23907051	chr2:101730305	TBC1D8	0.2	7.84	0.3	1.9e-14	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs36051895	0.658	rs62541531	chr9:5011795	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-8.77	-0.33	1.65e-17	Pediatric autoimmune diseases;
BRCA	cis	rs9473147	0.516	rs10948363	chr6:47487762	A/G	cg12968598	chr6:47444699	CD2AP	0.46	9.86	0.36	1.85e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg17063962	chr7:91808500	NA	-0.53	-12.21	-0.43	5.86e-31	Breast cancer;
BRCA	cis	rs6545883	0.929	rs10190332	chr2:61619267	T/G	cg15711740	chr2:61764176	XPO1	0.54	13.64	0.47	2.27e-37	Tuberculosis;
BRCA	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.64	-19.85	-0.62	1.18e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg07952391	chr2:88470173	THNSL2	0.67	9.18	0.34	5.92e-19	Plasma clusterin levels;
BRCA	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg27170947	chr2:26402098	FAM59B	0.98	17.0	0.56	9.48e-54	Gut microbiome composition (summer);
BRCA	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg17644776	chr2:200775616	C2orf69	0.43	8.61	0.32	5.51e-17	Osteoporosis;
BRCA	trans	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.62	-0.36	1.44e-20	Bladder cancer;
BRCA	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg08601574	chr20:25228251	PYGB	-0.37	-8.75	-0.33	1.94e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	13.77	0.48	6.03e-38	Lymphocyte counts;
BRCA	cis	rs68170813	0.559	rs78553765	chr7:106930787	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.65	-0.32	4.16e-17	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs2882667	0.537	rs10057545	chr5:138431008	G/A	cg04439458	chr5:138467593	SIL1	-0.29	-7.94	-0.3	9.24e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs208520	0.690	rs207740	chr6:66764132	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	21.05	0.64	4.24e-75	Exhaled nitric oxide output;
BRCA	trans	rs1997103	0.863	rs4480062	chr7:55401299	T/C	cg20935933	chr6:143382018	AIG1	0.6	11.42	0.41	1.32e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg22875332	chr1:76189707	ACADM	0.68	14.82	0.51	6.53e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg05791153	chr7:19748676	TWISTNB	-0.66	-11.68	-0.42	1.06e-28	Thyroid stimulating hormone;
BRCA	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg12310025	chr6:25882481	NA	0.42	9.35	0.35	1.44e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg13319975	chr6:146136371	FBXO30	0.36	8.25	0.31	9.35e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg14689365	chr7:158441557	NCAPG2	0.41	8.67	0.32	3.58e-17	Height;
BRCA	cis	rs1215050	0.791	rs165241	chr4:98681112	C/T	cg05340658	chr4:99064831	C4orf37	0.45	10.17	0.37	1.26e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg07817883	chr1:32538562	TMEM39B	-0.48	-8.25	-0.31	9.05e-16	Monocyte percentage of white cells;
BRCA	cis	rs10851411	0.697	rs72711767	chr15:42843970	T/G	cg21293051	chr15:42870591	STARD9	0.51	8.77	0.33	1.58e-17	Glucose homeostasis traits;
BRCA	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg02733842	chr7:1102375	C7orf50	-0.63	-11.61	-0.42	2e-28	Bronchopulmonary dysplasia;
BRCA	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg23711669	chr6:146136114	FBXO30	0.65	15.3	0.52	2.9e-45	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg19862616	chr7:65841803	NCRNA00174	0.81	25.64	0.71	3.13e-100	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg24101359	chr6:42928495	GNMT	0.63	15.44	0.52	6.4e-46	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs17253792	0.822	rs13379353	chr14:56050478	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.61	8.47	0.32	1.68e-16	Putamen volume;
BRCA	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg23711669	chr6:146136114	FBXO30	0.77	17.59	0.57	8.37e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.61	14.59	0.5	8.25e-42	Colorectal cancer;
BRCA	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg03354898	chr7:1950403	MAD1L1	-0.39	-8.25	-0.31	8.79e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs1568889	1.000	rs61889027	chr11:28281908	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	13.11	0.46	6e-35	Bipolar disorder;
BRCA	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg22906224	chr7:99728672	NA	0.46	8.75	0.33	1.9e-17	Coronary artery disease;
BRCA	cis	rs11229555	0.645	rs12291551	chr11:58176915	T/A	cg15696309	chr11:58395628	NA	-0.45	-9.77	-0.36	4.3e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.07	23.75	0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg08859206	chr1:53392774	SCP2	-0.48	-10.52	-0.38	5.77e-24	Monocyte count;
BRCA	cis	rs7246657	0.639	rs3112434	chr19:38198148	G/T	cg18154014	chr19:37997991	ZNF793	-0.49	-9.26	-0.34	3.1400000000000002e-19	Coronary artery calcification;
BRCA	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg11279151	chr3:101281821	RG9MTD1	0.6	14.48	0.5	2.78e-41	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg15704280	chr7:45808275	SEPT13	0.75	16.09	0.54	3.61e-49	Coronary artery disease;
BRCA	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg24690094	chr11:67383802	NA	-0.52	-11.6	-0.42	2.32e-28	Mean corpuscular volume;
BRCA	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-9.67	-0.36	9.78e-21	Alzheimer's disease (late onset);
BRCA	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg12573674	chr2:1569213	NA	-0.48	-9.26	-0.34	3.08e-19	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.64	-0.32	4.59e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg24829409	chr8:58192753	C8orf71	-0.49	-9.25	-0.34	3.45e-19	Developmental language disorder (linguistic errors);
BRCA	trans	rs1997103	1.000	rs6945937	chr7:55407140	C/T	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs3960554	0.932	rs11975745	chr7:75843524	T/C	cg19862616	chr7:65841803	NCRNA00174	0.6	11.68	0.42	1.08e-28	Eotaxin levels;
BRCA	cis	rs9549260	0.753	rs61963264	chr13:41154792	G/A	cg21288729	chr13:41239152	FOXO1	0.54	8.42	0.32	2.48e-16	Red blood cell count;
BRCA	cis	rs738322	0.772	rs9619724	chr22:38517880	T/G	cg20207973	chr22:38506712	BAIAP2L2	0.39	10.03	0.37	4.24e-22	Cutaneous nevi;
BRCA	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg15556689	chr8:8085844	FLJ10661	0.36	9.98	0.37	6.81e-22	Neuroticism;
BRCA	cis	rs4919694	1.000	rs3740394	chr10:104634474	A/G	cg04362960	chr10:104952993	NT5C2	0.89	14.05	0.49	2.9e-39	Arsenic metabolism;
BRCA	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg15017067	chr4:17643749	FAM184B	0.33	9.67	0.36	9.48e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24110177	chr3:50126178	RBM5	-0.39	-10.7	-0.39	1.08e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg17063962	chr7:91808500	NA	-0.53	-12.29	-0.44	2.63e-31	Breast cancer;
BRCA	trans	rs11976180	0.953	rs2951355	chr7:143760562	A/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.26	-0.31	8.66e-16	Obesity-related traits;
BRCA	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg03433033	chr1:76189801	ACADM	-0.4	-8.42	-0.32	2.57e-16	Daytime sleep phenotypes;
BRCA	cis	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg06521331	chr12:34319734	NA	-0.52	-10.34	-0.38	2.86e-23	Morning vs. evening chronotype;
BRCA	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.84	-0.53	6.33e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg24642439	chr20:33292090	TP53INP2	0.41	8.1	0.31	2.71e-15	Height;
BRCA	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg22800045	chr5:56110881	MAP3K1	-0.41	-8.19	-0.31	1.46e-15	Initial pursuit acceleration;
BRCA	trans	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg26043149	chr18:55253948	FECH	0.39	8.38	0.31	3.3e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs208520	1.000	rs208535	chr6:66962286	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-14.55	-0.5	1.17e-41	Exhaled nitric oxide output;
BRCA	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02176678	chr2:219576539	TTLL4	0.45	11.73	0.42	6.24e-29	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs593982	0.925	rs585272	chr11:65505289	A/G	cg08755490	chr11:65554678	OVOL1	1.27	29.33	0.76	1.95e-120	Atopic dermatitis;
BRCA	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18876405	chr7:65276391	NA	0.55	13.29	0.47	9.4e-36	Aortic root size;
BRCA	cis	rs17641971	0.684	rs1876717	chr8:49994968	T/G	cg00325661	chr8:49890786	NA	0.39	10.79	0.39	4.77e-25	Blood metabolite levels;
BRCA	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg24675658	chr1:53192096	ZYG11B	0.8	18.26	0.59	2.98e-60	Monocyte count;
BRCA	trans	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg06521331	chr12:34319734	NA	-0.43	-8.52	-0.32	1.16e-16	Bladder cancer;
BRCA	cis	rs6977660	0.714	rs13230381	chr7:19833896	T/C	cg07541023	chr7:19748670	TWISTNB	0.54	9.25	0.34	3.21e-19	Thyroid stimulating hormone;
BRCA	cis	rs838147	0.760	rs281408	chr19:49233406	A/C	cg13540341	chr19:49222985	MAMSTR	-0.35	-9.6	-0.35	1.83e-20	Dietary macronutrient intake;
BRCA	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg03433033	chr1:76189801	ACADM	-0.6	-12.27	-0.44	3.15e-31	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9811920	0.742	rs2316263	chr3:99900096	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.41	9.42	0.35	7.8e-20	Axial length;
BRCA	cis	rs36051895	0.659	rs10974935	chr9:5050307	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-9.83	-0.36	2.54e-21	Pediatric autoimmune diseases;
BRCA	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg08917208	chr2:24149416	ATAD2B	0.94	13.91	0.48	1.3e-38	Lymphocyte counts;
BRCA	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-9.86	-0.36	1.9e-21	Obesity-related traits;
BRCA	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg25358565	chr5:93447407	FAM172A	1.15	17.91	0.58	2.07e-58	Diabetic retinopathy;
BRCA	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg18225595	chr11:63971243	STIP1	0.53	9.59	0.35	1.91e-20	Mean platelet volume;
BRCA	cis	rs9942416	0.601	rs114547168	chr5:74991903	A/G	cg19683494	chr5:74908142	NA	0.44	8.68	0.32	3.17e-17	Age-related disease endophenotypes;
BRCA	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg06766960	chr11:133703094	NA	-0.62	-12.79	-0.45	1.71e-33	Childhood ear infection;
BRCA	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg11266682	chr4:10021025	SLC2A9	0.33	8.54	0.32	9.97e-17	Bone mineral density;
BRCA	cis	rs6942756	1.000	rs11979476	chr7:128993756	G/T	cg02491457	chr7:128862824	NA	0.69	13.6	0.47	3.68e-37	White matter hyperintensity burden;
BRCA	cis	rs9300255	0.664	rs7306755	chr12:123767929	G/A	cg00376283	chr12:123451042	ABCB9	-0.55	-10.67	-0.39	1.44e-24	Neutrophil percentage of white cells;
BRCA	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg04586622	chr2:25135609	ADCY3	0.43	11.09	0.4	3.06e-26	Body mass index in non-asthmatics;
BRCA	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-12.77	-0.45	2.05e-33	Bipolar disorder and schizophrenia;
BRCA	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg11663144	chr21:46675770	NA	-0.59	-13.78	-0.48	5.08e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4664304	0.620	rs1039932	chr2:160712772	G/A	cg14819504	chr2:160761413	LY75	0.34	8.27	0.31	7.8e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg11301795	chr4:187892539	NA	-0.28	-9.24	-0.34	3.54e-19	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05926928	chr17:57297772	GDPD1	1.2	16.07	0.54	4.68e-49	Opioid sensitivity;
BRCA	cis	rs6542838	0.641	rs6542841	chr2:99489039	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-8.9	-0.33	5.91e-18	Fear of minor pain;
BRCA	cis	rs4363385	0.818	rs2787629	chr1:153011966	A/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.61	-0.32	5.49e-17	Inflammatory skin disease;
BRCA	trans	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-15.54	-0.52	2.08e-46	Exhaled nitric oxide levels;
BRCA	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.45	-0.35	6.47e-20	Alzheimer's disease;
BRCA	cis	rs6709815	0.841	rs6740004	chr2:219663153	G/A	cg02176678	chr2:219576539	TTLL4	-0.39	-10.43	-0.38	1.28e-23	Reticulocyte count;High light scatter reticulocyte count;
BRCA	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg17509989	chr5:176798049	RGS14	0.77	11.93	0.43	9.57e-30	Urate levels in lean individuals;
BRCA	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.2	-0.4	1.08e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6087990	0.806	rs992472	chr20:31385269	G/T	cg13636640	chr20:31349939	DNMT3B	0.67	20.82	0.64	7.36e-74	Ulcerative colitis;
BRCA	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.48	-11.17	-0.4	1.34e-26	IgG glycosylation;
BRCA	cis	rs4363385	0.818	rs11205167	chr1:152989727	T/G	cg25856811	chr1:152973957	SPRR3	-0.31	-8.03	-0.3	4.6e-15	Inflammatory skin disease;
BRCA	cis	rs2882667	0.690	rs825759	chr5:138125939	G/A	cg04439458	chr5:138467593	SIL1	0.35	8.59	0.32	6.56e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs919433	0.963	rs12693815	chr2:198168403	T/C	cg10820045	chr2:198174542	NA	-0.38	-7.87	-0.3	1.57e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7524258	0.900	rs7551574	chr1:7314363	G/T	cg07173049	chr1:7289937	CAMTA1	0.4	9.97	0.37	7.52e-22	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.03	20.72	0.63	2.4e-73	Gut microbiome composition (summer);
BRCA	cis	rs7789940	1.000	rs11765693	chr7:75985373	A/G	cg10167463	chr7:75959203	YWHAG	-0.44	-8.8	-0.33	1.31e-17	Multiple sclerosis;
BRCA	cis	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg07460842	chr6:66804631	NA	0.59	10.46	0.38	9.37e-24	Type 2 diabetes;
BRCA	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg18964960	chr10:1102726	WDR37	0.63	8.49	0.32	1.48e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg25036284	chr2:26402008	FAM59B	-0.64	-10.63	-0.39	2.11e-24	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg04944784	chr2:26401820	FAM59B	0.95	16.17	0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs7147624	1.000	rs2411821	chr14:65896914	G/T	cg03016385	chr14:66212404	NA	-0.57	-8.9	-0.33	5.83e-18	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs1163251	0.837	rs658442	chr1:120244858	T/G	cg19096424	chr1:120255104	PHGDH	0.45	10.44	0.38	1.2e-23	Blood metabolite levels;
BRCA	cis	rs4363385	0.782	rs4845515	chr1:153003871	G/T	cg24667326	chr1:152973720	SPRR3	-0.32	-8.94	-0.33	4.23e-18	Inflammatory skin disease;
BRCA	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.93	0.56	2.24e-53	Hypertriglyceridemia;
BRCA	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg05665937	chr4:1216051	CTBP1	-0.38	-7.97	-0.3	7.35e-15	Obesity-related traits;
BRCA	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg24812749	chr6:127587940	RNF146	0.87	19.94	0.62	3.91e-69	Breast cancer;
BRCA	cis	rs7582720	1.000	rs72936348	chr2:204064839	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	12.22	0.44	5.16e-31	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03517284	chr6:25882590	NA	-0.52	-11.82	-0.42	2.78e-29	Blood metabolite levels;
BRCA	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg02951883	chr7:2050386	MAD1L1	0.51	13.02	0.46	1.48e-34	Bipolar disorder and schizophrenia;
BRCA	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg17063962	chr7:91808500	NA	0.58	13.65	0.48	2.13e-37	Breast cancer;
BRCA	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg23711669	chr6:146136114	FBXO30	0.63	14.65	0.5	4.22e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg06784218	chr1:46089804	CCDC17	0.45	10.85	0.39	2.66e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg04719120	chr6:96025338	MANEA	0.52	7.92	0.3	1.02e-14	Behavioural disinhibition (generation interaction);
BRCA	cis	rs7707921	0.881	rs6875409	chr5:81297077	A/G	cg15871215	chr5:81402204	ATG10	-0.4	-8.3	-0.31	6.37e-16	Breast cancer;
BRCA	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg13010199	chr12:38710504	ALG10B	0.4	8.24	0.31	9.71e-16	Bladder cancer;
BRCA	cis	rs2505998	0.833	rs1800858	chr10:43595968	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.43	-8.47	-0.32	1.72e-16	Hirschsprung disease;
BRCA	cis	rs9296092	0.538	rs9469487	chr6:33516943	G/T	cg13560919	chr6:33536144	NA	-0.85	-18.39	-0.59	6.35e-61	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18876405	chr7:65276391	NA	0.52	11.69	0.42	9.19e-29	Aortic root size;
BRCA	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg24642439	chr20:33292090	TP53INP2	0.41	8.06	0.3	3.73e-15	Height;
BRCA	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg19743168	chr1:23544995	NA	0.35	8.14	0.31	2.11e-15	Height;
BRCA	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg14019146	chr3:50243930	SLC38A3	0.45	10.75	0.39	6.71e-25	Body mass index;
BRCA	cis	rs2599510	0.783	rs2568464	chr2:32848658	C/T	cg02381751	chr2:32503542	YIPF4	-0.42	-8.29	-0.31	6.66e-16	Interleukin-18 levels;
BRCA	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg04362960	chr10:104952993	NT5C2	0.44	10.82	0.39	3.69e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg25817165	chr18:72167213	CNDP2	-0.75	-14.47	-0.5	2.95e-41	Refractive error;
BRCA	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg20307385	chr11:47447363	PSMC3	-0.43	-9.16	-0.34	7.25e-19	Subjective well-being;
BRCA	cis	rs6840258	1.000	rs6819155	chr4:87976178	G/A	cg08197287	chr4:87952173	AFF1	-0.43	-8.61	-0.32	5.69e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg11693508	chr17:37793320	STARD3	0.65	12.05	0.43	2.94e-30	Bipolar disorder;
BRCA	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11644478	chr21:40555479	PSMG1	-0.65	-13.77	-0.48	5.47e-38	Cognitive function;
BRCA	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg08132940	chr7:1081526	C7orf50	-0.59	-8.77	-0.33	1.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22307029	chr19:49891270	CCDC155	0.5	9.33	0.35	1.68e-19	Multiple sclerosis;
BRCA	cis	rs9788721	0.836	rs72738736	chr15:78765122	G/T	cg18825076	chr15:78729989	IREB2	-0.4	-8.39	-0.32	3.12e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	trans	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg13565492	chr6:43139072	SRF	-0.86	-15.87	-0.53	4.89e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg25214090	chr10:38739885	LOC399744	0.48	10.63	0.39	2.15e-24	Corneal astigmatism;
BRCA	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg22431228	chr1:16359049	CLCNKA	-0.44	-9.14	-0.34	8.46e-19	Dilated cardiomyopathy;
BRCA	cis	rs4363385	0.740	rs1697428	chr1:153015761	C/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.4	-0.32	2.96e-16	Inflammatory skin disease;
BRCA	cis	rs68170813	0.559	rs3823959	chr7:107009379	T/G	cg02696742	chr7:106810147	HBP1	-0.54	-8.68	-0.32	3.23e-17	Coronary artery disease;
BRCA	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg22705602	chr4:152727874	NA	-0.38	-10.48	-0.38	7.89e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs600806	0.850	rs4970751	chr1:109896600	A/C	cg20591472	chr1:110008990	SYPL2	0.33	8.2	0.31	1.35e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg11814155	chr7:99998594	ZCWPW1	0.43	8.07	0.3	3.42e-15	Platelet count;
BRCA	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg01877450	chr7:97915802	BRI3	-0.37	-8.49	-0.32	1.41e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg08999081	chr20:33150536	PIGU	0.45	12.54	0.44	2.02e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg07923666	chr12:49932857	KCNH3	-0.4	-7.85	-0.3	1.82e-14	Resting heart rate;
BRCA	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs78487399	0.710	rs6759383	chr2:43805228	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-7.95	-0.3	8.45e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs13136331	0.680	rs2627680	chr4:88667937	C/T	cg22416721	chr4:88570574	DMP1	0.5	12.06	0.43	2.55e-30	Sitting height ratio;
BRCA	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg02153584	chr22:29168773	CCDC117	-0.52	-11.22	-0.41	9.03e-27	Lymphocyte counts;
BRCA	cis	rs4845875	0.600	rs6699881	chr1:11836628	T/C	cg24844545	chr1:11908347	NPPA	0.37	8.5	0.32	1.29e-16	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs4363385	0.714	rs4845329	chr1:152974454	G/C	cg24667326	chr1:152973720	SPRR3	-0.35	-9.83	-0.36	2.5e-21	Inflammatory skin disease;
BRCA	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg07384165	chr1:10488281	NA	-0.43	-9.35	-0.35	1.49e-19	Prostate cancer;
BRCA	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg08000102	chr2:233561755	GIGYF2	-0.65	-14.0	-0.48	5.1e-39	Coronary artery disease;
BRCA	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg22800045	chr5:56110881	MAP3K1	0.65	12.3	0.44	2.42e-31	Initial pursuit acceleration;
BRCA	trans	rs208520	0.690	rs176289	chr6:66766522	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-21.0	-0.64	7.17e-75	Exhaled nitric oxide output;
BRCA	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg23029597	chr12:123009494	RSRC2	-0.62	-12.43	-0.44	6.52e-32	Body mass index;
BRCA	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg07169764	chr2:136633963	MCM6	1.22	23.88	0.69	1.36e-90	Corneal structure;
BRCA	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.83e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg23719950	chr11:63933701	MACROD1	-0.59	-9.85	-0.36	2.09e-21	Mean platelet volume;
BRCA	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.17	0.31	1.69e-15	Menarche (age at onset);
BRCA	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg25036284	chr2:26402008	FAM59B	0.89	15.63	0.53	7.3e-47	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg11764359	chr7:65958608	NA	-0.67	-14.99	-0.51	9.55e-44	Aortic root size;
BRCA	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg23711669	chr6:146136114	FBXO30	0.62	14.39	0.49	7.15e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	20.27	0.63	6.75e-71	Electrocardiographic conduction measures;
BRCA	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.92	0.33	4.74e-18	Tonsillectomy;
BRCA	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg02951883	chr7:2050386	MAD1L1	-0.5	-10.87	-0.4	2.29e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs113835537	0.529	rs11227502	chr11:66274148	T/G	cg24851651	chr11:66362959	CCS	0.44	8.4	0.32	3e-16	Airway imaging phenotypes;
BRCA	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg16606324	chr3:10149918	C3orf24	0.5	9.65	0.36	1.14e-20	Alzheimer's disease;
BRCA	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg04362960	chr10:104952993	NT5C2	0.43	10.38	0.38	1.93e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.37	-0.31	3.52e-16	Schizophrenia;
BRCA	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg16414030	chr3:133502952	NA	0.53	12.12	0.43	1.37e-30	Iron status biomarkers;
BRCA	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg17691542	chr6:26056736	HIST1H1C	0.5	10.21	0.37	9.12e-23	Height;
BRCA	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg14440974	chr22:39074834	NA	-0.38	-9.13	-0.34	8.96e-19	Menopause (age at onset);
BRCA	cis	rs117623576	0.941	rs211424	chr10:32398895	A/G	cg03047570	chr10:32398778	NA	0.55	8.49	0.32	1.42e-16	Anti-saccade response;
BRCA	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg12419862	chr22:24373484	LOC391322	-0.64	-14.11	-0.49	1.53e-39	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg09184832	chr6:79620586	NA	-0.52	-11.37	-0.41	2.02e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-11.37	-0.41	2.14e-27	Resting heart rate;
BRCA	cis	rs4285028	0.747	rs11928871	chr3:121483388	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.9	-16.27	-0.54	4.89e-50	Multiple sclerosis;
BRCA	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.69e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7072216	0.691	rs7910973	chr10:100166732	G/A	cg26618903	chr10:100175079	PYROXD2	-0.31	-9.04	-0.34	1.87e-18	Metabolite levels;
BRCA	cis	rs4891159	0.756	rs55763305	chr18:74161249	G/C	cg24786174	chr18:74118243	ZNF516	-0.7	-16.26	-0.54	5.2e-50	Longevity;
BRCA	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg23422044	chr7:1970798	MAD1L1	-0.64	-13.92	-0.48	1.19e-38	Bipolar disorder;
BRCA	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg09307838	chr4:120376055	NA	0.69	14.02	0.49	3.82e-39	Corneal astigmatism;
BRCA	cis	rs6820391	0.816	rs1369355	chr4:54446860	G/A	cg04173182	chr4:54446035	LNX1	0.52	11.65	0.42	1.38e-28	Cervical artery dissection;
BRCA	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg23711669	chr6:146136114	FBXO30	0.66	13.23	0.46	1.73e-35	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs8073060	0.586	rs2523116	chr17:34025460	T/C	cg19694781	chr19:47549865	TMEM160	-1.05	-20.92	-0.64	2.11e-74	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs7246967	0.673	rs12985825	chr19:22953451	A/C	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs965469	0.779	rs6037548	chr20:3299299	G/A	cg25506879	chr20:3388711	C20orf194	-0.43	-8.73	-0.33	2.23e-17	IFN-related cytopenia;
BRCA	cis	rs9287719	0.649	rs7589694	chr2:10700874	T/C	cg00105475	chr2:10696890	NA	0.41	9.15	0.34	7.71e-19	Prostate cancer;
BRCA	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg26597838	chr10:835615	NA	0.85	15.42	0.52	7.67e-46	Eosinophil percentage of granulocytes;
BRCA	cis	rs1595825	0.891	rs16866940	chr2:198509058	C/T	cg19156104	chr2:198669113	PLCL1	-0.43	-8.19	-0.31	1.41e-15	Ulcerative colitis;
BRCA	cis	rs3740540	0.507	rs10794161	chr10:126291327	C/A	cg04949429	chr10:126290192	LHPP	0.43	12.1	0.43	1.69e-30	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg11189052	chr15:85197271	WDR73	-0.33	-7.85	-0.3	1.8e-14	P wave terminal force;
BRCA	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12826209	chr6:26865740	GUSBL1	0.58	10.3	0.38	3.9699999999999997e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg18512352	chr11:47633146	NA	-0.34	-8.24	-0.31	9.79e-16	Body mass index;
BRCA	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.39	-8.26	-0.31	8.62e-16	Body mass index;
BRCA	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.0	0.56	9.54e-54	Morning vs. evening chronotype;
BRCA	cis	rs6543140	0.964	rs62154972	chr2:103048738	G/A	cg04239558	chr2:103089729	SLC9A4	0.34	9.39	0.35	1.04e-19	Blood protein levels;
BRCA	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg04586622	chr2:25135609	ADCY3	0.46	11.59	0.42	2.64e-28	Body mass index;
BRCA	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.05e-17	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs6479891	1.000	rs4746195	chr10:65307653	A/G	cg14819942	chr15:35414228	NA	0.34	8.25	0.31	9.01e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs9462027	0.651	rs9469870	chr6:34744349	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.27	-8.23	-0.31	1.08e-15	Systemic lupus erythematosus;
BRCA	cis	rs9359856	0.529	rs72915915	chr6:90430593	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.66	-8.24	-0.31	9.81e-16	Bipolar disorder;
BRCA	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg03146154	chr1:46216737	IPP	0.49	10.87	0.4	2.28e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9308731	0.644	rs3789064	chr2:111915322	T/C	cg04780086	chr2:111875790	ACOXL	0.28	7.91	0.3	1.11e-14	Chronic lymphocytic leukemia;
BRCA	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-9.73	-0.36	5.87e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12292205	chr6:26970375	C6orf41	-0.49	-8.27	-0.31	7.96e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg08807101	chr21:30365312	RNF160	-0.44	-9.38	-0.35	1.17e-19	Dental caries;
BRCA	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg05347473	chr6:146136440	FBXO30	0.41	8.07	0.3	3.41e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.52	-0.35	3.47e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6580649	1.000	rs9805048	chr12:48403692	C/T	cg05342945	chr12:48394962	COL2A1	-0.42	-8.68	-0.32	3.39e-17	Lung cancer;
BRCA	trans	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg06521331	chr12:34319734	NA	-0.45	-8.33	-0.31	4.76e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg05347473	chr6:146136440	FBXO30	0.39	7.94	0.3	9.39e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg02659138	chr7:134003124	SLC35B4	0.36	9.99	0.37	6.2e-22	Mean platelet volume;
BRCA	trans	rs7746199	0.673	rs72847313	chr6:27730082	C/T	cg01620082	chr3:125678407	NA	-0.92	-10.32	-0.38	3.23e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1223245	0.740	rs360063	chr1:226036309	A/G	cg27179622	chr1:226127290	LEFTY2	-0.32	-9.09	-0.34	1.2e-18	Preschool internalizing problems;
BRCA	cis	rs7833986	0.501	rs72653953	chr8:56970795	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	13.18	0.46	2.8e-35	Height;
BRCA	trans	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.07	0.3	3.49e-15	Endometrial cancer;
BRCA	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg15208524	chr1:10270712	KIF1B	0.38	7.9	0.3	1.23e-14	Hepatocellular carcinoma;
BRCA	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg08999081	chr20:33150536	PIGU	-0.45	-12.33	-0.44	1.73e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg21573476	chr21:45109991	RRP1B	0.34	8.69	0.33	3.01e-17	Mean corpuscular volume;
BRCA	cis	rs7246657	0.551	rs4806413	chr19:37617716	A/T	cg18154014	chr19:37997991	ZNF793	0.5	8.11	0.31	2.68e-15	Coronary artery calcification;
BRCA	cis	rs4588572	0.644	rs9293751	chr5:77778296	A/G	cg11547950	chr5:77652471	NA	-0.42	-8.39	-0.32	3.08e-16	Triglycerides;
BRCA	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg09904177	chr6:26538194	HMGN4	-0.45	-14.14	-0.49	1.13e-39	Intelligence (multi-trait analysis);
BRCA	cis	rs2302729	0.578	rs10774052	chr12:2772171	C/T	cg19945202	chr12:2788847	CACNA1C	-0.44	-9.83	-0.36	2.39e-21	Sleep quality;
BRCA	cis	rs10193935	0.901	rs1496329	chr2:42688797	T/C	cg27598129	chr2:42591480	NA	0.8	12.94	0.46	3.58e-34	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.6	-12.49	-0.44	3.34e-32	Lymphocyte counts;
BRCA	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg01877450	chr7:97915802	BRI3	-0.39	-8.98	-0.33	3.1e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.47	0.66	7.52e-83	Chronic sinus infection;
BRCA	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12516959	chr21:47718080	NA	-0.42	-9.59	-0.35	1.96e-20	Testicular germ cell tumor;
BRCA	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg05343316	chr1:45956843	TESK2	0.7	14.2	0.49	5.92e-40	Platelet count;
BRCA	cis	rs2191566	0.506	rs396116	chr19:44494583	A/G	cg20607764	chr19:44506953	ZNF230	0.36	7.88	0.3	1.46e-14	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg25801113	chr15:45476975	SHF	0.31	8.05	0.3	4.02e-15	Uric acid levels;
BRCA	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.13	0.37	1.89e-22	Bladder cancer;
BRCA	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg14458575	chr2:238380390	NA	0.48	10.47	0.38	8.87e-24	Prostate cancer;
BRCA	cis	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-8.86	-0.33	8.2e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg25036284	chr2:26402008	FAM59B	0.66	10.8	0.39	4.38e-25	Gut microbiome composition (summer);
BRCA	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg05347473	chr6:146136440	FBXO30	0.42	8.33	0.31	4.77e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.41	8.56	0.32	8.4e-17	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs509477	1.000	rs531558	chr18:32575286	A/T	cg23791764	chr18:32556832	MAPRE2	-0.35	-8.37	-0.31	3.69e-16	Cerebrospinal fluid AB1-42 levels;
BRCA	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	8.93	0.33	4.67e-18	Bipolar disorder;
BRCA	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg25036284	chr2:26402008	FAM59B	0.77	10.7	0.39	1.08e-24	Gut microbiome composition (summer);
BRCA	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg03929089	chr4:120376271	NA	-0.79	-18.87	-0.6	1.83e-63	Coronary artery disease;
BRCA	cis	rs12474201	0.928	rs35825831	chr2:46932544	T/G	cg06386533	chr2:46925753	SOCS5	0.87	18.88	0.6	1.58e-63	Height;
BRCA	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg06115741	chr20:33292138	TP53INP2	0.45	9.94	0.37	9.8e-22	Coronary artery disease;
BRCA	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg27535305	chr1:53392650	SCP2	0.32	7.93	0.3	9.73e-15	Monocyte count;
BRCA	cis	rs7617773	0.780	rs6793223	chr3:48364101	C/T	cg11946769	chr3:48343235	NME6	0.67	13.64	0.47	2.37e-37	Coronary artery disease;
BRCA	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg08085267	chr17:45401833	C17orf57	-0.68	-15.07	-0.51	3.79e-44	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs10208940	0.920	rs72903979	chr2:68813938	C/T	cg12452813	chr2:68675892	NA	0.47	8.23	0.31	1.06e-15	Urate levels in lean individuals;
BRCA	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.63	10.83	0.39	3.23e-25	Lung function (FEV1/FVC);
BRCA	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.17	-0.43	8.86e-31	Total cholesterol levels;
BRCA	cis	rs3824867	0.879	rs4752837	chr11:47465955	G/A	cg20307385	chr11:47447363	PSMC3	0.51	11.55	0.42	3.77e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg16362232	chr11:430036	ANO9	0.5	8.03	0.3	4.82e-15	Body mass index;
BRCA	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg08999081	chr20:33150536	PIGU	-0.46	-12.62	-0.45	9.12e-33	Glomerular filtration rate (creatinine);
BRCA	cis	rs7072216	0.727	rs7913541	chr10:100172479	A/G	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.72	-0.36	6.14e-21	Metabolite levels;
BRCA	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11890956	chr21:40555474	PSMG1	-0.62	-13.99	-0.48	5.67e-39	Menarche (age at onset);
BRCA	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	14.88	0.51	3.41e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2880765	0.835	rs12324277	chr15:86041735	G/A	cg10818794	chr15:86012489	AKAP13	-0.31	-8.66	-0.32	3.7e-17	Coronary artery disease;
BRCA	cis	rs7095944	0.582	rs10901823	chr10:126488660	C/T	cg08799069	chr10:126477246	METTL10	-0.35	-8.46	-0.32	1.88e-16	Asthma;
BRCA	cis	rs1891275	0.509	rs34190234	chr10:93443074	A/C	cg07889827	chr10:93443413	NA	-0.44	-12.54	-0.44	2.03e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.6	0.42	2.29e-28	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg14558114	chr2:88469736	THNSL2	0.63	9.17	0.34	6.56e-19	Plasma clusterin levels;
BRCA	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg04362960	chr10:104952993	NT5C2	0.43	9.77	0.36	4.15e-21	Arsenic metabolism;
BRCA	cis	rs4594175	0.926	rs114230179	chr14:51601974	C/T	cg23942311	chr14:51606299	NA	0.34	8.47	0.32	1.72e-16	Cancer;
BRCA	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.03	15.95	0.53	1.8e-48	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1577917	1.000	rs6454513	chr6:86720049	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.42	11.2	0.41	1.02e-26	Response to antipsychotic treatment;
BRCA	cis	rs7124681	0.585	rs10838773	chr11:47834346	G/A	cg20307385	chr11:47447363	PSMC3	0.39	8.8	0.33	1.25e-17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs7737355	0.853	rs593767	chr5:131043660	T/G	cg06307176	chr5:131281290	NA	0.52	10.06	0.37	3.22e-22	Life satisfaction;
BRCA	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg03354898	chr7:1950403	MAD1L1	-0.49	-10.65	-0.39	1.65e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg27433088	chr4:174089019	GALNT7	0.35	9.7	0.36	7.73e-21	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg15133208	chr4:90757351	SNCA	-0.43	-8.73	-0.33	2.28e-17	Neuroticism;
BRCA	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	17.71	0.57	2.01e-57	Hip circumference adjusted for BMI;
BRCA	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg13119609	chr19:45449297	APOC2	0.47	12.99	0.46	1.99e-34	Blood protein levels;
BRCA	cis	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg06521331	chr12:34319734	NA	-0.63	-12.2	-0.43	6.34e-31	Morning vs. evening chronotype;
BRCA	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00166722	chr3:10149974	C3orf24	0.65	11.25	0.41	6.34e-27	Alzheimer's disease;
BRCA	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11890956	chr21:40555474	PSMG1	-0.81	-19.18	-0.6	4.11e-65	Cognitive function;
BRCA	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg11833968	chr6:79620685	NA	-0.43	-9.6	-0.35	1.8e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg21252483	chr19:49399788	TULP2	-0.51	-11.09	-0.4	2.84e-26	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg24642439	chr20:33292090	TP53INP2	0.68	13.9	0.48	1.45e-38	Coronary artery disease;
BRCA	trans	rs61931739	0.963	rs1817759	chr12:34101521	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-8.96	-0.33	3.4e-18	Morning vs. evening chronotype;
BRCA	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg13010199	chr12:38710504	ALG10B	0.45	9.01	0.34	2.38e-18	Bladder cancer;
BRCA	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg01483505	chr11:975446	AP2A2	0.33	9.07	0.34	1.44e-18	Alzheimer's disease (late onset);
BRCA	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg10223061	chr2:219282414	VIL1	-0.28	-8.32	-0.31	5.35e-16	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs11958404	0.932	rs12514557	chr5:157418954	T/C	cg05962755	chr5:157440814	NA	0.5	9.57	0.35	2.34e-20	IgG glycosylation;
BRCA	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	ch.11.42038R	chr11:967971	AP2A2	0.52	16.71	0.55	2.67e-52	Alzheimer's disease (late onset);
BRCA	trans	rs7939886	0.764	rs79601668	chr11:55753767	G/C	cg15704280	chr7:45808275	SEPT13	0.62	7.94	0.3	9.08e-15	Myopia (pathological);
BRCA	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	13.16	0.46	3.48e-35	Bone mineral density;
BRCA	cis	rs4845875	0.626	rs12734761	chr1:11834182	G/A	cg24844545	chr1:11908347	NPPA	0.31	7.95	0.3	8.34e-15	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg18357645	chr12:58087776	OS9	-0.34	-8.22	-0.31	1.1e-15	Multiple sclerosis;
BRCA	cis	rs4481887	0.861	rs7412034	chr1:248434150	G/C	cg00666640	chr1:248458726	OR2T12	0.28	7.94	0.3	9.22e-15	Common traits (Other);
BRCA	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg03146154	chr1:46216737	IPP	0.52	11.61	0.42	2.16e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg06784218	chr1:46089804	CCDC17	-0.44	-10.47	-0.38	8.95e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18876405	chr7:65276391	NA	-0.51	-11.78	-0.42	3.9e-29	Aortic root size;
BRCA	cis	rs4363385	0.747	rs2879489	chr1:152970465	A/G	cg21543102	chr1:152974771	SPRR3	-0.28	-8.04	-0.3	4.2e-15	Inflammatory skin disease;
BRCA	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg19628046	chr18:33552617	C18orf21	0.59	11.78	0.42	3.86e-29	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00149659	chr3:10157352	C3orf10	0.79	13.83	0.48	2.94e-38	Alzheimer's disease;
BRCA	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg13256891	chr4:100009986	ADH5	0.38	8.04	0.3	4.36e-15	Alcohol dependence;
BRCA	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg24006582	chr15:45444508	DUOX1	0.54	10.72	0.39	9.21e-25	Uric acid levels;
BRCA	cis	rs7301826	0.651	rs7968675	chr12:131303377	C/T	cg11011512	chr12:131303247	STX2	0.53	14.01	0.48	4.53e-39	Plasma plasminogen activator levels;
BRCA	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg09904177	chr6:26538194	HMGN4	0.41	9.29	0.34	2.48e-19	Small cell lung carcinoma;
BRCA	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.72e-18	Alzheimer's disease (late onset);
BRCA	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg06784218	chr1:46089804	CCDC17	0.49	11.33	0.41	2.91e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg13010199	chr12:38710504	ALG10B	-0.38	-8.36	-0.31	4.03e-16	Morning vs. evening chronotype;
BRCA	cis	rs7714584	1.000	rs931058	chr5:150333698	A/T	cg22134413	chr5:150180641	NA	0.75	10.24	0.38	6.66e-23	Crohn's disease;
BRCA	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.38	8.23	0.31	1.05e-15	Cognitive ability;
BRCA	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg05868516	chr6:26286170	HIST1H4H	0.49	10.85	0.39	2.67e-25	Educational attainment;
BRCA	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg04998671	chr14:104000505	TRMT61A	-0.43	-9.74	-0.36	5.2e-21	Coronary artery disease;
BRCA	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg24803719	chr17:45855879	NA	-0.32	-8.54	-0.32	9.76e-17	IgG glycosylation;
BRCA	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18876405	chr7:65276391	NA	0.56	13.15	0.46	3.81e-35	Aortic root size;
BRCA	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg26384229	chr12:38710491	ALG10B	-0.51	-12.31	-0.44	2.05e-31	Morning vs. evening chronotype;
BRCA	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02187348	chr16:89574699	SPG7	0.54	13.02	0.46	1.54e-34	Multiple myeloma (IgH translocation);
BRCA	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg21475434	chr5:93447410	FAM172A	0.67	8.74	0.33	2.03e-17	Diabetic retinopathy;
BRCA	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg27170947	chr2:26402098	FAM59B	0.95	15.52	0.52	2.53e-46	Gut microbiome composition (summer);
BRCA	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg22491629	chr6:157744540	C6orf35	-0.64	-12.21	-0.43	5.86e-31	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6121246	0.511	rs879982	chr20:30398510	A/G	cg21427119	chr20:30132790	HM13	-0.35	-7.99	-0.3	6.19e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg07636037	chr3:49044803	WDR6	-0.76	-18.46	-0.59	2.75e-61	Menarche (age at onset);
BRCA	cis	rs1018836	0.923	rs13255452	chr8:91582988	A/G	cg16814680	chr8:91681699	NA	-0.58	-12.42	-0.44	6.93e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6138458	1.000	rs1977540	chr20:24900290	G/T	cg06937882	chr20:24974362	C20orf3	0.44	8.35	0.31	4.34e-16	Blood protein levels;
BRCA	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg22974920	chr21:40686053	BRWD1	-0.35	-7.84	-0.3	1.85e-14	Menarche (age at onset);
BRCA	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg12935359	chr14:103987150	CKB	0.61	13.88	0.48	1.79e-38	Intelligence (multi-trait analysis);
BRCA	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg02493740	chr2:85810744	VAMP5	-0.56	-11.85	-0.42	1.92e-29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg06970220	chr1:156163860	SLC25A44	0.4	9.58	0.35	2.04e-20	Testicular germ cell tumor;
BRCA	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg18200150	chr17:30822561	MYO1D	0.35	9.0	0.34	2.6e-18	Schizophrenia;
BRCA	cis	rs7737355	0.645	rs7731071	chr5:130973483	A/G	cg06307176	chr5:131281290	NA	0.53	10.35	0.38	2.57e-23	Life satisfaction;
BRCA	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg11279151	chr3:101281821	RG9MTD1	-0.35	-8.11	-0.31	2.59e-15	Colorectal cancer;
BRCA	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg22800045	chr5:56110881	MAP3K1	0.63	11.9	0.43	1.23e-29	Initial pursuit acceleration;
BRCA	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg23625390	chr15:77176239	SCAPER	0.54	14.03	0.49	3.58e-39	Blood metabolite levels;
BRCA	cis	rs897984	0.806	rs1046276	chr16:30914626	A/G	cg02466173	chr16:30829666	NA	0.49	11.27	0.41	5.58e-27	Dementia with Lewy bodies;
BRCA	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14829155	chr15:31115871	NA	-0.56	-13.17	-0.46	3.25e-35	Huntington's disease progression;
BRCA	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg25174290	chr11:3078921	CARS	0.42	12.03	0.43	3.3e-30	Longevity;
BRCA	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11644478	chr21:40555479	PSMG1	0.85	19.88	0.62	8.28e-69	Cognitive function;
BRCA	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg05863683	chr7:1912471	MAD1L1	0.37	8.2	0.31	1.31e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	20.06	0.62	8.33e-70	Platelet count;
BRCA	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.8e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs1953600	0.870	rs2236557	chr10:81923961	A/G	cg04850286	chr10:81895943	PLAC9	0.31	8.65	0.32	4e-17	Sarcoidosis;
BRCA	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg13256891	chr4:100009986	ADH5	0.47	9.06	0.34	1.52e-18	Alcohol dependence;
BRCA	trans	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg01620082	chr3:125678407	NA	0.76	9.63	0.36	1.36e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs67478160	0.595	rs12433109	chr14:104196607	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.47	-11.81	-0.42	3.09e-29	Schizophrenia;
BRCA	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg24060327	chr5:131705240	SLC22A5	-0.46	-9.15	-0.34	7.57e-19	Acylcarnitine levels;
BRCA	trans	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg25214090	chr10:38739885	LOC399744	0.53	10.77	0.39	5.54e-25	Corneal astigmatism;
BRCA	cis	rs698833	0.508	rs698765	chr2:44573671	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	10.36	0.38	2.27e-23	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs3820928	0.874	rs7423610	chr2:227836262	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.34	-0.31	4.47e-16	Pulmonary function;
BRCA	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg11062466	chr8:58055876	NA	0.41	7.94	0.3	9.37e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.41	-7.91	-0.3	1.13e-14	Bronchopulmonary dysplasia;
BRCA	cis	rs760805	1.000	rs10903115	chr1:25261696	A/G	cg22509179	chr1:25234806	RUNX3	-0.57	-14.82	-0.51	6.64e-43	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs6138458	1.000	rs227615	chr20:24908721	T/C	cg26195577	chr20:24973756	C20orf3	0.98	24.76	0.7	2.17e-95	Blood protein levels;
BRCA	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg13319975	chr6:146136371	FBXO30	0.41	9.22	0.34	4.41e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg06145435	chr7:1022769	CYP2W1	0.49	9.15	0.34	7.7e-19	Bronchopulmonary dysplasia;
BRCA	trans	rs4596713	0.568	rs10124710	chr9:71748279	G/A	cg16512924	chr15:28394682	HERC2	0.42	9.99	0.37	5.96e-22	Headache;
BRCA	cis	rs10129255	0.518	rs12590732	chr14:107187851	C/T	cg07958169	chr14:107095056	NA	0.38	8.2	0.31	1.31e-15	Kawasaki disease;
BRCA	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg04691961	chr3:161091175	C3orf57	-0.37	-7.9	-0.3	1.21e-14	Parkinson's disease;
BRCA	cis	rs4730250	0.707	rs257373	chr7:106798290	G/A	cg02696742	chr7:106810147	HBP1	-0.59	-9.66	-0.36	1.09e-20	Osteoarthritis;
BRCA	cis	rs4853036	0.629	rs10210787	chr2:70016053	C/T	cg02498382	chr2:70120550	SNRNP27	-0.44	-8.19	-0.31	1.41e-15	Colorectal or endometrial cancer;
BRCA	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.32	-0.31	5.29e-16	Depression;
BRCA	cis	rs7572733	0.534	rs1464209	chr2:198814396	A/G	cg00792783	chr2:198669748	PLCL1	0.45	9.89	0.36	1.47e-21	Dermatomyositis;
BRCA	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg09307838	chr4:120376055	NA	0.59	12.37	0.44	1.19e-31	Corneal astigmatism;
BRCA	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.77	12.2	0.43	6.34e-31	Platelet count;
BRCA	cis	rs897080	0.515	rs1067334	chr2:44626633	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	9.37	0.35	1.23e-19	Height;
BRCA	cis	rs813218	0.527	rs793450	chr3:99532532	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-8.64	-0.32	4.57e-17	Orofacial clefts;
BRCA	cis	rs12714314	0.830	rs10207910	chr2:1963781	T/C	cg22511877	chr2:1942942	MYT1L	0.39	8.2	0.31	1.36e-15	Type 2 diabetes (age of onset);
BRCA	cis	rs6977660	1.000	rs12672557	chr7:19804237	G/A	cg07541023	chr7:19748670	TWISTNB	0.44	7.92	0.3	1.04e-14	Thyroid stimulating hormone;
BRCA	cis	rs7953508	0.506	rs2200160	chr12:93963873	C/T	cg18151635	chr12:93972918	NA	-0.45	-8.98	-0.33	2.92e-18	Pubertal anthropometrics;
BRCA	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg04455712	chr21:45112962	RRP1B	-0.43	-10.83	-0.39	3.25e-25	Mean corpuscular volume;
BRCA	cis	rs2066819	1.000	rs79824801	chr12:56728137	T/C	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.02	15.64	0.53	6.41e-47	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24549020	chr5:56110836	MAP3K1	-0.38	-8.01	-0.3	5.4e-15	Initial pursuit acceleration;
BRCA	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06028605	chr16:24865363	SLC5A11	-0.47	-10.23	-0.38	7.54e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg04414720	chr1:150670196	GOLPH3L	0.35	7.84	0.3	1.88e-14	Tonsillectomy;
BRCA	cis	rs501916	0.634	rs10851459	chr15:48061510	C/A	cg16110827	chr15:48056943	SEMA6D	-0.43	-9.08	-0.34	1.29e-18	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg04553112	chr3:125709451	NA	-0.55	-8.34	-0.31	4.47e-16	Blood pressure (smoking interaction);
BRCA	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg27279351	chr12:120934652	DYNLL1	0.56	13.24	0.46	1.62e-35	High light scatter reticulocyte count;
BRCA	cis	rs6545883	0.860	rs6545847	chr2:61445333	C/T	cg15711740	chr2:61764176	XPO1	0.52	13.13	0.46	4.85e-35	Tuberculosis;
BRCA	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg02734326	chr4:10020555	SLC2A9	0.35	7.82	0.3	2.11e-14	Bone mineral density;
BRCA	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg08888203	chr3:10149979	C3orf24	0.67	14.09	0.49	1.89e-39	Alzheimer's disease;
BRCA	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-17.81	-0.58	6.55e-58	Chronic sinus infection;
BRCA	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg01028140	chr2:1542097	TPO	-0.56	-11.88	-0.43	1.5e-29	IgG glycosylation;
BRCA	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg17971929	chr21:40555470	PSMG1	0.77	18.23	0.58	4.34e-60	Cognitive function;
BRCA	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg02951883	chr7:2050386	MAD1L1	-0.55	-12.93	-0.46	3.8e-34	Bipolar disorder and schizophrenia;
BRCA	cis	rs6878727	0.850	rs1363308	chr5:123707222	A/G	cg01806427	chr5:123737813	NA	0.4	9.36	0.35	1.39e-19	Breast cancer;
BRCA	cis	rs644148	0.836	rs2686775	chr19:45000059	C/T	cg15540054	chr19:45004280	ZNF180	-0.57	-12.31	-0.44	2.15e-31	Personality dimensions;
BRCA	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg18305652	chr10:134549665	INPP5A	0.5	11.51	0.41	5.37e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs365132	0.875	rs187114	chr5:176364039	A/G	cg16309518	chr5:176445507	NA	-0.41	-10.0	-0.37	5.89e-22	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs2051211	1.000	rs2051211	chr3:38559749	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.5	-10.18	-0.37	1.2e-22	QRS duration;
BRCA	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg18795169	chr1:18902165	NA	0.97	29.55	0.76	1.3e-121	Urate levels in lean individuals;
BRCA	cis	rs13136331	0.641	rs2627682	chr4:88662490	A/G	cg12990093	chr4:88570587	DMP1	-0.4	-8.22	-0.31	1.17e-15	Sitting height ratio;
BRCA	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg08754654	chr5:154026448	NA	0.43	9.87	0.36	1.72e-21	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg27446573	chr6:127587934	RNF146	0.9	21.19	0.64	6.68e-76	Breast cancer;
BRCA	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.83	-0.3	2.08e-14	Electroencephalogram traits;
BRCA	cis	rs2882667	0.690	rs167009	chr5:138200457	G/C	cg04439458	chr5:138467593	SIL1	0.35	8.55	0.32	9.12e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18876405	chr7:65276391	NA	0.55	13.31	0.47	7.25e-36	Aortic root size;
BRCA	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg24642439	chr20:33292090	TP53INP2	0.7	15.97	0.53	1.41e-48	Coronary artery disease;
BRCA	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg24642439	chr20:33292090	TP53INP2	0.41	8.09	0.3	3.03e-15	Height;
BRCA	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7833986	0.501	rs17815934	chr8:57038395	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	13.06	0.46	9.86e-35	Height;
BRCA	cis	rs6121246	0.559	rs12479491	chr20:30265450	T/C	cg21427119	chr20:30132790	HM13	-0.35	-8.06	-0.3	3.7e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.24	0.63	8.98e-71	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg08601574	chr20:25228251	PYGB	-0.36	-8.67	-0.32	3.48e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-9.35	-0.35	1.51e-19	Fear of minor pain;
BRCA	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg09436375	chr6:42928200	GNMT	-0.28	-10.61	-0.39	2.38e-24	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg27171569	chr16:83987465	OSGIN1	0.42	12.31	0.44	2.16e-31	Pursuit maintenance gain;
BRCA	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg23587288	chr2:27483067	SLC30A3	-0.38	-8.9	-0.33	5.91e-18	Blood metabolite levels;
BRCA	cis	rs312273	0.590	rs278920	chr12:41377914	T/G	cg17827154	chr12:41323612	CNTN1	-0.39	-10.2	-0.37	1.02e-22	Bipolar disorder;
BRCA	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg09307838	chr4:120376055	NA	0.74	16.14	0.54	2.13e-49	Corneal astigmatism;
BRCA	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg24296786	chr1:45957014	TESK2	0.65	16.1	0.54	3.21e-49	High light scatter reticulocyte count;
BRCA	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-8.69	-0.33	3e-17	Obesity-related traits;
BRCA	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg02734326	chr4:10020555	SLC2A9	0.38	8.2	0.31	1.28e-15	Bone mineral density;
BRCA	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg01304814	chr3:48885189	PRKAR2A	0.57	7.91	0.3	1.11e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg08000102	chr2:233561755	GIGYF2	-0.46	-10.05	-0.37	3.72e-22	Coronary artery disease;
BRCA	cis	rs9300255	0.510	rs1727322	chr12:123699520	A/G	cg00376283	chr12:123451042	ABCB9	0.55	10.54	0.38	4.47e-24	Neutrophil percentage of white cells;
BRCA	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg02297831	chr4:17616191	MED28	0.37	8.61	0.32	5.47e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	12.3	0.44	2.24e-31	Response to bleomycin (chromatid breaks);
BRCA	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.05	29.57	0.76	9.97e-122	Cognitive ability;
BRCA	cis	rs1710278	0.935	rs898319	chr10:127746372	C/T	cg22975853	chr10:127789788	ADAM12	0.33	8.52	0.32	1.16e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
BRCA	cis	rs6901250	0.851	rs339361	chr6:117162515	C/T	cg12892004	chr6:117198278	RFX6	0.48	11.09	0.4	2.96e-26	C-reactive protein levels;
BRCA	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg03188948	chr7:1209495	NA	0.58	11.11	0.4	2.54e-26	Longevity;Endometriosis;
BRCA	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05025164	chr4:1340916	KIAA1530	-0.63	-12.7	-0.45	3.94e-33	Obesity-related traits;
BRCA	cis	rs7178424	0.935	rs8032433	chr15:62284101	A/G	cg00456672	chr15:62358751	C2CD4A	-0.38	-8.66	-0.32	3.72e-17	Height;
BRCA	cis	rs1003719	0.680	rs3737540	chr21:38523266	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-12.29	-0.44	2.55e-31	Eye color traits;
BRCA	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.43	8.26	0.31	8.63e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-12.58	-0.45	1.41e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7172677	0.737	rs4886668	chr15:75448034	T/C	cg14664628	chr15:75095509	CSK	-0.42	-9.02	-0.34	2.13e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs9369695	0.842	rs2396825	chr6:47568696	A/G	cg12968598	chr6:47444699	CD2AP	0.44	9.56	0.35	2.56e-20	Reticulocyte count;
BRCA	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.95	0.33	3.85e-18	Ovarian reserve;
BRCA	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg06159980	chr1:16340746	HSPB7	-0.33	-7.81	-0.3	2.33e-14	Dilated cardiomyopathy;
BRCA	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg12062639	chr20:23401060	NAPB	0.95	13.22	0.46	1.89e-35	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	13.3	0.47	8.13e-36	Platelet count;
BRCA	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg02016764	chr4:38805732	TLR1	-0.62	-9.69	-0.36	8.13e-21	Breast cancer;
BRCA	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg21045802	chr8:109455806	TTC35	0.34	7.87	0.3	1.52e-14	Dupuytren's disease;
BRCA	cis	rs7789940	1.000	rs76024966	chr7:75995021	C/T	cg10167463	chr7:75959203	YWHAG	-0.44	-8.69	-0.33	3e-17	Multiple sclerosis;
BRCA	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.4	0.38	1.71e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg00686598	chr14:53173677	PSMC6	1.16	15.74	0.53	2.07e-47	Alzheimer's disease (late onset);
BRCA	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg15017067	chr4:17643749	FAM184B	0.26	7.81	0.3	2.27e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg06191203	chr2:152266755	RIF1	-0.28	-8.12	-0.31	2.41e-15	Lung cancer;
BRCA	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	11.11	0.4	2.5e-26	Rheumatoid arthritis;
BRCA	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg26031613	chr14:104095156	KLC1	-0.43	-8.5	-0.32	1.38e-16	Schizophrenia;
BRCA	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg26384229	chr12:38710491	ALG10B	0.74	17.6	0.57	8.15e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08564027	chr20:61660810	NA	0.85	22.66	0.67	6.95e-84	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg03342759	chr3:160939853	NMD3	-0.62	-12.96	-0.46	2.75e-34	Morning vs. evening chronotype;
BRCA	cis	rs6772849	0.796	rs9841521	chr3:128392274	A/G	cg16766828	chr3:128327626	NA	-0.41	-8.79	-0.33	1.34e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg26384229	chr12:38710491	ALG10B	0.59	13.54	0.47	6.37e-37	Morning vs. evening chronotype;
BRCA	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg02176678	chr2:219576539	TTLL4	-0.42	-11.67	-0.42	1.21e-28	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2882667	0.690	rs288035	chr5:138212417	A/T	cg04439458	chr5:138467593	SIL1	-0.35	-8.56	-0.32	8.34e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs1493916	0.601	rs7237379	chr18:31322540	C/T	cg27147174	chr7:100797783	AP1S1	0.47	9.48	0.35	4.69e-20	Life satisfaction;
BRCA	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg16405210	chr4:1374714	KIAA1530	-0.43	-9.64	-0.36	1.25e-20	Longevity;
BRCA	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	13.1	0.46	6.77e-35	Schizophrenia;
BRCA	cis	rs6060717	0.536	rs6058356	chr20:34491530	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-8.06	-0.3	3.8e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.25	8.12	0.31	2.41e-15	Parkinson's disease;
BRCA	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg17063962	chr7:91808500	NA	-0.53	-12.43	-0.44	6.48e-32	Breast cancer;
BRCA	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg19622623	chr12:86230825	RASSF9	-0.33	-9.28	-0.34	2.49e-19	Major depressive disorder;
BRCA	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg02951883	chr7:2050386	MAD1L1	-0.49	-10.84	-0.39	2.98e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs2425143	1.000	rs57963833	chr20:34344225	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.02	-0.34	2.18e-18	Blood protein levels;
BRCA	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22496380	chr5:211416	CCDC127	-1.0	-14.24	-0.49	3.65e-40	Breast cancer;
BRCA	trans	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.8	15.45	0.52	5.66e-46	Exhaled nitric oxide levels;
BRCA	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg06627628	chr2:24431161	ITSN2	-0.8	-15.16	-0.51	1.4e-44	Asthma;
BRCA	cis	rs9986765	1.000	rs76467433	chr7:142824852	C/T	cg15652212	chr7:142981776	TMEM139	0.63	9.92	0.37	1.16e-21	Cancer;Dermatomyositis;
BRCA	cis	rs6772849	0.896	rs4557179	chr3:128366726	A/C	cg16766828	chr3:128327626	NA	-0.4	-8.77	-0.33	1.68e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs778371	0.723	rs2592104	chr2:233645970	G/A	cg08000102	chr2:233561755	GIGYF2	0.81	18.91	0.6	1.19e-63	Schizophrenia;
BRCA	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg05472934	chr7:22766657	IL6	0.52	13.77	0.48	5.71e-38	Lung cancer;
BRCA	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.06	29.89	0.76	1.71e-123	Cognitive ability;
BRCA	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-8.56	-0.32	8.56e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs3820928	0.874	rs10933165	chr2:227883648	C/G	cg11843606	chr2:227700838	RHBDD1	0.38	8.34	0.31	4.55e-16	Pulmonary function;
BRCA	trans	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg11693508	chr17:37793320	STARD3	0.51	8.98	0.33	3.01e-18	Neuroticism;
BRCA	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg13010199	chr12:38710504	ALG10B	0.51	10.09	0.37	2.48e-22	Bladder cancer;
BRCA	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.32	0.57	2.11e-55	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs3857536	0.813	rs6904511	chr6:66939102	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs965469	0.779	rs6037568	chr20:3333245	C/T	cg25506879	chr20:3388711	C20orf194	-0.43	-8.74	-0.33	2.11e-17	IFN-related cytopenia;
BRCA	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg24466277	chr1:23519622	HTR1D	-0.4	-8.68	-0.32	3.22e-17	Height;
BRCA	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg12011299	chr4:100065546	ADH4	0.46	11.16	0.4	1.57e-26	Alcohol dependence;
BRCA	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-10.14	-0.37	1.7e-22	Schizophrenia;
BRCA	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg08601574	chr20:25228251	PYGB	0.36	8.51	0.32	1.27e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg25809561	chr17:30822961	MYO1D	-0.51	-12.36	-0.44	1.23e-31	Schizophrenia;
BRCA	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-13.29	-0.47	9.55e-36	Platelet count;
BRCA	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg24846343	chr22:24311635	DDTL	0.57	14.85	0.51	4.33e-43	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs12530845	0.673	rs4269479	chr7:135332379	C/T	cg23117316	chr7:135346802	PL-5283	-0.39	-8.02	-0.3	5.07e-15	Red blood cell traits;
BRCA	cis	rs870825	0.616	rs6552808	chr4:185642865	G/T	cg04058563	chr4:185651563	MLF1IP	0.77	17.2	0.56	9.11e-55	Blood protein levels;
BRCA	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.67	-13.35	-0.47	4.9e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-10.45	-0.38	1.07e-23	IgG glycosylation;
BRCA	cis	rs11608355	0.515	rs11613718	chr12:109912332	C/T	cg05360138	chr12:110035743	NA	0.69	12.69	0.45	4.46e-33	Neuroticism;
BRCA	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.45	-10.66	-0.39	1.62e-24	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs881375	0.526	rs1930785	chr9:123691237	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.37	7.8	0.3	2.45e-14	Rheumatoid arthritis;
BRCA	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg06484146	chr7:12443880	VWDE	-0.72	-10.73	-0.39	8.24e-25	Coronary artery disease;
BRCA	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg14983838	chr19:29218262	NA	0.57	11.56	0.42	3.42e-28	Methadone dose in opioid dependence;
BRCA	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg02475777	chr4:1388615	CRIPAK	0.37	8.1	0.31	2.7e-15	Longevity;
BRCA	trans	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg21775007	chr8:11205619	TDH	0.43	8.78	0.33	1.5e-17	Mood instability;
BRCA	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.24	0.34	3.64e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg08470875	chr2:26401718	FAM59B	-0.71	-11.35	-0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs7524258	0.868	rs4908451	chr1:7299618	C/G	cg07173049	chr1:7289937	CAMTA1	-0.53	-12.95	-0.46	3.22e-34	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg09307838	chr4:120376055	NA	0.66	14.25	0.49	3.43e-40	Corneal astigmatism;
BRCA	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg11062466	chr8:58055876	NA	0.41	7.84	0.3	1.84e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg08755490	chr11:65554678	OVOL1	0.54	11.17	0.4	1.34e-26	Acne (severe);
BRCA	cis	rs61990749	0.597	rs2364584	chr14:78152286	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.44	-7.91	-0.3	1.17e-14	Fibroblast growth factor basic levels;
BRCA	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg01528321	chr10:82214614	TSPAN14	0.81	17.34	0.57	1.76e-55	Post bronchodilator FEV1;
BRCA	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg18131467	chr2:239335373	ASB1	0.92	31.46	0.78	6.35e-132	Multiple system atrophy;
BRCA	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg23711669	chr6:146136114	FBXO30	0.75	17.23	0.56	6.5e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg07741184	chr6:167504864	NA	0.28	8.4	0.32	2.81e-16	Rheumatoid arthritis;
BRCA	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05901451	chr6:126070800	HEY2	0.7	20.3	0.63	4.35e-71	Brugada syndrome;
BRCA	cis	rs6545883	0.929	rs778154	chr2:61646631	T/C	cg15711740	chr2:61764176	XPO1	0.55	13.48	0.47	1.28e-36	Tuberculosis;
BRCA	cis	rs11711311	0.747	rs11928494	chr3:113343219	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-8.75	-0.33	1.83e-17	IgG glycosylation;
BRCA	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11644478	chr21:40555479	PSMG1	-0.52	-11.05	-0.4	4.13e-26	Menarche (age at onset);
BRCA	trans	rs10242455	0.702	rs73711280	chr7:99039604	C/T	cg09045935	chr12:6379348	NA	0.84	8.26	0.31	8.16e-16	Blood metabolite levels;
BRCA	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg10729496	chr3:10149963	C3orf24	0.48	9.0	0.34	2.49e-18	Alzheimer's disease;
BRCA	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg12011299	chr4:100065546	ADH4	0.48	10.81	0.39	4.06e-25	Smoking initiation;
BRCA	cis	rs4664304	0.710	rs9636280	chr2:160717852	C/T	cg02280532	chr2:160761244	LY75	-0.35	-7.83	-0.3	2.07e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs1371614	0.632	rs3739088	chr2:27167784	C/T	cg00617064	chr2:27272375	NA	0.32	8.29	0.31	6.53e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg03709012	chr19:19516395	GATAD2A	0.91	17.64	0.57	4.93e-57	Nonalcoholic fatty liver disease;
BRCA	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-11.94	-0.43	7.99e-30	Gut microbiome composition (summer);
BRCA	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.86	-14.51	-0.5	1.88e-41	Alzheimer's disease;
BRCA	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg13010199	chr12:38710504	ALG10B	0.5	10.4	0.38	1.62e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17601876	0.814	rs11636639	chr15:51563092	T/G	cg19946085	chr15:51559439	CYP19A1	-0.39	-11.65	-0.42	1.43e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.35	-0.31	4.39e-16	Aortic root size;
BRCA	cis	rs1003719	0.715	rs2835657	chr21:38565064	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.44	-0.5	4.29e-41	Eye color traits;
BRCA	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg25036284	chr2:26402008	FAM59B	-0.77	-12.12	-0.43	1.42e-30	Gut microbiome composition (summer);
BRCA	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-13.08	-0.46	8.41e-35	Migraine;Coronary artery disease;
BRCA	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.15	0.31	1.93e-15	Total cholesterol levels;
BRCA	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg05340658	chr4:99064831	C4orf37	0.66	15.53	0.52	2.34e-46	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg10295955	chr4:187884368	NA	-0.99	-30.95	-0.77	3.18e-129	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg20290983	chr6:43655470	MRPS18A	1.1	40.85	0.85	2.33e-180	IgG glycosylation;
BRCA	cis	rs9487051	0.708	rs378447	chr6:109526823	G/A	cg21918786	chr6:109611834	NA	-0.34	-8.97	-0.33	3.3e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg02734326	chr4:10020555	SLC2A9	0.41	8.92	0.33	4.74e-18	Bone mineral density;
BRCA	trans	rs4714291	0.963	rs1304602	chr6:40013471	T/G	cg02267698	chr19:7991119	CTXN1	0.4	7.85	0.3	1.71e-14	Strep throat;
BRCA	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.78	-0.33	1.45e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6942756	0.806	rs10257620	chr7:128901429	C/A	cg02491457	chr7:128862824	NA	0.59	12.56	0.45	1.63e-32	White matter hyperintensity burden;
BRCA	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg13736514	chr6:26305472	NA	0.35	11.81	0.42	2.95e-29	Educational attainment;
BRCA	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg27170947	chr2:26402098	FAM59B	0.92	16.52	0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-10.45	-0.38	1.09e-23	Schizophrenia;
BRCA	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg20887711	chr4:1340912	KIAA1530	0.59	13.25	0.46	1.42e-35	Longevity;
BRCA	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg20476274	chr7:133979776	SLC35B4	0.65	19.38	0.61	3.63e-66	Mean platelet volume;
BRCA	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg13047869	chr3:10149882	C3orf24	-0.55	-10.18	-0.37	1.16e-22	Alzheimer's disease;
BRCA	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg22713356	chr15:30763199	NA	1.19	24.18	0.69	3.39e-92	Uric acid levels;
BRCA	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	17.04	0.56	5.99e-54	Colorectal cancer;
BRCA	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg10560079	chr2:191398806	TMEM194B	-0.77	-13.14	-0.46	4.64e-35	Diastolic blood pressure;
BRCA	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg14847009	chr1:175162515	KIAA0040	0.25	9.65	0.36	1.14e-20	Diastolic blood pressure;
BRCA	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.47	0.55	4.76e-51	Hypertriglyceridemia;
BRCA	cis	rs3771570	1.000	rs12619369	chr2:242282957	A/T	cg21155796	chr2:242212141	HDLBP	0.54	8.99	0.33	2.83e-18	Prostate cancer;
BRCA	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.51	0.35	3.8e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg00012203	chr2:219082015	ARPC2	0.51	10.54	0.38	4.58e-24	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs6138458	1.000	rs227615	chr20:24908721	T/C	cg06937882	chr20:24974362	C20orf3	-0.44	-8.38	-0.31	3.34e-16	Blood protein levels;
BRCA	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.39	0.49	7.08e-41	Motion sickness;
BRCA	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13046373	0.535	rs7281489	chr21:31978125	C/T	cg06468780	chr21:31798236	KRTAP13-3	0.37	9.38	0.35	1.11e-19	HDL cholesterol;
BRCA	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-7.97	-0.3	7.2e-15	Ulcerative colitis;
BRCA	cis	rs4285028	0.747	rs9808981	chr3:121429561	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-13.97	-0.48	6.66e-39	Multiple sclerosis;
BRCA	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24110177	chr3:50126178	RBM5	-0.36	-9.59	-0.35	1.96e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg00074818	chr8:8560427	CLDN23	0.35	7.88	0.3	1.45e-14	Obesity-related traits;
BRCA	cis	rs1829883	0.835	rs2682139	chr5:98909924	G/A	cg08333243	chr5:99726346	NA	0.36	8.48	0.32	1.62e-16	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6426558	0.514	rs3754418	chr1:227348473	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.47	-9.36	-0.35	1.31e-19	Neutrophil percentage of white cells;
BRCA	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg22764044	chr5:178986830	RUFY1	0.4	10.29	0.38	4.36e-23	Lung cancer;
BRCA	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg07148914	chr20:33460835	GGT7	0.46	9.76	0.36	4.67e-21	Height;
BRCA	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg23939001	chr4:940644	TMEM175	0.42	10.2	0.37	9.94e-23	Sjögren's syndrome;
BRCA	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs1577917	0.876	rs11752223	chr6:86573394	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.43	-0.41	1.14e-27	Response to antipsychotic treatment;
BRCA	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-10.5	-0.38	6.5e-24	Mean corpuscular volume;
BRCA	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg24324837	chr19:49891574	CCDC155	0.45	7.88	0.3	1.39e-14	Multiple sclerosis;
BRCA	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.12	0.31	2.36e-15	Breast cancer;
BRCA	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg03709012	chr19:19516395	GATAD2A	0.8	18.61	0.59	4.56e-62	Tonsillectomy;
BRCA	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg21856205	chr7:94953877	PON1	-0.38	-8.24	-0.31	1e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs312273	0.806	rs2289522	chr12:41330531	T/C	cg17827154	chr12:41323612	CNTN1	-0.43	-11.11	-0.4	2.47e-26	Bipolar disorder;
BRCA	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg06627628	chr2:24431161	ITSN2	-0.51	-8.28	-0.31	7.01e-16	Lymphocyte counts;
BRCA	cis	rs4766646	0.619	rs7304559	chr12:110289501	T/G	cg01252219	chr12:110302105	GLTP	0.36	7.88	0.3	1.46e-14	Metabolite levels (MHPG);
BRCA	cis	rs10463316	0.894	rs10062856	chr5:150768196	C/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.33	-0.31	4.96e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg26597838	chr10:835615	NA	1.01	18.07	0.58	2.9e-59	Eosinophil percentage of granulocytes;
BRCA	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg15485101	chr11:133734466	NA	0.4	9.66	0.36	1.07e-20	Childhood ear infection;
BRCA	cis	rs7408868	0.706	rs7257550	chr19:15292088	C/G	cg14696996	chr19:15285081	NOTCH3	0.79	12.36	0.44	1.34e-31	Pulse pressure;
BRCA	trans	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg15704280	chr7:45808275	SEPT13	0.52	7.86	0.3	1.62e-14	Axial length;
BRCA	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	7e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg00383909	chr3:49044727	WDR6	0.59	11.1	0.4	2.77e-26	Cognitive ability (multi-trait analysis);
BRCA	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg20290983	chr6:43655470	MRPS18A	1.1	41.39	0.85	5.5e-183	IgG glycosylation;
BRCA	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.01	22.16	0.66	3.76e-81	Gut microbiome composition (summer);
BRCA	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg05863683	chr7:1912471	MAD1L1	0.36	8.35	0.31	4.35e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg24692254	chr21:30365293	RNF160	-0.47	-8.12	-0.31	2.39e-15	Cognitive test performance;
BRCA	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08280861	chr8:58055591	NA	0.54	8.78	0.33	1.45e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg06108461	chr20:60628389	TAF4	-0.79	-17.05	-0.56	5.51e-54	Body mass index;
BRCA	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	5.1e-16	Tonsillectomy;
BRCA	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg02016764	chr4:38805732	TLR1	-0.6	-9.25	-0.34	3.2e-19	Breast cancer;
BRCA	cis	rs12618769	0.625	rs76362434	chr2:99118005	C/T	cg10123293	chr2:99228465	UNC50	0.45	8.66	0.32	3.95e-17	Bipolar disorder;
BRCA	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs2018683	1.000	rs160837	chr7:29012732	C/G	cg19402173	chr7:128379420	CALU	-0.59	-14.84	-0.51	5.09e-43	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.07e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs36051895	0.658	rs10815145	chr9:5013309	G/A	cg02405213	chr9:5042618	JAK2	-0.46	-8.54	-0.32	9.74e-17	Pediatric autoimmune diseases;
BRCA	trans	rs2840044	1.000	rs225243	chr17:33947212	A/G	cg19694781	chr19:47549865	TMEM160	-0.45	-10.54	-0.38	4.69e-24	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg26384229	chr12:38710491	ALG10B	0.75	17.26	0.56	4.56e-55	Bladder cancer;
BRCA	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	11.16	0.4	1.46e-26	IgG glycosylation;
BRCA	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08280861	chr8:58055591	NA	0.53	8.46	0.32	1.87e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6763687	0.765	rs11923349	chr3:171771749	T/C	cg16233210	chr3:171778391	FNDC3B	0.37	7.92	0.3	1.07e-14	Red cell distribution width;
BRCA	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-11.0	-0.4	6.63e-26	Gut microbiome composition (summer);
BRCA	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg03709012	chr19:19516395	GATAD2A	0.91	17.64	0.57	4.93e-57	Nonalcoholic fatty liver disease;
BRCA	cis	rs7766436	0.648	rs3734214	chr6:22571414	C/G	cg13666174	chr6:22585274	NA	-0.39	-10.0	-0.37	5.5e-22	Coronary artery disease;
BRCA	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg17420585	chr12:42539391	GXYLT1	-0.49	-10.62	-0.39	2.28e-24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs524281	0.861	rs10896087	chr11:65924549	A/G	cg16950941	chr11:66035639	RAB1B	-0.37	-7.84	-0.3	1.91e-14	Electroencephalogram traits;
BRCA	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.72	-0.33	2.37e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs250677	0.522	rs1432801	chr5:148390979	T/C	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.45	-0.32	2e-16	Breast cancer;
BRCA	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg10523679	chr1:76189770	ACADM	0.7	12.72	0.45	3.51e-33	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs752010	0.806	rs943375	chr1:42092152	A/G	cg06885757	chr1:42089581	HIVEP3	0.28	10.23	0.38	7.7e-23	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg08999081	chr20:33150536	PIGU	0.46	12.85	0.45	8.96e-34	Coronary artery disease;
BRCA	trans	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg17675199	chr6:35436792	RPL10A	-0.3	-8.14	-0.31	2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg20283391	chr11:68216788	NA	-0.47	-9.17	-0.34	6.26e-19	Total body bone mineral density;
BRCA	cis	rs495337	1.000	rs2281216	chr20:48568503	C/T	cg17835207	chr20:48524531	SPATA2	-0.64	-15.09	-0.51	3.27e-44	Psoriasis;
BRCA	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.72e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7264396	0.836	rs6120995	chr20:34185726	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-11.81	-0.42	3e-29	Total cholesterol levels;
BRCA	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg23711669	chr6:146136114	FBXO30	-0.72	-17.11	-0.56	2.7e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs58235267	0.656	rs13410889	chr2:63087778	T/C	cg17519650	chr2:63277830	OTX1	0.42	9.13	0.34	8.74e-19	Prostate-specific antigen levels (conditioned on lead SNPs);
BRCA	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg12463550	chr7:65579703	CRCP	0.38	8.11	0.31	2.58e-15	Aortic root size;
BRCA	trans	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg25214090	chr10:38739885	LOC399744	0.46	10.36	0.38	2.3e-23	Corneal astigmatism;
BRCA	cis	rs35740288	0.539	rs4843101	chr15:86339661	G/T	cg20737812	chr15:86336631	KLHL25	-0.39	-8.5	-0.32	1.31e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg07636037	chr3:49044803	WDR6	0.97	29.41	0.76	6.97e-121	Parkinson's disease;
BRCA	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	14.55	0.5	1.22e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.69	-0.36	8.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.37	-9.61	-0.36	1.58e-20	Bone mineral density;
BRCA	cis	rs7246657	0.507	rs8107654	chr19:37453534	C/T	cg18154014	chr19:37997991	ZNF793	0.51	7.89	0.3	1.29e-14	Coronary artery calcification;
BRCA	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg04450456	chr4:17643702	FAM184B	0.37	11.13	0.4	2.09e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg07080220	chr10:102295463	HIF1AN	0.6	13.13	0.46	4.71e-35	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7809950	1.000	rs10267907	chr7:107184466	C/T	cg23024343	chr7:107201750	COG5	-0.41	-9.24	-0.34	3.62e-19	Coronary artery disease;
BRCA	cis	rs7246967	0.673	rs3853650	chr19:22880490	A/G	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs7246657	0.722	rs2909105	chr19:38167906	A/G	cg23950597	chr19:37808831	NA	0.5	8.57	0.32	7.91e-17	Coronary artery calcification;
BRCA	cis	rs10504073	0.669	rs55948643	chr8:50026403	C/G	cg00325661	chr8:49890786	NA	0.38	11.22	0.41	8.47e-27	Blood metabolite ratios;
BRCA	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.06	0.3	3.74e-15	Tonsillectomy;
BRCA	cis	rs28374715	0.662	rs72737786	chr15:41500361	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.83	-17.39	-0.57	9.52e-56	Ulcerative colitis;
BRCA	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg11764359	chr7:65958608	NA	0.65	11.14	0.4	1.9e-26	Aortic root size;
BRCA	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg13906792	chr15:75199810	C15orf17	0.35	8.1	0.31	2.74e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
BRCA	trans	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg15556689	chr8:8085844	FLJ10661	0.29	7.9	0.3	1.23e-14	Retinal vascular caliber;
BRCA	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-9.75	-0.36	5.06e-21	Tonsillectomy;
BRCA	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg06064525	chr11:970664	AP2A2	-0.48	-16.27	-0.54	4.72e-50	Alzheimer's disease (late onset);
BRCA	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.85	18.41	0.59	5.11e-61	IgG glycosylation;
BRCA	cis	rs220324	0.688	rs9975464	chr21:43560055	T/C	cg09727148	chr21:43560719	UMODL1	0.5	8.88	0.33	6.65e-18	Idiopathic osteonecrosis of the femoral head;
BRCA	cis	rs6580649	0.783	rs1635526	chr12:48396785	C/T	cg05342945	chr12:48394962	COL2A1	-0.49	-9.73	-0.36	5.98e-21	Lung cancer;
BRCA	cis	rs9649465	0.967	rs10269196	chr7:123321073	G/T	cg04330084	chr7:123175371	IQUB	-0.32	-8.77	-0.33	1.55e-17	Migraine;
BRCA	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg08493051	chr2:3487164	NA	-0.43	-9.22	-0.34	4.1e-19	Neurofibrillary tangles;
BRCA	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg24110177	chr3:50126178	RBM5	0.39	10.35	0.38	2.63e-23	Menarche (age at onset);
BRCA	cis	rs4363385	0.791	rs512198	chr1:153006245	C/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.29	-0.31	6.75e-16	Inflammatory skin disease;
BRCA	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg11062466	chr8:58055876	NA	0.41	7.84	0.3	1.84e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs7172677	0.737	rs7178625	chr15:75441017	A/G	cg14664628	chr15:75095509	CSK	-0.39	-8.05	-0.3	4.04e-15	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs2354432	0.607	rs12402309	chr1:146721983	T/A	cg25205988	chr1:146714368	CHD1L	-0.95	-13.57	-0.47	4.88e-37	Mitochondrial DNA levels;
BRCA	cis	rs7851660	0.967	rs3021526	chr9:100617021	C/T	cg13688889	chr9:100608707	NA	-0.36	-8.7	-0.33	2.78e-17	Strep throat;
BRCA	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg07636037	chr3:49044803	WDR6	-0.77	-15.44	-0.52	5.92e-46	Menarche (age at onset);
BRCA	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg08822215	chr16:89438651	ANKRD11	-0.38	-7.99	-0.3	6.42e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs17209837	0.607	rs17149644	chr7:87086218	T/C	cg00919237	chr7:87102261	ABCB4	-0.53	-10.24	-0.38	6.86e-23	Gallbladder cancer;
BRCA	cis	rs870825	0.616	rs57271221	chr4:185627198	C/T	cg20176042	chr4:185552304	CASP3	-0.53	-8.12	-0.31	2.38e-15	Blood protein levels;
BRCA	cis	rs7903847	0.620	rs61863815	chr10:99124389	A/G	cg08345082	chr10:99160200	RRP12	-0.28	-8.05	-0.3	4.06e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7408868	1.000	rs2074617	chr19:15276055	C/G	cg14696996	chr19:15285081	NOTCH3	0.98	14.37	0.49	8.85e-41	Pulse pressure;
BRCA	cis	rs10465746	0.780	rs7550413	chr1:84423891	T/A	cg10977910	chr1:84465055	TTLL7	0.58	12.03	0.43	3.39e-30	Obesity-related traits;
BRCA	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02176678	chr2:219576539	TTLL4	-0.51	-13.19	-0.46	2.56e-35	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg06521331	chr12:34319734	NA	-0.52	-9.3	-0.35	2.25e-19	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-8.49	-0.32	1.4e-16	Menarche (age at onset);
BRCA	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg22920501	chr2:26401640	FAM59B	0.76	10.54	0.38	4.83e-24	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11764359	chr7:65958608	NA	-0.75	-16.67	-0.55	4.5e-52	Aortic root size;
BRCA	cis	rs888194	0.686	rs11067376	chr12:110027795	A/G	cg05360138	chr12:110035743	NA	0.39	8.52	0.32	1.18e-16	Neuroticism;
BRCA	cis	rs11229555	0.609	rs4598685	chr11:58216864	A/G	cg15696309	chr11:58395628	NA	-0.45	-9.6	-0.35	1.79e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11229555	0.645	rs12794534	chr11:58179568	C/A	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6430585	0.527	rs62168830	chr2:136443900	A/T	cg07169764	chr2:136633963	MCM6	1.0	19.4	0.61	2.78e-66	Corneal structure;
BRCA	trans	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-7.81	-0.3	2.3e-14	Menarche (age at onset);
BRCA	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg04944784	chr2:26401820	FAM59B	-0.84	-13.2	-0.46	2.48e-35	Gut microbiome composition (summer);
BRCA	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	8.11	0.31	2.64e-15	Breast cancer;
BRCA	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.95	0.51	1.56e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12826209	chr6:26865740	GUSBL1	0.58	10.3	0.38	3.88e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.13	0.49	1.22e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.59	11.79	0.42	3.65e-29	Height;
BRCA	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.46	8.75	0.33	1.96e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2712381	0.797	rs62270806	chr3:128376269	C/T	cg16766828	chr3:128327626	NA	-0.43	-9.6	-0.36	1.71e-20	Monocyte count;
BRCA	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg04450456	chr4:17643702	FAM184B	0.38	11.44	0.41	1.06e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs312273	0.693	rs7314287	chr12:41334075	G/A	cg17827154	chr12:41323612	CNTN1	-0.39	-10.08	-0.37	2.72e-22	Bipolar disorder;
BRCA	cis	rs7737355	1.000	rs27421	chr5:130743771	C/T	cg06307176	chr5:131281290	NA	-0.45	-8.79	-0.33	1.38e-17	Life satisfaction;
BRCA	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg26769984	chr7:1090371	C7orf50	0.47	8.99	0.34	2.67e-18	Bronchopulmonary dysplasia;
BRCA	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21659725	chr3:3221576	CRBN	-0.49	-10.32	-0.38	3.47e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg00666640	chr1:248458726	OR2T12	0.3	8.39	0.32	3.12e-16	Common traits (Other);
BRCA	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg17143192	chr8:8559678	CLDN23	0.57	11.08	0.4	3.24e-26	Obesity-related traits;
BRCA	cis	rs11229555	0.645	rs34794607	chr11:58188401	A/T	cg15696309	chr11:58395628	NA	-0.52	-10.83	-0.39	3.19e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg04362960	chr10:104952993	NT5C2	0.42	10.14	0.37	1.67e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs701145	0.938	rs701144	chr3:154059576	C/T	cg17054900	chr3:154042577	DHX36	0.67	11.69	0.42	9.13e-29	Coronary artery disease;
BRCA	trans	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg07211511	chr3:129823064	LOC729375	-0.62	-10.85	-0.39	2.79e-25	Blood pressure (smoking interaction);
BRCA	trans	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg26043149	chr18:55253948	FECH	-0.37	-8.17	-0.31	1.71e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.51	8.31	0.31	5.63e-16	Renal function-related traits (BUN);
BRCA	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24308560	chr3:49941425	MST1R	-0.4	-8.6	-0.32	6.12e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg20290983	chr6:43655470	MRPS18A	-1.1	-41.38	-0.85	5.93e-183	IgG glycosylation;
BRCA	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg23711669	chr6:146136114	FBXO30	0.66	15.36	0.52	1.47e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4478858	0.735	rs10914344	chr1:31769025	T/C	cg00250761	chr1:31883323	NA	-0.31	-8.01	-0.3	5.55e-15	Alcohol dependence;
BRCA	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.23	0.31	1.03e-15	Cognitive ability;
BRCA	trans	rs17685	0.753	rs869804	chr7:75688954	A/G	cg19862616	chr7:65841803	NCRNA00174	0.84	27.55	0.74	9.65e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg12292205	chr6:26970375	C6orf41	-0.56	-12.3	-0.44	2.35e-31	Schizophrenia;
BRCA	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.05	-0.34	1.65e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2404602	0.684	rs3910756	chr15:76945369	C/T	cg23625390	chr15:77176239	SCAPER	-0.53	-12.01	-0.43	4.07e-30	Blood metabolite levels;
BRCA	cis	rs2637266	0.967	rs12246605	chr10:78352994	G/A	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	trans	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.38	0.49	8.24e-41	Exhaled nitric oxide output;
BRCA	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-12.6	-0.45	1.13e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg23950597	chr19:37808831	NA	-0.62	-11.37	-0.41	2.02e-27	Coronary artery calcification;
BRCA	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg11301795	chr4:187892539	NA	-0.26	-8.71	-0.33	2.57e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg23649088	chr2:200775458	C2orf69	0.7	15.4	0.52	9.44e-46	Osteoporosis;
BRCA	trans	rs1493916	0.748	rs34501189	chr18:31314196	A/G	cg15819921	chr19:927150	ARID3A	-0.42	-8.03	-0.3	4.63e-15	Life satisfaction;
BRCA	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.77	16.29	0.54	3.91e-50	Smoking behavior;
BRCA	cis	rs2652822	0.525	rs2899691	chr15:63519088	T/A	cg02713581	chr15:63449717	RPS27L	0.4	7.83	0.3	2.02e-14	Metabolic traits;
BRCA	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.89	-0.33	6.32e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6546550	0.935	rs2305523	chr2:70039677	G/T	cg02498382	chr2:70120550	SNRNP27	0.48	10.22	0.37	8.06e-23	Prevalent atrial fibrillation;
BRCA	cis	rs7586879	0.828	rs13428789	chr2:25087643	C/T	cg04586622	chr2:25135609	ADCY3	0.37	9.05	0.34	1.64e-18	Body mass index;
BRCA	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.27	0.31	7.73e-16	Aortic root size;
BRCA	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.43	-8.82	-0.33	1.09e-17	Response to bleomycin (chromatid breaks);
BRCA	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg05340658	chr4:99064831	C4orf37	0.63	15.15	0.51	1.51e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg18132916	chr6:79620363	NA	0.45	10.59	0.39	2.96e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-11.17	-0.4	1.37e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg02734326	chr4:10020555	SLC2A9	0.4	8.86	0.33	8.2e-18	Bone mineral density;
BRCA	cis	rs1577917	0.883	rs2660575	chr6:86684995	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.34	-9.03	-0.34	2.06e-18	Response to antipsychotic treatment;
BRCA	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg07169764	chr2:136633963	MCM6	1.27	26.4	0.72	2.13e-104	Corneal structure;
BRCA	trans	rs877282	0.735	rs111609055	chr10:826539	A/G	cg22713356	chr15:30763199	NA	0.87	14.23	0.49	4e-40	Uric acid levels;
BRCA	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.77	-0.5	1.05e-42	Total cholesterol levels;
BRCA	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	10.41	0.38	1.57e-23	Height;
BRCA	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg15485101	chr11:133734466	NA	0.4	9.46	0.35	5.7e-20	Childhood ear infection;
BRCA	cis	rs7586879	0.828	rs1077641	chr2:25123665	G/A	cg04586622	chr2:25135609	ADCY3	0.4	9.55	0.35	2.77e-20	Body mass index;
BRCA	cis	rs752010	1.000	rs6664724	chr1:42093821	G/A	cg06885757	chr1:42089581	HIVEP3	0.27	9.65	0.36	1.17e-20	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs2658782	0.789	rs3020057	chr11:93118515	C/T	cg15737290	chr11:93063684	CCDC67	0.47	9.6	0.35	1.8e-20	Pulmonary function decline;
BRCA	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	12.24	0.44	4.41e-31	Lung cancer in ever smokers;
BRCA	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.27	0.38	5.13e-23	Bladder cancer;
BRCA	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.05	0.37	3.52e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg01206211	chr2:36825736	FEZ2	-0.44	-10.58	-0.39	3.14e-24	Height;
BRCA	cis	rs6558530	0.897	rs7838456	chr8:1707591	T/G	cg19131313	chr8:1704013	NA	-0.37	-8.02	-0.3	5.08e-15	Systolic blood pressure;
BRCA	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg11814155	chr7:99998594	ZCWPW1	0.59	10.07	0.37	3.03e-22	Platelet count;
BRCA	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg13880726	chr7:1868755	MAD1L1	0.38	7.84	0.3	1.88e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg07138768	chr7:917805	C7orf20	0.31	8.99	0.34	2.73e-18	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-8.52	-0.32	1.1e-16	Schizophrenia;
BRCA	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg08975724	chr8:8085496	FLJ10661	0.43	8.0	0.3	5.84e-15	Retinal vascular caliber;
BRCA	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg04455712	chr21:45112962	RRP1B	0.42	11.07	0.4	3.5e-26	Mean corpuscular volume;
BRCA	cis	rs17253792	0.822	rs75509578	chr14:56133493	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-10.09	-0.37	2.66e-22	Putamen volume;
BRCA	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.32	0.66	4.72e-82	Chronic sinus infection;
BRCA	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	4.01e-15	Alzheimer's disease (late onset);
BRCA	cis	rs62229266	0.771	rs11701590	chr21:37384730	A/C	cg12218747	chr21:37451666	NA	-0.34	-8.11	-0.31	2.57e-15	Mitral valve prolapse;
BRCA	cis	rs2953145	0.568	rs1133352	chr2:241522252	A/G	cg07929629	chr2:241523174	NA	-0.53	-11.8	-0.42	3.21e-29	Bipolar disorder;
BRCA	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg13628971	chr7:2884303	GNA12	0.47	9.21	0.34	4.6e-19	Height;
BRCA	cis	rs7246967	0.673	rs57027767	chr19:22876535	A/G	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs7927771	0.524	rs10742824	chr11:47864842	C/T	cg20307385	chr11:47447363	PSMC3	0.42	9.49	0.35	4.65e-20	Subjective well-being;
BRCA	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg11266682	chr4:10021025	SLC2A9	0.49	13.11	0.46	5.99e-35	Bone mineral density;
BRCA	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg06917634	chr15:78832804	PSMA4	-0.55	-11.98	-0.43	5.61e-30	Sudden cardiac arrest;
BRCA	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18876405	chr7:65276391	NA	-0.62	-15.48	-0.52	3.8e-46	Aortic root size;
BRCA	cis	rs2281845	0.507	rs942703	chr1:201092979	A/G	cg06714761	chr1:201096289	NA	-0.54	-13.98	-0.48	5.85e-39	Permanent tooth development;
BRCA	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	14.16	0.49	8.35e-40	Mean corpuscular hemoglobin;
BRCA	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg05535760	chr7:792225	HEATR2	-0.73	-11.61	-0.42	2.11e-28	Cerebrospinal P-tau181p levels;
BRCA	cis	rs600806	0.778	rs518697	chr1:110014778	G/A	cg20591472	chr1:110008990	SYPL2	0.31	7.9	0.3	1.25e-14	Intelligence (multi-trait analysis);
BRCA	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg27147174	chr7:100797783	AP1S1	-0.54	-10.72	-0.39	8.93e-25	Life satisfaction;
BRCA	cis	rs72772090	0.908	rs6864233	chr5:96044681	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.45	10.63	0.39	2.09e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg17971929	chr21:40555470	PSMG1	0.6	9.69	0.36	7.98e-21	Cognitive function;
BRCA	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg21782813	chr7:2030301	MAD1L1	0.41	10.83	0.39	3.14e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-9.97	-0.37	7.59e-22	Aortic root size;
BRCA	cis	rs2425143	1.000	rs6060643	chr20:34449851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.54	-0.32	9.92e-17	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.79	0.39	4.76e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg21045802	chr8:109455806	TTC35	0.39	8.63	0.32	4.97e-17	Dupuytren's disease;
BRCA	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg11764359	chr7:65958608	NA	-0.68	-15.19	-0.52	9.94e-45	Aortic root size;
BRCA	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg12379764	chr21:47803548	PCNT	-0.37	-7.86	-0.3	1.61e-14	Testicular germ cell tumor;
BRCA	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg07148914	chr20:33460835	GGT7	-0.43	-9.17	-0.34	6.56e-19	Height;
BRCA	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	13.93	0.48	1.01e-38	Total cholesterol levels;
BRCA	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg19622623	chr12:86230825	RASSF9	-0.34	-9.6	-0.36	1.79e-20	Major depressive disorder;
BRCA	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	13.86	0.48	2.19e-38	Colorectal cancer;
BRCA	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg16414030	chr3:133502952	NA	-0.49	-11.29	-0.41	4.33e-27	Iron status biomarkers;
BRCA	cis	rs9290065	0.519	rs6770180	chr3:160703786	C/T	cg03342759	chr3:160939853	NMD3	-0.49	-9.95	-0.37	9.17e-22	Kawasaki disease;
BRCA	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-11.12	-0.4	2.2e-26	Schizophrenia;
BRCA	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg19156104	chr2:198669113	PLCL1	-0.44	-8.18	-0.31	1.58e-15	Ulcerative colitis;
BRCA	cis	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.44	7.87	0.3	1.52e-14	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.33	-7.82	-0.3	2.22e-14	Electroencephalogram traits;
BRCA	cis	rs7903847	0.642	rs12258560	chr10:99137048	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.62	-0.32	5.45e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs870825	0.616	rs41278579	chr4:185622402	A/G	cg20176042	chr4:185552304	CASP3	-0.53	-8.12	-0.31	2.38e-15	Blood protein levels;
BRCA	cis	rs965469	0.724	rs2007022	chr20:3237674	C/A	cg25506879	chr20:3388711	C20orf194	-0.43	-8.68	-0.32	3.38e-17	IFN-related cytopenia;
BRCA	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg11833968	chr6:79620685	NA	-0.39	-8.71	-0.33	2.58e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7903847	0.620	rs954149	chr10:99122936	G/A	cg20016023	chr10:99160130	RRP12	-0.26	-8.34	-0.31	4.62e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs12541635	0.966	rs62525736	chr8:107000638	G/C	cg10147462	chr8:107024639	NA	0.38	9.89	0.36	1.54e-21	Age of smoking initiation;
BRCA	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.43e-36	High light scatter reticulocyte count;
BRCA	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg22974920	chr21:40686053	BRWD1	-0.38	-8.7	-0.33	2.86e-17	Cognitive function;
BRCA	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg21573476	chr21:45109991	RRP1B	-0.44	-10.68	-0.39	1.26e-24	Mean corpuscular volume;
BRCA	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg08392591	chr16:89556376	ANKRD11	0.46	11.12	0.4	2.19e-26	Multiple myeloma (IgH translocation);
BRCA	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.5	7.94	0.3	9.05e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg16325326	chr1:53192061	ZYG11B	-0.56	-11.5	-0.41	5.71e-28	Monocyte count;
BRCA	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg24558204	chr6:135376177	HBS1L	0.49	13.6	0.47	3.69e-37	Red blood cell count;
BRCA	cis	rs4478858	0.647	rs11577679	chr1:31726185	T/C	cg00250761	chr1:31883323	NA	-0.32	-8.29	-0.31	6.93e-16	Alcohol dependence;
BRCA	cis	rs4363385	0.747	rs1055935	chr1:152975941	C/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.07	-0.34	1.48e-18	Inflammatory skin disease;
BRCA	cis	rs36051895	0.623	rs76960049	chr9:5064548	G/A	cg02405213	chr9:5042618	JAK2	-0.52	-10.0	-0.37	5.78e-22	Pediatric autoimmune diseases;
BRCA	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg26384229	chr12:38710491	ALG10B	0.77	17.45	0.57	4.59e-56	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	12.39	0.44	9.29e-32	Mean platelet volume;
BRCA	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.61	-12.75	-0.45	2.45e-33	Lymphocyte counts;
BRCA	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-8.91	-0.33	5.12e-18	Total body bone mineral density;
BRCA	cis	rs10489202	0.608	rs35059151	chr1:168079393	C/A	cg24449463	chr1:168025552	DCAF6	-0.46	-15.12	-0.51	2.29e-44	Schizophrenia;
BRCA	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg21573476	chr21:45109991	RRP1B	-0.41	-11.19	-0.4	1.11e-26	Mean corpuscular volume;
BRCA	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14169450	chr9:139327907	INPP5E	-0.41	-9.78	-0.36	3.91e-21	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg24642439	chr20:33292090	TP53INP2	0.51	11.35	0.41	2.44e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg26874164	chr19:58962979	ZNF324B	0.44	9.39	0.35	1.03e-19	Uric acid clearance;
BRCA	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg17063962	chr7:91808500	NA	0.52	12.44	0.44	5.66e-32	Breast cancer;
BRCA	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg08738300	chr3:44038990	NA	0.44	8.6	0.32	6.11e-17	Coronary artery disease;
BRCA	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.49	0.47	1.16e-36	Colorectal cancer;
BRCA	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-9.31	-0.35	1.95e-19	Tonsillectomy;
BRCA	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg24209194	chr3:40518798	ZNF619	-0.4	-8.3	-0.31	6.37e-16	Renal cell carcinoma;
BRCA	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07080220	chr10:102295463	HIF1AN	0.5	11.39	0.41	1.76e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg24829409	chr8:58192753	C8orf71	-0.44	-8.82	-0.33	1.05e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg00701064	chr4:6280414	WFS1	0.67	17.2	0.56	8.78e-55	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg07541023	chr7:19748670	TWISTNB	0.64	10.52	0.38	5.59e-24	Thyroid stimulating hormone;
BRCA	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg23231163	chr10:75533350	FUT11	-0.34	-8.83	-0.33	9.85e-18	Inflammatory bowel disease;
BRCA	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg26898376	chr11:64110657	CCDC88B	0.36	7.84	0.3	1.95e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg23055938	chr1:160991191	F11R	-0.55	-10.77	-0.39	5.5e-25	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg11764359	chr7:65958608	NA	-0.66	-12.07	-0.43	2.28e-30	Aortic root size;
BRCA	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg21475434	chr5:93447410	FAM172A	0.67	8.97	0.33	3.29e-18	Diabetic retinopathy;
BRCA	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.8	0.36	3.22e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs708547	0.581	rs6554400	chr4:57805306	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.33	-8.32	-0.31	5.22e-16	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg22467129	chr15:76604101	ETFA	0.55	12.74	0.45	2.77e-33	Blood metabolite levels;
BRCA	cis	rs3125734	0.660	rs10733769	chr10:63974255	G/T	cg09941381	chr10:64027924	RTKN2	-0.29	-8.66	-0.32	3.7e-17	Rheumatoid arthritis;
BRCA	cis	rs2066819	1.000	rs77447765	chr12:56690662	G/A	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg25358565	chr5:93447407	FAM172A	1.2	19.89	0.62	7.04e-69	Diabetic retinopathy;
BRCA	trans	rs6479891	1.000	rs10733790	chr10:65100334	G/C	cg14819942	chr15:35414228	NA	-0.34	-8.48	-0.32	1.54e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg11822812	chr5:140052017	DND1	-0.3	-8.28	-0.31	7.41e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg10818794	chr15:86012489	AKAP13	-0.31	-8.68	-0.32	3.36e-17	Coronary artery disease;
BRCA	cis	rs1564271	0.506	rs1148163	chr10:26929671	G/C	cg13837822	chr10:26931731	LOC731789	0.38	8.51	0.32	1.28e-16	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
BRCA	cis	rs2617583	0.679	rs2652511	chr5:1446389	A/G	cg07151155	chr5:1473589	LPCAT1	-0.37	-8.07	-0.3	3.41e-15	Breast cancer;
BRCA	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg03929089	chr4:120376271	NA	-0.77	-17.75	-0.57	1.39e-57	Coronary artery disease;
BRCA	cis	rs11229555	0.645	rs11560908	chr11:58434545	A/C	cg15696309	chr11:58395628	NA	0.5	9.76	0.36	4.72e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7178424	0.711	rs4283171	chr15:62172384	G/T	cg00456672	chr15:62358751	C2CD4A	-0.36	-8.67	-0.32	3.69e-17	Height;
BRCA	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg24060327	chr5:131705240	SLC22A5	-0.59	-10.81	-0.39	4.01e-25	Blood metabolite levels;
BRCA	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18404041	chr3:52824283	ITIH1	-0.37	-11.31	-0.41	3.51e-27	Electroencephalogram traits;
BRCA	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.48	0.35	4.95e-20	Lung cancer in ever smokers;
BRCA	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg08601574	chr20:25228251	PYGB	0.39	9.45	0.35	6.06e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg21775007	chr8:11205619	TDH	0.45	8.79	0.33	1.35e-17	Retinal vascular caliber;
BRCA	trans	rs2018683	0.624	rs2286219	chr7:28998663	G/A	cg19402173	chr7:128379420	CALU	-0.49	-11.82	-0.42	2.84e-29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg26384229	chr12:38710491	ALG10B	0.74	17.23	0.56	6.19e-55	Bladder cancer;
BRCA	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08219700	chr8:58056026	NA	0.48	8.48	0.32	1.56e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.05	-18.99	-0.6	4.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg09163369	chr1:210001066	C1orf107	0.64	12.36	0.44	1.33e-31	Orofacial clefts;
BRCA	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg05457628	chr5:178986728	RUFY1	0.5	11.84	0.42	2.19e-29	Lung cancer;
BRCA	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07636037	chr3:49044803	WDR6	0.76	16.53	0.55	2.38e-51	Childhood ear infection;
BRCA	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.19	0.4	1.17e-26	Bipolar disorder;
BRCA	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg17366294	chr4:99064904	C4orf37	0.52	11.56	0.42	3.32e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-17.81	-0.58	6.55e-58	Chronic sinus infection;
BRCA	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg15704280	chr7:45808275	SEPT13	-0.47	-9.12	-0.34	9.76e-19	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg06212747	chr3:49208901	KLHDC8B	0.48	9.85	0.36	2.05e-21	Parkinson's disease;
BRCA	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg02493740	chr2:85810744	VAMP5	-0.39	-8.18	-0.31	1.58e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg08999081	chr20:33150536	PIGU	0.43	12.36	0.44	1.3e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs9503598	0.636	rs6596978	chr6:3468878	C/T	cg00476032	chr6:3446245	SLC22A23	0.37	9.09	0.34	1.26e-18	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg25036284	chr2:26402008	FAM59B	-0.64	-10.61	-0.39	2.57e-24	Gut microbiome composition (summer);
BRCA	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg11262906	chr1:85462892	MCOLN2	-0.49	-9.33	-0.35	1.78e-19	Serum sulfate level;
BRCA	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg16230307	chr14:35515116	FAM177A1	0.74	15.49	0.52	3.31e-46	Psoriasis;
BRCA	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs9811920	0.555	rs68092024	chr3:99691522	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.57	-13.21	-0.46	2.15e-35	Axial length;
BRCA	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg11887960	chr12:57824829	NA	0.5	8.33	0.31	5e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.45	0.35	6.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs977987	0.806	rs2285225	chr16:75429252	T/C	cg03315344	chr16:75512273	CHST6	0.53	12.42	0.44	7.36e-32	Dupuytren's disease;
BRCA	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg08847533	chr14:75593920	NEK9	-0.95	-24.92	-0.7	2.86e-96	Height;
BRCA	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg04450456	chr4:17643702	FAM184B	-0.38	-10.5	-0.38	6.72e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9462846	1.000	rs2092555	chr6:42863842	C/G	cg02353165	chr6:42928485	GNMT	0.42	7.83	0.3	2.09e-14	Blood protein levels;
BRCA	cis	rs3774749	0.565	rs2624839	chr3:50202231	T/C	cg14019146	chr3:50243930	SLC38A3	-0.43	-10.57	-0.39	3.44e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg22676075	chr6:135203613	NA	0.44	8.74	0.33	2.02e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg09526685	chr4:187126073	CYP4V2	0.7	9.47	0.35	5.21e-20	Blood protein levels;
BRCA	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg12311346	chr5:56204834	C5orf35	-0.62	-13.08	-0.46	7.94e-35	Initial pursuit acceleration;
BRCA	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.44	-9.24	-0.34	3.72e-19	Extrinsic epigenetic age acceleration;
BRCA	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg15704280	chr7:45808275	SEPT13	-0.7	-14.47	-0.5	3.13e-41	Coronary artery disease;
BRCA	cis	rs11690935	0.885	rs7602037	chr2:172817794	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.81	-24.64	-0.7	9.32e-95	Schizophrenia;
BRCA	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05535760	chr7:792225	HEATR2	0.85	14.55	0.5	1.24e-41	Cerebrospinal P-tau181p levels;
BRCA	trans	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg23533926	chr12:111358616	MYL2	0.41	8.11	0.31	2.58e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.3	8.15	0.31	1.85e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1003719	0.715	rs2835639	chr21:38537016	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.48	-0.5	2.67e-41	Eye color traits;
BRCA	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg19077165	chr18:44547161	KATNAL2	-0.51	-10.98	-0.4	8.06e-26	Personality dimensions;
BRCA	cis	rs7737355	0.947	rs6890784	chr5:130939540	T/C	cg06307176	chr5:131281290	NA	0.53	10.32	0.38	3.29e-23	Life satisfaction;
BRCA	trans	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	8.83	0.33	1e-17	Mean corpuscular volume;
BRCA	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg27279351	chr12:120934652	DYNLL1	0.56	13.17	0.46	3.14e-35	High light scatter reticulocyte count;
BRCA	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg13385521	chr17:29058706	SUZ12P	0.63	8.57	0.32	7.5e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg13010199	chr12:38710504	ALG10B	0.53	11.42	0.41	1.24e-27	Heart rate;
BRCA	cis	rs6580649	0.831	rs1635528	chr12:48395900	C/T	cg05342945	chr12:48394962	COL2A1	-0.48	-9.6	-0.36	1.76e-20	Lung cancer;
BRCA	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11764359	chr7:65958608	NA	0.75	16.57	0.55	1.37e-51	Aortic root size;
BRCA	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg20129853	chr10:51489980	NA	-0.32	-8.57	-0.32	7.96e-17	Prostate-specific antigen levels;
BRCA	cis	rs4812048	0.602	rs59637156	chr20:57619618	T/C	cg14073986	chr20:57617431	SLMO2	0.8	13.37	0.47	4.19e-36	Mean platelet volume;
BRCA	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg06623918	chr6:96969491	KIAA0776	0.92	27.12	0.73	2.38e-108	Headache;
BRCA	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg26384229	chr12:38710491	ALG10B	0.74	17.25	0.56	4.8e-55	Bladder cancer;
BRCA	cis	rs9359856	0.600	rs17584763	chr6:90502088	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.67	-8.71	-0.33	2.58e-17	Bipolar disorder;
BRCA	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg03560586	chr2:239334908	ASB1	-0.52	-11.65	-0.42	1.46e-28	Multiple system atrophy;
BRCA	cis	rs12618769	0.597	rs1961651	chr2:99049674	G/C	cg10123293	chr2:99228465	UNC50	0.41	8.21	0.31	1.24e-15	Bipolar disorder;
BRCA	cis	rs912057	0.695	rs1294419	chr6:6742549	C/G	cg06612196	chr6:6737390	NA	0.39	8.58	0.32	7.28e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg09307838	chr4:120376055	NA	0.59	12.83	0.45	1.12e-33	Educational attainment;
BRCA	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg26195577	chr20:24973756	C20orf3	1.02	26.77	0.73	1.94e-106	Blood protein levels;
BRCA	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26314531	chr2:26401878	FAM59B	0.96	16.5	0.55	3.12e-51	Gut microbiome composition (summer);
BRCA	trans	rs3857536	0.813	rs2093253	chr6:66937702	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg24060327	chr5:131705240	SLC22A5	-0.63	-11.79	-0.42	3.77e-29	Acylcarnitine levels;
BRCA	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg16850897	chr7:100343110	ZAN	0.35	8.0	0.3	6.03e-15	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs9487051	0.768	rs2483913	chr6:109521042	G/A	cg21918786	chr6:109611834	NA	-0.34	-9.15	-0.34	7.44e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs6580649	1.000	rs7132668	chr12:48405860	C/T	cg24011408	chr12:48396354	COL2A1	0.54	8.98	0.33	3.04e-18	Lung cancer;
BRCA	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg20891558	chr2:74357851	NA	0.54	13.08	0.46	8.03e-35	Gestational age at birth (maternal effect);
BRCA	trans	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	8.73	0.33	2.28e-17	Mean corpuscular volume;
BRCA	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg24101359	chr6:42928495	GNMT	0.55	12.72	0.45	3.2e-33	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs1997103	0.863	rs2140916	chr7:55403154	A/C	cg20935933	chr6:143382018	AIG1	0.6	11.42	0.41	1.32e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs11165623	0.602	rs4619021	chr1:97025910	T/C	cg10631902	chr5:14652156	NA	-0.43	-12.48	-0.44	3.91e-32	Hip circumference;Waist circumference;
BRCA	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg23933602	chr10:16859644	RSU1	0.97	32.04	0.79	4.76e-135	Platelet distribution width;
BRCA	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg06618935	chr21:46677482	NA	-0.37	-8.07	-0.3	3.48e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg00814883	chr7:100076585	TSC22D4	-0.47	-10.6	-0.39	2.63e-24	Platelet count;
BRCA	cis	rs2742234	0.955	rs2503865	chr10:43659536	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.42	-8.98	-0.33	3.12e-18	Hirschsprung disease;
BRCA	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg10523679	chr1:76189770	ACADM	-0.51	-9.97	-0.37	7.61e-22	Daytime sleep phenotypes;
BRCA	cis	rs7809950	0.911	rs1015411	chr7:107135612	C/T	cg23024343	chr7:107201750	COG5	-0.42	-9.7	-0.36	7.52e-21	Coronary artery disease;
BRCA	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg04349561	chr1:21808255	NBPF3	-0.33	-7.84	-0.3	1.96e-14	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg06115741	chr20:33292138	TP53INP2	-0.37	-8.12	-0.31	2.48e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg14683738	chr19:37701593	ZNF585B	0.45	8.03	0.3	4.71e-15	Coronary artery calcification;
BRCA	trans	rs877282	0.945	rs10904555	chr10:787740	C/A	cg22713356	chr15:30763199	NA	1.42	28.54	0.75	3.84e-116	Uric acid levels;
BRCA	cis	rs7617773	0.780	rs35778847	chr3:48346985	G/T	cg11946769	chr3:48343235	NME6	0.68	13.86	0.48	2.24e-38	Coronary artery disease;
BRCA	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.41	11.41	0.41	1.36e-27	Monocyte percentage of white cells;
BRCA	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg01849466	chr14:104193079	ZFYVE21	0.42	10.74	0.39	7.59e-25	Schizophrenia;
BRCA	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg09060608	chr5:178986726	RUFY1	0.62	16.3	0.54	3.22e-50	Lung cancer;
BRCA	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg25457927	chr22:38595422	NA	0.4	15.53	0.52	2.12e-46	Cutaneous nevi;
BRCA	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg13010199	chr12:38710504	ALG10B	0.51	10.01	0.37	5e-22	Morning vs. evening chronotype;
BRCA	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-12.03	-0.43	3.51e-30	Alzheimer's disease;
BRCA	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.35	-0.38	2.53e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9462846	0.959	rs9471954	chr6:42880326	C/A	cg02353165	chr6:42928485	GNMT	0.52	9.42	0.35	8.22e-20	Blood protein levels;
BRCA	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	5.1e-16	Tonsillectomy;
BRCA	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg26587870	chr6:27730563	NA	-0.55	-8.44	-0.32	2.2e-16	Depression;
BRCA	cis	rs877282	0.583	rs12358255	chr10:828626	C/T	cg15764593	chr10:829463	NA	-0.61	-10.28	-0.38	4.79e-23	Uric acid levels;
BRCA	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg11814155	chr7:99998594	ZCWPW1	0.46	8.4	0.32	2.93e-16	Platelet count;
BRCA	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg06766960	chr11:133703094	NA	0.6	12.62	0.45	8.93e-33	Childhood ear infection;
BRCA	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.7	0.39	1.11e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg06784218	chr1:46089804	CCDC17	0.44	10.59	0.39	2.87e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.86	12.59	0.45	1.21e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21659725	chr3:3221576	CRBN	-0.46	-11.62	-0.42	1.82e-28	Intelligence (multi-trait analysis);
BRCA	trans	rs75804782	0.572	rs77008212	chr2:239307113	A/G	cg01134436	chr17:81009848	B3GNTL1	0.74	7.89	0.3	1.29e-14	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg07395648	chr5:131743802	NA	-0.36	-8.86	-0.33	7.68e-18	Blood metabolite levels;
BRCA	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg04025307	chr7:1156635	C7orf50	0.54	13.21	0.46	2.09e-35	Longevity;Endometriosis;
BRCA	cis	rs897984	0.762	rs897986	chr16:30980902	T/C	cg00531865	chr16:30841666	NA	0.39	9.25	0.34	3.21e-19	Dementia with Lewy bodies;
BRCA	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg23649088	chr2:200775458	C2orf69	0.58	8.55	0.32	8.73e-17	Schizophrenia;
BRCA	trans	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg01620082	chr3:125678407	NA	-0.55	-8.01	-0.3	5.41e-15	Depression;
BRCA	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg00686598	chr14:53173677	PSMC6	1.07	15.05	0.51	4.72e-44	Alzheimer's disease (late onset);
BRCA	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg12310025	chr6:25882481	NA	0.56	13.84	0.48	2.64e-38	Blood metabolite levels;
BRCA	cis	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg06521331	chr12:34319734	NA	-0.52	-10.57	-0.39	3.7e-24	Morning vs. evening chronotype;
BRCA	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg03585969	chr10:35415529	CREM	0.56	11.54	0.42	3.91e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg15556689	chr8:8085844	FLJ10661	-0.33	-8.76	-0.33	1.76e-17	Joint mobility (Beighton score);
BRCA	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg25173405	chr17:45401733	C17orf57	-0.56	-12.12	-0.43	1.46e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg24558204	chr6:135376177	HBS1L	0.46	12.66	0.45	6.33e-33	Red blood cell count;
BRCA	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg11247378	chr22:39784982	NA	-0.45	-8.22	-0.31	1.1e-15	IgG glycosylation;
BRCA	trans	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg15704280	chr7:45808275	SEPT13	0.59	8.84	0.33	9.53e-18	Axial length;
BRCA	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-11.74	-0.42	6.1e-29	Morning vs. evening chronotype;
BRCA	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg04978709	chr7:75101039	POM121C	0.34	8.83	0.33	9.66e-18	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	20.35	0.63	2.32e-71	Platelet count;
BRCA	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.39	-0.41	1.68e-27	Electroencephalogram traits;
BRCA	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg17691542	chr6:26056736	HIST1H1C	0.48	9.55	0.35	2.75e-20	Iron status biomarkers;
BRCA	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg13770153	chr20:60521292	NA	-0.45	-10.71	-0.39	9.65e-25	Body mass index;
BRCA	cis	rs9462027	0.540	rs9469867	chr6:34742449	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.89	-0.3	1.33e-14	Systemic lupus erythematosus;
BRCA	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.34	-9.5	-0.35	4.15e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg02734326	chr4:10020555	SLC2A9	-0.35	-7.93	-0.3	9.93e-15	Bone mineral density;
BRCA	cis	rs1882538	0.564	rs12707090	chr7:133115163	G/A	cg10665199	chr7:133106180	EXOC4	0.44	9.09	0.34	1.22e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg03609598	chr5:56110824	MAP3K1	0.48	8.38	0.31	3.48e-16	Initial pursuit acceleration;
BRCA	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.18	0.4	1.24e-26	Bipolar disorder;
BRCA	cis	rs7095944	0.614	rs3824765	chr10:126433570	C/G	cg08799069	chr10:126477246	METTL10	-0.4	-9.49	-0.35	4.41e-20	Asthma;
BRCA	cis	rs2249625	0.844	rs2496502	chr6:72885412	G/A	cg18830697	chr6:72922368	RIMS1	-0.37	-7.86	-0.3	1.63e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs11958404	0.932	rs112993559	chr5:157414712	A/C	cg05962755	chr5:157440814	NA	0.51	9.76	0.36	4.6e-21	IgG glycosylation;
BRCA	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	17.39	0.57	9.21e-56	Electrocardiographic conduction measures;
BRCA	cis	rs2745967	0.740	rs2796253	chr1:208067409	G/A	cg09788693	chr1:208063733	CD34	0.37	7.84	0.3	1.86e-14	Resting heart rate;
BRCA	cis	rs10489202	0.608	rs7556350	chr1:168077797	C/T	cg24449463	chr1:168025552	DCAF6	-0.46	-14.51	-0.5	1.88e-41	Schizophrenia;
BRCA	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg26597838	chr10:835615	NA	1.0	17.52	0.57	1.93e-56	Eosinophil percentage of granulocytes;
BRCA	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg19077165	chr18:44547161	KATNAL2	-0.59	-13.3	-0.47	8.39e-36	Personality dimensions;
BRCA	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12292205	chr6:26970375	C6orf41	-0.49	-8.23	-0.31	1.08e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4074536	0.574	rs10923355	chr1:116291439	T/G	cg21648376	chr1:116311395	CASQ2	-0.49	-8.66	-0.32	3.83e-17	QRS duration;
BRCA	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg16405210	chr4:1374714	KIAA1530	-0.94	-20.9	-0.64	2.54e-74	Longevity;
BRCA	cis	rs13102973	0.666	rs10007311	chr4:135898716	A/T	cg14419869	chr4:135874104	NA	0.46	8.97	0.33	3.14e-18	Subjective well-being;
BRCA	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg06115741	chr20:33292138	TP53INP2	0.5	10.19	0.37	1.07e-22	Coronary artery disease;
BRCA	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg11822812	chr5:140052017	DND1	-0.29	-8.1	-0.31	2.75e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7264396	0.563	rs17093093	chr20:34380925	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-11.02	-0.4	5.55e-26	Total cholesterol levels;
BRCA	cis	rs17270561	0.609	rs9379778	chr6:25687579	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	8.15	0.31	1.98e-15	Iron status biomarkers;
BRCA	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg27478167	chr7:817139	HEATR2	-0.57	-11.58	-0.42	2.69e-28	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7560272	0.723	rs1052161	chr2:73828538	A/G	cg20560298	chr2:73613845	ALMS1	-0.4	-10.95	-0.4	1.05e-25	Schizophrenia;
BRCA	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg09307838	chr4:120376055	NA	0.69	14.02	0.49	3.82e-39	Corneal astigmatism;
BRCA	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg07884673	chr3:53033167	SFMBT1	-0.73	-9.37	-0.35	1.28e-19	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	8.02e-19	Lymphocyte counts;
BRCA	cis	rs870825	0.616	rs56232457	chr4:185628153	T/G	cg04058563	chr4:185651563	MLF1IP	0.79	17.51	0.57	2.37e-56	Blood protein levels;
BRCA	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg20848291	chr7:100343083	ZAN	0.37	8.32	0.31	5.39e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg07080220	chr10:102295463	HIF1AN	-0.44	-9.84	-0.36	2.24e-21	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg25237894	chr2:233734115	C2orf82	0.4	11.58	0.42	2.71e-28	Coronary artery disease;
BRCA	cis	rs11690935	0.877	rs13024846	chr2:172835803	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.9	-28.11	-0.74	8.22e-114	Schizophrenia;
BRCA	cis	rs858239	0.539	rs2103281	chr7:23194231	A/G	cg23682824	chr7:23144976	KLHL7	0.36	9.63	0.36	1.39e-20	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.62	0.32	5.1e-17	Platelet count;
BRCA	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg27129171	chr3:47204927	SETD2	0.77	20.12	0.62	3.85e-70	Colorectal cancer;
BRCA	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg20203395	chr5:56204925	C5orf35	-0.43	-9.66	-0.36	1.04e-20	Initial pursuit acceleration;
BRCA	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg03188948	chr7:1209495	NA	0.83	11.33	0.41	2.93e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg26384229	chr12:38710491	ALG10B	0.76	17.09	0.56	3.13e-54	Bladder cancer;
BRCA	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg12011299	chr4:100065546	ADH4	0.48	10.9	0.4	1.65e-25	Alcohol dependence;
BRCA	cis	rs9815354	0.812	rs17216919	chr3:41888938	G/C	cg03022575	chr3:42003672	ULK4	0.68	9.46	0.35	5.93e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg07148914	chr20:33460835	GGT7	-0.37	-8.09	-0.3	2.95e-15	Height;
BRCA	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg22961513	chr11:14280813	SPON1	0.33	8.47	0.32	1.74e-16	Mitochondrial DNA levels;
BRCA	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.11	0.31	2.54e-15	Tonsillectomy;
BRCA	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg18964960	chr10:1102726	WDR37	0.63	8.67	0.32	3.6e-17	Eosinophil percentage of granulocytes;
BRCA	trans	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.89	-0.3	1.27e-14	Corneal astigmatism;
BRCA	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg19508488	chr2:152266495	RIF1	0.46	9.21	0.34	4.51e-19	Lung cancer;
BRCA	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg23173402	chr1:227635558	NA	-0.45	-8.33	-0.31	4.89e-16	Major depressive disorder;
BRCA	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg17971929	chr21:40555470	PSMG1	-0.47	-10.48	-0.38	8.36e-24	Menarche (age at onset);
BRCA	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg13047869	chr3:10149882	C3orf24	0.57	12.11	0.43	1.57e-30	Alzheimer's disease;
BRCA	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg11663144	chr21:46675770	NA	-0.49	-9.12	-0.34	9.98e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg19077165	chr18:44547161	KATNAL2	-0.4	-8.33	-0.31	4.76e-16	Educational attainment;
BRCA	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg02187348	chr16:89574699	SPG7	0.4	9.27	0.34	2.85e-19	Multiple myeloma (IgH translocation);
BRCA	trans	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg15704280	chr7:45808275	SEPT13	0.6	8.94	0.33	4.02e-18	Axial length;
BRCA	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	19.97	0.62	2.65e-69	Platelet count;
BRCA	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg21143896	chr7:2802374	GNA12	0.34	8.69	0.32	3.13e-17	Height;
BRCA	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg14784868	chr12:69753453	YEATS4	0.67	19.0	0.6	3.82e-64	Blood protein levels;
BRCA	cis	rs10824518	0.744	rs3900539	chr10:79159158	C/G	cg22796248	chr10:79159275	KCNMA1	0.38	7.83	0.3	2.06e-14	Myopia;
BRCA	cis	rs13064411	0.696	rs6787026	chr3:113162117	A/G	cg18753928	chr3:113234510	CCDC52	-0.55	-9.98	-0.37	6.92e-22	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs10504073	0.669	rs57085792	chr8:50018355	T/C	cg00325661	chr8:49890786	NA	0.38	11.26	0.41	5.95e-27	Blood metabolite ratios;
BRCA	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08564027	chr20:61660810	NA	0.87	23.25	0.68	4.03e-87	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg16576597	chr16:28551801	NUPR1	0.35	9.65	0.36	1.17e-20	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs3125734	0.633	rs6479791	chr10:63980341	T/C	cg09941381	chr10:64027924	RTKN2	-0.29	-8.72	-0.33	2.4e-17	Rheumatoid arthritis;
BRCA	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg03929089	chr4:120376271	NA	-0.48	-9.04	-0.34	1.81e-18	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg09654669	chr8:57350985	NA	-0.39	-8.59	-0.32	6.42e-17	Obesity-related traits;
BRCA	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg26384229	chr12:38710491	ALG10B	0.77	17.38	0.57	1.06e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs13095912	0.785	rs6807927	chr3:185324933	A/G	cg11274856	chr3:185301563	NA	-0.52	-12.62	-0.45	9e-33	Systolic blood pressure;
BRCA	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg25173405	chr17:45401733	C17orf57	0.48	10.01	0.37	5.22e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2540552	0.600	rs2540567	chr7:91208344	C/G	cg15143024	chr7:91199642	NA	0.47	11.73	0.42	6.34e-29	IgG glycosylation;
BRCA	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg16586182	chr3:47516702	SCAP	0.55	12.22	0.44	5.26e-31	Colorectal cancer;
BRCA	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.33	0.35	1.64e-19	Tonsillectomy;
BRCA	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.59	-0.39	2.86e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg11366901	chr6:160182831	ACAT2	0.84	16.34	0.54	2e-50	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg17845761	chr1:175162550	KIAA0040	0.26	9.91	0.37	1.19e-21	Alcohol dependence;
BRCA	cis	rs6815814	0.950	rs5743560	chr4:38806200	G/T	cg06935464	chr4:38784597	TLR10	0.51	8.49	0.32	1.46e-16	Breast cancer;
BRCA	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg10253484	chr15:75165896	SCAMP2	0.47	8.53	0.32	1.02e-16	Systemic lupus erythematosus;
BRCA	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg06159980	chr1:16340746	HSPB7	-0.39	-9.03	-0.34	1.95e-18	Systolic blood pressure;
BRCA	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg16482183	chr6:26056742	HIST1H1C	0.46	8.88	0.33	6.81e-18	Iron status biomarkers;
BRCA	cis	rs3772130	1.000	rs11721318	chr3:121429485	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	9.61	0.36	1.57e-20	Cognitive performance;
BRCA	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg06159980	chr1:16340746	HSPB7	-0.38	-8.84	-0.33	9.14e-18	Dilated cardiomyopathy;
BRCA	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg24747557	chr10:131355152	MGMT	-0.31	-7.91	-0.3	1.12e-14	Response to temozolomide;
BRCA	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg03709012	chr19:19516395	GATAD2A	1.09	21.52	0.65	1.2e-77	Nonalcoholic fatty liver disease;
BRCA	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21659725	chr3:3221576	CRBN	0.48	12.09	0.43	1.86e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	17.89	0.58	2.45e-58	Platelet count;
BRCA	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.2e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg26597838	chr10:835615	NA	1.32	22.06	0.66	1.34e-80	Eosinophil percentage of granulocytes;
BRCA	cis	rs8014204	0.657	rs2884668	chr14:75281576	T/A	cg06637938	chr14:75390232	RPS6KL1	0.43	8.9	0.33	5.54e-18	Caffeine consumption;
BRCA	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg10523679	chr1:76189770	ACADM	-0.49	-9.54	-0.35	2.99e-20	Daytime sleep phenotypes;
BRCA	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg08493051	chr2:3487164	NA	-0.43	-9.25	-0.34	3.33e-19	Neurofibrillary tangles;
BRCA	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-9.2	-0.34	4.95e-19	Monocyte percentage of white cells;
BRCA	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg04944784	chr2:26401820	FAM59B	0.99	16.67	0.55	4.37e-52	Gut microbiome composition (summer);
BRCA	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.53	-0.35	3.1e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2191566	0.576	rs393195	chr19:44493142	T/G	cg20607764	chr19:44506953	ZNF230	0.38	8.33	0.31	5.06e-16	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs13095912	0.785	rs6800725	chr3:185298156	C/A	cg11274856	chr3:185301563	NA	0.56	13.58	0.47	4.54e-37	Systolic blood pressure;
BRCA	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg11814155	chr7:99998594	ZCWPW1	0.47	8.52	0.32	1.16e-16	Platelet count;
BRCA	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg18016565	chr1:150552671	MCL1	0.35	8.03	0.3	4.85e-15	Melanoma;
BRCA	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.96	0.33	3.51e-18	Tonsillectomy;
BRCA	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg03711944	chr11:47377212	SPI1	-0.37	-9.31	-0.35	2.04e-19	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg06108461	chr20:60628389	TAF4	-0.71	-14.85	-0.51	4.36e-43	Body mass index;
BRCA	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg11663144	chr21:46675770	NA	-0.61	-14.24	-0.49	3.65e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs698813	0.851	rs698807	chr2:44701659	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	9.2	0.34	5.1e-19	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg12386194	chr3:101231763	SENP7	0.46	9.85	0.36	2.01e-21	Colorectal cancer;
BRCA	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg17063962	chr7:91808500	NA	-0.52	-12.25	-0.44	3.9e-31	Breast cancer;
BRCA	cis	rs6545883	0.894	rs35292974	chr2:61522047	T/C	cg15711740	chr2:61764176	XPO1	0.52	13.23	0.46	1.68e-35	Tuberculosis;
BRCA	trans	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs4268898	0.552	rs12620938	chr2:24367122	C/A	cg26838691	chr2:24397539	C2orf84	0.39	7.96	0.3	8.05e-15	Asthma;
BRCA	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22307029	chr19:49891270	CCDC155	0.61	10.85	0.39	2.84e-25	Multiple sclerosis;
BRCA	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg00981070	chr1:2046702	PRKCZ	0.31	8.21	0.31	1.24e-15	Height;
BRCA	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg21143896	chr7:2802374	GNA12	-0.35	-8.45	-0.32	2e-16	Height;
BRCA	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.65e-23	Motion sickness;
BRCA	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg07169764	chr2:136633963	MCM6	-1.16	-25.42	-0.71	5.08e-99	Corneal structure;
BRCA	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg10560079	chr2:191398806	TMEM194B	-0.65	-12.47	-0.44	4.17e-32	Diastolic blood pressure;
BRCA	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.8	-0.42	3.21e-29	Response to antipsychotic treatment;
BRCA	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg13010199	chr12:38710504	ALG10B	0.57	12.46	0.44	4.82e-32	Heart rate;
BRCA	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.55	8.44	0.32	2.17e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs16958440	1.000	rs62096464	chr18:44629207	T/A	cg17192377	chr18:44677553	HDHD2	0.67	9.75	0.36	4.96e-21	Sitting height ratio;
BRCA	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-10.4	-0.38	1.62e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg12140854	chr5:148520817	ABLIM3	0.41	8.61	0.32	5.87e-17	Breast cancer;
BRCA	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.53	-0.35	3.1e-20	Total body bone mineral density;
BRCA	cis	rs7727544	0.647	rs6898270	chr5:131421190	C/T	cg14196790	chr5:131705035	SLC22A5	0.37	9.07	0.34	1.4e-18	Blood metabolite levels;
BRCA	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg10792982	chr14:105748885	BRF1	0.46	10.74	0.39	7.66e-25	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.32	-0.31	5.27e-16	Depression;
BRCA	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg00677455	chr12:58241039	CTDSP2	0.54	12.63	0.45	8.58e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg06212747	chr3:49208901	KLHDC8B	0.47	9.53	0.35	3.25e-20	Parkinson's disease;
BRCA	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg23625390	chr15:77176239	SCAPER	0.41	10.02	0.37	4.84e-22	Blood metabolite levels;
BRCA	cis	rs6545883	0.895	rs7588814	chr2:61695589	A/T	cg15711740	chr2:61764176	XPO1	-0.53	-13.37	-0.47	3.92e-36	Tuberculosis;
BRCA	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg08975724	chr8:8085496	FLJ10661	0.48	10.23	0.38	7.76e-23	Mood instability;
BRCA	cis	rs77633900	0.614	rs280013	chr15:76978139	C/T	cg21673338	chr15:77095150	SCAPER	0.54	9.73	0.36	5.85e-21	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg15017067	chr4:17643749	FAM184B	0.29	8.91	0.33	5.26e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2204008	0.776	rs3861074	chr12:38483021	C/T	cg13010199	chr12:38710504	ALG10B	0.51	9.82	0.36	2.6e-21	Bladder cancer;
BRCA	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg01448562	chr3:133502909	NA	-0.4	-9.11	-0.34	1.03e-18	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.4	-8.7	-0.33	2.7e-17	Aortic root size;
BRCA	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25427524	chr10:38739819	LOC399744	0.63	14.2	0.49	5.7e-40	Extrinsic epigenetic age acceleration;
BRCA	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg15557168	chr22:42548783	NA	-0.32	-8.83	-0.33	9.79e-18	Cognitive function;
BRCA	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00166722	chr3:10149974	C3orf24	0.65	12.86	0.45	8.28e-34	Alzheimer's disease;
BRCA	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg00981070	chr1:2046702	PRKCZ	0.26	8.04	0.3	4.51e-15	Height;
BRCA	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg05283184	chr6:79620031	NA	-0.41	-10.63	-0.39	2.12e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.66	-9.71	-0.36	7.17e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	9.13	0.34	8.96e-19	Systemic lupus erythematosus;
BRCA	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg25358565	chr5:93447407	FAM172A	1.2	18.84	0.6	2.54e-63	Diabetic retinopathy;
BRCA	cis	rs11605275	1.000	rs77993017	chr11:20031388	C/G	cg14835545	chr11:20032148	NAV2	-0.59	-9.32	-0.35	1.87e-19	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18876405	chr7:65276391	NA	-0.51	-11.64	-0.42	1.56e-28	Aortic root size;
BRCA	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg08061076	chr7:1943177	MAD1L1	0.35	8.01	0.3	5.57e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg11530693	chr1:120165357	ZNF697	0.62	14.94	0.51	1.68e-43	Systemic lupus erythematosus;
BRCA	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg19743168	chr1:23544995	NA	0.69	17.43	0.57	5.77e-56	Height;
BRCA	cis	rs868036	0.881	rs12708496	chr15:68054098	T/C	cg05925327	chr15:68127851	NA	0.34	8.53	0.32	1.06e-16	Restless legs syndrome;
BRCA	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg26384229	chr12:38710491	ALG10B	0.42	9.32	0.35	1.91e-19	Morning vs. evening chronotype;
BRCA	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg09455208	chr3:40491958	NA	0.41	9.64	0.36	1.22e-20	Renal cell carcinoma;
BRCA	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26314531	chr2:26401878	FAM59B	0.9	16.24	0.54	6.54e-50	Gut microbiome composition (summer);
BRCA	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	17.83	0.58	5.12e-58	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg08999081	chr20:33150536	PIGU	-0.47	-12.84	-0.45	9.74e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs727479	0.543	rs12900487	chr15:51523159	T/C	cg19946085	chr15:51559439	CYP19A1	-0.29	-7.96	-0.3	7.98e-15	Estradiol levels;
BRCA	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02176678	chr2:219576539	TTLL4	0.47	12.15	0.43	1.01e-30	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg24531977	chr5:56204891	C5orf35	-0.42	-8.44	-0.32	2.16e-16	Coronary artery disease;
BRCA	trans	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.97	-0.3	7.12e-15	Corneal astigmatism;
BRCA	cis	rs13046373	0.505	rs2832962	chr21:32008332	T/C	cg16431978	chr21:31797932	KRTAP13-3	0.36	8.97	0.33	3.26e-18	HDL cholesterol;
BRCA	cis	rs68170813	0.559	rs2189501	chr7:106942766	A/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.68	-0.32	3.38e-17	Coronary artery disease;
BRCA	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg11812906	chr14:75593930	NEK9	-0.61	-13.97	-0.48	7e-39	Height;
BRCA	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg09904177	chr6:26538194	HMGN4	0.56	18.25	0.59	3.23e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs6910061	1.000	rs13214666	chr6:11103537	C/A	cg27233058	chr6:11094804	LOC221710	0.54	9.62	0.36	1.54e-20	Diabetic kidney disease;
BRCA	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg24069376	chr3:38537580	EXOG	0.4	11.4	0.41	1.51e-27	Electrocardiographic conduction measures;
BRCA	cis	rs4363385	0.747	rs1338180	chr1:152981404	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.35	-0.31	4.24e-16	Inflammatory skin disease;
BRCA	cis	rs4730250	0.708	rs3801965	chr7:106825628	G/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.41	-0.32	2.73e-16	Osteoarthritis;
BRCA	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	5.1e-16	Tonsillectomy;
BRCA	cis	rs12541635	0.966	rs55762012	chr8:107033218	T/C	cg10147462	chr8:107024639	NA	0.36	9.39	0.35	1.02e-19	Age of smoking initiation;
BRCA	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.63	0.42	1.63e-28	Homoarginine levels;
BRCA	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg06784218	chr1:46089804	CCDC17	0.45	10.93	0.4	1.28e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3750965	0.959	rs4930265	chr11:68855954	A/G	cg06818126	chr11:68850279	TPCN2	-0.35	-8.41	-0.32	2.75e-16	Hair color;
BRCA	cis	rs6820391	0.781	rs7680855	chr4:54447248	G/A	cg04173182	chr4:54446035	LNX1	0.53	11.76	0.42	4.8e-29	Cervical artery dissection;
BRCA	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06544989	chr22:39130855	UNC84B	0.39	9.37	0.35	1.23e-19	Menopause (age at onset);
BRCA	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg14582100	chr15:45693742	SPATA5L1	0.36	11.85	0.42	1.97e-29	Homoarginine levels;
BRCA	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg21605333	chr4:119757512	SEC24D	1.34	13.89	0.48	1.64e-38	Cannabis dependence symptom count;
BRCA	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg04025307	chr7:1156635	C7orf50	0.47	9.24	0.34	3.52e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg06917634	chr15:78832804	PSMA4	-0.62	-13.27	-0.46	1.1e-35	Sudden cardiac arrest;
BRCA	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg08501292	chr6:25962987	TRIM38	0.59	8.25	0.31	9.02e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.41	-8.98	-0.33	2.97e-18	Personality dimensions;
BRCA	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg10596483	chr8:143751796	JRK	-0.45	-9.44	-0.35	6.92e-20	Schizophrenia;
BRCA	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg23950597	chr19:37808831	NA	-0.62	-11.37	-0.41	2.02e-27	Coronary artery calcification;
BRCA	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.27	8.45	0.32	2.02e-16	Electroencephalogram traits;
BRCA	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg01858014	chr14:56050164	KTN1	-0.77	-11.14	-0.4	1.75e-26	Putamen volume;
BRCA	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg17063962	chr7:91808500	NA	0.51	11.99	0.43	5.18e-30	Breast cancer;
BRCA	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg00105475	chr2:10696890	NA	0.44	10.29	0.38	4.38e-23	Prostate cancer;
BRCA	cis	rs939658	1.000	rs12439908	chr15:79456381	T/C	cg17916960	chr15:79447300	NA	0.39	9.83	0.36	2.55e-21	Refractive error;
BRCA	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.44	7.89	0.3	1.27e-14	Height;
BRCA	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-15.74	-0.53	1.97e-47	Bipolar disorder and schizophrenia;
BRCA	cis	rs9443645	0.527	rs12194642	chr6:79538791	G/A	cg05283184	chr6:79620031	NA	-0.37	-8.64	-0.32	4.48e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg13628971	chr7:2884303	GNA12	0.47	9.02	0.34	2.14e-18	Height;
BRCA	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg02187348	chr16:89574699	SPG7	0.48	11.28	0.41	4.72e-27	Multiple myeloma (IgH translocation);
BRCA	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.59	-15.78	-0.53	1.23e-47	Urate levels in overweight individuals;
BRCA	cis	rs495337	1.000	rs486206	chr20:48516733	C/G	cg17835207	chr20:48524531	SPATA2	-0.64	-14.6	-0.5	6.85e-42	Psoriasis;
BRCA	cis	rs897080	0.515	rs1085488	chr2:44618004	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	8.67	0.32	3.57e-17	Height;
BRCA	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.03	-0.37	4.43e-22	Bladder cancer;
BRCA	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-7.98	-0.3	6.83e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1538970	0.924	rs7531253	chr1:45890183	T/C	cg05343316	chr1:45956843	TESK2	0.62	12.48	0.44	3.73e-32	Platelet count;
BRCA	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23583168	chr7:148888333	NA	-0.8	-19.11	-0.6	9.56e-65	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9816226	0.938	rs55742087	chr3:185830488	C/T	cg00760338	chr3:185826511	ETV5	-0.53	-8.98	-0.33	2.99e-18	Obesity;Body mass index;
BRCA	cis	rs7766436	0.885	rs11759879	chr6:22587130	C/T	cg13666174	chr6:22585274	NA	-0.45	-9.79	-0.36	3.47e-21	Coronary artery disease;
BRCA	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg05347473	chr6:146136440	FBXO30	0.4	7.9	0.3	1.27e-14	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg03929089	chr4:120376271	NA	0.57	9.88	0.36	1.61e-21	Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	10.06	0.37	3.5e-22	Mean corpuscular volume;
BRCA	trans	rs1829883	0.804	rs2511924	chr5:98721643	C/T	cg08333243	chr5:99726346	NA	0.34	8.41	0.32	2.72e-16	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg06484146	chr7:12443880	VWDE	-0.75	-10.68	-0.39	1.35e-24	Coronary artery disease;
BRCA	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg07741184	chr6:167504864	NA	0.34	9.79	0.36	3.57e-21	Crohn's disease;
BRCA	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg16049864	chr8:95962084	TP53INP1	-0.49	-12.25	-0.44	3.77e-31	Type 2 diabetes;
BRCA	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg05754148	chr16:3507555	NAT15	0.38	8.05	0.3	4.02e-15	Tuberculosis;
BRCA	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg18512352	chr11:47633146	NA	-0.33	-7.97	-0.3	7.07e-15	Subjective well-being;
BRCA	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg27432699	chr2:27873401	GPN1	0.43	9.19	0.34	5.65e-19	Oral cavity cancer;
BRCA	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg17063962	chr7:91808500	NA	0.59	13.94	0.48	9.79e-39	Breast cancer;
BRCA	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.67	0.39	1.44e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg06784218	chr1:46089804	CCDC17	0.45	10.65	0.39	1.71e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4478858	0.698	rs4949385	chr1:31793256	C/T	cg00250761	chr1:31883323	NA	-0.33	-8.54	-0.32	9.92e-17	Alcohol dependence;
BRCA	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.33	10.21	0.37	9.11e-23	Bipolar disorder;
BRCA	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00149659	chr3:10157352	C3orf10	-1.08	-18.55	-0.59	8.53e-62	Alzheimer's disease;
BRCA	cis	rs7394190	0.748	rs11000772	chr10:75533988	T/G	cg07699608	chr10:75541558	CHCHD1	0.65	9.64	0.36	1.26e-20	Incident atrial fibrillation;
BRCA	cis	rs4690686	0.500	rs2168032	chr4:177272957	A/G	cg17059388	chr4:177262070	NA	0.51	10.71	0.39	9.86e-25	Essential tremor;
BRCA	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg03709012	chr19:19516395	GATAD2A	1.07	21.12	0.64	1.62e-75	Nonalcoholic fatty liver disease;
BRCA	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg03433033	chr1:76189801	ACADM	0.72	16.63	0.55	7.58e-52	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg06521331	chr12:34319734	NA	-0.56	-10.0	-0.37	5.64e-22	Morning vs. evening chronotype;
BRCA	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.16	0.31	1.83e-15	Depression;
BRCA	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg08885076	chr2:99613938	TSGA10	0.44	10.2	0.37	1.02e-22	Chronic sinus infection;
BRCA	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.25	8.02	0.3	5.21e-15	Cardiac Troponin-T levels;
BRCA	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg05714579	chr10:131428358	MGMT	0.57	14.08	0.49	2.01e-39	Response to temozolomide;
BRCA	cis	rs9837602	0.810	rs35777905	chr3:99690970	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.58	8.71	0.33	2.5e-17	Breast cancer;
BRCA	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg08508325	chr11:3079039	CARS	0.28	8.43	0.32	2.22e-16	Calcium levels;
BRCA	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg17987982	chr7:158820591	NA	-0.43	-8.17	-0.31	1.65e-15	Facial morphology (factor 20);
BRCA	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11890956	chr21:40555474	PSMG1	0.96	24.24	0.69	1.45e-92	Cognitive function;
BRCA	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg18132916	chr6:79620363	NA	0.48	10.58	0.39	3.33e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg22920501	chr2:26401640	FAM59B	-0.67	-11.61	-0.42	2.04e-28	Gut microbiome composition (summer);
BRCA	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg23649088	chr2:200775458	C2orf69	-0.64	-10.38	-0.38	1.99e-23	Schizophrenia;
BRCA	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg04362960	chr10:104952993	NT5C2	0.44	10.12	0.37	1.97e-22	Arsenic metabolism;
BRCA	cis	rs78456975	0.622	rs11888851	chr2:1518254	C/G	cg12573674	chr2:1569213	NA	-0.41	-8.17	-0.31	1.61e-15	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs3784262	0.533	rs12148525	chr15:58196456	A/G	cg12031962	chr15:58353849	ALDH1A2	0.34	8.04	0.3	4.5e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.95	0.33	3.68e-18	Motion sickness;
BRCA	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg06145435	chr7:1022769	CYP2W1	0.42	9.03	0.34	2.03e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg25358565	chr5:93447407	FAM172A	1.24	19.21	0.61	2.89e-65	Diabetic retinopathy;
BRCA	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg04518342	chr5:131593106	PDLIM4	-0.4	-9.41	-0.35	8.68e-20	Acylcarnitine levels;
BRCA	cis	rs367943	0.799	rs2115209	chr5:112973494	A/G	cg12552261	chr5:112820674	MCC	0.5	9.9	0.36	1.3e-21	Type 2 diabetes;
BRCA	cis	rs17092148	0.790	rs6058079	chr20:33142873	G/A	cg16810054	chr20:33298113	TP53INP2	-0.45	-10.08	-0.37	2.74e-22	Neuroticism;
BRCA	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	8.1	0.31	2.78e-15	Educational attainment;
BRCA	trans	rs3960554	0.808	rs57721466	chr7:75710049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.6	11.98	0.43	5.53e-30	Eotaxin levels;
BRCA	cis	rs17253792	0.545	rs3742571	chr14:56016704	A/G	cg01858014	chr14:56050164	KTN1	-0.6	-7.87	-0.3	1.57e-14	Putamen volume;
BRCA	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12379764	chr21:47803548	PCNT	-0.39	-8.51	-0.32	1.2e-16	Testicular germ cell tumor;
BRCA	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg13175981	chr1:150552382	MCL1	0.48	10.72	0.39	8.79e-25	Tonsillectomy;
BRCA	cis	rs11958404	0.932	rs72816549	chr5:157417957	G/A	cg05962755	chr5:157440814	NA	0.5	9.57	0.35	2.34e-20	IgG glycosylation;
BRCA	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg22529645	chr1:3704559	LRRC47	0.28	8.47	0.32	1.67e-16	Red cell distribution width;
BRCA	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg04607235	chr12:12878440	APOLD1	-0.62	-9.91	-0.37	1.21e-21	Systemic lupus erythematosus;
BRCA	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.37	-8.32	-0.31	5.42e-16	Longevity;Endometriosis;
BRCA	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg21535247	chr6:8435926	SLC35B3	0.42	9.42	0.35	7.86e-20	Motion sickness;
BRCA	cis	rs12200560	0.505	rs984520	chr6:97076454	A/G	cg06623918	chr6:96969491	KIAA0776	-0.54	-13.09	-0.46	7.64e-35	Coronary heart disease;
BRCA	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg01877450	chr7:97915802	BRI3	-0.41	-8.68	-0.32	3.38e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg18200150	chr17:30822561	MYO1D	-0.5	-13.29	-0.47	9e-36	Schizophrenia;
BRCA	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.41	-0.38	1.46e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg11812906	chr14:75593930	NEK9	-0.6	-13.47	-0.47	1.34e-36	Height;
BRCA	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg05294307	chr14:35346193	BAZ1A	-0.63	-10.64	-0.39	1.95e-24	Psoriasis;
BRCA	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7715811	1.000	rs1502042	chr5:13758344	G/A	cg07548982	chr5:13769939	DNAH5	-0.38	-8.37	-0.31	3.64e-16	Subclinical atherosclerosis traits (other);
BRCA	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	8.83	0.33	1.01e-17	Iron status biomarkers;
BRCA	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-9.95	-0.37	8.59e-22	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7520050	0.966	rs11211208	chr1:46334256	A/C	cg24296786	chr1:45957014	TESK2	0.44	9.92	0.37	1.18e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10150615	chr22:24372951	LOC391322	0.44	9.83	0.36	2.51e-21	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg17063962	chr7:91808500	NA	-0.56	-12.65	-0.45	6.91e-33	Breast cancer;
BRCA	cis	rs3917254	0.543	rs6543106	chr2:102746449	A/G	cg22835712	chr2:102737379	NA	-0.55	-9.26	-0.34	3.02e-19	Blood protein levels;
BRCA	cis	rs4561483	0.801	rs251723	chr16:11953080	G/C	cg08843971	chr16:11963173	GSPT1	-0.51	-11.42	-0.41	1.26e-27	Testicular germ cell tumor;
BRCA	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19723775	chr5:179050963	HNRNPH1	0.37	9.07	0.34	1.43e-18	Lung cancer;
BRCA	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg03676636	chr4:99064102	C4orf37	0.24	8.48	0.32	1.52e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg04455712	chr21:45112962	RRP1B	0.41	10.39	0.38	1.78e-23	Mean corpuscular volume;
BRCA	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg24692254	chr21:30365293	RNF160	-0.48	-8.53	-0.32	1.05e-16	Cognitive test performance;
BRCA	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg26395211	chr5:140044315	WDR55	0.37	8.52	0.32	1.16e-16	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs12517041	0.935	rs1428628	chr5:23311925	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.48	-8.5	-0.32	1.38e-16	Calcium levels;
BRCA	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.39	0.32	3.09e-16	Platelet count;
BRCA	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-8.16	-0.31	1.79e-15	Prostate cancer;
BRCA	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg07755735	chr2:20870362	GDF7	-0.35	-8.61	-0.32	5.73e-17	Abdominal aortic aneurysm;
BRCA	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.58	-0.32	7.15e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg03477792	chr4:77819574	ANKRD56	0.62	14.97	0.51	1.22e-43	Emphysema distribution in smoking;
BRCA	cis	rs7246657	0.722	rs8100646	chr19:38107943	T/C	cg23950597	chr19:37808831	NA	-0.48	-8.23	-0.31	1.06e-15	Coronary artery calcification;
BRCA	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg25358565	chr5:93447407	FAM172A	1.17	18.45	0.59	3.07e-61	Diabetic retinopathy;
BRCA	cis	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg05623727	chr3:50126028	RBM5	0.42	9.94	0.37	9.6e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg11663144	chr21:46675770	NA	-0.57	-13.32	-0.47	7.04e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs929596	0.606	rs7604115	chr2:234658116	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-10.79	-0.39	4.79e-25	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.11	0.34	1.01e-18	Platelet count;
BRCA	trans	rs11976180	1.000	rs2961128	chr7:143763483	A/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.26	-0.31	8.66e-16	Obesity-related traits;
BRCA	trans	rs6076960	0.684	rs3909041	chr20:6249598	C/G	cg21095983	chr6:86352623	SYNCRIP	0.42	9.06	0.34	1.53e-18	Smooth-surface caries;
BRCA	cis	rs4891159	0.526	rs2848961	chr18:74129886	C/G	cg24786174	chr18:74118243	ZNF516	-0.8	-22.94	-0.67	1.93e-85	Longevity;
BRCA	cis	rs365132	1.000	rs353464	chr5:176403023	A/G	cg16309518	chr5:176445507	NA	-0.52	-13.42	-0.47	2.31e-36	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs7818345	1.000	rs7823194	chr8:19292528	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.04	0.3	4.3e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs7903847	0.642	rs1537646	chr10:99149922	T/C	cg08345082	chr10:99160200	RRP12	-0.31	-9.09	-0.34	1.28e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	12.84	0.45	9.71e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10044254	0.563	rs6554897	chr5:15695253	A/G	cg07238450	chr5:15720153	FBXL7	-0.38	-7.81	-0.3	2.32e-14	Asthma (corticosteroid response);
BRCA	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg21798802	chr22:38057573	PDXP	0.48	12.94	0.46	3.47e-34	Fat distribution (HIV);
BRCA	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg13010199	chr12:38710504	ALG10B	-0.38	-7.99	-0.3	6.34e-15	Bladder cancer;
BRCA	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg24846343	chr22:24311635	DDTL	0.54	14.16	0.49	9.11e-40	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs208520	0.690	rs851459	chr6:66813989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-20.99	-0.64	8.24e-75	Exhaled nitric oxide output;
BRCA	cis	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg07460842	chr6:66804631	NA	0.64	13.82	0.48	3.46e-38	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.25	0.31	9.38e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2882667	0.822	rs11738376	chr5:138398172	G/A	cg04439458	chr5:138467593	SIL1	-0.43	-10.87	-0.4	2.2e-25	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-9.11	-0.34	1.06e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.86	13.54	0.47	6.44e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00166722	chr3:10149974	C3orf24	0.55	10.74	0.39	7.48e-25	Alzheimer's disease;
BRCA	trans	rs2834485	0.816	rs1547356	chr21:35822572	C/T	cg07474852	chr4:123073612	NA	0.41	8.21	0.31	1.27e-15	Cancer;
BRCA	cis	rs9470366	0.816	rs7742159	chr6:36619452	A/C	cg08179530	chr6:36648295	CDKN1A	0.5	9.99	0.37	6.13e-22	QRS duration;
BRCA	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg22963979	chr7:1858916	MAD1L1	0.46	9.31	0.35	2.06e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.8e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs528301	0.584	rs7604640	chr2:45121466	G/A	cg02372786	chr2:45167549	SIX3	-0.42	-9.25	-0.34	3.34e-19	Alcohol and nicotine co-dependence;
BRCA	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg20387954	chr3:183756860	HTR3D	0.39	8.92	0.33	4.74e-18	Anterior chamber depth;
BRCA	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.32	0.35	1.85e-19	Morning vs. evening chronotype;
BRCA	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg20607287	chr7:12443886	VWDE	-0.57	-8.31	-0.31	5.93e-16	Coronary artery disease;
BRCA	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg05868516	chr6:26286170	HIST1H4H	0.5	11.25	0.41	6.6e-27	Educational attainment;
BRCA	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg22875332	chr1:76189707	ACADM	0.81	19.72	0.62	5.72e-68	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	11.53	0.41	4.48e-28	Platelet count;
BRCA	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg13319975	chr6:146136371	FBXO30	-0.37	-8.51	-0.32	1.2e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg23625390	chr15:77176239	SCAPER	0.41	10.2	0.37	9.44e-23	Blood metabolite levels;
BRCA	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg00677455	chr12:58241039	CTDSP2	0.59	13.07	0.46	8.71e-35	Multiple sclerosis;
BRCA	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg15704280	chr7:45808275	SEPT13	-0.42	-8.17	-0.31	1.66e-15	HDL cholesterol;
BRCA	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg26597838	chr10:835615	NA	0.98	14.98	0.51	1.07e-43	Eosinophil percentage of granulocytes;
BRCA	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs1568889	0.838	rs1483858	chr11:28189639	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.41	0.63	1.15e-71	Bipolar disorder;
BRCA	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg09469691	chr10:81107165	PPIF	0.49	10.3	0.38	3.86e-23	Height;
BRCA	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg15395560	chr15:45543142	SLC28A2	0.3	8.3	0.31	6.2e-16	Uric acid levels;
BRCA	cis	rs7737355	1.000	rs12654593	chr5:130756867	C/T	cg06307176	chr5:131281290	NA	-0.51	-9.97	-0.37	7.4e-22	Life satisfaction;
BRCA	cis	rs2625529	0.586	rs59975112	chr15:72423710	G/T	cg16672083	chr15:72433130	SENP8	0.67	16.38	0.54	1.25e-50	Red blood cell count;
BRCA	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg08885076	chr2:99613938	TSGA10	-0.59	-13.08	-0.46	8e-35	Chronic sinus infection;
BRCA	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg11663144	chr21:46675770	NA	-0.62	-14.32	-0.49	1.53e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4389656	0.740	rs274706	chr5:6726629	T/C	cg10857441	chr5:6722123	POLS	-0.25	-7.82	-0.3	2.21e-14	Coronary artery disease;
BRCA	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.69	0.55	3.53e-52	Hypertriglyceridemia;
BRCA	cis	rs62380364	0.602	rs650702	chr5:88055313	G/A	cg22951263	chr5:87985283	NA	-0.38	-10.65	-0.39	1.69e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs2637030	0.559	rs6881928	chr5:52988609	C/A	cg06476337	chr5:52856530	NDUFS4	0.37	8.41	0.32	2.67e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg25214090	chr10:38739885	LOC399744	0.56	12.33	0.44	1.68e-31	Corneal astigmatism;
BRCA	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg20701182	chr2:24300061	SF3B14	0.59	9.31	0.35	2.03e-19	Lymphocyte counts;
BRCA	cis	rs778371	0.723	rs737027	chr2:233641083	G/C	cg08000102	chr2:233561755	GIGYF2	0.85	21.22	0.64	5.01e-76	Schizophrenia;
BRCA	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.07e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12220238	1.000	rs10824085	chr10:75911984	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.49	7.87	0.3	1.56e-14	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg12311346	chr5:56204834	C5orf35	-0.8	-16.01	-0.54	9.43e-49	Initial pursuit acceleration;
BRCA	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-13.82	-0.48	3.23e-38	Blood metabolite levels;
BRCA	cis	rs6545883	0.929	rs2256615	chr2:61679894	C/G	cg15711740	chr2:61764176	XPO1	-0.53	-12.64	-0.45	7.37e-33	Tuberculosis;
BRCA	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg18964960	chr10:1102726	WDR37	-0.52	-9.15	-0.34	7.48e-19	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg11833968	chr6:79620685	NA	-0.43	-9.5	-0.35	4e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-13.91	-0.48	1.23e-38	Morning vs. evening chronotype;
BRCA	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg06917634	chr15:78832804	PSMA4	-0.76	-17.64	-0.57	5.08e-57	Sudden cardiac arrest;
BRCA	cis	rs218264	0.592	rs1396069	chr4:55369478	C/A	cg17105814	chr4:55365203	NA	-0.39	-8.17	-0.31	1.71e-15	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg03060546	chr3:49711283	APEH	-0.55	-8.39	-0.32	3.03e-16	Menarche (age at onset);
BRCA	cis	rs6138458	0.961	rs11700073	chr20:24975215	C/G	cg06937882	chr20:24974362	C20orf3	-0.47	-9.23	-0.34	3.82e-19	Blood protein levels;
BRCA	cis	rs4594175	0.926	rs10873044	chr14:51615856	T/C	cg23942311	chr14:51606299	NA	0.34	8.52	0.32	1.15e-16	Cancer;
BRCA	cis	rs4285028	0.948	rs12488851	chr3:121687192	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.88	-0.4	2.15e-25	Multiple sclerosis;
BRCA	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg20290983	chr6:43655470	MRPS18A	1.1	39.62	0.84	3.07e-174	IgG glycosylation;
BRCA	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1568889	0.838	rs7131379	chr11:28085789	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.46	0.63	6.26e-72	Bipolar disorder;
BRCA	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg20307385	chr11:47447363	PSMC3	-0.43	-8.82	-0.33	1.08e-17	Subjective well-being;
BRCA	cis	rs701145	0.585	rs1727879	chr3:153835819	C/T	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.89e-18	Coronary artery disease;
BRCA	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg13319975	chr6:146136371	FBXO30	-0.41	-9.4	-0.35	9.53e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg07460842	chr6:66804631	NA	0.99	19.85	0.62	1.08e-68	Exhaled nitric oxide output;
BRCA	cis	rs9658691	0.607	rs9658788	chr10:90776486	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.54	-7.93	-0.3	9.9e-15	Mosquito bite size;
BRCA	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-8.74	-0.33	2.03e-17	Monocyte percentage of white cells;
BRCA	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg17724175	chr1:150552817	MCL1	-0.33	-10.94	-0.4	1.14e-25	Urate levels;
BRCA	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-9.01	-0.34	2.4e-18	Alzheimer's disease (late onset);
BRCA	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg03585969	chr10:35415529	CREM	0.57	11.66	0.42	1.32e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs17092148	0.652	rs4911154	chr20:32996101	A/G	cg16810054	chr20:33298113	TP53INP2	-0.42	-9.28	-0.34	2.68e-19	Neuroticism;
BRCA	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.45	-0.41	9.57e-28	Schizophrenia;
BRCA	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg08755490	chr11:65554678	OVOL1	0.55	11.5	0.41	5.88e-28	Acne (severe);
BRCA	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg07262247	chr5:131593730	PDLIM4	0.36	8.58	0.32	7.25e-17	Acylcarnitine levels;
BRCA	cis	rs7122539	0.506	rs11227625	chr11:66684151	T/G	cg24851651	chr11:66362959	CCS	0.36	7.9	0.3	1.24e-14	HIV-1 susceptibility;
BRCA	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.54	0.67	2.99e-83	Chronic sinus infection;
BRCA	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg12310025	chr6:25882481	NA	-0.61	-13.46	-0.47	1.6e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg15083037	chr5:83017644	HAPLN1	0.44	9.61	0.36	1.68e-20	Prostate cancer;
BRCA	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	10.45	0.38	1.03e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9359856	0.510	rs6454775	chr6:90465000	A/T	cg13799429	chr6:90582589	CASP8AP2	0.72	11.06	0.4	3.84e-26	Bipolar disorder;
BRCA	cis	rs7524258	0.900	rs6577425	chr1:7306338	G/T	cg07173049	chr1:7289937	CAMTA1	0.41	9.87	0.36	1.75e-21	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.92	0.4	1.43e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg05528280	chr10:464225	DIP2C	-0.38	-7.83	-0.3	2e-14	Psychosis in Alzheimer's disease;
BRCA	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg14675211	chr2:100938903	LONRF2	0.52	11.96	0.43	7.15e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.15	-0.4	1.74e-26	Schizophrenia;
BRCA	cis	rs4891159	0.527	rs34956524	chr18:74130480	A/G	cg24786174	chr18:74118243	ZNF516	0.83	25.27	0.71	3.13e-98	Longevity;
BRCA	cis	rs9788721	0.836	rs72738718	chr15:78735438	G/C	cg18825076	chr15:78729989	IREB2	-0.4	-8.34	-0.31	4.52e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.78	-0.53	1.24e-47	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg18200150	chr17:30822561	MYO1D	-0.34	-8.53	-0.32	1.09e-16	Schizophrenia;
BRCA	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.8	-0.33	1.23e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg26195577	chr20:24973756	C20orf3	1.02	26.39	0.72	2.33e-104	Blood protein levels;
BRCA	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.61	12.59	0.45	1.22e-32	Lymphocyte counts;
BRCA	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.57	-10.18	-0.37	1.13e-22	Gut microbiome composition (summer);
BRCA	cis	rs9462027	0.561	rs3798348	chr6:34771892	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.83	-0.3	1.98e-14	Systemic lupus erythematosus;
BRCA	cis	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg05491587	chr18:77659695	KCNG2	0.33	8.39	0.32	3.05e-16	Schizophrenia;
BRCA	trans	rs629535	0.821	rs680993	chr8:70050247	G/A	cg21567404	chr3:27674614	NA	1.0	20.86	0.64	4.2e-74	Dupuytren's disease;
BRCA	cis	rs7590368	1.000	rs7576898	chr2:10958956	A/G	cg15705551	chr2:10952987	PDIA6	0.43	8.01	0.3	5.48e-15	Educational attainment (years of education);
BRCA	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg20503657	chr10:835505	NA	1.04	18.15	0.58	1.14e-59	Eosinophil percentage of granulocytes;
BRCA	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg07636037	chr3:49044803	WDR6	0.97	29.54	0.76	1.35e-121	Parkinson's disease;
BRCA	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg07080220	chr10:102295463	HIF1AN	0.59	12.32	0.44	1.97e-31	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg10560079	chr2:191398806	TMEM194B	-0.74	-13.43	-0.47	2.14e-36	Diastolic blood pressure;
BRCA	cis	rs12618769	0.652	rs7588254	chr2:99217785	G/T	cg10123293	chr2:99228465	UNC50	0.42	8.68	0.32	3.37e-17	Bipolar disorder;
BRCA	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.9	0.62	6.05e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10992471	0.603	rs13301537	chr9:95229047	A/G	cg14631576	chr9:95140430	CENPP	-0.38	-9.27	-0.34	2.93e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg12311346	chr5:56204834	C5orf35	0.57	11.49	0.41	6.82e-28	Initial pursuit acceleration;
BRCA	trans	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg26043149	chr18:55253948	FECH	0.4	8.71	0.33	2.66e-17	Bone mineral density;
BRCA	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg12365402	chr11:9010492	NRIP3	0.43	9.51	0.35	3.75e-20	Hemoglobin concentration;
BRCA	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg09998033	chr7:158218633	PTPRN2	-0.41	-9.6	-0.35	1.81e-20	Obesity-related traits;
BRCA	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	11.25	0.41	6.76e-27	Monocyte percentage of white cells;
BRCA	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg05340658	chr4:99064831	C4orf37	0.52	8.63	0.32	5.01e-17	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg13628971	chr7:2884303	GNA12	0.38	8.48	0.32	1.6e-16	Height;
BRCA	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg09307838	chr4:120376055	NA	0.66	14.32	0.49	1.48e-40	Corneal astigmatism;
BRCA	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg19628046	chr18:33552617	C18orf21	0.63	13.0	0.46	1.88e-34	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.79	11.31	0.41	3.77e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs870825	0.616	rs6843185	chr4:185649878	A/C	cg04058563	chr4:185651563	MLF1IP	0.79	17.87	0.58	3.04e-58	Blood protein levels;
BRCA	cis	rs4780401	0.609	rs35649585	chr16:11813899	G/A	cg01061890	chr16:11836724	TXNDC11	-0.55	-13.06	-0.46	9.81e-35	Rheumatoid arthritis;
BRCA	cis	rs3857067	0.806	rs72665629	chr4:95112160	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.49	-0.35	4.67e-20	QT interval;
BRCA	cis	rs2816062	0.786	rs2745317	chr1:18896552	G/A	cg18795169	chr1:18902165	NA	-0.97	-29.66	-0.76	2.93e-122	Urate levels in lean individuals;
BRCA	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg14784868	chr12:69753453	YEATS4	0.68	19.81	0.62	1.79e-68	Blood protein levels;
BRCA	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.87	-0.33	7.27e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs13046373	0.562	rs12627602	chr21:32022924	G/A	cg22337977	chr21:31811175	KRTAP15-1	0.33	7.86	0.3	1.62e-14	HDL cholesterol;
BRCA	cis	rs4268898	0.552	rs11125455	chr2:24374557	C/G	cg06627628	chr2:24431161	ITSN2	0.41	8.57	0.32	8.03e-17	Asthma;
BRCA	cis	rs4566357	0.615	rs3769642	chr2:227917323	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-9.65	-0.36	1.12e-20	Coronary artery disease;
BRCA	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	7.99e-21	Bladder cancer;
BRCA	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-9.63	-0.36	1.35e-20	Neuroticism;
BRCA	cis	rs13136331	0.532	rs1462367	chr4:88570528	T/C	cg22416721	chr4:88570574	DMP1	0.62	15.02	0.51	7.04e-44	Sitting height ratio;
BRCA	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.12	0.31	2.38e-15	Depression;
BRCA	cis	rs921968	0.565	rs7595901	chr2:219606931	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-11.2	-0.41	1.01e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg21280719	chr6:42927975	GNMT	-0.33	-14.12	-0.49	1.34e-39	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.38	-0.31	3.45e-16	Bipolar disorder;
BRCA	cis	rs4363385	0.747	rs2225919	chr1:152969603	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.1	-0.34	1.14e-18	Inflammatory skin disease;
BRCA	cis	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg14019146	chr3:50243930	SLC38A3	-0.48	-11.57	-0.42	2.94e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg20701182	chr2:24300061	SF3B14	-0.71	-13.27	-0.46	1.16e-35	Lymphocyte counts;
BRCA	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg07701084	chr6:150067640	NUP43	0.42	12.23	0.44	4.68e-31	Lung cancer;
BRCA	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.52	-11.46	-0.41	9.22e-28	Menopause (age at onset);
BRCA	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-12.11	-0.43	1.56e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.39	9.13	0.34	9.05e-19	Multiple sclerosis;
BRCA	cis	rs9560113	1.000	rs9555811	chr13:112181532	A/C	cg10483660	chr13:112241077	NA	0.32	7.97	0.3	7.17e-15	Menarche (age at onset);
BRCA	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg02187348	chr16:89574699	SPG7	0.39	9.12	0.34	9.46e-19	Multiple myeloma (IgH translocation);
BRCA	cis	rs61990749	0.597	rs4632066	chr14:78247282	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.59	-9.56	-0.35	2.59e-20	Fibroblast growth factor basic levels;
BRCA	trans	rs800082	0.698	rs800074	chr3:144347638	A/G	cg24215973	chr2:240111563	HDAC4	-0.6	-14.58	-0.5	8.91e-42	Smoking behavior;
BRCA	cis	rs6723226	0.503	rs4952262	chr2:32597234	G/A	cg02381751	chr2:32503542	YIPF4	-0.45	-9.32	-0.35	1.9e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-13.11	-0.46	6.06e-35	Platelet count;
BRCA	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg23505145	chr19:12996616	KLF1	0.56	12.63	0.45	8.41e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg21782813	chr7:2030301	MAD1L1	0.38	11.25	0.41	6.78e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg26608667	chr7:1196370	ZFAND2A	0.44	10.3	0.38	3.93e-23	Longevity;Endometriosis;
BRCA	cis	rs7677751	0.767	rs890205	chr4:55063373	C/A	cg17187183	chr4:55093834	PDGFRA	0.4	8.27	0.31	7.82e-16	Corneal astigmatism;
BRCA	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg02659138	chr7:134003124	SLC35B4	0.32	9.78	0.36	3.74e-21	Mean platelet volume;
BRCA	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03517284	chr6:25882590	NA	-0.51	-11.55	-0.42	3.53e-28	Blood metabolite levels;
BRCA	cis	rs4141404	0.737	rs5998058	chr22:32006408	C/T	cg02404636	chr22:31891804	SFI1	0.42	8.85	0.33	8.46e-18	Paclitaxel-induced neuropathy;
BRCA	trans	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg06521331	chr12:34319734	NA	-0.54	-9.72	-0.36	6.44e-21	Bladder cancer;
BRCA	trans	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg06521331	chr12:34319734	NA	-0.5	-8.98	-0.33	3.01e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.45	-0.41	1e-27	Personality dimensions;
BRCA	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg06766960	chr11:133703094	NA	-0.61	-12.96	-0.46	2.89e-34	Childhood ear infection;
BRCA	trans	rs7395662	0.926	rs11039893	chr11:48657754	G/A	cg00717180	chr2:96193071	NA	-0.31	-8.61	-0.32	5.57e-17	HDL cholesterol;
BRCA	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg03929089	chr4:120376271	NA	-0.55	-11.06	-0.4	3.8e-26	Coronary artery disease;
BRCA	cis	rs7586879	0.828	rs10184813	chr2:25090236	T/C	cg04586622	chr2:25135609	ADCY3	0.38	9.09	0.34	1.19e-18	Body mass index;
BRCA	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1499972	0.887	rs73168397	chr3:117657197	C/T	cg07612923	chr3:117604196	NA	0.6	8.11	0.31	2.61e-15	Schizophrenia;
BRCA	cis	rs365132	0.875	rs353495	chr5:176430723	T/C	cg16309518	chr5:176445507	NA	-0.4	-9.72	-0.36	6.35e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs7582720	0.511	rs116219813	chr2:204081675	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	12.22	0.44	5.05e-31	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg04013093	chr6:42928303	GNMT	-0.29	-8.82	-0.33	1.12e-17	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs17270561	0.609	rs4711093	chr6:25687895	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	8.15	0.31	1.98e-15	Iron status biomarkers;
BRCA	cis	rs965469	0.744	rs6139093	chr20:3334838	A/G	cg25506879	chr20:3388711	C20orf194	-0.44	-8.77	-0.33	1.66e-17	IFN-related cytopenia;
BRCA	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg04450456	chr4:17643702	FAM184B	0.32	9.35	0.35	1.41e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs586533	0.846	rs619391	chr11:99498525	A/G	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg26043149	chr18:55253948	FECH	-0.4	-8.86	-0.33	8.01e-18	Bone mineral density;
BRCA	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg02187348	chr16:89574699	SPG7	-0.37	-8.47	-0.32	1.73e-16	Multiple myeloma (IgH translocation);
BRCA	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.69	-17.97	-0.58	1.01e-58	Longevity;Endometriosis;
BRCA	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.0	22.58	0.67	1.81e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg22705602	chr4:152727874	NA	-0.33	-8.22	-0.31	1.1e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs68170813	0.599	rs77878465	chr7:106890996	G/A	cg02696742	chr7:106810147	HBP1	-0.47	-8.34	-0.31	4.72e-16	Coronary artery disease;
BRCA	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.64	-0.32	4.41e-17	Electroencephalogram traits;
BRCA	cis	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg09307838	chr4:120376055	NA	0.6	11.17	0.4	1.44e-26	Corneal astigmatism;
BRCA	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg07636037	chr3:49044803	WDR6	-0.99	-29.98	-0.76	6.1e-124	Parkinson's disease;
BRCA	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg16482183	chr6:26056742	HIST1H1C	0.53	10.31	0.38	3.75e-23	Height;
BRCA	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg09307838	chr4:120376055	NA	-0.65	-12.73	-0.45	2.94e-33	Corneal astigmatism;
BRCA	cis	rs698813	0.763	rs1067335	chr2:44625958	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	9.25	0.34	3.25e-19	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg23285459	chr7:2802560	GNA12	-0.32	-8.18	-0.31	1.5e-15	Height;
BRCA	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.87	-0.33	7.09e-18	Total body bone mineral density;
BRCA	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg24562669	chr7:97807699	LMTK2	0.47	12.55	0.44	1.93e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs17401966	0.838	rs11580854	chr1:10293565	G/A	cg03954927	chr1:10346856	KIF1B	0.42	13.26	0.46	1.29e-35	Hepatocellular carcinoma;
BRCA	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg01819863	chr10:32635814	EPC1	1.21	20.81	0.64	8.38e-74	Sexual dysfunction (female);
BRCA	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg04166393	chr7:2884313	GNA12	0.48	9.82	0.36	2.81e-21	Height;
BRCA	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.73	0.55	2.12e-52	Colorectal cancer;
BRCA	cis	rs7617773	0.815	rs9825637	chr3:48372282	T/C	cg11946769	chr3:48343235	NME6	0.63	13.3	0.47	8.36e-36	Coronary artery disease;
BRCA	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.43	0.35	7.76e-20	Tonsillectomy;
BRCA	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg21385522	chr1:16154831	NA	-0.6	-11.25	-0.41	6.55e-27	Dilated cardiomyopathy;
BRCA	cis	rs8114671	0.647	rs945959	chr20:33734905	G/C	cg07148914	chr20:33460835	GGT7	0.35	7.98	0.3	6.93e-15	Height;
BRCA	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg20607287	chr7:12443886	VWDE	-0.58	-8.36	-0.31	4.04e-16	Coronary artery disease;
BRCA	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.43	-0.32	2.33e-16	Colorectal cancer;
BRCA	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-15.69	-0.53	3.55e-47	Chronic sinus infection;
BRCA	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg09658497	chr7:2847517	GNA12	-0.41	-8.58	-0.32	7.35e-17	Height;
BRCA	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg13010199	chr12:38710504	ALG10B	0.41	8.37	0.31	3.72e-16	Bladder cancer;
BRCA	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg20891283	chr12:69753455	YEATS4	0.73	21.96	0.66	4.86e-80	Blood protein levels;
BRCA	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg11764359	chr7:65958608	NA	0.67	15.04	0.51	5.33e-44	Aortic root size;
BRCA	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg11941060	chr3:133502564	NA	-0.6	-14.42	-0.5	4.95e-41	Iron status biomarkers;
BRCA	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.49	10.91	0.4	1.58e-25	Cognitive ability;
BRCA	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg06784218	chr1:46089804	CCDC17	0.49	11.66	0.42	1.34e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg08917208	chr2:24149416	ATAD2B	1.06	14.39	0.49	7.51e-41	Lymphocyte counts;
BRCA	cis	rs4074536	0.574	rs10923353	chr1:116290727	G/A	cg21648376	chr1:116311395	CASQ2	-0.49	-8.71	-0.33	2.5e-17	QRS duration;
BRCA	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg00071950	chr4:10020882	SLC2A9	-0.47	-11.19	-0.4	1.16e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs13082711	0.522	rs569960	chr3:27329540	C/T	cg02860705	chr3:27208620	NA	0.42	8.83	0.33	1.01e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-8.46	-0.32	1.79e-16	Daytime sleep phenotypes;
BRCA	cis	rs7523050	0.730	rs12729728	chr1:109431110	C/A	cg08274380	chr1:109419600	GPSM2	1.19	15.71	0.53	2.82e-47	Fat distribution (HIV);
BRCA	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg16325326	chr1:53192061	ZYG11B	0.96	26.73	0.73	2.94e-106	Monocyte count;
BRCA	cis	rs858239	0.896	rs1637192	chr7:23260514	G/A	cg23682824	chr7:23144976	KLHL7	0.34	8.88	0.33	6.69e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.09	0.34	1.24e-18	Tonsillectomy;
BRCA	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	10.62	0.39	2.29e-24	Motion sickness;
BRCA	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06108461	chr20:60628389	TAF4	-1.01	-22.74	-0.67	2.4e-84	Body mass index;
BRCA	cis	rs3772130	1.000	rs3772130	chr3:121344140	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	9.67	0.36	1.02e-20	Cognitive performance;
BRCA	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg11657440	chr19:46296263	DMWD	-0.54	-12.72	-0.45	3.2e-33	Coronary artery disease;
BRCA	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg16414030	chr3:133502952	NA	-0.47	-11.12	-0.4	2.32e-26	Iron status biomarkers;
BRCA	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg01256987	chr12:42539512	GXYLT1	-0.45	-9.11	-0.34	1.02e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	18.79	0.6	4.58e-63	Smoking behavior;
BRCA	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg27478167	chr7:817139	HEATR2	-0.57	-11.49	-0.41	6.87e-28	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	11.53	0.42	4.35e-28	Coronary artery disease;
BRCA	trans	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg25206134	chr2:45395956	NA	0.53	8.76	0.33	1.76e-17	Bipolar disorder;
BRCA	cis	rs17688601	1.000	rs17688583	chr7:40865696	C/T	cg05119115	chr7:40866195	C7orf10	-0.6	-11.65	-0.42	1.45e-28	Pancreatic cancer;
BRCA	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg23442198	chr4:187126114	CYP4V2	0.92	10.79	0.39	4.94e-25	Blood protein levels;
BRCA	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg18806716	chr10:30721971	MAP3K8	-0.41	-9.61	-0.36	1.6e-20	Itch intensity from mosquito bite;
BRCA	cis	rs877529	0.967	rs139405	chr22:39549526	C/A	cg12193277	chr22:39547181	CBX7	0.46	12.33	0.44	1.8e-31	Multiple myeloma;
BRCA	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg23625390	chr15:77176239	SCAPER	-0.54	-13.62	-0.47	2.72e-37	Blood metabolite levels;
BRCA	cis	rs877282	0.947	rs4133015	chr10:774131	T/C	cg17470449	chr10:769945	NA	0.5	9.55	0.35	2.74e-20	Uric acid levels;
BRCA	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg08999081	chr20:33150536	PIGU	-0.45	-12.16	-0.43	9.91e-31	Glomerular filtration rate (creatinine);
BRCA	trans	rs3010562	1.000	rs3010562	chr6:167765251	A/G	cg13033054	chr21:33948561	TCP10L	0.34	8.31	0.31	5.71e-16	Gut microbiome composition (summer and winter);
BRCA	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg02176678	chr2:219576539	TTLL4	0.39	10.31	0.38	3.65e-23	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg25174290	chr11:3078921	CARS	0.44	13.28	0.47	1.01e-35	Longevity;
BRCA	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	8.65e-21	Menopause (age at onset);
BRCA	cis	rs9311474	0.713	rs181274	chr3:52233861	T/A	cg15698299	chr3:52233019	ALAS1	-0.4	-9.46	-0.35	6.03e-20	Electroencephalogram traits;
BRCA	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg15112475	chr7:1198522	ZFAND2A	0.4	8.66	0.32	3.86e-17	Longevity;Endometriosis;
BRCA	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg22875332	chr1:76189707	ACADM	0.64	12.06	0.43	2.44e-30	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg02734326	chr4:10020555	SLC2A9	0.37	8.37	0.31	3.66e-16	Bone mineral density;
BRCA	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21659725	chr3:3221576	CRBN	-0.47	-12.07	-0.43	2.42e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs7586879	0.789	rs67221599	chr2:25131948	T/C	cg04586622	chr2:25135609	ADCY3	0.4	9.52	0.35	3.59e-20	Body mass index;
BRCA	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg27165867	chr14:105738592	BRF1	-0.35	-8.31	-0.31	5.74e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs1865721	0.771	rs6566092	chr18:73136496	C/T	cg26385618	chr18:73139727	C18orf62	-0.43	-10.64	-0.39	1.88e-24	Intelligence;
BRCA	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.64	-0.42	1.5e-28	Alcohol dependence;
BRCA	trans	rs1997103	1.000	rs10270618	chr7:55396712	T/A	cg20935933	chr6:143382018	AIG1	0.6	11.52	0.41	4.77e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7617773	0.780	rs4392440	chr3:48343920	C/T	cg11946769	chr3:48343235	NME6	0.69	13.87	0.48	2.01e-38	Coronary artery disease;
BRCA	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg22875332	chr1:76189707	ACADM	0.7	14.98	0.51	1.07e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg13319975	chr6:146136371	FBXO30	-0.41	-9.45	-0.35	6.3e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6496044	0.547	rs1564719	chr15:86054266	C/T	cg10818794	chr15:86012489	AKAP13	-0.32	-8.68	-0.32	3.24e-17	Interstitial lung disease;
BRCA	cis	rs4908768	0.539	rs6675443	chr1:8651582	T/A	cg20416874	chr1:8611966	RERE	-0.3	-8.34	-0.31	4.48e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg26769984	chr7:1090371	C7orf50	0.48	9.14	0.34	7.88e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg17366294	chr4:99064904	C4orf37	0.41	9.74	0.36	5.54e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6815814	0.950	rs5743593	chr4:38802913	A/G	cg06935464	chr4:38784597	TLR10	0.51	8.52	0.32	1.18e-16	Breast cancer;
BRCA	trans	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg17830980	chr10:43048298	ZNF37B	-0.4	-9.31	-0.35	2.06e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2455601	0.882	rs11042106	chr11:8896083	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.48	8.09	0.3	2.99e-15	Schizophrenia;
BRCA	trans	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg06606381	chr12:133084897	FBRSL1	-0.78	-8.32	-0.31	5.37e-16	Depression;
BRCA	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg26384229	chr12:38710491	ALG10B	-0.72	-16.32	-0.54	2.63e-50	Morning vs. evening chronotype;
BRCA	cis	rs4664304	0.620	rs10929956	chr2:160714615	C/T	cg01092293	chr2:160761427	LY75	0.36	8.53	0.32	1.05e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	8.73	0.33	2.21e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4363385	0.720	rs6704498	chr1:152964740	C/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.51	-0.35	3.76e-20	Inflammatory skin disease;
BRCA	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg24692254	chr21:30365293	RNF160	-0.6	-15.25	-0.52	4.97e-45	Dental caries;
BRCA	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.69	0.39	1.24e-24	IgG glycosylation;
BRCA	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08564027	chr20:61660810	NA	0.85	22.93	0.67	2.35e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg11608241	chr8:8085544	FLJ10661	0.27	7.86	0.3	1.64e-14	Neuroticism;
BRCA	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg18305652	chr10:134549665	INPP5A	-0.3	-8.63	-0.32	4.76e-17	Migraine;
BRCA	cis	rs10504073	0.584	rs62507177	chr8:49937306	C/A	cg00325661	chr8:49890786	NA	0.47	13.48	0.47	1.31e-36	Blood metabolite ratios;
BRCA	cis	rs10089	0.552	rs1351141	chr5:127550055	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.5	-10.25	-0.38	6.39e-23	Ileal carcinoids;
BRCA	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00149659	chr3:10157352	C3orf10	0.8	13.88	0.48	1.79e-38	Alzheimer's disease;
BRCA	trans	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg06521331	chr12:34319734	NA	-0.49	-9.15	-0.34	7.35e-19	Bladder cancer;
BRCA	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg26384229	chr12:38710491	ALG10B	0.66	15.04	0.51	5.67e-44	Bladder cancer;
BRCA	cis	rs4664304	0.620	rs2048436	chr2:160712119	A/G	cg18514922	chr2:160761262	LY75	0.34	7.97	0.3	7.22e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs13064411	0.696	rs6783965	chr3:113198722	C/T	cg18753928	chr3:113234510	CCDC52	-0.58	-11.7	-0.42	8.4e-29	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.44	0.38	1.12e-23	Motion sickness;
BRCA	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08219700	chr8:58056026	NA	0.59	9.48	0.35	4.84e-20	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.93	0.3	1.01e-14	Corneal astigmatism;
BRCA	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-9.16	-0.34	7.22e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-7.99	-0.3	6.42e-15	Total body bone mineral density;
BRCA	cis	rs6120849	0.901	rs6058194	chr20:33739831	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	8.71	0.33	2.63e-17	Protein C levels;
BRCA	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11764359	chr7:65958608	NA	-0.7	-15.03	-0.51	5.83e-44	Aortic root size;
BRCA	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg05623727	chr3:50126028	RBM5	-0.44	-10.38	-0.38	2e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg23202291	chr11:1979235	NA	0.41	9.23	0.34	3.93e-19	DNA methylation (parent-of-origin);DNA methylation (variation);
BRCA	cis	rs2625529	0.652	rs1481862	chr15:72245648	G/A	cg16672083	chr15:72433130	SENP8	0.64	15.37	0.52	1.38e-45	Red blood cell count;
BRCA	cis	rs7944584	0.632	rs749067	chr11:47318157	T/C	cg20307385	chr11:47447363	PSMC3	0.58	11.69	0.42	9.24e-29	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.5e-36	High light scatter reticulocyte count;
BRCA	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg11764359	chr7:65958608	NA	-0.74	-16.09	-0.54	3.77e-49	Aortic root size;
BRCA	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg04756594	chr16:24857601	SLC5A11	0.34	8.31	0.31	5.84e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9296092	0.560	rs9469505	chr6:33527348	A/G	cg13560919	chr6:33536144	NA	-0.85	-18.69	-0.59	1.6e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	8.02	0.3	4.98e-15	Monocyte percentage of white cells;
BRCA	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg06671706	chr8:8559999	CLDN23	-0.4	-8.04	-0.3	4.37e-15	Obesity-related traits;
BRCA	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg20476274	chr7:133979776	SLC35B4	0.65	19.4	0.61	2.78e-66	Mean platelet volume;
BRCA	cis	rs2108225	0.872	rs2051955	chr7:107441154	C/T	cg18560240	chr7:107437656	SLC26A3	-0.55	-11.52	-0.41	4.83e-28	Ulcerative colitis;
BRCA	cis	rs6604026	0.740	rs10782945	chr1:93304272	C/T	cg17283838	chr1:93427260	FAM69A	-0.4	-8.3	-0.31	6.15e-16	Multiple sclerosis;
BRCA	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	19.65	0.61	1.3e-67	Smoking behavior;
BRCA	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.56	-9.78	-0.36	3.77e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg00484396	chr16:3507460	NAT15	0.46	9.99	0.37	6.34e-22	Tuberculosis;
BRCA	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg12923728	chr3:195709715	SDHAP1	0.38	7.85	0.3	1.72e-14	Mean corpuscular volume;
BRCA	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg11189052	chr15:85197271	WDR73	-0.33	-7.98	-0.3	6.92e-15	P wave terminal force;
BRCA	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.24	-0.46	1.63e-35	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg16230307	chr14:35515116	FAM177A1	0.7	14.69	0.5	2.74e-42	Psoriasis;
BRCA	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-9.23	-0.34	4.04e-19	Pulmonary function;
BRCA	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg02659138	chr7:134003124	SLC35B4	0.33	10.58	0.39	3.38e-24	Mean platelet volume;
BRCA	trans	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg23533926	chr12:111358616	MYL2	-0.41	-8.06	-0.3	3.65e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg06521331	chr12:34319734	NA	-0.52	-9.45	-0.35	6.17e-20	Bladder cancer;
BRCA	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.81e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg09436375	chr6:42928200	GNMT	-0.3	-11.24	-0.41	6.95e-27	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg03709012	chr19:19516395	GATAD2A	-0.75	-17.01	-0.56	8.07e-54	Tonsillectomy;
BRCA	cis	rs1371614	0.611	rs877272	chr2:27139888	C/T	cg12368169	chr2:27073192	DPYSL5	0.3	9.0	0.34	2.53e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11764359	chr7:65958608	NA	-0.75	-16.53	-0.55	2.26e-51	Aortic root size;
BRCA	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.86e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7617773	0.817	rs9834095	chr3:48327751	G/A	cg11946769	chr3:48343235	NME6	0.63	13.47	0.47	1.45e-36	Coronary artery disease;
BRCA	trans	rs10242455	0.702	rs73403247	chr7:99088730	G/A	cg09045935	chr12:6379348	NA	0.88	8.55	0.32	8.86e-17	Blood metabolite levels;
BRCA	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg12143784	chr7:64541923	NA	0.38	8.09	0.3	3.08e-15	Calcium levels;
BRCA	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-11.07	-0.4	3.42e-26	Uric acid levels;
BRCA	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg12310025	chr6:25882481	NA	-0.76	-17.94	-0.58	1.31e-58	Intelligence (multi-trait analysis);
BRCA	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg03585969	chr10:35415529	CREM	0.56	11.5	0.41	5.98e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg12935359	chr14:103987150	CKB	0.64	15.01	0.51	8.04e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg17845761	chr1:175162550	KIAA0040	0.25	9.71	0.36	6.88e-21	Alcohol dependence;
BRCA	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg23791538	chr6:167370224	RNASET2	-0.33	-7.97	-0.3	7.1e-15	Crohn's disease;
BRCA	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg01528321	chr10:82214614	TSPAN14	0.74	15.74	0.53	1.94e-47	Post bronchodilator FEV1;
BRCA	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg18301423	chr5:131593218	PDLIM4	0.33	8.02	0.3	5.23e-15	Acylcarnitine levels;
BRCA	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24549020	chr5:56110836	MAP3K1	0.66	13.4	0.47	2.87e-36	Initial pursuit acceleration;
BRCA	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg08975724	chr8:8085496	FLJ10661	0.36	7.81	0.3	2.43e-14	Joint mobility (Beighton score);
BRCA	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg26384229	chr12:38710491	ALG10B	0.65	13.67	0.48	1.64e-37	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg26384229	chr12:38710491	ALG10B	0.63	13.71	0.48	1.11e-37	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.654	rs1129654	chr1:152958238	A/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.79	-0.33	1.41e-17	Inflammatory skin disease;
BRCA	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg07169764	chr2:136633963	MCM6	1.22	23.88	0.69	1.37e-90	Corneal structure;
BRCA	cis	rs13395090	1.000	rs11687349	chr2:3717496	A/C	cg19052272	chr2:3704530	ALLC	-0.32	-7.97	-0.3	7.33e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg03433033	chr1:76189801	ACADM	0.89	23.73	0.68	9.91e-90	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4862307	0.836	rs4507404	chr4:185003767	C/T	cg06737308	chr4:185021514	ENPP6	-0.37	-8.17	-0.31	1.7e-15	Serum dimethylarginine levels (asymmetric/symetric ratio);
BRCA	cis	rs7640424	0.716	rs35703078	chr3:107859558	A/G	cg09227934	chr3:107805635	CD47	-0.43	-8.91	-0.33	5.36e-18	Body mass index;
BRCA	cis	rs9644630	0.696	rs13261824	chr8:19313912	C/G	cg06562184	chr8:19319451	CSGALNACT1	0.34	8.06	0.3	3.85e-15	Oropharynx cancer;
BRCA	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg22972055	chr7:872293	UNC84A	0.39	8.69	0.32	3.12e-17	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7945718	0.967	rs10765990	chr11:12769444	G/A	cg25843174	chr11:12811716	TEAD1	0.23	8.75	0.33	1.88e-17	Educational attainment (years of education);
BRCA	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg09307838	chr4:120376055	NA	0.76	16.73	0.55	2.21e-52	Corneal astigmatism;
BRCA	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg12011299	chr4:100065546	ADH4	0.5	11.51	0.41	5.61e-28	Alcohol dependence;
BRCA	cis	rs113835537	0.529	rs2305532	chr11:66298594	C/T	cg24851651	chr11:66362959	CCS	0.48	8.72	0.33	2.46e-17	Airway imaging phenotypes;
BRCA	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg18252515	chr7:66147081	NA	-0.41	-8.77	-0.33	1.61e-17	Corneal structure;
BRCA	trans	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg25214090	chr10:38739885	LOC399744	0.54	12.24	0.44	4.06e-31	Corneal astigmatism;
BRCA	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg06671706	chr8:8559999	CLDN23	-0.41	-8.21	-0.31	1.24e-15	Obesity-related traits;
BRCA	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg06885757	chr1:42089581	HIVEP3	0.28	10.43	0.38	1.21e-23	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs2652834	1.000	rs8032104	chr15:63400584	A/G	cg05507819	chr15:63340323	TPM1	0.45	8.03	0.3	4.77e-15	HDL cholesterol;
BRCA	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg17366294	chr4:99064904	C4orf37	0.54	11.58	0.42	2.76e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs72634258	0.554	rs4908704	chr1:7918904	A/G	cg00042356	chr1:8021962	PARK7	0.54	8.59	0.32	6.85e-17	Inflammatory bowel disease;
BRCA	cis	rs11051970	0.611	rs10844197	chr12:32561015	A/C	cg24626660	chr12:32551988	NA	0.31	9.18	0.34	6.02e-19	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-8.55	-0.32	9.01e-17	Schizophrenia;
BRCA	cis	rs2279817	1.000	rs35148872	chr1:18020184	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.53	-13.44	-0.47	1.98e-36	Neuroticism;
BRCA	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	8.97	0.33	3.36e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg00409905	chr10:38381863	ZNF37A	-0.51	-10.9	-0.4	1.69e-25	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg11645453	chr3:52864694	ITIH4	0.39	9.18	0.34	5.99e-19	Schizophrenia;
BRCA	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	14.21	0.49	5.27e-40	Electrocardiographic conduction measures;
BRCA	cis	rs7756236	0.521	rs9470363	chr6:36624713	G/A	cg08179530	chr6:36648295	CDKN1A	0.38	8.25	0.31	9.2e-16	QRS duration;
BRCA	trans	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-10.3	-0.38	3.98e-23	Morning vs. evening chronotype;
BRCA	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg21798802	chr22:38057573	PDXP	0.49	13.18	0.46	2.91e-35	Fat distribution (HIV);
BRCA	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg05294307	chr14:35346193	BAZ1A	-0.61	-10.41	-0.38	1.57e-23	Psoriasis;
BRCA	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg04944784	chr2:26401820	FAM59B	-0.82	-14.79	-0.5	8.78e-43	Gut microbiome composition (summer);
BRCA	cis	rs17601876	0.814	rs8042086	chr15:51561478	C/T	cg19946085	chr15:51559439	CYP19A1	-0.39	-11.62	-0.42	1.87e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg10932868	chr11:921992	NA	0.51	13.27	0.46	1.17e-35	Alzheimer's disease (late onset);
BRCA	cis	rs4074536	0.574	rs10754350	chr1:116291885	A/G	cg21648376	chr1:116311395	CASQ2	-0.49	-8.66	-0.32	3.83e-17	QRS duration;
BRCA	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg11764359	chr7:65958608	NA	-0.69	-15.53	-0.52	2.29e-46	Aortic root size;
BRCA	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg12365402	chr11:9010492	NRIP3	-0.4	-9.33	-0.35	1.68e-19	Hemoglobin concentration;
BRCA	cis	rs9503598	0.636	rs6596975	chr6:3465925	G/A	cg00476032	chr6:3446245	SLC22A23	0.38	9.27	0.34	2.73e-19	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg07080220	chr10:102295463	HIF1AN	0.57	13.04	0.46	1.19e-34	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-15.94	-0.53	2.15e-48	Alzheimer's disease (late onset);
BRCA	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.9	-28.32	-0.75	5.92e-115	Schizophrenia;
BRCA	trans	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg07461501	chr17:79650226	HGS;ARL16	0.39	10.0	0.37	5.83e-22	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg07636037	chr3:49044803	WDR6	-0.53	-8.74	-0.33	2.06e-17	Menarche (age at onset);
BRCA	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg23711669	chr6:146136114	FBXO30	0.77	18.22	0.58	4.85e-60	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg04944784	chr2:26401820	FAM59B	0.73	11.88	0.43	1.47e-29	Gut microbiome composition (summer);
BRCA	cis	rs4664304	0.620	rs2048436	chr2:160712119	A/G	cg02280532	chr2:160761244	LY75	0.35	7.85	0.3	1.81e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg23625390	chr15:77176239	SCAPER	0.39	9.61	0.36	1.64e-20	Blood metabolite levels;
BRCA	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg04990556	chr1:26633338	UBXN11	-0.47	-9.32	-0.35	1.84e-19	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg07169764	chr2:136633963	MCM6	1.0	20.29	0.63	4.98e-71	Corneal structure;
BRCA	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00934597	chr7:893267	UNC84A	0.51	11.27	0.41	5.35e-27	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg04315214	chr1:2043799	PRKCZ	0.48	12.56	0.45	1.63e-32	Height;
BRCA	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.36	-0.31	3.97e-16	Retinal vascular caliber;
BRCA	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg11301795	chr4:187892539	NA	-0.27	-8.81	-0.33	1.17e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg20607798	chr8:58055168	NA	0.48	8.36	0.31	3.99e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs524281	0.861	rs7935336	chr11:65865325	C/T	cg16950941	chr11:66035639	RAB1B	-0.38	-8.05	-0.3	4.15e-15	Electroencephalogram traits;
BRCA	cis	rs2267137	0.868	rs174770	chr22:29766895	C/T	cg07256473	chr22:29710276	RASL10A	0.36	8.78	0.33	1.46e-17	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs939658	0.805	rs2010524	chr15:79435825	G/T	cg17916960	chr15:79447300	NA	-0.45	-11.22	-0.41	8.53e-27	Refractive error;
BRCA	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg02734326	chr4:10020555	SLC2A9	0.39	8.45	0.32	1.96e-16	Bone mineral density;
BRCA	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg08645402	chr16:4508243	NA	0.37	8.81	0.33	1.14e-17	Schizophrenia;
BRCA	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg26384229	chr12:38710491	ALG10B	0.76	17.15	0.56	1.68e-54	Bladder cancer;
BRCA	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg09526685	chr4:187126073	CYP4V2	0.87	9.03	0.34	2.07e-18	Blood protein levels;
BRCA	trans	rs208520	0.874	rs208456	chr6:66907942	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-15.98	-0.53	1.37e-48	Exhaled nitric oxide output;
BRCA	cis	rs4363385	0.818	rs532743	chr1:153011758	T/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.27	-0.34	2.84e-19	Inflammatory skin disease;
BRCA	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	8.1	0.31	2.71e-15	Uric acid levels;
BRCA	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	13.11	0.46	5.99e-35	Bone mineral density;
BRCA	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08859206	chr1:53392774	SCP2	0.67	13.8	0.48	4.09e-38	Monocyte count;
BRCA	cis	rs73086581	0.838	rs56401022	chr20:4024281	A/G	cg02187196	chr20:3869020	PANK2	0.5	9.23	0.34	4.07e-19	Response to antidepressants in depression;
BRCA	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg22491629	chr6:157744540	C6orf35	-0.68	-12.56	-0.44	1.79e-32	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg09307838	chr4:120376055	NA	0.68	13.64	0.47	2.39e-37	Corneal astigmatism;
BRCA	cis	rs757081	0.667	rs12577388	chr11:17101155	C/T	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.59	-0.32	6.73e-17	Systolic blood pressure;
BRCA	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.46	-10.35	-0.38	2.65e-23	Reticulocyte count;
BRCA	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02176678	chr2:219576539	TTLL4	0.43	10.99	0.4	7.63e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg13175981	chr1:150552382	MCL1	0.42	9.4	0.35	9.26e-20	Tonsillectomy;
BRCA	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-12.94	-0.46	3.61e-34	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs7264396	0.887	rs224354	chr20:34054609	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-8.32	-0.31	5.29e-16	Total cholesterol levels;
BRCA	trans	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg11693508	chr17:37793320	STARD3	0.53	8.98	0.33	3.03e-18	Neuroticism;
BRCA	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg14683738	chr19:37701593	ZNF585B	0.44	7.89	0.3	1.3e-14	Coronary artery calcification;
BRCA	cis	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg08601574	chr20:25228251	PYGB	0.34	7.93	0.3	9.57e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg07460842	chr6:66804631	NA	0.6	10.34	0.38	2.78e-23	Type 2 diabetes;
BRCA	cis	rs9503598	0.636	rs7766753	chr6:3467708	A/C	cg00476032	chr6:3446245	SLC22A23	0.38	8.83	0.33	9.92e-18	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs3784262	0.564	rs34958088	chr15:58328332	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.35	-0.38	2.56e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg23788917	chr6:8435910	SLC35B3	-0.43	-9.27	-0.34	2.91e-19	Motion sickness;
BRCA	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg20818283	chr2:191399100	TMEM194B	0.43	9.81	0.36	3.05e-21	Pulse pressure;
BRCA	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.14	-0.31	2.1e-15	Depression;
BRCA	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg11502198	chr6:26597334	ABT1	0.56	12.02	0.43	3.88e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg16586182	chr3:47516702	SCAP	0.54	11.85	0.42	1.93e-29	Colorectal cancer;
BRCA	cis	rs1451375	0.698	rs12669770	chr7:50656334	G/A	cg18232548	chr7:50535776	DDC	0.4	9.25	0.34	3.2e-19	Malaria;
BRCA	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg12011299	chr4:100065546	ADH4	0.41	10.2	0.37	9.45e-23	Alcohol dependence;
BRCA	cis	rs1868673	1.000	rs1450344	chr3:150185745	G/A	cg04908077	chr3:150187338	NA	-0.32	-8.61	-0.32	5.76e-17	Waist circumference;
BRCA	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.36	9.14	0.34	7.88e-19	Resting heart rate;
BRCA	trans	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg09719594	chr16:21412588	NA	0.33	8.07	0.3	3.6e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-16.41	-0.54	9.23e-51	Extrinsic epigenetic age acceleration;
BRCA	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	13.82	0.48	3.34e-38	Lymphocyte counts;
BRCA	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg01448562	chr3:133502909	NA	-0.74	-18.35	-0.59	1.04e-60	Iron status biomarkers;
BRCA	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.29	0.49	2.05e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs701145	0.556	rs357502	chr3:153955950	C/T	cg16511985	chr3:153974050	SGEF	0.46	10.59	0.39	3.09e-24	Coronary artery disease;
BRCA	cis	rs36051895	0.659	rs12343065	chr9:5083533	C/T	cg02405213	chr9:5042618	JAK2	-0.55	-9.62	-0.36	1.52e-20	Pediatric autoimmune diseases;
BRCA	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg01802117	chr1:53393560	SCP2	-0.4	-9.0	-0.34	2.61e-18	Monocyte count;
BRCA	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.54	8.4	0.32	2.86e-16	HIV-1 control;
BRCA	cis	rs586533	0.881	rs683621	chr11:99501423	G/A	cg22878054	chr11:99397252	CNTN5	0.32	8.11	0.31	2.53e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg11584989	chr19:19387371	SF4	0.69	13.59	0.47	3.96e-37	Bipolar disorder;
BRCA	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-11.68	-0.42	1.01e-28	Hemoglobin concentration;
BRCA	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg11941060	chr3:133502564	NA	-0.51	-12.03	-0.43	3.31e-30	Iron status biomarkers;
BRCA	cis	rs2016266	0.929	rs7399003	chr12:53659536	C/T	cg26875137	chr12:53738046	NA	0.35	9.71	0.36	6.92e-21	Bone mineral density (spine);Bone mineral density;
BRCA	trans	rs526821	0.595	rs551665	chr11:55343268	G/A	cg15704280	chr7:45808275	SEPT13	-0.42	-7.84	-0.3	1.92e-14	Pediatric bone mineral density (spine);
BRCA	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg27661571	chr11:113659931	NA	-0.82	-12.19	-0.43	7.07e-31	Hip circumference adjusted for BMI;
BRCA	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg09307838	chr4:120376055	NA	0.46	9.58	0.35	2.17e-20	Diastolic blood pressure;
BRCA	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg02493740	chr2:85810744	VAMP5	-0.53	-10.91	-0.4	1.6e-25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs7020830	0.867	rs55845273	chr9:37362219	C/T	cg14294708	chr9:37120828	ZCCHC7	1.12	35.95	0.82	1.25e-155	Schizophrenia;
BRCA	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg27588902	chr6:42928151	GNMT	-0.3	-9.88	-0.36	1.63e-21	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg24562669	chr7:97807699	LMTK2	-0.43	-11.34	-0.41	2.67e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg18225595	chr11:63971243	STIP1	0.4	9.85	0.36	2.04e-21	Platelet count;
BRCA	cis	rs6060717	0.536	rs6060699	chr20:34523833	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-10.63	-0.39	2.13e-24	Hip circumference adjusted for BMI;
BRCA	cis	rs10851411	0.697	rs12439377	chr15:42861362	C/T	cg21293051	chr15:42870591	STARD9	0.51	8.82	0.33	1.05e-17	Glucose homeostasis traits;
BRCA	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11764359	chr7:65958608	NA	0.8	18.81	0.6	4.01e-63	Aortic root size;
BRCA	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg16606324	chr3:10149918	C3orf24	0.5	9.56	0.35	2.53e-20	Alzheimer's disease;
BRCA	cis	rs1003719	0.843	rs1003721	chr21:38492657	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.57	13.04	0.46	1.19e-34	Eye color traits;
BRCA	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18876405	chr7:65276391	NA	0.52	11.67	0.42	1.13e-28	Aortic root size;
BRCA	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.41	8.77	0.33	1.64e-17	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg26384229	chr12:38710491	ALG10B	0.75	17.0	0.56	9.67e-54	Bladder cancer;
BRCA	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg09307838	chr4:120376055	NA	0.72	15.33	0.52	2.14e-45	Corneal astigmatism;
BRCA	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg03474202	chr17:45855739	NA	-0.47	-12.49	-0.44	3.33e-32	IgG glycosylation;
BRCA	cis	rs7789940	1.000	rs73140069	chr7:75986790	T/A	cg10167463	chr7:75959203	YWHAG	-0.44	-8.8	-0.33	1.31e-17	Multiple sclerosis;
BRCA	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg06484146	chr7:12443880	VWDE	-0.75	-10.68	-0.39	1.35e-24	Coronary artery disease;
BRCA	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg15448220	chr1:150897856	SETDB1	0.37	8.29	0.31	6.49e-16	Melanoma;
BRCA	cis	rs698833	0.521	rs35627501	chr2:44506971	G/C	cg04920474	chr2:44395004	PPM1B	0.38	8.92	0.33	4.82e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	trans	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg25214090	chr10:38739885	LOC399744	0.53	12.03	0.43	3.51e-30	Corneal astigmatism;
BRCA	cis	rs10463316	0.894	rs10042030	chr5:150768028	T/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.33	-0.31	4.91e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg08888203	chr3:10149979	C3orf24	0.67	14.02	0.49	3.85e-39	Alzheimer's disease;
BRCA	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg12193833	chr17:30244370	NA	-0.62	-9.96	-0.37	8.2e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	16.42	0.54	8.59e-51	Colorectal cancer;
BRCA	trans	rs2736337	0.532	rs6998387	chr8:11293458	C/T	cg06636001	chr8:8085503	FLJ10661	0.44	8.77	0.33	1.61e-17	Rheumatoid arthritis;
BRCA	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.76	-0.42	5.05e-29	Alcohol dependence;
BRCA	cis	rs1569175	0.655	rs166847	chr2:200840612	A/G	cg23649088	chr2:200775458	C2orf69	-0.65	-8.28	-0.31	7.49e-16	Response to treatment for acute lymphoblastic leukemia;
BRCA	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-9.07	-0.34	1.44e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7635838	0.684	rs2594966	chr3:11325276	A/G	cg00170343	chr3:11313890	ATG7	-0.41	-8.5	-0.32	1.35e-16	HDL cholesterol;
BRCA	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07343612	chr16:622815	PIGQ	-0.68	-22.12	-0.66	6.29e-81	Height;
BRCA	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.36	-8.28	-0.31	7.47e-16	Longevity;Endometriosis;
BRCA	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg21475434	chr5:93447410	FAM172A	0.69	9.16	0.34	6.78e-19	Diabetic retinopathy;
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg03188948	chr7:1209495	NA	0.54	9.92	0.37	1.13e-21	Longevity;Endometriosis;
BRCA	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg00677455	chr12:58241039	CTDSP2	-0.35	-8.02	-0.3	5e-15	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg20503657	chr10:835505	NA	-1.28	-21.13	-0.64	1.38e-75	Eosinophil percentage of granulocytes;
BRCA	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg06713675	chr4:122721982	EXOSC9	-0.53	-12.37	-0.44	1.19e-31	Type 2 diabetes;
BRCA	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.13	0.31	2.28e-15	Total cholesterol levels;
BRCA	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.39	-0.38	1.87e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs4845875	0.600	rs4846040	chr1:11837048	C/G	cg24844545	chr1:11908347	NPPA	0.37	8.68	0.32	3.35e-17	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg04362960	chr10:104952993	NT5C2	0.46	10.73	0.39	8.24e-25	Arsenic metabolism;
BRCA	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg27398817	chr8:82754497	SNX16	0.49	9.26	0.34	2.97e-19	Diastolic blood pressure;
BRCA	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg18196295	chr10:418757	DIP2C	-0.49	-10.07	-0.37	3.05e-22	Psychosis in Alzheimer's disease;
BRCA	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.93	-0.33	4.63e-18	Height;
BRCA	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.33	0.38	3.11e-23	Bipolar disorder;
BRCA	cis	rs9790314	0.779	rs12493960	chr3:160899772	T/C	cg04691961	chr3:161091175	C3orf57	-0.51	-11.13	-0.4	1.98e-26	Morning vs. evening chronotype;
BRCA	cis	rs67981189	0.896	rs2810100	chr14:71432172	C/A	cg15816911	chr14:71606274	NA	-0.35	-7.94	-0.3	9.17e-15	Schizophrenia;
BRCA	trans	rs11088226	0.681	rs11702499	chr21:33938565	C/T	cg09050820	chr6:167586206	TCP10L2	0.77	13.24	0.46	1.49e-35	Gastritis;
BRCA	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg09754948	chr16:28834200	ATXN2L	0.38	7.94	0.3	9e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg01292856	chr11:65242576	NA	0.33	8.0	0.3	5.89e-15	Bone mineral density;
BRCA	trans	rs11088226	0.846	rs13047501	chr21:33924660	G/A	cg09050820	chr6:167586206	TCP10L2	0.57	10.88	0.4	2.15e-25	Gastritis;
BRCA	cis	rs7617773	0.817	rs6801801	chr3:48326433	T/C	cg11946769	chr3:48343235	NME6	0.62	13.68	0.48	1.48e-37	Coronary artery disease;
BRCA	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg06159980	chr1:16340746	HSPB7	-0.38	-7.95	-0.3	8.43e-15	Dilated cardiomyopathy;
BRCA	trans	rs12310956	0.532	rs2171534	chr12:33838998	C/T	cg26384229	chr12:38710491	ALG10B	0.44	10.0	0.37	5.63e-22	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19346786	chr7:2764209	NA	-0.35	-10.56	-0.39	3.95e-24	Height;
BRCA	cis	rs6960043	0.818	rs10238161	chr7:15053827	A/T	cg19272540	chr7:15055459	NA	0.22	7.94	0.3	9.27e-15	Type 2 diabetes;
BRCA	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	11.72	0.42	7.01e-29	Bipolar disorder;
BRCA	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg10811474	chr19:8428787	ANGPTL4	-0.34	-8.74	-0.33	2.13e-17	HDL cholesterol;
BRCA	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg25174290	chr11:3078921	CARS	0.43	12.96	0.46	2.94e-34	Longevity;
BRCA	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.86	-15.01	-0.51	7.95e-44	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7572733	0.555	rs35563720	chr2:198923075	A/G	cg00792783	chr2:198669748	PLCL1	0.39	8.48	0.32	1.62e-16	Dermatomyositis;
BRCA	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.29	0.44	2.59e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6546550	0.901	rs3732266	chr2:70057448	T/G	cg02498382	chr2:70120550	SNRNP27	-0.51	-10.65	-0.39	1.69e-24	Prevalent atrial fibrillation;
BRCA	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg13010199	chr12:38710504	ALG10B	0.33	7.94	0.3	9.36e-15	Heart rate;
BRCA	cis	rs2479724	0.755	rs4318867	chr6:41753670	G/T	cg17623882	chr6:41773611	USP49	0.33	8.85	0.33	8.49e-18	Menarche (age at onset);
BRCA	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg15832292	chr6:96025679	MANEA	0.5	8.04	0.3	4.51e-15	Behavioural disinhibition (generation interaction);
BRCA	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg15103426	chr22:29168792	CCDC117	-0.51	-12.17	-0.43	8.71e-31	Lymphocyte counts;
BRCA	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg22834771	chr12:69754056	YEATS4	-0.39	-9.64	-0.36	1.29e-20	Blood protein levels;
BRCA	cis	rs2742234	0.955	rs2503849	chr10:43672776	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.43	-8.91	-0.33	5.1e-18	Hirschsprung disease;
BRCA	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	18.28	0.59	2.22e-60	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs9309711	0.922	rs7561600	chr2:3486093	G/C	cg10845886	chr2:3471009	TTC15	-0.74	-15.74	-0.53	2.05e-47	Neurofibrillary tangles;
BRCA	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg17366294	chr4:99064904	C4orf37	-0.45	-10.78	-0.39	5.04e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.45	-9.25	-0.34	3.29e-19	Body mass index;
BRCA	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-10.93	-0.4	1.27e-25	Neuroticism;
BRCA	cis	rs9467773	0.572	rs3846846	chr6:26445039	A/G	cg09904177	chr6:26538194	HMGN4	-0.37	-9.81	-0.36	3.06e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg01884057	chr2:25150051	NA	-0.33	-8.84	-0.33	9.21e-18	Body mass index;
BRCA	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22455342	chr2:225449267	CUL3	0.63	16.53	0.55	2.23e-51	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg20703242	chr1:230279135	GALNT2	-0.46	-9.52	-0.35	3.57e-20	Coronary artery disease;
BRCA	cis	rs2710642	0.861	rs2710644	chr2:63248968	A/C	cg17519650	chr2:63277830	OTX1	0.42	8.68	0.32	3.35e-17	LDL cholesterol levels;LDL cholesterol;
BRCA	trans	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg06521331	chr12:34319734	NA	-0.51	-9.21	-0.34	4.77e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg11584989	chr19:19387371	SF4	0.66	14.35	0.49	1.12e-40	Bipolar disorder;
BRCA	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg10518572	chr11:65560635	OVOL1	-0.3	-8.41	-0.32	2.71e-16	Acne (severe);
BRCA	cis	rs9837602	1.000	rs793499	chr3:99565576	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.59	-11.06	-0.4	3.81e-26	Breast cancer;
BRCA	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg03923535	chr7:1197113	ZFAND2A	0.53	11.0	0.4	6.73e-26	Longevity;Endometriosis;
BRCA	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18876405	chr7:65276391	NA	-0.5	-11.23	-0.41	7.86e-27	Aortic root size;
BRCA	cis	rs7945718	0.905	rs10831908	chr11:12812419	G/A	cg25843174	chr11:12811716	TEAD1	0.25	9.35	0.35	1.41e-19	Educational attainment (years of education);
BRCA	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg12826209	chr6:26865740	GUSBL1	-0.59	-7.96	-0.3	8.15e-15	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs6076960	0.629	rs6054008	chr20:6212370	C/T	cg17788362	chr6:86352627	SYNCRIP	0.43	8.45	0.32	1.93e-16	Smooth-surface caries;
BRCA	cis	rs738322	0.775	rs4375	chr22:38539041	T/C	cg20207973	chr22:38506712	BAIAP2L2	0.32	8.1	0.31	2.75e-15	Cutaneous nevi;
BRCA	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg20090143	chr19:45452003	APOC2	0.27	8.04	0.3	4.46e-15	Blood protein levels;
BRCA	cis	rs6545883	0.894	rs12620105	chr2:61512321	A/T	cg15711740	chr2:61764176	XPO1	0.51	12.3	0.44	2.46e-31	Tuberculosis;
BRCA	cis	rs812925	0.502	rs6545868	chr2:61655365	T/C	cg15711740	chr2:61764176	XPO1	0.33	8.16	0.31	1.76e-15	Immature fraction of reticulocytes;
BRCA	cis	rs2084898	0.527	rs605374	chr11:120005633	A/C	cg07435449	chr11:120005650	TRIM29	0.36	8.82	0.33	1.12e-17	Stroke (pediatric);
BRCA	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg09307838	chr4:120376055	NA	0.49	10.72	0.39	9.2e-25	Diastolic blood pressure;
BRCA	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg22906224	chr7:99728672	NA	-0.42	-7.87	-0.3	1.54e-14	Coronary artery disease;
BRCA	cis	rs9487051	0.735	rs396000	chr6:109519611	A/G	cg21918786	chr6:109611834	NA	0.36	9.53	0.35	3.25e-20	Reticulocyte fraction of red cells;
BRCA	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg16339924	chr4:17578868	LAP3	0.59	14.46	0.5	3.17e-41	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg01620082	chr3:125678407	NA	-0.7	-8.64	-0.32	4.42e-17	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg21659725	chr3:3221576	CRBN	-0.46	-9.91	-0.36	1.27e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7715811	0.913	rs4368727	chr5:13770248	C/T	cg07548982	chr5:13769939	DNAH5	-0.38	-8.45	-0.32	2.01e-16	Subclinical atherosclerosis traits (other);
BRCA	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg11764359	chr7:65958608	NA	-0.63	-11.2	-0.41	1.04e-26	Aortic root size;
BRCA	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23583168	chr7:148888333	NA	-0.86	-20.07	-0.62	7.29e-70	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6542838	0.641	rs11123756	chr2:99508012	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.4	8.89	0.33	6.44e-18	Fear of minor pain;
BRCA	cis	rs7617773	0.743	rs11715876	chr3:48377922	G/A	cg11946769	chr3:48343235	NME6	0.66	13.23	0.46	1.71e-35	Coronary artery disease;
BRCA	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg04455712	chr21:45112962	RRP1B	0.38	9.78	0.36	3.69e-21	Mean corpuscular volume;
BRCA	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg16576597	chr16:28551801	NUPR1	0.35	8.79	0.33	1.39e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs1493916	0.748	rs1389535	chr18:31310416	A/G	cg27147174	chr7:100797783	AP1S1	0.42	8.36	0.31	3.89e-16	Life satisfaction;
BRCA	trans	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04565464	chr8:145669602	NFKBIL2	0.38	8.6	0.32	6.2e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs7072216	0.763	rs45523432	chr10:100167436	T/C	cg26618903	chr10:100175079	PYROXD2	-0.31	-8.96	-0.33	3.58e-18	Metabolite levels;
BRCA	cis	rs2964802	0.617	rs13174269	chr5:10804759	C/T	cg14521931	chr5:10832172	NA	-0.45	-10.02	-0.37	4.68e-22	Major depressive disorder;Recurrent major depressive disorder;
BRCA	cis	rs600231	0.542	rs10896008	chr11:65245904	C/G	cg01292856	chr11:65242576	NA	0.67	14.67	0.5	3.4e-42	Bone mineral density;
BRCA	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg24558204	chr6:135376177	HBS1L	0.59	16.06	0.54	5.41e-49	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg14926445	chr8:58193284	C8orf71	-0.41	-7.94	-0.3	9.14e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	9.02	0.34	2.12e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg12564285	chr5:131593104	PDLIM4	0.34	7.84	0.3	1.84e-14	Breast cancer;
BRCA	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7809950	1.000	rs10274041	chr7:107261556	C/T	cg23024343	chr7:107201750	COG5	0.37	8.47	0.32	1.66e-16	Coronary artery disease;
BRCA	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg09998033	chr7:158218633	PTPRN2	-0.39	-9.27	-0.34	2.81e-19	Obesity-related traits;
BRCA	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.02	0.49	3.86e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4919694	1.000	rs12257941	chr10:104833161	C/T	cg04362960	chr10:104952993	NT5C2	0.94	14.57	0.5	1.01e-41	Arsenic metabolism;
BRCA	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-13.34	-0.47	5.51e-36	Monocyte count;
BRCA	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg13770153	chr20:60521292	NA	-0.45	-10.67	-0.39	1.43e-24	Body mass index;
BRCA	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg12379764	chr21:47803548	PCNT	-0.37	-7.86	-0.3	1.61e-14	Testicular germ cell tumor;
BRCA	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg25767906	chr1:53392781	SCP2	-0.39	-8.85	-0.33	8.59e-18	Monocyte count;
BRCA	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-17.83	-0.58	4.93e-58	Chronic sinus infection;
BRCA	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg08000102	chr2:233561755	GIGYF2	0.62	13.23	0.46	1.69e-35	Coronary artery disease;
BRCA	trans	rs4714291	0.963	rs1721412	chr6:40100606	T/G	cg02267698	chr19:7991119	CTXN1	0.43	8.41	0.32	2.76e-16	Strep throat;
BRCA	trans	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg25214090	chr10:38739885	LOC399744	0.56	12.85	0.45	9.31e-34	Corneal astigmatism;
BRCA	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg01324343	chr3:183735012	ABCC5	0.85	21.71	0.65	1.08e-78	Anterior chamber depth;
BRCA	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg13010199	chr12:38710504	ALG10B	0.44	8.77	0.33	1.67e-17	Morning vs. evening chronotype;
BRCA	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg19784903	chr17:45786737	TBKBP1	0.34	8.13	0.31	2.24e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-10.49	-0.38	7.18e-24	Mean corpuscular volume;
BRCA	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.54	-11.4	-0.41	1.49e-27	Multiple sclerosis;
BRCA	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg00376283	chr12:123451042	ABCB9	-0.54	-13.65	-0.48	2.09e-37	Height;Educational attainment;Head circumference (infant);
BRCA	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg15112475	chr7:1198522	ZFAND2A	0.37	8.07	0.3	3.59e-15	Longevity;Endometriosis;
BRCA	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg24505687	chr6:33548425	BAK1	0.57	12.15	0.43	1e-30	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
BRCA	cis	rs2274273	0.840	rs943590	chr14:55738596	T/C	cg04306507	chr14:55594613	LGALS3	0.3	8.51	0.32	1.21e-16	Protein biomarker;
BRCA	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.76	-0.57	1.24e-57	Chronic sinus infection;
BRCA	cis	rs2412208	0.509	rs7546792	chr1:7124346	C/T	cg20434152	chr1:7120926	CAMTA1	-0.39	-9.58	-0.35	2.07e-20	Survival in sporadic amyotrophic lateral sclerosis;
BRCA	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	19.2	0.6	3.14e-65	Alzheimer's disease;
BRCA	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg17788362	chr6:86352627	SYNCRIP	0.4	8.14	0.31	2.04e-15	Smooth-surface caries;
BRCA	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg21475434	chr5:93447410	FAM172A	0.67	9.1	0.34	1.1e-18	Diabetic retinopathy;
BRCA	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.01	-26.37	-0.72	2.85e-104	Cognitive ability;
BRCA	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs3739998	0.509	rs61841115	chr10:30333025	C/T	cg12786570	chr10:30316432	KIAA1462	0.48	9.52	0.35	3.47e-20	Coronary heart disease;
BRCA	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21659725	chr3:3221576	CRBN	-0.71	-21.8	-0.65	3.27e-79	Intelligence (multi-trait analysis);
BRCA	trans	rs10242455	0.557	rs73401516	chr7:99068351	C/A	cg09045935	chr12:6379348	NA	0.84	8.4	0.32	2.93e-16	Blood metabolite levels;
BRCA	trans	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.56	-0.35	2.48e-20	Bladder cancer;
BRCA	cis	rs12618769	0.597	rs55900716	chr2:99109132	G/A	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs12210905	0.688	rs9393814	chr6:27372978	C/T	cg08851530	chr6:28072375	NA	0.84	8.27	0.31	7.72e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg00757033	chr12:89920650	WDR51B	0.53	10.71	0.39	1.02e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs10779751	0.686	rs1148478	chr1:11174067	A/T	cg08854313	chr1:11322531	MTOR	0.73	14.45	0.5	3.64e-41	Body mass index;
BRCA	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg16606324	chr3:10149918	C3orf24	0.57	11.01	0.4	5.98e-26	Alzheimer's disease;
BRCA	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg23711669	chr6:146136114	FBXO30	0.73	17.3	0.56	2.77e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg25427524	chr10:38739819	LOC399744	0.51	9.43	0.35	7.31e-20	Obesity (extreme);
BRCA	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg18200150	chr17:30822561	MYO1D	-0.35	-9.08	-0.34	1.36e-18	Schizophrenia;
BRCA	trans	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg25214090	chr10:38739885	LOC399744	-0.46	-9.77	-0.36	4.32e-21	Corneal astigmatism;
BRCA	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	trans	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg17145862	chr1:211918768	LPGAT1	0.7	18.33	0.59	1.24e-60	Leprosy;
BRCA	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg05340658	chr4:99064831	C4orf37	0.5	11.64	0.42	1.48e-28	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg17986701	chr20:44574422	PCIF1	0.37	8.87	0.33	7.22e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg07817883	chr1:32538562	TMEM39B	-0.44	-8.52	-0.32	1.12e-16	Monocyte percentage of white cells;
BRCA	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg01262667	chr19:19385393	TM6SF2	0.42	10.97	0.4	9.28e-26	Tonsillectomy;
BRCA	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg24675658	chr1:53192096	ZYG11B	0.62	13.91	0.48	1.31e-38	Monocyte count;
BRCA	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.84	0.67	7.19e-85	Chronic sinus infection;
BRCA	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg10295955	chr4:187884368	NA	-0.9	-26.36	-0.72	3.28e-104	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-11.98	-0.43	5.79e-30	Alzheimer's disease;
BRCA	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg18232548	chr7:50535776	DDC	-0.53	-13.22	-0.46	1.99e-35	Systemic sclerosis;
BRCA	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg20991723	chr1:152506922	NA	0.39	9.07	0.34	1.4e-18	Hair morphology;
BRCA	trans	rs9944715	0.954	rs62096523	chr18:43737966	T/A	cg01718231	chr17:29326311	RNF135	0.44	8.9	0.33	5.77e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg08885076	chr2:99613938	TSGA10	0.45	10.67	0.39	1.46e-24	Chronic sinus infection;
BRCA	cis	rs6545883	0.630	rs12998475	chr2:61437487	T/C	cg15711740	chr2:61764176	XPO1	0.45	10.9	0.4	1.7e-25	Tuberculosis;
BRCA	cis	rs2882667	0.537	rs7704790	chr5:138410096	A/C	cg04439458	chr5:138467593	SIL1	-0.3	-8.17	-0.31	1.6e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg02880119	chr16:3481970	NA	-0.41	-7.98	-0.3	6.65e-15	Body mass index (adult);
BRCA	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg15556689	chr8:8085844	FLJ10661	0.35	9.11	0.34	1.01e-18	Neuroticism;
BRCA	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg07741184	chr6:167504864	NA	0.29	8.27	0.31	7.5e-16	Crohn's disease;
BRCA	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg20307385	chr11:47447363	PSMC3	-0.42	-9.06	-0.34	1.61e-18	Subjective well-being;
BRCA	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg23285459	chr7:2802560	GNA12	-0.37	-9.45	-0.35	6.14e-20	Height;
BRCA	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13012494	chr21:47604986	C21orf56	0.44	8.92	0.33	5.06e-18	Testicular germ cell tumor;
BRCA	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg04691961	chr3:161091175	C3orf57	-0.41	-10.17	-0.37	1.33e-22	Morning vs. evening chronotype;
BRCA	cis	rs17767294	0.708	rs72848755	chr6:27878553	T/C	cg08851530	chr6:28072375	NA	0.92	8.91	0.33	5.15e-18	Parkinson's disease;
BRCA	trans	rs9951602	0.512	rs1599635	chr18:76643819	G/A	cg02800362	chr5:177631904	HNRNPAB	0.76	17.56	0.57	1.25e-56	Obesity-related traits;
BRCA	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg04166393	chr7:2884313	GNA12	0.5	11.03	0.4	5.23e-26	Height;
BRCA	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18918831	chr3:195489782	MUC4	0.62	9.47	0.35	5.39e-20	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg26384229	chr12:38710491	ALG10B	0.77	17.45	0.57	4.59e-56	Bladder cancer;
BRCA	cis	rs116979167	0.575	rs67661063	chr7:105187259	T/G	cg19920283	chr7:105172520	RINT1	0.44	9.21	0.34	4.45e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg23285459	chr7:2802560	GNA12	-0.35	-8.62	-0.32	5.24e-17	Height;
BRCA	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg22920501	chr2:26401640	FAM59B	-0.9	-16.11	-0.54	3.04e-49	Gut microbiome composition (summer);
BRCA	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg16506815	chr2:162101123	NA	0.72	18.1	0.58	1.99e-59	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	trans	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg06521331	chr12:34319734	NA	-0.51	-9.36	-0.35	1.32e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	9.87	0.36	1.77e-21	Tonsillectomy;
BRCA	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg15017067	chr4:17643749	FAM184B	0.3	9.01	0.34	2.32e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg23231163	chr10:75533350	FUT11	-0.32	-8.35	-0.31	4.18e-16	Inflammatory bowel disease;
BRCA	cis	rs13053817	1.000	rs13055556	chr22:29840367	A/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.49	-9.74	-0.36	5.3e-21	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.34	-0.35	1.53e-19	Body mass index;
BRCA	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08564027	chr20:61660810	NA	0.85	22.97	0.67	1.42e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg15790184	chr11:494944	RNH1	0.64	9.54	0.35	2.93e-20	Body mass index;
BRCA	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.59	-0.42	2.56e-28	Platelet count;
BRCA	cis	rs67981189	0.574	rs2010713	chr14:71368735	T/G	cg15816911	chr14:71606274	NA	-0.38	-8.83	-0.33	1e-17	Schizophrenia;
BRCA	cis	rs9473147	0.516	rs9381564	chr6:47443806	A/G	cg12968598	chr6:47444699	CD2AP	0.44	9.25	0.34	3.42e-19	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg12386194	chr3:101231763	SENP7	0.39	8.42	0.32	2.48e-16	Colorectal cancer;
BRCA	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg21782813	chr7:2030301	MAD1L1	-0.33	-9.45	-0.35	6.17e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg21143896	chr7:2802374	GNA12	-0.36	-8.97	-0.33	3.19e-18	Height;
BRCA	cis	rs10789491	1.000	rs10789491	chr1:47179310	A/G	cg15501359	chr1:47185051	KIAA0494	0.66	18.26	0.59	3.04e-60	Response to hepatitis C treatment;
BRCA	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-8.62	-0.32	5.23e-17	Schizophrenia;
BRCA	cis	rs2836950	0.805	rs62223042	chr21:40683740	A/G	cg11890956	chr21:40555474	PSMG1	-0.52	-10.57	-0.39	3.44e-24	Menarche (age at onset);
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.57	-15.63	-0.53	7.37e-47	Longevity;Endometriosis;
BRCA	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg10523679	chr1:76189770	ACADM	0.78	18.78	0.6	5.17e-63	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.63	0.39	2.04e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.52	-10.33	-0.38	3.09e-23	Body mass index;
BRCA	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg07403899	chr19:39283540	NA	-0.25	-8.3	-0.31	6.02e-16	Heart rate;
BRCA	cis	rs6772849	0.930	rs4467479	chr3:128369055	C/G	cg16766828	chr3:128327626	NA	-0.4	-8.86	-0.33	7.7e-18	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.91	0.4	1.61e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg02655711	chr22:19163373	SLC25A1	0.57	14.36	0.49	9.47e-41	Metabolite levels;
BRCA	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg02659138	chr7:134003124	SLC35B4	0.36	10.36	0.38	2.37e-23	Mean platelet volume;
BRCA	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.38	8.95	0.33	3.76e-18	Platelet count;
BRCA	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg13073564	chr4:8508604	NA	0.31	7.95	0.3	8.33e-15	Response to antineoplastic agents;
BRCA	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg25237894	chr2:233734115	C2orf82	-0.41	-11.77	-0.42	4.34e-29	Coronary artery disease;
BRCA	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg13385794	chr1:248469461	NA	0.27	7.85	0.3	1.75e-14	Common traits (Other);
BRCA	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg02551604	chr5:131831745	NA	-0.39	-14.68	-0.5	2.84e-42	Asthma (sex interaction);
BRCA	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg10556349	chr10:835070	NA	0.73	9.88	0.36	1.6e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs7172677	0.737	rs6495154	chr15:75437262	G/C	cg14664628	chr15:75095509	CSK	-0.39	-8.05	-0.3	3.93e-15	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg14196790	chr5:131705035	SLC22A5	0.4	10.23	0.38	7.44e-23	Blood metabolite levels;
BRCA	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg23711669	chr6:146136114	FBXO30	-0.72	-17.09	-0.56	3.25e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg04025307	chr7:1156635	C7orf50	0.53	10.42	0.38	1.43e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs16976116	0.901	rs8027098	chr15:55492269	C/T	cg11288833	chr15:55489084	RSL24D1	0.47	10.58	0.39	3.14e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs490234	0.552	rs3122938	chr9:128157326	A/G	cg14078157	chr9:128172775	NA	0.43	10.2	0.37	9.92e-23	Mean arterial pressure;
BRCA	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	18.31	0.59	1.54e-60	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs600806	0.713	rs10857786	chr1:110010110	C/G	cg20591472	chr1:110008990	SYPL2	0.31	7.98	0.3	6.93e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg19622623	chr12:86230825	RASSF9	-0.35	-9.99	-0.37	6.37e-22	Major depressive disorder;
BRCA	cis	rs16854884	0.657	rs1867608	chr3:143752938	G/A	cg06585982	chr3:143692056	C3orf58	0.44	9.44	0.35	6.81e-20	Economic and political preferences (feminism/equality);
BRCA	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.36	-7.96	-0.3	7.92e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg12386194	chr3:101231763	SENP7	0.46	9.28	0.34	2.64e-19	Colorectal cancer;
BRCA	cis	rs36051895	0.664	rs12340866	chr9:5094185	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-9.02	-0.34	2.13e-18	Pediatric autoimmune diseases;
BRCA	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-18.64	-0.59	3.1e-62	Monocyte count;
BRCA	cis	rs78487399	0.808	rs72865297	chr2:43743248	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-7.96	-0.3	7.89e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs11112613	0.609	rs11112585	chr12:105933442	A/G	cg03607813	chr12:105948248	NA	-0.51	-8.03	-0.3	4.82e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg05340658	chr4:99064831	C4orf37	0.59	10.45	0.38	1.08e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9296092	0.538	rs5000098	chr6:33519231	T/G	cg13560919	chr6:33536144	NA	-0.85	-18.62	-0.59	3.9e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg05347473	chr6:146136440	FBXO30	0.54	10.4	0.38	1.68e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg04267008	chr7:1944627	MAD1L1	0.37	8.01	0.3	5.53e-15	Schizophrenia;
BRCA	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.14e-19	Total body bone mineral density;
BRCA	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07930192	chr7:1003750	NA	-0.4	-8.65	-0.32	4.22e-17	Longevity;Endometriosis;
BRCA	trans	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.55	0.42	3.6e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg03711944	chr11:47377212	SPI1	-0.36	-8.38	-0.31	3.29e-16	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg08088566	chr11:430123	ANO9	0.56	8.3	0.31	6.17e-16	Body mass index;
BRCA	cis	rs7520050	0.966	rs1768816	chr1:46528599	T/C	cg24296786	chr1:45957014	TESK2	0.41	9.17	0.34	6.24e-19	Red blood cell count;Reticulocyte count;
BRCA	trans	rs75804782	0.581	rs13415491	chr2:239319901	C/T	cg01134436	chr17:81009848	B3GNTL1	0.77	9.69	0.36	8.3e-21	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs6066825	0.644	rs6019393	chr20:47334435	G/C	cg18078177	chr20:47281410	PREX1	0.38	9.42	0.35	8.09e-20	Colorectal cancer;
BRCA	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg09455208	chr3:40491958	NA	0.41	9.56	0.35	2.42e-20	Renal cell carcinoma;
BRCA	trans	rs867371	0.502	rs1846908	chr15:82522526	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.33	-8.97	-0.33	3.15e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.3	-0.44	2.46e-31	Alzheimer's disease;
BRCA	cis	rs7123876	0.587	rs184654	chr11:72364405	C/G	cg03713592	chr11:72463424	ARAP1	0.59	9.45	0.35	6.41e-20	Body mass index;
BRCA	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg24562669	chr7:97807699	LMTK2	0.44	11.85	0.42	2.01e-29	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs8002861	0.870	rs4942255	chr13:44451844	A/T	cg17145862	chr1:211918768	LPGAT1	-0.62	-14.95	-0.51	1.46e-43	Leprosy;
BRCA	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg26597838	chr10:835615	NA	1.0	17.58	0.57	1.05e-56	Eosinophil percentage of granulocytes;
BRCA	trans	rs1941687	0.563	rs7238931	chr18:31334993	G/A	cg15819921	chr19:927150	ARID3A	-0.47	-8.94	-0.33	4.15e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	trans	rs6479891	1.000	rs12784772	chr10:65195455	T/A	cg14819942	chr15:35414228	NA	0.35	8.6	0.32	6e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg04414720	chr1:150670196	GOLPH3L	0.35	7.84	0.3	1.88e-14	Tonsillectomy;
BRCA	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18876405	chr7:65276391	NA	-0.62	-15.48	-0.52	3.8e-46	Aortic root size;
BRCA	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg23711669	chr6:146136114	FBXO30	0.66	15.34	0.52	1.79e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3125734	0.608	rs7905731	chr10:64018472	T/C	cg19640130	chr10:64028056	RTKN2	-0.3	-8.5	-0.32	1.39e-16	Rheumatoid arthritis;
BRCA	cis	rs3125734	0.582	rs7904465	chr10:64002393	G/A	cg19640130	chr10:64028056	RTKN2	-0.32	-9.24	-0.34	3.61e-19	Rheumatoid arthritis;
BRCA	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.75	-0.39	7.03e-25	Personality dimensions;
BRCA	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg11764359	chr7:65958608	NA	0.65	11.55	0.42	3.54e-28	Aortic root size;
BRCA	cis	rs9790314	0.638	rs1374793	chr3:160638505	G/A	cg03342759	chr3:160939853	NMD3	0.44	8.76	0.33	1.74e-17	Morning vs. evening chronotype;
BRCA	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03264133	chr6:25882463	NA	-0.55	-12.61	-0.45	1.01e-32	Blood metabolite levels;
BRCA	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03517284	chr6:25882590	NA	-0.46	-9.64	-0.36	1.28e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs35000415	0.506	rs34288126	chr7:128735438	G/A	cg02365945	chr7:128766374	LOC407835	-0.57	-8.34	-0.31	4.48e-16	Systemic lupus erythematosus;
BRCA	cis	rs9560113	1.000	rs9560110	chr13:112181233	C/T	cg10483660	chr13:112241077	NA	0.32	7.98	0.3	6.63e-15	Menarche (age at onset);
BRCA	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg03711944	chr11:47377212	SPI1	-0.49	-12.58	-0.45	1.33e-32	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg02466173	chr16:30829666	NA	-0.52	-11.08	-0.4	3.13e-26	Multiple myeloma;
BRCA	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21659725	chr3:3221576	CRBN	0.46	11.67	0.42	1.12e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg20848291	chr7:100343083	ZAN	0.37	8.32	0.31	5.39e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	trans	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg26043149	chr18:55253948	FECH	0.39	8.38	0.31	3.3e-16	Bone mineral density;
BRCA	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg19077165	chr18:44547161	KATNAL2	-0.49	-10.15	-0.37	1.57e-22	Educational attainment;
BRCA	cis	rs4363385	0.818	rs6587719	chr1:152993409	G/C	cg24667326	chr1:152973720	SPRR3	-0.32	-8.86	-0.33	7.61e-18	Inflammatory skin disease;
BRCA	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg03188948	chr7:1209495	NA	0.68	11.13	0.4	1.94e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-13.02	-0.46	1.49e-34	Bipolar disorder;
BRCA	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg08999081	chr20:33150536	PIGU	0.47	13.15	0.46	3.96e-35	Glomerular filtration rate (creatinine);
BRCA	cis	rs6450176	0.909	rs7732139	chr5:53292017	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-14.11	-0.49	1.51e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg01884057	chr2:25150051	NA	-0.35	-8.61	-0.32	5.85e-17	Body mass index;
BRCA	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12379764	chr21:47803548	PCNT	-0.42	-8.59	-0.32	6.58e-17	Testicular germ cell tumor;
BRCA	cis	rs17253792	0.822	rs78386830	chr14:56069224	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-10.5	-0.38	6.49e-24	Putamen volume;
BRCA	cis	rs6484504	0.576	rs158139	chr11:31216076	C/T	cg26647111	chr11:31128758	NA	-0.44	-9.67	-0.36	9.59e-21	Red blood cell count;
BRCA	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg00383909	chr3:49044727	WDR6	0.97	15.54	0.52	1.9e-46	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs17601876	0.545	rs4775936	chr15:51536022	A/G	cg19946085	chr15:51559439	CYP19A1	0.3	8.12	0.31	2.48e-15	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs7593730	0.636	rs10181181	chr2:161087411	C/T	cg22609984	chr2:161126801	NA	-0.39	-8.5	-0.32	1.36e-16	Type 2 diabetes;
BRCA	cis	rs870825	0.616	rs4386643	chr4:185624281	A/T	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs290268	1.000	rs290268	chr9:93552450	A/G	cg02608019	chr9:93564028	SYK	0.54	11.83	0.42	2.45e-29	Platelet count;
BRCA	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24549020	chr5:56110836	MAP3K1	0.61	12.43	0.44	6.56e-32	Initial pursuit acceleration;
BRCA	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg01181863	chr3:195395398	SDHAP2	-0.46	-8.16	-0.31	1.83e-15	Pancreatic cancer;
BRCA	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg19539972	chr4:7069911	GRPEL1	-0.62	-11.53	-0.41	4.67e-28	Monocyte percentage of white cells;
BRCA	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg10523679	chr1:76189770	ACADM	-0.55	-10.03	-0.37	4.19e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg03934865	chr2:198174659	NA	-0.44	-9.67	-0.36	9.81e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-9.85	-0.36	2.1e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2625529	0.668	rs35206011	chr15:72539494	T/C	cg16672083	chr15:72433130	SENP8	-0.83	-17.54	-0.57	1.69e-56	Red blood cell count;
BRCA	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg11663144	chr21:46675770	NA	-0.56	-13.1	-0.46	6.42e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg22705602	chr4:152727874	NA	-0.32	-8.14	-0.31	2.04e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg15556689	chr8:8085844	FLJ10661	0.33	8.01	0.3	5.31e-15	Neuroticism;
BRCA	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg16576597	chr16:28551801	NUPR1	0.34	8.63	0.32	4.95e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.85	-28.12	-0.74	7.91e-114	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.61	-12.73	-0.45	3e-33	Lymphocyte counts;
BRCA	cis	rs3784262	0.669	rs4646623	chr15:58257123	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.32	-0.38	3.46e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	trans	rs7939886	0.920	rs58405266	chr11:55863225	G/A	cg15704280	chr7:45808275	SEPT13	0.6	7.86	0.3	1.58e-14	Myopia (pathological);
BRCA	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg27129171	chr3:47204927	SETD2	-0.69	-16.55	-0.55	1.83e-51	Colorectal cancer;
BRCA	cis	rs7524258	0.901	rs11120884	chr1:7305361	C/A	cg07173049	chr1:7289937	CAMTA1	0.41	9.96	0.37	8.24e-22	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg12011299	chr4:100065546	ADH4	0.36	9.0	0.34	2.49e-18	Alcohol dependence;
BRCA	cis	rs6543140	0.964	rs1523205	chr2:103070176	G/T	cg04239558	chr2:103089729	SLC9A4	0.34	9.56	0.35	2.4e-20	Blood protein levels;
BRCA	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-10.07	-0.37	2.99e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg04553112	chr3:125709451	NA	-0.58	-9.24	-0.34	3.73e-19	Blood pressure (smoking interaction);
BRCA	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg14675211	chr2:100938903	LONRF2	0.47	10.13	0.37	1.81e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg22920501	chr2:26401640	FAM59B	0.91	13.96	0.48	7.9e-39	Gut microbiome composition (summer);
BRCA	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24531977	chr5:56204891	C5orf35	0.86	17.41	0.57	7.53e-56	Initial pursuit acceleration;
BRCA	cis	rs738322	0.600	rs6001030	chr22:38555904	T/G	cg25457927	chr22:38595422	NA	-0.34	-11.72	-0.42	7.44e-29	Cutaneous nevi;
BRCA	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.66	-14.34	-0.49	1.2e-40	Lung cancer;
BRCA	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg21573476	chr21:45109991	RRP1B	-0.33	-8.44	-0.32	2.16e-16	Mean corpuscular volume;
BRCA	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.95	0.56	1.78e-53	Colorectal cancer;
BRCA	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg15212455	chr7:39170539	POU6F2	0.45	9.9	0.36	1.34e-21	IgG glycosylation;
BRCA	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg17971929	chr21:40555470	PSMG1	0.62	14.43	0.5	4.63e-41	Cognitive function;
BRCA	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg03188948	chr7:1209495	NA	0.91	14.34	0.49	1.21e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6809651	0.524	rs12638263	chr3:185795855	A/C	cg00760338	chr3:185826511	ETV5	-0.42	-8.06	-0.3	3.71e-15	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
BRCA	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg23711669	chr6:146136114	FBXO30	-0.7	-13.88	-0.48	1.77e-38	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.37	-8.14	-0.31	2.1e-15	Blood protein levels;
BRCA	cis	rs4363385	0.693	rs6668311	chr1:152964586	A/G	cg25856811	chr1:152973957	SPRR3	-0.35	-9.43	-0.35	7.39e-20	Inflammatory skin disease;
BRCA	trans	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04565464	chr8:145669602	NFKBIL2	0.43	9.82	0.36	2.64e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg22907277	chr7:1156413	C7orf50	0.59	9.19	0.34	5.33e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6684428	0.706	rs61774839	chr1:56336609	G/A	cg11651538	chr1:56320950	NA	-0.49	-8.36	-0.31	3.81e-16	Airflow obstruction;
BRCA	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.35	8.05	0.3	4.06e-15	Alzheimer's disease (late onset);
BRCA	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg24110177	chr3:50126178	RBM5	-0.53	-15.92	-0.53	2.75e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg02574844	chr11:5959923	NA	-0.43	-8.5	-0.32	1.37e-16	DNA methylation (variation);
BRCA	cis	rs3815700	1.000	rs8109768	chr19:33095463	A/G	cg02997394	chr19:33096574	ANKRD27	0.69	11.47	0.41	7.98e-28	Eosinophilic esophagitis;
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg09033563	chr22:24373618	LOC391322	-0.58	-12.55	-0.44	1.82e-32	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6750047	0.549	rs151096	chr2:38316571	A/C	cg07380506	chr2:38303506	CYP1B1	-0.41	-9.35	-0.35	1.44e-19	Cutaneous malignant melanoma;Melanoma;
BRCA	trans	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.25	0.31	9.3e-16	Corneal astigmatism;
BRCA	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg06108461	chr20:60628389	TAF4	-0.83	-17.59	-0.57	9.2e-57	Body mass index;
BRCA	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg26647111	chr11:31128758	NA	-0.45	-9.74	-0.36	5.44e-21	Red blood cell count;
BRCA	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02176678	chr2:219576539	TTLL4	0.46	11.92	0.43	9.84e-30	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg24829409	chr8:58192753	C8orf71	-0.55	-11.6	-0.42	2.34e-28	Developmental language disorder (linguistic errors);
BRCA	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg25817165	chr18:72167213	CNDP2	-0.72	-12.73	-0.45	3.16e-33	Refractive error;
BRCA	cis	rs9463078	0.809	rs6899845	chr6:45043352	A/C	cg25276700	chr6:44698697	NA	-0.39	-9.07	-0.34	1.43e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg18129178	chr5:148520854	ABLIM3	0.65	12.93	0.46	3.88e-34	Breast cancer;
BRCA	cis	rs4363385	0.818	rs4284210	chr1:152985711	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.45	-0.32	1.91e-16	Inflammatory skin disease;
BRCA	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg00071950	chr4:10020882	SLC2A9	-0.47	-11.11	-0.4	2.48e-26	Bone mineral density;
BRCA	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg27661571	chr11:113659931	NA	-0.64	-9.97	-0.37	7.66e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg08660285	chr1:67390436	MIER1;WDR78	0.63	13.81	0.48	3.77e-38	Lymphocyte percentage of white cells;
BRCA	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg10523679	chr1:76189770	ACADM	0.6	10.95	0.4	1.06e-25	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03517284	chr6:25882590	NA	-0.4	-9.19	-0.34	5.27e-19	Blood metabolite levels;
BRCA	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg04117972	chr1:227635322	NA	0.49	8.82	0.33	1.09e-17	Major depressive disorder;
BRCA	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25427524	chr10:38739819	LOC399744	-0.65	-15.75	-0.53	1.83e-47	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-10.39	-0.38	1.73e-23	Blood metabolite levels;
BRCA	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-12.03	-0.43	3.28e-30	Response to antipsychotic treatment;
BRCA	trans	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.15	0.31	1.98e-15	Mean corpuscular volume;
BRCA	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg04455712	chr21:45112962	RRP1B	-0.39	-10.01	-0.37	5.02e-22	Mean corpuscular volume;
BRCA	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg18232548	chr7:50535776	DDC	-0.53	-12.29	-0.44	2.59e-31	Systemic sclerosis;
BRCA	cis	rs11971779	0.585	rs3922848	chr7:139046210	T/C	cg07862535	chr7:139043722	LUC7L2	0.38	10.28	0.38	4.63e-23	Diisocyanate-induced asthma;
BRCA	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg14403583	chr14:105418241	AHNAK2	-0.38	-8.97	-0.33	3.29e-18	Rheumatoid arthritis;
BRCA	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg25036284	chr2:26402008	FAM59B	0.9	15.81	0.53	9.61e-48	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.36e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	12.02	0.43	3.77e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.44	-0.41	1.04e-27	Schizophrenia;
BRCA	cis	rs35110281	0.667	rs4819293	chr21:45125863	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-9.73	-0.36	5.86e-21	Mean corpuscular volume;
BRCA	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg05552183	chr6:42928497	GNMT	0.69	15.72	0.53	2.53e-47	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg22800045	chr5:56110881	MAP3K1	0.56	10.52	0.38	5.82e-24	Initial pursuit acceleration;
BRCA	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg20991723	chr1:152506922	NA	0.36	8.13	0.31	2.24e-15	Hair morphology;
BRCA	cis	rs10484885	0.878	rs72921937	chr6:90579863	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.46	-0.35	5.86e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg15103426	chr22:29168792	CCDC117	0.51	12.13	0.43	1.26e-30	Lymphocyte counts;
BRCA	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.44	-8.79	-0.33	1.36e-17	Body mass index;
BRCA	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg12365402	chr11:9010492	NRIP3	-0.39	-9.05	-0.34	1.69e-18	Hemoglobin concentration;
BRCA	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg05347473	chr6:146136440	FBXO30	0.39	7.85	0.3	1.76e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg12311346	chr5:56204834	C5orf35	-0.79	-16.15	-0.54	1.8e-49	Initial pursuit acceleration;
BRCA	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.57	-13.92	-0.48	1.12e-38	Longevity;Endometriosis;
BRCA	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg20129853	chr10:51489980	NA	-0.33	-8.57	-0.32	7.83e-17	Prostate-specific antigen levels;
BRCA	trans	rs629535	0.814	rs654452	chr8:70074344	C/G	cg21567404	chr3:27674614	NA	1.01	21.24	0.64	3.84e-76	Dupuytren's disease;
BRCA	cis	rs7520050	0.898	rs785502	chr1:46581444	T/C	cg24296786	chr1:45957014	TESK2	0.41	9.12	0.34	9.94e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg22535103	chr8:58192502	C8orf71	0.45	8.93	0.33	4.35e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs501916	0.833	rs10519143	chr15:48055567	T/G	cg16110827	chr15:48056943	SEMA6D	-0.44	-9.21	-0.34	4.48e-19	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs752010	0.871	rs10890149	chr1:42092791	T/A	cg06885757	chr1:42089581	HIVEP3	0.24	8.71	0.33	2.69e-17	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg21775979	chr11:780331	NA	0.4	9.0	0.34	2.49e-18	Breast cancer;
BRCA	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg20587970	chr11:113659929	NA	-1.36	-23.91	-0.69	9.46e-91	Hip circumference adjusted for BMI;
BRCA	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg27398817	chr8:82754497	SNX16	-0.37	-8.0	-0.3	5.93e-15	Diastolic blood pressure;
BRCA	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg10556349	chr10:835070	NA	0.59	8.09	0.3	3.05e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs919433	0.589	rs7601800	chr2:198395099	T/C	cg00792783	chr2:198669748	PLCL1	0.36	8.36	0.31	3.79e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg26597838	chr10:835615	NA	0.84	15.34	0.52	1.85e-45	Eosinophil percentage of granulocytes;
BRCA	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.71	16.58	0.55	1.22e-51	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	10.53	0.38	4.91e-24	Motion sickness;
BRCA	cis	rs977987	0.806	rs8050059	chr16:75388731	C/T	cg03315344	chr16:75512273	CHST6	0.52	12.1	0.43	1.71e-30	Dupuytren's disease;
BRCA	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg24829409	chr8:58192753	C8orf71	-0.47	-9.12	-0.34	9.38e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg20283391	chr11:68216788	NA	-0.48	-9.31	-0.35	2.06e-19	Total body bone mineral density;
BRCA	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.17	0.56	1.31e-54	Bladder cancer;
BRCA	cis	rs1003719	0.667	rs3753073	chr21:38466615	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.53	11.32	0.41	3.27e-27	Eye color traits;
BRCA	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg00071950	chr4:10020882	SLC2A9	0.65	16.24	0.54	6.46e-50	Bone mineral density;
BRCA	cis	rs7617773	0.817	rs17786132	chr3:48249420	C/G	cg11946769	chr3:48343235	NME6	0.68	14.01	0.48	4.49e-39	Coronary artery disease;
BRCA	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg00071950	chr4:10020882	SLC2A9	0.55	13.19	0.46	2.62e-35	Bone mineral density;
BRCA	cis	rs365132	0.840	rs58400555	chr5:176454081	A/T	cg16309518	chr5:176445507	NA	-0.51	-12.95	-0.46	3.19e-34	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg22906224	chr7:99728672	NA	0.43	7.93	0.3	9.58e-15	Coronary artery disease;
BRCA	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg25427524	chr10:38739819	LOC399744	0.58	10.64	0.39	1.85e-24	Obesity (extreme);
BRCA	cis	rs6684514	0.922	rs12128785	chr1:156269389	A/G	cg16558208	chr1:156270281	VHLL	0.35	8.18	0.31	1.57e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	9.79e-41	Motion sickness;
BRCA	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.39	9.27	0.34	2.79e-19	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg04362960	chr10:104952993	NT5C2	0.42	10.14	0.37	1.67e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	trans	rs1997103	1.000	rs4947500	chr7:55407270	C/A	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg06453172	chr10:134556979	INPP5A	-0.58	-12.05	-0.43	2.87e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg09184832	chr6:79620586	NA	-0.43	-8.45	-0.32	2.03e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs17401966	1.000	rs17401924	chr1:10384439	A/G	cg03954927	chr1:10346856	KIF1B	0.46	13.05	0.46	1.1e-34	Hepatocellular carcinoma;
BRCA	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg07917127	chr4:99064746	C4orf37	0.44	8.06	0.3	3.71e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs4596713	0.568	rs10122932	chr9:71746053	C/G	cg16512924	chr15:28394682	HERC2	0.39	9.51	0.35	3.76e-20	Headache;
BRCA	cis	rs778371	0.522	rs6704768	chr2:233592501	C/T	cg08000102	chr2:233561755	GIGYF2	0.72	17.71	0.57	2.06e-57	Schizophrenia;
BRCA	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg23791538	chr6:167370224	RNASET2	0.37	8.87	0.33	7.17e-18	Crohn's disease;
BRCA	cis	rs7178424	0.811	rs12910541	chr15:62248911	C/T	cg00456672	chr15:62358751	C2CD4A	0.36	8.77	0.33	1.56e-17	Height;
BRCA	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg26818010	chr10:134567672	INPP5A	0.7	14.83	0.51	5.56e-43	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs3784262	0.669	rs4646635	chr15:58252277	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.24	-0.38	6.66e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06634786	chr22:41940651	POLR3H	-0.5	-8.2	-0.31	1.33e-15	Vitiligo;
BRCA	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.27	0.49	2.52e-40	Motion sickness;
BRCA	cis	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg17469321	chr7:55412551	NA	0.5	9.53	0.35	3.24e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg23978390	chr7:1156363	C7orf50	0.44	10.1	0.37	2.36e-22	Longevity;Endometriosis;
BRCA	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Tonsillectomy;
BRCA	cis	rs3740540	0.761	rs34496154	chr10:126284336	C/T	cg04949429	chr10:126290192	LHPP	-0.41	-9.01	-0.34	2.28e-18	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9837602	1.000	rs62285478	chr3:99822135	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.18	0.4	1.3e-26	Breast cancer;
BRCA	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg08999081	chr20:33150536	PIGU	-0.33	-8.71	-0.33	2.57e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg21132104	chr15:45694354	SPATA5L1	0.72	16.11	0.54	3.09e-49	Homoarginine levels;
BRCA	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-9.44	-0.35	7.1e-20	Menopause (age at onset);
BRCA	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg21775007	chr8:11205619	TDH	0.72	17.31	0.56	2.48e-55	Retinal vascular caliber;
BRCA	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11644478	chr21:40555479	PSMG1	0.84	19.09	0.6	1.29e-64	Cognitive function;
BRCA	cis	rs11608355	0.705	rs4766601	chr12:109890080	C/G	cg05360138	chr12:110035743	NA	0.44	8.49	0.32	1.5e-16	Neuroticism;
BRCA	cis	rs1712517	0.588	rs12220267	chr10:105075712	C/T	cg04362960	chr10:104952993	NT5C2	-0.39	-7.85	-0.3	1.71e-14	Migraine;
BRCA	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg12379764	chr21:47803548	PCNT	-0.37	-7.86	-0.3	1.61e-14	Testicular germ cell tumor;
BRCA	trans	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg23762105	chr12:34175262	ALG10	0.36	8.25	0.31	9.3e-16	Morning vs. evening chronotype;
BRCA	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11764359	chr7:65958608	NA	-0.73	-16.1	-0.54	3.49e-49	Aortic root size;
BRCA	cis	rs2652834	1.000	rs2652833	chr15:63396885	C/A	cg05507819	chr15:63340323	TPM1	0.44	8.08	0.3	3.16e-15	HDL cholesterol;
BRCA	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg11993925	chr19:44307056	LYPD5	0.37	8.89	0.33	6.39e-18	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs7072216	0.727	rs10748728	chr10:100171198	C/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.71	-0.36	7.24e-21	Metabolite levels;
BRCA	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.31	-0.38	3.71e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11644478	chr21:40555479	PSMG1	0.83	19.1	0.6	1.15e-64	Cognitive function;
BRCA	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg25358565	chr5:93447407	FAM172A	0.66	11.49	0.41	6.43e-28	Diabetic retinopathy;
BRCA	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.35	8.27	0.31	8.01e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs5771242	0.518	rs6010216	chr22:50679471	C/T	cg08875078	chr22:50639485	SELO	0.38	7.84	0.3	1.85e-14	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
BRCA	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg01939980	chr4:1354348	KIAA1530	0.3	8.39	0.31	3.17e-16	Longevity;
BRCA	cis	rs6565180	1.000	rs6565180	chr16:30361341	G/T	cg17640201	chr16:30407289	ZNF48	-0.78	-19.86	-0.62	1.02e-68	Tonsillectomy;
BRCA	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg14186256	chr22:23484241	RTDR1	0.72	20.54	0.63	2.23e-72	Bone mineral density;
BRCA	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.42	-9.33	-0.35	1.72e-19	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.07	-0.37	3.18e-22	Mean corpuscular volume;
BRCA	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg25358565	chr5:93447407	FAM172A	1.03	16.07	0.54	4.56e-49	Diabetic retinopathy;
BRCA	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg06640241	chr16:89574553	SPG7	0.58	12.77	0.45	2.02e-33	Multiple myeloma (IgH translocation);
BRCA	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.58	12.16	0.43	9.56e-31	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.83e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg08859206	chr1:53392774	SCP2	0.41	8.37	0.31	3.73e-16	Monocyte count;
BRCA	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg11764359	chr7:65958608	NA	0.62	13.41	0.47	2.63e-36	Aortic root size;
BRCA	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg24692254	chr21:30365293	RNF160	-0.68	-18.76	-0.6	7.17e-63	Dental caries;
BRCA	cis	rs11920090	0.858	rs73167792	chr3:170690375	A/C	cg09710316	chr3:170744871	SLC2A2	0.51	8.2	0.31	1.35e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg03146154	chr1:46216737	IPP	0.52	11.63	0.42	1.68e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	21.17	0.64	8.76e-76	Smoking behavior;
BRCA	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-16.49	-0.55	3.7e-51	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9649465	0.967	rs7809453	chr7:123301940	A/G	cg04330084	chr7:123175371	IQUB	-0.3	-8.34	-0.31	4.46e-16	Migraine;
BRCA	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg27490568	chr2:178487706	NA	0.5	8.4	0.32	2.91e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs783540	0.933	rs2567636	chr15:83263428	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.26	-8.16	-0.31	1.83e-15	Schizophrenia;
BRCA	cis	rs30380	0.632	rs26495	chr5:96137840	A/G	cg16492584	chr5:96139282	ERAP1	-0.47	-11.09	-0.4	2.87e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg21535247	chr6:8435926	SLC35B3	0.41	9.48	0.35	5.09e-20	Motion sickness;
BRCA	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.8	-0.36	3.12e-21	Alcohol dependence;
BRCA	cis	rs6426558	0.537	rs498020	chr1:227304180	G/A	cg10327440	chr1:227177885	CDC42BPA	0.47	9.27	0.34	2.83e-19	Neutrophil percentage of white cells;
BRCA	cis	rs7737355	0.947	rs2021774	chr5:130920831	G/A	cg06307176	chr5:131281290	NA	0.52	10.6	0.39	2.81e-24	Life satisfaction;
BRCA	trans	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.53	0.32	1.05e-16	Corneal astigmatism;
BRCA	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg26384229	chr12:38710491	ALG10B	0.69	16.25	0.54	5.7e-50	Bladder cancer;
BRCA	cis	rs2742234	0.590	rs2293020	chr10:43692887	A/G	cg15436174	chr10:43711423	RASGEF1A	0.51	10.65	0.39	1.64e-24	Hirschsprung disease;
BRCA	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.37	-8.42	-0.32	2.47e-16	Axial length;
BRCA	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg09904177	chr6:26538194	HMGN4	0.47	14.71	0.5	2.15e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.32	-8.41	-0.32	2.63e-16	Height;
BRCA	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg27165867	chr14:105738592	BRF1	-0.39	-9.02	-0.34	2.18e-18	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg09526685	chr4:187126073	CYP4V2	0.99	11.31	0.41	3.75e-27	Blood protein levels;
BRCA	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg00074818	chr8:8560427	CLDN23	0.38	8.31	0.31	5.64e-16	Obesity-related traits;
BRCA	cis	rs752010	0.714	rs7552928	chr1:42086664	C/T	cg06885757	chr1:42089581	HIVEP3	0.3	10.72	0.39	8.97e-25	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs9815354	0.951	rs9850310	chr3:41891098	T/C	cg03022575	chr3:42003672	ULK4	0.49	7.99	0.3	6.4e-15	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg05347473	chr6:146136440	FBXO30	0.41	8.05	0.3	4.05e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6763687	0.964	rs1563436	chr3:171786094	C/T	cg16233210	chr3:171778391	FNDC3B	0.49	11.7	0.42	8.8e-29	Red cell distribution width;
BRCA	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg21775007	chr8:11205619	TDH	0.64	12.5	0.44	3.27e-32	Retinal vascular caliber;
BRCA	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg19622623	chr12:86230825	RASSF9	-0.34	-9.6	-0.36	1.79e-20	Major depressive disorder;
BRCA	cis	rs4363385	0.791	rs3120744	chr1:153010330	G/A	cg24667326	chr1:152973720	SPRR3	-0.33	-9.17	-0.34	6.49e-19	Inflammatory skin disease;
BRCA	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg27398817	chr8:82754497	SNX16	0.38	8.71	0.33	2.64e-17	Diastolic blood pressure;
BRCA	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg19628046	chr18:33552617	C18orf21	0.6	12.38	0.44	1.01e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg00757033	chr12:89920650	WDR51B	0.51	10.42	0.38	1.34e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg02659138	chr7:134003124	SLC35B4	0.33	10.38	0.38	1.95e-23	Mean platelet volume;
BRCA	cis	rs7095944	0.584	rs11245347	chr10:126427037	G/T	cg08799069	chr10:126477246	METTL10	-0.41	-10.19	-0.37	1.1e-22	Asthma;
BRCA	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg15017067	chr4:17643749	FAM184B	0.34	10.35	0.38	2.6e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9487051	0.734	rs56214745	chr6:109536748	G/T	cg21918786	chr6:109611834	NA	-0.35	-9.22	-0.34	4.22e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs30380	0.632	rs26500	chr5:96133712	A/C	cg16492584	chr5:96139282	ERAP1	-0.46	-10.91	-0.4	1.57e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-13.27	-0.46	1.09e-35	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg23950597	chr19:37808831	NA	-0.74	-13.09	-0.46	7.77e-35	Coronary artery calcification;
BRCA	cis	rs4363385	0.818	rs11205174	chr1:153001230	C/T	cg25856811	chr1:152973957	SPRR3	0.32	8.27	0.31	7.64e-16	Inflammatory skin disease;
BRCA	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg08807101	chr21:30365312	RNF160	-0.4	-8.22	-0.31	1.12e-15	Cognitive test performance;
BRCA	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg05340658	chr4:99064831	C4orf37	0.58	11.11	0.4	2.33e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14240646	chr10:27532245	ACBD5	-0.62	-9.58	-0.35	2.13e-20	Breast cancer;
BRCA	cis	rs11229555	0.645	rs34054511	chr11:58204943	A/C	cg15696309	chr11:58395628	NA	-0.45	-9.65	-0.36	1.17e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg27284194	chr4:1044797	NA	-0.42	-8.92	-0.33	4.96e-18	Recombination rate (males);
BRCA	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg02544614	chr20:61657117	NA	0.28	8.15	0.31	1.93e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg17807903	chr1:86174739	ZNHIT6	0.45	10.34	0.38	2.77e-23	Urate levels in overweight individuals;
BRCA	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg02527881	chr3:46936655	PTH1R	-0.38	-9.45	-0.35	6.25e-20	Colorectal cancer;
BRCA	trans	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg26043149	chr18:55253948	FECH	-0.37	-8.05	-0.3	3.94e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg15556689	chr8:8085844	FLJ10661	0.34	8.13	0.31	2.28e-15	Neuroticism;
BRCA	trans	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg26384229	chr12:38710491	ALG10B	0.43	10.38	0.38	2.0500000000000001e-23	Morning vs. evening chronotype;
BRCA	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.93	-0.3	9.91e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs586533	0.881	rs1790266	chr11:99512424	A/G	cg22878054	chr11:99397252	CNTN5	0.31	7.86	0.3	1.59e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg14458575	chr2:238380390	NA	0.53	11.76	0.42	4.93e-29	Prostate cancer;
BRCA	cis	rs2625529	0.775	rs4777489	chr15:72430434	C/T	cg16672083	chr15:72433130	SENP8	0.83	17.83	0.58	4.8e-58	Red blood cell count;
BRCA	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.64	10.09	0.37	2.64e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2629540	0.847	rs11245342	chr10:126414084	C/T	cg08799069	chr10:126477246	METTL10	0.48	9.47	0.35	5.55e-20	Cocaine dependence;
BRCA	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-7.86	-0.3	1.65e-14	Axial length;
BRCA	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg05347473	chr6:146136440	FBXO30	0.39	8.12	0.31	2.44e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.02	0.3	4.93e-15	Corneal astigmatism;
BRCA	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg11707556	chr5:10655725	ANKRD33B	0.39	9.38	0.35	1.13e-19	Coronary artery disease;
BRCA	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg24531977	chr5:56204891	C5orf35	-0.41	-8.38	-0.31	3.3e-16	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg08807101	chr21:30365312	RNF160	-0.76	-20.09	-0.62	5.8e-70	Dental caries;
BRCA	cis	rs2731664	0.819	rs449351	chr5:176872591	T/C	cg23176889	chr5:176863531	GRK6	-0.6	-15.94	-0.53	2.09e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg04990556	chr1:26633338	UBXN11	0.77	17.4	0.57	8.21e-56	Obesity-related traits;
BRCA	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	18.74	0.6	8.38e-63	Platelet count;
BRCA	cis	rs12200560	0.505	rs60879781	chr6:97075466	A/T	cg06623918	chr6:96969491	KIAA0776	0.53	12.83	0.45	1.14e-33	Coronary heart disease;
BRCA	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg19196401	chr6:110721138	DDO	0.4	9.71	0.36	7.08e-21	Platelet distribution width;
BRCA	cis	rs7580658	0.963	rs12479003	chr2:128118553	C/T	cg09760422	chr2:128146352	NA	-0.35	-7.85	-0.3	1.82e-14	Protein C levels;
BRCA	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg13877915	chr19:58951672	ZNF132	0.46	10.85	0.39	2.81e-25	Uric acid clearance;
BRCA	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg09307838	chr4:120376055	NA	0.59	11.08	0.4	3.21e-26	Corneal astigmatism;
BRCA	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg04727924	chr7:799746	HEATR2	-0.52	-9.26	-0.34	2.97e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.5	0.57	2.57e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2425143	0.818	rs2378414	chr20:34534374	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.18	-0.31	1.59e-15	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.75e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05731713	chr7:157510257	PTPRN2	0.4	10.3	0.38	4.01e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg03585969	chr10:35415529	CREM	0.49	10.32	0.38	3.28e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg17971929	chr21:40555470	PSMG1	-0.63	-13.96	-0.48	7.69e-39	Cognitive function;
BRCA	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg02569458	chr12:86230093	RASSF9	0.31	7.84	0.3	1.9e-14	Major depressive disorder;
BRCA	cis	rs12760731	0.565	rs71628268	chr1:178151908	T/C	cg00404053	chr1:178313656	RASAL2	0.71	7.97	0.3	7.29e-15	Obesity-related traits;
BRCA	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.35	-9.76	-0.36	4.5e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.41	8.94	0.33	4.24e-18	IgG glycosylation;
BRCA	trans	rs3858145	0.588	rs78041174	chr10:70038771	G/A	cg04882175	chr6:131122610	NA	-0.36	-8.66	-0.32	3.91e-17	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
BRCA	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06544989	chr22:39130855	UNC84B	0.34	7.91	0.3	1.18e-14	Menopause (age at onset);
BRCA	cis	rs4919694	0.615	rs78384860	chr10:105003019	G/T	cg04362960	chr10:104952993	NT5C2	0.83	11.36	0.41	2.29e-27	Arsenic metabolism;
BRCA	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg20476274	chr7:133979776	SLC35B4	0.66	19.45	0.61	1.55e-66	Mean platelet volume;
BRCA	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.54e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg21573476	chr21:45109991	RRP1B	-0.35	-9.13	-0.34	8.69e-19	Mean corpuscular volume;
BRCA	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg23711669	chr6:146136114	FBXO30	0.71	17.07	0.56	4.4e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11229555	0.957	rs10896796	chr11:58394256	A/G	cg15696309	chr11:58395628	NA	-0.53	-11.58	-0.42	2.85e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg12373951	chr3:133503437	NA	0.34	8.11	0.31	2.68e-15	Iron status biomarkers;
BRCA	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg07636037	chr3:49044803	WDR6	0.45	8.98	0.33	2.92e-18	Resting heart rate;
BRCA	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.06	0.34	1.52e-18	Platelet count;
BRCA	cis	rs6840258	1.000	rs114701347	chr4:87965001	C/T	cg08197287	chr4:87952173	AFF1	-0.45	-8.99	-0.34	2.68e-18	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs4766646	0.619	rs10850883	chr12:110292513	G/A	cg01252219	chr12:110302105	GLTP	0.38	8.57	0.32	7.96e-17	Metabolite levels (MHPG);
BRCA	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg06784218	chr1:46089804	CCDC17	0.51	12.22	0.44	5.44e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg08508325	chr11:3079039	CARS	-0.4	-14.35	-0.49	1.1e-40	Longevity;
BRCA	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06420487	chr17:61919686	SMARCD2	-0.4	-8.11	-0.31	2.57e-15	Height;
BRCA	cis	rs6942756	0.747	rs691124	chr7:129098439	A/G	cg02491457	chr7:128862824	NA	-0.56	-11.62	-0.42	1.9e-28	White matter hyperintensity burden;
BRCA	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg10433463	chr1:1889099	KIAA1751	-0.33	-8.82	-0.33	1.12e-17	Body mass index;
BRCA	trans	rs8073060	0.544	rs8072676	chr17:33999517	C/T	cg19694781	chr19:47549865	TMEM160	-1.02	-21.48	-0.65	1.9e-77	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.35	-0.38	2.53e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-16.61	-0.55	9.26e-52	Monocyte count;
BRCA	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg11366901	chr6:160182831	ACAT2	0.81	15.88	0.53	4.15e-48	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.02	-0.4	5.64e-26	Schizophrenia;
BRCA	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-10.74	-0.39	7.28e-25	Lymphocyte counts;
BRCA	cis	rs6700896	0.931	rs4655584	chr1:66155515	T/G	cg04111102	chr1:66153794	NA	0.34	8.47	0.32	1.68e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg02659138	chr7:134003124	SLC35B4	0.34	10.71	0.39	1.02e-24	Mean platelet volume;
BRCA	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	7.85	0.3	1.71e-14	Menarche (age at onset);
BRCA	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	23.75	0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.85	0.33	8.73e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.47	8.28	0.31	7.11e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg05279229	chr7:1896384	MAD1L1	-0.39	-7.83	-0.3	1.99e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs7617773	0.779	rs77957078	chr3:48331286	G/C	cg11946769	chr3:48343235	NME6	0.67	13.87	0.48	2.01e-38	Coronary artery disease;
BRCA	cis	rs7246657	0.722	rs11083432	chr19:38182633	A/G	cg14683738	chr19:37701593	ZNF585B	-0.49	-8.8	-0.33	1.23e-17	Coronary artery calcification;
BRCA	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg17143192	chr8:8559678	CLDN23	0.57	11.08	0.4	3.3e-26	Obesity-related traits;
BRCA	cis	rs17209837	0.607	rs2109505	chr7:87079406	T/A	cg00919237	chr7:87102261	ABCB4	-0.5	-8.97	-0.33	3.17e-18	Gallbladder cancer;
BRCA	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg14061069	chr19:46274453	DMPK	-0.45	-11.29	-0.41	4.25e-27	Coronary artery disease;
BRCA	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg26647111	chr11:31128758	NA	-0.45	-9.72	-0.36	6.19e-21	Red blood cell count;
BRCA	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.68	0.39	1.25e-24	IgG glycosylation;
BRCA	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg20387954	chr3:183756860	HTR3D	0.57	12.4	0.44	8.62e-32	Anterior chamber depth;
BRCA	cis	rs7618915	0.547	rs11719685	chr3:52676065	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-7.99	-0.3	6.53e-15	Bipolar disorder;
BRCA	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg12310025	chr6:25882481	NA	-0.4	-9.12	-0.34	9.94e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg03709012	chr19:19516395	GATAD2A	0.91	17.82	0.58	5.94e-58	Nonalcoholic fatty liver disease;
BRCA	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg17691542	chr6:26056736	HIST1H1C	0.51	10.31	0.38	3.84e-23	Iron status biomarkers;
BRCA	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg23649088	chr2:200775458	C2orf69	-0.55	-7.86	-0.3	1.68e-14	Schizophrenia;
BRCA	cis	rs1832871	0.538	rs6924801	chr6:158718805	A/G	cg07215822	chr6:158701037	NA	0.5	10.35	0.38	2.49e-23	Height;
BRCA	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg18252515	chr7:66147081	NA	-1.08	-16.09	-0.54	3.78e-49	Diabetic kidney disease;
BRCA	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.49	0.38	7.52e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.88	-16.07	-0.54	4.79e-49	Body mass index;
BRCA	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.97	21.07	0.64	2.94e-75	Lymphocyte percentage of white cells;
BRCA	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg24642439	chr20:33292090	TP53INP2	-0.44	-8.68	-0.32	3.35e-17	Height;
BRCA	cis	rs1635	0.826	rs115041649	chr6:28274653	G/C	cg15743358	chr6:28303923	ZNF323	-0.73	-7.92	-0.3	1.06e-14	Schizophrenia;
BRCA	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg13271783	chr10:134563150	INPP5A	-0.51	-9.7	-0.36	7.73e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.43	12.5	0.44	3.05e-32	Response to antipsychotic treatment;
BRCA	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24110177	chr3:50126178	RBM5	0.55	16.43	0.54	7.66e-51	Body mass index;
BRCA	cis	rs3784262	0.669	rs2414527	chr15:58256672	A/G	cg12031962	chr15:58353849	ALDH1A2	0.36	9.84	0.36	2.22e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs5167	0.504	rs892101	chr19:45455458	G/A	cg13119609	chr19:45449297	APOC2	0.47	13.15	0.46	3.79e-35	Blood protein levels;
BRCA	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07080220	chr10:102295463	HIF1AN	0.54	13.0	0.46	1.89e-34	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg14863265	chr7:2801509	GNA12	-0.45	-9.69	-0.36	8.13e-21	Height;
BRCA	trans	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.26	0.31	8.38e-16	Corneal astigmatism;
BRCA	cis	rs7172677	0.737	rs8025412	chr15:75444033	C/T	cg14664628	chr15:75095509	CSK	-0.41	-8.84	-0.33	9.4e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs2797160	1.000	rs1418948	chr6:126007018	C/T	cg05901451	chr6:126070800	HEY2	0.39	9.42	0.35	7.86e-20	Endometrial cancer;
BRCA	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg04166393	chr7:2884313	GNA12	0.6	12.16	0.43	9.13e-31	Height;
BRCA	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23248424	chr5:179741104	GFPT2	-0.64	-13.39	-0.47	3.12e-36	Height;
BRCA	cis	rs7766436	0.885	rs6908600	chr6:22582002	C/T	cg13666174	chr6:22585274	NA	-0.49	-11.52	-0.41	4.92e-28	Coronary artery disease;
BRCA	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg11764359	chr7:65958608	NA	0.68	15.21	0.52	8.16e-45	Aortic root size;
BRCA	cis	rs490234	0.783	rs10986848	chr9:128461889	T/C	cg14078157	chr9:128172775	NA	-0.43	-9.71	-0.36	6.97e-21	Mean arterial pressure;
BRCA	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.4	-0.38	1.65e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg00147160	chr1:26503991	CNKSR1	0.28	9.22	0.34	4.24e-19	Height;
BRCA	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg24558204	chr6:135376177	HBS1L	0.45	12.33	0.44	1.66e-31	Red blood cell count;
BRCA	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02353165	chr6:42928485	GNMT	0.73	16.66	0.55	4.9e-52	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	11.88	0.43	1.49e-29	Personality dimensions;
BRCA	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg24675658	chr1:53192096	ZYG11B	-0.57	-12.55	-0.44	1.83e-32	Monocyte count;
BRCA	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg10560079	chr2:191398806	TMEM194B	-0.36	-7.99	-0.3	6.1e-15	Pulse pressure;
BRCA	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg18016565	chr1:150552671	MCL1	0.34	8.05	0.3	4.08e-15	Tonsillectomy;
BRCA	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18404041	chr3:52824283	ITIH1	-0.42	-12.49	-0.44	3.62e-32	Bipolar disorder;
BRCA	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg19901468	chr14:105411992	AHNAK2	-0.5	-12.12	-0.43	1.36e-30	Rheumatoid arthritis;
BRCA	cis	rs10242455	0.702	rs41385645	chr7:98974038	A/T	cg18809830	chr7:99032528	PTCD1	-0.57	-7.94	-0.3	9.01e-15	Blood metabolite levels;
BRCA	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg04944784	chr2:26401820	FAM59B	0.81	11.15	0.4	1.67e-26	Gut microbiome composition (summer);
BRCA	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg17420585	chr12:42539391	GXYLT1	-0.58	-14.53	-0.5	1.62e-41	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg23711669	chr6:146136114	FBXO30	0.69	15.84	0.53	6.42e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs868036	0.881	rs12708496	chr15:68054098	T/C	cg08079166	chr15:68083412	MAP2K5	-0.33	-8.72	-0.33	2.35e-17	Restless legs syndrome;
BRCA	cis	rs3857067	0.806	rs1876918	chr4:95099424	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.33	-0.35	1.77e-19	QT interval;
BRCA	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg03342759	chr3:160939853	NMD3	-0.67	-14.38	-0.49	7.57e-41	Morning vs. evening chronotype;
BRCA	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg23029597	chr12:123009494	RSRC2	-0.64	-12.92	-0.46	4.48e-34	Body mass index;
BRCA	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg09021430	chr5:549028	NA	-0.68	-14.14	-0.49	1.07e-39	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg26384229	chr12:38710491	ALG10B	0.77	17.6	0.57	8.14e-57	Bladder cancer;
BRCA	cis	rs9875589	0.957	rs35485647	chr3:13937937	G/C	cg19554555	chr3:13937349	NA	0.41	8.62	0.32	5.43e-17	Ovarian reserve;
BRCA	cis	rs9682041	0.932	rs9841852	chr3:170067049	C/G	cg11886554	chr3:170076028	SKIL	0.69	12.97	0.46	2.47e-34	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-11.59	-0.42	2.52e-28	Lymphocyte counts;
BRCA	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg00012203	chr2:219082015	ARPC2	-0.48	-9.27	-0.34	2.92e-19	Colorectal cancer;
BRCA	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg02551604	chr5:131831745	NA	-0.39	-14.68	-0.5	2.84e-42	Asthma (sex interaction);
BRCA	cis	rs4363385	0.693	rs582345	chr1:153033406	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.19	-0.31	1.46e-15	Inflammatory skin disease;
BRCA	trans	rs208520	0.754	rs851594	chr6:66876695	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-19.39	-0.61	3.14e-66	Exhaled nitric oxide output;
BRCA	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg20203395	chr5:56204925	C5orf35	-0.5	-10.61	-0.39	2.55e-24	Initial pursuit acceleration;
BRCA	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg27398817	chr8:82754497	SNX16	-0.41	-7.88	-0.3	1.39e-14	Diastolic blood pressure;
BRCA	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg24397884	chr7:158709396	WDR60	-0.88	-14.96	-0.51	1.26e-43	Height;
BRCA	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.28	0.38	4.77e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg16850897	chr7:100343110	ZAN	-0.58	-12.33	-0.44	1.82e-31	Other erythrocyte phenotypes;
BRCA	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg19622623	chr12:86230825	RASSF9	-0.29	-8.19	-0.31	1.45e-15	Major depressive disorder;
BRCA	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg00852783	chr1:26633632	UBXN11	-0.47	-8.29	-0.31	6.69e-16	Obesity-related traits;
BRCA	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.23	0.56	6.19e-55	Bladder cancer;
BRCA	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.92	0.33	5.07e-18	Motion sickness;
BRCA	cis	rs9807989	0.507	rs6710528	chr2:103016142	A/G	cg03938978	chr2:103052716	IL18RAP	-0.29	-8.64	-0.32	4.38e-17	Asthma;
BRCA	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.72	-0.33	2.47e-17	Alzheimer's disease (late onset);
BRCA	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24549020	chr5:56110836	MAP3K1	0.59	11.95	0.43	7.8e-30	Initial pursuit acceleration;
BRCA	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg04727924	chr7:799746	HEATR2	-0.55	-10.78	-0.39	5.21e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg14993813	chr1:46806288	NSUN4	-0.47	-9.07	-0.34	1.48e-18	Menopause (age at onset);
BRCA	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03264133	chr6:25882463	NA	0.41	8.8	0.33	1.29e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg09035930	chr12:129282057	SLC15A4	0.56	16.77	0.55	1.41e-52	Systemic lupus erythematosus;
BRCA	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg08999081	chr20:33150536	PIGU	0.44	12.26	0.44	3.36e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg06784218	chr1:46089804	CCDC17	0.52	12.67	0.45	5.52e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg27170947	chr2:26402098	FAM59B	-0.66	-11.37	-0.41	2.08e-27	Gut microbiome composition (summer);
BRCA	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg23033748	chr14:75592666	NEK9	0.4	9.49	0.35	4.57e-20	Height;
BRCA	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg12564285	chr5:131593104	PDLIM4	0.35	9.4	0.35	9.57e-20	Blood metabolite levels;
BRCA	cis	rs7727544	0.514	rs3846728	chr5:131436217	G/A	cg14196790	chr5:131705035	SLC22A5	0.36	8.91	0.33	5.44e-18	Blood metabolite levels;
BRCA	trans	rs3857536	0.813	rs9363554	chr6:66930183	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.1	-0.31	2.78e-15	Blood trace element (Cu levels);
BRCA	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg26587870	chr6:27730563	NA	-0.71	-9.67	-0.36	1e-20	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg12072164	chr19:44306565	LYPD5	0.38	8.44	0.32	2.08e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs7301826	1.000	rs2001483	chr12:131318645	A/G	cg11011512	chr12:131303247	STX2	0.4	10.11	0.37	2.18e-22	Plasma plasminogen activator levels;
BRCA	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg11814155	chr7:99998594	ZCWPW1	0.48	8.82	0.33	1.05e-17	Platelet count;
BRCA	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg13319975	chr6:146136371	FBXO30	-0.38	-8.76	-0.33	1.81e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg21280719	chr6:42927975	GNMT	-0.34	-14.18	-0.49	7.25e-40	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	18.95	0.6	7.21e-64	Hip circumference adjusted for BMI;
BRCA	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg20790798	chr5:1857306	NA	-0.36	-8.39	-0.31	3.14e-16	Cardiovascular disease risk factors;
BRCA	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg11057378	chr10:81107060	PPIF	0.37	9.22	0.34	4.26e-19	Height;
BRCA	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg14019146	chr3:50243930	SLC38A3	-0.39	-9.64	-0.36	1.22e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11890956	chr21:40555474	PSMG1	1.06	31.62	0.78	8.54e-133	Cognitive function;
BRCA	cis	rs3820928	0.874	rs10199655	chr2:227892428	T/C	cg11843606	chr2:227700838	RHBDD1	-0.35	-7.89	-0.3	1.36e-14	Pulmonary function;
BRCA	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.42	-8.41	-0.32	2.78e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg26528668	chr16:1614120	IFT140	0.37	8.37	0.31	3.52e-16	Coronary artery disease;
BRCA	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13732083	chr21:47605072	C21orf56	0.38	8.06	0.3	3.79e-15	Testicular germ cell tumor;
BRCA	cis	rs9341808	0.718	rs2322631	chr6:80843956	A/C	cg08355045	chr6:80787529	NA	0.37	9.43	0.35	7.43e-20	Sitting height ratio;
BRCA	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	13.82	0.48	3.34e-38	Lymphocyte counts;
BRCA	trans	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	28.23	0.74	1.93e-114	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2882667	0.690	rs288016	chr5:138194988	C/T	cg04439458	chr5:138467593	SIL1	0.31	7.96	0.3	7.85e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg17063962	chr7:91808500	NA	-0.52	-11.93	-0.43	8.84e-30	Breast cancer;
BRCA	cis	rs367943	0.666	rs12332129	chr5:112977983	A/G	cg12552261	chr5:112820674	MCC	0.39	8.18	0.31	1.57e-15	Type 2 diabetes;
BRCA	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg18357645	chr12:58087776	OS9	-0.31	-7.98	-0.3	6.96e-15	Multiple sclerosis;
BRCA	cis	rs36051895	0.632	rs12349918	chr9:5125250	A/G	cg02405213	chr9:5042618	JAK2	-0.47	-8.61	-0.32	5.74e-17	Pediatric autoimmune diseases;
BRCA	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg05623727	chr3:50126028	RBM5	0.43	8.35	0.31	4.15e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg12310025	chr6:25882481	NA	-0.54	-12.83	-0.45	1.04e-33	Blood metabolite levels;
BRCA	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg06627628	chr2:24431161	ITSN2	0.62	11.78	0.42	4.13e-29	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg18479299	chr3:125709523	NA	-0.56	-8.79	-0.33	1.41e-17	Blood pressure (smoking interaction);
BRCA	cis	rs3087591	0.881	rs2905804	chr17:29519995	T/C	cg24425628	chr17:29625626	OMG;NF1	0.41	8.03	0.3	4.65e-15	Hip circumference;
BRCA	cis	rs11112613	0.713	rs73184081	chr12:105951745	C/T	cg03607813	chr12:105948248	NA	0.56	10.51	0.38	6.18e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.35e-15	Prostate cancer;
BRCA	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg17063962	chr7:91808500	NA	0.6	14.47	0.5	2.89e-41	Breast cancer;
BRCA	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg23950597	chr19:37808831	NA	-0.71	-12.6	-0.45	1.16e-32	Coronary artery calcification;
BRCA	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg00071950	chr4:10020882	SLC2A9	0.54	13.38	0.47	3.69e-36	Bone mineral density;
BRCA	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg23791538	chr6:167370224	RNASET2	0.49	12.41	0.44	7.5e-32	Crohn's disease;
BRCA	cis	rs6028335	0.610	rs67343649	chr20:37557894	A/G	cg16355469	chr20:37678765	NA	0.44	8.05	0.3	4.16e-15	Alcohol and nicotine co-dependence;
BRCA	trans	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00166722	chr3:10149974	C3orf24	0.66	13.38	0.47	3.63e-36	Alzheimer's disease;
BRCA	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg11062466	chr8:58055876	NA	0.5	8.62	0.32	5.13e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9790314	0.723	rs1026572	chr3:160887654	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-11.51	-0.41	5.62e-28	Morning vs. evening chronotype;
BRCA	cis	rs9463078	0.845	rs9349315	chr6:45172289	A/G	cg25276700	chr6:44698697	NA	-0.36	-8.14	-0.31	2.05e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25427524	chr10:38739819	LOC399744	-0.68	-16.56	-0.55	1.72e-51	Extrinsic epigenetic age acceleration;
BRCA	trans	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg26043149	chr18:55253948	FECH	-0.4	-9.07	-0.34	1.42e-18	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg26384229	chr12:38710491	ALG10B	0.8	19.69	0.61	7.86e-68	Heart rate;
BRCA	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg03453431	chr7:157225567	NA	-0.47	-9.6	-0.35	1.84e-20	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	11.58	0.42	2.78e-28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs2629540	0.765	rs12221075	chr10:126534855	G/A	cg08799069	chr10:126477246	METTL10	-0.35	-8.03	-0.3	4.86e-15	Cocaine dependence;
BRCA	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.49	-0.32	1.39e-16	Aortic root size;
BRCA	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg22800045	chr5:56110881	MAP3K1	0.65	12.22	0.44	5.19e-31	Initial pursuit acceleration;
BRCA	cis	rs7580658	0.926	rs79789049	chr2:128145472	G/A	cg09760422	chr2:128146352	NA	-0.35	-7.91	-0.3	1.13e-14	Protein C levels;
BRCA	cis	rs6733011	0.578	rs10169003	chr2:99508866	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.35	7.94	0.3	9.25e-15	Bipolar disorder;
BRCA	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11764359	chr7:65958608	NA	-0.74	-16.11	-0.54	3.1e-49	Aortic root size;
BRCA	cis	rs2742417	0.603	rs13059502	chr3:45781380	A/G	cg04837898	chr3:45731254	SACM1L	-0.38	-7.81	-0.3	2.31e-14	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.65	16.49	0.55	3.66e-51	Colorectal cancer;
BRCA	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg23950597	chr19:37808831	NA	-0.73	-12.68	-0.45	4.81e-33	Coronary artery calcification;
BRCA	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg17366294	chr4:99064904	C4orf37	0.46	10.82	0.39	3.67e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	10.47	0.38	8.64e-24	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.09	0.4	2.92e-26	Bipolar disorder;
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.49	-11.2	-0.41	1.04e-26	Longevity;Endometriosis;
BRCA	cis	rs2731664	0.792	rs335466	chr5:176889530	C/A	cg23176889	chr5:176863531	GRK6	-0.62	-17.03	-0.56	6.91e-54	Intelligence (multi-trait analysis);
BRCA	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg15605315	chr1:45957053	TESK2	0.5	10.3	0.38	4.2e-23	High light scatter reticulocyte count;
BRCA	trans	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg26384229	chr12:38710491	ALG10B	0.4	9.27	0.34	2.72e-19	Morning vs. evening chronotype;
BRCA	cis	rs6942407	0.546	rs10257953	chr7:86799726	C/T	cg02420886	chr7:86849541	C7orf23	0.54	8.03	0.3	4.54e-15	Food allergy;
BRCA	cis	rs77741769	0.571	rs11065283	chr12:121266453	A/G	cg02419362	chr12:121203948	SPPL3	0.34	7.82	0.3	2.17e-14	Mean corpuscular volume;
BRCA	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg13319975	chr6:146136371	FBXO30	0.42	9.83	0.36	2.44e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	15.63	0.53	7.23e-47	Colorectal cancer;
BRCA	cis	rs34779708	0.733	rs4298846	chr10:35547380	A/G	cg03585969	chr10:35415529	CREM	0.44	9.1	0.34	1.17e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10779751	0.770	rs11121695	chr1:11229515	G/A	cg08854313	chr1:11322531	MTOR	-0.71	-14.09	-0.49	1.84e-39	Body mass index;
BRCA	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg03146154	chr1:46216737	IPP	-0.42	-9.0	-0.34	2.52e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26314531	chr2:26401878	FAM59B	-0.66	-11.21	-0.41	9.67e-27	Gut microbiome composition (summer);
BRCA	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg12310025	chr6:25882481	NA	0.51	12.09	0.43	1.96e-30	Blood metabolite levels;
BRCA	cis	rs7394190	0.748	rs11000777	chr10:75545063	G/C	cg07699608	chr10:75541558	CHCHD1	0.66	10.0	0.37	5.62e-22	Incident atrial fibrillation;
BRCA	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg14847009	chr1:175162515	KIAA0040	-0.25	-9.45	-0.35	6.06e-20	Alcohol dependence;
BRCA	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg05340658	chr4:99064831	C4orf37	0.63	15.11	0.51	2.45e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs72772090	0.539	rs17481759	chr5:96114695	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.22	-0.44	5.27e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg04455712	chr21:45112962	RRP1B	-0.42	-11.18	-0.4	1.27e-26	Mean corpuscular volume;
BRCA	cis	rs41005	0.967	rs41002	chr2:8113921	C/T	cg03155496	chr2:8117019	LOC339788	0.63	18.27	0.59	2.68e-60	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs6446731	0.517	rs2071671	chr4:3269787	C/G	cg08886695	chr4:3369023	RGS12	0.37	9.84	0.36	2.31e-21	Mean platelet volume;
BRCA	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg22800045	chr5:56110881	MAP3K1	0.42	8.36	0.31	4.07e-16	Coronary artery disease;
BRCA	cis	rs17818399	0.815	rs17819022	chr2:46850571	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.46	8.08	0.3	3.34e-15	Height;
BRCA	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	23.24	0.68	4.9e-87	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	trans	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg23762105	chr12:34175262	ALG10	0.35	7.86	0.3	1.66e-14	Morning vs. evening chronotype;
BRCA	cis	rs2066819	1.000	rs41423244	chr12:56693520	A/C	cg26734620	chr12:56694298	CS	-0.88	-10.19	-0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.81	0.39	4.11e-25	Bipolar disorder;
BRCA	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg03146154	chr1:46216737	IPP	-0.45	-10.13	-0.37	1.84e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10193935	0.901	rs2374405	chr2:42479874	A/C	cg27598129	chr2:42591480	NA	-0.94	-14.7	-0.5	2.32e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08109568	chr15:31115862	NA	-0.35	-8.54	-0.32	1.01e-16	Huntington's disease progression;
BRCA	cis	rs11971779	0.648	rs6467849	chr7:139080512	C/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg17063962	chr7:91808500	NA	-0.52	-12.28	-0.44	2.88e-31	Breast cancer;
BRCA	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg23649088	chr2:200775458	C2orf69	0.5	9.94	0.37	9.36e-22	Osteoporosis;
BRCA	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg20503657	chr10:835505	NA	-0.53	-9.83	-0.36	2.59e-21	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg09307838	chr4:120376055	NA	0.64	13.9	0.48	1.39e-38	Corneal astigmatism;
BRCA	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg23422044	chr7:1970798	MAD1L1	-0.45	-9.53	-0.35	3.34e-20	Neuroticism;
BRCA	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.48	0.35	4.85e-20	Morning vs. evening chronotype;
BRCA	cis	rs7561273	0.586	rs116650625	chr2:24353212	C/G	cg04809136	chr2:24300158	SF3B14	-0.4	-8.94	-0.33	4.13e-18	Quantitative traits;
BRCA	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg26647111	chr11:31128758	NA	-0.45	-9.7	-0.36	7.87e-21	Red blood cell count;
BRCA	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg19077165	chr18:44547161	KATNAL2	-0.55	-11.72	-0.42	7.41e-29	Personality dimensions;
BRCA	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg13010199	chr12:38710504	ALG10B	0.5	10.31	0.38	3.67e-23	Bladder cancer;
BRCA	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg06159980	chr1:16340746	HSPB7	-0.37	-7.88	-0.3	1.39e-14	Dilated cardiomyopathy;
BRCA	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	10.01	0.37	5.17e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10267417	0.535	rs10272487	chr7:19862415	A/T	cg07541023	chr7:19748670	TWISTNB	0.53	9.43	0.35	7.52e-20	Night sleep phenotypes;
BRCA	trans	rs877282	0.891	rs12767043	chr10:797943	C/T	cg22713356	chr15:30763199	NA	1.41	28.95	0.75	2.23e-118	Uric acid levels;
BRCA	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg09877947	chr5:131593287	PDLIM4	0.37	7.96	0.3	8e-15	Breast cancer;
BRCA	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg01304814	chr3:48885189	PRKAR2A	0.56	7.86	0.3	1.69e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg16586182	chr3:47516702	SCAP	0.56	12.53	0.44	2.25e-32	Colorectal cancer;
BRCA	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.44	10.68	0.39	1.29e-24	IgG glycosylation;
BRCA	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg00409905	chr10:38381863	ZNF37A	-0.48	-10.22	-0.37	8.3300000000000006e-23	Extrinsic epigenetic age acceleration;
BRCA	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.49	-9.33	-0.35	1.76e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs354225	0.546	rs10170646	chr2:54799606	T/C	cg26097391	chr2:54893211	SPTBN1	0.29	8.73	0.33	2.21e-17	Schizophrenia;
BRCA	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg23033748	chr14:75592666	NEK9	-0.43	-10.46	-0.38	9.28e-24	Height;
BRCA	cis	rs9341808	0.667	rs1408292	chr6:80883906	G/T	cg08355045	chr6:80787529	NA	0.33	8.12	0.31	2.47e-15	Sitting height ratio;
BRCA	cis	rs9976767	0.608	rs3746923	chr21:43826344	C/T	cg23042151	chr21:43824109	UBASH3A	-0.27	-8.38	-0.31	3.28e-16	Type 1 diabetes;
BRCA	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-15.95	-0.53	1.75e-48	Heart rate;
BRCA	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.12	-0.6	9.11e-65	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6484504	0.576	rs208103	chr11:31167400	A/G	cg14844989	chr11:31128820	NA	-0.45	-9.53	-0.35	3.16e-20	Red blood cell count;
BRCA	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25427524	chr10:38739819	LOC399744	-0.7	-16.7	-0.55	3.21e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg23649088	chr2:200775458	C2orf69	-0.45	-8.05	-0.3	4.07e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.98	0.4	8.23e-26	Bipolar disorder;
BRCA	cis	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg05901451	chr6:126070800	HEY2	0.4	9.65	0.36	1.2e-20	Endometrial cancer;
BRCA	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	7.96	0.3	7.92e-15	Tonsillectomy;
BRCA	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg03146154	chr1:46216737	IPP	0.47	10.37	0.38	2.16e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg05623727	chr3:50126028	RBM5	-0.48	-11.64	-0.42	1.63e-28	Body mass index;
BRCA	cis	rs7572733	0.534	rs6434943	chr2:198762192	T/G	cg00792783	chr2:198669748	PLCL1	0.48	10.31	0.38	3.72e-23	Dermatomyositis;
BRCA	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg10802521	chr3:52805072	NEK4	-0.32	-7.95	-0.3	8.7e-15	Bipolar disorder;
BRCA	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg01324343	chr3:183735012	ABCC5	0.85	21.67	0.65	1.68e-78	Anterior chamber depth;
BRCA	cis	rs6066835	1.000	rs6063311	chr20:47325315	C/T	cg18078177	chr20:47281410	PREX1	0.72	7.83	0.3	2.06e-14	Multiple myeloma;
BRCA	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg23711669	chr6:146136114	FBXO30	0.64	14.89	0.51	2.9e-43	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg13565492	chr6:43139072	SRF	-0.79	-10.84	-0.39	2.99e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg25214090	chr10:38739885	LOC399744	0.52	12.03	0.43	3.48e-30	Corneal astigmatism;
BRCA	cis	rs11229555	1.000	rs11229543	chr11:58370698	G/A	cg15696309	chr11:58395628	NA	-0.53	-11.58	-0.42	2.85e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg02544614	chr20:61657117	NA	0.28	8.15	0.31	1.93e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg08392591	chr16:89556376	ANKRD11	0.41	9.78	0.36	3.87e-21	Multiple myeloma (IgH translocation);
BRCA	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg12011299	chr4:100065546	ADH4	0.42	10.46	0.38	9.74e-24	Alcohol dependence;
BRCA	trans	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg26384229	chr12:38710491	ALG10B	0.47	10.66	0.39	1.5e-24	Morning vs. evening chronotype;
BRCA	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg16482183	chr6:26056742	HIST1H1C	-0.44	-8.48	-0.32	1.58e-16	Iron status biomarkers;
BRCA	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.29	0.41	4.47e-27	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.48e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg22676075	chr6:135203613	NA	0.44	8.68	0.32	3.23e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg03474202	chr17:45855739	NA	-0.47	-12.62	-0.45	9.36e-33	IgG glycosylation;
BRCA	cis	rs9880211	0.948	rs13321721	chr3:136209550	A/G	cg21827317	chr3:136751795	NA	-0.46	-8.31	-0.31	5.54e-16	Body mass index;Height;
BRCA	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.99	15.2	0.52	8.85e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs7246760	0.867	rs55800282	chr19:9833530	A/G	cg02900749	chr2:68251473	NA	-0.48	-7.93	-0.3	1e-14	Pursuit maintenance gain;
BRCA	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg24296786	chr1:45957014	TESK2	0.63	15.01	0.51	7.95e-44	High light scatter reticulocyte count;
BRCA	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg05457628	chr5:178986728	RUFY1	0.57	14.34	0.49	1.26e-40	Lung cancer;
BRCA	cis	rs7523050	0.643	rs67091034	chr1:109402567	C/G	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg08999081	chr20:33150536	PIGU	-0.47	-12.94	-0.46	3.37e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	8.05	0.3	4.02e-15	Menarche (age at onset);
BRCA	cis	rs1163251	0.902	rs627707	chr1:120217133	C/G	cg19096424	chr1:120255104	PHGDH	0.44	9.73	0.36	5.98e-21	Blood metabolite levels;
BRCA	cis	rs10208940	0.777	rs6726966	chr2:68855856	A/G	cg12452813	chr2:68675892	NA	0.49	8.76	0.33	1.79e-17	Urate levels in lean individuals;
BRCA	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg14863265	chr7:2801509	GNA12	-0.47	-10.07	-0.37	2.97e-22	Height;
BRCA	cis	rs312274	0.550	rs17621741	chr12:41300290	G/T	cg17827154	chr12:41323612	CNTN1	0.41	10.44	0.38	1.2e-23	Metabolite levels  (X-11787);
BRCA	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.88	19.6	0.61	2.39e-67	Cognitive ability;
BRCA	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-11.09	-0.4	2.84e-26	Lymphocyte counts;
BRCA	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.76	-0.5	1.19e-42	Chronic sinus infection;
BRCA	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.37	0.35	1.19e-19	Morning vs. evening chronotype;
BRCA	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg22907277	chr7:1156413	C7orf50	0.61	12.02	0.43	3.94e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs919433	0.783	rs805497	chr2:198222548	A/T	cg00792783	chr2:198669748	PLCL1	0.37	8.34	0.31	4.62e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg08236123	chr12:132219811	SFRS8	-0.49	-11.1	-0.4	2.78e-26	Migraine;
BRCA	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs654950	0.783	rs668359	chr1:42003425	A/C	cg06885757	chr1:42089581	HIVEP3	-0.25	-8.78	-0.33	1.52e-17	Airway imaging phenotypes;
BRCA	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg19508488	chr2:152266495	RIF1	0.48	8.83	0.33	1.03e-17	Lung cancer;
BRCA	cis	rs9487051	0.702	rs670414	chr6:109529912	A/G	cg21918786	chr6:109611834	NA	0.36	9.2	0.34	5.1e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg19773385	chr1:10388646	KIF1B	0.37	8.18	0.31	1.48e-15	Hepatocellular carcinoma;
BRCA	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg04586622	chr2:25135609	ADCY3	0.46	11.45	0.41	9.79e-28	Body mass index;
BRCA	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-12.27	-0.44	3.26e-31	Bone mineral density;
BRCA	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.03	0.3	4.61e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs858239	0.600	rs28483572	chr7:23131785	A/G	cg23682824	chr7:23144976	KLHL7	0.45	11.89	0.43	1.36e-29	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.72	16.18	0.54	1.34e-49	Hip circumference adjusted for BMI;
BRCA	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg12219531	chr12:120966889	COQ5	0.55	11.56	0.42	3.51e-28	Reticulocyte fraction of red cells;
BRCA	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg04944784	chr2:26401820	FAM59B	-0.85	-13.27	-0.46	1.19e-35	Gut microbiome composition (summer);
BRCA	cis	rs1953600	0.870	rs2789690	chr10:81938204	G/T	cg04850286	chr10:81895943	PLAC9	0.31	8.93	0.33	4.44e-18	Sarcoidosis;
BRCA	cis	rs7091068	0.671	rs588912	chr10:95402929	T/C	cg20715218	chr10:95462985	C10orf4	-0.46	-8.32	-0.31	5.3e-16	Urinary tract infection frequency;
BRCA	cis	rs929596	0.728	rs6744284	chr2:234625297	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-12.41	-0.44	7.57e-32	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs2066819	1.000	rs59295315	chr12:56708576	G/A	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg06640241	chr16:89574553	SPG7	0.78	19.07	0.6	1.69e-64	Multiple myeloma (IgH translocation);
BRCA	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11644478	chr21:40555479	PSMG1	0.85	19.85	0.62	1.1e-68	Cognitive function;
BRCA	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg23895963	chr12:117471115	NA	0.54	9.61	0.36	1.58e-20	Subcortical brain region volumes;Hippocampal volume;
BRCA	trans	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg25206134	chr2:45395956	NA	0.51	8.22	0.31	1.11e-15	Neuroticism;
BRCA	cis	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg05491587	chr18:77659695	KCNG2	0.32	8.1	0.31	2.82e-15	Schizophrenia;
BRCA	trans	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.26	0.31	8.38e-16	Corneal astigmatism;
BRCA	cis	rs9649213	0.614	rs3801258	chr7:97988428	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.58	-15.78	-0.53	1.24e-47	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg24562669	chr7:97807699	LMTK2	0.43	11.7	0.42	8.48e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4363385	0.747	rs4845508	chr1:152968421	G/C	cg25856811	chr1:152973957	SPRR3	-0.34	-9.08	-0.34	1.35e-18	Inflammatory skin disease;
BRCA	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg13010199	chr12:38710504	ALG10B	0.42	9.03	0.34	2.09e-18	Morning vs. evening chronotype;
BRCA	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg06494592	chr3:125709126	NA	-0.53	-8.18	-0.31	1.53e-15	Blood pressure (smoking interaction);
BRCA	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21582582	chr3:182698605	DCUN1D1	0.36	9.52	0.35	3.44e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg01017244	chr2:74357527	NA	0.41	8.95	0.33	3.92e-18	Gestational age at birth (maternal effect);
BRCA	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.51	-11.09	-0.4	3e-26	Colorectal cancer;
BRCA	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-16.79	-0.55	1.14e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg05347473	chr6:146136440	FBXO30	0.61	12.12	0.43	1.47e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg20701182	chr2:24300061	SF3B14	0.71	13.26	0.46	1.27e-35	Lymphocyte counts;
BRCA	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	11.58	0.42	2.74e-28	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	12.28	0.44	2.94e-31	Exhaled nitric oxide output;
BRCA	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg18132916	chr6:79620363	NA	-0.44	-10.07	-0.37	3.15e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.56	-0.32	8.13e-17	Breast cancer;
BRCA	cis	rs1953600	0.754	rs2573348	chr10:81925785	C/T	cg04850286	chr10:81895943	PLAC9	-0.32	-8.98	-0.33	2.91e-18	Sarcoidosis;
BRCA	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.18	0.58	7.51e-60	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg07395648	chr5:131743802	NA	-0.36	-9.15	-0.34	7.58e-19	Blood metabolite levels;
BRCA	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg06697600	chr4:7070879	GRPEL1	-0.55	-11.44	-0.41	1.08e-27	Monocyte percentage of white cells;
BRCA	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.94	13.91	0.48	1.23e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7560272	0.501	rs2006997	chr2:73947846	G/A	cg20560298	chr2:73613845	ALMS1	0.33	8.23	0.31	1.05e-15	Schizophrenia;
BRCA	cis	rs698833	0.780	rs9309115	chr2:44510146	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	9.31	0.35	2.02e-19	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg16325326	chr1:53192061	ZYG11B	-0.65	-16.23	-0.54	7.41e-50	Monocyte count;
BRCA	cis	rs10746514	1.000	rs12129814	chr1:232251730	C/A	cg09506761	chr1:232265262	NA	0.4	8.07	0.3	3.5e-15	Response to statin therapy;
BRCA	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg23625390	chr15:77176239	SCAPER	-0.54	-13.4	-0.47	2.99e-36	Blood metabolite levels;
BRCA	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02176678	chr2:219576539	TTLL4	0.46	11.94	0.43	8.44e-30	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg01324343	chr3:183735012	ABCC5	0.84	21.16	0.64	1.03e-75	Anterior chamber depth;
BRCA	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg23711669	chr6:146136114	FBXO30	0.65	15.32	0.52	2.47e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg18230493	chr5:56204884	C5orf35	0.61	12.94	0.46	3.57e-34	Initial pursuit acceleration;
BRCA	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.59	-12.35	-0.44	1.39e-31	Lymphocyte counts;
BRCA	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg08601574	chr20:25228251	PYGB	-0.35	-8.31	-0.31	5.92e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10227331	1.000	rs11979293	chr7:157293586	C/T	cg04156418	chr7:157293606	NA	0.38	11.11	0.4	2.51e-26	Inattentive symptoms;
BRCA	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg17524180	chr13:113633600	MCF2L	-0.33	-8.41	-0.32	2.75e-16	Systolic blood pressure;
BRCA	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg20607798	chr8:58055168	NA	0.45	8.03	0.3	4.7e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9467773	0.595	rs9366657	chr6:26434914	C/G	cg09904177	chr6:26538194	HMGN4	0.37	9.75	0.36	5.1e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg26587870	chr6:27730563	NA	-0.4	-8.49	-0.32	1.43e-16	Parkinson's disease;
BRCA	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg21775007	chr8:11205619	TDH	0.73	16.87	0.56	4.13e-53	Retinal vascular caliber;
BRCA	cis	rs2637030	0.559	rs187659	chr5:52916018	G/A	cg06476337	chr5:52856530	NDUFS4	0.38	8.77	0.33	1.62e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg13010199	chr12:38710504	ALG10B	0.45	9.47	0.35	5.17e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10788264	0.513	rs10749455	chr10:124035030	A/G	cg09507567	chr10:124027408	NA	0.38	7.98	0.3	7e-15	Total body bone mineral density;
BRCA	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07343612	chr16:622815	PIGQ	-0.68	-22.12	-0.66	6.32e-81	Height;
BRCA	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	11.84	0.42	2.3e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg09184832	chr6:79620586	NA	-0.51	-11.2	-0.4	1.07e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg12863693	chr15:85201151	NMB	-0.37	-8.98	-0.33	3.07e-18	P wave terminal force;
BRCA	cis	rs11690935	0.885	rs6750058	chr2:172786909	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.8	-23.44	-0.68	3.87e-88	Schizophrenia;
BRCA	cis	rs7131987	0.834	rs1989478	chr12:29442229	C/T	cg09582351	chr12:29534625	ERGIC2	-0.48	-11.56	-0.42	3.21e-28	QT interval;
BRCA	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-8.11	-0.31	2.67e-15	Gut microbiome composition (summer);
BRCA	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg10523679	chr1:76189770	ACADM	0.68	12.42	0.44	7.22e-32	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9300255	0.679	rs12829456	chr12:123725395	C/T	cg00376283	chr12:123451042	ABCB9	-0.55	-10.63	-0.39	2.12e-24	Neutrophil percentage of white cells;
BRCA	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg13047869	chr3:10149882	C3orf24	0.6	12.73	0.45	3.12e-33	Alzheimer's disease;
BRCA	cis	rs2882667	0.522	rs7731574	chr5:138454192	A/G	cg04439458	chr5:138467593	SIL1	0.3	8.0	0.3	5.85e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7809950	0.953	rs3094383	chr7:107143164	G/A	cg23024343	chr7:107201750	COG5	-0.4	-9.12	-0.34	9.56e-19	Coronary artery disease;
BRCA	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.46	9.5	0.35	4.27e-20	HDL cholesterol;
BRCA	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-10.43	-0.38	1.31e-23	Mean corpuscular volume;
BRCA	cis	rs1997103	1.000	rs4947503	chr7:55409427	G/T	cg17469321	chr7:55412551	NA	0.51	9.62	0.36	1.53e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs939658	0.805	rs35230534	chr15:79441093	T/C	cg17916960	chr15:79447300	NA	-0.43	-10.98	-0.4	8.11e-26	Refractive error;
BRCA	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	8.41	0.32	2.68e-16	Iron status biomarkers;
BRCA	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg05347473	chr6:146136440	FBXO30	0.4	7.94	0.3	9.15e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.32	-0.31	5.32e-16	Bipolar disorder;
BRCA	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24531977	chr5:56204891	C5orf35	-0.88	-18.17	-0.58	8.2e-60	Initial pursuit acceleration;
BRCA	cis	rs7520050	0.872	rs1707308	chr1:46604315	G/A	cg24296786	chr1:45957014	TESK2	0.38	8.4	0.32	2.78e-16	Red blood cell count;Reticulocyte count;
BRCA	cis	rs55883249	1.000	rs62119422	chr2:9726599	A/G	cg23886495	chr2:9695866	ADAM17	0.56	7.97	0.3	7.16e-15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
BRCA	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	11.35	0.41	2.54e-27	Systemic lupus erythematosus;
BRCA	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg21918786	chr6:109611834	NA	-0.46	-12.86	-0.45	7.82e-34	Reticulocyte fraction of red cells;
BRCA	trans	rs7980799	0.654	rs1482987	chr12:33614283	G/C	cg26384229	chr12:38710491	ALG10B	-0.49	-10.67	-0.39	1.46e-24	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	26.54	0.72	3.54e-105	Body mass index (adult);
BRCA	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg21747090	chr2:27597821	SNX17	-0.44	-9.64	-0.36	1.25e-20	Total body bone mineral density;
BRCA	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg04362960	chr10:104952993	NT5C2	0.4	9.57	0.35	2.3e-20	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs9815354	0.812	rs35263917	chr3:41952852	T/C	cg03022575	chr3:42003672	ULK4	0.69	9.62	0.36	1.44e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg01657329	chr11:68192670	LRP5	-0.4	-9.96	-0.37	8.02e-22	Total body bone mineral density;
BRCA	cis	rs965469	0.843	rs6037597	chr20:3408374	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-10.17	-0.37	1.25e-22	IFN-related cytopenia;
BRCA	cis	rs6459788	0.934	rs10251462	chr7:157258183	C/G	cg03453431	chr7:157225567	NA	-0.39	-8.1	-0.31	2.84e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg23018236	chr17:30244563	NA	-0.73	-12.0	-0.43	4.79e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg21770322	chr7:97807741	LMTK2	0.43	11.14	0.4	1.9e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg19346786	chr7:2764209	NA	-0.3	-9.46	-0.35	5.94e-20	Height;
BRCA	cis	rs4653767	1.000	rs10495249	chr1:226919119	A/G	cg05049329	chr1:226924846	ITPKB	0.33	9.31	0.35	2.01e-19	Parkinson's disease;
BRCA	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg21918786	chr6:109611834	NA	-0.49	-14.16	-0.49	8.35e-40	Reticulocyte fraction of red cells;
BRCA	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg27446573	chr6:127587934	RNF146	0.86	20.0	0.62	1.76e-69	Breast cancer;
BRCA	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.16	-0.49	8.76e-40	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4880487	0.924	rs10903404	chr10:1248591	C/A	cg03183215	chr10:1252341	ADARB2	-0.39	-8.51	-0.32	1.26e-16	Migraine;
BRCA	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-9.35	-0.35	1.4e-19	Aortic root size;
BRCA	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg26597838	chr10:835615	NA	-0.9	-15.35	-0.52	1.62e-45	Eosinophil percentage of granulocytes;
BRCA	cis	rs4478137	0.931	rs56233753	chr4:164249023	A/G	cg06758707	chr4:164254230	NPY1R	0.53	11.61	0.42	2.09e-28	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs870825	0.616	rs6552804	chr4:185637699	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	17.32	0.57	2.07e-55	Blood protein levels;
BRCA	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	9.93	0.37	1.03e-21	Tonsillectomy;
BRCA	cis	rs9309473	0.519	rs2421545	chr2:73639476	T/C	cg20560298	chr2:73613845	ALMS1	0.41	11.21	0.41	9.76e-27	Metabolite levels;
BRCA	cis	rs6893300	0.560	rs1019443	chr5:179207547	A/G	cg14593053	chr5:179126677	CANX	-0.47	-12.41	-0.44	7.5e-32	Resting heart rate;
BRCA	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg15704280	chr7:45808275	SEPT13	0.7	13.95	0.48	8.34e-39	Coronary artery disease;
BRCA	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg11645453	chr3:52864694	ITIH4	0.47	10.97	0.4	8.95e-26	Schizophrenia;
BRCA	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg09307838	chr4:120376055	NA	0.59	12.89	0.45	5.65e-34	Corneal astigmatism;
BRCA	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg15017067	chr4:17643749	FAM184B	0.28	8.48	0.32	1.51e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg24562669	chr7:97807699	LMTK2	0.47	12.62	0.45	8.98e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.89	-0.33	6e-18	Total body bone mineral density;
BRCA	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg20503657	chr10:835505	NA	0.87	15.96	0.53	1.75e-48	Eosinophil percentage of granulocytes;
BRCA	cis	rs7937840	0.581	rs4963461	chr11:61884044	G/A	cg01969543	chr11:61895209	INCENP	-0.38	-8.28	-0.31	7.49e-16	Breast cancer;
BRCA	cis	rs965469	0.545	rs6051846	chr20:3403824	A/G	cg25506879	chr20:3388711	C20orf194	0.46	9.82	0.36	2.62e-21	IFN-related cytopenia;
BRCA	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg21573476	chr21:45109991	RRP1B	-0.34	-8.64	-0.32	4.57e-17	Mean corpuscular volume;
BRCA	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg04267008	chr7:1944627	MAD1L1	-0.65	-13.6	-0.47	3.45e-37	Bipolar disorder and schizophrenia;
BRCA	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg00383909	chr3:49044727	WDR6	0.7	10.52	0.38	5.52e-24	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
BRCA	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg20628663	chr10:43360327	NA	-0.7	-13.62	-0.47	2.75e-37	Blood protein levels;
BRCA	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg11833968	chr6:79620685	NA	-0.44	-9.97	-0.37	7.64e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7737355	0.947	rs10073137	chr5:131091089	A/G	cg06307176	chr5:131281290	NA	0.53	10.18	0.37	1.16e-22	Life satisfaction;
BRCA	cis	rs17253792	0.822	rs13379343	chr14:56050205	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.61	8.47	0.32	1.68e-16	Putamen volume;
BRCA	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg23285459	chr7:2802560	GNA12	0.35	9.11	0.34	1.05e-18	Height;
BRCA	cis	rs6495367	1.000	rs745030	chr15:79381705	G/A	cg17916960	chr15:79447300	NA	0.34	8.35	0.31	4.33e-16	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg05084668	chr3:125655381	ALG1L	-0.47	-8.08	-0.3	3.23e-15	Blood pressure (smoking interaction);
BRCA	cis	rs7301826	1.000	rs1609985	chr12:131320170	A/G	cg11011512	chr12:131303247	STX2	0.41	10.37	0.38	2.2e-23	Plasma plasminogen activator levels;
BRCA	trans	rs6479891	1.000	rs72837070	chr10:65274679	T/C	cg14819942	chr15:35414228	NA	0.34	8.37	0.31	3.74e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23583168	chr7:148888333	NA	-0.89	-21.58	-0.65	5.66e-78	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg08847533	chr14:75593920	NEK9	-0.8	-19.35	-0.61	4.97e-66	Height;
BRCA	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg26384229	chr12:38710491	ALG10B	0.53	13.39	0.47	3.17e-36	Morning vs. evening chronotype;
BRCA	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg00106254	chr7:1943704	MAD1L1	-0.31	-8.24	-0.31	1.01e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs68170813	0.559	rs75932578	chr7:106844694	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.33	-0.31	4.95e-16	Coronary artery disease;
BRCA	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	17.41	0.57	7.55e-56	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05890377	chr2:74357713	NA	0.48	11.65	0.42	1.4e-28	Gestational age at birth (maternal effect);
BRCA	trans	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.62	-0.36	1.48e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg20307385	chr11:47447363	PSMC3	-0.43	-8.75	-0.33	1.87e-17	Subjective well-being;
BRCA	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs758324	0.853	rs4705902	chr5:131150267	C/G	cg06307176	chr5:131281290	NA	0.53	10.28	0.38	4.8e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg02551604	chr5:131831745	NA	-0.39	-14.68	-0.5	2.84e-42	Asthma (sex interaction);
BRCA	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-12.6	-0.45	1.18e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs6088813	0.845	rs2378349	chr20:33925843	C/A	cg14752227	chr20:34000481	UQCC	0.4	8.54	0.32	9.96e-17	Height;
BRCA	cis	rs12618769	0.520	rs72821904	chr2:99084882	G/A	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg27478167	chr7:817139	HEATR2	-0.45	-9.66	-0.36	1.08e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7809950	0.954	rs2712193	chr7:107125885	A/C	cg23024343	chr7:107201750	COG5	-0.41	-9.54	-0.35	2.86e-20	Coronary artery disease;
BRCA	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg08885076	chr2:99613938	TSGA10	0.45	10.69	0.39	1.17e-24	Chronic sinus infection;
BRCA	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg03709012	chr19:19516395	GATAD2A	-0.8	-18.43	-0.59	3.95e-61	Tonsillectomy;
BRCA	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.56	-0.44	1.71e-32	Migraine;Coronary artery disease;
BRCA	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.99	0.67	1.05e-85	Chronic sinus infection;
BRCA	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	ch.11.42038R	chr11:967971	AP2A2	0.51	15.98	0.53	1.27e-48	Alzheimer's disease (late onset);
BRCA	cis	rs4363385	0.818	rs653332	chr1:153010481	C/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.18	-0.34	5.72e-19	Inflammatory skin disease;
BRCA	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg05255149	chr17:80675120	FN3KRP	-0.39	-7.83	-0.3	2.05e-14	Glycated hemoglobin levels;
BRCA	cis	rs4595586	0.679	rs4768471	chr12:39325960	G/A	cg26384229	chr12:38710491	ALG10B	0.38	8.69	0.33	2.97e-17	Morning vs. evening chronotype;
BRCA	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg26031613	chr14:104095156	KLC1	-0.43	-8.47	-0.32	1.74e-16	Schizophrenia;
BRCA	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg04450456	chr4:17643702	FAM184B	0.32	9.39	0.35	1.08e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4800452	0.826	rs8094261	chr18:20746728	C/G	cg26136497	chr18:20735537	CABLES1	-0.39	-9.39	-0.35	1.05e-19	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
BRCA	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg17830980	chr10:43048298	ZNF37B	0.43	10.19	0.37	1.04e-22	Extrinsic epigenetic age acceleration;
BRCA	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg26384229	chr12:38710491	ALG10B	0.75	16.69	0.55	3.44e-52	Morning vs. evening chronotype;
BRCA	cis	rs870825	1.000	rs870825	chr4:185588045	A/G	cg20176042	chr4:185552304	CASP3	-0.55	-8.03	-0.3	4.67e-15	Blood protein levels;
BRCA	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg14926445	chr8:58193284	C8orf71	-0.42	-8.19	-0.31	1.43e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.84	-14.69	-0.5	2.71e-42	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7737355	0.947	rs31240	chr5:130811146	T/A	cg06307176	chr5:131281290	NA	0.52	10.38	0.38	2e-23	Life satisfaction;
BRCA	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg18758796	chr5:131593413	PDLIM4	0.32	8.28	0.31	7.42e-16	Breast cancer;
BRCA	cis	rs3845702	1.000	rs3768837	chr2:180835792	T/A	cg01881094	chr2:180872142	CWC22	-0.68	-13.65	-0.48	2.08e-37	Schizophrenia;
BRCA	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	9.1	0.34	1.14e-18	Renal function-related traits (BUN);
BRCA	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18404041	chr3:52824283	ITIH1	-0.4	-12.16	-0.43	9.1e-31	Bipolar disorder;
BRCA	cis	rs36051895	0.623	rs57707737	chr9:5062844	A/T	cg02405213	chr9:5042618	JAK2	-0.53	-9.47	-0.35	5.33e-20	Pediatric autoimmune diseases;
BRCA	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg18850127	chr7:39170497	POU6F2	0.48	10.31	0.38	3.76e-23	IgG glycosylation;
BRCA	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-12.06	-0.43	2.55e-30	Mood instability;
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg26608667	chr7:1196370	ZFAND2A	0.42	9.36	0.35	1.36e-19	Longevity;Endometriosis;
BRCA	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg10523679	chr1:76189770	ACADM	0.76	15.93	0.53	2.31e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg03711944	chr11:47377212	SPI1	-0.42	-11.35	-0.41	2.63e-27	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.61	0.42	2.12e-28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs7737355	1.000	rs27708	chr5:130743541	C/T	cg06307176	chr5:131281290	NA	-0.49	-9.78	-0.36	3.96e-21	Life satisfaction;
BRCA	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg20991723	chr1:152506922	NA	0.39	9.07	0.34	1.4e-18	Hair morphology;
BRCA	cis	rs72772090	1.000	rs72772090	chr5:96036311	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-11.84	-0.42	2.24e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7631605	0.905	rs7649344	chr3:37006396	C/T	cg15934958	chr3:37212084	LRRFIP2	-0.41	-9.73	-0.36	5.71e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg08807101	chr21:30365312	RNF160	0.34	7.9	0.3	1.19e-14	Pancreatic cancer;
BRCA	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	15.59	0.52	1.15e-46	Colorectal cancer;
BRCA	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg13047869	chr3:10149882	C3orf24	0.59	12.48	0.44	3.86e-32	Alzheimer's disease;
BRCA	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	11.0	0.4	6.75e-26	Bipolar disorder;
BRCA	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	11.4	0.41	1.54e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02353165	chr6:42928485	GNMT	0.79	19.31	0.61	8.54e-66	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6545883	0.868	rs28749199	chr2:61827052	A/G	cg15711740	chr2:61764176	XPO1	-0.55	-13.25	-0.46	1.4e-35	Tuberculosis;
BRCA	cis	rs2839627	0.561	rs4148970	chr21:44313293	A/G	cg03543861	chr21:44258195	NA	0.4	8.15	0.31	1.91e-15	Information processing speed;
BRCA	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg04586622	chr2:25135609	ADCY3	0.4	10.4	0.38	1.58e-23	Body mass index in non-asthmatics;
BRCA	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg00981070	chr1:2046702	PRKCZ	0.31	8.22	0.31	1.1e-15	Height;
BRCA	cis	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg06521331	chr12:34319734	NA	-0.52	-10.27	-0.38	5.25e-23	Morning vs. evening chronotype;
BRCA	cis	rs858239	0.601	rs6461693	chr7:23160133	A/G	cg23682824	chr7:23144976	KLHL7	-0.42	-11.12	-0.4	2.19e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1506636	0.962	rs1506640	chr7:123349627	T/G	cg03229431	chr7:123269106	ASB15	-0.61	-14.03	-0.49	3.68e-39	Plateletcrit;Platelet count;
BRCA	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg03433033	chr1:76189801	ACADM	-0.51	-10.82	-0.39	3.51e-25	Daytime sleep phenotypes;
BRCA	trans	rs2270927	0.510	rs35966882	chr5:75577716	A/G	cg13563193	chr19:33072644	PDCD5	0.86	10.94	0.4	1.24e-25	Mean corpuscular volume;
BRCA	cis	rs6546550	0.933	rs6546555	chr2:70135760	A/G	cg02498382	chr2:70120550	SNRNP27	-0.52	-11.47	-0.41	7.91e-28	Prevalent atrial fibrillation;
BRCA	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg18252515	chr7:66147081	NA	-1.07	-15.95	-0.53	1.77e-48	Gout;
BRCA	cis	rs9394841	0.692	rs34073739	chr6:41829970	A/G	cg08135965	chr6:41755394	TOMM6	0.51	8.34	0.31	4.72e-16	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.58	-9.1	-0.34	1.18e-18	Platelet count;
BRCA	cis	rs1468333	1.000	rs2967781	chr5:137557609	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.43	8.55	0.32	9.07e-17	Resting heart rate;
BRCA	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23978390	chr7:1156363	C7orf50	0.38	9.22	0.34	4.24e-19	Longevity;Endometriosis;
BRCA	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg06713675	chr4:122721982	EXOSC9	-0.55	-12.78	-0.45	1.84e-33	Type 2 diabetes;
BRCA	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg25801113	chr15:45476975	SHF	-0.33	-8.3	-0.31	6.21e-16	Uric acid levels;
BRCA	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg01483505	chr11:975446	AP2A2	0.33	9.04	0.34	1.88e-18	Alzheimer's disease (late onset);
BRCA	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg21535247	chr6:8435926	SLC35B3	0.41	9.34	0.35	1.59e-19	Motion sickness;
BRCA	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg20991723	chr1:152506922	NA	0.38	8.63	0.32	4.93e-17	Hair morphology;
BRCA	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	9.34	0.35	1.53e-19	Parkinson's disease;
BRCA	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.38	-8.17	-0.31	1.62e-15	Schizophrenia;
BRCA	cis	rs10896135	0.526	rs484262	chr11:66399681	C/T	cg24851651	chr11:66362959	CCS	-0.43	-8.86	-0.33	7.67e-18	Bipolar disorder;
BRCA	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg07169764	chr2:136633963	MCM6	1.27	22.58	0.67	1.9e-83	Corneal structure;
BRCA	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.05	0.3	4.07e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.15	-0.31	1.9e-15	Depression;
BRCA	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.22e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg06026331	chr20:60912101	LAMA5	0.4	8.08	0.3	3.24e-15	Colorectal cancer;
BRCA	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg02297831	chr4:17616191	MED28	0.36	8.29	0.31	6.84e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.54	0.42	3.95e-28	Bipolar disorder;
BRCA	trans	rs6964833	0.786	rs35633336	chr7:74058292	G/T	cg07504079	chr7:72649617	NCF1B	-0.47	-9.13	-0.34	8.91e-19	Menarche (age at onset);
BRCA	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg08601574	chr20:25228251	PYGB	0.42	9.78	0.36	3.85e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18876405	chr7:65276391	NA	0.55	13.03	0.46	1.41e-34	Aortic root size;
BRCA	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg05552183	chr6:42928497	GNMT	0.8	19.37	0.61	4.27e-66	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs3815700	1.000	rs8104726	chr19:33094675	G/A	cg02997394	chr19:33096574	ANKRD27	0.69	11.47	0.41	7.98e-28	Eosinophilic esophagitis;
BRCA	cis	rs3772130	0.962	rs9878086	chr3:121488353	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.68	0.39	1.28e-24	Cognitive performance;
BRCA	cis	rs6025261	0.761	rs6092390	chr20:55510339	C/T	cg04763273	chr20:55502381	NA	0.32	7.9	0.3	1.23e-14	Verbal memory performance (delayed recall level);
BRCA	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg05347473	chr6:146136440	FBXO30	0.42	8.2	0.31	1.33e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg13010199	chr12:38710504	ALG10B	0.44	8.84	0.33	9.41e-18	Bladder cancer;
BRCA	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg17063962	chr7:91808500	NA	0.52	12.27	0.44	3.04e-31	Breast cancer;
BRCA	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg22920501	chr2:26401640	FAM59B	0.95	16.66	0.55	4.8e-52	Gut microbiome composition (summer);
BRCA	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg11812906	chr14:75593930	NEK9	-0.63	-14.44	-0.5	4.13e-41	Height;
BRCA	cis	rs9788682	0.792	rs35031105	chr15:78772806	C/T	cg24631222	chr15:78858424	CHRNA5	0.46	9.12	0.34	9.72e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg15934090	chr1:100435551	SLC35A3	0.35	8.18	0.31	1.48e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-13.21	-0.46	2.03e-35	Response to antipsychotic treatment;
BRCA	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg19729930	chr2:74357872	NA	0.59	14.58	0.5	8.99e-42	Gestational age at birth (maternal effect);
BRCA	cis	rs7737355	0.947	rs6596029	chr5:130899079	T/C	cg06307176	chr5:131281290	NA	0.53	10.44	0.38	1.18e-23	Life satisfaction;
BRCA	cis	rs7524258	0.868	rs1304711	chr1:7270320	G/T	cg07173049	chr1:7289937	CAMTA1	-0.44	-10.89	-0.4	1.81e-25	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg01475735	chr3:40494733	NA	0.43	7.94	0.3	9.25e-15	Renal cell carcinoma;
BRCA	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg27446573	chr6:127587934	RNF146	0.88	19.86	0.62	9.48e-69	Breast cancer;
BRCA	cis	rs10129255	0.500	rs6576231	chr14:107191930	T/C	cg07958169	chr14:107095056	NA	-0.4	-8.52	-0.32	1.17e-16	Kawasaki disease;
BRCA	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.44	8.36	0.31	3.92e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg10792982	chr14:105748885	BRF1	0.5	11.39	0.41	1.67e-27	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg10523679	chr1:76189770	ACADM	0.88	20.7	0.63	2.98e-73	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg26043149	chr18:55253948	FECH	-0.38	-8.35	-0.31	4.17e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4074536	0.574	rs10733095	chr1:116289164	A/G	cg21648376	chr1:116311395	CASQ2	-0.49	-8.71	-0.33	2.5e-17	QRS duration;
BRCA	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg11887960	chr12:57824829	NA	0.52	8.15	0.31	1.89e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.74	-0.33	2.03e-17	Colorectal cancer;
BRCA	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.15	-0.49	9.24e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.42	-0.61	2.35e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg09184832	chr6:79620586	NA	-0.53	-11.68	-0.42	1.05e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs920590	0.796	rs7820520	chr8:19634864	A/G	cg03894339	chr8:19674705	INTS10	-0.39	-7.97	-0.3	7.14e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.59	8.44	0.32	2.05e-16	Schizophrenia;
BRCA	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.5	11.01	0.4	5.91e-26	IgG glycosylation;
BRCA	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.54	7.97	0.3	7.43e-15	Cerebrospinal P-tau181p levels;
BRCA	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg03929089	chr4:120376271	NA	0.57	9.83	0.36	2.59e-21	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs4285028	0.948	rs7651226	chr3:121670802	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.58	-10.76	-0.39	6.38e-25	Multiple sclerosis;
BRCA	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg21132104	chr15:45694354	SPATA5L1	0.74	16.42	0.54	8.34e-51	Homoarginine levels;
BRCA	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg25173405	chr17:45401733	C17orf57	-0.51	-10.59	-0.39	2.89e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs2018683	0.707	rs4722875	chr7:28969632	A/G	cg19402173	chr7:128379420	CALU	-0.42	-10.05	-0.37	3.77e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	11.35	0.41	2.44e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs13088281	1.000	rs13088281	chr3:53147576	A/C	cg07884673	chr3:53033167	SFMBT1	-0.69	-8.54	-0.32	9.89e-17	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs7246657	0.551	rs4806414	chr19:37638788	T/C	cg18154014	chr19:37997991	ZNF793	0.52	8.64	0.32	4.44e-17	Coronary artery calcification;
BRCA	trans	rs4714291	0.925	rs847747	chr6:40080069	G/T	cg02267698	chr19:7991119	CTXN1	0.4	7.91	0.3	1.16e-14	Strep throat;
BRCA	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg18512352	chr11:47633146	NA	-0.34	-8.32	-0.31	5.4e-16	Subjective well-being;
BRCA	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.27	-8.06	-0.3	3.78e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg25019033	chr10:957182	NA	0.32	7.87	0.3	1.5e-14	Eosinophil percentage of granulocytes;
BRCA	trans	rs9393777	0.920	rs35716472	chr6:27406607	C/G	cg01620082	chr3:125678407	NA	-0.73	-9.67	-0.36	9.61e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.5	-9.59	-0.35	1.97e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg00031303	chr3:195681400	NA	0.5	9.57	0.35	2.33e-20	Pancreatic cancer;
BRCA	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg14343924	chr8:8086146	FLJ10661	0.48	9.56	0.35	2.56e-20	Neuroticism;
BRCA	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.98	-22.05	-0.66	1.47e-80	Lymphocyte percentage of white cells;
BRCA	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg27286337	chr10:134555280	INPP5A	0.85	21.38	0.65	6.66e-77	Migraine;
BRCA	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg08477640	chr19:41863820	B9D2	0.39	8.13	0.31	2.15e-15	Migraine;Coronary artery disease;
BRCA	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg11833968	chr6:79620685	NA	0.4	9.05	0.34	1.67e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg03213289	chr20:61660250	NA	0.61	16.28	0.54	4.14e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg20701182	chr2:24300061	SF3B14	0.58	9.2	0.34	5.02e-19	Lymphocyte counts;
BRCA	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08280861	chr8:58055591	NA	0.53	8.59	0.32	6.62e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg17425144	chr1:10567563	PEX14	-0.54	-13.55	-0.47	6.11e-37	Prostate cancer;
BRCA	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg11843238	chr5:131593191	PDLIM4	-0.38	-9.58	-0.35	2.09e-20	Acylcarnitine levels;
BRCA	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg10818794	chr15:86012489	AKAP13	-0.3	-8.52	-0.32	1.17e-16	Coronary artery disease;
BRCA	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg08917208	chr2:24149416	ATAD2B	0.89	12.76	0.45	2.2e-33	Lymphocyte counts;
BRCA	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00149659	chr3:10157352	C3orf10	0.72	12.57	0.45	1.49e-32	Alzheimer's disease;
BRCA	cis	rs4664304	0.620	rs10186586	chr2:160715334	T/C	cg18514922	chr2:160761262	LY75	0.33	7.9	0.3	1.21e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.95	0.43	7.46e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg08213375	chr14:104286397	PPP1R13B	0.51	11.02	0.4	5.78e-26	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg24069376	chr3:38537580	EXOG	0.34	9.41	0.35	8.96e-20	Electrocardiographic conduction measures;
BRCA	cis	rs708547	0.647	rs12621	chr4:57897570	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.4	10.59	0.39	2.85e-24	Response to bleomycin (chromatid breaks);
BRCA	cis	rs490234	0.776	rs10115455	chr9:128458850	T/C	cg14078157	chr9:128172775	NA	-0.44	-9.85	-0.36	2.13e-21	Mean arterial pressure;
BRCA	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg03864215	chr11:17408437	KCNJ11	-0.26	-7.85	-0.3	1.75e-14	Type 2 diabetes;
BRCA	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg10495392	chr1:46806563	NSUN4	0.47	8.7	0.33	2.71e-17	Menopause (age at onset);
BRCA	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg15934090	chr1:100435551	SLC35A3	0.35	8.18	0.31	1.54e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6714710	0.603	rs55776387	chr2:98405034	T/C	cg26665480	chr2:98280029	ACTR1B	0.6	13.85	0.48	2.52e-38	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg06784218	chr1:46089804	CCDC17	-0.53	-12.82	-0.45	1.25e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.85	0.33	8.55e-18	Motion sickness;
BRCA	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg18898632	chr2:242989856	NA	-0.46	-7.88	-0.3	1.39e-14	Obesity-related traits;
BRCA	cis	rs6840258	1.000	rs7695426	chr4:87921277	C/T	cg08197287	chr4:87952173	AFF1	-0.45	-8.75	-0.33	1.86e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.53	-0.38	4.89e-24	Morning vs. evening chronotype;
BRCA	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg25237894	chr2:233734115	C2orf82	-0.39	-11.1	-0.4	2.62e-26	Coronary artery disease;
BRCA	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	12.45	0.44	5.22e-32	Lung cancer in ever smokers;
BRCA	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.46e-34	Alzheimer's disease (late onset);
BRCA	cis	rs754466	0.651	rs11815015	chr10:79625482	C/T	cg17075019	chr10:79541650	NA	-0.73	-17.59	-0.57	8.49e-57	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs3741151	0.773	rs73542990	chr11:73134398	C/T	cg17517138	chr11:73019481	ARHGEF17	0.93	13.14	0.46	4.36e-35	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-17.8	-0.58	7.61e-58	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs4650994	0.625	rs6681348	chr1:178526271	A/C	cg05059571	chr16:84539110	KIAA1609	-0.42	-9.44	-0.35	7.1e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg25036284	chr2:26402008	FAM59B	-0.79	-12.41	-0.44	7.62e-32	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.17	-0.31	1.69e-15	Aortic root size;
BRCA	cis	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg07460842	chr6:66804631	NA	0.6	10.31	0.38	3.59e-23	Type 2 diabetes;
BRCA	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg23533926	chr12:111358616	MYL2	-0.41	-8.59	-0.32	6.69e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg21747090	chr2:27597821	SNX17	-0.43	-9.43	-0.35	7.24e-20	Total body bone mineral density;
BRCA	cis	rs9837602	0.872	rs34996634	chr3:99738219	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	10.53	0.38	5.15e-24	Breast cancer;
BRCA	trans	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg25214090	chr10:38739885	LOC399744	0.46	10.46	0.38	9.56e-24	Corneal astigmatism;
BRCA	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg25554036	chr4:6271136	WFS1	0.42	9.99	0.37	6.36e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg08917208	chr2:24149416	ATAD2B	1.12	15.76	0.53	1.55e-47	Lymphocyte counts;
BRCA	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg04450456	chr4:17643702	FAM184B	0.39	10.8	0.39	4.19e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg26384229	chr12:38710491	ALG10B	0.59	13.39	0.47	3.37e-36	Heart rate;
BRCA	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg03433033	chr1:76189801	ACADM	0.75	16.75	0.55	1.7e-52	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg08805041	chr16:621841	PIGQ	-0.32	-8.81	-0.33	1.14e-17	Height;
BRCA	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg08514558	chr10:81106712	PPIF	0.38	8.75	0.33	1.9e-17	Height;
BRCA	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	12.07	0.43	2.33e-30	Tonsillectomy;
BRCA	cis	rs6878727	0.562	rs2633527	chr5:123638706	A/G	cg01806427	chr5:123737813	NA	-0.37	-8.22	-0.31	1.15e-15	Breast cancer;
BRCA	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.0	21.9	0.65	9.17e-80	Gut microbiome composition (summer);
BRCA	cis	rs6484504	0.625	rs796341	chr11:31414151	G/A	cg26647111	chr11:31128758	NA	0.45	9.66	0.36	1.05e-20	Red blood cell count;
BRCA	cis	rs4233802	1.000	rs4425095	chr2:151139757	C/T	cg25300694	chr2:151184358	NA	0.76	8.13	0.31	2.29e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg21856205	chr7:94953877	PON1	-0.37	-7.92	-0.3	1.02e-14	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg16950941	chr11:66035639	RAB1B	0.46	12.3	0.44	2.24e-31	Gout;
BRCA	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00149659	chr3:10157352	C3orf10	1.06	18.02	0.58	5.43e-59	Alzheimer's disease;
BRCA	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg09184832	chr6:79620586	NA	-0.52	-11.51	-0.41	5.68e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	13.29	0.47	9.44e-36	Mean platelet volume;
BRCA	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg15997130	chr1:24165203	NA	0.44	11.3	0.41	4.15e-27	Immature fraction of reticulocytes;
BRCA	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.36	-8.22	-0.31	1.14e-15	Longevity;Endometriosis;
BRCA	cis	rs7474896	0.559	rs1735629	chr10:38178309	C/T	cg25427524	chr10:38739819	LOC399744	0.56	10.05	0.37	3.55e-22	Obesity (extreme);
BRCA	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg27535305	chr1:53392650	SCP2	0.32	8.07	0.3	3.4e-15	Monocyte count;
BRCA	cis	rs13046373	0.507	rs2832959	chr21:31982934	C/T	cg06468780	chr21:31798236	KRTAP13-3	0.36	9.04	0.34	1.88e-18	HDL cholesterol;
BRCA	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.78	-11.25	-0.41	6.26e-27	Schizophrenia;
BRCA	cis	rs1595825	0.891	rs79745588	chr2:198516835	G/A	cg19156104	chr2:198669113	PLCL1	-0.46	-8.57	-0.32	7.95e-17	Ulcerative colitis;
BRCA	cis	rs1371614	0.610	rs6547317	chr2:27151919	A/G	cg00617064	chr2:27272375	NA	-0.31	-8.06	-0.3	3.89e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs17253792	0.822	rs78395034	chr14:56069783	G/A	cg01858014	chr14:56050164	KTN1	-0.74	-9.35	-0.35	1.43e-19	Putamen volume;
BRCA	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg23231163	chr10:75533350	FUT11	-0.35	-9.24	-0.34	3.57e-19	Inflammatory bowel disease;
BRCA	cis	rs7131987	0.868	rs10771508	chr12:29414211	G/A	cg09582351	chr12:29534625	ERGIC2	-0.39	-9.37	-0.35	1.26e-19	QT interval;
BRCA	cis	rs870825	0.616	rs6818447	chr4:185650154	G/A	cg04058563	chr4:185651563	MLF1IP	0.79	17.79	0.58	7.74e-58	Blood protein levels;
BRCA	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg08807101	chr21:30365312	RNF160	-0.62	-16.01	-0.53	9.78e-49	Dental caries;
BRCA	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg08000102	chr2:233561755	GIGYF2	0.64	13.86	0.48	2.19e-38	Coronary artery disease;
BRCA	cis	rs2637266	0.935	rs2252652	chr10:78405022	C/T	cg18941641	chr10:78392320	NA	0.35	8.13	0.31	2.3e-15	Pulmonary function;
BRCA	cis	rs867371	0.896	rs8033831	chr15:82513294	C/A	cg00614314	chr15:82944287	LOC80154	0.45	9.58	0.35	2.18e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg24812749	chr6:127587940	RNF146	0.68	15.51	0.52	2.63e-46	Breast cancer;
BRCA	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg20503657	chr10:835505	NA	0.51	8.73	0.33	2.28e-17	Response to angiotensin II receptor blocker therapy;
BRCA	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg06636001	chr8:8085503	FLJ10661	0.54	10.19	0.37	1.11e-22	Retinal vascular caliber;
BRCA	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg09035930	chr12:129282057	SLC15A4	-0.49	-13.87	-0.48	2.06e-38	Systemic lupus erythematosus;
BRCA	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg20307385	chr11:47447363	PSMC3	0.5	11.87	0.43	1.67e-29	Neuroticism;Neuroticism (multi-trait analysis);
BRCA	cis	rs6598955	0.502	rs6683157	chr1:26545865	G/A	cg04990556	chr1:26633338	UBXN11	0.69	11.85	0.42	1.96e-29	Obesity-related traits;
BRCA	cis	rs1003719	0.715	rs58008706	chr21:38540506	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-13.71	-0.48	1.05e-37	Eye color traits;
BRCA	cis	rs4742903	0.904	rs10991187	chr9:106996271	C/T	cg21169611	chr9:106856078	SMC2	0.31	8.06	0.3	3.66e-15	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.18	0.46	2.94e-35	Electroencephalogram traits;
BRCA	trans	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg25214090	chr10:38739885	LOC399744	0.46	10.59	0.39	2.85e-24	Educational attainment;
BRCA	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	7.98	0.3	7e-15	Tonsillectomy;
BRCA	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg26516362	chr5:178986906	RUFY1	0.48	13.84	0.48	2.64e-38	Lung cancer;
BRCA	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg03213289	chr20:61660250	NA	0.63	16.5	0.55	3.33e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg06627628	chr2:24431161	ITSN2	0.48	9.91	0.37	1.21e-21	Asthma;
BRCA	cis	rs4853036	0.629	rs7577864	chr2:70017435	A/G	cg02498382	chr2:70120550	SNRNP27	-0.46	-8.01	-0.3	5.62e-15	Colorectal or endometrial cancer;
BRCA	trans	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.0	0.3	5.66e-15	Corneal astigmatism;
BRCA	cis	rs2070997	0.756	rs2987903	chr9:133711263	G/A	cg11464064	chr9:133710261	ABL1	0.59	9.37	0.35	1.21e-19	Response to amphetamines;
BRCA	cis	rs754466	0.651	rs55738779	chr10:79652395	C/T	cg17075019	chr10:79541650	NA	-0.72	-16.45	-0.55	6.12e-51	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10208940	0.841	rs6731066	chr2:68796618	A/G	cg12452813	chr2:68675892	NA	0.5	8.82	0.33	1.09e-17	Urate levels in lean individuals;
BRCA	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg12310025	chr6:25882481	NA	-0.5	-12.1	-0.43	1.71e-30	Blood metabolite levels;
BRCA	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg16576597	chr16:28551801	NUPR1	0.3	8.37	0.31	3.68e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg17063962	chr7:91808500	NA	-0.52	-11.93	-0.43	8.84e-30	Breast cancer;
BRCA	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg03709012	chr19:19516395	GATAD2A	-0.75	-17.0	-0.56	1e-53	Tonsillectomy;
BRCA	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg15704280	chr7:45808275	SEPT13	0.7	14.26	0.49	3.07e-40	Coronary artery disease;
BRCA	cis	rs4285028	0.699	rs7637495	chr3:121573850	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.71	-13.28	-0.47	9.84e-36	Multiple sclerosis;
BRCA	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.23e-24	Motion sickness;
BRCA	cis	rs7572733	0.534	rs700692	chr2:198728500	T/C	cg00792783	chr2:198669748	PLCL1	0.47	10.18	0.37	1.21e-22	Dermatomyositis;
BRCA	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg23422044	chr7:1970798	MAD1L1	-0.41	-8.53	-0.32	1.04e-16	Neuroticism;
BRCA	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg11833968	chr6:79620685	NA	-0.44	-9.85	-0.36	2.02e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7264396	0.887	rs224370	chr20:34073379	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-8.19	-0.31	1.4e-15	Total cholesterol levels;
BRCA	cis	rs6942756	0.531	rs4731569	chr7:128930828	C/T	cg02491457	chr7:128862824	NA	0.46	9.53	0.35	3.3e-20	White matter hyperintensity burden;
BRCA	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg10729496	chr3:10149963	C3orf24	0.51	8.46	0.32	1.78e-16	Alzheimer's disease;
BRCA	cis	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.54	-0.32	9.97e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg22907277	chr7:1156413	C7orf50	0.6	11.48	0.41	6.93e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg05340658	chr4:99064831	C4orf37	0.65	15.98	0.53	1.36e-48	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs925228	0.504	rs6729231	chr2:24292597	A/T	cg01493198	chr2:24299560	SF3B14	0.56	7.81	0.3	2.4e-14	Reticulocyte fraction of red cells;Reticulocyte count;
BRCA	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg26384229	chr12:38710491	ALG10B	0.66	15.39	0.52	1.1e-45	Bladder cancer;
BRCA	cis	rs6963495	0.546	rs2697020	chr7:105150046	C/T	cg19920283	chr7:105172520	RINT1	0.43	8.93	0.33	4.67e-18	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg23711669	chr6:146136114	FBXO30	-0.79	-18.91	-0.6	1.19e-63	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg03929089	chr4:120376271	NA	0.77	17.21	0.56	7.87e-55	Coronary artery disease;
BRCA	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.53	8.13	0.31	2.24e-15	Renal function-related traits (BUN);
BRCA	cis	rs3917254	0.596	rs3755294	chr2:102768376	G/A	cg22835712	chr2:102737379	NA	-0.5	-8.25	-0.31	9.05e-16	Blood protein levels;
BRCA	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg24110177	chr3:50126178	RBM5	-0.45	-11.27	-0.41	5.34e-27	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg25214090	chr10:38739885	LOC399744	0.57	12.45	0.44	5.24e-32	Corneal astigmatism;
BRCA	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18402987	chr7:1209562	NA	0.61	12.52	0.44	2.58e-32	Longevity;Endometriosis;
BRCA	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg17366294	chr4:99064904	C4orf37	0.49	8.41	0.32	2.75e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23583168	chr7:148888333	NA	-0.76	-16.44	-0.55	6.73e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg03433033	chr1:76189801	ACADM	-0.39	-7.98	-0.3	6.57e-15	Daytime sleep phenotypes;
BRCA	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg24692254	chr21:30365293	RNF160	-0.59	-14.72	-0.5	1.9e-42	Dental caries;
BRCA	cis	rs7512552	0.809	rs9436108	chr1:150360930	A/G	cg15654264	chr1:150340011	RPRD2	0.38	8.4	0.32	2.96e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs490234	0.702	rs3814129	chr9:128365953	A/G	cg14078157	chr9:128172775	NA	-0.43	-9.85	-0.36	2.02e-21	Mean arterial pressure;
BRCA	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	14.82	0.51	6.58e-43	Multiple sclerosis;
BRCA	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	18.21	0.58	5.05e-60	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6142102	0.580	rs761233	chr20:32568886	A/G	cg24642439	chr20:33292090	TP53INP2	0.39	7.83	0.3	2.1e-14	Skin pigmentation;
BRCA	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg05552183	chr6:42928497	GNMT	-0.81	-18.93	-0.6	8.91e-64	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg04586622	chr2:25135609	ADCY3	0.45	11.5	0.41	6.04e-28	Body mass index in non-asthmatics;
BRCA	cis	rs1864400	0.690	rs7098237	chr10:43740513	T/A	cg15436174	chr10:43711423	RASGEF1A	0.5	9.97	0.37	7.18e-22	Hirschsprung disease;
BRCA	cis	rs11608355	0.545	rs12822974	chr12:109909154	G/T	cg05360138	chr12:110035743	NA	0.71	13.09	0.46	7.36e-35	Neuroticism;
BRCA	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg04586622	chr2:25135609	ADCY3	0.42	11.07	0.4	3.61e-26	Body mass index in non-asthmatics;
BRCA	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg08807101	chr21:30365312	RNF160	-0.55	-13.43	-0.47	2.08e-36	Dental caries;
BRCA	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg02551604	chr5:131831745	NA	-0.39	-13.73	-0.48	8.48e-38	Asthma (sex interaction);
BRCA	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg23950597	chr19:37808831	NA	-0.75	-13.2	-0.46	2.34e-35	Coronary artery calcification;
BRCA	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg04317338	chr11:64019027	PLCB3	0.56	9.68	0.36	9.17e-21	Mean platelet volume;
BRCA	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09263875	chr16:632152	PIGQ	0.72	21.6	0.65	4.29e-78	Height;
BRCA	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg24642439	chr20:33292090	TP53INP2	-0.42	-8.64	-0.32	4.42e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs9467773	0.609	rs12663780	chr6:26397573	T/C	cg09904177	chr6:26538194	HMGN4	-0.36	-9.35	-0.35	1.42e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg05347473	chr6:146136440	FBXO30	-0.43	-8.43	-0.32	2.33e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg12463550	chr7:65579703	CRCP	-0.37	-7.96	-0.3	8.11e-15	Aortic root size;
BRCA	cis	rs4730250	0.634	rs11767623	chr7:106792332	C/T	cg02696742	chr7:106810147	HBP1	0.57	9.43	0.35	7.51e-20	Osteoarthritis;
BRCA	cis	rs67981189	0.865	rs2189806	chr14:71388398	T/A	cg15816911	chr14:71606274	NA	-0.37	-8.25	-0.31	9.14e-16	Schizophrenia;
BRCA	cis	rs600806	0.778	rs4970765	chr1:110009171	C/T	cg20591472	chr1:110008990	SYPL2	0.31	7.98	0.3	6.93e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21659725	chr3:3221576	CRBN	0.46	11.56	0.42	3.34e-28	Intelligence (multi-trait analysis);
BRCA	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg15556689	chr8:8085844	FLJ10661	-0.35	-8.85	-0.33	8.85e-18	Neuroticism;
BRCA	cis	rs36051895	0.695	rs10124627	chr9:5025746	T/G	cg02405213	chr9:5042618	JAK2	-0.46	-8.56	-0.32	8.48e-17	Pediatric autoimmune diseases;
BRCA	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.88	-0.36	1.65e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg13770153	chr20:60521292	NA	-0.39	-9.41	-0.35	8.96e-20	Body mass index;
BRCA	cis	rs977987	0.806	rs11862582	chr16:75431295	T/C	cg03315344	chr16:75512273	CHST6	0.54	12.72	0.45	3.26e-33	Dupuytren's disease;
BRCA	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	10.45	0.38	1.08e-23	Aortic root size;
BRCA	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg24675658	chr1:53192096	ZYG11B	-0.52	-11.57	-0.42	2.99e-28	Monocyte count;
BRCA	trans	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg26043149	chr18:55253948	FECH	-0.38	-8.44	-0.32	2.1e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg13010199	chr12:38710504	ALG10B	-0.41	-9.59	-0.35	2e-20	Heart rate;
BRCA	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg14458575	chr2:238380390	NA	-0.56	-12.86	-0.45	8.38e-34	Prostate cancer;
BRCA	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg14440974	chr22:39074834	NA	-0.38	-9.13	-0.34	8.96e-19	Menopause (age at onset);
BRCA	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.4	-8.66	-0.32	3.76e-17	Aortic root size;
BRCA	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg03188948	chr7:1209495	NA	0.51	8.56	0.32	8.1e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg25319279	chr11:5960081	NA	-0.43	-8.4	-0.32	3e-16	DNA methylation (variation);
BRCA	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg04317338	chr11:64019027	PLCB3	0.55	9.52	0.35	3.59e-20	Mean platelet volume;
BRCA	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg23649088	chr2:200775458	C2orf69	-0.61	-7.94	-0.3	9.36e-15	Schizophrenia;
BRCA	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg12927641	chr6:109611667	NA	-0.41	-10.63	-0.39	2.12e-24	Reticulocyte fraction of red cells;
BRCA	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg14019146	chr3:50243930	SLC38A3	0.36	8.78	0.33	1.46e-17	Body mass index;
BRCA	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg18196295	chr10:418757	DIP2C	-0.46	-9.56	-0.35	2.57e-20	Psychosis in Alzheimer's disease;
BRCA	trans	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg06521331	chr12:34319734	NA	-0.5	-9.31	-0.35	1.97e-19	Bladder cancer;
BRCA	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg08859206	chr1:53392774	SCP2	-0.51	-10.85	-0.39	2.71e-25	Monocyte count;
BRCA	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg11530693	chr1:120165357	ZNF697	-0.58	-13.67	-0.48	1.74e-37	Systemic lupus erythematosus;
BRCA	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg01262667	chr19:19385393	TM6SF2	0.41	10.74	0.39	7.82e-25	Tonsillectomy;
BRCA	cis	rs6815814	0.950	rs11722788	chr4:38810738	C/G	cg06935464	chr4:38784597	TLR10	0.51	8.4	0.32	2.88e-16	Breast cancer;
BRCA	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.48e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg21644426	chr2:191273491	MFSD6	-0.43	-10.95	-0.4	1.06e-25	Pulse pressure;
BRCA	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg20283391	chr11:68216788	NA	-0.47	-9.15	-0.34	7.86e-19	Total body bone mineral density;
BRCA	cis	rs6878727	0.813	rs10063748	chr5:123704134	T/C	cg01806427	chr5:123737813	NA	0.42	8.65	0.32	4.29e-17	Breast cancer;
BRCA	cis	rs9394159	0.583	rs6457738	chr6:33617464	C/T	cg14003231	chr6:33640908	ITPR3	-0.4	-10.07	-0.37	3.07e-22	Graves' disease;
BRCA	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.33	-8.72	-0.33	2.41e-17	Ovarian reserve;
BRCA	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg08000102	chr2:233561755	GIGYF2	-0.63	-13.77	-0.48	5.96e-38	Coronary artery disease;
BRCA	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg11941060	chr3:133502564	NA	-0.5	-11.73	-0.42	6.6e-29	Iron status biomarkers;
BRCA	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg06784218	chr1:46089804	CCDC17	-0.45	-10.77	-0.39	5.85e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6840360	0.593	rs1877186	chr4:152692418	C/G	cg22705602	chr4:152727874	NA	-0.38	-10.51	-0.38	6.35e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08704250	chr15:31115839	NA	-0.34	-8.58	-0.32	7.26e-17	Huntington's disease progression;
BRCA	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.57	-12.33	-0.44	1.74e-31	IgG glycosylation;
BRCA	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.45e-23	Prostate cancer;
BRCA	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg14186256	chr22:23484241	RTDR1	0.76	22.61	0.67	1.31e-83	Bone mineral density;
BRCA	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg04362960	chr10:104952993	NT5C2	0.46	10.73	0.39	8.24e-25	Arsenic metabolism;
BRCA	cis	rs2294693	0.947	rs9369254	chr6:40989408	T/C	cg14418226	chr6:40996092	UNC5CL	0.45	8.3	0.31	6.16e-16	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs651907	0.617	rs797776	chr3:101610243	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.36	9.08	0.34	1.39e-18	Colorectal cancer;
BRCA	cis	rs7607369	0.536	rs6436089	chr2:219668813	A/G	cg02176678	chr2:219576539	TTLL4	-0.38	-10.16	-0.37	1.4e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg20908204	chr19:46285434	DMPK	0.29	8.94	0.33	4.14e-18	Coronary artery disease;
BRCA	trans	rs931812	0.757	rs4734492	chr8:101901901	C/T	cg20993868	chr7:22813445	NA	-0.43	-12.96	-0.46	2.87e-34	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg07636037	chr3:49044803	WDR6	0.79	18.81	0.6	3.72e-63	Subjective well-being (multi-trait analysis);Menarche (age at onset);
BRCA	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg12311346	chr5:56204834	C5orf35	-0.81	-16.07	-0.54	4.6e-49	Initial pursuit acceleration;
BRCA	trans	rs208520	0.690	rs207081	chr6:66773742	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-21.39	-0.65	5.51e-77	Exhaled nitric oxide output;
BRCA	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg18512352	chr11:47633146	NA	-0.34	-8.24	-0.31	9.79e-16	Subjective well-being;
BRCA	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg02743256	chr7:2109353	MAD1L1	-0.4	-7.97	-0.3	7.25e-15	Neuroticism;
BRCA	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg04546413	chr19:29218101	NA	0.46	9.52	0.35	3.59e-20	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs4653767	1.000	rs708773	chr1:226920730	T/C	cg05049329	chr1:226924846	ITPKB	0.34	9.54	0.35	2.96e-20	Parkinson's disease;
BRCA	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	12.5	0.44	3.17e-32	Mean platelet volume;
BRCA	cis	rs919433	0.617	rs700645	chr2:198605514	A/G	cg00792783	chr2:198669748	PLCL1	0.46	9.93	0.37	1.06e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg04450456	chr4:17643702	FAM184B	-0.33	-9.46	-0.35	5.74e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg01262667	chr19:19385393	TM6SF2	0.42	10.97	0.4	9.28e-26	Tonsillectomy;
BRCA	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg14844989	chr11:31128820	NA	-0.45	-9.65	-0.36	1.18e-20	Red blood cell count;
BRCA	cis	rs754466	1.000	rs67059283	chr10:79683235	C/T	cg17075019	chr10:79541650	NA	-0.68	-12.85	-0.45	8.95e-34	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-13.25	-0.46	1.39e-35	Gut microbiome composition (summer);
BRCA	cis	rs6546550	0.901	rs13015457	chr2:70125763	G/T	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.53	-0.41	4.52e-28	Prevalent atrial fibrillation;
BRCA	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg13256891	chr4:100009986	ADH5	0.53	9.77	0.36	4.33e-21	Smoking initiation;
BRCA	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg26395211	chr5:140044315	WDR55	0.37	8.52	0.32	1.16e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24531977	chr5:56204891	C5orf35	-0.86	-18.04	-0.58	4.05e-59	Initial pursuit acceleration;
BRCA	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07080220	chr10:102295463	HIF1AN	-0.5	-11.96	-0.43	6.65e-30	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg24692254	chr21:30365293	RNF160	-0.37	-8.56	-0.32	8.66e-17	Pancreatic cancer;
BRCA	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg05623727	chr3:50126028	RBM5	0.48	11.83	0.42	2.45e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs6763687	0.611	rs4894806	chr3:171818000	G/A	cg16233210	chr3:171778391	FNDC3B	0.4	9.16	0.34	7.17e-19	Red cell distribution width;
BRCA	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg13256891	chr4:100009986	ADH5	0.4	8.55	0.32	9.39e-17	Alcohol dependence;
BRCA	cis	rs965469	0.553	rs6051767	chr20:3324521	C/T	cg25506879	chr20:3388711	C20orf194	-0.41	-8.51	-0.32	1.24e-16	IFN-related cytopenia;
BRCA	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg12365402	chr11:9010492	NRIP3	0.44	9.61	0.36	1.59e-20	Hemoglobin concentration;
BRCA	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg00814883	chr7:100076585	TSC22D4	-0.49	-9.95	-0.37	8.76e-22	Platelet count;
BRCA	cis	rs7394190	0.748	rs4082339	chr10:75539812	C/T	cg07699608	chr10:75541558	CHCHD1	-0.58	-8.71	-0.33	2.65e-17	Incident atrial fibrillation;
BRCA	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg25801113	chr15:45476975	SHF	0.31	8.05	0.3	4.02e-15	Uric acid levels;
BRCA	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg23950597	chr19:37808831	NA	-0.62	-11.51	-0.41	5.55e-28	Coronary artery calcification;
BRCA	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg04450456	chr4:17643702	FAM184B	0.33	9.49	0.35	4.69e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs35661897	0.920	rs12469727	chr2:227301483	A/G	cg03426602	chr2:227312417	NA	0.52	8.76	0.33	1.7e-17	Urinary tract infection frequency;
BRCA	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11890956	chr21:40555474	PSMG1	1.04	29.41	0.76	7.29e-121	Cognitive function;
BRCA	cis	rs7301826	0.627	rs7978987	chr12:131281494	G/A	cg11011512	chr12:131303247	STX2	-0.46	-11.36	-0.41	2.19e-27	Plasma plasminogen activator levels;
BRCA	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18876405	chr7:65276391	NA	-0.55	-13.32	-0.47	6.66e-36	Aortic root size;
BRCA	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.98	0.43	5.89e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg25482853	chr8:67687455	SGK3	0.79	13.14	0.46	4.28e-35	Obesity-related traits;
BRCA	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg09184832	chr6:79620586	NA	-0.53	-11.87	-0.42	1.6800000000000001e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs4478858	0.647	rs10798836	chr1:31709214	C/T	cg00250761	chr1:31883323	NA	-0.31	-8.18	-0.31	1.49e-15	Alcohol dependence;
BRCA	cis	rs9463078	0.616	rs2211393	chr6:44716366	A/C	cg25276700	chr6:44698697	NA	0.37	8.57	0.32	7.53e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.5	0.63	3.81e-72	Chronic sinus infection;
BRCA	trans	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg17675199	chr6:35436792	RPL10A	-0.3	-8.05	-0.3	3.9e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs61990749	0.597	rs12887282	chr14:78200585	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.44	7.91	0.3	1.15e-14	Fibroblast growth factor basic levels;
BRCA	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg20469991	chr17:27169893	C17orf63	-0.45	-8.79	-0.33	1.37e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs7301826	0.651	rs4759519	chr12:131289508	G/A	cg11011512	chr12:131303247	STX2	0.51	13.6	0.47	3.4e-37	Plasma plasminogen activator levels;
BRCA	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg08917208	chr2:24149416	ATAD2B	1.02	13.65	0.48	1.97e-37	Lymphocyte counts;
BRCA	cis	rs55882075	0.808	rs6867806	chr5:179179585	C/G	cg14593053	chr5:179126677	CANX	0.4	10.05	0.37	3.83e-22	Monocyte percentage of white cells;
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03188948	chr7:1209495	NA	0.69	15.29	0.52	3.49e-45	Longevity;Endometriosis;
BRCA	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00149659	chr3:10157352	C3orf10	0.71	12.54	0.44	2.2e-32	Alzheimer's disease;
BRCA	cis	rs6981523	0.553	rs11783890	chr8:11056388	T/C	cg21775007	chr8:11205619	TDH	-0.48	-8.88	-0.33	6.53e-18	Neuroticism;
BRCA	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21659725	chr3:3221576	CRBN	-0.71	-21.92	-0.66	7.62e-80	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs16854884	0.657	rs920159	chr3:143753194	A/T	cg06585982	chr3:143692056	C3orf58	0.42	8.93	0.33	4.41e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg03709012	chr19:19516395	GATAD2A	0.9	17.31	0.57	2.34e-55	Nonalcoholic fatty liver disease;
BRCA	cis	rs708547	0.575	rs6847086	chr4:57791864	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.41	-10.65	-0.39	1.68e-24	Response to bleomycin (chromatid breaks);
BRCA	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14019695	chr9:139328340	INPP5E	0.39	10.35	0.38	2.52e-23	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg17366294	chr4:99064904	C4orf37	-0.45	-10.52	-0.38	5.51e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10044254	0.724	rs4702108	chr5:15780376	G/C	cg07238450	chr5:15720153	FBXL7	0.37	7.84	0.3	1.94e-14	Asthma (corticosteroid response);
BRCA	trans	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	8.22	0.31	1.16e-15	Mean corpuscular volume;
BRCA	trans	rs6479891	1.000	rs16918573	chr10:65300805	T/A	cg14819942	chr15:35414228	NA	0.34	8.25	0.31	9.01e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs9283706	0.608	rs12523505	chr5:66334631	C/T	cg11590213	chr5:66331682	MAST4	0.38	7.98	0.3	6.69e-15	Coronary artery disease;
BRCA	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg09307838	chr4:120376055	NA	0.68	13.72	0.48	9.37e-38	Corneal astigmatism;
BRCA	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00149659	chr3:10157352	C3orf10	0.68	12.05	0.43	2.79e-30	Alzheimer's disease;
BRCA	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg05527609	chr1:210001259	C1orf107	0.83	18.96	0.6	6.42e-64	Orofacial clefts;
BRCA	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.6	-11.42	-0.41	1.29e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg18402987	chr7:1209562	NA	0.88	14.46	0.5	3.5e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg07138768	chr7:917805	C7orf20	0.29	8.4	0.32	2.85e-16	Perceived unattractiveness to mosquitoes;
BRCA	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg04842962	chr6:43655489	MRPS18A	1.01	22.8	0.67	1.25e-84	IgG glycosylation;
BRCA	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg00012203	chr2:219082015	ARPC2	-0.47	-9.2	-0.34	5.2e-19	Colorectal cancer;
BRCA	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26314531	chr2:26401878	FAM59B	-0.79	-12.6	-0.45	1.18e-32	Gut microbiome composition (summer);
BRCA	cis	rs1113500	0.933	rs61797344	chr1:108622580	C/T	cg06207961	chr1:108661230	NA	0.45	11.09	0.4	2.99e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg04990556	chr1:26633338	UBXN11	0.54	8.87	0.33	7.24e-18	Obesity-related traits;
BRCA	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg18252515	chr7:66147081	NA	-0.83	-12.11	-0.43	1.56e-30	Diabetic kidney disease;
BRCA	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11644478	chr21:40555479	PSMG1	0.75	15.79	0.53	1.17e-47	Cognitive function;
BRCA	cis	rs9815354	0.767	rs111708447	chr3:41809583	G/A	cg03022575	chr3:42003672	ULK4	0.7	9.61	0.36	1.66e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs10193935	0.901	rs222483	chr2:42652184	T/G	cg27598129	chr2:42591480	NA	-0.81	-13.74	-0.48	7.65e-38	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg21045802	chr8:109455806	TTC35	0.35	8.08	0.3	3.25e-15	Dupuytren's disease;
BRCA	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03517284	chr6:25882590	NA	-0.36	-8.28	-0.31	7.44e-16	Height;
BRCA	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg13736514	chr6:26305472	NA	-0.36	-12.1	-0.43	1.67e-30	Educational attainment;
BRCA	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg13175981	chr1:150552382	MCL1	0.46	10.34	0.38	2.76e-23	Tonsillectomy;
BRCA	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg15556689	chr8:8085844	FLJ10661	0.36	9.59	0.35	2.01e-20	Neuroticism;
BRCA	cis	rs490234	0.756	rs10986849	chr9:128469683	A/G	cg14078157	chr9:128172775	NA	-0.39	-8.77	-0.33	1.58e-17	Mean arterial pressure;
BRCA	cis	rs2652822	0.525	rs11634159	chr15:63507422	C/T	cg02713581	chr15:63449717	RPS27L	0.41	8.31	0.31	5.92e-16	Metabolic traits;
BRCA	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg25801113	chr15:45476975	SHF	0.31	8.05	0.3	4.02e-15	Uric acid levels;
BRCA	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg01819863	chr10:32635814	EPC1	1.13	19.97	0.62	2.46e-69	Sexual dysfunction (female);
BRCA	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg18811423	chr2:55921094	PNPT1	0.71	22.55	0.67	2.72e-83	Metabolic syndrome;
BRCA	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg18230493	chr5:56204884	C5orf35	-0.44	-8.9	-0.33	5.74e-18	Coronary artery disease;
BRCA	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg04025307	chr7:1156635	C7orf50	0.44	8.27	0.31	7.82e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs9487051	0.768	rs458740	chr6:109525527	C/T	cg21918786	chr6:109611834	NA	-0.34	-9.05	-0.34	1.68e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg05340658	chr4:99064831	C4orf37	0.58	11.81	0.42	2.88e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg05973401	chr12:123451056	ABCB9	0.42	7.98	0.3	7.04e-15	Neutrophil percentage of white cells;
BRCA	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg23711669	chr6:146136114	FBXO30	0.72	17.59	0.57	8.45e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg13256891	chr4:100009986	ADH5	-0.4	-9.32	-0.35	1.82e-19	Alcohol dependence;
BRCA	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg26116260	chr4:7069785	GRPEL1	0.94	27.7	0.74	1.52e-111	Monocyte percentage of white cells;
BRCA	cis	rs17601876	0.814	rs8039089	chr15:51561328	T/G	cg19946085	chr15:51559439	CYP19A1	-0.39	-11.62	-0.42	1.87e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs7631605	0.935	rs4647218	chr3:37042082	A/G	cg15934958	chr3:37212084	LRRFIP2	0.41	9.57	0.35	2.38e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.21	-0.31	1.23e-15	Height;
BRCA	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-16.51	-0.55	2.75e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	13.95	0.48	8.22e-39	Alzheimer's disease;
BRCA	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.33	-10.72	-0.39	9.2e-25	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4363385	0.588	rs7540609	chr1:153024589	C/A	cg25856811	chr1:152973957	SPRR3	-0.31	-8.0	-0.3	6.06e-15	Inflammatory skin disease;
BRCA	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg22117172	chr7:91764530	CYP51A1	0.24	8.14	0.31	2.01e-15	Breast cancer;
BRCA	cis	rs7512552	0.809	rs9436112	chr1:150406449	A/C	cg15654264	chr1:150340011	RPRD2	0.37	8.16	0.31	1.76e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs13064411	0.696	rs6799610	chr3:113248748	A/C	cg18753928	chr3:113234510	CCDC52	0.56	11.65	0.42	1.44e-28	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs10465746	0.570	rs11163884	chr1:84472760	A/G	cg10977910	chr1:84465055	TTLL7	0.54	11.08	0.4	3.22e-26	Obesity-related traits;
BRCA	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.59	-14.3	-0.49	1.94e-40	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs34779708	0.931	rs35886556	chr10:35334985	C/T	cg03585969	chr10:35415529	CREM	0.55	11.39	0.41	1.72e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg14061069	chr19:46274453	DMPK	-0.42	-10.01	-0.37	5.06e-22	Coronary artery disease;
BRCA	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	12.06	0.43	2.64e-30	Total cholesterol levels;
BRCA	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-11.99	-0.43	4.86e-30	Total cholesterol levels;
BRCA	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg14993813	chr1:46806288	NSUN4	0.48	9.22	0.34	4.19e-19	Menopause (age at onset);
BRCA	cis	rs775227	0.574	rs35274817	chr3:113266391	A/G	cg18753928	chr3:113234510	CCDC52	-0.57	-9.66	-0.36	1.08e-20	Dental caries;
BRCA	cis	rs4594175	0.926	rs4617765	chr14:51598843	T/C	cg23942311	chr14:51606299	NA	0.34	8.47	0.32	1.72e-16	Cancer;
BRCA	cis	rs4919087	1.000	rs4919087	chr10:99072507	C/T	cg25902810	chr10:99078978	FRAT1	-0.53	-11.96	-0.43	7.01e-30	Monocyte count;
BRCA	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg26516362	chr5:178986906	RUFY1	0.44	12.41	0.44	7.61e-32	Lung cancer;
BRCA	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-13.48	-0.47	1.2e-36	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg06521331	chr12:34319734	NA	-0.57	-11.15	-0.4	1.71e-26	Morning vs. evening chronotype;
BRCA	trans	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.04	0.3	4.39e-15	Mean corpuscular volume;
BRCA	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.51	-11.0	-0.4	7.06e-26	Longevity;Endometriosis;
BRCA	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg06618935	chr21:46677482	NA	-0.37	-8.24	-0.31	9.65e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg20848291	chr7:100343083	ZAN	0.36	8.15	0.31	1.87e-15	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs1467026	0.584	rs11712581	chr3:12807781	T/C	cg24848339	chr3:12840334	CAND2	0.39	9.82	0.36	2.74e-21	P wave duration;
BRCA	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.56	8.73	0.33	2.29e-17	HIV-1 control;
BRCA	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs208520	0.690	rs851458	chr6:66813279	T/G	cg07460842	chr6:66804631	NA	-1.0	-20.09	-0.62	5.77e-70	Exhaled nitric oxide output;
BRCA	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg23205692	chr1:25664452	TMEM50A	0.41	9.8	0.36	3.21e-21	Erythrocyte sedimentation rate;
BRCA	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg05863683	chr7:1912471	MAD1L1	0.36	8.3	0.31	6.21e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs7617773	0.780	rs11714944	chr3:48366971	C/A	cg11946769	chr3:48343235	NME6	0.67	13.64	0.47	2.37e-37	Coronary artery disease;
BRCA	trans	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg18811423	chr2:55921094	PNPT1	-0.51	-13.18	-0.46	3.06e-35	Metabolic syndrome;
BRCA	cis	rs9296092	0.517	rs9461876	chr6:33516657	C/T	cg13560919	chr6:33536144	NA	-0.83	-16.87	-0.56	4.55e-53	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs12367572	0.601	rs10880730	chr12:45422443	G/A	cg04608330	chr12:45269318	NELL2	-0.46	-10.05	-0.37	3.77e-22	Gut microbiome composition (summer);
BRCA	cis	rs61990749	0.597	rs6574391	chr14:78208121	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.64	9.85	0.36	2.06e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg03877680	chr5:178157825	ZNF354A	0.78	14.54	0.5	1.38e-41	Neutrophil percentage of white cells;
BRCA	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs28374715	0.532	rs7168431	chr15:41672384	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.09	-24.82	-0.7	9.65e-96	Ulcerative colitis;
BRCA	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg12310025	chr6:25882481	NA	-0.43	-10.04	-0.37	3.87e-22	Intelligence (multi-trait analysis);
BRCA	trans	rs11039798	0.698	rs78553793	chr11:48947336	C/A	cg15704280	chr7:45808275	SEPT13	0.66	7.91	0.3	1.11e-14	Axial length;
BRCA	cis	rs243505	1.000	rs243519	chr7:148423624	G/A	cg09806900	chr7:148480153	CUL1	-0.4	-8.39	-0.31	3.16e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	18.59	0.59	5.56e-62	Alzheimer's disease;
BRCA	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20916646	chr4:852691	GAK	0.5	10.97	0.4	8.84e-26	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
BRCA	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg14019146	chr3:50243930	SLC38A3	0.37	9.18	0.34	6.06e-19	Body mass index;
BRCA	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg25801113	chr15:45476975	SHF	0.31	7.84	0.3	1.83e-14	Uric acid levels;
BRCA	cis	rs12530845	0.623	rs7798256	chr7:135344211	C/A	cg23117316	chr7:135346802	PL-5283	-0.41	-8.31	-0.31	5.82e-16	Red blood cell traits;
BRCA	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg06159980	chr1:16340746	HSPB7	-0.39	-9.04	-0.34	1.89e-18	Dilated cardiomyopathy;
BRCA	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg25554036	chr4:6271136	WFS1	0.42	9.97	0.37	7.45e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs9469578	0.710	rs77213792	chr6:33713952	C/G	cg18708504	chr6:33715942	IP6K3	0.7	10.18	0.37	1.12e-22	Phosphorus levels;
BRCA	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg13628971	chr7:2884303	GNA12	0.46	9.09	0.34	1.25e-18	Height;
BRCA	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.49	0.41	6.46e-28	Bipolar disorder;
BRCA	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg01528321	chr10:82214614	TSPAN14	0.81	17.1	0.56	2.94e-54	Post bronchodilator FEV1;
BRCA	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg26597838	chr10:835615	NA	1.04	18.42	0.59	4.13e-61	Eosinophil percentage of granulocytes;
BRCA	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg19000871	chr14:103996768	TRMT61A	-0.35	-8.11	-0.31	2.65e-15	Coronary artery disease;
BRCA	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg24296786	chr1:45957014	TESK2	0.62	15.49	0.52	3.63e-46	High light scatter reticulocyte count;
BRCA	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg18357645	chr12:58087776	OS9	0.48	13.81	0.48	3.69e-38	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg03146154	chr1:46216737	IPP	0.47	10.51	0.38	6.17e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg07211511	chr3:129823064	LOC729375	-0.58	-10.64	-0.39	1.84e-24	Blood pressure (smoking interaction);
BRCA	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg04518342	chr5:131593106	PDLIM4	0.38	9.7	0.36	7.55e-21	Breast cancer;
BRCA	cis	rs7598759	0.548	rs1584462	chr2:232369798	A/G	cg19187155	chr2:232395269	NMUR1	0.69	16.53	0.55	2.2e-51	Noise-induced hearing loss;
BRCA	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg05340658	chr4:99064831	C4orf37	0.48	10.91	0.4	1.56e-25	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg23285459	chr7:2802560	GNA12	-0.38	-9.55	-0.35	2.77e-20	Height;
BRCA	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg07169764	chr2:136633963	MCM6	0.9	17.33	0.57	1.87e-55	Corneal structure;
BRCA	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg10876282	chr6:28092338	ZSCAN16	0.42	8.38	0.31	3.25e-16	Cardiac Troponin-T levels;
BRCA	cis	rs9318086	0.935	rs9652081	chr13:24435510	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.29	-8.4	-0.32	2.99e-16	Myopia (pathological);
BRCA	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg04518342	chr5:131593106	PDLIM4	0.45	11.32	0.41	3.22e-27	Acylcarnitine levels;
BRCA	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg10556349	chr10:835070	NA	0.73	9.88	0.36	1.58e-21	Eosinophil percentage of granulocytes;
BRCA	trans	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-21.13	-0.64	1.45e-75	Exhaled nitric oxide output;
BRCA	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg00383909	chr3:49044727	WDR6	0.42	9.41	0.35	9.11e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg18252515	chr7:66147081	NA	-0.82	-11.88	-0.43	1.52e-29	Diabetic kidney disease;
BRCA	cis	rs870825	0.587	rs28454955	chr4:185632701	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	17.4	0.57	8.32e-56	Blood protein levels;
BRCA	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg24397884	chr7:158709396	WDR60	0.89	14.1	0.49	1.68e-39	Height;
BRCA	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05025164	chr4:1340916	KIAA1530	-0.62	-12.78	-0.45	1.73e-33	Longevity;
BRCA	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	17.3	0.56	2.93e-55	Nonalcoholic fatty liver disease;
BRCA	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg06784218	chr1:46089804	CCDC17	0.49	11.59	0.42	2.55e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	16.23	0.54	7.45e-50	Hypertriglyceridemia;
BRCA	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.01	0.34	2.33e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	9.61	0.36	1.6e-20	Bipolar disorder;
BRCA	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.09	15.62	0.53	8.32e-47	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6750047	0.567	rs336039	chr2:38258827	C/T	cg07380506	chr2:38303506	CYP1B1	-0.39	-8.61	-0.32	5.66e-17	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg14675211	chr2:100938903	LONRF2	0.49	11.23	0.41	8.09e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs7607369	0.559	rs4674343	chr2:219660346	C/T	cg02176678	chr2:219576539	TTLL4	0.4	10.55	0.39	4.26e-24	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	trans	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg01620082	chr3:125678407	NA	-0.69	-8.45	-0.32	1.98e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg08859206	chr1:53392774	SCP2	0.47	10.46	0.38	9.59e-24	Monocyte count;
BRCA	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.82	18.99	0.6	4.23e-64	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs3857067	0.806	rs2865343	chr4:95103005	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.26	-0.34	2.97e-19	QT interval;
BRCA	cis	rs3771570	1.000	rs62190370	chr2:242384194	C/G	cg21155796	chr2:242212141	HDLBP	0.61	9.34	0.35	1.6e-19	Prostate cancer;
BRCA	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg11833968	chr6:79620685	NA	-0.44	-9.8	-0.36	3.14e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg22676075	chr6:135203613	NA	0.45	8.86	0.33	7.85e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg15017067	chr4:17643749	FAM184B	0.29	8.98	0.33	3.08e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg00981070	chr1:2046702	PRKCZ	0.31	8.29	0.31	6.49e-16	Height;
BRCA	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg00277334	chr10:82204260	NA	-0.47	-9.94	-0.37	9.2e-22	Post bronchodilator FEV1;
BRCA	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg17971929	chr21:40555470	PSMG1	0.77	18.12	0.58	1.53e-59	Cognitive function;
BRCA	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18404041	chr3:52824283	ITIH1	-0.44	-13.02	-0.46	1.49e-34	Bipolar disorder;
BRCA	cis	rs11229555	0.609	rs7927730	chr11:58187906	G/A	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.13e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.81	0.39	3.95e-25	Bipolar disorder;
BRCA	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.08	0.56	3.74e-54	Fuchs's corneal dystrophy;
BRCA	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg10523679	chr1:76189770	ACADM	0.87	20.48	0.63	4.56e-72	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg08847533	chr14:75593920	NEK9	-0.78	-18.04	-0.58	3.88e-59	Height;
BRCA	cis	rs4363385	0.643	rs11576457	chr1:152918556	C/T	cg07796016	chr1:152779584	LCE1C	0.45	8.93	0.33	4.59e-18	Inflammatory skin disease;
BRCA	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18876405	chr7:65276391	NA	0.5	11.1	0.4	2.7e-26	Aortic root size;
BRCA	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg23422044	chr7:1970798	MAD1L1	-0.42	-8.24	-0.31	9.93e-16	Neuroticism;
BRCA	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.52	7.99	0.3	6.55e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-8.93	-0.33	4.67e-18	Alzheimer's disease;
BRCA	cis	rs2742417	0.603	rs2064064	chr3:45759995	C/T	cg04837898	chr3:45731254	SACM1L	-0.4	-8.09	-0.3	3.07e-15	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.61	-0.32	5.73e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	8.37	0.31	3.56e-16	Axial length;
BRCA	cis	rs311392	1.000	rs413974	chr8:55088510	A/G	cg11783602	chr8:55087084	NA	-0.32	-9.28	-0.34	2.66e-19	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs9297145	1.000	rs9297145	chr7:98759117	A/C	cg05967295	chr7:98741636	SMURF1	0.84	20.08	0.62	6.92e-70	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.34	-0.35	1.53e-19	Body mass index;
BRCA	cis	rs3008870	0.628	rs2755257	chr1:67515309	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.46	9.4	0.35	9.37e-20	Lymphocyte percentage of white cells;
BRCA	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg04989706	chr14:50066350	PPIL5	-0.49	-9.23	-0.34	4.03e-19	Carotid intima media thickness;
BRCA	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg26597838	chr10:835615	NA	1.32	22.06	0.66	1.34e-80	Eosinophil percentage of granulocytes;
BRCA	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg08470875	chr2:26401718	FAM59B	-0.72	-11.89	-0.43	1.31e-29	Gut microbiome composition (summer);
BRCA	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg08859206	chr1:53392774	SCP2	0.49	11.0	0.4	6.95e-26	Monocyte count;
BRCA	cis	rs1468333	1.000	rs34927605	chr5:137580418	T/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.44	9.2	0.34	5.2e-19	Resting heart rate;
BRCA	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.43	-10.39	-0.38	1.73e-23	IgG glycosylation;
BRCA	cis	rs243505	0.691	rs243480	chr7:148452905	G/T	cg09806900	chr7:148480153	CUL1	-0.44	-7.96	-0.3	7.88e-15	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4722166	0.532	rs4719713	chr7:22758811	G/A	cg05472934	chr7:22766657	IL6	0.43	10.71	0.39	9.62e-25	Lung cancer;
BRCA	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg23791538	chr6:167370224	RNASET2	0.5	12.95	0.46	3.21e-34	Crohn's disease;
BRCA	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg01528321	chr10:82214614	TSPAN14	0.67	14.14	0.49	1.03e-39	Post bronchodilator FEV1;
BRCA	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg08213375	chr14:104286397	PPP1R13B	0.63	18.11	0.58	1.69e-59	Schizophrenia;
BRCA	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs6878727	0.665	rs161010	chr5:123675617	C/T	cg01806427	chr5:123737813	NA	-0.37	-8.42	-0.32	2.49e-16	Breast cancer;
BRCA	cis	rs68170813	0.559	rs6946036	chr7:106853659	G/A	cg02696742	chr7:106810147	HBP1	-0.52	-8.45	-0.32	1.92e-16	Coronary artery disease;
BRCA	cis	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg07460842	chr6:66804631	NA	0.61	10.35	0.38	2.54e-23	Type 2 diabetes;
BRCA	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg19508488	chr2:152266495	RIF1	0.51	10.39	0.38	1.74e-23	Lung cancer;
BRCA	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg24642439	chr20:33292090	TP53INP2	0.53	11.6	0.42	2.23e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg16850897	chr7:100343110	ZAN	0.38	8.48	0.32	1.55e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.19	0.31	1.44e-15	Menarche (age at onset);
BRCA	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg07274523	chr3:49395745	GPX1	0.46	8.11	0.31	2.65e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg00530320	chr1:46809349	NSUN4	0.48	9.74	0.36	5.54e-21	Menopause (age at onset);
BRCA	cis	rs3849570	0.925	rs7641973	chr3:81910489	G/A	cg07356753	chr3:81810745	GBE1	-0.43	-10.15	-0.37	1.49e-22	Waist circumference;Body mass index;
BRCA	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	20.15	0.62	2.91e-70	Chronic sinus infection;
BRCA	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg00074818	chr8:8560427	CLDN23	0.38	8.38	0.31	3.43e-16	Obesity-related traits;
BRCA	cis	rs6942756	0.915	rs6946938	chr7:129004662	A/C	cg02491457	chr7:128862824	NA	-0.62	-12.47	-0.44	4.23e-32	White matter hyperintensity burden;
BRCA	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg22907277	chr7:1156413	C7orf50	0.58	8.91	0.33	5.37e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05901451	chr6:126070800	HEY2	-0.56	-14.88	-0.51	3.19e-43	Brugada syndrome;
BRCA	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg26384229	chr12:38710491	ALG10B	0.76	17.28	0.56	3.49e-55	Bladder cancer;
BRCA	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg16950941	chr11:66035639	RAB1B	0.42	11.34	0.41	2.81e-27	Gout;
BRCA	cis	rs919433	0.680	rs788022	chr2:198280586	T/C	cg00792783	chr2:198669748	PLCL1	0.38	8.57	0.32	7.95e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs2204008	0.617	rs11831608	chr12:38210687	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-10.51	-0.38	6.27e-24	Bladder cancer;
BRCA	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.22	-0.31	1.17e-15	Depression;
BRCA	cis	rs13053817	1.000	rs12484859	chr22:29844884	A/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.51	-9.47	-0.35	5.43e-20	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs78487399	0.908	rs73925553	chr2:43810646	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-7.85	-0.3	1.82e-14	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.41	9.23	0.34	3.9e-19	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg18512352	chr11:47633146	NA	-0.37	-9.1	-0.34	1.1e-18	Subjective well-being;
BRCA	cis	rs1568889	1.000	rs7949704	chr11:28373543	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	12.95	0.46	3.11e-34	Bipolar disorder;
BRCA	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06221963	chr1:154839813	KCNN3	-0.56	-15.65	-0.53	5.51e-47	Prostate cancer;
BRCA	trans	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg07211511	chr3:129823064	LOC729375	-0.78	-15.1	-0.51	2.81e-44	Blood pressure (smoking interaction);
BRCA	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.3	-0.31	6.24e-16	Gut microbiome composition (summer);
BRCA	cis	rs9300255	0.722	rs11830103	chr12:123823546	A/G	cg00376283	chr12:123451042	ABCB9	-0.49	-11.16	-0.4	1.49e-26	Neutrophil percentage of white cells;
BRCA	cis	rs72634258	0.554	rs68024107	chr1:7914066	G/C	cg26816564	chr1:7831052	VAMP3	0.47	9.5	0.35	4.1e-20	Inflammatory bowel disease;
BRCA	cis	rs3770081	1.000	rs3770066	chr2:86392350	A/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.56	-7.82	-0.3	2.17e-14	Facial emotion recognition (sad faces);
BRCA	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg05347473	chr6:146136440	FBXO30	-0.42	-8.36	-0.31	3.91e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6484504	0.600	rs1323738	chr11:31344898	T/C	cg14844989	chr11:31128820	NA	0.45	9.56	0.35	2.53e-20	Red blood cell count;
BRCA	cis	rs11874712	0.966	rs8094902	chr18:43666774	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.21	0.31	1.24e-15	Migraine - clinic-based;
BRCA	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg02951883	chr7:2050386	MAD1L1	-0.57	-13.96	-0.48	7.58e-39	Bipolar disorder and schizophrenia;
BRCA	cis	rs838147	0.733	rs12978499	chr19:49237552	A/C	cg13540341	chr19:49222985	MAMSTR	0.34	9.18	0.34	5.71e-19	Dietary macronutrient intake;
BRCA	cis	rs6543140	0.964	rs1035126	chr2:103019981	C/T	cg04239558	chr2:103089729	SLC9A4	0.33	9.14	0.34	8.53e-19	Blood protein levels;
BRCA	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg13880726	chr7:1868755	MAD1L1	-0.41	-8.5	-0.32	1.36e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg13256891	chr4:100009986	ADH5	0.39	8.21	0.31	1.25e-15	Alcohol dependence;
BRCA	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.41	0.5	5.57e-41	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10267417	0.603	rs10244374	chr7:19863170	C/T	cg05791153	chr7:19748676	TWISTNB	0.48	9.08	0.34	1.33e-18	Night sleep phenotypes;
BRCA	cis	rs8044868	0.530	rs12918956	chr16:72224335	A/G	cg16558253	chr16:72132732	DHX38	0.38	9.13	0.34	8.74e-19	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	cis	rs7394190	0.810	rs7394152	chr10:75421446	C/T	cg07699608	chr10:75541558	CHCHD1	0.55	8.73	0.33	2.3e-17	Incident atrial fibrillation;
BRCA	cis	rs243505	0.668	rs2072406	chr7:148483760	G/A	cg09806900	chr7:148480153	CUL1	0.52	10.94	0.4	1.16e-25	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs68170813	0.559	rs2395881	chr7:107074323	A/C	cg02696742	chr7:106810147	HBP1	-0.51	-7.98	-0.3	6.78e-15	Coronary artery disease;
BRCA	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	14.41	0.5	5.73e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg01017244	chr2:74357527	NA	-0.49	-10.54	-0.38	4.57e-24	Gestational age at birth (maternal effect);
BRCA	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg21132104	chr15:45694354	SPATA5L1	0.73	16.58	0.55	1.26e-51	Homoarginine levels;
BRCA	cis	rs72634258	0.945	rs28624	chr1:8084355	G/T	cg00042356	chr1:8021962	PARK7	-0.49	-8.55	-0.32	8.92e-17	Inflammatory bowel disease;
BRCA	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg26528668	chr16:1614120	IFT140	0.39	8.99	0.34	2.8e-18	Coronary artery disease;
BRCA	cis	rs4919694	1.000	rs12246689	chr10:104817031	C/T	cg04362960	chr10:104952993	NT5C2	0.95	14.59	0.5	7.86e-42	Arsenic metabolism;
BRCA	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg03060546	chr3:49711283	APEH	0.6	10.21	0.37	8.9e-23	Menarche (age at onset);
BRCA	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg03146154	chr1:46216737	IPP	0.47	10.5	0.38	6.48e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg23505145	chr19:12996616	KLF1	0.56	12.63	0.45	8.41e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg07460842	chr6:66804631	NA	-1.0	-19.6	-0.61	2.44e-67	Exhaled nitric oxide output;
BRCA	cis	rs6545883	0.783	rs12713442	chr2:61848078	G/A	cg15711740	chr2:61764176	XPO1	-0.47	-11.67	-0.42	1.11e-28	Tuberculosis;
BRCA	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg11833968	chr6:79620685	NA	-0.4	-8.9	-0.33	5.7e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg21724239	chr8:58056113	NA	0.77	19.13	0.6	7.97e-65	Developmental language disorder (linguistic errors);
BRCA	cis	rs4588572	0.643	rs10942857	chr5:77760241	A/G	cg11547950	chr5:77652471	NA	-0.48	-8.41	-0.32	2.77e-16	Triglycerides;
BRCA	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	19.62	0.61	1.82e-67	Platelet count;
BRCA	cis	rs9807989	0.507	rs10200952	chr2:103027651	A/C	cg03938978	chr2:103052716	IL18RAP	0.29	8.33	0.31	4.81e-16	Asthma;
BRCA	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg08807101	chr21:30365312	RNF160	0.57	12.31	0.44	2.09e-31	Selective IgA deficiency;
BRCA	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg10223061	chr2:219282414	VIL1	-0.29	-8.13	-0.31	2.28e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs868036	1.000	rs6494696	chr15:68103206	C/G	cg24579218	chr15:68104479	NA	0.3	7.81	0.3	2.38e-14	Restless legs syndrome;
BRCA	cis	rs2882667	0.858	rs66839813	chr5:138442322	A/T	cg04439458	chr5:138467593	SIL1	-0.42	-10.66	-0.39	1.54e-24	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg13256891	chr4:100009986	ADH5	0.54	10.18	0.37	1.21e-22	Smoking initiation;
BRCA	trans	rs4650994	0.544	rs2811311	chr1:178617337	A/G	cg05059571	chr16:84539110	KIAA1609	0.56	12.23	0.44	4.61e-31	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.64e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4845875	0.600	rs4846039	chr1:11836868	A/G	cg24844545	chr1:11908347	NPPA	0.37	8.68	0.32	3.35e-17	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg04990556	chr1:26633338	UBXN11	0.54	8.87	0.33	7.24e-18	Obesity-related traits;
BRCA	cis	rs698833	0.741	rs2340808	chr2:44511861	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	10.58	0.39	3.12e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.31	-7.83	-0.3	1.98e-14	Response to antipsychotic treatment;
BRCA	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg04315214	chr1:2043799	PRKCZ	-0.48	-13.34	-0.47	5.28e-36	Height;
BRCA	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg08917208	chr2:24149416	ATAD2B	1.1	15.5	0.52	3.23e-46	Lymphocyte counts;
BRCA	cis	rs367943	0.965	rs463249	chr5:112797430	A/C	cg12552261	chr5:112820674	MCC	-0.55	-12.0	-0.43	4.74e-30	Type 2 diabetes;
BRCA	cis	rs7607369	0.536	rs4674345	chr2:219671598	A/G	cg02176678	chr2:219576539	TTLL4	-0.36	-9.58	-0.35	2.09e-20	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs501916	0.833	rs3809486	chr15:48051549	G/T	cg16110827	chr15:48056943	SEMA6D	-0.43	-9.29	-0.34	2.42e-19	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg06766960	chr11:133703094	NA	-0.62	-12.86	-0.45	7.96e-34	Childhood ear infection;
BRCA	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21659725	chr3:3221576	CRBN	0.51	12.14	0.43	1.16e-30	Resting heart rate;
BRCA	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg18252515	chr7:66147081	NA	-0.91	-13.01	-0.46	1.66e-34	Diabetic kidney disease;
BRCA	cis	rs5167	0.504	rs10426750	chr19:45457684	G/C	cg13119609	chr19:45449297	APOC2	0.47	12.92	0.46	4.46e-34	Blood protein levels;
BRCA	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg16339924	chr4:17578868	LAP3	0.62	15.3	0.52	3.13e-45	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4690686	0.500	rs11725547	chr4:177268444	T/C	cg17059388	chr4:177262070	NA	0.53	11.05	0.4	4.09e-26	Essential tremor;
BRCA	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg24011408	chr12:48396354	COL2A1	0.43	9.57	0.35	2.23e-20	Plateletcrit;
BRCA	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg26587870	chr6:27730563	NA	-0.53	-8.11	-0.31	2.53e-15	Depression;
BRCA	cis	rs4566357	0.615	rs2272204	chr2:227915601	G/T	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.22	-0.31	1.13e-15	Coronary artery disease;
BRCA	cis	rs9318086	0.901	rs7336730	chr13:24452104	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.28	-8.05	-0.3	4.04e-15	Myopia (pathological);
BRCA	cis	rs4363385	0.720	rs6672735	chr1:152981086	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.33	-0.31	4.81e-16	Inflammatory skin disease;
BRCA	cis	rs4363385	0.818	rs11205167	chr1:152989727	T/G	cg24667326	chr1:152973720	SPRR3	-0.31	-8.24	-0.31	1.01e-15	Inflammatory skin disease;
BRCA	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg06627628	chr2:24431161	ITSN2	-0.73	-13.77	-0.48	5.8e-38	Asthma;
BRCA	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg00106254	chr7:1943704	MAD1L1	0.4	10.88	0.4	1.98e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg10932868	chr11:921992	NA	0.49	12.59	0.45	1.21e-32	Alzheimer's disease (late onset);
BRCA	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg07169764	chr2:136633963	MCM6	1.28	28.6	0.75	1.86e-116	Corneal structure;
BRCA	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.48	-8.76	-0.33	1.69e-17	Gut microbiome composition (summer);
BRCA	cis	rs6545883	0.826	rs1186697	chr2:61661417	G/A	cg15711740	chr2:61764176	XPO1	-0.51	-12.37	-0.44	1.12e-31	Tuberculosis;
BRCA	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-11.75	-0.42	5.56e-29	Mood instability;
BRCA	cis	rs4561483	0.801	rs154148	chr16:11956478	T/C	cg08843971	chr16:11963173	GSPT1	-0.52	-11.7	-0.42	8.84e-29	Testicular germ cell tumor;
BRCA	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg05340658	chr4:99064831	C4orf37	0.66	15.65	0.53	5.39e-47	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg08917208	chr2:24149416	ATAD2B	0.55	8.52	0.32	1.12e-16	Lymphocyte counts;
BRCA	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg00074818	chr8:8560427	CLDN23	0.4	8.66	0.32	3.79e-17	Obesity-related traits;
BRCA	cis	rs2882667	0.690	rs6872423	chr5:138246778	T/C	cg04439458	chr5:138467593	SIL1	-0.31	-7.95	-0.3	8.32e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2555155	1.000	rs11040899	chr11:6520015	A/C	cg18103150	chr11:6518907	DNHD1	0.36	8.31	0.31	5.81e-16	DNA methylation (variation);
BRCA	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.56	11.44	0.41	1.05e-27	Personality dimensions;
BRCA	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg06698575	chr12:117470875	NA	0.45	8.06	0.3	3.76e-15	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg13902645	chr11:5959945	NA	-0.54	-11.14	-0.4	1.88e-26	DNA methylation (variation);
BRCA	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03517284	chr6:25882590	NA	-0.7	-15.05	-0.51	4.78e-44	Intelligence (multi-trait analysis);
BRCA	trans	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg16141378	chr3:129829833	LOC729375	-0.34	-7.93	-0.3	9.65e-15	Mood instability;
BRCA	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.32	-8.19	-0.31	1.43e-15	Total body bone mineral density;
BRCA	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg25801113	chr15:45476975	SHF	-0.33	-8.26	-0.31	8.52e-16	Uric acid levels;
BRCA	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg24562669	chr7:97807699	LMTK2	0.45	12.01	0.43	4.07e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg08601574	chr20:25228251	PYGB	-0.34	-8.12	-0.31	2.42e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg16339924	chr4:17578868	LAP3	-0.74	-17.85	-0.58	3.89e-58	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs78761021	0.867	rs8077037	chr17:9788746	G/A	cg26853458	chr17:9805074	RCVRN	0.36	8.28	0.31	7.34e-16	Type 2 diabetes;
BRCA	cis	rs1691799	0.867	rs1168343	chr12:66758581	C/T	cg16791601	chr12:66731901	HELB	-0.66	-18.04	-0.58	4.35e-59	White blood cell count (basophil);
BRCA	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg19626725	chr5:178986131	RUFY1	0.28	8.09	0.3	3.03e-15	Lung cancer;
BRCA	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg04450456	chr4:17643702	FAM184B	0.39	11.78	0.42	3.83e-29	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23708337	chr7:1209742	NA	0.59	12.86	0.45	8.32e-34	Longevity;Endometriosis;
BRCA	cis	rs701145	0.585	rs357480	chr3:153891182	A/G	cg17054900	chr3:154042577	DHX36	0.56	9.48	0.35	4.82e-20	Coronary artery disease;
BRCA	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg22676075	chr6:135203613	NA	0.4	8.18	0.31	1.51e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg00750074	chr16:89608354	SPG7	0.29	7.86	0.3	1.68e-14	Multiple myeloma (IgH translocation);
BRCA	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11644478	chr21:40555479	PSMG1	0.67	15.19	0.52	1.01e-44	Cognitive function;
BRCA	cis	rs10992471	0.528	rs6479423	chr9:95265580	A/T	cg14631576	chr9:95140430	CENPP	-0.33	-8.4	-0.32	2.98e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg07636037	chr3:49044803	WDR6	0.88	23.11	0.67	2.25e-86	Parkinson's disease;
BRCA	cis	rs28374715	0.681	rs77187862	chr15:41619276	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.81	-17.94	-0.58	1.43e-58	Ulcerative colitis;
BRCA	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg04414720	chr1:150670196	GOLPH3L	0.35	7.9	0.3	1.22e-14	Tonsillectomy;
BRCA	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg15017067	chr4:17643749	FAM184B	0.34	10.48	0.38	8.32e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11764359	chr7:65958608	NA	-0.65	-14.23	-0.49	3.95e-40	Aortic root size;
BRCA	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg16482183	chr6:26056742	HIST1H1C	0.45	8.64	0.32	4.64e-17	Iron status biomarkers;
BRCA	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg13175981	chr1:150552382	MCL1	0.35	7.92	0.3	1.02e-14	Urate levels;
BRCA	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg18479299	chr3:125709523	NA	-0.54	-8.46	-0.32	1.82e-16	Blood pressure (smoking interaction);
BRCA	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24549020	chr5:56110836	MAP3K1	-0.59	-12.0	-0.43	4.83e-30	Initial pursuit acceleration;
BRCA	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg15819921	chr19:927150	ARID3A	-0.53	-9.75	-0.36	4.78e-21	Life satisfaction;
BRCA	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg07395648	chr5:131743802	NA	-0.37	-8.7	-0.33	2.86e-17	Breast cancer;Mosquito bite size;
BRCA	cis	rs2425143	0.908	rs6060632	chr20:34422601	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.21	-0.31	1.27e-15	Blood protein levels;
BRCA	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-11.79	-0.42	3.63e-29	Gut microbiome composition (summer);
BRCA	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg08807101	chr21:30365312	RNF160	-0.44	-9.4	-0.35	9.88e-20	Dental caries;
BRCA	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06022373	chr22:39101656	GTPBP1	0.74	18.2	0.58	5.93e-60	Menopause (age at onset);
BRCA	cis	rs1843834	0.734	rs1908251	chr2:225487865	T/C	cg22455342	chr2:225449267	CUL3	0.37	9.12	0.34	9.84e-19	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.89	-0.33	6.26e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs600806	0.888	rs4603158	chr1:109879549	C/T	cg20591472	chr1:110008990	SYPL2	0.32	8.12	0.31	2.5e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg16950941	chr11:66035639	RAB1B	0.45	12.09	0.43	1.95e-30	Gout;
BRCA	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg16414030	chr3:133502952	NA	-0.49	-11.41	-0.41	1.43e-27	Iron status biomarkers;
BRCA	trans	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.89	-0.3	1.27e-14	Corneal astigmatism;
BRCA	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg22535103	chr8:58192502	C8orf71	-0.46	-9.06	-0.34	1.59e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs367943	1.000	rs348958	chr5:112821137	G/A	cg12552261	chr5:112820674	MCC	-0.55	-12.1	-0.43	1.66e-30	Type 2 diabetes;
BRCA	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg04775059	chr7:64541387	NA	0.46	8.49	0.32	1.49e-16	Calcium levels;
BRCA	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg12270520	chr8:146023939	ZNF517	-0.4	-9.18	-0.34	5.85e-19	Age at first birth;
BRCA	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.35	-0.41	2.4e-27	Mean corpuscular volume;
BRCA	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.43	8.59	0.32	6.57e-17	Monocyte percentage of white cells;
BRCA	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.63	10.54	0.38	4.46e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg13010199	chr12:38710504	ALG10B	0.45	9.38	0.35	1.16e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg07080220	chr10:102295463	HIF1AN	0.56	13.04	0.46	1.19e-34	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.5	-10.11	-0.37	2.21e-22	Body mass index;
BRCA	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg19717773	chr7:2847554	GNA12	-0.48	-11.28	-0.41	5.09e-27	Height;
BRCA	cis	rs6931421	0.800	rs12662365	chr6:80905389	T/A	cg08355045	chr6:80787529	NA	0.44	9.61	0.36	1.62e-20	Sitting height ratio;
BRCA	cis	rs4285028	0.898	rs73855476	chr3:121633412	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.64	-11.59	-0.42	2.52e-28	Multiple sclerosis;
BRCA	cis	rs495337	0.760	rs2769975	chr20:48516511	A/C	cg17835207	chr20:48524531	SPATA2	-0.68	-16.29	-0.54	3.78e-50	Psoriasis;
BRCA	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.39	-0.32	3.11e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg02734326	chr4:10020555	SLC2A9	0.41	8.93	0.33	4.44e-18	Bone mineral density;
BRCA	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg18964960	chr10:1102726	WDR37	0.63	8.71	0.33	2.65e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs6120849	0.901	rs6060266	chr20:33733078	T/C	cg24642439	chr20:33292090	TP53INP2	0.48	8.38	0.31	3.42e-16	Protein C levels;
BRCA	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11764359	chr7:65958608	NA	0.79	19.08	0.6	1.37e-64	Aortic root size;
BRCA	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg15640734	chr5:494837	SLC9A3	0.4	7.96	0.3	8.11e-15	Cystic fibrosis severity;
BRCA	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg05340658	chr4:99064831	C4orf37	-0.47	-10.94	-0.4	1.23e-25	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1468333	0.964	rs2350306	chr5:137512178	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	-0.43	-9.05	-0.34	1.7e-18	Resting heart rate;
BRCA	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02176678	chr2:219576539	TTLL4	0.46	12.16	0.43	9.47e-31	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs2262909	0.962	rs11673195	chr19:22313814	T/C	cg17074339	chr11:11642133	GALNTL4	0.45	8.83	0.33	1.01e-17	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg00684032	chr4:1343700	KIAA1530	0.31	7.93	0.3	1.01e-14	Obesity-related traits;
BRCA	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg09877947	chr5:131593287	PDLIM4	0.34	8.43	0.32	2.3e-16	Blood metabolite levels;
BRCA	cis	rs897984	0.542	rs3751855	chr16:31091209	T/C	cg00531865	chr16:30841666	NA	-0.38	-9.09	-0.34	1.21e-18	Dementia with Lewy bodies;
BRCA	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.36	-8.38	-0.31	3.41e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2882667	0.931	rs6596457	chr5:138323379	T/C	cg04439458	chr5:138467593	SIL1	-0.34	-9.17	-0.34	6.56e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg13047869	chr3:10149882	C3orf24	0.6	12.62	0.45	9.38e-33	Alzheimer's disease;
BRCA	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21659725	chr3:3221576	CRBN	0.5	11.85	0.42	2.08e-29	Resting heart rate;
BRCA	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg12365402	chr11:9010492	NRIP3	-0.37	-8.35	-0.31	4.17e-16	Hematocrit;
BRCA	cis	rs10899021	0.920	rs7112664	chr11:74348426	T/C	cg25880958	chr11:74394337	NA	-0.49	-7.88	-0.3	1.43e-14	Response to metformin (IC50);
BRCA	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg27490568	chr2:178487706	NA	0.56	8.91	0.33	5.34e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.06	-0.34	1.53e-18	Total body bone mineral density;
BRCA	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg20573242	chr4:122745356	CCNA2	0.5	12.83	0.45	1.05e-33	Type 2 diabetes;
BRCA	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg20219911	chr3:52813652	ITIH1	0.3	8.21	0.31	1.18e-15	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	1.98e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17228212	0.555	rs7179840	chr15:67458930	A/G	cg26876701	chr15:67458665	SMAD3	-0.37	-8.63	-0.32	4.71e-17	Coronary heart disease;
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg27094323	chr7:1216898	NA	-0.35	-8.09	-0.3	3.08e-15	Longevity;Endometriosis;
BRCA	cis	rs12200560	0.505	rs211175	chr6:97073320	C/T	cg06623918	chr6:96969491	KIAA0776	0.52	12.48	0.44	3.91e-32	Coronary heart disease;
BRCA	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26314531	chr2:26401878	FAM59B	-0.88	-15.31	-0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg13256891	chr4:100009986	ADH5	0.38	8.06	0.3	3.66e-15	Alcohol dependence;
BRCA	cis	rs727479	0.543	rs1065778	chr15:51520206	T/C	cg19946085	chr15:51559439	CYP19A1	-0.29	-7.97	-0.3	7.44e-15	Estradiol levels;
BRCA	trans	rs7980799	0.935	rs10772076	chr12:33553574	A/C	cg26384229	chr12:38710491	ALG10B	-0.39	-8.18	-0.31	1.51e-15	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.64	-14.25	-0.49	3.37e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg06784218	chr1:46089804	CCDC17	-0.52	-12.72	-0.45	3.23e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg24829409	chr8:58192753	C8orf71	-0.47	-8.15	-0.31	1.98e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg18016565	chr1:150552671	MCL1	-0.36	-8.24	-0.31	9.94e-16	Tonsillectomy;
BRCA	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg03929089	chr4:120376271	NA	-0.5	-9.47	-0.35	5.34e-20	Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.16	0.4	1.48e-26	Bipolar disorder;
BRCA	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg07636037	chr3:49044803	WDR6	0.97	28.46	0.75	1.02e-115	Parkinson's disease;
BRCA	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg23029597	chr12:123009494	RSRC2	-0.61	-12.25	-0.44	4.02e-31	Body mass index;
BRCA	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg13319975	chr6:146136371	FBXO30	-0.38	-8.37	-0.31	3.51e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg08000102	chr2:233561755	GIGYF2	0.64	13.98	0.48	6e-39	Coronary artery disease;
BRCA	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg17470723	chr8:74884337	TCEB1	0.4	8.72	0.33	2.46e-17	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17712092	chr4:129076599	LARP1B	0.54	13.08	0.46	8.53e-35	Breast cancer;
BRCA	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg04450456	chr4:17643702	FAM184B	0.41	12.47	0.44	4.04e-32	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg26043149	chr18:55253948	FECH	-0.38	-8.23	-0.31	1.03e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.82	-0.33	1.04e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg11764359	chr7:65958608	NA	0.46	9.06	0.34	1.51e-18	Calcium levels;
BRCA	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg10523679	chr1:76189770	ACADM	0.75	15.61	0.53	8.73e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.77	-0.42	4.42e-29	Alcohol dependence;
BRCA	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg18404041	chr3:52824283	ITIH1	-0.35	-9.09	-0.34	1.23e-18	Schizophrenia;
BRCA	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-13.97	-0.48	7.03e-39	Chronic sinus infection;
BRCA	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14240646	chr10:27532245	ACBD5	-0.58	-9.72	-0.36	6.21e-21	Breast cancer;
BRCA	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg16339924	chr4:17578868	LAP3	0.66	16.62	0.55	8.01e-52	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs9929218	1.000	rs9936621	chr16:68798682	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-13.92	-0.48	1.18e-38	Colorectal cancer;
BRCA	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg02297831	chr4:17616191	MED28	0.38	8.85	0.33	8.39e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg05868516	chr6:26286170	HIST1H4H	0.46	9.25	0.34	3.4e-19	Educational attainment;
BRCA	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.66	-0.39	1.61e-24	Retinal vascular caliber;
BRCA	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.52	8.51	0.32	1.21e-16	Renal function-related traits (BUN);
BRCA	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.31	-0.31	5.66e-16	Total body bone mineral density;
BRCA	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg20307385	chr11:47447363	PSMC3	-0.8	-19.71	-0.61	6.16e-68	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.94	0.58	1.34e-58	Fuchs's corneal dystrophy;
BRCA	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-8.97	-0.33	3.22e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs36051895	0.632	rs12115301	chr9:5180548	A/G	cg02405213	chr9:5042618	JAK2	0.46	8.74	0.33	2.11e-17	Pediatric autoimmune diseases;
BRCA	cis	rs6740322	0.895	rs6760797	chr2:43559612	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-11.65	-0.42	1.46e-28	Coronary artery disease;
BRCA	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.51	-0.41	5.23e-28	Personality dimensions;
BRCA	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg00750074	chr16:89608354	SPG7	-0.41	-11.11	-0.4	2.43e-26	Multiple myeloma (IgH translocation);
BRCA	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.4	0.49	6.57e-41	Motion sickness;
BRCA	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26734620	chr12:56694298	CS	-0.86	-10.24	-0.38	7.13e-23	Psoriasis vulgaris;
BRCA	trans	rs1459104	1.000	rs35597725	chr11:55311828	T/G	cg15704280	chr7:45808275	SEPT13	0.64	8.07	0.3	3.57e-15	Body mass index;
BRCA	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg22963979	chr7:1858916	MAD1L1	-0.45	-9.18	-0.34	5.77e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs9986765	1.000	rs10243198	chr7:142822210	C/T	cg22531018	chr7:142981779	TMEM139	0.6	10.29	0.38	4.37e-23	Cancer;Dermatomyositis;
BRCA	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg17691542	chr6:26056736	HIST1H1C	0.48	9.82	0.36	2.8e-21	Height;
BRCA	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg18876405	chr7:65276391	NA	0.53	11.72	0.42	7.42e-29	Calcium levels;
BRCA	cis	rs6586163	0.527	rs3824730	chr10:90752128	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.57	13.14	0.46	4.22e-35	Chronic lymphocytic leukemia;
BRCA	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg16586182	chr3:47516702	SCAP	0.52	11.28	0.41	4.82e-27	Colorectal cancer;
BRCA	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg26587870	chr6:27730563	NA	-0.52	-8.02	-0.3	5.04e-15	Breast cancer;
BRCA	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	11.43	0.41	1.15e-27	Mood instability;
BRCA	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.36	-8.99	-0.33	2.83e-18	Total body bone mineral density;
BRCA	cis	rs4363385	0.720	rs1338178	chr1:152981550	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.36	-0.31	3.79e-16	Inflammatory skin disease;
BRCA	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg09877947	chr5:131593287	PDLIM4	0.4	10.05	0.37	3.83e-22	Breast cancer;
BRCA	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg20607287	chr7:12443886	VWDE	-0.52	-8.19	-0.31	1.45e-15	Coronary artery disease;
BRCA	cis	rs4566357	0.615	rs4350744	chr2:227918146	A/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-9.56	-0.35	2.41e-20	Coronary artery disease;
BRCA	cis	rs61990749	0.597	rs2032781	chr14:78214875	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.64	9.82	0.36	2.75e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs3820928	0.874	rs7562776	chr2:227806550	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.88	-0.33	6.91e-18	Pulmonary function;
BRCA	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg05347473	chr6:146136440	FBXO30	0.4	7.86	0.3	1.65e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg20203395	chr5:56204925	C5orf35	-0.37	-8.42	-0.32	2.4e-16	Coronary artery disease;
BRCA	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg12011299	chr4:100065546	ADH4	0.48	11.37	0.41	2.04e-27	Smoking initiation;
BRCA	cis	rs1499972	0.941	rs62264762	chr3:117634443	C/A	cg07612923	chr3:117604196	NA	0.6	8.12	0.31	2.32e-15	Schizophrenia;
BRCA	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg23625390	chr15:77176239	SCAPER	-0.54	-13.99	-0.48	5.47e-39	Blood metabolite levels;
BRCA	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-16.11	-0.54	3.06e-49	Total cholesterol levels;
BRCA	cis	rs708547	1.000	rs10003229	chr4:57809598	A/C	cg25525207	chr4:57843836	C4orf14;POLR2B	0.5	8.54	0.32	9.51e-17	Response to bleomycin (chromatid breaks);
BRCA	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg14863265	chr7:2801509	GNA12	-0.48	-10.16	-0.37	1.43e-22	Height;
BRCA	trans	rs2797160	1.000	rs61299898	chr6:126007651	G/C	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.92	0.3	1.05e-14	Endometrial cancer;
BRCA	trans	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg25214090	chr10:38739885	LOC399744	-0.4	-9.25	-0.34	3.38e-19	Corneal astigmatism;
BRCA	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg03477792	chr4:77819574	ANKRD56	0.66	15.67	0.53	4.35e-47	Emphysema distribution in smoking;
BRCA	cis	rs965469	1.000	rs6037554	chr20:3315613	G/A	cg25506879	chr20:3388711	C20orf194	-0.53	-10.56	-0.39	3.9e-24	IFN-related cytopenia;
BRCA	trans	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg06521331	chr12:34319734	NA	-0.5	-9.31	-0.35	1.97e-19	Bladder cancer;
BRCA	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.94e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6740322	0.748	rs6544635	chr2:43486704	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.72	-13.11	-0.46	5.86e-35	Coronary artery disease;
BRCA	cis	rs1712517	1.000	rs1712517	chr10:105033015	C/T	cg05636881	chr10:105038444	INA	0.35	8.18	0.31	1.49e-15	Migraine;
BRCA	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg24006582	chr15:45444508	DUOX1	0.56	11.14	0.4	1.85e-26	Uric acid levels;
BRCA	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg25358565	chr5:93447407	FAM172A	1.23	18.35	0.59	1.04e-60	Diabetic retinopathy;
BRCA	cis	rs1577917	0.958	rs2197648	chr6:86543887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.43	-0.41	1.14e-27	Response to antipsychotic treatment;
BRCA	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg12310025	chr6:25882481	NA	-0.43	-10.01	-0.37	5.23e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg05707623	chr12:122985044	ZCCHC8	0.47	9.36	0.35	1.33e-19	Body mass index;
BRCA	cis	rs921968	0.565	rs2037622	chr2:219609440	T/C	cg02176678	chr2:219576539	TTLL4	-0.41	-10.98	-0.4	8.53e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6120849	0.707	rs6120826	chr20:33671831	G/A	cg24642439	chr20:33292090	TP53INP2	0.59	10.18	0.37	1.16e-22	Protein C levels;
BRCA	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18876405	chr7:65276391	NA	0.5	11.04	0.4	4.74e-26	Aortic root size;
BRCA	cis	rs11083475	0.681	rs62121377	chr19:39257296	G/A	cg07905965	chr19:39260460	NA	0.49	11.42	0.41	1.34e-27	Heart rate;
BRCA	trans	rs1478897	0.804	rs9329246	chr8:11392880	A/G	cg15556689	chr8:8085844	FLJ10661	0.35	9.06	0.34	1.6e-18	Systemic lupus erythematosus;
BRCA	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg23018236	chr17:30244563	NA	-0.61	-10.05	-0.37	3.63e-22	Hip circumference adjusted for BMI;
BRCA	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21659725	chr3:3221576	CRBN	-0.46	-9.84	-0.36	2.3e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs600806	0.778	rs10857787	chr1:110010289	C/T	cg20591472	chr1:110008990	SYPL2	0.31	7.89	0.3	1.33e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7147624	1.000	rs10135969	chr14:65982345	C/T	cg03016385	chr14:66212404	NA	-0.58	-8.63	-0.32	4.99e-17	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs10463316	0.832	rs246482	chr5:150731857	C/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-8.58	-0.32	7.3e-17	Metabolite levels (Pyroglutamine);
BRCA	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg05347473	chr6:146136440	FBXO30	0.39	7.81	0.3	2.32e-14	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs637571	0.726	rs526631	chr11:65681965	T/G	cg17712092	chr4:129076599	LARP1B	-0.68	-17.32	-0.57	2.3e-55	Eosinophil percentage of white cells;
BRCA	cis	rs12997796	0.556	rs34353387	chr2:86974834	A/C	cg25203885	chr2:87302643	LOC285074	-0.58	-9.48	-0.35	4.75e-20	Schizophrenia;
BRCA	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg26647111	chr11:31128758	NA	0.45	9.8	0.36	3.31e-21	Red blood cell count;
BRCA	cis	rs10489202	0.683	rs2294817	chr1:168073601	C/A	cg24449463	chr1:168025552	DCAF6	-0.48	-15.11	-0.51	2.37e-44	Schizophrenia;
BRCA	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg09021430	chr5:549028	NA	-0.65	-16.58	-0.55	1.34e-51	Ulcerative colitis;
BRCA	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg09537434	chr19:41945824	ATP5SL	-0.61	-12.73	-0.45	3.05e-33	Migraine;Coronary artery disease;
BRCA	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg17691542	chr6:26056736	HIST1H1C	0.51	10.1	0.37	2.35e-22	Iron status biomarkers;
BRCA	cis	rs701145	0.730	rs701141	chr3:154061053	G/A	cg17054900	chr3:154042577	DHX36	0.66	11.41	0.41	1.46e-27	Coronary artery disease;
BRCA	trans	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-10.0	-0.37	5.51e-22	Retinal vascular caliber;
BRCA	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg21475434	chr5:93447410	FAM172A	0.66	8.75	0.33	1.92e-17	Diabetic retinopathy;
BRCA	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23583168	chr7:148888333	NA	-0.73	-15.55	-0.52	1.73e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2712184	0.967	rs2541385	chr2:217669595	C/T	cg05032264	chr2:217675019	NA	-0.44	-10.95	-0.4	1.08e-25	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg00666640	chr1:248458726	OR2T12	0.32	8.71	0.33	2.49e-17	Common traits (Other);
BRCA	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.17	-0.4	1.36e-26	Schizophrenia;
BRCA	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg24642844	chr7:1081250	C7orf50	-0.52	-11.2	-0.4	1.09e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.6	-14.33	-0.49	1.36e-40	Age at first birth;
BRCA	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg00958927	chr1:175162553	KIAA0040	-0.21	-7.85	-0.3	1.71e-14	Alcohol dependence;
BRCA	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs2580764	0.566	rs2968795	chr2:55287989	G/A	cg09592903	chr2:55203963	RTN4	0.36	9.27	0.34	2.77e-19	Mean platelet volume;
BRCA	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg20307385	chr11:47447363	PSMC3	0.4	8.67	0.32	3.49e-17	Subjective well-being;
BRCA	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg16325326	chr1:53192061	ZYG11B	-0.95	-26.34	-0.72	4.09e-104	Monocyte count;
BRCA	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg25482853	chr8:67687455	SGK3	0.99	15.46	0.52	5.17e-46	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9815354	0.638	rs12634670	chr3:41875299	G/C	cg03022575	chr3:42003672	ULK4	0.68	9.46	0.35	5.93e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg21747090	chr2:27597821	SNX17	-0.44	-9.62	-0.36	1.51e-20	Menopause (age at onset);
BRCA	cis	rs11247915	0.540	rs11582416	chr1:26677721	A/G	cg15628303	chr1:26608928	UBXN11	-0.3	-8.03	-0.3	4.7e-15	Obesity-related traits;
BRCA	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.48	8.85	0.33	8.21e-18	Breast cancer;
BRCA	cis	rs6063312	1.000	rs6095261	chr20:47346494	C/A	cg18078177	chr20:47281410	PREX1	0.65	11.26	0.41	5.84e-27	Tonometry;
BRCA	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	22.2	0.66	2.32e-81	Platelet count;
BRCA	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg03676636	chr4:99064102	C4orf37	0.21	8.01	0.3	5.42e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.27	-0.34	2.73e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg12386194	chr3:101231763	SENP7	0.43	9.61	0.36	1.61e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11890956	chr21:40555474	PSMG1	1.06	31.74	0.78	1.95e-133	Cognitive function;
BRCA	cis	rs2286885	1.000	rs10819169	chr9:129249625	C/T	cg15282417	chr9:129245246	FAM125B	0.31	8.03	0.3	4.59e-15	Intraocular pressure;
BRCA	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-9.9	-0.36	1.4e-21	Alzheimer's disease (late onset);
BRCA	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg21535247	chr6:8435926	SLC35B3	-0.66	-13.28	-0.47	1.04e-35	Motion sickness;
BRCA	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg19336497	chr11:14380999	RRAS2	-0.48	-11.97	-0.43	6.18e-30	Sense of smell;
BRCA	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg21905437	chr5:178450457	ZNF879	0.49	9.9	0.36	1.36e-21	Pubertal anthropometrics;
BRCA	cis	rs7903847	0.619	rs10786336	chr10:99134953	A/C	cg08345082	chr10:99160200	RRP12	-0.29	-8.6	-0.32	6.17e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	30.54	0.77	5.46e-127	Chronic sinus infection;
BRCA	cis	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg07988820	chr12:82153109	PPFIA2	-0.6	-9.71	-0.36	7.15e-21	Resting heart rate;
BRCA	cis	rs6782228	0.606	rs9828893	chr3:128332925	T/C	cg16766828	chr3:128327626	NA	-0.4	-8.79	-0.33	1.33e-17	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg18811423	chr2:55921094	PNPT1	0.71	22.76	0.67	1.91e-84	Metabolic syndrome;
BRCA	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	12.82	0.45	1.18e-33	Mean platelet volume;
BRCA	cis	rs16944613	0.541	rs4566137	chr15:91097964	A/G	cg26821196	chr15:91095069	CRTC3	0.48	8.77	0.33	1.57e-17	Colorectal cancer;
BRCA	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg22800045	chr5:56110881	MAP3K1	-0.5	-8.21	-0.31	1.19e-15	Initial pursuit acceleration;
BRCA	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg08999081	chr20:33150536	PIGU	0.46	12.92	0.46	4.19e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg05729581	chr11:3078854	CARS	-0.33	-8.28	-0.31	7.32e-16	Longevity;
BRCA	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.24	0.38	7e-23	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg23762105	chr12:34175262	ALG10	-0.37	-9.47	-0.35	5.25e-20	Morning vs. evening chronotype;
BRCA	cis	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg06521331	chr12:34319734	NA	-0.52	-10.42	-0.38	1.42e-23	Morning vs. evening chronotype;
BRCA	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg16606324	chr3:10149918	C3orf24	0.56	10.85	0.39	2.78e-25	Alzheimer's disease;
BRCA	cis	rs4074536	0.574	rs10737733	chr1:116288825	T/C	cg21648376	chr1:116311395	CASQ2	-0.49	-8.71	-0.33	2.5e-17	QRS duration;
BRCA	cis	rs6669008	1.000	rs6669008	chr1:114166561	A/G	cg26035817	chr1:114414802	PTPN22	0.34	8.2	0.31	1.28e-15	Bacteremia;
BRCA	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg26818010	chr10:134567672	INPP5A	-0.63	-13.98	-0.48	5.91e-39	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-16.21	-0.54	8.87e-50	Heart rate;
BRCA	cis	rs16958440	0.867	rs28587821	chr18:44687906	G/A	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg11663144	chr21:46675770	NA	-0.48	-9.73	-0.36	6.13e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg00012203	chr2:219082015	ARPC2	0.72	16.43	0.54	7.67e-51	Colorectal cancer;
BRCA	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg18225595	chr11:63971243	STIP1	0.53	13.14	0.46	4.21e-35	Platelet count;
BRCA	cis	rs858239	0.738	rs13225593	chr7:23260307	A/G	cg23682824	chr7:23144976	KLHL7	0.36	9.31	0.35	2.02e-19	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs17490626	0.568	rs12413523	chr10:71211664	C/G	cg12610070	chr10:71211762	TSPAN15	-0.33	-11.77	-0.42	4.44e-29	Thrombosis;
BRCA	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg03146154	chr1:46216737	IPP	0.54	12.03	0.43	3.34e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs735860	0.737	rs2115564	chr6:53173482	C/A	cg10236188	chr6:53219634	NA	-0.41	-8.81	-0.33	1.21e-17	Glaucoma;
BRCA	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg18964960	chr10:1102726	WDR37	0.6	8.04	0.3	4.44e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19346786	chr7:2764209	NA	-0.3	-9.4	-0.35	9.79e-20	Height;
BRCA	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.32	-0.44	1.9e-31	Alzheimer's disease;
BRCA	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg16486109	chr11:613632	IRF7	0.42	8.83	0.33	1.01e-17	Systemic lupus erythematosus;
BRCA	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg21918786	chr6:109611834	NA	-0.44	-11.8	-0.42	3.23e-29	Reticulocyte fraction of red cells;
BRCA	cis	rs858239	0.600	rs13438188	chr7:23144197	C/T	cg23682824	chr7:23144976	KLHL7	-0.4	-10.44	-0.38	1.17e-23	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg07636037	chr3:49044803	WDR6	-0.69	-14.02	-0.49	3.91e-39	Menarche (age at onset);
BRCA	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.16	-0.31	1.78e-15	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg22117172	chr7:91764530	CYP51A1	0.24	8.11	0.31	2.51e-15	Breast cancer;
BRCA	cis	rs7395581	0.918	rs10742799	chr11:47293702	T/C	cg25783544	chr11:47291846	MADD	0.43	9.65	0.36	1.13e-20	HDL cholesterol;
BRCA	cis	rs10189230	0.967	rs13012429	chr2:222350788	C/T	cg14652038	chr2:222343519	EPHA4	0.48	13.26	0.46	1.3e-35	Urate levels in lean individuals;
BRCA	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.55	0.32	8.8e-17	Rheumatoid arthritis;
BRCA	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg12935359	chr14:103987150	CKB	-0.58	-13.24	-0.46	1.58e-35	Body mass index;
BRCA	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg01689657	chr7:91764605	CYP51A1	0.23	8.37	0.31	3.68e-16	Breast cancer;
BRCA	cis	rs6121246	0.559	rs6060944	chr20:30372114	G/A	cg21427119	chr20:30132790	HM13	-0.36	-8.12	-0.31	2.35e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg00071950	chr4:10020882	SLC2A9	0.55	13.19	0.46	2.62e-35	Bone mineral density;
BRCA	cis	rs6840258	0.660	rs72667739	chr4:87877499	A/C	cg08197287	chr4:87952173	AFF1	-0.47	-8.47	-0.32	1.71e-16	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	trans	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg25214090	chr10:38739885	LOC399744	-0.34	-7.85	-0.3	1.73e-14	Diastolic blood pressure;
BRCA	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg01579765	chr21:45077557	HSF2BP	-0.46	-12.54	-0.44	2.01e-32	Mean corpuscular volume;
BRCA	cis	rs701145	0.556	rs355762	chr3:154012614	G/A	cg12800244	chr3:153838788	SGEF	0.42	8.45	0.32	2.03e-16	Coronary artery disease;
BRCA	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.78e-21	Total body bone mineral density;
BRCA	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg26395211	chr5:140044315	WDR55	0.35	7.9	0.3	1.24e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg26384229	chr12:38710491	ALG10B	0.7	15.74	0.53	2.14e-47	Bladder cancer;
BRCA	cis	rs7737355	0.898	rs31590	chr5:131005181	A/G	cg06307176	chr5:131281290	NA	0.52	10.23	0.38	7.41e-23	Life satisfaction;
BRCA	cis	rs1969363	0.531	rs11495331	chr12:38110702	A/G	cg26384229	chr12:38710491	ALG10B	0.44	9.81	0.36	3.06e-21	Morning vs. evening chronotype;
BRCA	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.01	14.77	0.5	1.1e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2882667	0.690	rs288040	chr5:138204894	A/T	cg04439458	chr5:138467593	SIL1	-0.35	-8.55	-0.32	9.12e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.44	9.59	0.35	1.87e-20	Iron status biomarkers;
BRCA	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.12	-0.31	2.37e-15	Depression;
BRCA	cis	rs62229266	0.839	rs11088335	chr21:37470335	C/T	cg12218747	chr21:37451666	NA	-0.36	-8.65	-0.32	4.01e-17	Mitral valve prolapse;
BRCA	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg22705602	chr4:152727874	NA	-0.39	-10.68	-0.39	1.27e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06544989	chr22:39130855	UNC84B	0.38	8.75	0.33	1.89e-17	Menopause (age at onset);
BRCA	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.05	29.3	0.76	2.96e-120	Cognitive ability;
BRCA	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-14.66	-0.5	3.8e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2742234	0.910	rs2503866	chr10:43646261	T/A	cg15436174	chr10:43711423	RASGEF1A	-0.43	-9.15	-0.34	7.36e-19	Hirschsprung disease;
BRCA	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg14675211	chr2:100938903	LONRF2	0.52	11.5	0.41	5.86e-28	Intelligence (multi-trait analysis);
BRCA	trans	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg26043149	chr18:55253948	FECH	-0.37	-8.17	-0.31	1.63e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg07460842	chr6:66804631	NA	0.88	15.61	0.53	8.47e-47	Exhaled nitric oxide levels;
BRCA	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg04691961	chr3:161091175	C3orf57	-0.59	-14.0	-0.48	4.87e-39	Morning vs. evening chronotype;
BRCA	trans	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg06521331	chr12:34319734	NA	-0.51	-9.21	-0.34	4.77e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg24642439	chr20:33292090	TP53INP2	0.41	8.66	0.32	3.76e-17	Height;
BRCA	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25427524	chr10:38739819	LOC399744	-0.64	-15.09	-0.51	3.06e-44	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg00080972	chr5:178986291	RUFY1	-0.52	-14.83	-0.51	5.36e-43	Lung cancer;
BRCA	cis	rs13046373	0.535	rs1961491	chr21:31973685	C/T	cg24082983	chr21:31802169	KRTAP13-4	0.34	8.59	0.32	6.86e-17	HDL cholesterol;
BRCA	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg21775007	chr8:11205619	TDH	0.6	12.08	0.43	2.12e-30	Retinal vascular caliber;
BRCA	cis	rs483180	0.511	rs496198	chr1:120207177	A/G	cg19096424	chr1:120255104	PHGDH	-0.42	-9.3	-0.35	2.12e-19	Macular telangiectasia type 2;
BRCA	cis	rs6834538	0.597	rs4834291	chr4:113482718	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.44	10.6	0.39	2.69e-24	Free thyroxine concentration;
BRCA	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg18904891	chr8:8559673	CLDN23	0.59	11.31	0.41	3.67e-27	Obesity-related traits;
BRCA	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg18252515	chr7:66147081	NA	-0.55	-11.03	-0.4	4.99e-26	Corneal structure;
BRCA	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg06640241	chr16:89574553	SPG7	0.76	17.84	0.58	4.62e-58	Multiple myeloma (IgH translocation);
BRCA	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-11.96	-0.43	6.58e-30	Bone mineral density;
BRCA	cis	rs312274	0.698	rs1854482	chr12:41212586	A/G	cg17827154	chr12:41323612	CNTN1	0.36	8.82	0.33	1.06e-17	Metabolite levels  (X-11787);
BRCA	cis	rs3772130	0.564	rs28760466	chr3:121601510	A/G	cg20356878	chr3:121714668	ILDR1	0.43	9.98	0.37	6.6e-22	Cognitive performance;
BRCA	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg14820908	chr5:178986412	RUFY1	0.44	11.18	0.4	1.24e-26	Lung cancer;
BRCA	cis	rs4363385	0.747	rs6684188	chr1:152974285	A/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.84	-0.36	2.35e-21	Inflammatory skin disease;
BRCA	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.32	8.84	0.33	9.03e-18	Response to antipsychotic treatment;
BRCA	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	22.34	0.66	4e-82	Platelet count;
BRCA	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg01420254	chr6:26195488	NA	0.55	8.58	0.32	7.05e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg01256987	chr12:42539512	GXYLT1	-0.56	-11.41	-0.41	1.37e-27	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg04990556	chr1:26633338	UBXN11	-0.47	-9.28	-0.34	2.53e-19	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg15395560	chr15:45543142	SLC28A2	0.3	8.3	0.31	6.2e-16	Uric acid levels;
BRCA	cis	rs66731853	0.769	rs476582	chr1:20894450	A/G	cg04087271	chr1:20915334	CDA	-0.47	-9.03	-0.34	1.97e-18	Mean corpuscular volume;
BRCA	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg09085632	chr11:111637200	PPP2R1B	1.0	23.81	0.69	3.45e-90	Primary sclerosing cholangitis;
BRCA	cis	rs1712517	0.873	rs7913461	chr10:105001325	A/G	cg05636881	chr10:105038444	INA	0.36	8.05	0.3	4.17e-15	Migraine;
BRCA	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02475777	chr4:1388615	CRIPAK	0.68	13.05	0.46	1.08e-34	Longevity;
BRCA	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	10.01	0.37	5.23e-22	Tonsillectomy;
BRCA	cis	rs586533	0.881	rs1628747	chr11:99507950	C/T	cg22878054	chr11:99397252	CNTN5	0.31	7.88	0.3	1.46e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg02297831	chr4:17616191	MED28	0.37	8.56	0.32	8.7e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg07169764	chr2:136633963	MCM6	1.25	30.25	0.77	1.89e-125	Corneal structure;
BRCA	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg08807101	chr21:30365312	RNF160	-0.57	-13.87	-0.48	2.01e-38	Dental caries;
BRCA	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.69	-11.74	-0.42	5.92e-29	Platelet count;
BRCA	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg00277334	chr10:82204260	NA	-0.85	-24.82	-0.7	9.19e-96	Post bronchodilator FEV1;
BRCA	cis	rs9487051	0.660	rs2884036	chr6:109642916	A/G	cg01475377	chr6:109611718	NA	0.49	11.51	0.41	5.29e-28	Reticulocyte fraction of red cells;
BRCA	cis	rs17604090	0.793	rs10226095	chr7:29690059	A/G	cg19413766	chr7:29689036	LOC646762	0.48	7.84	0.3	1.85e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg12419862	chr22:24373484	LOC391322	0.69	15.57	0.52	1.4e-46	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg07148914	chr20:33460835	GGT7	-0.43	-9.15	-0.34	7.77e-19	Height;
BRCA	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg07080220	chr10:102295463	HIF1AN	0.59	14.22	0.49	4.51e-40	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg05313129	chr8:58192883	C8orf71	-0.46	-9.53	-0.35	3.34e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs3806933	0.522	rs13153937	chr5:110434307	C/T	cg04022379	chr5:110408740	TSLP	0.48	10.67	0.39	1.45e-24	Eosinophilic esophagitis;
BRCA	cis	rs16854884	0.657	rs7642774	chr3:143723272	T/A	cg06585982	chr3:143692056	C3orf58	0.43	8.92	0.33	4.69e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs4363385	0.747	rs2339495	chr1:152975116	A/T	cg25856811	chr1:152973957	SPRR3	-0.35	-9.29	-0.34	2.4e-19	Inflammatory skin disease;
BRCA	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg13073564	chr4:8508604	NA	0.43	11.63	0.42	1.79e-28	Response to antineoplastic agents;
BRCA	cis	rs13040088	0.872	rs13039291	chr20:61572760	C/T	cg23096297	chr20:61557774	DIDO1	0.9	17.35	0.57	1.54e-55	Menopause (age at onset);
BRCA	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg08885076	chr2:99613938	TSGA10	-0.59	-13.21	-0.46	2.12e-35	Chronic sinus infection;
BRCA	trans	rs2562456	0.876	rs62110202	chr19:21754601	C/T	cg25042112	chr7:64838748	ZNF92	-0.43	-8.27	-0.31	7.53e-16	Pain;
BRCA	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg12310025	chr6:25882481	NA	-0.52	-11.79	-0.42	3.63e-29	Intelligence (multi-trait analysis);
BRCA	trans	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg15704280	chr7:45808275	SEPT13	0.58	8.7	0.33	2.84e-17	Axial length;
BRCA	trans	rs4596713	0.568	rs7034179	chr9:71746838	C/T	cg16512924	chr15:28394682	HERC2	0.4	9.56	0.35	2.47e-20	Headache;
BRCA	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg18904891	chr8:8559673	CLDN23	0.64	12.43	0.44	6.37e-32	Obesity-related traits;
BRCA	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg14019146	chr3:50243930	SLC38A3	0.34	8.03	0.3	4.59e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7683537	0.501	rs2171838	chr4:185667404	A/G	cg04058563	chr4:185651563	MLF1IP	-0.57	-11.41	-0.41	1.38e-27	Systemic lupus erythematosus;
BRCA	cis	rs9612	0.950	rs11351	chr19:44271066	A/C	cg08581076	chr19:44259116	C19orf61	0.47	8.82	0.33	1.05e-17	Exhaled nitric oxide output;
BRCA	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.03	0.58	4.79e-59	Fuchs's corneal dystrophy;
BRCA	cis	rs36051895	0.632	rs7030853	chr9:5179002	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-8.82	-0.33	1.07e-17	Pediatric autoimmune diseases;
BRCA	cis	rs965469	1.000	rs6051732	chr20:3294182	G/A	cg25506879	chr20:3388711	C20orf194	-0.54	-10.42	-0.38	1.39e-23	IFN-related cytopenia;
BRCA	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg00339695	chr16:24857497	SLC5A11	0.52	11.02	0.4	5.61e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-9.74	-0.36	5.28e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg13010199	chr12:38710504	ALG10B	0.51	9.97	0.37	7.46e-22	Bladder cancer;
BRCA	cis	rs17023223	0.537	rs10923759	chr1:119692194	A/G	cg05756136	chr1:119680316	WARS2	0.43	8.33	0.31	4.97e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg16586182	chr3:47516702	SCAP	0.44	8.91	0.33	5.2e-18	Birth weight;
BRCA	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg09658497	chr7:2847517	GNA12	-0.39	-8.02	-0.3	5.01e-15	Height;
BRCA	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg19920283	chr7:105172520	RINT1	0.59	9.22	0.34	4.15e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg14266287	chr2:239334506	ASB1	-0.33	-8.03	-0.3	4.64e-15	Multiple system atrophy;
BRCA	cis	rs61990749	0.544	rs11628888	chr14:78161506	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.62	-9.52	-0.35	3.62e-20	Fibroblast growth factor basic levels;
BRCA	cis	rs867371	1.000	rs7181655	chr15:82455616	T/C	cg00614314	chr15:82944287	LOC80154	0.44	9.12	0.34	9.34e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-11.67	-0.42	1.2e-28	Neuroticism;
BRCA	trans	rs2270927	0.510	rs2913265	chr5:75603886	C/A	cg13563193	chr19:33072644	PDCD5	0.93	10.48	0.38	8.24e-24	Mean corpuscular volume;
BRCA	cis	rs7903847	0.642	rs11817875	chr10:99158414	G/A	cg08345082	chr10:99160200	RRP12	-0.31	-8.89	-0.33	6.36e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs35123781	1.000	rs589153	chr5:139057548	A/G	cg05227215	chr5:139057496	CXXC5	0.33	8.06	0.3	3.89e-15	Schizophrenia;
BRCA	cis	rs2882667	0.858	rs11242444	chr5:138406379	T/A	cg04439458	chr5:138467593	SIL1	-0.43	-10.8	-0.39	4.4e-25	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg06784218	chr1:46089804	CCDC17	0.46	10.91	0.4	1.58e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1555322	0.530	rs6060341	chr20:33863633	C/T	cg17927777	chr20:33865990	NA	-0.49	-9.58	-0.35	2.07e-20	Attention deficit hyperactivity disorder;
BRCA	cis	rs2354432	0.607	rs7553584	chr1:146693429	A/G	cg25205988	chr1:146714368	CHD1L	-0.86	-10.94	-0.4	1.19e-25	Mitochondrial DNA levels;
BRCA	cis	rs8038465	0.568	rs62004592	chr15:73878019	A/G	cg15420318	chr15:73925796	NPTN	0.47	10.08	0.37	2.74e-22	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg04546413	chr19:29218101	NA	0.64	12.29	0.44	2.61e-31	Methadone dose in opioid dependence;
BRCA	cis	rs17095355	1.000	rs17126886	chr10:111695257	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.39	-10.05	-0.37	3.83e-22	Biliary atresia;
BRCA	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg08859206	chr1:53392774	SCP2	0.49	10.84	0.39	2.91e-25	Monocyte count;
BRCA	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg08213375	chr14:104286397	PPP1R13B	0.65	18.16	0.58	9.46e-60	Schizophrenia;
BRCA	trans	rs877282	0.947	rs7904978	chr10:768078	C/T	cg22713356	chr15:30763199	NA	1.35	26.99	0.73	1.24e-107	Uric acid levels;
BRCA	cis	rs9649465	1.000	rs1006764	chr7:123337873	C/T	cg04330084	chr7:123175371	IQUB	-0.3	-8.32	-0.31	5.51e-16	Migraine;
BRCA	cis	rs4302748	0.865	rs59011914	chr7:36185290	C/T	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs1691799	0.867	rs1027399	chr12:66760942	G/A	cg16791601	chr12:66731901	HELB	-0.65	-17.62	-0.57	6.52e-57	White blood cell count (basophil);
BRCA	cis	rs1003719	0.788	rs8133549	chr21:38447489	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.17	0.49	7.56e-40	Eye color traits;
BRCA	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg13628971	chr7:2884303	GNA12	0.6	13.71	0.48	1.12e-37	Height;
BRCA	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-10.46	-0.38	9.8599999999999993e-24	Mean corpuscular volume;
BRCA	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg08000102	chr2:233561755	GIGYF2	-0.6	-13.4	-0.47	2.85e-36	Coronary artery disease;
BRCA	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg07636037	chr3:49044803	WDR6	0.94	27.28	0.73	2.99e-109	Parkinson's disease;
BRCA	cis	rs12458462	0.509	rs3786241	chr18:77494328	A/C	cg11879182	chr18:77439856	CTDP1	0.43	9.49	0.35	4.58e-20	Monocyte count;
BRCA	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg18252515	chr7:66147081	NA	-1.07	-15.54	-0.52	2.03e-46	Diabetic kidney disease;
BRCA	cis	rs4363385	0.818	rs382292	chr1:153006641	G/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.18e-19	Inflammatory skin disease;
BRCA	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg08213375	chr14:104286397	PPP1R13B	0.4	8.47	0.32	1.68e-16	Reticulocyte count;
BRCA	cis	rs12997796	0.556	rs35129240	chr2:86929217	G/A	cg25203885	chr2:87302643	LOC285074	-0.59	-9.49	-0.35	4.46e-20	Schizophrenia;
BRCA	cis	rs908922	0.628	rs488393	chr1:152489548	C/T	cg20991723	chr1:152506922	NA	0.39	9.12	0.34	9.93e-19	Hair morphology;
BRCA	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-11.79	-0.42	3.7e-29	Alzheimer's disease;
BRCA	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg13902645	chr11:5959945	NA	-0.57	-11.54	-0.42	4e-28	DNA methylation (variation);
BRCA	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.31	0.66	5.54e-82	Chronic sinus infection;
BRCA	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08859206	chr1:53392774	SCP2	-0.51	-11.23	-0.41	7.8e-27	Monocyte count;
BRCA	cis	rs1499972	0.941	rs62263119	chr3:117630175	T/G	cg07612923	chr3:117604196	NA	0.6	8.15	0.31	1.97e-15	Schizophrenia;
BRCA	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg11062466	chr8:58055876	NA	0.41	7.93	0.3	9.62e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg04691961	chr3:161091175	C3orf57	-0.42	-10.17	-0.37	1.23e-22	Morning vs. evening chronotype;
BRCA	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg23029597	chr12:123009494	RSRC2	-0.6	-12.19	-0.43	6.73e-31	Body mass index;
BRCA	cis	rs4478858	0.611	rs10914338	chr1:31733782	T/A	cg00250761	chr1:31883323	NA	-0.32	-8.26	-0.31	8.51e-16	Alcohol dependence;
BRCA	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg04944784	chr2:26401820	FAM59B	-0.95	-16.25	-0.54	5.83e-50	Gut microbiome composition (summer);
BRCA	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg23625390	chr15:77176239	SCAPER	-0.54	-13.38	-0.47	3.74e-36	Blood metabolite levels;
BRCA	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg12395012	chr8:11607386	GATA4	-0.37	-8.5	-0.32	1.31e-16	Myopia (pathological);
BRCA	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg04546413	chr19:29218101	NA	0.68	13.89	0.48	1.64e-38	Methadone dose in opioid dependence;
BRCA	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg01884057	chr2:25150051	NA	0.34	9.22	0.34	4.21e-19	Body mass index;
BRCA	cis	rs2282802	0.711	rs1864970	chr5:139633042	T/C	cg26211634	chr5:139558579	C5orf32	0.35	8.31	0.31	5.88e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.3e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11764359	chr7:65958608	NA	-0.61	-13.38	-0.47	3.61e-36	Aortic root size;
BRCA	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg20701182	chr2:24300061	SF3B14	0.67	9.77	0.36	4.1e-21	Lymphocyte counts;
BRCA	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg11266682	chr4:10021025	SLC2A9	0.5	13.18	0.46	3.04e-35	Bone mineral density;
BRCA	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.29	8.04	0.3	4.31e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg03709012	chr19:19516395	GATAD2A	0.72	15.68	0.53	4.14e-47	Tonsillectomy;
BRCA	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg04362960	chr10:104952993	NT5C2	0.94	14.51	0.5	1.96e-41	Arsenic metabolism;
BRCA	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg12311346	chr5:56204834	C5orf35	-0.79	-16.15	-0.54	1.8e-49	Initial pursuit acceleration;
BRCA	cis	rs652260	0.819	rs55656533	chr19:7902976	G/C	cg26014689	chr19:7917955	EVI5L	-0.51	-11.65	-0.42	1.46e-28	Menarche (age at onset);
BRCA	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg20503657	chr10:835505	NA	1.04	17.35	0.57	1.6e-55	Eosinophil percentage of granulocytes;
BRCA	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg01689657	chr7:91764605	CYP51A1	0.23	8.09	0.3	2.93e-15	Breast cancer;
BRCA	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg10011062	chr15:43941034	CATSPER2	-0.53	-7.98	-0.3	6.85e-15	Lung cancer in ever smokers;
BRCA	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.2	0.46	2.35e-35	Bipolar disorder;
BRCA	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.5	10.52	0.38	5.6e-24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02475777	chr4:1388615	CRIPAK	-0.54	-10.6	-0.39	2.69e-24	Longevity;
BRCA	cis	rs8017423	0.615	rs12586761	chr14:90820897	A/G	cg04374321	chr14:90722782	PSMC1	-0.5	-11.92	-0.43	9.86e-30	Mortality in heart failure;
BRCA	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg09307838	chr4:120376055	NA	0.6	13.0	0.46	1.91e-34	Corneal astigmatism;
BRCA	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-9.26	-0.34	3.09e-19	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg07051648	chr19:49177693	NTN5;SEC1	-0.43	-8.06	-0.3	3.74e-15	Dietary macronutrient intake;
BRCA	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.36	9.49	0.35	4.68e-20	IgG glycosylation;
BRCA	cis	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-8.52	-0.32	1.17e-16	Obesity-related traits;
BRCA	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.35	-0.41	2.61e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1568889	1.000	rs7945367	chr11:28166272	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	14.88	0.51	3.26e-43	Bipolar disorder;
BRCA	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.71	-0.36	6.79e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg07169764	chr2:136633963	MCM6	1.01	21.03	0.64	5.41e-75	Corneal structure;
BRCA	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg02544614	chr20:61657117	NA	0.28	8.15	0.31	1.93e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2230307	0.656	rs568089	chr1:100495392	A/G	cg24955406	chr1:100503596	HIAT1	0.47	7.92	0.3	1.04e-14	Carotid intima media thickness;
BRCA	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg24296786	chr1:45957014	TESK2	-0.55	-13.31	-0.47	7.59e-36	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7246657	0.722	rs1975937	chr19:38091932	A/T	cg23950597	chr19:37808831	NA	-0.5	-8.57	-0.32	7.48e-17	Coronary artery calcification;
BRCA	cis	rs7043114	0.525	rs10820969	chr9:95106678	G/C	cg14631576	chr9:95140430	CENPP	-0.34	-8.38	-0.31	3.29e-16	Height;
BRCA	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg15704280	chr7:45808275	SEPT13	0.76	16.05	0.54	6.08e-49	Coronary artery disease;
BRCA	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg03342759	chr3:160939853	NMD3	-0.72	-15.7	-0.53	3.19e-47	Morning vs. evening chronotype;
BRCA	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg08601574	chr20:25228251	PYGB	-0.34	-8.18	-0.31	1.53e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03517284	chr6:25882590	NA	-0.49	-10.08	-0.37	2.78e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg00383909	chr3:49044727	WDR6	0.52	10.26	0.38	5.98e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.48	-12.5	-0.44	3.15e-32	Height;
BRCA	cis	rs6815814	0.950	rs114719937	chr4:38808585	G/C	cg02016764	chr4:38805732	TLR1	-0.6	-9.49	-0.35	4.33e-20	Breast cancer;
BRCA	trans	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg13565492	chr6:43139072	SRF	-0.78	-7.95	-0.3	8.28e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg06484146	chr7:12443880	VWDE	-0.73	-11.02	-0.4	5.45e-26	Coronary artery disease;
BRCA	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11644478	chr21:40555479	PSMG1	-0.53	-11.32	-0.41	3.27e-27	Menarche (age at onset);
BRCA	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg23229984	chr5:148520753	ABLIM3	0.35	8.77	0.33	1.66e-17	Breast cancer;
BRCA	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg26384229	chr12:38710491	ALG10B	0.69	14.85	0.51	4.42e-43	Bladder cancer;
BRCA	cis	rs11785693	0.862	rs62491171	chr8:4987177	G/A	cg26367366	chr8:4980734	NA	0.63	11.43	0.41	1.18e-27	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg22105103	chr4:187893119	NA	0.41	13.27	0.46	1.16e-35	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs495337	1.000	rs4809769	chr20:48579164	C/A	cg17835207	chr20:48524531	SPATA2	-0.58	-13.13	-0.46	4.95e-35	Psoriasis;
BRCA	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.47	10.98	0.4	8.03e-26	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg16006841	chr5:176797999	RGS14	0.59	11.75	0.42	5.33e-29	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg23358479	chr7:1110784	C7orf50	-0.47	-7.95	-0.3	8.75e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-8.17	-0.31	1.61e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg13752114	chr3:195489708	MUC4	0.52	8.56	0.32	8.65e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6582630	0.562	rs35080195	chr12:38310866	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-10.05	-0.37	3.79e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6750047	0.628	rs2855655	chr2:38304488	T/C	cg07380506	chr2:38303506	CYP1B1	0.49	11.27	0.41	5.52e-27	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs13064411	0.542	rs13082603	chr3:113223362	T/C	cg18753928	chr3:113234510	CCDC52	-0.45	-9.6	-0.35	1.8e-20	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg24747557	chr10:131355152	MGMT	-0.35	-8.08	-0.3	3.14e-15	Response to temozolomide;
BRCA	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg02659138	chr7:134003124	SLC35B4	0.34	10.47	0.38	8.85e-24	Mean platelet volume;
BRCA	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg08601574	chr20:25228251	PYGB	0.34	8.36	0.31	3.94e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Colorectal cancer;
BRCA	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg15017067	chr4:17643749	FAM184B	0.34	10.6	0.39	2.63e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12760731	0.565	rs7550699	chr1:178209584	T/G	cg00404053	chr1:178313656	RASAL2	0.65	7.86	0.3	1.68e-14	Obesity-related traits;
BRCA	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg22875332	chr1:76189707	ACADM	0.66	15.78	0.53	1.35e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs737008	1.000	rs737008	chr16:11374866	G/T	cg00044050	chr16:11439710	C16orf75	-0.36	-7.82	-0.3	2.26e-14	Obesity-related traits;
BRCA	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg13010199	chr12:38710504	ALG10B	0.56	12.22	0.44	5.11e-31	Heart rate;
BRCA	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg13010199	chr12:38710504	ALG10B	-0.39	-8.46	-0.32	1.78e-16	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg26384229	chr12:38710491	ALG10B	0.66	13.92	0.48	1.18e-38	Morning vs. evening chronotype;
BRCA	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg24558204	chr6:135376177	HBS1L	0.45	12.24	0.44	4.21e-31	Red blood cell count;
BRCA	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21659725	chr3:3221576	CRBN	0.5	11.8	0.42	3.17e-29	Resting heart rate;
BRCA	cis	rs1506403	0.685	rs10281506	chr7:142823928	C/T	cg21852589	chr7:142981689	TMEM139	0.4	7.89	0.3	1.34e-14	Cancer;
BRCA	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg01448562	chr3:133502909	NA	0.75	19.56	0.61	4.2e-67	Iron status biomarkers;
BRCA	cis	rs11605924	0.901	rs7112505	chr11:45840939	A/T	ch.11.939596F	chr11:45881766	CRY2	-0.44	-9.64	-0.36	1.31e-20	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.45	0.5	3.64e-41	Colorectal cancer;
BRCA	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg21573476	chr21:45109991	RRP1B	-0.35	-9.05	-0.34	1.67e-18	Mean corpuscular volume;
BRCA	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-11.17	-0.4	1.36e-26	Monocyte percentage of white cells;
BRCA	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg19346786	chr7:2764209	NA	-0.33	-9.86	-0.36	1.98e-21	Height;
BRCA	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg08859206	chr1:53392774	SCP2	-0.42	-8.46	-0.32	1.84e-16	Monocyte count;
BRCA	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg15595755	chr5:1867978	NA	0.35	8.34	0.31	4.67e-16	Cardiovascular disease risk factors;
BRCA	cis	rs10193935	0.901	rs10174872	chr2:42459807	T/G	cg27598129	chr2:42591480	NA	-0.97	-15.01	-0.51	7.46e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg12072164	chr19:44306565	LYPD5	0.37	8.73	0.33	2.23e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs4363385	0.693	rs582345	chr1:153033406	G/A	cg24667326	chr1:152973720	SPRR3	-0.3	-8.09	-0.3	2.91e-15	Inflammatory skin disease;
BRCA	cis	rs250677	0.522	rs4705302	chr5:148354962	G/C	cg12140854	chr5:148520817	ABLIM3	0.41	8.47	0.32	1.7e-16	Breast cancer;
BRCA	cis	rs2171564	0.537	rs9815847	chr3:112439054	G/A	cg06685282	chr3:112453648	NA	0.54	12.41	0.44	8.04e-32	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg20203395	chr5:56204925	C5orf35	0.36	7.88	0.3	1.46e-14	Type 2 diabetes;
BRCA	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg05234568	chr11:5960015	NA	-0.51	-10.15	-0.37	1.55e-22	DNA methylation (variation);
BRCA	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-9.51	-0.35	3.7e-20	Aortic root size;
BRCA	trans	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg06521331	chr12:34319734	NA	-0.45	-8.32	-0.31	5.14e-16	Bladder cancer;
BRCA	cis	rs250677	0.522	rs3763022	chr5:148381078	A/G	cg18129178	chr5:148520854	ABLIM3	-0.52	-10.4	-0.38	1.58e-23	Breast cancer;
BRCA	trans	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg06521331	chr12:34319734	NA	-0.53	-9.6	-0.36	1.81e-20	Bladder cancer;
BRCA	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg04450456	chr4:17643702	FAM184B	0.41	12.12	0.43	1.46e-30	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs16866061	1.000	rs72974219	chr2:225423784	G/C	cg12698349	chr2:225449008	CUL3	0.78	21.13	0.64	1.39e-75	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.33	-10.91	-0.4	1.51e-25	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg01620082	chr3:125678407	NA	-0.56	-7.96	-0.3	7.74e-15	Depression;
BRCA	cis	rs11051970	0.879	rs2088807	chr12:32592101	C/G	cg02745156	chr12:32552066	NA	0.27	8.85	0.33	8.74e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-9.73	-0.36	5.71e-21	IgG glycosylation;
BRCA	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.23e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg18129178	chr5:148520854	ABLIM3	-0.57	-11.68	-0.42	1.01e-28	Breast cancer;
BRCA	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg22713356	chr15:30763199	NA	1.35	27.49	0.74	2.08e-110	Uric acid levels;
BRCA	cis	rs4900538	0.927	rs1190544	chr14:102903398	G/A	cg18135206	chr14:102964638	TECPR2	-1.06	-29.85	-0.76	3.05e-123	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.81	0.36	2.99e-21	Morning vs. evening chronotype;
BRCA	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg19318889	chr4:1322082	MAEA	0.34	8.05	0.3	4.1e-15	Longevity;
BRCA	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg05343316	chr1:45956843	TESK2	0.62	12.54	0.44	2.15e-32	Platelet count;
BRCA	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg27446573	chr6:127587934	RNF146	0.69	15.09	0.51	3.27e-44	Breast cancer;
BRCA	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg05775895	chr3:12838266	CAND2	0.35	7.84	0.3	1.84e-14	QRS complex (12-leadsum);
BRCA	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg10224037	chr5:178157518	ZNF354A	0.79	18.04	0.58	4.01e-59	Neutrophil percentage of white cells;
BRCA	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.68e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg18357645	chr12:58087776	OS9	0.48	13.8	0.48	4.19e-38	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg26384229	chr12:38710491	ALG10B	0.75	16.93	0.56	2.16e-53	Bladder cancer;
BRCA	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg24675658	chr1:53192096	ZYG11B	0.83	18.84	0.6	2.53e-63	Monocyte count;
BRCA	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.37	0.38	2.08e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6894249	0.874	rs11745587	chr5:131796922	A/G	cg02551604	chr5:131831745	NA	0.24	8.61	0.32	5.57e-17	Asthma;
BRCA	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg13397359	chr6:42928475	GNMT	0.68	16.24	0.54	6.67e-50	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg16325326	chr1:53192061	ZYG11B	0.9	24.98	0.7	1.36e-96	Monocyte count;
BRCA	cis	rs7833986	0.501	rs2976036	chr8:57031721	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	12.88	0.45	6.83e-34	Height;
BRCA	cis	rs1371614	0.566	rs11695406	chr2:27178129	A/G	cg00617064	chr2:27272375	NA	0.3	7.86	0.3	1.67e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg21427119	chr20:30132790	HM13	-0.41	-8.78	-0.33	1.53e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs6752107	0.935	rs11690131	chr2:234148383	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	10.65	0.39	1.74e-24	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg12311346	chr5:56204834	C5orf35	-0.8	-15.65	-0.53	5.83e-47	Initial pursuit acceleration;
BRCA	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg12011299	chr4:100065546	ADH4	0.41	11.04	0.4	4.6e-26	Alcohol dependence;
BRCA	cis	rs10189230	0.967	rs13012331	chr2:222350600	G/A	cg14652038	chr2:222343519	EPHA4	0.48	13.26	0.46	1.28e-35	Urate levels in lean individuals;
BRCA	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg00631329	chr6:26305371	NA	-0.34	-9.73	-0.36	5.83e-21	Educational attainment;
BRCA	cis	rs7131987	0.621	rs3782506	chr12:29445422	A/C	cg09582351	chr12:29534625	ERGIC2	0.46	10.97	0.4	9.15e-26	QT interval;
BRCA	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg08917208	chr2:24149416	ATAD2B	0.52	8.2	0.31	1.3e-15	Asthma;
BRCA	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg05340658	chr4:99064831	C4orf37	-0.48	-11.14	-0.4	1.9e-26	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	8.39	0.32	3.06e-16	Personality dimensions;
BRCA	trans	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg13565492	chr6:43139072	SRF	-0.84	-11.44	-0.41	1.02e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	14.45	0.5	3.6700000000000003e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs78707713	0.841	rs7475662	chr10:71210744	G/C	cg12610070	chr10:71211762	TSPAN15	-0.32	-8.18	-0.31	1.54e-15	Venous thromboembolism;
BRCA	trans	rs4714291	0.963	rs847759	chr6:40024483	G/A	cg02267698	chr19:7991119	CTXN1	0.42	8.08	0.3	3.26e-15	Strep throat;
BRCA	cis	rs17092148	0.887	rs6058104	chr20:33271052	G/A	cg16810054	chr20:33298113	TP53INP2	-0.5	-10.66	-0.39	1.5e-24	Neuroticism;
BRCA	cis	rs10411936	0.712	rs8103486	chr19:16603107	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.46	9.44	0.35	6.69e-20	White blood cell count;Multiple sclerosis;
BRCA	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg08000102	chr2:233561755	GIGYF2	-0.46	-9.97	-0.37	7.41e-22	Coronary artery disease;
BRCA	cis	rs16976116	0.901	rs28630909	chr15:55500102	G/A	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg17366294	chr4:99064904	C4orf37	0.45	10.6	0.39	2.78e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg06618935	chr21:46677482	NA	-0.37	-7.99	-0.3	6.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	13.92	0.48	1.2e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11690256	0.798	rs11678720	chr2:129542628	C/T	cg16353174	chr2:129543148	NA	-0.39	-7.98	-0.3	6.85e-15	Symmetrical dimethylarginine levels;
BRCA	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg18230493	chr5:56204884	C5orf35	-0.73	-14.78	-0.5	9.97e-43	Initial pursuit acceleration;
BRCA	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg00074818	chr8:8560427	CLDN23	0.36	7.85	0.3	1.78e-14	Obesity-related traits;
BRCA	cis	rs12354486	1	rs12354486	chr10:104124055	C/G	cg15320455	chr10:103880129	LDB1	0.5	8.03	0.3	4.73e-15	Educational attainment (college completion);
BRCA	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg26248373	chr2:1572462	NA	-0.47	-9.18	-0.34	5.84e-19	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg08822215	chr16:89438651	ANKRD11	0.53	11.95	0.43	7.36e-30	Multiple myeloma (IgH translocation);
BRCA	cis	rs2016266	0.855	rs4759086	chr12:53666713	A/G	cg26875137	chr12:53738046	NA	0.37	9.38	0.35	1.15e-19	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs6893300	0.785	rs6887507	chr5:179186237	A/G	cg14593053	chr5:179126677	CANX	-0.35	-7.84	-0.3	1.92e-14	Resting heart rate;
BRCA	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg21427119	chr20:30132790	HM13	-0.41	-8.75	-0.33	1.93e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11764359	chr7:65958608	NA	-0.76	-17.54	-0.57	1.61e-56	Aortic root size;
BRCA	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.67	-11.4	-0.41	1.52e-27	Resting heart rate;
BRCA	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg11645453	chr3:52864694	ITIH4	-0.37	-9.67	-0.36	9.43e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-10.7	-0.39	1.12e-24	Mean corpuscular volume;
BRCA	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg12432903	chr7:1882776	MAD1L1	-0.44	-7.87	-0.3	1.47e-14	Bipolar disorder;
BRCA	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-12.16	-0.43	9.59e-31	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1577917	0.958	rs16876530	chr6:86595641	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-10.97	-0.4	9.25e-26	Response to antipsychotic treatment;
BRCA	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-12.81	-0.45	1.32e-33	Bipolar disorder;
BRCA	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg24692254	chr21:30365293	RNF160	-0.66	-17.9	-0.58	2.24e-58	Dental caries;
BRCA	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg13010199	chr12:38710504	ALG10B	0.49	9.56	0.35	2.42e-20	Morning vs. evening chronotype;
BRCA	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg08213375	chr14:104286397	PPP1R13B	0.64	18.27	0.59	2.57e-60	Schizophrenia;
BRCA	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg01444801	chr10:135216882	MTG1	-0.5	-11.03	-0.4	5.2e-26	Systemic lupus erythematosus;
BRCA	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg01256987	chr12:42539512	GXYLT1	-0.68	-16.52	-0.55	2.71e-51	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg13385521	chr17:29058706	SUZ12P	0.62	8.49	0.32	1.49e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs11608355	0.545	rs11613021	chr12:109897998	T/G	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg03433033	chr1:76189801	ACADM	0.66	14.04	0.49	3.19e-39	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg15704280	chr7:45808275	SEPT13	0.74	15.67	0.53	4.33e-47	Coronary artery disease;
BRCA	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg26384229	chr12:38710491	ALG10B	0.42	9.35	0.35	1.48e-19	Morning vs. evening chronotype;
BRCA	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg25482853	chr8:67687455	SGK3	1.05	17.55	0.57	1.44e-56	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg05347473	chr6:146136440	FBXO30	-0.4	-7.84	-0.3	1.83e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg08601574	chr20:25228251	PYGB	0.33	8.2	0.31	1.3e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg17366294	chr4:99064904	C4orf37	0.43	10.28	0.38	4.81e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	29.89	0.76	1.85e-123	Chronic sinus infection;
BRCA	trans	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg06521331	chr12:34319734	NA	-0.54	-10.34	-0.38	2.7e-23	Bladder cancer;
BRCA	cis	rs4900538	0.855	rs762105	chr14:102830175	A/G	cg18135206	chr14:102964638	TECPR2	-0.93	-21.79	-0.65	3.76e-79	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg24069376	chr3:38537580	EXOG	0.33	9.19	0.34	5.34e-19	Electrocardiographic conduction measures;
BRCA	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg23055938	chr1:160991191	F11R	-0.48	-9.46	-0.35	5.58e-20	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg10876282	chr6:28092338	ZSCAN16	0.41	8.0	0.3	5.69e-15	Parkinson's disease;
BRCA	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12756686	chr19:29218302	NA	0.57	10.9	0.4	1.77e-25	Methadone dose in opioid dependence;
BRCA	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	16.63	0.55	7.51e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-18.07	-0.58	3e-59	Chronic sinus infection;
BRCA	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.72	11.67	0.42	1.18e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg12373951	chr3:133503437	NA	0.45	10.3	0.38	3.96e-23	Iron status biomarkers;
BRCA	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg00666640	chr1:248458726	OR2T12	0.29	8.08	0.3	3.13e-15	Common traits (Other);
BRCA	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	28.21	0.74	2.43e-114	Chronic sinus infection;
BRCA	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.51	-11.82	-0.42	2.8e-29	Longevity;Endometriosis;
BRCA	cis	rs9487051	0.768	rs9480910	chr6:109521707	T/C	cg21918786	chr6:109611834	NA	-0.35	-9.24	-0.34	3.73e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg17509989	chr5:176798049	RGS14	0.63	12.59	0.45	1.22e-32	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg22920501	chr2:26401640	FAM59B	-0.79	-14.85	-0.51	4.6e-43	Gut microbiome composition (summer);
BRCA	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	8.2	0.31	1.28e-15	Menarche (age at onset);
BRCA	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg04944784	chr2:26401820	FAM59B	0.82	11.21	0.41	9.44e-27	Gut microbiome composition (summer);
BRCA	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.22	0.31	1.17e-15	Tonsillectomy;
BRCA	cis	rs754466	0.580	rs2579178	chr10:79529215	A/G	cg17075019	chr10:79541650	NA	0.79	19.16	0.6	5.51e-65	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg05234568	chr11:5960015	NA	-0.49	-9.69	-0.36	7.99e-21	DNA methylation (variation);
BRCA	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg05347473	chr6:146136440	FBXO30	-0.4	-7.85	-0.3	1.74e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg01579765	chr21:45077557	HSF2BP	0.38	10.14	0.37	1.6e-22	Mean corpuscular volume;
BRCA	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.83	-0.58	5.25e-58	Chronic sinus infection;
BRCA	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.52	9.91	0.36	1.25e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg04727924	chr7:799746	HEATR2	-0.54	-9.82	-0.36	2.62e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.75	-0.55	1.78e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg06784218	chr1:46089804	CCDC17	0.45	10.79	0.39	4.89e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg23992470	chr4:843637	GAK	0.55	8.19	0.31	1.42e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg04025307	chr7:1156635	C7orf50	0.77	20.22	0.62	1.22e-70	Longevity;Endometriosis;
BRCA	trans	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg06521331	chr12:34319734	NA	-0.45	-8.44	-0.32	2.06e-16	Bladder cancer;
BRCA	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.3e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg18811423	chr2:55921094	PNPT1	0.7	22.16	0.66	3.94e-81	Metabolic syndrome;
BRCA	cis	rs2882667	0.931	rs12719518	chr5:138340976	T/C	cg04439458	chr5:138467593	SIL1	-0.33	-9.03	-0.34	2.08e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg03526776	chr6:41159608	TREML2	0.39	8.31	0.31	5.79e-16	Alzheimer's disease (late onset);
BRCA	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.42	-8.1	-0.31	2.8e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg08807101	chr21:30365312	RNF160	-0.44	-9.33	-0.35	1.66e-19	Dental caries;
BRCA	cis	rs3761847	0.500	rs10760132	chr9:123739993	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	8.56	0.32	8.35e-17	Rheumatoid arthritis;
BRCA	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg04155289	chr7:94953770	PON1	0.4	7.82	0.3	2.2e-14	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs701145	0.556	rs355763	chr3:154012881	C/T	cg12800244	chr3:153838788	SGEF	0.44	8.97	0.33	3.33e-18	Coronary artery disease;
BRCA	cis	rs9324022	0.929	rs9635184	chr14:101173056	C/T	cg18089426	chr14:101175970	NA	0.68	12.91	0.45	4.54e-34	Plateletcrit;
BRCA	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.91	0.37	1.2e-21	Bladder cancer;
BRCA	cis	rs208520	1.000	rs208529	chr6:66957549	T/C	cg07460842	chr6:66804631	NA	-0.79	-13.3	-0.47	8.34e-36	Exhaled nitric oxide output;
BRCA	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg24812749	chr6:127587940	RNF146	0.89	20.97	0.64	1.08e-74	Breast cancer;
BRCA	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.31	0.49	1.63e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg07148914	chr20:33460835	GGT7	-0.37	-7.99	-0.3	6.25e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs2882667	0.628	rs3749663	chr5:138271187	A/T	cg04439458	chr5:138467593	SIL1	-0.32	-8.04	-0.3	4.26e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.98	0.37	6.69e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.49	-0.32	1.45e-16	Bipolar disorder;
BRCA	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg12011299	chr4:100065546	ADH4	0.48	10.94	0.4	1.22e-25	Smoking initiation;
BRCA	cis	rs9309711	0.698	rs9750503	chr2:3491772	A/G	cg16153549	chr2:3496821	NA	0.44	10.05	0.37	3.6e-22	Neurofibrillary tangles;
BRCA	cis	rs10857712	0.687	rs11101742	chr10:135224372	C/G	cg00491522	chr10:135256596	NA	0.44	9.24	0.34	3.66e-19	Systemic lupus erythematosus;
BRCA	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg01181863	chr3:195395398	SDHAP2	-0.46	-8.2	-0.31	1.36e-15	Pancreatic cancer;
BRCA	trans	rs11165623	0.564	rs6669908	chr1:96998261	G/A	cg10631902	chr5:14652156	NA	-0.43	-12.14	-0.43	1.11e-30	Hip circumference;Waist circumference;
BRCA	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg09307838	chr4:120376055	NA	0.76	17.1	0.56	2.9e-54	Corneal astigmatism;
BRCA	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.92	-0.3	1.08e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg08888203	chr3:10149979	C3orf24	0.58	11.86	0.42	1.8e-29	Alzheimer's disease;
BRCA	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg12016809	chr21:47604291	C21orf56	0.4	8.38	0.31	3.37e-16	Testicular germ cell tumor;
BRCA	cis	rs9469578	1.000	rs6923565	chr6:33707112	G/A	cg18708504	chr6:33715942	IP6K3	0.72	10.42	0.38	1.43e-23	Phosphorus levels;
BRCA	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg16576597	chr16:28551801	NUPR1	0.28	7.98	0.3	6.98e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.73	0.36	5.76e-21	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.54	0.57	1.68e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2336384	1.000	rs2878677	chr1:12053264	C/T	cg13216073	chr1:12042593	MFN2	-0.41	-9.15	-0.34	7.58e-19	Platelet count;
BRCA	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.69	-0.33	3.04e-17	Breast cancer;
BRCA	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg23711669	chr6:146136114	FBXO30	0.74	16.73	0.55	2.23e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg22920501	chr2:26401640	FAM59B	-0.67	-11.5	-0.41	5.96e-28	Gut microbiome composition (summer);
BRCA	cis	rs17092148	1.000	rs910872	chr20:33334540	T/C	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.31	-0.41	3.74e-27	Neuroticism;
BRCA	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.03	0.58	4.79e-59	Fuchs's corneal dystrophy;
BRCA	trans	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg13565492	chr6:43139072	SRF	-0.79	-10.84	-0.39	2.99e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg03929089	chr4:120376271	NA	0.71	14.75	0.5	1.37e-42	Coronary artery disease;
BRCA	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg05901451	chr6:126070800	HEY2	-0.51	-12.57	-0.45	1.62e-32	High light scatter reticulocyte count;
BRCA	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg03733263	chr8:22462867	KIAA1967	0.88	18.96	0.6	6.32e-64	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-7.85	-0.3	1.8e-14	Colorectal cancer;
BRCA	cis	rs490234	1.000	rs490234	chr9:128303734	T/C	cg14078157	chr9:128172775	NA	0.33	7.89	0.3	1.3e-14	Mean arterial pressure;
BRCA	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	9.48	0.35	4.78e-20	Aortic root size;
BRCA	cis	rs858239	0.600	rs2072368	chr7:23146112	C/T	cg23682824	chr7:23144976	KLHL7	0.42	11.18	0.4	1.22e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg18230493	chr5:56204884	C5orf35	-0.74	-14.04	-0.49	3.24e-39	Initial pursuit acceleration;
BRCA	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg16325326	chr1:53192061	ZYG11B	-0.71	-18.64	-0.59	3.1e-62	Monocyte count;
BRCA	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg20701182	chr2:24300061	SF3B14	-0.71	-13.09	-0.46	7.06e-35	Lymphocyte counts;
BRCA	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	11.56	0.42	3.29e-28	Bipolar disorder;
BRCA	cis	rs9811920	0.732	rs793446	chr3:99578114	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.54	-13.17	-0.46	3.37e-35	Axial length;
BRCA	trans	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-10.39	-0.38	1.86e-23	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg25036284	chr2:26402008	FAM59B	0.9	14.79	0.5	9.2e-43	Gut microbiome composition (summer);
BRCA	cis	rs273218	0.951	rs428213	chr5:53382790	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.39	-8.2	-0.31	1.34e-15	Migraine;
BRCA	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg22535103	chr8:58192502	C8orf71	-0.46	-9.06	-0.34	1.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg01528321	chr10:82214614	TSPAN14	0.65	14.07	0.49	2.21e-39	Post bronchodilator FEV1;
BRCA	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg18154014	chr19:37997991	ZNF793	0.62	11.59	0.42	2.63e-28	Coronary artery calcification;
BRCA	cis	rs57590327	0.508	rs13093082	chr3:81949958	C/T	cg07356753	chr3:81810745	GBE1	-0.36	-8.46	-0.32	1.8e-16	Extraversion;
BRCA	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg18811423	chr2:55921094	PNPT1	0.79	27.76	0.74	7.39e-112	Metabolic syndrome;
BRCA	cis	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05901451	chr6:126070800	HEY2	0.42	10.04	0.37	4.01e-22	Endometrial cancer;
BRCA	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg08885076	chr2:99613938	TSGA10	-0.53	-9.59	-0.35	1.95e-20	Chronic sinus infection;
BRCA	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg05868516	chr6:26286170	HIST1H4H	0.5	11.25	0.41	6.6e-27	Educational attainment;
BRCA	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg18357645	chr12:58087776	OS9	0.47	13.47	0.47	1.45e-36	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7903847	0.642	rs61863819	chr10:99142400	T/C	cg20016023	chr10:99160130	RRP12	-0.26	-8.01	-0.3	5.35e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg26384229	chr12:38710491	ALG10B	0.77	17.67	0.57	3.37e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg13319975	chr6:146136371	FBXO30	-0.39	-8.9	-0.33	5.92e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4919694	1.000	rs78214351	chr10:104822688	A/G	cg04362960	chr10:104952993	NT5C2	0.94	14.59	0.5	8.2e-42	Arsenic metabolism;
BRCA	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg07741184	chr6:167504864	NA	0.36	10.48	0.38	7.88e-24	Rheumatoid arthritis;
BRCA	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg18154014	chr19:37997991	ZNF793	0.53	10.14	0.37	1.74e-22	Coronary artery calcification;
BRCA	cis	rs7072216	0.770	rs1061115	chr10:100177049	G/A	cg26618903	chr10:100175079	PYROXD2	-0.27	-8.19	-0.31	1.38e-15	Metabolite levels;
BRCA	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg26384229	chr12:38710491	ALG10B	0.74	17.21	0.56	7.75e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg25817165	chr18:72167213	CNDP2	-0.73	-14.46	-0.5	3.2e-41	Refractive error;
BRCA	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg05347473	chr6:146136440	FBXO30	0.42	8.34	0.31	4.63e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6060717	0.536	rs11167279	chr20:34509107	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.1	-0.31	2.73e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs10501293	0.912	rs4755694	chr11:43088582	A/G	cg03447554	chr11:43094025	NA	-0.48	-8.95	-0.33	3.95e-18	Cognitive performance;
BRCA	trans	rs75804782	0.521	rs56087929	chr2:239455564	G/A	cg01134436	chr17:81009848	B3GNTL1	0.63	8.36	0.31	3.83e-16	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg12310025	chr6:25882481	NA	-0.56	-14.03	-0.49	3.6e-39	Blood metabolite levels;
BRCA	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg02079420	chr8:82753780	SNX16	0.31	8.38	0.31	3.42e-16	Diastolic blood pressure;
BRCA	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg09998033	chr7:158218633	PTPRN2	-0.33	-7.81	-0.3	2.42e-14	Obesity-related traits;
BRCA	cis	rs6594713	0.642	rs13169748	chr5:112848999	C/T	cg12552261	chr5:112820674	MCC	0.49	7.81	0.3	2.34e-14	Brain cytoarchitecture;
BRCA	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg23533926	chr12:111358616	MYL2	-0.41	-8.49	-0.32	1.4e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg09184832	chr6:79620586	NA	-0.52	-11.42	-0.41	1.3e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11644478	chr21:40555479	PSMG1	0.84	19.14	0.6	6.9e-65	Cognitive function;
BRCA	cis	rs698833	0.848	rs696596	chr2:44718058	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	9.29	0.35	2.35e-19	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg22800045	chr5:56110881	MAP3K1	-0.46	-9.11	-0.34	1.03e-18	Initial pursuit acceleration;
BRCA	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg07636037	chr3:49044803	WDR6	0.95	27.61	0.74	4.77e-111	Parkinson's disease;
BRCA	cis	rs2882667	0.690	rs6596453	chr5:138151891	T/G	cg04439458	chr5:138467593	SIL1	0.35	8.47	0.32	1.63e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.75	-0.55	1.78e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs849141	0.857	rs1708299	chr7:28189946	A/G	cg22892036	chr7:28189139	JAZF1	0.47	8.31	0.31	5.81e-16	Height;Hip circumference adjusted for BMI;
BRCA	cis	rs332507	0.830	rs3772781	chr3:124387439	G/T	cg05980111	chr3:124395277	KALRN	0.37	8.58	0.32	7.31e-17	Plateletcrit;
BRCA	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg02297831	chr4:17616191	MED28	0.36	7.88	0.3	1.43e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg23055938	chr1:160991191	F11R	-0.55	-10.77	-0.39	5.5e-25	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7715811	1.000	rs10050673	chr5:13761643	G/A	cg07548982	chr5:13769939	DNAH5	-0.38	-8.33	-0.31	4.98e-16	Subclinical atherosclerosis traits (other);
BRCA	cis	rs10504073	0.584	rs115370638	chr8:49916452	A/G	cg00325661	chr8:49890786	NA	0.52	15.26	0.52	4.62e-45	Blood metabolite ratios;
BRCA	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	15.23	0.52	6.88e-45	Colorectal cancer;
BRCA	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg18876405	chr7:65276391	NA	0.58	13.95	0.48	8.13e-39	Aortic root size;
BRCA	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.46	9.68	0.36	9.34e-21	HDL cholesterol;
BRCA	cis	rs67460515	0.665	rs28384382	chr3:160939141	C/T	cg17135325	chr3:160939158	NMD3	0.47	9.1	0.34	1.12e-18	Parkinson's disease;
BRCA	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11890956	chr21:40555474	PSMG1	1.05	29.75	0.76	9.7e-123	Cognitive function;
BRCA	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg12311346	chr5:56204834	C5orf35	-0.78	-15.9	-0.53	3.47e-48	Initial pursuit acceleration;
BRCA	cis	rs7246657	0.722	rs4802029	chr19:38055612	A/T	cg23950597	chr19:37808831	NA	-0.5	-8.62	-0.32	5.36e-17	Coronary artery calcification;
BRCA	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg21385522	chr1:16154831	NA	-0.57	-13.26	-0.46	1.24e-35	Dilated cardiomyopathy;
BRCA	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg23358479	chr7:1110784	C7orf50	-0.47	-7.99	-0.3	6.1e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg21573476	chr21:45109991	RRP1B	-0.44	-10.84	-0.39	3.01e-25	Mean corpuscular volume;
BRCA	cis	rs11997175	0.603	rs66828270	chr8:33790155	C/G	ch.8.33884649F	chr8:33765107	NA	0.39	9.19	0.34	5.39e-19	Body mass index;
BRCA	cis	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg04990556	chr1:26633338	UBXN11	0.56	9.15	0.34	7.48e-19	Obesity-related traits;
BRCA	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	13.82	0.48	3.53e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg04691961	chr3:161091175	C3orf57	-0.5	-12.55	-0.44	1.92e-32	Morning vs. evening chronotype;
BRCA	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24531977	chr5:56204891	C5orf35	-0.86	-17.48	-0.57	3.46e-56	Initial pursuit acceleration;
BRCA	cis	rs12367572	0.930	rs11615964	chr12:45261564	C/T	cg04608330	chr12:45269318	NELL2	-0.63	-13.33	-0.47	5.95e-36	Gut microbiome composition (summer);
BRCA	cis	rs9400271	0.632	rs9386784	chr6:109591208	C/A	cg01475377	chr6:109611718	NA	-0.44	-10.4	-0.38	1.7e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	11.68	0.42	1.06e-28	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9287719	0.601	rs759401	chr2:10709922	G/A	cg00105475	chr2:10696890	NA	0.47	10.33	0.38	3.19e-23	Prostate cancer;
BRCA	cis	rs7092929	0.941	rs835325	chr10:3571175	A/G	cg14308648	chr10:3568949	NA	0.44	8.12	0.31	2.44e-15	Coronary artery calcification;
BRCA	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	16.32	0.54	2.48e-50	Lymphocyte counts;
BRCA	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg06623918	chr6:96969491	KIAA0776	0.89	25.59	0.71	5.41e-100	Headache;
BRCA	cis	rs11971779	0.625	rs2355784	chr7:139072493	G/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs7851660	0.933	rs1867277	chr9:100615914	A/G	cg13688889	chr9:100608707	NA	-0.36	-8.72	-0.33	2.42e-17	Strep throat;
BRCA	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg07952391	chr2:88470173	THNSL2	0.66	9.05	0.34	1.64e-18	Plasma clusterin levels;
BRCA	cis	rs1003719	0.680	rs2835664	chr21:38573429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.73	-0.5	1.77e-42	Eye color traits;
BRCA	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.19e-40	Motion sickness;
BRCA	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg05623727	chr3:50126028	RBM5	-0.43	-10.34	-0.38	2.76e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs67981189	0.788	rs2526860	chr14:71411878	T/C	cg15816911	chr14:71606274	NA	-0.37	-8.18	-0.31	1.52e-15	Schizophrenia;
BRCA	cis	rs919433	0.679	rs67492914	chr2:198523402	T/G	cg00792783	chr2:198669748	PLCL1	0.39	9.02	0.34	2.24e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18876405	chr7:65276391	NA	-0.49	-11.0	-0.4	6.6900000000000006e-26	Aortic root size;
BRCA	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg25237894	chr2:233734115	C2orf82	0.39	11.36	0.41	2.26e-27	Coronary artery disease;
BRCA	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg26408565	chr15:76604113	ETFA	-0.36	-8.0	-0.3	5.91e-15	Blood metabolite levels;
BRCA	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg10876282	chr6:28092338	ZSCAN16	0.42	8.15	0.31	1.86e-15	Cardiac Troponin-T levels;
BRCA	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-8.34	-0.31	4.6e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	trans	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg25214090	chr10:38739885	LOC399744	0.45	10.64	0.39	1.93e-24	Corneal astigmatism;
BRCA	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg24642439	chr20:33292090	TP53INP2	0.71	16.27	0.54	4.9e-50	Coronary artery disease;
BRCA	trans	rs61931739	0.963	rs12310956	chr12:33970682	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-8.85	-0.33	8.87e-18	Morning vs. evening chronotype;
BRCA	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg06784218	chr1:46089804	CCDC17	0.47	11.39	0.41	1.69e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg04450456	chr4:17643702	FAM184B	0.32	9.33	0.35	1.7e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	19.18	0.6	4.26e-65	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg07741184	chr6:167504864	NA	0.33	9.8	0.36	3.32e-21	Primary biliary cholangitis;
BRCA	cis	rs10463316	0.894	rs7723379	chr5:150765025	T/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.37	-0.31	3.51e-16	Metabolite levels (Pyroglutamine);
BRCA	trans	rs8073060	0.586	rs225300	chr17:33922428	C/T	cg19694781	chr19:47549865	TMEM160	-1.01	-21.06	-0.64	3.73e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.93	0.33	4.64e-18	Tonsillectomy;
BRCA	cis	rs1003719	0.762	rs1015551	chr21:38449510	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.25	0.49	3.29e-40	Eye color traits;
BRCA	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg05283184	chr6:79620031	NA	-0.41	-10.51	-0.38	6.1e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg00277334	chr10:82204260	NA	-0.42	-8.23	-0.31	1.04e-15	Post bronchodilator FEV1;
BRCA	trans	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg19694781	chr19:47549865	TMEM160	-1.04	-21.89	-0.65	1.12e-79	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg17063962	chr7:91808500	NA	0.52	12.33	0.44	1.69e-31	Breast cancer;
BRCA	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg12564285	chr5:131593104	PDLIM4	0.36	8.06	0.3	3.75e-15	Breast cancer;
BRCA	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg06784218	chr1:46089804	CCDC17	-0.45	-10.84	-0.39	2.92e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg05347473	chr6:146136440	FBXO30	0.43	8.55	0.32	8.98e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1003719	0.680	rs2835629	chr21:38521660	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.43	-0.5	4.76e-41	Eye color traits;
BRCA	cis	rs7572733	0.534	rs700672	chr2:198691455	G/A	cg00792783	chr2:198669748	PLCL1	0.47	10.2	0.37	1.01e-22	Dermatomyositis;
BRCA	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg12311346	chr5:56204834	C5orf35	-0.81	-16.16	-0.54	1.65e-49	Initial pursuit acceleration;
BRCA	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11890956	chr21:40555474	PSMG1	-0.6	-13.36	-0.47	4.47e-36	Menarche (age at onset);
BRCA	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg04025307	chr7:1156635	C7orf50	0.56	13.27	0.46	1.17e-35	Longevity;Endometriosis;
BRCA	cis	rs11229555	0.645	rs12786744	chr11:58177549	T/C	cg15696309	chr11:58395628	NA	-0.52	-10.78	-0.39	5.3e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg17691542	chr6:26056736	HIST1H1C	0.5	10.55	0.39	4.14e-24	Height;
BRCA	cis	rs2882667	1.000	rs2882667	chr5:138314106	C/T	cg04439458	chr5:138467593	SIL1	-0.39	-10.32	-0.38	3.33e-23	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11890956	chr21:40555474	PSMG1	1.03	27.91	0.74	1.1e-112	Cognitive function;
BRCA	trans	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg25214090	chr10:38739885	LOC399744	-0.44	-10.17	-0.37	1.31e-22	Corneal astigmatism;
BRCA	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg12310025	chr6:25882481	NA	-0.42	-10.26	-0.38	5.99e-23	Height;
BRCA	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg16325326	chr1:53192061	ZYG11B	0.91	25.09	0.7	3.34e-97	Monocyte count;
BRCA	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg14683738	chr19:37701593	ZNF585B	0.48	8.3	0.31	6.07e-16	Coronary artery calcification;
BRCA	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg15549821	chr19:49342101	PLEKHA4	-1.06	-16.65	-0.55	5.51e-52	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg14019146	chr3:50243930	SLC38A3	-0.56	-11.77	-0.42	4.4e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07636037	chr3:49044803	WDR6	0.73	15.85	0.53	5.73e-48	Menarche (age at onset);
BRCA	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg27398817	chr8:82754497	SNX16	-0.36	-8.17	-0.31	1.68e-15	Diastolic blood pressure;
BRCA	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg17063962	chr7:91808500	NA	0.58	13.72	0.48	9.56e-38	Breast cancer;
BRCA	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg07700843	chr1:2391317	NA	-0.5	-11.59	-0.42	2.42e-28	Schizophrenia;
BRCA	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg15212455	chr7:39170539	POU6F2	0.36	7.85	0.3	1.8e-14	IgG glycosylation;
BRCA	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.84	-0.33	9.56e-18	Total body bone mineral density;
BRCA	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26119090	chr2:26468346	HADHA;HADHB	0.75	11.82	0.42	2.63e-29	Gut microbiome composition (summer);
BRCA	cis	rs877282	1.000	rs12779159	chr10:772143	T/C	cg17470449	chr10:769945	NA	0.5	8.91	0.33	5.45e-18	Uric acid levels;
BRCA	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg08885076	chr2:99613938	TSGA10	-0.59	-13.17	-0.46	3.23e-35	Chronic sinus infection;
BRCA	cis	rs7617773	0.778	rs11715776	chr3:48377611	G/C	cg11946769	chr3:48343235	NME6	0.67	13.46	0.47	1.62e-36	Coronary artery disease;
BRCA	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg18196295	chr10:418757	DIP2C	0.49	11.84	0.42	2.21e-29	Psychosis in Alzheimer's disease;
BRCA	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg02659138	chr7:134003124	SLC35B4	0.37	11.63	0.42	1.73e-28	Mean platelet volume;
BRCA	cis	rs41005	1.000	rs193932	chr2:8107383	C/T	cg03155496	chr2:8117019	LOC339788	-0.55	-14.66	-0.5	3.81e-42	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs13046373	0.535	rs7281767	chr21:32022062	T/C	cg14062083	chr21:31802829	KRTAP13-4	0.34	9.46	0.35	5.95e-20	HDL cholesterol;
BRCA	cis	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg06521331	chr12:34319734	NA	-0.51	-10.12	-0.37	1.98e-22	Morning vs. evening chronotype;
BRCA	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00802000	chr16:706648	WDR90	-0.4	-9.4	-0.35	9.77e-20	Height;
BRCA	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg24675658	chr1:53192096	ZYG11B	0.55	12.59	0.45	1.31e-32	Monocyte count;
BRCA	cis	rs11051970	0.918	rs325417	chr12:32574217	A/G	cg02745156	chr12:32552066	NA	0.28	9.01	0.34	2.4e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.72	11.84	0.42	2.3e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4671400	0.543	rs2290324	chr2:61448776	A/C	cg15711740	chr2:61764176	XPO1	0.44	8.79	0.33	1.41e-17	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs700651	0.789	rs116165148	chr2:198888347	T/G	cg00792783	chr2:198669748	PLCL1	0.38	8.74	0.33	2.06e-17	Intracranial aneurysm;
BRCA	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21659725	chr3:3221576	CRBN	-0.47	-11.88	-0.43	1.57e-29	Intelligence (multi-trait analysis);
BRCA	trans	rs66887589	0.967	rs1480933	chr4:120433248	C/T	cg25214090	chr10:38739885	LOC399744	0.36	8.1	0.31	2.72e-15	Diastolic blood pressure;
BRCA	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg16606324	chr3:10149918	C3orf24	0.57	11.38	0.41	1.87e-27	Alzheimer's disease;
BRCA	cis	rs9337951	0.596	rs3739998	chr10:30316072	C/G	cg12786570	chr10:30316432	KIAA1462	0.37	7.89	0.3	1.29e-14	Pulse pressure;Coronary artery disease;
BRCA	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-19.58	-0.61	3.29e-67	Systemic lupus erythematosus;
BRCA	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg20607287	chr7:12443886	VWDE	-0.58	-8.32	-0.31	5.31e-16	Coronary artery disease;
BRCA	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.28e-23	Prostate cancer;
BRCA	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg05863683	chr7:1912471	MAD1L1	0.38	8.21	0.31	1.22e-15	Schizophrenia;
BRCA	trans	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg25482853	chr8:67687455	SGK3	0.75	13.43	0.47	2.05e-36	Obesity-related traits;
BRCA	cis	rs3768617	0.811	rs6424883	chr1:183037695	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.46	9.94	0.37	9.49e-22	Fuchs's corneal dystrophy;
BRCA	cis	rs11955398	0.585	rs2085409	chr5:60021183	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.38	-9.13	-0.34	8.56e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24110177	chr3:50126178	RBM5	-0.37	-9.81	-0.36	2.96e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg21775007	chr8:11205619	TDH	-0.47	-9.36	-0.35	1.32e-19	Retinal vascular caliber;
BRCA	cis	rs870825	0.581	rs28602720	chr4:185630598	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	17.14	0.56	1.9e-54	Blood protein levels;
BRCA	cis	rs1468333	0.897	rs2269957	chr5:137501396	A/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.43	8.99	0.34	2.77e-18	Resting heart rate;
BRCA	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-16.9	-0.56	3.03e-53	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg16606324	chr3:10149918	C3orf24	0.56	11.01	0.4	5.91e-26	Alzheimer's disease;
BRCA	cis	rs1018836	1.000	rs1018836	chr8:91570362	A/G	cg16814680	chr8:91681699	NA	-0.57	-12.35	-0.44	1.47e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg23033748	chr14:75592666	NEK9	0.36	8.42	0.32	2.47e-16	Height;
BRCA	trans	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	29.23	0.76	6.58e-120	Colorectal cancer;
BRCA	trans	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg26043149	chr18:55253948	FECH	0.38	8.69	0.33	3.13e-17	Bone mineral density;
BRCA	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg06212747	chr3:49208901	KLHDC8B	0.53	11.11	0.4	2.43e-26	Parkinson's disease;
BRCA	trans	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg25042112	chr7:64838748	ZNF92	-0.45	-8.42	-0.32	2.47e-16	Pain;
BRCA	trans	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.85	-0.33	8.59e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4728302	0.869	rs7792905	chr7:133595602	G/T	cg07491979	chr7:133331646	EXOC4	0.36	7.84	0.3	1.88e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg14061069	chr19:46274453	DMPK	0.66	18.91	0.6	1.11e-63	Coronary artery disease;
BRCA	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-10.36	-0.38	2.35e-23	Neuroticism;
BRCA	cis	rs4819852	0.958	rs1034564	chr22:19984013	A/G	cg07821417	chr22:19972146	ARVCF	-0.46	-10.84	-0.39	2.87e-25	Pulse pressure;
BRCA	cis	rs7147624	0.766	rs11158597	chr14:65913536	T/G	cg03016385	chr14:66212404	NA	-0.57	-8.81	-0.33	1.15e-17	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08280861	chr8:58055591	NA	0.53	8.62	0.32	5.17e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs654351	0.543	rs622388	chr6:10387117	T/G	cg04978078	chr6:10383147	NA	-0.44	-8.61	-0.32	5.65e-17	Squamous cell lung carcinoma;
BRCA	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	11.01	0.4	6.16e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg18200150	chr17:30822561	MYO1D	0.35	8.81	0.33	1.19e-17	Schizophrenia;
BRCA	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.14	-0.31	2.03e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2617583	0.967	rs2617594	chr5:1448288	A/G	cg07151155	chr5:1473589	LPCAT1	-0.42	-9.0	-0.34	2.59e-18	Breast cancer;
BRCA	cis	rs250677	0.522	rs12523526	chr5:148349107	A/C	cg12140854	chr5:148520817	ABLIM3	0.42	8.43	0.32	2.27e-16	Breast cancer;
BRCA	cis	rs6785206	0.892	rs2712429	chr3:128336221	A/C	cg16766828	chr3:128327626	NA	-0.8	-11.64	-0.42	1.54e-28	Lymphocyte percentage of white cells;
BRCA	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11890956	chr21:40555474	PSMG1	-0.82	-19.62	-0.61	1.92e-67	Cognitive function;
BRCA	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24110177	chr3:50126178	RBM5	0.53	15.95	0.53	1.85e-48	Body mass index;
BRCA	cis	rs10465746	0.570	rs11163885	chr1:84472956	A/G	cg10977910	chr1:84465055	TTLL7	0.54	11.08	0.4	3.22e-26	Obesity-related traits;
BRCA	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11764359	chr7:65958608	NA	0.62	13.46	0.47	1.5e-36	Aortic root size;
BRCA	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.61	0.36	1.57e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.41	-9.17	-0.34	6.25e-19	Personality dimensions;
BRCA	cis	rs68170813	0.559	rs77185844	chr7:106812916	A/C	cg02696742	chr7:106810147	HBP1	-0.54	-8.61	-0.32	5.6e-17	Coronary artery disease;
BRCA	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg05896524	chr21:47604654	C21orf56	0.52	10.58	0.39	3.38e-24	Testicular germ cell tumor;
BRCA	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg03709012	chr19:19516395	GATAD2A	0.81	18.85	0.6	2.32e-63	Tonsillectomy;
BRCA	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg08999081	chr20:33150536	PIGU	0.44	12.51	0.44	2.96e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg08999081	chr20:33150536	PIGU	0.35	9.06	0.34	1.52e-18	Coronary artery disease;
BRCA	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg24163568	chr5:669837	TPPP	-0.35	-9.46	-0.35	5.56e-20	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
BRCA	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.14	-0.4	1.81e-26	Extrinsic epigenetic age acceleration;
BRCA	trans	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg21659725	chr3:3221576	CRBN	0.49	11.2	0.41	1.07e-26	Resting heart rate;
BRCA	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg07636037	chr3:49044803	WDR6	-0.5	-8.49	-0.32	1.45e-16	Menarche (age at onset);
BRCA	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg25036284	chr2:26402008	FAM59B	0.84	11.41	0.41	1.45e-27	Gut microbiome composition (summer);
BRCA	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25427524	chr10:38739819	LOC399744	-0.74	-18.27	-0.59	2.53e-60	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg24060327	chr5:131705240	SLC22A5	0.61	11.38	0.41	1.91e-27	Breast cancer;
BRCA	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg19622623	chr12:86230825	RASSF9	-0.35	-9.78	-0.36	3.71e-21	Major depressive disorder;
BRCA	trans	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg25214090	chr10:38739885	LOC399744	0.49	11.41	0.41	1.48e-27	Corneal astigmatism;
BRCA	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg03060546	chr3:49711283	APEH	-0.59	-10.42	-0.38	1.39e-23	Menarche (age at onset);
BRCA	cis	rs11723261	0.582	rs4582104	chr4:136942	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.34	8.37	0.31	3.77e-16	Immune response to smallpox vaccine (IL-6);
BRCA	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg23602478	chr1:26503979	CNKSR1	0.23	8.03	0.3	4.83e-15	Height;
BRCA	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg21918786	chr6:109611834	NA	-0.49	-14.14	-0.49	1.05e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11905131	chr22:24372483	LOC391322	0.54	12.21	0.43	5.69e-31	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg07741184	chr6:167504864	NA	0.32	9.87	0.36	1.78e-21	Crohn's disease;
BRCA	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg17691542	chr6:26056736	HIST1H1C	0.53	11.44	0.41	1.06e-27	Iron status biomarkers;
BRCA	trans	rs7980799	0.772	rs6488162	chr12:33593127	T/C	cg26384229	chr12:38710491	ALG10B	-0.41	-8.62	-0.32	5.42e-17	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg20307385	chr11:47447363	PSMC3	0.42	8.78	0.33	1.48e-17	Subjective well-being;
BRCA	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg10792982	chr14:105748885	BRF1	0.5	11.39	0.41	1.67e-27	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg11189052	chr15:85197271	WDR73	-0.43	-7.96	-0.3	8.09e-15	Schizophrenia;
BRCA	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg27129171	chr3:47204927	SETD2	0.57	12.93	0.46	3.79e-34	Colorectal cancer;
BRCA	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg27129171	chr3:47204927	SETD2	0.72	17.7	0.57	2.28e-57	Colorectal cancer;
BRCA	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.02e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg22563815	chr15:78856949	CHRNA5	-0.35	-8.43	-0.32	2.38e-16	Sudden cardiac arrest;
BRCA	cis	rs1113500	0.933	rs11185255	chr1:108633191	T/A	cg06207961	chr1:108661230	NA	0.46	11.24	0.41	6.95e-27	Growth-regulated protein alpha levels;
BRCA	cis	rs12760731	0.641	rs11588490	chr1:178328139	T/A	cg00404053	chr1:178313656	RASAL2	0.62	8.48	0.32	1.55e-16	Obesity-related traits;
BRCA	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg11887960	chr12:57824829	NA	0.52	8.15	0.31	1.89e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs4149577	0.630	rs4149570	chr12:6451590	A/C	cg11268190	chr12:6442526	TNFRSF1A	0.27	7.96	0.3	7.96e-15	Monocyte count;
BRCA	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg02734326	chr4:10020555	SLC2A9	0.41	8.92	0.33	4.81e-18	Bone mineral density;
BRCA	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg11764359	chr7:65958608	NA	-0.61	-13.03	-0.46	1.35e-34	Aortic root size;
BRCA	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg03213289	chr20:61660250	NA	0.61	16.2	0.54	1e-49	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6121246	0.559	rs6060599	chr20:30257754	T/G	cg21427119	chr20:30132790	HM13	-0.37	-8.34	-0.31	4.52e-16	Mean corpuscular hemoglobin;
BRCA	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg13319975	chr6:146136371	FBXO30	0.42	9.39	0.35	1.02e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19346786	chr7:2764209	NA	-0.34	-10.04	-0.37	4.13e-22	Height;
BRCA	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs6600671	0.934	rs12131379	chr1:121293437	T/C	cg17023122	chr1:144479586	NA	0.34	7.88	0.3	1.38e-14	Hip geometry;
BRCA	cis	rs7254827	0.737	rs71338609	chr19:17173418	A/G	cg19418318	chr19:17219073	MYO9B	-0.48	-10.04	-0.37	3.85e-22	Mean platelet volume;
BRCA	cis	rs1451375	0.617	rs10276473	chr7:50612997	A/C	cg18232548	chr7:50535776	DDC	-0.42	-9.0	-0.34	2.54e-18	Malaria;
BRCA	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg15839431	chr19:19639596	YJEFN3	-0.38	-8.36	-0.31	3.93e-16	Bipolar disorder;
BRCA	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg00071950	chr4:10020882	SLC2A9	0.5	11.98	0.43	5.81e-30	Bone mineral density;
BRCA	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00166722	chr3:10149974	C3orf24	-0.57	-11.37	-0.41	2.14e-27	Alzheimer's disease;
BRCA	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.22e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs1190552	0.846	rs3783382	chr14:102965437	A/T	cg18135206	chr14:102964638	TECPR2	0.46	8.9	0.33	5.89e-18	Blood protein levels;
BRCA	cis	rs6723226	0.638	rs6543657	chr2:32705085	T/C	cg02381751	chr2:32503542	YIPF4	0.57	12.43	0.44	6.1e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.4	-7.89	-0.3	1.29e-14	Rheumatoid arthritis;
BRCA	cis	rs77633900	0.614	rs2629021	chr15:76974083	C/T	cg21673338	chr15:77095150	SCAPER	-0.53	-9.84	-0.36	2.24e-21	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs1568889	0.887	rs2062269	chr11:28116537	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.36	0.63	2.12e-71	Bipolar disorder;
BRCA	cis	rs61935443	0.720	rs892493	chr12:95283943	T/C	cg21533806	chr12:95267307	NA	0.44	8.63	0.32	4.7e-17	Schizophrenia;
BRCA	cis	rs4631830	0.720	rs11004422	chr10:51498336	A/G	cg20129853	chr10:51489980	NA	0.32	8.66	0.32	3.98e-17	Prostate-specific antigen levels;
BRCA	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.89	-0.33	6.16e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6088813	1.000	rs4911492	chr20:33951799	G/A	cg14752227	chr20:34000481	UQCC	-0.4	-8.67	-0.32	3.66e-17	Height;
BRCA	cis	rs4363385	0.818	rs1415966	chr1:153002864	A/G	cg24667326	chr1:152973720	SPRR3	-0.32	-8.81	-0.33	1.17e-17	Inflammatory skin disease;
BRCA	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg04586622	chr2:25135609	ADCY3	0.43	10.75	0.39	6.65e-25	Body mass index;
BRCA	cis	rs9837602	0.688	rs11537816	chr3:99886662	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	8.48	0.32	1.57e-16	Breast cancer;
BRCA	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg16586182	chr3:47516702	SCAP	0.6	13.3	0.47	8.12e-36	Colorectal cancer;
BRCA	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg17366294	chr4:99064904	C4orf37	0.43	10.14	0.37	1.74e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg11764359	chr7:65958608	NA	0.65	11.67	0.42	1.12e-28	Aortic root size;
BRCA	cis	rs10870270	0.500	rs9419217	chr10:133758379	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.53	-11.74	-0.42	5.85e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg19346786	chr7:2764209	NA	0.27	8.1	0.31	2.8e-15	Height;
BRCA	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.36	0.44	1.23e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2505998	0.787	rs28502801	chr10:43584039	A/T	cg15436174	chr10:43711423	RASGEF1A	-0.41	-7.98	-0.3	6.72e-15	Hirschsprung disease;
BRCA	cis	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.22	-0.31	1.14e-15	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg00012203	chr2:219082015	ARPC2	-0.47	-9.22	-0.34	4.42e-19	Colorectal cancer;
BRCA	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg18811423	chr2:55921094	PNPT1	-0.52	-12.7	-0.45	4.25e-33	Metabolic syndrome;
BRCA	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg05347473	chr6:146136440	FBXO30	0.38	7.86	0.3	1.61e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg17691542	chr6:26056736	HIST1H1C	0.43	8.72	0.33	2.41e-17	Iron status biomarkers;
BRCA	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg06547715	chr2:218990976	CXCR2	0.32	7.92	0.3	1.05e-14	Ulcerative colitis;
BRCA	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg26314531	chr2:26401878	FAM59B	-0.61	-10.0	-0.37	5.78e-22	Gut microbiome composition (summer);
BRCA	cis	rs13040088	1.000	rs6090155	chr20:61527378	G/A	cg23096297	chr20:61557774	DIDO1	0.89	17.1	0.56	3.08e-54	Menopause (age at onset);
BRCA	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.71	-0.42	7.56e-29	Alcohol dependence;
BRCA	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg16405210	chr4:1374714	KIAA1530	-0.89	-22.13	-0.66	5.24e-81	Longevity;
BRCA	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg27478167	chr7:817139	HEATR2	-0.4	-8.46	-0.32	1.83e-16	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg22834771	chr12:69754056	YEATS4	-0.39	-9.64	-0.36	1.29e-20	Blood protein levels;
BRCA	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-11.21	-0.41	9.48e-27	Gut microbiome composition (summer);
BRCA	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg02297831	chr4:17616191	MED28	0.38	8.22	0.31	1.17e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	21.19	0.64	7.26e-76	Nonalcoholic fatty liver disease;
BRCA	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg16482183	chr6:26056742	HIST1H1C	0.4	8.19	0.31	1.39e-15	Iron status biomarkers;
BRCA	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg08859206	chr1:53392774	SCP2	-0.48	-10.31	-0.38	3.64e-23	Monocyte count;
BRCA	cis	rs2282802	0.685	rs13177186	chr5:139640476	A/G	cg26211634	chr5:139558579	C5orf32	0.35	8.22	0.31	1.12e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-8.79	-0.33	1.37e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2387326	0.717	rs12252256	chr10:129944616	C/T	cg16087940	chr10:129947807	NA	-0.44	-7.86	-0.3	1.6e-14	Select biomarker traits;
BRCA	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.0	0.34	2.65e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg25457927	chr22:38595422	NA	-0.32	-11.94	-0.43	8.19e-30	Cutaneous nevi;
BRCA	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.48	10.02	0.37	4.57e-22	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs9807989	0.507	rs1420097	chr2:103009354	C/G	cg03938978	chr2:103052716	IL18RAP	-0.28	-8.21	-0.31	1.21e-15	Asthma;
BRCA	trans	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17712092	chr4:129076599	LARP1B	0.49	11.93	0.43	9.59e-30	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs7809950	0.862	rs58391518	chr7:107030787	T/C	cg23024343	chr7:107201750	COG5	-0.4	-8.97	-0.33	3.3e-18	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg18279126	chr7:2041391	MAD1L1	0.38	8.42	0.32	2.5e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs701145	0.585	rs4680125	chr3:153784698	G/A	cg17054900	chr3:154042577	DHX36	-0.54	-9.18	-0.34	5.74e-19	Coronary artery disease;
BRCA	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg25173405	chr17:45401733	C17orf57	-0.55	-11.79	-0.42	3.5e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg05340658	chr4:99064831	C4orf37	0.48	11.38	0.41	1.96e-27	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.18	-0.34	6e-19	Bipolar disorder;
BRCA	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	1e-40	Motion sickness;
BRCA	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-14.19	-0.49	6.44e-40	Morning vs. evening chronotype;
BRCA	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg21252483	chr19:49399788	TULP2	-0.42	-9.36	-0.35	1.3e-19	Red cell distribution width;
BRCA	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	11.07	0.4	3.59e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.89	-0.33	6.26e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg14196790	chr5:131705035	SLC22A5	0.32	8.52	0.32	1.16e-16	Breast cancer;
BRCA	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg13119609	chr19:45449297	APOC2	0.48	13.24	0.46	1.64e-35	Blood protein levels;
BRCA	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg22431228	chr1:16359049	CLCNKA	-0.44	-9.75	-0.36	5.02e-21	Dilated cardiomyopathy;
BRCA	cis	rs2089162	1	rs2089162	chr15:78739763	A/G	cg18825076	chr15:78729989	IREB2	-0.46	-8.76	-0.33	1.72e-17	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg20946044	chr11:1010712	AP2A2	0.37	7.89	0.3	1.32e-14	Alzheimer's disease (late onset);
BRCA	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg00321850	chr1:175162397	KIAA0040	-0.44	-12.02	-0.43	3.83e-30	Diastolic blood pressure;
BRCA	cis	rs16976116	0.855	rs28649719	chr15:55500211	C/T	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg23950597	chr19:37808831	NA	-0.65	-11.1	-0.4	2.75e-26	Coronary artery calcification;
BRCA	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-8.75	-0.33	1.88e-17	Morning vs. evening chronotype;
BRCA	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.67	-0.39	1.46e-24	Personality dimensions;
BRCA	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg22903471	chr2:27725779	GCKR	-0.35	-8.34	-0.31	4.52e-16	Total body bone mineral density;
BRCA	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	11.52	0.41	4.8e-28	Bone mineral density;
BRCA	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg03433033	chr1:76189801	ACADM	0.76	17.22	0.56	6.95e-55	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg06191203	chr2:152266755	RIF1	-0.44	-12.85	-0.45	8.82e-34	Lung cancer;
BRCA	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg27279351	chr12:120934652	DYNLL1	0.56	13.26	0.46	1.24e-35	High light scatter reticulocyte count;
BRCA	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg07493874	chr5:1342172	CLPTM1L	-0.49	-13.55	-0.47	6.21e-37	Lung cancer;
BRCA	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg03929089	chr4:120376271	NA	-0.69	-13.62	-0.47	2.83e-37	Coronary artery disease;
BRCA	cis	rs9394841	0.692	rs9349202	chr6:41805581	A/C	cg08135965	chr6:41755394	TOMM6	0.52	8.35	0.31	4.14e-16	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg17691542	chr6:26056736	HIST1H1C	0.45	8.77	0.33	1.61e-17	Iron status biomarkers;
BRCA	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg03711944	chr11:47377212	SPI1	-0.39	-9.25	-0.34	3.28e-19	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.92	-0.3	1.04e-14	Prostate cancer;
BRCA	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.39	-7.9	-0.3	1.23e-14	Longevity;Endometriosis;
BRCA	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg18964960	chr10:1102726	WDR37	-0.47	-8.45	-0.32	1.95e-16	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03517284	chr6:25882590	NA	-0.5	-11.34	-0.41	2.87e-27	Blood metabolite levels;
BRCA	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg02187348	chr16:89574699	SPG7	0.49	11.66	0.42	1.23e-28	Multiple myeloma (IgH translocation);
BRCA	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.07	-36.73	-0.82	1.21e-159	Myeloid white cell count;
BRCA	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.85	0.33	8.55e-18	Motion sickness;
BRCA	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.45	-0.38	1.05e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg04944784	chr2:26401820	FAM59B	1.0	16.52	0.55	2.54e-51	Gut microbiome composition (summer);
BRCA	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.05	-0.3	4.01e-15	Total body bone mineral density;
BRCA	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg25486957	chr4:152246857	NA	-0.36	-7.9	-0.3	1.26e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg14664628	chr15:75095509	CSK	0.35	7.96	0.3	8.05e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
BRCA	cis	rs11779988	0.545	rs404186	chr8:17795496	A/G	cg01800426	chr8:17659068	MTUS1	-0.4	-8.21	-0.31	1.19e-15	Breast cancer;
BRCA	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg06784218	chr1:46089804	CCDC17	0.44	10.65	0.39	1.76e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12468557	0.545	rs7587791	chr2:211499979	A/C	cg07063745	chr2:211341572	LANCL1;CPS1	-0.36	-8.04	-0.3	4.44e-15	Body mass index in asthmatics;
BRCA	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg07636037	chr3:49044803	WDR6	-0.59	-8.54	-0.32	9.91e-17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs10751667	0.621	rs11246375	chr11:999620	T/C	cg01483505	chr11:975446	AP2A2	0.33	8.86	0.33	8.11e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7178424	0.875	rs7179506	chr15:62187955	T/G	cg00456672	chr15:62358751	C2CD4A	-0.41	-9.08	-0.34	1.32e-18	Height;
BRCA	cis	rs600806	0.850	rs4970729	chr1:109979202	G/A	cg20591472	chr1:110008990	SYPL2	0.33	8.24	0.31	9.86e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7523273	1.000	rs12410786	chr1:207976205	T/A	cg22525895	chr1:207977042	MIR29B2	-0.48	-11.88	-0.43	1.51e-29	Schizophrenia;
BRCA	trans	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg09719594	chr16:21412588	NA	-0.34	-8.27	-0.31	7.88e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg22117172	chr7:91764530	CYP51A1	0.23	7.84	0.3	1.9e-14	Breast cancer;
BRCA	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg13628971	chr7:2884303	GNA12	0.47	9.45	0.35	6.1e-20	Height;
BRCA	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	10.03	0.37	4.56e-22	Lung cancer in ever smokers;
BRCA	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg16606324	chr3:10149918	C3orf24	0.58	10.28	0.38	4.75e-23	Alzheimer's disease;
BRCA	cis	rs965469	0.779	rs2207994	chr20:3294304	C/T	cg25506879	chr20:3388711	C20orf194	-0.43	-8.71	-0.33	2.61e-17	IFN-related cytopenia;
BRCA	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-9.82	-0.36	2.68e-21	Bladder cancer;
BRCA	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11890956	chr21:40555474	PSMG1	-0.62	-13.8	-0.48	4.27e-38	Menarche (age at onset);
BRCA	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11764359	chr7:65958608	NA	-0.74	-16.29	-0.54	3.72e-50	Aortic root size;
BRCA	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07080220	chr10:102295463	HIF1AN	0.47	10.57	0.39	3.61e-24	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4363385	0.679	rs6686286	chr1:152984562	T/C	cg24667326	chr1:152973720	SPRR3	-0.33	-8.99	-0.34	2.75e-18	Inflammatory skin disease;
BRCA	cis	rs6714710	0.603	rs34502870	chr2:98405929	A/G	cg26665480	chr2:98280029	ACTR1B	0.58	13.58	0.47	4.32e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08045932	chr20:61659980	NA	0.5	11.51	0.41	5.25e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg23950597	chr19:37808831	NA	-0.75	-13.01	-0.46	1.65e-34	Coronary artery calcification;
BRCA	cis	rs9473147	0.516	rs1931837	chr6:47442377	C/T	cg12968598	chr6:47444699	CD2AP	0.45	9.38	0.35	1.1e-19	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18876405	chr7:65276391	NA	-0.51	-11.08	-0.4	3.14e-26	Aortic root size;
BRCA	cis	rs7095944	0.585	rs7080838	chr10:126419841	A/G	cg08799069	chr10:126477246	METTL10	0.38	8.9	0.33	5.58e-18	Asthma;
BRCA	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg27129171	chr3:47204927	SETD2	-0.71	-17.51	-0.57	2.3e-56	Colorectal cancer;
BRCA	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg00686598	chr14:53173677	PSMC6	1.25	16.47	0.55	4.61e-51	Alzheimer's disease (late onset);
BRCA	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg16230307	chr14:35515116	FAM177A1	0.73	15.25	0.52	5.11e-45	Psoriasis;
BRCA	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18404041	chr3:52824283	ITIH1	-0.47	-14.62	-0.5	5.78e-42	Bipolar disorder;
BRCA	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16024904	chr19:17905718	B3GNT3	0.38	8.05	0.3	4.16e-15	Tumor biomarkers;
BRCA	cis	rs16854884	0.657	rs35067746	chr3:143747147	T/A	cg06585982	chr3:143692056	C3orf58	0.42	8.93	0.33	4.41e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg17971929	chr21:40555470	PSMG1	-0.43	-9.21	-0.34	4.77e-19	Menarche (age at onset);
BRCA	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg11764359	chr7:65958608	NA	0.68	15.21	0.52	8.16e-45	Aortic root size;
BRCA	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg08085267	chr17:45401833	C17orf57	-0.63	-14.02	-0.48	4.02e-39	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg11663144	chr21:46675770	NA	0.48	8.85	0.33	8.2e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg02574844	chr11:5959923	NA	-0.43	-9.46	-0.35	5.71e-20	DNA methylation (variation);
BRCA	trans	rs72766638	0.895	rs11795079	chr9:136930134	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-9.95	-0.37	8.49e-22	Mosquito bite size;
BRCA	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg22029157	chr1:209979665	IRF6	0.54	11.21	0.41	9.28e-27	Cleft lip with or without cleft palate;
BRCA	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg04414720	chr1:150670196	GOLPH3L	0.37	8.39	0.32	3.06e-16	Melanoma;
BRCA	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg13902645	chr11:5959945	NA	-0.57	-11.6	-0.42	2.4e-28	DNA methylation (variation);
BRCA	cis	rs858239	0.600	rs28646184	chr7:23139595	T/C	cg23682824	chr7:23144976	KLHL7	0.46	12.31	0.44	2.15e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg18196295	chr10:418757	DIP2C	0.4	9.36	0.35	1.31e-19	Psychosis in Alzheimer's disease;
BRCA	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg20503657	chr10:835505	NA	1.01	17.77	0.58	1.09e-57	Eosinophil percentage of granulocytes;
BRCA	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg07080220	chr10:102295463	HIF1AN	0.49	11.41	0.41	1.4e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs10242455	0.702	rs73397481	chr7:99030108	C/T	cg18809830	chr7:99032528	PTCD1	-0.67	-8.47	-0.32	1.63e-16	Blood metabolite levels;
BRCA	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.58	10.28	0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg06636001	chr8:8085503	FLJ10661	0.47	10.16	0.37	1.43e-22	Myopia (pathological);
BRCA	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg11266682	chr4:10021025	SLC2A9	0.43	11.09	0.4	2.84e-26	Bone mineral density;
BRCA	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.15	-0.31	1.9e-15	Parkinson's disease;
BRCA	cis	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg06521331	chr12:34319734	NA	-0.52	-10.17	-0.37	1.26e-22	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs17604090	0.938	rs68072609	chr7:29682467	C/T	cg19413766	chr7:29689036	LOC646762	-0.56	-7.83	-0.3	1.97e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs4566357	0.615	rs10198214	chr2:227913314	A/C	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.12	-0.31	2.44e-15	Coronary artery disease;
BRCA	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg25767906	chr1:53392781	SCP2	0.38	8.7	0.33	2.78e-17	Monocyte count;
BRCA	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg01528321	chr10:82214614	TSPAN14	0.62	13.08	0.46	8.44e-35	Post bronchodilator FEV1;
BRCA	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.74	0.33	2.06e-17	Motion sickness;
BRCA	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg08601574	chr20:25228251	PYGB	0.36	8.58	0.32	7.39e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-13.53	-0.47	7.74e-37	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg22800045	chr5:56110881	MAP3K1	0.66	12.22	0.44	4.98e-31	Initial pursuit acceleration;
BRCA	cis	rs4679121	0.642	rs55708952	chr3:126188912	A/G	cg05485589	chr3:126194908	ZXDC	-0.75	-8.42	-0.32	2.5e-16	Pursuit maintenance gain;
BRCA	cis	rs9682041	0.561	rs9856511	chr3:170140165	C/G	cg11886554	chr3:170076028	SKIL	0.41	7.86	0.3	1.59e-14	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11764359	chr7:65958608	NA	-0.75	-16.49	-0.55	3.67e-51	Aortic root size;
BRCA	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg11814155	chr7:99998594	ZCWPW1	0.42	7.85	0.3	1.71e-14	Platelet count;
BRCA	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.15	0.56	1.54e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2191566	0.959	rs7256345	chr19:44510905	T/G	cg20607764	chr19:44506953	ZNF230	-0.44	-9.95	-0.37	8.47e-22	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	6.83e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg13010199	chr12:38710504	ALG10B	0.44	8.84	0.33	9.41e-18	Bladder cancer;
BRCA	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg08755490	chr11:65554678	OVOL1	0.54	11.35	0.41	2.51e-27	Acne (severe);
BRCA	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg17971929	chr21:40555470	PSMG1	0.79	18.49	0.59	1.87e-61	Cognitive function;
BRCA	cis	rs9296092	0.538	rs9461880	chr6:33518714	C/T	cg13560919	chr6:33536144	NA	-0.85	-17.59	-0.57	8.63e-57	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs72928364	1.000	rs13099053	chr3:100620904	C/A	cg10123952	chr3:100791384	NA	0.54	8.07	0.3	3.62e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg21252483	chr19:49399788	TULP2	-0.42	-9.36	-0.35	1.3e-19	Red cell distribution width;
BRCA	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.55	14.82	0.51	6.22e-43	Response to bleomycin (chromatid breaks);
BRCA	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg13010199	chr12:38710504	ALG10B	0.54	11.98	0.43	5.39e-30	Heart rate;
BRCA	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.36	-8.18	-0.31	1.59e-15	Colorectal cancer;
BRCA	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg14675211	chr2:100938903	LONRF2	-0.42	-9.52	-0.35	3.51e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26314531	chr2:26401878	FAM59B	-0.63	-10.83	-0.39	3.28e-25	Gut microbiome composition (summer);
BRCA	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg07636037	chr3:49044803	WDR6	-0.77	-15.58	-0.52	1.31e-46	Menarche (age at onset);
BRCA	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg07917127	chr4:99064746	C4orf37	0.41	7.84	0.3	1.94e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs708547	0.723	rs35982175	chr4:57841365	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.41	10.73	0.39	8.5e-25	Response to bleomycin (chromatid breaks);
BRCA	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg13736514	chr6:26305472	NA	-0.35	-11.82	-0.42	2.62e-29	Educational attainment;
BRCA	cis	rs7727544	0.582	rs3828675	chr5:131546868	G/A	cg14196790	chr5:131705035	SLC22A5	0.37	9.16	0.34	6.78e-19	Blood metabolite levels;
BRCA	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg05347473	chr6:146136440	FBXO30	-0.4	-7.91	-0.3	1.14e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg05340658	chr4:99064831	C4orf37	0.62	14.94	0.51	1.58e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg16482183	chr6:26056742	HIST1H1C	0.51	10.58	0.39	3.17e-24	Height;
BRCA	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg08917208	chr2:24149416	ATAD2B	-0.51	-7.93	-0.3	9.46e-15	Lymphocyte counts;
BRCA	trans	rs931812	0.895	rs4734013	chr8:101908687	A/C	cg20993868	chr7:22813445	NA	0.56	16.06	0.54	5.38e-49	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs4664304	0.620	rs2729705	chr2:160710922	T/C	cg01092293	chr2:160761427	LY75	-0.35	-8.35	-0.31	4.11e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs10046574	0.519	rs112479683	chr7:135203288	G/A	cg27474649	chr7:135195673	CNOT4	0.63	10.58	0.39	3.24e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7707921	0.881	rs57621982	chr5:81406770	C/T	cg15871215	chr5:81402204	ATG10	-0.39	-8.21	-0.31	1.26e-15	Breast cancer;
BRCA	cis	rs10463316	0.894	rs12153347	chr5:150765471	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.38	-0.31	3.35e-16	Metabolite levels (Pyroglutamine);
BRCA	trans	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs7944584	0.611	rs10838696	chr11:47363285	A/G	cg20307385	chr11:47447363	PSMC3	-0.61	-13.14	-0.46	4.32e-35	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-11.23	-0.41	7.76e-27	Lymphocyte counts;
BRCA	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.56	-10.35	-0.38	2.65e-23	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6867913	0.709	rs2338874	chr5:141466926	G/A	cg08523384	chr5:141488047	NDFIP1	-0.35	-8.57	-0.32	7.82e-17	Asthma;
BRCA	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24110177	chr3:50126178	RBM5	-0.4	-10.95	-0.4	1.11e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg16850897	chr7:100343110	ZAN	0.38	8.62	0.32	5.46e-17	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg13319975	chr6:146136371	FBXO30	-0.41	-9.45	-0.35	6.3e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.68	-14.52	-0.5	1.73e-41	Platelet distribution width;
BRCA	cis	rs910873	0.505	rs6058089	chr20:33194257	C/T	cg16810054	chr20:33298113	TP53INP2	0.47	10.14	0.37	1.7e-22	Melanoma;
BRCA	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg04025307	chr7:1156635	C7orf50	0.41	9.9	0.36	1.35e-21	Longevity;Endometriosis;
BRCA	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg03585969	chr10:35415529	CREM	0.54	11.07	0.4	3.42e-26	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs629535	0.814	rs62513371	chr8:70077779	T/A	cg21567404	chr3:27674614	NA	-1.0	-21.77	-0.65	4.97e-79	Dupuytren's disease;
BRCA	trans	rs9929218	0.861	rs8056206	chr16:68802072	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-13.75	-0.48	6.85e-38	Colorectal cancer;
BRCA	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.49	-0.41	6.45e-28	Platelet count;
BRCA	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.5	10.3	0.38	4.14e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg11833968	chr6:79620685	NA	-0.46	-10.19	-0.37	1.11e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg02951883	chr7:2050386	MAD1L1	0.39	8.36	0.31	3.89e-16	Neuroticism;
BRCA	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg04362960	chr10:104952993	NT5C2	0.44	10.71	0.39	1.02e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg13852791	chr20:30311386	BCL2L1	0.79	15.11	0.51	2.57e-44	Mean corpuscular hemoglobin;
BRCA	cis	rs11055008	0.620	rs2111941	chr12:12829404	A/T	cg04607235	chr12:12878440	APOLD1	0.42	8.33	0.31	4.9e-16	Pulse pressure;
BRCA	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	14.89	0.51	3.04e-43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs8073060	0.586	rs2626625	chr17:34027607	C/G	cg19694781	chr19:47549865	TMEM160	-1.08	-21.33	-0.64	1.19e-76	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg05234568	chr11:5960015	NA	-0.43	-8.94	-0.33	4.05e-18	DNA methylation (variation);
BRCA	cis	rs4285028	0.699	rs1574115	chr3:121469225	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.87	-15.37	-0.52	1.28e-45	Multiple sclerosis;
BRCA	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg08470875	chr2:26401718	FAM59B	-0.7	-11.27	-0.41	5.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs1595825	0.891	rs6751690	chr2:198574523	G/A	cg19156104	chr2:198669113	PLCL1	-0.46	-8.24	-0.31	9.94e-16	Ulcerative colitis;
BRCA	trans	rs61931739	0.635	rs1352208	chr12:33932543	T/C	cg26384229	chr12:38710491	ALG10B	0.39	8.91	0.33	5.5e-18	Morning vs. evening chronotype;
BRCA	cis	rs1997103	1.000	rs6945937	chr7:55407140	C/T	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.48	-9.89	-0.36	1.44e-21	HDL cholesterol;
BRCA	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg15501526	chr10:2543763	NA	0.59	13.42	0.47	2.44e-36	Age-related hearing impairment;
BRCA	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg12483005	chr1:23474871	LUZP1	0.45	9.94	0.37	9.75e-22	Height;
BRCA	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg26384229	chr12:38710491	ALG10B	0.5	11.45	0.41	9.62e-28	Bladder cancer;
BRCA	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	8.29	0.31	6.45e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg18806716	chr10:30721971	MAP3K8	-0.46	-10.85	-0.39	2.64e-25	Inflammatory bowel disease;
BRCA	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg03060546	chr3:49711283	APEH	-0.53	-10.62	-0.39	2.21e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg07828340	chr4:882639	GAK	1.03	12.5	0.44	3.04e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg11843238	chr5:131593191	PDLIM4	0.31	7.89	0.3	1.36e-14	Blood metabolite levels;
BRCA	cis	rs28735056	0.935	rs11662267	chr18:77641902	C/G	cg20368463	chr18:77673604	PQLC1	-0.34	-7.91	-0.3	1.1e-14	Schizophrenia;
BRCA	cis	rs6545883	0.931	rs778768	chr2:61790289	C/G	cg15711740	chr2:61764176	XPO1	-0.56	-14.11	-0.49	1.51e-39	Tuberculosis;
BRCA	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.58	11.31	0.41	3.68e-27	HDL cholesterol;
BRCA	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg13880726	chr7:1868755	MAD1L1	0.52	10.3	0.38	4.07e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs10193935	0.901	rs10200000	chr2:42442212	A/G	cg27598129	chr2:42591480	NA	-0.95	-15.18	-0.51	1.18e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg01283332	chr5:1856932	NA	-0.35	-8.45	-0.32	1.91e-16	Cardiovascular disease risk factors;
BRCA	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg03146154	chr1:46216737	IPP	0.45	10.05	0.37	3.69e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7766436	0.885	rs13202434	chr6:22583694	G/C	cg13666174	chr6:22585274	NA	-0.49	-11.63	-0.42	1.65e-28	Coronary artery disease;
BRCA	trans	rs9409565	0.787	rs11789704	chr9:97233408	C/T	cg05679027	chr9:99775184	HIATL2	-0.35	-7.94	-0.3	9.11e-15	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs919433	0.963	rs12618612	chr2:198171058	G/T	cg10820045	chr2:198174542	NA	-0.39	-8.07	-0.3	3.47e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg26608667	chr7:1196370	ZFAND2A	0.35	8.06	0.3	3.67e-15	Longevity;Endometriosis;
BRCA	cis	rs798766	0.779	rs55895920	chr4:1735930	C/T	cg05874882	chr4:1763078	NA	-0.47	-8.51	-0.32	1.19e-16	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs13095912	0.752	rs62291883	chr3:185313842	T/C	cg11274856	chr3:185301563	NA	0.52	12.35	0.44	1.46e-31	Systolic blood pressure;
BRCA	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	8.24	0.31	9.41e-16	Schizophrenia;
BRCA	cis	rs62158211	0.955	rs1823125	chr2:114090412	C/T	cg17784749	chr2:114082611	LOC440839	-0.54	-9.55	-0.35	2.72e-20	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
BRCA	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg22907277	chr7:1156413	C7orf50	0.59	9.11	0.34	1.09e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg02466173	chr16:30829666	NA	-0.53	-11.5	-0.41	6.03e-28	Multiple myeloma;
BRCA	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg13010199	chr12:38710504	ALG10B	0.46	9.04	0.34	1.78e-18	Morning vs. evening chronotype;
BRCA	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg04705435	chr11:17411270	KCNJ11	0.44	9.36	0.35	1.35e-19	Type 2 diabetes;
BRCA	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg08917208	chr2:24149416	ATAD2B	0.52	8.16	0.31	1.77e-15	Lymphocyte counts;
BRCA	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.54	-8.6	-0.32	6.1e-17	Gut microbiome composition (summer);
BRCA	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg20701182	chr2:24300061	SF3B14	0.71	13.55	0.47	6.09e-37	Lymphocyte counts;
BRCA	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg00631329	chr6:26305371	NA	-0.55	-15.74	-0.53	2.01e-47	Educational attainment;
BRCA	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg18357645	chr12:58087776	OS9	0.47	13.29	0.47	8.77e-36	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.6	-0.32	6.2e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.58	0.55	1.29e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs30380	1.000	rs151964	chr5:96123666	G/T	cg16492584	chr5:96139282	ERAP1	-0.31	-7.9	-0.3	1.19e-14	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.2	-0.31	1.28e-15	Depression;
BRCA	cis	rs2625529	0.824	rs12906711	chr15:72215065	A/G	cg16672083	chr15:72433130	SENP8	-0.83	-17.16	-0.56	1.39e-54	Red blood cell count;
BRCA	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg15395560	chr15:45543142	SLC28A2	0.3	8.43	0.32	2.33e-16	Uric acid levels;
BRCA	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg09184832	chr6:79620586	NA	-0.47	-10.25	-0.38	6.3e-23	Intelligence (multi-trait analysis);
BRCA	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.04	-0.34	1.92e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg08859206	chr1:53392774	SCP2	0.52	10.73	0.39	8.36e-25	Monocyte count;
BRCA	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg09455208	chr3:40491958	NA	0.41	9.69	0.36	8.45e-21	Renal cell carcinoma;
BRCA	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg26597838	chr10:835615	NA	1.29	21.15	0.64	1.22e-75	Eosinophil percentage of granulocytes;
BRCA	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg10174797	chr19:8464628	RAB11B	0.35	9.01	0.34	2.4e-18	HDL cholesterol;
BRCA	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	13.42	0.47	2.36e-36	Mean platelet volume;
BRCA	cis	rs208520	0.955	rs208538	chr6:66964492	C/G	cg07460842	chr6:66804631	NA	-0.79	-13.3	-0.47	8.34e-36	Exhaled nitric oxide output;
BRCA	cis	rs12612619	0.732	rs6716275	chr2:27227707	C/T	cg00617064	chr2:27272375	NA	0.31	8.34	0.31	4.45e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg05535760	chr7:792225	HEATR2	-0.73	-11.8	-0.42	3.22e-29	Cerebrospinal P-tau181p levels;
BRCA	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg03929089	chr4:120376271	NA	-0.69	-13.25	-0.46	1.44e-35	Coronary artery disease;
BRCA	cis	rs13064411	0.542	rs11537650	chr3:113222036	G/A	cg18753928	chr3:113234510	CCDC52	-0.46	-9.82	-0.36	2.69e-21	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg22705602	chr4:152727874	NA	-0.34	-8.55	-0.32	9.01e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs16958440	1.000	rs2289131	chr18:44602864	G/A	cg17192377	chr18:44677553	HDHD2	0.65	9.52	0.35	3.37e-20	Sitting height ratio;
BRCA	cis	rs738321	0.762	rs4820321	chr22:38579569	T/A	cg25457927	chr22:38595422	NA	-0.39	-13.29	-0.47	8.77e-36	Breast cancer;
BRCA	cis	rs6450176	1.000	rs60652351	chr5:53306140	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-15.32	-0.52	2.36e-45	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg22800045	chr5:56110881	MAP3K1	0.63	12.3	0.44	2.43e-31	Initial pursuit acceleration;
BRCA	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg01579765	chr21:45077557	HSF2BP	0.44	11.86	0.42	1.91e-29	Mean corpuscular volume;
BRCA	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg11814155	chr7:99998594	ZCWPW1	0.45	8.16	0.31	1.73e-15	Platelet count;
BRCA	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08045932	chr20:61659980	NA	0.49	11.18	0.4	1.31e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.48	8.75	0.33	1.9e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg19862616	chr7:65841803	NCRNA00174	0.83	27.27	0.73	3.26e-109	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4363385	0.782	rs1933381	chr1:153003255	C/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.44	-0.32	2.1e-16	Inflammatory skin disease;
BRCA	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg06238570	chr21:40685208	BRWD1	-0.42	-8.51	-0.32	1.22e-16	Cognitive function;
BRCA	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg14458575	chr2:238380390	NA	0.58	13.17	0.46	3.22e-35	Prostate cancer;
BRCA	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg13628971	chr7:2884303	GNA12	0.48	9.51	0.35	3.67e-20	Height;
BRCA	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.85	-0.33	8.29e-18	Alzheimer's disease (late onset);
BRCA	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.61	-0.39	2.37e-24	Tonsillectomy;
BRCA	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg05564831	chr3:52568323	NT5DC2	0.34	8.06	0.3	3.88e-15	Electroencephalogram traits;
BRCA	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg08601574	chr20:25228251	PYGB	0.34	8.31	0.31	5.72e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg26384229	chr12:38710491	ALG10B	0.74	17.66	0.57	3.84e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	18.46	0.59	2.66e-61	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs7301016	0.846	rs7302094	chr12:62967430	C/T	cg11441379	chr12:63026424	NA	0.46	8.69	0.32	3.13e-17	IgG glycosylation;
BRCA	cis	rs62229266	0.740	rs4817759	chr21:37389559	G/A	cg12218747	chr21:37451666	NA	-0.34	-8.02	-0.3	4.91e-15	Mitral valve prolapse;
BRCA	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg23933602	chr10:16859644	RSU1	0.52	8.59	0.32	6.41e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg25358565	chr5:93447407	FAM172A	1.23	19.33	0.61	6.85e-66	Diabetic retinopathy;
BRCA	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.78	-0.36	3.82e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg23711669	chr6:146136114	FBXO30	0.61	13.95	0.48	8.27e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.81	0.55	9.28e-53	Alzheimer's disease (late onset);
BRCA	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg13010199	chr12:38710504	ALG10B	0.43	9.12	0.34	9.77e-19	Morning vs. evening chronotype;
BRCA	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg24531977	chr5:56204891	C5orf35	-0.44	-8.99	-0.33	2.86e-18	Coronary artery disease;
BRCA	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg06453172	chr10:134556979	INPP5A	-0.48	-10.3	-0.38	4.04e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg13385521	chr17:29058706	SUZ12P	0.62	8.49	0.32	1.49e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs11677370	0.603	rs10171309	chr2:3851690	C/T	cg17052675	chr2:3827356	NA	-0.53	-12.84	-0.45	1.02e-33	Type 2 diabetes;
BRCA	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs7178424	1.000	rs17271431	chr15:62381016	C/T	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.21	-0.31	1.27e-15	Height;
BRCA	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg05623727	chr3:50126028	RBM5	0.41	9.74	0.36	5.59e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg26384229	chr12:38710491	ALG10B	0.74	17.32	0.57	2.11e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9815354	0.812	rs4577439	chr3:41952540	T/A	cg03022575	chr3:42003672	ULK4	0.69	9.62	0.36	1.44e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.43	-0.38	1.23e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg21143896	chr7:2802374	GNA12	-0.31	-8.25	-0.31	9.37e-16	Height;
BRCA	cis	rs7818345	0.845	rs11785649	chr8:19268233	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.35	8.93	0.33	4.59e-18	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs2795502	0.872	rs2744062	chr10:43254789	T/A	cg20628663	chr10:43360327	NA	-0.7	-11.87	-0.43	1.67e-29	Blood protein levels;
BRCA	cis	rs10129255	0.518	rs7143784	chr14:107143294	A/G	cg07958169	chr14:107095056	NA	-0.37	-7.91	-0.3	1.13e-14	Kawasaki disease;
BRCA	cis	rs2625529	0.824	rs55854204	chr15:72433182	C/T	cg16672083	chr15:72433130	SENP8	-0.86	-18.21	-0.58	5.62e-60	Red blood cell count;
BRCA	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg06636001	chr8:8085503	FLJ10661	0.49	9.21	0.34	4.52e-19	Retinal vascular caliber;
BRCA	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg06115741	chr20:33292138	TP53INP2	-0.4	-8.8	-0.33	1.25e-17	Glomerular filtration rate (creatinine);
BRCA	trans	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.81	0.3	2.38e-14	Corneal astigmatism;
BRCA	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-9.73	-0.36	5.71e-21	IgG glycosylation;
BRCA	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.9	0.36	1.36e-21	Bipolar disorder;
BRCA	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg17971929	chr21:40555470	PSMG1	0.79	18.65	0.59	2.76e-62	Cognitive function;
BRCA	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	13.29	0.47	9.05e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg25214090	chr10:38739885	LOC399744	0.45	10.38	0.38	2.04e-23	Corneal astigmatism;
BRCA	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg15704280	chr7:45808275	SEPT13	0.52	8.92	0.33	4.69e-18	Axial length;
BRCA	cis	rs7524258	0.867	rs35399313	chr1:7277293	T/C	cg07173049	chr1:7289937	CAMTA1	0.37	8.98	0.33	2.96e-18	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	trans	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg25042112	chr7:64838748	ZNF92	-0.45	-8.34	-0.31	4.45e-16	Pain;
BRCA	cis	rs4919694	0.611	rs77328741	chr10:105066314	T/C	cg04362960	chr10:104952993	NT5C2	0.72	11.29	0.41	4.47e-27	Arsenic metabolism;
BRCA	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.76	-11.5	-0.41	5.98e-28	Schizophrenia;
BRCA	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg25036284	chr2:26402008	FAM59B	-0.7	-12.28	-0.44	3e-31	Gut microbiome composition (summer);
BRCA	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.62	-0.32	5.3e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.65	-9.79	-0.36	3.39e-21	Schizophrenia;
BRCA	cis	rs6545883	0.894	rs6709441	chr2:61436930	A/T	cg15711740	chr2:61764176	XPO1	0.53	12.99	0.46	2.13e-34	Tuberculosis;
BRCA	cis	rs17641971	0.662	rs1828495	chr8:49945281	C/T	cg00325661	chr8:49890786	NA	0.37	10.31	0.38	3.54e-23	Blood metabolite levels;
BRCA	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11644478	chr21:40555479	PSMG1	-0.67	-14.51	-0.5	1.86e-41	Cognitive function;
BRCA	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg24558204	chr6:135376177	HBS1L	0.46	12.6	0.45	1.19e-32	Red blood cell count;
BRCA	cis	rs11997175	0.766	rs6983113	chr8:33699513	G/A	ch.8.33884649F	chr8:33765107	NA	0.34	8.0	0.3	5.85e-15	Body mass index;
BRCA	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg05623727	chr3:50126028	RBM5	0.51	12.25	0.44	3.9e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.53	-0.32	1.07e-16	Bipolar disorder;
BRCA	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23583168	chr7:148888333	NA	-0.83	-19.15	-0.6	5.92e-65	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	21.43	0.65	3.48e-77	Platelet count;
BRCA	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.61	-0.32	5.7e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg23505145	chr19:12996616	KLF1	0.56	12.69	0.45	4.46e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg09307838	chr4:120376055	NA	0.59	10.95	0.4	1.11e-25	Corneal astigmatism;
BRCA	trans	rs75804782	0.521	rs72994973	chr2:239428315	C/T	cg01134436	chr17:81009848	B3GNTL1	0.69	8.81	0.33	1.17e-17	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg25173405	chr17:45401733	C17orf57	0.47	9.73	0.36	5.82e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg04998671	chr14:104000505	TRMT61A	-0.43	-9.5	-0.35	4.27e-20	Coronary artery disease;
BRCA	cis	rs11605924	0.766	rs12419690	chr11:45858584	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.44	-9.64	-0.36	1.28e-20	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26314531	chr2:26401878	FAM59B	-0.66	-11.2	-0.4	1.08e-26	Gut microbiome composition (summer);
BRCA	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg00814883	chr7:100076585	TSC22D4	-0.48	-9.92	-0.37	1.19e-21	Platelet count;
BRCA	cis	rs10992471	0.528	rs1535754	chr9:95201917	T/G	cg14631576	chr9:95140430	CENPP	-0.35	-8.66	-0.32	3.97e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.69	-0.33	3.04e-17	Breast cancer;
BRCA	trans	rs11088226	0.681	rs8131384	chr21:33944127	C/T	cg09050820	chr6:167586206	TCP10L2	0.84	14.52	0.5	1.73e-41	Gastritis;
BRCA	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-10.21	-0.37	9.19e-23	Personality dimensions;
BRCA	cis	rs4642101	0.694	rs12631514	chr3:12838293	G/C	cg05775895	chr3:12838266	CAND2	0.39	8.62	0.32	5.1e-17	QRS complex (12-leadsum);
BRCA	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg14844989	chr11:31128820	NA	-0.43	-9.18	-0.34	6.07e-19	Red blood cell count;
BRCA	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg04824913	chr4:887549	GAK	0.76	14.97	0.51	1.26e-43	Systemic sclerosis;
BRCA	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg21724239	chr8:58056113	NA	0.66	10.45	0.38	1.05e-23	Developmental language disorder (linguistic errors);
BRCA	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg24596788	chr1:163392923	NA	-0.32	-8.53	-0.32	1.06e-16	Motion sickness;
BRCA	cis	rs3820928	0.874	rs7576081	chr2:227843634	C/G	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.33	-0.31	4.85e-16	Pulmonary function;
BRCA	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.42	-8.05	-0.3	4.01e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	11.73	0.42	6.55e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg16586182	chr3:47516702	SCAP	-0.54	-12.16	-0.43	9.16e-31	Colorectal cancer;
BRCA	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg20933634	chr6:27740509	NA	0.48	9.52	0.35	3.58e-20	Parkinson's disease;
BRCA	trans	rs75804782	0.641	rs55844289	chr2:239323207	C/T	cg01134436	chr17:81009848	B3GNTL1	0.77	9.69	0.36	8.3e-21	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs867371	0.896	rs6495647	chr15:82537049	C/G	cg00614314	chr15:82944287	LOC80154	0.43	8.95	0.33	3.83e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-9.63	-0.36	1.39e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs528301	0.707	rs338070	chr2:45175289	C/G	cg02372786	chr2:45167549	SIX3	-0.57	-13.11	-0.46	5.91e-35	Alcohol and nicotine co-dependence;
BRCA	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg27535305	chr1:53392650	SCP2	-0.34	-7.98	-0.3	6.67e-15	Monocyte count;
BRCA	cis	rs3857536	0.740	rs7769722	chr6:66891363	C/T	cg07460842	chr6:66804631	NA	-0.46	-8.86	-0.33	8.14e-18	Blood trace element (Cu levels);
BRCA	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.91	-30.23	-0.77	2.47e-125	Schizophrenia;
BRCA	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg25554036	chr4:6271136	WFS1	0.42	9.79	0.36	3.61e-21	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg24803719	chr17:45855879	NA	-0.31	-8.05	-0.3	4.15e-15	IgG glycosylation;
BRCA	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.66	-0.42	1.31e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02176678	chr2:219576539	TTLL4	0.46	11.84	0.42	2.25e-29	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg08888203	chr3:10149979	C3orf24	0.67	13.89	0.48	1.65e-38	Alzheimer's disease;
BRCA	cis	rs61990749	0.597	rs176971	chr14:78191599	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.63	9.68	0.36	8.69e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs57590327	0.503	rs7631052	chr3:81866235	C/A	cg07356753	chr3:81810745	GBE1	-0.42	-9.84	-0.36	2.19e-21	Extraversion;
BRCA	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg07414643	chr4:187882934	NA	0.29	9.91	0.37	1.21e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13082711	0.554	rs34066402	chr3:27387987	G/A	cg02860705	chr3:27208620	NA	0.68	11.74	0.42	5.98e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs4285028	0.747	rs3732407	chr3:121416623	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.86	-15.24	-0.52	5.66e-45	Multiple sclerosis;
BRCA	cis	rs9986765	1.000	rs28672333	chr7:142826798	G/A	cg22531018	chr7:142981779	TMEM139	0.58	9.72	0.36	6.44e-21	Cancer;Dermatomyositis;
BRCA	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18876405	chr7:65276391	NA	0.48	10.79	0.39	4.64e-25	Aortic root size;
BRCA	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.6	9.82	0.36	2.72e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs72634258	0.520	rs12078018	chr1:7857309	G/A	cg26816564	chr1:7831052	VAMP3	0.69	12.67	0.45	5.73e-33	Inflammatory bowel disease;
BRCA	cis	rs877282	1.000	rs11253370	chr10:773712	G/A	cg17470449	chr10:769945	NA	0.49	9.36	0.35	1.37e-19	Uric acid levels;
BRCA	cis	rs9467773	0.587	rs9467722	chr6:26352566	T/C	cg09904177	chr6:26538194	HMGN4	-0.32	-8.57	-0.32	7.66e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs783540	0.681	rs1259178	chr15:83271876	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.32	-8.85	-0.33	8.66e-18	Schizophrenia;
BRCA	cis	rs507080	0.883	rs693306	chr11:118558333	A/G	cg09144398	chr11:118550485	TREH	-0.37	-8.96	-0.33	3.5e-18	Serum metabolite levels;
BRCA	trans	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	8.87	0.33	7.08e-18	Mean corpuscular volume;
BRCA	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg01884057	chr2:25150051	NA	0.34	9.06	0.34	1.55e-18	Body mass index;
BRCA	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg26149184	chr10:133730230	NA	0.4	8.2	0.31	1.37e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs4930561	0.765	rs10896304	chr11:67981714	T/G	cg16338278	chr11:67432957	ALDH3B2	0.43	8.62	0.32	5.39e-17	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs79839061	0.536	rs3775128	chr4:885828	T/C	cg07828340	chr4:882639	GAK	0.58	9.2	0.34	5.08e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg23422044	chr7:1970798	MAD1L1	-0.44	-9.26	-0.34	3.01e-19	Neuroticism;
BRCA	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg24531977	chr5:56204891	C5orf35	-0.41	-8.36	-0.31	3.98e-16	Coronary artery disease;
BRCA	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg24296786	chr1:45957014	TESK2	-0.56	-13.19	-0.46	2.75e-35	High light scatter reticulocyte count;
BRCA	cis	rs36051895	0.695	rs12352214	chr9:5018041	G/A	cg02405213	chr9:5042618	JAK2	-0.45	-8.41	-0.32	2.76e-16	Pediatric autoimmune diseases;
BRCA	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg12641515	chr19:46296257	DMWD	0.68	16.63	0.55	7.35e-52	Coronary artery disease;
BRCA	trans	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg06521331	chr12:34319734	NA	-0.46	-8.54	-0.32	1e-16	Bladder cancer;
BRCA	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg11814155	chr7:99998594	ZCWPW1	0.46	8.24	0.31	9.66e-16	Platelet count;
BRCA	cis	rs6121246	0.559	rs6060621	chr20:30261562	G/C	cg21427119	chr20:30132790	HM13	-0.36	-8.17	-0.31	1.71e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10819733	chr22:24237672	NA	0.3	8.28	0.31	7.12e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg24069376	chr3:38537580	EXOG	-0.42	-11.91	-0.43	1.13e-29	Electrocardiographic conduction measures;
BRCA	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg26031613	chr14:104095156	KLC1	-0.55	-9.7	-0.36	7.4e-21	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs3762637	1.000	rs7609972	chr3:122199426	T/G	cg24169773	chr3:122142474	KPNA1	-0.43	-8.04	-0.3	4.29e-15	LDL cholesterol levels;
BRCA	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg01802117	chr1:53393560	SCP2	-0.36	-8.31	-0.31	5.97e-16	Monocyte count;
BRCA	cis	rs10924970	0.781	rs10802589	chr1:235444049	A/G	cg26050004	chr1:235667680	B3GALNT2	0.35	8.74	0.33	2.02e-17	Asthma;
BRCA	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg20933634	chr6:27740509	NA	0.45	9.01	0.34	2.3e-18	Parkinson's disease;
BRCA	cis	rs877282	0.842	rs35117541	chr10:764683	C/T	cg17470449	chr10:769945	NA	0.47	7.96	0.3	8.16e-15	Uric acid levels;
BRCA	cis	rs189798	0.807	rs9949	chr8:8994512	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	8.48	0.32	1.58e-16	Myopia (pathological);
BRCA	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg18016565	chr1:150552671	MCL1	0.35	8.02	0.3	5.04e-15	Melanoma;
BRCA	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg12386194	chr3:101231763	SENP7	-0.46	-9.78	-0.36	3.95e-21	Colorectal cancer;
BRCA	cis	rs654950	1.000	rs646228	chr1:41986066	A/C	cg06885757	chr1:42089581	HIVEP3	0.29	9.74	0.36	5.43e-21	Airway imaging phenotypes;
BRCA	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	11.5	0.41	6.27e-28	Neuroticism;
BRCA	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg06092702	chr1:163392909	NA	-0.37	-9.77	-0.36	4.34e-21	Motion sickness;
BRCA	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg13047869	chr3:10149882	C3orf24	0.6	12.93	0.46	3.76e-34	Alzheimer's disease;
BRCA	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg06115741	chr20:33292138	TP53INP2	-0.37	-7.92	-0.3	1.09e-14	Glomerular filtration rate (creatinine);
BRCA	cis	rs6772849	0.896	rs35535737	chr3:128383406	G/A	cg16766828	chr3:128327626	NA	-0.39	-8.63	-0.32	4.91e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg17366294	chr4:99064904	C4orf37	0.42	9.92	0.37	1.13e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg00383909	chr3:49044727	WDR6	0.45	9.64	0.36	1.3e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs67981189	0.896	rs2526878	chr14:71377295	A/G	cg15816911	chr14:71606274	NA	-0.37	-8.21	-0.31	1.27e-15	Schizophrenia;
BRCA	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.59	0.5	7.57e-42	Personality dimensions;
BRCA	cis	rs1003719	0.582	rs2835634	chr21:38528270	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.49	-0.5	2.41e-41	Eye color traits;
BRCA	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg27432699	chr2:27873401	GPN1	0.45	9.34	0.35	1.51e-19	Oral cavity cancer;
BRCA	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg16482183	chr6:26056742	HIST1H1C	0.5	9.41	0.35	8.9e-20	Iron status biomarkers;
BRCA	cis	rs758324	0.648	rs31474	chr5:131405027	A/G	cg06307176	chr5:131281290	NA	-0.36	-7.83	-0.3	2.06e-14	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg04944784	chr2:26401820	FAM59B	1.01	16.64	0.55	6.66e-52	Gut microbiome composition (summer);
BRCA	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg14983838	chr19:29218262	NA	0.54	10.08	0.37	2.78e-22	Methadone dose in opioid dependence;
BRCA	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg22875332	chr1:76189707	ACADM	0.69	14.56	0.5	1.11e-41	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg12386194	chr3:101231763	SENP7	0.46	9.7	0.36	7.74e-21	Colorectal cancer;
BRCA	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg20362242	chr5:692897	TPPP	0.52	8.34	0.31	4.5e-16	Lung disease severity in cystic fibrosis;
BRCA	trans	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg06521331	chr12:34319734	NA	0.44	8.54	0.32	9.75e-17	Bladder cancer;
BRCA	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg08213375	chr14:104286397	PPP1R13B	0.57	14.86	0.51	4.16e-43	Schizophrenia;
BRCA	cis	rs4664304	0.658	rs2667012	chr2:160867553	G/T	cg14819504	chr2:160761413	LY75	-0.33	-8.09	-0.3	2.98e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7191700	0.511	rs243330	chr16:11350991	C/T	cg00044050	chr16:11439710	C16orf75	0.38	9.04	0.34	1.86e-18	Multiple sclerosis;
BRCA	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg02153584	chr22:29168773	CCDC117	0.52	10.83	0.39	3.42e-25	Lymphocyte counts;
BRCA	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg00717180	chr2:96193071	NA	-0.4	-11.14	-0.4	1.88e-26	Coronary artery disease;
BRCA	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg05234568	chr11:5960015	NA	-0.5	-10.25	-0.38	6.48e-23	DNA methylation (variation);
BRCA	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg05340658	chr4:99064831	C4orf37	0.67	16.59	0.55	1.2e-51	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg23762105	chr12:34175262	ALG10	0.34	8.0	0.3	5.92e-15	Morning vs. evening chronotype;
BRCA	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.56	-0.32	8.48e-17	Electroencephalogram traits;
BRCA	cis	rs1400816	0.850	rs2037164	chr2:172542238	C/T	cg13550731	chr2:172543902	DYNC1I2	0.54	8.48	0.32	1.56e-16	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs17401966	0.838	rs61775885	chr1:10281445	T/C	cg03954927	chr1:10346856	KIF1B	0.44	13.75	0.48	7.09e-38	Hepatocellular carcinoma;
BRCA	cis	rs3761847	0.622	rs10818500	chr9:123810883	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.38	-7.92	-0.3	1.07e-14	Rheumatoid arthritis;
BRCA	cis	rs752010	0.695	rs12134166	chr1:42105867	C/T	cg06885757	chr1:42089581	HIVEP3	0.23	8.35	0.31	4.34e-16	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	12.4	0.44	8.58e-32	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg26384229	chr12:38710491	ALG10B	0.61	15.44	0.52	6.46e-46	Morning vs. evening chronotype;
BRCA	cis	rs10499694	0.933	rs11575334	chr7:50597301	G/A	cg18232548	chr7:50535776	DDC	-0.39	-9.41	-0.35	9.06e-20	Body mass index;
BRCA	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6088813	0.961	rs6088791	chr20:33907909	A/G	cg14752227	chr20:34000481	UQCC	0.4	8.38	0.31	3.45e-16	Height;
BRCA	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg00321850	chr1:175162397	KIAA0040	0.43	12.31	0.44	2.06e-31	Alcohol dependence;
BRCA	trans	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	10.79	0.39	4.67e-25	Mean corpuscular volume;
BRCA	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg23533926	chr12:111358616	MYL2	-0.43	-8.94	-0.33	4.09e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg12669354	chr11:831584	CD151;EFCAB4A	-0.37	-8.01	-0.3	5.36e-15	Mean platelet volume;
BRCA	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg24642439	chr20:33292090	TP53INP2	-0.43	-8.7	-0.33	2.89e-17	Height;
BRCA	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg21747090	chr2:27597821	SNX17	-0.4	-8.76	-0.33	1.76e-17	Total body bone mineral density;
BRCA	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg07828340	chr4:882639	GAK	1.04	12.39	0.44	9.94e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs3741151	0.773	rs17244596	chr11:73179236	A/G	cg17517138	chr11:73019481	ARHGEF17	0.87	12.43	0.44	6.12e-32	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg11764359	chr7:65958608	NA	0.59	12.93	0.46	3.82e-34	Aortic root size;
BRCA	cis	rs586533	0.793	rs680485	chr11:99502078	A/G	cg22878054	chr11:99397252	CNTN5	0.32	8.13	0.31	2.29e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg26838691	chr2:24397539	C2orf84	-0.53	-9.25	-0.34	3.38e-19	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.1	0.34	1.11e-18	Menopause (age at onset);
BRCA	trans	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg01620082	chr3:125678407	NA	-0.59	-8.24	-0.31	1.01e-15	Depression;
BRCA	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg07741184	chr6:167504864	NA	0.39	11.17	0.4	1.4e-26	Primary biliary cholangitis;
BRCA	cis	rs13046373	0.535	rs1354866	chr21:31981559	A/T	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.45	0.32	2.02e-16	HDL cholesterol;
BRCA	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg08807101	chr21:30365312	RNF160	0.6	15.07	0.51	3.86e-44	Dental caries;
BRCA	cis	rs13046373	0.535	rs7281767	chr21:32022062	T/C	cg06468780	chr21:31798236	KRTAP13-3	0.33	8.37	0.31	3.62e-16	HDL cholesterol;
BRCA	trans	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg06521331	chr12:34319734	NA	-0.49	-9.11	-0.34	1.06e-18	Bladder cancer;
BRCA	cis	rs7524258	0.868	rs916393	chr1:7272250	T/C	cg07173049	chr1:7289937	CAMTA1	0.48	11.73	0.42	6.79e-29	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg03709012	chr19:19516395	GATAD2A	-0.74	-16.48	-0.55	4.07e-51	Tonsillectomy;
BRCA	cis	rs11249608	0.548	rs11951738	chr5:178491228	G/A	cg21905437	chr5:178450457	ZNF879	0.49	9.51	0.35	3.81e-20	Pubertal anthropometrics;
BRCA	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg13256891	chr4:100009986	ADH5	0.52	9.67	0.36	1e-20	Alcohol dependence;
BRCA	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg22189786	chr22:42395067	WBP2NL	0.41	8.17	0.31	1.69e-15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	trans	rs877282	0.891	rs12357999	chr10:796468	A/C	cg22713356	chr15:30763199	NA	1.41	28.52	0.75	5.26e-116	Uric acid levels;
BRCA	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.0	-0.4	6.78e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg24562669	chr7:97807699	LMTK2	-0.61	-18.1	-0.58	1.94e-59	Breast cancer;
BRCA	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg18279126	chr7:2041391	MAD1L1	0.4	8.79	0.33	1.39e-17	Bipolar disorder and schizophrenia;
BRCA	trans	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.33	8.8	0.33	1.3e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6743226	0.901	rs7599888	chr2:242248033	C/G	cg10021735	chr2:242295487	FARP2	-0.39	-10.63	-0.39	2.04e-24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg10224037	chr5:178157518	ZNF354A	0.76	16.01	0.54	9.58e-49	Neutrophil percentage of white cells;
BRCA	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg19678392	chr7:94953810	PON1	0.43	9.4	0.35	9.53e-20	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-9.14	-0.34	8.07e-19	Morning vs. evening chronotype;
BRCA	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg21573476	chr21:45109991	RRP1B	-0.36	-9.05	-0.34	1.65e-18	Mean corpuscular volume;
BRCA	trans	rs9929218	0.954	rs2059254	chr16:68817439	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-13.49	-0.47	1.11e-36	Colorectal cancer;
BRCA	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg25457927	chr22:38595422	NA	-0.33	-12.28	-0.44	2.73e-31	Cutaneous nevi;
BRCA	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.72	12.09	0.43	1.98e-30	Schizophrenia;
BRCA	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08109568	chr15:31115862	NA	-0.45	-10.66	-0.39	1.62e-24	Huntington's disease progression;
BRCA	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg13902645	chr11:5959945	NA	-0.54	-11.27	-0.41	5.35e-27	DNA methylation (variation);
BRCA	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.93	0.56	2.25e-53	Colorectal cancer;
BRCA	cis	rs9470366	0.816	rs7774130	chr6:36623756	C/T	cg08179530	chr6:36648295	CDKN1A	0.51	10.29	0.38	4.51e-23	QRS duration;
BRCA	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-19.83	-0.62	1.4e-68	Systemic lupus erythematosus;
BRCA	cis	rs4919087	0.926	rs2861875	chr10:98990139	C/G	cg25902810	chr10:99078978	FRAT1	-0.43	-9.23	-0.34	4.03e-19	Monocyte count;
BRCA	cis	rs9811920	0.535	rs704571	chr3:99481946	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.41	-9.67	-0.36	9.66e-21	Axial length;
BRCA	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg11941060	chr3:133502564	NA	-0.5	-12.17	-0.43	8.81e-31	Iron status biomarkers;
BRCA	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg20790798	chr5:1857306	NA	-0.4	-9.39	-0.35	1.04e-19	Cardiovascular disease risk factors;
BRCA	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg19920283	chr7:105172520	RINT1	0.59	9.4	0.35	9.51e-20	Bipolar disorder (body mass index interaction);
BRCA	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg20587970	chr11:113659929	NA	-1.2	-22.06	-0.66	1.33e-80	Hip circumference adjusted for BMI;
BRCA	cis	rs9341808	0.754	rs3793000	chr6:80995137	G/A	cg08355045	chr6:80787529	NA	0.36	9.21	0.34	4.75e-19	Sitting height ratio;
BRCA	cis	rs11229555	0.645	rs7929868	chr11:58209418	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs8114671	0.967	rs2069948	chr20:33762489	C/T	cg07148914	chr20:33460835	GGT7	0.38	8.03	0.3	4.77e-15	Height;
BRCA	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg08470875	chr2:26401718	FAM59B	-0.5	-8.17	-0.31	1.65e-15	Gut microbiome composition (summer);
BRCA	cis	rs4363385	0.747	rs6678107	chr1:152966818	T/G	cg25856811	chr1:152973957	SPRR3	-0.35	-9.53	-0.35	3.12e-20	Inflammatory skin disease;
BRCA	trans	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg07817883	chr1:32538562	TMEM39B	1.05	16.03	0.54	7.14e-49	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg11189052	chr15:85197271	WDR73	-0.42	-8.45	-0.32	1.99e-16	Schizophrenia;
BRCA	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg16405210	chr4:1374714	KIAA1530	0.36	8.06	0.3	3.81e-15	Obesity-related traits;
BRCA	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg07537917	chr2:241836409	C2orf54	-0.48	-11.34	-0.41	2.83e-27	Urinary metabolites;
BRCA	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg23018236	chr17:30244563	NA	-0.68	-10.57	-0.39	3.45e-24	Hip circumference adjusted for BMI;
BRCA	cis	rs2882667	0.858	rs11242442	chr5:138380489	C/T	cg04439458	chr5:138467593	SIL1	-0.43	-10.72	-0.39	8.66e-25	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg24848339	chr3:12840334	CAND2	0.47	12.31	0.44	2.2e-31	QRS complex (12-leadsum);
BRCA	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg08807101	chr21:30365312	RNF160	-0.38	-8.33	-0.31	4.94e-16	Pancreatic cancer;
BRCA	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg01262667	chr19:19385393	TM6SF2	0.41	8.94	0.33	4.01e-18	Nonalcoholic fatty liver disease;
BRCA	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.38	-7.82	-0.3	2.13e-14	Axial length;
BRCA	cis	rs3815700	1.000	rs8104328	chr19:33094371	G/A	cg02997394	chr19:33096574	ANKRD27	0.69	11.53	0.41	4.63e-28	Eosinophilic esophagitis;
BRCA	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09263875	chr16:632152	PIGQ	0.73	21.29	0.64	2.12e-76	Height;
BRCA	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg14061069	chr19:46274453	DMPK	-0.48	-11.63	-0.42	1.79e-28	Coronary artery disease;
BRCA	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg02493740	chr2:85810744	VAMP5	-0.56	-11.58	-0.42	2.88e-28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg03433033	chr1:76189801	ACADM	-0.4	-8.42	-0.32	2.57e-16	Daytime sleep phenotypes;
BRCA	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg11057378	chr10:81107060	PPIF	0.41	9.89	0.36	1.42e-21	Height;
BRCA	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs10193935	1.000	rs12618105	chr2:42414146	T/G	cg27598129	chr2:42591480	NA	-0.94	-15.03	-0.51	6.18e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6942756	0.806	rs7788327	chr7:128986519	C/T	cg02491457	chr7:128862824	NA	-0.58	-12.43	-0.44	6.63e-32	White matter hyperintensity burden;
BRCA	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg24692254	chr21:30365293	RNF160	-0.59	-15.06	-0.51	4.21e-44	Dental caries;
BRCA	trans	rs3857536	0.776	rs9294687	chr6:66942919	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg18132916	chr6:79620363	NA	-0.5	-11.42	-0.41	1.28e-27	Intelligence (multi-trait analysis);
BRCA	trans	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg06521331	chr12:34319734	NA	-0.48	-9.24	-0.34	3.75e-19	Bladder cancer;
BRCA	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg08822215	chr16:89438651	ANKRD11	-0.4	-8.48	-0.32	1.53e-16	Multiple myeloma (IgH translocation);
BRCA	trans	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg26043149	chr18:55253948	FECH	-0.37	-8.02	-0.3	5.17e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg18904891	chr8:8559673	CLDN23	0.65	12.91	0.45	4.83e-34	Obesity-related traits;
BRCA	trans	rs2562456	0.917	rs2650793	chr19:21676115	C/G	cg25042112	chr7:64838748	ZNF92	0.41	8.03	0.3	4.68e-15	Pain;
BRCA	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-16.95	-0.56	1.78e-53	Colorectal cancer;
BRCA	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg07952391	chr2:88470173	THNSL2	0.67	9.26	0.34	2.98e-19	Plasma clusterin levels;
BRCA	cis	rs7737355	0.947	rs9885286	chr5:130883270	C/T	cg06307176	chr5:131281290	NA	0.54	10.79	0.39	4.78e-25	Life satisfaction;
BRCA	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg27170947	chr2:26402098	FAM59B	-0.66	-11.24	-0.41	7.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg18402987	chr7:1209562	NA	0.76	11.58	0.42	2.67e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg27170947	chr2:26402098	FAM59B	-0.64	-11.31	-0.41	3.51e-27	Gut microbiome composition (summer);
BRCA	cis	rs7953508	0.506	rs768775	chr12:93968197	T/C	cg18151635	chr12:93972918	NA	-0.46	-9.19	-0.34	5.6e-19	Pubertal anthropometrics;
BRCA	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.23e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.34	-0.35	1.6e-19	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg17366294	chr4:99064904	C4orf37	0.46	10.95	0.4	1.07e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2742234	0.541	rs1879310	chr10:43734775	A/G	cg15436174	chr10:43711423	RASGEF1A	0.5	10.05	0.37	3.62e-22	Hirschsprung disease;
BRCA	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.54	0.55	1.98e-51	Hypertriglyceridemia;
BRCA	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg06238570	chr21:40685208	BRWD1	-0.45	-8.95	-0.33	3.77e-18	Cognitive function;
BRCA	cis	rs7011049	1.000	rs72640868	chr8:53843812	C/A	cg26025543	chr8:53854495	NA	0.56	9.66	0.36	1.11e-20	Systolic blood pressure;
BRCA	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg13770153	chr20:60521292	NA	0.56	11.81	0.42	2.89e-29	Body mass index;
BRCA	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.62	0.55	8.25e-52	Alzheimer's disease (late onset);
BRCA	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-10.58	-0.39	3.38e-24	Lymphocyte counts;
BRCA	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg11663144	chr21:46675770	NA	-0.47	-11.04	-0.4	4.77e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg23708337	chr7:1209742	NA	0.43	8.19	0.31	1.4e-15	Longevity;Endometriosis;
BRCA	cis	rs11229555	0.874	rs10896788	chr11:58292976	G/A	cg15696309	chr11:58395628	NA	-0.53	-11.38	-0.41	1.83e-27	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg12219531	chr12:120966889	COQ5	0.53	11.13	0.4	2.04e-26	High light scatter reticulocyte count;
BRCA	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.46	10.26	0.38	5.58e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs654351	0.541	rs556554	chr6:10388774	T/C	cg04978078	chr6:10383147	NA	-0.43	-8.33	-0.31	4.83e-16	Squamous cell lung carcinoma;
BRCA	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg18512352	chr11:47633146	NA	-0.38	-9.23	-0.34	3.81e-19	Subjective well-being;
BRCA	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg15557168	chr22:42548783	NA	-0.32	-8.9	-0.33	5.6e-18	Schizophrenia;
BRCA	cis	rs10501293	1.000	rs2862694	chr11:43064753	C/T	cg03447554	chr11:43094025	NA	0.49	9.08	0.34	1.31e-18	Cognitive performance;
BRCA	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg09060608	chr5:178986726	RUFY1	0.54	13.11	0.46	5.75e-35	Lung cancer;
BRCA	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg00750074	chr16:89608354	SPG7	-0.33	-8.78	-0.33	1.5e-17	Multiple myeloma (IgH translocation);
BRCA	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	9.91	0.37	1.19e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs12541635	0.902	rs13277300	chr8:107062819	C/T	cg10147462	chr8:107024639	NA	-0.34	-9.48	-0.35	4.96e-20	Age of smoking initiation;
BRCA	cis	rs77633900	0.614	rs280029	chr15:77031235	A/G	cg21673338	chr15:77095150	SCAPER	-0.53	-9.43	-0.35	7.28e-20	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg03433033	chr1:76189801	ACADM	-0.46	-9.6	-0.35	1.8e-20	Daytime sleep phenotypes;
BRCA	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-9.12	-0.34	9.31e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg11502198	chr6:26597334	ABT1	0.47	9.48	0.35	4.75e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.97	0.33	3.29e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg20587970	chr11:113659929	NA	-1.35	-23.98	-0.69	3.91e-91	Hip circumference adjusted for BMI;
BRCA	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6714710	0.603	rs2305143	chr2:98413781	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	13.61	0.47	3.28e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg21132104	chr15:45694354	SPATA5L1	0.75	17.09	0.56	3.4e-54	Homoarginine levels;
BRCA	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	cis	rs41005	1.000	rs13402078	chr2:8113107	C/T	cg03155496	chr2:8117019	LOC339788	-0.57	-15.06	-0.51	4.35e-44	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.86	0.36	1.98e-21	Retinal vascular caliber;
BRCA	cis	rs3820928	0.874	rs55959848	chr2:227805426	C/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-9.04	-0.34	1.9e-18	Pulmonary function;
BRCA	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg16325326	chr1:53192061	ZYG11B	0.69	17.45	0.57	4.78e-56	Monocyte count;
BRCA	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.67	-13.67	-0.48	1.7e-37	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2882667	0.690	rs6884198	chr5:138164307	C/T	cg04439458	chr5:138467593	SIL1	0.31	7.81	0.3	2.28e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg04362960	chr10:104952993	NT5C2	0.45	10.36	0.38	2.38e-23	Arsenic metabolism;
BRCA	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.45	8.65	0.32	4.32e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2016266	0.859	rs7953656	chr12:53738433	G/T	cg26875137	chr12:53738046	NA	0.46	11.99	0.43	4.97e-30	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs1451375	0.617	rs9942686	chr7:50596381	G/A	cg18232548	chr7:50535776	DDC	0.44	9.28	0.34	2.67e-19	Malaria;
BRCA	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg05279229	chr7:1896384	MAD1L1	-0.42	-7.98	-0.3	6.56e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs4780401	0.609	rs55934118	chr16:11820003	G/C	cg01061890	chr16:11836724	TXNDC11	-0.56	-13.35	-0.47	5.15e-36	Rheumatoid arthritis;
BRCA	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg06766960	chr11:133703094	NA	-0.62	-12.87	-0.45	7.37e-34	Childhood ear infection;
BRCA	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26314531	chr2:26401878	FAM59B	0.95	16.42	0.54	8.01e-51	Gut microbiome composition (summer);
BRCA	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg12661370	chr5:149340060	SLC26A2	0.54	8.01	0.3	5.46e-15	HIV-1 control;
BRCA	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg09658497	chr7:2847517	GNA12	-0.39	-8.07	-0.3	3.47e-15	Height;
BRCA	cis	rs1506636	0.646	rs805789	chr7:123221920	G/T	cg03229431	chr7:123269106	ASB15	-0.6	-12.81	-0.45	1.32e-33	Plateletcrit;Platelet count;
BRCA	cis	rs7945718	0.967	rs1440286	chr11:12809152	G/A	cg25843174	chr11:12811716	TEAD1	0.23	8.84	0.33	9.5e-18	Educational attainment (years of education);
BRCA	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-8.07	-0.3	3.61e-15	Alzheimer's disease (late onset);
BRCA	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg01579765	chr21:45077557	HSF2BP	0.41	11.41	0.41	1.43e-27	Mean corpuscular volume;
BRCA	trans	rs9409565	0.826	rs9409546	chr9:97209066	T/C	cg05679027	chr9:99775184	HIATL2	-0.43	-9.47	-0.35	5.15e-20	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs7781557	0.938	rs73192015	chr7:102511732	C/T	cg18108683	chr7:102477205	FBXL13	-0.4	-8.02	-0.3	5.22e-15	Colorectal adenoma (advanced);
BRCA	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg10560079	chr2:191398806	TMEM194B	-0.67	-11.49	-0.41	6.35e-28	Diastolic blood pressure;
BRCA	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg22974920	chr21:40686053	BRWD1	-0.4	-8.76	-0.33	1.73e-17	Cognitive function;
BRCA	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg08601574	chr20:25228251	PYGB	-0.36	-8.6	-0.32	6.12e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg23711669	chr6:146136114	FBXO30	-0.63	-14.67	-0.5	3.46e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg24596788	chr1:163392923	NA	-0.41	-10.92	-0.4	1.4e-25	Motion sickness;
BRCA	cis	rs3845702	0.736	rs2678936	chr2:180872179	G/C	cg01881094	chr2:180872142	CWC22	1.04	18.93	0.6	8.75e-64	Schizophrenia;
BRCA	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg24675658	chr1:53192096	ZYG11B	-0.53	-11.32	-0.41	3.28e-27	Monocyte count;
BRCA	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg09462578	chr12:12878428	APOLD1	-0.67	-11.55	-0.42	3.77e-28	Systemic lupus erythematosus;
BRCA	cis	rs11605275	1.000	rs78091560	chr11:20032279	G/A	cg14835545	chr11:20032148	NAV2	-0.59	-9.36	-0.35	1.28e-19	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg11266682	chr4:10021025	SLC2A9	0.38	9.74	0.36	5.56e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg00750074	chr16:89608354	SPG7	-0.41	-10.93	-0.4	1.28e-25	Multiple myeloma (IgH translocation);
BRCA	cis	rs12210905	0.688	rs12215353	chr6:27407022	C/T	cg08851530	chr6:28072375	NA	0.81	7.89	0.3	1.3e-14	Hip circumference adjusted for BMI;
BRCA	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg09462578	chr12:12878428	APOLD1	0.7	12.18	0.43	8.01e-31	Systemic lupus erythematosus;
BRCA	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	11.18	0.4	1.28e-26	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg08668359	chr10:1443807	ADARB2	0.49	9.46	0.35	5.91e-20	Radiation response;
BRCA	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-14.04	-0.49	3.32e-39	Morning vs. evening chronotype;
BRCA	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg24829409	chr8:58192753	C8orf71	-0.59	-12.3	-0.44	2.45e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	10.69	0.39	1.17e-24	Platelet count;
BRCA	cis	rs1832871	0.965	rs861179	chr6:158712720	A/G	cg07215822	chr6:158701037	NA	-0.43	-7.83	-0.3	1.97e-14	Height;
BRCA	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg02187348	chr16:89574699	SPG7	0.47	11.14	0.4	1.9e-26	Multiple myeloma (IgH translocation);
BRCA	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg17294928	chr15:75287854	SCAMP5	0.71	15.14	0.51	1.82e-44	Blood trace element (Zn levels);
BRCA	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg04586622	chr2:25135609	ADCY3	0.42	10.61	0.39	2.39e-24	Body mass index;
BRCA	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.91	-0.43	1.13e-29	Total cholesterol levels;
BRCA	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg01262667	chr19:19385393	TM6SF2	0.4	10.38	0.38	1.98e-23	Tonsillectomy;
BRCA	cis	rs495337	0.720	rs2869937	chr20:48536618	C/G	cg17835207	chr20:48524531	SPATA2	-0.69	-16.83	-0.55	7.01e-53	Psoriasis;
BRCA	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg24069376	chr3:38537580	EXOG	0.4	11.52	0.41	4.95e-28	Electrocardiographic conduction measures;
BRCA	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg10932868	chr11:921992	NA	0.47	12.11	0.43	1.62e-30	Alzheimer's disease (late onset);
BRCA	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg06917634	chr15:78832804	PSMA4	0.6	13.27	0.46	1.1e-35	Sudden cardiac arrest;
BRCA	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11764359	chr7:65958608	NA	-0.77	-17.73	-0.57	1.71e-57	Aortic root size;
BRCA	cis	rs13064411	0.518	rs9842559	chr3:113252705	A/C	cg18753928	chr3:113234510	CCDC52	-0.41	-9.09	-0.34	1.2e-18	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg17971929	chr21:40555470	PSMG1	0.78	18.39	0.59	6.47e-61	Cognitive function;
BRCA	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg11645453	chr3:52864694	ITIH4	-0.36	-9.53	-0.35	3.31e-20	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg08000102	chr2:233561755	GIGYF2	-0.77	-16.82	-0.55	8.09e-53	Schizophrenia;
BRCA	cis	rs10267417	0.603	rs10258555	chr7:19868344	T/G	cg07541023	chr7:19748670	TWISTNB	0.51	9.25	0.34	3.23e-19	Night sleep phenotypes;
BRCA	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.08	0.34	1.39e-18	Tonsillectomy;
BRCA	cis	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg07460842	chr6:66804631	NA	-0.98	-18.46	-0.59	2.69e-61	Exhaled nitric oxide output;
BRCA	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg04691961	chr3:161091175	C3orf57	-0.44	-10.68	-0.39	1.3e-24	Morning vs. evening chronotype;
BRCA	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14240646	chr10:27532245	ACBD5	-0.6	-9.96	-0.37	8.38e-22	Breast cancer;
BRCA	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg15017067	chr4:17643749	FAM184B	-0.27	-8.1	-0.31	2.82e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg08085267	chr17:45401833	C17orf57	-0.6	-12.11	-0.43	1.48e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7178424	0.875	rs7172967	chr15:62218568	A/C	cg00456672	chr15:62358751	C2CD4A	0.37	8.39	0.31	3.17e-16	Height;
BRCA	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg16414030	chr3:133502952	NA	0.44	10.66	0.39	1.51e-24	Iron status biomarkers;
BRCA	cis	rs9427116	0.502	rs9426829	chr1:154592201	T/C	cg17218026	chr1:154582156	ADAR	0.28	8.23	0.31	1.05e-15	Blood protein levels;
BRCA	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg11764359	chr7:65958608	NA	-0.68	-15.19	-0.52	9.74e-45	Aortic root size;
BRCA	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg13010199	chr12:38710504	ALG10B	0.49	9.58	0.35	2.14e-20	Morning vs. evening chronotype;
BRCA	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg01483505	chr11:975446	AP2A2	0.31	8.31	0.31	5.63e-16	Alzheimer's disease (late onset);
BRCA	cis	rs13046373	0.535	rs2832957	chr21:31973140	C/T	cg24082983	chr21:31802169	KRTAP13-4	0.34	8.54	0.32	9.67e-17	HDL cholesterol;
BRCA	cis	rs57590327	0.503	rs11706976	chr3:81899653	C/T	cg07356753	chr3:81810745	GBE1	-0.44	-10.06	-0.37	3.41e-22	Extraversion;
BRCA	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-14.89	-0.51	2.92e-43	Chronic sinus infection;
BRCA	cis	rs7707921	0.752	rs34981833	chr5:81272732	T/C	cg15871215	chr5:81402204	ATG10	-0.39	-8.21	-0.31	1.22e-15	Breast cancer;
BRCA	cis	rs12618769	0.520	rs4851135	chr2:99050705	T/A	cg10123293	chr2:99228465	UNC50	0.4	8.17	0.31	1.62e-15	Bipolar disorder;
BRCA	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11890956	chr21:40555474	PSMG1	-0.62	-13.8	-0.48	4.27e-38	Menarche (age at onset);
BRCA	cis	rs6433895	0.677	rs6716261	chr2:182031232	A/C	cg00481216	chr2:181971175	NA	0.41	7.82	0.3	2.13e-14	Lymphocyte counts;
BRCA	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg04317338	chr11:64019027	PLCB3	0.55	9.5	0.35	4.22e-20	Mean platelet volume;
BRCA	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg04518342	chr5:131593106	PDLIM4	0.35	8.83	0.33	9.94e-18	Breast cancer;
BRCA	cis	rs698833	0.886	rs786613	chr2:44590066	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.6	-12.54	-0.44	2.2e-32	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs4664304	0.966	rs925407	chr2:160767502	A/C	cg14819504	chr2:160761413	LY75	-0.4	-9.87	-0.36	1.76e-21	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg19717773	chr7:2847554	GNA12	-0.42	-9.01	-0.34	2.3e-18	Height;
BRCA	cis	rs2764980	1.000	rs2764978	chr10:3283385	C/G	cg18054281	chr10:3284093	NA	-0.31	-7.86	-0.3	1.6e-14	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs2658782	0.724	rs2658770	chr11:93261886	A/G	cg15737290	chr11:93063684	CCDC67	0.47	9.1	0.34	1.12e-18	Pulmonary function decline;
BRCA	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg19920283	chr7:105172520	RINT1	0.59	9.53	0.35	3.29e-20	Bipolar disorder (body mass index interaction);
BRCA	trans	rs3960554	0.808	rs2286829	chr7:75677739	G/A	cg19862616	chr7:65841803	NCRNA00174	0.59	12.53	0.44	2.26e-32	Eotaxin levels;
BRCA	cis	rs17401966	0.931	rs34225619	chr1:10371987	C/T	cg03954927	chr1:10346856	KIF1B	0.45	13.15	0.46	4e-35	Hepatocellular carcinoma;
BRCA	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg11707556	chr5:10655725	ANKRD33B	0.44	9.97	0.37	7.29e-22	Coronary artery disease;
BRCA	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg05868516	chr6:26286170	HIST1H4H	0.41	7.96	0.3	7.79e-15	Educational attainment;
BRCA	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg13319975	chr6:146136371	FBXO30	-0.4	-9.15	-0.34	7.47e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg07988820	chr12:82153109	PPFIA2	-0.65	-10.43	-0.38	1.32e-23	Resting heart rate;
BRCA	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg15557168	chr22:42548783	NA	-0.31	-8.58	-0.32	7.15e-17	Cognitive function;
BRCA	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg11502198	chr6:26597334	ABT1	0.61	9.44	0.35	6.79e-20	Small cell lung carcinoma;
BRCA	trans	rs61931739	0.892	rs61931711	chr12:34045374	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.38	-0.35	1.09e-19	Morning vs. evening chronotype;
BRCA	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg07169764	chr2:136633963	MCM6	1.32	32.0	0.78	8.09e-135	Corneal structure;
BRCA	trans	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg13010199	chr12:38710504	ALG10B	-0.4	-8.07	-0.3	3.56e-15	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg23285459	chr7:2802560	GNA12	-0.35	-8.75	-0.33	1.86e-17	Height;
BRCA	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg08807101	chr21:30365312	RNF160	-0.44	-9.36	-0.35	1.36e-19	Dental caries;
BRCA	cis	rs16958440	1.000	rs2289132	chr18:44602292	G/A	cg17192377	chr18:44677553	HDHD2	0.65	9.52	0.35	3.37e-20	Sitting height ratio;
BRCA	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	14.31	0.49	1.79e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg26384229	chr12:38710491	ALG10B	-0.5	-13.14	-0.46	4.29e-35	Morning vs. evening chronotype;
BRCA	cis	rs12413816	0.963	rs12359348	chr10:13765950	C/T	cg16485048	chr10:13749193	FRMD4A	-0.56	-13.48	-0.47	1.31e-36	Red cell distribution width;
BRCA	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg00540400	chr15:79124168	NA	-0.28	-7.83	-0.3	2.06e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg24296786	chr1:45957014	TESK2	0.44	10.16	0.37	1.37e-22	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2016266	0.859	rs10747668	chr12:53737461	C/T	cg26875137	chr12:53738046	NA	0.46	11.81	0.42	2.87e-29	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	17.01	0.56	8.21e-54	Electrocardiographic conduction measures;
BRCA	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.06	-0.43	2.49e-30	Alzheimer's disease;
BRCA	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.4e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg03146154	chr1:46216737	IPP	0.48	10.52	0.38	5.71e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11890956	chr21:40555474	PSMG1	-0.58	-12.66	-0.45	6.22e-33	Menarche (age at onset);
BRCA	cis	rs7552167	0.925	rs4489498	chr1:24512055	A/G	cg01960748	chr1:24522592	NA	0.59	10.69	0.39	1.23e-24	Psoriasis vulgaris;
BRCA	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03264133	chr6:25882463	NA	-0.43	-9.2	-0.34	5.09e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs17270561	0.609	rs4711094	chr6:25706174	T/A	cg17691542	chr6:26056736	HIST1H1C	0.43	8.35	0.31	4.1e-16	Iron status biomarkers;
BRCA	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg12927641	chr6:109611667	NA	0.42	10.93	0.4	1.28e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs72772090	0.634	rs72773906	chr5:96092274	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-13.46	-0.47	1.57e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg21747090	chr2:27597821	SNX17	0.38	8.23	0.31	1.03e-15	Total body bone mineral density;
BRCA	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg18811423	chr2:55921094	PNPT1	0.73	23.12	0.67	1.97e-86	Metabolic syndrome;
BRCA	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.3	-0.38	4.13e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.6	9.68	0.36	9.22e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg11502198	chr6:26597334	ABT1	0.48	9.67	0.36	1.01e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg11822812	chr5:140052017	DND1	-0.32	-8.72	-0.33	2.43e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg07148914	chr20:33460835	GGT7	-0.36	-7.85	-0.3	1.8e-14	Glomerular filtration rate (creatinine);
BRCA	cis	rs701145	0.585	rs1542254	chr3:153864296	C/T	cg17054900	chr3:154042577	DHX36	0.44	8.09	0.3	2.93e-15	Coronary artery disease;
BRCA	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11764359	chr7:65958608	NA	0.76	17.49	0.57	2.79e-56	Aortic root size;
BRCA	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	9.66	0.36	1.03e-20	Lung cancer in ever smokers;
BRCA	cis	rs2559856	1.000	rs2695298	chr12:102082589	G/A	cg12924262	chr12:102091054	CHPT1	0.36	8.13	0.31	2.22e-15	Blood protein levels;
BRCA	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg27478167	chr7:817139	HEATR2	0.54	10.48	0.38	7.72e-24	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg15017067	chr4:17643749	FAM184B	-0.27	-7.99	-0.3	6.5e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs870825	0.616	rs57316663	chr4:185630011	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.28	0.56	3.69e-55	Blood protein levels;
BRCA	trans	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg06521331	chr12:34319734	NA	0.43	8.4	0.32	2.86e-16	Bladder cancer;
BRCA	cis	rs17253792	0.545	rs12879564	chr14:56017694	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-7.95	-0.3	8.3e-15	Putamen volume;
BRCA	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg18305652	chr10:134549665	INPP5A	0.49	11.17	0.4	1.39e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.2	0.54	9.97e-50	Morning vs. evening chronotype;
BRCA	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22857025	chr5:266934	NA	-1.03	-20.11	-0.62	4.43e-70	Breast cancer;
BRCA	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.3	0.35	2.25e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4730250	0.654	rs12705405	chr7:106792517	C/T	cg02696742	chr7:106810147	HBP1	0.57	9.43	0.35	7.51e-20	Osteoarthritis;
BRCA	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.48	0.38	8.08e-24	Motion sickness;
BRCA	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.22	-0.34	4.31e-19	Electroencephalogram traits;
BRCA	cis	rs11605275	1.000	rs11603592	chr11:20023522	C/T	cg14835545	chr11:20032148	NAV2	-0.6	-8.97	-0.33	3.22e-18	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11764359	chr7:65958608	NA	0.77	17.35	0.57	1.46e-55	Aortic root size;
BRCA	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg18252515	chr7:66147081	NA	-0.91	-12.95	-0.46	3.02e-34	Diabetic kidney disease;
BRCA	trans	rs6600671	1.000	rs10903159	chr1:121181997	G/T	cg17023122	chr1:144479586	NA	0.33	7.85	0.3	1.71e-14	Hip geometry;
BRCA	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg06627628	chr2:24431161	ITSN2	-0.85	-15.66	-0.53	5.08e-47	Asthma;
BRCA	cis	rs7903847	0.642	rs7084654	chr10:99135262	G/A	cg20016023	chr10:99160130	RRP12	-0.27	-8.67	-0.32	3.59e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg09658497	chr7:2847517	GNA12	-0.39	-8.03	-0.3	4.85e-15	Height;
BRCA	trans	rs7746199	0.736	rs13212093	chr6:27606716	C/T	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.5	-0.32	1.38e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	trans	rs12517041	1.000	rs10057246	chr5:23294721	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg00757033	chr12:89920650	WDR51B	0.53	10.71	0.39	1.02e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs12545109	0.879	rs1975285	chr8:57358682	G/C	cg09654669	chr8:57350985	NA	-0.43	-8.13	-0.31	2.2e-15	Obesity-related traits;
BRCA	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg27398817	chr8:82754497	SNX16	-0.44	-8.57	-0.32	7.59e-17	Diastolic blood pressure;
BRCA	cis	rs751728	0.643	rs12173787	chr6:33735471	G/C	cg25922239	chr6:33757077	LEMD2	0.37	8.75	0.33	1.85e-17	Crohn's disease;
BRCA	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.65	0.55	5.99e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs490234	0.719	rs13287525	chr9:128219180	T/C	cg14078157	chr9:128172775	NA	-0.39	-8.93	-0.33	4.65e-18	Mean arterial pressure;
BRCA	cis	rs9296092	0.538	rs80012910	chr6:33519542	G/A	cg13560919	chr6:33536144	NA	-0.85	-18.66	-0.59	2.26e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs72781680	0.821	rs72796378	chr2:24167385	G/A	cg08917208	chr2:24149416	ATAD2B	0.64	10.79	0.39	4.83e-25	Lymphocyte counts;
BRCA	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08045932	chr20:61659980	NA	0.5	11.43	0.41	1.2100000000000001e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9463078	0.764	rs10948194	chr6:44951990	A/C	cg25276700	chr6:44698697	NA	-0.37	-8.53	-0.32	1.02e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg17845761	chr1:175162550	KIAA0040	-0.26	-9.91	-0.37	1.23e-21	Alcohol dependence;
BRCA	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg13010199	chr12:38710504	ALG10B	0.45	9.31	0.35	2.04e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.77e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg20607798	chr8:58055168	NA	0.59	8.94	0.33	4.21e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.48	11.36	0.41	2.28e-27	Menarche (age at onset);
BRCA	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06544989	chr22:39130855	UNC84B	-0.33	-7.89	-0.3	1.36e-14	Menopause (age at onset);
BRCA	cis	rs2066819	1.000	rs78495928	chr12:56635080	G/C	cg26734620	chr12:56694298	CS	0.86	9.88	0.36	1.64e-21	Psoriasis vulgaris;
BRCA	cis	rs9309711	0.922	rs13431788	chr2:3482912	G/A	cg10845886	chr2:3471009	TTC15	-0.81	-17.81	-0.58	6.52e-58	Neurofibrillary tangles;
BRCA	trans	rs61931739	0.591	rs10743834	chr12:33916129	A/C	cg26384229	chr12:38710491	ALG10B	0.39	8.91	0.33	5.5e-18	Morning vs. evening chronotype;
BRCA	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg00409905	chr10:38381863	ZNF37A	-0.48	-10.46	-0.38	9.62e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.75	-0.33	1.96e-17	Resting heart rate;
BRCA	cis	rs4363385	0.703	rs4845517	chr1:153003893	T/A	cg24667326	chr1:152973720	SPRR3	-0.32	-8.96	-0.33	3.53e-18	Inflammatory skin disease;
BRCA	trans	rs7395662	0.736	rs4882036	chr11:48749384	A/G	cg00717180	chr2:96193071	NA	-0.32	-8.7	-0.33	2.76e-17	HDL cholesterol;
BRCA	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg02544614	chr20:61657117	NA	0.28	8.13	0.31	2.22e-15	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg17470723	chr8:74884337	TCEB1	0.4	8.62	0.32	5.44e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg17724175	chr1:150552817	MCL1	0.26	8.52	0.32	1.12e-16	Tonsillectomy;
BRCA	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.88	-0.4	2.11e-25	Bone mineral density;
BRCA	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg25036284	chr2:26402008	FAM59B	-0.64	-10.99	-0.4	7.42e-26	Gut microbiome composition (summer);
BRCA	cis	rs936229	0.768	rs936226	chr15:75069282	C/T	cg14664628	chr15:75095509	CSK	-0.93	-26.31	-0.72	6.27e-104	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	9.95	0.37	8.73e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg00105475	chr2:10696890	NA	0.44	10.3	0.38	4.11e-23	Prostate cancer;
BRCA	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg00814883	chr7:100076585	TSC22D4	-0.49	-9.95	-0.37	8.76e-22	Platelet count;
BRCA	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg24812749	chr6:127587940	RNF146	0.68	15.39	0.52	1.1e-45	Breast cancer;
BRCA	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.18	-0.37	1.15e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.34	0.59	1.18e-60	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24110177	chr3:50126178	RBM5	-0.36	-9.85	-0.36	2.05e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs6484504	0.625	rs7940420	chr11:31366700	T/A	cg14844989	chr11:31128820	NA	0.45	9.55	0.35	2.74e-20	Red blood cell count;
BRCA	cis	rs7520050	0.966	rs785495	chr1:46587887	A/G	cg24296786	chr1:45957014	TESK2	0.43	9.73	0.36	5.64e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.0	15.21	0.52	8.07e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg24562669	chr7:97807699	LMTK2	0.47	11.85	0.42	2.05e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7945718	0.839	rs11022512	chr11:12835952	G/A	cg25843174	chr11:12811716	TEAD1	0.22	8.51	0.32	1.23e-16	Educational attainment (years of education);
BRCA	cis	rs897984	0.568	rs8050107	chr16:30893451	C/T	cg02466173	chr16:30829666	NA	0.44	8.77	0.33	1.64e-17	Dementia with Lewy bodies;
BRCA	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg26769984	chr7:1090371	C7orf50	-0.61	-10.98	-0.4	8.42e-26	Bronchopulmonary dysplasia;
BRCA	cis	rs36052053	0.908	rs34739891	chr6:109611467	C/G	cg12927641	chr6:109611667	NA	-0.52	-7.81	-0.3	2.38e-14	Red cell distribution width;
BRCA	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg16590910	chr6:42928470	GNMT	0.43	9.61	0.36	1.61e-20	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg22705602	chr4:152727874	NA	-0.33	-8.26	-0.31	8.67e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg11584989	chr19:19387371	SF4	0.3	7.85	0.3	1.78e-14	Tonsillectomy;
BRCA	cis	rs6580649	1.000	rs10783227	chr12:48400617	C/T	cg24011408	chr12:48396354	COL2A1	0.55	9.35	0.35	1.5e-19	Lung cancer;
BRCA	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg01028140	chr2:1542097	TPO	-0.72	-13.82	-0.48	3.5e-38	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg08000102	chr2:233561755	GIGYF2	-0.64	-14.28	-0.49	2.42e-40	Schizophrenia;
BRCA	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	13.53	0.47	7.36e-37	Mean platelet volume;
BRCA	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11644478	chr21:40555479	PSMG1	0.84	19.75	0.62	4.13e-68	Cognitive function;
BRCA	trans	rs6479891	1.000	rs4747045	chr10:64926482	C/T	cg14819942	chr15:35414228	NA	0.35	8.59	0.32	6.6e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg27535305	chr1:53392650	SCP2	0.46	10.6	0.39	2.78e-24	Monocyte count;
BRCA	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg14784868	chr12:69753453	YEATS4	0.78	25.08	0.7	3.65e-97	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg17330251	chr7:94953956	PON1	-0.37	-8.0	-0.3	5.82e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs113835537	0.529	rs11824771	chr11:66262550	T/C	cg24851651	chr11:66362959	CCS	0.42	8.08	0.3	3.16e-15	Airway imaging phenotypes;
BRCA	cis	rs2953174	0.720	rs2975794	chr2:241515813	C/T	cg07929629	chr2:241523174	NA	0.49	8.81	0.33	1.18e-17	Bipolar disorder;
BRCA	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg12011299	chr4:100065546	ADH4	0.48	10.87	0.4	2.26e-25	Alcohol dependence;
BRCA	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg16339924	chr4:17578868	LAP3	0.57	13.82	0.48	3.54e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg25214090	chr10:38739885	LOC399744	0.57	12.38	0.44	1e-31	Corneal astigmatism;
BRCA	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg08213375	chr14:104286397	PPP1R13B	0.65	18.67	0.59	2.17e-62	Schizophrenia;
BRCA	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg24747557	chr10:131355152	MGMT	0.38	9.52	0.35	3.64e-20	Response to temozolomide;
BRCA	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg02012338	chr4:187126139	CYP4V2	0.81	8.99	0.33	2.87e-18	Blood protein levels;
BRCA	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg22974920	chr21:40686053	BRWD1	-0.38	-8.64	-0.32	4.6e-17	Cognitive function;
BRCA	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg11608241	chr8:8085544	FLJ10661	-0.32	-8.99	-0.34	2.69e-18	Mood instability;
BRCA	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24531977	chr5:56204891	C5orf35	-1.06	-22.83	-0.67	8.61e-85	Initial pursuit acceleration;
BRCA	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.39	0.41	1.73e-27	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg24069376	chr3:38537580	EXOG	0.42	12.03	0.43	3.52e-30	Electrocardiographic conduction measures;
BRCA	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.46	-0.38	9.45e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg18301423	chr5:131593218	PDLIM4	0.35	8.75	0.33	1.93e-17	Acylcarnitine levels;
BRCA	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	11.88	0.43	1.51e-29	Personality dimensions;
BRCA	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg13010199	chr12:38710504	ALG10B	0.5	10.11	0.37	2.19e-22	Bladder cancer;
BRCA	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg23895963	chr12:117471115	NA	-0.53	-9.62	-0.36	1.52e-20	Subcortical brain region volumes;Hippocampal volume;
BRCA	trans	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.37	7.94	0.3	8.81e-15	Mean corpuscular volume;
BRCA	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg03146154	chr1:46216737	IPP	0.45	10.01	0.37	5.09e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg01448562	chr3:133502909	NA	0.36	8.19	0.31	1.46e-15	Alcohol consumption (transferrin glycosylation);
BRCA	trans	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.02	0.3	5.1e-15	Corneal astigmatism;
BRCA	trans	rs11989744	0.597	rs2033788	chr8:23574847	G/T	cg03492747	chr16:86543808	FOXF1	-0.41	-10.01	-0.37	5.14e-22	Waist-hip ratio;
BRCA	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	4.98e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg18904891	chr8:8559673	CLDN23	0.59	11.56	0.42	3.28e-28	Obesity-related traits;
BRCA	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg20607798	chr8:58055168	NA	0.59	8.96	0.33	3.59e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs73086581	1.000	rs17287822	chr20:3978536	C/T	cg02187196	chr20:3869020	PANK2	0.5	9.02	0.34	2.18e-18	Response to antidepressants in depression;
BRCA	cis	rs12431939	1.000	rs34063246	chr14:51663719	G/C	cg23942311	chr14:51606299	NA	-0.43	-8.04	-0.3	4.35e-15	Cancer;
BRCA	trans	rs7939886	0.920	rs11227273	chr11:55893034	T/G	cg15704280	chr7:45808275	SEPT13	0.61	7.83	0.3	1.98e-14	Myopia (pathological);
BRCA	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg26031613	chr14:104095156	KLC1	-0.55	-9.79	-0.36	3.57e-21	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-8.91	-0.33	5.43e-18	Response to antipsychotic treatment;
BRCA	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.16	-0.49	8.86e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	10.01	0.37	5.23e-22	Tonsillectomy;
BRCA	trans	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg07211511	chr3:129823064	LOC729375	-0.62	-11.18	-0.4	1.21e-26	Blood pressure (smoking interaction);
BRCA	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	8.02	0.3	4.9e-15	Tonsillectomy;
BRCA	cis	rs6793245	0.810	rs1805126	chr3:38592406	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.37	8.35	0.31	4.08e-16	QT interval;
BRCA	cis	rs9831754	0.654	rs9837024	chr3:78451637	C/T	cg06138941	chr3:78371609	NA	0.57	12.17	0.43	8.79e-31	Calcium levels;
BRCA	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg17691542	chr6:26056736	HIST1H1C	0.51	10.37	0.38	2.13e-23	Height;
BRCA	cis	rs2991971	0.776	rs12139364	chr1:45890155	T/C	cg15605315	chr1:45957053	TESK2	0.45	8.86	0.33	8.08e-18	High light scatter reticulocyte count;
BRCA	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg15103426	chr22:29168792	CCDC117	-0.48	-12.03	-0.43	3.5e-30	Red cell distribution width;
BRCA	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	18.86	0.6	2.09e-63	Alzheimer's disease (late onset);
BRCA	cis	rs11955398	0.678	rs12522801	chr5:59978406	A/G	cg02684056	chr5:59996105	DEPDC1B	0.39	9.34	0.35	1.5700000000000001e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg14683738	chr19:37701593	ZNF585B	0.5	8.48	0.32	1.57e-16	Coronary artery calcification;
BRCA	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg08470875	chr2:26401718	FAM59B	0.71	11.44	0.41	1.02e-27	Gut microbiome composition (summer);
BRCA	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.67	-0.32	3.58e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03517284	chr6:25882590	NA	-0.55	-11.2	-0.41	1.03e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg22906224	chr7:99728672	NA	0.46	8.75	0.33	1.9e-17	Coronary artery disease;
BRCA	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	8.14	0.31	2.07e-15	Bipolar disorder;
BRCA	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg07169764	chr2:136633963	MCM6	1.01	22.6	0.67	1.49e-83	Corneal structure;
BRCA	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg20587970	chr11:113659929	NA	-1.37	-24.14	-0.69	5.33e-92	Hip circumference adjusted for BMI;
BRCA	cis	rs9790314	0.639	rs6769642	chr3:160763469	C/A	cg04691961	chr3:161091175	C3orf57	-0.41	-8.58	-0.32	7.35e-17	Morning vs. evening chronotype;
BRCA	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg14675211	chr2:100938903	LONRF2	0.52	12.09	0.43	1.87e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs858239	0.669	rs6461687	chr7:23116580	A/G	cg23682824	chr7:23144976	KLHL7	0.34	8.71	0.33	2.67e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg20307385	chr11:47447363	PSMC3	0.76	16.73	0.55	2.31e-52	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.31	8.54	0.32	9.87e-17	Response to antipsychotic treatment;
BRCA	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21659725	chr3:3221576	CRBN	0.44	10.83	0.39	3.15e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg11301795	chr4:187892539	NA	-0.31	-10.27	-0.38	5.22e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12618769	0.597	rs2278206	chr2:99172244	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.44	0.32	2.1e-16	Bipolar disorder;
BRCA	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg18252515	chr7:66147081	NA	-1.08	-16.09	-0.54	3.78e-49	Diabetic kidney disease;
BRCA	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg25801113	chr15:45476975	SHF	-0.32	-7.97	-0.3	7.13e-15	Uric acid levels;
BRCA	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.06	-0.34	1.6e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07256732	chr16:621771	PIGQ	-0.35	-9.53	-0.35	3.18e-20	Height;
BRCA	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg18351406	chr4:77819688	ANKRD56	0.58	12.65	0.45	6.65e-33	Emphysema distribution in smoking;
BRCA	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.33	0.31	4.95e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.51	-12.67	-0.45	5.43e-33	Bipolar disorder and schizophrenia;
BRCA	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg24110177	chr3:50126178	RBM5	0.44	11.27	0.41	5.27e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg27478167	chr7:817139	HEATR2	-0.41	-8.97	-0.33	3.24e-18	Cerebrospinal P-tau181p levels;
BRCA	trans	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg23762105	chr12:34175262	ALG10	0.34	7.84	0.3	1.83e-14	Morning vs. evening chronotype;
BRCA	cis	rs13095912	1.000	rs34965813	chr3:185333012	T/C	cg11274856	chr3:185301563	NA	0.34	8.45	0.32	1.9e-16	Systolic blood pressure;
BRCA	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.37	8.72	0.33	2.32e-17	Tonsillectomy;
BRCA	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg17971929	chr21:40555470	PSMG1	0.79	18.53	0.59	1.18e-61	Cognitive function;
BRCA	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg23231163	chr10:75533350	FUT11	-0.34	-8.89	-0.33	6e-18	Inflammatory bowel disease;
BRCA	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg17063962	chr7:91808500	NA	0.57	13.11	0.46	6.29e-35	Breast cancer;
BRCA	trans	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg17675199	chr6:35436792	RPL10A	-0.3	-8.21	-0.31	1.2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-11.68	-0.42	1.01e-28	Caffeine consumption;
BRCA	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-11.01	-0.4	6.12e-26	Personality dimensions;
BRCA	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19748678	chr4:122722346	EXOSC9	0.72	15.64	0.53	6.71e-47	Type 2 diabetes;
BRCA	cis	rs870825	0.655	rs67380800	chr4:185623788	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	16.89	0.56	3.35e-53	Blood protein levels;
BRCA	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	8.65e-21	Menopause (age at onset);
BRCA	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg05665937	chr4:1216051	CTBP1	-0.37	-7.85	-0.3	1.71e-14	Obesity-related traits;
BRCA	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg20387954	chr3:183756860	HTR3D	0.35	8.18	0.31	1.49e-15	Anterior chamber depth;
BRCA	cis	rs7586879	1.000	rs1865687	chr2:25112885	G/A	cg01884057	chr2:25150051	NA	0.33	8.24	0.31	9.61e-16	Body mass index;
BRCA	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.51	-11.26	-0.41	5.77e-27	Colorectal cancer;
BRCA	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg02297831	chr4:17616191	MED28	0.36	8.33	0.31	4.96e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.59	-12.31	-0.44	2.1e-31	Lymphocyte counts;
BRCA	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg25036284	chr2:26402008	FAM59B	-0.87	-15.81	-0.53	9.3e-48	Gut microbiome composition (summer);
BRCA	cis	rs30380	0.553	rs152280	chr5:96161942	T/G	cg16492584	chr5:96139282	ERAP1	-0.44	-10.05	-0.37	3.83e-22	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg24692254	chr21:30365293	RNF160	0.43	7.86	0.3	1.66e-14	Cognitive test performance;
BRCA	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-8.09	-0.3	2.91e-15	Blood pressure (smoking interaction);
BRCA	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg05340658	chr4:99064831	C4orf37	-0.48	-11.16	-0.4	1.59e-26	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2012796	0.956	rs7147254	chr14:81820503	G/A	cg02996355	chr14:81879375	NA	0.51	9.98	0.37	6.92e-22	Night sleep phenotypes;
BRCA	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg18904891	chr8:8559673	CLDN23	0.65	12.97	0.46	2.56e-34	Obesity-related traits;
BRCA	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg08085267	chr17:45401833	C17orf57	-0.56	-11.56	-0.42	3.47e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4363385	0.818	rs454993	chr1:153008992	C/G	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-16.3	-0.54	3.41e-50	Bipolar disorder;
BRCA	cis	rs4363385	0.747	rs6704105	chr1:152964397	C/G	cg25856811	chr1:152973957	SPRR3	-0.35	-9.56	-0.35	2.58e-20	Inflammatory skin disease;
BRCA	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.57	-11.9	-0.43	1.26e-29	Lymphocyte counts;
BRCA	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg03161606	chr19:29218774	NA	0.46	8.11	0.31	2.56e-15	Methadone dose in opioid dependence;
BRCA	cis	rs7520050	0.778	rs2934857	chr1:46039612	A/G	cg24296786	chr1:45957014	TESK2	-0.49	-11.66	-0.42	1.33e-28	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg22467129	chr15:76604101	ETFA	-0.49	-10.63	-0.39	2.11e-24	Blood metabolite levels;
BRCA	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.17e-19	Total body bone mineral density;
BRCA	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.81	-0.36	2.89e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs10746514	0.833	rs2026302	chr1:232264047	A/G	cg09506761	chr1:232265262	NA	-0.42	-8.77	-0.33	1.57e-17	Response to statin therapy;
BRCA	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg06115741	chr20:33292138	TP53INP2	0.5	11.11	0.4	2.47e-26	Coronary artery disease;
BRCA	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-11.28	-0.41	4.79e-27	Chronic sinus infection;
BRCA	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg20387954	chr3:183756860	HTR3D	0.45	10.03	0.37	4.19e-22	Anterior chamber depth;
BRCA	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-8.98	-0.33	3.08e-18	Alzheimer's disease (late onset);
BRCA	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	ch.11.42038R	chr11:967971	AP2A2	0.52	16.6	0.55	9.93e-52	Alzheimer's disease (late onset);
BRCA	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg02734326	chr4:10020555	SLC2A9	0.35	7.83	0.3	2.07e-14	Bone mineral density;
BRCA	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg08222618	chr4:941054	TMEM175	0.4	9.4	0.35	9.62e-20	Sjögren's syndrome;
BRCA	trans	rs783540	0.900	rs783525	chr15:83284629	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.28	-8.9	-0.33	5.85e-18	Schizophrenia;
BRCA	cis	rs4074536	0.536	rs6687961	chr1:116289824	T/C	cg21648376	chr1:116311395	CASQ2	-0.49	-8.71	-0.33	2.5e-17	QRS duration;
BRCA	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg03354898	chr7:1950403	MAD1L1	-0.46	-10.07	-0.37	3.04e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg04990556	chr1:26633338	UBXN11	0.52	8.73	0.33	2.14e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7818345	0.904	rs6997164	chr8:19287856	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.3	7.9	0.3	1.18e-14	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	20.17	0.62	2.26e-70	Smoking behavior;
BRCA	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg12365402	chr11:9010492	NRIP3	-0.44	-10.4	-0.38	1.66e-23	Hemoglobin concentration;
BRCA	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg21770322	chr7:97807741	LMTK2	0.46	11.9	0.43	1.23e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs829883	0.738	rs249854	chr12:98862772	G/A	cg25150519	chr12:98850993	NA	0.68	16.4	0.54	1.01e-50	Colorectal adenoma (advanced);
BRCA	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.36	-8.03	-0.3	4.71e-15	Longevity;Endometriosis;
BRCA	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg24558204	chr6:135376177	HBS1L	0.46	12.59	0.45	1.23e-32	Red blood cell count;
BRCA	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.83	-0.36	2.54e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10754283	0.870	rs2390764	chr1:90112827	T/G	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.31e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg26893861	chr17:41843967	DUSP3	0.69	13.23	0.46	1.74e-35	Triglycerides;
BRCA	cis	rs4285028	0.699	rs6771068	chr3:121478745	A/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.76	14.29	0.49	2.12e-40	Multiple sclerosis;
BRCA	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg24631222	chr15:78858424	CHRNA5	0.49	9.49	0.35	4.6e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg15485101	chr11:133734466	NA	0.41	9.76	0.36	4.46e-21	Childhood ear infection;
BRCA	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg26248373	chr2:1572462	NA	-0.66	-15.48	-0.52	3.7e-46	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg18154014	chr19:37997991	ZNF793	0.47	8.78	0.33	1.45e-17	Coronary artery calcification;
BRCA	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg18512352	chr11:47633146	NA	-0.38	-9.1	-0.34	1.1e-18	Subjective well-being;
BRCA	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	16.69	0.55	3.7e-52	Alzheimer's disease;
BRCA	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg07371521	chr5:154026371	NA	0.42	8.13	0.31	2.25e-15	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg08885076	chr2:99613938	TSGA10	-0.6	-13.41	-0.47	2.63e-36	Chronic sinus infection;
BRCA	cis	rs1209950	0.966	rs1209948	chr21:40170078	C/T	cg01359822	chr21:40176597	ETS2	0.34	8.51	0.32	1.24e-16	Non-small cell lung cancer (survival);
BRCA	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg21475434	chr5:93447410	FAM172A	0.67	8.65	0.32	4.14e-17	Diabetic retinopathy;
BRCA	cis	rs7715811	1.000	rs7446025	chr5:13773800	T/A	cg07548982	chr5:13769939	DNAH5	-0.41	-9.06	-0.34	1.57e-18	Subclinical atherosclerosis traits (other);
BRCA	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg23711669	chr6:146136114	FBXO30	-0.78	-18.78	-0.6	5.47e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg27129171	chr3:47204927	SETD2	0.76	19.31	0.61	8.16e-66	Colorectal cancer;
BRCA	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07256732	chr16:621771	PIGQ	-0.35	-9.21	-0.34	4.54e-19	Height;
BRCA	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg04450456	chr4:17643702	FAM184B	-0.35	-9.98	-0.37	7.06e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs651907	1.000	rs651907	chr3:101600724	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.35	8.21	0.31	1.19e-15	Colorectal cancer;
BRCA	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.44	0.35	6.85e-20	Tonsillectomy;
BRCA	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg26149184	chr10:133730230	NA	0.39	7.89	0.3	1.35e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.53	8.26	0.31	8.43e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7560272	0.538	rs13014700	chr2:73920121	C/G	cg20560298	chr2:73613845	ALMS1	0.35	9.18	0.34	5.74e-19	Schizophrenia;
BRCA	cis	rs3820928	0.874	rs10166736	chr2:227900419	C/T	cg11843606	chr2:227700838	RHBDD1	-0.35	-7.88	-0.3	1.45e-14	Pulmonary function;
BRCA	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg24069376	chr3:38537580	EXOG	-0.42	-11.85	-0.42	2.11e-29	Electrocardiographic conduction measures;
BRCA	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg05985134	chr18:33552581	C18orf21	0.65	12.36	0.44	1.25e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg10523679	chr1:76189770	ACADM	0.91	22.35	0.66	3.42e-82	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.39	0.38	1.77e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06108461	chr20:60628389	TAF4	-0.73	-15.3	-0.52	3e-45	Body mass index;
BRCA	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg00898013	chr13:113819073	PROZ	-0.35	-8.61	-0.32	5.77e-17	Platelet distribution width;
BRCA	cis	rs922182	0.595	rs9302232	chr15:64205358	C/T	cg24729988	chr15:64271149	DAPK2	0.48	10.0	0.37	5.88e-22	Blood protein levels;
BRCA	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg23018236	chr17:30244563	NA	0.61	9.24	0.34	3.49e-19	Hip circumference adjusted for BMI;
BRCA	cis	rs738321	0.725	rs5756926	chr22:38542613	T/C	cg20207973	chr22:38506712	BAIAP2L2	0.38	9.22	0.34	4.39e-19	Breast cancer;
BRCA	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg26384229	chr12:38710491	ALG10B	0.81	20.78	0.64	1.13e-73	Heart rate;
BRCA	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg00677455	chr12:58241039	CTDSP2	0.61	13.77	0.48	5.58e-38	Multiple sclerosis;
BRCA	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg21770322	chr7:97807741	LMTK2	0.41	10.94	0.4	1.14e-25	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.5	0.35	4e-20	Menopause (age at onset);
BRCA	cis	rs9287719	0.649	rs10190774	chr2:10718746	T/A	cg00105475	chr2:10696890	NA	0.41	9.18	0.34	5.97e-19	Prostate cancer;
BRCA	cis	rs6714710	0.580	rs11692470	chr2:98520564	T/C	cg26665480	chr2:98280029	ACTR1B	0.59	13.64	0.47	2.36e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs6484504	0.576	rs158140	chr11:31212971	T/C	cg26647111	chr11:31128758	NA	-0.44	-9.67	-0.36	9.59e-21	Red blood cell count;
BRCA	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00149659	chr3:10157352	C3orf10	0.8	13.68	0.48	1.56e-37	Alzheimer's disease;
BRCA	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg18964960	chr10:1102726	WDR37	0.66	9.22	0.34	4.41e-19	Response to angiotensin II receptor blocker therapy;
BRCA	trans	rs1973993	0.567	rs2800431	chr1:97000998	C/T	cg10631902	chr5:14652156	NA	0.47	14.22	0.49	4.78e-40	Weight;
BRCA	cis	rs13064411	0.627	rs28536176	chr3:113143625	T/C	cg18753928	chr3:113234510	CCDC52	-0.52	-9.73	-0.36	5.87e-21	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg18806716	chr10:30721971	MAP3K8	0.43	10.12	0.37	2.04e-22	Inflammatory bowel disease;
BRCA	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	9.24	0.34	3.63e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6121246	0.609	rs2376998	chr20:30340663	T/C	cg13852791	chr20:30311386	BCL2L1	0.84	18.19	0.58	7.19e-60	Mean corpuscular hemoglobin;
BRCA	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	15.47	0.52	4.14e-46	Colorectal cancer;
BRCA	trans	rs6600671	0.934	rs12131379	chr1:121293437	T/C	cg00646200	chr1:148855367	NA	0.32	8.21	0.31	1.24e-15	Hip geometry;
BRCA	cis	rs16976116	0.901	rs28589384	chr15:55494366	A/G	cg11288833	chr15:55489084	RSL24D1	0.48	10.67	0.39	1.39e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg20503657	chr10:835505	NA	1.09	18.05	0.58	3.54e-59	Eosinophil percentage of granulocytes;
BRCA	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg01324343	chr3:183735012	ABCC5	-0.85	-21.93	-0.66	7.07e-80	Anterior chamber depth;
BRCA	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg05340658	chr4:99064831	C4orf37	0.61	14.56	0.5	1.14e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs16854884	0.558	rs6768153	chr3:143667429	C/A	cg06585982	chr3:143692056	C3orf58	0.43	8.71	0.33	2.67e-17	Economic and political preferences (feminism/equality);
BRCA	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.58	12.38	0.44	1.07e-31	Lymphocyte percentage of white cells;
BRCA	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.48	-13.91	-0.48	1.24e-38	Lung cancer;
BRCA	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg08805041	chr16:621841	PIGQ	-0.3	-8.05	-0.3	4.03e-15	Height;
BRCA	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.33	0.38	3.05e-23	Bladder cancer;
BRCA	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.17	-0.4	1.33e-26	Schizophrenia;
BRCA	trans	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	20.79	0.64	1.05e-73	Exhaled nitric oxide output;
BRCA	cis	rs700651	0.789	rs1813106	chr2:198880589	A/G	cg00792783	chr2:198669748	PLCL1	0.38	8.75	0.33	1.91e-17	Intracranial aneurysm;
BRCA	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-17.74	-0.57	1.42e-57	Chronic sinus infection;
BRCA	cis	rs11229555	0.645	rs7117080	chr11:58178677	C/G	cg15696309	chr11:58395628	NA	-0.4	-8.9	-0.33	5.8e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6545883	0.894	rs2600672	chr2:61536740	A/G	cg15711740	chr2:61764176	XPO1	-0.51	-13.15	-0.46	3.79e-35	Tuberculosis;
BRCA	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	12.02	0.43	3.94e-30	Tonsillectomy;
BRCA	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg22906224	chr7:99728672	NA	0.46	8.72	0.33	2.31e-17	Coronary artery disease;
BRCA	cis	rs2625529	0.689	rs12161990	chr15:72202440	T/C	cg16672083	chr15:72433130	SENP8	0.7	16.17	0.54	1.44e-49	Red blood cell count;
BRCA	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg11663144	chr21:46675770	NA	-0.57	-13.28	-0.47	1.03e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg15549821	chr19:49342101	PLEKHA4	-0.66	-9.91	-0.36	1.24e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs490234	0.841	rs513568	chr9:128411854	G/A	cg14078157	chr9:128172775	NA	-0.34	-7.98	-0.3	6.88e-15	Mean arterial pressure;
BRCA	cis	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.13	-0.4	2.05e-26	Morning vs. evening chronotype;
BRCA	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg15704280	chr7:45808275	SEPT13	-0.92	-24.75	-0.7	2.5e-95	Coronary artery disease;
BRCA	cis	rs2882667	0.690	rs288002	chr5:138232087	T/C	cg04439458	chr5:138467593	SIL1	-0.34	-8.4	-0.32	2.97e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg05347473	chr6:146136440	FBXO30	0.41	8.07	0.3	3.41e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	12.18	0.43	7.65e-31	Mean platelet volume;
BRCA	cis	rs77972916	0.519	rs13411327	chr2:43515483	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-8.64	-0.32	4.57e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg08885076	chr2:99613938	TSGA10	0.41	9.63	0.36	1.4e-20	Chronic sinus infection;
BRCA	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.85	-0.77	1.15e-128	Schizophrenia;
BRCA	cis	rs6132905	0.520	rs2422824	chr20:2647370	C/T	cg01629329	chr20:2633258	NOP56;MIR1292	-0.4	-7.91	-0.3	1.16e-14	Mumps;
BRCA	cis	rs10129255	0.536	rs3944157	chr14:107138303	C/T	cg07958169	chr14:107095056	NA	-0.36	-7.84	-0.3	1.83e-14	Kawasaki disease;
BRCA	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg20673091	chr1:2541236	MMEL1	0.33	8.51	0.32	1.27e-16	Ulcerative colitis;
BRCA	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.15	-0.43	1.08e-30	Total cholesterol levels;
BRCA	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg27478167	chr7:817139	HEATR2	-0.42	-9.08	-0.34	1.33e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7617773	0.832	rs6775114	chr3:48182620	G/C	cg11946769	chr3:48343235	NME6	-0.41	-9.07	-0.34	1.49e-18	Coronary artery disease;
BRCA	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg17366294	chr4:99064904	C4orf37	0.42	9.92	0.37	1.13e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.58	-10.76	-0.39	6.54e-25	Renal function-related traits (BUN);
BRCA	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.4	7.99	0.3	6.48e-15	Tonsillectomy;
BRCA	cis	rs3820928	0.874	rs1917122	chr2:227835681	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.43	-0.32	2.26e-16	Pulmonary function;
BRCA	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.5	0.32	1.34e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs965469	0.779	rs6051820	chr20:3365301	A/G	cg25506879	chr20:3388711	C20orf194	-0.48	-9.47	-0.35	5.34e-20	IFN-related cytopenia;
BRCA	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	trans	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg01620082	chr3:125678407	NA	-0.66	-8.19	-0.31	1.43e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg13256891	chr4:100009986	ADH5	0.54	10.01	0.37	5.06e-22	Smoking initiation;
BRCA	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg12927641	chr6:109611667	NA	-0.42	-10.89	-0.4	1.94e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg06627628	chr2:24431161	ITSN2	-0.5	-8.24	-0.31	9.770000000000001e-16	Lymphocyte counts;
BRCA	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg14004847	chr7:1930337	MAD1L1	0.44	8.52	0.32	1.12e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg16482183	chr6:26056742	HIST1H1C	0.55	11.71	0.42	7.66e-29	Height;
BRCA	cis	rs1190552	0.846	rs11160683	chr14:102933347	A/G	cg18135206	chr14:102964638	TECPR2	0.43	8.4	0.32	2.92e-16	Blood protein levels;
BRCA	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg20701182	chr2:24300061	SF3B14	0.58	9.05	0.34	1.68e-18	Lymphocyte counts;
BRCA	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.32	0.49	1.57e-40	Motion sickness;
BRCA	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg04691961	chr3:161091175	C3orf57	-0.4	-9.05	-0.34	1.77e-18	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg23649088	chr2:200775458	C2orf69	0.6	8.89	0.33	6.23e-18	Schizophrenia;
BRCA	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg00717180	chr2:96193071	NA	-0.37	-10.34	-0.38	2.76e-23	HDL cholesterol;
BRCA	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg04013166	chr16:89971882	TCF25	0.52	9.51	0.35	3.7799999999999997e-20	Skin colour saturation;
BRCA	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg00666640	chr1:248458726	OR2T12	0.32	8.94	0.33	4.09e-18	Common traits (Other);
BRCA	cis	rs2282802	0.685	rs2116790	chr5:139654115	G/A	cg26211634	chr5:139558579	C5orf32	0.35	8.34	0.31	4.62e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg06060754	chr5:176797920	RGS14	-0.66	-10.19	-0.37	1.1e-22	Urate levels in lean individuals;
BRCA	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg04450456	chr4:17643702	FAM184B	0.34	9.77	0.36	4.31e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-11.34	-0.41	2.9e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-8.47	-0.32	1.74e-16	Personality dimensions;
BRCA	cis	rs1568889	1.000	rs12803716	chr11:28055111	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	14.66	0.5	3.63e-42	Bipolar disorder;
BRCA	cis	rs7760949	0.889	rs9396262	chr6:13927418	C/T	cg27413430	chr6:13925136	RNF182	0.47	9.37	0.35	1.26e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg06494592	chr3:125709126	NA	-0.49	-8.3	-0.31	6.03e-16	Blood pressure (smoking interaction);
BRCA	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	8.84	0.33	9.07e-18	Motion sickness;
BRCA	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg06618935	chr21:46677482	NA	-0.36	-7.88	-0.3	1.43e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg26043149	chr18:55253948	FECH	-0.41	-9.11	-0.34	1.07e-18	Bone mineral density;
BRCA	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg16141378	chr3:129829833	LOC729375	0.33	8.43	0.32	2.36e-16	Mood instability;
BRCA	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg24829409	chr8:58192753	C8orf71	-0.47	-9.04	-0.34	1.81e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08280861	chr8:58055591	NA	0.54	8.82	0.33	1.12e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs637571	0.726	rs689274	chr11:65665988	A/G	cg17712092	chr4:129076599	LARP1B	-0.67	-17.13	-0.56	2.03e-54	Eosinophil percentage of white cells;
BRCA	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.23e-24	Motion sickness;
BRCA	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg08917208	chr2:24149416	ATAD2B	0.87	12.43	0.44	6.24e-32	Lymphocyte counts;
BRCA	cis	rs16976116	0.806	rs28466870	chr15:55495113	C/T	cg11288833	chr15:55489084	RSL24D1	0.48	10.68	0.39	1.25e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1784581	0.928	rs1789995	chr6:162396518	C/T	cg17173639	chr6:162384350	PARK2	-0.44	-10.6	-0.39	2.69e-24	Itch intensity from mosquito bite;
BRCA	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg26384229	chr12:38710491	ALG10B	-0.46	-10.43	-0.38	1.3e-23	Bladder cancer;
BRCA	cis	rs2964802	0.505	rs7717266	chr5:10832134	C/G	cg14521931	chr5:10832172	NA	-0.58	-12.99	-0.46	2.1e-34	Major depressive disorder;Recurrent major depressive disorder;
BRCA	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg08885076	chr2:99613938	TSGA10	0.46	10.71	0.39	1.04e-24	Chronic sinus infection;
BRCA	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg17063962	chr7:91808500	NA	0.53	12.45	0.44	5.16e-32	Breast cancer;
BRCA	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg21782813	chr7:2030301	MAD1L1	-0.38	-10.21	-0.37	9.35e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg16590910	chr6:42928470	GNMT	-0.36	-7.92	-0.3	1.04e-14	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2806561	0.734	rs10799788	chr1:23356864	G/A	cg19743168	chr1:23544995	NA	0.35	8.04	0.3	4.5e-15	Height;
BRCA	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg08885076	chr2:99613938	TSGA10	0.46	10.66	0.39	1.52e-24	Chronic sinus infection;
BRCA	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16744531	chr19:17905626	B3GNT3	0.54	11.77	0.42	4.59e-29	Tumor biomarkers;
BRCA	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg05340658	chr4:99064831	C4orf37	-0.45	-10.44	-0.38	1.18e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs9300255	0.782	rs12809602	chr12:123768916	T/G	cg00376283	chr12:123451042	ABCB9	-0.55	-11.17	-0.4	1.39e-26	Neutrophil percentage of white cells;
BRCA	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg05623727	chr3:50126028	RBM5	-0.52	-12.41	-0.44	7.83e-32	Body mass index;
BRCA	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg00981070	chr1:2046702	PRKCZ	0.31	8.15	0.31	1.92e-15	Height;
BRCA	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg03354898	chr7:1950403	MAD1L1	-0.43	-9.41	-0.35	8.72e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-9.88	-0.36	1.66e-21	Schizophrenia;
BRCA	cis	rs72627509	0.857	rs56155140	chr4:57824451	G/A	cg26694713	chr4:57773883	REST	0.49	9.43	0.35	7.34e-20	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs11674184	0.564	rs746579	chr2:11744694	C/T	cg07314298	chr2:11723111	GREB1	-0.66	-12.83	-0.45	1.06e-33	Endometriosis;
BRCA	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg02079420	chr8:82753780	SNX16	0.31	8.38	0.31	3.42e-16	Diastolic blood pressure;
BRCA	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.28e-23	Prostate cancer;
BRCA	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg12641515	chr19:46296257	DMWD	0.68	16.47	0.55	4.45e-51	Coronary artery disease;
BRCA	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg22920501	chr2:26401640	FAM59B	-0.91	-16.27	-0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg07636037	chr3:49044803	WDR6	0.98	29.26	0.76	4.37e-120	Parkinson's disease;
BRCA	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg27446573	chr6:127587934	RNF146	0.89	20.78	0.64	1.15e-73	Breast cancer;
BRCA	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg01483505	chr11:975446	AP2A2	0.33	9.05	0.34	1.71e-18	Alzheimer's disease (late onset);
BRCA	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg18811423	chr2:55921094	PNPT1	0.73	24.24	0.69	1.54e-92	Metabolic syndrome;
BRCA	trans	rs8002861	0.641	rs6561148	chr13:44426269	C/T	cg17145862	chr1:211918768	LPGAT1	0.46	10.33	0.38	3.21e-23	Leprosy;
BRCA	cis	rs6973256	0.897	rs12530581	chr7:133342955	A/T	cg07491979	chr7:133331646	EXOC4	-0.39	-9.05	-0.34	1.69e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs7181230	0.885	rs17723133	chr15:40365418	A/G	cg22705835	chr10:65332833	REEP3	0.41	9.37	0.35	1.21e-19	Dehydroepiandrosterone sulphate levels;
BRCA	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.45e-23	Prostate cancer;
BRCA	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg02891314	chr5:179741120	GFPT2	-0.69	-13.97	-0.48	6.98e-39	Height;
BRCA	cis	rs600806	0.888	rs2228604	chr1:109884775	A/C	cg20591472	chr1:110008990	SYPL2	0.32	8.16	0.31	1.83e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21659725	chr3:3221576	CRBN	0.5	12.9	0.45	5.2e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs6745190	0.575	rs6711938	chr2:181977028	C/T	cg00481216	chr2:181971175	NA	0.4	9.45	0.35	6.15e-20	White blood cell count;
BRCA	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg21385522	chr1:16154831	NA	0.44	8.16	0.31	1.73e-15	Dilated cardiomyopathy;
BRCA	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg04450456	chr4:17643702	FAM184B	-0.32	-9.29	-0.34	2.43e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg23711669	chr6:146136114	FBXO30	0.63	14.68	0.5	2.85e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-9.13	-0.34	8.78e-19	Monocyte percentage of white cells;
BRCA	cis	rs1712517	0.771	rs61869827	chr10:105079439	T/C	cg05636881	chr10:105038444	INA	0.35	7.99	0.3	6.39e-15	Migraine;
BRCA	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg12219531	chr12:120966889	COQ5	0.52	10.98	0.4	7.98e-26	High light scatter reticulocyte count;
BRCA	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg11764359	chr7:65958608	NA	0.65	11.58	0.42	2.9e-28	Aortic root size;
BRCA	cis	rs7246657	0.722	rs3101746	chr19:38146400	T/A	cg18154014	chr19:37997991	ZNF793	-0.49	-9.18	-0.34	6.1e-19	Coronary artery calcification;
BRCA	trans	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg17675199	chr6:35436792	RPL10A	-0.3	-8.11	-0.31	2.52e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg02187348	chr16:89574699	SPG7	-0.39	-8.75	-0.33	1.84e-17	Multiple myeloma (IgH translocation);
BRCA	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg20701182	chr2:24300061	SF3B14	0.59	9.19	0.34	5.66e-19	Lymphocyte counts;
BRCA	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg12292205	chr6:26970375	C6orf41	0.72	16.32	0.54	2.62e-50	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9807989	0.507	rs10204757	chr2:102998974	A/C	cg03938978	chr2:103052716	IL18RAP	0.29	8.41	0.32	2.59e-16	Asthma;
BRCA	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg05623727	chr3:50126028	RBM5	0.4	8.57	0.32	7.93e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs897984	0.553	rs2125293	chr16:30863875	T/C	cg02466173	chr16:30829666	NA	0.45	8.99	0.33	2.85e-18	Dementia with Lewy bodies;
BRCA	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg15839431	chr19:19639596	YJEFN3	-0.34	-7.81	-0.3	2.28e-14	Bipolar disorder;
BRCA	cis	rs2637266	0.935	rs2579771	chr10:78407544	A/G	cg18941641	chr10:78392320	NA	0.36	8.27	0.31	7.75e-16	Pulmonary function;
BRCA	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg16230307	chr14:35515116	FAM177A1	0.69	14.5	0.5	2.22e-41	Psoriasis;
BRCA	cis	rs12618769	0.625	rs2278207	chr2:99163261	T/A	cg10123293	chr2:99228465	UNC50	0.44	8.52	0.32	1.11e-16	Bipolar disorder;
BRCA	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.18	0.46	2.94e-35	Electroencephalogram traits;
BRCA	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg07810366	chr2:100720526	AFF3	-0.31	-7.92	-0.3	1.05e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs13082711	0.911	rs3755652	chr3:27472936	A/G	cg02860705	chr3:27208620	NA	-0.59	-10.87	-0.4	2.21e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.01	-0.48	4.47e-39	Extrinsic epigenetic age acceleration;
BRCA	trans	rs1459104	1.000	rs12575696	chr11:55057235	C/T	cg03929089	chr4:120376271	NA	0.64	7.84	0.3	1.95e-14	Body mass index;
BRCA	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg03433033	chr1:76189801	ACADM	-0.76	-17.43	-0.57	5.73e-56	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10046574	0.831	rs10239457	chr7:135116926	A/G	cg27474649	chr7:135195673	CNOT4	-0.58	-8.32	-0.31	5.43e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2953145	0.545	rs2975755	chr2:241524919	G/A	cg07929629	chr2:241523174	NA	0.55	11.94	0.43	8.39e-30	Bipolar disorder;
BRCA	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.14e-19	Total body bone mineral density;
BRCA	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg01528321	chr10:82214614	TSPAN14	1.05	20.22	0.62	1.19e-70	Post bronchodilator FEV1;
BRCA	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg26752003	chr8:145688521	CYHR1	0.38	8.62	0.32	5.36e-17	Age at first birth;
BRCA	cis	rs1003719	0.654	rs764175	chr21:38517058	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.4	-0.49	6.44e-41	Eye color traits;
BRCA	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg03433033	chr1:76189801	ACADM	0.4	8.21	0.31	1.18e-15	Daytime sleep phenotypes;
BRCA	cis	rs1832871	0.578	rs262820	chr6:158663101	G/T	cg07215822	chr6:158701037	NA	-0.49	-10.32	-0.38	3.33e-23	Height;
BRCA	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg10818794	chr15:86012489	AKAP13	-0.31	-8.68	-0.32	3.25e-17	Coronary artery disease;
BRCA	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg23711669	chr6:146136114	FBXO30	0.73	16.96	0.56	1.59e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.45	8.02	0.3	5e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg01256987	chr12:42539512	GXYLT1	-0.46	-9.09	-0.34	1.26e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg23711669	chr6:146136114	FBXO30	-0.69	-16.31	-0.54	2.95e-50	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg00106254	chr7:1943704	MAD1L1	-0.38	-9.31	-0.35	2.08e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-10.31	-0.38	3.66e-23	Blood metabolite levels;
BRCA	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg13319975	chr6:146136371	FBXO30	0.42	9.76	0.36	4.71e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg01802117	chr1:53393560	SCP2	-0.36	-8.39	-0.31	3.16e-16	Monocyte count;
BRCA	trans	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	9.35e-15	Corneal astigmatism;
BRCA	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg13402656	chr8:1511478	DLGAP2	-0.48	-11.14	-0.4	1.83e-26	Lung cancer;
BRCA	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.89	17.71	0.57	2.18e-57	Smoking behavior;
BRCA	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg04691961	chr3:161091175	C3orf57	-0.59	-14.1	-0.49	1.64e-39	Morning vs. evening chronotype;
BRCA	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg01884057	chr2:25150051	NA	0.34	9.0	0.34	2.62e-18	Body mass index;
BRCA	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg14983838	chr19:29218262	NA	0.56	10.85	0.39	2.64e-25	Methadone dose in opioid dependence;
BRCA	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-9.91	-0.37	1.23e-21	Monocyte percentage of white cells;
BRCA	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2882667	0.690	rs13177415	chr5:138249940	G/T	cg04439458	chr5:138467593	SIL1	-0.31	-7.85	-0.3	1.77e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00149659	chr3:10157352	C3orf10	0.81	14.21	0.49	5.29e-40	Alzheimer's disease;
BRCA	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg18252515	chr7:66147081	NA	-1.05	-15.87	-0.53	4.76e-48	Diabetic kidney disease;
BRCA	trans	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.28	0.31	7.06e-16	Mean corpuscular volume;
BRCA	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg16325326	chr1:53192061	ZYG11B	0.91	24.68	0.7	5.47e-95	Monocyte count;
BRCA	cis	rs1451375	0.550	rs10239830	chr7:50603829	A/G	cg18232548	chr7:50535776	DDC	0.44	9.24	0.34	3.68e-19	Malaria;
BRCA	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Parkinson's disease;
BRCA	cis	rs2839627	0.638	rs9974287	chr21:44317003	T/G	cg03543861	chr21:44258195	NA	0.43	8.05	0.3	3.95e-15	Information processing speed;
BRCA	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg03585969	chr10:35415529	CREM	0.56	11.58	0.42	2.9e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7520050	0.966	rs7540325	chr1:46338217	A/T	cg24296786	chr1:45957014	TESK2	0.44	9.89	0.36	1.5e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg21138405	chr5:131827807	IRF1	0.36	10.75	0.39	7.05e-25	Asthma (sex interaction);
BRCA	cis	rs858239	0.601	rs10255228	chr7:23158863	G/T	cg23682824	chr7:23144976	KLHL7	0.45	12.06	0.43	2.53e-30	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg00106254	chr7:1943704	MAD1L1	-0.32	-7.89	-0.3	1.34e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg07169764	chr2:136633963	MCM6	1.27	26.67	0.73	6.92e-106	Corneal structure;
BRCA	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.75	16.11	0.54	2.92e-49	HIV-1 control;
BRCA	cis	rs3784262	0.528	rs11071364	chr15:58334113	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.4	-0.35	9.93e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs13046373	0.534	rs9305426	chr21:31964916	A/C	cg06468780	chr21:31798236	KRTAP13-3	0.38	9.2	0.34	5e-19	HDL cholesterol;
BRCA	cis	rs13046373	0.535	rs2832957	chr21:31973140	C/T	cg06468780	chr21:31798236	KRTAP13-3	0.36	8.97	0.33	3.29e-18	HDL cholesterol;
BRCA	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg08917208	chr2:24149416	ATAD2B	0.92	13.73	0.48	8.4e-38	Lymphocyte counts;
BRCA	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.76	-11.6	-0.42	2.39e-28	Schizophrenia;
BRCA	cis	rs13082711	0.516	rs13084067	chr3:27358935	A/T	cg02860705	chr3:27208620	NA	0.61	11.73	0.42	6.55e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs17401966	0.964	rs34215045	chr1:10361679	G/A	cg03954927	chr1:10346856	KIF1B	0.46	13.08	0.46	8.41e-35	Hepatocellular carcinoma;
BRCA	cis	rs6942756	1.000	rs7780886	chr7:128879347	G/A	cg02491457	chr7:128862824	NA	-0.73	-14.91	-0.51	2.25e-43	White matter hyperintensity burden;
BRCA	trans	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg04565464	chr8:145669602	NFKBIL2	0.4	8.65	0.32	4.09e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg09307838	chr4:120376055	NA	0.69	14.02	0.49	3.82e-39	Corneal astigmatism;
BRCA	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg09537434	chr19:41945824	ATP5SL	-1.0	-23.23	-0.68	5.32e-87	Height;
BRCA	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg03188948	chr7:1209495	NA	0.83	11.33	0.41	2.93e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg07507251	chr3:52567010	NT5DC2	0.39	9.31	0.35	1.97e-19	Hemoglobin concentration;
BRCA	trans	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg06521331	chr12:34319734	NA	-0.51	-9.16	-0.34	7.24e-19	Bladder cancer;
BRCA	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg21951975	chr1:209979733	IRF6	0.39	8.18	0.31	1.5e-15	Cleft lip with or without cleft palate;
BRCA	cis	rs17092148	0.887	rs4911431	chr20:33158318	G/A	cg16810054	chr20:33298113	TP53INP2	-0.48	-10.39	-0.38	1.83e-23	Neuroticism;
BRCA	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg09904177	chr6:26538194	HMGN4	0.36	7.82	0.3	2.16e-14	Small cell lung carcinoma;
BRCA	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg16482183	chr6:26056742	HIST1H1C	0.61	12.35	0.44	1.47e-31	Height;
BRCA	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	15.51	0.52	2.68e-46	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11696845	0.604	rs1980577	chr20:43382112	A/G	cg25301532	chr20:43378953	KCNK15	0.46	10.84	0.39	3.13e-25	Obesity-related traits;
BRCA	cis	rs6028335	0.577	rs16987738	chr20:37625015	G/T	cg16355469	chr20:37678765	NA	-0.47	-8.56	-0.32	8.4e-17	Alcohol and nicotine co-dependence;
BRCA	cis	rs1997103	1.000	rs4947499	chr7:55407196	T/C	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg11833968	chr6:79620685	NA	-0.46	-10.52	-0.38	5.42e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.47	-11.21	-0.41	9.83e-27	IgG glycosylation;
BRCA	trans	rs629535	0.814	rs571682	chr8:70062793	A/G	cg21567404	chr3:27674614	NA	0.89	18.27	0.59	2.64e-60	Dupuytren's disease;
BRCA	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg14926445	chr8:58193284	C8orf71	-0.47	-8.92	-0.33	4.83e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs11229555	0.645	rs4367960	chr11:58194961	C/G	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg25482853	chr8:67687455	SGK3	1.06	17.17	0.56	1.31e-54	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7512552	0.839	rs3896342	chr1:150411312	T/C	cg15654264	chr1:150340011	RPRD2	0.43	9.25	0.34	3.25e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs59698941	0.550	rs12652469	chr5:132182765	A/G	cg14825688	chr5:132208181	LEAP2	-0.37	-8.65	-0.32	4.12e-17	Apolipoprotein A-IV levels;
BRCA	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg16230307	chr14:35515116	FAM177A1	0.73	15.28	0.52	3.85e-45	Psoriasis;
BRCA	cis	rs3849570	1.000	rs4411908	chr3:81802418	A/C	cg07356753	chr3:81810745	GBE1	-0.44	-10.67	-0.39	1.42e-24	Waist circumference;Body mass index;
BRCA	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.33	10.99	0.4	7.42e-26	Systemic lupus erythematosus;
BRCA	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.46	-9.49	-0.35	4.6e-20	Body mass index;
BRCA	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg21475434	chr5:93447410	FAM172A	0.74	9.2	0.34	4.89e-19	Diabetic retinopathy;
BRCA	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11764359	chr7:65958608	NA	0.75	16.57	0.55	1.37e-51	Aortic root size;
BRCA	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	10.01	0.37	5.18e-22	Tonsillectomy;
BRCA	cis	rs113835537	0.597	rs7939759	chr11:66337964	C/T	cg24851651	chr11:66362959	CCS	0.44	8.41	0.32	2.67e-16	Airway imaging phenotypes;
BRCA	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg12641515	chr19:46296257	DMWD	-0.54	-11.74	-0.42	5.67e-29	Coronary artery disease;
BRCA	trans	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg25214090	chr10:38739885	LOC399744	0.55	12.23	0.44	4.59e-31	Corneal astigmatism;
BRCA	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg06552810	chr11:31128660	NA	-0.39	-8.65	-0.32	4.1e-17	Red blood cell count;
BRCA	cis	rs17401966	0.522	rs10864450	chr1:10333959	G/T	cg03954927	chr1:10346856	KIF1B	0.34	10.29	0.38	4.51e-23	Hepatocellular carcinoma;
BRCA	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg12863693	chr15:85201151	NMB	-0.37	-8.86	-0.33	8.17e-18	P wave terminal force;
BRCA	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19723775	chr5:179050963	HNRNPH1	0.37	8.94	0.33	4.15e-18	Lung cancer;
BRCA	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg22920501	chr2:26401640	FAM59B	-0.67	-11.5	-0.41	5.96e-28	Gut microbiome composition (summer);
BRCA	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg02475777	chr4:1388615	CRIPAK	0.37	8.16	0.31	1.84e-15	Longevity;
BRCA	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg22974920	chr21:40686053	BRWD1	-0.37	-8.55	-0.32	8.87e-17	Cognitive function;
BRCA	trans	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg07211511	chr3:129823064	LOC729375	-0.62	-10.96	-0.4	9.45e-26	Blood pressure (smoking interaction);
BRCA	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg23625390	chr15:77176239	SCAPER	-0.54	-13.18	-0.46	2.81e-35	Blood metabolite levels;
BRCA	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg01689657	chr7:91764605	CYP51A1	0.23	8.31	0.31	5.54e-16	Breast cancer;
BRCA	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg11764359	chr7:65958608	NA	-0.67	-14.9	-0.51	2.48e-43	Aortic root size;
BRCA	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg01741372	chr11:783889	NA	0.44	10.51	0.38	6.3e-24	Breast cancer;
BRCA	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-8.58	-0.32	7.34e-17	Daytime sleep phenotypes;
BRCA	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg12863693	chr15:85201151	NMB	0.57	12.07	0.43	2.33e-30	Schizophrenia;
BRCA	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg11789530	chr4:8429930	ACOX3	0.59	14.86	0.51	4.12e-43	Response to antineoplastic agents;
BRCA	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg10729496	chr3:10149963	C3orf24	-0.47	-8.97	-0.33	3.22e-18	Alzheimer's disease;
BRCA	cis	rs3820928	0.874	rs1054413	chr2:227867719	A/G	cg11843606	chr2:227700838	RHBDD1	0.4	8.78	0.33	1.51e-17	Pulmonary function;
BRCA	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08045932	chr20:61659980	NA	0.5	11.43	0.41	1.2100000000000001e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg00409905	chr10:38381863	ZNF37A	0.55	11.86	0.42	1.82e-29	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12379764	chr21:47803548	PCNT	0.64	15.6	0.53	9.68e-47	Testicular germ cell tumor;
BRCA	cis	rs3739998	0.692	rs11007864	chr10:30313117	T/C	cg12786570	chr10:30316432	KIAA1462	0.45	9.45	0.35	6.37e-20	Coronary heart disease;
BRCA	cis	rs76419734	0.510	rs3943980	chr4:106676766	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.43	-9.3	-0.35	2.16e-19	Post bronchodilator FEV1;
BRCA	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.8	-0.33	1.28e-17	Mood instability;
BRCA	cis	rs6060717	0.536	rs8125966	chr20:34511823	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.12	-0.31	2.41e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg03709012	chr19:19516395	GATAD2A	0.72	15.68	0.53	4.14e-47	Tonsillectomy;
BRCA	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21385522	chr1:16154831	NA	-0.53	-9.93	-0.37	1.05e-21	Dilated cardiomyopathy;
BRCA	cis	rs9942416	0.517	rs116509898	chr5:74994361	C/T	cg19683494	chr5:74908142	NA	0.49	9.17	0.34	6.53e-19	Age-related disease endophenotypes;
BRCA	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	13.22	0.46	1.94e-35	Response to antipsychotic treatment;
BRCA	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg17366294	chr4:99064904	C4orf37	0.44	10.44	0.38	1.1e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg05340658	chr4:99064831	C4orf37	0.56	10.89	0.4	1.86e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg20283391	chr11:68216788	NA	-0.46	-9.07	-0.34	1.41e-18	Total body bone mineral density;
BRCA	cis	rs4671400	0.516	rs2600671	chr2:61394851	A/G	cg15711740	chr2:61764176	XPO1	-0.45	-9.23	-0.34	3.88e-19	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg08601574	chr20:25228251	PYGB	0.35	8.49	0.32	1.48e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs459571	0.606	rs457420	chr9:136909261	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.47	9.1	0.34	1.17e-18	Platelet distribution width;
BRCA	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg23533926	chr12:111358616	MYL2	-0.44	-9.17	-0.34	6.19e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg05347473	chr6:146136440	FBXO30	-0.42	-8.25	-0.31	9.23e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg03213289	chr20:61660250	NA	-0.55	-14.5	-0.5	2.06e-41	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6005807	0.719	rs60693420	chr22:29045930	T/C	cg12565055	chr22:29076175	TTC28	0.5	9.36	0.35	1.32e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-11.68	-0.42	1.1e-28	Alcohol dependence;
BRCA	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg03161606	chr19:29218774	NA	0.43	8.03	0.3	4.74e-15	Methadone dose in opioid dependence;
BRCA	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg04727924	chr7:799746	HEATR2	0.46	7.83	0.3	2.06e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6087990	0.899	rs4911107	chr20:31374991	G/A	cg13636640	chr20:31349939	DNMT3B	0.69	22.77	0.67	1.65e-84	Ulcerative colitis;
BRCA	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg00666640	chr1:248458726	OR2T12	0.34	9.07	0.34	1.42e-18	Common traits (Other);
BRCA	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg15133208	chr4:90757351	SNCA	-0.44	-9.08	-0.34	1.29e-18	Neuroticism;
BRCA	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg07828340	chr4:882639	GAK	1.05	14.37	0.49	8.71e-41	Intelligence (multi-trait analysis);
BRCA	trans	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg06521331	chr12:34319734	NA	-0.53	-9.62	-0.36	1.55e-20	Bladder cancer;
BRCA	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.85	-0.42	2.08e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg20503657	chr10:835505	NA	0.95	14.3	0.49	1.8e-40	Eosinophil percentage of granulocytes;
BRCA	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg03146154	chr1:46216737	IPP	-0.47	-10.14	-0.37	1.61e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4074536	0.622	rs28563907	chr1:116319365	C/T	cg21648376	chr1:116311395	CASQ2	-0.54	-8.91	-0.33	5.14e-18	QRS duration;
BRCA	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08219700	chr8:58056026	NA	0.61	9.75	0.36	4.97e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09307838	chr4:120376055	NA	0.76	17.11	0.56	2.47e-54	Corneal astigmatism;
BRCA	cis	rs7809950	0.678	rs62482507	chr7:107024488	T/G	cg23024343	chr7:107201750	COG5	-0.49	-9.95	-0.37	8.9e-22	Coronary artery disease;
BRCA	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg02176678	chr2:219576539	TTLL4	0.4	10.84	0.39	3.1e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4234798	0.500	rs10937793	chr4:7219614	C/T	cg18431297	chr4:7219810	SORCS2	0.38	10.67	0.39	1.43e-24	Insulin-like growth factors;
BRCA	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg17063962	chr7:91808500	NA	-0.51	-11.83	-0.42	2.54e-29	Breast cancer;
BRCA	cis	rs6815814	0.861	rs28393318	chr4:38784267	A/G	cg06935464	chr4:38784597	TLR10	0.46	9.03	0.34	2.03e-18	Breast cancer;
BRCA	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.65	0.39	1.73e-24	Motion sickness;
BRCA	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg21475434	chr5:93447410	FAM172A	0.66	8.55	0.32	9.24e-17	Diabetic retinopathy;
BRCA	cis	rs12618769	0.597	rs17031905	chr2:99070902	A/G	cg10123293	chr2:99228465	UNC50	0.4	8.13	0.31	2.32e-15	Bipolar disorder;
BRCA	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg04455712	chr21:45112962	RRP1B	0.4	10.47	0.38	8.8e-24	Mean corpuscular volume;
BRCA	cis	rs9942416	0.660	rs67054144	chr5:74991443	G/A	cg19683494	chr5:74908142	NA	0.48	9.01	0.34	2.33e-18	Age-related disease endophenotypes;
BRCA	cis	rs4363385	0.818	rs2339492	chr1:152985552	G/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.04	-0.34	1.83e-18	Inflammatory skin disease;
BRCA	cis	rs965469	0.779	rs6037581	chr20:3351595	C/T	cg25506879	chr20:3388711	C20orf194	-0.44	-8.86	-0.33	7.9e-18	IFN-related cytopenia;
BRCA	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg24829409	chr8:58192753	C8orf71	0.5	8.53	0.32	1.06e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.37	0.38	2.18e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg01529538	chr14:23388837	RBM23	0.41	11.11	0.4	2.43e-26	Cognitive ability (multi-trait analysis);
BRCA	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg17691542	chr6:26056736	HIST1H1C	0.46	8.77	0.33	1.65e-17	Iron status biomarkers;
BRCA	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg15212455	chr7:39170539	POU6F2	0.39	8.54	0.32	9.93e-17	IgG glycosylation;
BRCA	cis	rs10193935	0.901	rs92303	chr2:42656337	A/G	cg27598129	chr2:42591480	NA	0.79	13.27	0.46	1.19e-35	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg15485101	chr11:133734466	NA	0.39	9.37	0.35	1.18e-19	Childhood ear infection;
BRCA	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	14.94	0.51	1.71e-43	Colorectal cancer;
BRCA	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.61	15.06	0.51	4.2e-44	Colorectal cancer;
BRCA	cis	rs13046373	0.535	rs7276743	chr21:31984545	C/T	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.05	0.3	4.19e-15	HDL cholesterol;
BRCA	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.3	8.59	0.32	6.75e-17	Monocyte percentage of white cells;
BRCA	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg06697600	chr4:7070879	GRPEL1	-0.57	-10.08	-0.37	2.82e-22	Monocyte percentage of white cells;
BRCA	cis	rs9790314	0.696	rs9290069	chr3:160890946	A/G	cg04691961	chr3:161091175	C3orf57	-0.35	-7.96	-0.3	7.85e-15	Morning vs. evening chronotype;
BRCA	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-9.5	-0.35	4.21e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	trans	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg06521331	chr12:34319734	NA	-0.46	-8.54	-0.32	9.43e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4363385	0.747	rs2075739	chr1:152975495	G/A	cg24667326	chr1:152973720	SPRR3	-0.35	-9.82	-0.36	2.63e-21	Inflammatory skin disease;
BRCA	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.88	-0.3	1.46e-14	Electroencephalogram traits;
BRCA	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.56	-11.18	-0.4	1.27e-26	Response to bleomycin (chromatid breaks);
BRCA	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg01262667	chr19:19385393	TM6SF2	0.39	9.73	0.36	5.99e-21	Tonsillectomy;
BRCA	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	14.36	0.49	9.93e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs10899021	0.920	rs11236181	chr11:74345823	A/C	cg25880958	chr11:74394337	NA	-0.47	-7.87	-0.3	1.57e-14	Response to metformin (IC50);
BRCA	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg23711669	chr6:146136114	FBXO30	0.67	13.65	0.48	1.97e-37	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	13.0	0.46	1.82e-34	Colorectal cancer;
BRCA	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-11.06	-0.4	3.82e-26	Lymphocyte counts;
BRCA	cis	rs4588572	0.644	rs10061149	chr5:77744201	G/A	cg11547950	chr5:77652471	NA	-0.45	-8.59	-0.32	6.86e-17	Triglycerides;
BRCA	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg18154014	chr19:37997991	ZNF793	0.48	9.56	0.35	2.54e-20	Coronary artery calcification;
BRCA	cis	rs9287719	0.601	rs9287718	chr2:10701629	A/T	cg00105475	chr2:10696890	NA	-0.47	-10.36	-0.38	2.46e-23	Prostate cancer;
BRCA	cis	rs243505	0.898	rs243528	chr7:148415740	T/C	cg09806900	chr7:148480153	CUL1	-0.38	-7.92	-0.3	1.04e-14	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs13161895	1.000	rs4129403	chr5:179476610	A/G	cg02702477	chr5:179499311	RNF130	0.49	8.83	0.33	1.02e-17	LDL cholesterol;
BRCA	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg04450456	chr4:17643702	FAM184B	0.34	9.74	0.36	5.17e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg01874867	chr7:94954059	PON1	-0.4	-8.21	-0.31	1.19e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg25019033	chr10:957182	NA	-0.41	-7.87	-0.3	1.57e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	10.67	0.39	1.36e-24	Motion sickness;
BRCA	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg23933602	chr10:16859644	RSU1	0.58	9.04	0.34	1.88e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.49	9.76	0.36	4.39e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.33	-0.31	5.04e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2282802	0.685	rs6867870	chr5:139641896	C/A	cg26211634	chr5:139558579	C5orf32	0.35	8.22	0.31	1.12e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg21433313	chr16:3507492	NAT15	0.44	9.37	0.35	1.26e-19	Tuberculosis;
BRCA	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-16.65	-0.55	5.47e-52	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs1003719	0.715	rs9980353	chr21:38558812	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.49	-0.5	2.46e-41	Eye color traits;
BRCA	trans	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg23762105	chr12:34175262	ALG10	0.38	8.84	0.33	9.16e-18	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.929	rs10844730	chr12:34026721	C/G	cg26384229	chr12:38710491	ALG10B	-0.44	-10.28	-0.38	5.01e-23	Morning vs. evening chronotype;
BRCA	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg10876282	chr6:28092338	ZSCAN16	0.42	8.17	0.31	1.68e-15	Parkinson's disease;
BRCA	trans	rs8002861	0.781	rs7322781	chr13:44442238	T/C	cg17145862	chr1:211918768	LPGAT1	0.64	16.44	0.55	6.25e-51	Leprosy;
BRCA	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07636037	chr3:49044803	WDR6	-0.73	-15.84	-0.53	6.49e-48	Menarche (age at onset);
BRCA	cis	rs791888	0.858	rs2180968	chr10:89418730	A/C	cg13926569	chr10:89418898	PAPSS2	0.35	8.38	0.31	3.27e-16	Magnesium levels;
BRCA	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-16.27	-0.54	4.64e-50	Alzheimer's disease (late onset);
BRCA	cis	rs4478858	0.735	rs7526095	chr1:31797581	C/T	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs6484504	0.600	rs7122895	chr11:31346620	G/C	cg14844989	chr11:31128820	NA	0.45	9.63	0.36	1.33e-20	Red blood cell count;
BRCA	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg19318889	chr4:1322082	MAEA	0.58	11.87	0.42	1.71e-29	Longevity;
BRCA	cis	rs7659604	0.689	rs4283687	chr4:122663460	A/G	cg19748678	chr4:122722346	EXOSC9	0.42	8.55	0.32	8.87e-17	Type 2 diabetes;
BRCA	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	9.93	0.37	1.08e-21	Menarche (age at onset);
BRCA	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg27147174	chr7:100797783	AP1S1	0.55	11.1	0.4	2.59e-26	Life satisfaction;
BRCA	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	23.03	0.67	6.2e-86	Platelet count;
BRCA	cis	rs27434	0.583	rs34761	chr5:96153624	C/T	cg16492584	chr5:96139282	ERAP1	-0.52	-12.78	-0.45	1.77e-33	Ankylosing spondylitis;
BRCA	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-14.7	-0.5	2.33e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3784262	0.565	rs2899613	chr15:58347260	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.35	-9.23	-0.34	3.86e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs3741151	0.773	rs73544716	chr11:73170061	C/T	cg17517138	chr11:73019481	ARHGEF17	0.87	12.43	0.44	6.65e-32	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.35	0.57	1.6e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg23711669	chr6:146136114	FBXO30	0.75	17.47	0.57	3.78e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6088813	1.000	rs2248393	chr20:33926103	C/G	cg14752227	chr20:34000481	UQCC	0.39	8.21	0.31	1.21e-15	Height;
BRCA	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.68	-14.25	-0.49	3.21e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs911119	0.913	rs13043610	chr20:23586941	G/A	cg16589663	chr20:23618590	CST3	0.43	7.87	0.3	1.5e-14	Chronic kidney disease;
BRCA	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.37	9.73	0.36	5.67e-21	IgG glycosylation;
BRCA	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.33	-7.92	-0.3	1.08e-14	Bipolar disorder;
BRCA	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg08885076	chr2:99613938	TSGA10	0.45	10.61	0.39	2.51e-24	Chronic sinus infection;
BRCA	cis	rs2742234	0.955	rs2503865	chr10:43659536	C/T	cg02780029	chr10:43622663	RET	-0.4	-9.94	-0.37	9.98e-22	Hirschsprung disease;
BRCA	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg17724175	chr1:150552817	MCL1	0.25	8.19	0.31	1.47e-15	Tonsillectomy;
BRCA	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg03213289	chr20:61660250	NA	0.61	16.28	0.54	4.14e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	15.48	0.52	3.93e-46	Colorectal cancer;
BRCA	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg24060327	chr5:131705240	SLC22A5	0.6	11.13	0.4	2.01e-26	Breast cancer;
BRCA	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg02551604	chr5:131831745	NA	-0.4	-14.94	-0.51	1.73e-43	Asthma (sex interaction);
BRCA	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg25801113	chr15:45476975	SHF	-0.33	-7.98	-0.3	6.83e-15	Uric acid levels;
BRCA	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg25237894	chr2:233734115	C2orf82	-0.42	-12.76	-0.45	2.13e-33	Coronary artery disease;
BRCA	cis	rs6867032	0.527	rs4975720	chr5:2010455	C/G	cg26168224	chr5:2018326	NA	0.44	11.71	0.42	8.05e-29	Gut microbiome composition (winter);
BRCA	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg10556349	chr10:835070	NA	0.6	8.38	0.31	3.46e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg09035930	chr12:129282057	SLC15A4	0.58	17.23	0.56	6.42e-55	Systemic lupus erythematosus;
BRCA	cis	rs3925075	1.000	rs11859274	chr16:31361059	C/T	cg02846316	chr16:31340340	ITGAM	0.53	12.98	0.46	2.25e-34	IgA nephropathy;
BRCA	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00166722	chr3:10149974	C3orf24	0.63	12.17	0.43	8.51e-31	Alzheimer's disease;
BRCA	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg23505145	chr19:12996616	KLF1	0.54	12.19	0.43	7.29e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24531977	chr5:56204891	C5orf35	-0.87	-18.4	-0.59	5.13e-61	Initial pursuit acceleration;
BRCA	cis	rs6450176	1.000	rs12521454	chr5:53297304	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-15.07	-0.51	3.76e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs372883	0.532	rs388707	chr21:30714776	T/C	cg08807101	chr21:30365312	RNF160	-0.35	-8.02	-0.3	5.13e-15	Pancreatic cancer;
BRCA	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg09658497	chr7:2847517	GNA12	-0.39	-7.99	-0.3	6.54e-15	Height;
BRCA	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs17490626	0.533	rs5030925	chr10:71211150	A/C	cg12610070	chr10:71211762	TSPAN15	-0.33	-11.67	-0.42	1.11e-28	Thrombosis;
BRCA	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg04944784	chr2:26401820	FAM59B	0.95	16.37	0.54	1.44e-50	Gut microbiome composition (summer);
BRCA	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg11822812	chr5:140052017	DND1	0.31	8.42	0.32	2.49e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs16854884	0.657	rs35877644	chr3:143701755	A/G	cg06585982	chr3:143692056	C3orf58	0.42	8.81	0.33	1.14e-17	Economic and political preferences (feminism/equality);
BRCA	cis	rs1997103	1.000	rs6958664	chr7:55404958	T/G	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg00852783	chr1:26633632	UBXN11	-0.46	-7.98	-0.3	6.7e-15	Obesity-related traits;
BRCA	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg03934865	chr2:198174659	NA	-0.43	-9.39	-0.35	1.08e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg08888203	chr3:10149979	C3orf24	0.67	14.34	0.49	1.21e-40	Alzheimer's disease;
BRCA	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg03146154	chr1:46216737	IPP	-0.42	-8.94	-0.33	4.06e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17604090	0.938	rs28664977	chr7:29685369	C/T	cg19413766	chr7:29689036	LOC646762	-0.51	-7.99	-0.3	6.22e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24110177	chr3:50126178	RBM5	0.52	15.68	0.53	4e-47	Body mass index;
BRCA	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg07423050	chr13:99094983	FARP1	-0.43	-9.3	-0.35	2.23e-19	Longevity;
BRCA	cis	rs7760949	0.852	rs9475800	chr6:13932230	A/G	cg27413430	chr6:13925136	RNF182	0.46	9.27	0.34	2.74e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs672059	1.000	rs566625	chr1:183161441	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.63	0.32	4.72e-17	Hypertriglyceridemia;
BRCA	cis	rs7727544	0.582	rs116749111	chr5:131462918	G/T	cg14196790	chr5:131705035	SLC22A5	0.37	9.06	0.34	1.61e-18	Blood metabolite levels;
BRCA	cis	rs1113500	0.933	rs12132785	chr1:108633083	A/T	cg06207961	chr1:108661230	NA	0.46	11.23	0.41	7.89e-27	Growth-regulated protein alpha levels;
BRCA	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg10978503	chr1:24200527	CNR2	0.52	13.93	0.48	9.94e-39	Immature fraction of reticulocytes;
BRCA	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg20887711	chr4:1340912	KIAA1530	0.6	13.2	0.46	2.43e-35	Longevity;
BRCA	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs61990749	0.597	rs1978416	chr14:78227901	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.66	10.57	0.39	3.61e-24	Fibroblast growth factor basic levels;
BRCA	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg27490568	chr2:178487706	NA	0.43	8.13	0.31	2.22e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-13.37	-0.47	4.1e-36	Bone mineral density;
BRCA	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg22705602	chr4:152727874	NA	-0.32	-8.24	-0.31	9.68e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg16011800	chr17:1958478	HIC1	-0.52	-8.47	-0.32	1.73e-16	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs4363385	0.667	rs78426057	chr1:152964528	T/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.26	-0.34	3.18e-19	Inflammatory skin disease;
BRCA	cis	rs858239	0.862	rs1728292	chr7:23263474	C/G	cg23682824	chr7:23144976	KLHL7	0.31	7.92	0.3	1.07e-14	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg23029597	chr12:123009494	RSRC2	-0.59	-11.39	-0.41	1.69e-27	Body mass index;
BRCA	trans	rs7916697	0.520	rs12265247	chr10:70038398	A/G	cg04882175	chr6:131122610	NA	-0.31	-8.13	-0.31	2.28e-15	Optic disc area;
BRCA	cis	rs4074536	0.622	rs12125807	chr1:116321310	G/C	cg21648376	chr1:116311395	CASQ2	-0.55	-9.13	-0.34	9e-19	QRS duration;
BRCA	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.62	12.66	0.45	5.97e-33	Lymphocyte counts;
BRCA	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg11189052	chr15:85197271	WDR73	-0.33	-7.87	-0.3	1.53e-14	P wave terminal force;
BRCA	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg24397884	chr7:158709396	WDR60	-0.98	-24.94	-0.7	2.12e-96	Height;
BRCA	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg25554036	chr4:6271136	WFS1	-0.38	-9.36	-0.35	1.38e-19	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg08999081	chr20:33150536	PIGU	0.35	9.0	0.34	2.55e-18	Coronary artery disease;
BRCA	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.33	-0.38	3.2e-23	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9368481	0.524	rs9393768	chr6:26885619	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.23	7.94	0.3	8.94e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs698813	0.604	rs1596010	chr2:44491804	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	7.88	0.3	1.4e-14	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg04166393	chr7:2884313	GNA12	0.5	9.97	0.37	7.58e-22	Height;
BRCA	cis	rs6942407	0.546	rs10228392	chr7:86799673	A/T	cg02420886	chr7:86849541	C7orf23	0.53	7.85	0.3	1.75e-14	Food allergy;
BRCA	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03264133	chr6:25882463	NA	-0.53	-11.12	-0.4	2.27e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs10162002	1.000	rs17078796	chr13:24043830	A/G	cg00158254	chr13:24040743	NA	-0.56	-9.07	-0.34	1.39e-18	Hypothyroidism;
BRCA	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.58	-0.32	7.01e-17	Monocyte percentage of white cells;
BRCA	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08048268	chr3:133502702	NA	-0.33	-8.3	-0.31	6.21e-16	Iron status biomarkers;
BRCA	cis	rs10046574	0.561	rs17481974	chr7:135195701	A/G	cg27474649	chr7:135195673	CNOT4	0.67	10.95	0.4	1.07e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg08847533	chr14:75593920	NEK9	-0.86	-21.93	-0.66	6.26e-80	Height;
BRCA	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11890956	chr21:40555474	PSMG1	-0.62	-13.99	-0.48	5.46e-39	Menarche (age at onset);
BRCA	cis	rs4363385	0.747	rs1984198	chr1:152958584	T/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.29	-0.34	2.45e-19	Inflammatory skin disease;
BRCA	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg07423050	chr13:99094983	FARP1	0.47	10.64	0.39	1.92e-24	Longevity;
BRCA	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg02466173	chr16:30829666	NA	-0.54	-11.41	-0.41	1.37e-27	Multiple myeloma;
BRCA	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg18016565	chr1:150552671	MCL1	-0.42	-9.56	-0.35	2.55e-20	Tonsillectomy;
BRCA	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg18758796	chr5:131593413	PDLIM4	0.34	8.9	0.33	5.83e-18	Breast cancer;
BRCA	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg06191203	chr2:152266755	RIF1	-0.36	-10.75	-0.39	6.81e-25	Lung cancer;
BRCA	cis	rs17741873	0.836	rs11000797	chr10:75628224	A/G	cg07699608	chr10:75541558	CHCHD1	0.55	8.4	0.32	2.78e-16	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.71	0.57	2.03e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg06064525	chr11:970664	AP2A2	-0.51	-17.21	-0.56	8.11e-55	Alzheimer's disease (late onset);
BRCA	cis	rs4900538	0.855	rs12590993	chr14:102844064	A/G	cg18135206	chr14:102964638	TECPR2	-0.93	-21.69	-0.65	1.42e-78	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	13.94	0.48	9.84e-39	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2116941	1.000	rs8104426	chr19:10338676	G/T	cg01850179	chr19:10340795	S1PR2	0.63	12.79	0.45	1.57e-33	Pulse pressure;
BRCA	cis	rs17023223	0.537	rs61319010	chr1:119743011	T/A	cg05756136	chr1:119680316	WARS2	-0.43	-8.25	-0.31	8.87e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg06521331	chr12:34319734	NA	-0.47	-8.77	-0.33	1.59e-17	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg13010199	chr12:38710504	ALG10B	0.4	8.09	0.3	3.05e-15	Morning vs. evening chronotype;
BRCA	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-10.63	-0.39	2e-24	Mean corpuscular volume;
BRCA	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11890956	chr21:40555474	PSMG1	1.05	29.89	0.76	1.74e-123	Cognitive function;
BRCA	cis	rs2677744	0.626	rs3743452	chr15:91497515	C/T	cg23684204	chr15:91497937	RCCD1	-0.43	-9.27	-0.34	2.71e-19	Attention deficit hyperactivity disorder;
BRCA	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18404041	chr3:52824283	ITIH1	-0.37	-11.27	-0.41	5.23e-27	Electroencephalogram traits;
BRCA	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg26384229	chr12:38710491	ALG10B	-0.53	-13.44	-0.47	1.85e-36	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.87e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10046574	0.831	rs28613647	chr7:135129443	G/A	cg27474649	chr7:135195673	CNOT4	0.59	8.34	0.31	4.43e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26314531	chr2:26401878	FAM59B	0.88	15.31	0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs2421770	0.530	rs4756218	chr11:35370113	G/A	cg13971030	chr11:35366721	SLC1A2	-0.44	-10.04	-0.37	3.9e-22	Staphylococcus aureus nasal carriage (persistent);
BRCA	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg16325326	chr1:53192061	ZYG11B	0.53	11.66	0.42	1.34e-28	Monocyte count;
BRCA	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg01529538	chr14:23388837	RBM23	0.42	11.56	0.42	3.25e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg03709012	chr19:19516395	GATAD2A	1.08	20.88	0.64	3.37e-74	Nonalcoholic fatty liver disease;
BRCA	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	9.86	0.36	1.95e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.16	-0.34	6.69e-19	Resting heart rate;
BRCA	trans	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg26384229	chr12:38710491	ALG10B	0.55	11.87	0.43	1.74e-29	Morning vs. evening chronotype;
BRCA	cis	rs600806	0.815	rs10745356	chr1:109960270	C/A	cg20591472	chr1:110008990	SYPL2	0.32	7.89	0.3	1.35e-14	Intelligence (multi-trait analysis);
BRCA	trans	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg14791747	chr16:20752902	THUMPD1	0.4	9.35	0.35	1.49e-19	Cognitive test performance;
BRCA	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.71	-0.33	2.54e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.34	-8.81	-0.33	1.16e-17	Total body bone mineral density;
BRCA	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22029157	chr1:209979665	IRF6	0.56	12.58	0.45	1.39e-32	Cleft lip with or without cleft palate;
BRCA	cis	rs61990749	0.597	rs28534379	chr14:78172140	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.64	-10.03	-0.37	4.19e-22	Fibroblast growth factor basic levels;
BRCA	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg15557168	chr22:42548783	NA	-0.31	-8.5	-0.32	1.29e-16	Cognitive function;
BRCA	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg06784218	chr1:46089804	CCDC17	0.5	12.08	0.43	2.02e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9831754	1.000	rs9822043	chr3:78352113	T/C	cg06138941	chr3:78371609	NA	-0.81	-17.5	-0.57	2.48e-56	Calcium levels;
BRCA	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg25036284	chr2:26402008	FAM59B	0.96	15.95	0.53	1.78e-48	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.87	0.3	1.5e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.46	-11.62	-0.42	1.82e-28	Longevity;Endometriosis;
BRCA	cis	rs9381107	0.932	rs11756620	chr6:9423799	T/C	cg14735645	chr6:9486422	NA	-0.47	-8.18	-0.31	1.59e-15	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	17.62	0.57	6.44e-57	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg21747090	chr2:27597821	SNX17	-0.41	-8.98	-0.33	2.91e-18	Total body bone mineral density;
BRCA	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg00012203	chr2:219082015	ARPC2	-0.47	-8.98	-0.33	2.9e-18	Colorectal cancer;
BRCA	cis	rs6545883	0.525	rs1729658	chr2:61373520	C/T	cg15711740	chr2:61764176	XPO1	-0.46	-11.32	-0.41	3.35e-27	Tuberculosis;
BRCA	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg08822215	chr16:89438651	ANKRD11	-0.4	-8.47	-0.32	1.68e-16	Multiple myeloma (IgH translocation);
BRCA	cis	rs10496034	1.000	rs80194342	chr2:55223107	T/A	cg16098955	chr2:55172992	EML6	0.52	8.61	0.32	5.61e-17	Refractive astigmatism;
BRCA	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.68	-11.18	-0.4	1.25e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9815354	0.680	rs73073262	chr3:42018443	G/T	cg03022575	chr3:42003672	ULK4	0.75	9.65	0.36	1.2e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg09021430	chr5:549028	NA	-0.7	-15.45	-0.52	5.35e-46	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9324022	0.860	rs72698720	chr14:101178715	C/G	cg18089426	chr14:101175970	NA	0.64	12.15	0.43	1.03e-30	Plateletcrit;
BRCA	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg00531865	chr16:30841666	NA	-0.35	-8.19	-0.31	1.45e-15	Dementia with Lewy bodies;
BRCA	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg07262247	chr5:131593730	PDLIM4	0.39	9.41	0.35	9.08e-20	Acylcarnitine levels;
BRCA	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg11663144	chr21:46675770	NA	-0.62	-14.71	-0.5	2.18e-42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs73242632	1.000	rs73242625	chr4:57856339	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	0.7	8.49	0.32	1.49e-16	Congenital heart disease (maternal effect);
BRCA	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg11789530	chr4:8429930	ACOX3	0.67	17.36	0.57	1.34e-55	Response to antineoplastic agents;
BRCA	cis	rs2904967	0.929	rs554122	chr11:65033874	T/C	cg09225861	chr11:65069680	NA	0.39	8.07	0.3	3.62e-15	Mean corpuscular volume;
BRCA	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg09877947	chr5:131593287	PDLIM4	0.42	9.77	0.36	4.16e-21	Acylcarnitine levels;
BRCA	trans	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg25517755	chr10:38738941	LOC399744	-0.38	-8.04	-0.3	4.28e-15	Corneal astigmatism;
BRCA	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg12292205	chr6:26970375	C6orf41	0.72	16.24	0.54	6.81e-50	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg08738300	chr3:44038990	NA	0.47	8.79	0.33	1.34e-17	Coronary artery disease;
BRCA	cis	rs1975991	0.765	rs6764972	chr3:187960329	C/T	cg15417654	chr3:187959138	LPP	-0.34	-8.85	-0.33	8.75e-18	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg03711944	chr11:47377212	SPI1	-0.49	-12.48	-0.44	3.65e-32	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg16405210	chr4:1374714	KIAA1530	-0.91	-20.66	-0.63	5.26e-73	Longevity;
BRCA	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg26528668	chr16:1614120	IFT140	0.39	9.0	0.34	2.6e-18	Coronary artery disease;
BRCA	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-8.92	-0.33	5.03e-18	Eosinophil percentage of white cells;
BRCA	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg27490568	chr2:178487706	NA	0.5	8.39	0.32	3.01e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.43	-9.77	-0.36	4.24e-21	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg12310025	chr6:25882481	NA	-0.5	-11.89	-0.43	1.37e-29	Blood metabolite levels;
BRCA	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-11.53	-0.41	4.6e-28	Gut microbiome composition (summer);
BRCA	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg18131467	chr2:239335373	ASB1	0.86	21.85	0.65	1.88e-79	Multiple system atrophy;
BRCA	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg06636001	chr8:8085503	FLJ10661	0.53	10.27	0.38	5.15e-23	Neuroticism;
BRCA	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg23711669	chr6:146136114	FBXO30	0.71	16.97	0.56	1.28e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1113500	0.933	rs11185259	chr1:108635062	A/G	cg06207961	chr1:108661230	NA	-0.44	-10.57	-0.39	3.58e-24	Growth-regulated protein alpha levels;
BRCA	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26314531	chr2:26401878	FAM59B	-0.9	-16.15	-0.54	1.92e-49	Gut microbiome composition (summer);
BRCA	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.54	-14.06	-0.49	2.58e-39	Electrocardiographic conduction measures;
BRCA	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg16423285	chr20:60520624	NA	0.43	8.15	0.31	1.95e-15	Body mass index;
BRCA	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg23711669	chr6:146136114	FBXO30	-0.73	-17.29	-0.56	3.15e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg05283184	chr6:79620031	NA	-0.43	-10.82	-0.39	3.77e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg08355456	chr11:67383691	NA	-0.42	-8.61	-0.32	5.75e-17	Mean corpuscular volume;
BRCA	cis	rs701145	0.585	rs1727887	chr3:153839465	G/T	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.82e-18	Coronary artery disease;
BRCA	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg26031613	chr14:104095156	KLC1	-0.44	-8.0	-0.3	6.01e-15	Coronary artery disease;
BRCA	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg24812749	chr6:127587940	RNF146	0.87	19.75	0.62	4.07e-68	Breast cancer;
BRCA	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.13	0.62	3.46e-70	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg00701064	chr4:6280414	WFS1	0.64	16.01	0.54	9.19e-49	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs11676348	0.783	rs13035513	chr2:218960680	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.41	-8.53	-0.32	1.09e-16	Ulcerative colitis;
BRCA	trans	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.39	0.49	7.25e-41	Exhaled nitric oxide output;
BRCA	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.68	11.62	0.42	1.94e-28	Renal function-related traits (BUN);
BRCA	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg27432699	chr2:27873401	GPN1	-0.5	-10.51	-0.38	6.02e-24	Oral cavity cancer;
BRCA	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.31	10.05	0.37	3.54e-22	Electroencephalogram traits;
BRCA	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg03213289	chr20:61660250	NA	0.62	15.95	0.53	1.88e-48	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg21918786	chr6:109611834	NA	-0.48	-13.92	-0.48	1.16e-38	Reticulocyte fraction of red cells;
BRCA	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18876405	chr7:65276391	NA	-0.57	-13.62	-0.47	3e-37	Aortic root size;
BRCA	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg01256987	chr12:42539512	GXYLT1	-0.42	-8.12	-0.31	2.48e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	trans	rs75804782	0.521	rs56176151	chr2:239440220	T/C	cg01134436	chr17:81009848	B3GNTL1	0.68	8.66	0.32	3.96e-17	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs4664304	0.772	rs12692572	chr2:160743793	G/A	cg14819504	chr2:160761413	LY75	0.35	8.42	0.32	2.45e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	10.23	0.38	7.56e-23	Height;
BRCA	cis	rs1865721	1.000	rs62089503	chr18:73177766	C/T	cg26385618	chr18:73139727	C18orf62	-0.41	-9.2	-0.34	5.01e-19	Intelligence;
BRCA	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg00105475	chr2:10696890	NA	0.44	10.21	0.37	8.73e-23	Prostate cancer;
BRCA	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg14784868	chr12:69753453	YEATS4	0.66	17.8	0.58	6.95e-58	Blood protein levels;
BRCA	cis	rs2425143	1.000	rs56904633	chr20:34400757	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.92	-0.33	4.83e-18	Blood protein levels;
BRCA	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg24558204	chr6:135376177	HBS1L	0.49	13.31	0.47	7.44e-36	Red blood cell count;
BRCA	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg25554036	chr4:6271136	WFS1	0.39	9.25	0.34	3.35e-19	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.55	10.5	0.38	6.45e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18876405	chr7:65276391	NA	-0.54	-12.75	-0.45	2.54e-33	Aortic root size;
BRCA	cis	rs7617773	0.817	rs936427	chr3:48301074	A/G	cg11946769	chr3:48343235	NME6	-0.68	-13.97	-0.48	6.45e-39	Coronary artery disease;
BRCA	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-7.95	-0.3	8.35e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.33	-9.08	-0.34	1.31e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg08645402	chr16:4508243	NA	0.4	9.49	0.35	4.63e-20	Schizophrenia;
BRCA	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg15133208	chr4:90757351	SNCA	0.4	7.9	0.3	1.2e-14	Neuroticism;
BRCA	cis	rs17095355	0.901	rs12569425	chr10:111758177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.77	-0.36	4.23e-21	Biliary atresia;
BRCA	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg00745463	chr17:30367425	LRRC37B	-0.62	-9.93	-0.37	1.06e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg23285459	chr7:2802560	GNA12	-0.39	-9.51	-0.35	3.94e-20	Height;
BRCA	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg13319975	chr6:146136371	FBXO30	0.43	10.04	0.37	4.06e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg11764359	chr7:65958608	NA	0.67	14.94	0.51	1.71e-43	Aortic root size;
BRCA	cis	rs2559856	0.935	rs7957666	chr12:102081551	T/C	cg12213457	chr12:102090980	CHPT1	-0.37	-8.09	-0.3	3.12e-15	Blood protein levels;
BRCA	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.38	-0.31	3.26e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11969893	0.850	rs3734351	chr6:101307131	C/T	cg12253828	chr6:101329408	ASCC3	1.18	17.53	0.57	1.86e-56	Economic and political preferences (immigration/crime);
BRCA	cis	rs7131987	0.903	rs7302129	chr12:29415280	A/T	cg09582351	chr12:29534625	ERGIC2	-0.49	-11.77	-0.42	4.32e-29	QT interval;
BRCA	cis	rs9470366	0.816	rs1321310	chr6:36623124	C/T	cg08179530	chr6:36648295	CDKN1A	-0.5	-10.21	-0.37	8.87e-23	QRS duration;
BRCA	cis	rs2979489	0.891	rs3824107	chr8:30353412	A/G	cg26383811	chr8:30366931	RBPMS	0.45	10.71	0.39	1.02e-24	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
BRCA	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg06623918	chr6:96969491	KIAA0776	0.73	12.97	0.46	2.56e-34	Migraine;Coronary artery disease;
BRCA	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg13385521	chr17:29058706	SUZ12P	0.62	8.49	0.32	1.49e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs28830936	1.000	rs2004162	chr15:41965542	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.32	-9.24	-0.34	3.5e-19	Diastolic blood pressure;
BRCA	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg20476274	chr7:133979776	SLC35B4	-0.57	-15.82	-0.53	8.5e-48	Mean platelet volume;
BRCA	cis	rs2249625	0.874	rs2463733	chr6:72882996	T/C	cg18830697	chr6:72922368	RIMS1	-0.37	-7.86	-0.3	1.63e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	trans	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg18876405	chr7:65276391	NA	0.47	10.4	0.38	1.69e-23	Corneal structure;
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07308232	chr7:1071921	C7orf50	-0.43	-8.65	-0.32	4.03e-17	Longevity;Endometriosis;
BRCA	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg01420254	chr6:26195488	NA	0.52	8.28	0.31	7.28e-16	Gout;Renal underexcretion gout;
BRCA	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg26384229	chr12:38710491	ALG10B	0.86	23.54	0.68	1.1e-88	Heart rate;
BRCA	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg25182066	chr10:30743637	MAP3K8	-0.35	-8.28	-0.31	7.2e-16	Inflammatory bowel disease;
BRCA	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	4.15e-15	Alzheimer's disease (late onset);
BRCA	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg06784218	chr1:46089804	CCDC17	0.45	10.79	0.39	4.55e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03517284	chr6:25882590	NA	0.7	15.88	0.53	4.03e-48	Blood metabolite levels;
BRCA	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg21918786	chr6:109611834	NA	-0.49	-14.24	-0.49	3.85e-40	Reticulocyte fraction of red cells;
BRCA	cis	rs1003719	0.679	rs1133001	chr21:38512956	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.4	-0.49	6.44e-41	Eye color traits;
BRCA	cis	rs16958440	0.867	rs77599321	chr18:44689642	T/C	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	trans	rs1941687	0.563	rs9947894	chr18:31328720	G/T	cg27147174	chr7:100797783	AP1S1	0.46	9.08	0.34	1.33e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg05283184	chr6:79620031	NA	-0.43	-10.88	-0.4	2.06e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	8.67	0.32	3.62e-17	Recombination measurement;
BRCA	trans	rs2262909	0.719	rs12461632	chr19:22245089	G/A	cg17074339	chr11:11642133	GALNTL4	0.43	8.2	0.31	1.35e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.74	-0.33	2e-17	Total body bone mineral density;
BRCA	trans	rs1493916	0.805	rs1452648	chr18:31411003	G/T	cg27147174	chr7:100797783	AP1S1	-0.42	-8.52	-0.32	1.17e-16	Life satisfaction;
BRCA	cis	rs59482735	1	rs59482735	chr9:123643426	T/TAA	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	8.62	0.32	5.33e-17	Prostate-specific antigen levels;
BRCA	cis	rs7809950	1.000	rs7793613	chr7:107250484	C/T	cg23024343	chr7:107201750	COG5	-0.38	-8.67	-0.32	3.5e-17	Coronary artery disease;
BRCA	cis	rs867371	1.000	rs9944197	chr15:82450602	G/A	cg00614314	chr15:82944287	LOC80154	0.43	9.18	0.34	5.68e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg16606324	chr3:10149918	C3orf24	-0.46	-8.09	-0.3	3.03e-15	Alzheimer's disease;
BRCA	cis	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.31e-22	Morning vs. evening chronotype;
BRCA	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg16586182	chr3:47516702	SCAP	-0.56	-12.48	-0.44	3.88e-32	Colorectal cancer;
BRCA	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg27489772	chr12:121021490	NA	-0.5	-8.65	-0.32	4e-17	Type 1 diabetes nephropathy;
BRCA	cis	rs2066819	1.000	rs871130	chr12:56648777	A/G	cg26734620	chr12:56694298	CS	-0.85	-10.24	-0.38	6.72e-23	Psoriasis vulgaris;
BRCA	cis	rs2625529	0.816	rs8025504	chr15:72294757	C/T	cg16672083	chr15:72433130	SENP8	-0.85	-17.81	-0.58	6.64e-58	Red blood cell count;
BRCA	cis	rs72772090	0.539	rs55773007	chr5:96124918	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.13	-0.43	1.28e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg16325326	chr1:53192061	ZYG11B	0.57	12.72	0.45	3.27e-33	Monocyte count;
BRCA	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.26	7.81	0.3	2.28e-14	Parkinson's disease;
BRCA	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.58	-0.35	2.04e-20	Body mass index;
BRCA	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11764359	chr7:65958608	NA	-0.76	-16.82	-0.55	7.85e-53	Aortic root size;
BRCA	cis	rs965469	1.000	rs6037547	chr20:3299228	C/A	cg25506879	chr20:3388711	C20orf194	-0.53	-10.29	-0.38	4.41e-23	IFN-related cytopenia;
BRCA	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg00074818	chr8:8560427	CLDN23	0.36	7.86	0.3	1.6e-14	Obesity-related traits;
BRCA	cis	rs4478858	0.775	rs6701667	chr1:31707971	A/C	cg00250761	chr1:31883323	NA	-0.34	-9.0	-0.34	2.47e-18	Alcohol dependence;
BRCA	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg18446336	chr7:2847575	GNA12	-0.33	-7.86	-0.3	1.68e-14	Height;
BRCA	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg23711669	chr6:146136114	FBXO30	0.73	17.3	0.56	2.77e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.58	-0.32	7.19e-17	Total body bone mineral density;
BRCA	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg04944784	chr2:26401820	FAM59B	-0.85	-13.29	-0.47	9.7e-36	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26314531	chr2:26401878	FAM59B	-0.82	-15.28	-0.52	3.63e-45	Gut microbiome composition (summer);
BRCA	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-10.77	-0.39	5.72e-25	Gut microbiome composition (summer);
BRCA	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10802521	chr3:52805072	NEK4	0.32	8.14	0.31	2.11e-15	Bipolar disorder;
BRCA	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg03146154	chr1:46216737	IPP	0.52	11.59	0.42	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6138458	0.961	rs227625	chr20:24911618	T/C	cg26195577	chr20:24973756	C20orf3	0.98	24.72	0.7	3.46e-95	Blood protein levels;
BRCA	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	15.62	0.53	7.77e-47	Colorectal cancer;
BRCA	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23583168	chr7:148888333	NA	-0.84	-17.85	-0.58	3.98e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg18854424	chr1:2615690	NA	0.32	8.11	0.31	2.68e-15	Ulcerative colitis;
BRCA	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg24848339	chr3:12840334	CAND2	0.49	13.41	0.47	2.65e-36	QRS complex (12-leadsum);
BRCA	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg24642844	chr7:1081250	C7orf50	-0.89	-16.0	-0.53	1.07e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs1829883	0.776	rs2511923	chr5:98721641	C/T	cg08333243	chr5:99726346	NA	0.34	8.41	0.32	2.72e-16	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03517284	chr6:25882590	NA	-0.5	-11.34	-0.41	2.87e-27	Blood metabolite levels;
BRCA	cis	rs12711979	0.509	rs13035992	chr2:3826597	G/A	cg17052675	chr2:3827356	NA	-0.7	-23.88	-0.69	1.5e-90	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg17971929	chr21:40555470	PSMG1	0.77	17.64	0.57	4.64e-57	Cognitive function;
BRCA	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg13256891	chr4:100009986	ADH5	0.52	9.85	0.36	2.07e-21	Alcohol dependence;
BRCA	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	19.05	0.6	2.01e-64	Alzheimer's disease (late onset);
BRCA	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg11764359	chr7:65958608	NA	-0.48	-9.35	-0.35	1.49e-19	Calcium levels;
BRCA	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.15	-48.94	-0.89	2.43e-218	Myeloid white cell count;
BRCA	cis	rs3784262	0.692	rs3784256	chr15:58263046	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.27	-0.38	5.28e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg10932868	chr11:921992	NA	0.49	12.4	0.44	8.43e-32	Alzheimer's disease (late onset);
BRCA	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg09555818	chr19:45449301	APOC2	0.47	12.21	0.43	5.76e-31	Blood protein levels;
BRCA	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg03733263	chr8:22462867	KIAA1967	0.75	14.83	0.51	5.76e-43	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs6815814	0.950	rs5743595	chr4:38802644	A/G	cg06935464	chr4:38784597	TLR10	0.51	8.46	0.32	1.8e-16	Breast cancer;
BRCA	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	20.79	0.64	9.64e-74	Smoking behavior;
BRCA	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg21475434	chr5:93447410	FAM172A	0.69	8.68	0.32	3.36e-17	Diabetic retinopathy;
BRCA	cis	rs365132	1.000	rs353468	chr5:176445494	A/T	cg16309518	chr5:176445507	NA	-0.52	-13.24	-0.46	1.51e-35	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg03060546	chr3:49711283	APEH	0.55	9.22	0.34	4.32e-19	Menarche (age at onset);
BRCA	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg09307838	chr4:120376055	NA	0.69	13.93	0.48	9.94e-39	Corneal astigmatism;
BRCA	cis	rs3740540	0.507	rs897292	chr10:126290035	A/G	cg04949429	chr10:126290192	LHPP	0.44	12.31	0.44	2.05e-31	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-10.92	-0.4	1.42e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs332507	0.830	rs3772786	chr3:124395250	A/C	cg05980111	chr3:124395277	KALRN	0.37	8.46	0.32	1.83e-16	Plateletcrit;
BRCA	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg27284194	chr4:1044797	NA	0.43	9.4	0.35	9.39e-20	Recombination rate (males);
BRCA	cis	rs2882667	0.898	rs6890272	chr5:138371116	G/A	cg04439458	chr5:138467593	SIL1	-0.32	-8.79	-0.33	1.36e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs56399783	0.901	rs6964740	chr7:2819656	C/G	cg19731401	chr7:2775893	GNA12	0.45	8.02	0.3	5.2e-15	Childhood ear infection;
BRCA	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg20307385	chr11:47447363	PSMC3	0.76	16.8	0.55	1.02e-52	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.02	14.23	0.49	3.95e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg04756594	chr16:24857601	SLC5A11	-0.55	-12.3	-0.44	2.38e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg04553112	chr3:125709451	NA	-0.55	-8.27	-0.31	7.6e-16	Blood pressure (smoking interaction);
BRCA	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg03709012	chr19:19516395	GATAD2A	0.68	14.22	0.49	4.51e-40	Tonsillectomy;
BRCA	trans	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg01620082	chr3:125678407	NA	-0.65	-8.7	-0.33	2.73e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs67517081	1	rs67517081	chr16:30987380	GT/G	cg02466173	chr16:30829666	NA	0.47	10.23	0.38	7.5e-23	Mean corpuscular hemoglobin;
BRCA	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg13010199	chr12:38710504	ALG10B	0.5	9.89	0.36	1.54e-21	Bladder cancer;
BRCA	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24308560	chr3:49941425	MST1R	-0.39	-8.52	-0.32	1.12e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg06627628	chr2:24431161	ITSN2	-0.54	-10.45	-0.38	1.04e-23	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	16.0	0.53	9.98e-49	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg06784218	chr1:46089804	CCDC17	-0.46	-10.53	-0.38	5.1900000000000004e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg15128208	chr22:42549153	NA	-0.5	-8.27	-0.31	7.57e-16	Birth weight;
BRCA	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.52	-10.97	-0.4	9.28e-26	Lymphocyte counts;
BRCA	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.01	-0.46	1.66e-34	Migraine;Coronary artery disease;
BRCA	cis	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.48	9.14	0.34	8.42e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2580764	0.565	rs6760429	chr2:55228499	C/T	cg09592903	chr2:55203963	RTN4	-0.41	-10.39	-0.38	1.86e-23	Mean platelet volume;
BRCA	cis	rs4074536	0.574	rs10801967	chr1:116286983	A/G	cg21648376	chr1:116311395	CASQ2	-0.48	-8.43	-0.32	2.24e-16	QRS duration;
BRCA	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.89	-17.65	-0.57	4.5e-57	Body mass index;
BRCA	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.03	-0.37	4.37e-22	Mean corpuscular volume;
BRCA	cis	rs2617583	0.967	rs2550948	chr5:1450444	C/T	cg07151155	chr5:1473589	LPCAT1	-0.42	-9.17	-0.34	6.22e-19	Breast cancer;
BRCA	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.39	-8.33	-0.31	4.88e-16	Body mass index;
BRCA	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11644478	chr21:40555479	PSMG1	0.86	19.58	0.61	3.05e-67	Cognitive function;
BRCA	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg13047869	chr3:10149882	C3orf24	0.6	12.81	0.45	1.29e-33	Alzheimer's disease;
BRCA	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg20387954	chr3:183756860	HTR3D	0.45	9.97	0.37	7.24e-22	Anterior chamber depth;
BRCA	cis	rs6435161	1.000	rs72926957	chr2:203487023	G/C	cg18429434	chr2:203499731	FAM117B	-0.44	-9.01	-0.34	2.28e-18	Total cholesterol levels;
BRCA	cis	rs9463078	0.656	rs227843	chr6:44691703	A/G	cg25276700	chr6:44698697	NA	0.37	8.12	0.31	2.48e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs67981189	0.593	rs221924	chr14:71580778	G/A	cg15816911	chr14:71606274	NA	-0.37	-8.31	-0.31	5.94e-16	Schizophrenia;
BRCA	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.35	0.35	1.42e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10992471	0.528	rs10115290	chr9:95195858	G/A	cg14631576	chr9:95140430	CENPP	-0.35	-8.65	-0.32	4.13e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg05347473	chr6:146136440	FBXO30	0.4	7.91	0.3	1.1e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	9.92	0.37	1.12e-21	Lung function (FEV1/FVC);
BRCA	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-10.56	-0.39	4.01e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg21138405	chr5:131827807	IRF1	-0.4	-13.19	-0.46	2.66e-35	Asthma (sex interaction);
BRCA	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.24	-19.67	-0.61	1.03e-67	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.74	16.08	0.54	4.26e-49	Cognitive ability;
BRCA	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg01620082	chr3:125678407	NA	-0.74	-9.52	-0.35	3.59e-20	Depression;
BRCA	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg18446336	chr7:2847575	GNA12	-0.34	-7.85	-0.3	1.8e-14	Height;
BRCA	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg13010199	chr12:38710504	ALG10B	-0.42	-9.21	-0.34	4.52e-19	Morning vs. evening chronotype;
BRCA	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg01475377	chr6:109611718	NA	-0.52	-13.12	-0.46	5.69e-35	Reticulocyte fraction of red cells;
BRCA	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05890377	chr2:74357713	NA	0.48	11.74	0.42	6.09e-29	Gestational age at birth (maternal effect);
BRCA	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg05872129	chr22:39784769	NA	-0.57	-13.0	-0.46	1.81e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs7246657	0.551	rs12978093	chr19:37584416	C/T	cg18154014	chr19:37997991	ZNF793	0.53	8.7	0.33	2.75e-17	Coronary artery calcification;
BRCA	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg07636037	chr3:49044803	WDR6	0.96	27.96	0.74	5.73e-113	Parkinson's disease;
BRCA	cis	rs243505	0.762	rs933436	chr7:148487329	A/C	cg09806900	chr7:148480153	CUL1	-0.54	-11.44	-0.41	1.09e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg08859206	chr1:53392774	SCP2	-0.41	-8.91	-0.33	5.17e-18	Monocyte count;
BRCA	trans	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.4	8.13	0.31	2.22e-15	Menarche (age at onset);
BRCA	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.54	12.06	0.43	2.64e-30	Electrocardiographic conduction measures;
BRCA	cis	rs7945718	0.806	rs11022507	chr11:12829753	A/T	cg25843174	chr11:12811716	TEAD1	0.24	9.01	0.34	2.39e-18	Educational attainment (years of education);
BRCA	cis	rs6120849	0.617	rs12480442	chr20:33648388	C/G	cg24642439	chr20:33292090	TP53INP2	0.61	10.47	0.38	8.5e-24	Protein C levels;
BRCA	cis	rs56399783	0.901	rs73051469	chr7:2877811	A/G	cg19731401	chr7:2775893	GNA12	0.54	8.25	0.31	9.25e-16	Childhood ear infection;
BRCA	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg20503657	chr10:835505	NA	1.05	18.71	0.59	1.3e-62	Eosinophil percentage of granulocytes;
BRCA	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	12.96	0.46	3e-34	Lymphocyte counts;
BRCA	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg02551604	chr5:131831745	NA	-0.4	-15.09	-0.51	3e-44	Asthma (sex interaction);
BRCA	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18252515	chr7:66147081	NA	-0.35	-7.81	-0.3	2.44e-14	Aortic root size;
BRCA	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg00757033	chr12:89920650	WDR51B	-0.48	-9.82	-0.36	2.8e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	trans	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg23762105	chr12:34175262	ALG10	0.35	8.12	0.31	2.36e-15	Morning vs. evening chronotype;
BRCA	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	18.64	0.59	2.88e-62	Total body bone mineral density;
BRCA	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg03585969	chr10:35415529	CREM	0.5	10.46	0.38	9.82e-24	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6138458	1.000	rs227618	chr20:24909472	T/C	cg06937882	chr20:24974362	C20orf3	-0.44	-8.36	-0.31	3.88e-16	Blood protein levels;
BRCA	trans	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg26043149	chr18:55253948	FECH	-0.37	-8.29	-0.31	6.69e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg25206134	chr2:45395956	NA	0.51	8.66	0.32	3.71e-17	Bipolar disorder;
BRCA	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24110177	chr3:50126178	RBM5	0.41	11.45	0.41	9.98e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27286337	chr10:134555280	INPP5A	0.62	10.3	0.38	4.07e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg10224037	chr5:178157518	ZNF354A	0.76	15.97	0.53	1.55e-48	Neutrophil percentage of white cells;
BRCA	cis	rs752010	0.905	rs2038977	chr1:42094659	A/G	cg06885757	chr1:42089581	HIVEP3	0.29	10.16	0.37	1.4e-22	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg14926445	chr8:58193284	C8orf71	-0.46	-8.88	-0.33	6.81e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg05901451	chr6:126070800	HEY2	0.42	10.27	0.38	5.34e-23	Endometrial cancer;
BRCA	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	8.34	0.31	4.5e-16	Schizophrenia;
BRCA	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg05623727	chr3:50126028	RBM5	0.43	10.1	0.37	2.27e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg21535247	chr6:8435926	SLC35B3	0.41	9.34	0.35	1.52e-19	Motion sickness;
BRCA	cis	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg04990556	chr1:26633338	UBXN11	0.55	8.73	0.33	2.24e-17	Obesity-related traits;
BRCA	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg11663144	chr21:46675770	NA	0.53	11.38	0.41	1.88e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg13010199	chr12:38710504	ALG10B	0.48	9.37	0.35	1.2e-19	Morning vs. evening chronotype;
BRCA	trans	rs800082	0.698	rs800073	chr3:144347599	G/A	cg24215973	chr2:240111563	HDAC4	-0.6	-14.58	-0.5	8.91e-42	Smoking behavior;
BRCA	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg11266682	chr4:10021025	SLC2A9	0.45	11.99	0.43	4.9e-30	Bone mineral density;
BRCA	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg03146154	chr1:46216737	IPP	0.53	11.75	0.42	5.61e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11764359	chr7:65958608	NA	-0.75	-16.52	-0.55	2.69e-51	Aortic root size;
BRCA	cis	rs4363385	0.747	rs946100	chr1:152971663	C/T	cg25856811	chr1:152973957	SPRR3	0.33	8.72	0.33	2.39e-17	Inflammatory skin disease;
BRCA	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg20887711	chr4:1340912	KIAA1530	-0.73	-15.52	-0.52	2.52e-46	Longevity;
BRCA	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg06115741	chr20:33292138	TP53INP2	0.4	8.86	0.33	7.8e-18	Glomerular filtration rate (creatinine);
BRCA	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg18305652	chr10:134549665	INPP5A	-0.3	-8.73	-0.33	2.16e-17	Migraine;
BRCA	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06544989	chr22:39130855	UNC84B	0.35	8.34	0.31	4.4e-16	Menopause (age at onset);
BRCA	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg24130564	chr14:104152367	KLC1	0.36	8.14	0.31	2.06e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs3820928	0.904	rs10933161	chr2:227764872	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.39	-0.32	3.1e-16	Pulmonary function;
BRCA	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg13010199	chr12:38710504	ALG10B	0.43	9.11	0.34	1.04e-18	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg13319975	chr6:146136371	FBXO30	-0.42	-9.79	-0.36	3.63e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2797160	1.000	rs984040	chr6:126021277	A/G	cg05901451	chr6:126070800	HEY2	0.38	9.38	0.35	1.11e-19	Endometrial cancer;
BRCA	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg09307838	chr4:120376055	NA	0.63	13.82	0.48	3.27e-38	Corneal astigmatism;
BRCA	trans	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg06521331	chr12:34319734	NA	-0.52	-9.81	-0.36	2.88e-21	Bladder cancer;
BRCA	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg08085267	chr17:45401833	C17orf57	-0.63	-13.49	-0.47	1.08e-36	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4363385	0.747	rs6587716	chr1:152966705	C/T	cg21543102	chr1:152974771	SPRR3	-0.3	-8.62	-0.32	5.43e-17	Inflammatory skin disease;
BRCA	cis	rs10411936	0.750	rs8112401	chr19:16593012	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.45	9.66	0.36	1.07e-20	White blood cell count;Multiple sclerosis;
BRCA	trans	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	20.79	0.64	1.05e-73	Exhaled nitric oxide output;
BRCA	cis	rs4285028	0.699	rs4676758	chr3:121583415	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.72	13.37	0.47	3.8e-36	Multiple sclerosis;
BRCA	cis	rs965469	1.000	rs6051751	chr20:3310049	G/C	cg25506879	chr20:3388711	C20orf194	-0.54	-10.53	-0.38	4.92e-24	IFN-related cytopenia;
BRCA	cis	rs1003719	1.000	rs2835608	chr21:38493455	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	14.17	0.49	7.99e-40	Eye color traits;
BRCA	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg12292205	chr6:26970375	C6orf41	-0.64	-10.48	-0.38	7.73e-24	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-9.39	-0.35	1.05e-19	Reticulocyte count;
BRCA	cis	rs34779708	0.931	rs34375045	chr10:35362356	A/C	cg03585969	chr10:35415529	CREM	0.55	11.47	0.41	7.79e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg18305652	chr10:134549665	INPP5A	-0.29	-8.37	-0.31	3.66e-16	Migraine;
BRCA	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg09754948	chr16:28834200	ATXN2L	0.45	8.32	0.31	5.46e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg24531977	chr5:56204891	C5orf35	-0.54	-11.34	-0.41	2.69e-27	Coronary artery disease;
BRCA	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg16339924	chr4:17578868	LAP3	0.6	14.59	0.5	8.4e-42	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs34779708	0.966	rs17500582	chr10:35498788	T/A	cg03585969	chr10:35415529	CREM	0.48	10.0	0.37	5.48e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg22676075	chr6:135203613	NA	-0.62	-13.49	-0.47	1.12e-36	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg03188948	chr7:1209495	NA	0.51	9.44	0.35	6.94e-20	Longevity;Endometriosis;
BRCA	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg15704280	chr7:45808275	SEPT13	-0.48	-9.28	-0.34	2.58e-19	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.72	-0.36	6.32e-21	Developmental language disorder (linguistic errors);
BRCA	trans	rs3960554	0.932	rs4728614	chr7:75841589	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.59	-11.74	-0.42	5.69e-29	Eotaxin levels;
BRCA	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.33	0.38	3.17e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg23285459	chr7:2802560	GNA12	-0.38	-9.66	-0.36	1.09e-20	Height;
BRCA	cis	rs6142102	0.502	rs58393429	chr20:32545802	C/G	cg24642439	chr20:33292090	TP53INP2	0.39	7.81	0.3	2.35e-14	Skin pigmentation;
BRCA	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.43	-9.2	-0.34	4.84e-19	Longevity;Endometriosis;
BRCA	cis	rs12611088	0.600	rs2682578	chr19:44012880	A/G	cg15012607	chr19:44012195	ETHE1	-0.34	-8.39	-0.31	3.19e-16	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.82	-0.42	2.81e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg23711669	chr6:146136114	FBXO30	0.62	14.31	0.49	1.7e-40	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs9951602	0.512	rs3859325	chr18:76652175	A/G	cg02800362	chr5:177631904	HNRNPAB	0.77	18.23	0.58	4.3e-60	Obesity-related traits;
BRCA	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg00983440	chr10:79422392	NA	-0.54	-10.13	-0.37	1.79e-22	Bone mineral density;
BRCA	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg18016565	chr1:150552671	MCL1	0.35	8.02	0.3	5.05e-15	Melanoma;
BRCA	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg03146154	chr1:46216737	IPP	0.47	10.4	0.38	1.62e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg13770153	chr20:60521292	NA	-0.45	-9.82	-0.36	2.79e-21	Body mass index;
BRCA	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg02503808	chr4:7069936	GRPEL1	0.8	18.6	0.59	4.7e-62	Monocyte percentage of white cells;
BRCA	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06108461	chr20:60628389	TAF4	-0.98	-22.13	-0.66	5.43e-81	Body mass index;
BRCA	cis	rs4853036	0.629	rs10496171	chr2:70015181	A/G	cg02498382	chr2:70120550	SNRNP27	0.43	7.98	0.3	6.94e-15	Colorectal or endometrial cancer;
BRCA	cis	rs7586879	0.964	rs4077680	chr2:25122942	A/G	cg04586622	chr2:25135609	ADCY3	0.4	9.23	0.34	3.91e-19	Body mass index;
BRCA	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.56	13.2	0.46	2.43e-35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg04842962	chr6:43655489	MRPS18A	-0.88	-23.94	-0.69	6.7e-91	IgG glycosylation;
BRCA	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.68	0.42	1.1e-28	Homoarginine levels;
BRCA	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg09307838	chr4:120376055	NA	0.67	14.71	0.5	2.2e-42	Corneal astigmatism;
BRCA	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg15242686	chr22:24348715	GSTTP1	0.36	9.0	0.34	2.49e-18	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg22535103	chr8:58192502	C8orf71	-0.61	-13.3	-0.47	8.07e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg15212455	chr7:39170539	POU6F2	0.34	7.88	0.3	1.39e-14	IgG glycosylation;
BRCA	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg24296786	chr1:45957014	TESK2	-0.47	-10.67	-0.39	1.44e-24	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1018836	0.923	rs13254212	chr8:91582355	T/C	cg16814680	chr8:91681699	NA	-0.58	-12.34	-0.44	1.51e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.57	-0.47	4.99e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	18.08	0.58	2.44e-59	Menopause (age at onset);
BRCA	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg01256987	chr12:42539512	GXYLT1	-0.46	-9.2	-0.34	4.95e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs3857536	0.740	rs4710571	chr6:66890250	T/C	cg07460842	chr6:66804631	NA	-0.46	-8.86	-0.33	8.01e-18	Blood trace element (Cu levels);
BRCA	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg12386194	chr3:101231763	SENP7	0.54	10.65	0.39	1.67e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg22903471	chr2:27725779	GCKR	-0.37	-8.96	-0.33	3.41e-18	Total body bone mineral density;
BRCA	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	12.48	0.44	3.86e-32	Mean platelet volume;
BRCA	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg23711669	chr6:146136114	FBXO30	-0.78	-18.57	-0.59	7.07e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg07741184	chr6:167504864	NA	0.33	9.92	0.37	1.19e-21	Primary biliary cholangitis;
BRCA	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21582582	chr3:182698605	DCUN1D1	0.39	10.11	0.37	2.08e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6005807	0.719	rs2144922	chr22:28923317	A/G	cg12565055	chr22:29076175	TTC28	0.43	8.37	0.31	3.65e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg04896959	chr15:78267971	NA	-0.48	-8.57	-0.32	8.01e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	9.02	0.34	2.22e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg27347728	chr4:17578864	LAP3	0.44	8.62	0.32	5.41e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4363385	0.747	rs2339493	chr1:152975277	G/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.32	-0.31	5.23e-16	Inflammatory skin disease;
BRCA	cis	rs4594175	0.886	rs11157801	chr14:51622918	C/T	cg23942311	chr14:51606299	NA	0.34	8.63	0.32	5.05e-17	Cancer;
BRCA	trans	rs970548	0.688	rs10900228	chr10:46082128	A/G	cg20477318	chr10:51623047	TIMM23	0.44	7.93	0.3	9.99e-15	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
BRCA	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.35	-9.78	-0.36	3.66e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg19338460	chr6:170058176	WDR27	-0.49	-8.58	-0.32	7.01e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs7617773	0.746	rs7619865	chr3:48370580	G/A	cg11946769	chr3:48343235	NME6	0.51	11.39	0.41	1.68e-27	Coronary artery disease;
BRCA	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg02196655	chr2:10830764	NOL10	-0.3	-8.05	-0.3	4.2e-15	Prostate cancer;
BRCA	cis	rs12367572	0.965	rs1506676	chr12:45237401	T/C	cg04608330	chr12:45269318	NELL2	-0.61	-12.8	-0.45	1.55e-33	Gut microbiome composition (summer);
BRCA	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg03433033	chr1:76189801	ACADM	-0.41	-8.33	-0.31	4.82e-16	Daytime sleep phenotypes;
BRCA	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg20387954	chr3:183756860	HTR3D	0.47	10.38	0.38	1.94e-23	Anterior chamber depth;
BRCA	cis	rs1551570	0.819	rs11666402	chr19:10219076	A/G	cg16327482	chr19:10226339	EIF3G	0.38	9.77	0.36	4.23e-21	Narcolepsy;
BRCA	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg02551604	chr5:131831745	NA	0.42	15.77	0.53	1.4e-47	Asthma (sex interaction);
BRCA	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg27446573	chr6:127587934	RNF146	0.67	14.98	0.51	1.11e-43	Breast cancer;
BRCA	cis	rs7809950	0.637	rs2701685	chr7:107299584	A/G	cg23024343	chr7:107201750	COG5	0.4	8.92	0.33	4.91e-18	Coronary artery disease;
BRCA	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.6	8.43	0.32	2.33e-16	Yeast infection;
BRCA	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.76	-0.42	5.05e-29	Alcohol dependence;
BRCA	trans	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg26043149	chr18:55253948	FECH	-0.36	-8.05	-0.3	4.03e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg14343924	chr8:8086146	FLJ10661	-0.4	-8.17	-0.31	1.62e-15	Systolic blood pressure;
BRCA	cis	rs3849570	0.961	rs11915042	chr3:81834060	G/A	cg07356753	chr3:81810745	GBE1	-0.47	-11.33	-0.41	3.13e-27	Waist circumference;Body mass index;
BRCA	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	cg06064525	chr11:970664	AP2A2	-0.31	-9.0	-0.34	2.54e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.74e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.42	-0.38	1.36e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-9.96	-0.37	8.08e-22	Alzheimer's disease (late onset);
BRCA	trans	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg19862616	chr7:65841803	NCRNA00174	0.83	27.56	0.74	8.71e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg03433033	chr1:76189801	ACADM	0.73	18.87	0.6	1.74e-63	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg04546413	chr19:29218101	NA	0.5	8.64	0.32	4.33e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg08807101	chr21:30365312	RNF160	-0.55	-12.39	-0.44	9.7e-32	Cognitive test performance;
BRCA	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08219700	chr8:58056026	NA	0.54	8.77	0.33	1.6e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg23533926	chr12:111358616	MYL2	-0.43	-8.97	-0.33	3.19e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4363385	0.747	rs4845504	chr1:152960043	G/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.81	-0.33	1.15e-17	Inflammatory skin disease;
BRCA	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg03585969	chr10:35415529	CREM	0.56	11.55	0.42	3.61e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs36051895	0.664	rs10117501	chr9:5094246	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-9.71	-0.36	6.97e-21	Pediatric autoimmune diseases;
BRCA	cis	rs2625529	0.590	rs7183196	chr15:72544401	A/G	cg16672083	chr15:72433130	SENP8	-0.69	-15.18	-0.51	1.18e-44	Red blood cell count;
BRCA	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg18154014	chr19:37997991	ZNF793	0.48	9.56	0.35	2.54e-20	Coronary artery calcification;
BRCA	cis	rs2731664	0.756	rs4976695	chr5:176862963	T/A	cg23176889	chr5:176863531	GRK6	-0.59	-15.47	-0.52	4.3e-46	Intelligence (multi-trait analysis);
BRCA	trans	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg06521331	chr12:34319734	NA	-0.49	-9.11	-0.34	1.06e-18	Bladder cancer;
BRCA	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg10223061	chr2:219282414	VIL1	-0.27	-7.92	-0.3	1.04e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7818345	0.845	rs17407039	chr8:19268056	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.33	8.25	0.31	8.86e-16	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.41	-7.97	-0.3	7.08e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.6	-10.05	-0.37	3.56e-22	Ankle injury;
BRCA	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg23033748	chr14:75592666	NEK9	-0.4	-9.61	-0.36	1.68e-20	Height;
BRCA	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg12311346	chr5:56204834	C5orf35	-0.78	-14.61	-0.5	6.65e-42	Initial pursuit acceleration;
BRCA	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg05564831	chr3:52568323	NT5DC2	0.34	8.05	0.3	3.96e-15	Electroencephalogram traits;
BRCA	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.77	0.39	5.84e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.5	0.38	6.63e-24	Motion sickness;
BRCA	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.51	-9.49	-0.35	4.57e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.54	7.98	0.3	6.89e-15	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg02659138	chr7:134003124	SLC35B4	0.33	10.18	0.37	1.2e-22	Mean platelet volume;
BRCA	cis	rs9463078	0.665	rs4714816	chr6:44715168	T/C	cg25276700	chr6:44698697	NA	0.41	9.56	0.35	2.55e-20	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.42	0.47	2.35e-36	Colorectal cancer;
BRCA	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg15839431	chr19:19639596	YJEFN3	-0.43	-9.37	-0.35	1.23e-19	Bipolar disorder;
BRCA	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21659725	chr3:3221576	CRBN	0.46	11.56	0.42	3.34e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg25208724	chr1:156163844	SLC25A44	0.88	17.72	0.57	1.93e-57	Testicular germ cell tumor;
BRCA	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.55	11.85	0.42	1.95e-29	Monocyte percentage of white cells;
BRCA	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg27446573	chr6:127587934	RNF146	0.88	20.81	0.64	8.36e-74	Breast cancer;
BRCA	cis	rs1568889	0.775	rs35243076	chr11:28250618	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.59	0.63	1.26e-72	Bipolar disorder;
BRCA	cis	rs2051211	0.947	rs60479981	chr3:38568611	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.52	-10.05	-0.37	3.65e-22	QRS duration;
BRCA	trans	rs6479901	0.557	rs4746125	chr10:65152885	G/A	cg14819942	chr15:35414228	NA	0.3	7.93	0.3	1.01e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs6543140	0.964	rs2160200	chr2:103033963	G/T	cg04239558	chr2:103089729	SLC9A4	0.33	9.25	0.34	3.24e-19	Blood protein levels;
BRCA	cis	rs67981189	0.574	rs4467005	chr14:71498656	C/T	cg15816911	chr14:71606274	NA	0.37	8.34	0.31	4.55e-16	Schizophrenia;
BRCA	cis	rs273218	1.000	rs156440	chr5:53373656	A/T	ch.5.1024479R	chr5:53302184	ARL15	0.43	8.89	0.33	6.38e-18	Migraine;
BRCA	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg22139774	chr2:100720529	AFF3	0.32	8.91	0.33	5.41e-18	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22509189	chr2:225307070	NA	0.43	9.1	0.34	1.13e-18	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs586533	0.881	rs590114	chr11:99500472	G/A	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6484504	0.652	rs578666	chr11:31404484	C/T	cg14844989	chr11:31128820	NA	0.44	9.39	0.35	1.05e-19	Red blood cell count;
BRCA	cis	rs1691799	0.899	rs903590	chr12:66745777	C/G	cg16791601	chr12:66731901	HELB	-0.63	-17.02	-0.56	7.32e-54	White blood cell count (basophil);
BRCA	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg07636037	chr3:49044803	WDR6	0.55	8.74	0.33	2.09e-17	Menarche (age at onset);
BRCA	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.62	-0.39	2.3e-24	Bipolar disorder;
BRCA	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg09307838	chr4:120376055	NA	0.74	16.0	0.53	1.01e-48	Corneal astigmatism;
BRCA	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.35	8.22	0.31	1.13e-15	Tonsillectomy;
BRCA	cis	rs4363385	0.818	rs572821	chr1:153008276	G/A	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg25358565	chr5:93447407	FAM172A	1.17	18.43	0.59	3.64e-61	Diabetic retinopathy;
BRCA	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg06026331	chr20:60912101	LAMA5	0.4	8.16	0.31	1.83e-15	Colorectal cancer;
BRCA	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg17063962	chr7:91808500	NA	0.56	12.7	0.45	3.95e-33	Breast cancer;
BRCA	trans	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23583168	chr7:148888333	NA	-0.78	-17.93	-0.58	1.61e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg02551604	chr5:131831745	NA	0.39	13.99	0.48	5.63e-39	Asthma (sex interaction);
BRCA	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg06212747	chr3:49208901	KLHDC8B	0.47	9.4	0.35	9.73e-20	Parkinson's disease;
BRCA	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg12826209	chr6:26865740	GUSBL1	0.56	9.23	0.34	3.92e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs4690686	0.500	rs7657249	chr4:177275198	A/G	cg17059388	chr4:177262070	NA	0.54	11.13	0.4	2.02e-26	Essential tremor;
BRCA	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg14019146	chr3:50243930	SLC38A3	0.36	8.9	0.33	5.88e-18	Body mass index;
BRCA	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.53	-9.49	-0.35	4.41e-20	Glomerular filtration rate in chronic kidney disease;
BRCA	trans	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg25214090	chr10:38739885	LOC399744	0.54	11.89	0.43	1.43e-29	Corneal astigmatism;
BRCA	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg18252515	chr7:66147081	NA	-1.05	-15.27	-0.52	4.34e-45	Diabetic kidney disease;
BRCA	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22029157	chr1:209979665	IRF6	0.59	17.96	0.58	1.01e-58	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
BRCA	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.71	12.06	0.43	2.49e-30	Schizophrenia;
BRCA	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg24130564	chr14:104152367	KLC1	-0.41	-8.9	-0.33	5.54e-18	Reticulocyte count;
BRCA	trans	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg26043149	chr18:55253948	FECH	-0.37	-8.29	-0.31	6.69e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg27398817	chr8:82754497	SNX16	-0.36	-8.17	-0.31	1.6e-15	Diastolic blood pressure;
BRCA	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-13.23	-0.46	1.75e-35	Bladder cancer;
BRCA	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg25358565	chr5:93447407	FAM172A	1.14	18.39	0.59	6.32e-61	Diabetic retinopathy;
BRCA	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.36	-0.41	2.36e-27	Colorectal cancer;
BRCA	cis	rs68170813	0.559	rs12537011	chr7:107027833	G/A	cg02696742	chr7:106810147	HBP1	-0.54	-8.66	-0.32	3.93e-17	Coronary artery disease;
BRCA	trans	rs7200543	1.000	rs3803575	chr16:15138447	T/C	cg24683922	chr1:11983373	KIAA2013	-0.37	-8.5	-0.32	1.34e-16	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs10463316	0.817	rs906679	chr5:150779302	T/A	cg03212797	chr5:150827313	SLC36A1	-0.4	-7.97	-0.3	7.39e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg26384229	chr12:38710491	ALG10B	0.69	15.89	0.53	3.53e-48	Bladder cancer;
BRCA	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-16.27	-0.54	4.64e-50	Alzheimer's disease (late onset);
BRCA	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12292205	chr6:26970375	C6orf41	-0.49	-8.27	-0.31	7.96e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs13046373	0.535	rs35909098	chr21:32021649	C/T	cg16431978	chr21:31797932	KRTAP13-3	0.36	9.11	0.34	1.05e-18	HDL cholesterol;
BRCA	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-21.48	-0.65	1.76e-77	Lymphocyte percentage of white cells;
BRCA	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.57	-0.32	7.75e-17	Total body bone mineral density;
BRCA	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	7.93e-19	Lymphocyte counts;
BRCA	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg22535103	chr8:58192502	C8orf71	-0.6	-13.05	-0.46	1.1e-34	Developmental language disorder (linguistic errors);
BRCA	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.69	0.39	1.24e-24	Bladder cancer;
BRCA	cis	rs2505998	0.833	rs2505533	chr10:43594453	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.42	-8.35	-0.31	4.2e-16	Hirschsprung disease;
BRCA	cis	rs698833	0.518	rs7562945	chr2:44552772	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	8.16	0.31	1.83e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg13010199	chr12:38710504	ALG10B	0.43	9.16	0.34	6.75e-19	Morning vs. evening chronotype;
BRCA	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg03609598	chr5:56110824	MAP3K1	-0.47	-8.19	-0.31	1.42e-15	Initial pursuit acceleration;
BRCA	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg13319975	chr6:146136371	FBXO30	-0.48	-10.7	-0.39	1.11e-24	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg19622623	chr12:86230825	RASSF9	0.31	8.6	0.32	6.38e-17	Major depressive disorder;
BRCA	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg20891283	chr12:69753455	YEATS4	0.84	28.41	0.75	1.93e-115	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4588572	0.643	rs1035950	chr5:77785858	G/A	cg11547950	chr5:77652471	NA	-0.48	-8.42	-0.32	2.55e-16	Triglycerides;
BRCA	cis	rs17604090	0.938	rs115369413	chr7:29685040	T/G	cg19413766	chr7:29689036	LOC646762	-0.55	-8.59	-0.32	6.49e-17	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-19.27	-0.61	1.44e-65	Chronic sinus infection;
BRCA	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg27129171	chr3:47204927	SETD2	-0.68	-15.95	-0.53	1.86e-48	Colorectal cancer;
BRCA	cis	rs300703	0.515	rs424292	chr2:191931	C/T	cg21211680	chr2:198530	NA	-0.39	-8.82	-0.33	1.11e-17	Blood protein levels;
BRCA	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg12373951	chr3:133503437	NA	0.34	8.15	0.31	1.95e-15	Iron status biomarkers;
BRCA	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.71	10.9	0.4	1.69e-25	Lung function (FEV1/FVC);
BRCA	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26314531	chr2:26401878	FAM59B	-0.63	-10.83	-0.39	3.28e-25	Gut microbiome composition (summer);
BRCA	cis	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg06521331	chr12:34319734	NA	-0.54	-10.83	-0.39	3.27e-25	Morning vs. evening chronotype;
BRCA	cis	rs57024841	0.819	rs11145948	chr9:139857912	C/T	cg00693599	chr9:139836323	FBXW5	-0.34	-8.18	-0.31	1.53e-15	Beta-trace protein levels;
BRCA	cis	rs754466	0.606	rs55854323	chr10:79589904	C/T	cg17075019	chr10:79541650	NA	-0.81	-19.61	-0.61	2.18e-67	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs7939886	0.920	rs11227321	chr11:55904828	A/G	cg15704280	chr7:45808275	SEPT13	0.63	7.84	0.3	1.88e-14	Myopia (pathological);
BRCA	cis	rs4268898	0.516	rs7597149	chr2:24371962	C/T	cg06627628	chr2:24431161	ITSN2	0.42	8.68	0.32	3.17e-17	Asthma;
BRCA	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg12935359	chr14:103987150	CKB	-0.53	-12.64	-0.45	7.42e-33	Body mass index;
BRCA	cis	rs1018836	0.847	rs4735225	chr8:91569100	G/C	cg16814680	chr8:91681699	NA	-0.64	-14.24	-0.49	3.76e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9467160	0.651	rs7755403	chr6:24453447	C/G	cg20631270	chr6:24437470	GPLD1	0.43	8.63	0.32	4.88e-17	Liver enzyme levels;
BRCA	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg06115741	chr20:33292138	TP53INP2	-0.37	-8.14	-0.31	2.05e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs2425143	0.908	rs6060625	chr20:34414318	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-8.3	-0.31	5.99e-16	Blood protein levels;
BRCA	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg14784868	chr12:69753453	YEATS4	0.66	19.09	0.6	1.27e-64	Blood protein levels;
BRCA	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg20891283	chr12:69753455	YEATS4	0.83	27.97	0.74	5.23e-113	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11764359	chr7:65958608	NA	-0.76	-16.74	-0.55	1.98e-52	Aortic root size;
BRCA	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.48	9.55	0.35	2.75e-20	Iron status biomarkers;
BRCA	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg21784768	chr11:537496	LRRC56	-0.64	-8.28	-0.31	7.08e-16	Body mass index;
BRCA	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg10560079	chr2:191398806	TMEM194B	-0.72	-12.94	-0.46	3.61e-34	Diastolic blood pressure;
BRCA	cis	rs208520	0.874	rs208514	chr6:66945520	G/A	cg07460842	chr6:66804631	NA	-0.82	-14.74	-0.5	1.51e-42	Exhaled nitric oxide output;
BRCA	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg00074818	chr8:8560427	CLDN23	0.39	8.45	0.32	1.96e-16	Obesity-related traits;
BRCA	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg23708337	chr7:1209742	NA	0.6	8.31	0.31	5.89e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-7.93	-0.3	9.75e-15	Ulcerative colitis;
BRCA	cis	rs17253792	0.822	rs10150498	chr14:56064124	G/T	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs921968	0.529	rs6729341	chr2:219611434	T/G	cg02176678	chr2:219576539	TTLL4	-0.41	-11.12	-0.4	2.15e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg13319975	chr6:146136371	FBXO30	-0.35	-8.09	-0.3	3.11e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg19077165	chr18:44547161	KATNAL2	0.62	14.21	0.49	4.86e-40	Personality dimensions;
BRCA	cis	rs6005807	0.640	rs73432205	chr22:29028132	C/T	cg12565055	chr22:29076175	TTC28	0.49	9.36	0.35	1.35e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.35	0.38	2.49e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg17691542	chr6:26056736	HIST1H1C	0.53	11.21	0.41	9.28e-27	Height;
BRCA	cis	rs3857067	0.806	rs6857967	chr4:95112303	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.25	-0.34	3.46e-19	QT interval;
BRCA	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	ch.11.42038R	chr11:967971	AP2A2	0.5	15.89	0.53	3.66e-48	Alzheimer's disease (late onset);
BRCA	cis	rs4363385	0.747	rs2075739	chr1:152975495	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-9.29	-0.34	2.4e-19	Inflammatory skin disease;
BRCA	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg13319975	chr6:146136371	FBXO30	-0.53	-11.77	-0.42	4.25e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg05083358	chr7:2394359	EIF3B	-0.5	-8.11	-0.31	2.52e-15	Multiple sclerosis;
BRCA	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24110177	chr3:50126178	RBM5	0.4	11.1	0.4	2.55e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.32	0.49	1.55e-40	Motion sickness;
BRCA	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg01028140	chr2:1542097	TPO	-0.7	-13.1	-0.46	6.38e-35	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg26384229	chr12:38710491	ALG10B	0.51	13.56	0.47	5.65e-37	Morning vs. evening chronotype;
BRCA	cis	rs1127311	0.875	rs9427102	chr1:154586957	A/G	cg17218026	chr1:154582156	ADAR	0.29	8.58	0.32	7.16e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
BRCA	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-14.44	-0.5	4.25e-41	Response to antipsychotic treatment;
BRCA	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg24562669	chr7:97807699	LMTK2	0.46	12.25	0.44	3.81e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2014572	0.901	rs35658377	chr19:57755627	T/G	cg24459738	chr19:57751996	ZNF805	-0.34	-8.09	-0.3	2.94e-15	Hyperactive-impulsive symptoms;
BRCA	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg23711669	chr6:146136114	FBXO30	0.67	15.49	0.52	3.54e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg08000102	chr2:233561755	GIGYF2	-0.74	-15.56	-0.52	1.5e-46	Schizophrenia;
BRCA	cis	rs6723226	0.572	rs176404	chr2:32638846	T/C	cg02381751	chr2:32503542	YIPF4	-0.46	-9.65	-0.36	1.17e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24549020	chr5:56110836	MAP3K1	0.66	13.4	0.47	3.01e-36	Initial pursuit acceleration;
BRCA	cis	rs4409675	0.576	rs10751724	chr1:28215631	C/T	cg23691781	chr1:28212827	C1orf38	0.32	11.12	0.4	2.22e-26	Corneal astigmatism;
BRCA	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg00717180	chr2:96193071	NA	-0.38	-10.34	-0.38	2.9e-23	HDL cholesterol;
BRCA	trans	rs2262909	0.962	rs17459246	chr19:22278121	T/C	cg17074339	chr11:11642133	GALNTL4	0.44	8.52	0.32	1.19e-16	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.81	-0.33	1.2e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6430585	0.591	rs1374330	chr2:136420908	A/C	cg07169764	chr2:136633963	MCM6	1.13	20.13	0.62	3.73e-70	Corneal structure;
BRCA	cis	rs2171564	0.727	rs6788567	chr3:112437047	A/C	cg06685282	chr3:112453648	NA	-0.37	-8.78	-0.33	1.5e-17	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg08999081	chr20:33150536	PIGU	0.45	12.12	0.43	1.39e-30	Coronary artery disease;
BRCA	cis	rs9323205	0.906	rs11629336	chr14:51686620	A/C	cg23942311	chr14:51606299	NA	0.42	8.68	0.32	3.26e-17	Cancer;
BRCA	cis	rs698813	0.604	rs58667148	chr2:44481443	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.55	0.32	8.9e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs6120849	0.573	rs3746429	chr20:33703607	A/G	cg24642439	chr20:33292090	TP53INP2	-0.58	-8.52	-0.32	1.11e-16	Protein C levels;
BRCA	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg07148914	chr20:33460835	GGT7	0.37	8.48	0.32	1.62e-16	Height;
BRCA	trans	rs2262909	0.962	rs411020	chr19:22231102	G/A	cg17074339	chr11:11642133	GALNTL4	-0.41	-7.98	-0.3	6.96e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg17063962	chr7:91808500	NA	0.52	12.41	0.44	7.57e-32	Breast cancer;
BRCA	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg27433088	chr4:174089019	GALNT7	-0.36	-9.93	-0.37	1.08e-21	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.57	-0.61	3.67e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg25754956	chr12:51612065	POU6F1	0.85	16.56	0.55	1.6e-51	Cisplatin-induced ototoxicity;
BRCA	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg10057126	chr4:77819792	ANKRD56	0.65	14.93	0.51	1.94e-43	Emphysema distribution in smoking;
BRCA	cis	rs13102973	0.899	rs10213137	chr4:135900543	T/C	cg14419869	chr4:135874104	NA	-0.52	-10.64	-0.39	1.82e-24	Subjective well-being;
BRCA	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg18016565	chr1:150552671	MCL1	-0.35	-8.17	-0.31	1.66e-15	Melanoma;
BRCA	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.22e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.33	-0.44	1.69e-31	Chronic sinus infection;
BRCA	cis	rs2455601	0.786	rs10279	chr11:8969309	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-7.83	-0.3	1.97e-14	Schizophrenia;
BRCA	cis	rs2012796	1.000	rs7153469	chr14:81820979	T/G	cg02996355	chr14:81879375	NA	0.51	10.03	0.37	4.53e-22	Night sleep phenotypes;
BRCA	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg26516362	chr5:178986906	RUFY1	0.43	11.13	0.4	2.05e-26	Lung cancer;
BRCA	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	trans	rs11039798	0.764	rs76882342	chr11:48939091	A/T	cg15704280	chr7:45808275	SEPT13	0.6	8.89	0.33	6.42e-18	Axial length;
BRCA	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	14.59	0.5	7.84e-42	Platelet count;
BRCA	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg07636037	chr3:49044803	WDR6	0.41	8.41	0.32	2.69e-16	Resting heart rate;
BRCA	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg07828340	chr4:882639	GAK	1.01	11.71	0.42	7.8e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	9.98	0.37	6.66e-22	Aortic root size;
BRCA	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg05340658	chr4:99064831	C4orf37	0.61	14.49	0.5	2.33e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg11812906	chr14:75593930	NEK9	-0.62	-14.2	-0.49	5.61e-40	Height;
BRCA	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.45	-10.54	-0.38	4.83e-24	Urate levels in overweight individuals;
BRCA	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg01819863	chr10:32635814	EPC1	1.15	18.71	0.6	1.22e-62	Sexual dysfunction (female);
BRCA	trans	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg07461501	chr17:79650226	HGS;ARL16	0.4	10.09	0.37	2.53e-22	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg22800045	chr5:56110881	MAP3K1	0.56	10.52	0.38	5.82e-24	Initial pursuit acceleration;
BRCA	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	18.31	0.59	1.63e-60	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg06092702	chr1:163392909	NA	-0.35	-9.45	-0.35	6.23e-20	Motion sickness;
BRCA	cis	rs9318086	0.687	rs9507182	chr13:24442365	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.31	9.08	0.34	1.37e-18	Myopia (pathological);
BRCA	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.35	9.12	0.34	9.44e-19	IgG glycosylation;
BRCA	cis	rs13095912	0.962	rs7644758	chr3:185328197	G/T	cg11274856	chr3:185301563	NA	-0.36	-8.84	-0.33	9.31e-18	Systolic blood pressure;
BRCA	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-11.7	-0.42	8.57e-29	Morning vs. evening chronotype;
BRCA	trans	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-15.67	-0.53	4.47e-47	Obesity-related traits;
BRCA	cis	rs1215050	0.765	rs588851	chr4:98678247	C/T	cg05340658	chr4:99064831	C4orf37	0.44	10.07	0.37	3.12e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7809950	0.559	rs2248465	chr7:107303628	C/T	cg23024343	chr7:107201750	COG5	0.38	8.43	0.32	2.27e-16	Coronary artery disease;
BRCA	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg08885076	chr2:99613938	TSGA10	-0.52	-9.59	-0.35	1.99e-20	Chronic sinus infection;
BRCA	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg13175981	chr1:150552382	MCL1	0.54	11.84	0.42	2.18e-29	Tonsillectomy;
BRCA	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	14.67	0.5	3.39e-42	Colorectal cancer;
BRCA	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg10932868	chr11:921992	NA	0.38	9.12	0.34	9.94e-19	Alzheimer's disease (late onset);
BRCA	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg09537434	chr19:41945824	ATP5SL	-1.0	-23.64	-0.68	3e-89	Height;
BRCA	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg12386194	chr3:101231763	SENP7	0.62	12.27	0.44	3.04e-31	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg17420585	chr12:42539391	GXYLT1	-0.48	-10.33	-0.38	3.19e-23	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	trans	rs1478897	0.898	rs2248932	chr8:11391650	A/G	cg06636001	chr8:8085503	FLJ10661	-0.38	-7.85	-0.3	1.76e-14	Systemic lupus erythematosus;
BRCA	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg27446573	chr6:127587934	RNF146	0.88	20.44	0.63	7.82e-72	Breast cancer;
BRCA	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.66	-15.16	-0.51	1.45e-44	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg03060546	chr3:49711283	APEH	-0.59	-10.38	-0.38	1.9e-23	Menarche (age at onset);
BRCA	cis	rs9463078	0.764	rs9367208	chr6:44830180	G/A	cg25276700	chr6:44698697	NA	-0.36	-8.32	-0.31	5.53e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg24812749	chr6:127587940	RNF146	0.87	20.07	0.62	7.99e-70	Breast cancer;
BRCA	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg08470875	chr2:26401718	FAM59B	0.76	11.99	0.43	4.93e-30	Gut microbiome composition (summer);
BRCA	trans	rs853679	0.546	rs35017208	chr6:28345282	C/T	cg06606381	chr12:133084897	FBRSL1	-0.9	-8.85	-0.33	8.67e-18	Depression;
BRCA	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.65	18.58	0.59	5.9e-62	Schizophrenia;
BRCA	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.05	0.3	3.95e-15	Menarche (age at onset);
BRCA	cis	rs4727443	0.866	rs13243708	chr7:99616291	T/C	cg22004693	chr7:99632812	ZKSCAN1	0.41	9.12	0.34	9.64e-19	Interstitial lung disease;
BRCA	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg07169764	chr2:136633963	MCM6	1.27	26.71	0.73	3.86e-106	Corneal structure;
BRCA	trans	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg06521331	chr12:34319734	NA	-0.51	-9.35	-0.35	1.41e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg03354898	chr7:1950403	MAD1L1	-0.39	-8.19	-0.31	1.42e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg13319975	chr6:146136371	FBXO30	-0.37	-8.22	-0.31	1.1e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.747	rs1933383	chr1:152963468	C/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.65	-0.32	4.05e-17	Inflammatory skin disease;
BRCA	cis	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.72	-0.33	2.31e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.91	0.37	1.24e-21	Bladder cancer;
BRCA	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg26031613	chr14:104095156	KLC1	-0.45	-8.85	-0.33	8.71e-18	Schizophrenia;
BRCA	trans	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg15704280	chr7:45808275	SEPT13	0.6	8.88	0.33	6.87e-18	Axial length;
BRCA	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	9.73	0.36	5.94e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg03929089	chr4:120376271	NA	-0.66	-13.07	-0.46	9.57e-35	Coronary artery disease;
BRCA	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg08997352	chr12:9597637	DDX12	-0.54	-10.21	-0.37	8.78e-23	Breast size;
BRCA	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	28.21	0.74	2.43e-114	Chronic sinus infection;
BRCA	cis	rs10489202	0.634	rs11582396	chr1:168077636	C/T	cg24449463	chr1:168025552	DCAF6	-0.47	-14.7	-0.5	2.37e-42	Schizophrenia;
BRCA	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg00277334	chr10:82204260	NA	-0.5	-10.7	-0.39	1.05e-24	Post bronchodilator FEV1;
BRCA	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg25237894	chr2:233734115	C2orf82	0.41	11.9	0.43	1.23e-29	Coronary artery disease;
BRCA	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.74	-10.53	-0.38	4.89e-24	Initial pursuit acceleration;
BRCA	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.73	0.57	1.64e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg04362960	chr10:104952993	NT5C2	0.46	10.7	0.39	1.05e-24	Arsenic metabolism;
BRCA	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.1	-0.37	2.46e-22	Mean corpuscular volume;
BRCA	trans	rs2270927	1.000	rs4546360	chr5:75577563	T/C	cg13563193	chr19:33072644	PDCD5	0.84	11.5	0.41	5.9e-28	Mean corpuscular volume;
BRCA	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg04546413	chr19:29218101	NA	0.49	8.47	0.32	1.63e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs12618769	0.625	rs56240302	chr2:99148970	C/T	cg10123293	chr2:99228465	UNC50	0.42	8.15	0.31	1.92e-15	Bipolar disorder;
BRCA	trans	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg19894588	chr14:64061835	NA	0.36	8.14	0.31	2.09e-15	Glioblastoma;Glioma;
BRCA	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.13	0.49	1.16e-39	Motion sickness;
BRCA	cis	rs7394190	0.748	rs2306325	chr10:75506674	T/C	cg07699608	chr10:75541558	CHCHD1	0.6	8.87	0.33	7.03e-18	Incident atrial fibrillation;
BRCA	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg13852791	chr20:30311386	BCL2L1	0.84	17.93	0.58	1.62e-58	Mean corpuscular hemoglobin;
BRCA	cis	rs11229555	0.645	rs11229460	chr11:58208343	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07636037	chr3:49044803	WDR6	-0.73	-15.84	-0.53	6.49e-48	Menarche (age at onset);
BRCA	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.23e-24	Motion sickness;
BRCA	cis	rs7586879	1.000	rs1865687	chr2:25112885	G/A	cg04586622	chr2:25135609	ADCY3	0.4	9.39	0.35	1.07e-19	Body mass index;
BRCA	cis	rs775227	0.574	rs34286076	chr3:113269695	G/C	cg18753928	chr3:113234510	CCDC52	-0.57	-9.32	-0.35	1.79e-19	Dental caries;
BRCA	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.6	-12.71	-0.45	3.81e-33	Lymphocyte counts;
BRCA	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg20203395	chr5:56204925	C5orf35	0.64	12.56	0.45	1.65e-32	Initial pursuit acceleration;
BRCA	trans	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg25214090	chr10:38739885	LOC399744	0.52	10.95	0.4	1.08e-25	Corneal astigmatism;
BRCA	trans	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.74	-14.81	-0.51	7.31e-43	Platelet distribution width;
BRCA	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg08000102	chr2:233561755	GIGYF2	-0.59	-12.6	-0.45	1.13e-32	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg13047869	chr3:10149882	C3orf24	0.48	10.4	0.38	1.59e-23	Alzheimer's disease;
BRCA	trans	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg25214090	chr10:38739885	LOC399744	0.48	11.01	0.4	6.44e-26	Corneal astigmatism;
BRCA	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg01528321	chr10:82214614	TSPAN14	0.69	14.59	0.5	7.96e-42	Post bronchodilator FEV1;
BRCA	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg09555818	chr19:45449301	APOC2	0.47	12.52	0.44	2.6e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18404041	chr3:52824283	ITIH1	-0.37	-11.41	-0.41	1.39e-27	Bipolar disorder;
BRCA	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.45	10.34	0.38	2.9e-23	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6785206	0.803	rs2712380	chr3:128338661	A/C	cg16766828	chr3:128327626	NA	-0.8	-11.66	-0.42	1.34e-28	Lymphocyte percentage of white cells;
BRCA	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg04450456	chr4:17643702	FAM184B	-0.35	-9.62	-0.36	1.5e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.55	0.55	1.84e-51	Alzheimer's disease (late onset);
BRCA	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg24642439	chr20:33292090	TP53INP2	0.73	17.05	0.56	4.99e-54	Coronary artery disease;
BRCA	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg09307838	chr4:120376055	NA	0.69	14.02	0.49	3.82e-39	Corneal astigmatism;
BRCA	cis	rs17818399	0.708	rs13000706	chr2:46838247	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.43	8.81	0.33	1.18e-17	Height;
BRCA	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg22974920	chr21:40686053	BRWD1	-0.41	-9.0	-0.34	2.65e-18	Cognitive function;
BRCA	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	16.14	0.54	2.01e-49	Metabolite levels (small molecules and protein measures);
BRCA	cis	rs3772130	0.962	rs17742508	chr3:121559895	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.75	0.39	6.71e-25	Cognitive performance;
BRCA	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg13010199	chr12:38710504	ALG10B	0.57	12.56	0.44	1.79e-32	Heart rate;
BRCA	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg12927641	chr6:109611667	NA	-0.42	-10.89	-0.4	1.88e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-15.14	-0.51	1.71e-44	Bipolar disorder and schizophrenia;
BRCA	cis	rs701145	0.938	rs813141	chr3:154066521	T/C	cg17054900	chr3:154042577	DHX36	0.66	11.41	0.41	1.46e-27	Coronary artery disease;
BRCA	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg26384229	chr12:38710491	ALG10B	0.43	9.61	0.36	1.69e-20	Morning vs. evening chronotype;
BRCA	cis	rs9462027	0.628	rs7739771	chr6:34779801	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.84	-0.3	1.96e-14	Systemic lupus erythematosus;
BRCA	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg24920358	chr1:40204285	PPIE	0.33	7.81	0.3	2.3e-14	Blood protein levels;
BRCA	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg22920501	chr2:26401640	FAM59B	0.64	11.46	0.41	8.99e-28	Gut microbiome composition (summer);
BRCA	cis	rs6684514	1.000	rs59468948	chr1:156288058	A/T	cg16558208	chr1:156270281	VHLL	0.36	8.28	0.31	6.96e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs7560272	0.512	rs4530394	chr2:73929650	T/C	cg20560298	chr2:73613845	ALMS1	0.34	8.86	0.33	7.81e-18	Schizophrenia;
BRCA	trans	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg23762105	chr12:34175262	ALG10	0.35	7.87	0.3	1.51e-14	Morning vs. evening chronotype;
BRCA	cis	rs7072216	0.770	rs1737	chr10:100176366	T/C	cg26618903	chr10:100175079	PYROXD2	-0.27	-8.17	-0.31	1.66e-15	Metabolite levels;
BRCA	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg04317338	chr11:64019027	PLCB3	0.52	7.9	0.3	1.19e-14	Mean platelet volume;
BRCA	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.77	0.36	4.3e-21	Bipolar disorder;
BRCA	cis	rs6450176	0.909	rs6884760	chr5:53293077	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.59	-13.85	-0.48	2.33e-38	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg20908204	chr19:46285434	DMPK	-0.29	-8.56	-0.32	8.25e-17	Coronary artery disease;
BRCA	cis	rs11051970	0.879	rs2171373	chr12:32575777	C/T	cg24626660	chr12:32551988	NA	0.29	8.16	0.31	1.75e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs9287719	0.649	rs10184776	chr2:10726446	C/T	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	4.95e-19	Prostate cancer;
BRCA	cis	rs9649465	0.967	rs1005567	chr7:123305836	A/T	cg04330084	chr7:123175371	IQUB	0.3	8.38	0.31	3.32e-16	Migraine;
BRCA	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg13319975	chr6:146136371	FBXO30	-0.34	-7.95	-0.3	8.48e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg06713675	chr4:122721982	EXOSC9	-0.53	-12.57	-0.45	1.56e-32	Type 2 diabetes;
BRCA	cis	rs4363385	0.747	rs4319267	chr1:152972699	T/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.02	-0.34	2.12e-18	Inflammatory skin disease;
BRCA	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg12573674	chr2:1569213	NA	-0.64	-14.48	-0.5	2.8e-41	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs11955398	0.563	rs4700385	chr5:60032599	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.41	-9.5	-0.35	4.27e-20	Intelligence (multi-trait analysis);
BRCA	trans	rs8002861	0.967	rs7321596	chr13:44472255	G/A	cg17145862	chr1:211918768	LPGAT1	0.7	18.22	0.58	4.67e-60	Leprosy;
BRCA	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg22535103	chr8:58192502	C8orf71	-0.5	-8.86	-0.33	7.85e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9815354	0.761	rs73083329	chr3:41927151	C/T	cg03022575	chr3:42003672	ULK4	0.69	9.49	0.35	4.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs9309473	1.000	rs10190219	chr2:73658331	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-11.41	-0.41	1.38e-27	Metabolite levels;
BRCA	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg23625390	chr15:77176239	SCAPER	-0.53	-11.33	-0.41	3.14e-27	Blood metabolite levels;
BRCA	cis	rs6005807	0.719	rs134547	chr22:28801009	A/G	cg12565055	chr22:29076175	TTC28	0.46	9.03	0.34	2.03e-18	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-9.49	-0.35	4.48e-20	Menopause (age at onset);
BRCA	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg01528321	chr10:82214614	TSPAN14	0.74	16.88	0.56	4.06e-53	Post bronchodilator FEV1;
BRCA	cis	rs600806	0.778	rs4970731	chr1:109995459	T/C	cg20591472	chr1:110008990	SYPL2	0.31	7.86	0.3	1.69e-14	Intelligence (multi-trait analysis);
BRCA	trans	rs1941687	0.509	rs7238029	chr18:31317755	A/G	cg27147174	chr7:100797783	AP1S1	-0.48	-9.13	-0.34	8.55e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg19077165	chr18:44547161	KATNAL2	0.41	8.73	0.33	2.14e-17	Educational attainment;
BRCA	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-8.53	-0.32	1.06e-16	Chronic sinus infection;
BRCA	cis	rs7149337	0.805	rs7146561	chr14:51608889	C/G	cg23942311	chr14:51606299	NA	0.45	13.31	0.47	7.73e-36	Cancer;
BRCA	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00152838	chr16:24741724	TNRC6A	-0.35	-7.96	-0.3	7.96e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1185460	1.000	rs1185460	chr11:118943433	C/T	cg23280166	chr11:118938394	VPS11	-0.4	-9.52	-0.35	3.36e-20	Coronary artery disease;
BRCA	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.25	7.9	0.3	1.26e-14	Parkinson's disease;
BRCA	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.5	-0.38	6.61e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg25767906	chr1:53392781	SCP2	0.34	7.88	0.3	1.42e-14	Monocyte count;
BRCA	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.28	-0.34	2.52e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1011018	0.628	rs7793114	chr7:139450785	A/G	cg03224163	chr7:139420300	HIPK2	-0.52	-8.04	-0.3	4.25e-15	Systolic blood pressure;
BRCA	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15506890	chr2:3487001	NA	-0.58	-13.14	-0.46	4.26e-35	Neurofibrillary tangles;
BRCA	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00166722	chr3:10149974	C3orf24	0.56	11.16	0.4	1.5e-26	Alzheimer's disease;
BRCA	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg24130564	chr14:104152367	KLC1	-0.39	-8.93	-0.33	4.67e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs4880487	0.888	rs35341304	chr10:1252526	T/C	cg03183215	chr10:1252341	ADARB2	-0.37	-8.4	-0.32	2.82e-16	Migraine;
BRCA	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-16.3	-0.54	3.4e-50	Monocyte count;
BRCA	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg20283391	chr11:68216788	NA	-0.45	-9.32	-0.35	1.81e-19	Total body bone mineral density;
BRCA	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg11764359	chr7:65958608	NA	0.65	11.9	0.43	1.21e-29	Aortic root size;
BRCA	cis	rs2625529	0.824	rs4777471	chr15:72207804	A/G	cg16672083	chr15:72433130	SENP8	-0.83	-17.22	-0.56	7.38e-55	Red blood cell count;
BRCA	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg15395560	chr15:45543142	SLC28A2	-0.29	-7.93	-0.3	1.01e-14	Uric acid levels;
BRCA	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg14289826	chr9:140003911	NA	-0.54	-15.06	-0.51	4.18e-44	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs12540874	0.500	rs12719030	chr7:50485073	T/C	cg18232548	chr7:50535776	DDC	-0.48	-12.14	-0.43	1.12e-30	Systemic sclerosis;
BRCA	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg01304814	chr3:48885189	PRKAR2A	0.77	7.9	0.3	1.18e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg17063962	chr7:91808500	NA	0.53	12.5	0.44	3.23e-32	Breast cancer;
BRCA	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg03354898	chr7:1950403	MAD1L1	-0.6	-14.43	-0.5	4.83e-41	Bipolar disorder and schizophrenia;
BRCA	cis	rs778371	0.624	rs6733495	chr2:233616709	A/G	cg08000102	chr2:233561755	GIGYF2	0.84	20.64	0.63	6.87e-73	Schizophrenia;
BRCA	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg16339924	chr4:17578868	LAP3	0.71	17.02	0.56	7.17e-54	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg07460842	chr6:66804631	NA	-1.02	-20.03	-0.62	1.26e-69	Exhaled nitric oxide output;
BRCA	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg14675211	chr2:100938903	LONRF2	0.45	9.77	0.36	4.13e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg18232548	chr7:50535776	DDC	0.43	9.68	0.36	8.73e-21	Malaria;
BRCA	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg04989706	chr14:50066350	PPIL5	-0.48	-9.2	-0.34	5.18e-19	Carotid intima media thickness;
BRCA	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.55	9.36	0.35	1.34e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	trans	rs6479891	1.000	rs61855465	chr10:64956607	A/T	cg14819942	chr15:35414228	NA	0.35	8.52	0.32	1.13e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg08807101	chr21:30365312	RNF160	0.62	13.57	0.47	4.6e-37	Selective IgA deficiency;
BRCA	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg07148914	chr20:33460835	GGT7	-0.43	-9.17	-0.34	6.56e-19	Height;
BRCA	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg16405210	chr4:1374714	KIAA1530	0.84	17.4	0.57	8.09e-56	Longevity;
BRCA	cis	rs7833986	1.000	rs72654002	chr8:57095939	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.46	8.27	0.31	8.08e-16	Height;
BRCA	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-12.13	-0.43	1.22e-30	Chronic sinus infection;
BRCA	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03352830	chr11:487213	PTDSS2	-0.8	-11.94	-0.43	8.59e-30	Body mass index;
BRCA	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg00677455	chr12:58241039	CTDSP2	0.63	14.19	0.49	6.18e-40	Multiple sclerosis;
BRCA	cis	rs7560272	0.501	rs11891140	chr2:73944084	A/G	cg20560298	chr2:73613845	ALMS1	0.33	8.45	0.32	1.96e-16	Schizophrenia;
BRCA	cis	rs2839627	0.598	rs2246573	chr21:44253016	C/T	cg03543861	chr21:44258195	NA	-0.42	-8.68	-0.32	3.28e-17	Information processing speed;
BRCA	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.54	-0.35	2.91e-20	Hip circumference adjusted for BMI;
BRCA	cis	rs4853036	0.723	rs3732268	chr2:70046262	G/A	cg02498382	chr2:70120550	SNRNP27	-0.53	-8.56	-0.32	8.42e-17	Colorectal or endometrial cancer;
BRCA	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg03433033	chr1:76189801	ACADM	0.74	19.0	0.6	4e-64	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg25042112	chr7:64838748	ZNF92	-0.44	-8.04	-0.3	4.31e-15	Pain;
BRCA	cis	rs3761847	0.651	rs1323472	chr9:123826335	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	8.38	0.31	3.28e-16	Rheumatoid arthritis;
BRCA	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg22920501	chr2:26401640	FAM59B	0.72	13.34	0.47	5.7e-36	Gut microbiome composition (summer);
BRCA	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.16e-47	Alzheimer's disease (late onset);
BRCA	cis	rs897984	0.568	rs4889653	chr16:30895713	C/T	cg02466173	chr16:30829666	NA	0.43	8.66	0.32	3.83e-17	Dementia with Lewy bodies;
BRCA	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg21782813	chr7:2030301	MAD1L1	0.33	8.79	0.33	1.34e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.47	-0.32	1.73e-16	Total body bone mineral density;
BRCA	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.63	-0.61	1.65e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg00277334	chr10:82204260	NA	-0.47	-7.95	-0.3	8.74e-15	Post bronchodilator FEV1;
BRCA	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23583168	chr7:148888333	NA	-0.82	-19.5	-0.61	8.67e-67	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2279817	0.735	rs11580813	chr1:17981913	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.5	11.81	0.42	3.05e-29	Neuroticism;
BRCA	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg20701182	chr2:24300061	SF3B14	0.58	9.06	0.34	1.57e-18	Lymphocyte counts;
BRCA	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	25.51	0.71	1.6e-99	Chronic sinus infection;
BRCA	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg21535247	chr6:8435926	SLC35B3	0.4	8.98	0.33	3.04e-18	Motion sickness;
BRCA	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	29.81	0.76	4.96e-123	Chronic sinus infection;
BRCA	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.64	-13.63	-0.47	2.59e-37	Lung cancer;
BRCA	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-13.09	-0.46	7.18e-35	Gut microbiome composition (summer);
BRCA	cis	rs1997103	0.954	rs1917769	chr7:55392325	T/A	cg17469321	chr7:55412551	NA	0.52	9.82	0.36	2.79e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.81	-0.3	2.36e-14	Aortic root size;
BRCA	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg23708337	chr7:1209742	NA	0.6	8.31	0.31	5.89e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg27170947	chr2:26402098	FAM59B	0.97	16.91	0.56	2.72e-53	Gut microbiome composition (summer);
BRCA	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg24692254	chr21:30365293	RNF160	-0.64	-16.28	-0.54	4.16e-50	Dental caries;
BRCA	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.08e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11031096	0.727	rs2268168	chr11:4142069	C/T	cg18678763	chr11:4115507	RRM1	-0.37	-8.22	-0.31	1.18e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs6005807	0.719	rs9625520	chr22:29037864	C/A	cg12565055	chr22:29076175	TTC28	0.49	9.23	0.34	3.82e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs312273	0.806	rs55638600	chr12:41338491	G/A	cg17827154	chr12:41323612	CNTN1	-0.43	-11.13	-0.4	1.97e-26	Bipolar disorder;
BRCA	cis	rs7633857	0.536	rs2889391	chr3:160696186	A/G	cg03342759	chr3:160939853	NMD3	-0.49	-10.01	-0.37	5.33e-22	Educational attainment (years of education);
BRCA	cis	rs919433	0.963	rs12617117	chr2:198155170	T/A	cg10820045	chr2:198174542	NA	-0.39	-7.97	-0.3	7.24e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.54	10.92	0.4	1.45e-25	Monocyte percentage of white cells;
BRCA	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg11833968	chr6:79620685	NA	0.42	9.27	0.34	2.74e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg23978390	chr7:1156363	C7orf50	0.43	9.81	0.36	3.02e-21	Bronchopulmonary dysplasia;
BRCA	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg03474202	chr17:45855739	NA	-0.47	-12.78	-0.45	1.78e-33	IgG glycosylation;
BRCA	cis	rs4594175	0.926	rs10135534	chr14:51617970	C/A	cg23942311	chr14:51606299	NA	0.33	8.41	0.32	2.69e-16	Cancer;
BRCA	cis	rs1505368	0.781	rs4673664	chr2:213277649	T/C	cg20637307	chr2:213403960	ERBB4	0.38	9.26	0.34	3.08e-19	Symmetrical dimethylarginine levels;
BRCA	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.59	-9.49	-0.35	4.56e-20	Body mass index (adult);
BRCA	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18876405	chr7:65276391	NA	0.53	12.16	0.43	9.33e-31	Aortic root size;
BRCA	cis	rs2294693	0.947	rs736795	chr6:40998141	G/A	cg14418226	chr6:40996092	UNC5CL	0.46	8.36	0.31	3.78e-16	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11764359	chr7:65958608	NA	-0.62	-13.48	-0.47	1.19e-36	Aortic root size;
BRCA	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg21605333	chr4:119757512	SEC24D	-1.26	-13.57	-0.47	4.91e-37	Cannabis dependence symptom count;
BRCA	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08045932	chr20:61659980	NA	0.5	11.43	0.41	1.2100000000000001e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6598955	0.543	rs112752634	chr1:26534217	G/A	cg04990556	chr1:26633338	UBXN11	0.7	11.69	0.42	9.64e-29	Obesity-related traits;
BRCA	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg12751644	chr20:60527061	NA	0.36	7.96	0.3	7.63e-15	Obesity-related traits;
BRCA	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.49	0.38	7.33e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg05340658	chr4:99064831	C4orf37	0.62	14.78	0.5	9.83e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.51	-10.11	-0.37	2.19e-22	Body mass index;
BRCA	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.42	-8.27	-0.31	8.04e-16	Longevity;Endometriosis;
BRCA	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg06108461	chr20:60628389	TAF4	-0.79	-16.99	-0.56	1.13e-53	Body mass index;
BRCA	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg18230493	chr5:56204884	C5orf35	-0.74	-14.72	-0.5	1.98e-42	Initial pursuit acceleration;
BRCA	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg13256891	chr4:100009986	ADH5	0.55	10.15	0.37	1.58e-22	Smoking initiation;
BRCA	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg01819863	chr10:32635814	EPC1	1.16	20.46	0.63	6.39e-72	Sexual dysfunction (female);
BRCA	cis	rs701145	0.585	rs1609205	chr3:153793923	G/A	cg17054900	chr3:154042577	DHX36	0.54	9.14	0.34	8.17e-19	Coronary artery disease;
BRCA	cis	rs4908768	0.501	rs2016084	chr1:8613418	C/A	cg20416874	chr1:8611966	RERE	-0.28	-8.17	-0.31	1.7e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg23711669	chr6:146136114	FBXO30	0.72	16.15	0.54	1.91e-49	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg25214090	chr10:38739885	LOC399744	0.45	10.38	0.38	2.04e-23	Corneal astigmatism;
BRCA	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg24110177	chr3:50126178	RBM5	-0.46	-11.53	-0.42	4.37e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg07395648	chr5:131743802	NA	0.38	8.64	0.32	4.45e-17	Breast cancer;Mosquito bite size;
BRCA	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg23711669	chr6:146136114	FBXO30	-0.77	-18.38	-0.59	6.56e-61	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg04944784	chr2:26401820	FAM59B	0.95	16.17	0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg11266682	chr4:10021025	SLC2A9	0.41	10.86	0.39	2.57e-25	Bone mineral density;
BRCA	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	12.69	0.45	4.38e-33	Bone mineral density;
BRCA	trans	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg01620082	chr3:125678407	NA	0.87	10.82	0.39	3.45e-25	Depression;
BRCA	cis	rs4845875	0.600	rs10779765	chr1:11838011	T/C	cg24844545	chr1:11908347	NPPA	0.37	8.68	0.32	3.35e-17	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.54	-0.35	2.86e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08704250	chr15:31115839	NA	-0.35	-8.82	-0.33	1.09e-17	Huntington's disease progression;
BRCA	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg20607287	chr7:12443886	VWDE	-0.54	-8.28	-0.31	7.46e-16	Coronary artery disease;
BRCA	cis	rs1451375	0.583	rs3807555	chr7:50610569	A/G	cg18232548	chr7:50535776	DDC	0.42	9.0	0.34	2.63e-18	Malaria;
BRCA	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg02297831	chr4:17616191	MED28	0.36	8.38	0.31	3.31e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.48	-0.41	7.3e-28	Personality dimensions;
BRCA	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg14092571	chr14:90743983	NA	-0.34	-8.12	-0.31	2.36e-15	Mortality in heart failure;
BRCA	cis	rs6782228	0.606	rs2001703	chr3:128383097	A/G	cg16766828	chr3:128327626	NA	-0.44	-9.8	-0.36	3.11e-21	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg14675211	chr2:100938903	LONRF2	0.53	12.03	0.43	3.34e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.818	rs2152994	chr1:152991060	C/T	cg25856811	chr1:152973957	SPRR3	0.3	8.27	0.31	7.58e-16	Inflammatory skin disease;
BRCA	cis	rs6435161	0.919	rs2162495	chr2:203578008	A/G	cg18429434	chr2:203499731	FAM117B	-0.45	-8.87	-0.33	7e-18	Total cholesterol levels;
BRCA	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24110177	chr3:50126178	RBM5	0.36	9.75	0.36	4.79e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg11645453	chr3:52864694	ITIH4	-0.43	-10.9	-0.4	1.78e-25	Schizophrenia;
BRCA	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-7.96	-0.3	8.15e-15	Total body bone mineral density;
BRCA	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg06623918	chr6:96969491	KIAA0776	0.9	25.45	0.71	3.19e-99	Headache;
BRCA	cis	rs6754311	0.861	rs12475139	chr2:136786651	A/T	cg07169764	chr2:136633963	MCM6	0.65	13.43	0.47	2.02e-36	Mosquito bite size;
BRCA	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.56	-0.32	8.25e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-13.52	-0.47	8.51e-37	Hemoglobin concentration;
BRCA	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg21770322	chr7:97807741	LMTK2	0.41	10.8	0.39	4.32e-25	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.51	-0.35	3.7e-20	Bladder cancer;
BRCA	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg16339924	chr4:17578868	LAP3	0.57	14.01	0.48	4.42e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg24069376	chr3:38537580	EXOG	-0.42	-12.05	-0.43	2.72e-30	Electrocardiographic conduction measures;
BRCA	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02187348	chr16:89574699	SPG7	0.5	11.98	0.43	5.78e-30	Multiple myeloma (IgH translocation);
BRCA	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg22920501	chr2:26401640	FAM59B	0.91	16.27	0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11890956	chr21:40555474	PSMG1	1.05	29.89	0.76	1.68e-123	Cognitive function;
BRCA	trans	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	8.92e-15	Corneal astigmatism;
BRCA	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.89	0.33	6.17e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9381107	0.932	rs10484246	chr6:9451197	T/A	cg14735645	chr6:9486422	NA	-0.45	-7.92	-0.3	1.09e-14	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg16414030	chr3:133502952	NA	-0.42	-9.13	-0.34	8.66e-19	Iron status biomarkers;
BRCA	cis	rs12474201	0.928	rs34186074	chr2:46965010	T/C	cg06386533	chr2:46925753	SOCS5	0.9	19.94	0.62	3.63e-69	Height;
BRCA	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg04362960	chr10:104952993	NT5C2	0.43	9.77	0.36	4.15e-21	Arsenic metabolism;
BRCA	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg13385794	chr1:248469461	NA	0.27	7.85	0.3	1.75e-14	Common traits (Other);
BRCA	cis	rs4938330	0.629	rs12269901	chr11:116973929	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.41	-7.89	-0.3	1.33e-14	Blood protein levels;
BRCA	cis	rs698833	0.892	rs1085483	chr2:44616047	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	10.25	0.38	6.05e-23	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg24562669	chr7:97807699	LMTK2	-0.45	-11.81	-0.42	2.92e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.06	-0.34	1.56e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg24642439	chr20:33292090	TP53INP2	-0.44	-8.82	-0.33	1.12e-17	Height;
BRCA	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg08888203	chr3:10149979	C3orf24	0.66	14.05	0.49	2.78e-39	Alzheimer's disease;
BRCA	cis	rs9462846	0.959	rs57514728	chr6:42860748	C/T	cg02353165	chr6:42928485	GNMT	0.49	8.64	0.32	4.47e-17	Blood protein levels;
BRCA	cis	rs586533	0.793	rs681361	chr11:99501905	A/G	cg22878054	chr11:99397252	CNTN5	0.32	8.11	0.31	2.53e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg24562669	chr7:97807699	LMTK2	0.46	12.19	0.43	6.71e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4363385	0.747	rs4240868	chr1:152981599	G/A	cg24667326	chr1:152973720	SPRR3	-0.35	-9.87	-0.36	1.81e-21	Inflammatory skin disease;
BRCA	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg03877680	chr5:178157825	ZNF354A	0.79	14.65	0.5	4.19e-42	Neutrophil percentage of white cells;
BRCA	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg15485101	chr11:133734466	NA	-0.37	-9.4	-0.35	9.25e-20	Childhood ear infection;
BRCA	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.16	0.31	1.81e-15	Tonsillectomy;
BRCA	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-10.82	-0.39	3.73e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg12432903	chr7:1882776	MAD1L1	0.44	8.02	0.3	5.17e-15	Bipolar disorder;
BRCA	cis	rs734999	0.967	rs10797434	chr1:2511280	C/T	cg20673091	chr1:2541236	MMEL1	0.33	8.53	0.32	1.08e-16	Ulcerative colitis;
BRCA	cis	rs36051895	0.695	rs60221565	chr9:5029077	T/G	cg02405213	chr9:5042618	JAK2	-0.51	-9.12	-0.34	9.7e-19	Pediatric autoimmune diseases;
BRCA	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg17847044	chr15:42102381	MAPKBP1	0.51	19.84	0.62	1.21e-68	Diastolic blood pressure;
BRCA	cis	rs30380	0.632	rs149189	chr5:96137804	A/G	cg16492584	chr5:96139282	ERAP1	-0.47	-11.09	-0.4	2.87e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs752010	0.756	rs6600380	chr1:42054814	C/T	cg06885757	chr1:42089581	HIVEP3	-0.22	-8.04	-0.3	4.42e-15	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.91	-0.33	5.1e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7927771	0.524	rs7943464	chr11:47886639	T/A	cg20307385	chr11:47447363	PSMC3	0.42	9.47	0.35	5.32e-20	Subjective well-being;
BRCA	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg04362960	chr10:104952993	NT5C2	0.43	9.75	0.36	4.83e-21	Arsenic metabolism;
BRCA	cis	rs858239	0.601	rs6948469	chr7:23174766	G/T	cg23682824	chr7:23144976	KLHL7	0.42	10.98	0.4	8.11e-26	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs853679	0.599	rs149990	chr6:27998258	G/A	cg01620082	chr3:125678407	NA	-0.53	-8.02	-0.3	5e-15	Depression;
BRCA	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.5	-9.71	-0.36	7.11e-21	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg26384229	chr12:38710491	ALG10B	0.59	13.54	0.47	6.37e-37	Morning vs. evening chronotype;
BRCA	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg14343924	chr8:8086146	FLJ10661	-0.41	-8.53	-0.32	1.09e-16	Mood instability;
BRCA	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg03188948	chr7:1209495	NA	0.88	13.83	0.48	3.04e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg21659725	chr3:3221576	CRBN	-0.47	-8.41	-0.32	2.76e-16	Menarche (age at onset);
BRCA	cis	rs6435862	0.593	rs34732883	chr2:215674371	C/T	cg04530015	chr2:215796436	ABCA12	0.39	8.57	0.32	7.69e-17	Neuroblastoma (high-risk);
BRCA	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg04455712	chr21:45112962	RRP1B	0.45	11.58	0.42	2.67e-28	Mean corpuscular volume;
BRCA	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.64	-0.32	4.39e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4478858	0.684	rs4949202	chr1:31736800	T/C	cg00250761	chr1:31883323	NA	-0.31	-8.17	-0.31	1.63e-15	Alcohol dependence;
BRCA	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg14675211	chr2:100938903	LONRF2	0.52	11.82	0.42	2.63e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs243505	0.762	rs734004	chr7:148505460	C/G	cg09806900	chr7:148480153	CUL1	0.5	10.52	0.38	5.46e-24	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	9.25	0.34	3.19e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg22920501	chr2:26401640	FAM59B	-0.66	-11.44	-0.41	1.1e-27	Gut microbiome composition (summer);
BRCA	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.95	0.56	1.78e-53	Hypertriglyceridemia;
BRCA	trans	rs853679	0.546	rs36092177	chr6:28357807	C/T	cg01620082	chr3:125678407	NA	-0.97	-11.01	-0.4	6.21e-26	Depression;
BRCA	trans	rs9951602	0.512	rs4799244	chr18:76649763	T/C	cg02800362	chr5:177631904	HNRNPAB	0.77	18.04	0.58	4.16e-59	Obesity-related traits;
BRCA	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg11645453	chr3:52864694	ITIH4	0.42	9.99	0.37	6.14e-22	Bipolar disorder;
BRCA	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg12011299	chr4:100065546	ADH4	0.48	10.88	0.4	2.02e-25	Smoking initiation;
BRCA	trans	rs6479891	1.000	rs11818194	chr10:65180452	G/A	cg14819942	chr15:35414228	NA	0.35	8.6	0.32	6.09e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg13385794	chr1:248469461	NA	0.28	8.02	0.3	5.16e-15	Common traits (Other);
BRCA	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg13010199	chr12:38710504	ALG10B	0.44	10.46	0.38	9.29e-24	Heart rate;
BRCA	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	14.3	0.49	1.97e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4588572	0.644	rs6873144	chr5:77741784	C/T	cg11547950	chr5:77652471	NA	-0.42	-8.04	-0.3	4.5e-15	Triglycerides;
BRCA	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg13271783	chr10:134563150	INPP5A	-0.49	-9.76	-0.36	4.4e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02018176	chr4:1364513	KIAA1530	0.39	8.18	0.31	1.57e-15	Longevity;
BRCA	cis	rs6558530	0.666	rs6558526	chr8:1702572	A/G	cg19131313	chr8:1704013	NA	-0.39	-7.97	-0.3	7.25e-15	Systolic blood pressure;
BRCA	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg19077165	chr18:44547161	KATNAL2	0.57	12.84	0.45	1.02e-33	Personality dimensions;
BRCA	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg17420585	chr12:42539391	GXYLT1	-0.38	-8.01	-0.3	5.63e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg05347473	chr6:146136440	FBXO30	0.4	8.02	0.3	5.03e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg21573476	chr21:45109991	RRP1B	-0.36	-9.65	-0.36	1.21e-20	Mean corpuscular volume;
BRCA	cis	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.3	-0.31	6.42e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7851660	0.527	rs7870540	chr9:100573925	T/C	cg13688889	chr9:100608707	NA	-0.51	-11.54	-0.42	4.24e-28	Strep throat;
BRCA	cis	rs7631605	0.905	rs11129752	chr3:37257793	A/G	cg15934958	chr3:37212084	LRRFIP2	-0.5	-10.52	-0.38	5.7e-24	Cerebrospinal P-tau181p levels;
BRCA	cis	rs72772090	0.539	rs11750934	chr5:96118487	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.18	-0.43	7.64e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs5771242	0.769	rs4838865	chr22:50664612	A/G	cg16473166	chr22:50639996	SELO	0.64	10.95	0.4	1.1e-25	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
BRCA	cis	rs113835537	0.529	rs7950407	chr11:66258006	A/G	cg24851651	chr11:66362959	CCS	0.43	8.24	0.31	9.91e-16	Airway imaging phenotypes;
BRCA	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21659725	chr3:3221576	CRBN	-0.35	-8.41	-0.32	2.69e-16	Body mass index;
BRCA	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-12.87	-0.45	7.5e-34	Mood instability;
BRCA	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	14.09	0.49	1.8e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg08601574	chr20:25228251	PYGB	-0.35	-8.57	-0.32	7.91e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9837602	1.000	rs6802422	chr3:99778655	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-11.0	-0.4	6.8e-26	Breast cancer;
BRCA	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg17135325	chr3:160939158	NMD3	0.39	7.82	0.3	2.14e-14	Parkinson's disease;
BRCA	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.56	10.07	0.37	3.2e-22	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.58	10.28	0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg04362960	chr10:104952993	NT5C2	0.43	10.36	0.38	2.42e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	trans	rs3857536	0.740	rs7751095	chr6:66891318	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-9.49	-0.35	4.6e-20	Blood trace element (Cu levels);
BRCA	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03264133	chr6:25882463	NA	0.49	10.93	0.4	1.34e-25	Blood metabolite levels;
BRCA	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg18131467	chr2:239335373	ASB1	0.93	32.86	0.79	2.09e-139	Multiple system atrophy;
BRCA	cis	rs78707713	0.560	rs17569412	chr10:71237536	C/A	cg12610070	chr10:71211762	TSPAN15	-0.33	-10.03	-0.37	4.25e-22	Venous thromboembolism;
BRCA	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg17971929	chr21:40555470	PSMG1	0.79	18.41	0.59	4.77e-61	Cognitive function;
BRCA	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg08601574	chr20:25228251	PYGB	0.35	8.49	0.32	1.48e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg25173405	chr17:45401733	C17orf57	-0.51	-10.73	-0.39	8.42e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs490234	0.932	rs474489	chr9:128317881	C/G	cg14078157	chr9:128172775	NA	0.38	9.13	0.34	8.65e-19	Mean arterial pressure;
BRCA	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg03213289	chr20:61660250	NA	0.63	16.54	0.55	2.05e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6750047	0.585	rs336033	chr2:38263808	A/G	cg07380506	chr2:38303506	CYP1B1	-0.47	-10.12	-0.37	2e-22	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg06784218	chr1:46089804	CCDC17	0.51	12.22	0.44	5.44e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7903847	0.642	rs11189192	chr10:99149403	G/A	cg20016023	chr10:99160130	RRP12	-0.26	-8.55	-0.32	9.13e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18876405	chr7:65276391	NA	0.51	11.2	0.4	1.08e-26	Aortic root size;
BRCA	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08045932	chr20:61659980	NA	-0.49	-10.71	-0.39	9.72e-25	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg01420254	chr6:26195488	NA	0.58	9.03	0.34	2.08e-18	Gout;Renal underexcretion gout;
BRCA	cis	rs28374715	0.662	rs28587487	chr15:41495460	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.87	-18.15	-0.58	1.07e-59	Ulcerative colitis;
BRCA	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg00666640	chr1:248458726	OR2T12	0.3	8.39	0.32	3.12e-16	Common traits (Other);
BRCA	trans	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg23762105	chr12:34175262	ALG10	0.35	7.86	0.3	1.66e-14	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs208520	1.000	rs208535	chr6:66962286	G/A	cg07460842	chr6:66804631	NA	-0.86	-14.32	-0.49	1.47e-40	Exhaled nitric oxide output;
BRCA	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg12481786	chr1:38455876	SF3A3	-0.36	-8.53	-0.32	1.1e-16	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg05340658	chr4:99064831	C4orf37	0.65	16.04	0.54	6.49e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg04944784	chr2:26401820	FAM59B	0.68	11.43	0.41	1.2100000000000001e-27	Gut microbiome composition (summer);
BRCA	cis	rs116979167	0.514	rs1706915	chr7:105196437	A/G	cg19920283	chr7:105172520	RINT1	0.44	8.95	0.33	3.92e-18	Bipolar disorder (body mass index interaction);
BRCA	cis	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg09307838	chr4:120376055	NA	0.6	11.44	0.41	1.08e-27	Corneal astigmatism;
BRCA	cis	rs7172677	0.737	rs7169545	chr15:75436123	A/G	cg10253484	chr15:75165896	SCAMP2	-0.45	-8.34	-0.31	4.42e-16	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	10.97	0.4	9.14e-26	Rheumatoid arthritis;
BRCA	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg23533926	chr12:111358616	MYL2	-0.42	-8.86	-0.33	7.72e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg03676636	chr4:99064102	C4orf37	0.2	7.81	0.3	2.43e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs939658	0.805	rs11631590	chr15:79446199	C/T	cg17916960	chr15:79447300	NA	-0.47	-12.17	-0.43	8.61e-31	Refractive error;
BRCA	cis	rs2014572	1.000	rs3746231	chr19:57760057	G/A	cg24459738	chr19:57751996	ZNF805	-0.36	-8.37	-0.31	3.76e-16	Hyperactive-impulsive symptoms;
BRCA	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-11.51	-0.41	5.7e-28	Electroencephalogram traits;
BRCA	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg04450456	chr4:17643702	FAM184B	0.38	11.29	0.41	4.51e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg11742103	chr11:62369870	EML3;MTA2	0.48	12.68	0.45	5.16e-33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg22907277	chr7:1156413	C7orf50	0.6	9.01	0.34	2.28e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	21.71	0.65	9.89e-79	Platelet count;
BRCA	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-13.88	-0.48	1.82e-38	Morning vs. evening chronotype;
BRCA	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	3.94e-15	Alzheimer's disease (late onset);
BRCA	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.49	0.38	7.33e-24	Bladder cancer;
BRCA	cis	rs6545883	0.931	rs778765	chr2:61786385	A/T	cg15711740	chr2:61764176	XPO1	-0.55	-13.92	-0.48	1.12e-38	Tuberculosis;
BRCA	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg08999081	chr20:33150536	PIGU	0.38	9.8	0.36	3.22e-21	Coronary artery disease;
BRCA	cis	rs4363385	0.747	rs1611760	chr1:152957573	T/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.29	-0.34	2.43e-19	Inflammatory skin disease;
BRCA	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg19678392	chr7:94953810	PON1	-0.42	-9.11	-0.34	1.03e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg04565464	chr8:145669602	NFKBIL2	0.37	8.72	0.33	2.43e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg08807101	chr21:30365312	RNF160	-0.57	-13.92	-0.48	1.12e-38	Dental caries;
BRCA	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg15145296	chr3:125709740	NA	-0.52	-8.91	-0.33	5.31e-18	Blood pressure (smoking interaction);
BRCA	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-8.23	-0.31	1.05e-15	Total body bone mineral density;
BRCA	cis	rs17818399	0.749	rs4142759	chr2:46783890	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.58	10.9	0.4	1.69e-25	Height;
BRCA	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg11266682	chr4:10021025	SLC2A9	0.42	11.1	0.4	2.56e-26	Bone mineral density;
BRCA	cis	rs6723226	0.766	rs398290	chr2:32503526	T/C	cg02381751	chr2:32503542	YIPF4	0.73	16.16	0.54	1.74e-49	Intelligence (multi-trait analysis);
BRCA	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg20503657	chr10:835505	NA	1.01	15.58	0.52	1.25e-46	Eosinophil percentage of granulocytes;
BRCA	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg14530993	chr4:882597	GAK	0.61	9.95	0.37	8.58e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg17691542	chr6:26056736	HIST1H1C	0.41	8.4	0.32	2.99e-16	Iron status biomarkers;
BRCA	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg01689657	chr7:91764605	CYP51A1	0.23	8.15	0.31	1.97e-15	Breast cancer;
BRCA	cis	rs939658	0.776	rs4778925	chr15:79443791	C/T	cg17916960	chr15:79447300	NA	-0.45	-11.09	-0.4	2.94e-26	Refractive error;
BRCA	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg03146154	chr1:46216737	IPP	0.52	11.59	0.42	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4363385	0.818	rs382653	chr1:153006761	G/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.57	-0.32	7.61e-17	Inflammatory skin disease;
BRCA	cis	rs243505	0.898	rs243543	chr7:148402984	C/G	cg09806900	chr7:148480153	CUL1	-0.39	-8.09	-0.3	3.11e-15	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.52	-0.38	5.69e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.43	9.18	0.34	5.8e-19	Ulcerative colitis;
BRCA	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.53	8.69	0.33	2.99e-17	Lung function (FEV1/FVC);
BRCA	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24110177	chr3:50126178	RBM5	-0.4	-10.95	-0.4	1.11e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11764359	chr7:65958608	NA	0.76	16.79	0.55	1.14e-52	Aortic root size;
BRCA	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg25036284	chr2:26402008	FAM59B	-0.77	-12.0	-0.43	4.62e-30	Gut microbiome composition (summer);
BRCA	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg08422745	chr4:174089978	GALNT7	0.69	14.29	0.49	2.24e-40	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-11.62	-0.42	1.97e-28	Homoarginine levels;
BRCA	cis	rs775227	0.574	rs66866534	chr3:113147315	T/C	cg18753928	chr3:113234510	CCDC52	-0.57	-9.55	-0.35	2.63e-20	Dental caries;
BRCA	trans	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.99	0.3	6.52e-15	Corneal astigmatism;
BRCA	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.91	-30.72	-0.77	6.03e-128	Schizophrenia;
BRCA	cis	rs6545883	0.965	rs2305156	chr2:61729268	T/C	cg15711740	chr2:61764176	XPO1	-0.55	-14.07	-0.49	2.38e-39	Tuberculosis;
BRCA	cis	rs10911363	0.592	rs2702178	chr1:183452545	G/A	cg09173681	chr1:183549694	NCF2	0.49	10.7	0.39	1.05e-24	Systemic lupus erythematosus;
BRCA	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg04727924	chr7:799746	HEATR2	-0.56	-11.14	-0.4	1.88e-26	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg08888203	chr3:10149979	C3orf24	0.66	14.05	0.49	2.73e-39	Alzheimer's disease;
BRCA	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg24296786	chr1:45957014	TESK2	-0.47	-10.86	-0.39	2.42e-25	Red blood cell count;Reticulocyte count;
BRCA	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.44	0.35	6.85e-20	Tonsillectomy;
BRCA	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg17366294	chr4:99064904	C4orf37	0.52	11.45	0.41	9.76e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4363385	0.679	rs6686286	chr1:152984562	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.65	-0.32	4.31e-17	Inflammatory skin disease;
BRCA	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg21782813	chr7:2030301	MAD1L1	0.33	8.96	0.33	3.68e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.6	-12.37	-0.44	1.18e-31	Lymphocyte counts;
BRCA	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	14.59	0.5	8.31e-42	Hip circumference adjusted for BMI;
BRCA	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg26769984	chr7:1090371	C7orf50	0.49	9.14	0.34	7.91e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs6987853	0.787	rs2923441	chr8:42429937	G/T	cg09913449	chr8:42400586	C8orf40	-0.38	-7.99	-0.3	6.18e-15	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg15556689	chr8:8085844	FLJ10661	-0.35	-8.54	-0.32	9.84e-17	Retinal vascular caliber;
BRCA	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg01304814	chr3:48885189	PRKAR2A	0.72	7.9	0.3	1.2e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs74181299	0.892	rs2249105	chr2:65287896	C/T	cg05010058	chr2:65284262	CEP68	-0.3	-8.58	-0.32	7.06e-17	Pulse pressure;
BRCA	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg13319975	chr6:146136371	FBXO30	-0.62	-14.54	-0.5	1.44e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg20469991	chr17:27169893	C17orf63	-0.45	-8.84	-0.33	9.22e-18	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs3761847	0.622	rs1323471	chr9:123826315	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	8.31	0.31	5.61e-16	Rheumatoid arthritis;
BRCA	cis	rs7011049	1.000	rs72643600	chr8:53854530	T/G	cg26025543	chr8:53854495	NA	0.55	9.49	0.35	4.66e-20	Systolic blood pressure;
BRCA	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg04691961	chr3:161091175	C3orf57	-0.56	-13.42	-0.47	2.31e-36	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.35	-8.87	-0.33	7.53e-18	Total body bone mineral density;
BRCA	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg14983838	chr19:29218262	NA	0.54	9.75	0.36	5.1e-21	Methadone dose in opioid dependence;
BRCA	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.05	21.83	0.65	2.38e-79	Gut microbiome composition (summer);
BRCA	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.35	7.99	0.3	6.36e-15	Alzheimer's disease (late onset);
BRCA	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg13256891	chr4:100009986	ADH5	-0.48	-9.17	-0.34	6.17e-19	Alcohol dependence;
BRCA	cis	rs4919087	1.000	rs10786330	chr10:99074959	C/A	cg25902810	chr10:99078978	FRAT1	0.52	11.25	0.41	6.57e-27	Monocyte count;
BRCA	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg22974920	chr21:40686053	BRWD1	-0.35	-7.89	-0.3	1.35e-14	Menarche (age at onset);
BRCA	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg20503657	chr10:835505	NA	1.03	18.17	0.58	9.16e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg24747557	chr10:131355152	MGMT	0.31	8.06	0.3	3.76e-15	Response to temozolomide;
BRCA	cis	rs1953600	0.837	rs2236556	chr10:81932790	T/C	cg04850286	chr10:81895943	PLAC9	0.32	8.98	0.33	2.93e-18	Sarcoidosis;
BRCA	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg21573476	chr21:45109991	RRP1B	-0.35	-8.89	-0.33	6.24e-18	Mean corpuscular volume;
BRCA	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg22920501	chr2:26401640	FAM59B	-0.85	-16.06	-0.54	5.38e-49	Gut microbiome composition (summer);
BRCA	trans	rs2018683	0.768	rs10282015	chr7:29022138	G/A	cg19402173	chr7:128379420	CALU	-0.47	-11.3	-0.41	4.07e-27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs9815354	0.812	rs59583650	chr3:41809063	A/G	cg03022575	chr3:42003672	ULK4	0.7	9.61	0.36	1.66e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg20891283	chr12:69753455	YEATS4	0.53	10.91	0.4	1.58e-25	Response to diuretic therapy;
BRCA	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	10.65	0.39	1.72e-24	Platelet count;
BRCA	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.01	-18.69	-0.59	1.63e-62	Gut microbiome composition (summer);
BRCA	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.5	-11.04	-0.4	4.74e-26	IgG glycosylation;
BRCA	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg25801113	chr15:45476975	SHF	0.31	7.83	0.3	2e-14	Uric acid levels;
BRCA	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg00750074	chr16:89608354	SPG7	-0.42	-11.24	-0.41	7.08e-27	Multiple myeloma (IgH translocation);
BRCA	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11644478	chr21:40555479	PSMG1	0.82	18.56	0.59	8.19e-62	Cognitive function;
BRCA	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg04705435	chr11:17411270	KCNJ11	0.44	9.44	0.35	6.91e-20	Type 2 diabetes;
BRCA	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg06115741	chr20:33292138	TP53INP2	-0.38	-8.51	-0.32	1.24e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg26343298	chr8:95960752	TP53INP1	0.3	8.77	0.33	1.57e-17	Type 2 diabetes;
BRCA	cis	rs910873	0.505	rs67260051	chr20:33448417	C/T	cg16810054	chr20:33298113	TP53INP2	0.47	10.3	0.38	3.91e-23	Melanoma;
BRCA	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg21782813	chr7:2030301	MAD1L1	0.43	12.34	0.44	1.53e-31	Bipolar disorder and schizophrenia;
BRCA	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg17830980	chr10:43048298	ZNF37B	0.54	13.26	0.46	1.25e-35	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs13046373	0.535	rs9977510	chr21:32027920	A/G	cg16431978	chr21:31797932	KRTAP13-3	0.35	8.64	0.32	4.4e-17	HDL cholesterol;
BRCA	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg11693508	chr17:37793320	STARD3	0.65	13.15	0.46	4.1e-35	Bipolar disorder;
BRCA	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	9.0	0.34	2.51e-18	Schizophrenia;
BRCA	cis	rs12618769	0.597	rs72821920	chr2:99111591	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	trans	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.61	-0.36	1.65e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6121246	0.512	rs45443696	chr20:30311396	A/C	cg13852791	chr20:30311386	BCL2L1	0.97	23.22	0.68	6.25e-87	Mean corpuscular hemoglobin;
BRCA	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08564027	chr20:61660810	NA	0.84	22.75	0.67	2.34e-84	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg21775007	chr8:11205619	TDH	-0.4	-8.74	-0.33	2.09e-17	Retinal vascular caliber;
BRCA	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg26850624	chr5:429559	AHRR	0.33	7.98	0.3	6.89e-15	Cystic fibrosis severity;
BRCA	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg05347473	chr6:146136440	FBXO30	-0.6	-11.51	-0.41	5.21e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4787491	0.704	rs66467443	chr16:30050494	G/A	cg06326092	chr16:30034487	C16orf92	0.35	8.91	0.33	5.18e-18	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	8.44	0.32	2.16e-16	Mean corpuscular volume;
BRCA	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.58	-14.11	-0.49	1.58e-39	Longevity;Endometriosis;
BRCA	cis	rs12472274	0.817	rs12621791	chr2:239104061	G/A	cg17459225	chr2:239074497	NA	0.63	12.88	0.45	6.5e-34	Phospholipid levels (plasma);
BRCA	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.66	-12.94	-0.46	3.67e-34	Ankle injury;
BRCA	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21659725	chr3:3221576	CRBN	0.46	9.49	0.35	4.62e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg04450456	chr4:17643702	FAM184B	0.42	12.53	0.44	2.37e-32	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3820928	0.874	rs10188770	chr2:227877037	G/A	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.09	-0.3	2.95e-15	Pulmonary function;
BRCA	cis	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg05901451	chr6:126070800	HEY2	0.4	9.69	0.36	8.1e-21	Endometrial cancer;
BRCA	trans	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-10.82	-0.39	3.59e-25	Type 2 diabetes;
BRCA	cis	rs7301826	0.580	rs12821464	chr12:131322719	T/G	cg11011512	chr12:131303247	STX2	-0.45	-11.0	-0.4	6.56e-26	Plasma plasminogen activator levels;
BRCA	cis	rs12367572	1.000	rs12822444	chr12:45276677	G/A	cg04608330	chr12:45269318	NELL2	-0.62	-13.76	-0.48	6.36e-38	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03452623	chr4:187889614	NA	-0.35	-11.44	-0.41	1.08e-27	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg22800045	chr5:56110881	MAP3K1	-0.5	-8.41	-0.32	2.59e-16	Initial pursuit acceleration;
BRCA	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg25358565	chr5:93447407	FAM172A	1.17	18.19	0.58	6.98e-60	Diabetic retinopathy;
BRCA	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg24558204	chr6:135376177	HBS1L	0.6	16.25	0.54	5.98e-50	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg26647111	chr11:31128758	NA	-0.44	-9.61	-0.36	1.63e-20	Red blood cell count;
BRCA	cis	rs1784581	0.706	rs9346895	chr6:162431168	T/C	cg17173639	chr6:162384350	PARK2	0.37	8.75	0.33	1.96e-17	Itch intensity from mosquito bite;
BRCA	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	17.32	0.57	2.22e-55	Alzheimer's disease;
BRCA	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg08917208	chr2:24149416	ATAD2B	0.91	13.42	0.47	2.48e-36	Lymphocyte counts;
BRCA	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21659725	chr3:3221576	CRBN	0.51	12.26	0.44	3.67e-31	Resting heart rate;
BRCA	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.95	0.33	3.76e-18	Tonsillectomy;
BRCA	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg07952391	chr2:88470173	THNSL2	-0.39	-7.95	-0.3	8.48e-15	Response to metformin (IC50);
BRCA	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg09754948	chr16:28834200	ATXN2L	0.46	8.45	0.32	2.02e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.4	8.76	0.33	1.73e-17	Aortic root size;
BRCA	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg24250549	chr1:154909240	PMVK	0.69	18.08	0.58	2.42e-59	Prostate cancer;
BRCA	cis	rs870825	0.616	rs7700216	chr4:185648510	G/T	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs72928364	0.929	rs13065684	chr3:100773738	T/C	cg10123952	chr3:100791384	NA	0.58	8.43	0.32	2.3e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg20503657	chr10:835505	NA	1.3	21.68	0.65	1.61e-78	Eosinophil percentage of granulocytes;
BRCA	cis	rs6546537	0.824	rs3771543	chr2:69784255	C/T	cg10773587	chr2:69614142	GFPT1	-0.42	-8.85	-0.33	8.42e-18	Serum thyroid-stimulating hormone levels;
BRCA	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.86	-0.3	1.61e-14	Electroencephalogram traits;
BRCA	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.17	-0.31	1.62e-15	Gut microbiome composition (summer);
BRCA	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg26384229	chr12:38710491	ALG10B	0.6	16.64	0.55	6.53e-52	Heart rate;
BRCA	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11644478	chr21:40555479	PSMG1	0.53	11.58	0.42	2.72e-28	Cognitive function;
BRCA	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg00677455	chr12:58241039	CTDSP2	0.63	15.48	0.52	4.01e-46	Multiple sclerosis;
BRCA	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg21475434	chr5:93447410	FAM172A	0.71	8.87	0.33	7.51e-18	Diabetic retinopathy;
BRCA	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-12.23	-0.44	4.83e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg26597838	chr10:835615	NA	1.03	15.79	0.53	1.13e-47	Eosinophil percentage of granulocytes;
BRCA	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg06640241	chr16:89574553	SPG7	0.6	13.17	0.46	3.18e-35	Multiple myeloma (IgH translocation);
BRCA	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg04362960	chr10:104952993	NT5C2	0.43	10.37	0.38	2.12e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02176678	chr2:219576539	TTLL4	0.45	11.62	0.42	1.97e-28	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.98	-0.3	6.75e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg21724239	chr8:58056113	NA	0.58	9.23	0.34	3.88e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs56399783	0.901	rs79932907	chr7:2827901	C/G	cg19731401	chr7:2775893	GNA12	0.51	8.33	0.31	4.77e-16	Childhood ear infection;
BRCA	cis	rs6973256	0.897	rs10236819	chr7:133345983	A/T	cg07491979	chr7:133331646	EXOC4	-0.39	-8.95	-0.33	3.96e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg03188948	chr7:1209495	NA	0.82	11.41	0.41	1.43e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.62	-0.32	5.36e-17	Total body bone mineral density;
BRCA	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg23978390	chr7:1156363	C7orf50	0.49	10.3	0.38	4.14e-23	Bronchopulmonary dysplasia;
BRCA	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg23029597	chr12:123009494	RSRC2	-0.59	-12.41	-0.44	8.01e-32	Body mass index;
BRCA	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	19.95	0.62	3.51e-69	Platelet count;
BRCA	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21659725	chr3:3221576	CRBN	0.46	11.51	0.41	5.58e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg03213289	chr20:61660250	NA	0.62	16.31	0.54	3.07e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg05623727	chr3:50126028	RBM5	-0.41	-9.9	-0.36	1.3e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.32	-0.38	3.3e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7715806	0.500	rs17563974	chr5:75004175	G/A	cg19683494	chr5:74908142	NA	0.53	8.64	0.32	4.46e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6684428	0.706	rs11206677	chr1:56335237	C/A	cg11651538	chr1:56320950	NA	-0.49	-8.41	-0.32	2.66e-16	Airflow obstruction;
BRCA	cis	rs2652834	0.808	rs4775614	chr15:63351687	A/G	cg05507819	chr15:63340323	TPM1	0.53	9.22	0.34	4.21e-19	HDL cholesterol;
BRCA	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg23533926	chr12:111358616	MYL2	-0.41	-8.57	-0.32	7.8e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg09654669	chr8:57350985	NA	-0.39	-8.45	-0.32	1.98e-16	Obesity-related traits;
BRCA	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg20307385	chr11:47447363	PSMC3	0.4	8.44	0.32	2.1e-16	Subjective well-being;
BRCA	cis	rs6546550	0.901	rs6739780	chr2:70138111	G/A	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.62	-0.42	1.93e-28	Prevalent atrial fibrillation;
BRCA	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg25767906	chr1:53392781	SCP2	0.43	9.78	0.36	3.87e-21	Monocyte count;
BRCA	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg10295955	chr4:187884368	NA	-0.97	-28.35	-0.75	4.32e-115	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.33	0.31	4.94e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	12.07	0.43	2.33e-30	Tonsillectomy;
BRCA	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.63	10.2	0.37	9.88e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg15556689	chr8:8085844	FLJ10661	0.39	9.29	0.34	2.31e-19	Retinal vascular caliber;
BRCA	cis	rs921968	0.540	rs6746040	chr2:219588890	G/T	cg02176678	chr2:219576539	TTLL4	-0.42	-11.18	-0.4	1.21e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs829883	0.639	rs829898	chr12:98857675	A/C	cg25150519	chr12:98850993	NA	0.68	16.46	0.55	5.41e-51	Colorectal adenoma (advanced);
BRCA	trans	rs9944715	1.000	rs9944767	chr18:43831057	A/G	cg01718231	chr17:29326311	RNF135	0.46	8.99	0.34	2.78e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs501916	0.605	rs11632156	chr15:48082099	A/G	cg16110827	chr15:48056943	SEMA6D	-0.38	-8.13	-0.31	2.29e-15	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg13852791	chr20:30311386	BCL2L1	0.86	16.78	0.55	1.31e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs372883	0.583	rs117214	chr21:30720834	A/G	cg08807101	chr21:30365312	RNF160	0.34	8.03	0.3	4.57e-15	Pancreatic cancer;
BRCA	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg06784218	chr1:46089804	CCDC17	0.51	12.22	0.44	5.44e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.62	-11.71	-0.42	7.9e-29	Breast cancer;
BRCA	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg14019695	chr9:139328340	INPP5E	0.31	8.14	0.31	2.11e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg27478167	chr7:817139	HEATR2	-0.42	-8.94	-0.33	4.01e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6121246	0.559	rs1484994	chr20:30305975	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	23.15	0.68	1.5e-86	Mean corpuscular hemoglobin;
BRCA	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg15556689	chr8:8085844	FLJ10661	-0.31	-7.9	-0.3	1.19e-14	Neuroticism;
BRCA	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg04455712	chr21:45112962	RRP1B	0.39	10.55	0.39	4.17e-24	Mean corpuscular volume;
BRCA	cis	rs273218	0.573	rs16882051	chr5:53342979	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.73	-13.71	-0.48	1.12e-37	Migraine;
BRCA	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg07395648	chr5:131743802	NA	0.38	8.23	0.31	1.02e-15	Blood metabolite levels;
BRCA	cis	rs12997796	1.000	rs12997796	chr2:86974318	A/G	cg25203885	chr2:87302643	LOC285074	-0.47	-8.22	-0.31	1.13e-15	Schizophrenia;
BRCA	cis	rs17601876	0.814	rs7181429	chr15:51559496	G/A	cg19946085	chr15:51559439	CYP19A1	-0.38	-11.59	-0.42	2.51e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	trans	rs7200543	1.000	rs16966953	chr16:15135854	A/G	cg24683922	chr1:11983373	KIAA2013	-0.37	-8.45	-0.32	1.97e-16	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg18252515	chr7:66147081	NA	-1.06	-15.53	-0.52	2.19e-46	Gout;
BRCA	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg21724239	chr8:58056113	NA	0.64	15.16	0.51	1.41e-44	Developmental language disorder (linguistic errors);
BRCA	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg14186256	chr22:23484241	RTDR1	0.77	23.78	0.69	5.07e-90	Bone mineral density;
BRCA	cis	rs1451375	1.000	rs1451375	chr7:50622712	A/C	cg18232548	chr7:50535776	DDC	-0.44	-10.04	-0.37	3.86e-22	Malaria;
BRCA	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11764359	chr7:65958608	NA	0.74	16.68	0.55	3.87e-52	Aortic root size;
BRCA	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg25817165	chr18:72167213	CNDP2	-0.72	-12.62	-0.45	9.39e-33	Refractive error;
BRCA	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21518248	chr2:162101506	NA	0.71	17.56	0.57	1.2e-56	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs1506636	1.000	rs12706545	chr7:123348744	C/T	cg03229431	chr7:123269106	ASB15	-0.6	-14.0	-0.48	4.74e-39	Plateletcrit;Platelet count;
BRCA	cis	rs6782228	0.606	rs6787559	chr3:128381086	T/C	cg16766828	chr3:128327626	NA	-0.44	-9.8	-0.36	3.11e-21	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg15133208	chr4:90757351	SNCA	0.38	7.89	0.3	1.33e-14	Neuroticism;
BRCA	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg08085267	chr17:45401833	C17orf57	0.6	12.31	0.44	2.05e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg23285459	chr7:2802560	GNA12	0.35	8.57	0.32	7.76e-17	Height;
BRCA	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg25664220	chr3:72788482	NA	-0.53	-11.1	-0.4	2.62e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03264133	chr6:25882463	NA	-0.77	-16.71	-0.55	2.88e-52	Intelligence (multi-trait analysis);
BRCA	cis	rs28374715	0.532	rs28897479	chr15:41690851	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.1	-24.83	-0.7	9.11e-96	Ulcerative colitis;
BRCA	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg00012203	chr2:219082015	ARPC2	-0.43	-8.31	-0.31	5.77e-16	Ulcerative colitis;
BRCA	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg02951883	chr7:2050386	MAD1L1	-0.37	-8.91	-0.33	5.4e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.22	0.31	1.13e-15	Total cholesterol levels;
BRCA	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg08470875	chr2:26401718	FAM59B	-0.71	-11.35	-0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs3857536	0.740	rs7763555	chr6:66889930	C/T	cg07460842	chr6:66804631	NA	-0.47	-9.09	-0.34	1.25e-18	Blood trace element (Cu levels);
BRCA	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg26647111	chr11:31128758	NA	-0.44	-9.59	-0.35	1.97e-20	Red blood cell count;
BRCA	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg13395646	chr4:1353034	KIAA1530	-0.48	-9.03	-0.34	2.06e-18	Obesity-related traits;
BRCA	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg12463550	chr7:65579703	CRCP	-0.37	-7.99	-0.3	6.48e-15	Aortic root size;
BRCA	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg20503657	chr10:835505	NA	0.89	13.76	0.48	6.13e-38	Eosinophil percentage of granulocytes;
BRCA	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11644478	chr21:40555479	PSMG1	-0.67	-15.11	-0.51	2.37e-44	Cognitive function;
BRCA	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg04362960	chr10:104952993	NT5C2	0.43	10.45	0.38	1.08e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs10489202	1.000	rs17485889	chr1:168018840	G/T	cg24449463	chr1:168025552	DCAF6	-0.41	-11.14	-0.4	1.84e-26	Schizophrenia;
BRCA	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg25062951	chr7:817576	HEATR2	-0.38	-7.8	-0.3	2.45e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg03474202	chr17:45855739	NA	-0.47	-12.56	-0.45	1.65e-32	IgG glycosylation;
BRCA	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg01262667	chr19:19385393	TM6SF2	0.41	10.57	0.39	3.41e-24	Tonsillectomy;
BRCA	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.31	10.35	0.38	2.49e-23	Electroencephalogram traits;
BRCA	cis	rs6430585	0.527	rs961360	chr2:136393658	A/G	cg07169764	chr2:136633963	MCM6	0.98	19.22	0.61	2.58e-65	Corneal structure;
BRCA	cis	rs9815354	0.812	rs10510733	chr3:42009192	T/C	cg03022575	chr3:42003672	ULK4	0.73	10.09	0.37	2.48e-22	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	19.2	0.6	3.14e-65	Alzheimer's disease;
BRCA	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.74	11.43	0.41	1.14e-27	Gut microbiome composition (summer);
BRCA	cis	rs10754283	0.967	rs10801757	chr1:90103080	A/G	cg21401794	chr1:90099060	LRRC8C	0.45	11.03	0.4	5.11e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	trans	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg25214090	chr10:38739885	LOC399744	0.45	10.38	0.38	2.04e-23	Corneal astigmatism;
BRCA	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg13319975	chr6:146136371	FBXO30	-0.41	-9.39	-0.35	9.97e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg22875332	chr1:76189707	ACADM	-0.48	-9.18	-0.34	5.87e-19	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs3762637	0.943	rs9872708	chr3:122242807	C/G	cg24169773	chr3:122142474	KPNA1	-0.43	-8.01	-0.3	5.54e-15	LDL cholesterol levels;
BRCA	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.81	12.37	0.44	1.14e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg06521331	chr12:34319734	NA	0.47	9.31	0.35	1.98e-19	Bladder cancer;
BRCA	cis	rs1113500	0.933	rs11185261	chr1:108638703	G/A	cg06207961	chr1:108661230	NA	0.44	10.84	0.39	2.89e-25	Growth-regulated protein alpha levels;
BRCA	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg13852791	chr20:30311386	BCL2L1	0.84	16.41	0.54	9.67e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	26.78	0.73	1.74e-106	Chronic sinus infection;
BRCA	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.82	0.42	2.6e-29	Tonsillectomy;
BRCA	trans	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg25517755	chr10:38738941	LOC399744	-0.38	-7.88	-0.3	1.39e-14	Corneal astigmatism;
BRCA	cis	rs4853036	1.000	rs13020991	chr2:70068642	A/G	cg02498382	chr2:70120550	SNRNP27	-0.51	-9.35	-0.35	1.51e-19	Colorectal or endometrial cancer;
BRCA	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.53	11.38	0.41	1.83e-27	Colorectal cancer;
BRCA	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg23625390	chr15:77176239	SCAPER	-0.55	-12.83	-0.45	1.08e-33	Blood metabolite levels;
BRCA	cis	rs1829883	0.717	rs2682166	chr5:98888088	A/G	cg08333243	chr5:99726346	NA	-0.36	-8.16	-0.31	1.75e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-9.33	-0.35	1.65e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.27	8.7	0.33	2.73e-17	Electroencephalogram traits;
BRCA	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg00484396	chr16:3507460	NAT15	0.44	9.33	0.35	1.78e-19	Tuberculosis;
BRCA	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg10876282	chr6:28092338	ZSCAN16	0.42	8.39	0.31	3.14e-16	Cardiac Troponin-T levels;
BRCA	cis	rs7520050	0.931	rs11211189	chr1:46261584	A/T	cg24296786	chr1:45957014	TESK2	0.44	9.96	0.37	8.03e-22	Red blood cell count;Reticulocyte count;
BRCA	cis	rs11785693	0.862	rs7009771	chr8:4990189	C/T	cg26367366	chr8:4980734	NA	0.6	10.7	0.39	1.09e-24	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.01	0.34	2.36e-18	Motion sickness;
BRCA	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg23229984	chr5:148520753	ABLIM3	-0.36	-8.86	-0.33	8.16e-18	Breast cancer;
BRCA	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg03060546	chr3:49711283	APEH	-0.61	-12.3	-0.44	2.28e-31	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg00852783	chr1:26633632	UBXN11	-0.47	-8.51	-0.32	1.22e-16	Obesity-related traits;
BRCA	cis	rs911119	1.000	rs73318135	chr20:23618571	T/G	cg16589663	chr20:23618590	CST3	0.46	8.72	0.33	2.36e-17	Chronic kidney disease;
BRCA	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg21475434	chr5:93447410	FAM172A	-0.57	-7.89	-0.3	1.27e-14	Diabetic retinopathy;
BRCA	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg10729496	chr3:10149963	C3orf24	0.48	9.0	0.34	2.49e-18	Alzheimer's disease;
BRCA	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.05	0.34	1.69e-18	Tonsillectomy;
BRCA	cis	rs2731664	0.765	rs2630766	chr5:176874941	A/C	cg23176889	chr5:176863531	GRK6	-0.63	-17.62	-0.57	6.5e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg12292205	chr6:26970375	C6orf41	-0.73	-16.7	-0.55	3.24e-52	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs61931739	0.613	rs1525898	chr12:33904445	G/T	cg26384229	chr12:38710491	ALG10B	0.41	9.17	0.34	6.33e-19	Morning vs. evening chronotype;
BRCA	cis	rs7903847	0.620	rs954149	chr10:99122936	G/A	cg08345082	chr10:99160200	RRP12	-0.28	-8.06	-0.3	3.84e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg16586182	chr3:47516702	SCAP	0.55	11.51	0.41	5.69e-28	Colorectal cancer;
BRCA	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg08470875	chr2:26401718	FAM59B	-0.5	-8.17	-0.31	1.65e-15	Gut microbiome composition (summer);
BRCA	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-8.33	-0.31	4.9e-16	Blood pressure (smoking interaction);
BRCA	cis	rs10754283	0.967	rs10737708	chr1:90119804	A/G	cg21401794	chr1:90099060	LRRC8C	0.47	11.61	0.42	2.07e-28	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs3741151	0.773	rs7110369	chr11:73160946	C/A	cg17517138	chr11:73019481	ARHGEF17	0.87	12.43	0.44	6.65e-32	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg15017067	chr4:17643749	FAM184B	0.31	9.64	0.36	1.27e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg26384229	chr12:38710491	ALG10B	0.78	18.0	0.58	6.47e-59	Heart rate;
BRCA	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg04944784	chr2:26401820	FAM59B	-0.99	-17.0	-0.56	9.04e-54	Gut microbiome composition (summer);
BRCA	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.9	0.62	6.05e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs30380	0.632	rs26497	chr5:96138767	T/C	cg16492584	chr5:96139282	ERAP1	-0.48	-11.23	-0.41	7.7e-27	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg07080220	chr10:102295463	HIF1AN	0.62	15.3	0.52	2.93e-45	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs68170813	0.559	rs10953530	chr7:106827796	A/C	cg02696742	chr7:106810147	HBP1	-0.54	-8.93	-0.33	4.66e-18	Coronary artery disease;
BRCA	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg15839431	chr19:19639596	YJEFN3	-0.41	-9.02	-0.34	2.19e-18	Bipolar disorder;
BRCA	trans	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04565464	chr8:145669602	NFKBIL2	0.44	9.96	0.37	8.07e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.54	-9.64	-0.36	1.26e-20	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg10876282	chr6:28092338	ZSCAN16	0.41	8.13	0.31	2.17e-15	Parkinson's disease;
BRCA	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	8.05	0.3	4.14e-15	Uric acid levels;
BRCA	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg07636037	chr3:49044803	WDR6	0.52	8.46	0.32	1.81e-16	Menarche (age at onset);
BRCA	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg14631576	chr9:95140430	CENPP	-0.35	-8.35	-0.31	4.17e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	trans	rs12310956	0.510	rs4931759	chr12:33871969	T/C	cg26384229	chr12:38710491	ALG10B	0.41	9.68	0.36	8.66e-21	Morning vs. evening chronotype;
BRCA	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.52	8.96	0.33	3.55e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg10932868	chr11:921992	NA	0.49	12.59	0.45	1.21e-32	Alzheimer's disease (late onset);
BRCA	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg15145296	chr3:125709740	NA	-0.57	-9.37	-0.35	1.19e-19	Blood pressure (smoking interaction);
BRCA	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.29	-9.59	-0.35	1.93e-20	Systemic lupus erythematosus;
BRCA	cis	rs7617773	0.780	rs13082158	chr3:48372470	T/C	cg11946769	chr3:48343235	NME6	0.67	13.41	0.47	2.67e-36	Coronary artery disease;
BRCA	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-9.47	-0.35	5.33e-20	Fear of minor pain;
BRCA	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg03342759	chr3:160939853	NMD3	-0.67	-15.65	-0.53	5.43e-47	Morning vs. evening chronotype;
BRCA	cis	rs2625529	0.652	rs2957735	chr15:72265173	T/C	cg16672083	chr15:72433130	SENP8	0.68	16.23	0.54	7.44e-50	Red blood cell count;
BRCA	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg06784218	chr1:46089804	CCDC17	0.49	11.79	0.42	3.79e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg25326776	chr5:148520934	ABLIM3	-0.45	-8.07	-0.3	3.42e-15	Breast cancer;
BRCA	cis	rs4965272	1.000	rs28473493	chr15:100583942	T/C	cg27344315	chr15:100560801	ADAMTS17	-0.39	-8.15	-0.31	1.93e-15	Gastroesophageal reflux disease;
BRCA	cis	rs55665837	1.000	rs10047457	chr11:14439459	T/A	cg19336497	chr11:14380999	RRAS2	-0.36	-9.48	-0.35	4.83e-20	Vitamin D levels;
BRCA	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	ch.11.42038R	chr11:967971	AP2A2	-0.52	-16.73	-0.55	2.28e-52	Alzheimer's disease (late onset);
BRCA	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg10223061	chr2:219282414	VIL1	0.35	9.87	0.36	1.69e-21	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs9649465	0.935	rs1506641	chr7:123390143	G/A	cg04330084	chr7:123175371	IQUB	-0.3	-8.23	-0.31	1.04e-15	Migraine;
BRCA	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-9.28	-0.34	2.63e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11229555	0.645	rs4347409	chr11:58176252	C/T	cg15696309	chr11:58395628	NA	0.44	9.55	0.35	2.75e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6930083	0.713	rs1321308	chr6:36638691	A/C	cg08179530	chr6:36648295	CDKN1A	-0.67	-15.96	-0.53	1.57e-48	Coronary artery disease;
BRCA	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg03433033	chr1:76189801	ACADM	0.89	23.79	0.69	4.26e-90	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg13628971	chr7:2884303	GNA12	0.49	9.79	0.36	3.56e-21	Height;
BRCA	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	12.94	0.46	3.34e-34	Migraine;Coronary artery disease;
BRCA	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-9.54	-0.35	3.04e-20	Alzheimer's disease (late onset);
BRCA	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg15017067	chr4:17643749	FAM184B	0.31	9.36	0.35	1.31e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg23029597	chr12:123009494	RSRC2	-0.59	-11.43	-0.41	1.19e-27	Body mass index;
BRCA	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	12.7	0.45	3.91e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.38	-8.13	-0.31	2.27e-15	Total cholesterol levels;
BRCA	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg24449463	chr1:168025552	DCAF6	0.52	17.99	0.58	7.95e-59	Schizophrenia;
BRCA	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg00852783	chr1:26633632	UBXN11	0.5	10.79	0.39	4.83e-25	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg08601574	chr20:25228251	PYGB	0.41	9.62	0.36	1.49e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg26384229	chr12:38710491	ALG10B	0.79	20.5	0.63	3.74e-72	Heart rate;
BRCA	cis	rs8054556	0.539	rs12596543	chr16:30029135	A/G	cg06326092	chr16:30034487	C16orf92	0.34	8.52	0.32	1.12e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.81	-0.33	1.15e-17	Breast cancer;
BRCA	cis	rs62229266	0.626	rs2835268	chr21:37449136	C/G	cg12218747	chr21:37451666	NA	-0.46	-11.71	-0.42	8.08e-29	Mitral valve prolapse;
BRCA	cis	rs208520	0.586	rs208442	chr6:66900618	T/A	cg07460842	chr6:66804631	NA	-0.6	-11.03	-0.4	5.37e-26	Exhaled nitric oxide output;
BRCA	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg04944784	chr2:26401820	FAM59B	-0.84	-12.99	-0.46	2.03e-34	Gut microbiome composition (summer);
BRCA	cis	rs1113500	0.836	rs1539553	chr1:108589998	C/T	cg06207961	chr1:108661230	NA	-0.39	-9.2	-0.34	5.12e-19	Growth-regulated protein alpha levels;
BRCA	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg07148914	chr20:33460835	GGT7	-0.43	-8.94	-0.33	4.22e-18	Height;
BRCA	cis	rs4948102	0.653	rs6593294	chr7:56063201	G/C	cg09872392	chr7:56161020	PHKG1	-0.4	-9.1	-0.34	1.1e-18	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg06484146	chr7:12443880	VWDE	-0.65	-8.9	-0.33	5.91e-18	Coronary artery disease;
BRCA	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg13256891	chr4:100009986	ADH5	0.48	10.77	0.39	5.87e-25	Alcohol dependence;
BRCA	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg27432699	chr2:27873401	GPN1	0.44	9.31	0.35	2.01e-19	Oral cavity cancer;
BRCA	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11890956	chr21:40555474	PSMG1	1.05	29.77	0.76	8.13e-123	Cognitive function;
BRCA	cis	rs6429082	0.715	rs2291687	chr1:235594182	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.55	-12.82	-0.45	1.18e-33	Adiposity;
BRCA	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg01657329	chr11:68192670	LRP5	0.36	8.08	0.3	3.22e-15	Bone mineral density (spine);
BRCA	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-10.96	-0.4	1.02e-25	Personality dimensions;
BRCA	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.49	0.57	2.8e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.51	-0.32	1.24e-16	Colorectal cancer;
BRCA	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.54e-19	Morning vs. evening chronotype;
BRCA	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg09877947	chr5:131593287	PDLIM4	0.37	7.86	0.3	1.62e-14	Breast cancer;
BRCA	cis	rs9462027	0.651	rs7769820	chr6:34760228	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.88	-0.3	1.44e-14	Systemic lupus erythematosus;
BRCA	cis	rs2108225	0.934	rs2283044	chr7:107440553	A/G	cg18560240	chr7:107437656	SLC26A3	0.54	11.44	0.41	1.09e-27	Ulcerative colitis;
BRCA	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg13010199	chr12:38710504	ALG10B	0.43	9.11	0.34	1.09e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs654950	0.934	rs641974	chr1:42002137	G/A	cg06885757	chr1:42089581	HIVEP3	-0.28	-9.81	-0.36	2.9e-21	Airway imaging phenotypes;
BRCA	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00149659	chr3:10157352	C3orf10	0.8	13.63	0.47	2.44e-37	Alzheimer's disease;
BRCA	trans	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.61	13.7	0.48	1.21e-37	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.28	-0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-7.98	-0.3	6.69e-15	Blood pressure (smoking interaction);
BRCA	cis	rs210138	0.706	rs3916279	chr6:33574950	A/C	cg17865955	chr6:33601177	ITPR3	0.37	7.91	0.3	1.14e-14	Testicular germ cell tumor;
BRCA	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg08601574	chr20:25228251	PYGB	0.36	8.37	0.31	3.65e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg23711669	chr6:146136114	FBXO30	0.81	19.42	0.61	2.14e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg00701064	chr4:6280414	WFS1	0.68	17.71	0.57	2.26e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg24060327	chr5:131705240	SLC22A5	-0.47	-9.67	-0.36	1e-20	Blood metabolite levels;
BRCA	cis	rs67072384	1.000	rs7124056	chr11:72444747	C/T	cg04827223	chr11:72435913	ARAP1	0.64	10.9	0.4	1.7e-25	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
BRCA	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg01181863	chr3:195395398	SDHAP2	-0.46	-8.01	-0.3	5.54e-15	Pancreatic cancer;
BRCA	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg04727924	chr7:799746	HEATR2	-0.54	-10.19	-0.37	1.08e-22	Cerebrospinal P-tau181p levels;
BRCA	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18876405	chr7:65276391	NA	-0.49	-10.81	-0.39	3.81e-25	Aortic root size;
BRCA	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg04034577	chr2:241836375	C2orf54	-0.57	-13.89	-0.48	1.66e-38	Urinary metabolites;
BRCA	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	19.33	0.61	6.67e-66	Smoking behavior;
BRCA	cis	rs909002	0.849	rs2280386	chr1:32086912	A/C	cg13919466	chr1:32135498	COL16A1	-0.28	-9.53	-0.35	3.22e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs10046574	0.831	rs111522774	chr7:135135327	C/A	cg27474649	chr7:135195673	CNOT4	0.6	8.54	0.32	9.88e-17	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.36	-0.41	2.25e-27	Gut microbiome composition (summer);
BRCA	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.19	-0.34	5.29e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg23285459	chr7:2802560	GNA12	-0.38	-9.68	-0.36	8.74e-21	Height;
BRCA	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.98	14.5	0.5	2.25e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs870825	0.616	rs28450662	chr4:185638900	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	17.38	0.57	1.04e-55	Blood protein levels;
BRCA	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26314531	chr2:26401878	FAM59B	0.88	15.31	0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg27284194	chr4:1044797	NA	0.44	9.44	0.35	6.9e-20	Recombination rate (males);
BRCA	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	18.05	0.58	3.8e-59	Alzheimer's disease;
BRCA	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg23708337	chr7:1209742	NA	0.63	8.84	0.33	9.2e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	13.38	0.47	3.61e-36	Height;
BRCA	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg16141378	chr3:129829833	LOC729375	0.33	8.13	0.31	2.16e-15	Mood instability;
BRCA	cis	rs6545883	0.525	rs2049747	chr2:61364154	G/A	cg15711740	chr2:61764176	XPO1	0.45	11.04	0.4	4.76e-26	Tuberculosis;
BRCA	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11890956	chr21:40555474	PSMG1	0.96	24.22	0.69	2.01e-92	Cognitive function;
BRCA	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg20283391	chr11:68216788	NA	-0.45	-8.93	-0.33	4.39e-18	Total body bone mineral density;
BRCA	cis	rs12530845	0.943	rs60858457	chr7:135336918	T/C	cg23117316	chr7:135346802	PL-5283	-0.37	-8.65	-0.32	4.18e-17	Red blood cell traits;
BRCA	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-11.25	-0.41	6.77e-27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4566357	0.787	rs6748048	chr2:227822440	T/C	cg11843606	chr2:227700838	RHBDD1	-0.48	-9.88	-0.36	1.67e-21	Coronary artery disease;
BRCA	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg11502198	chr6:26597334	ABT1	-0.5	-9.81	-0.36	2.99e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs7395662	0.804	rs8186428	chr11:48734677	C/T	cg00717180	chr2:96193071	NA	-0.32	-8.73	-0.33	2.2e-17	HDL cholesterol;
BRCA	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg23018236	chr17:30244563	NA	-0.63	-10.18	-0.37	1.19e-22	Hip circumference adjusted for BMI;
BRCA	trans	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	14.63	0.5	5.12e-42	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs13053817	1.000	rs13054354	chr22:29840180	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.5	-9.67	-0.36	9.47e-21	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-9.43	-0.35	7.58e-20	Daytime sleep phenotypes;
BRCA	cis	rs17253792	0.822	rs10147380	chr14:56054354	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.57	7.98	0.3	6.98e-15	Putamen volume;
BRCA	trans	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg25214090	chr10:38739885	LOC399744	0.52	10.84	0.39	3.14e-25	Corneal astigmatism;
BRCA	cis	rs9814567	0.727	rs4435681	chr3:134344435	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-16.02	-0.54	8.27e-49	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg13256891	chr4:100009986	ADH5	0.42	7.86	0.3	1.59e-14	Alcohol dependence;
BRCA	cis	rs7474896	0.537	rs1208591	chr10:38212502	A/T	cg25427524	chr10:38739819	LOC399744	-0.48	-8.9	-0.33	5.7e-18	Obesity (extreme);
BRCA	cis	rs73072330	1.000	rs17729010	chr3:47912703	A/G	cg04507495	chr3:47563649	NA	-1.12	-11.59	-0.42	2.61e-28	Stem cell growth factor beta levels;
BRCA	trans	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg06521331	chr12:34319734	NA	-0.5	-9.23	-0.34	4.03e-19	Bladder cancer;
BRCA	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg17063962	chr7:91808500	NA	-0.51	-12.06	-0.43	2.48e-30	Breast cancer;
BRCA	cis	rs1595825	0.891	rs77032596	chr2:198603185	T/G	cg19156104	chr2:198669113	PLCL1	-0.47	-8.42	-0.32	2.4e-16	Ulcerative colitis;
BRCA	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07080220	chr10:102295463	HIF1AN	0.55	13.43	0.47	2.14e-36	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9392556	0.829	rs643232	chr6:4122249	C/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.37	-8.01	-0.3	5.46e-15	Blood metabolite levels;
BRCA	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.71	-0.33	2.57e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg10862848	chr6:42927986	GNMT	-0.35	-14.8	-0.51	8.08e-43	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs6479891	1.000	rs10995543	chr10:65239547	T/C	cg14819942	chr15:35414228	NA	0.35	8.51	0.32	1.23e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	7.15e-19	Alzheimer's disease (late onset);
BRCA	cis	rs950776	0.642	rs12905641	chr15:78964362	A/G	cg06917634	chr15:78832804	PSMA4	-0.43	-8.38	-0.31	3.37e-16	Sudden cardiac arrest;
BRCA	trans	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.61	10.88	0.4	2.09e-25	Type 2 diabetes;
BRCA	cis	rs2652834	1.000	rs2729785	chr15:63402574	G/A	cg05507819	chr15:63340323	TPM1	0.45	8.32	0.31	5.39e-16	HDL cholesterol;
BRCA	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg13010199	chr12:38710504	ALG10B	-0.43	-10.06	-0.37	3.3e-22	Heart rate;
BRCA	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.37	-0.31	3.76e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4818225	0.895	rs2183588	chr21:42626882	A/G	cg21268422	chr21:42620091	BACE2	0.41	7.82	0.3	2.13e-14	Educational attainment;
BRCA	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg22920501	chr2:26401640	FAM59B	-0.67	-11.53	-0.42	4.47e-28	Gut microbiome composition (summer);
BRCA	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg04989706	chr14:50066350	PPIL5	-0.5	-10.02	-0.37	4.88e-22	Carotid intima media thickness;
BRCA	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18876405	chr7:65276391	NA	0.62	15.35	0.52	1.6e-45	Aortic root size;
BRCA	cis	rs1997103	1.000	rs6593237	chr7:55411015	T/C	cg17469321	chr7:55412551	NA	0.5	9.64	0.36	1.28e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.69e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg27661571	chr11:113659931	NA	-0.76	-11.59	-0.42	2.46e-28	Hip circumference adjusted for BMI;
BRCA	cis	rs1874326	0.545	rs6964218	chr7:138112861	A/G	cg18008034	chr7:138118925	NA	-0.4	-8.42	-0.32	2.52e-16	Quantitative traits;
BRCA	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg09359103	chr1:154839909	KCNN3	-0.55	-14.53	-0.5	1.55e-41	Prostate cancer;
BRCA	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg20701182	chr2:24300061	SF3B14	0.67	9.81	0.36	2.93e-21	Lymphocyte counts;
BRCA	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg06808227	chr14:105710500	BRF1	-0.82	-16.21	-0.54	9.87e-50	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg20607798	chr8:58055168	NA	0.48	8.4	0.32	3e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg12311346	chr5:56204834	C5orf35	-0.61	-12.96	-0.46	2.87e-34	Initial pursuit acceleration;
BRCA	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg16325326	chr1:53192061	ZYG11B	0.93	25.5	0.71	1.89e-99	Monocyte count;
BRCA	cis	rs9811920	0.799	rs9832134	chr3:99836722	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	12.19	0.43	6.71e-31	Axial length;
BRCA	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg24558204	chr6:135376177	HBS1L	0.49	13.18	0.46	2.92e-35	Red blood cell count;
BRCA	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg13334819	chr7:99746414	C7orf59	-0.41	-9.57	-0.35	2.24e-20	Coronary artery disease;
BRCA	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg06970220	chr1:156163860	SLC25A44	-0.39	-9.46	-0.35	5.61e-20	Testicular germ cell tumor;
BRCA	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.5	9.26	0.34	3.02e-19	Birth weight;
BRCA	cis	rs7945718	0.934	rs4553350	chr11:12759834	A/G	cg25843174	chr11:12811716	TEAD1	-0.24	-9.17	-0.34	6.24e-19	Educational attainment (years of education);
BRCA	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.68	0.61	9.04e-68	Alzheimer's disease;
BRCA	cis	rs895636	0.898	rs10205310	chr2:45188646	A/G	cg16198908	chr2:45192207	NA	0.5	9.53	0.35	3.12e-20	Metabolite levels;Fasting plasma glucose;
BRCA	cis	rs6121246	0.559	rs6058465	chr20:30397691	G/A	cg21427119	chr20:30132790	HM13	-0.35	-7.95	-0.3	8.21e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs919433	0.680	rs7590010	chr2:198400668	C/T	cg00792783	chr2:198669748	PLCL1	0.36	8.38	0.31	3.45e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.51	0.55	2.91e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg23285459	chr7:2802560	GNA12	-0.38	-9.51	-0.35	3.81e-20	Height;
BRCA	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs919433	0.680	rs1961558	chr2:198487278	C/T	cg00792783	chr2:198669748	PLCL1	0.35	8.02	0.3	4.99e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg12863693	chr15:85201151	NMB	0.56	12.03	0.43	3.39e-30	Schizophrenia;
BRCA	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg26384229	chr12:38710491	ALG10B	0.81	20.34	0.63	2.82e-71	Heart rate;
BRCA	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg16339924	chr4:17578868	LAP3	0.66	15.57	0.52	1.33e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.58	0.55	1.25e-51	Hypertriglyceridemia;
BRCA	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg16482183	chr6:26056742	HIST1H1C	0.53	11.4	0.41	1.5e-27	Height;
BRCA	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg22972055	chr7:872293	UNC84A	0.39	8.64	0.32	4.49e-17	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg07741184	chr6:167504864	NA	0.33	9.82	0.36	2.83e-21	Primary biliary cholangitis;
BRCA	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg16230307	chr14:35515116	FAM177A1	0.69	14.26	0.49	3.01e-40	Psoriasis;
BRCA	cis	rs7927771	0.524	rs10838782	chr11:47877800	A/G	cg20307385	chr11:47447363	PSMC3	0.41	9.27	0.34	2.75e-19	Subjective well-being;
BRCA	cis	rs9815354	0.812	rs17280952	chr3:41810834	T/C	cg03022575	chr3:42003672	ULK4	0.7	9.61	0.36	1.66e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09263875	chr16:632152	PIGQ	0.73	21.2	0.64	6.33e-76	Height;
BRCA	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.84	-0.3	1.88e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs243505	0.528	rs1558419	chr7:148480233	C/T	cg09806900	chr7:148480153	CUL1	0.47	9.93	0.37	1.02e-21	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg11189052	chr15:85197271	WDR73	-0.34	-8.2	-0.31	1.27e-15	P wave terminal force;
BRCA	cis	rs4746818	1.000	rs7091695	chr10:70964997	A/G	cg11621586	chr10:70884670	VPS26A	-0.75	-13.26	-0.46	1.21e-35	Left atrial antero-posterior diameter;
BRCA	trans	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.42	8.95	0.33	3.72e-18	Menarche (age at onset);
BRCA	cis	rs868036	1.000	rs4633663	chr15:68106378	G/C	cg08079166	chr15:68083412	MAP2K5	0.35	9.46	0.35	5.8e-20	Restless legs syndrome;
BRCA	trans	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg23762105	chr12:34175262	ALG10	0.36	8.47	0.32	1.73e-16	Morning vs. evening chronotype;
BRCA	cis	rs7580658	0.963	rs2090574	chr2:128131391	C/A	cg09760422	chr2:128146352	NA	-0.35	-7.84	-0.3	1.83e-14	Protein C levels;
BRCA	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg16339924	chr4:17578868	LAP3	0.67	16.2	0.54	1.04e-49	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg25208724	chr1:156163844	SLC25A44	1.03	33.1	0.79	1.05e-140	Testicular germ cell tumor;
BRCA	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg16339924	chr4:17578868	LAP3	0.57	13.86	0.48	2.16e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10267417	0.603	rs7789051	chr7:19956618	A/T	cg05791153	chr7:19748676	TWISTNB	0.42	7.86	0.3	1.65e-14	Night sleep phenotypes;
BRCA	cis	rs2637030	0.533	rs2607511	chr5:52930471	G/A	cg06476337	chr5:52856530	NDUFS4	0.38	8.82	0.33	1.09e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg20203395	chr5:56204925	C5orf35	-0.5	-10.3	-0.38	3.93e-23	Initial pursuit acceleration;
BRCA	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg12011299	chr4:100065546	ADH4	0.5	11.61	0.42	2.12e-28	Alcohol dependence;
BRCA	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg07741184	chr6:167504864	NA	0.33	9.88	0.36	1.64e-21	Primary biliary cholangitis;
BRCA	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.53	11.06	0.4	4.01e-26	Personality dimensions;
BRCA	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg14558114	chr2:88469736	THNSL2	0.59	8.36	0.31	3.96e-16	Plasma clusterin levels;
BRCA	cis	rs11785693	0.862	rs11780705	chr8:4988221	G/A	cg26367366	chr8:4980734	NA	0.7	12.0	0.43	4.41e-30	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs7336332	0.527	rs1475219	chr13:28037415	A/G	cg22138327	chr13:27999177	GTF3A	0.43	8.57	0.32	7.6e-17	Weight;
BRCA	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg27129171	chr3:47204927	SETD2	-0.71	-17.4	-0.57	8.85e-56	Colorectal cancer;
BRCA	cis	rs7254114	0.686	rs7249565	chr19:11302807	C/T	cg02815516	chr19:11306319	KANK2	-0.35	-10.51	-0.38	5.87e-24	Immature fraction of reticulocytes;
BRCA	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg14844989	chr11:31128820	NA	-0.44	-9.46	-0.35	5.96e-20	Red blood cell count;
BRCA	cis	rs1371614	0.566	rs11887401	chr2:27181112	G/T	cg00617064	chr2:27272375	NA	-0.3	-8.04	-0.3	4.24e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs6426558	0.559	rs7549520	chr1:227258858	G/C	cg10327440	chr1:227177885	CDC42BPA	0.48	9.44	0.35	6.67e-20	Neutrophil percentage of white cells;
BRCA	cis	rs4363385	0.818	rs1591736	chr1:152987497	A/C	cg24667326	chr1:152973720	SPRR3	-0.32	-8.74	-0.33	2.1e-17	Inflammatory skin disease;
BRCA	cis	rs11190604	0.731	rs10883480	chr10:102163821	G/T	cg07080220	chr10:102295463	HIF1AN	-0.47	-10.52	-0.38	5.66e-24	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6942756	0.955	rs55638303	chr7:128885770	C/T	cg02491457	chr7:128862824	NA	-0.71	-13.69	-0.48	1.4e-37	White matter hyperintensity burden;
BRCA	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg14440974	chr22:39074834	NA	-0.38	-9.02	-0.34	2.24e-18	Menopause (age at onset);
BRCA	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-9.88	-0.36	1.67e-21	Mean corpuscular volume;
BRCA	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg19717773	chr7:2847554	GNA12	-0.43	-9.71	-0.36	6.85e-21	Height;
BRCA	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11644478	chr21:40555479	PSMG1	0.84	19.22	0.61	2.53e-65	Cognitive function;
BRCA	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg18898632	chr2:242989856	NA	-0.5	-8.31	-0.31	5.75e-16	Obesity-related traits;
BRCA	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg21775007	chr8:11205619	TDH	0.61	11.92	0.43	1.02e-29	Retinal vascular caliber;
BRCA	cis	rs16867335	0.652	rs1528439	chr2:181462035	C/T	cg23363182	chr2:181467187	NA	-0.44	-9.12	-0.34	9.52e-19	Survival in rectal cancer;
BRCA	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg26446133	chr18:72167187	CNDP2	-0.74	-12.91	-0.45	4.65e-34	Refractive error;
BRCA	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	26.42	0.72	1.58e-104	Chronic sinus infection;
BRCA	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26314531	chr2:26401878	FAM59B	0.91	16.27	0.54	4.67e-50	Gut microbiome composition (summer);
BRCA	cis	rs9788721	0.836	rs17483686	chr15:78733390	A/T	cg18825076	chr15:78729989	IREB2	-0.39	-8.27	-0.31	7.67e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg20701182	chr2:24300061	SF3B14	0.66	9.39	0.35	1.01e-19	Lymphocyte counts;
BRCA	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg17366294	chr4:99064904	C4orf37	0.42	8.34	0.31	4.7e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg22705602	chr4:152727874	NA	-0.33	-8.2	-0.31	1.29e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg13880726	chr7:1868755	MAD1L1	-0.52	-9.73	-0.36	6.02e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg00757033	chr12:89920650	WDR51B	0.51	10.0	0.37	5.63e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs16854884	0.526	rs7643341	chr3:143726980	C/T	cg06585982	chr3:143692056	C3orf58	0.51	10.21	0.37	8.73e-23	Economic and political preferences (feminism/equality);
BRCA	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.23	-20.32	-0.63	3.25e-71	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs2425143	0.558	rs7274724	chr20:34539466	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.3	-0.31	6.41e-16	Blood protein levels;
BRCA	trans	rs75804782	0.521	rs55657931	chr2:239422072	A/G	cg01134436	chr17:81009848	B3GNTL1	0.59	8.29	0.31	6.5e-16	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg04705435	chr11:17411270	KCNJ11	0.43	9.37	0.35	1.22e-19	Type 2 diabetes;
BRCA	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18876405	chr7:65276391	NA	-0.58	-13.8	-0.48	3.98e-38	Aortic root size;
BRCA	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-13.69	-0.48	1.38e-37	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg24692254	chr21:30365293	RNF160	0.79	22.34	0.66	3.96e-82	Dental caries;
BRCA	cis	rs3820928	0.874	rs13430941	chr2:227904447	G/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.32	-0.31	5.39e-16	Pulmonary function;
BRCA	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg11057378	chr10:81107060	PPIF	0.36	9.09	0.34	1.23e-18	Height;
BRCA	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg21095983	chr6:86352623	SYNCRIP	0.43	9.65	0.36	1.12e-20	Smooth-surface caries;
BRCA	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg18850127	chr7:39170497	POU6F2	0.43	9.46	0.35	5.57e-20	IgG glycosylation;
BRCA	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-9.98	-0.37	7.01e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg06521331	chr12:34319734	NA	0.45	8.88	0.33	6.77e-18	Bladder cancer;
BRCA	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg19628046	chr18:33552617	C18orf21	0.54	10.88	0.4	2e-25	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg05340658	chr4:99064831	C4orf37	0.56	11.14	0.4	1.86e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18876405	chr7:65276391	NA	0.5	11.2	0.4	1.09e-26	Aortic root size;
BRCA	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg17143192	chr8:8559678	CLDN23	0.57	11.1	0.4	2.73e-26	Obesity-related traits;
BRCA	trans	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg25214090	chr10:38739885	LOC399744	0.53	11.74	0.42	5.97e-29	Corneal astigmatism;
BRCA	cis	rs6484504	0.600	rs972714	chr11:31358875	T/G	cg14844989	chr11:31128820	NA	0.46	9.59	0.35	1.95e-20	Red blood cell count;
BRCA	trans	rs208520	0.802	rs208499	chr6:66932146	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-15.24	-0.52	5.55e-45	Exhaled nitric oxide output;
BRCA	trans	rs1997103	1.000	rs6973337	chr7:55411534	T/C	cg20935933	chr6:143382018	AIG1	0.61	11.7	0.42	8.67e-29	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg05623727	chr3:50126028	RBM5	-0.41	-9.76	-0.36	4.49e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg14004847	chr7:1930337	MAD1L1	-0.44	-8.96	-0.33	3.43e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs7553864	0.835	rs4415539	chr1:87604245	C/T	cg17420885	chr1:87600446	LOC339524	0.38	8.2	0.31	1.34e-15	Smoking behavior;
BRCA	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.12	0.4	2.15e-26	Bipolar disorder;
BRCA	cis	rs3845702	1.000	rs3845697	chr2:180798553	C/T	cg01881094	chr2:180872142	CWC22	0.68	13.26	0.46	1.29e-35	Schizophrenia;
BRCA	trans	rs3857536	0.813	rs9354404	chr6:66948408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	2.02e-14	Blood trace element (Cu levels);
BRCA	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.86	-12.83	-0.45	1.14e-33	Platelet count;
BRCA	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg23625390	chr15:77176239	SCAPER	0.38	8.98	0.33	3.06e-18	Blood metabolite levels;
BRCA	cis	rs4566357	0.595	rs6707286	chr2:227911400	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.48	-0.35	4.75e-20	Coronary artery disease;
BRCA	cis	rs12612619	0.689	rs11681145	chr2:27290525	A/G	cg00617064	chr2:27272375	NA	-0.32	-7.97	-0.3	7.18e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg11752832	chr7:134001865	SLC35B4	0.52	13.53	0.47	7.69e-37	Mean platelet volume;
BRCA	cis	rs6820391	0.748	rs7675771	chr4:54447002	G/C	cg04173182	chr4:54446035	LNX1	0.53	11.9	0.43	1.27e-29	Cervical artery dissection;
BRCA	cis	rs77972916	0.505	rs11899984	chr2:43578246	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-10.89	-0.4	1.81e-25	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.07	0.37	2.99e-22	Bladder cancer;
BRCA	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg19653624	chr11:20408972	PRMT3	-0.43	-10.0	-0.37	5.61e-22	Pursuit maintenance gain;
BRCA	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.39	8.02	0.3	5.09e-15	Personality dimensions;
BRCA	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg18016565	chr1:150552671	MCL1	0.34	7.91	0.3	1.1e-14	Melanoma;
BRCA	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg21252483	chr19:49399788	TULP2	0.39	9.14	0.34	7.94e-19	Red cell distribution width;
BRCA	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg13319975	chr6:146136371	FBXO30	0.41	9.35	0.35	1.47e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg03733263	chr8:22462867	KIAA1967	1.03	24.63	0.7	1.03e-94	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg16339924	chr4:17578868	LAP3	0.57	13.96	0.48	7.72e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg11812906	chr14:75593930	NEK9	-0.69	-16.07	-0.54	4.66e-49	Height;
BRCA	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg15017067	chr4:17643749	FAM184B	-0.31	-9.36	-0.35	1.39e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg26043149	chr18:55253948	FECH	0.39	8.34	0.31	4.61e-16	Bone mineral density;
BRCA	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg18279126	chr7:2041391	MAD1L1	-0.39	-8.88	-0.33	6.47e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs6076065	0.630	rs2424559	chr20:23430519	A/G	cg11657817	chr20:23433608	CST11	0.43	10.23	0.38	7.57e-23	Facial morphology (factor 15, philtrum width);
BRCA	trans	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg19862616	chr7:65841803	NCRNA00174	0.57	12.2	0.43	6.59e-31	Eotaxin levels;
BRCA	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg18016565	chr1:150552671	MCL1	0.34	7.83	0.3	2.01e-14	Melanoma;
BRCA	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg27170947	chr2:26402098	FAM59B	-0.92	-16.52	-0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs10242455	0.702	rs17161700	chr7:98977067	A/G	cg18809830	chr7:99032528	PTCD1	-0.62	-8.21	-0.31	1.23e-15	Blood metabolite levels;
BRCA	cis	rs7095944	0.614	rs10901818	chr10:126449428	G/A	cg08799069	chr10:126477246	METTL10	-0.4	-10.09	-0.37	2.69e-22	Asthma;
BRCA	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	19.13	0.6	7.84e-65	Tonsillectomy;
BRCA	cis	rs752010	0.695	rs10890155	chr1:42107843	C/T	cg06885757	chr1:42089581	HIVEP3	0.22	8.17	0.31	1.64e-15	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs68170813	0.559	rs7798223	chr7:106829223	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-8.35	-0.31	4.12e-16	Coronary artery disease;
BRCA	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg13319975	chr6:146136371	FBXO30	-0.34	-8.03	-0.3	4.84e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9815354	0.597	rs60690674	chr3:41997811	G/C	cg03022575	chr3:42003672	ULK4	0.65	9.34	0.35	1.53e-19	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg25358565	chr5:93447407	FAM172A	1.13	18.07	0.58	2.97e-59	Diabetic retinopathy;
BRCA	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg25358565	chr5:93447407	FAM172A	-0.66	-11.16	-0.4	1.51e-26	Diabetic retinopathy;
BRCA	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg18964960	chr10:1102726	WDR37	-0.52	-8.99	-0.33	2.86e-18	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	12.69	0.45	4.39e-33	Mean platelet volume;
BRCA	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg20701182	chr2:24300061	SF3B14	0.7	13.41	0.47	2.62e-36	Lymphocyte counts;
BRCA	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-12.3	-0.44	2.27e-31	Alzheimer's disease;
BRCA	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg01448562	chr3:133502909	NA	-0.61	-14.5	-0.5	2.21e-41	Iron status biomarkers;
BRCA	cis	rs858239	0.571	rs6953020	chr7:23172132	T/C	cg23682824	chr7:23144976	KLHL7	0.42	10.87	0.39	2.35e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg20469991	chr17:27169893	C17orf63	-0.45	-8.8	-0.33	1.25e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg13628971	chr7:2884303	GNA12	0.45	10.19	0.37	1.07e-22	Height;
BRCA	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06108461	chr20:60628389	TAF4	-0.8	-17.52	-0.57	2.09e-56	Body mass index;
BRCA	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.44	-0.32	2.17e-16	Total body bone mineral density;
BRCA	cis	rs919433	0.617	rs2037590	chr2:198584775	T/A	cg00792783	chr2:198669748	PLCL1	-0.44	-9.73	-0.36	5.68e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6909752	0.611	rs7770180	chr6:22565043	T/C	cg13666174	chr6:22585274	NA	-0.35	-7.94	-0.3	8.84e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
BRCA	cis	rs7903847	0.642	rs2297668	chr10:99160046	C/T	cg20016023	chr10:99160130	RRP12	-0.26	-8.35	-0.31	4.4e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg12165864	chr7:66369176	NA	-0.41	-9.51	-0.35	3.94e-20	Corneal structure;
BRCA	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	8.35	0.31	4.18e-16	Menarche (age at onset);
BRCA	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg24675658	chr1:53192096	ZYG11B	-0.66	-14.82	-0.51	6.35e-43	Monocyte count;
BRCA	trans	rs2270927	0.510	rs6876070	chr5:75579237	T/A	cg13563193	chr19:33072644	PDCD5	0.88	10.26	0.38	5.98e-23	Mean corpuscular volume;
BRCA	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg24692254	chr21:30365293	RNF160	-0.64	-16.62	-0.55	7.79e-52	Dental caries;
BRCA	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg12310025	chr6:25882481	NA	-0.54	-12.34	-0.44	1.54e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs1568889	1.000	rs12802157	chr11:28060285	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	14.71	0.5	2.14e-42	Bipolar disorder;
BRCA	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg09877947	chr5:131593287	PDLIM4	0.44	9.97	0.37	7.34e-22	Acylcarnitine levels;
BRCA	trans	rs8002861	0.619	rs9562516	chr13:44431738	T/C	cg17145862	chr1:211918768	LPGAT1	0.47	10.51	0.38	6.23e-24	Leprosy;
BRCA	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.57	8.41	0.32	2.78e-16	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-9.14	-0.34	8.44e-19	Menopause (age at onset);
BRCA	cis	rs7246967	0.673	rs7245540	chr19:22881504	C/G	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-10.47	-0.38	8.43e-24	Retinal vascular caliber;
BRCA	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg12310025	chr6:25882481	NA	-0.39	-9.08	-0.34	1.3e-18	Height;
BRCA	cis	rs6565180	0.963	rs4787642	chr16:30359408	T/C	cg17640201	chr16:30407289	ZNF48	-0.7	-15.86	-0.53	5.17e-48	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.76	0.39	6.07e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg12386194	chr3:101231763	SENP7	0.66	12.93	0.46	3.92e-34	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22307029	chr19:49891270	CCDC155	0.62	11.31	0.41	3.82e-27	Multiple sclerosis;
BRCA	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg24531977	chr5:56204891	C5orf35	-0.41	-8.31	-0.31	5.85e-16	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg20469991	chr17:27169893	C17orf63	-0.44	-8.77	-0.33	1.57e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg24006582	chr15:45444508	DUOX1	-0.51	-10.65	-0.39	1.69e-24	Uric acid levels;
BRCA	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.51	-0.35	3.8e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.59e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg01689657	chr7:91764605	CYP51A1	0.24	8.79	0.33	1.34e-17	Breast cancer;
BRCA	cis	rs477692	0.673	rs556253	chr10:131355781	G/A	cg24747557	chr10:131355152	MGMT	-0.37	-8.99	-0.33	2.89e-18	Response to temozolomide;
BRCA	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs16976116	0.901	rs28489312	chr15:55494048	A/C	cg11288833	chr15:55489084	RSL24D1	0.48	10.67	0.39	1.49e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg03709012	chr19:19516395	GATAD2A	0.78	18.25	0.59	3.43e-60	Tonsillectomy;
BRCA	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg17063962	chr7:91808500	NA	0.53	12.23	0.44	4.94e-31	Breast cancer;
BRCA	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg27432699	chr2:27873401	GPN1	0.41	8.84	0.33	9.46e-18	Oral cavity cancer;
BRCA	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-11.64	-0.42	1.57e-28	Psoriasis;
BRCA	cis	rs2230307	0.656	rs7531066	chr1:100463804	A/G	cg24955406	chr1:100503596	HIAT1	0.54	9.42	0.35	8.29e-20	Carotid intima media thickness;
BRCA	cis	rs9811920	0.965	rs6767441	chr3:99863183	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	12.56	0.44	1.72e-32	Axial length;
BRCA	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	27.2	0.73	7.83e-109	Chronic sinus infection;
BRCA	cis	rs1891275	0.515	rs7475294	chr10:93508199	T/C	cg07889827	chr10:93443413	NA	-0.4	-10.96	-0.4	9.54e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs12760731	0.565	rs11583503	chr1:178169663	G/C	cg00404053	chr1:178313656	RASAL2	0.64	7.83	0.3	2.09e-14	Obesity-related traits;
BRCA	cis	rs12973672	1.000	rs1052033	chr19:35770471	C/T	cg12095397	chr19:35769544	USF2	0.38	8.38	0.31	3.28e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26314531	chr2:26401878	FAM59B	-0.66	-11.34	-0.41	2.81e-27	Gut microbiome composition (summer);
BRCA	cis	rs4478858	0.654	rs113490486	chr1:31712863	C/G	cg00250761	chr1:31883323	NA	-0.31	-8.07	-0.3	3.51e-15	Alcohol dependence;
BRCA	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg05872129	chr22:39784769	NA	-0.56	-12.93	-0.46	3.82e-34	Intelligence (multi-trait analysis);
BRCA	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg15556689	chr8:8085844	FLJ10661	-0.38	-9.29	-0.34	2.39e-19	Triglycerides;
BRCA	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg09526685	chr4:187126073	CYP4V2	0.91	10.57	0.39	3.65e-24	Activated partial thromboplastin time;
BRCA	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg05347473	chr6:146136440	FBXO30	-0.4	-7.83	-0.3	1.98e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.43	-9.61	-0.36	1.6e-20	Personality dimensions;
BRCA	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.45	-0.32	1.98e-16	Menopause (age at onset);
BRCA	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg11663144	chr21:46675770	NA	-0.57	-13.12	-0.46	5.54e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs1973993	0.561	rs3851275	chr1:96990823	G/A	cg10631902	chr5:14652156	NA	-0.41	-10.11	-0.37	2.16e-22	Weight;
BRCA	trans	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg15556689	chr8:8085844	FLJ10661	0.36	8.44	0.32	2.15e-16	Neuroticism;
BRCA	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.5	0.38	6.9e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs13046373	0.535	rs7276743	chr21:31984545	C/T	cg22337977	chr21:31811175	KRTAP15-1	0.34	7.82	0.3	2.11e-14	HDL cholesterol;
BRCA	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg12444411	chr7:2802554	GNA12	-0.38	-9.42	-0.35	7.8e-20	Height;
BRCA	trans	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg26043149	chr18:55253948	FECH	0.39	8.34	0.31	4.61e-16	Bone mineral density;
BRCA	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg22139774	chr2:100720529	AFF3	0.29	8.35	0.31	4.25e-16	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	trans	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg07211511	chr3:129823064	LOC729375	-0.78	-15.04	-0.51	5.2e-44	Blood pressure (smoking interaction);
BRCA	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg18512352	chr11:47633146	NA	-0.34	-8.24	-0.31	9.79e-16	Subjective well-being;
BRCA	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg11822812	chr5:140052017	DND1	-0.29	-7.84	-0.3	1.91e-14	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21582582	chr3:182698605	DCUN1D1	0.37	9.83	0.36	2.51e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.57	-11.51	-0.41	5.53e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg26384229	chr12:38710491	ALG10B	0.69	15.86	0.53	5.25e-48	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg12011299	chr4:100065546	ADH4	0.41	11.61	0.42	2.12e-28	Alcohol dependence;
BRCA	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg23711669	chr6:146136114	FBXO30	0.74	17.03	0.56	6.71e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	8.87	0.33	7.51e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg01191920	chr7:158217561	PTPRN2	-0.37	-9.23	-0.34	3.88e-19	Obesity-related traits;
BRCA	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg21775007	chr8:11205619	TDH	-0.45	-9.2	-0.34	5.02e-19	Triglycerides;
BRCA	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	7.97	0.3	7.36e-15	Educational attainment;
BRCA	cis	rs7246657	0.598	rs10417545	chr19:37654263	C/G	cg18154014	chr19:37997991	ZNF793	0.53	8.87	0.33	7.33e-18	Coronary artery calcification;
BRCA	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.78e-21	Total body bone mineral density;
BRCA	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg19156104	chr2:198669113	PLCL1	-0.45	-8.28	-0.31	7.34e-16	Ulcerative colitis;
BRCA	cis	rs7246657	0.525	rs10401417	chr19:37467540	C/T	cg18154014	chr19:37997991	ZNF793	0.5	8.56	0.32	8.66e-17	Coronary artery calcification;
BRCA	cis	rs6930083	0.527	rs9368950	chr6:36627872	T/C	cg08179530	chr6:36648295	CDKN1A	-0.53	-11.45	-0.41	1.01e-27	Coronary artery disease;
BRCA	cis	rs11112613	0.713	rs11112590	chr12:105951376	C/G	cg03607813	chr12:105948248	NA	-0.56	-9.72	-0.36	6.2e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs10493773	1.000	rs55654440	chr1:86176158	G/C	cg17807903	chr1:86174739	ZNHIT6	-0.45	-9.31	-0.35	2.1e-19	Urate levels in overweight individuals;
BRCA	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg13334819	chr7:99746414	C7orf59	-0.35	-7.93	-0.3	9.57e-15	Coronary artery disease;
BRCA	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg09021430	chr5:549028	NA	-0.65	-13.57	-0.47	5.08e-37	Lung disease severity in cystic fibrosis;
BRCA	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.89	-0.33	6e-18	Total body bone mineral density;
BRCA	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg16386425	chr10:429943	DIP2C	-0.4	-8.53	-0.32	1.1e-16	Psychosis in Alzheimer's disease;
BRCA	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg07395648	chr5:131743802	NA	0.4	9.95	0.37	8.89e-22	Blood metabolite levels;
BRCA	cis	rs12310956	0.532	rs2087270	chr12:33850109	C/T	cg06521331	chr12:34319734	NA	-0.39	-7.82	-0.3	2.15e-14	Morning vs. evening chronotype;
BRCA	cis	rs9815354	1.000	rs9873207	chr3:41884750	C/T	cg03022575	chr3:42003672	ULK4	0.49	7.99	0.3	6.4e-15	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg17691542	chr6:26056736	HIST1H1C	0.51	10.41	0.38	1.49e-23	Height;
BRCA	cis	rs9837602	1.000	rs9837602	chr3:99824685	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.18	0.4	1.3e-26	Breast cancer;
BRCA	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.61	-13.9	-0.48	1.47e-38	Ulcerative colitis;
BRCA	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.63	-13.14	-0.46	4.35e-35	Lymphocyte counts;
BRCA	cis	rs6546550	0.901	rs11902198	chr2:70144596	C/A	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.47	-0.41	7.78e-28	Prevalent atrial fibrillation;
BRCA	cis	rs7520050	1.000	rs7540699	chr1:46338585	A/G	cg24296786	chr1:45957014	TESK2	0.44	9.89	0.36	1.5e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.39	8.03	0.3	4.8e-15	Personality dimensions;
BRCA	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg25358565	chr5:93447407	FAM172A	1.24	19.5	0.61	8.3e-67	Diabetic retinopathy;
BRCA	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg15839431	chr19:19639596	YJEFN3	-0.39	-8.54	-0.32	1.01e-16	Bipolar disorder;
BRCA	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg07148914	chr20:33460835	GGT7	0.48	10.33	0.38	3e-23	Height;
BRCA	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg13854012	chr2:162103682	NA	-0.39	-8.72	-0.33	2.4e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg06115741	chr20:33292138	TP53INP2	0.35	7.95	0.3	8.75e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg20283391	chr11:68216788	NA	-0.48	-9.31	-0.35	2.06e-19	Total body bone mineral density;
BRCA	cis	rs250677	1.000	rs40525	chr5:148432932	G/T	cg18129178	chr5:148520854	ABLIM3	0.56	11.16	0.4	1.55e-26	Breast cancer;
BRCA	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	9.86	0.36	1.98e-21	Personality dimensions;
BRCA	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg12826209	chr6:26865740	GUSBL1	0.61	8.1	0.31	2.75e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg01689657	chr7:91764605	CYP51A1	0.23	8.04	0.3	4.22e-15	Breast cancer;
BRCA	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg17211192	chr8:82754475	SNX16	0.54	12.22	0.44	5.41e-31	Diastolic blood pressure;
BRCA	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg06191203	chr2:152266755	RIF1	-0.4	-11.38	-0.41	1.88e-27	Lung cancer;
BRCA	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg25664220	chr3:72788482	NA	-0.56	-11.89	-0.43	1.35e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg16850897	chr7:100343110	ZAN	0.36	8.1	0.31	2.82e-15	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg04362960	chr10:104952993	NT5C2	0.43	10.26	0.38	5.87e-23	Arsenic metabolism;
BRCA	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.36	-0.38	2.35e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg03060546	chr3:49711283	APEH	-0.51	-10.44	-0.38	1.2e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4853036	0.953	rs3771539	chr2:70033711	G/C	cg02498382	chr2:70120550	SNRNP27	-0.41	-8.01	-0.3	5.64e-15	Colorectal or endometrial cancer;
BRCA	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg06484146	chr7:12443880	VWDE	-0.62	-8.99	-0.33	2.88e-18	Coronary artery disease;
BRCA	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg26769984	chr7:1090371	C7orf50	0.49	9.09	0.34	1.27e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg07148914	chr20:33460835	GGT7	-0.42	-9.19	-0.34	5.39e-19	Height;
BRCA	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg16329650	chr2:213403929	ERBB4	0.64	17.84	0.58	4.51e-58	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6750047	0.515	rs13417487	chr2:38289162	G/T	cg07380506	chr2:38303506	CYP1B1	0.55	12.46	0.44	4.53e-32	Cutaneous malignant melanoma;Melanoma;
BRCA	trans	rs3857536	0.813	rs7770349	chr6:66946659	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	2.02e-14	Blood trace element (Cu levels);
BRCA	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg27147174	chr7:100797783	AP1S1	-0.53	-10.61	-0.39	2.46e-24	Life satisfaction;
BRCA	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	14.96	0.51	1.38e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg22875332	chr1:76189707	ACADM	0.68	12.12	0.43	1.34e-30	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg15704280	chr7:45808275	SEPT13	-0.48	-8.11	-0.31	2.55e-15	Axial length;
BRCA	cis	rs6594713	0.717	rs10056194	chr5:112857862	T/G	cg12552261	chr5:112820674	MCC	0.48	8.38	0.31	3.39e-16	Brain cytoarchitecture;
BRCA	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg01324343	chr3:183735012	ABCC5	0.63	15.35	0.52	1.61e-45	Anterior chamber depth;
BRCA	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg04450456	chr4:17643702	FAM184B	0.36	10.38	0.38	2.02e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9287719	0.649	rs6722126	chr2:10721642	A/G	cg00105475	chr2:10696890	NA	0.39	8.71	0.33	2.63e-17	Prostate cancer;
BRCA	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg23750338	chr8:142222470	SLC45A4	0.51	12.52	0.44	2.47e-32	Immature fraction of reticulocytes;
BRCA	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg02403541	chr12:121454288	C12orf43	-0.54	-10.35	-0.38	2.65e-23	N-glycan levels;
BRCA	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	16.92	0.56	2.33e-53	Platelet count;
BRCA	cis	rs1018836	0.923	rs6998150	chr8:91645969	A/C	cg16814680	chr8:91681699	NA	-0.6	-12.67	-0.45	5.74e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg03146154	chr1:46216737	IPP	0.45	10.11	0.37	2.13e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg20307385	chr11:47447363	PSMC3	0.41	8.55	0.32	8.95e-17	Subjective well-being;
BRCA	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	8.82	0.33	1.09e-17	Obesity-related traits;
BRCA	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg23711669	chr6:146136114	FBXO30	0.79	18.59	0.59	5.62e-62	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs8073060	0.544	rs225258	chr17:33956883	C/T	cg19694781	chr19:47549865	TMEM160	-1.03	-22.16	-0.66	3.86e-81	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs9296092	0.538	rs76589475	chr6:33519517	G/C	cg13560919	chr6:33536144	NA	-0.85	-18.62	-0.59	3.9e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg21770322	chr7:97807741	LMTK2	0.44	11.06	0.4	3.85e-26	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg15704280	chr7:45808275	SEPT13	0.58	9.92	0.37	1.1e-21	Axial length;
BRCA	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg17330251	chr7:94953956	PON1	-0.57	-13.91	-0.48	1.28e-38	Paraoxonase activity;
BRCA	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg08601574	chr20:25228251	PYGB	-0.36	-8.6	-0.32	6.12e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg09163369	chr1:210001066	C1orf107	0.52	9.62	0.36	1.54e-20	Orofacial clefts;
BRCA	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.09	0.49	1.88e-39	Eye color traits;
BRCA	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg26149184	chr10:133730230	NA	0.4	8.2	0.31	1.37e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	trans	rs12517041	1.000	rs28421903	chr5:23281290	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.9	-0.3	1.19e-14	Calcium levels;
BRCA	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg03433033	chr1:76189801	ACADM	0.76	17.24	0.56	5.59e-55	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7408868	0.563	rs10404382	chr19:15301389	C/A	cg14696996	chr19:15285081	NOTCH3	0.8	12.14	0.43	1.21e-30	Pulse pressure;
BRCA	cis	rs6426558	0.537	rs6692080	chr1:227390162	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.47	-9.14	-0.34	8.04e-19	Neutrophil percentage of white cells;
BRCA	cis	rs1050631	0.536	rs1785928	chr18:33725931	A/G	cg19453250	chr18:33710783	SLC39A6;ELP2	0.29	7.87	0.3	1.57e-14	Esophageal squamous cell cancer (length of survival);
BRCA	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg07636037	chr3:49044803	WDR6	0.98	28.88	0.75	5.69e-118	Parkinson's disease;
BRCA	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg15557168	chr22:42548783	NA	-0.32	-8.83	-0.33	9.8e-18	Cognitive function;
BRCA	cis	rs9463078	0.506	rs4714820	chr6:44736737	T/A	cg25276700	chr6:44698697	NA	0.35	8.05	0.3	4.19e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs4690686	1.000	rs4690686	chr4:177242959	C/T	cg17059388	chr4:177262070	NA	0.36	7.94	0.3	9.09e-15	Essential tremor;
BRCA	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg17971929	chr21:40555470	PSMG1	-0.49	-10.98	-0.4	8.08e-26	Menarche (age at onset);
BRCA	cis	rs6580649	0.883	rs4760621	chr12:48561262	A/G	cg24011408	chr12:48396354	COL2A1	0.44	7.87	0.3	1.47e-14	Lung cancer;
BRCA	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg15485101	chr11:133734466	NA	0.41	9.84	0.36	2.25e-21	Childhood ear infection;
BRCA	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg24675658	chr1:53192096	ZYG11B	-0.66	-14.48	-0.5	2.63e-41	Monocyte count;
BRCA	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg09307838	chr4:120376055	NA	0.64	13.69	0.48	1.3e-37	Corneal astigmatism;
BRCA	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg22139774	chr2:100720529	AFF3	-0.31	-8.54	-0.32	9.94e-17	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg23422044	chr7:1970798	MAD1L1	-0.45	-9.5	-0.35	4.07e-20	Neuroticism;
BRCA	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11890956	chr21:40555474	PSMG1	1.05	29.88	0.76	2.06e-123	Cognitive function;
BRCA	cis	rs68170813	0.559	rs17349904	chr7:106897237	A/C	cg02696742	chr7:106810147	HBP1	-0.49	-7.82	-0.3	2.11e-14	Coronary artery disease;
BRCA	cis	rs7394190	0.748	rs60632610	chr10:75415677	C/T	cg07699608	chr10:75541558	CHCHD1	0.56	8.73	0.33	2.21e-17	Incident atrial fibrillation;
BRCA	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.37	8.0	0.3	5.91e-15	Osteoporosis;
BRCA	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg22467129	chr15:76604101	ETFA	-0.54	-12.59	-0.45	1.3e-32	Blood metabolite levels;
BRCA	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg11663144	chr21:46675770	NA	-0.6	-14.21	-0.49	5.23e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg06521331	chr12:34319734	NA	-0.52	-9.3	-0.35	2.25e-19	Bladder cancer;
BRCA	cis	rs2282802	0.685	rs2337082	chr5:139649201	G/A	cg26211634	chr5:139558579	C5orf32	0.35	8.4	0.32	2.78e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg01528321	chr10:82214614	TSPAN14	0.74	15.74	0.53	1.94e-47	Post bronchodilator FEV1;
BRCA	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.4	8.06	0.3	3.78e-15	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg04362960	chr10:104952993	NT5C2	0.48	10.54	0.38	4.79e-24	Arsenic metabolism;
BRCA	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-9.55	-0.35	2.65e-20	Gut microbiome composition (summer);
BRCA	cis	rs10779751	1.000	rs1205592	chr1:11305663	C/T	cg08854313	chr1:11322531	MTOR	0.75	15.28	0.52	3.79e-45	Body mass index;
BRCA	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg22105103	chr4:187893119	NA	0.41	13.28	0.47	1.05e-35	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg20607798	chr8:58055168	NA	-0.53	-8.32	-0.31	5.3e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6546550	0.901	rs12613947	chr2:70161342	A/G	cg02498382	chr2:70120550	SNRNP27	-0.51	-11.11	-0.4	2.48e-26	Prevalent atrial fibrillation;
BRCA	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg14019146	chr3:50243930	SLC38A3	-0.58	-14.1	-0.49	1.65e-39	Intelligence (multi-trait analysis);
BRCA	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg06115741	chr20:33292138	TP53INP2	0.4	8.82	0.33	1.09e-17	Coronary artery disease;
BRCA	cis	rs1209950	0.866	rs1734587	chr21:40180884	A/G	cg01359822	chr21:40176597	ETS2	0.34	8.63	0.32	4.89e-17	Non-small cell lung cancer (survival);
BRCA	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg11645453	chr3:52864694	ITIH4	-0.41	-10.03	-0.37	4.44e-22	Schizophrenia;
BRCA	cis	rs7727544	0.548	rs35696821	chr5:131508017	C/T	cg14196790	chr5:131705035	SLC22A5	0.37	9.17	0.34	6.34e-19	Blood metabolite levels;
BRCA	cis	rs2559856	0.935	rs2695287	chr12:102088361	T/C	cg12924262	chr12:102091054	CHPT1	0.38	8.57	0.32	7.72e-17	Blood protein levels;
BRCA	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.76	-0.42	5.05e-29	Alcohol dependence;
BRCA	trans	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg26043149	chr18:55253948	FECH	0.36	8.08	0.3	3.24e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg10523679	chr1:76189770	ACADM	0.62	10.33	0.38	2.97e-23	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg22535103	chr8:58192502	C8orf71	-0.51	-10.84	-0.39	3.07e-25	Developmental language disorder (linguistic errors);
BRCA	cis	rs78456975	0.622	rs11888851	chr2:1518254	C/G	cg01028140	chr2:1542097	TPO	-0.61	-12.38	-0.44	1e-31	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs116979167	0.575	rs1728649	chr7:105170570	A/G	cg19920283	chr7:105172520	RINT1	0.46	9.47	0.35	5.26e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg11657440	chr19:46296263	DMWD	-0.54	-12.65	-0.45	6.93e-33	Coronary artery disease;
BRCA	trans	rs3960554	0.741	rs10232162	chr7:75702505	C/T	cg19862616	chr7:65841803	NCRNA00174	0.59	12.55	0.44	1.93e-32	Eotaxin levels;
BRCA	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg01475377	chr6:109611718	NA	-0.52	-13.16	-0.46	3.54e-35	Reticulocyte fraction of red cells;
BRCA	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg21161173	chr5:140098174	VTRNA1-2	0.31	7.86	0.3	1.68e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg21211680	chr2:198530	NA	0.39	8.55	0.32	9.36e-17	Blood protein levels;
BRCA	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg18357645	chr12:58087776	OS9	0.43	11.97	0.43	6.07e-30	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	19.42	0.61	2.15e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-9.61	-0.36	1.62e-20	Mood instability;
BRCA	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs17384381	1.000	rs12758237	chr1:85870783	G/A	cg16011679	chr1:85725395	C1orf52	0.53	8.2	0.31	1.32e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9462027	0.628	rs9469886	chr6:34758824	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.94	-0.3	9.2e-15	Systemic lupus erythematosus;
BRCA	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.9	0.3	1.19e-14	Axial length;
BRCA	cis	rs1868673	1.000	rs6810143	chr3:150174510	A/T	cg04908077	chr3:150187338	NA	0.31	8.4	0.32	2.96e-16	Waist circumference;
BRCA	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	17.64	0.57	4.66e-57	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs2882667	0.898	rs11950819	chr5:138397100	T/C	cg04439458	chr5:138467593	SIL1	-0.33	-8.85	-0.33	8.3e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	14.53	0.5	1.58e-41	Exhaled nitric oxide levels;
BRCA	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg20503657	chr10:835505	NA	0.83	15.21	0.52	7.74e-45	Eosinophil percentage of granulocytes;
BRCA	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg15017067	chr4:17643749	FAM184B	0.31	9.7	0.36	7.64e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9297145	0.565	rs7794690	chr7:98764768	G/A	cg05967295	chr7:98741636	SMURF1	-0.61	-13.72	-0.48	9.61e-38	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg14863265	chr7:2801509	GNA12	-0.42	-9.82	-0.36	2.73e-21	Height;
BRCA	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	19.36	0.61	4.72e-66	Platelet count;
BRCA	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-8.09	-0.3	2.98e-15	Bipolar disorder;
BRCA	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg14683738	chr19:37701593	ZNF585B	0.45	8.07	0.3	3.37e-15	Coronary artery calcification;
BRCA	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg00071950	chr4:10020882	SLC2A9	0.66	16.76	0.55	1.6e-52	Bone mineral density;
BRCA	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11051970	0.636	rs325421	chr12:32571595	C/T	cg02745156	chr12:32552066	NA	0.25	8.18	0.31	1.52e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg22376730	chr1:1715039	NA	0.32	8.35	0.31	4.19e-16	Body mass index;
BRCA	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg07988820	chr12:82153109	PPFIA2	-0.68	-11.35	-0.41	2.49e-27	Resting heart rate;
BRCA	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg15017067	chr4:17643749	FAM184B	0.32	9.8	0.36	3.34e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-14.51	-0.5	1.85e-41	Blood metabolite levels;
BRCA	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.28	0.31	7.1e-16	Aortic root size;
BRCA	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg08917208	chr2:24149416	ATAD2B	1.06	14.75	0.5	1.39e-42	Lymphocyte counts;
BRCA	cis	rs3916	0.955	rs35771722	chr12:121154000	A/G	cg21892295	chr12:121157589	UNC119B	-0.38	-9.77	-0.36	4.18e-21	Urinary metabolites (H-NMR features);
BRCA	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg05868516	chr6:26286170	HIST1H4H	0.42	8.65	0.32	4.09e-17	Educational attainment;
BRCA	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg24562669	chr7:97807699	LMTK2	0.43	11.7	0.42	8.48e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9549260	0.753	rs1986649	chr13:41178824	C/T	cg21288729	chr13:41239152	FOXO1	0.54	8.73	0.33	2.22e-17	Red blood cell count;
BRCA	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg12386194	chr3:101231763	SENP7	0.65	12.83	0.45	1.03e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4363385	0.668	rs6587717	chr1:152984443	G/C	cg25856811	chr1:152973957	SPRR3	-0.34	-9.14	-0.34	8.11e-19	Inflammatory skin disease;
BRCA	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg23625390	chr15:77176239	SCAPER	-0.48	-11.49	-0.41	6.71e-28	Blood metabolite levels;
BRCA	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg25319279	chr11:5960081	NA	-0.41	-8.58	-0.32	6.98e-17	DNA methylation (variation);
BRCA	cis	rs911119	1.000	rs734801	chr20:23612791	A/G	cg16589663	chr20:23618590	CST3	0.46	8.77	0.33	1.58e-17	Chronic kidney disease;
BRCA	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg11301795	chr4:187892539	NA	-0.28	-9.48	-0.35	4.83e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg13770153	chr20:60521292	NA	-0.42	-9.24	-0.34	3.52e-19	Body mass index;
BRCA	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7766436	0.767	rs62391062	chr6:22598736	G/A	cg13666174	chr6:22585274	NA	-0.33	-7.96	-0.3	7.84e-15	Coronary artery disease;
BRCA	cis	rs7402982	0.934	rs8027457	chr15:99204101	A/G	cg03437748	chr15:99193247	IGF1R	0.71	17.97	0.58	9.79e-59	Birth weight;
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg04025307	chr7:1156635	C7orf50	0.53	13.48	0.47	1.21e-36	Longevity;Endometriosis;
BRCA	trans	rs6479901	0.557	rs7920768	chr10:65060514	C/T	cg14819942	chr15:35414228	NA	-0.35	-8.58	-0.32	7.23e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.47	-8.8	-0.33	1.27e-17	Monocyte count;
BRCA	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg07636037	chr3:49044803	WDR6	0.7	15.39	0.52	1.06e-45	Menarche (age at onset);
BRCA	cis	rs7178424	1.000	rs12592402	chr15:62349020	A/G	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.01	-0.3	5.27e-15	Height;
BRCA	cis	rs17741873	0.779	rs3812634	chr10:75594486	C/T	cg07699608	chr10:75541558	CHCHD1	0.5	8.19	0.31	1.38e-15	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs2425143	1.000	rs2295356	chr20:34252856	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.8	-0.33	1.31e-17	Blood protein levels;
BRCA	cis	rs2191566	0.576	rs431509	chr19:44496070	A/G	cg20607764	chr19:44506953	ZNF230	0.4	8.48	0.32	1.61e-16	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6121246	0.512	rs6060941	chr20:30367383	C/T	cg13852791	chr20:30311386	BCL2L1	0.96	23.37	0.68	8.7e-88	Mean corpuscular hemoglobin;
BRCA	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg10295955	chr4:187884368	NA	-0.97	-28.18	-0.74	3.44e-114	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	13.13	0.46	5.05e-35	Menarche (age at onset);
BRCA	cis	rs1595825	0.891	rs60582020	chr2:198520555	A/C	cg19156104	chr2:198669113	PLCL1	-0.42	-8.19	-0.31	1.47e-15	Ulcerative colitis;
BRCA	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg04362960	chr10:104952993	NT5C2	0.42	10.04	0.37	4.07e-22	Arsenic metabolism;
BRCA	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.77	0.39	5.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.39	8.1	0.31	2.78e-15	Alzheimer's disease (late onset);
BRCA	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg24531977	chr5:56204891	C5orf35	-0.4	-8.45	-0.32	1.99e-16	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg16329650	chr2:213403929	ERBB4	0.41	9.71	0.36	6.9299999999999992e-21	Symmetrical dimethylarginine levels;
BRCA	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg05340658	chr4:99064831	C4orf37	0.56	10.77	0.39	5.98e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg06618935	chr21:46677482	NA	-0.36	-7.98	-0.3	6.64e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1371614	0.523	rs2891534	chr2:27184446	A/G	cg00617064	chr2:27272375	NA	-0.34	-8.74	-0.33	2.02e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs4363385	0.693	rs821755	chr1:153036245	G/C	cg24667326	chr1:152973720	SPRR3	-0.31	-8.11	-0.31	2.53e-15	Inflammatory skin disease;
BRCA	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg03709012	chr19:19516395	GATAD2A	0.86	13.07	0.46	9.57e-35	Nonalcoholic fatty liver disease;
BRCA	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg03146154	chr1:46216737	IPP	0.45	9.94	0.37	9.83e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	9.1e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg21775007	chr8:11205619	TDH	-0.45	-9.01	-0.34	2.39e-18	Triglycerides;
BRCA	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg17971929	chr21:40555470	PSMG1	0.73	16.33	0.54	2.45e-50	Cognitive function;
BRCA	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-10.15	-0.37	1.49e-22	Bladder cancer;
BRCA	trans	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg19894588	chr14:64061835	NA	-0.49	-10.37	-0.38	2.15e-23	Optic cup area;Vertical cup-disc ratio;
BRCA	cis	rs2625529	0.652	rs11634608	chr15:72255718	A/G	cg16672083	chr15:72433130	SENP8	0.68	16.14	0.54	2.12e-49	Red blood cell count;
BRCA	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.64	0.42	1.55e-28	Homoarginine levels;
BRCA	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg13256891	chr4:100009986	ADH5	0.52	9.75	0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg11845111	chr2:191398756	TMEM194B	-0.78	-15.07	-0.51	3.93e-44	Diastolic blood pressure;
BRCA	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg20203395	chr5:56204925	C5orf35	-0.52	-10.32	-0.38	3.23e-23	Initial pursuit acceleration;
BRCA	trans	rs1459104	1.000	rs56359124	chr11:55135075	A/G	cg15704280	chr7:45808275	SEPT13	0.64	8.0	0.3	5.74e-15	Body mass index;
BRCA	cis	rs4363385	0.720	rs1415967	chr1:152965585	C/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.53	-0.35	3.29e-20	Inflammatory skin disease;
BRCA	cis	rs7577696	0.512	rs212736	chr2:32473126	T/C	cg02381751	chr2:32503542	YIPF4	0.44	8.15	0.31	1.86e-15	Inflammatory biomarkers;
BRCA	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	7.82	0.3	2.18e-14	Tonsillectomy;
BRCA	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10802521	chr3:52805072	NEK4	-0.35	-9.51	-0.35	3.8e-20	Bipolar disorder;
BRCA	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg11645453	chr3:52864694	ITIH4	-0.47	-11.21	-0.41	9.86e-27	Schizophrenia;
BRCA	cis	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg07460842	chr6:66804631	NA	0.99	19.84	0.62	1.25e-68	Exhaled nitric oxide output;
BRCA	cis	rs6546886	0.912	rs13021880	chr2:74310787	C/G	cg14702570	chr2:74259524	NA	-0.31	-7.92	-0.3	1.03e-14	Dialysis-related mortality;
BRCA	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg15448220	chr1:150897856	SETDB1	0.36	8.13	0.31	2.26e-15	Melanoma;
BRCA	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.63	0.55	7.2e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg19336497	chr11:14380999	RRAS2	-0.48	-12.05	-0.43	2.72e-30	Sense of smell;
BRCA	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg08885076	chr2:99613938	TSGA10	0.53	12.0	0.43	4.42e-30	Chronic sinus infection;
BRCA	cis	rs877529	0.967	rs139407	chr22:39552075	G/A	cg12193277	chr22:39547181	CBX7	0.46	12.55	0.44	1.97e-32	Multiple myeloma;
BRCA	cis	rs7072216	0.763	rs3814140	chr10:100170762	C/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.71	-0.36	7.24e-21	Metabolite levels;
BRCA	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg03425785	chr20:62221387	GMEB2	-0.51	-8.33	-0.31	5.08e-16	Glioblastoma;
BRCA	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg09307838	chr4:120376055	NA	0.72	15.26	0.52	4.65e-45	Corneal astigmatism;
BRCA	cis	rs16958440	0.867	rs80106524	chr18:44676639	G/A	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs9311474	0.713	rs181274	chr3:52233861	T/A	cg18404041	chr3:52824283	ITIH1	-0.28	-8.0	-0.3	5.83e-15	Electroencephalogram traits;
BRCA	cis	rs3806933	0.522	rs12522383	chr5:110455266	C/T	cg04022379	chr5:110408740	TSLP	0.4	8.85	0.33	8.84e-18	Eosinophilic esophagitis;
BRCA	cis	rs9287719	0.556	rs10168351	chr2:10736810	T/C	cg00105475	chr2:10696890	NA	0.48	10.55	0.39	4.24e-24	Prostate cancer;
BRCA	cis	rs7301016	0.846	rs11174569	chr12:63021161	A/C	cg11441379	chr12:63026424	NA	0.49	8.95	0.33	3.85e-18	IgG glycosylation;
BRCA	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg01262667	chr19:19385393	TM6SF2	-0.4	-10.26	-0.38	5.68e-23	Tonsillectomy;
BRCA	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-10.02	-0.37	4.75e-22	Personality dimensions;
BRCA	trans	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	7.99e-21	Bladder cancer;
BRCA	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-9.44	-0.35	6.86e-20	Personality dimensions;
BRCA	cis	rs9649465	1.000	rs3807635	chr7:123382152	A/C	cg04330084	chr7:123175371	IQUB	-0.33	-8.89	-0.33	6.08e-18	Migraine;
BRCA	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg10560079	chr2:191398806	TMEM194B	-0.37	-8.31	-0.31	5.73e-16	Pulse pressure;
BRCA	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03526776	chr6:41159608	TREML2	-0.42	-8.78	-0.33	1.55e-17	Alzheimer's disease (late onset);
BRCA	cis	rs8044868	0.586	rs12917999	chr16:72089451	T/C	cg16558253	chr16:72132732	DHX38	-0.45	-10.74	-0.39	7.26e-25	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	cis	rs600806	0.821	rs1030522	chr1:109900707	C/G	cg20591472	chr1:110008990	SYPL2	0.32	8.12	0.31	2.4e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.93	0.3	9.47e-15	Corneal astigmatism;
BRCA	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-18.85	-0.6	2.28e-63	Electrocardiographic conduction measures;
BRCA	trans	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg04565464	chr8:145669602	NFKBIL2	-0.38	-8.23	-0.31	1.05e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg11584989	chr19:19387371	SF4	-0.59	-13.38	-0.47	3.44e-36	Bipolar disorder;
BRCA	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg07741184	chr6:167504864	NA	0.27	8.1	0.31	2.78e-15	Crohn's disease;
BRCA	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.98	-20.81	-0.64	7.65e-74	Lymphocyte percentage of white cells;
BRCA	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg12573674	chr2:1569213	NA	-0.5	-8.99	-0.34	2.74e-18	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6060960	0.537	rs6087787	chr20:30452089	G/A	cg13852791	chr20:30311386	BCL2L1	0.6	8.07	0.3	3.53e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	9.78	0.36	3.78e-21	Mood instability;
BRCA	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg12564285	chr5:131593104	PDLIM4	-0.34	-8.04	-0.3	4.43e-15	Breast cancer;
BRCA	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14442939	chr10:27389572	ANKRD26	-0.68	-12.86	-0.45	7.8e-34	Breast cancer;
BRCA	cis	rs6484504	0.576	rs169623	chr11:31184157	T/C	cg06552810	chr11:31128660	NA	-0.38	-8.5	-0.32	1.36e-16	Red blood cell count;
BRCA	cis	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg05901451	chr6:126070800	HEY2	0.4	9.62	0.36	1.48e-20	Endometrial cancer;
BRCA	cis	rs7586879	1.000	rs7586879	chr2:25116977	C/T	cg01884057	chr2:25150051	NA	0.32	8.01	0.3	5.3e-15	Body mass index;
BRCA	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.25	8.18	0.31	1.56e-15	Cardiac Troponin-T levels;
BRCA	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg23649088	chr2:200775458	C2orf69	0.58	8.54	0.32	9.56e-17	Schizophrenia;
BRCA	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.78	19.73	0.62	5.08e-68	Systemic lupus erythematosus;
BRCA	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.42	-9.52	-0.35	3.47e-20	Personality dimensions;
BRCA	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-15.73	-0.53	2.29e-47	Electrocardiographic conduction measures;
BRCA	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg04455712	chr21:45112962	RRP1B	0.36	9.36	0.35	1.31e-19	Mean corpuscular volume;
BRCA	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg20503657	chr10:835505	NA	0.9	13.79	0.48	4.67e-38	Eosinophil percentage of granulocytes;
BRCA	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.83	0.3	1.98e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg23762105	chr12:34175262	ALG10	-0.34	-8.57	-0.32	7.76e-17	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.59e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg03351412	chr1:154909251	PMVK	0.61	14.08	0.49	2.12e-39	Prostate cancer;
BRCA	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg24642439	chr20:33292090	TP53INP2	-0.52	-11.19	-0.4	1.1e-26	Glomerular filtration rate (creatinine);
BRCA	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03923535	chr7:1197113	ZFAND2A	0.52	11.3	0.41	3.93e-27	Longevity;Endometriosis;
BRCA	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs4722585	0.533	rs12334205	chr7:26202490	G/A	cg07876897	chr7:26191696	NFE2L3	0.4	8.75	0.33	1.89e-17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
BRCA	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11764359	chr7:65958608	NA	-0.8	-19.34	-0.61	5.76e-66	Aortic root size;
BRCA	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg21573476	chr21:45109991	RRP1B	-0.34	-8.77	-0.33	1.64e-17	Mean corpuscular volume;
BRCA	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.35	-8.92	-0.33	4.84e-18	Total body bone mineral density;
BRCA	cis	rs72772090	0.710	rs10515244	chr5:96078337	C/G	cg24982541	chr5:96078678	CAST	-0.46	-8.03	-0.3	4.58e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg11663144	chr21:46675770	NA	-0.59	-13.52	-0.47	8.14e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-10.09	-0.37	2.52e-22	Bipolar disorder and schizophrenia;
BRCA	trans	rs11088226	0.645	rs2833904	chr21:33941089	T/C	cg09050820	chr6:167586206	TCP10L2	0.76	13.11	0.46	6.28e-35	Gastritis;
BRCA	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.26	-0.34	3.03e-19	Educational attainment;
BRCA	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-10.77	-0.39	5.57e-25	Bone mineral density;
BRCA	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg23422044	chr7:1970798	MAD1L1	-0.68	-12.33	-0.44	1.75e-31	Bipolar disorder;
BRCA	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg24558204	chr6:135376177	HBS1L	0.46	12.61	0.45	9.8e-33	Red blood cell count;
BRCA	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg20503657	chr10:835505	NA	1.06	18.8	0.6	4.35e-63	Eosinophil percentage of granulocytes;
BRCA	trans	rs208520	0.837	rs208486	chr6:66926255	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.34	-0.54	2.18e-50	Exhaled nitric oxide output;
BRCA	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg12927641	chr6:109611667	NA	-0.36	-8.87	-0.33	7.54e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs7586879	0.789	rs13398155	chr2:25128550	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.47	0.35	5.47e-20	Body mass index;
BRCA	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.3e-23	Motion sickness;
BRCA	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg10560079	chr2:191398806	TMEM194B	-0.75	-12.92	-0.46	4.47e-34	Diastolic blood pressure;
BRCA	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18876405	chr7:65276391	NA	-0.51	-11.63	-0.42	1.67e-28	Aortic root size;
BRCA	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg01475377	chr6:109611718	NA	-0.6	-16.61	-0.55	8.83e-52	Reticulocyte fraction of red cells;
BRCA	cis	rs7395581	0.797	rs10838681	chr11:47275064	C/T	cg25783544	chr11:47291846	MADD	0.4	8.61	0.32	5.8e-17	HDL cholesterol;
BRCA	cis	rs9394841	0.667	rs3747749	chr6:41770604	G/A	cg08135965	chr6:41755394	TOMM6	0.5	8.13	0.31	2.18e-15	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg17691542	chr6:26056736	HIST1H1C	0.48	9.83	0.36	2.59e-21	Height;
BRCA	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg08213375	chr14:104286397	PPP1R13B	0.66	18.77	0.6	5.93e-63	Schizophrenia;
BRCA	cis	rs17253792	0.822	rs76201070	chr14:56063604	A/C	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs34779708	0.931	rs4934697	chr10:35287192	C/T	cg03585969	chr10:35415529	CREM	0.56	11.48	0.41	7.58e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg25019033	chr10:957182	NA	-0.41	-8.05	-0.3	3.98e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg08917208	chr2:24149416	ATAD2B	1.06	14.75	0.5	1.39e-42	Lymphocyte percentage of white cells;
BRCA	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11644478	chr21:40555479	PSMG1	0.82	18.31	0.59	1.59e-60	Cognitive function;
BRCA	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg15605315	chr1:45957053	TESK2	0.46	9.38	0.35	1.18e-19	High light scatter reticulocyte count;
BRCA	trans	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg15704280	chr7:45808275	SEPT13	0.55	8.22	0.31	1.18e-15	Axial length;
BRCA	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg04553112	chr3:125709451	NA	-0.54	-8.12	-0.31	2.34e-15	Blood pressure (smoking interaction);
BRCA	cis	rs13046373	0.508	rs2253516	chr21:31993317	C/T	cg16431978	chr21:31797932	KRTAP13-3	0.35	8.83	0.33	9.83e-18	HDL cholesterol;
BRCA	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg00750074	chr16:89608354	SPG7	-0.36	-9.56	-0.35	2.49e-20	Multiple myeloma (IgH translocation);
BRCA	cis	rs1018836	0.651	rs2339175	chr8:91565805	A/T	cg16814680	chr8:91681699	NA	-0.64	-14.14	-0.49	1.11e-39	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg08313168	chr12:7315531	NA	0.5	8.05	0.3	4.19e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg00409905	chr10:38381863	ZNF37A	-0.57	-12.44	-0.44	5.9e-32	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.49	0.38	7.52e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg18811423	chr2:55921094	PNPT1	0.78	27.65	0.74	2.65e-111	Metabolic syndrome;
BRCA	cis	rs1555322	0.530	rs932562	chr20:33871310	T/C	cg03689076	chr20:33865952	NA	0.44	8.01	0.3	5.51e-15	Attention deficit hyperactivity disorder;
BRCA	cis	rs312273	0.806	rs3794248	chr12:41359944	T/G	cg17827154	chr12:41323612	CNTN1	-0.41	-10.71	-0.39	9.77e-25	Bipolar disorder;
BRCA	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg22713356	chr15:30763199	NA	1.42	29.11	0.76	2.94e-119	Uric acid levels;
BRCA	cis	rs9807989	0.507	rs4851572	chr2:103019031	G/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.49	0.32	1.49e-16	Asthma;
BRCA	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg18225595	chr11:63971243	STIP1	0.49	8.4	0.32	2.84e-16	Mean platelet volume;
BRCA	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.14	0.4	1.77e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00149659	chr3:10157352	C3orf10	0.73	12.8	0.45	1.46e-33	Alzheimer's disease;
BRCA	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg27572855	chr1:25598939	RHD	0.47	13.35	0.47	4.68e-36	Plateletcrit;Mean corpuscular volume;
BRCA	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg03929089	chr4:120376271	NA	0.6	10.37	0.38	2.13e-23	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg14004847	chr7:1930337	MAD1L1	-0.46	-8.72	-0.33	2.41e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs7131987	0.650	rs11050187	chr12:29472876	T/C	cg09582351	chr12:29534625	ERGIC2	-0.46	-10.53	-0.38	5.29e-24	QT interval;
BRCA	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg25237894	chr2:233734115	C2orf82	0.39	11.23	0.41	7.83e-27	Coronary artery disease;
BRCA	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg03709012	chr19:19516395	GATAD2A	1.07	21.17	0.64	9.29e-76	Nonalcoholic fatty liver disease;
BRCA	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg03060546	chr3:49711283	APEH	-0.52	-10.87	-0.39	2.36e-25	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg24578937	chr1:2090814	PRKCZ	0.57	17.88	0.58	2.83e-58	Height;
BRCA	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg07741184	chr6:167504864	NA	0.31	9.13	0.34	9.05e-19	Primary biliary cholangitis;
BRCA	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg13010199	chr12:38710504	ALG10B	0.44	8.82	0.33	1.11e-17	Bladder cancer;
BRCA	cis	rs273218	1.000	rs156442	chr5:53373029	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.41	8.53	0.32	1.03e-16	Migraine;
BRCA	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg05552183	chr6:42928497	GNMT	0.71	16.16	0.54	1.74e-49	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg20607798	chr8:58055168	NA	0.55	8.61	0.32	5.84e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6772849	0.930	rs4857912	chr3:128329224	G/A	cg16766828	chr3:128327626	NA	-0.4	-8.93	-0.33	4.5e-18	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg06212747	chr3:49208901	KLHDC8B	0.44	8.94	0.33	4.3e-18	Parkinson's disease;
BRCA	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg06046430	chr4:77819534	ANKRD56	0.6	13.44	0.47	1.83e-36	Emphysema distribution in smoking;
BRCA	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-13.52	-0.47	8.57e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs17253792	0.822	rs28681420	chr14:56088403	G/T	cg01858014	chr14:56050164	KTN1	-0.76	-10.26	-0.38	5.65e-23	Putamen volume;
BRCA	cis	rs4766646	0.619	rs4766638	chr12:110298858	T/C	cg01252219	chr12:110302105	GLTP	0.36	8.08	0.3	3.16e-15	Metabolite levels (MHPG);
BRCA	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.92	0.4	1.43e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11083475	0.686	rs73040728	chr19:39257601	C/G	cg07905965	chr19:39260460	NA	0.48	11.23	0.41	7.5e-27	Heart rate;
BRCA	trans	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg26384229	chr12:38710491	ALG10B	-0.44	-10.99	-0.4	7.63e-26	Morning vs. evening chronotype;
BRCA	cis	rs11608355	0.515	rs11609630	chr12:109918934	C/T	cg05360138	chr12:110035743	NA	0.74	13.58	0.47	4.43e-37	Neuroticism;
BRCA	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg23711669	chr6:146136114	FBXO30	0.71	16.46	0.55	5.02e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg05283184	chr6:79620031	NA	-0.41	-10.43	-0.38	1.31e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs367615	0.918	rs10067984	chr5:108872684	C/T	cg17395555	chr5:108820864	NA	0.37	9.39	0.35	1.03e-19	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg24562669	chr7:97807699	LMTK2	0.45	11.93	0.43	9.3e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1371614	0.523	rs893789	chr2:27183970	C/T	cg00617064	chr2:27272375	NA	-0.31	-8.24	-0.31	1e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08564027	chr20:61660810	NA	0.84	22.72	0.67	3.32e-84	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11764359	chr7:65958608	NA	0.81	19.65	0.61	1.26e-67	Aortic root size;
BRCA	cis	rs897080	0.515	rs1067346	chr2:44618811	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	10.0	0.37	5.46e-22	Height;
BRCA	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg03060546	chr3:49711283	APEH	0.55	9.22	0.34	4.32e-19	Menarche (age at onset);
BRCA	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.9e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg12573674	chr2:1569213	NA	-0.45	-9.2	-0.34	5.21e-19	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7264396	0.887	rs224364	chr20:34063865	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-8.33	-0.31	4.97e-16	Total cholesterol levels;
BRCA	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg06115741	chr20:33292138	TP53INP2	0.49	9.84	0.36	2.25e-21	Coronary artery disease;
BRCA	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg04362960	chr10:104952993	NT5C2	0.44	9.92	0.37	1.15e-21	Arsenic metabolism;
BRCA	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.32	0.41	3.2e-27	Electroencephalogram traits;
BRCA	cis	rs7408868	1.000	rs4809029	chr19:15273248	A/C	cg14696996	chr19:15285081	NOTCH3	0.99	14.45	0.5	3.81e-41	Pulse pressure;
BRCA	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.39	2.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg18016565	chr1:150552671	MCL1	0.34	8.03	0.3	4.72e-15	Tonsillectomy;
BRCA	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-11.56	-0.42	3.45e-28	Neuroticism;
BRCA	trans	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg06521331	chr12:34319734	NA	-0.47	-8.83	-0.33	9.63e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg05313129	chr8:58192883	C8orf71	-0.46	-9.17	-0.34	6.37e-19	Developmental language disorder (linguistic errors);
BRCA	trans	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg17712092	chr4:129076599	LARP1B	-0.54	-12.54	-0.44	2.19e-32	Eosinophil percentage of white cells;
BRCA	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg18196295	chr10:418757	DIP2C	-0.37	-8.79	-0.33	1.35e-17	Psychosis in Alzheimer's disease;
BRCA	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg01475377	chr6:109611718	NA	-0.51	-12.94	-0.46	3.48e-34	Reticulocyte fraction of red cells;
BRCA	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg22834771	chr12:69754056	YEATS4	-0.42	-10.58	-0.39	3.25e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg12444411	chr7:2802554	GNA12	-0.38	-9.33	-0.35	1.67e-19	Height;
BRCA	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg01262667	chr19:19385393	TM6SF2	0.42	10.97	0.4	9.28e-26	Tonsillectomy;
BRCA	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.31	0.49	1.77e-40	Motion sickness;
BRCA	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg23202291	chr11:1979235	NA	0.41	9.34	0.35	1.56e-19	DNA methylation (parent-of-origin);DNA methylation (variation);
BRCA	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg00666640	chr1:248458726	OR2T12	0.32	8.77	0.33	1.63e-17	Common traits (Other);
BRCA	cis	rs9815354	1.000	rs3774372	chr3:41877414	A/G	cg03022575	chr3:42003672	ULK4	0.49	7.93	0.3	1e-14	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg08885076	chr2:99613938	TSGA10	-0.59	-12.91	-0.45	4.64e-34	Chronic sinus infection;
BRCA	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	14.08	0.49	2.12e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg24829409	chr8:58192753	C8orf71	-0.55	-11.53	-0.41	4.62e-28	Developmental language disorder (linguistic errors);
BRCA	cis	rs7394190	0.748	rs11000771	chr10:75524458	T/G	cg07699608	chr10:75541558	CHCHD1	0.61	9.37	0.35	1.19e-19	Incident atrial fibrillation;
BRCA	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg26116260	chr4:7069785	GRPEL1	-0.84	-17.21	-0.56	8.24e-55	Monocyte percentage of white cells;
BRCA	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-13.14	-0.46	4.59e-35	Lymphocyte counts;
BRCA	trans	rs459571	1.000	rs456207	chr9:136911140	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-14.63	-0.5	5.07e-42	Platelet distribution width;
BRCA	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	25.73	0.71	9.83e-101	Chronic sinus infection;
BRCA	cis	rs7598759	0.588	rs6737291	chr2:232329559	T/C	cg19187155	chr2:232395269	NMUR1	0.37	7.83	0.3	2.07e-14	Noise-induced hearing loss;
BRCA	cis	rs9341808	0.644	rs76102095	chr6:80942026	G/C	cg08355045	chr6:80787529	NA	-0.32	-7.85	-0.3	1.72e-14	Sitting height ratio;
BRCA	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg03709012	chr19:19516395	GATAD2A	0.81	18.91	0.6	1.2e-63	Tonsillectomy;
BRCA	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	11.68	0.42	1.03e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg09367891	chr1:107599246	PRMT6	-0.55	-10.09	-0.37	2.67e-22	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg26874164	chr19:58962979	ZNF324B	0.44	9.34	0.35	1.61e-19	Uric acid clearance;
BRCA	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	1.01e-40	Motion sickness;
BRCA	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg24692254	chr21:30365293	RNF160	0.61	15.44	0.52	6.02e-46	Dental caries;
BRCA	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg11764359	chr7:65958608	NA	-0.67	-14.98	-0.51	1.07e-43	Aortic root size;
BRCA	cis	rs737008	0.959	rs11865598	chr16:11403432	T/C	cg00044050	chr16:11439710	C16orf75	0.38	8.31	0.31	5.86e-16	Obesity-related traits;
BRCA	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	30.03	0.77	3.03e-124	Cognitive ability;
BRCA	cis	rs13064411	0.735	rs6778800	chr3:113149236	A/G	cg18753928	chr3:113234510	CCDC52	-0.43	-8.51	-0.32	1.2e-16	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs2882667	0.537	rs7701116	chr5:138406078	C/T	cg04439458	chr5:138467593	SIL1	-0.32	-8.77	-0.33	1.56e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg25036284	chr2:26402008	FAM59B	-0.96	-16.14	-0.54	2.09e-49	Gut microbiome composition (summer);
BRCA	cis	rs3784262	0.669	rs12148281	chr15:58311061	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.27	-0.38	5.18e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg06212747	chr3:49208901	KLHDC8B	0.51	8.0	0.3	5.96e-15	Menarche (age at onset);
BRCA	cis	rs7520050	0.966	rs6677007	chr1:46400590	A/G	cg24296786	chr1:45957014	TESK2	0.44	9.87	0.36	1.74e-21	Red blood cell count;Reticulocyte count;
BRCA	trans	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.64	-0.32	4.54e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13012494	chr21:47604986	C21orf56	0.45	9.42	0.35	7.84e-20	Testicular germ cell tumor;
BRCA	cis	rs12541635	0.739	rs1896915	chr8:107083520	G/T	cg10147462	chr8:107024639	NA	0.32	8.71	0.33	2.65e-17	Age of smoking initiation;
BRCA	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03264133	chr6:25882463	NA	0.41	8.64	0.32	4.45e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg11502198	chr6:26597334	ABT1	0.56	12.07	0.43	2.29e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg24069376	chr3:38537580	EXOG	-0.32	-8.98	-0.33	3.1e-18	Electrocardiographic conduction measures;
BRCA	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg00958927	chr1:175162553	KIAA0040	-0.21	-7.85	-0.3	1.71e-14	Alcohol dependence;
BRCA	trans	rs2018683	0.707	rs2391718	chr7:28974988	T/C	cg19402173	chr7:128379420	CALU	-0.42	-10.07	-0.37	3.07e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.02	0.48	4.01e-39	Motion sickness;
BRCA	cis	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.42	-0.32	2.51e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg15997130	chr1:24165203	NA	0.49	13.05	0.46	1.11e-34	Immature fraction of reticulocytes;
BRCA	cis	rs7633770	0.786	rs9845998	chr3:46683710	G/A	cg11219411	chr3:46661640	NA	0.65	16.96	0.56	1.59e-53	Coronary artery disease;
BRCA	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg19622623	chr12:86230825	RASSF9	-0.33	-9.27	-0.34	2.75e-19	Major depressive disorder;
BRCA	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-45.93	-0.88	1.27e-204	Myeloid white cell count;
BRCA	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.19	-22.4	-0.66	1.76e-82	Platelet count;
BRCA	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg24596788	chr1:163392923	NA	-0.35	-9.29	-0.34	2.37e-19	Motion sickness;
BRCA	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg24069376	chr3:38537580	EXOG	0.34	9.37	0.35	1.26e-19	Electrocardiographic conduction measures;
BRCA	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg06115741	chr20:33292138	TP53INP2	-0.38	-8.4	-0.32	2.8e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	17.27	0.56	3.83e-55	Alzheimer's disease;
BRCA	cis	rs220324	0.688	rs2012103	chr21:43561369	A/G	cg09727148	chr21:43560719	UMODL1	0.5	8.77	0.33	1.61e-17	Idiopathic osteonecrosis of the femoral head;
BRCA	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Tonsillectomy;
BRCA	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	9.95	0.37	8.78e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg06115741	chr20:33292138	TP53INP2	0.39	8.65	0.32	4.14e-17	Coronary artery disease;
BRCA	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg08470875	chr2:26401718	FAM59B	-0.5	-8.11	-0.31	2.57e-15	Gut microbiome composition (summer);
BRCA	cis	rs36051895	0.603	rs10974972	chr9:5130146	G/A	cg02405213	chr9:5042618	JAK2	-0.44	-8.29	-0.31	6.58e-16	Pediatric autoimmune diseases;
BRCA	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg24006582	chr15:45444508	DUOX1	-0.55	-11.33	-0.41	3.01e-27	Uric acid levels;
BRCA	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg27129171	chr3:47204927	SETD2	0.73	17.74	0.57	1.4e-57	Colorectal cancer;
BRCA	cis	rs6700896	0.864	rs12030956	chr1:66115298	G/T	cg04111102	chr1:66153794	NA	0.34	8.42	0.32	2.57e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs6546550	0.901	rs4852375	chr2:70125988	C/G	cg02498382	chr2:70120550	SNRNP27	-0.54	-11.63	-0.42	1.7e-28	Prevalent atrial fibrillation;
BRCA	cis	rs12612619	0.732	rs12613822	chr2:27217102	A/T	cg00617064	chr2:27272375	NA	-0.33	-8.55	-0.32	9.29e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg05623727	chr3:50126028	RBM5	0.46	10.82	0.39	3.77e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs2599510	0.811	rs2583713	chr2:32822729	A/G	cg02381751	chr2:32503542	YIPF4	0.42	8.13	0.31	2.17e-15	Interleukin-18 levels;
BRCA	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.2e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.74e-18	Motion sickness;
BRCA	cis	rs36051895	0.659	rs10121491	chr9:5046935	T/C	cg02405213	chr9:5042618	JAK2	-0.5	-9.5	-0.35	4e-20	Pediatric autoimmune diseases;
BRCA	cis	rs4919694	1.000	rs76255497	chr10:104651955	T/C	cg04362960	chr10:104952993	NT5C2	0.9	14.59	0.5	8.3e-42	Arsenic metabolism;
BRCA	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.75	0.62	3.7e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs10499694	0.967	rs11765748	chr7:50615616	T/A	cg18232548	chr7:50535776	DDC	-0.37	-8.97	-0.33	3.3e-18	Body mass index;
BRCA	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg12591125	chr7:1885375	MAD1L1	0.43	8.7	0.33	2.76e-17	Bipolar disorder;
BRCA	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18876405	chr7:65276391	NA	0.5	11.2	0.4	1.09e-26	Aortic root size;
BRCA	cis	rs4363385	0.693	rs576941	chr1:153040165	A/G	cg25856811	chr1:152973957	SPRR3	0.32	8.25	0.31	9.28e-16	Inflammatory skin disease;
BRCA	trans	rs8002861	0.754	rs4053664	chr13:44429172	A/C	cg17145862	chr1:211918768	LPGAT1	0.63	16.18	0.54	1.32e-49	Leprosy;
BRCA	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg23711669	chr6:146136114	FBXO30	-0.77	-17.91	-0.58	1.88e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg06609049	chr19:2785107	THOP1	0.57	11.89	0.43	1.39e-29	Total cholesterol levels;
BRCA	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.52	-0.32	1.15e-16	Monocyte percentage of white cells;
BRCA	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-10.59	-0.39	3.03e-24	Gut microbiome composition (summer);
BRCA	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg19418458	chr7:158789849	NA	-0.44	-9.87	-0.36	1.8e-21	Facial morphology (factor 20);
BRCA	cis	rs1499972	0.941	rs56310214	chr3:117640127	G/A	cg07612923	chr3:117604196	NA	0.6	8.1	0.31	2.82e-15	Schizophrenia;
BRCA	cis	rs6545883	0.894	rs10496092	chr2:61524679	C/T	cg15711740	chr2:61764176	XPO1	0.49	11.81	0.42	2.98e-29	Tuberculosis;
BRCA	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg03676636	chr4:99064102	C4orf37	0.24	8.33	0.31	4.76e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg23711669	chr6:146136114	FBXO30	0.66	13.45	0.47	1.76e-36	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.94	0.33	4.25e-18	Iron status biomarkers;
BRCA	cis	rs6942756	1.000	rs1473236	chr7:128880831	G/T	cg02491457	chr7:128862824	NA	-0.72	-14.66	-0.5	3.51e-42	White matter hyperintensity burden;
BRCA	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.87	0.4	2.18e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg15017067	chr4:17643749	FAM184B	0.34	10.36	0.38	2.37e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18402987	chr7:1209562	NA	0.55	10.82	0.39	3.77e-25	Longevity;Endometriosis;
BRCA	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-9.52	-0.35	3.52e-20	Aortic root size;
BRCA	cis	rs2637266	0.967	rs4979898	chr10:78355672	G/A	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	cis	rs6546550	0.867	rs1048266	chr2:70132676	A/G	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.62	-0.42	1.93e-28	Prevalent atrial fibrillation;
BRCA	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4566357	0.615	rs12328878	chr2:227918962	G/A	cg05526886	chr2:227700861	RHBDD1	-0.4	-8.07	-0.3	3.48e-15	Coronary artery disease;
BRCA	cis	rs1967309	0.625	rs730242	chr16:4070433	C/T	cg00061520	chr16:4070371	ADCY9	0.34	8.03	0.3	4.58e-15	Response to Dalcetrapib treatment in acute coronary syndrome;
BRCA	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg23950597	chr19:37808831	NA	-0.62	-11.46	-0.41	8.48e-28	Coronary artery calcification;
BRCA	cis	rs27434	0.605	rs39840	chr5:96120054	G/C	cg16492584	chr5:96139282	ERAP1	-0.4	-8.15	-0.31	1.98e-15	Ankylosing spondylitis;
BRCA	trans	rs7944735	0.517	rs12274550	chr11:48196752	C/A	cg03929089	chr4:120376271	NA	0.51	7.85	0.3	1.75e-14	Intraocular pressure;
BRCA	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg09021430	chr5:549028	NA	-0.65	-13.67	-0.48	1.7e-37	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22307029	chr19:49891270	CCDC155	0.52	8.9	0.33	5.86e-18	Multiple sclerosis;
BRCA	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg12311346	chr5:56204834	C5orf35	1.01	20.1	0.62	5.35e-70	Initial pursuit acceleration;
BRCA	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg25358565	chr5:93447407	FAM172A	0.7	11.94	0.43	8.08e-30	Diabetic retinopathy;
BRCA	cis	rs1577917	1.000	rs2812972	chr6:86669880	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-11.29	-0.41	4.5e-27	Response to antipsychotic treatment;
BRCA	cis	rs4919694	0.572	rs12261294	chr10:104934952	C/T	cg04362960	chr10:104952993	NT5C2	0.71	12.33	0.44	1.66e-31	Arsenic metabolism;
BRCA	cis	rs2625529	0.730	rs12912771	chr15:72162928	A/T	cg16672083	chr15:72433130	SENP8	-0.66	-15.52	-0.52	2.61e-46	Red blood cell count;
BRCA	cis	rs7918232	0.567	rs11015463	chr10:27319258	A/G	cg14442939	chr10:27389572	ANKRD26	0.46	8.43	0.32	2.38e-16	Breast cancer;
BRCA	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.39	-8.77	-0.33	1.55e-17	Colorectal cancer;
BRCA	cis	rs1568889	0.838	rs11030229	chr11:28173634	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.53	0.63	2.42e-72	Bipolar disorder;
BRCA	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg09537434	chr19:41945824	ATP5SL	-1.01	-24.95	-0.7	1.78e-96	Height;
BRCA	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.54e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg06238570	chr21:40685208	BRWD1	-0.41	-8.21	-0.31	1.25e-15	Menarche (age at onset);
BRCA	cis	rs2637266	1.000	rs12774835	chr10:78352226	C/G	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	cis	rs7254114	0.578	rs3745682	chr19:11313256	C/T	cg02815516	chr19:11306319	KANK2	-0.35	-9.82	-0.36	2.62e-21	Immature fraction of reticulocytes;
BRCA	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg06784218	chr1:46089804	CCDC17	-0.53	-12.92	-0.46	4.13e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg05340658	chr4:99064831	C4orf37	-0.43	-9.85	-0.36	2.09e-21	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.61	11.36	0.41	2.22e-27	Type 2 diabetes;
BRCA	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	8.21	0.31	1.22e-15	Uric acid levels;
BRCA	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg14675211	chr2:100938903	LONRF2	0.52	11.97	0.43	6.47e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg08645402	chr16:4508243	NA	0.4	9.88	0.36	1.59e-21	Schizophrenia;
BRCA	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-12.73	-0.45	3.01e-33	Chronic sinus infection;
BRCA	cis	rs6540556	0.723	rs11487867	chr1:209892070	G/T	cg05527609	chr1:210001259	C1orf107	-0.52	-8.72	-0.33	2.39e-17	Red blood cell count;
BRCA	trans	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg23762105	chr12:34175262	ALG10	0.39	9.59	0.35	1.8899999999999998e-20	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.84	-0.33	9.56e-18	Total body bone mineral density;
BRCA	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg07169764	chr2:136633963	MCM6	0.71	14.6	0.5	7.22e-42	Mosquito bite size;
BRCA	cis	rs6580649	0.941	rs7310579	chr12:48427523	G/A	cg05342945	chr12:48394962	COL2A1	0.41	7.95	0.3	8.57e-15	Lung cancer;
BRCA	trans	rs11088226	0.681	rs2833901	chr21:33939318	T/C	cg09050820	chr6:167586206	TCP10L2	0.76	13.22	0.46	1.86e-35	Gastritis;
BRCA	cis	rs6060717	0.536	rs6060669	chr20:34480557	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-7.88	-0.3	1.37e-14	Hip circumference adjusted for BMI;
BRCA	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg01420254	chr6:26195488	NA	0.54	8.57	0.32	7.84e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-10.39	-0.38	1.77e-23	Resting heart rate;
BRCA	cis	rs17818399	0.502	rs1451152	chr2:46800150	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.48	9.87	0.36	1.7e-21	Height;
BRCA	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg18129178	chr5:148520854	ABLIM3	-0.59	-11.71	-0.42	8.16e-29	Breast cancer;
BRCA	trans	rs9784649	1.000	rs1493479	chr5:24987768	A/G	cg08600765	chr20:34638493	LOC647979	-0.52	-8.87	-0.33	7.45e-18	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg08085267	chr17:45401833	C17orf57	0.67	14.93	0.51	1.88e-43	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg12219531	chr12:120966889	COQ5	0.55	11.43	0.41	1.22e-27	High light scatter reticulocyte count;
BRCA	cis	rs2652822	0.525	rs1910094	chr15:63485527	G/C	cg02713581	chr15:63449717	RPS27L	0.42	8.42	0.32	2.53e-16	Metabolic traits;
BRCA	cis	rs57590327	0.503	rs13073613	chr3:81888512	C/A	cg07356753	chr3:81810745	GBE1	-0.43	-9.99	-0.37	6.18e-22	Extraversion;
BRCA	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg18230493	chr5:56204884	C5orf35	-0.62	-13.37	-0.47	4.03e-36	Initial pursuit acceleration;
BRCA	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg25174290	chr11:3078921	CARS	0.47	14.62	0.5	5.62e-42	Longevity;
BRCA	cis	rs7172677	1.000	rs8032261	chr15:75424012	A/T	cg14664628	chr15:75095509	CSK	-0.39	-8.14	-0.31	2.09e-15	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg11189052	chr15:85197271	WDR73	-0.35	-8.31	-0.31	5.72e-16	P wave terminal force;
BRCA	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg15556689	chr8:8085844	FLJ10661	0.37	8.72	0.33	2.33e-17	Retinal vascular caliber;
BRCA	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	9.29	0.34	2.48e-19	Rheumatoid arthritis;
BRCA	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.35	-0.31	4.1e-16	Total body bone mineral density;
BRCA	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg00071950	chr4:10020882	SLC2A9	0.57	13.99	0.48	5.71e-39	Bone mineral density;
BRCA	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg06885757	chr1:42089581	HIVEP3	0.29	10.49	0.38	7.65e-24	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg19628046	chr18:33552617	C18orf21	0.54	10.1	0.37	2.28e-22	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs7147624	0.938	rs10467734	chr14:65913947	C/T	cg03016385	chr14:66212404	NA	-0.57	-8.53	-0.32	1.06e-16	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.48	-10.82	-0.39	3.53e-25	Bipolar disorder;
BRCA	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.67	11.47	0.41	8.17e-28	Renal function-related traits (BUN);
BRCA	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg19729930	chr2:74357872	NA	0.59	14.54	0.5	1.44e-41	Gestational age at birth (maternal effect);
BRCA	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg03146154	chr1:46216737	IPP	-0.49	-10.8	-0.39	4.43e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg22764044	chr5:178986830	RUFY1	0.37	8.56	0.32	8.69e-17	Lung cancer;
BRCA	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.69	0.39	1.24e-24	IgG glycosylation;
BRCA	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg19717773	chr7:2847554	GNA12	-0.43	-9.56	-0.35	2.54e-20	Height;
BRCA	cis	rs7809950	0.530	rs34021916	chr7:106817901	A/G	cg23024343	chr7:107201750	COG5	-0.42	-8.6	-0.32	6.12e-17	Coronary artery disease;
BRCA	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.96	14.0	0.48	4.96e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg03433033	chr1:76189801	ACADM	0.64	12.33	0.44	1.77e-31	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2320614	0.967	rs11938737	chr4:164045391	G/C	cg15586945	chr4:164088095	NAF1	-0.41	-8.16	-0.31	1.72e-15	Lung adenocarcinoma;
BRCA	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg06636001	chr8:8085503	FLJ10661	-0.39	-8.22	-0.31	1.16e-15	Neuroticism;
BRCA	cis	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg07460842	chr6:66804631	NA	0.88	14.23	0.49	4.1e-40	Exhaled nitric oxide output;
BRCA	trans	rs1325195	0.507	rs10798652	chr1:179061427	A/G	cg11624085	chr17:8464688	MYH10	0.28	8.67	0.32	3.42e-17	IgE grass sensitization;
BRCA	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg19077165	chr18:44547161	KATNAL2	0.58	12.93	0.46	3.86e-34	Personality dimensions;
BRCA	cis	rs6433895	0.710	rs7581267	chr2:182008301	T/C	cg00481216	chr2:181971175	NA	0.45	8.2	0.31	1.32e-15	Lymphocyte counts;
BRCA	cis	rs9462027	0.583	rs9462022	chr6:34761684	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.88	-0.3	1.44e-14	Systemic lupus erythematosus;
BRCA	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.96	-0.3	7.72e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7178424	0.875	rs1436966	chr15:62358682	A/G	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.59	-0.32	6.75e-17	Height;
BRCA	cis	rs7633770	0.805	rs11130098	chr3:46661926	A/G	cg11219411	chr3:46661640	NA	-0.7	-20.15	-0.62	2.91e-70	Coronary artery disease;
BRCA	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg05347473	chr6:146136440	FBXO30	0.6	11.22	0.41	8.77e-27	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2066819	1.000	rs79750959	chr12:56702012	C/A	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg02551604	chr5:131831745	NA	-0.32	-11.63	-0.42	1.65e-28	Breast cancer;Mosquito bite size;
BRCA	cis	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg06521331	chr12:34319734	NA	-0.62	-11.07	-0.4	3.39e-26	Morning vs. evening chronotype;
BRCA	cis	rs3772130	1.000	rs62268732	chr3:121370455	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	9.4	0.35	9.71e-20	Cognitive performance;
BRCA	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg02733842	chr7:1102375	C7orf50	-0.63	-11.54	-0.42	4.23e-28	Bronchopulmonary dysplasia;
BRCA	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg12463550	chr7:65579703	CRCP	-0.36	-7.83	-0.3	2.06e-14	Aortic root size;
BRCA	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg08847533	chr14:75593920	NEK9	-0.8	-19.87	-0.62	9.38e-69	Height;
BRCA	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg10523679	chr1:76189770	ACADM	-0.42	-7.93	-0.3	9.99e-15	Daytime sleep phenotypes;
BRCA	cis	rs61990749	0.597	rs2364584	chr14:78152286	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.64	-10.17	-0.37	1.27e-22	Fibroblast growth factor basic levels;
BRCA	trans	rs1459104	0.929	rs12794656	chr11:55289878	G/A	cg15704280	chr7:45808275	SEPT13	0.64	8.1	0.31	2.84e-15	Body mass index;
BRCA	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-32.47	-0.79	2.47e-137	Height;
BRCA	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	14.07	0.49	2.2e-39	Lymphocyte counts;
BRCA	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23221052	chr5:179740743	GFPT2	-0.62	-12.83	-0.45	1.06e-33	Height;
BRCA	cis	rs6973256	0.865	rs2483509	chr7:133341162	G/A	cg07491979	chr7:133331646	EXOC4	-0.39	-8.98	-0.33	2.92e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg12661370	chr5:149340060	SLC26A2	-0.56	-9.67	-0.36	9.73e-21	HIV-1 control;
BRCA	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg26384229	chr12:38710491	ALG10B	0.67	13.91	0.48	1.34e-38	Morning vs. evening chronotype;
BRCA	cis	rs72781680	0.665	rs2953028	chr2:24068126	T/C	cg08917208	chr2:24149416	ATAD2B	0.6	10.29	0.38	4.31e-23	Lymphocyte counts;
BRCA	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg26587870	chr6:27730563	NA	-0.52	-7.98	-0.3	6.65e-15	Depression;
BRCA	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg13010199	chr12:38710504	ALG10B	0.51	10.07	0.37	2.99e-22	Bladder cancer;
BRCA	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg01262667	chr19:19385393	TM6SF2	0.39	7.95	0.3	8.56e-15	Nonalcoholic fatty liver disease;
BRCA	cis	rs6429082	0.634	rs3856245	chr1:235571428	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.53	-12.14	-0.43	1.15e-30	Adiposity;
BRCA	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg00631329	chr6:26305371	NA	-0.55	-15.65	-0.53	5.64e-47	Educational attainment;
BRCA	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg01262667	chr19:19385393	TM6SF2	0.4	10.4	0.38	1.6e-23	Tonsillectomy;
BRCA	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg03929089	chr4:120376271	NA	0.66	12.81	0.45	1.29e-33	Height;
BRCA	cis	rs7572733	0.555	rs6729473	chr2:198763928	G/A	cg00792783	chr2:198669748	PLCL1	0.48	10.31	0.38	3.72e-23	Dermatomyositis;
BRCA	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg15017067	chr4:17643749	FAM184B	0.26	7.81	0.3	2.42e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs12517041	1.000	rs6452110	chr5:23299802	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	trans	rs9951602	0.512	rs7240758	chr18:76650677	T/C	cg02800362	chr5:177631904	HNRNPAB	0.77	18.01	0.58	5.8e-59	Obesity-related traits;
BRCA	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg06627628	chr2:24431161	ITSN2	0.63	12.23	0.44	4.5e-31	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs2625529	0.590	rs713048	chr15:72543084	G/A	cg16672083	chr15:72433130	SENP8	-0.73	-15.64	-0.53	6.2e-47	Red blood cell count;
BRCA	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.34	-9.75	-0.36	4.77e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg04586622	chr2:25135609	ADCY3	0.41	10.4	0.38	1.69e-23	Body mass index;
BRCA	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg07537917	chr2:241836409	C2orf54	-0.49	-11.74	-0.42	5.67e-29	Urinary metabolites;
BRCA	cis	rs7633770	0.805	rs11710264	chr3:46661579	T/C	cg11219411	chr3:46661640	NA	0.72	21.1	0.64	2.01e-75	Coronary artery disease;
BRCA	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg13628971	chr7:2884303	GNA12	0.4	9.12	0.34	9.5e-19	Height;
BRCA	cis	rs1568889	1.000	rs12794100	chr11:28332785	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	13.09	0.46	7.38e-35	Bipolar disorder;
BRCA	cis	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg00576331	chr11:65640516	EFEMP2	0.42	9.35	0.35	1.47e-19	DNA methylation (variation);
BRCA	cis	rs131805	1.000	rs3091397	chr22:50957520	C/T	cg05418105	chr22:50981406	NA	-0.48	-8.76	-0.33	1.74e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	10.47	0.38	8.92e-24	Rheumatoid arthritis;
BRCA	cis	rs7246657	0.722	rs4802051	chr19:38072328	C/A	cg18154014	chr19:37997991	ZNF793	0.49	9.24	0.34	3.49e-19	Coronary artery calcification;
BRCA	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg03929089	chr4:120376271	NA	-0.48	-9.1	-0.34	1.18e-18	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7395581	0.918	rs7120957	chr11:47340649	A/G	cg25783544	chr11:47291846	MADD	0.42	9.52	0.35	3.45e-20	HDL cholesterol;
BRCA	trans	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.19	0.31	1.47e-15	Corneal astigmatism;
BRCA	cis	rs4074536	0.574	rs10801971	chr1:116291201	A/G	cg21648376	chr1:116311395	CASQ2	-0.49	-8.68	-0.32	3.19e-17	QRS duration;
BRCA	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg18131467	chr2:239335373	ASB1	0.81	20.97	0.64	1.12e-74	Multiple system atrophy;
BRCA	trans	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg23762105	chr12:34175262	ALG10	0.34	7.92	0.3	1.09e-14	Morning vs. evening chronotype;
BRCA	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg22875332	chr1:76189707	ACADM	0.63	11.05	0.4	4.2e-26	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-9.97	-0.37	7.34e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg25019033	chr10:957182	NA	-0.42	-8.8	-0.33	1.27e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg20607287	chr7:12443886	VWDE	-0.56	-7.89	-0.3	1.3e-14	Coronary artery disease;
BRCA	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg01324343	chr3:183735012	ABCC5	0.82	20.45	0.63	7.08e-72	Anterior chamber depth;
BRCA	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg00277334	chr10:82204260	NA	-0.84	-24.27	-0.69	1.06e-92	Post bronchodilator FEV1;
BRCA	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg21385522	chr1:16154831	NA	-0.48	-10.08	-0.37	2.74e-22	Systolic blood pressure;
BRCA	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg27398817	chr8:82754497	SNX16	-0.35	-8.05	-0.3	4.1e-15	Diastolic blood pressure;
BRCA	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg18232548	chr7:50535776	DDC	-0.52	-13.28	-0.47	1e-35	Systemic sclerosis;
BRCA	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.67	14.3	0.49	1.81e-40	Lymphocyte counts;
BRCA	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg08470875	chr2:26401718	FAM59B	0.76	12.06	0.43	2.68e-30	Gut microbiome composition (summer);
BRCA	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg09658497	chr7:2847517	GNA12	-0.41	-8.62	-0.32	5.23e-17	Height;
BRCA	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg17971929	chr21:40555470	PSMG1	0.75	15.58	0.52	1.22e-46	Cognitive function;
BRCA	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg16325326	chr1:53192061	ZYG11B	0.69	17.45	0.57	4.78e-56	Monocyte count;
BRCA	cis	rs2625529	0.689	rs12898728	chr15:72112853	C/T	cg16672083	chr15:72433130	SENP8	-0.64	-15.0	-0.51	8.31e-44	Red blood cell count;
BRCA	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.09	-40.2	-0.85	4.12e-177	Myeloid white cell count;
BRCA	cis	rs2992756	0.663	rs12750779	chr1:18805048	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.39	-7.95	-0.3	8.77e-15	Breast cancer;
BRCA	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11644478	chr21:40555479	PSMG1	-0.54	-11.54	-0.42	3.91e-28	Menarche (age at onset);
BRCA	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg24642439	chr20:33292090	TP53INP2	0.73	16.56	0.55	1.59e-51	Coronary artery disease;
BRCA	cis	rs68170813	0.599	rs12532849	chr7:106959226	A/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.64	-0.32	4.37e-17	Coronary artery disease;
BRCA	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	13.98	0.48	5.88e-39	Eosinophil percentage of white cells;
BRCA	trans	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.41	0.32	2.73e-16	Mean corpuscular volume;
BRCA	cis	rs7617773	0.743	rs71323397	chr3:48374874	A/G	cg11946769	chr3:48343235	NME6	0.67	13.43	0.47	2.05e-36	Coronary artery disease;
BRCA	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg17143192	chr8:8559678	CLDN23	0.54	10.38	0.38	1.9e-23	Obesity-related traits;
BRCA	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg01475377	chr6:109611718	NA	-0.57	-15.39	-0.52	1.07e-45	Reticulocyte fraction of red cells;
BRCA	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-11.22	-0.41	8.71e-27	Colorectal cancer;
BRCA	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18404041	chr3:52824283	ITIH1	-0.39	-11.88	-0.43	1.43e-29	Electroencephalogram traits;
BRCA	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg22974920	chr21:40686053	BRWD1	-0.36	-8.14	-0.31	2.1e-15	Menarche (age at onset);
BRCA	cis	rs12493885	0.818	rs62276828	chr3:153775941	C/T	cg17054900	chr3:154042577	DHX36	-0.5	-8.65	-0.32	4.07e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg26031613	chr14:104095156	KLC1	0.61	13.19	0.46	2.62e-35	Body mass index;
BRCA	cis	rs6942756	0.659	rs624118	chr7:129096653	C/T	cg02491457	chr7:128862824	NA	-0.55	-11.39	-0.41	1.76e-27	White matter hyperintensity burden;
BRCA	cis	rs6426558	0.515	rs7521110	chr1:227384459	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.47	-9.36	-0.35	1.36e-19	Neutrophil percentage of white cells;
BRCA	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg23711669	chr6:146136114	FBXO30	-0.79	-18.77	-0.6	6.03e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg26031613	chr14:104095156	KLC1	-0.46	-8.96	-0.33	3.46e-18	Schizophrenia;
BRCA	cis	rs2625529	0.689	rs2957742	chr15:72302894	C/G	cg16672083	chr15:72433130	SENP8	0.66	15.63	0.53	7.1e-47	Red blood cell count;
BRCA	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.21	0.34	4.65e-19	Tonsillectomy;
BRCA	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg26597838	chr10:835615	NA	1.01	17.82	0.58	5.87e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg25237894	chr2:233734115	C2orf82	-0.41	-11.84	-0.42	2.14e-29	Coronary artery disease;
BRCA	cis	rs4780401	0.609	rs7205994	chr16:11815964	C/T	cg01061890	chr16:11836724	TXNDC11	-0.57	-13.38	-0.47	3.53e-36	Rheumatoid arthritis;
BRCA	cis	rs6973256	0.897	rs2909224	chr7:133331041	C/G	cg07491979	chr7:133331646	EXOC4	-0.39	-8.8	-0.33	1.22e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg17691542	chr6:26056736	HIST1H1C	0.4	8.51	0.32	1.21e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs10242455	0.702	rs112475236	chr7:99044679	A/G	cg09045935	chr12:6379348	NA	0.88	9.02	0.34	2.23e-18	Blood metabolite levels;
BRCA	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.1	-0.43	1.71e-30	Response to antipsychotic treatment;
BRCA	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg13010199	chr12:38710504	ALG10B	0.51	10.24	0.38	6.86e-23	Heart rate;
BRCA	cis	rs62380364	0.602	rs448809	chr5:88005828	G/T	cg22951263	chr5:87985283	NA	-0.39	-10.77	-0.39	5.88e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.96	0.3	7.96e-15	Depression;
BRCA	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg12863693	chr15:85201151	NMB	-0.33	-7.9	-0.3	1.26e-14	P wave terminal force;
BRCA	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02475777	chr4:1388615	CRIPAK	0.67	13.14	0.46	4.55e-35	Longevity;
BRCA	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg12573674	chr2:1569213	NA	-0.64	-14.4	-0.49	6.47e-41	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	cis	rs586533	0.881	rs656031	chr11:99502178	G/T	cg22878054	chr11:99397252	CNTN5	0.32	8.12	0.31	2.47e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg24296786	chr1:45957014	TESK2	-0.53	-12.27	-0.44	3.09e-31	High light scatter reticulocyte count;
BRCA	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg03676636	chr4:99064102	C4orf37	0.2	7.87	0.3	1.5e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.7	16.29	0.54	3.74e-50	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.93	-0.33	4.63e-18	Alzheimer's disease (late onset);
BRCA	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg25486957	chr4:152246857	NA	-0.36	-7.9	-0.3	1.26e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg16606324	chr3:10149918	C3orf24	0.56	11.01	0.4	5.91e-26	Alzheimer's disease;
BRCA	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-10.28	-0.38	4.63e-23	Schizophrenia;
BRCA	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.75	-0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs1371614	0.611	rs3910615	chr2:27131022	A/G	cg12368169	chr2:27073192	DPYSL5	-0.29	-8.63	-0.32	5.05e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs6542838	0.641	rs883773	chr2:99491635	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-8.98	-0.33	3.13e-18	Fear of minor pain;
BRCA	cis	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg04990556	chr1:26633338	UBXN11	0.54	8.86	0.33	8.17e-18	Obesity-related traits;
BRCA	cis	rs6435161	1.000	rs72927001	chr2:203530332	T/C	cg18429434	chr2:203499731	FAM117B	-0.45	-8.91	-0.33	5.44e-18	Total cholesterol levels;
BRCA	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11764359	chr7:65958608	NA	-0.76	-17.47	-0.57	3.7e-56	Aortic root size;
BRCA	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg02038168	chr22:39784481	NA	0.42	8.68	0.32	3.32e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg14683738	chr19:37701593	ZNF585B	0.44	7.89	0.3	1.3e-14	Coronary artery calcification;
BRCA	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.06	-0.34	1.62e-18	Total body bone mineral density;
BRCA	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11644478	chr21:40555479	PSMG1	-0.51	-10.83	-0.39	3.18e-25	Menarche (age at onset);
BRCA	cis	rs10128251	0.962	rs4748018	chr10:5711507	T/A	cg24097872	chr10:5724021	NA	0.51	11.08	0.4	3.12e-26	Childhood ear infection;
BRCA	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.28	0.49	2.49e-40	Motion sickness;
BRCA	cis	rs9790314	0.605	rs2593812	chr3:160703069	T/G	cg03342759	chr3:160939853	NMD3	0.46	8.82	0.33	1.11e-17	Morning vs. evening chronotype;
BRCA	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg21573476	chr21:45109991	RRP1B	-0.36	-9.35	-0.35	1.5e-19	Mean corpuscular volume;
BRCA	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.28	0.31	6.96e-16	Aortic root size;
BRCA	cis	rs1468333	1.000	rs2906124	chr5:137528835	A/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.43	9.12	0.34	9.58e-19	Resting heart rate;
BRCA	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	18.65	0.59	2.59e-62	Platelet count;
BRCA	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg04455712	chr21:45112962	RRP1B	0.4	10.08	0.37	2.76e-22	Mean corpuscular volume;
BRCA	cis	rs12986413	0.624	rs12460763	chr19:2138507	A/G	cg09261902	chr19:2140048	AP3D1	0.41	10.83	0.39	3.17e-25	Height;
BRCA	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg20607798	chr8:58055168	NA	0.6	9.1	0.34	1.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs11229555	0.574	rs12271501	chr11:58214969	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.64	-0.36	1.27e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-13.83	-0.48	3.01e-38	Morning vs. evening chronotype;
BRCA	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13012494	chr21:47604986	C21orf56	-0.44	-8.72	-0.33	2.41e-17	Testicular germ cell tumor;
BRCA	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg21138405	chr5:131827807	IRF1	-0.37	-12.09	-0.43	1.94e-30	Asthma (sex interaction);
BRCA	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg09877947	chr5:131593287	PDLIM4	0.39	9.91	0.36	1.26e-21	Breast cancer;
BRCA	cis	rs4566357	0.595	rs10206912	chr2:227921095	A/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-9.75	-0.36	4.97e-21	Coronary artery disease;
BRCA	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg08000102	chr2:233561755	GIGYF2	-0.61	-13.4	-0.47	2.83e-36	Coronary artery disease;
BRCA	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg27170947	chr2:26402098	FAM59B	0.64	10.92	0.4	1.44e-25	Gut microbiome composition (summer);
BRCA	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg06238570	chr21:40685208	BRWD1	-0.39	-7.92	-0.3	1.06e-14	Menarche (age at onset);
BRCA	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.96	0.4	9.71e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.59	12.26	0.44	3.48e-31	Lymphocyte counts;
BRCA	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg08601574	chr20:25228251	PYGB	-0.34	-8.25	-0.31	9.18e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg17063962	chr7:91808500	NA	0.48	11.12	0.4	2.25e-26	Breast cancer;
BRCA	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg08088566	chr11:430123	ANO9	0.56	8.3	0.31	6.17e-16	Body mass index;
BRCA	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.34	-0.31	4.72e-16	Colorectal cancer;
BRCA	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-11.56	-0.42	3.28e-28	Lymphocyte counts;
BRCA	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg07080220	chr10:102295463	HIF1AN	0.66	15.57	0.52	1.34e-46	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs11634851	0.966	rs34887414	chr15:81024204	T/C	cg03950166	chr15:80988613	FAM108C1	-0.35	-7.93	-0.3	1.01e-14	Systolic blood pressure;
BRCA	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11764359	chr7:65958608	NA	-0.76	-16.94	-0.56	1.88e-53	Aortic root size;
BRCA	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg00677455	chr12:58241039	CTDSP2	0.45	10.73	0.39	8.25e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs1400816	0.850	rs2028671	chr2:172852839	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.51	-7.87	-0.3	1.56e-14	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg03709012	chr19:19516395	GATAD2A	0.81	19.03	0.6	2.53e-64	Tonsillectomy;
BRCA	cis	rs6545883	0.929	rs7563678	chr2:61741811	C/T	cg15711740	chr2:61764176	XPO1	0.52	13.03	0.46	1.32e-34	Tuberculosis;
BRCA	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-13.85	-0.48	2.39e-38	Blood metabolite levels;
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.4	-9.05	-0.34	1.69e-18	Longevity;Endometriosis;
BRCA	cis	rs68092024	0.704	rs704576	chr3:99487154	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-10.53	-0.38	5.12e-24	Cleft lip with or without cleft palate;
BRCA	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg00666640	chr1:248458726	OR2T12	0.35	8.92	0.33	4.98e-18	Common traits (Other);
BRCA	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg05623727	chr3:50126028	RBM5	0.4	8.55	0.32	9.42e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg03433033	chr1:76189801	ACADM	-0.46	-8.95	-0.33	3.76e-18	Daytime sleep phenotypes;
BRCA	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg14683738	chr19:37701593	ZNF585B	0.44	7.89	0.3	1.3e-14	Coronary artery calcification;
BRCA	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg25036284	chr2:26402008	FAM59B	0.94	15.92	0.53	2.57e-48	Gut microbiome composition (summer);
BRCA	cis	rs4845570	1.000	rs3811415	chr1:151763767	C/T	cg07092448	chr1:151763213	TDRKH	-0.94	-16.25	-0.54	5.77e-50	Coronary artery disease;
BRCA	trans	rs9784649	0.760	rs17403440	chr5:25054004	C/T	cg08600765	chr20:34638493	LOC647979	-0.68	-11.73	-0.42	6.31e-29	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	trans	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.94	-0.3	9.44e-15	Retinal vascular caliber;
BRCA	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg08738300	chr3:44038990	NA	0.44	8.56	0.32	8.6e-17	Coronary artery disease;
BRCA	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18876405	chr7:65276391	NA	-0.49	-10.88	-0.4	2.14e-25	Aortic root size;
BRCA	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg16606324	chr3:10149918	C3orf24	0.48	9.47	0.35	5.5e-20	Alzheimer's disease;
BRCA	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.38	-0.38	1.93e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs877282	1.000	rs2004479	chr10:770854	G/A	cg22713356	chr15:30763199	NA	1.23	24.66	0.7	7.46e-95	Uric acid levels;
BRCA	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg04362960	chr10:104952993	NT5C2	0.44	10.12	0.37	1.97e-22	Arsenic metabolism;
BRCA	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07080220	chr10:102295463	HIF1AN	0.49	11.15	0.4	1.7e-26	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg25457927	chr22:38595422	NA	-0.36	-13.4	-0.47	2.98e-36	Cutaneous nevi;
BRCA	cis	rs73001065	0.636	rs11668104	chr19:19426181	G/A	cg03709012	chr19:19516395	GATAD2A	0.92	13.87	0.48	2.02e-38	LDL cholesterol;
BRCA	cis	rs17401966	0.838	rs7553935	chr1:10375179	G/A	cg03954927	chr1:10346856	KIF1B	0.43	13.56	0.47	5.39e-37	Hepatocellular carcinoma;
BRCA	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg08645402	chr16:4508243	NA	0.39	8.5	0.32	1.31e-16	Schizophrenia;
BRCA	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.43	0.55	7.1e-51	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg22496339	chr2:162101262	NA	0.41	8.08	0.3	3.2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg11833968	chr6:79620685	NA	-0.41	-8.94	-0.33	4.1e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg08085267	chr17:45401833	C17orf57	-0.67	-14.83	-0.51	5.78e-43	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.21	0.31	1.27e-15	Tonsillectomy;
BRCA	cis	rs3099143	1.000	rs2046415	chr15:77085253	A/G	cg21673338	chr15:77095150	SCAPER	-0.53	-9.46	-0.35	5.82e-20	Recalcitrant atopic dermatitis;
BRCA	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg23625390	chr15:77176239	SCAPER	0.39	9.56	0.35	2.41e-20	Blood metabolite levels;
BRCA	trans	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg26043149	chr18:55253948	FECH	0.4	8.48	0.32	1.59e-16	Bone mineral density;
BRCA	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg20019720	chr6:154832845	CNKSR3	0.52	10.31	0.38	3.64e-23	Lipoprotein (a) levels;
BRCA	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.21e-40	Motion sickness;
BRCA	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg04450456	chr4:17643702	FAM184B	0.29	8.42	0.32	2.4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.48	-11.84	-0.42	2.27e-29	Longevity;Endometriosis;
BRCA	cis	rs13046373	0.535	rs7281489	chr21:31978125	C/T	cg16431978	chr21:31797932	KRTAP13-3	0.37	9.45	0.35	6.12e-20	HDL cholesterol;
BRCA	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg07636037	chr3:49044803	WDR6	0.46	9.23	0.34	3.96e-19	Resting heart rate;
BRCA	cis	rs2463822	1.000	rs2513074	chr11:62100880	A/C	cg06239285	chr11:62104954	ASRGL1	0.66	11.05	0.4	4.1e-26	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg25319279	chr11:5960081	NA	-0.41	-8.05	-0.3	4.18e-15	DNA methylation (variation);
BRCA	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	21.22	0.64	4.94e-76	Platelet count;
BRCA	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg03060546	chr3:49711283	APEH	-0.58	-11.84	-0.42	2.29e-29	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.12	0.31	2.44e-15	Corneal astigmatism;
BRCA	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18876405	chr7:65276391	NA	-0.49	-10.81	-0.39	3.86e-25	Aortic root size;
BRCA	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg23711669	chr6:146136114	FBXO30	0.63	14.76	0.5	1.25e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg03146154	chr1:46216737	IPP	0.49	10.89	0.4	1.84e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs4596713	0.507	rs9314865	chr9:71801495	A/G	cg16512924	chr15:28394682	HERC2	0.45	10.64	0.39	1.81e-24	Headache;
BRCA	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.7	-12.65	-0.45	6.62e-33	Iron status biomarkers;
BRCA	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.84	0.51	5.21e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6684514	1.000	rs2296375	chr1:156309372	G/C	cg16558208	chr1:156270281	VHLL	0.36	7.99	0.3	6.51e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-8.58	-0.32	7.09e-17	Coronary artery disease;
BRCA	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg00677455	chr12:58241039	CTDSP2	-0.69	-15.82	-0.53	7.91e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg00071950	chr4:10020882	SLC2A9	0.64	16.0	0.53	1.06e-48	Bone mineral density;
BRCA	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg05283184	chr6:79620031	NA	-0.43	-11.4	-0.41	1.54e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15664640	chr17:80829946	TBCD	0.41	10.99	0.4	7.71e-26	Breast cancer;
BRCA	trans	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg04565464	chr8:145669602	NFKBIL2	0.41	8.75	0.33	1.96e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg11657440	chr19:46296263	DMWD	0.71	19.05	0.6	2.06e-64	Coronary artery disease;
BRCA	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	cis	rs701145	0.585	rs1727879	chr3:153835819	C/T	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.2e-14	Coronary artery disease;
BRCA	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	18.05	0.58	3.73e-59	Platelet count;
BRCA	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg06784218	chr1:46089804	CCDC17	0.46	10.82	0.39	3.46e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg00012203	chr2:219082015	ARPC2	0.72	16.21	0.54	9.19e-50	Colorectal cancer;
BRCA	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00149659	chr3:10157352	C3orf10	0.8	13.73	0.48	9.11e-38	Alzheimer's disease;
BRCA	cis	rs12545109	0.879	rs1581129	chr8:57377476	T/C	cg09654669	chr8:57350985	NA	-0.46	-8.69	-0.33	3.08e-17	Obesity-related traits;
BRCA	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg09184832	chr6:79620586	NA	-0.48	-10.83	-0.39	3.17e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.73	-0.36	5.81e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg12193833	chr17:30244370	NA	-0.54	-8.56	-0.32	8.58e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg11814155	chr7:99998594	ZCWPW1	0.47	8.41	0.32	2.62e-16	Platelet count;
BRCA	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg15819921	chr19:927150	ARID3A	-0.52	-9.67	-0.36	1.01e-20	Life satisfaction;
BRCA	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg09021430	chr5:549028	NA	-0.43	-12.35	-0.44	1.37e-31	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
BRCA	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.81e-23	Prostate cancer;
BRCA	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg11941060	chr3:133502564	NA	-0.59	-14.83	-0.51	5.7e-43	Iron status biomarkers;
BRCA	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg26838691	chr2:24397539	C2orf84	0.4	8.07	0.3	3.41e-15	Asthma;
BRCA	cis	rs17092148	0.652	rs6088515	chr20:33110042	C/T	cg16810054	chr20:33298113	TP53INP2	-0.43	-9.35	-0.35	1.51e-19	Neuroticism;
BRCA	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg13880726	chr7:1868755	MAD1L1	0.52	9.78	0.36	3.94e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg13010199	chr12:38710504	ALG10B	0.5	10.4	0.38	1.67e-23	Bladder cancer;
BRCA	cis	rs36051895	0.659	rs7046511	chr9:5045695	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-9.59	-0.35	1.9e-20	Pediatric autoimmune diseases;
BRCA	cis	rs4730250	0.707	rs257382	chr7:106804249	A/G	cg02696742	chr7:106810147	HBP1	-0.57	-9.46	-0.35	5.66e-20	Osteoarthritis;
BRCA	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg09307838	chr4:120376055	NA	0.64	13.93	0.48	1.02e-38	Corneal astigmatism;
BRCA	cis	rs6495367	0.898	rs1443658	chr15:79386366	A/G	cg17916960	chr15:79447300	NA	0.38	9.01	0.34	2.4e-18	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-9.87	-0.36	1.79e-21	Triglycerides;
BRCA	trans	rs9951602	1.000	rs1903723	chr18:76646571	A/G	cg02800362	chr5:177631904	HNRNPAB	0.76	13.09	0.46	7.5e-35	Obesity-related traits;
BRCA	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg16950941	chr11:66035639	RAB1B	0.42	11.87	0.43	1.67e-29	Gout;
BRCA	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.39	13.48	0.47	1.29e-36	Bipolar disorder;
BRCA	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18876405	chr7:65276391	NA	-0.56	-13.29	-0.47	8.93e-36	Aortic root size;
BRCA	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg15145296	chr3:125709740	NA	-0.55	-8.69	-0.33	3.04e-17	Blood pressure (smoking interaction);
BRCA	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg22800045	chr5:56110881	MAP3K1	0.65	12.18	0.43	7.48e-31	Initial pursuit acceleration;
BRCA	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg27478167	chr7:817139	HEATR2	-0.4	-8.95	-0.33	3.98e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg00106254	chr7:1943704	MAD1L1	-0.41	-10.08	-0.37	2.79e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs679087	1.000	rs672107	chr12:29917266	T/A	cg14258853	chr12:29935411	TMTC1	-0.42	-8.85	-0.33	8.36e-18	Schizophrenia;
BRCA	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg07636037	chr3:49044803	WDR6	0.98	28.87	0.75	6.39e-118	Parkinson's disease;
BRCA	cis	rs724568	0.546	rs1430769	chr2:67932210	A/T	cg17945962	chr2:67939740	NA	-0.38	-9.93	-0.37	1.02e-21	Major depressive disorder (broad);
BRCA	trans	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.4	-9.03	-0.34	2.01e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg05084668	chr3:125655381	ALG1L	-0.55	-9.0	-0.34	2.63e-18	Blood pressure (smoking interaction);
BRCA	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg21280719	chr6:42927975	GNMT	0.33	13.66	0.48	1.83e-37	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.4	-0.44	8.74e-32	Type 2 diabetes;
BRCA	cis	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg06521331	chr12:34319734	NA	-0.51	-10.12	-0.37	1.93e-22	Morning vs. evening chronotype;
BRCA	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.65	8.01	0.3	5.62e-15	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg18402987	chr7:1209562	NA	0.87	12.28	0.44	2.89e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-10.16	-0.37	1.35e-22	Mood instability;
BRCA	trans	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg13010199	chr12:38710504	ALG10B	0.4	8.09	0.3	3.05e-15	Morning vs. evening chronotype;
BRCA	cis	rs10193935	0.901	rs62142599	chr2:42548935	G/A	cg27598129	chr2:42591480	NA	-0.65	-11.03	-0.4	5.17e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg08132940	chr7:1081526	C7orf50	-0.59	-8.77	-0.33	1.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg00409905	chr10:38381863	ZNF37A	0.45	9.22	0.34	4.18e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg13047869	chr3:10149882	C3orf24	0.53	10.94	0.4	1.14e-25	Alzheimer's disease;
BRCA	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg26384229	chr12:38710491	ALG10B	0.83	22.36	0.66	2.87e-82	Heart rate;
BRCA	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg06064525	chr11:970664	AP2A2	-0.32	-9.67	-0.36	9.52e-21	Alzheimer's disease (late onset);
BRCA	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg03060546	chr3:49711283	APEH	-0.58	-9.91	-0.37	1.2e-21	Menarche (age at onset);
BRCA	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-12.63	-0.45	8.09e-33	Bone mineral density;
BRCA	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	11.72	0.42	6.97e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	12.13	0.43	1.31e-30	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg12935359	chr14:103987150	CKB	-0.58	-13.69	-0.48	1.36e-37	Body mass index;
BRCA	trans	rs208520	0.690	rs851465	chr6:66840293	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-21.02	-0.64	6.06e-75	Exhaled nitric oxide output;
BRCA	cis	rs11690462	0.528	rs11691698	chr2:26642190	A/G	cg04944784	chr2:26401820	FAM59B	0.49	8.13	0.31	2.17e-15	Coronary artery disease;
BRCA	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg22713356	chr15:30763199	NA	1.15	23.26	0.68	3.6e-87	Uric acid levels;
BRCA	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg13256891	chr4:100009986	ADH5	0.49	9.25	0.34	3.45e-19	Alcohol dependence;
BRCA	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.52	0.32	1.13e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4363385	0.818	rs435633	chr1:153011811	A/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs10992471	0.639	rs10821008	chr9:95487497	C/T	cg14631576	chr9:95140430	CENPP	-0.32	-7.86	-0.3	1.68e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg07384165	chr1:10488281	NA	-0.41	-8.77	-0.33	1.62e-17	Prostate cancer;
BRCA	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18876405	chr7:65276391	NA	0.62	15.49	0.52	3.58e-46	Aortic root size;
BRCA	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg14664628	chr15:75095509	CSK	0.54	13.08	0.46	8.68e-35	Breast cancer;
BRCA	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg24296786	chr1:45957014	TESK2	0.43	8.66	0.32	3.96e-17	Homocysteine levels;
BRCA	cis	rs17601876	0.814	rs35939475	chr15:51554710	C/A	cg19946085	chr15:51559439	CYP19A1	-0.38	-11.06	-0.4	3.7e-26	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg19920283	chr7:105172520	RINT1	0.59	9.46	0.35	5.64e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18876405	chr7:65276391	NA	-0.71	-18.73	-0.6	1.04e-62	Calcium levels;
BRCA	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-14.11	-0.49	1.44e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg25237894	chr2:233734115	C2orf82	0.4	11.55	0.42	3.79e-28	Coronary artery disease;
BRCA	cis	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg06521331	chr12:34319734	NA	0.61	11.22	0.41	8.44e-27	Morning vs. evening chronotype;
BRCA	cis	rs1371614	0.655	rs509047	chr2:27128529	T/C	cg00617064	chr2:27272375	NA	0.3	8.07	0.3	3.42e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs7789940	0.857	rs12532935	chr7:75939698	G/C	cg24663003	chr7:76039223	ZP3;SRCRB4D	0.36	7.84	0.3	1.83e-14	Multiple sclerosis;
BRCA	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg19077165	chr18:44547161	KATNAL2	-0.49	-10.16	-0.37	1.36e-22	Personality dimensions;
BRCA	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg23711669	chr6:146136114	FBXO30	0.65	15.14	0.51	1.84e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg25457927	chr22:38595422	NA	-0.32	-11.88	-0.43	1.54e-29	Cutaneous nevi;
BRCA	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	14.55	0.5	1.22e-41	Motion sickness;
BRCA	cis	rs9815354	0.812	rs17283929	chr3:41941898	C/G	cg03022575	chr3:42003672	ULK4	-0.7	-9.84	-0.36	2.26e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-8.36	-0.31	3.96e-16	Monocyte percentage of white cells;
BRCA	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07343612	chr16:622815	PIGQ	-0.66	-21.11	-0.64	1.87e-75	Height;
BRCA	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg14664628	chr15:75095509	CSK	-0.94	-29.77	-0.76	7.73e-123	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs3820928	0.874	rs13383070	chr2:227904939	C/T	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.39	-0.32	3.03e-16	Pulmonary function;
BRCA	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15506890	chr2:3487001	NA	-0.58	-13.14	-0.46	4.26e-35	Neurofibrillary tangles;
BRCA	trans	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg21775007	chr8:11205619	TDH	0.44	9.06	0.34	1.63e-18	Mood instability;
BRCA	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24531977	chr5:56204891	C5orf35	1.07	22.52	0.67	4.17e-83	Initial pursuit acceleration;
BRCA	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg06671706	chr8:8559999	CLDN23	0.44	8.43	0.32	2.22e-16	Obesity-related traits;
BRCA	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg25358565	chr5:93447407	FAM172A	1.2	19.15	0.6	6.01e-65	Diabetic retinopathy;
BRCA	cis	rs9287719	0.649	rs10198971	chr2:10718699	G/C	cg00105475	chr2:10696890	NA	0.41	9.19	0.34	5.62e-19	Prostate cancer;
BRCA	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg00278107	chr5:1061253	SLC12A7	0.58	11.34	0.41	2.81e-27	QT interval;
BRCA	cis	rs586533	0.837	rs605937	chr11:99499253	G/A	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	18.14	0.58	1.24e-59	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-8.99	-0.34	2.81e-18	IgG glycosylation;
BRCA	trans	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg23711669	chr6:146136114	FBXO30	0.71	13.96	0.48	7.68e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg13319975	chr6:146136371	FBXO30	0.41	9.35	0.35	1.49e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg21770322	chr7:97807741	LMTK2	0.57	16.23	0.54	7.07e-50	Breast cancer;
BRCA	cis	rs4891159	0.548	rs690414	chr18:74117840	T/C	cg24786174	chr18:74118243	ZNF516	0.84	26.04	0.72	1.91e-102	Longevity;
BRCA	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg06108461	chr20:60628389	TAF4	0.5	8.31	0.31	5.62e-16	Obesity-related traits;
BRCA	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg13047869	chr3:10149882	C3orf24	0.55	11.49	0.41	6.78e-28	Alzheimer's disease;
BRCA	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	11.77	0.42	4.61e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14240646	chr10:27532245	ACBD5	0.53	8.58	0.32	7.22e-17	Breast cancer;
BRCA	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	11.95	0.43	7.69e-30	Tonsillectomy;
BRCA	cis	rs9308433	0.529	rs55760458	chr1:214491536	G/C	cg06198575	chr1:214491504	SMYD2	0.58	12.6	0.45	1.13e-32	IgG glycosylation;
BRCA	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	22.76	0.67	2.09e-84	Platelet count;
BRCA	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg04362960	chr10:104952993	NT5C2	0.44	10.79	0.39	4.71e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-9.2	-0.34	5.08e-19	Monocyte percentage of white cells;
BRCA	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg05347473	chr6:146136440	FBXO30	0.45	8.85	0.33	8.22e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg24531977	chr5:56204891	C5orf35	0.71	15.44	0.52	6.37e-46	Initial pursuit acceleration;
BRCA	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg04691961	chr3:161091175	C3orf57	-0.59	-14.05	-0.49	2.95e-39	Morning vs. evening chronotype;
BRCA	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-14.95	-0.51	1.46e-43	Coronary artery disease;
BRCA	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg12483005	chr1:23474871	LUZP1	0.37	8.02	0.3	4.97e-15	Height;
BRCA	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg08999081	chr20:33150536	PIGU	0.37	8.72	0.33	2.41e-17	Coronary artery disease;
BRCA	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg24692254	chr21:30365293	RNF160	0.5	10.88	0.4	1.98e-25	Pancreatic cancer;
BRCA	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg16482183	chr6:26056742	HIST1H1C	0.49	9.66	0.36	1.1e-20	Iron status biomarkers;
BRCA	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs67460515	0.500	rs1868105	chr3:160645335	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-12.89	-0.45	5.81e-34	Parkinson's disease;
BRCA	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg24562669	chr7:97807699	LMTK2	0.54	15.7	0.53	3.21e-47	Breast cancer;
BRCA	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg25767906	chr1:53392781	SCP2	-0.45	-10.15	-0.37	1.57e-22	Monocyte count;
BRCA	cis	rs3784262	0.669	rs3784259	chr15:58257847	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.07	-0.37	3.01e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.37	0.49	8.98e-41	Motion sickness;
BRCA	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg23018236	chr17:30244563	NA	-0.71	-11.12	-0.4	2.27e-26	Hip circumference adjusted for BMI;
BRCA	cis	rs2540552	0.600	rs62467818	chr7:91199485	A/G	cg15143024	chr7:91199642	NA	-0.46	-11.59	-0.42	2.57e-28	IgG glycosylation;
BRCA	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg05340658	chr4:99064831	C4orf37	0.63	15.11	0.51	2.54e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-9.68	-0.36	9.11e-21	Alzheimer's disease (late onset);
BRCA	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg06671706	chr8:8559999	CLDN23	0.43	8.41	0.32	2.77e-16	Obesity-related traits;
BRCA	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg23950597	chr19:37808831	NA	-0.62	-11.36	-0.41	2.35e-27	Coronary artery calcification;
BRCA	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.59	-12.31	-0.44	2.07e-31	Lymphocyte counts;
BRCA	cis	rs8017423	0.607	rs10142482	chr14:90848280	G/T	cg04374321	chr14:90722782	PSMC1	-0.5	-11.44	-0.41	1.02e-27	Mortality in heart failure;
BRCA	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg18402987	chr7:1209562	NA	0.87	9.18	0.34	5.73e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7577696	0.525	rs2366547	chr2:32251109	G/A	cg02381751	chr2:32503542	YIPF4	-0.42	-7.99	-0.3	6.3e-15	Inflammatory biomarkers;
BRCA	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	8.98	0.33	2.91e-18	Tonsillectomy;
BRCA	cis	rs4853036	0.904	rs13015957	chr2:70032316	C/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-8.93	-0.33	4.53e-18	Colorectal or endometrial cancer;
BRCA	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.53	-13.2	-0.46	2.36e-35	Urate levels in overweight individuals;
BRCA	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg21775007	chr8:11205619	TDH	-0.38	-7.82	-0.3	2.25e-14	Triglycerides;
BRCA	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg14530993	chr4:882597	GAK	0.51	8.69	0.33	2.94e-17	Parkinson's disease;
BRCA	cis	rs17655565	0.533	rs12825729	chr12:52706854	G/A	cg08257133	chr12:52711352	KRT83	0.37	10.79	0.39	4.77e-25	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg24675658	chr1:53192096	ZYG11B	-0.68	-15.47	-0.52	4.56e-46	Monocyte count;
BRCA	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg18512352	chr11:47633146	NA	0.32	8.06	0.3	3.73e-15	Subjective well-being;
BRCA	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg02196655	chr2:10830764	NOL10	-0.3	-8.05	-0.3	4.13e-15	Prostate cancer;
BRCA	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg13010199	chr12:38710504	ALG10B	0.43	8.89	0.33	6.05e-18	Bladder cancer;
BRCA	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg22907277	chr7:1156413	C7orf50	0.47	10.69	0.39	1.16e-24	Longevity;Endometriosis;
BRCA	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg00701064	chr4:6280414	WFS1	0.66	16.07	0.54	4.74e-49	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	9.49	0.35	4.65e-20	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg24112000	chr20:60950667	NA	-0.48	-9.23	-0.34	4.06e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs870825	0.616	rs6552805	chr4:185637894	C/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.32	0.57	2.07e-55	Blood protein levels;
BRCA	cis	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.43	-9.66	-0.36	1.03e-20	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs30380	0.922	rs246453	chr5:96123336	T/C	cg16492584	chr5:96139282	ERAP1	-0.31	-7.96	-0.3	7.6e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-13.46	-0.47	1.53e-36	Bipolar disorder and schizophrenia;
BRCA	cis	rs17604090	0.823	rs28415620	chr7:29701104	T/C	cg19413766	chr7:29689036	LOC646762	-0.61	-8.16	-0.31	1.85e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs644148	0.836	rs2686774	chr19:44999827	T/C	cg15540054	chr19:45004280	ZNF180	-0.57	-12.28	-0.44	2.9e-31	Personality dimensions;
BRCA	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	9.69	0.36	8.1e-21	Iron status biomarkers;
BRCA	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg04455712	chr21:45112962	RRP1B	-0.43	-10.04	-0.37	4.03e-22	Mean corpuscular volume;
BRCA	cis	rs2677744	0.626	rs11854429	chr15:91489685	C/T	cg23684204	chr15:91497937	RCCD1	-0.41	-8.46	-0.32	1.89e-16	Attention deficit hyperactivity disorder;
BRCA	cis	rs6435161	0.919	rs72928971	chr2:203591967	A/G	cg18429434	chr2:203499731	FAM117B	-0.42	-8.54	-0.32	9.53e-17	Total cholesterol levels;
BRCA	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg21427119	chr20:30132790	HM13	-0.41	-8.8	-0.33	1.32e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs13046373	0.535	rs8129571	chr21:31980646	G/A	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.51	0.35	3.76e-20	HDL cholesterol;
BRCA	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg06917634	chr15:78832804	PSMA4	-0.55	-11.6	-0.42	2.18e-28	Sudden cardiac arrest;
BRCA	trans	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg26043149	chr18:55253948	FECH	0.41	8.91	0.33	5.1e-18	Bone mineral density;
BRCA	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg26116260	chr4:7069785	GRPEL1	0.89	25.38	0.71	8.08e-99	Monocyte percentage of white cells;
BRCA	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26168224	chr5:2018326	NA	-0.54	-13.04	-0.46	1.25e-34	Gut microbiome composition (winter);
BRCA	cis	rs4604732	0.536	rs4925674	chr1:247636906	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.4	7.83	0.3	2.05e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
BRCA	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg05340658	chr4:99064831	C4orf37	0.68	16.96	0.56	1.53e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg06521331	chr12:34319734	NA	-0.47	-8.68	-0.32	3.32e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg04362960	chr10:104952993	NT5C2	0.42	10.13	0.37	1.77e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	trans	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.25	0.31	8.78e-16	Corneal astigmatism;
BRCA	cis	rs11585357	0.671	rs2501776	chr1:17619279	C/T	cg08277548	chr1:17600880	PADI3	0.44	8.85	0.33	8.72e-18	Hair shape;
BRCA	cis	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.82	16.61	0.55	9.35e-52	HIV-1 control;
BRCA	cis	rs8038465	0.615	rs6495076	chr15:73982965	G/A	cg15420318	chr15:73925796	NPTN	0.38	8.72	0.33	2.37e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg22920501	chr2:26401640	FAM59B	-0.91	-17.48	-0.57	3.17e-56	Gut microbiome composition (summer);
BRCA	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg11057378	chr10:81107060	PPIF	0.36	8.83	0.33	9.91e-18	Height;
BRCA	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg20307385	chr11:47447363	PSMC3	0.8	19.14	0.6	6.89e-65	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg13736514	chr6:26305472	NA	-0.36	-12.25	-0.44	3.7e-31	Educational attainment;
BRCA	cis	rs7944584	0.879	rs11039182	chr11:47346723	T/C	cg20307385	chr11:47447363	PSMC3	0.62	11.95	0.43	7.94e-30	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs17401966	0.931	rs10864448	chr1:10277497	A/T	cg03954927	chr1:10346856	KIF1B	0.48	14.75	0.5	1.29e-42	Hepatocellular carcinoma;
BRCA	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg00031303	chr3:195681400	NA	0.46	8.67	0.32	3.6e-17	Pancreatic cancer;
BRCA	cis	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg07460842	chr6:66804631	NA	0.59	10.19	0.37	1.06e-22	Type 2 diabetes;
BRCA	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg20476274	chr7:133979776	SLC35B4	0.69	20.55	0.63	1.96e-72	Mean platelet volume;
BRCA	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg04025307	chr7:1156635	C7orf50	0.49	8.27	0.31	8e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.48e-23	Motion sickness;
BRCA	cis	rs778371	0.676	rs13024330	chr2:233715487	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	16.13	0.54	2.28e-49	Schizophrenia;
BRCA	cis	rs4363385	0.510	rs6587724	chr1:153034501	T/A	cg25856811	chr1:152973957	SPRR3	-0.31	-7.9	-0.3	1.23e-14	Inflammatory skin disease;
BRCA	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg05985134	chr18:33552581	C18orf21	0.67	12.75	0.45	2.36e-33	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg11814155	chr7:99998594	ZCWPW1	0.49	8.72	0.33	2.48e-17	Platelet count;
BRCA	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg13877915	chr19:58951672	ZNF132	0.47	11.05	0.4	4.29e-26	Uric acid clearance;
BRCA	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg13010199	chr12:38710504	ALG10B	0.44	8.84	0.33	9.41e-18	Bladder cancer;
BRCA	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg12615879	chr12:58013172	SLC26A10	0.3	8.31	0.31	5.59e-16	Multiple sclerosis;
BRCA	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg02773041	chr1:40204384	PPIE	0.45	9.71	0.36	7.12e-21	Blood protein levels;
BRCA	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	26.57	0.72	2.26e-105	Chronic sinus infection;
BRCA	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	17.28	0.56	3.5e-55	Electrocardiographic conduction measures;
BRCA	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs2882667	0.898	rs6882526	chr5:138382368	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-8.99	-0.33	2.85e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg09719594	chr16:21412588	NA	-0.33	-8.01	-0.3	5.43e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-11.94	-0.43	7.99e-30	Gut microbiome composition (summer);
BRCA	trans	rs6076960	0.564	rs3852935	chr20:6143180	C/G	cg21095983	chr6:86352623	SYNCRIP	0.36	8.49	0.32	1.41e-16	Smooth-surface caries;
BRCA	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.07	0.4	3.52e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg05472934	chr7:22766657	IL6	0.53	13.77	0.48	5.64e-38	Lung cancer;
BRCA	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg08067268	chr2:26466485	HADHB;HADHA	0.58	10.28	0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg27624424	chr6:160112604	SOD2	0.38	8.31	0.31	5.96e-16	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg22705602	chr4:152727874	NA	-0.38	-10.26	-0.38	5.71e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.35	-8.91	-0.33	5.34e-18	Menopause (age at onset);
BRCA	cis	rs698833	0.813	rs3768919	chr2:44512971	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	10.57	0.39	3.43e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs6543140	0.601	rs7558013	chr2:102992806	G/T	cg04239558	chr2:103089729	SLC9A4	0.33	7.9	0.3	1.23e-14	Blood protein levels;
BRCA	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.91	-0.33	5.1e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs35740288	0.929	rs11635081	chr15:86304260	G/A	cg20737812	chr15:86336631	KLHL25	-0.33	-8.03	-0.3	4.54e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.38	-7.99	-0.3	6.34e-15	Longevity;Endometriosis;
BRCA	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg18402987	chr7:1209562	NA	0.42	8.27	0.31	7.57e-16	Longevity;Endometriosis;
BRCA	cis	rs208520	0.874	rs208470	chr6:66916402	G/A	cg07460842	chr6:66804631	NA	-0.89	-15.67	-0.53	4.35e-47	Exhaled nitric oxide output;
BRCA	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.07	0.3	3.58e-15	Menarche (age at onset);
BRCA	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg02297831	chr4:17616191	MED28	0.37	8.58	0.32	6.93e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21659725	chr3:3221576	CRBN	-0.47	-10.21	-0.37	9.35e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg12140854	chr5:148520817	ABLIM3	-0.42	-9.09	-0.34	1.23e-18	Breast cancer;
BRCA	cis	rs10838687	0.736	rs7933246	chr11:47262648	G/C	cg25783544	chr11:47291846	MADD	0.42	7.81	0.3	2.44e-14	Proinsulin levels;
BRCA	cis	rs17641971	0.684	rs7819763	chr8:50030513	C/T	cg00325661	chr8:49890786	NA	0.36	9.68	0.36	8.67e-21	Blood metabolite levels;
BRCA	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg24829409	chr8:58192753	C8orf71	-0.47	-9.12	-0.34	9.38e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs9296092	0.560	rs7765263	chr6:33525559	A/G	cg13560919	chr6:33536144	NA	-0.85	-18.96	-0.6	5.84e-64	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg19920283	chr7:105172520	RINT1	0.59	9.47	0.35	5.25e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03264133	chr6:25882463	NA	-0.42	-9.18	-0.34	5.95e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.9	0.56	3.08e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg00071950	chr4:10020882	SLC2A9	0.56	13.53	0.47	7.59e-37	Bone mineral density;
BRCA	cis	rs17253792	0.822	rs10137885	chr14:56173590	A/G	cg01858014	chr14:56050164	KTN1	-0.6	-9.1	-0.34	1.17e-18	Putamen volume;
BRCA	trans	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg26384229	chr12:38710491	ALG10B	0.57	12.26	0.44	3.38e-31	Morning vs. evening chronotype;
BRCA	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg21951975	chr1:209979733	IRF6	0.39	8.95	0.33	3.75e-18	Cleft lip with or without cleft palate;
BRCA	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.31	9.88	0.36	1.58e-21	Electroencephalogram traits;
BRCA	cis	rs6028335	0.610	rs6729	chr20:37668272	A/G	cg16355469	chr20:37678765	NA	0.5	8.82	0.33	1.06e-17	Alcohol and nicotine co-dependence;
BRCA	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.72	-0.33	2.47e-17	Alzheimer's disease (late onset);
BRCA	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09256448	chr16:638327	NA	0.3	7.96	0.3	7.8e-15	Height;
BRCA	cis	rs6867032	0.527	rs9312971	chr5:2012888	C/A	cg26168224	chr5:2018326	NA	0.46	12.42	0.44	7.11e-32	Gut microbiome composition (winter);
BRCA	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.36	0.63	2.22e-71	Electrocardiographic conduction measures;
BRCA	cis	rs311392	0.967	rs4463399	chr8:55089449	T/C	cg11783602	chr8:55087084	NA	-0.32	-9.49	-0.35	4.38e-20	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs757081	0.667	rs17473243	chr11:17266259	G/A	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.68	-0.32	3.37e-17	Systolic blood pressure;
BRCA	cis	rs7394190	0.630	rs113799665	chr10:75575138	C/T	cg07699608	chr10:75541558	CHCHD1	0.67	9.77	0.36	4.05e-21	Incident atrial fibrillation;
BRCA	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg02569458	chr12:86230093	RASSF9	0.32	8.02	0.3	5.07e-15	Major depressive disorder;
BRCA	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg25237894	chr2:233734115	C2orf82	-0.41	-11.75	-0.42	5.12e-29	Coronary artery disease;
BRCA	cis	rs35110281	0.667	rs914197	chr21:45117439	A/G	cg04455712	chr21:45112962	RRP1B	0.43	11.25	0.41	6.33e-27	Mean corpuscular volume;
BRCA	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg12863693	chr15:85201151	NMB	-0.36	-8.5	-0.32	1.34e-16	P wave terminal force;
BRCA	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg21280719	chr6:42927975	GNMT	-0.31	-12.93	-0.46	3.77e-34	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg14019146	chr3:50243930	SLC38A3	-0.36	-8.88	-0.33	6.57e-18	Body mass index;
BRCA	cis	rs12220238	1.000	rs12256105	chr10:75909634	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.5	8.09	0.3	3.05e-15	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs4566357	0.615	rs2894626	chr2:227916039	T/C	cg05526886	chr2:227700861	RHBDD1	-0.4	-8.26	-0.31	8.56e-16	Coronary artery disease;
BRCA	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg23649088	chr2:200775458	C2orf69	0.72	16.2	0.54	1.1e-49	Osteoporosis;
BRCA	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg08999081	chr20:33150536	PIGU	-0.46	-12.77	-0.45	2.05e-33	Glomerular filtration rate (creatinine);
BRCA	cis	rs6598955	0.543	rs6698557	chr1:26561220	G/C	cg04990556	chr1:26633338	UBXN11	0.69	12.0	0.43	4.75e-30	Obesity-related traits;
BRCA	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg02196655	chr2:10830764	NOL10	-0.29	-7.91	-0.3	1.16e-14	Prostate cancer;
BRCA	cis	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg04990556	chr1:26633338	UBXN11	0.54	9.11	0.34	1.04e-18	Obesity-related traits;
BRCA	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24531977	chr5:56204891	C5orf35	-0.86	-17.48	-0.57	3.46e-56	Initial pursuit acceleration;
BRCA	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg13010199	chr12:38710504	ALG10B	0.41	8.35	0.31	4.19e-16	Bladder cancer;
BRCA	cis	rs2425143	1.000	rs11699044	chr20:34312713	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.64	10.32	0.38	3.42e-23	Blood protein levels;
BRCA	trans	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.75	-0.36	5.06e-21	Morning vs. evening chronotype;
BRCA	cis	rs3740540	0.530	rs2362503	chr10:126290538	T/C	cg04949429	chr10:126290192	LHPP	0.43	12.12	0.43	1.46e-30	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg23625390	chr15:77176239	SCAPER	-0.52	-12.79	-0.45	1.69e-33	Blood metabolite levels;
BRCA	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.37e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10754283	0.967	rs7513928	chr1:90104834	A/G	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.2e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg11266682	chr4:10021025	SLC2A9	-0.42	-11.1	-0.4	2.61e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs250677	0.522	rs55732303	chr5:148392538	C/T	cg18129178	chr5:148520854	ABLIM3	-0.55	-10.56	-0.39	3.95e-24	Breast cancer;
BRCA	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	12.44	0.44	5.91e-32	Multiple sclerosis;
BRCA	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg05313129	chr8:58192883	C8orf71	-0.46	-9.43	-0.35	7.75e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs1550582	1.000	rs7822348	chr8:135542483	C/G	cg17885191	chr8:135476712	NA	0.63	11.38	0.41	1.91e-27	Educational attainment;
BRCA	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.53	0.32	1.09e-16	Rheumatoid arthritis;
BRCA	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg26248373	chr2:1572462	NA	-0.53	-11.61	-0.42	1.98e-28	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7072216	0.763	rs4475861	chr10:100164989	C/T	cg26618903	chr10:100175079	PYROXD2	-0.27	-7.95	-0.3	8.27e-15	Metabolite levels;
BRCA	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg03146154	chr1:46216737	IPP	0.52	11.59	0.42	2.58e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1499972	0.887	rs817504	chr3:117678862	A/C	cg07612923	chr3:117604196	NA	-0.6	-8.25	-0.31	9.26e-16	Schizophrenia;
BRCA	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11890956	chr21:40555474	PSMG1	-0.61	-13.36	-0.47	4.64e-36	Menarche (age at onset);
BRCA	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg20891283	chr12:69753455	YEATS4	0.6	13.8	0.48	4.32e-38	Response to diuretic therapy;
BRCA	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg13047869	chr3:10149882	C3orf24	0.6	12.81	0.45	1.29e-33	Alzheimer's disease;
BRCA	cis	rs1635	0.655	rs73742539	chr6:28305471	C/T	cg15743358	chr6:28303923	ZNF323	-0.75	-8.75	-0.33	1.94e-17	Schizophrenia;
BRCA	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg00106254	chr7:1943704	MAD1L1	-0.37	-8.98	-0.33	3e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg12927641	chr6:109611667	NA	-0.36	-8.92	-0.33	4.89e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs243505	1.000	rs1019059	chr7:148424247	A/G	cg09806900	chr7:148480153	CUL1	-0.43	-8.81	-0.33	1.15e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg03934865	chr2:198174659	NA	-0.39	-8.39	-0.32	3.09e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	trans	rs146671954	1	rs146671954	chr9:136934203	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.68	-9.86	-0.36	1.93e-21	Red cell distribution width;
BRCA	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg03213289	chr20:61660250	NA	0.61	16.19	0.54	1.21e-49	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg24642439	chr20:33292090	TP53INP2	0.53	11.6	0.42	2.23e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	21.09	0.64	2.41e-75	Platelet count;
BRCA	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.35	-8.27	-0.31	7.69e-16	Insulin-like growth factors;
BRCA	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg26395211	chr5:140044315	WDR55	0.37	8.55	0.32	9.02e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs66725070	1	rs66725070	chr15:58267416	GACAT/G	cg12031962	chr15:58353849	ALDH1A2	-0.5	-13.22	-0.46	2.02e-35	Barrett's esophagus;
BRCA	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.13	-0.43	1.25e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	11.83	0.42	2.47e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs4965272	1.000	rs1585932	chr15:100585637	A/C	cg27344315	chr15:100560801	ADAMTS17	-0.38	-8.01	-0.3	5.4e-15	Gastroesophageal reflux disease;
BRCA	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg13010199	chr12:38710504	ALG10B	0.44	8.6	0.32	6.39e-17	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg13628971	chr7:2884303	GNA12	0.38	8.49	0.32	1.44e-16	Height;
BRCA	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24308560	chr3:49941425	MST1R	-0.4	-8.61	-0.32	5.78e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs1113500	0.933	rs4593854	chr1:108638519	A/G	cg06207961	chr1:108661230	NA	0.44	10.66	0.39	1.58e-24	Growth-regulated protein alpha levels;
BRCA	cis	rs5753037	0.653	rs140129	chr22:30150549	C/T	cg01021169	chr22:30184971	ASCC2	-0.34	-8.09	-0.3	3.08e-15	Type 1 diabetes;
BRCA	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	trans	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg04565464	chr8:145669602	NFKBIL2	-0.37	-9.33	-0.35	1.66e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs12760731	0.720	rs10913553	chr1:178423062	G/C	cg00404053	chr1:178313656	RASAL2	0.61	7.99	0.3	6.33e-15	Obesity-related traits;
BRCA	trans	rs2018683	0.770	rs10951208	chr7:29022504	G/T	cg19402173	chr7:128379420	CALU	-0.47	-11.3	-0.41	4.07e-27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg20283391	chr11:68216788	NA	-0.45	-9.36	-0.35	1.29e-19	Total body bone mineral density;
BRCA	trans	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg06521331	chr12:34319734	NA	-0.45	-8.56	-0.32	8.24e-17	Bladder cancer;
BRCA	cis	rs1355223	0.545	rs7111695	chr11:34874906	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-9.48	-0.35	4.85e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs6973256	0.583	rs2430768	chr7:133340287	T/C	cg07491979	chr7:133331646	EXOC4	-0.35	-8.13	-0.31	2.28e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg26384229	chr12:38710491	ALG10B	-0.62	-16.07	-0.54	4.8e-49	Heart rate;
BRCA	cis	rs10267417	0.603	rs10260797	chr7:19890181	A/G	cg07541023	chr7:19748670	TWISTNB	0.47	8.58	0.32	7.44e-17	Night sleep phenotypes;
BRCA	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg15605315	chr1:45957053	TESK2	0.45	9.26	0.34	3.1e-19	High light scatter reticulocyte count;
BRCA	cis	rs2836633	0.895	rs2836597	chr21:40024424	A/G	cg05519781	chr21:40033154	ERG	0.43	9.65	0.36	1.16e-20	Coronary artery disease;
BRCA	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	10.98	0.4	8.08e-26	Rheumatoid arthritis;
BRCA	trans	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.66	-0.36	1.04e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.24	0.59	3.53e-60	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg27129171	chr3:47204927	SETD2	-0.72	-17.91	-0.58	1.9e-58	Colorectal cancer;
BRCA	cis	rs1003719	0.788	rs4817843	chr21:38447040	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.25	0.49	3.17e-40	Eye color traits;
BRCA	cis	rs9463078	0.764	rs3846896	chr6:44834094	G/A	cg25276700	chr6:44698697	NA	-0.35	-8.12	-0.31	2.37e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg09537434	chr19:41945824	ATP5SL	-0.99	-23.03	-0.67	6.56e-86	Height;
BRCA	cis	rs2559856	1.000	rs2695286	chr12:102088507	T/C	cg12924262	chr12:102091054	CHPT1	0.38	8.57	0.32	7.9e-17	Blood protein levels;
BRCA	cis	rs7809950	0.817	rs4727679	chr7:107085018	T/C	cg23024343	chr7:107201750	COG5	-0.5	-10.49	-0.38	7.39e-24	Coronary artery disease;
BRCA	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg25358565	chr5:93447407	FAM172A	1.19	18.33	0.59	1.34e-60	Diabetic retinopathy;
BRCA	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg11843238	chr5:131593191	PDLIM4	0.35	9.1	0.34	1.1e-18	Breast cancer;
BRCA	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg15395560	chr15:45543142	SLC28A2	-0.29	-7.83	-0.3	2.02e-14	Uric acid levels;
BRCA	cis	rs7944584	0.655	rs2856653	chr11:47361084	T/C	cg20307385	chr11:47447363	PSMC3	-0.51	-11.26	-0.41	6.05e-27	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg05623727	chr3:50126028	RBM5	0.5	12.18	0.43	7.94e-31	Body mass index;
BRCA	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg26395211	chr5:140044315	WDR55	-0.35	-8.02	-0.3	5.09e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7301826	0.560	rs12829294	chr12:131309972	A/G	cg11011512	chr12:131303247	STX2	-0.44	-11.03	-0.4	4.9e-26	Plasma plasminogen activator levels;
BRCA	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg25206134	chr2:45395956	NA	0.51	8.77	0.33	1.65e-17	Bipolar disorder;
BRCA	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg04518342	chr5:131593106	PDLIM4	0.37	8.69	0.33	3.09e-17	Acylcarnitine levels;
BRCA	cis	rs2742234	0.541	rs1059484	chr10:43679800	T/G	cg02780029	chr10:43622663	RET	-0.35	-7.96	-0.3	7.97e-15	Hirschsprung disease;
BRCA	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg01017244	chr2:74357527	NA	0.66	12.91	0.45	4.66e-34	Gestational age at birth (maternal effect);
BRCA	cis	rs2625529	0.652	rs2957734	chr15:72261385	A/G	cg16672083	chr15:72433130	SENP8	0.68	16.19	0.54	1.14e-49	Red blood cell count;
BRCA	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg03146154	chr1:46216737	IPP	0.45	10.11	0.37	2.13e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs220324	0.688	rs915840	chr21:43560871	T/C	cg09727148	chr21:43560719	UMODL1	0.5	8.85	0.33	8.23e-18	Idiopathic osteonecrosis of the femoral head;
BRCA	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg13010199	chr12:38710504	ALG10B	0.43	9.11	0.34	1.05e-18	Morning vs. evening chronotype;
BRCA	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-12.76	-0.45	2.2e-33	Morning vs. evening chronotype;
BRCA	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg05623727	chr3:50126028	RBM5	0.38	8.02	0.3	5.12e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg03342759	chr3:160939853	NMD3	-0.63	-13.25	-0.46	1.38e-35	Morning vs. evening chronotype;
BRCA	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	27.27	0.73	3.24e-109	Chronic sinus infection;
BRCA	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg02228329	chr11:64053129	BAD;GPR137	0.53	11.69	0.42	9.94e-29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.42	-9.53	-0.35	3.28e-20	Electroencephalogram traits;
BRCA	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg04362960	chr10:104952993	NT5C2	0.42	10.14	0.37	1.67e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg17971929	chr21:40555470	PSMG1	0.78	18.44	0.59	3.54e-61	Cognitive function;
BRCA	trans	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	8.48	0.32	1.5e-16	Mean corpuscular volume;
BRCA	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02176678	chr2:219576539	TTLL4	-0.51	-13.15	-0.46	3.95e-35	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9837602	0.872	rs4928234	chr3:99704861	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.59	-11.28	-0.41	4.85e-27	Breast cancer;
BRCA	trans	rs2018683	0.707	rs1021689	chr7:28974223	G/T	cg19402173	chr7:128379420	CALU	-0.42	-9.93	-0.37	1e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg17063962	chr7:91808500	NA	-0.56	-12.82	-0.45	1.23e-33	Breast cancer;
BRCA	cis	rs897080	0.515	rs1085444	chr2:44624155	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	9.34	0.35	1.53e-19	Height;
BRCA	cis	rs6973256	0.897	rs2345941	chr7:133337635	C/T	cg07491979	chr7:133331646	EXOC4	0.38	8.61	0.32	5.84e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg21573476	chr21:45109991	RRP1B	-0.37	-9.28	-0.34	2.58e-19	Mean corpuscular volume;
BRCA	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.05e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg26608667	chr7:1196370	ZFAND2A	0.45	10.71	0.39	9.62e-25	Longevity;Endometriosis;
BRCA	cis	rs13046373	0.505	rs2832962	chr21:32008332	T/C	cg16812893	chr21:31813075	KRTAP15-1	0.38	9.5	0.35	4.26e-20	HDL cholesterol;
BRCA	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg19077165	chr18:44547161	KATNAL2	0.55	12.14	0.43	1.1e-30	Personality dimensions;
BRCA	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24549020	chr5:56110836	MAP3K1	0.6	12.38	0.44	1.05e-31	Initial pursuit acceleration;
BRCA	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg00631329	chr6:26305371	NA	-0.45	-13.64	-0.47	2.41e-37	Educational attainment;
BRCA	cis	rs2289583	0.573	rs12148555	chr15:75395475	C/T	cg14664628	chr15:75095509	CSK	0.39	9.08	0.34	1.31e-18	Systemic lupus erythematosus;
BRCA	cis	rs7178424	0.935	rs8034335	chr15:62287456	A/G	cg00456672	chr15:62358751	C2CD4A	0.42	9.68	0.36	9.05e-21	Height;
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg26608667	chr7:1196370	ZFAND2A	0.41	9.0	0.34	2.47e-18	Longevity;Endometriosis;
BRCA	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg06623918	chr6:96969491	KIAA0776	0.74	12.19	0.43	6.85e-31	Migraine;Coronary artery disease;
BRCA	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg12311346	chr5:56204834	C5orf35	0.61	12.61	0.45	9.85e-33	Initial pursuit acceleration;
BRCA	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg20701182	chr2:24300061	SF3B14	0.55	8.52	0.32	1.15e-16	Lymphocyte counts;
BRCA	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg01689657	chr7:91764605	CYP51A1	0.24	8.61	0.32	5.86e-17	Breast cancer;
BRCA	cis	rs3099143	1.000	rs3106380	chr15:77104377	G/A	cg21673338	chr15:77095150	SCAPER	-0.53	-9.4	-0.35	9.79e-20	Recalcitrant atopic dermatitis;
BRCA	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg18252515	chr7:66147081	NA	-0.97	-13.79	-0.48	4.42e-38	Diabetic kidney disease;
BRCA	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.41	0.5	5.45e-41	Motion sickness;
BRCA	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg08213375	chr14:104286397	PPP1R13B	0.65	18.38	0.59	6.72e-61	Schizophrenia;
BRCA	cis	rs2625529	0.590	rs8023703	chr15:72504059	G/A	cg16672083	chr15:72433130	SENP8	0.71	15.67	0.53	4.45e-47	Red blood cell count;
BRCA	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg22972055	chr7:872293	UNC84A	0.38	8.46	0.32	1.83e-16	Cerebrospinal P-tau181p levels;
BRCA	trans	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04565464	chr8:145669602	NFKBIL2	0.35	8.72	0.33	2.48e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs1018836	0.923	rs7837230	chr8:91574281	C/T	cg16814680	chr8:91681699	NA	-0.58	-12.53	-0.44	2.4e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	trans	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.45	0.32	1.97e-16	Corneal astigmatism;
BRCA	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-7.93	-0.3	1.01e-14	Colorectal cancer;
BRCA	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg07952391	chr2:88470173	THNSL2	-0.64	-8.65	-0.32	4.24e-17	Plasma clusterin levels;
BRCA	cis	rs11229555	0.645	rs36019763	chr11:58232283	G/T	cg15696309	chr11:58395628	NA	-0.52	-10.85	-0.39	2.81e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg13175981	chr1:150552382	MCL1	0.41	9.16	0.34	7.18e-19	Tonsillectomy;
BRCA	cis	rs7572733	0.515	rs11891555	chr2:198853540	G/T	cg00792783	chr2:198669748	PLCL1	0.44	9.53	0.35	3.28e-20	Dermatomyositis;
BRCA	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg18154014	chr19:37997991	ZNF793	0.59	11.15	0.4	1.72e-26	Coronary artery calcification;
BRCA	cis	rs4302748	0.862	rs11973172	chr7:36183435	A/T	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.3	8.43	0.32	2.37e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg08807101	chr21:30365312	RNF160	0.56	12.19	0.43	7.01e-31	Selective IgA deficiency;
BRCA	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg00666640	chr1:248458726	OR2T12	0.29	8.25	0.31	8.85e-16	Common traits (Other);
BRCA	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg00717180	chr2:96193071	NA	-0.38	-10.34	-0.38	2.9e-23	HDL cholesterol;
BRCA	cis	rs754466	0.606	rs12356375	chr10:79594514	C/A	cg17075019	chr10:79541650	NA	-0.81	-21.2	-0.64	5.98e-76	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg26043149	chr18:55253948	FECH	-0.4	-8.77	-0.33	1.66e-17	Bone mineral density;
BRCA	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24838063	chr12:130822603	PIWIL1	0.68	16.73	0.55	2.13e-52	Menopause (age at onset);
BRCA	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	8.27	0.31	7.75e-16	Rheumatoid arthritis;
BRCA	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg19743168	chr1:23544995	NA	-0.47	-11.79	-0.42	3.53e-29	Height;
BRCA	cis	rs10129255	0.500	rs988134	chr14:107184937	A/G	cg07958169	chr14:107095056	NA	-0.4	-8.62	-0.32	5.2e-17	Kawasaki disease;
BRCA	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg24642439	chr20:33292090	TP53INP2	0.53	11.5	0.41	5.99e-28	Coronary artery disease;
BRCA	cis	rs9318086	0.712	rs3794339	chr13:24434065	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.33	9.47	0.35	5.25e-20	Myopia (pathological);
BRCA	cis	rs1595825	0.836	rs79748557	chr2:198567912	G/T	cg19156104	chr2:198669113	PLCL1	-0.43	-7.89	-0.3	1.29e-14	Ulcerative colitis;
BRCA	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg06453172	chr10:134556979	INPP5A	-0.6	-11.77	-0.42	4.54e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg18357645	chr12:58087776	OS9	0.34	9.79	0.36	3.42e-21	Multiple sclerosis;
BRCA	cis	rs921968	0.565	rs7586384	chr2:219582897	T/C	cg02176678	chr2:219576539	TTLL4	-0.42	-11.05	-0.4	4.09e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg23711669	chr6:146136114	FBXO30	0.65	15.41	0.52	8.91e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17092148	0.887	rs6058077	chr20:33140999	G/A	cg16810054	chr20:33298113	TP53INP2	-0.46	-10.24	-0.38	6.71e-23	Neuroticism;
BRCA	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg09307838	chr4:120376055	NA	0.63	13.82	0.48	3.28e-38	Corneal astigmatism;
BRCA	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg08392591	chr16:89556376	ANKRD11	-0.36	-8.15	-0.31	1.95e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs9296092	0.517	rs76361685	chr6:33536458	G/C	cg13560919	chr6:33536144	NA	-0.91	-19.2	-0.6	3.31e-65	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg21479132	chr6:26055353	NA	0.6	8.1	0.31	2.72e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11229555	0.645	rs7926682	chr11:58189495	A/G	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7121446	0.521	rs12293988	chr11:121852633	C/T	cg13820391	chr11:121835505	NA	0.29	8.05	0.3	3.98e-15	Cardiovascular risk factors (age interaction);
BRCA	cis	rs6782228	0.651	rs9852825	chr3:128387357	C/G	cg16766828	chr3:128327626	NA	-0.43	-9.49	-0.35	4.68e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs7560272	0.538	rs12619258	chr2:73935915	G/T	cg20560298	chr2:73613845	ALMS1	0.35	8.86	0.33	7.97e-18	Schizophrenia;
BRCA	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05926928	chr17:57297772	GDPD1	1.17	15.84	0.53	6.24e-48	Opioid sensitivity;
BRCA	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg18964960	chr10:1102726	WDR37	0.61	8.07	0.3	3.53e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg11266682	chr4:10021025	SLC2A9	0.48	12.72	0.45	3.27e-33	Bone mineral density;
BRCA	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26314531	chr2:26401878	FAM59B	-0.86	-14.57	-0.5	9.9e-42	Gut microbiome composition (summer);
BRCA	cis	rs701145	0.585	rs2060622	chr3:153833862	A/T	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.2e-14	Coronary artery disease;
BRCA	cis	rs897984	0.609	rs35468353	chr16:31056433	A/G	cg00531865	chr16:30841666	NA	-0.38	-9.06	-0.34	1.62e-18	Dementia with Lewy bodies;
BRCA	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg01262667	chr19:19385393	TM6SF2	0.4	10.44	0.38	1.13e-23	Tonsillectomy;
BRCA	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.28	-0.38	4.75e-23	Psoriasis;
BRCA	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg23033748	chr14:75592666	NEK9	-0.43	-10.47	-0.38	9.17e-24	Height;
BRCA	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21659725	chr3:3221576	CRBN	0.47	11.79	0.42	3.65e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10802521	chr3:52805072	NEK4	0.32	8.03	0.3	4.79e-15	Bipolar disorder;
BRCA	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.48	-0.35	4.98e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs13046373	0.535	rs1961167	chr21:32030310	T/C	cg16431978	chr21:31797932	KRTAP13-3	0.35	8.7	0.33	2.81e-17	HDL cholesterol;
BRCA	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg00012203	chr2:219082015	ARPC2	-0.5	-9.98	-0.37	7.02e-22	Colorectal cancer;
BRCA	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	19.33	0.61	6.67e-66	Smoking behavior;
BRCA	cis	rs6820391	0.816	rs1002824	chr4:54445980	A/C	cg04173182	chr4:54446035	LNX1	-0.53	-11.54	-0.42	3.91e-28	Cervical artery dissection;
BRCA	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg26384229	chr12:38710491	ALG10B	0.42	9.33	0.35	1.73e-19	Morning vs. evening chronotype;
BRCA	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg26587870	chr6:27730563	NA	-0.71	-9.58	-0.35	2.11e-20	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
BRCA	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg02403541	chr12:121454288	C12orf43	0.7	15.06	0.51	4.5e-44	N-glycan levels;
BRCA	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	8.45	0.32	1.97e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg25036284	chr2:26402008	FAM59B	-0.88	-15.06	-0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs2841233	0.681	rs2582558	chr14:105347488	A/G	cg16576083	chr14:105354267	KIAA0284	-0.45	-11.7	-0.42	8.77e-29	IgG glycosylation;
BRCA	cis	rs6701037	0.522	rs7521981	chr1:175091151	C/T	cg00321850	chr1:175162397	KIAA0040	-0.31	-8.04	-0.3	4.43e-15	Alcohol dependence;
BRCA	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg03060546	chr3:49711283	APEH	0.55	9.21	0.34	4.6e-19	Menarche (age at onset);
BRCA	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg23029597	chr12:123009494	RSRC2	0.59	12.44	0.44	5.58e-32	Body mass index;
BRCA	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	11.46	0.41	8.82e-28	Mean platelet volume;
BRCA	cis	rs7903847	0.642	rs11189174	chr10:99139600	C/G	cg20016023	chr10:99160130	RRP12	-0.27	-8.64	-0.32	4.4e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg21535247	chr6:8435926	SLC35B3	0.41	9.45	0.35	6.39e-20	Motion sickness;
BRCA	cis	rs12950390	1.000	rs12950390	chr17:45830948	A/G	cg03474202	chr17:45855739	NA	-0.4	-9.14	-0.34	8.39e-19	IgG glycosylation;
BRCA	cis	rs7737355	0.947	rs6895841	chr5:130773534	A/G	cg06307176	chr5:131281290	NA	0.53	10.39	0.38	1.87e-23	Life satisfaction;
BRCA	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg15934090	chr1:100435551	SLC35A3	0.35	8.17	0.31	1.72e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10193935	0.901	rs12615383	chr2:42610551	A/G	cg27598129	chr2:42591480	NA	0.9	14.74	0.5	1.51e-42	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg20587970	chr11:113659929	NA	-1.24	-22.71	-0.67	3.66e-84	Hip circumference adjusted for BMI;
BRCA	cis	rs2131877	0.529	rs7644208	chr3:194855954	G/A	cg13868855	chr3:194833887	C3orf21	-0.34	-8.1	-0.31	2.75e-15	Non-small cell lung cancer;
BRCA	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg04455712	chr21:45112962	RRP1B	0.38	9.85	0.36	2.03e-21	Mean corpuscular volume;
BRCA	cis	rs7631605	0.935	rs3774341	chr3:37045233	A/C	cg15934958	chr3:37212084	LRRFIP2	0.42	9.6	0.35	1.79e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs17095355	1.000	rs975442	chr10:111705895	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.37	-9.43	-0.35	7.62e-20	Biliary atresia;
BRCA	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg22903471	chr2:27725779	GCKR	-0.37	-9.05	-0.34	1.77e-18	Total body bone mineral density;
BRCA	cis	rs921968	0.565	rs35358516	chr2:219625723	A/C	cg02176678	chr2:219576539	TTLL4	-0.4	-10.97	-0.4	8.71e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg02017074	chr12:117425053	FBXW8	0.59	10.84	0.39	3.01e-25	Subcortical brain region volumes;Hippocampal volume;
BRCA	trans	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.55	-0.35	2.78e-20	Bladder cancer;
BRCA	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg15017067	chr4:17643749	FAM184B	0.29	8.58	0.32	7.09e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs72781680	0.821	rs72796325	chr2:24134537	G/A	cg08917208	chr2:24149416	ATAD2B	0.63	10.71	0.39	9.66e-25	Lymphocyte counts;
BRCA	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg15704280	chr7:45808275	SEPT13	0.54	8.89	0.33	6.21e-18	D-dimer levels;
BRCA	cis	rs4887140	0.717	rs8040531	chr15:74052205	A/G	cg11789681	chr15:74046708	NA	0.52	8.09	0.3	3.08e-15	Glucose homeostasis traits;
BRCA	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.32	0.49	1.55e-40	Motion sickness;
BRCA	cis	rs10492096	1.000	rs10849462	chr12:6575992	C/T	cg13857086	chr12:6580257	VAMP1	0.44	8.57	0.32	8.03e-17	Hip geometry;
BRCA	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg03954927	chr1:10346856	KIF1B	0.48	14.58	0.5	9.03e-42	Hepatocellular carcinoma;
BRCA	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg08917208	chr2:24149416	ATAD2B	0.78	12.2	0.43	6.41e-31	Lymphocyte counts;
BRCA	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg02297831	chr4:17616191	MED28	0.37	8.52	0.32	1.13e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25427524	chr10:38739819	LOC399744	-0.74	-18.29	-0.59	1.97e-60	Extrinsic epigenetic age acceleration;
BRCA	cis	rs243505	0.898	rs243524	chr7:148418181	A/C	cg09806900	chr7:148480153	CUL1	-0.39	-7.95	-0.3	8.21e-15	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg19052272	chr2:3704530	ALLC	-0.38	-8.9	-0.33	5.82e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-10.77	-0.39	5.46e-25	Blood metabolite levels;
BRCA	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg24558204	chr6:135376177	HBS1L	0.53	14.75	0.5	1.34e-42	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg13628971	chr7:2884303	GNA12	0.37	7.94	0.3	8.96e-15	Height;
BRCA	cis	rs7116495	0.609	rs2503	chr11:71719403	C/T	cg10381502	chr11:71823885	C11orf51	0.93	9.5	0.35	4.19e-20	Severe influenza A (H1N1) infection;
BRCA	cis	rs2797160	0.967	rs1739358	chr6:126019736	G/A	cg05901451	chr6:126070800	HEY2	0.4	9.77	0.36	4.03e-21	Endometrial cancer;
BRCA	cis	rs17401966	1.000	rs35837142	chr1:10322358	C/G	cg03954927	chr1:10346856	KIF1B	0.46	12.9	0.45	5.43e-34	Hepatocellular carcinoma;
BRCA	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	11.0	0.4	6.57e-26	Bipolar disorder;
BRCA	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	ch.11.42038R	chr11:967971	AP2A2	0.5	15.89	0.53	3.66e-48	Alzheimer's disease (late onset);
BRCA	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.39	8.44	0.32	2.04e-16	Electroencephalogram traits;
BRCA	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg20203395	chr5:56204925	C5orf35	-0.5	-10.17	-0.37	1.24e-22	Initial pursuit acceleration;
BRCA	cis	rs1003719	0.788	rs7276917	chr21:38451334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.25	0.49	3.23e-40	Eye color traits;
BRCA	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg23649088	chr2:200775458	C2orf69	-0.62	-10.37	-0.38	2.23e-23	Schizophrenia;
BRCA	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.36	-8.34	-0.31	4.71e-16	Colorectal cancer;
BRCA	trans	rs11165623	0.792	rs6701031	chr1:96975515	C/T	cg10631902	chr5:14652156	NA	-0.5	-15.4	-0.52	9.79e-46	Hip circumference;Waist circumference;
BRCA	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.96	-0.48	7.91e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4466137	0.953	rs1585153	chr5:83000385	A/T	cg16102102	chr5:83017553	HAPLN1	-0.91	-18.35	-0.59	1.04e-60	Prostate cancer;
BRCA	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg12935359	chr14:103987150	CKB	-0.6	-14.31	-0.49	1.7e-40	Body mass index;
BRCA	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg12165864	chr7:66369176	NA	-0.44	-9.87	-0.36	1.69e-21	Corneal structure;
BRCA	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg21475434	chr5:93447410	FAM172A	0.69	8.96	0.33	3.44e-18	Diabetic retinopathy;
BRCA	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	23.44	0.68	3.67e-88	Platelet count;
BRCA	cis	rs56399783	0.901	rs56356906	chr7:2774383	G/A	cg19731401	chr7:2775893	GNA12	0.52	8.28	0.31	7.04e-16	Childhood ear infection;
BRCA	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg04553112	chr3:125709451	NA	-0.56	-8.41	-0.32	2.61e-16	Blood pressure (smoking interaction);
BRCA	cis	rs12760731	0.720	rs12022731	chr1:178416358	A/G	cg00404053	chr1:178313656	RASAL2	0.6	7.85	0.3	1.75e-14	Obesity-related traits;
BRCA	cis	rs117623576	0.618	rs211416	chr10:32397591	T/A	cg03047570	chr10:32398778	NA	0.56	8.83	0.33	1.04e-17	Anti-saccade response;
BRCA	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.59e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg09904177	chr6:26538194	HMGN4	0.55	17.71	0.57	2.06e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs9649465	0.934	rs7799354	chr7:123269819	A/G	cg03229431	chr7:123269106	ASB15	-0.36	-8.39	-0.31	3.2e-16	Migraine;
BRCA	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07234876	chr8:600039	NA	-0.78	-8.73	-0.33	2.14e-17	IgG glycosylation;
BRCA	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg14196790	chr5:131705035	SLC22A5	0.42	10.81	0.39	3.84e-25	Blood metabolite levels;
BRCA	cis	rs4853036	0.904	rs62152020	chr2:70147664	C/T	cg02498382	chr2:70120550	SNRNP27	-0.54	-9.61	-0.36	1.58e-20	Colorectal or endometrial cancer;
BRCA	cis	rs6430585	0.527	rs76380759	chr2:136438517	G/A	cg07169764	chr2:136633963	MCM6	0.99	19.16	0.6	5.54e-65	Corneal structure;
BRCA	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg18402987	chr7:1209562	NA	0.84	11.92	0.43	9.85e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	8.44	0.32	2.19e-16	Attention deficit hyperactivity disorder;
BRCA	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg05340658	chr4:99064831	C4orf37	0.62	14.89	0.51	2.75e-43	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg17712092	chr4:129076599	LARP1B	-0.53	-12.2	-0.43	6.61e-31	Eosinophil percentage of white cells;
BRCA	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg20587970	chr11:113659929	NA	-1.2	-22.13	-0.66	5.45e-81	Hip circumference adjusted for BMI;
BRCA	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg16414030	chr3:133502952	NA	-0.48	-11.27	-0.41	5.25e-27	Iron status biomarkers;
BRCA	cis	rs9487051	0.738	rs449850	chr6:109525045	A/G	cg01475377	chr6:109611718	NA	-0.44	-11.11	-0.4	2.51e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg21475434	chr5:93447410	FAM172A	0.71	8.9	0.33	5.68e-18	Diabetic retinopathy;
BRCA	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-9.0	-0.34	2.61e-18	Aortic root size;
BRCA	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg05340658	chr4:99064831	C4orf37	0.6	13.55	0.47	5.68e-37	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg21775007	chr8:11205619	TDH	0.53	10.51	0.38	6e-24	Triglycerides;
BRCA	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg20887711	chr4:1340912	KIAA1530	-0.73	-15.95	-0.53	1.92e-48	Longevity;
BRCA	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg26384229	chr12:38710491	ALG10B	0.74	17.66	0.57	3.84e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9914988	0.943	rs7215310	chr17:27088626	G/T	cg20469991	chr17:27169893	C17orf63	-0.44	-8.64	-0.32	4.39e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	trans	rs7200543	1.000	rs6498540	chr16:15130594	A/G	cg24683922	chr1:11983373	KIAA2013	-0.39	-8.86	-0.33	8.19e-18	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs1109501	1.000	rs11932207	chr4:71330534	G/A	cg22786090	chr4:71381880	NA	0.37	7.85	0.3	1.77e-14	Alcoholism (heaviness of drinking);
BRCA	cis	rs13082711	0.911	rs17682751	chr3:27497027	C/T	cg02860705	chr3:27208620	NA	-0.59	-11.01	-0.4	6.21e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs13095912	1.000	rs2034343	chr3:185337854	A/T	cg11274856	chr3:185301563	NA	0.34	8.39	0.31	3.22e-16	Systolic blood pressure;
BRCA	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs17685	0.535	rs41296542	chr7:75600008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.36	8.65	0.32	4.1e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.86	-0.33	8.18e-18	Total body bone mineral density;
BRCA	cis	rs9487051	0.768	rs386696	chr6:109520166	G/A	cg01475377	chr6:109611718	NA	-0.44	-11.28	-0.41	4.89e-27	Reticulocyte fraction of red cells;
BRCA	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg05347473	chr6:146136440	FBXO30	0.39	7.88	0.3	1.45e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.38	-9.15	-0.34	7.42e-19	Tonsillectomy;
BRCA	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg08917208	chr2:24149416	ATAD2B	-0.5	-8.33	-0.31	5.01e-16	Asthma;
BRCA	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg01119278	chr6:110721349	DDO	-0.43	-10.54	-0.38	4.87e-24	Platelet distribution width;
BRCA	cis	rs6723226	0.765	rs12612824	chr2:32579759	C/T	cg02381751	chr2:32503542	YIPF4	-0.67	-14.44	-0.5	3.96e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.92	19.19	0.6	3.64e-65	IgG glycosylation;
BRCA	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-8.56	-0.32	8.47e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg23708337	chr7:1209742	NA	0.38	7.94	0.3	9.24e-15	Longevity;Endometriosis;
BRCA	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg25204440	chr1:209979598	IRF6	0.43	8.58	0.32	7.08e-17	Cleft lip with or without cleft palate;
BRCA	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg11663144	chr21:46675770	NA	-0.6	-14.13	-0.49	1.24e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs698833	0.757	rs9309116	chr2:44557919	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	10.5	0.38	6.56e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.68	-0.32	3.33e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs36051895	0.664	rs62543877	chr9:5093465	C/A	cg02405213	chr9:5042618	JAK2	-0.51	-9.08	-0.34	1.35e-18	Pediatric autoimmune diseases;
BRCA	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.78	0.62	2.8e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg08000102	chr2:233561755	GIGYF2	0.63	13.88	0.48	1.8e-38	Coronary artery disease;
BRCA	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07256732	chr16:621771	PIGQ	-0.34	-8.87	-0.33	7.31e-18	Height;
BRCA	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.23	-0.54	7.7e-50	Alzheimer's disease (late onset);
BRCA	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg08000102	chr2:233561755	GIGYF2	-0.62	-13.63	-0.47	2.44e-37	Coronary artery disease;
BRCA	cis	rs9790314	0.715	rs9290065	chr3:160776964	A/G	cg03342759	chr3:160939853	NMD3	0.51	9.77	0.36	4.2e-21	Morning vs. evening chronotype;
BRCA	cis	rs9649465	0.902	rs10253850	chr7:123273095	T/C	cg03229431	chr7:123269106	ASB15	-0.37	-8.4	-0.32	2.82e-16	Migraine;
BRCA	trans	rs3960554	0.733	rs59170362	chr7:75629267	G/C	cg19862616	chr7:65841803	NCRNA00174	0.55	11.58	0.42	2.72e-28	Eotaxin levels;
BRCA	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg04025307	chr7:1156635	C7orf50	0.52	10.12	0.37	1.92e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg26043149	chr18:55253948	FECH	-0.41	-9.12	-0.34	9.72e-19	Bone mineral density;
BRCA	cis	rs17095355	1.000	rs734163	chr10:111698192	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.34	-8.84	-0.33	9.04e-18	Biliary atresia;
BRCA	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg08508325	chr11:3079039	CARS	0.27	8.32	0.31	5.53e-16	Calcium levels;
BRCA	cis	rs9427116	0.502	rs9426830	chr1:154594690	A/G	cg17218026	chr1:154582156	ADAR	0.28	8.53	0.32	1.09e-16	Blood protein levels;
BRCA	cis	rs524281	0.861	rs10896077	chr11:65851733	C/G	cg16950941	chr11:66035639	RAB1B	-0.38	-7.97	-0.3	7.32e-15	Electroencephalogram traits;
BRCA	cis	rs2061333	1.000	rs2061333	chr19:44614208	A/G	cg23489630	chr19:44645078	ZNF234	0.42	8.28	0.31	7.35e-16	Alzheimer's disease;
BRCA	cis	rs870825	0.616	rs7667449	chr4:185641711	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	16.76	0.55	1.57e-52	Blood protein levels;
BRCA	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg13010199	chr12:38710504	ALG10B	0.5	10.43	0.38	1.31e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	16.51	0.55	2.77e-51	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg04013093	chr6:42928303	GNMT	0.3	9.2	0.34	5.03e-19	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10242455	0.557	rs73403272	chr7:99134208	T/G	cg18809830	chr7:99032528	PTCD1	-0.58	-8.51	-0.32	1.22e-16	Blood metabolite levels;
BRCA	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg21770322	chr7:97807741	LMTK2	0.44	11.56	0.42	3.32e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg06521331	chr12:34319734	NA	-0.55	-9.87	-0.36	1.82e-21	Morning vs. evening chronotype;
BRCA	cis	rs4742903	0.904	rs10114234	chr9:107003646	C/T	cg21169611	chr9:106856078	SMC2	-0.32	-8.29	-0.31	6.62e-16	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg14019146	chr3:50243930	SLC38A3	0.41	10.03	0.37	4.27e-22	Body mass index;
BRCA	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-12.05	-0.43	2.87e-30	Bipolar disorder and schizophrenia;
BRCA	trans	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg06521331	chr12:34319734	NA	-0.48	-8.75	-0.33	1.9e-17	Bladder cancer;
BRCA	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.5	0.57	2.65e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	7.15e-19	Alzheimer's disease (late onset);
BRCA	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg09904177	chr6:26538194	HMGN4	0.55	17.65	0.57	4.4e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg21775007	chr8:11205619	TDH	0.61	11.76	0.42	4.84e-29	Retinal vascular caliber;
BRCA	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg20587970	chr11:113659929	NA	-1.21	-21.69	-0.65	1.43e-78	Hip circumference adjusted for BMI;
BRCA	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg26384229	chr12:38710491	ALG10B	0.42	9.36	0.35	1.39e-19	Morning vs. evening chronotype;
BRCA	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.71	-0.36	7.24e-21	Alcohol dependence;
BRCA	cis	rs4588572	0.606	rs2362828	chr5:77718835	C/T	cg11547950	chr5:77652471	NA	-0.43	-8.28	-0.31	7.41e-16	Triglycerides;
BRCA	cis	rs4363385	0.818	rs546666	chr1:153015385	A/G	cg24667326	chr1:152973720	SPRR3	-0.32	-8.83	-0.33	1.04e-17	Inflammatory skin disease;
BRCA	cis	rs400736	0.671	rs863171	chr1:7992615	A/G	cg25007680	chr1:8021821	PARK7	0.41	10.27	0.38	5.44e-23	Response to antidepressants and depression;
BRCA	cis	rs17270561	0.636	rs11794	chr6:25701718	G/A	cg17691542	chr6:26056736	HIST1H1C	0.47	8.92	0.33	4.72e-18	Iron status biomarkers;
BRCA	cis	rs6815814	0.950	rs56357984	chr4:38806462	G/A	cg02016764	chr4:38805732	TLR1	-0.57	-8.7	-0.33	2.83e-17	Breast cancer;
BRCA	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg13880726	chr7:1868755	MAD1L1	0.53	9.99	0.37	6.19e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	10.58	0.39	3.17e-24	Height;
BRCA	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg00080972	chr5:178986291	RUFY1	0.39	10.24	0.38	6.58e-23	Lung cancer;
BRCA	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg24692254	chr21:30365293	RNF160	0.62	13.96	0.48	7.52e-39	Selective IgA deficiency;
BRCA	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg19622623	chr12:86230825	RASSF9	-0.33	-9.32	-0.35	1.83e-19	Major depressive disorder;
BRCA	cis	rs7246657	0.722	rs968073	chr19:38192021	G/A	cg18154014	chr19:37997991	ZNF793	-0.51	-9.58	-0.35	2.03e-20	Coronary artery calcification;
BRCA	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg14019146	chr3:50243930	SLC38A3	-0.59	-12.07	-0.43	2.37e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19748678	chr4:122722346	EXOSC9	0.74	16.02	0.54	8.68e-49	Type 2 diabetes;
BRCA	trans	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg25214090	chr10:38739885	LOC399744	0.55	12.09	0.43	1.97e-30	Corneal astigmatism;
BRCA	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.96	0.3	7.77e-15	Depression;
BRCA	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	cis	rs701145	0.938	rs701138	chr3:154063609	T/C	cg17054900	chr3:154042577	DHX36	0.66	11.41	0.41	1.46e-27	Coronary artery disease;
BRCA	cis	rs6815814	0.898	rs73236616	chr4:38789675	G/A	cg02016764	chr4:38805732	TLR1	-0.63	-9.72	-0.36	6.24e-21	Breast cancer;
BRCA	cis	rs1941023	0.503	rs10750936	chr11:60144180	G/A	cg08716584	chr11:60157161	MS4A7	-0.44	-10.53	-0.38	5.33e-24	Congenital heart disease (maternal effect);
BRCA	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg06115741	chr20:33292138	TP53INP2	0.41	9.02	0.34	2.11e-18	Coronary artery disease;
BRCA	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg19628046	chr18:33552617	C18orf21	0.56	10.98	0.4	8.53e-26	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg03146154	chr1:46216737	IPP	0.53	11.81	0.42	2.91e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs698833	0.548	rs1067350	chr2:44669946	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	9.15	0.34	7.79e-19	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	trans	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-20.44	-0.63	7.57e-72	Exhaled nitric oxide output;
BRCA	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26818010	chr10:134567672	INPP5A	-0.66	-14.34	-0.49	1.19e-40	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg18132916	chr6:79620363	NA	-0.46	-10.47	-0.38	8.71e-24	Intelligence (multi-trait analysis);
BRCA	trans	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg26043149	chr18:55253948	FECH	-0.38	-7.92	-0.3	1.09e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg25427524	chr10:38739819	LOC399744	0.59	11.08	0.4	3.27e-26	Obesity (extreme);
BRCA	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg25801113	chr15:45476975	SHF	-0.33	-8.05	-0.3	4.19e-15	Uric acid levels;
BRCA	cis	rs7809950	1.000	rs67982599	chr7:107100104	T/G	cg23024343	chr7:107201750	COG5	-0.4	-9.3	-0.35	2.24e-19	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg08888203	chr3:10149979	C3orf24	0.68	14.46	0.5	3.41e-41	Alzheimer's disease;
BRCA	cis	rs754466	0.580	rs11002294	chr10:79540588	T/C	cg17075019	chr10:79541650	NA	-0.83	-20.46	-0.63	5.94e-72	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg12483005	chr1:23474871	LUZP1	0.44	9.81	0.36	2.84e-21	Height;
BRCA	cis	rs507080	0.845	rs510408	chr11:118558901	G/C	cg09144398	chr11:118550485	TREH	-0.37	-8.96	-0.33	3.5e-18	Serum metabolite levels;
BRCA	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.89	0.33	5.97e-18	Tonsillectomy;
BRCA	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg05863683	chr7:1912471	MAD1L1	0.4	8.38	0.31	3.27e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	20.1	0.62	5.33e-70	Smoking behavior;
BRCA	trans	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg26384229	chr12:38710491	ALG10B	0.48	11.07	0.4	3.59e-26	Morning vs. evening chronotype;
BRCA	cis	rs2425143	0.730	rs6058354	chr20:34491110	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.15	-0.31	1.89e-15	Blood protein levels;
BRCA	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.4	7.97	0.3	7.06e-15	Alzheimer's disease (late onset);
BRCA	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg05340658	chr4:99064831	C4orf37	0.45	10.39	0.38	1.79e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg18252515	chr7:66147081	NA	1.06	15.88	0.53	3.95e-48	Diabetic kidney disease;
BRCA	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg06808227	chr14:105710500	BRF1	-0.79	-16.1	-0.54	3.13e-49	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs1555322	0.530	rs6060341	chr20:33863633	C/T	cg07134254	chr20:33865797	NA	-0.43	-8.26	-0.31	8.72e-16	Attention deficit hyperactivity disorder;
BRCA	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg24562669	chr7:97807699	LMTK2	0.43	11.48	0.41	7.55e-28	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.98	-0.48	6.13e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg26597838	chr10:835615	NA	0.98	17.29	0.56	3.09e-55	Eosinophil percentage of granulocytes;
BRCA	cis	rs9462027	0.628	rs6905393	chr6:34776626	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.84	-0.3	1.96e-14	Systemic lupus erythematosus;
BRCA	cis	rs9815354	0.857	rs73830583	chr3:41996948	C/T	cg03022575	chr3:42003672	ULK4	0.73	10.08	0.37	2.94e-22	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg27490568	chr2:178487706	NA	0.49	8.43	0.32	2.29e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg26395211	chr5:140044315	WDR55	0.37	8.32	0.31	5.16e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.0	22.44	0.66	1.14e-82	Lymphocyte percentage of white cells;
BRCA	cis	rs672059	0.966	rs492228	chr1:183156476	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.64	0.32	4.48e-17	Hypertriglyceridemia;
BRCA	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg01448562	chr3:133502909	NA	-0.64	-15.19	-0.52	1.02e-44	Iron status biomarkers;
BRCA	cis	rs877282	0.945	rs71489301	chr10:770191	A/G	cg17470449	chr10:769945	NA	0.48	8.9	0.33	5.94e-18	Uric acid levels;
BRCA	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg07679836	chr6:33548423	BAK1	0.65	13.86	0.48	2.11e-38	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
BRCA	cis	rs7255436	0.830	rs4350678	chr19:8447366	A/G	cg10174797	chr19:8464628	RAB11B	0.35	8.91	0.33	5.26e-18	HDL cholesterol;
BRCA	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg15448220	chr1:150897856	SETDB1	0.35	7.9	0.3	1.26e-14	Melanoma;
BRCA	trans	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-10.3	-0.38	3.91e-23	Morning vs. evening chronotype;
BRCA	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg16482183	chr6:26056742	HIST1H1C	0.49	9.68	0.36	9.18e-21	Iron status biomarkers;
BRCA	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg19678392	chr7:94953810	PON1	-0.43	-8.98	-0.33	3e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs3849570	1.000	rs9817181	chr3:81827765	A/C	cg07356753	chr3:81810745	GBE1	-0.47	-11.29	-0.41	4.46e-27	Waist circumference;Body mass index;
BRCA	cis	rs10493773	1.000	rs3767163	chr1:86121895	T/G	cg17807903	chr1:86174739	ZNHIT6	-0.44	-9.12	-0.34	9.8e-19	Urate levels in overweight individuals;
BRCA	cis	rs12618769	0.597	rs2278213	chr2:99136059	A/G	cg10123293	chr2:99228465	UNC50	0.41	7.93	0.3	9.97e-15	Bipolar disorder;
BRCA	cis	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg06521331	chr12:34319734	NA	-0.56	-10.19	-0.37	1.09e-22	Morning vs. evening chronotype;
BRCA	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.61	14.8	0.51	7.61e-43	Colorectal cancer;
BRCA	cis	rs2066819	1.000	rs2306694	chr12:56680636	C/T	cg26714650	chr12:56694279	CS	1.18	15.85	0.53	5.52e-48	Psoriasis vulgaris;
BRCA	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg24642439	chr20:33292090	TP53INP2	-0.52	-11.5	-0.41	6.15e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg05347473	chr6:146136440	FBXO30	-0.44	-8.81	-0.33	1.17e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg21211680	chr2:198530	NA	-0.46	-10.03	-0.37	4.5e-22	Blood protein levels;
BRCA	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg16850897	chr7:100343110	ZAN	-0.58	-12.37	-0.44	1.16e-31	Other erythrocyte phenotypes;
BRCA	cis	rs4642101	0.561	rs9831765	chr3:12805934	A/T	cg24848339	chr3:12840334	CAND2	0.38	9.24	0.34	3.72e-19	QRS complex (12-leadsum);
BRCA	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg11752832	chr7:134001865	SLC35B4	0.53	13.81	0.48	3.83e-38	Mean platelet volume;
BRCA	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.87	-0.33	7.06e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg26384229	chr12:38710491	ALG10B	-0.57	-13.29	-0.47	9.4e-36	Bladder cancer;
BRCA	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03517284	chr6:25882590	NA	-0.73	-17.68	-0.57	2.92e-57	Uric acid levels;
BRCA	cis	rs7092929	0.941	rs661019	chr10:3586581	C/T	cg14308648	chr10:3568949	NA	0.45	8.1	0.31	2.73e-15	Coronary artery calcification;
BRCA	trans	rs11088226	0.681	rs2833926	chr21:33975279	A/G	cg09050820	chr6:167586206	TCP10L2	0.82	14.06	0.49	2.7e-39	Gastritis;
BRCA	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg14993813	chr1:46806288	NSUN4	-0.47	-9.05	-0.34	1.75e-18	Menopause (age at onset);
BRCA	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg09469691	chr10:81107165	PPIF	0.49	10.29	0.38	4.57e-23	Height;
BRCA	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg13877915	chr19:58951672	ZNF132	-0.45	-10.81	-0.39	3.99e-25	Uric acid clearance;
BRCA	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg23711669	chr6:146136114	FBXO30	0.74	17.1	0.56	2.91e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs5167	0.504	rs3760627	chr19:45457180	T/C	cg10169327	chr19:45448959	APOC2	0.31	7.84	0.3	1.94e-14	Blood protein levels;
BRCA	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg05082376	chr22:42548792	NA	-0.31	-7.86	-0.3	1.67e-14	Cognitive function;
BRCA	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg24558204	chr6:135376177	HBS1L	0.45	12.33	0.44	1.66e-31	Red blood cell count;
BRCA	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg17173187	chr15:85201210	NMB	0.42	8.71	0.33	2.55e-17	Schizophrenia;
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg04025307	chr7:1156635	C7orf50	0.55	13.31	0.47	7.19e-36	Longevity;Endometriosis;
BRCA	cis	rs1506636	1.000	rs2402669	chr7:123297460	C/G	cg03229431	chr7:123269106	ASB15	-0.64	-14.3	-0.49	1.95e-40	Plateletcrit;Platelet count;
BRCA	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg13319975	chr6:146136371	FBXO30	0.42	9.54	0.35	2.88e-20	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-16.89	-0.56	3.51e-53	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.35	0.35	1.49e-19	Tonsillectomy;
BRCA	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.57	0.35	2.25e-20	Lung cancer in ever smokers;
BRCA	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg23711669	chr6:146136114	FBXO30	-0.7	-16.77	-0.55	1.33e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg02544614	chr20:61657117	NA	0.3	8.22	0.31	1.15e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg24642439	chr20:33292090	TP53INP2	0.52	11.43	0.41	1.2e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs3925075	0.966	rs11645917	chr16:31359826	C/T	cg02846316	chr16:31340340	ITGAM	0.53	12.86	0.45	8.02e-34	IgA nephropathy;
BRCA	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg26597838	chr10:835615	NA	0.83	15.2	0.52	9.58e-45	Eosinophil percentage of granulocytes;
BRCA	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg25382214	chr1:3105252	PRDM16	-0.34	-7.93	-0.3	1.01e-14	Migraine;
BRCA	cis	rs7683537	0.887	rs4540092	chr4:185633546	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	17.4	0.57	8.32e-56	Systemic lupus erythematosus;
BRCA	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	8.39	0.32	3.1e-16	Iron status biomarkers;
BRCA	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg22713356	chr15:30763199	NA	1.25	20.77	0.63	1.25e-73	Uric acid levels;
BRCA	cis	rs9790314	0.747	rs1610158	chr3:160815050	A/G	cg04691961	chr3:161091175	C3orf57	0.38	8.37	0.31	3.61e-16	Morning vs. evening chronotype;
BRCA	cis	rs1163251	0.902	rs487081	chr1:120217389	G/A	cg19096424	chr1:120255104	PHGDH	0.44	9.73	0.36	5.98e-21	Blood metabolite levels;
BRCA	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg23229984	chr5:148520753	ABLIM3	0.36	8.74	0.33	2.06e-17	Breast cancer;
BRCA	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg23788917	chr6:8435910	SLC35B3	0.47	10.2	0.37	9.77e-23	Motion sickness;
BRCA	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg07636037	chr3:49044803	WDR6	-0.58	-7.94	-0.3	8.9e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg01028140	chr2:1542097	TPO	-0.57	-11.59	-0.42	2.6e-28	IgG glycosylation;
BRCA	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg24642439	chr20:33292090	TP53INP2	0.72	16.28	0.54	4.17e-50	Coronary artery disease;
BRCA	cis	rs1018836	0.923	rs4735260	chr8:91617157	C/G	cg16814680	chr8:91681699	NA	0.59	12.64	0.45	7.6e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.53	8.52	0.32	1.12e-16	Renal function-related traits (BUN);
BRCA	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-13.89	-0.48	1.57e-38	Personality dimensions;
BRCA	cis	rs2625529	0.617	rs2128112	chr15:72186286	A/T	cg16672083	chr15:72433130	SENP8	0.67	16.17	0.54	1.53e-49	Red blood cell count;
BRCA	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	20.08	0.62	7.08e-70	Smoking behavior;
BRCA	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.61	-11.79	-0.42	3.53e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg26043149	chr18:55253948	FECH	1.09	23.1	0.67	2.65e-86	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs8016982	0.698	rs8021385	chr14:81704682	G/A	cg01989461	chr14:81687754	GTF2A1	0.6	14.22	0.49	4.63e-40	Schizophrenia;
BRCA	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.52	-10.5	-0.38	6.98e-24	Menarche (age at onset);
BRCA	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg06784218	chr1:46089804	CCDC17	-0.45	-10.87	-0.4	2.17e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10501293	0.956	rs10837999	chr11:43068860	T/G	cg03447554	chr11:43094025	NA	0.5	9.09	0.34	1.27e-18	Cognitive performance;
BRCA	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg12219531	chr12:120966889	COQ5	0.56	11.52	0.41	5.18e-28	High light scatter reticulocyte count;
BRCA	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg02951883	chr7:2050386	MAD1L1	-0.53	-11.39	-0.41	1.75e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg20701182	chr2:24300061	SF3B14	0.59	9.31	0.35	2.03e-19	Lymphocyte counts;
BRCA	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg06108461	chr20:60628389	TAF4	-0.79	-16.9	-0.56	3.02e-53	Body mass index;
BRCA	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg13660082	chr14:53194042	PSMC6	-0.56	-8.19	-0.31	1.39e-15	Alzheimer's disease (late onset);
BRCA	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-11.37	-0.41	2.11e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg09436375	chr6:42928200	GNMT	-0.29	-10.89	-0.4	1.87e-25	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18876405	chr7:65276391	NA	0.62	15.22	0.52	7.6e-45	Aortic root size;
BRCA	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg22920501	chr2:26401640	FAM59B	-0.66	-11.52	-0.41	5e-28	Gut microbiome composition (summer);
BRCA	cis	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.75	-0.33	1.96e-17	Resting heart rate;
BRCA	cis	rs7707921	0.522	rs4703537	chr5:81480371	C/T	cg15871215	chr5:81402204	ATG10	0.35	8.86	0.33	7.62e-18	Breast cancer;
BRCA	trans	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg11693508	chr17:37793320	STARD3	0.39	8.06	0.3	3.8e-15	Bipolar disorder;
BRCA	cis	rs6942756	1.000	rs2718084	chr7:128897342	T/C	cg02491457	chr7:128862824	NA	0.64	13.01	0.46	1.69e-34	White matter hyperintensity burden;
BRCA	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg18252515	chr7:66147081	NA	-1.04	-15.49	-0.52	3.67e-46	Diabetic kidney disease;
BRCA	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg11789530	chr4:8429930	ACOX3	-0.68	-17.92	-0.58	1.65e-58	Response to antineoplastic agents;
BRCA	cis	rs2235642	1.000	rs2235642	chr16:1584866	T/C	cg26528668	chr16:1614120	IFT140	0.37	8.37	0.31	3.61e-16	Coronary artery disease;
BRCA	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg22535103	chr8:58192502	C8orf71	-0.61	-13.25	-0.46	1.34e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg18904891	chr8:8559673	CLDN23	0.64	12.61	0.45	1.06e-32	Obesity-related traits;
BRCA	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.83	-0.58	5.25e-58	Chronic sinus infection;
BRCA	cis	rs877529	0.967	rs139405	chr22:39549526	C/A	cg18708252	chr22:39545030	CBX7	-0.32	-8.24	-0.31	9.86e-16	Multiple myeloma;
BRCA	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg17691542	chr6:26056736	HIST1H1C	0.48	9.72	0.36	6.51e-21	Height;
BRCA	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg17063962	chr7:91808500	NA	0.53	11.81	0.42	3.01e-29	Breast cancer;
BRCA	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.48	9.85	0.36	2.07e-21	Systemic lupus erythematosus;
BRCA	trans	rs7980799	0.905	rs4244865	chr12:33511917	C/T	cg26384229	chr12:38710491	ALG10B	-0.4	-8.39	-0.32	3.09e-16	Heart rate;Heart rate variability traits (RMSSD);
BRCA	trans	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg01620082	chr3:125678407	NA	-0.83	-9.94	-0.37	9.21e-22	Depression;
BRCA	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	12.06	0.43	2.63e-30	Multiple sclerosis;
BRCA	cis	rs9296092	0.517	rs11751684	chr6:33528739	G/T	cg13560919	chr6:33536144	NA	-0.91	-19.42	-0.61	2.12e-66	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs870825	0.581	rs7675106	chr4:185652388	C/G	cg04058563	chr4:185651563	MLF1IP	-0.73	-15.84	-0.53	6.2e-48	Blood protein levels;
BRCA	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg22713356	chr15:30763199	NA	1.36	27.16	0.73	1.37e-108	Uric acid levels;
BRCA	trans	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.06	0.3	3.83e-15	Corneal astigmatism;
BRCA	cis	rs2663905	0.611	rs2663924	chr15:81392903	T/G	cg09888468	chr15:81410853	NA	-0.41	-8.77	-0.33	1.63e-17	QT interval (drug interaction);
BRCA	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg04450456	chr4:17643702	FAM184B	-0.32	-8.97	-0.33	3.36e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg21573476	chr21:45109991	RRP1B	-0.32	-8.33	-0.31	4.9e-16	Mean corpuscular volume;
BRCA	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg11752832	chr7:134001865	SLC35B4	0.5	11.89	0.43	1.3e-29	Mean platelet volume;
BRCA	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg10729496	chr3:10149963	C3orf24	0.48	8.98	0.33	2.93e-18	Alzheimer's disease;
BRCA	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.6	-12.69	-0.45	4.36e-33	Lymphocyte counts;
BRCA	cis	rs10899021	1.000	rs10899021	chr11:74338054	C/T	cg25880958	chr11:74394337	NA	0.48	8.39	0.31	3.22e-16	Response to metformin (IC50);
BRCA	cis	rs6435161	1.000	rs72926986	chr2:203519264	G/T	cg18429434	chr2:203499731	FAM117B	-0.44	-8.76	-0.33	1.78e-17	Total cholesterol levels;
BRCA	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.48	-10.4	-0.38	1.72e-23	Longevity;Endometriosis;
BRCA	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.53	8.09	0.3	2.97e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg08917208	chr2:24149416	ATAD2B	0.57	9.07	0.34	1.43e-18	Lymphocyte counts;
BRCA	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg08508325	chr11:3079039	CARS	-0.35	-12.55	-0.44	1.88e-32	Longevity;
BRCA	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg19901468	chr14:105411992	AHNAK2	-0.51	-12.45	-0.44	5.25e-32	Rheumatoid arthritis;
BRCA	cis	rs365132	0.875	rs547798	chr5:176326721	C/A	cg16309518	chr5:176445507	NA	-0.38	-9.33	-0.35	1.74e-19	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs312274	0.551	rs10879397	chr12:41340912	G/A	cg17827154	chr12:41323612	CNTN1	-0.36	-7.89	-0.3	1.36e-14	Metabolite levels  (X-11787);
BRCA	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg08738300	chr3:44038990	NA	0.45	8.61	0.32	5.58e-17	Coronary artery disease;
BRCA	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.84	0.36	2.26e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.17	-0.34	6.66e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs30380	1.000	rs246454	chr5:96123264	C/A	cg16492584	chr5:96139282	ERAP1	-0.31	-7.96	-0.3	7.6e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	8.3	0.31	6.09e-16	Breast cancer;
BRCA	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg11822812	chr5:140052017	DND1	-0.3	-8.24	-0.31	9.93e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4363385	0.747	rs946098	chr1:152975038	A/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.24	-0.31	1.01e-15	Inflammatory skin disease;
BRCA	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg18252515	chr7:66147081	NA	-0.8	-11.18	-0.4	1.23e-26	Diabetic kidney disease;
BRCA	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.43	9.53	0.35	3.16e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg09307838	chr4:120376055	NA	0.59	12.34	0.44	1.63e-31	Corneal astigmatism;
BRCA	cis	rs11997175	0.583	rs12680755	chr8:33815282	G/A	ch.8.33884649F	chr8:33765107	NA	0.37	8.29	0.31	6.68e-16	Body mass index;
BRCA	trans	rs9951602	0.512	rs4798994	chr18:76654327	T/G	cg02800362	chr5:177631904	HNRNPAB	0.78	18.3	0.59	1.73e-60	Obesity-related traits;
BRCA	cis	rs2742234	0.868	rs2505512	chr10:43633596	G/A	cg02780029	chr10:43622663	RET	-0.38	-9.26	-0.34	3.04e-19	Hirschsprung disease;
BRCA	cis	rs73242632	0.867	rs28545156	chr4:57879340	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.66	7.81	0.3	2.38e-14	Congenital heart disease (maternal effect);
BRCA	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg26384229	chr12:38710491	ALG10B	0.74	17.23	0.56	6.19e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6459788	0.934	rs10237947	chr7:157258109	G/T	cg03453431	chr7:157225567	NA	0.4	8.14	0.31	2.01e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg26384229	chr12:38710491	ALG10B	0.87	23.71	0.68	1.15e-89	Heart rate;
BRCA	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg26384229	chr12:38710491	ALG10B	-0.48	-11.23	-0.41	7.65e-27	Morning vs. evening chronotype;
BRCA	cis	rs7586879	1.000	rs10175064	chr2:25117537	T/C	cg01884057	chr2:25150051	NA	0.33	8.27	0.31	7.99e-16	Body mass index;
BRCA	cis	rs2130392	0.886	rs2077205	chr4:185637418	C/T	cg04058563	chr4:185651563	MLF1IP	0.34	8.27	0.31	7.53e-16	Kawasaki disease;
BRCA	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg11645453	chr3:52864694	ITIH4	0.42	10.23	0.38	7.6e-23	Bipolar disorder;
BRCA	cis	rs3849570	0.961	rs7620240	chr3:81762787	G/T	cg07356753	chr3:81810745	GBE1	-0.47	-11.35	-0.41	2.4200000000000002e-27	Waist circumference;Body mass index;
BRCA	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg04546413	chr19:29218101	NA	0.66	13.28	0.46	1.08e-35	Methadone dose in opioid dependence;
BRCA	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.11	0.62	4.73e-70	Electrocardiographic conduction measures;
BRCA	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg18404041	chr3:52824283	ITIH1	-0.34	-9.32	-0.35	1.84e-19	Bipolar disorder;
BRCA	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	0.32	8.33	0.31	4.77e-16	Total body bone mineral density;
BRCA	cis	rs55882075	0.634	rs12518476	chr5:179110850	A/G	cg14593053	chr5:179126677	CANX	0.38	9.54	0.35	3.04e-20	Monocyte percentage of white cells;
BRCA	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg22974920	chr21:40686053	BRWD1	-0.38	-8.26	-0.31	8.44e-16	Cognitive function;
BRCA	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg20503657	chr10:835505	NA	0.67	11.12	0.4	2.26e-26	Eosinophil percentage of granulocytes;
BRCA	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg20607798	chr8:58055168	NA	0.47	8.22	0.31	1.13e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1874326	0.545	rs4620232	chr7:138110210	A/G	cg18008034	chr7:138118925	NA	-0.45	-9.25	-0.34	3.29e-19	Quantitative traits;
BRCA	cis	rs68170813	0.523	rs75999022	chr7:107017135	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-8.53	-0.32	1.07e-16	Coronary artery disease;
BRCA	cis	rs3784262	0.669	rs4646645	chr15:58245151	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.99	-0.37	6.19e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs9790314	0.638	rs17236746	chr3:160646743	A/G	cg03342759	chr3:160939853	NMD3	0.44	8.4	0.32	2.8e-16	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg21747090	chr2:27597821	SNX17	-0.43	-9.43	-0.35	7.24e-20	Total body bone mineral density;
BRCA	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg07148914	chr20:33460835	GGT7	0.36	8.0	0.3	5.78e-15	Height;
BRCA	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11644478	chr21:40555479	PSMG1	-0.67	-14.31	-0.49	1.65e-40	Cognitive function;
BRCA	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg20503657	chr10:835505	NA	-0.41	-8.01	-0.3	5.47e-15	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs495337	0.760	rs6067275	chr20:48545873	C/A	cg17835207	chr20:48524531	SPATA2	-0.69	-16.8	-0.55	1.04e-52	Psoriasis;
BRCA	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg03709012	chr19:19516395	GATAD2A	1.07	21.38	0.65	6.4e-77	Nonalcoholic fatty liver disease;
BRCA	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg24692254	chr21:30365293	RNF160	-0.66	-17.95	-0.58	1.28e-58	Dental caries;
BRCA	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg26408565	chr15:76604113	ETFA	-0.4	-8.82	-0.33	1.11e-17	Blood metabolite levels;
BRCA	cis	rs9811920	0.893	rs9814549	chr3:99892190	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-11.79	-0.42	3.64e-29	Axial length;
BRCA	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.42	0.5	5.42e-41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg23933602	chr10:16859644	RSU1	0.58	12.98	0.46	2.44e-34	Platelet distribution width;
BRCA	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.76	-0.5	1.19e-42	Chronic sinus infection;
BRCA	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17509989	chr5:176798049	RGS14	0.66	13.03	0.46	1.32e-34	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg25358565	chr5:93447407	FAM172A	1.16	18.02	0.58	4.93e-59	Diabetic retinopathy;
BRCA	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg11645453	chr3:52864694	ITIH4	0.41	9.94	0.37	9.27e-22	Bipolar disorder;
BRCA	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg21427119	chr20:30132790	HM13	-0.42	-8.91	-0.33	5.48e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-10.73	-0.39	7.95e-25	Personality dimensions;
BRCA	cis	rs72772090	0.539	rs11747179	chr5:96112969	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.18	-0.43	8.07e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg16586182	chr3:47516702	SCAP	0.59	13.27	0.46	1.08e-35	Colorectal cancer;
BRCA	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg20991723	chr1:152506922	NA	0.37	8.29	0.31	6.78e-16	Hair morphology;
BRCA	cis	rs922182	0.617	rs28621460	chr15:64240232	C/T	cg24729988	chr15:64271149	DAPK2	0.49	10.74	0.39	7.31e-25	Blood protein levels;
BRCA	cis	rs36051895	0.659	rs1159782	chr9:5078117	T/C	cg02405213	chr9:5042618	JAK2	-0.55	-9.86	-0.36	1.99e-21	Pediatric autoimmune diseases;
BRCA	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg06627628	chr2:24431161	ITSN2	-0.65	-12.48	-0.44	4.03e-32	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs11971779	0.618	rs9640925	chr7:139085288	G/A	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18876405	chr7:65276391	NA	-0.51	-11.49	-0.41	6.61e-28	Aortic root size;
BRCA	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg25237894	chr2:233734115	C2orf82	0.38	11.07	0.4	3.67e-26	Coronary artery disease;
BRCA	cis	rs8017423	0.586	rs2896134	chr14:90831293	G/A	cg04374321	chr14:90722782	PSMC1	-0.48	-11.61	-0.42	2.06e-28	Mortality in heart failure;
BRCA	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg24642439	chr20:33292090	TP53INP2	0.41	8.89	0.33	6.23e-18	Height;
BRCA	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg26597838	chr10:835615	NA	1.02	17.86	0.58	3.47e-58	Eosinophil percentage of granulocytes;
BRCA	trans	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.38	-0.35	1.13e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg02891314	chr5:179741120	GFPT2	-0.69	-14.02	-0.49	3.96e-39	Height;
BRCA	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg03709012	chr19:19516395	GATAD2A	-0.49	-9.55	-0.35	2.68e-20	Tonsillectomy;
BRCA	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.62	0.32	5.45e-17	Rheumatoid arthritis;
BRCA	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg14847009	chr1:175162515	KIAA0040	0.28	10.73	0.39	7.97e-25	Alcohol dependence;
BRCA	cis	rs2387326	0.717	rs10829342	chr10:129944493	C/T	cg16087940	chr10:129947807	NA	-0.45	-8.01	-0.3	5.47e-15	Select biomarker traits;
BRCA	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg08999081	chr20:33150536	PIGU	0.46	12.83	0.45	1.11e-33	Glomerular filtration rate (creatinine);
BRCA	cis	rs13046373	0.535	rs9980934	chr21:31982988	C/T	cg16431978	chr21:31797932	KRTAP13-3	0.37	9.61	0.36	1.61e-20	HDL cholesterol;
BRCA	cis	rs4363385	0.747	rs1413848	chr1:152970210	C/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.41	-0.35	9.12e-20	Inflammatory skin disease;
BRCA	cis	rs12530845	0.887	rs61360007	chr7:135316879	G/A	cg23117316	chr7:135346802	PL-5283	-0.34	-8.07	-0.3	3.47e-15	Red blood cell traits;
BRCA	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg04362960	chr10:104952993	NT5C2	0.42	9.53	0.35	3.34e-20	Arsenic metabolism;
BRCA	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg06115741	chr20:33292138	TP53INP2	-0.36	-8.11	-0.31	2.57e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-7.81	-0.3	2.39e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2016266	0.929	rs1318648	chr12:53670545	C/A	cg26875137	chr12:53738046	NA	0.36	9.67	0.36	9.52e-21	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs1018836	0.818	rs715057	chr8:91624340	T/C	cg16814680	chr8:91681699	NA	-0.61	-13.66	-0.48	1.81e-37	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	ch.11.42038R	chr11:967971	AP2A2	0.52	16.55	0.55	1.84e-51	Alzheimer's disease (late onset);
BRCA	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg12641515	chr19:46296257	DMWD	-0.55	-12.13	-0.43	1.28e-30	Coronary artery disease;
BRCA	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-14.32	-0.49	1.48e-40	Platelet count;
BRCA	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg11663144	chr21:46675770	NA	-0.48	-11.34	-0.41	2.65e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg16339924	chr4:17578868	LAP3	-0.6	-14.83	-0.51	5.83e-43	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg04455712	chr21:45112962	RRP1B	0.36	9.15	0.34	7.38e-19	Mean corpuscular volume;
BRCA	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg08085267	chr17:45401833	C17orf57	0.61	12.51	0.44	2.97e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4478858	0.684	rs10798839	chr1:31731758	C/G	cg00250761	chr1:31883323	NA	-0.31	-8.08	-0.3	3.2e-15	Alcohol dependence;
BRCA	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg07828340	chr4:882639	GAK	1.01	14.1	0.49	1.72e-39	Intelligence (multi-trait analysis);
BRCA	cis	rs7246967	0.673	rs9676498	chr19:22910510	A/G	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.5e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg04013093	chr6:42928303	GNMT	-0.27	-8.26	-0.31	8.36e-16	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.66	-14.97	-0.51	1.15e-43	Ulcerative colitis;
BRCA	trans	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg06521331	chr12:34319734	NA	-0.44	-8.34	-0.31	4.57e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9487051	0.597	rs12664455	chr6:109590739	C/T	cg01475377	chr6:109611718	NA	-0.41	-7.84	-0.3	1.91e-14	Reticulocyte fraction of red cells;
BRCA	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg25036284	chr2:26402008	FAM59B	-0.64	-10.67	-0.39	1.39e-24	Gut microbiome composition (summer);
BRCA	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21659725	chr3:3221576	CRBN	0.51	12.09	0.43	1.98e-30	Resting heart rate;
BRCA	cis	rs3770081	1.000	rs12617717	chr2:86342303	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.66	-8.76	-0.33	1.79e-17	Facial emotion recognition (sad faces);
BRCA	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg14675211	chr2:100938903	LONRF2	0.49	11.18	0.4	1.22e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg26384229	chr12:38710491	ALG10B	0.55	12.5	0.44	3.26e-32	Bladder cancer;
BRCA	cis	rs9790314	0.779	rs1599376	chr3:160900533	C/G	cg03342759	chr3:160939853	NMD3	-0.56	-11.02	-0.4	5.8e-26	Morning vs. evening chronotype;
BRCA	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg13319975	chr6:146136371	FBXO30	-0.41	-9.39	-0.35	1e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg25036284	chr2:26402008	FAM59B	-0.64	-10.67	-0.39	1.37e-24	Gut microbiome composition (summer);
BRCA	cis	rs4911259	0.552	rs62208880	chr20:31463284	T/C	cg13636640	chr20:31349939	DNMT3B	-0.45	-11.89	-0.43	1.31e-29	Inflammatory bowel disease;
BRCA	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg18811423	chr2:55921094	PNPT1	-0.61	-16.91	-0.56	2.61e-53	Metabolic syndrome;
BRCA	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.39	8.02	0.3	5.15e-15	Personality dimensions;
BRCA	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg17724175	chr1:150552817	MCL1	0.26	8.53	0.32	1.08e-16	Tonsillectomy;
BRCA	cis	rs113835537	0.529	rs2298806	chr11:66282095	G/A	cg24851651	chr11:66362959	CCS	0.44	8.29	0.31	6.92e-16	Airway imaging phenotypes;
BRCA	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg09754948	chr16:28834200	ATXN2L	0.46	9.12	0.34	9.55e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg21573476	chr21:45109991	RRP1B	-0.35	-9.33	-0.35	1.68e-19	Mean corpuscular volume;
BRCA	cis	rs7301826	0.651	rs12820597	chr12:131280185	T/C	cg11011512	chr12:131303247	STX2	-0.46	-11.32	-0.41	3.49e-27	Plasma plasminogen activator levels;
BRCA	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg11663144	chr21:46675770	NA	-0.61	-14.0	-0.48	4.75e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.23	0.31	1.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg10556349	chr10:835070	NA	-0.73	-9.86	-0.36	1.84e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.35	8.27	0.31	8.01e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg14458575	chr2:238380390	NA	0.54	8.64	0.32	4.4e-17	Prostate cancer;
BRCA	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg11764359	chr7:65958608	NA	0.57	11.92	0.43	1e-29	Aortic root size;
BRCA	cis	rs11112613	0.713	rs60865625	chr12:105940256	A/C	cg03607813	chr12:105948248	NA	0.6	11.13	0.4	2.09e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg03342759	chr3:160939853	NMD3	-0.55	-12.24	-0.44	4.18e-31	Morning vs. evening chronotype;
BRCA	cis	rs7520050	0.966	rs12144263	chr1:46352446	G/A	cg24296786	chr1:45957014	TESK2	0.43	9.78	0.36	3.7e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs503734	0.502	rs348879	chr3:100979826	A/T	cg27318481	chr3:100970896	IMPG2	-0.41	-9.76	-0.36	4.59e-21	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg21475434	chr5:93447410	FAM172A	0.69	8.87	0.33	7.13e-18	Diabetic retinopathy;
BRCA	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg10578991	chr7:12443926	VWDE	-0.55	-7.86	-0.3	1.69e-14	Coronary artery disease;
BRCA	cis	rs6684514	0.922	rs11264475	chr1:156306918	G/A	cg16558208	chr1:156270281	VHLL	0.35	8.08	0.3	3.34e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs11608355	0.545	rs9943764	chr12:109905720	G/A	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs7590368	1.000	rs55771723	chr2:10961902	T/C	cg15705551	chr2:10952987	PDIA6	0.44	8.09	0.3	3.12e-15	Educational attainment (years of education);
BRCA	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.96	0.58	1.14e-58	Fuchs's corneal dystrophy;
BRCA	trans	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.33	0.38	3.01e-23	Mean corpuscular volume;
BRCA	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg03711944	chr11:47377212	SPI1	-0.42	-11.31	-0.41	3.51e-27	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs62229266	0.804	rs880221	chr21:37420785	C/T	cg12218747	chr21:37451666	NA	-0.33	-7.92	-0.3	1.05e-14	Mitral valve prolapse;
BRCA	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-12.77	-0.45	1.95e-33	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7737355	0.947	rs32113	chr5:131049585	G/T	cg06307176	chr5:131281290	NA	-0.56	-11.81	-0.42	2.9e-29	Life satisfaction;
BRCA	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg08601574	chr20:25228251	PYGB	0.37	8.94	0.33	4.11e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11644478	chr21:40555479	PSMG1	0.88	20.91	0.64	2.19e-74	Cognitive function;
BRCA	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg05340658	chr4:99064831	C4orf37	-0.49	-11.52	-0.41	4.93e-28	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.09	0.4	2.88e-26	Electroencephalogram traits;
BRCA	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.7	-11.4	-0.41	1.52e-27	Red cell distribution width;
BRCA	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg15103426	chr22:29168792	CCDC117	0.49	9.86	0.36	1.95e-21	Lymphocyte counts;
BRCA	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg21609526	chr1:3105151	PRDM16	0.38	9.19	0.34	5.43e-19	Migraine;
BRCA	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08219700	chr8:58056026	NA	0.57	9.52	0.35	3.35e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg13010199	chr12:38710504	ALG10B	0.53	11.07	0.4	3.38e-26	Heart rate;
BRCA	cis	rs7131987	0.868	rs11050151	chr12:29403008	T/A	cg09582351	chr12:29534625	ERGIC2	-0.38	-9.15	-0.34	7.26e-19	QT interval;
BRCA	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg14186256	chr22:23484241	RTDR1	0.77	23.78	0.69	5.1599999999999996e-90	Bone mineral density;
BRCA	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg12432903	chr7:1882776	MAD1L1	0.45	8.06	0.3	3.65e-15	Bipolar disorder;
BRCA	trans	rs1941687	0.509	rs2282632	chr18:31320229	A/G	cg27147174	chr7:100797783	AP1S1	-0.44	-8.69	-0.33	3.05e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg00071950	chr4:10020882	SLC2A9	0.56	13.66	0.48	1.77e-37	Bone mineral density;
BRCA	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg04414720	chr1:150670196	GOLPH3L	0.36	8.22	0.31	1.15e-15	Tonsillectomy;
BRCA	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg13628971	chr7:2884303	GNA12	0.48	9.57	0.35	2.33e-20	Height;
BRCA	cis	rs11190604	0.747	rs11190516	chr10:102173525	G/A	cg07080220	chr10:102295463	HIF1AN	0.51	10.36	0.38	2.26e-23	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg16576597	chr16:28551801	NUPR1	0.29	8.14	0.31	2.12e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2742234	0.541	rs10899778	chr10:43718509	G/C	cg15436174	chr10:43711423	RASGEF1A	0.54	10.65	0.39	1.66e-24	Hirschsprung disease;
BRCA	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-18.16	-0.58	1.03e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg16576597	chr16:28551801	NUPR1	0.28	7.9	0.3	1.26e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.33	-7.91	-0.3	1.11e-14	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg19920283	chr7:105172520	RINT1	0.57	10.15	0.37	1.52e-22	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg22974920	chr21:40686053	BRWD1	-0.37	-8.29	-0.31	6.9e-16	Cognitive function;
BRCA	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	7.9e-19	Lymphocyte counts;
BRCA	cis	rs858239	0.600	rs9691762	chr7:23125922	G/C	cg23682824	chr7:23144976	KLHL7	0.46	12.25	0.44	3.7e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg24747557	chr10:131355152	MGMT	-0.36	-8.81	-0.33	1.21e-17	Response to temozolomide;
BRCA	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-7.92	-0.3	1.04e-14	Response to antipsychotic treatment;
BRCA	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg21747090	chr2:27597821	SNX17	-0.37	-7.89	-0.3	1.33e-14	Total body bone mineral density;
BRCA	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-9.33	-0.35	1.75e-19	Menopause (age at onset);
BRCA	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg14675211	chr2:100938903	LONRF2	0.51	11.11	0.4	2.36e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg18850127	chr7:39170497	POU6F2	0.54	11.59	0.42	2.46e-28	IgG glycosylation;
BRCA	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg17366294	chr4:99064904	C4orf37	0.48	11.05	0.4	4.38e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.69	13.18	0.46	2.83e-35	Alzheimer's disease;
BRCA	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09307838	chr4:120376055	NA	-0.72	-15.68	-0.53	4.02e-47	Corneal astigmatism;
BRCA	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08048268	chr3:133502702	NA	-0.42	-10.57	-0.39	3.56e-24	Iron status biomarkers;
BRCA	cis	rs6815814	0.950	rs5743789	chr4:38833173	A/T	cg02016764	chr4:38805732	TLR1	-0.51	-8.02	-0.3	5.14e-15	Breast cancer;
BRCA	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg23422044	chr7:1970798	MAD1L1	-0.72	-13.04	-0.46	1.24e-34	Bipolar disorder;
BRCA	cis	rs13004237	1	rs13004237	chr2:172833139	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.77	-22.25	-0.66	1.16e-81	Schizophrenia;
BRCA	trans	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg07817883	chr1:32538562	TMEM39B	-0.45	-8.73	-0.33	2.18e-17	Monocyte percentage of white cells;
BRCA	cis	rs7805747	0.961	rs55779150	chr7:151406449	A/T	cg17611936	chr7:151411526	PRKAG2	0.41	7.91	0.3	1.15e-14	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
BRCA	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18876405	chr7:65276391	NA	0.55	13.18	0.46	3.03e-35	Aortic root size;
BRCA	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg19346786	chr7:2764209	NA	-0.28	-8.95	-0.33	3.76e-18	Height;
BRCA	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08564027	chr20:61660810	NA	0.86	22.59	0.67	1.77e-83	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	28.25	0.75	1.44e-114	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.52	8.98	0.33	2.98e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1163251	0.869	rs487884	chr1:120217330	C/T	cg19096424	chr1:120255104	PHGDH	0.44	9.73	0.36	5.98e-21	Blood metabolite levels;
BRCA	cis	rs7903847	0.596	rs869967	chr10:99147975	T/C	cg08345082	chr10:99160200	RRP12	-0.29	-8.57	-0.32	7.47e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4363385	0.818	rs529077	chr1:153012149	T/C	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg15737290	chr11:93063684	CCDC67	0.54	10.29	0.38	4.6e-23	Pulmonary function decline;
BRCA	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.5	-0.35	4.12e-20	Metabolite levels;
BRCA	cis	rs2992756	0.663	rs2992753	chr1:18808292	A/C	cg05040210	chr1:18807594	KLHDC7A	0.37	7.82	0.3	2.21e-14	Breast cancer;
BRCA	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg14349672	chr11:133703707	NA	-0.43	-9.58	-0.35	2.09e-20	Childhood ear infection;
BRCA	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg18016565	chr1:150552671	MCL1	0.34	8.23	0.31	1.05e-15	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6840360	0.593	rs4696287	chr4:152606723	C/T	cg22705602	chr4:152727874	NA	-0.38	-10.3	-0.38	4.13e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11644478	chr21:40555479	PSMG1	0.65	14.61	0.5	6.42e-42	Cognitive function;
BRCA	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg14829155	chr15:31115871	NA	0.41	8.11	0.31	2.5e-15	Huntington's disease progression;
BRCA	cis	rs9308433	0.529	rs10465697	chr1:214499948	T/C	cg06198575	chr1:214491504	SMYD2	0.55	12.1	0.43	1.65e-30	IgG glycosylation;
BRCA	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg14683738	chr19:37701593	ZNF585B	0.44	7.83	0.3	2.1e-14	Coronary artery calcification;
BRCA	cis	rs17641971	0.965	rs341815	chr8:49978424	A/C	cg00325661	chr8:49890786	NA	0.31	7.96	0.3	7.89e-15	Blood metabolite levels;
BRCA	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg05340658	chr4:99064831	C4orf37	0.69	17.5	0.57	2.45e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-13.34	-0.47	5.23e-36	Bipolar disorder and schizophrenia;
BRCA	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg08807101	chr21:30365312	RNF160	0.36	7.96	0.3	7.6e-15	Pancreatic cancer;
BRCA	cis	rs6740322	0.643	rs13390381	chr2:43534414	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-10.77	-0.39	5.64e-25	Coronary artery disease;
BRCA	cis	rs912057	1.000	rs1294410	chr6:6738752	C/T	cg06612196	chr6:6737390	NA	-0.45	-9.95	-0.37	9.03e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs6733011	0.538	rs10175560	chr2:99465418	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.37	-8.09	-0.3	3.01e-15	Bipolar disorder;
BRCA	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg17410650	chr12:54324560	NA	-0.38	-9.31	-0.35	2.06e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
BRCA	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg03806693	chr22:41940476	POLR3H	-1.02	-17.47	-0.57	3.59e-56	Vitiligo;
BRCA	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg01689657	chr7:91764605	CYP51A1	-0.23	-7.92	-0.3	1.08e-14	Breast cancer;
BRCA	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-8.7	-0.33	2.85e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg14186256	chr22:23484241	RTDR1	0.74	22.59	0.67	1.73e-83	Bone mineral density;
BRCA	cis	rs10045504	0.502	rs72746051	chr5:38759817	G/A	cg15396434	chr5:38725168	NA	-0.53	-10.21	-0.37	9.28e-23	Night sleep phenotypes;
BRCA	cis	rs1003719	0.715	rs2251952	chr21:38559711	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.56	-12.43	-0.44	6.21e-32	Eye color traits;
BRCA	cis	rs593982	0.777	rs534414	chr11:65475515	A/G	cg08755490	chr11:65554678	OVOL1	1.21	17.87	0.58	3.29e-58	Atopic dermatitis;
BRCA	cis	rs6005807	0.719	rs134524	chr22:28773804	G/A	cg12565055	chr22:29076175	TTC28	-0.43	-7.83	-0.3	2.09e-14	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg06521331	chr12:34319734	NA	-0.62	-11.13	-0.4	2.05e-26	Morning vs. evening chronotype;
BRCA	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs877529	0.967	rs139411	chr22:39552888	A/G	cg18708252	chr22:39545030	CBX7	-0.31	-8.17	-0.31	1.61e-15	Multiple myeloma;
BRCA	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	19.7	0.61	7.37e-68	Platelet count;
BRCA	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.43	9.3	0.35	2.29e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08045932	chr20:61659980	NA	0.5	11.49	0.41	6.62e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg01689657	chr7:91764605	CYP51A1	-0.22	-7.83	-0.3	2e-14	Breast cancer;
BRCA	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg23711669	chr6:146136114	FBXO30	0.71	17.08	0.56	3.5e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6580649	0.882	rs2286022	chr12:48436647	G/A	cg05342945	chr12:48394962	COL2A1	0.43	8.08	0.3	3.3e-15	Lung cancer;
BRCA	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg11645453	chr3:52864694	ITIH4	0.39	9.18	0.34	5.99e-19	Schizophrenia;
BRCA	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-9.76	-0.36	4.55e-21	Aortic root size;
BRCA	cis	rs7760949	0.852	rs9475801	chr6:13933115	G/A	cg27413430	chr6:13925136	RNF182	0.46	9.22	0.34	4.18e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg20607798	chr8:58055168	NA	0.48	8.43	0.32	2.29e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg15017067	chr4:17643749	FAM184B	0.34	10.6	0.39	2.63e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg15448220	chr1:150897856	SETDB1	0.35	7.87	0.3	1.52e-14	Melanoma;
BRCA	cis	rs524281	0.861	rs7941431	chr11:65960157	C/T	cg16950941	chr11:66035639	RAB1B	-0.38	-8.0	-0.3	6.03e-15	Electroencephalogram traits;
BRCA	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg09307838	chr4:120376055	NA	0.7	14.21	0.49	4.82e-40	Corneal astigmatism;
BRCA	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.51	8.43	0.32	2.23e-16	Renal function-related traits (BUN);
BRCA	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg04398451	chr17:18023971	MYO15A	0.72	17.12	0.56	2.3e-54	Total body bone mineral density;
BRCA	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	15.61	0.53	9.12e-47	Colorectal cancer;
BRCA	cis	rs2505998	1.000	rs1864410	chr10:43575625	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.43	-8.43	-0.32	2.25e-16	Hirschsprung disease;
BRCA	cis	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg07460842	chr6:66804631	NA	0.6	10.37	0.38	2.13e-23	Type 2 diabetes;
BRCA	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg19539972	chr4:7069911	GRPEL1	0.67	16.65	0.55	5.4e-52	Monocyte percentage of white cells;
BRCA	cis	rs13046373	0.535	rs7281489	chr21:31978125	C/T	cg13139843	chr21:31852793	KRTAP19-1	0.33	7.98	0.3	6.99e-15	HDL cholesterol;
BRCA	cis	rs6433895	0.677	rs72887083	chr2:181999530	A/G	cg00481216	chr2:181971175	NA	0.46	8.68	0.32	3.35e-17	Lymphocyte counts;
BRCA	trans	rs1422110	0.718	rs10079231	chr5:85439369	A/G	cg01787110	chr1:109008453	NBPF6	0.42	8.97	0.33	3.18e-18	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs701145	0.529	rs355746	chr3:153961627	C/G	cg16511985	chr3:153974050	SGEF	0.45	10.33	0.38	3.18e-23	Coronary artery disease;
BRCA	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg22139774	chr2:100720529	AFF3	0.27	8.01	0.3	5.53e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00166722	chr3:10149974	C3orf24	0.67	12.75	0.45	2.45e-33	Alzheimer's disease;
BRCA	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg26384229	chr12:38710491	ALG10B	-0.51	-11.36	-0.41	2.3e-27	Morning vs. evening chronotype;
BRCA	cis	rs3772130	0.962	rs9856641	chr3:121566859	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.76	0.39	6.04e-25	Cognitive performance;
BRCA	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	13.42	0.47	2.48e-36	Lymphocyte counts;
BRCA	cis	rs7572733	0.555	rs13395030	chr2:198750806	A/G	cg00792783	chr2:198669748	PLCL1	0.47	10.25	0.38	6.42e-23	Dermatomyositis;
BRCA	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg16850897	chr7:100343110	ZAN	-0.59	-12.31	-0.44	2.19e-31	Other erythrocyte phenotypes;
BRCA	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg05347473	chr6:146136440	FBXO30	0.4	8.13	0.31	2.28e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg24006582	chr15:45444508	DUOX1	-0.55	-11.31	-0.41	3.61e-27	Uric acid levels;
BRCA	cis	rs2797160	1.000	rs4897152	chr6:126002400	A/G	cg05901451	chr6:126070800	HEY2	-0.39	-9.45	-0.35	6.5e-20	Endometrial cancer;
BRCA	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg15934090	chr1:100435551	SLC35A3	0.36	8.43	0.32	2.38e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10208940	0.920	rs6742045	chr2:68811850	G/A	cg12452813	chr2:68675892	NA	0.49	8.52	0.32	1.15e-16	Urate levels in lean individuals;
BRCA	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18876405	chr7:65276391	NA	0.7	18.19	0.58	7.1e-60	Aortic root size;
BRCA	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-8.62	-0.32	5.23e-17	Schizophrenia;
BRCA	cis	rs10193935	0.792	rs13430031	chr2:42499968	C/T	cg27598129	chr2:42591480	NA	-0.89	-14.19	-0.49	6.22e-40	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg21045802	chr8:109455806	TTC35	0.35	8.02	0.3	5.13e-15	Dupuytren's disease;
BRCA	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg21770322	chr7:97807741	LMTK2	0.41	11.03	0.4	5.28e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg00321850	chr1:175162397	KIAA0040	0.42	12.08	0.43	2e-30	Alcohol dependence;
BRCA	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg04166393	chr7:2884313	GNA12	0.5	10.37	0.38	2.19e-23	Height;
BRCA	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.38	0.35	1.13e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.13	-0.43	1.25e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.51	0.35	3.84e-20	Morning vs. evening chronotype;
BRCA	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg08859206	chr1:53392774	SCP2	0.48	10.78	0.39	5.03e-25	Monocyte count;
BRCA	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.45	10.82	0.39	3.71e-25	IgG glycosylation;
BRCA	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg05665937	chr4:1216051	CTBP1	0.52	10.95	0.4	1.07e-25	Obesity-related traits;
BRCA	cis	rs2072438	0.503	rs2146838	chr9:123876305	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.39	-7.85	-0.3	1.72e-14	Rheumatoid arthritis;
BRCA	trans	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg26384229	chr12:38710491	ALG10B	0.51	11.1	0.4	2.57e-26	Morning vs. evening chronotype;
BRCA	cis	rs13064411	0.696	rs6773497	chr3:113186514	T/C	cg18753928	chr3:113234510	CCDC52	-0.55	-11.48	-0.41	7.08e-28	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.93	0.33	4.64e-18	Tonsillectomy;
BRCA	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.64	12.42	0.44	7.32e-32	Chronic sinus infection;
BRCA	cis	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg07460842	chr6:66804631	NA	0.6	10.2	0.37	1.01e-22	Type 2 diabetes;
BRCA	cis	rs4363385	0.818	rs678960	chr1:153011621	G/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg00409905	chr10:38381863	ZNF37A	0.5	10.71	0.39	9.56e-25	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg08975724	chr8:8085496	FLJ10661	0.45	9.1	0.34	1.13e-18	Mood instability;
BRCA	cis	rs10193935	0.792	rs10204778	chr2:42498121	G/T	cg27598129	chr2:42591480	NA	-0.9	-14.14	-0.49	1.1e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9487051	0.735	rs351756	chr6:109538773	A/G	cg21918786	chr6:109611834	NA	0.36	9.52	0.35	3.45e-20	Reticulocyte fraction of red cells;
BRCA	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.53	-11.45	-0.41	9.7e-28	IgG glycosylation;
BRCA	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg21573476	chr21:45109991	RRP1B	-0.37	-9.4	-0.35	9.61e-20	Mean corpuscular volume;
BRCA	trans	rs11976180	1.000	rs2951354	chr7:143761001	G/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.26	-0.31	8.66e-16	Obesity-related traits;
BRCA	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg11833968	chr6:79620685	NA	-0.45	-10.21	-0.37	8.67e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg16606324	chr3:10149918	C3orf24	0.56	10.99	0.4	7.61e-26	Alzheimer's disease;
BRCA	trans	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg21659725	chr3:3221576	CRBN	-0.47	-9.99	-0.37	6.41e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.82	0.62	1.64e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg05313129	chr8:58192883	C8orf71	-0.46	-9.63	-0.36	1.34e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.52	-8.45	-0.32	1.96e-16	Schizophrenia;
BRCA	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.49	0.38	7.33e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	9.16	0.34	6.84e-19	Bipolar disorder;
BRCA	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg13319975	chr6:146136371	FBXO30	0.44	10.31	0.38	3.74e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs524281	0.861	rs6591208	chr11:65949689	A/C	cg16950941	chr11:66035639	RAB1B	-0.37	-7.82	-0.3	2.14e-14	Electroencephalogram traits;
BRCA	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs9547692	0.938	rs7333607	chr13:37462010	A/G	cg01493522	chr13:37497338	NA	-0.4	-8.26	-0.31	8.34e-16	Coronary artery disease;
BRCA	cis	rs34779708	0.931	rs66887762	chr10:35330577	C/T	cg03585969	chr10:35415529	CREM	0.56	11.6	0.42	2.32e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs17401966	0.540	rs11121557	chr1:10448260	T/G	cg03954927	chr1:10346856	KIF1B	0.34	10.15	0.37	1.46e-22	Hepatocellular carcinoma;
BRCA	trans	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg26043149	chr18:55253948	FECH	-0.38	-8.47	-0.32	1.66e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg01017244	chr2:74357527	NA	0.61	12.65	0.45	6.76e-33	Gestational age at birth (maternal effect);
BRCA	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-10.85	-0.39	2.66e-25	Morning vs. evening chronotype;
BRCA	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg11266682	chr4:10021025	SLC2A9	0.45	12.02	0.43	3.9e-30	Bone mineral density;
BRCA	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.38	9.08	0.34	1.38e-18	Platelet count;
BRCA	cis	rs4363385	0.782	rs310105	chr1:153022253	A/G	cg24667326	chr1:152973720	SPRR3	-0.31	-8.29	-0.31	6.61e-16	Inflammatory skin disease;
BRCA	cis	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg07988820	chr12:82153109	PPFIA2	0.51	8.81	0.33	1.2e-17	Resting heart rate;
BRCA	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg20203395	chr5:56204925	C5orf35	0.39	8.57	0.32	7.72e-17	Initial pursuit acceleration;
BRCA	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg06606381	chr12:133084897	FBRSL1	-0.77	-8.04	-0.3	4.34e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg19743168	chr1:23544995	NA	0.4	9.63	0.36	1.36e-20	Height;
BRCA	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg13319975	chr6:146136371	FBXO30	-0.34	-7.91	-0.3	1.1e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8051149	0.652	rs9926829	chr16:87883089	A/G	cg01412419	chr16:87856264	NA	-0.44	-9.29	-0.34	2.48e-19	Blood metabolite levels;
BRCA	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	8.9	0.33	5.6e-18	Calcium levels;
BRCA	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg06640241	chr16:89574553	SPG7	0.47	8.71	0.33	2.55e-17	Multiple myeloma (IgH translocation);
BRCA	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg26384229	chr12:38710491	ALG10B	0.78	18.0	0.58	6.47e-59	Heart rate;
BRCA	cis	rs6484504	0.576	rs208090	chr11:31190992	T/C	cg26647111	chr11:31128758	NA	-0.44	-9.61	-0.36	1.65e-20	Red blood cell count;
BRCA	cis	rs1975991	0.711	rs1479934	chr3:187966553	A/G	cg15417654	chr3:187959138	LPP	0.33	8.36	0.31	3.94e-16	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg16006841	chr5:176797999	RGS14	0.61	11.82	0.42	2.64e-29	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg05340658	chr4:99064831	C4orf37	0.59	12.13	0.43	1.33e-30	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.88	0.3	1.4e-14	Endometrial cancer;
BRCA	cis	rs3784262	0.565	rs1899355	chr15:58286989	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-8.49	-0.32	1.4e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg12310025	chr6:25882481	NA	-0.41	-9.94	-0.37	9.63e-22	Height;
BRCA	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.3	-0.35	2.28e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs495337	0.760	rs6125825	chr20:48553703	A/G	cg17835207	chr20:48524531	SPATA2	-0.67	-16.65	-0.55	5.78e-52	Psoriasis;
BRCA	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg19920283	chr7:105172520	RINT1	0.59	9.54	0.35	2.83e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs8141797	0.901	rs17004848	chr22:24538918	C/T	cg00411358	chr22:24577142	SUSD2	-0.66	-8.35	-0.31	4.15e-16	Amyotrophic lateral sclerosis;Coronary artery disease;
BRCA	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg15103426	chr22:29168792	CCDC117	0.48	11.83	0.42	2.56e-29	Red cell distribution width;
BRCA	trans	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg15704280	chr7:45808275	SEPT13	0.52	7.97	0.3	7.45e-15	Intraocular pressure;
BRCA	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg01881094	chr2:180872142	CWC22	-0.65	-13.58	-0.47	4.19e-37	Schizophrenia;
BRCA	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.65	0.55	5.42e-52	Alzheimer's disease (late onset);
BRCA	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg05347473	chr6:146136440	FBXO30	0.39	7.86	0.3	1.66e-14	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6479891	1.000	rs868798	chr10:64895010	A/G	cg14819942	chr15:35414228	NA	0.34	8.51	0.32	1.2e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg03433033	chr1:76189801	ACADM	-0.45	-9.25	-0.34	3.36e-19	Daytime sleep phenotypes;
BRCA	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg11266682	chr4:10021025	SLC2A9	0.41	10.81	0.39	3.89e-25	Bone mineral density;
BRCA	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg13902645	chr11:5959945	NA	-0.52	-10.87	-0.4	2.2e-25	DNA methylation (variation);
BRCA	cis	rs600806	0.888	rs3853500	chr1:109864269	T/C	cg20591472	chr1:110008990	SYPL2	0.32	8.12	0.31	2.5e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1018836	0.923	rs7840846	chr8:91565501	T/A	cg16814680	chr8:91681699	NA	-0.64	-14.26	-0.49	2.9e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg10523679	chr1:76189770	ACADM	-0.63	-11.77	-0.42	4.25e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg15513719	chr13:114904418	NA	0.43	8.21	0.31	1.2e-15	Schizophrenia;
BRCA	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg21475434	chr5:93447410	FAM172A	0.68	8.7	0.33	2.86e-17	Diabetic retinopathy;
BRCA	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.95	0.33	3.76e-18	Tonsillectomy;
BRCA	trans	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg15556689	chr8:8085844	FLJ10661	0.34	9.19	0.34	5.38e-19	Retinal vascular caliber;
BRCA	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg01262667	chr19:19385393	TM6SF2	0.43	11.05	0.4	4.1e-26	Tonsillectomy;
BRCA	cis	rs490234	0.651	rs13301073	chr9:128284378	G/A	cg14078157	chr9:128172775	NA	-0.53	-11.76	-0.42	4.68e-29	Mean arterial pressure;
BRCA	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.58	0.47	4.49e-37	Colorectal cancer;
BRCA	cis	rs4722166	0.598	rs7804146	chr7:22800929	C/G	cg05472934	chr7:22766657	IL6	0.39	9.69	0.36	8.21e-21	Lung cancer;
BRCA	trans	rs9951602	0.512	rs12607561	chr18:76644284	G/A	cg02800362	chr5:177631904	HNRNPAB	0.75	17.49	0.57	2.96e-56	Obesity-related traits;
BRCA	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg14844989	chr11:31128820	NA	-0.45	-9.7	-0.36	7.9e-21	Red blood cell count;
BRCA	trans	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg25214090	chr10:38739885	LOC399744	0.46	10.62	0.39	2.31e-24	Corneal astigmatism;
BRCA	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg00666640	chr1:248458726	OR2T12	0.32	8.85	0.33	8.5e-18	Common traits (Other);
BRCA	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg24692254	chr21:30365293	RNF160	-0.46	-10.32	-0.38	3.45e-23	Pancreatic cancer;
BRCA	cis	rs7737355	0.945	rs245801	chr5:130666955	T/C	cg06307176	chr5:131281290	NA	-0.46	-9.04	-0.34	1.88e-18	Life satisfaction;
BRCA	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg08061076	chr7:1943177	MAD1L1	-0.35	-7.97	-0.3	7.13e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg26384229	chr12:38710491	ALG10B	0.73	17.03	0.56	6.96e-54	Bladder cancer;
BRCA	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg18132916	chr6:79620363	NA	-0.48	-10.78	-0.39	5.12e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs478304	0.934	rs509206	chr11:65493807	C/T	cg08755490	chr11:65554678	OVOL1	0.46	9.16	0.34	7.21e-19	Acne (severe);
BRCA	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg14186256	chr22:23484241	RTDR1	0.74	22.31	0.66	5.84e-82	Bone mineral density;
BRCA	cis	rs73242632	1.000	rs73242622	chr4:57818564	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.65	7.93	0.3	9.85e-15	Congenital heart disease (maternal effect);
BRCA	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.52	-0.32	1.13e-16	Breast cancer;
BRCA	cis	rs41005	0.967	rs1974696	chr2:8115782	A/G	cg03155496	chr2:8117019	LOC339788	0.63	18.17	0.58	8.7e-60	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg24812749	chr6:127587940	RNF146	0.88	20.87	0.64	3.85e-74	Breast cancer;
BRCA	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.66	12.81	0.45	1.37e-33	Alzheimer's disease;
BRCA	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg24642439	chr20:33292090	TP53INP2	0.41	8.1	0.31	2.71e-15	Height;
BRCA	trans	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.46	0.38	9.36e-24	Mean corpuscular volume;
BRCA	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg23018236	chr17:30244563	NA	-0.68	-10.6	-0.39	2.7e-24	Hip circumference adjusted for BMI;
BRCA	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-18.07	-0.58	3e-59	Chronic sinus infection;
BRCA	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg08027265	chr7:2291960	NA	-0.35	-8.11	-0.31	2.66e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg09184832	chr6:79620586	NA	-0.53	-11.72	-0.42	6.96e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	11.89	0.43	1.31e-29	Tonsillectomy;
BRCA	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg24812749	chr6:127587940	RNF146	0.87	19.99	0.62	2.03e-69	Breast cancer;
BRCA	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	15.64	0.53	6.44e-47	Platelet count;
BRCA	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11764359	chr7:65958608	NA	0.8	19.51	0.61	7.33e-67	Aortic root size;
BRCA	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg16006841	chr5:176797999	RGS14	0.61	11.88	0.43	1.57e-29	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06022373	chr22:39101656	GTPBP1	0.73	17.6	0.57	7.85e-57	Menopause (age at onset);
BRCA	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08219700	chr8:58056026	NA	0.57	9.4	0.35	9.75e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg00990874	chr7:1149470	C7orf50	-0.6	-12.17	-0.43	8.99e-31	Bronchopulmonary dysplasia;
BRCA	cis	rs7633770	0.805	rs12330414	chr3:46662428	T/C	cg11219411	chr3:46661640	NA	0.73	21.1	0.64	2.2e-75	Coronary artery disease;
BRCA	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg12698349	chr2:225449008	CUL3	0.61	12.61	0.45	1.06e-32	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg27170947	chr2:26402098	FAM59B	0.92	16.52	0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	trans	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.94	-0.37	9.45e-22	Bladder cancer;
BRCA	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg03146154	chr1:46216737	IPP	0.5	11.15	0.4	1.67e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg04025307	chr7:1156635	C7orf50	0.5	11.83	0.42	2.55e-29	Longevity;Endometriosis;
BRCA	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.5e-36	High light scatter reticulocyte count;
BRCA	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.08	-0.43	2.05e-30	Total cholesterol levels;
BRCA	cis	rs724568	0.565	rs13405830	chr2:67952260	A/G	cg17945962	chr2:67939740	NA	-0.37	-9.75	-0.36	5.01e-21	Major depressive disorder (broad);
BRCA	cis	rs10267417	0.603	rs36077006	chr7:19933853	A/G	cg05791153	chr7:19748676	TWISTNB	0.43	8.17	0.31	1.6e-15	Night sleep phenotypes;
BRCA	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	13.99	0.48	5.5e-39	Motion sickness;
BRCA	cis	rs10838687	0.800	rs4752977	chr11:47300429	T/C	cg25783544	chr11:47291846	MADD	0.41	7.96	0.3	7.98e-15	Proinsulin levels;
BRCA	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11764359	chr7:65958608	NA	0.62	13.46	0.47	1.49e-36	Calcium levels;
BRCA	cis	rs7617773	0.780	rs36075665	chr3:48343087	C/T	cg11946769	chr3:48343235	NME6	0.68	13.81	0.48	3.66e-38	Coronary artery disease;
BRCA	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg18404041	chr3:52824283	ITIH1	-0.47	-13.93	-0.48	1.01e-38	Bipolar disorder;
BRCA	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.52	8.5	0.32	1.38e-16	Renal function-related traits (BUN);
BRCA	cis	rs9287719	0.578	rs10175555	chr2:10703233	T/C	cg00105475	chr2:10696890	NA	0.46	10.13	0.37	1.77e-22	Prostate cancer;
BRCA	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg14863265	chr7:2801509	GNA12	-0.36	-8.11	-0.31	2.67e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
BRCA	cis	rs4363385	0.747	rs4845507	chr1:152968414	T/G	cg24667326	chr1:152973720	SPRR3	-0.36	-9.89	-0.36	1.54e-21	Inflammatory skin disease;
BRCA	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	18.57	0.59	7.14e-62	Alzheimer's disease;
BRCA	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.64	-15.72	-0.53	2.43e-47	Longevity;Endometriosis;
BRCA	trans	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg19862616	chr7:65841803	NCRNA00174	0.83	27.27	0.73	3.26e-109	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs66887589	0.934	rs41464847	chr4:120532401	A/G	cg09307838	chr4:120376055	NA	-0.42	-8.79	-0.33	1.36e-17	Diastolic blood pressure;
BRCA	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg19257562	chr1:2043853	PRKCZ	-0.34	-9.02	-0.34	2.13e-18	Height;
BRCA	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.63	-13.08	-0.46	7.94e-35	Lung cancer;
BRCA	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg06623918	chr6:96969491	KIAA0776	-0.92	-27.27	-0.73	3.36e-109	Headache;
BRCA	cis	rs1712517	0.771	rs11191654	chr10:105077124	C/A	cg05636881	chr10:105038444	INA	0.35	7.99	0.3	6.39e-15	Migraine;
BRCA	cis	rs12200560	0.505	rs211174	chr6:97071120	C/T	cg06623918	chr6:96969491	KIAA0776	0.51	12.03	0.43	3.35e-30	Coronary heart disease;
BRCA	cis	rs7617773	0.780	rs7645425	chr3:48362369	A/T	cg11946769	chr3:48343235	NME6	0.67	13.64	0.47	2.37e-37	Coronary artery disease;
BRCA	cis	rs360798	0.512	rs2539978	chr2:63195179	T/C	cg17519650	chr2:63277830	OTX1	0.39	8.58	0.32	7.09e-17	Coronary artery disease;
BRCA	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg00701064	chr4:6280414	WFS1	0.68	17.62	0.57	5.96e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs72772090	0.539	rs111237997	chr5:96114953	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.15	-0.43	9.97e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6942756	1.000	rs6974155	chr7:128914545	C/G	cg02491457	chr7:128862824	NA	-0.69	-13.88	-0.48	1.72e-38	White matter hyperintensity burden;
BRCA	cis	rs490234	0.676	rs13293034	chr9:128256951	C/T	cg14078157	chr9:128172775	NA	-0.53	-11.75	-0.42	5.48e-29	Mean arterial pressure;
BRCA	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg07395648	chr5:131743802	NA	0.36	9.08	0.34	1.38e-18	Blood metabolite levels;
BRCA	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg00677455	chr12:58241039	CTDSP2	-0.35	-7.89	-0.3	1.29e-14	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg08470875	chr2:26401718	FAM59B	-0.5	-8.17	-0.31	1.65e-15	Gut microbiome composition (summer);
BRCA	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg06623918	chr6:96969491	KIAA0776	-0.92	-27.15	-0.73	1.65e-108	Headache;
BRCA	cis	rs2625529	0.652	rs9302260	chr15:72174611	T/C	cg16672083	chr15:72433130	SENP8	0.66	15.65	0.53	5.83e-47	Red blood cell count;
BRCA	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg20701182	chr2:24300061	SF3B14	0.6	9.39	0.35	1.02e-19	Lymphocyte counts;
BRCA	cis	rs9309711	0.922	rs13385119	chr2:3484521	G/A	cg16153549	chr2:3496821	NA	-0.41	-9.58	-0.35	2.16e-20	Neurofibrillary tangles;
BRCA	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg16586182	chr3:47516702	SCAP	-0.56	-12.9	-0.45	5.05e-34	Colorectal cancer;
BRCA	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg01874867	chr7:94954059	PON1	-0.39	-7.81	-0.3	2.29e-14	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg17971929	chr21:40555470	PSMG1	-0.62	-14.45	-0.5	3.61e-41	Cognitive function;
BRCA	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg13319975	chr6:146136371	FBXO30	-0.39	-8.78	-0.33	1.51e-17	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.66	0.36	1.08e-20	Morning vs. evening chronotype;
BRCA	cis	rs7737355	0.947	rs10477736	chr5:130922125	T/C	cg06307176	chr5:131281290	NA	0.53	10.34	0.38	2.89e-23	Life satisfaction;
BRCA	cis	rs71636778	0.543	rs11810321	chr1:27220521	T/G	cg12203394	chr1:27248618	NUDC	0.62	9.59	0.35	1.92e-20	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg18016565	chr1:150552671	MCL1	0.34	8.12	0.31	2.43e-15	Tonsillectomy;
BRCA	cis	rs10733682	0.659	rs13287548	chr9:129466456	C/T	cg00232160	chr9:129468157	NA	0.41	9.51	0.35	3.92e-20	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs6121246	0.609	rs2377317	chr20:30402502	A/G	cg13852791	chr20:30311386	BCL2L1	-0.84	-18.3	-0.59	1.81e-60	Mean corpuscular hemoglobin;
BRCA	cis	rs7927771	0.793	rs3740686	chr11:47376363	A/G	cg20307385	chr11:47447363	PSMC3	0.41	8.56	0.32	8.72e-17	Subjective well-being;
BRCA	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg07395648	chr5:131743802	NA	0.38	8.28	0.31	7.37e-16	Breast cancer;
BRCA	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg13319975	chr6:146136371	FBXO30	-0.41	-9.39	-0.35	1e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg14675211	chr2:100938903	LONRF2	0.48	10.75	0.39	7.13e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg09367891	chr1:107599246	PRMT6	-0.56	-10.08	-0.37	2.81e-22	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18402987	chr7:1209562	NA	0.51	9.77	0.36	4.11e-21	Longevity;Endometriosis;
BRCA	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-8.9	-0.33	5.92e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-15.37	-0.52	1.43e-45	Systemic lupus erythematosus;
BRCA	cis	rs4787491	0.765	rs4788216	chr16:30048077	C/G	cg06326092	chr16:30034487	C16orf92	0.38	9.92	0.37	1.16e-21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	trans	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04565464	chr8:145669602	NFKBIL2	0.4	9.09	0.34	1.25e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg15997130	chr1:24165203	NA	-0.45	-9.96	-0.37	8.32e-22	Immature fraction of reticulocytes;
BRCA	cis	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg06521331	chr12:34319734	NA	-0.5	-9.57	-0.35	2.24e-20	Morning vs. evening chronotype;
BRCA	cis	rs10046574	0.831	rs17479687	chr7:135074833	C/G	cg27474649	chr7:135195673	CNOT4	0.57	8.42	0.32	2.49e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg15133208	chr4:90757351	SNCA	-0.39	-8.05	-0.3	4.1e-15	Neuroticism;
BRCA	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18876405	chr7:65276391	NA	-0.56	-13.13	-0.46	4.95e-35	Aortic root size;
BRCA	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg16339924	chr4:17578868	LAP3	0.62	15.33	0.52	2.18e-45	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg21782813	chr7:2030301	MAD1L1	-0.38	-11.24	-0.41	7.05e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	7.83	0.3	1.99e-14	Diabetic retinopathy;
BRCA	cis	rs7851660	0.967	rs7049054	chr9:100599969	T/G	cg13688889	chr9:100608707	NA	-0.36	-8.61	-0.32	5.84e-17	Strep throat;
BRCA	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg13010199	chr12:38710504	ALG10B	0.36	8.31	0.31	5.87e-16	Morning vs. evening chronotype;
BRCA	cis	rs7766436	0.614	rs2073030	chr6:22569634	A/T	cg13666174	chr6:22585274	NA	-0.4	-8.91	-0.33	5.33e-18	Coronary artery disease;
BRCA	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-12.81	-0.45	1.39e-33	Bipolar disorder;
BRCA	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24110177	chr3:50126178	RBM5	0.36	9.72	0.36	6.3e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs12618769	0.656	rs3820943	chr2:99123177	G/C	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-15.89	-0.53	3.7e-48	Total cholesterol levels;
BRCA	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg15556689	chr8:8085844	FLJ10661	0.38	9.07	0.34	1.4e-18	Retinal vascular caliber;
BRCA	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg08601574	chr20:25228251	PYGB	0.34	8.22	0.31	1.14e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg02820040	chr2:241836501	C2orf54	-0.53	-10.24	-0.38	7e-23	Urinary metabolites;
BRCA	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18876405	chr7:65276391	NA	0.5	11.33	0.41	3.02e-27	Aortic root size;
BRCA	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg04362960	chr10:104952993	NT5C2	0.42	10.04	0.37	4.11e-22	Arsenic metabolism;
BRCA	cis	rs6542838	0.611	rs13006398	chr2:99522323	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.39	-8.78	-0.33	1.44e-17	Fear of minor pain;
BRCA	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg23887609	chr12:130822674	PIWIL1	0.43	9.33	0.35	1.71e-19	Menopause (age at onset);
BRCA	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg24692254	chr21:30365293	RNF160	0.38	8.8	0.33	1.27e-17	Pancreatic cancer;
BRCA	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg02931644	chr1:25747376	RHCE	0.4	11.31	0.41	3.76e-27	Erythrocyte sedimentation rate;
BRCA	cis	rs2016266	0.859	rs11170507	chr12:53740682	C/A	cg26875137	chr12:53738046	NA	-0.44	-9.67	-0.36	9.75e-21	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs1568889	0.838	rs11030187	chr11:28044391	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	20.34	0.63	2.76e-71	Bipolar disorder;
BRCA	trans	rs7246760	0.867	rs58461110	chr19:9833390	G/A	cg02900749	chr2:68251473	NA	-0.48	-7.93	-0.3	1e-14	Pursuit maintenance gain;
BRCA	cis	rs2282802	0.685	rs7730245	chr5:139628163	C/A	cg26211634	chr5:139558579	C5orf32	0.35	8.34	0.31	4.45e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.747	rs1611753	chr1:152956381	C/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.44	-0.35	7.05e-20	Inflammatory skin disease;
BRCA	trans	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg06521331	chr12:34319734	NA	-0.52	-9.45	-0.35	6.17e-20	Bladder cancer;
BRCA	cis	rs778371	0.697	rs6717048	chr2:233586427	T/C	cg08000102	chr2:233561755	GIGYF2	0.85	20.93	0.64	1.86e-74	Schizophrenia;
BRCA	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg14844989	chr11:31128820	NA	-0.44	-9.54	-0.35	3.05e-20	Red blood cell count;
BRCA	cis	rs12210905	0.688	rs9368509	chr6:27379422	A/G	cg08851530	chr6:28072375	NA	-0.8	-7.93	-0.3	9.84e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	8.65e-21	Menopause (age at onset);
BRCA	trans	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg17675199	chr6:35436792	RPL10A	-0.29	-7.81	-0.3	2.31e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs17209837	0.527	rs45479991	chr7:87083339	A/T	cg00919237	chr7:87102261	ABCB4	-0.52	-10.01	-0.37	5.04e-22	Gallbladder cancer;
BRCA	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	12.33	0.44	1.74e-31	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg06521331	chr12:34319734	NA	-0.45	-8.58	-0.32	7.16e-17	Bladder cancer;
BRCA	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg00074818	chr8:8560427	CLDN23	-0.35	-8.01	-0.3	5.38e-15	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg03676636	chr4:99064102	C4orf37	0.21	7.94	0.3	8.94e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-9.75	-0.36	5.03e-21	Height;
BRCA	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07308232	chr7:1071921	C7orf50	-0.49	-10.24	-0.38	6.68e-23	Longevity;Endometriosis;
BRCA	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg14004847	chr7:1930337	MAD1L1	-0.41	-7.91	-0.3	1.17e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg20887711	chr4:1340912	KIAA1530	0.38	8.89	0.33	5.97e-18	Longevity;
BRCA	cis	rs12210905	0.688	rs12199806	chr6:27435943	A/C	cg08851530	chr6:28072375	NA	0.81	7.97	0.3	7.05e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg10253484	chr15:75165896	SCAMP2	0.42	8.38	0.31	3.37e-16	Systemic lupus erythematosus;
BRCA	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.85e-29	Chronic sinus infection;
BRCA	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17209837	0.607	rs2270187	chr7:87080698	T/C	cg00919237	chr7:87102261	ABCB4	-0.52	-10.15	-0.37	1.5e-22	Gallbladder cancer;
BRCA	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23583168	chr7:148888333	NA	-0.85	-19.57	-0.61	3.56e-67	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.28	-0.44	2.82e-31	Chronic sinus infection;
BRCA	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.63	-15.2	-0.52	9.18e-45	Longevity;Endometriosis;
BRCA	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.34	-0.31	4.61e-16	Total body bone mineral density;
BRCA	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg21573476	chr21:45109991	RRP1B	0.34	8.73	0.33	2.19e-17	Mean corpuscular volume;
BRCA	cis	rs17095355	0.901	rs7069128	chr10:111760075	C/T	cg00817464	chr10:111662876	XPNPEP1	0.37	9.48	0.35	4.95e-20	Biliary atresia;
BRCA	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg18105134	chr13:113819100	PROZ	-0.62	-14.3	-0.49	1.99e-40	Platelet distribution width;
BRCA	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	12.86	0.45	8.26e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg19743168	chr1:23544995	NA	0.35	8.15	0.31	1.89e-15	Height;
BRCA	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg01475377	chr6:109611718	NA	-0.56	-15.06	-0.51	4.31e-44	Reticulocyte fraction of red cells;
BRCA	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg21770322	chr7:97807741	LMTK2	0.42	11.27	0.41	5.33e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg22153463	chr1:85462885	MCOLN2	0.56	10.17	0.37	1.33e-22	Serum sulfate level;
BRCA	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg26516362	chr5:178986906	RUFY1	0.35	8.72	0.33	2.38e-17	Lung cancer;
BRCA	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-14.53	-0.5	1.5e-41	Chronic sinus infection;
BRCA	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg26597838	chr10:835615	NA	0.55	9.97	0.37	7.17e-22	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09256448	chr16:638327	NA	0.3	8.01	0.3	5.61e-15	Height;
BRCA	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.01	0.4	6.14e-26	Electroencephalogram traits;
BRCA	cis	rs7833986	0.818	rs79824205	chr8:57093233	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.46	8.27	0.31	7.97e-16	Height;
BRCA	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg08999081	chr20:33150536	PIGU	0.45	12.47	0.44	4.3e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs7072216	0.763	rs7911036	chr10:100167015	A/T	cg26618903	chr10:100175079	PYROXD2	-0.31	-8.96	-0.33	3.58e-18	Metabolite levels;
BRCA	cis	rs13046373	0.535	rs9977510	chr21:32027920	A/G	cg22337977	chr21:31811175	KRTAP15-1	0.34	7.83	0.3	2.06e-14	HDL cholesterol;
BRCA	cis	rs7809950	0.678	rs982447	chr7:106973534	T/C	cg23024343	chr7:107201750	COG5	-0.46	-9.51	-0.35	3.65e-20	Coronary artery disease;
BRCA	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg09307838	chr4:120376055	NA	0.69	14.55	0.5	1.29e-41	Corneal astigmatism;
BRCA	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg17691542	chr6:26056736	HIST1H1C	0.45	8.77	0.33	1.59e-17	Iron status biomarkers;
BRCA	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg19678392	chr7:94953810	PON1	-0.41	-8.68	-0.32	3.38e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg03934865	chr2:198174659	NA	0.38	8.17	0.31	1.6e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs208520	1.000	rs208520	chr6:66952828	G/T	cg07460842	chr6:66804631	NA	-0.79	-13.3	-0.47	8.34e-36	Exhaled nitric oxide output;
BRCA	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg06494592	chr3:125709126	NA	-0.53	-8.22	-0.31	1.17e-15	Blood pressure (smoking interaction);
BRCA	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg04315214	chr1:2043799	PRKCZ	0.47	12.82	0.45	1.23e-33	Height;
BRCA	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg04455712	chr21:45112962	RRP1B	0.38	9.8	0.36	3.29e-21	Mean corpuscular volume;
BRCA	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg08079166	chr15:68083412	MAP2K5	-0.36	-9.6	-0.36	1.76e-20	Restless legs syndrome;
BRCA	cis	rs10193935	1.000	rs13421289	chr2:42412808	T/C	cg27598129	chr2:42591480	NA	-0.93	-14.82	-0.51	6.13e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6066825	0.644	rs926629	chr20:47335736	A/G	cg18078177	chr20:47281410	PREX1	0.37	9.13	0.34	8.97e-19	Colorectal cancer;
BRCA	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg23033748	chr14:75592666	NEK9	-0.41	-9.81	-0.36	3.07e-21	Height;
BRCA	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg02221750	chr19:17393354	ANKLE1	-0.65	-12.55	-0.44	1.92e-32	Systemic lupus erythematosus;
BRCA	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg02544614	chr20:61657117	NA	0.28	7.85	0.3	1.8e-14	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12681287	0.640	rs6471309	chr8:87387760	C/T	cg27223183	chr8:87520930	FAM82B	-0.43	-8.23	-0.31	1.03e-15	Caudate activity during reward;
BRCA	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.35	9.04	0.34	1.9e-18	Resting heart rate;
BRCA	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	19.73	0.62	4.82e-68	Platelet count;
BRCA	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg23649088	chr2:200775458	C2orf69	-0.57	-8.58	-0.32	7.36e-17	Schizophrenia;
BRCA	trans	rs2797160	1.000	rs984040	chr6:126021277	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.37	8.44	0.32	2.16e-16	Endometrial cancer;
BRCA	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg11814155	chr7:99998594	ZCWPW1	0.46	8.22	0.31	1.16e-15	Platelet count;
BRCA	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg10523679	chr1:76189770	ACADM	0.88	20.7	0.63	2.98e-73	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	12.71	0.45	3.63e-33	Mean platelet volume;
BRCA	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg15605315	chr1:45957053	TESK2	-0.46	-9.26	-0.34	2.97e-19	High light scatter reticulocyte count;
BRCA	cis	rs13161895	1.000	rs13161895	chr5:179471201	C/T	cg02702477	chr5:179499311	RNF130	0.46	8.53	0.32	1.03e-16	LDL cholesterol;
BRCA	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg20307385	chr11:47447363	PSMC3	0.86	25.86	0.72	1.91e-101	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs13046373	0.562	rs12627602	chr21:32022924	G/A	cg06468780	chr21:31798236	KRTAP13-3	0.33	8.37	0.31	3.62e-16	HDL cholesterol;
BRCA	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.0	0.51	8.96e-44	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs3857536	0.706	rs1418854	chr6:66893284	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-9.48	-0.35	5e-20	Blood trace element (Cu levels);
BRCA	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg05535760	chr7:792225	HEATR2	-0.72	-11.64	-0.42	1.59e-28	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6495367	0.898	rs1443657	chr15:79386946	C/A	cg17916960	chr15:79447300	NA	0.4	9.41	0.35	8.72e-20	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg06060754	chr5:176797920	RGS14	0.56	10.88	0.4	2.08e-25	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs58785573	0.504	rs13151185	chr4:38609196	G/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.51	9.64	0.36	1.28e-20	Lymphocyte percentage of white cells;
BRCA	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg14092571	chr14:90743983	NA	-0.35	-8.16	-0.31	1.72e-15	Mortality in heart failure;
BRCA	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg26384229	chr12:38710491	ALG10B	0.77	17.42	0.57	6.85e-56	Bladder cancer;
BRCA	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg14675211	chr2:100938903	LONRF2	0.51	11.41	0.41	1.39e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg06640241	chr16:89574553	SPG7	0.57	12.66	0.45	6.48e-33	Multiple myeloma (IgH translocation);
BRCA	cis	rs13315871	0.929	rs13101057	chr3:58291467	A/G	cg20936604	chr3:58311152	NA	-0.67	-8.64	-0.32	4.35e-17	Cholesterol, total;
BRCA	trans	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	14.45	0.5	3.59e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg24642439	chr20:33292090	TP53INP2	-0.43	-8.7	-0.33	2.89e-17	Height;
BRCA	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-8.05	-0.3	4.12e-15	D-dimer levels;
BRCA	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.36	-0.31	3.89e-16	Colorectal cancer;
BRCA	cis	rs698833	0.962	rs698828	chr2:44730577	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	9.49	0.35	4.43e-20	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-18.0	-0.58	6.91e-59	Morning vs. evening chronotype;
BRCA	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg20476274	chr7:133979776	SLC35B4	0.53	13.48	0.47	1.22e-36	Mean platelet volume;
BRCA	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg09021430	chr5:549028	NA	-0.52	-14.07	-0.49	2.38e-39	Obesity-related traits;
BRCA	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg13010199	chr12:38710504	ALG10B	0.53	10.79	0.39	4.56e-25	Bladder cancer;
BRCA	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg09163369	chr1:210001066	C1orf107	0.52	9.71	0.36	6.7e-21	Orofacial clefts;
BRCA	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.94e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg13047869	chr3:10149882	C3orf24	0.57	10.42	0.38	1.43e-23	Alzheimer's disease;
BRCA	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.39	8.57	0.32	7.9e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02176678	chr2:219576539	TTLL4	0.46	11.97	0.43	6.09e-30	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-13.16	-0.46	3.71e-35	Neuroticism;
BRCA	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg09085632	chr11:111637200	PPP2R1B	0.81	15.49	0.52	3.63e-46	Primary sclerosing cholangitis;
BRCA	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.69	0.39	1.24e-24	IgG glycosylation;
BRCA	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg13319975	chr6:146136371	FBXO30	0.34	7.97	0.3	7.19e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9300255	0.663	rs7953929	chr12:123758235	C/G	cg00376283	chr12:123451042	ABCB9	0.5	10.23	0.38	7.71e-23	Neutrophil percentage of white cells;
BRCA	cis	rs2882667	0.690	rs288039	chr5:138206200	G/T	cg04439458	chr5:138467593	SIL1	-0.31	-7.94	-0.3	8.86e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg04455712	chr21:45112962	RRP1B	-0.43	-10.97	-0.4	8.91e-26	Mean corpuscular volume;
BRCA	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg01884057	chr2:25150051	NA	0.34	9.04	0.34	1.88e-18	Body mass index;
BRCA	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg17410650	chr12:54324560	NA	-0.48	-13.6	-0.47	3.65e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
BRCA	cis	rs999943	0.846	rs10947420	chr6:33611061	C/G	cg14003231	chr6:33640908	ITPR3	0.6	13.86	0.48	2.17e-38	Obesity (extreme);
BRCA	cis	rs208520	0.754	rs851592	chr6:66875175	G/T	cg07460842	chr6:66804631	NA	-0.98	-18.46	-0.59	2.69e-61	Exhaled nitric oxide output;
BRCA	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg21252483	chr19:49399788	TULP2	-0.51	-10.75	-0.39	7e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg11189052	chr15:85197271	WDR73	-0.38	-9.03	-0.34	1.97e-18	P wave terminal force;
BRCA	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	9.38	0.35	1.14e-19	Bipolar disorder;
BRCA	cis	rs7944584	0.632	rs11606683	chr11:47302733	C/T	cg03711944	chr11:47377212	SPI1	-0.37	-8.22	-0.31	1.1e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	20.1	0.62	5.33e-70	Smoking behavior;
BRCA	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg03146154	chr1:46216737	IPP	0.53	11.78	0.42	3.81e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg01529538	chr14:23388837	RBM23	0.42	11.45	0.41	9.89e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs7246657	0.722	rs28512414	chr19:38056574	T/A	cg18154014	chr19:37997991	ZNF793	0.48	9.13	0.34	8.69e-19	Coronary artery calcification;
BRCA	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.98	0.43	5.89e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9462846	0.960	rs12194860	chr6:42862934	C/T	cg02353165	chr6:42928485	GNMT	0.43	8.06	0.3	3.67e-15	Blood protein levels;
BRCA	cis	rs11971779	0.941	rs6954453	chr7:139031794	C/T	cg07862535	chr7:139043722	LUC7L2	0.53	12.93	0.46	3.82e-34	Diisocyanate-induced asthma;
BRCA	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg06092702	chr1:163392909	NA	0.35	9.77	0.36	4.3e-21	Motion sickness;
BRCA	cis	rs2336384	1.000	rs61776516	chr1:12047028	T/C	cg13216073	chr1:12042593	MFN2	0.44	9.59	0.35	1.93e-20	Platelet count;
BRCA	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg12432903	chr7:1882776	MAD1L1	0.45	8.1	0.31	2.88e-15	Bipolar disorder;
BRCA	cis	rs11030122	0.632	rs714380	chr11:4059653	A/T	cg18678763	chr11:4115507	RRM1	-0.35	-8.25	-0.31	8.95e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16024904	chr19:17905718	B3GNT3	0.38	8.05	0.3	4.02e-15	Tumor biomarkers;
BRCA	cis	rs72772090	0.710	rs1559085	chr5:96078702	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.76	-0.45	2.16e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2336384	1.000	rs2336384	chr1:12046063	A/C	cg13216073	chr1:12042593	MFN2	-0.45	-9.81	-0.36	3.08e-21	Platelet count;
BRCA	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.82	-0.33	1.08e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg06627628	chr2:24431161	ITSN2	-0.85	-15.66	-0.53	5.08e-47	Asthma;
BRCA	cis	rs4845875	0.534	rs6541003	chr1:11855867	G/A	cg24844545	chr1:11908347	NPPA	0.31	7.86	0.3	1.58e-14	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg07169764	chr2:136633963	MCM6	-1.25	-26.32	-0.72	5.82e-104	Corneal structure;
BRCA	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg13880726	chr7:1868755	MAD1L1	-0.55	-11.3	-0.41	3.87e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs6060717	0.536	rs6060704	chr20:34530270	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.04	-0.3	4.27e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs11229555	0.645	rs17474373	chr11:58191243	G/A	cg15696309	chr11:58395628	NA	-0.52	-10.83	-0.39	3.19e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg10560079	chr2:191398806	TMEM194B	0.73	13.36	0.47	4.5e-36	Diastolic blood pressure;
BRCA	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg05347473	chr6:146136440	FBXO30	-0.4	-7.9	-0.3	1.2e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg08999081	chr20:33150536	PIGU	-0.45	-12.4	-0.44	8.63e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg11057378	chr10:81107060	PPIF	0.4	9.28	0.34	2.65e-19	Height;
BRCA	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg15395560	chr15:45543142	SLC28A2	-0.3	-8.15	-0.31	1.93e-15	Uric acid levels;
BRCA	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.39	8.25	0.31	9.01e-16	Total cholesterol levels;
BRCA	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg20476274	chr7:133979776	SLC35B4	0.66	19.45	0.61	1.48e-66	Mean platelet volume;
BRCA	cis	rs9811920	0.683	rs1718235	chr3:99583484	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-10.77	-0.39	5.71e-25	Axial length;
BRCA	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg17796960	chr10:135278976	LOC619207	-0.43	-9.03	-0.34	2.03e-18	Systemic lupus erythematosus;
BRCA	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg11366901	chr6:160182831	ACAT2	0.84	16.6	0.55	1.02e-51	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg24675658	chr1:53192096	ZYG11B	-0.52	-11.44	-0.41	1.07e-27	Monocyte count;
BRCA	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg20991723	chr1:152506922	NA	0.41	9.47	0.35	5.21e-20	Hair morphology;
BRCA	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.64e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs11039798	0.610	rs11530356	chr11:48836290	C/A	cg15704280	chr7:45808275	SEPT13	0.6	8.92	0.33	4.77e-18	Axial length;
BRCA	trans	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg17675199	chr6:35436792	RPL10A	-0.3	-8.05	-0.3	3.9e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg11789530	chr4:8429930	ACOX3	-0.7	-17.99	-0.58	7.96e-59	Response to antineoplastic agents;
BRCA	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg21535247	chr6:8435926	SLC35B3	0.41	9.27	0.34	2.9e-19	Motion sickness;
BRCA	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg26384229	chr12:38710491	ALG10B	0.74	17.29	0.56	3.29e-55	Bladder cancer;
BRCA	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg23711669	chr6:146136114	FBXO30	0.65	15.23	0.52	6.75e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg24812749	chr6:127587940	RNF146	0.68	15.41	0.52	8.21e-46	Breast cancer;
BRCA	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg05872129	chr22:39784769	NA	0.56	11.83	0.42	2.41e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg22705602	chr4:152727874	NA	-0.33	-8.02	-0.3	5.22e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg22903471	chr2:27725779	GCKR	-0.35	-8.61	-0.32	5.83e-17	Total body bone mineral density;
BRCA	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg10495392	chr1:46806563	NSUN4	0.45	8.24	0.31	1.01e-15	Menopause (age at onset);
BRCA	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg07169764	chr2:136633963	MCM6	-0.9	-17.2	-0.56	8.61e-55	Corneal structure;
BRCA	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg06191203	chr2:152266755	RIF1	-0.27	-8.16	-0.31	1.83e-15	Lung cancer;
BRCA	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.06	-18.86	-0.6	1.99e-63	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs96067	0.772	rs1033891	chr1:36608402	A/G	cg24686825	chr1:36642396	MAP7D1	-0.46	-8.45	-0.32	2.04e-16	Corneal structure;
BRCA	cis	rs2386661	0.547	rs11259540	chr10:5646706	A/T	cg17085576	chr10:5658249	NA	-0.33	-8.21	-0.31	1.23e-15	Breast cancer;
BRCA	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-16.21	-0.54	8.87e-50	Heart rate;
BRCA	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg16576597	chr16:28551801	NUPR1	0.33	9.11	0.34	1.07e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.56	12.54	0.44	2.06e-32	Tonsillectomy;
BRCA	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.86	-0.48	2.11e-38	Extrinsic epigenetic age acceleration;
BRCA	trans	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.07	0.3	3.49e-15	Endometrial cancer;
BRCA	trans	rs1973993	0.967	rs10489741	chr1:96942406	G/A	cg10631902	chr5:14652156	NA	0.52	16.53	0.55	2.19e-51	Weight;
BRCA	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg03188948	chr7:1209495	NA	0.68	11.2	0.41	1.06e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.54	-15.47	-0.52	4.39e-46	Lung cancer;
BRCA	trans	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg07817883	chr1:32538562	TMEM39B	-0.44	-8.49	-0.32	1.44e-16	Monocyte percentage of white cells;
BRCA	cis	rs7831492	0.564	rs7831530	chr8:41614567	G/A	cg17182837	chr8:41585554	ANK1	-0.31	-8.25	-0.31	9.39e-16	Colorectal cancer;
BRCA	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg13010199	chr12:38710504	ALG10B	0.48	9.5	0.35	4.19e-20	Morning vs. evening chronotype;
BRCA	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.35	0.59	9.88e-61	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg13770153	chr20:60521292	NA	-0.45	-10.88	-0.4	2.1e-25	Body mass index;
BRCA	cis	rs1371614	0.545	rs4665930	chr2:27173520	C/T	cg00617064	chr2:27272375	NA	0.31	8.07	0.3	3.62e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-8.46	-0.32	1.85e-16	Personality dimensions;
BRCA	trans	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	14.75	0.5	1.35e-42	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg06618935	chr21:46677482	NA	-0.37	-8.37	-0.31	3.67e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs11098499	0.526	rs10026625	chr4:120280136	T/C	cg25214090	chr10:38739885	LOC399744	0.38	8.9	0.33	5.88e-18	Corneal astigmatism;
BRCA	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg06697600	chr4:7070879	GRPEL1	0.6	10.28	0.38	4.72e-23	Monocyte percentage of white cells;
BRCA	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg22974920	chr21:40686053	BRWD1	-0.39	-8.6	-0.32	5.97e-17	Cognitive function;
BRCA	trans	rs9329221	0.686	rs60755617	chr8:10243327	T/G	cg06636001	chr8:8085503	FLJ10661	0.53	10.05	0.37	3.68e-22	Neuroticism;
BRCA	trans	rs4714291	0.802	rs7759622	chr6:40114735	C/T	cg02267698	chr19:7991119	CTXN1	-0.46	-9.56	-0.35	2.49e-20	Strep throat;
BRCA	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.95	0.33	3.85e-18	Ovarian reserve;
BRCA	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	8.24	0.31	9.45e-16	Diabetic retinopathy;
BRCA	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg21475434	chr5:93447410	FAM172A	0.72	9.06	0.34	1.54e-18	Diabetic retinopathy;
BRCA	cis	rs4363385	0.720	rs6665527	chr1:152967009	C/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.26	-0.34	3.1400000000000002e-19	Inflammatory skin disease;
BRCA	cis	rs198389	0.589	rs535107	chr1:11889468	C/T	cg06193043	chr1:11908199	NPPA	0.32	8.21	0.31	1.27e-15	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
BRCA	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	13.87	0.48	1.97e-38	Platelet count;
BRCA	cis	rs427394	0.632	rs2279656	chr5:6737576	G/A	cg10857441	chr5:6722123	POLS	-0.32	-10.09	-0.37	2.64e-22	Menopause (age at onset);
BRCA	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg04944784	chr2:26401820	FAM59B	-0.95	-16.17	-0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg06521331	chr12:34319734	NA	-0.53	-10.29	-0.38	4.23e-23	Morning vs. evening chronotype;
BRCA	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-12.61	-0.45	1.06e-32	Blood protein levels;Circulating chemerin levels;
BRCA	trans	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs7520050	0.966	rs785492	chr1:46583607	G/A	cg24296786	chr1:45957014	TESK2	0.43	9.69	0.36	8.26e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg25237894	chr2:233734115	C2orf82	0.4	11.43	0.41	1.15e-27	Coronary artery disease;
BRCA	trans	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg13010199	chr12:38710504	ALG10B	0.4	8.16	0.31	1.74e-15	Morning vs. evening chronotype;
BRCA	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24549020	chr5:56110836	MAP3K1	-0.4	-8.33	-0.31	4.98e-16	Initial pursuit acceleration;
BRCA	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	16.19	0.54	1.13e-49	Platelet count;
BRCA	cis	rs919433	1.000	rs919433	chr2:198166565	G/A	cg10820045	chr2:198174542	NA	-0.39	-8.44	-0.32	2.12e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg23625390	chr15:77176239	SCAPER	-0.38	-9.16	-0.34	6.83e-19	Blood metabolite levels;
BRCA	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-9.54	-0.35	3.02e-20	HDL cholesterol;
BRCA	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.01	0.37	5e-22	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-10.91	-0.4	1.57e-25	Personality dimensions;
BRCA	trans	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg25482853	chr8:67687455	SGK3	0.79	13.2	0.46	2.48e-35	Obesity-related traits;
BRCA	cis	rs72848980	0.512	rs56984020	chr10:105386275	C/A	cg00126946	chr10:105363258	SH3PXD2A	0.44	8.49	0.32	1.42e-16	White matter hyperintensity burden;
BRCA	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg08807101	chr21:30365312	RNF160	-0.59	-14.68	-0.5	3.11e-42	Dental caries;
BRCA	cis	rs6930083	0.737	rs13196885	chr6:36632688	C/T	cg08179530	chr6:36648295	CDKN1A	-0.62	-14.38	-0.49	8.08e-41	Coronary artery disease;
BRCA	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg12011299	chr4:100065546	ADH4	0.48	10.82	0.39	3.58e-25	Alcohol dependence;
BRCA	cis	rs7512552	0.839	rs11590787	chr1:150398531	G/A	cg15654264	chr1:150340011	RPRD2	0.37	8.16	0.31	1.76e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg16325326	chr1:53192061	ZYG11B	0.91	24.96	0.7	1.71e-96	Monocyte count;
BRCA	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg08807101	chr21:30365312	RNF160	-0.6	-13.06	-0.46	9.83e-35	Selective IgA deficiency;
BRCA	cis	rs2015599	0.549	rs9738165	chr12:29443196	T/C	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.98	-0.3	6.94e-15	Mean platelet volume;Platelet count;
BRCA	cis	rs2415984	0.622	rs7156466	chr14:46933384	A/G	cg14871534	chr14:47121158	RPL10L	-0.37	-8.82	-0.33	1.12e-17	Number of children ever born;
BRCA	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg06159980	chr1:16340746	HSPB7	-0.39	-8.82	-0.33	1.11e-17	Systolic blood pressure;
BRCA	cis	rs11718455	0.960	rs17076254	chr3:44000361	C/T	cg08738300	chr3:44038990	NA	0.42	8.19	0.31	1.44e-15	Coronary artery disease;
BRCA	cis	rs5167	0.504	rs73047641	chr19:45457377	G/A	cg09555818	chr19:45449301	APOC2	0.46	11.91	0.43	1.08e-29	Blood protein levels;
BRCA	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	15.73	0.53	2.16e-47	Bone mineral density;
BRCA	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg24296786	chr1:45957014	TESK2	0.63	15.54	0.52	2.04e-46	High light scatter reticulocyte count;
BRCA	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.28	-0.44	2.76e-31	Response to antipsychotic treatment;
BRCA	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	17.85	0.58	4.24e-58	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11764359	chr7:65958608	NA	-0.74	-16.13	-0.54	2.3e-49	Aortic root size;
BRCA	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg00106254	chr7:1943704	MAD1L1	-0.33	-8.16	-0.31	1.8e-15	Schizophrenia;
BRCA	cis	rs13053817	1.000	rs7290684	chr22:29857664	C/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.48	-9.25	-0.34	3.35e-19	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs7715806	0.500	rs72633985	chr5:75006384	A/G	cg19683494	chr5:74908142	NA	0.5	8.1	0.31	2.81e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg07988820	chr12:82153109	PPFIA2	-0.58	-9.34	-0.35	1.53e-19	Resting heart rate;
BRCA	trans	rs1493916	0.837	rs11876492	chr18:31413804	T/C	cg15819921	chr19:927150	ARID3A	-0.42	-8.35	-0.31	4.15e-16	Life satisfaction;
BRCA	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg17691542	chr6:26056736	HIST1H1C	0.47	9.45	0.35	6.44e-20	Height;
BRCA	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18876405	chr7:65276391	NA	0.65	15.96	0.53	1.66e-48	Aortic root size;
BRCA	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg14530993	chr4:882597	GAK	0.59	9.84	0.36	2.27e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg26043149	chr18:55253948	FECH	-0.6	-13.28	-0.47	1.08e-35	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs7607369	0.559	rs4674341	chr2:219659911	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-10.33	-0.38	3.04e-23	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs7760949	0.889	rs9475787	chr6:13926102	G/C	cg27413430	chr6:13925136	RNF182	0.46	9.29	0.34	2.43e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9290065	0.519	rs1447608	chr3:160682019	G/T	cg03342759	chr3:160939853	NMD3	-0.46	-9.34	-0.35	1.54e-19	Kawasaki disease;
BRCA	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg04455712	chr21:45112962	RRP1B	0.39	10.38	0.38	1.97e-23	Mean corpuscular volume;
BRCA	cis	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.17	-0.4	1.44e-26	Morning vs. evening chronotype;
BRCA	cis	rs929596	0.561	rs11891311	chr2:234639310	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.43	11.25	0.41	6.41e-27	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg19052272	chr2:3704530	ALLC	-0.33	-8.09	-0.3	3.12e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-9.28	-0.34	2.69e-19	Mood instability;
BRCA	cis	rs965469	1.000	rs6051762	chr20:3321590	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-9.83	-0.36	2.45e-21	IFN-related cytopenia;
BRCA	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg17063962	chr7:91808500	NA	0.51	11.43	0.41	1.13e-27	Breast cancer;
BRCA	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	19.41	0.61	2.41e-66	Electrocardiographic conduction measures;
BRCA	cis	rs62380364	0.542	rs601499	chr5:88052687	A/C	cg22951263	chr5:87985283	NA	-0.38	-10.68	-0.39	1.3e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-10.78	-0.39	5.31e-25	Type 2 diabetes;
BRCA	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg26384229	chr12:38710491	ALG10B	0.72	17.04	0.56	6.04e-54	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1420338	0.967	rs10224203	chr7:34149593	C/T	cg01275685	chr7:34179230	BMPER	-0.45	-9.7	-0.36	7.76e-21	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg17211192	chr8:82754475	SNX16	-0.54	-11.48	-0.41	7.52e-28	Diastolic blood pressure;
BRCA	cis	rs2625529	0.938	rs2625530	chr15:72126034	G/A	cg16672083	chr15:72433130	SENP8	-0.82	-16.87	-0.56	4.51e-53	Red blood cell count;
BRCA	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg18761221	chr20:60518478	NA	-0.34	-8.36	-0.31	3.97e-16	Obesity-related traits;
BRCA	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg18016565	chr1:150552671	MCL1	0.35	8.23	0.31	1.08e-15	Tonsillectomy;
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.53	-11.5	-0.41	6.25e-28	Longevity;Endometriosis;
BRCA	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	17.82	0.58	5.88e-58	Platelet count;
BRCA	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg17366294	chr4:99064904	C4orf37	0.47	10.97	0.4	8.76e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg07080220	chr10:102295463	HIF1AN	-0.45	-10.1	-0.37	2.29e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg22029157	chr1:209979665	IRF6	0.41	8.0	0.3	5.98e-15	Cleft lip with or without cleft palate;
BRCA	trans	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.49	0.5	2.5e-41	Exhaled nitric oxide output;
BRCA	cis	rs7202877	0.610	rs4536500	chr16:75343197	C/G	cg03315344	chr16:75512273	CHST6	-0.53	-8.54	-0.32	1.02e-16	Type 2 diabetes;Type 1 diabetes;
BRCA	cis	rs17092148	1.000	rs6060017	chr20:33313042	G/T	cg16810054	chr20:33298113	TP53INP2	-0.49	-11.13	-0.4	2.07e-26	Neuroticism;
BRCA	cis	rs4730250	0.707	rs257381	chr7:106803963	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-9.54	-0.35	2.98e-20	Osteoarthritis;
BRCA	trans	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.48	9.38	0.35	1.16e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg22467129	chr15:76604101	ETFA	-0.49	-10.76	-0.39	6.38e-25	Blood metabolite levels;
BRCA	cis	rs11779988	0.545	rs439374	chr8:17786818	C/T	cg01800426	chr8:17659068	MTUS1	-0.38	-7.9	-0.3	1.26e-14	Breast cancer;
BRCA	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	8.77	0.33	1.57e-17	Platelet count;
BRCA	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.72	0.62	5.47e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.15	0.34	7.49e-19	Tonsillectomy;
BRCA	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg08807101	chr21:30365312	RNF160	0.55	13.23	0.46	1.81e-35	Dental caries;
BRCA	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg10862848	chr6:42927986	GNMT	-0.36	-15.02	-0.51	6.58e-44	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs4908768	0.539	rs4480384	chr1:8659714	A/G	cg20416874	chr1:8611966	RERE	-0.28	-7.87	-0.3	1.57e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.18	-0.31	1.49e-15	Depression;
BRCA	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg26597838	chr10:835615	NA	0.61	10.56	0.39	3.97e-24	Eosinophil percentage of granulocytes;
BRCA	cis	rs757081	0.671	rs214091	chr11:17296463	A/C	cg15432903	chr11:17409602	KCNJ11	-0.47	-8.1	-0.31	2.78e-15	Systolic blood pressure;
BRCA	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg09021430	chr5:549028	NA	-0.64	-15.17	-0.51	1.26e-44	Obesity-related traits;
BRCA	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg16606324	chr3:10149918	C3orf24	-0.56	-9.96	-0.37	8.39e-22	Alzheimer's disease;
BRCA	trans	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg08888203	chr3:10149979	C3orf24	0.66	13.86	0.48	2.18e-38	Alzheimer's disease;
BRCA	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18713687	chr3:195489789	MUC4	0.52	8.48	0.32	1.54e-16	Lung disease severity in cystic fibrosis;
BRCA	trans	rs12517041	1.000	rs10520890	chr5:23290143	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	0.46	8.34	0.31	4.52e-16	Calcium levels;
BRCA	cis	rs11229555	0.598	rs12289876	chr11:58185250	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11890956	chr21:40555474	PSMG1	1.04	29.41	0.76	7.29e-121	Cognitive function;
BRCA	cis	rs10754283	0.967	rs6428559	chr1:90099036	C/T	cg21401794	chr1:90099060	LRRC8C	0.52	12.61	0.45	1.03e-32	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs9309473	0.607	rs12478346	chr2:73584360	C/T	cg20560298	chr2:73613845	ALMS1	-0.41	-10.93	-0.4	1.33e-25	Metabolite levels;
BRCA	trans	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.46	0.32	1.79e-16	Corneal astigmatism;
BRCA	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-12.42	-0.44	6.83e-32	Platelet count;
BRCA	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg17366294	chr4:99064904	C4orf37	0.41	9.62	0.36	1.47e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7927771	0.542	rs7102205	chr11:47745374	C/T	cg20307385	chr11:47447363	PSMC3	0.42	9.6	0.35	1.84e-20	Subjective well-being;
BRCA	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg04362960	chr10:104952993	NT5C2	0.43	10.54	0.38	4.65e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg15556689	chr8:8085844	FLJ10661	-0.37	-9.48	-0.35	4.98e-20	Triglycerides;
BRCA	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.69	-9.92	-0.37	1.19e-21	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg07700843	chr1:2391317	NA	-0.45	-9.43	-0.35	7.74e-20	Non-obstructive azoospermia;
BRCA	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg03711944	chr11:47377212	SPI1	-0.39	-9.23	-0.34	3.8e-19	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs6834538	0.894	rs34712587	chr4:113485894	A/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.38	8.41	0.32	2.59e-16	Free thyroxine concentration;
BRCA	cis	rs7395581	0.877	rs10838691	chr11:47341729	T/C	cg25783544	chr11:47291846	MADD	0.4	8.96	0.33	3.47e-18	HDL cholesterol;
BRCA	cis	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg00677455	chr12:58241039	CTDSP2	0.63	14.19	0.49	6.18e-40	Multiple sclerosis;
BRCA	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg23649088	chr2:200775458	C2orf69	0.54	7.93	0.3	9.5e-15	Schizophrenia;
BRCA	cis	rs12618769	0.597	rs72819986	chr2:99045867	G/C	cg10123293	chr2:99228465	UNC50	0.41	8.14	0.31	2.05e-15	Bipolar disorder;
BRCA	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg16339924	chr4:17578868	LAP3	0.67	16.99	0.56	1.05e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6138458	1.000	rs227616	chr20:24908811	T/C	cg06937882	chr20:24974362	C20orf3	-0.44	-8.38	-0.31	3.34e-16	Blood protein levels;
BRCA	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg18252515	chr7:66147081	NA	-1.06	-15.7	-0.53	3.07e-47	Gout;
BRCA	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	11.95	0.43	7.88e-30	Tonsillectomy;
BRCA	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg00409905	chr10:38381863	ZNF37A	-0.57	-12.42	-0.44	6.72e-32	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg05283184	chr6:79620031	NA	-0.39	-9.89	-0.36	1.43e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7818345	0.935	rs6983973	chr8:19287867	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.02	0.3	5.16e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg04455712	chr21:45112962	RRP1B	0.43	11.69	0.42	9.25e-29	Mean corpuscular volume;
BRCA	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg06484146	chr7:12443880	VWDE	-0.71	-10.73	-0.39	8.16e-25	Coronary artery disease;
BRCA	trans	rs2840044	1.000	rs7212704	chr17:33898897	C/T	cg19694781	chr19:47549865	TMEM160	0.46	10.92	0.4	1.37e-25	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg25427524	chr10:38739819	LOC399744	-0.67	-13.65	-0.48	2.01e-37	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg18016565	chr1:150552671	MCL1	0.35	8.23	0.31	1.08e-15	Tonsillectomy;
BRCA	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg27170947	chr2:26402098	FAM59B	-0.92	-16.84	-0.55	6.2e-53	Gut microbiome composition (summer);
BRCA	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg10876282	chr6:28092338	ZSCAN16	0.4	7.87	0.3	1.48e-14	Cardiac Troponin-T levels;
BRCA	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg17691542	chr6:26056736	HIST1H1C	0.47	9.47	0.35	5.27e-20	Iron status biomarkers;
BRCA	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.83e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg13010199	chr12:38710504	ALG10B	0.45	9.64	0.36	1.25e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg08470875	chr2:26401718	FAM59B	0.76	11.99	0.43	4.93e-30	Gut microbiome composition (summer);
BRCA	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.95	-0.62	3.47e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg08807101	chr21:30365312	RNF160	-0.59	-14.68	-0.5	3.1e-42	Dental caries;
BRCA	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18876405	chr7:65276391	NA	-0.61	-14.59	-0.5	7.69e-42	Aortic root size;
BRCA	cis	rs208520	0.874	rs208485	chr6:66925654	T/C	cg07460842	chr6:66804631	NA	-0.9	-15.67	-0.53	4.71e-47	Exhaled nitric oxide output;
BRCA	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg27446573	chr6:127587934	RNF146	0.7	15.79	0.53	1.21e-47	Breast cancer;
BRCA	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.83	0.33	9.66e-18	Motion sickness;
BRCA	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.67	0.39	1.38e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.39	2.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg00083206	chr6:110721305	DDO	-0.4	-9.77	-0.36	4.07e-21	Platelet distribution width;
BRCA	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.68	0.36	9.18e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11764359	chr7:65958608	NA	-0.76	-16.82	-0.55	7.85e-53	Aortic root size;
BRCA	trans	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg19894588	chr14:64061835	NA	-0.38	-9.13	-0.34	9.17e-19	Glioblastoma;Glioma;
BRCA	trans	rs1422110	0.647	rs10063838	chr5:85530546	T/C	cg01787110	chr1:109008453	NBPF6	-0.51	-10.29	-0.38	4.49e-23	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg14926445	chr8:58193284	C8orf71	-0.46	-8.83	-0.33	1.01e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6545883	0.929	rs2252662	chr2:61670731	T/C	cg15711740	chr2:61764176	XPO1	-0.52	-13.18	-0.46	2.96e-35	Tuberculosis;
BRCA	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg16586182	chr3:47516702	SCAP	-0.55	-12.31	-0.44	2.1e-31	Colorectal cancer;
BRCA	cis	rs4363385	0.747	rs11205151	chr1:152961496	G/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.81	-0.33	1.18e-17	Inflammatory skin disease;
BRCA	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11764359	chr7:65958608	NA	0.8	19.49	0.61	9.4e-67	Aortic root size;
BRCA	cis	rs11955398	0.716	rs1379115	chr5:59997886	A/C	cg02684056	chr5:59996105	DEPDC1B	0.39	9.35	0.35	1.42e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs3824867	0.920	rs7107853	chr11:47453518	T/C	cg20307385	chr11:47447363	PSMC3	-0.51	-11.48	-0.41	6.99e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg02175503	chr12:58329896	NA	0.52	11.74	0.42	5.81e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs61990749	0.597	rs759808	chr14:78250845	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	9.3	0.35	2.19e-19	Fibroblast growth factor basic levels;
BRCA	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Tonsillectomy;
BRCA	cis	rs758324	0.947	rs11948962	chr5:131113830	C/T	cg06307176	chr5:131281290	NA	0.53	10.2	0.37	9.47e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg09307838	chr4:120376055	NA	0.72	15.26	0.52	4.91e-45	Corneal astigmatism;
BRCA	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg04989706	chr14:50066350	PPIL5	-0.47	-8.74	-0.33	2.03e-17	Carotid intima media thickness;
BRCA	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-11.12	-0.4	2.2e-26	Longevity;Endometriosis;
BRCA	cis	rs483180	0.859	rs478093	chr1:120255126	C/T	cg19096424	chr1:120255104	PHGDH	-0.6	-13.72	-0.48	1.01e-37	Macular telangiectasia type 2;
BRCA	cis	rs3772130	0.962	rs9841595	chr3:121483326	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.75	0.39	7.12e-25	Cognitive performance;
BRCA	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg17724175	chr1:150552817	MCL1	0.26	8.53	0.32	1.03e-16	Tonsillectomy;
BRCA	cis	rs9359856	0.510	rs2768936	chr6:90441851	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.7	-10.56	-0.39	3.86e-24	Bipolar disorder;
BRCA	cis	rs7520050	0.966	rs1707304	chr1:46598269	C/A	cg24296786	chr1:45957014	TESK2	0.4	8.89	0.33	6.41e-18	Red blood cell count;Reticulocyte count;
BRCA	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg08885076	chr2:99613938	TSGA10	-0.6	-13.12	-0.46	5.45e-35	Chronic sinus infection;
BRCA	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg06532163	chr17:45867833	NA	0.39	7.94	0.3	9.3e-15	IgG glycosylation;
BRCA	cis	rs6728642	0.908	rs10207116	chr2:98018281	G/A	cg26665480	chr2:98280029	ACTR1B	-0.54	-8.54	-0.32	9.9900000000000006e-17	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs4285028	0.747	rs7648343	chr3:121426195	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.86	-15.22	-0.52	7.62e-45	Multiple sclerosis;
BRCA	cis	rs870825	0.929	rs871253	chr4:185589234	G/A	cg04058563	chr4:185651563	MLF1IP	0.7	11.61	0.42	1.99e-28	Blood protein levels;
BRCA	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg17120908	chr11:65337727	SSSCA1	0.55	9.97	0.37	7.12e-22	Bone mineral density;
BRCA	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	12.76	0.45	2.23e-33	Lung cancer in ever smokers;
BRCA	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg26597838	chr10:835615	NA	1.02	18.05	0.58	3.47e-59	Eosinophil percentage of granulocytes;
BRCA	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg23422044	chr7:1970798	MAD1L1	0.6	11.16	0.4	1.53e-26	Bipolar disorder;
BRCA	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.63	0.5	5.25e-42	Personality dimensions;
BRCA	cis	rs919433	0.648	rs6434933	chr2:198426960	G/A	cg00792783	chr2:198669748	PLCL1	0.36	8.33	0.31	5.03e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07256732	chr16:621771	PIGQ	-0.35	-9.51	-0.35	3.68e-20	Height;
BRCA	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg25358565	chr5:93447407	FAM172A	1.21	18.81	0.6	3.62e-63	Diabetic retinopathy;
BRCA	trans	rs6011368	0.792	rs6512309	chr20:62892584	A/G	cg13869341	chr1:15865	WASH5P	0.35	7.97	0.3	7.32e-15	Clozapine-induced cytotoxicity;
BRCA	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg25036284	chr2:26402008	FAM59B	-0.66	-11.21	-0.41	9.28e-27	Gut microbiome composition (summer);
BRCA	cis	rs1865721	0.771	rs72975985	chr18:73127648	C/T	cg26385618	chr18:73139727	C18orf62	-0.43	-10.29	-0.38	4.6e-23	Intelligence;
BRCA	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-10.16	-0.37	1.36e-22	Neuroticism;
BRCA	cis	rs4363385	0.747	rs4845506	chr1:152968407	G/A	cg21543102	chr1:152974771	SPRR3	-0.3	-8.3	-0.31	6.13e-16	Inflammatory skin disease;
BRCA	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg24006582	chr15:45444508	DUOX1	-0.56	-11.58	-0.42	2.68e-28	Uric acid levels;
BRCA	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg13319975	chr6:146136371	FBXO30	-0.36	-8.33	-0.31	4.89e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	13.76	0.48	6.16e-38	Platelet count;
BRCA	cis	rs738322	0.532	rs9622746	chr22:38564041	C/G	cg20207973	chr22:38506712	BAIAP2L2	0.38	9.28	0.34	2.55e-19	Cutaneous nevi;
BRCA	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg12444411	chr7:2802554	GNA12	-0.33	-8.08	-0.3	3.3e-15	Height;
BRCA	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg25767906	chr1:53392781	SCP2	-0.38	-8.61	-0.32	5.89e-17	Monocyte count;
BRCA	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-17.83	-0.58	5.39e-58	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs2262909	0.962	rs422344	chr19:22230956	C/G	cg17074339	chr11:11642133	GALNTL4	0.41	7.86	0.3	1.63e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg21475434	chr5:93447410	FAM172A	0.7	9.03	0.34	2.02e-18	Diabetic retinopathy;
BRCA	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg12311346	chr5:56204834	C5orf35	-0.79	-15.31	-0.52	2.62e-45	Initial pursuit acceleration;
BRCA	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	8.9	0.33	5.81e-18	Personality dimensions;
BRCA	cis	rs6087990	0.735	rs2424928	chr20:31388636	T/C	cg13636640	chr20:31349939	DNMT3B	0.62	17.13	0.56	2.03e-54	Ulcerative colitis;
BRCA	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs16958440	0.867	rs58061761	chr18:44686165	T/C	cg17192377	chr18:44677553	HDHD2	1.0	13.6	0.47	3.59e-37	Sitting height ratio;
BRCA	cis	rs7639513	0.767	rs9878151	chr3:12703714	G/C	cg23032965	chr3:12705835	RAF1	0.71	15.64	0.53	6.21e-47	Itch intensity from mosquito bite;
BRCA	cis	rs7727544	0.582	rs10478998	chr5:131516531	G/A	cg14196790	chr5:131705035	SLC22A5	0.37	9.16	0.34	6.91e-19	Blood metabolite levels;
BRCA	cis	rs79387448	0.638	rs7600961	chr2:103035455	G/A	cg09003973	chr2:102972529	NA	0.52	7.88	0.3	1.46e-14	Gut microbiota (bacterial taxa);
BRCA	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg18154014	chr19:37997991	ZNF793	0.48	9.56	0.35	2.54e-20	Coronary artery calcification;
BRCA	trans	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs2204008	0.645	rs9989043	chr12:38238505	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-10.12	-0.37	2.02e-22	Bladder cancer;
BRCA	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg08885076	chr2:99613938	TSGA10	0.44	10.29	0.38	4.34e-23	Chronic sinus infection;
BRCA	cis	rs9329289	0.510	rs2029604	chr10:2554700	T/C	cg15501526	chr10:2543763	NA	0.42	9.82	0.36	2.64e-21	Age-related hearing impairment;
BRCA	cis	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05901451	chr6:126070800	HEY2	0.4	9.72	0.36	6.35e-21	Endometrial cancer;
BRCA	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03264133	chr6:25882463	NA	-0.52	-11.75	-0.42	5.15e-29	Blood metabolite levels;
BRCA	cis	rs9309473	0.607	rs2421489	chr2:73593448	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-12.84	-0.45	1.02e-33	Metabolite levels;
BRCA	cis	rs7474896	0.559	rs1208779	chr10:38077729	A/C	cg25427524	chr10:38739819	LOC399744	-0.54	-9.7	-0.36	7.57e-21	Obesity (extreme);
BRCA	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg09436375	chr6:42928200	GNMT	0.23	7.99	0.3	6.16e-15	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
BRCA	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.91	-31.24	-0.78	9.67e-131	Schizophrenia;
BRCA	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg13319975	chr6:146136371	FBXO30	-0.42	-9.44	-0.35	7.12e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg00339695	chr16:24857497	SLC5A11	-0.48	-9.28	-0.34	2.66e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs1865721	0.804	rs3745084	chr18:73142510	T/G	cg26385618	chr18:73139727	C18orf62	-0.43	-10.39	-0.38	1.88e-23	Intelligence;
BRCA	cis	rs9815354	0.716	rs76313799	chr3:41931751	A/C	cg03022575	chr3:42003672	ULK4	0.69	9.5	0.35	4.17e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13126279	chr21:47581558	C21orf56	-0.41	-9.03	-0.34	2e-18	Testicular germ cell tumor;
BRCA	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.29	8.29	0.31	6.83e-16	Parkinson's disease;
BRCA	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.88	-16.07	-0.54	4.79e-49	Body mass index;
BRCA	cis	rs9814567	0.574	rs4974488	chr3:134168137	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.44	-12.91	-0.45	4.66e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2835872	0.709	rs1709819	chr21:39036115	A/C	cg06728970	chr21:39037746	KCNJ6	0.45	12.83	0.45	1.09e-33	Electroencephalographic traits in alcoholism;
BRCA	cis	rs2016266	0.784	rs12424778	chr12:53737840	A/T	cg26875137	chr12:53738046	NA	0.46	11.92	0.43	9.72e-30	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg16584290	chr5:462447	EXOC3	0.54	15.19	0.52	9.91e-45	Cystic fibrosis severity;
BRCA	cis	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg07460842	chr6:66804631	NA	0.87	14.19	0.49	6.35e-40	Exhaled nitric oxide output;
BRCA	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg13160058	chr8:26243215	BNIP3L	0.43	11.5	0.41	6.0500000000000004e-28	Red cell distribution width;
BRCA	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg04756594	chr16:24857601	SLC5A11	0.55	12.45	0.44	4.94e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs13046373	0.535	rs1961491	chr21:31973685	C/T	cg06468780	chr21:31798236	KRTAP13-3	0.36	8.98	0.33	3.05e-18	HDL cholesterol;
BRCA	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg27446573	chr6:127587934	RNF146	0.73	15.05	0.51	5.07e-44	Breast cancer;
BRCA	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.47	0.32	1.71e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg18512352	chr11:47633146	NA	-0.34	-8.09	-0.3	2.98e-15	Subjective well-being;
BRCA	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg20203395	chr5:56204925	C5orf35	-0.49	-10.35	-0.38	2.49e-23	Initial pursuit acceleration;
BRCA	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg05147244	chr20:61493195	TCFL5	-0.73	-10.0	-0.37	5.79e-22	Obesity-related traits;
BRCA	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg08885076	chr2:99613938	TSGA10	-0.6	-13.28	-0.47	1.04e-35	Chronic sinus infection;
BRCA	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12923728	chr3:195709715	SDHAP1	0.59	12.65	0.45	6.67e-33	Pancreatic cancer;
BRCA	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg03929089	chr4:120376271	NA	-0.53	-8.81	-0.33	1.21e-17	Axial length;
BRCA	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.59	-12.47	-0.44	4.37e-32	Lymphocyte percentage of white cells;
BRCA	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg21770322	chr7:97807741	LMTK2	0.45	11.76	0.42	4.92e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg00074818	chr8:8560427	CLDN23	0.37	8.31	0.31	5.61e-16	Obesity-related traits;
BRCA	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06544989	chr22:39130855	UNC84B	-0.38	-8.95	-0.33	3.74e-18	Menopause (age at onset);
BRCA	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg16482183	chr6:26056742	HIST1H1C	0.56	11.79	0.42	3.48e-29	Height;
BRCA	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg00701064	chr4:6280414	WFS1	0.68	17.63	0.57	5.63e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg09307838	chr4:120376055	NA	0.72	15.37	0.52	1.39e-45	Corneal astigmatism;
BRCA	cis	rs273218	1.000	rs156438	chr5:53374120	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.41	8.44	0.32	2.13e-16	Migraine;
BRCA	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	11.58	0.42	2.82e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4919694	1.000	rs12253284	chr10:104665145	G/C	cg04362960	chr10:104952993	NT5C2	0.93	14.96	0.51	1.31e-43	Arsenic metabolism;
BRCA	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg13256891	chr4:100009986	ADH5	-0.53	-9.87	-0.36	1.82e-21	Alcohol dependence;
BRCA	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg27432699	chr2:27873401	GPN1	0.39	8.31	0.31	5.63e-16	Oral cavity cancer;
BRCA	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.34	-0.31	4.61e-16	Axial length;
BRCA	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg08132940	chr7:1081526	C7orf50	-0.59	-8.77	-0.33	1.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg23719950	chr11:63933701	MACROD1	-0.59	-9.61	-0.36	1.65e-20	Mean platelet volume;
BRCA	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24110177	chr3:50126178	RBM5	0.37	10.12	0.37	1.98e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.21	0.68	6.53e-87	Chronic sinus infection;
BRCA	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg13319975	chr6:146136371	FBXO30	-0.41	-9.59	-0.35	1.86e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.818	rs11205164	chr1:152986023	A/T	cg24667326	chr1:152973720	SPRR3	-0.32	-8.91	-0.33	5.26e-18	Inflammatory skin disease;
BRCA	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11644478	chr21:40555479	PSMG1	0.66	14.58	0.5	8.87e-42	Cognitive function;
BRCA	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.38	-0.35	1.12e-19	Retinal vascular caliber;
BRCA	cis	rs2282802	0.685	rs11750229	chr5:139559014	T/G	cg26211634	chr5:139558579	C5orf32	-0.34	-8.11	-0.31	2.56e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg05729581	chr11:3078854	CARS	-0.34	-8.41	-0.32	2.75e-16	Longevity;
BRCA	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.68	-0.5	2.95e-42	Chronic sinus infection;
BRCA	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg17063962	chr7:91808500	NA	0.53	12.22	0.44	5.31e-31	Breast cancer;
BRCA	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg07884673	chr3:53033167	SFMBT1	0.74	9.15	0.34	7.57e-19	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.52	-10.97	-0.4	9.19e-26	Lymphocyte counts;
BRCA	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-11.18	-0.4	1.27e-26	Gut microbiome composition (summer);
BRCA	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg11833968	chr6:79620685	NA	-0.43	-9.72	-0.36	6.42e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg21770322	chr7:97807741	LMTK2	0.42	11.31	0.41	3.74e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg27284194	chr4:1044797	NA	0.41	8.93	0.33	4.59e-18	Recombination rate (males);
BRCA	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.58	12.04	0.43	3.27e-30	Monocyte percentage of white cells;
BRCA	cis	rs7927771	0.524	rs9633830	chr11:47849470	T/G	cg20307385	chr11:47447363	PSMC3	0.41	9.4	0.35	9.67e-20	Subjective well-being;
BRCA	cis	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg07460842	chr6:66804631	NA	-1.02	-20.03	-0.62	1.26e-69	Exhaled nitric oxide output;
BRCA	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg12463550	chr7:65579703	CRCP	-0.37	-8.04	-0.3	4.23e-15	Aortic root size;
BRCA	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg07080220	chr10:102295463	HIF1AN	0.52	12.01	0.43	4.25e-30	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg06494592	chr3:125709126	NA	-0.53	-8.22	-0.31	1.17e-15	Blood pressure (smoking interaction);
BRCA	cis	rs1511802	0.501	rs7661323	chr4:187115996	T/G	cg24794857	chr4:187113578	CYP4V2	0.38	8.28	0.31	7.31e-16	Blood protein levels;
BRCA	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg24130564	chr14:104152367	KLC1	-0.39	-8.86	-0.33	8.08e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.68	-15.52	-0.52	2.49e-46	Axial length;
BRCA	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg21545522	chr1:205238299	TMCC2	0.4	8.38	0.31	3.31e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-9.73	-0.36	5.87e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg05084668	chr3:125655381	ALG1L	-0.81	-11.23	-0.41	7.87e-27	Blood pressure (smoking interaction);
BRCA	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg24069376	chr3:38537580	EXOG	0.33	9.08	0.34	1.32e-18	Electrocardiographic conduction measures;
BRCA	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg02544614	chr20:61657117	NA	0.29	7.97	0.3	7.19e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.85e-29	Chronic sinus infection;
BRCA	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg21724239	chr8:58056113	NA	0.45	8.01	0.3	5.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg01262667	chr19:19385393	TM6SF2	0.4	10.28	0.38	4.75e-23	Tonsillectomy;
BRCA	cis	rs9290065	0.558	rs9846254	chr3:160770370	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-10.6	-0.39	2.68e-24	Kawasaki disease;
BRCA	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg10523679	chr1:76189770	ACADM	0.76	15.96	0.53	1.62e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg08859206	chr1:53392774	SCP2	0.45	10.09	0.37	2.5e-22	Monocyte count;
BRCA	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg26248373	chr2:1572462	NA	-0.61	-13.78	-0.48	5.39e-38	IgG glycosylation;
BRCA	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.26e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg09307838	chr4:120376055	NA	0.71	13.83	0.48	3.04e-38	Corneal astigmatism;
BRCA	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg12292205	chr6:26970375	C6orf41	0.58	12.87	0.45	6.99e-34	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.19e-40	Motion sickness;
BRCA	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg05340658	chr4:99064831	C4orf37	0.65	16.02	0.54	7.99e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12549902	0.800	rs4736999	chr8:41506152	C/G	cg21772509	chr8:41503840	NKX6-3	0.46	11.07	0.4	3.5e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
BRCA	cis	rs7572733	0.534	rs1518361	chr2:198812874	A/G	cg00792783	chr2:198669748	PLCL1	0.45	9.94	0.37	9.5e-22	Dermatomyositis;
BRCA	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg08027265	chr7:2291960	NA	-0.36	-8.37	-0.31	3.72e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg21770322	chr7:97807741	LMTK2	-0.46	-12.3	-0.44	2.23e-31	Breast cancer;
BRCA	cis	rs4722166	0.598	rs35658589	chr7:22800435	C/A	cg05472934	chr7:22766657	IL6	0.39	9.69	0.36	8.47e-21	Lung cancer;
BRCA	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg15556689	chr8:8085844	FLJ10661	-0.31	-8.14	-0.31	2.15e-15	Retinal vascular caliber;
BRCA	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg16606324	chr3:10149918	C3orf24	0.46	9.37	0.35	1.18e-19	Alzheimer's disease;
BRCA	cis	rs7172677	1.000	rs4243032	chr15:75426884	C/G	cg14664628	chr15:75095509	CSK	-0.4	-8.32	-0.31	5.16e-16	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.46	-9.44	-0.35	6.73e-20	Body mass index;
BRCA	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg18252515	chr7:66147081	NA	1.06	15.88	0.53	3.95e-48	Diabetic kidney disease;
BRCA	cis	rs7394190	0.810	rs7394178	chr10:75421580	G/A	cg07699608	chr10:75541558	CHCHD1	0.54	8.66	0.32	3.95e-17	Incident atrial fibrillation;
BRCA	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg11814155	chr7:99998594	ZCWPW1	0.45	8.1	0.31	2.86e-15	Platelet count;
BRCA	cis	rs6815814	0.799	rs11466640	chr4:38778903	A/G	cg02016764	chr4:38805732	TLR1	0.5	7.85	0.3	1.82e-14	Breast cancer;
BRCA	trans	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg19862616	chr7:65841803	NCRNA00174	0.77	23.8	0.69	4.16e-90	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg13944838	chr5:179740914	GFPT2	-0.69	-14.59	-0.5	7.57e-42	Height;
BRCA	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg25358565	chr5:93447407	FAM172A	1.15	17.79	0.58	8.61e-58	Diabetic retinopathy;
BRCA	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg02734326	chr4:10020555	SLC2A9	0.35	7.84	0.3	1.9e-14	Bone mineral density;
BRCA	cis	rs2425143	0.818	rs6060726	chr20:34555878	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.01	-0.3	5.5e-15	Blood protein levels;
BRCA	cis	rs7520050	0.966	rs12405451	chr1:46384326	T/A	cg24296786	chr1:45957014	TESK2	0.44	9.76	0.36	4.46e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg25319279	chr11:5960081	NA	-0.41	-8.05	-0.3	4.09e-15	DNA methylation (variation);
BRCA	cis	rs6942756	0.915	rs6966595	chr7:129006202	A/C	cg02491457	chr7:128862824	NA	-0.62	-12.58	-0.45	1.45e-32	White matter hyperintensity burden;
BRCA	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg27129171	chr3:47204927	SETD2	0.72	17.76	0.57	1.24e-57	Colorectal cancer;
BRCA	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg05340658	chr4:99064831	C4orf37	0.61	14.76	0.5	1.19e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07930192	chr7:1003750	NA	0.41	8.82	0.33	1.1e-17	Longevity;Endometriosis;
BRCA	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg20283391	chr11:68216788	NA	-0.45	-8.88	-0.33	6.46e-18	Total body bone mineral density;
BRCA	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg24977027	chr2:88469347	THNSL2	0.56	9.56	0.35	2.4e-20	Plasma clusterin levels;
BRCA	cis	rs6545883	0.965	rs12713439	chr2:61752154	G/A	cg15711740	chr2:61764176	XPO1	-0.55	-14.17	-0.49	7.9e-40	Tuberculosis;
BRCA	cis	rs72772090	0.539	rs11741100	chr5:96113245	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.18	-0.43	8.07e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg16325326	chr1:53192061	ZYG11B	-0.91	-24.89	-0.7	3.95e-96	Monocyte count;
BRCA	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg25922239	chr6:33757077	LEMD2	0.6	15.96	0.53	1.69e-48	Crohn's disease;
BRCA	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg25208724	chr1:156163844	SLC25A44	1.05	34.41	0.81	1.4e-147	Testicular germ cell tumor;
BRCA	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg09065629	chr16:1709722	CRAMP1L	0.35	8.02	0.3	5.2e-15	Coronary artery disease;
BRCA	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg01528321	chr10:82214614	TSPAN14	0.81	17.21	0.56	8.09e-55	Post bronchodilator FEV1;
BRCA	cis	rs757110	0.526	rs757081	chr11:17351683	C/G	cg15432903	chr11:17409602	KCNJ11	-0.57	-11.16	-0.4	1.5e-26	Type 2 diabetes;
BRCA	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg14863265	chr7:2801509	GNA12	-0.42	-9.65	-0.36	1.2e-20	Height;
BRCA	cis	rs7586879	0.796	rs10187348	chr2:25078415	G/C	cg04586622	chr2:25135609	ADCY3	0.36	8.66	0.32	3.71e-17	Body mass index;
BRCA	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg02297831	chr4:17616191	MED28	0.38	8.98	0.33	3.06e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-15.95	-0.53	1.75e-48	Heart rate;
BRCA	cis	rs6973256	0.605	rs6467499	chr7:133348922	G/T	cg07491979	chr7:133331646	EXOC4	-0.35	-7.94	-0.3	8.8e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7301016	1.000	rs11520127	chr12:62906965	C/G	cg01804193	chr12:63026212	NA	0.46	7.95	0.3	8.27e-15	IgG glycosylation;
BRCA	cis	rs6542838	0.641	rs4499468	chr2:99475204	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.36	-8.19	-0.31	1.46e-15	Fear of minor pain;
BRCA	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg01802117	chr1:53393560	SCP2	-0.4	-9.0	-0.34	2.62e-18	Monocyte count;
BRCA	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.56	-0.52	1.55e-46	Chronic sinus infection;
BRCA	cis	rs11971779	0.523	rs10234578	chr7:139037988	T/C	cg07862535	chr7:139043722	LUC7L2	0.39	10.38	0.38	1.95e-23	Diisocyanate-induced asthma;
BRCA	cis	rs9463078	0.874	rs7743116	chr6:45142858	T/C	cg25276700	chr6:44698697	NA	-0.36	-8.17	-0.31	1.61e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs9986765	1.000	rs73725075	chr7:142823479	C/A	cg21852589	chr7:142981689	TMEM139	0.56	9.69	0.36	8.1899999999999992e-21	Cancer;Dermatomyositis;
BRCA	cis	rs2637030	0.559	rs256087	chr5:52895233	G/A	cg06476337	chr5:52856530	NDUFS4	0.38	8.62	0.32	5.24e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg09060608	chr5:178986726	RUFY1	0.54	13.2	0.46	2.49e-35	Lung cancer;
BRCA	trans	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.46	0.5	3.3e-41	Exhaled nitric oxide output;
BRCA	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.39	-8.07	-0.3	3.52e-15	Body mass index;
BRCA	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-12.95	-0.46	3.08e-34	Lymphocyte counts;
BRCA	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-18.18	-0.58	7.68e-60	Headache;
BRCA	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg09754948	chr16:28834200	ATXN2L	0.45	8.32	0.31	5.46e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg08508325	chr11:3079039	CARS	0.28	8.49	0.32	1.5e-16	Calcium levels;
BRCA	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg24692254	chr21:30365293	RNF160	-0.79	-21.89	-0.65	1.13e-79	Dental caries;
BRCA	cis	rs724568	0.546	rs1430769	chr2:67932210	A/T	cg14046302	chr2:67939758	NA	-0.39	-10.27	-0.38	5.11e-23	Major depressive disorder (broad);
BRCA	cis	rs13046373	0.535	rs2832964	chr21:32014012	A/C	cg16431978	chr21:31797932	KRTAP13-3	0.35	8.95	0.33	3.81e-18	HDL cholesterol;
BRCA	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	8.63	0.32	4.76e-17	Bipolar disorder;
BRCA	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg14847009	chr1:175162515	KIAA0040	0.25	9.63	0.36	1.38e-20	Alcohol dependence;
BRCA	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	20.05	0.62	9.49e-70	Platelet count;
BRCA	cis	rs858239	0.539	rs6945510	chr7:23192240	C/T	cg23682824	chr7:23144976	KLHL7	0.41	10.95	0.4	1.06e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-9.98	-0.37	6.84e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg13010199	chr12:38710504	ALG10B	0.51	9.9	0.36	1.35e-21	Bladder cancer;
BRCA	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-14.4	-0.49	6.44e-41	Birth weight;
BRCA	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg04476341	chr5:669733	TPPP	0.39	10.62	0.39	2.17e-24	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
BRCA	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	20.11	0.62	4.61e-70	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.87	-0.33	7e-18	Breast cancer;
BRCA	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg12698349	chr2:225449008	CUL3	0.84	28.94	0.75	2.66e-118	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs1865721	1.000	rs8096298	chr18:73187608	C/T	cg26385618	chr18:73139727	C18orf62	-0.4	-9.1	-0.34	1.14e-18	Intelligence;
BRCA	cis	rs12617721	0.718	rs72819964	chr2:99019138	T/C	cg10123293	chr2:99228465	UNC50	0.51	8.9	0.33	5.8e-18	Bipolar disorder with mood-incongruent psychosis;
BRCA	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25427524	chr10:38739819	LOC399744	-0.61	-14.71	-0.5	2.18e-42	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6088813	1.000	rs56306402	chr20:33937704	G/A	cg14752227	chr20:34000481	UQCC	-0.43	-9.15	-0.34	7.53e-19	Height;
BRCA	cis	rs10465746	0.725	rs12070578	chr1:84349607	A/G	cg10977910	chr1:84465055	TTLL7	0.62	13.31	0.47	7.37e-36	Obesity-related traits;
BRCA	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	14.07	0.49	2.42e-39	Lymphocyte counts;
BRCA	cis	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.77	-0.33	1.58e-17	Resting heart rate;
BRCA	cis	rs7255436	1.000	rs7255436	chr19:8433196	C/A	cg10811474	chr19:8428787	ANGPTL4	-0.33	-8.24	-0.31	9.53e-16	HDL cholesterol;
BRCA	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg13770153	chr20:60521292	NA	-0.44	-9.73	-0.36	5.93e-21	Body mass index;
BRCA	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg10495392	chr1:46806563	NSUN4	0.44	8.15	0.31	1.97e-15	Menopause (age at onset);
BRCA	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg01028140	chr2:1542097	TPO	-0.57	-11.62	-0.42	1.91e-28	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg23711669	chr6:146136114	FBXO30	-0.8	-19.23	-0.61	2.22e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg12140854	chr5:148520817	ABLIM3	-0.4	-8.47	-0.32	1.71e-16	Breast cancer;
BRCA	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg12165864	chr7:66369176	NA	-0.44	-9.77	-0.36	4.34e-21	Corneal structure;
BRCA	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg23231163	chr10:75533350	FUT11	-0.33	-8.65	-0.32	4.07e-17	Psoriasis vulgaris;Psoriasis;
BRCA	cis	rs2066819	1.000	rs77768890	chr12:56725121	A/G	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.64	-9.67	-0.36	9.91e-21	Body mass index (adult);
BRCA	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg17063962	chr7:91808500	NA	0.57	13.47	0.47	1.4e-36	Breast cancer;
BRCA	trans	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg19862616	chr7:65841803	NCRNA00174	0.83	27.5	0.74	1.81e-110	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs10193935	0.901	rs13375	chr2:42559288	A/G	cg27598129	chr2:42591480	NA	-0.6	-10.38	-0.38	1.94e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-9.54	-0.35	3.04e-20	Alzheimer's disease (late onset);
BRCA	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg12193833	chr17:30244370	NA	-0.54	-8.66	-0.32	3.95e-17	Hip circumference adjusted for BMI;
BRCA	trans	rs783540	0.500	rs783541	chr15:83255061	T/C	cg16105309	chr15:79090380	ADAMTS7	0.34	8.8	0.33	1.26e-17	Schizophrenia;
BRCA	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg08601574	chr20:25228251	PYGB	-0.34	-8.2	-0.31	1.31e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs3772130	0.962	rs11719093	chr3:121487686	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.06	0.37	3.42e-22	Cognitive performance;
BRCA	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg09658497	chr7:2847517	GNA12	-0.44	-8.79	-0.33	1.35e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
BRCA	cis	rs68170813	0.559	rs1018947	chr7:106851939	A/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.66	-0.32	3.8e-17	Coronary artery disease;
BRCA	cis	rs7818345	0.967	rs35029660	chr8:19308126	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.32	8.08	0.3	3.17e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg14530993	chr4:882597	GAK	0.53	9.85	0.36	2.1e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg06484146	chr7:12443880	VWDE	-0.75	-10.62	-0.39	2.31e-24	Coronary artery disease;
BRCA	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg01256987	chr12:42539512	GXYLT1	-0.57	-11.69	-0.42	9.97e-29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg21475434	chr5:93447410	FAM172A	0.67	8.87	0.33	7.13e-18	Diabetic retinopathy;
BRCA	cis	rs10416265	0.528	rs17884930	chr19:33595390	A/G	cg17764715	chr19:33622953	WDR88	0.51	8.34	0.31	4.54e-16	Bone properties (heel);
BRCA	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg00677455	chr12:58241039	CTDSP2	0.64	15.73	0.53	2.4e-47	Multiple sclerosis;
BRCA	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	19.91	0.62	5.48e-69	Electrocardiographic conduction measures;
BRCA	cis	rs4908760	0.965	rs7542312	chr1:8573471	G/C	cg20416874	chr1:8611966	RERE	-0.28	-7.98	-0.3	6.88e-15	Vitiligo;
BRCA	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg22980127	chr19:33182716	NUDT19	-0.88	-19.76	-0.62	3.39e-68	Red blood cell traits;
BRCA	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg06623918	chr6:96969491	KIAA0776	0.89	23.0	0.67	9.18e-86	Headache;
BRCA	cis	rs6745190	0.575	rs6433892	chr2:181971237	A/G	cg00481216	chr2:181971175	NA	0.38	8.93	0.33	4.34e-18	White blood cell count;
BRCA	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg23950597	chr19:37808831	NA	-0.62	-11.45	-0.41	9.88e-28	Coronary artery calcification;
BRCA	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg08132940	chr7:1081526	C7orf50	-0.59	-8.84	-0.33	9.29e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	13.74	0.48	7.67e-38	Lymphocyte counts;
BRCA	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.5	10.18	0.37	1.13e-22	Lymphocyte counts;
BRCA	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg08885076	chr2:99613938	TSGA10	-0.46	-8.84	-0.33	8.97e-18	Chronic sinus infection;
BRCA	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg18904891	chr8:8559673	CLDN23	0.58	11.3	0.41	4.07e-27	Obesity-related traits;
BRCA	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg01529538	chr14:23388837	RBM23	0.42	11.47	0.41	8.31e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.05	-19.05	-0.6	1.99e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs59698941	0.550	rs60042615	chr5:132193220	A/G	cg14825688	chr5:132208181	LEAP2	-0.37	-8.67	-0.32	3.6e-17	Apolipoprotein A-IV levels;
BRCA	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg13010199	chr12:38710504	ALG10B	0.51	10.15	0.37	1.53e-22	Bladder cancer;
BRCA	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg26384229	chr12:38710491	ALG10B	0.85	23.4	0.68	6.5e-88	Heart rate;
BRCA	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg00105475	chr2:10696890	NA	-0.41	-9.35	-0.35	1.4e-19	Prostate cancer;
BRCA	cis	rs2522056	0.808	rs7704457	chr5:131744790	C/T	cg24060327	chr5:131705240	SLC22A5	-0.53	-8.95	-0.33	3.79e-18	Lymphocyte counts;Fibrinogen;
BRCA	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg05283184	chr6:79620031	NA	-0.43	-11.33	-0.41	3.01e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg17063962	chr7:91808500	NA	0.53	12.58	0.45	1.4e-32	Breast cancer;
BRCA	cis	rs4722166	0.532	rs1880242	chr7:22759607	A/C	cg05472934	chr7:22766657	IL6	-0.43	-10.56	-0.39	3.83e-24	Lung cancer;
BRCA	cis	rs858239	0.676	rs3807459	chr7:23389751	T/C	cg23682824	chr7:23144976	KLHL7	0.31	7.98	0.3	6.97e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg04450456	chr4:17643702	FAM184B	0.38	11.16	0.4	1.54e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs870825	0.616	rs55685500	chr4:185614810	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	16.66	0.55	5.07e-52	Blood protein levels;
BRCA	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg02951883	chr7:2050386	MAD1L1	0.39	8.08	0.3	3.12e-15	Neuroticism;
BRCA	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.26	7.97	0.3	7.2e-15	Depression;
BRCA	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18876405	chr7:65276391	NA	-0.71	-18.63	-0.59	3.31e-62	Aortic root size;
BRCA	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg02275930	chr1:2372054	NA	-0.36	-8.85	-0.33	8.82e-18	Schizophrenia;
BRCA	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg03146154	chr1:46216737	IPP	0.45	10.13	0.37	1.87e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg26384229	chr12:38710491	ALG10B	0.66	15.28	0.52	3.89e-45	Bladder cancer;
BRCA	cis	rs12612619	0.732	rs893790	chr2:27201857	T/C	cg00617064	chr2:27272375	NA	0.32	8.39	0.31	3.17e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-11.21	-0.41	9.65e-27	Gut microbiome composition (summer);
BRCA	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	14.59	0.5	7.97e-42	Eye color traits;
BRCA	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg11663144	chr21:46675770	NA	-0.59	-13.71	-0.48	1.05e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.45	-0.35	6.47e-20	Alzheimer's disease;
BRCA	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg09877947	chr5:131593287	PDLIM4	0.41	10.41	0.38	1.48e-23	Breast cancer;
BRCA	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.68	13.77	0.48	5.5e-38	Lymphocyte counts;
BRCA	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.54	-10.89	-0.4	1.89e-25	Lymphocyte counts;
BRCA	trans	rs3857536	0.813	rs4710580	chr6:66935200	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.24e-15	Blood trace element (Cu levels);
BRCA	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg00990874	chr7:1149470	C7orf50	-0.59	-11.89	-0.43	1.36e-29	Bronchopulmonary dysplasia;
BRCA	cis	rs7523273	0.565	rs11118453	chr1:207887996	A/C	cg22525895	chr1:207977042	MIR29B2	0.33	7.85	0.3	1.7e-14	Schizophrenia;
BRCA	trans	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg06521331	chr12:34319734	NA	-0.51	-9.41	-0.35	8.45e-20	Bladder cancer;
BRCA	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-8.96	-0.33	3.65e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4302748	0.862	rs11971718	chr7:36184620	T/C	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs9420	0.528	rs11607122	chr11:57389737	G/A	cg19752551	chr11:57585705	CTNND1	-0.38	-9.31	-0.35	1.95e-19	Schizophrenia;
BRCA	cis	rs4908760	0.864	rs1463052	chr1:8701231	A/G	cg20416874	chr1:8611966	RERE	-0.28	-8.13	-0.31	2.27e-15	Vitiligo;
BRCA	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg09307838	chr4:120376055	NA	0.72	15.33	0.52	2.14e-45	Corneal astigmatism;
BRCA	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.51	-8.44	-0.32	2.16e-16	Schizophrenia;
BRCA	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg11366901	chr6:160182831	ACAT2	0.77	14.97	0.51	1.25e-43	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg11645453	chr3:52864694	ITIH4	0.37	9.57	0.35	2.21e-20	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2742234	0.955	rs2075910	chr10:43614230	G/A	cg02780029	chr10:43622663	RET	-0.41	-10.09	-0.37	2.51e-22	Hirschsprung disease;
BRCA	cis	rs9473147	0.543	rs9381578	chr6:47556634	C/T	cg12968598	chr6:47444699	CD2AP	0.44	9.62	0.36	1.56e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg24558204	chr6:135376177	HBS1L	0.46	12.55	0.44	1.82e-32	Red blood cell count;
BRCA	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg02493740	chr2:85810744	VAMP5	-0.51	-10.58	-0.39	3.16e-24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs7903847	0.642	rs11189183	chr10:99144321	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.66	-0.32	3.7e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.23	0.49	3.97e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.1	0.56	2.83e-54	Bladder cancer;
BRCA	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg06784218	chr1:46089804	CCDC17	0.51	12.14	0.43	1.2e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg27366882	chr3:133540807	NA	-0.32	-8.01	-0.3	5.46e-15	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs312273	0.522	rs1442182	chr12:41308829	T/A	cg17827154	chr12:41323612	CNTN1	-0.35	-8.67	-0.32	3.63e-17	Bipolar disorder;
BRCA	cis	rs6867032	0.527	rs4975792	chr5:2010496	T/G	cg26168224	chr5:2018326	NA	0.44	11.71	0.42	8.05e-29	Gut microbiome composition (winter);
BRCA	cis	rs10838687	1.000	rs4752979	chr11:47339180	A/G	cg25783544	chr11:47291846	MADD	0.42	8.45	0.32	2.04e-16	Proinsulin levels;
BRCA	cis	rs9296092	0.538	rs62407566	chr6:33535786	C/T	cg13560919	chr6:33536144	NA	-0.92	-19.27	-0.61	1.47e-65	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg20701182	chr2:24300061	SF3B14	0.58	9.11	0.34	1.04e-18	Lymphocyte counts;
BRCA	trans	rs4650994	0.525	rs11806608	chr1:178511375	T/C	cg05059571	chr16:84539110	KIAA1609	-0.58	-13.41	-0.47	2.58e-36	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs36051895	0.632	rs10815167	chr9:5150058	A/G	cg02405213	chr9:5042618	JAK2	-0.44	-8.6	-0.32	6.14e-17	Pediatric autoimmune diseases;
BRCA	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg01483505	chr11:975446	AP2A2	0.33	8.98	0.33	2.93e-18	Alzheimer's disease (late onset);
BRCA	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg07636037	chr3:49044803	WDR6	0.85	22.97	0.67	1.31e-85	Parkinson's disease;
BRCA	cis	rs17253792	0.822	rs74935793	chr14:56143277	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-9.37	-0.35	1.25e-19	Putamen volume;
BRCA	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg09307838	chr4:120376055	NA	0.6	11.15	0.4	1.65e-26	Corneal astigmatism;
BRCA	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg05623727	chr3:50126028	RBM5	-0.44	-10.64	-0.39	1.85e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg21782813	chr7:2030301	MAD1L1	0.34	9.13	0.34	8.97e-19	Schizophrenia;
BRCA	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg18016565	chr1:150552671	MCL1	-0.37	-8.27	-0.31	7.78e-16	Tonsillectomy;
BRCA	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg23033748	chr14:75592666	NEK9	-0.39	-9.35	-0.35	1.44e-19	Height;
BRCA	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-15.46	-0.52	5.03e-46	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg15819921	chr19:927150	ARID3A	-0.47	-9.04	-0.34	1.84e-18	Life satisfaction;
BRCA	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg20684491	chr1:25596433	NA	-0.33	-8.57	-0.32	7.51e-17	Erythrocyte sedimentation rate;
BRCA	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.75	0.55	1.71e-52	Hypertriglyceridemia;
BRCA	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg17470723	chr8:74884337	TCEB1	0.41	8.88	0.33	6.78e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg24692254	chr21:30365293	RNF160	-0.47	-10.43	-0.38	1.23e-23	Pancreatic cancer;
BRCA	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-12.29	-0.44	2.54e-31	Calcium levels;
BRCA	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18876405	chr7:65276391	NA	0.62	15.37	0.52	1.28e-45	Aortic root size;
BRCA	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg05896524	chr21:47604654	C21orf56	-0.5	-10.21	-0.37	8.89e-23	Testicular germ cell tumor;
BRCA	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg13047869	chr3:10149882	C3orf24	0.57	10.42	0.38	1.33e-23	Alzheimer's disease;
BRCA	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg11814155	chr7:99998594	ZCWPW1	0.48	8.7	0.33	2.76e-17	Platelet count;
BRCA	cis	rs9462027	0.606	rs2038841	chr6:34738203	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.96	-0.3	7.8e-15	Systemic lupus erythematosus;
BRCA	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg16576597	chr16:28551801	NUPR1	0.31	8.57	0.32	7.87e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7072216	0.763	rs1061437	chr10:100176154	C/T	cg26618903	chr10:100175079	PYROXD2	-0.31	-8.84	-0.33	9.49e-18	Metabolite levels;
BRCA	cis	rs701145	0.585	rs1713852	chr3:153795487	C/G	cg17054900	chr3:154042577	DHX36	0.54	9.14	0.34	8.17e-19	Coronary artery disease;
BRCA	trans	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.89	0.3	1.31e-14	Aortic root size;
BRCA	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg25358565	chr5:93447407	FAM172A	1.25	19.1	0.6	1.13e-64	Diabetic retinopathy;
BRCA	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.52	-0.35	3.46e-20	Bladder cancer;
BRCA	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	9.95	0.37	8.73e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-9.73	-0.36	5.87e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.45	-0.35	6.47e-20	Alzheimer's disease;
BRCA	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.72	-0.39	9.03e-25	Tonsillectomy;
BRCA	cis	rs365132	1.000	rs1700490	chr5:176402401	G/A	cg16309518	chr5:176445507	NA	-0.51	-13.06	-0.46	9.65e-35	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg13047869	chr3:10149882	C3orf24	0.59	12.34	0.44	1.65e-31	Alzheimer's disease;
BRCA	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg23992470	chr4:843637	GAK	-0.48	-8.13	-0.31	2.21e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23248424	chr5:179741104	GFPT2	-0.67	-14.23	-0.49	4.1e-40	Height;
BRCA	cis	rs3849570	0.961	rs3772912	chr3:81698481	A/G	cg07356753	chr3:81810745	GBE1	-0.41	-9.29	-0.34	2.39e-19	Waist circumference;Body mass index;
BRCA	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg09915433	chr19:53449742	NA	-0.74	-17.03	-0.56	6.96e-54	Psoriasis;
BRCA	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg24642439	chr20:33292090	TP53INP2	0.6	10.37	0.38	2.13e-23	Protein C levels;
BRCA	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg16339924	chr4:17578868	LAP3	-0.57	-13.78	-0.48	5.18e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-7.81	-0.3	2.3e-14	Menarche (age at onset);
BRCA	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13732083	chr21:47605072	C21orf56	0.38	8.1	0.31	2.84e-15	Testicular germ cell tumor;
BRCA	cis	rs1044826	0.642	rs407958	chr3:139213632	T/C	cg00490450	chr3:139108681	COPB2	0.45	8.82	0.33	1.07e-17	Obesity-related traits;
BRCA	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg24675658	chr1:53192096	ZYG11B	-0.65	-14.38	-0.49	8.03e-41	Monocyte count;
BRCA	cis	rs897080	0.516	rs1067361	chr2:44661217	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	9.27	0.34	2.87e-19	Height;
BRCA	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.37	7.86	0.3	1.62e-14	Total cholesterol levels;
BRCA	cis	rs4919694	1.000	rs77505796	chr10:104647774	A/T	cg04362960	chr10:104952993	NT5C2	0.95	13.16	0.46	3.59e-35	Arsenic metabolism;
BRCA	trans	rs615632	0.530	rs10092464	chr8:9804185	C/G	cg15556689	chr8:8085844	FLJ10661	-0.35	-8.19	-0.31	1.47e-15	Neuroticism;
BRCA	trans	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.96	0.3	7.74e-15	Aortic root size;
BRCA	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg26384229	chr12:38710491	ALG10B	0.55	11.66	0.42	1.23e-28	Morning vs. evening chronotype;
BRCA	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.79	19.04	0.6	2.27e-64	Multiple sclerosis;
BRCA	trans	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg25214090	chr10:38739885	LOC399744	0.56	12.39	0.44	9.8e-32	Corneal astigmatism;
BRCA	cis	rs897984	0.609	rs55979739	chr16:31049155	A/G	cg00531865	chr16:30841666	NA	-0.36	-8.44	-0.32	2.18e-16	Dementia with Lewy bodies;
BRCA	cis	rs672059	1.000	rs672059	chr1:183162539	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.38	8.67	0.32	3.46e-17	Hypertriglyceridemia;
BRCA	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg18154014	chr19:37997991	ZNF793	-0.48	-9.52	-0.35	3.43e-20	Coronary artery calcification;
BRCA	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	15.87	0.53	4.42e-48	Cognitive ability;
BRCA	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg09904177	chr6:26538194	HMGN4	0.56	18.45	0.59	3.08e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg25237894	chr2:233734115	C2orf82	-0.29	-8.45	-0.32	1.96e-16	Coronary artery disease;
BRCA	cis	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg04990556	chr1:26633338	UBXN11	0.54	8.79	0.33	1.34e-17	Obesity-related traits;
BRCA	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg01528321	chr10:82214614	TSPAN14	1.04	20.39	0.63	1.49e-71	Post bronchodilator FEV1;
BRCA	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg20701182	chr2:24300061	SF3B14	0.68	12.61	0.45	1.04e-32	Lymphocyte counts;
BRCA	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	17.7	0.57	2.51e-57	Platelet count;
BRCA	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg19539972	chr4:7069911	GRPEL1	0.67	15.87	0.53	4.58e-48	Monocyte percentage of white cells;
BRCA	cis	rs727479	0.543	rs2414096	chr15:51529779	G/A	cg19946085	chr15:51559439	CYP19A1	-0.29	-8.06	-0.3	3.77e-15	Estradiol levels;
BRCA	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg01939980	chr4:1354348	KIAA1530	0.29	7.86	0.3	1.68e-14	Longevity;
BRCA	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.18	-0.49	7.04e-40	Extrinsic epigenetic age acceleration;
BRCA	cis	rs72928364	1.000	rs34999788	chr3:100617668	G/T	cg10123952	chr3:100791384	NA	0.53	7.9	0.3	1.21e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg23625390	chr15:77176239	SCAPER	-0.54	-12.79	-0.45	1.59e-33	Blood metabolite levels;
BRCA	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg00071950	chr4:10020882	SLC2A9	0.6	14.68	0.5	2.83e-42	Bone mineral density;
BRCA	cis	rs2230307	0.536	rs2784173	chr1:100639752	A/G	cg24955406	chr1:100503596	HIAT1	-0.45	-8.49	-0.32	1.49e-16	Carotid intima media thickness;
BRCA	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.53	-9.9	-0.36	1.36e-21	Aortic root size;
BRCA	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg15704280	chr7:45808275	SEPT13	0.62	10.32	0.38	3.25e-23	Axial length;
BRCA	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14442939	chr10:27389572	ANKRD26	0.66	10.92	0.4	1.5e-25	Breast cancer;
BRCA	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-9.68	-0.36	9.18e-21	Tonsillectomy;
BRCA	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg23711669	chr6:146136114	FBXO30	-0.77	-17.95	-0.58	1.15e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg16576597	chr16:28551801	NUPR1	0.3	8.44	0.32	2.14e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs965469	1.000	rs6051807	chr20:3350485	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-9.76	-0.36	4.73e-21	IFN-related cytopenia;
BRCA	cis	rs6433895	0.736	rs13020845	chr2:181987553	C/T	cg00481216	chr2:181971175	NA	0.4	8.67	0.32	3.6e-17	Lymphocyte counts;
BRCA	cis	rs11055008	0.620	rs12816452	chr12:12833006	A/T	cg09462578	chr12:12878428	APOLD1	-0.39	-8.62	-0.32	5.32e-17	Pulse pressure;
BRCA	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg12292205	chr6:26970375	C6orf41	0.58	12.99	0.46	2.15e-34	Schizophrenia;
BRCA	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.25	-0.34	3.42e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg08601574	chr20:25228251	PYGB	0.38	8.93	0.33	4.41e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg16414030	chr3:133502952	NA	-0.49	-11.47	-0.41	8.25e-28	Iron status biomarkers;
BRCA	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg13852791	chr20:30311386	BCL2L1	0.86	17.08	0.56	3.77e-54	Mean corpuscular hemoglobin;
BRCA	cis	rs460214	0.564	rs9979888	chr21:40022099	A/G	cg21578987	chr21:40029669	ERG	-0.35	-8.53	-0.32	1.05e-16	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs9790314	0.645	rs10936224	chr3:160902531	G/A	cg04691961	chr3:161091175	C3orf57	-0.35	-8.16	-0.31	1.84e-15	Morning vs. evening chronotype;
BRCA	trans	rs12517041	1.000	rs6891825	chr5:23299740	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.9	-0.3	1.2e-14	Calcium levels;
BRCA	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18876405	chr7:65276391	NA	-0.5	-11.14	-0.4	1.82e-26	Aortic root size;
BRCA	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.68e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg19847866	chr10:1019161	NA	0.56	11.99	0.43	5.19e-30	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.82	0.36	2.79e-21	Lung cancer in ever smokers;
BRCA	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg05714579	chr10:131428358	MGMT	0.56	13.27	0.46	1.11e-35	Response to temozolomide;
BRCA	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg13010199	chr12:38710504	ALG10B	-0.4	-8.57	-0.32	7.58e-17	Bladder cancer;
BRCA	cis	rs7520050	0.966	rs785494	chr1:46586626	C/A	cg24296786	chr1:45957014	TESK2	0.41	9.12	0.34	1e-18	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg05707623	chr12:122985044	ZCCHC8	0.48	9.32	0.35	1.92e-19	Body mass index;
BRCA	cis	rs738322	0.600	rs7286105	chr22:38557821	A/G	cg25457927	chr22:38595422	NA	-0.35	-12.86	-0.45	8.05e-34	Cutaneous nevi;
BRCA	cis	rs12579753	0.917	rs7138651	chr12:82253615	A/G	cg07988820	chr12:82153109	PPFIA2	0.47	7.93	0.3	9.96e-15	Resting heart rate;
BRCA	cis	rs6908034	0.607	rs12525152	chr6:19809424	A/T	cg02682789	chr6:19804855	NA	0.76	9.1	0.34	1.14e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
BRCA	cis	rs7833986	0.534	rs17813240	chr8:56925791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	13.55	0.47	6.15e-37	Height;
BRCA	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg27279351	chr12:120934652	DYNLL1	0.57	13.17	0.46	3.12e-35	High light scatter reticulocyte count;
BRCA	cis	rs4363385	0.818	rs11205176	chr1:153002481	A/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.42	-0.32	2.38e-16	Inflammatory skin disease;
BRCA	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg26384229	chr12:38710491	ALG10B	0.55	11.66	0.42	1.25e-28	Morning vs. evening chronotype;
BRCA	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg10876282	chr6:28092338	ZSCAN16	0.42	8.19	0.31	1.45e-15	Parkinson's disease;
BRCA	cis	rs6893300	0.785	rs3797762	chr5:179202688	A/G	cg14593053	chr5:179126677	CANX	-0.36	-8.02	-0.3	4.98e-15	Resting heart rate;
BRCA	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08109568	chr15:31115862	NA	-0.44	-10.32	-0.38	3.28e-23	Huntington's disease progression;
BRCA	cis	rs4363385	0.588	rs1577960	chr1:153025687	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.09	-0.3	3.08e-15	Inflammatory skin disease;
BRCA	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg23711669	chr6:146136114	FBXO30	0.7	16.91	0.56	2.75e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7188861	0.768	rs243315	chr16:11385011	C/T	cg01510278	chr16:11456238	NA	0.42	8.1	0.31	2.71e-15	HDL cholesterol;
BRCA	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-8.17	-0.31	1.64e-15	Tonsillectomy;
BRCA	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg17366294	chr4:99064904	C4orf37	0.44	10.33	0.38	3e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6942756	0.840	rs963465	chr7:128875612	C/G	cg02491457	chr7:128862824	NA	0.6	13.19	0.46	2.51e-35	White matter hyperintensity burden;
BRCA	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg27490568	chr2:178487706	NA	0.5	8.52	0.32	1.15e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg04362960	chr10:104952993	NT5C2	0.49	10.92	0.4	1.44e-25	Arsenic metabolism;
BRCA	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg04990556	chr1:26633338	UBXN11	0.62	14.25	0.49	3.45e-40	Obesity-related traits;
BRCA	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.41	-9.12	-0.34	9.46e-19	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	trans	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.48	-10.33	-0.38	3.18e-23	Mean corpuscular volume;
BRCA	cis	rs701145	0.938	rs355770	chr3:154040273	G/A	cg17054900	chr3:154042577	DHX36	0.68	11.88	0.43	1.56e-29	Coronary artery disease;
BRCA	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg08859206	chr1:53392774	SCP2	0.45	9.84	0.36	2.29e-21	Monocyte count;
BRCA	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg06115741	chr20:33292138	TP53INP2	0.49	11.14	0.4	1.89e-26	Coronary artery disease;
BRCA	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg04362960	chr10:104952993	NT5C2	0.46	10.62	0.39	2.17e-24	Arsenic metabolism;
BRCA	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg00071950	chr4:10020882	SLC2A9	0.46	11.21	0.41	9.43e-27	Bone mineral density;
BRCA	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg14558114	chr2:88469736	THNSL2	-0.42	-9.19	-0.34	5.47e-19	Response to metformin (IC50);
BRCA	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg18252515	chr7:66147081	NA	-1.07	-15.74	-0.53	2.04e-47	Gout;
BRCA	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg15819921	chr19:927150	ARID3A	-0.47	-9.1	-0.34	1.13e-18	Life satisfaction;
BRCA	cis	rs4900538	0.787	rs11704	chr14:102808655	C/G	cg18135206	chr14:102964638	TECPR2	0.91	20.66	0.63	5.06e-73	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg13334819	chr7:99746414	C7orf59	-0.37	-8.31	-0.31	5.77e-16	Coronary artery disease;
BRCA	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg26587870	chr6:27730563	NA	-0.41	-8.82	-0.33	1.13e-17	Parkinson's disease;
BRCA	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	12.33	0.44	1.82e-31	Coronary artery disease;
BRCA	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg03213289	chr20:61660250	NA	0.61	16.16	0.54	1.63e-49	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.791	rs372490	chr1:153008971	A/G	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs698813	0.805	rs804877	chr2:44702751	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.7	0.33	2.76e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg04166393	chr7:2884313	GNA12	0.52	10.02	0.37	4.63e-22	Height;
BRCA	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-10.13	-0.37	1.9e-22	Neuroticism;
BRCA	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg26441486	chr22:50317300	CRELD2	0.32	8.54	0.32	9.9e-17	Schizophrenia;
BRCA	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg00701064	chr4:6280414	WFS1	0.69	17.75	0.57	1.31e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg03929089	chr4:120376271	NA	-0.98	-29.5	-0.76	2.38e-121	Height;
BRCA	trans	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg25214090	chr10:38739885	LOC399744	0.56	12.8	0.45	1.55e-33	Corneal astigmatism;
BRCA	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg17143192	chr8:8559678	CLDN23	0.57	11.29	0.41	4.39e-27	Obesity-related traits;
BRCA	cis	rs2016266	0.787	rs61928080	chr12:53752204	G/A	cg26875137	chr12:53738046	NA	-0.43	-9.34	-0.35	1.5700000000000001e-19	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00149659	chr3:10157352	C3orf10	-0.75	-12.91	-0.45	4.66e-34	Alzheimer's disease;
BRCA	cis	rs13095912	1.000	rs35497918	chr3:185310312	C/T	cg11274856	chr3:185301563	NA	0.34	8.53	0.32	1.1e-16	Systolic blood pressure;
BRCA	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg08422745	chr4:174089978	GALNT7	-0.81	-17.82	-0.58	5.73e-58	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.39	9.61	0.36	1.57e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg26248373	chr2:1572462	NA	-0.57	-12.92	-0.46	4.13e-34	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg22681709	chr2:178499509	PDE11A	-0.38	-8.22	-0.31	1.15e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-15.57	-0.52	1.35e-46	Migraine;Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg21659725	chr3:3221576	CRBN	-0.48	-8.65	-0.32	4.23e-17	Menarche (age at onset);
BRCA	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg20503657	chr10:835505	NA	1.01	15.7	0.53	3.27e-47	Eosinophil percentage of granulocytes;
BRCA	trans	rs2262909	0.962	rs11667209	chr19:22259467	A/G	cg17074339	chr11:11642133	GALNTL4	0.42	8.14	0.31	2.13e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2742234	0.579	rs2503881	chr10:43686026	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.54	-11.11	-0.4	2.36e-26	Hirschsprung disease;
BRCA	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg00383909	chr3:49044727	WDR6	-0.42	-9.08	-0.34	1.32e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg04450456	chr4:17643702	FAM184B	0.38	9.93	0.37	1.09e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06028605	chr16:24865363	SLC5A11	0.46	10.05	0.37	3.8e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs13046373	0.535	rs7281767	chr21:32022062	T/C	cg22337977	chr21:31811175	KRTAP15-1	0.33	7.86	0.3	1.6e-14	HDL cholesterol;
BRCA	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg16482183	chr6:26056742	HIST1H1C	0.43	8.38	0.31	3.46e-16	Iron status biomarkers;
BRCA	cis	rs4423214	0.765	rs2002064	chr11:71163420	A/G	cg05163923	chr11:71159392	DHCR7	-0.55	-11.19	-0.4	1.2e-26	Vitamin D levels;
BRCA	cis	rs12545109	0.879	rs1513317	chr8:57372966	C/G	cg09654669	chr8:57350985	NA	-0.46	-8.66	-0.32	3.82e-17	Obesity-related traits;
BRCA	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22029157	chr1:209979665	IRF6	0.56	12.49	0.44	3.54e-32	Cleft lip with or without cleft palate;
BRCA	cis	rs13046373	0.535	rs9636840	chr21:32029979	A/G	cg06468780	chr21:31798236	KRTAP13-3	-0.32	-7.89	-0.3	1.35e-14	HDL cholesterol;
BRCA	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg12292205	chr6:26970375	C6orf41	0.64	14.45	0.5	3.77e-41	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg25019033	chr10:957182	NA	-0.42	-8.73	-0.33	2.23e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs6750047	0.541	rs162330	chr2:38319496	C/A	cg07380506	chr2:38303506	CYP1B1	0.41	9.27	0.34	2.85e-19	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg11266682	chr4:10021025	SLC2A9	-0.37	-9.37	-0.35	1.23e-19	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	21.09	0.64	2.41e-75	Platelet count;
BRCA	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg03146154	chr1:46216737	IPP	0.45	10.11	0.37	2.12e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1267303	0.642	rs11588450	chr1:47000996	C/T	cg25110126	chr1:46999211	NA	-0.54	-10.58	-0.39	3.19e-24	Monobrow;
BRCA	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	8.38	0.31	3.42e-16	Axial length;
BRCA	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11890956	chr21:40555474	PSMG1	-0.62	-13.86	-0.48	2.19e-38	Menarche (age at onset);
BRCA	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg18446336	chr7:2847575	GNA12	-0.35	-8.4	-0.32	2.88e-16	Height;
BRCA	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg03342759	chr3:160939853	NMD3	-0.8	-18.89	-0.6	1.45e-63	Parkinson's disease;
BRCA	cis	rs68170813	0.559	rs3815148	chr7:106938420	G/T	cg02696742	chr7:106810147	HBP1	0.47	8.55	0.32	9.4e-17	Coronary artery disease;
BRCA	trans	rs1973993	0.561	rs56983671	chr1:96988608	C/T	cg10631902	chr5:14652156	NA	-0.41	-10.11	-0.37	2.16e-22	Weight;
BRCA	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.55	8.26	0.31	8.69e-16	Platelet count;
BRCA	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-8.97	-0.33	3.18e-18	Alzheimer's disease (late onset);
BRCA	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg04117972	chr1:227635322	NA	0.48	8.67	0.32	3.58e-17	Major depressive disorder;
BRCA	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.56	11.42	0.41	1.27e-27	Lymphocyte counts;
BRCA	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg14343924	chr8:8086146	FLJ10661	0.4	8.25	0.31	9.1e-16	Mood instability;
BRCA	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.88	-0.36	1.65e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg10560079	chr2:191398806	TMEM194B	-0.72	-13.27	-0.46	1.14e-35	Diastolic blood pressure;
BRCA	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg07828340	chr4:882639	GAK	0.86	10.53	0.38	4.98e-24	Parkinson's disease;
BRCA	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg22903471	chr2:27725779	GCKR	0.39	9.63	0.36	1.37e-20	Total body bone mineral density;
BRCA	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.73	10.34	0.38	2.71e-23	Initial pursuit acceleration;
BRCA	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-7.99	-0.3	6.13e-15	Total body bone mineral density;
BRCA	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.53	-0.42	4.44e-28	Bipolar disorder;
BRCA	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg22431228	chr1:16359049	CLCNKA	-0.44	-9.91	-0.37	1.19e-21	Dilated cardiomyopathy;
BRCA	cis	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg26695010	chr11:65641043	EFEMP2	0.36	7.91	0.3	1.17e-14	DNA methylation (variation);
BRCA	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23583168	chr7:148888333	NA	-0.82	-18.5	-0.59	1.62e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg22903471	chr2:27725779	GCKR	-0.36	-8.73	-0.33	2.29e-17	Total body bone mineral density;
BRCA	cis	rs1577917	0.839	rs6454492	chr6:86483214	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.36	-9.33	-0.35	1.72e-19	Response to antipsychotic treatment;
BRCA	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg21573476	chr21:45109991	RRP1B	0.37	9.18	0.34	5.89e-19	Mean corpuscular volume;
BRCA	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg05234568	chr11:5960015	NA	-0.51	-9.95	-0.37	8.59e-22	DNA methylation (variation);
BRCA	cis	rs10463316	0.894	rs13357969	chr5:150751557	A/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-8.82	-0.33	1.04e-17	Metabolite levels (Pyroglutamine);
BRCA	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg05084668	chr3:125655381	ALG1L	-0.49	-9.3	-0.35	2.24e-19	Blood pressure (smoking interaction);
BRCA	trans	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg23762105	chr12:34175262	ALG10	-0.4	-9.83	-0.36	2.42e-21	Morning vs. evening chronotype;
BRCA	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg23711669	chr6:146136114	FBXO30	0.74	17.43	0.57	5.6e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg08470875	chr2:26401718	FAM59B	-0.5	-8.17	-0.31	1.65e-15	Gut microbiome composition (summer);
BRCA	cis	rs34779708	0.931	rs35848945	chr10:35287561	G/T	cg03585969	chr10:35415529	CREM	0.55	11.38	0.41	1.89e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg13010199	chr12:38710504	ALG10B	0.4	8.24	0.31	1e-15	Bladder cancer;
BRCA	cis	rs332507	0.830	rs333355	chr3:124393595	A/G	cg05980111	chr3:124395277	KALRN	0.32	7.84	0.3	1.84e-14	Plateletcrit;
BRCA	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18876405	chr7:65276391	NA	0.5	11.07	0.4	3.5e-26	Aortic root size;
BRCA	cis	rs4787491	0.679	rs7204852	chr16:30040178	C/G	cg06326092	chr16:30034487	C16orf92	0.38	9.93	0.37	1.07e-21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18876405	chr7:65276391	NA	-0.5	-11.23	-0.41	7.86e-27	Aortic root size;
BRCA	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg21782813	chr7:2030301	MAD1L1	-0.34	-9.99	-0.37	6.38e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs7312933	0.645	rs11181404	chr12:42683840	T/C	cg01256987	chr12:42539512	GXYLT1	-0.42	-8.13	-0.31	2.19e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg07148914	chr20:33460835	GGT7	0.41	8.57	0.32	7.83e-17	Height;
BRCA	trans	rs7944735	0.517	rs11039520	chr11:48130794	A/G	cg15704280	chr7:45808275	SEPT13	0.55	7.85	0.3	1.81e-14	Intraocular pressure;
BRCA	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg24642439	chr20:33292090	TP53INP2	0.4	8.45	0.32	2e-16	Height;
BRCA	trans	rs4650994	0.524	rs2811299	chr1:178586377	A/G	cg05059571	chr16:84539110	KIAA1609	0.53	11.66	0.42	1.28e-28	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg11584989	chr19:19387371	SF4	0.65	14.22	0.49	4.32e-40	Bipolar disorder;
BRCA	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg08975724	chr8:8085496	FLJ10661	0.38	8.11	0.31	2.67e-15	Mood instability;
BRCA	cis	rs6782228	0.606	rs2712419	chr3:128340896	T/C	cg16766828	chr3:128327626	NA	-0.42	-9.53	-0.35	3.08e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg08514558	chr10:81106712	PPIF	0.37	8.53	0.32	1.02e-16	Height;
BRCA	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg17802220	chr15:77601643	NA	-0.47	-10.39	-0.38	1.81e-23	Type 2 diabetes;
BRCA	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg18252515	chr7:66147081	NA	-0.9	-12.92	-0.46	4.23e-34	Diabetic kidney disease;
BRCA	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg27446573	chr6:127587934	RNF146	0.67	15.13	0.51	2.02e-44	Breast cancer;
BRCA	cis	rs7809950	0.678	rs2395869	chr7:106940098	C/A	cg23024343	chr7:107201750	COG5	-0.42	-9.07	-0.34	1.49e-18	Coronary artery disease;
BRCA	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg26384229	chr12:38710491	ALG10B	0.8	19.19	0.6	3.8e-65	Heart rate;
BRCA	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg06623918	chr6:96969491	KIAA0776	0.72	14.12	0.49	1.31e-39	Migraine;Coronary artery disease;
BRCA	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg26384229	chr12:38710491	ALG10B	0.74	17.78	0.58	9.46e-58	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23583168	chr7:148888333	NA	-0.96	-25.5	-0.71	1.85e-99	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03264133	chr6:25882463	NA	-0.5	-10.54	-0.38	4.63e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg24110177	chr3:50126178	RBM5	0.5	14.23	0.49	4.17e-40	Body mass index;
BRCA	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-12.23	-0.44	4.76e-31	Personality dimensions;
BRCA	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.56	11.67	0.42	1.12e-28	Monocyte percentage of white cells;
BRCA	cis	rs3008870	0.585	rs2815382	chr1:67515228	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.45	9.42	0.35	8.36e-20	Lymphocyte percentage of white cells;
BRCA	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-9.94	-0.37	9.99e-22	Body mass index;
BRCA	cis	rs9309473	0.607	rs7573719	chr2:73582986	G/A	cg20560298	chr2:73613845	ALMS1	-0.42	-10.98	-0.4	7.99e-26	Metabolite levels;
BRCA	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg23033748	chr14:75592666	NEK9	-0.43	-10.27	-0.38	5.45e-23	Height;
BRCA	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-9.71	-0.36	6.72e-21	Height;
BRCA	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.4	-8.78	-0.33	1.5e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.85	0.42	1.99e-29	Homoarginine levels;
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg23978390	chr7:1156363	C7orf50	0.49	11.22	0.41	8.56e-27	Longevity;Endometriosis;
BRCA	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg07541023	chr7:19748670	TWISTNB	-0.64	-10.52	-0.38	5.52e-24	Thyroid stimulating hormone;
BRCA	trans	rs11039798	0.623	rs584851	chr11:48416321	A/G	cg15704280	chr7:45808275	SEPT13	-0.55	-8.36	-0.31	3.98e-16	Axial length;
BRCA	cis	rs9462027	0.628	rs7752060	chr6:34760325	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.93	-0.3	9.97e-15	Systemic lupus erythematosus;
BRCA	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11890956	chr21:40555474	PSMG1	1.06	29.94	0.76	9.99e-124	Cognitive function;
BRCA	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg16423285	chr20:60520624	NA	-0.4	-7.86	-0.3	1.68e-14	Body mass index;
BRCA	cis	rs13082711	0.863	rs13062327	chr3:27495573	G/A	cg02860705	chr3:27208620	NA	0.53	10.56	0.39	3.86e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs12168402	0.510	rs1076116	chr22:39237837	C/G	cg06022373	chr22:39101656	GTPBP1	0.37	8.02	0.3	5.03e-15	Subjective well-being;
BRCA	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg03146154	chr1:46216737	IPP	-0.45	-9.45	-0.35	6.07e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg26384229	chr12:38710491	ALG10B	0.55	11.33	0.41	2.96e-27	Morning vs. evening chronotype;
BRCA	cis	rs7572263	0.724	rs6705133	chr2:209054422	G/A	cg23998903	chr2:209048830	C2orf80	-0.42	-8.67	-0.32	3.43e-17	Glioma;Non-glioblastoma glioma;
BRCA	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg26384229	chr12:38710491	ALG10B	0.48	11.32	0.41	3.27e-27	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg15395560	chr15:45543142	SLC28A2	0.28	7.92	0.3	1.06e-14	Uric acid levels;
BRCA	cis	rs2075371	0.871	rs418135	chr7:133949898	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	11.68	0.42	1.08e-28	Mean platelet volume;
BRCA	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-10.81	-0.39	4.07e-25	Bladder cancer;
BRCA	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg23131131	chr22:24373011	LOC391322	0.48	11.45	0.41	9.54e-28	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1941023	0.606	rs7946122	chr11:60172770	G/A	cg08716584	chr11:60157161	MS4A7	-0.42	-9.73	-0.36	5.75e-21	Congenital heart disease (maternal effect);
BRCA	cis	rs7588746	0.521	rs73054585	chr2:201144386	T/A	cg23649088	chr2:200775458	C2orf69	-0.46	-8.06	-0.3	3.78e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs3784262	0.669	rs12594082	chr15:58267779	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.24	-0.38	7.14e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs3739998	0.509	rs4749523	chr10:30332445	C/T	cg00730780	chr10:30316187	KIAA1462	-0.54	-10.6	-0.39	2.79e-24	Coronary heart disease;
BRCA	cis	rs10267417	0.657	rs6963367	chr7:19857873	A/C	cg05791153	chr7:19748676	TWISTNB	0.51	9.79	0.36	3.43e-21	Night sleep phenotypes;
BRCA	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.34	8.71	0.33	2.69e-17	IgG glycosylation;
BRCA	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg06046430	chr4:77819534	ANKRD56	0.62	13.94	0.48	9.77e-39	Emphysema distribution in smoking;
BRCA	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg13010199	chr12:38710504	ALG10B	-0.57	-12.66	-0.45	6.12e-33	Heart rate;
BRCA	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg26769984	chr7:1090371	C7orf50	0.65	11.45	0.41	9.62e-28	Bronchopulmonary dysplasia;
BRCA	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg22676075	chr6:135203613	NA	0.45	8.89	0.33	6.22e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg20701182	chr2:24300061	SF3B14	0.67	9.81	0.36	2.93e-21	Immature fraction of reticulocytes;
BRCA	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg21132104	chr15:45694354	SPATA5L1	0.76	17.04	0.56	6e-54	Homoarginine levels;
BRCA	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.82	0.51	6.59e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg13010199	chr12:38710504	ALG10B	0.5	10.56	0.39	4.03e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	14.69	0.5	2.62e-42	Hip circumference adjusted for BMI;
BRCA	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg25208724	chr1:156163844	SLC25A44	0.83	16.62	0.55	8.47e-52	Testicular germ cell tumor;
BRCA	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg04455712	chr21:45112962	RRP1B	0.37	9.51	0.35	3.66e-20	Mean corpuscular volume;
BRCA	cis	rs921968	0.565	rs1529382	chr2:219626489	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-11.01	-0.4	5.95e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10740039	0.804	rs1837950	chr10:62444965	C/T	cg02922035	chr10:62493342	NA	-0.42	-8.0	-0.3	5.8e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg09307838	chr4:120376055	NA	0.74	16.17	0.54	1.53e-49	Corneal astigmatism;
BRCA	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.56	-0.47	5.53e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9790314	0.747	rs1599386	chr3:160856314	C/T	cg04691961	chr3:161091175	C3orf57	0.44	9.78	0.36	3.78e-21	Morning vs. evening chronotype;
BRCA	cis	rs96067	0.772	rs2231318	chr1:36602943	C/T	cg24686825	chr1:36642396	MAP7D1	-0.45	-8.58	-0.32	6.95e-17	Corneal structure;
BRCA	cis	rs7552167	1.000	rs7552167	chr1:24518643	A/G	cg01960748	chr1:24522592	NA	-0.6	-10.3	-0.38	3.95e-23	Psoriasis vulgaris;
BRCA	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	16.91	0.56	2.68e-53	Alzheimer's disease;
BRCA	trans	rs783540	0.967	rs2870966	chr15:83295244	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.27	-8.58	-0.32	7.32e-17	Schizophrenia;
BRCA	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg24642439	chr20:33292090	TP53INP2	0.43	9.12	0.34	9.75e-19	Height;
BRCA	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-17.25	-0.56	5.06e-55	Chronic sinus infection;
BRCA	cis	rs11098499	0.526	rs10026625	chr4:120280136	T/C	cg09307838	chr4:120376055	NA	0.49	10.68	0.39	1.28e-24	Corneal astigmatism;
BRCA	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg06784218	chr1:46089804	CCDC17	0.48	11.44	0.41	1.1e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg01849466	chr14:104193079	ZFYVE21	0.43	11.0	0.4	6.62e-26	Schizophrenia;
BRCA	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg20503657	chr10:835505	NA	1.04	17.35	0.57	1.6e-55	Eosinophil percentage of granulocytes;
BRCA	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.96	0.33	3.4e-18	Tonsillectomy;
BRCA	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg02403541	chr12:121454288	C12orf43	0.56	12.1	0.43	1.71e-30	Subjective well-being;Cardiovascular disease risk factors;
BRCA	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08109568	chr15:31115862	NA	0.57	14.58	0.5	8.98e-42	Huntington's disease progression;
BRCA	cis	rs10838687	0.669	rs830084	chr11:47251652	T/C	cg25783544	chr11:47291846	MADD	-0.42	-7.96	-0.3	7.85e-15	Proinsulin levels;
BRCA	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg04727924	chr7:799746	HEATR2	-0.53	-9.41	-0.35	8.8e-20	Cerebrospinal P-tau181p levels;
BRCA	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.79	-0.45	1.59e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9837602	1.000	rs9832186	chr3:99728503	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	11.05	0.4	4.21e-26	Breast cancer;
BRCA	cis	rs1190552	0.846	rs11623570	chr14:102959277	G/T	cg18135206	chr14:102964638	TECPR2	0.44	8.59	0.32	6.62e-17	Blood protein levels;
BRCA	cis	rs6446731	0.593	rs2858083	chr4:3272331	T/A	cg08886695	chr4:3369023	RGS12	-0.38	-9.95	-0.37	8.78e-22	Mean platelet volume;
BRCA	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg05084668	chr3:125655381	ALG1L	-0.47	-8.14	-0.31	2.08e-15	Blood pressure (smoking interaction);
BRCA	cis	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg06521331	chr12:34319734	NA	-0.55	-10.09	-0.37	2.66e-22	Morning vs. evening chronotype;
BRCA	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg20503657	chr10:835505	NA	-0.52	-9.39	-0.35	1.06e-19	Response to angiotensin II receptor blocker therapy;
BRCA	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21659725	chr3:3221576	CRBN	0.35	8.39	0.32	3.19e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg02297831	chr4:17616191	MED28	0.36	8.5	0.32	1.39e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9815354	0.951	rs9849393	chr3:41875369	G/C	cg03022575	chr3:42003672	ULK4	0.49	7.99	0.3	6.4e-15	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg19077165	chr18:44547161	KATNAL2	-0.37	-7.83	-0.3	2.01e-14	Educational attainment;
BRCA	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg11502198	chr6:26597334	ABT1	0.49	9.73	0.36	5.8e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg18357645	chr12:58087776	OS9	-0.33	-8.34	-0.31	4.55e-16	Multiple sclerosis;
BRCA	cis	rs1468333	1.000	rs4835671	chr5:137511801	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.45	8.7	0.33	2.9e-17	Resting heart rate;
BRCA	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg00074818	chr8:8560427	CLDN23	0.37	8.29	0.31	6.69e-16	Obesity-related traits;
BRCA	cis	rs6723226	0.732	rs390480	chr2:32510072	A/C	cg02381751	chr2:32503542	YIPF4	-0.69	-15.11	-0.51	2.42e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24549020	chr5:56110836	MAP3K1	0.64	13.05	0.46	1.1e-34	Initial pursuit acceleration;
BRCA	cis	rs7737355	0.947	rs6864145	chr5:130637861	C/T	cg06307176	chr5:131281290	NA	0.45	8.67	0.32	3.65e-17	Life satisfaction;
BRCA	trans	rs6076960	0.652	rs3852946	chr20:6255311	C/T	cg21095983	chr6:86352623	SYNCRIP	0.37	8.68	0.32	3.41e-17	Smooth-surface caries;
BRCA	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg03351412	chr1:154909251	PMVK	0.58	13.44	0.47	1.85e-36	Prostate cancer;
BRCA	cis	rs9287719	0.699	rs4669602	chr2:10787967	C/T	cg00105475	chr2:10696890	NA	0.36	8.4	0.32	2.93e-16	Prostate cancer;
BRCA	cis	rs4742903	0.509	rs10991115	chr9:106896111	C/T	cg14250997	chr9:106856677	SMC2	0.29	8.51	0.32	1.22e-16	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.57	12.2	0.43	6.11e-31	Monocyte percentage of white cells;
BRCA	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.55	-8.19	-0.31	1.39e-15	Yeast infection;
BRCA	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg04842962	chr6:43655489	MRPS18A	0.84	21.48	0.65	1.86e-77	IgG glycosylation;
BRCA	cis	rs11051970	0.636	rs2733705	chr12:32561564	T/C	cg02745156	chr12:32552066	NA	0.25	8.4	0.32	2.93e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg08027265	chr7:2291960	NA	-0.36	-8.23	-0.31	1.04e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs11229555	0.645	rs12797488	chr11:58174653	A/T	cg15696309	chr11:58395628	NA	-0.53	-11.02	-0.4	5.84e-26	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg25214090	chr10:38739885	LOC399744	0.53	10.82	0.39	3.7e-25	Corneal astigmatism;
BRCA	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg21143896	chr7:2802374	GNA12	-0.32	-8.09	-0.3	3.05e-15	Height;
BRCA	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.96	0.37	8.22e-22	Bladder cancer;
BRCA	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-11.79	-0.42	3.56e-29	Personality dimensions;
BRCA	cis	rs6005807	0.640	rs2013784	chr22:28923933	C/T	cg12565055	chr22:29076175	TTC28	-0.41	-8.03	-0.3	4.62e-15	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg11789530	chr4:8429930	ACOX3	-0.69	-17.67	-0.57	3.35e-57	Response to antineoplastic agents;
BRCA	cis	rs7301826	0.934	rs10848212	chr12:131322000	C/G	cg11011512	chr12:131303247	STX2	-0.4	-9.76	-0.36	4.52e-21	Plasma plasminogen activator levels;
BRCA	cis	rs208520	0.690	rs207107	chr6:66794385	T/C	cg07460842	chr6:66804631	NA	-1.02	-20.41	-0.63	1.11e-71	Exhaled nitric oxide output;
BRCA	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg16339924	chr4:17578868	LAP3	0.59	14.52	0.5	1.8e-41	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1011018	0.628	rs56840127	chr7:139438467	G/C	cg03224163	chr7:139420300	HIPK2	-0.51	-9.0	-0.34	2.63e-18	Systolic blood pressure;
BRCA	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg18132916	chr6:79620363	NA	-0.47	-10.76	-0.39	6.33e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	12.21	0.43	5.69e-31	Platelet count;
BRCA	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg00504896	chr12:9437009	LOC642846	-0.49	-10.7	-0.39	1.12e-24	Breast size;
BRCA	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg08213375	chr14:104286397	PPP1R13B	0.52	11.64	0.42	1.57e-28	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg02743256	chr7:2109353	MAD1L1	-0.44	-7.86	-0.3	1.61e-14	Bipolar disorder;
BRCA	cis	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg07460842	chr6:66804631	NA	0.98	19.65	0.61	1.36e-67	Exhaled nitric oxide output;
BRCA	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg09307838	chr4:120376055	NA	-0.62	-13.75	-0.48	7.48e-38	Corneal astigmatism;
BRCA	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg03877680	chr5:178157825	ZNF354A	-0.77	-14.38	-0.49	7.97e-41	Neutrophil percentage of white cells;
BRCA	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg03585969	chr10:35415529	CREM	0.56	11.5	0.41	5.98e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-11.78	-0.42	3.86e-29	Tonsillectomy;
BRCA	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg26384229	chr12:38710491	ALG10B	0.76	17.26	0.56	4.21e-55	Bladder cancer;
BRCA	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg04374321	chr14:90722782	PSMC1	0.43	8.63	0.32	4.93e-17	Gut microbiota (bacterial taxa);
BRCA	trans	rs867371	0.519	rs1566560	chr15:82524457	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.32	-8.59	-0.32	6.76e-17	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs8014204	0.762	rs10139018	chr14:75274292	T/C	cg06637938	chr14:75390232	RPS6KL1	0.42	8.6	0.32	6.1e-17	Caffeine consumption;
BRCA	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg11266682	chr4:10021025	SLC2A9	-0.37	-9.61	-0.36	1.58e-20	Bone mineral density;
BRCA	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg22907277	chr7:1156413	C7orf50	0.6	9.01	0.34	2.28e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.59	0.39	2.99e-24	IgG glycosylation;
BRCA	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg04990556	chr1:26633338	UBXN11	-0.46	-8.91	-0.33	5.19e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs72772090	0.522	rs79613279	chr5:95995040	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-8.5	-0.32	1.3e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg05313129	chr8:58192883	C8orf71	-0.48	-9.83	-0.36	2.58e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg02297831	chr4:17616191	MED28	0.39	8.64	0.32	4.47e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7809950	1.000	rs17154077	chr7:107077941	C/T	cg23024343	chr7:107201750	COG5	0.4	9.35	0.35	1.41e-19	Coronary artery disease;
BRCA	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11905131	chr22:24372483	LOC391322	-0.41	-8.92	-0.33	4.86e-18	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs6479891	0.778	rs7896676	chr10:65065302	T/C	cg14819942	chr15:35414228	NA	-0.35	-8.56	-0.32	8.37e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs13095912	1.000	rs6784948	chr3:185342787	C/T	cg11274856	chr3:185301563	NA	0.33	8.29	0.31	6.53e-16	Systolic blood pressure;
BRCA	cis	rs6809651	0.524	rs4686728	chr3:185795333	C/T	cg00760338	chr3:185826511	ETV5	0.5	10.29	0.38	4.44e-23	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
BRCA	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg02659138	chr7:134003124	SLC35B4	0.33	10.38	0.38	1.94e-23	Mean platelet volume;
BRCA	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.42	0.47	2.35e-36	Colorectal cancer;
BRCA	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg08601574	chr20:25228251	PYGB	-0.35	-8.31	-0.31	5.95e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7301826	1.000	rs4759524	chr12:131315610	G/A	cg11011512	chr12:131303247	STX2	0.43	10.95	0.4	1.1e-25	Plasma plasminogen activator levels;
BRCA	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg08132940	chr7:1081526	C7orf50	-0.59	-8.77	-0.33	1.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs1997103	0.871	rs1997101	chr7:55399652	A/T	cg20935933	chr6:143382018	AIG1	0.6	11.52	0.41	4.77e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs3960554	0.867	rs76408713	chr7:75829540	G/A	cg19862616	chr7:65841803	NCRNA00174	0.59	11.78	0.42	3.93e-29	Eotaxin levels;
BRCA	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	19.68	0.61	9.55e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.59	0.39	2.94e-24	Motion sickness;
BRCA	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg23711669	chr6:146136114	FBXO30	0.67	15.63	0.53	7.2e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg17757837	chr7:157058334	UBE3C	-0.69	-17.16	-0.56	1.43e-54	Body mass index;
BRCA	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg18016565	chr1:150552671	MCL1	-0.43	-9.61	-0.36	1.62e-20	Tonsillectomy;
BRCA	trans	rs7980799	0.933	rs11052705	chr12:33588388	T/C	cg26384229	chr12:38710491	ALG10B	-0.41	-8.53	-0.32	1.05e-16	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.69	-0.33	3.09e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15541040	chr2:3486749	NA	-0.47	-10.42	-0.38	1.39e-23	Neurofibrillary tangles;
BRCA	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg25319279	chr11:5960081	NA	0.46	9.84	0.36	2.31e-21	DNA methylation (variation);
BRCA	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg20476274	chr7:133979776	SLC35B4	0.65	19.4	0.61	2.78e-66	Mean platelet volume;
BRCA	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.81	-0.3	2.42e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg27102117	chr16:15229624	NA	-0.41	-9.76	-0.36	4.61e-21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs72772090	0.539	rs56213813	chr5:96112284	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.08	-0.43	2.05e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7020830	0.861	rs2291589	chr9:37079661	T/G	cg14294708	chr9:37120828	ZCCHC7	1.16	40.16	0.85	5.94e-177	Schizophrenia;
BRCA	cis	rs919433	0.963	rs1896857	chr2:198164530	A/G	cg10820045	chr2:198174542	NA	-0.38	-8.38	-0.31	3.29e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs13102973	0.931	rs12499856	chr4:135868573	C/T	cg14419869	chr4:135874104	NA	0.52	11.1	0.4	2.74e-26	Subjective well-being;
BRCA	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg23533926	chr12:111358616	MYL2	-0.44	-9.2	-0.34	4.96e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg20701182	chr2:24300061	SF3B14	0.59	9.21	0.34	4.53e-19	Lymphocyte counts;
BRCA	cis	rs10046574	0.519	rs7781819	chr7:135205700	A/T	cg27474649	chr7:135195673	CNOT4	0.64	10.67	0.39	1.44e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs6543140	0.964	rs4851589	chr2:103077145	A/G	cg04239558	chr2:103089729	SLC9A4	0.31	8.74	0.33	2.11e-17	Blood protein levels;
BRCA	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg15145296	chr3:125709740	NA	-0.53	-9.12	-0.34	9.63e-19	Blood pressure (smoking interaction);
BRCA	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg23711669	chr6:146136114	FBXO30	0.65	14.88	0.51	3.11e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg23708337	chr7:1209742	NA	0.63	8.86	0.33	8.16e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg00071950	chr4:10020882	SLC2A9	-0.43	-9.96	-0.37	8.02e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg04691961	chr3:161091175	C3orf57	-0.39	-8.71	-0.33	2.66e-17	Parkinson's disease;
BRCA	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg13319975	chr6:146136371	FBXO30	0.4	8.95	0.33	3.88e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2742234	0.541	rs12416428	chr10:43708998	G/A	cg15436174	chr10:43711423	RASGEF1A	0.56	10.95	0.4	1.13e-25	Hirschsprung disease;
BRCA	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg25237894	chr2:233734115	C2orf82	-0.45	-14.46	-0.5	3.26e-41	Coronary artery disease;
BRCA	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg27129171	chr3:47204927	SETD2	-0.65	-14.38	-0.49	8.17e-41	Birth weight;
BRCA	trans	rs3857536	0.740	rs9354392	chr6:66894555	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-9.34	-0.35	1.63e-19	Blood trace element (Cu levels);
BRCA	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.53e-15	Tonsillectomy;
BRCA	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.52	0.5	1.78e-41	Motion sickness;
BRCA	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.35	-9.84	-0.36	2.26e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg27347728	chr4:17578864	LAP3	0.45	8.81	0.33	1.18e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg06212747	chr3:49208901	KLHDC8B	0.47	9.51	0.35	3.87e-20	Parkinson's disease;
BRCA	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg01884057	chr2:25150051	NA	0.31	8.25	0.31	9.38e-16	Body mass index;
BRCA	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg13660082	chr14:53194042	PSMC6	-0.56	-8.05	-0.3	4.16e-15	Alzheimer's disease (late onset);
BRCA	cis	rs2625529	0.824	rs12902006	chr15:72252996	C/T	cg16672083	chr15:72433130	SENP8	-0.84	-17.46	-0.57	4.01e-56	Red blood cell count;
BRCA	cis	rs698833	0.892	rs698797	chr2:44689905	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	10.61	0.39	2.38e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18402987	chr7:1209562	NA	0.59	11.59	0.42	2.47e-28	Longevity;Endometriosis;
BRCA	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.52	8.22	0.31	1.13e-15	Renal function-related traits (BUN);
BRCA	cis	rs4074536	0.536	rs10923352	chr1:116290716	T/G	cg21648376	chr1:116311395	CASQ2	-0.49	-8.71	-0.33	2.5e-17	QRS duration;
BRCA	trans	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg11693508	chr17:37793320	STARD3	0.47	10.13	0.37	1.75e-22	Bipolar disorder;
BRCA	cis	rs4713675	0.584	rs9380375	chr6:33682391	G/A	cg14003231	chr6:33640908	ITPR3	0.35	8.72	0.33	2.3e-17	Plateletcrit;
BRCA	cis	rs11785693	0.862	rs17351027	chr8:4987098	A/G	cg26367366	chr8:4980734	NA	-0.61	-11.21	-0.41	9.13e-27	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11644478	chr21:40555479	PSMG1	-0.52	-10.93	-0.4	1.36e-25	Menarche (age at onset);
BRCA	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg05348668	chr2:190686969	PMS1	-0.36	-7.93	-0.3	9.6e-15	Mosquito bite size;
BRCA	cis	rs36051895	0.658	rs10975029	chr9:5251068	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-8.48	-0.32	1.6e-16	Pediatric autoimmune diseases;
BRCA	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.37	7.88	0.3	1.4e-14	Electroencephalogram traits;
BRCA	cis	rs3740540	0.507	rs942014	chr10:126290070	C/T	cg04949429	chr10:126290192	LHPP	0.43	12.05	0.43	2.72e-30	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg09074113	chr2:20870087	GDF7	0.32	8.3	0.31	6.3e-16	Abdominal aortic aneurysm;
BRCA	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg09998033	chr7:158218633	PTPRN2	-0.37	-9.32	-0.35	1.8e-19	Obesity-related traits;
BRCA	cis	rs4774830	0.661	rs62045239	chr15:56294642	G/A	cg24530489	chr15:56299380	NA	-0.8	-8.99	-0.34	2.82e-18	Delta-5 desaturase activity;
BRCA	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.75	-13.22	-0.46	1.93e-35	Smoking behavior;
BRCA	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25427524	chr10:38739819	LOC399744	-0.7	-16.92	-0.56	2.46e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2882667	0.690	rs700625	chr5:138099597	A/T	cg04439458	chr5:138467593	SIL1	0.31	7.87	0.3	1.47e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg26168224	chr5:2018326	NA	-0.51	-11.45	-0.41	1.01e-27	Gut microbiome composition (winter);
BRCA	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21582582	chr3:182698605	DCUN1D1	0.37	9.87	0.36	1.82e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4908768	0.539	rs6670508	chr1:8647917	G/C	cg20416874	chr1:8611966	RERE	-0.28	-7.83	-0.3	2.02e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.06	-0.3	3.75e-15	Height;
BRCA	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg14863265	chr7:2801509	GNA12	-0.41	-8.77	-0.33	1.64e-17	Height;
BRCA	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10802521	chr3:52805072	NEK4	-0.33	-9.08	-0.34	1.3e-18	Bipolar disorder;
BRCA	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-12.16	-0.43	9.45e-31	Electroencephalogram traits;
BRCA	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg14061069	chr19:46274453	DMPK	-0.49	-12.2	-0.43	6.19e-31	Coronary artery disease;
BRCA	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg02187348	chr16:89574699	SPG7	-0.38	-8.05	-0.3	4.1e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs67478160	0.506	rs6575998	chr14:104250417	A/G	cg08213375	chr14:104286397	PPP1R13B	0.57	15.03	0.51	5.86e-44	Schizophrenia;
BRCA	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.2	0.34	5.04e-19	Tonsillectomy;
BRCA	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg04546413	chr19:29218101	NA	0.65	12.37	0.44	1.19e-31	Methadone dose in opioid dependence;
BRCA	cis	rs7520050	0.966	rs4660319	chr1:46341623	C/T	cg24296786	chr1:45957014	TESK2	0.44	9.89	0.36	1.5e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg03585969	chr10:35415529	CREM	0.55	11.23	0.41	7.79e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs17401966	1.000	rs12407992	chr1:10311983	A/C	cg15208524	chr1:10270712	KIF1B	0.38	8.44	0.32	2.11e-16	Hepatocellular carcinoma;
BRCA	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg04317338	chr11:64019027	PLCB3	0.55	9.46	0.35	5.59e-20	Mean platelet volume;
BRCA	trans	rs853679	0.546	rs36092177	chr6:28357807	C/T	cg06606381	chr12:133084897	FBRSL1	-0.9	-8.84	-0.33	9.38e-18	Depression;
BRCA	trans	rs3857536	0.776	rs1002764	chr6:66945760	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	1.99e-14	Blood trace element (Cu levels);
BRCA	cis	rs17601876	0.545	rs17523284	chr15:51538723	G/A	cg19946085	chr15:51559439	CYP19A1	-0.31	-8.07	-0.3	3.4e-15	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.65	12.34	0.44	1.51e-31	Gut microbiome composition (summer);
BRCA	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg23231163	chr10:75533350	FUT11	-0.34	-8.89	-0.33	6e-18	Inflammatory bowel disease;
BRCA	cis	rs6840258	1.000	rs56390363	chr4:87943087	G/A	cg08197287	chr4:87952173	AFF1	-0.44	-8.56	-0.32	8.47e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-11.15	-0.4	1.71e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg12927641	chr6:109611667	NA	-0.38	-9.85	-0.36	2.11e-21	Reticulocyte fraction of red cells;
BRCA	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg07395648	chr5:131743802	NA	0.38	8.26	0.31	8.54e-16	Breast cancer;
BRCA	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg04944784	chr2:26401820	FAM59B	0.99	14.85	0.51	4.4e-43	Gut microbiome composition (summer);
BRCA	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg17845761	chr1:175162550	KIAA0040	0.26	9.92	0.37	1.17e-21	Diastolic blood pressure;
BRCA	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg15432903	chr11:17409602	KCNJ11	0.71	15.5	0.52	3.09e-46	Type 2 diabetes;
BRCA	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-14.85	-0.51	4.28e-43	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg13010199	chr12:38710504	ALG10B	0.51	10.69	0.39	1.24e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9463078	0.764	rs3799971	chr6:44819319	G/C	cg25276700	chr6:44698697	NA	-0.36	-8.3	-0.31	6.15e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.9	0.36	1.36e-21	Bipolar disorder;
BRCA	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg14186256	chr22:23484241	RTDR1	0.76	23.09	0.67	3.08e-86	Bone mineral density;
BRCA	cis	rs9815354	0.812	rs17282671	chr3:41887455	T/C	cg03022575	chr3:42003672	ULK4	0.71	9.71	0.36	7.25e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg12365402	chr11:9010492	NRIP3	-0.42	-9.92	-0.37	1.18e-21	Hemoglobin concentration;
BRCA	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-11.19	-0.4	1.14e-26	Morning vs. evening chronotype;
BRCA	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg16329650	chr2:213403929	ERBB4	0.66	19.56	0.61	4.1e-67	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs13053817	1.000	rs12485237	chr22:29837286	A/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.51	-9.1	-0.34	1.13e-18	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs738322	0.533	rs2284064	chr22:38547395	A/C	cg25457927	chr22:38595422	NA	-0.36	-12.9	-0.45	5.4e-34	Cutaneous nevi;
BRCA	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	11.83	0.42	2.48e-29	Lung cancer in ever smokers;
BRCA	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg12564285	chr5:131593104	PDLIM4	0.35	7.98	0.3	6.85e-15	Breast cancer;
BRCA	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg02297831	chr4:17616191	MED28	0.38	9.03	0.34	2.03e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11605924	0.967	rs7121611	chr11:45864142	A/T	ch.11.939596F	chr11:45881766	CRY2	-0.47	-10.2	-0.37	1.02e-22	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg01448562	chr3:133502909	NA	-0.61	-14.46	-0.5	3.17e-41	Iron status biomarkers;
BRCA	cis	rs4900538	0.927	rs1190547	chr14:102905087	G/C	cg18135206	chr14:102964638	TECPR2	-1.04	-28.84	-0.75	9.1e-118	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	trans	rs61931739	0.635	rs1852224	chr12:33963080	A/C	cg26384229	chr12:38710491	ALG10B	0.39	8.87	0.33	7e-18	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg17366294	chr4:99064904	C4orf37	0.43	9.93	0.37	1e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg12011299	chr4:100065546	ADH4	0.49	11.02	0.4	5.78e-26	Smoking initiation;
BRCA	cis	rs9815354	0.812	rs55916855	chr3:42002761	A/G	cg03022575	chr3:42003672	ULK4	0.73	10.08	0.37	2.94e-22	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	16.33	0.54	2.23e-50	Colorectal cancer;
BRCA	cis	rs3857067	0.806	rs722486	chr4:95092315	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.45	-0.35	6.42e-20	QT interval;
BRCA	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg08873628	chr1:175162347	KIAA0040	0.33	7.89	0.3	1.31e-14	Alcohol dependence;
BRCA	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-14.79	-0.51	8.68e-43	Hemoglobin concentration;
BRCA	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg21573476	chr21:45109991	RRP1B	-0.49	-12.84	-0.45	9.49e-34	Mean corpuscular volume;
BRCA	trans	rs9951602	0.512	rs9953258	chr18:76651199	A/C	cg02800362	chr5:177631904	HNRNPAB	0.77	18.01	0.58	5.8e-59	Obesity-related traits;
BRCA	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg03474202	chr17:45855739	NA	-0.48	-12.72	-0.45	3.53e-33	IgG glycosylation;
BRCA	cis	rs600806	0.778	rs2039694	chr1:109991700	A/G	cg20591472	chr1:110008990	SYPL2	0.33	8.3	0.31	6.14e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg06521331	chr12:34319734	NA	-0.53	-10.09	-0.37	2.64e-22	Bladder cancer;
BRCA	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.15	-0.34	7.47e-19	Bipolar disorder;
BRCA	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg26384229	chr12:38710491	ALG10B	0.67	14.06	0.49	2.68e-39	Morning vs. evening chronotype;
BRCA	trans	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg07211511	chr3:129823064	LOC729375	-1.05	-18.39	-0.59	5.85e-61	Blood pressure (smoking interaction);
BRCA	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg03585969	chr10:35415529	CREM	0.55	11.47	0.41	7.99e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.74	-0.33	2.07e-17	Total body bone mineral density;
BRCA	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg11822812	chr5:140052017	DND1	-0.32	-8.69	-0.33	3.01e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs17384381	0.859	rs12724823	chr1:85906385	G/T	cg16011679	chr1:85725395	C1orf52	0.51	7.84	0.3	1.95e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg08601574	chr20:25228251	PYGB	0.34	8.17	0.31	1.65e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg21138405	chr5:131827807	IRF1	-0.4	-13.38	-0.47	3.51e-36	Asthma (sex interaction);
BRCA	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg08997352	chr12:9597637	DDX12	-0.49	-9.65	-0.36	1.19e-20	Breast size;
BRCA	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg23262073	chr20:60523788	NA	0.55	13.61	0.47	3.28e-37	Obesity-related traits;
BRCA	cis	rs7020830	0.898	rs308523	chr9:37338785	C/T	cg14294708	chr9:37120828	ZCCHC7	1.03	29.32	0.76	2.17e-120	Schizophrenia;
BRCA	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18876405	chr7:65276391	NA	0.62	15.48	0.52	3.92e-46	Aortic root size;
BRCA	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	19.61	0.61	2.24e-67	Platelet count;
BRCA	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg24812749	chr6:127587940	RNF146	0.86	19.72	0.62	5.43e-68	Breast cancer;
BRCA	trans	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg25214090	chr10:38739885	LOC399744	0.51	10.48	0.38	7.8e-24	Corneal astigmatism;
BRCA	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg15934090	chr1:100435551	SLC35A3	0.36	8.32	0.31	5.13e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg23711669	chr6:146136114	FBXO30	-0.78	-18.09	-0.58	2.33e-59	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg17211192	chr8:82754475	SNX16	0.59	11.63	0.42	1.73e-28	Diastolic blood pressure;
BRCA	trans	rs6479891	1.000	rs61853635	chr10:65276510	T/G	cg14819942	chr15:35414228	NA	0.36	8.72	0.33	2.33e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs4911259	0.552	rs6057663	chr20:31463071	G/T	cg13636640	chr20:31349939	DNMT3B	-0.45	-11.89	-0.43	1.36e-29	Inflammatory bowel disease;
BRCA	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg02196655	chr2:10830764	NOL10	-0.3	-7.87	-0.3	1.52e-14	Prostate cancer;
BRCA	cis	rs6977660	0.619	rs10231972	chr7:19789354	C/G	cg07541023	chr7:19748670	TWISTNB	0.46	8.62	0.32	5.34e-17	Thyroid stimulating hormone;
BRCA	cis	rs17601876	0.843	rs12901187	chr15:51549537	G/A	cg19946085	chr15:51559439	CYP19A1	-0.35	-9.5	-0.35	4.11e-20	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg04450456	chr4:17643702	FAM184B	0.37	11.03	0.4	5.08e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg01689657	chr7:91764605	CYP51A1	0.25	8.92	0.33	4.78e-18	Breast cancer;
BRCA	cis	rs4409675	0.576	rs2078328	chr1:28224976	A/G	cg23691781	chr1:28212827	C1orf38	0.33	10.95	0.4	1.11e-25	Corneal astigmatism;
BRCA	trans	rs2262909	0.962	rs409439	chr19:22227432	C/T	cg17074339	chr11:11642133	GALNTL4	-0.43	-8.4	-0.32	3e-16	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02176678	chr2:219576539	TTLL4	0.46	12.2	0.43	6.39e-31	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	17.7	0.57	2.51e-57	Platelet count;
BRCA	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg13010199	chr12:38710504	ALG10B	-0.41	-9.78	-0.36	3.9e-21	Heart rate;
BRCA	cis	rs4363385	0.693	rs490553	chr1:153033277	A/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.34	-0.31	4.7e-16	Inflammatory skin disease;
BRCA	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-11.18	-0.4	1.27e-26	Mean corpuscular volume;
BRCA	cis	rs9341808	0.935	rs9343974	chr6:80924645	A/G	cg08355045	chr6:80787529	NA	0.33	8.23	0.31	1.03e-15	Sitting height ratio;
BRCA	cis	rs7945718	0.934	rs10831909	chr11:12817182	C/G	cg25843174	chr11:12811716	TEAD1	0.25	9.36	0.35	1.31e-19	Educational attainment (years of education);
BRCA	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	20.12	0.62	4.1e-70	Smoking behavior;
BRCA	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg08645402	chr16:4508243	NA	0.35	7.89	0.3	1.34e-14	Schizophrenia;
BRCA	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg08085267	chr17:45401833	C17orf57	0.65	14.51	0.5	1.94e-41	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg27170947	chr2:26402098	FAM59B	0.97	17.16	0.56	1.38e-54	Gut microbiome composition (summer);
BRCA	trans	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg06636001	chr8:8085503	FLJ10661	0.43	8.45	0.32	1.97e-16	Retinal vascular caliber;
BRCA	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.19	0.46	2.76e-35	Electroencephalogram traits;
BRCA	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg17366294	chr4:99064904	C4orf37	0.41	9.49	0.35	4.41e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9394841	0.667	rs71558769	chr6:41782107	T/C	cg08135965	chr6:41755394	TOMM6	0.5	8.22	0.31	1.09e-15	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg06618935	chr21:46677482	NA	-0.37	-8.03	-0.3	4.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg26384229	chr12:38710491	ALG10B	-0.67	-16.7	-0.55	3.07e-52	Morning vs. evening chronotype;
BRCA	cis	rs300703	0.542	rs189762	chr2:180079	A/T	cg21211680	chr2:198530	NA	-0.38	-8.26	-0.31	8.23e-16	Blood protein levels;
BRCA	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg23711669	chr6:146136114	FBXO30	-0.71	-16.94	-0.56	2e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-8.63	-0.32	4.92e-17	Monocyte percentage of white cells;
BRCA	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg01292856	chr11:65242576	NA	0.32	8.09	0.3	2.99e-15	Bone mineral density;
BRCA	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg06640241	chr16:89574553	SPG7	0.81	19.88	0.62	8.28e-69	Multiple myeloma (IgH translocation);
BRCA	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg04546413	chr19:29218101	NA	0.64	12.33	0.44	1.75e-31	Methadone dose in opioid dependence;
BRCA	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25427524	chr10:38739819	LOC399744	-0.73	-17.57	-0.57	1.1e-56	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7149337	0.869	rs7159770	chr14:51691835	G/A	cg23942311	chr14:51606299	NA	0.4	11.05	0.4	4.11e-26	Cancer;
BRCA	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg27170947	chr2:26402098	FAM59B	0.92	16.52	0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-11.87	-0.42	1.69e-29	Bipolar disorder;
BRCA	cis	rs1011018	0.628	rs73158613	chr7:139435454	G/A	cg03224163	chr7:139420300	HIPK2	-0.54	-9.23	-0.34	3.9e-19	Systolic blood pressure;
BRCA	cis	rs7523273	1.000	rs1142469	chr1:207965427	G/A	cg22525895	chr1:207977042	MIR29B2	-0.5	-11.93	-0.43	9.51e-30	Schizophrenia;
BRCA	trans	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg26043149	chr18:55253948	FECH	1.07	23.48	0.68	2.18e-88	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs7020830	0.898	rs308495	chr9:37277603	G/T	cg14294708	chr9:37120828	ZCCHC7	1.04	30.85	0.77	1.21e-128	Schizophrenia;
BRCA	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg09307838	chr4:120376055	NA	0.69	14.02	0.49	3.82e-39	Corneal astigmatism;
BRCA	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg12310025	chr6:25882481	NA	-0.38	-8.72	-0.33	2.44e-17	Height;
BRCA	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg24675658	chr1:53192096	ZYG11B	0.66	15.54	0.52	1.95e-46	Monocyte count;
BRCA	cis	rs1975991	0.765	rs7637952	chr3:187948630	T/G	cg15417654	chr3:187959138	LPP	0.33	8.37	0.31	3.58e-16	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg02574844	chr11:5959923	NA	-0.38	-8.27	-0.31	7.71e-16	DNA methylation (variation);
BRCA	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.22e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs938554	0.612	rs28592748	chr4:9998605	T/C	cg00071950	chr4:10020882	SLC2A9	0.41	7.87	0.3	1.5e-14	Blood metabolite levels;
BRCA	cis	rs9942416	0.660	rs2307113	chr5:74998264	C/T	cg19683494	chr5:74908142	NA	0.48	9.02	0.34	2.18e-18	Age-related disease endophenotypes;
BRCA	cis	rs9503598	0.778	rs10155771	chr6:3465930	G/A	cg00476032	chr6:3446245	SLC22A23	0.43	10.6	0.39	2.83e-24	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs10465746	0.725	rs10127737	chr1:84368642	G/A	cg10977910	chr1:84465055	TTLL7	0.59	12.66	0.45	6.17e-33	Obesity-related traits;
BRCA	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg09307838	chr4:120376055	NA	0.72	15.17	0.51	1.29e-44	Corneal astigmatism;
BRCA	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-9.26	-0.34	3.04e-19	Colorectal cancer;
BRCA	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-14.82	-0.51	6.55e-43	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg05340658	chr4:99064831	C4orf37	0.44	10.18	0.37	1.12e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.83	12.67	0.45	5.35e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.03	-0.3	4.58e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs11955398	0.501	rs10057004	chr5:60041034	G/C	cg02684056	chr5:59996105	DEPDC1B	-0.36	-8.3	-0.31	6.24e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.43	-0.32	2.28e-16	Total body bone mineral density;
BRCA	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.47	-11.6	-0.42	2.38e-28	Longevity;Endometriosis;
BRCA	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg23711669	chr6:146136114	FBXO30	0.78	18.79	0.6	4.89e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg11584989	chr19:19387371	SF4	0.63	13.52	0.47	7.85e-37	Bipolar disorder;
BRCA	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg10523679	chr1:76189770	ACADM	-0.44	-8.38	-0.31	3.34e-16	Daytime sleep phenotypes;
BRCA	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg00745463	chr17:30367425	LRRC37B	-0.6	-9.77	-0.36	4.04e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg22105103	chr4:187893119	NA	-0.41	-13.25	-0.46	1.35e-35	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	8.02e-19	Lymphocyte counts;
BRCA	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg12140854	chr5:148520817	ABLIM3	-0.42	-9.02	-0.34	2.18e-18	Breast cancer;
BRCA	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-9.02	-0.34	2.12e-18	Monocyte percentage of white cells;
BRCA	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg23992470	chr4:843637	GAK	0.56	8.27	0.31	8.04e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg06521331	chr12:34319734	NA	-0.53	-9.28	-0.34	2.62e-19	Resting heart rate;
BRCA	trans	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg25214090	chr10:38739885	LOC399744	0.45	10.38	0.38	2.04e-23	Corneal astigmatism;
BRCA	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg08470875	chr2:26401718	FAM59B	-0.64	-9.54	-0.35	2.95e-20	Gut microbiome composition (summer);
BRCA	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg21226059	chr5:178986404	RUFY1	0.53	15.07	0.51	3.8e-44	Lung cancer;
BRCA	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.49	0.32	1.44e-16	Rheumatoid arthritis;
BRCA	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03264133	chr6:25882463	NA	-0.82	-19.86	-0.62	9.97e-69	Urate levels;
BRCA	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg14675211	chr2:100938903	LONRF2	0.43	9.94	0.37	9.9e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs698833	0.729	rs4952708	chr2:44517072	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	9.58	0.35	2.19e-20	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg24531977	chr5:56204891	C5orf35	-0.42	-8.55	-0.32	9.39e-17	Coronary artery disease;
BRCA	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg24578937	chr1:2090814	PRKCZ	0.57	17.81	0.58	6.82e-58	Height;
BRCA	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg13047869	chr3:10149882	C3orf24	0.58	12.07	0.43	2.41e-30	Alzheimer's disease;
BRCA	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg12310025	chr6:25882481	NA	-0.79	-18.67	-0.59	2.09e-62	Intelligence (multi-trait analysis);
BRCA	cis	rs1538970	0.962	rs9429075	chr1:45818421	G/A	cg05343316	chr1:45956843	TESK2	0.55	10.93	0.4	1.31e-25	Platelet count;
BRCA	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	12.63	0.45	8.73e-33	Mean platelet volume;
BRCA	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg13385794	chr1:248469461	NA	0.28	7.81	0.3	2.28e-14	Common traits (Other);
BRCA	cis	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg07460842	chr6:66804631	NA	0.99	19.93	0.62	4.01e-69	Exhaled nitric oxide output;
BRCA	trans	rs2665103	0.655	rs1501367	chr15:82522816	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.33	-8.97	-0.33	3.15e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg15145296	chr3:125709740	NA	-0.56	-8.89	-0.33	5.97e-18	Blood pressure (smoking interaction);
BRCA	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg04546413	chr19:29218101	NA	0.66	13.26	0.46	1.32e-35	Methadone dose in opioid dependence;
BRCA	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.21	-0.31	1.2e-15	Bipolar disorder;
BRCA	cis	rs10504073	0.669	rs341809	chr8:50042557	C/T	cg00325661	chr8:49890786	NA	0.38	10.83	0.39	3.22e-25	Blood metabolite ratios;
BRCA	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg01448562	chr3:133502909	NA	-0.76	-19.22	-0.61	2.55e-65	Iron status biomarkers;
BRCA	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg12193833	chr17:30244370	NA	-0.55	-8.77	-0.33	1.62e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg21770322	chr7:97807741	LMTK2	0.45	12.0	0.43	4.73e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg04034577	chr2:241836375	C2orf54	-0.5	-12.55	-0.44	1.95e-32	Urinary metabolites;
BRCA	cis	rs9463078	0.804	rs9395086	chr6:45225331	T/A	cg25276700	chr6:44698697	NA	-0.35	-7.95	-0.3	8.75e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg13256891	chr4:100009986	ADH5	0.52	9.67	0.36	9.98e-21	Alcohol dependence;
BRCA	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg11266682	chr4:10021025	SLC2A9	0.49	12.91	0.45	4.67e-34	Bone mineral density;
BRCA	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg27279351	chr12:120934652	DYNLL1	0.51	11.98	0.43	5.8e-30	High light scatter reticulocyte count;
BRCA	cis	rs10751667	0.600	rs7395387	chr11:1008664	G/C	ch.11.42038R	chr11:967971	AP2A2	0.47	14.28	0.49	2.43e-40	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg08470875	chr2:26401718	FAM59B	-0.51	-8.21	-0.31	1.21e-15	Gut microbiome composition (summer);
BRCA	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	-0.56	-11.18	-0.4	1.25e-26	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	15.63	0.53	7.54e-47	Smoking behavior;
BRCA	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg24006582	chr15:45444508	DUOX1	0.51	10.21	0.37	9.21e-23	Uric acid levels;
BRCA	cis	rs2764980	1.000	rs2764978	chr10:3283385	C/G	cg11630169	chr10:3283847	NA	-0.4	-9.23	-0.34	3.82e-19	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg15017067	chr4:17643749	FAM184B	0.34	10.41	0.38	1.57e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03264133	chr6:25882463	NA	0.48	10.86	0.39	2.49e-25	Blood metabolite levels;
BRCA	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg16322792	chr1:120165303	ZNF697	0.58	15.43	0.52	6.54e-46	Systemic lupus erythematosus;
BRCA	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg00339695	chr16:24857497	SLC5A11	-0.37	-9.42	-0.35	8.11e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7092929	0.941	rs611726	chr10:3572073	T/C	cg14308648	chr10:3568949	NA	0.45	8.04	0.3	4.42e-15	Coronary artery calcification;
BRCA	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg02153584	chr22:29168773	CCDC117	0.54	11.43	0.41	1.13e-27	Lymphocyte counts;
BRCA	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-9.06	-0.34	1.57e-18	Schizophrenia;
BRCA	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11644478	chr21:40555479	PSMG1	0.59	8.76	0.33	1.73e-17	Cognitive function;
BRCA	cis	rs72781680	0.821	rs2176265	chr2:24158638	C/G	cg08917208	chr2:24149416	ATAD2B	0.63	10.57	0.39	3.64e-24	Lymphocyte counts;
BRCA	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg08085267	chr17:45401833	C17orf57	0.58	12.19	0.43	7.29e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.74	0.36	5.54e-21	Menopause (age at onset);
BRCA	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg24829409	chr8:58192753	C8orf71	-0.47	-9.0	-0.34	2.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10899021	1.000	rs11236202	chr11:74376692	A/G	cg25880958	chr11:74394337	NA	-0.72	-9.39	-0.35	1.03e-19	Response to metformin (IC50);
BRCA	cis	rs68170813	0.559	rs1121312	chr7:106927820	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.52	-0.32	1.14e-16	Coronary artery disease;
BRCA	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26314531	chr2:26401878	FAM59B	0.88	15.31	0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00166722	chr3:10149974	C3orf24	0.65	13.07	0.46	8.76e-35	Alzheimer's disease;
BRCA	trans	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	13.36	0.47	4.29e-36	Exhaled nitric oxide output;
BRCA	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg10876282	chr6:28092338	ZSCAN16	0.42	8.37	0.31	3.7e-16	Cardiac Troponin-T levels;
BRCA	cis	rs13315871	0.929	rs9818581	chr3:58293101	A/G	cg20936604	chr3:58311152	NA	-0.66	-8.47	-0.32	1.65e-16	Cholesterol, total;
BRCA	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg05535760	chr7:792225	HEATR2	0.71	13.0	0.46	1.92e-34	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6735179	0.607	rs10185594	chr2:1746661	G/A	cg10160682	chr2:1713001	PXDN	-0.37	-7.9	-0.3	1.26e-14	Response to antipsychotic treatment;
BRCA	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg10295955	chr4:187884368	NA	-0.9	-26.24	-0.72	1.48e-103	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6788895	1.000	rs41372346	chr3:150489116	C/G	cg09723797	chr3:150481914	SIAH2	0.7	8.47	0.32	1.67e-16	Breast cancer;
BRCA	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg20203395	chr5:56204925	C5orf35	-0.47	-9.79	-0.36	3.62e-21	Initial pursuit acceleration;
BRCA	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35740288	0.520	rs56183577	chr15:86319706	A/G	cg20737812	chr15:86336631	KLHL25	-0.39	-8.49	-0.32	1.42e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.35	-9.84	-0.36	2.27e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9467773	0.587	rs3208733	chr6:26414425	C/T	cg09904177	chr6:26538194	HMGN4	-0.37	-9.75	-0.36	4.82e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg12311346	chr5:56204834	C5orf35	-0.81	-16.73	-0.55	2.22e-52	Initial pursuit acceleration;
BRCA	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg24531977	chr5:56204891	C5orf35	-0.5	-10.41	-0.38	1.56e-23	Coronary artery disease;
BRCA	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs4742903	0.935	rs10820602	chr9:106861282	C/T	cg21169611	chr9:106856078	SMC2	0.35	9.25	0.34	3.19e-19	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg14683738	chr19:37701593	ZNF585B	0.45	7.98	0.3	6.65e-15	Coronary artery calcification;
BRCA	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg26446133	chr18:72167187	CNDP2	-0.76	-14.55	-0.5	1.18e-41	Refractive error;
BRCA	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg20503657	chr10:835505	NA	1.05	18.42	0.59	4.21e-61	Eosinophil percentage of granulocytes;
BRCA	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg17971929	chr21:40555470	PSMG1	-0.63	-14.91	-0.51	2.36e-43	Cognitive function;
BRCA	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02018176	chr4:1364513	KIAA1530	0.37	7.93	0.3	9.81e-15	Longevity;
BRCA	cis	rs7520050	0.831	rs61783170	chr1:46256329	T/C	cg24296786	chr1:45957014	TESK2	0.45	9.92	0.37	1.17e-21	Red blood cell count;Reticulocyte count;
BRCA	trans	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg11693508	chr17:37793320	STARD3	0.53	9.18	0.34	5.95e-19	Neuroticism;
BRCA	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.8	0.36	3.13e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg05926928	chr17:57297772	GDPD1	-0.58	-8.83	-0.33	1e-17	Opioid sensitivity;
BRCA	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10802521	chr3:52805072	NEK4	-0.3	-7.99	-0.3	6.35e-15	Electroencephalogram traits;
BRCA	cis	rs4363385	0.655	rs11205163	chr1:152983677	C/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.36	-0.35	1.29e-19	Inflammatory skin disease;
BRCA	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg06552810	chr11:31128660	NA	-0.38	-8.76	-0.33	1.71e-17	Red blood cell count;
BRCA	cis	rs61990749	0.597	rs1477260	chr14:78256818	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.66	10.11	0.37	2.09e-22	Fibroblast growth factor basic levels;
BRCA	cis	rs6121246	0.559	rs6060944	chr20:30372114	G/A	cg13852791	chr20:30311386	BCL2L1	0.96	23.37	0.68	8.7e-88	Mean corpuscular hemoglobin;
BRCA	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg26893861	chr17:41843967	DUSP3	-0.57	-11.67	-0.42	1.16e-28	Triglycerides;
BRCA	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg05234568	chr11:5960015	NA	-0.51	-9.98	-0.37	6.72e-22	DNA methylation (variation);
BRCA	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg11752832	chr7:134001865	SLC35B4	0.52	13.17	0.46	3.21e-35	Mean platelet volume;
BRCA	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.33	-10.29	-0.38	4.52e-23	Bipolar disorder;
BRCA	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg25767906	chr1:53392781	SCP2	0.38	8.7	0.33	2.86e-17	Monocyte count;
BRCA	cis	rs4233802	1.000	rs4425094	chr2:151139891	C/T	cg25300694	chr2:151184358	NA	0.76	8.13	0.31	2.29e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg18252515	chr7:66147081	NA	-1.04	-15.52	-0.52	2.55e-46	Diabetic kidney disease;
BRCA	cis	rs4363385	0.747	rs1413849	chr1:152970233	C/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.72	-0.33	2.44e-17	Inflammatory skin disease;
BRCA	cis	rs2835872	0.758	rs1787394	chr21:39036176	C/A	cg06728970	chr21:39037746	KCNJ6	0.45	12.88	0.45	6.44e-34	Electroencephalographic traits in alcoholism;
BRCA	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-12.2	-0.43	6.44e-31	Alzheimer's disease;
BRCA	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.49	-0.47	1.15e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs365132	0.715	rs181330	chr5:176404962	A/G	cg16309518	chr5:176445507	NA	-0.4	-9.8	-0.36	3.14e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-9.28	-0.34	2.56e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg14847009	chr1:175162515	KIAA0040	-0.25	-9.43	-0.35	7.54e-20	Alcohol dependence;
BRCA	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	9.24	0.34	3.68e-19	Systemic lupus erythematosus;
BRCA	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg27170947	chr2:26402098	FAM59B	0.97	16.95	0.56	1.71e-53	Gut microbiome composition (summer);
BRCA	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.63	0.32	4.73e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9341808	0.718	rs3805920	chr6:80892745	T/C	cg08355045	chr6:80787529	NA	0.39	9.92	0.37	1.09e-21	Sitting height ratio;
BRCA	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg25237894	chr2:233734115	C2orf82	-0.41	-11.91	-0.43	1.1e-29	Coronary artery disease;
BRCA	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg22903471	chr2:27725779	GCKR	-0.35	-8.36	-0.31	3.85e-16	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg18252515	chr7:66147081	NA	1.03	15.25	0.52	5.04e-45	Diabetic kidney disease;
BRCA	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg20933634	chr6:27740509	NA	0.49	9.82	0.36	2.62e-21	Parkinson's disease;
BRCA	cis	rs7246657	0.722	rs968073	chr19:38192021	G/A	cg14683738	chr19:37701593	ZNF585B	-0.47	-8.04	-0.3	4.5e-15	Coronary artery calcification;
BRCA	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg25809561	chr17:30822961	MYO1D	0.37	8.85	0.33	8.29e-18	Schizophrenia;
BRCA	cis	rs4285028	0.747	rs4048703	chr3:121374361	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.83	-15.96	-0.53	1.71e-48	Multiple sclerosis;
BRCA	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.8	12.9	0.45	5.53e-34	Platelet count;
BRCA	cis	rs4363385	0.740	rs1338181	chr1:153010301	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.05e-17	Inflammatory skin disease;
BRCA	cis	rs72928364	1.000	rs62275199	chr3:100695413	A/G	cg10123952	chr3:100791384	NA	0.53	7.85	0.3	1.71e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6087990	0.871	rs4911252	chr20:31330115	A/G	cg13636640	chr20:31349939	DNMT3B	-0.7	-20.72	-0.63	2.45e-73	Ulcerative colitis;
BRCA	cis	rs7520050	0.933	rs6661163	chr1:46255004	A/G	cg24296786	chr1:45957014	TESK2	0.44	9.59	0.35	1.95e-20	Red blood cell count;Reticulocyte count;
BRCA	cis	rs6121246	0.559	rs6060922	chr20:30333909	C/T	cg13852791	chr20:30311386	BCL2L1	0.96	23.39	0.68	6.61e-88	Mean corpuscular hemoglobin;
BRCA	cis	rs2505998	1.000	rs2506006	chr10:43581501	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.4	-7.97	-0.3	7.06e-15	Hirschsprung disease;
BRCA	cis	rs897080	0.515	rs1067332	chr2:44626972	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	10.49	0.38	7.55e-24	Height;
BRCA	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.52	8.03	0.3	4.54e-15	Renal function-related traits (BUN);
BRCA	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg23285459	chr7:2802560	GNA12	-0.37	-9.23	-0.34	3.92e-19	Height;
BRCA	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.64	-13.64	-0.47	2.37e-37	Lymphocyte counts;
BRCA	cis	rs6728642	0.708	rs115507803	chr2:97752054	T/C	cg26665480	chr2:98280029	ACTR1B	-0.67	-8.09	-0.3	2.96e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs17209837	0.607	rs60040620	chr7:87085379	C/A	cg00919237	chr7:87102261	ABCB4	-0.53	-10.22	-0.37	8.29e-23	Gallbladder cancer;
BRCA	cis	rs10782582	0.609	rs12138898	chr1:76375183	G/T	cg03433033	chr1:76189801	ACADM	-0.39	-8.04	-0.3	4.28e-15	Daytime sleep phenotypes;
BRCA	cis	rs7917772	0.582	rs7922780	chr10:104401203	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.38	-10.18	-0.37	1.18e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	14.07	0.49	2.42e-39	Lymphocyte counts;
BRCA	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg11764359	chr7:65958608	NA	-0.67	-14.98	-0.51	1.09e-43	Aortic root size;
BRCA	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg12193833	chr17:30244370	NA	-0.55	-8.68	-0.32	3.16e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg08470875	chr2:26401718	FAM59B	-0.64	-9.54	-0.35	2.95e-20	Gut microbiome composition (summer);
BRCA	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08048268	chr3:133502702	NA	-0.43	-10.74	-0.39	7.2e-25	Iron status biomarkers;
BRCA	cis	rs1011018	0.628	rs1015121	chr7:139455384	T/C	cg03224163	chr7:139420300	HIPK2	-0.59	-8.86	-0.33	7.62e-18	Systolic blood pressure;
BRCA	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg18230493	chr5:56204884	C5orf35	0.57	12.3	0.44	2.36e-31	Initial pursuit acceleration;
BRCA	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00684032	chr4:1343700	KIAA1530	-0.41	-10.13	-0.37	1.85e-22	Obesity-related traits;
BRCA	cis	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg07460842	chr6:66804631	NA	-1.02	-19.99	-0.62	1.91e-69	Exhaled nitric oxide output;
BRCA	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg03808351	chr9:123631620	PHF19	0.61	12.83	0.45	1.05e-33	Birth weight;
BRCA	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	11.62	0.42	1.88e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.38	-0.38	1.89e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs13315871	1.000	rs13060489	chr3:58339287	G/A	cg20936604	chr3:58311152	NA	-0.64	-7.81	-0.3	2.27e-14	Cholesterol, total;
BRCA	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg20476274	chr7:133979776	SLC35B4	0.62	17.75	0.57	1.35e-57	Mean platelet volume;
BRCA	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	18.16	0.58	9.71e-60	Platelet count;
BRCA	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg04450456	chr4:17643702	FAM184B	0.32	9.35	0.35	1.44e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7903847	0.596	rs869967	chr10:99147975	T/C	cg20016023	chr10:99160130	RRP12	-0.26	-8.49	-0.32	1.44e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg07080220	chr10:102295463	HIF1AN	-0.61	-13.74	-0.48	7.59e-38	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg08807101	chr21:30365312	RNF160	-0.55	-12.39	-0.44	9.28e-32	Cognitive test performance;
BRCA	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg23029597	chr12:123009494	RSRC2	-0.59	-12.28	-0.44	2.98e-31	Body mass index;
BRCA	cis	rs897984	0.542	rs6565217	chr16:31083324	C/T	cg02466173	chr16:30829666	NA	-0.43	-9.74	-0.36	5.28e-21	Dementia with Lewy bodies;
BRCA	cis	rs12530845	0.943	rs55889179	chr7:135331631	C/T	cg23117316	chr7:135346802	PL-5283	-0.37	-8.79	-0.33	1.36e-17	Red blood cell traits;
BRCA	cis	rs870825	0.929	rs72689258	chr4:185590550	G/C	cg04058563	chr4:185651563	MLF1IP	0.69	11.83	0.42	2.39e-29	Blood protein levels;
BRCA	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg19156104	chr2:198669113	PLCL1	-0.44	-8.13	-0.31	2.26e-15	Ulcerative colitis;
BRCA	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg11812906	chr14:75593930	NEK9	-0.62	-14.2	-0.49	5.61e-40	Height;
BRCA	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg17971929	chr21:40555470	PSMG1	0.73	16.33	0.54	2.45e-50	Cognitive function;
BRCA	cis	rs7903847	0.646	rs10882924	chr10:99159304	T/A	cg20016023	chr10:99160130	RRP12	-0.26	-8.43	-0.32	2.23e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg04455712	chr21:45112962	RRP1B	0.42	11.13	0.4	1.99e-26	Mean corpuscular volume;
BRCA	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg20701182	chr2:24300061	SF3B14	0.58	9.2	0.34	5.02e-19	Lymphocyte counts;
BRCA	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg08999081	chr20:33150536	PIGU	0.44	12.2	0.43	6.33e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs36051895	0.593	rs12340379	chr9:5176352	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-8.87	-0.33	7.36e-18	Pediatric autoimmune diseases;
BRCA	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7586879	0.964	rs4077680	chr2:25122942	A/G	cg01884057	chr2:25150051	NA	0.34	8.49	0.32	1.4e-16	Body mass index;
BRCA	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg22800045	chr5:56110881	MAP3K1	0.62	11.98	0.43	5.7e-30	Initial pursuit acceleration;
BRCA	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg19257562	chr1:2043853	PRKCZ	-0.34	-9.0	-0.34	2.54e-18	Height;
BRCA	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11764359	chr7:65958608	NA	-0.79	-19.09	-0.6	1.26e-64	Aortic root size;
BRCA	trans	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg06521331	chr12:34319734	NA	-0.5	-9.09	-0.34	1.26e-18	Heart rate;
BRCA	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg04511125	chr2:88470314	THNSL2	0.95	13.73	0.48	8.71e-38	Plasma clusterin levels;
BRCA	cis	rs6594713	0.717	rs9326891	chr5:112873928	C/T	cg12552261	chr5:112820674	MCC	0.52	8.57	0.32	7.9e-17	Brain cytoarchitecture;
BRCA	cis	rs9788682	0.642	rs2568483	chr15:78752343	A/G	cg24631222	chr15:78858424	CHRNA5	0.48	9.73	0.36	6.1e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg20307385	chr11:47447363	PSMC3	0.42	9.51	0.35	3.86e-20	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg20387954	chr3:183756860	HTR3D	0.44	9.91	0.36	1.28e-21	Anterior chamber depth;
BRCA	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg16329650	chr2:213403929	ERBB4	0.45	9.94	0.37	9.46e-22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg18850127	chr7:39170497	POU6F2	-0.41	-8.42	-0.32	2.41e-16	IgG glycosylation;
BRCA	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg15832292	chr6:96025679	MANEA	0.57	8.54	0.32	9.87e-17	Behavioural disinhibition (generation interaction);
BRCA	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg11752832	chr7:134001865	SLC35B4	0.42	9.22	0.34	4.12e-19	Mean platelet volume;
BRCA	cis	rs78487399	0.710	rs17031133	chr2:43844833	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.57	8.83	0.33	1.03e-17	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	trans	rs10242455	0.702	rs45461000	chr7:99052710	A/G	cg09045935	chr12:6379348	NA	0.86	8.35	0.31	4.08e-16	Blood metabolite levels;
BRCA	trans	rs587242	0.910	rs12751763	chr1:96997655	C/T	cg10631902	chr5:14652156	NA	0.35	8.58	0.32	7.27e-17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
BRCA	cis	rs733175	0.855	rs10018666	chr4:10004805	C/T	cg00071950	chr4:10020882	SLC2A9	0.41	8.57	0.32	7.66e-17	Psychosis and Alzheimer's disease;
BRCA	cis	rs7523273	0.565	rs2104303	chr1:207886684	C/T	cg22525895	chr1:207977042	MIR29B2	-0.35	-8.21	-0.31	1.19e-15	Schizophrenia;
BRCA	cis	rs67460515	0.596	rs4856700	chr3:160922951	A/C	cg03342759	chr3:160939853	NMD3	-0.73	-15.02	-0.51	7.06e-44	Parkinson's disease;
BRCA	cis	rs4478858	0.684	rs16834336	chr1:31751512	G/A	cg00250761	chr1:31883323	NA	-0.32	-8.33	-0.31	4.93e-16	Alcohol dependence;
BRCA	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg17063962	chr7:91808500	NA	0.53	12.46	0.44	4.72e-32	Breast cancer;
BRCA	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg12311346	chr5:56204834	C5orf35	0.58	11.94	0.43	8.33e-30	Initial pursuit acceleration;
BRCA	cis	rs68170813	0.559	rs76208112	chr7:106964222	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.66	-0.32	3.98e-17	Coronary artery disease;
BRCA	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg11833968	chr6:79620685	NA	-0.44	-9.93	-0.37	1.06e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg00631329	chr6:26305371	NA	0.39	11.74	0.42	5.99e-29	Educational attainment;
BRCA	cis	rs10193935	1.000	rs10210866	chr2:42387879	A/G	cg27598129	chr2:42591480	NA	-0.86	-14.56	-0.5	1.11e-41	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9929218	1.000	rs28450087	chr16:68803726	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-13.89	-0.48	1.66e-38	Colorectal cancer;
BRCA	cis	rs11690935	0.921	rs3770445	chr2:172708919	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.91	-29.86	-0.76	2.63e-123	Schizophrenia;
BRCA	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg08807101	chr21:30365312	RNF160	0.62	13.22	0.46	1.87e-35	Selective IgA deficiency;
BRCA	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.32	8.74	0.33	2.11e-17	Monocyte percentage of white cells;
BRCA	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg12386194	chr3:101231763	SENP7	0.45	9.49	0.35	4.35e-20	Colorectal cancer;
BRCA	trans	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg23762105	chr12:34175262	ALG10	-0.41	-10.11	-0.37	2.08e-22	Morning vs. evening chronotype;
BRCA	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg04450456	chr4:17643702	FAM184B	0.33	9.7	0.36	7.52e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg21770322	chr7:97807741	LMTK2	0.41	11.0	0.4	6.63e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4363385	0.747	rs3806219	chr1:152972522	C/T	cg25856811	chr1:152973957	SPRR3	0.35	9.26	0.34	3.09e-19	Inflammatory skin disease;
BRCA	cis	rs1113500	0.805	rs11185244	chr1:108601147	C/T	cg06207961	chr1:108661230	NA	0.34	8.13	0.31	2.27e-15	Growth-regulated protein alpha levels;
BRCA	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg12062639	chr20:23401060	NAPB	0.87	10.46	0.38	9.93e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg08603382	chr10:743973	NA	0.4	8.49	0.32	1.44e-16	Psychosis in Alzheimer's disease;
BRCA	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.05	-0.37	3.55e-22	IgG glycosylation;
BRCA	cis	rs1468333	1.000	rs17171767	chr5:137493528	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	-0.42	-8.94	-0.33	4.21e-18	Resting heart rate;
BRCA	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg05343316	chr1:45956843	TESK2	0.63	12.86	0.45	7.65e-34	Platelet count;
BRCA	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg03342759	chr3:160939853	NMD3	-0.67	-15.64	-0.53	6.51e-47	Morning vs. evening chronotype;
BRCA	cis	rs151349	1.000	rs151346	chr20:57587040	C/A	cg23907860	chr20:57583709	CTSZ	-0.45	-10.87	-0.39	2.38e-25	Platelet distribution width;
BRCA	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-15.05	-0.51	4.79e-44	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg23788917	chr6:8435910	SLC35B3	0.47	10.29	0.38	4.23e-23	Motion sickness;
BRCA	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg10729496	chr3:10149963	C3orf24	0.47	8.84	0.33	8.98e-18	Alzheimer's disease;
BRCA	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg20129853	chr10:51489980	NA	0.31	8.33	0.31	4.92e-16	Prostate-specific antigen levels;
BRCA	trans	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg26384229	chr12:38710491	ALG10B	0.48	10.8	0.39	4.23e-25	Morning vs. evening chronotype;
BRCA	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg25358565	chr5:93447407	FAM172A	1.25	19.37	0.61	4.3e-66	Diabetic retinopathy;
BRCA	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg01475735	chr3:40494733	NA	-0.39	-8.03	-0.3	4.55e-15	Renal cell carcinoma;
BRCA	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	14.31	0.49	1.79e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9527	0.590	rs10883839	chr10:104920341	A/G	cg04362960	chr10:104952993	NT5C2	0.44	10.2	0.37	9.52e-23	Arsenic metabolism;
BRCA	cis	rs7737355	0.947	rs13174006	chr5:130963473	A/G	cg06307176	chr5:131281290	NA	0.5	9.85	0.36	2.04e-21	Life satisfaction;
BRCA	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	21.16	0.64	1.05e-75	Lymphocyte percentage of white cells;
BRCA	cis	rs7246657	0.598	rs28660259	chr19:37658681	C/T	cg18154014	chr19:37997991	ZNF793	0.54	8.97	0.33	3.19e-18	Coronary artery calcification;
BRCA	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg16606324	chr3:10149918	C3orf24	0.52	10.36	0.38	2.35e-23	Alzheimer's disease;
BRCA	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg22601191	chr20:60968625	CABLES2	0.35	8.81	0.33	1.22e-17	Colorectal cancer;
BRCA	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.48	0.35	4.87e-20	Morning vs. evening chronotype;
BRCA	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg19920283	chr7:105172520	RINT1	0.59	10.74	0.39	7.65e-25	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg23711669	chr6:146136114	FBXO30	-0.75	-17.5	-0.57	2.48e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7927771	0.757	rs1057233	chr11:47376448	G/A	cg20307385	chr11:47447363	PSMC3	0.37	7.82	0.3	2.25e-14	Subjective well-being;
BRCA	cis	rs62229266	0.804	rs56279140	chr21:37424361	C/T	cg12218747	chr21:37451666	NA	-0.33	-7.94	-0.3	9.24e-15	Mitral valve prolapse;
BRCA	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg17691542	chr6:26056736	HIST1H1C	0.48	9.61	0.36	1.7e-20	Iron status biomarkers;
BRCA	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg23711669	chr6:146136114	FBXO30	0.64	14.47	0.5	2.83e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg18811423	chr2:55921094	PNPT1	0.71	22.36	0.66	3.18e-82	Metabolic syndrome;
BRCA	cis	rs1568889	1.000	rs34140872	chr11:28335872	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	13.13	0.46	4.99e-35	Bipolar disorder;
BRCA	cis	rs2712184	0.756	rs2541388	chr2:217664284	A/G	cg05032264	chr2:217675019	NA	0.41	9.99	0.37	6.48e-22	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg06784218	chr1:46089804	CCDC17	0.48	11.59	0.42	2.48e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs953387	1.000	rs10803550	chr2:136907790	C/T	cg05194412	chr2:137003533	NA	-0.37	-8.58	-0.32	7.26e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs877282	0.891	rs12767062	chr10:797961	C/T	cg17470449	chr10:769945	NA	0.5	8.57	0.32	7.78e-17	Uric acid levels;
BRCA	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.64e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg23625390	chr15:77176239	SCAPER	-0.54	-13.18	-0.46	2.81e-35	Blood metabolite levels;
BRCA	cis	rs9470366	0.545	rs4713999	chr6:36633069	A/G	cg08179530	chr6:36648295	CDKN1A	-0.51	-11.36	-0.41	2.38e-27	QRS duration;
BRCA	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg24848339	chr3:12840334	CAND2	0.5	13.35	0.47	5.13e-36	QRS complex (12-leadsum);
BRCA	cis	rs9921222	0.786	rs3848365	chr16:374617	C/T	cg12437481	chr16:420112	MRPL28	-0.34	-7.85	-0.3	1.76e-14	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg00383909	chr3:49044727	WDR6	0.97	15.54	0.52	1.9e-46	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg06917634	chr15:78832804	PSMA4	-0.76	-17.81	-0.58	6.52e-58	Sudden cardiac arrest;
BRCA	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg01324343	chr3:183735012	ABCC5	0.7	16.49	0.55	3.52e-51	Anterior chamber depth;
BRCA	cis	rs7940866	1.000	rs7940866	chr11:130817579	A/T	cg12179176	chr11:130786555	SNX19	-0.58	-12.41	-0.44	7.86e-32	Schizophrenia;
BRCA	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.06	-25.8	-0.71	4.21e-101	Ulcerative colitis;
BRCA	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	19.45	0.61	1.46e-66	Platelet count;
BRCA	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg06970220	chr1:156163860	SLC25A44	0.39	9.45	0.35	6.04e-20	Testicular germ cell tumor;
BRCA	trans	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17712092	chr4:129076599	LARP1B	0.56	13.47	0.47	1.34e-36	Eosinophil percentage of white cells;
BRCA	cis	rs943466	1.000	rs6921487	chr6:33749293	G/A	cg25922239	chr6:33757077	LEMD2	-0.38	-8.4	-0.32	2.92e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg06484146	chr7:12443880	VWDE	-0.71	-9.89	-0.36	1.49e-21	Coronary artery disease;
BRCA	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.85	20.81	0.64	8.03e-74	Birth weight;
BRCA	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg09904177	chr6:26538194	HMGN4	0.47	14.7	0.5	2.33e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg06212747	chr3:49208901	KLHDC8B	0.48	9.85	0.36	2.01e-21	Parkinson's disease;
BRCA	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	15.2	0.52	9.03e-45	Platelet count;
BRCA	cis	rs534126	0.778	rs10256011	chr7:142936243	G/A	cg21852589	chr7:142981689	TMEM139	0.44	10.05	0.37	3.56e-22	Cancer;
BRCA	cis	rs7264396	0.563	rs2425136	chr20:34344782	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.54	-0.42	3.9e-28	Total cholesterol levels;
BRCA	cis	rs10733682	0.659	rs3861879	chr9:129464856	A/G	cg00232160	chr9:129468157	NA	0.4	9.14	0.34	8.38e-19	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs698833	0.509	rs10198291	chr2:44539009	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.32	0.31	5.39e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	trans	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-8.14	-0.31	2.03e-15	Menarche (age at onset);
BRCA	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.55	0.39	4.3e-24	Motion sickness;
BRCA	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg18867708	chr6:26865862	GUSBL1	0.42	8.26	0.31	8.42e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2014572	0.967	rs10421632	chr19:57764770	G/A	cg24459738	chr19:57751996	ZNF805	-0.37	-8.59	-0.32	6.39e-17	Hyperactive-impulsive symptoms;
BRCA	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg18252515	chr7:66147081	NA	-0.86	-12.42	-0.44	7.02e-32	Diabetic kidney disease;
BRCA	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-16.81	-0.55	9.16e-53	Axial length;
BRCA	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	9.58	0.35	2.04e-20	Neuroticism;
BRCA	cis	rs7178424	0.967	rs933807	chr15:62274940	C/G	cg00456672	chr15:62358751	C2CD4A	0.39	8.82	0.33	1.12e-17	Height;
BRCA	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg13010199	chr12:38710504	ALG10B	-0.41	-9.57	-0.35	2.35e-20	Heart rate;
BRCA	cis	rs9986765	1.000	rs73452570	chr7:142817482	T/A	cg15652212	chr7:142981776	TMEM139	0.55	9.19	0.34	5.62e-19	Cancer;Dermatomyositis;
BRCA	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg08470875	chr2:26401718	FAM59B	0.52	8.31	0.31	5.72e-16	Gut microbiome composition (summer);
BRCA	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.32	-8.6	-0.32	6.14e-17	Crohn's disease;
BRCA	cis	rs9487051	0.724	rs13200047	chr6:109633244	T/C	cg01475377	chr6:109611718	NA	-0.45	-10.21	-0.37	9.28e-23	Reticulocyte fraction of red cells;
BRCA	cis	rs55882075	0.765	rs34329357	chr5:179130408	G/C	cg14593053	chr5:179126677	CANX	0.51	13.82	0.48	3.56e-38	Monocyte percentage of white cells;
BRCA	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg17143192	chr8:8559678	CLDN23	0.54	10.3	0.38	3.9e-23	Obesity-related traits;
BRCA	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg21775007	chr8:11205619	TDH	-0.42	-8.71	-0.33	2.5e-17	Mood instability;
BRCA	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	9.3	0.35	2.23e-19	Systemic lupus erythematosus;
BRCA	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg25358565	chr5:93447407	FAM172A	1.15	17.85	0.58	3.92e-58	Diabetic retinopathy;
BRCA	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	10.69	0.39	1.2e-24	Bipolar disorder;
BRCA	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-9.61	-0.36	1.69e-20	Menopause (age at onset);
BRCA	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg18252515	chr7:66147081	NA	-0.82	-11.88	-0.43	1.52e-29	Diabetic kidney disease;
BRCA	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.63	11.99	0.43	5.05e-30	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.26	0.49	2.83e-40	Motion sickness;
BRCA	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg01475377	chr6:109611718	NA	-0.52	-13.07	-0.46	9.12e-35	Reticulocyte fraction of red cells;
BRCA	cis	rs11250464	0.794	rs11250487	chr10:1434168	C/A	cg26394196	chr10:1453818	ADARB2	-0.36	-7.99	-0.3	6.45e-15	Radiation response;
BRCA	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg21433313	chr16:3507492	NAT15	0.43	8.9	0.33	5.63e-18	Tuberculosis;
BRCA	cis	rs6424115	0.594	rs10799802	chr1:24009544	C/T	cg15997130	chr1:24165203	NA	0.35	8.07	0.3	3.46e-15	Immature fraction of reticulocytes;
BRCA	trans	rs8073060	0.586	rs6505484	chr17:33993152	G/A	cg19694781	chr19:47549865	TMEM160	-1.05	-21.6	-0.65	4.01e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg03929089	chr4:120376271	NA	-0.5	-9.33	-0.35	1.66e-19	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg04315214	chr1:2043799	PRKCZ	-0.48	-12.7	-0.45	4.15e-33	Height;
BRCA	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg23950597	chr19:37808831	NA	-0.62	-11.45	-0.41	9.99e-28	Coronary artery calcification;
BRCA	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg24803719	chr17:45855879	NA	-0.32	-8.46	-0.32	1.84e-16	IgG glycosylation;
BRCA	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg11262906	chr1:85462892	MCOLN2	-0.51	-9.63	-0.36	1.33e-20	Serum sulfate level;
BRCA	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg06808227	chr14:105710500	BRF1	-0.8	-15.93	-0.53	2.39e-48	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs6495367	1.000	rs3851677	chr15:79380869	C/T	cg17916960	chr15:79447300	NA	0.33	7.96	0.3	7.93e-15	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.51	-0.44	2.72e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg07211511	chr3:129823064	LOC729375	-0.59	-10.73	-0.39	8.36e-25	Blood pressure (smoking interaction);
BRCA	cis	rs701145	0.585	rs1727946	chr3:153826470	C/T	cg12800244	chr3:153838788	SGEF	0.63	7.87	0.3	1.47e-14	Coronary artery disease;
BRCA	cis	rs751728	0.717	rs3763260	chr6:33774070	C/T	cg25922239	chr6:33757077	LEMD2	0.52	11.64	0.42	1.52e-28	Crohn's disease;
BRCA	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.33	10.36	0.38	2.27e-23	Bipolar disorder;
BRCA	trans	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg26384229	chr12:38710491	ALG10B	0.52	11.18	0.4	1.26e-26	Morning vs. evening chronotype;
BRCA	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg09065629	chr16:1709722	CRAMP1L	0.36	8.39	0.32	3.1e-16	Coronary artery disease;
BRCA	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07080220	chr10:102295463	HIF1AN	0.5	11.56	0.42	3.25e-28	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg07395648	chr5:131743802	NA	0.37	9.27	0.34	2.75e-19	Blood metabolite levels;
BRCA	cis	rs738322	0.805	rs2235344	chr22:38518083	G/A	cg25457927	chr22:38595422	NA	-0.31	-11.35	-0.41	2.49e-27	Cutaneous nevi;
BRCA	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg23422044	chr7:1970798	MAD1L1	-0.44	-9.46	-0.35	5.75e-20	Neuroticism;
BRCA	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg05985134	chr18:33552581	C18orf21	0.71	13.6	0.47	3.54e-37	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11890956	chr21:40555474	PSMG1	1.06	31.9	0.78	2.54e-134	Cognitive function;
BRCA	cis	rs6782228	0.565	rs67445542	chr3:128330526	T/C	cg16766828	chr3:128327626	NA	-0.4	-8.89	-0.33	6.11e-18	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg14547644	chr6:28411285	ZSCAN23	-0.35	-7.84	-0.3	1.96e-14	Pubertal anthropometrics;
BRCA	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	11.49	0.41	6.55e-28	Monocyte percentage of white cells;
BRCA	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg18252515	chr7:66147081	NA	-0.81	-11.34	-0.41	2.84e-27	Diabetic kidney disease;
BRCA	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.83	-0.39	3.18e-25	Mean corpuscular volume;
BRCA	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg02187348	chr16:89574699	SPG7	-0.36	-8.08	-0.3	3.24e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg04455712	chr21:45112962	RRP1B	0.46	11.85	0.42	1.97e-29	Mean corpuscular volume;
BRCA	cis	rs61990749	0.597	rs12887282	chr14:78200585	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.66	10.59	0.39	2.86e-24	Fibroblast growth factor basic levels;
BRCA	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.62	10.37	0.38	2.1e-23	Renal function-related traits (BUN);
BRCA	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.21	-0.34	4.63e-19	Bipolar disorder;
BRCA	cis	rs2882667	0.861	rs10043676	chr5:138389561	C/T	cg04439458	chr5:138467593	SIL1	-0.33	-9.07	-0.34	1.51e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10181042	0.565	rs62150982	chr2:61280675	T/C	cg15711740	chr2:61764176	XPO1	0.37	9.2	0.34	5.18e-19	Crohn's disease;
BRCA	cis	rs16910800	0.638	rs12273883	chr11:23164569	C/G	cg20040320	chr11:23191996	NA	0.56	9.25	0.34	3.21e-19	Cancer;
BRCA	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg02176678	chr2:219576539	TTLL4	0.4	10.84	0.39	3.1e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2415984	0.622	rs61993302	chr14:46949684	C/T	cg14871534	chr14:47121158	RPL10L	-0.33	-8.07	-0.3	3.56e-15	Number of children ever born;
BRCA	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg18811423	chr2:55921094	PNPT1	0.69	21.1	0.64	2.14e-75	Metabolic syndrome;
BRCA	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg21775007	chr8:11205619	TDH	-0.62	-12.34	-0.44	1.56e-31	Retinal vascular caliber;
BRCA	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.97	-0.3	7.07e-15	Depression;
BRCA	cis	rs4423214	0.802	rs2276358	chr11:71184498	G/A	cg05163923	chr11:71159392	DHCR7	-0.56	-11.35	-0.41	2.58e-27	Vitamin D levels;
BRCA	cis	rs2191566	0.576	rs381759	chr19:44495145	A/G	cg20607764	chr19:44506953	ZNF230	-0.37	-7.98	-0.3	6.83e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/C	cg19183879	chr15:85880815	NA	-0.43	-10.89	-0.4	1.94e-25	Central corneal thickness;Corneal structure;
BRCA	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg18758796	chr5:131593413	PDLIM4	0.33	8.57	0.32	7.54e-17	Breast cancer;
BRCA	cis	rs59698941	0.527	rs1032764	chr5:132185419	A/C	cg14825688	chr5:132208181	LEAP2	-0.37	-8.61	-0.32	5.63e-17	Apolipoprotein A-IV levels;
BRCA	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg22987457	chr7:157211561	NA	0.33	7.96	0.3	7.81e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	cis	rs12618769	0.597	rs2278208	chr2:99154229	C/T	cg10123293	chr2:99228465	UNC50	0.44	8.5	0.32	1.3e-16	Bipolar disorder;
BRCA	trans	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.06	-32.76	-0.79	6.5e-139	Colorectal cancer;
BRCA	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg00173435	chr12:106696525	TCP11L2	0.56	9.81	0.36	2.85e-21	Tourette syndrome;
BRCA	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg04374321	chr14:90722782	PSMC1	0.71	18.43	0.59	3.71e-61	Mortality in heart failure;
BRCA	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.47	-0.32	1.7e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg13010199	chr12:38710504	ALG10B	0.42	8.84	0.33	8.99e-18	Bladder cancer;
BRCA	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg01420254	chr6:26195488	NA	0.55	8.49	0.32	1.49e-16	Gout;Renal underexcretion gout;
BRCA	cis	rs7590368	0.961	rs13432104	chr2:10960661	T/C	cg15705551	chr2:10952987	PDIA6	0.44	8.14	0.31	2.02e-15	Educational attainment (years of education);
BRCA	cis	rs12540874	0.965	rs9791887	chr7:50661170	A/C	cg18232548	chr7:50535776	DDC	-0.37	-8.24	-0.31	9.46e-16	Systemic sclerosis;
BRCA	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	7.95	0.3	8.58e-15	Total cholesterol levels;
BRCA	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg01292856	chr11:65242576	NA	0.32	8.05	0.3	3.91e-15	Bone mineral density;
BRCA	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg04691961	chr3:161091175	C3orf57	-0.39	-9.01	-0.34	2.32e-18	Morning vs. evening chronotype;
BRCA	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg20534287	chr10:135191450	PAOX	0.51	8.9	0.33	5.53e-18	Lifespan;
BRCA	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg25204440	chr1:209979598	IRF6	0.42	8.39	0.31	3.21e-16	Cleft lip with or without cleft palate;
BRCA	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.09	-0.34	1.27e-18	Total body bone mineral density;
BRCA	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-9.72	-0.36	6.46e-21	Response to bleomycin (chromatid breaks);
BRCA	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg08917208	chr2:24149416	ATAD2B	0.55	8.28	0.31	7.02e-16	Lymphocyte counts;
BRCA	cis	rs914187	1.000	rs914187	chr21:42619749	A/G	cg21268422	chr21:42620091	BACE2	0.58	12.31	0.44	2.2e-31	Body mass index;
BRCA	cis	rs6910061	1.000	rs6938867	chr6:11095303	A/G	cg27233058	chr6:11094804	LOC221710	0.52	9.31	0.35	1.94e-19	Diabetic kidney disease;
BRCA	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg21475434	chr5:93447410	FAM172A	0.67	8.75	0.33	1.86e-17	Diabetic retinopathy;
BRCA	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg22862634	chr11:62369728	EML3;MTA2	0.49	12.22	0.44	5.22e-31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.4	9.17	0.34	6.66e-19	Bipolar disorder;
BRCA	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	11.1	0.4	2.63e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.27	-0.41	5.58e-27	Gut microbiome composition (summer);
BRCA	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg00631329	chr6:26305371	NA	-0.44	-13.0	-0.46	1.8e-34	Educational attainment;
BRCA	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg25206134	chr2:45395956	NA	0.48	8.4	0.32	2.99e-16	Bipolar disorder;
BRCA	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg26587870	chr6:27730563	NA	-0.41	-8.83	-0.33	9.71e-18	Parkinson's disease;
BRCA	cis	rs12997796	0.503	rs4366909	chr2:87021001	G/A	cg25203885	chr2:87302643	LOC285074	-0.52	-8.53	-0.32	1.07e-16	Schizophrenia;
BRCA	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg01884057	chr2:25150051	NA	0.32	8.45	0.32	1.9e-16	Body mass index;
BRCA	trans	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.28	0.31	7.45e-16	Corneal astigmatism;
BRCA	cis	rs4722166	0.568	rs1880241	chr7:22759469	A/G	cg05472934	chr7:22766657	IL6	0.38	9.93	0.37	1.09e-21	Lung cancer;
BRCA	cis	rs10465746	0.725	rs4907188	chr1:84361608	C/T	cg10977910	chr1:84465055	TTLL7	0.61	12.84	0.45	9.64e-34	Obesity-related traits;
BRCA	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg03477792	chr4:77819574	ANKRD56	0.65	15.56	0.52	1.5e-46	Emphysema distribution in smoking;
BRCA	cis	rs950776	0.720	rs11633223	chr15:78935476	T/C	cg06917634	chr15:78832804	PSMA4	0.52	10.35	0.38	2.47e-23	Sudden cardiac arrest;
BRCA	cis	rs1506636	0.962	rs10243279	chr7:123441262	T/A	cg03229431	chr7:123269106	ASB15	0.56	12.31	0.44	2.09e-31	Plateletcrit;Platelet count;
BRCA	cis	rs8032158	1.000	rs67505007	chr15:56196253	C/T	cg02198044	chr15:56286336	NEDD4	-0.38	-9.03	-0.34	2.06e-18	Keloid;
BRCA	cis	rs9682041	0.569	rs11914970	chr3:170112307	T/G	cg11886554	chr3:170076028	SKIL	0.48	9.84	0.36	2.31e-21	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs7975161	0.786	rs10861181	chr12:104651110	T/C	cg25273343	chr12:104657179	TXNRD1	-0.5	-10.84	-0.39	3.07e-25	Toenail selenium levels;
BRCA	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.46	0.5	3.27e-41	Colorectal cancer;
BRCA	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg03433033	chr1:76189801	ACADM	-0.39	-8.09	-0.3	3.06e-15	Daytime sleep phenotypes;
BRCA	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	10.85	0.39	2.66e-25	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.28	-0.31	7.31e-16	Breast cancer;
BRCA	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg09462578	chr12:12878428	APOLD1	-0.67	-11.41	-0.41	1.39e-27	Systemic lupus erythematosus;
BRCA	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg19784903	chr17:45786737	TBKBP1	-0.37	-8.69	-0.33	2.94e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.71	11.87	0.42	1.72e-29	Schizophrenia;
BRCA	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg27588902	chr6:42928151	GNMT	-0.31	-10.4	-0.38	1.7e-23	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg19077165	chr18:44547161	KATNAL2	-0.39	-8.14	-0.31	2.13e-15	Educational attainment;
BRCA	cis	rs897080	0.515	rs2850290	chr2:44636055	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	9.09	0.34	1.21e-18	Height;
BRCA	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg09555818	chr19:45449301	APOC2	0.47	12.21	0.43	5.72e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg05623727	chr3:50126028	RBM5	-0.37	-8.73	-0.33	2.27e-17	Menarche (age at onset);
BRCA	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-18.07	-0.58	3e-59	Chronic sinus infection;
BRCA	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg14186256	chr22:23484241	RTDR1	-0.8	-24.36	-0.69	3.14e-93	Bone mineral density;
BRCA	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg00504896	chr12:9437009	LOC642846	-0.46	-9.96	-0.37	7.79e-22	Breast size;
BRCA	cis	rs67981189	0.593	rs8007425	chr14:71508200	A/G	cg15816911	chr14:71606274	NA	0.38	8.63	0.32	4.7e-17	Schizophrenia;
BRCA	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg06784218	chr1:46089804	CCDC17	0.45	10.86	0.39	2.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.53e-15	Tonsillectomy;
BRCA	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg03146154	chr1:46216737	IPP	0.49	10.82	0.39	3.49e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11764359	chr7:65958608	NA	-0.8	-19.27	-0.61	1.42e-65	Aortic root size;
BRCA	cis	rs12367572	1.000	rs7304472	chr12:45262324	A/G	cg04608330	chr12:45269318	NELL2	-0.64	-14.18	-0.49	7e-40	Gut microbiome composition (summer);
BRCA	cis	rs113835537	0.529	rs11227501	chr11:66274072	T/C	cg24851651	chr11:66362959	CCS	0.44	8.3	0.31	6.12e-16	Airway imaging phenotypes;
BRCA	cis	rs644148	0.730	rs2117383	chr19:44978298	A/C	cg15540054	chr19:45004280	ZNF180	0.49	9.58	0.35	2.1e-20	Personality dimensions;
BRCA	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg17063962	chr7:91808500	NA	-0.55	-12.71	-0.45	3.76e-33	Breast cancer;
BRCA	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.77	12.18	0.43	7.45e-31	Platelet count;
BRCA	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg00677455	chr12:58241039	CTDSP2	0.63	15.47	0.52	4.28e-46	Multiple sclerosis;
BRCA	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.11	0.49	1.43e-39	Motion sickness;
BRCA	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg03146154	chr1:46216737	IPP	0.52	11.57	0.42	2.96e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2011503	0.597	rs8103992	chr19:19665643	A/C	cg15839431	chr19:19639596	YJEFN3	0.37	8.73	0.33	2.18e-17	Bipolar disorder;
BRCA	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.65	13.27	0.46	1.13e-35	Lymphocyte counts;
BRCA	cis	rs7178424	0.934	rs4775455	chr15:62347274	A/T	cg00456672	chr15:62358751	C2CD4A	-0.35	-7.95	-0.3	8.48e-15	Height;
BRCA	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg14675211	chr2:100938903	LONRF2	0.49	11.2	0.4	1.07e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg13319975	chr6:146136371	FBXO30	0.41	9.3	0.35	2.13e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg18132916	chr6:79620363	NA	-0.38	-7.81	-0.3	2.32e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs13315871	0.929	rs13322000	chr3:58286929	G/A	cg20936604	chr3:58311152	NA	-0.66	-8.46	-0.32	1.83e-16	Cholesterol, total;
BRCA	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg18351406	chr4:77819688	ANKRD56	0.58	12.63	0.45	8.58e-33	Emphysema distribution in smoking;
BRCA	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg19901468	chr14:105411992	AHNAK2	0.49	12.09	0.43	1.93e-30	Rheumatoid arthritis;
BRCA	trans	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg06521331	chr12:34319734	NA	-0.45	-8.57	-0.32	7.61e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9796	0.621	rs2928142	chr15:41470449	T/C	cg18705301	chr15:41695430	NDUFAF1	0.37	7.92	0.3	1.03e-14	Menopause (age at onset);
BRCA	cis	rs6121246	0.512	rs6058384	chr20:30276409	A/T	cg21427119	chr20:30132790	HM13	-0.35	-8.05	-0.3	4.04e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg10621924	chr7:39171070	POU6F2	0.38	7.82	0.3	2.21e-14	IgG glycosylation;
BRCA	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg25237894	chr2:233734115	C2orf82	-0.43	-13.39	-0.47	3.1e-36	Coronary artery disease;
BRCA	cis	rs11718455	0.767	rs11130019	chr3:43989348	C/A	cg08738300	chr3:44038990	NA	0.48	8.99	0.34	2.67e-18	Coronary artery disease;
BRCA	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.86	-0.42	1.86e-29	Response to antipsychotic treatment;
BRCA	cis	rs847577	0.677	rs1495525	chr7:97826232	G/A	cg24562669	chr7:97807699	LMTK2	-0.49	-12.85	-0.45	8.91e-34	Breast cancer;
BRCA	cis	rs36051895	0.664	rs11793659	chr9:5109707	A/G	cg02405213	chr9:5042618	JAK2	-0.5	-9.14	-0.34	8.2e-19	Pediatric autoimmune diseases;
BRCA	cis	rs2425143	0.908	rs58448091	chr20:34325470	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.96	-0.33	3.53e-18	Blood protein levels;
BRCA	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.47	-10.89	-0.4	1.94e-25	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.32	-7.97	-0.3	7.24e-15	Total body bone mineral density;
BRCA	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.44	0.35	6.82e-20	Morning vs. evening chronotype;
BRCA	cis	rs10465746	0.780	rs11163865	chr1:84366917	C/T	cg10977910	chr1:84465055	TTLL7	0.56	11.7	0.42	8.62e-29	Obesity-related traits;
BRCA	trans	rs6479891	0.908	rs12412946	chr10:65289552	T/G	cg14819942	chr15:35414228	NA	0.35	8.41	0.32	2.7e-16	Arthritis (juvenile idiopathic);
BRCA	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26384229	chr12:38710491	ALG10B	0.74	16.62	0.55	8.14e-52	Morning vs. evening chronotype;
BRCA	trans	rs783540	0.900	rs12916980	chr15:83306447	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.28	-8.87	-0.33	7.55e-18	Schizophrenia;
BRCA	cis	rs939658	0.935	rs954292	chr15:79449237	C/T	cg17916960	chr15:79447300	NA	0.39	9.85	0.36	2.12e-21	Refractive error;
BRCA	cis	rs6684514	1.000	rs12022194	chr1:156312331	T/A	cg16558208	chr1:156270281	VHLL	0.37	8.32	0.31	5.29e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg03954927	chr1:10346856	KIF1B	0.48	14.87	0.51	3.63e-43	Hepatocellular carcinoma;
BRCA	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg11644478	chr21:40555479	PSMG1	-0.45	-9.34	-0.35	1.6e-19	Menarche (age at onset);
BRCA	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	ch.11.42038R	chr11:967971	AP2A2	0.58	18.87	0.6	1.74e-63	Alzheimer's disease (late onset);
BRCA	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg27094323	chr7:1216898	NA	-0.36	-8.19	-0.31	1.45e-15	Longevity;Endometriosis;
BRCA	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg15704280	chr7:45808275	SEPT13	0.65	11.44	0.41	1.06e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg05623727	chr3:50126028	RBM5	0.43	10.16	0.37	1.41e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7587476	0.784	rs34112702	chr2:215696002	A/G	cg04004882	chr2:215674386	BARD1	0.65	11.96	0.43	6.71e-30	Neuroblastoma;
BRCA	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg17063962	chr7:91808500	NA	0.57	13.13	0.46	4.95e-35	Breast cancer;
BRCA	cis	rs10465746	0.935	rs12406984	chr1:84416215	C/G	cg10977910	chr1:84465055	TTLL7	0.5	10.0	0.37	5.86e-22	Obesity-related traits;
BRCA	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg20607798	chr8:58055168	NA	0.47	8.09	0.3	3.07e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	14.11	0.49	1.45e-39	Platelet count;
BRCA	trans	rs62103177	0.608	rs613847	chr18:77845644	A/G	cg05926928	chr17:57297772	GDPD1	-0.77	-10.8	-0.39	4.27e-25	Opioid sensitivity;
BRCA	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg18758796	chr5:131593413	PDLIM4	0.34	9.0	0.34	2.47e-18	Breast cancer;
BRCA	cis	rs250677	0.522	rs62378210	chr5:148384885	G/A	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.3	-0.31	6.24e-16	Breast cancer;
BRCA	cis	rs4664304	0.710	rs9636280	chr2:160717852	C/T	cg14819504	chr2:160761413	LY75	-0.37	-9.0	-0.34	2.54e-18	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.13	0.31	2.29e-15	Breast cancer;
BRCA	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg00495681	chr13:53174319	NA	0.41	8.73	0.33	2.22e-17	Lewy body disease;
BRCA	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08219700	chr8:58056026	NA	0.44	7.89	0.3	1.3e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs3784262	0.565	rs12914603	chr15:58350896	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.57	-0.35	2.36e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-16.21	-0.54	8.87e-50	Heart rate;
BRCA	cis	rs4363385	0.668	rs6587717	chr1:152984443	G/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.28	-0.31	7.23e-16	Inflammatory skin disease;
BRCA	cis	rs36051895	0.623	rs11790680	chr9:5248768	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-8.25	-0.31	9.31e-16	Pediatric autoimmune diseases;
BRCA	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg05283184	chr6:79620031	NA	-0.38	-9.51	-0.35	3.95e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg08470875	chr2:26401718	FAM59B	0.59	7.98	0.3	7.02e-15	Gut microbiome composition (summer);
BRCA	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.03	0.49	3.57e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg08917208	chr2:24149416	ATAD2B	0.89	12.98	0.46	2.32e-34	Lymphocyte counts;
BRCA	cis	rs73001065	0.818	rs12610185	chr19:19721722	G/A	cg03709012	chr19:19516395	GATAD2A	0.76	9.18	0.34	5.84e-19	LDL cholesterol;
BRCA	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	15.86	0.53	4.91e-48	Alzheimer's disease;
BRCA	cis	rs11051970	0.553	rs325419	chr12:32572460	A/G	cg24626660	chr12:32551988	NA	0.28	8.24	0.31	9.87e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	8.12	0.31	2.49e-15	Uric acid levels;
BRCA	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05890377	chr2:74357713	NA	0.52	11.05	0.4	4.46e-26	Gestational age at birth (maternal effect);
BRCA	cis	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg20368463	chr18:77673604	PQLC1	0.35	8.79	0.33	1.39e-17	Schizophrenia;
BRCA	cis	rs208520	0.690	rs207082	chr6:66773796	G/A	cg07460842	chr6:66804631	NA	-1.01	-20.21	-0.62	1.32e-70	Exhaled nitric oxide output;
BRCA	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.2	-19.07	-0.6	1.58e-64	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.45	-11.55	-0.42	3.65e-28	Schizophrenia;
BRCA	cis	rs9309473	0.950	rs11126412	chr2:73887634	A/T	cg20560298	chr2:73613845	ALMS1	-0.46	-10.77	-0.39	5.93e-25	Metabolite levels;
BRCA	cis	rs1882538	0.512	rs13241734	chr7:133122742	C/G	cg10665199	chr7:133106180	EXOC4	0.45	9.18	0.34	6.1e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs919433	0.680	rs3792160	chr2:198403519	G/A	cg00792783	chr2:198669748	PLCL1	0.36	8.36	0.31	3.88e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg01028140	chr2:1542097	TPO	-0.72	-13.92	-0.48	1.14e-38	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs858239	0.600	rs6960001	chr7:23130876	T/C	cg23682824	chr7:23144976	KLHL7	0.45	12.23	0.44	4.63e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.45	-0.35	6.47e-20	Alzheimer's disease;
BRCA	cis	rs737337	0.623	rs4804154	chr19:11334179	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.55	10.11	0.37	2.24e-22	HDL cholesterol;HDL cholesterol levels;
BRCA	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg00677455	chr12:58241039	CTDSP2	-0.35	-7.9	-0.3	1.19e-14	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	14.14	0.49	1.06e-39	Colorectal cancer;
BRCA	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.42	9.04	0.34	1.93e-18	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9810890	1.000	rs73196983	chr3:128452500	G/T	cg15033153	chr3:128514015	RAB7A	0.7	8.08	0.3	3.34e-15	Dental caries;
BRCA	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg18351406	chr4:77819688	ANKRD56	0.62	14.07	0.49	2.2e-39	Emphysema distribution in smoking;
BRCA	cis	rs2882667	0.931	rs10069528	chr5:138354027	A/G	cg04439458	chr5:138467593	SIL1	-0.34	-9.17	-0.34	6.17e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7707921	0.881	rs73134739	chr5:81370760	T/C	cg15871215	chr5:81402204	ATG10	-0.39	-8.12	-0.31	2.42e-15	Breast cancer;
BRCA	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg05340658	chr4:99064831	C4orf37	-0.43	-9.8	-0.36	3.27e-21	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg00225070	chr15:80189496	MTHFS	0.41	10.01	0.37	5.41e-22	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
BRCA	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18876405	chr7:65276391	NA	-0.56	-13.8	-0.48	4.16e-38	Aortic root size;
BRCA	cis	rs10788264	0.621	rs7907952	chr10:124056774	C/T	cg09507567	chr10:124027408	NA	-0.39	-8.19	-0.31	1.47e-15	Total body bone mineral density;
BRCA	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21659725	chr3:3221576	CRBN	-0.34	-8.27	-0.31	7.54e-16	Body mass index;
BRCA	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26314531	chr2:26401878	FAM59B	0.95	16.54	0.55	2.07e-51	Gut microbiome composition (summer);
BRCA	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg05665937	chr4:1216051	CTBP1	-0.38	-8.0	-0.3	5.94e-15	Obesity-related traits;
BRCA	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg21475434	chr5:93447410	FAM172A	0.66	8.65	0.32	4.01e-17	Diabetic retinopathy;
BRCA	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg20283391	chr11:68216788	NA	-0.46	-8.97	-0.33	3.25e-18	Total body bone mineral density;
BRCA	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg15017067	chr4:17643749	FAM184B	-0.26	-7.9	-0.3	1.22e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	13.09	0.46	7.21e-35	Personality dimensions;
BRCA	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg08859206	chr1:53392774	SCP2	-0.4	-8.68	-0.32	3.28e-17	Monocyte count;
BRCA	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03517284	chr6:25882590	NA	0.48	10.84	0.39	3.03e-25	Blood metabolite levels;
BRCA	cis	rs2637266	0.935	rs4353214	chr10:78393149	C/T	cg18941641	chr10:78392320	NA	-0.34	-7.84	-0.3	1.93e-14	Pulmonary function;
BRCA	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.19	-0.37	1.06e-22	Aortic root size;
BRCA	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.38	8.34	0.31	4.51e-16	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg07274523	chr3:49395745	GPX1	0.46	7.84	0.3	1.84e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg19784903	chr17:45786737	TBKBP1	-0.34	-8.02	-0.3	5.07e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg14343924	chr8:8086146	FLJ10661	0.39	8.15	0.31	1.88e-15	Mood instability;
BRCA	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg09307838	chr4:120376055	NA	0.72	15.36	0.52	1.52e-45	Corneal astigmatism;
BRCA	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg13770153	chr20:60521292	NA	-0.42	-9.45	-0.35	6.5e-20	Body mass index;
BRCA	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg21479132	chr6:26055353	NA	0.58	8.16	0.31	1.77e-15	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs61931739	0.513	rs2200555	chr12:33899381	C/G	cg26384229	chr12:38710491	ALG10B	0.46	10.77	0.39	5.91e-25	Morning vs. evening chronotype;
BRCA	cis	rs13046373	0.535	rs13051135	chr21:32005278	G/A	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.25	0.31	9.08e-16	HDL cholesterol;
BRCA	cis	rs6815814	0.950	rs5743556	chr4:38806851	A/G	cg02016764	chr4:38805732	TLR1	-0.6	-9.56	-0.35	2.42e-20	Breast cancer;
BRCA	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg11663144	chr21:46675770	NA	-0.61	-13.91	-0.48	1.22e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21659725	chr3:3221576	CRBN	0.5	12.72	0.45	3.48e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg20607798	chr8:58055168	NA	0.47	8.07	0.3	3.41e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg23711669	chr6:146136114	FBXO30	0.8	19.17	0.6	4.69e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.28	0.56	3.49e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.35	0.31	4.19e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.34	-7.82	-0.3	2.26e-14	High light scatter reticulocyte count;
BRCA	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg06935464	chr4:38784597	TLR10	0.49	8.27	0.31	7.85e-16	Breast cancer;
BRCA	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg21427119	chr20:30132790	HM13	-0.43	-9.0	-0.34	2.54e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs897984	0.542	rs7197717	chr16:31083075	A/C	cg00531865	chr16:30841666	NA	-0.38	-9.11	-0.34	1.09e-18	Dementia with Lewy bodies;
BRCA	trans	rs526821	0.595	rs565859	chr11:55297367	T/C	cg15704280	chr7:45808275	SEPT13	-0.41	-7.83	-0.3	2e-14	Pediatric bone mineral density (spine);
BRCA	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg12310025	chr6:25882481	NA	-0.75	-19.81	-0.62	1.95e-68	Uric acid levels;
BRCA	cis	rs9815354	0.680	rs73073239	chr3:42014597	G/C	cg03022575	chr3:42003672	ULK4	0.79	10.08	0.37	2.84e-22	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.01	0.3	5.61e-15	Mean corpuscular volume;
BRCA	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg22117172	chr7:91764530	CYP51A1	0.24	8.43	0.32	2.33e-16	Breast cancer;
BRCA	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.89	0.56	3.65e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4423214	1.000	rs4944957	chr11:71168035	C/T	cg05163923	chr11:71159392	DHCR7	-0.6	-13.53	-0.47	7.21e-37	Vitamin D levels;
BRCA	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.6	11.66	0.42	1.27e-28	Gut microbiome composition (summer);
BRCA	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg24692254	chr21:30365293	RNF160	0.46	10.16	0.37	1.39e-22	Pancreatic cancer;
BRCA	cis	rs4919087	1.000	rs11189122	chr10:99072595	G/A	cg25902810	chr10:99078978	FRAT1	0.52	11.76	0.42	4.9e-29	Monocyte count;
BRCA	cis	rs12618769	0.597	rs4850875	chr2:99069815	A/G	cg10123293	chr2:99228465	UNC50	0.41	8.09	0.3	3.07e-15	Bipolar disorder;
BRCA	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg20476274	chr7:133979776	SLC35B4	-0.52	-12.84	-0.45	9.94e-34	Mean platelet volume;
BRCA	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg04450456	chr4:17643702	FAM184B	0.37	11.02	0.4	5.63e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	17.22	0.56	6.76e-55	Alzheimer's disease;
BRCA	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg02493740	chr2:85810744	VAMP5	-0.54	-11.2	-0.41	1.01e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.36	7.87	0.3	1.47e-14	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg05283184	chr6:79620031	NA	-0.44	-11.4	-0.41	1.61e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs1506636	1.000	rs2429617	chr7:123418027	A/G	cg03229431	chr7:123269106	ASB15	0.61	13.54	0.47	6.54e-37	Plateletcrit;Platelet count;
BRCA	cis	rs870825	0.616	rs7659201	chr4:185632013	G/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.4	0.57	8.32e-56	Blood protein levels;
BRCA	trans	rs1973993	0.561	rs7554152	chr1:96987865	G/C	cg10631902	chr5:14652156	NA	-0.41	-10.11	-0.37	2.16e-22	Weight;
BRCA	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.71	16.69	0.55	3.38e-52	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.69	-12.85	-0.45	9.29e-34	Alzheimer's disease;
BRCA	cis	rs250677	0.687	rs250679	chr5:148434952	A/T	cg23229984	chr5:148520753	ABLIM3	-0.34	-8.37	-0.31	3.52e-16	Breast cancer;
BRCA	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.63	-0.32	4.88e-17	Breast cancer;
BRCA	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg03188948	chr7:1209495	NA	0.83	11.33	0.41	2.93e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	19.77	0.62	3.21e-68	Platelet count;
BRCA	cis	rs4974559	0.947	rs28711287	chr4:1346682	G/C	cg02980000	chr4:1222292	CTBP1	0.76	12.85	0.45	9.05e-34	Systolic blood pressure;
BRCA	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-11.51	-0.41	5.46e-28	Alcohol dependence;
BRCA	cis	rs208520	0.802	rs208499	chr6:66932146	C/T	cg07460842	chr6:66804631	NA	-0.82	-14.6	-0.5	6.82e-42	Exhaled nitric oxide output;
BRCA	cis	rs7523273	0.565	rs12733108	chr1:207887210	C/T	cg22525895	chr1:207977042	MIR29B2	0.33	7.86	0.3	1.62e-14	Schizophrenia;
BRCA	cis	rs7246967	0.611	rs73022711	chr19:22875404	G/A	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs10493773	1.000	rs7523292	chr1:86134992	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.45	-9.22	-0.34	4.23e-19	Urate levels in overweight individuals;
BRCA	cis	rs354225	0.586	rs966003	chr2:54884870	C/T	cg26097391	chr2:54893211	SPTBN1	0.28	8.39	0.32	3.06e-16	Schizophrenia;
BRCA	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00802000	chr16:706648	WDR90	-0.39	-9.39	-0.35	1.02e-19	Height;
BRCA	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg22875332	chr1:76189707	ACADM	0.63	12.95	0.46	3.11e-34	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg17063962	chr7:91808500	NA	0.53	12.51	0.44	2.79e-32	Breast cancer;
BRCA	cis	rs4566357	0.615	rs4350744	chr2:227918146	A/T	cg05526886	chr2:227700861	RHBDD1	-0.4	-8.18	-0.31	1.51e-15	Coronary artery disease;
BRCA	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00166722	chr3:10149974	C3orf24	0.58	11.34	0.41	2.64e-27	Alzheimer's disease;
BRCA	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg03954927	chr1:10346856	KIF1B	0.47	14.23	0.49	4.3e-40	Hepatocellular carcinoma;
BRCA	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg05283184	chr6:79620031	NA	-0.39	-9.97	-0.37	7.68e-22	Intelligence (multi-trait analysis);
BRCA	trans	rs7395662	0.864	rs11039917	chr11:48695428	G/A	cg00717180	chr2:96193071	NA	-0.28	-7.9	-0.3	1.26e-14	HDL cholesterol;
BRCA	trans	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg16141378	chr3:129829833	LOC729375	-0.39	-9.24	-0.34	3.53e-19	Neuroticism;
BRCA	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg14004847	chr7:1930337	MAD1L1	-0.44	-8.95	-0.33	3.78e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.54	-15.27	-0.52	4.09e-45	Lung cancer;
BRCA	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg01324343	chr3:183735012	ABCC5	0.7	16.58	0.55	1.32e-51	Anterior chamber depth;
BRCA	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.06	0.46	1.02e-34	Bipolar disorder;
BRCA	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg16576597	chr16:28551801	NUPR1	0.36	9.68	0.36	8.82e-21	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg14675211	chr2:100938903	LONRF2	0.51	11.26	0.41	5.84e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.15	-0.34	7.45e-19	Bipolar disorder;
BRCA	cis	rs2882667	0.537	rs7701338	chr5:138405994	C/T	cg04439458	chr5:138467593	SIL1	-0.31	-8.44	-0.32	2.14e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	trans	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg07211511	chr3:129823064	LOC729375	-0.77	-14.78	-0.5	9.85e-43	Blood pressure (smoking interaction);
BRCA	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg00106254	chr7:1943704	MAD1L1	-0.37	-8.99	-0.34	2.8e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg08000102	chr2:233561755	GIGYF2	-0.63	-13.77	-0.48	5.96e-38	Coronary artery disease;
BRCA	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg12927641	chr6:109611667	NA	-0.35	-8.65	-0.32	4.3e-17	Reticulocyte fraction of red cells;
BRCA	cis	rs27434	0.583	rs34760	chr5:96153491	T/C	cg16492584	chr5:96139282	ERAP1	-0.51	-12.82	-0.45	1.2e-33	Ankylosing spondylitis;
BRCA	trans	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17712092	chr4:129076599	LARP1B	0.54	13.03	0.46	1.34e-34	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.21	-0.41	9.53e-27	Morning vs. evening chronotype;
BRCA	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.91	-29.23	-0.76	6.7e-120	Schizophrenia;
BRCA	cis	rs6484504	0.576	rs16922084	chr11:31371109	C/T	cg06552810	chr11:31128660	NA	0.4	8.73	0.33	2.16e-17	Red blood cell count;
BRCA	cis	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg06521331	chr12:34319734	NA	-0.51	-10.15	-0.37	1.58e-22	Morning vs. evening chronotype;
BRCA	cis	rs6484504	0.600	rs208063	chr11:31159777	C/T	cg06552810	chr11:31128660	NA	-0.39	-8.62	-0.32	5.39e-17	Red blood cell count;
BRCA	trans	rs7944735	0.517	rs12274550	chr11:48196752	C/A	cg15704280	chr7:45808275	SEPT13	0.56	8.77	0.33	1.67e-17	Intraocular pressure;
BRCA	trans	rs12517041	1.000	rs58571178	chr5:23294196	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs36051895	0.632	rs7040922	chr9:5174829	A/G	cg02405213	chr9:5042618	JAK2	0.46	8.85	0.33	8.75e-18	Pediatric autoimmune diseases;
BRCA	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21659725	chr3:3221576	CRBN	0.72	22.05	0.66	1.5e-80	Intelligence (multi-trait analysis);
BRCA	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg24006582	chr15:45444508	DUOX1	-0.56	-11.54	-0.42	4.12e-28	Uric acid levels;
BRCA	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg08668359	chr10:1443807	ADARB2	0.48	9.52	0.35	3.49e-20	Radiation response;
BRCA	cis	rs754466	0.580	rs10762763	chr10:79560803	C/G	cg17075019	chr10:79541650	NA	-0.75	-19.32	-0.61	7.89e-66	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	11.93	0.43	9.33e-30	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg06521331	chr12:34319734	NA	-0.46	-8.54	-0.32	9.43e-17	Bladder cancer;
BRCA	trans	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg07211511	chr3:129823064	LOC729375	-0.63	-11.21	-0.41	9.17e-27	Blood pressure (smoking interaction);
BRCA	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg18270830	chr10:32634957	EPC1	0.56	9.73	0.36	5.86e-21	Sexual dysfunction (female);
BRCA	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg11812906	chr14:75593930	NEK9	-0.53	-11.55	-0.42	3.63e-28	Height;
BRCA	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg05340658	chr4:99064831	C4orf37	0.62	14.94	0.51	1.7e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11229555	0.645	rs11229445	chr11:58199458	G/A	cg15696309	chr11:58395628	NA	-0.45	-9.69	-0.36	8.44e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11051970	0.879	rs2467065	chr12:32586065	A/G	cg24626660	chr12:32551988	NA	0.28	8.03	0.3	4.67e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03713592	chr11:72463424	ARAP1	0.94	13.57	0.47	4.97e-37	Type 2 diabetes;
BRCA	cis	rs10733682	0.659	rs1887970	chr9:129464827	C/T	cg00232160	chr9:129468157	NA	0.36	8.32	0.31	5.48e-16	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs11874712	1.000	rs28699609	chr18:43674879	A/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.05	0.3	4.16e-15	Migraine - clinic-based;
BRCA	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg03806693	chr22:41940476	POLR3H	0.89	13.72	0.48	9.65e-38	Vitiligo;
BRCA	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	8.95	0.33	3.75e-18	Mean platelet volume;
BRCA	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg07148914	chr20:33460835	GGT7	-0.43	-9.22	-0.34	4.16e-19	Height;
BRCA	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg10862848	chr6:42927986	GNMT	-0.35	-14.58	-0.5	9.38e-42	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg13660082	chr14:53194042	PSMC6	-0.57	-8.46	-0.32	1.76e-16	Alzheimer's disease (late onset);
BRCA	trans	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.5	0.38	6.63e-24	Mean corpuscular volume;
BRCA	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg03433033	chr1:76189801	ACADM	-0.4	-8.44	-0.32	2.16e-16	Daytime sleep phenotypes;
BRCA	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg01028140	chr2:1542097	TPO	-0.58	-11.82	-0.42	2.63e-29	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs1113500	0.799	rs1777459	chr1:108584999	G/C	cg06207961	chr1:108661230	NA	-0.4	-9.73	-0.36	6.02e-21	Growth-regulated protein alpha levels;
BRCA	cis	rs838147	0.733	rs12975781	chr19:49249698	A/G	cg13540341	chr19:49222985	MAMSTR	-0.3	-7.92	-0.3	1.09e-14	Dietary macronutrient intake;
BRCA	cis	rs9463078	0.715	rs9357459	chr6:44782562	C/T	cg25276700	chr6:44698697	NA	-0.36	-8.31	-0.31	5.79e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs10504073	0.647	rs62507245	chr8:50006939	A/T	cg00325661	chr8:49890786	NA	0.44	12.45	0.44	4.95e-32	Blood metabolite ratios;
BRCA	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg10223061	chr2:219282414	VIL1	0.3	8.48	0.32	1.58e-16	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg14019146	chr3:50243930	SLC38A3	-0.57	-11.67	-0.42	1.19e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs3925075	0.966	rs12935192	chr16:31359330	G/A	cg02846316	chr16:31340340	ITGAM	0.53	12.94	0.46	3.34e-34	IgA nephropathy;
BRCA	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.52	0.32	1.14e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9309711	0.736	rs13412581	chr2:3497187	G/A	cg16153549	chr2:3496821	NA	-0.46	-10.6	-0.39	2.67e-24	Neurofibrillary tangles;
BRCA	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.02	0.49	3.85e-39	Motion sickness;
BRCA	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg03146154	chr1:46216737	IPP	-0.43	-9.42	-0.35	8.22e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg10523679	chr1:76189770	ACADM	0.69	12.27	0.44	3.21e-31	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg09307838	chr4:120376055	NA	0.63	12.27	0.44	3.07e-31	Corneal astigmatism;
BRCA	cis	rs2249625	0.504	rs2496508	chr6:72891398	A/G	cg18830697	chr6:72922368	RIMS1	-0.63	-14.33	-0.49	1.35e-40	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg03929089	chr4:120376271	NA	-0.44	-8.32	-0.31	5.47e-16	Height;
BRCA	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.51	12.31	0.44	2.13e-31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4988958	0.565	rs3755265	chr2:103052816	C/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.48	0.32	1.53e-16	Asthma (childhood onset);
BRCA	trans	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg06521331	chr12:34319734	NA	-0.47	-8.83	-0.33	1.02e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg03609598	chr5:56110824	MAP3K1	-0.45	-8.02	-0.3	5.19e-15	Initial pursuit acceleration;
BRCA	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg04414720	chr1:150670196	GOLPH3L	0.35	7.84	0.3	1.88e-14	Tonsillectomy;
BRCA	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg18479299	chr3:125709523	NA	-0.54	-8.39	-0.32	3.1e-16	Blood pressure (smoking interaction);
BRCA	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11644478	chr21:40555479	PSMG1	-0.52	-10.97	-0.4	8.72e-26	Menarche (age at onset);
BRCA	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.11	0.49	1.43e-39	Eye color traits;
BRCA	cis	rs2835872	0.737	rs1787404	chr21:39049362	C/T	cg06728970	chr21:39037746	KCNJ6	-0.33	-8.7	-0.33	2.84e-17	Electroencephalographic traits in alcoholism;
BRCA	cis	rs5167	0.504	rs7246900	chr19:45454236	G/A	cg09555818	chr19:45449301	APOC2	0.47	12.17	0.43	8.45e-31	Blood protein levels;
BRCA	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.88	0.64	3.29e-74	Chronic sinus infection;
BRCA	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-11.54	-0.42	4.13e-28	Glomerular filtration rate (creatinine);
BRCA	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg26384229	chr12:38710491	ALG10B	0.68	14.34	0.49	1.23e-40	Morning vs. evening chronotype;
BRCA	cis	rs2425143	0.818	rs11700299	chr20:34548865	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-7.96	-0.3	8.03e-15	Blood protein levels;
BRCA	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg01579765	chr21:45077557	HSF2BP	0.39	10.62	0.39	2.3e-24	Mean corpuscular volume;
BRCA	trans	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-20.56	-0.63	1.76e-72	Exhaled nitric oxide output;
BRCA	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg22764044	chr5:178986830	RUFY1	0.51	14.25	0.49	3.37e-40	Lung cancer;
BRCA	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg24110177	chr3:50126178	RBM5	-0.52	-15.43	-0.52	6.61e-46	Intelligence (multi-trait analysis);
BRCA	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg19913688	chr11:428466	ANO9	-0.67	-9.76	-0.36	4.67e-21	Body mass index;
BRCA	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.56	11.02	0.4	5.8e-26	Lymphocyte counts;
BRCA	trans	rs9951602	0.512	rs8089247	chr18:76651467	C/A	cg02800362	chr5:177631904	HNRNPAB	0.77	17.9	0.58	2.09e-58	Obesity-related traits;
BRCA	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg13010199	chr12:38710504	ALG10B	0.53	11.32	0.41	3.31e-27	Heart rate;
BRCA	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg25173405	chr17:45401733	C17orf57	-0.54	-11.59	-0.42	2.61e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.0	-0.37	5.54e-22	IgG glycosylation;
BRCA	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	9.04	0.34	1.82e-18	Platelet count;
BRCA	cis	rs6738485	0.763	rs11681976	chr2:106841591	C/A	cg23109721	chr2:106886537	NA	-0.36	-7.89	-0.3	1.36e-14	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
BRCA	cis	rs9549260	0.753	rs9532562	chr13:41153585	A/G	cg21288729	chr13:41239152	FOXO1	0.53	8.52	0.32	1.13e-16	Red blood cell count;
BRCA	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg16339924	chr4:17578868	LAP3	0.57	14.23	0.49	4.3e-40	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7188861	0.813	rs7189989	chr16:11442710	G/A	cg01510278	chr16:11456238	NA	-0.41	-8.72	-0.33	2.34e-17	HDL cholesterol;
BRCA	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.46	-9.26	-0.34	3.09e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.99	-0.34	2.68e-18	Alzheimer's disease (late onset);
BRCA	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg15934090	chr1:100435551	SLC35A3	0.36	8.43	0.32	2.38e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07308232	chr7:1071921	C7orf50	-0.41	-8.17	-0.31	1.62e-15	Longevity;Endometriosis;
BRCA	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg11584989	chr19:19387371	SF4	0.31	7.97	0.3	7.48e-15	Tonsillectomy;
BRCA	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08219700	chr8:58056026	NA	0.56	9.17	0.34	6.42e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg08027265	chr7:2291960	NA	-0.35	-8.47	-0.32	1.7e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg27165867	chr14:105738592	BRF1	-0.36	-8.68	-0.32	3.4e-17	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg11789530	chr4:8429930	ACOX3	0.58	14.62	0.5	5.97e-42	Response to antineoplastic agents;
BRCA	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg23649088	chr2:200775458	C2orf69	0.44	9.41	0.35	8.85e-20	Systolic blood pressure;
BRCA	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.21	-0.37	9.22e-23	Psoriasis;
BRCA	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg18132916	chr6:79620363	NA	-0.4	-8.49	-0.32	1.5e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7590720	0.851	rs13006614	chr2:216876204	C/T	cg12620499	chr2:216877984	MREG	0.79	23.82	0.69	3.1e-90	Alcohol dependence;
BRCA	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02187348	chr16:89574699	SPG7	0.53	12.64	0.45	7.67e-33	Multiple myeloma (IgH translocation);
BRCA	cis	rs2882667	0.690	rs17031	chr5:138270542	A/T	cg04439458	chr5:138467593	SIL1	-0.33	-8.26	-0.31	8.3e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	6.69e-19	Alzheimer's disease (late onset);
BRCA	cis	rs7843479	0.930	rs4871903	chr8:21827833	C/T	cg17168535	chr8:21777572	XPO7	-0.39	-8.66	-0.32	3.89e-17	Mean corpuscular volume;
BRCA	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg06115741	chr20:33292138	TP53INP2	0.49	10.94	0.4	1.18e-25	Coronary artery disease;
BRCA	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg04944784	chr2:26401820	FAM59B	-0.85	-13.38	-0.47	3.72e-36	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg05340658	chr4:99064831	C4orf37	0.64	14.74	0.5	1.47e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg13057898	chr1:3703894	LRRC47	0.31	8.8	0.33	1.29e-17	Red cell distribution width;
BRCA	cis	rs7975161	1.000	rs7960443	chr12:104645363	G/A	cg25273343	chr12:104657179	TXNRD1	-0.52	-11.5	-0.41	5.76e-28	Toenail selenium levels;
BRCA	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2625529	0.775	rs4777484	chr15:72376543	T/C	cg16672083	chr15:72433130	SENP8	-0.84	-17.45	-0.57	4.79e-56	Red blood cell count;
BRCA	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.7	-11.51	-0.41	5.66e-28	Red cell distribution width;
BRCA	cis	rs11690935	0.959	rs10184866	chr2:172608956	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.94	-32.36	-0.79	8.91e-137	Schizophrenia;
BRCA	cis	rs13315871	0.929	rs13080398	chr3:58300282	A/G	cg20936604	chr3:58311152	NA	-0.67	-8.65	-0.32	4.09e-17	Cholesterol, total;
BRCA	cis	rs11971779	0.816	rs11979272	chr7:139074069	C/T	cg07862535	chr7:139043722	LUC7L2	0.53	12.91	0.45	4.62e-34	Diisocyanate-induced asthma;
BRCA	trans	rs208520	1.000	rs208536	chr6:66963440	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-14.55	-0.5	1.24e-41	Exhaled nitric oxide output;
BRCA	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg23649088	chr2:200775458	C2orf69	0.59	8.64	0.32	4.43e-17	Schizophrenia;
BRCA	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg03433033	chr1:76189801	ACADM	-0.41	-8.39	-0.32	3.02e-16	Daytime sleep phenotypes;
BRCA	cis	rs977987	0.806	rs4887823	chr16:75433074	T/A	cg03315344	chr16:75512273	CHST6	0.52	12.38	0.44	1.02e-31	Dupuytren's disease;
BRCA	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18876405	chr7:65276391	NA	-0.55	-12.97	-0.46	2.6e-34	Aortic root size;
BRCA	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.47	0.38	8.84e-24	Motion sickness;
BRCA	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg26384229	chr12:38710491	ALG10B	-0.43	-9.99	-0.37	6.19e-22	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg18876405	chr7:65276391	NA	-0.62	-14.82	-0.51	6.1e-43	Aortic root size;
BRCA	cis	rs6426558	0.515	rs7543579	chr1:227377699	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.47	-9.36	-0.35	1.31e-19	Neutrophil percentage of white cells;
BRCA	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg26031613	chr14:104095156	KLC1	-0.53	-9.36	-0.35	1.32e-19	Reticulocyte count;
BRCA	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg25358565	chr5:93447407	FAM172A	0.69	11.87	0.42	1.73e-29	Diabetic retinopathy;
BRCA	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg16386425	chr10:429943	DIP2C	-0.42	-8.91	-0.33	5.27e-18	Psychosis in Alzheimer's disease;
BRCA	cis	rs8063761	0.689	rs4785763	chr16:90066936	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.37	-8.54	-0.32	9.76e-17	Squamous cell carcinoma;
BRCA	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg09436375	chr6:42928200	GNMT	-0.29	-10.79	-0.39	4.72e-25	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	11.13	0.4	2.02e-26	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg05714579	chr10:131428358	MGMT	0.57	13.96	0.48	7.94e-39	Response to temozolomide;
BRCA	cis	rs10193935	0.901	rs6544536	chr2:42522042	G/A	cg27598129	chr2:42591480	NA	-0.6	-10.32	-0.38	3.49e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg01483505	chr11:975446	AP2A2	0.33	8.87	0.33	7.11e-18	Alzheimer's disease (late onset);
BRCA	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg16414030	chr3:133502952	NA	-0.53	-12.36	-0.44	1.3e-31	Iron status biomarkers;
BRCA	cis	rs17092148	1.000	rs6088594	chr20:33343157	A/G	cg16810054	chr20:33298113	TP53INP2	0.48	11.01	0.4	6.1e-26	Neuroticism;
BRCA	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg16586182	chr3:47516702	SCAP	0.53	11.9	0.43	1.21e-29	Colorectal cancer;
BRCA	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg23711669	chr6:146136114	FBXO30	0.65	15.23	0.52	6.75e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2463822	0.925	rs2513075	chr11:62102408	C/T	cg06239285	chr11:62104954	ASRGL1	0.67	11.13	0.4	1.92e-26	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	trans	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg04565464	chr8:145669602	NFKBIL2	0.42	9.15	0.34	7.49e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg19000871	chr14:103996768	TRMT61A	-0.35	-8.24	-0.31	9.89e-16	Coronary artery disease;
BRCA	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg17691542	chr6:26056736	HIST1H1C	0.51	10.91	0.4	1.53e-25	Height;
BRCA	cis	rs6714710	0.580	rs57681139	chr2:98454473	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	13.6	0.47	3.4e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.46	-13.82	-0.48	3.56e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.04	-0.3	4.35e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg24250549	chr1:154909240	PMVK	0.63	15.87	0.53	4.79e-48	Prostate cancer;
BRCA	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00166722	chr3:10149974	C3orf24	0.67	13.44	0.47	1.83e-36	Alzheimer's disease;
BRCA	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-10.19	-0.37	1.04e-22	Blood metabolite levels;
BRCA	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg22974920	chr21:40686053	BRWD1	-0.38	-8.66	-0.32	3.82e-17	Cognitive function;
BRCA	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg07080220	chr10:102295463	HIF1AN	0.54	10.87	0.4	2.27e-25	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07343612	chr16:622815	PIGQ	-0.67	-21.89	-0.65	1.05e-79	Height;
BRCA	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg06494592	chr3:125709126	NA	-0.53	-8.37	-0.31	3.74e-16	Blood pressure (smoking interaction);
BRCA	cis	rs9462027	0.628	rs9469892	chr6:34769101	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.88	-0.3	1.39e-14	Systemic lupus erythematosus;
BRCA	cis	rs12472274	1.000	rs12472274	chr2:239095422	G/A	cg17459225	chr2:239074497	NA	0.63	12.97	0.46	2.69e-34	Phospholipid levels (plasma);
BRCA	cis	rs4800452	0.826	rs28625207	chr18:20746672	A/G	cg26136497	chr18:20735537	CABLES1	-0.41	-9.68	-0.36	8.92e-21	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
BRCA	trans	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg25214090	chr10:38739885	LOC399744	0.52	11.68	0.42	1.09e-28	Corneal astigmatism;
BRCA	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg22903471	chr2:27725779	GCKR	-0.39	-9.42	-0.35	8.08e-20	Total body bone mineral density;
BRCA	trans	rs2562456	0.720	rs6511250	chr19:21656046	C/T	cg25042112	chr7:64838748	ZNF92	0.42	7.84	0.3	1.87e-14	Pain;
BRCA	cis	rs887829	0.667	rs7577677	chr2:234590616	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-8.53	-0.32	1.09e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg15448220	chr1:150897856	SETDB1	0.36	8.23	0.31	1.05e-15	Melanoma;
BRCA	cis	rs12989701	1.000	rs13004848	chr2:127887560	C/T	cg08168897	chr2:127865431	BIN1	-0.79	-13.38	-0.47	3.5e-36	Alzheimer's disease (late onset);
BRCA	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg13010199	chr12:38710504	ALG10B	0.44	8.93	0.33	4.46e-18	Bladder cancer;
BRCA	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.71	14.49	0.5	2.29e-41	HIV-1 control;
BRCA	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg07636037	chr3:49044803	WDR6	0.66	13.19	0.46	2.6e-35	Menarche (age at onset);
BRCA	cis	rs6960043	0.738	rs10950549	chr7:15057829	G/A	cg19272540	chr7:15055459	NA	0.22	7.81	0.3	2.29e-14	Type 2 diabetes;
BRCA	cis	rs10463316	0.928	rs10060441	chr5:150750006	A/G	cg03212797	chr5:150827313	SLC36A1	-0.41	-7.98	-0.3	6.63e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg05791153	chr7:19748676	TWISTNB	0.65	11.71	0.42	7.81e-29	Thyroid stimulating hormone;
BRCA	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	19.61	0.61	2.24e-67	Platelet count;
BRCA	trans	rs8073060	0.586	rs2428464	chr17:34021994	C/G	cg19694781	chr19:47549865	TMEM160	-1.07	-21.69	-0.65	1.28e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs3780378	0.875	rs4372063	chr9:5003338	C/T	cg02405213	chr9:5042618	JAK2	-0.41	-7.85	-0.3	1.75e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs7246657	0.606	rs2972439	chr19:38212581	T/C	cg23950597	chr19:37808831	NA	0.5	8.62	0.32	5.24e-17	Coronary artery calcification;
BRCA	trans	rs3857536	0.740	rs7756519	chr6:66892275	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-9.49	-0.35	4.6e-20	Blood trace element (Cu levels);
BRCA	cis	rs17401966	0.838	rs4846206	chr1:10310258	G/C	cg03954927	chr1:10346856	KIF1B	0.43	13.5	0.47	9.75e-37	Hepatocellular carcinoma;
BRCA	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg01448562	chr3:133502909	NA	-0.64	-15.29	-0.52	3.21e-45	Iron status biomarkers;
BRCA	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	10.01	0.37	5.17e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7737355	0.812	rs10054168	chr5:130788698	C/T	cg06307176	chr5:131281290	NA	-0.48	-10.41	-0.38	1.52e-23	Life satisfaction;
BRCA	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18876405	chr7:65276391	NA	-0.51	-11.6	-0.42	2.26e-28	Aortic root size;
BRCA	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg04450456	chr4:17643702	FAM184B	0.31	8.99	0.34	2.76e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9581857	0.519	rs9581880	chr13:28105850	C/A	cg22138327	chr13:27999177	GTF3A	0.56	7.97	0.3	7.37e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
BRCA	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg09455208	chr3:40491958	NA	0.4	9.5	0.35	4.23e-20	Renal cell carcinoma;
BRCA	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.73	0.42	6.65e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg18758796	chr5:131593413	PDLIM4	0.4	10.11	0.37	2.18e-22	Acylcarnitine levels;
BRCA	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg03354898	chr7:1950403	MAD1L1	0.45	9.17	0.34	6.54e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08564027	chr20:61660810	NA	0.84	23.09	0.67	3.27e-86	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs68170813	0.599	rs12533516	chr7:106937135	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.76	-0.33	1.8e-17	Coronary artery disease;
BRCA	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg16576597	chr16:28551801	NUPR1	0.32	8.58	0.32	7.04e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.71	-0.33	2.64e-17	Retinal vascular caliber;
BRCA	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg08999081	chr20:33150536	PIGU	-0.45	-12.43	-0.44	6.29e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs1215050	0.818	rs165238	chr4:98712138	G/T	cg05340658	chr4:99064831	C4orf37	0.43	9.76	0.36	4.5e-21	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.52	10.33	0.38	2.97e-23	Height;
BRCA	cis	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg07460842	chr6:66804631	NA	-1.02	-20.08	-0.62	6.48e-70	Exhaled nitric oxide output;
BRCA	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg04034577	chr2:241836375	C2orf54	-0.56	-13.99	-0.48	5.17e-39	Urinary metabolites;
BRCA	trans	rs1941687	0.510	rs1452649	chr18:31410858	A/G	cg15819921	chr19:927150	ARID3A	-0.41	-8.11	-0.31	2.57e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg00376283	chr12:123451042	ABCB9	0.51	9.97	0.37	7.2e-22	Neutrophil percentage of white cells;
BRCA	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.42	0.41	1.25e-27	Homoarginine levels;
BRCA	cis	rs943466	1.000	rs6933568	chr6:33751261	G/A	cg25922239	chr6:33757077	LEMD2	-0.38	-7.88	-0.3	1.38e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg23262073	chr20:60523788	NA	0.57	13.8	0.48	4.17e-38	Obesity-related traits;
BRCA	trans	rs17742757	0.522	rs899364	chr8:11329544	G/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-8.17	-0.31	1.62e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
BRCA	cis	rs6484504	0.512	rs2774402	chr11:31312897	G/C	cg06552810	chr11:31128660	NA	0.39	8.95	0.33	3.89e-18	Red blood cell count;
BRCA	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg12011299	chr4:100065546	ADH4	0.42	10.89	0.4	1.89e-25	Alcohol dependence;
BRCA	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg07395648	chr5:131743802	NA	-0.44	-10.28	-0.38	4.8e-23	Breast cancer;Mosquito bite size;
BRCA	trans	rs629535	0.862	rs598548	chr8:70032438	C/T	cg21567404	chr3:27674614	NA	1.0	21.1	0.64	2.04e-75	Dupuytren's disease;
BRCA	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.42	-8.61	-0.32	5.71e-17	Body mass index;
BRCA	cis	rs2463822	1.000	rs2463822	chr11:62103420	T/C	cg06239285	chr11:62104954	ASRGL1	0.62	9.19	0.34	5.35e-19	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg03929089	chr4:120376271	NA	0.65	12.8	0.45	1.46e-33	Coronary artery disease;
BRCA	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg12386194	chr3:101231763	SENP7	0.62	11.38	0.41	1.88e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4975616	0.807	rs28379291	chr5:1313701	A/G	cg06550200	chr5:1325588	CLPTM1L	0.56	11.26	0.41	6.1e-27	Lung cancer;
BRCA	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg07828340	chr4:882639	GAK	0.79	11.41	0.41	1.47e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs4588572	0.643	rs1560196	chr5:77701982	G/C	cg11547950	chr5:77652471	NA	0.46	8.37	0.31	3.72e-16	Triglycerides;
BRCA	trans	rs4819388	0.751	rs12482807	chr21:45642363	G/A	cg17383793	chr5:52405638	MOCS2	-0.48	-10.76	-0.39	6.06e-25	Celiac disease;
BRCA	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg11663144	chr21:46675770	NA	0.61	14.29	0.49	2.17e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27286337	chr10:134555280	INPP5A	0.8	13.09	0.46	7.19e-35	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1113500	0.933	rs11185250	chr1:108616417	A/G	cg06207961	chr1:108661230	NA	0.45	11.09	0.4	2.99e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14240646	chr10:27532245	ACBD5	-0.69	-10.77	-0.39	5.59e-25	Breast cancer;
BRCA	cis	rs6714710	0.603	rs34373359	chr2:98442202	G/A	cg26665480	chr2:98280029	ACTR1B	0.6	13.82	0.48	3.49e-38	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg14675211	chr2:100938903	LONRF2	0.48	11.07	0.4	3.7e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg19156104	chr2:198669113	PLCL1	-0.44	-8.13	-0.31	2.26e-15	Ulcerative colitis;
BRCA	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg03526776	chr6:41159608	TREML2	-0.4	-8.25	-0.31	8.99e-16	Alzheimer's disease (late onset);
BRCA	cis	rs9355610	0.609	rs9366076	chr6:167373708	C/T	cg23791538	chr6:167370224	RNASET2	0.44	8.7	0.33	2.81e-17	Graves' disease;
BRCA	trans	rs4650994	1.000	rs35810840	chr1:178522642	G/A	cg05059571	chr16:84539110	KIAA1609	-0.42	-9.5	-0.35	3.97e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	trans	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.35	0.31	4.08e-16	Aortic root size;
BRCA	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg12011299	chr4:100065546	ADH4	0.5	11.72	0.42	7.29e-29	Alcohol dependence;
BRCA	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg22906224	chr7:99728672	NA	0.43	8.19	0.31	1.37e-15	Coronary artery disease;
BRCA	trans	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg13010199	chr12:38710504	ALG10B	0.39	8.05	0.3	3.99e-15	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	trans	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg01620082	chr3:125678407	NA	-0.64	-8.56	-0.32	8.69e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg13010199	chr12:38710504	ALG10B	-0.38	-8.24	-0.31	9.75e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs16973500	0.732	rs1549292	chr16:71983664	A/C	cg00732059	chr16:71740210	PHLPP2	-0.59	-9.8	-0.36	3.2e-21	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18876405	chr7:65276391	NA	-0.52	-11.48	-0.41	7.03e-28	Aortic root size;
BRCA	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg26384229	chr12:38710491	ALG10B	0.74	17.72	0.57	1.89e-57	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs7939886	0.920	rs11231821	chr11:55777052	C/G	cg15704280	chr7:45808275	SEPT13	0.62	7.91	0.3	1.11e-14	Myopia (pathological);
BRCA	cis	rs6138458	0.701	rs6138474	chr20:25012427	T/A	cg26195577	chr20:24973756	C20orf3	0.62	14.79	0.51	8.31e-43	Blood protein levels;
BRCA	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg22974920	chr21:40686053	BRWD1	-0.35	-7.83	-0.3	1.98e-14	Menarche (age at onset);
BRCA	trans	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg25214090	chr10:38739885	LOC399744	0.55	11.92	0.43	1.04e-29	Corneal astigmatism;
BRCA	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-12.6	-0.45	1.15e-32	Alzheimer's disease;
BRCA	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-16.39	-0.54	1.15e-50	Heart rate;
BRCA	cis	rs56399783	0.901	rs73049327	chr7:2795544	T/G	cg23627948	chr7:2760692	NA	0.48	7.81	0.3	2.4e-14	Childhood ear infection;
BRCA	cis	rs6121246	0.633	rs6060986	chr20:30426297	G/A	cg13852791	chr20:30311386	BCL2L1	0.88	20.17	0.62	2.32e-70	Mean corpuscular hemoglobin;
BRCA	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.37	-0.38	2.18e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10911251	0.528	rs10911263	chr1:183115018	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.36	0.54	1.69e-50	Colorectal cancer;
BRCA	cis	rs10493773	0.577	rs17398175	chr1:86074710	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.43	-8.15	-0.31	1.96e-15	Urate levels in overweight individuals;
BRCA	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg14004847	chr7:1930337	MAD1L1	-0.45	-9.13	-0.34	8.73e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg16586182	chr3:47516702	SCAP	-0.53	-11.83	-0.42	2.45e-29	Colorectal cancer;
BRCA	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg02503808	chr4:7069936	GRPEL1	0.78	18.24	0.59	3.58e-60	Monocyte percentage of white cells;
BRCA	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.39	-8.56	-0.32	8.6e-17	HDL cholesterol;
BRCA	cis	rs6088813	1.000	rs735531	chr20:33947730	T/C	cg14752227	chr20:34000481	UQCC	-0.43	-9.16	-0.34	6.86e-19	Height;
BRCA	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg20701182	chr2:24300061	SF3B14	0.58	9.01	0.34	2.37e-18	Lymphocyte counts;
BRCA	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg03585969	chr10:35415529	CREM	0.5	10.51	0.38	6.02e-24	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs11976180	1.000	rs2951308	chr7:143767149	A/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	0.42	7.93	0.3	9.96e-15	Obesity-related traits;
BRCA	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.35	-0.38	2.53e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg18404041	chr3:52824283	ITIH1	-0.31	-7.88	-0.3	1.43e-14	Schizophrenia;
BRCA	trans	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg25214090	chr10:38739885	LOC399744	0.52	11.79	0.42	3.78e-29	Corneal astigmatism;
BRCA	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg16482183	chr6:26056742	HIST1H1C	0.5	10.69	0.39	1.16e-24	Height;
BRCA	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg22467129	chr15:76604101	ETFA	0.48	10.62	0.39	2.3e-24	Blood metabolite levels;
BRCA	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg11657440	chr19:46296263	DMWD	0.71	19.19	0.6	3.74e-65	Coronary artery disease;
BRCA	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg00376283	chr12:123451042	ABCB9	0.54	11.0	0.4	6.76e-26	Neutrophil percentage of white cells;
BRCA	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg00071950	chr4:10020882	SLC2A9	0.64	15.64	0.53	6.38e-47	Bone mineral density;
BRCA	cis	rs8032158	1.000	rs10851599	chr15:56154064	T/G	cg02198044	chr15:56286336	NEDD4	-0.37	-8.84	-0.33	8.98e-18	Keloid;
BRCA	cis	rs483180	0.512	rs598685	chr1:120215269	G/A	cg19096424	chr1:120255104	PHGDH	0.44	9.59	0.35	1.93e-20	Macular telangiectasia type 2;
BRCA	cis	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg06521331	chr12:34319734	NA	-0.62	-11.19	-0.4	1.1e-26	Morning vs. evening chronotype;
BRCA	cis	rs7737355	0.812	rs6896132	chr5:130773561	C/G	cg06307176	chr5:131281290	NA	0.47	10.19	0.37	1.05e-22	Life satisfaction;
BRCA	cis	rs2742234	0.955	rs2503841	chr10:43675721	C/T	cg02780029	chr10:43622663	RET	-0.39	-9.87	-0.36	1.81e-21	Hirschsprung disease;
BRCA	cis	rs6840360	0.593	rs4696107	chr4:152606823	G/A	cg22705602	chr4:152727874	NA	-0.38	-10.3	-0.38	4.15e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg14844989	chr11:31128820	NA	-0.45	-9.65	-0.36	1.14e-20	Red blood cell count;
BRCA	trans	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.49	9.43	0.35	7.28e-20	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg04553112	chr3:125709451	NA	-0.56	-8.47	-0.32	1.68e-16	Blood pressure (smoking interaction);
BRCA	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg03684893	chr10:554711	DIP2C	-0.4	-9.59	-0.35	2.01e-20	Psychosis in Alzheimer's disease;
BRCA	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg10932868	chr11:921992	NA	0.49	12.63	0.45	8.39e-33	Alzheimer's disease (late onset);
BRCA	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg23788917	chr6:8435910	SLC35B3	0.47	10.18	0.37	1.19e-22	Motion sickness;
BRCA	cis	rs4363385	0.818	rs3181787	chr1:153004809	T/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.22	-0.34	4.35e-19	Inflammatory skin disease;
BRCA	trans	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-15.27	-0.52	4.23e-45	Obesity-related traits;
BRCA	cis	rs2288912	0.808	rs35670684	chr19:45455985	A/C	cg09555818	chr19:45449301	APOC2	0.47	12.07	0.43	2.28e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg15212455	chr7:39170539	POU6F2	0.43	9.55	0.35	2.79e-20	IgG glycosylation;
BRCA	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06108461	chr20:60628389	TAF4	-0.75	-15.63	-0.53	7.54e-47	Body mass index;
BRCA	cis	rs61990749	0.597	rs1549119	chr14:78219812	A/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.44	7.97	0.3	7.44e-15	Fibroblast growth factor basic levels;
BRCA	cis	rs17741873	0.836	rs4745723	chr10:75603338	T/C	cg07699608	chr10:75541558	CHCHD1	0.53	8.55	0.32	8.84e-17	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg10729496	chr3:10149963	C3orf24	0.41	7.88	0.3	1.44e-14	Alzheimer's disease;
BRCA	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	17.63	0.57	5.22e-57	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.54	11.7	0.42	9.11e-29	Colorectal cancer;
BRCA	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg05872129	chr22:39784769	NA	-0.55	-11.99	-0.43	5.27e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs10267417	0.603	rs79323924	chr7:19924321	T/G	cg05791153	chr7:19748676	TWISTNB	0.44	8.16	0.31	1.8e-15	Night sleep phenotypes;
BRCA	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg01884057	chr2:25150051	NA	0.3	8.02	0.3	4.91e-15	Body mass index;
BRCA	cis	rs1003719	0.646	rs2032063	chr21:38576657	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.73	-0.5	1.77e-42	Eye color traits;
BRCA	cis	rs6534441	0.727	rs77899971	chr4:125419177	C/G	cg21609808	chr4:125404261	NA	0.35	7.88	0.3	1.4e-14	Major depressive disorder;
BRCA	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg04362960	chr10:104952993	NT5C2	0.45	10.28	0.38	4.8e-23	Arsenic metabolism;
BRCA	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg22029157	chr1:209979665	IRF6	0.55	11.41	0.41	1.39e-27	Cleft lip with or without cleft palate;
BRCA	cis	rs727479	0.523	rs8034835	chr15:51512664	A/G	cg19946085	chr15:51559439	CYP19A1	-0.3	-8.54	-0.32	1.02e-16	Estradiol levels;
BRCA	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg27432699	chr2:27873401	GPN1	0.47	9.93	0.37	1.09e-21	Oral cavity cancer;
BRCA	cis	rs752010	0.695	rs10789408	chr1:42106579	T/C	cg06885757	chr1:42089581	HIVEP3	0.23	8.35	0.31	4.34e-16	Lupus nephritis in systemic lupus erythematosus;
BRCA	trans	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.41	8.05	0.3	4.13e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs12618769	0.597	rs3754880	chr2:99132215	G/C	cg10123293	chr2:99228465	UNC50	0.41	8.24	0.31	9.45e-16	Bipolar disorder;
BRCA	cis	rs6782228	0.606	rs2811489	chr3:128337371	A/G	cg16766828	chr3:128327626	NA	0.42	9.35	0.35	1.41e-19	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs3824867	0.879	rs10742806	chr11:47456226	T/A	cg20307385	chr11:47447363	PSMC3	0.51	11.55	0.42	3.81e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs10992471	0.528	rs10514815	chr9:95256695	C/A	cg14631576	chr9:95140430	CENPP	-0.34	-8.55	-0.32	8.74e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg23711669	chr6:146136114	FBXO30	0.74	16.67	0.55	4.5e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1538970	0.924	rs12097497	chr1:45880669	C/T	cg05343316	chr1:45956843	TESK2	0.64	12.89	0.45	5.63e-34	Platelet count;
BRCA	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18876405	chr7:65276391	NA	-0.63	-15.65	-0.53	5.63e-47	Aortic root size;
BRCA	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg13334819	chr7:99746414	C7orf59	-0.35	-8.22	-0.31	1.11e-15	Coronary artery disease;
BRCA	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg27446573	chr6:127587934	RNF146	0.68	15.54	0.52	1.94e-46	Breast cancer;
BRCA	cis	rs12986413	1.000	rs12986413	chr19:2170954	A/T	cg09261902	chr19:2140048	AP3D1	-0.36	-9.56	-0.35	2.45e-20	Height;
BRCA	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg04166393	chr7:2884313	GNA12	0.52	9.97	0.37	7.38e-22	Height;
BRCA	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg03462622	chr3:195777018	TFRC	-0.38	-8.63	-0.32	4.83e-17	Mean corpuscular volume;
BRCA	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg21475434	chr5:93447410	FAM172A	0.67	8.44	0.32	2.16e-16	Diabetic retinopathy;
BRCA	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg26446133	chr18:72167187	CNDP2	-0.77	-13.69	-0.48	1.42e-37	Refractive error;
BRCA	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.07	0.4	3.39e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.61	13.69	0.48	1.37e-37	Eosinophil percentage of white cells;
BRCA	cis	rs4363385	0.747	rs10494285	chr1:152982285	G/A	cg24667326	chr1:152973720	SPRR3	-0.35	-9.87	-0.36	1.81e-21	Inflammatory skin disease;
BRCA	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-11.79	-0.42	3.7e-29	Alzheimer's disease;
BRCA	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg06115741	chr20:33292138	TP53INP2	0.39	8.68	0.32	3.35e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs10782582	0.569	rs2131557	chr1:76388589	A/C	cg03433033	chr1:76189801	ACADM	0.4	8.48	0.32	1.55e-16	Daytime sleep phenotypes;
BRCA	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.63	13.88	0.48	1.69e-38	Lymphocyte percentage of white cells;
BRCA	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg24562669	chr7:97807699	LMTK2	0.44	11.78	0.42	3.9e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00149659	chr3:10157352	C3orf10	0.84	14.73	0.5	1.63e-42	Alzheimer's disease;
BRCA	cis	rs12493885	0.818	rs10935972	chr3:153774029	G/A	cg17054900	chr3:154042577	DHX36	-0.5	-8.64	-0.32	4.41e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg04450456	chr4:17643702	FAM184B	0.39	11.59	0.42	2.46e-28	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg06212747	chr3:49208901	KLHDC8B	0.49	10.23	0.38	7.29e-23	Parkinson's disease;
BRCA	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg19920283	chr7:105172520	RINT1	0.58	9.39	0.35	1.07e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs4363385	0.747	rs11205149	chr1:152958840	C/T	cg21543102	chr1:152974771	SPRR3	-0.28	-8.19	-0.31	1.38e-15	Inflammatory skin disease;
BRCA	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06481639	chr22:41940642	POLR3H	0.54	8.41	0.32	2.68e-16	Vitiligo;
BRCA	cis	rs1215050	0.782	rs6532693	chr4:98655815	T/C	cg05340658	chr4:99064831	C4orf37	-0.44	-9.97	-0.37	7.4e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg18811423	chr2:55921094	PNPT1	0.77	26.01	0.72	2.74e-102	Metabolic syndrome;
BRCA	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00908189	chr16:619842	PIGQ	0.66	16.49	0.55	3.73e-51	Height;
BRCA	cis	rs867371	1.000	rs1392976	chr15:82446175	A/G	cg00614314	chr15:82944287	LOC80154	-0.43	-9.16	-0.34	6.9e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25427524	chr10:38739819	LOC399744	0.69	16.91	0.56	2.7e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg03585969	chr10:35415529	CREM	0.57	11.63	0.42	1.63e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg20503657	chr10:835505	NA	1.31	21.98	0.66	3.63e-80	Eosinophil percentage of granulocytes;
BRCA	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg02175503	chr12:58329896	NA	0.56	13.34	0.47	5.6e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.23	7.96	0.3	8.14e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg24044776	chr19:53454761	ZNF816A	-0.41	-9.31	-0.35	2.09e-19	Psoriasis;
BRCA	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24308560	chr3:49941425	MST1R	-0.4	-8.59	-0.32	6.45e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg08601574	chr20:25228251	PYGB	-0.35	-8.31	-0.31	5.95e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg21535247	chr6:8435926	SLC35B3	0.41	9.34	0.35	1.59e-19	Motion sickness;
BRCA	cis	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg08601574	chr20:25228251	PYGB	0.34	8.16	0.31	1.74e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7593730	0.636	rs7583157	chr2:161114552	A/G	cg22609984	chr2:161126801	NA	0.43	9.2	0.34	4.96e-19	Type 2 diabetes;
BRCA	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg08885076	chr2:99613938	TSGA10	-0.59	-13.08	-0.46	8e-35	Chronic sinus infection;
BRCA	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg00277334	chr10:82204260	NA	-0.43	-8.48	-0.32	1.53e-16	Post bronchodilator FEV1;
BRCA	cis	rs1691799	0.867	rs1168311	chr12:66725912	A/C	cg16791601	chr12:66731901	HELB	0.63	17.08	0.56	3.49e-54	White blood cell count (basophil);
BRCA	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg22974920	chr21:40686053	BRWD1	-0.37	-8.37	-0.31	3.68e-16	Cognitive function;
BRCA	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-14.89	-0.51	2.92e-43	Chronic sinus infection;
BRCA	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-11.79	-0.42	3.5e-29	Alzheimer's disease;
BRCA	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg25767906	chr1:53392781	SCP2	-0.46	-10.27	-0.38	5.21e-23	Monocyte count;
BRCA	trans	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.48	-0.35	4.76e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs11723261	0.582	rs6599293	chr4:133027	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.34	7.9	0.3	1.18e-14	Immune response to smallpox vaccine (IL-6);
BRCA	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg09537434	chr19:41945824	ATP5SL	-0.6	-10.96	-0.4	1e-25	Colorectal cancer;
BRCA	cis	rs877282	0.945	rs11253390	chr10:788678	A/G	cg17470449	chr10:769945	NA	0.51	8.63	0.32	4.87e-17	Uric acid levels;
BRCA	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg04267008	chr7:1944627	MAD1L1	0.4	8.88	0.33	6.69e-18	Bipolar disorder and schizophrenia;
BRCA	trans	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg25214090	chr10:38739885	LOC399744	0.55	11.82	0.42	2.68e-29	Corneal astigmatism;
BRCA	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.35	-7.88	-0.3	1.4e-14	Bipolar disorder;
BRCA	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg00757033	chr12:89920650	WDR51B	0.54	11.13	0.4	1.99e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	trans	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg25214090	chr10:38739885	LOC399744	0.53	12.03	0.43	3.51e-30	Corneal astigmatism;
BRCA	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg05347473	chr6:146136440	FBXO30	0.39	7.87	0.3	1.54e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg05340658	chr4:99064831	C4orf37	0.67	16.49	0.55	3.48e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.94	0.3	8.88e-15	Depression;
BRCA	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg20607798	chr8:58055168	NA	0.48	8.4	0.32	2.81e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	11.46	0.41	8.82e-28	Mean platelet volume;
BRCA	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg08888203	chr3:10149979	C3orf24	0.67	14.07	0.49	2.42e-39	Alzheimer's disease;
BRCA	cis	rs3740540	0.530	rs10794163	chr10:126291398	A/G	cg04949429	chr10:126290192	LHPP	0.43	12.01	0.43	4.06e-30	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg03060546	chr3:49711283	APEH	-0.58	-11.57	-0.42	3.06e-28	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs870825	0.616	rs7659101	chr4:185632158	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	17.25	0.56	4.74e-55	Blood protein levels;
BRCA	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg20701182	chr2:24300061	SF3B14	0.71	13.2	0.46	2.28e-35	Lymphocyte counts;
BRCA	cis	rs6543140	0.964	rs6543136	chr2:103065547	G/A	cg04239558	chr2:103089729	SLC9A4	0.34	9.62	0.36	1.47e-20	Blood protein levels;
BRCA	cis	rs2625529	0.668	rs34189331	chr15:72404573	A/T	cg16672083	chr15:72433130	SENP8	-0.77	-16.61	-0.55	9.22e-52	Red blood cell count;
BRCA	cis	rs7000551	0.715	rs7828610	chr8:22307326	C/T	cg12081754	chr8:22256438	SLC39A14	0.39	7.92	0.3	1.07e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg06494592	chr3:125709126	NA	-0.53	-8.21	-0.31	1.22e-15	Blood pressure (smoking interaction);
BRCA	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.41	-0.44	8.14e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00166722	chr3:10149974	C3orf24	0.57	11.15	0.4	1.61e-26	Alzheimer's disease;
BRCA	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg18811423	chr2:55921094	PNPT1	0.71	22.76	0.67	2.07e-84	Metabolic syndrome;
BRCA	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.28	-0.38	5.01e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.29	-0.41	4.62e-27	Gut microbiome composition (summer);
BRCA	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg23649088	chr2:200775458	C2orf69	-0.4	-8.36	-0.31	4.03e-16	QT interval;
BRCA	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	9.54	0.35	2.85e-20	Lymphocyte counts;
BRCA	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg02951883	chr7:2050386	MAD1L1	-0.4	-8.82	-0.33	1.06e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs2629540	0.889	rs10901815	chr10:126435598	G/A	cg08799069	chr10:126477246	METTL10	-0.53	-11.66	-0.42	1.29e-28	Cocaine dependence;
BRCA	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg16606324	chr3:10149918	C3orf24	0.57	10.22	0.37	8.35e-23	Alzheimer's disease;
BRCA	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.49	-14.12	-0.49	1.35e-39	Lung cancer;
BRCA	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg16482183	chr6:26056742	HIST1H1C	0.6	12.16	0.43	9.47e-31	Iron status biomarkers;
BRCA	cis	rs10128251	0.743	rs2386636	chr10:5712087	G/T	cg24097872	chr10:5724021	NA	0.44	9.95	0.37	9.16e-22	Childhood ear infection;
BRCA	cis	rs17095355	0.901	rs17126938	chr10:111761351	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.44	-10.06	-0.37	3.35e-22	Biliary atresia;
BRCA	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg05347473	chr6:146136440	FBXO30	-0.42	-8.42	-0.32	2.5e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6545883	1.000	rs6545883	chr2:61772257	A/G	cg15711740	chr2:61764176	XPO1	-0.51	-12.98	-0.46	2.34e-34	Tuberculosis;
BRCA	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg22800045	chr5:56110881	MAP3K1	0.65	12.18	0.43	7.48e-31	Initial pursuit acceleration;
BRCA	cis	rs7395581	0.797	rs10742801	chr11:47342220	A/C	cg25783544	chr11:47291846	MADD	0.4	9.02	0.34	2.11e-18	HDL cholesterol;
BRCA	cis	rs2816062	0.813	rs2816044	chr1:18892826	A/G	cg18795169	chr1:18902165	NA	-0.93	-27.62	-0.74	4.26e-111	Urate levels in lean individuals;
BRCA	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg03929089	chr4:120376271	NA	-0.66	-12.93	-0.46	3.9e-34	Coronary artery disease;
BRCA	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg14631576	chr9:95140430	CENPP	-0.37	-8.92	-0.33	4.99e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs9287719	0.649	rs6714787	chr2:10729032	C/T	cg00105475	chr2:10696890	NA	0.41	9.18	0.34	5.88e-19	Prostate cancer;
BRCA	cis	rs67981189	0.858	rs2526862	chr14:71409614	T/C	cg15816911	chr14:71606274	NA	-0.37	-8.18	-0.31	1.52e-15	Schizophrenia;
BRCA	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg08392591	chr16:89556376	ANKRD11	0.38	9.15	0.34	7.84e-19	Multiple myeloma (IgH translocation);
BRCA	cis	rs2731664	0.792	rs2731662	chr5:176872494	C/T	cg23176889	chr5:176863531	GRK6	0.63	17.73	0.57	1.66e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26314531	chr2:26401878	FAM59B	-0.78	-12.15	-0.43	1.06e-30	Gut microbiome composition (summer);
BRCA	trans	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04565464	chr8:145669602	NFKBIL2	0.33	8.03	0.3	4.84e-15	Bipolar disorder and schizophrenia;
BRCA	trans	rs1941687	0.563	rs9953034	chr18:31335294	A/G	cg27147174	chr7:100797783	AP1S1	-0.43	-8.38	-0.31	3.42e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs9790314	0.779	rs1599374	chr3:160891727	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-11.29	-0.41	4.44e-27	Morning vs. evening chronotype;
BRCA	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08564027	chr20:61660810	NA	0.85	22.97	0.67	1.42e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg01324343	chr3:183735012	ABCC5	0.85	21.17	0.64	9.3e-76	Anterior chamber depth;
BRCA	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-8.19	-0.31	1.47e-15	Total body bone mineral density;
BRCA	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg09582351	chr12:29534625	ERGIC2	-0.48	-11.65	-0.42	1.4e-28	QT interval;
BRCA	cis	rs2742234	0.955	rs2503849	chr10:43672776	G/A	cg02780029	chr10:43622663	RET	-0.39	-9.59	-0.35	1.95e-20	Hirschsprung disease;
BRCA	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg03060546	chr3:49711283	APEH	-0.56	-11.48	-0.41	7.03e-28	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs5167	0.539	rs4803783	chr19:45470458	G/C	cg09555818	chr19:45449301	APOC2	-0.35	-7.95	-0.3	8.52e-15	Blood protein levels;
BRCA	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg17366294	chr4:99064904	C4orf37	0.49	8.34	0.31	4.67e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg23625390	chr15:77176239	SCAPER	0.41	10.13	0.37	1.82e-22	Blood metabolite levels;
BRCA	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg06238570	chr21:40685208	BRWD1	-0.4	-8.18	-0.31	1.54e-15	Menarche (age at onset);
BRCA	trans	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg25206134	chr2:45395956	NA	0.53	8.93	0.33	4.46e-18	Bipolar disorder;
BRCA	cis	rs600806	0.850	rs11102981	chr1:109967323	G/C	cg20591472	chr1:110008990	SYPL2	0.33	8.31	0.31	5.69e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg00105475	chr2:10696890	NA	0.44	10.21	0.37	9.35e-23	Prostate cancer;
BRCA	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs13046373	0.508	rs1911572	chr21:32031648	A/G	cg16812893	chr21:31813075	KRTAP15-1	-0.37	-9.33	-0.35	1.71e-19	HDL cholesterol;
BRCA	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	25.82	0.71	2.97e-101	Chronic sinus infection;
BRCA	cis	rs2882667	0.964	rs12108892	chr5:138299630	G/A	cg04439458	chr5:138467593	SIL1	-0.32	-8.77	-0.33	1.58e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg22920501	chr2:26401640	FAM59B	0.95	16.32	0.54	2.51e-50	Gut microbiome composition (summer);
BRCA	cis	rs6930083	0.713	rs1321309	chr6:36638636	G/A	cg08179530	chr6:36648295	CDKN1A	-0.68	-16.36	-0.54	1.58e-50	Coronary artery disease;
BRCA	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg16606324	chr3:10149918	C3orf24	0.55	10.84	0.39	2.97e-25	Alzheimer's disease;
BRCA	cis	rs8044868	1.000	rs8052408	chr16:72158077	C/T	cg16558253	chr16:72132732	DHX38	-0.37	-8.83	-0.33	9.94e-18	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg22431228	chr1:16359049	CLCNKA	-0.43	-9.71	-0.36	6.72e-21	Dilated cardiomyopathy;
BRCA	cis	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg12165864	chr7:66369176	NA	-0.34	-8.33	-0.31	4.86e-16	Corneal structure;
BRCA	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	9.14	0.34	8.49e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg03433033	chr1:76189801	ACADM	-0.4	-8.14	-0.31	2.01e-15	Daytime sleep phenotypes;
BRCA	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg10523679	chr1:76189770	ACADM	0.88	20.7	0.63	2.98e-73	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26314531	chr2:26401878	FAM59B	-0.79	-12.64	-0.45	7.76e-33	Gut microbiome composition (summer);
BRCA	cis	rs2637266	0.935	rs1866890	chr10:78397073	C/T	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg09085632	chr11:111637200	PPP2R1B	0.96	19.42	0.61	2.35e-66	Primary sclerosing cholangitis;
BRCA	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.1	0.4	2.68e-26	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg17366294	chr4:99064904	C4orf37	-0.43	-9.65	-0.36	1.19e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.85e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7512552	0.839	rs1260367	chr1:150344514	C/T	cg15654264	chr1:150340011	RPRD2	0.38	8.44	0.32	2.06e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11890956	chr21:40555474	PSMG1	-0.6	-13.33	-0.47	6.34e-36	Menarche (age at onset);
BRCA	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg22980127	chr19:33182716	NUDT19	0.9	18.21	0.58	5.64e-60	Red blood cell traits;
BRCA	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.57	-14.17	-0.49	8.2e-40	Longevity;Endometriosis;
BRCA	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg05340658	chr4:99064831	C4orf37	0.7	17.55	0.57	1.4e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg01689657	chr7:91764605	CYP51A1	0.25	8.84	0.33	9.31e-18	Breast cancer;
BRCA	cis	rs17401966	0.537	rs3748575	chr1:10342352	C/T	cg03954927	chr1:10346856	KIF1B	0.34	10.22	0.37	8.55e-23	Hepatocellular carcinoma;
BRCA	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg17063962	chr7:91808500	NA	0.57	13.52	0.47	8.47e-37	Breast cancer;
BRCA	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg08470875	chr2:26401718	FAM59B	0.74	10.26	0.38	5.59e-23	Gut microbiome composition (summer);
BRCA	cis	rs6815814	0.950	rs5743571	chr4:38805489	C/T	cg06935464	chr4:38784597	TLR10	0.51	8.49	0.32	1.46e-16	Breast cancer;
BRCA	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg07549590	chr16:15018862	NA	-0.36	-8.96	-0.33	3.63e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.39	-8.37	-0.31	3.69e-16	Longevity;Endometriosis;
BRCA	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg01884057	chr2:25150051	NA	0.29	7.86	0.3	1.67e-14	Body mass index in non-asthmatics;
BRCA	cis	rs9647379	0.935	rs17460016	chr3:171774601	G/C	cg16233210	chr3:171778391	FNDC3B	0.41	8.78	0.33	1.52e-17	Heart rate;
BRCA	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg15556689	chr8:8085844	FLJ10661	0.33	8.44	0.32	2.14e-16	Neuroticism;
BRCA	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg18230493	chr5:56204884	C5orf35	0.88	16.87	0.56	4.31e-53	Initial pursuit acceleration;
BRCA	cis	rs2066819	1.000	rs79101914	chr12:56729739	A/G	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg06494592	chr3:125709126	NA	-0.51	-7.9	-0.3	1.18e-14	Blood pressure (smoking interaction);
BRCA	cis	rs6901250	0.819	rs9374623	chr6:117127312	C/A	cg12892004	chr6:117198278	RFX6	0.49	11.44	0.41	1.03e-27	C-reactive protein levels;
BRCA	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg22920501	chr2:26401640	FAM59B	-0.63	-11.21	-0.41	9.73e-27	Gut microbiome composition (summer);
BRCA	cis	rs735860	0.763	rs6458912	chr6:53147965	G/A	cg10236188	chr6:53219634	NA	-0.39	-8.27	-0.31	8.02e-16	Glaucoma;
BRCA	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg24977027	chr2:88469347	THNSL2	0.57	9.58	0.35	2.04e-20	Plasma clusterin levels;
BRCA	cis	rs13102973	0.931	rs12643821	chr4:135859614	A/G	cg14419869	chr4:135874104	NA	-0.59	-12.96	-0.46	2.78e-34	Subjective well-being;
BRCA	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg22903471	chr2:27725779	GCKR	-0.35	-8.57	-0.32	7.99e-17	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11644478	chr21:40555479	PSMG1	0.85	19.39	0.61	3.4e-66	Cognitive function;
BRCA	cis	rs858239	0.541	rs4624924	chr7:23168843	A/C	cg23682824	chr7:23144976	KLHL7	0.41	10.97	0.4	9.04e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs427394	0.664	rs274696	chr5:6732213	A/C	cg10857441	chr5:6722123	POLS	-0.32	-10.9	-0.4	1.66e-25	Menopause (age at onset);
BRCA	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg26384229	chr12:38710491	ALG10B	0.78	18.25	0.59	3.33e-60	Heart rate;
BRCA	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg04944784	chr2:26401820	FAM59B	-0.48	-8.46	-0.32	1.76e-16	Gut microbiome composition (summer);
BRCA	cis	rs11997175	0.766	rs60855034	chr8:33684732	G/A	ch.8.33884649F	chr8:33765107	NA	0.35	8.09	0.3	2.94e-15	Body mass index;
BRCA	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg08917208	chr2:24149416	ATAD2B	0.94	14.03	0.49	3.44e-39	Lymphocyte counts;
BRCA	trans	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg15556689	chr8:8085844	FLJ10661	-0.35	-8.65	-0.32	4.21e-17	Triglycerides;
BRCA	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg24006582	chr15:45444508	DUOX1	0.56	11.23	0.41	8.18e-27	Uric acid levels;
BRCA	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22455342	chr2:225449267	CUL3	-0.66	-17.26	-0.56	4.58e-55	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-13.08	-0.46	8.41e-35	Migraine;Coronary artery disease;
BRCA	trans	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-20.65	-0.63	5.57e-73	Exhaled nitric oxide output;
BRCA	cis	rs887829	0.694	rs869283	chr2:234626287	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.37	-9.17	-0.34	6.59e-19	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs705471	0.762	rs7919625	chr10:3669970	A/G	cg14308648	chr10:3568949	NA	0.39	10.08	0.37	2.78e-22	Capecitabine sensitivity;
BRCA	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.16	-0.31	1.75e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg14019146	chr3:50243930	SLC38A3	0.36	8.96	0.33	3.53e-18	Body mass index;
BRCA	cis	rs1904096	0.506	rs4693378	chr4:95168552	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.2	-0.37	9.63e-23	Type 2 diabetes;
BRCA	trans	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	8.97	0.33	3.17e-18	Mean corpuscular volume;
BRCA	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg12165864	chr7:66369176	NA	-0.46	-10.34	-0.38	2.74e-23	Corneal structure;
BRCA	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg00800038	chr16:89945340	TCF25	-0.55	-8.22	-0.31	1.15e-15	Skin colour saturation;
BRCA	cis	rs929596	0.639	rs7571915	chr2:234586574	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.38	-9.47	-0.35	5.23e-20	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-11.87	-0.42	1.6800000000000001e-29	Tonsillectomy;
BRCA	cis	rs4074536	0.574	rs10754351	chr1:116292355	G/A	cg21648376	chr1:116311395	CASQ2	-0.49	-8.63	-0.32	4.94e-17	QRS duration;
BRCA	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg02574844	chr11:5959923	NA	-0.38	-8.33	-0.31	4.91e-16	DNA methylation (variation);
BRCA	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.3	0.44	2.45e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	9.31	0.35	1.97e-19	Cognitive function;
BRCA	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg21770322	chr7:97807741	LMTK2	0.42	11.28	0.41	4.79e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg20701182	chr2:24300061	SF3B14	0.58	9.0	0.34	2.55e-18	Lymphocyte counts;
BRCA	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg01283332	chr5:1856932	NA	-0.36	-8.87	-0.33	7.31e-18	Cardiovascular disease risk factors;
BRCA	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg06064525	chr11:970664	AP2A2	-0.48	-16.23	-0.54	7.7e-50	Alzheimer's disease (late onset);
BRCA	cis	rs897984	0.520	rs4889534	chr16:30865440	T/C	cg02466173	chr16:30829666	NA	0.46	9.23	0.34	4.05e-19	Dementia with Lewy bodies;
BRCA	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.28	-0.52	3.72e-45	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg11941060	chr3:133502564	NA	0.38	8.64	0.32	4.44e-17	Iron status biomarkers;
BRCA	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg08085267	chr17:45401833	C17orf57	-0.68	-15.24	-0.52	5.78e-45	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg26384229	chr12:38710491	ALG10B	0.67	14.37	0.49	9.24e-41	Heart rate;
BRCA	cis	rs4988958	0.548	rs6543127	chr2:103028301	A/C	cg03938978	chr2:103052716	IL18RAP	0.29	8.37	0.31	3.63e-16	Asthma (childhood onset);
BRCA	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.77	0.39	5.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	cis	rs7737355	0.947	rs31583	chr5:130992432	T/C	cg06307176	chr5:131281290	NA	0.53	10.39	0.38	1.87e-23	Life satisfaction;
BRCA	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15506890	chr2:3487001	NA	-0.59	-13.33	-0.47	5.98e-36	Neurofibrillary tangles;
BRCA	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.56	11.87	0.42	1.74e-29	Monocyte percentage of white cells;
BRCA	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs870825	0.860	rs72703526	chr4:185605676	A/T	cg04058563	chr4:185651563	MLF1IP	0.67	11.59	0.42	2.49e-28	Blood protein levels;
BRCA	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13732083	chr21:47605072	C21orf56	0.38	8.14	0.31	2.01e-15	Testicular germ cell tumor;
BRCA	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21659725	chr3:3221576	CRBN	-0.33	-7.93	-0.3	9.93e-15	Body mass index;
BRCA	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg04450456	chr4:17643702	FAM184B	0.36	10.65	0.39	1.71e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.4	10.29	0.38	4.58e-23	Total body bone mineral density;
BRCA	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07930192	chr7:1003750	NA	0.44	9.94	0.37	9.66e-22	Longevity;Endometriosis;
BRCA	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg24562669	chr7:97807699	LMTK2	0.46	12.4	0.44	8.74e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg20607798	chr8:58055168	NA	0.56	8.74	0.33	2.1e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs877282	0.838	rs34778553	chr10:796865	T/C	cg17470449	chr10:769945	NA	0.51	8.76	0.33	1.76e-17	Uric acid levels;
BRCA	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg03433033	chr1:76189801	ACADM	-0.76	-17.09	-0.56	3.47e-54	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-11.57	-0.42	3.02e-28	Gut microbiome composition (summer);
BRCA	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg15691649	chr6:25882328	NA	-0.56	-10.46	-0.38	9.7e-24	Urate levels;
BRCA	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg25801113	chr15:45476975	SHF	-0.33	-8.05	-0.3	3.99e-15	Uric acid levels;
BRCA	cis	rs698833	0.518	rs2033951	chr2:44556298	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	9.0	0.34	2.5e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs2882667	0.628	rs10076629	chr5:138255961	G/C	cg04439458	chr5:138467593	SIL1	-0.35	-8.54	-0.32	9.46e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.66	-9.58	-0.35	2.1e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.57	0.32	7.83e-17	Cognitive ability;
BRCA	cis	rs9942416	0.660	rs2047059	chr5:75008193	T/C	cg19683494	chr5:74908142	NA	0.43	8.37	0.31	3.6e-16	Age-related disease endophenotypes;
BRCA	trans	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs7131987	0.650	rs7957339	chr12:29456495	T/C	cg09582351	chr12:29534625	ERGIC2	-0.43	-9.93	-0.37	1.07e-21	QT interval;
BRCA	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg11663144	chr21:46675770	NA	0.55	12.98	0.46	2.4e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7590720	1.000	rs6755934	chr2:216907198	C/A	cg12620499	chr2:216877984	MREG	0.78	21.41	0.65	4.36e-77	Alcohol dependence;
BRCA	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg09537434	chr19:41945824	ATP5SL	-0.99	-23.39	-0.68	7.13e-88	Height;
BRCA	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18876405	chr7:65276391	NA	0.55	13.15	0.46	3.95e-35	Aortic root size;
BRCA	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg00504896	chr12:9437009	LOC642846	-0.37	-7.96	-0.3	7.96e-15	Breast size;
BRCA	cis	rs9811920	0.809	rs793437	chr3:99559854	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.53	-12.6	-0.45	1.1e-32	Axial length;
BRCA	trans	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg06521331	chr12:34319734	NA	-0.47	-8.62	-0.32	5.41e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-16.25	-0.54	5.74e-50	Total cholesterol levels;
BRCA	cis	rs11229555	1.000	rs11229545	chr11:58386650	A/G	cg15696309	chr11:58395628	NA	-0.53	-11.58	-0.42	2.85e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18876405	chr7:65276391	NA	-0.51	-11.59	-0.42	2.49e-28	Aortic root size;
BRCA	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg22491629	chr6:157744540	C6orf35	-0.67	-12.37	-0.44	1.15e-31	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg12373951	chr3:133503437	NA	-0.5	-11.57	-0.42	3.09e-28	Iron status biomarkers;
BRCA	trans	rs4596713	0.507	rs2309424	chr9:71806370	A/G	cg16512924	chr15:28394682	HERC2	0.44	10.41	0.38	1.49e-23	Headache;
BRCA	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg07636037	chr3:49044803	WDR6	0.88	23.95	0.69	5.82e-91	Parkinson's disease;
BRCA	trans	rs3857536	0.740	rs6455080	chr6:66887413	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.49	-9.77	-0.36	4.07e-21	Blood trace element (Cu levels);
BRCA	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	11.1	0.4	2.68e-26	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.49e-34	Alzheimer's disease (late onset);
BRCA	cis	rs12579753	0.917	rs6539580	chr12:82184765	T/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-8.37	-0.31	3.52e-16	Resting heart rate;
BRCA	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg24642439	chr20:33292090	TP53INP2	0.61	13.3	0.47	8.37e-36	Coronary artery disease;
BRCA	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg26384229	chr12:38710491	ALG10B	0.68	14.05	0.49	2.73e-39	Morning vs. evening chronotype;
BRCA	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg15556689	chr8:8085844	FLJ10661	0.47	13.08	0.46	8.11e-35	Mood instability;
BRCA	cis	rs5753037	0.543	rs140126	chr22:30147038	A/G	cg01021169	chr22:30184971	ASCC2	-0.4	-9.6	-0.35	1.84e-20	Type 1 diabetes;
BRCA	cis	rs868036	1.000	rs4776377	chr15:68103387	T/C	cg08079166	chr15:68083412	MAP2K5	0.35	9.46	0.35	5.8e-20	Restless legs syndrome;
BRCA	trans	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.36	7.95	0.3	8.19e-15	Endometrial cancer;
BRCA	cis	rs13095912	0.638	rs6791369	chr3:185289989	C/A	cg11274856	chr3:185301563	NA	0.54	12.83	0.45	1.1e-33	Systolic blood pressure;
BRCA	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.6	0.39	2.83e-24	Motion sickness;
BRCA	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	9.02	0.34	2.13e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs36051895	0.659	rs62541538	chr9:5038164	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-9.17	-0.34	6.66e-19	Pediatric autoimmune diseases;
BRCA	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg04455712	chr21:45112962	RRP1B	-0.37	-9.87	-0.36	1.76e-21	Mean corpuscular volume;
BRCA	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	11.32	0.41	3.25e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg09307838	chr4:120376055	NA	-0.61	-11.68	-0.42	1.02e-28	Corneal astigmatism;
BRCA	cis	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05901451	chr6:126070800	HEY2	0.45	11.14	0.4	1.79e-26	Endometrial cancer;
BRCA	cis	rs2652834	0.821	rs7174174	chr15:63372327	A/G	cg05507819	chr15:63340323	TPM1	-0.43	-8.62	-0.32	5.4e-17	HDL cholesterol;
BRCA	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg06784218	chr1:46089804	CCDC17	0.45	10.76	0.39	6.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg20701182	chr2:24300061	SF3B14	0.62	8.86	0.33	8.1e-18	Lymphocyte counts;
BRCA	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg07403899	chr19:39283540	NA	-0.32	-11.01	-0.4	6.1e-26	Heart rate;
BRCA	cis	rs6546550	0.867	rs7592647	chr2:70139134	C/T	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.46	-0.41	8.89e-28	Prevalent atrial fibrillation;
BRCA	cis	rs11229555	0.574	rs12272096	chr11:58186118	A/G	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg21770322	chr7:97807741	LMTK2	0.41	10.69	0.39	1.16e-24	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.7	-0.36	7.54e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.29	0.49	2.24e-40	Colorectal cancer;
BRCA	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg09163369	chr1:210001066	C1orf107	-0.58	-10.18	-0.37	1.19e-22	Orofacial clefts;
BRCA	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.62	0.39	2.18e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg05340658	chr4:99064831	C4orf37	0.68	17.25	0.56	4.98e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9463078	0.547	rs4711798	chr6:44750777	A/G	cg25276700	chr6:44698697	NA	-0.35	-7.85	-0.3	1.73e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.7	-0.39	1.12e-24	Tonsillectomy;
BRCA	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.1e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg09307838	chr4:120376055	NA	0.73	15.87	0.53	4.5e-48	Corneal astigmatism;
BRCA	cis	rs13046373	0.535	rs13051529	chr21:32029743	G/C	cg16431978	chr21:31797932	KRTAP13-3	0.35	8.59	0.32	6.47e-17	HDL cholesterol;
BRCA	cis	rs1113500	0.836	rs1618973	chr1:108586767	T/C	cg06207961	chr1:108661230	NA	-0.41	-9.78	-0.36	3.87e-21	Growth-regulated protein alpha levels;
BRCA	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg23711669	chr6:146136114	FBXO30	0.64	14.92	0.51	2e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg21747090	chr2:27597821	SNX17	-0.43	-9.22	-0.34	4.27e-19	Total body bone mineral density;
BRCA	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg03929089	chr4:120376271	NA	-0.42	-7.85	-0.3	1.74e-14	Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg15556689	chr8:8085844	FLJ10661	0.37	8.52	0.32	1.13e-16	Retinal vascular caliber;
BRCA	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg17971929	chr21:40555470	PSMG1	0.78	18.36	0.59	8.61e-61	Cognitive function;
BRCA	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg11663144	chr21:46675770	NA	-0.57	-13.57	-0.47	5e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs10411161	0.702	rs7250138	chr19:52385232	G/C	cg22319618	chr22:45562946	NUP50	-0.41	-7.86	-0.3	1.62e-14	Breast cancer;
BRCA	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.52	8.37	0.31	3.53e-16	Renal function-related traits (BUN);
BRCA	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg17788362	chr6:86352627	SYNCRIP	0.44	8.6	0.32	6.08e-17	Smooth-surface caries;
BRCA	cis	rs10754283	0.934	rs6661282	chr1:90119992	C/T	cg21401794	chr1:90099060	LRRC8C	0.49	11.67	0.42	1.15e-28	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg09307838	chr4:120376055	NA	0.72	15.24	0.52	5.6e-45	Corneal astigmatism;
BRCA	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg24296786	chr1:45957014	TESK2	0.62	15.39	0.52	1.12e-45	High light scatter reticulocyte count;
BRCA	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg17971929	chr21:40555470	PSMG1	-0.49	-10.98	-0.4	8.4e-26	Menarche (age at onset);
BRCA	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg09877947	chr5:131593287	PDLIM4	0.39	10.05	0.37	3.72e-22	Breast cancer;
BRCA	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg03354898	chr7:1950403	MAD1L1	-0.45	-8.65	-0.32	4.06e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs1018836	0.739	rs4734247	chr8:91569144	A/G	cg16814680	chr8:91681699	NA	-0.57	-12.34	-0.44	1.54e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9400271	0.527	rs11759269	chr6:109640488	C/T	cg01475377	chr6:109611718	NA	-0.36	-8.15	-0.31	1.91e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	trans	rs7980799	0.682	rs1601005	chr12:33634658	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-10.46	-0.38	9.36e-24	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg00106254	chr7:1943704	MAD1L1	-0.31	-8.21	-0.31	1.19e-15	Schizophrenia;
BRCA	cis	rs7512552	0.839	rs834229	chr1:150384665	G/C	cg15654264	chr1:150340011	RPRD2	0.43	9.21	0.34	4.75e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg07636037	chr3:49044803	WDR6	0.7	14.87	0.51	3.64e-43	Menarche (age at onset);
BRCA	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	14.09	0.49	1.82e-39	Alzheimer's disease;
BRCA	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg09654669	chr8:57350985	NA	-0.39	-8.59	-0.32	6.42e-17	Obesity-related traits;
BRCA	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg27588902	chr6:42928151	GNMT	-0.31	-10.37	-0.38	2.22e-23	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg00814883	chr7:100076585	TSC22D4	-0.47	-10.57	-0.39	3.41e-24	Platelet count;
BRCA	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg13010199	chr12:38710504	ALG10B	0.5	10.43	0.38	1.31e-23	Bladder cancer;
BRCA	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg07549590	chr16:15018862	NA	-0.36	-8.93	-0.33	4.4e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.52	11.59	0.42	2.52e-28	Multiple sclerosis;
BRCA	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.28	0.31	7.05e-16	Aortic root size;
BRCA	cis	rs7178424	1.000	rs12594658	chr15:62305090	A/G	cg00456672	chr15:62358751	C2CD4A	-0.39	-8.79	-0.33	1.41e-17	Height;
BRCA	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg14784868	chr12:69753453	YEATS4	0.79	25.23	0.71	5.18e-98	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	15.7	0.53	3.05e-47	Mood instability;
BRCA	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.52	10.96	0.4	1.02e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.8	-0.36	3.32e-21	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs55986470	0.670	rs56313033	chr2:239346202	C/T	cg01134436	chr17:81009848	B3GNTL1	0.77	9.84	0.36	2.29e-21	Chronotype;
BRCA	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-14.79	-0.51	8.48e-43	Personality dimensions;
BRCA	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg03060546	chr3:49711283	APEH	-0.6	-10.41	-0.38	1.47e-23	Menarche (age at onset);
BRCA	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg02751453	chr18:77725136	HSBP1L1	0.38	9.2	0.34	4.99e-19	Opioid sensitivity;
BRCA	cis	rs12986413	0.967	rs2108524	chr19:2170764	A/G	cg09261902	chr19:2140048	AP3D1	0.37	9.76	0.36	4.41e-21	Height;
BRCA	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg24642844	chr7:1081250	C7orf50	-0.69	-13.09	-0.46	7.38e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs312273	0.582	rs312268	chr12:41250534	C/A	cg17827154	chr12:41323612	CNTN1	-0.34	-7.89	-0.3	1.34e-14	Bipolar disorder;
BRCA	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg15704280	chr7:45808275	SEPT13	-0.54	-10.77	-0.39	5.61e-25	HDL cholesterol;
BRCA	cis	rs9341808	0.690	rs2322634	chr6:80874014	A/C	cg08355045	chr6:80787529	NA	0.37	9.25	0.34	3.25e-19	Sitting height ratio;
BRCA	cis	rs870825	0.616	rs7681824	chr4:185617525	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	16.71	0.55	2.8e-52	Blood protein levels;
BRCA	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg15704280	chr7:45808275	SEPT13	-0.49	-9.64	-0.36	1.29e-20	HDL cholesterol;
BRCA	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg03146154	chr1:46216737	IPP	-0.43	-9.13	-0.34	8.71e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg16586182	chr3:47516702	SCAP	-0.64	-15.01	-0.51	7.9e-44	Colorectal cancer;
BRCA	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg10932868	chr11:921992	NA	0.47	12.11	0.43	1.62e-30	Alzheimer's disease (late onset);
BRCA	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.08	-21.82	-0.65	2.51e-79	Platelet count;
BRCA	cis	rs56399783	0.901	rs56356906	chr7:2774383	G/A	cg23627948	chr7:2760692	NA	0.51	8.23	0.31	1.03e-15	Childhood ear infection;
BRCA	trans	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg25214090	chr10:38739885	LOC399744	0.45	10.32	0.38	3.46e-23	Corneal astigmatism;
BRCA	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg05519781	chr21:40033154	ERG	0.45	9.59	0.35	1.8899999999999998e-20	Coronary artery disease;
BRCA	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg03146154	chr1:46216737	IPP	-0.34	-8.01	-0.3	5.34e-15	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg24881330	chr22:46731750	TRMU	0.42	7.87	0.3	1.51e-14	LDL cholesterol;Cholesterol, total;
BRCA	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.2e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.45	-9.08	-0.34	1.35e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	11.77	0.42	4.61e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg24642439	chr20:33292090	TP53INP2	0.43	9.35	0.35	1.45e-19	Height;
BRCA	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg08805041	chr16:621841	PIGQ	-0.31	-8.32	-0.31	5.26e-16	Height;
BRCA	cis	rs1506636	1.000	rs2215554	chr7:123347063	A/C	cg03229431	chr7:123269106	ASB15	-0.59	-13.13	-0.46	4.7e-35	Plateletcrit;Platelet count;
BRCA	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg22972055	chr7:872293	UNC84A	0.39	8.68	0.32	3.38e-17	Cerebrospinal P-tau181p levels;
BRCA	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.12	-0.31	2.49e-15	Depression;
BRCA	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	19.13	0.6	8.2e-65	Platelet count;
BRCA	cis	rs2836633	0.929	rs62217519	chr21:40034390	G/A	cg05519781	chr21:40033154	ERG	0.45	9.57	0.35	2.34e-20	Coronary artery disease;
BRCA	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg20946044	chr11:1010712	AP2A2	-0.37	-7.87	-0.3	1.58e-14	Alzheimer's disease (late onset);
BRCA	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg19052272	chr2:3704530	ALLC	-0.45	-10.09	-0.37	2.64e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03452623	chr4:187889614	NA	0.35	11.6	0.42	2.21e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4074536	0.574	rs7518735	chr1:116287982	G/C	cg21648376	chr1:116311395	CASQ2	-0.49	-8.67	-0.32	3.44e-17	QRS duration;
BRCA	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-9.4	-0.35	9.47e-20	Menopause (age at onset);
BRCA	trans	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg21659725	chr3:3221576	CRBN	-0.49	-8.5	-0.32	1.31e-16	Menarche (age at onset);
BRCA	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26314531	chr2:26401878	FAM59B	0.88	15.31	0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs243505	1.000	rs243507	chr7:148434600	G/A	cg09806900	chr7:148480153	CUL1	-0.44	-8.87	-0.33	7.47e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg06521331	chr12:34319734	NA	-0.46	-8.48	-0.32	1.58e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs11249608	0.548	rs6875473	chr5:178451387	C/A	cg21905437	chr5:178450457	ZNF879	0.54	11.31	0.41	3.58e-27	Pubertal anthropometrics;
BRCA	cis	rs6723226	0.803	rs176415	chr2:32649778	G/A	cg02381751	chr2:32503542	YIPF4	-0.72	-16.01	-0.53	9.72e-49	Intelligence (multi-trait analysis);
BRCA	trans	rs2797160	1.000	rs77678056	chr6:126019738	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.85	0.3	1.75e-14	Endometrial cancer;
BRCA	trans	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg23762105	chr12:34175262	ALG10	-0.39	-9.6	-0.36	1.75e-20	Morning vs. evening chronotype;
BRCA	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg13010199	chr12:38710504	ALG10B	0.44	8.95	0.33	3.88e-18	Bladder cancer;
BRCA	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.49	-0.44	3.43e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg10223061	chr2:219282414	VIL1	0.3	8.79	0.33	1.37e-17	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs12541635	0.677	rs2029879	chr8:107024695	T/A	cg10147462	chr8:107024639	NA	0.4	10.98	0.4	7.87e-26	Age of smoking initiation;
BRCA	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	11.37	0.41	2.09e-27	Personality dimensions;
BRCA	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-13.66	-0.48	1.81e-37	Hemoglobin concentration;
BRCA	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.52	-11.86	-0.42	1.81e-29	Longevity;Endometriosis;
BRCA	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.25	-0.41	6.69e-27	Schizophrenia;
BRCA	cis	rs7524258	0.903	rs763197	chr1:7289959	A/G	cg07173049	chr1:7289937	CAMTA1	0.55	13.42	0.47	2.47e-36	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs9469578	0.901	rs16869459	chr6:33714908	G/A	cg18708504	chr6:33715942	IP6K3	0.7	10.2	0.37	9.54e-23	Phosphorus levels;
BRCA	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg07169764	chr2:136633963	MCM6	1.22	25.69	0.71	1.7e-100	Corneal structure;
BRCA	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	9.22	0.34	4.11e-19	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg27535305	chr1:53392650	SCP2	-0.49	-12.3	-0.44	2.25e-31	Monocyte count;
BRCA	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg22508957	chr16:3507546	NAT15	0.66	11.45	0.41	9.26e-28	Tuberculosis;
BRCA	cis	rs7072216	0.763	rs12259939	chr10:100169021	T/C	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.61	-0.36	1.62e-20	Metabolite levels;
BRCA	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg04455712	chr21:45112962	RRP1B	0.4	10.7	0.39	1.1e-24	Mean corpuscular volume;
BRCA	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg21747090	chr2:27597821	SNX17	-0.41	-8.98	-0.33	3.08e-18	Total body bone mineral density;
BRCA	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg06238570	chr21:40685208	BRWD1	-0.4	-8.03	-0.3	4.86e-15	Menarche (age at onset);
BRCA	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg02176678	chr2:219576539	TTLL4	0.41	10.82	0.39	3.46e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg16606324	chr3:10149918	C3orf24	0.48	9.47	0.35	5.5e-20	Alzheimer's disease;
BRCA	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	19.97	0.62	2.72e-69	Smoking behavior;
BRCA	trans	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg26043149	chr18:55253948	FECH	0.4	8.64	0.32	4.54e-17	Bone mineral density;
BRCA	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg03146154	chr1:46216737	IPP	0.46	10.24	0.38	7.01e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg01689657	chr7:91764605	CYP51A1	0.24	8.71	0.33	2.53e-17	Breast cancer;
BRCA	cis	rs11734570	0.581	rs73811715	chr4:38590569	A/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.52	9.7	0.36	7.44e-21	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg21475434	chr5:93447410	FAM172A	0.67	8.84	0.33	9.32e-18	Diabetic retinopathy;
BRCA	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11890956	chr21:40555474	PSMG1	-0.82	-19.2	-0.6	3.23e-65	Cognitive function;
BRCA	cis	rs929596	0.556	rs35984508	chr2:234587852	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.35	-8.94	-0.33	4.02e-18	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs7523273	0.526	rs2745980	chr1:208018367	A/C	cg22525895	chr1:207977042	MIR29B2	0.47	12.15	0.43	1.1e-30	Schizophrenia;
BRCA	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.36	12.3	0.44	2.26e-31	Bipolar disorder;
BRCA	cis	rs9473147	0.543	rs4715025	chr6:47483653	C/G	cg12968598	chr6:47444699	CD2AP	0.46	9.86	0.36	1.85e-21	Platelet distribution width;Mean platelet volume;
BRCA	trans	rs3857536	0.776	rs7765531	chr6:66932886	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.11	-0.31	2.53e-15	Blood trace element (Cu levels);
BRCA	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg14061069	chr19:46274453	DMPK	0.66	18.72	0.6	1.09e-62	Coronary artery disease;
BRCA	cis	rs9473147	0.516	rs4715018	chr6:47441871	T/C	cg12968598	chr6:47444699	CD2AP	0.45	9.37	0.35	1.24e-19	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs6120849	0.707	rs6120799	chr20:33614955	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	10.29	0.38	4.57e-23	Protein C levels;
BRCA	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-9.47	-0.35	5.29e-20	Menopause (age at onset);
BRCA	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg15704280	chr7:45808275	SEPT13	0.65	11.36	0.41	2.3e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg24829409	chr8:58192753	C8orf71	-0.49	-7.96	-0.3	7.93e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs11605275	0.892	rs16937352	chr11:20032010	G/C	cg14835545	chr11:20032148	NAV2	-0.59	-9.36	-0.35	1.28e-19	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs6484504	0.600	rs972714	chr11:31358875	T/G	cg06552810	chr11:31128660	NA	0.39	8.58	0.32	7.02e-17	Red blood cell count;
BRCA	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg21138405	chr5:131827807	IRF1	0.39	11.87	0.43	1.66e-29	Asthma (sex interaction);
BRCA	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg16049864	chr8:95962084	TP53INP1	-0.44	-10.77	-0.39	5.57e-25	Type 2 diabetes;
BRCA	cis	rs10037055	1.000	rs10037055	chr5:176691279	G/T	cg06733329	chr5:176740039	MXD3	0.42	9.84	0.36	2.33e-21	Migraine without aura;
BRCA	cis	rs796364	0.616	rs1523818	chr2:200684704	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	8.34	0.31	4.51e-16	Schizophrenia;
BRCA	cis	rs4891159	0.790	rs4891018	chr18:74127082	A/T	cg24786174	chr18:74118243	ZNF516	-0.75	-18.95	-0.6	6.95e-64	Longevity;
BRCA	trans	rs877282	0.945	rs11253398	chr10:790012	T/C	cg22713356	chr15:30763199	NA	1.42	28.55	0.75	3.22e-116	Uric acid levels;
BRCA	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg25173405	chr17:45401733	C17orf57	0.51	10.65	0.39	1.66e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg01579765	chr21:45077557	HSF2BP	0.34	8.61	0.32	5.53e-17	Mean corpuscular volume;
BRCA	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg01420254	chr6:26195488	NA	0.54	8.51	0.32	1.24e-16	Gout;Renal underexcretion gout;
BRCA	cis	rs9359856	0.564	rs10484885	chr6:90395016	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.67	-8.56	-0.32	8.24e-17	Bipolar disorder;
BRCA	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	13.93	0.48	1.01e-38	Lymphocyte counts;
BRCA	cis	rs13095912	0.785	rs35637544	chr3:185329958	A/G	cg11274856	chr3:185301563	NA	0.54	13.14	0.46	4.56e-35	Systolic blood pressure;
BRCA	trans	rs3858145	0.588	rs4142048	chr10:70044031	T/C	cg04882175	chr6:131122610	NA	-0.34	-7.86	-0.3	1.65e-14	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
BRCA	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg08079166	chr15:68083412	MAP2K5	-0.34	-8.94	-0.33	4.17e-18	Restless legs syndrome;
BRCA	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12826209	chr6:26865740	GUSBL1	0.59	10.45	0.38	1.08e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg26384229	chr12:38710491	ALG10B	0.76	17.01	0.56	8.73e-54	Morning vs. evening chronotype;
BRCA	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg06623918	chr6:96969491	KIAA0776	0.9	25.83	0.71	2.76e-101	Headache;
BRCA	cis	rs7727544	0.570	rs7701237	chr5:131534381	C/T	cg14196790	chr5:131705035	SLC22A5	0.37	9.16	0.34	6.86e-19	Blood metabolite levels;
BRCA	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg10523679	chr1:76189770	ACADM	-0.62	-11.83	-0.42	2.38e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg14061069	chr19:46274453	DMPK	-0.48	-11.84	-0.42	2.32e-29	Coronary artery disease;
BRCA	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1865721	0.771	rs727893	chr18:73136931	G/A	cg26385618	chr18:73139727	C18orf62	-0.43	-10.51	-0.38	5.85e-24	Intelligence;
BRCA	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg09035930	chr12:129282057	SLC15A4	0.47	11.98	0.43	5.41e-30	Systemic lupus erythematosus;
BRCA	cis	rs7246657	0.722	rs11083432	chr19:38182633	A/G	cg18154014	chr19:37997991	ZNF793	-0.45	-8.77	-0.33	1.65e-17	Coronary artery calcification;
BRCA	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-7.96	-0.3	8.09e-15	Response to antipsychotic treatment;
BRCA	cis	rs35740288	0.929	rs11630585	chr15:86306004	C/A	cg20737812	chr15:86336631	KLHL25	-0.33	-8.0	-0.3	6e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg24562669	chr7:97807699	LMTK2	0.44	11.76	0.42	4.77e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg21252483	chr19:49399788	TULP2	-0.42	-9.36	-0.35	1.3e-19	Red cell distribution width;
BRCA	cis	rs701145	0.878	rs187357	chr3:153958876	C/A	cg17054900	chr3:154042577	DHX36	0.67	11.71	0.42	8.15e-29	Coronary artery disease;
BRCA	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.03	-0.3	4.72e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg07460842	chr6:66804631	NA	0.88	14.15	0.49	1.01e-39	Exhaled nitric oxide output;
BRCA	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.82	-0.62	1.74e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg23625390	chr15:77176239	SCAPER	-0.53	-13.09	-0.46	7.77e-35	Blood metabolite levels;
BRCA	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg09824328	chr1:43425412	SLC2A1	-0.52	-8.47	-0.32	1.72e-16	Monocyte count;
BRCA	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.82	0.3	2.22e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.57	9.76	0.36	4.64e-21	Renal function-related traits (BUN);
BRCA	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11764359	chr7:65958608	NA	0.8	19.31	0.61	8.47e-66	Aortic root size;
BRCA	trans	rs7395662	0.782	rs4882064	chr11:48455757	C/T	cg00717180	chr2:96193071	NA	0.28	7.84	0.3	1.84e-14	HDL cholesterol;
BRCA	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	8.31	0.31	5.87e-16	Axial length;
BRCA	cis	rs17428076	0.514	rs3821095	chr2:172684006	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.52	-13.2	-0.46	2.28e-35	Myopia;
BRCA	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg05793240	chr7:2802953	GNA12	-0.31	-8.32	-0.31	5.48e-16	Height;
BRCA	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg22907277	chr7:1156413	C7orf50	0.65	12.49	0.44	3.59e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs68170813	0.559	rs17428126	chr7:106897037	C/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.6	-0.32	6.15e-17	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.85	0.33	8.53e-18	Motion sickness;
BRCA	cis	rs250677	0.524	rs183140	chr5:148438803	G/T	cg18129178	chr5:148520854	ABLIM3	-0.46	-9.76	-0.36	4.55e-21	Breast cancer;
BRCA	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg12927641	chr6:109611667	NA	-0.37	-8.98	-0.33	2.89e-18	Reticulocyte fraction of red cells;
BRCA	trans	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.37	-8.33	-0.31	4.81e-16	Endometrial cancer;
BRCA	cis	rs17095355	0.818	rs61881638	chr10:111863396	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.43	-9.13	-0.34	8.62e-19	Biliary atresia;
BRCA	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg12193833	chr17:30244370	NA	-0.54	-8.72	-0.33	2.47e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	17.4	0.57	8.6e-56	Electrocardiographic conduction measures;
BRCA	cis	rs72627123	0.867	rs17093884	chr14:74482039	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.68	8.1	0.31	2.87e-15	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg23711669	chr6:146136114	FBXO30	0.79	19.31	0.61	8.9e-66	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg13010199	chr12:38710504	ALG10B	0.48	9.08	0.34	1.39e-18	Morning vs. evening chronotype;
BRCA	cis	rs36051895	0.695	rs11794778	chr9:5023794	G/T	cg02405213	chr9:5042618	JAK2	-0.5	-8.78	-0.33	1.45e-17	Pediatric autoimmune diseases;
BRCA	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00149659	chr3:10157352	C3orf10	0.75	12.66	0.45	6.36e-33	Alzheimer's disease;
BRCA	cis	rs28830936	0.966	rs1918310	chr15:42065253	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.34	-9.71	-0.36	6.97e-21	Diastolic blood pressure;
BRCA	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg23587288	chr2:27483067	SLC30A3	-0.38	-8.96	-0.33	3.44e-18	Blood metabolite levels;
BRCA	cis	rs6545883	0.929	rs12612982	chr2:61747355	G/A	cg15711740	chr2:61764176	XPO1	-0.54	-13.82	-0.48	3.34e-38	Tuberculosis;
BRCA	trans	rs57046232	0.552	rs1887412	chr20:6340856	A/G	cg21095983	chr6:86352623	SYNCRIP	0.38	7.97	0.3	7.18e-15	Colorectal cancer;
BRCA	cis	rs2652834	1.000	rs2652838	chr15:63396088	A/G	cg05507819	chr15:63340323	TPM1	0.45	8.39	0.32	3.12e-16	HDL cholesterol;
BRCA	cis	rs4478858	0.735	rs11576621	chr1:31795460	A/G	cg00250761	chr1:31883323	NA	-0.32	-8.51	-0.32	1.2e-16	Alcohol dependence;
BRCA	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg04013093	chr6:42928303	GNMT	-0.28	-8.82	-0.33	1.07e-17	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg20790798	chr5:1857306	NA	-0.38	-8.88	-0.33	6.48e-18	Cardiovascular disease risk factors;
BRCA	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg09307838	chr4:120376055	NA	0.74	16.18	0.54	1.34e-49	Corneal astigmatism;
BRCA	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg11502198	chr6:26597334	ABT1	0.66	10.74	0.39	7.63e-25	Small cell lung carcinoma;
BRCA	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11890956	chr21:40555474	PSMG1	-1.06	-31.65	-0.78	5.61e-133	Cognitive function;
BRCA	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg08999081	chr20:33150536	PIGU	-0.33	-8.71	-0.33	2.57e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg17135325	chr3:160939158	NMD3	0.45	8.58	0.32	7.26e-17	Parkinson's disease;
BRCA	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg01475377	chr6:109611718	NA	-0.59	-16.55	-0.55	1.79e-51	Reticulocyte fraction of red cells;
BRCA	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg21433313	chr16:3507492	NAT15	0.45	9.98	0.37	6.9e-22	Tuberculosis;
BRCA	cis	rs2386661	0.547	rs72781996	chr10:5646485	C/G	cg17085576	chr10:5658249	NA	-0.33	-8.25	-0.31	9.17e-16	Breast cancer;
BRCA	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.98	0.3	6.92e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-9.58	-0.35	2.15e-20	Chronic sinus infection;
BRCA	trans	rs1459104	1.000	rs35218816	chr11:55087104	C/A	cg03929089	chr4:120376271	NA	0.65	7.9	0.3	1.25e-14	Body mass index;
BRCA	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	16.22	0.54	8.5e-50	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11890956	chr21:40555474	PSMG1	1.07	32.4	0.79	5.59e-137	Cognitive function;
BRCA	trans	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg25482853	chr8:67687455	SGK3	0.78	13.07	0.46	8.85e-35	Obesity-related traits;
BRCA	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg17127132	chr2:85788382	GGCX	0.35	8.0	0.3	5.72e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	trans	rs6479891	1.000	rs10995506	chr10:65094466	A/G	cg14819942	chr15:35414228	NA	-0.34	-8.48	-0.32	1.54e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg06623918	chr6:96969491	KIAA0776	0.89	25.59	0.71	6.04e-100	Headache;
BRCA	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg24846343	chr22:24311635	DDTL	0.4	9.71	0.36	7.2e-21	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg04978709	chr7:75101039	POM121C	-0.35	-9.17	-0.34	6.38e-19	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg08917208	chr2:24149416	ATAD2B	0.55	8.37	0.31	3.64e-16	Lymphocyte counts;
BRCA	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg09469691	chr10:81107165	PPIF	0.51	11.08	0.4	3.27e-26	Height;
BRCA	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg06808227	chr14:105710500	BRF1	-0.75	-15.52	-0.52	2.61e-46	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg21775007	chr8:11205619	TDH	-0.39	-7.95	-0.3	8.36e-15	Neuroticism;
BRCA	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	19.95	0.62	3.19e-69	Smoking behavior;
BRCA	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03264133	chr6:25882463	NA	-0.48	-10.85	-0.39	2.68e-25	Blood metabolite levels;
BRCA	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.09	0.49	1.91e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg08917208	chr2:24149416	ATAD2B	0.56	8.61	0.32	5.89e-17	Lymphocyte counts;
BRCA	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg03585969	chr10:35415529	CREM	0.49	10.36	0.38	2.31e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2115536	1.000	rs2115536	chr15:80194247	C/T	cg00225070	chr15:80189496	MTHFS	0.4	9.41	0.35	8.55e-20	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
BRCA	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg02951883	chr7:2050386	MAD1L1	-0.61	-15.14	-0.51	1.71e-44	Bipolar disorder and schizophrenia;
BRCA	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg20701182	chr2:24300061	SF3B14	0.58	9.11	0.34	1.04e-18	Lymphocyte counts;
BRCA	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg15934090	chr1:100435551	SLC35A3	0.37	8.56	0.32	8.42e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg08807101	chr21:30365312	RNF160	-0.42	-8.9	-0.33	5.57e-18	Pancreatic cancer;
BRCA	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg09035930	chr12:129282057	SLC15A4	0.51	14.56	0.5	1.13e-41	Systemic lupus erythematosus;
BRCA	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.51	-0.52	2.66e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	8.18	0.31	1.56e-15	Monocyte percentage of white cells;
BRCA	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	8.1	0.31	2.71e-15	Uric acid levels;
BRCA	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg22920501	chr2:26401640	FAM59B	0.95	16.82	0.55	7.55e-53	Gut microbiome composition (summer);
BRCA	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-9.11	-0.34	1.06e-18	Alzheimer's disease;
BRCA	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.06	-25.8	-0.71	4.21e-101	Ulcerative colitis;
BRCA	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg22713356	chr15:30763199	NA	1.18	24.01	0.69	2.83e-91	Uric acid levels;
BRCA	cis	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg08601574	chr20:25228251	PYGB	0.34	8.08	0.3	3.14e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg21770322	chr7:97807741	LMTK2	0.64	19.15	0.6	5.86e-65	Breast cancer;
BRCA	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg22105103	chr4:187893119	NA	-0.4	-12.1	-0.43	1.64e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.19e-40	Motion sickness;
BRCA	cis	rs3849570	1.000	rs11711331	chr3:81819040	A/G	cg07356753	chr3:81810745	GBE1	0.46	11.16	0.4	1.52e-26	Waist circumference;Body mass index;
BRCA	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg13010199	chr12:38710504	ALG10B	0.41	8.34	0.31	4.59e-16	Morning vs. evening chronotype;
BRCA	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg08917208	chr2:24149416	ATAD2B	0.92	13.6	0.47	3.66e-37	Lymphocyte counts;
BRCA	trans	rs225245	0.817	rs225255	chr17:33955243	A/G	cg19694781	chr19:47549865	TMEM160	0.32	7.85	0.3	1.8e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg08888203	chr3:10149979	C3orf24	0.66	14.05	0.49	2.73e-39	Alzheimer's disease;
BRCA	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg09184832	chr6:79620586	NA	-0.54	-11.87	-0.43	1.65e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg11993925	chr19:44307056	LYPD5	0.45	10.42	0.38	1.42e-23	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg05714579	chr10:131428358	MGMT	0.59	14.4	0.49	6.55e-41	Response to temozolomide;
BRCA	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11644478	chr21:40555479	PSMG1	0.66	14.68	0.5	3.02e-42	Cognitive function;
BRCA	cis	rs4363385	0.747	rs4323653	chr1:152983359	T/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.9	-0.36	1.41e-21	Inflammatory skin disease;
BRCA	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg23442198	chr4:187126114	CYP4V2	-0.9	-11.23	-0.41	7.71e-27	Blood protein levels;
BRCA	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg18479299	chr3:125709523	NA	-0.54	-8.33	-0.31	4.84e-16	Blood pressure (smoking interaction);
BRCA	cis	rs55882075	0.730	rs10794700	chr5:179148335	C/G	cg14593053	chr5:179126677	CANX	0.48	12.75	0.45	2.51e-33	Monocyte percentage of white cells;
BRCA	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg25358565	chr5:93447407	FAM172A	1.21	18.37	0.59	7.73e-61	Diabetic retinopathy;
BRCA	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg21918786	chr6:109611834	NA	-0.43	-11.79	-0.42	3.56e-29	Reticulocyte fraction of red cells;
BRCA	cis	rs7903847	0.642	rs1537645	chr10:99149914	T/C	cg20016023	chr10:99160130	RRP12	-0.26	-8.55	-0.32	9.17e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg14582100	chr15:45693742	SPATA5L1	0.36	11.72	0.42	7.51e-29	Homoarginine levels;
BRCA	trans	rs9784649	0.760	rs72755820	chr5:25066181	G/A	cg08600765	chr20:34638493	LOC647979	-0.63	-10.54	-0.38	4.86e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs17253792	0.732	rs8017891	chr14:56172967	A/G	cg01858014	chr14:56050164	KTN1	0.56	9.0	0.34	2.55e-18	Putamen volume;
BRCA	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.95	-0.33	3.7e-18	Alzheimer's disease (late onset);
BRCA	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.5	-0.44	2.98e-32	Developmental language disorder (linguistic errors);
BRCA	trans	rs2262909	0.925	rs404822	chr19:22215967	A/C	cg17074339	chr11:11642133	GALNTL4	-0.41	-7.81	-0.3	2.39e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs858239	0.676	rs274032	chr7:23374559	C/G	cg23682824	chr7:23144976	KLHL7	0.36	8.69	0.33	3.02e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg12935359	chr14:103987150	CKB	-0.59	-14.22	-0.49	4.73e-40	Body mass index;
BRCA	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.38	9.14	0.34	8.42e-19	Eosinophil percentage of white cells;
BRCA	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg04025307	chr7:1156635	C7orf50	0.59	9.46	0.35	5.6e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg26587870	chr6:27730563	NA	-0.47	-8.25	-0.31	9.15e-16	Lung cancer in ever smokers;
BRCA	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg18230493	chr5:56204884	C5orf35	0.62	13.04	0.46	1.3e-34	Initial pursuit acceleration;
BRCA	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg23711669	chr6:146136114	FBXO30	0.63	14.65	0.5	4.22e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3815700	1.000	rs8101356	chr19:33093402	C/T	cg02997394	chr19:33096574	ANKRD27	0.69	11.52	0.41	4.75e-28	Eosinophilic esophagitis;
BRCA	trans	rs8073060	0.586	rs72829923	chr17:34045089	T/A	cg19694781	chr19:47549865	TMEM160	1.07	20.64	0.63	6.34e-73	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs7833986	0.501	rs2667978	chr8:56897951	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	11.03	0.4	5.18e-26	Height;
BRCA	cis	rs12545109	0.800	rs2576599	chr8:57388410	G/A	cg09654669	chr8:57350985	NA	-0.42	-8.16	-0.31	1.72e-15	Obesity-related traits;
BRCA	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg13319975	chr6:146136371	FBXO30	-0.4	-9.2	-0.34	5.12e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7737355	1.000	rs59808242	chr5:130754894	G/A	cg06307176	chr5:131281290	NA	-0.51	-9.97	-0.37	7.4e-22	Life satisfaction;
BRCA	cis	rs17641971	0.645	rs10504073	chr8:50024944	C/T	cg00325661	chr8:49890786	NA	0.36	10.1	0.37	2.28e-22	Blood metabolite levels;
BRCA	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg13334819	chr7:99746414	C7orf59	-0.41	-9.79	-0.36	3.38e-21	Coronary artery disease;
BRCA	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg04025307	chr7:1156635	C7orf50	0.46	9.19	0.34	5.44e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg01420254	chr6:26195488	NA	0.59	9.16	0.34	6.84e-19	Gout;Renal underexcretion gout;
BRCA	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-12.07	-0.43	2.24e-30	Response to antipsychotic treatment;
BRCA	cis	rs858239	0.601	rs2068459	chr7:23154313	A/C	cg23682824	chr7:23144976	KLHL7	0.4	10.42	0.38	1.42e-23	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs10267417	0.603	rs10267511	chr7:19896924	A/G	cg07541023	chr7:19748670	TWISTNB	0.46	8.31	0.31	5.72e-16	Night sleep phenotypes;
BRCA	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.39	-8.36	-0.31	4.07e-16	Longevity;Endometriosis;
BRCA	trans	rs1997103	1.000	rs4947499	chr7:55407196	T/C	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs250677	0.522	rs6580590	chr5:148360374	C/T	cg18129178	chr5:148520854	ABLIM3	0.54	10.41	0.38	1.57e-23	Breast cancer;
BRCA	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.07e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs9309473	0.632	rs6706179	chr2:73578577	C/T	cg20560298	chr2:73613845	ALMS1	-0.42	-10.87	-0.4	2.17e-25	Metabolite levels;
BRCA	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg13010199	chr12:38710504	ALG10B	0.35	8.6	0.32	6.06e-17	Morning vs. evening chronotype;
BRCA	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg10845886	chr2:3471009	TTC15	-0.47	-9.74	-0.36	5.17e-21	Neurofibrillary tangles;
BRCA	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg09307838	chr4:120376055	NA	0.72	15.37	0.52	1.35e-45	Corneal astigmatism;
BRCA	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg24642439	chr20:33292090	TP53INP2	0.52	11.43	0.41	1.2e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08048268	chr3:133502702	NA	-0.33	-8.24	-0.31	9.47e-16	Iron status biomarkers;
BRCA	trans	rs62103177	0.525	rs612913	chr18:77845882	A/G	cg05926928	chr17:57297772	GDPD1	-0.76	-10.8	-0.39	4.27e-25	Opioid sensitivity;
BRCA	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.32e-32	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg25214090	chr10:38739885	LOC399744	0.48	10.53	0.38	5e-24	Corneal astigmatism;
BRCA	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg06784218	chr1:46089804	CCDC17	-0.45	-10.63	-0.39	2e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11252926	0.897	rs7092330	chr10:583771	G/C	cg18196295	chr10:418757	DIP2C	-0.45	-9.88	-0.36	1.66e-21	Psychosis in Alzheimer's disease;
BRCA	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg11645453	chr3:52864694	ITIH4	0.3	7.85	0.3	1.8e-14	Body mass index;
BRCA	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg12863693	chr15:85201151	NMB	-0.4	-9.4	-0.35	9.82e-20	P wave terminal force;
BRCA	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg06618935	chr21:46677482	NA	-0.37	-8.17	-0.31	1.65e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg20790798	chr5:1857306	NA	-0.4	-9.27	-0.34	2.75e-19	Cardiovascular disease risk factors;
BRCA	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.87	-0.43	1.6e-29	Response to antipsychotic treatment;
BRCA	cis	rs6815814	0.904	rs7664239	chr4:38786304	T/C	cg06935464	chr4:38784597	TLR10	0.48	9.6	0.36	1.75e-20	Breast cancer;
BRCA	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.01	-0.3	5.54e-15	Retinal vascular caliber;
BRCA	cis	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg21775007	chr8:11205619	TDH	-0.51	-10.01	-0.37	5.14e-22	Triglycerides;
BRCA	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg16339924	chr4:17578868	LAP3	0.6	14.74	0.5	1.48e-42	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9341808	0.714	rs9448911	chr6:80913859	A/G	cg08355045	chr6:80787529	NA	0.32	8.04	0.3	4.2e-15	Sitting height ratio;
BRCA	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg00012203	chr2:219082015	ARPC2	-0.63	-13.62	-0.47	2.78e-37	Colorectal cancer;
BRCA	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg15704280	chr7:45808275	SEPT13	-0.47	-9.07	-0.34	1.43e-18	Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs12517041	1.000	rs1428621	chr5:23283431	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.32	-0.31	5.27e-16	Calcium levels;
BRCA	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg13010199	chr12:38710504	ALG10B	0.43	9.16	0.34	6.75e-19	Morning vs. evening chronotype;
BRCA	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg23625390	chr15:77176239	SCAPER	0.39	9.23	0.34	3.88e-19	Blood metabolite levels;
BRCA	cis	rs7119038	0.629	rs10892272	chr11:118602707	C/G	cg19308663	chr11:118741387	NA	0.33	8.28	0.31	7.45e-16	Sjögren's syndrome;
BRCA	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11644478	chr21:40555479	PSMG1	0.81	18.09	0.58	2.26e-59	Cognitive function;
BRCA	cis	rs4891159	0.505	rs680253	chr18:74167427	A/C	cg24786174	chr18:74118243	ZNF516	-0.74	-20.26	-0.63	7.38e-71	Longevity;
BRCA	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg18252515	chr7:66147081	NA	1.07	15.95	0.53	1.77e-48	Gout;
BRCA	cis	rs4690686	0.538	rs10520346	chr4:177259088	C/G	cg17059388	chr4:177262070	NA	0.49	9.9	0.36	1.33e-21	Essential tremor;
BRCA	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-8.0	-0.3	6.08e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg25358565	chr5:93447407	FAM172A	1.17	18.51	0.59	1.49e-61	Diabetic retinopathy;
BRCA	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	10.35	0.38	2.5e-23	Protein C levels;
BRCA	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.34	-0.38	2.72e-23	Schizophrenia;
BRCA	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg16950941	chr11:66035639	RAB1B	0.43	11.55	0.42	3.66e-28	Gout;
BRCA	cis	rs72634258	0.945	rs12748993	chr1:8129507	A/G	cg00042356	chr1:8021962	PARK7	0.73	11.71	0.42	8.12e-29	Inflammatory bowel disease;
BRCA	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg17971929	chr21:40555470	PSMG1	0.77	18.05	0.58	3.77e-59	Cognitive function;
BRCA	cis	rs4363385	0.818	rs409986	chr1:153014741	A/C	cg25856811	chr1:152973957	SPRR3	0.32	8.33	0.31	4.9e-16	Inflammatory skin disease;
BRCA	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg15017067	chr4:17643749	FAM184B	0.27	8.22	0.31	1.15e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg22713356	chr15:30763199	NA	1.31	24.8	0.7	1.26e-95	Uric acid levels;
BRCA	trans	rs11039798	0.920	rs116109043	chr11:48976940	C/T	cg15704280	chr7:45808275	SEPT13	0.6	8.93	0.33	4.6e-18	Axial length;
BRCA	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.79	19.16	0.6	5.3e-65	Multiple sclerosis;
BRCA	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg21699342	chr2:239360505	ASB1	0.47	11.16	0.4	1.58e-26	Multiple system atrophy;
BRCA	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.16	-0.34	6.74e-19	Total body bone mineral density;
BRCA	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.32	0.49	1.58e-40	Colorectal cancer;
BRCA	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg23018236	chr17:30244563	NA	-0.52	-9.47	-0.35	5.47e-20	Hip circumference adjusted for BMI;
BRCA	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg03342759	chr3:160939853	NMD3	-0.68	-15.72	-0.53	2.69e-47	Morning vs. evening chronotype;
BRCA	cis	rs11229555	0.609	rs7928676	chr11:58188022	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3784262	0.669	rs4646626	chr15:58256127	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.03	-0.37	4.51e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg04944784	chr2:26401820	FAM59B	-0.66	-11.26	-0.41	5.91e-27	Gut microbiome composition (summer);
BRCA	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg00383909	chr3:49044727	WDR6	0.77	13.03	0.46	1.34e-34	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg06784218	chr1:46089804	CCDC17	0.45	10.7	0.39	1.08e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg20701182	chr2:24300061	SF3B14	0.56	8.58	0.32	7.27e-17	Lymphocyte counts;
BRCA	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg22903471	chr2:27725779	GCKR	-0.36	-8.73	-0.33	2.29e-17	Total body bone mineral density;
BRCA	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg07988820	chr12:82153109	PPFIA2	-0.61	-9.86	-0.36	1.85e-21	Resting heart rate;
BRCA	trans	rs1997103	1.000	rs4947503	chr7:55409427	G/T	cg20935933	chr6:143382018	AIG1	0.61	11.73	0.42	6.24e-29	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg21143896	chr7:2802374	GNA12	-0.34	-8.32	-0.31	5.22e-16	Height;
BRCA	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.82	0.33	1.1e-17	Ovarian reserve;
BRCA	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.74	0.65	7.41e-79	Lymphocyte percentage of white cells;
BRCA	cis	rs1018836	0.798	rs28568272	chr8:91652958	A/G	cg16814680	chr8:91681699	NA	-0.74	-16.87	-0.56	4.29e-53	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4742903	0.967	rs10125661	chr9:106868443	A/G	cg14250997	chr9:106856677	SMC2	0.34	10.96	0.4	1e-25	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg20933634	chr6:27740509	NA	0.47	8.87	0.33	7.41e-18	Parkinson's disease;
BRCA	cis	rs2070433	0.556	rs8129460	chr21:47822544	C/T	cg12379764	chr21:47803548	PCNT	0.55	10.19	0.37	1.03e-22	Lymphocyte counts;
BRCA	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg24060327	chr5:131705240	SLC22A5	0.6	11.06	0.4	3.91e-26	Breast cancer;
BRCA	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg02556042	chr12:117471086	NA	-0.57	-10.02	-0.37	4.63e-22	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg24578937	chr1:2090814	PRKCZ	0.58	17.99	0.58	7.63e-59	Height;
BRCA	cis	rs6543140	0.964	rs11903551	chr2:103084181	C/G	cg04239558	chr2:103089729	SLC9A4	0.35	9.89	0.36	1.52e-21	Blood protein levels;
BRCA	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg03709012	chr19:19516395	GATAD2A	-0.8	-18.12	-0.58	1.59e-59	Tonsillectomy;
BRCA	cis	rs7714584	1.000	rs12652003	chr5:150231945	T/C	cg22134413	chr5:150180641	NA	0.69	10.38	0.38	1.94e-23	Crohn's disease;
BRCA	cis	rs17767294	0.708	rs72848752	chr6:27878268	A/C	cg08851530	chr6:28072375	NA	0.75	7.86	0.3	1.61e-14	Parkinson's disease;
BRCA	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.66	-12.92	-0.46	4.19e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4953076	0.574	rs4953074	chr2:44464629	C/T	cg04920474	chr2:44395004	PPM1B	0.54	11.56	0.42	3.46e-28	Height;
BRCA	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg09163369	chr1:210001066	C1orf107	-0.52	-9.64	-0.36	1.28e-20	Orofacial clefts;
BRCA	cis	rs7191700	1.000	rs7191700	chr16:11406803	C/T	cg00044050	chr16:11439710	C16orf75	0.39	8.12	0.31	2.39e-15	Multiple sclerosis;
BRCA	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg15790184	chr11:494944	RNH1	-0.66	-9.97	-0.37	7.58e-22	Body mass index;
BRCA	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.06	-0.34	1.53e-18	Total body bone mineral density;
BRCA	cis	rs6429082	0.967	rs834143	chr1:235626406	C/T	cg26050004	chr1:235667680	B3GALNT2	0.39	9.58	0.35	2.05e-20	Adiposity;
BRCA	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.42	9.54	0.35	3e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg27129171	chr3:47204927	SETD2	0.64	14.81	0.51	7.22e-43	Colorectal cancer;
BRCA	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	9.87	0.36	1.77e-21	Tonsillectomy;
BRCA	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.25	0.31	9.38e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg12011299	chr4:100065546	ADH4	0.42	10.5	0.38	6.88e-24	Alcohol dependence;
BRCA	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg13010199	chr12:38710504	ALG10B	0.51	10.07	0.37	2.99e-22	Bladder cancer;
BRCA	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg04317338	chr11:64019027	PLCB3	0.52	7.98	0.3	7.04e-15	Mean platelet volume;
BRCA	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg08601574	chr20:25228251	PYGB	0.34	8.15	0.31	1.86e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1003719	0.645	rs8131944	chr21:38547215	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.36	-0.49	1e-40	Eye color traits;
BRCA	cis	rs1595825	0.891	rs16867018	chr2:198521490	C/T	cg19156104	chr2:198669113	PLCL1	-0.42	-8.15	-0.31	1.91e-15	Ulcerative colitis;
BRCA	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.43	-8.76	-0.33	1.73e-17	Body mass index;
BRCA	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	8.76	0.33	1.71e-17	Personality dimensions;
BRCA	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg26384229	chr12:38710491	ALG10B	0.87	23.81	0.69	3.35e-90	Heart rate;
BRCA	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg04058563	chr4:185651563	MLF1IP	-0.35	-8.73	-0.33	2.17e-17	Kawasaki disease;
BRCA	cis	rs4253772	0.550	rs9615347	chr22:46728153	A/G	cg24881330	chr22:46731750	TRMU	0.7	8.0	0.3	5.91e-15	LDL cholesterol;Cholesterol, total;
BRCA	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg08859206	chr1:53392774	SCP2	0.42	8.31	0.31	5.65e-16	Monocyte count;
BRCA	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-23.08	-0.67	3.67e-86	Gut microbiome composition (summer);
BRCA	cis	rs312274	0.550	rs11178982	chr12:41301332	A/G	cg17827154	chr12:41323612	CNTN1	-0.41	-10.39	-0.38	1.73e-23	Metabolite levels  (X-11787);
BRCA	cis	rs2197308	0.549	rs10785517	chr12:38577992	G/T	cg26384229	chr12:38710491	ALG10B	0.42	9.94	0.37	1e-21	Morning vs. evening chronotype;
BRCA	cis	rs9473147	0.571	rs9463335	chr6:47479136	G/A	cg12968598	chr6:47444699	CD2AP	0.46	9.91	0.36	1.28e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg19678392	chr7:94953810	PON1	-0.42	-8.67	-0.32	3.47e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs4363385	0.693	rs576941	chr1:153040165	A/G	cg24667326	chr1:152973720	SPRR3	0.3	8.06	0.3	3.89e-15	Inflammatory skin disease;
BRCA	cis	rs925228	0.504	rs6755030	chr2:24318343	C/T	cg01493198	chr2:24299560	SF3B14	0.6	9.63	0.36	1.34e-20	Reticulocyte fraction of red cells;Reticulocyte count;
BRCA	cis	rs495337	1.000	rs4287819	chr20:48551956	T/G	cg17835207	chr20:48524531	SPATA2	-0.64	-15.1	-0.51	2.82e-44	Psoriasis;
BRCA	cis	rs4742903	0.967	rs6479215	chr9:106885243	A/G	cg21169611	chr9:106856078	SMC2	-0.38	-10.05	-0.37	3.66e-22	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs4975616	0.773	rs10078017	chr5:1314009	C/T	cg06550200	chr5:1325588	CLPTM1L	0.56	11.3	0.41	4.17e-27	Lung cancer;
BRCA	cis	rs17641971	0.708	rs2137013	chr8:49981091	C/T	cg00325661	chr8:49890786	NA	0.38	10.52	0.38	5.49e-24	Blood metabolite levels;
BRCA	trans	rs10411161	0.702	rs10424202	chr19:52387297	G/A	cg22319618	chr22:45562946	NUP50	-0.43	-8.01	-0.3	5.43e-15	Breast cancer;
BRCA	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg06115741	chr20:33292138	TP53INP2	0.4	8.85	0.33	8.31e-18	Coronary artery disease;
BRCA	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27286337	chr10:134555280	INPP5A	0.64	10.63	0.39	2.13e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg21775007	chr8:11205619	TDH	-0.61	-12.04	-0.43	3.16e-30	Retinal vascular caliber;
BRCA	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg22535103	chr8:58192502	C8orf71	-0.46	-9.06	-0.34	1.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs17601876	0.843	rs17523541	chr15:51554844	G/A	cg19946085	chr15:51559439	CYP19A1	-0.38	-11.08	-0.4	3.13e-26	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.38	0.35	1.15e-19	Morning vs. evening chronotype;
BRCA	cis	rs2066819	1.000	rs77131854	chr12:56664231	C/T	cg26714650	chr12:56694279	CS	-1.16	-15.21	-0.52	8.38e-45	Psoriasis vulgaris;
BRCA	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.15	0.37	1.53e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg01475377	chr6:109611718	NA	-0.6	-16.64	-0.55	6.5e-52	Reticulocyte fraction of red cells;
BRCA	trans	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.01	0.3	5.51e-15	Corneal astigmatism;
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg22907277	chr7:1156413	C7orf50	0.49	11.95	0.43	7.3e-30	Longevity;Endometriosis;
BRCA	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg07080220	chr10:102295463	HIF1AN	0.44	9.67	0.36	9.41e-21	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2559856	1.000	rs2559857	chr12:102089399	A/C	cg12924262	chr12:102091054	CHPT1	0.38	8.65	0.32	4.28e-17	Blood protein levels;
BRCA	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg00745463	chr17:30367425	LRRC37B	-0.53	-8.91	-0.33	5.36e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs4780401	0.728	rs6498239	chr16:11780774	T/C	cg01061890	chr16:11836724	TXNDC11	-0.41	-9.02	-0.34	2.26e-18	Rheumatoid arthritis;
BRCA	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg13550731	chr2:172543902	DYNC1I2	0.93	30.67	0.77	1.14e-127	Schizophrenia;
BRCA	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-13.11	-0.46	6.04e-35	Migraine;Coronary artery disease;
BRCA	cis	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg07460842	chr6:66804631	NA	-0.66	-14.51	-0.5	1.84e-41	Blood trace element (Cu levels);
BRCA	cis	rs3824867	0.920	rs7111873	chr11:47469439	A/G	cg20307385	chr11:47447363	PSMC3	0.51	11.52	0.41	4.99e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg00106254	chr7:1943704	MAD1L1	-0.39	-9.6	-0.36	1.72e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs3862030	0.720	rs7081110	chr10:104231651	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.14	-0.43	1.11e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg15704280	chr7:45808275	SEPT13	0.63	10.89	0.4	1.85e-25	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6684514	1.000	rs10908502	chr1:156300082	A/G	cg16558208	chr1:156270281	VHLL	0.35	8.08	0.3	3.34e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg04362960	chr10:104952993	NT5C2	0.43	10.31	0.38	3.84e-23	Arsenic metabolism;
BRCA	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg05519781	chr21:40033154	ERG	0.46	9.83	0.36	2.38e-21	Coronary artery disease;
BRCA	cis	rs9837602	0.810	rs35885423	chr3:99813218	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.18	0.4	1.3e-26	Breast cancer;
BRCA	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22590775	chr19:49891494	CCDC155	0.45	8.13	0.31	2.24e-15	Multiple sclerosis;
BRCA	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg17507749	chr15:85114479	UBE2QP1	0.52	8.76	0.33	1.81e-17	Schizophrenia;
BRCA	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg16576597	chr16:28551801	NUPR1	0.28	7.98	0.3	6.87e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg23950597	chr19:37808831	NA	-0.74	-13.06	-0.46	1.05e-34	Coronary artery calcification;
BRCA	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg09307838	chr4:120376055	NA	0.6	11.15	0.4	1.65e-26	Corneal astigmatism;
BRCA	cis	rs6723226	0.750	rs1033751	chr2:32695759	T/C	cg02381751	chr2:32503542	YIPF4	0.47	10.02	0.37	4.93e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2742417	0.624	rs2742394	chr3:45757591	C/T	cg04837898	chr3:45731254	SACM1L	-0.4	-8.15	-0.31	1.87e-15	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs4268898	0.516	rs7597149	chr2:24371962	C/T	cg26838691	chr2:24397539	C2orf84	0.4	8.16	0.31	1.75e-15	Asthma;
BRCA	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	9.1	0.34	1.1e-18	Personality dimensions;
BRCA	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg24596788	chr1:163392923	NA	-0.36	-9.42	-0.35	8.15e-20	Motion sickness;
BRCA	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg06552810	chr11:31128660	NA	-0.38	-8.34	-0.31	4.65e-16	Red blood cell count;
BRCA	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.58	0.55	1.25e-51	Hypertriglyceridemia;
BRCA	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.38	0.49	7.88e-41	Motion sickness;
BRCA	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.7	-0.36	7.43e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7352944	0.896	rs6067309	chr20:48610293	C/T	cg17835207	chr20:48524531	SPATA2	0.46	10.53	0.38	4.88e-24	Psoriasis;
BRCA	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.48e-23	Motion sickness;
BRCA	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg12011299	chr4:100065546	ADH4	-0.52	-12.69	-0.45	4.47e-33	Alcohol dependence;
BRCA	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg04362960	chr10:104952993	NT5C2	0.44	10.56	0.39	3.92e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg26384229	chr12:38710491	ALG10B	0.43	10.3	0.38	4.17e-23	Bladder cancer;
BRCA	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg12011299	chr4:100065546	ADH4	0.51	11.77	0.42	4.27e-29	Alcohol dependence;
BRCA	cis	rs12997796	0.556	rs35594332	chr2:86982651	G/A	cg25203885	chr2:87302643	LOC285074	-0.6	-9.51	-0.35	3.69e-20	Schizophrenia;
BRCA	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg09307838	chr4:120376055	NA	0.69	14.25	0.49	3.17e-40	Corneal astigmatism;
BRCA	cis	rs7246657	0.722	rs2075284	chr19:38189616	T/C	cg14683738	chr19:37701593	ZNF585B	-0.47	-7.85	-0.3	1.74e-14	Coronary artery calcification;
BRCA	cis	rs6977660	0.714	rs17141945	chr7:19805056	T/A	cg07541023	chr7:19748670	TWISTNB	0.57	9.72	0.36	6.52e-21	Thyroid stimulating hormone;
BRCA	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27297192	chr10:134578999	INPP5A	0.44	8.3	0.31	6.43e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.26	8.19	0.31	1.45e-15	Electroencephalogram traits;
BRCA	cis	rs9837602	1.000	rs4279135	chr3:99733096	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	11.1	0.4	2.74e-26	Breast cancer;
BRCA	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg03806693	chr22:41940476	POLR3H	-0.98	-17.55	-0.57	1.46e-56	Vitiligo;
BRCA	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11644478	chr21:40555479	PSMG1	-0.68	-15.39	-0.52	1.14e-45	Cognitive function;
BRCA	cis	rs2066819	1.000	rs1802236	chr12:56679751	A/G	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg00166722	chr3:10149974	C3orf24	0.64	11.27	0.41	5.44e-27	Alzheimer's disease;
BRCA	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg21535247	chr6:8435926	SLC35B3	0.42	9.64	0.36	1.22e-20	Motion sickness;
BRCA	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg08470875	chr2:26401718	FAM59B	-0.62	-9.28	-0.34	2.57e-19	Gut microbiome composition (summer);
BRCA	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg02659138	chr7:134003124	SLC35B4	0.36	10.4	0.38	1.69e-23	Mean platelet volume;
BRCA	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	8.22	0.31	1.1e-15	Mean platelet volume;
BRCA	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg08807101	chr21:30365312	RNF160	0.77	20.38	0.63	1.67e-71	Dental caries;
BRCA	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg01292856	chr11:65242576	NA	-0.35	-8.11	-0.31	2.66e-15	Bone mineral density;
BRCA	cis	rs7975161	0.572	rs7132418	chr12:104603591	C/A	cg25273343	chr12:104657179	TXNRD1	-0.61	-10.11	-0.37	2.09e-22	Toenail selenium levels;
BRCA	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg12641515	chr19:46296257	DMWD	-0.58	-12.91	-0.45	4.57e-34	Coronary artery disease;
BRCA	cis	rs7617773	0.817	rs35456569	chr3:48250899	T/A	cg11946769	chr3:48343235	NME6	0.68	14.01	0.48	4.49e-39	Coronary artery disease;
BRCA	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg26597838	chr10:835615	NA	1.0	17.88	0.58	2.64e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg20387954	chr3:183756860	HTR3D	0.45	10.12	0.37	2.06e-22	Anterior chamber depth;
BRCA	cis	rs208520	0.690	rs851464	chr6:66839802	C/T	cg07460842	chr6:66804631	NA	-1.02	-20.15	-0.62	2.95e-70	Exhaled nitric oxide output;
BRCA	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg21782813	chr7:2030301	MAD1L1	0.34	8.62	0.32	5.1e-17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg04317338	chr11:64019027	PLCB3	0.58	9.99	0.37	6.17e-22	Mean platelet volume;
BRCA	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg21782813	chr7:2030301	MAD1L1	0.34	9.07	0.34	1.45e-18	Schizophrenia;
BRCA	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg13319975	chr6:146136371	FBXO30	-0.36	-8.16	-0.31	1.73e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10802521	chr3:52805072	NEK4	-0.31	-7.94	-0.3	8.93e-15	Bipolar disorder;
BRCA	cis	rs644148	0.867	rs2571060	chr19:44971647	C/G	cg15540054	chr19:45004280	ZNF180	-0.58	-12.13	-0.43	1.3e-30	Personality dimensions;
BRCA	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg05863683	chr7:1912471	MAD1L1	0.38	8.41	0.32	2.64e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg02297831	chr4:17616191	MED28	0.38	8.88	0.33	6.63e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg08601574	chr20:25228251	PYGB	-0.34	-8.08	-0.3	3.15e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2637030	0.559	rs7728496	chr5:52867330	G/T	cg06476337	chr5:52856530	NDUFS4	-0.36	-8.19	-0.31	1.44e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	trans	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.17	0.31	1.71e-15	Corneal astigmatism;
BRCA	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg00666640	chr1:248458726	OR2T12	0.33	9.04	0.34	1.79e-18	Common traits (Other);
BRCA	cis	rs9469578	0.892	rs73743333	chr6:33714042	G/A	cg18708504	chr6:33715942	IP6K3	0.7	10.23	0.38	7.52e-23	Phosphorus levels;
BRCA	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.64e-24	Motion sickness;
BRCA	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg19257562	chr1:2043853	PRKCZ	-0.31	-8.55	-0.32	8.97e-17	Height;
BRCA	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg18305652	chr10:134549665	INPP5A	0.49	11.96	0.43	6.91e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-9.72	-0.36	6.14e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.69	-0.42	9.93e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg08859206	chr1:53392774	SCP2	0.44	8.86	0.33	7.74e-18	Monocyte count;
BRCA	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg13175981	chr1:150552382	MCL1	0.36	8.25	0.31	9.28e-16	Tonsillectomy;
BRCA	cis	rs1109501	0.959	rs10021214	chr4:71326670	T/C	cg22786090	chr4:71381880	NA	0.36	7.86	0.3	1.67e-14	Alcoholism (heaviness of drinking);
BRCA	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg09021430	chr5:549028	NA	0.65	14.6	0.5	7.09e-42	Obesity-related traits;
BRCA	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.67	13.04	0.46	1.29e-34	Height;
BRCA	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.09	0.56	3.2e-54	Fuchs's corneal dystrophy;
BRCA	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg11812906	chr14:75593930	NEK9	-0.63	-14.63	-0.5	4.98e-42	Height;
BRCA	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.29	-0.31	6.47e-16	Axial length;
BRCA	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg12311346	chr5:56204834	C5orf35	0.56	11.38	0.41	1.86e-27	Initial pursuit acceleration;
BRCA	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.17	-18.81	-0.6	3.73e-63	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.07	0.4	3.57e-26	Bipolar disorder;
BRCA	cis	rs12986413	0.874	rs4806832	chr19:2184652	C/T	cg09261902	chr19:2140048	AP3D1	0.4	10.48	0.38	8.38e-24	Height;
BRCA	cis	rs9649465	0.967	rs1005568	chr7:123306470	G/A	cg04330084	chr7:123175371	IQUB	-0.3	-8.34	-0.31	4.66e-16	Migraine;
BRCA	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg24562669	chr7:97807699	LMTK2	0.44	11.75	0.42	5.32e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg06697600	chr4:7070879	GRPEL1	-0.53	-10.66	-0.39	1.58e-24	Monocyte percentage of white cells;
BRCA	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg11168104	chr5:1857477	NA	-0.34	-8.74	-0.33	2.07e-17	Cardiovascular disease risk factors;
BRCA	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	12.66	0.45	6.38e-33	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-11.23	-0.41	7.63e-27	Chronic sinus infection;
BRCA	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg22906224	chr7:99728672	NA	0.44	8.26	0.31	8.37e-16	Coronary artery disease;
BRCA	trans	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg14791747	chr16:20752902	THUMPD1	0.4	9.31	0.35	2.11e-19	Cognitive test performance;
BRCA	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-16.42	-0.54	8.48e-51	Alzheimer's disease (late onset);
BRCA	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg08999081	chr20:33150536	PIGU	-0.46	-12.54	-0.44	2.14e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.5	9.83	0.36	2.58e-21	Birth weight;
BRCA	trans	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17712092	chr4:129076599	LARP1B	0.56	13.47	0.47	1.47e-36	Eosinophil percentage of white cells;
BRCA	trans	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.46	0.38	9.36e-24	Mean corpuscular volume;
BRCA	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg23711669	chr6:146136114	FBXO30	0.73	17.03	0.56	6.83e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg07636037	chr3:49044803	WDR6	0.41	8.4	0.32	2.89e-16	Resting heart rate;
BRCA	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg09184832	chr6:79620586	NA	-0.5	-10.76	-0.39	6.16e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs9612	1.000	rs9612	chr19:44235517	A/G	cg08581076	chr19:44259116	C19orf61	0.56	9.83	0.36	2.44e-21	Exhaled nitric oxide output;
BRCA	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg24562669	chr7:97807699	LMTK2	0.44	11.75	0.42	5.51e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3916	0.910	rs7306541	chr12:121130046	A/G	cg21892295	chr12:121157589	UNC119B	-0.38	-9.7	-0.36	7.38e-21	Urinary metabolites (H-NMR features);
BRCA	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	10.38	0.38	1.97e-23	Bipolar disorder;
BRCA	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11890956	chr21:40555474	PSMG1	-0.6	-13.39	-0.47	3.1e-36	Menarche (age at onset);
BRCA	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg04691961	chr3:161091175	C3orf57	-0.4	-9.15	-0.34	7.42e-19	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg17366294	chr4:99064904	C4orf37	0.45	10.64	0.39	1.87e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7395662	0.784	rs2170661	chr11:48378186	C/T	cg00717180	chr2:96193071	NA	-0.29	-8.19	-0.31	1.44e-15	HDL cholesterol;
BRCA	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg16405210	chr4:1374714	KIAA1530	-0.92	-20.93	-0.64	1.71e-74	Longevity;
BRCA	cis	rs41005	0.967	rs193927	chr2:8108055	G/A	cg03155496	chr2:8117019	LOC339788	0.57	15.05	0.51	4.8e-44	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg11952622	chr19:58962976	ZNF324B	0.43	8.86	0.33	7.99e-18	Uric acid clearance;
BRCA	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg17691542	chr6:26056736	HIST1H1C	0.56	11.7	0.42	8.36e-29	Height;
BRCA	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03923535	chr7:1197113	ZFAND2A	0.5	10.86	0.39	2.55e-25	Longevity;Endometriosis;
BRCA	cis	rs677665	0.537	rs6688233	chr1:9335745	A/G	cg25755851	chr1:9335794	NA	-0.83	-17.7	-0.57	2.27e-57	Eosinophil percentage of white cells;
BRCA	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26314531	chr2:26401878	FAM59B	-0.9	-16.15	-0.54	1.92e-49	Gut microbiome composition (summer);
BRCA	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg06671706	chr8:8559999	CLDN23	0.44	8.48	0.32	1.54e-16	Obesity-related traits;
BRCA	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg01475735	chr3:40494733	NA	-0.4	-8.19	-0.31	1.39e-15	Renal cell carcinoma;
BRCA	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg04315214	chr1:2043799	PRKCZ	-0.48	-12.57	-0.45	1.58e-32	Height;
BRCA	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg12062639	chr20:23401060	NAPB	-0.92	-13.17	-0.46	3.2e-35	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	trans	rs11165623	0.740	rs11165638	chr1:96921357	C/A	cg10631902	chr5:14652156	NA	-0.51	-16.06	-0.54	5.42e-49	Hip circumference;Waist circumference;
BRCA	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg00071950	chr4:10020882	SLC2A9	-0.48	-11.7	-0.42	8.81e-29	Bone mineral density;
BRCA	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.52	-0.44	2.53e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.54	0.42	4.13e-28	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg02751453	chr18:77725136	HSBP1L1	-0.48	-11.03	-0.4	5.19e-26	Opioid sensitivity;
BRCA	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs9815354	0.812	rs7639859	chr3:42001987	C/T	cg03022575	chr3:42003672	ULK4	0.62	9.12	0.34	9.65e-19	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.46	-0.32	1.85e-16	Total body bone mineral density;
BRCA	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg08847533	chr14:75593920	NEK9	-0.85	-21.6	-0.65	4.13e-78	Height;
BRCA	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg26384229	chr12:38710491	ALG10B	0.87	23.88	0.69	1.49e-90	Heart rate;
BRCA	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg22705602	chr4:152727874	NA	-0.38	-10.37	-0.38	2.15e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs73001065	0.711	rs58489806	chr19:19456917	C/T	cg03709012	chr19:19516395	GATAD2A	0.89	11.98	0.43	5.63e-30	LDL cholesterol;
BRCA	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.4	-8.75	-0.33	1.84e-17	Aortic root size;
BRCA	cis	rs1003719	0.788	rs2835574	chr21:38455324	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.18	0.49	7.08e-40	Eye color traits;
BRCA	cis	rs72634258	0.554	rs4908699	chr1:7905274	G/A	cg26816564	chr1:7831052	VAMP3	0.7	12.86	0.45	7.69e-34	Inflammatory bowel disease;
BRCA	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg08885076	chr2:99613938	TSGA10	-0.59	-13.2	-0.46	2.29e-35	Chronic sinus infection;
BRCA	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.49	-9.35	-0.35	1.44e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.26e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6120849	0.707	rs6088703	chr20:33676049	T/A	cg24642439	chr20:33292090	TP53INP2	0.57	9.73	0.36	6.02e-21	Protein C levels;
BRCA	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg09163369	chr1:210001066	C1orf107	0.55	10.61	0.39	2.4e-24	Orofacial clefts;
BRCA	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.22e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-11.66	-0.42	1.28e-28	Joint mobility (Beighton score);
BRCA	cis	rs4363385	0.818	rs10888524	chr1:153000125	A/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.38	-0.31	3.34e-16	Inflammatory skin disease;
BRCA	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg22496339	chr2:162101262	NA	0.58	13.12	0.46	5.49e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.19e-40	Motion sickness;
BRCA	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.09e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg08917208	chr2:24149416	ATAD2B	0.52	8.16	0.31	1.77e-15	Lymphocyte counts;
BRCA	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07080220	chr10:102295463	HIF1AN	0.49	11.15	0.4	1.7e-26	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg22920501	chr2:26401640	FAM59B	0.9	14.59	0.5	7.9e-42	Gut microbiome composition (summer);
BRCA	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18876405	chr7:65276391	NA	-0.49	-10.77	-0.39	5.56e-25	Aortic root size;
BRCA	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg13047869	chr3:10149882	C3orf24	0.59	12.55	0.44	1.94e-32	Alzheimer's disease;
BRCA	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg03929089	chr4:120376271	NA	0.57	9.82	0.36	2.63e-21	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs858239	0.899	rs2268745	chr7:23317600	G/A	cg23682824	chr7:23144976	KLHL7	0.34	8.49	0.32	1.45e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg00106254	chr7:1943704	MAD1L1	-0.32	-8.53	-0.32	1.07e-16	Schizophrenia;
BRCA	cis	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg21775007	chr8:11205619	TDH	-0.48	-9.6	-0.36	1.78e-20	Neuroticism;
BRCA	cis	rs9796	0.621	rs690733	chr15:41476465	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.37	-8.01	-0.3	5.56e-15	Menopause (age at onset);
BRCA	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg16586182	chr3:47516702	SCAP	0.66	15.18	0.51	1.16e-44	Colorectal cancer;
BRCA	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.56	0.35	2.51e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg00012203	chr2:219082015	ARPC2	-0.51	-9.79	-0.36	3.66e-21	Colorectal cancer;
BRCA	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	12.64	0.45	7.93e-33	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg18402987	chr7:1209562	NA	0.84	11.92	0.43	9.85e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.05	15.99	0.53	1.18e-48	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg04025307	chr7:1156635	C7orf50	0.57	10.98	0.4	7.82e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6942756	1.000	rs2103232	chr7:128951232	G/T	cg02491457	chr7:128862824	NA	-0.71	-13.98	-0.48	6.22e-39	White matter hyperintensity burden;
BRCA	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.83	-0.36	2.54e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.33	-0.41	3.17e-27	Schizophrenia;
BRCA	cis	rs16976116	0.901	rs1061823	chr15:55496043	T/A	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.49e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg13902645	chr11:5959945	NA	-0.41	-8.83	-0.33	1.02e-17	DNA methylation (variation);
BRCA	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05025164	chr4:1340916	KIAA1530	-0.76	-14.92	-0.51	2.16e-43	Longevity;
BRCA	cis	rs919433	0.617	rs700646	chr2:198608511	C/T	cg00792783	chr2:198669748	PLCL1	0.46	10.07	0.37	3.04e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg11812906	chr14:75593930	NEK9	-0.61	-13.79	-0.48	4.55e-38	Height;
BRCA	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg07636037	chr3:49044803	WDR6	0.51	8.57	0.32	7.96e-17	Menarche (age at onset);
BRCA	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg17063962	chr7:91808500	NA	0.54	12.61	0.45	1.07e-32	Breast cancer;
BRCA	cis	rs4305276	0.557	rs7607996	chr2:241470735	T/C	cg03743720	chr2:241460002	ANKMY1	0.21	8.56	0.32	8.61e-17	Mean platelet volume;
BRCA	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg14993813	chr1:46806288	NSUN4	-0.46	-8.86	-0.33	7.98e-18	Menopause (age at onset);
BRCA	trans	rs78049276	0.736	rs10305838	chr4:148400256	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	-0.43	-8.01	-0.3	5.59e-15	Pulse pressure;
BRCA	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg21772509	chr8:41503840	NKX6-3	0.48	11.28	0.41	4.91e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
BRCA	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.82	-22.31	-0.66	5.68e-82	Height;
BRCA	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg26384229	chr12:38710491	ALG10B	0.67	16.04	0.54	6.77e-49	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs919433	0.963	rs4850787	chr2:198181750	G/A	cg10820045	chr2:198174542	NA	-0.38	-8.38	-0.31	3.32e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg25208724	chr1:156163844	SLC25A44	0.9	26.45	0.72	1.1e-104	Testicular germ cell tumor;
BRCA	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg05347473	chr6:146136440	FBXO30	-0.44	-8.89	-0.33	6.26e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6542838	0.641	rs6741166	chr2:99534926	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-9.2	-0.34	5.11e-19	Fear of minor pain;
BRCA	trans	rs2018683	0.677	rs2057956	chr7:28973460	G/A	cg19402173	chr7:128379420	CALU	-0.42	-9.88	-0.36	1.64e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs6121246	0.559	rs6060950	chr20:30378031	T/C	cg21427119	chr20:30132790	HM13	-0.36	-8.14	-0.31	2.08e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.81	-0.36	2.98e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.2	0.41	1.02e-26	Bipolar disorder;
BRCA	cis	rs7833986	1.000	rs36103212	chr8:57101475	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.46	8.22	0.31	1.17e-15	Height;
BRCA	cis	rs7215564	0.818	rs901063	chr17:78595696	A/T	cg06153925	chr17:78755379	RPTOR	-0.48	-8.2	-0.31	1.31e-15	Myopia (pathological);
BRCA	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.62	0.36	1.5e-20	Morning vs. evening chronotype;
BRCA	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	20.07	0.62	7.34e-70	Platelet count;
BRCA	cis	rs6484504	0.576	rs208071	chr11:31144996	C/T	cg06552810	chr11:31128660	NA	-0.38	-8.41	-0.32	2.64e-16	Red blood cell count;
BRCA	trans	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg17712092	chr4:129076599	LARP1B	-0.54	-12.3	-0.44	2.28e-31	Eosinophil percentage of white cells;
BRCA	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.23	-19.5	-0.61	8.19e-67	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	12.91	0.45	4.62e-34	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs13102973	0.614	rs56199725	chr4:135873448	T/C	cg14419869	chr4:135874104	NA	-0.52	-11.05	-0.4	4.13e-26	Subjective well-being;
BRCA	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg10932868	chr11:921992	NA	0.49	12.51	0.44	2.84e-32	Alzheimer's disease (late onset);
BRCA	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	trans	rs3857536	0.776	rs4710583	chr6:66940101	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.41	0.35	8.9e-20	Tonsillectomy;
BRCA	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg04455712	chr21:45112962	RRP1B	0.41	10.44	0.38	1.19e-23	Mean corpuscular volume;
BRCA	cis	rs312274	0.515	rs2772458	chr12:41252465	G/A	cg17827154	chr12:41323612	CNTN1	-0.42	-10.07	-0.37	2.96e-22	Metabolite levels  (X-11787);
BRCA	trans	rs1493916	0.748	rs2040203	chr18:31307420	G/T	cg27147174	chr7:100797783	AP1S1	-0.42	-8.37	-0.31	3.71e-16	Life satisfaction;
BRCA	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.07	0.3	3.55e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.6	-0.67	1.57e-83	Lymphocyte percentage of white cells;
BRCA	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg19257562	chr1:2043853	PRKCZ	-0.34	-9.65	-0.36	1.21e-20	Height;
BRCA	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg06238570	chr21:40685208	BRWD1	-0.4	-8.18	-0.31	1.55e-15	Menarche (age at onset);
BRCA	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg17063962	chr7:91808500	NA	-0.53	-12.33	-0.44	1.78e-31	Breast cancer;
BRCA	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg04362960	chr10:104952993	NT5C2	0.4	9.57	0.35	2.3e-20	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.75	0.36	5.03e-21	Bipolar disorder;
BRCA	cis	rs2652822	1.000	rs2652822	chr15:63422772	C/T	cg02713581	chr15:63449717	RPS27L	-0.41	-8.45	-0.32	1.95e-16	Metabolic traits;
BRCA	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg15145296	chr3:125709740	NA	-0.55	-8.69	-0.33	3.04e-17	Blood pressure (smoking interaction);
BRCA	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg15017067	chr4:17643749	FAM184B	0.28	8.27	0.31	7.51e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.6	-0.32	6.18e-17	Total body bone mineral density;
BRCA	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg01528321	chr10:82214614	TSPAN14	0.81	17.21	0.56	8.09e-55	Post bronchodilator FEV1;
BRCA	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.66	-15.24	-0.52	5.84e-45	Systemic lupus erythematosus;
BRCA	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.36	9.14	0.34	7.95e-19	Resting heart rate;
BRCA	cis	rs8032158	1.000	rs28660477	chr15:56145267	T/C	cg02198044	chr15:56286336	NEDD4	-0.38	-9.04	-0.34	1.8e-18	Keloid;
BRCA	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg05639522	chr1:247681581	NA	0.53	11.63	0.42	1.75e-28	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs113835537	0.529	rs3741360	chr11:66300348	A/G	cg24851651	chr11:66362959	CCS	0.46	8.56	0.32	8.11e-17	Airway imaging phenotypes;
BRCA	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg00825309	chr19:58991885	ZNF446	-0.59	-12.89	-0.45	5.93e-34	Uric acid clearance;
BRCA	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg23978390	chr7:1156363	C7orf50	0.4	9.33	0.35	1.69e-19	Longevity;Endometriosis;
BRCA	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg20307385	chr11:47447363	PSMC3	-0.45	-10.5	-0.38	6.56e-24	Subjective well-being;
BRCA	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	13.66	0.48	1.8e-37	Personality dimensions;
BRCA	cis	rs16958440	0.867	rs12326457	chr18:44678425	A/G	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs11955398	0.585	rs10063407	chr5:60009063	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.37	-9.1	-0.34	1.1e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.83	-0.51	5.74e-43	Total cholesterol levels;
BRCA	cis	rs12210905	0.688	rs72843151	chr6:27359268	A/C	cg08851530	chr6:28072375	NA	0.84	8.3	0.31	6.28e-16	Hip circumference adjusted for BMI;
BRCA	trans	rs877282	0.945	rs10904554	chr10:786768	T/C	cg22713356	chr15:30763199	NA	1.35	27.01	0.73	9.19e-108	Uric acid levels;
BRCA	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg26597838	chr10:835615	NA	1.02	17.81	0.58	6.47e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg25358565	chr5:93447407	FAM172A	1.17	18.25	0.59	3.42e-60	Diabetic retinopathy;
BRCA	cis	rs7178572	0.568	rs3743479	chr15:77406396	A/G	cg22256960	chr15:77711686	NA	0.38	8.21	0.31	1.27e-15	Type 2 diabetes;
BRCA	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg08213375	chr14:104286397	PPP1R13B	0.6	16.35	0.54	1.85e-50	Schizophrenia;
BRCA	cis	rs7246657	0.722	rs2927746	chr19:38156570	G/A	cg18154014	chr19:37997991	ZNF793	-0.49	-9.15	-0.34	7.83e-19	Coronary artery calcification;
BRCA	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg03676636	chr4:99064102	C4orf37	0.2	7.81	0.3	2.43e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	13.15	0.46	3.9e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.74e-16	Obesity-related traits;
BRCA	cis	rs12347191	0.500	rs907580	chr9:100622597	T/C	cg13688889	chr9:100608707	NA	-0.48	-9.76	-0.36	4.62e-21	Orofacial clefts;
BRCA	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg18252515	chr7:66147081	NA	-1.07	-15.86	-0.53	4.97e-48	Gout;
BRCA	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18876405	chr7:65276391	NA	-0.49	-11.0	-0.4	6.88e-26	Aortic root size;
BRCA	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg00990874	chr7:1149470	C7orf50	-0.63	-13.23	-0.46	1.71e-35	Bronchopulmonary dysplasia;
BRCA	cis	rs12367572	1.000	rs7295923	chr12:45269284	C/T	cg04608330	chr12:45269318	NELL2	-0.64	-14.31	-0.49	1.77e-40	Gut microbiome composition (summer);
BRCA	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg15704280	chr7:45808275	SEPT13	0.65	11.44	0.41	1.06e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs61990749	0.597	rs6574402	chr14:78267950	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.65	9.9	0.36	1.33e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs9467773	0.804	rs2073526	chr6:26374658	C/T	cg09904177	chr6:26538194	HMGN4	-0.37	-9.86	-0.36	1.86e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24110177	chr3:50126178	RBM5	-0.4	-11.04	-0.4	4.86e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg08992911	chr2:238395768	MLPH	0.49	8.16	0.31	1.82e-15	Prostate cancer;
BRCA	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-16.96	-0.56	1.56e-53	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg05283184	chr6:79620031	NA	-0.41	-10.62	-0.39	2.34e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg20503657	chr10:835505	NA	0.98	14.97	0.51	1.18e-43	Eosinophil percentage of granulocytes;
BRCA	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18876405	chr7:65276391	NA	0.62	15.36	0.52	1.43e-45	Aortic root size;
BRCA	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg23533926	chr12:111358616	MYL2	-0.44	-9.21	-0.34	4.48e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	12.01	0.43	4.29e-30	Bone mineral density;
BRCA	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg06191203	chr2:152266755	RIF1	-0.27	-8.04	-0.3	4.25e-15	Lung cancer;
BRCA	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08219700	chr8:58056026	NA	0.44	7.91	0.3	1.12e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg27170947	chr2:26402098	FAM59B	-0.94	-16.9	-0.56	3.15e-53	Gut microbiome composition (summer);
BRCA	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-10.56	-0.39	3.78e-24	Bladder cancer;
BRCA	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	11.67	0.42	1.12e-28	Schizophrenia;
BRCA	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg11887960	chr12:57824829	NA	0.55	8.57	0.32	7.74e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs17384381	1.000	rs12133722	chr1:85873237	C/T	cg16011679	chr1:85725395	C1orf52	0.52	8.06	0.3	3.87e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg11833968	chr6:79620685	NA	-0.42	-9.37	-0.35	1.24e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	9.4	0.35	9.41e-20	Aortic root size;
BRCA	cis	rs2414095	0.520	rs3784307	chr15:51506634	G/A	cg19946085	chr15:51559439	CYP19A1	-0.31	-8.66	-0.32	3.98e-17	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
BRCA	cis	rs887829	0.508	rs1104892	chr2:234620272	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.34	-8.49	-0.32	1.5e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg18446336	chr7:2847575	GNA12	-0.35	-8.3	-0.31	6.43e-16	Height;
BRCA	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg13647721	chr17:30228624	UTP6	0.56	10.06	0.37	3.31e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg04450456	chr4:17643702	FAM184B	0.39	11.78	0.42	3.97e-29	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-12.98	-0.46	2.36e-34	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs4730250	0.802	rs77936580	chr7:106946343	G/A	cg02696742	chr7:106810147	HBP1	-0.54	-8.6	-0.32	6.14e-17	Osteoarthritis;
BRCA	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg13395646	chr4:1353034	KIAA1530	-0.51	-9.41	-0.35	9e-20	Obesity-related traits;
BRCA	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg04518342	chr5:131593106	PDLIM4	0.4	9.13	0.34	9e-19	Acylcarnitine levels;
BRCA	cis	rs10267417	0.557	rs10249101	chr7:19895397	T/G	cg07541023	chr7:19748670	TWISTNB	0.46	8.4	0.32	2.86e-16	Night sleep phenotypes;
BRCA	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg07537917	chr2:241836409	C2orf54	-0.45	-10.18	-0.37	1.16e-22	Urinary metabolites;
BRCA	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.21	-0.31	1.19e-15	Gut microbiome composition (summer);
BRCA	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg08859206	chr1:53392774	SCP2	-0.41	-8.23	-0.31	1.02e-15	Monocyte count;
BRCA	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg21143896	chr7:2802374	GNA12	-0.35	-8.88	-0.33	6.7e-18	Height;
BRCA	cis	rs9487051	0.597	rs9400265	chr6:109594932	A/C	cg01475377	chr6:109611718	NA	-0.41	-8.17	-0.31	1.69e-15	Reticulocyte fraction of red cells;
BRCA	cis	rs6121246	0.559	rs6087771	chr20:30306724	A/G	cg21427119	chr20:30132790	HM13	-0.35	-7.89	-0.3	1.33e-14	Mean corpuscular hemoglobin;
BRCA	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg09307838	chr4:120376055	NA	-0.59	-12.91	-0.45	4.74e-34	Corneal astigmatism;
BRCA	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg06784218	chr1:46089804	CCDC17	-0.46	-10.92	-0.4	1.4e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9420	0.922	rs35808061	chr11:57547000	T/C	cg19752551	chr11:57585705	CTNND1	-0.51	-12.56	-0.45	1.65e-32	Schizophrenia;
BRCA	cis	rs701145	0.556	rs355751	chr3:153971602	T/C	cg12800244	chr3:153838788	SGEF	0.43	8.37	0.31	3.6e-16	Coronary artery disease;
BRCA	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	13.07	0.46	9.51e-35	Hip circumference adjusted for BMI;
BRCA	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.6	-14.44	-0.5	4.19e-41	Hemoglobin concentration;
BRCA	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg20224285	chr3:52813920	ITIH1	0.32	8.16	0.31	1.78e-15	Bipolar disorder;
BRCA	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg19628046	chr18:33552617	C18orf21	0.54	10.88	0.4	2e-25	Endometriosis;Drug-induced torsades de pointes;
BRCA	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg26384229	chr12:38710491	ALG10B	-0.66	-13.87	-0.48	2e-38	Morning vs. evening chronotype;
BRCA	cis	rs7945718	0.967	rs10741602	chr11:12761699	A/T	cg25843174	chr11:12811716	TEAD1	0.23	8.73	0.33	2.22e-17	Educational attainment (years of education);
BRCA	cis	rs68170813	0.523	rs79607134	chr7:107033619	A/T	cg02696742	chr7:106810147	HBP1	-0.51	-8.45	-0.32	1.93e-16	Coronary artery disease;
BRCA	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg13565492	chr6:43139072	SRF	-0.79	-10.84	-0.39	2.99e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg11266682	chr4:10021025	SLC2A9	0.39	10.35	0.38	2.47e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	21.34	0.65	1.06e-76	Platelet count;
BRCA	cis	rs13315871	0.929	rs76226186	chr3:58318499	C/T	cg20936604	chr3:58311152	NA	-0.66	-8.48	-0.32	1.5e-16	Cholesterol, total;
BRCA	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg21475434	chr5:93447410	FAM172A	0.68	8.96	0.33	3.44e-18	Diabetic retinopathy;
BRCA	cis	rs7903847	0.642	rs7078782	chr10:99168604	C/T	cg08345082	chr10:99160200	RRP12	-0.3	-8.76	-0.33	1.77e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg16339924	chr4:17578868	LAP3	0.55	13.27	0.46	1.13e-35	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg16423285	chr20:60520624	NA	0.43	8.09	0.3	3.09e-15	Body mass index;
BRCA	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg06191203	chr2:152266755	RIF1	-0.31	-9.12	-0.34	9.48e-19	Lung cancer;
BRCA	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg09307838	chr4:120376055	NA	0.6	11.15	0.4	1.65e-26	Corneal astigmatism;
BRCA	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg02403541	chr12:121454288	C12orf43	0.54	10.3	0.38	3.9699999999999997e-23	N-glycan levels;
BRCA	cis	rs2882667	0.861	rs11242445	chr5:138417054	G/T	cg04439458	chr5:138467593	SIL1	-0.37	-10.37	-0.38	2.13e-23	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7572733	0.514	rs700686	chr2:198721054	G/A	cg00792783	chr2:198669748	PLCL1	0.47	10.12	0.37	1.95e-22	Dermatomyositis;
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.39	-8.36	-0.31	3.78e-16	Longevity;Endometriosis;
BRCA	cis	rs9811920	0.809	rs4577503	chr3:99657922	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.55	-13.62	-0.47	2.71e-37	Axial length;
BRCA	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg05283184	chr6:79620031	NA	-0.43	-11.1	-0.4	2.77e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs2011503	0.509	rs76347963	chr19:19780145	C/T	cg11584989	chr19:19387371	SF4	0.4	7.98	0.3	6.96e-15	Bipolar disorder;
BRCA	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.03	-0.3	4.73e-15	Total body bone mineral density;
BRCA	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg21535247	chr6:8435926	SLC35B3	0.41	9.38	0.35	1.09e-19	Motion sickness;
BRCA	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg02891314	chr5:179741120	GFPT2	-0.69	-14.06	-0.49	2.67e-39	Height;
BRCA	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg17211192	chr8:82754475	SNX16	-0.53	-11.22	-0.41	8.52e-27	Diastolic blood pressure;
BRCA	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.57	12.13	0.43	1.3e-30	Monocyte percentage of white cells;
BRCA	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11890956	chr21:40555474	PSMG1	0.98	23.59	0.68	5.27e-89	Cognitive function;
BRCA	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg08917208	chr2:24149416	ATAD2B	1.12	15.97	0.53	1.45e-48	Lymphocyte counts;
BRCA	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06108461	chr20:60628389	TAF4	-0.64	-13.43	-0.47	2.18e-36	Body mass index;
BRCA	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg12419862	chr22:24373484	LOC391322	0.7	15.81	0.53	9.36e-48	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-13.42	-0.47	2.38e-36	Gut microbiome composition (summer);
BRCA	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg23533926	chr12:111358616	MYL2	-0.41	-8.51	-0.32	1.2e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg21775007	chr8:11205619	TDH	0.62	13.54	0.47	6.95e-37	Retinal vascular caliber;
BRCA	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg05872129	chr22:39784769	NA	0.56	11.67	0.42	1.16e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg24006582	chr15:45444508	DUOX1	0.55	10.71	0.39	9.9e-25	Uric acid levels;
BRCA	trans	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg26384229	chr12:38710491	ALG10B	0.43	10.46	0.38	9.72e-24	Morning vs. evening chronotype;
BRCA	cis	rs701145	0.617	rs7426835	chr3:154049539	C/T	cg16511985	chr3:153974050	SGEF	0.41	8.85	0.33	8.5e-18	Coronary artery disease;
BRCA	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg14926445	chr8:58193284	C8orf71	-0.47	-9.08	-0.34	1.37e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11890956	chr21:40555474	PSMG1	0.59	13.25	0.46	1.38e-35	Menarche (age at onset);
BRCA	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg10169327	chr19:45448959	APOC2	0.31	7.81	0.3	2.28e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-8.06	-0.3	3.9e-15	Tonsillectomy;
BRCA	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg09904177	chr6:26538194	HMGN4	0.47	14.7	0.5	2.27e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg24562669	chr7:97807699	LMTK2	0.45	11.98	0.43	5.55e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg24060327	chr5:131705240	SLC22A5	0.62	11.66	0.42	1.24e-28	Breast cancer;
BRCA	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg23533926	chr12:111358616	MYL2	-0.44	-8.94	-0.33	4.28e-18	Extrinsic epigenetic age acceleration;
BRCA	trans	rs8002861	0.840	rs1819597	chr13:44429553	G/A	cg17145862	chr1:211918768	LPGAT1	0.63	16.04	0.54	6.57e-49	Leprosy;
BRCA	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg26384229	chr12:38710491	ALG10B	0.68	14.54	0.5	1.35e-41	Morning vs. evening chronotype;
BRCA	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg08501292	chr6:25962987	TRIM38	0.57	8.04	0.3	4.27e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.85e-29	Chronic sinus infection;
BRCA	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg13736514	chr6:26305472	NA	-0.36	-11.99	-0.43	5.24e-30	Educational attainment;
BRCA	trans	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg14791747	chr16:20752902	THUMPD1	0.45	14.26	0.49	3.08e-40	Cognitive test performance;
BRCA	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.32	8.84	0.33	9.09e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9837602	0.551	rs1630555	chr3:99423273	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.7	-0.33	2.86e-17	Breast cancer;
BRCA	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06022373	chr22:39101656	GTPBP1	-0.68	-16.54	-0.55	2.13e-51	Menopause (age at onset);
BRCA	cis	rs7264396	0.779	rs6087723	chr20:34175783	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.54	11.17	0.4	1.44e-26	Total cholesterol levels;
BRCA	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.57	12.24	0.44	4.35e-31	Monocyte percentage of white cells;
BRCA	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.19	-0.34	5.64e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00166722	chr3:10149974	C3orf24	0.65	13.07	0.46	8.76e-35	Alzheimer's disease;
BRCA	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg09307838	chr4:120376055	NA	0.69	14.05	0.49	2.92e-39	Corneal astigmatism;
BRCA	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.05	0.3	3.98e-15	Breast cancer;
BRCA	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg13385521	chr17:29058706	SUZ12P	0.63	8.58	0.32	7.12e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.02	-0.49	3.77e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg01292856	chr11:65242576	NA	0.35	8.74	0.33	2.08e-17	Bone mineral density;
BRCA	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg06115741	chr20:33292138	TP53INP2	-0.38	-8.33	-0.31	4.82e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs2668423	0.502	rs7254913	chr19:1388320	A/G	cg02639931	chr19:1387894	NDUFS7	0.88	27.63	0.74	3.6e-111	Nonalcoholic fatty liver disease;
BRCA	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg22676075	chr6:135203613	NA	0.45	8.73	0.33	2.18e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg08470875	chr2:26401718	FAM59B	0.77	11.99	0.43	4.89e-30	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.23e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg16262614	chr3:133464971	TF	0.24	7.91	0.3	1.15e-14	Iron status biomarkers (transferrin levels);
BRCA	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.24	-0.31	9.74e-16	Axial length;
BRCA	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg07148914	chr20:33460835	GGT7	-0.42	-9.03	-0.34	1.99e-18	Height;
BRCA	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.91	22.85	0.67	6.4e-85	Subjective well-being;
BRCA	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26314531	chr2:26401878	FAM59B	-0.65	-10.97	-0.4	8.96e-26	Gut microbiome composition (summer);
BRCA	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg06108461	chr20:60628389	TAF4	-0.64	-13.19	-0.46	2.75e-35	Body mass index;
BRCA	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg24558204	chr6:135376177	HBS1L	0.44	12.16	0.43	9.19e-31	Red blood cell count;
BRCA	cis	rs6714710	0.603	rs17489984	chr2:98421364	A/G	cg26665480	chr2:98280029	ACTR1B	0.6	13.83	0.48	2.95e-38	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg09904177	chr6:26538194	HMGN4	0.51	14.33	0.49	1.38e-40	Intelligence (multi-trait analysis);
BRCA	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	9.38	0.35	1.17e-19	Lung cancer in ever smokers;
BRCA	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-8.91	-0.33	5.22e-18	Alzheimer's disease (late onset);
BRCA	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg17971929	chr21:40555470	PSMG1	0.77	17.88	0.58	2.89e-58	Cognitive function;
BRCA	cis	rs1003719	0.751	rs7280371	chr21:38450008	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.61	14.25	0.49	3.28e-40	Eye color traits;
BRCA	cis	rs2985684	0.894	rs6572585	chr14:50021075	A/G	cg04989706	chr14:50066350	PPIL5	-0.45	-8.69	-0.33	3.06e-17	Carotid intima media thickness;
BRCA	trans	rs1459104	0.866	rs67929427	chr11:54824182	C/T	cg15704280	chr7:45808275	SEPT13	0.63	8.25	0.31	8.87e-16	Body mass index;
BRCA	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg03146154	chr1:46216737	IPP	0.45	10.01	0.37	5.27e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg07460842	chr6:66804631	NA	0.9	16.73	0.55	2.16e-52	Exhaled nitric oxide levels;
BRCA	trans	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg26043149	chr18:55253948	FECH	-0.38	-7.92	-0.3	1.09e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg04450456	chr4:17643702	FAM184B	0.33	9.51	0.35	3.8e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg10556349	chr10:835070	NA	0.59	8.31	0.31	5.59e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs4631830	0.832	rs11005089	chr10:51510813	C/A	cg20129853	chr10:51489980	NA	0.3	8.01	0.3	5.37e-15	Prostate-specific antigen levels;
BRCA	cis	rs11955398	0.583	rs7719726	chr5:59949537	T/C	cg02684056	chr5:59996105	DEPDC1B	0.38	8.83	0.33	9.8e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs76025697	1	rs76025697	chr5:179184488	G/A	cg14593053	chr5:179126677	CANX	0.4	10.15	0.37	1.49e-22	Granulocyte percentage of myeloid white cells;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Granulocyte count;
BRCA	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg01528321	chr10:82214614	TSPAN14	0.62	13.05	0.46	1.07e-34	Post bronchodilator FEV1;
BRCA	cis	rs7809950	0.678	rs75617662	chr7:107030439	G/A	cg23024343	chr7:107201750	COG5	-0.49	-9.73	-0.36	5.87e-21	Coronary artery disease;
BRCA	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg03585969	chr10:35415529	CREM	0.49	10.27	0.38	5.04e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06627557	chr7:32535165	LSM5;AVL9	1.06	30.03	0.77	3.03e-124	Cognitive ability;
BRCA	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9392556	0.829	rs613260	chr6:4120567	C/G	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.38	-8.2	-0.31	1.37e-15	Blood metabolite levels;
BRCA	cis	rs6558530	0.692	rs6558522	chr8:1702370	C/G	cg19131313	chr8:1704013	NA	0.38	7.97	0.3	7.46e-15	Systolic blood pressure;
BRCA	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg15395560	chr15:45543142	SLC28A2	-0.29	-7.89	-0.3	1.27e-14	Uric acid levels;
BRCA	cis	rs3784262	0.679	rs4238326	chr15:58336000	C/T	cg12031962	chr15:58353849	ALDH1A2	0.55	14.07	0.49	2.37e-39	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg04025307	chr7:1156635	C7orf50	0.59	9.31	0.35	2e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg09060608	chr5:178986726	RUFY1	0.56	14.09	0.49	1.86e-39	Lung cancer;
BRCA	cis	rs11229555	0.645	rs7945992	chr11:58187755	T/A	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs36052053	0.908	rs71558364	chr6:109616239	A/T	cg12927641	chr6:109611667	NA	-0.51	-7.9	-0.3	1.26e-14	Red cell distribution width;
BRCA	cis	rs9790314	0.747	rs9990115	chr3:160838412	C/G	cg03342759	chr3:160939853	NMD3	-0.53	-10.33	-0.38	2.95e-23	Morning vs. evening chronotype;
BRCA	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.93	0.33	4.4e-18	Tonsillectomy;
BRCA	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg14458575	chr2:238380390	NA	0.59	13.48	0.47	1.21e-36	Prostate cancer;
BRCA	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08045932	chr20:61659980	NA	0.5	11.5	0.41	5.92e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg26608667	chr7:1196370	ZFAND2A	0.37	8.34	0.31	4.57e-16	Longevity;Endometriosis;
BRCA	cis	rs2806561	1.000	rs1757044	chr1:23515631	T/C	cg19743168	chr1:23544995	NA	0.42	10.41	0.38	1.5e-23	Height;
BRCA	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg24130564	chr14:104152367	KLC1	0.36	8.07	0.3	3.37e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg20701182	chr2:24300061	SF3B14	0.68	12.9	0.45	5.2e-34	Lymphocyte counts;
BRCA	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg02733842	chr7:1102375	C7orf50	-0.72	-12.42	-0.44	7.02e-32	Bronchopulmonary dysplasia;
BRCA	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg23505145	chr19:12996616	KLF1	0.54	12.17	0.43	8.48e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.39	8.29	0.31	6.64e-16	Total cholesterol levels;
BRCA	cis	rs897080	0.516	rs1067393	chr2:44638832	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.8	0.33	1.28e-17	Height;
BRCA	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg25208724	chr1:156163844	SLC25A44	0.89	17.57	0.57	1.08e-56	Testicular germ cell tumor;
BRCA	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg16586182	chr3:47516702	SCAP	0.63	13.66	0.48	1.8e-37	Colorectal cancer;
BRCA	cis	rs1832871	0.672	rs11751553	chr6:158774750	C/T	cg07165851	chr6:158734300	TULP4	-0.62	-12.31	-0.44	2.08e-31	Height;
BRCA	cis	rs2742234	0.541	rs871763	chr10:43734188	C/T	cg02780029	chr10:43622663	RET	0.35	7.85	0.3	1.7e-14	Hirschsprung disease;
BRCA	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg20503657	chr10:835505	NA	-0.53	-10.06	-0.37	3.31e-22	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg08470875	chr2:26401718	FAM59B	0.75	11.81	0.42	3.12e-29	Mean corpuscular hemoglobin;
BRCA	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg00074818	chr8:8560427	CLDN23	0.39	8.44	0.32	2.11e-16	Obesity-related traits;
BRCA	cis	rs12200560	0.505	rs211178	chr6:97074094	T/A	cg06623918	chr6:96969491	KIAA0776	0.53	12.64	0.45	7.46e-33	Coronary heart disease;
BRCA	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg04362960	chr10:104952993	NT5C2	0.44	10.8	0.39	4.26e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg07636037	chr3:49044803	WDR6	-0.67	-13.08	-0.46	7.91e-35	Menarche (age at onset);
BRCA	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24531977	chr5:56204891	C5orf35	-0.86	-16.86	-0.55	4.81e-53	Initial pursuit acceleration;
BRCA	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg12310025	chr6:25882481	NA	-0.5	-11.91	-0.43	1.13e-29	Blood metabolite levels;
BRCA	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg13010199	chr12:38710504	ALG10B	0.51	10.33	0.38	3.05e-23	Bladder cancer;
BRCA	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	17.01	0.56	8.75e-54	Alzheimer's disease;
BRCA	cis	rs11608355	0.515	rs4766606	chr12:109934390	C/G	cg05360138	chr12:110035743	NA	0.72	13.3	0.47	8.56e-36	Neuroticism;
BRCA	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg24642439	chr20:33292090	TP53INP2	0.42	8.39	0.32	3.12e-16	Height;
BRCA	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg05535760	chr7:792225	HEATR2	0.69	12.46	0.44	4.7e-32	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.83	-0.42	2.56e-29	Platelet count;
BRCA	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.43	9.59	0.35	1.8899999999999998e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.48	0.38	8.25e-24	Motion sickness;
BRCA	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.18	0.4	1.22e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg01256987	chr12:42539512	GXYLT1	-0.57	-11.42	-0.41	1.26e-27	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.53	-11.93	-0.43	9.31e-30	Personality dimensions;
BRCA	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg06766960	chr11:133703094	NA	-0.6	-13.18	-0.46	2.93e-35	Childhood ear infection;
BRCA	cis	rs2617583	0.967	rs2652509	chr5:1448247	A/G	cg07151155	chr5:1473589	LPCAT1	-0.37	-8.06	-0.3	3.75e-15	Breast cancer;
BRCA	cis	rs10754283	0.967	rs10801760	chr1:90113824	G/A	cg21401794	chr1:90099060	LRRC8C	0.46	11.06	0.4	4.04e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-9.01	-0.34	2.3e-18	Eosinophil percentage of white cells;
BRCA	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg18904891	chr8:8559673	CLDN23	0.65	12.88	0.45	6.78e-34	Obesity-related traits;
BRCA	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg02297831	chr4:17616191	MED28	-0.39	-8.15	-0.31	1.99e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg23711669	chr6:146136114	FBXO30	0.64	14.9	0.51	2.57e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-11.22	-0.41	8.71e-27	Colorectal cancer;
BRCA	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg24562669	chr7:97807699	LMTK2	0.45	12.28	0.44	2.88e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	10.41	0.38	1.54e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-14.22	-0.49	4.54e-40	Brugada syndrome;
BRCA	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	15.91	0.53	2.78e-48	Electrocardiographic conduction measures;
BRCA	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg25767906	chr1:53392781	SCP2	-0.38	-8.49	-0.32	1.48e-16	Monocyte count;
BRCA	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11270836	1	rs11270836	chr4:38625915	T/TACATTATGTCATTTCACA	cg18361445	chr4:38666374	KLF3;FLJ13197	0.57	10.99	0.4	7.41e-26	Mumps;
BRCA	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08045932	chr20:61659980	NA	0.5	11.51	0.41	5.25e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg13010199	chr12:38710504	ALG10B	0.52	10.91	0.4	1.58e-25	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg26384229	chr12:38710491	ALG10B	-0.48	-11.28	-0.41	5.03e-27	Morning vs. evening chronotype;
BRCA	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg17691542	chr6:26056736	HIST1H1C	0.51	10.43	0.38	1.29e-23	Height;
BRCA	cis	rs7766436	0.885	rs13198355	chr6:22577119	C/G	cg13666174	chr6:22585274	NA	-0.45	-9.68	-0.36	9.33e-21	Coronary artery disease;
BRCA	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg13902645	chr11:5959945	NA	-0.47	-9.97	-0.37	7.7e-22	DNA methylation (variation);
BRCA	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	11.89	0.43	1.35e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-8.68	-0.32	3.22e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg00071950	chr4:10020882	SLC2A9	0.47	10.94	0.4	1.18e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg06115741	chr20:33292138	TP53INP2	0.48	10.68	0.39	1.25e-24	Coronary artery disease;
BRCA	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg01689657	chr7:91764605	CYP51A1	0.22	8.05	0.3	3.98e-15	Breast cancer;
BRCA	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg26838691	chr2:24397539	C2orf84	-0.54	-9.54	-0.35	2.89e-20	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs722599	0.748	rs2537824	chr14:75367349	T/C	cg08847533	chr14:75593920	NEK9	-0.44	-7.96	-0.3	8.16e-15	IgG glycosylation;
BRCA	cis	rs68170813	0.527	rs75382408	chr7:107010406	C/T	cg02696742	chr7:106810147	HBP1	-0.49	-8.29	-0.31	6.49e-16	Coronary artery disease;
BRCA	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11764359	chr7:65958608	NA	0.77	17.35	0.57	1.46e-55	Aortic root size;
BRCA	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg27129171	chr3:47204927	SETD2	0.71	17.08	0.56	3.81e-54	Colorectal cancer;
BRCA	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg00677455	chr12:58241039	CTDSP2	0.62	13.96	0.48	7.36e-39	Multiple sclerosis;
BRCA	cis	rs10785877	0.570	rs7043538	chr9:137109051	A/G	cg21243944	chr9:137118148	NA	0.3	7.93	0.3	9.81e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
BRCA	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21659725	chr3:3221576	CRBN	-0.33	-7.93	-0.3	9.93e-15	Body mass index;
BRCA	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg19622623	chr12:86230825	RASSF9	-0.33	-9.31	-0.35	2.09e-19	Major depressive disorder;
BRCA	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg15017067	chr4:17643749	FAM184B	0.29	9.01	0.34	2.37e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2797160	0.967	rs984041	chr6:126021328	A/T	cg05901451	chr6:126070800	HEY2	0.39	9.51	0.35	3.95e-20	Endometrial cancer;
BRCA	cis	rs4478858	0.735	rs10914361	chr1:31817542	T/G	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs2652834	0.851	rs4238370	chr15:63347363	T/G	cg05507819	chr15:63340323	TPM1	0.47	8.38	0.31	3.31e-16	HDL cholesterol;
BRCA	trans	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg26043149	chr18:55253948	FECH	-0.37	-8.12	-0.31	2.34e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24531977	chr5:56204891	C5orf35	-0.87	-18.47	-0.59	2.43e-61	Initial pursuit acceleration;
BRCA	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg05340658	chr4:99064831	C4orf37	0.61	14.59	0.5	8.39e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg12140854	chr5:148520817	ABLIM3	-0.43	-9.07	-0.34	1.41e-18	Breast cancer;
BRCA	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.58	0.32	7.26e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg17063962	chr7:91808500	NA	0.51	11.98	0.43	5.88e-30	Breast cancer;
BRCA	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg26587870	chr6:27730563	NA	-0.53	-8.14	-0.31	2.13e-15	Depression;
BRCA	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	11.43	0.41	1.2e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs11229555	0.645	rs12269745	chr11:58176875	G/A	cg15696309	chr11:58395628	NA	-0.45	-9.77	-0.36	4.3e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12618769	0.597	rs3769727	chr2:99103318	C/T	cg10123293	chr2:99228465	UNC50	0.42	8.37	0.31	3.7e-16	Bipolar disorder;
BRCA	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg06784218	chr1:46089804	CCDC17	0.45	10.89	0.4	1.9e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.02e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.17	-0.31	1.61e-15	Schizophrenia;
BRCA	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-8.11	-0.31	2.67e-15	Obesity-related traits;
BRCA	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg08742575	chr21:47604166	C21orf56	0.41	8.28	0.31	7.21e-16	Testicular germ cell tumor;
BRCA	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	17.73	0.57	1.77e-57	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-9.87	-0.36	1.78e-21	Gut microbiome composition (summer);
BRCA	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg09904177	chr6:26538194	HMGN4	0.56	18.26	0.59	3.11e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10802521	chr3:52805072	NEK4	-0.31	-8.11	-0.31	2.57e-15	Electroencephalogram traits;
BRCA	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-13.8	-0.48	4.25e-38	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6977660	0.714	rs9969381	chr7:19827454	C/T	cg07541023	chr7:19748670	TWISTNB	0.57	9.79	0.36	3.58e-21	Thyroid stimulating hormone;
BRCA	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg05340658	chr4:99064831	C4orf37	0.62	14.59	0.5	7.73e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4363385	0.818	rs378010	chr1:153007987	A/G	cg24667326	chr1:152973720	SPRR3	-0.33	-8.94	-0.33	4.25e-18	Inflammatory skin disease;
BRCA	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.51	-10.03	-0.37	4.32e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3767633	0.800	rs2880055	chr1:161922365	C/T	cg09175582	chr1:161736000	ATF6	0.46	8.1	0.31	2.87e-15	IgG glycosylation;
BRCA	cis	rs8023845	1.000	rs3759843	chr15:40453075	A/G	cg20259534	chr15:40453036	BUB1B	-0.59	-9.04	-0.34	1.79e-18	Chronic lymphocytic leukemia;
BRCA	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.63	0.61	1.63e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg03161606	chr19:29218774	NA	0.46	8.15	0.31	1.91e-15	Methadone dose in opioid dependence;
BRCA	trans	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg25214090	chr10:38739885	LOC399744	0.42	9.67	0.36	9.88e-21	Corneal astigmatism;
BRCA	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.53	-0.42	4.34e-28	Total cholesterol levels;
BRCA	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg01324343	chr3:183735012	ABCC5	0.67	16.11	0.54	3.04e-49	Anterior chamber depth;
BRCA	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	16.93	0.56	2.14e-53	Platelet count;
BRCA	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	9.9	0.36	1.33e-21	Aortic root size;
BRCA	cis	rs11229555	0.609	rs7128459	chr11:58179291	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1568889	0.838	rs10835299	chr11:28277693	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.78	-20.53	-0.63	2.57e-72	Bipolar disorder;
BRCA	cis	rs4363385	0.818	rs1415965	chr1:153002750	G/A	cg24667326	chr1:152973720	SPRR3	-0.32	-8.81	-0.33	1.17e-17	Inflammatory skin disease;
BRCA	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg27446573	chr6:127587934	RNF146	0.69	15.17	0.51	1.23e-44	Breast cancer;
BRCA	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg10876282	chr6:28092338	ZSCAN16	0.41	8.13	0.31	2.17e-15	Parkinson's disease;
BRCA	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg26528668	chr16:1614120	IFT140	0.35	7.94	0.3	8.89e-15	Coronary artery disease;
BRCA	cis	rs698813	0.674	rs4952707	chr2:44500683	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	8.75	0.33	1.93e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.74	-22.42	-0.66	1.37e-82	Longevity;Endometriosis;
BRCA	cis	rs12478296	0.591	rs12468297	chr2:242996474	A/G	cg06360820	chr2:242988706	NA	-0.64	-13.12	-0.46	5.48e-35	Obesity-related traits;
BRCA	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg12573674	chr2:1569213	NA	-0.58	-12.54	-0.44	2.11e-32	IgG glycosylation;
BRCA	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18876405	chr7:65276391	NA	0.55	13.18	0.46	3.03e-35	Aortic root size;
BRCA	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg25358565	chr5:93447407	FAM172A	1.15	17.91	0.58	1.94e-58	Diabetic retinopathy;
BRCA	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	25.97	0.72	4.89e-102	Platelet count;
BRCA	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg12311346	chr5:56204834	C5orf35	-0.49	-9.73	-0.36	6.07e-21	Coronary artery disease;
BRCA	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg05347473	chr6:146136440	FBXO30	0.39	7.93	0.3	9.59e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg08888203	chr3:10149979	C3orf24	0.68	14.48	0.5	2.55e-41	Alzheimer's disease;
BRCA	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg05340658	chr4:99064831	C4orf37	0.45	10.41	0.38	1.48e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg18305652	chr10:134549665	INPP5A	0.46	10.57	0.39	3.6e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg01689657	chr7:91764605	CYP51A1	0.21	7.85	0.3	1.74e-14	Breast cancer;
BRCA	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg08085267	chr17:45401833	C17orf57	-0.62	-13.1	-0.46	6.95e-35	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	4.98e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs36051895	0.589	rs10491650	chr9:5203054	C/T	cg02405213	chr9:5042618	JAK2	0.43	8.41	0.32	2.67e-16	Pediatric autoimmune diseases;
BRCA	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg00814883	chr7:100076585	TSC22D4	-0.49	-9.99	-0.37	6.05e-22	Platelet count;
BRCA	trans	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.5e-50	Obesity-related traits;
BRCA	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.64	0.55	6.17e-52	Colorectal cancer;
BRCA	cis	rs1476679	0.962	rs34995835	chr7:99990364	T/G	cg19116668	chr7:99932089	PMS2L1	0.48	8.65	0.32	4.01e-17	Alzheimer's disease (late onset);
BRCA	cis	rs7560272	0.723	rs2421548	chr2:73641240	A/G	cg20560298	chr2:73613845	ALMS1	0.42	11.33	0.41	2.96e-27	Schizophrenia;
BRCA	cis	rs939658	0.805	rs8024813	chr15:79427260	A/G	cg17916960	chr15:79447300	NA	-0.46	-11.52	-0.41	4.77e-28	Refractive error;
BRCA	cis	rs4363385	0.747	rs1129655	chr1:152958267	T/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.07	-0.34	1.4e-18	Inflammatory skin disease;
BRCA	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg24558204	chr6:135376177	HBS1L	0.53	14.81	0.51	7.1e-43	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg14582100	chr15:45693742	SPATA5L1	0.37	12.14	0.43	1.1e-30	Homoarginine levels;
BRCA	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg24692254	chr21:30365293	RNF160	-0.46	-10.16	-0.37	1.36e-22	Dental caries;
BRCA	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg24296786	chr1:45957014	TESK2	-0.46	-10.54	-0.38	4.86e-24	Red blood cell count;Reticulocyte count;
BRCA	cis	rs701145	0.585	rs1960241	chr3:153858398	T/C	cg17054900	chr3:154042577	DHX36	0.55	9.23	0.34	3.79e-19	Coronary artery disease;
BRCA	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg09904177	chr6:26538194	HMGN4	0.56	18.3	0.59	1.77e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	11.8	0.42	3.13e-29	Tonsillectomy;
BRCA	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg09021430	chr5:549028	NA	-0.64	-15.17	-0.51	1.26e-44	Obesity-related traits;
BRCA	cis	rs10744422	1.000	rs1587856	chr12:123342229	A/G	cg25930673	chr12:123319894	HIP1R	-0.53	-8.14	-0.31	2.06e-15	Schizophrenia;
BRCA	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg17802220	chr15:77601643	NA	-0.45	-10.12	-0.37	1.96e-22	Type 2 diabetes;
BRCA	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	8.8	0.33	1.28e-17	Iron status biomarkers;
BRCA	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg25036284	chr2:26402008	FAM59B	0.85	15.12	0.51	2.13e-44	Gut microbiome composition (summer);
BRCA	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg16558253	chr16:72132732	DHX38	-0.39	-9.51	-0.35	3.86e-20	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg06935464	chr4:38784597	TLR10	0.5	8.21	0.31	1.24e-15	Breast cancer;
BRCA	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg12292205	chr6:26970375	C6orf41	-0.8	-19.68	-0.61	9.64e-68	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg04315214	chr1:2043799	PRKCZ	0.47	12.86	0.45	8.3e-34	Height;
BRCA	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg04455712	chr21:45112962	RRP1B	0.44	12.31	0.44	2.18e-31	Mean corpuscular volume;
BRCA	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.51	-0.32	1.2e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg04990556	chr1:26633338	UBXN11	0.55	8.44	0.32	2.2e-16	Obesity-related traits;
BRCA	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg26384229	chr12:38710491	ALG10B	0.7	15.82	0.53	8.18e-48	Morning vs. evening chronotype;
BRCA	cis	rs6496044	0.568	rs6496040	chr15:86064129	C/G	cg10818794	chr15:86012489	AKAP13	-0.29	-7.91	-0.3	1.1e-14	Interstitial lung disease;
BRCA	cis	rs9815354	0.723	rs79741604	chr3:41947321	C/T	cg03022575	chr3:42003672	ULK4	0.68	9.48	0.35	4.82e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg14019146	chr3:50243930	SLC38A3	-0.57	-11.9	-0.43	1.24e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs11605275	1.000	rs76399107	chr11:20029148	C/T	cg14835545	chr11:20032148	NAV2	-0.58	-8.68	-0.32	3.3e-17	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26314531	chr2:26401878	FAM59B	-0.88	-16.41	-0.54	9.34e-51	Gut microbiome composition (summer);
BRCA	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg03433033	chr1:76189801	ACADM	-0.59	-11.81	-0.42	3.04e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.25	0.34	3.44e-19	Morning vs. evening chronotype;
BRCA	cis	rs36051895	0.589	rs10491651	chr9:5200060	A/G	cg02405213	chr9:5042618	JAK2	-0.42	-7.98	-0.3	6.6e-15	Pediatric autoimmune diseases;
BRCA	cis	rs1371614	0.635	rs4665923	chr2:27138911	C/T	cg12368169	chr2:27073192	DPYSL5	0.28	8.45	0.32	2.04e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs3768617	0.782	rs12146099	chr1:182968079	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	8.52	0.32	1.12e-16	Fuchs's corneal dystrophy;
BRCA	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs11249608	0.548	rs62393072	chr5:178450056	C/T	cg21905437	chr5:178450457	ZNF879	0.54	11.23	0.41	7.64e-27	Pubertal anthropometrics;
BRCA	cis	rs939658	0.805	rs11634679	chr15:79432475	T/C	cg17916960	chr15:79447300	NA	-0.45	-11.23	-0.41	7.81e-27	Refractive error;
BRCA	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg04025307	chr7:1156635	C7orf50	0.59	9.46	0.35	5.74e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg00080972	chr5:178986291	RUFY1	0.37	8.43	0.32	2.37e-16	Lung cancer;
BRCA	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg22713356	chr15:30763199	NA	1.3	24.11	0.69	7.71e-92	Uric acid levels;
BRCA	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.62	0.36	1.49e-20	Menopause (age at onset);
BRCA	cis	rs7520050	1.000	rs785473	chr1:46516863	T/C	cg24296786	chr1:45957014	TESK2	0.41	9.22	0.34	4.28e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg23992470	chr4:843637	GAK	0.48	8.12	0.31	2.42e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg15556689	chr8:8085844	FLJ10661	0.36	9.21	0.34	4.58e-19	Neuroticism;
BRCA	cis	rs4285028	0.747	rs7623901	chr3:121529011	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.89	16.82	0.55	7.5e-53	Multiple sclerosis;
BRCA	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg13010199	chr12:38710504	ALG10B	0.44	8.97	0.33	3.33e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.57	-0.45	1.6e-32	Response to antipsychotic treatment;
BRCA	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.11	18.71	0.59	1.23e-62	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-11.79	-0.42	3.69e-29	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	9.89	0.36	1.45e-21	Aortic root size;
BRCA	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-10.47	-0.38	8.67e-24	Schizophrenia;
BRCA	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg26031613	chr14:104095156	KLC1	-0.43	-8.56	-0.32	8.44e-17	Schizophrenia;
BRCA	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg04450456	chr4:17643702	FAM184B	0.36	9.7	0.36	7.64e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9341808	0.727	rs4706834	chr6:81012605	G/T	cg08355045	chr6:80787529	NA	0.35	9.01	0.34	2.29e-18	Sitting height ratio;
BRCA	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg21775007	chr8:11205619	TDH	0.7	17.27	0.56	3.98e-55	Retinal vascular caliber;
BRCA	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg00800038	chr16:89945340	TCF25	-0.7	-10.58	-0.39	3.23e-24	Skin colour saturation;
BRCA	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg22105103	chr4:187893119	NA	0.41	13.33	0.47	5.9e-36	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg19077165	chr18:44547161	KATNAL2	-0.56	-12.24	-0.44	4.24e-31	Personality dimensions;
BRCA	cis	rs36051895	0.632	rs12001334	chr9:5152604	C/A	cg02405213	chr9:5042618	JAK2	-0.44	-8.57	-0.32	7.48e-17	Pediatric autoimmune diseases;
BRCA	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg03342759	chr3:160939853	NMD3	-0.63	-13.31	-0.47	7.41e-36	Morning vs. evening chronotype;
BRCA	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-12.31	-0.44	2.1e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs12042938	0.905	rs823160	chr1:231776636	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.37	8.16	0.31	1.82e-15	Neuranatomic and neurocognitive phenotypes;
BRCA	cis	rs897984	0.572	rs4889526	chr16:31030344	C/A	cg02466173	chr16:30829666	NA	-0.43	-9.74	-0.36	5.48e-21	Dementia with Lewy bodies;
BRCA	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg20712883	chr12:51590929	POU6F1	0.39	7.93	0.3	9.7e-15	Cisplatin-induced ototoxicity;
BRCA	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg22920501	chr2:26401640	FAM59B	0.91	16.27	0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg14582100	chr15:45693742	SPATA5L1	0.37	11.89	0.43	1.39e-29	Homoarginine levels;
BRCA	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg08885076	chr2:99613938	TSGA10	-0.42	-9.82	-0.36	2.68e-21	Chronic sinus infection;
BRCA	cis	rs10838687	0.867	rs2633082	chr11:47248050	C/G	cg25783544	chr11:47291846	MADD	-0.42	-8.3	-0.31	6.1e-16	Proinsulin levels;
BRCA	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg13119609	chr19:45449297	APOC2	-0.53	-14.74	-0.5	1.56e-42	Blood protein levels;
BRCA	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg16590910	chr6:42928470	GNMT	0.41	9.15	0.34	7.36e-19	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18876405	chr7:65276391	NA	-0.57	-13.67	-0.48	1.64e-37	Aortic root size;
BRCA	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg13385794	chr1:248469461	NA	0.27	7.85	0.3	1.75e-14	Common traits (Other);
BRCA	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg24006582	chr15:45444508	DUOX1	0.55	10.71	0.39	9.9e-25	Uric acid levels;
BRCA	cis	rs3007729	0.509	rs6665151	chr1:18800247	A/G	cg04846421	chr1:18800208	NA	-0.44	-10.78	-0.39	5.44e-25	Diabetic retinopathy;
BRCA	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg11752832	chr7:134001865	SLC35B4	-0.5	-11.9	-0.43	1.25e-29	Mean platelet volume;
BRCA	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.64	11.66	0.42	1.34e-28	Height;
BRCA	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg04025307	chr7:1156635	C7orf50	0.45	10.02	0.37	4.98e-22	Longevity;Endometriosis;
BRCA	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg09307838	chr4:120376055	NA	0.59	12.29	0.44	2.66e-31	Corneal astigmatism;
BRCA	cis	rs9469890	0.604	rs11756281	chr6:34503446	T/C	cg14254433	chr6:34482411	PACSIN1	-0.44	-9.07	-0.34	1.44e-18	Pubertal anthropometrics;Coronary artery disease;
BRCA	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-8.81	-0.33	1.19e-17	Response to antipsychotic treatment;
BRCA	cis	rs7539409	0.651	rs7521788	chr1:84309320	G/T	cg10977910	chr1:84465055	TTLL7	0.68	10.45	0.38	1.05e-23	Alzheimer's disease;
BRCA	cis	rs7264396	0.887	rs224351	chr20:34052273	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-8.3	-0.31	6.37e-16	Total cholesterol levels;
BRCA	cis	rs6429082	0.714	rs184108	chr1:235646160	A/G	cg26050004	chr1:235667680	B3GALNT2	0.57	14.17	0.49	7.83e-40	Adiposity;
BRCA	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg21132104	chr15:45694354	SPATA5L1	0.75	17.09	0.56	3.4e-54	Homoarginine levels;
BRCA	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg01528321	chr10:82214614	TSPAN14	0.64	14.58	0.5	9.02e-42	Post bronchodilator FEV1;
BRCA	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg10253484	chr15:75165896	SCAMP2	-0.56	-11.67	-0.42	1.16e-28	Breast cancer;
BRCA	cis	rs4690686	0.538	rs7436387	chr4:177257723	T/G	cg17059388	chr4:177262070	NA	0.49	9.89	0.36	1.47e-21	Essential tremor;
BRCA	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg03585969	chr10:35415529	CREM	0.49	10.38	0.38	2.0500000000000001e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg01283332	chr5:1856932	NA	-0.35	-8.59	-0.32	6.56e-17	Cardiovascular disease risk factors;
BRCA	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.34	-0.61	6.06e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg27432699	chr2:27873401	GPN1	-0.52	-10.83	-0.39	3.2e-25	Oral cavity cancer;
BRCA	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.63	13.83	0.48	3.13e-38	Lymphocyte percentage of white cells;
BRCA	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg08888203	chr3:10149979	C3orf24	0.65	11.86	0.42	1.89e-29	Alzheimer's disease;
BRCA	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg05625103	chr10:2543513	NA	0.41	9.03	0.34	1.94e-18	Age-related hearing impairment;
BRCA	cis	rs10267417	0.603	rs10281428	chr7:19857374	G/A	cg07541023	chr7:19748670	TWISTNB	0.51	9.08	0.34	1.37e-18	Night sleep phenotypes;
BRCA	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg15448220	chr1:150897856	SETDB1	0.36	8.2	0.31	1.27e-15	Melanoma;
BRCA	cis	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg20368463	chr18:77673604	PQLC1	-0.34	-8.06	-0.3	3.7e-15	Schizophrenia;
BRCA	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg19077165	chr18:44547161	KATNAL2	-0.57	-12.4	-0.44	9.01e-32	Personality dimensions;
BRCA	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg05347473	chr6:146136440	FBXO30	-0.61	-12.08	-0.43	2.04e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs397969	0.596	rs7209653	chr17:19882084	A/G	cg13482628	chr17:19912719	NA	0.42	10.11	0.37	2.12e-22	Platelet count;
BRCA	cis	rs4268898	0.552	rs7560342	chr2:24371691	T/C	cg06627628	chr2:24431161	ITSN2	0.41	8.64	0.32	4.53e-17	Asthma;
BRCA	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	12.21	0.43	5.69e-31	Platelet count;
BRCA	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11644478	chr21:40555479	PSMG1	0.85	19.84	0.62	1.29e-68	Cognitive function;
BRCA	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg24296786	chr1:45957014	TESK2	0.59	14.37	0.49	9.24e-41	High light scatter reticulocyte count;
BRCA	trans	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg15934090	chr1:100435551	SLC35A3	0.37	8.22	0.31	1.14e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg25237894	chr2:233734115	C2orf82	0.4	11.47	0.41	8.37e-28	Coronary artery disease;
BRCA	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg12311346	chr5:56204834	C5orf35	-0.78	-15.99	-0.53	1.18e-48	Initial pursuit acceleration;
BRCA	cis	rs68170813	0.559	rs12534676	chr7:106943640	G/A	cg02696742	chr7:106810147	HBP1	-0.52	-8.46	-0.32	1.77e-16	Coronary artery disease;
BRCA	cis	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg07460842	chr6:66804631	NA	-1.0	-20.09	-0.62	5.87e-70	Exhaled nitric oxide output;
BRCA	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg14675211	chr2:100938903	LONRF2	0.47	10.88	0.4	2.05e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-12.12	-0.43	1.39e-30	Gut microbiome composition (summer);
BRCA	cis	rs7809950	1.000	rs2237672	chr7:107131563	A/C	cg23024343	chr7:107201750	COG5	-0.4	-9.3	-0.35	2.24e-19	Coronary artery disease;
BRCA	cis	rs13082711	0.519	rs13091109	chr3:27229125	G/A	cg02860705	chr3:27208620	NA	0.55	10.98	0.4	8.44e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg26384229	chr12:38710491	ALG10B	0.77	17.59	0.57	8.61e-57	Bladder cancer;
BRCA	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg24060327	chr5:131705240	SLC22A5	0.45	8.95	0.33	3.97e-18	Blood metabolite levels;
BRCA	cis	rs939658	0.805	rs34478496	chr15:79440997	C/A	cg17916960	chr15:79447300	NA	-0.43	-10.98	-0.4	8.11e-26	Refractive error;
BRCA	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.88	19.64	0.61	1.6e-67	Cognitive ability;
BRCA	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	14.55	0.5	1.22e-41	Motion sickness;
BRCA	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.58	11.05	0.4	4.22e-26	Height;
BRCA	cis	rs36051895	0.659	rs62543863	chr9:5085417	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-9.41	-0.35	8.61e-20	Pediatric autoimmune diseases;
BRCA	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg22139774	chr2:100720529	AFF3	-0.3	-8.39	-0.31	3.14e-16	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg12573674	chr2:1569213	NA	-0.51	-9.7	-0.36	7.42e-21	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.78	0.33	1.48e-17	Motion sickness;
BRCA	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.55	-0.32	9.39e-17	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7980799	0.682	rs4931719	chr12:33602986	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-10.99	-0.4	7.56e-26	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs2882667	0.554	rs1368425	chr5:138280217	A/G	cg04439458	chr5:138467593	SIL1	-0.32	-8.07	-0.3	3.56e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3768617	0.706	rs11588675	chr1:182988052	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.48	11.16	0.4	1.52e-26	Fuchs's corneal dystrophy;
BRCA	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg19187155	chr2:232395269	NMUR1	0.59	13.67	0.48	1.7e-37	Height;
BRCA	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg06618935	chr21:46677482	NA	-0.36	-7.86	-0.3	1.6e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7586879	1.000	rs11683212	chr2:25120196	T/C	cg04586622	chr2:25135609	ADCY3	0.4	9.33	0.35	1.68e-19	Body mass index;
BRCA	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-13.37	-0.47	4.17e-36	Response to antipsychotic treatment;
BRCA	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.35	-0.41	2.61e-27	Extrinsic epigenetic age acceleration;
BRCA	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.68	-0.48	1.47e-37	Extrinsic epigenetic age acceleration;
BRCA	cis	rs8114671	0.967	rs6088747	chr20:33754604	G/T	cg07148914	chr20:33460835	GGT7	0.39	8.29	0.31	6.8e-16	Height;
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.47	-10.66	-0.39	1.52e-24	Longevity;Endometriosis;
BRCA	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg18964960	chr10:1102726	WDR37	0.61	8.22	0.31	1.1e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs1113500	0.933	rs10785833	chr1:108639082	A/G	cg06207961	chr1:108661230	NA	0.45	10.95	0.4	1.11e-25	Growth-regulated protein alpha levels;
BRCA	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg27129171	chr3:47204927	SETD2	0.74	18.61	0.59	4.14e-62	Colorectal cancer;
BRCA	trans	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg15704280	chr7:45808275	SEPT13	0.6	8.83	0.33	1.02e-17	Axial length;
BRCA	trans	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.86	-28.72	-0.75	3.81e-117	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg00677455	chr12:58241039	CTDSP2	0.47	11.56	0.42	3.43e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11644478	chr21:40555479	PSMG1	0.85	19.42	0.61	2.19e-66	Cognitive function;
BRCA	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg01028140	chr2:1542097	TPO	-0.56	-11.48	-0.41	7.52e-28	IgG glycosylation;
BRCA	cis	rs868036	1.000	rs884202	chr15:68054388	G/A	cg08079166	chr15:68083412	MAP2K5	-0.33	-8.71	-0.33	2.52e-17	Restless legs syndrome;
BRCA	trans	rs783540	0.934	rs10400906	chr15:83297138	A/G	cg18393722	chr15:85113863	UBE2QP1	0.28	8.77	0.33	1.57e-17	Schizophrenia;
BRCA	cis	rs57590327	0.528	rs2229519	chr3:81698130	T/C	cg07356753	chr3:81810745	GBE1	-0.42	-9.72	-0.36	6.32e-21	Extraversion;
BRCA	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg14675211	chr2:100938903	LONRF2	0.41	9.2	0.34	4.82e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs12618769	0.625	rs17034241	chr2:99224998	C/G	cg10123293	chr2:99228465	UNC50	0.43	8.6	0.32	6.35e-17	Bipolar disorder;
BRCA	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	trans	rs2270927	0.510	rs31244	chr5:75594743	G/A	cg13563193	chr19:33072644	PDCD5	0.87	10.38	0.38	2.0500000000000001e-23	Mean corpuscular volume;
BRCA	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg06784218	chr1:46089804	CCDC17	0.51	12.25	0.44	3.85e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg27661571	chr11:113659931	NA	0.66	10.44	0.38	1.19e-23	Hip circumference adjusted for BMI;
BRCA	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg27284194	chr4:1044797	NA	0.43	9.26	0.34	3.13e-19	Recombination rate (males);
BRCA	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg05639522	chr1:247681581	NA	0.47	10.61	0.39	2.39e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg10223061	chr2:219282414	VIL1	-0.27	-7.92	-0.3	1.04e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1595825	0.732	rs7577835	chr2:198378056	T/C	cg19156104	chr2:198669113	PLCL1	-0.47	-8.27	-0.31	7.54e-16	Ulcerative colitis;
BRCA	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg02079420	chr8:82753780	SNX16	0.35	7.91	0.3	1.12e-14	Diastolic blood pressure;
BRCA	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg06784218	chr1:46089804	CCDC17	0.45	10.8	0.39	4.2e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg15133208	chr4:90757351	SNCA	-0.4	-8.3	-0.31	6e-16	Neuroticism;
BRCA	cis	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg08807101	chr21:30365312	RNF160	-0.46	-7.89	-0.3	1.3e-14	Cognitive test performance;
BRCA	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg21479132	chr6:26055353	NA	0.58	8.16	0.31	1.77e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6545883	0.929	rs12617911	chr2:61740825	A/G	cg15711740	chr2:61764176	XPO1	-0.55	-14.13	-0.49	1.18e-39	Tuberculosis;
BRCA	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg11764359	chr7:65958608	NA	0.78	18.69	0.59	1.55e-62	Aortic root size;
BRCA	cis	rs11874712	1.000	rs1800639	chr18:43671240	G/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.35	8.24	0.31	9.99e-16	Migraine - clinic-based;
BRCA	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg08999081	chr20:33150536	PIGU	-0.33	-8.47	-0.32	1.72e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18876405	chr7:65276391	NA	0.51	11.57	0.42	2.98e-28	Aortic root size;
BRCA	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg26597838	chr10:835615	NA	0.87	15.6	0.53	9.49e-47	Eosinophil percentage of granulocytes;
BRCA	trans	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg04565464	chr8:145669602	NFKBIL2	-0.35	-8.82	-0.33	1.07e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs13095912	1.000	rs7374856	chr3:185311964	A/C	cg11274856	chr3:185301563	NA	0.34	8.53	0.32	1.1e-16	Systolic blood pressure;
BRCA	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg25427524	chr10:38739819	LOC399744	0.59	13.44	0.47	1.85e-36	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg10523679	chr1:76189770	ACADM	0.76	15.91	0.53	2.83e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.29	0.31	6.45e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7833986	0.501	rs2719227	chr8:57043794	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.63	-11.58	-0.42	2.89e-28	Height;
BRCA	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11764359	chr7:65958608	NA	0.74	16.46	0.55	4.94e-51	Aortic root size;
BRCA	cis	rs2046867	0.862	rs75638790	chr3:72830502	C/T	cg25664220	chr3:72788482	NA	-0.55	-11.41	-0.41	1.49e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg07169764	chr2:136633963	MCM6	-0.72	-15.01	-0.51	7.75e-44	Mosquito bite size;
BRCA	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18876405	chr7:65276391	NA	-0.52	-11.77	-0.42	4.46e-29	Aortic root size;
BRCA	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg11789530	chr4:8429930	ACOX3	-0.68	-17.65	-0.57	4.31e-57	Response to antineoplastic agents;
BRCA	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	9.19	0.34	5.37e-19	Systemic lupus erythematosus;
BRCA	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg12935359	chr14:103987150	CKB	-0.54	-13.28	-0.46	1.07e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg23978390	chr7:1156363	C7orf50	0.35	7.84	0.3	1.9e-14	Bronchopulmonary dysplasia;
BRCA	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg11707556	chr5:10655725	ANKRD33B	0.47	10.63	0.39	1.99e-24	Height;
BRCA	cis	rs72766638	0.806	rs56303154	chr9:136936376	C/T	cg13789015	chr9:136890014	NCRNA00094	0.55	8.78	0.33	1.49e-17	Mosquito bite size;
BRCA	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg08847533	chr14:75593920	NEK9	-0.84	-20.9	-0.64	2.6e-74	Height;
BRCA	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23248424	chr5:179741104	GFPT2	-0.67	-14.31	-0.49	1.68e-40	Height;
BRCA	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.4	7.86	0.3	1.66e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs939658	0.776	rs35904425	chr15:79444567	G/A	cg17916960	chr15:79447300	NA	-0.46	-11.45	-0.41	9.24e-28	Refractive error;
BRCA	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-9.94	-0.37	9.65e-22	Alzheimer's disease (late onset);
BRCA	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg08738300	chr3:44038990	NA	0.45	8.78	0.33	1.47e-17	Coronary artery disease;
BRCA	cis	rs7737355	0.947	rs2108869	chr5:131086880	A/G	cg06307176	chr5:131281290	NA	0.52	10.07	0.37	2.99e-22	Life satisfaction;
BRCA	cis	rs2625529	0.938	rs9120	chr15:72115763	G/A	cg16672083	chr15:72433130	SENP8	-0.81	-16.62	-0.55	8.55e-52	Red blood cell count;
BRCA	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg24642439	chr20:33292090	TP53INP2	0.56	12.4	0.44	8.36e-32	Coronary artery disease;
BRCA	cis	rs6545883	0.562	rs777588	chr2:61426820	G/A	cg15711740	chr2:61764176	XPO1	-0.47	-11.83	-0.42	2.56e-29	Tuberculosis;
BRCA	trans	rs12517041	1.000	rs12514453	chr5:23289951	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	0.45	8.16	0.31	1.78e-15	Calcium levels;
BRCA	cis	rs10193935	0.582	rs13394853	chr2:42630900	T/C	cg27598129	chr2:42591480	NA	-0.79	-13.41	-0.47	2.69e-36	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	8.31e-21	Bladder cancer;
BRCA	cis	rs281408	0.559	rs281381	chr19:49214748	C/T	cg13540341	chr19:49222985	MAMSTR	-0.38	-10.02	-0.37	4.9e-22	Urinary metabolites (H-NMR features);
BRCA	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg17971929	chr21:40555470	PSMG1	0.77	17.64	0.57	4.64e-57	Cognitive function;
BRCA	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg06623918	chr6:96969491	KIAA0776	0.73	12.9	0.45	5.51e-34	Migraine;Coronary artery disease;
BRCA	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg13010199	chr12:38710504	ALG10B	0.45	9.34	0.35	1.53e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg09307838	chr4:120376055	NA	0.68	13.41	0.47	2.68e-36	Corneal astigmatism;
BRCA	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10802521	chr3:52805072	NEK4	0.33	8.86	0.33	8.06e-18	Bipolar disorder;
BRCA	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.51	-10.33	-0.38	3.16e-23	Gut microbiome composition (summer);
BRCA	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg06697600	chr4:7070879	GRPEL1	-0.53	-10.84	-0.39	2.93e-25	Monocyte percentage of white cells;
BRCA	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg16850897	chr7:100343110	ZAN	0.37	8.44	0.32	2.14e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.61	-0.32	5.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7766436	0.885	rs1418312	chr6:22589704	C/T	cg13666174	chr6:22585274	NA	-0.49	-11.55	-0.42	3.57e-28	Coronary artery disease;
BRCA	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg02753203	chr1:228287806	NA	-0.58	-12.38	-0.44	1.04e-31	Diastolic blood pressure;
BRCA	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg01256987	chr12:42539512	GXYLT1	-0.56	-11.5	-0.41	5.81e-28	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs4363385	0.818	rs10888526	chr1:153000311	G/T	cg24667326	chr1:152973720	SPRR3	-0.32	-8.58	-0.32	7.18e-17	Inflammatory skin disease;
BRCA	cis	rs11718455	0.883	rs2372579	chr3:44034003	A/T	cg08738300	chr3:44038990	NA	0.47	8.92	0.33	4.97e-18	Coronary artery disease;
BRCA	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg12863693	chr15:85201151	NMB	-0.36	-8.54	-0.32	9.87e-17	P wave terminal force;
BRCA	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.15	-0.49	9.24e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg18132916	chr6:79620363	NA	-0.43	-9.75	-0.36	4.99e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.49	-9.49	-0.35	4.31e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3857536	0.740	rs9342532	chr6:66886297	T/C	cg07460842	chr6:66804631	NA	-0.48	-9.27	-0.34	2.78e-19	Blood trace element (Cu levels);
BRCA	cis	rs1113500	0.862	rs2336128	chr1:108640739	G/T	cg06207961	chr1:108661230	NA	0.45	10.98	0.4	8.47e-26	Growth-regulated protein alpha levels;
BRCA	trans	rs12517041	1.000	rs6859293	chr5:23312935	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-8.27	-0.31	7.52e-16	Calcium levels;
BRCA	cis	rs6977660	0.714	rs6943204	chr7:19818671	A/G	cg05791153	chr7:19748676	TWISTNB	0.48	9.42	0.35	7.97e-20	Thyroid stimulating hormone;
BRCA	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg21132104	chr15:45694354	SPATA5L1	0.75	17.08	0.56	3.89e-54	Homoarginine levels;
BRCA	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg18230493	chr5:56204884	C5orf35	-0.73	-14.29	-0.49	2.21e-40	Initial pursuit acceleration;
BRCA	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg15448220	chr1:150897856	SETDB1	0.35	7.97	0.3	7.24e-15	Melanoma;
BRCA	cis	rs1891275	0.515	rs2421694	chr10:93516104	A/G	cg07889827	chr10:93443413	NA	-0.41	-11.24	-0.41	7.05e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs11603020	0.851	rs10896631	chr11:57381263	T/C	cg19752551	chr11:57585705	CTNND1	-0.42	-9.63	-0.36	1.41e-20	Blood protein levels;
BRCA	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg17330251	chr7:94953956	PON1	-0.42	-8.64	-0.32	4.63e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg17063962	chr7:91808500	NA	0.52	12.14	0.43	1.15e-30	Breast cancer;
BRCA	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg03709012	chr19:19516395	GATAD2A	0.91	17.32	0.57	2.19e-55	Nonalcoholic fatty liver disease;
BRCA	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg26597838	chr10:835615	NA	1.02	17.81	0.58	6.22e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg16405210	chr4:1374714	KIAA1530	-0.58	-14.02	-0.49	3.93e-39	Longevity;
BRCA	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg06627628	chr2:24431161	ITSN2	-0.51	-10.39	-0.38	1.86e-23	Asthma;
BRCA	cis	rs7677751	0.806	rs1800810	chr4:55094031	C/G	cg17187183	chr4:55093834	PDGFRA	0.44	9.27	0.34	2.73e-19	Corneal astigmatism;
BRCA	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg20991723	chr1:152506922	NA	0.37	8.3	0.31	6.04e-16	Hair morphology;
BRCA	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg12219531	chr12:120966889	COQ5	0.55	11.42	0.41	1.25e-27	High light scatter reticulocyte count;
BRCA	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg20628663	chr10:43360327	NA	-0.7	-13.62	-0.47	2.75e-37	Blood protein levels;
BRCA	cis	rs9462027	0.628	rs28675115	chr6:34732514	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.96	-0.3	7.8e-15	Systemic lupus erythematosus;
BRCA	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.89	0.4	1.85e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg06623918	chr6:96969491	KIAA0776	-0.76	-13.44	-0.47	1.88e-36	Migraine;Coronary artery disease;
BRCA	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg26838691	chr2:24397539	C2orf84	0.39	7.84	0.3	1.85e-14	Asthma;
BRCA	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg22920501	chr2:26401640	FAM59B	-0.63	-11.21	-0.41	9.3e-27	Gut microbiome composition (summer);
BRCA	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg08742575	chr21:47604166	C21orf56	0.41	7.91	0.3	1.15e-14	Testicular germ cell tumor;
BRCA	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg09455208	chr3:40491958	NA	0.36	8.67	0.32	3.61e-17	Renal cell carcinoma;
BRCA	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.67	-0.61	9.89e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg13770153	chr20:60521292	NA	-0.43	-9.46	-0.35	5.93e-20	Body mass index;
BRCA	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-8.26	-0.31	8.65e-16	Schizophrenia;
BRCA	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22442454	chr1:209979470	IRF6	0.42	10.99	0.4	7.4e-26	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
BRCA	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg21475434	chr5:93447410	FAM172A	0.68	9.19	0.34	5.41e-19	Diabetic retinopathy;
BRCA	cis	rs12367572	0.620	rs1857924	chr12:45344212	T/G	cg04608330	chr12:45269318	NELL2	-0.4	-8.53	-0.32	1.08e-16	Gut microbiome composition (summer);
BRCA	cis	rs752010	0.695	rs12123834	chr1:42105727	T/C	cg06885757	chr1:42089581	HIVEP3	0.23	8.35	0.31	4.36e-16	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs4363385	0.818	rs419721	chr1:153006902	C/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg21475434	chr5:93447410	FAM172A	0.7	8.9	0.33	5.82e-18	Diabetic retinopathy;
BRCA	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg23711669	chr6:146136114	FBXO30	0.72	17.48	0.57	3.15e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg18252515	chr7:66147081	NA	-0.51	-10.5	-0.38	6.87e-24	Corneal structure;
BRCA	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.4	0.66	1.74e-82	Chronic sinus infection;
BRCA	cis	rs7178424	0.711	rs11635569	chr15:62213597	G/A	cg00456672	chr15:62358751	C2CD4A	-0.39	-9.29	-0.34	2.39e-19	Height;
BRCA	cis	rs66530629	0.958	rs4024244	chr1:25050228	G/A	cg01905478	chr1:25040257	NA	0.36	8.28	0.31	7.13e-16	Plateletcrit;
BRCA	cis	rs6450176	0.585	rs255761	chr5:53321956	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.52	-10.98	-0.4	8.15e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs9815354	1.000	rs9824731	chr3:41889698	G/T	cg03022575	chr3:42003672	ULK4	0.49	7.99	0.3	6.4e-15	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg26043149	chr18:55253948	FECH	0.39	8.8	0.33	1.28e-17	Bone mineral density;
BRCA	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg06784218	chr1:46089804	CCDC17	0.5	12.02	0.43	3.67e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	23.75	0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg04944784	chr2:26401820	FAM59B	0.76	12.37	0.44	1.18e-31	Gut microbiome composition (summer);
BRCA	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22857025	chr5:266934	NA	-1.02	-19.96	-0.62	3.08e-69	Breast cancer;
BRCA	trans	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg26043149	chr18:55253948	FECH	-0.38	-8.3	-0.31	6.1e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg05340658	chr4:99064831	C4orf37	0.64	14.85	0.51	4.59e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6763687	0.725	rs7615743	chr3:171799045	G/C	cg16233210	chr3:171778391	FNDC3B	0.37	8.15	0.31	1.91e-15	Red cell distribution width;
BRCA	cis	rs36051895	0.659	rs7046077	chr9:5045328	C/G	cg02405213	chr9:5042618	JAK2	-0.5	-9.65	-0.36	1.2e-20	Pediatric autoimmune diseases;
BRCA	cis	rs10911363	0.592	rs2761581	chr1:183474850	G/C	cg09173681	chr1:183549694	NCF2	0.54	11.29	0.41	4.49e-27	Systemic lupus erythematosus;
BRCA	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg25036284	chr2:26402008	FAM59B	-0.93	-14.35	-0.49	1.11e-40	Gut microbiome composition (summer);
BRCA	cis	rs7523273	0.597	rs2761437	chr1:207923081	A/G	cg22525895	chr1:207977042	MIR29B2	0.41	8.59	0.32	6.82e-17	Schizophrenia;
BRCA	trans	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg06521331	chr12:34319734	NA	-0.45	-8.6	-0.32	6.09e-17	Bladder cancer;
BRCA	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00166722	chr3:10149974	C3orf24	0.65	12.78	0.45	1.82e-33	Alzheimer's disease;
BRCA	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg19077165	chr18:44547161	KATNAL2	-0.37	-7.97	-0.3	7.06e-15	Educational attainment;
BRCA	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-13.19	-0.46	2.56e-35	Response to antipsychotic treatment;
BRCA	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	12.71	0.45	3.85e-33	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9394841	0.692	rs3806113	chr6:41876335	C/T	cg08135965	chr6:41755394	TOMM6	0.51	8.65	0.32	4.14e-17	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg25174290	chr11:3078921	CARS	-0.35	-10.19	-0.37	1.1e-22	Longevity;
BRCA	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg07148914	chr20:33460835	GGT7	0.38	8.57	0.32	7.57e-17	Height;
BRCA	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-9.37	-0.35	1.24e-19	Personality dimensions;
BRCA	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg08807892	chr2:162101083	NA	-0.46	-8.15	-0.31	1.94e-15	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
BRCA	cis	rs7617773	0.817	rs9837228	chr3:48324466	A/T	cg11946769	chr3:48343235	NME6	-0.63	-13.84	-0.48	2.83e-38	Coronary artery disease;
BRCA	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg09307838	chr4:120376055	NA	0.68	14.34	0.49	1.23e-40	Corneal astigmatism;
BRCA	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg24675658	chr1:53192096	ZYG11B	-0.51	-11.25	-0.41	6.58e-27	Monocyte count;
BRCA	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg03425785	chr20:62221387	GMEB2	0.53	8.58	0.32	7.01e-17	Glioblastoma;
BRCA	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.47	-10.15	-0.37	1.47e-22	Multiple sclerosis;
BRCA	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg23978390	chr7:1156363	C7orf50	0.4	7.95	0.3	8.36e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg04025307	chr7:1156635	C7orf50	0.46	10.24	0.38	6.86e-23	Longevity;Endometriosis;
BRCA	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg13047869	chr3:10149882	C3orf24	0.57	10.33	0.38	3.02e-23	Alzheimer's disease;
BRCA	cis	rs9487051	0.773	rs351749	chr6:109533353	A/T	cg21918786	chr6:109611834	NA	-0.34	-8.99	-0.34	2.7e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg23711669	chr6:146136114	FBXO30	-0.68	-15.95	-0.53	1.83e-48	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg00071950	chr4:10020882	SLC2A9	0.67	16.82	0.55	7.99e-53	Bone mineral density;
BRCA	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg24110177	chr3:50126178	RBM5	-0.47	-11.89	-0.43	1.33e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs13102973	1.000	rs7439938	chr4:135897696	G/A	cg14419869	chr4:135874104	NA	-0.56	-11.95	-0.43	7.24e-30	Subjective well-being;
BRCA	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg20307385	chr11:47447363	PSMC3	0.82	20.88	0.64	3.43e-74	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg12641515	chr19:46296257	DMWD	-0.57	-12.7	-0.45	4.18e-33	Coronary artery disease;
BRCA	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg18225595	chr11:63971243	STIP1	0.56	13.54	0.47	6.93e-37	Platelet count;
BRCA	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-14.1	-0.49	1.71e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs6743226	0.840	rs10933549	chr2:242240702	A/G	cg10021735	chr2:242295487	FARP2	0.37	10.26	0.38	5.55e-23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs1577917	0.883	rs1415749	chr6:86779084	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.33	8.63	0.32	4.75e-17	Response to antipsychotic treatment;
BRCA	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg13010199	chr12:38710504	ALG10B	0.49	9.48	0.35	4.87e-20	Morning vs. evening chronotype;
BRCA	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10802521	chr3:52805072	NEK4	-0.32	-8.12	-0.31	2.44e-15	Bipolar disorder;
BRCA	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg07606381	chr6:8435919	SLC35B3	-0.57	-12.19	-0.43	7.19e-31	Motion sickness;
BRCA	cis	rs490234	0.702	rs4838274	chr9:128345994	C/A	cg14078157	chr9:128172775	NA	-0.51	-11.33	-0.41	2.97e-27	Mean arterial pressure;
BRCA	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.57	8.09	0.3	3.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg25214090	chr10:38739885	LOC399744	0.52	10.95	0.4	1.08e-25	Corneal astigmatism;
BRCA	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg07537917	chr2:241836409	C2orf54	-0.49	-11.74	-0.42	5.86e-29	Urinary metabolites;
BRCA	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-14.34	-0.49	1.3e-40	Response to antipsychotic treatment;
BRCA	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.87	0.56	4.53e-53	Colorectal cancer;
BRCA	cis	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg20368463	chr18:77673604	PQLC1	-0.52	-12.66	-0.45	6.1e-33	Schizophrenia;
BRCA	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg26597838	chr10:835615	NA	-1.27	-21.21	-0.64	5.42e-76	Eosinophil percentage of granulocytes;
BRCA	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg17470723	chr8:74884337	TCEB1	0.4	8.62	0.32	5.44e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg16339924	chr4:17578868	LAP3	0.66	16.94	0.56	2.01e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg03161606	chr19:29218774	NA	0.46	8.14	0.31	2.04e-15	Methadone dose in opioid dependence;
BRCA	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg08027265	chr7:2291960	NA	-0.35	-8.26	-0.31	8.3e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs9815354	1.000	rs13325965	chr3:41914942	G/T	cg03022575	chr3:42003672	ULK4	0.51	8.15	0.31	1.91e-15	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg01420254	chr6:26195488	NA	0.55	8.54	0.32	9.6e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg09307838	chr4:120376055	NA	0.44	9.05	0.34	1.68e-18	Diastolic blood pressure;
BRCA	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	12.92	0.46	4.2e-34	Lung cancer in ever smokers;
BRCA	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg21535247	chr6:8435926	SLC35B3	0.41	9.34	0.35	1.59e-19	Motion sickness;
BRCA	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg11764359	chr7:65958608	NA	-0.65	-11.56	-0.42	3.42e-28	Aortic root size;
BRCA	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg16102102	chr5:83017553	HAPLN1	-0.91	-17.9	-0.58	2.08e-58	Prostate cancer;
BRCA	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03264133	chr6:25882463	NA	-0.4	-9.04	-0.34	1.86e-18	Height;
BRCA	trans	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg01620082	chr3:125678407	NA	-0.98	-11.11	-0.4	2.38e-26	Depression;
BRCA	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg19743168	chr1:23544995	NA	-0.66	-16.62	-0.55	7.97e-52	Height;
BRCA	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.45	-0.41	1e-27	Mean corpuscular volume;
BRCA	cis	rs4509693	0.882	rs7911997	chr10:102492380	A/G	cg24179445	chr10:102496915	NA	0.37	9.1	0.34	1.1e-18	Alzheimer's disease;
BRCA	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg00021532	chr16:4324280	TFAP4	0.58	15.78	0.53	1.25e-47	Prostate-specific antigen levels;
BRCA	trans	rs4714291	0.928	rs761799	chr6:39990050	T/A	cg02267698	chr19:7991119	CTXN1	0.4	7.93	0.3	1.01e-14	Strep throat;
BRCA	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-12.81	-0.45	1.34e-33	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10949834	0.529	rs7785826	chr7:73548785	C/A	cg07137043	chr7:73588983	EIF4H	-0.62	-9.28	-0.34	2.59e-19	Verbal memory performance (residualized delayed recall change);
BRCA	cis	rs2859741	1.000	rs2859741	chr1:37509352	C/T	cg09363841	chr1:37513479	NA	-0.65	-16.06	-0.54	5.1e-49	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	ch.11.42038R	chr11:967971	AP2A2	0.5	15.86	0.53	5.38e-48	Alzheimer's disease (late onset);
BRCA	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg05340658	chr4:99064831	C4orf37	0.56	10.75	0.39	6.82e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.67	-16.03	-0.54	7.19e-49	Ulcerative colitis;
BRCA	cis	rs867371	1.000	rs4778982	chr15:82475272	T/G	cg00614314	chr15:82944287	LOC80154	0.43	9.09	0.34	1.21e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg11764359	chr7:65958608	NA	0.68	15.17	0.51	1.34e-44	Aortic root size;
BRCA	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-11.06	-0.4	3.82e-26	Lymphocyte counts;
BRCA	trans	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.03	0.3	4.79e-15	Corneal astigmatism;
BRCA	cis	rs61990749	0.597	rs12887606	chr14:78200620	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.44	7.91	0.3	1.15e-14	Fibroblast growth factor basic levels;
BRCA	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg14186256	chr22:23484241	RTDR1	0.8	25.19	0.71	8.7e-98	Bone mineral density;
BRCA	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg21573476	chr21:45109991	RRP1B	-0.4	-10.6	-0.39	2.63e-24	Mean corpuscular volume;
BRCA	cis	rs9815354	0.812	rs77047799	chr3:41958895	T/C	cg03022575	chr3:42003672	ULK4	0.68	9.67	0.36	9.71e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg00166722	chr3:10149974	C3orf24	0.55	11.06	0.4	3.73e-26	Alzheimer's disease;
BRCA	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg18252515	chr7:66147081	NA	0.87	12.48	0.44	3.79e-32	Diabetic kidney disease;
BRCA	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-12.36	-0.44	1.32e-31	Tonsillectomy;
BRCA	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg05457628	chr5:178986728	RUFY1	0.53	12.12	0.43	1.44e-30	Lung cancer;
BRCA	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.35	-8.38	-0.31	3.45e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2731664	0.792	rs335432	chr5:176866258	G/A	cg23176889	chr5:176863531	GRK6	-0.58	-15.25	-0.52	5.08e-45	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg07917127	chr4:99064746	C4orf37	0.43	8.02	0.3	5.05e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.13	0.31	2.29e-15	Corneal astigmatism;
BRCA	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.43	-8.52	-0.32	1.14e-16	Tonsillectomy;
BRCA	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg21775007	chr8:11205619	TDH	0.38	8.42	0.32	2.43e-16	Mood instability;
BRCA	cis	rs68170813	0.559	rs78440378	chr7:106962782	C/A	cg02696742	chr7:106810147	HBP1	-0.53	-8.54	-0.32	1.01e-16	Coronary artery disease;
BRCA	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg04511125	chr2:88470314	THNSL2	-0.93	-13.17	-0.46	3.1e-35	Plasma clusterin levels;
BRCA	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-10.48	-0.38	7.7e-24	Resting heart rate;
BRCA	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg01483505	chr11:975446	AP2A2	0.31	8.27	0.31	7.92e-16	Alzheimer's disease (late onset);
BRCA	cis	rs3820928	0.874	rs55748731	chr2:227818629	C/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.66	-0.32	3.83e-17	Pulmonary function;
BRCA	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg00981070	chr1:2046702	PRKCZ	0.31	8.22	0.31	1.14e-15	Height;
BRCA	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg00012203	chr2:219082015	ARPC2	-0.43	-8.48	-0.32	1.57e-16	Ulcerative colitis;
BRCA	cis	rs3767633	0.800	rs6685369	chr1:161754834	T/C	cg09175582	chr1:161736000	ATF6	0.5	8.35	0.31	4.35e-16	IgG glycosylation;
BRCA	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-11.21	-0.41	9.48e-27	Gut microbiome composition (summer);
BRCA	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg22800045	chr5:56110881	MAP3K1	0.64	12.28	0.44	2.77e-31	Initial pursuit acceleration;
BRCA	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-13.22	-0.46	1.99e-35	Platelet count;
BRCA	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg10150615	chr22:24372951	LOC391322	0.42	9.16	0.34	6.8e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10802521	chr3:52805072	NEK4	-0.33	-8.48	-0.32	1.61e-16	Bipolar disorder;
BRCA	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg06108461	chr20:60628389	TAF4	-0.79	-17.09	-0.56	3.11e-54	Body mass index;
BRCA	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg04362960	chr10:104952993	NT5C2	0.43	9.87	0.36	1.81e-21	Arsenic metabolism;
BRCA	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg13010199	chr12:38710504	ALG10B	0.52	10.86	0.39	2.58e-25	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs965469	0.779	rs6037543	chr20:3289505	A/G	cg25506879	chr20:3388711	C20orf194	-0.44	-8.75	-0.33	1.85e-17	IFN-related cytopenia;
BRCA	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg00383909	chr3:49044727	WDR6	0.96	15.77	0.53	1.48e-47	Cognitive function;
BRCA	trans	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg06521331	chr12:34319734	NA	0.46	9.28	0.34	2.58e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.1	-0.34	1.15e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-17.83	-0.58	5.39e-58	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22029157	chr1:209979665	IRF6	0.56	12.59	0.45	1.26e-32	Cleft lip with or without cleft palate;
BRCA	trans	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04565464	chr8:145669602	NFKBIL2	0.38	8.93	0.33	4.59e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg20607287	chr7:12443886	VWDE	-0.51	-8.14	-0.31	2e-15	Coronary artery disease;
BRCA	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg20891283	chr12:69753455	YEATS4	-0.58	-14.9	-0.51	2.62e-43	Blood protein levels;
BRCA	cis	rs6750047	0.756	rs336038	chr2:38260750	C/G	cg07380506	chr2:38303506	CYP1B1	0.42	9.48	0.35	5.07e-20	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg05901451	chr6:126070800	HEY2	0.4	9.65	0.36	1.2e-20	Endometrial cancer;
BRCA	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg17063962	chr7:91808500	NA	-0.54	-12.28	-0.44	2.75e-31	Breast cancer;
BRCA	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-13.07	-0.46	9.55e-35	Response to antipsychotic treatment;
BRCA	cis	rs2882667	0.690	rs700619	chr5:138088749	G/C	cg04439458	chr5:138467593	SIL1	0.33	8.15	0.31	1.95e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs12612619	0.732	rs11680032	chr2:27198148	C/T	cg00617064	chr2:27272375	NA	-0.3	-8.09	-0.3	3.01e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg03676636	chr4:99064102	C4orf37	0.22	8.1	0.31	2.7e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11971779	0.588	rs6972408	chr7:139071474	T/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg25174290	chr11:3078921	CARS	0.41	12.6	0.45	1.11e-32	Longevity;
BRCA	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg11764359	chr7:65958608	NA	-0.54	-11.09	-0.4	2.97e-26	Calcium levels;
BRCA	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.38	-9.13	-0.34	8.88e-19	Tonsillectomy;
BRCA	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	11.27	0.41	5.3e-27	Height;
BRCA	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg05283184	chr6:79620031	NA	-0.43	-10.97	-0.4	9.31e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7523050	0.643	rs12725689	chr1:109405151	T/C	cg08274380	chr1:109419600	GPSM2	1.15	15.38	0.52	1.21e-45	Fat distribution (HIV);
BRCA	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.08	-0.4	3.12e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.53	-13.41	-0.47	2.56e-36	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs911186	0.740	rs6938200	chr6:27231150	A/G	cg12292205	chr6:26970375	C6orf41	-0.6	-10.27	-0.38	5.36e-23	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs60843830	0.508	rs300750	chr2:208794	T/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.38	8.3	0.31	6.41e-16	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6546886	0.912	rs13006407	chr2:74280275	G/A	cg14702570	chr2:74259524	NA	-0.32	-8.13	-0.31	2.22e-15	Dialysis-related mortality;
BRCA	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg17691542	chr6:26056736	HIST1H1C	0.53	11.37	0.41	2.14e-27	Height;
BRCA	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg11833968	chr6:79620685	NA	-0.4	-8.98	-0.33	2.92e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg04025307	chr7:1156635	C7orf50	0.47	9.39	0.35	1e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs12530845	0.887	rs6948382	chr7:135323576	G/A	cg23117316	chr7:135346802	PL-5283	-0.35	-8.13	-0.31	2.3e-15	Red blood cell traits;
BRCA	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	5.83e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs13102973	0.640	rs13113331	chr4:135838729	C/T	cg14419869	chr4:135874104	NA	0.45	9.09	0.34	1.24e-18	Subjective well-being;
BRCA	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg00750074	chr16:89608354	SPG7	-0.4	-10.59	-0.39	3.02e-24	Multiple myeloma (IgH translocation);
BRCA	cis	rs2637266	1.000	rs7478008	chr10:78355575	T/A	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	cis	rs6484504	0.625	rs1535741	chr11:31375072	T/C	cg26647111	chr11:31128758	NA	0.42	9.36	0.35	1.35e-19	Red blood cell count;
BRCA	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.43	9.78	0.36	3.76e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg11645453	chr3:52864694	ITIH4	0.34	8.54	0.32	9.97e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-13.21	-0.46	2.18e-35	Morning vs. evening chronotype;
BRCA	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg17971929	chr21:40555470	PSMG1	-0.63	-14.16	-0.49	9.11e-40	Cognitive function;
BRCA	cis	rs9880211	1.000	rs6768743	chr3:136205007	C/T	cg21827317	chr3:136751795	NA	0.42	7.81	0.3	2.29e-14	Body mass index;Height;
BRCA	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg24578937	chr1:2090814	PRKCZ	0.35	11.27	0.41	5.49e-27	Height;
BRCA	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	10.33	0.38	3.11e-23	Height;
BRCA	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg03146154	chr1:46216737	IPP	0.47	10.52	0.38	5.5e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg22875332	chr1:76189707	ACADM	0.65	11.83	0.42	2.55e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6088813	1.000	rs6141546	chr20:33949282	T/C	cg14752227	chr20:34000481	UQCC	-0.41	-8.77	-0.33	1.65e-17	Height;
BRCA	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg00666640	chr1:248458726	OR2T12	0.3	8.38	0.31	3.43e-16	Common traits (Other);
BRCA	cis	rs7927771	0.524	rs7933896	chr11:47882782	C/T	cg20307385	chr11:47447363	PSMC3	0.42	9.46	0.35	5.68e-20	Subjective well-being;
BRCA	trans	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.25	0.31	8.86e-16	Mean corpuscular volume;
BRCA	trans	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.11	0.31	2.62e-15	Mean corpuscular volume;
BRCA	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg09307838	chr4:120376055	NA	-0.62	-13.59	-0.47	3.92e-37	Corneal astigmatism;
BRCA	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg16414030	chr3:133502952	NA	-0.54	-12.32	-0.44	1.94e-31	Iron status biomarkers;
BRCA	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg04025307	chr7:1156635	C7orf50	0.59	9.46	0.35	5.6e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg03929089	chr4:120376271	NA	0.49	8.25	0.31	9e-16	Axial length;
BRCA	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-19.55	-0.61	4.38e-67	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg14440974	chr22:39074834	NA	0.38	9.21	0.34	4.48e-19	Menopause (age at onset);
BRCA	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg22681709	chr2:178499509	PDE11A	-0.41	-8.93	-0.33	4.34e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs1973993	0.603	rs56827884	chr1:97021972	T/C	cg10631902	chr5:14652156	NA	-0.39	-9.73	-0.36	5.96e-21	Weight;
BRCA	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2131877	0.529	rs1009642	chr3:194857586	A/G	cg13868855	chr3:194833887	C3orf21	0.36	8.74	0.33	2.1e-17	Non-small cell lung cancer;
BRCA	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg03452623	chr4:187889614	NA	-0.31	-10.25	-0.38	6.02e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.818	rs3806222	chr1:153002606	C/T	cg24667326	chr1:152973720	SPRR3	-0.32	-8.81	-0.33	1.17e-17	Inflammatory skin disease;
BRCA	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.45	-0.32	1.98e-16	Menopause (age at onset);
BRCA	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	30.03	0.77	3.03e-124	Cognitive ability;
BRCA	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg07423050	chr13:99094983	FARP1	-0.48	-10.79	-0.39	4.71e-25	Longevity;
BRCA	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg18301423	chr5:131593218	PDLIM4	0.33	8.55	0.32	8.88e-17	Breast cancer;
BRCA	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg02551604	chr5:131831745	NA	0.41	15.82	0.53	8.2e-48	Asthma (sex interaction);
BRCA	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg23711669	chr6:146136114	FBXO30	0.76	18.59	0.59	5.46e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs701145	0.617	rs9820619	chr3:154028294	G/T	cg16511985	chr3:153974050	SGEF	0.44	9.84	0.36	2.27e-21	Coronary artery disease;
BRCA	cis	rs7766436	0.885	rs4712698	chr6:22592807	C/T	cg13666174	chr6:22585274	NA	-0.49	-11.49	-0.41	6.42e-28	Coronary artery disease;
BRCA	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg26031613	chr14:104095156	KLC1	0.52	9.36	0.35	1.37e-19	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg18016565	chr1:150552671	MCL1	-0.41	-9.37	-0.35	1.19e-19	Tonsillectomy;
BRCA	trans	rs236907	0.812	rs17657363	chr1:171801416	C/T	cg13482142	chr2:234261155	NA	-0.5	-8.28	-0.31	7.37e-16	Mean platelet volume;
BRCA	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg01689657	chr7:91764605	CYP51A1	0.25	8.78	0.33	1.49e-17	Breast cancer;
BRCA	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg00074818	chr8:8560427	CLDN23	0.39	8.39	0.32	3.1e-16	Obesity-related traits;
BRCA	cis	rs3125734	0.719	rs4529854	chr10:64043975	C/T	cg19640130	chr10:64028056	RTKN2	-0.29	-8.17	-0.31	1.63e-15	Rheumatoid arthritis;
BRCA	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	8.29	0.31	6.45e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs7020830	0.858	rs13293465	chr9:37127678	C/T	cg14294708	chr9:37120828	ZCCHC7	1.17	40.2	0.85	3.93e-177	Schizophrenia;
BRCA	cis	rs3820928	0.804	rs4144327	chr2:227790262	C/T	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.9	-0.33	5.57e-18	Pulmonary function;
BRCA	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.28	-0.44	2.79e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs4631830	0.683	rs11004409	chr10:51498019	G/C	cg16070123	chr10:51489643	NA	0.35	7.85	0.3	1.73e-14	Prostate-specific antigen levels;
BRCA	cis	rs4285028	0.948	rs79103597	chr3:121667629	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.8	-0.39	4.4e-25	Multiple sclerosis;
BRCA	cis	rs847577	0.508	rs12538837	chr7:97684468	C/T	cg24562669	chr7:97807699	LMTK2	0.39	8.9	0.33	5.76e-18	Breast cancer;
BRCA	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg22903471	chr2:27725779	GCKR	-0.37	-9.06	-0.34	1.61e-18	Total body bone mineral density;
BRCA	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.34	-0.38	2.73e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg27446573	chr6:127587934	RNF146	0.9	21.49	0.65	1.64e-77	Breast cancer;
BRCA	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10802521	chr3:52805072	NEK4	-0.34	-9.29	-0.35	2.31e-19	Electroencephalogram traits;
BRCA	cis	rs2625529	0.668	rs12914070	chr15:72334279	T/C	cg16672083	chr15:72433130	SENP8	-0.84	-17.6	-0.57	8.19e-57	Red blood cell count;
BRCA	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.2e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg08847533	chr14:75593920	NEK9	-0.79	-18.95	-0.6	7.17e-64	Height;
BRCA	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg13010199	chr12:38710504	ALG10B	0.51	10.58	0.39	3.27e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg04025307	chr7:1156635	C7orf50	0.51	9.86	0.36	1.87e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs586533	0.881	rs590592	chr11:99506929	C/T	cg22878054	chr11:99397252	CNTN5	0.32	8.18	0.31	1.49e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3925075	0.531	rs56392848	chr16:31360892	A/G	cg02846316	chr16:31340340	ITGAM	0.42	8.59	0.32	6.47e-17	IgA nephropathy;
BRCA	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg21573476	chr21:45109991	RRP1B	-0.34	-8.89	-0.33	6.02e-18	Mean corpuscular volume;
BRCA	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg04362960	chr10:104952993	NT5C2	0.43	9.74	0.36	5.33e-21	Arsenic metabolism;
BRCA	cis	rs10044254	0.587	rs4312881	chr5:15739807	T/G	cg07238450	chr5:15720153	FBXL7	-0.38	-7.9	-0.3	1.19e-14	Asthma (corticosteroid response);
BRCA	cis	rs7617773	0.780	rs4479622	chr3:48338173	C/T	cg11946769	chr3:48343235	NME6	0.68	14.05	0.49	2.93e-39	Coronary artery disease;
BRCA	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg26528668	chr16:1614120	IFT140	0.4	9.12	0.34	9.77e-19	Coronary artery disease;
BRCA	cis	rs9394152	0.845	rs769051	chr6:33473894	T/G	cg13560919	chr6:33536144	NA	0.62	12.65	0.45	6.6e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	11.79	0.42	3.77e-29	Platelet count;
BRCA	cis	rs6484504	0.652	rs485265	chr11:31407788	G/A	cg26647111	chr11:31128758	NA	0.45	9.71	0.36	6.87e-21	Red blood cell count;
BRCA	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg08213375	chr14:104286397	PPP1R13B	0.64	18.11	0.58	1.82e-59	Schizophrenia;
BRCA	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg07080220	chr10:102295463	HIF1AN	0.44	9.61	0.36	1.65e-20	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.2	-0.31	1.28e-15	Prostate cancer;
BRCA	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg23289794	chr7:2394357	EIF3B	-0.46	-9.52	-0.35	3.38e-20	Multiple sclerosis;
BRCA	trans	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.44	-9.15	-0.34	7.82e-19	Mean corpuscular volume;
BRCA	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg07917127	chr4:99064746	C4orf37	0.44	8.1	0.31	2.86e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg12463550	chr7:65579703	CRCP	-0.37	-8.16	-0.31	1.82e-15	Aortic root size;
BRCA	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg26248373	chr2:1572462	NA	-0.58	-13.04	-0.46	1.26e-34	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg10295955	chr4:187884368	NA	-0.98	-31.37	-0.78	1.78e-131	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg13397359	chr6:42928475	GNMT	0.66	15.91	0.53	3.04e-48	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	11.77	0.42	4.22e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg01256987	chr12:42539512	GXYLT1	-0.46	-9.17	-0.34	6.47e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs36051895	0.554	rs10975027	chr9:5248827	G/A	cg02405213	chr9:5042618	JAK2	-0.44	-7.88	-0.3	1.41e-14	Pediatric autoimmune diseases;
BRCA	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg13944838	chr5:179740914	GFPT2	-0.7	-14.39	-0.49	6.88e-41	Height;
BRCA	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg00012203	chr2:219082015	ARPC2	0.52	10.51	0.38	6.28e-24	Colorectal cancer;
BRCA	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg08755490	chr11:65554678	OVOL1	0.53	10.97	0.4	8.98e-26	Acne (severe);
BRCA	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg08885076	chr2:99613938	TSGA10	0.42	9.73	0.36	5.81e-21	Chronic sinus infection;
BRCA	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-13.64	-0.47	2.38e-37	Monocyte count;
BRCA	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg04586622	chr2:25135609	ADCY3	0.43	10.72	0.39	9.03e-25	Body mass index;
BRCA	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg13010199	chr12:38710504	ALG10B	0.41	8.87	0.33	7.46e-18	Bladder cancer;
BRCA	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg11502198	chr6:26597334	ABT1	0.58	12.51	0.44	2.71e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg13628971	chr7:2884303	GNA12	0.38	8.49	0.32	1.42e-16	Height;
BRCA	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg02176678	chr2:219576539	TTLL4	-0.38	-10.11	-0.37	2.13e-22	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.05	15.3	0.52	2.95e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg09537434	chr19:41945824	ATP5SL	-1.0	-24.37	-0.69	2.95e-93	Height;
BRCA	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg11833968	chr6:79620685	NA	-0.44	-9.79	-0.36	3.58e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs16976116	0.901	rs2899580	chr15:55491571	A/G	cg11288833	chr15:55489084	RSL24D1	0.47	10.57	0.39	3.49e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	13.27	0.46	1.14e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg24006582	chr15:45444508	DUOX1	-0.56	-11.54	-0.42	4.12e-28	Uric acid levels;
BRCA	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-9.07	-0.34	1.5e-18	Colorectal cancer;
BRCA	cis	rs11249608	0.510	rs6861539	chr5:178452307	A/G	cg21905437	chr5:178450457	ZNF879	0.52	10.83	0.39	3.21e-25	Pubertal anthropometrics;
BRCA	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	10.75	0.39	6.64e-25	Motion sickness;
BRCA	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00149659	chr3:10157352	C3orf10	0.81	14.21	0.49	5.29e-40	Alzheimer's disease;
BRCA	trans	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg25214090	chr10:38739885	LOC399744	0.53	11.98	0.43	5.63e-30	Corneal astigmatism;
BRCA	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg11657440	chr19:46296263	DMWD	-0.53	-12.6	-0.45	1.08e-32	Coronary artery disease;
BRCA	cis	rs72634258	0.554	rs12092614	chr1:7865710	C/T	cg26816564	chr1:7831052	VAMP3	0.66	12.26	0.44	3.39e-31	Inflammatory bowel disease;
BRCA	cis	rs7809615	0.792	rs45618033	chr7:99046617	G/A	cg12290671	chr7:99195819	NA	-0.51	-8.57	-0.32	7.75e-17	Blood metabolite ratios;
BRCA	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.43e-36	High light scatter reticulocyte count;
BRCA	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg07541023	chr7:19748670	TWISTNB	0.57	9.68	0.36	9.2e-21	Thyroid stimulating hormone;
BRCA	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg08888203	chr3:10149979	C3orf24	0.65	11.93	0.43	8.91e-30	Alzheimer's disease;
BRCA	cis	rs1400816	0.702	rs1554165	chr2:172551602	T/C	cg13550731	chr2:172543902	DYNC1I2	0.54	8.48	0.32	1.56e-16	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg20701182	chr2:24300061	SF3B14	0.62	8.87	0.33	7.2e-18	Lymphocyte counts;
BRCA	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.54	-11.82	-0.42	2.7e-29	Personality dimensions;
BRCA	cis	rs68170813	0.523	rs4730241	chr7:107057361	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-8.18	-0.31	1.59e-15	Coronary artery disease;
BRCA	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18876405	chr7:65276391	NA	-0.63	-15.77	-0.53	1.42e-47	Aortic root size;
BRCA	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.3	10.18	0.37	1.15e-22	Bipolar disorder;
BRCA	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg19622623	chr12:86230825	RASSF9	-0.29	-8.14	-0.31	2.02e-15	Major depressive disorder;
BRCA	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg20701182	chr2:24300061	SF3B14	0.66	9.54	0.35	3.02e-20	Lymphocyte counts;
BRCA	cis	rs13040088	1.000	rs2273412	chr20:61553802	G/A	cg23096297	chr20:61557774	DIDO1	0.93	18.13	0.58	1.33e-59	Menopause (age at onset);
BRCA	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg02734326	chr4:10020555	SLC2A9	0.36	7.86	0.3	1.59e-14	Bone mineral density;
BRCA	cis	rs8114671	0.647	rs1415771	chr20:33734493	G/A	cg07148914	chr20:33460835	GGT7	0.35	7.92	0.3	1.08e-14	Height;
BRCA	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg02734326	chr4:10020555	SLC2A9	0.39	8.41	0.32	2.7e-16	Bone mineral density;
BRCA	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.46	-11.09	-0.4	2.88e-26	IgG glycosylation;
BRCA	cis	rs17021463	0.902	rs11097413	chr4:95249286	C/T	cg11021082	chr4:95130006	SMARCAD1	0.41	9.62	0.36	1.44e-20	Testicular germ cell tumor;
BRCA	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.29	-0.49	2.14e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg23711669	chr6:146136114	FBXO30	-0.71	-16.86	-0.55	4.78e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg21385522	chr1:16154831	NA	0.48	10.41	0.38	1.5e-23	Systolic blood pressure;
BRCA	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg05283184	chr6:79620031	NA	-0.43	-10.85	-0.39	2.82e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg18904891	chr8:8559673	CLDN23	0.64	12.33	0.44	1.79e-31	Obesity-related traits;
BRCA	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-8.75	-0.33	1.94e-17	Monocyte percentage of white cells;
BRCA	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.55	0.67	2.65e-83	Chronic sinus infection;
BRCA	cis	rs9788682	0.747	rs2568497	chr15:78721397	G/T	cg24631222	chr15:78858424	CHRNA5	-0.49	-9.47	-0.35	5.31e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00149659	chr3:10157352	C3orf10	0.8	14.1	0.49	1.58e-39	Alzheimer's disease;
BRCA	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14240646	chr10:27532245	ACBD5	0.64	9.49	0.35	4.66e-20	Breast cancer;
BRCA	cis	rs11971779	0.590	rs9642120	chr7:139083971	C/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.8	-0.33	1.23e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg16339924	chr4:17578868	LAP3	0.67	17.03	0.56	6.59e-54	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg23762105	chr12:34175262	ALG10	-0.41	-10.18	-0.37	1.16e-22	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg21747090	chr2:27597821	SNX17	-0.44	-9.55	-0.35	2.74e-20	Total body bone mineral density;
BRCA	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg11822812	chr5:140052017	DND1	-0.31	-8.49	-0.32	1.5e-16	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04565464	chr8:145669602	NFKBIL2	0.42	9.47	0.35	5.25e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs75804782	0.581	rs3191996	chr2:239344412	A/G	cg18131467	chr2:239335373	ASB1	0.63	8.25	0.31	9.1e-16	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg07262247	chr5:131593730	PDLIM4	-0.36	-8.21	-0.31	1.22e-15	Acylcarnitine levels;
BRCA	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.58	-0.52	1.25e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-12.62	-0.45	9.25e-33	Alzheimer's disease;
BRCA	cis	rs4302748	0.862	rs11974209	chr7:36184479	A/G	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs6450176	0.625	rs11747281	chr5:53289047	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-15.18	-0.51	1.15e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.25e-23	Motion sickness;
BRCA	cis	rs6952809	0.561	rs1548598	chr7:2438912	T/C	cg23289794	chr7:2394357	EIF3B	-0.52	-10.24	-0.38	6.86e-23	Multiple sclerosis;
BRCA	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg25173405	chr17:45401733	C17orf57	-0.55	-11.79	-0.42	3.64e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg25237894	chr2:233734115	C2orf82	-0.36	-10.62	-0.39	2.2e-24	Coronary artery disease;
BRCA	cis	rs7586879	0.828	rs12986610	chr2:25106265	A/G	cg04586622	chr2:25135609	ADCY3	-0.4	-9.9	-0.36	1.31e-21	Body mass index;
BRCA	cis	rs10044254	0.614	rs4574543	chr5:15740147	G/A	cg07238450	chr5:15720153	FBXL7	-0.38	-7.89	-0.3	1.35e-14	Asthma (corticosteroid response);
BRCA	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.36	-8.01	-0.3	5.25e-15	Longevity;Endometriosis;
BRCA	cis	rs2066819	1.000	rs78149779	chr12:56694817	A/G	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg27661571	chr11:113659931	NA	-0.73	-11.27	-0.41	5.14e-27	Hip circumference adjusted for BMI;
BRCA	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg20387954	chr3:183756860	HTR3D	0.45	10.17	0.37	1.31e-22	Anterior chamber depth;
BRCA	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21659725	chr3:3221576	CRBN	-0.35	-8.7	-0.33	2.74e-17	Body mass index;
BRCA	trans	rs12517041	1.000	rs4701360	chr5:23292240	C/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.36	-0.31	4.04e-16	Calcium levels;
BRCA	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg09658497	chr7:2847517	GNA12	-0.41	-8.67	-0.32	3.44e-17	Height;
BRCA	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg04025307	chr7:1156635	C7orf50	0.72	18.87	0.6	1.92e-63	Longevity;Endometriosis;
BRCA	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-12.29	-0.44	2.57e-31	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.26	0.38	5.62e-23	Motion sickness;
BRCA	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-13.05	-0.46	1.16e-34	Gut microbiome composition (summer);
BRCA	cis	rs7520050	0.966	rs34102169	chr1:46424864	G/T	cg24296786	chr1:45957014	TESK2	0.43	9.56	0.35	2.43e-20	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg14169450	chr9:139327907	INPP5E	0.38	8.56	0.32	8.31e-17	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg07148914	chr20:33460835	GGT7	-0.41	-8.94	-0.33	4e-18	Height;
BRCA	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg09184832	chr6:79620586	NA	-0.48	-10.32	-0.38	3.33e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg23711669	chr6:146136114	FBXO30	0.74	15.73	0.53	2.32e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg08975724	chr8:8085496	FLJ10661	0.51	10.59	0.39	2.92e-24	Systolic blood pressure;
BRCA	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg16989086	chr20:62203971	PRIC285	0.54	9.18	0.34	5.88e-19	Glioblastoma;
BRCA	trans	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg25214090	chr10:38739885	LOC399744	0.55	12.09	0.43	1.97e-30	Corneal astigmatism;
BRCA	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg07414643	chr4:187882934	NA	0.28	9.48	0.35	4.74e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg17063962	chr7:91808500	NA	0.54	12.38	0.44	1.08e-31	Breast cancer;
BRCA	cis	rs2111398	0.645	rs7309370	chr12:13053001	A/C	cg03534847	chr12:13053055	GPRC5A	0.37	8.61	0.32	5.85e-17	Cutaneous malignant melanoma;
BRCA	cis	rs10501293	1.000	rs6485394	chr11:43080041	A/C	cg03447554	chr11:43094025	NA	-0.48	-8.92	-0.33	4.75e-18	Cognitive performance;
BRCA	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07343612	chr16:622815	PIGQ	-0.67	-22.48	-0.66	6.65e-83	Height;
BRCA	cis	rs7537052	0.646	rs6680302	chr1:36653540	C/T	cg24686825	chr1:36642396	MAP7D1	-0.52	-12.11	-0.43	1.5e-30	Schizophrenia;
BRCA	cis	rs909002	0.849	rs3753611	chr1:32082486	C/T	cg13919466	chr1:32135498	COL16A1	-0.27	-9.25	-0.34	3.39e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07256732	chr16:621771	PIGQ	-0.36	-9.51	-0.35	3.73e-20	Height;
BRCA	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.34	8.78	0.33	1.47e-17	IgG glycosylation;
BRCA	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg27279351	chr12:120934652	DYNLL1	0.57	13.5	0.47	1.05e-36	High light scatter reticulocyte count;
BRCA	cis	rs1113500	0.933	rs4517375	chr1:108638330	A/C	cg06207961	chr1:108661230	NA	-0.45	-11.12	-0.4	2.17e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs6973256	0.828	rs10954431	chr7:133430901	A/C	cg07491979	chr7:133331646	EXOC4	0.4	8.57	0.32	7.83e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg26031613	chr14:104095156	KLC1	1.01	27.66	0.74	2.59e-111	Body mass index;
BRCA	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg25356066	chr3:128598488	ACAD9	-0.37	-8.58	-0.32	7.24e-17	IgG glycosylation;
BRCA	cis	rs16910800	0.731	rs35725172	chr11:23185968	G/A	cg20040320	chr11:23191996	NA	-0.58	-9.99	-0.37	6.08e-22	Cancer;
BRCA	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg08213375	chr14:104286397	PPP1R13B	0.64	18.05	0.58	3.53e-59	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.03	0.3	4.61e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12541635	0.966	rs12674846	chr8:107007178	A/G	cg10147462	chr8:107024639	NA	0.37	10.06	0.37	3.49e-22	Age of smoking initiation;
BRCA	cis	rs16958440	1.000	rs76594057	chr18:44637272	A/G	cg17192377	chr18:44677553	HDHD2	0.67	9.8	0.36	3.33e-21	Sitting height ratio;
BRCA	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg12165864	chr7:66369176	NA	-0.43	-9.78	-0.36	3.69e-21	Corneal structure;
BRCA	cis	rs7191700	0.583	rs243314	chr16:11385104	G/C	cg00044050	chr16:11439710	C16orf75	0.46	11.09	0.4	2.86e-26	Multiple sclerosis;
BRCA	cis	rs4853036	1.000	rs62134009	chr2:70054296	G/A	cg02498382	chr2:70120550	SNRNP27	-0.5	-9.2	-0.34	5.09e-19	Colorectal or endometrial cancer;
BRCA	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg10729496	chr3:10149963	C3orf24	0.46	7.86	0.3	1.59e-14	Alzheimer's disease;
BRCA	trans	rs61931739	1.000	rs12298806	chr12:34036528	C/G	cg26384229	chr12:38710491	ALG10B	-0.42	-9.38	-0.35	1.09e-19	Morning vs. evening chronotype;
BRCA	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.36	-8.2	-0.31	1.33e-15	Longevity;Endometriosis;
BRCA	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.13	-0.4	1.98e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg06521331	chr12:34319734	NA	0.61	11.02	0.4	5.44e-26	Morning vs. evening chronotype;
BRCA	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg26677194	chr12:130822605	PIWIL1	0.6	14.33	0.49	1.31e-40	Menopause (age at onset);
BRCA	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg16339924	chr4:17578868	LAP3	0.64	15.88	0.53	4.17e-48	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg11764359	chr7:65958608	NA	0.59	12.85	0.45	9.21e-34	Aortic root size;
BRCA	cis	rs66887589	0.934	rs7672519	chr4:120544112	C/T	cg09307838	chr4:120376055	NA	-0.44	-9.13	-0.34	8.96e-19	Diastolic blood pressure;
BRCA	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26314531	chr2:26401878	FAM59B	-0.87	-16.3	-0.54	3.37e-50	Gut microbiome composition (summer);
BRCA	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg02544614	chr20:61657117	NA	0.29	8.16	0.31	1.77e-15	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.7	-0.36	7.7e-21	Bladder cancer;
BRCA	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg10253484	chr15:75165896	SCAMP2	-0.58	-11.0	-0.4	6.64e-26	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.54	-13.86	-0.48	2.13e-38	Longevity;Endometriosis;
BRCA	cis	rs2580764	0.598	rs6755468	chr2:55240026	A/C	cg09592903	chr2:55203963	RTN4	-0.4	-10.35	-0.38	2.64e-23	Mean platelet volume;
BRCA	cis	rs9790314	0.715	rs7622047	chr3:160770505	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-8.78	-0.33	1.5e-17	Morning vs. evening chronotype;
BRCA	trans	rs1994135	0.617	rs10743824	chr12:33733764	C/T	cg26384229	chr12:38710491	ALG10B	0.39	8.92	0.33	4.94e-18	Resting heart rate;
BRCA	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg06115741	chr20:33292138	TP53INP2	0.39	8.63	0.32	4.81e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs7973719	0.868	rs7315553	chr12:7353838	A/C	cg07052231	chr12:7363540	PEX5	0.36	8.21	0.31	1.23e-15	IgG glycosylation;
BRCA	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	9.1	0.34	1.15e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6120849	0.754	rs6120790	chr20:33599090	A/T	cg24642439	chr20:33292090	TP53INP2	0.59	10.21	0.37	8.99e-23	Protein C levels;
BRCA	trans	rs75804782	0.521	rs55690022	chr2:239407783	C/T	cg01134436	chr17:81009848	B3GNTL1	0.67	8.56	0.32	8.1e-17	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg16405210	chr4:1374714	KIAA1530	-0.93	-20.93	-0.64	1.72e-74	Longevity;
BRCA	cis	rs1595825	0.891	rs77706948	chr2:198608441	T/G	cg19156104	chr2:198669113	PLCL1	-0.48	-8.58	-0.32	7.39e-17	Ulcerative colitis;
BRCA	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-11.41	-0.41	1.37e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg11833968	chr6:79620685	NA	-0.43	-9.61	-0.36	1.6e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg21535247	chr6:8435926	SLC35B3	0.42	9.44	0.35	6.85e-20	Motion sickness;
BRCA	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.68	-15.99	-0.53	1.2e-48	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg16109817	chr1:16162209	FLJ37453	0.35	10.2	0.37	9.83e-23	Dilated cardiomyopathy;
BRCA	cis	rs8114671	0.647	rs6060268	chr20:33734293	T/C	cg07148914	chr20:33460835	GGT7	0.35	7.92	0.3	1.08e-14	Height;
BRCA	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-12.31	-0.44	2.1e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	14.07	0.49	2.2e-39	Lymphocyte counts;
BRCA	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg07080220	chr10:102295463	HIF1AN	0.63	13.75	0.48	7.42e-38	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2625529	0.824	rs12595228	chr15:72267215	T/C	cg16672083	chr15:72433130	SENP8	-0.85	-17.65	-0.57	4.2e-57	Red blood cell count;
BRCA	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11644478	chr21:40555479	PSMG1	0.82	18.58	0.59	6.03e-62	Cognitive function;
BRCA	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg20587970	chr11:113659929	NA	-1.2	-22.15	-0.66	4.31e-81	Hip circumference adjusted for BMI;
BRCA	cis	rs12210905	0.688	rs12209905	chr6:27404592	C/G	cg08851530	chr6:28072375	NA	0.81	7.89	0.3	1.3e-14	Hip circumference adjusted for BMI;
BRCA	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg27572855	chr1:25598939	RHD	0.45	13.13	0.46	5.11e-35	Erythrocyte sedimentation rate;
BRCA	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg02659138	chr7:134003124	SLC35B4	0.33	10.13	0.37	1.75e-22	Mean platelet volume;
BRCA	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg06623918	chr6:96969491	KIAA0776	0.75	12.34	0.44	1.59e-31	Migraine;Coronary artery disease;
BRCA	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg06212747	chr3:49208901	KLHDC8B	0.59	8.28	0.31	7.36e-16	Menarche (age at onset);
BRCA	cis	rs4919694	0.572	rs12255989	chr10:104867206	C/T	cg04362960	chr10:104952993	NT5C2	0.73	12.72	0.45	3.27e-33	Arsenic metabolism;
BRCA	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	8.41	0.32	2.77e-16	Personality dimensions;
BRCA	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.66	-15.88	-0.53	4.3e-48	Ulcerative colitis;
BRCA	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg14440974	chr22:39074834	NA	-0.38	-9.13	-0.34	8.96e-19	Menopause (age at onset);
BRCA	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg08470875	chr2:26401718	FAM59B	0.76	12.04	0.43	3.12e-30	Gut microbiome composition (summer);
BRCA	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg20933634	chr6:27740509	NA	0.45	9.01	0.34	2.33e-18	Parkinson's disease;
BRCA	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg03709012	chr19:19516395	GATAD2A	0.8	18.53	0.59	1.15e-61	Tonsillectomy;
BRCA	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26314531	chr2:26401878	FAM59B	-0.59	-10.11	-0.37	2.09e-22	Gut microbiome composition (summer);
BRCA	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg00152838	chr16:24741724	TNRC6A	-0.37	-7.98	-0.3	6.84e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg23711669	chr6:146136114	FBXO30	-0.72	-17.11	-0.56	2.7e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg19678392	chr7:94953810	PON1	-0.43	-9.1	-0.34	1.11e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs2979489	0.591	rs62508371	chr8:30422060	C/T	cg26383811	chr8:30366931	RBPMS	-0.51	-12.01	-0.43	4.22e-30	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
BRCA	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg01028140	chr2:1542097	TPO	-0.57	-11.78	-0.42	4.16e-29	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg22875332	chr1:76189707	ACADM	-0.68	-14.52	-0.5	1.81e-41	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6142102	0.602	rs2268086	chr20:32648738	C/T	cg24642439	chr20:33292090	TP53INP2	-0.38	-7.87	-0.3	1.47e-14	Skin pigmentation;
BRCA	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	22.76	0.67	2.09e-84	Platelet count;
BRCA	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.71	0.39	1.01e-24	Cognitive ability;
BRCA	cis	rs35123781	0.696	rs13154510	chr5:139071301	A/C	cg10513866	chr5:139070639	NA	0.44	9.71	0.36	6.9e-21	Schizophrenia;
BRCA	trans	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg26043149	chr18:55253948	FECH	-0.41	-9.02	-0.34	2.11e-18	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs3768617	0.706	rs10797801	chr1:182971965	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.5	11.66	0.42	1.28e-28	Fuchs's corneal dystrophy;
BRCA	cis	rs1451375	0.652	rs7779110	chr7:50625651	T/C	cg18232548	chr7:50535776	DDC	0.38	8.01	0.3	5.28e-15	Malaria;
BRCA	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg05535760	chr7:792225	HEATR2	-0.73	-13.41	-0.47	2.7e-36	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg14582100	chr15:45693742	SPATA5L1	0.37	11.67	0.42	1.17e-28	Homoarginine levels;
BRCA	cis	rs12545109	0.876	rs1992120	chr8:57337112	G/A	cg09654669	chr8:57350985	NA	-0.43	-8.01	-0.3	5.39e-15	Obesity-related traits;
BRCA	cis	rs12431939	1.000	rs11845886	chr14:51635873	G/A	cg23942311	chr14:51606299	NA	-0.43	-8.29	-0.31	6.89e-16	Cancer;
BRCA	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg05084668	chr3:125655381	ALG1L	-0.47	-8.05	-0.3	4.02e-15	Blood pressure (smoking interaction);
BRCA	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.17	0.31	1.68e-15	Depression;
BRCA	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg25554036	chr4:6271136	WFS1	0.41	9.58	0.35	2.18e-20	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.97	18.22	0.58	5.01e-60	Platelet count;
BRCA	cis	rs752010	0.967	rs6675999	chr1:42099024	T/G	cg06885757	chr1:42089581	HIVEP3	0.25	8.86	0.33	8.07e-18	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg05234568	chr11:5960015	NA	-0.41	-7.92	-0.3	1.02e-14	DNA methylation (variation);
BRCA	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg02951883	chr7:2050386	MAD1L1	0.44	10.65	0.39	1.68e-24	Schizophrenia;
BRCA	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg08601574	chr20:25228251	PYGB	-0.39	-9.0	-0.34	2.53e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg05623727	chr3:50126028	RBM5	0.37	8.48	0.32	1.62e-16	Menarche (age at onset);
BRCA	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-11.05	-0.4	4.41e-26	IgG glycosylation;
BRCA	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg24562669	chr7:97807699	LMTK2	0.47	12.62	0.45	8.93e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.6	-14.19	-0.49	5.99e-40	Hemoglobin concentration;
BRCA	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg02733842	chr7:1102375	C7orf50	-0.64	-11.8	-0.42	3.32e-29	Bronchopulmonary dysplasia;
BRCA	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg07461501	chr17:79650226	HGS;ARL16	0.4	10.08	0.37	2.87e-22	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.41	-8.63	-0.32	4.8e-17	Eosinophil percentage of white cells;
BRCA	trans	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.13	0.31	2.2e-15	Corneal astigmatism;
BRCA	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg20503657	chr10:835505	NA	1.03	18.27	0.59	2.63e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg16586182	chr3:47516702	SCAP	0.62	14.44	0.5	4.04e-41	Colorectal cancer;
BRCA	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg07537917	chr2:241836409	C2orf54	-0.43	-10.39	-0.38	1.73e-23	Urinary metabolites;
BRCA	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg23711669	chr6:146136114	FBXO30	0.74	15.67	0.53	4.66e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.46	0.47	1.63e-36	Colorectal cancer;
BRCA	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg00012203	chr2:219082015	ARPC2	0.58	11.99	0.43	5e-30	Colorectal cancer;
BRCA	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg04455712	chr21:45112962	RRP1B	-0.43	-11.03	-0.4	5.21e-26	Mean corpuscular volume;
BRCA	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg18479299	chr3:125709523	NA	-0.54	-8.46	-0.32	1.84e-16	Blood pressure (smoking interaction);
BRCA	cis	rs3936840	0.539	rs3742445	chr14:102975552	T/A	cg18135206	chr14:102964638	TECPR2	0.48	9.53	0.35	3.23e-20	Plateletcrit;
BRCA	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg11764359	chr7:65958608	NA	0.67	15.2	0.52	9.48e-45	Aortic root size;
BRCA	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg20503657	chr10:835505	NA	1.3	21.72	0.65	9.26e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.55	9.9	0.36	1.33e-21	Height;
BRCA	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg13010199	chr12:38710504	ALG10B	0.42	9.01	0.34	2.3e-18	Morning vs. evening chronotype;
BRCA	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg17640201	chr16:30407289	ZNF48	0.83	21.68	0.65	1.45e-78	Tonsillectomy;
BRCA	cis	rs6688613	0.694	rs3820387	chr1:166820284	A/T	ch.1.3259774R	chr1:166827647	TADA1	0.41	8.55	0.32	8.97e-17	Refractive astigmatism;
BRCA	trans	rs783540	0.656	rs783538	chr15:83253143	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.32	-8.89	-0.33	6.06e-18	Schizophrenia;
BRCA	trans	rs3812049	0.784	rs7734927	chr5:127453735	T/A	cg16011800	chr17:1958478	HIC1	-0.54	-8.92	-0.33	4.81e-18	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg11502198	chr6:26597334	ABT1	0.61	11.53	0.41	4.48e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg08807101	chr21:30365312	RNF160	0.36	8.11	0.31	2.69e-15	Selective IgA deficiency;
BRCA	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg26031613	chr14:104095156	KLC1	-0.45	-8.1	-0.3	2.88e-15	Coronary artery disease;
BRCA	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg00012203	chr2:219082015	ARPC2	-0.73	-16.29	-0.54	3.74e-50	Colorectal cancer;
BRCA	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg22508957	chr16:3507546	NAT15	0.65	11.23	0.41	8.06e-27	Tuberculosis;
BRCA	cis	rs9296092	0.538	rs56205713	chr6:33517510	A/G	cg13560919	chr6:33536144	NA	-0.84	-18.3	-0.59	1.78e-60	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs10992471	0.603	rs7873397	chr9:95205928	G/C	cg14631576	chr9:95140430	CENPP	-0.39	-9.32	-0.35	1.83e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg23815491	chr16:72088622	HP	-0.35	-8.46	-0.32	1.8e-16	Fibrinogen levels;
BRCA	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04267008	chr7:1944627	MAD1L1	-0.6	-12.84	-0.45	9.34e-34	Bipolar disorder and schizophrenia;
BRCA	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg03864215	chr11:17408437	KCNJ11	-0.27	-8.0	-0.3	5.96e-15	Type 2 diabetes;
BRCA	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg13319975	chr6:146136371	FBXO30	-0.36	-8.37	-0.31	3.72e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg09307838	chr4:120376055	NA	0.68	13.62	0.47	2.83e-37	Corneal astigmatism;
BRCA	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg13770153	chr20:60521292	NA	-0.4	-9.44	-0.35	6.84e-20	Body mass index;
BRCA	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.61	-9.73	-0.36	5.73e-21	Schizophrenia;
BRCA	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25427524	chr10:38739819	LOC399744	-0.65	-15.67	-0.53	4.79e-47	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4787491	0.679	rs12933575	chr16:30022564	A/G	cg06326092	chr16:30034487	C16orf92	0.33	8.46	0.32	1.83e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg24578937	chr1:2090814	PRKCZ	0.36	11.33	0.41	3.16e-27	Height;
BRCA	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg17640201	chr16:30407289	ZNF48	-0.8	-20.39	-0.63	1.42e-71	Tonsillectomy;
BRCA	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg06784218	chr1:46089804	CCDC17	-0.48	-11.26	-0.41	6.11e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs701145	0.585	rs1542254	chr3:153864296	C/T	cg12800244	chr3:153838788	SGEF	0.58	8.15	0.31	1.9e-15	Coronary artery disease;
BRCA	trans	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg11062466	chr8:58055876	NA	0.41	7.84	0.3	1.84e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs7617773	0.817	rs13059037	chr3:48287879	A/G	cg11946769	chr3:48343235	NME6	0.67	13.85	0.48	2.39e-38	Coronary artery disease;
BRCA	cis	rs9682041	0.696	rs10936627	chr3:170104406	C/T	cg11886554	chr3:170076028	SKIL	0.51	10.18	0.37	1.22e-22	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg06917634	chr15:78832804	PSMA4	0.77	17.59	0.57	8.51e-57	Sudden cardiac arrest;
BRCA	cis	rs34779708	0.966	rs57081218	chr10:35434608	A/G	cg03585969	chr10:35415529	CREM	0.45	9.47	0.35	5.12e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs701145	0.537	rs437396	chr3:153923273	A/G	cg17054900	chr3:154042577	DHX36	0.57	9.59	0.35	1.96e-20	Coronary artery disease;
BRCA	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg19901468	chr14:105411992	AHNAK2	0.5	11.75	0.42	5.3e-29	Rheumatoid arthritis;
BRCA	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18404041	chr3:52824283	ITIH1	-0.39	-11.81	-0.42	3.09e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg22907277	chr7:1156413	C7orf50	0.45	10.41	0.38	1.49e-23	Longevity;Endometriosis;
BRCA	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg22029157	chr1:209979665	IRF6	-0.51	-8.16	-0.31	1.82e-15	Coronary artery disease;
BRCA	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.44	-8.33	-0.31	4.84e-16	Tuberculosis;
BRCA	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25427524	chr10:38739819	LOC399744	-0.73	-18.24	-0.59	3.68e-60	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg25319279	chr11:5960081	NA	-0.43	-8.37	-0.31	3.65e-16	DNA methylation (variation);
BRCA	cis	rs68170813	0.559	rs7803290	chr7:106907353	T/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.67	-0.32	3.43e-17	Coronary artery disease;
BRCA	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.26	0.38	5.81e-23	Bipolar disorder;
BRCA	cis	rs490234	0.932	rs506874	chr9:128319066	G/A	cg14078157	chr9:128172775	NA	0.33	7.89	0.3	1.3e-14	Mean arterial pressure;
BRCA	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg21475434	chr5:93447410	FAM172A	0.66	8.73	0.33	2.29e-17	Diabetic retinopathy;
BRCA	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg05623727	chr3:50126028	RBM5	-0.42	-10.06	-0.37	3.34e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg23950597	chr19:37808831	NA	-0.72	-12.59	-0.45	1.28e-32	Coronary artery calcification;
BRCA	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.43	-0.38	1.3e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg13047869	chr3:10149882	C3orf24	0.58	12.11	0.43	1.53e-30	Alzheimer's disease;
BRCA	cis	rs477692	0.905	rs489966	chr10:131422115	C/G	cg05714579	chr10:131428358	MGMT	-0.58	-14.07	-0.49	2.21e-39	Response to temozolomide;
BRCA	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg02551604	chr5:131831745	NA	0.4	15.16	0.51	1.43e-44	Asthma (sex interaction);
BRCA	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg23978390	chr7:1156363	C7orf50	0.42	10.08	0.37	2.76e-22	Longevity;Endometriosis;
BRCA	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg08885076	chr2:99613938	TSGA10	0.44	10.29	0.38	4.46e-23	Chronic sinus infection;
BRCA	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg04013093	chr6:42928303	GNMT	-0.28	-8.53	-0.32	1.05e-16	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg06808227	chr14:105710500	BRF1	-0.79	-16.18	-0.54	1.36e-49	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs13082711	0.595	rs17317435	chr3:27339326	A/G	cg02860705	chr3:27208620	NA	0.78	14.65	0.5	4.32e-42	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-10.53	-0.38	5.08e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg06521331	chr12:34319734	NA	-0.55	-10.13	-0.37	1.88e-22	Morning vs. evening chronotype;
BRCA	cis	rs2249625	0.545	rs2463743	chr6:72874741	C/T	cg18830697	chr6:72922368	RIMS1	-0.64	-14.66	-0.5	3.57e-42	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg11764359	chr7:65958608	NA	0.62	13.19	0.46	2.52e-35	Aortic root size;
BRCA	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.49	0.63	3.97e-72	Chronic sinus infection;
BRCA	cis	rs17818399	0.926	rs13033177	chr2:46831062	C/A	cg02822958	chr2:46747628	ATP6V1E2	0.55	9.85	0.36	2.13e-21	Height;
BRCA	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.42	-8.1	-0.31	2.85e-15	Dietary macronutrient intake;
BRCA	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10802521	chr3:52805072	NEK4	-0.33	-9.03	-0.34	2.06e-18	Bipolar disorder;
BRCA	cis	rs700651	0.757	rs6748683	chr2:198878008	T/A	cg00792783	chr2:198669748	PLCL1	0.42	9.31	0.35	1.96e-19	Intracranial aneurysm;
BRCA	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg00540400	chr15:79124168	NA	-0.28	-7.89	-0.3	1.33e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs4363385	0.747	rs1415960	chr1:152973571	G/T	cg24667326	chr1:152973720	SPRR3	-0.35	-9.81	-0.36	2.89e-21	Inflammatory skin disease;
BRCA	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg06784218	chr1:46089804	CCDC17	0.51	12.23	0.44	4.9e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.39	9.02	0.34	2.2e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg05340658	chr4:99064831	C4orf37	0.64	14.83	0.51	5.78e-43	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg06521331	chr12:34319734	NA	-0.52	-9.39	-0.35	1.08e-19	Bladder cancer;
BRCA	cis	rs4363385	0.747	rs946099	chr1:152971618	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.28	-0.31	7.41e-16	Inflammatory skin disease;
BRCA	cis	rs12042938	0.600	rs823161	chr1:231775017	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	8.9	0.33	5.73e-18	Neuranatomic and neurocognitive phenotypes;
BRCA	cis	rs7809950	1.000	rs2237676	chr7:107198079	C/A	cg23024343	chr7:107201750	COG5	-0.4	-9.05	-0.34	1.71e-18	Coronary artery disease;
BRCA	cis	rs965469	0.696	rs6037570	chr20:3334292	C/A	cg25506879	chr20:3388711	C20orf194	-0.42	-8.09	-0.3	2.93e-15	IFN-related cytopenia;
BRCA	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.69	0.33	3e-17	Personality dimensions;
BRCA	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.64e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.92	-0.51	2.19e-43	Chronic sinus infection;
BRCA	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	8.99	0.34	2.7e-18	Personality dimensions;
BRCA	cis	rs4363385	0.703	rs4845517	chr1:153003893	T/A	cg25856811	chr1:152973957	SPRR3	-0.31	-8.27	-0.31	7.82e-16	Inflammatory skin disease;
BRCA	cis	rs10504073	0.584	rs1511368	chr8:49949523	A/T	cg00325661	chr8:49890786	NA	0.45	13.07	0.46	9.48e-35	Blood metabolite ratios;
BRCA	cis	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg06521331	chr12:34319734	NA	0.49	8.78	0.33	1.47e-17	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-8.26	-0.31	8.36e-16	Total body bone mineral density;
BRCA	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18876405	chr7:65276391	NA	0.55	13.26	0.46	1.28e-35	Aortic root size;
BRCA	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg15103426	chr22:29168792	CCDC117	0.51	11.82	0.42	2.6e-29	Lymphocyte counts;
BRCA	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.58	9.78	0.36	3.7e-21	Gut microbiome composition (summer);
BRCA	cis	rs12618769	0.597	rs11902825	chr2:99129137	T/C	cg10123293	chr2:99228465	UNC50	0.42	8.19	0.31	1.38e-15	Bipolar disorder;
BRCA	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg18196295	chr10:418757	DIP2C	0.5	11.87	0.43	1.59e-29	Psychosis in Alzheimer's disease;
BRCA	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg05340658	chr4:99064831	C4orf37	0.48	10.66	0.39	1.61e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg20607798	chr8:58055168	NA	0.46	8.15	0.31	1.91e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	21.36	0.65	8.04e-77	Platelet count;
BRCA	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg08917208	chr2:24149416	ATAD2B	0.53	8.25	0.31	8.81e-16	Asthma;
BRCA	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.55	11.92	0.43	1e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-8.84	-0.33	9.58e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6545883	0.929	rs7606167	chr2:61742654	C/G	cg15711740	chr2:61764176	XPO1	-0.56	-14.22	-0.49	4.63e-40	Tuberculosis;
BRCA	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg07169764	chr2:136633963	MCM6	1.15	23.84	0.69	2.37e-90	Corneal structure;
BRCA	trans	rs800082	0.646	rs2717394	chr3:144280612	A/T	cg24215973	chr2:240111563	HDAC4	0.4	10.35	0.38	2.57e-23	Smoking behavior;
BRCA	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg06494592	chr3:125709126	NA	-0.52	-8.52	-0.32	1.15e-16	Blood pressure (smoking interaction);
BRCA	cis	rs311392	1.000	rs2671804	chr8:55088853	C/T	cg11783602	chr8:55087084	NA	-0.33	-9.61	-0.36	1.58e-20	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.9	0.62	6.05e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg09537434	chr19:41945824	ATP5SL	-0.99	-23.65	-0.68	2.59e-89	Height;
BRCA	cis	rs9807989	0.507	rs6758936	chr2:102991369	A/G	cg03938978	chr2:103052716	IL18RAP	-0.29	-8.61	-0.32	5.69e-17	Asthma;
BRCA	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	8.69	0.33	3.01e-17	Iron status biomarkers;
BRCA	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg16606324	chr3:10149918	C3orf24	0.52	8.84	0.33	9.31e-18	Alzheimer's disease;
BRCA	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg11764359	chr7:65958608	NA	0.68	15.19	0.52	9.94e-45	Aortic root size;
BRCA	cis	rs17401966	1.000	rs12130220	chr1:10359944	T/G	cg03954927	chr1:10346856	KIF1B	0.45	13.17	0.46	3.26e-35	Hepatocellular carcinoma;
BRCA	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg10729496	chr3:10149963	C3orf24	0.42	8.08	0.3	3.25e-15	Alzheimer's disease;
BRCA	trans	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg25206134	chr2:45395956	NA	0.52	8.47	0.32	1.63e-16	Neuroticism;
BRCA	cis	rs1865721	1.000	rs72977879	chr18:73193696	T/C	cg26385618	chr18:73139727	C18orf62	-0.39	-9.0	-0.34	2.66e-18	Intelligence;
BRCA	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg25358565	chr5:93447407	FAM172A	1.16	18.43	0.59	3.73e-61	Diabetic retinopathy;
BRCA	cis	rs4363385	0.720	rs11205150	chr1:152959266	C/T	cg21543102	chr1:152974771	SPRR3	-0.3	-8.75	-0.33	1.84e-17	Inflammatory skin disease;
BRCA	cis	rs7246967	0.541	rs16999009	chr19:22909658	A/G	cg23217946	chr19:22817039	ZNF492	-0.48	-8.69	-0.32	3.13e-17	Bronchopulmonary dysplasia;
BRCA	cis	rs13082711	0.520	rs2643825	chr3:27562613	A/G	cg02860705	chr3:27208620	NA	0.42	8.41	0.32	2.6e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs1003719	0.751	rs2835585	chr21:38460488	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.1	0.49	1.6e-39	Eye color traits;
BRCA	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg08859206	chr1:53392774	SCP2	-0.4	-7.9	-0.3	1.26e-14	Monocyte count;
BRCA	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg25358565	chr5:93447407	FAM172A	1.19	19.65	0.61	1.39e-67	Diabetic retinopathy;
BRCA	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg05279229	chr7:1896384	MAD1L1	-0.42	-7.81	-0.3	2.29e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg08400316	chr16:204221	HBZ	-0.75	-16.57	-0.55	1.36e-51	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.38	0.49	8.02e-41	Motion sickness;
BRCA	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.85	20.73	0.63	2.18e-73	Birth weight;
BRCA	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg24397884	chr7:158709396	WDR60	0.97	24.77	0.7	1.81e-95	Height;
BRCA	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	ch.11.42038R	chr11:967971	AP2A2	0.5	15.89	0.53	3.78e-48	Alzheimer's disease (late onset);
BRCA	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.68	-0.32	3.33e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.09e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg27211696	chr2:191398769	TMEM194B	0.52	11.91	0.43	1.14e-29	Pulse pressure;
BRCA	cis	rs1891275	0.515	rs11186666	chr10:93477919	T/C	cg07889827	chr10:93443413	NA	-0.4	-10.9	-0.4	1.76e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg01802117	chr1:53393560	SCP2	-0.36	-8.38	-0.31	3.43e-16	Monocyte count;
BRCA	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg21475434	chr5:93447410	FAM172A	0.66	8.42	0.32	2.47e-16	Diabetic retinopathy;
BRCA	trans	rs11088226	0.681	rs16989507	chr21:33939509	T/G	cg09050820	chr6:167586206	TCP10L2	0.77	13.24	0.46	1.49e-35	Gastritis;
BRCA	cis	rs13046373	0.535	rs13051529	chr21:32029743	G/C	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.08	0.34	1.3e-18	HDL cholesterol;
BRCA	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg27446573	chr6:127587934	RNF146	0.9	21.32	0.64	1.39e-76	Breast cancer;
BRCA	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg06784218	chr1:46089804	CCDC17	-0.54	-13.13	-0.46	4.69e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3784262	0.616	rs2704197	chr15:58323236	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.34	-8.6	-0.32	6.14e-17	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs1904096	0.506	rs11097408	chr4:95165662	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.41	-9.51	-0.35	3.81e-20	Type 2 diabetes;
BRCA	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg19743168	chr1:23544995	NA	0.47	11.73	0.42	6.7200000000000006e-29	Height;
BRCA	cis	rs16910800	0.731	rs7125729	chr11:23181637	A/G	cg20040320	chr11:23191996	NA	-0.59	-10.15	-0.37	1.47e-22	Cancer;
BRCA	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11764359	chr7:65958608	NA	0.76	17.07	0.56	4.29e-54	Aortic root size;
BRCA	trans	rs6479891	1.000	rs4746994	chr10:64905324	T/A	cg14819942	chr15:35414228	NA	0.35	8.54	0.32	1e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-7.94	-0.3	9.19e-15	Homocysteine levels;
BRCA	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg19622623	chr12:86230825	RASSF9	-0.3	-8.29	-0.31	6.78e-16	Major depressive disorder;
BRCA	trans	rs12458462	0.509	rs3786241	chr18:77494328	A/C	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.45	-9.4	-0.35	9.56e-20	Monocyte count;
BRCA	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.49	-10.58	-0.39	3.13e-24	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg00857998	chr1:205179979	DSTYK	0.45	8.41	0.32	2.62e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs7236492	0.505	rs11663549	chr18:77181989	A/G	cg15644404	chr18:77186268	NFATC1	0.67	8.14	0.31	2.08e-15	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3820928	0.839	rs58580037	chr2:227876274	G/T	cg11843606	chr2:227700838	RHBDD1	-0.37	-8.08	-0.3	3.23e-15	Pulmonary function;
BRCA	cis	rs7766436	0.885	rs13200219	chr6:22595428	C/T	cg13666174	chr6:22585274	NA	-0.45	-9.69	-0.36	8.56e-21	Coronary artery disease;
BRCA	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg09537434	chr19:41945824	ATP5SL	-1.0	-23.23	-0.68	5.32e-87	Height;
BRCA	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg18404041	chr3:52824283	ITIH1	-0.34	-9.01	-0.34	2.38e-18	Schizophrenia;
BRCA	cis	rs9815354	0.812	rs17214987	chr3:41810481	C/T	cg03022575	chr3:42003672	ULK4	-0.72	-9.84	-0.36	2.22e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg12436631	chr1:155007014	DCST1;DCST2	0.27	8.43	0.32	2.27e-16	Prostate cancer;
BRCA	cis	rs586533	0.881	rs646017	chr11:99497150	T/G	cg22878054	chr11:99397252	CNTN5	0.32	8.02	0.3	5.08e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg03146154	chr1:46216737	IPP	0.52	11.55	0.42	3.78e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.86e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg01884057	chr2:25150051	NA	0.34	9.0	0.34	2.66e-18	Body mass index;
BRCA	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg18357645	chr12:58087776	OS9	-0.47	-13.43	-0.47	2.1e-36	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.35	0.35	1.49e-19	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg20290983	chr6:43655470	MRPS18A	-1.09	-38.59	-0.84	4.08e-169	IgG glycosylation;
BRCA	cis	rs1468333	1.000	rs13356202	chr5:137564588	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.43	8.26	0.31	8.61e-16	Resting heart rate;
BRCA	cis	rs6785206	0.730	rs9861429	chr3:128425749	A/G	cg16766828	chr3:128327626	NA	-0.6	-9.18	-0.34	6e-19	Lymphocyte percentage of white cells;
BRCA	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg14547644	chr6:28411285	ZSCAN23	-0.35	-7.83	-0.3	2e-14	Pubertal anthropometrics;
BRCA	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg18904891	chr8:8559673	CLDN23	0.6	11.92	0.43	1.05e-29	Obesity-related traits;
BRCA	cis	rs965469	0.947	rs4611719	chr20:3228423	G/A	cg25506879	chr20:3388711	C20orf194	-0.54	-10.33	-0.38	3.02e-23	IFN-related cytopenia;
BRCA	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg13736514	chr6:26305472	NA	-0.35	-11.68	-0.42	1.08e-28	Educational attainment;
BRCA	cis	rs12367572	0.965	rs11182706	chr12:45223339	T/C	cg04608330	chr12:45269318	NELL2	-0.61	-12.81	-0.45	1.39e-33	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.64e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.39	9.09	0.34	1.19e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10267417	0.603	rs28770193	chr7:19860804	A/T	cg05791153	chr7:19748676	TWISTNB	0.48	9.4	0.35	9.26e-20	Night sleep phenotypes;
BRCA	cis	rs72772090	0.710	rs17400741	chr5:96066576	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.7	-0.45	4.13e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs35995292	0.500	rs28369620	chr7:38921872	C/T	cg19327137	chr7:38886074	VPS41	0.38	12.68	0.45	4.91e-33	Subjective well-being (multi-trait analysis);
BRCA	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg23625390	chr15:77176239	SCAPER	0.39	9.06	0.34	1.56e-18	Blood metabolite levels;
BRCA	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg26384229	chr12:38710491	ALG10B	0.43	10.42	0.38	1.38e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12220238	0.908	rs11000937	chr10:75998785	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.5	8.33	0.31	5.03e-16	Soluble interleukin-2 receptor subunit alpha;
BRCA	cis	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg04374321	chr14:90722782	PSMC1	0.73	19.14	0.6	6.5e-65	Mortality in heart failure;
BRCA	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-11.55	-0.42	3.6e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg25214090	chr10:38739885	LOC399744	0.51	10.48	0.38	7.8e-24	Corneal astigmatism;
BRCA	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg00750074	chr16:89608354	SPG7	-0.39	-10.4	-0.38	1.67e-23	Multiple myeloma (IgH translocation);
BRCA	cis	rs312274	0.569	rs11178848	chr12:41266263	A/G	cg17827154	chr12:41323612	CNTN1	-0.36	-9.0	-0.34	2.59e-18	Metabolite levels  (X-11787);
BRCA	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg26944245	chr16:421049	TMEM8A;MRPL28	0.41	9.1	0.34	1.1e-18	Bone mineral density (spine);Bone mineral density;
BRCA	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg03929089	chr4:120376271	NA	-0.69	-13.73	-0.48	8.73e-38	Height;
BRCA	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg18132916	chr6:79620363	NA	-0.48	-10.88	-0.4	2.04e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs1712517	0.771	rs7921655	chr10:105113701	C/T	cg05636881	chr10:105038444	INA	0.36	7.96	0.3	7.99e-15	Migraine;
BRCA	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.29	-0.41	4.26e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs897984	0.568	rs72799330	chr16:30893555	C/A	cg00531865	chr16:30841666	NA	-0.38	-7.83	-0.3	2.02e-14	Dementia with Lewy bodies;
BRCA	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	13.98	0.48	5.93e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.23	-0.31	1.07e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg24642439	chr20:33292090	TP53INP2	0.52	11.5	0.41	6.16e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg16584290	chr5:462447	EXOC3	-0.38	-9.19	-0.34	5.42e-19	Cystic fibrosis severity;
BRCA	cis	rs9649465	1.000	rs10228367	chr7:123370903	C/T	cg04330084	chr7:123175371	IQUB	-0.31	-8.64	-0.32	4.49e-17	Migraine;
BRCA	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg04691961	chr3:161091175	C3orf57	-0.39	-9.03	-0.34	1.99e-18	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg23711669	chr6:146136114	FBXO30	0.73	17.14	0.56	1.74e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg22029157	chr1:209979665	IRF6	0.44	8.33	0.31	4.95e-16	Cleft lip with or without cleft palate;
BRCA	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg24296786	chr1:45957014	TESK2	0.43	8.49	0.32	1.45e-16	Homocysteine levels;
BRCA	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg10223061	chr2:219282414	VIL1	0.29	8.26	0.31	8.21e-16	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.94e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg17509989	chr5:176798049	RGS14	0.68	13.26	0.46	1.27e-35	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg23888215	chr10:79422304	NA	-0.56	-10.46	-0.38	9.69e-24	Bone mineral density;
BRCA	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg05472934	chr7:22766657	IL6	0.52	13.31	0.47	7.36e-36	Lung cancer;
BRCA	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg00666640	chr1:248458726	OR2T12	0.32	8.83	0.33	9.7e-18	Common traits (Other);
BRCA	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.24	8.2	0.31	1.28e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg06521331	chr12:34319734	NA	-0.57	-11.13	-0.4	1.93e-26	Morning vs. evening chronotype;
BRCA	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.34	8.25	0.31	9.12e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg08061076	chr7:1943177	MAD1L1	-0.37	-7.81	-0.3	2.28e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg16606324	chr3:10149918	C3orf24	0.57	10.04	0.37	3.9e-22	Alzheimer's disease;
BRCA	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg26597838	chr10:835615	NA	0.81	14.51	0.5	1.97e-41	Eosinophil percentage of granulocytes;
BRCA	cis	rs7715806	0.500	rs72633983	chr5:75002845	C/T	cg19683494	chr5:74908142	NA	0.5	8.06	0.3	3.69e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg19717773	chr7:2847554	GNA12	-0.43	-9.62	-0.36	1.47e-20	Height;
BRCA	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg09904177	chr6:26538194	HMGN4	0.47	14.72	0.5	1.97e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg06221963	chr1:154839813	KCNN3	0.53	14.08	0.49	2.17e-39	Prostate cancer;
BRCA	trans	rs11088226	0.681	rs11700671	chr21:33938621	T/A	cg09050820	chr6:167586206	TCP10L2	0.77	13.24	0.46	1.49e-35	Gastritis;
BRCA	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg15556689	chr8:8085844	FLJ10661	0.34	8.6	0.32	5.99e-17	Neuroticism;
BRCA	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg11764359	chr7:65958608	NA	0.65	11.51	0.41	5.31e-28	Aortic root size;
BRCA	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg03709012	chr19:19516395	GATAD2A	0.81	18.91	0.6	1.2e-63	Tonsillectomy;
BRCA	cis	rs4812048	0.649	rs6100319	chr20:57626568	A/C	cg14073986	chr20:57617431	SLMO2	0.77	11.9	0.43	1.22e-29	Mean platelet volume;
BRCA	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg00376283	chr12:123451042	ABCB9	-0.49	-11.27	-0.41	5.3e-27	Neutrophil percentage of white cells;
BRCA	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11764359	chr7:65958608	NA	0.71	15.49	0.52	3.29e-46	Aortic root size;
BRCA	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg24829409	chr8:58192753	C8orf71	-0.47	-8.94	-0.33	4.23e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg11843238	chr5:131593191	PDLIM4	0.33	8.57	0.32	8e-17	Breast cancer;
BRCA	cis	rs11229555	0.645	rs11530830	chr11:58252992	C/G	cg15696309	chr11:58395628	NA	0.52	10.93	0.4	1.28e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg19156104	chr2:198669113	PLCL1	-0.45	-8.32	-0.31	5.51e-16	Ulcerative colitis;
BRCA	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg14440974	chr22:39074834	NA	0.38	8.33	0.31	5.09e-16	Menopause (age at onset);
BRCA	cis	rs1865721	0.771	rs7228890	chr18:73137492	C/A	cg26385618	chr18:73139727	C18orf62	-0.44	-10.69	-0.39	1.24e-24	Intelligence;
BRCA	cis	rs9462027	0.628	rs2814968	chr6:34713138	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.83	-0.3	2e-14	Systemic lupus erythematosus;
BRCA	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg00012203	chr2:219082015	ARPC2	-0.51	-10.46	-0.38	9.84e-24	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg15704280	chr7:45808275	SEPT13	-0.71	-14.61	-0.5	6.51e-42	Height;
BRCA	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.52	12.01	0.43	4.31e-30	Hemoglobin concentration;
BRCA	trans	rs629535	0.814	rs72654071	chr8:70079484	A/G	cg21567404	chr3:27674614	NA	-1.01	-21.77	-0.65	5.17e-79	Dupuytren's disease;
BRCA	trans	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg25214090	chr10:38739885	LOC399744	0.55	12.55	0.44	1.83e-32	Corneal astigmatism;
BRCA	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg09904177	chr6:26538194	HMGN4	0.56	18.47	0.59	2.43e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs1775715	0.737	rs11817598	chr10:32206259	A/G	cg14930904	chr10:32216787	ARHGAP12	0.34	7.85	0.3	1.72e-14	Bipolar disorder with mood-incongruent psychosis;
BRCA	cis	rs11874712	1.000	rs1800636	chr18:43670420	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.18	0.31	1.57e-15	Migraine - clinic-based;
BRCA	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg20476274	chr7:133979776	SLC35B4	0.7	21.34	0.65	1.05e-76	Mean platelet volume;
BRCA	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg08601574	chr20:25228251	PYGB	0.36	8.34	0.31	4.66e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10501293	0.828	rs17497596	chr11:43102898	A/G	cg03447554	chr11:43094025	NA	0.44	8.37	0.31	3.71e-16	Cognitive performance;
BRCA	cis	rs7520050	0.931	rs11211213	chr1:46342517	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.89	0.36	1.5e-21	Red blood cell count;Reticulocyte count;
BRCA	trans	rs9929218	1.000	rs4500718	chr16:68754312	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-15.59	-0.52	1.15e-46	Colorectal cancer;
BRCA	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.37	0.38	2.09e-23	Motion sickness;
BRCA	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg07395648	chr5:131743802	NA	-0.38	-8.8	-0.33	1.28e-17	Breast cancer;Mosquito bite size;
BRCA	cis	rs11679072	1.000	rs13410440	chr2:240447304	C/T	cg03276489	chr2:240449683	NA	0.53	7.82	0.3	2.18e-14	Blood pressure (smoking interaction);
BRCA	cis	rs17092148	1.000	rs6058112	chr20:33322006	G/C	cg16810054	chr20:33298113	TP53INP2	-0.51	-11.37	-0.41	2.13e-27	Neuroticism;
BRCA	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14442939	chr10:27389572	ANKRD26	0.53	9.14	0.34	8.03e-19	Breast cancer;
BRCA	cis	rs6840258	0.825	rs79998318	chr4:87954166	A/G	cg08197287	chr4:87952173	AFF1	-0.44	-8.77	-0.33	1.61e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08219700	chr8:58056026	NA	0.54	8.85	0.33	8.66e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2070997	0.667	rs7869508	chr9:133716802	T/C	cg11464064	chr9:133710261	ABL1	0.53	9.6	0.35	1.81e-20	Response to amphetamines;
BRCA	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg26384229	chr12:38710491	ALG10B	0.59	13.61	0.47	3.04e-37	Morning vs. evening chronotype;
BRCA	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg25358565	chr5:93447407	FAM172A	1.21	18.73	0.6	1.05e-62	Diabetic retinopathy;
BRCA	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg26395211	chr5:140044315	WDR55	0.37	8.52	0.32	1.16e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg12072164	chr19:44306565	LYPD5	0.36	8.6	0.32	5.99e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg03433033	chr1:76189801	ACADM	-0.71	-18.22	-0.58	4.72e-60	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs812925	0.512	rs1177309	chr2:61385248	A/G	cg15711740	chr2:61764176	XPO1	-0.32	-8.02	-0.3	4.96e-15	Immature fraction of reticulocytes;
BRCA	cis	rs3125734	0.633	rs10761616	chr10:64009076	G/A	cg09941381	chr10:64027924	RTKN2	-0.29	-8.21	-0.31	1.24e-15	Rheumatoid arthritis;
BRCA	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.39	-9.14	-0.34	8.46e-19	Longevity;Endometriosis;
BRCA	trans	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg17145862	chr1:211918768	LPGAT1	0.69	18.14	0.58	1.25e-59	Leprosy;
BRCA	cis	rs1210638	0.706	rs2518798	chr22:18970403	T/C	cg09619624	chr22:18985632	NA	0.34	8.08	0.3	3.27e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
BRCA	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg18016565	chr1:150552671	MCL1	0.34	8.05	0.3	4.08e-15	Tonsillectomy;
BRCA	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg21248554	chr2:27665150	KRTCAP3	0.32	8.43	0.32	2.34e-16	Total body bone mineral density;
BRCA	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.39	-10.15	-0.37	1.56e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg20701182	chr2:24300061	SF3B14	0.58	9.11	0.34	1.04e-18	Lymphocyte counts;
BRCA	cis	rs2070433	1.000	rs2070433	chr21:47961386	G/A	cg05998816	chr21:47859926	PCNT	0.36	8.5	0.32	1.38e-16	Lymphocyte counts;
BRCA	cis	rs8028182	0.501	rs7166281	chr15:75928192	G/T	cg20655648	chr15:75932815	IMP3	-0.48	-9.57	-0.35	2.21e-20	Sudden cardiac arrest;
BRCA	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg09035930	chr12:129282057	SLC15A4	0.5	13.98	0.48	6.25e-39	Systemic lupus erythematosus;
BRCA	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.34	-9.23	-0.34	3.84e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs9400271	0.632	rs6930844	chr6:109590286	C/A	cg01475377	chr6:109611718	NA	-0.43	-10.34	-0.38	2.9e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg27165867	chr14:105738592	BRF1	-0.38	-8.85	-0.33	8.51e-18	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-8.13	-0.31	2.25e-15	Obesity-related traits;
BRCA	trans	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.23	0.31	1.04e-15	Endometrial cancer;
BRCA	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg21535247	chr6:8435926	SLC35B3	0.41	9.46	0.35	5.8e-20	Motion sickness;
BRCA	trans	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg25214090	chr10:38739885	LOC399744	0.51	10.99	0.4	7.57e-26	Corneal astigmatism;
BRCA	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg00012203	chr2:219082015	ARPC2	0.56	11.9	0.43	1.27e-29	Colorectal cancer;
BRCA	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg17712092	chr4:129076599	LARP1B	-0.5	-10.89	-0.4	1.83e-25	Breast cancer;
BRCA	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.81	0.55	8.35e-53	Axial length;
BRCA	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg03929089	chr4:120376271	NA	-0.44	-8.25	-0.31	8.77e-16	HDL cholesterol;
BRCA	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	18.9	0.6	1.21e-63	Smoking behavior;
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.65	-15.85	-0.53	6.11e-48	Longevity;Endometriosis;
BRCA	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg06115741	chr20:33292138	TP53INP2	0.51	11.22	0.41	8.49e-27	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00149659	chr3:10157352	C3orf10	0.8	13.73	0.48	9.11e-38	Alzheimer's disease;
BRCA	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.22	0.49	4.42e-40	Motion sickness;
BRCA	cis	rs12545109	0.959	rs12546307	chr8:57314790	T/A	cg09654669	chr8:57350985	NA	-0.39	-8.1	-0.31	2.86e-15	Obesity-related traits;
BRCA	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg17063962	chr7:91808500	NA	-0.56	-12.82	-0.45	1.23e-33	Breast cancer;
BRCA	cis	rs10193935	1.000	rs13391906	chr2:42538617	C/G	cg27598129	chr2:42591480	NA	-0.96	-14.93	-0.51	1.87e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg01802117	chr1:53393560	SCP2	0.34	7.86	0.3	1.67e-14	Monocyte count;
BRCA	cis	rs13046373	0.535	rs1961167	chr21:32030310	T/C	cg22337977	chr21:31811175	KRTAP15-1	0.34	7.83	0.3	2.09e-14	HDL cholesterol;
BRCA	cis	rs365132	0.875	rs353491	chr5:176432947	C/G	cg16309518	chr5:176445507	NA	-0.41	-9.82	-0.36	2.63e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg02659138	chr7:134003124	SLC35B4	0.33	10.22	0.37	7.85e-23	Mean platelet volume;
BRCA	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg27279351	chr12:120934652	DYNLL1	0.57	13.38	0.47	3.5e-36	High light scatter reticulocyte count;
BRCA	trans	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg04565464	chr8:145669602	NFKBIL2	0.4	9.73	0.36	5.71e-21	Schizophrenia;
BRCA	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15664640	chr17:80829946	TBCD	0.43	11.64	0.42	1.49e-28	Breast cancer;
BRCA	cis	rs4919694	1.000	rs10509758	chr10:104681710	T/C	cg04362960	chr10:104952993	NT5C2	0.93	14.99	0.51	9.22e-44	Arsenic metabolism;
BRCA	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.33	-0.31	4.93e-16	Total body bone mineral density;
BRCA	cis	rs17253792	0.822	rs13379353	chr14:56050478	G/C	cg01858014	chr14:56050164	KTN1	-0.77	-11.27	-0.41	5.52e-27	Putamen volume;
BRCA	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg03146154	chr1:46216737	IPP	0.45	10.01	0.37	5.27e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1511802	0.579	rs7682918	chr4:187115841	C/T	cg24794857	chr4:187113578	CYP4V2	0.37	7.86	0.3	1.65e-14	Blood protein levels;
BRCA	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg16049864	chr8:95962084	TP53INP1	0.39	8.36	0.31	3.99e-16	Type 2 diabetes;
BRCA	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.56	-0.32	8.45e-17	Total body bone mineral density;
BRCA	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11764359	chr7:65958608	NA	0.8	19.53	0.61	6.05e-67	Aortic root size;
BRCA	cis	rs858239	0.539	rs10247268	chr7:23187179	G/A	cg23682824	chr7:23144976	KLHL7	0.37	9.64	0.36	1.27e-20	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg25817165	chr18:72167213	CNDP2	-0.75	-13.59	-0.47	3.72e-37	Refractive error;
BRCA	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg24977027	chr2:88469347	THNSL2	0.47	8.03	0.3	4.81e-15	Plasma clusterin levels;
BRCA	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg12923728	chr3:195709715	SDHAP1	-0.47	-8.94	-0.33	4.14e-18	Pancreatic cancer;
BRCA	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	12.26	0.44	3.37e-31	Lung cancer in ever smokers;
BRCA	cis	rs16976116	0.901	rs28508034	chr15:55499010	T/C	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.99	-0.34	2.68e-18	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg08470875	chr2:26401718	FAM59B	-0.71	-11.35	-0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg04287289	chr16:89883240	FANCA	-0.59	-13.38	-0.47	3.66e-36	Vitiligo;
BRCA	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg05340658	chr4:99064831	C4orf37	0.44	10.14	0.37	1.74e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	10.12	0.37	2.02e-22	Eosinophil percentage of white cells;
BRCA	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg14863265	chr7:2801509	GNA12	-0.45	-9.98	-0.37	6.92e-22	Height;
BRCA	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg11584989	chr19:19387371	SF4	0.3	7.85	0.3	1.71e-14	Tonsillectomy;
BRCA	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg22800045	chr5:56110881	MAP3K1	0.56	10.52	0.38	5.82e-24	Initial pursuit acceleration;
BRCA	cis	rs10046574	0.831	rs10243569	chr7:135063466	G/A	cg27474649	chr7:135195673	CNOT4	0.58	8.3	0.31	6.41e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-19.43	-0.61	2.06e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg01256987	chr12:42539512	GXYLT1	-0.42	-8.31	-0.31	5.95e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs1468333	0.724	rs7726580	chr5:137608666	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	-0.38	-7.95	-0.3	8.21e-15	Resting heart rate;
BRCA	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg23711669	chr6:146136114	FBXO30	0.65	15.25	0.52	5.11e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg10224037	chr5:178157518	ZNF354A	0.78	17.8	0.58	7.13e-58	Neutrophil percentage of white cells;
BRCA	cis	rs2652834	0.904	rs2729826	chr15:63360446	C/G	cg05507819	chr15:63340323	TPM1	-0.48	-8.77	-0.33	1.58e-17	HDL cholesterol;
BRCA	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-18.04	-0.58	4.15e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.47	10.87	0.39	2.34e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs483180	0.512	rs612430	chr1:120216025	A/G	cg19096424	chr1:120255104	PHGDH	0.43	9.54	0.35	2.85e-20	Macular telangiectasia type 2;
BRCA	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg16230307	chr14:35515116	FAM177A1	0.69	14.27	0.49	2.52e-40	Psoriasis;
BRCA	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg26384229	chr12:38710491	ALG10B	0.77	17.76	0.57	1.24e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg05340658	chr4:99064831	C4orf37	0.41	8.7	0.33	2.88e-17	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	14.1	0.49	1.66e-39	Personality dimensions;
BRCA	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06634786	chr22:41940651	POLR3H	-0.59	-10.44	-0.38	1.12e-23	Vitiligo;
BRCA	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg13047869	chr3:10149882	C3orf24	0.59	12.55	0.44	1.94e-32	Alzheimer's disease;
BRCA	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg20587970	chr11:113659929	NA	-1.34	-24.49	-0.7	6.49e-94	Hip circumference adjusted for BMI;
BRCA	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg05665937	chr4:1216051	CTBP1	0.39	8.47	0.32	1.66e-16	Obesity-related traits;
BRCA	trans	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg07211511	chr3:129823064	LOC729375	-0.6	-11.53	-0.41	4.5e-28	Blood pressure (smoking interaction);
BRCA	cis	rs367943	1.000	rs348952	chr5:112821990	G/T	cg12552261	chr5:112820674	MCC	-0.55	-12.11	-0.43	1.59e-30	Type 2 diabetes;
BRCA	cis	rs4494114	1.000	rs4388668	chr1:39360730	A/T	cg25970120	chr1:39325951	RRAGC	-0.37	-7.91	-0.3	1.11e-14	Blood protein levels;
BRCA	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg08000102	chr2:233561755	GIGYF2	-0.46	-9.97	-0.37	7.41e-22	Coronary artery disease;
BRCA	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-11.34	-0.41	2.88e-27	Mood instability;
BRCA	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21659725	chr3:3221576	CRBN	-0.47	-12.18	-0.43	7.65e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg01262667	chr19:19385393	TM6SF2	0.43	11.09	0.4	2.97e-26	Tonsillectomy;
BRCA	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg24531977	chr5:56204891	C5orf35	-0.4	-8.59	-0.32	6.77e-17	Coronary artery disease;
BRCA	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg18225595	chr11:63971243	STIP1	0.53	9.39	0.35	1.05e-19	Mean platelet volume;
BRCA	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg19773385	chr1:10388646	KIF1B	0.38	8.44	0.32	2.18e-16	Hepatocellular carcinoma;
BRCA	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg08847533	chr14:75593920	NEK9	-0.94	-24.98	-0.7	1.27e-96	Height;
BRCA	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.47	-0.77	1.31e-126	Schizophrenia;
BRCA	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg09021430	chr5:549028	NA	-0.69	-15.85	-0.53	5.74e-48	Lung disease severity in cystic fibrosis;
BRCA	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.51	-0.44	2.87e-32	Type 2 diabetes;
BRCA	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08045932	chr20:61659980	NA	0.5	11.51	0.41	5.25e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg08807101	chr21:30365312	RNF160	-0.55	-12.4	-0.44	8.38e-32	Cognitive test performance;
BRCA	cis	rs4953076	0.573	rs9973609	chr2:44450435	T/C	cg04920474	chr2:44395004	PPM1B	0.49	9.67	0.36	9.47e-21	Height;
BRCA	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.22	-0.31	1.13e-15	Depression;
BRCA	cis	rs6138458	0.546	rs6050118	chr20:24891895	C/T	cg26195577	chr20:24973756	C20orf3	-0.74	-11.07	-0.4	3.66e-26	Blood protein levels;
BRCA	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg04362960	chr10:104952993	NT5C2	-0.51	-10.66	-0.39	1.56e-24	Arsenic metabolism;
BRCA	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-10.73	-0.39	8.08e-25	Response to bleomycin (chromatid breaks);
BRCA	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg03929089	chr4:120376271	NA	0.6	10.37	0.38	2.13e-23	Acute lymphoblastic leukemia (childhood);
BRCA	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-9.16	-0.34	7.23e-19	Retinal vascular caliber;
BRCA	cis	rs2479724	0.901	rs33954419	chr6:41786136	A/G	cg17623882	chr6:41773611	USP49	-0.36	-9.97	-0.37	7.26e-22	Menarche (age at onset);
BRCA	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg25036284	chr2:26402008	FAM59B	-0.88	-15.06	-0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg21045802	chr8:109455806	TTC35	0.35	8.02	0.3	5.19e-15	Dupuytren's disease;
BRCA	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.1	-0.37	2.28e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg19987790	chr17:43696684	MGC57346	-0.52	-9.25	-0.34	3.31e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
BRCA	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg00857998	chr1:205179979	DSTYK	0.42	8.15	0.31	1.98e-15	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg00666640	chr1:248458726	OR2T12	0.31	8.31	0.31	5.74e-16	Common traits (Other);
BRCA	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg22974920	chr21:40686053	BRWD1	-0.35	-7.87	-0.3	1.51e-14	Menarche (age at onset);
BRCA	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg03560586	chr2:239334908	ASB1	-0.38	-8.0	-0.3	5.72e-15	Multiple system atrophy;
BRCA	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.71	16.82	0.55	7.74e-53	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg05340658	chr4:99064831	C4orf37	0.42	8.9	0.33	5.58e-18	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg19077165	chr18:44547161	KATNAL2	-0.58	-13.02	-0.46	1.57e-34	Personality dimensions;
BRCA	cis	rs12760731	0.720	rs722321	chr1:178420220	C/T	cg00404053	chr1:178313656	RASAL2	0.67	8.31	0.31	5.57e-16	Obesity-related traits;
BRCA	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg27432699	chr2:27873401	GPN1	0.42	8.93	0.33	4.38e-18	Oral cavity cancer;
BRCA	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg07884673	chr3:53033167	SFMBT1	-0.58	-8.75	-0.33	1.9e-17	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg12641515	chr19:46296257	DMWD	-0.53	-11.83	-0.42	2.39e-29	Coronary artery disease;
BRCA	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16744531	chr19:17905626	B3GNT3	0.54	11.92	0.43	9.87e-30	Tumor biomarkers;
BRCA	cis	rs66887589	0.934	rs2389873	chr4:120554714	A/G	cg09307838	chr4:120376055	NA	-0.44	-9.14	-0.34	8.1e-19	Diastolic blood pressure;
BRCA	cis	rs775227	0.574	rs3732809	chr3:113045561	A/G	cg18753928	chr3:113234510	CCDC52	-0.54	-9.22	-0.34	4.19e-19	Dental caries;
BRCA	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.44	-0.38	1.17e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg18964960	chr10:1102726	WDR37	0.64	8.7	0.33	2.81e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.81	11.22	0.41	8.84e-27	Initial pursuit acceleration;
BRCA	trans	rs3857536	0.813	rs1891599	chr6:66941699	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-14.94	-0.51	1.61e-43	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs939658	0.805	rs34222382	chr15:79440748	C/T	cg17916960	chr15:79447300	NA	-0.46	-11.55	-0.42	3.8e-28	Refractive error;
BRCA	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.03	-18.48	-0.59	2e-61	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg13565492	chr6:43139072	SRF	-0.79	-11.09	-0.4	3.05e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg18357645	chr12:58087776	OS9	-0.33	-8.0	-0.3	5.66e-15	Multiple sclerosis;
BRCA	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg24069376	chr3:38537580	EXOG	0.42	12.02	0.43	3.84e-30	Electrocardiographic conduction measures;
BRCA	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg19717773	chr7:2847554	GNA12	-0.4	-9.13	-0.34	8.89e-19	Height;
BRCA	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg13393036	chr8:95962371	TP53INP1	-0.34	-9.34	-0.35	1.58e-19	Type 2 diabetes;
BRCA	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg18225595	chr11:63971243	STIP1	0.52	9.46	0.35	6.01e-20	Mean platelet volume;
BRCA	cis	rs7818345	1.000	rs7818345	chr8:19306618	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.32	8.42	0.32	2.49e-16	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg11833968	chr6:79620685	NA	-0.41	-9.07	-0.34	1.45e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.65	16.27	0.54	4.6e-50	Chronic sinus infection;
BRCA	trans	rs783540	0.843	rs28374463	chr15:83299364	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.27	-8.47	-0.32	1.71e-16	Schizophrenia;
BRCA	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg12310025	chr6:25882481	NA	0.74	17.89	0.58	2.58e-58	Blood metabolite levels;
BRCA	cis	rs1355223	0.525	rs10836316	chr11:34874295	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-9.48	-0.35	4.85e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.3	8.43	0.32	2.37e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs4650994	1.000	rs4650993	chr1:178515187	A/G	cg05059571	chr16:84539110	KIAA1609	-0.43	-9.77	-0.36	4.24e-21	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs68170813	0.559	rs17427158	chr7:106824259	G/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.41	-0.32	2.67e-16	Coronary artery disease;
BRCA	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-10.41	-0.38	1.5e-23	Schizophrenia;
BRCA	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.76	16.55	0.55	1.86e-51	Lymphocyte counts;
BRCA	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg05340658	chr4:99064831	C4orf37	0.57	11.12	0.4	2.13e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12210905	0.688	rs12209174	chr6:27443952	G/A	cg08851530	chr6:28072375	NA	0.81	7.97	0.3	7.05e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg12661370	chr5:149340060	SLC26A2	0.57	8.39	0.32	3.06e-16	HIV-1 control;
BRCA	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg20673091	chr1:2541236	MMEL1	-0.34	-8.16	-0.31	1.83e-15	Ulcerative colitis;
BRCA	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg15485101	chr11:133734466	NA	-0.43	-11.2	-0.41	1.01e-26	Childhood ear infection;
BRCA	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.42	-0.32	2.42e-16	Monocyte percentage of white cells;
BRCA	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.4	-0.41	1.57e-27	Electroencephalogram traits;
BRCA	cis	rs11603020	0.950	rs78624400	chr11:57375463	G/C	cg19752551	chr11:57585705	CTNND1	-0.41	-9.7	-0.36	7.35e-21	Blood protein levels;
BRCA	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg16230307	chr14:35515116	FAM177A1	0.77	15.42	0.52	7.64e-46	Psoriasis;
BRCA	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	12.15	0.43	1.03e-30	Mood instability;
BRCA	trans	rs783540	0.935	rs2278355	chr15:83331155	C/T	cg18393722	chr15:85113863	UBE2QP1	0.26	8.03	0.3	4.65e-15	Schizophrenia;
BRCA	cis	rs7131987	0.621	rs11050181	chr12:29467669	C/T	cg09582351	chr12:29534625	ERGIC2	-0.43	-9.96	-0.37	8.3e-22	QT interval;
BRCA	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.46	10.13	0.37	1.77e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg09307838	chr4:120376055	NA	0.58	11.03	0.4	5.03e-26	Corneal astigmatism;
BRCA	cis	rs66887589	0.934	rs12648182	chr4:120503891	T/A	cg09307838	chr4:120376055	NA	-0.44	-9.27	-0.34	2.93e-19	Diastolic blood pressure;
BRCA	cis	rs3845702	0.668	rs6759271	chr2:180844303	T/C	cg01881094	chr2:180872142	CWC22	-1.04	-18.5	-0.59	1.71e-61	Schizophrenia;
BRCA	cis	rs2629540	0.889	rs4962699	chr10:126477209	A/G	cg08799069	chr10:126477246	METTL10	-0.54	-12.11	-0.43	1.58e-30	Cocaine dependence;
BRCA	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg04511125	chr2:88470314	THNSL2	0.8	11.47	0.41	8.04e-28	Plasma clusterin levels;
BRCA	cis	rs7599312	0.963	rs6735267	chr2:213403863	C/T	cg16329650	chr2:213403929	ERBB4	0.46	9.75	0.36	5.07e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27286337	chr10:134555280	INPP5A	0.78	12.76	0.45	2.3e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6809651	0.524	rs6444105	chr3:185811301	C/T	cg00760338	chr3:185826511	ETV5	-0.48	-9.56	-0.35	2.57e-20	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
BRCA	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.16	0.31	1.83e-15	Breast cancer;
BRCA	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg03877680	chr5:178157825	ZNF354A	0.77	14.59	0.5	8.19e-42	Neutrophil percentage of white cells;
BRCA	trans	rs5756813	0.661	rs2285177	chr22:38205894	A/G	cg19894588	chr14:64061835	NA	-0.52	-11.41	-0.41	1.44e-27	Optic cup area;Vertical cup-disc ratio;
BRCA	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6973256	0.897	rs6970448	chr7:133343642	G/A	cg07491979	chr7:133331646	EXOC4	-0.39	-9.05	-0.34	1.69e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs807669	0.525	rs9604934	chr22:19194868	C/T	cg02655711	chr22:19163373	SLC25A1	0.43	9.99	0.37	6.41e-22	Metabolite levels;
BRCA	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg20283391	chr11:68216788	NA	-0.46	-8.99	-0.33	2.87e-18	Total body bone mineral density;
BRCA	trans	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg26384229	chr12:38710491	ALG10B	0.56	12.16	0.43	9.7e-31	Morning vs. evening chronotype;
BRCA	cis	rs68170813	0.559	rs80153759	chr7:106944145	C/A	cg02696742	chr7:106810147	HBP1	-0.52	-8.59	-0.32	6.47e-17	Coronary artery disease;
BRCA	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg03585969	chr10:35415529	CREM	0.56	11.62	0.42	1.84e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg02734326	chr4:10020555	SLC2A9	0.39	8.28	0.31	7.31e-16	Bone mineral density;
BRCA	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg20933634	chr6:27740509	NA	0.44	8.43	0.32	2.27e-16	Parkinson's disease;
BRCA	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg17691542	chr6:26056736	HIST1H1C	0.66	13.7	0.48	1.19e-37	Height;
BRCA	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.48	0.35	4.77e-20	Morning vs. evening chronotype;
BRCA	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg19156104	chr2:198669113	PLCL1	-0.45	-8.37	-0.31	3.61e-16	Ulcerative colitis;
BRCA	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg08000102	chr2:233561755	GIGYF2	0.63	13.77	0.48	5.88e-38	Coronary artery disease;
BRCA	cis	rs600806	0.745	rs4970763	chr1:110006349	G/A	cg20591472	chr1:110008990	SYPL2	0.31	7.93	0.3	1.01e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2599510	0.744	rs4952212	chr2:32618493	G/C	cg02381751	chr2:32503542	YIPF4	-0.43	-8.51	-0.32	1.27e-16	Interleukin-18 levels;
BRCA	cis	rs897984	0.542	rs11865038	chr16:31095171	C/T	cg02466173	chr16:30829666	NA	-0.44	-9.79	-0.36	3.39e-21	Dementia with Lewy bodies;
BRCA	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	11.68	0.42	1.06e-28	Height;
BRCA	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg11366901	chr6:160182831	ACAT2	0.82	15.87	0.53	4.47e-48	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-9.88	-0.36	1.6e-21	Alzheimer's disease (late onset);
BRCA	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg07537917	chr2:241836409	C2orf54	0.49	11.62	0.42	1.94e-28	Urinary metabolites;
BRCA	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg14689365	chr7:158441557	NCAPG2	-0.44	-9.05	-0.34	1.78e-18	Height;
BRCA	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg13047869	chr3:10149882	C3orf24	0.59	12.27	0.44	3.13e-31	Alzheimer's disease;
BRCA	cis	rs6495367	1.000	rs1961579	chr15:79380516	G/A	cg17916960	chr15:79447300	NA	0.32	8.11	0.31	2.66e-15	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.36	-8.13	-0.31	2.18e-15	Mean platelet volume;
BRCA	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-12.07	-0.43	2.3e-30	Bipolar disorder;
BRCA	cis	rs4363385	0.765	rs11205165	chr1:152986928	G/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.19	-0.31	1.42e-15	Inflammatory skin disease;
BRCA	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	10.58	0.39	3.17e-24	Height;
BRCA	cis	rs12368653	0.840	rs10877020	chr12:58188014	G/A	cg02175503	chr12:58329896	NA	-0.42	-8.97	-0.33	3.13e-18	Multiple sclerosis;
BRCA	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg24642439	chr20:33292090	TP53INP2	-0.43	-8.75	-0.33	1.83e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs2882667	0.619	rs6861556	chr5:138188040	C/T	cg04439458	chr5:138467593	SIL1	0.35	8.58	0.32	7.29e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg04362960	chr10:104952993	NT5C2	-0.39	-9.52	-0.35	3.55e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg02951883	chr7:2050386	MAD1L1	-0.5	-11.37	-0.41	2e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg07080220	chr10:102295463	HIF1AN	0.61	14.56	0.5	1.16e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg23285459	chr7:2802560	GNA12	-0.34	-8.53	-0.32	1.05e-16	Height;
BRCA	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.27	-0.34	2.9e-19	Alzheimer's disease (late onset);
BRCA	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg19683494	chr5:74908142	NA	0.56	9.57	0.35	2.32e-20	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
BRCA	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	cg20946044	chr11:1010712	AP2A2	-0.37	-7.87	-0.3	1.56e-14	Alzheimer's disease (late onset);
BRCA	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	14.22	0.49	4.41e-40	Eosinophil percentage of white cells;
BRCA	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg18404041	chr3:52824283	ITIH1	-0.34	-9.11	-0.34	1.05e-18	Schizophrenia;
BRCA	cis	rs72772090	0.522	rs112272517	chr5:95987246	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-8.15	-0.31	1.91e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11764359	chr7:65958608	NA	-0.8	-19.58	-0.61	3.16e-67	Aortic root size;
BRCA	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21659725	chr3:3221576	CRBN	-0.33	-7.83	-0.3	2e-14	Body mass index;
BRCA	cis	rs911119	0.913	rs34792920	chr20:23581876	C/T	cg16589663	chr20:23618590	CST3	0.45	8.2	0.31	1.35e-15	Chronic kidney disease;
BRCA	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg11584989	chr19:19387371	SF4	-0.59	-13.38	-0.47	3.66e-36	Bipolar disorder;
BRCA	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11890956	chr21:40555474	PSMG1	1.04	28.31	0.75	6.97e-115	Cognitive function;
BRCA	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.22	0.34	4.35e-19	Tonsillectomy;
BRCA	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.51	0.44	2.88e-32	Electroencephalogram traits;
BRCA	cis	rs6942756	0.513	rs10954224	chr7:128893513	T/A	cg02491457	chr7:128862824	NA	0.45	9.53	0.35	3.21e-20	White matter hyperintensity burden;
BRCA	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg25036284	chr2:26402008	FAM59B	-0.79	-12.41	-0.44	7.62e-32	Gut microbiome composition (summer);
BRCA	cis	rs2742234	0.590	rs2503848	chr10:43672785	G/A	cg02780029	chr10:43622663	RET	-0.35	-7.96	-0.3	7.99e-15	Hirschsprung disease;
BRCA	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-8.34	-0.31	4.51e-16	Response to antipsychotic treatment;
BRCA	cis	rs72772090	0.710	rs10515244	chr5:96078337	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.76	-0.45	2.16e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg22105103	chr4:187893119	NA	0.41	13.33	0.47	5.9e-36	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.36	-0.41	2.25e-27	Gut microbiome composition (summer);
BRCA	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.04	-17.32	-0.57	2.31e-55	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-7.88	-0.3	1.39e-14	Colorectal cancer;
BRCA	cis	rs67981189	0.593	rs2877708	chr14:71484126	C/G	cg15816911	chr14:71606274	NA	0.37	8.45	0.32	1.98e-16	Schizophrenia;
BRCA	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg10932868	chr11:921992	NA	0.48	12.19	0.43	7.02e-31	Alzheimer's disease (late onset);
BRCA	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg19336497	chr11:14380999	RRAS2	-0.48	-11.99	-0.43	4.92e-30	Sense of smell;
BRCA	cis	rs870825	0.616	rs7682557	chr4:185640773	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	17.18	0.56	1.08e-54	Blood protein levels;
BRCA	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg21132104	chr15:45694354	SPATA5L1	0.72	15.59	0.53	1.08e-46	Homoarginine levels;
BRCA	trans	rs10242455	0.557	rs45529541	chr7:99048143	C/A	cg09045935	chr12:6379348	NA	0.87	9.16	0.34	7.05e-19	Blood metabolite levels;
BRCA	cis	rs877282	0.891	rs11253355	chr10:768367	C/G	cg17470449	chr10:769945	NA	0.49	8.52	0.32	1.15e-16	Uric acid levels;
BRCA	trans	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg25214090	chr10:38739885	LOC399744	-0.43	-10.27	-0.38	5.49e-23	Corneal astigmatism;
BRCA	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11890956	chr21:40555474	PSMG1	1.04	29.48	0.76	3.03e-121	Cognitive function;
BRCA	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg03474202	chr17:45855739	NA	-0.45	-11.99	-0.43	4.97e-30	IgG glycosylation;
BRCA	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg03188948	chr7:1209495	NA	0.5	9.4	0.35	9.55e-20	Longevity;Endometriosis;
BRCA	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg26384229	chr12:38710491	ALG10B	0.67	16.24	0.54	6.76e-50	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17092148	0.652	rs61341205	chr20:33072578	A/G	cg16810054	chr20:33298113	TP53INP2	0.43	9.46	0.35	5.64e-20	Neuroticism;
BRCA	cis	rs838147	0.760	rs412712	chr19:49234299	A/T	cg12258179	chr19:49232187	RASIP1	0.33	8.24	0.31	9.61e-16	Dietary macronutrient intake;
BRCA	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg24642844	chr7:1081250	C7orf50	-0.56	-11.4	-0.41	1.51e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg22972055	chr7:872293	UNC84A	0.39	8.76	0.33	1.68e-17	Cerebrospinal P-tau181p levels;
BRCA	trans	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg17470723	chr8:74884337	TCEB1	0.39	8.13	0.31	2.25e-15	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs61931739	0.513	rs1608908	chr12:33895389	C/A	cg26384229	chr12:38710491	ALG10B	0.47	10.83	0.39	3.42e-25	Morning vs. evening chronotype;
BRCA	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21659725	chr3:3221576	CRBN	-0.34	-7.96	-0.3	7.94e-15	Body mass index;
BRCA	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg00105475	chr2:10696890	NA	0.44	10.4	0.38	1.66e-23	Prostate cancer;
BRCA	cis	rs698813	0.763	rs698764	chr2:44573658	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.61	11.75	0.42	5.39e-29	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06108461	chr20:60628389	TAF4	-0.71	-14.63	-0.5	5.25e-42	Body mass index;
BRCA	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg01256987	chr12:42539512	GXYLT1	-0.56	-11.37	-0.41	2.11e-27	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	19.45	0.61	1.49e-66	Platelet count;
BRCA	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg14349672	chr11:133703707	NA	-0.43	-9.54	-0.35	2.93e-20	Childhood ear infection;
BRCA	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.81	0.39	3.9e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg27129171	chr3:47204927	SETD2	0.71	17.36	0.57	1.36e-55	Colorectal cancer;
BRCA	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg07636037	chr3:49044803	WDR6	0.71	14.21	0.49	5.02e-40	Menarche (age at onset);
BRCA	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg22800045	chr5:56110881	MAP3K1	0.65	12.32	0.44	1.9e-31	Initial pursuit acceleration;
BRCA	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg12310025	chr6:25882481	NA	0.4	9.31	0.35	2.01e-19	Blood metabolite levels;
BRCA	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg00271210	chr6:167070053	RPS6KA2	0.33	8.8	0.33	1.22e-17	Crohn's disease;
BRCA	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.9	-0.4	1.67e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.73	-0.33	2.15e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.01	0.4	6.48e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg20476274	chr7:133979776	SLC35B4	0.65	19.36	0.61	4.76e-66	Mean platelet volume;
BRCA	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg25801113	chr15:45476975	SHF	0.31	8.05	0.3	4.02e-15	Uric acid levels;
BRCA	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04267008	chr7:1944627	MAD1L1	-0.52	-12.05	-0.43	2.81e-30	Bipolar disorder and schizophrenia;
BRCA	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs1997103	0.954	rs4947505	chr7:55409448	T/C	cg17469321	chr7:55412551	NA	0.51	9.62	0.36	1.53e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.51	0.35	3.79e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs868036	1.000	rs4633663	chr15:68106378	G/C	cg05925327	chr15:68127851	NA	-0.31	-7.9	-0.3	1.23e-14	Restless legs syndrome;
BRCA	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg05340658	chr4:99064831	C4orf37	0.68	17.09	0.56	3.15e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19346786	chr7:2764209	NA	-0.37	-11.1	-0.4	2.57e-26	Height;
BRCA	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg24110177	chr3:50126178	RBM5	0.37	10.05	0.37	3.59e-22	Menarche (age at onset);
BRCA	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg14675211	chr2:100938903	LONRF2	0.52	11.82	0.42	2.63e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs11051970	0.879	rs2243815	chr12:32576158	C/T	cg24626660	chr12:32551988	NA	0.29	8.16	0.31	1.75e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg12573674	chr2:1569213	NA	-0.47	-9.14	-0.34	8.54e-19	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg00101154	chr16:420108	MRPL28	-0.39	-8.44	-0.32	2.18e-16	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	8.0	0.3	6.06e-15	Tonsillectomy;
BRCA	cis	rs4930561	0.765	rs4930564	chr11:67983281	C/T	cg16338278	chr11:67432957	ALDH3B2	-0.43	-8.94	-0.33	4.08e-18	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs4074536	0.574	rs10801972	chr1:116291575	T/C	cg21648376	chr1:116311395	CASQ2	-0.49	-8.66	-0.32	3.83e-17	QRS duration;
BRCA	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.08	0.3	3.2e-15	Uric acid levels;
BRCA	cis	rs17253792	0.822	rs78820104	chr14:56068854	C/T	cg01858014	chr14:56050164	KTN1	-0.76	-10.5	-0.38	6.49e-24	Putamen volume;
BRCA	cis	rs367943	1.000	rs348955	chr5:112821643	C/T	cg12552261	chr5:112820674	MCC	-0.55	-12.09	-0.43	1.9e-30	Type 2 diabetes;
BRCA	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg02196730	chr15:80188777	MTHFS	0.37	8.5	0.32	1.35e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
BRCA	cis	rs9549260	0.753	rs4943794	chr13:41173408	G/C	cg21288729	chr13:41239152	FOXO1	0.55	8.8	0.33	1.3e-17	Red blood cell count;
BRCA	cis	rs7589342	0.862	rs10469862	chr2:106509907	C/T	cg14210321	chr2:106509881	NCK2	-0.37	-8.0	-0.3	6.02e-15	Addiction;
BRCA	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg24324837	chr19:49891574	CCDC155	0.57	10.46	0.38	9.79e-24	Multiple sclerosis;
BRCA	cis	rs16958440	0.867	rs61689863	chr18:44669157	A/T	cg17192377	chr18:44677553	HDHD2	0.99	13.87	0.48	1.94e-38	Sitting height ratio;
BRCA	cis	rs1975974	0.935	rs41361749	chr17:21732693	A/G	cg18423549	chr17:21743878	NA	0.52	11.29	0.41	4.41e-27	Psoriasis;
BRCA	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg06784218	chr1:46089804	CCDC17	0.51	12.22	0.44	5.44e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg16586182	chr3:47516702	SCAP	0.65	15.01	0.51	7.76e-44	Colorectal cancer;
BRCA	cis	rs4653767	1.000	rs4653767	chr1:226916078	T/C	cg05049329	chr1:226924846	ITPKB	0.33	9.25	0.34	3.28e-19	Parkinson's disease;
BRCA	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg03146154	chr1:46216737	IPP	-0.44	-9.9	-0.36	1.39e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg08000102	chr2:233561755	GIGYF2	-0.64	-14.95	-0.51	1.43e-43	Coronary artery disease;
BRCA	cis	rs12760731	0.565	rs12732507	chr1:178098296	A/G	cg00404053	chr1:178313656	RASAL2	0.67	8.04	0.3	4.51e-15	Obesity-related traits;
BRCA	cis	rs9420	0.961	rs7117205	chr11:57641883	A/G	cg19752551	chr11:57585705	CTNND1	-0.5	-12.33	-0.44	1.82e-31	Schizophrenia;
BRCA	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg16586182	chr3:47516702	SCAP	0.65	15.16	0.51	1.46e-44	Colorectal cancer;
BRCA	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.36	-0.41	2.36e-27	Colorectal cancer;
BRCA	cis	rs6594713	0.605	rs11241213	chr5:112851088	T/A	cg12552261	chr5:112820674	MCC	0.5	8.01	0.3	5.62e-15	Brain cytoarchitecture;
BRCA	cis	rs6738485	0.763	rs11681976	chr2:106841591	C/A	cg16099169	chr2:106886729	NA	-0.49	-10.56	-0.39	3.82e-24	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
BRCA	trans	rs12517041	1.000	rs7722738	chr5:23288074	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg18357645	chr12:58087776	OS9	-0.32	-8.02	-0.3	5.21e-15	Multiple sclerosis;
BRCA	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg16586182	chr3:47516702	SCAP	-0.53	-12.12	-0.43	1.37e-30	Colorectal cancer;
BRCA	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg20607798	chr8:58055168	NA	0.47	8.02	0.3	4.97e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.23e-24	Motion sickness;
BRCA	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	8.79	0.33	1.33e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg27446573	chr6:127587934	RNF146	0.7	15.28	0.52	3.52e-45	Breast cancer;
BRCA	trans	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg25214090	chr10:38739885	LOC399744	0.44	10.27	0.38	5.09e-23	Corneal astigmatism;
BRCA	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg08917208	chr2:24149416	ATAD2B	0.87	12.43	0.44	6.24e-32	Lymphocyte counts;
BRCA	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-11.12	-0.4	2.26e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs72928364	1.000	rs35517882	chr3:100697174	T/C	cg10123952	chr3:100791384	NA	0.53	7.85	0.3	1.71e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6484504	0.652	rs674035	chr11:31399014	G/A	cg14844989	chr11:31128820	NA	0.45	9.61	0.36	1.6e-20	Red blood cell count;
BRCA	trans	rs61931739	0.635	rs4442626	chr12:33912530	C/T	cg26384229	chr12:38710491	ALG10B	0.4	8.93	0.33	4.5e-18	Morning vs. evening chronotype;
BRCA	cis	rs2046867	0.862	rs7648954	chr3:72838756	C/A	cg25664220	chr3:72788482	NA	-0.45	-9.8	-0.36	3.3e-21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	trans	rs35110281	0.667	rs914197	chr21:45117439	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	8.83	0.33	9.62e-18	Mean corpuscular volume;
BRCA	cis	rs12618769	0.597	rs17505088	chr2:99149473	C/T	cg10123293	chr2:99228465	UNC50	0.42	8.15	0.31	1.95e-15	Bipolar disorder;
BRCA	trans	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg25214090	chr10:38739885	LOC399744	0.52	11.67	0.42	1.14e-28	Corneal astigmatism;
BRCA	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg08999081	chr20:33150536	PIGU	-0.34	-8.69	-0.33	2.93e-17	Glomerular filtration rate (creatinine);
BRCA	trans	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-10.97	-0.4	8.96e-26	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.58	-0.32	7.06e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.49	0.5	2.37e-41	Motion sickness;
BRCA	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg25173405	chr17:45401733	C17orf57	-0.5	-10.58	-0.39	3.31e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9287719	0.649	rs10166765	chr2:10725673	T/C	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	5.17e-19	Prostate cancer;
BRCA	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.78	-0.33	1.46e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	8.41	0.32	2.63e-16	Educational attainment;
BRCA	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg18357645	chr12:58087776	OS9	0.43	11.94	0.43	8.5e-30	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg07169764	chr2:136633963	MCM6	1.0	20.32	0.63	3.65e-71	Mosquito bite size;
BRCA	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg24110177	chr3:50126178	RBM5	-0.44	-9.74	-0.36	5.46e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs11030122	0.702	rs10835402	chr11:3990914	T/C	cg18678763	chr11:4115507	RRM1	-0.36	-8.15	-0.31	1.97e-15	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg03146154	chr1:46216737	IPP	0.45	9.99	0.37	6.45e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg12935359	chr14:103987150	CKB	-0.54	-13.2	-0.46	2.42e-35	Body mass index;
BRCA	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg06064525	chr11:970664	AP2A2	0.32	9.61	0.36	1.67e-20	Alzheimer's disease (late onset);
BRCA	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg01420254	chr6:26195488	NA	0.58	9.03	0.34	2.08e-18	Gout;Renal underexcretion gout;
BRCA	cis	rs654950	1.000	rs654950	chr1:41987868	G/C	cg06885757	chr1:42089581	HIVEP3	-0.29	-9.44	-0.35	6.61e-20	Airway imaging phenotypes;
BRCA	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg12311346	chr5:56204834	C5orf35	0.57	11.65	0.42	1.42e-28	Type 2 diabetes;
BRCA	cis	rs2742234	0.541	rs4648313	chr10:43716739	G/A	cg02780029	chr10:43622663	RET	0.35	7.86	0.3	1.69e-14	Hirschsprung disease;
BRCA	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11644478	chr21:40555479	PSMG1	-0.65	-13.74	-0.48	8.12e-38	Cognitive function;
BRCA	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg26384229	chr12:38710491	ALG10B	0.5	12.27	0.44	3.3e-31	Morning vs. evening chronotype;
BRCA	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg08807892	chr2:162101083	NA	0.46	9.11	0.34	1.08e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg16405210	chr4:1374714	KIAA1530	-0.92	-21.01	-0.64	6.92e-75	Longevity;
BRCA	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg26384229	chr12:38710491	ALG10B	0.75	16.58	0.55	1.31e-51	Morning vs. evening chronotype;
BRCA	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg26031613	chr14:104095156	KLC1	-0.47	-9.32	-0.35	1.92e-19	Schizophrenia;
BRCA	cis	rs11955398	0.521	rs6449489	chr5:60026236	A/G	cg02684056	chr5:59996105	DEPDC1B	-0.4	-9.32	-0.35	1.79e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs3784262	0.565	rs4646605	chr15:58287912	C/A	cg12031962	chr15:58353849	ALDH1A2	0.32	8.31	0.31	5.65e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg01877450	chr7:97915802	BRI3	-0.38	-8.45	-0.32	2.01e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg09307838	chr4:120376055	NA	-0.43	-8.96	-0.33	3.41e-18	Diastolic blood pressure;
BRCA	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16680214	chr1:154839983	KCNN3	-0.41	-11.24	-0.41	7.02e-27	Prostate cancer;
BRCA	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg16586182	chr3:47516702	SCAP	0.65	15.07	0.51	3.99e-44	Colorectal cancer;
BRCA	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	11.53	0.42	4.4e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	11.58	0.42	2.74e-28	Tonsillectomy;
BRCA	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg10876282	chr6:28092338	ZSCAN16	0.42	8.15	0.31	1.87e-15	Parkinson's disease;
BRCA	cis	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg06521331	chr12:34319734	NA	-0.56	-10.14	-0.37	1.7e-22	Morning vs. evening chronotype;
BRCA	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg15605315	chr1:45957053	TESK2	0.45	9.17	0.34	6.53e-19	High light scatter reticulocyte count;
BRCA	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.4	10.06	0.37	3.3e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg02175503	chr12:58329896	NA	0.54	11.48	0.41	7.01e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs1163251	0.902	rs514491	chr1:120216743	C/T	cg19096424	chr1:120255104	PHGDH	0.44	9.73	0.36	5.98e-21	Blood metabolite levels;
BRCA	cis	rs2455601	0.786	rs3751064	chr11:8958903	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-8.62	-0.32	5.21e-17	Schizophrenia;
BRCA	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg00106254	chr7:1943704	MAD1L1	-0.42	-10.3	-0.38	4.03e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg01819863	chr10:32635814	EPC1	1.21	21.32	0.64	1.36e-76	Sexual dysfunction (female);
BRCA	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg14675211	chr2:100938903	LONRF2	0.46	10.58	0.39	3.16e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs7092929	0.941	rs615019	chr10:3563318	T/C	cg14308648	chr10:3568949	NA	0.41	7.88	0.3	1.4e-14	Coronary artery calcification;
BRCA	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	21.71	0.65	9.89e-79	Platelet count;
BRCA	cis	rs10129255	0.500	rs34326748	chr14:107190760	G/C	cg07958169	chr14:107095056	NA	-0.4	-8.6	-0.32	6.3e-17	Kawasaki disease;
BRCA	trans	rs12505749	1.000	rs12505749	chr4:57334112	C/G	cg09583921	chr3:87101925	NA	0.8	9.78	0.36	3.79e-21	Airflow obstruction;
BRCA	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-11.86	-0.42	1.89e-29	Bipolar disorder and schizophrenia;
BRCA	trans	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg23762105	chr12:34175262	ALG10	0.4	9.73	0.36	5.95e-21	Morning vs. evening chronotype;
BRCA	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18404041	chr3:52824283	ITIH1	-0.42	-12.35	-0.44	1.42e-31	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.2e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7945718	0.967	rs2241857	chr11:12815831	C/T	cg25843174	chr11:12811716	TEAD1	-0.22	-8.26	-0.31	8.49e-16	Educational attainment (years of education);
BRCA	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg19862616	chr7:65841803	NCRNA00174	0.81	25.64	0.71	3.13e-100	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs11966931	0.948	rs17528484	chr6:108095573	A/G	cg10566610	chr6:108093680	SCML4	0.28	8.03	0.3	4.55e-15	Neutrophil percentage of white cells;
BRCA	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg09065629	chr16:1709722	CRAMP1L	0.36	8.6	0.32	6.18e-17	Coronary artery disease;
BRCA	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg22535103	chr8:58192502	C8orf71	-0.54	-9.19	-0.34	5.5e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08109568	chr15:31115862	NA	0.45	10.47	0.38	9.04e-24	Huntington's disease progression;
BRCA	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg22834771	chr12:69754056	YEATS4	-0.4	-9.99	-0.37	6.34e-22	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.51	-9.38	-0.35	1.14e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg05527609	chr1:210001259	C1orf107	-0.59	-12.76	-0.45	2.31e-33	Orofacial clefts;
BRCA	cis	rs17125944	0.686	rs7160582	chr14:53341445	G/T	cg00686598	chr14:53173677	PSMC6	0.68	8.07	0.3	3.53e-15	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg04944784	chr2:26401820	FAM59B	1.0	16.79	0.55	1.16e-52	Gut microbiome composition (summer);
BRCA	cis	rs6450176	0.625	rs35027270	chr5:53289068	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-15.11	-0.51	2.57e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs3772130	0.923	rs13090798	chr3:121482768	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.75	0.39	7.12e-25	Cognitive performance;
BRCA	cis	rs17095355	1.000	rs12246851	chr10:111726340	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.8	-0.36	3.23e-21	Biliary atresia;
BRCA	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg17830980	chr10:43048298	ZNF37B	-0.54	-13.04	-0.46	1.2e-34	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg05347473	chr6:146136440	FBXO30	0.39	7.94	0.3	9.39e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.33	-0.38	3.05e-23	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg27588902	chr6:42928151	GNMT	-0.3	-9.86	-0.36	1.88e-21	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg27170947	chr2:26402098	FAM59B	0.92	16.52	0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs12367572	0.540	rs7954773	chr12:45455769	C/T	cg04608330	chr12:45269318	NELL2	0.38	7.9	0.3	1.24e-14	Gut microbiome composition (summer);
BRCA	cis	rs12711979	0.740	rs6711963	chr2:3820915	A/T	cg17052675	chr2:3827356	NA	-0.48	-14.31	-0.49	1.8e-40	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26314531	chr2:26401878	FAM59B	-0.93	-16.24	-0.54	6.53e-50	Gut microbiome composition (summer);
BRCA	cis	rs1506636	0.886	rs6945841	chr7:123266094	G/A	cg03229431	chr7:123269106	ASB15	-0.68	-15.75	-0.53	1.75e-47	Plateletcrit;Platelet count;
BRCA	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.45	10.05	0.37	3.66e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	11.37	0.41	2.13e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs72792276	1.000	rs72794370	chr5:127444907	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	10.71	0.39	9.84e-25	Red cell distribution width;
BRCA	cis	rs36051895	0.664	rs10116560	chr9:5096433	A/G	cg02405213	chr9:5042618	JAK2	-0.51	-9.2	-0.34	5.1e-19	Pediatric autoimmune diseases;
BRCA	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg00757033	chr12:89920650	WDR51B	0.5	9.63	0.36	1.37e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7851660	0.967	rs907577	chr9:100615117	C/T	cg13688889	chr9:100608707	NA	-0.36	-8.72	-0.33	2.42e-17	Strep throat;
BRCA	trans	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	14.39	0.49	6.92e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	11.99	0.43	5.35e-30	Personality dimensions;
BRCA	cis	rs10465746	0.725	rs6694752	chr1:84389960	C/T	cg10977910	chr1:84465055	TTLL7	0.62	13.0	0.46	1.92e-34	Obesity-related traits;
BRCA	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg16482183	chr6:26056742	HIST1H1C	0.71	14.49	0.5	2.4e-41	Iron status biomarkers;
BRCA	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08704250	chr15:31115839	NA	0.45	12.43	0.44	6.15e-32	Huntington's disease progression;
BRCA	cis	rs870825	0.616	rs6844146	chr4:185636396	G/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.32	0.57	2.07e-55	Blood protein levels;
BRCA	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg26384229	chr12:38710491	ALG10B	0.8	19.69	0.61	7.86e-68	Heart rate;
BRCA	trans	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	14.36	0.49	9.95e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg21280719	chr6:42927975	GNMT	-0.32	-13.22	-0.46	2e-35	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg21770322	chr7:97807741	LMTK2	-0.56	-16.08	-0.54	4.26e-49	Breast cancer;
BRCA	trans	rs1997103	1.000	rs2177805	chr7:55404381	T/A	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9649213	0.614	rs9640655	chr7:98017099	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.58	-15.87	-0.53	4.83e-48	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.07	16.15	0.54	1.85e-49	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs11585357	0.689	rs2977293	chr1:17599444	C/T	cg08277548	chr1:17600880	PADI3	-0.52	-9.53	-0.35	3.11e-20	Hair shape;
BRCA	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg03433033	chr1:76189801	ACADM	-0.41	-8.36	-0.31	3.8e-16	Daytime sleep phenotypes;
BRCA	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg26597838	chr10:835615	NA	1.02	17.92	0.58	1.75e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.08	0.49	1.97e-39	Motion sickness;
BRCA	cis	rs921968	0.541	rs933994	chr2:219650616	C/T	cg02176678	chr2:219576539	TTLL4	-0.4	-10.58	-0.39	3.17e-24	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg20290983	chr6:43655470	MRPS18A	-0.83	-22.55	-0.67	2.73e-83	IgG glycosylation;
BRCA	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg07988820	chr12:82153109	PPFIA2	-0.62	-10.1	-0.37	2.44e-22	Resting heart rate;
BRCA	cis	rs9503598	0.714	rs7758776	chr6:3452245	C/T	cg00476032	chr6:3446245	SLC22A23	0.44	11.14	0.4	1.83e-26	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	15.35	0.52	1.63e-45	Chronic sinus infection;
BRCA	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg20933634	chr6:27740509	NA	0.47	8.87	0.33	7.41e-18	Parkinson's disease;
BRCA	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	11.3	0.41	4e-27	Monocyte percentage of white cells;
BRCA	cis	rs13315871	0.929	rs7635697	chr3:58313706	G/A	cg20936604	chr3:58311152	NA	-0.64	-8.2	-0.31	1.36e-15	Cholesterol, total;
BRCA	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-8.96	-0.33	3.55e-18	Pulmonary function;
BRCA	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg08807101	chr21:30365312	RNF160	0.74	19.34	0.61	5.64e-66	Dental caries;
BRCA	trans	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.38	7.96	0.3	7.64e-15	Menarche (age at onset);
BRCA	cis	rs13053817	1.000	rs13057815	chr22:29853526	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.47	-8.95	-0.33	3.83e-18	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs2191566	0.576	rs396148	chr19:44494548	A/T	cg20607764	chr19:44506953	ZNF230	0.37	7.99	0.3	6.17e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11890956	chr21:40555474	PSMG1	1.04	28.18	0.74	3.6e-114	Cognitive function;
BRCA	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	17.54	0.57	1.57e-56	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs7939886	0.920	rs12223067	chr11:55915420	C/A	cg15704280	chr7:45808275	SEPT13	0.63	7.84	0.3	1.88e-14	Myopia (pathological);
BRCA	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg26384229	chr12:38710491	ALG10B	0.69	16.21	0.54	9.67e-50	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4363385	0.747	rs4845504	chr1:152960043	G/A	cg24667326	chr1:152973720	SPRR3	-0.33	-9.39	-0.35	1.06e-19	Inflammatory skin disease;
BRCA	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg14675211	chr2:100938903	LONRF2	0.42	9.34	0.35	1.63e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs495337	0.760	rs492702	chr20:48522585	G/A	cg17835207	chr20:48524531	SPATA2	-0.67	-15.97	-0.53	1.4e-48	Psoriasis;
BRCA	cis	rs7737355	1.000	rs2549018	chr5:130698949	C/T	cg06307176	chr5:131281290	NA	-0.44	-8.64	-0.32	4.51e-17	Life satisfaction;
BRCA	trans	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg06521331	chr12:34319734	NA	-0.43	-8.1	-0.31	2.79e-15	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg20007245	chr22:24372913	LOC391322	0.8	19.87	0.62	8.56e-69	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg17971929	chr21:40555470	PSMG1	0.8	18.64	0.59	2.88e-62	Cognitive function;
BRCA	cis	rs10754283	0.967	rs1934045	chr1:90107799	A/C	cg21401794	chr1:90099060	LRRC8C	-0.45	-10.82	-0.39	3.66e-25	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg19508488	chr2:152266495	RIF1	-0.49	-9.73	-0.36	5.98e-21	Lung cancer;
BRCA	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.35	-12.14	-0.43	1.2e-30	Bipolar disorder;
BRCA	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg22467129	chr15:76604101	ETFA	-0.49	-10.79	-0.39	4.79e-25	Blood metabolite levels;
BRCA	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg17845761	chr1:175162550	KIAA0040	-0.25	-9.33	-0.35	1.74e-19	Diastolic blood pressure;
BRCA	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg00106254	chr7:1943704	MAD1L1	-0.39	-9.62	-0.36	1.44e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg22467129	chr15:76604101	ETFA	-0.49	-10.82	-0.39	3.71e-25	Blood metabolite levels;
BRCA	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg03351412	chr1:154909251	PMVK	-0.57	-12.64	-0.45	7.3e-33	Prostate cancer;
BRCA	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.61	-15.79	-0.53	1.14e-47	Longevity;Endometriosis;
BRCA	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg22875332	chr1:76189707	ACADM	-0.51	-9.8	-0.36	3.14e-21	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.96	0.51	1.35e-43	Colorectal cancer;
BRCA	cis	rs1568889	0.838	rs10767708	chr11:28294847	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	19.53	0.61	5.57e-67	Bipolar disorder;
BRCA	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg25817165	chr18:72167213	CNDP2	-0.78	-14.18	-0.49	7.13e-40	Refractive error;
BRCA	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg08601574	chr20:25228251	PYGB	-0.39	-9.05	-0.34	1.77e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.34	-11.73	-0.42	6.71e-29	Electroencephalogram traits;
BRCA	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-13.28	-0.47	9.99e-36	Blood metabolite levels;
BRCA	cis	rs3818285	0.959	rs3740137	chr10:111630917	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.35	-8.75	-0.33	1.94e-17	Superior crus of antihelix expression;
BRCA	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18402987	chr7:1209562	NA	0.62	13.12	0.46	5.3e-35	Longevity;Endometriosis;
BRCA	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.29	-0.44	2.57e-31	Alzheimer's disease;
BRCA	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.71	-0.53	2.9e-47	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg12698349	chr2:225449008	CUL3	0.6	13.17	0.46	3.24e-35	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg05283184	chr6:79620031	NA	-0.43	-11.03	-0.4	4.97e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg26587870	chr6:27730563	NA	-0.57	-8.6	-0.32	6.17e-17	Depression;
BRCA	trans	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg25214090	chr10:38739885	LOC399744	0.35	7.92	0.3	1.04e-14	Diastolic blood pressure;
BRCA	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg26677194	chr12:130822605	PIWIL1	0.6	14.33	0.49	1.31e-40	Menopause (age at onset);
BRCA	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	13.57	0.47	4.68e-37	Response to antipsychotic treatment;
BRCA	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg10560079	chr2:191398806	TMEM194B	0.4	8.85	0.33	8.67e-18	Pulse pressure;
BRCA	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg03213289	chr20:61660250	NA	0.62	16.24	0.54	6.75e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg19678392	chr7:94953810	PON1	-0.43	-9.14	-0.34	8e-19	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.94	0.3	8.88e-15	Parkinson's disease;
BRCA	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg14926445	chr8:58193284	C8orf71	-0.47	-8.93	-0.33	4.61e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs11608355	0.545	rs6606724	chr12:109905179	T/C	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	trans	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	27.27	0.73	3.26e-109	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg09307838	chr4:120376055	NA	0.69	14.02	0.49	3.82e-39	Corneal astigmatism;
BRCA	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18876405	chr7:65276391	NA	0.7	18.57	0.59	6.72e-62	Aortic root size;
BRCA	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg04842962	chr6:43655489	MRPS18A	-1.11	-39.21	-0.84	3.28e-172	IgG glycosylation;
BRCA	trans	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg09719594	chr16:21412588	NA	-0.36	-8.25	-0.31	9.28e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg18154014	chr19:37997991	ZNF793	0.48	9.45	0.35	6.08e-20	Coronary artery calcification;
BRCA	cis	rs6433895	0.736	rs13011751	chr2:181985765	A/T	cg00481216	chr2:181971175	NA	0.41	8.74	0.33	2.02e-17	Lymphocyte counts;
BRCA	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg03954927	chr1:10346856	KIF1B	0.48	14.58	0.5	9.03e-42	Hepatocellular carcinoma;
BRCA	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg19628046	chr18:33552617	C18orf21	-0.56	-11.59	-0.42	2.47e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg08470875	chr2:26401718	FAM59B	0.51	8.24	0.31	9.42e-16	Gut microbiome composition (summer);
BRCA	cis	rs1784581	1.000	rs1784582	chr6:162400712	A/G	cg17173639	chr6:162384350	PARK2	-0.43	-10.1	-0.37	2.33e-22	Itch intensity from mosquito bite;
BRCA	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.83	0.65	2.21e-79	Lymphocyte percentage of white cells;
BRCA	cis	rs365132	0.870	rs2454949	chr5:176466011	G/A	cg16309518	chr5:176445507	NA	-0.51	-12.95	-0.46	3.29e-34	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	trans	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	8.92e-15	Corneal astigmatism;
BRCA	cis	rs16958440	1.000	rs62096463	chr18:44628928	A/G	cg17192377	chr18:44677553	HDHD2	0.67	9.75	0.36	4.96e-21	Sitting height ratio;
BRCA	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg11168104	chr5:1857477	NA	-0.34	-8.98	-0.33	3.12e-18	Cardiovascular disease risk factors;
BRCA	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-15.46	-0.52	4.8e-46	Mood instability;
BRCA	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08280861	chr8:58055591	NA	0.54	8.68	0.32	3.35e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg09307838	chr4:120376055	NA	0.47	9.75	0.36	4.82e-21	Diastolic blood pressure;
BRCA	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs4074536	0.574	rs10801973	chr1:116291664	A/C	cg21648376	chr1:116311395	CASQ2	-0.49	-8.66	-0.32	3.83e-17	QRS duration;
BRCA	trans	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg25214090	chr10:38739885	LOC399744	-0.46	-9.72	-0.36	6.52e-21	Corneal astigmatism;
BRCA	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg03929089	chr4:120376271	NA	0.78	18.1	0.58	2.1e-59	Coronary artery disease;
BRCA	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.35	0.35	1.47e-19	Morning vs. evening chronotype;
BRCA	cis	rs7809950	0.953	rs1468336	chr7:107208250	T/C	cg23024343	chr7:107201750	COG5	0.39	8.59	0.32	6.81e-17	Coronary artery disease;
BRCA	cis	rs6878727	0.850	rs2408163	chr5:123707016	C/T	cg01806427	chr5:123737813	NA	0.41	9.46	0.35	5.6e-20	Breast cancer;
BRCA	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg27661571	chr11:113659931	NA	-0.83	-12.14	-0.43	1.15e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg26384229	chr12:38710491	ALG10B	0.73	17.15	0.56	1.68e-54	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.53	11.76	0.42	4.62e-29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg07741184	chr6:167504864	NA	0.36	10.48	0.38	7.88e-24	Rheumatoid arthritis;
BRCA	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg02196730	chr15:80188777	MTHFS	0.35	8.0	0.3	5.75e-15	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
BRCA	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg23711669	chr6:146136114	FBXO30	0.71	16.31	0.54	3.01e-50	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg24069376	chr3:38537580	EXOG	0.42	11.92	0.43	9.72e-30	Electrocardiographic conduction measures;
BRCA	cis	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg06521331	chr12:34319734	NA	-0.65	-11.98	-0.43	5.75e-30	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg22920501	chr2:26401640	FAM59B	0.92	16.83	0.55	6.68e-53	Gut microbiome composition (summer);
BRCA	cis	rs2015599	0.549	rs6487799	chr12:29444020	A/G	cg09582351	chr12:29534625	ERGIC2	-0.35	-8.23	-0.31	1.05e-15	Mean platelet volume;Platelet count;
BRCA	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg18357526	chr6:26021779	HIST1H4A	0.47	8.72	0.33	2.37e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.28	-0.34	2.6e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg20129853	chr10:51489980	NA	0.31	8.36	0.31	3.84e-16	Prostate-specific antigen levels;
BRCA	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18404041	chr3:52824283	ITIH1	-0.4	-12.18	-0.43	7.56e-31	Electroencephalogram traits;
BRCA	cis	rs7715806	0.500	rs72633984	chr5:75005899	A/G	cg19683494	chr5:74908142	NA	0.5	8.1	0.31	2.81e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg21518248	chr2:162101506	NA	0.51	10.92	0.4	1.48e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs701145	0.762	rs896014	chr3:153842691	A/G	cg12800244	chr3:153838788	SGEF	0.63	7.87	0.3	1.53e-14	Coronary artery disease;
BRCA	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-9.13	-0.34	8.66e-19	IgG glycosylation;
BRCA	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg15485101	chr11:133734466	NA	0.4	9.46	0.35	5.7e-20	Childhood ear infection;
BRCA	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg02951883	chr7:2050386	MAD1L1	-0.54	-12.3	-0.44	2.23e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs9837602	1.000	rs9873878	chr3:99711816	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	11.28	0.41	4.85e-27	Breast cancer;
BRCA	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg06618935	chr21:46677482	NA	-0.39	-8.63	-0.32	4.85e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg12311346	chr5:56204834	C5orf35	-0.63	-13.29	-0.47	9.39e-36	Initial pursuit acceleration;
BRCA	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19346786	chr7:2764209	NA	-0.32	-9.4	-0.35	9.36e-20	Height;
BRCA	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs11165623	0.792	rs9437607	chr1:96977788	G/A	cg10631902	chr5:14652156	NA	-0.49	-15.39	-0.52	1.06e-45	Hip circumference;Waist circumference;
BRCA	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	14.28	0.49	2.44e-40	Alzheimer's disease;
BRCA	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg14086364	chr5:150678334	SLC36A3	0.53	14.7	0.5	2.44e-42	Skin aging (microtopography measurement);
BRCA	cis	rs9287719	0.649	rs12621977	chr2:10721931	T/C	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	5.17e-19	Prostate cancer;
BRCA	cis	rs7301016	0.802	rs11613011	chr12:63023078	T/C	cg11441379	chr12:63026424	NA	0.49	8.94	0.33	4.06e-18	IgG glycosylation;
BRCA	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg12379764	chr21:47803548	PCNT	-0.37	-8.05	-0.3	4.13e-15	Testicular germ cell tumor;
BRCA	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg20307385	chr11:47447363	PSMC3	-0.39	-9.16	-0.34	7.09e-19	Subjective well-being;
BRCA	cis	rs758324	0.947	rs4705903	chr5:131206594	A/C	cg06307176	chr5:131281290	NA	0.57	12.0	0.43	4.56e-30	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg18252515	chr7:66147081	NA	-1.06	-15.7	-0.53	3.07e-47	Gout;
BRCA	cis	rs7095944	0.614	rs1055256	chr10:126446592	A/G	cg08799069	chr10:126477246	METTL10	-0.4	-10.05	-0.37	3.72e-22	Asthma;
BRCA	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg17063962	chr7:91808500	NA	0.57	13.29	0.47	9.33e-36	Breast cancer;
BRCA	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.83	16.51	0.55	3.07e-51	HIV-1 control;
BRCA	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg11366901	chr6:160182831	ACAT2	0.83	16.16	0.54	1.67e-49	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg04025307	chr7:1156635	C7orf50	-0.49	-9.85	-0.36	2.11e-21	Bronchopulmonary dysplasia;
BRCA	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg26384229	chr12:38710491	ALG10B	0.85	22.52	0.67	3.94e-83	Heart rate;
BRCA	cis	rs3772130	0.962	rs6791046	chr3:121394707	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	9.28	0.34	2.58e-19	Cognitive performance;
BRCA	cis	rs752010	0.714	rs7513753	chr1:42079232	A/G	cg06885757	chr1:42089581	HIVEP3	0.27	10.14	0.37	1.69e-22	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs897984	0.568	rs4889651	chr16:30895545	C/T	cg02466173	chr16:30829666	NA	-0.4	-8.2	-0.31	1.28e-15	Dementia with Lewy bodies;
BRCA	cis	rs67366981	1.000	rs56357623	chr14:77697393	C/A	cg22824376	chr14:77648248	TMEM63C	0.62	9.17	0.34	6.45e-19	Obsessive-compulsive symptoms;
BRCA	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg08601574	chr20:25228251	PYGB	-0.34	-8.37	-0.31	3.55e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08704250	chr15:31115839	NA	0.34	8.72	0.33	2.49e-17	Huntington's disease progression;
BRCA	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00149659	chr3:10157352	C3orf10	-0.68	-11.89	-0.43	1.34e-29	Alzheimer's disease;
BRCA	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg02551604	chr5:131831745	NA	0.35	9.97	0.37	7.43e-22	Asthma (sex interaction);
BRCA	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.7	0.55	3.14e-52	Hypertriglyceridemia;
BRCA	cis	rs6728642	1.000	rs75297860	chr2:97600078	G/A	cg26665480	chr2:98280029	ACTR1B	-0.68	-7.81	-0.3	2.3e-14	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg11266682	chr4:10021025	SLC2A9	0.47	12.59	0.45	1.2e-32	Bone mineral density;
BRCA	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg09307838	chr4:120376055	NA	0.58	10.92	0.4	1.48e-25	Corneal astigmatism;
BRCA	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	8.82	0.33	1.06e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg03585969	chr10:35415529	CREM	0.5	10.42	0.38	1.36e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs783540	0.967	rs1145172	chr15:83223616	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.26	-8.13	-0.31	2.27e-15	Schizophrenia;
BRCA	cis	rs9341808	0.739	rs4706831	chr6:81007699	T/C	cg08355045	chr6:80787529	NA	0.36	9.32	0.35	1.88e-19	Sitting height ratio;
BRCA	cis	rs6700896	0.866	rs6588158	chr1:66160621	T/C	cg04111102	chr1:66153794	NA	-0.34	-8.5	-0.32	1.3e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.06	-25.8	-0.71	4.21e-101	Ulcerative colitis;
BRCA	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-11.1	-0.4	2.55e-26	Bone mineral density;
BRCA	cis	rs652260	0.646	rs693941	chr19:7903851	C/T	cg26014689	chr19:7917955	EVI5L	-0.62	-14.79	-0.5	9.27e-43	Menarche (age at onset);
BRCA	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg20203395	chr5:56204925	C5orf35	-0.5	-10.39	-0.38	1.72e-23	Initial pursuit acceleration;
BRCA	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg07636037	chr3:49044803	WDR6	0.68	12.26	0.44	3.36e-31	Menarche (age at onset);
BRCA	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg20703242	chr1:230279135	GALNT2	0.48	10.32	0.38	3.32e-23	Coronary artery disease;
BRCA	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg25019033	chr10:957182	NA	-0.41	-7.9	-0.3	1.25e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg25358565	chr5:93447407	FAM172A	1.18	19.74	0.62	4.16e-68	Diabetic retinopathy;
BRCA	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg21770322	chr7:97807741	LMTK2	0.44	11.86	0.42	1.77e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg09307838	chr4:120376055	NA	0.63	12.63	0.45	8.32e-33	Corneal astigmatism;
BRCA	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg14530993	chr4:882597	GAK	-0.56	-9.84	-0.36	2.28e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg21573476	chr21:45109991	RRP1B	0.37	9.71	0.36	7.19e-21	Mean corpuscular volume;
BRCA	trans	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg04565464	chr8:145669602	NFKBIL2	0.41	8.76	0.33	1.74e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.78	0.33	1.48e-17	Motion sickness;
BRCA	cis	rs870825	0.549	rs10015956	chr4:185614705	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.1	0.56	2.98e-54	Blood protein levels;
BRCA	trans	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.16	0.31	1.73e-15	Corneal astigmatism;
BRCA	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg00852783	chr1:26633632	UBXN11	0.51	10.97	0.4	9.2e-26	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	16.41	0.54	9.04e-51	Platelet count;
BRCA	cis	rs9420	0.961	rs77993055	chr11:57522840	C/T	cg19752551	chr11:57585705	CTNND1	-0.51	-12.56	-0.45	1.68e-32	Schizophrenia;
BRCA	cis	rs644148	0.967	rs613876	chr19:44968788	T/C	cg15540054	chr19:45004280	ZNF180	-0.57	-12.07	-0.43	2.42e-30	Personality dimensions;
BRCA	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg11062466	chr8:58055876	NA	0.55	9.28	0.34	2.6e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg02012338	chr4:187126139	CYP4V2	0.88	10.36	0.38	2.38e-23	Blood protein levels;
BRCA	cis	rs4690686	0.538	rs4690428	chr4:177263665	C/T	cg17059388	chr4:177262070	NA	0.51	10.68	0.39	1.34e-24	Essential tremor;
BRCA	cis	rs17095355	0.642	rs57822924	chr10:111702078	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.38	-9.56	-0.35	2.58e-20	Biliary atresia;
BRCA	cis	rs6901250	0.851	rs2175622	chr6:117149667	T/A	cg12892004	chr6:117198278	RFX6	0.49	11.34	0.41	2.67e-27	C-reactive protein levels;
BRCA	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg06238570	chr21:40685208	BRWD1	-0.42	-8.65	-0.32	4.03e-17	Cognitive function;
BRCA	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg17971929	chr21:40555470	PSMG1	-0.78	-18.82	-0.6	3.35e-63	Cognitive function;
BRCA	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg23625390	chr15:77176239	SCAPER	0.39	9.65	0.36	1.18e-20	Blood metabolite levels;
BRCA	cis	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.38	-0.41	1.83e-27	Morning vs. evening chronotype;
BRCA	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg15556689	chr8:8085844	FLJ10661	-0.34	-8.45	-0.32	1.91e-16	Retinal vascular caliber;
BRCA	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.05e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	13.36	0.47	4.56e-36	Height;
BRCA	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg15782153	chr7:917662	C7orf20	0.39	9.36	0.35	1.3e-19	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg01877450	chr7:97915802	BRI3	-0.37	-8.42	-0.32	2.41e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9487051	0.698	rs4301336	chr6:109650140	A/T	cg21918786	chr6:109611834	NA	0.37	8.57	0.32	8.05e-17	Reticulocyte fraction of red cells;
BRCA	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.31	-7.84	-0.3	1.84e-14	Total body bone mineral density;
BRCA	cis	rs9807989	0.507	rs4851579	chr2:103028984	G/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.37	0.31	3.62e-16	Asthma;
BRCA	cis	rs7394190	0.748	rs11541237	chr10:75530962	C/T	cg07699608	chr10:75541558	CHCHD1	0.65	9.64	0.36	1.26e-20	Incident atrial fibrillation;
BRCA	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	18.99	0.6	4.37e-64	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.39	8.22	0.31	1.14e-15	Multiple sclerosis;
BRCA	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg22491629	chr6:157744540	C6orf35	0.62	11.18	0.4	1.26e-26	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs67460515	0.506	rs935497	chr3:160600563	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-13.13	-0.46	4.98e-35	Parkinson's disease;
BRCA	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg15485101	chr11:133734466	NA	0.41	9.71	0.36	6.75e-21	Childhood ear infection;
BRCA	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg16482183	chr6:26056742	HIST1H1C	0.45	8.74	0.33	2.11e-17	Iron status biomarkers;
BRCA	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-13.47	-0.47	1.4e-36	Morning vs. evening chronotype;
BRCA	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg09307838	chr4:120376055	NA	0.59	12.25	0.44	4.04e-31	Corneal astigmatism;
BRCA	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.52	-0.32	1.13e-16	Menopause (age at onset);
BRCA	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg10253484	chr15:75165896	SCAMP2	-0.53	-10.09	-0.37	2.7e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs6901250	0.587	rs339357	chr6:117198291	G/C	cg12892004	chr6:117198278	RFX6	-0.5	-11.51	-0.41	5.51e-28	C-reactive protein levels;
BRCA	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg17143192	chr8:8559678	CLDN23	0.56	11.03	0.4	5.36e-26	Obesity-related traits;
BRCA	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19748678	chr4:122722346	EXOSC9	0.71	15.24	0.52	5.59e-45	Type 2 diabetes;
BRCA	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg02503808	chr4:7069936	GRPEL1	0.72	14.0	0.48	4.85e-39	Monocyte percentage of white cells;
BRCA	cis	rs6484504	0.600	rs10835763	chr11:31345574	G/A	cg06552810	chr11:31128660	NA	0.4	8.66	0.32	3.75e-17	Red blood cell count;
BRCA	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-8.15	-0.31	1.9e-15	Alzheimer's disease (late onset);
BRCA	trans	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.1	0.31	2.88e-15	Corneal astigmatism;
BRCA	cis	rs6435161	1.000	rs72926990	chr2:203520420	G/A	cg18429434	chr2:203499731	FAM117B	-0.44	-8.76	-0.33	1.78e-17	Total cholesterol levels;
BRCA	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.55	-0.32	9.19e-17	Monocyte percentage of white cells;
BRCA	trans	rs7200543	0.961	rs1741	chr16:15130351	G/C	cg24683922	chr1:11983373	KIAA2013	-0.39	-8.73	-0.33	2.23e-17	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	trans	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-14.47	-0.5	3.14e-41	Obesity-related traits;
BRCA	cis	rs7646881	1.000	rs73015655	chr3:158451882	A/C	cg19483011	chr3:158453295	NA	-0.41	-8.05	-0.3	3.97e-15	Tetralogy of Fallot;
BRCA	cis	rs6901250	0.851	rs7740481	chr6:117149307	G/C	cg12892004	chr6:117198278	RFX6	0.48	11.29	0.41	4.59e-27	C-reactive protein levels;
BRCA	trans	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg04565464	chr8:145669602	NFKBIL2	0.41	9.22	0.34	4.42e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs490234	0.841	rs7044663	chr9:128268263	C/T	cg14078157	chr9:128172775	NA	-0.35	-8.11	-0.31	2.6e-15	Mean arterial pressure;
BRCA	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09263875	chr16:632152	PIGQ	0.66	18.53	0.59	1.17e-61	Height;
BRCA	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12667521	chr19:29218732	NA	0.47	8.77	0.33	1.63e-17	Methadone dose in opioid dependence;
BRCA	cis	rs16867321	0.614	rs12693245	chr2:181445110	T/C	cg23363182	chr2:181467187	NA	0.47	10.26	0.38	5.74e-23	Obesity;
BRCA	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg05868516	chr6:26286170	HIST1H4H	0.49	11.04	0.4	4.82e-26	Educational attainment;
BRCA	cis	rs26949	0.526	rs6887637	chr5:60035640	A/G	cg02684056	chr5:59996105	DEPDC1B	-0.35	-8.18	-0.31	1.48e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs877282	0.945	rs11253391	chr10:788752	G/A	cg22713356	chr15:30763199	NA	1.42	28.55	0.75	3.22e-116	Uric acid levels;
BRCA	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg25358565	chr5:93447407	FAM172A	1.17	18.19	0.58	6.98e-60	Diabetic retinopathy;
BRCA	cis	rs4833079	0.562	rs11944291	chr4:38631620	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.56	12.01	0.43	4.07e-30	Body mass index;
BRCA	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg21573476	chr21:45109991	RRP1B	-0.33	-8.56	-0.32	8.44e-17	Mean corpuscular volume;
BRCA	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg00376283	chr12:123451042	ABCB9	0.54	10.87	0.4	2.21e-25	Neutrophil percentage of white cells;
BRCA	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg05985134	chr18:33552581	C18orf21	0.63	11.13	0.4	2.07e-26	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs9420	0.961	rs576859	chr11:57480623	A/C	cg19752551	chr11:57585705	CTNND1	0.41	10.44	0.38	1.12e-23	Schizophrenia;
BRCA	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04267008	chr7:1944627	MAD1L1	0.59	12.45	0.44	5.41e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg24692254	chr21:30365293	RNF160	-0.46	-10.21	-0.37	9.05e-23	Dental caries;
BRCA	trans	rs1493916	0.837	rs8088362	chr18:31413016	A/G	cg15819921	chr19:927150	ARID3A	-0.41	-7.96	-0.3	7.78e-15	Life satisfaction;
BRCA	trans	rs8073060	0.586	rs226089	chr17:34016935	C/T	cg19694781	chr19:47549865	TMEM160	-1.06	-21.42	-0.65	4.16e-77	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs2070488	0.560	rs1381798	chr3:38437471	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.53	-11.03	-0.4	4.97e-26	Electrocardiographic conduction measures;
BRCA	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg01939980	chr4:1354348	KIAA1530	0.29	7.96	0.3	7.95e-15	Obesity-related traits;
BRCA	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18876405	chr7:65276391	NA	0.62	15.39	0.52	1.1e-45	Aortic root size;
BRCA	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg12927641	chr6:109611667	NA	-0.42	-10.81	-0.39	4.03e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg08601574	chr20:25228251	PYGB	0.41	9.5	0.35	4.11e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg17691542	chr6:26056736	HIST1H1C	0.43	9.27	0.34	2.89e-19	Iron status biomarkers;
BRCA	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg10664184	chr19:17420304	DDA1	-0.37	-10.36	-0.38	2.32e-23	Systemic lupus erythematosus;
BRCA	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.75	-13.29	-0.47	9.33e-36	Gut microbiome composition (summer);
BRCA	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg11941060	chr3:133502564	NA	-0.33	-7.82	-0.3	2.2e-14	Iron status biomarkers;
BRCA	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg19539972	chr4:7069911	GRPEL1	0.59	12.06	0.43	2.55e-30	Monocyte percentage of white cells;
BRCA	cis	rs6750047	0.625	rs336037	chr2:38261124	T/C	cg07380506	chr2:38303506	CYP1B1	-0.48	-10.44	-0.38	1.19e-23	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs9420	0.816	rs674094	chr11:57665336	A/C	cg19752551	chr11:57585705	CTNND1	0.45	10.33	0.38	3.22e-23	Schizophrenia;
BRCA	cis	rs793571	0.590	rs474875	chr15:59086703	A/C	cg05156742	chr15:59063176	FAM63B	0.55	11.5	0.41	5.72e-28	Schizophrenia;
BRCA	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg21644426	chr2:191273491	MFSD6	0.45	11.46	0.41	8.71e-28	Pulse pressure;
BRCA	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.2	0.37	9.55e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00166722	chr3:10149974	C3orf24	0.65	12.73	0.45	3.17e-33	Alzheimer's disease;
BRCA	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg09307838	chr4:120376055	NA	0.64	14.05	0.49	2.77e-39	Corneal astigmatism;
BRCA	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.68	0.57	3.2e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.39	2.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg09307838	chr4:120376055	NA	0.69	13.97	0.48	6.93e-39	Corneal astigmatism;
BRCA	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg06238570	chr21:40685208	BRWD1	-0.42	-8.65	-0.32	4.11e-17	Cognitive function;
BRCA	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg14440974	chr22:39074834	NA	-0.38	-9.13	-0.34	8.96e-19	Menopause (age at onset);
BRCA	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.42	8.09	0.3	2.94e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg12463550	chr7:65579703	CRCP	-0.38	-8.24	-0.31	1.01e-15	Aortic root size;
BRCA	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg11645453	chr3:52864694	ITIH4	0.34	8.38	0.31	3.35e-16	Body mass index;
BRCA	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg03709012	chr19:19516395	GATAD2A	0.98	18.19	0.58	6.69e-60	Nonalcoholic fatty liver disease;
BRCA	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.38	-10.12	-0.37	2.05e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg13397359	chr6:42928475	GNMT	-0.76	-18.95	-0.6	6.59e-64	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg04756594	chr16:24857601	SLC5A11	0.46	9.68	0.36	8.82e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs6121246	0.559	rs6119652	chr20:30259445	C/G	cg13852791	chr20:30311386	BCL2L1	0.95	23.01	0.67	8.32e-86	Mean corpuscular hemoglobin;
BRCA	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-10.86	-0.39	2.47e-25	Personality dimensions;
BRCA	cis	rs921968	0.613	rs1344642	chr2:219555262	G/A	cg02176678	chr2:219576539	TTLL4	-0.39	-10.48	-0.38	8.33e-24	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4409675	0.597	rs1467464	chr1:28211650	T/C	cg23691781	chr1:28212827	C1orf38	0.33	11.03	0.4	5.03e-26	Corneal astigmatism;
BRCA	cis	rs16867321	0.950	rs12477283	chr2:181501355	G/T	cg23363182	chr2:181467187	NA	-0.44	-8.33	-0.31	5.05e-16	Obesity;
BRCA	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg00383909	chr3:49044727	WDR6	0.98	15.72	0.53	2.59e-47	Cognitive function;
BRCA	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg13880726	chr7:1868755	MAD1L1	0.51	10.01	0.37	5.32e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg23711669	chr6:146136114	FBXO30	-0.67	-15.71	-0.53	2.78e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg20503657	chr10:835505	NA	1.05	18.42	0.59	4.49e-61	Eosinophil percentage of granulocytes;
BRCA	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18876405	chr7:65276391	NA	0.61	15.07	0.51	3.99e-44	Aortic root size;
BRCA	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg22535103	chr8:58192502	C8orf71	-0.46	-9.11	-0.34	1.01e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs965469	1.000	rs6037590	chr20:3374085	G/A	cg25506879	chr20:3388711	C20orf194	-0.55	-10.55	-0.39	4.41e-24	IFN-related cytopenia;
BRCA	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg18016565	chr1:150552671	MCL1	-0.35	-8.4	-0.32	2.79e-16	Tonsillectomy;
BRCA	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.2	-0.34	5.21e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg18402987	chr7:1209562	NA	0.46	8.8	0.33	1.26e-17	Longevity;Endometriosis;
BRCA	cis	rs897984	0.609	rs4889609	chr16:31026427	A/G	cg02466173	chr16:30829666	NA	-0.43	-9.75	-0.36	4.92e-21	Dementia with Lewy bodies;
BRCA	cis	rs690037	0.641	rs538525	chr3:16376279	A/G	cg23474789	chr3:16306055	DPH3;OXNAD1	0.4	8.38	0.31	3.47e-16	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
BRCA	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg15704280	chr7:45808275	SEPT13	0.65	11.44	0.41	1.06e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg23887609	chr12:130822674	PIWIL1	0.43	9.33	0.35	1.71e-19	Menopause (age at onset);
BRCA	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg13010199	chr12:38710504	ALG10B	0.43	9.1	0.34	1.14e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs68170813	0.559	rs78888729	chr7:106940957	G/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.59	-0.32	6.47e-17	Coronary artery disease;
BRCA	cis	rs751728	0.717	rs3763258	chr6:33773744	A/G	cg15252951	chr6:33757062	LEMD2	0.37	8.51	0.32	1.24e-16	Crohn's disease;
BRCA	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg03709012	chr19:19516395	GATAD2A	0.99	17.61	0.57	6.6e-57	Nonalcoholic fatty liver disease;
BRCA	trans	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg23762105	chr12:34175262	ALG10	0.34	7.96	0.3	7.76e-15	Morning vs. evening chronotype;
BRCA	cis	rs600806	0.815	rs10858088	chr1:109923586	C/T	cg20591472	chr1:110008990	SYPL2	0.33	8.22	0.31	1.14e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4308124	0.708	rs28766030	chr2:111962429	T/C	cg04571233	chr2:111982156	NA	-0.45	-9.67	-0.36	9.67e-21	Vitiligo;
BRCA	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.06	0.34	1.54e-18	Tonsillectomy;
BRCA	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.23e-24	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	15.31	0.52	2.78e-45	Intelligence (multi-trait analysis);
BRCA	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg00825309	chr19:58991885	ZNF446	0.63	14.2	0.49	5.47e-40	Uric acid clearance;
BRCA	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg20469991	chr17:27169893	C17orf63	-0.44	-8.48	-0.32	1.51e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg10820045	chr2:198174542	NA	-0.38	-7.87	-0.3	1.49e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg24829409	chr8:58192753	C8orf71	-0.45	-8.8	-0.33	1.32e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6973256	0.637	rs12539993	chr7:133418799	C/T	cg07491979	chr7:133331646	EXOC4	0.35	7.88	0.3	1.43e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg03885332	chr11:832357	CD151	-0.32	-8.91	-0.33	5.18e-18	Mean platelet volume;
BRCA	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg08807892	chr2:162101083	NA	0.47	8.84	0.33	9.17e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14442939	chr10:27389572	ANKRD26	0.62	10.37	0.38	2.16e-23	Breast cancer;
BRCA	cis	rs96067	0.805	rs4652902	chr1:36612955	C/A	cg24686825	chr1:36642396	MAP7D1	-0.49	-8.95	-0.33	3.7e-18	Corneal structure;
BRCA	trans	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.0	0.3	5.96e-15	Corneal astigmatism;
BRCA	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg16339924	chr4:17578868	LAP3	0.61	15.0	0.51	8.07e-44	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13082711	0.911	rs13078798	chr3:27445971	A/G	cg02860705	chr3:27208620	NA	-0.51	-10.23	-0.38	7.43e-23	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs6684514	1.000	rs2273832	chr1:156233143	A/G	cg16558208	chr1:156270281	VHLL	0.37	8.07	0.3	3.41e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg11833968	chr6:79620685	NA	-0.44	-9.81	-0.36	2.92e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg17724175	chr1:150552817	MCL1	0.26	8.49	0.32	1.41e-16	Melanoma;
BRCA	trans	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg16011800	chr17:1958478	HIC1	-0.51	-8.43	-0.32	2.28e-16	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs7301826	0.651	rs1554807	chr12:131280417	C/T	cg11011512	chr12:131303247	STX2	-0.52	-13.75	-0.48	7.06e-38	Plasma plasminogen activator levels;
BRCA	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg27535305	chr1:53392650	SCP2	0.32	7.93	0.3	9.7e-15	Monocyte count;
BRCA	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg27286337	chr10:134555280	INPP5A	-0.85	-20.85	-0.64	4.56e-74	Migraine;
BRCA	cis	rs9790314	0.690	rs6799130	chr3:160847801	C/G	cg03342759	chr3:160939853	NMD3	-0.53	-11.44	-0.41	1.09e-27	Morning vs. evening chronotype;
BRCA	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.42	-0.38	1.36e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1506636	1.000	rs689341	chr7:123403974	C/A	cg03229431	chr7:123269106	ASB15	0.61	13.57	0.47	4.64e-37	Plateletcrit;Platelet count;
BRCA	cis	rs6820391	0.816	rs4864801	chr4:54442182	C/T	cg04173182	chr4:54446035	LNX1	0.49	10.51	0.38	6.02e-24	Cervical artery dissection;
BRCA	trans	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-20.79	-0.64	1.07e-73	Exhaled nitric oxide output;
BRCA	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg12311346	chr5:56204834	C5orf35	-0.56	-11.7	-0.42	8.64e-29	Coronary artery disease;
BRCA	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03264133	chr6:25882463	NA	-0.42	-8.89	-0.33	6.14e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg23306229	chr2:178417860	TTC30B	-0.52	-8.04	-0.3	4.22e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg23018236	chr17:30244563	NA	-0.61	-10.05	-0.37	3.63e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs2108225	0.837	rs6959729	chr7:107446180	A/C	cg18560240	chr7:107437656	SLC26A3	-0.53	-11.15	-0.4	1.75e-26	Ulcerative colitis;
BRCA	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg22875332	chr1:76189707	ACADM	0.61	11.51	0.41	5.23e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.63	0.5	4.95e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg08603382	chr10:743973	NA	-0.45	-8.39	-0.31	3.19e-16	Psychosis in Alzheimer's disease;
BRCA	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1538970	1.000	rs1538970	chr1:45847562	G/A	cg05343316	chr1:45956843	TESK2	0.59	12.18	0.43	8.1e-31	Platelet count;
BRCA	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.83	-0.3	1.98e-14	Electroencephalogram traits;
BRCA	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg10426581	chr7:100472382	SRRT	0.65	11.33	0.41	3.14e-27	Resting heart rate;
BRCA	trans	rs1997103	0.954	rs6593222	chr7:55372932	A/C	cg20935933	chr6:143382018	AIG1	0.6	11.43	0.41	1.16e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg05347473	chr6:146136440	FBXO30	0.41	8.05	0.3	3.96e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs911119	1.000	rs6048956	chr20:23609301	C/T	cg16589663	chr20:23618590	CST3	0.45	8.5	0.32	1.35e-16	Chronic kidney disease;
BRCA	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg17830980	chr10:43048298	ZNF37B	0.43	10.12	0.37	1.95e-22	Extrinsic epigenetic age acceleration;
BRCA	trans	rs8073060	0.586	rs3859284	chr17:34012792	C/T	cg19694781	chr19:47549865	TMEM160	-1.06	-21.56	-0.65	7.18e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg04267008	chr7:1944627	MAD1L1	0.41	9.23	0.34	4.01e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg18196295	chr10:418757	DIP2C	-0.44	-9.99	-0.37	6.42e-22	Psychosis in Alzheimer's disease;
BRCA	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg11707556	chr5:10655725	ANKRD33B	0.43	9.52	0.35	3.53e-20	Coronary artery disease;
BRCA	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg02734326	chr4:10020555	SLC2A9	0.38	7.97	0.3	7.1e-15	Bone mineral density;
BRCA	cis	rs1451375	0.698	rs11238226	chr7:50645827	A/G	cg18232548	chr7:50535776	DDC	0.38	8.96	0.33	3.63e-18	Malaria;
BRCA	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg23625390	chr15:77176239	SCAPER	0.4	9.5	0.35	4.06e-20	Blood metabolite levels;
BRCA	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg00750074	chr16:89608354	SPG7	-0.42	-11.34	-0.41	2.69e-27	Multiple myeloma (IgH translocation);
BRCA	cis	rs965469	0.948	rs6139079	chr20:3314374	C/T	cg25506879	chr20:3388711	C20orf194	0.5	9.55	0.35	2.62e-20	IFN-related cytopenia;
BRCA	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg12386194	chr3:101231763	SENP7	0.45	9.71	0.36	6.78e-21	Colorectal cancer;
BRCA	cis	rs13190036	1.000	rs35535623	chr5:176629296	A/G	cg06733329	chr5:176740039	MXD3	0.46	8.27	0.31	7.9e-16	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	trans	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg26043149	chr18:55253948	FECH	0.39	8.78	0.33	1.46e-17	Bone mineral density;
BRCA	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.31	-7.82	-0.3	2.25e-14	Response to antipsychotic treatment;
BRCA	cis	rs9323205	0.953	rs11623710	chr14:51694261	C/T	cg23942311	chr14:51606299	NA	-0.43	-8.76	-0.33	1.69e-17	Cancer;
BRCA	cis	rs8010715	0.785	rs2877611	chr14:24595430	C/T	cg23112188	chr14:24563095	PCK2	-0.33	-8.18	-0.31	1.57e-15	IgG glycosylation;
BRCA	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg14186256	chr22:23484241	RTDR1	-0.78	-24.3	-0.69	6.98e-93	Bone mineral density;
BRCA	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.52	-0.44	2.53e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg21747090	chr2:27597821	SNX17	-0.43	-9.43	-0.35	7.62e-20	Total body bone mineral density;
BRCA	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg25036284	chr2:26402008	FAM59B	-0.63	-10.55	-0.39	4.14e-24	Gut microbiome composition (summer);
BRCA	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg15704280	chr7:45808275	SEPT13	0.6	10.23	0.38	7.19e-23	Axial length;
BRCA	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.36	-10.0	-0.37	5.81e-22	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg06532163	chr17:45867833	NA	0.37	7.81	0.3	2.41e-14	IgG glycosylation;
BRCA	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21659725	chr3:3221576	CRBN	-0.44	-10.77	-0.39	5.9e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18876405	chr7:65276391	NA	0.7	18.55	0.59	9.27e-62	Aortic root size;
BRCA	cis	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-8.9	-0.33	5.69e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7474896	0.583	rs10764144	chr10:37975732	G/C	cg25427524	chr10:38739819	LOC399744	-0.52	-9.46	-0.35	5.68e-20	Obesity (extreme);
BRCA	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-9.05	-0.34	1.66e-18	Fear of minor pain;
BRCA	cis	rs7715806	0.500	rs17649362	chr5:75008958	C/T	cg19683494	chr5:74908142	NA	0.53	8.59	0.32	6.64e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg16482183	chr6:26056742	HIST1H1C	0.45	8.76	0.33	1.76e-17	Iron status biomarkers;
BRCA	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg14196790	chr5:131705035	SLC22A5	-0.33	-8.72	-0.33	2.36e-17	Breast cancer;
BRCA	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg00106254	chr7:1943704	MAD1L1	-0.42	-10.27	-0.38	5.37e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg00277334	chr10:82204260	NA	-0.85	-25.09	-0.7	3.28e-97	Post bronchodilator FEV1;
BRCA	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg04511125	chr2:88470314	THNSL2	0.95	13.67	0.48	1.66e-37	Plasma clusterin levels;
BRCA	cis	rs4853036	0.540	rs10204989	chr2:69999727	T/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.91	-0.3	1.17e-14	Colorectal or endometrial cancer;
BRCA	trans	rs2262909	1.000	rs2078089	chr19:22209753	A/T	cg17074339	chr11:11642133	GALNTL4	-0.41	-7.81	-0.3	2.42e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg07460842	chr6:66804631	NA	-1.0	-20.11	-0.62	4.5e-70	Exhaled nitric oxide output;
BRCA	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg26384229	chr12:38710491	ALG10B	0.5	12.36	0.44	1.24e-31	Morning vs. evening chronotype;
BRCA	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg09367891	chr1:107599246	PRMT6	0.51	9.47	0.35	5.52e-20	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	9.42	0.35	8.31e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4722585	0.533	rs2158359	chr7:26193309	A/C	cg07876897	chr7:26191696	NFE2L3	-0.4	-8.73	-0.33	2.24e-17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
BRCA	cis	rs4363385	0.597	rs55667413	chr1:152976849	G/T	cg24667326	chr1:152973720	SPRR3	-0.35	-9.78	-0.36	3.71e-21	Inflammatory skin disease;
BRCA	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg10578991	chr7:12443926	VWDE	-0.55	-7.9	-0.3	1.2e-14	Coronary artery disease;
BRCA	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg06238570	chr21:40685208	BRWD1	-0.39	-7.99	-0.3	6.49e-15	Menarche (age at onset);
BRCA	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg26408565	chr15:76604113	ETFA	-0.47	-10.13	-0.37	1.87e-22	Blood metabolite levels;
BRCA	cis	rs858239	0.600	rs28499396	chr7:23124098	A/G	cg23682824	chr7:23144976	KLHL7	0.45	11.83	0.42	2.53e-29	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg13010199	chr12:38710504	ALG10B	0.4	8.0	0.3	5.92e-15	Morning vs. evening chronotype;
BRCA	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.15	0.37	1.53e-22	Bladder cancer;
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23978390	chr7:1156363	C7orf50	0.51	11.88	0.43	1.53e-29	Longevity;Endometriosis;
BRCA	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg06697600	chr4:7070879	GRPEL1	-0.55	-10.79	-0.39	4.71e-25	Monocyte percentage of white cells;
BRCA	cis	rs4363385	0.747	rs1055935	chr1:152975941	C/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.54	-0.35	2.94e-20	Inflammatory skin disease;
BRCA	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg10495392	chr1:46806563	NSUN4	-0.44	-8.17	-0.31	1.65e-15	Menopause (age at onset);
BRCA	cis	rs7091068	0.518	rs913045	chr10:95431535	C/T	cg20715218	chr10:95462985	C10orf4	0.48	10.3	0.38	4.04e-23	Urinary tract infection frequency;
BRCA	cis	rs9487051	0.646	rs7773490	chr6:109623048	T/C	cg01475377	chr6:109611718	NA	-0.4	-8.76	-0.33	1.79e-17	Reticulocyte fraction of red cells;
BRCA	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.96	-0.33	3.58e-18	Monocyte percentage of white cells;
BRCA	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.39	-0.44	9.32e-32	Chronic sinus infection;
BRCA	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg00071950	chr4:10020882	SLC2A9	-0.52	-12.12	-0.43	1.45e-30	Bone mineral density;
BRCA	cis	rs10189230	0.935	rs3770146	chr2:222344196	G/A	cg14652038	chr2:222343519	EPHA4	0.47	12.53	0.44	2.38e-32	Urate levels in lean individuals;
BRCA	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg20573242	chr4:122745356	CCNA2	0.42	9.35	0.35	1.44e-19	Type 2 diabetes;
BRCA	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg12011299	chr4:100065546	ADH4	0.42	10.56	0.39	3.95e-24	Alcohol dependence;
BRCA	cis	rs6733011	0.531	rs13004923	chr2:99497561	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.37	-8.53	-0.32	1.03e-16	Bipolar disorder;
BRCA	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-12.92	-0.45	4.51e-34	Lymphocyte counts;
BRCA	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg24675658	chr1:53192096	ZYG11B	0.56	12.76	0.45	2.24e-33	Monocyte count;
BRCA	cis	rs3916	0.911	rs3999408	chr12:121167387	C/T	cg21892295	chr12:121157589	UNC119B	-0.37	-9.66	-0.36	1.04e-20	Urinary metabolites (H-NMR features);
BRCA	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg12661370	chr5:149340060	SLC26A2	0.5	9.36	0.35	1.39e-19	HIV-1 control;
BRCA	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	18.46	0.59	2.64e-61	Alzheimer's disease;
BRCA	cis	rs9381107	0.505	rs1001384	chr6:9485556	G/A	cg14735645	chr6:9486422	NA	-0.44	-8.67	-0.32	3.46e-17	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.26	0.38	5.62e-23	Motion sickness;
BRCA	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg27432699	chr2:27873401	GPN1	0.42	8.9	0.33	5.55e-18	Oral cavity cancer;
BRCA	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg24110177	chr3:50126178	RBM5	-0.51	-14.22	-0.49	4.4e-40	Body mass index;
BRCA	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg13175981	chr1:150552382	MCL1	0.47	10.51	0.38	5.93e-24	Tonsillectomy;
BRCA	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.33	-9.05	-0.34	1.76e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg24631222	chr15:78858424	CHRNA5	-0.5	-9.95	-0.37	8.52e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.27	0.49	2.6e-40	Motion sickness;
BRCA	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg08470875	chr2:26401718	FAM59B	0.76	11.94	0.43	8.04e-30	Gut microbiome composition (summer);
BRCA	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg05294307	chr14:35346193	BAZ1A	-0.6	-11.78	-0.42	4.11e-29	Psoriasis;
BRCA	cis	rs17092148	1.000	rs6058117	chr20:33366905	A/G	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.26	-0.41	5.82e-27	Neuroticism;
BRCA	cis	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg07988820	chr12:82153109	PPFIA2	-0.55	-9.2	-0.34	5e-19	Resting heart rate;
BRCA	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.34	-0.52	1.99e-45	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs16958440	1.000	rs2289130	chr18:44626630	T/G	cg17192377	chr18:44677553	HDHD2	0.67	9.75	0.36	4.96e-21	Sitting height ratio;
BRCA	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg01802117	chr1:53393560	SCP2	-0.34	-8.01	-0.3	5.42e-15	Monocyte count;
BRCA	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg15839431	chr19:19639596	YJEFN3	-0.41	-9.08	-0.34	1.35e-18	Bipolar disorder;
BRCA	cis	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg06521331	chr12:34319734	NA	-0.52	-10.24	-0.38	6.79e-23	Morning vs. evening chronotype;
BRCA	trans	rs9929218	1.000	rs12448448	chr16:68802516	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-13.92	-0.48	1.13e-38	Colorectal cancer;
BRCA	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg13010199	chr12:38710504	ALG10B	0.5	10.0	0.37	5.92e-22	Bladder cancer;
BRCA	cis	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg21775007	chr8:11205619	TDH	-0.52	-10.48	-0.38	8.15e-24	Retinal vascular caliber;
BRCA	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	19.05	0.6	2.01e-64	Alzheimer's disease (late onset);
BRCA	trans	rs3857536	0.673	rs7759888	chr6:66891922	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-9.49	-0.35	4.6e-20	Blood trace element (Cu levels);
BRCA	cis	rs17095355	0.901	rs9783184	chr10:111760499	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.77	-0.36	4.23e-21	Biliary atresia;
BRCA	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.42	-8.67	-0.32	3.47e-17	Body mass index;
BRCA	cis	rs751728	0.687	rs4711355	chr6:33759906	G/T	cg25922239	chr6:33757077	LEMD2	0.49	12.31	0.44	2.1e-31	Crohn's disease;
BRCA	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg20476274	chr7:133979776	SLC35B4	0.7	21.4	0.65	5.31e-77	Mean platelet volume;
BRCA	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg26384229	chr12:38710491	ALG10B	0.42	9.33	0.35	1.73e-19	Morning vs. evening chronotype;
BRCA	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg26031613	chr14:104095156	KLC1	-0.42	-8.52	-0.32	1.14e-16	Schizophrenia;
BRCA	cis	rs9309473	1.000	rs7564890	chr2:73641853	T/C	cg20560298	chr2:73613845	ALMS1	-0.43	-10.65	-0.39	1.79e-24	Metabolite levels;
BRCA	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-11.91	-0.43	1.15e-29	Response to antipsychotic treatment;
BRCA	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg08847533	chr14:75593920	NEK9	-0.84	-20.9	-0.64	2.57e-74	Height;
BRCA	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg10556349	chr10:835070	NA	0.6	8.41	0.32	2.75e-16	Eosinophil percentage of granulocytes;
BRCA	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg07332563	chr6:291687	DUSP22	0.57	11.72	0.42	6.94e-29	Menopause (age at onset);
BRCA	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27286337	chr10:134555280	INPP5A	0.8	12.94	0.46	3.49e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7043114	0.525	rs2516567	chr9:95187418	C/T	cg14631576	chr9:95140430	CENPP	-0.32	-7.88	-0.3	1.45e-14	Height;
BRCA	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg00945666	chr1:160990265	F11R	-0.3	-8.65	-0.32	4.27e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg21573476	chr21:45109991	RRP1B	-0.32	-8.63	-0.32	4.88e-17	Mean corpuscular volume;
BRCA	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg09307838	chr4:120376055	NA	0.64	14.17	0.49	8.18e-40	Corneal astigmatism;
BRCA	cis	rs11249608	0.703	rs7726601	chr5:178444713	A/G	cg21905437	chr5:178450457	ZNF879	-0.48	-9.82	-0.36	2.76e-21	Pubertal anthropometrics;
BRCA	cis	rs7043114	0.507	rs10761154	chr9:95144086	A/G	cg14631576	chr9:95140430	CENPP	-0.33	-8.33	-0.31	4.77e-16	Height;
BRCA	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg01256987	chr12:42539512	GXYLT1	-0.42	-8.28	-0.31	7.06e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.49	0.38	7.33e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.39	8.71	0.33	2.67e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.43	-0.32	2.32e-16	Total body bone mineral density;
BRCA	cis	rs11252926	0.897	rs7092330	chr10:583771	G/C	cg08603382	chr10:743973	NA	-0.4	-8.06	-0.3	3.65e-15	Psychosis in Alzheimer's disease;
BRCA	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	18.53	0.59	1.19e-61	Platelet count;
BRCA	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.71	11.37	0.41	2.1e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs847577	0.540	rs3847055	chr7:97680645	A/G	cg24562669	chr7:97807699	LMTK2	-0.41	-9.33	-0.35	1.74e-19	Breast cancer;
BRCA	cis	rs6484504	0.576	rs2616792	chr11:31324298	T/G	cg06552810	chr11:31128660	NA	0.39	8.52	0.32	1.16e-16	Red blood cell count;
BRCA	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg10295955	chr4:187884368	NA	-0.95	-28.11	-0.74	8.57e-114	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8032158	0.963	rs12102020	chr15:56125578	G/A	cg02198044	chr15:56286336	NEDD4	-0.38	-9.04	-0.34	1.8e-18	Keloid;
BRCA	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg16405210	chr4:1374714	KIAA1530	0.36	7.95	0.3	8.65e-15	Obesity-related traits;
BRCA	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02176678	chr2:219576539	TTLL4	0.46	12.16	0.43	9.47e-31	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg13770153	chr20:60521292	NA	-0.41	-9.12	-0.34	9.68e-19	Body mass index;
BRCA	cis	rs72766638	0.895	rs11795079	chr9:136930134	T/C	cg13789015	chr9:136890014	NCRNA00094	0.58	9.09	0.34	1.19e-18	Mosquito bite size;
BRCA	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	13.06	0.46	1.03e-34	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg03709012	chr19:19516395	GATAD2A	0.74	16.53	0.55	2.31e-51	Tonsillectomy;
BRCA	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.35	0.38	2.64e-23	Motion sickness;
BRCA	cis	rs6545883	0.894	rs2694649	chr2:61573826	G/A	cg15711740	chr2:61764176	XPO1	0.52	13.25	0.46	1.42e-35	Tuberculosis;
BRCA	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg17470723	chr8:74884337	TCEB1	0.41	8.88	0.33	6.51e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.51	-19.65	-0.61	1.25e-67	Diastolic blood pressure;
BRCA	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg15839431	chr19:19639596	YJEFN3	0.35	7.96	0.3	7.7e-15	Bipolar disorder;
BRCA	trans	rs4714291	0.862	rs2984445	chr6:40069935	C/T	cg02267698	chr19:7991119	CTXN1	-0.45	-9.39	-0.35	1.07e-19	Strep throat;
BRCA	trans	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg01620082	chr3:125678407	NA	-0.91	-10.26	-0.38	5.88e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg02175503	chr12:58329896	NA	-0.75	-18.66	-0.59	2.45e-62	Intelligence (multi-trait analysis);
BRCA	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg19077165	chr18:44547161	KATNAL2	-0.54	-11.61	-0.42	2.14e-28	Personality dimensions;
BRCA	cis	rs6580649	0.943	rs1859444	chr12:48399403	T/C	cg05342945	chr12:48394962	COL2A1	-0.49	-9.83	-0.36	2.46e-21	Lung cancer;
BRCA	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg08847533	chr14:75593920	NEK9	-0.87	-22.33	-0.66	4.66e-82	Height;
BRCA	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg04546413	chr19:29218101	NA	0.64	10.9	0.4	1.79e-25	Methadone dose in opioid dependence;
BRCA	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.38	8.34	0.31	4.57e-16	Cognitive ability;
BRCA	cis	rs3820928	0.967	rs12622456	chr2:227768868	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-8.97	-0.33	3.37e-18	Pulmonary function;
BRCA	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.48	-0.35	4.88e-20	Body mass index;
BRCA	cis	rs7520050	0.966	rs4073846	chr1:46462881	C/T	cg24296786	chr1:45957014	TESK2	-0.43	-9.56	-0.35	2.47e-20	Red blood cell count;Reticulocyte count;
BRCA	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.71	-11.33	-0.41	2.94e-27	Red cell distribution width;
BRCA	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.73	-16.2	-0.54	1.01e-49	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs897984	0.568	rs72799330	chr16:30893555	C/A	cg02466173	chr16:30829666	NA	-0.47	-9.16	-0.34	6.96e-19	Dementia with Lewy bodies;
BRCA	cis	rs13046373	0.535	rs2226377	chr21:32031915	T/C	cg24082983	chr21:31802169	KRTAP13-4	0.34	8.26	0.31	8.39e-16	HDL cholesterol;
BRCA	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg20701182	chr2:24300061	SF3B14	0.55	8.19	0.31	1.37e-15	Lymphocyte counts;
BRCA	cis	rs34779708	0.897	rs4934527	chr10:35281118	T/A	cg03585969	chr10:35415529	CREM	0.48	10.11	0.37	2.25e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg26536863	chr7:158807979	LOC154822	0.36	8.29	0.31	6.79e-16	Facial morphology (factor 20);
BRCA	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg24459738	chr19:57751996	ZNF805	-0.35	-8.3	-0.31	6.28e-16	Hyperactive-impulsive symptoms;
BRCA	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg18479299	chr3:125709523	NA	-0.54	-8.3	-0.31	6.41e-16	Blood pressure (smoking interaction);
BRCA	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	19.86	0.62	1.07e-68	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-8.63	-0.32	4.87e-17	Pulmonary function;
BRCA	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	15.46	0.52	5.04e-46	Colorectal cancer;
BRCA	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.06	-0.34	1.53e-18	Total body bone mineral density;
BRCA	cis	rs6426558	0.537	rs10495253	chr1:227471820	A/T	cg10327440	chr1:227177885	CDC42BPA	0.48	9.6	0.36	1.73e-20	Neutrophil percentage of white cells;
BRCA	cis	rs2249625	0.874	rs1819063	chr6:72908180	A/G	cg18830697	chr6:72922368	RIMS1	-0.37	-7.84	-0.3	1.84e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg22105103	chr4:187893119	NA	0.38	11.66	0.42	1.23e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg03342759	chr3:160939853	NMD3	-0.7	-13.73	-0.48	9.24e-38	Parkinson's disease;
BRCA	cis	rs4845875	0.626	rs10864542	chr1:11842144	C/G	cg24844545	chr1:11908347	NPPA	0.33	8.26	0.31	8.22e-16	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs9649465	1.000	rs3779260	chr7:123348315	A/G	cg04330084	chr7:123175371	IQUB	0.31	8.45	0.32	2e-16	Migraine;
BRCA	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg23711669	chr6:146136114	FBXO30	0.63	14.31	0.49	1.72e-40	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg27147174	chr7:100797783	AP1S1	-0.58	-11.79	-0.42	3.49e-29	Life satisfaction;
BRCA	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18876405	chr7:65276391	NA	0.55	12.97	0.46	2.45e-34	Aortic root size;
BRCA	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg08807101	chr21:30365312	RNF160	-0.35	-7.88	-0.3	1.43e-14	Pancreatic cancer;
BRCA	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg00339695	chr16:24857497	SLC5A11	0.53	11.33	0.41	2.91e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs11971779	0.680	rs111461944	chr7:139077903	G/C	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg14993813	chr1:46806288	NSUN4	-0.47	-9.04	-0.34	1.91e-18	Menopause (age at onset);
BRCA	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg01877450	chr7:97915802	BRI3	-0.39	-8.98	-0.33	3.1e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg26343298	chr8:95960752	TP53INP1	0.29	8.06	0.3	3.78e-15	Type 2 diabetes;
BRCA	trans	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg13010199	chr12:38710504	ALG10B	0.4	8.08	0.3	3.19e-15	Morning vs. evening chronotype;
BRCA	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.07	-0.3	3.54e-15	Aortic root size;
BRCA	cis	rs4561483	0.767	rs33633	chr16:11994857	A/C	cg08843971	chr16:11963173	GSPT1	-0.54	-12.22	-0.44	5.31e-31	Testicular germ cell tumor;
BRCA	cis	rs829883	0.724	rs1439774	chr12:98907692	C/T	cg25150519	chr12:98850993	NA	-0.51	-9.37	-0.35	1.25e-19	Colorectal adenoma (advanced);
BRCA	cis	rs6450176	1.000	rs1445887	chr5:53299376	A/T	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-15.11	-0.51	2.49e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg12140854	chr5:148520817	ABLIM3	-0.43	-8.77	-0.33	1.65e-17	Breast cancer;
BRCA	cis	rs4880487	1.000	rs4880487	chr10:1246883	C/T	cg03183215	chr10:1252341	ADARB2	-0.37	-8.43	-0.32	2.35e-16	Migraine;
BRCA	trans	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-15.49	-0.52	3.38e-46	Obesity-related traits;
BRCA	cis	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg02951883	chr7:2050386	MAD1L1	0.39	8.36	0.31	3.89e-16	Neuroticism;
BRCA	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23583168	chr7:148888333	NA	-0.83	-18.43	-0.59	3.78e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06544989	chr22:39130855	UNC84B	0.34	7.94	0.3	9.19e-15	Menopause (age at onset);
BRCA	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-7.96	-0.3	8.15e-15	Total body bone mineral density;
BRCA	cis	rs2652834	0.904	rs7175602	chr15:63367032	T/C	cg05507819	chr15:63340323	TPM1	-0.57	-10.34	-0.38	2.73e-23	HDL cholesterol;
BRCA	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.8	0.36	3.22e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.81	25.64	0.71	3.13e-100	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg14664628	chr15:75095509	CSK	-0.94	-29.63	-0.76	4.61e-122	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg06494592	chr3:125709126	NA	-0.54	-8.33	-0.31	4.81e-16	Blood pressure (smoking interaction);
BRCA	cis	rs7789940	0.904	rs61294900	chr7:75937212	A/T	cg10167463	chr7:75959203	YWHAG	-0.43	-8.42	-0.32	2.55e-16	Multiple sclerosis;
BRCA	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg26528668	chr16:1614120	IFT140	0.4	9.12	0.34	9.7e-19	Coronary artery disease;
BRCA	cis	rs9287719	0.601	rs13427815	chr2:10707985	C/T	cg00105475	chr2:10696890	NA	0.47	10.32	0.38	3.5e-23	Prostate cancer;
BRCA	trans	rs11165623	0.564	rs9887897	chr1:96996671	T/C	cg10631902	chr5:14652156	NA	-0.43	-12.06	-0.43	2.43e-30	Hip circumference;Waist circumference;
BRCA	cis	rs367943	1.000	rs348954	chr5:112821716	A/G	cg12552261	chr5:112820674	MCC	-0.55	-12.09	-0.43	1.9e-30	Type 2 diabetes;
BRCA	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg10560079	chr2:191398806	TMEM194B	-0.65	-12.42	-0.44	6.99e-32	Diastolic blood pressure;
BRCA	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg16482183	chr6:26056742	HIST1H1C	0.54	11.05	0.4	4.27e-26	Height;
BRCA	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg16386425	chr10:429943	DIP2C	0.42	8.44	0.32	2.14e-16	Psychosis in Alzheimer's disease;
BRCA	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.43	12.17	0.43	8.18e-31	Monocyte percentage of white cells;
BRCA	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.67	-0.61	9.89e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4953076	0.573	rs6544746	chr2:44407985	C/T	cg04920474	chr2:44395004	PPM1B	0.47	9.56	0.35	2.58e-20	Height;
BRCA	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg09469691	chr10:81107165	PPIF	0.53	11.06	0.4	3.99e-26	Height;
BRCA	cis	rs9487051	0.768	rs463503	chr6:109525757	T/C	cg01475377	chr6:109611718	NA	-0.43	-10.88	-0.4	2.13e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs9420	0.961	rs12146541	chr11:57508678	G/C	cg19752551	chr11:57585705	CTNND1	-0.51	-12.59	-0.45	1.22e-32	Schizophrenia;
BRCA	cis	rs7631605	0.935	rs1558528	chr3:37056990	C/A	cg15934958	chr3:37212084	LRRFIP2	0.41	9.57	0.35	2.39e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	18.71	0.59	1.26e-62	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs9986765	1.000	rs73725075	chr7:142823479	C/A	cg22531018	chr7:142981779	TMEM139	0.58	9.74	0.36	5.56e-21	Cancer;Dermatomyositis;
BRCA	cis	rs13082711	0.595	rs4973761	chr3:27358620	T/C	cg02860705	chr3:27208620	NA	0.78	14.35	0.49	1.1e-40	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11764359	chr7:65958608	NA	-0.75	-16.67	-0.55	4.5e-52	Aortic root size;
BRCA	cis	rs9649465	0.967	rs11765790	chr7:123293152	A/C	cg03229431	chr7:123269106	ASB15	-0.34	-7.81	-0.3	2.42e-14	Migraine;
BRCA	trans	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11764359	chr7:65958608	NA	-0.75	-16.5	-0.55	3.37e-51	Aortic root size;
BRCA	trans	rs3857536	0.741	rs9363556	chr6:66934399	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.12	-0.31	2.43e-15	Blood trace element (Cu levels);
BRCA	cis	rs11971779	0.584	rs10236055	chr7:139069991	A/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg02569458	chr12:86230093	RASSF9	0.32	7.95	0.3	8.28e-15	Major depressive disorder;
BRCA	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg02503808	chr4:7069936	GRPEL1	0.78	17.92	0.58	1.66e-58	Monocyte percentage of white cells;
BRCA	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg01420254	chr6:26195488	NA	0.55	8.54	0.32	9.51e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03264133	chr6:25882463	NA	-0.49	-11.02	-0.4	5.68e-26	Blood metabolite levels;
BRCA	cis	rs17001868	0.568	rs470113	chr22:40729614	A/G	cg07138101	chr22:40742427	ADSL	0.53	9.12	0.34	9.74e-19	Mammographic density (dense area);
BRCA	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.25	-0.41	6.69e-27	Response to antipsychotic treatment;
BRCA	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg01416388	chr22:39784598	NA	-0.38	-7.89	-0.3	1.3e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg22800045	chr5:56110881	MAP3K1	0.68	12.8	0.45	1.42e-33	Initial pursuit acceleration;
BRCA	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg00080972	chr5:178986291	RUFY1	0.53	14.96	0.51	1.27e-43	Lung cancer;
BRCA	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg00071950	chr4:10020882	SLC2A9	-0.43	-9.96	-0.37	8.02e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs870825	0.790	rs12513128	chr4:185576729	G/C	cg04058563	chr4:185651563	MLF1IP	0.66	11.06	0.4	3.92e-26	Blood protein levels;
BRCA	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.17	-0.34	6.4e-19	Total body bone mineral density;
BRCA	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg24846343	chr22:24311635	DDTL	0.44	10.63	0.39	2.04e-24	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg07148914	chr20:33460835	GGT7	-0.43	-9.16	-0.34	7.16e-19	Height;
BRCA	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg20573242	chr4:122745356	CCNA2	0.47	10.32	0.38	3.35e-23	Type 2 diabetes;
BRCA	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg04586622	chr2:25135609	ADCY3	0.45	11.42	0.41	1.34e-27	Body mass index;
BRCA	cis	rs7539409	0.651	rs979757	chr1:84296605	T/C	cg10977910	chr1:84465055	TTLL7	0.61	9.31	0.35	2.04e-19	Alzheimer's disease;
BRCA	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.83	-0.58	5.25e-58	Chronic sinus infection;
BRCA	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	11.5	0.41	6.17e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.02	0.4	5.6e-26	Bipolar disorder;
BRCA	cis	rs9811920	0.683	rs793502	chr3:99588417	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.45	10.85	0.39	2.67e-25	Axial length;
BRCA	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg17366294	chr4:99064904	C4orf37	0.46	10.86	0.39	2.42e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs55882075	0.750	rs13184690	chr5:179146993	T/C	cg14593053	chr5:179126677	CANX	0.48	12.75	0.45	2.51e-33	Monocyte percentage of white cells;
BRCA	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg03146154	chr1:46216737	IPP	0.51	11.41	0.41	1.39e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7818345	0.737	rs17407149	chr8:19274848	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.31	7.96	0.3	7.66e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg16850897	chr7:100343110	ZAN	0.35	8.08	0.3	3.16e-15	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs12973672	1.000	rs28365136	chr19:35769561	T/G	cg12095397	chr19:35769544	USF2	0.38	8.38	0.31	3.28e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg13902645	chr11:5959945	NA	-0.54	-10.85	-0.39	2.78e-25	DNA methylation (variation);
BRCA	trans	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg06521331	chr12:34319734	NA	-0.44	-8.35	-0.31	4.37e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg24977027	chr2:88469347	THNSL2	0.57	9.58	0.35	2.04e-20	Plasma clusterin levels;
BRCA	cis	rs2455601	0.882	rs10840139	chr11:8894838	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-8.1	-0.31	2.84e-15	Schizophrenia;
BRCA	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg26597838	chr10:835615	NA	0.9	14.09	0.49	1.77e-39	Eosinophil percentage of granulocytes;
BRCA	cis	rs9420	0.961	rs10896647	chr11:57571883	C/T	cg19752551	chr11:57585705	CTNND1	-0.5	-12.35	-0.44	1.41e-31	Schizophrenia;
BRCA	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18404041	chr3:52824283	ITIH1	-0.42	-12.35	-0.44	1.36e-31	Bipolar disorder;
BRCA	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg09307838	chr4:120376055	NA	0.72	15.26	0.52	4.47e-45	Corneal astigmatism;
BRCA	cis	rs6684514	1.000	rs12045339	chr1:156294211	C/T	cg16558208	chr1:156270281	VHLL	0.35	8.1	0.31	2.72e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-9.72	-0.36	6.48e-21	Alzheimer's disease;
BRCA	cis	rs3771570	1.000	rs55634485	chr2:242268994	T/C	cg21155796	chr2:242212141	HDLBP	0.6	9.3	0.35	2.25e-19	Prostate cancer;
BRCA	trans	rs6479891	1.000	rs7099425	chr10:64960717	C/T	cg14819942	chr15:35414228	NA	-0.32	-8.17	-0.31	1.66e-15	Arthritis (juvenile idiopathic);
BRCA	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg03342759	chr3:160939853	NMD3	-0.66	-14.31	-0.49	1.77e-40	Morning vs. evening chronotype;
BRCA	cis	rs11997175	0.846	rs34860600	chr8:33761566	C/A	ch.8.33884649F	chr8:33765107	NA	0.5	12.37	0.44	1.21e-31	Body mass index;
BRCA	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-9.86	-0.36	1.94e-21	Daytime sleep phenotypes;
BRCA	cis	rs4919694	1.000	rs12266291	chr10:104806884	G/A	cg04362960	chr10:104952993	NT5C2	0.94	14.5	0.5	2.26e-41	Arsenic metabolism;
BRCA	trans	rs877282	0.891	rs11253406	chr10:796297	G/A	cg22713356	chr15:30763199	NA	1.41	28.52	0.75	5.26e-116	Uric acid levels;
BRCA	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg01528321	chr10:82214614	TSPAN14	0.64	14.52	0.5	1.65e-41	Post bronchodilator FEV1;
BRCA	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg00750074	chr16:89608354	SPG7	0.34	9.0	0.34	2.53e-18	Multiple myeloma (IgH translocation);
BRCA	cis	rs10484885	0.824	rs72921954	chr6:90586656	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-9.52	-0.35	3.48e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg03585969	chr10:35415529	CREM	0.56	11.54	0.42	3.91e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2964802	0.505	rs13179252	chr5:10805662	A/G	cg14521931	chr5:10832172	NA	-0.58	-13.03	-0.46	1.38e-34	Major depressive disorder;Recurrent major depressive disorder;
BRCA	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg07636037	chr3:49044803	WDR6	0.98	29.32	0.76	2.26e-120	Parkinson's disease;
BRCA	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-18.93	-0.6	8.81e-64	Chronic sinus infection;
BRCA	trans	rs1351696	1	rs1351696	chr11:48382471	A/G	cg15704280	chr7:45808275	SEPT13	-0.55	-8.37	-0.31	3.7e-16	D-dimer levels;
BRCA	cis	rs6534441	0.697	rs56194872	chr4:125418343	G/T	cg21609808	chr4:125404261	NA	0.36	7.89	0.3	1.28e-14	Major depressive disorder;
BRCA	cis	rs6968419	0.747	rs1004109	chr7:115862296	A/T	cg02561103	chr7:115862891	TES	0.35	7.83	0.3	2.08e-14	Intraocular pressure;
BRCA	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.1	0.4	2.64e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs12439619	0.921	rs56042848	chr15:82527585	A/T	cg04831495	chr15:85060580	GOLGA6L5	-0.46	-11.2	-0.41	9.98e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs10189230	0.546	rs6727259	chr2:222358292	C/G	cg14652038	chr2:222343519	EPHA4	-0.37	-9.06	-0.34	1.57e-18	Urate levels in lean individuals;
BRCA	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg20607798	chr8:58055168	NA	0.46	8.09	0.3	2.92e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.56	0.55	1.58e-51	Morning vs. evening chronotype;
BRCA	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.58	12.05	0.43	2.86e-30	Monocyte percentage of white cells;
BRCA	cis	rs6484504	0.576	rs158144	chr11:31211795	A/C	cg14844989	chr11:31128820	NA	-0.44	-9.48	-0.35	5.02e-20	Red blood cell count;
BRCA	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg02153584	chr22:29168773	CCDC117	0.52	10.84	0.39	2.94e-25	Lymphocyte counts;
BRCA	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-8.97	-0.33	3.21e-18	Alzheimer's disease;
BRCA	cis	rs10492096	0.947	rs11559082	chr12:6602367	C/T	cg13857086	chr12:6580257	VAMP1	0.44	8.49	0.32	1.4e-16	Hip geometry;
BRCA	trans	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg12806826	chr1:1091669	NA	0.32	8.13	0.31	2.27e-15	Menarche (age at onset);
BRCA	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03517284	chr6:25882590	NA	-0.52	-12.02	-0.43	3.78e-30	Blood metabolite levels;
BRCA	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg25174290	chr11:3078921	CARS	0.41	12.05	0.43	2.88e-30	Longevity;
BRCA	cis	rs6694270	0.913	rs3935030	chr1:19116956	C/T	cg26220594	chr1:19110978	NA	-0.47	-8.79	-0.33	1.36e-17	Drug-induced liver injury (nitrofurantoin);
BRCA	cis	rs10254118	0.730	rs6961517	chr7:133130940	G/T	cg10665199	chr7:133106180	EXOC4	0.45	9.69	0.36	8.15e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg17063962	chr7:91808500	NA	0.55	12.92	0.46	4.16e-34	Breast cancer;
BRCA	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.68	-0.48	1.51e-37	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4409675	0.576	rs12062621	chr1:28230404	A/G	cg23691781	chr1:28212827	C1orf38	0.32	10.64	0.39	1.86e-24	Corneal astigmatism;
BRCA	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg11822812	chr5:140052017	DND1	-0.3	-8.23	-0.31	1.03e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	12.54	0.44	2.17e-32	Ileal carcinoids;
BRCA	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg21427119	chr20:30132790	HM13	-0.41	-8.72	-0.33	2.4e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-17.83	-0.58	5.39e-58	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg24829409	chr8:58192753	C8orf71	0.54	9.39	0.35	1.07e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs9467160	0.559	rs2753911	chr6:24442288	C/T	cg20631270	chr6:24437470	GPLD1	0.55	11.53	0.41	4.63e-28	Liver enzyme levels;
BRCA	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.48	0.32	1.52e-16	Platelet count;
BRCA	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg05347473	chr6:146136440	FBXO30	0.62	12.15	0.43	1.07e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2066819	1.000	rs116849218	chr12:56683975	C/T	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg13073564	chr4:8508604	NA	-0.4	-10.68	-0.39	1.31e-24	Response to antineoplastic agents;
BRCA	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-13.78	-0.48	5.01e-38	Ulcerative colitis;
BRCA	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg04013093	chr6:42928303	GNMT	-0.28	-8.73	-0.33	2.16e-17	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg01689657	chr7:91764605	CYP51A1	0.22	8.11	0.31	2.58e-15	Breast cancer;
BRCA	cis	rs9807989	0.507	rs6743516	chr2:103036335	A/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.35	0.31	4.32e-16	Asthma;
BRCA	cis	rs2191566	0.761	rs446016	chr19:44501518	A/G	cg20607764	chr19:44506953	ZNF230	-0.45	-9.39	-0.35	1.02e-19	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9790314	0.581	rs6772578	chr3:160760851	T/A	cg03342759	chr3:160939853	NMD3	-0.49	-9.31	-0.35	2e-19	Morning vs. evening chronotype;
BRCA	cis	rs3768617	0.811	rs6674729	chr1:183059143	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.46	10.24	0.38	6.77e-23	Fuchs's corneal dystrophy;
BRCA	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.5	-0.32	1.37e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.48	0.32	1.51e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-12.65	-0.45	6.73e-33	Monocyte percentage of white cells;
BRCA	cis	rs1712517	0.566	rs7917388	chr10:105054963	C/T	cg04362960	chr10:104952993	NT5C2	-0.39	-7.84	-0.3	1.94e-14	Migraine;
BRCA	cis	rs10267417	0.603	rs34087364	chr7:19860293	A/C	cg07541023	chr7:19748670	TWISTNB	0.5	8.98	0.33	2.91e-18	Night sleep phenotypes;
BRCA	trans	rs3857536	0.813	rs7757647	chr6:66947207	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	2.02e-14	Blood trace element (Cu levels);
BRCA	cis	rs7493	0.851	rs11770903	chr7:95026327	A/G	cg19678392	chr7:94953810	PON1	-0.4	-8.13	-0.31	2.27e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.39	-0.44	9.24e-32	Type 2 diabetes;
BRCA	cis	rs10924970	0.967	rs8179454	chr1:235460719	C/G	cg26050004	chr1:235667680	B3GALNT2	0.34	8.32	0.31	5.46e-16	Asthma;
BRCA	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.64	0.32	4.39e-17	Motion sickness;
BRCA	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg25554036	chr4:6271136	WFS1	0.42	9.98	0.37	6.91e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7631605	0.905	rs7651903	chr3:37006686	T/C	cg15934958	chr3:37212084	LRRFIP2	0.42	9.8	0.36	3.08e-21	Cerebrospinal P-tau181p levels;
BRCA	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21659725	chr3:3221576	CRBN	0.5	11.82	0.42	2.71e-29	Resting heart rate;
BRCA	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.37	0.35	1.21e-19	Tonsillectomy;
BRCA	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg24812749	chr6:127587940	RNF146	-0.52	-11.64	-0.42	1.5e-28	Breast cancer;
BRCA	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-16.72	-0.55	2.49e-52	Axial length;
BRCA	cis	rs9394152	0.845	rs4713632	chr6:33472990	G/T	cg13560919	chr6:33536144	NA	0.62	12.76	0.45	2.26e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs34779708	0.702	rs4007272	chr10:35546859	T/G	cg03585969	chr10:35415529	CREM	0.44	9.1	0.34	1.17e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg25237894	chr2:233734115	C2orf82	-0.44	-14.22	-0.49	4.61e-40	Coronary artery disease;
BRCA	cis	rs67981189	0.613	rs4366661	chr14:71452316	A/T	cg15816911	chr14:71606274	NA	-0.37	-8.39	-0.32	3.1e-16	Schizophrenia;
BRCA	cis	rs13095912	1.000	rs4686666	chr3:185342847	T/C	cg11274856	chr3:185301563	NA	0.34	8.37	0.31	3.72e-16	Systolic blood pressure;
BRCA	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-8.14	-0.31	2.1e-15	Response to antipsychotic treatment;
BRCA	cis	rs10181042	0.565	rs2564117	chr2:61233022	A/T	cg15711740	chr2:61764176	XPO1	-0.35	-8.26	-0.31	8.15e-16	Crohn's disease;
BRCA	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.42	9.04	0.34	1.81e-18	Alzheimer's disease (late onset);
BRCA	cis	rs1018836	0.892	rs7819519	chr8:91565504	C/T	cg16814680	chr8:91681699	NA	-0.57	-12.34	-0.44	1.63e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg00666640	chr1:248458726	OR2T12	0.32	8.94	0.33	4.09e-18	Common traits (Other);
BRCA	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08109568	chr15:31115862	NA	-0.44	-10.39	-0.38	1.77e-23	Huntington's disease progression;
BRCA	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.06	30.03	0.77	3.03e-124	Cognitive ability;
BRCA	cis	rs9309473	0.718	rs6546829	chr2:73613789	C/G	cg20560298	chr2:73613845	ALMS1	-0.51	-14.11	-0.49	1.58e-39	Metabolite levels;
BRCA	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg18225595	chr11:63971243	STIP1	-0.41	-10.45	-0.38	1.08e-23	Platelet count;
BRCA	cis	rs812925	0.512	rs1729674	chr2:61389737	T/G	cg15711740	chr2:61764176	XPO1	-0.32	-7.98	-0.3	6.89e-15	Immature fraction of reticulocytes;
BRCA	cis	rs9682041	0.800	rs7643085	chr3:170070371	A/G	cg11886554	chr3:170076028	SKIL	0.69	12.87	0.45	7.58e-34	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.39	8.56	0.32	8.52e-17	Bipolar disorder;
BRCA	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg25801113	chr15:45476975	SHF	-0.33	-8.1	-0.31	2.78e-15	Uric acid levels;
BRCA	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	10.29	0.38	4.52e-23	Protein C levels;
BRCA	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg00149659	chr3:10157352	C3orf10	1.1	18.73	0.6	1.05e-62	Alzheimer's disease;
BRCA	cis	rs7737355	0.947	rs31254	chr5:130829404	C/T	cg06307176	chr5:131281290	NA	0.52	10.46	0.38	9.23e-24	Life satisfaction;
BRCA	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg26597838	chr10:835615	NA	1.0	15.64	0.53	6.72e-47	Eosinophil percentage of granulocytes;
BRCA	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg04455712	chr21:45112962	RRP1B	0.39	9.98	0.37	6.59e-22	Mean corpuscular volume;
BRCA	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg26384229	chr12:38710491	ALG10B	0.67	14.11	0.49	1.43e-39	Morning vs. evening chronotype;
BRCA	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg12386194	chr3:101231763	SENP7	0.45	9.53	0.35	3.27e-20	Colorectal cancer;
BRCA	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg27535305	chr1:53392650	SCP2	0.32	8.07	0.3	3.46e-15	Monocyte count;
BRCA	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.82	0.3	2.17e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-8.04	-0.3	4.53e-15	Total body bone mineral density;
BRCA	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg12373951	chr3:133503437	NA	0.46	10.75	0.39	6.63e-25	Iron status biomarkers;
BRCA	trans	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg25214090	chr10:38739885	LOC399744	0.54	12.25	0.44	3.83e-31	Corneal astigmatism;
BRCA	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.43	-0.32	2.27e-16	Menopause (age at onset);
BRCA	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.07	-0.37	3.2e-22	Morning vs. evening chronotype;
BRCA	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.24	0.34	3.5e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg19920283	chr7:105172520	RINT1	0.58	9.39	0.35	1e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg20703242	chr1:230279135	GALNT2	-0.47	-10.5	-0.38	6.86e-24	Coronary artery disease;
BRCA	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg26384229	chr12:38710491	ALG10B	0.59	13.52	0.47	8.1e-37	Morning vs. evening chronotype;
BRCA	cis	rs1371614	0.552	rs35538505	chr2:27126027	G/T	cg00617064	chr2:27272375	NA	0.31	7.83	0.3	1.97e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg24642439	chr20:33292090	TP53INP2	0.54	11.64	0.42	1.48e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs13136331	0.684	rs1903798	chr4:88720018	A/G	cg22416721	chr4:88570574	DMP1	0.39	8.39	0.32	3.09e-16	Sitting height ratio;
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07308232	chr7:1071921	C7orf50	-0.41	-8.39	-0.32	3.07e-16	Longevity;Endometriosis;
BRCA	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg05340658	chr4:99064831	C4orf37	0.45	10.41	0.38	1.45e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-9.62	-0.36	1.5e-20	Height;
BRCA	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg23711669	chr6:146136114	FBXO30	-0.72	-14.66	-0.5	3.73e-42	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg20587970	chr11:113659929	NA	-0.83	-15.85	-0.53	6.11e-48	Hip circumference adjusted for BMI;
BRCA	cis	rs7944584	0.610	rs2596407	chr11:47361838	A/G	cg20307385	chr11:47447363	PSMC3	-0.5	-11.11	-0.4	2.46e-26	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg20607798	chr8:58055168	NA	0.58	9.19	0.34	5.3e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10802521	chr3:52805072	NEK4	-0.31	-8.19	-0.31	1.44e-15	Bipolar disorder;
BRCA	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg01304814	chr3:48885189	PRKAR2A	0.57	7.96	0.3	7.88e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg27129171	chr3:47204927	SETD2	0.72	17.52	0.57	2.13e-56	Colorectal cancer;
BRCA	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-9.6	-0.36	1.76e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg18252515	chr7:66147081	NA	-1.06	-15.55	-0.52	1.79e-46	Diabetic kidney disease;
BRCA	cis	rs28830936	1.000	rs12440747	chr15:42036690	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.37	-11.36	-0.41	2.25e-27	Diastolic blood pressure;
BRCA	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg05343316	chr1:45956843	TESK2	0.7	14.3	0.49	1.84e-40	Platelet count;
BRCA	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.55	-13.43	-0.47	2.13e-36	Longevity;Endometriosis;
BRCA	cis	rs6920965	0.507	rs9401853	chr6:126215197	A/T	cg05901451	chr6:126070800	HEY2	-0.42	-10.34	-0.38	2.74e-23	High light scatter reticulocyte count;
BRCA	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg06784218	chr1:46089804	CCDC17	0.5	12.03	0.43	3.45e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.44	-0.32	2.09e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00166722	chr3:10149974	C3orf24	0.61	8.83	0.33	9.7e-18	Alzheimer's disease;
BRCA	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg08859206	chr1:53392774	SCP2	0.4	8.26	0.31	8.35e-16	Monocyte count;
BRCA	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg21798802	chr22:38057573	PDXP	0.49	13.2	0.46	2.34e-35	Fat distribution (HIV);
BRCA	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg07741184	chr6:167504864	NA	0.33	9.88	0.36	1.64e-21	Primary biliary cholangitis;
BRCA	cis	rs13064411	0.696	rs11921931	chr3:113015091	G/A	cg18753928	chr3:113234510	CCDC52	-0.44	-8.21	-0.31	1.21e-15	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.67	-0.32	3.43e-17	Total body bone mineral density;
BRCA	cis	rs8038465	0.622	rs2509	chr15:73859488	A/T	cg15420318	chr15:73925796	NPTN	-0.43	-9.3	-0.35	2.26e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg12935359	chr14:103987150	CKB	0.64	14.67	0.5	3.48e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs10789491	0.767	rs4660359	chr1:47190019	C/G	cg15501359	chr1:47185051	KIAA0494	0.64	15.75	0.53	1.81e-47	Response to hepatitis C treatment;
BRCA	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg12292205	chr6:26970375	C6orf41	-0.62	-10.03	-0.37	4.3e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9837602	0.938	rs1021341	chr3:99786289	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.5	9.81	0.36	2.89e-21	Breast cancer;
BRCA	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.15	0.31	1.88e-15	Breast cancer;
BRCA	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06022373	chr22:39101656	GTPBP1	-0.75	-18.9	-0.6	1.3e-63	Menopause (age at onset);
BRCA	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg15557168	chr22:42548783	NA	-0.33	-8.5	-0.32	1.35e-16	Schizophrenia;
BRCA	cis	rs73086581	1.000	rs11906274	chr20:3945536	G/A	cg02187196	chr20:3869020	PANK2	0.51	9.28	0.34	2.51e-19	Response to antidepressants in depression;
BRCA	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg13114125	chr14:105738426	BRF1	-0.53	-11.07	-0.4	3.42e-26	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06544989	chr22:39130855	UNC84B	0.41	9.33	0.35	1.75e-19	Menopause (age at onset);
BRCA	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg27279351	chr12:120934652	DYNLL1	0.56	13.01	0.46	1.74e-34	High light scatter reticulocyte count;
BRCA	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10802521	chr3:52805072	NEK4	-0.31	-8.07	-0.3	3.44e-15	Bipolar disorder;
BRCA	cis	rs2019216	1.000	rs2019216	chr17:21909650	C/T	cg22648282	chr17:21454238	C17orf51	-0.36	-8.19	-0.31	1.47e-15	Pelvic organ prolapse;
BRCA	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg06618935	chr21:46677482	NA	-0.37	-7.99	-0.3	6.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.91	0.45	4.89e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11764359	chr7:65958608	NA	-0.77	-17.87	-0.58	3.29e-58	Aortic root size;
BRCA	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.64	-0.5	4.62e-42	Chronic sinus infection;
BRCA	trans	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg25214090	chr10:38739885	LOC399744	0.51	10.99	0.4	7.33e-26	Corneal astigmatism;
BRCA	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg26384229	chr12:38710491	ALG10B	-0.48	-11.49	-0.41	6.5e-28	Morning vs. evening chronotype;
BRCA	cis	rs7586879	0.765	rs11683429	chr2:25120733	T/A	cg04586622	chr2:25135609	ADCY3	0.4	9.59	0.35	1.93e-20	Body mass index;
BRCA	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12618769	0.597	rs1847550	chr2:99052299	C/T	cg10123293	chr2:99228465	UNC50	0.4	8.17	0.31	1.71e-15	Bipolar disorder;
BRCA	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg24578937	chr1:2090814	PRKCZ	-0.34	-10.18	-0.37	1.22e-22	Height;
BRCA	cis	rs4949454	0.542	rs10914457	chr1:32094261	A/C	cg11573219	chr1:32083031	HCRTR1	-0.27	-8.09	-0.3	3e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs701145	0.585	rs6789213	chr3:153792795	T/C	cg17054900	chr3:154042577	DHX36	0.54	9.15	0.34	7.49e-19	Coronary artery disease;
BRCA	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg24642439	chr20:33292090	TP53INP2	-0.43	-8.7	-0.33	2.89e-17	Height;
BRCA	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.39	-8.33	-0.31	4.88e-16	Body mass index;
BRCA	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.67	-18.07	-0.58	3e-59	Longevity;Endometriosis;
BRCA	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg12311346	chr5:56204834	C5orf35	-0.78	-16.19	-0.54	1.22e-49	Initial pursuit acceleration;
BRCA	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg20607287	chr7:12443886	VWDE	-0.53	-8.23	-0.31	1.03e-15	Coronary artery disease;
BRCA	cis	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-8.76	-0.33	1.74e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24110177	chr3:50126178	RBM5	0.53	15.89	0.53	3.76e-48	Body mass index;
BRCA	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg20476274	chr7:133979776	SLC35B4	0.59	15.46	0.52	4.63e-46	Mean platelet volume;
BRCA	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg22633769	chr20:60982531	CABLES2	0.44	8.01	0.3	5.28e-15	Colorectal cancer;
BRCA	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-16.21	-0.54	9.72e-50	Mean platelet volume;
BRCA	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.29	0.44	2.59e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg04267008	chr7:1944627	MAD1L1	-0.6	-13.11	-0.46	6.01e-35	Bipolar disorder and schizophrenia;
BRCA	trans	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg26384229	chr12:38710491	ALG10B	-0.43	-10.31	-0.38	3.53e-23	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg21724239	chr8:58056113	NA	0.58	9.41	0.35	8.76e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs2294693	0.945	rs9369253	chr6:40986538	A/G	cg14418226	chr6:40996092	UNC5CL	0.45	8.0	0.3	6.06e-15	Gastric cancer;Non-cardia gastric cancer;
BRCA	trans	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg15371732	chr17:78194151	SLC26A11;SGSH	0.37	9.1	0.34	1.14e-18	Cystic fibrosis severity;
BRCA	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg25124228	chr12:125621409	AACS	0.5	11.46	0.41	9.13e-28	Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs12493885	0.769	rs11710560	chr3:153777276	A/G	cg17054900	chr3:154042577	DHX36	-0.5	-8.64	-0.32	4.44e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg22491629	chr6:157744540	C6orf35	-0.67	-12.04	-0.43	3.02e-30	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-17.94	-0.58	1.32e-58	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg05623727	chr3:50126028	RBM5	-0.49	-11.7	-0.42	8.58e-29	Body mass index;
BRCA	cis	rs4363385	0.818	rs684305	chr1:153006242	G/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.28	-0.34	2.62e-19	Inflammatory skin disease;
BRCA	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg08888203	chr3:10149979	C3orf24	0.61	13.03	0.46	1.34e-34	Alzheimer's disease;
BRCA	cis	rs9807989	0.507	rs1592458	chr2:103031749	A/T	cg03938978	chr2:103052716	IL18RAP	0.29	8.37	0.31	3.62e-16	Asthma;
BRCA	cis	rs55883249	1.000	rs62119429	chr2:9743585	G/C	cg23886495	chr2:9695866	ADAM17	0.55	7.89	0.3	1.27e-14	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
BRCA	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.62	-0.32	5.38e-17	Monocyte percentage of white cells;
BRCA	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg24675658	chr1:53192096	ZYG11B	-0.51	-11.25	-0.41	6.58e-27	Monocyte count;
BRCA	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg11502198	chr6:26597334	ABT1	0.56	12.0	0.43	4.68e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs4074536	0.536	rs6687777	chr1:116289707	T/C	cg21648376	chr1:116311395	CASQ2	-0.49	-8.71	-0.33	2.5e-17	QRS duration;
BRCA	cis	rs9816226	0.938	rs73052046	chr3:185832414	C/T	cg00760338	chr3:185826511	ETV5	-0.53	-8.83	-0.33	1.03e-17	Obesity;Body mass index;
BRCA	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-12.28	-0.44	2.95e-31	Tonsillectomy;
BRCA	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg25036284	chr2:26402008	FAM59B	0.67	11.0	0.4	7.11e-26	Gut microbiome composition (summer);
BRCA	cis	rs6545883	0.929	rs2121660	chr2:61653058	T/C	cg15711740	chr2:61764176	XPO1	0.53	12.78	0.45	1.79e-33	Tuberculosis;
BRCA	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg04944784	chr2:26401820	FAM59B	-0.95	-16.17	-0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.79	0.36	3.51e-21	Bladder cancer;
BRCA	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26314531	chr2:26401878	FAM59B	-0.69	-11.53	-0.41	4.68e-28	Gut microbiome composition (summer);
BRCA	cis	rs6840258	0.943	rs72667748	chr4:87927034	C/T	cg08197287	chr4:87952173	AFF1	-0.44	-8.71	-0.33	2.67e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg06618935	chr21:46677482	NA	-0.35	-8.0	-0.3	5.93e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg25427524	chr10:38739819	LOC399744	-0.54	-9.95	-0.37	9.15e-22	Obesity (extreme);
BRCA	cis	rs6088813	0.857	rs1886692	chr20:33986549	C/T	cg14752227	chr20:34000481	UQCC	-0.42	-8.83	-0.33	1.02e-17	Height;
BRCA	cis	rs6433895	1.000	rs55900432	chr2:182017904	G/A	cg00481216	chr2:181971175	NA	0.39	8.91	0.33	5.34e-18	Lymphocyte counts;
BRCA	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg04691961	chr3:161091175	C3orf57	-0.59	-14.13	-0.49	1.26e-39	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg03676636	chr4:99064102	C4orf37	0.2	7.92	0.3	1.03e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg18016565	chr1:150552671	MCL1	0.34	8.05	0.3	3.95e-15	Tonsillectomy;
BRCA	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg20607798	chr8:58055168	NA	0.46	8.27	0.31	7.96e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs1493916	0.837	rs2123333	chr18:31410730	G/A	cg27147174	chr7:100797783	AP1S1	-0.42	-8.52	-0.32	1.17e-16	Life satisfaction;
BRCA	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg11502198	chr6:26597334	ABT1	0.44	8.22	0.31	1.17e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg25036284	chr2:26402008	FAM59B	0.63	10.7	0.39	1.09e-24	Gut microbiome composition (summer);
BRCA	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	16.22	0.54	8.5e-50	Intelligence (multi-trait analysis);
BRCA	cis	rs9487051	0.768	rs351742	chr6:109527325	C/T	cg21918786	chr6:109611834	NA	0.34	9.16	0.34	7.03e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.51	12.03	0.43	3.34e-30	Eye color traits;
BRCA	cis	rs2108225	0.900	rs7805114	chr7:107450033	G/T	cg18560240	chr7:107437656	SLC26A3	0.53	11.31	0.41	3.66e-27	Ulcerative colitis;
BRCA	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.36	7.83	0.3	2.1e-14	Electroencephalogram traits;
BRCA	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg11645453	chr3:52864694	ITIH4	0.44	10.65	0.39	1.73e-24	Schizophrenia;
BRCA	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-10.95	-0.4	1.12e-25	Personality dimensions;
BRCA	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg08807892	chr2:162101083	NA	0.51	10.1	0.37	2.35e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9487051	0.698	rs9374081	chr6:109631782	A/G	cg21918786	chr6:109611834	NA	-0.36	-8.34	-0.31	4.74e-16	Reticulocyte fraction of red cells;
BRCA	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	13.61	0.47	3.3e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg24803719	chr17:45855879	NA	-0.33	-8.71	-0.33	2.57e-17	IgG glycosylation;
BRCA	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg15501526	chr10:2543763	NA	0.55	12.54	0.44	2.18e-32	Age-related hearing impairment;
BRCA	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg16405210	chr4:1374714	KIAA1530	-0.91	-19.55	-0.61	4.62e-67	Longevity;
BRCA	cis	rs2066819	1.000	rs78121408	chr12:56684798	C/T	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg22491629	chr6:157744540	C6orf35	-0.65	-11.66	-0.42	1.31e-28	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7512552	0.839	rs832622	chr1:150392830	A/G	cg15654264	chr1:150340011	RPRD2	0.37	8.16	0.31	1.76e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg05985134	chr18:33552581	C18orf21	0.65	12.29	0.44	2.63e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg26898376	chr11:64110657	CCDC88B	0.36	7.96	0.3	8.02e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg20290983	chr6:43655470	MRPS18A	1.1	38.39	0.84	4.28e-168	IgG glycosylation;
BRCA	cis	rs7523273	0.927	rs2796275	chr1:207950490	C/T	cg22525895	chr1:207977042	MIR29B2	0.47	11.3	0.41	3.88e-27	Schizophrenia;
BRCA	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.14	-44.45	-0.87	1.14e-197	Myeloid white cell count;
BRCA	trans	rs1422110	0.616	rs6452688	chr5:85445038	C/T	cg01787110	chr1:109008453	NBPF6	0.41	8.7	0.33	2.9e-17	Attention function in attention deficit hyperactive disorder;
BRCA	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg23231163	chr10:75533350	FUT11	-0.33	-8.78	-0.33	1.47e-17	Inflammatory bowel disease;
BRCA	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg22535103	chr8:58192502	C8orf71	-0.46	-9.05	-0.34	1.71e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg08501292	chr6:25962987	TRIM38	0.57	8.02	0.3	5.07e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs16958440	0.581	rs11082564	chr18:44659149	C/G	cg17192377	chr18:44677553	HDHD2	0.49	8.3	0.31	6.37e-16	Sitting height ratio;
BRCA	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg00717180	chr2:96193071	NA	-0.37	-10.28	-0.38	4.74e-23	HDL cholesterol;
BRCA	cis	rs72781680	0.821	rs12623521	chr2:24181670	C/T	cg08917208	chr2:24149416	ATAD2B	0.62	10.39	0.38	1.76e-23	Lymphocyte counts;
BRCA	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	12.35	0.44	1.49e-31	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.41	-0.32	2.7e-16	Height;
BRCA	cis	rs858239	1.000	rs166663	chr7:23316742	A/C	cg23682824	chr7:23144976	KLHL7	0.35	8.83	0.33	9.73e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg26874164	chr19:58962979	ZNF324B	0.44	9.3	0.35	2.11e-19	Uric acid clearance;
BRCA	trans	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17712092	chr4:129076599	LARP1B	0.56	13.53	0.47	7.72e-37	Eosinophil percentage of white cells;
BRCA	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg18225595	chr11:63971243	STIP1	0.51	9.4	0.35	9.82e-20	Mean platelet volume;
BRCA	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.78	-0.58	9.4e-58	Chronic sinus infection;
BRCA	trans	rs57046232	0.552	rs2009127	chr20:6341680	C/T	cg21095983	chr6:86352623	SYNCRIP	0.38	7.97	0.3	7.18e-15	Colorectal cancer;
BRCA	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg10223061	chr2:219282414	VIL1	0.29	8.47	0.32	1.66e-16	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7927771	0.524	rs7111576	chr11:47787445	G/A	cg20307385	chr11:47447363	PSMC3	0.42	9.56	0.35	2.48e-20	Subjective well-being;
BRCA	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg03146154	chr1:46216737	IPP	-0.49	-10.78	-0.39	5.08e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4664304	0.620	rs12692568	chr2:160718440	T/C	cg01092293	chr2:160761427	LY75	0.35	8.41	0.32	2.66e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg11764359	chr7:65958608	NA	-0.67	-14.9	-0.51	2.68e-43	Aortic root size;
BRCA	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00166722	chr3:10149974	C3orf24	-0.68	-13.63	-0.47	2.47e-37	Alzheimer's disease;
BRCA	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg27446573	chr6:127587934	RNF146	0.6	12.9	0.45	5.33e-34	Breast cancer;
BRCA	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg13010199	chr12:38710504	ALG10B	0.4	8.34	0.31	4.52e-16	Bladder cancer;
BRCA	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.79	-0.42	3.58e-29	Bipolar disorder;
BRCA	cis	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.24	-0.38	6.79e-23	Morning vs. evening chronotype;
BRCA	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20916646	chr4:852691	GAK	0.44	10.33	0.38	3.14e-23	Sjögren's syndrome;
BRCA	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg02297831	chr4:17616191	MED28	0.37	8.71	0.33	2.68e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg02493740	chr2:85810744	VAMP5	0.63	14.32	0.49	1.57e-40	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs2880765	0.835	rs11638498	chr15:86023018	T/C	cg10818794	chr15:86012489	AKAP13	-0.3	-8.52	-0.32	1.14e-16	Coronary artery disease;
BRCA	cis	rs939658	0.776	rs869672	chr15:79430860	G/A	cg17916960	chr15:79447300	NA	-0.46	-11.41	-0.41	1.45e-27	Refractive error;
BRCA	trans	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg25214090	chr10:38739885	LOC399744	0.56	12.92	0.46	4.23e-34	Corneal astigmatism;
BRCA	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg09307838	chr4:120376055	NA	-0.49	-9.27	-0.34	2.75e-19	Corneal astigmatism;
BRCA	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs9549260	0.755	rs9549236	chr13:41147158	C/T	cg21288729	chr13:41239152	FOXO1	-0.64	-13.49	-0.47	1.16e-36	Red blood cell count;
BRCA	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.34	-0.38	2.72e-23	Schizophrenia;
BRCA	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg04842962	chr6:43655489	MRPS18A	0.97	22.27	0.66	9.55e-82	IgG glycosylation;
BRCA	trans	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg06521331	chr12:34319734	NA	-0.47	-8.7	-0.33	2.8e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.35	0.49	1.13e-40	Motion sickness;
BRCA	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.27	-0.41	5.49e-27	Schizophrenia;
BRCA	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg16230307	chr14:35515116	FAM177A1	0.75	14.98	0.51	1.08e-43	Psoriasis;
BRCA	cis	rs7799006	1.000	rs7810970	chr7:2276385	A/G	cg08027265	chr7:2291960	NA	-0.41	-10.51	-0.38	6.36e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.34	0.49	1.23e-40	Personality dimensions;
BRCA	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg01324343	chr3:183735012	ABCC5	-0.43	-9.73	-0.36	5.9e-21	Anterior chamber depth;
BRCA	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-12.6	-0.45	1.11e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.4	-9.32	-0.35	1.88e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg00106254	chr7:1943704	MAD1L1	-0.38	-9.48	-0.35	5.07e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg08470875	chr2:26401718	FAM59B	-0.63	-9.5	-0.35	3.99e-20	Gut microbiome composition (summer);
BRCA	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.71	0.39	9.67e-25	Aortic root size;
BRCA	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-20.41	-0.63	1.2e-71	Gut microbiome composition (summer);
BRCA	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg24069376	chr3:38537580	EXOG	0.41	11.79	0.42	3.67e-29	Electrocardiographic conduction measures;
BRCA	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg09307838	chr4:120376055	NA	0.74	16.17	0.54	1.53e-49	Corneal astigmatism;
BRCA	cis	rs12493885	0.818	rs10935971	chr3:153773945	C/T	cg17054900	chr3:154042577	DHX36	-0.5	-8.65	-0.32	4.07e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs243505	0.898	rs243532	chr7:148412371	A/G	cg09806900	chr7:148480153	CUL1	-0.42	-8.46	-0.32	1.85e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6714710	0.603	rs1875699	chr2:98580724	G/T	cg26665480	chr2:98280029	ACTR1B	0.57	13.43	0.47	2.09e-36	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs11971779	0.680	rs3924296	chr7:139041927	T/C	cg07862535	chr7:139043722	LUC7L2	0.38	10.37	0.38	2.13e-23	Diisocyanate-induced asthma;
BRCA	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg04369109	chr6:150039330	LATS1	-0.39	-9.07	-0.34	1.49e-18	Lung cancer;
BRCA	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg00825309	chr19:58991885	ZNF446	-0.58	-12.62	-0.45	8.95e-33	Uric acid clearance;
BRCA	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg10523679	chr1:76189770	ACADM	-0.62	-11.38	-0.41	1.97e-27	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg06623918	chr6:96969491	KIAA0776	0.9	25.97	0.72	4.85e-102	Headache;
BRCA	cis	rs6901250	0.807	rs1606366	chr6:117132438	C/G	cg12892004	chr6:117198278	RFX6	0.49	11.44	0.41	1.03e-27	C-reactive protein levels;
BRCA	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg10876282	chr6:28092338	ZSCAN16	0.41	7.98	0.3	7.03e-15	Parkinson's disease;
BRCA	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg21535247	chr6:8435926	SLC35B3	0.4	9.14	0.34	8.36e-19	Motion sickness;
BRCA	trans	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg23950597	chr19:37808831	NA	-0.62	-11.45	-0.41	9.99e-28	Coronary artery calcification;
BRCA	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	18.39	0.59	6.38e-61	Alzheimer's disease;
BRCA	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg04727924	chr7:799746	HEATR2	-0.55	-10.79	-0.39	4.91e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.64	0.55	6.17e-52	Colorectal cancer;
BRCA	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg21770322	chr7:97807741	LMTK2	0.58	16.92	0.56	2.4e-53	Breast cancer;
BRCA	cis	rs367943	1.000	rs348948	chr5:112822452	A/C	cg12552261	chr5:112820674	MCC	-0.55	-12.09	-0.43	1.98e-30	Type 2 diabetes;
BRCA	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg13010199	chr12:38710504	ALG10B	0.5	10.16	0.37	1.34e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-11.95	-0.43	7.86e-30	Bone mineral density;
BRCA	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg04944784	chr2:26401820	FAM59B	0.6	9.75	0.36	4.87e-21	Gut microbiome composition (summer);
BRCA	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg19622623	chr12:86230825	RASSF9	-0.33	-9.38	-0.35	1.14e-19	Major depressive disorder;
BRCA	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg13010199	chr12:38710504	ALG10B	0.47	9.03	0.34	2.04e-18	Morning vs. evening chronotype;
BRCA	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg11764359	chr7:65958608	NA	-0.5	-10.71	-0.39	1.03e-24	Aortic root size;
BRCA	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.95	0.62	3.47e-69	Platelet count;
BRCA	cis	rs4363385	0.818	rs2070963	chr1:153004004	G/A	cg24667326	chr1:152973720	SPRR3	-0.33	-9.17	-0.34	6.35e-19	Inflammatory skin disease;
BRCA	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg06636001	chr8:8085503	FLJ10661	0.65	15.22	0.52	7.18e-45	Mood instability;
BRCA	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.59	8.12	0.31	2.39e-15	Diabetic retinopathy;
BRCA	cis	rs2742234	0.541	rs10899786	chr10:43744583	G/A	cg15436174	chr10:43711423	RASGEF1A	0.52	10.11	0.37	2.2e-22	Hirschsprung disease;
BRCA	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg14500267	chr11:67383377	NA	-0.42	-9.34	-0.35	1.59e-19	Mean corpuscular volume;
BRCA	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-15.95	-0.53	1.8e-48	Alzheimer's disease (late onset);
BRCA	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.05	0.34	1.7e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg05340658	chr4:99064831	C4orf37	0.57	10.94	0.4	1.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg27478167	chr7:817139	HEATR2	-0.42	-9.01	-0.34	2.28e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7646881	1.000	rs59313096	chr3:158452242	G/C	cg19483011	chr3:158453295	NA	-0.5	-9.37	-0.35	1.22e-19	Tetralogy of Fallot;
BRCA	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg26384229	chr12:38710491	ALG10B	-0.5	-11.07	-0.4	3.61e-26	Morning vs. evening chronotype;
BRCA	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg13902645	chr11:5959945	NA	-0.48	-10.18	-0.37	1.21e-22	DNA methylation (variation);
BRCA	trans	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.26	0.31	8.38e-16	Corneal astigmatism;
BRCA	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg13944838	chr5:179740914	GFPT2	-0.71	-15.06	-0.51	4.28e-44	Height;
BRCA	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-21.47	-0.65	2.24e-77	Height;
BRCA	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg27661571	chr11:113659931	NA	-0.73	-11.22	-0.41	8.26e-27	Hip circumference adjusted for BMI;
BRCA	trans	rs10411161	0.702	rs11878580	chr19:52388485	C/T	cg22319618	chr22:45562946	NUP50	-0.42	-8.02	-0.3	4.89e-15	Breast cancer;
BRCA	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg10664184	chr19:17420304	DDA1	0.36	10.24	0.38	6.85e-23	Systemic lupus erythematosus;
BRCA	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg26373071	chr5:1325741	CLPTM1L	0.42	9.9	0.36	1.35e-21	Lung cancer;
BRCA	cis	rs11874712	0.932	rs8092674	chr18:43665982	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.18	0.31	1.57e-15	Migraine - clinic-based;
BRCA	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg24006582	chr15:45444508	DUOX1	-0.55	-11.35	-0.41	2.48e-27	Uric acid levels;
BRCA	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg06885757	chr1:42089581	HIVEP3	0.42	13.52	0.47	8.16e-37	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.54e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg09654669	chr8:57350985	NA	-0.38	-8.34	-0.31	4.55e-16	Obesity-related traits;
BRCA	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg11833968	chr6:79620685	NA	-0.43	-9.7	-0.36	7.32e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs483180	0.512	rs594400	chr1:120214275	G/T	cg19096424	chr1:120255104	PHGDH	-0.43	-9.61	-0.36	1.66e-20	Macular telangiectasia type 2;
BRCA	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-8.93	-0.33	4.35e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs3857536	0.740	rs9354391	chr6:66890183	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.46	9.37	0.35	1.21e-19	Blood trace element (Cu levels);
BRCA	cis	rs706334	0.905	rs706333	chr4:140517700	A/G	cg22540532	chr4:140518177	NA	-0.46	-10.33	-0.38	3.03e-23	LDL peak particle diameter (total fat intake interaction);
BRCA	cis	rs7254114	0.618	rs7250652	chr19:11302606	A/G	cg02815516	chr19:11306319	KANK2	-0.34	-9.97	-0.37	7.49e-22	Immature fraction of reticulocytes;
BRCA	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg00106254	chr7:1943704	MAD1L1	-0.41	-10.02	-0.37	4.7e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg09904177	chr6:26538194	HMGN4	0.47	14.7	0.5	2.29e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg07884673	chr3:53033167	SFMBT1	0.87	10.25	0.38	6.37e-23	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.27	9.01	0.34	2.35e-18	Systemic lupus erythematosus;
BRCA	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg21475434	chr5:93447410	FAM172A	0.68	8.9	0.33	5.7e-18	Diabetic retinopathy;
BRCA	trans	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg26043149	chr18:55253948	FECH	0.4	8.53	0.32	1.07e-16	Bone mineral density;
BRCA	cis	rs10267417	0.657	rs12668709	chr7:19858946	T/G	cg05791153	chr7:19748676	TWISTNB	0.52	9.83	0.36	2.55e-21	Night sleep phenotypes;
BRCA	cis	rs2019216	0.542	rs3829569	chr17:21909222	T/C	cg22648282	chr17:21454238	C17orf51	-0.41	-9.44	-0.35	6.98e-20	Pelvic organ prolapse;
BRCA	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg14926445	chr8:58193284	C8orf71	-0.47	-8.93	-0.33	4.61e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11764359	chr7:65958608	NA	-0.77	-17.56	-0.57	1.3e-56	Aortic root size;
BRCA	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg23711669	chr6:146136114	FBXO30	0.64	15.0	0.51	8.96e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg26395211	chr5:140044315	WDR55	-0.37	-8.41	-0.32	2.61e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.34	-10.78	-0.39	5.2e-25	Bipolar disorder;
BRCA	cis	rs7264396	1.000	rs224435	chr20:34154087	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-9.39	-0.35	1e-19	Total cholesterol levels;
BRCA	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg18132916	chr6:79620363	NA	-0.47	-10.66	-0.39	1.6e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs2505998	0.833	rs2742244	chr10:43603592	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.39	-7.98	-0.3	6.97e-15	Hirschsprung disease;
BRCA	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg13010199	chr12:38710504	ALG10B	0.51	9.95	0.37	8.8e-22	Bladder cancer;
BRCA	cis	rs10499694	0.933	rs998850	chr7:50607388	G/C	cg18232548	chr7:50535776	DDC	-0.39	-9.26	-0.34	2.95e-19	Body mass index;
BRCA	cis	rs4988958	0.565	rs6760621	chr2:102999952	T/C	cg03938978	chr2:103052716	IL18RAP	0.29	8.41	0.32	2.59e-16	Asthma (childhood onset);
BRCA	cis	rs9462027	0.539	rs9469883	chr6:34758627	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.88	-0.3	1.42e-14	Systemic lupus erythematosus;
BRCA	cis	rs7833986	0.534	rs17814089	chr8:56965563	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.71	-13.56	-0.47	5.67e-37	Height;
BRCA	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg12311346	chr5:56204834	C5orf35	-0.48	-9.93	-0.37	1.04e-21	Coronary artery disease;
BRCA	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.39	8.33	0.31	4.82e-16	Multiple sclerosis;
BRCA	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.04	0.3	4.33e-15	Total cholesterol levels;
BRCA	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg17372223	chr3:52568218	NT5DC2	0.38	9.21	0.34	4.7e-19	Hemoglobin concentration;
BRCA	trans	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.25	0.38	6.12e-23	Mean corpuscular volume;
BRCA	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg08923669	chr16:420230	MRPL28	-0.49	-11.71	-0.42	7.97e-29	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18876405	chr7:65276391	NA	0.51	11.55	0.42	3.58e-28	Aortic root size;
BRCA	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg13010199	chr12:38710504	ALG10B	0.47	9.15	0.34	7.74e-19	Morning vs. evening chronotype;
BRCA	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg01420254	chr6:26195488	NA	0.55	8.56	0.32	8.61e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs61990749	0.597	rs1978416	chr14:78227901	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.44	7.97	0.3	7.44e-15	Fibroblast growth factor basic levels;
BRCA	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg08859206	chr1:53392774	SCP2	-0.41	-8.75	-0.33	1.96e-17	Monocyte count;
BRCA	trans	rs2797160	1.000	rs1777222	chr6:126021030	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.36	8.25	0.31	9.21e-16	Endometrial cancer;
BRCA	cis	rs1829883	0.835	rs2511961	chr5:98878673	A/G	cg08333243	chr5:99726346	NA	0.34	8.16	0.31	1.79e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg06766960	chr11:133703094	NA	-0.61	-12.91	-0.45	4.99e-34	Childhood ear infection;
BRCA	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg16606324	chr3:10149918	C3orf24	0.48	9.47	0.35	5.5e-20	Alzheimer's disease;
BRCA	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg16141378	chr3:129829833	LOC729375	-0.33	-8.4	-0.32	2.98e-16	Neuroticism;
BRCA	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg08885076	chr2:99613938	TSGA10	-0.6	-13.45	-0.47	1.74e-36	Chronic sinus infection;
BRCA	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18876405	chr7:65276391	NA	0.55	13.2	0.46	2.49e-35	Aortic root size;
BRCA	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.54	0.44	2.18e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.33	-0.38	3.1e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg07308232	chr7:1071921	C7orf50	-0.47	-10.0	-0.37	5.64e-22	Longevity;Endometriosis;
BRCA	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.86	0.39	2.42e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg12751644	chr20:60527061	NA	-0.33	-7.96	-0.3	7.71e-15	Body mass index;
BRCA	trans	rs7980799	0.649	rs7972688	chr12:33653477	T/C	cg26384229	chr12:38710491	ALG10B	-0.47	-10.17	-0.37	1.26e-22	Heart rate;Heart rate variability traits (RMSSD);
BRCA	trans	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-12.57	-0.45	1.56e-32	Brugada syndrome;
BRCA	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg21132104	chr15:45694354	SPATA5L1	0.74	16.37	0.54	1.48e-50	Homoarginine levels;
BRCA	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg26031613	chr14:104095156	KLC1	-0.43	-8.56	-0.32	8.44e-17	Schizophrenia;
BRCA	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg17470723	chr8:74884337	TCEB1	0.41	8.87	0.33	7.36e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12618769	0.652	rs3769701	chr2:99195111	A/C	cg10123293	chr2:99228465	UNC50	0.43	8.53	0.32	1.05e-16	Bipolar disorder;
BRCA	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg05714579	chr10:131428358	MGMT	-0.81	-22.14	-0.66	4.71e-81	Response to temozolomide;
BRCA	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg03146154	chr1:46216737	IPP	0.54	12.03	0.43	3.34e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg03146154	chr1:46216737	IPP	0.47	10.26	0.38	5.77e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs747782	0.528	rs624348	chr11:48400795	G/A	cg15704280	chr7:45808275	SEPT13	-0.55	-8.36	-0.31	3.98e-16	Intraocular pressure;
BRCA	cis	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg07169764	chr2:136633963	MCM6	1.06	23.41	0.68	5.24e-88	Corneal structure;
BRCA	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg21132104	chr15:45694354	SPATA5L1	0.7	15.45	0.52	5.52e-46	Homoarginine levels;
BRCA	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.83	11.91	0.43	1.14e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.23	-0.54	7.7e-50	Alzheimer's disease (late onset);
BRCA	trans	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg16011800	chr17:1958478	HIC1	-0.55	-8.77	-0.33	1.68e-17	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg25358565	chr5:93447407	FAM172A	-0.52	-9.69	-0.36	7.93e-21	Diabetic retinopathy;
BRCA	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg05896524	chr21:47604654	C21orf56	0.5	9.82	0.36	2.75e-21	Testicular germ cell tumor;
BRCA	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg25358565	chr5:93447407	FAM172A	1.21	18.93	0.6	8.69e-64	Diabetic retinopathy;
BRCA	cis	rs9394152	0.810	rs9380364	chr6:33471721	T/C	cg13560919	chr6:33536144	NA	0.62	12.76	0.45	2.26e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg18252515	chr7:66147081	NA	-0.82	-11.87	-0.42	1.69e-29	Diabetic kidney disease;
BRCA	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg07395648	chr5:131743802	NA	-0.37	-9.03	-0.34	1.95e-18	Blood metabolite levels;
BRCA	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg15448220	chr1:150897856	SETDB1	0.35	7.82	0.3	2.16e-14	Melanoma;
BRCA	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg01483505	chr11:975446	AP2A2	0.35	9.22	0.34	4.3e-19	Alzheimer's disease (late onset);
BRCA	cis	rs733592	1.000	rs1859440	chr12:48427329	T/C	cg24011408	chr12:48396354	COL2A1	-0.44	-9.37	-0.35	1.22e-19	Plateletcrit;
BRCA	cis	rs733592	0.507	rs10875739	chr12:48480919	C/T	cg24011408	chr12:48396354	COL2A1	0.44	9.78	0.36	3.85e-21	Plateletcrit;
BRCA	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	18.28	0.59	2.27e-60	Platelet count;
BRCA	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg15103426	chr22:29168792	CCDC117	0.52	12.03	0.43	3.59e-30	Lymphocyte counts;
BRCA	trans	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.73	-0.36	6.1e-21	Morning vs. evening chronotype;
BRCA	trans	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg19862616	chr7:65841803	NCRNA00174	0.81	25.65	0.71	2.55e-100	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs11585357	0.947	rs11585119	chr1:17605792	C/A	cg19159961	chr1:17633534	PADI4	0.57	8.9	0.33	5.53e-18	Hair shape;
BRCA	cis	rs7301016	0.846	rs11174576	chr12:63026436	C/T	cg11441379	chr12:63026424	NA	0.49	9.06	0.34	1.59e-18	IgG glycosylation;
BRCA	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg08807101	chr21:30365312	RNF160	-0.58	-14.35	-0.49	1.13e-40	Dental caries;
BRCA	cis	rs2559856	0.903	rs10128996	chr12:102081498	G/A	cg12213457	chr12:102090980	CHPT1	-0.37	-8.05	-0.3	4.16e-15	Blood protein levels;
BRCA	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg21535247	chr6:8435926	SLC35B3	0.4	9.0	0.34	2.61e-18	Motion sickness;
BRCA	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg07080220	chr10:102295463	HIF1AN	0.62	14.54	0.5	1.42e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.68	15.81	0.53	9.48e-48	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg22455342	chr2:225449267	CUL3	0.33	8.9	0.33	5.92e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg08742575	chr21:47604166	C21orf56	-0.4	-7.82	-0.3	2.2e-14	Testicular germ cell tumor;
BRCA	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg12310025	chr6:25882481	NA	-0.54	-11.82	-0.42	2.76e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs2882667	0.690	rs288030	chr5:138216283	A/G	cg04439458	chr5:138467593	SIL1	-0.31	-7.99	-0.3	6.43e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.53	7.94	0.3	9.32e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg08601574	chr20:25228251	PYGB	0.36	8.65	0.32	4.06e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg10057126	chr4:77819792	ANKRD56	0.65	14.81	0.51	6.83e-43	Emphysema distribution in smoking;
BRCA	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg04025307	chr7:1156635	C7orf50	0.4	9.8	0.36	3.09e-21	Longevity;Endometriosis;
BRCA	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg11584989	chr19:19387371	SF4	0.66	14.37	0.49	9.05e-41	Bipolar disorder;
BRCA	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg00701064	chr4:6280414	WFS1	0.68	17.68	0.57	3.11e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg13397359	chr6:42928475	GNMT	-0.61	-11.44	-0.41	1.07e-27	Blood protein levels;
BRCA	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.58	-0.32	7.19e-17	Total body bone mineral density;
BRCA	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg08213375	chr14:104286397	PPP1R13B	0.41	8.85	0.33	8.76e-18	Reticulocyte count;
BRCA	cis	rs10754283	0.967	rs7546518	chr1:90109956	C/T	cg21401794	chr1:90099060	LRRC8C	0.5	11.76	0.42	4.96e-29	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24531977	chr5:56204891	C5orf35	1.07	22.49	0.66	5.77e-83	Initial pursuit acceleration;
BRCA	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.38	0.49	7.88e-41	Motion sickness;
BRCA	cis	rs3099143	1.000	rs3099134	chr15:77133168	T/G	cg21673338	chr15:77095150	SCAPER	-0.52	-9.23	-0.34	3.96e-19	Recalcitrant atopic dermatitis;
BRCA	cis	rs701145	0.938	rs355747	chr3:153962973	T/C	cg17054900	chr3:154042577	DHX36	0.67	11.71	0.42	8.15e-29	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-12.19	-0.43	6.83e-31	Alzheimer's disease;
BRCA	cis	rs7555523	0.887	rs10918274	chr1:165714416	T/C	cg24409356	chr1:165738333	TMCO1	0.51	8.21	0.31	1.23e-15	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg11814155	chr7:99998594	ZCWPW1	0.51	9.1	0.34	1.16e-18	Platelet count;
BRCA	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.12	0.67	2.18e-86	Chronic sinus infection;
BRCA	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg15448220	chr1:150897856	SETDB1	0.35	7.97	0.3	7.45e-15	Melanoma;
BRCA	cis	rs926392	0.572	rs6129157	chr20:37672247	G/T	cg16355469	chr20:37678765	NA	0.49	11.09	0.4	2.96e-26	Dialysis-related mortality;
BRCA	trans	rs783540	1.000	rs803688	chr15:83216793	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.26	-8.0	-0.3	5.84e-15	Schizophrenia;
BRCA	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg26384229	chr12:38710491	ALG10B	0.67	14.05	0.49	2.98e-39	Morning vs. evening chronotype;
BRCA	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg09904177	chr6:26538194	HMGN4	0.43	11.96	0.43	6.91e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg13550731	chr2:172543902	DYNC1I2	0.91	30.25	0.77	1.86e-125	Schizophrenia;
BRCA	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.37	10.45	0.38	1.02e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg27129171	chr3:47204927	SETD2	-0.69	-16.62	-0.55	7.83e-52	Colorectal cancer;
BRCA	trans	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg13565492	chr6:43139072	SRF	-0.84	-12.9	-0.45	5.51e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg21573476	chr21:45109991	RRP1B	-0.37	-9.32	-0.35	1.85e-19	Mean corpuscular volume;
BRCA	cis	rs708547	0.647	rs1713982	chr4:57881715	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.37	9.76	0.36	4.61e-21	Response to bleomycin (chromatid breaks);
BRCA	trans	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg26384229	chr12:38710491	ALG10B	0.44	9.33	0.35	1.66e-19	Morning vs. evening chronotype;
BRCA	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	10.88	0.4	2.05e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-8.43	-0.32	2.33e-16	Total body bone mineral density;
BRCA	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg12751644	chr20:60527061	NA	-0.33	-7.95	-0.3	8.44e-15	Body mass index;
BRCA	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg11584989	chr19:19387371	SF4	0.33	8.26	0.31	8.6e-16	Tonsillectomy;
BRCA	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.44	-0.32	2.15e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6005807	0.719	rs9625514	chr22:29022188	T/C	cg12565055	chr22:29076175	TTC28	0.49	9.36	0.35	1.35e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg04362960	chr10:104952993	NT5C2	-0.42	-10.11	-0.37	2.08e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs4363385	0.720	rs1611754	chr1:152956415	A/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.72	-0.36	6.16e-21	Inflammatory skin disease;
BRCA	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg20790798	chr5:1857306	NA	-0.37	-8.6	-0.32	5.93e-17	Cardiovascular disease risk factors;
BRCA	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.55	11.18	0.4	1.29e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.52	0.5	1.78e-41	Motion sickness;
BRCA	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg04586622	chr2:25135609	ADCY3	0.42	10.78	0.39	5.3e-25	Body mass index in non-asthmatics;
BRCA	cis	rs2422052	0.639	rs1433531	chr2:118646201	A/C	cg22545206	chr2:118617499	NA	0.38	9.4	0.35	9.57e-20	Mosquito bite size;
BRCA	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg06671706	chr8:8559999	CLDN23	0.46	8.81	0.33	1.16e-17	Obesity-related traits;
BRCA	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg11814155	chr7:99998594	ZCWPW1	0.57	9.55	0.35	2.63e-20	Platelet count;
BRCA	trans	rs1997103	1.000	rs6593237	chr7:55411015	T/C	cg20935933	chr6:143382018	AIG1	0.59	11.39	0.41	1.76e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg18357645	chr12:58087776	OS9	-0.34	-8.26	-0.31	8.59e-16	Multiple sclerosis;
BRCA	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg14664628	chr15:75095509	CSK	0.4	9.03	0.34	2.03e-18	Systemic lupus erythematosus;
BRCA	cis	rs250677	0.522	rs17109208	chr5:148378475	G/A	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.39	-0.32	3.09e-16	Breast cancer;
BRCA	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg14664628	chr15:75095509	CSK	-0.93	-27.26	-0.73	3.77e-109	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg18305652	chr10:134549665	INPP5A	-0.47	-10.99	-0.4	7.22e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg16339924	chr4:17578868	LAP3	0.58	14.07	0.49	2.4e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs78049276	0.736	rs72957606	chr4:148400011	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.43	-7.9	-0.3	1.26e-14	Pulse pressure;
BRCA	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg00024416	chr22:24240387	NA	0.47	11.21	0.41	9.45e-27	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg14558114	chr2:88469736	THNSL2	-0.4	-8.75	-0.33	1.96e-17	Response to metformin (IC50);
BRCA	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg22491629	chr6:157744540	C6orf35	-0.64	-12.25	-0.44	3.78e-31	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg04756594	chr16:24857601	SLC5A11	0.54	12.07	0.43	2.34e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs965469	1.000	rs6051809	chr20:3352551	A/C	cg25506879	chr20:3388711	C20orf194	-0.53	-10.54	-0.38	4.61e-24	IFN-related cytopenia;
BRCA	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg13010199	chr12:38710504	ALG10B	-0.38	-8.7	-0.33	2.89e-17	Morning vs. evening chronotype;
BRCA	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg08885076	chr2:99613938	TSGA10	-0.44	-10.31	-0.38	3.66e-23	Chronic sinus infection;
BRCA	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.75	-0.33	1.96e-17	Colorectal cancer;
BRCA	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.27	-0.34	2.88e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7737355	0.853	rs26005	chr5:130988029	A/G	cg06307176	chr5:131281290	NA	0.56	12.09	0.43	1.93e-30	Life satisfaction;
BRCA	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg17724175	chr1:150552817	MCL1	0.25	7.98	0.3	6.97e-15	Melanoma;
BRCA	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg06970220	chr1:156163860	SLC25A44	0.39	9.45	0.35	6.4e-20	Testicular germ cell tumor;
BRCA	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	10.06	0.37	3.49e-22	Lung cancer in ever smokers;
BRCA	trans	rs7939886	0.920	rs17150096	chr11:55902996	C/T	cg15704280	chr7:45808275	SEPT13	0.63	7.84	0.3	1.88e-14	Myopia (pathological);
BRCA	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg20203395	chr5:56204925	C5orf35	-0.49	-10.01	-0.37	5.06e-22	Initial pursuit acceleration;
BRCA	cis	rs7011049	1.000	rs72643579	chr8:53846705	C/A	cg26025543	chr8:53854495	NA	0.55	9.57	0.35	2.31e-20	Systolic blood pressure;
BRCA	cis	rs6594499	0.872	rs7723819	chr5:110427347	A/G	cg04022379	chr5:110408740	TSLP	-0.35	-7.99	-0.3	6.3e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg25482853	chr8:67687455	SGK3	1.05	16.53	0.55	2.24e-51	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.33	0.31	4.94e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08219700	chr8:58056026	NA	-0.54	-8.8	-0.33	1.23e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg23978390	chr7:1156363	C7orf50	0.4	9.38	0.35	1.14e-19	Longevity;Endometriosis;
BRCA	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	3.94e-15	Alzheimer's disease (late onset);
BRCA	trans	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	14.75	0.5	1.34e-42	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg20607798	chr8:58055168	NA	0.47	8.17	0.31	1.61e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7833986	0.534	rs2667972	chr8:56906661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	12.57	0.45	1.6e-32	Height;
BRCA	cis	rs12949688	1.000	rs886926	chr17:55817413	A/G	cg12582317	chr17:55822272	NA	-0.33	-7.94	-0.3	9.46e-15	Schizophrenia;
BRCA	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18876405	chr7:65276391	NA	-0.57	-13.62	-0.47	3e-37	Aortic root size;
BRCA	cis	rs858239	0.570	rs10271613	chr7:23162586	G/A	cg23682824	chr7:23144976	KLHL7	0.45	12.18	0.43	7.99e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs9788721	0.836	rs55983731	chr15:78735269	C/T	cg18825076	chr15:78729989	IREB2	-0.4	-8.34	-0.31	4.52e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg11584989	chr19:19387371	SF4	-0.56	-12.43	-0.44	6.14e-32	Bipolar disorder;
BRCA	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg15145296	chr3:125709740	NA	0.52	8.25	0.31	9.29e-16	Blood pressure (smoking interaction);
BRCA	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg04117972	chr1:227635322	NA	0.49	8.9	0.33	5.78e-18	Major depressive disorder;
BRCA	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06108461	chr20:60628389	TAF4	0.9	16.87	0.56	4.34e-53	Body mass index;
BRCA	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg09324608	chr17:30823087	MYO1D	-0.45	-9.8	-0.36	3.35e-21	Schizophrenia;
BRCA	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	9.69	0.36	8.02e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.6	-12.71	-0.45	3.83e-33	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.48e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg12826209	chr6:26865740	GUSBL1	0.73	7.8	0.3	2.44e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.35	0.38	2.69e-23	Motion sickness;
BRCA	trans	rs3960554	0.808	rs78478514	chr7:75655896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.59	12.34	0.44	1.54e-31	Eotaxin levels;
BRCA	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg18404041	chr3:52824283	ITIH1	-0.35	-9.31	-0.35	2.02e-19	Schizophrenia;
BRCA	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg09904177	chr6:26538194	HMGN4	0.57	18.49	0.59	1.8e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs2559856	1.000	rs2251187	chr12:102081889	G/A	cg12213457	chr12:102090980	CHPT1	-0.37	-8.03	-0.3	4.74e-15	Blood protein levels;
BRCA	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-11.12	-0.4	2.17e-26	Schizophrenia;
BRCA	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.56	10.71	0.39	9.87e-25	Birth weight;
BRCA	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg11062466	chr8:58055876	NA	0.52	9.13	0.34	8.55e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg26384229	chr12:38710491	ALG10B	0.74	17.17	0.56	1.24e-54	Bladder cancer;
BRCA	cis	rs9473147	0.543	rs9349417	chr6:47580657	A/G	cg12968598	chr6:47444699	CD2AP	0.44	9.58	0.35	2.15e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg04944784	chr2:26401820	FAM59B	1.0	14.63	0.5	4.93e-42	Gut microbiome composition (summer);
BRCA	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.68	-15.33	-0.52	2.04e-45	Breast cancer;
BRCA	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-14.9	-0.51	2.7e-43	Personality dimensions;
BRCA	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.24	0.34	3.64e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs586533	0.881	rs587925	chr11:99520831	A/G	cg22878054	chr11:99397252	CNTN5	0.33	8.13	0.31	2.17e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6878727	0.600	rs2619946	chr5:123641239	C/G	cg01806427	chr5:123737813	NA	-0.36	-8.0	-0.3	5.76e-15	Breast cancer;
BRCA	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23583168	chr7:148888333	NA	0.95	24.85	0.7	7.04e-96	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.77	-0.42	4.32e-29	Alcohol dependence;
BRCA	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg13334819	chr7:99746414	C7orf59	-0.36	-8.28	-0.31	7.36e-16	Coronary artery disease;
BRCA	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg13010199	chr12:38710504	ALG10B	0.52	10.4	0.38	1.62e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs34779708	0.677	rs112355105	chr10:35550294	A/T	cg03585969	chr10:35415529	CREM	0.43	8.65	0.32	4.22e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg11789530	chr4:8429930	ACOX3	-0.68	-17.77	-0.58	9.83e-58	Response to antineoplastic agents;
BRCA	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg03340356	chr1:67600835	NA	-0.35	-7.9	-0.3	1.25e-14	Psoriasis;
BRCA	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	11.23	0.41	7.91e-27	Monocyte percentage of white cells;
BRCA	cis	rs7927771	0.800	rs11039200	chr11:47379646	A/C	cg18512352	chr11:47633146	NA	-0.35	-8.24	-0.31	9.78e-16	Subjective well-being;
BRCA	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.86	13.54	0.47	6.44e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg03585969	chr10:35415529	CREM	0.55	11.37	0.41	2.17e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs13046373	0.505	rs2832934	chr21:31899760	A/G	cg24082983	chr21:31802169	KRTAP13-4	0.36	8.88	0.33	6.49e-18	HDL cholesterol;
BRCA	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg08470875	chr2:26401718	FAM59B	0.51	8.29	0.31	6.69e-16	Gut microbiome composition (summer);
BRCA	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12379764	chr21:47803548	PCNT	-0.61	-12.22	-0.44	5.46e-31	Testicular germ cell tumor;
BRCA	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg07395648	chr5:131743802	NA	0.37	7.99	0.3	6.21e-15	Breast cancer;
BRCA	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.76	0.36	4.39e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg01262667	chr19:19385393	TM6SF2	0.41	10.57	0.39	3.41e-24	Tonsillectomy;
BRCA	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg13010199	chr12:38710504	ALG10B	0.4	8.34	0.31	4.52e-16	Bladder cancer;
BRCA	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg14675211	chr2:100938903	LONRF2	0.43	9.62	0.36	1.54e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg11584989	chr19:19387371	SF4	0.63	13.58	0.47	4.17e-37	Bipolar disorder;
BRCA	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-11.12	-0.4	2.2e-26	Schizophrenia;
BRCA	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg20701182	chr2:24300061	SF3B14	0.56	8.72	0.33	2.3e-17	Lymphocyte counts;
BRCA	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg26608667	chr7:1196370	ZFAND2A	0.42	9.55	0.35	2.67e-20	Longevity;Endometriosis;
BRCA	trans	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg26043149	chr18:55253948	FECH	-0.37	-8.14	-0.31	2e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg08917208	chr2:24149416	ATAD2B	1.05	14.36	0.49	9.8e-41	Lymphocyte counts;
BRCA	cis	rs12612619	0.579	rs827884	chr2:27094842	C/G	cg12368169	chr2:27073192	DPYSL5	-0.31	-9.14	-0.34	8.4e-19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.46	9.25	0.34	3.3e-19	Tonsillectomy;
BRCA	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg05283184	chr6:79620031	NA	-0.36	-8.35	-0.31	4.12e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg17366294	chr4:99064904	C4orf37	0.44	10.22	0.37	8.18e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6684514	1.000	rs12118238	chr1:156235221	G/A	cg16558208	chr1:156270281	VHLL	0.37	8.21	0.31	1.19e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg26343298	chr8:95960752	TP53INP1	0.3	8.74	0.33	2.07e-17	Type 2 diabetes;
BRCA	trans	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg16011800	chr17:1958478	HIC1	-0.54	-8.69	-0.33	3.08e-17	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg04455712	chr21:45112962	RRP1B	0.43	11.5	0.41	5.74e-28	Mean corpuscular volume;
BRCA	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.85	0.45	8.83e-34	Bipolar disorder;
BRCA	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg25754956	chr12:51612065	POU6F1	0.79	17.34	0.57	1.77e-55	Cisplatin-induced ototoxicity;
BRCA	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg00409905	chr10:38381863	ZNF37A	-0.51	-10.84	-0.39	3.13e-25	Extrinsic epigenetic age acceleration;
BRCA	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	9.62	0.36	1.54e-20	Tonsillectomy;
BRCA	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.53	-11.34	-0.41	2.71e-27	HIV-1 control;
BRCA	cis	rs68170813	0.559	rs10953536	chr7:107021691	G/A	cg02696742	chr7:106810147	HBP1	-0.56	-8.66	-0.32	3.78e-17	Coronary artery disease;
BRCA	cis	rs1904096	0.506	rs13435702	chr4:95167751	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-10.07	-0.37	3.06e-22	Type 2 diabetes;
BRCA	cis	rs1506636	1.000	rs652497	chr7:123423671	G/T	cg03229431	chr7:123269106	ASB15	0.61	13.54	0.47	6.54e-37	Plateletcrit;Platelet count;
BRCA	trans	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg06636001	chr8:8085503	FLJ10661	0.38	8.21	0.31	1.19e-15	Retinal vascular caliber;
BRCA	trans	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg25214090	chr10:38739885	LOC399744	0.47	10.51	0.38	6.02e-24	Corneal astigmatism;
BRCA	cis	rs3125734	0.633	rs4979773	chr10:63967731	G/C	cg09941381	chr10:64027924	RTKN2	-0.29	-8.76	-0.33	1.81e-17	Rheumatoid arthritis;
BRCA	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg24803719	chr17:45855879	NA	0.32	8.44	0.32	2.15e-16	IgG glycosylation;
BRCA	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.51	-12.84	-0.45	9.41e-34	Longevity;Endometriosis;
BRCA	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-9.5	-0.35	4.24e-20	Height;
BRCA	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg15017067	chr4:17643749	FAM184B	0.29	8.37	0.31	3.53e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9469578	1.000	rs9469581	chr6:33715904	C/A	cg18708504	chr6:33715942	IP6K3	0.68	9.99	0.37	6.04e-22	Phosphorus levels;
BRCA	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.53	-0.35	3.25e-20	Total body bone mineral density;
BRCA	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg10011062	chr15:43941034	CATSPER2	-0.59	-8.94	-0.33	4.31e-18	Lung cancer in ever smokers;
BRCA	trans	rs4650994	0.525	rs4650996	chr1:178517365	A/G	cg05059571	chr16:84539110	KIAA1609	-0.58	-12.94	-0.46	3.37e-34	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs1595825	0.891	rs73054817	chr2:198623751	A/G	cg19156104	chr2:198669113	PLCL1	-0.44	-8.33	-0.31	4.87e-16	Ulcerative colitis;
BRCA	cis	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg05084668	chr3:125655381	ALG1L	-0.55	-9.0	-0.34	2.63e-18	Blood pressure (smoking interaction);
BRCA	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.7	14.18	0.49	7.13e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg26384229	chr12:38710491	ALG10B	-0.43	-10.06	-0.37	3.25e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs965469	1.000	rs6051703	chr20:3252347	A/T	cg25506879	chr20:3388711	C20orf194	-0.55	-10.79	-0.39	4.75e-25	IFN-related cytopenia;
BRCA	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.43	0.35	7.61e-20	Tonsillectomy;
BRCA	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.04	0.3	4.33e-15	Total cholesterol levels;
BRCA	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08704250	chr15:31115839	NA	-0.36	-9.13	-0.34	9e-19	Huntington's disease progression;
BRCA	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21659725	chr3:3221576	CRBN	0.7	20.95	0.64	1.37e-74	Intelligence (multi-trait analysis);
BRCA	cis	rs870825	0.698	rs7673203	chr4:185625397	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-13.18	-0.46	2.84e-35	Response to antipsychotic treatment;
BRCA	cis	rs10899021	0.920	rs7112384	chr11:74348205	T/G	cg25880958	chr11:74394337	NA	-0.49	-7.88	-0.3	1.43e-14	Response to metformin (IC50);
BRCA	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg20848291	chr7:100343083	ZAN	0.37	8.32	0.31	5.39e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18876405	chr7:65276391	NA	-0.56	-13.42	-0.47	2.42e-36	Aortic root size;
BRCA	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-9.83	-0.36	2.48e-21	Bladder cancer;
BRCA	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg18252515	chr7:66147081	NA	1.03	15.25	0.52	5.04e-45	Diabetic kidney disease;
BRCA	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-16.76	-0.55	1.62e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.38	-8.47	-0.32	1.63e-16	Breast cancer;
BRCA	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.47	-0.32	1.73e-16	Total body bone mineral density;
BRCA	cis	rs9462027	0.583	rs9469862	chr6:34729848	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.99	-0.3	6.37e-15	Systemic lupus erythematosus;
BRCA	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg09640425	chr7:158790006	NA	0.37	7.87	0.3	1.48e-14	Facial morphology (factor 20);
BRCA	cis	rs2742234	0.504	rs10899780	chr10:43725796	T/C	cg02780029	chr10:43622663	RET	0.35	7.9	0.3	1.26e-14	Hirschsprung disease;
BRCA	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg08807101	chr21:30365312	RNF160	-0.4	-8.12	-0.31	2.44e-15	Cognitive test performance;
BRCA	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg23533926	chr12:111358616	MYL2	-0.44	-9.2	-0.34	4.98e-19	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg23029597	chr12:123009494	RSRC2	-0.61	-11.79	-0.42	3.46e-29	Body mass index;
BRCA	trans	rs10411161	0.702	rs11878583	chr19:52388546	C/T	cg22319618	chr22:45562946	NUP50	0.42	7.99	0.3	6.51e-15	Breast cancer;
BRCA	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg06238570	chr21:40685208	BRWD1	-0.41	-8.13	-0.31	2.17e-15	Menarche (age at onset);
BRCA	trans	rs7200543	1.000	rs4985124	chr16:15125441	A/C	cg24683922	chr1:11983373	KIAA2013	-0.36	-8.19	-0.31	1.46e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs360798	0.512	rs11893131	chr2:63079528	C/A	cg17519650	chr2:63277830	OTX1	0.38	8.36	0.31	3.94e-16	Coronary artery disease;
BRCA	trans	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg25042112	chr7:64838748	ZNF92	-0.45	-8.27	-0.31	8.04e-16	Pain;
BRCA	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg15704280	chr7:45808275	SEPT13	0.54	8.15	0.31	1.9e-15	Intraocular pressure;
BRCA	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg09624528	chr10:1369823	ADARB2	0.41	8.47	0.32	1.71e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg04727924	chr7:799746	HEATR2	-0.52	-10.58	-0.39	3.1e-24	Cerebrospinal P-tau181p levels;
BRCA	cis	rs877282	0.945	rs12776447	chr10:790625	A/G	cg17470449	chr10:769945	NA	0.51	8.62	0.32	5.29e-17	Uric acid levels;
BRCA	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg21475434	chr5:93447410	FAM172A	0.67	8.62	0.32	5.14e-17	Diabetic retinopathy;
BRCA	cis	rs9463078	0.547	rs34907292	chr6:44729708	A/G	cg25276700	chr6:44698697	NA	0.36	8.31	0.31	5.7e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs490234	0.691	rs3104551	chr9:128164279	G/A	cg14078157	chr9:128172775	NA	-0.37	-8.1	-0.31	2.87e-15	Mean arterial pressure;
BRCA	cis	rs72928364	0.860	rs62274066	chr3:100801179	A/C	cg10123952	chr3:100791384	NA	0.57	8.28	0.31	7.2e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4713675	0.584	rs7759668	chr6:33670406	C/T	cg14003231	chr6:33640908	ITPR3	-0.32	-7.84	-0.3	1.91e-14	Plateletcrit;
BRCA	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.53	11.52	0.41	4.94e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12826209	chr6:26865740	GUSBL1	0.59	10.31	0.38	3.81e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs13082711	0.595	rs6783818	chr3:27361988	C/G	cg02860705	chr3:27208620	NA	0.78	14.39	0.49	6.76e-41	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	trans	rs8002861	0.664	rs2184882	chr13:44450346	C/T	cg17145862	chr1:211918768	LPGAT1	0.48	10.9	0.4	1.8e-25	Leprosy;
BRCA	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg00666640	chr1:248458726	OR2T12	0.31	8.46	0.32	1.77e-16	Common traits (Other);
BRCA	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.39	-0.32	3.01e-16	Total body bone mineral density;
BRCA	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg12011299	chr4:100065546	ADH4	0.53	12.95	0.46	3.03e-34	Alcohol dependence;
BRCA	cis	rs6430585	0.527	rs59413285	chr2:136444185	G/T	cg07169764	chr2:136633963	MCM6	1.0	19.33	0.61	6.73e-66	Corneal structure;
BRCA	cis	rs7809950	0.953	rs28687365	chr7:107106712	A/C	cg23024343	chr7:107201750	COG5	-0.41	-9.38	-0.35	1.1e-19	Coronary artery disease;
BRCA	cis	rs11605924	0.901	rs6485644	chr11:45855998	C/T	ch.11.939596F	chr11:45881766	CRY2	-0.45	-9.68	-0.36	9.35e-21	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs74181299	1.000	rs74181299	chr2:65283972	T/C	cg05010058	chr2:65284262	CEP68	0.32	8.83	0.33	9.93e-18	Pulse pressure;
BRCA	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg08000102	chr2:233561755	GIGYF2	-0.46	-9.98	-0.37	6.79e-22	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg17366294	chr4:99064904	C4orf37	0.44	10.49	0.38	7.52e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg03713592	chr11:72463424	ARAP1	0.42	8.0	0.3	5.69e-15	Body mass index;
BRCA	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg02753203	chr1:228287806	NA	-0.57	-12.05	-0.43	2.8e-30	Diastolic blood pressure;
BRCA	cis	rs10493773	0.510	rs11161645	chr1:86092872	T/C	cg17807903	chr1:86174739	ZNHIT6	0.35	7.88	0.3	1.37e-14	Urate levels in overweight individuals;
BRCA	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg21782813	chr7:2030301	MAD1L1	0.3	8.25	0.31	8.81e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg27489772	chr12:121021490	NA	0.44	7.95	0.3	8.79e-15	Type 1 diabetes nephropathy;
BRCA	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg16989086	chr20:62203971	PRIC285	0.54	9.15	0.34	7.51e-19	Glioblastoma;
BRCA	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg24006582	chr15:45444508	DUOX1	-0.53	-10.98	-0.4	7.9e-26	Uric acid levels;
BRCA	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg20573242	chr4:122745356	CCNA2	0.48	10.69	0.39	1.14e-24	Type 2 diabetes;
BRCA	cis	rs4953318	0.619	rs10183887	chr2:46361808	T/A	cg12428440	chr2:46370979	PRKCE	0.49	10.76	0.39	6.19e-25	Red blood cell count;Hematocrit;Red blood cell traits;
BRCA	cis	rs2354432	0.607	rs6593751	chr1:146726023	A/G	cg25205988	chr1:146714368	CHD1L	-0.97	-12.75	-0.45	2.59e-33	Mitochondrial DNA levels;
BRCA	cis	rs7945718	0.839	rs10831911	chr11:12834858	C/T	cg25843174	chr11:12811716	TEAD1	0.21	8.24	0.31	9.88e-16	Educational attainment (years of education);
BRCA	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg12444411	chr7:2802554	GNA12	-0.35	-8.33	-0.31	4.86e-16	Height;
BRCA	cis	rs7851660	0.967	rs10046805	chr9:100613956	G/A	cg13688889	chr9:100608707	NA	-0.36	-8.71	-0.33	2.56e-17	Strep throat;
BRCA	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.87	-0.3	1.52e-14	Prostate cancer;
BRCA	cis	rs7766436	0.767	rs6456496	chr6:22599386	G/C	cg13666174	chr6:22585274	NA	-0.37	-9.58	-0.35	2.11e-20	Coronary artery disease;
BRCA	cis	rs7799006	0.582	rs7781284	chr7:2339405	G/T	cg08027265	chr7:2291960	NA	-0.37	-9.8	-0.36	3.23e-21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs2070997	0.816	rs1800609	chr9:133731184	A/G	cg11464064	chr9:133710261	ABL1	0.54	8.87	0.33	7.55e-18	Response to amphetamines;
BRCA	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg04455712	chr21:45112962	RRP1B	0.38	9.63	0.36	1.39e-20	Mean corpuscular volume;
BRCA	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg20887711	chr4:1340912	KIAA1530	0.41	9.66	0.36	1.04e-20	Longevity;
BRCA	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg26384229	chr12:38710491	ALG10B	-0.54	-13.47	-0.47	1.4e-36	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.57	0.32	7.83e-17	Motion sickness;
BRCA	cis	rs10992471	0.627	rs4744138	chr9:95291909	A/G	cg14631576	chr9:95140430	CENPP	-0.36	-8.5	-0.32	1.31e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs17401966	0.931	rs4240911	chr1:10307453	A/G	cg19773385	chr1:10388646	KIF1B	-0.36	-8.35	-0.31	4.13e-16	Hepatocellular carcinoma;
BRCA	cis	rs6740322	0.895	rs10210125	chr2:43556433	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-11.9	-0.43	1.23e-29	Coronary artery disease;
BRCA	cis	rs10465746	0.687	rs6576954	chr1:84323701	C/T	cg10977910	chr1:84465055	TTLL7	-0.43	-8.11	-0.31	2.68e-15	Obesity-related traits;
BRCA	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-11.79	-0.42	3.7e-29	Alzheimer's disease;
BRCA	cis	rs4919694	0.611	rs2271750	chr10:105174869	A/G	cg04362960	chr10:104952993	NT5C2	-0.64	-11.04	-0.4	4.49e-26	Arsenic metabolism;
BRCA	cis	rs507080	0.885	rs693037	chr11:118553326	C/T	cg08498647	chr11:118550644	TREH	-0.38	-8.35	-0.31	4.11e-16	Serum metabolite levels;
BRCA	cis	rs17253792	0.915	rs74580958	chr14:56181511	G/A	cg01858014	chr14:56050164	KTN1	-0.68	-8.36	-0.31	3.99e-16	Putamen volume;
BRCA	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg03954927	chr1:10346856	KIF1B	0.48	14.82	0.51	6.34e-43	Hepatocellular carcinoma;
BRCA	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg18252515	chr7:66147081	NA	1.07	15.95	0.53	1.77e-48	Gout;
BRCA	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.95	-0.33	3.97e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg11752832	chr7:134001865	SLC35B4	0.52	13.42	0.47	2.36e-36	Mean platelet volume;
BRCA	cis	rs9473147	0.516	rs6904764	chr6:47503497	A/T	cg12968598	chr6:47444699	CD2AP	0.44	9.71	0.36	7.19e-21	Platelet distribution width;Mean platelet volume;
BRCA	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-16.22	-0.54	8.53e-50	Intelligence (multi-trait analysis);
BRCA	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg20848291	chr7:100343083	ZAN	-0.61	-13.15	-0.46	3.81e-35	Other erythrocyte phenotypes;
BRCA	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.12	-0.34	1e-18	Bipolar disorder;
BRCA	cis	rs2731664	0.756	rs335433	chr5:176867207	T/C	cg23176889	chr5:176863531	GRK6	-0.59	-15.51	-0.52	2.74e-46	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.35	-8.23	-0.31	1.08e-15	Bipolar disorder;
BRCA	cis	rs10754283	0.901	rs6663526	chr1:90110862	T/C	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.31e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg00106254	chr7:1943704	MAD1L1	-0.39	-9.45	-0.35	6.3e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs35995292	0.534	rs917322	chr7:38943165	A/T	cg19327137	chr7:38886074	VPS41	-0.38	-12.64	-0.45	7.31e-33	Subjective well-being (multi-trait analysis);
BRCA	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg20007245	chr22:24372913	LOC391322	-0.54	-11.98	-0.43	5.45e-30	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs909341	0.710	rs6089953	chr20:62291008	C/T	cg03425785	chr20:62221387	GMEB2	0.54	8.83	0.33	1.03e-17	Atopic dermatitis;
BRCA	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.54	-0.32	9.96e-17	Total body bone mineral density;
BRCA	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg20307385	chr11:47447363	PSMC3	0.42	9.62	0.36	1.52e-20	Subjective well-being;
BRCA	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg12292205	chr6:26970375	C6orf41	0.58	12.99	0.46	2.15e-34	Schizophrenia;
BRCA	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg18132916	chr6:79620363	NA	-0.44	-10.07	-0.37	3.15e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4073582	0.576	rs556595	chr11:66058082	T/G	cg16950941	chr11:66035639	RAB1B	0.44	11.58	0.42	2.87e-28	Gout;
BRCA	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.08	-0.34	1.32e-18	Bipolar disorder;
BRCA	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-11.47	-0.41	8.06e-28	Platelet count;
BRCA	cis	rs9296092	0.560	rs3846853	chr6:33528194	C/G	cg13560919	chr6:33536144	NA	-0.85	-18.69	-0.59	1.6e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs884366	0.724	rs4946960	chr6:109641677	A/G	cg01475377	chr6:109611718	NA	0.36	7.92	0.3	1.08e-14	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs10911363	0.592	rs2702205	chr1:183457198	A/G	cg09173681	chr1:183549694	NCF2	0.49	10.7	0.39	1.05e-24	Systemic lupus erythematosus;
BRCA	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg03676636	chr4:99064102	C4orf37	0.23	8.2	0.31	1.29e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg09307838	chr4:120376055	NA	0.63	12.64	0.45	7.35e-33	Corneal astigmatism;
BRCA	cis	rs13082711	0.595	rs62255583	chr3:27309704	G/T	cg02860705	chr3:27208620	NA	0.78	14.4	0.49	6.51e-41	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg15412446	chr2:106886593	NA	-0.48	-8.2	-0.31	1.33e-15	Facial morphology (factor 23);
BRCA	cis	rs7131987	0.650	rs16934135	chr12:29483963	T/G	cg09582351	chr12:29534625	ERGIC2	-0.45	-10.41	-0.38	1.46e-23	QT interval;
BRCA	trans	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.48	0.32	1.57e-16	Mean corpuscular volume;
BRCA	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg09307838	chr4:120376055	NA	0.64	14.08	0.49	1.96e-39	Corneal astigmatism;
BRCA	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg21518248	chr2:162101506	NA	0.42	8.64	0.32	4.62e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs10949834	0.529	rs150861	chr7:73524901	T/C	cg07137043	chr7:73588983	EIF4H	0.51	8.81	0.33	1.15e-17	Verbal memory performance (residualized delayed recall change);
BRCA	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg25019033	chr10:957182	NA	0.43	8.35	0.31	4.15e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-16.37	-0.54	1.44e-50	Chronic sinus infection;
BRCA	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg04414720	chr1:150670196	GOLPH3L	0.35	8.04	0.3	4.33e-15	Tonsillectomy;
BRCA	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg16325326	chr1:53192061	ZYG11B	0.9	25.11	0.7	2.37e-97	Monocyte count;
BRCA	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26314531	chr2:26401878	FAM59B	-0.63	-10.83	-0.39	3.28e-25	Gut microbiome composition (summer);
BRCA	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg08501292	chr6:25962987	TRIM38	0.58	7.87	0.3	1.52e-14	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs6561151	0.957	rs3764147	chr13:44457925	C/T	cg12856521	chr11:46389249	DGKZ	-0.44	-8.96	-0.33	3.5e-18	Crohn's disease;
BRCA	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg21475434	chr5:93447410	FAM172A	0.67	8.51	0.32	1.24e-16	Diabetic retinopathy;
BRCA	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg09469691	chr10:81107165	PPIF	0.53	11.01	0.4	6.33e-26	Height;
BRCA	trans	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.96	0.4	9.84e-26	Type 2 diabetes;
BRCA	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-12.27	-0.44	3.27e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.07e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg11766577	chr21:47581405	C21orf56	-0.5	-10.79	-0.39	4.75e-25	Testicular germ cell tumor;
BRCA	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.7	14.32	0.49	1.57e-40	Cognitive ability;
BRCA	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg06784218	chr1:46089804	CCDC17	0.51	12.27	0.44	3.26e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg08885076	chr2:99613938	TSGA10	0.46	10.69	0.39	1.19e-24	Chronic sinus infection;
BRCA	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg27588902	chr6:42928151	GNMT	-0.31	-10.59	-0.39	3.07e-24	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs495337	1.000	rs6125826	chr20:48556461	C/T	cg17835207	chr20:48524531	SPATA2	-0.6	-13.74	-0.48	8e-38	Psoriasis;
BRCA	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	8.91	0.33	5.17e-18	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg08601574	chr20:25228251	PYGB	-0.38	-9.03	-0.34	2.02e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.19	-0.43	6.89e-31	Breast cancer;
BRCA	trans	rs9951602	0.512	rs1599634	chr18:76643645	T/C	cg02800362	chr5:177631904	HNRNPAB	0.75	17.49	0.57	2.96e-56	Obesity-related traits;
BRCA	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg04455712	chr21:45112962	RRP1B	0.42	10.99	0.4	7.27e-26	Mean corpuscular volume;
BRCA	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	8.15	0.31	1.86e-15	Mean platelet volume;
BRCA	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.87	-0.43	1.6e-29	Response to antipsychotic treatment;
BRCA	cis	rs1003719	1.000	rs2835607	chr21:38491973	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	14.18	0.49	7.02e-40	Eye color traits;
BRCA	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg18230493	chr5:56204884	C5orf35	-0.72	-14.12	-0.49	1.41e-39	Initial pursuit acceleration;
BRCA	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-11.97	-0.43	6.16e-30	Bipolar disorder;
BRCA	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg19743168	chr1:23544995	NA	0.69	17.18	0.56	1.16e-54	Height;
BRCA	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg21095983	chr6:86352623	SYNCRIP	0.4	9.0	0.34	2.63e-18	Smooth-surface caries;
BRCA	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.68	-18.43	-0.59	3.98e-61	Longevity;Endometriosis;
BRCA	cis	rs758324	0.738	rs413185	chr5:131315225	A/G	cg06307176	chr5:131281290	NA	0.51	10.85	0.39	2.75e-25	Alzheimer's disease in APOE e4- carriers;
BRCA	trans	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg26043149	chr18:55253948	FECH	-0.38	-8.34	-0.31	4.43e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg14598338	chr9:96623480	NA	-0.32	-7.86	-0.3	1.61e-14	DNA methylation (variation);
BRCA	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	8.78	0.33	1.54e-17	Schizophrenia;
BRCA	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.81	0.55	8.35e-53	Axial length;
BRCA	cis	rs17095355	1.000	rs12569906	chr10:111706856	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.39	-9.97	-0.37	7.61e-22	Biliary atresia;
BRCA	cis	rs6714710	0.603	rs13020776	chr2:98402753	T/A	cg26665480	chr2:98280029	ACTR1B	0.58	13.59	0.47	4.06e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs7523273	0.606	rs2796266	chr1:207922945	C/T	cg22525895	chr1:207977042	MIR29B2	-0.48	-12.08	-0.43	1.99e-30	Schizophrenia;
BRCA	trans	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg06521331	chr12:34319734	NA	-0.47	-8.68	-0.32	3.27e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7020830	0.898	rs12000309	chr9:37230844	G/A	cg14294708	chr9:37120828	ZCCHC7	1.16	42.1	0.86	1.93e-186	Schizophrenia;
BRCA	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	14.45	0.5	3.6e-41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg20307385	chr11:47447363	PSMC3	0.76	17.93	0.58	1.5e-58	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.61	-0.32	5.58e-17	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg21775007	chr8:11205619	TDH	0.45	9.39	0.35	1.02e-19	Neuroticism;
BRCA	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg02773041	chr1:40204384	PPIE	0.45	9.64	0.36	1.25e-20	Blood protein levels;
BRCA	cis	rs2479724	0.935	rs2254936	chr6:41846569	A/G	cg17623882	chr6:41773611	USP49	-0.38	-10.24	-0.38	6.9e-23	Menarche (age at onset);
BRCA	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	ch.11.42038R	chr11:967971	AP2A2	0.5	15.01	0.51	7.22e-44	Alzheimer's disease (late onset);
BRCA	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg19717773	chr7:2847554	GNA12	-0.49	-11.67	-0.42	1.16e-28	Height;
BRCA	cis	rs113835537	0.529	rs17065	chr11:66277035	G/A	cg24851651	chr11:66362959	CCS	0.5	8.73	0.33	2.25e-17	Airway imaging phenotypes;
BRCA	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg18850127	chr7:39170497	POU6F2	0.56	12.08	0.43	2.05e-30	IgG glycosylation;
BRCA	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg21918786	chr6:109611834	NA	-0.48	-13.73	-0.48	8.68e-38	Reticulocyte fraction of red cells;
BRCA	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg06108461	chr20:60628389	TAF4	-0.72	-15.13	-0.51	2.04e-44	Body mass index;
BRCA	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg19717773	chr7:2847554	GNA12	-0.43	-9.73	-0.36	5.89e-21	Height;
BRCA	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg00531865	chr16:30841666	NA	-0.58	-13.66	-0.48	1.77e-37	Multiple myeloma;
BRCA	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg09537434	chr19:41945824	ATP5SL	-0.98	-24.22	-0.69	2.02e-92	Height;
BRCA	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.09	0.56	3.13e-54	Bladder cancer;
BRCA	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg17143192	chr8:8559678	CLDN23	0.54	10.27	0.38	5.39e-23	Obesity-related traits;
BRCA	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.43	-0.38	1.21e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs965469	0.779	rs2236115	chr20:3296279	G/A	cg25506879	chr20:3388711	C20orf194	-0.43	-8.71	-0.33	2.61e-17	IFN-related cytopenia;
BRCA	cis	rs12618769	0.625	rs3769726	chr2:99105827	G/C	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.0	-0.34	2.59e-18	Menopause (age at onset);
BRCA	cis	rs477692	0.673	rs556253	chr10:131355781	G/A	cg05714579	chr10:131428358	MGMT	0.5	10.81	0.39	3.93e-25	Response to temozolomide;
BRCA	cis	rs17023223	0.553	rs11484962	chr1:119725186	G/A	cg05756136	chr1:119680316	WARS2	-0.42	-8.05	-0.3	3.98e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11890956	chr21:40555474	PSMG1	0.96	24.22	0.69	2.01e-92	Cognitive function;
BRCA	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg18230493	chr5:56204884	C5orf35	0.85	16.14	0.54	2.01e-49	Initial pursuit acceleration;
BRCA	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00166722	chr3:10149974	C3orf24	0.64	11.32	0.41	3.47e-27	Alzheimer's disease;
BRCA	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg10223061	chr2:219282414	VIL1	0.3	8.45	0.32	2e-16	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	13.92	0.48	1.12e-38	Mean corpuscular hemoglobin;
BRCA	cis	rs11603020	0.950	rs28362950	chr11:57371918	G/A	cg19752551	chr11:57585705	CTNND1	-0.42	-9.86	-0.36	1.84e-21	Blood protein levels;
BRCA	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.51	8.64	0.32	4.61e-17	Lung function (FEV1/FVC);
BRCA	cis	rs72772090	0.522	rs17398838	chr5:96003785	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-8.32	-0.31	5.28e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	11.8	0.42	3.18e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg18230493	chr5:56204884	C5orf35	-0.61	-13.01	-0.46	1.75e-34	Initial pursuit acceleration;
BRCA	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-16.05	-0.54	5.86e-49	Colorectal cancer;
BRCA	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26314531	chr2:26401878	FAM59B	-0.66	-11.25	-0.41	6.63e-27	Gut microbiome composition (summer);
BRCA	cis	rs4812048	1.000	rs6070692	chr20:57586374	A/G	cg14073986	chr20:57617431	SLMO2	0.56	8.18	0.31	1.58e-15	Mean platelet volume;
BRCA	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21659725	chr3:3221576	CRBN	0.51	12.03	0.43	3.32e-30	Resting heart rate;
BRCA	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg18876405	chr7:65276391	NA	0.66	17.1	0.56	3.01e-54	Aortic root size;
BRCA	trans	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.95	0.3	8.6e-15	Corneal astigmatism;
BRCA	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg16482183	chr6:26056742	HIST1H1C	0.46	9.45	0.35	6.15e-20	Iron status biomarkers;
BRCA	cis	rs4285028	0.898	rs12491991	chr3:121706021	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.96	0.4	1e-25	Multiple sclerosis;
BRCA	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg11845111	chr2:191398756	TMEM194B	0.4	9.29	0.35	2.32e-19	Pulse pressure;
BRCA	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg21798802	chr22:38057573	PDXP	0.32	9.01	0.34	2.39e-18	Fat distribution (HIV);
BRCA	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12893428	chr3:195717962	SDHAP1	0.33	8.1	0.31	2.86e-15	Pancreatic cancer;
BRCA	trans	rs2562456	1.000	rs2359155	chr19:21671869	C/A	cg25042112	chr7:64838748	ZNF92	0.41	7.99	0.3	6.28e-15	Pain;
BRCA	cis	rs11690935	0.921	rs4668414	chr2:172704291	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.89	-27.4	-0.73	6.56e-110	Schizophrenia;
BRCA	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12923728	chr3:195709715	SDHAP1	-0.57	-12.16	-0.43	9.67e-31	Pancreatic cancer;
BRCA	cis	rs10851411	0.542	rs10454692	chr15:42857055	T/C	cg21293051	chr15:42870591	STARD9	0.52	8.8	0.33	1.29e-17	Glucose homeostasis traits;
BRCA	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg05347473	chr6:146136440	FBXO30	-0.42	-8.51	-0.32	1.26e-16	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg23533926	chr12:111358616	MYL2	-0.48	-10.21	-0.37	8.87e-23	Breast cancer;
BRCA	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg11822812	chr5:140052017	DND1	-0.3	-8.24	-0.31	9.59e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6684514	0.922	rs12022657	chr1:156314147	A/G	cg16558208	chr1:156270281	VHLL	0.37	8.34	0.31	4.59e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg09658497	chr7:2847517	GNA12	-0.41	-8.62	-0.32	5.42e-17	Height;
BRCA	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg13385521	chr17:29058706	SUZ12P	-0.66	-10.32	-0.38	3.45e-23	Body mass index;
BRCA	cis	rs12348691	0.503	rs1867279	chr9:100616041	T/C	cg13688889	chr9:100608707	NA	-0.49	-9.9	-0.36	1.32e-21	Alopecia areata;
BRCA	cis	rs9828933	0.938	rs2578011	chr3:64004819	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.62	-11.5	-0.41	6.09e-28	Type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.65	-14.27	-0.49	2.76e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg12219531	chr12:120966889	COQ5	0.55	11.43	0.41	1.17e-27	High light scatter reticulocyte count;
BRCA	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.49	0.47	1.16e-36	Colorectal cancer;
BRCA	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg15704280	chr7:45808275	SEPT13	-0.53	-10.27	-0.38	5.34e-23	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs8067545	0.641	rs119672	chr17:19818601	A/G	cg13482628	chr17:19912719	NA	0.46	11.51	0.41	5.28e-28	Schizophrenia;
BRCA	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.59e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10992471	0.603	rs10820974	chr9:95211876	T/C	cg14631576	chr9:95140430	CENPP	-0.35	-8.74	-0.33	2.07e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-11.63	-0.42	1.68e-28	Hemoglobin concentration;
BRCA	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.43	9.7	0.36	7.47e-21	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11764359	chr7:65958608	NA	-0.79	-18.86	-0.6	2.17e-63	Aortic root size;
BRCA	cis	rs10484885	0.877	rs17735389	chr6:90323139	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.63	-8.12	-0.31	2.35e-15	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-8.27	-0.31	7.83e-16	Depression;
BRCA	cis	rs6815814	0.950	rs73236617	chr4:38793860	C/G	cg06935464	chr4:38784597	TLR10	0.51	8.21	0.31	1.18e-15	Breast cancer;
BRCA	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg00531865	chr16:30841666	NA	-0.49	-11.5	-0.41	5.85e-28	Multiple myeloma;
BRCA	cis	rs6088813	1.000	rs4911491	chr20:33947285	C/G	cg14752227	chr20:34000481	UQCC	-0.41	-8.78	-0.33	1.55e-17	Height;
BRCA	cis	rs3772130	0.603	rs35489993	chr3:121411876	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.56	11.4	0.41	1.59e-27	Cognitive performance;
BRCA	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg17366294	chr4:99064904	C4orf37	0.41	9.66	0.36	1.04e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6087990	0.871	rs2424905	chr20:31352927	T/C	cg13636640	chr20:31349939	DNMT3B	0.71	20.65	0.63	5.86e-73	Ulcerative colitis;
BRCA	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg18944383	chr4:111397179	ENPEP	0.35	7.93	0.3	1.02e-14	Height;
BRCA	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg03146154	chr1:46216737	IPP	0.45	10.09	0.37	2.49e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24549020	chr5:56110836	MAP3K1	-0.37	-7.87	-0.3	1.57e-14	Initial pursuit acceleration;
BRCA	cis	rs2882667	0.898	rs13182437	chr5:138387149	T/C	cg04439458	chr5:138467593	SIL1	-0.33	-8.84	-0.33	9.53e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg20607798	chr8:58055168	NA	0.48	8.43	0.32	2.29e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg06159980	chr1:16340746	HSPB7	-0.38	-7.9	-0.3	1.19e-14	Dilated cardiomyopathy;
BRCA	cis	rs2505998	0.833	rs2505535	chr10:43593043	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.43	-8.49	-0.32	1.46e-16	Hirschsprung disease;
BRCA	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg06191203	chr2:152266755	RIF1	0.39	10.92	0.4	1.49e-25	Lung cancer;
BRCA	cis	rs7903847	0.619	rs10882912	chr10:99138077	C/T	cg20016023	chr10:99160130	RRP12	-0.27	-8.59	-0.32	6.67e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg23625390	chr15:77176239	SCAPER	-0.51	-12.05	-0.43	2.69e-30	Blood metabolite levels;
BRCA	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.34	-8.55	-0.32	9.02e-17	Menopause (age at onset);
BRCA	cis	rs17092148	0.836	rs6059910	chr20:33142107	T/C	cg16810054	chr20:33298113	TP53INP2	-0.46	-10.38	-0.38	1.97e-23	Neuroticism;
BRCA	cis	rs312273	0.774	rs3794247	chr12:41359761	C/A	cg17827154	chr12:41323612	CNTN1	-0.41	-10.71	-0.39	9.75e-25	Bipolar disorder;
BRCA	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg25173405	chr17:45401733	C17orf57	0.55	11.57	0.42	3.11e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg01877450	chr7:97915802	BRI3	-0.36	-8.17	-0.31	1.6e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg13010199	chr12:38710504	ALG10B	0.51	9.8	0.36	3.24e-21	Bladder cancer;
BRCA	cis	rs7043114	0.507	rs7856204	chr9:95173814	G/C	cg14631576	chr9:95140430	CENPP	-0.31	-7.81	-0.3	2.3e-14	Height;
BRCA	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg03146154	chr1:46216737	IPP	0.45	10.0	0.37	5.54e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504073	0.647	rs28685207	chr8:50003484	A/G	cg00325661	chr8:49890786	NA	0.38	11.35	0.41	2.43e-27	Blood metabolite ratios;
BRCA	cis	rs11785693	0.862	rs11778306	chr8:4988269	A/C	cg26367366	chr8:4980734	NA	0.6	10.49	0.38	7.49e-24	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg10636054	chr15:40330586	SRP14	0.89	13.15	0.46	4.18e-35	Corneal curvature;
BRCA	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg18131467	chr2:239335373	ASB1	0.86	21.85	0.65	1.88e-79	Multiple system atrophy;
BRCA	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08219700	chr8:58056026	NA	0.56	9.15	0.34	7.49e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs13046373	0.508	rs1507393	chr21:31992779	A/G	cg14062083	chr21:31802829	KRTAP13-4	0.34	9.23	0.34	3.92e-19	HDL cholesterol;
BRCA	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg17644776	chr2:200775616	C2orf69	0.45	9.39	0.35	1.07e-19	Osteoporosis;
BRCA	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg05863683	chr7:1912471	MAD1L1	0.4	8.38	0.31	3.27e-16	Bipolar disorder and schizophrenia;
BRCA	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-13.88	-0.48	1.7e-38	Morning vs. evening chronotype;
BRCA	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-16.2	-0.54	1.11e-49	Alzheimer's disease (late onset);
BRCA	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg01017244	chr2:74357527	NA	0.53	12.68	0.45	5.08e-33	Gestational age at birth (maternal effect);
BRCA	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg14784868	chr12:69753453	YEATS4	0.48	11.22	0.41	8.97e-27	Response to diuretic therapy;
BRCA	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg22705602	chr4:152727874	NA	-0.37	-10.04	-0.37	4.13e-22	Intelligence (multi-trait analysis);
BRCA	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	16.52	0.55	2.62e-51	Intelligence (multi-trait analysis);
BRCA	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg04362960	chr10:104952993	NT5C2	0.46	10.74	0.39	7.57e-25	Arsenic metabolism;
BRCA	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05901451	chr6:126070800	HEY2	-0.54	-14.42	-0.5	5.18e-41	Brugada syndrome;
BRCA	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg25036284	chr2:26402008	FAM59B	0.94	14.81	0.51	7.39e-43	Gut microbiome composition (summer);
BRCA	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	10.91	0.4	1.61e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.64	0.36	1.22e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg04455712	chr21:45112962	RRP1B	0.47	12.95	0.46	3.25e-34	Mean corpuscular volume;
BRCA	trans	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg25214090	chr10:38739885	LOC399744	0.53	12.1	0.43	1.8e-30	Corneal astigmatism;
BRCA	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg20891283	chr12:69753455	YEATS4	0.73	21.68	0.65	1.5e-78	Blood protein levels;
BRCA	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-8.54	-0.32	9.5e-17	Bladder cancer;
BRCA	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg10756475	chr4:1757242	NA	-0.39	-8.97	-0.33	3.3e-18	Bladder cancer;Urinary bladder cancer;
BRCA	cis	rs192264	0.614	rs7186848	chr16:65987204	A/G	cg03491821	chr16:65994309	NA	0.32	7.89	0.3	1.28e-14	Subjective well-being;
BRCA	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-12.89	-0.45	6.04e-34	Gut microbiome composition (summer);
BRCA	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg03709012	chr19:19516395	GATAD2A	0.78	18.24	0.59	3.93e-60	Tonsillectomy;
BRCA	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg03213289	chr20:61660250	NA	0.63	16.54	0.55	2.05e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18876405	chr7:65276391	NA	0.55	13.29	0.47	9.4e-36	Aortic root size;
BRCA	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg27478167	chr7:817139	HEATR2	-0.42	-8.98	-0.33	3.03e-18	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7246967	0.673	rs937078	chr19:22811667	G/A	cg23217946	chr19:22817039	ZNF492	0.47	8.43	0.32	2.22e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs11112613	0.713	rs4015312	chr12:105948757	A/G	cg03607813	chr12:105948248	NA	0.6	9.46	0.35	5.86e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg23285459	chr7:2802560	GNA12	0.32	8.15	0.31	1.94e-15	Height;
BRCA	cis	rs4363385	0.818	rs4576617	chr1:152985729	G/A	cg24667326	chr1:152973720	SPRR3	-0.32	-8.91	-0.33	5.26e-18	Inflammatory skin disease;
BRCA	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg04455712	chr21:45112962	RRP1B	0.41	10.88	0.4	2.13e-25	Mean corpuscular volume;
BRCA	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg02248941	chr16:2239361	CASKIN1	0.48	11.21	0.41	9.91e-27	Height;
BRCA	cis	rs11585357	0.895	rs877552	chr1:17631236	C/T	cg08277548	chr1:17600880	PADI3	-0.69	-11.79	-0.42	3.58e-29	Hair shape;
BRCA	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg20701182	chr2:24300061	SF3B14	0.58	9.11	0.34	1.04e-18	Lymphocyte counts;
BRCA	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg06627628	chr2:24431161	ITSN2	0.44	9.1	0.34	1.18e-18	Asthma;
BRCA	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg10174797	chr19:8464628	RAB11B	0.35	9.01	0.34	2.4e-18	HDL cholesterol;
BRCA	cis	rs1163251	0.902	rs511059	chr1:120217081	G/T	cg19096424	chr1:120255104	PHGDH	0.44	9.68	0.36	9.06e-21	Blood metabolite levels;
BRCA	cis	rs12413816	0.784	rs35537139	chr10:13768894	G/A	cg16485048	chr10:13749193	FRMD4A	0.58	12.81	0.45	1.3e-33	Red cell distribution width;
BRCA	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg23625390	chr15:77176239	SCAPER	0.53	12.59	0.45	1.22e-32	Blood metabolite levels;
BRCA	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24308560	chr3:49941425	MST1R	0.38	7.91	0.3	1.13e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg06521331	chr12:34319734	NA	-0.56	-10.84	-0.39	2.95e-25	Morning vs. evening chronotype;
BRCA	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg11822812	chr5:140052017	DND1	-0.32	-8.69	-0.33	3.01e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg16006841	chr5:176797999	RGS14	-0.68	-10.84	-0.39	2.9e-25	Urate levels in lean individuals;
BRCA	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg26818010	chr10:134567672	INPP5A	-0.79	-15.79	-0.53	1.13e-47	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg09537434	chr19:41945824	ATP5SL	-0.99	-23.35	-0.68	1.14e-87	Height;
BRCA	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg25019033	chr10:957182	NA	-0.41	-7.93	-0.3	9.72e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-9.86	-0.36	1.94e-21	Daytime sleep phenotypes;
BRCA	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg16325326	chr1:53192061	ZYG11B	0.86	25.56	0.71	7.97e-100	Monocyte count;
BRCA	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg10876282	chr6:28092338	ZSCAN16	0.4	7.91	0.3	1.17e-14	Parkinson's disease;
BRCA	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg18279126	chr7:2041391	MAD1L1	0.39	8.76	0.33	1.74e-17	Bipolar disorder and schizophrenia;
BRCA	trans	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg06521331	chr12:34319734	NA	-0.44	-8.35	-0.31	4.37e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	14.94	0.51	1.61e-43	Hip circumference adjusted for BMI;
BRCA	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg23711669	chr6:146136114	FBXO30	-0.8	-19.42	-0.61	2.14e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg01689657	chr7:91764605	CYP51A1	0.22	8.05	0.3	4.16e-15	Breast cancer;
BRCA	cis	rs2710642	0.962	rs2058567	chr2:63091426	T/C	cg17519650	chr2:63277830	OTX1	0.36	7.93	0.3	9.58e-15	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.85	-0.33	8.29e-18	Alzheimer's disease (late onset);
BRCA	cis	rs4363385	0.620	rs4388644	chr1:152983674	A/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.78	-0.36	3.98e-21	Inflammatory skin disease;
BRCA	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg01819863	chr10:32635814	EPC1	1.14	20.12	0.62	4.08e-70	Sexual dysfunction (female);
BRCA	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg09035930	chr12:129282057	SLC15A4	0.57	17.35	0.57	1.48e-55	Systemic lupus erythematosus;
BRCA	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg24642844	chr7:1081250	C7orf50	-0.88	-16.14	-0.54	2.03e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.07	0.3	3.4e-15	Uric acid levels;
BRCA	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg18230493	chr5:56204884	C5orf35	0.87	16.37	0.54	1.48e-50	Initial pursuit acceleration;
BRCA	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg18129178	chr5:148520854	ABLIM3	0.58	11.94	0.43	8.41e-30	Breast cancer;
BRCA	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.45	10.52	0.38	5.34e-24	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg05347473	chr6:146136440	FBXO30	-0.41	-8.06	-0.3	3.86e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2415984	0.622	rs10131871	chr14:46931700	A/G	cg14871534	chr14:47121158	RPL10L	0.36	8.6	0.32	6.09e-17	Number of children ever born;
BRCA	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.71	15.02	0.51	7.21e-44	Lymphocyte counts;
BRCA	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg06618935	chr21:46677482	NA	-0.37	-7.99	-0.3	6.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg21252483	chr19:49399788	TULP2	-0.51	-10.75	-0.39	7e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg00530320	chr1:46809349	NSUN4	0.48	9.6	0.35	1.83e-20	Menopause (age at onset);
BRCA	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.54	0.38	4.55e-24	IgG glycosylation;
BRCA	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.64	-13.56	-0.47	5.61e-37	Lung cancer;
BRCA	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs7586879	0.828	rs1968482	chr2:25086858	T/C	cg04586622	chr2:25135609	ADCY3	0.39	9.19	0.34	5.48e-19	Body mass index;
BRCA	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg12751644	chr20:60527061	NA	-0.33	-7.88	-0.3	1.4e-14	Body mass index;
BRCA	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg05793240	chr7:2802953	GNA12	-0.34	-8.77	-0.33	1.67e-17	Height;
BRCA	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg02551604	chr5:131831745	NA	-0.4	-15.26	-0.52	4.76e-45	Asthma (sex interaction);
BRCA	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg13175981	chr1:150552382	MCL1	0.49	10.93	0.4	1.31e-25	Tonsillectomy;
BRCA	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg05234568	chr11:5960015	NA	-0.44	-9.49	-0.35	4.45e-20	DNA methylation (variation);
BRCA	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg02951883	chr7:2050386	MAD1L1	-0.41	-9.55	-0.35	2.83e-20	Schizophrenia;
BRCA	cis	rs1044826	0.642	rs186103	chr3:139211942	C/A	cg00490450	chr3:139108681	COPB2	0.45	8.96	0.33	3.66e-18	Obesity-related traits;
BRCA	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg25036284	chr2:26402008	FAM59B	0.88	15.06	0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg08807101	chr21:30365312	RNF160	-0.76	-19.95	-0.62	3.21e-69	Dental caries;
BRCA	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg16680214	chr1:154839983	KCNN3	-0.45	-12.42	-0.44	6.9e-32	Prostate cancer;
BRCA	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.51	-0.35	3.69e-20	Hip circumference adjusted for BMI;
BRCA	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06108461	chr20:60628389	TAF4	-0.98	-22.18	-0.66	2.8e-81	Body mass index;
BRCA	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg24692254	chr21:30365293	RNF160	0.5	11.25	0.41	6.76e-27	Cognitive test performance;
BRCA	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.44	12.93	0.46	4e-34	Response to antipsychotic treatment;
BRCA	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg21132104	chr15:45694354	SPATA5L1	0.71	15.82	0.53	8.38e-48	Homoarginine levels;
BRCA	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg23711669	chr6:146136114	FBXO30	0.67	15.72	0.53	2.52e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg13385521	chr17:29058706	SUZ12P	0.62	8.49	0.32	1.49e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	trans	rs3960554	0.867	rs11489553	chr7:75843062	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	11.68	0.42	1.08e-28	Eotaxin levels;
BRCA	trans	rs931812	0.895	rs4236763	chr8:101913022	G/A	cg20993868	chr7:22813445	NA	0.52	14.22	0.49	4.5e-40	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg00852783	chr1:26633632	UBXN11	-0.46	-8.09	-0.3	2.9e-15	Obesity-related traits;
BRCA	cis	rs10170846	0.800	rs10194743	chr2:223518151	A/G	cg25565276	chr2:223520875	FARSB	0.48	13.04	0.46	1.2e-34	Schizophrenia (inflammation and infection response interaction);
BRCA	trans	rs2736345	0.516	rs7844858	chr8:11392659	T/A	cg06636001	chr8:8085503	FLJ10661	0.41	8.4	0.32	2.89e-16	Sjögren's syndrome;Systemic lupus erythematosus;
BRCA	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.44	-0.32	2.08e-16	Monocyte percentage of white cells;
BRCA	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg03060546	chr3:49711283	APEH	-0.59	-11.93	-0.43	9.23e-30	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs1874326	0.504	rs7793703	chr7:138113421	T/G	cg18008034	chr7:138118925	NA	-0.44	-9.04	-0.34	1.78e-18	Quantitative traits;
BRCA	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.91	-18.14	-0.58	1.23e-59	Alzheimer's disease;
BRCA	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg13010199	chr12:38710504	ALG10B	0.43	9.22	0.34	4.33e-19	Morning vs. evening chronotype;
BRCA	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg01874867	chr7:94954059	PON1	-0.39	-7.83	-0.3	2.03e-14	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs736801	0.759	rs11741255	chr5:131811182	G/A	cg07395648	chr5:131743802	NA	-0.38	-8.49	-0.32	1.46e-16	Breast cancer;Mosquito bite size;
BRCA	cis	rs2742234	0.541	rs10793422	chr10:43703874	G/A	cg15436174	chr10:43711423	RASGEF1A	0.56	11.34	0.41	2.82e-27	Hirschsprung disease;
BRCA	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg00074818	chr8:8560427	CLDN23	0.37	8.25	0.31	9.1e-16	Obesity-related traits;
BRCA	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.28e-23	Prostate cancer;
BRCA	cis	rs11051970	0.879	rs2728669	chr12:32590651	C/T	cg02745156	chr12:32552066	NA	0.27	8.64	0.32	4.45e-17	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.88	0.4	2.02e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1215050	0.791	rs13114823	chr4:98671119	G/A	cg05340658	chr4:99064831	C4orf37	-0.44	-9.88	-0.36	1.57e-21	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10465746	0.714	rs12730621	chr1:84433745	C/G	cg10977910	chr1:84465055	TTLL7	0.57	11.92	0.43	1.01e-29	Obesity-related traits;
BRCA	cis	rs1832871	0.672	rs9456289	chr6:158740347	G/A	cg07165851	chr6:158734300	TULP4	0.63	12.61	0.45	9.95e-33	Height;
BRCA	cis	rs34293785	0.565	rs59710023	chr1:66137193	T/C	cg04111102	chr1:66153794	NA	0.36	8.71	0.33	2.67e-17	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;
BRCA	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg06453172	chr10:134556979	INPP5A	-0.49	-10.67	-0.39	1.47e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg05623727	chr3:50126028	RBM5	-0.51	-12.14	-0.43	1.2e-30	Body mass index;
BRCA	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-8.73	-0.33	2.19e-17	Monocyte percentage of white cells;
BRCA	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22455342	chr2:225449267	CUL3	0.37	8.71	0.33	2.57e-17	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.59	-12.34	-0.44	1.56e-31	Lymphocyte counts;
BRCA	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg08470875	chr2:26401718	FAM59B	-0.51	-8.21	-0.31	1.19e-15	Gut microbiome composition (summer);
BRCA	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg05294307	chr14:35346193	BAZ1A	-0.6	-10.39	-0.38	1.88e-23	Psoriasis;
BRCA	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.7	0.36	7.73e-21	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg03676636	chr4:99064102	C4orf37	0.21	7.94	0.3	9.23e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6580649	1.000	rs3825404	chr12:48399931	A/G	cg24011408	chr12:48396354	COL2A1	0.52	8.95	0.33	3.72e-18	Lung cancer;
BRCA	cis	rs9487051	0.803	rs11153161	chr6:109541774	A/G	cg21918786	chr6:109611834	NA	-0.35	-8.59	-0.32	6.46e-17	Reticulocyte fraction of red cells;
BRCA	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17830980	chr10:43048298	ZNF37B	0.57	14.06	0.49	2.5e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4919087	0.884	rs4917762	chr10:98976471	G/T	cg25902810	chr10:99078978	FRAT1	0.4	8.5	0.32	1.31e-16	Monocyte count;
BRCA	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.77	12.92	0.46	4.48e-34	Schizophrenia;
BRCA	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.6	0.32	6.26e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00166722	chr3:10149974	C3orf24	0.58	10.03	0.37	4.48e-22	Alzheimer's disease;
BRCA	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19723775	chr5:179050963	HNRNPH1	0.37	8.71	0.33	2.67e-17	Lung cancer;
BRCA	trans	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg25214090	chr10:38739885	LOC399744	0.37	8.78	0.33	1.52e-17	Diastolic blood pressure;
BRCA	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg13319975	chr6:146136371	FBXO30	-0.34	-8.03	-0.3	4.84e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg23708337	chr7:1209742	NA	0.63	8.86	0.33	8.16e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4660306	0.961	rs945179	chr1:45992460	A/G	cg24296786	chr1:45957014	TESK2	-0.44	-8.86	-0.33	7.94e-18	Homocysteine levels;
BRCA	cis	rs4953076	0.573	rs67537903	chr2:44422111	G/A	cg04920474	chr2:44395004	PPM1B	0.51	10.13	0.37	1.81e-22	Height;
BRCA	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg22535103	chr8:58192502	C8orf71	-0.46	-8.09	-0.3	2.94e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg16850897	chr7:100343110	ZAN	0.45	9.83	0.36	2.48e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg13319975	chr6:146136371	FBXO30	0.34	8.0	0.3	5.98e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4900538	0.855	rs1190537	chr14:102887816	C/T	cg18135206	chr14:102964638	TECPR2	-0.91	-21.41	-0.65	4.58e-77	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.08	-0.43	2.06e-30	Total cholesterol levels;
BRCA	cis	rs17092148	0.887	rs4911430	chr20:33145404	C/G	cg16810054	chr20:33298113	TP53INP2	-0.45	-10.09	-0.37	2.64e-22	Neuroticism;
BRCA	cis	rs701145	0.556	rs355758	chr3:154007682	C/G	cg12800244	chr3:153838788	SGEF	-0.42	-8.37	-0.31	3.62e-16	Coronary artery disease;
BRCA	cis	rs965469	1.000	rs6051713	chr20:3265779	C/T	cg25506879	chr20:3388711	C20orf194	0.51	10.32	0.38	3.32e-23	IFN-related cytopenia;
BRCA	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg19274703	chr22:41806451	NA	0.34	7.9	0.3	1.23e-14	Vitiligo;
BRCA	trans	rs4650994	0.525	rs2811295	chr1:178551267	C/T	cg05059571	chr16:84539110	KIAA1609	0.54	12.45	0.44	5.11e-32	HDL cholesterol levels;HDL cholesterol;
BRCA	trans	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg06521331	chr12:34319734	NA	0.53	10.15	0.37	1.54e-22	Bladder cancer;
BRCA	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.8	-0.33	1.23e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.12	0.4	2.24e-26	Bipolar disorder;
BRCA	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.59	0.32	6.78e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4930561	0.765	rs7931502	chr11:67959607	A/C	cg16338278	chr11:67432957	ALDH3B2	-0.41	-8.41	-0.32	2.75e-16	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg06636001	chr8:8085503	FLJ10661	0.55	10.4	0.38	1.61e-23	Retinal vascular caliber;
BRCA	cis	rs6063312	1.000	rs6063313	chr20:47343532	G/A	cg18078177	chr20:47281410	PREX1	0.65	11.26	0.41	5.84e-27	Tonometry;
BRCA	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg13010199	chr12:38710504	ALG10B	0.5	10.72	0.39	9.15e-25	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg06026331	chr20:60912101	LAMA5	0.63	12.51	0.44	2.91e-32	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs12611088	0.515	rs2599454	chr19:44025201	T/C	cg15012607	chr19:44012195	ETHE1	-0.35	-9.02	-0.34	2.09e-18	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs1555322	0.530	rs2297789	chr20:33867248	A/T	cg03689076	chr20:33865952	NA	0.46	8.47	0.32	1.73e-16	Attention deficit hyperactivity disorder;
BRCA	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	14.13	0.49	1.18e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg26043149	chr18:55253948	FECH	-0.37	-8.25	-0.31	9.22e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg02030672	chr11:45687055	CHST1	-0.37	-7.91	-0.3	1.1e-14	Obesity-related traits;
BRCA	trans	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg17971929	chr21:40555470	PSMG1	-0.48	-10.57	-0.39	3.68e-24	Menarche (age at onset);
BRCA	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg20090143	chr19:45452003	APOC2	0.27	8.04	0.3	4.44e-15	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.37e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.39	-0.35	1e-19	Body mass index;
BRCA	trans	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-10.61	-0.39	2.36e-24	Triglycerides;
BRCA	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-9.09	-0.34	1.2e-18	Schizophrenia;
BRCA	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg26384229	chr12:38710491	ALG10B	0.68	14.43	0.5	4.38e-41	Morning vs. evening chronotype;
BRCA	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg22496339	chr2:162101262	NA	0.4	8.1	0.31	2.83e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10227331	1.000	rs10227331	chr7:157294938	A/T	cg04156418	chr7:157293606	NA	0.37	10.97	0.4	9.05e-26	Inattentive symptoms;
BRCA	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg09436375	chr6:42928200	GNMT	-0.3	-11.12	-0.4	2.14e-26	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7524258	0.868	rs4908607	chr1:7269323	A/G	cg07173049	chr1:7289937	CAMTA1	0.45	11.14	0.4	1.91e-26	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg04317338	chr11:64019027	PLCB3	0.56	9.56	0.35	2.43e-20	Mean platelet volume;
BRCA	cis	rs2731664	0.792	rs335468	chr5:176892349	A/G	cg23176889	chr5:176863531	GRK6	0.59	15.55	0.52	1.8e-46	Intelligence (multi-trait analysis);
BRCA	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.16	0.31	1.74e-15	Menarche (age at onset);
BRCA	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg26587870	chr6:27730563	NA	-0.43	-7.86	-0.3	1.64e-14	Lung cancer in ever smokers;
BRCA	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.27e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg08601574	chr20:25228251	PYGB	-0.34	-8.25	-0.31	9.18e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg06484146	chr7:12443880	VWDE	-0.62	-9.86	-0.36	1.98e-21	Coronary artery disease;
BRCA	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg20307385	chr11:47447363	PSMC3	0.4	8.44	0.32	2.1e-16	Subjective well-being;
BRCA	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.71	19.47	0.61	1.28e-66	Chronic sinus infection;
BRCA	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg06212747	chr3:49208901	KLHDC8B	0.47	9.56	0.35	2.4e-20	Parkinson's disease;
BRCA	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	9.31e-21	Menopause (age at onset);
BRCA	trans	rs3960554	0.674	rs113848658	chr7:75791858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.59	11.94	0.43	8.64e-30	Eotaxin levels;
BRCA	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.65	-14.76	-0.5	1.2e-42	Breast cancer;
BRCA	cis	rs68170813	0.559	rs76534758	chr7:106963262	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-8.85	-0.33	8.5e-18	Coronary artery disease;
BRCA	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg08885076	chr2:99613938	TSGA10	0.45	10.46	0.38	9.8599999999999993e-24	Chronic sinus infection;
BRCA	cis	rs9790314	0.747	rs1610158	chr3:160815050	A/G	cg03342759	chr3:160939853	NMD3	0.5	10.1	0.37	2.34e-22	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.89	0.36	1.44e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg06640241	chr16:89574553	SPG7	-0.75	-18.4	-0.59	5.61e-61	Multiple myeloma (IgH translocation);
BRCA	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg04362960	chr10:104952993	NT5C2	0.46	9.95	0.37	8.89e-22	Arsenic metabolism;
BRCA	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg07636037	chr3:49044803	WDR6	0.58	9.29	0.35	2.3e-19	Menarche (age at onset);
BRCA	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg09526685	chr4:187126073	CYP4V2	-1.0	-11.98	-0.43	5.42e-30	Blood protein levels;
BRCA	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg06623918	chr6:96969491	KIAA0776	-0.77	-13.77	-0.48	5.7800000000000005e-38	Migraine;Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg20607798	chr8:58055168	NA	0.47	8.07	0.3	3.41e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg00701064	chr4:6280414	WFS1	0.66	14.53	0.5	1.54e-41	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	trans	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg25214090	chr10:38739885	LOC399744	0.45	10.41	0.38	1.48e-23	Corneal astigmatism;
BRCA	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06544989	chr22:39130855	UNC84B	-0.38	-8.4	-0.32	3e-16	Menopause (age at onset);
BRCA	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg24812749	chr6:127587940	RNF146	0.88	20.56	0.63	1.81e-72	Breast cancer;
BRCA	cis	rs1371614	0.655	rs7579579	chr2:27151842	C/T	cg00617064	chr2:27272375	NA	0.31	7.9	0.3	1.22e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs4588572	0.645	rs10059940	chr5:77680873	T/C	cg11547950	chr5:77652471	NA	0.44	7.84	0.3	1.95e-14	Triglycerides;
BRCA	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.78	-0.33	1.48e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg13456504	chr1:91191583	NA	-0.53	-9.97	-0.37	7.35e-22	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.55	8.33	0.31	4.93e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7092929	0.882	rs535539	chr10:3574757	T/C	cg14308648	chr10:3568949	NA	0.46	8.17	0.31	1.7e-15	Coronary artery calcification;
BRCA	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-14.17	-0.49	7.89e-40	Chronic sinus infection;
BRCA	cis	rs13064411	0.660	rs11916690	chr3:113012343	A/C	cg18753928	chr3:113234510	CCDC52	-0.42	-7.84	-0.3	1.94e-14	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.16	-0.31	1.75e-15	Total body bone mineral density;
BRCA	cis	rs1712517	0.771	rs11191645	chr10:105059308	G/T	cg05636881	chr10:105038444	INA	0.35	7.87	0.3	1.52e-14	Migraine;
BRCA	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24549020	chr5:56110836	MAP3K1	0.37	8.06	0.3	3.64e-15	Coronary artery disease;
BRCA	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18404041	chr3:52824283	ITIH1	-0.28	-8.21	-0.31	1.19e-15	Electroencephalogram traits;
BRCA	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg21918786	chr6:109611834	NA	0.48	13.64	0.47	2.3e-37	Reticulocyte fraction of red cells;
BRCA	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg13256891	chr4:100009986	ADH5	0.47	9.06	0.34	1.52e-18	Alcohol dependence;
BRCA	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-15.6	-0.53	1.01e-46	Electrocardiographic conduction measures;
BRCA	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg04267008	chr7:1944627	MAD1L1	-0.56	-11.94	-0.43	8.21e-30	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18713687	chr3:195489789	MUC4	0.55	8.59	0.32	6.62e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg18129178	chr5:148520854	ABLIM3	-0.58	-11.65	-0.42	1.44e-28	Breast cancer;
BRCA	cis	rs919433	0.713	rs10172961	chr2:198446859	T/C	cg00792783	chr2:198669748	PLCL1	0.34	7.9	0.3	1.25e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg10224037	chr5:178157518	ZNF354A	0.73	15.45	0.52	5.33e-46	Neutrophil percentage of white cells;
BRCA	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-12.97	-0.46	2.56e-34	Migraine;Coronary artery disease;
BRCA	trans	rs61931739	0.635	rs10772122	chr12:33964674	A/C	cg26384229	chr12:38710491	ALG10B	0.39	8.88	0.33	6.71e-18	Morning vs. evening chronotype;
BRCA	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg13256891	chr4:100009986	ADH5	0.53	12.16	0.43	9.14e-31	HDL cholesterol;HDL cholesterol levels;
BRCA	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg21770322	chr7:97807741	LMTK2	0.44	11.53	0.41	4.62e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11955398	0.678	rs1824120	chr5:59997929	G/A	cg02684056	chr5:59996105	DEPDC1B	0.39	9.35	0.35	1.42e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7707921	0.881	rs324910	chr5:81400264	A/C	cg15871215	chr5:81402204	ATG10	-0.38	-8.09	-0.3	3.09e-15	Breast cancer;
BRCA	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00149659	chr3:10157352	C3orf10	0.65	10.1	0.37	2.47e-22	Alzheimer's disease;
BRCA	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg18132916	chr6:79620363	NA	0.46	10.37	0.38	2.11e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg10578991	chr7:12443926	VWDE	-0.55	-8.04	-0.3	4.22e-15	Coronary artery disease;
BRCA	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-9.65	-0.36	1.2e-20	Menopause (age at onset);
BRCA	cis	rs6546550	0.935	rs6747542	chr2:70106832	T/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-9.5	-0.35	4.09e-20	Prevalent atrial fibrillation;
BRCA	cis	rs2066819	1.000	rs871130	chr12:56648777	A/G	cg26714650	chr12:56694279	CS	1.05	14.03	0.49	3.71e-39	Psoriasis vulgaris;
BRCA	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg24562669	chr7:97807699	LMTK2	0.47	12.45	0.44	5.09e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg26384229	chr12:38710491	ALG10B	-0.62	-16.28	-0.54	4.3e-50	Heart rate;
BRCA	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.68	-11.83	-0.42	2.36e-29	Smoking behavior;
BRCA	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg18154014	chr19:37997991	ZNF793	0.48	9.41	0.35	8.49e-20	Coronary artery calcification;
BRCA	cis	rs912057	0.526	rs201061	chr6:6730512	C/T	cg06612196	chr6:6737390	NA	-0.54	-13.44	-0.47	2e-36	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg17211192	chr8:82754475	SNX16	-0.5	-11.16	-0.4	1.51e-26	Diastolic blood pressure;
BRCA	cis	rs701145	0.938	rs701147	chr3:154048295	C/T	cg17054900	chr3:154042577	DHX36	0.68	11.88	0.43	1.56e-29	Coronary artery disease;
BRCA	cis	rs7555523	0.779	rs6662839	chr1:165722646	T/G	cg24409356	chr1:165738333	TMCO1	0.51	8.25	0.31	9.16e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	trans	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg15704280	chr7:45808275	SEPT13	0.54	8.09	0.3	3.03e-15	Axial length;
BRCA	cis	rs4409675	0.527	rs12067053	chr1:28227122	T/G	cg23691781	chr1:28212827	C1orf38	0.32	10.91	0.4	1.51e-25	Corneal astigmatism;
BRCA	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg03923535	chr7:1197113	ZFAND2A	0.47	9.55	0.35	2.7e-20	Longevity;Endometriosis;
BRCA	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg03808351	chr9:123631620	PHF19	0.39	7.81	0.3	2.3e-14	Rheumatoid arthritis;
BRCA	cis	rs7737355	0.947	rs6596007	chr5:130588550	A/G	cg06307176	chr5:131281290	NA	-0.44	-8.58	-0.32	7.31e-17	Life satisfaction;
BRCA	cis	rs9837602	1.000	rs13323143	chr3:99811553	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.18	0.4	1.25e-26	Breast cancer;
BRCA	trans	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-9.5	-0.35	4.26e-20	Retinal vascular caliber;
BRCA	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg25174290	chr11:3078921	CARS	0.44	12.84	0.45	9.5e-34	Longevity;
BRCA	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.87	19.3	0.61	9.47e-66	Cognitive ability;
BRCA	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg15704280	chr7:45808275	SEPT13	-0.8	-19.07	-0.6	1.55e-64	Coronary artery disease;
BRCA	cis	rs812925	0.553	rs1177307	chr2:61387388	T/C	cg15711740	chr2:61764176	XPO1	-0.32	-7.98	-0.3	6.66e-15	Immature fraction of reticulocytes;
BRCA	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	ch.11.42038R	chr11:967971	AP2A2	0.47	14.4	0.49	6.56e-41	Alzheimer's disease (late onset);
BRCA	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18876405	chr7:65276391	NA	-0.51	-11.59	-0.42	2.49e-28	Aortic root size;
BRCA	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	9.87	0.36	1.84e-21	Aortic root size;
BRCA	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg27446573	chr6:127587934	RNF146	0.89	21.1	0.64	2.1e-75	Breast cancer;
BRCA	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg17063962	chr7:91808500	NA	0.57	13.11	0.46	6.29e-35	Breast cancer;
BRCA	cis	rs10871290	0.881	rs7498574	chr16:74472661	A/G	cg01733217	chr16:74700730	RFWD3	-0.53	-12.42	-0.44	7.29e-32	Breast cancer;
BRCA	cis	rs2882667	0.690	rs3749664	chr5:138271421	T/C	cg04439458	chr5:138467593	SIL1	-0.32	-8.08	-0.3	3.13e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg21132104	chr15:45694354	SPATA5L1	0.71	15.37	0.52	1.32e-45	Homoarginine levels;
BRCA	cis	rs1018836	0.923	rs7007102	chr8:91629730	T/A	cg16814680	chr8:91681699	NA	-0.6	-12.86	-0.45	8.05e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08564027	chr20:61660810	NA	0.85	22.97	0.67	1.42e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg02734326	chr4:10020555	SLC2A9	0.36	7.88	0.3	1.37e-14	Bone mineral density;
BRCA	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-11.77	-0.42	4.6e-29	Homoarginine levels;
BRCA	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg13010199	chr12:38710504	ALG10B	0.5	9.96	0.37	8.03e-22	Bladder cancer;
BRCA	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.34	-8.77	-0.33	1.61e-17	Total body bone mineral density;
BRCA	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg20203395	chr5:56204925	C5orf35	0.4	8.69	0.32	3.12e-17	Coronary artery disease;
BRCA	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg21856205	chr7:94953877	PON1	-0.37	-7.97	-0.3	7.26e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg13047869	chr3:10149882	C3orf24	0.52	10.91	0.4	1.6e-25	Alzheimer's disease;
BRCA	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg02951883	chr7:2050386	MAD1L1	0.51	12.99	0.46	2.18e-34	Bipolar disorder and schizophrenia;
BRCA	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg22974920	chr21:40686053	BRWD1	-0.41	-8.96	-0.33	3.5e-18	Cognitive function;
BRCA	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06022373	chr22:39101656	GTPBP1	0.7	15.93	0.53	2.26e-48	Menopause (age at onset);
BRCA	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg07080220	chr10:102295463	HIF1AN	0.5	10.35	0.38	2.59e-23	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9462027	0.630	rs7341267	chr6:34727031	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.01	-0.3	5.38e-15	Systemic lupus erythematosus;
BRCA	cis	rs6878727	0.549	rs2561485	chr5:123645843	C/G	cg01806427	chr5:123737813	NA	0.39	9.01	0.34	2.44e-18	Breast cancer;
BRCA	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg21252483	chr19:49399788	TULP2	-0.51	-10.82	-0.39	3.49e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs3771570	1.000	rs1056801	chr2:242292307	T/C	cg21155796	chr2:242212141	HDLBP	0.6	9.3	0.35	2.25e-19	Prostate cancer;
BRCA	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg01305625	chr5:131593812	PDLIM4	0.34	8.07	0.3	3.4e-15	Acylcarnitine levels;
BRCA	trans	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.4	-0.35	9.72e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	11.06	0.4	3.86e-26	Monocyte percentage of white cells;
BRCA	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg02574844	chr11:5959923	NA	-0.39	-7.96	-0.3	7.99e-15	DNA methylation (variation);
BRCA	cis	rs9420	0.528	rs11229075	chr11:57391023	A/C	cg19752551	chr11:57585705	CTNND1	-0.41	-9.55	-0.35	2.7e-20	Schizophrenia;
BRCA	trans	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-8.24	-0.31	9.44e-16	Menarche (age at onset);
BRCA	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	13.45	0.47	1.66e-36	Mean platelet volume;
BRCA	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	trans	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.65	-0.36	1.17e-20	Bladder cancer;
BRCA	cis	rs929596	0.561	rs6431625	chr2:234637912	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-9.94	-0.37	9.64e-22	Total bilirubin levels in HIV-1 infection;
BRCA	trans	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg25214090	chr10:38739885	LOC399744	0.5	10.98	0.4	8.36e-26	Corneal astigmatism;
BRCA	cis	rs754466	0.606	rs11002315	chr10:79617385	T/G	cg17075019	chr10:79541650	NA	-0.73	-17.63	-0.57	5.75e-57	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	8.25	0.31	9.2e-16	Axial length;
BRCA	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg02503808	chr4:7069936	GRPEL1	-0.75	-14.94	-0.51	1.66e-43	Monocyte percentage of white cells;
BRCA	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg18512352	chr11:47633146	NA	-0.34	-8.24	-0.31	9.79e-16	Subjective well-being;
BRCA	cis	rs11191270	0.554	rs11191265	chr10:104102118	G/A	cg15320455	chr10:103880129	LDB1	0.71	10.44	0.38	1.12e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg00339695	chr16:24857497	SLC5A11	0.5	9.96	0.37	8.18e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs4908768	0.501	rs11121199	chr1:8600192	G/A	cg20416874	chr1:8611966	RERE	-0.28	-8.02	-0.3	5.06e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg00666640	chr1:248458726	OR2T12	-0.3	-8.29	-0.31	6.76e-16	Common traits (Other);
BRCA	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg18154014	chr19:37997991	ZNF793	0.48	9.41	0.35	8.49e-20	Coronary artery calcification;
BRCA	cis	rs36051895	0.664	rs3780372	chr9:5097544	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-9.91	-0.36	1.29e-21	Pediatric autoimmune diseases;
BRCA	cis	rs12474201	0.889	rs2346878	chr2:46922870	C/T	cg06386533	chr2:46925753	SOCS5	0.91	19.96	0.62	2.87e-69	Height;
BRCA	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg17366294	chr4:99064904	C4orf37	0.41	9.64	0.36	1.28e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1568889	0.877	rs34351528	chr11:28304293	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	13.13	0.46	4.93e-35	Bipolar disorder;
BRCA	cis	rs897984	0.571	rs7184567	chr16:31021078	C/T	cg02466173	chr16:30829666	NA	-0.44	-9.85	-0.36	2.17e-21	Dementia with Lewy bodies;
BRCA	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg17366294	chr4:99064904	C4orf37	0.45	10.76	0.39	6.24e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-13.87	-0.48	2.03e-38	Personality dimensions;
BRCA	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg18270830	chr10:32634957	EPC1	0.61	10.26	0.38	5.64e-23	Sexual dysfunction (female);
BRCA	trans	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg25214090	chr10:38739885	LOC399744	0.53	11.77	0.42	4.25e-29	Corneal astigmatism;
BRCA	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.18	-0.31	1.53e-15	Bipolar disorder;
BRCA	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg03676636	chr4:99064102	C4orf37	0.22	8.1	0.31	2.7e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg14829155	chr15:31115871	NA	-0.5	-12.3	-0.44	2.4e-31	Huntington's disease progression;
BRCA	cis	rs1190552	0.841	rs56144019	chr14:102949731	G/A	cg18135206	chr14:102964638	TECPR2	0.44	8.51	0.32	1.19e-16	Blood protein levels;
BRCA	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	12.03	0.43	3.31e-30	Mood instability;
BRCA	cis	rs911119	1.000	rs13038305	chr20:23610262	C/T	cg16589663	chr20:23618590	CST3	0.45	8.56	0.32	8.7e-17	Chronic kidney disease;
BRCA	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.8	0.33	1.28e-17	Motion sickness;
BRCA	cis	rs4363385	0.747	rs6665575	chr1:152960506	G/A	cg24667326	chr1:152973720	SPRR3	-0.32	-9.0	-0.34	2.56e-18	Inflammatory skin disease;
BRCA	trans	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg22153745	chr1:153894579	GATAD2B	-0.49	-9.64	-0.36	1.24e-20	Total cholesterol levels;
BRCA	cis	rs7727544	0.557	rs715285	chr5:131485383	A/G	cg14196790	chr5:131705035	SLC22A5	0.36	8.91	0.33	5.2e-18	Blood metabolite levels;
BRCA	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg13256891	chr4:100009986	ADH5	0.49	10.3	0.38	3.9699999999999997e-23	Alcohol dependence;
BRCA	cis	rs6738485	0.601	rs7566680	chr2:106851657	G/A	cg16099169	chr2:106886729	NA	-0.4	-8.58	-0.32	7.34e-17	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
BRCA	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.54	0.5	1.33e-41	Motion sickness;
BRCA	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg13550731	chr2:172543902	DYNC1I2	0.92	30.43	0.77	2.21e-126	Schizophrenia;
BRCA	cis	rs9341808	0.754	rs3805925	chr6:80883833	T/C	cg08355045	chr6:80787529	NA	0.39	10.01	0.37	5.38e-22	Sitting height ratio;
BRCA	trans	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg26043149	chr18:55253948	FECH	0.4	8.48	0.32	1.59e-16	Bone mineral density;
BRCA	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg10560079	chr2:191398806	TMEM194B	-0.79	-13.35	-0.47	4.91e-36	Diastolic blood pressure;
BRCA	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.78e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg00383909	chr3:49044727	WDR6	0.71	12.63	0.45	8.28e-33	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg11657440	chr19:46296263	DMWD	-0.54	-12.71	-0.45	3.8e-33	Coronary artery disease;
BRCA	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.04	0.4	4.78e-26	Rheumatoid arthritis;
BRCA	cis	rs523395	0.630	rs616111	chr1:120269991	C/G	cg19096424	chr1:120255104	PHGDH	-0.43	-9.58	-0.35	2.12e-20	Red blood cell count;
BRCA	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg12863693	chr15:85201151	NMB	0.57	12.09	0.43	1.83e-30	Schizophrenia;
BRCA	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg03060546	chr3:49711283	APEH	-0.6	-10.41	-0.38	1.47e-23	Menarche (age at onset);
BRCA	trans	rs6479891	1.000	rs2616630	chr10:65213339	A/C	cg14819942	chr15:35414228	NA	0.35	8.55	0.32	8.78e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg18252515	chr7:66147081	NA	-0.97	-13.78	-0.48	5.15e-38	Diabetic kidney disease;
BRCA	cis	rs9308433	0.733	rs11120300	chr1:214509499	A/T	cg06198575	chr1:214491504	SMYD2	-0.43	-10.0	-0.37	5.89e-22	IgG glycosylation;
BRCA	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg22903471	chr2:27725779	GCKR	-0.36	-8.78	-0.33	1.47e-17	Total body bone mineral density;
BRCA	trans	rs12517041	1.000	rs2081953	chr5:23295682	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs12612619	0.658	rs112794902	chr2:27151586	T/C	cg00617064	chr2:27272375	NA	-0.3	-7.95	-0.3	8.67e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.11	-0.31	2.68e-15	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9811920	0.965	rs9289981	chr3:99868104	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	12.95	0.46	3.02e-34	Axial length;
BRCA	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg09467607	chr2:36825704	FEZ2	0.62	15.25	0.52	5.21e-45	Height;
BRCA	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.71	0.39	1.03e-24	Bladder cancer;
BRCA	cis	rs12493885	0.769	rs61791540	chr3:153757041	G/A	cg17054900	chr3:154042577	DHX36	-0.47	-8.13	-0.31	2.23e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg22800045	chr5:56110881	MAP3K1	0.64	12.29	0.44	2.59e-31	Initial pursuit acceleration;
BRCA	trans	rs783540	0.656	rs783524	chr15:83284144	A/C	cg16105309	chr15:79090380	ADAMTS7	0.34	9.46	0.35	5.56e-20	Schizophrenia;
BRCA	cis	rs7590720	1.000	rs934154	chr2:216901933	C/T	cg12620499	chr2:216877984	MREG	0.78	22.03	0.66	1.94e-80	Alcohol dependence;
BRCA	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg13319975	chr6:146136371	FBXO30	0.42	9.75	0.36	4.84e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.53	10.6	0.39	2.8e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg06046430	chr4:77819534	ANKRD56	-0.59	-13.51	-0.47	9.05e-37	Emphysema distribution in smoking;
BRCA	cis	rs11603020	0.904	rs11606677	chr11:57383377	G/A	cg19752551	chr11:57585705	CTNND1	-0.42	-9.63	-0.36	1.41e-20	Blood protein levels;
BRCA	trans	rs61931739	0.635	rs1525895	chr12:33966496	A/G	cg26384229	chr12:38710491	ALG10B	0.38	8.73	0.33	2.23e-17	Morning vs. evening chronotype;
BRCA	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg01420254	chr6:26195488	NA	0.55	8.53	0.32	1.04e-16	Gout;Renal underexcretion gout;
BRCA	trans	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	8.14	0.31	2.11e-15	Mean corpuscular volume;
BRCA	trans	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	20.36	0.63	1.98e-71	Exhaled nitric oxide output;
BRCA	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.16	0.31	1.85e-15	Breast cancer;
BRCA	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg03188948	chr7:1209495	NA	0.74	12.46	0.44	4.9e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg11941060	chr3:133502564	NA	-0.33	-7.82	-0.3	2.2e-14	Iron status biomarkers;
BRCA	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg20362242	chr5:692897	TPPP	0.53	8.64	0.32	4.51e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg24562669	chr7:97807699	LMTK2	0.47	12.37	0.44	1.13e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-12.53	-0.44	2.41e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg14458575	chr2:238380390	NA	0.72	15.6	0.53	1.03e-46	Prostate cancer;
BRCA	cis	rs1568889	0.838	rs10835273	chr11:28156598	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	20.72	0.63	2.49e-73	Bipolar disorder;
BRCA	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg02659138	chr7:134003124	SLC35B4	0.28	8.69	0.33	2.95e-17	Mean platelet volume;
BRCA	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg24812749	chr6:127587940	RNF146	0.84	19.93	0.62	4.29e-69	Breast cancer;
BRCA	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg05347473	chr6:146136440	FBXO30	0.39	7.95	0.3	8.46e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.91	0.4	1.61e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.35	-8.0	-0.3	5.76e-15	Bipolar disorder;
BRCA	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg13010199	chr12:38710504	ALG10B	-0.39	-8.96	-0.33	3.58e-18	Morning vs. evening chronotype;
BRCA	cis	rs17818399	0.620	rs6544906	chr2:46863872	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.41	8.08	0.3	3.34e-15	Height;
BRCA	cis	rs2742234	0.910	rs2505513	chr10:43633537	C/G	cg15436174	chr10:43711423	RASGEF1A	-0.41	-8.79	-0.33	1.34e-17	Hirschsprung disease;
BRCA	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg05347473	chr6:146136440	FBXO30	0.43	8.6	0.32	6.02e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4853036	0.951	rs6718298	chr2:70145450	A/C	cg02498382	chr2:70120550	SNRNP27	-0.5	-9.88	-0.36	1.55e-21	Colorectal or endometrial cancer;
BRCA	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.45	-9.84	-0.36	2.25e-21	Coronary artery disease;
BRCA	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg04455712	chr21:45112962	RRP1B	0.35	8.76	0.33	1.71e-17	Mean corpuscular volume;
BRCA	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21659725	chr3:3221576	CRBN	0.53	13.67	0.48	1.61e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23583168	chr7:148888333	NA	-0.72	-15.67	-0.53	4.36e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg07988820	chr12:82153109	PPFIA2	-0.56	-9.16	-0.34	7.17e-19	Resting heart rate;
BRCA	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.55	0.39	4.07e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1451375	0.712	rs11974297	chr7:50618260	A/G	cg18232548	chr7:50535776	DDC	0.47	12.15	0.43	1.06e-30	Malaria;
BRCA	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.27	8.43	0.32	2.27e-16	Prostate cancer;
BRCA	cis	rs9039	1.000	rs11075212	chr16:9203899	G/A	cg08831531	chr16:9218945	NA	-0.65	-12.23	-0.44	4.93e-31	Menopause (age at onset);
BRCA	cis	rs867371	0.892	rs4344697	chr15:82545214	A/T	cg00614314	chr15:82944287	LOC80154	0.43	8.95	0.33	3.93e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs10463316	0.894	rs13361316	chr5:150765593	T/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.32	-0.31	5.39e-16	Metabolite levels (Pyroglutamine);
BRCA	trans	rs6479891	1.000	rs9414803	chr10:65188069	G/A	cg14819942	chr15:35414228	NA	0.35	8.58	0.32	7.31e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg00277334	chr10:82204260	NA	-0.5	-10.7	-0.39	1.05e-24	Post bronchodilator FEV1;
BRCA	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.32	-0.44	1.9e-31	Alzheimer's disease;
BRCA	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.02	0.58	5.02e-59	Fuchs's corneal dystrophy;
BRCA	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg22974920	chr21:40686053	BRWD1	0.38	8.71	0.33	2.59e-17	Cognitive function;
BRCA	cis	rs11971779	0.793	rs4732366	chr7:139027845	G/C	cg07862535	chr7:139043722	LUC7L2	0.45	12.0	0.43	4.41e-30	Diisocyanate-induced asthma;
BRCA	cis	rs12210905	0.541	rs62617138	chr6:27463766	C/A	cg08851530	chr6:28072375	NA	0.81	7.97	0.3	7.34e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.53	-9.19	-0.34	5.48e-19	Schizophrenia;
BRCA	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.85	-0.33	8.34e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9323205	0.861	rs56137183	chr14:51693463	C/A	cg23942311	chr14:51606299	NA	-0.41	-8.19	-0.31	1.41e-15	Cancer;
BRCA	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg00677455	chr12:58241039	CTDSP2	0.68	15.77	0.53	1.45e-47	Intelligence (multi-trait analysis);
BRCA	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg15704280	chr7:45808275	SEPT13	-0.53	-10.26	-0.38	5.58e-23	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13012494	chr21:47604986	C21orf56	0.44	8.77	0.33	1.67e-17	Testicular germ cell tumor;
BRCA	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg15103426	chr22:29168792	CCDC117	0.53	12.56	0.45	1.69e-32	Lymphocyte counts;
BRCA	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.56	8.22	0.31	1.11e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg10253484	chr15:75165896	SCAMP2	-0.52	-9.94	-0.37	9.53e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs72781680	0.716	rs2712056	chr2:23959131	C/T	cg08917208	chr2:24149416	ATAD2B	0.66	10.48	0.38	7.73e-24	Lymphocyte counts;
BRCA	cis	rs9463078	0.774	rs4373351	chr6:45276324	T/C	cg25276700	chr6:44698697	NA	-0.36	-8.13	-0.31	2.22e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18404041	chr3:52824283	ITIH1	-0.43	-12.81	-0.45	1.32e-33	Bipolar disorder;
BRCA	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18357526	chr6:26021779	HIST1H4A	0.47	8.37	0.31	3.67e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg22563815	chr15:78856949	CHRNA5	0.36	8.7	0.33	2.85e-17	Sudden cardiac arrest;
BRCA	cis	rs7766436	0.848	rs13207207	chr6:22579066	G/A	cg13666174	chr6:22585274	NA	-0.49	-11.29	-0.41	4.4e-27	Coronary artery disease;
BRCA	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg12292205	chr6:26970375	C6orf41	0.58	12.99	0.46	2.15e-34	Schizophrenia;
BRCA	cis	rs9815354	0.812	rs73071325	chr3:41809989	T/G	cg03022575	chr3:42003672	ULK4	0.72	9.86	0.36	1.95e-21	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.02	-0.49	3.77e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg24675658	chr1:53192096	ZYG11B	0.55	12.65	0.45	6.62e-33	Monocyte count;
BRCA	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg12454169	chr2:30669597	LCLAT1	0.98	12.96	0.46	3e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
BRCA	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg21226059	chr5:178986404	RUFY1	0.45	11.26	0.41	5.95e-27	Lung cancer;
BRCA	trans	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg25042112	chr7:64838748	ZNF92	-0.45	-8.27	-0.31	8.04e-16	Pain;
BRCA	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-7.86	-0.3	1.68e-14	Colorectal cancer;
BRCA	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.64	-13.19	-0.46	2.63e-35	Platelet distribution width;
BRCA	cis	rs7572263	0.724	rs6704765	chr2:209054267	C/G	cg23998903	chr2:209048830	C2orf80	-0.41	-8.45	-0.32	2.01e-16	Glioma;Non-glioblastoma glioma;
BRCA	trans	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg00953403	chr17:74099816	EXOC7	-0.45	-8.18	-0.31	1.52e-15	Psychosis in Alzheimer's disease;
BRCA	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08219700	chr8:58056026	NA	0.44	7.91	0.3	1.12e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg08392591	chr16:89556376	ANKRD11	0.49	11.63	0.42	1.73e-28	Multiple myeloma (IgH translocation);
BRCA	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	13.92	0.48	1.2e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg10523679	chr1:76189770	ACADM	-0.59	-11.06	-0.4	4.06e-26	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	20.8	0.64	8.64e-74	Platelet count;
BRCA	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg22920501	chr2:26401640	FAM59B	0.95	16.34	0.54	1.98e-50	Gut microbiome composition (summer);
BRCA	cis	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg07460842	chr6:66804631	NA	-1.16	-37.81	-0.83	3.83e-165	Exhaled nitric oxide output;
BRCA	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.3	8.15	0.31	1.99e-15	Hemoglobin concentration;
BRCA	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.58	-8.83	-0.33	1.01e-17	Body mass index (adult);
BRCA	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.24	-0.38	7.02e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg02175503	chr12:58329896	NA	0.45	8.9	0.33	5.56e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg25237894	chr2:233734115	C2orf82	-0.44	-14.16	-0.49	8.36e-40	Coronary artery disease;
BRCA	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg06484146	chr7:12443880	VWDE	-0.62	-8.57	-0.32	7.55e-17	Coronary artery disease;
BRCA	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg05347473	chr6:146136440	FBXO30	0.42	8.48	0.32	1.57e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg04455712	chr21:45112962	RRP1B	0.41	10.57	0.39	3.59e-24	Mean corpuscular volume;
BRCA	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg18795169	chr1:18902165	NA	0.95	28.7	0.75	4.92e-117	Urate levels in lean individuals;
BRCA	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18402987	chr7:1209562	NA	0.51	10.05	0.37	3.65e-22	Longevity;Endometriosis;
BRCA	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg23625390	chr15:77176239	SCAPER	0.38	8.98	0.33	3.06e-18	Blood metabolite levels;
BRCA	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21582582	chr3:182698605	DCUN1D1	0.39	10.16	0.37	1.38e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00166722	chr3:10149974	C3orf24	0.64	11.13	0.4	1.96e-26	Alzheimer's disease;
BRCA	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	trans	rs629535	0.911	rs688612	chr8:70011887	C/T	cg21567404	chr3:27674614	NA	-0.98	-20.45	-0.63	7.02e-72	Dupuytren's disease;
BRCA	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg16325326	chr1:53192061	ZYG11B	0.55	11.93	0.43	9.04e-30	Monocyte count;
BRCA	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg00666640	chr1:248458726	OR2T12	0.33	8.46	0.32	1.84e-16	Common traits (Other);
BRCA	cis	rs727479	0.502	rs3825800	chr15:51506663	A/C	cg19946085	chr15:51559439	CYP19A1	-0.31	-8.53	-0.32	1.03e-16	Estradiol levels;
BRCA	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg09307838	chr4:120376055	NA	0.63	12.66	0.45	6.37e-33	Corneal astigmatism;
BRCA	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg18132916	chr6:79620363	NA	-0.49	-11.0	-0.4	6.52e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.47	10.29	0.38	4.42e-23	Cognitive ability;
BRCA	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg03146154	chr1:46216737	IPP	0.46	10.16	0.37	1.42e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6882046	0.513	rs2431391	chr5:88046590	C/T	cg22951263	chr5:87985283	NA	-0.38	-10.73	-0.39	7.9e-25	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg18154014	chr19:37997991	ZNF793	0.61	11.44	0.41	1.11e-27	Coronary artery calcification;
BRCA	cis	rs932287	0.666	rs10840161	chr11:9053824	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.4	8.33	0.31	5.12e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs698813	0.774	rs786625	chr2:44604156	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	10.05	0.37	3.72e-22	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.42	-0.32	2.42e-16	Cotinine glucuronidation;
BRCA	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.87e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg08949735	chr16:89699720	DPEP1	-0.45	-8.57	-0.32	7.6e-17	Vitiligo;
BRCA	cis	rs881375	0.526	rs1930785	chr9:123691237	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	10.21	0.37	8.73e-23	Rheumatoid arthritis;
BRCA	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18404041	chr3:52824283	ITIH1	-0.42	-12.26	-0.44	3.51e-31	Bipolar disorder;
BRCA	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.54	-0.32	9.62e-17	Total body bone mineral density;
BRCA	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg25664220	chr3:72788482	NA	0.52	11.42	0.41	1.3e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.46	8.02	0.3	5.04e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg05283184	chr6:79620031	NA	-0.36	-8.09	-0.3	2.95e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	11.98	0.43	5.87e-30	Tonsillectomy;
BRCA	cis	rs10851411	0.657	rs1048571	chr15:42862024	A/G	cg21293051	chr15:42870591	STARD9	0.51	8.77	0.33	1.58e-17	Glucose homeostasis traits;
BRCA	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14829155	chr15:31115871	NA	-0.42	-9.36	-0.35	1.36e-19	Huntington's disease progression;
BRCA	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.72	-0.33	2.47e-17	Alzheimer's disease (late onset);
BRCA	cis	rs829880	0.570	rs844205	chr12:98846053	A/G	cg25150519	chr12:98850993	NA	0.65	14.87	0.51	3.52e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg10556349	chr10:835070	NA	0.59	8.35	0.31	4.39e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.74	0.65	7.41e-79	Lymphocyte percentage of white cells;
BRCA	trans	rs7200543	1.000	rs6498541	chr16:15140657	A/G	cg24683922	chr1:11983373	KIAA2013	-0.36	-8.26	-0.31	8.23e-16	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg20387954	chr3:183756860	HTR3D	0.36	8.33	0.31	4.75e-16	Anterior chamber depth;
BRCA	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg12432903	chr7:1882776	MAD1L1	0.44	7.95	0.3	8.54e-15	Bipolar disorder;
BRCA	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg04691961	chr3:161091175	C3orf57	-0.4	-9.13	-0.34	8.56e-19	Parkinson's disease;
BRCA	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.54e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg23285459	chr7:2802560	GNA12	-0.34	-8.43	-0.32	2.24e-16	Height;
BRCA	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg21479132	chr6:26055353	NA	0.56	7.93	0.3	9.65e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11249608	0.636	rs62393070	chr5:178447943	A/G	cg21905437	chr5:178450457	ZNF879	0.48	9.46	0.35	5.93e-20	Pubertal anthropometrics;
BRCA	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.48e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7246657	0.722	rs10402671	chr19:38117086	C/T	cg14683738	chr19:37701593	ZNF585B	0.47	8.11	0.31	2.51e-15	Coronary artery calcification;
BRCA	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15541040	chr2:3486749	NA	0.47	10.42	0.38	1.43e-23	Neurofibrillary tangles;
BRCA	cis	rs10501293	0.917	rs7951266	chr11:43110728	C/T	cg03447554	chr11:43094025	NA	0.43	8.21	0.31	1.23e-15	Cognitive performance;
BRCA	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.39	8.42	0.32	2.49e-16	Multiple sclerosis;
BRCA	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg25173405	chr17:45401733	C17orf57	0.44	8.95	0.33	3.92e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg08132940	chr7:1081526	C7orf50	-0.46	-7.95	-0.3	8.38e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.53	-12.12	-0.43	1.38e-30	Personality dimensions;
BRCA	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg26384229	chr12:38710491	ALG10B	0.68	14.43	0.5	4.38e-41	Morning vs. evening chronotype;
BRCA	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg17135325	chr3:160939158	NMD3	0.42	7.9	0.3	1.27e-14	Parkinson's disease;
BRCA	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg11941060	chr3:133502564	NA	0.5	12.19	0.43	6.82e-31	Iron status biomarkers;
BRCA	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg18305652	chr10:134549665	INPP5A	0.42	11.58	0.42	2.81e-28	Migraine;
BRCA	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg01528321	chr10:82214614	TSPAN14	0.63	14.24	0.49	3.58e-40	Post bronchodilator FEV1;
BRCA	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg04166393	chr7:2884313	GNA12	0.64	13.82	0.48	3.5e-38	Height;
BRCA	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15506890	chr2:3487001	NA	-0.59	-13.33	-0.47	5.98e-36	Neurofibrillary tangles;
BRCA	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-8.29	-0.31	6.77e-16	Alzheimer's disease (late onset);
BRCA	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg01877450	chr7:97915802	BRI3	0.38	8.75	0.33	1.9e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg04450456	chr4:17643702	FAM184B	0.32	9.02	0.34	2.14e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg09307838	chr4:120376055	NA	0.69	14.08	0.49	2.13e-39	Corneal astigmatism;
BRCA	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg01528321	chr10:82214614	TSPAN14	-0.76	-16.86	-0.55	4.75e-53	Post bronchodilator FEV1;
BRCA	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg07169764	chr2:136633963	MCM6	1.28	28.78	0.75	1.99e-117	Corneal structure;
BRCA	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg03954927	chr1:10346856	KIF1B	0.42	13.41	0.47	2.63e-36	Hepatocellular carcinoma;
BRCA	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.96	0.58	1.14e-58	Fuchs's corneal dystrophy;
BRCA	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.38	10.08	0.37	2.76e-22	IgG glycosylation;
BRCA	cis	rs113835537	0.529	rs4930378	chr11:66255515	T/C	cg24851651	chr11:66362959	CCS	0.43	8.22	0.31	1.12e-15	Airway imaging phenotypes;
BRCA	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg22713356	chr15:30763199	NA	1.3	24.11	0.69	7.71e-92	Uric acid levels;
BRCA	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18876405	chr7:65276391	NA	-0.54	-12.94	-0.46	3.52e-34	Aortic root size;
BRCA	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg00757033	chr12:89920650	WDR51B	0.54	11.14	0.4	1.92e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.24	0.49	3.5e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs17601876	0.807	rs10519299	chr15:51551346	C/G	cg19946085	chr15:51559439	CYP19A1	-0.38	-10.83	-0.39	3.36e-25	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	11.74	0.42	5.64e-29	Lung cancer in ever smokers;
BRCA	cis	rs7572733	0.534	rs1435568	chr2:198762879	T/C	cg00792783	chr2:198669748	PLCL1	0.47	10.31	0.38	3.72e-23	Dermatomyositis;
BRCA	trans	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	14.18	0.49	7.29e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	8.93	0.33	4.38e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg21475434	chr5:93447410	FAM172A	0.69	8.86	0.33	7.58e-18	Diabetic retinopathy;
BRCA	cis	rs600806	0.627	rs2359652	chr1:110008720	T/A	cg20591472	chr1:110008990	SYPL2	0.31	7.92	0.3	1.03e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg21775007	chr8:11205619	TDH	-0.6	-11.89	-0.43	1.31e-29	Retinal vascular caliber;
BRCA	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18404041	chr3:52824283	ITIH1	-0.4	-12.17	-0.43	8.18e-31	Electroencephalogram traits;
BRCA	cis	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg06521331	chr12:34319734	NA	-0.52	-10.27	-0.38	5.32e-23	Morning vs. evening chronotype;
BRCA	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg09307838	chr4:120376055	NA	0.63	12.74	0.45	2.8e-33	Corneal astigmatism;
BRCA	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg07148914	chr20:33460835	GGT7	0.42	9.15	0.34	7.41e-19	Height;
BRCA	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg07148914	chr20:33460835	GGT7	0.38	8.54	0.32	1e-16	Height;
BRCA	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg21427119	chr20:30132790	HM13	-0.41	-8.78	-0.33	1.53e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs11671664	0.732	rs67775326	chr19:46160969	A/G	cg13320842	chr19:46175254	GIPR	0.61	10.48	0.38	7.86e-24	Type 2 diabetes;Body mass index;Body mass index (SNP x SNP interaction);
BRCA	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg00745463	chr17:30367425	LRRC37B	-0.51	-8.44	-0.32	2.08e-16	Hip circumference adjusted for BMI;
BRCA	trans	rs6479891	1.000	rs724553	chr10:65140384	G/C	cg14819942	chr15:35414228	NA	0.35	8.65	0.32	4.02e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs67981189	0.593	rs7154437	chr14:71441385	A/G	cg15816911	chr14:71606274	NA	0.36	8.41	0.32	2.72e-16	Schizophrenia;
BRCA	cis	rs509477	1.000	rs531558	chr18:32575286	A/T	cg00449728	chr18:32561817	MAPRE2	-0.34	-7.84	-0.3	1.84e-14	Cerebrospinal fluid AB1-42 levels;
BRCA	cis	rs9300255	0.544	rs1727310	chr12:123660510	A/G	cg00376283	chr12:123451042	ABCB9	0.54	10.24	0.38	6.99e-23	Neutrophil percentage of white cells;
BRCA	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg03433033	chr1:76189801	ACADM	0.73	18.53	0.59	1.12e-61	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg24848339	chr3:12840334	CAND2	0.46	12.1	0.43	1.65e-30	P wave duration;
BRCA	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18876405	chr7:65276391	NA	-0.49	-10.65	-0.39	1.78e-24	Aortic root size;
BRCA	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg20991723	chr1:152506922	NA	0.37	8.32	0.31	5.36e-16	Hair morphology;
BRCA	cis	rs2282802	0.677	rs9686454	chr5:139627813	T/C	cg26211634	chr5:139558579	C5orf32	0.35	8.27	0.31	7.56e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.7	0.33	2.8e-17	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.6	-0.32	6.28e-17	Menopause (age at onset);
BRCA	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg26597838	chr10:835615	NA	1.03	18.04	0.58	3.99e-59	Eosinophil percentage of granulocytes;
BRCA	trans	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.46	0.38	9.35e-24	Mean corpuscular volume;
BRCA	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg19052272	chr2:3704530	ALLC	0.5	11.72	0.42	7.44e-29	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs2554380	0.943	rs2585038	chr15:84337258	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.33	-7.97	-0.3	7.53e-15	Height;
BRCA	cis	rs6138458	1.000	rs227616	chr20:24908811	T/C	cg26195577	chr20:24973756	C20orf3	0.98	24.76	0.7	2.17e-95	Blood protein levels;
BRCA	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg21427119	chr20:30132790	HM13	-0.35	-7.86	-0.3	1.6e-14	Mean corpuscular hemoglobin;
BRCA	cis	rs7633770	0.786	rs950190	chr3:46683377	C/T	cg11219411	chr3:46661640	NA	0.65	16.96	0.56	1.59e-53	Coronary artery disease;
BRCA	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg23711669	chr6:146136114	FBXO30	0.67	15.63	0.53	7.19e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg26384229	chr12:38710491	ALG10B	0.76	16.85	0.55	5.61e-53	Bladder cancer;
BRCA	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.63	-0.32	4.77e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg18252515	chr7:66147081	NA	-0.9	-12.9	-0.45	5.33e-34	Diabetic kidney disease;
BRCA	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg11766577	chr21:47581405	C21orf56	-0.49	-10.93	-0.4	1.28e-25	Testicular germ cell tumor;
BRCA	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg26597838	chr10:835615	NA	-0.52	-9.63	-0.36	1.38e-20	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs1691799	0.867	rs6581677	chr12:66770379	C/G	cg16791601	chr12:66731901	HELB	-0.64	-17.83	-0.58	5.06e-58	White blood cell count (basophil);
BRCA	cis	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg21775007	chr8:11205619	TDH	-0.46	-9.65	-0.36	1.13e-20	Triglycerides;
BRCA	cis	rs10463316	0.832	rs246483	chr5:150731062	C/G	cg03212797	chr5:150827313	SLC36A1	-0.48	-9.05	-0.34	1.74e-18	Metabolite levels (Pyroglutamine);
BRCA	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03517284	chr6:25882590	NA	0.46	10.31	0.38	3.82e-23	Blood metabolite levels;
BRCA	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.91	-0.3	1.15e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06481639	chr22:41940642	POLR3H	-0.51	-8.42	-0.32	2.42e-16	Vitiligo;
BRCA	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.58	9.87	0.36	1.74e-21	Gut microbiome composition (summer);
BRCA	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	4.04e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg02551604	chr5:131831745	NA	-0.39	-14.68	-0.5	2.84e-42	Asthma (sex interaction);
BRCA	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg00666640	chr1:248458726	OR2T12	0.32	8.77	0.33	1.63e-17	Common traits (Other);
BRCA	cis	rs1018836	0.923	rs2023626	chr8:91619264	G/T	cg16814680	chr8:91681699	NA	0.6	12.93	0.46	3.99e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg17470723	chr8:74884337	TCEB1	0.41	8.75	0.33	1.95e-17	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs11246602	1	rs11246602	chr11:51512090	T/C	cg03929089	chr4:120376271	NA	0.63	8.01	0.3	5.41e-15	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs877282	0.786	rs10904558	chr10:797509	C/T	cg17470449	chr10:769945	NA	0.48	8.4	0.32	2.88e-16	Uric acid levels;
BRCA	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	16.59	0.55	1.09e-51	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg06671706	chr8:8559999	CLDN23	0.41	8.16	0.31	1.78e-15	Obesity-related traits;
BRCA	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg16606324	chr3:10149918	C3orf24	0.57	11.21	0.41	9.2e-27	Alzheimer's disease;
BRCA	cis	rs7607369	0.536	rs13013510	chr2:219667227	A/G	cg02176678	chr2:219576539	TTLL4	-0.38	-10.15	-0.37	1.48e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg20991723	chr1:152506922	NA	0.41	9.24	0.34	3.73e-19	Hair morphology;
BRCA	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg13628971	chr7:2884303	GNA12	0.48	11.25	0.41	6.34e-27	Height;
BRCA	cis	rs7091068	0.567	rs1572773	chr10:95432968	T/C	cg20715218	chr10:95462985	C10orf4	0.48	10.28	0.38	4.96e-23	Urinary tract infection frequency;
BRCA	cis	rs7520050	0.807	rs3013594	chr1:46138000	T/C	cg24296786	chr1:45957014	TESK2	-0.45	-10.09	-0.37	2.61e-22	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-13.21	-0.46	2.19e-35	Migraine;Coronary artery disease;
BRCA	cis	rs1997103	0.954	rs1997099	chr7:55405540	T/C	cg17469321	chr7:55412551	NA	0.5	9.61	0.36	1.58e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs6763687	0.796	rs34814303	chr3:171781839	C/A	cg16233210	chr3:171778391	FNDC3B	0.38	8.37	0.31	3.58e-16	Red cell distribution width;
BRCA	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.21	-0.37	9.06e-23	Gut microbiome composition (summer);
BRCA	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03264133	chr6:25882463	NA	-0.53	-11.99	-0.43	4.97e-30	Blood metabolite levels;
BRCA	cis	rs4660306	0.961	rs1494813	chr1:45957290	T/C	cg24296786	chr1:45957014	TESK2	0.42	8.38	0.31	3.31e-16	Homocysteine levels;
BRCA	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg11584989	chr19:19387371	SF4	0.66	14.26	0.49	2.8e-40	Bipolar disorder;
BRCA	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg06618935	chr21:46677482	NA	-0.36	-8.1	-0.31	2.81e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1371614	0.655	rs509047	chr2:27128529	T/C	cg12368169	chr2:27073192	DPYSL5	-0.3	-9.09	-0.34	1.25e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	ch.11.42038R	chr11:967971	AP2A2	0.52	16.68	0.55	4.17e-52	Alzheimer's disease (late onset);
BRCA	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18876405	chr7:65276391	NA	-0.62	-15.57	-0.52	1.42e-46	Aortic root size;
BRCA	cis	rs4845875	0.557	rs6659541	chr1:11836442	G/A	cg24844545	chr1:11908347	NPPA	0.32	8.09	0.3	2.93e-15	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg23649088	chr2:200775458	C2orf69	0.72	16.2	0.54	1.1e-49	Osteoporosis;
BRCA	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.7	0.33	2.7e-17	Motion sickness;
BRCA	cis	rs7246657	0.722	rs2909093	chr19:38199462	T/C	cg23950597	chr19:37808831	NA	0.52	8.78	0.33	1.49e-17	Coronary artery calcification;
BRCA	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.4	-8.89	-0.33	6.38e-18	Ulcerative colitis;Inflammatory bowel disease;
BRCA	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg15934090	chr1:100435551	SLC35A3	0.35	8.18	0.31	1.48e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg09307838	chr4:120376055	NA	0.72	15.28	0.52	3.69e-45	Corneal astigmatism;
BRCA	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg04455712	chr21:45112962	RRP1B	-0.35	-8.54	-0.32	9.73e-17	Mean corpuscular volume;
BRCA	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	12.76	0.45	2.23e-33	Bone mineral density;
BRCA	cis	rs17401966	1.000	rs58053556	chr1:10442903	A/G	cg03954927	chr1:10346856	KIF1B	0.45	12.09	0.43	1.85e-30	Hepatocellular carcinoma;
BRCA	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg22676075	chr6:135203613	NA	0.44	8.6	0.32	6.06e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg15556689	chr8:8085844	FLJ10661	0.37	9.14	0.34	8.48e-19	Retinal vascular caliber;
BRCA	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg06618935	chr21:46677482	NA	-0.37	-8.3	-0.31	6.41e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10267417	0.535	rs10272487	chr7:19862415	A/T	cg05791153	chr7:19748676	TWISTNB	0.53	10.19	0.37	1.07e-22	Night sleep phenotypes;
BRCA	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15506890	chr2:3487001	NA	-0.52	-11.3	-0.41	3.96e-27	Neurofibrillary tangles;
BRCA	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg06552810	chr11:31128660	NA	-0.39	-8.71	-0.33	2.51e-17	Red blood cell count;
BRCA	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11644478	chr21:40555479	PSMG1	-0.51	-10.84	-0.39	3.13e-25	Menarche (age at onset);
BRCA	cis	rs7179456	0.513	rs593742	chr15:59045774	A/G	cg05156742	chr15:59063176	FAM63B	0.42	8.56	0.32	8.33e-17	Asperger disorder;
BRCA	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18876405	chr7:65276391	NA	-0.62	-15.19	-0.52	1.02e-44	Aortic root size;
BRCA	cis	rs760805	1.000	rs3845302	chr1:25259884	C/G	cg22509179	chr1:25234806	RUNX3	-0.56	-14.46	-0.5	3.29e-41	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg06238570	chr21:40685208	BRWD1	-0.41	-8.37	-0.31	3.58e-16	Cognitive function;
BRCA	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.33	-0.44	1.69e-31	Chronic sinus infection;
BRCA	cis	rs72928364	1.000	rs67991823	chr3:100631677	C/T	cg10123952	chr3:100791384	NA	0.54	7.94	0.3	8.87e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	ch.11.42038R	chr11:967971	AP2A2	0.52	16.63	0.55	7.59e-52	Alzheimer's disease (late onset);
BRCA	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24838063	chr12:130822603	PIWIL1	0.68	16.73	0.55	2.13e-52	Menopause (age at onset);
BRCA	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.31	-8.03	-0.3	4.74e-15	Total body bone mineral density;
BRCA	cis	rs4566357	0.615	rs12618793	chr2:227909552	T/C	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.03	-0.3	4.81e-15	Coronary artery disease;
BRCA	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg06671706	chr8:8559999	CLDN23	0.42	8.06	0.3	3.83e-15	Obesity-related traits;
BRCA	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26314531	chr2:26401878	FAM59B	-0.78	-12.34	-0.44	1.54e-31	Gut microbiome composition (summer);
BRCA	cis	rs1710278	0.967	rs1278271	chr10:127747972	G/A	cg22975853	chr10:127789788	ADAM12	0.32	8.21	0.31	1.21e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
BRCA	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg00271210	chr6:167070053	RPS6KA2	-0.33	-8.73	-0.33	2.22e-17	Crohn's disease;
BRCA	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg22105103	chr4:187893119	NA	-0.38	-11.77	-0.42	4.2e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23221052	chr5:179740743	GFPT2	-0.64	-13.49	-0.47	1.17e-36	Height;
BRCA	cis	rs7072216	0.763	rs942805	chr10:100168372	G/A	cg26618903	chr10:100175079	PYROXD2	-0.31	-9.01	-0.34	2.38e-18	Metabolite levels;
BRCA	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg21475434	chr5:93447410	FAM172A	0.67	8.72	0.33	2.43e-17	Diabetic retinopathy;
BRCA	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg13256891	chr4:100009986	ADH5	0.47	9.7	0.36	7.83e-21	Alcohol dependence;
BRCA	trans	rs6076960	0.652	rs6085467	chr20:6259004	T/C	cg21095983	chr6:86352623	SYNCRIP	0.36	8.27	0.31	7.68e-16	Smooth-surface caries;
BRCA	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg16325326	chr1:53192061	ZYG11B	0.69	17.45	0.57	4.84e-56	Monocyte count;
BRCA	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg15704280	chr7:45808275	SEPT13	0.7	14.24	0.49	3.57e-40	Height;
BRCA	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg10818794	chr15:86012489	AKAP13	-0.31	-8.61	-0.32	5.47e-17	Coronary artery disease;
BRCA	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.39	-9.02	-0.34	2.26e-18	Longevity;Endometriosis;
BRCA	cis	rs858239	0.601	rs10239760	chr7:23149950	C/T	cg23682824	chr7:23144976	KLHL7	0.4	10.42	0.38	1.39e-23	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg21775007	chr8:11205619	TDH	0.61	11.95	0.43	7.8e-30	Retinal vascular caliber;
BRCA	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg10523679	chr1:76189770	ACADM	-0.47	-9.18	-0.34	5.94e-19	Daytime sleep phenotypes;
BRCA	cis	rs7246967	0.673	rs8103430	chr19:22931498	A/G	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs13046373	0.535	rs35909098	chr21:32021649	C/T	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.39	0.35	1e-19	HDL cholesterol;
BRCA	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg18016565	chr1:150552671	MCL1	-0.36	-8.27	-0.31	7.51e-16	Tonsillectomy;
BRCA	trans	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg07211511	chr3:129823064	LOC729375	-0.96	-13.54	-0.47	6.91e-37	Blood pressure (smoking interaction);
BRCA	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg25817165	chr18:72167213	CNDP2	-0.49	-11.59	-0.42	2.62e-28	Refractive error;
BRCA	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.7	0.33	2.82e-17	Iron status biomarkers;
BRCA	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg27432699	chr2:27873401	GPN1	0.43	9.19	0.34	5.5e-19	Oral cavity cancer;
BRCA	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-10.89	-0.4	1.88e-25	IgG glycosylation;
BRCA	cis	rs12413816	0.963	rs10796116	chr10:13762786	C/T	cg16485048	chr10:13749193	FRMD4A	-0.58	-14.42	-0.5	5.08e-41	Red cell distribution width;
BRCA	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg08000102	chr2:233561755	GIGYF2	-0.59	-12.68	-0.45	5.09e-33	Coronary artery disease;
BRCA	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.96	0.33	3.45e-18	Tonsillectomy;
BRCA	cis	rs2637266	1.000	rs4979784	chr10:78355476	T/A	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg20503657	chr10:835505	NA	1.05	18.71	0.59	1.3e-62	Eosinophil percentage of granulocytes;
BRCA	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs6740322	0.841	rs10210507	chr2:43556636	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-12.12	-0.43	1.38e-30	Coronary artery disease;
BRCA	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-14.8	-0.51	7.47e-43	Parkinson's disease;
BRCA	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	13.57	0.47	4.72e-37	Lymphocyte counts;
BRCA	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.47	10.73	0.39	7.92e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs72928364	0.929	rs13060849	chr3:100773483	A/C	cg10123952	chr3:100791384	NA	0.58	8.43	0.32	2.3e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg13047869	chr3:10149882	C3orf24	0.6	12.62	0.45	9.38e-33	Alzheimer's disease;
BRCA	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23583168	chr7:148888333	NA	-0.81	-18.33	-0.59	1.34e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.05	-0.56	4.99e-54	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.21	-0.34	4.59e-19	Menopause (age at onset);
BRCA	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.34	8.64	0.32	4.46e-17	IgG glycosylation;
BRCA	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg04455712	chr21:45112962	RRP1B	0.44	10.4	0.38	1.71e-23	Mean corpuscular volume;
BRCA	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg14820908	chr5:178986412	RUFY1	-0.46	-12.02	-0.43	3.77e-30	Lung cancer;
BRCA	cis	rs4595586	0.679	rs5017082	chr12:39314564	A/C	cg26384229	chr12:38710491	ALG10B	-0.36	-7.82	-0.3	2.23e-14	Morning vs. evening chronotype;
BRCA	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg15704280	chr7:45808275	SEPT13	0.62	10.36	0.38	2.45e-23	Axial length;
BRCA	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24110177	chr3:50126178	RBM5	-0.37	-9.81	-0.36	2.89e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.29	-0.35	2.31e-19	Electroencephalogram traits;
BRCA	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	19.2	0.6	3.14e-65	Alzheimer's disease;
BRCA	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg11766577	chr21:47581405	C21orf56	0.5	10.79	0.39	4.71e-25	Testicular germ cell tumor;
BRCA	cis	rs4727443	0.653	rs6465759	chr7:99587980	T/C	cg22004693	chr7:99632812	ZKSCAN1	-0.38	-8.51	-0.32	1.28e-16	Interstitial lung disease;
BRCA	cis	rs12579753	0.917	rs7138533	chr12:82187885	C/G	cg07988820	chr12:82153109	PPFIA2	-0.49	-8.42	-0.32	2.38e-16	Resting heart rate;
BRCA	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4891159	0.790	rs683306	chr18:74112473	C/G	cg24786174	chr18:74118243	ZNF516	-0.73	-18.24	-0.59	3.68e-60	Longevity;
BRCA	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg18129178	chr5:148520854	ABLIM3	-0.58	-11.64	-0.42	1.59e-28	Breast cancer;
BRCA	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24308560	chr3:49941425	MST1R	0.4	8.49	0.32	1.47e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg12292205	chr6:26970375	C6orf41	0.58	13.01	0.46	1.76e-34	Schizophrenia;
BRCA	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg04518342	chr5:131593106	PDLIM4	0.37	8.69	0.32	3.13e-17	Acylcarnitine levels;
BRCA	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.78	0.42	4.11e-29	Tonsillectomy;
BRCA	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg21775007	chr8:11205619	TDH	0.44	9.03	0.34	2.07e-18	Retinal vascular caliber;
BRCA	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg24812749	chr6:127587940	RNF146	0.68	15.41	0.52	8.21e-46	Breast cancer;
BRCA	cis	rs72772090	0.539	rs11747148	chr5:96112863	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.08	-0.43	2.05e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6028335	0.622	rs73621984	chr20:37639209	A/G	cg16355469	chr20:37678765	NA	0.44	8.33	0.31	5.01e-16	Alcohol and nicotine co-dependence;
BRCA	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg09184832	chr6:79620586	NA	-0.51	-11.21	-0.41	9.04e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg08847533	chr14:75593920	NEK9	-0.74	-16.86	-0.55	5.07e-53	Height;
BRCA	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05535760	chr7:792225	HEATR2	0.84	14.66	0.5	3.52e-42	Cerebrospinal P-tau181p levels;
BRCA	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.55	-0.35	2.8e-20	Tonsillectomy;
BRCA	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg24531977	chr5:56204891	C5orf35	-0.44	-8.99	-0.33	2.86e-18	Coronary artery disease;
BRCA	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg27432699	chr2:27873401	GPN1	0.43	9.11	0.34	1.07e-18	Oral cavity cancer;
BRCA	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-12.78	-0.45	1.88e-33	Bipolar disorder;
BRCA	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.65	14.26	0.49	2.96e-40	Lymphocyte counts;
BRCA	trans	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	16.05	0.54	5.66e-49	Exhaled nitric oxide levels;
BRCA	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18402987	chr7:1209562	NA	0.72	12.15	0.43	1.02e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10499694	0.868	rs1470749	chr7:50578023	G/T	cg18232548	chr7:50535776	DDC	-0.4	-9.48	-0.35	5.09e-20	Body mass index;
BRCA	cis	rs6598955	0.671	rs12354062	chr1:26608761	C/T	cg04990556	chr1:26633338	UBXN11	0.55	8.54	0.32	9.88e-17	Obesity-related traits;
BRCA	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg11764359	chr7:65958608	NA	0.68	15.19	0.52	9.95e-45	Aortic root size;
BRCA	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg03609598	chr5:56110824	MAP3K1	-0.45	-7.94	-0.3	9.2e-15	Initial pursuit acceleration;
BRCA	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.27e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.33	-0.31	5.04e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg21770322	chr7:97807741	LMTK2	0.44	11.54	0.42	4.07e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg05084668	chr3:125655381	ALG1L	-0.47	-8.05	-0.3	4.07e-15	Blood pressure (smoking interaction);
BRCA	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg13047869	chr3:10149882	C3orf24	0.59	12.48	0.44	3.79e-32	Alzheimer's disease;
BRCA	cis	rs28830936	1.000	rs17677199	chr15:41954613	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.34	-9.64	-0.36	1.27e-20	Diastolic blood pressure;
BRCA	cis	rs2014572	0.967	rs11084492	chr19:57756026	A/T	cg24459738	chr19:57751996	ZNF805	-0.33	-7.98	-0.3	6.85e-15	Hyperactive-impulsive symptoms;
BRCA	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg20887711	chr4:1340912	KIAA1530	0.36	8.63	0.32	4.8e-17	Longevity;
BRCA	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg01017244	chr2:74357527	NA	0.57	13.32	0.47	6.89e-36	Gestational age at birth (maternal effect);
BRCA	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	ch.11.42038R	chr11:967971	AP2A2	0.58	19.11	0.6	1.02e-64	Alzheimer's disease (late onset);
BRCA	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg00383909	chr3:49044727	WDR6	0.75	13.14	0.46	4.21e-35	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg09307838	chr4:120376055	NA	0.62	13.08	0.46	8.24e-35	Corneal astigmatism;
BRCA	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg27029518	chr18:72166324	CNDP2	-0.31	-8.65	-0.32	4.06e-17	Refractive error;
BRCA	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg16325326	chr1:53192061	ZYG11B	-0.77	-19.39	-0.61	3.38e-66	Monocyte count;
BRCA	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	9.18	0.34	5.96e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg00757033	chr12:89920650	WDR51B	0.52	10.53	0.38	5.15e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg21475434	chr5:93447410	FAM172A	0.7	8.65	0.32	4.16e-17	Diabetic retinopathy;
BRCA	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg13175981	chr1:150552382	MCL1	0.37	7.98	0.3	6.76e-15	Blood protein levels;
BRCA	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg08470875	chr2:26401718	FAM59B	-0.72	-11.51	-0.41	5.3e-28	Gut microbiome composition (summer);
BRCA	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg01579765	chr21:45077557	HSF2BP	0.43	11.58	0.42	2.83e-28	Mean corpuscular volume;
BRCA	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg04518342	chr5:131593106	PDLIM4	0.42	10.1	0.37	2.41e-22	Acylcarnitine levels;
BRCA	trans	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg01620082	chr3:125678407	NA	-0.7	-8.74	-0.33	2e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4363385	0.747	rs1999886	chr1:152955522	T/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.31	-0.31	5.96e-16	Inflammatory skin disease;
BRCA	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg13073564	chr4:8508604	NA	0.44	12.23	0.44	4.53e-31	Response to antineoplastic agents;
BRCA	trans	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.63	-0.36	1.36e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg11062466	chr8:58055876	NA	0.51	8.81	0.33	1.19e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs921968	0.565	rs1079177	chr2:219605929	G/A	cg02176678	chr2:219576539	TTLL4	-0.41	-11.05	-0.4	4.43e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.84	21.23	0.64	4.45e-76	Body mass index (adult);
BRCA	cis	rs965469	0.779	rs2236109	chr20:3286439	C/A	cg25506879	chr20:3388711	C20orf194	-0.44	-8.78	-0.33	1.45e-17	IFN-related cytopenia;
BRCA	cis	rs12458462	0.812	rs34583578	chr18:77491070	C/T	cg23301140	chr18:77439876	CTDP1	0.35	7.85	0.3	1.82e-14	Monocyte count;
BRCA	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23583168	chr7:148888333	NA	-0.83	-18.79	-0.6	4.58e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4742903	0.967	rs7871759	chr9:106865438	A/G	cg14250997	chr9:106856677	SMC2	0.35	11.08	0.4	3.32e-26	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg26384229	chr12:38710491	ALG10B	0.76	17.16	0.56	1.47e-54	Bladder cancer;
BRCA	cis	rs250677	0.522	rs4431331	chr5:148353574	A/C	cg12140854	chr5:148520817	ABLIM3	-0.39	-7.86	-0.3	1.7e-14	Breast cancer;
BRCA	cis	rs868036	1.000	rs3784719	chr15:68098180	C/T	cg05925327	chr15:68127851	NA	-0.31	-7.91	-0.3	1.17e-14	Restless legs syndrome;
BRCA	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9811920	0.641	rs58704213	chr3:99690331	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-11.09	-0.4	2.87e-26	Axial length;
BRCA	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.29	0.44	2.59e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg02297831	chr4:17616191	MED28	0.36	8.46	0.32	1.79e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg18230493	chr5:56204884	C5orf35	-0.62	-13.37	-0.47	4.03e-36	Initial pursuit acceleration;
BRCA	cis	rs990171	0.506	rs4141631	chr2:102757216	A/G	cg22835712	chr2:102737379	NA	0.58	11.02	0.4	5.7e-26	Lymphocyte counts;
BRCA	trans	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg25214090	chr10:38739885	LOC399744	0.45	10.36	0.38	2.38e-23	Corneal astigmatism;
BRCA	cis	rs9311474	0.652	rs352158	chr3:52217704	C/T	cg15698299	chr3:52233019	ALAS1	-0.36	-8.21	-0.31	1.22e-15	Electroencephalogram traits;
BRCA	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.7	-15.86	-0.53	5.21e-48	Multiple sclerosis;
BRCA	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg26816564	chr1:7831052	VAMP3	0.64	12.1	0.43	1.78e-30	Inflammatory bowel disease;
BRCA	cis	rs9682041	0.627	rs11917188	chr3:170088607	C/T	cg11886554	chr3:170076028	SKIL	0.48	9.78	0.36	3.72e-21	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg06159980	chr1:16340746	HSPB7	-0.37	-8.2	-0.31	1.29e-15	Systolic blood pressure;
BRCA	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg23422044	chr7:1970798	MAD1L1	-0.61	-11.71	-0.42	8.22e-29	Bipolar disorder;
BRCA	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg01483505	chr11:975446	AP2A2	0.3	8.05	0.3	3.94e-15	Alzheimer's disease (late onset);
BRCA	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg21770322	chr7:97807741	LMTK2	0.43	10.98	0.4	7.84e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.42	-9.02	-0.34	2.15e-18	Longevity;Endometriosis;
BRCA	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-10.32	-0.38	3.51e-23	Blood metabolite levels;
BRCA	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg24450063	chr1:156163899	SLC25A44	1.09	34.81	0.81	1.1e-149	Testicular germ cell tumor;
BRCA	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	13.04	0.46	1.26e-34	Menarche (age at onset);
BRCA	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs10267417	0.584	rs10247789	chr7:19863570	G/C	cg07541023	chr7:19748670	TWISTNB	0.49	8.97	0.33	3.16e-18	Night sleep phenotypes;
BRCA	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.66	-0.39	1.51e-24	Tonsillectomy;
BRCA	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg14789911	chr21:47582049	C21orf56	0.37	7.93	0.3	9.73e-15	Testicular germ cell tumor;
BRCA	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg26384229	chr12:38710491	ALG10B	0.66	13.84	0.48	2.82e-38	Morning vs. evening chronotype;
BRCA	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg22705602	chr4:152727874	NA	-0.32	-7.84	-0.3	1.88e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2580764	0.540	rs2920893	chr2:55270629	C/T	cg09592903	chr2:55203963	RTN4	0.38	9.7	0.36	7.68e-21	Mean platelet volume;
BRCA	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg00383909	chr3:49044727	WDR6	0.63	11.36	0.41	2.33e-27	Cognitive function;
BRCA	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg08601574	chr20:25228251	PYGB	0.34	8.04	0.3	4.52e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.14e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg05340658	chr4:99064831	C4orf37	0.59	12.13	0.43	1.28e-30	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg21918786	chr6:109611834	NA	-0.49	-14.04	-0.49	3.1e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-14.02	-0.48	4.06e-39	Gut microbiome composition (summer);
BRCA	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06481639	chr22:41940642	POLR3H	-0.52	-8.21	-0.31	1.25e-15	Vitiligo;
BRCA	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg23711669	chr6:146136114	FBXO30	0.71	16.54	0.55	1.99e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg09537434	chr19:41945824	ATP5SL	-0.96	-23.39	-0.68	6.85e-88	Height;
BRCA	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03517284	chr6:25882590	NA	-0.72	-15.4	-0.52	1e-45	Intelligence (multi-trait analysis);
BRCA	cis	rs6815814	0.898	rs73236616	chr4:38789675	G/A	cg06935464	chr4:38784597	TLR10	0.51	8.29	0.31	6.7e-16	Breast cancer;
BRCA	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03452623	chr4:187889614	NA	-0.33	-11.08	-0.4	3.22e-26	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg04727924	chr7:799746	HEATR2	-0.54	-9.47	-0.35	5.45e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12618769	0.597	rs3754879	chr2:99164541	G/T	cg10123293	chr2:99228465	UNC50	0.44	8.52	0.32	1.11e-16	Bipolar disorder;
BRCA	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg04691961	chr3:161091175	C3orf57	-0.38	-8.02	-0.3	5.16e-15	Parkinson's disease;
BRCA	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg06640241	chr16:89574553	SPG7	0.83	21.25	0.64	3.38e-76	Multiple myeloma (IgH translocation);
BRCA	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg25358565	chr5:93447407	FAM172A	-1.2	-18.76	-0.6	6.87e-63	Diabetic retinopathy;
BRCA	cis	rs74181299	0.750	rs13421845	chr2:65336033	G/A	cg05010058	chr2:65284262	CEP68	-0.3	-8.26	-0.31	8.36e-16	Pulse pressure;
BRCA	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.35	-0.38	2.61e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg24692254	chr21:30365293	RNF160	-0.46	-10.01	-0.37	5.32e-22	Dental caries;
BRCA	cis	rs7715806	0.500	rs17649332	chr5:75003878	T/C	cg19683494	chr5:74908142	NA	0.5	8.1	0.31	2.81e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg12292205	chr6:26970375	C6orf41	0.58	12.99	0.46	2.15e-34	Schizophrenia;
BRCA	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg13880726	chr7:1868755	MAD1L1	0.42	7.94	0.3	9.02e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs1997103	0.765	rs55686950	chr7:55396552	A/C	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.72e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg20290983	chr6:43655470	MRPS18A	1.11	40.89	0.85	1.61e-180	IgG glycosylation;
BRCA	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg22907277	chr7:1156413	C7orf50	0.6	9.66	0.36	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.74	0.42	6.16e-29	Tonsillectomy;
BRCA	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg04727924	chr7:799746	HEATR2	-0.54	-10.64	-0.39	1.96e-24	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg17063962	chr7:91808500	NA	0.57	13.07	0.46	8.78e-35	Breast cancer;
BRCA	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-10.29	-0.38	4.42e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg23711669	chr6:146136114	FBXO30	-0.67	-15.63	-0.53	7.08e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.46	0.38	9.8599999999999993e-24	Aortic root size;
BRCA	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	9.1e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg26528668	chr16:1614120	IFT140	0.37	8.28	0.31	7.3e-16	Coronary artery disease;
BRCA	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg18154014	chr19:37997991	ZNF793	0.61	11.38	0.41	1.85e-27	Coronary artery calcification;
BRCA	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03923535	chr7:1197113	ZFAND2A	0.47	10.29	0.38	4.58e-23	Longevity;Endometriosis;
BRCA	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg03929089	chr4:120376271	NA	-0.67	-12.99	-0.46	2.19e-34	Coronary artery disease;
BRCA	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-9.95	-0.37	9.02e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.47	-0.32	1.66e-16	Breast cancer;
BRCA	cis	rs11718455	0.767	rs11708363	chr3:43966585	G/A	cg08738300	chr3:44038990	NA	0.5	9.19	0.34	5.41e-19	Coronary artery disease;
BRCA	cis	rs4853036	0.951	rs35344582	chr2:70148093	C/T	cg02498382	chr2:70120550	SNRNP27	-0.54	-9.61	-0.36	1.58e-20	Colorectal or endometrial cancer;
BRCA	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg09060608	chr5:178986726	RUFY1	-0.59	-15.74	-0.53	2.05e-47	Lung cancer;
BRCA	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.62	0.39	2.17e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.95	13.93	0.48	1.02e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs6479891	1.000	rs6479899	chr10:65139047	T/A	cg14819942	chr15:35414228	NA	-0.32	-8.41	-0.32	2.73e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs2281845	0.507	rs11589642	chr1:201100748	A/G	cg06714761	chr1:201096289	NA	-0.47	-11.15	-0.4	1.64e-26	Permanent tooth development;
BRCA	trans	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg13565492	chr6:43139072	SRF	-0.79	-10.83	-0.39	3.16e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.77	-0.55	1.45e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.89	-0.33	6.32e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg18404041	chr3:52824283	ITIH1	-0.29	-8.13	-0.31	2.24e-15	Electroencephalogram traits;
BRCA	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08045932	chr20:61659980	NA	0.49	11.3	0.41	4.21e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.05	15.61	0.53	8.49e-47	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6815814	0.950	rs5743565	chr4:38805983	T/C	cg02016764	chr4:38805732	TLR1	-0.61	-9.73	-0.36	5.9e-21	Breast cancer;
BRCA	cis	rs2797160	0.967	rs1954360	chr6:126001064	A/G	cg05901451	chr6:126070800	HEY2	-0.39	-9.48	-0.35	4.8e-20	Endometrial cancer;
BRCA	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg00083206	chr6:110721305	DDO	-0.39	-9.47	-0.35	5.18e-20	Platelet distribution width;
BRCA	cis	rs724568	0.546	rs966443	chr2:67940867	G/A	cg17945962	chr2:67939740	NA	-0.39	-10.57	-0.39	3.59e-24	Major depressive disorder (broad);
BRCA	cis	rs56804039	1.000	rs58361948	chr8:8380995	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-9.31	-0.35	2.02e-19	Cervical cancer;
BRCA	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.22	0.31	1.13e-15	Total cholesterol levels;
BRCA	cis	rs2731664	0.792	rs337374	chr5:176890416	A/G	cg23176889	chr5:176863531	GRK6	0.61	16.77	0.55	1.35e-52	Intelligence (multi-trait analysis);
BRCA	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	13.53	0.47	7.4e-37	Colorectal cancer;
BRCA	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg23649088	chr2:200775458	C2orf69	0.5	8.65	0.32	4.06e-17	Schizophrenia;
BRCA	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.57	8.41	0.32	2.78e-16	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg11266682	chr4:10021025	SLC2A9	0.46	11.95	0.43	7.24e-30	Bone mineral density;
BRCA	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg26597838	chr10:835615	NA	1.02	15.65	0.53	5.92e-47	Eosinophil percentage of granulocytes;
BRCA	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.88e-23	Prostate cancer;
BRCA	cis	rs68170813	0.559	rs2299422	chr7:106959832	A/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.59	-0.32	6.41e-17	Coronary artery disease;
BRCA	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.55	-10.72	-0.39	8.77e-25	Schizophrenia;
BRCA	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	12.88	0.45	6.29e-34	Response to antipsychotic treatment;
BRCA	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg24642439	chr20:33292090	TP53INP2	0.71	16.2	0.54	1.06e-49	Coronary artery disease;
BRCA	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.64	10.15	0.37	1.55e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg03342759	chr3:160939853	NMD3	-0.72	-17.97	-0.58	9.09e-59	Morning vs. evening chronotype;
BRCA	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg21770322	chr7:97807741	LMTK2	0.43	11.35	0.41	2.5e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06028605	chr16:24865363	SLC5A11	0.4	8.23	0.31	1.03e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg22974920	chr21:40686053	BRWD1	-0.41	-8.93	-0.33	4.5e-18	Cognitive function;
BRCA	cis	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg07988820	chr12:82153109	PPFIA2	-0.62	-10.15	-0.37	1.53e-22	Resting heart rate;
BRCA	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg13010199	chr12:38710504	ALG10B	0.41	8.41	0.32	2.74e-16	Bladder cancer;
BRCA	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.2	0.37	1.01e-22	Aortic root size;
BRCA	cis	rs6120849	0.754	rs6087666	chr20:33640242	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	10.31	0.38	3.78e-23	Protein C levels;
BRCA	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12667521	chr19:29218732	NA	0.46	8.79	0.33	1.33e-17	Methadone dose in opioid dependence;
BRCA	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	8.25	0.31	9.04e-16	Personality dimensions;
BRCA	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg27446573	chr6:127587934	RNF146	0.88	20.22	0.62	1.17e-70	Breast cancer;
BRCA	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-8.72	-0.33	2.31e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.61	-13.1	-0.46	6.69e-35	Lymphocyte counts;
BRCA	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13012494	chr21:47604986	C21orf56	-0.43	-8.7	-0.33	2.91e-17	Testicular germ cell tumor;
BRCA	cis	rs4363385	0.747	rs6671414	chr1:152974119	C/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.33	-0.31	4.8e-16	Inflammatory skin disease;
BRCA	cis	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.41	9.44	0.35	6.94e-20	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.58	-12.83	-0.45	1.1e-33	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg14675211	chr2:100938903	LONRF2	0.51	11.68	0.42	1.07e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg01256987	chr12:42539512	GXYLT1	-0.43	-8.28	-0.31	7.25e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.57	-9.71	-0.36	6.91e-21	Gut microbiome composition (summer);
BRCA	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.54	13.28	0.47	1.01e-35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs858239	0.508	rs7805071	chr7:23190212	C/T	cg23682824	chr7:23144976	KLHL7	0.37	9.66	0.36	1.11e-20	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg26384229	chr12:38710491	ALG10B	-0.55	-13.65	-0.48	2.13e-37	Morning vs. evening chronotype;
BRCA	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg19920283	chr7:105172520	RINT1	0.59	9.54	0.35	2.83e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-8.01	-0.3	5.39e-15	Monocyte percentage of white cells;
BRCA	cis	rs11958404	0.932	rs113494689	chr5:157428078	G/T	cg05962755	chr5:157440814	NA	0.51	10.01	0.37	5.38e-22	IgG glycosylation;
BRCA	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg08807101	chr21:30365312	RNF160	-0.6	-15.35	-0.52	1.77e-45	Dental caries;
BRCA	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-11.37	-0.41	1.99e-27	Mood instability;
BRCA	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg24812749	chr6:127587940	RNF146	0.89	20.97	0.64	1.08e-74	Breast cancer;
BRCA	cis	rs6910061	0.830	rs58969617	chr6:11110865	C/G	cg27233058	chr6:11094804	LOC221710	0.5	8.52	0.32	1.15e-16	Diabetic kidney disease;
BRCA	trans	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg21659725	chr3:3221576	CRBN	-0.49	-8.5	-0.32	1.31e-16	Menarche (age at onset);
BRCA	cis	rs2455601	1.000	rs72632952	chr11:8917976	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-8.43	-0.32	2.24e-16	Schizophrenia;
BRCA	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg27398817	chr8:82754497	SNX16	0.44	8.8	0.33	1.28e-17	Diastolic blood pressure;
BRCA	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg04709771	chr16:646395	RAB40C	0.45	11.43	0.41	1.22e-27	Height;
BRCA	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg25767906	chr1:53392781	SCP2	0.37	8.6	0.32	6.07e-17	Monocyte count;
BRCA	cis	rs2073300	1.000	rs6137967	chr20:23447108	A/T	cg12062639	chr20:23401060	NAPB	-0.58	-8.24	-0.31	9.85e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg14343924	chr8:8086146	FLJ10661	0.41	8.49	0.32	1.41e-16	Mood instability;
BRCA	trans	rs8002861	0.935	rs7320988	chr13:44413523	C/T	cg17145862	chr1:211918768	LPGAT1	0.68	17.75	0.57	1.37e-57	Leprosy;
BRCA	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg18154014	chr19:37997991	ZNF793	0.49	9.55	0.35	2.63e-20	Coronary artery calcification;
BRCA	cis	rs4285028	0.948	rs2091664	chr3:121684749	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-11.01	-0.4	6.18e-26	Multiple sclerosis;
BRCA	cis	rs13102973	0.899	rs13122646	chr4:135906123	T/C	cg14419869	chr4:135874104	NA	0.45	8.99	0.34	2.75e-18	Subjective well-being;
BRCA	cis	rs754466	0.580	rs10824575	chr10:79549047	A/G	cg17075019	chr10:79541650	NA	-0.88	-23.78	-0.69	5.35e-90	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs12541635	1.000	rs1366969	chr8:107092851	A/T	cg10147462	chr8:107024639	NA	-0.3	-8.2	-0.31	1.29e-15	Age of smoking initiation;
BRCA	trans	rs877282	0.945	rs11253388	chr10:787852	A/G	cg22713356	chr15:30763199	NA	1.42	28.54	0.75	3.84e-116	Uric acid levels;
BRCA	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg16989086	chr20:62203971	PRIC285	0.52	8.89	0.33	6.31e-18	Glioblastoma;
BRCA	cis	rs858239	0.536	rs6961109	chr7:23252413	C/T	cg23682824	chr7:23144976	KLHL7	0.32	8.34	0.31	4.44e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-10.61	-0.39	2.51e-24	Colorectal cancer;
BRCA	trans	rs3960554	0.673	rs57358338	chr7:75732923	T/C	cg19862616	chr7:65841803	NCRNA00174	0.57	12.16	0.43	9.08e-31	Eotaxin levels;
BRCA	trans	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg07211511	chr3:129823064	LOC729375	-0.63	-11.13	-0.4	1.99e-26	Blood pressure (smoking interaction);
BRCA	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg02951883	chr7:2050386	MAD1L1	-0.53	-11.38	-0.41	1.83e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg06521331	chr12:34319734	NA	-0.53	-10.61	-0.39	2.4e-24	Morning vs. evening chronotype;
BRCA	cis	rs7617773	0.963	rs6766754	chr3:48182589	T/C	cg11946769	chr3:48343235	NME6	-0.41	-9.07	-0.34	1.49e-18	Coronary artery disease;
BRCA	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	14.65	0.5	4.04e-42	Platelet count;
BRCA	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg16586182	chr3:47516702	SCAP	0.51	11.21	0.41	9.89e-27	Colorectal cancer;
BRCA	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg16482183	chr6:26056742	HIST1H1C	0.55	11.7	0.42	8.82e-29	Height;
BRCA	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.73	-0.36	5.88e-21	Alcohol dependence;
BRCA	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg15704280	chr7:45808275	SEPT13	-0.47	-9.07	-0.34	1.41e-18	Height;
BRCA	cis	rs17799476	1.000	rs17799476	chr2:46352326	C/G	cg12428440	chr2:46370979	PRKCE	0.49	8.71	0.33	2.63e-17	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg04315214	chr1:2043799	PRKCZ	-0.48	-12.62	-0.45	9.65e-33	Height;
BRCA	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.81	-19.01	-0.6	3.23e-64	Ulcerative colitis;
BRCA	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg20290983	chr6:43655470	MRPS18A	1.1	41.39	0.85	5.5e-183	IgG glycosylation;
BRCA	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-12.01	-0.43	4.19e-30	Gut microbiome composition (summer);
BRCA	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg24642439	chr20:33292090	TP53INP2	0.52	11.43	0.41	1.2e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg03060546	chr3:49711283	APEH	0.52	10.85	0.39	2.8e-25	Resting heart rate;
BRCA	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg23711669	chr6:146136114	FBXO30	0.78	18.5	0.59	1.6e-61	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11112613	0.713	rs11112592	chr12:105951702	C/T	cg03607813	chr12:105948248	NA	-0.55	-10.65	-0.39	1.75e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs10465746	0.780	rs1570691	chr1:84370393	A/C	cg10977910	chr1:84465055	TTLL7	0.55	11.46	0.41	8.86e-28	Obesity-related traits;
BRCA	cis	rs9868809	0.881	rs13063312	chr3:48661985	G/A	cg00383909	chr3:49044727	WDR6	0.53	8.03	0.3	4.61e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs897984	0.609	rs11862744	chr16:31057800	G/A	cg00531865	chr16:30841666	NA	-0.38	-9.06	-0.34	1.62e-18	Dementia with Lewy bodies;
BRCA	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.66	-13.04	-0.46	1.22e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg26384229	chr12:38710491	ALG10B	0.77	17.62	0.57	6.36e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4409675	0.576	rs7535816	chr1:28234054	A/G	cg23691781	chr1:28212827	C1orf38	0.32	10.79	0.39	4.97e-25	Corneal astigmatism;
BRCA	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.43	-0.38	1.21e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg26384229	chr12:38710491	ALG10B	0.69	16.17	0.54	1.53e-49	Bladder cancer;
BRCA	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg22907277	chr7:1156413	C7orf50	0.62	10.77	0.39	5.48e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs17092148	1.000	rs3787223	chr20:33331385	C/T	cg16810054	chr20:33298113	TP53INP2	0.49	11.18	0.4	1.23e-26	Neuroticism;
BRCA	cis	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg06521331	chr12:34319734	NA	-0.5	-9.58	-0.35	2.09e-20	Morning vs. evening chronotype;
BRCA	cis	rs3820928	0.874	rs4675137	chr2:227883910	G/C	cg11843606	chr2:227700838	RHBDD1	-0.36	-7.89	-0.3	1.28e-14	Pulmonary function;
BRCA	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg11814155	chr7:99998594	ZCWPW1	0.44	8.32	0.31	5.27e-16	Platelet count;
BRCA	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24531977	chr5:56204891	C5orf35	-0.86	-17.8	-0.58	7.44e-58	Initial pursuit acceleration;
BRCA	cis	rs6545883	0.868	rs2518932	chr2:61801277	T/A	cg15711740	chr2:61764176	XPO1	-0.54	-13.73	-0.48	9.31e-38	Tuberculosis;
BRCA	trans	rs1941687	0.563	rs7238931	chr18:31334993	G/A	cg27147174	chr7:100797783	AP1S1	-0.46	-8.93	-0.33	4.4e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg07169764	chr2:136633963	MCM6	-1.26	-28.52	-0.75	5.08e-116	Corneal structure;
BRCA	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg21535247	chr6:8435926	SLC35B3	0.42	9.49	0.35	4.56e-20	Motion sickness;
BRCA	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg16325326	chr1:53192061	ZYG11B	0.93	25.57	0.71	7.65e-100	Monocyte count;
BRCA	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg06618935	chr21:46677482	NA	-0.35	-7.81	-0.3	2.32e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg18446336	chr7:2847575	GNA12	-0.35	-7.91	-0.3	1.1e-14	Height;
BRCA	cis	rs68170813	0.523	rs11766131	chr7:107071138	T/C	cg02696742	chr7:106810147	HBP1	-0.52	-8.18	-0.31	1.58e-15	Coronary artery disease;
BRCA	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg05347473	chr6:146136440	FBXO30	0.41	8.38	0.31	3.49e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg18132916	chr6:79620363	NA	-0.48	-10.82	-0.39	3.74e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs3960554	0.932	rs76873475	chr7:75829199	C/A	cg19862616	chr7:65841803	NCRNA00174	0.59	12.0	0.43	4.67e-30	Eotaxin levels;
BRCA	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg27170947	chr2:26402098	FAM59B	-0.92	-16.52	-0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs495337	1.000	rs632376	chr20:48520610	A/G	cg17835207	chr20:48524531	SPATA2	-0.55	-11.83	-0.42	2.46e-29	Psoriasis;
BRCA	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.39	9.47	0.35	5.42e-20	Response to antipsychotic treatment;
BRCA	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg27588902	chr6:42928151	GNMT	-0.31	-10.31	-0.38	3.85e-23	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.26	7.87	0.3	1.56e-14	Electroencephalogram traits;
BRCA	cis	rs2559856	0.967	rs2695297	chr12:102082218	T/C	cg12924262	chr12:102091054	CHPT1	0.36	8.13	0.31	2.22e-15	Blood protein levels;
BRCA	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.46	9.25	0.34	3.3e-19	Tonsillectomy;
BRCA	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02176678	chr2:219576539	TTLL4	0.46	11.78	0.42	4.07e-29	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg06521331	chr12:34319734	NA	-0.56	-9.91	-0.37	1.24e-21	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg26384229	chr12:38710491	ALG10B	-0.41	-9.61	-0.36	1.68e-20	Morning vs. evening chronotype;
BRCA	cis	rs2066819	1.000	rs2291361	chr12:56717805	G/A	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg16339924	chr4:17578868	LAP3	0.66	16.94	0.56	2.01e-53	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.53	0.38	5.1900000000000004e-24	Motion sickness;
BRCA	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg16606324	chr3:10149918	C3orf24	0.55	10.84	0.39	2.97e-25	Alzheimer's disease;
BRCA	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg21770322	chr7:97807741	LMTK2	0.42	11.06	0.4	3.78e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg24562669	chr7:97807699	LMTK2	0.45	12.05	0.43	2.92e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs73242632	1.000	rs2227902	chr4:57797100	G/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.65	7.81	0.3	2.38e-14	Congenital heart disease (maternal effect);
BRCA	cis	rs7586879	0.789	rs17046737	chr2:25127835	C/T	cg01884057	chr2:25150051	NA	0.31	7.83	0.3	2.11e-14	Body mass index;
BRCA	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg08508325	chr11:3079039	CARS	0.28	8.45	0.32	2e-16	Calcium levels;
BRCA	cis	rs870825	0.860	rs72703529	chr4:185607351	T/C	cg04058563	chr4:185651563	MLF1IP	0.65	11.26	0.41	5.77e-27	Blood protein levels;
BRCA	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg01877450	chr7:97915802	BRI3	0.35	8.24	0.31	9.73e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs858239	0.539	rs6949363	chr7:23192394	A/G	cg23682824	chr7:23144976	KLHL7	0.41	10.89	0.4	1.84e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg23978390	chr7:1156363	C7orf50	0.5	11.92	0.43	1.04e-29	Longevity;Endometriosis;
BRCA	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg09877947	chr5:131593287	PDLIM4	0.42	10.65	0.39	1.65e-24	Breast cancer;
BRCA	cis	rs17253792	0.822	rs75437558	chr14:56066798	C/T	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs1506636	1.000	rs656425	chr7:123424525	A/C	cg03229431	chr7:123269106	ASB15	0.61	13.54	0.47	6.54e-37	Plateletcrit;Platelet count;
BRCA	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg26031613	chr14:104095156	KLC1	-0.43	-8.58	-0.32	7.26e-17	Schizophrenia;
BRCA	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg27170947	chr2:26402098	FAM59B	0.98	17.0	0.56	9.48e-54	Gut microbiome composition (summer);
BRCA	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.27	0.34	2.84e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.39	8.02	0.3	5.09e-15	Personality dimensions;
BRCA	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg24812749	chr6:127587940	RNF146	0.88	20.74	0.63	1.82e-73	Breast cancer;
BRCA	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.51	8.26	0.31	8.15e-16	Renal function-related traits (BUN);
BRCA	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg11266682	chr4:10021025	SLC2A9	0.4	10.6	0.39	2.76e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg14784868	chr12:69753453	YEATS4	0.48	11.18	0.4	1.28e-26	Response to diuretic therapy;
BRCA	cis	rs10754283	0.967	rs12058749	chr1:90105604	C/T	cg21401794	chr1:90099060	LRRC8C	0.49	11.38	0.41	1.87e-27	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg11598736	chr3:195384522	SDHAP2	0.68	11.81	0.42	3.09e-29	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg23708337	chr7:1209742	NA	0.63	8.88	0.33	6.66e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg02734326	chr4:10020555	SLC2A9	0.36	7.96	0.3	7.66e-15	Bone mineral density;
BRCA	cis	rs7178424	1.000	rs7162536	chr15:62373459	A/C	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.46	-0.32	1.81e-16	Height;
BRCA	cis	rs8028182	0.636	rs4886703	chr15:75730366	C/T	cg20655648	chr15:75932815	IMP3	0.4	7.81	0.3	2.38e-14	Sudden cardiac arrest;
BRCA	cis	rs1577917	0.917	rs2218594	chr6:86543766	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.43	-0.41	1.14e-27	Response to antipsychotic treatment;
BRCA	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg04553112	chr3:125709451	NA	-0.56	-8.41	-0.32	2.61e-16	Blood pressure (smoking interaction);
BRCA	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08219700	chr8:58056026	NA	-0.56	-9.07	-0.34	1.41e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.57	9.37	0.35	1.23e-19	Birth weight;
BRCA	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg23711669	chr6:146136114	FBXO30	0.71	16.91	0.56	2.63e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg08885076	chr2:99613938	TSGA10	0.41	9.63	0.36	1.4e-20	Chronic sinus infection;
BRCA	cis	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-12.54	-0.44	2.01e-32	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg11502198	chr6:26597334	ABT1	0.49	9.73	0.36	5.8e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	16.31	0.54	3.1e-50	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs483180	0.532	rs561931	chr1:120254506	A/G	cg19096424	chr1:120255104	PHGDH	0.47	11.02	0.4	5.44e-26	Macular telangiectasia type 2;
BRCA	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg02527881	chr3:46936655	PTH1R	-0.34	-8.16	-0.31	1.77e-15	Birth weight;
BRCA	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg17691542	chr6:26056736	HIST1H1C	0.48	9.64	0.36	1.24e-20	Iron status biomarkers;
BRCA	cis	rs9880211	0.800	rs9813376	chr3:136475426	C/T	cg21827317	chr3:136751795	NA	-0.45	-7.87	-0.3	1.47e-14	Body mass index;Height;
BRCA	cis	rs6973256	0.862	rs11762935	chr7:133327950	G/T	cg07491979	chr7:133331646	EXOC4	-0.39	-8.85	-0.33	8.22e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg19622623	chr12:86230825	RASSF9	-0.33	-9.28	-0.34	2.49e-19	Major depressive disorder;
BRCA	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg11952622	chr19:58962976	ZNF324B	0.44	9.02	0.34	2.15e-18	Uric acid clearance;
BRCA	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg18538332	chr22:24372958	LOC391322	0.44	9.46	0.35	5.67e-20	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	cis	rs9682041	0.877	rs6804688	chr3:170071191	T/G	cg11886554	chr3:170076028	SKIL	0.52	10.71	0.39	1.03e-24	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg26031613	chr14:104095156	KLC1	-0.52	-9.32	-0.35	1.9e-19	Reticulocyte count;
BRCA	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	14.67	0.5	3.27e-42	Coronary artery disease;
BRCA	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11644478	chr21:40555479	PSMG1	0.85	19.85	0.62	1.1e-68	Cognitive function;
BRCA	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg01448562	chr3:133502909	NA	-0.43	-9.38	-0.35	1.17e-19	Iron status biomarkers;
BRCA	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg23533926	chr12:111358616	MYL2	-0.4	-8.34	-0.31	4.7e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00149659	chr3:10157352	C3orf10	0.79	13.83	0.48	3.03e-38	Alzheimer's disease;
BRCA	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.4	-8.38	-0.31	3.27e-16	Aortic root size;
BRCA	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.83	-0.36	2.54e-21	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs931812	0.757	rs13251801	chr8:101902629	A/T	cg20993868	chr7:22813445	NA	0.45	13.71	0.48	1.06e-37	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-11.58	-0.42	2.69e-28	Hemoglobin concentration;
BRCA	cis	rs8028182	0.636	rs8028277	chr15:75684085	A/G	cg20655648	chr15:75932815	IMP3	0.4	7.85	0.3	1.73e-14	Sudden cardiac arrest;
BRCA	cis	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg06521331	chr12:34319734	NA	-0.56	-10.01	-0.37	5.41e-22	Morning vs. evening chronotype;
BRCA	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg10495392	chr1:46806563	NSUN4	-0.45	-8.38	-0.31	3.26e-16	Menopause (age at onset);
BRCA	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.84e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8028182	0.636	rs28623700	chr15:75849714	T/A	cg20655648	chr15:75932815	IMP3	0.44	8.7	0.33	2.74e-17	Sudden cardiac arrest;
BRCA	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11890956	chr21:40555474	PSMG1	-0.61	-13.36	-0.47	4.64e-36	Menarche (age at onset);
BRCA	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg03433033	chr1:76189801	ACADM	-0.47	-9.49	-0.35	4.43e-20	Daytime sleep phenotypes;
BRCA	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg11584989	chr19:19387371	SF4	0.48	10.8	0.39	4.46e-25	Tonsillectomy;
BRCA	cis	rs12612619	0.732	rs13032059	chr2:27233789	T/C	cg00617064	chr2:27272375	NA	-0.3	-7.97	-0.3	7.44e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs7786808	0.776	rs11983316	chr7:158209742	A/G	cg09998033	chr7:158218633	PTPRN2	-0.33	-7.81	-0.3	2.32e-14	Obesity-related traits;
BRCA	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg27170947	chr2:26402098	FAM59B	-0.92	-16.52	-0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg17971929	chr21:40555470	PSMG1	-0.45	-9.84	-0.36	2.34e-21	Menarche (age at onset);
BRCA	cis	rs791888	0.858	rs1555434	chr10:89419143	G/C	cg13926569	chr10:89418898	PAPSS2	-0.35	-8.11	-0.31	2.6e-15	Magnesium levels;
BRCA	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg12062639	chr20:23401060	NAPB	0.94	13.44	0.47	1.85e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs4302748	0.862	rs12530870	chr7:36181501	A/G	cg24442661	chr7:36192818	EEPD1	0.44	8.28	0.31	7.31e-16	Platelet count;
BRCA	cis	rs1005224	0.889	rs12717566	chr14:76147507	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.35	-8.11	-0.31	2.65e-15	Large artery stroke;
BRCA	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg10876282	chr6:28092338	ZSCAN16	0.41	7.89	0.3	1.32e-14	Parkinson's disease;
BRCA	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg11584989	chr19:19387371	SF4	0.67	14.72	0.5	1.86e-42	Bipolar disorder;
BRCA	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg27432699	chr2:27873401	GPN1	-0.42	-8.61	-0.32	5.5e-17	Oral cavity cancer;
BRCA	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg00105475	chr2:10696890	NA	0.44	10.37	0.38	2.16e-23	Prostate cancer;
BRCA	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg21535247	chr6:8435926	SLC35B3	0.41	9.34	0.35	1.54e-19	Motion sickness;
BRCA	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg08999081	chr20:33150536	PIGU	-0.46	-12.55	-0.44	1.89e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg24803719	chr17:45855879	NA	-0.31	-8.32	-0.31	5.29e-16	IgG glycosylation;
BRCA	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg22705602	chr4:152727874	NA	-0.39	-10.64	-0.39	1.94e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg27170947	chr2:26402098	FAM59B	-0.66	-11.39	-0.41	1.75e-27	Gut microbiome composition (summer);
BRCA	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg24130564	chr14:104152367	KLC1	-0.34	-8.04	-0.3	4.46e-15	Body mass index;
BRCA	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg22875332	chr1:76189707	ACADM	0.64	12.06	0.43	2.44e-30	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg10253484	chr15:75165896	SCAMP2	-0.56	-11.56	-0.42	3.36e-28	Breast cancer;
BRCA	cis	rs490234	0.702	rs13302549	chr9:128284775	T/C	cg14078157	chr9:128172775	NA	-0.51	-11.38	-0.41	1.89e-27	Mean arterial pressure;
BRCA	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg03709012	chr19:19516395	GATAD2A	1.0	18.63	0.59	3.29e-62	Nonalcoholic fatty liver disease;
BRCA	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg03585969	chr10:35415529	CREM	0.49	10.22	0.37	8.41e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs13064411	0.735	rs7636128	chr3:113133701	A/T	cg18753928	chr3:113234510	CCDC52	-0.42	-8.19	-0.31	1.46e-15	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.92	0.4	1.42e-25	Bipolar disorder;
BRCA	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.8	0.39	4.48e-25	Bipolar disorder;
BRCA	cis	rs9463078	0.683	rs911524	chr6:44747204	G/A	cg25276700	chr6:44698697	NA	0.36	8.08	0.3	3.32e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs1371614	0.552	rs35538505	chr2:27126027	G/T	cg12368169	chr2:27073192	DPYSL5	-0.29	-8.31	-0.31	5.69e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg19743168	chr1:23544995	NA	0.34	7.97	0.3	7.51e-15	Height;
BRCA	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg04450456	chr4:17643702	FAM184B	0.38	11.19	0.4	1.12e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	8.17	0.31	1.71e-15	Menarche (age at onset);
BRCA	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg04455712	chr21:45112962	RRP1B	0.44	11.34	0.41	2.64e-27	Mean corpuscular volume;
BRCA	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-9.9	-0.36	1.36e-21	Mean corpuscular volume;
BRCA	trans	rs4942242	1.000	rs9533572	chr13:44234265	A/C	cg19169023	chr15:41853346	TYRO3	-0.52	-11.66	-0.42	1.29e-28	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19346786	chr7:2764209	NA	-0.33	-9.81	-0.36	2.93e-21	Height;
BRCA	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg24296786	chr1:45957014	TESK2	-0.46	-10.64	-0.39	1.87e-24	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2742234	0.955	rs2435385	chr10:43665750	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.44	-9.13	-0.34	8.96e-19	Hirschsprung disease;
BRCA	cis	rs6815814	0.861	rs1135430	chr4:38789361	T/C	cg06935464	chr4:38784597	TLR10	0.47	9.07	0.34	1.5e-18	Breast cancer;
BRCA	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg18305652	chr10:134549665	INPP5A	-0.3	-8.47	-0.32	1.67e-16	Migraine;
BRCA	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.97	-0.33	3.26e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9814567	0.727	rs4245908	chr3:134349205	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-15.99	-0.53	1.17e-48	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-13.51	-0.47	9.34e-37	Morning vs. evening chronotype;
BRCA	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.16	-0.49	8.76e-40	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg18105134	chr13:113819100	PROZ	-0.63	-14.24	-0.49	3.69e-40	Platelet distribution width;
BRCA	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	9.24	0.34	3.63e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs3767633	0.925	rs4233380	chr1:161892483	A/C	cg09175582	chr1:161736000	ATF6	0.55	8.92	0.33	4.71e-18	IgG glycosylation;
BRCA	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08048268	chr3:133502702	NA	-0.42	-10.42	-0.38	1.35e-23	Iron status biomarkers;
BRCA	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg14004847	chr7:1930337	MAD1L1	0.41	8.53	0.32	1.06e-16	Schizophrenia;
BRCA	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.64	0.32	4.65e-17	Motion sickness;
BRCA	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-18.16	-0.58	1.03e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9487051	0.768	rs445796	chr6:109520145	T/C	cg21918786	chr6:109611834	NA	-0.34	-9.15	-0.34	7.85e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs10504073	0.669	rs341802	chr8:50039313	C/T	cg00325661	chr8:49890786	NA	0.37	10.57	0.39	3.64e-24	Blood metabolite ratios;
BRCA	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.52	0.38	5.57e-24	Motion sickness;
BRCA	cis	rs4363385	0.791	rs4041401	chr1:152985629	A/G	cg24667326	chr1:152973720	SPRR3	-0.33	-9.04	-0.34	1.83e-18	Inflammatory skin disease;
BRCA	cis	rs586533	0.781	rs639161	chr11:99495147	G/A	cg22878054	chr11:99397252	CNTN5	0.32	8.03	0.3	4.67e-15	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg22713356	chr15:30763199	NA	1.19	24.18	0.69	3.39e-92	Uric acid levels;
BRCA	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg01528321	chr10:82214614	TSPAN14	0.81	17.34	0.57	1.76e-55	Post bronchodilator FEV1;
BRCA	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03517284	chr6:25882590	NA	-0.47	-9.52	-0.35	3.47e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg07988820	chr12:82153109	PPFIA2	-0.65	-10.43	-0.38	1.32e-23	Resting heart rate;
BRCA	trans	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg26043149	chr18:55253948	FECH	0.39	8.38	0.31	3.34e-16	Bone mineral density;
BRCA	cis	rs4561483	0.801	rs40311	chr16:11963190	C/G	cg08843971	chr16:11963173	GSPT1	0.53	11.72	0.42	7.27e-29	Testicular germ cell tumor;
BRCA	trans	rs11165623	0.792	rs6593599	chr1:96911468	C/T	cg10631902	chr5:14652156	NA	-0.51	-16.13	-0.54	2.38e-49	Hip circumference;Waist circumference;
BRCA	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23221052	chr5:179740743	GFPT2	-0.67	-14.07	-0.49	2.4e-39	Height;
BRCA	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	10.21	0.37	8.8e-23	Lung cancer in ever smokers;
BRCA	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.68	-0.42	1.08e-28	Gut microbiome composition (summer);
BRCA	cis	rs10736390	1.000	rs10736390	chr1:55103945	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.6	-14.49	-0.5	2.5e-41	Survival in pancreatic cancer;
BRCA	cis	rs400736	0.602	rs6694154	chr1:8163520	G/A	cg25007680	chr1:8021821	PARK7	-0.35	-8.59	-0.32	6.88e-17	Response to antidepressants and depression;
BRCA	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg05863683	chr7:1912471	MAD1L1	0.38	8.41	0.32	2.73e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg03462622	chr3:195777018	TFRC	-0.38	-8.61	-0.32	5.5e-17	Mean corpuscular volume;
BRCA	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg03585969	chr10:35415529	CREM	0.55	11.41	0.41	1.39e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg14926445	chr8:58193284	C8orf71	-0.46	-8.7	-0.33	2.73e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	14.68	0.5	2.94e-42	Motion sickness;
BRCA	cis	rs2279817	1.000	rs2279815	chr1:18022066	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.54	16.01	0.54	9.3e-49	Neuroticism;
BRCA	cis	rs897080	0.552	rs1067389	chr2:44642290	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.45	0.35	6.32e-20	Height;
BRCA	trans	rs9409565	0.826	rs2139189	chr9:97238538	A/G	cg05679027	chr9:99775184	HIATL2	-0.42	-9.34	-0.35	1.62e-19	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg12310025	chr6:25882481	NA	-0.42	-9.97	-0.37	7.67e-22	Height;
BRCA	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-10.05	-0.37	3.67e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.49	8.62	0.32	5.17e-17	Mean platelet volume;
BRCA	cis	rs8044868	0.586	rs6499557	chr16:72082654	A/G	cg16558253	chr16:72132732	DHX38	-0.45	-10.76	-0.39	6.27e-25	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	9.15	0.34	7.27e-19	Bipolar disorder;
BRCA	cis	rs1555322	0.530	rs7004	chr20:33866753	G/C	cg03689076	chr20:33865952	NA	0.47	8.5	0.32	1.34e-16	Attention deficit hyperactivity disorder;
BRCA	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg18301423	chr5:131593218	PDLIM4	0.35	8.75	0.33	1.93e-17	Acylcarnitine levels;
BRCA	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg09877947	chr5:131593287	PDLIM4	0.46	11.17	0.4	1.37e-26	Acylcarnitine levels;
BRCA	cis	rs9487051	0.768	rs442405	chr6:109526980	T/G	cg01475377	chr6:109611718	NA	-0.41	-10.29	-0.38	4.49e-23	Reticulocyte fraction of red cells;
BRCA	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.89	-0.33	6e-18	Total body bone mineral density;
BRCA	trans	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg25214090	chr10:38739885	LOC399744	0.56	12.92	0.46	4.23e-34	Corneal astigmatism;
BRCA	trans	rs11088226	0.581	rs2833856	chr21:33877691	A/G	cg09050820	chr6:167586206	TCP10L2	-0.39	-8.03	-0.3	4.63e-15	Gastritis;
BRCA	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03352830	chr11:487213	PTDSS2	0.86	12.96	0.46	2.94e-34	Body mass index;
BRCA	cis	rs501916	0.833	rs11855134	chr15:48047676	A/G	cg16110827	chr15:48056943	SEMA6D	-0.43	-9.06	-0.34	1.57e-18	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	11.45	0.41	9.37e-28	Bipolar disorder and schizophrenia;
BRCA	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg15704280	chr7:45808275	SEPT13	0.52	8.96	0.33	3.48e-18	Axial length;
BRCA	cis	rs7095944	0.644	rs965484	chr10:126453481	T/C	cg08799069	chr10:126477246	METTL10	-0.4	-9.49	-0.35	4.41e-20	Asthma;
BRCA	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19346786	chr7:2764209	NA	-0.33	-10.4	-0.38	1.69e-23	Height;
BRCA	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg10057126	chr4:77819792	ANKRD56	0.67	15.63	0.53	7.02e-47	Emphysema distribution in smoking;
BRCA	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03517284	chr6:25882590	NA	0.38	8.02	0.3	4.93e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg25358565	chr5:93447407	FAM172A	1.24	19.5	0.61	8.3e-67	Diabetic retinopathy;
BRCA	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg06784218	chr1:46089804	CCDC17	0.46	10.93	0.4	1.34e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18404041	chr3:52824283	ITIH1	-0.42	-12.29	-0.44	2.59e-31	Bipolar disorder;
BRCA	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-12.45	-0.44	5.36e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg16325326	chr1:53192061	ZYG11B	0.89	24.58	0.7	2.15e-94	Monocyte count;
BRCA	trans	rs75804782	0.641	rs72983834	chr2:239319895	G/A	cg01134436	chr17:81009848	B3GNTL1	0.77	9.69	0.36	8.3e-21	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg23711669	chr6:146136114	FBXO30	0.8	19.17	0.6	4.48e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg20818283	chr2:191399100	TMEM194B	-0.38	-8.88	-0.33	6.82e-18	Pulse pressure;
BRCA	cis	rs4240897	0.935	rs4846082	chr1:12042443	C/T	cg13216073	chr1:12042593	MFN2	0.56	13.86	0.48	2.2e-38	Tuberculosis;
BRCA	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	22.11	0.66	6.54e-81	Gut microbiome composition (summer);
BRCA	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg01028140	chr2:1542097	TPO	-0.82	-15.46	-0.52	5.06e-46	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg00677455	chr12:58241039	CTDSP2	0.63	15.47	0.52	4.28e-46	Multiple sclerosis;
BRCA	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.45	-8.71	-0.33	2.59e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1499972	0.941	rs817506	chr3:117679394	A/G	cg07612923	chr3:117604196	NA	-0.6	-8.25	-0.31	9.26e-16	Schizophrenia;
BRCA	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg04518342	chr5:131593106	PDLIM4	0.35	8.76	0.33	1.74e-17	Breast cancer;
BRCA	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg21385522	chr1:16154831	NA	-0.62	-11.47	-0.41	7.68e-28	Dilated cardiomyopathy;
BRCA	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00166722	chr3:10149974	C3orf24	0.58	10.07	0.37	3.22e-22	Alzheimer's disease;
BRCA	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg13047869	chr3:10149882	C3orf24	0.56	10.4	0.38	1.67e-23	Alzheimer's disease;
BRCA	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg00684032	chr4:1343700	KIAA1530	0.31	8.0	0.3	5.76e-15	Obesity-related traits;
BRCA	cis	rs7408868	1.000	rs10415431	chr19:15277027	G/A	cg14696996	chr19:15285081	NOTCH3	1.0	14.59	0.5	7.93e-42	Pulse pressure;
BRCA	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.51	-0.32	1.29e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.4	-0.32	2.91e-16	Alzheimer's disease (late onset);
BRCA	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.46	10.18	0.37	1.2e-22	Alzheimer's disease (late onset);
BRCA	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11764359	chr7:65958608	NA	-0.76	-17.43	-0.57	5.6e-56	Aortic root size;
BRCA	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.42	0.47	2.35e-36	Colorectal cancer;
BRCA	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs9487051	0.768	rs398944	chr6:109523444	T/G	cg01475377	chr6:109611718	NA	-0.45	-11.4	-0.41	1.58e-27	Reticulocyte fraction of red cells;
BRCA	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs59698941	0.527	rs11742089	chr5:132178930	G/A	cg14825688	chr5:132208181	LEAP2	-0.37	-8.48	-0.32	1.58e-16	Apolipoprotein A-IV levels;
BRCA	cis	rs807669	0.544	rs2040771	chr22:19161935	C/T	cg02655711	chr22:19163373	SLC25A1	0.51	11.93	0.43	9.11e-30	Metabolite levels;
BRCA	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.68	0.57	3.2e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.2	-0.43	6.43e-31	Response to antipsychotic treatment;
BRCA	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.56	-12.89	-0.45	5.94e-34	IgG glycosylation;
BRCA	cis	rs34779708	0.966	rs4934735	chr10:35496730	C/T	cg03585969	chr10:35415529	CREM	-0.48	-10.08	-0.37	2.81e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6788895	0.661	rs77431731	chr3:150489911	T/G	cg09723797	chr3:150481914	SIAH2	0.73	8.94	0.33	4.26e-18	Breast cancer;
BRCA	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg27588902	chr6:42928151	GNMT	-0.3	-9.59	-0.35	1.94e-20	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg27478167	chr7:817139	HEATR2	0.5	10.32	0.38	3.42e-23	Cerebrospinal P-tau181p levels;
BRCA	cis	rs897984	0.572	rs112906665	chr16:31040139	T/C	cg02466173	chr16:30829666	NA	-0.42	-9.36	-0.35	1.38e-19	Dementia with Lewy bodies;
BRCA	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg03929089	chr4:120376271	NA	0.44	8.31	0.31	5.9e-16	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs1593	0.532	rs11132388	chr4:187219418	T/C	cg14349977	chr4:187219430	NA	-0.64	-11.19	-0.4	1.09e-26	Activated partial thromboplastin time;
BRCA	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg24130564	chr14:104152367	KLC1	-0.41	-8.74	-0.33	2.04e-17	Reticulocyte count;
BRCA	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-14.07	-0.49	2.41e-39	Hemoglobin concentration;
BRCA	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.37e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs919433	0.857	rs36071109	chr2:198183191	C/A	cg10820045	chr2:198174542	NA	-0.38	-8.0	-0.3	5.73e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs9814567	0.806	rs9857242	chr3:134316378	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	17.21	0.56	8.29e-55	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg15704280	chr7:45808275	SEPT13	0.55	8.02	0.3	5.04e-15	Intraocular pressure;
BRCA	cis	rs758324	0.947	rs1604080	chr5:131176644	A/G	cg06307176	chr5:131281290	NA	-0.52	-10.37	-0.38	2.12e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs9443645	0.527	rs1413968	chr6:79791042	A/G	cg05283184	chr6:79620031	NA	-0.36	-8.42	-0.32	2.41e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg08132940	chr7:1081526	C7orf50	-0.6	-8.74	-0.33	2.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9311474	0.652	rs614288	chr3:52220203	T/C	cg15698299	chr3:52233019	ALAS1	-0.34	-7.82	-0.3	2.23e-14	Electroencephalogram traits;
BRCA	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.03	-23.98	-0.69	4e-91	Ulcerative colitis;
BRCA	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg00071950	chr4:10020882	SLC2A9	0.43	10.27	0.38	5.04e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs72772090	0.908	rs17086588	chr5:96044914	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.45	10.46	0.38	9.28e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	12.86	0.45	8.04e-34	Mean platelet volume;
BRCA	trans	rs1973993	0.603	rs1967769	chr1:96993449	C/T	cg10631902	chr5:14652156	NA	0.4	10.06	0.37	3.27e-22	Weight;
BRCA	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.5	0.5	2.04e-41	Colorectal cancer;
BRCA	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.47	-0.44	4.14e-32	Developmental language disorder (linguistic errors);
BRCA	trans	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.69	-0.36	8.55e-21	Bladder cancer;
BRCA	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg06636001	chr8:8085503	FLJ10661	0.52	10.33	0.38	3.09e-23	Retinal vascular caliber;
BRCA	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.89	14.34	0.49	1.28e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.9	-28.25	-0.75	1.46e-114	Schizophrenia;
BRCA	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg26838691	chr2:24397539	C2orf84	-0.48	-8.67	-0.32	3.46e-17	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg26597838	chr10:835615	NA	0.87	15.6	0.53	9.49e-47	Eosinophil percentage of granulocytes;
BRCA	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.66	-0.32	3.86e-17	Alzheimer's disease (late onset);
BRCA	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg24829409	chr8:58192753	C8orf71	-0.47	-8.0	-0.3	6.03e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg18357645	chr12:58087776	OS9	0.44	12.43	0.44	6.21e-32	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg01304814	chr3:48885189	PRKAR2A	0.56	7.86	0.3	1.69e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs11165623	0.564	rs7523597	chr1:97000989	A/G	cg10631902	chr5:14652156	NA	-0.43	-12.14	-0.43	1.11e-30	Hip circumference;Waist circumference;
BRCA	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg12310025	chr6:25882481	NA	-0.49	-11.89	-0.43	1.34e-29	Blood metabolite levels;
BRCA	cis	rs7520050	0.966	rs809775	chr1:46538040	A/T	cg24296786	chr1:45957014	TESK2	0.41	9.19	0.34	5.41e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs3770081	1.000	rs2303340	chr2:86333193	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.62	-8.56	-0.32	8.26e-17	Facial emotion recognition (sad faces);
BRCA	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg03929089	chr4:120376271	NA	0.64	12.64	0.45	7.27e-33	Height;
BRCA	cis	rs1788820	0.917	rs1788762	chr18:21132571	G/C	cg14672496	chr18:21087552	C18orf8	0.34	8.29	0.31	6.45e-16	Body mass index;
BRCA	cis	rs72781680	0.821	rs72796369	chr2:24162663	G/T	cg08917208	chr2:24149416	ATAD2B	0.64	10.71	0.39	9.64e-25	Lymphocyte counts;
BRCA	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg26769984	chr7:1090371	C7orf50	0.52	9.69	0.36	8.13e-21	Bronchopulmonary dysplasia;
BRCA	cis	rs4900538	0.963	rs1190553	chr14:102915331	G/T	cg18135206	chr14:102964638	TECPR2	-1.04	-28.84	-0.75	8.88e-118	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs7267979	0.789	rs9927	chr20:25277244	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.32	0.31	5.51e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10465746	0.967	rs7531537	chr1:84414924	C/T	cg10977910	chr1:84465055	TTLL7	0.49	9.89	0.36	1.45e-21	Obesity-related traits;
BRCA	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg06640241	chr16:89574553	SPG7	0.56	12.66	0.45	6.3e-33	Multiple myeloma (IgH translocation);
BRCA	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.72	-0.33	2.47e-17	Alzheimer's disease (late onset);
BRCA	cis	rs7927771	0.524	rs10742814	chr11:47554337	G/A	cg20307385	chr11:47447363	PSMC3	0.45	10.18	0.37	1.14e-22	Subjective well-being;
BRCA	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg13047869	chr3:10149882	C3orf24	0.53	10.03	0.37	4.34e-22	Alzheimer's disease;
BRCA	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-10.24	-0.38	7.06e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs483180	0.512	rs677277	chr1:120202298	C/T	cg19096424	chr1:120255104	PHGDH	-0.39	-8.73	-0.33	2.13e-17	Macular telangiectasia type 2;
BRCA	cis	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg09307838	chr4:120376055	NA	0.44	9.54	0.35	2.91e-20	Diastolic blood pressure;
BRCA	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg14186256	chr22:23484241	RTDR1	0.75	22.88	0.67	4.12e-85	Bone mineral density;
BRCA	cis	rs12365397	0.552	rs7122200	chr11:43163328	C/G	cg03447554	chr11:43094025	NA	0.44	8.19	0.31	1.38e-15	Migraine;
BRCA	cis	rs6546550	0.901	rs6546559	chr2:70145833	G/A	cg02498382	chr2:70120550	SNRNP27	-0.52	-11.33	-0.41	3.09e-27	Prevalent atrial fibrillation;
BRCA	cis	rs17095355	1.000	rs11194926	chr10:111700922	A/G	cg00817464	chr10:111662876	XPNPEP1	0.4	10.01	0.37	5.13e-22	Biliary atresia;
BRCA	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg13319975	chr6:146136371	FBXO30	0.42	9.78	0.36	3.73e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg25036284	chr2:26402008	FAM59B	-0.63	-10.54	-0.38	4.75e-24	Gut microbiome composition (summer);
BRCA	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	7.98	0.3	6.61e-15	Tonsillectomy;
BRCA	trans	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg07211511	chr3:129823064	LOC729375	-0.63	-11.04	-0.4	4.71e-26	Blood pressure (smoking interaction);
BRCA	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	10.01	0.37	5.17e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg03354898	chr7:1950403	MAD1L1	0.38	8.51	0.32	1.25e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs6064559	0.545	rs1062600	chr20:56137798	G/A	cg16101800	chr20:56136569	PCK1	-0.45	-11.56	-0.42	3.23e-28	Hemoglobin concentration;
BRCA	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14240646	chr10:27532245	ACBD5	-0.67	-12.04	-0.43	3.01e-30	Breast cancer;
BRCA	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	14.11	0.49	1.56e-39	Colorectal cancer;
BRCA	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06544989	chr22:39130855	UNC84B	0.36	8.59	0.32	6.75e-17	Menopause (age at onset);
BRCA	cis	rs6138458	0.585	rs1007881	chr20:25014385	A/G	cg26195577	chr20:24973756	C20orf3	0.6	14.62	0.5	5.67e-42	Blood protein levels;
BRCA	cis	rs2304069	0.550	rs216144	chr5:149445480	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.56	10.88	0.4	2.01e-25	HIV-1 control;
BRCA	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg26597838	chr10:835615	NA	0.92	14.69	0.5	2.79e-42	Eosinophil percentage of granulocytes;
BRCA	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg05340658	chr4:99064831	C4orf37	0.61	14.79	0.5	8.91e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6433857	0.657	rs2368178	chr2:181501938	T/C	cg23363182	chr2:181467187	NA	-0.45	-9.73	-0.36	5.81e-21	Body mass index;
BRCA	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	11.04	0.4	4.47e-26	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg21659725	chr3:3221576	CRBN	-0.47	-9.99	-0.37	6.33e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs586533	0.881	rs636893	chr11:99504897	G/C	cg22878054	chr11:99397252	CNTN5	0.32	8.12	0.31	2.44e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7474896	0.559	rs1212108	chr10:38094322	A/C	cg25427524	chr10:38739819	LOC399744	-0.53	-9.06	-0.34	1.63e-18	Obesity (extreme);
BRCA	cis	rs7903847	0.642	rs10882915	chr10:99142184	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.66	-0.32	3.88e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg14664628	chr15:75095509	CSK	-0.74	-18.05	-0.58	3.45e-59	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg18230493	chr5:56204884	C5orf35	0.61	13.0	0.46	1.88e-34	Initial pursuit acceleration;
BRCA	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg18154014	chr19:37997991	ZNF793	0.61	11.38	0.41	1.85e-27	Coronary artery calcification;
BRCA	cis	rs72772090	0.522	rs17477045	chr5:95987984	A/C	cg17330273	chr5:96107758	CAST;ERAP1	0.52	8.1	0.31	2.82e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg17063962	chr7:91808500	NA	0.53	12.45	0.44	5.15e-32	Breast cancer;
BRCA	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.09	0.34	1.25e-18	Motion sickness;
BRCA	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg24558204	chr6:135376177	HBS1L	0.44	11.94	0.43	8.18e-30	Red blood cell count;
BRCA	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg23711669	chr6:146136114	FBXO30	0.64	14.97	0.51	1.25e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.48e-23	Motion sickness;
BRCA	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg17971929	chr21:40555470	PSMG1	0.77	18.33	0.59	1.3e-60	Cognitive function;
BRCA	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg13628971	chr7:2884303	GNA12	0.39	8.5	0.32	1.31e-16	Height;
BRCA	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.05	0.51	4.81e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg04398451	chr17:18023971	MYO15A	-0.69	-14.86	-0.51	4e-43	Total body bone mineral density;
BRCA	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg08885076	chr2:99613938	TSGA10	-0.54	-12.41	-0.44	7.59e-32	Chronic sinus infection;
BRCA	cis	rs758324	0.947	rs6596040	chr5:131198777	C/T	cg06307176	chr5:131281290	NA	0.53	10.32	0.38	3.51e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg16482183	chr6:26056742	HIST1H1C	0.54	11.63	0.42	1.67e-28	Height;
BRCA	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg12661370	chr5:149340060	SLC26A2	0.51	8.05	0.3	4.18e-15	HIV-1 control;
BRCA	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.38	-9.55	-0.35	2.68e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg26384229	chr12:38710491	ALG10B	0.43	9.61	0.36	1.69e-20	Morning vs. evening chronotype;
BRCA	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg14993813	chr1:46806288	NSUN4	-0.49	-9.61	-0.36	1.69e-20	Menopause (age at onset);
BRCA	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg05552183	chr6:42928497	GNMT	0.82	20.58	0.63	1.37e-72	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg15448220	chr1:150897856	SETDB1	0.36	7.95	0.3	8.34e-15	Melanoma;
BRCA	cis	rs2742234	0.541	rs11528481	chr10:43737767	C/A	cg15436174	chr10:43711423	RASGEF1A	0.49	9.7	0.36	7.4e-21	Hirschsprung disease;
BRCA	cis	rs68170813	0.522	rs12535814	chr7:107038432	A/T	cg02696742	chr7:106810147	HBP1	-0.48	-8.27	-0.31	8.02e-16	Coronary artery disease;
BRCA	cis	rs6714710	0.557	rs17490429	chr2:98449024	G/A	cg26665480	chr2:98280029	ACTR1B	0.6	13.82	0.48	3.49e-38	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg23260525	chr10:116636907	FAM160B1	0.3	7.93	0.3	1e-14	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.02	-0.3	5.22e-15	Parkinson's disease;
BRCA	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02475777	chr4:1388615	CRIPAK	-0.67	-12.51	-0.44	2.8099999999999997e-32	Longevity;
BRCA	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg22875332	chr1:76189707	ACADM	-0.54	-10.17	-0.37	1.26e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.45	-8.91	-0.33	5.2e-18	Menarche (age at onset);
BRCA	cis	rs7903847	0.642	rs12359257	chr10:99136359	A/T	cg08345082	chr10:99160200	RRP12	-0.3	-8.29	-0.31	6.72e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg21161173	chr5:140098174	VTRNA1-2	0.31	7.84	0.3	1.94e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs858239	0.899	rs5850	chr7:23314547	C/T	cg23682824	chr7:23144976	KLHL7	0.34	8.6	0.32	6.12e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs10851411	0.697	rs17709867	chr15:42800767	C/T	cg21293051	chr15:42870591	STARD9	0.57	9.02	0.34	2.13e-18	Glucose homeostasis traits;
BRCA	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg23505145	chr19:12996616	KLF1	0.56	12.69	0.45	4.46e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10193935	0.901	rs9309082	chr2:42581412	A/G	cg27598129	chr2:42591480	NA	-0.87	-14.28	-0.49	2.3e-40	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7766436	0.961	rs6900627	chr6:22570245	G/A	cg13666174	chr6:22585274	NA	-0.4	-9.14	-0.34	8.22e-19	Coronary artery disease;
BRCA	cis	rs7091068	0.522	rs10882322	chr10:95483273	C/G	cg20715218	chr10:95462985	C10orf4	0.48	9.13	0.34	8.67e-19	Urinary tract infection frequency;
BRCA	cis	rs2806561	0.734	rs7548692	chr1:23354877	T/A	cg19743168	chr1:23544995	NA	0.36	8.39	0.31	3.21e-16	Height;
BRCA	cis	rs365132	1.000	rs353467	chr5:176445698	T/C	cg16309518	chr5:176445507	NA	-0.52	-13.24	-0.46	1.51e-35	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg18252515	chr7:66147081	NA	0.91	13.02	0.46	1.61e-34	Diabetic kidney disease;
BRCA	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.43	-0.32	2.35e-16	Colorectal cancer;
BRCA	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg06784218	chr1:46089804	CCDC17	0.45	10.76	0.39	6.02e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg23018236	chr17:30244563	NA	-0.61	-10.02	-0.37	4.87e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg20487152	chr13:99095054	FARP1	0.4	10.31	0.38	3.65e-23	Neuroticism;
BRCA	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg13010199	chr12:38710504	ALG10B	-0.38	-8.7	-0.33	2.89e-17	Morning vs. evening chronotype;
BRCA	cis	rs2559856	1.000	rs2559855	chr12:102090080	A/G	cg12924262	chr12:102091054	CHPT1	-0.38	-8.74	-0.33	2.05e-17	Blood protein levels;
BRCA	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg26384229	chr12:38710491	ALG10B	0.78	18.13	0.58	1.41e-59	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg26384229	chr12:38710491	ALG10B	0.68	14.12	0.49	1.32e-39	Morning vs. evening chronotype;
BRCA	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.89	19.5	0.61	8.03e-67	Cognitive ability;
BRCA	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg00012203	chr2:219082015	ARPC2	-0.51	-10.39	-0.38	1.88e-23	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23221052	chr5:179740743	GFPT2	-0.67	-14.04	-0.49	3.33e-39	Height;
BRCA	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg24642439	chr20:33292090	TP53INP2	0.68	14.02	0.49	3.95e-39	Coronary artery disease;
BRCA	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg01475735	chr3:40494733	NA	0.48	10.01	0.37	5.26e-22	Renal cell carcinoma;
BRCA	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg23625390	chr15:77176239	SCAPER	0.4	9.36	0.35	1.34e-19	Blood metabolite levels;
BRCA	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg05340658	chr4:99064831	C4orf37	0.55	10.76	0.39	6.32e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg08888203	chr3:10149979	C3orf24	0.56	11.7	0.42	9.05e-29	Alzheimer's disease;
BRCA	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.62e-19	Morning vs. evening chronotype;
BRCA	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	16.43	0.54	7.78e-51	Hip circumference adjusted for BMI;
BRCA	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.44	-0.35	6.83e-20	Tonsillectomy;
BRCA	cis	rs72781680	0.821	rs116583405	chr2:24208221	T/C	cg08917208	chr2:24149416	ATAD2B	0.62	10.47	0.38	8.48e-24	Lymphocyte counts;
BRCA	trans	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg18876405	chr7:65276391	NA	0.43	8.47	0.32	1.63e-16	Corneal structure;
BRCA	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg11833968	chr6:79620685	NA	-0.43	-9.58	-0.35	2.12e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg03709012	chr19:19516395	GATAD2A	-0.75	-17.01	-0.56	8.07e-54	Tonsillectomy;
BRCA	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg18230493	chr5:56204884	C5orf35	-0.74	-14.69	-0.5	2.79e-42	Initial pursuit acceleration;
BRCA	cis	rs870825	0.616	rs6419939	chr4:185642869	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	17.2	0.56	9.11e-55	Blood protein levels;
BRCA	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.74	-0.39	7.47e-25	Mean corpuscular volume;
BRCA	cis	rs1710278	0.967	rs1017723	chr10:127746825	A/G	cg22975853	chr10:127789788	ADAM12	-0.33	-8.61	-0.32	5.49e-17	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
BRCA	cis	rs9359856	0.564	rs72917989	chr6:90470385	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.7	-8.55	-0.32	8.85e-17	Bipolar disorder;
BRCA	cis	rs2599510	0.755	rs67257914	chr2:32804018	G/A	cg02381751	chr2:32503542	YIPF4	0.43	8.32	0.31	5.44e-16	Interleukin-18 levels;
BRCA	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.54e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg04181038	chr4:183730758	NA	0.53	10.1	0.37	2.28e-22	Pediatric autoimmune diseases;
BRCA	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.96	0.3	7.63e-15	Depression;
BRCA	cis	rs10838687	0.736	rs4647741	chr11:47254010	T/C	cg25783544	chr11:47291846	MADD	0.42	7.84	0.3	1.83e-14	Proinsulin levels;
BRCA	cis	rs6893300	0.542	rs3797774	chr5:179193970	C/T	cg14593053	chr5:179126677	CANX	0.48	12.99	0.46	2.04e-34	Resting heart rate;
BRCA	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg26597838	chr10:835615	NA	0.91	16.26	0.54	5.33e-50	Eosinophil percentage of granulocytes;
BRCA	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.75	12.15	0.43	1.1e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg17691542	chr6:26056736	HIST1H1C	0.48	9.83	0.36	2.59e-21	Height;
BRCA	cis	rs7246657	0.722	rs2927739	chr19:38149330	C/A	cg23950597	chr19:37808831	NA	0.52	8.86	0.33	8.12e-18	Coronary artery calcification;
BRCA	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg19622623	chr12:86230825	RASSF9	-0.28	-8.09	-0.3	3.04e-15	Major depressive disorder;
BRCA	trans	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg13010199	chr12:38710504	ALG10B	0.42	7.92	0.3	1.05e-14	Resting heart rate;
BRCA	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-14.13	-0.49	1.22e-39	Migraine;Coronary artery disease;
BRCA	cis	rs11945232	1.000	rs10027786	chr4:88347512	A/G	cg23841344	chr4:88312519	HSD17B11	-0.47	-9.5	-0.35	4.02e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9473147	0.543	rs9473119	chr6:47450618	G/A	cg12968598	chr6:47444699	CD2AP	0.44	9.56	0.35	2.48e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg27535305	chr1:53392650	SCP2	0.49	11.33	0.41	3.02e-27	Monocyte count;
BRCA	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg10169327	chr19:45448959	APOC2	0.31	7.81	0.3	2.28e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg22117172	chr7:91764530	CYP51A1	0.23	7.84	0.3	1.9e-14	Breast cancer;
BRCA	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg13010199	chr12:38710504	ALG10B	0.49	9.53	0.35	3.12e-20	Morning vs. evening chronotype;
BRCA	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24110177	chr3:50126178	RBM5	-0.36	-9.67	-0.36	9.88e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11890956	chr21:40555474	PSMG1	0.78	19.15	0.6	6.19e-65	Cognitive function;
BRCA	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-13.43	-0.47	2.1e-36	Morning vs. evening chronotype;
BRCA	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.47	-9.07	-0.34	1.4e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.22	0.37	8.39e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.59	-0.39	2.86e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.15	-0.49	9.24e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg11764359	chr7:65958608	NA	0.65	11.66	0.42	1.27e-28	Aortic root size;
BRCA	cis	rs7264396	0.836	rs961020	chr20:34182069	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-10.43	-0.38	1.24e-23	Total cholesterol levels;
BRCA	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg22535103	chr8:58192502	C8orf71	-0.46	-9.2	-0.34	4.87e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg03146154	chr1:46216737	IPP	0.54	12.11	0.43	1.49e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs701145	0.938	rs1515653	chr3:154076654	A/G	cg17054900	chr3:154042577	DHX36	0.67	11.54	0.42	4e-28	Coronary artery disease;
BRCA	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg10932868	chr11:921992	NA	0.49	12.59	0.45	1.21e-32	Alzheimer's disease (late onset);
BRCA	cis	rs7809950	1.000	rs17154104	chr7:107090698	C/T	cg23024343	chr7:107201750	COG5	-0.43	-9.93	-0.37	1.09e-21	Coronary artery disease;
BRCA	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg26384229	chr12:38710491	ALG10B	0.69	14.64	0.5	4.48e-42	Morning vs. evening chronotype;
BRCA	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg06623918	chr6:96969491	KIAA0776	-0.77	-13.98	-0.48	6.03e-39	Migraine;Coronary artery disease;
BRCA	cis	rs6088813	1.000	rs6087704	chr20:34001058	C/T	cg14752227	chr20:34000481	UQCC	-0.43	-9.08	-0.34	1.39e-18	Height;
BRCA	trans	rs12517041	1.000	rs6868335	chr5:23316641	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-8.09	-0.3	2.99e-15	Calcium levels;
BRCA	trans	rs7200543	0.883	rs4985148	chr16:15147788	A/C	cg24683922	chr1:11983373	KIAA2013	-0.37	-8.6	-0.32	6.24e-17	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.48	-10.3	-0.38	3.88e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg18016565	chr1:150552671	MCL1	-0.37	-8.66	-0.32	3.79e-17	Tonsillectomy;
BRCA	cis	rs778371	0.723	rs6704763	chr2:233592487	C/T	cg08000102	chr2:233561755	GIGYF2	0.85	20.94	0.64	1.52e-74	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.82e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.93	-30.68	-0.77	9.06e-128	Schizophrenia;
BRCA	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg05985134	chr18:33552581	C18orf21	0.62	10.75	0.39	6.85e-25	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg05283184	chr6:79620031	NA	-0.36	-8.12	-0.31	2.46e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.62	0.55	8.5e-52	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg00717180	chr2:96193071	NA	-0.38	-10.24	-0.38	6.67e-23	HDL cholesterol;
BRCA	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12667521	chr19:29218732	NA	0.47	8.92	0.33	4.75e-18	Methadone dose in opioid dependence;
BRCA	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs6815814	0.847	rs11725309	chr4:38783848	T/C	cg02016764	chr4:38805732	TLR1	-0.61	-9.54	-0.35	3.01e-20	Breast cancer;
BRCA	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg12564285	chr5:131593104	PDLIM4	0.35	7.98	0.3	6.85e-15	Breast cancer;
BRCA	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg26695010	chr11:65641043	EFEMP2	0.39	9.13	0.34	8.65e-19	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg22189786	chr22:42395067	WBP2NL	0.43	8.65	0.32	4.27e-17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg20302533	chr7:39170763	POU6F2	0.38	7.97	0.3	7.41e-15	IgG glycosylation;
BRCA	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg10518572	chr11:65560635	OVOL1	-0.28	-8.13	-0.31	2.19e-15	Acne (severe);
BRCA	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.78	0.42	4.11e-29	Tonsillectomy;
BRCA	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg26516362	chr5:178986906	RUFY1	0.33	7.92	0.3	1.05e-14	Lung cancer;
BRCA	cis	rs6450176	0.909	rs2448	chr5:53302354	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-14.52	-0.5	1.65e-41	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs490234	0.783	rs2416967	chr9:128440014	T/C	cg14078157	chr9:128172775	NA	-0.42	-9.48	-0.35	4.83e-20	Mean arterial pressure;
BRCA	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.08	0.3	3.2e-15	Uric acid levels;
BRCA	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg05340658	chr4:99064831	C4orf37	0.6	12.88	0.45	6.34e-34	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	8.42	0.32	2.39e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs922692	0.715	rs11072803	chr15:79077878	G/A	cg04896959	chr15:78267971	NA	0.37	8.62	0.32	5.15e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg25767906	chr1:53392781	SCP2	-0.48	-10.67	-0.39	1.49e-24	Monocyte count;
BRCA	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11764359	chr7:65958608	NA	-0.79	-18.63	-0.59	3.45e-62	Aortic root size;
BRCA	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11644478	chr21:40555479	PSMG1	0.74	14.89	0.51	2.74e-43	Cognitive function;
BRCA	cis	rs12760731	0.565	rs12047117	chr1:178132608	G/A	cg00404053	chr1:178313656	RASAL2	0.64	7.96	0.3	7.93e-15	Obesity-related traits;
BRCA	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg14403583	chr14:105418241	AHNAK2	-0.38	-8.91	-0.33	5.48e-18	Rheumatoid arthritis;
BRCA	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	8.08	0.3	3.33e-15	Platelet count;
BRCA	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg20701182	chr2:24300061	SF3B14	0.59	9.19	0.34	5.66e-19	Lymphocyte counts;
BRCA	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg13319975	chr6:146136371	FBXO30	-0.41	-9.43	-0.35	7.32e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg00383909	chr3:49044727	WDR6	0.72	12.36	0.44	1.31e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg09307838	chr4:120376055	NA	0.72	15.28	0.52	3.69e-45	Corneal astigmatism;
BRCA	cis	rs2463822	1.000	rs7481995	chr11:62129312	G/C	cg06239285	chr11:62104954	ASRGL1	0.69	11.52	0.41	4.72e-28	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg00339695	chr16:24857497	SLC5A11	-0.43	-8.04	-0.3	4.52e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6840258	1.000	rs56201818	chr4:87952633	T/C	cg08197287	chr4:87952173	AFF1	-0.43	-8.58	-0.32	7.08e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs10089	0.552	rs58595196	chr5:127558338	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	9.56	0.35	2.52e-20	Ileal carcinoids;
BRCA	cis	rs10493773	0.928	rs12751296	chr1:86176968	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.45	-9.31	-0.35	2.1e-19	Urate levels in overweight individuals;
BRCA	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.18	0.4	1.22e-26	Bipolar disorder;
BRCA	cis	rs17095355	1.000	rs12571674	chr10:111717608	C/T	cg00817464	chr10:111662876	XPNPEP1	0.42	9.3	0.35	2.25e-19	Biliary atresia;
BRCA	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18876405	chr7:65276391	NA	-0.59	-14.15	-0.49	1e-39	Aortic root size;
BRCA	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	12.97	0.46	2.51e-34	Bipolar disorder;
BRCA	cis	rs1322639	0.618	rs9505942	chr6:169591793	T/C	cg03254818	chr6:169586852	NA	0.46	7.87	0.3	1.49e-14	Pulse pressure;
BRCA	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03517284	chr6:25882590	NA	0.7	15.88	0.53	4.03e-48	Blood metabolite levels;
BRCA	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg14993813	chr1:46806288	NSUN4	-0.49	-9.61	-0.36	1.69e-20	Menopause (age at onset);
BRCA	cis	rs17092148	1.000	rs6060040	chr20:33359054	G/C	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.34	-0.41	2.82e-27	Neuroticism;
BRCA	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg01475735	chr3:40494733	NA	-0.43	-7.91	-0.3	1.13e-14	Renal cell carcinoma;
BRCA	cis	rs4280164	0.945	rs11158635	chr14:24776769	G/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.46	-7.91	-0.3	1.15e-14	Parent of origin effect on language impairment (paternal);
BRCA	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-10.4	-0.38	1.68e-23	Monocyte percentage of white cells;
BRCA	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg13047869	chr3:10149882	C3orf24	0.57	10.42	0.38	1.43e-23	Alzheimer's disease;
BRCA	cis	rs17228212	1.000	rs731874	chr15:67446831	C/T	cg26876701	chr15:67458665	SMAD3	-0.44	-8.48	-0.32	1.57e-16	Coronary heart disease;
BRCA	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg10553204	chr2:20871195	GDF7	-0.29	-7.84	-0.3	1.9e-14	Abdominal aortic aneurysm;
BRCA	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg04450456	chr4:17643702	FAM184B	0.38	10.52	0.38	5.64e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg05340658	chr4:99064831	C4orf37	0.67	16.82	0.55	8.18e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.35	-8.46	-0.32	1.88e-16	Electroencephalogram traits;
BRCA	cis	rs1635	0.655	rs73742536	chr6:28303243	G/A	cg15743358	chr6:28303923	ZNF323	-0.75	-8.56	-0.32	8.52e-17	Schizophrenia;
BRCA	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.74	0.39	7.72e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs953387	1.000	rs6715785	chr2:136910273	C/T	cg05194412	chr2:137003533	NA	-0.38	-8.83	-0.33	1.04e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg14664628	chr15:75095509	CSK	-0.5	-11.68	-0.42	1.09e-28	Breast cancer;
BRCA	cis	rs4566357	0.576	rs10187255	chr2:227913442	T/A	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.08	-0.3	3.32e-15	Coronary artery disease;
BRCA	cis	rs4845875	0.530	rs4846048	chr1:11846252	A/G	cg06193043	chr1:11908199	NPPA	-0.34	-7.84	-0.3	1.85e-14	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs416603	0.967	rs11640138	chr16:11362729	A/G	cg00044050	chr16:11439710	C16orf75	0.42	9.6	0.36	1.72e-20	Type 1 diabetes;
BRCA	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11644478	chr21:40555479	PSMG1	0.71	13.93	0.48	9.98e-39	Cognitive function;
BRCA	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg18446336	chr7:2847575	GNA12	0.43	9.78	0.36	3.92e-21	Loneliness (linear analysis);
BRCA	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg11502198	chr6:26597334	ABT1	0.56	11.95	0.43	7.89e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg07741184	chr6:167504864	NA	0.32	9.87	0.36	1.78e-21	Crohn's disease;
BRCA	trans	rs61931739	1.000	rs11502817	chr12:34010676	T/C	cg26384229	chr12:38710491	ALG10B	-0.41	-9.3	-0.35	2.27e-19	Morning vs. evening chronotype;
BRCA	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08048268	chr3:133502702	NA	-0.34	-8.37	-0.31	3.61e-16	Iron status biomarkers;
BRCA	cis	rs6815814	0.851	rs4274855	chr4:38777471	C/T	cg06935464	chr4:38784597	TLR10	0.47	7.86	0.3	1.63e-14	Breast cancer;
BRCA	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg09307838	chr4:120376055	NA	0.62	12.32	0.44	1.86e-31	Corneal astigmatism;
BRCA	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg02659138	chr7:134003124	SLC35B4	0.33	10.16	0.37	1.43e-22	Mean platelet volume;
BRCA	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	11.0	0.4	6.59e-26	Bipolar disorder;
BRCA	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg04518342	chr5:131593106	PDLIM4	0.38	8.89	0.33	6.44e-18	Acylcarnitine levels;
BRCA	trans	rs9944715	0.954	rs6507691	chr18:43808648	T/C	cg01718231	chr17:29326311	RNF135	-0.45	-8.53	-0.32	1.09e-16	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs9463078	0.764	rs6458415	chr6:44881592	G/C	cg25276700	chr6:44698697	NA	-0.35	-8.09	-0.3	2.91e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs2742234	0.541	rs1059484	chr10:43679800	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.54	-10.87	-0.4	2.25e-25	Hirschsprung disease;
BRCA	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.93e-24	Motion sickness;
BRCA	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00166722	chr3:10149974	C3orf24	0.64	11.21	0.41	9.37e-27	Alzheimer's disease;
BRCA	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg06238570	chr21:40685208	BRWD1	-0.41	-8.34	-0.31	4.42e-16	Cognitive function;
BRCA	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg08888203	chr3:10149979	C3orf24	0.61	13.03	0.46	1.34e-34	Alzheimer's disease;
BRCA	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg10495392	chr1:46806563	NSUN4	0.43	7.84	0.3	1.96e-14	Menopause (age at onset);
BRCA	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg23422044	chr7:1970798	MAD1L1	-0.71	-12.87	-0.45	7.28e-34	Bipolar disorder;
BRCA	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg12311346	chr5:56204834	C5orf35	-0.44	-9.06	-0.34	1.59e-18	Coronary artery disease;
BRCA	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg07148914	chr20:33460835	GGT7	0.38	8.58	0.32	7.05e-17	Height;
BRCA	cis	rs2415984	0.600	rs61993295	chr14:46932614	T/C	cg14871534	chr14:47121158	RPL10L	-0.37	-8.76	-0.33	1.68e-17	Number of children ever born;
BRCA	cis	rs701145	0.585	rs1632688	chr3:153874139	C/A	cg17054900	chr3:154042577	DHX36	0.55	9.29	0.35	2.32e-19	Coronary artery disease;
BRCA	cis	rs7903847	0.642	rs6584127	chr10:99142948	A/C	cg20016023	chr10:99160130	RRP12	-0.27	-8.76	-0.33	1.71e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.12	0.37	1.91e-22	Bladder cancer;
BRCA	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.56	-0.52	1.55e-46	Chronic sinus infection;
BRCA	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg22638593	chr5:131593259	PDLIM4	0.32	7.86	0.3	1.7e-14	Acylcarnitine levels;
BRCA	trans	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.54	-0.35	2.86e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg23711669	chr6:146136114	FBXO30	0.64	15.03	0.51	5.92e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13064411	0.660	rs3829889	chr3:113015464	G/A	cg18753928	chr3:113234510	CCDC52	-0.43	-8.11	-0.31	2.64e-15	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.23	-0.31	1.07e-15	Total body bone mineral density;
BRCA	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.51	0.63	3.08e-72	Electrocardiographic conduction measures;
BRCA	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg21226059	chr5:178986404	RUFY1	0.51	13.29	0.47	9.17e-36	Lung cancer;
BRCA	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg22676075	chr6:135203613	NA	0.41	8.27	0.31	7.76e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg25358565	chr5:93447407	FAM172A	-0.51	-9.15	-0.34	7.84e-19	Diabetic retinopathy;
BRCA	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg17063962	chr7:91808500	NA	0.53	9.42	0.35	7.94e-20	Breast cancer;
BRCA	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg06046430	chr4:77819534	ANKRD56	0.61	13.51	0.47	9.58e-37	Emphysema distribution in smoking;
BRCA	cis	rs7766436	0.922	rs2066338	chr6:22611393	C/T	cg13666174	chr6:22585274	NA	-0.43	-9.21	-0.34	4.49e-19	Coronary artery disease;
BRCA	trans	rs783540	0.681	rs1259178	chr15:83271876	T/C	cg16105309	chr15:79090380	ADAMTS7	0.33	9.21	0.34	4.44e-19	Schizophrenia;
BRCA	cis	rs7598759	0.527	rs4973417	chr2:232349636	G/T	cg19187155	chr2:232395269	NMUR1	0.7	16.66	0.55	4.83e-52	Noise-induced hearing loss;
BRCA	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg17971929	chr21:40555470	PSMG1	0.79	18.92	0.6	1.04e-63	Cognitive function;
BRCA	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.53	-9.03	-0.34	1.93e-18	Schizophrenia;
BRCA	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg27129171	chr3:47204927	SETD2	-0.73	-17.66	-0.57	3.78e-57	Colorectal cancer;
BRCA	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg24006582	chr15:45444508	DUOX1	-0.53	-10.88	-0.4	2e-25	Uric acid levels;
BRCA	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg26031613	chr14:104095156	KLC1	-0.53	-9.42	-0.35	8.08e-20	Reticulocyte count;
BRCA	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.11	-0.34	1.08e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.82	-13.7	-0.48	1.17e-37	Platelet count;
BRCA	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	11.96	0.43	7.08e-30	Mean platelet volume;
BRCA	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg23422044	chr7:1970798	MAD1L1	0.58	10.74	0.39	7.56e-25	Bipolar disorder;
BRCA	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	10.03	0.37	4.4e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg26677194	chr12:130822605	PIWIL1	0.6	14.55	0.5	1.23e-41	Menopause (age at onset);
BRCA	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg19773385	chr1:10388646	KIF1B	-0.38	-8.25	-0.31	8.98e-16	Hepatocellular carcinoma;
BRCA	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg12641515	chr19:46296257	DMWD	-0.54	-11.79	-0.42	3.57e-29	Coronary artery disease;
BRCA	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg05234568	chr11:5960015	NA	-0.45	-9.06	-0.34	1.56e-18	DNA methylation (variation);
BRCA	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg21132104	chr15:45694354	SPATA5L1	0.49	9.73	0.36	5.94e-21	Response to fenofibrate (adiponectin levels);
BRCA	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.27	8.39	0.31	3.2e-16	Electroencephalogram traits;
BRCA	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg13736514	chr6:26305472	NA	-0.45	-14.69	-0.5	2.79e-42	Educational attainment;
BRCA	cis	rs7582720	1.000	rs4675310	chr2:203880834	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.76	-12.37	-0.44	1.2e-31	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.24	0.34	3.56e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs13102973	1.000	rs4611981	chr4:135902585	C/T	cg14419869	chr4:135874104	NA	0.48	9.97	0.37	7.55e-22	Subjective well-being;
BRCA	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27286337	chr10:134555280	INPP5A	0.6	10.87	0.4	2.19e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg08601574	chr20:25228251	PYGB	0.33	8.05	0.3	4.14e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg01579765	chr21:45077557	HSF2BP	-0.44	-11.67	-0.42	1.14e-28	Mean corpuscular volume;
BRCA	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg14784868	chr12:69753453	YEATS4	0.68	19.81	0.62	1.97e-68	Blood protein levels;
BRCA	cis	rs10045504	0.502	rs17352751	chr5:38737836	G/A	cg15396434	chr5:38725168	NA	-0.57	-11.05	-0.4	4.13e-26	Night sleep phenotypes;
BRCA	cis	rs6484504	0.576	rs208071	chr11:31144996	C/T	cg26647111	chr11:31128758	NA	-0.43	-9.25	-0.34	3.43e-19	Red blood cell count;
BRCA	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11890956	chr21:40555474	PSMG1	1.05	29.55	0.76	1.2e-121	Cognitive function;
BRCA	cis	rs698833	0.892	rs698796	chr2:44689669	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	10.36	0.38	2.25e-23	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs698833	0.962	rs698832	chr2:44734823	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.49	-10.02	-0.37	4.6e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg04511125	chr2:88470314	THNSL2	0.95	13.73	0.48	8.71e-38	Plasma clusterin levels;
BRCA	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg16586182	chr3:47516702	SCAP	0.61	14.11	0.49	1.55e-39	Colorectal cancer;
BRCA	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	8.51	0.32	1.23e-16	Personality dimensions;
BRCA	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg17425144	chr1:10567563	PEX14	0.64	16.66	0.55	5e-52	Breast size;
BRCA	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg07402062	chr16:89894098	SPIRE2	-0.28	-10.02	-0.37	4.59e-22	Vitiligo;
BRCA	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07636037	chr3:49044803	WDR6	0.76	16.5	0.55	3.36e-51	Menarche (age at onset);
BRCA	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-8.09	-0.3	2.98e-15	Bipolar disorder;
BRCA	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg26695010	chr11:65641043	EFEMP2	0.45	10.09	0.37	2.57e-22	Eosinophil percentage of white cells;
BRCA	trans	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg16011800	chr17:1958478	HIC1	-0.55	-8.85	-0.33	8.58e-18	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg24675658	chr1:53192096	ZYG11B	-0.52	-11.44	-0.41	1.07e-27	Monocyte count;
BRCA	cis	rs6543140	0.929	rs7602207	chr2:103032366	C/G	cg04239558	chr2:103089729	SLC9A4	0.33	9.25	0.34	3.24e-19	Blood protein levels;
BRCA	cis	rs9297145	0.724	rs6954584	chr7:98766930	G/A	cg05967295	chr7:98741636	SMURF1	0.96	18.2	0.58	6.09e-60	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-8.75	-0.33	1.96e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs27434	0.583	rs151953	chr5:96157648	C/G	cg16492584	chr5:96139282	ERAP1	-0.44	-10.96	-0.4	1.02e-25	Ankylosing spondylitis;
BRCA	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg18252515	chr7:66147081	NA	-1.02	-14.91	-0.51	2.26e-43	Diabetic kidney disease;
BRCA	cis	rs7520050	0.966	rs785491	chr1:46583418	G/A	cg24296786	chr1:45957014	TESK2	0.41	9.11	0.34	1.03e-18	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg03806693	chr22:41940476	POLR3H	-0.55	-9.66	-0.36	1.06e-20	Neuroticism;
BRCA	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4722585	0.533	rs6964215	chr7:26196819	G/A	cg07876897	chr7:26191696	NFE2L3	0.39	8.29	0.31	6.94e-16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
BRCA	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg15839431	chr19:19639596	YJEFN3	-0.4	-8.71	-0.33	2.56e-17	Bipolar disorder;
BRCA	cis	rs11608355	0.545	rs4766603	chr12:109892106	T/C	cg05360138	chr12:110035743	NA	0.71	13.18	0.46	2.85e-35	Neuroticism;
BRCA	cis	rs708547	0.915	rs28605409	chr4:57766261	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.48	-8.31	-0.31	5.77e-16	Response to bleomycin (chromatid breaks);
BRCA	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg25358565	chr5:93447407	FAM172A	1.17	18.44	0.59	3.18e-61	Diabetic retinopathy;
BRCA	cis	rs1865721	0.958	rs72977878	chr18:73193037	T/G	cg26385618	chr18:73139727	C18orf62	-0.39	-9.0	-0.34	2.66e-18	Intelligence;
BRCA	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg09307838	chr4:120376055	NA	0.68	13.99	0.48	5.27e-39	Corneal astigmatism;
BRCA	cis	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.21	-0.41	9.26e-27	Morning vs. evening chronotype;
BRCA	cis	rs4702	0.611	rs1894401	chr15:91429042	C/T	cg05469396	chr15:91419421	FURIN	0.33	8.4	0.32	2.8e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs9300255	0.739	rs6633	chr12:123745809	G/T	cg00376283	chr12:123451042	ABCB9	-0.55	-10.84	-0.39	3.01e-25	Neutrophil percentage of white cells;
BRCA	trans	rs3857536	0.813	rs9294688	chr6:66945904	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-7.83	-0.3	2.02e-14	Blood trace element (Cu levels);
BRCA	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg08132940	chr7:1081526	C7orf50	-0.59	-8.73	-0.33	2.29e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-9.4	-0.35	9.44e-20	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.720	rs1134220	chr1:152976306	T/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.32	-0.31	5.46e-16	Inflammatory skin disease;
BRCA	cis	rs9487051	0.768	rs461487	chr6:109525504	A/G	cg21918786	chr6:109611834	NA	-0.34	-9.05	-0.34	1.68e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs9309473	1.000	rs6705489	chr2:73648811	G/T	cg20560298	chr2:73613845	ALMS1	-0.44	-10.69	-0.39	1.24e-24	Metabolite levels;
BRCA	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg01483505	chr11:975446	AP2A2	0.33	9.07	0.34	1.41e-18	Alzheimer's disease (late onset);
BRCA	cis	rs6545883	0.894	rs2167566	chr2:61519408	G/T	cg15711740	chr2:61764176	XPO1	-0.5	-12.53	-0.44	2.29e-32	Tuberculosis;
BRCA	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg27170947	chr2:26402098	FAM59B	-0.7	-11.65	-0.42	1.4e-28	Gut microbiome composition (summer);
BRCA	cis	rs367943	1.000	rs348928	chr5:112815295	C/T	cg12552261	chr5:112820674	MCC	-0.56	-12.28	-0.44	2.97e-31	Type 2 diabetes;
BRCA	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg00814883	chr7:100076585	TSC22D4	-0.49	-9.4	-0.35	9.19e-20	Platelet count;
BRCA	cis	rs1163251	0.756	rs539799	chr1:120208472	C/T	cg19096424	chr1:120255104	PHGDH	0.34	7.91	0.3	1.16e-14	Blood metabolite levels;
BRCA	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-8.17	-0.31	1.71e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs9649465	1.000	rs3807634	chr7:123382290	C/T	cg04330084	chr7:123175371	IQUB	-0.32	-8.76	-0.33	1.72e-17	Migraine;
BRCA	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg14983838	chr19:29218262	NA	0.48	8.12	0.31	2.4e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg11833968	chr6:79620685	NA	-0.39	-8.7	-0.33	2.76e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08045932	chr20:61659980	NA	0.49	11.15	0.4	1.75e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg07460842	chr6:66804631	NA	0.62	11.13	0.4	2.1e-26	Type 2 diabetes;
BRCA	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg17845761	chr1:175162550	KIAA0040	-0.26	-9.8	-0.36	3.31e-21	Alcohol dependence;
BRCA	cis	rs3820928	0.874	rs12467261	chr2:227888838	T/C	cg11843606	chr2:227700838	RHBDD1	-0.35	-7.88	-0.3	1.42e-14	Pulmonary function;
BRCA	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.89	-0.33	6e-18	Total body bone mineral density;
BRCA	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg09307838	chr4:120376055	NA	0.63	13.59	0.47	3.72e-37	Corneal astigmatism;
BRCA	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg03929089	chr4:120376271	NA	-0.53	-8.81	-0.33	1.21e-17	Axial length;
BRCA	cis	rs7264396	1.000	rs7264396	chr20:34154741	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.43	8.97	0.33	3.24e-18	Total cholesterol levels;
BRCA	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.55	-0.32	8.98e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4742903	1.000	rs7854630	chr9:106875277	A/C	cg21169611	chr9:106856078	SMC2	-0.36	-9.28	-0.34	2.63e-19	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg02297831	chr4:17616191	MED28	0.39	9.05	0.34	1.74e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg20991723	chr1:152506922	NA	0.39	8.95	0.33	3.87e-18	Hair morphology;
BRCA	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.14	-0.31	2.02e-15	Total body bone mineral density;
BRCA	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.59	-0.61	2.67e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg07169764	chr2:136633963	MCM6	1.28	28.4	0.75	2.18e-115	Corneal structure;
BRCA	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg11752832	chr7:134001865	SLC35B4	0.5	11.35	0.41	2.45e-27	Mean platelet volume;
BRCA	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg26384229	chr12:38710491	ALG10B	-0.46	-10.71	-0.39	9.72e-25	Morning vs. evening chronotype;
BRCA	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg02574844	chr11:5959923	NA	-0.42	-8.32	-0.31	5.27e-16	DNA methylation (variation);
BRCA	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg23173402	chr1:227635558	NA	0.46	8.45	0.32	1.94e-16	Major depressive disorder;
BRCA	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg16586182	chr3:47516702	SCAP	-0.55	-12.43	-0.44	6.46e-32	Colorectal cancer;
BRCA	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg10057126	chr4:77819792	ANKRD56	0.67	15.27	0.52	4.03e-45	Emphysema distribution in smoking;
BRCA	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08045932	chr20:61659980	NA	0.5	11.51	0.41	5.25e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.3	-7.85	-0.3	1.8e-14	Response to antipsychotic treatment;
BRCA	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg13866156	chr1:1669148	SLC35E2	0.51	10.8	0.39	4.33e-25	Body mass index;
BRCA	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg03060546	chr3:49711283	APEH	-0.51	-10.51	-0.38	6.34e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.38	-9.62	-0.36	1.48e-20	Blood protein levels;Circulating chemerin levels;
BRCA	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg15704280	chr7:45808275	SEPT13	-0.78	-17.34	-0.57	1.81e-55	Coronary artery disease;
BRCA	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg02743256	chr7:2109353	MAD1L1	0.46	8.66	0.32	3.78e-17	Bipolar disorder;
BRCA	cis	rs7593730	0.636	rs1020731	chr2:161144055	A/G	cg22609984	chr2:161126801	NA	-0.38	-7.84	-0.3	1.93e-14	Type 2 diabetes;
BRCA	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg19274703	chr22:41806451	NA	0.39	8.85	0.33	8.45e-18	Vitiligo;
BRCA	cis	rs4561483	0.771	rs12924398	chr16:11972948	T/A	cg08843971	chr16:11963173	GSPT1	-0.39	-8.17	-0.31	1.6e-15	Testicular germ cell tumor;
BRCA	trans	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg23762105	chr12:34175262	ALG10	0.37	8.52	0.32	1.17e-16	Morning vs. evening chronotype;
BRCA	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.64	-13.78	-0.48	5.18e-38	Lymphocyte counts;
BRCA	cis	rs12474201	0.572	rs7596521	chr2:46918665	A/G	cg06386533	chr2:46925753	SOCS5	0.51	9.89	0.36	1.44e-21	Height;
BRCA	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.66	-15.61	-0.53	9.03e-47	Systemic lupus erythematosus;
BRCA	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.53	0.35	3.33e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg06618935	chr21:46677482	NA	-0.37	-7.99	-0.3	6.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9612	1.000	rs2074634	chr19:44238347	C/T	cg08581076	chr19:44259116	C19orf61	-0.63	-11.45	-0.41	9.69e-28	Exhaled nitric oxide output;
BRCA	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-24.01	-0.69	2.89e-91	Height;
BRCA	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg10495392	chr1:46806563	NSUN4	0.44	8.19	0.31	1.43e-15	Menopause (age at onset);
BRCA	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg04362960	chr10:104952993	NT5C2	0.42	10.41	0.38	1.45e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs4728302	0.869	rs10155909	chr7:133593036	A/G	cg07491979	chr7:133331646	EXOC4	0.36	7.89	0.3	1.31e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg06636001	chr8:8085503	FLJ10661	0.53	10.22	0.37	8.37e-23	Retinal vascular caliber;
BRCA	trans	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.89	0.3	1.36e-14	Endometrial cancer;
BRCA	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05901451	chr6:126070800	HEY2	0.57	14.79	0.51	8.35e-43	Brugada syndrome;
BRCA	cis	rs3772130	0.583	rs7618041	chr3:121566481	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	14.39	0.49	7.2e-41	Cognitive performance;
BRCA	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.79	-0.42	3.6e-29	Bipolar disorder;
BRCA	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg24578937	chr1:2090814	PRKCZ	0.57	17.81	0.58	6.82e-58	Height;
BRCA	cis	rs6545883	0.894	rs2694642	chr2:61596180	A/G	cg15711740	chr2:61764176	XPO1	0.51	12.44	0.44	5.81e-32	Tuberculosis;
BRCA	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg23625390	chr15:77176239	SCAPER	-0.52	-12.81	-0.45	1.33e-33	Blood metabolite levels;
BRCA	cis	rs7246967	0.673	rs4933027	chr19:22903972	A/C	cg23217946	chr19:22817039	ZNF492	-0.49	-9.24	-0.34	3.54e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg04546413	chr19:29218101	NA	0.65	12.1	0.43	1.64e-30	Methadone dose in opioid dependence;
BRCA	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg21770322	chr7:97807741	LMTK2	0.41	10.97	0.4	8.81e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg04851639	chr8:1020857	NA	-0.35	-10.12	-0.37	2.01e-22	Schizophrenia;
BRCA	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg18230493	chr5:56204884	C5orf35	0.43	8.85	0.33	8.62e-18	Coronary artery disease;
BRCA	cis	rs870825	0.616	rs28375770	chr4:185647395	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	trans	rs7939886	0.920	rs17150038	chr11:55863414	A/T	cg15704280	chr7:45808275	SEPT13	0.6	7.88	0.3	1.38e-14	Myopia (pathological);
BRCA	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg02951883	chr7:2050386	MAD1L1	-0.57	-13.69	-0.48	1.31e-37	Bipolar disorder and schizophrenia;
BRCA	cis	rs6545883	0.794	rs12053388	chr2:61532320	G/A	cg15711740	chr2:61764176	XPO1	0.5	12.04	0.43	3.19e-30	Tuberculosis;
BRCA	cis	rs7191700	0.674	rs12597893	chr16:11426331	A/G	cg00044050	chr16:11439710	C16orf75	0.46	11.16	0.4	1.54e-26	Multiple sclerosis;
BRCA	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg24803719	chr17:45855879	NA	-0.31	-8.1	-0.31	2.77e-15	IgG glycosylation;
BRCA	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	20.07	0.62	7.34e-70	Platelet count;
BRCA	cis	rs6594499	0.872	rs10038058	chr5:110443281	A/G	cg04022379	chr5:110408740	TSLP	0.36	8.2	0.31	1.31e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg19901468	chr14:105411992	AHNAK2	-0.51	-12.38	-0.44	1.03e-31	Rheumatoid arthritis;
BRCA	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg02297831	chr4:17616191	MED28	0.38	8.9	0.33	5.66e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg18016565	chr1:150552671	MCL1	0.34	8.05	0.3	4.08e-15	Tonsillectomy;
BRCA	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg08085267	chr17:45401833	C17orf57	0.67	14.93	0.51	1.88e-43	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg18404041	chr3:52824283	ITIH1	-0.47	-14.0	-0.48	5.07e-39	Bipolar disorder;
BRCA	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06022373	chr22:39101656	GTPBP1	0.71	16.0	0.53	1.03e-48	Menopause (age at onset);
BRCA	trans	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg25214090	chr10:38739885	LOC399744	0.45	10.36	0.38	2.38e-23	Corneal astigmatism;
BRCA	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg04025307	chr7:1156635	C7orf50	0.74	18.81	0.6	3.93e-63	Longevity;Endometriosis;
BRCA	trans	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg26043149	chr18:55253948	FECH	0.37	8.18	0.31	1.57e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs868036	1.000	rs868037	chr15:68054996	A/G	cg08079166	chr15:68083412	MAP2K5	-0.33	-8.68	-0.32	3.23e-17	Restless legs syndrome;
BRCA	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg22907277	chr7:1156413	C7orf50	0.59	9.1	0.34	1.11e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg10932868	chr11:921992	NA	0.39	9.34	0.35	1.64e-19	Alzheimer's disease (late onset);
BRCA	cis	rs34779708	0.897	rs35784065	chr10:35353574	C/T	cg03585969	chr10:35415529	CREM	0.55	11.41	0.41	1.41e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg26384229	chr12:38710491	ALG10B	0.59	13.52	0.47	8.1e-37	Morning vs. evening chronotype;
BRCA	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg11879182	chr18:77439856	CTDP1	0.59	12.64	0.45	7.58e-33	Monocyte count;
BRCA	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-8.85	-0.33	8.54e-18	Neuroticism;
BRCA	cis	rs4363385	0.818	rs407448	chr1:153007504	C/T	cg24667326	chr1:152973720	SPRR3	-0.33	-8.92	-0.33	4.73e-18	Inflammatory skin disease;
BRCA	cis	rs10254118	0.757	rs6467491	chr7:133138761	A/G	cg10665199	chr7:133106180	EXOC4	0.48	10.16	0.37	1.42e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg25767906	chr1:53392781	SCP2	-0.38	-8.61	-0.32	5.89e-17	Monocyte count;
BRCA	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg21770322	chr7:97807741	LMTK2	0.42	11.27	0.41	5.33e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg19743168	chr1:23544995	NA	0.46	11.45	0.41	1.01e-27	Height;
BRCA	trans	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg13565492	chr6:43139072	SRF	-0.88	-16.2	-0.54	1.08e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-8.95	-0.33	3.89e-18	Alzheimer's disease (late onset);
BRCA	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg23029597	chr12:123009494	RSRC2	-0.59	-11.49	-0.41	6.43e-28	Body mass index;
BRCA	cis	rs12541635	0.677	rs2163124	chr8:107058862	G/T	cg10147462	chr8:107024639	NA	0.4	10.75	0.39	7.04e-25	Age of smoking initiation;
BRCA	trans	rs61931739	0.929	rs1825358	chr12:34011895	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.43	-0.35	7.61e-20	Morning vs. evening chronotype;
BRCA	trans	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg26043149	chr18:55253948	FECH	-0.37	-8.14	-0.31	2.06e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.73	0.33	2.22e-17	Motion sickness;
BRCA	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg14092571	chr14:90743983	NA	-0.34	-8.02	-0.3	5.07e-15	Mortality in heart failure;
BRCA	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.61	-11.48	-0.41	7.48e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg00383909	chr3:49044727	WDR6	0.58	10.53	0.38	4.92e-24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg09658497	chr7:2847517	GNA12	-0.4	-8.6	-0.32	6.26e-17	Height;
BRCA	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-11.19	-0.4	1.19e-26	Gut microbiome composition (summer);
BRCA	trans	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg06521331	chr12:34319734	NA	-0.49	-9.15	-0.34	7.35e-19	Bladder cancer;
BRCA	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-11.24	-0.41	6.81e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs4974559	0.947	rs10018627	chr4:1356358	G/A	cg02980000	chr4:1222292	CTBP1	0.75	12.66	0.45	6.36e-33	Systolic blood pressure;
BRCA	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg27279351	chr12:120934652	DYNLL1	0.57	13.17	0.46	3.18e-35	High light scatter reticulocyte count;
BRCA	cis	rs6545883	0.868	rs7574631	chr2:61825142	T/G	cg15711740	chr2:61764176	XPO1	-0.55	-14.01	-0.48	4.49e-39	Tuberculosis;
BRCA	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg01475377	chr6:109611718	NA	-0.6	-16.64	-0.55	6.57e-52	Reticulocyte fraction of red cells;
BRCA	cis	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg21775007	chr8:11205619	TDH	-0.48	-10.06	-0.37	3.43e-22	Triglycerides;
BRCA	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.56	-8.66	-0.32	3.92e-17	HIV-1 control;
BRCA	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg09035930	chr12:129282057	SLC15A4	0.48	13.49	0.47	1.07e-36	Systemic lupus erythematosus;
BRCA	cis	rs17209837	0.607	rs4148810	chr7:87102251	C/T	cg00919237	chr7:87102261	ABCB4	-0.53	-10.23	-0.38	7.27e-23	Gallbladder cancer;
BRCA	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg25173405	chr17:45401733	C17orf57	0.47	9.77	0.36	4.26e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.37	-0.38	2.13e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg07636037	chr3:49044803	WDR6	-0.6	-8.15	-0.31	1.97e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7395581	0.918	rs11039166	chr11:47316691	A/C	cg25783544	chr11:47291846	MADD	0.43	9.76	0.36	4.54e-21	HDL cholesterol;
BRCA	cis	rs1568889	0.877	rs57202579	chr11:28221677	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.61	0.5	6.33e-42	Bipolar disorder;
BRCA	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg15017067	chr4:17643749	FAM184B	0.29	8.93	0.33	4.45e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg14728415	chr7:32535168	LSM5;AVL9	-0.4	-8.89	-0.33	6.15e-18	Cognitive ability;
BRCA	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg01939980	chr4:1354348	KIAA1530	0.31	8.47	0.32	1.62e-16	Obesity-related traits;
BRCA	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-13.23	-0.46	1.74e-35	Gut microbiome composition (summer);
BRCA	cis	rs7178424	1.000	rs4564516	chr15:62365107	G/C	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.44	-0.32	2.2e-16	Height;
BRCA	cis	rs12618769	0.597	rs4850874	chr2:99069799	G/A	cg10123293	chr2:99228465	UNC50	0.41	8.18	0.31	1.57e-15	Bipolar disorder;
BRCA	trans	rs1997103	1.000	rs2331068	chr7:55408220	G/A	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg18446336	chr7:2847575	GNA12	-0.42	-10.41	-0.38	1.56e-23	Plateletcrit;
BRCA	trans	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.81	0.3	2.3e-14	Corneal astigmatism;
BRCA	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg05552183	chr6:42928497	GNMT	0.66	14.13	0.49	1.2e-39	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7011049	1.000	rs72643580	chr8:53846710	T/G	cg26025543	chr8:53854495	NA	0.55	9.57	0.35	2.31e-20	Systolic blood pressure;
BRCA	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg27478167	chr7:817139	HEATR2	0.52	10.18	0.37	1.17e-22	Cerebrospinal P-tau181p levels;
BRCA	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg01579765	chr21:45077557	HSF2BP	-0.44	-11.99	-0.43	5.11e-30	Mean corpuscular volume;
BRCA	trans	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg23762105	chr12:34175262	ALG10	-0.4	-9.76	-0.36	4.39e-21	Morning vs. evening chronotype;
BRCA	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg24069376	chr3:38537580	EXOG	0.42	12.09	0.43	1.85e-30	Electrocardiographic conduction measures;
BRCA	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-12.03	-0.43	3.49e-30	Gut microbiome composition (summer);
BRCA	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg01529538	chr14:23388837	RBM23	0.42	11.56	0.42	3.3e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg14675211	chr2:100938903	LONRF2	0.43	9.62	0.36	1.54e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg06238570	chr21:40685208	BRWD1	0.43	8.59	0.32	6.55e-17	Cognitive function;
BRCA	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs11608355	0.545	rs36094325	chr12:109911542	A/T	cg05360138	chr12:110035743	NA	0.71	13.05	0.46	1.09e-34	Neuroticism;
BRCA	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg24829409	chr8:58192753	C8orf71	-0.48	-9.14	-0.34	7.94e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg23602478	chr1:26503979	CNKSR1	0.23	7.95	0.3	8.44e-15	Height;
BRCA	cis	rs2425143	0.818	rs35448195	chr20:34542365	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-7.97	-0.3	7.27e-15	Blood protein levels;
BRCA	trans	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg15556689	chr8:8085844	FLJ10661	-0.34	-8.49	-0.32	1.39e-16	Neuroticism;
BRCA	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg13256891	chr4:100009986	ADH5	0.47	9.06	0.34	1.52e-18	Alcohol dependence;
BRCA	cis	rs2289583	0.642	rs67624860	chr15:75391557	A/G	cg14664628	chr15:75095509	CSK	0.39	9.09	0.34	1.26e-18	Systemic lupus erythematosus;
BRCA	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg20503657	chr10:835505	NA	1.31	21.75	0.65	6.72e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.03	-0.43	3.53e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg02820040	chr2:241836501	C2orf54	-0.52	-9.99	-0.37	5.96e-22	Urinary metabolites;
BRCA	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg14019146	chr3:50243930	SLC38A3	0.36	8.96	0.33	3.53e-18	Body mass index;
BRCA	cis	rs2070433	1.000	rs2839306	chr21:47954219	G/T	cg05998816	chr21:47859926	PCNT	-0.34	-8.24	-0.31	9.85e-16	Lymphocyte counts;
BRCA	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg17830980	chr10:43048298	ZNF37B	0.56	13.61	0.47	3.18e-37	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2637266	1.000	rs7098790	chr10:78361077	T/A	cg18941641	chr10:78392320	NA	0.35	7.84	0.3	1.83e-14	Pulmonary function;
BRCA	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg25174290	chr11:3078921	CARS	-0.3	-8.02	-0.3	5.12e-15	Calcium levels;
BRCA	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.48	9.85	0.36	2.13e-21	Tonsillectomy;
BRCA	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg00409905	chr10:38381863	ZNF37A	-0.51	-10.92	-0.4	1.44e-25	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg05623727	chr3:50126028	RBM5	-0.37	-8.14	-0.31	2.01e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.78e-21	Total body bone mineral density;
BRCA	cis	rs6700896	0.931	rs12034502	chr1:66099831	C/T	cg04111102	chr1:66153794	NA	0.33	8.23	0.31	1.09e-15	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs7524258	0.868	rs2157499	chr1:7271472	C/T	cg07173049	chr1:7289937	CAMTA1	0.45	11.06	0.4	3.85e-26	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg04025307	chr7:1156635	C7orf50	0.59	9.45	0.35	6.35e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs700651	0.789	rs2196176	chr2:198904914	A/G	cg00792783	chr2:198669748	PLCL1	0.38	8.41	0.32	2.7e-16	Intracranial aneurysm;
BRCA	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07080220	chr10:102295463	HIF1AN	0.49	11.33	0.41	2.98e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7000551	0.689	rs10110254	chr8:22309551	G/T	cg12081754	chr8:22256438	SLC39A14	0.42	8.24	0.31	9.78e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs4727443	0.899	rs886453	chr7:99588225	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.39	8.84	0.33	9.53e-18	Interstitial lung disease;
BRCA	trans	rs2562456	1.000	rs2562456	chr19:21666210	A/G	cg25042112	chr7:64838748	ZNF92	-0.42	-8.32	-0.31	5.3e-16	Pain;
BRCA	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg21095983	chr6:86352623	SYNCRIP	0.46	9.89	0.36	1.46e-21	Smooth-surface caries;
BRCA	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	ch.11.42038R	chr11:967971	AP2A2	-0.5	-15.8	-0.53	1.02e-47	Alzheimer's disease (late onset);
BRCA	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23248424	chr5:179741104	GFPT2	-0.66	-13.57	-0.47	4.84e-37	Height;
BRCA	cis	rs36051895	0.659	rs12351277	chr9:5061405	A/C	cg02405213	chr9:5042618	JAK2	-0.5	-9.18	-0.34	6.1e-19	Pediatric autoimmune diseases;
BRCA	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg12292205	chr6:26970375	C6orf41	0.72	16.4	0.54	1.09e-50	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23583168	chr7:148888333	NA	-0.97	-26.31	-0.72	5.93e-104	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	11.03	0.4	5.12e-26	Height;
BRCA	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg21798802	chr22:38057573	PDXP	0.49	13.22	0.46	2.02e-35	Fat distribution (HIV);
BRCA	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6545883	0.507	rs2442025	chr2:61571445	G/A	cg15711740	chr2:61764176	XPO1	0.31	7.81	0.3	2.29e-14	Tuberculosis;
BRCA	trans	rs2797160	1.000	rs1739367	chr6:126004720	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.35	-7.83	-0.3	2.01e-14	Endometrial cancer;
BRCA	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08280861	chr8:58055591	NA	0.53	8.59	0.32	6.53e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	11.56	0.42	3.26e-28	Rheumatoid arthritis;
BRCA	cis	rs16976116	0.855	rs11856010	chr15:55495008	A/G	cg11288833	chr15:55489084	RSL24D1	0.48	10.68	0.39	1.25e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs476633	0.691	rs11858115	chr15:41542591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.4	-8.79	-0.33	1.42e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg22875332	chr1:76189707	ACADM	0.69	14.65	0.5	4.09e-42	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg11693508	chr17:37793320	STARD3	0.57	10.81	0.39	4.14e-25	Bipolar disorder;
BRCA	cis	rs11723261	0.621	rs6599307	chr4:143777	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.32	7.98	0.3	6.56e-15	Immune response to smallpox vaccine (IL-6);
BRCA	cis	rs9463078	0.547	rs1338908	chr6:44728812	C/T	cg25276700	chr6:44698697	NA	0.36	8.29	0.31	6.81e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg17724175	chr1:150552817	MCL1	-0.34	-11.05	-0.4	4.22e-26	Blood protein levels;
BRCA	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-12.59	-0.45	1.32e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs2249625	0.584	rs2496506	chr6:72891324	A/C	cg18830697	chr6:72922368	RIMS1	-0.63	-14.34	-0.49	1.19e-40	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg16586182	chr3:47516702	SCAP	0.56	12.51	0.44	2.85e-32	Colorectal cancer;
BRCA	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.68	-0.32	3.33e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.95	0.4	1.12e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.94	0.58	1.43e-58	Fuchs's corneal dystrophy;
BRCA	cis	rs2354432	0.607	rs7545467	chr1:146746248	A/G	cg25205988	chr1:146714368	CHD1L	-0.95	-12.44	-0.44	5.87e-32	Mitochondrial DNA levels;
BRCA	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.39	-8.2	-0.31	1.29e-15	Ulcerative colitis;
BRCA	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg17845761	chr1:175162550	KIAA0040	0.26	9.91	0.37	1.19e-21	Alcohol dependence;
BRCA	cis	rs10465746	0.570	rs6658559	chr1:84467412	A/G	cg10977910	chr1:84465055	TTLL7	0.54	11.07	0.4	3.53e-26	Obesity-related traits;
BRCA	cis	rs13064411	0.597	rs2291905	chr3:113010466	C/T	cg18753928	chr3:113234510	CCDC52	-0.42	-9.01	-0.34	2.44e-18	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg23205692	chr1:25664452	TMEM50A	0.4	9.83	0.36	2.5e-21	Erythrocyte sedimentation rate;
BRCA	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg24069376	chr3:38537580	EXOG	0.32	9.04	0.34	1.78e-18	Electrocardiographic conduction measures;
BRCA	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg00071950	chr4:10020882	SLC2A9	0.58	14.11	0.49	1.55e-39	Bone mineral density;
BRCA	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg01236616	chr12:121019343	POP5	1.24	27.07	0.73	4.13e-108	Type 1 diabetes nephropathy;
BRCA	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg18016565	chr1:150552671	MCL1	-0.37	-8.58	-0.32	7.01e-17	Tonsillectomy;
BRCA	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg06046430	chr4:77819534	ANKRD56	0.62	14.02	0.49	3.92e-39	Emphysema distribution in smoking;
BRCA	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg08975724	chr8:8085496	FLJ10661	-0.36	-7.88	-0.3	1.44e-14	Systolic blood pressure;
BRCA	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg07541023	chr7:19748670	TWISTNB	0.98	21.43	0.65	3.65e-77	Night sleep phenotypes;
BRCA	cis	rs870825	0.616	rs6552809	chr4:185643984	G/A	cg04058563	chr4:185651563	MLF1IP	0.76	17.12	0.56	2.3e-54	Blood protein levels;
BRCA	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03264133	chr6:25882463	NA	-0.53	-11.99	-0.43	5.08e-30	Blood metabolite levels;
BRCA	cis	rs367943	1.000	rs348961	chr5:112819944	A/C	cg12552261	chr5:112820674	MCC	-0.59	-12.24	-0.44	4.35e-31	Type 2 diabetes;
BRCA	cis	rs9790314	0.663	rs10513562	chr3:160743579	G/A	cg03342759	chr3:160939853	NMD3	-0.44	-9.13	-0.34	8.97e-19	Morning vs. evening chronotype;
BRCA	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg14343924	chr8:8086146	FLJ10661	0.39	7.86	0.3	1.59e-14	Retinal vascular caliber;
BRCA	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.31	7.9	0.3	1.24e-14	IgG glycosylation;
BRCA	cis	rs490234	0.783	rs28729336	chr9:128405488	T/G	cg14078157	chr9:128172775	NA	-0.47	-10.65	-0.39	1.76e-24	Mean arterial pressure;
BRCA	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg16850897	chr7:100343110	ZAN	-0.62	-12.88	-0.45	6.75e-34	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg01028140	chr2:1542097	TPO	-0.77	-15.23	-0.52	6.2e-45	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	10.01	0.37	5.17e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg06115741	chr20:33292138	TP53INP2	0.53	11.64	0.42	1.57e-28	Coronary artery disease;
BRCA	cis	rs9287719	0.601	rs10178751	chr2:10734203	T/C	cg00105475	chr2:10696890	NA	0.41	9.26	0.34	3e-19	Prostate cancer;
BRCA	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-11.37	-0.41	2.05e-27	Pulmonary function;
BRCA	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg07636037	chr3:49044803	WDR6	0.95	26.92	0.73	2.75e-107	Parkinson's disease;
BRCA	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg04450456	chr4:17643702	FAM184B	0.32	9.34	0.35	1.5700000000000001e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg03060546	chr3:49711283	APEH	-0.54	-10.99	-0.4	7.38e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.43	8.25	0.31	9.14e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.44	-8.08	-0.3	3.15e-15	Huntington's disease progression;
BRCA	trans	rs9784649	1.000	rs56205870	chr5:24958870	A/G	cg08600765	chr20:34638493	LOC647979	-0.5	-8.15	-0.31	1.96e-15	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg21280719	chr6:42927975	GNMT	-0.31	-13.23	-0.46	1.68e-35	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs3820928	0.874	rs56324594	chr2:227868854	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.29	-0.31	6.54e-16	Pulmonary function;
BRCA	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg24296786	chr1:45957014	TESK2	0.65	16.16	0.54	1.65e-49	High light scatter reticulocyte count;
BRCA	cis	rs1371614	0.632	rs6718978	chr2:27161591	G/A	cg00617064	chr2:27272375	NA	-0.3	-7.91	-0.3	1.15e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs10465746	0.725	rs980417	chr1:84365331	C/A	cg10977910	chr1:84465055	TTLL7	0.59	12.66	0.45	6.17e-33	Obesity-related traits;
BRCA	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg21395723	chr22:39101663	GTPBP1	0.39	8.33	0.31	4.9e-16	Menopause (age at onset);
BRCA	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.93	0.37	1.05e-21	Bipolar disorder;
BRCA	trans	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04565464	chr8:145669602	NFKBIL2	0.33	8.06	0.3	3.66e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.95	0.43	7.46e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.28e-23	Prostate cancer;
BRCA	cis	rs17641971	0.619	rs6983929	chr8:49984896	T/C	cg00325661	chr8:49890786	NA	0.37	10.47	0.38	8.86e-24	Blood metabolite levels;
BRCA	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg14847009	chr1:175162515	KIAA0040	-0.25	-9.47	-0.35	5.44e-20	Alcohol dependence;
BRCA	cis	rs2235642	0.507	rs2235643	chr16:1585115	A/G	cg03034668	chr16:1723424	CRAMP1L	0.44	9.41	0.35	8.48e-20	Coronary artery disease;
BRCA	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg07395648	chr5:131743802	NA	-0.36	-9.09	-0.34	1.25e-18	Blood metabolite levels;
BRCA	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	8.6	0.32	6.04e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs72480748	0.509	rs3865457	chr19:41398969	C/T	cg04176888	chr19:41596066	CYP2A13	0.3	8.13	0.31	2.16e-15	Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
BRCA	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg27398817	chr8:82754497	SNX16	0.35	8.0	0.3	5.8e-15	Diastolic blood pressure;
BRCA	cis	rs7607369	0.536	rs7566656	chr2:219664519	A/G	cg02176678	chr2:219576539	TTLL4	-0.38	-10.22	-0.37	8.27e-23	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg03929089	chr4:120376271	NA	0.5	8.24	0.31	9.49e-16	Axial length;
BRCA	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg06784218	chr1:46089804	CCDC17	-0.52	-12.53	-0.44	2.37e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs701145	0.585	rs1727887	chr3:153839465	G/T	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.22e-14	Coronary artery disease;
BRCA	cis	rs4566357	1.000	rs6436649	chr2:227923952	A/G	cg11843606	chr2:227700838	RHBDD1	-0.37	-7.81	-0.3	2.43e-14	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg08888203	chr3:10149979	C3orf24	0.64	13.7	0.48	1.16e-37	Alzheimer's disease;
BRCA	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11764359	chr7:65958608	NA	0.79	19.31	0.61	8.49e-66	Aortic root size;
BRCA	cis	rs36051895	0.632	rs10974980	chr9:5140671	C/G	cg02405213	chr9:5042618	JAK2	-0.51	-9.28	-0.34	2.51e-19	Pediatric autoimmune diseases;
BRCA	cis	rs10493773	0.502	rs12066742	chr1:86081149	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.41	-8.49	-0.32	1.47e-16	Urate levels in overweight individuals;
BRCA	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27286337	chr10:134555280	INPP5A	0.64	11.36	0.41	2.38e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg26384229	chr12:38710491	ALG10B	0.74	16.32	0.54	2.74e-50	Morning vs. evening chronotype;
BRCA	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	19.65	0.61	1.3e-67	Smoking behavior;
BRCA	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg22705602	chr4:152727874	NA	-0.32	-8.24	-0.31	9.68e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9420	0.961	rs11602109	chr11:57435296	G/A	cg19752551	chr11:57585705	CTNND1	-0.5	-12.3	-0.44	2.36e-31	Schizophrenia;
BRCA	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg22906224	chr7:99728672	NA	0.46	8.66	0.32	3.97e-17	Coronary artery disease;
BRCA	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg05347473	chr6:146136440	FBXO30	0.43	8.74	0.33	1.98e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg20503657	chr10:835505	NA	0.99	15.06	0.51	4.16e-44	Eosinophil percentage of granulocytes;
BRCA	cis	rs593982	0.858	rs537385	chr11:65504900	G/A	cg08755490	chr11:65554678	OVOL1	1.27	29.33	0.76	1.95e-120	Atopic dermatitis;
BRCA	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg24642439	chr20:33292090	TP53INP2	0.61	13.43	0.47	2.19e-36	Coronary artery disease;
BRCA	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg00376283	chr12:123451042	ABCB9	-0.49	-11.35	-0.41	2.63e-27	Neutrophil percentage of white cells;
BRCA	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg01483505	chr11:975446	AP2A2	0.31	8.31	0.31	5.63e-16	Alzheimer's disease (late onset);
BRCA	trans	rs6479891	0.908	rs2616631	chr10:65207914	T/A	cg14819942	chr15:35414228	NA	0.35	8.55	0.32	8.9e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs6878727	0.665	rs698185	chr5:123664565	A/G	cg01806427	chr5:123737813	NA	0.35	7.97	0.3	7.26e-15	Breast cancer;
BRCA	cis	rs17095355	0.818	rs61881639	chr10:111863501	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.43	-9.01	-0.34	2.36e-18	Biliary atresia;
BRCA	cis	rs12367572	0.623	rs10880718	chr12:45362806	G/C	cg04608330	chr12:45269318	NELL2	-0.47	-10.33	-0.38	3.05e-23	Gut microbiome composition (summer);
BRCA	trans	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg18876405	chr7:65276391	NA	0.44	8.49	0.32	1.45e-16	Corneal structure;
BRCA	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.57	-0.47	4.99e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs7246657	0.722	rs10410588	chr19:38042410	C/G	cg23950597	chr19:37808831	NA	-0.5	-8.58	-0.32	7.44e-17	Coronary artery calcification;
BRCA	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg24829409	chr8:58192753	C8orf71	-0.51	-8.32	-0.31	5.35e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.39	-8.14	-0.31	2.04e-15	Ulcerative colitis;
BRCA	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg04586622	chr2:25135609	ADCY3	0.43	10.77	0.39	5.87e-25	Body mass index;
BRCA	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg16482183	chr6:26056742	HIST1H1C	0.54	11.56	0.42	3.44e-28	Height;
BRCA	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg24296786	chr1:45957014	TESK2	0.65	15.98	0.53	1.25e-48	High light scatter reticulocyte count;
BRCA	cis	rs73086581	1.000	rs34640283	chr20:3989576	T/A	cg02187196	chr20:3869020	PANK2	0.53	9.34	0.35	1.6e-19	Response to antidepressants in depression;
BRCA	cis	rs1371614	0.566	rs10203050	chr2:27186561	C/T	cg00617064	chr2:27272375	NA	0.31	8.05	0.3	4.2e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg10845886	chr2:3471009	TTC15	-0.54	-12.17	-0.43	8.44e-31	Neurofibrillary tangles;
BRCA	cis	rs7523273	0.586	rs2724359	chr1:207935706	A/G	cg22525895	chr1:207977042	MIR29B2	0.47	12.07	0.43	2.39e-30	Schizophrenia;
BRCA	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg02951883	chr7:2050386	MAD1L1	-0.37	-8.3	-0.31	6.4e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.09	0.49	1.94e-39	Motion sickness;
BRCA	trans	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.34	-8.05	-0.3	4.09e-15	Corneal astigmatism;
BRCA	cis	rs4363385	0.747	rs3753454	chr1:152973776	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.77	-0.33	1.57e-17	Inflammatory skin disease;
BRCA	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.19	0.4	1.11e-26	Bipolar disorder;
BRCA	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg14784868	chr12:69753453	YEATS4	0.66	17.61	0.57	7.06e-57	Blood protein levels;
BRCA	cis	rs4891159	0.790	rs72975929	chr18:74144630	G/C	cg24786174	chr18:74118243	ZNF516	-0.76	-18.49	-0.59	1.75e-61	Longevity;
BRCA	cis	rs7520050	0.902	rs7514192	chr1:46248977	A/G	cg24296786	chr1:45957014	TESK2	0.44	10.01	0.37	5.02e-22	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4363385	0.747	rs6671524	chr1:152974247	C/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.82	-0.36	2.6e-21	Inflammatory skin disease;
BRCA	cis	rs4363385	0.818	rs57311099	chr1:153005597	A/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.56	-0.32	8.46e-17	Inflammatory skin disease;
BRCA	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg03060546	chr3:49711283	APEH	0.6	10.37	0.38	2.2e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.39	0.57	9.59e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9880211	0.898	rs13434116	chr3:136353074	G/C	cg21827317	chr3:136751795	NA	-0.45	-7.97	-0.3	7.59e-15	Body mass index;Height;
BRCA	cis	rs7607369	0.536	rs6436092	chr2:219669148	T/A	cg02176678	chr2:219576539	TTLL4	-0.38	-10.16	-0.37	1.45e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.56	-0.39	3.75e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg00530320	chr1:46809349	NSUN4	0.49	9.72	0.36	6.42e-21	Menopause (age at onset);
BRCA	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg08470875	chr2:26401718	FAM59B	-0.77	-12.04	-0.43	3.14e-30	Gut microbiome composition (summer);
BRCA	trans	rs2797160	1.000	rs2747723	chr6:126010790	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.35	8.01	0.3	5.47e-15	Endometrial cancer;
BRCA	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg05665937	chr4:1216051	CTBP1	0.38	7.96	0.3	8.15e-15	Obesity-related traits;
BRCA	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg26898376	chr11:64110657	CCDC88B	0.36	7.96	0.3	8.16e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-11.23	-0.41	7.69e-27	Resting heart rate;
BRCA	cis	rs4478858	0.684	rs4949374	chr1:31754511	G/C	cg00250761	chr1:31883323	NA	-0.31	-8.17	-0.31	1.63e-15	Alcohol dependence;
BRCA	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg22455342	chr2:225449267	CUL3	0.34	9.13	0.34	9.24e-19	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs4363385	0.693	rs490553	chr1:153033277	A/G	cg24667326	chr1:152973720	SPRR3	-0.31	-8.2	-0.31	1.28e-15	Inflammatory skin disease;
BRCA	cis	rs9790314	0.779	rs1609688	chr3:160877096	T/G	cg03342759	chr3:160939853	NMD3	-0.54	-10.64	-0.39	1.93e-24	Morning vs. evening chronotype;
BRCA	cis	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.8	-0.42	3.25e-29	Morning vs. evening chronotype;
BRCA	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg19539972	chr4:7069911	GRPEL1	0.35	8.71	0.33	2.54e-17	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
BRCA	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg16414030	chr3:133502952	NA	0.47	11.17	0.4	1.44e-26	Iron status biomarkers;
BRCA	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.69	-0.33	3.04e-17	Breast cancer;
BRCA	cis	rs1971762	0.523	rs7135101	chr12:54080605	G/A	cg23533419	chr12:54090519	NA	-0.34	-8.48	-0.32	1.57e-16	Height;
BRCA	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.34	0.57	1.77e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs220324	0.647	rs9981668	chr21:43559780	G/T	cg09727148	chr21:43560719	UMODL1	0.48	8.1	0.3	2.89e-15	Idiopathic osteonecrosis of the femoral head;
BRCA	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg26597838	chr10:835615	NA	0.57	9.88	0.36	1.57e-21	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs4588572	0.643	rs7701154	chr5:77716621	G/A	cg11547950	chr5:77652471	NA	-0.47	-8.44	-0.32	2.13e-16	Triglycerides;
BRCA	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.01	-0.46	1.72e-34	Migraine;Coronary artery disease;
BRCA	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.43	11.73	0.42	6.3e-29	Response to bleomycin (chromatid breaks);
BRCA	trans	rs66887589	0.934	rs41464847	chr4:120532401	A/G	cg25214090	chr10:38739885	LOC399744	-0.34	-7.93	-0.3	9.68e-15	Diastolic blood pressure;
BRCA	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg18154014	chr19:37997991	ZNF793	0.53	10.29	0.38	4.47e-23	Coronary artery calcification;
BRCA	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg19920283	chr7:105172520	RINT1	0.59	9.54	0.35	2.83e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.38	0.35	1.12e-19	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg04944784	chr2:26401820	FAM59B	0.96	16.64	0.55	6.31e-52	Gut microbiome composition (summer);
BRCA	cis	rs1371614	0.611	rs3845685	chr2:27130332	C/T	cg12368169	chr2:27073192	DPYSL5	-0.29	-8.6	-0.32	6.29e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg15704280	chr7:45808275	SEPT13	0.63	10.97	0.4	9.37e-26	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg21045802	chr8:109455806	TTC35	0.35	8.03	0.3	4.64e-15	Dupuytren's disease;
BRCA	trans	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg08975724	chr8:8085496	FLJ10661	0.43	8.06	0.3	3.68e-15	Retinal vascular caliber;
BRCA	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.8	-0.33	1.23e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-11.23	-0.41	7.66e-27	Morning vs. evening chronotype;
BRCA	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg16606324	chr3:10149918	C3orf24	0.55	10.84	0.39	2.97e-25	Alzheimer's disease;
BRCA	trans	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg06636001	chr8:8085503	FLJ10661	0.53	10.05	0.37	3.77e-22	Neuroticism;
BRCA	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg04944784	chr2:26401820	FAM59B	-0.95	-16.17	-0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.5	-10.07	-0.37	3.07e-22	Tonsillectomy;
BRCA	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg24692254	chr21:30365293	RNF160	0.63	14.49	0.5	2.49e-41	Selective IgA deficiency;
BRCA	cis	rs3741151	1.000	rs3741151	chr11:73020846	G/T	cg17517138	chr11:73019481	ARHGEF17	1.08	15.14	0.51	1.81e-44	GIP levels in response to oral glucose tolerance test (120 minutes);
BRCA	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg11584989	chr19:19387371	SF4	0.63	13.42	0.47	2.3e-36	Bipolar disorder;
BRCA	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg12935359	chr14:103987150	CKB	0.64	15.06	0.51	4.38e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg03161606	chr19:29218774	NA	0.46	8.11	0.31	2.56e-15	Methadone dose in opioid dependence;
BRCA	cis	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg16473166	chr22:50639996	SELO	-0.65	-11.64	-0.42	1.53e-28	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
BRCA	trans	rs11165623	0.765	rs11807955	chr1:96891623	C/T	cg10631902	chr5:14652156	NA	-0.53	-17.12	-0.56	2.2e-54	Hip circumference;Waist circumference;
BRCA	cis	rs6456156	1.000	rs7761159	chr6:167519907	T/A	cg07741184	chr6:167504864	NA	0.27	8.22	0.31	1.18e-15	Primary biliary cholangitis;
BRCA	cis	rs7737355	0.947	rs6883034	chr5:130920415	T/C	cg06307176	chr5:131281290	NA	0.53	10.41	0.38	1.5e-23	Life satisfaction;
BRCA	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg20607798	chr8:58055168	NA	0.48	8.24	0.31	9.65e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg11843238	chr5:131593191	PDLIM4	0.3	7.84	0.3	1.9e-14	Blood metabolite levels;
BRCA	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg13010199	chr12:38710504	ALG10B	0.49	9.42	0.35	7.88e-20	Morning vs. evening chronotype;
BRCA	cis	rs28374715	0.532	rs28584379	chr15:41670408	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.09	-24.87	-0.7	5.23e-96	Ulcerative colitis;
BRCA	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-12.5	-0.44	2.99e-32	Chronic sinus infection;
BRCA	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg07636037	chr3:49044803	WDR6	0.48	8.13	0.31	2.18e-15	Menarche (age at onset);
BRCA	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.14	0.34	7.92e-19	Platelet count;
BRCA	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg24675658	chr1:53192096	ZYG11B	-0.59	-13.53	-0.47	7.15e-37	Monocyte count;
BRCA	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.6	-14.44	-0.5	4e-41	Hemoglobin concentration;
BRCA	cis	rs7301826	0.651	rs1973834	chr12:131280157	C/T	cg11011512	chr12:131303247	STX2	0.5	13.33	0.47	6.31e-36	Plasma plasminogen activator levels;
BRCA	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	18.51	0.59	1.48e-61	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg19622623	chr12:86230825	RASSF9	-0.35	-9.68	-0.36	9.34e-21	Major depressive disorder;
BRCA	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.4	0.32	2.97e-16	Rheumatoid arthritis;
BRCA	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg11843238	chr5:131593191	PDLIM4	0.41	10.35	0.38	2.63e-23	Acylcarnitine levels;
BRCA	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.65	-9.82	-0.36	2.77e-21	Schizophrenia;
BRCA	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg26031613	chr14:104095156	KLC1	0.46	8.27	0.31	7.68e-16	Coronary artery disease;
BRCA	cis	rs7246967	0.673	rs34671960	chr19:22948693	G/A	cg23217946	chr19:22817039	ZNF492	0.5	9.07	0.34	1.46e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg02659138	chr7:134003124	SLC35B4	0.33	10.38	0.38	1.95e-23	Mean platelet volume;
BRCA	trans	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	27.56	0.74	8.71e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs11955398	0.585	rs10063166	chr5:60008844	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.37	-9.04	-0.34	1.91e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs9381107	0.932	rs9349224	chr6:9471146	G/T	cg14735645	chr6:9486422	NA	-0.45	-8.01	-0.3	5.36e-15	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg23029597	chr12:123009494	RSRC2	-0.54	-11.14	-0.4	1.84e-26	Body mass index;
BRCA	cis	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg07460842	chr6:66804631	NA	0.8	12.82	0.45	1.16e-33	Exhaled nitric oxide output;
BRCA	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg25358565	chr5:93447407	FAM172A	1.21	18.7	0.59	1.45e-62	Diabetic retinopathy;
BRCA	trans	rs9944715	1.000	rs9952654	chr18:43849568	T/G	cg01718231	chr17:29326311	RNF135	-0.43	-8.63	-0.32	4.74e-17	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	12.45	0.44	5.35e-32	Calcium levels;
BRCA	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	19.22	0.61	2.53e-65	Alzheimer's disease;
BRCA	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg18230493	chr5:56204884	C5orf35	0.74	14.85	0.51	4.63e-43	Initial pursuit acceleration;
BRCA	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12667521	chr19:29218732	NA	0.47	8.73	0.33	2.28e-17	Methadone dose in opioid dependence;
BRCA	trans	rs12517041	0.935	rs10077662	chr5:23294524	C/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.45	-8.13	-0.31	2.16e-15	Calcium levels;
BRCA	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03264133	chr6:25882463	NA	-1.0	-26.7	-0.73	4.28e-106	Urate levels;
BRCA	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg22139774	chr2:100720529	AFF3	-0.32	-8.83	-0.33	9.86e-18	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg12927641	chr6:109611667	NA	-0.4	-10.43	-0.38	1.3e-23	Reticulocyte fraction of red cells;
BRCA	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg27489772	chr12:121021490	NA	-0.48	-8.09	-0.3	3.04e-15	Type 1 diabetes nephropathy;
BRCA	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg03711944	chr11:47377212	SPI1	0.45	11.97	0.43	6.11e-30	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18876405	chr7:65276391	NA	0.54	12.91	0.45	4.74e-34	Aortic root size;
BRCA	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg17063962	chr7:91808500	NA	0.58	12.16	0.43	9.48e-31	Breast cancer;
BRCA	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg13010199	chr12:38710504	ALG10B	0.44	8.88	0.33	6.92e-18	Bladder cancer;
BRCA	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-10.53	-0.38	5.05e-24	Lymphocyte counts;
BRCA	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02353165	chr6:42928485	GNMT	0.77	19.06	0.6	1.75e-64	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg15704280	chr7:45808275	SEPT13	-0.71	-14.55	-0.5	1.24e-41	Coronary artery disease;
BRCA	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-12.46	-0.44	4.72e-32	Bipolar disorder;
BRCA	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg20203395	chr5:56204925	C5orf35	-0.5	-10.31	-0.38	3.84e-23	Initial pursuit acceleration;
BRCA	cis	rs6893300	0.524	rs62404348	chr5:179146026	G/A	cg14593053	chr5:179126677	CANX	0.48	12.75	0.45	2.51e-33	Resting heart rate;
BRCA	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg05625103	chr10:2543513	NA	0.42	9.06	0.34	1.57e-18	Age-related hearing impairment;
BRCA	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg03609598	chr5:56110824	MAP3K1	-0.46	-7.85	-0.3	1.82e-14	Initial pursuit acceleration;
BRCA	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06108461	chr20:60628389	TAF4	0.93	17.75	0.57	1.29e-57	Body mass index;
BRCA	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.08	-0.43	2.14e-30	Alzheimer's disease;
BRCA	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-12.31	-0.44	2.08e-31	Alzheimer's disease;
BRCA	cis	rs13082711	0.640	rs66941564	chr3:27259702	C/A	cg02860705	chr3:27208620	NA	0.57	11.63	0.42	1.67e-28	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	trans	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg25214090	chr10:38739885	LOC399744	0.48	10.67	0.39	1.41e-24	Corneal astigmatism;
BRCA	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg23283495	chr1:209979779	IRF6	0.37	8.99	0.34	2.68e-18	Cleft lip with or without cleft palate;
BRCA	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg24848339	chr3:12840334	CAND2	0.43	11.42	0.41	1.24e-27	QRS complex (12-leadsum);
BRCA	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.66	-9.66	-0.36	1.02e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	trans	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg13565492	chr6:43139072	SRF	-0.79	-11.17	-0.4	1.32e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	13.13	0.46	5.15e-35	Personality dimensions;
BRCA	cis	rs11874712	0.966	rs8093880	chr18:43666786	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.21	0.31	1.24e-15	Migraine - clinic-based;
BRCA	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.62	11.55	0.42	3.8e-28	Gut microbiome composition (summer);
BRCA	cis	rs757081	0.671	rs214072	chr11:17305270	C/T	cg15432903	chr11:17409602	KCNJ11	-0.49	-8.59	-0.32	6.68e-17	Systolic blood pressure;
BRCA	cis	rs758324	0.947	rs1566427	chr5:131191672	G/A	cg06307176	chr5:131281290	NA	0.54	10.46	0.38	9.95e-24	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs3845702	0.736	rs6433816	chr2:180809317	G/C	cg01881094	chr2:180872142	CWC22	-1.02	-16.85	-0.55	5.38e-53	Schizophrenia;
BRCA	trans	rs9929218	1.000	rs28660361	chr16:68800838	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-13.93	-0.48	1.03e-38	Colorectal cancer;
BRCA	cis	rs6087990	0.669	rs2424929	chr20:31389518	A/G	cg13636640	chr20:31349939	DNMT3B	0.62	17.13	0.56	2.03e-54	Ulcerative colitis;
BRCA	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg18196295	chr10:418757	DIP2C	0.5	11.29	0.41	4.33e-27	Psychosis in Alzheimer's disease;
BRCA	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.86	-0.42	1.83e-29	Alcohol dependence;
BRCA	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	26.73	0.73	3.22e-106	Chronic sinus infection;
BRCA	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.86e-24	Motion sickness;
BRCA	cis	rs7560272	0.538	rs11126414	chr2:73932044	G/A	cg20560298	chr2:73613845	ALMS1	0.34	8.72	0.33	2.45e-17	Schizophrenia;
BRCA	cis	rs7246657	0.722	rs8110865	chr19:38047387	G/A	cg18154014	chr19:37997991	ZNF793	0.48	9.13	0.34	8.69e-19	Coronary artery calcification;
BRCA	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg12927641	chr6:109611667	NA	-0.42	-10.89	-0.4	1.94e-25	Reticulocyte fraction of red cells;
BRCA	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg08601574	chr20:25228251	PYGB	0.36	8.58	0.32	7.39e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.48	8.71	0.33	2.58e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.16	0.34	7.24e-19	Tonsillectomy;
BRCA	cis	rs17209837	0.607	rs4148811	chr7:87101486	T/G	cg00919237	chr7:87102261	ABCB4	-0.53	-10.19	-0.37	1.04e-22	Gallbladder cancer;
BRCA	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg10862848	chr6:42927986	GNMT	-0.36	-15.05	-0.51	5.11e-44	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.65	-0.36	1.18e-20	Bladder cancer;
BRCA	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg22349387	chr12:9600060	DDX12	-0.39	-8.92	-0.33	5.02e-18	Breast size;
BRCA	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15501526	chr10:2543763	NA	0.57	13.99	0.48	5.32e-39	Age-related hearing impairment;
BRCA	cis	rs250677	1.000	rs190378	chr5:148434275	G/T	cg18129178	chr5:148520854	ABLIM3	-0.57	-11.72	-0.42	7.24e-29	Breast cancer;
BRCA	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg15395560	chr15:45543142	SLC28A2	0.29	8.12	0.31	2.49e-15	Uric acid levels;
BRCA	cis	rs72781680	0.583	rs6731333	chr2:24113354	C/T	cg08917208	chr2:24149416	ATAD2B	0.54	9.23	0.34	3.85e-19	Lymphocyte counts;
BRCA	cis	rs870825	0.616	rs6552806	chr4:185638231	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	17.32	0.57	2.07e-55	Blood protein levels;
BRCA	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02187348	chr16:89574699	SPG7	0.52	12.34	0.44	1.54e-31	Multiple myeloma (IgH translocation);
BRCA	cis	rs11030122	0.702	rs1349583	chr11:3972236	G/A	cg18678763	chr11:4115507	RRM1	-0.36	-8.43	-0.32	2.28e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg25019033	chr10:957182	NA	-0.43	-8.89	-0.33	6.11e-18	Eosinophil percentage of granulocytes;
BRCA	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00934597	chr7:893267	UNC84A	-0.53	-11.87	-0.42	1.69e-29	Perceived unattractiveness to mosquitoes;
BRCA	trans	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg06521331	chr12:34319734	NA	0.45	9.01	0.34	2.42e-18	Bladder cancer;
BRCA	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11764359	chr7:65958608	NA	0.61	13.25	0.46	1.43e-35	Aortic root size;
BRCA	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg24675658	chr1:53192096	ZYG11B	0.56	12.72	0.45	3.21e-33	Monocyte count;
BRCA	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg08601574	chr20:25228251	PYGB	0.36	8.58	0.32	7.39e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.24	-20.53	-0.63	2.46e-72	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.78	11.9	0.43	1.24e-29	Platelet count;
BRCA	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg09307838	chr4:120376055	NA	0.59	12.89	0.45	5.65e-34	Corneal astigmatism;
BRCA	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg10932868	chr11:921992	NA	0.5	12.76	0.45	2.15e-33	Alzheimer's disease (late onset);
BRCA	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg05084668	chr3:125655381	ALG1L	-0.47	-8.16	-0.31	1.79e-15	Blood pressure (smoking interaction);
BRCA	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11764359	chr7:65958608	NA	0.62	13.48	0.47	1.26e-36	Calcium levels;
BRCA	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg14789911	chr21:47582049	C21orf56	0.38	7.94	0.3	9.42e-15	Testicular germ cell tumor;
BRCA	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg21545522	chr1:205238299	TMCC2	0.39	8.22	0.31	1.13e-15	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg06108461	chr20:60628389	TAF4	-0.79	-16.99	-0.56	1.11e-53	Body mass index;
BRCA	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg05729581	chr11:3078854	CARS	-0.34	-8.45	-0.32	1.98e-16	Longevity;
BRCA	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg17366294	chr4:99064904	C4orf37	0.42	8.29	0.31	6.76e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg03213289	chr20:61660250	NA	0.63	16.54	0.55	2.05e-51	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs12517041	1.000	rs2081952	chr5:23295605	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg10523679	chr1:76189770	ACADM	-0.45	-8.18	-0.31	1.49e-15	Daytime sleep phenotypes;
BRCA	cis	rs7395581	0.877	rs7127907	chr11:47324472	A/C	cg25783544	chr11:47291846	MADD	0.43	9.61	0.36	1.57e-20	HDL cholesterol;
BRCA	cis	rs10193935	0.892	rs12622152	chr2:42482929	C/A	cg27598129	chr2:42591480	NA	-0.94	-14.7	-0.5	2.32e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg17366294	chr4:99064904	C4orf37	0.52	11.13	0.4	1.97e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.81	0.55	8.35e-53	Axial length;
BRCA	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg10057126	chr4:77819792	ANKRD56	-0.64	-14.99	-0.51	9.31e-44	Emphysema distribution in smoking;
BRCA	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg18225595	chr11:63971243	STIP1	-0.41	-10.17	-0.37	1.23e-22	Platelet count;
BRCA	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	18.02	0.58	4.98e-59	Fuchs's corneal dystrophy;
BRCA	cis	rs9811920	0.535	rs792833	chr3:99475268	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.42	10.07	0.37	3.15e-22	Axial length;
BRCA	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg16586182	chr3:47516702	SCAP	0.51	11.42	0.41	1.25e-27	Colorectal cancer;
BRCA	cis	rs919433	0.726	rs11904247	chr2:198238424	T/G	cg00792783	chr2:198669748	PLCL1	0.39	8.57	0.32	7.81e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg16576597	chr16:28551801	NUPR1	0.35	9.68	0.36	9.01e-21	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12016809	chr21:47604291	C21orf56	0.39	7.83	0.3	2.04e-14	Testicular germ cell tumor;
BRCA	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg14004847	chr7:1930337	MAD1L1	-0.4	-7.98	-0.3	7.04e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14442939	chr10:27389572	ANKRD26	0.66	10.92	0.4	1.5e-25	Breast cancer;
BRCA	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.52	-10.21	-0.37	8.95e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-9.76	-0.36	4.55e-21	Resting heart rate;
BRCA	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12667521	chr19:29218732	NA	0.48	9.43	0.35	7.38e-20	Methadone dose in opioid dependence;
BRCA	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.55	13.07	0.46	9.18e-35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs3772130	0.962	rs11707504	chr3:121496734	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.67	0.39	1.38e-24	Cognitive performance;
BRCA	cis	rs2625529	0.652	rs2957745	chr15:72288077	T/C	cg16672083	chr15:72433130	SENP8	0.66	15.69	0.53	3.43e-47	Red blood cell count;
BRCA	cis	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg07460842	chr6:66804631	NA	0.8	12.82	0.45	1.16e-33	Exhaled nitric oxide output;
BRCA	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg26384229	chr12:38710491	ALG10B	-0.44	-10.14	-0.37	1.63e-22	Heart rate;
BRCA	cis	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg06521331	chr12:34319734	NA	-0.63	-12.21	-0.43	5.64e-31	Morning vs. evening chronotype;
BRCA	cis	rs858239	0.539	rs6461695	chr7:23197784	C/A	cg23682824	chr7:23144976	KLHL7	0.36	9.44	0.35	6.71e-20	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs870825	0.860	rs72689297	chr4:185600957	A/T	cg04058563	chr4:185651563	MLF1IP	0.82	13.82	0.48	3.56e-38	Blood protein levels;
BRCA	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg17063962	chr7:91808500	NA	0.55	13.11	0.46	6.08e-35	Breast cancer;
BRCA	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg00666640	chr1:248458726	OR2T12	0.32	8.77	0.33	1.63e-17	Common traits (Other);
BRCA	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11644478	chr21:40555479	PSMG1	-0.52	-10.88	-0.4	1.99e-25	Menarche (age at onset);
BRCA	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg26248373	chr2:1572462	NA	-0.63	-14.96	-0.51	1.4e-43	IgG glycosylation;
BRCA	cis	rs7149337	0.752	rs8021773	chr14:51691528	C/T	cg23942311	chr14:51606299	NA	0.5	13.83	0.48	3.19e-38	Cancer;
BRCA	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.56	-0.32	8.26e-17	Total body bone mineral density;
BRCA	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg27129171	chr3:47204927	SETD2	-0.72	-17.49	-0.57	2.94e-56	Colorectal cancer;
BRCA	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg21535247	chr6:8435926	SLC35B3	0.4	9.0	0.34	2.56e-18	Motion sickness;
BRCA	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg05347473	chr6:146136440	FBXO30	-0.61	-12.08	-0.43	2.04e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4478858	0.735	rs12129941	chr1:31871958	C/G	cg00250761	chr1:31883323	NA	-0.34	-8.66	-0.32	3.91e-17	Alcohol dependence;
BRCA	cis	rs9649465	0.967	rs11769381	chr7:123264804	C/T	cg04330084	chr7:123175371	IQUB	-0.33	-9.04	-0.34	1.85e-18	Migraine;
BRCA	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg18252515	chr7:66147081	NA	1.06	15.97	0.53	1.49e-48	Diabetic kidney disease;
BRCA	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg02574844	chr11:5959923	NA	0.37	7.98	0.3	6.71e-15	DNA methylation (variation);
BRCA	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg00599163	chr2:162100495	NA	0.27	8.9	0.33	5.59e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs16866061	1.000	rs7588380	chr2:225341304	A/T	cg12698349	chr2:225449008	CUL3	-0.76	-20.79	-0.64	9.58e-74	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs17095355	1.000	rs11194922	chr10:111695656	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.39	-10.05	-0.37	3.83e-22	Biliary atresia;
BRCA	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg20607798	chr8:58055168	NA	0.58	9.32	0.35	1.88e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg20848291	chr7:100343083	ZAN	0.37	8.27	0.31	7.6e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	16.07	0.54	4.49e-49	Coronary artery disease;
BRCA	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg19622623	chr12:86230825	RASSF9	-0.33	-9.31	-0.35	2.09e-19	Major depressive disorder;
BRCA	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg04362960	chr10:104952993	NT5C2	0.94	14.51	0.5	1.96e-41	Arsenic metabolism;
BRCA	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-14.94	-0.51	1.73e-43	Coronary artery disease;
BRCA	cis	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg07460842	chr6:66804631	NA	0.99	19.93	0.62	4.01e-69	Exhaled nitric oxide output;
BRCA	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg13047869	chr3:10149882	C3orf24	0.58	10.55	0.39	4.35e-24	Alzheimer's disease;
BRCA	cis	rs9467773	0.529	rs7356988	chr6:26396727	G/T	cg09904177	chr6:26538194	HMGN4	-0.36	-9.39	-0.35	1.01e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg07080220	chr10:102295463	HIF1AN	0.44	9.8	0.36	3.18e-21	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.96	22.06	0.66	1.26e-80	Smoking behavior;
BRCA	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg23711669	chr6:146136114	FBXO30	0.71	16.78	0.55	1.24e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs835154	0.900	rs835153	chr5:14877474	A/G	cg18064842	chr5:14874549	NA	-0.4	-10.39	-0.38	1.8e-23	Blood metabolite levels;
BRCA	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-7.89	-0.3	1.36e-14	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.58	0.35	2.03e-20	Morning vs. evening chronotype;
BRCA	cis	rs2463822	1.000	rs72921501	chr11:62115622	A/T	cg06239285	chr11:62104954	ASRGL1	-0.68	-9.75	-0.36	5.02e-21	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.62	-0.32	5.3e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg01884057	chr2:25150051	NA	0.33	8.67	0.32	3.47e-17	Body mass index;
BRCA	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg18964960	chr10:1102726	WDR37	0.59	8.0	0.3	5.81e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs9287719	0.649	rs10186984	chr2:10734192	C/G	cg00105475	chr2:10696890	NA	-0.4	-8.92	-0.33	4.99e-18	Prostate cancer;
BRCA	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg03929089	chr4:120376271	NA	-0.74	-15.93	-0.53	2.31e-48	Coronary artery disease;
BRCA	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg24069376	chr3:38537580	EXOG	-0.4	-12.03	-0.43	3.48e-30	Electrocardiographic conduction measures;
BRCA	cis	rs1691799	0.899	rs1168321	chr12:66744517	C/G	cg16791601	chr12:66731901	HELB	0.69	19.56	0.61	4.03e-67	White blood cell count (basophil);
BRCA	trans	rs10242455	0.702	rs6974831	chr7:99131605	A/G	cg09045935	chr12:6379348	NA	0.85	8.24	0.31	9.68e-16	Blood metabolite levels;
BRCA	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg08477640	chr19:41863820	B9D2	0.52	9.97	0.37	7.58e-22	Colorectal cancer;
BRCA	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg14266287	chr2:239334506	ASB1	-0.35	-8.63	-0.32	4.86e-17	Multiple system atrophy;
BRCA	cis	rs72627123	0.867	rs74395411	chr14:74478584	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.66	7.93	0.3	9.93e-15	Morning vs. evening chronotype;
BRCA	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg22376730	chr1:1715039	NA	-0.36	-9.43	-0.35	7.59e-20	Body mass index;
BRCA	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg08000102	chr2:233561755	GIGYF2	-0.43	-9.31	-0.35	1.98e-19	Coronary artery disease;
BRCA	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg01689657	chr7:91764605	CYP51A1	-0.22	-8.02	-0.3	5.04e-15	Breast cancer;
BRCA	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-17.97	-0.58	9.17e-59	Morning vs. evening chronotype;
BRCA	cis	rs3761847	0.622	rs4837807	chr9:123792005	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	7.9	0.3	1.21e-14	Rheumatoid arthritis;
BRCA	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.83	-19.57	-0.61	3.66e-67	Ulcerative colitis;
BRCA	trans	rs5756813	0.661	rs5995500	chr22:38204640	A/G	cg19894588	chr14:64061835	NA	-0.55	-11.58	-0.42	2.82e-28	Optic cup area;Vertical cup-disc ratio;
BRCA	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.96	0.37	8.29e-22	Bipolar disorder;
BRCA	trans	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-7.93	-0.3	9.63e-15	Menarche (age at onset);
BRCA	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg24006582	chr15:45444508	DUOX1	-0.56	-11.57	-0.42	2.96e-28	Uric acid levels;
BRCA	cis	rs2354432	0.607	rs4314933	chr1:146821386	T/C	cg25205988	chr1:146714368	CHD1L	0.88	12.64	0.45	7.25e-33	Mitochondrial DNA levels;
BRCA	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg12011299	chr4:100065546	ADH4	0.48	10.8	0.39	4.48e-25	Smoking initiation;
BRCA	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg08477640	chr19:41863820	B9D2	-0.54	-10.49	-0.38	7.56e-24	Colorectal cancer;
BRCA	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs953387	1.000	rs4954566	chr2:136901513	A/G	cg05194412	chr2:137003533	NA	0.37	8.56	0.32	8.65e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg23719950	chr11:63933701	MACROD1	-0.56	-8.93	-0.33	4.54e-18	Mean platelet volume;
BRCA	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg20607798	chr8:58055168	NA	0.48	8.43	0.32	2.29e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4845875	0.626	rs7538516	chr1:11836682	C/T	cg24844545	chr1:11908347	NPPA	0.32	8.09	0.3	2.93e-15	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	11.44	0.41	1.11e-27	Height;
BRCA	cis	rs999943	0.774	rs10947421	chr6:33611278	G/T	cg14003231	chr6:33640908	ITPR3	0.62	14.08	0.49	2.06e-39	Obesity (extreme);
BRCA	cis	rs12541635	0.966	rs7839195	chr8:107020193	G/A	cg10147462	chr8:107024639	NA	0.35	9.54	0.35	3.04e-20	Age of smoking initiation;
BRCA	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg24642439	chr20:33292090	TP53INP2	0.71	15.86	0.53	5.49e-48	Coronary artery disease;
BRCA	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg23533926	chr12:111358616	MYL2	-0.41	-8.49	-0.32	1.4e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg24531977	chr5:56204891	C5orf35	0.4	7.99	0.3	6.16e-15	Breast cancer;Breast cancer (early onset);
BRCA	cis	rs2425143	1.000	rs8124505	chr20:34307247	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.88	-0.33	6.53e-18	Blood protein levels;
BRCA	cis	rs7945718	0.967	rs12291695	chr11:12795662	A/G	cg25843174	chr11:12811716	TEAD1	-0.24	-8.98	-0.33	2.94e-18	Educational attainment (years of education);
BRCA	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg19077165	chr18:44547161	KATNAL2	0.64	14.8	0.51	7.87e-43	Personality dimensions;
BRCA	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.7	-14.84	-0.51	5.18e-43	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2479724	0.875	rs2253961	chr6:41827011	A/G	cg17623882	chr6:41773611	USP49	-0.34	-9.07	-0.34	1.43e-18	Menarche (age at onset);
BRCA	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	trans	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-9.79	-0.36	3.58e-21	Retinal vascular caliber;
BRCA	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-12.08	-0.43	2.14e-30	Alzheimer's disease;
BRCA	trans	rs9944715	0.911	rs7230154	chr18:43835793	C/T	cg01718231	chr17:29326311	RNF135	-0.47	-9.34	-0.35	1.61e-19	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg11530693	chr1:120165357	ZNF697	0.62	14.94	0.51	1.68e-43	Systemic lupus erythematosus;
BRCA	cis	rs3771570	0.901	rs56129392	chr2:242242439	C/T	cg21155796	chr2:242212141	HDLBP	0.61	9.63	0.36	1.43e-20	Prostate cancer;
BRCA	trans	rs6076960	0.652	rs3843045	chr20:6264593	C/T	cg21095983	chr6:86352623	SYNCRIP	-0.35	-8.1	-0.31	2.82e-15	Smooth-surface caries;
BRCA	cis	rs483180	0.531	rs541503	chr1:120208297	A/G	cg19096424	chr1:120255104	PHGDH	-0.43	-9.56	-0.35	2.56e-20	Macular telangiectasia type 2;
BRCA	trans	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg06636001	chr8:8085503	FLJ10661	0.43	8.55	0.32	8.86e-17	Retinal vascular caliber;
BRCA	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg21775007	chr8:11205619	TDH	-0.44	-8.67	-0.32	3.47e-17	Triglycerides;
BRCA	cis	rs6882046	0.513	rs34316	chr5:88015545	A/C	cg22951263	chr5:87985283	NA	-0.39	-10.61	-0.39	2.47e-24	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg22875332	chr1:76189707	ACADM	-0.65	-12.34	-0.44	1.59e-31	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg20469991	chr17:27169893	C17orf63	-0.45	-8.81	-0.33	1.13e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg14844989	chr11:31128820	NA	-0.44	-9.54	-0.35	3.05e-20	Red blood cell count;
BRCA	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg08213375	chr14:104286397	PPP1R13B	0.41	8.81	0.33	1.16e-17	Reticulocyte count;
BRCA	cis	rs7520050	0.872	rs2486445	chr1:46605369	C/T	cg24296786	chr1:45957014	TESK2	0.4	8.91	0.33	5.39e-18	Red blood cell count;Reticulocyte count;
BRCA	cis	rs68170813	0.523	rs12154285	chr7:106993573	G/A	cg02696742	chr7:106810147	HBP1	-0.54	-8.76	-0.33	1.82e-17	Coronary artery disease;
BRCA	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg12311346	chr5:56204834	C5orf35	-0.79	-14.91	-0.51	2.27e-43	Initial pursuit acceleration;
BRCA	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg11946769	chr3:48343235	NME6	0.68	13.65	0.48	2.13e-37	Coronary artery disease;
BRCA	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg17691542	chr6:26056736	HIST1H1C	0.55	11.83	0.42	2.54e-29	Height;
BRCA	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg13010199	chr12:38710504	ALG10B	0.44	9.22	0.34	4.31e-19	Morning vs. evening chronotype;
BRCA	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg12826209	chr6:26865740	GUSBL1	0.56	9.23	0.34	3.92e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs208520	0.690	rs207112	chr6:66792092	C/T	cg07460842	chr6:66804631	NA	-1.02	-20.41	-0.63	1.11e-71	Exhaled nitric oxide output;
BRCA	trans	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.85	0.3	1.7e-14	Corneal astigmatism;
BRCA	cis	rs7766436	0.767	rs6456498	chr6:22603610	A/G	cg13666174	chr6:22585274	NA	0.36	9.2	0.34	5.08e-19	Coronary artery disease;
BRCA	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.36	-7.97	-0.3	7.08e-15	Longevity;Endometriosis;
BRCA	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg06623918	chr6:96969491	KIAA0776	-0.85	-22.22	-0.66	1.65e-81	Headache;
BRCA	cis	rs3743102	0.591	rs17841171	chr15:83358388	C/T	cg00614314	chr15:82944287	LOC80154	0.58	8.31	0.31	5.66e-16	Colorectal adenoma (advanced);
BRCA	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg24920358	chr1:40204285	PPIE	0.33	7.81	0.3	2.3e-14	Blood protein levels;
BRCA	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27286337	chr10:134555280	INPP5A	0.63	11.25	0.41	6.61e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg19862616	chr7:65841803	NCRNA00174	0.83	26.67	0.73	6.33e-106	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg09307838	chr4:120376055	NA	0.59	12.83	0.45	1.12e-33	Corneal astigmatism;
BRCA	cis	rs3862030	0.720	rs7342070	chr10:104223628	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-12.52	-0.44	2.68e-32	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg01528321	chr10:82214614	TSPAN14	0.82	18.35	0.59	1.05e-60	Post bronchodilator FEV1;
BRCA	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg04455712	chr21:45112962	RRP1B	0.39	9.99	0.37	6.34e-22	Mean corpuscular volume;
BRCA	cis	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg27411982	chr8:10470053	RP1L1	-0.32	-8.02	-0.3	5.16e-15	Neuroticism;
BRCA	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.66	10.48	0.38	8.08e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.29	0.31	6.45e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.26	0.31	8.38e-16	Corneal astigmatism;
BRCA	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg06784218	chr1:46089804	CCDC17	0.46	10.93	0.4	1.34e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-11.16	-0.4	1.55e-26	Retinal vascular caliber;
BRCA	cis	rs4891159	0.660	rs4891160	chr18:74102135	C/T	cg24786174	chr18:74118243	ZNF516	0.65	17.04	0.56	5.63e-54	Longevity;
BRCA	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg06060754	chr5:176797920	RGS14	0.57	10.96	0.4	9.78e-26	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08564027	chr20:61660810	NA	0.84	22.45	0.66	9.41e-83	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs28830936	1.000	rs2412622	chr15:41960311	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.32	-9.21	-0.34	4.55e-19	Diastolic blood pressure;
BRCA	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg06238570	chr21:40685208	BRWD1	-0.4	-8.19	-0.31	1.41e-15	Menarche (age at onset);
BRCA	cis	rs11608355	0.515	rs4766609	chr12:109973297	A/G	cg05360138	chr12:110035743	NA	0.73	13.34	0.47	5.74e-36	Neuroticism;
BRCA	cis	rs738322	0.805	rs2016755	chr22:38539604	A/G	cg25457927	chr22:38595422	NA	-0.33	-12.16	-0.43	9.55e-31	Cutaneous nevi;
BRCA	cis	rs4423214	0.840	rs1123007	chr11:71185357	G/A	cg05163923	chr11:71159392	DHCR7	-0.57	-11.36	-0.41	2.3e-27	Vitamin D levels;
BRCA	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg11941060	chr3:133502564	NA	-0.52	-12.3	-0.44	2.34e-31	Iron status biomarkers;
BRCA	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.3	-7.99	-0.3	6.09e-15	Total body bone mineral density;
BRCA	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg05340658	chr4:99064831	C4orf37	0.7	17.71	0.57	2.09e-57	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-12.74	-0.45	2.85e-33	Platelet count;
BRCA	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg24101359	chr6:42928495	GNMT	0.62	14.93	0.51	1.93e-43	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs8073060	0.586	rs2523114	chr17:34023762	G/A	cg19694781	chr19:47549865	TMEM160	-1.07	-21.74	-0.65	6.98e-79	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg26384229	chr12:38710491	ALG10B	0.58	13.14	0.46	4.59e-35	Morning vs. evening chronotype;
BRCA	cis	rs1371614	0.566	rs10184824	chr2:27177952	C/A	cg00617064	chr2:27272375	NA	0.3	7.83	0.3	2.09e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg24450063	chr1:156163899	SLC25A44	1.08	34.46	0.81	7.64e-148	Testicular germ cell tumor;
BRCA	cis	rs3125734	0.633	rs4979773	chr10:63967731	G/C	cg19640130	chr10:64028056	RTKN2	-0.31	-8.86	-0.33	8.19e-18	Rheumatoid arthritis;
BRCA	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg24531977	chr5:56204891	C5orf35	-0.41	-8.31	-0.31	5.65e-16	Coronary artery disease;
BRCA	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.57	-9.97	-0.37	7.31e-22	Gut microbiome composition (summer);
BRCA	trans	rs1493916	0.777	rs1941685	chr18:31304318	G/T	cg15819921	chr19:927150	ARID3A	-0.43	-8.39	-0.32	3.06e-16	Life satisfaction;
BRCA	cis	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg06521331	chr12:34319734	NA	-0.65	-11.92	-0.43	1.01e-29	Morning vs. evening chronotype;
BRCA	cis	rs6684514	1.000	rs12027741	chr1:156248148	T/G	cg16558208	chr1:156270281	VHLL	0.35	7.95	0.3	8.56e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.72	-0.62	5.65e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg01689657	chr7:91764605	CYP51A1	0.22	8.05	0.3	3.98e-15	Breast cancer;
BRCA	cis	rs10276381	1.000	rs10276381	chr7:28190121	A/G	cg23620719	chr7:28220237	JAZF1	-0.56	-9.63	-0.36	1.42e-20	Crohn's disease;
BRCA	cis	rs7631605	0.905	rs11714667	chr3:37222360	G/A	cg15934958	chr3:37212084	LRRFIP2	0.4	9.28	0.34	2.58e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.52	13.29	0.47	9.34e-36	Response to bleomycin (chromatid breaks);
BRCA	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg19773385	chr1:10388646	KIF1B	-0.38	-8.18	-0.31	1.5e-15	Hepatocellular carcinoma;
BRCA	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg21770322	chr7:97807741	LMTK2	0.44	11.54	0.42	3.92e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs600806	0.815	rs4970754	chr1:109969721	A/G	cg20591472	chr1:110008990	SYPL2	0.33	8.34	0.31	4.7e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg00857998	chr1:205179979	DSTYK	0.44	8.4	0.32	2.98e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg05863683	chr7:1912471	MAD1L1	0.39	8.48	0.32	1.62e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05901451	chr6:126070800	HEY2	-0.55	-13.48	-0.47	1.3e-36	Brugada syndrome;
BRCA	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.8	-0.62	2.12e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs3772130	1.000	rs3732408	chr3:121421179	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	9.61	0.36	1.57e-20	Cognitive performance;
BRCA	cis	rs7177699	0.557	rs9806363	chr15:79110302	A/G	cg00540400	chr15:79124168	NA	-0.28	-7.84	-0.3	1.95e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg11266682	chr4:10021025	SLC2A9	-0.44	-11.39	-0.41	1.75e-27	Bone mineral density;
BRCA	cis	rs7246657	0.653	rs28701616	chr19:37681098	G/A	cg18154014	chr19:37997991	ZNF793	0.53	8.73	0.33	2.18e-17	Coronary artery calcification;
BRCA	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg00677455	chr12:58241039	CTDSP2	-0.35	-7.92	-0.3	1.07e-14	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg14664628	chr15:75095509	CSK	0.92	29.06	0.75	5.33e-119	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg26528668	chr16:1614120	IFT140	0.36	7.88	0.3	1.39e-14	Coronary artery disease;
BRCA	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.89	-0.33	6.26e-18	Total body bone mineral density;
BRCA	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00149659	chr3:10157352	C3orf10	1.07	18.1	0.58	2.08e-59	Alzheimer's disease;
BRCA	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-16.03	-0.54	7.53e-49	Total cholesterol levels;
BRCA	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg25358565	chr5:93447407	FAM172A	-0.67	-11.57	-0.42	2.94e-28	Diabetic retinopathy;
BRCA	cis	rs654351	0.572	rs813274	chr6:10387731	C/T	cg17959970	chr6:10383164	NA	-0.41	-8.71	-0.33	2.61e-17	Squamous cell lung carcinoma;
BRCA	cis	rs7178424	0.743	rs8032681	chr15:62162243	T/C	cg00456672	chr15:62358751	C2CD4A	-0.37	-8.9	-0.33	5.79e-18	Height;
BRCA	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg06238570	chr21:40685208	BRWD1	-0.4	-8.18	-0.31	1.55e-15	Menarche (age at onset);
BRCA	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg21479132	chr6:26055353	NA	0.57	7.97	0.3	7.48e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg16339924	chr4:17578868	LAP3	0.64	16.11	0.54	2.94e-49	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg05340658	chr4:99064831	C4orf37	0.68	17.05	0.56	5.48e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg14789911	chr21:47582049	C21orf56	-0.38	-7.96	-0.3	7.68e-15	Testicular germ cell tumor;
BRCA	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg04756594	chr16:24857601	SLC5A11	0.34	8.31	0.31	5.53e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg03213289	chr20:61660250	NA	0.62	15.65	0.53	5.63e-47	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26314531	chr2:26401878	FAM59B	0.96	16.47	0.55	4.54e-51	Gut microbiome composition (summer);
BRCA	trans	rs61931739	0.513	rs10743833	chr12:33897481	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.47e-20	Morning vs. evening chronotype;
BRCA	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg10495392	chr1:46806563	NSUN4	0.45	8.22	0.31	1.12e-15	Menopause (age at onset);
BRCA	cis	rs30380	0.632	rs30186	chr5:96124447	G/C	cg16492584	chr5:96139282	ERAP1	-0.45	-10.81	-0.39	4.13e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg01420254	chr6:26195488	NA	0.57	8.81	0.33	1.15e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-11.99	-0.43	5.2e-30	Bipolar disorder;
BRCA	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.05	0.34	1.7e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg19622623	chr12:86230825	RASSF9	-0.28	-8.0	-0.3	5.93e-15	Major depressive disorder;
BRCA	trans	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg25214090	chr10:38739885	LOC399744	0.52	11.42	0.41	1.26e-27	Corneal astigmatism;
BRCA	cis	rs11051970	0.636	rs325421	chr12:32571595	C/T	cg24626660	chr12:32551988	NA	0.32	9.14	0.34	8.08e-19	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs9462027	0.628	rs9469859	chr6:34722902	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.27	-8.25	-0.31	9.32e-16	Systemic lupus erythematosus;
BRCA	cis	rs2882667	0.964	rs12055237	chr5:138307306	A/G	cg04439458	chr5:138467593	SIL1	-0.34	-9.19	-0.34	5.57e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07636037	chr3:49044803	WDR6	-0.75	-15.35	-0.52	1.62e-45	Menarche (age at onset);
BRCA	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg17366294	chr4:99064904	C4orf37	0.42	9.7	0.36	7.56e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs757081	0.667	rs615424	chr11:17210481	G/A	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.68	-0.32	3.16e-17	Systolic blood pressure;
BRCA	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg24060327	chr5:131705240	SLC22A5	0.6	11.01	0.4	6.21e-26	Breast cancer;
BRCA	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg13010199	chr12:38710504	ALG10B	0.5	10.45	0.38	1.07e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02475777	chr4:1388615	CRIPAK	0.56	11.2	0.41	1.01e-26	Longevity;
BRCA	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24549020	chr5:56110836	MAP3K1	-0.47	-8.21	-0.31	1.25e-15	Initial pursuit acceleration;
BRCA	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.8	0.36	3.22e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs28595532	0.623	rs34082100	chr4:119220563	C/T	cg21605333	chr4:119757512	SEC24D	0.81	8.49	0.32	1.49e-16	Cannabis dependence symptom count;
BRCA	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg02880119	chr16:3481970	NA	0.42	7.92	0.3	1.06e-14	Body mass index (adult);
BRCA	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg08917208	chr2:24149416	ATAD2B	0.51	8.12	0.31	2.38e-15	Asthma;
BRCA	cis	rs2289583	0.573	rs8025880	chr15:75394881	G/C	cg14664628	chr15:75095509	CSK	0.39	9.11	0.34	1.08e-18	Systemic lupus erythematosus;
BRCA	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.8	0.33	1.28e-17	Platelet count;
BRCA	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.54	-0.52	1.93e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27286337	chr10:134555280	INPP5A	0.78	12.77	0.45	2.09e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-9.87	-0.36	1.71e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg05552183	chr6:42928497	GNMT	0.7	15.79	0.53	1.2e-47	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg23978390	chr7:1156363	C7orf50	0.41	9.25	0.34	3.22e-19	Longevity;Endometriosis;
BRCA	cis	rs11585357	0.895	rs2977305	chr1:17613737	A/T	cg08277548	chr1:17600880	PADI3	0.62	11.01	0.4	6e-26	Hair shape;
BRCA	cis	rs11874712	0.899	rs11664764	chr18:43675364	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.05	0.3	4.16e-15	Migraine - clinic-based;
BRCA	cis	rs28735056	1.000	rs28865701	chr18:77620911	A/G	cg20368463	chr18:77673604	PQLC1	-0.33	-7.98	-0.3	6.68e-15	Schizophrenia;
BRCA	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg01114163	chr5:1856713	NA	-0.36	-8.01	-0.3	5.27e-15	Cardiovascular disease risk factors;
BRCA	cis	rs6815814	0.950	rs73236632	chr4:38836071	G/A	cg02016764	chr4:38805732	TLR1	-0.52	-8.1	-0.31	2.7e-15	Breast cancer;
BRCA	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.02	0.48	4.03e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg16576597	chr16:28551801	NUPR1	0.3	8.52	0.32	1.14e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7617773	0.784	rs9850672	chr3:48301172	C/A	cg11946769	chr3:48343235	NME6	0.62	13.61	0.47	3.25e-37	Coronary artery disease;
BRCA	trans	rs4714291	0.928	rs1923461	chr6:39984670	A/T	cg02267698	chr19:7991119	CTXN1	0.4	7.9	0.3	1.18e-14	Strep throat;
BRCA	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg10223061	chr2:219282414	VIL1	-0.27	-8.03	-0.3	4.76e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs72928364	1.000	rs34272575	chr3:100615407	C/G	cg10123952	chr3:100791384	NA	0.53	7.89	0.3	1.33e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg22920501	chr2:26401640	FAM59B	-0.96	-16.92	-0.56	2.42e-53	Gut microbiome composition (summer);
BRCA	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.04	0.37	3.97e-22	Morning vs. evening chronotype;
BRCA	cis	rs7640424	0.754	rs182736	chr3:107838891	C/A	cg09227934	chr3:107805635	CD47	0.4	8.45	0.32	1.92e-16	Body mass index;
BRCA	cis	rs7178424	0.811	rs12593844	chr15:62247067	T/C	cg00456672	chr15:62358751	C2CD4A	0.34	8.32	0.31	5.46e-16	Height;
BRCA	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg20387954	chr3:183756860	HTR3D	0.37	8.61	0.32	5.73e-17	Anterior chamber depth;
BRCA	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00908189	chr16:619842	PIGQ	0.71	17.86	0.58	3.47e-58	Height;
BRCA	cis	rs4409675	0.576	rs7533918	chr1:28230667	G/A	cg23691781	chr1:28212827	C1orf38	0.32	10.85	0.39	2.62e-25	Corneal astigmatism;
BRCA	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg00012203	chr2:219082015	ARPC2	-0.72	-16.17	-0.54	1.45e-49	Colorectal cancer;
BRCA	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	13.76	0.48	6.16e-38	Platelet count;
BRCA	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg26384229	chr12:38710491	ALG10B	0.59	13.53	0.47	7.42e-37	Morning vs. evening chronotype;
BRCA	cis	rs1020064	0.895	rs2250659	chr2:105889684	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.65	12.05	0.43	2.95e-30	AIDS;
BRCA	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg08132940	chr7:1081526	C7orf50	-0.46	-8.35	-0.31	4.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs8030485	0.728	rs13379886	chr15:79394894	A/G	cg17916960	chr15:79447300	NA	-0.35	-8.22	-0.31	1.11e-15	Left ventricle wall thickness;
BRCA	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg24642844	chr7:1081250	C7orf50	-0.89	-16.0	-0.53	1.07e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg08888203	chr3:10149979	C3orf24	0.69	14.79	0.51	8.7e-43	Alzheimer's disease;
BRCA	trans	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg25214090	chr10:38739885	LOC399744	0.48	10.6	0.39	2.75e-24	Corneal astigmatism;
BRCA	trans	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg26384229	chr12:38710491	ALG10B	0.44	9.56	0.35	2.44e-20	Resting heart rate;
BRCA	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg27432699	chr2:27873401	GPN1	-0.54	-11.32	-0.41	3.2e-27	Oral cavity cancer;
BRCA	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-12.6	-0.45	1.15e-32	Alzheimer's disease;
BRCA	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg03213289	chr20:61660250	NA	0.57	12.77	0.45	2.09e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg11822812	chr5:140052017	DND1	-0.29	-7.88	-0.3	1.37e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg07460842	chr6:66804631	NA	-0.57	-11.26	-0.41	6.15e-27	Initial pursuit acceleration in psychotic disorders;
BRCA	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg23505145	chr19:12996616	KLF1	0.54	12.33	0.44	1.69e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs332507	0.830	rs12639478	chr3:124404958	T/A	cg05980111	chr3:124395277	KALRN	0.37	8.65	0.32	4.31e-17	Plateletcrit;
BRCA	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg24006582	chr15:45444508	DUOX1	-0.56	-11.54	-0.42	4.12e-28	Uric acid levels;
BRCA	cis	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg19338460	chr6:170058176	WDR27	-0.45	-8.0	-0.3	5.76e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs9473147	0.516	rs9349416	chr6:47551938	G/A	cg12968598	chr6:47444699	CD2AP	0.44	9.59	0.35	1.92e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg14019146	chr3:50243930	SLC38A3	0.36	8.96	0.33	3.53e-18	Body mass index;
BRCA	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24549020	chr5:56110836	MAP3K1	0.64	13.12	0.46	5.31e-35	Initial pursuit acceleration;
BRCA	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg20307385	chr11:47447363	PSMC3	0.42	9.23	0.34	3.77e-19	Subjective well-being;
BRCA	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg15145296	chr3:125709740	NA	-0.55	-8.81	-0.33	1.22e-17	Blood pressure (smoking interaction);
BRCA	cis	rs867371	1.000	rs881308	chr15:82475797	A/G	cg00614314	chr15:82944287	LOC80154	0.43	9.09	0.34	1.21e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	12.04	0.43	3.26e-30	Personality dimensions;
BRCA	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg18132916	chr6:79620363	NA	-0.43	-9.8	-0.36	3.27e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs1974653	0.918	rs9606250	chr22:20090192	A/T	cg20152630	chr19:46405944	MYPOP	0.48	9.83	0.36	2.38e-21	Schizophrenia;
BRCA	cis	rs965469	0.779	rs2236119	chr20:3303576	G/T	cg25506879	chr20:3388711	C20orf194	-0.43	-8.65	-0.32	4.13e-17	IFN-related cytopenia;
BRCA	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg18132916	chr6:79620363	NA	-0.46	-10.05	-0.37	3.68e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg11843238	chr5:131593191	PDLIM4	0.34	9.04	0.34	1.85e-18	Breast cancer;
BRCA	cis	rs12618769	0.652	rs17506535	chr2:99222834	G/C	cg10123293	chr2:99228465	UNC50	0.44	8.71	0.33	2.51e-17	Bipolar disorder;
BRCA	cis	rs6714710	0.603	rs34974566	chr2:98552299	C/G	cg26665480	chr2:98280029	ACTR1B	0.59	13.57	0.47	4.65e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs4588572	0.644	rs2115435	chr5:77723700	A/C	cg11547950	chr5:77652471	NA	-0.44	-8.54	-0.32	9.65e-17	Triglycerides;
BRCA	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg06784218	chr1:46089804	CCDC17	0.45	10.78	0.39	5.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs921968	0.565	rs4672897	chr2:219588134	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-10.97	-0.4	9.26e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs3772130	0.962	rs13061326	chr3:121493125	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.68	0.39	1.31e-24	Cognitive performance;
BRCA	cis	rs4423214	0.840	rs4435028	chr11:71183690	C/A	cg05163923	chr11:71159392	DHCR7	-0.56	-11.35	-0.41	2.58e-27	Vitamin D levels;
BRCA	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg13770153	chr20:60521292	NA	-0.55	-12.01	-0.43	4.17e-30	Body mass index;
BRCA	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg02820040	chr2:241836501	C2orf54	-0.54	-10.25	-0.38	6.25e-23	Urinary metabolites;
BRCA	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.7	-0.36	7.54e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.4	8.12	0.31	2.38e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg07395648	chr5:131743802	NA	-0.36	-7.98	-0.3	6.73e-15	Breast cancer;
BRCA	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.78	-0.36	3.67e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.53	8.77	0.33	1.57e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg06636001	chr8:8085503	FLJ10661	0.51	11.08	0.4	3.26e-26	Retinal vascular caliber;
BRCA	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg26031613	chr14:104095156	KLC1	-0.43	-8.48	-0.32	1.58e-16	Schizophrenia;
BRCA	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg22903471	chr2:27725779	GCKR	-0.34	-8.13	-0.31	2.3e-15	Total body bone mineral density;
BRCA	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg04511125	chr2:88470314	THNSL2	-0.53	-10.97	-0.4	8.63e-26	Response to metformin (IC50);
BRCA	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg16606324	chr3:10149918	C3orf24	0.5	10.02	0.37	4.84e-22	Alzheimer's disease;
BRCA	cis	rs6594713	0.921	rs34316732	chr5:112699627	T/C	cg12552261	chr5:112820674	MCC	0.47	7.86	0.3	1.63e-14	Brain cytoarchitecture;
BRCA	cis	rs4711336	1.000	rs2229642	chr6:33659472	C/G	cg14003231	chr6:33640908	ITPR3	0.32	7.84	0.3	1.92e-14	Height;
BRCA	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg05347473	chr6:146136440	FBXO30	0.42	8.24	0.31	1.01e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg19628046	chr18:33552617	C18orf21	0.63	12.98	0.46	2.24e-34	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	11.47	0.41	7.87e-28	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.32	8.9	0.33	5.72e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg06521331	chr12:34319734	NA	-0.43	-7.82	-0.3	2.16e-14	Bladder cancer;
BRCA	cis	rs2066819	1.000	rs77032009	chr12:56679971	A/G	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs9463078	0.547	rs720576	chr6:44729974	A/T	cg25276700	chr6:44698697	NA	0.36	8.29	0.31	6.81e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	7.96	0.3	7.72e-15	Breast cancer;
BRCA	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs2268241	0.938	rs11088251	chr21:34770810	A/C	cg14850771	chr21:34775459	IFNGR2	0.81	16.7	0.55	3.34e-52	Obesity-related traits;
BRCA	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	9.16	0.34	6.94e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7246657	0.653	rs10425441	chr19:37670648	T/C	cg23950597	chr19:37808831	NA	-0.67	-10.31	-0.38	3.57e-23	Coronary artery calcification;
BRCA	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg09417038	chr21:47716443	C21orf57	-0.32	-8.01	-0.3	5.61e-15	Testicular germ cell tumor;
BRCA	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg18230493	chr5:56204884	C5orf35	-0.72	-14.03	-0.49	3.47e-39	Initial pursuit acceleration;
BRCA	cis	rs651907	0.617	rs797776	chr3:101610243	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.39	9.0	0.34	2.52e-18	Colorectal cancer;
BRCA	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.62	10.0	0.37	5.63e-22	Renal function-related traits (BUN);
BRCA	cis	rs7072216	0.763	rs10748730	chr10:100171440	C/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.68	-0.36	9.24e-21	Metabolite levels;
BRCA	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg24562669	chr7:97807699	LMTK2	0.43	11.68	0.42	1.02e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6878727	0.850	rs11241738	chr5:123721425	A/T	cg01806427	chr5:123737813	NA	0.4	9.04	0.34	1.88e-18	Breast cancer;
BRCA	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg24578937	chr1:2090814	PRKCZ	-0.57	-17.77	-0.58	1.03e-57	Height;
BRCA	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg16576597	chr16:28551801	NUPR1	0.27	7.94	0.3	9.22e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs629535	0.508	rs56207225	chr8:70146628	C/A	cg21567404	chr3:27674614	NA	-0.96	-17.44	-0.57	5.27e-56	Dupuytren's disease;
BRCA	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07308232	chr7:1071921	C7orf50	-0.42	-8.59	-0.32	6.89e-17	Longevity;Endometriosis;
BRCA	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg04691961	chr3:161091175	C3orf57	-0.42	-10.17	-0.37	1.23e-22	Morning vs. evening chronotype;
BRCA	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg24812749	chr6:127587940	RNF146	0.88	20.63	0.63	7.68e-73	Breast cancer;
BRCA	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.55	9.07	0.34	1.47e-18	Renal function-related traits (BUN);
BRCA	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	11.35	0.41	2.43e-27	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg07148914	chr20:33460835	GGT7	-0.42	-9.04	-0.34	1.92e-18	Height;
BRCA	cis	rs2066819	1.000	rs79824801	chr12:56728137	T/C	cg26714650	chr12:56694279	CS	-1.19	-15.73	-0.53	2.35e-47	Psoriasis vulgaris;
BRCA	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-10.29	-0.38	4.51e-23	Reticulocyte count;
BRCA	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg08917208	chr2:24149416	ATAD2B	0.93	13.75	0.48	7.07e-38	Lymphocyte counts;
BRCA	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	6.83e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.94e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg09021430	chr5:549028	NA	0.44	12.88	0.45	6.82e-34	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
BRCA	trans	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg23762105	chr12:34175262	ALG10	-0.41	-10.1	-0.37	2.42e-22	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg13319975	chr6:146136371	FBXO30	-0.41	-9.38	-0.35	1.12e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	14.22	0.49	4.65e-40	Colorectal cancer;
BRCA	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg13334819	chr7:99746414	C7orf59	0.34	7.9	0.3	1.25e-14	Coronary artery disease;
BRCA	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11644478	chr21:40555479	PSMG1	0.82	18.71	0.59	1.22e-62	Cognitive function;
BRCA	cis	rs11734570	0.581	rs4401459	chr4:38585268	G/T	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.48	-8.82	-0.33	1.05e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg12062639	chr20:23401060	NAPB	0.96	13.45	0.47	1.64e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	trans	rs526821	0.553	rs510095	chr11:55289154	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-8.23	-0.31	1.03e-15	Pediatric bone mineral density (spine);
BRCA	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg22800045	chr5:56110881	MAP3K1	0.6	10.27	0.38	5.43e-23	Initial pursuit acceleration;
BRCA	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg13010199	chr12:38710504	ALG10B	0.54	11.98	0.43	5.39e-30	Heart rate;
BRCA	cis	rs4671400	0.571	rs2421116	chr2:61488411	A/G	cg15711740	chr2:61764176	XPO1	0.43	9.03	0.34	2.02e-18	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05025164	chr4:1340916	KIAA1530	0.76	15.54	0.52	1.92e-46	Longevity;
BRCA	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg11189052	chr15:85197271	WDR73	-0.35	-8.38	-0.31	3.42e-16	P wave terminal force;
BRCA	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg08508325	chr11:3079039	CARS	0.28	8.5	0.32	1.38e-16	Calcium levels;
BRCA	cis	rs7707921	0.522	rs10070637	chr5:81490608	A/G	cg15871215	chr5:81402204	ATG10	0.35	8.82	0.33	1.1e-17	Breast cancer;
BRCA	cis	rs9811920	0.809	rs766778	chr3:99751480	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.57	-13.67	-0.48	1.72e-37	Axial length;
BRCA	cis	rs10992471	0.528	rs4744135	chr9:95251874	A/C	cg14631576	chr9:95140430	CENPP	0.34	8.43	0.32	2.29e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs1018836	0.663	rs2205151	chr8:91483468	A/C	cg16814680	chr8:91681699	NA	-0.48	-10.15	-0.37	1.49e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg04944784	chr2:26401820	FAM59B	-0.95	-16.58	-0.55	1.26e-51	Gut microbiome composition (summer);
BRCA	cis	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg05901451	chr6:126070800	HEY2	0.4	9.65	0.36	1.2e-20	Endometrial cancer;
BRCA	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg11941060	chr3:133502564	NA	-0.5	-12.1	-0.43	1.67e-30	Iron status biomarkers;
BRCA	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-8.66	-0.32	3.7e-17	Personality dimensions;
BRCA	cis	rs10046574	0.831	rs7785527	chr7:135063685	C/T	cg27474649	chr7:135195673	CNOT4	0.58	8.3	0.31	6.41e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg24549020	chr5:56110836	MAP3K1	-0.46	-9.83	-0.36	2.47e-21	Type 2 diabetes;
BRCA	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg18129178	chr5:148520854	ABLIM3	0.6	12.37	0.44	1.11e-31	Breast cancer;
BRCA	cis	rs10845606	1.000	rs11055013	chr12:12829037	T/C	cg04607235	chr12:12878440	APOLD1	-0.62	-10.02	-0.37	4.86e-22	Systemic lupus erythematosus;
BRCA	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18876405	chr7:65276391	NA	0.56	13.34	0.47	5.75e-36	Aortic root size;
BRCA	cis	rs1941023	0.503	rs12798266	chr11:60118851	G/A	cg08716584	chr11:60157161	MS4A7	-0.41	-9.65	-0.36	1.16e-20	Congenital heart disease (maternal effect);
BRCA	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg03954927	chr1:10346856	KIF1B	0.45	12.82	0.45	1.19e-33	Hepatocellular carcinoma;
BRCA	cis	rs6942756	0.955	rs9641849	chr7:128899238	C/T	cg02491457	chr7:128862824	NA	-0.69	-13.61	-0.47	3.23e-37	White matter hyperintensity burden;
BRCA	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg18154014	chr19:37997991	ZNF793	0.62	11.63	0.42	1.75e-28	Coronary artery calcification;
BRCA	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg13010199	chr12:38710504	ALG10B	0.44	9.22	0.34	4.31e-19	Morning vs. evening chronotype;
BRCA	cis	rs6433895	1.000	rs34601234	chr2:182013120	T/G	cg00481216	chr2:181971175	NA	0.37	8.72	0.33	2.49e-17	Lymphocyte counts;
BRCA	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.45	-11.77	-0.42	4.22e-29	Schizophrenia;
BRCA	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg08470875	chr2:26401718	FAM59B	0.72	11.89	0.43	1.31e-29	Gut microbiome composition (summer);
BRCA	cis	rs6963495	0.556	rs818481	chr7:105158467	G/C	cg19920283	chr7:105172520	RINT1	0.44	9.12	0.34	9.93e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	ch.11.42038R	chr11:967971	AP2A2	0.52	16.68	0.55	4.22e-52	Alzheimer's disease (late onset);
BRCA	cis	rs2191566	0.576	rs395803	chr19:44494694	A/G	cg20607764	chr19:44506953	ZNF230	0.37	8.01	0.3	5.57e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	16.67	0.55	4.65e-52	Alzheimer's disease;
BRCA	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9369695	0.883	rs9473128	chr6:47505010	C/T	cg12968598	chr6:47444699	CD2AP	0.44	9.71	0.36	7.19e-21	Reticulocyte count;
BRCA	cis	rs17253792	0.822	rs78143160	chr14:56150097	A/G	cg01858014	chr14:56050164	KTN1	-0.75	-9.37	-0.35	1.2e-19	Putamen volume;
BRCA	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09256448	chr16:638327	NA	0.31	8.45	0.32	1.91e-16	Height;
BRCA	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg07988820	chr12:82153109	PPFIA2	-0.65	-10.39	-0.38	1.86e-23	Resting heart rate;
BRCA	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg23708337	chr7:1209742	NA	0.44	8.66	0.32	3.93e-17	Longevity;Endometriosis;
BRCA	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg24642439	chr20:33292090	TP53INP2	0.43	9.19	0.34	5.43e-19	Height;
BRCA	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg22920501	chr2:26401640	FAM59B	0.91	16.27	0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	8.16	0.31	1.84e-15	Menarche (age at onset);
BRCA	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg15017067	chr4:17643749	FAM184B	-0.27	-7.99	-0.3	6.5e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs526821	0.595	rs485555	chr11:55323570	A/G	cg11707556	chr5:10655725	ANKRD33B	0.37	8.3	0.31	6.37e-16	Pediatric bone mineral density (spine);
BRCA	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.29	0.41	4.47e-27	Bipolar disorder;
BRCA	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-8.96	-0.33	3.47e-18	Aortic root size;
BRCA	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.42	-9.33	-0.35	1.72e-19	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg24812749	chr6:127587940	RNF146	0.88	20.63	0.63	7.68e-73	Breast cancer;
BRCA	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg13010199	chr12:38710504	ALG10B	0.47	8.99	0.34	2.82e-18	Morning vs. evening chronotype;
BRCA	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg06627557	chr7:32535165	LSM5;AVL9	1.06	27.25	0.73	4.36e-109	Cognitive ability;
BRCA	cis	rs6543140	0.927	rs917999	chr2:103067869	G/A	cg04239558	chr2:103089729	SLC9A4	0.34	9.55	0.35	2.73e-20	Blood protein levels;
BRCA	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg20628663	chr10:43360327	NA	0.65	13.31	0.47	7.84e-36	Blood protein levels;
BRCA	cis	rs752010	0.645	rs1109254	chr1:42091770	T/C	cg06885757	chr1:42089581	HIVEP3	0.41	13.38	0.47	3.72e-36	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03517284	chr6:25882590	NA	-0.38	-8.25	-0.31	9.11e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg14186256	chr22:23484241	RTDR1	0.75	22.02	0.66	2.19e-80	Bone mineral density;
BRCA	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	19.65	0.61	1.3e-67	Smoking behavior;
BRCA	cis	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.23	-0.41	7.8e-27	Morning vs. evening chronotype;
BRCA	cis	rs698813	0.614	rs811494	chr2:44725047	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	8.36	0.31	3.85e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12756686	chr19:29218302	NA	0.57	10.98	0.4	8.46e-26	Methadone dose in opioid dependence;
BRCA	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg11530693	chr1:120165357	ZNF697	0.62	14.77	0.5	1.1e-42	Systemic lupus erythematosus;
BRCA	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg12573674	chr2:1569213	NA	-0.58	-12.54	-0.44	2.11e-32	IgG glycosylation;
BRCA	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06022373	chr22:39101656	GTPBP1	-0.73	-17.88	-0.58	2.92e-58	Menopause (age at onset);
BRCA	cis	rs11249608	0.548	rs6894076	chr5:178449813	T/C	cg21905437	chr5:178450457	ZNF879	0.52	10.85	0.39	2.68e-25	Pubertal anthropometrics;
BRCA	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg13319975	chr6:146136371	FBXO30	-0.43	-9.83	-0.36	2.42e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.59	13.3	0.47	8.2e-36	Eosinophil percentage of white cells;
BRCA	cis	rs10899021	1.000	rs61900635	chr11:74359010	C/G	cg25880958	chr11:74394337	NA	-0.52	-8.05	-0.3	4e-15	Response to metformin (IC50);
BRCA	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06636551	chr8:101224915	SPAG1	-0.38	-8.72	-0.33	2.39e-17	Atrioventricular conduction;
BRCA	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg02073558	chr3:44770973	ZNF501	0.38	7.94	0.3	9.25e-15	Depressive symptoms;
BRCA	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg14963724	chr18:72166303	CNDP2	-0.34	-9.54	-0.35	3.05e-20	Refractive error;
BRCA	cis	rs2066819	1.000	rs744051	chr12:56667298	C/T	cg26714650	chr12:56694279	CS	1.16	15.27	0.52	3.93e-45	Psoriasis vulgaris;
BRCA	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg05527609	chr1:210001259	C1orf107	0.84	20.09	0.62	5.66e-70	Orofacial clefts;
BRCA	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg15242686	chr22:24348715	GSTTP1	0.32	7.97	0.3	7.43e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs400736	0.655	rs11121086	chr1:8151224	C/T	cg25007680	chr1:8021821	PARK7	-0.35	-8.53	-0.32	1.02e-16	Response to antidepressants and depression;
BRCA	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg18811423	chr2:55921094	PNPT1	0.59	16.38	0.54	1.38e-50	Metabolic syndrome;
BRCA	cis	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg06521331	chr12:34319734	NA	-0.5	-9.09	-0.34	1.26e-18	Resting heart rate;
BRCA	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs919433	0.679	rs9967823	chr2:198531529	A/G	cg00792783	chr2:198669748	PLCL1	0.4	9.19	0.34	5.63e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg03806693	chr22:41940476	POLR3H	-0.55	-9.71	-0.36	6.86e-21	Neuroticism;
BRCA	cis	rs55665837	1.000	rs10832254	chr11:14434698	A/G	cg19336497	chr11:14380999	RRAS2	-0.36	-9.49	-0.35	4.37e-20	Vitamin D levels;
BRCA	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg20607798	chr8:58055168	NA	0.46	9.85	0.36	2.14e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg21479132	chr6:26055353	NA	0.57	8.03	0.3	4.79e-15	Autism spectrum disorder or schizophrenia;
BRCA	trans	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	9.18	0.34	5.71e-19	Mean corpuscular volume;
BRCA	cis	rs7927771	0.524	rs12785949	chr11:47729770	C/T	cg20307385	chr11:47447363	PSMC3	0.42	9.58	0.35	2.07e-20	Subjective well-being;
BRCA	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg16606324	chr3:10149918	C3orf24	0.57	10.0	0.37	5.57e-22	Alzheimer's disease;
BRCA	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg25801113	chr15:45476975	SHF	-0.34	-8.23	-0.31	1.07e-15	Uric acid levels;
BRCA	cis	rs7178424	0.967	rs8039105	chr15:62359085	C/T	cg00456672	chr15:62358751	C2CD4A	-0.42	-9.51	-0.35	3.88e-20	Height;
BRCA	cis	rs1030877	0.557	rs2576752	chr2:105978761	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.49	10.92	0.4	1.41e-25	Obesity-related traits;
BRCA	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg20503657	chr10:835505	NA	1.03	18.12	0.58	1.6e-59	Eosinophil percentage of granulocytes;
BRCA	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.15	0.31	1.95e-15	Breast cancer;
BRCA	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07080220	chr10:102295463	HIF1AN	0.48	11.01	0.4	5.96e-26	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg23711669	chr6:146136114	FBXO30	0.73	17.0	0.56	1e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg04362960	chr10:104952993	NT5C2	0.37	8.25	0.31	9.05e-16	Arsenic metabolism;
BRCA	cis	rs4363385	0.818	rs679378	chr1:153011716	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.44	-0.32	2.1e-16	Inflammatory skin disease;
BRCA	trans	rs3857536	0.813	rs6455084	chr6:66935658	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg13047869	chr3:10149882	C3orf24	0.57	10.45	0.38	1.08e-23	Alzheimer's disease;
BRCA	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg04450456	chr4:17643702	FAM184B	0.36	10.34	0.38	2.88e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs6479891	1.000	rs1904295	chr10:64982876	G/A	cg14819942	chr15:35414228	NA	-0.34	-8.48	-0.32	1.58e-16	Arthritis (juvenile idiopathic);
BRCA	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg22713356	chr15:30763199	NA	1.25	20.77	0.63	1.25e-73	Uric acid levels;
BRCA	cis	rs11229555	0.645	rs12800531	chr11:58180099	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg12444411	chr7:2802554	GNA12	-0.33	-8.55	-0.32	8.94e-17	Height;
BRCA	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg21479132	chr6:26055353	NA	0.56	7.94	0.3	9.43e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg04944784	chr2:26401820	FAM59B	-0.66	-11.29	-0.41	4.4e-27	Gut microbiome composition (summer);
BRCA	trans	rs7980799	0.649	rs11559754	chr12:33649229	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-9.63	-0.36	1.4e-20	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg18479299	chr3:125709523	NA	-0.53	-9.11	-0.34	1.07e-18	Blood pressure (smoking interaction);
BRCA	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg11366901	chr6:160182831	ACAT2	0.82	15.94	0.53	2.09e-48	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg06453172	chr10:134556979	INPP5A	-0.59	-12.4	-0.44	8.87e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg21535247	chr6:8435926	SLC35B3	-0.4	-9.16	-0.34	6.93e-19	Motion sickness;
BRCA	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg02297831	chr4:17616191	MED28	0.36	8.4	0.32	2.9e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg25173405	chr17:45401733	C17orf57	-0.57	-12.24	-0.44	4.26e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.74e-18	Motion sickness;
BRCA	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg05347473	chr6:146136440	FBXO30	0.42	8.39	0.32	3.1e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg21747090	chr2:27597821	SNX17	-0.41	-9.05	-0.34	1.72e-18	Total body bone mineral density;
BRCA	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg05234568	chr11:5960015	NA	-0.47	-9.45	-0.35	6.54e-20	DNA methylation (variation);
BRCA	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-9.83	-0.36	2.39e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg20283391	chr11:68216788	NA	-0.46	-8.97	-0.33	3.25e-18	Total body bone mineral density;
BRCA	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06636551	chr8:101224915	SPAG1	-0.38	-8.52	-0.32	1.18e-16	Atrioventricular conduction;
BRCA	cis	rs6429082	0.818	rs291386	chr1:235647050	C/T	cg26050004	chr1:235667680	B3GALNT2	0.54	12.85	0.45	8.53e-34	Adiposity;
BRCA	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg02175503	chr12:58329896	NA	0.55	11.54	0.42	4.13e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg26168224	chr5:2018326	NA	-0.61	-15.84	-0.53	6.49e-48	Gut microbiome composition (winter);
BRCA	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg18016565	chr1:150552671	MCL1	-0.43	-9.61	-0.36	1.62e-20	Tonsillectomy;
BRCA	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg25358565	chr5:93447407	FAM172A	1.16	18.34	0.59	1.15e-60	Diabetic retinopathy;
BRCA	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg07636037	chr3:49044803	WDR6	-0.56	-8.05	-0.3	3.95e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11644478	chr21:40555479	PSMG1	0.83	18.42	0.59	4.11e-61	Cognitive function;
BRCA	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-8.3	-0.31	6.13e-16	Monocyte percentage of white cells;
BRCA	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg25208724	chr1:156163844	SLC25A44	-1.0	-32.73	-0.79	1.03e-138	Testicular germ cell tumor;
BRCA	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg26384229	chr12:38710491	ALG10B	0.66	13.95	0.48	8.57e-39	Morning vs. evening chronotype;
BRCA	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg01262667	chr19:19385393	TM6SF2	0.42	10.97	0.4	9.28e-26	Tonsillectomy;
BRCA	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg17366294	chr4:99064904	C4orf37	0.44	10.44	0.38	1.1e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.57	-0.42	2.97e-28	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.34	0.38	2.78e-23	Motion sickness;
BRCA	cis	rs9595066	0.715	rs9567366	chr13:44682973	A/C	cg04068111	chr13:44716778	NA	0.44	8.69	0.33	2.97e-17	Schizophrenia;
BRCA	trans	rs11165623	0.765	rs12749081	chr1:96970371	A/C	cg10631902	chr5:14652156	NA	-0.5	-15.57	-0.52	1.48e-46	Hip circumference;Waist circumference;
BRCA	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg08508325	chr11:3079039	CARS	-0.42	-14.93	-0.51	1.93e-43	Longevity;
BRCA	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.77	0.39	5.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2625529	0.824	rs4445848	chr15:72354598	C/T	cg16672083	chr15:72433130	SENP8	-0.84	-17.45	-0.57	4.66e-56	Red blood cell count;
BRCA	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg15698299	chr3:52233019	ALAS1	0.4	9.42	0.35	7.93e-20	Electroencephalogram traits;
BRCA	cis	rs17601876	0.814	rs2899474	chr15:51562076	C/T	cg19946085	chr15:51559439	CYP19A1	-0.39	-11.65	-0.42	1.47e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg08807101	chr21:30365312	RNF160	0.76	20.08	0.62	6.32e-70	Dental caries;
BRCA	cis	rs9457247	0.508	rs7760495	chr6:167506795	C/T	cg07741184	chr6:167504864	NA	0.32	9.77	0.36	4.12e-21	Crohn's disease;
BRCA	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg03885332	chr11:832357	CD151	-0.34	-9.4	-0.35	9.62e-20	Mean platelet volume;
BRCA	cis	rs6545883	0.859	rs7561672	chr2:61519094	G/A	cg15711740	chr2:61764176	XPO1	0.49	12.13	0.43	1.23e-30	Tuberculosis;
BRCA	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11764359	chr7:65958608	NA	-0.75	-16.87	-0.55	4.61e-53	Aortic root size;
BRCA	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.03	-0.3	4.66e-15	Total body bone mineral density;
BRCA	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.39	8.57	0.32	7.9e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg03188948	chr7:1209495	NA	0.46	8.9	0.33	5.77e-18	Longevity;Endometriosis;
BRCA	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg13334819	chr7:99746414	C7orf59	-0.47	-10.84	-0.39	3.07e-25	Coronary artery disease;
BRCA	cis	rs3760982	0.585	rs4803659	chr19:44290235	C/T	cg11993925	chr19:44307056	LYPD5	0.37	8.81	0.33	1.14e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg05283184	chr6:79620031	NA	0.42	10.89	0.4	1.95e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs11718455	0.767	rs9861276	chr3:43989595	C/T	cg08738300	chr3:44038990	NA	0.48	8.9	0.33	5.94e-18	Coronary artery disease;
BRCA	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg14440974	chr22:39074834	NA	0.33	8.12	0.31	2.4e-15	Menopause (age at onset);
BRCA	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg04944784	chr2:26401820	FAM59B	-0.68	-11.19	-0.4	1.19e-26	Gut microbiome composition (summer);
BRCA	cis	rs61990749	0.544	rs176979	chr14:78198072	A/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.66	10.67	0.39	1.45e-24	Fibroblast growth factor basic levels;
BRCA	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg06115741	chr20:33292138	TP53INP2	0.48	10.48	0.38	8.32e-24	Coronary artery disease;
BRCA	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg18512352	chr11:47633146	NA	-0.33	-8.05	-0.3	4.02e-15	Subjective well-being;
BRCA	cis	rs9296092	0.560	rs9469506	chr6:33527897	A/G	cg13560919	chr6:33536144	NA	-0.85	-18.69	-0.59	1.6e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg11789530	chr4:8429930	ACOX3	0.67	17.63	0.57	5.43e-57	Response to antineoplastic agents;
BRCA	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg24692254	chr21:30365293	RNF160	0.78	21.75	0.65	6.72e-79	Dental caries;
BRCA	cis	rs7635838	0.617	rs347587	chr3:11287155	A/G	cg00170343	chr3:11313890	ATG7	-0.47	-9.51	-0.35	3.87e-20	HDL cholesterol;
BRCA	cis	rs2625529	0.824	rs2279283	chr15:72243666	T/C	cg16672083	chr15:72433130	SENP8	-0.82	-17.0	-0.56	9.76e-54	Red blood cell count;
BRCA	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg04025307	chr7:1156635	C7orf50	0.47	10.86	0.39	2.4e-25	Bronchopulmonary dysplasia;
BRCA	trans	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg15704280	chr7:45808275	SEPT13	0.59	8.75	0.33	1.95e-17	Axial length;
BRCA	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	1.98e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs495337	0.760	rs6122844	chr20:48541545	G/T	cg17835207	chr20:48524531	SPATA2	-0.69	-16.83	-0.55	6.92e-53	Psoriasis;
BRCA	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg06115741	chr20:33292138	TP53INP2	0.39	8.62	0.32	5.23e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs12368653	0.557	rs903067	chr12:58011857	G/A	cg12615879	chr12:58013172	SLC26A10	-0.31	-8.55	-0.32	9.07e-17	Multiple sclerosis;
BRCA	cis	rs13082711	0.595	rs6778612	chr3:27370789	T/C	cg02860705	chr3:27208620	NA	-0.58	-11.23	-0.41	7.73e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11764359	chr7:65958608	NA	0.79	19.19	0.6	3.68e-65	Aortic root size;
BRCA	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg03676636	chr4:99064102	C4orf37	0.21	7.97	0.3	7.11e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	25.91	0.72	1.01e-101	Chronic sinus infection;
BRCA	cis	rs10267417	0.603	rs1557772	chr7:19908535	A/C	cg05791153	chr7:19748676	TWISTNB	0.43	8.65	0.32	4.04e-17	Night sleep phenotypes;
BRCA	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg03405983	chr8:143858548	LYNX1	-0.37	-8.01	-0.3	5.41e-15	Urinary tract infection frequency;
BRCA	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg20387954	chr3:183756860	HTR3D	0.46	10.56	0.39	3.94e-24	Anterior chamber depth;
BRCA	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg04166393	chr7:2884313	GNA12	0.38	8.1	0.3	2.89e-15	Height;
BRCA	cis	rs34779708	0.931	rs4934731	chr10:35431636	T/C	cg03585969	chr10:35415529	CREM	0.44	9.31	0.35	2.02e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6083	0.571	rs17190678	chr15:58847372	C/G	cg05156742	chr15:59063176	FAM63B	-0.45	-9.56	-0.35	2.57e-20	Schizophrenia;
BRCA	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-9.8	-0.36	3.23e-21	Mean corpuscular volume;
BRCA	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.56	-0.68	8.48e-89	Gut microbiome composition (summer);
BRCA	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg22676075	chr6:135203613	NA	0.45	8.79	0.33	1.4e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs11622475	1.000	rs2236247	chr14:104378087	C/T	cg12183467	chr14:104352244	NA	-0.45	-9.84	-0.36	2.18e-21	Bipolar disorder;
BRCA	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg11822812	chr5:140052017	DND1	-0.31	-8.4	-0.32	2.86e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg07460842	chr6:66804631	NA	0.75	11.26	0.41	6.05e-27	Exhaled nitric oxide output;
BRCA	cis	rs9837602	1.000	rs6790877	chr3:99779658	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	11.25	0.41	6.35e-27	Breast cancer;
BRCA	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg15556689	chr8:8085844	FLJ10661	0.42	11.09	0.4	2.98e-26	Mood instability;
BRCA	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg04166393	chr7:2884313	GNA12	0.51	9.56	0.35	2.48e-20	Height;
BRCA	cis	rs990171	0.560	rs4851548	chr2:102767532	A/G	cg22835712	chr2:102737379	NA	0.51	8.03	0.3	4.56e-15	Lymphocyte counts;
BRCA	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg01802117	chr1:53393560	SCP2	-0.36	-8.26	-0.31	8.3e-16	Monocyte count;
BRCA	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg11663144	chr21:46675770	NA	0.44	8.74	0.33	1.99e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs911119	0.955	rs59059917	chr20:23595675	C/T	cg16589663	chr20:23618590	CST3	0.46	8.43	0.32	2.31e-16	Chronic kidney disease;
BRCA	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg27572855	chr1:25598939	RHD	0.48	13.52	0.47	8.33e-37	Erythrocyte sedimentation rate;
BRCA	trans	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.95	-0.3	8.73e-15	Corneal astigmatism;
BRCA	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.89	-0.33	6e-18	Total body bone mineral density;
BRCA	cis	rs10046574	0.519	rs34274894	chr7:135214725	G/C	cg27474649	chr7:135195673	CNOT4	0.64	10.75	0.39	7.17e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg26893861	chr17:41843967	DUSP3	0.56	10.21	0.37	9.35e-23	Triglycerides;
BRCA	cis	rs27434	0.583	rs40091	chr5:96154919	A/G	cg16492584	chr5:96139282	ERAP1	-0.51	-12.82	-0.45	1.15e-33	Ankylosing spondylitis;
BRCA	cis	rs6545883	0.772	rs1186709	chr2:61689380	G/A	cg15711740	chr2:61764176	XPO1	-0.57	-14.37	-0.49	8.59e-41	Tuberculosis;
BRCA	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg12591125	chr7:1885375	MAD1L1	0.51	8.91	0.33	5.21e-18	Bipolar disorder;
BRCA	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg10621924	chr7:39171070	POU6F2	0.38	8.12	0.31	2.39e-15	IgG glycosylation;
BRCA	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg22535103	chr8:58192502	C8orf71	-0.46	-9.05	-0.34	1.75e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg26408565	chr15:76604113	ETFA	-0.48	-10.35	-0.38	2.51e-23	Blood metabolite levels;
BRCA	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.72	0.57	1.98e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.52	-9.34	-0.35	1.55e-19	Glomerular filtration rate in chronic kidney disease;
BRCA	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg26384229	chr12:38710491	ALG10B	0.58	13.2	0.46	2.26e-35	Morning vs. evening chronotype;
BRCA	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.59	0.32	6.75e-17	Rheumatoid arthritis;
BRCA	cis	rs10463316	0.817	rs6895187	chr5:150775909	G/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.32	-0.31	5.27e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg05896524	chr21:47604654	C21orf56	0.49	9.98	0.37	6.87e-22	Testicular germ cell tumor;
BRCA	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg24578937	chr1:2090814	PRKCZ	-0.38	-11.55	-0.42	3.55e-28	Height;
BRCA	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg14963724	chr18:72166303	CNDP2	-0.34	-9.44	-0.35	6.73e-20	Refractive error;
BRCA	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg16482183	chr6:26056742	HIST1H1C	0.46	8.88	0.33	6.81e-18	Iron status biomarkers;
BRCA	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.43	9.5	0.35	3.99e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg02297831	chr4:17616191	MED28	0.38	8.85	0.33	8.39e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg09455208	chr3:40491958	NA	0.41	9.68	0.36	9.39e-21	Renal cell carcinoma;
BRCA	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg08917208	chr2:24149416	ATAD2B	0.89	12.73	0.45	3.15e-33	Lymphocyte counts;
BRCA	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg10011062	chr15:43941034	CATSPER2	-0.53	-7.98	-0.3	6.85e-15	Lung cancer in ever smokers;
BRCA	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg04691961	chr3:161091175	C3orf57	0.38	8.62	0.32	5.18e-17	Morning vs. evening chronotype;
BRCA	trans	rs61931739	0.612	rs2004961	chr12:33994599	A/G	cg26384229	chr12:38710491	ALG10B	0.4	9.01	0.34	2.32e-18	Morning vs. evening chronotype;
BRCA	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg16230307	chr14:35515116	FAM177A1	0.73	15.25	0.52	5.11e-45	Psoriasis;
BRCA	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.08	-0.4	3.36e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.76	-0.36	4.38e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg09307838	chr4:120376055	NA	0.6	13.04	0.46	1.24e-34	Corneal astigmatism;
BRCA	cis	rs6484504	0.532	rs11031342	chr11:31309818	G/A	cg26647111	chr11:31128758	NA	-0.45	-9.79	-0.36	3.41e-21	Red blood cell count;
BRCA	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25427524	chr10:38739819	LOC399744	-0.64	-15.28	-0.52	3.9e-45	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg21770322	chr7:97807741	LMTK2	0.45	11.74	0.42	5.91e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg06060754	chr5:176797920	RGS14	0.6	11.21	0.41	9.62e-27	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs1113500	0.933	rs10881500	chr1:108638895	C/T	cg06207961	chr1:108661230	NA	0.44	10.82	0.39	3.75e-25	Growth-regulated protein alpha levels;
BRCA	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg26384229	chr12:38710491	ALG10B	0.75	16.26	0.54	5.37e-50	Bladder cancer;
BRCA	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg24642439	chr20:33292090	TP53INP2	0.7	16.19	0.54	1.17e-49	Coronary artery disease;
BRCA	cis	rs9837602	1.000	rs35521705	chr3:99716690	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	11.28	0.41	4.85e-27	Breast cancer;
BRCA	cis	rs870825	0.616	rs28444118	chr4:185621692	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg24399712	chr22:39784796	NA	0.59	13.77	0.48	5.85e-38	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
BRCA	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg26149184	chr10:133730230	NA	0.4	8.08	0.3	3.16e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	trans	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg25214090	chr10:38739885	LOC399744	0.54	12.59	0.45	1.29e-32	Corneal astigmatism;
BRCA	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg16339924	chr4:17578868	LAP3	0.58	14.07	0.49	2.4e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs35740288	0.597	rs12900830	chr15:86326154	T/C	cg20737812	chr15:86336631	KLHL25	-0.38	-8.43	-0.32	2.29e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg21770322	chr7:97807741	LMTK2	0.41	10.95	0.4	1.04e-25	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg07828340	chr4:882639	GAK	-0.91	-11.62	-0.42	1.92e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg01256987	chr12:42539512	GXYLT1	-0.46	-9.21	-0.34	4.74e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg24069376	chr3:38537580	EXOG	0.34	9.34	0.35	1.6e-19	Electrocardiographic conduction measures;
BRCA	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg26343298	chr8:95960752	TP53INP1	0.29	8.23	0.31	1.05e-15	Type 2 diabetes;
BRCA	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.05	-0.34	1.65e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg12373951	chr3:133503437	NA	0.43	10.16	0.37	1.43e-22	Iron status biomarkers;
BRCA	cis	rs4363385	0.747	rs1415971	chr1:152965779	T/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.49	-0.32	1.42e-16	Inflammatory skin disease;
BRCA	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-9.81	-0.36	2.91e-21	Alzheimer's disease (late onset);
BRCA	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.42	-0.61	2.35e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg01620082	chr3:125678407	NA	-0.59	-8.22	-0.31	1.14e-15	Depression;
BRCA	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.74	16.14	0.54	2.13e-49	Lymphocyte counts;
BRCA	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg22455342	chr2:225449267	CUL3	0.34	9.13	0.34	9.24e-19	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg22963979	chr7:1858916	MAD1L1	-0.37	-7.9	-0.3	1.21e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg22907277	chr7:1156413	C7orf50	0.59	9.17	0.34	6.51e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg20607798	chr8:58055168	NA	0.47	8.26	0.31	8.19e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg13010199	chr12:38710504	ALG10B	0.41	8.5	0.32	1.31e-16	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg13010199	chr12:38710504	ALG10B	0.44	9.22	0.34	4.31e-19	Morning vs. evening chronotype;
BRCA	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg07741184	chr6:167504864	NA	0.36	10.44	0.38	1.12e-23	Crohn's disease;
BRCA	cis	rs708547	0.581	rs781661	chr4:57780307	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	0.42	8.0	0.3	5.78e-15	Response to bleomycin (chromatid breaks);
BRCA	cis	rs3106136	0.527	rs10030586	chr4:95150805	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.16	-0.37	1.39e-22	Capecitabine sensitivity;
BRCA	trans	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-20.24	-0.63	9.77e-71	Exhaled nitric oxide output;
BRCA	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg17063962	chr7:91808500	NA	-0.52	-12.22	-0.44	5.29e-31	Breast cancer;
BRCA	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.41	9.01	0.34	2.41e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg12641515	chr19:46296257	DMWD	-0.54	-11.92	-0.43	1.03e-29	Coronary artery disease;
BRCA	cis	rs4302748	0.909	rs35766501	chr7:36186069	G/A	cg24442661	chr7:36192818	EEPD1	0.46	8.73	0.33	2.21e-17	Platelet count;
BRCA	cis	rs11112613	0.713	rs73184084	chr12:105952615	T/A	cg03607813	chr12:105948248	NA	0.55	10.43	0.38	1.25e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg08085267	chr17:45401833	C17orf57	-0.56	-11.07	-0.4	3.51e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg06808227	chr14:105710500	BRF1	0.76	15.88	0.53	4.09e-48	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-17.33	-0.57	1.9e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-12.04	-0.43	3.04e-30	Response to antipsychotic treatment;
BRCA	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg00012203	chr2:219082015	ARPC2	-0.72	-16.0	-0.53	1.02e-48	Colorectal cancer;
BRCA	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg27284194	chr4:1044797	NA	0.43	9.38	0.35	1.09e-19	Recombination rate (males);
BRCA	trans	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg26384229	chr12:38710491	ALG10B	0.46	10.09	0.37	2.61e-22	Morning vs. evening chronotype;
BRCA	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.02	0.4	5.67e-26	Rheumatoid arthritis;
BRCA	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg05775895	chr3:12838266	CAND2	0.38	8.39	0.32	3.06e-16	QRS complex (12-leadsum);
BRCA	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	13.93	0.48	1.01e-38	Lymphocyte percentage of white cells;
BRCA	cis	rs4787491	0.729	rs11544328	chr16:30037128	A/C	cg06326092	chr16:30034487	C16orf92	0.38	9.83	0.36	2.56e-21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg16325326	chr1:53192061	ZYG11B	0.69	17.17	0.56	1.36e-54	Monocyte count;
BRCA	cis	rs7587476	1.000	rs2121285	chr2:215656168	C/G	cg04004882	chr2:215674386	BARD1	-0.55	-10.21	-0.37	8.95e-23	Neuroblastoma;
BRCA	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.68	-0.42	1.08e-28	Gut microbiome composition (summer);
BRCA	trans	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04565464	chr8:145669602	NFKBIL2	0.43	9.49	0.35	4.34e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg02551604	chr5:131831745	NA	-0.4	-14.95	-0.51	1.56e-43	Asthma (sex interaction);
BRCA	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg10664184	chr19:17420304	DDA1	0.36	10.24	0.38	7e-23	Systemic lupus erythematosus;
BRCA	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.84e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4953076	0.613	rs11124981	chr2:44462133	A/T	cg04920474	chr2:44395004	PPM1B	0.49	9.96	0.37	7.83e-22	Height;
BRCA	cis	rs6910061	0.750	rs6456870	chr6:11115486	C/T	cg27233058	chr6:11094804	LOC221710	0.5	8.51	0.32	1.21e-16	Diabetic kidney disease;
BRCA	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-8.63	-0.32	4.76e-17	Tonsillectomy;
BRCA	cis	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05901451	chr6:126070800	HEY2	-0.41	-9.92	-0.37	1.12e-21	Endometrial cancer;
BRCA	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00802000	chr16:706648	WDR90	-0.4	-9.22	-0.34	4.21e-19	Height;
BRCA	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg03146154	chr1:46216737	IPP	-0.42	-8.98	-0.33	3.03e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg24130564	chr14:104152367	KLC1	-0.41	-8.79	-0.33	1.42e-17	Reticulocyte count;
BRCA	cis	rs751728	0.648	rs6922275	chr6:33749739	G/A	cg25922239	chr6:33757077	LEMD2	0.5	12.69	0.45	4.58e-33	Crohn's disease;
BRCA	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	18.8	0.6	4.37e-63	Smoking behavior;
BRCA	trans	rs9951602	0.512	rs12607612	chr18:76651799	G/A	cg02800362	chr5:177631904	HNRNPAB	0.77	18.23	0.58	4.3e-60	Obesity-related traits;
BRCA	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-11.0	-0.4	6.89e-26	Mood instability;
BRCA	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.93	20.62	0.63	8.32e-73	Smoking behavior;
BRCA	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg15212455	chr7:39170539	POU6F2	0.46	9.88	0.36	1.64e-21	IgG glycosylation;
BRCA	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg18230493	chr5:56204884	C5orf35	0.59	12.49	0.44	3.58e-32	Initial pursuit acceleration;
BRCA	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-16.62	-0.55	8.18e-52	Axial length;
BRCA	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg04944784	chr2:26401820	FAM59B	0.95	16.58	0.55	1.27e-51	Gut microbiome composition (summer);
BRCA	cis	rs17253792	0.822	rs10083499	chr14:56066590	T/A	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs7246657	0.722	rs11083432	chr19:38182633	A/G	cg23950597	chr19:37808831	NA	0.45	7.85	0.3	1.76e-14	Coronary artery calcification;
BRCA	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg17691542	chr6:26056736	HIST1H1C	-0.47	-9.32	-0.35	1.8e-19	Iron status biomarkers;
BRCA	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg01877450	chr7:97915802	BRI3	-0.37	-8.48	-0.32	1.57e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg20503657	chr10:835505	NA	1.32	21.46	0.65	2.31e-77	Eosinophil percentage of granulocytes;
BRCA	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg26031613	chr14:104095156	KLC1	-0.53	-9.46	-0.35	5.66e-20	Reticulocyte count;
BRCA	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg08508325	chr11:3079039	CARS	-0.4	-14.16	-0.49	8.42e-40	Longevity;
BRCA	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg05347473	chr6:146136440	FBXO30	0.42	8.44	0.32	2.18e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg10556349	chr10:835070	NA	0.73	9.89	0.36	1.45e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.33	8.77	0.33	1.58e-17	Ovarian reserve;
BRCA	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg26043149	chr18:55253948	FECH	0.4	8.5	0.32	1.29e-16	Bone mineral density;
BRCA	cis	rs9790314	0.747	rs6789244	chr3:160866230	A/C	cg03342759	chr3:160939853	NMD3	-0.57	-12.62	-0.45	9e-33	Morning vs. evening chronotype;
BRCA	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg13770153	chr20:60521292	NA	-0.56	-12.13	-0.43	1.31e-30	Body mass index;
BRCA	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg16586182	chr3:47516702	SCAP	0.54	11.92	0.43	1e-29	Colorectal cancer;
BRCA	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg16414030	chr3:133502952	NA	-0.48	-11.22	-0.41	8.35e-27	Iron status biomarkers;
BRCA	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg18225595	chr11:63971243	STIP1	0.53	9.89	0.36	1.44e-21	Mean platelet volume;
BRCA	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-10.27	-0.38	5.3e-23	Aortic root size;
BRCA	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg23625390	chr15:77176239	SCAPER	-0.53	-12.35	-0.44	1.42e-31	Blood metabolite levels;
BRCA	cis	rs1163251	0.837	rs839612	chr1:120247176	T/C	cg19096424	chr1:120255104	PHGDH	0.45	10.44	0.38	1.2e-23	Blood metabolite levels;
BRCA	cis	rs4713675	0.584	rs3818527	chr6:33661035	A/G	cg14003231	chr6:33640908	ITPR3	-0.34	-8.46	-0.32	1.78e-16	Plateletcrit;
BRCA	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11890956	chr21:40555474	PSMG1	1.05	29.98	0.76	6.03e-124	Cognitive function;
BRCA	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg12292205	chr6:26970375	C6orf41	-0.57	-12.69	-0.45	4.35e-33	Schizophrenia;
BRCA	cis	rs1215050	0.791	rs7681599	chr4:98664109	C/T	cg05340658	chr4:99064831	C4orf37	-0.44	-10.13	-0.37	1.76e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg08885076	chr2:99613938	TSGA10	0.43	10.31	0.38	3.72e-23	Chronic sinus infection;
BRCA	trans	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg06521331	chr12:34319734	NA	-0.45	-8.63	-0.32	4.82e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10754283	0.967	rs10922680	chr1:90101326	C/T	cg21401794	chr1:90099060	LRRC8C	-0.49	-11.72	-0.42	7.41e-29	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg27446573	chr6:127587934	RNF146	0.9	21.07	0.64	2.99e-75	Breast cancer;
BRCA	cis	rs1953600	1.000	rs2789679	chr10:81907884	A/T	cg04850286	chr10:81895943	PLAC9	-0.33	-9.56	-0.35	2.56e-20	Sarcoidosis;
BRCA	cis	rs4363385	0.654	rs1129654	chr1:152958238	A/G	cg24667326	chr1:152973720	SPRR3	-0.33	-9.28	-0.34	2.54e-19	Inflammatory skin disease;
BRCA	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg25664220	chr3:72788482	NA	0.53	10.99	0.4	7.19e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg16414030	chr3:133502952	NA	0.34	7.95	0.3	8.32e-15	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.54	8.14	0.31	2.02e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs490234	0.756	rs2416963	chr9:128241414	C/T	cg14078157	chr9:128172775	NA	-0.36	-8.47	-0.32	1.75e-16	Mean arterial pressure;
BRCA	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg26384229	chr12:38710491	ALG10B	0.51	13.46	0.47	1.47e-36	Morning vs. evening chronotype;
BRCA	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	14.42	0.5	5.31e-41	Colorectal cancer;
BRCA	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	13.14	0.46	4.57e-35	Lymphocyte counts;
BRCA	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg18512352	chr11:47633146	NA	-0.34	-8.03	-0.3	4.74e-15	Subjective well-being;
BRCA	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg18811423	chr2:55921094	PNPT1	-0.51	-13.23	-0.46	1.67e-35	Metabolic syndrome;
BRCA	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-11.97	-0.43	6.27e-30	Bipolar disorder;
BRCA	trans	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg07393940	chr7:158741817	NA	-0.53	-10.13	-0.37	1.8e-22	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs6834538	0.577	rs10034556	chr4:113449650	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.43	10.34	0.38	2.83e-23	Free thyroxine concentration;
BRCA	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg26384229	chr12:38710491	ALG10B	0.66	15.2	0.52	9.06e-45	Bladder cancer;
BRCA	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.41	-0.32	2.76e-16	Total body bone mineral density;
BRCA	cis	rs939658	0.935	rs34859518	chr15:79450422	A/G	cg17916960	chr15:79447300	NA	-0.42	-10.48	-0.38	8.07e-24	Refractive error;
BRCA	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.3	-0.35	2.14e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24549020	chr5:56110836	MAP3K1	0.56	10.25	0.38	6.16e-23	Initial pursuit acceleration;
BRCA	cis	rs7633857	0.532	rs9839984	chr3:160768912	C/T	cg03342759	chr3:160939853	NMD3	-0.58	-12.22	-0.44	5.13e-31	Educational attainment (years of education);
BRCA	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg06784218	chr1:46089804	CCDC17	0.44	10.65	0.39	1.76e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08219700	chr8:58056026	NA	0.63	10.07	0.37	3.05e-22	Developmental language disorder (linguistic errors);
BRCA	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg06784218	chr1:46089804	CCDC17	-0.46	-10.78	-0.39	5.33e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10911363	0.571	rs6424897	chr1:183419203	T/C	cg09173681	chr1:183549694	NCF2	-0.48	-10.46	-0.38	9.58e-24	Systemic lupus erythematosus;
BRCA	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg05343316	chr1:45956843	TESK2	0.62	12.54	0.44	1.99e-32	Platelet count;
BRCA	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg25358565	chr5:93447407	FAM172A	1.21	18.91	0.6	1.11e-63	Diabetic retinopathy;
BRCA	cis	rs367943	0.604	rs10477502	chr5:113007126	C/T	cg12552261	chr5:112820674	MCC	0.42	8.27	0.31	8.06e-16	Type 2 diabetes;
BRCA	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg05084668	chr3:125655381	ALG1L	-0.59	-10.98	-0.4	7.97e-26	Blood pressure (smoking interaction);
BRCA	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg24977027	chr2:88469347	THNSL2	0.46	7.98	0.3	6.56e-15	Plasma clusterin levels;
BRCA	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.67	-0.61	1.01e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7147624	0.882	rs7141367	chr14:65938641	C/T	cg03016385	chr14:66212404	NA	-0.57	-8.78	-0.33	1.51e-17	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg15704280	chr7:45808275	SEPT13	-0.73	-14.98	-0.51	1.01e-43	Coronary artery disease;
BRCA	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.09	0.49	1.91e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4478858	0.735	rs6679393	chr1:31770944	T/C	cg00250761	chr1:31883323	NA	-0.32	-8.3	-0.31	6.2e-16	Alcohol dependence;
BRCA	cis	rs7766436	0.614	rs2066335	chr6:22566590	C/T	cg13666174	chr6:22585274	NA	-0.41	-8.66	-0.32	3.86e-17	Coronary artery disease;
BRCA	trans	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.21	-0.34	4.77e-19	Neuroticism;
BRCA	cis	rs3772130	0.564	rs28620947	chr3:121585631	G/A	cg20356878	chr3:121714668	ILDR1	0.43	9.9	0.36	1.41e-21	Cognitive performance;
BRCA	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg11833968	chr6:79620685	NA	-0.45	-10.0	-0.37	5.81e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	7.82	0.3	2.17e-14	Putamen volume;
BRCA	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg25173405	chr17:45401733	C17orf57	-0.56	-12.07	-0.43	2.25e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.47	-0.32	1.66e-16	Total body bone mineral density;
BRCA	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.56	8.65	0.32	4.28e-17	HIV-1 control;
BRCA	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg23625390	chr15:77176239	SCAPER	0.41	10.25	0.38	6.33e-23	Blood metabolite levels;
BRCA	cis	rs6840258	1.000	rs7682652	chr4:87913444	C/T	cg08197287	chr4:87952173	AFF1	-0.44	-8.63	-0.32	5.02e-17	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg19678392	chr7:94953810	PON1	-0.43	-8.98	-0.33	3.01e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg00666640	chr1:248458726	OR2T12	0.3	8.39	0.31	3.15e-16	Common traits (Other);
BRCA	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg22903471	chr2:27725779	GCKR	-0.32	-7.85	-0.3	1.77e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
BRCA	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-14.26	-0.49	3e-40	Platelet count;
BRCA	cis	rs12791968	0.765	rs12790121	chr11:45001089	G/A	cg11846598	chr11:44996168	LOC221122	-0.48	-8.67	-0.32	3.63e-17	Inhibitory control;
BRCA	cis	rs3857067	0.806	rs10212784	chr4:95101638	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.34	-0.35	1.56e-19	QT interval;
BRCA	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg06026331	chr20:60912101	LAMA5	-0.41	-8.32	-0.31	5.23e-16	Colorectal cancer;
BRCA	cis	rs13046373	0.535	rs1395775	chr21:32025065	G/A	cg24082983	chr21:31802169	KRTAP13-4	0.32	8.18	0.31	1.58e-15	HDL cholesterol;
BRCA	cis	rs7617773	0.780	rs11720026	chr3:48377921	T/C	cg11946769	chr3:48343235	NME6	0.66	13.21	0.46	2.22e-35	Coronary artery disease;
BRCA	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg24812749	chr6:127587940	RNF146	0.75	16.48	0.55	3.9e-51	Breast cancer;
BRCA	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.62e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7020830	0.931	rs13297576	chr9:37142189	A/C	cg14294708	chr9:37120828	ZCCHC7	1.18	42.39	0.86	7.85e-188	Schizophrenia;
BRCA	cis	rs7586879	0.789	rs67221599	chr2:25131948	T/C	cg01884057	chr2:25150051	NA	0.31	7.86	0.3	1.62e-14	Body mass index;
BRCA	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.75	16.78	0.55	1.29e-52	Lymphocyte counts;
BRCA	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	19.53	0.61	5.76e-67	Platelet count;
BRCA	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.35	-0.49	1.13e-40	Chronic sinus infection;
BRCA	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08219700	chr8:58056026	NA	0.44	7.91	0.3	1.1e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg01689657	chr7:91764605	CYP51A1	0.21	7.86	0.3	1.6e-14	Breast cancer;
BRCA	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg15448220	chr1:150897856	SETDB1	0.35	7.84	0.3	1.89e-14	Melanoma;
BRCA	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg13877915	chr19:58951672	ZNF132	0.39	9.34	0.35	1.61e-19	Uric acid clearance;
BRCA	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.53	-0.47	7.65e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00149659	chr3:10157352	C3orf10	1.03	17.36	0.57	1.41e-55	Alzheimer's disease;
BRCA	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.13	-0.31	2.26e-15	Depression;
BRCA	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg04727924	chr7:799746	HEATR2	-0.54	-9.47	-0.35	5.45e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-28.7	-0.75	4.96e-117	Schizophrenia;
BRCA	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg11764359	chr7:65958608	NA	0.66	11.98	0.43	5.68e-30	Aortic root size;
BRCA	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg00717180	chr2:96193071	NA	0.3	8.35	0.31	4.36e-16	Coronary artery disease;
BRCA	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.5	0.32	1.31e-16	Rheumatoid arthritis;
BRCA	cis	rs2882667	0.858	rs11744972	chr5:138428789	A/G	cg04439458	chr5:138467593	SIL1	-0.37	-9.77	-0.36	4.16e-21	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.59	-15.44	-0.52	6.06e-46	Electrocardiographic conduction measures;
BRCA	trans	rs11165623	0.602	rs7521690	chr1:97015761	A/C	cg10631902	chr5:14652156	NA	-0.43	-12.23	-0.44	4.54e-31	Hip circumference;Waist circumference;
BRCA	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-11.48	-0.41	7.28e-28	Bipolar disorder and schizophrenia;
BRCA	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-15.89	-0.53	3.6e-48	Alzheimer's disease (late onset);
BRCA	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.91	-0.4	1.62e-25	Retinal vascular caliber;
BRCA	cis	rs1904096	0.506	rs8336	chr4:95211610	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-10.06	-0.37	3.44e-22	Type 2 diabetes;
BRCA	cis	rs7903847	0.619	rs9888116	chr10:99159482	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-8.86	-0.33	7.98e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg15640734	chr5:494837	SLC9A3	-0.42	-8.1	-0.31	2.75e-15	Cystic fibrosis severity;
BRCA	cis	rs7707921	0.767	rs178931	chr5:81575601	T/A	cg15871215	chr5:81402204	ATG10	0.36	8.21	0.31	1.26e-15	Breast cancer;
BRCA	cis	rs7072216	0.727	rs7915108	chr10:100164441	T/C	cg26618903	chr10:100175079	PYROXD2	-0.31	-8.67	-0.32	3.68e-17	Metabolite levels;
BRCA	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg12292205	chr6:26970375	C6orf41	-0.63	-9.87	-0.36	1.71e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg11502198	chr6:26597334	ABT1	0.56	11.97	0.43	6.47e-30	Intelligence (multi-trait analysis);
BRCA	trans	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg26043149	chr18:55253948	FECH	-0.37	-8.13	-0.31	2.18e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg08999081	chr20:33150536	PIGU	-0.46	-12.81	-0.45	1.27e-33	Glomerular filtration rate (creatinine);
BRCA	cis	rs3820928	0.934	rs66959645	chr2:227761582	C/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.76	-0.33	1.78e-17	Pulmonary function;
BRCA	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.32	-0.68	1.6e-87	Gut microbiome composition (summer);
BRCA	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12826209	chr6:26865740	GUSBL1	0.59	10.4	0.38	1.65e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg23788917	chr6:8435910	SLC35B3	0.47	10.31	0.38	3.56e-23	Motion sickness;
BRCA	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.17	0.74	4.21e-114	Chronic sinus infection;
BRCA	cis	rs2505998	0.719	rs10900296	chr10:43572507	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.39	-7.82	-0.3	2.2e-14	Hirschsprung disease;
BRCA	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg13770153	chr20:60521292	NA	-0.43	-9.64	-0.36	1.32e-20	Body mass index;
BRCA	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	7.93	0.3	9.75e-15	Tonsillectomy;
BRCA	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.0	21.9	0.65	9.17e-80	Gut microbiome composition (summer);
BRCA	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg26384229	chr12:38710491	ALG10B	0.64	14.93	0.51	1.8e-43	Bladder cancer;
BRCA	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg03929089	chr4:120376271	NA	-0.71	-13.98	-0.48	6.06e-39	Coronary artery disease;
BRCA	cis	rs2742234	0.503	rs1254968	chr10:43691691	C/T	cg15436174	chr10:43711423	RASGEF1A	0.55	11.33	0.41	3.14e-27	Hirschsprung disease;
BRCA	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg00225070	chr15:80189496	MTHFS	0.41	9.85	0.36	2.13e-21	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
BRCA	cis	rs651907	1.000	rs665211	chr3:101600028	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.32	8.25	0.31	8.97e-16	Colorectal cancer;
BRCA	cis	rs6878727	0.707	rs7737676	chr5:123718822	T/A	cg01806427	chr5:123737813	NA	0.39	9.04	0.34	1.85e-18	Breast cancer;
BRCA	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.73	0.57	1.73e-57	Colorectal cancer;
BRCA	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.15	-0.31	1.92e-15	Bipolar disorder;
BRCA	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg07080220	chr10:102295463	HIF1AN	0.55	12.21	0.43	5.97e-31	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	13.05	0.46	1.08e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03264133	chr6:25882463	NA	-0.5	-10.38	-0.38	2e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg09307838	chr4:120376055	NA	0.69	13.72	0.48	1.03e-37	Corneal astigmatism;
BRCA	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.11	0.54	2.88e-49	Fuchs's corneal dystrophy;
BRCA	cis	rs9469890	0.604	rs11756281	chr6:34503446	T/C	cg17674042	chr6:34482479	PACSIN1	-0.33	-8.56	-0.32	8.1e-17	Pubertal anthropometrics;Coronary artery disease;
BRCA	trans	rs783540	0.900	rs4778686	chr15:83310835	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.28	-8.66	-0.32	3.93e-17	Schizophrenia;
BRCA	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06108461	chr20:60628389	TAF4	-0.73	-15.3	-0.52	3e-45	Body mass index;
BRCA	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg18016565	chr1:150552671	MCL1	-0.45	-10.22	-0.37	7.86e-23	Tonsillectomy;
BRCA	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.49	-9.54	-0.35	2.87e-20	Body mass index;
BRCA	cis	rs7953508	0.506	rs3782415	chr12:93967755	T/C	cg18151635	chr12:93972918	NA	-0.46	-9.27	-0.34	2.83e-19	Pubertal anthropometrics;
BRCA	cis	rs281408	0.559	rs281386	chr19:49217305	A/G	cg13540341	chr19:49222985	MAMSTR	0.39	9.98	0.37	6.62e-22	Urinary metabolites (H-NMR features);
BRCA	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.26	0.34	3.13e-19	Tonsillectomy;
BRCA	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg15145296	chr3:125709740	NA	-0.53	-9.12	-0.34	9.41e-19	Blood pressure (smoking interaction);
BRCA	cis	rs9473147	0.516	rs9296564	chr6:47494759	A/G	cg12968598	chr6:47444699	CD2AP	0.44	9.68	0.36	8.85e-21	Platelet distribution width;Mean platelet volume;
BRCA	trans	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg26043149	chr18:55253948	FECH	-0.4	-8.62	-0.32	5.38e-17	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg02951883	chr7:2050386	MAD1L1	-0.6	-15.13	-0.51	2.09e-44	Bipolar disorder and schizophrenia;
BRCA	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg12310025	chr6:25882481	NA	-0.54	-13.09	-0.46	7.43e-35	Blood metabolite levels;
BRCA	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.54	8.48	0.32	1.55e-16	Renal function-related traits (BUN);
BRCA	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-8.97	-0.33	3.23e-18	Total body bone mineral density;
BRCA	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg12935359	chr14:103987150	CKB	-0.64	-14.93	-0.51	1.86e-43	Intelligence (multi-trait analysis);
BRCA	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg20891283	chr12:69753455	YEATS4	0.56	11.45	0.41	9.77e-28	Response to diuretic therapy;
BRCA	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg16606324	chr3:10149918	C3orf24	0.51	9.99	0.37	6.1e-22	Alzheimer's disease;
BRCA	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg19773385	chr1:10388646	KIF1B	-0.36	-7.97	-0.3	7.53e-15	Hepatocellular carcinoma;
BRCA	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.37e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.98	-0.33	2.9e-18	Lung cancer in ever smokers;
BRCA	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg25427524	chr10:38739819	LOC399744	0.59	11.32	0.41	3.36e-27	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	10.65	0.39	1.79e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4363385	0.818	rs10788854	chr1:153002320	C/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.06	-0.34	1.62e-18	Inflammatory skin disease;
BRCA	cis	rs7020830	0.898	rs13284651	chr9:37222681	G/T	cg14294708	chr9:37120828	ZCCHC7	-1.08	-33.02	-0.79	2.84e-140	Schizophrenia;
BRCA	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.57	-11.5	-0.41	5.93e-28	Lymphocyte counts;
BRCA	cis	rs6754311	0.551	rs6739713	chr2:136488978	A/G	cg07169764	chr2:136633963	MCM6	0.49	8.94	0.33	4.01e-18	Mosquito bite size;
BRCA	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg05347473	chr6:146136440	FBXO30	0.39	7.94	0.3	9.39e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs57994353	0.861	rs3812591	chr9:139341612	C/T	cg14019695	chr9:139328340	INPP5E	-0.43	-9.15	-0.34	7.83e-19	Eosinophil counts;Cutaneous squamous cell carcinoma;
BRCA	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg27478167	chr7:817139	HEATR2	-0.42	-9.13	-0.34	9.23e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg05294307	chr14:35346193	BAZ1A	-0.62	-10.53	-0.38	4.88e-24	Psoriasis;
BRCA	cis	rs6750047	0.625	rs59363818	chr2:38261973	A/C	cg07380506	chr2:38303506	CYP1B1	-0.49	-10.61	-0.39	2.39e-24	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg22920501	chr2:26401640	FAM59B	-0.66	-11.6	-0.42	2.35e-28	Gut microbiome composition (summer);
BRCA	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg16606324	chr3:10149918	C3orf24	0.57	10.04	0.37	3.9e-22	Alzheimer's disease;
BRCA	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg07741184	chr6:167504864	NA	0.33	9.82	0.36	2.75e-21	Primary biliary cholangitis;
BRCA	cis	rs12549902	0.800	rs7825337	chr8:41507237	C/T	cg21772509	chr8:41503840	NKX6-3	0.44	10.39	0.38	1.88e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
BRCA	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg24558204	chr6:135376177	HBS1L	0.45	12.42	0.44	7.31e-32	Red blood cell count;
BRCA	cis	rs7903847	0.642	rs10882908	chr10:99134970	T/C	cg08345082	chr10:99160200	RRP12	-0.29	-8.6	-0.32	6.17e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg03354898	chr7:1950403	MAD1L1	0.38	8.2	0.31	1.35e-15	Schizophrenia;
BRCA	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg10556349	chr10:835070	NA	0.63	8.66	0.32	3.75e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg11752832	chr7:134001865	SLC35B4	0.53	13.73	0.48	8.72e-38	Mean platelet volume;
BRCA	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg06766960	chr11:133703094	NA	-0.63	-13.39	-0.47	3.35e-36	Childhood ear infection;
BRCA	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg08847533	chr14:75593920	NEK9	0.77	18.07	0.58	2.75e-59	Height;
BRCA	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.58	-0.61	3.27e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2625529	0.730	rs2957737	chr15:72265410	A/G	cg16672083	chr15:72433130	SENP8	0.72	16.86	0.55	4.94e-53	Red blood cell count;
BRCA	trans	rs1459104	1.000	rs12577374	chr11:55216921	A/T	cg15704280	chr7:45808275	SEPT13	0.65	8.15	0.31	1.85e-15	Body mass index;
BRCA	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg03146154	chr1:46216737	IPP	0.54	12.02	0.43	3.92e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	13.73	0.48	8.4e-38	Lymphocyte counts;
BRCA	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg04511125	chr2:88470314	THNSL2	0.79	11.47	0.41	8.16e-28	Plasma clusterin levels;
BRCA	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg18230493	chr5:56204884	C5orf35	-0.73	-14.83	-0.51	5.63e-43	Initial pursuit acceleration;
BRCA	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-15.94	-0.53	2.15e-48	Alzheimer's disease (late onset);
BRCA	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg03060546	chr3:49711283	APEH	0.6	9.83	0.36	2.5e-21	Menarche (age at onset);
BRCA	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg03146154	chr1:46216737	IPP	0.45	10.01	0.37	5.27e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg08859206	chr1:53392774	SCP2	-0.52	-11.34	-0.41	2.72e-27	Monocyte count;
BRCA	cis	rs4363385	0.818	rs4452994	chr1:152986871	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.41	-0.32	2.64e-16	Inflammatory skin disease;
BRCA	cis	rs13046373	0.508	rs13048637	chr21:31999055	T/G	cg22337977	chr21:31811175	KRTAP15-1	0.33	8.0	0.3	5.71e-15	HDL cholesterol;
BRCA	cis	rs6066825	0.644	rs6019386	chr20:47326440	T/G	cg18078177	chr20:47281410	PREX1	0.4	10.06	0.37	3.39e-22	Colorectal cancer;
BRCA	cis	rs698833	0.509	rs1946932	chr2:44543125	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	7.97	0.3	7.31e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg09307838	chr4:120376055	NA	0.52	10.67	0.39	1.49e-24	Educational attainment;
BRCA	cis	rs495337	1.000	rs495337	chr20:48522330	G/A	cg17835207	chr20:48524531	SPATA2	-0.57	-12.89	-0.45	5.73e-34	Psoriasis;
BRCA	cis	rs6700896	0.864	rs11208718	chr1:66158995	G/A	cg04111102	chr1:66153794	NA	0.34	8.5	0.32	1.3e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg27535305	chr1:53392650	SCP2	0.33	8.11	0.31	2.53e-15	Monocyte count;
BRCA	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg25173405	chr17:45401733	C17orf57	0.52	11.12	0.4	2.15e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7851660	0.967	rs12348304	chr9:100611233	T/C	cg13688889	chr9:100608707	NA	-0.36	-8.7	-0.33	2.81e-17	Strep throat;
BRCA	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.09e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg17211192	chr8:82754475	SNX16	0.64	12.03	0.43	3.56e-30	Diastolic blood pressure;
BRCA	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg13319975	chr6:146136371	FBXO30	-0.4	-8.95	-0.33	3.7e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18357526	chr6:26021779	HIST1H4A	0.5	8.99	0.34	2.69e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg01528321	chr10:82214614	TSPAN14	0.83	18.2	0.58	6.31e-60	Post bronchodilator FEV1;
BRCA	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11644478	chr21:40555479	PSMG1	0.84	19.05	0.6	1.94e-64	Cognitive function;
BRCA	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg06784218	chr1:46089804	CCDC17	0.45	10.73	0.39	8.12e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6446731	0.636	rs2157091	chr4:3273099	G/A	cg08886695	chr4:3369023	RGS12	-0.37	-9.7	-0.36	7.62e-21	Mean platelet volume;
BRCA	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg20203395	chr5:56204925	C5orf35	-0.43	-9.62	-0.36	1.45e-20	Initial pursuit acceleration;
BRCA	trans	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg25835954	chr13:50160062	RCBTB1	0.44	8.66	0.32	3.74e-17	Cortisol levels (saliva);
BRCA	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.97	0.33	3.23e-18	Tonsillectomy;
BRCA	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-13.41	-0.47	2.55e-36	Response to antipsychotic treatment;
BRCA	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg26384229	chr12:38710491	ALG10B	0.65	15.55	0.52	1.7e-46	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4588572	0.643	rs1560197	chr5:77768302	T/C	cg11547950	chr5:77652471	NA	-0.49	-8.64	-0.32	4.55e-17	Triglycerides;
BRCA	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg18252515	chr7:66147081	NA	-1.06	-15.58	-0.52	1.26e-46	Diabetic kidney disease;
BRCA	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.45	-16.57	-0.55	1.52e-51	Diastolic blood pressure;
BRCA	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg17063962	chr7:91808500	NA	0.51	11.01	0.4	6.31e-26	Breast cancer;
BRCA	cis	rs13046373	0.508	rs13048637	chr21:31999055	T/G	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.34	0.35	1.62e-19	HDL cholesterol;
BRCA	cis	rs939658	0.805	rs35832166	chr15:79417994	G/T	cg17916960	chr15:79447300	NA	-0.45	-11.05	-0.4	4.22e-26	Refractive error;
BRCA	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg12463550	chr7:65579703	CRCP	0.37	7.92	0.3	1.03e-14	Aortic root size;
BRCA	cis	rs10056811	0.538	rs3923323	chr5:74372141	C/T	cg19683494	chr5:74908142	NA	-0.55	-8.53	-0.32	1.03e-16	Coronary artery disease;
BRCA	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg22963979	chr7:1858916	MAD1L1	-0.45	-9.06	-0.34	1.51e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.51	-0.47	9.38e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs4664304	0.658	rs2667015	chr2:160868586	T/C	cg14819504	chr2:160761413	LY75	-0.33	-8.14	-0.31	2.13e-15	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs1712517	1.000	rs1163084	chr10:105039048	T/C	cg05636881	chr10:105038444	INA	0.36	8.35	0.31	4.15e-16	Migraine;
BRCA	cis	rs1949733	1.000	rs3103067	chr4:8511223	A/G	cg11789530	chr4:8429930	ACOX3	0.62	15.84	0.53	6.63e-48	Response to antineoplastic agents;
BRCA	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg13770153	chr20:60521292	NA	-0.4	-9.47	-0.35	5.12e-20	Body mass index;
BRCA	cis	rs4845875	0.626	rs11121827	chr1:11832100	T/A	cg24844545	chr1:11908347	NPPA	0.31	7.85	0.3	1.78e-14	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs7264396	1.000	rs224440	chr20:34159447	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-10.68	-0.39	1.3e-24	Total cholesterol levels;
BRCA	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg16386425	chr10:429943	DIP2C	0.42	9.04	0.34	1.88e-18	Psychosis in Alzheimer's disease;
BRCA	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg04727924	chr7:799746	HEATR2	-0.58	-11.35	-0.41	2.56e-27	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03264133	chr6:25882463	NA	0.41	8.76	0.33	1.79e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.43	-10.94	-0.4	1.14e-25	Schizophrenia;
BRCA	trans	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg19862616	chr7:65841803	NCRNA00174	0.79	24.67	0.7	6.38e-95	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.3	8.18	0.31	1.53e-15	Birth weight;
BRCA	cis	rs7301016	0.901	rs12369961	chr12:62966584	C/T	cg11441379	chr12:63026424	NA	0.46	8.69	0.32	3.13e-17	IgG glycosylation;
BRCA	cis	rs6882046	0.513	rs681446	chr5:88054292	C/T	cg22951263	chr5:87985283	NA	0.39	11.18	0.4	1.21e-26	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg02891314	chr5:179741120	GFPT2	-0.66	-13.28	-0.47	9.96e-36	Height;
BRCA	cis	rs208520	0.690	rs207740	chr6:66764132	T/G	cg07460842	chr6:66804631	NA	1.0	20.0	0.62	1.76e-69	Exhaled nitric oxide output;
BRCA	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	16.89	0.56	3.36e-53	Alzheimer's disease;
BRCA	cis	rs9649465	1.000	rs6466881	chr7:123337734	G/C	cg04330084	chr7:123175371	IQUB	-0.3	-8.32	-0.31	5.51e-16	Migraine;
BRCA	cis	rs490234	0.812	rs4838285	chr9:128446888	C/T	cg14078157	chr9:128172775	NA	-0.34	-8.05	-0.3	4.03e-15	Mean arterial pressure;
BRCA	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg11814155	chr7:99998594	ZCWPW1	0.56	9.51	0.35	3.79e-20	Platelet count;
BRCA	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.62	-0.36	1.46e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs17253792	0.822	rs76819679	chr14:56134672	C/G	cg01858014	chr14:56050164	KTN1	-0.74	-9.16	-0.34	7.09e-19	Putamen volume;
BRCA	cis	rs9837602	0.745	rs9816538	chr3:99907924	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.51	8.18	0.31	1.58e-15	Breast cancer;
BRCA	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.88	0.33	6.89e-18	Tonsillectomy;
BRCA	cis	rs2742234	0.590	rs1254965	chr10:43689853	C/T	cg15436174	chr10:43711423	RASGEF1A	0.55	11.25	0.41	6.37e-27	Hirschsprung disease;
BRCA	cis	rs4722166	1.000	rs4722166	chr7:22738762	G/T	cg26061582	chr7:22766209	IL6	0.39	7.92	0.3	1.04e-14	Lung cancer;
BRCA	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg06064525	chr11:970664	AP2A2	0.49	16.35	0.54	1.82e-50	Alzheimer's disease (late onset);
BRCA	cis	rs35661897	0.920	rs12476220	chr2:227312391	A/C	cg03426602	chr2:227312417	NA	0.53	8.76	0.33	1.73e-17	Urinary tract infection frequency;
BRCA	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg08601574	chr20:25228251	PYGB	0.35	8.39	0.31	3.21e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs858239	0.539	rs2141305	chr7:23191899	T/C	cg23682824	chr7:23144976	KLHL7	0.41	10.94	0.4	1.21e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.41	0.35	8.9e-20	Tonsillectomy;
BRCA	cis	rs7095944	0.583	rs12218394	chr10:126480591	G/C	cg08799069	chr10:126477246	METTL10	-0.39	-9.32	-0.35	1.89e-19	Asthma;
BRCA	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	13.82	0.48	3.31e-38	Eosinophil percentage of white cells;
BRCA	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg23711669	chr6:146136114	FBXO30	0.77	17.89	0.58	2.48e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1020064	0.636	rs2576726	chr2:105936412	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.42	8.2	0.31	1.3e-15	AIDS;
BRCA	cis	rs858239	0.600	rs2072369	chr7:23146189	A/G	cg23682824	chr7:23144976	KLHL7	0.45	12.18	0.43	7.48e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg23625390	chr15:77176239	SCAPER	-0.54	-13.89	-0.48	1.67e-38	Blood metabolite levels;
BRCA	trans	rs800082	0.671	rs800099	chr3:144398547	A/T	cg24215973	chr2:240111563	HDAC4	-0.64	-14.59	-0.5	8.35e-42	Smoking behavior;
BRCA	cis	rs758324	0.947	rs2133707	chr5:131181280	C/T	cg06307176	chr5:131281290	NA	0.52	10.09	0.37	2.49e-22	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg00409905	chr10:38381863	ZNF37A	-0.47	-9.82	-0.36	2.81e-21	Breast cancer;
BRCA	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10802521	chr3:52805072	NEK4	-0.3	-7.82	-0.3	2.16e-14	Electroencephalogram traits;
BRCA	cis	rs4074536	0.574	rs10801970	chr1:116287651	G/A	cg21648376	chr1:116311395	CASQ2	-0.48	-8.43	-0.32	2.24e-16	QRS duration;
BRCA	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg01528321	chr10:82214614	TSPAN14	0.64	13.63	0.47	2.58e-37	Post bronchodilator FEV1;
BRCA	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07636037	chr3:49044803	WDR6	0.7	14.99	0.51	9.83e-44	Menarche (age at onset);
BRCA	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26378065	chr17:18585709	ZNF286B	0.43	9.12	0.34	9.28e-19	Educational attainment (years of education);
BRCA	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-9.74	-0.36	5.28e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	trans	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.53	0.32	1.05e-16	Corneal astigmatism;
BRCA	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg08999081	chr20:33150536	PIGU	-0.34	-8.8	-0.33	1.26e-17	Glomerular filtration rate (creatinine);
BRCA	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg17470723	chr8:74884337	TCEB1	0.4	8.64	0.32	4.64e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg06627628	chr2:24431161	ITSN2	-0.41	-8.53	-0.32	1.04e-16	Asthma;
BRCA	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg06212747	chr3:49208901	KLHDC8B	0.46	9.25	0.34	3.19e-19	Parkinson's disease;
BRCA	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg08477640	chr19:41863820	B9D2	0.38	7.92	0.3	1.09e-14	Migraine;Coronary artery disease;
BRCA	cis	rs938554	0.577	rs7683856	chr4:10000947	A/G	cg00071950	chr4:10020882	SLC2A9	0.42	7.9	0.3	1.26e-14	Blood metabolite levels;
BRCA	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg03342759	chr3:160939853	NMD3	0.66	12.92	0.46	4.26e-34	Parkinson's disease;
BRCA	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg25427524	chr10:38739819	LOC399744	0.52	9.61	0.36	1.58e-20	Obesity (extreme);
BRCA	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg26061582	chr7:22766209	IL6	0.34	7.95	0.3	8.54e-15	Lung cancer;
BRCA	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg00814883	chr7:100076585	TSC22D4	-0.49	-10.05	-0.37	3.65e-22	Platelet count;
BRCA	cis	rs2580764	0.566	rs2972075	chr2:55292322	T/G	cg09592903	chr2:55203963	RTN4	0.36	9.25	0.34	3.25e-19	Mean platelet volume;
BRCA	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg13628971	chr7:2884303	GNA12	-0.49	-10.01	-0.37	5.25e-22	Height;
BRCA	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg00745463	chr17:30367425	LRRC37B	-0.54	-8.89	-0.33	6.17e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs2066819	1.000	rs59626664	chr12:56636975	C/G	cg26714650	chr12:56694279	CS	-1.18	-15.33	-0.52	2.13e-45	Psoriasis vulgaris;
BRCA	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg07541023	chr7:19748670	TWISTNB	0.65	10.86	0.39	2.52e-25	Thyroid stimulating hormone;
BRCA	cis	rs8032158	0.963	rs1912402	chr15:56161919	C/T	cg02198044	chr15:56286336	NEDD4	-0.37	-8.93	-0.33	4.47e-18	Keloid;
BRCA	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg01114163	chr5:1856713	NA	-0.35	-7.89	-0.3	1.29e-14	Cardiovascular disease risk factors;
BRCA	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg18252515	chr7:66147081	NA	-0.85	-12.36	-0.44	1.23e-31	Diabetic kidney disease;
BRCA	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.17	0.31	1.67e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg13770153	chr20:60521292	NA	-0.45	-10.75	-0.39	7.07e-25	Body mass index;
BRCA	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	11.23	0.41	7.85e-27	Schizophrenia;
BRCA	cis	rs12618769	0.597	rs2278212	chr2:99136266	T/C	cg10123293	chr2:99228465	UNC50	0.41	8.24	0.31	9.93e-16	Bipolar disorder;
BRCA	cis	rs16958440	1.000	rs62096466	chr18:44636171	T/G	cg17192377	chr18:44677553	HDHD2	0.67	9.8	0.36	3.33e-21	Sitting height ratio;
BRCA	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.89	0.3	1.31e-14	Aortic root size;
BRCA	trans	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg11693508	chr17:37793320	STARD3	0.39	8.14	0.31	2.09e-15	Neuroticism;
BRCA	trans	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.99	-0.34	2.81e-18	Triglycerides;
BRCA	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.83e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg11366901	chr6:160182831	ACAT2	0.79	15.3	0.52	3.03e-45	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs250677	0.522	rs56309414	chr5:148376026	C/G	cg18129178	chr5:148520854	ABLIM3	-0.55	-10.42	-0.38	1.4e-23	Breast cancer;
BRCA	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg03146154	chr1:46216737	IPP	0.52	11.61	0.42	2.16e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2599510	0.744	rs2254106	chr2:32768797	G/A	cg02381751	chr2:32503542	YIPF4	0.48	9.94	0.37	9.73e-22	Interleukin-18 levels;
BRCA	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.77	16.95	0.56	1.74e-53	Cognitive ability;
BRCA	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg18512352	chr11:47633146	NA	-0.33	-8.0	-0.3	5.8e-15	Subjective well-being;
BRCA	cis	rs6429082	0.510	rs2789369	chr1:235503515	A/G	cg26050004	chr1:235667680	B3GALNT2	0.32	7.85	0.3	1.71e-14	Adiposity;
BRCA	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg16339924	chr4:17578868	LAP3	0.66	16.52	0.55	2.48e-51	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1421811	0.532	rs17540044	chr5:32692238	C/G	cg16267343	chr5:32710456	NPR3	-0.64	-12.52	-0.44	2.47e-32	Blood pressure;
BRCA	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-11.94	-0.43	7.99e-30	Gut microbiome composition (summer);
BRCA	cis	rs534126	0.736	rs10239488	chr7:142949599	C/G	cg21852589	chr7:142981689	TMEM139	0.44	10.06	0.37	3.23e-22	Cancer;
BRCA	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg12463550	chr7:65579703	CRCP	-0.37	-8.04	-0.3	4.46e-15	Aortic root size;
BRCA	cis	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg17469321	chr7:55412551	NA	0.51	9.68	0.36	8.77e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03713592	chr11:72463424	ARAP1	0.74	11.35	0.41	2.45e-27	Type 2 diabetes;
BRCA	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg02733842	chr7:1102375	C7orf50	-0.71	-12.78	-0.45	1.85e-33	Bronchopulmonary dysplasia;
BRCA	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg04013093	chr6:42928303	GNMT	-0.28	-8.65	-0.32	4.31e-17	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs30380	0.632	rs26496	chr5:96137882	A/G	cg16492584	chr5:96139282	ERAP1	-0.47	-11.27	-0.41	5.16e-27	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg26384229	chr12:38710491	ALG10B	0.67	15.75	0.53	1.84e-47	Bladder cancer;
BRCA	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg13010199	chr12:38710504	ALG10B	0.55	12.16	0.43	9.04e-31	Heart rate;
BRCA	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg04362960	chr10:104952993	NT5C2	0.4	9.67	0.36	9.97e-21	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs4363385	0.747	rs61811427	chr1:152968419	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-8.8	-0.33	1.23e-17	Inflammatory skin disease;
BRCA	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg20007245	chr22:24372913	LOC391322	0.51	10.12	0.37	1.91e-22	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	trans	rs61931739	0.513	rs4931760	chr12:33898361	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.66	0.36	1.08e-20	Morning vs. evening chronotype;
BRCA	trans	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-18.36	-0.59	9.01e-61	Exhaled nitric oxide output;
BRCA	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg20587970	chr11:113659929	NA	-0.85	-16.39	-0.54	1.14e-50	Hip circumference adjusted for BMI;
BRCA	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg13647721	chr17:30228624	UTP6	0.5	8.7	0.33	2.89e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11890956	chr21:40555474	PSMG1	1.07	30.18	0.77	4.67e-125	Cognitive function;
BRCA	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg16473166	chr22:50639996	SELO	-0.47	-10.66	-0.39	1.57e-24	Obesity-related traits;
BRCA	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.33	-8.37	-0.31	3.65e-16	Total body bone mineral density;
BRCA	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	14.07	0.49	2.2e-39	Lymphocyte counts;
BRCA	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-11.98	-0.43	5.89e-30	Developmental language disorder (linguistic errors);
BRCA	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg10223061	chr2:219282414	VIL1	0.3	8.77	0.33	1.61e-17	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg20203395	chr5:56204925	C5orf35	-0.5	-10.15	-0.37	1.54e-22	Initial pursuit acceleration;
BRCA	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	trans	rs877282	0.786	rs11253392	chr10:788768	G/A	cg22713356	chr15:30763199	NA	1.42	28.55	0.75	3.22e-116	Uric acid levels;
BRCA	cis	rs2191566	0.576	rs381628	chr19:44494333	T/C	cg20607764	chr19:44506953	ZNF230	0.37	7.98	0.3	6.74e-15	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9796	0.558	rs7166905	chr15:41514876	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.36	-7.85	-0.3	1.75e-14	Menopause (age at onset);
BRCA	cis	rs6815814	0.950	rs5743794	chr4:38832727	C/T	cg02016764	chr4:38805732	TLR1	-0.52	-8.09	-0.3	2.92e-15	Breast cancer;
BRCA	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg24812749	chr6:127587940	RNF146	0.86	19.78	0.62	2.55e-68	Breast cancer;
BRCA	cis	rs701145	0.585	rs959376	chr3:153866707	A/T	cg12800244	chr3:153838788	SGEF	0.57	7.91	0.3	1.12e-14	Coronary artery disease;
BRCA	cis	rs7631605	0.935	rs6550447	chr3:37078280	G/C	cg15934958	chr3:37212084	LRRFIP2	0.42	9.77	0.36	4.05e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9633740	1.000	rs10748526	chr10:82273079	T/C	cg01528321	chr10:82214614	TSPAN14	0.84	16.9	0.56	2.95e-53	Post bronchodilator FEV1;
BRCA	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-8.63	-0.32	4.79e-17	Schizophrenia;
BRCA	cis	rs7555523	0.887	rs2814471	chr1:165739598	C/T	cg24409356	chr1:165738333	TMCO1	0.5	8.28	0.31	6.99e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg10253484	chr15:75165896	SCAMP2	-0.52	-9.92	-0.37	1.1e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	12.58	0.45	1.41e-32	Menarche (age at onset);
BRCA	cis	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-10.39	-0.38	1.86e-23	Resting heart rate;
BRCA	trans	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.62	0.39	2.17e-24	Motion sickness;
BRCA	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg18132916	chr6:79620363	NA	-0.49	-11.06	-0.4	3.87e-26	Intelligence (multi-trait analysis);
BRCA	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.57	0.35	2.29e-20	Morning vs. evening chronotype;
BRCA	cis	rs12760731	0.720	rs34194793	chr1:178329065	G/T	cg00404053	chr1:178313656	RASAL2	0.62	8.48	0.32	1.55e-16	Obesity-related traits;
BRCA	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg01884057	chr2:25150051	NA	0.35	9.26	0.34	2.97e-19	Body mass index;
BRCA	trans	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg26384229	chr12:38710491	ALG10B	0.48	10.6	0.39	2.73e-24	Morning vs. evening chronotype;
BRCA	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11890956	chr21:40555474	PSMG1	-0.82	-19.39	-0.61	3.15e-66	Cognitive function;
BRCA	cis	rs7215564	0.818	rs34760119	chr17:78604583	G/T	cg06153925	chr17:78755379	RPTOR	0.41	7.87	0.3	1.52e-14	Myopia (pathological);
BRCA	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00166722	chr3:10149974	C3orf24	0.59	11.74	0.42	5.94e-29	Alzheimer's disease;
BRCA	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg19187155	chr2:232395269	NMUR1	0.69	17.47	0.57	3.91e-56	Height;
BRCA	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.65	0.36	1.14e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4363385	0.818	rs409986	chr1:153014741	A/C	cg24667326	chr1:152973720	SPRR3	0.32	8.64	0.32	4.63e-17	Inflammatory skin disease;
BRCA	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg23711669	chr6:146136114	FBXO30	0.64	14.98	0.51	1.1e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-13.42	-0.47	2.3e-36	Response to antipsychotic treatment;
BRCA	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg26384229	chr12:38710491	ALG10B	0.43	10.27	0.38	5.36e-23	Heart rate;
BRCA	cis	rs2795502	0.554	rs1620395	chr10:43341185	G/A	cg20628663	chr10:43360327	NA	-0.49	-11.09	-0.4	3.07e-26	Blood protein levels;
BRCA	cis	rs7903847	0.642	rs2297668	chr10:99160046	C/T	cg08345082	chr10:99160200	RRP12	-0.3	-8.74	-0.33	2.11e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg13114125	chr14:105738426	BRF1	-0.48	-10.32	-0.38	3.26e-23	Mean platelet volume;Platelet distribution width;
BRCA	trans	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg16141378	chr3:129829833	LOC729375	-0.33	-8.16	-0.31	1.81e-15	Mood instability;
BRCA	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg04944784	chr2:26401820	FAM59B	0.89	14.13	0.49	1.26e-39	Gut microbiome composition (summer);
BRCA	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg04025307	chr7:1156635	C7orf50	0.51	8.34	0.31	4.59e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.57	-0.47	4.99e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg12615879	chr12:58013172	SLC26A10	0.28	7.92	0.3	1.03e-14	Multiple sclerosis;
BRCA	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg25930673	chr12:123319894	HIP1R	-0.52	-7.93	-0.3	1.02e-14	Schizophrenia;
BRCA	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg08236123	chr12:132219811	SFRS8	0.44	9.5	0.35	4.14e-20	Migraine;
BRCA	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg21573476	chr21:45109991	RRP1B	-0.35	-9.09	-0.34	1.24e-18	Mean corpuscular volume;
BRCA	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs877282	0.945	rs877280	chr10:771599	C/T	cg17470449	chr10:769945	NA	0.53	9.25	0.34	3.45e-19	Uric acid levels;
BRCA	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg23260525	chr10:116636907	FAM160B1	0.31	8.18	0.31	1.55e-15	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg23750338	chr8:142222470	SLC45A4	-0.5	-12.44	-0.44	5.54e-32	Immature fraction of reticulocytes;
BRCA	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg27170947	chr2:26402098	FAM59B	-0.81	-12.87	-0.45	6.96e-34	Gut microbiome composition (summer);
BRCA	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg01304814	chr3:48885189	PRKAR2A	0.7	7.94	0.3	9.33e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs2479724	0.935	rs1887718	chr6:41857691	C/T	cg17623882	chr6:41773611	USP49	-0.39	-10.6	-0.39	2.79e-24	Menarche (age at onset);
BRCA	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.14	0.37	1.62e-22	Bladder cancer;
BRCA	cis	rs10496034	1.000	rs4671993	chr2:55141989	T/C	cg16098955	chr2:55172992	EML6	0.52	9.08	0.34	1.38e-18	Refractive astigmatism;
BRCA	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	8.38	0.31	3.26e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg11764359	chr7:65958608	NA	-0.67	-14.9	-0.51	2.48e-43	Aortic root size;
BRCA	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.62	-8.33	-0.31	4.92e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs12618769	0.597	rs10514774	chr2:99028695	A/G	cg10123293	chr2:99228465	UNC50	0.4	7.97	0.3	7.5e-15	Bipolar disorder;
BRCA	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg17063962	chr7:91808500	NA	0.53	12.5	0.44	3.23e-32	Breast cancer;
BRCA	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg08859206	chr1:53392774	SCP2	0.41	8.03	0.3	4.78e-15	Monocyte count;
BRCA	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg23711669	chr6:146136114	FBXO30	0.64	14.79	0.5	8.86e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg26373071	chr5:1325741	CLPTM1L	0.5	12.35	0.44	1.36e-31	Lung cancer;
BRCA	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg12062639	chr20:23401060	NAPB	0.96	13.42	0.47	2.36e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg21770322	chr7:97807741	LMTK2	0.44	11.53	0.41	4.62e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	19.18	0.6	4.23e-65	Alzheimer's disease (late onset);
BRCA	cis	rs2882667	0.893	rs7717375	chr5:138291405	A/G	cg04439458	chr5:138467593	SIL1	-0.31	-8.31	-0.31	5.61e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-11.89	-0.43	1.36e-29	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	trans	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg06521331	chr12:34319734	NA	-0.41	-8.16	-0.31	1.76e-15	Bladder cancer;
BRCA	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg13256891	chr4:100009986	ADH5	-0.53	-9.87	-0.36	1.82e-21	Alcohol dependence;
BRCA	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg04362960	chr10:104952993	NT5C2	0.41	9.86	0.36	1.85e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg24675658	chr1:53192096	ZYG11B	-0.52	-11.39	-0.41	1.74e-27	Monocyte count;
BRCA	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg04166393	chr7:2884313	GNA12	0.39	8.4	0.32	2.83e-16	Height;
BRCA	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg00083206	chr6:110721305	DDO	0.38	9.03	0.34	1.97e-18	Platelet distribution width;
BRCA	cis	rs495337	0.509	rs8123655	chr20:48518254	G/A	cg17835207	chr20:48524531	SPATA2	0.42	8.95	0.33	3.82e-18	Psoriasis;
BRCA	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02176678	chr2:219576539	TTLL4	-0.51	-12.93	-0.46	4.09e-34	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs73086581	1.000	rs17215054	chr20:3944779	T/C	cg02187196	chr20:3869020	PANK2	0.54	9.62	0.36	1.48e-20	Response to antidepressants in depression;
BRCA	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg15448220	chr1:150897856	SETDB1	0.35	7.98	0.3	6.93e-15	Melanoma;
BRCA	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg27446573	chr6:127587934	RNF146	0.89	20.5	0.63	3.86e-72	Breast cancer;
BRCA	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.18	-0.34	6e-19	Bipolar disorder;
BRCA	cis	rs13095912	1.000	rs13100034	chr3:185318804	G/A	cg11274856	chr3:185301563	NA	0.34	8.53	0.32	1.06e-16	Systolic blood pressure;
BRCA	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-10.25	-0.38	6.02e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-8.23	-0.31	1.04e-15	Electroencephalogram traits;
BRCA	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg06784218	chr1:46089804	CCDC17	0.44	10.65	0.39	1.65e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg03954927	chr1:10346856	KIF1B	0.43	13.44	0.47	2e-36	Hepatocellular carcinoma;
BRCA	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-11.16	-0.4	1.56e-26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg11707556	chr5:10655725	ANKRD33B	0.42	9.47	0.35	5.41e-20	Coronary artery disease;
BRCA	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg04709771	chr16:646395	RAB40C	0.44	11.12	0.4	2.31e-26	Height;
BRCA	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg21770322	chr7:97807741	LMTK2	0.41	10.97	0.4	8.81e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg06623918	chr6:96969491	KIAA0776	0.86	23.81	0.69	3.28e-90	Headache;
BRCA	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg15017067	chr4:17643749	FAM184B	0.28	8.62	0.32	5.26e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg25214090	chr10:38739885	LOC399744	0.51	11.56	0.42	3.34e-28	Corneal astigmatism;
BRCA	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.54	8.51	0.32	1.26e-16	Gut microbiome composition (summer);
BRCA	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.75	-13.02	-0.46	1.58e-34	Platelet count;
BRCA	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg11764359	chr7:65958608	NA	0.63	10.9	0.4	1.68e-25	Aortic root size;
BRCA	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.58	0.39	3.38e-24	Motion sickness;
BRCA	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg01802117	chr1:53393560	SCP2	0.41	8.59	0.32	6.79e-17	Monocyte count;
BRCA	cis	rs72772090	0.539	rs56319744	chr5:96141938	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-11.66	-0.42	1.25e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00339695	chr16:24857497	SLC5A11	0.34	7.89	0.3	1.35e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	4.98e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg19784903	chr17:45786737	TBKBP1	0.36	8.49	0.32	1.47e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg23422044	chr7:1970798	MAD1L1	-0.47	-9.92	-0.37	1.17e-21	Bipolar disorder;
BRCA	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg17063962	chr7:91808500	NA	0.59	13.94	0.48	9.79e-39	Breast cancer;
BRCA	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21385522	chr1:16154831	NA	0.46	8.46	0.32	1.87e-16	Dilated cardiomyopathy;
BRCA	cis	rs4642101	0.824	rs9825233	chr3:12843368	A/G	cg24848339	chr3:12840334	CAND2	-0.41	-10.46	-0.38	9.49e-24	QRS complex (12-leadsum);
BRCA	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg23711669	chr6:146136114	FBXO30	0.63	14.67	0.5	3.38e-42	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs4631830	0.863	rs2843550	chr10:51521452	C/T	cg20129853	chr10:51489980	NA	-0.29	-7.9	-0.3	1.19e-14	Prostate-specific antigen levels;
BRCA	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.92	0.4	1.43e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg26384229	chr12:38710491	ALG10B	0.7	15.96	0.53	1.67e-48	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs3772130	0.923	rs28674947	chr3:121529421	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.91	0.4	1.63e-25	Cognitive performance;
BRCA	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg15605315	chr1:45957053	TESK2	0.46	9.24	0.34	3.67e-19	High light scatter reticulocyte count;
BRCA	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.59	12.99	0.46	2.19e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	21.61	0.65	3.58e-78	Platelet count;
BRCA	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02176678	chr2:219576539	TTLL4	0.46	12.15	0.43	1.04e-30	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg26384229	chr12:38710491	ALG10B	0.69	16.02	0.54	8.05e-49	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg12292205	chr6:26970375	C6orf41	-0.6	-14.18	-0.49	7.28e-40	Schizophrenia;
BRCA	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg00376283	chr12:123451042	ABCB9	0.54	10.8	0.39	4.16e-25	Neutrophil percentage of white cells;
BRCA	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg05623727	chr3:50126028	RBM5	0.43	10.09	0.37	2.63e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg26384229	chr12:38710491	ALG10B	0.67	15.12	0.51	2.21e-44	Resting heart rate;
BRCA	trans	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg22153745	chr1:153894579	GATAD2B	-0.49	-9.5	-0.35	4.18e-20	Total cholesterol levels;
BRCA	cis	rs3770081	1.000	rs17584578	chr2:86307624	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.58	8.28	0.31	7.12e-16	Facial emotion recognition (sad faces);
BRCA	cis	rs4321325	0.733	rs4284779	chr2:127946500	T/C	cg11380483	chr2:127933992	NA	0.43	8.47	0.32	1.69e-16	Protein C levels;
BRCA	cis	rs4766646	0.600	rs3782893	chr12:110293678	G/C	cg01252219	chr12:110302105	GLTP	0.36	7.98	0.3	6.65e-15	Metabolite levels (MHPG);
BRCA	cis	rs1165668	0.727	rs2722176	chr12:104313943	T/C	cg21863207	chr12:104234989	NT5DC3	0.39	7.99	0.3	6.5e-15	Coronary heart disease (SNP X SNP interaction);
BRCA	cis	rs4664304	0.620	rs1828480	chr2:160720384	G/A	cg01092293	chr2:160761427	LY75	0.36	8.51	0.32	1.24e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs2840044	0.711	rs225301	chr17:33922411	T/A	cg19694781	chr19:47549865	TMEM160	-0.75	-15.59	-0.52	1.11e-46	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg25036284	chr2:26402008	FAM59B	-0.64	-10.63	-0.39	2.11e-24	Gut microbiome composition (summer);
BRCA	cis	rs507080	0.845	rs510408	chr11:118558901	G/C	cg08498647	chr11:118550644	TREH	-0.38	-8.26	-0.31	8.53e-16	Serum metabolite levels;
BRCA	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	11.44	0.41	1.08e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg08885076	chr2:99613938	TSGA10	-0.6	-13.44	-0.47	1.91e-36	Chronic sinus infection;
BRCA	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg08999081	chr20:33150536	PIGU	0.47	12.95	0.46	3.15e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs965469	0.947	rs965470	chr20:3381588	C/G	cg25506879	chr20:3388711	C20orf194	-0.52	-10.22	-0.37	8.29e-23	IFN-related cytopenia;
BRCA	trans	rs61931739	0.963	rs3912355	chr12:34079616	A/G	cg26384229	chr12:38710491	ALG10B	0.41	9.14	0.34	8.15e-19	Morning vs. evening chronotype;
BRCA	cis	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg09307838	chr4:120376055	NA	0.43	8.98	0.33	3.01e-18	Diastolic blood pressure;
BRCA	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg09754948	chr16:28834200	ATXN2L	0.46	9.12	0.34	9.55e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg04691961	chr3:161091175	C3orf57	-0.42	-10.17	-0.37	1.23e-22	Morning vs. evening chronotype;
BRCA	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs701145	0.556	rs191651	chr3:153973887	T/G	cg16511985	chr3:153974050	SGEF	0.47	10.69	0.39	1.15e-24	Coronary artery disease;
BRCA	cis	rs367943	0.966	rs348932	chr5:112812457	G/A	cg12552261	chr5:112820674	MCC	-0.56	-12.28	-0.44	2.97e-31	Type 2 diabetes;
BRCA	cis	rs75229567	0.618	rs11177819	chr12:70134836	T/G	cg10114359	chr12:70132523	RAB3IP	0.76	9.87	0.36	1.76e-21	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
BRCA	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg00677455	chr12:58241039	CTDSP2	0.62	14.27	0.49	2.5e-40	Multiple sclerosis;
BRCA	cis	rs1011018	0.628	rs73158611	chr7:139425430	G/C	cg03224163	chr7:139420300	HIPK2	-0.54	-9.18	-0.34	5.9e-19	Systolic blood pressure;
BRCA	cis	rs12618769	0.572	rs4851141	chr2:99112966	A/C	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg13397359	chr6:42928475	GNMT	0.75	19.14	0.6	6.8e-65	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18876405	chr7:65276391	NA	-0.62	-15.44	-0.52	5.85e-46	Cotinine glucuronidation;
BRCA	cis	rs11690935	0.802	rs34636594	chr2:172911094	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-24.35	-0.69	3.78e-93	Schizophrenia;
BRCA	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg06618935	chr21:46677482	NA	0.36	8.02	0.3	4.89e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06022373	chr22:39101656	GTPBP1	0.75	18.43	0.59	3.62e-61	Menopause (age at onset);
BRCA	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg07080220	chr10:102295463	HIF1AN	0.6	14.26	0.49	3.07e-40	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg04317338	chr11:64019027	PLCB3	0.55	9.57	0.35	2.29e-20	Mean platelet volume;
BRCA	cis	rs3784262	0.869	rs12903792	chr15:58261280	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.46	-12.35	-0.44	1.42e-31	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.22	-0.37	8.46e-23	Psoriasis;
BRCA	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.0	-0.46	1.92e-34	Migraine;Coronary artery disease;
BRCA	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg16558253	chr16:72132732	DHX38	-0.39	-9.5	-0.35	4.11e-20	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	trans	rs1459104	0.789	rs28896554	chr11:54812637	C/T	cg15704280	chr7:45808275	SEPT13	0.63	8.25	0.31	8.87e-16	Body mass index;
BRCA	cis	rs9420	0.961	rs11604325	chr11:57497011	C/A	cg19752551	chr11:57585705	CTNND1	-0.51	-12.43	-0.44	6.13e-32	Schizophrenia;
BRCA	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.34	-0.35	1.62e-19	Total body bone mineral density;
BRCA	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg05340658	chr4:99064831	C4orf37	-0.43	-9.64	-0.36	1.31e-20	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg25554036	chr4:6271136	WFS1	0.37	8.83	0.33	1.01e-17	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	11.03	0.4	4.9e-26	Bipolar disorder;
BRCA	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.34	-0.44	1.64e-31	Developmental language disorder (linguistic errors);
BRCA	trans	rs7980799	0.682	rs1601006	chr12:33629519	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-10.34	-0.38	2.92e-23	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs4566357	0.615	rs10178260	chr2:227914458	G/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-9.26	-0.34	3.06e-19	Coronary artery disease;
BRCA	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg00686598	chr14:53173677	PSMC6	1.15	15.97	0.53	1.5e-48	Alzheimer's disease (late onset);
BRCA	trans	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg16141378	chr3:129829833	LOC729375	0.33	7.98	0.3	6.77e-15	Joint mobility (Beighton score);
BRCA	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03188948	chr7:1209495	NA	0.69	15.13	0.51	1.98e-44	Longevity;Endometriosis;
BRCA	cis	rs66569888	0.523	rs4522599	chr2:106926004	G/C	cg16099169	chr2:106886729	NA	0.6	11.91	0.43	1.07e-29	Facial morphology (factor 23);
BRCA	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg08807101	chr21:30365312	RNF160	0.62	13.24	0.46	1.51e-35	Selective IgA deficiency;
BRCA	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg22681709	chr2:178499509	PDE11A	-0.38	-8.24	-0.31	9.55e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs11874712	1.000	rs9945751	chr18:43673265	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.09	0.3	2.98e-15	Migraine - clinic-based;
BRCA	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.1	0.4	2.58e-26	Bipolar disorder;
BRCA	cis	rs2835872	0.758	rs1709832	chr21:39038167	A/C	cg06728970	chr21:39037746	KCNJ6	0.43	12.06	0.43	2.67e-30	Electroencephalographic traits in alcoholism;
BRCA	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg04450456	chr4:17643702	FAM184B	0.38	11.12	0.4	2.16e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg23933602	chr10:16859644	RSU1	0.85	23.2	0.68	7.44e-87	Platelet distribution width;
BRCA	trans	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg15556689	chr8:8085844	FLJ10661	-0.33	-8.04	-0.3	4.4e-15	Neuroticism;
BRCA	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.11	0.37	2.23e-22	Aortic root size;
BRCA	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-12.03	-0.43	3.55e-30	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs3925075	0.553	rs9888907	chr16:31349040	A/G	cg02846316	chr16:31340340	ITGAM	0.42	9.07	0.34	1.51e-18	IgA nephropathy;
BRCA	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.46	8.64	0.32	4.64e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.54	7.89	0.3	1.29e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6901250	0.655	rs1117046	chr6:117136978	G/C	cg12892004	chr6:117198278	RFX6	0.37	9.12	0.34	9.43e-19	C-reactive protein levels;
BRCA	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg11663144	chr21:46675770	NA	-0.5	-10.11	-0.37	2.23e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg18252515	chr7:66147081	NA	1.05	15.64	0.53	6.07e-47	Diabetic kidney disease;
BRCA	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.17	0.46	3.12e-35	Bipolar disorder;
BRCA	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg25319279	chr11:5960081	NA	-0.4	-7.84	-0.3	1.95e-14	DNA methylation (variation);
BRCA	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.68	-0.42	1.08e-28	Gut microbiome composition (summer);
BRCA	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg25173405	chr17:45401733	C17orf57	-0.45	-8.77	-0.33	1.67e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs1941687	0.563	rs7232237	chr18:31324934	C/T	cg15819921	chr19:927150	ARID3A	0.42	7.96	0.3	7.82e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg22974920	chr21:40686053	BRWD1	-0.42	-9.21	-0.34	4.81e-19	Cognitive function;
BRCA	cis	rs7598759	0.712	rs997400	chr2:232332847	C/T	cg19187155	chr2:232395269	NMUR1	0.37	7.83	0.3	2.1e-14	Noise-induced hearing loss;
BRCA	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg17971929	chr21:40555470	PSMG1	0.77	17.81	0.58	6.22e-58	Cognitive function;
BRCA	trans	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg25214090	chr10:38739885	LOC399744	-0.55	-12.11	-0.43	1.6e-30	Corneal astigmatism;
BRCA	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg21132104	chr15:45694354	SPATA5L1	0.7	15.29	0.52	3.3e-45	Homoarginine levels;
BRCA	trans	rs617791	0.530	rs735942	chr11:65749337	A/G	cg17712092	chr4:129076599	LARP1B	-0.49	-10.84	-0.39	2.97e-25	Breast cancer;
BRCA	trans	rs61931739	0.926	rs1995966	chr12:34095420	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-8.99	-0.34	2.85e-18	Morning vs. evening chronotype;
BRCA	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg06636001	chr8:8085503	FLJ10661	0.52	10.93	0.4	1.31e-25	Neuroticism;
BRCA	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25427524	chr10:38739819	LOC399744	-0.64	-15.08	-0.51	3.58e-44	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10992471	0.603	rs10761160	chr9:95208701	A/T	cg14631576	chr9:95140430	CENPP	-0.39	-9.31	-0.35	1.96e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs16976116	0.901	rs73409851	chr15:55502516	G/A	cg11288833	chr15:55489084	RSL24D1	0.47	10.73	0.39	8.2e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs13046373	0.507	rs2832959	chr21:31982934	C/T	cg24082983	chr21:31802169	KRTAP13-4	0.34	8.76	0.33	1.78e-17	HDL cholesterol;
BRCA	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg16482183	chr6:26056742	HIST1H1C	0.46	8.92	0.33	4.88e-18	Iron status biomarkers;
BRCA	cis	rs75229567	0.618	rs11495622	chr12:70161286	G/A	cg10114359	chr12:70132523	RAB3IP	0.76	9.71	0.36	7.03e-21	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
BRCA	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.68	0.39	1.28e-24	Tonsillectomy;
BRCA	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg26384229	chr12:38710491	ALG10B	0.8	20.33	0.63	2.96e-71	Heart rate;
BRCA	cis	rs17092148	0.731	rs35507767	chr20:33361364	A/T	cg16810054	chr20:33298113	TP53INP2	-0.49	-11.22	-0.41	8.24e-27	Neuroticism;
BRCA	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11764359	chr7:65958608	NA	-0.75	-16.75	-0.55	1.72e-52	Aortic root size;
BRCA	cis	rs7560272	0.538	rs6732812	chr2:73922475	T/C	cg20560298	chr2:73613845	ALMS1	0.35	9.0	0.34	2.53e-18	Schizophrenia;
BRCA	cis	rs9649465	0.561	rs600081	chr7:123414591	A/T	cg03229431	chr7:123269106	ASB15	0.44	10.25	0.38	6.36e-23	Migraine;
BRCA	cis	rs651907	0.712	rs796410	chr3:101610189	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.39	9.1	0.34	1.18e-18	Colorectal cancer;
BRCA	trans	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg26384229	chr12:38710491	ALG10B	0.44	9.33	0.35	1.7e-19	Resting heart rate;
BRCA	cis	rs2073300	1.000	rs6137960	chr20:23442886	G/A	cg12062639	chr20:23401060	NAPB	0.87	10.46	0.38	9.93e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	trans	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg17063962	chr7:91808500	NA	-0.53	-12.42	-0.44	7.33e-32	Breast cancer;
BRCA	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6484504	0.576	rs208088	chr11:31192686	T/C	cg06552810	chr11:31128660	NA	-0.39	-8.58	-0.32	7.04e-17	Red blood cell count;
BRCA	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg16586182	chr3:47516702	SCAP	0.65	15.14	0.51	1.73e-44	Colorectal cancer;
BRCA	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	20.7	0.63	3.04e-73	Lymphocyte percentage of white cells;
BRCA	cis	rs11971779	0.584	rs6942519	chr7:139070090	A/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.32	0.38	3.39e-23	Diisocyanate-induced asthma;
BRCA	trans	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg06521331	chr12:34319734	NA	0.46	9.05	0.34	1.74e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg27478167	chr7:817139	HEATR2	0.54	10.57	0.39	3.63e-24	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg05623727	chr3:50126028	RBM5	0.51	12.34	0.44	1.59e-31	Body mass index;
BRCA	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg14196790	chr5:131705035	SLC22A5	-0.42	-10.24	-0.38	7.13e-23	Breast cancer;Mosquito bite size;
BRCA	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.03	20.77	0.63	1.34e-73	Gut microbiome composition (summer);
BRCA	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07988820	chr12:82153109	PPFIA2	-0.69	-11.83	-0.42	2.39e-29	Resting heart rate;
BRCA	cis	rs12200560	0.505	rs4839848	chr6:97076577	G/A	cg06623918	chr6:96969491	KIAA0776	0.53	12.7	0.45	4.04e-33	Coronary heart disease;
BRCA	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg03433033	chr1:76189801	ACADM	-0.39	-8.21	-0.31	1.23e-15	Daytime sleep phenotypes;
BRCA	trans	rs330048	0.545	rs11774353	chr8:9153127	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	12.53	0.44	2.36e-32	Systemic lupus erythematosus;
BRCA	cis	rs11608355	0.515	rs12818537	chr12:109902150	C/T	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs35123781	1.000	rs673632	chr5:139057237	G/T	cg05227215	chr5:139057496	CXXC5	0.35	8.42	0.32	2.45e-16	Schizophrenia;
BRCA	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg11822812	chr5:140052017	DND1	-0.32	-8.92	-0.33	4.91e-18	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2625529	0.668	rs72733369	chr15:72567260	G/A	cg16672083	chr15:72433130	SENP8	-0.81	-16.93	-0.56	2.05e-53	Red blood cell count;
BRCA	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.15	-0.49	9.24e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2652822	0.525	rs11632192	chr15:63515946	A/G	cg02713581	chr15:63449717	RPS27L	0.41	8.3	0.31	6.28e-16	Metabolic traits;
BRCA	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.67	-0.61	9.89e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg07148914	chr20:33460835	GGT7	0.36	8.01	0.3	5.62e-15	Height;
BRCA	cis	rs7301016	0.846	rs17732089	chr12:63023658	A/G	cg11441379	chr12:63026424	NA	-0.49	-8.91	-0.33	5.25e-18	IgG glycosylation;
BRCA	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg12310025	chr6:25882481	NA	-0.55	-12.29	-0.44	2.71e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg07395648	chr5:131743802	NA	-0.36	-8.01	-0.3	5.42e-15	Acylcarnitine levels;
BRCA	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg26061582	chr7:22766209	IL6	0.39	9.39	0.35	1.02e-19	Lung cancer;
BRCA	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg14186256	chr22:23484241	RTDR1	0.78	24.33	0.69	5.11e-93	Bone mineral density;
BRCA	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg17691542	chr6:26056736	HIST1H1C	0.43	9.25	0.34	3.23e-19	Iron status biomarkers;
BRCA	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.6	-12.55	-0.44	1.84e-32	Lymphocyte counts;
BRCA	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg00012203	chr2:219082015	ARPC2	-0.52	-10.01	-0.37	5.22e-22	Colorectal cancer;
BRCA	cis	rs9560113	1.000	rs9560107	chr13:112180146	G/A	cg10483660	chr13:112241077	NA	0.31	7.84	0.3	1.91e-14	Menarche (age at onset);
BRCA	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg05863683	chr7:1912471	MAD1L1	0.4	8.52	0.32	1.13e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg18252515	chr7:66147081	NA	1.06	16.03	0.54	7.81e-49	Diabetic kidney disease;
BRCA	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.48e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10046574	0.517	rs7782727	chr7:135200299	A/G	cg27474649	chr7:135195673	CNOT4	0.67	11.09	0.4	3.01e-26	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg23791538	chr6:167370224	RNASET2	-0.32	-7.85	-0.3	1.78e-14	Crohn's disease;
BRCA	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.61	-13.87	-0.48	1.89e-38	Ulcerative colitis;
BRCA	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg24006582	chr15:45444508	DUOX1	-0.55	-11.32	-0.41	3.19e-27	Uric acid levels;
BRCA	cis	rs12618769	0.597	rs3769719	chr2:99124404	T/C	cg10123293	chr2:99228465	UNC50	0.42	8.37	0.31	3.7e-16	Bipolar disorder;
BRCA	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg13047869	chr3:10149882	C3orf24	0.59	12.52	0.44	2.55e-32	Alzheimer's disease;
BRCA	cis	rs1003719	0.762	rs6517402	chr21:38447423	A/C	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.17	0.49	7.56e-40	Eye color traits;
BRCA	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.36	-0.31	3.91e-16	Bipolar disorder;
BRCA	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg00031303	chr3:195681400	NA	0.45	8.59	0.32	6.74e-17	Pancreatic cancer;
BRCA	cis	rs3815148	0.569	rs12705406	chr7:106792554	A/G	cg02696742	chr7:106810147	HBP1	0.68	8.47	0.32	1.65e-16	Osteoarthritis;
BRCA	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg22920501	chr2:26401640	FAM59B	-0.94	-16.53	-0.55	2.36e-51	Gut microbiome composition (summer);
BRCA	cis	rs1506636	1.000	rs684548	chr7:123397102	A/T	cg03229431	chr7:123269106	ASB15	0.61	13.66	0.48	1.88e-37	Plateletcrit;Platelet count;
BRCA	cis	rs11030122	0.702	rs4910868	chr11:3980224	A/C	cg18678763	chr11:4115507	RRM1	-0.35	-7.87	-0.3	1.53e-14	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs10754283	0.967	rs1953821	chr1:90107098	C/G	cg21401794	chr1:90099060	LRRC8C	0.45	10.78	0.39	5.23e-25	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs17401966	1.000	rs2275424	chr1:10356562	C/A	cg15208524	chr1:10270712	KIF1B	0.4	8.63	0.32	4.7e-17	Hepatocellular carcinoma;
BRCA	cis	rs9473147	0.516	rs2151974	chr6:47515630	G/A	cg12968598	chr6:47444699	CD2AP	0.44	9.7	0.36	7.41e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg23711669	chr6:146136114	FBXO30	-0.79	-18.87	-0.6	1.73e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg17366294	chr4:99064904	C4orf37	0.45	10.76	0.39	6.07e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg13736514	chr6:26305472	NA	0.32	10.93	0.4	1.33e-25	Educational attainment;
BRCA	cis	rs5771242	0.518	rs7290465	chr22:50679758	C/T	cg16473166	chr22:50639996	SELO	-0.59	-11.91	-0.43	1.14e-29	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
BRCA	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-9.76	-0.36	4.42e-21	Coronary artery disease;
BRCA	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg04455712	chr21:45112962	RRP1B	0.47	12.57	0.45	1.53e-32	Mean corpuscular volume;
BRCA	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg25214090	chr10:38739885	LOC399744	0.35	8.12	0.31	2.48e-15	Diastolic blood pressure;
BRCA	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg03146154	chr1:46216737	IPP	-0.45	-10.07	-0.37	3.16e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs526821	0.595	rs504661	chr11:55312683	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.36	-8.19	-0.31	1.4e-15	Pediatric bone mineral density (spine);
BRCA	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg17366294	chr4:99064904	C4orf37	0.51	11.46	0.41	8.52e-28	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg26384229	chr12:38710491	ALG10B	0.53	11.45	0.41	9.8e-28	Morning vs. evening chronotype;
BRCA	cis	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg06521331	chr12:34319734	NA	-0.44	-8.16	-0.31	1.83e-15	Resting heart rate;
BRCA	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg00666640	chr1:248458726	OR2T12	0.29	8.21	0.31	1.26e-15	Common traits (Other);
BRCA	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg08601574	chr20:25228251	PYGB	-0.34	-8.24	-0.31	9.54e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg08885076	chr2:99613938	TSGA10	0.45	10.46	0.38	9.8599999999999993e-24	Chronic sinus infection;
BRCA	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.06	0.74	1.58e-113	Chronic sinus infection;
BRCA	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg11833968	chr6:79620685	NA	-0.46	-10.29	-0.38	4.47e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.58	9.91	0.36	1.3e-21	Gut microbiome composition (summer);
BRCA	cis	rs897984	0.542	rs59061704	chr16:31062704	G/C	cg00531865	chr16:30841666	NA	-0.35	-8.22	-0.31	1.13e-15	Dementia with Lewy bodies;
BRCA	cis	rs13064411	0.735	rs7631138	chr3:113231925	A/T	cg18753928	chr3:113234510	CCDC52	-0.58	-12.25	-0.44	3.88e-31	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg11845111	chr2:191398756	TMEM194B	-0.83	-14.48	-0.5	2.77e-41	Diastolic blood pressure;
BRCA	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.2e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg25214090	chr10:38739885	LOC399744	0.54	11.89	0.43	1.36e-29	Corneal astigmatism;
BRCA	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18876405	chr7:65276391	NA	-0.48	-10.52	-0.38	5.64e-24	Aortic root size;
BRCA	cis	rs7833986	0.501	rs72653962	chr8:56997505	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	12.99	0.46	2.13e-34	Height;
BRCA	cis	rs2014572	0.933	rs8107516	chr19:57758445	A/G	cg24459738	chr19:57751996	ZNF805	-0.37	-8.63	-0.32	4.85e-17	Hyperactive-impulsive symptoms;
BRCA	cis	rs738322	0.511	rs2267370	chr22:38576826	G/A	cg25457927	chr22:38595422	NA	-0.36	-11.97	-0.43	6.17e-30	Cutaneous nevi;
BRCA	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg00677455	chr12:58241039	CTDSP2	0.63	14.61	0.5	6.29e-42	Multiple sclerosis;
BRCA	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07256732	chr16:621771	PIGQ	-0.34	-9.02	-0.34	2.15e-18	Height;
BRCA	cis	rs12949688	1.000	rs886925	chr17:55817649	G/C	cg12582317	chr17:55822272	NA	0.32	8.05	0.3	3.98e-15	Schizophrenia;
BRCA	cis	rs4363385	0.747	rs2339496	chr1:152970719	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-9.1	-0.34	1.14e-18	Inflammatory skin disease;
BRCA	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg06191203	chr2:152266755	RIF1	-0.35	-10.09	-0.37	2.5e-22	Squamous cell lung carcinoma;
BRCA	cis	rs72772090	0.539	rs11749811	chr5:96115925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.09	-0.43	1.97e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs9986765	0.609	rs73452600	chr7:142828104	C/A	cg15652212	chr7:142981776	TMEM139	0.62	9.86	0.36	1.87e-21	Cancer;Dermatomyositis;
BRCA	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg06618935	chr21:46677482	NA	-0.38	-8.42	-0.32	2.4e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9811920	0.625	rs9847283	chr3:99910320	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-8.83	-0.33	1.01e-17	Axial length;
BRCA	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg23978390	chr7:1156363	C7orf50	-0.46	-10.59	-0.39	3.05e-24	Longevity;Endometriosis;
BRCA	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg04450456	chr4:17643702	FAM184B	0.41	12.13	0.43	1.25e-30	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10802521	chr3:52805072	NEK4	-0.29	-7.83	-0.3	2.11e-14	Cognitive function;
BRCA	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg01262667	chr19:19385393	TM6SF2	0.41	10.63	0.39	2.12e-24	Tonsillectomy;
BRCA	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg26384229	chr12:38710491	ALG10B	0.74	17.53	0.57	1.85e-56	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.33	0.41	3.05e-27	Homoarginine levels;
BRCA	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg05347473	chr6:146136440	FBXO30	0.61	12.03	0.43	3.38e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg11266682	chr4:10021025	SLC2A9	0.38	9.86	0.36	1.98e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg05340658	chr4:99064831	C4orf37	0.62	14.74	0.5	1.46e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9790314	0.582	rs11922752	chr3:160600599	G/C	cg03342759	chr3:160939853	NMD3	0.42	8.45	0.32	2.01e-16	Morning vs. evening chronotype;
BRCA	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg06212747	chr3:49208901	KLHDC8B	0.47	9.59	0.35	1.93e-20	Parkinson's disease;
BRCA	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-18.4	-0.59	5.63e-61	Gut microbiome composition (summer);
BRCA	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-17.57	-0.57	1.1e-56	Extrinsic epigenetic age acceleration;
BRCA	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg21433313	chr16:3507492	NAT15	-0.59	-8.1	-0.31	2.84e-15	Tuberculosis;
BRCA	cis	rs12618769	0.597	rs4851142	chr2:99133611	A/C	cg10123293	chr2:99228465	UNC50	0.41	8.05	0.3	3.94e-15	Bipolar disorder;
BRCA	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.66	13.58	0.47	4.27e-37	Lymphocyte counts;
BRCA	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg15704280	chr7:45808275	SEPT13	0.62	10.32	0.38	3.42e-23	Axial length;
BRCA	trans	rs7246760	0.867	rs8102257	chr19:9830795	C/T	cg02900749	chr2:68251473	NA	-0.5	-8.4	-0.32	2.8e-16	Pursuit maintenance gain;
BRCA	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.52	-11.6	-0.42	2.2e-28	Longevity;Endometriosis;
BRCA	cis	rs13095912	1.000	rs9714158	chr3:185328780	C/T	cg11274856	chr3:185301563	NA	0.36	8.84	0.33	9.31e-18	Systolic blood pressure;
BRCA	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21582582	chr3:182698605	DCUN1D1	0.39	10.16	0.37	1.38e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs1451375	0.959	rs17133878	chr7:50620927	T/C	cg18232548	chr7:50535776	DDC	0.39	9.55	0.35	2.79e-20	Malaria;
BRCA	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.61	-12.95	-0.46	3.17e-34	Lymphocyte counts;
BRCA	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg12386194	chr3:101231763	SENP7	0.46	9.91	0.36	1.29e-21	Colorectal cancer;
BRCA	cis	rs870825	0.616	rs28490461	chr4:185651638	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	17.79	0.58	7.74e-58	Blood protein levels;
BRCA	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg10523679	chr1:76189770	ACADM	0.91	22.27	0.66	9.05e-82	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg14403583	chr14:105418241	AHNAK2	-0.38	-8.97	-0.33	3.29e-18	Rheumatoid arthritis;
BRCA	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg06238570	chr21:40685208	BRWD1	-0.45	-8.93	-0.33	4.56e-18	Cognitive function;
BRCA	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.78	0.67	1.59e-84	Chronic sinus infection;
BRCA	cis	rs7512552	0.839	rs11577843	chr1:150398258	A/G	cg15654264	chr1:150340011	RPRD2	0.37	8.16	0.31	1.76e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg02734326	chr4:10020555	SLC2A9	0.39	8.39	0.32	3.04e-16	Bone mineral density;
BRCA	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.62	-11.86	-0.42	1.77e-29	Iron status biomarkers;
BRCA	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg21535247	chr6:8435926	SLC35B3	0.42	9.44	0.35	6.79e-20	Motion sickness;
BRCA	trans	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg25214090	chr10:38739885	LOC399744	0.52	11.65	0.42	1.41e-28	Corneal astigmatism;
BRCA	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19346786	chr7:2764209	NA	-0.31	-8.88	-0.33	6.49e-18	Height;
BRCA	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg15839431	chr19:19639596	YJEFN3	-0.43	-9.26	-0.34	3.07e-19	Bipolar disorder;
BRCA	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs11231017	0.514	rs953169	chr11:62083542	C/T	cg23876832	chr11:62092739	NA	-0.33	-8.52	-0.32	1.16e-16	HIV-1 viral setpoint;
BRCA	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.12	0.43	1.37e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-12.35	-0.44	1.44e-31	Gut microbiome composition (summer);
BRCA	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-13.44	-0.47	1.88e-36	Migraine;Coronary artery disease;
BRCA	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg00071950	chr4:10020882	SLC2A9	0.54	13.0	0.46	1.8e-34	Bone mineral density;
BRCA	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg14196790	chr5:131705035	SLC22A5	0.33	8.58	0.32	7.09e-17	Breast cancer;
BRCA	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.41	-8.07	-0.3	3.62e-15	Eosinophil percentage of white cells;
BRCA	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.05	-19.05	-0.6	1.99e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.52	11.98	0.43	5.55e-30	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7737355	1.000	rs798412	chr5:130698474	C/A	cg06307176	chr5:131281290	NA	-0.46	-9.0	-0.34	2.54e-18	Life satisfaction;
BRCA	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg05347473	chr6:146136440	FBXO30	0.44	8.65	0.32	4.19e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg05347473	chr6:146136440	FBXO30	0.4	8.11	0.31	2.64e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2742234	0.541	rs7073849	chr10:43740474	G/C	cg02780029	chr10:43622663	RET	0.35	7.94	0.3	9.1e-15	Hirschsprung disease;
BRCA	cis	rs3770081	1.000	rs12620810	chr2:86391481	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.61	-8.3	-0.31	6.17e-16	Facial emotion recognition (sad faces);
BRCA	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg18131467	chr2:239335373	ASB1	0.79	22.07	0.66	1.11e-80	Multiple system atrophy;
BRCA	cis	rs7766436	0.885	rs13199041	chr6:22577718	A/G	cg13666174	chr6:22585274	NA	-0.49	-11.29	-0.41	4.4e-27	Coronary artery disease;
BRCA	cis	rs4363385	0.669	rs2937264	chr1:153011026	C/T	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg03188948	chr7:1209495	NA	0.55	10.17	0.37	1.3e-22	Longevity;Endometriosis;
BRCA	cis	rs6735179	0.603	rs10164788	chr2:1753379	G/A	cg10160682	chr2:1713001	PXDN	-0.36	-7.84	-0.3	1.88e-14	Response to antipsychotic treatment;
BRCA	cis	rs68170813	0.641	rs12532953	chr7:106865920	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.47	-0.32	1.62e-16	Coronary artery disease;
BRCA	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg23711669	chr6:146136114	FBXO30	0.69	16.31	0.54	3.09e-50	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs922182	0.579	rs13329518	chr15:64241080	T/C	cg24729988	chr15:64271149	DAPK2	0.49	10.65	0.39	1.69e-24	Blood protein levels;
BRCA	trans	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg23505145	chr19:12996616	KLF1	0.56	12.56	0.44	1.72e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-9.16	-0.34	7.19e-19	Alzheimer's disease;
BRCA	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg03254818	chr6:169586852	NA	-0.4	-8.56	-0.32	8.61e-17	Pulse pressure;
BRCA	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg05340658	chr4:99064831	C4orf37	0.62	14.83	0.51	5.37e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.86	0.45	7.85e-34	Bipolar disorder;
BRCA	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg08601574	chr20:25228251	PYGB	0.41	9.57	0.35	2.2e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7011049	1.000	rs72643574	chr8:53844501	G/C	cg26025543	chr8:53854495	NA	0.55	9.64	0.36	1.25e-20	Systolic blood pressure;
BRCA	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg08213375	chr14:104286397	PPP1R13B	0.5	10.69	0.39	1.24e-24	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg05368731	chr17:41323189	NBR1	-0.64	-17.73	-0.57	1.7e-57	Menopause (age at onset);
BRCA	cis	rs9837602	0.872	rs35154249	chr3:99738230	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	10.53	0.38	5.15e-24	Breast cancer;
BRCA	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg10223061	chr2:219282414	VIL1	-0.36	-8.57	-0.32	7.63e-17	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg18230493	chr5:56204884	C5orf35	-0.68	-13.41	-0.47	2.57e-36	Initial pursuit acceleration;
BRCA	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.23	0.31	1.02e-15	Uric acid levels;
BRCA	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	13.12	0.46	5.53e-35	Mean platelet volume;
BRCA	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg13660082	chr14:53194042	PSMC6	-0.57	-8.73	-0.33	2.14e-17	Alzheimer's disease (late onset);
BRCA	trans	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.28	0.31	7.45e-16	Corneal astigmatism;
BRCA	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22029157	chr1:209979665	IRF6	0.56	12.49	0.44	3.54e-32	Cleft lip with or without cleft palate;
BRCA	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg11812906	chr14:75593930	NEK9	-0.61	-13.87	-0.48	1.91e-38	Height;
BRCA	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg27588902	chr6:42928151	GNMT	-0.3	-10.05	-0.37	3.77e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg06521331	chr12:34319734	NA	-0.47	-8.68	-0.32	3.27e-17	Bladder cancer;
BRCA	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg09184832	chr6:79620586	NA	-0.51	-11.28	-0.41	4.77e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs11677370	0.603	rs11675498	chr2:3850943	G/T	cg17052675	chr2:3827356	NA	-0.53	-12.68	-0.45	5.06e-33	Type 2 diabetes;
BRCA	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg02659138	chr7:134003124	SLC35B4	0.33	10.05	0.37	3.59e-22	Mean platelet volume;
BRCA	cis	rs4363385	0.747	rs2339493	chr1:152975277	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-9.29	-0.34	2.4e-19	Inflammatory skin disease;
BRCA	trans	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg25214090	chr10:38739885	LOC399744	0.41	9.19	0.34	5.33e-19	Educational attainment;
BRCA	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg20607798	chr8:58055168	NA	0.47	8.02	0.3	5.03e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg13565492	chr6:43139072	SRF	-0.56	-8.33	-0.31	5.12e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg24562669	chr7:97807699	LMTK2	0.46	12.25	0.44	3.81e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg07148914	chr20:33460835	GGT7	0.38	8.57	0.32	7.57e-17	Height;
BRCA	cis	rs3087591	0.887	rs2905796	chr17:29537586	G/A	cg24425628	chr17:29625626	OMG;NF1	0.47	9.53	0.35	3.18e-20	Hip circumference;
BRCA	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.5	-9.94	-0.37	9.99e-22	Body mass index;
BRCA	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg11584989	chr19:19387371	SF4	-0.62	-13.38	-0.47	3.41e-36	Bipolar disorder;
BRCA	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07256732	chr16:621771	PIGQ	-0.35	-9.33	-0.35	1.75e-19	Height;
BRCA	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21659725	chr3:3221576	CRBN	-0.47	-10.03	-0.37	4.52e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg01114163	chr5:1856713	NA	-0.36	-7.94	-0.3	9.07e-15	Cardiovascular disease risk factors;
BRCA	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	ch.11.42038R	chr11:967971	AP2A2	0.57	18.79	0.6	4.8e-63	Alzheimer's disease (late onset);
BRCA	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg08601574	chr20:25228251	PYGB	-0.35	-8.27	-0.31	7.94e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12549902	0.871	rs4736819	chr8:41509915	C/T	cg21772509	chr8:41503840	NKX6-3	0.45	10.68	0.39	1.32e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
BRCA	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	0.54	12.57	0.45	1.48e-32	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg25173405	chr17:45401733	C17orf57	-0.51	-10.66	-0.39	1.62e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg08859206	chr1:53392774	SCP2	-0.48	-10.35	-0.38	2.6e-23	Monocyte count;
BRCA	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg06636001	chr8:8085503	FLJ10661	0.65	14.69	0.5	2.71e-42	Mood instability;
BRCA	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03264133	chr6:25882463	NA	-0.49	-10.24	-0.38	7.06e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg26384229	chr12:38710491	ALG10B	0.66	14.34	0.49	1.26e-40	Morning vs. evening chronotype;
BRCA	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg21644426	chr2:191273491	MFSD6	0.45	11.13	0.4	1.94e-26	Pulse pressure;
BRCA	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg22491629	chr6:157744540	C6orf35	-0.45	-9.38	-0.35	1.18e-19	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-9.84	-0.36	2.21e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00166722	chr3:10149974	C3orf24	0.65	13.07	0.46	8.76e-35	Alzheimer's disease;
BRCA	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg16322792	chr1:120165303	ZNF697	0.58	15.43	0.52	6.54e-46	Systemic lupus erythematosus;
BRCA	cis	rs2479724	0.840	rs10498752	chr6:41768510	T/C	cg17623882	chr6:41773611	USP49	0.37	9.92	0.37	1.15e-21	Menarche (age at onset);
BRCA	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg22431228	chr1:16359049	CLCNKA	-0.44	-9.91	-0.37	1.19e-21	Dilated cardiomyopathy;
BRCA	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg06238570	chr21:40685208	BRWD1	-0.42	-8.49	-0.32	1.41e-16	Cognitive function;
BRCA	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg03060546	chr3:49711283	APEH	0.5	10.71	0.39	9.52e-25	Resting heart rate;
BRCA	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg15412446	chr2:106886593	NA	-0.49	-9.03	-0.34	2.05e-18	Facial morphology (factor 23);
BRCA	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg11663144	chr21:46675770	NA	-0.55	-12.76	-0.45	2.26e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.74	0.39	7.86e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11051970	0.636	rs2733703	chr12:32561794	C/T	cg24626660	chr12:32551988	NA	0.31	9.18	0.34	5.82e-19	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.32	0.49	1.48e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs495337	0.965	rs4810999	chr20:48580969	A/T	cg17835207	chr20:48524531	SPATA2	-0.61	-14.08	-0.49	2.15e-39	Psoriasis;
BRCA	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg20387954	chr3:183756860	HTR3D	0.4	9.08	0.34	1.39e-18	Anterior chamber depth;
BRCA	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg24829409	chr8:58192753	C8orf71	-0.47	-8.1	-0.31	2.77e-15	Developmental language disorder (linguistic errors);
BRCA	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.48	-0.32	1.55e-16	Coronary artery disease;
BRCA	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	21.77	0.65	5.24e-79	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18876405	chr7:65276391	NA	-0.51	-11.75	-0.42	5.48e-29	Aortic root size;
BRCA	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg22875332	chr1:76189707	ACADM	0.69	14.84	0.51	5.09e-43	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.36	8.7	0.33	2.84e-17	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs7246657	0.722	rs8100646	chr19:38107943	T/C	cg18154014	chr19:37997991	ZNF793	0.5	9.55	0.35	2.6e-20	Coronary artery calcification;
BRCA	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26314531	chr2:26401878	FAM59B	-0.79	-12.64	-0.45	7.76e-33	Gut microbiome composition (summer);
BRCA	trans	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17712092	chr4:129076599	LARP1B	0.55	13.37	0.47	4.05e-36	Eosinophil percentage of white cells;
BRCA	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.24	0.49	3.5e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	8.73	0.33	2.29e-17	Response to antipsychotic treatment;
BRCA	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg08470875	chr2:26401718	FAM59B	0.71	11.35	0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	trans	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.37	-9.03	-0.34	1.96e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg13256891	chr4:100009986	ADH5	0.38	8.11	0.31	2.55e-15	Alcohol dependence;
BRCA	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg09307838	chr4:120376055	NA	0.75	16.17	0.54	1.48e-49	Corneal astigmatism;
BRCA	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg01689657	chr7:91764605	CYP51A1	0.24	8.55	0.32	9.28e-17	Breast cancer;
BRCA	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.33	0.31	4.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg23711669	chr6:146136114	FBXO30	0.77	17.96	0.58	1.11e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg21535247	chr6:8435926	SLC35B3	0.42	9.64	0.36	1.24e-20	Motion sickness;
BRCA	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg11645453	chr3:52864694	ITIH4	-0.36	-9.72	-0.36	6.65e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.49	-8.52	-0.32	1.16e-16	Renal function-related traits (BUN);
BRCA	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg01292856	chr11:65242576	NA	0.33	8.19	0.31	1.42e-15	Bone mineral density;
BRCA	cis	rs778371	0.676	rs2293780	chr2:233635213	T/C	cg08000102	chr2:233561755	GIGYF2	0.85	21.2	0.64	6.23e-76	Schizophrenia;
BRCA	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg07395648	chr5:131743802	NA	0.37	8.67	0.32	3.49e-17	Breast cancer;Mosquito bite size;
BRCA	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg21045802	chr8:109455806	TTC35	0.34	7.84	0.3	1.93e-14	Dupuytren's disease;
BRCA	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg03433033	chr1:76189801	ACADM	0.69	12.83	0.45	1.1e-33	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg15819921	chr19:927150	ARID3A	-0.52	-10.14	-0.37	1.63e-22	Life satisfaction;
BRCA	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg18753928	chr3:113234510	CCDC52	-0.58	-12.31	-0.44	2.2e-31	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs12541635	0.966	rs6469023	chr8:106989558	T/C	cg10147462	chr8:107024639	NA	0.39	10.31	0.38	3.69e-23	Age of smoking initiation;
BRCA	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg21770322	chr7:97807741	LMTK2	0.42	11.34	0.41	2.69e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg00825309	chr19:58991885	ZNF446	-0.58	-12.62	-0.45	8.94e-33	Uric acid clearance;
BRCA	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.13	-0.4	1.98e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg24675658	chr1:53192096	ZYG11B	-0.67	-15.03	-0.51	5.91e-44	Monocyte count;
BRCA	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.23	-0.41	7.77e-27	Schizophrenia;
BRCA	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg03060546	chr3:49711283	APEH	0.52	10.8	0.39	4.28e-25	Resting heart rate;
BRCA	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.37	8.0	0.3	5.67e-15	Platelet count;
BRCA	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.26	-0.38	5.58e-23	Mean corpuscular volume;
BRCA	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg23711669	chr6:146136114	FBXO30	0.84	20.2	0.62	1.5e-70	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg18132916	chr6:79620363	NA	-0.46	-10.68	-0.39	1.33e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg03354898	chr7:1950403	MAD1L1	-0.44	-9.24	-0.34	3.74e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.5	-11.05	-0.4	4.27e-26	IgG glycosylation;
BRCA	cis	rs6763687	0.687	rs6762040	chr3:171803713	C/T	cg16233210	chr3:171778391	FNDC3B	0.35	7.92	0.3	1.06e-14	Red cell distribution width;
BRCA	cis	rs16958440	0.867	rs3809966	chr18:44677627	C/T	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg04827223	chr11:72435913	ARAP1	-0.67	-15.55	-0.52	1.84e-46	Type 2 diabetes;
BRCA	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg27446573	chr6:127587934	RNF146	0.67	15.13	0.51	2.02e-44	Breast cancer;
BRCA	cis	rs10128251	0.746	rs9424194	chr10:5724073	A/G	cg24097872	chr10:5724021	NA	0.59	13.26	0.46	1.29e-35	Childhood ear infection;
BRCA	cis	rs6546537	0.824	rs13011186	chr2:69778558	C/T	cg10773587	chr2:69614142	GFPT1	-0.4	-8.64	-0.32	4.44e-17	Serum thyroid-stimulating hormone levels;
BRCA	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.39	-8.08	-0.3	3.22e-15	Ulcerative colitis;
BRCA	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg12863693	chr15:85201151	NMB	-0.39	-8.97	-0.33	3.35e-18	P wave terminal force;
BRCA	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg13271783	chr10:134563150	INPP5A	-0.49	-9.87	-0.36	1.69e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-11.6	-0.42	2.34e-28	Developmental language disorder (linguistic errors);
BRCA	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg20307385	chr11:47447363	PSMC3	0.75	16.59	0.55	1.18e-51	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26384229	chr12:38710491	ALG10B	0.75	16.67	0.55	4.32e-52	Morning vs. evening chronotype;
BRCA	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg10011062	chr15:43941034	CATSPER2	-0.55	-8.09	-0.3	3.05e-15	Lung cancer in ever smokers;
BRCA	trans	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-15.49	-0.52	3.38e-46	Obesity-related traits;
BRCA	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg08213375	chr14:104286397	PPP1R13B	-0.64	-17.71	-0.57	2.25e-57	Schizophrenia;
BRCA	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg14573099	chr2:101761014	TBC1D8	-0.33	-8.23	-0.31	1.08e-15	Mosquito bite size;
BRCA	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.65	17.03	0.56	6.65e-54	Electrocardiographic conduction measures;
BRCA	cis	rs701145	0.556	rs355771	chr3:154039385	G/C	cg16511985	chr3:153974050	SGEF	0.46	10.32	0.38	3.24e-23	Coronary artery disease;
BRCA	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg10223061	chr2:219282414	VIL1	0.29	8.39	0.32	3.07e-16	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg21427119	chr20:30132790	HM13	-0.41	-8.71	-0.33	2.68e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs6066835	1.000	rs6095244	chr20:47318774	T/C	cg18078177	chr20:47281410	PREX1	0.69	8.21	0.31	1.25e-15	Multiple myeloma;
BRCA	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg10845886	chr2:3471009	TTC15	-0.56	-12.55	-0.44	1.89e-32	Neurofibrillary tangles;
BRCA	trans	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg15704280	chr7:45808275	SEPT13	0.59	8.85	0.33	8.8e-18	Axial length;
BRCA	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg08601574	chr20:25228251	PYGB	-0.35	-8.39	-0.31	3.15e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9473147	0.543	rs1872505	chr6:47480975	C/G	cg12968598	chr6:47444699	CD2AP	0.44	9.59	0.35	1.93e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg17063962	chr7:91808500	NA	-0.52	-12.19	-0.43	7.28e-31	Breast cancer;
BRCA	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	10.95	0.4	1.12e-25	Mean platelet volume;
BRCA	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg07080220	chr10:102295463	HIF1AN	0.63	14.78	0.5	9.71e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.48	9.86	0.36	1.91e-21	Tonsillectomy;
BRCA	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg25174290	chr11:3078921	CARS	0.45	13.42	0.47	2.26e-36	Longevity;
BRCA	cis	rs4566357	0.615	rs12474622	chr2:227912793	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.44	-0.35	6.61e-20	Coronary artery disease;
BRCA	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg20933634	chr6:27740509	NA	0.47	8.87	0.33	7.05e-18	Parkinson's disease;
BRCA	cis	rs4561483	0.801	rs33623	chr16:12007435	A/G	cg08843971	chr16:11963173	GSPT1	0.54	12.39	0.44	9.71e-32	Testicular germ cell tumor;
BRCA	cis	rs13136331	0.759	rs6855426	chr4:88646335	A/G	cg22416721	chr4:88570574	DMP1	-0.45	-10.89	-0.4	1.88e-25	Sitting height ratio;
BRCA	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg01528321	chr10:82214614	TSPAN14	0.82	17.4	0.57	8.14e-56	Post bronchodilator FEV1;
BRCA	cis	rs12612619	0.732	rs1866654	chr2:27263122	A/G	cg00617064	chr2:27272375	NA	-0.33	-8.54	-0.32	9.66e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg00814883	chr7:100076585	TSC22D4	-0.48	-9.96	-0.37	7.73e-22	Platelet count;
BRCA	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-13.43	-0.47	2.13e-36	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19717773	chr7:2847554	GNA12	-0.42	-8.0	-0.3	6.03e-15	Height;
BRCA	cis	rs1883415	0.534	rs2817205	chr6:24477134	G/A	cg20631270	chr6:24437470	GPLD1	0.4	8.11	0.31	2.54e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7119038	0.509	rs10892257	chr11:118579327	G/A	cg19308663	chr11:118741387	NA	0.38	8.53	0.32	1.1e-16	Sjögren's syndrome;
BRCA	cis	rs1707322	1.000	rs1613296	chr1:46546852	A/C	cg06784218	chr1:46089804	CCDC17	-0.39	-9.08	-0.34	1.34e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10802521	chr3:52805072	NEK4	-0.31	-7.87	-0.3	1.56e-14	Bipolar disorder;
BRCA	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11764359	chr7:65958608	NA	-0.77	-17.73	-0.57	1.71e-57	Aortic root size;
BRCA	trans	rs3960554	0.808	rs13438599	chr7:75768022	G/A	cg19862616	chr7:65841803	NCRNA00174	0.59	12.13	0.43	1.28e-30	Eotaxin levels;
BRCA	cis	rs10267417	0.603	rs6976553	chr7:19869113	T/C	cg07541023	chr7:19748670	TWISTNB	0.51	9.19	0.34	5.25e-19	Night sleep phenotypes;
BRCA	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.56	11.83	0.42	2.35e-29	Monocyte percentage of white cells;
BRCA	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.52	8.49	0.32	1.41e-16	Renal function-related traits (BUN);
BRCA	cis	rs3845702	0.736	rs72958863	chr2:180808144	C/T	cg01881094	chr2:180872142	CWC22	1.03	16.59	0.55	1.19e-51	Schizophrenia;
BRCA	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-8.93	-0.33	4.67e-18	Alzheimer's disease;
BRCA	cis	rs2882667	0.537	rs11743534	chr5:138409007	G/T	cg04439458	chr5:138467593	SIL1	-0.33	-8.99	-0.34	2.74e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg06212747	chr3:49208901	KLHDC8B	0.47	9.57	0.35	2.37e-20	Parkinson's disease;
BRCA	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.58	-0.32	7.02e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.79	10.93	0.4	1.35e-25	Initial pursuit acceleration;
BRCA	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg25319279	chr11:5960081	NA	-0.43	-8.02	-0.3	4.89e-15	DNA methylation (variation);
BRCA	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg15704280	chr7:45808275	SEPT13	0.53	9.04	0.34	1.84e-18	Axial length;
BRCA	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg08999081	chr20:33150536	PIGU	-0.47	-12.95	-0.46	3.13e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg02297831	chr4:17616191	MED28	0.36	8.4	0.32	2.97e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg26384229	chr12:38710491	ALG10B	0.59	13.55	0.47	5.69e-37	Morning vs. evening chronotype;
BRCA	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg04511125	chr2:88470314	THNSL2	0.94	13.18	0.46	2.99e-35	Plasma clusterin levels;
BRCA	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-14.48	-0.5	2.76e-41	Total cholesterol levels;
BRCA	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	21.96	0.66	4.85e-80	Platelet count;
BRCA	trans	rs4596713	0.538	rs10114369	chr9:71799697	T/A	cg16512924	chr15:28394682	HERC2	0.45	10.67	0.39	1.44e-24	Headache;
BRCA	cis	rs6121246	0.559	rs6058465	chr20:30397691	G/A	cg13852791	chr20:30311386	BCL2L1	0.95	23.06	0.67	4.46e-86	Mean corpuscular hemoglobin;
BRCA	cis	rs7799006	1.000	rs7787274	chr7:2275993	G/A	cg08027265	chr7:2291960	NA	-0.42	-10.65	-0.39	1.67e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg00012203	chr2:219082015	ARPC2	-0.57	-12.05	-0.43	2.87e-30	Colorectal cancer;
BRCA	cis	rs2463822	1.000	rs118049526	chr11:62107508	C/T	cg06239285	chr11:62104954	ASRGL1	-0.7	-9.73	-0.36	5.89e-21	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg08601574	chr20:25228251	PYGB	0.35	8.47	0.32	1.63e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.57	-0.32	7.75e-17	Total body bone mineral density;
BRCA	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg11764359	chr7:65958608	NA	-0.66	-14.47	-0.5	2.97e-41	Aortic root size;
BRCA	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg10253484	chr15:75165896	SCAMP2	0.42	8.36	0.31	3.91e-16	Systemic lupus erythematosus;
BRCA	trans	rs4698048	0.510	rs12509714	chr4:10107091	C/G	cg26043149	chr18:55253948	FECH	0.44	9.98	0.37	6.58e-22	Skin aging (microtopography measurement);
BRCA	cis	rs2425143	1.000	rs6058304	chr20:34299851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.0	-0.34	2.6e-18	Blood protein levels;
BRCA	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.62	14.24	0.49	3.48e-40	Colorectal cancer;
BRCA	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.9	0.33	5.78e-18	Personality dimensions;
BRCA	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg10057126	chr4:77819792	ANKRD56	0.63	14.73	0.5	1.76e-42	Emphysema distribution in smoking;
BRCA	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg06046430	chr4:77819534	ANKRD56	0.56	12.2	0.43	6.54e-31	Emphysema distribution in smoking;
BRCA	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg23711669	chr6:146136114	FBXO30	-0.79	-18.02	-0.58	4.97e-59	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-13.02	-0.46	1.47e-34	Platelet count;
BRCA	cis	rs7918232	0.567	rs11015463	chr10:27319258	A/G	cg14240646	chr10:27532245	ACBD5	-0.48	-8.29	-0.31	6.63e-16	Breast cancer;
BRCA	cis	rs7586879	1.000	rs7586879	chr2:25116977	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.22	0.34	4.12e-19	Body mass index;
BRCA	cis	rs897984	0.721	rs28360557	chr16:30983260	A/C	cg02466173	chr16:30829666	NA	0.49	11.14	0.4	1.89e-26	Dementia with Lewy bodies;
BRCA	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-9.93	-0.37	1.07e-21	Tonsillectomy;
BRCA	trans	rs1391576	1	rs1391576	chr11:51394932	C/T	cg15704280	chr7:45808275	SEPT13	0.62	8.53	0.32	1.09e-16	Body mass index;
BRCA	cis	rs6840258	0.941	rs6854749	chr4:87968798	A/T	cg08197287	chr4:87952173	AFF1	-0.44	-8.83	-0.33	9.67e-18	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-12.94	-0.46	3.44e-34	Hemoglobin concentration;
BRCA	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg04944784	chr2:26401820	FAM59B	-1.0	-16.8	-0.55	9.74e-53	Gut microbiome composition (summer);
BRCA	cis	rs17401966	0.931	rs12409754	chr1:10457540	T/C	cg03954927	chr1:10346856	KIF1B	0.47	14.09	0.49	1.77e-39	Hepatocellular carcinoma;
BRCA	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.51	-0.47	9.57e-37	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13012494	chr21:47604986	C21orf56	0.43	9.06	0.34	1.53e-18	Testicular germ cell tumor;
BRCA	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg19077165	chr18:44547161	KATNAL2	-0.58	-13.02	-0.46	1.57e-34	Personality dimensions;
BRCA	cis	rs12367572	0.663	rs1224436	chr12:45400397	C/T	cg04608330	chr12:45269318	NELL2	-0.36	-7.92	-0.3	1.06e-14	Gut microbiome composition (summer);
BRCA	cis	rs4478858	0.735	rs7523438	chr1:31788313	C/T	cg00250761	chr1:31883323	NA	0.32	8.37	0.31	3.57e-16	Alcohol dependence;
BRCA	cis	rs1635	0.655	rs2281041	chr6:28303845	G/C	cg15743358	chr6:28303923	ZNF323	-0.75	-8.56	-0.32	8.52e-17	Schizophrenia;
BRCA	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg14829155	chr15:31115871	NA	0.42	9.99	0.37	6.31e-22	Huntington's disease progression;
BRCA	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.18	0.34	5.8e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs698813	0.604	rs12712916	chr2:44482099	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.74	0.33	2.08e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.53	8.16	0.31	1.83e-15	Renal function-related traits (BUN);
BRCA	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06108461	chr20:60628389	TAF4	-0.79	-17.05	-0.56	5.4e-54	Body mass index;
BRCA	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg08807101	chr21:30365312	RNF160	0.6	12.66	0.45	6.34e-33	Selective IgA deficiency;
BRCA	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg01420254	chr6:26195488	NA	0.56	8.65	0.32	4.11e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg24558204	chr6:135376177	HBS1L	0.45	12.26	0.44	3.46e-31	Red blood cell count;
BRCA	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg07636037	chr3:49044803	WDR6	0.98	29.32	0.76	2.17e-120	Parkinson's disease;
BRCA	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg14926445	chr8:58193284	C8orf71	-0.44	-8.25	-0.31	8.87e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22455342	chr2:225449267	CUL3	0.65	17.08	0.56	3.54e-54	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-12.09	-0.43	1.88e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.59	-0.32	6.49e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg12698349	chr2:225449008	CUL3	0.61	13.05	0.46	1.14e-34	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	9.05	0.34	1.69e-18	Bipolar disorder;
BRCA	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-13.32	-0.47	6.49e-36	Lymphocyte counts;
BRCA	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg13397359	chr6:42928475	GNMT	0.68	16.39	0.54	1.23e-50	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg00990874	chr7:1149470	C7orf50	-0.6	-10.33	-0.38	3.05e-23	Bronchopulmonary dysplasia;
BRCA	cis	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg06521331	chr12:34319734	NA	-0.49	-9.41	-0.35	8.53e-20	Resting heart rate;
BRCA	cis	rs28374715	0.662	rs521890	chr15:41473143	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.78	-16.64	-0.55	6.45e-52	Ulcerative colitis;
BRCA	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg20891283	chr12:69753455	YEATS4	0.84	28.4	0.75	2.24e-115	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg07211511	chr3:129823064	LOC729375	-0.77	-14.86	-0.51	4.12e-43	Blood pressure (smoking interaction);
BRCA	cis	rs6714710	0.603	rs6738389	chr2:98386731	A/G	cg26665480	chr2:98280029	ACTR1B	0.61	14.05	0.49	2.86e-39	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs16858210	0.529	rs10937154	chr3:183569489	C/T	cg25686905	chr3:183603175	PARL	-0.39	-8.39	-0.31	3.14e-16	Menopause (age at onset);
BRCA	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg10223061	chr2:219282414	VIL1	-0.27	-8.16	-0.31	1.85e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg16322792	chr1:120165303	ZNF697	0.58	15.43	0.52	6.54e-46	Systemic lupus erythematosus;
BRCA	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.58	12.91	0.45	4.89e-34	Hemoglobin concentration;
BRCA	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.26	-0.31	8.35e-16	Total body bone mineral density;
BRCA	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg09307838	chr4:120376055	NA	0.64	14.08	0.49	1.96e-39	Corneal astigmatism;
BRCA	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg18252515	chr7:66147081	NA	-0.87	-12.09	-0.43	1.84e-30	Diabetic kidney disease;
BRCA	cis	rs4363385	0.693	rs689008	chr1:153047100	G/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.04	-0.3	4.26e-15	Inflammatory skin disease;
BRCA	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg14983838	chr19:29218262	NA	0.54	10.08	0.37	2.78e-22	Methadone dose in opioid dependence;
BRCA	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	8.1	0.31	2.74e-15	Renal function-related traits (BUN);
BRCA	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg14019146	chr3:50243930	SLC38A3	0.39	9.44	0.35	6.68e-20	Menarche (age at onset);
BRCA	cis	rs1506636	0.962	rs629474	chr7:123399684	C/T	cg03229431	chr7:123269106	ASB15	0.61	13.78	0.48	4.97e-38	Plateletcrit;Platelet count;
BRCA	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	14.55	0.5	1.27e-41	Motion sickness;
BRCA	cis	rs4363385	0.747	rs10494285	chr1:152982285	G/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.36	-0.31	3.82e-16	Inflammatory skin disease;
BRCA	trans	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg26043149	chr18:55253948	FECH	-0.38	-8.28	-0.31	7.15e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1669338	0.588	rs3864050	chr3:3186769	T/C	cg16797762	chr3:3221439	CRBN	-0.69	-10.49	-0.38	7.27e-24	White matter integrity;
BRCA	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg19717773	chr7:2847554	GNA12	-0.5	-11.83	-0.42	2.41e-29	Plateletcrit;
BRCA	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.2	0.41	1.02e-26	Rheumatoid arthritis;
BRCA	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.02	15.04	0.51	5.48e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs17095355	1.000	rs17095350	chr10:111701708	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.39	-10.25	-0.38	6.11e-23	Biliary atresia;
BRCA	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg14036092	chr11:66035641	RAB1B	0.4	10.76	0.39	6.55e-25	Gout;
BRCA	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg02733842	chr7:1102375	C7orf50	-0.61	-11.52	-0.41	4.99e-28	Bronchopulmonary dysplasia;
BRCA	cis	rs1568889	0.592	rs17652117	chr11:28483645	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.48	-8.45	-0.32	2.02e-16	Bipolar disorder;
BRCA	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg02475777	chr4:1388615	CRIPAK	0.37	7.94	0.3	9.15e-15	Longevity;
BRCA	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.21	-0.31	1.26e-15	Total body bone mineral density;
BRCA	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.37	-8.94	-0.33	4.26e-18	Bipolar disorder;
BRCA	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg08917208	chr2:24149416	ATAD2B	1.06	14.57	0.5	1.01e-41	Lymphocyte counts;
BRCA	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg23888215	chr10:79422304	NA	0.6	11.27	0.41	5.41e-27	Bone mineral density;
BRCA	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23583168	chr7:148888333	NA	-0.85	-19.52	-0.61	6.96e-67	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4660306	1.000	rs4660870	chr1:45995231	T/A	cg24296786	chr1:45957014	TESK2	0.45	9.45	0.35	6.14e-20	Homocysteine levels;
BRCA	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.52	-0.32	1.13e-16	Monocyte percentage of white cells;
BRCA	trans	rs2562456	0.917	rs2681376	chr19:21715525	T/G	cg25042112	chr7:64838748	ZNF92	0.47	8.6	0.32	6.31e-17	Pain;
BRCA	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-12.45	-0.44	5.26e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs2559856	1.000	rs2559858	chr12:102089300	A/G	cg12924262	chr12:102091054	CHPT1	0.38	8.74	0.33	2.11e-17	Blood protein levels;
BRCA	cis	rs73242632	1.000	rs28474684	chr4:57875469	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	0.66	7.81	0.3	2.38e-14	Congenital heart disease (maternal effect);
BRCA	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.59	-13.55	-0.47	6.16e-37	Ulcerative colitis;
BRCA	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg07636037	chr3:49044803	WDR6	-0.49	-8.28	-0.31	7.32e-16	Menarche (age at onset);
BRCA	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg08847533	chr14:75593920	NEK9	-0.8	-18.81	-0.6	3.78e-63	Height;
BRCA	cis	rs6598955	0.543	rs4585968	chr1:26535146	G/A	cg12744634	chr1:26560303	CCDC21	0.32	8.64	0.32	4.46e-17	Obesity-related traits;
BRCA	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg00666640	chr1:248458726	OR2T12	0.33	9.04	0.34	1.79e-18	Common traits (Other);
BRCA	cis	rs4727443	0.966	rs66748925	chr7:99589843	A/G	cg22004693	chr7:99632812	ZKSCAN1	0.39	8.87	0.33	7.48e-18	Interstitial lung disease;
BRCA	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg16325326	chr1:53192061	ZYG11B	0.91	25.0	0.7	9.57e-97	Monocyte count;
BRCA	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.97	-0.33	3.38e-18	Neuroticism;
BRCA	cis	rs7617773	0.817	rs13072018	chr3:48320332	G/A	cg11946769	chr3:48343235	NME6	0.67	13.79	0.48	4.88e-38	Coronary artery disease;
BRCA	cis	rs1577917	1.000	rs2816821	chr6:86657084	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.45	-0.41	9.28e-28	Response to antipsychotic treatment;
BRCA	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg18252515	chr7:66147081	NA	-0.84	-12.14	-0.43	1.2e-30	Diabetic kidney disease;
BRCA	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg06627628	chr2:24431161	ITSN2	-0.79	-15.02	-0.51	6.5e-44	Asthma;
BRCA	cis	rs16854884	0.657	rs7637912	chr3:143749777	G/A	cg06585982	chr3:143692056	C3orf58	0.42	8.93	0.33	4.41e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg19052272	chr2:3704530	ALLC	0.35	8.36	0.31	4.02e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs4363385	0.818	rs4845512	chr1:152995241	C/T	cg25856811	chr1:152973957	SPRR3	-0.31	-8.2	-0.31	1.28e-15	Inflammatory skin disease;
BRCA	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg05714579	chr10:131428358	MGMT	-0.53	-12.35	-0.44	1.46e-31	Response to temozolomide;
BRCA	cis	rs6580649	0.598	rs1793913	chr12:48387025	T/A	cg05342945	chr12:48394962	COL2A1	-0.47	-9.43	-0.35	7.64e-20	Lung cancer;
BRCA	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg12463550	chr7:65579703	CRCP	0.38	8.12	0.31	2.38e-15	Aortic root size;
BRCA	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	8.18	0.31	1.48e-15	Menarche (age at onset);
BRCA	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.54	-0.32	9.45e-17	Total body bone mineral density;
BRCA	cis	rs4664304	1.000	rs55977890	chr2:160776866	C/T	cg01092293	chr2:160761427	LY75	-0.41	-9.62	-0.36	1.56e-20	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7903847	0.642	rs10882926	chr10:99160690	C/T	cg20016023	chr10:99160130	RRP12	0.26	8.3	0.31	6.14e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg04166393	chr7:2884313	GNA12	0.48	10.28	0.38	4.84e-23	Height;
BRCA	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.0	-0.46	1.92e-34	Migraine;Coronary artery disease;
BRCA	cis	rs793571	0.590	rs4775094	chr15:59115995	A/G	cg05156742	chr15:59063176	FAM63B	0.5	10.17	0.37	1.25e-22	Schizophrenia;
BRCA	trans	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg07817883	chr1:32538562	TMEM39B	-0.43	-8.5	-0.32	1.3e-16	Monocyte percentage of white cells;
BRCA	trans	rs208520	0.742	rs208454	chr6:66907783	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-15.98	-0.53	1.37e-48	Exhaled nitric oxide output;
BRCA	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	18.23	0.58	4.19e-60	Platelet count;
BRCA	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg25482853	chr8:67687455	SGK3	0.98	15.22	0.52	7.22e-45	Lung disease severity in cystic fibrosis;
BRCA	trans	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg06521331	chr12:34319734	NA	-0.51	-9.31	-0.35	2.03e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg13385521	chr17:29058706	SUZ12P	0.62	8.49	0.32	1.49e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg22907277	chr7:1156413	C7orf50	0.59	8.98	0.33	3.05e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg03676636	chr4:99064102	C4orf37	0.23	8.19	0.31	1.47e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg21573476	chr21:45109991	RRP1B	-0.35	-8.92	-0.33	4.7e-18	Mean corpuscular volume;
BRCA	cis	rs17092148	0.652	rs7269526	chr20:33053293	G/C	cg16810054	chr20:33298113	TP53INP2	0.44	9.46	0.35	5.74e-20	Neuroticism;
BRCA	cis	rs1941023	0.606	rs3825020	chr11:60184191	G/A	cg08716584	chr11:60157161	MS4A7	-0.36	-8.53	-0.32	1.08e-16	Congenital heart disease (maternal effect);
BRCA	cis	rs55665837	1.000	rs11023215	chr11:14436970	C/T	cg19336497	chr11:14380999	RRAS2	-0.36	-9.34	-0.35	1.6e-19	Vitamin D levels;
BRCA	trans	rs3960554	0.529	rs6465049	chr7:75874489	A/G	cg19862616	chr7:65841803	NCRNA00174	0.46	10.36	0.38	2.44e-23	Eotaxin levels;
BRCA	trans	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg11693508	chr17:37793320	STARD3	-0.55	-10.46	-0.38	9.66e-24	Bipolar disorder;
BRCA	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg04455712	chr21:45112962	RRP1B	0.41	10.51	0.38	5.95e-24	Mean corpuscular volume;
BRCA	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.93e-24	Motion sickness;
BRCA	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg01483505	chr11:975446	AP2A2	0.32	8.72	0.33	2.44e-17	Alzheimer's disease (late onset);
BRCA	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg18132916	chr6:79620363	NA	-0.48	-11.03	-0.4	5.2e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg08601574	chr20:25228251	PYGB	0.35	8.39	0.31	3.21e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.68	0.61	9.04e-68	Alzheimer's disease;
BRCA	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg05340658	chr4:99064831	C4orf37	0.7	17.4	0.57	8.36e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12618769	0.652	rs1516085	chr2:99232312	G/A	cg10123293	chr2:99228465	UNC50	0.41	8.4	0.32	2.87e-16	Bipolar disorder;
BRCA	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18404041	chr3:52824283	ITIH1	-0.39	-11.67	-0.42	1.13e-28	Bipolar disorder;
BRCA	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg10932868	chr11:921992	NA	0.49	12.57	0.45	1.54e-32	Alzheimer's disease (late onset);
BRCA	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg03146154	chr1:46216737	IPP	0.45	10.13	0.37	1.84e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6604026	0.740	rs6700585	chr1:93364156	T/G	cg17283838	chr1:93427260	FAM69A	-0.4	-8.16	-0.31	1.82e-15	Multiple sclerosis;
BRCA	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.6	12.61	0.45	1.02e-32	Personality dimensions;
BRCA	trans	rs3857536	0.706	rs7755994	chr6:66891747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-9.49	-0.35	4.6e-20	Blood trace element (Cu levels);
BRCA	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-11.56	-0.42	3.35e-28	Lymphocyte counts;
BRCA	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg08847533	chr14:75593920	NEK9	-0.79	-18.58	-0.59	6.17e-62	Height;
BRCA	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg17845761	chr1:175162550	KIAA0040	0.25	9.55	0.35	2.79e-20	Alcohol dependence;
BRCA	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	8.11	0.31	2.6e-15	Uric acid levels;
BRCA	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg17757837	chr7:157058334	UBE3C	-0.62	-14.74	-0.5	1.46e-42	Body mass index;
BRCA	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg01324343	chr3:183735012	ABCC5	0.8	17.9	0.58	2.13e-58	Anterior chamber depth;
BRCA	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg26608667	chr7:1196370	ZFAND2A	0.41	9.99	0.37	6.22e-22	Longevity;Endometriosis;
BRCA	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.6	12.25	0.44	3.77e-31	Monocyte percentage of white cells;
BRCA	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg26384229	chr12:38710491	ALG10B	0.83	22.31	0.66	5.94e-82	Heart rate;
BRCA	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg15704280	chr7:45808275	SEPT13	-0.73	-15.02	-0.51	7e-44	Height;
BRCA	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg07395648	chr5:131743802	NA	0.37	8.1	0.31	2.77e-15	Breast cancer;
BRCA	cis	rs11677370	0.603	rs1454242	chr2:3848532	G/A	cg17052675	chr2:3827356	NA	-0.51	-12.58	-0.45	1.4e-32	Type 2 diabetes;
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg23978390	chr7:1156363	C7orf50	0.48	11.2	0.41	9.98e-27	Longevity;Endometriosis;
BRCA	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg18357645	chr12:58087776	OS9	-0.31	-8.3	-0.31	6.06e-16	Multiple sclerosis;
BRCA	trans	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg06521331	chr12:34319734	NA	-0.51	-9.11	-0.34	1.04e-18	Bladder cancer;
BRCA	trans	rs11039798	0.841	rs7294179	chr11:48765408	G/A	cg15704280	chr7:45808275	SEPT13	0.65	7.82	0.3	2.18e-14	Axial length;
BRCA	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg17845761	chr1:175162550	KIAA0040	-0.27	-10.05	-0.37	3.53e-22	Alcohol dependence;
BRCA	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg04450456	chr4:17643702	FAM184B	-0.34	-9.84	-0.36	2.23e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg15704280	chr7:45808275	SEPT13	-0.49	-9.4	-0.35	9.44e-20	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	13.11	0.46	6.16e-35	Bone mineral density;
BRCA	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg08999081	chr20:33150536	PIGU	-0.47	-12.84	-0.45	9.74e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12826209	chr6:26865740	GUSBL1	0.58	10.33	0.38	3.08e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg24675658	chr1:53192096	ZYG11B	0.63	15.2	0.52	8.74e-45	Monocyte count;
BRCA	cis	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.42	-0.32	2.51e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg17330251	chr7:94953956	PON1	-0.43	-9.08	-0.34	1.33e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg16339924	chr4:17578868	LAP3	0.57	13.86	0.48	2.17e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg11062466	chr8:58055876	NA	0.41	7.84	0.3	1.84e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs7020830	0.898	rs12554874	chr9:37073902	C/T	cg14294708	chr9:37120828	ZCCHC7	1.17	40.29	0.85	1.44e-177	Schizophrenia;
BRCA	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg03433033	chr1:76189801	ACADM	0.46	9.67	0.36	9.77e-21	Daytime sleep phenotypes;
BRCA	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg23649088	chr2:200775458	C2orf69	0.56	8.22	0.31	1.1e-15	Schizophrenia;
BRCA	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.53	-11.02	-0.4	5.67e-26	Lymphocyte counts;
BRCA	cis	rs1018836	0.884	rs2073640	chr8:91594853	A/G	cg16814680	chr8:91681699	NA	-0.57	-12.49	-0.44	3.47e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13046373	0.535	rs13051529	chr21:32029743	G/C	cg06468780	chr21:31798236	KRTAP13-3	0.34	8.31	0.31	5.76e-16	HDL cholesterol;
BRCA	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg15556689	chr8:8085844	FLJ10661	0.37	8.73	0.33	2.21e-17	Retinal vascular caliber;
BRCA	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg26384229	chr12:38710491	ALG10B	0.84	22.26	0.66	1.06e-81	Heart rate;
BRCA	cis	rs7593730	0.636	rs6757491	chr2:161147743	G/C	cg22609984	chr2:161126801	NA	0.37	8.09	0.3	3.05e-15	Type 2 diabetes;
BRCA	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg11645453	chr3:52864694	ITIH4	0.44	10.65	0.39	1.73e-24	Schizophrenia;
BRCA	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.69	0.42	9.44e-29	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.33	0.57	1.88e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13046373	0.535	rs1395778	chr21:31985502	G/C	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.26	0.31	8.46e-16	HDL cholesterol;
BRCA	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.79	-11.37	-0.41	2.07e-27	Schizophrenia;
BRCA	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg02753203	chr1:228287806	NA	-0.57	-11.98	-0.43	5.42e-30	Diastolic blood pressure;
BRCA	cis	rs2559856	1.000	rs2559860	chr12:102087636	C/T	cg12924262	chr12:102091054	CHPT1	0.37	8.5	0.32	1.32e-16	Blood protein levels;
BRCA	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg12292205	chr6:26970375	C6orf41	-0.64	-10.0	-0.37	5.8e-22	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg08917208	chr2:24149416	ATAD2B	-0.56	-8.62	-0.32	5.44e-17	Lymphocyte counts;
BRCA	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg12311346	chr5:56204834	C5orf35	-0.45	-9.2	-0.34	5.03e-19	Coronary artery disease;
BRCA	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg15017067	chr4:17643749	FAM184B	0.32	9.82	0.36	2.68e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg26384229	chr12:38710491	ALG10B	0.57	12.23	0.44	4.52e-31	Morning vs. evening chronotype;
BRCA	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg09307838	chr4:120376055	NA	0.69	14.89	0.51	2.79e-43	Corneal astigmatism;
BRCA	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg18154014	chr19:37997991	ZNF793	0.47	9.37	0.35	1.25e-19	Coronary artery calcification;
BRCA	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-15.44	-0.52	6.09e-46	Total cholesterol levels;
BRCA	cis	rs11229555	0.874	rs11605297	chr11:58296806	G/A	cg15696309	chr11:58395628	NA	-0.53	-11.54	-0.42	4.18e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs1997103	1.000	rs4947501	chr7:55407342	C/T	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg09165964	chr15:75287851	SCAMP5	0.83	18.89	0.6	1.44e-63	Blood trace element (Zn levels);
BRCA	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.5	-9.86	-0.36	1.97e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs13082711	0.911	rs13089870	chr3:27447626	C/T	cg02860705	chr3:27208620	NA	0.54	10.73	0.39	8.04e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24531977	chr5:56204891	C5orf35	-0.86	-17.89	-0.58	2.57e-58	Initial pursuit acceleration;
BRCA	cis	rs9875589	0.957	rs62234598	chr3:13964610	G/A	cg19554555	chr3:13937349	NA	0.4	8.46	0.32	1.8e-16	Ovarian reserve;
BRCA	trans	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.75	-0.36	4.89e-21	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.818	rs3820141	chr1:153004778	C/T	cg24667326	chr1:152973720	SPRR3	-0.33	-9.22	-0.34	4.37e-19	Inflammatory skin disease;
BRCA	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.25	0.34	3.4e-19	Tonsillectomy;
BRCA	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.13	0.31	2.28e-15	Total cholesterol levels;
BRCA	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	8.14	0.31	2.14e-15	Aortic root size;
BRCA	cis	rs3820928	1.000	rs10197757	chr2:227763244	A/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.53	-0.32	1.04e-16	Pulmonary function;
BRCA	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg25208724	chr1:156163844	SLC25A44	1.03	33.1	0.79	1.08e-140	Testicular germ cell tumor;
BRCA	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	ch.11.42038R	chr11:967971	AP2A2	0.52	16.63	0.55	7.59e-52	Alzheimer's disease (late onset);
BRCA	cis	rs6120849	0.754	rs6087667	chr20:33651887	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	10.28	0.38	4.66e-23	Protein C levels;
BRCA	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg17063962	chr7:91808500	NA	0.61	14.57	0.5	9.53e-42	Breast cancer;
BRCA	cis	rs738321	0.723	rs9622726	chr22:38506688	A/G	cg25457927	chr22:38595422	NA	-0.33	-11.38	-0.41	1.94e-27	Breast cancer;
BRCA	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg23711669	chr6:146136114	FBXO30	-0.71	-16.98	-0.56	1.23e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg18357645	chr12:58087776	OS9	0.35	9.51	0.35	3.7799999999999997e-20	Multiple sclerosis;
BRCA	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg24642439	chr20:33292090	TP53INP2	-0.41	-8.19	-0.31	1.42e-15	Height;
BRCA	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.84	0.36	2.34e-21	Bipolar disorder;
BRCA	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg03146154	chr1:46216737	IPP	0.52	11.63	0.42	1.68e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs2840044	0.554	rs225267	chr17:33964228	T/C	cg19694781	chr19:47549865	TMEM160	-1.06	-21.58	-0.65	5.04e-78	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg20283391	chr11:68216788	NA	-0.45	-8.88	-0.33	6.46e-18	Total body bone mineral density;
BRCA	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg03060546	chr3:49711283	APEH	-0.56	-10.88	-0.4	2.16e-25	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9394841	0.667	rs3747750	chr6:41760372	C/G	cg08135965	chr6:41755394	TOMM6	0.5	8.13	0.31	2.18e-15	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs17095355	1.000	rs1376111	chr10:111707255	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.38	-9.92	-0.37	1.14e-21	Biliary atresia;
BRCA	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.35	0.49	1.13e-40	Motion sickness;
BRCA	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.06	0.37	3.41e-22	Bladder cancer;
BRCA	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg08392591	chr16:89556376	ANKRD11	0.55	13.45	0.47	1.7e-36	Multiple myeloma (IgH translocation);
BRCA	cis	rs13161895	1.000	rs35135297	chr5:179469532	T/C	cg02702477	chr5:179499311	RNF130	0.46	8.53	0.32	1.03e-16	LDL cholesterol;
BRCA	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg06212747	chr3:49208901	KLHDC8B	0.47	9.4	0.35	9.73e-20	Parkinson's disease;
BRCA	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg16576597	chr16:28551801	NUPR1	0.35	9.64	0.36	1.28e-20	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg05868516	chr6:26286170	HIST1H4H	0.43	9.61	0.36	1.6e-20	Educational attainment;
BRCA	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg19274703	chr22:41806451	NA	0.39	9.44	0.35	6.82e-20	Vitiligo;
BRCA	cis	rs10208940	0.920	rs10205573	chr2:68829419	A/T	cg12452813	chr2:68675892	NA	0.5	8.73	0.33	2.14e-17	Urate levels in lean individuals;
BRCA	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-9.04	-0.34	1.88e-18	Tonsillectomy;
BRCA	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.22	-0.37	8.46e-23	Psoriasis;
BRCA	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg14196790	chr5:131705035	SLC22A5	-0.41	-10.1	-0.37	2.35e-22	Breast cancer;Mosquito bite size;
BRCA	cis	rs4363385	0.747	rs1577963	chr1:152961882	T/C	cg21543102	chr1:152974771	SPRR3	-0.28	-8.15	-0.31	1.88e-15	Inflammatory skin disease;
BRCA	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.27e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg10523679	chr1:76189770	ACADM	0.68	12.51	0.44	2.85e-32	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.31	-9.5	-0.35	4.18e-20	Bipolar disorder;
BRCA	cis	rs10899021	1.000	rs11236186	chr11:74362865	G/A	cg25880958	chr11:74394337	NA	-0.5	-7.89	-0.3	1.29e-14	Response to metformin (IC50);
BRCA	cis	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg04990556	chr1:26633338	UBXN11	0.54	8.86	0.33	8.17e-18	Obesity-related traits;
BRCA	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.54	0.42	4.17e-28	Bipolar disorder;
BRCA	cis	rs36051895	0.664	rs10974963	chr9:5101305	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-8.81	-0.33	1.15e-17	Pediatric autoimmune diseases;
BRCA	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg11764359	chr7:65958608	NA	0.64	11.31	0.41	3.77e-27	Aortic root size;
BRCA	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg24060327	chr5:131705240	SLC22A5	0.47	9.64	0.36	1.29e-20	Blood metabolite levels;
BRCA	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	11.55	0.42	3.81e-28	Iron status biomarkers;
BRCA	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.64	0.55	6.41e-52	Colorectal cancer;
BRCA	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.66	-15.04	-0.51	5.76e-44	Axial length;
BRCA	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg01877450	chr7:97915802	BRI3	-0.39	-8.86	-0.33	7.95e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6087990	0.806	rs6141814	chr20:31368960	C/A	cg13636640	chr20:31349939	DNMT3B	0.62	19.09	0.6	1.19e-64	Ulcerative colitis;
BRCA	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg24101359	chr6:42928495	GNMT	0.55	12.55	0.44	1.87e-32	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18876405	chr7:65276391	NA	0.69	17.99	0.58	7.89e-59	Aortic root size;
BRCA	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11764359	chr7:65958608	NA	-0.76	-16.96	-0.56	1.47e-53	Aortic root size;
BRCA	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.74	16.27	0.54	4.93e-50	Cognitive ability;
BRCA	cis	rs4742903	1.000	rs3780535	chr9:106894211	A/C	cg21169611	chr9:106856078	SMC2	0.37	9.69	0.36	8.6e-21	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg21535247	chr6:8435926	SLC35B3	0.42	9.42	0.35	7.86e-20	Motion sickness;
BRCA	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg08601574	chr20:25228251	PYGB	0.35	8.49	0.32	1.46e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-8.56	-0.32	8.56e-17	Bladder cancer;
BRCA	cis	rs9287719	0.674	rs12622551	chr2:10720443	G/A	cg00105475	chr2:10696890	NA	0.41	9.19	0.34	5.52e-19	Prostate cancer;
BRCA	cis	rs7851660	0.967	rs12348691	chr9:100608682	G/A	cg13688889	chr9:100608707	NA	-0.35	-8.63	-0.32	5.03e-17	Strep throat;
BRCA	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11890956	chr21:40555474	PSMG1	0.98	22.85	0.67	6.67e-85	Cognitive function;
BRCA	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.45	-10.74	-0.39	7.49e-25	IgG glycosylation;
BRCA	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg15704280	chr7:45808275	SEPT13	-0.53	-10.26	-0.38	5.58e-23	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg22974920	chr21:40686053	BRWD1	0.39	8.95	0.33	3.88e-18	Cognitive function;
BRCA	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg00080972	chr5:178986291	RUFY1	0.44	10.98	0.4	7.99e-26	Lung cancer;
BRCA	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg12564285	chr5:131593104	PDLIM4	0.33	8.28	0.31	7.07e-16	Blood metabolite levels;
BRCA	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg24829409	chr8:58192753	C8orf71	-0.5	-8.21	-0.31	1.24e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg25358565	chr5:93447407	FAM172A	1.23	18.11	0.58	1.82e-59	Diabetic retinopathy;
BRCA	trans	rs629535	0.783	rs510632	chr8:70034570	A/G	cg21567404	chr3:27674614	NA	1.0	21.1	0.64	2.04e-75	Dupuytren's disease;
BRCA	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.5	-0.35	4.13e-20	Tonsillectomy;
BRCA	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.79	-0.33	1.43e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.27	8.86	0.33	7.79e-18	Systemic lupus erythematosus;
BRCA	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg08514558	chr10:81106712	PPIF	0.37	8.91	0.33	5.23e-18	Height;
BRCA	cis	rs10189230	0.868	rs5002064	chr2:222353508	G/A	cg14652038	chr2:222343519	EPHA4	0.47	13.02	0.46	1.53e-34	Urate levels in lean individuals;
BRCA	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06028605	chr16:24865363	SLC5A11	0.4	8.34	0.31	4.6e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg00105475	chr2:10696890	NA	0.44	10.28	0.38	4.62e-23	Prostate cancer;
BRCA	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.63	-13.61	-0.47	3.22e-37	Lymphocyte percentage of white cells;
BRCA	cis	rs6545883	0.759	rs777585	chr2:61412559	A/G	cg15711740	chr2:61764176	XPO1	0.48	11.86	0.42	1.82e-29	Tuberculosis;
BRCA	cis	rs7523050	0.908	rs12405585	chr1:109397229	C/A	cg08274380	chr1:109419600	GPSM2	0.84	12.88	0.45	6.8e-34	Fat distribution (HIV);
BRCA	cis	rs7020830	0.867	rs1339553	chr9:37266123	C/G	cg14294708	chr9:37120828	ZCCHC7	1.13	37.13	0.83	1.11e-161	Schizophrenia;
BRCA	cis	rs2742234	0.541	rs871763	chr10:43734188	C/T	cg15436174	chr10:43711423	RASGEF1A	0.52	10.43	0.38	1.25e-23	Hirschsprung disease;
BRCA	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg06238570	chr21:40685208	BRWD1	-0.43	-8.53	-0.32	1.04e-16	Cognitive function;
BRCA	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg03128534	chr1:43423976	SLC2A1	0.51	12.28	0.44	2.84e-31	Red cell distribution width;
BRCA	cis	rs7246657	0.722	rs16958863	chr19:38124235	A/G	cg18154014	chr19:37997991	ZNF793	0.47	8.98	0.33	2.9e-18	Coronary artery calcification;
BRCA	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	9.29	0.34	2.48e-19	Rheumatoid arthritis;
BRCA	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg08885076	chr2:99613938	TSGA10	0.46	10.91	0.4	1.53e-25	Chronic sinus infection;
BRCA	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.47	-0.32	1.73e-16	Total body bone mineral density;
BRCA	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg05623727	chr3:50126028	RBM5	0.37	8.69	0.33	2.96e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg05083358	chr7:2394359	EIF3B	-0.52	-8.12	-0.31	2.44e-15	Multiple sclerosis;
BRCA	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg26384229	chr12:38710491	ALG10B	0.47	12.21	0.43	5.95e-31	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.17	-0.34	6.43e-19	Extrinsic epigenetic age acceleration;
BRCA	trans	rs6499188	0.522	rs8046299	chr16:68672346	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.48	8.7	0.33	2.82e-17	Ulcerative colitis;
BRCA	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg02951883	chr7:2050386	MAD1L1	-0.4	-8.83	-0.33	9.67e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs9790314	0.718	rs6774635	chr3:160847908	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-10.5	-0.38	6.55e-24	Morning vs. evening chronotype;
BRCA	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg21045802	chr8:109455806	TTC35	0.39	8.97	0.33	3.35e-18	Dupuytren's disease;
BRCA	cis	rs77972916	0.536	rs11694173	chr2:43590899	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.66	10.28	0.38	4.61e-23	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.46	0.55	5.2e-51	Colorectal cancer;
BRCA	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg17366294	chr4:99064904	C4orf37	0.41	9.27	0.34	2.92e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9790314	0.690	rs4679930	chr3:160842875	C/G	cg03342759	chr3:160939853	NMD3	-0.53	-11.33	-0.41	3.02e-27	Morning vs. evening chronotype;
BRCA	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-11.02	-0.4	5.54e-26	Uric acid levels;
BRCA	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg13073564	chr4:8508604	NA	-0.39	-10.56	-0.39	3.78e-24	Response to antineoplastic agents;
BRCA	trans	rs8002861	0.641	rs4942252	chr13:44443039	C/T	cg12856521	chr11:46389249	DGKZ	0.37	8.02	0.3	5.16e-15	Leprosy;
BRCA	trans	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-8.05	-0.3	4.18e-15	Triglycerides;
BRCA	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	11.39	0.41	1.65e-27	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11764359	chr7:65958608	NA	-0.77	-17.87	-0.58	3.29e-58	Aortic root size;
BRCA	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg08501292	chr6:25962987	TRIM38	0.59	8.07	0.3	3.59e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs752010	0.841	rs6661784	chr1:42080312	A/T	cg06885757	chr1:42089581	HIVEP3	0.24	9.15	0.34	7.69e-19	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs9503598	0.644	rs10498663	chr6:3430439	C/T	cg09127107	chr6:3438702	SLC22A23	0.28	7.99	0.3	6.29e-15	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00802000	chr16:706648	WDR90	-0.39	-9.37	-0.35	1.24e-19	Height;
BRCA	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg14675211	chr2:100938903	LONRF2	0.44	9.66	0.36	1.08e-20	Intelligence (multi-trait analysis);
BRCA	trans	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg13565492	chr6:43139072	SRF	-0.78	-10.66	-0.39	1.5e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg00750074	chr16:89608354	SPG7	0.37	10.07	0.37	3.16e-22	Multiple myeloma (IgH translocation);
BRCA	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08219700	chr8:58056026	NA	0.47	8.51	0.32	1.22e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9309711	0.736	rs28619526	chr2:3496804	T/C	cg16153549	chr2:3496821	NA	-0.45	-10.82	-0.39	3.6e-25	Neurofibrillary tangles;
BRCA	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg03676636	chr4:99064102	C4orf37	0.21	8.11	0.31	2.58e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs68170813	0.599	rs11769901	chr7:106958505	G/A	cg02696742	chr7:106810147	HBP1	-0.54	-8.72	-0.33	2.46e-17	Coronary artery disease;
BRCA	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.31	-7.88	-0.3	1.46e-14	Total body bone mineral density;
BRCA	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg00277334	chr10:82204260	NA	0.41	8.13	0.31	2.27e-15	Post bronchodilator FEV1;
BRCA	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18876405	chr7:65276391	NA	-0.63	-15.5	-0.52	3.07e-46	Aortic root size;
BRCA	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.5	8.77	0.33	1.61e-17	Body mass index (adult);
BRCA	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg08470875	chr2:26401718	FAM59B	-0.62	-9.44	-0.35	6.78e-20	Gut microbiome composition (summer);
BRCA	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.35e-15	Prostate cancer;
BRCA	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03264133	chr6:25882463	NA	-0.6	-12.42	-0.44	7.38e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg18132916	chr6:79620363	NA	-0.49	-11.13	-0.4	2.05e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs735860	0.726	rs209507	chr6:53194768	T/A	cg10236188	chr6:53219634	NA	0.38	8.05	0.3	4.13e-15	Glaucoma;
BRCA	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.37	-8.63	-0.32	4.96e-17	Longevity;Endometriosis;
BRCA	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg08992911	chr2:238395768	MLPH	-0.36	-7.85	-0.3	1.78e-14	Prostate cancer;
BRCA	cis	rs7737355	0.947	rs1468303	chr5:130804400	T/C	cg06307176	chr5:131281290	NA	-0.53	-10.47	-0.38	8.48e-24	Life satisfaction;
BRCA	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.63	-13.2	-0.46	2.3e-35	Lung cancer;
BRCA	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg10820045	chr2:198174542	NA	-0.4	-9.38	-0.35	1.09e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg09307838	chr4:120376055	NA	-0.58	-12.34	-0.44	1.57e-31	Corneal astigmatism;
BRCA	cis	rs12618769	0.597	rs2278214	chr2:99135738	A/G	cg10123293	chr2:99228465	UNC50	-0.41	-7.97	-0.3	7.52e-15	Bipolar disorder;
BRCA	cis	rs7633770	0.786	rs1607737	chr3:46681846	G/C	cg11219411	chr3:46661640	NA	0.65	16.96	0.56	1.59e-53	Coronary artery disease;
BRCA	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg20503657	chr10:835505	NA	-0.54	-9.75	-0.36	4.95e-21	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg08754654	chr5:154026448	NA	-0.42	-10.07	-0.37	2.95e-22	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg11247378	chr22:39784982	NA	-0.63	-15.43	-0.52	6.89e-46	Intelligence (multi-trait analysis);
BRCA	cis	rs7903847	0.620	rs9787454	chr10:99155561	A/T	cg20016023	chr10:99160130	RRP12	-0.26	-8.53	-0.32	1.03e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg08754654	chr5:154026448	NA	-0.41	-9.9	-0.36	1.32e-21	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.97	13.78	0.48	5.34e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9837602	0.938	rs17393059	chr3:99761908	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	10.54	0.38	4.86e-24	Breast cancer;
BRCA	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg07395648	chr5:131743802	NA	-0.4	-8.5	-0.32	1.29e-16	Blood metabolite levels;
BRCA	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg06064525	chr11:970664	AP2A2	-0.48	-16.28	-0.54	4.02e-50	Alzheimer's disease (late onset);
BRCA	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-12.67	-0.45	5.36e-33	Neuroticism;
BRCA	cis	rs67981189	0.896	rs2010061	chr14:71366196	A/G	cg15816911	chr14:71606274	NA	-0.36	-8.2	-0.31	1.32e-15	Schizophrenia;
BRCA	cis	rs7586879	0.964	rs11688665	chr2:25121168	G/T	cg04586622	chr2:25135609	ADCY3	0.4	9.29	0.34	2.44e-19	Body mass index;
BRCA	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg06784218	chr1:46089804	CCDC17	0.45	10.91	0.4	1.54e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	7.15e-19	Alzheimer's disease (late onset);
BRCA	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg11766577	chr21:47581405	C21orf56	-0.49	-10.59	-0.39	2.87e-24	Testicular germ cell tumor;
BRCA	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg02196655	chr2:10830764	NOL10	-0.31	-8.37	-0.31	3.73e-16	Prostate cancer;
BRCA	cis	rs6450176	0.625	rs3822499	chr5:53289459	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-15.15	-0.51	1.55e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg15704280	chr7:45808275	SEPT13	0.54	9.1	0.34	1.11e-18	Axial length;
BRCA	cis	rs412050	0.501	rs2876980	chr22:22106535	C/T	cg17089214	chr22:22089827	YPEL1	-0.59	-9.29	-0.34	2.46e-19	Attention deficit hyperactivity disorder;
BRCA	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.58	10.28	0.38	5.01e-23	Gut microbiome composition (summer);
BRCA	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg03929089	chr4:120376271	NA	0.76	17.67	0.57	3.58e-57	Coronary artery disease;
BRCA	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg00757033	chr12:89920650	WDR51B	0.52	10.44	0.38	1.13e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg00757033	chr12:89920650	WDR51B	0.54	11.01	0.4	6.42e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg11789530	chr4:8429930	ACOX3	-0.52	-12.27	-0.44	3.27e-31	Response to antineoplastic agents;
BRCA	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg05340658	chr4:99064831	C4orf37	-0.45	-10.24	-0.38	6.58e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7589728	1.000	rs11893832	chr2:88507537	G/C	cg04511125	chr2:88470314	THNSL2	0.72	9.97	0.37	7.35e-22	Plasma clusterin levels;
BRCA	cis	rs2882667	0.690	rs288031	chr5:138216066	T/C	cg04439458	chr5:138467593	SIL1	-0.31	-7.96	-0.3	7.69e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg01236616	chr12:121019343	POP5	1.24	27.02	0.73	8.09e-108	Type 1 diabetes nephropathy;
BRCA	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg26597838	chr10:835615	NA	1.3	21.81	0.65	2.87e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg24692254	chr21:30365293	RNF160	0.62	14.15	0.49	9.85e-40	Selective IgA deficiency;
BRCA	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	10.65	0.39	1.76e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9469578	1.000	rs60447213	chr6:33715159	G/T	cg18708504	chr6:33715942	IP6K3	0.7	10.19	0.37	1.09e-22	Phosphorus levels;
BRCA	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg22903657	chr4:1355424	KIAA1530	-0.37	-8.08	-0.3	3.34e-15	Obesity-related traits;
BRCA	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	10.67	0.39	1.36e-24	Motion sickness;
BRCA	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg26384229	chr12:38710491	ALG10B	0.77	17.64	0.57	4.77e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6580649	0.941	rs1793933	chr12:48396450	G/T	cg24011408	chr12:48396354	COL2A1	0.55	9.26	0.34	3.07e-19	Lung cancer;
BRCA	trans	rs629535	0.748	rs58675625	chr8:70034924	T/C	cg21567404	chr3:27674614	NA	1.0	21.1	0.64	2.04e-75	Dupuytren's disease;
BRCA	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg08999081	chr20:33150536	PIGU	0.37	9.54	0.35	2.89e-20	Coronary artery disease;
BRCA	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg23229984	chr5:148520753	ABLIM3	0.35	8.83	0.33	1.03e-17	Breast cancer;
BRCA	cis	rs4077515	0.901	rs11791262	chr9:139271919	C/T	cg14019695	chr9:139328340	INPP5E	0.32	8.13	0.31	2.28e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.28	8.51	0.32	1.26e-16	Prostate cancer;
BRCA	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg08859206	chr1:53392774	SCP2	-0.4	-8.3	-0.31	6.42e-16	Monocyte count;
BRCA	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg26395211	chr5:140044315	WDR55	0.38	8.55	0.32	9.05e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-11.47	-0.41	8.14e-28	Gut microbiome composition (summer);
BRCA	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg00666640	chr1:248458726	OR2T12	0.3	8.3	0.31	6.21e-16	Common traits (Other);
BRCA	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg02175503	chr12:58329896	NA	0.57	13.72	0.48	9.48e-38	Intelligence (multi-trait analysis);
BRCA	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.91	-0.36	1.21e-21	Triglycerides;
BRCA	cis	rs9790314	0.747	rs9820825	chr3:160848155	A/G	cg03342759	chr3:160939853	NMD3	-0.5	-10.14	-0.37	1.7e-22	Morning vs. evening chronotype;
BRCA	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.71	-0.53	2.9e-47	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7072216	0.763	rs12763044	chr10:100167451	C/G	cg26618903	chr10:100175079	PYROXD2	-0.31	-8.96	-0.33	3.58e-18	Metabolite levels;
BRCA	cis	rs812925	0.502	rs2084318	chr2:61652601	C/T	cg15711740	chr2:61764176	XPO1	0.34	8.3	0.31	6.14e-16	Immature fraction of reticulocytes;
BRCA	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg15556689	chr8:8085844	FLJ10661	-0.34	-9.29	-0.34	2.42e-19	Monocyte count;
BRCA	cis	rs34779708	0.733	rs7087099	chr10:35541982	C/T	cg03585969	chr10:35415529	CREM	0.45	9.14	0.34	7.92e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12050794	0.636	rs4506844	chr15:72509138	C/T	cg16672083	chr15:72433130	SENP8	0.63	14.87	0.51	3.5e-43	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg12437481	chr16:420112	MRPL28	-0.4	-8.74	-0.33	1.99e-17	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg12432903	chr7:1882776	MAD1L1	0.45	8.03	0.3	4.66e-15	Bipolar disorder;
BRCA	cis	rs3767633	0.925	rs2055539	chr1:161807866	T/C	cg09175582	chr1:161736000	ATF6	0.53	8.81	0.33	1.18e-17	IgG glycosylation;
BRCA	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg10932868	chr11:921992	NA	0.49	12.63	0.45	8.39e-33	Alzheimer's disease (late onset);
BRCA	cis	rs10992471	0.528	rs10429459	chr9:95258119	C/T	cg14631576	chr9:95140430	CENPP	0.34	8.61	0.32	5.49e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg23711669	chr6:146136114	FBXO30	-0.78	-18.84	-0.6	2.64e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg11764359	chr7:65958608	NA	0.63	10.87	0.39	2.38e-25	Aortic root size;
BRCA	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.58	0.39	3.28e-24	IgG glycosylation;
BRCA	cis	rs2652834	0.904	rs34786874	chr15:63397504	A/G	cg05507819	chr15:63340323	TPM1	0.45	8.09	0.3	3.04e-15	HDL cholesterol;
BRCA	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg14784868	chr12:69753453	YEATS4	0.79	25.23	0.71	5.18e-98	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.43	-9.58	-0.35	2.12e-20	Longevity;Endometriosis;
BRCA	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg26516362	chr5:178986906	RUFY1	0.38	10.61	0.39	2.43e-24	Lung cancer;
BRCA	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg16339924	chr4:17578868	LAP3	-0.54	-12.49	-0.44	3.58e-32	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs495337	0.721	rs11696404	chr20:48548280	A/C	cg17835207	chr20:48524531	SPATA2	-0.69	-16.8	-0.55	1.04e-52	Psoriasis;
BRCA	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg09877947	chr5:131593287	PDLIM4	-0.36	-7.91	-0.3	1.11e-14	Breast cancer;
BRCA	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg13319975	chr6:146136371	FBXO30	-0.35	-8.15	-0.31	1.97e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg06623918	chr6:96969491	KIAA0776	0.9	25.8	0.71	3.81e-101	Headache;
BRCA	trans	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	10.08	0.37	2.75e-22	Mean corpuscular volume;
BRCA	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11764359	chr7:65958608	NA	0.62	13.52	0.47	7.83e-37	Aortic root size;
BRCA	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07080220	chr10:102295463	HIF1AN	0.48	11.1	0.4	2.65e-26	Palmitoleic acid (16:1n-7) levels;
BRCA	trans	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.29	0.38	4.46e-23	Mean corpuscular volume;
BRCA	cis	rs11229555	0.645	rs12802819	chr11:58174747	T/G	cg15696309	chr11:58395628	NA	-0.45	-9.74	-0.36	5.23e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05025164	chr4:1340916	KIAA1530	0.78	15.89	0.53	3.59e-48	Longevity;
BRCA	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg04727924	chr7:799746	HEATR2	-0.55	-10.78	-0.39	5.21e-25	Cerebrospinal P-tau181p levels;
BRCA	trans	rs526821	0.595	rs532278	chr11:55344983	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.37	-8.2	-0.31	1.36e-15	Pediatric bone mineral density (spine);
BRCA	cis	rs9420	0.961	rs80304923	chr11:57522823	C/G	cg19752551	chr11:57585705	CTNND1	-0.51	-12.56	-0.45	1.68e-32	Schizophrenia;
BRCA	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg10932868	chr11:921992	NA	0.39	9.46	0.35	5.65e-20	Alzheimer's disease (late onset);
BRCA	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg02659138	chr7:134003124	SLC35B4	0.35	9.98	0.37	6.88e-22	Mean platelet volume;
BRCA	trans	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17712092	chr4:129076599	LARP1B	0.82	21.88	0.65	1.22e-79	Eosinophil percentage of white cells;
BRCA	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	11.51	0.41	5.21e-28	Electroencephalogram traits;
BRCA	cis	rs7539409	0.651	rs6696140	chr1:84317468	C/T	cg10977910	chr1:84465055	TTLL7	-0.69	-10.92	-0.4	1.48e-25	Alzheimer's disease;
BRCA	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg11502198	chr6:26597334	ABT1	0.47	9.48	0.35	4.85e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4891159	0.790	rs11150953	chr18:74145491	G/A	cg24786174	chr18:74118243	ZNF516	-0.77	-18.19	-0.58	6.88e-60	Longevity;
BRCA	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg14863265	chr7:2801509	GNA12	0.46	10.39	0.38	1.86e-23	Height;
BRCA	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.54e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504073	0.584	rs10957337	chr8:49959027	G/T	cg00325661	chr8:49890786	NA	0.48	13.72	0.48	9.95e-38	Blood metabolite ratios;
BRCA	cis	rs2882667	0.931	rs10068237	chr5:138337960	T/A	cg04439458	chr5:138467593	SIL1	-0.34	-9.16	-0.34	6.81e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg24450063	chr1:156163899	SLC25A44	1.11	35.2	0.81	9.83e-152	Testicular germ cell tumor;
BRCA	cis	rs7586879	0.796	rs11684619	chr2:25078859	G/A	cg04586622	chr2:25135609	ADCY3	0.37	8.98	0.33	2.95e-18	Body mass index;
BRCA	cis	rs17253792	0.915	rs79100824	chr14:56179606	C/T	cg01858014	chr14:56050164	KTN1	-0.67	-8.24	-0.31	9.82e-16	Putamen volume;
BRCA	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-10.34	-0.38	2.93e-23	Bipolar disorder;
BRCA	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg18446336	chr7:2847575	GNA12	-0.35	-8.25	-0.31	9.02e-16	Height;
BRCA	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.38	-9.48	-0.35	4.72e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.47	-0.32	1.7e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg22029157	chr1:209979665	IRF6	0.41	8.05	0.3	4.02e-15	Cleft lip with or without cleft palate;
BRCA	cis	rs367943	0.698	rs9326900	chr5:112972859	A/G	cg12552261	chr5:112820674	MCC	0.37	7.88	0.3	1.41e-14	Type 2 diabetes;
BRCA	cis	rs10465746	0.573	rs12121175	chr1:84468961	T/G	cg10977910	chr1:84465055	TTLL7	0.53	10.93	0.4	1.34e-25	Obesity-related traits;
BRCA	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11890956	chr21:40555474	PSMG1	-0.83	-20.96	-0.64	1.2e-74	Cognitive function;
BRCA	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11764359	chr7:65958608	NA	0.8	19.34	0.61	5.7e-66	Aortic root size;
BRCA	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg25358565	chr5:93447407	FAM172A	1.23	18.97	0.6	5.19e-64	Diabetic retinopathy;
BRCA	cis	rs7903847	0.620	rs61863815	chr10:99124389	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.34	-0.31	4.45e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.37	-8.72	-0.33	2.46e-17	Longevity;Endometriosis;
BRCA	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg24110177	chr3:50126178	RBM5	-0.51	-14.44	-0.5	3.99e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg24692254	chr21:30365293	RNF160	-0.49	-11.0	-0.4	6.74e-26	Pancreatic cancer;
BRCA	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg25427524	chr10:38739819	LOC399744	0.55	10.12	0.37	1.94e-22	Obesity (extreme);
BRCA	cis	rs2354432	0.607	rs3766524	chr1:146729093	A/G	cg25205988	chr1:146714368	CHD1L	-0.97	-12.74	-0.45	2.87e-33	Mitochondrial DNA levels;
BRCA	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.56	12.09	0.43	1.89e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg03146154	chr1:46216737	IPP	0.45	10.11	0.37	2.13e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs679087	1.000	rs436124	chr12:29916839	C/T	cg14258853	chr12:29935411	TMTC1	0.41	8.74	0.33	2.06e-17	Schizophrenia;
BRCA	cis	rs4891159	0.790	rs8098821	chr18:74140345	T/C	cg24786174	chr18:74118243	ZNF516	-0.77	-17.87	-0.58	3.15e-58	Longevity;
BRCA	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg09904177	chr6:26538194	HMGN4	-0.46	-14.48	-0.5	2.68e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03264133	chr6:25882463	NA	-0.49	-11.09	-0.4	3.07e-26	Blood metabolite levels;
BRCA	trans	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.4	8.13	0.31	2.22e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs13102973	0.965	rs6535051	chr4:135874869	G/A	cg14419869	chr4:135874104	NA	-0.59	-13.0	-0.46	1.93e-34	Subjective well-being;
BRCA	cis	rs17095355	1.000	rs12571872	chr10:111676114	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.42	-8.91	-0.33	5.36e-18	Biliary atresia;
BRCA	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-11.27	-0.41	5.27e-27	Colorectal cancer;
BRCA	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	9.29	0.35	2.32e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-10.7	-0.39	1.09e-24	Schizophrenia;
BRCA	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11890956	chr21:40555474	PSMG1	0.85	21.98	0.66	3.35e-80	Cognitive function;
BRCA	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.43	8.18	0.31	1.58e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg03954927	chr1:10346856	KIF1B	0.45	12.54	0.44	1.99e-32	Hepatocellular carcinoma;
BRCA	cis	rs7789940	1.000	rs758944	chr7:75953297	G/T	cg10167463	chr7:75959203	YWHAG	-0.44	-9.0	-0.34	2.55e-18	Multiple sclerosis;
BRCA	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.35	-8.99	-0.34	2.8e-18	Total body bone mineral density;
BRCA	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07343612	chr16:622815	PIGQ	-0.66	-20.87	-0.64	3.96e-74	Height;
BRCA	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.77	0.39	5.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg23958373	chr8:599963	NA	-0.65	-8.27	-0.31	7.72e-16	IgG glycosylation;
BRCA	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.58	-10.84	-0.39	3e-25	Renal function-related traits (BUN);
BRCA	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg14019146	chr3:50243930	SLC38A3	-0.45	-10.94	-0.4	1.24e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg14582100	chr15:45693742	SPATA5L1	0.36	11.67	0.42	1.12e-28	Homoarginine levels;
BRCA	cis	rs6484504	0.576	rs208083	chr11:31196880	C/T	cg14844989	chr11:31128820	NA	-0.44	-9.4	-0.35	9.4e-20	Red blood cell count;
BRCA	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg25554036	chr4:6271136	WFS1	0.44	9.31	0.35	2.04e-19	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg20503657	chr10:835505	NA	1.3	21.76	0.65	5.72e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg18867708	chr6:26865862	GUSBL1	0.42	8.34	0.31	4.65e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg09184832	chr6:79620586	NA	-0.53	-11.62	-0.42	1.85e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.48	-11.13	-0.4	2.1e-26	IgG glycosylation;
BRCA	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg01420254	chr6:26195488	NA	0.57	8.75	0.33	1.88e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs2282802	0.660	rs7726176	chr5:139547971	T/A	cg26211634	chr5:139558579	C5orf32	-0.34	-8.12	-0.31	2.46e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg01877450	chr7:97915802	BRI3	-0.38	-8.55	-0.32	9.39e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs57590327	0.583	rs13062245	chr3:81833718	G/T	cg07356753	chr3:81810745	GBE1	-0.48	-11.17	-0.4	1.41e-26	Extraversion;
BRCA	cis	rs7131987	0.874	rs10843366	chr12:29407903	T/C	cg09582351	chr12:29534625	ERGIC2	-0.47	-11.56	-0.42	3.34e-28	QT interval;
BRCA	cis	rs9682041	0.696	rs6798399	chr3:170086482	G/A	cg11886554	chr3:170076028	SKIL	0.52	10.28	0.38	4.62e-23	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg24060327	chr5:131705240	SLC22A5	-0.45	-9.1	-0.34	1.09e-18	Blood metabolite levels;
BRCA	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.65e-23	Motion sickness;
BRCA	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	11.49	0.41	6.29e-28	Height;
BRCA	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg23625390	chr15:77176239	SCAPER	0.35	7.97	0.3	7.24e-15	Blood metabolite levels;
BRCA	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg11843238	chr5:131593191	PDLIM4	0.4	9.49	0.35	4.53e-20	Acylcarnitine levels;
BRCA	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg26395211	chr5:140044315	WDR55	-0.38	-8.6	-0.32	5.99e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-8.87	-0.33	7.45e-18	IgG glycosylation;
BRCA	cis	rs3818285	0.556	rs941864	chr10:111656948	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.37	-9.91	-0.36	1.26e-21	Superior crus of antihelix expression;
BRCA	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.32	0.41	3.45e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs13082711	0.871	rs73046194	chr3:27454558	C/T	cg02860705	chr3:27208620	NA	0.53	10.56	0.39	3.99e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	trans	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg25214090	chr10:38739885	LOC399744	0.57	13.01	0.46	1.79e-34	Corneal astigmatism;
BRCA	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg00666640	chr1:248458726	OR2T12	0.32	8.77	0.33	1.63e-17	Common traits (Other);
BRCA	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg08999081	chr20:33150536	PIGU	-0.46	-12.73	-0.45	3.12e-33	Glomerular filtration rate (creatinine);
BRCA	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg02297831	chr4:17616191	MED28	-0.36	-8.21	-0.31	1.22e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg07636037	chr3:49044803	WDR6	-0.57	-7.87	-0.3	1.52e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg09537434	chr19:41945824	ATP5SL	-0.99	-23.84	-0.69	2.47e-90	Height;
BRCA	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg26384229	chr12:38710491	ALG10B	-0.45	-10.34	-0.38	2.73e-23	Heart rate;
BRCA	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg23711669	chr6:146136114	FBXO30	0.73	16.97	0.56	1.39e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg03188948	chr7:1209495	NA	0.87	11.85	0.42	2.11e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg27170947	chr2:26402098	FAM59B	-0.6	-10.88	-0.4	2.05e-25	Gut microbiome composition (summer);
BRCA	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg13010199	chr12:38710504	ALG10B	0.44	9.2	0.34	5.22e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs250677	0.522	rs12520924	chr5:148349149	C/T	cg18129178	chr5:148520854	ABLIM3	0.54	10.33	0.38	2.95e-23	Breast cancer;
BRCA	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg20887711	chr4:1340912	KIAA1530	0.41	10.01	0.37	5.27e-22	Longevity;
BRCA	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg26384229	chr12:38710491	ALG10B	-0.46	-10.66	-0.39	1.51e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9790314	0.718	rs6774635	chr3:160847908	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-9.95	-0.37	8.57e-22	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg23711669	chr6:146136114	FBXO30	0.77	18.29	0.59	2.05e-60	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	8.57	0.32	7.48e-17	Rheumatoid arthritis;
BRCA	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg02403541	chr12:121454288	C12orf43	0.53	9.98	0.37	7.02e-22	N-glycan levels;
BRCA	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.49	-10.31	-0.38	3.81e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.79	13.08	0.46	8.17e-35	Platelet count;
BRCA	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg12311346	chr5:56204834	C5orf35	-0.78	-15.64	-0.53	6.56e-47	Initial pursuit acceleration;
BRCA	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg05340658	chr4:99064831	C4orf37	0.56	10.8	0.39	4.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9487051	0.646	rs11153166	chr6:109622494	C/T	cg01475377	chr6:109611718	NA	0.39	8.65	0.32	4.28e-17	Reticulocyte fraction of red cells;
BRCA	cis	rs1008375	0.646	rs13145480	chr4:17565143	T/C	cg16339924	chr4:17578868	LAP3	-0.55	-12.62	-0.45	9.1e-33	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs1493916	0.592	rs1389068	chr18:31312738	G/T	cg15819921	chr19:927150	ARID3A	-0.43	-8.17	-0.31	1.61e-15	Life satisfaction;
BRCA	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg17063962	chr7:91808500	NA	0.57	13.54	0.47	6.61e-37	Breast cancer;
BRCA	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg18898632	chr2:242989856	NA	-0.47	-8.1	-0.31	2.85e-15	Obesity-related traits;
BRCA	cis	rs6684428	0.611	rs6657176	chr1:56328238	G/T	cg11651538	chr1:56320950	NA	-0.41	-7.96	-0.3	7.67e-15	Airflow obstruction;
BRCA	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg21252483	chr19:49399788	TULP2	-0.52	-11.3	-0.41	3.95e-27	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs9815354	0.597	rs17283481	chr3:41924015	T/C	cg03022575	chr3:42003672	ULK4	0.71	9.74	0.36	5.4e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg22496339	chr2:162101262	NA	0.44	9.07	0.34	1.42e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg19622623	chr12:86230825	RASSF9	-0.29	-8.18	-0.31	1.57e-15	Major depressive disorder;
BRCA	cis	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg06521331	chr12:34319734	NA	-0.62	-12.41	-0.44	8.14e-32	Morning vs. evening chronotype;
BRCA	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.97	14.94	0.51	1.6e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1883415	0.534	rs2760143	chr6:24479472	C/T	cg20631270	chr6:24437470	GPLD1	0.4	8.16	0.31	1.78e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10242455	0.702	rs55927283	chr7:99057191	G/C	cg18809830	chr7:99032528	PTCD1	-0.56	-8.34	-0.31	4.49e-16	Blood metabolite levels;
BRCA	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg03060546	chr3:49711283	APEH	-0.56	-11.23	-0.41	7.67e-27	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs847649	0.842	rs7789252	chr7:102624227	C/A	cg18108683	chr7:102477205	FBXL13	-0.42	-9.86	-0.36	1.9e-21	Morning vs. evening chronotype;
BRCA	cis	rs1635	0.512	rs73742545	chr6:28319023	T/G	cg15743358	chr6:28303923	ZNF323	-0.76	-8.86	-0.33	8.09e-18	Schizophrenia;
BRCA	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg05343316	chr1:45956843	TESK2	0.55	11.51	0.41	5.57e-28	Platelet count;
BRCA	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg18225595	chr11:63971243	STIP1	0.51	12.08	0.43	2.16e-30	Platelet count;
BRCA	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg26384229	chr12:38710491	ALG10B	0.74	16.52	0.55	2.57e-51	Morning vs. evening chronotype;
BRCA	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg08132940	chr7:1081526	C7orf50	-0.59	-8.84	-0.33	9.37e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs524281	0.861	rs9645684	chr11:65907964	G/A	cg16950941	chr11:66035639	RAB1B	-0.38	-8.01	-0.3	5.32e-15	Electroencephalogram traits;
BRCA	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg22105103	chr4:187893119	NA	-0.33	-10.32	-0.38	3.46e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs77972916	0.505	rs6727824	chr2:43528377	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-11.61	-0.42	2.12e-28	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10045504	0.502	rs72746054	chr5:38762351	C/T	cg15396434	chr5:38725168	NA	-0.56	-10.69	-0.39	1.23e-24	Night sleep phenotypes;
BRCA	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.87	-0.36	1.83e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.61	-13.09	-0.46	7.5e-35	Lymphocyte counts;
BRCA	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg11271282	chr2:238384023	NA	0.49	9.08	0.34	1.36e-18	Prostate cancer;
BRCA	cis	rs3936840	0.964	rs10150698	chr14:102977876	A/G	cg18135206	chr14:102964638	TECPR2	0.64	14.18	0.49	7.25e-40	Plateletcrit;
BRCA	cis	rs7737355	0.741	rs6875363	chr5:130581195	A/G	cg06307176	chr5:131281290	NA	-0.45	-8.31	-0.31	5.8e-16	Life satisfaction;
BRCA	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg21475434	chr5:93447410	FAM172A	0.67	9.02	0.34	2.19e-18	Diabetic retinopathy;
BRCA	cis	rs13046373	0.535	rs8129571	chr21:31980646	G/A	cg16431978	chr21:31797932	KRTAP13-3	0.36	9.17	0.34	6.19e-19	HDL cholesterol;
BRCA	cis	rs965469	0.779	rs6133034	chr20:3337661	A/G	cg25506879	chr20:3388711	C20orf194	-0.44	-8.77	-0.33	1.66e-17	IFN-related cytopenia;
BRCA	cis	rs7520050	0.966	rs785485	chr1:46574424	C/T	cg24296786	chr1:45957014	TESK2	0.41	9.02	0.34	2.21e-18	Red blood cell count;Reticulocyte count;
BRCA	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.27	-0.41	5.51e-27	Mean corpuscular volume;
BRCA	cis	rs7000551	0.715	rs7839577	chr8:22307325	T/A	cg12081754	chr8:22256438	SLC39A14	0.39	7.84	0.3	1.86e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs9463078	0.874	rs2093901	chr6:45177315	C/G	cg25276700	chr6:44698697	NA	-0.36	-8.02	-0.3	5.18e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg03342759	chr3:160939853	NMD3	-0.66	-14.31	-0.49	1.77e-40	Morning vs. evening chronotype;
BRCA	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg09877947	chr5:131593287	PDLIM4	-0.42	-10.06	-0.37	3.26e-22	Acylcarnitine levels;
BRCA	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	21.17	0.64	8.76e-76	Smoking behavior;
BRCA	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg18200150	chr17:30822561	MYO1D	0.56	16.9	0.56	2.94e-53	Schizophrenia;
BRCA	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03517284	chr6:25882590	NA	-0.48	-10.29	-0.38	4.45e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6728642	1.000	rs113863815	chr2:97657813	A/G	cg26665480	chr2:98280029	ACTR1B	-0.67	-7.86	-0.3	1.65e-14	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.63	0.39	2.04e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg12140854	chr5:148520817	ABLIM3	-0.42	-9.05	-0.34	1.71e-18	Breast cancer;
BRCA	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg27661571	chr11:113659931	NA	-0.53	-8.93	-0.33	4.64e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.02e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4481887	0.927	rs6666903	chr1:248465582	T/A	cg00666640	chr1:248458726	OR2T12	0.31	8.55	0.32	8.95e-17	Common traits (Other);
BRCA	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg18252515	chr7:66147081	NA	-0.87	-12.08	-0.43	2.13e-30	Diabetic kidney disease;
BRCA	cis	rs7799006	0.929	rs7781856	chr7:2257199	C/T	cg08027265	chr7:2291960	NA	-0.4	-9.94	-0.37	9.92e-22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg05234568	chr11:5960015	NA	-0.5	-9.63	-0.36	1.43e-20	DNA methylation (variation);
BRCA	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg11812906	chr14:75593930	NEK9	-0.56	-12.55	-0.44	1.96e-32	Height;
BRCA	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11644478	chr21:40555479	PSMG1	-0.53	-11.31	-0.41	3.72e-27	Menarche (age at onset);
BRCA	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.8	0.36	3.22e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00149659	chr3:10157352	C3orf10	0.72	12.57	0.45	1.49e-32	Alzheimer's disease;
BRCA	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg09658497	chr7:2847517	GNA12	-0.46	-10.05	-0.37	3.75e-22	Height;
BRCA	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.96	-0.3	7.72e-15	Neuroticism;
BRCA	cis	rs41005	1.000	rs41008	chr2:8108588	G/T	cg03155496	chr2:8117019	LOC339788	0.57	15.11	0.51	2.38e-44	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-15.63	-0.53	7.26e-47	Extrinsic epigenetic age acceleration;
BRCA	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.47	8.77	0.33	1.63e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg05340658	chr4:99064831	C4orf37	0.44	10.14	0.37	1.74e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs13006833	0.668	rs2582746	chr2:191163784	T/C	cg27211696	chr2:191398769	TMEM194B	0.36	7.87	0.3	1.57e-14	Urinary metabolites;
BRCA	cis	rs12474201	0.832	rs4952843	chr2:46957845	A/G	cg06386533	chr2:46925753	SOCS5	0.87	19.14	0.6	7.24e-65	Height;
BRCA	trans	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg06521331	chr12:34319734	NA	-0.43	-8.12	-0.31	2.41e-15	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg24006582	chr15:45444508	DUOX1	-0.55	-11.32	-0.41	3.19e-27	Uric acid levels;
BRCA	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.3	-8.29	-0.31	6.44e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg23711669	chr6:146136114	FBXO30	-0.62	-14.09	-0.49	1.95e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg24562669	chr7:97807699	LMTK2	0.45	12.17	0.43	8.41e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg21573476	chr21:45109991	RRP1B	-0.34	-8.71	-0.33	2.58e-17	Mean corpuscular volume;
BRCA	cis	rs2882667	0.690	rs288038	chr5:138207533	G/A	cg04439458	chr5:138467593	SIL1	-0.31	-7.94	-0.3	8.86e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4240897	0.835	rs4845891	chr1:12042506	T/C	cg13216073	chr1:12042593	MFN2	0.56	13.64	0.47	2.25e-37	Tuberculosis;
BRCA	cis	rs67478160	0.595	rs12433109	chr14:104196607	G/A	cg26031613	chr14:104095156	KLC1	-0.46	-8.79	-0.33	1.39e-17	Schizophrenia;
BRCA	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg05347473	chr6:146136440	FBXO30	0.41	8.03	0.3	4.76e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg15103426	chr22:29168792	CCDC117	0.51	11.9	0.43	1.18e-29	Lymphocyte counts;
BRCA	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg11301795	chr4:187892539	NA	-0.27	-8.71	-0.33	2.5e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg11822812	chr5:140052017	DND1	0.31	8.46	0.32	1.85e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10046574	0.831	rs7455447	chr7:135062056	C/T	cg27474649	chr7:135195673	CNOT4	0.57	8.01	0.3	5.31e-15	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-11.59	-0.42	2.62e-28	Platelet count;
BRCA	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg01420254	chr6:26195488	NA	0.56	8.65	0.32	4.11e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg18305652	chr10:134549665	INPP5A	0.3	8.87	0.33	7.35e-18	Migraine;
BRCA	cis	rs1971762	0.602	rs4759283	chr12:54079243	C/T	cg23533419	chr12:54090519	NA	-0.33	-8.3	-0.31	6.17e-16	Height;
BRCA	cis	rs7246657	0.722	rs2972430	chr19:38182111	C/T	cg18154014	chr19:37997991	ZNF793	-0.51	-9.64	-0.36	1.27e-20	Coronary artery calcification;
BRCA	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg06115741	chr20:33292138	TP53INP2	0.36	8.01	0.3	5.54e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs12464559	0.522	rs7583060	chr2:152620943	C/A	cg01189475	chr2:152685088	ARL5A	0.61	9.3	0.35	2.12e-19	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg03676636	chr4:99064102	C4orf37	0.21	7.98	0.3	6.8e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6426558	0.572	rs2670471	chr1:227454328	T/C	cg10327440	chr1:227177885	CDC42BPA	0.48	9.66	0.36	1.07e-20	Neutrophil percentage of white cells;
BRCA	cis	rs7640424	0.750	rs13074183	chr3:107851467	G/A	cg09227934	chr3:107805635	CD47	-0.43	-9.01	-0.34	2.29e-18	Body mass index;
BRCA	cis	rs3772130	1.000	rs56314138	chr3:121356656	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	9.49	0.35	4.34e-20	Cognitive performance;
BRCA	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg23505145	chr19:12996616	KLF1	0.56	12.79	0.45	1.66e-33	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.96	0.3	7.89e-15	Corneal astigmatism;
BRCA	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg24562669	chr7:97807699	LMTK2	0.44	11.75	0.42	5.51e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg00852783	chr1:26633632	UBXN11	-0.47	-8.34	-0.31	4.72e-16	Obesity-related traits;
BRCA	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg00071950	chr4:10020882	SLC2A9	-0.43	-10.03	-0.37	4.28e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs12517041	1.000	rs4701365	chr5:23315034	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-8.11	-0.31	2.55e-15	Calcium levels;
BRCA	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	9.89	0.36	1.52e-21	Eosinophil percentage of white cells;
BRCA	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg14558114	chr2:88469736	THNSL2	0.63	9.15	0.34	7.55e-19	Plasma clusterin levels;
BRCA	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg18154014	chr19:37997991	ZNF793	0.48	9.56	0.35	2.54e-20	Coronary artery calcification;
BRCA	cis	rs1577917	0.958	rs4707236	chr6:86583967	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.22	-0.41	8.84e-27	Response to antipsychotic treatment;
BRCA	cis	rs2652822	0.933	rs7170846	chr15:63449543	A/C	cg02713581	chr15:63449717	RPS27L	0.49	10.07	0.37	3.21e-22	Metabolic traits;
BRCA	trans	rs11088226	0.681	rs1015048	chr21:33949306	T/C	cg09050820	chr6:167586206	TCP10L2	0.85	15.85	0.53	5.9e-48	Gastritis;
BRCA	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg03146154	chr1:46216737	IPP	-0.5	-10.83	-0.39	3.15e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-9.93	-0.37	1.06e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs3857536	0.740	rs9342532	chr6:66886297	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.49	-9.77	-0.36	4.07e-21	Blood trace element (Cu levels);
BRCA	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-11.75	-0.42	5.1e-29	Chronic sinus infection;
BRCA	cis	rs4363385	0.818	rs377768	chr1:153016594	T/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.46	-0.32	1.88e-16	Inflammatory skin disease;
BRCA	cis	rs586533	0.813	rs2458166	chr11:99500840	A/G	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg23711669	chr6:146136114	FBXO30	0.83	20.4	0.63	1.24e-71	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg23229984	chr5:148520753	ABLIM3	0.31	7.84	0.3	1.92e-14	Breast cancer;
BRCA	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg09021430	chr5:549028	NA	-0.68	-14.14	-0.49	1.07e-39	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.64	-0.42	1.56e-28	Alcohol dependence;
BRCA	cis	rs7737355	0.947	rs6879005	chr5:130615445	C/T	cg06307176	chr5:131281290	NA	0.46	8.97	0.33	3.29e-18	Life satisfaction;
BRCA	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg07148914	chr20:33460835	GGT7	0.45	9.67	0.36	1.02e-20	Height;
BRCA	cis	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg00852783	chr1:26633632	UBXN11	-0.47	-8.5	-0.32	1.31e-16	Obesity-related traits;
BRCA	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg22676075	chr6:135203613	NA	-0.43	-9.05	-0.34	1.71e-18	Red blood cell count;
BRCA	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg01262667	chr19:19385393	TM6SF2	0.39	8.01	0.3	5.51e-15	Nonalcoholic fatty liver disease;
BRCA	cis	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.25	0.34	3.25e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg17971929	chr21:40555470	PSMG1	0.8	18.56	0.59	8.04e-62	Cognitive function;
BRCA	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg06212747	chr3:49208901	KLHDC8B	0.51	10.25	0.38	6.36e-23	Parkinson's disease;
BRCA	cis	rs9487051	0.735	rs419106	chr6:109520067	C/G	cg01475377	chr6:109611718	NA	-0.47	-11.93	-0.43	9.51e-30	Reticulocyte fraction of red cells;
BRCA	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.34	0.31	4.42e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs72634258	0.554	rs35307738	chr1:7919839	C/G	cg00042356	chr1:8021962	PARK7	0.53	8.31	0.31	5.8e-16	Inflammatory bowel disease;
BRCA	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.98	-0.48	6.13e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10754283	0.967	rs6698273	chr1:90106791	T/A	cg21401794	chr1:90099060	LRRC8C	0.46	11.13	0.4	2e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs2455601	0.573	rs2653573	chr11:8989874	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-8.37	-0.31	3.72e-16	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg27170947	chr2:26402098	FAM59B	-0.64	-11.48	-0.41	7.44e-28	Gut microbiome composition (summer);
BRCA	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg22535103	chr8:58192502	C8orf71	-0.47	-9.24	-0.34	3.68e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg24596788	chr1:163392923	NA	-0.37	-9.61	-0.36	1.61e-20	Motion sickness;
BRCA	cis	rs6426558	0.537	rs4500279	chr1:227484482	G/A	cg10327440	chr1:227177885	CDC42BPA	0.47	9.46	0.35	5.83e-20	Neutrophil percentage of white cells;
BRCA	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26314531	chr2:26401878	FAM59B	-0.64	-11.13	-0.4	2.02e-26	Gut microbiome composition (summer);
BRCA	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg15448220	chr1:150897856	SETDB1	0.36	8.06	0.3	3.83e-15	Melanoma;
BRCA	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12016809	chr21:47604291	C21orf56	-0.4	-7.92	-0.3	1.08e-14	Testicular germ cell tumor;
BRCA	cis	rs13272623	0.502	rs268599	chr8:71517401	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.44	-9.31	-0.35	1.98e-19	IgG glycosylation;
BRCA	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg03709012	chr19:19516395	GATAD2A	0.81	19.06	0.6	1.89e-64	Tonsillectomy;
BRCA	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21659725	chr3:3221576	CRBN	0.45	9.42	0.35	8.42e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg18305652	chr10:134549665	INPP5A	0.5	11.55	0.42	3.89e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg12311346	chr5:56204834	C5orf35	-0.81	-16.08	-0.54	4.04e-49	Initial pursuit acceleration;
BRCA	trans	rs9784649	1.000	rs56004901	chr5:24998968	A/G	cg08600765	chr20:34638493	LOC647979	-0.52	-8.65	-0.32	4e-17	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	11.37	0.41	2.13e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg21573476	chr21:45109991	RRP1B	-0.35	-8.84	-0.33	9.44e-18	Mean corpuscular volume;
BRCA	cis	rs68170813	0.559	rs3801958	chr7:106961139	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.52	-0.32	1.17e-16	Coronary artery disease;
BRCA	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg12454169	chr2:30669597	LCLAT1	0.5	9.22	0.34	4.26e-19	Pre-treatment pain in head and neck squamous cell carcinoma;
BRCA	cis	rs3784262	0.631	rs4646625	chr15:58256296	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.03	-0.37	4.51e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7092929	0.941	rs575738	chr10:3579283	C/A	cg14308648	chr10:3568949	NA	0.45	8.13	0.31	2.25e-15	Coronary artery calcification;
BRCA	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg18252515	chr7:66147081	NA	-0.88	-12.64	-0.45	7.81e-33	Diabetic kidney disease;
BRCA	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg15997130	chr1:24165203	NA	0.55	14.67	0.5	3.13e-42	Immature fraction of reticulocytes;
BRCA	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg17143192	chr8:8559678	CLDN23	0.58	11.28	0.41	5.1e-27	Obesity-related traits;
BRCA	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg26384229	chr12:38710491	ALG10B	0.66	15.04	0.51	5.67e-44	Bladder cancer;
BRCA	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg09184832	chr6:79620586	NA	-0.52	-11.62	-0.42	1.83e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg27432699	chr2:27873401	GPN1	0.47	9.87	0.36	1.81e-21	Oral cavity cancer;
BRCA	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg26597838	chr10:835615	NA	-0.42	-8.47	-0.32	1.73e-16	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03517284	chr6:25882590	NA	-0.47	-10.71	-0.39	9.52e-25	Blood metabolite levels;
BRCA	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.74	0.5	1.61e-42	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg26043149	chr18:55253948	FECH	-0.37	-8.19	-0.31	1.42e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg01579765	chr21:45077557	HSF2BP	-0.44	-12.09	-0.43	1.87e-30	Mean corpuscular volume;
BRCA	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg04455712	chr21:45112962	RRP1B	0.41	11.02	0.4	5.51e-26	Mean corpuscular volume;
BRCA	cis	rs7903847	0.692	rs7900255	chr10:99157575	G/A	cg08345082	chr10:99160200	RRP12	-0.3	-8.7	-0.33	2.88e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7677751	0.806	rs4864860	chr4:55090021	T/C	cg17187183	chr4:55093834	PDGFRA	0.44	9.35	0.35	1.48e-19	Corneal astigmatism;
BRCA	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.17	-0.43	8.86e-31	Total cholesterol levels;
BRCA	cis	rs3820928	0.874	rs10439363	chr2:227815065	C/T	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.8	-0.33	1.23e-17	Pulmonary function;
BRCA	trans	rs9650657	0.803	rs13276026	chr8:10609955	G/A	cg15556689	chr8:8085844	FLJ10661	-0.29	-7.92	-0.3	1.06e-14	Neuroticism;
BRCA	cis	rs9469578	0.792	rs73743331	chr6:33714036	G/T	cg18708504	chr6:33715942	IP6K3	0.7	10.23	0.38	7.52e-23	Phosphorus levels;
BRCA	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.09	-28.05	-0.74	1.79e-113	Ulcerative colitis;
BRCA	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.49	-0.44	3.52e-32	Bipolar disorder;
BRCA	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg20891558	chr2:74357851	NA	0.63	12.62	0.45	9.49e-33	Gestational age at birth (maternal effect);
BRCA	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.08	-0.3	3.21e-15	Total body bone mineral density;
BRCA	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.13	0.37	1.89e-22	Bladder cancer;
BRCA	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	9.42	0.35	7.94e-20	Tonsillectomy;
BRCA	cis	rs4660306	0.961	rs2991966	chr1:45999503	G/A	cg24296786	chr1:45957014	TESK2	0.44	8.77	0.33	1.58e-17	Homocysteine levels;
BRCA	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	10.57	0.39	3.65e-24	Bone mineral density;
BRCA	cis	rs4722404	0.502	rs13223548	chr7:3110446	T/C	cg19214707	chr7:3157722	NA	-0.37	-7.81	-0.3	2.44e-14	Atopic dermatitis;
BRCA	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg17691542	chr6:26056736	HIST1H1C	0.51	10.34	0.38	2.87e-23	Height;
BRCA	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg07169764	chr2:136633963	MCM6	1.25	30.25	0.77	1.89e-125	Corneal structure;
BRCA	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg15556689	chr8:8085844	FLJ10661	0.5	14.26	0.49	2.8e-40	Mood instability;
BRCA	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg27279351	chr12:120934652	DYNLL1	0.51	12.39	0.44	9.44e-32	High light scatter reticulocyte count;
BRCA	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08219700	chr8:58056026	NA	0.57	9.48	0.35	4.72e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg26168224	chr5:2018326	NA	-0.61	-15.84	-0.53	6.79e-48	Gut microbiome composition (winter);
BRCA	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18876405	chr7:65276391	NA	0.5	11.07	0.4	3.5e-26	Aortic root size;
BRCA	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.36e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg23711669	chr6:146136114	FBXO30	0.79	19.09	0.6	1.27e-64	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.17	-0.31	1.63e-15	Triglycerides;
BRCA	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.24	-0.31	9.65e-16	Bipolar disorder;
BRCA	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg09537434	chr19:41945824	ATP5SL	0.61	12.69	0.45	4.73e-33	Migraine;Coronary artery disease;
BRCA	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg18811423	chr2:55921094	PNPT1	0.78	26.62	0.73	1.31e-105	Metabolic syndrome;
BRCA	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.05	0.51	4.81e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	9.77	0.36	4.08e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg22713356	chr15:30763199	NA	1.25	20.77	0.63	1.25e-73	Uric acid levels;
BRCA	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg21775007	chr8:11205619	TDH	0.68	15.93	0.53	2.47e-48	Retinal vascular caliber;
BRCA	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg08859206	chr1:53392774	SCP2	0.43	8.69	0.33	2.94e-17	Monocyte count;
BRCA	cis	rs9462846	0.881	rs34498470	chr6:42879551	C/T	cg05552183	chr6:42928497	GNMT	0.45	7.99	0.3	6.17e-15	Blood protein levels;
BRCA	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg13010199	chr12:38710504	ALG10B	0.49	9.62	0.36	1.5e-20	Morning vs. evening chronotype;
BRCA	cis	rs11893307	0.599	rs12617417	chr2:191663571	C/G	cg05765582	chr2:191677683	NA	0.44	8.06	0.3	3.77e-15	Mean platelet volume;
BRCA	cis	rs758324	0.853	rs6865911	chr5:131204659	A/G	cg06307176	chr5:131281290	NA	0.53	10.2	0.37	9.83e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.4	8.39	0.31	3.17e-16	Alzheimer's disease (late onset);
BRCA	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07930192	chr7:1003750	NA	0.41	8.81	0.33	1.17e-17	Longevity;Endometriosis;
BRCA	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.4	-7.96	-0.3	7.85e-15	Bronchopulmonary dysplasia;
BRCA	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg09184832	chr6:79620586	NA	-0.52	-11.36	-0.41	2.37e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs12367572	0.580	rs1495034	chr12:45414203	C/T	cg04608330	chr12:45269318	NELL2	-0.4	-8.64	-0.32	4.52e-17	Gut microbiome composition (summer);
BRCA	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.95	14.38	0.49	8.38e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs1941687	0.509	rs6507060	chr18:31322278	C/T	cg15819921	chr19:927150	ARID3A	0.44	8.37	0.31	3.54e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg10729496	chr3:10149963	C3orf24	0.49	9.41	0.35	8.99e-20	Alzheimer's disease;
BRCA	trans	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg25214090	chr10:38739885	LOC399744	0.5	10.94	0.4	1.2e-25	Corneal astigmatism;
BRCA	cis	rs870825	0.616	rs6552807	chr4:185640531	A/G	cg04058563	chr4:185651563	MLF1IP	0.76	16.76	0.55	1.57e-52	Blood protein levels;
BRCA	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.74e-16	Menopause (age at onset);
BRCA	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg05457628	chr5:178986728	RUFY1	0.54	12.46	0.44	4.7e-32	Lung cancer;
BRCA	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.62	-0.32	5.09e-17	Aortic root size;
BRCA	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg23422044	chr7:1970798	MAD1L1	-0.5	-9.53	-0.35	3.12e-20	Neuroticism;
BRCA	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg10150615	chr22:24372951	LOC391322	-0.42	-9.27	-0.34	2.88e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.66	-15.95	-0.53	1.84e-48	Ulcerative colitis;
BRCA	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg13010199	chr12:38710504	ALG10B	0.42	8.72	0.33	2.48e-17	Bladder cancer;
BRCA	cis	rs938554	0.744	rs7675964	chr4:9941434	C/T	cg00071950	chr4:10020882	SLC2A9	-0.36	-7.86	-0.3	1.62e-14	Blood metabolite levels;
BRCA	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg08132940	chr7:1081526	C7orf50	-0.58	-8.81	-0.33	1.21e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg11752832	chr7:134001865	SLC35B4	0.53	13.77	0.48	5.95e-38	Mean platelet volume;
BRCA	cis	rs10504073	0.647	rs9643395	chr8:50014500	A/C	cg00325661	chr8:49890786	NA	0.38	11.32	0.41	3.24e-27	Blood metabolite ratios;
BRCA	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg25457927	chr22:38595422	NA	-0.32	-11.87	-0.43	1.63e-29	Cutaneous nevi;
BRCA	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg25358565	chr5:93447407	FAM172A	-1.09	-15.87	-0.53	4.42e-48	Diabetic retinopathy;
BRCA	cis	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.17	-0.37	1.23e-22	Morning vs. evening chronotype;
BRCA	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg17135325	chr3:160939158	NMD3	0.43	8.35	0.31	4.09e-16	Parkinson's disease;
BRCA	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg15556689	chr8:8085844	FLJ10661	0.39	9.05	0.34	1.68e-18	Systolic blood pressure;
BRCA	cis	rs6920965	0.503	rs2475851	chr6:126174215	T/C	cg05901451	chr6:126070800	HEY2	-0.35	-8.55	-0.32	9.08e-17	High light scatter reticulocyte count;
BRCA	trans	rs8002861	0.934	rs9533685	chr13:44468331	A/G	cg17145862	chr1:211918768	LPGAT1	0.73	19.51	0.61	7.82e-67	Leprosy;
BRCA	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg13628971	chr7:2884303	GNA12	0.48	9.42	0.35	8.2e-20	Height;
BRCA	cis	rs6772849	0.930	rs13434160	chr3:128374770	T/C	cg16766828	chr3:128327626	NA	-0.39	-8.72	-0.33	2.43e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	trans	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg26043149	chr18:55253948	FECH	-0.37	-8.25	-0.31	8.96e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg21659725	chr3:3221576	CRBN	-0.34	-8.27	-0.31	7.62e-16	Menarche (age at onset);
BRCA	cis	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg06521331	chr12:34319734	NA	-0.51	-10.06	-0.37	3.35e-22	Morning vs. evening chronotype;
BRCA	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	18.18	0.58	7.82e-60	Platelet count;
BRCA	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg05340658	chr4:99064831	C4orf37	0.63	15.08	0.51	3.55e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs66887589	0.967	rs1480933	chr4:120433248	C/T	cg09307838	chr4:120376055	NA	0.47	9.74	0.36	5.59e-21	Diastolic blood pressure;
BRCA	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.86	-0.33	7.74e-18	Total body bone mineral density;
BRCA	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg14863265	chr7:2801509	GNA12	-0.42	-9.4	-0.35	9.55e-20	Height;
BRCA	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg03477792	chr4:77819574	ANKRD56	-0.62	-15.29	-0.52	3.24e-45	Emphysema distribution in smoking;
BRCA	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg04025307	chr7:1156635	C7orf50	0.56	13.9	0.48	1.49e-38	Longevity;Endometriosis;
BRCA	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	18.47	0.59	2.24e-61	Platelet count;
BRCA	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg18806716	chr10:30721971	MAP3K8	0.57	13.4	0.47	3.04e-36	Inflammatory bowel disease;
BRCA	cis	rs4722166	0.532	rs6963591	chr7:22757270	G/T	cg05472934	chr7:22766657	IL6	-0.43	-10.75	-0.39	7.15e-25	Lung cancer;
BRCA	trans	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg07461501	chr17:79650226	HGS;ARL16	0.38	9.72	0.36	6.51e-21	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg23018236	chr17:30244563	NA	-0.61	-9.97	-0.37	7.27e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs1371614	0.610	rs2384511	chr2:27152735	G/A	cg00617064	chr2:27272375	NA	-0.31	-7.98	-0.3	6.97e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.84	-0.33	9.52e-18	Alzheimer's disease (late onset);
BRCA	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.76	12.67	0.45	5.84e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7553864	0.667	rs1886633	chr1:87610356	G/A	cg17420885	chr1:87600446	LOC339524	-0.44	-9.03	-0.34	2.06e-18	Smoking behavior;
BRCA	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.74	0.33	2.06e-17	Motion sickness;
BRCA	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg18032046	chr6:28092343	ZSCAN16	0.5	8.03	0.3	4.78e-15	Depression;
BRCA	cis	rs6426558	0.502	rs6697665	chr1:227474665	T/C	cg10327440	chr1:227177885	CDC42BPA	0.48	9.54	0.35	2.89e-20	Neutrophil percentage of white cells;
BRCA	trans	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	9.4	0.35	9.64e-20	Mean corpuscular volume;
BRCA	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg14675211	chr2:100938903	LONRF2	0.52	11.96	0.43	7.15e-30	Intelligence (multi-trait analysis);
BRCA	trans	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg06521331	chr12:34319734	NA	-0.52	-9.54	-0.35	3.06e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7246967	0.611	rs16999571	chr19:22904764	C/A	cg23217946	chr19:22817039	ZNF492	0.51	9.41	0.35	8.44e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs9815354	0.556	rs56201224	chr3:42004427	A/C	cg03022575	chr3:42003672	ULK4	0.65	9.47	0.35	5.34e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg26898376	chr11:64110657	CCDC88B	0.36	7.84	0.3	1.95e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs6545883	0.860	rs6545848	chr2:61461183	G/T	cg15711740	chr2:61764176	XPO1	0.51	13.06	0.46	1.06e-34	Tuberculosis;
BRCA	cis	rs4919087	1.000	rs4919090	chr10:99088419	C/G	cg25902810	chr10:99078978	FRAT1	-0.45	-9.36	-0.35	1.32e-19	Monocyte count;
BRCA	cis	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.15	-0.4	1.6e-26	Morning vs. evening chronotype;
BRCA	trans	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg23762105	chr12:34175262	ALG10	-0.41	-10.09	-0.37	2.7e-22	Morning vs. evening chronotype;
BRCA	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg03709012	chr19:19516395	GATAD2A	0.8	18.71	0.6	1.21e-62	Tonsillectomy;
BRCA	cis	rs10044254	0.563	rs4701641	chr5:15697062	C/T	cg07238450	chr5:15720153	FBXL7	-0.38	-8.03	-0.3	4.81e-15	Asthma (corticosteroid response);
BRCA	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg08601574	chr20:25228251	PYGB	-0.36	-8.68	-0.32	3.18e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg20607798	chr8:58055168	NA	-0.45	-7.84	-0.3	1.88e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg17211192	chr8:82754475	SNX16	-0.5	-10.8	-0.39	4.51e-25	Diastolic blood pressure;
BRCA	trans	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.5	-0.35	4.12e-20	Bladder cancer;
BRCA	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg24044776	chr19:53454761	ZNF816A	-0.39	-8.69	-0.33	2.93e-17	Psoriasis;
BRCA	cis	rs4268898	0.552	rs11125454	chr2:24373669	T/C	cg26838691	chr2:24397539	C2orf84	0.39	8.01	0.3	5.52e-15	Asthma;
BRCA	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-13.79	-0.48	4.62e-38	Bipolar disorder and schizophrenia;
BRCA	cis	rs11229555	0.645	rs11229431	chr11:58181253	A/G	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.49	-9.59	-0.35	1.87e-20	Body mass index;
BRCA	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	12.99	0.46	2.1e-34	Migraine;Coronary artery disease;
BRCA	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-9.51	-0.35	3.81e-20	Tonsillectomy;
BRCA	cis	rs11112613	0.713	rs11112586	chr12:105939816	C/T	cg03607813	chr12:105948248	NA	0.53	9.37	0.35	1.2e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-11.28	-0.41	4.74e-27	IgG glycosylation;
BRCA	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg06784218	chr1:46089804	CCDC17	-0.43	-10.3	-0.38	4.04e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.65	10.69	0.39	1.2e-24	Renal function-related traits (BUN);
BRCA	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	19.68	0.61	9.04e-68	Alzheimer's disease;
BRCA	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.09e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg07148914	chr20:33460835	GGT7	0.4	8.9	0.33	5.87e-18	Height;
BRCA	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.43	-0.38	1.3e-23	Coronary artery disease;
BRCA	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	15.8	0.53	1.05e-47	Coronary artery disease;
BRCA	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.61	7.81	0.3	2.34e-14	Yeast infection;
BRCA	cis	rs11608355	0.545	rs2302704	chr12:109898797	A/G	cg05360138	chr12:110035743	NA	0.69	12.74	0.45	2.67e-33	Neuroticism;
BRCA	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg20607287	chr7:12443886	VWDE	-0.58	-8.44	-0.32	2.17e-16	Coronary artery disease;
BRCA	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg06453172	chr10:134556979	INPP5A	-0.61	-11.66	-0.42	1.32e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg23649088	chr2:200775458	C2orf69	-0.39	-8.25	-0.31	8.94e-16	Asthma (bronchodilator response);
BRCA	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg18252515	chr7:66147081	NA	-1.06	-15.95	-0.53	1.89e-48	Diabetic kidney disease;
BRCA	cis	rs710865	0.627	rs10799710	chr1:19483209	A/G	cg13387374	chr1:19411106	UBR4	0.44	9.75	0.36	4.86e-21	Brain structure;
BRCA	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg06917634	chr15:78832804	PSMA4	-0.58	-12.89	-0.45	6.04e-34	Sudden cardiac arrest;
BRCA	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg12311346	chr5:56204834	C5orf35	-0.54	-11.43	-0.41	1.17e-27	Coronary artery disease;
BRCA	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg25319279	chr11:5960081	NA	-0.42	-8.3	-0.31	6.06e-16	DNA methylation (variation);
BRCA	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg25036284	chr2:26402008	FAM59B	0.96	15.93	0.53	2.36e-48	Gut microbiome composition (summer);
BRCA	cis	rs7903847	0.642	rs7092499	chr10:99140313	A/G	cg08345082	chr10:99160200	RRP12	-0.29	-8.42	-0.32	2.53e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.81	17.52	0.57	2.09e-56	Body mass index (adult);
BRCA	cis	rs9649465	1.000	rs2299985	chr7:123369044	T/C	cg04330084	chr7:123175371	IQUB	-0.31	-8.44	-0.32	2.13e-16	Migraine;
BRCA	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg11752832	chr7:134001865	SLC35B4	0.49	12.54	0.44	2.19e-32	Mean platelet volume;
BRCA	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-17.9	-0.58	2.24e-58	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9527	0.830	rs3740392	chr10:104636855	T/C	cg04362960	chr10:104952993	NT5C2	0.5	10.79	0.39	4.89e-25	Arsenic metabolism;
BRCA	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg04450456	chr4:17643702	FAM184B	0.36	10.43	0.38	1.26e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg11057378	chr10:81107060	PPIF	0.4	9.55	0.35	2.72e-20	Height;
BRCA	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg21609526	chr1:3105151	PRDM16	-0.38	-9.07	-0.34	1.42e-18	Migraine;
BRCA	cis	rs12618769	0.597	rs11901568	chr2:99128621	C/T	cg10123293	chr2:99228465	UNC50	-0.41	-8.1	-0.31	2.72e-15	Bipolar disorder;
BRCA	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg04691961	chr3:161091175	C3orf57	-0.36	-8.28	-0.31	7.09e-16	Morning vs. evening chronotype;
BRCA	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27286337	chr10:134555280	INPP5A	0.78	12.8	0.45	1.48e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg22800045	chr5:56110881	MAP3K1	-0.45	-9.1	-0.34	1.17e-18	Initial pursuit acceleration;
BRCA	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg12310025	chr6:25882481	NA	-0.54	-13.03	-0.46	1.3600000000000001e-34	Blood metabolite levels;
BRCA	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg21573476	chr21:45109991	RRP1B	-0.33	-8.43	-0.32	2.32e-16	Mean corpuscular volume;
BRCA	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg01028140	chr2:1542097	TPO	-0.8	-15.97	-0.53	1.43e-48	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.55	12.08	0.43	2.18e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-16.54	-0.55	2.07e-51	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-16.05	-0.54	6.08e-49	Chronic sinus infection;
BRCA	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg09163369	chr1:210001066	C1orf107	0.5	9.45	0.35	6.45e-20	Orofacial clefts;
BRCA	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.85	-0.33	8.34e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-15.83	-0.53	7e-48	Heart rate;
BRCA	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.52	-0.52	2.6e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg16325326	chr1:53192061	ZYG11B	0.9	25.02	0.7	7.91e-97	Monocyte count;
BRCA	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg06623918	chr6:96969491	KIAA0776	0.78	14.06	0.49	2.59e-39	Migraine;Coronary artery disease;
BRCA	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.79	0.55	1.16e-52	Hypertriglyceridemia;
BRCA	cis	rs6121246	0.609	rs4453755	chr20:30331047	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	18.23	0.58	4.23e-60	Mean corpuscular hemoglobin;
BRCA	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg11266682	chr4:10021025	SLC2A9	0.48	12.86	0.45	8.33e-34	Bone mineral density;
BRCA	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg03354898	chr7:1950403	MAD1L1	-0.44	-9.41	-0.35	9.04e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs921968	0.565	rs7603709	chr2:219642601	C/T	cg02176678	chr2:219576539	TTLL4	-0.4	-10.92	-0.4	1.41e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.24	-0.38	7.11e-23	Psoriasis;
BRCA	cis	rs8016982	0.662	rs8014406	chr14:81657760	A/C	cg01989461	chr14:81687754	GTF2A1	0.45	8.24	0.31	9.56e-16	Schizophrenia;
BRCA	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.68	-15.85	-0.53	6.14e-48	Systemic lupus erythematosus;
BRCA	cis	rs2882667	0.690	rs288029	chr5:138217305	A/G	cg04439458	chr5:138467593	SIL1	-0.35	-8.41	-0.32	2.69e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03264133	chr6:25882463	NA	-0.42	-9.37	-0.35	1.18e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg03060546	chr3:49711283	APEH	-0.55	-11.06	-0.4	4.04e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg17691542	chr6:26056736	HIST1H1C	0.48	9.55	0.35	2.75e-20	Iron status biomarkers;
BRCA	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg22974920	chr21:40686053	BRWD1	-0.38	-8.49	-0.32	1.45e-16	Cognitive function;
BRCA	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg12140854	chr5:148520817	ABLIM3	0.45	9.22	0.34	4.12e-19	Breast cancer;
BRCA	cis	rs8038465	0.638	rs12594175	chr15:73973186	C/T	cg15420318	chr15:73925796	NPTN	0.41	9.22	0.34	4.24e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg22920501	chr2:26401640	FAM59B	-0.64	-11.15	-0.4	1.66e-26	Gut microbiome composition (summer);
BRCA	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg12219531	chr12:120966889	COQ5	0.55	11.48	0.41	7.31e-28	High light scatter reticulocyte count;
BRCA	cis	rs990171	0.506	rs4141632	chr2:102757139	A/G	cg22835712	chr2:102737379	NA	0.58	11.07	0.4	3.54e-26	Lymphocyte counts;
BRCA	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg18964960	chr10:1102726	WDR37	0.62	8.57	0.32	7.51e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg13550731	chr2:172543902	DYNC1I2	0.94	31.96	0.78	1.28e-134	Schizophrenia;
BRCA	trans	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg25482853	chr8:67687455	SGK3	0.65	12.51	0.44	2.87e-32	Obesity-related traits;
BRCA	trans	rs3198697	0.663	rs12928099	chr16:15150505	C/A	cg04146151	chr16:2155961	PKD1	-0.72	-12.43	-0.44	6.57e-32	Triglycerides;
BRCA	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-13.23	-0.46	1.74e-35	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg05340658	chr4:99064831	C4orf37	0.66	16.19	0.54	1.17e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg03711944	chr11:47377212	SPI1	-0.41	-9.89	-0.36	1.46e-21	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg18904891	chr8:8559673	CLDN23	-0.64	-12.56	-0.45	1.66e-32	Obesity-related traits;
BRCA	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg03709012	chr19:19516395	GATAD2A	1.08	21.32	0.64	1.41e-76	Nonalcoholic fatty liver disease;
BRCA	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg08992911	chr2:238395768	MLPH	0.49	8.15	0.31	1.9e-15	Prostate cancer;
BRCA	cis	rs117623576	0.715	rs11008755	chr10:32360053	C/T	cg03047570	chr10:32398778	NA	0.5	7.89	0.3	1.36e-14	Anti-saccade response;
BRCA	cis	rs13136331	0.532	rs2627670	chr4:88564988	A/G	cg22416721	chr4:88570574	DMP1	-0.6	-14.45	-0.5	3.53e-41	Sitting height ratio;
BRCA	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	trans	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg26384229	chr12:38710491	ALG10B	0.68	14.24	0.49	3.75e-40	Morning vs. evening chronotype;
BRCA	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg07884673	chr3:53033167	SFMBT1	0.88	10.31	0.38	3.62e-23	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-9.43	-0.35	7.52e-20	Blood metabolite levels;
BRCA	cis	rs11955398	0.563	rs10471493	chr5:60035222	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.38	-9.0	-0.34	2.64e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg25482853	chr8:67687455	SGK3	0.78	13.72	0.48	1.03e-37	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg06552810	chr11:31128660	NA	-0.38	-8.77	-0.33	1.58e-17	Red blood cell count;
BRCA	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg17971929	chr21:40555470	PSMG1	0.62	14.38	0.49	8.35e-41	Cognitive function;
BRCA	cis	rs4478858	0.735	rs10798845	chr1:31822636	A/G	cg00250761	chr1:31883323	NA	0.32	8.4	0.32	2.91e-16	Alcohol dependence;
BRCA	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg04315214	chr1:2043799	PRKCZ	-0.47	-13.16	-0.46	3.5e-35	Height;
BRCA	cis	rs919433	0.963	rs10166569	chr2:198183439	G/A	cg10820045	chr2:198174542	NA	-0.39	-8.0	-0.3	6.04e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs6450176	0.909	rs12659966	chr5:53292892	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.59	14.11	0.49	1.52e-39	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg16339924	chr4:17578868	LAP3	0.62	15.37	0.52	1.3e-45	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.75	15.62	0.53	7.86e-47	Smoking behavior;
BRCA	cis	rs10489202	0.608	rs7553238	chr1:168076768	G/A	cg24449463	chr1:168025552	DCAF6	-0.46	-14.51	-0.5	1.88e-41	Schizophrenia;
BRCA	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg20203395	chr5:56204925	C5orf35	-0.52	-10.5	-0.38	6.58e-24	Initial pursuit acceleration;
BRCA	cis	rs9837602	1.000	rs9833980	chr3:99767096	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.18	0.4	1.29e-26	Breast cancer;
BRCA	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.49	9.6	0.35	1.79e-20	Birth weight;
BRCA	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-11.0	-0.4	6.6900000000000006e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg16414030	chr3:133502952	NA	-0.45	-10.61	-0.39	2.42e-24	Iron status biomarkers;
BRCA	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-9.65	-0.36	1.14e-20	Axial length;
BRCA	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg21747090	chr2:27597821	SNX17	-0.42	-9.13	-0.34	9.17e-19	Total body bone mineral density;
BRCA	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg05340658	chr4:99064831	C4orf37	0.5	11.58	0.42	2.71e-28	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs243505	0.861	rs243531	chr7:148412513	A/G	cg09806900	chr7:148480153	CUL1	-0.4	-8.23	-0.31	1.03e-15	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg19653624	chr11:20408972	PRMT3	-0.44	-10.02	-0.37	4.65e-22	Pursuit maintenance gain;
BRCA	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg24558204	chr6:135376177	HBS1L	0.46	12.59	0.45	1.23e-32	Red blood cell count;
BRCA	cis	rs495337	0.736	rs537672	chr20:48473546	T/A	cg17835207	chr20:48524531	SPATA2	-0.5	-11.06	-0.4	3.87e-26	Psoriasis;
BRCA	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.85	0.51	4.29e-43	Colorectal cancer;
BRCA	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.39	2.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg16586182	chr3:47516702	SCAP	0.52	11.43	0.41	1.16e-27	Colorectal cancer;
BRCA	cis	rs4423214	0.879	rs1792283	chr11:71135136	T/C	cg05163923	chr11:71159392	DHCR7	-0.51	-10.24	-0.38	6.61e-23	Vitamin D levels;
BRCA	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg18538332	chr22:24372958	LOC391322	-0.56	-14.09	-0.49	1.93e-39	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1113500	0.730	rs1781080	chr1:108593415	G/A	cg06207961	chr1:108661230	NA	-0.33	-7.82	-0.3	2.17e-14	Growth-regulated protein alpha levels;
BRCA	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg26384229	chr12:38710491	ALG10B	0.68	14.03	0.49	3.7e-39	Morning vs. evening chronotype;
BRCA	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.55	-14.19	-0.49	6.49e-40	Electrocardiographic conduction measures;
BRCA	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.45	0.35	6.36e-20	Tonsillectomy;
BRCA	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg13047869	chr3:10149882	C3orf24	0.57	11.77	0.42	4.49e-29	Alzheimer's disease;
BRCA	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg14835575	chr10:16859367	RSU1	0.61	13.05	0.46	1.09e-34	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs6815814	0.950	rs5743563	chr4:38806019	A/G	cg06935464	chr4:38784597	TLR10	0.51	8.49	0.32	1.46e-16	Breast cancer;
BRCA	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg11584989	chr19:19387371	SF4	0.6	13.8	0.48	3.99e-38	Bipolar disorder;
BRCA	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg10523679	chr1:76189770	ACADM	0.69	12.23	0.44	4.79e-31	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	8.73	0.33	2.27e-17	Rheumatoid arthritis;
BRCA	cis	rs3845702	0.736	rs115569960	chr2:180848214	C/T	cg01881094	chr2:180872142	CWC22	1.01	16.94	0.56	1.88e-53	Schizophrenia;
BRCA	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg12444411	chr7:2802554	GNA12	-0.35	-8.45	-0.32	1.98e-16	Height;
BRCA	cis	rs9815354	0.812	rs113772069	chr3:41933389	T/C	cg03022575	chr3:42003672	ULK4	0.69	9.5	0.35	4.17e-20	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs2018683	0.523	rs1499227	chr7:29025615	C/T	cg19402173	chr7:128379420	CALU	-0.37	-8.15	-0.31	1.86e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.58	-0.32	7.44e-17	Aortic root size;
BRCA	trans	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg21659725	chr3:3221576	CRBN	0.46	8.34	0.31	4.55e-16	Menarche (age at onset);
BRCA	cis	rs708547	0.874	rs1315006	chr4:57858193	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.48	10.65	0.39	1.72e-24	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11890956	chr21:40555474	PSMG1	-0.81	-19.11	-0.6	9.6e-65	Cognitive function;
BRCA	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	14.31	0.49	1.77e-40	Colorectal cancer;
BRCA	cis	rs3892630	0.612	rs10413282	chr19:33182751	A/G	cg22980127	chr19:33182716	NUDT19	0.97	23.93	0.69	7.47e-91	Red blood cell traits;
BRCA	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-13.83	-0.48	3.01e-38	Morning vs. evening chronotype;
BRCA	cis	rs6942756	0.747	rs598412	chr7:129127736	C/T	cg02491457	chr7:128862824	NA	0.56	11.75	0.42	5.27e-29	White matter hyperintensity burden;
BRCA	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg11502198	chr6:26597334	ABT1	0.47	9.48	0.35	4.75e-20	Intelligence (multi-trait analysis);
BRCA	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg00717180	chr2:96193071	NA	-0.4	-11.17	-0.4	1.43e-26	HDL cholesterol;
BRCA	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.78e-21	Total body bone mineral density;
BRCA	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg13010199	chr12:38710504	ALG10B	0.5	9.73	0.36	5.91e-21	Morning vs. evening chronotype;
BRCA	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-12.39	-0.44	9.69e-32	Hemoglobin concentration;
BRCA	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg02544614	chr20:61657117	NA	0.28	8.15	0.31	1.93e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs77972916	0.536	rs7562101	chr2:43592756	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-10.96	-0.4	9.85e-26	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg05793240	chr7:2802953	GNA12	-0.31	-7.85	-0.3	1.75e-14	Height;
BRCA	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	10.45	0.38	1.02e-23	Height;
BRCA	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg26149184	chr10:133730230	NA	0.41	8.15	0.31	1.85e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18876405	chr7:65276391	NA	-0.61	-15.33	-0.52	2.17e-45	Aortic root size;
BRCA	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg25767906	chr1:53392781	SCP2	-0.38	-8.57	-0.32	7.5e-17	Monocyte count;
BRCA	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	19.62	0.61	1.99e-67	Platelet count;
BRCA	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg18305652	chr10:134549665	INPP5A	0.42	11.88	0.43	1.54e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg20503657	chr10:835505	NA	1.06	18.28	0.59	2.34e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25427524	chr10:38739819	LOC399744	0.67	16.23	0.54	7.29e-50	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg05775895	chr3:12838266	CAND2	0.36	7.9	0.3	1.2e-14	QRS complex (12-leadsum);
BRCA	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg05294307	chr14:35346193	BAZ1A	-0.62	-10.45	-0.38	1e-23	Psoriasis;
BRCA	trans	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg23762105	chr12:34175262	ALG10	0.34	7.96	0.3	7.76e-15	Morning vs. evening chronotype;
BRCA	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02176678	chr2:219576539	TTLL4	0.45	11.62	0.42	1.97e-28	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	22.2	0.66	2.32e-81	Platelet count;
BRCA	cis	rs56804039	1.000	rs7017341	chr8:8381664	C/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-9.31	-0.35	2e-19	Cervical cancer;
BRCA	cis	rs189798	0.738	rs330908	chr8:8995166	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	8.09	0.3	2.91e-15	Myopia (pathological);
BRCA	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg11752832	chr7:134001865	SLC35B4	0.56	14.43	0.5	4.5e-41	Mean platelet volume;
BRCA	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg01689657	chr7:91764605	CYP51A1	-0.23	-8.29	-0.31	6.78e-16	Breast cancer;
BRCA	cis	rs870825	0.616	rs10025167	chr4:185649551	A/C	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs2304069	0.644	rs216131	chr5:149431223	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.61	11.76	0.42	5.04e-29	HIV-1 control;
BRCA	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.56	8.75	0.33	1.94e-17	Lung function (FEV1/FVC);
BRCA	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03264133	chr6:25882463	NA	-0.42	-9.74	-0.36	5.23e-21	Height;
BRCA	cis	rs3768617	0.745	rs4546885	chr1:183025555	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.44	9.51	0.35	3.73e-20	Fuchs's corneal dystrophy;
BRCA	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg10224037	chr5:178157518	ZNF354A	0.72	15.34	0.52	2e-45	Neutrophil percentage of white cells;
BRCA	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg06627628	chr2:24431161	ITSN2	-0.63	-12.02	-0.43	3.88e-30	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-12.96	-0.46	2.7200000000000002e-34	Migraine;Coronary artery disease;
BRCA	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg27279351	chr12:120934652	DYNLL1	0.56	13.23	0.46	1.7000000000000001e-35	High light scatter reticulocyte count;
BRCA	cis	rs6066835	1.000	rs73136396	chr20:47337174	T/A	cg18078177	chr20:47281410	PREX1	0.72	7.84	0.3	1.96e-14	Multiple myeloma;
BRCA	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.36	8.32	0.31	5.3e-16	Bipolar disorder;
BRCA	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg12310025	chr6:25882481	NA	0.52	12.29	0.44	2.7e-31	Blood metabolite levels;
BRCA	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg07741184	chr6:167504864	NA	0.33	9.87	0.36	1.8e-21	Primary biliary cholangitis;
BRCA	cis	rs4363385	0.818	rs4845522	chr1:153011099	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg23505145	chr19:12996616	KLF1	0.56	12.79	0.45	1.66e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4363385	0.720	rs1415968	chr1:152970219	C/G	cg21543102	chr1:152974771	SPRR3	-0.28	-8.04	-0.3	4.2e-15	Inflammatory skin disease;
BRCA	trans	rs931812	0.757	rs35569317	chr8:101907971	T/C	cg20993868	chr7:22813445	NA	0.45	13.33	0.47	6.03e-36	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg25036284	chr2:26402008	FAM59B	-0.63	-10.96	-0.4	1.02e-25	Gut microbiome composition (summer);
BRCA	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg08859206	chr1:53392774	SCP2	-0.43	-8.62	-0.32	5.43e-17	Monocyte count;
BRCA	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9420	0.925	rs488769	chr11:57450720	A/C	cg19752551	chr11:57585705	CTNND1	-0.42	-10.52	-0.38	5.42e-24	Schizophrenia;
BRCA	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10802521	chr3:52805072	NEK4	-0.3	-7.82	-0.3	2.16e-14	Electroencephalogram traits;
BRCA	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg06636001	chr8:8085503	FLJ10661	0.59	13.42	0.47	2.26e-36	Mood instability;
BRCA	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg04166393	chr7:2884313	GNA12	0.49	9.38	0.35	1.1e-19	Height;
BRCA	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	14.87	0.51	3.63e-43	Hip circumference adjusted for BMI;
BRCA	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	19.65	0.61	1.42e-67	Platelet count;
BRCA	cis	rs7539409	0.833	rs2057083	chr1:84269942	T/G	cg10977910	chr1:84465055	TTLL7	0.67	9.64	0.36	1.26e-20	Alzheimer's disease;
BRCA	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg13073564	chr4:8508604	NA	0.44	11.88	0.43	1.55e-29	Response to antineoplastic agents;
BRCA	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg16506815	chr2:162101123	NA	0.72	18.05	0.58	3.57e-59	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg24558204	chr6:135376177	HBS1L	0.59	15.94	0.53	2.02e-48	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg10295955	chr4:187884368	NA	-0.88	-25.8	-0.71	4.27e-101	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs365132	0.934	rs183686	chr5:176494102	A/G	cg16309518	chr5:176445507	NA	-0.52	-12.97	-0.46	2.7e-34	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs3739998	0.692	rs11007864	chr10:30313117	T/C	cg00730780	chr10:30316187	KIAA1462	0.55	11.4	0.41	1.57e-27	Coronary heart disease;
BRCA	trans	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg06521331	chr12:34319734	NA	-0.49	-9.15	-0.34	7.35e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.54	-0.32	9.46e-17	Aortic root size;
BRCA	cis	rs2274471	0.645	rs73639261	chr9:5084215	G/A	cg03390472	chr9:5043263	JAK2	-0.47	-7.85	-0.3	1.76e-14	Crohn's disease;
BRCA	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09256448	chr16:638327	NA	0.3	7.94	0.3	8.99e-15	Height;
BRCA	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.8	18.55	0.59	8.36e-62	Birth weight;
BRCA	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	12.4	0.44	8.54e-32	Coronary artery disease;
BRCA	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg08885076	chr2:99613938	TSGA10	0.41	9.63	0.36	1.4e-20	Chronic sinus infection;
BRCA	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg15737290	chr11:93063684	CCDC67	0.58	13.57	0.47	5.01e-37	Pulmonary function decline;
BRCA	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.56	9.29	0.34	2.45e-19	Renal function-related traits (BUN);
BRCA	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.05	-19.05	-0.6	1.99e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg04705435	chr11:17411270	KCNJ11	0.46	9.62	0.36	1.45e-20	Type 2 diabetes;
BRCA	cis	rs2629751	0.512	rs2723868	chr12:104422317	C/T	cg14987745	chr12:104360022	TDG	-0.5	-9.42	-0.35	8.1e-20	Hepatitis C induced liver fibrosis;
BRCA	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg24642844	chr7:1081250	C7orf50	-0.88	-15.99	-0.53	1.13e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11585357	0.947	rs2977303	chr1:17611548	A/T	cg19159961	chr1:17633534	PADI4	0.46	8.48	0.32	1.57e-16	Hair shape;
BRCA	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24549020	chr5:56110836	MAP3K1	0.41	8.58	0.32	7.34e-17	Initial pursuit acceleration;
BRCA	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg23791538	chr6:167370224	RNASET2	-0.37	-9.22	-0.34	4.17e-19	Crohn's disease;
BRCA	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.61	7.81	0.3	2.34e-14	Yeast infection;
BRCA	cis	rs8032158	1.000	rs8029247	chr15:56273446	C/T	cg02198044	chr15:56286336	NEDD4	0.36	8.66	0.32	3.9e-17	Keloid;
BRCA	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24549020	chr5:56110836	MAP3K1	0.67	13.19	0.46	2.7e-35	Initial pursuit acceleration;
BRCA	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg25019033	chr10:957182	NA	-0.42	-8.68	-0.32	3.28e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg16049864	chr8:95962084	TP53INP1	-0.49	-12.25	-0.44	3.9e-31	Type 2 diabetes;
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11141652	chr22:24348549	GSTTP1	-0.43	-8.8	-0.33	1.26e-17	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg01802117	chr1:53393560	SCP2	0.41	8.59	0.32	6.73e-17	Monocyte count;
BRCA	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	11.37	0.41	2.16e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2425143	0.908	rs75331436	chr20:34391052	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.99	-0.34	2.73e-18	Blood protein levels;
BRCA	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg14228332	chr4:119757509	SEC24D	0.62	7.99	0.3	6.18e-15	Cannabis dependence symptom count;
BRCA	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg09307838	chr4:120376055	NA	-0.69	-13.9	-0.48	1.38e-38	Corneal astigmatism;
BRCA	cis	rs17741873	0.779	rs10509346	chr10:75596014	A/G	cg07699608	chr10:75541558	CHCHD1	-0.51	-8.26	-0.31	8.58e-16	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg06917634	chr15:78832804	PSMA4	-0.55	-11.73	-0.42	6.6e-29	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.72	0.57	1.98e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17253792	0.822	rs76472022	chr14:56053660	C/T	cg01858014	chr14:56050164	KTN1	-0.73	-9.37	-0.35	1.19e-19	Putamen volume;
BRCA	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg08738300	chr3:44038990	NA	0.44	8.52	0.32	1.16e-16	Coronary artery disease;
BRCA	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg18230493	chr5:56204884	C5orf35	-0.73	-14.9	-0.51	2.68e-43	Initial pursuit acceleration;
BRCA	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg22676075	chr6:135203613	NA	-0.45	-8.95	-0.33	3.77e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg13010199	chr12:38710504	ALG10B	0.5	10.53	0.38	4.99e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg13119609	chr19:45449297	APOC2	0.47	13.12	0.46	5.38e-35	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg02297831	chr4:17616191	MED28	0.37	8.71	0.33	2.68e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg23229984	chr5:148520753	ABLIM3	0.36	8.84	0.33	9.05e-18	Breast cancer;
BRCA	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12667521	chr19:29218732	NA	0.47	8.68	0.32	3.4e-17	Methadone dose in opioid dependence;
BRCA	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg04851639	chr8:1020857	NA	-0.31	-8.91	-0.33	5.39e-18	Schizophrenia;
BRCA	cis	rs9811920	0.516	rs793485	chr3:99492383	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-9.86	-0.36	1.97e-21	Axial length;
BRCA	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-8.98	-0.33	3.09e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2710642	0.678	rs11125946	chr2:63298150	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-9.41	-0.35	8.63e-20	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.39	-8.35	-0.31	4.22e-16	Total cholesterol levels;
BRCA	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg17691542	chr6:26056736	HIST1H1C	0.76	13.47	0.47	1.44e-36	Iron status biomarkers;
BRCA	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg06784218	chr1:46089804	CCDC17	0.5	12.02	0.43	3.67e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg24642439	chr20:33292090	TP53INP2	0.55	9.67	0.36	9.67e-21	Protein C levels;
BRCA	cis	rs250677	0.522	rs998304	chr5:148382365	C/A	cg18129178	chr5:148520854	ABLIM3	-0.54	-10.51	-0.38	6.29e-24	Breast cancer;
BRCA	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.1	0.49	1.73e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19723775	chr5:179050963	HNRNPH1	-0.38	-9.39	-0.35	1.05e-19	Lung cancer;
BRCA	cis	rs72781680	0.716	rs2712068	chr2:23984000	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	10.15	0.37	1.57e-22	Lymphocyte counts;
BRCA	cis	rs68170813	0.527	rs78133594	chr7:107025260	T/C	cg02696742	chr7:106810147	HBP1	-0.49	-8.53	-0.32	1.05e-16	Coronary artery disease;
BRCA	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11764359	chr7:65958608	NA	0.76	16.82	0.55	7.85e-53	Aortic root size;
BRCA	cis	rs2267137	0.903	rs2283850	chr22:29772391	G/C	cg07256473	chr22:29710276	RASL10A	0.36	8.91	0.33	5.47e-18	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg07414643	chr4:187882934	NA	0.28	9.48	0.35	4.74e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg10495392	chr1:46806563	NSUN4	0.45	8.22	0.31	1.12e-15	Menopause (age at onset);
BRCA	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg20362242	chr5:692897	TPPP	0.53	8.51	0.32	1.28e-16	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2171564	0.967	rs9874987	chr3:112435997	G/C	cg06685282	chr3:112453648	NA	-0.36	-7.81	-0.3	2.42e-14	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs34779708	0.643	rs4275563	chr10:35545286	G/A	cg03585969	chr10:35415529	CREM	0.45	9.13	0.34	8.8e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg23711669	chr6:146136114	FBXO30	0.77	17.97	0.58	9.78e-59	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.4	8.72	0.33	2.48e-17	Cognitive ability;
BRCA	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg03585969	chr10:35415529	CREM	0.56	11.54	0.42	3.91e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9487051	0.803	rs410449	chr6:109539853	C/T	cg01475377	chr6:109611718	NA	-0.42	-10.01	-0.37	5.25e-22	Reticulocyte fraction of red cells;
BRCA	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg17971929	chr21:40555470	PSMG1	-0.61	-13.89	-0.48	1.67e-38	Cognitive function;
BRCA	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	8.68	0.32	3.31e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg18196295	chr10:418757	DIP2C	0.49	11.74	0.42	5.63e-29	Psychosis in Alzheimer's disease;
BRCA	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.57	-8.45	-0.32	2.03e-16	Cerebrospinal P-tau181p levels;
BRCA	trans	rs2840044	1.000	rs17637907	chr17:33891386	A/G	cg19694781	chr19:47549865	TMEM160	0.46	11.02	0.4	5.72e-26	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg06627628	chr2:24431161	ITSN2	-0.55	-8.93	-0.33	4.59e-18	Lymphocyte counts;
BRCA	cis	rs877529	1.000	rs877529	chr22:39542292	G/A	cg12193277	chr22:39547181	CBX7	0.46	12.74	0.45	2.6e-33	Multiple myeloma;
BRCA	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	11.37	0.41	2.16e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg23205692	chr1:25664452	TMEM50A	0.39	9.58	0.35	2.05e-20	Erythrocyte sedimentation rate;
BRCA	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.44	0.38	1.1e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs16866061	0.962	rs16825685	chr2:225434256	C/G	cg12698349	chr2:225449008	CUL3	0.78	21.46	0.65	2.47e-77	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg08847533	chr14:75593920	NEK9	-0.87	-22.08	-0.66	1e-80	Height;
BRCA	cis	rs708547	1.000	rs2412770	chr4:57794660	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.48	10.84	0.39	3.09e-25	Response to bleomycin (chromatid breaks);
BRCA	cis	rs7560272	0.501	rs17350188	chr2:73964842	C/G	cg20560298	chr2:73613845	ALMS1	-0.35	-8.88	-0.33	6.73e-18	Schizophrenia;
BRCA	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg06064525	chr11:970664	AP2A2	-0.48	-15.94	-0.53	2.06e-48	Alzheimer's disease (late onset);
BRCA	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg10523679	chr1:76189770	ACADM	0.76	15.91	0.53	2.96e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11971779	0.680	rs11764236	chr7:139118514	C/T	cg07862535	chr7:139043722	LUC7L2	0.39	10.38	0.38	2.02e-23	Diisocyanate-induced asthma;
BRCA	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.35	-7.83	-0.3	2.06e-14	Longevity;Endometriosis;
BRCA	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg22491629	chr6:157744540	C6orf35	-0.65	-11.68	-0.42	1.07e-28	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11890956	chr21:40555474	PSMG1	1.0	24.69	0.7	5.17e-95	Cognitive function;
BRCA	trans	rs8073060	0.821	rs11080355	chr17:33872694	T/A	cg19694781	chr19:47549865	TMEM160	0.56	11.84	0.42	2.33e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg07395648	chr5:131743802	NA	-0.37	-8.07	-0.3	3.45e-15	Blood metabolite levels;
BRCA	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg04166393	chr7:2884313	GNA12	0.63	13.77	0.48	5.94e-38	Height;
BRCA	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg13256891	chr4:100009986	ADH5	0.52	9.56	0.35	2.46e-20	Alcohol dependence;
BRCA	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	8.73	0.33	2.27e-17	Rheumatoid arthritis;
BRCA	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.32	0.35	1.93e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11890956	chr21:40555474	PSMG1	-0.65	-14.96	-0.51	1.4e-43	Menarche (age at onset);
BRCA	cis	rs7631605	0.935	rs4647224	chr3:37043230	G/A	cg15934958	chr3:37212084	LRRFIP2	0.41	9.53	0.35	3.19e-20	Cerebrospinal P-tau181p levels;
BRCA	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg27661571	chr11:113659931	NA	-0.7	-10.88	-0.4	2e-25	Hip circumference adjusted for BMI;
BRCA	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg11707556	chr5:10655725	ANKRD33B	0.44	9.74	0.36	5.31e-21	Coronary artery disease;
BRCA	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	9.39	0.35	1.02e-19	Personality dimensions;
BRCA	cis	rs16976116	0.901	rs62020097	chr15:55491007	A/T	cg11288833	chr15:55489084	RSL24D1	0.47	10.61	0.39	2.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg20007245	chr22:24372913	LOC391322	-0.45	-8.54	-0.32	1.02e-16	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	cis	rs68170813	0.523	rs12532447	chr7:106940476	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.65	-0.32	4.3e-17	Coronary artery disease;
BRCA	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg06212747	chr3:49208901	KLHDC8B	0.47	9.61	0.36	1.65e-20	Parkinson's disease;
BRCA	cis	rs775227	0.574	rs13067967	chr3:113265215	C/G	cg18753928	chr3:113234510	CCDC52	-0.57	-9.66	-0.36	1.1e-20	Dental caries;
BRCA	cis	rs2479724	0.870	rs3747753	chr6:41753380	G/T	cg17623882	chr6:41773611	USP49	0.38	10.45	0.38	1.07e-23	Menarche (age at onset);
BRCA	cis	rs1538970	0.962	rs7544178	chr1:45819069	C/T	cg05343316	chr1:45956843	TESK2	0.58	11.69	0.42	9.38e-29	Platelet count;
BRCA	cis	rs4363385	0.693	rs662506	chr1:153048386	A/C	cg25856811	chr1:152973957	SPRR3	0.3	7.85	0.3	1.78e-14	Inflammatory skin disease;
BRCA	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg25237894	chr2:233734115	C2orf82	0.39	11.04	0.4	4.74e-26	Coronary artery disease;
BRCA	cis	rs9463078	0.753	rs10948186	chr6:44903248	C/T	cg25276700	chr6:44698697	NA	-0.37	-8.65	-0.32	4.27e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs71636778	0.509	rs71636795	chr1:27241025	A/G	cg12203394	chr1:27248618	NUDC	0.6	9.46	0.35	5.7e-20	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.53	8.67	0.32	3.63e-17	HIV-1 control;
BRCA	cis	rs6815814	0.847	rs11725309	chr4:38783848	T/C	cg06935464	chr4:38784597	TLR10	0.5	8.19	0.31	1.42e-15	Breast cancer;
BRCA	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs72772090	0.539	rs3333	chr5:96115111	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-12.17	-0.43	9e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs701145	0.556	rs355779	chr3:153977253	T/C	cg12800244	chr3:153838788	SGEF	0.43	8.61	0.32	5.67e-17	Coronary artery disease;
BRCA	cis	rs17641971	0.662	rs10435575	chr8:49996107	C/T	cg00325661	chr8:49890786	NA	0.39	10.8	0.39	4.5e-25	Blood metabolite levels;
BRCA	cis	rs12711979	0.509	rs10181286	chr2:3824567	G/A	cg17052675	chr2:3827356	NA	-0.7	-23.65	-0.68	2.6e-89	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs4268898	0.735	rs34125395	chr2:24558242	C/T	cg06627628	chr2:24431161	ITSN2	0.42	8.84	0.33	9.53e-18	Asthma;
BRCA	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.32	-7.94	-0.3	9.31e-15	Total body bone mineral density;
BRCA	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg18105134	chr13:113819100	PROZ	-0.63	-14.22	-0.49	4.32e-40	Platelet distribution width;
BRCA	cis	rs9616064	0.740	rs6520049	chr22:46996309	C/T	cg05621596	chr22:47072043	GRAMD4	-0.37	-8.4	-0.32	2.95e-16	Urate levels in obese individuals;
BRCA	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg17063962	chr7:91808500	NA	0.52	12.36	0.44	1.27e-31	Breast cancer;
BRCA	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	18.92	0.6	1.05e-63	Alzheimer's disease;
BRCA	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.8	-0.36	3.32e-21	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs783540	0.967	rs783527	chr15:83285847	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.27	-8.35	-0.31	4.19e-16	Schizophrenia;
BRCA	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg21770322	chr7:97807741	LMTK2	0.42	10.94	0.4	1.15e-25	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	8.09	0.3	3.12e-15	Bipolar disorder;
BRCA	cis	rs6542838	0.583	rs12712040	chr2:99513416	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.36	-8.1	-0.3	2.89e-15	Fear of minor pain;
BRCA	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg09537434	chr19:41945824	ATP5SL	0.98	23.49	0.68	2.05e-88	Height;
BRCA	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.89	0.56	3.65e-53	Colorectal cancer;
BRCA	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	26.47	0.72	8.31e-105	Chronic sinus infection;
BRCA	cis	rs365132	1.000	rs7718874	chr5:176358065	A/G	cg16309518	chr5:176445507	NA	-0.51	-13.29	-0.47	9.27e-36	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs3849570	0.673	rs13068700	chr3:81975817	G/C	cg07356753	chr3:81810745	GBE1	-0.36	-8.35	-0.31	4.36e-16	Waist circumference;Body mass index;
BRCA	cis	rs61990749	0.597	rs176946	chr14:78178439	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	9.33	0.35	1.72e-19	Fibroblast growth factor basic levels;
BRCA	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg00814883	chr7:100076585	TSC22D4	-0.54	-11.86	-0.42	1.81e-29	Platelet count;
BRCA	trans	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg26384229	chr12:38710491	ALG10B	0.6	12.16	0.43	9.04e-31	Resting heart rate;
BRCA	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.39	8.45	0.32	2.02e-16	Cognitive ability;
BRCA	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg24101359	chr6:42928495	GNMT	0.63	15.5	0.52	3.2e-46	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg04553112	chr3:125709451	NA	-0.59	-9.23	-0.34	3.86e-19	Blood pressure (smoking interaction);
BRCA	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg01475377	chr6:109611718	NA	-0.6	-16.63	-0.55	7.2e-52	Reticulocyte fraction of red cells;
BRCA	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg25838465	chr1:92012736	NA	-0.46	-9.16	-0.34	7.12e-19	Eosinophil percentage of white cells;
BRCA	trans	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.56	-0.35	2.48e-20	Bladder cancer;
BRCA	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg11663144	chr21:46675770	NA	-0.61	-14.25	-0.49	3.42e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg01483505	chr11:975446	AP2A2	0.33	9.16	0.34	7.15e-19	Alzheimer's disease (late onset);
BRCA	trans	rs9951602	0.512	rs12454617	chr18:76656007	C/T	cg02800362	chr5:177631904	HNRNPAB	0.78	18.07	0.58	2.81e-59	Obesity-related traits;
BRCA	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg14784868	chr12:69753453	YEATS4	0.77	25.11	0.7	2.54e-97	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg11663144	chr21:46675770	NA	-0.62	-14.32	-0.49	1.53e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg05573699	chr3:52720067	GNL3;PBRM1	-0.37	-8.96	-0.33	3.47e-18	Bipolar disorder;
BRCA	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12756686	chr19:29218302	NA	0.57	10.93	0.4	1.36e-25	Methadone dose in opioid dependence;
BRCA	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg16606324	chr3:10149918	C3orf24	0.58	11.69	0.42	1e-28	Alzheimer's disease;
BRCA	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg21479132	chr6:26055353	NA	0.57	8.03	0.3	4.79e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs12474201	1.000	rs12474201	chr2:46921285	C/T	cg06386533	chr2:46925753	SOCS5	0.81	18.15	0.58	1.11e-59	Height;
BRCA	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg08807101	chr21:30365312	RNF160	0.36	7.96	0.3	7.6e-15	Pancreatic cancer;
BRCA	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.7	11.07	0.4	3.4e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs73001065	0.792	rs17216588	chr19:19664077	C/T	cg03709012	chr19:19516395	GATAD2A	0.85	9.27	0.34	2.91e-19	LDL cholesterol;
BRCA	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg24060327	chr5:131705240	SLC22A5	-0.47	-9.74	-0.36	5.25e-21	Blood metabolite levels;
BRCA	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg03433033	chr1:76189801	ACADM	0.86	22.18	0.66	2.75e-81	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs9929218	1.000	rs12446407	chr16:68804068	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-13.84	-0.48	2.75e-38	Colorectal cancer;
BRCA	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-11.99	-0.43	5.2e-30	Bipolar disorder;
BRCA	trans	rs8073060	0.963	rs11080353	chr17:33871281	C/T	cg19694781	chr19:47549865	TMEM160	0.6	13.46	0.47	1.59e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs28374715	0.617	rs16971733	chr15:41562030	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.56	-12.13	-0.43	1.23e-30	Ulcerative colitis;
BRCA	cis	rs17641971	0.684	rs12680366	chr8:49930674	T/C	cg00325661	chr8:49890786	NA	0.35	9.52	0.35	3.62e-20	Blood metabolite levels;
BRCA	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg08000102	chr2:233561755	GIGYF2	-0.6	-13.0	-0.46	1.86e-34	Coronary artery disease;
BRCA	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-16.07	-0.54	4.8e-49	Heart rate;
BRCA	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.19	-0.4	1.2e-26	Schizophrenia;
BRCA	cis	rs73242632	1.000	rs73242621	chr4:57818081	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	0.65	7.93	0.3	9.85e-15	Congenital heart disease (maternal effect);
BRCA	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.17	-0.43	8.86e-31	Total cholesterol levels;
BRCA	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg08000102	chr2:233561755	GIGYF2	0.63	13.88	0.48	1.8e-38	Coronary artery disease;
BRCA	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg12165864	chr7:66369176	NA	-0.44	-10.03	-0.37	4.4e-22	Corneal structure;
BRCA	cis	rs4363385	0.747	rs10399896	chr1:152975083	T/A	cg24667326	chr1:152973720	SPRR3	-0.35	-9.59	-0.35	1.92e-20	Inflammatory skin disease;
BRCA	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg05340658	chr4:99064831	C4orf37	0.69	17.39	0.57	9.59e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06544989	chr22:39130855	UNC84B	0.34	7.94	0.3	9.19e-15	Menopause (age at onset);
BRCA	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg04362960	chr10:104952993	NT5C2	0.46	10.74	0.39	7.57e-25	Arsenic metabolism;
BRCA	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg24130564	chr14:104152367	KLC1	-0.39	-8.84	-0.33	8.97e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg03709012	chr19:19516395	GATAD2A	0.81	18.91	0.6	1.2e-63	Tonsillectomy;
BRCA	cis	rs7246657	0.653	rs28701616	chr19:37681098	G/A	cg23950597	chr19:37808831	NA	-0.67	-10.31	-0.38	3.79e-23	Coronary artery calcification;
BRCA	cis	rs6558530	0.626	rs6558524	chr8:1702512	T/G	cg19131313	chr8:1704013	NA	-0.39	-7.82	-0.3	2.16e-14	Systolic blood pressure;
BRCA	trans	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-12.6	-0.45	1.1e-32	Brugada syndrome;
BRCA	cis	rs3784262	0.934	rs4646611	chr15:58265083	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.46	-12.26	-0.44	3.6e-31	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg18225595	chr11:63971243	STIP1	0.59	14.22	0.49	4.44e-40	Platelet count;
BRCA	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-9.45	-0.35	6.4e-20	Tonsillectomy;
BRCA	cis	rs6484504	0.600	rs1323738	chr11:31344898	T/C	cg26647111	chr11:31128758	NA	0.45	9.64	0.36	1.25e-20	Red blood cell count;
BRCA	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.92	15.23	0.52	6.5e-45	Gut microbiome composition (summer);
BRCA	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg13010199	chr12:38710504	ALG10B	0.43	9.22	0.34	4.33e-19	Morning vs. evening chronotype;
BRCA	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.42	-0.32	2.42e-16	Monocyte percentage of white cells;
BRCA	trans	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg25214090	chr10:38739885	LOC399744	0.46	10.69	0.39	1.16e-24	Corneal astigmatism;
BRCA	cis	rs10193935	0.901	rs10179237	chr2:42515501	C/T	cg27598129	chr2:42591480	NA	-0.67	-11.16	-0.4	1.52e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg04586622	chr2:25135609	ADCY3	0.46	11.66	0.42	1.28e-28	Body mass index;
BRCA	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03452623	chr4:187889614	NA	-0.35	-11.18	-0.4	1.31e-26	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2742234	0.590	rs2503863	chr10:43667398	G/A	cg02780029	chr10:43622663	RET	-0.35	-7.81	-0.3	2.42e-14	Hirschsprung disease;
BRCA	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg10523679	chr1:76189770	ACADM	0.76	15.75	0.53	1.8e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.42	9.04	0.34	1.81e-18	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.65	-17.28	-0.56	3.53e-55	Fuchs's corneal dystrophy;
BRCA	cis	rs6121246	0.512	rs6060938	chr20:30363645	T/C	cg21427119	chr20:30132790	HM13	-0.36	-8.12	-0.31	2.35e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs4948102	0.924	rs13241866	chr7:56090878	C/G	cg09872392	chr7:56161020	PHKG1	-0.38	-8.96	-0.33	3.49e-18	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs4363385	0.720	rs1338178	chr1:152981550	A/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.87	-0.36	1.81e-21	Inflammatory skin disease;
BRCA	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-16.03	-0.54	7.33e-49	Alzheimer's disease (late onset);
BRCA	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg15704280	chr7:45808275	SEPT13	0.7	14.41	0.5	5.45e-41	Coronary artery disease;
BRCA	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg18016565	chr1:150552671	MCL1	0.35	8.12	0.31	2.45e-15	Melanoma;
BRCA	cis	rs7903847	0.642	rs7088410	chr10:99135539	G/T	cg20016023	chr10:99160130	RRP12	-0.27	-8.67	-0.32	3.62e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs12541635	0.677	rs10808408	chr8:107005034	C/T	cg10147462	chr8:107024639	NA	0.39	10.7	0.39	1.07e-24	Age of smoking initiation;
BRCA	cis	rs17209837	0.646	rs10452935	chr7:87094247	A/T	cg00919237	chr7:87102261	ABCB4	-0.55	-10.73	-0.39	7.91e-25	Gallbladder cancer;
BRCA	cis	rs12760731	0.565	rs77024410	chr1:178164121	A/C	cg00404053	chr1:178313656	RASAL2	0.64	7.85	0.3	1.75e-14	Obesity-related traits;
BRCA	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg26384229	chr12:38710491	ALG10B	0.55	11.75	0.42	5.1e-29	Morning vs. evening chronotype;
BRCA	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg12011299	chr4:100065546	ADH4	0.48	10.81	0.39	4.06e-25	Smoking initiation;
BRCA	cis	rs3820928	0.874	rs116652884	chr2:227902285	C/T	cg11843606	chr2:227700838	RHBDD1	-0.36	-7.9	-0.3	1.2e-14	Pulmonary function;
BRCA	cis	rs7072216	0.763	rs733346	chr10:100164325	A/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-8.5	-0.32	1.38e-16	Metabolite levels;
BRCA	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg16606324	chr3:10149918	C3orf24	0.49	9.82	0.36	2.67e-21	Alzheimer's disease;
BRCA	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg11645453	chr3:52864694	ITIH4	0.41	9.84	0.36	2.28e-21	Schizophrenia;
BRCA	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg20587970	chr11:113659929	NA	-1.34	-24.49	-0.7	6.49e-94	Hip circumference adjusted for BMI;
BRCA	cis	rs7714584	1.000	rs3900064	chr5:150264414	C/G	cg22134413	chr5:150180641	NA	-0.56	-8.53	-0.32	1.08e-16	Crohn's disease;
BRCA	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg05283184	chr6:79620031	NA	-0.35	-7.88	-0.3	1.4e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.61	0.32	5.85e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg02551604	chr5:131831745	NA	0.42	15.89	0.53	3.71e-48	Asthma (sex interaction);
BRCA	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg18154014	chr19:37997991	ZNF793	0.56	10.28	0.38	4.82e-23	Coronary artery calcification;
BRCA	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg14582100	chr15:45693742	SPATA5L1	0.36	11.95	0.43	7.75e-30	Homoarginine levels;
BRCA	cis	rs698833	1.000	rs1067352	chr2:44669724	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	8.95	0.33	3.9e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.45	-9.84	-0.36	2.21e-21	Height;
BRCA	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.35	-0.38	2.53e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12541635	0.934	rs62527400	chr8:107054229	G/A	cg10147462	chr8:107024639	NA	0.37	9.67	0.36	9.83e-21	Age of smoking initiation;
BRCA	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg13852791	chr20:30311386	BCL2L1	0.84	16.41	0.54	9.67e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg24977027	chr2:88469347	THNSL2	0.57	9.56	0.35	2.42e-20	Plasma clusterin levels;
BRCA	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.85	-0.33	8.28e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2066819	1.000	rs57279772	chr12:56698960	G/A	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.91	-0.37	1.2e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7586879	0.964	rs6545795	chr2:25116783	C/T	cg01884057	chr2:25150051	NA	0.32	8.16	0.31	1.83e-15	Body mass index;
BRCA	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg24829409	chr8:58192753	C8orf71	-0.48	-9.25	-0.34	3.23e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg19052272	chr2:3704530	ALLC	-0.45	-10.09	-0.37	2.64e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-8.94	-0.33	4e-18	Daytime sleep phenotypes;
BRCA	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg08470875	chr2:26401718	FAM59B	-0.72	-11.43	-0.41	1.14e-27	Gut microbiome composition (summer);
BRCA	cis	rs870825	0.616	rs7683615	chr4:185618373	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.38	-10.16	-0.37	1.45e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg23933602	chr10:16859644	RSU1	0.59	10.55	0.39	4.18e-24	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	trans	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg01620082	chr3:125678407	NA	-0.7	-9.15	-0.34	7.58e-19	Intelligence (multi-trait analysis);
BRCA	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg04842962	chr6:43655489	MRPS18A	1.12	38.91	0.84	1.05e-170	IgG glycosylation;
BRCA	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg05535760	chr7:792225	HEATR2	0.71	12.97	0.46	2.67e-34	Cerebrospinal P-tau181p levels;
BRCA	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg08847533	chr14:75593920	NEK9	0.94	23.79	0.69	4.48e-90	Height;
BRCA	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg26031613	chr14:104095156	KLC1	-0.53	-9.42	-0.35	8.09e-20	Reticulocyte count;
BRCA	cis	rs858239	0.539	rs2178140	chr7:23191625	G/C	cg23682824	chr7:23144976	KLHL7	0.41	10.92	0.4	1.41e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-12.31	-0.44	2.14e-31	Bipolar disorder;
BRCA	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	16.48	0.55	4.22e-51	Platelet count;
BRCA	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg11266682	chr4:10021025	SLC2A9	0.49	13.11	0.46	5.99e-35	Bone mineral density;
BRCA	cis	rs13046373	0.535	rs7276743	chr21:31984545	C/T	cg16812893	chr21:31813075	KRTAP15-1	0.37	8.92	0.33	4.87e-18	HDL cholesterol;
BRCA	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	14.7	0.5	2.42e-42	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9986765	1.000	rs76467433	chr7:142824852	C/T	cg22531018	chr7:142981779	TMEM139	0.65	10.31	0.38	3.6e-23	Cancer;Dermatomyositis;
BRCA	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg21475434	chr5:93447410	FAM172A	0.72	8.96	0.33	3.63e-18	Diabetic retinopathy;
BRCA	cis	rs9633740	0.945	rs6586030	chr10:82254047	C/T	cg01528321	chr10:82214614	TSPAN14	-1.03	-17.24	-0.56	5.59e-55	Post bronchodilator FEV1;
BRCA	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.57	-0.32	7.8e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.42	-8.99	-0.34	2.82e-18	Longevity;Endometriosis;
BRCA	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg12935359	chr14:103987150	CKB	-0.61	-13.91	-0.48	1.27e-38	Intelligence (multi-trait analysis);
BRCA	cis	rs558133	0.964	rs6860725	chr5:78419809	C/T	cg25119155	chr5:78426943	BHMT	-0.45	-9.84	-0.36	2.38e-21	Blood and toenail selenium levels;
BRCA	trans	rs4650994	0.967	rs4650998	chr1:178531850	G/A	cg05059571	chr16:84539110	KIAA1609	-0.38	-8.53	-0.32	1.04e-16	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg27478167	chr7:817139	HEATR2	-0.48	-9.97	-0.37	7.14e-22	Cerebrospinal P-tau181p levels;
BRCA	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg13798912	chr7:905769	UNC84A	-0.49	-7.9	-0.3	1.18e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg08885076	chr2:99613938	TSGA10	0.45	10.69	0.39	1.17e-24	Chronic sinus infection;
BRCA	cis	rs7945705	0.846	rs905290	chr11:8753729	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.52	10.71	0.39	9.48e-25	Hemoglobin concentration;
BRCA	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg04944784	chr2:26401820	FAM59B	-0.97	-14.88	-0.51	3.18e-43	Gut microbiome composition (summer);
BRCA	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg16506815	chr2:162101123	NA	-0.41	-8.62	-0.32	5.26e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg16576597	chr16:28551801	NUPR1	0.29	8.23	0.31	1.02e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg24692254	chr21:30365293	RNF160	-0.59	-15.06	-0.51	4.31e-44	Dental caries;
BRCA	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg11366901	chr6:160182831	ACAT2	0.81	16.05	0.54	5.82e-49	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6484504	0.652	rs485265	chr11:31407788	G/A	cg14844989	chr11:31128820	NA	0.44	9.37	0.35	1.27e-19	Red blood cell count;
BRCA	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg23649088	chr2:200775458	C2orf69	0.62	10.74	0.39	7.54e-25	Schizophrenia;
BRCA	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.87	0.42	1.7e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9831754	0.906	rs2089934	chr3:78382448	T/C	cg06138941	chr3:78371609	NA	-0.77	-16.81	-0.55	9.21e-53	Calcium levels;
BRCA	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.38	8.56	0.32	8.46e-17	Multiple sclerosis;
BRCA	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.39	9.25	0.34	3.26e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-11.67	-0.42	1.14e-28	Gut microbiome composition (summer);
BRCA	cis	rs6820391	0.816	rs10016971	chr4:54444792	G/C	cg04173182	chr4:54446035	LNX1	0.54	12.06	0.43	2.62e-30	Cervical artery dissection;
BRCA	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.8	0.39	4.48e-25	Bipolar disorder;
BRCA	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg26384229	chr12:38710491	ALG10B	0.75	17.25	0.56	4.78e-55	Bladder cancer;
BRCA	cis	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg06521331	chr12:34319734	NA	-0.52	-10.24	-0.38	6.79e-23	Morning vs. evening chronotype;
BRCA	cis	rs2835872	0.932	rs73222345	chr21:39036569	G/A	cg06728970	chr21:39037746	KCNJ6	-0.32	-7.81	-0.3	2.37e-14	Electroencephalographic traits in alcoholism;
BRCA	cis	rs36051895	0.664	rs3824433	chr9:5113577	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-9.01	-0.34	2.34e-18	Pediatric autoimmune diseases;
BRCA	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	10.25	0.38	6.11e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs8002861	0.870	rs1348671	chr13:44449505	C/T	cg17145862	chr1:211918768	LPGAT1	0.66	16.85	0.55	5.39e-53	Leprosy;
BRCA	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg13397359	chr6:42928475	GNMT	0.67	16.29	0.54	3.89e-50	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.84	-0.33	9.56e-18	Total body bone mineral density;
BRCA	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg21770322	chr7:97807741	LMTK2	0.42	11.06	0.4	3.78e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7267979	0.789	rs9927	chr20:25277244	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.12	0.31	2.4e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	18.9	0.6	1.21e-63	Smoking behavior;
BRCA	cis	rs17253792	0.731	rs8008528	chr14:56062052	C/T	cg01858014	chr14:56050164	KTN1	-0.73	-9.19	-0.34	5.56e-19	Putamen volume;
BRCA	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg22920501	chr2:26401640	FAM59B	0.57	9.73	0.36	5.95e-21	Gut microbiome composition (summer);
BRCA	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg26597838	chr10:835615	NA	0.95	14.86	0.51	4.14e-43	Eosinophil percentage of granulocytes;
BRCA	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg12386194	chr3:101231763	SENP7	0.39	8.41	0.32	2.71e-16	Colorectal cancer;
BRCA	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06634786	chr22:41940651	POLR3H	-0.56	-9.98	-0.37	6.62e-22	Vitiligo;
BRCA	cis	rs68170813	0.559	rs12533767	chr7:106860245	A/C	cg02696742	chr7:106810147	HBP1	-0.51	-8.31	-0.31	5.71e-16	Coronary artery disease;
BRCA	cis	rs7703051	0.513	rs59014134	chr5:74589385	C/T	cg19683494	chr5:74908142	NA	0.54	8.78	0.33	1.5e-17	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
BRCA	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg03060546	chr3:49711283	APEH	0.58	9.49	0.35	4.62e-20	Menarche (age at onset);
BRCA	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg03342759	chr3:160939853	NMD3	-0.8	-17.17	-0.56	1.24e-54	Parkinson's disease;
BRCA	cis	rs13046373	0.535	rs2832964	chr21:32014012	A/C	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.42	0.35	7.84e-20	HDL cholesterol;
BRCA	cis	rs939658	0.626	rs11631406	chr15:79445789	C/T	cg17916960	chr15:79447300	NA	-0.38	-9.51	-0.35	3.7e-20	Refractive error;
BRCA	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg06627628	chr2:24431161	ITSN2	-0.56	-10.9	-0.4	1.72e-25	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg17747265	chr1:1875780	NA	0.51	15.05	0.51	4.71e-44	Body mass index;
BRCA	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-16.48	-0.55	4.35e-51	Heart rate;
BRCA	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg25173405	chr17:45401733	C17orf57	-0.49	-10.53	-0.38	5.0600000000000004e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.37	8.69	0.33	3.09e-17	Tonsillectomy;
BRCA	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg26384229	chr12:38710491	ALG10B	0.76	17.24	0.56	5.65e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg04546413	chr19:29218101	NA	0.64	12.33	0.44	1.75e-31	Methadone dose in opioid dependence;
BRCA	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg18301423	chr5:131593218	PDLIM4	0.34	7.83	0.3	2.05e-14	Acylcarnitine levels;
BRCA	cis	rs9807989	0.507	rs10203558	chr2:103027640	T/C	cg03938978	chr2:103052716	IL18RAP	0.29	8.33	0.31	4.8e-16	Asthma;
BRCA	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg01557791	chr16:72042693	DHODH	0.5	11.15	0.4	1.65e-26	Fibrinogen levels;
BRCA	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg23719950	chr11:63933701	MACROD1	-0.58	-9.45	-0.35	6.44e-20	Mean platelet volume;
BRCA	cis	rs2625529	0.652	rs8027164	chr15:72407733	A/T	cg16672083	chr15:72433130	SENP8	0.67	16.09	0.54	3.72e-49	Red blood cell count;
BRCA	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg20607798	chr8:58055168	NA	0.46	7.93	0.3	9.69e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg03433033	chr1:76189801	ACADM	-0.44	-8.89	-0.33	6.2e-18	Daytime sleep phenotypes;
BRCA	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg09904177	chr6:26538194	HMGN4	0.56	18.25	0.59	3.12e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg04234412	chr22:24373322	LOC391322	-0.62	-15.42	-0.52	7.41e-46	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg18132916	chr6:79620363	NA	-0.44	-9.88	-0.36	1.55e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs311392	0.833	rs6473917	chr8:55090430	A/G	cg11783602	chr8:55087084	NA	-0.31	-9.24	-0.34	3.74e-19	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.31	9.28	0.34	2.58e-19	Bipolar disorder;
BRCA	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg01884057	chr2:25150051	NA	0.34	9.13	0.34	8.63e-19	Body mass index;
BRCA	cis	rs6138458	1.000	rs1977540	chr20:24900290	G/T	cg26195577	chr20:24973756	C20orf3	-0.98	-24.65	-0.7	8.06e-95	Blood protein levels;
BRCA	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Urate levels;
BRCA	cis	rs977987	0.806	rs11643410	chr16:75428306	C/T	cg03315344	chr16:75512273	CHST6	0.53	12.55	0.44	1.91e-32	Dupuytren's disease;
BRCA	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg06784218	chr1:46089804	CCDC17	0.44	10.65	0.39	1.65e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg02951883	chr7:2050386	MAD1L1	-0.51	-11.9	-0.43	1.24e-29	Bipolar disorder and schizophrenia;
BRCA	cis	rs2652834	1.000	rs34575783	chr15:63397686	G/C	cg05507819	chr15:63340323	TPM1	0.44	8.05	0.3	4.07e-15	HDL cholesterol;
BRCA	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg14664628	chr15:75095509	CSK	-0.52	-12.46	-0.44	4.81e-32	Breast cancer;
BRCA	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg08822215	chr16:89438651	ANKRD11	-0.41	-8.89	-0.33	6.37e-18	Multiple myeloma (IgH translocation);
BRCA	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.87	0.36	1.75e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.13	-38.25	-0.83	2.23e-167	Exhaled nitric oxide output;
BRCA	cis	rs6728642	0.614	rs113485946	chr2:97866442	T/C	cg26665480	chr2:98280029	ACTR1B	-0.66	-7.95	-0.3	8.34e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg01475377	chr6:109611718	NA	0.58	15.91	0.53	3.06e-48	Reticulocyte fraction of red cells;
BRCA	cis	rs1953600	0.870	rs2788295	chr10:81941007	C/G	cg04850286	chr10:81895943	PLAC9	0.32	9.07	0.34	1.5e-18	Sarcoidosis;
BRCA	cis	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg07460842	chr6:66804631	NA	0.99	19.85	0.62	1.08e-68	Exhaled nitric oxide output;
BRCA	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.58	9.93	0.37	1.03e-21	Gut microbiome composition (summer);
BRCA	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg15212455	chr7:39170539	POU6F2	0.43	9.61	0.36	1.68e-20	IgG glycosylation;
BRCA	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs9463078	0.803	rs9463083	chr6:45272062	T/G	cg25276700	chr6:44698697	NA	-0.36	-8.14	-0.31	2.01e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg20307385	chr11:47447363	PSMC3	0.8	19.12	0.6	8.23e-65	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg10729496	chr3:10149963	C3orf24	0.49	9.33	0.35	1.68e-19	Alzheimer's disease;
BRCA	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg20891283	chr12:69753455	YEATS4	0.84	28.1	0.74	9.91e-114	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg24642439	chr20:33292090	TP53INP2	0.53	11.49	0.41	6.56e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18402987	chr7:1209562	NA	0.65	14.8	0.51	7.44e-43	Longevity;Endometriosis;
BRCA	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg06115741	chr20:33292138	TP53INP2	-0.37	-8.28	-0.31	7.13e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg08847533	chr14:75593920	NEK9	-0.93	-24.74	-0.7	2.81e-95	Height;
BRCA	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	8.35	0.31	4.19e-16	Schizophrenia;
BRCA	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.37	7.82	0.3	2.25e-14	Depressive symptoms;
BRCA	cis	rs78707713	0.560	rs61848398	chr10:71226103	G/A	cg12610070	chr10:71211762	TSPAN15	-0.33	-10.2	-0.37	9.84e-23	Venous thromboembolism;
BRCA	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.84	-0.3	1.91e-14	Electroencephalogram traits;
BRCA	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg01579765	chr21:45077557	HSF2BP	0.38	8.96	0.33	3.54e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg21427119	chr20:30132790	HM13	-0.41	-8.78	-0.33	1.53e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg21782813	chr7:2030301	MAD1L1	0.39	10.18	0.37	1.22e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	8.26	0.31	8.22e-16	Aortic root size;
BRCA	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-8.82	-0.33	1.05e-17	Alzheimer's disease (late onset);
BRCA	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.35	0.59	9.88e-61	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs73086581	1.000	rs3746665	chr20:3910406	C/T	cg02187196	chr20:3869020	PANK2	-0.51	-9.69	-0.36	8.25e-21	Response to antidepressants in depression;
BRCA	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.81	0.39	3.9e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg02544614	chr20:61657117	NA	0.29	8.2	0.31	1.36e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg11766577	chr21:47581405	C21orf56	-0.5	-10.79	-0.39	4.75e-25	Testicular germ cell tumor;
BRCA	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg21782813	chr7:2030301	MAD1L1	0.4	10.74	0.39	7.59e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg15017067	chr4:17643749	FAM184B	0.29	8.38	0.31	3.28e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.56	-0.39	3.73e-24	Intelligence (multi-trait analysis);
BRCA	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21659725	chr3:3221576	CRBN	0.5	12.9	0.45	5.2e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg06618935	chr21:46677482	NA	-0.37	-7.99	-0.3	6.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs312274	0.515	rs10784901	chr12:41232263	C/A	cg17827154	chr12:41323612	CNTN1	0.36	9.01	0.34	2.43e-18	Metabolite levels  (X-11787);
BRCA	cis	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg24110177	chr3:50126178	RBM5	-0.37	-9.91	-0.36	1.26e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg11502198	chr6:26597334	ABT1	0.47	9.48	0.35	4.75e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg09555818	chr19:45449301	APOC2	0.47	12.22	0.44	5.19e-31	Blood protein levels;
BRCA	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg02466173	chr16:30829666	NA	-0.47	-10.31	-0.38	3.66e-23	Multiple myeloma;
BRCA	cis	rs16958440	0.867	rs114475395	chr18:44691010	A/G	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg03517284	chr6:25882590	NA	0.37	7.88	0.3	1.46e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs4919087	0.962	rs3814164	chr10:98982749	G/A	cg25902810	chr10:99078978	FRAT1	0.41	8.82	0.33	1.07e-17	Monocyte count;
BRCA	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg03433033	chr1:76189801	ACADM	0.76	17.35	0.57	1.59e-55	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.85e-29	Chronic sinus infection;
BRCA	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.47	-0.38	9.07e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	12.16	0.43	9.75e-31	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11141652	chr22:24348549	GSTTP1	0.38	7.89	0.3	1.31e-14	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg07606381	chr6:8435919	SLC35B3	-0.64	-13.99	-0.48	5.64e-39	Motion sickness;
BRCA	cis	rs3784262	0.669	rs2197092	chr15:58247781	C/T	cg12031962	chr15:58353849	ALDH1A2	0.36	10.13	0.37	1.8e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	14.26	0.49	2.91e-40	Alzheimer's disease;
BRCA	cis	rs11024102	0.830	rs11024110	chr11:17028390	T/A	cg15084286	chr11:17036142	PLEKHA7	0.49	8.8	0.33	1.32e-17	Glaucoma (primary angle closure);
BRCA	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg00666640	chr1:248458726	OR2T12	0.3	8.55	0.32	9.35e-17	Common traits (Other);
BRCA	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.72	0.55	2.67e-52	Colorectal cancer;
BRCA	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.09	0.46	7.48e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.58	0.32	7.26e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg16590910	chr6:42928470	GNMT	0.36	7.89	0.3	1.35e-14	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.76	0.6	6.96e-63	Platelet count;
BRCA	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.21	-0.34	4.59e-19	Menopause (age at onset);
BRCA	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg26384229	chr12:38710491	ALG10B	-0.43	-10.07	-0.37	3.08e-22	Morning vs. evening chronotype;
BRCA	cis	rs6815814	0.950	rs45588337	chr4:38807328	A/G	cg06935464	chr4:38784597	TLR10	0.51	8.42	0.32	2.52e-16	Breast cancer;
BRCA	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg16049864	chr8:95962084	TP53INP1	-0.43	-10.59	-0.39	3.05e-24	Type 2 diabetes;
BRCA	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00802000	chr16:706648	WDR90	-0.41	-9.56	-0.35	2.48e-20	Height;
BRCA	cis	rs4268898	0.760	rs55863105	chr2:24570695	C/T	cg06627628	chr2:24431161	ITSN2	0.42	8.82	0.33	1.12e-17	Asthma;
BRCA	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg05340658	chr4:99064831	C4orf37	0.45	10.39	0.38	1.83e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg06115741	chr20:33292138	TP53INP2	0.39	8.64	0.32	4.62e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg06618935	chr21:46677482	NA	-0.36	-8.14	-0.31	2.02e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.15	-0.31	1.9e-15	Depression;
BRCA	cis	rs2797160	1.000	rs2747717	chr6:126008435	A/G	cg05901451	chr6:126070800	HEY2	0.4	9.71	0.36	6.73e-21	Endometrial cancer;
BRCA	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.3	-0.31	5.98e-16	Monocyte percentage of white cells;
BRCA	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08219700	chr8:58056026	NA	0.47	8.56	0.32	8.63e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.58	7.87	0.3	1.56e-14	Diabetic retinopathy;
BRCA	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg06092702	chr1:163392909	NA	0.27	7.98	0.3	6.61e-15	Motion sickness;
BRCA	cis	rs17095355	0.818	rs10509907	chr10:111781715	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.45	-9.7	-0.36	7.79e-21	Biliary atresia;
BRCA	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg18252515	chr7:66147081	NA	-1.06	-15.67	-0.53	4.51e-47	Diabetic kidney disease;
BRCA	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.24	8.31	0.31	5.89e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9647379	0.712	rs4894808	chr3:171833266	C/G	cg16233210	chr3:171778391	FNDC3B	0.35	8.02	0.3	4.92e-15	Heart rate;
BRCA	cis	rs4363385	0.747	rs1338180	chr1:152981404	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.07	-0.34	1.44e-18	Inflammatory skin disease;
BRCA	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.94	0.3	9.1e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg06697600	chr4:7070879	GRPEL1	0.63	10.93	0.4	1.27e-25	Monocyte percentage of white cells;
BRCA	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-11.71	-0.42	7.97e-29	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs829883	1.000	rs249837	chr12:98876535	A/G	cg25150519	chr12:98850993	NA	0.58	11.78	0.42	4.01e-29	Colorectal adenoma (advanced);
BRCA	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18252515	chr7:66147081	NA	-0.54	-11.05	-0.4	4.4e-26	Corneal structure;
BRCA	cis	rs6543140	0.964	rs6543143	chr2:103085420	A/C	cg04239558	chr2:103089729	SLC9A4	0.35	9.89	0.36	1.52e-21	Blood protein levels;
BRCA	cis	rs4363385	0.747	rs4314835	chr1:152984901	C/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.35	-0.31	4.16e-16	Inflammatory skin disease;
BRCA	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg00958927	chr1:175162553	KIAA0040	-0.21	-7.85	-0.3	1.71e-14	Alcohol dependence;
BRCA	trans	rs12310956	0.532	rs10772114	chr12:33853970	G/A	cg26384229	chr12:38710491	ALG10B	0.42	9.47	0.35	5.4e-20	Morning vs. evening chronotype;
BRCA	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07234876	chr8:600039	NA	-0.69	-9.87	-0.36	1.83e-21	IgG glycosylation;
BRCA	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg05985134	chr18:33552581	C18orf21	0.64	12.21	0.43	5.7e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	trans	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.38	8.49	0.32	1.39e-16	Corneal astigmatism;
BRCA	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg12311346	chr5:56204834	C5orf35	0.61	12.82	0.45	1.23e-33	Initial pursuit acceleration;
BRCA	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg25319279	chr11:5960081	NA	-0.42	-8.23	-0.31	1.05e-15	DNA methylation (variation);
BRCA	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03517284	chr6:25882590	NA	-0.45	-9.44	-0.35	6.8e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9420	0.961	rs682503	chr11:57640994	C/G	cg19752551	chr11:57585705	CTNND1	0.43	10.79	0.39	4.63e-25	Schizophrenia;
BRCA	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg27211696	chr2:191398769	TMEM194B	0.52	11.76	0.42	5.03e-29	Pulse pressure;
BRCA	cis	rs701145	0.585	rs1727944	chr3:153826603	A/C	cg12800244	chr3:153838788	SGEF	-0.62	-7.93	-0.3	1e-14	Coronary artery disease;
BRCA	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg10523679	chr1:76189770	ACADM	-0.47	-9.19	-0.34	5.31e-19	Daytime sleep phenotypes;
BRCA	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg10523679	chr1:76189770	ACADM	0.77	15.91	0.53	3.01e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.92	0.33	4.74e-18	Motion sickness;
BRCA	cis	rs4400599	0.618	rs9803862	chr1:154192143	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.32	7.93	0.3	1.02e-14	Platelet distribution width;
BRCA	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18876405	chr7:65276391	NA	0.62	15.37	0.52	1.28e-45	Aortic root size;
BRCA	cis	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.6	8.14	0.31	2.03e-15	Schizophrenia;
BRCA	cis	rs7512552	0.839	rs1694385	chr1:150377960	G/A	cg15654264	chr1:150340011	RPRD2	0.37	8.16	0.31	1.82e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg11764359	chr7:65958608	NA	0.75	18.31	0.59	1.59e-60	Aortic root size;
BRCA	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg18357645	chr12:58087776	OS9	0.46	13.35	0.47	4.92e-36	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.34	-0.38	2.72e-23	Schizophrenia;
BRCA	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg02551604	chr5:131831745	NA	0.4	15.48	0.52	3.98e-46	Asthma (sex interaction);
BRCA	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg10224037	chr5:178157518	ZNF354A	0.76	16.24	0.54	6.3e-50	Neutrophil percentage of white cells;
BRCA	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg04058563	chr4:185651563	MLF1IP	0.87	16.7	0.55	3.23e-52	Blood protein levels;
BRCA	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg03709012	chr19:19516395	GATAD2A	0.79	18.0	0.58	6.76e-59	Tonsillectomy;
BRCA	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.01	0.4	6.48e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6878727	0.638	rs42267	chr5:123656298	A/G	cg01806427	chr5:123737813	NA	-0.35	-8.0	-0.3	5.93e-15	Breast cancer;
BRCA	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg03342759	chr3:160939853	NMD3	-0.6	-11.77	-0.42	4.6e-29	Parkinson's disease;
BRCA	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg11764359	chr7:65958608	NA	-0.67	-14.97	-0.51	1.13e-43	Aortic root size;
BRCA	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.41	8.1	0.31	2.77e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg10495392	chr1:46806563	NSUN4	0.46	8.46	0.32	1.82e-16	Menopause (age at onset);
BRCA	trans	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg13010199	chr12:38710504	ALG10B	0.4	8.0	0.3	5.92e-15	Morning vs. evening chronotype;
BRCA	cis	rs7617773	0.780	rs13084616	chr3:48339699	A/G	cg11946769	chr3:48343235	NME6	-0.69	-14.56	-0.5	1.09e-41	Coronary artery disease;
BRCA	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg16482183	chr6:26056742	HIST1H1C	0.46	8.88	0.33	6.52e-18	Iron status biomarkers;
BRCA	cis	rs6484504	0.652	rs494464	chr11:31386150	C/T	cg06552810	chr11:31128660	NA	0.37	8.47	0.32	1.69e-16	Red blood cell count;
BRCA	cis	rs7809950	1.000	rs986994	chr7:107104115	G/T	cg23024343	chr7:107201750	COG5	-0.39	-8.74	-0.33	2.03e-17	Coronary artery disease;
BRCA	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg09165964	chr15:75287851	SCAMP5	-0.85	-20.39	-0.63	1.51e-71	Blood trace element (Zn levels);
BRCA	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.33	-0.31	5.02e-16	Monocyte percentage of white cells;
BRCA	trans	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.8	-0.33	1.28e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6684428	0.706	rs10493187	chr1:56320969	C/T	cg11651538	chr1:56320950	NA	-0.45	-7.94	-0.3	8.88e-15	Airflow obstruction;
BRCA	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg26061582	chr7:22766209	IL6	0.38	8.96	0.33	3.62e-18	Lung cancer;
BRCA	cis	rs7727544	0.582	rs10075459	chr5:131541363	C/G	cg14196790	chr5:131705035	SLC22A5	0.37	9.06	0.34	1.6e-18	Blood metabolite levels;
BRCA	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg07169764	chr2:136633963	MCM6	1.16	22.46	0.66	8.89e-83	Corneal structure;
BRCA	cis	rs9790314	0.747	rs9820825	chr3:160848155	A/G	cg04691961	chr3:161091175	C3orf57	-0.37	-8.18	-0.31	1.49e-15	Morning vs. evening chronotype;
BRCA	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06108461	chr20:60628389	TAF4	-0.97	-21.8	-0.65	3.32e-79	Body mass index;
BRCA	cis	rs2979489	0.891	rs4733495	chr8:30366883	A/G	cg26383811	chr8:30366931	RBPMS	0.56	14.62	0.5	6.03e-42	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
BRCA	cis	rs6782228	0.509	rs4481172	chr3:128372657	C/A	cg16766828	chr3:128327626	NA	-0.43	-9.69	-0.36	8.58e-21	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg00105475	chr2:10696890	NA	0.42	9.61	0.36	1.65e-20	Prostate cancer;
BRCA	cis	rs6743226	0.870	rs67652230	chr2:242235446	A/T	cg10021735	chr2:242295487	FARP2	0.37	10.17	0.37	1.24e-22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs7586879	0.828	rs11685125	chr2:25092104	A/G	cg04586622	chr2:25135609	ADCY3	0.38	8.99	0.34	2.76e-18	Body mass index;
BRCA	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.18	-0.34	5.91e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg26446133	chr18:72167187	CNDP2	-0.54	-11.67	-0.42	1.18e-28	Mononucleosis;
BRCA	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.39	-9.26	-0.34	2.99e-19	Tonsillectomy;
BRCA	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg16586182	chr3:47516702	SCAP	0.55	12.36	0.44	1.3e-31	Colorectal cancer;
BRCA	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-12.31	-0.44	2.1e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs11893307	0.566	rs10203824	chr2:191595850	A/C	cg05765582	chr2:191677683	NA	0.44	8.2	0.31	1.31e-15	Mean platelet volume;
BRCA	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.86	-0.39	2.59e-25	Bipolar disorder;
BRCA	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg26384229	chr12:38710491	ALG10B	-0.5	-11.33	-0.41	3.17e-27	Morning vs. evening chronotype;
BRCA	trans	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.4	-10.08	-0.37	2.83e-22	Obesity-related traits;
BRCA	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	18.61	0.59	4.36e-62	Platelet count;
BRCA	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg22105103	chr4:187893119	NA	0.35	10.8	0.39	4.5e-25	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7756236	0.521	rs6907793	chr6:36625206	A/G	cg08179530	chr6:36648295	CDKN1A	0.38	8.19	0.31	1.47e-15	QRS duration;
BRCA	cis	rs7246657	0.722	rs3829688	chr19:38077100	T/C	cg23950597	chr19:37808831	NA	-0.5	-8.64	-0.32	4.63e-17	Coronary artery calcification;
BRCA	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	13.81	0.48	3.83e-38	Hip circumference adjusted for BMI;
BRCA	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg22920501	chr2:26401640	FAM59B	-0.91	-16.23	-0.54	7.78e-50	Gut microbiome composition (summer);
BRCA	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg05340658	chr4:99064831	C4orf37	0.45	10.39	0.38	1.79e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg18252515	chr7:66147081	NA	-1.08	-16.09	-0.54	3.78e-49	Diabetic kidney disease;
BRCA	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.56	8.69	0.32	3.15e-17	HIV-1 control;
BRCA	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg24578937	chr1:2090814	PRKCZ	-0.37	-11.81	-0.42	2.86e-29	Height;
BRCA	cis	rs4780401	0.933	rs7203803	chr16:11812291	A/G	cg01061890	chr16:11836724	TXNDC11	0.35	7.9	0.3	1.25e-14	Rheumatoid arthritis;
BRCA	trans	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	27.72	0.74	1.23e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9470366	0.883	rs12199346	chr6:36641546	C/A	cg08179530	chr6:36648295	CDKN1A	0.58	10.88	0.4	2.04e-25	QRS duration;
BRCA	cis	rs11229555	0.645	rs34350060	chr11:58184902	T/C	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg08888203	chr3:10149979	C3orf24	0.68	14.48	0.5	2.55e-41	Alzheimer's disease;
BRCA	cis	rs13040088	0.935	rs62200158	chr20:61557906	C/T	cg23096297	chr20:61557774	DIDO1	0.92	19.25	0.61	1.76e-65	Menopause (age at onset);
BRCA	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg00105475	chr2:10696890	NA	-0.38	-8.73	-0.33	2.3e-17	Prostate cancer;
BRCA	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg08601574	chr20:25228251	PYGB	0.35	8.39	0.31	3.21e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6598955	0.671	rs3924325	chr1:26616320	T/C	cg04990556	chr1:26633338	UBXN11	0.55	8.65	0.32	4.23e-17	Obesity-related traits;
BRCA	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg20119798	chr7:94954144	PON1	-0.43	-9.76	-0.36	4.58e-21	Paraoxonase activity;
BRCA	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg23711669	chr6:146136114	FBXO30	0.84	20.2	0.62	1.53e-70	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-13.19	-0.46	2.63e-35	Response to antipsychotic treatment;
BRCA	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-7.95	-0.3	8.2e-15	Total body bone mineral density;
BRCA	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-12.07	-0.43	2.24e-30	Response to antipsychotic treatment;
BRCA	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg26031613	chr14:104095156	KLC1	-0.42	-8.33	-0.31	4.82e-16	Schizophrenia;
BRCA	cis	rs919433	0.679	rs7600862	chr2:198534514	C/T	cg00792783	chr2:198669748	PLCL1	0.39	8.99	0.33	2.83e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg05340658	chr4:99064831	C4orf37	0.67	16.67	0.55	4.42e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg12193833	chr17:30244370	NA	-0.58	-8.78	-0.33	1.54e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg10932868	chr11:921992	NA	0.33	7.87	0.3	1.53e-14	Alzheimer's disease (late onset);
BRCA	cis	rs9310732	0.604	rs6797410	chr3:24192284	A/G	cg15359321	chr3:24203479	THRB	0.44	10.6	0.39	2.69e-24	Schizophrenia;
BRCA	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-19.85	-0.62	1.21e-68	Systemic lupus erythematosus;
BRCA	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg14530993	chr4:882597	GAK	-0.53	-9.3	-0.35	2.22e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg17691542	chr6:26056736	HIST1H1C	0.5	10.47	0.38	9.13e-24	Height;
BRCA	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg18252515	chr7:66147081	NA	-0.84	-12.23	-0.44	4.53e-31	Diabetic kidney disease;
BRCA	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg05863683	chr7:1912471	MAD1L1	-0.34	-7.93	-0.3	1.01e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.13	0.37	1.8e-22	Aortic root size;
BRCA	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-10.76	-0.39	6.47e-25	IgG glycosylation;
BRCA	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg22800045	chr5:56110881	MAP3K1	-0.46	-9.05	-0.34	1.66e-18	Initial pursuit acceleration;
BRCA	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg24631222	chr15:78858424	CHRNA5	-0.48	-9.58	-0.35	2.18e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs7809950	1.000	rs2520269	chr7:107191327	T/C	cg23024343	chr7:107201750	COG5	-0.39	-8.75	-0.33	1.86e-17	Coronary artery disease;
BRCA	trans	rs587242	0.823	rs12025601	chr1:97024285	A/G	cg10631902	chr5:14652156	NA	-0.35	-8.06	-0.3	3.88e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
BRCA	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.31	-8.05	-0.3	4.16e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1865721	0.682	rs3745081	chr18:73142923	A/G	cg26385618	chr18:73139727	C18orf62	-0.37	-9.06	-0.34	1.62e-18	Intelligence;
BRCA	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg13770153	chr20:60521292	NA	0.81	20.25	0.63	7.72e-71	Obesity-related traits;
BRCA	cis	rs12711979	0.509	rs13021385	chr2:3826387	T/C	cg17052675	chr2:3827356	NA	-0.69	-23.53	-0.68	1.21e-88	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs400736	0.894	rs225092	chr1:8036075	G/C	cg25007680	chr1:8021821	PARK7	0.48	12.03	0.43	3.55e-30	Response to antidepressants and depression;
BRCA	trans	rs10411161	0.702	rs8110546	chr19:52383556	C/A	cg22319618	chr22:45562946	NUP50	-0.41	-7.84	-0.3	1.95e-14	Breast cancer;
BRCA	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21659725	chr3:3221576	CRBN	0.35	8.68	0.32	3.27e-17	Body mass index;
BRCA	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg27489772	chr12:121021490	NA	0.44	7.95	0.3	8.79e-15	Type 1 diabetes nephropathy;
BRCA	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.76e-18	Motion sickness;
BRCA	cis	rs870825	0.550	rs59051283	chr4:185646476	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	17.84	0.58	4.63e-58	Blood protein levels;
BRCA	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg13010199	chr12:38710504	ALG10B	0.51	10.12	0.37	1.94e-22	Bladder cancer;
BRCA	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg02297831	chr4:17616191	MED28	0.38	8.9	0.33	5.66e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg25214090	chr10:38739885	LOC399744	0.55	12.09	0.43	1.97e-30	Corneal astigmatism;
BRCA	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg08645402	chr16:4508243	NA	0.42	9.6	0.36	1.71e-20	Schizophrenia;
BRCA	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.29	-8.48	-0.32	1.58e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg02631126	chr6:28058918	ZSCAN12L1	-0.27	-8.16	-0.31	1.83e-15	Depression;
BRCA	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-7.87	-0.3	1.51e-14	Platelet count;
BRCA	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg14349672	chr11:133703707	NA	0.38	8.72	0.33	2.32e-17	Childhood ear infection;
BRCA	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg09307838	chr4:120376055	NA	0.74	16.17	0.54	1.53e-49	Corneal astigmatism;
BRCA	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.48	9.13	0.34	9.23e-19	Gut microbiome composition (summer);
BRCA	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg05347473	chr6:146136440	FBXO30	0.41	8.07	0.3	3.38e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.39	8.4	0.32	2.89e-16	Electroencephalogram traits;
BRCA	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11890956	chr21:40555474	PSMG1	-0.62	-13.91	-0.48	1.27e-38	Menarche (age at onset);
BRCA	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg08807101	chr21:30365312	RNF160	-0.42	-9.42	-0.35	7.82e-20	Dental caries;
BRCA	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg02297831	chr4:17616191	MED28	0.37	8.68	0.32	3.41e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs208520	0.779	rs208446	chr6:66903515	T/C	cg07460842	chr6:66804631	NA	-0.89	-15.26	-0.52	4.77e-45	Exhaled nitric oxide output;
BRCA	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.74	16.37	0.54	1.48e-50	Lymphocyte counts;
BRCA	cis	rs10484885	0.752	rs72921948	chr6:90582560	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.88	-17.0	-0.56	9.97e-54	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg00254258	chr1:3105189	PRDM16	-0.47	-11.0	-0.4	6.92e-26	Migraine;
BRCA	cis	rs4566357	0.615	rs12618793	chr2:227909552	T/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.33	-0.35	1.73e-19	Coronary artery disease;
BRCA	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	17.42	0.57	6.53e-56	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg00666640	chr1:248458726	OR2T12	0.32	8.83	0.33	9.7e-18	Common traits (Other);
BRCA	cis	rs495337	0.720	rs6067271	chr20:48541663	G/A	cg17835207	chr20:48524531	SPATA2	-0.69	-16.83	-0.55	6.92e-53	Psoriasis;
BRCA	cis	rs7646881	1.000	rs7646987	chr3:158453442	A/G	cg19483011	chr3:158453295	NA	0.47	9.0	0.34	2.65e-18	Tetralogy of Fallot;
BRCA	trans	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.17	0.31	1.66e-15	Corneal astigmatism;
BRCA	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg24562669	chr7:97807699	LMTK2	0.45	12.23	0.44	4.63e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg08805041	chr16:621841	PIGQ	-0.3	-8.01	-0.3	5.4e-15	Height;
BRCA	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg12927641	chr6:109611667	NA	-0.36	-8.97	-0.33	3.24e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg02733842	chr7:1102375	C7orf50	-0.72	-12.45	-0.44	5.08e-32	Bronchopulmonary dysplasia;
BRCA	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08564027	chr20:61660810	NA	0.85	22.5	0.66	5.11e-83	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg24562669	chr7:97807699	LMTK2	-0.43	-11.59	-0.42	2.49e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.67	-16.24	-0.54	6.98e-50	Ulcerative colitis;
BRCA	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg18305652	chr10:134549665	INPP5A	0.51	13.24	0.46	1.52e-35	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg26446133	chr18:72167187	CNDP2	-0.77	-18.89	-0.6	1.46e-63	Refractive error;
BRCA	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg20607798	chr8:58055168	NA	0.48	8.43	0.32	2.29e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg11814155	chr7:99998594	ZCWPW1	0.49	8.74	0.33	2.1e-17	Platelet count;
BRCA	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg13397359	chr6:42928475	GNMT	0.68	16.23	0.54	7.73e-50	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg00677455	chr12:58241039	CTDSP2	-0.61	-13.8	-0.48	4.19e-38	Multiple sclerosis;
BRCA	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.68	0.55	3.88e-52	Hypertriglyceridemia;
BRCA	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg15017067	chr4:17643749	FAM184B	0.32	9.86	0.36	1.96e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg26061582	chr7:22766209	IL6	-0.4	-9.37	-0.35	1.18e-19	Lung cancer;
BRCA	cis	rs698833	0.532	rs698810	chr2:44703171	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	8.76	0.33	1.74e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs8005677	1.000	rs10148215	chr14:23382345	C/T	cg01529538	chr14:23388837	RBM23	0.42	11.49	0.41	6.82e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.28	-0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs12612619	0.732	rs1078809	chr2:27288915	C/T	cg00617064	chr2:27272375	NA	-0.32	-8.45	-0.32	2.02e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg04362960	chr10:104952993	NT5C2	0.42	10.19	0.37	1.04e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs1506636	0.962	rs2456551	chr7:123394610	C/G	cg03229431	chr7:123269106	ASB15	0.61	13.82	0.48	3.22e-38	Plateletcrit;Platelet count;
BRCA	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg18402987	chr7:1209562	NA	0.43	8.17	0.31	1.65e-15	Longevity;Endometriosis;
BRCA	cis	rs10782582	0.609	rs2029680	chr1:76363505	A/C	cg03433033	chr1:76189801	ACADM	-0.39	-7.92	-0.3	1.08e-14	Daytime sleep phenotypes;
BRCA	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg13010199	chr12:38710504	ALG10B	0.43	8.86	0.33	7.63e-18	Bladder cancer;
BRCA	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.12	0.56	2.19e-54	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs13064411	0.735	rs10511326	chr3:113216325	T/C	cg18753928	chr3:113234510	CCDC52	-0.59	-12.52	-0.44	2.53e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.55	9.3	0.35	2.11e-19	Renal function-related traits (BUN);
BRCA	cis	rs12618769	0.625	rs4850878	chr2:99112180	T/A	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-15.0	-0.51	8.89e-44	Total cholesterol levels;
BRCA	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg17509989	chr5:176798049	RGS14	0.77	13.95	0.48	8.82e-39	Urinary electrolytes (magnesium/calcium ratio);
BRCA	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg23762105	chr12:34175262	ALG10	0.37	8.55	0.32	8.75e-17	Morning vs. evening chronotype;
BRCA	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg03146154	chr1:46216737	IPP	-0.53	-12.01	-0.43	4.03e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg27446573	chr6:127587934	RNF146	0.88	20.78	0.64	1.12e-73	Breast cancer;
BRCA	cis	rs13095912	0.785	rs62291882	chr3:185313278	T/C	cg11274856	chr3:185301563	NA	0.54	13.03	0.46	1.32e-34	Systolic blood pressure;
BRCA	cis	rs6973256	0.834	rs10244670	chr7:133323417	A/G	cg07491979	chr7:133331646	EXOC4	-0.38	-8.58	-0.32	7.07e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg09582351	chr12:29534625	ERGIC2	-0.48	-11.67	-0.42	1.16e-28	QT interval;
BRCA	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg03188948	chr7:1209495	NA	0.83	11.56	0.42	3.33e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.85	-0.3	1.81e-14	Aortic root size;
BRCA	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg16339924	chr4:17578868	LAP3	0.68	16.51	0.55	2.83e-51	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg13902645	chr11:5959945	NA	0.42	9.22	0.34	4.21e-19	DNA methylation (variation);
BRCA	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg05985134	chr18:33552581	C18orf21	0.66	12.77	0.45	1.94e-33	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg07404485	chr7:94953653	PON1	-0.37	-8.34	-0.31	4.49e-16	Paraoxonase activity;
BRCA	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg03929089	chr4:120376271	NA	0.65	12.91	0.45	4.67e-34	Coronary artery disease;
BRCA	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg26597838	chr10:835615	NA	1.07	17.87	0.58	3.23e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs68170813	0.559	rs74925723	chr7:106954536	G/C	cg02696742	chr7:106810147	HBP1	-0.54	-8.67	-0.32	3.66e-17	Coronary artery disease;
BRCA	cis	rs7424096	0.613	rs72873859	chr2:37246738	T/G	cg14987922	chr2:37194071	STRN	0.45	8.12	0.31	2.41e-15	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.5	0.63	3.81e-72	Chronic sinus infection;
BRCA	cis	rs6066835	1.000	rs742645	chr20:47323655	G/A	cg18078177	chr20:47281410	PREX1	0.72	7.83	0.3	2.06e-14	Multiple myeloma;
BRCA	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.72	-14.83	-0.51	5.56e-43	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg10253484	chr15:75165896	SCAMP2	0.39	8.01	0.3	5.32e-15	Systemic lupus erythematosus;
BRCA	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg06618935	chr21:46677482	NA	-0.35	-8.0	-0.3	5.93e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.39	0.35	1.02e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg23762105	chr12:34175262	ALG10	0.34	7.96	0.3	7.76e-15	Morning vs. evening chronotype;
BRCA	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg02951883	chr7:2050386	MAD1L1	-0.54	-12.24	-0.44	4.41e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg20224285	chr3:52813920	ITIH1	0.32	8.01	0.3	5.3e-15	Bipolar disorder;
BRCA	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.4	-0.32	2.93e-16	Monocyte percentage of white cells;
BRCA	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg04906043	chr13:21280425	IL17D	-0.48	-10.82	-0.39	3.53e-25	Dental caries;
BRCA	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg26031613	chr14:104095156	KLC1	-0.53	-9.49	-0.35	4.35e-20	Reticulocyte count;
BRCA	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg15997130	chr1:24165203	NA	-0.44	-10.03	-0.37	4.41e-22	Immature fraction of reticulocytes;
BRCA	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.57	10.13	0.37	1.9e-22	Gut microbiome composition (summer);
BRCA	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg06784218	chr1:46089804	CCDC17	0.52	12.49	0.44	3.51e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg10223061	chr2:219282414	VIL1	-0.28	-8.22	-0.31	1.11e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg11764359	chr7:65958608	NA	0.66	11.94	0.43	8.13e-30	Aortic root size;
BRCA	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg09658497	chr7:2847517	GNA12	-0.4	-8.51	-0.32	1.27e-16	Height;
BRCA	trans	rs12517041	1.000	rs995215	chr5:23285366	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.32	-0.31	5.27e-16	Calcium levels;
BRCA	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	14.3	0.49	1.97e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg05279229	chr7:1896384	MAD1L1	-0.4	-7.87	-0.3	1.47e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg24578937	chr1:2090814	PRKCZ	0.38	11.53	0.42	4.44e-28	Height;
BRCA	cis	rs12367572	0.620	rs2731040	chr12:45416383	G/A	cg04608330	chr12:45269318	NELL2	-0.4	-8.34	-0.31	4.75e-16	Gut microbiome composition (summer);
BRCA	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25427524	chr10:38739819	LOC399744	-0.71	-17.42	-0.57	6.9e-56	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	8.46	0.32	1.89e-16	Iron status biomarkers;
BRCA	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg11812906	chr14:75593930	NEK9	-0.61	-14.13	-0.49	1.17e-39	Height;
BRCA	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.59	-0.35	2.01e-20	Chronic sinus infection;
BRCA	trans	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.15	0.31	1.85e-15	Corneal astigmatism;
BRCA	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg07080220	chr10:102295463	HIF1AN	0.63	14.91	0.51	2.3e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg15017067	chr4:17643749	FAM184B	0.26	8.02	0.3	5.06e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12369635	0.929	rs3851667	chr12:129550552	G/T	cg01909103	chr12:129572610	TMEM132D	0.61	7.81	0.3	2.31e-14	Schizophrenia (inflammation and infection response interaction);
BRCA	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg12179176	chr11:130786555	SNX19	0.68	16.81	0.55	8.96e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	12.28	0.44	2.89e-31	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7617773	0.674	rs13069029	chr3:48355024	A/G	cg11946769	chr3:48343235	NME6	0.69	13.83	0.48	3e-38	Coronary artery disease;
BRCA	cis	rs7654585	0.645	rs1123943	chr4:25924426	A/G	cg10409131	chr4:25915609	C4orf52	-0.41	-8.58	-0.32	7.21e-17	Obesity-related traits;
BRCA	cis	rs26949	0.526	rs1960479	chr5:60036215	T/G	cg02684056	chr5:59996105	DEPDC1B	-0.34	-7.91	-0.3	1.16e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg13385794	chr1:248469461	NA	-0.28	-7.83	-0.3	1.99e-14	Common traits (Other);
BRCA	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg22139774	chr2:100720529	AFF3	-0.31	-8.67	-0.32	3.51e-17	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	18.25	0.59	3.36e-60	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.31	9.94	0.37	9.5e-22	Electroencephalogram traits;
BRCA	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21659725	chr3:3221576	CRBN	-0.72	-22.05	-0.66	1.49e-80	Blood protein levels;
BRCA	cis	rs708547	0.957	rs2458552	chr4:57773442	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.48	11.06	0.4	3.82e-26	Response to bleomycin (chromatid breaks);
BRCA	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg24692254	chr21:30365293	RNF160	0.47	10.39	0.38	1.82e-23	Pancreatic cancer;
BRCA	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.5	-0.32	1.31e-16	Total body bone mineral density;
BRCA	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg04944784	chr2:26401820	FAM59B	0.73	12.95	0.46	3.31e-34	Gut microbiome composition (summer);
BRCA	cis	rs11690935	0.885	rs10202823	chr2:172780132	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.81	-23.56	-0.68	7.76e-89	Schizophrenia;
BRCA	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg24558204	chr6:135376177	HBS1L	0.56	15.12	0.51	2.31e-44	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg13010199	chr12:38710504	ALG10B	0.48	9.23	0.34	3.94e-19	Morning vs. evening chronotype;
BRCA	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg08738300	chr3:44038990	NA	0.46	8.96	0.33	3.56e-18	Coronary artery disease;
BRCA	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-10.37	-0.38	2.25e-23	Neuroticism;
BRCA	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.6	0.42	2.29e-28	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7523050	0.908	rs17621644	chr1:109399023	C/T	cg08274380	chr1:109419600	GPSM2	0.82	12.5	0.44	3.02e-32	Fat distribution (HIV);
BRCA	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg08847533	chr14:75593920	NEK9	0.91	23.74	0.68	8.08e-90	Height;
BRCA	trans	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg06606381	chr12:133084897	FBRSL1	-0.88	-8.75	-0.33	1.87e-17	Depression;
BRCA	cis	rs36051895	0.664	rs17425819	chr9:5114773	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-8.09	-0.3	2.93e-15	Pediatric autoimmune diseases;
BRCA	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg24812749	chr6:127587940	RNF146	0.87	19.75	0.62	4.07e-68	Breast cancer;
BRCA	cis	rs16858210	0.648	rs57604063	chr3:183578689	A/T	cg25686905	chr3:183603175	PARL	-0.39	-8.41	-0.32	2.7e-16	Menopause (age at onset);
BRCA	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg23625390	chr15:77176239	SCAPER	0.39	9.15	0.34	7.86e-19	Blood metabolite levels;
BRCA	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00149659	chr3:10157352	C3orf10	1.1	18.64	0.59	2.97e-62	Alzheimer's disease;
BRCA	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	13.88	0.48	1.83e-38	Personality dimensions;
BRCA	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg06212747	chr3:49208901	KLHDC8B	0.54	11.76	0.42	4.65e-29	Menarche (age at onset);
BRCA	cis	rs2658782	0.724	rs2605626	chr11:93253903	A/G	cg15737290	chr11:93063684	CCDC67	0.44	8.64	0.32	4.66e-17	Pulmonary function decline;
BRCA	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg15017067	chr4:17643749	FAM184B	-0.29	-8.76	-0.33	1.77e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg13010199	chr12:38710504	ALG10B	-0.43	-9.92	-0.37	1.1e-21	Heart rate;
BRCA	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg14689365	chr7:158441557	NCAPG2	-0.43	-8.76	-0.33	1.8e-17	Height;
BRCA	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg19077165	chr18:44547161	KATNAL2	0.39	8.32	0.31	5.33e-16	Personality dimensions;
BRCA	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg01819863	chr10:32635814	EPC1	1.15	20.31	0.63	3.9e-71	Sexual dysfunction (female);
BRCA	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg12573674	chr2:1569213	NA	-0.51	-9.63	-0.36	1.38e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	trans	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg06606381	chr12:133084897	FBRSL1	-0.88	-8.75	-0.33	1.87e-17	Lung cancer in ever smokers;
BRCA	cis	rs9815354	0.812	rs113144620	chr3:42008312	A/G	cg03022575	chr3:42003672	ULK4	0.7	9.97	0.37	7.64e-22	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg01620082	chr3:125678407	NA	-0.91	-10.25	-0.38	6.18e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.33	-9.14	-0.34	7.92e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg03684893	chr10:554711	DIP2C	-0.43	-10.21	-0.37	8.8e-23	Psychosis in Alzheimer's disease;
BRCA	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg06808227	chr14:105710500	BRF1	-0.69	-14.91	-0.51	2.35e-43	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg23711669	chr6:146136114	FBXO30	0.8	18.91	0.6	1.14e-63	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-9.2	-0.34	4.83e-19	Schizophrenia;
BRCA	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg21138405	chr5:131827807	IRF1	0.4	12.93	0.46	3.89e-34	Asthma (sex interaction);
BRCA	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg22105103	chr4:187893119	NA	0.33	10.72	0.39	8.67e-25	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs9944715	0.911	rs8085138	chr18:43768751	G/A	cg01718231	chr17:29326311	RNF135	-0.42	-8.72	-0.33	2.38e-17	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg08999081	chr20:33150536	PIGU	0.35	8.95	0.33	3.94e-18	Coronary artery disease;
BRCA	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg11271282	chr2:238384023	NA	-0.41	-7.94	-0.3	9.44e-15	Prostate cancer;
BRCA	cis	rs17253792	0.822	rs80328469	chr14:56067701	G/A	cg01858014	chr14:56050164	KTN1	-0.74	-9.35	-0.35	1.43e-19	Putamen volume;
BRCA	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg11584989	chr19:19387371	SF4	0.62	13.0	0.46	1.89e-34	Bipolar disorder;
BRCA	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg02038168	chr22:39784481	NA	-0.42	-8.66	-0.32	3.87e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs921968	0.565	rs6761437	chr2:219598092	G/A	cg02176678	chr2:219576539	TTLL4	-0.41	-11.04	-0.4	4.6e-26	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs931812	1.000	rs4734495	chr8:101917817	C/A	cg20993868	chr7:22813445	NA	0.5	13.76	0.48	6.15e-38	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs6142102	0.580	rs4911139	chr20:32551535	G/A	cg24642439	chr20:33292090	TP53INP2	0.4	8.05	0.3	4.2e-15	Skin pigmentation;
BRCA	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg13902645	chr11:5959945	NA	-0.47	-10.42	-0.38	1.42e-23	DNA methylation (variation);
BRCA	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-11.68	-0.42	1.1e-28	Chronic sinus infection;
BRCA	cis	rs754466	0.580	rs1866437	chr10:79526766	A/G	cg17075019	chr10:79541650	NA	-0.82	-19.71	-0.61	6.7e-68	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg24812749	chr6:127587940	RNF146	0.88	20.66	0.63	4.91e-73	Breast cancer;
BRCA	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg22974920	chr21:40686053	BRWD1	-0.41	-9.06	-0.34	1.56e-18	Cognitive function;
BRCA	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg13010199	chr12:38710504	ALG10B	0.52	10.33	0.38	3.14e-23	Morning vs. evening chronotype;
BRCA	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg04025307	chr7:1156635	C7orf50	0.42	8.28	0.31	7.16e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26314531	chr2:26401878	FAM59B	-0.67	-11.46	-0.41	8.59e-28	Gut microbiome composition (summer);
BRCA	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg20587970	chr11:113659929	NA	-1.24	-22.64	-0.67	8.57e-84	Hip circumference adjusted for BMI;
BRCA	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	13.92	0.48	1.16e-38	Colorectal cancer;
BRCA	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.68	-0.36	8.73e-21	Alcohol dependence;
BRCA	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg08501292	chr6:25962987	TRIM38	0.59	8.03	0.3	4.71e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg14820908	chr5:178986412	RUFY1	-0.5	-13.32	-0.47	6.58e-36	Lung cancer;
BRCA	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg13385794	chr1:248469461	NA	0.28	7.97	0.3	7.1e-15	Common traits (Other);
BRCA	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg12379764	chr21:47803548	PCNT	-0.37	-8.05	-0.3	4.13e-15	Testicular germ cell tumor;
BRCA	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg21775007	chr8:11205619	TDH	-0.59	-13.01	-0.46	1.72e-34	Retinal vascular caliber;
BRCA	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.31	0.35	1.96e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg18811423	chr2:55921094	PNPT1	-0.65	-19.98	-0.62	2.26e-69	Metabolic syndrome;
BRCA	cis	rs7903847	0.642	rs4635018	chr10:99137839	C/G	cg08345082	chr10:99160200	RRP12	0.3	8.86	0.33	7.78e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.47	-0.32	1.65e-16	Total body bone mineral density;
BRCA	cis	rs921968	0.521	rs56923478	chr2:219638539	A/G	cg02176678	chr2:219576539	TTLL4	-0.41	-11.02	-0.4	5.7e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs73242632	0.881	rs10034395	chr4:57863131	G/A	cg20415529	chr4:57845134	POLR2B;C4orf14	0.67	8.0	0.3	6.05e-15	Congenital heart disease (maternal effect);
BRCA	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	14.44	0.5	4.02e-41	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg18279126	chr7:2041391	MAD1L1	0.37	8.21	0.31	1.22e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg23649088	chr2:200775458	C2orf69	0.6	8.92	0.33	4.89e-18	Schizophrenia;
BRCA	cis	rs2526882	0.541	rs2526859	chr14:71412207	C/T	cg15816911	chr14:71606274	NA	-0.38	-8.46	-0.32	1.8e-16	Schizophrenia;
BRCA	cis	rs1971762	0.583	rs1527068	chr12:54088688	A/G	cg23533419	chr12:54090519	NA	-0.33	-8.39	-0.31	3.22e-16	Height;
BRCA	cis	rs4478858	0.684	rs7549245	chr1:31752187	A/G	cg00250761	chr1:31883323	NA	-0.31	-8.17	-0.31	1.63e-15	Alcohol dependence;
BRCA	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg01324343	chr3:183735012	ABCC5	0.83	20.88	0.64	3.3e-74	Anterior chamber depth;
BRCA	cis	rs9462027	0.628	rs2814971	chr6:34714209	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.26	8.06	0.3	3.79e-15	Systemic lupus erythematosus;
BRCA	cis	rs6484504	0.512	rs2761594	chr11:31318244	A/G	cg26647111	chr11:31128758	NA	0.45	9.79	0.36	3.41e-21	Red blood cell count;
BRCA	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg16325326	chr1:53192061	ZYG11B	0.86	25.3	0.71	2.2e-98	Monocyte count;
BRCA	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.87e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg20283391	chr11:68216788	NA	-0.49	-9.58	-0.35	2.18e-20	Total body bone mineral density;
BRCA	cis	rs3820928	0.933	rs1429267	chr2:227767593	G/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.63	-0.32	4.82e-17	Pulmonary function;
BRCA	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg05868516	chr6:26286170	HIST1H4H	0.51	11.2	0.41	1.04e-26	Educational attainment;
BRCA	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg21918786	chr6:109611834	NA	-0.43	-11.52	-0.41	5.1e-28	Reticulocyte fraction of red cells;
BRCA	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	17.87	0.58	3.21e-58	Electrocardiographic conduction measures;
BRCA	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg25767906	chr1:53392781	SCP2	0.34	7.88	0.3	1.42e-14	Monocyte count;
BRCA	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00934597	chr7:893267	UNC84A	-0.42	-8.92	-0.33	5.06e-18	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg04117972	chr1:227635322	NA	0.45	8.14	0.31	2.02e-15	Major depressive disorder;
BRCA	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg17623882	chr6:41773611	USP49	-0.36	-9.71	-0.36	7.09e-21	Menarche (age at onset);
BRCA	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg17366294	chr4:99064904	C4orf37	-0.45	-10.68	-0.39	1.31e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6743226	0.934	rs7604465	chr2:242249828	C/T	cg10021735	chr2:242295487	FARP2	0.36	10.14	0.37	1.66e-22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
BRCA	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg22431228	chr1:16359049	CLCNKA	-0.44	-9.81	-0.36	2.97e-21	Dilated cardiomyopathy;
BRCA	cis	rs887829	0.570	rs13015720	chr2:234600999	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.48	-0.32	1.53e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg05665937	chr4:1216051	CTBP1	-0.39	-8.44	-0.32	2.2e-16	Obesity-related traits;
BRCA	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg19913688	chr11:428466	ANO9	-0.71	-10.01	-0.37	5.02e-22	Body mass index;
BRCA	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.01	-0.3	5.35e-15	Aortic root size;
BRCA	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg11833968	chr6:79620685	NA	-0.45	-10.12	-0.37	1.92e-22	Intelligence (multi-trait analysis);
BRCA	trans	rs208520	0.690	rs864314	chr6:66814830	G/T	cg08225398	chr13:45563328	KIAA1704;NUFIP1	0.79	9.95	0.37	8.65e-22	Exhaled nitric oxide output;
BRCA	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.34	9.44	0.35	6.71e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.05	29.38	0.76	1.06e-120	Cognitive ability;
BRCA	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-10.58	-0.39	3.38e-24	Lymphocyte counts;
BRCA	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg05283184	chr6:79620031	NA	-0.41	-10.51	-0.38	6.16e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs13136331	0.718	rs2627690	chr4:88653616	A/G	cg22416721	chr4:88570574	DMP1	-0.49	-12.17	-0.43	8.6e-31	Sitting height ratio;
BRCA	cis	rs7184046	0.797	rs13737	chr15:75932129	G/T	cg20655648	chr15:75932815	IMP3	0.51	9.92	0.37	1.09e-21	Height;
BRCA	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg15017067	chr4:17643749	FAM184B	0.32	9.86	0.36	1.96e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg13010199	chr12:38710504	ALG10B	0.4	8.1	0.31	2.77e-15	Morning vs. evening chronotype;
BRCA	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg02659138	chr7:134003124	SLC35B4	0.33	10.4	0.38	1.67e-23	Mean platelet volume;
BRCA	trans	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.16	0.31	1.81e-15	Corneal astigmatism;
BRCA	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg18446336	chr7:2847575	GNA12	-0.33	-7.93	-0.3	9.94e-15	Height;
BRCA	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg04450456	chr4:17643702	FAM184B	0.36	9.77	0.36	4.16e-21	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg13902645	chr11:5959945	NA	-0.47	-10.09	-0.37	2.5e-22	DNA methylation (variation);
BRCA	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg13902645	chr11:5959945	NA	-0.46	-9.94	-0.37	9.75e-22	DNA methylation (variation);
BRCA	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg18016565	chr1:150552671	MCL1	0.34	8.05	0.3	4.08e-15	Tonsillectomy;
BRCA	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-9.06	-0.34	1.6e-18	Alzheimer's disease (late onset);
BRCA	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.49	0.65	1.55e-77	Lymphocyte percentage of white cells;
BRCA	cis	rs13046373	0.535	rs1395778	chr21:31985502	G/C	cg16431978	chr21:31797932	KRTAP13-3	0.35	8.76	0.33	1.7e-17	HDL cholesterol;
BRCA	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg00825309	chr19:58991885	ZNF446	-0.59	-12.77	-0.45	1.95e-33	Uric acid clearance;
BRCA	cis	rs28374715	0.532	rs316607	chr15:41772693	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.08	-24.92	-0.7	2.91e-96	Ulcerative colitis;
BRCA	cis	rs9796	0.621	rs9972349	chr15:41491656	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.37	-7.84	-0.3	1.92e-14	Menopause (age at onset);
BRCA	cis	rs6066835	1.000	rs6066832	chr20:47354132	C/A	cg18078177	chr20:47281410	PREX1	0.69	8.6	0.32	6.2e-17	Multiple myeloma;
BRCA	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg25358565	chr5:93447407	FAM172A	1.2	18.7	0.59	1.46e-62	Diabetic retinopathy;
BRCA	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	9.35	0.35	1.45e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs2882667	0.690	rs12186373	chr5:138248574	T/A	cg04439458	chr5:138467593	SIL1	-0.34	-8.36	-0.31	4.05e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00149659	chr3:10157352	C3orf10	0.8	14.11	0.49	1.53e-39	Alzheimer's disease;
BRCA	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg03060546	chr3:49711283	APEH	0.55	9.22	0.34	4.32e-19	Menarche (age at onset);
BRCA	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg05340658	chr4:99064831	C4orf37	0.63	15.15	0.51	1.51e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg24069376	chr3:38537580	EXOG	0.39	11.26	0.41	6.04e-27	Electrocardiographic conduction measures;
BRCA	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg01689657	chr7:91764605	CYP51A1	0.24	8.86	0.33	7.58e-18	Breast cancer;
BRCA	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg08523384	chr5:141488047	NDFIP1	-0.42	-9.68	-0.36	9.11e-21	Crohn's disease;
BRCA	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg03146154	chr1:46216737	IPP	0.49	10.62	0.39	2.27e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg08313168	chr12:7315531	NA	0.5	8.09	0.3	2.95e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg06145435	chr7:1022769	CYP2W1	0.44	8.39	0.32	3.08e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg27398817	chr8:82754497	SNX16	-0.42	-8.68	-0.32	3.2e-17	Diastolic blood pressure;
BRCA	cis	rs57590327	0.508	rs9820349	chr3:81958587	A/G	cg07356753	chr3:81810745	GBE1	-0.37	-8.73	-0.33	2.26e-17	Extraversion;
BRCA	cis	rs72928364	0.860	rs13081830	chr3:100791262	G/A	cg10123952	chr3:100791384	NA	0.59	8.45	0.32	1.97e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg11845111	chr2:191398756	TMEM194B	0.41	9.23	0.34	4.02e-19	Pulse pressure;
BRCA	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg01262667	chr19:19385393	TM6SF2	0.41	10.56	0.39	3.79e-24	Tonsillectomy;
BRCA	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg05234568	chr11:5960015	NA	0.47	9.19	0.34	5.45e-19	DNA methylation (variation);
BRCA	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.39	8.9	0.33	5.51e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs3857067	0.506	rs282450	chr4:95139598	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-10.04	-0.37	3.99e-22	QT interval;
BRCA	cis	rs7523273	0.627	rs2724389	chr1:207933648	T/C	cg22525895	chr1:207977042	MIR29B2	0.47	12.05	0.43	2.91e-30	Schizophrenia;
BRCA	cis	rs507080	0.922	rs625513	chr11:118555719	A/C	cg09144398	chr11:118550485	TREH	-0.38	-9.05	-0.34	1.69e-18	Serum metabolite levels;
BRCA	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg13852791	chr20:30311386	BCL2L1	0.84	16.5	0.55	3.24e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg08975724	chr8:8085496	FLJ10661	0.5	10.69	0.39	1.2e-24	Mood instability;
BRCA	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.26	0.49	3.04e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg04317338	chr11:64019027	PLCB3	0.56	9.69	0.36	7.93e-21	Mean platelet volume;
BRCA	cis	rs2386661	0.712	rs11259544	chr10:5646708	T/C	cg17085576	chr10:5658249	NA	-0.33	-8.18	-0.31	1.57e-15	Breast cancer;
BRCA	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg20933634	chr6:27740509	NA	0.44	8.43	0.32	2.27e-16	Parkinson's disease;
BRCA	cis	rs11874712	0.965	rs12954944	chr18:43664115	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.18	0.31	1.57e-15	Migraine - clinic-based;
BRCA	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.91	0.4	1.61e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg21573476	chr21:45109991	RRP1B	0.42	10.39	0.38	1.76e-23	Mean corpuscular volume;
BRCA	cis	rs10463316	0.894	rs6579866	chr5:150762524	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-8.22	-0.31	1.12e-15	Metabolite levels (Pyroglutamine);
BRCA	cis	rs11690935	0.851	rs10174055	chr2:172858214	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.8	-23.34	-0.68	1.37e-87	Schizophrenia;
BRCA	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg24531977	chr5:56204891	C5orf35	-0.43	-8.66	-0.32	3.83e-17	Coronary artery disease;
BRCA	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg26446133	chr18:72167187	CNDP2	-0.74	-13.01	-0.46	1.79e-34	Refractive error;
BRCA	trans	rs8073060	0.544	rs8071584	chr17:33999435	G/A	cg19694781	chr19:47549865	TMEM160	-1.04	-21.49	-0.65	1.61e-77	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	trans	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg05926928	chr17:57297772	GDPD1	-0.42	-8.41	-0.32	2.64e-16	Schizophrenia;
BRCA	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg00852783	chr1:26633632	UBXN11	0.51	11.0	0.4	6.85e-26	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.3	0.31	6.28e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8017423	0.647	rs12589952	chr14:90821364	T/C	cg04374321	chr14:90722782	PSMC1	-0.49	-12.06	-0.43	2.51e-30	Mortality in heart failure;
BRCA	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-12.54	-0.44	2.03e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg00409905	chr10:38381863	ZNF37A	-0.48	-10.13	-0.37	1.79e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-9.11	-0.34	1.06e-18	Alzheimer's disease;
BRCA	cis	rs2712184	0.652	rs13000985	chr2:217644361	T/G	cg05032264	chr2:217675019	NA	0.34	7.98	0.3	6.68e-15	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs9287719	0.600	rs10197187	chr2:10726639	A/T	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	5.17e-19	Prostate cancer;
BRCA	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg06623918	chr6:96969491	KIAA0776	0.74	12.19	0.43	6.85e-31	Migraine;Coronary artery disease;
BRCA	cis	rs7264396	0.836	rs41293080	chr20:34187697	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-12.15	-0.43	1.06e-30	Total cholesterol levels;
BRCA	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg16414030	chr3:133502952	NA	-0.48	-11.1	-0.4	2.56e-26	Iron status biomarkers;
BRCA	cis	rs17092148	0.887	rs2295443	chr20:33173827	T/C	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.67	-0.39	1.46e-24	Neuroticism;
BRCA	cis	rs2882667	0.858	rs2043271	chr5:138459108	A/G	cg04439458	chr5:138467593	SIL1	-0.41	-10.51	-0.38	6.16e-24	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02176678	chr2:219576539	TTLL4	0.45	11.73	0.42	6.24e-29	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2464469	0.526	rs2899612	chr15:58335867	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-9.93	-0.37	1.09e-21	Barrett's esophagus  or Esophageal adenocarcinoma;
BRCA	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg08885076	chr2:99613938	TSGA10	-0.52	-11.73	-0.42	6.2e-29	Chronic sinus infection;
BRCA	cis	rs965469	0.779	rs6037516	chr20:3233142	C/G	cg25506879	chr20:3388711	C20orf194	-0.43	-8.68	-0.32	3.38e-17	IFN-related cytopenia;
BRCA	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg01579765	chr21:45077557	HSF2BP	-0.43	-10.91	-0.4	1.63e-25	Mean corpuscular volume;
BRCA	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg05623727	chr3:50126028	RBM5	-0.49	-12.16	-0.43	9.5e-31	Body mass index;
BRCA	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg24596788	chr1:163392923	NA	-0.37	-9.91	-0.36	1.25e-21	Motion sickness;
BRCA	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21659725	chr3:3221576	CRBN	-0.72	-21.74	-0.65	6.94e-79	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg03676636	chr4:99064102	C4orf37	-0.2	-7.9	-0.3	1.26e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.75	0.55	1.76e-52	Hypertriglyceridemia;
BRCA	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg12444411	chr7:2802554	GNA12	-0.36	-9.1	-0.34	1.11e-18	Height;
BRCA	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg03146154	chr1:46216737	IPP	-0.53	-11.86	-0.42	1.87e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	4.85e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg16482183	chr6:26056742	HIST1H1C	0.46	8.82	0.33	1.04e-17	Iron status biomarkers;
BRCA	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg25237894	chr2:233734115	C2orf82	0.39	11.35	0.41	2.4200000000000002e-27	Coronary artery disease;
BRCA	cis	rs8017423	0.647	rs12883000	chr14:90820557	G/A	cg04374321	chr14:90722782	PSMC1	-0.5	-11.92	-0.43	9.86e-30	Mortality in heart failure;
BRCA	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg04166393	chr7:2884313	GNA12	0.48	9.23	0.34	3.97e-19	Height;
BRCA	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg03433033	chr1:76189801	ACADM	-0.47	-9.83	-0.36	2.43e-21	Daytime sleep phenotypes;
BRCA	trans	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg07817883	chr1:32538562	TMEM39B	-0.44	-8.57	-0.32	7.59e-17	Monocyte percentage of white cells;
BRCA	cis	rs13046373	0.535	rs2832957	chr21:31973140	C/T	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.59	0.35	1.86e-20	HDL cholesterol;
BRCA	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg26384229	chr12:38710491	ALG10B	0.68	14.16	0.49	8.91e-40	Morning vs. evening chronotype;
BRCA	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg17330251	chr7:94953956	PON1	-0.42	-8.78	-0.33	1.45e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs7072216	0.763	rs12763326	chr10:100167396	A/G	cg26618903	chr10:100175079	PYROXD2	0.3	8.85	0.33	8.39e-18	Metabolite levels;
BRCA	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg26384229	chr12:38710491	ALG10B	0.78	18.11	0.58	1.71e-59	Bladder cancer;
BRCA	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg19418458	chr7:158789849	NA	-0.45	-10.01	-0.37	5.16e-22	Facial morphology (factor 20);
BRCA	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg16325326	chr1:53192061	ZYG11B	0.58	12.58	0.45	1.42e-32	Monocyte count;
BRCA	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08109568	chr15:31115862	NA	-0.45	-10.67	-0.39	1.45e-24	Huntington's disease progression;
BRCA	trans	rs2270927	1.000	rs13174383	chr5:75580416	T/G	cg13563193	chr19:33072644	PDCD5	0.86	11.76	0.42	4.72e-29	Mean corpuscular volume;
BRCA	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21659725	chr3:3221576	CRBN	0.72	22.39	0.66	1.95e-82	Intelligence (multi-trait analysis);
BRCA	cis	rs7524258	0.900	rs1476047	chr1:7312172	C/T	cg07173049	chr1:7289937	CAMTA1	0.42	10.86	0.39	2.58e-25	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.39	8.11	0.31	2.52e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-9.93	-0.37	1.07e-21	Heart rate;
BRCA	cis	rs698833	0.926	rs1067353	chr2:44666626	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	11.05	0.4	4.35e-26	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg12935359	chr14:103987150	CKB	-0.59	-14.08	-0.49	2.04e-39	Body mass index;
BRCA	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.78	0.67	1.59e-84	Chronic sinus infection;
BRCA	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	17.67	0.57	3.55e-57	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg12365402	chr11:9010492	NRIP3	0.43	9.65	0.36	1.21e-20	Tonsillectomy;
BRCA	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.3	0.31	6.36e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg22535103	chr8:58192502	C8orf71	-0.53	-9.03	-0.34	1.93e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg14458575	chr2:238380390	NA	0.57	12.87	0.45	7.3e-34	Prostate cancer;
BRCA	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.54e-23	Motion sickness;
BRCA	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg13319975	chr6:146136371	FBXO30	0.43	10.01	0.37	5.33e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg16586182	chr3:47516702	SCAP	-0.55	-12.8	-0.45	1.49e-33	Colorectal cancer;
BRCA	cis	rs11920090	0.860	rs7643425	chr3:170737395	A/G	cg09710316	chr3:170744871	SLC2A2	0.48	8.84	0.33	9.14e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07256732	chr16:621771	PIGQ	-0.35	-9.31	-0.35	1.97e-19	Height;
BRCA	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg22875332	chr1:76189707	ACADM	0.69	14.66	0.5	3.54e-42	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg25214090	chr10:38739885	LOC399744	0.51	11.16	0.4	1.56e-26	Corneal astigmatism;
BRCA	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg08601574	chr20:25228251	PYGB	-0.34	-8.19	-0.31	1.4e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg26587870	chr6:27730563	NA	-0.55	-8.23	-0.31	1.05e-15	Depression;
BRCA	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg08645402	chr16:4508243	NA	0.36	7.82	0.3	2.13e-14	Schizophrenia;
BRCA	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg07817648	chr10:79422355	NA	-0.68	-12.48	-0.44	3.74e-32	Bone mineral density;
BRCA	cis	rs701145	0.529	rs355746	chr3:153961627	C/G	cg12800244	chr3:153838788	SGEF	0.45	8.92	0.33	4.82e-18	Coronary artery disease;
BRCA	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07080220	chr10:102295463	HIF1AN	0.49	11.24	0.41	7.04e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	9.82	0.36	2.62e-21	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg08470875	chr2:26401718	FAM59B	-0.51	-8.3	-0.31	6.38e-16	Gut microbiome composition (summer);
BRCA	trans	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.41	-8.49	-0.32	1.4e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg06238570	chr21:40685208	BRWD1	-0.45	-8.8	-0.33	1.24e-17	Cognitive function;
BRCA	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.41	-0.44	8.14e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg16576597	chr16:28551801	NUPR1	0.29	8.21	0.31	1.24e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-11.49	-0.41	6.65e-28	Personality dimensions;
BRCA	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.4	-7.91	-0.3	1.12e-14	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg13010199	chr12:38710504	ALG10B	0.51	9.94	0.37	9.79e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg17802220	chr15:77601643	NA	-0.47	-10.43	-0.38	1.24e-23	Type 2 diabetes;
BRCA	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg22920501	chr2:26401640	FAM59B	-0.94	-15.9	-0.53	3.19e-48	Gut microbiome composition (summer);
BRCA	cis	rs6745190	0.575	rs7580796	chr2:181977769	T/C	cg00481216	chr2:181971175	NA	0.4	9.45	0.35	6.15e-20	White blood cell count;
BRCA	cis	rs9831754	0.704	rs1512492	chr3:78471190	A/C	cg06138941	chr3:78371609	NA	-0.51	-11.45	-0.41	9.46e-28	Calcium levels;
BRCA	cis	rs877282	1.000	rs2004479	chr10:770854	G/A	cg17470449	chr10:769945	NA	0.52	9.51	0.35	3.85e-20	Uric acid levels;
BRCA	cis	rs12612619	0.704	rs10185736	chr2:27321224	T/C	cg00617064	chr2:27272375	NA	0.33	8.27	0.31	7.6e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6450176	0.909	rs255755	chr5:53307772	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-14.46	-0.5	3.51e-41	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs7091068	0.536	rs7893369	chr10:95410147	A/G	cg20715218	chr10:95462985	C10orf4	0.58	10.65	0.39	1.75e-24	Urinary tract infection frequency;
BRCA	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg16989086	chr20:62203971	PRIC285	0.52	8.77	0.33	1.63e-17	Glioblastoma;
BRCA	cis	rs6723226	0.699	rs805830	chr2:32501475	T/C	cg02381751	chr2:32503542	YIPF4	0.64	13.23	0.46	1.79e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg00814883	chr7:100076585	TSC22D4	-0.48	-10.72	-0.39	9.02e-25	Platelet count;
BRCA	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg21427119	chr20:30132790	HM13	-0.42	-8.89	-0.33	6.37e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg03146154	chr1:46216737	IPP	-0.49	-10.73	-0.39	8.52e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7639513	0.591	rs9849171	chr3:12622623	G/C	cg23032965	chr3:12705835	RAF1	0.65	14.07	0.49	2.35e-39	Itch intensity from mosquito bite;
BRCA	cis	rs400736	0.860	rs371452	chr1:8084051	C/T	cg25007680	chr1:8021821	PARK7	0.47	11.7	0.42	8.38e-29	Response to antidepressants and depression;
BRCA	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg13334819	chr7:99746414	C7orf59	-0.35	-7.93	-0.3	9.57e-15	Coronary artery disease;
BRCA	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg26597838	chr10:835615	NA	1.03	17.3	0.56	2.73e-55	Eosinophil percentage of granulocytes;
BRCA	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs847577	0.715	rs12665986	chr7:97719676	A/G	cg24562669	chr7:97807699	LMTK2	-0.51	-14.12	-0.49	1.35e-39	Breast cancer;
BRCA	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg23711669	chr6:146136114	FBXO30	0.72	17.39	0.57	9.73e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1997103	1.000	rs6973450	chr7:55396537	A/G	cg17469321	chr7:55412551	NA	0.51	9.71	0.36	6.72e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs9393777	0.920	rs13207689	chr6:27369704	C/G	cg01620082	chr3:125678407	NA	-0.85	-10.31	-0.38	3.56e-23	Intelligence (multi-trait analysis);
BRCA	trans	rs3960554	0.610	rs11971800	chr7:75731608	C/T	cg19862616	chr7:65841803	NCRNA00174	0.57	12.15	0.43	1.03e-30	Eotaxin levels;
BRCA	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg20891558	chr2:74357851	NA	0.51	12.41	0.44	7.62e-32	Gestational age at birth (maternal effect);
BRCA	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg05623727	chr3:50126028	RBM5	-0.42	-9.97	-0.37	7.66e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs28735056	0.903	rs56185453	chr18:77638297	A/G	cg20368463	chr18:77673604	PQLC1	-0.42	-10.73	-0.39	7.91e-25	Schizophrenia;
BRCA	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg05868516	chr6:26286170	HIST1H4H	0.51	11.27	0.41	5.38e-27	Educational attainment;
BRCA	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg05707623	chr12:122985044	ZCCHC8	0.5	9.68	0.36	9.36e-21	Body mass index;
BRCA	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg13798912	chr7:905769	UNC84A	-0.49	-7.82	-0.3	2.25e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg24130564	chr14:104152367	KLC1	-0.4	-9.03	-0.34	2.03e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-10.0	-0.37	5.53e-22	Neuroticism;
BRCA	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg00677455	chr12:58241039	CTDSP2	0.62	14.39	0.49	6.78e-41	Multiple sclerosis;
BRCA	cis	rs1865721	0.682	rs3745082	chr18:73142734	G/T	cg26385618	chr18:73139727	C18orf62	-0.36	-9.0	-0.34	2.47e-18	Intelligence;
BRCA	cis	rs4363385	0.747	rs1415961	chr1:152973464	G/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.25	-0.31	8.93e-16	Inflammatory skin disease;
BRCA	trans	rs75804782	0.521	rs56120037	chr2:239398464	G/A	cg01134436	chr17:81009848	B3GNTL1	0.68	8.66	0.32	3.77e-17	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg08798685	chr6:27730294	NA	-0.71	-8.81	-0.33	1.17e-17	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
BRCA	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg20684491	chr1:25596433	NA	0.31	8.16	0.31	1.74e-15	Erythrocyte sedimentation rate;
BRCA	cis	rs7617773	0.780	rs9846818	chr3:48375685	C/T	cg11946769	chr3:48343235	NME6	0.51	11.21	0.41	9.1e-27	Coronary artery disease;
BRCA	cis	rs6450176	1.000	rs4334835	chr5:53300612	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-15.14	-0.51	1.8e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs4474465	0.850	rs10793326	chr11:78255422	A/C	cg27205649	chr11:78285834	NARS2	0.34	9.73	0.36	5.75e-21	Alzheimer's disease (survival time);
BRCA	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg26384229	chr12:38710491	ALG10B	0.59	13.52	0.47	7.99e-37	Morning vs. evening chronotype;
BRCA	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg01884057	chr2:25150051	NA	0.34	9.04	0.34	1.88e-18	Body mass index;
BRCA	cis	rs6594499	0.903	rs1438672	chr5:110467753	G/A	cg04022379	chr5:110408740	TSLP	0.35	8.04	0.3	4.41e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.81	13.42	0.47	2.44e-36	Schizophrenia;
BRCA	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.65	-9.9	-0.36	1.3e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg19784903	chr17:45786737	TBKBP1	0.34	8.06	0.3	3.7e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg27211696	chr2:191398769	TMEM194B	0.49	11.33	0.41	3.17e-27	Pulse pressure;
BRCA	trans	rs6598955	0.671	rs3924325	chr1:26616320	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-14.64	-0.5	4.83e-42	Obesity-related traits;
BRCA	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-9.54	-0.35	2.85e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs2731664	0.792	rs335420	chr5:176898619	C/T	cg23176889	chr5:176863531	GRK6	0.59	15.54	0.52	1.92e-46	Intelligence (multi-trait analysis);
BRCA	cis	rs61990749	0.597	rs4903643	chr14:78254791	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.66	9.86	0.36	1.92e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg20891283	chr12:69753455	YEATS4	0.84	28.33	0.75	5.67e-115	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.35	-0.35	1.39e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs1904096	0.506	rs28701470	chr4:95167088	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-9.85	-0.36	2.06e-21	Type 2 diabetes;
BRCA	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg08888203	chr3:10149979	C3orf24	0.6	12.56	0.45	1.68e-32	Alzheimer's disease;
BRCA	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.31	-0.35	1.98e-19	Total body bone mineral density;
BRCA	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg17971929	chr21:40555470	PSMG1	-0.64	-14.1	-0.49	1.72e-39	Cognitive function;
BRCA	cis	rs754466	0.580	rs10824577	chr10:79577408	G/C	cg17075019	chr10:79541650	NA	-0.86	-23.55	-0.68	8.94e-89	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg12310025	chr6:25882481	NA	-0.54	-12.83	-0.45	1.04e-33	Blood metabolite levels;
BRCA	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.63	10.07	0.37	2.95e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg11822812	chr5:140052017	DND1	-0.31	-8.44	-0.32	2.18e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs12530845	0.943	rs58577912	chr7:135329269	T/G	cg23117316	chr7:135346802	PL-5283	-0.37	-8.79	-0.33	1.36e-17	Red blood cell traits;
BRCA	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg07414643	chr4:187882934	NA	-0.27	-9.52	-0.35	3.52e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs724568	0.527	rs1430768	chr2:67929165	A/G	cg17945962	chr2:67939740	NA	-0.37	-9.85	-0.36	2.06e-21	Major depressive disorder (broad);
BRCA	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.16	-17.72	-0.57	1.9e-57	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-8.1	-0.31	2.84e-15	Blood pressure (smoking interaction);
BRCA	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.33	9.2	0.34	5.16e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs8017423	0.522	rs12887028	chr14:90819605	A/G	cg04374321	chr14:90722782	PSMC1	-0.5	-11.92	-0.43	9.86e-30	Mortality in heart failure;
BRCA	cis	rs7020830	0.867	rs563132	chr9:37245476	A/T	cg14294708	chr9:37120828	ZCCHC7	1.06	32.0	0.78	7.28e-135	Schizophrenia;
BRCA	cis	rs7072216	0.763	rs2147901	chr10:100165496	A/C	cg26618903	chr10:100175079	PYROXD2	0.28	8.17	0.31	1.61e-15	Metabolite levels;
BRCA	cis	rs2040771	0.804	rs2073754	chr22:19221406	G/T	cg02655711	chr22:19163373	SLC25A1	-0.39	-9.09	-0.34	1.25e-18	Metabolite levels (small molecules and protein measures);
BRCA	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.54	-17.61	-0.57	7.07e-57	Alzheimer's disease (late onset);
BRCA	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg01256987	chr12:42539512	GXYLT1	-0.46	-9.1	-0.34	1.17e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg23711669	chr6:146136114	FBXO30	0.72	16.53	0.55	2.2e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg17366294	chr4:99064904	C4orf37	0.42	9.76	0.36	4.4e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg17691542	chr6:26056736	HIST1H1C	0.51	10.47	0.38	9.1e-24	Height;
BRCA	cis	rs7789940	0.951	rs7787526	chr7:75947553	C/T	cg10167463	chr7:75959203	YWHAG	-0.45	-8.82	-0.33	1.06e-17	Multiple sclerosis;
BRCA	cis	rs10267417	0.603	rs12666448	chr7:19859119	G/A	cg07541023	chr7:19748670	TWISTNB	0.48	8.85	0.33	8.88e-18	Night sleep phenotypes;
BRCA	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg02503808	chr4:7069936	GRPEL1	0.82	18.21	0.58	5.58e-60	Monocyte percentage of white cells;
BRCA	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg26587870	chr6:27730563	NA	-0.39	-8.29	-0.31	6.75e-16	Parkinson's disease;
BRCA	cis	rs78707713	0.836	rs112843485	chr10:71211707	T/C	cg12610070	chr10:71211762	TSPAN15	-0.32	-8.18	-0.31	1.54e-15	Venous thromboembolism;
BRCA	cis	rs4949454	0.542	rs10914457	chr1:32094261	A/C	cg13919466	chr1:32135498	COL16A1	0.25	8.11	0.31	2.65e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg05793240	chr7:2802953	GNA12	-0.33	-8.12	-0.31	2.4e-15	Height;
BRCA	cis	rs4363385	0.818	rs559236	chr1:153010510	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg05313129	chr8:58192883	C8orf71	-0.46	-9.44	-0.35	7e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12667521	chr19:29218732	NA	0.47	8.68	0.32	3.4e-17	Methadone dose in opioid dependence;
BRCA	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.77e-24	Motion sickness;
BRCA	cis	rs6484504	0.600	rs942272	chr11:31364368	C/T	cg14844989	chr11:31128820	NA	0.46	9.59	0.35	1.88e-20	Red blood cell count;
BRCA	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.57	-9.85	-0.36	2.04e-21	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg05340658	chr4:99064831	C4orf37	0.64	15.62	0.53	8.31e-47	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg11952622	chr19:58962976	ZNF324B	0.43	8.86	0.33	7.99e-18	Uric acid clearance;
BRCA	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg16482183	chr6:26056742	HIST1H1C	0.72	14.46	0.5	3.3e-41	Iron status biomarkers;
BRCA	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg17971929	chr21:40555470	PSMG1	-0.72	-16.24	-0.54	6.36e-50	Cognitive function;
BRCA	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.51	-14.88	-0.51	3.07e-43	Lung cancer;
BRCA	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg21535247	chr6:8435926	SLC35B3	0.38	8.61	0.32	5.74e-17	Motion sickness;
BRCA	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.46	10.27	0.38	5.04e-23	IgG glycosylation;
BRCA	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg04414720	chr1:150670196	GOLPH3L	0.35	8.06	0.3	3.7e-15	Tonsillectomy;
BRCA	cis	rs7209700	0.889	rs11079769	chr17:45349731	A/T	cg08085267	chr17:45401833	C17orf57	0.43	7.96	0.3	7.89e-15	IgG glycosylation;
BRCA	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg09021430	chr5:549028	NA	-0.68	-14.24	-0.49	3.68e-40	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9296092	0.538	rs34222093	chr6:33519584	G/C	cg13560919	chr6:33536144	NA	-0.85	-18.66	-0.59	2.26e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24531977	chr5:56204891	C5orf35	0.73	16.06	0.54	5.03e-49	Initial pursuit acceleration;
BRCA	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg01448562	chr3:133502909	NA	0.62	14.97	0.51	1.23e-43	Iron status biomarkers;
BRCA	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg15017067	chr4:17643749	FAM184B	0.26	7.81	0.3	2.31e-14	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10819733	chr22:24237672	NA	-0.3	-8.16	-0.31	1.85e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg21775007	chr8:11205619	TDH	0.61	11.79	0.42	3.48e-29	Retinal vascular caliber;
BRCA	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-10.07	-0.37	3.04e-22	Crohn's disease;
BRCA	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg25358565	chr5:93447407	FAM172A	-0.65	-11.23	-0.41	7.98e-27	Diabetic retinopathy;
BRCA	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.53	-8.42	-0.32	2.48e-16	Schizophrenia;
BRCA	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg15704280	chr7:45808275	SEPT13	0.75	16.09	0.54	3.61e-49	Coronary artery disease;
BRCA	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-8.79	-0.33	1.32e-17	Mean corpuscular volume;
BRCA	cis	rs654950	0.774	rs941972	chr1:42040740	T/C	cg06885757	chr1:42089581	HIVEP3	-0.3	-10.21	-0.37	8.63e-23	Airway imaging phenotypes;
BRCA	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.77	-0.55	1.45e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.36	8.17	0.31	1.6e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.6	13.7	0.48	1.22e-37	Eosinophil percentage of white cells;
BRCA	cis	rs4594175	0.926	rs4901084	chr14:51634131	G/A	cg23942311	chr14:51606299	NA	0.33	8.29	0.31	6.56e-16	Cancer;
BRCA	cis	rs36051895	0.625	rs12340344	chr9:5176281	C/A	cg02405213	chr9:5042618	JAK2	-0.47	-8.92	-0.33	5.05e-18	Pediatric autoimmune diseases;
BRCA	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg03188948	chr7:1209495	NA	0.45	8.74	0.33	1.99e-17	Longevity;Endometriosis;
BRCA	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg07636037	chr3:49044803	WDR6	-0.58	-8.14	-0.31	2.09e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs8030485	0.536	rs1915724	chr15:79441027	A/G	cg17916960	chr15:79447300	NA	0.39	9.45	0.35	6.44e-20	Left ventricle wall thickness;
BRCA	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.66	-15.05	-0.51	5.01e-44	Axial length;
BRCA	cis	rs7760949	0.963	rs9475771	chr6:13914869	A/G	cg27413430	chr6:13925136	RNF182	-0.37	-7.85	-0.3	1.7e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg16586182	chr3:47516702	SCAP	0.56	12.5	0.44	3.02e-32	Colorectal cancer;
BRCA	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg01475377	chr6:109611718	NA	-0.51	-12.85	-0.45	9.18e-34	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
BRCA	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg01292856	chr11:65242576	NA	-0.33	-7.82	-0.3	2.26e-14	Bone mineral density;
BRCA	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11644478	chr21:40555479	PSMG1	-0.47	-9.81	-0.36	2.98e-21	Menarche (age at onset);
BRCA	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg05863683	chr7:1912471	MAD1L1	-0.4	-8.57	-0.32	7.88e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs6088813	1.000	rs2425066	chr20:33927006	A/C	cg14752227	chr20:34000481	UQCC	0.4	8.49	0.32	1.43e-16	Height;
BRCA	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg08859206	chr1:53392774	SCP2	-0.51	-11.21	-0.41	9.67e-27	Monocyte count;
BRCA	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg16576597	chr16:28551801	NUPR1	0.29	8.25	0.31	9.34e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-13.01	-0.46	1.7e-34	Bipolar disorder and schizophrenia;
BRCA	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg00277334	chr10:82204260	NA	-0.42	-8.01	-0.3	5.35e-15	Post bronchodilator FEV1;
BRCA	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg08885076	chr2:99613938	TSGA10	0.41	9.63	0.36	1.4e-20	Chronic sinus infection;
BRCA	trans	rs58106596	0.950	rs11695646	chr2:232584807	C/T	cg01370599	chr3:116745421	NA	-0.32	-8.77	-0.33	1.57e-17	White blood cell count;Lymphocyte counts;
BRCA	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg11657440	chr19:46296263	DMWD	-0.55	-12.91	-0.45	4.63e-34	Coronary artery disease;
BRCA	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg21535247	chr6:8435926	SLC35B3	0.4	8.91	0.33	5.22e-18	Motion sickness;
BRCA	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg11645453	chr3:52864694	ITIH4	-0.37	-9.76	-0.36	4.41e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg07460842	chr6:66804631	NA	1.13	35.62	0.82	6.44e-154	Exhaled nitric oxide output;
BRCA	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg06046430	chr4:77819534	ANKRD56	0.58	12.7	0.45	3.94e-33	Emphysema distribution in smoking;
BRCA	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg03808351	chr9:123631620	PHF19	0.39	7.81	0.3	2.39e-14	Rheumatoid arthritis;
BRCA	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.45	8.6	0.32	6.13e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg02997394	chr19:33096574	ANKRD27	0.66	10.14	0.37	1.67e-22	Eosinophilic esophagitis;
BRCA	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg22713356	chr15:30763199	NA	1.25	20.77	0.63	1.25e-73	Uric acid levels;
BRCA	cis	rs7586879	0.861	rs10164466	chr2:25114069	T/C	cg04586622	chr2:25135609	ADCY3	0.4	9.63	0.36	1.35e-20	Body mass index;
BRCA	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg14458575	chr2:238380390	NA	0.5	11.51	0.41	5.23e-28	Prostate cancer;
BRCA	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.96	0.3	7.63e-15	Depression;
BRCA	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg18402987	chr7:1209562	NA	0.87	12.28	0.44	2.89e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg03709012	chr19:19516395	GATAD2A	-0.75	-16.92	-0.56	2.43e-53	Tonsillectomy;
BRCA	trans	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg25214090	chr10:38739885	LOC399744	0.51	11.51	0.41	5.53e-28	Corneal astigmatism;
BRCA	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg14993813	chr1:46806288	NSUN4	-0.49	-9.61	-0.36	1.69e-20	Menopause (age at onset);
BRCA	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg23285459	chr7:2802560	GNA12	-0.33	-8.51	-0.32	1.29e-16	Height;
BRCA	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg03264133	chr6:25882463	NA	0.41	8.71	0.33	2.61e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg23029597	chr12:123009494	RSRC2	-0.59	-11.43	-0.41	1.19e-27	Body mass index;
BRCA	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg03709012	chr19:19516395	GATAD2A	-0.81	-18.76	-0.6	6.65e-63	Tonsillectomy;
BRCA	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg27211696	chr2:191398769	TMEM194B	-0.47	-7.88	-0.3	1.39e-14	Diastolic blood pressure;
BRCA	trans	rs11227306	0.934	rs10896056	chr11:65587905	A/G	cg17712092	chr4:129076599	LARP1B	0.42	8.73	0.33	2.3e-17	DNA methylation (variation);
BRCA	cis	rs3771570	0.901	rs62190410	chr2:242410621	C/T	cg21155796	chr2:242212141	HDLBP	0.62	9.56	0.35	2.44e-20	Prostate cancer;
BRCA	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg27490568	chr2:178487706	NA	-0.54	-9.23	-0.34	4.06e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg11941060	chr3:133502564	NA	-0.57	-13.72	-0.48	9.4e-38	Iron status biomarkers;
BRCA	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg26597838	chr10:835615	NA	1.03	18.26	0.59	3.04e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg11764359	chr7:65958608	NA	-0.62	-13.42	-0.47	2.4e-36	Aortic root size;
BRCA	cis	rs17253792	0.822	rs10147688	chr14:56054642	T/C	cg01858014	chr14:56050164	KTN1	-0.73	-10.81	-0.39	3.79e-25	Putamen volume;
BRCA	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg26384229	chr12:38710491	ALG10B	0.68	14.12	0.49	1.27e-39	Morning vs. evening chronotype;
BRCA	cis	rs7737355	0.947	rs244736	chr5:130816178	T/C	cg06307176	chr5:131281290	NA	0.54	11.21	0.41	9.6800000000000007e-27	Life satisfaction;
BRCA	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-9.16	-0.34	6.85e-19	Morning vs. evening chronotype;
BRCA	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg05283184	chr6:79620031	NA	-0.43	-11.22	-0.41	8.77e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.7	0.33	2.74e-17	Motion sickness;
BRCA	cis	rs7903847	0.642	rs10882909	chr10:99137998	G/C	cg20016023	chr10:99160130	RRP12	-0.27	-8.66	-0.32	3.9e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	13.16	0.46	3.7e-35	Lymphocyte counts;
BRCA	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14442939	chr10:27389572	ANKRD26	0.66	10.92	0.4	1.5e-25	Breast cancer;
BRCA	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.39	9.02	0.34	2.2e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2249625	0.904	rs2496514	chr6:72904071	A/G	cg18830697	chr6:72922368	RIMS1	-0.38	-8.13	-0.31	2.28e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg12863693	chr15:85201151	NMB	-0.34	-8.01	-0.3	5.38e-15	P wave terminal force;
BRCA	cis	rs2742234	0.578	rs2435354	chr10:43652445	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.56	-11.28	-0.41	4.68e-27	Hirschsprung disease;
BRCA	cis	rs4363385	0.617	rs5010885	chr1:152973141	C/T	cg24667326	chr1:152973720	SPRR3	-0.35	-9.79	-0.36	3.44e-21	Inflammatory skin disease;
BRCA	cis	rs1506636	1.000	rs641491	chr7:123399726	C/A	cg03229431	chr7:123269106	ASB15	0.61	13.78	0.48	4.97e-38	Plateletcrit;Platelet count;
BRCA	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.33	-0.44	1.76e-31	Breast cancer;
BRCA	cis	rs6740322	0.793	rs13414908	chr2:43546658	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-12.09	-0.43	1.88e-30	Coronary artery disease;
BRCA	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg04727924	chr7:799746	HEATR2	-0.57	-11.25	-0.41	6.38e-27	Cerebrospinal P-tau181p levels;
BRCA	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg27129171	chr3:47204927	SETD2	-0.71	-17.11	-0.56	2.72e-54	Colorectal cancer;
BRCA	cis	rs2933343	0.553	rs789212	chr3:128686912	A/C	cg11901034	chr3:128598214	ACAD9	-0.34	-8.13	-0.31	2.26e-15	IgG glycosylation;
BRCA	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg13319975	chr6:146136371	FBXO30	0.41	9.25	0.34	3.38e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.87	-0.3	1.54e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg18755752	chr8:142205143	DENND3	0.37	8.18	0.31	1.49e-15	Immature fraction of reticulocytes;
BRCA	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg05313129	chr8:58192883	C8orf71	-0.46	-9.63	-0.36	1.33e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg18512352	chr11:47633146	NA	-0.33	-8.15	-0.31	1.99e-15	Subjective well-being;
BRCA	cis	rs61990749	0.544	rs2544567	chr14:78181739	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.64	10.06	0.37	3.36e-22	Fibroblast growth factor basic levels;
BRCA	cis	rs6546550	0.901	rs7598283	chr2:70128717	A/G	cg02498382	chr2:70120550	SNRNP27	-0.52	-11.47	-0.41	7.91e-28	Prevalent atrial fibrillation;
BRCA	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.21	0.68	7.15e-87	Chronic sinus infection;
BRCA	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg07148914	chr20:33460835	GGT7	-0.45	-9.74	-0.36	5.56e-21	Height;
BRCA	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg11752832	chr7:134001865	SLC35B4	0.49	12.1	0.43	1.76e-30	Mean platelet volume;
BRCA	cis	rs4742903	0.935	rs10120101	chr9:107000909	C/T	cg14250997	chr9:106856677	SMC2	0.28	8.98	0.33	2.99e-18	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.15	0.4	1.64e-26	Bipolar disorder;
BRCA	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	17.27	0.56	3.87e-55	Hip circumference adjusted for BMI;
BRCA	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg21427119	chr20:30132790	HM13	-0.42	-8.92	-0.33	4.92e-18	Mean corpuscular hemoglobin;
BRCA	trans	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-9.95	-0.37	8.46e-22	Brugada syndrome;
BRCA	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg13736514	chr6:26305472	NA	0.39	11.88	0.43	1.52e-29	Mosquito bite size;
BRCA	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg25427524	chr10:38739819	LOC399744	-0.44	-9.27	-0.34	2.91e-19	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12826209	chr6:26865740	GUSBL1	-0.58	-10.23	-0.38	7.51e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg03354898	chr7:1950403	MAD1L1	0.47	10.5	0.38	6.59e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs7598759	0.712	rs6727510	chr2:232332016	T/C	cg19187155	chr2:232395269	NMUR1	0.37	7.83	0.3	2.1e-14	Noise-induced hearing loss;
BRCA	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg01483505	chr11:975446	AP2A2	0.33	9.09	0.34	1.25e-18	Alzheimer's disease (late onset);
BRCA	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-14.42	-0.5	4.89e-41	Coronary artery disease;
BRCA	cis	rs4074536	0.547	rs7527858	chr1:116288105	C/T	cg21648376	chr1:116311395	CASQ2	-0.49	-8.68	-0.32	3.25e-17	QRS duration;
BRCA	cis	rs9287719	0.649	rs12617968	chr2:10721945	C/T	cg00105475	chr2:10696890	NA	0.41	9.17	0.34	6.17e-19	Prostate cancer;
BRCA	cis	rs1003719	0.679	rs2835638	chr21:38534533	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-14.54	-0.5	1.43e-41	Eye color traits;
BRCA	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs4891159	0.790	rs11872411	chr18:74132051	C/T	cg24786174	chr18:74118243	ZNF516	-0.75	-18.66	-0.59	2.26e-62	Longevity;
BRCA	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg26384229	chr12:38710491	ALG10B	0.76	16.93	0.56	2.14e-53	Bladder cancer;
BRCA	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-10.74	-0.39	7.58e-25	Lymphocyte counts;
BRCA	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.7	11.62	0.42	1.98e-28	Lung function (FEV1/FVC);
BRCA	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg23711669	chr6:146136114	FBXO30	0.63	14.47	0.5	2.87e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg23933602	chr10:16859644	RSU1	0.88	24.01	0.69	2.75e-91	Platelet distribution width;
BRCA	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg27170947	chr2:26402098	FAM59B	-0.92	-16.84	-0.55	6.2e-53	Gut microbiome composition (summer);
BRCA	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.5	-0.32	1.38e-16	Monocyte percentage of white cells;
BRCA	cis	rs11955398	0.521	rs4298206	chr5:60012235	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.41	-9.61	-0.36	1.6e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.59	-12.93	-0.46	3.77e-34	Lymphocyte percentage of white cells;
BRCA	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02176678	chr2:219576539	TTLL4	-0.51	-13.07	-0.46	9.29e-35	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg18758796	chr5:131593413	PDLIM4	0.31	8.12	0.31	2.35e-15	Blood metabolite levels;
BRCA	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg03474202	chr17:45855739	NA	-0.46	-12.23	-0.44	4.53e-31	IgG glycosylation;
BRCA	cis	rs10044254	0.563	rs4702102	chr5:15698919	A/T	cg07238450	chr5:15720153	FBXL7	-0.38	-8.08	-0.3	3.15e-15	Asthma (corticosteroid response);
BRCA	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg05985134	chr18:33552581	C18orf21	0.64	12.31	0.44	2.12e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs2806561	0.808	rs4654834	chr1:23364919	T/C	cg19743168	chr1:23544995	NA	-0.42	-9.96	-0.37	7.88e-22	Height;
BRCA	trans	rs1493916	0.837	rs11876492	chr18:31413804	T/C	cg27147174	chr7:100797783	AP1S1	-0.43	-8.73	-0.33	2.16e-17	Life satisfaction;
BRCA	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-16.08	-0.54	4.29e-49	Parkinson's disease;
BRCA	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg20790798	chr5:1857306	NA	-0.35	-7.94	-0.3	8.86e-15	Cardiovascular disease risk factors;
BRCA	cis	rs6088813	0.925	rs1540928	chr20:33961845	C/A	cg14752227	chr20:34000481	UQCC	-0.41	-8.72	-0.33	2.36e-17	Height;
BRCA	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	trans	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg25214090	chr10:38739885	LOC399744	0.55	12.05	0.43	2.91e-30	Corneal astigmatism;
BRCA	cis	rs12618769	0.597	rs3769712	chr2:99153443	A/T	cg10123293	chr2:99228465	UNC50	0.44	8.5	0.32	1.3e-16	Bipolar disorder;
BRCA	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg09307838	chr4:120376055	NA	0.75	16.23	0.54	7.77e-50	Corneal astigmatism;
BRCA	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-8.3	-0.31	6.02e-16	Total body bone mineral density;
BRCA	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg13010199	chr12:38710504	ALG10B	0.51	9.99	0.37	6.08e-22	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26314531	chr2:26401878	FAM59B	-0.65	-11.17	-0.4	1.42e-26	Gut microbiome composition (summer);
BRCA	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg08999081	chr20:33150536	PIGU	-0.44	-12.38	-0.44	1.01e-31	Glomerular filtration rate (creatinine);
BRCA	trans	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg17145862	chr1:211918768	LPGAT1	-0.73	-19.26	-0.61	1.49e-65	Leprosy;
BRCA	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.3	0.31	6.24e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg12011299	chr4:100065546	ADH4	-0.5	-11.55	-0.42	3.59e-28	Alcohol dependence;
BRCA	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg25703541	chr22:24373054	LOC391322	0.67	15.21	0.52	7.96e-45	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg23711669	chr6:146136114	FBXO30	0.74	17.76	0.57	1.2e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2882667	0.861	rs10037106	chr5:138365490	G/T	cg04439458	chr5:138467593	SIL1	-0.32	-8.77	-0.33	1.62e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg17691542	chr6:26056736	HIST1H1C	0.56	11.84	0.42	2.28e-29	Height;
BRCA	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.05e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg12193833	chr17:30244370	NA	-0.57	-8.43	-0.32	2.29e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs6495367	1.000	rs13380104	chr15:79378821	C/T	cg17916960	chr15:79447300	NA	0.32	8.16	0.31	1.77e-15	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7131987	0.845	rs2042511	chr12:29408780	C/T	cg09582351	chr12:29534625	ERGIC2	-0.47	-11.56	-0.42	3.34e-28	QT interval;
BRCA	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.43	-10.88	-0.4	2.11e-25	Schizophrenia;
BRCA	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg09184832	chr6:79620586	NA	-0.5	-11.16	-0.4	1.48e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs939658	1.000	rs8031019	chr15:79458512	C/T	cg17916960	chr15:79447300	NA	-0.39	-9.92	-0.37	1.1e-21	Refractive error;
BRCA	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg14582100	chr15:45693742	SPATA5L1	0.36	11.59	0.42	2.61e-28	Homoarginine levels;
BRCA	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg00383909	chr3:49044727	WDR6	0.6	11.0	0.4	6.96e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-14.88	-0.51	3.14e-43	Exhaled nitric oxide output;
BRCA	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg05340658	chr4:99064831	C4orf37	0.62	14.5	0.5	2.19e-41	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9951602	0.573	rs8098953	chr18:76648734	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	18.26	0.59	2.77e-60	Obesity-related traits;
BRCA	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg08088566	chr11:430123	ANO9	0.55	7.85	0.3	1.74e-14	Body mass index;
BRCA	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg02544614	chr20:61657117	NA	0.28	7.81	0.3	2.32e-14	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07256732	chr16:621771	PIGQ	-0.34	-8.9	-0.33	5.58e-18	Height;
BRCA	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg06784218	chr1:46089804	CCDC17	0.46	10.88	0.4	2.1e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg00745463	chr17:30367425	LRRC37B	-0.62	-9.87	-0.36	1.73e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs10503871	1.000	rs10503871	chr8:30436852	A/G	cg26383811	chr8:30366931	RBPMS	-0.32	-8.63	-0.32	4.91e-17	Metabolite levels  (X-11787);
BRCA	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg00409905	chr10:38381863	ZNF37A	-0.57	-12.44	-0.44	5.9e-32	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1832871	0.541	rs10945546	chr6:158892209	A/G	cg07165851	chr6:158734300	TULP4	0.47	9.35	0.35	1.46e-19	Height;
BRCA	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg14844989	chr11:31128820	NA	-0.44	-9.34	-0.35	1.56e-19	Red blood cell count;
BRCA	cis	rs6901250	0.788	rs571296	chr6:117092558	A/G	cg12892004	chr6:117198278	RFX6	-0.45	-10.62	-0.39	2.22e-24	C-reactive protein levels;
BRCA	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg08000102	chr2:233561755	GIGYF2	0.62	13.74	0.48	8.31e-38	Coronary artery disease;
BRCA	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg24579218	chr15:68104479	NA	0.33	8.04	0.3	4.48e-15	Restless legs syndrome;
BRCA	cis	rs4363385	0.818	rs1048296	chr1:153012240	A/C	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10802521	chr3:52805072	NEK4	-0.31	-7.89	-0.3	1.35e-14	Bipolar disorder;
BRCA	cis	rs6878727	0.526	rs149445	chr5:123680698	G/A	cg01806427	chr5:123737813	NA	-0.39	-8.0	-0.3	5.77e-15	Breast cancer;
BRCA	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg14675211	chr2:100938903	LONRF2	0.51	11.77	0.42	4.61e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg05623727	chr3:50126028	RBM5	-0.39	-8.42	-0.32	2.5e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg08885076	chr2:99613938	TSGA10	-0.52	-11.83	-0.42	2.45e-29	Chronic sinus infection;
BRCA	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07636037	chr3:49044803	WDR6	0.71	15.32	0.52	2.25e-45	Menarche (age at onset);
BRCA	cis	rs13102973	0.899	rs11735890	chr4:135902143	A/G	cg14419869	chr4:135874104	NA	0.46	9.22	0.34	4.42e-19	Subjective well-being;
BRCA	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg16590910	chr6:42928470	GNMT	0.36	7.81	0.3	2.35e-14	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs1459104	0.759	rs7939392	chr11:55257285	C/T	cg03929089	chr4:120376271	NA	0.54	8.74	0.33	2.04e-17	Body mass index;
BRCA	trans	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg06521331	chr12:34319734	NA	0.46	8.93	0.33	4.55e-18	Morning vs. evening chronotype;
BRCA	cis	rs9341808	0.754	rs9341810	chr6:80974838	G/A	cg08355045	chr6:80787529	NA	0.37	9.56	0.35	2.58e-20	Sitting height ratio;
BRCA	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg11845111	chr2:191398756	TMEM194B	-0.36	-8.42	-0.32	2.49e-16	Pulse pressure;
BRCA	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg08999081	chr20:33150536	PIGU	-0.34	-8.8	-0.33	1.26e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.51	0.38	6.04e-24	Aortic root size;
BRCA	cis	rs690037	0.673	rs690573	chr3:16376440	G/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.41	-8.47	-0.32	1.71e-16	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
BRCA	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-12.01	-0.43	4.19e-30	Gut microbiome composition (summer);
BRCA	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg26838691	chr2:24397539	C2orf84	-0.49	-8.87	-0.33	7.07e-18	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg00383909	chr3:49044727	WDR6	0.96	13.4	0.47	2.89e-36	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg03146154	chr1:46216737	IPP	0.46	10.24	0.38	7.01e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg23711669	chr6:146136114	FBXO30	0.65	15.23	0.52	6.75e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-13.25	-0.46	1.38e-35	Morning vs. evening chronotype;
BRCA	cis	rs4566357	0.615	rs10198406	chr2:227913539	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.4	-0.35	9.56e-20	Coronary artery disease;
BRCA	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.35	0.35	1.49e-19	Tonsillectomy;
BRCA	cis	rs113835537	0.529	rs75683511	chr11:66275026	A/G	cg24851651	chr11:66362959	CCS	0.5	8.74	0.33	2.05e-17	Airway imaging phenotypes;
BRCA	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7707921	0.881	rs17243791	chr5:81322547	A/G	cg15871215	chr5:81402204	ATG10	-0.38	-7.97	-0.3	7.37e-15	Breast cancer;
BRCA	cis	rs7555523	0.778	rs2790052	chr1:165738463	G/C	cg24409356	chr1:165738333	TMCO1	0.51	8.26	0.31	8.67e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg01256987	chr12:42539512	GXYLT1	-0.46	-9.05	-0.34	1.7e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs9463078	0.553	rs227837	chr6:44683123	A/G	cg25276700	chr6:44698697	NA	-0.39	-8.53	-0.32	1.1e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.61	0.36	1.7e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12612619	0.732	rs11677841	chr2:27239949	G/T	cg00617064	chr2:27272375	NA	-0.32	-8.49	-0.32	1.44e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs7631605	0.905	rs1468712	chr3:37106013	C/T	cg15934958	chr3:37212084	LRRFIP2	-0.46	-10.68	-0.39	1.27e-24	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg06494592	chr3:125709126	NA	-0.54	-8.58	-0.32	7.14e-17	Blood pressure (smoking interaction);
BRCA	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg11833968	chr6:79620685	NA	-0.44	-9.97	-0.37	7.34e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	9.73	0.36	6.08e-21	Renal function-related traits (BUN);
BRCA	cis	rs7246967	0.673	rs2361021	chr19:22816324	T/G	cg23217946	chr19:22817039	ZNF492	0.47	8.45	0.32	2e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs7011049	0.915	rs11997706	chr8:53833202	T/G	cg26025543	chr8:53854495	NA	0.55	9.92	0.37	1.1e-21	Systolic blood pressure;
BRCA	cis	rs9611519	0.507	rs12484525	chr22:41443877	G/C	cg03806693	chr22:41940476	POLR3H	-0.46	-8.79	-0.33	1.39e-17	Neuroticism;
BRCA	cis	rs7572733	0.515	rs35730302	chr2:198818626	A/T	cg00792783	chr2:198669748	PLCL1	-0.46	-10.03	-0.37	4.24e-22	Dermatomyositis;
BRCA	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg24006582	chr15:45444508	DUOX1	-0.55	-11.28	-0.41	5e-27	Uric acid levels;
BRCA	cis	rs4845875	0.559	rs4846047	chr1:11843632	C/G	cg06193043	chr1:11908199	NPPA	0.35	7.95	0.3	8.18e-15	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs870825	0.616	rs7678864	chr4:185635158	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	17.57	0.57	1.07e-56	Blood protein levels;
BRCA	cis	rs698833	0.962	rs698830	chr2:44730863	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	9.7	0.36	7.9e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs477692	1.000	rs4750759	chr10:131436603	G/A	cg05714579	chr10:131428358	MGMT	-0.45	-10.6	-0.39	2.67e-24	Response to temozolomide;
BRCA	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-13.07	-0.46	9.55e-35	Response to antipsychotic treatment;
BRCA	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-8.72	-0.33	2.38e-17	IgG glycosylation;
BRCA	cis	rs1595825	0.627	rs1435567	chr2:198748726	T/C	cg19156104	chr2:198669113	PLCL1	-0.44	-8.15	-0.31	1.9e-15	Ulcerative colitis;
BRCA	cis	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg07460842	chr6:66804631	NA	0.72	12.07	0.43	2.27e-30	Exhaled nitric oxide output;
BRCA	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.22	-0.31	1.16e-15	Menopause (age at onset);
BRCA	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg21918786	chr6:109611834	NA	-0.49	-14.06	-0.49	2.49e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs4919694	0.611	rs7091462	chr10:104948615	C/T	cg04362960	chr10:104952993	NT5C2	0.73	12.77	0.45	2.07e-33	Arsenic metabolism;
BRCA	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.26e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg12219531	chr12:120966889	COQ5	0.55	11.61	0.42	2.02e-28	High light scatter reticulocyte count;
BRCA	cis	rs4642101	0.793	rs3889513	chr3:12844070	G/A	cg24848339	chr3:12840334	CAND2	0.41	10.53	0.38	4.9299999999999996e-24	QRS complex (12-leadsum);
BRCA	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg27432699	chr2:27873401	GPN1	-0.43	-9.1	-0.34	1.11e-18	Oral cavity cancer;
BRCA	cis	rs9790314	0.645	rs6778254	chr3:160892792	T/C	cg04691961	chr3:161091175	C3orf57	-0.35	-8.04	-0.3	4.4e-15	Morning vs. evening chronotype;
BRCA	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg03709012	chr19:19516395	GATAD2A	0.72	15.67	0.53	4.71e-47	Tonsillectomy;
BRCA	trans	rs1973993	0.561	rs56142427	chr1:96992318	A/G	cg10631902	chr5:14652156	NA	-0.41	-10.04	-0.37	4.08e-22	Weight;
BRCA	cis	rs7254114	0.578	rs6511727	chr19:11315817	G/T	cg06870470	chr19:11315767	DOCK6	-0.39	-9.06	-0.34	1.61e-18	Immature fraction of reticulocytes;
BRCA	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg09537434	chr19:41945824	ATP5SL	-1.0	-23.92	-0.69	8.58e-91	Height;
BRCA	trans	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg12856521	chr11:46389249	DGKZ	-0.36	-7.82	-0.3	2.18e-14	Leprosy;
BRCA	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9462846	1.000	rs2395941	chr6:42867821	G/A	cg02353165	chr6:42928485	GNMT	0.49	8.61	0.32	5.54e-17	Blood protein levels;
BRCA	cis	rs67981189	0.574	rs2526884	chr14:71367967	G/A	cg15816911	chr14:71606274	NA	-0.38	-8.58	-0.32	7.37e-17	Schizophrenia;
BRCA	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg16576597	chr16:28551801	NUPR1	0.3	8.37	0.31	3.53e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.66	-14.15	-0.49	9.46e-40	Monocyte percentage of white cells;
BRCA	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg25703541	chr22:24373054	LOC391322	-0.93	-24.87	-0.7	5.22e-96	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg19678392	chr7:94953810	PON1	-0.41	-8.84	-0.33	9.41e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg01802117	chr1:53393560	SCP2	-0.35	-7.97	-0.3	7.16e-15	Monocyte count;
BRCA	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	30.68	0.77	9.96e-128	Chronic sinus infection;
BRCA	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg26384229	chr12:38710491	ALG10B	0.42	9.43	0.35	7.36e-20	Morning vs. evening chronotype;
BRCA	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg12292205	chr6:26970375	C6orf41	0.8	19.5	0.61	8.44e-67	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg18252515	chr7:66147081	NA	-0.54	-10.94	-0.4	1.15e-25	Corneal structure;
BRCA	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.45	-0.35	6.47e-20	Alzheimer's disease;
BRCA	cis	rs12791968	0.765	rs12794751	chr11:44998769	C/G	cg11846598	chr11:44996168	LOC221122	-0.47	-8.54	-0.32	1.02e-16	Inhibitory control;
BRCA	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg17143192	chr8:8559678	CLDN23	0.53	10.01	0.37	5.05e-22	Obesity-related traits;
BRCA	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.56	-0.32	8.43e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs698813	0.851	rs786420	chr2:44719893	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	8.33	0.31	5.07e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.55	17.83	0.58	4.99e-58	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs56399783	0.614	rs116929101	chr7:2760325	G/A	cg23627948	chr7:2760692	NA	0.53	8.61	0.32	5.63e-17	Childhood ear infection;
BRCA	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg05896524	chr21:47604654	C21orf56	0.44	8.79	0.33	1.33e-17	Testicular germ cell tumor;
BRCA	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg01579765	chr21:45077557	HSF2BP	-0.45	-12.14	-0.43	1.11e-30	Mean corpuscular volume;
BRCA	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg24130564	chr14:104152367	KLC1	-0.37	-8.85	-0.33	8.63e-18	Body mass index;
BRCA	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg11752832	chr7:134001865	SLC35B4	0.52	13.41	0.47	2.76e-36	Mean platelet volume;
BRCA	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg02951883	chr7:2050386	MAD1L1	-0.49	-11.43	-0.41	1.19e-27	Schizophrenia;
BRCA	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg05754148	chr16:3507555	NAT15	0.37	7.84	0.3	1.86e-14	Tuberculosis;
BRCA	cis	rs311392	1.000	rs2666871	chr8:55089184	C/T	cg11783602	chr8:55087084	NA	-0.33	-9.95	-0.37	8.62e-22	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs6987853	0.787	rs2923427	chr8:42385748	A/C	cg09913449	chr8:42400586	C8orf40	0.41	9.18	0.34	6.01e-19	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.57	0.35	2.32e-20	Morning vs. evening chronotype;
BRCA	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg17135325	chr3:160939158	NMD3	0.42	8.07	0.3	3.54e-15	Parkinson's disease;
BRCA	trans	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg19862616	chr7:65841803	NCRNA00174	0.84	27.04	0.73	6.53e-108	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg10518572	chr11:65560635	OVOL1	-0.28	-8.07	-0.3	3.56e-15	Acne (severe);
BRCA	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg18446336	chr7:2847575	GNA12	-0.41	-10.18	-0.37	1.12e-22	Height;
BRCA	cis	rs7586879	1.000	rs7603153	chr2:25116966	T/C	cg01884057	chr2:25150051	NA	0.33	8.25	0.31	8.82e-16	Body mass index;
BRCA	cis	rs10193935	0.901	rs7570083	chr2:42517859	G/A	cg27598129	chr2:42591480	NA	-0.64	-10.7	-0.39	1.12e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg08888203	chr3:10149979	C3orf24	0.67	14.07	0.49	2.42e-39	Alzheimer's disease;
BRCA	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg14186256	chr22:23484241	RTDR1	0.73	21.23	0.64	4.04e-76	Bone mineral density;
BRCA	trans	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg23762105	chr12:34175262	ALG10	-0.38	-9.68	-0.36	8.87e-21	Morning vs. evening chronotype;
BRCA	cis	rs11030122	0.702	rs17081	chr11:3987830	A/G	cg18678763	chr11:4115507	RRM1	0.36	8.24	0.31	9.84e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs877529	0.967	rs139386	chr22:39530859	T/C	cg12193277	chr22:39547181	CBX7	0.48	13.13	0.46	5.12e-35	Multiple myeloma;
BRCA	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg20607798	chr8:58055168	NA	0.59	9.44	0.35	6.62e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs36051895	0.589	rs62543574	chr9:5204090	A/T	cg02405213	chr9:5042618	JAK2	-0.44	-8.26	-0.31	8.59e-16	Pediatric autoimmune diseases;
BRCA	cis	rs4728302	0.534	rs6976069	chr7:133152898	T/C	cg10665199	chr7:133106180	EXOC4	0.43	9.34	0.35	1.54e-19	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg05234568	chr11:5960015	NA	0.42	9.11	0.34	1.03e-18	DNA methylation (variation);
BRCA	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.5	10.52	0.38	5.41e-24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs7551345	0.653	rs6425717	chr1:31694103	A/G	cg19084893	chr1:31688959	NA	0.48	10.08	0.37	2.78e-22	Schizophrenia;
BRCA	cis	rs524281	0.861	rs10896085	chr11:65913832	A/T	cg16950941	chr11:66035639	RAB1B	-0.37	-7.95	-0.3	8.41e-15	Electroencephalogram traits;
BRCA	cis	rs6684514	0.961	rs11264469	chr1:156276746	A/G	cg16558208	chr1:156270281	VHLL	0.34	8.03	0.3	4.54e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg16325326	chr1:53192061	ZYG11B	0.69	16.99	0.56	1.11e-53	Monocyte count;
BRCA	cis	rs6815814	0.950	rs67206233	chr4:38807853	T/C	cg06935464	chr4:38784597	TLR10	0.5	8.27	0.31	7.76e-16	Breast cancer;
BRCA	cis	rs10751667	0.600	rs7395387	chr11:1008664	G/C	cg06064525	chr11:970664	AP2A2	-0.27	-7.98	-0.3	6.88e-15	Alzheimer's disease (late onset);
BRCA	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.41	11.7	0.42	8.82e-29	Monocyte percentage of white cells;
BRCA	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.88	-19.94	-0.62	3.73e-69	Primary sclerosing cholangitis;
BRCA	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg22907277	chr7:1156413	C7orf50	0.47	10.37	0.38	2.23e-23	Longevity;Endometriosis;
BRCA	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg08645402	chr16:4508243	NA	0.37	8.3	0.31	6.04e-16	Schizophrenia;
BRCA	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg13628971	chr7:2884303	GNA12	0.46	9.26	0.34	3.1e-19	Height;
BRCA	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.53	11.66	0.42	1.28e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg26384229	chr12:38710491	ALG10B	0.75	17.0	0.56	9.05e-54	Bladder cancer;
BRCA	cis	rs11031096	0.502	rs4910875	chr11:4047855	C/G	cg18678763	chr11:4115507	RRM1	-0.35	-7.88	-0.3	1.46e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg07741184	chr6:167504864	NA	0.27	8.0	0.3	5.67e-15	Crohn's disease;
BRCA	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg13010199	chr12:38710504	ALG10B	-0.41	-8.12	-0.31	2.45e-15	Morning vs. evening chronotype;
BRCA	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.17	0.46	3.08e-35	Electroencephalogram traits;
BRCA	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg10327440	chr1:227177885	CDC42BPA	1.07	36.95	0.83	9.33e-161	Myeloid white cell count;
BRCA	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg04362960	chr10:104952993	NT5C2	0.43	9.78	0.36	3.98e-21	Arsenic metabolism;
BRCA	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg10556349	chr10:835070	NA	0.73	9.88	0.36	1.6e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg25801113	chr15:45476975	SHF	0.31	8.05	0.3	4.16e-15	Uric acid levels;
BRCA	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg27029518	chr18:72166324	CNDP2	-0.3	-8.3	-0.31	6.17e-16	Refractive error;
BRCA	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-9.11	-0.34	1.02e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg05347473	chr6:146136440	FBXO30	0.42	8.39	0.32	3.1e-16	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6479891	0.841	rs7092504	chr10:65089439	A/G	cg14819942	chr15:35414228	NA	-0.34	-8.37	-0.31	3.53e-16	Arthritis (juvenile idiopathic);
BRCA	trans	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg25214090	chr10:38739885	LOC399744	0.51	10.48	0.38	7.88e-24	Corneal astigmatism;
BRCA	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.31	-8.0	-0.3	5.99e-15	Total body bone mineral density;
BRCA	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg13770153	chr20:60521292	NA	-0.47	-11.17	-0.4	1.4e-26	Body mass index;
BRCA	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg08999081	chr20:33150536	PIGU	0.49	14.03	0.49	3.73e-39	Glomerular filtration rate (creatinine);
BRCA	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg11814155	chr7:99998594	ZCWPW1	0.48	8.7	0.33	2.76e-17	Platelet count;
BRCA	cis	rs6750047	0.516	rs458704	chr2:38318134	G/A	cg07380506	chr2:38303506	CYP1B1	0.4	9.11	0.34	1.02e-18	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg08213375	chr14:104286397	PPP1R13B	0.51	11.23	0.41	7.99e-27	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs3770081	1.000	rs78032828	chr2:86309032	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.58	-8.31	-0.31	5.78e-16	Facial emotion recognition (sad faces);
BRCA	cis	rs16858210	0.520	rs10460892	chr3:183546124	C/T	cg03417191	chr3:183542750	MAP6D1	-0.68	-10.34	-0.38	2.84e-23	Menopause (age at onset);
BRCA	cis	rs1355223	0.506	rs11032899	chr11:34870234	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-9.42	-0.35	8.42e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg04025307	chr7:1156635	C7orf50	0.59	9.36	0.35	1.33e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg08470875	chr2:26401718	FAM59B	0.77	11.95	0.43	7.7e-30	Gut microbiome composition (summer);
BRCA	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25427524	chr10:38739819	LOC399744	0.66	16.09	0.54	3.7e-49	Extrinsic epigenetic age acceleration;
BRCA	trans	rs3857536	0.813	rs2188589	chr6:66939570	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.45	-0.32	1.98e-16	Total body bone mineral density;
BRCA	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg14675211	chr2:100938903	LONRF2	0.52	11.49	0.41	6.31e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg11663144	chr21:46675770	NA	-0.55	-12.94	-0.46	3.54e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg13736514	chr6:26305472	NA	-0.35	-11.99	-0.43	4.93e-30	Educational attainment;
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.66	-16.39	-0.54	1.18e-50	Longevity;Endometriosis;
BRCA	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg04455712	chr21:45112962	RRP1B	0.41	10.52	0.38	5.4e-24	Mean corpuscular volume;
BRCA	cis	rs6088813	1.000	rs6087703	chr20:33996433	T/C	cg14752227	chr20:34000481	UQCC	-0.43	-9.14	-0.34	7.97e-19	Height;
BRCA	cis	rs6066835	1.000	rs4568007	chr20:47316575	C/G	cg18078177	chr20:47281410	PREX1	0.69	8.04	0.3	4.27e-15	Multiple myeloma;
BRCA	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg12661370	chr5:149340060	SLC26A2	0.54	7.9	0.3	1.2e-14	HIV-1 control;
BRCA	cis	rs6545883	0.524	rs7561697	chr2:61519165	G/C	cg15711740	chr2:61764176	XPO1	0.31	7.81	0.3	2.31e-14	Tuberculosis;
BRCA	cis	rs3820928	1.000	rs9288617	chr2:227762815	G/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.38	-0.31	3.46e-16	Pulmonary function;
BRCA	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg10523679	chr1:76189770	ACADM	0.77	18.74	0.6	8.51e-63	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg02951883	chr7:2050386	MAD1L1	-0.54	-12.19	-0.43	7.11e-31	Bipolar disorder and schizophrenia;
BRCA	trans	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg25214090	chr10:38739885	LOC399744	0.48	10.62	0.39	2.18e-24	Corneal astigmatism;
BRCA	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-9.01	-0.34	2.39e-18	Alzheimer's disease (late onset);
BRCA	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.5	-10.11	-0.37	2.16e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11764359	chr7:65958608	NA	0.77	17.23	0.56	6.13e-55	Aortic root size;
BRCA	cis	rs3772130	0.962	rs9812137	chr3:121539103	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.92	0.4	1.39e-25	Cognitive performance;
BRCA	cis	rs2742234	0.955	rs2075913	chr10:43622368	T/A	cg02780029	chr10:43622663	RET	-0.4	-9.93	-0.37	1e-21	Hirschsprung disease;
BRCA	cis	rs6084875	0.733	rs6037959	chr20:4741723	A/G	cg05143360	chr20:4741328	NA	0.36	7.91	0.3	1.15e-14	Systemic lupus erythematosus;
BRCA	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.98	-0.3	6.73e-15	Prostate cancer;
BRCA	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg18850127	chr7:39170497	POU6F2	0.54	11.82	0.42	2.64e-29	IgG glycosylation;
BRCA	trans	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg23762105	chr12:34175262	ALG10	-0.4	-9.91	-0.36	1.24e-21	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.747	rs7521181	chr1:152955223	G/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.73	-0.36	5.77e-21	Inflammatory skin disease;
BRCA	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg23649088	chr2:200775458	C2orf69	0.61	8.94	0.33	4.04e-18	Schizophrenia;
BRCA	cis	rs13046373	0.508	rs2253516	chr21:31993317	C/T	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.3	0.35	2.13e-19	HDL cholesterol;
BRCA	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg09904177	chr6:26538194	HMGN4	0.47	15.09	0.51	3.22e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs7301826	0.966	rs4759795	chr12:131300900	G/A	cg11011512	chr12:131303247	STX2	0.4	9.94	0.37	9.57e-22	Plasma plasminogen activator levels;
BRCA	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	9.89	0.36	1.54e-21	Lung cancer in ever smokers;
BRCA	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg19626725	chr5:178986131	RUFY1	0.3	8.28	0.31	7.4e-16	Lung cancer;
BRCA	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.57	-0.32	7.57e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.39	8.79	0.33	1.34e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg19743168	chr1:23544995	NA	0.47	11.77	0.42	4.24e-29	Height;
BRCA	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg12373951	chr3:133503437	NA	0.46	11.07	0.4	3.69e-26	Iron status biomarkers;
BRCA	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg23131131	chr22:24373011	LOC391322	-0.35	-8.0	-0.3	5.82e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg13010199	chr12:38710504	ALG10B	0.42	8.83	0.33	1.03e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg15485101	chr11:133734466	NA	0.41	9.82	0.36	2.66e-21	Childhood ear infection;
BRCA	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg24558204	chr6:135376177	HBS1L	0.46	12.59	0.45	1.23e-32	Red blood cell count;
BRCA	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.49	-0.47	1.15e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs7799006	0.964	rs3757440	chr7:2272936	A/G	cg08027265	chr7:2291960	NA	-0.4	-10.33	-0.38	3.13e-23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs250677	1.000	rs190378	chr5:148434275	G/T	cg23229984	chr5:148520753	ABLIM3	0.32	8.03	0.3	4.84e-15	Breast cancer;
BRCA	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg26384229	chr12:38710491	ALG10B	0.8	19.72	0.62	5.75e-68	Heart rate;
BRCA	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg22907277	chr7:1156413	C7orf50	0.64	10.9	0.4	1.76e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2742234	0.541	rs10899782	chr10:43736361	A/T	cg15436174	chr10:43711423	RASGEF1A	0.49	9.6	0.36	1.74e-20	Hirschsprung disease;
BRCA	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.72	-0.33	2.47e-17	Alzheimer's disease (late onset);
BRCA	trans	rs1493916	0.837	rs9952002	chr18:31414314	C/G	cg15819921	chr19:927150	ARID3A	-0.42	-8.35	-0.31	4.15e-16	Life satisfaction;
BRCA	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.46	-8.34	-0.31	4.43e-16	Mean platelet volume;
BRCA	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg01528321	chr10:82214614	TSPAN14	0.79	16.67	0.55	4.64e-52	Post bronchodilator FEV1;
BRCA	cis	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.25	-0.41	6.25e-27	Morning vs. evening chronotype;
BRCA	cis	rs6750047	0.932	rs11124631	chr2:38274908	A/G	cg07380506	chr2:38303506	CYP1B1	-0.42	-9.72	-0.36	6.31e-21	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	16.94	0.56	1.88e-53	Platelet count;
BRCA	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg03351412	chr1:154909251	PMVK	0.56	12.79	0.45	1.7e-33	Prostate cancer;
BRCA	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg17063962	chr7:91808500	NA	0.54	12.3	0.44	2.26e-31	Breast cancer;
BRCA	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg17330251	chr7:94953956	PON1	-0.42	-8.98	-0.33	3.07e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6028335	0.610	rs12624452	chr20:37554781	G/T	cg16355469	chr20:37678765	NA	0.45	8.16	0.31	1.76e-15	Alcohol and nicotine co-dependence;
BRCA	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg20307385	chr11:47447363	PSMC3	0.79	18.71	0.59	1.35e-62	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg21138405	chr5:131827807	IRF1	-0.33	-8.18	-0.31	1.49e-15	Asthma (sex interaction);
BRCA	cis	rs367615	0.552	rs2963024	chr5:108730773	C/T	cg17395555	chr5:108820864	NA	-0.3	-8.8	-0.33	1.28e-17	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs11955398	0.585	rs10041431	chr5:60010917	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.37	-9.04	-0.34	1.91e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1451375	0.794	rs11238134	chr7:50542927	A/C	cg18232548	chr7:50535776	DDC	-0.47	-10.87	-0.39	2.3e-25	Malaria;
BRCA	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	15.0	0.51	8.13e-44	Mean corpuscular hemoglobin;
BRCA	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-15.69	-0.53	3.55e-47	Chronic sinus infection;
BRCA	cis	rs2637266	0.935	rs2583059	chr10:78395178	G/C	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg18811423	chr2:55921094	PNPT1	0.71	22.36	0.66	3.18e-82	Metabolic syndrome;
BRCA	cis	rs7618915	0.547	rs11719685	chr3:52676065	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.4	0.38	1.7e-23	Bipolar disorder;
BRCA	cis	rs9283706	0.689	rs11956654	chr5:66318196	A/G	cg11590213	chr5:66331682	MAST4	0.4	7.89	0.3	1.29e-14	Coronary artery disease;
BRCA	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg23719950	chr11:63933701	MACROD1	-0.58	-9.52	-0.35	3.45e-20	Mean platelet volume;
BRCA	trans	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.39	8.15	0.31	1.93e-15	Menarche (age at onset);
BRCA	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.53	-0.52	2.14e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-12.07	-0.43	2.3e-30	Bipolar disorder;
BRCA	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg12444411	chr7:2802554	GNA12	-0.36	-9.08	-0.34	1.37e-18	Height;
BRCA	cis	rs36051895	0.626	rs10815149	chr9:5063701	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-9.47	-0.35	5.35e-20	Pediatric autoimmune diseases;
BRCA	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg10560079	chr2:191398806	TMEM194B	-0.77	-13.16	-0.46	3.76e-35	Diastolic blood pressure;
BRCA	cis	rs977987	0.736	rs4888392	chr16:75412262	T/C	cg03315344	chr16:75512273	CHST6	0.53	12.62	0.45	9.48e-33	Dupuytren's disease;
BRCA	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	11.45	0.41	9.27e-28	Multiple sclerosis;
BRCA	trans	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg25214090	chr10:38739885	LOC399744	0.5	10.93	0.4	1.35e-25	Corneal astigmatism;
BRCA	cis	rs3818285	0.655	rs623980	chr10:111646147	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.43	-14.01	-0.48	4.58e-39	Superior crus of antihelix expression;
BRCA	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg22535103	chr8:58192502	C8orf71	-0.46	-9.06	-0.34	1.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg00825309	chr19:58991885	ZNF446	-0.58	-12.73	-0.45	2.97e-33	Uric acid clearance;
BRCA	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg23711669	chr6:146136114	FBXO30	0.69	16.02	0.54	7.97e-49	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	11.61	0.42	1.98e-28	Rheumatoid arthritis;
BRCA	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg16482183	chr6:26056742	HIST1H1C	0.48	9.65	0.36	1.12e-20	Iron status biomarkers;
BRCA	cis	rs10267417	0.603	rs28510133	chr7:19935487	A/T	cg05791153	chr7:19748676	TWISTNB	0.41	7.82	0.3	2.21e-14	Night sleep phenotypes;
BRCA	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg20129853	chr10:51489980	NA	0.31	8.55	0.32	8.74e-17	Prostate-specific antigen levels;
BRCA	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg04234412	chr22:24373322	LOC391322	-0.57	-14.17	-0.49	7.46e-40	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.46	-11.03	-0.4	5.31e-26	IgG glycosylation;
BRCA	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg14664628	chr15:75095509	CSK	-0.73	-17.73	-0.57	1.73e-57	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg18232548	chr7:50535776	DDC	-0.55	-14.23	-0.49	4.18e-40	Systemic sclerosis;
BRCA	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10802521	chr3:52805072	NEK4	-0.34	-9.32	-0.35	1.89e-19	Bipolar disorder;
BRCA	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.36	-0.41	2.39e-27	Extrinsic epigenetic age acceleration;
BRCA	trans	rs9409565	0.717	rs61470662	chr9:97189472	T/C	cg05679027	chr9:99775184	HIATL2	-0.42	-9.25	-0.34	3.21e-19	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs1691799	0.867	rs1168356	chr12:66750469	A/G	cg16791601	chr12:66731901	HELB	-0.62	-16.42	-0.54	7.93e-51	White blood cell count (basophil);
BRCA	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Tonsillectomy;
BRCA	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg08847533	chr14:75593920	NEK9	0.81	19.35	0.61	5.21e-66	Height;
BRCA	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg23791538	chr6:167370224	RNASET2	-0.37	-9.17	-0.34	6.65e-19	Crohn's disease;
BRCA	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg03808351	chr9:123631620	PHF19	0.61	12.43	0.44	6.19e-32	Birth weight;
BRCA	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-13.33	-0.47	6e-36	Lymphocyte counts;
BRCA	cis	rs7523050	0.908	rs72697202	chr1:109398704	A/G	cg08274380	chr1:109419600	GPSM2	0.82	12.5	0.44	3.02e-32	Fat distribution (HIV);
BRCA	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg26384229	chr12:38710491	ALG10B	0.74	17.12	0.56	2.19e-54	Bladder cancer;
BRCA	cis	rs832187	0.776	rs854622	chr3:63862842	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.38	-7.82	-0.3	2.15e-14	Schizophrenia;
BRCA	cis	rs4363385	0.720	rs9325996	chr1:152965347	A/G	cg21543102	chr1:152974771	SPRR3	-0.3	-8.56	-0.32	8.53e-17	Inflammatory skin disease;
BRCA	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg02524346	chr8:600233	NA	-0.69	-9.96	-0.37	7.91e-22	IgG glycosylation;
BRCA	cis	rs7524258	0.868	rs2412152	chr1:7303213	C/T	cg07173049	chr1:7289937	CAMTA1	0.54	13.01	0.46	1.68e-34	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs4363385	0.818	rs11205164	chr1:152986023	A/T	cg25856811	chr1:152973957	SPRR3	-0.32	-8.41	-0.32	2.64e-16	Inflammatory skin disease;
BRCA	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg25019033	chr10:957182	NA	-0.44	-8.25	-0.31	9.08e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs870825	0.860	rs56180712	chr4:185600223	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	13.82	0.48	3.56e-38	Blood protein levels;
BRCA	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-9.79	-0.36	3.41e-21	Myopia (pathological);
BRCA	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.53	12.49	0.44	3.4e-32	Schizophrenia;
BRCA	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg20891558	chr2:74357851	NA	0.51	12.11	0.43	1.53e-30	Gestational age at birth (maternal effect);
BRCA	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg08917208	chr2:24149416	ATAD2B	0.53	8.36	0.31	3.99e-16	Asthma;
BRCA	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24549020	chr5:56110836	MAP3K1	-0.47	-8.4	-0.32	2.96e-16	Initial pursuit acceleration;
BRCA	cis	rs10046574	0.561	rs17403528	chr7:135195531	C/T	cg27474649	chr7:135195673	CNOT4	0.66	10.49	0.38	7.12e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg03433033	chr1:76189801	ACADM	0.57	11.59	0.42	2.44e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg22920501	chr2:26401640	FAM59B	0.89	16.29	0.54	3.91e-50	Gut microbiome composition (summer);
BRCA	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg27535305	chr1:53392650	SCP2	-0.47	-11.4	-0.41	1.55e-27	Monocyte count;
BRCA	trans	rs9409565	0.826	rs4612412	chr9:97208627	C/G	cg05679027	chr9:99775184	HIATL2	-0.43	-9.49	-0.35	4.59e-20	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.62e-18	Alzheimer's disease (late onset);
BRCA	cis	rs9283706	0.676	rs6449842	chr5:66323159	C/G	cg11590213	chr5:66331682	MAST4	0.4	7.92	0.3	1.05e-14	Coronary artery disease;
BRCA	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg04727924	chr7:799746	HEATR2	0.54	9.46	0.35	5.69e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg14675211	chr2:100938903	LONRF2	-0.45	-10.2	-0.37	9.76e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.2	-0.49	5.8e-40	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg11502198	chr6:26597334	ABT1	0.56	11.97	0.43	6.47e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs6087771	0.890	rs6089056	chr20:30325773	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	23.39	0.68	6.61e-88	Subcortical brain region volumes;Putamen volume;
BRCA	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg23978390	chr7:1156363	C7orf50	0.41	9.33	0.35	1.73e-19	Longevity;Endometriosis;
BRCA	cis	rs2235642	0.671	rs2235641	chr16:1608177	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.41	-9.1	-0.34	1.17e-18	Coronary artery disease;
BRCA	cis	rs10129255	0.500	rs10143385	chr14:107190796	G/A	cg07958169	chr14:107095056	NA	-0.4	-8.6	-0.32	6.3e-17	Kawasaki disease;
BRCA	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.55	-10.68	-0.39	1.36e-24	IgG glycosylation;
BRCA	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg11764359	chr7:65958608	NA	0.68	15.21	0.52	8.16e-45	Aortic root size;
BRCA	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.43	8.19	0.31	1.41e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.64	-13.7	-0.48	1.25e-37	Lymphocyte counts;
BRCA	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg06064525	chr11:970664	AP2A2	-0.48	-16.03	-0.54	7.33e-49	Alzheimer's disease (late onset);
BRCA	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.52	8.13	0.31	2.29e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg08807101	chr21:30365312	RNF160	-0.39	-8.12	-0.31	2.4e-15	Cognitive test performance;
BRCA	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg22906224	chr7:99728672	NA	0.41	8.24	0.31	9.71e-16	Coronary artery disease;
BRCA	cis	rs977987	0.778	rs11858992	chr16:75411445	A/C	cg03315344	chr16:75512273	CHST6	0.53	12.62	0.45	9.22e-33	Dupuytren's disease;
BRCA	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09263875	chr16:632152	PIGQ	0.73	21.21	0.64	5.35e-76	Height;
BRCA	cis	rs10504073	0.584	rs74457150	chr8:49890753	C/G	cg00325661	chr8:49890786	NA	0.52	15.12	0.51	2.25e-44	Blood metabolite ratios;
BRCA	cis	rs68170813	0.559	rs77422419	chr7:106957932	A/G	cg02696742	chr7:106810147	HBP1	-0.54	-8.65	-0.32	4.3e-17	Coronary artery disease;
BRCA	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg10295955	chr4:187884368	NA	-0.86	-24.64	-0.7	1.01e-94	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs62103177	0.608	rs551643	chr18:77838970	C/G	cg05926928	chr17:57297772	GDPD1	-0.75	-10.75	-0.39	6.98e-25	Opioid sensitivity;
BRCA	cis	rs11112613	0.775	rs12371537	chr12:105971425	T/C	cg03607813	chr12:105948248	NA	0.58	10.07	0.37	3.22e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	9.3	0.35	2.18e-19	Retinal vascular caliber;
BRCA	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg24596788	chr1:163392923	NA	-0.37	-10.0	-0.37	5.49e-22	Motion sickness;
BRCA	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.53	8.36	0.31	3.87e-16	Platelet count;
BRCA	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg05347473	chr6:146136440	FBXO30	-0.61	-12.02	-0.43	3.63e-30	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.14	-0.4	1.81e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg01884057	chr2:25150051	NA	0.32	8.37	0.31	3.67e-16	Body mass index in non-asthmatics;
BRCA	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg22117172	chr7:91764530	CYP51A1	-0.23	-7.92	-0.3	1.03e-14	Breast cancer;
BRCA	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.1	0.31	2.81e-15	Tonsillectomy;
BRCA	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg22800045	chr5:56110881	MAP3K1	0.45	8.94	0.33	4.32e-18	Initial pursuit acceleration;
BRCA	trans	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.36	-7.81	-0.3	2.35e-14	Mean corpuscular volume;
BRCA	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg16989086	chr20:62203971	PRIC285	0.52	8.96	0.33	3.43e-18	Glioblastoma;
BRCA	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg14829155	chr15:31115871	NA	-0.4	-9.3	-0.35	2.13e-19	Huntington's disease progression;
BRCA	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10802521	chr3:52805072	NEK4	-0.34	-9.28	-0.34	2.64e-19	Electroencephalogram traits;
BRCA	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg17063962	chr7:91808500	NA	0.51	10.97	0.4	8.74e-26	Breast cancer;
BRCA	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg12935359	chr14:103987150	CKB	0.65	15.04	0.51	5.76e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs11690935	0.959	rs7608403	chr2:172646765	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.91	-31.17	-0.78	2.07e-130	Schizophrenia;
BRCA	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08045932	chr20:61659980	NA	0.47	10.39	0.38	1.86e-23	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.3	-8.5	-0.32	1.32e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg20701182	chr2:24300061	SF3B14	0.59	9.19	0.34	5.66e-19	Lymphocyte counts;
BRCA	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.33	-7.82	-0.3	2.24e-14	Mean platelet volume;
BRCA	cis	rs427394	1.000	rs274672	chr5:6744176	G/A	cg10857441	chr5:6722123	POLS	-0.31	-10.49	-0.38	7.42e-24	Menopause (age at onset);
BRCA	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg20203395	chr5:56204925	C5orf35	-0.5	-10.29	-0.38	4.54e-23	Initial pursuit acceleration;
BRCA	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.62	-0.32	5.25e-17	Aortic root size;
BRCA	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg00071950	chr4:10020882	SLC2A9	0.4	8.48	0.32	1.61e-16	Blood metabolite levels;
BRCA	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13636640	chr20:31349939	DNMT3B	0.59	17.52	0.57	2.11e-56	Ulcerative colitis;
BRCA	trans	rs1459104	1.000	rs17578206	chr11:55171677	T/C	cg15704280	chr7:45808275	SEPT13	0.63	8.0	0.3	5.74e-15	Body mass index;
BRCA	cis	rs1003719	0.715	rs2835646	chr21:38546574	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.36	-0.49	1e-40	Eye color traits;
BRCA	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg18016565	chr1:150552671	MCL1	0.34	8.01	0.3	5.32e-15	Tonsillectomy;
BRCA	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg10523679	chr1:76189770	ACADM	0.88	20.81	0.64	7.76e-74	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.51	-0.35	3.76e-20	Metabolite levels;
BRCA	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	13.87	0.48	1.91e-38	Height;
BRCA	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.43	-10.88	-0.4	2.13e-25	Schizophrenia;
BRCA	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.43	-9.6	-0.36	1.77e-20	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.25	0.49	3.24e-40	Motion sickness;
BRCA	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg26516362	chr5:178986906	RUFY1	-0.47	-13.86	-0.48	2.12e-38	Lung cancer;
BRCA	cis	rs4853036	0.672	rs12988897	chr2:70028976	A/G	cg02498382	chr2:70120550	SNRNP27	-0.45	-7.9	-0.3	1.21e-14	Colorectal or endometrial cancer;
BRCA	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg08975724	chr8:8085496	FLJ10661	0.42	8.75	0.33	1.86e-17	Retinal vascular caliber;
BRCA	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg04374321	chr14:90722782	PSMC1	0.73	19.03	0.6	2.59e-64	Mortality in heart failure;
BRCA	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.57	-0.35	2.21e-20	Total body bone mineral density;
BRCA	cis	rs6809651	0.524	rs79262908	chr3:185803594	C/T	cg00760338	chr3:185826511	ETV5	-0.48	-9.57	-0.35	2.34e-20	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
BRCA	cis	rs2731664	0.792	rs335434	chr5:176867276	A/G	cg23176889	chr5:176863531	GRK6	-0.6	-15.86	-0.53	5.03e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg06238570	chr21:40685208	BRWD1	-0.41	-8.49	-0.32	1.45e-16	Menarche (age at onset);
BRCA	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.51	-10.29	-0.38	4.36e-23	Body mass index;
BRCA	cis	rs9300255	0.679	rs12817892	chr12:123728702	G/A	cg00376283	chr12:123451042	ABCB9	-0.55	-10.78	-0.39	5.09e-25	Neutrophil percentage of white cells;
BRCA	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg00339695	chr16:24857497	SLC5A11	0.51	11.14	0.4	1.79e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg12140854	chr5:148520817	ABLIM3	-0.43	-9.06	-0.34	1.58e-18	Breast cancer;
BRCA	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg16230307	chr14:35515116	FAM177A1	0.71	14.5	0.5	2.23e-41	Psoriasis;
BRCA	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	14.32	0.49	1.48e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg03711944	chr11:47377212	SPI1	-0.49	-12.56	-0.44	1.7e-32	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg20307385	chr11:47447363	PSMC3	0.75	21.25	0.64	3.33e-76	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs2882667	0.690	rs288009	chr5:138228662	G/A	cg04439458	chr5:138467593	SIL1	-0.34	-8.28	-0.31	7.37e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs990171	0.607	rs1558642	chr2:102763960	T/G	cg22835712	chr2:102737379	NA	0.56	9.8	0.36	3.11e-21	Lymphocyte counts;
BRCA	cis	rs7246657	0.722	rs2927746	chr19:38156570	G/A	cg23950597	chr19:37808831	NA	0.54	9.13	0.34	9.22e-19	Coronary artery calcification;
BRCA	cis	rs6740322	0.748	rs6732337	chr2:43462822	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.76	14.79	0.51	8.61e-43	Coronary artery disease;
BRCA	cis	rs965469	0.779	rs2236112	chr20:3294983	C/G	cg25506879	chr20:3388711	C20orf194	-0.43	-8.71	-0.33	2.61e-17	IFN-related cytopenia;
BRCA	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.55	10.99	0.4	7.18e-26	Height;
BRCA	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg04709771	chr16:646395	RAB40C	0.44	11.12	0.4	2.31e-26	Height;
BRCA	trans	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.38	7.96	0.3	7.9e-15	Menarche (age at onset);
BRCA	cis	rs4900538	0.855	rs72698597	chr14:102868633	C/T	cg18135206	chr14:102964638	TECPR2	-0.92	-21.34	-0.65	1.08e-76	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg00105475	chr2:10696890	NA	0.44	10.34	0.38	2.87e-23	Prostate cancer;
BRCA	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.29	0.31	6.59e-16	Aortic root size;
BRCA	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg21798802	chr22:38057573	PDXP	0.48	12.66	0.45	6.11e-33	Fat distribution (HIV);
BRCA	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	10.72	0.39	9.29e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs6005807	0.719	rs12165715	chr22:29005595	T/C	cg12565055	chr22:29076175	TTC28	0.48	8.79	0.33	1.41e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg26384229	chr12:38710491	ALG10B	0.75	16.9	0.56	3.07e-53	Bladder cancer;
BRCA	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-11.94	-0.43	8.31e-30	Personality dimensions;
BRCA	cis	rs897080	0.552	rs698799	chr2:44690618	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	9.45	0.35	6.34e-20	Height;
BRCA	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg04450456	chr4:17643702	FAM184B	0.35	10.37	0.38	2.11e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg27279351	chr12:120934652	DYNLL1	0.57	13.42	0.47	2.43e-36	Reticulocyte fraction of red cells;
BRCA	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg21143896	chr7:2802374	GNA12	-0.31	-7.94	-0.3	8.87e-15	Height;
BRCA	cis	rs868036	1.000	rs868036	chr15:68055013	T/A	cg08079166	chr15:68083412	MAP2K5	-0.33	-8.71	-0.33	2.52e-17	Restless legs syndrome;
BRCA	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg15556689	chr8:8085844	FLJ10661	0.33	8.4	0.32	2.97e-16	Neuroticism;
BRCA	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.6	13.91	0.48	1.26e-38	Eye color traits;
BRCA	cis	rs7178424	0.967	rs1030859	chr15:62364932	A/G	cg00456672	chr15:62358751	C2CD4A	0.34	8.03	0.3	4.6e-15	Height;
BRCA	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg22920501	chr2:26401640	FAM59B	-0.67	-11.53	-0.42	4.47e-28	Gut microbiome composition (summer);
BRCA	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.61	-0.45	1.03e-32	Bipolar disorder;
BRCA	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12667521	chr19:29218732	NA	0.47	8.85	0.33	8.64e-18	Methadone dose in opioid dependence;
BRCA	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg17063962	chr7:91808500	NA	-0.6	-14.4	-0.49	6.44e-41	Breast cancer;
BRCA	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg08885076	chr2:99613938	TSGA10	0.46	10.82	0.39	3.68e-25	Chronic sinus infection;
BRCA	cis	rs10754283	0.871	rs72712569	chr1:90125657	G/C	cg21401794	chr1:90099060	LRRC8C	-0.44	-9.79	-0.36	3.56e-21	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs7809950	0.678	rs7790080	chr7:107031322	G/A	cg23024343	chr7:107201750	COG5	-0.49	-9.73	-0.36	5.87e-21	Coronary artery disease;
BRCA	cis	rs9815354	0.767	rs73069245	chr3:41951452	G/A	cg03022575	chr3:42003672	ULK4	0.69	9.62	0.36	1.44e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24549020	chr5:56110836	MAP3K1	0.67	13.23	0.46	1.77e-35	Initial pursuit acceleration;
BRCA	cis	rs6088813	0.961	rs3795159	chr20:33896262	C/G	cg14752227	chr20:34000481	UQCC	0.4	8.38	0.31	3.28e-16	Height;
BRCA	trans	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	30.46	0.77	1.41e-126	Colorectal cancer;
BRCA	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg23711669	chr6:146136114	FBXO30	-0.67	-15.75	-0.53	1.92e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs36051895	0.623	rs12351715	chr9:5262349	A/G	cg02405213	chr9:5042618	JAK2	-0.43	-8.1	-0.31	2.77e-15	Pediatric autoimmune diseases;
BRCA	cis	rs6543140	0.890	rs61122764	chr2:102999520	A/G	cg04239558	chr2:103089729	SLC9A4	0.34	9.29	0.35	2.3e-19	Blood protein levels;
BRCA	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg15704280	chr7:45808275	SEPT13	-0.58	-11.74	-0.42	5.87e-29	Coronary artery disease;
BRCA	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg05025164	chr4:1340916	KIAA1530	0.37	8.3	0.31	6.19e-16	Longevity;
BRCA	trans	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg27600084	chr12:12264075	NA	0.37	8.56	0.32	8.47e-17	Breast size;
BRCA	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg12292205	chr6:26970375	C6orf41	0.64	14.57	0.5	9.93e-42	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg16586182	chr3:47516702	SCAP	0.56	12.34	0.44	1.64e-31	QT interval;
BRCA	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg11584989	chr19:19387371	SF4	0.64	13.49	0.47	1.14e-36	Bipolar disorder;
BRCA	cis	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg00540400	chr15:79124168	NA	0.27	7.81	0.3	2.44e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs1003719	0.788	rs2835575	chr21:38455936	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.18	0.49	7.08e-40	Eye color traits;
BRCA	cis	rs6005807	0.719	rs73430179	chr22:28998821	T/C	cg12565055	chr22:29076175	TTC28	0.5	9.42	0.35	7.86e-20	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg25036284	chr2:26402008	FAM59B	0.89	15.63	0.53	7.3e-47	Gut microbiome composition (summer);
BRCA	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.49e-52	Hypertriglyceridemia;
BRCA	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg15704280	chr7:45808275	SEPT13	0.54	9.12	0.34	9.9e-19	Axial length;
BRCA	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11890956	chr21:40555474	PSMG1	-0.65	-14.8	-0.51	7.8e-43	Menarche (age at onset);
BRCA	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg01475377	chr6:109611718	NA	-0.53	-13.39	-0.47	3.1e-36	Reticulocyte fraction of red cells;
BRCA	cis	rs909002	1.000	rs909002	chr1:32139635	C/T	cg13919466	chr1:32135498	COL16A1	-0.32	-10.98	-0.4	8.57e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-11.55	-0.42	3.64e-28	Colorectal cancer;
BRCA	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg01884057	chr2:25150051	NA	-0.33	-8.88	-0.33	6.59e-18	Body mass index;
BRCA	trans	rs9951602	0.512	rs7241419	chr18:76640778	C/G	cg02800362	chr5:177631904	HNRNPAB	0.76	17.64	0.57	4.82e-57	Obesity-related traits;
BRCA	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00475322	chr7:917719	C7orf20	0.45	11.57	0.42	3.04e-28	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	8.99	0.33	2.83e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg05535760	chr7:792225	HEATR2	0.72	13.25	0.46	1.46e-35	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7618915	0.547	rs11719685	chr3:52676065	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.48	0.35	4.75e-20	Bipolar disorder;
BRCA	cis	rs75804782	0.641	rs60841092	chr2:239349640	G/A	cg18131467	chr2:239335373	ASB1	-0.63	-8.08	-0.3	3.14e-15	Morning vs. evening chronotype;Chronotype;
BRCA	trans	rs1941687	0.510	rs1452649	chr18:31410858	A/G	cg27147174	chr7:100797783	AP1S1	-0.42	-8.52	-0.32	1.17e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg19622623	chr12:86230825	RASSF9	-0.32	-8.78	-0.33	1.45e-17	Major depressive disorder;
BRCA	cis	rs754466	0.651	rs11002316	chr10:79617511	C/G	cg17075019	chr10:79541650	NA	-0.75	-18.1	-0.58	2.08e-59	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg05347473	chr6:146136440	FBXO30	0.43	8.55	0.32	9.29e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg25110126	chr1:46999211	NA	0.59	11.88	0.43	1.57e-29	Monobrow;
BRCA	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg02734326	chr4:10020555	SLC2A9	0.41	8.92	0.33	4.81e-18	Bone mineral density;
BRCA	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg18131467	chr2:239335373	ASB1	0.96	34.72	0.81	3.22e-149	Multiple system atrophy;
BRCA	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg21045802	chr8:109455806	TTC35	0.35	7.87	0.3	1.54e-14	Dupuytren's disease;
BRCA	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg03923535	chr7:1197113	ZFAND2A	0.52	10.53	0.38	5.31e-24	Longevity;Endometriosis;
BRCA	cis	rs7246967	0.673	rs16999580	chr19:22923487	C/T	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	16.99	0.56	1.08e-53	Hip circumference adjusted for BMI;
BRCA	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg05863683	chr7:1912471	MAD1L1	0.44	9.84	0.36	2.29e-21	Bipolar disorder and schizophrenia;
BRCA	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg01620082	chr3:125678407	NA	-0.84	-9.88	-0.36	1.61e-21	Depression;
BRCA	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg08213375	chr14:104286397	PPP1R13B	0.64	18.41	0.59	4.97e-61	Schizophrenia;
BRCA	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.35	-0.38	2.53e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg24558204	chr6:135376177	HBS1L	0.46	12.62	0.45	8.89e-33	Red blood cell count;
BRCA	cis	rs7301826	0.651	rs2277336	chr12:131286119	A/G	cg11011512	chr12:131303247	STX2	-0.47	-11.78	-0.42	3.93e-29	Plasma plasminogen activator levels;
BRCA	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg09163369	chr1:210001066	C1orf107	0.65	12.4	0.44	8.9e-32	Orofacial clefts;
BRCA	cis	rs9837602	1.000	rs7627991	chr3:99808338	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.18	0.4	1.3e-26	Breast cancer;
BRCA	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg27165867	chr14:105738592	BRF1	-0.35	-8.28	-0.31	6.96e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.0	0.37	5.63e-22	Bladder cancer;
BRCA	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg16230307	chr14:35515116	FAM177A1	0.73	15.06	0.51	4.55e-44	Psoriasis;
BRCA	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg03425785	chr20:62221387	GMEB2	0.53	8.46	0.32	1.87e-16	Glioblastoma;
BRCA	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18876405	chr7:65276391	NA	-0.5	-11.12	-0.4	2.15e-26	Aortic root size;
BRCA	cis	rs7589728	0.925	rs78829281	chr2:88502293	T/A	cg04511125	chr2:88470314	THNSL2	0.73	10.17	0.37	1.27e-22	Plasma clusterin levels;
BRCA	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	19.36	0.61	4.71e-66	Platelet count;
BRCA	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg12564285	chr5:131593104	PDLIM4	0.32	8.19	0.31	1.38e-15	Blood metabolite levels;
BRCA	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg02297831	chr4:17616191	MED28	0.36	8.24	0.31	9.56e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9986765	1.000	rs73725075	chr7:142823479	C/A	cg15652212	chr7:142981776	TMEM139	0.56	9.29	0.34	2.37e-19	Cancer;Dermatomyositis;
BRCA	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg03425785	chr20:62221387	GMEB2	0.51	8.28	0.31	7.22e-16	Glioma;Non-glioblastoma glioma;Glioblastoma;
BRCA	cis	rs62229266	0.771	rs7277791	chr21:37383227	C/A	cg12218747	chr21:37451666	NA	-0.34	-8.1	-0.31	2.87e-15	Mitral valve prolapse;
BRCA	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg22875332	chr1:76189707	ACADM	0.61	11.8	0.42	3.37e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg24692254	chr21:30365293	RNF160	-0.64	-16.62	-0.55	7.79e-52	Dental caries;
BRCA	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg17143192	chr8:8559678	CLDN23	0.54	10.29	0.38	4.23e-23	Obesity-related traits;
BRCA	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg16606324	chr3:10149918	C3orf24	0.54	10.56	0.39	3.83e-24	Alzheimer's disease;
BRCA	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.52	-0.32	1.11e-16	Monocyte percentage of white cells;
BRCA	cis	rs7617773	0.817	rs9830016	chr3:48282494	A/G	cg11946769	chr3:48343235	NME6	0.63	14.36	0.49	1.02e-40	Coronary artery disease;
BRCA	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg03146154	chr1:46216737	IPP	0.46	10.15	0.37	1.56e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg20307385	chr11:47447363	PSMC3	-0.43	-9.09	-0.34	1.23e-18	Subjective well-being;
BRCA	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-15.04	-0.51	5.27e-44	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.07	0.49	2.26e-39	Motion sickness;
BRCA	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg13010199	chr12:38710504	ALG10B	0.44	8.83	0.33	9.9e-18	Bladder cancer;
BRCA	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg08470875	chr2:26401718	FAM59B	-0.72	-12.33	-0.44	1.77e-31	Gut microbiome composition (summer);
BRCA	cis	rs9341808	0.718	rs11962614	chr6:80823306	A/T	cg08355045	chr6:80787529	NA	0.37	9.37	0.35	1.24e-19	Sitting height ratio;
BRCA	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.13	-0.34	9.27e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg22431228	chr1:16359049	CLCNKA	-0.43	-9.71	-0.36	6.72e-21	Dilated cardiomyopathy;
BRCA	cis	rs4363385	0.818	rs678960	chr1:153011621	G/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg19920283	chr7:105172520	RINT1	0.58	9.39	0.35	1e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg08975724	chr8:8085496	FLJ10661	0.54	11.71	0.42	7.95e-29	Parkinson's disease;
BRCA	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23583168	chr7:148888333	NA	-0.78	-18.85	-0.6	2.33e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg10978503	chr1:24200527	CNR2	0.47	12.38	0.44	1.1e-31	Immature fraction of reticulocytes;
BRCA	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	20.13	0.62	3.41e-70	Chronic sinus infection;
BRCA	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24531977	chr5:56204891	C5orf35	-0.88	-19.03	-0.6	2.55e-64	Initial pursuit acceleration;
BRCA	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg25801113	chr15:45476975	SHF	0.31	7.82	0.3	2.22e-14	Uric acid levels;
BRCA	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg18252515	chr7:66147081	NA	-1.08	-16.09	-0.54	3.78e-49	Diabetic kidney disease;
BRCA	cis	rs12760731	0.565	rs12034657	chr1:178099354	A/C	cg00404053	chr1:178313656	RASAL2	-0.63	-8.04	-0.3	4.49e-15	Obesity-related traits;
BRCA	cis	rs11958404	0.860	rs7723564	chr5:157449396	C/T	cg05962755	chr5:157440814	NA	0.59	10.79	0.39	4.96e-25	IgG glycosylation;
BRCA	cis	rs2797160	0.967	rs2747715	chr6:126007719	A/T	cg05901451	chr6:126070800	HEY2	0.39	9.49	0.35	4.49e-20	Endometrial cancer;
BRCA	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg00071950	chr4:10020882	SLC2A9	0.63	16.17	0.54	1.49e-49	Bone mineral density;
BRCA	cis	rs36051895	0.632	rs11788164	chr9:5129395	A/G	cg02405213	chr9:5042618	JAK2	-0.48	-9.09	-0.34	1.2e-18	Pediatric autoimmune diseases;
BRCA	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.63	0.39	2.13e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg06046430	chr4:77819534	ANKRD56	0.62	13.96	0.48	7.77e-39	Emphysema distribution in smoking;
BRCA	cis	rs4865169	0.934	rs3796531	chr4:57850846	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.31	-8.23	-0.31	1.07e-15	Breast cancer;
BRCA	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg22535103	chr8:58192502	C8orf71	-0.41	-8.46	-0.32	1.81e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg04013093	chr6:42928303	GNMT	-0.29	-8.83	-0.33	9.86e-18	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.38	0.38	2.02e-23	Motion sickness;
BRCA	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg23018236	chr17:30244563	NA	-0.62	-10.14	-0.37	1.72e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs17384381	0.953	rs12130145	chr1:85828970	G/C	cg16011679	chr1:85725395	C1orf52	0.53	8.07	0.3	3.46e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.22e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.54	7.87	0.3	1.54e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg22676075	chr6:135203613	NA	0.39	7.81	0.3	2.42e-14	Red blood cell count;
BRCA	cis	rs11971779	0.648	rs6967836	chr7:139079944	C/G	cg07862535	chr7:139043722	LUC7L2	0.39	10.58	0.39	3.17e-24	Diisocyanate-induced asthma;
BRCA	cis	rs72772090	0.539	rs72773969	chr5:96145196	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-11.86	-0.42	1.91e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7635838	0.686	rs347589	chr3:11288419	A/G	cg00170343	chr3:11313890	ATG7	0.43	8.4	0.32	2.92e-16	HDL cholesterol;
BRCA	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg09658497	chr7:2847517	GNA12	-0.41	-8.61	-0.32	5.83e-17	Height;
BRCA	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.67	0.36	9.63e-21	Morning vs. evening chronotype;
BRCA	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.59	0.32	6.78e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17490626	0.568	rs2033371	chr10:71212310	G/A	cg12610070	chr10:71211762	TSPAN15	-0.31	-11.0	-0.4	6.91e-26	Thrombosis;
BRCA	cis	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg06521331	chr12:34319734	NA	-0.56	-9.99	-0.37	6.47e-22	Morning vs. evening chronotype;
BRCA	trans	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg21659725	chr3:3221576	CRBN	-0.48	-8.87	-0.33	7.34e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs12618769	0.597	rs12619665	chr2:99126551	A/T	cg10123293	chr2:99228465	UNC50	0.41	8.43	0.32	2.34e-16	Bipolar disorder;
BRCA	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg22800045	chr5:56110881	MAP3K1	-0.67	-12.48	-0.44	3.77e-32	Initial pursuit acceleration;
BRCA	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg08601574	chr20:25228251	PYGB	-0.35	-8.51	-0.32	1.24e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	10.86	0.39	2.59e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.53	0.41	4.68e-28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs9470366	0.545	rs4711457	chr6:36633160	T/C	cg08179530	chr6:36648295	CDKN1A	-0.53	-12.06	-0.43	2.51e-30	QRS duration;
BRCA	cis	rs849141	0.961	rs537124	chr7:28203142	C/T	cg22892036	chr7:28189139	JAZF1	0.46	8.43	0.32	2.3e-16	Height;Hip circumference adjusted for BMI;
BRCA	cis	rs7131987	0.650	rs7301188	chr12:29455391	C/T	cg09582351	chr12:29534625	ERGIC2	-0.46	-10.61	-0.39	2.46e-24	QT interval;
BRCA	cis	rs3849570	0.695	rs6804587	chr3:81873423	T/C	cg07356753	chr3:81810745	GBE1	-0.4	-9.65	-0.36	1.16e-20	Waist circumference;Body mass index;
BRCA	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg26384229	chr12:38710491	ALG10B	0.67	15.81	0.53	8.83e-48	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg24692254	chr21:30365293	RNF160	-0.68	-18.76	-0.6	7.17e-63	Dental caries;
BRCA	cis	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg06521331	chr12:34319734	NA	-0.62	-12.18	-0.43	7.72e-31	Morning vs. evening chronotype;
BRCA	cis	rs68170813	0.559	rs1002935	chr7:106832361	G/A	cg02696742	chr7:106810147	HBP1	-0.53	-8.69	-0.33	2.93e-17	Coronary artery disease;
BRCA	trans	rs6964833	0.935	rs13238996	chr7:74069645	A/G	cg07504079	chr7:72649617	NCF1B	-0.5	-9.68	-0.36	8.7e-21	Menarche (age at onset);
BRCA	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07636037	chr3:49044803	WDR6	0.76	16.5	0.55	3.36e-51	Menarche (age at onset);
BRCA	cis	rs6088813	0.961	rs981818	chr20:33924130	C/A	cg14752227	chr20:34000481	UQCC	0.41	8.61	0.32	5.48e-17	Height;
BRCA	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg08917208	chr2:24149416	ATAD2B	1.08	15.0	0.51	8.89e-44	Lymphocyte counts;
BRCA	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg01939980	chr4:1354348	KIAA1530	0.3	8.09	0.3	3.02e-15	Longevity;
BRCA	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg18753928	chr3:113234510	CCDC52	-0.58	-12.22	-0.44	5.01e-31	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg03354898	chr7:1950403	MAD1L1	-0.45	-9.43	-0.35	7.33e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg13010199	chr12:38710504	ALG10B	0.5	10.31	0.38	3.67e-23	Bladder cancer;
BRCA	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.81	0.51	7.41e-43	Colorectal cancer;
BRCA	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg21427119	chr20:30132790	HM13	-0.43	-9.12	-0.34	9.28e-19	Mean corpuscular hemoglobin;
BRCA	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg12379764	chr21:47803548	PCNT	0.59	14.19	0.49	6.51e-40	Testicular germ cell tumor;
BRCA	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg04455712	chr21:45112962	RRP1B	0.44	11.54	0.42	4.14e-28	Mean corpuscular volume;
BRCA	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.43	-10.89	-0.4	1.88e-25	Schizophrenia;
BRCA	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg25358565	chr5:93447407	FAM172A	-0.68	-11.67	-0.42	1.15e-28	Diabetic retinopathy;
BRCA	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	14.13	0.49	1.25e-39	Lymphocyte counts;
BRCA	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg22875332	chr1:76189707	ACADM	-0.7	-14.72	-0.5	2e-42	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg15212455	chr7:39170539	POU6F2	0.36	7.87	0.3	1.48e-14	IgG glycosylation;
BRCA	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg04450456	chr4:17643702	FAM184B	0.32	9.35	0.35	1.41e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs965469	0.842	rs6051776	chr20:3332062	T/C	cg25506879	chr20:3388711	C20orf194	-0.48	-9.46	-0.35	5.74e-20	IFN-related cytopenia;
BRCA	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg18758796	chr5:131593413	PDLIM4	0.37	9.14	0.34	8.44e-19	Acylcarnitine levels;
BRCA	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg08514558	chr10:81106712	PPIF	0.35	8.41	0.32	2.61e-16	Height;
BRCA	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg21475434	chr5:93447410	FAM172A	0.67	8.87	0.33	7.36e-18	Diabetic retinopathy;
BRCA	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg03690763	chr11:133734501	NA	0.29	10.28	0.38	4.76e-23	Childhood ear infection;
BRCA	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg20607798	chr8:58055168	NA	0.48	8.41	0.32	2.61e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg16230307	chr14:35515116	FAM177A1	0.73	15.06	0.51	4.55e-44	Psoriasis;
BRCA	trans	rs6479891	1.000	rs72837025	chr10:65194491	A/C	cg14819942	chr15:35414228	NA	0.35	8.6	0.32	6.06e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs758324	0.898	rs11956351	chr5:131137224	G/A	cg06307176	chr5:131281290	NA	0.53	10.27	0.38	5.48e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg04851639	chr8:1020857	NA	-0.3	-8.35	-0.31	4.29e-16	Schizophrenia;
BRCA	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.55	10.6	0.39	2.83e-24	HDL cholesterol;
BRCA	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg08888203	chr3:10149979	C3orf24	0.65	13.64	0.47	2.35e-37	Alzheimer's disease;
BRCA	cis	rs67981189	0.752	rs2332477	chr14:71403311	T/C	cg15816911	chr14:71606274	NA	-0.37	-8.23	-0.31	1.04e-15	Schizophrenia;
BRCA	cis	rs1595825	0.891	rs57340905	chr2:198565823	C/T	cg19156104	chr2:198669113	PLCL1	-0.48	-8.57	-0.32	7.75e-17	Ulcerative colitis;
BRCA	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg13175981	chr1:150552382	MCL1	0.52	11.39	0.41	1.71e-27	Tonsillectomy;
BRCA	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg23625390	chr15:77176239	SCAPER	0.39	9.08	0.34	1.38e-18	Blood metabolite levels;
BRCA	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg19729930	chr2:74357872	NA	0.61	15.28	0.52	3.71e-45	Gestational age at birth (maternal effect);
BRCA	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg05535760	chr7:792225	HEATR2	-0.72	-11.36	-0.41	2.19e-27	Cerebrospinal P-tau181p levels;
BRCA	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26384229	chr12:38710491	ALG10B	0.74	16.62	0.55	8.14e-52	Morning vs. evening chronotype;
BRCA	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.74	11.76	0.42	4.72e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs17253792	0.545	rs35466279	chr14:56017022	C/T	cg01858014	chr14:56050164	KTN1	-0.61	-7.95	-0.3	8.3e-15	Putamen volume;
BRCA	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg20587970	chr11:113659929	NA	-1.37	-24.14	-0.69	5.33e-92	Hip circumference adjusted for BMI;
BRCA	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg06115741	chr20:33292138	TP53INP2	0.39	8.62	0.32	5.23e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs73242632	1.000	rs28681160	chr4:57889166	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.66	7.82	0.3	2.17e-14	Congenital heart disease (maternal effect);
BRCA	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg21775007	chr8:11205619	TDH	-0.38	-8.09	-0.3	3.07e-15	Neuroticism;
BRCA	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg06808227	chr14:105710500	BRF1	-0.74	-15.2	-0.52	9.09e-45	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs6543140	0.964	rs4851010	chr2:103056127	A/T	cg04239558	chr2:103089729	SLC9A4	-0.34	-9.49	-0.35	4.46e-20	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg05340658	chr4:99064831	C4orf37	0.61	14.57	0.5	1.05e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-13.08	-0.46	8.25e-35	Response to antipsychotic treatment;
BRCA	cis	rs4566357	0.615	rs4675140	chr2:227908665	C/T	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.01	-0.3	5.46e-15	Coronary artery disease;
BRCA	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg16482183	chr6:26056742	HIST1H1C	0.5	10.38	0.38	1.99e-23	Height;
BRCA	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	18.46	0.59	2.64e-61	Alzheimer's disease;
BRCA	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg16339924	chr4:17578868	LAP3	-0.58	-13.83	-0.48	3.15e-38	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg21770322	chr7:97807741	LMTK2	0.45	11.74	0.42	5.76e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg25036284	chr2:26402008	FAM59B	-0.64	-10.67	-0.39	1.39e-24	Gut microbiome composition (summer);
BRCA	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg10495392	chr1:46806563	NSUN4	0.46	8.31	0.31	5.61e-16	Menopause (age at onset);
BRCA	cis	rs9469578	1.000	rs73743323	chr6:33705355	C/T	cg18708504	chr6:33715942	IP6K3	0.73	10.46	0.38	9.62e-24	Phosphorus levels;
BRCA	cis	rs4919694	1.000	rs75691516	chr10:104652045	C/T	cg04362960	chr10:104952993	NT5C2	0.9	14.59	0.5	8.3e-42	Arsenic metabolism;
BRCA	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg23109721	chr2:106886537	NA	-0.46	-7.82	-0.3	2.15e-14	Facial morphology (factor 23);
BRCA	cis	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg07460842	chr6:66804631	NA	-0.88	-14.64	-0.5	4.52e-42	Exhaled nitric oxide output;
BRCA	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg15934090	chr1:100435551	SLC35A3	0.35	8.15	0.31	1.91e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3772130	0.926	rs66653099	chr3:121393089	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.53	9.02	0.34	2.13e-18	Cognitive performance;
BRCA	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.66	-17.32	-0.57	2.21e-55	Longevity;Endometriosis;
BRCA	cis	rs6834538	1.000	rs2351761	chr4:113447911	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.41	9.13	0.34	8.76e-19	Free thyroxine concentration;
BRCA	cis	rs10992471	0.603	rs6479422	chr9:95190694	G/T	cg14631576	chr9:95140430	CENPP	-0.39	-9.22	-0.34	4.34e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg22705602	chr4:152727874	NA	-0.32	-8.02	-0.3	5.2e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg27446573	chr6:127587934	RNF146	0.9	21.36	0.65	8.49e-77	Breast cancer;
BRCA	cis	rs12618769	0.652	rs72823794	chr2:99216593	T/A	cg10123293	chr2:99228465	UNC50	0.42	8.53	0.32	1.07e-16	Bipolar disorder;
BRCA	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg26248373	chr2:1572462	NA	-0.62	-14.78	-0.5	1e-42	IgG glycosylation;
BRCA	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	10.01	0.37	5.05e-22	Bipolar disorder;
BRCA	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg08470875	chr2:26401718	FAM59B	-0.5	-8.17	-0.31	1.65e-15	Gut microbiome composition (summer);
BRCA	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg01475377	chr6:109611718	NA	-0.59	-16.52	-0.55	2.62e-51	Reticulocyte fraction of red cells;
BRCA	cis	rs7715811	1.000	rs67731984	chr5:13774014	G/A	cg07548982	chr5:13769939	DNAH5	-0.41	-9.04	-0.34	1.79e-18	Subclinical atherosclerosis traits (other);
BRCA	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg00383909	chr3:49044727	WDR6	0.77	12.98	0.46	2.39e-34	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	19.8	0.62	2.19e-68	Platelet count;
BRCA	trans	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg02030672	chr11:45687055	CHST1	-0.41	-9.14	-0.34	8.5e-19	Obesity-related traits;
BRCA	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg26395211	chr5:140044315	WDR55	0.38	8.62	0.32	5.4e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs11605275	1.000	rs73434177	chr11:20023995	G/A	cg14835545	chr11:20032148	NAV2	-0.64	-9.16	-0.34	7.24e-19	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg13770153	chr20:60521292	NA	-0.38	-8.88	-0.33	6.77e-18	Body mass index;
BRCA	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.69	0.39	1.24e-24	IgG glycosylation;
BRCA	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg12165864	chr7:66369176	NA	-0.44	-9.77	-0.36	4.01e-21	Corneal structure;
BRCA	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg11663144	chr21:46675770	NA	-0.61	-14.26	-0.49	3.03e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg08888203	chr3:10149979	C3orf24	0.64	11.9	0.43	1.24e-29	Alzheimer's disease;
BRCA	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg17507749	chr15:85114479	UBE2QP1	0.57	10.82	0.39	3.45e-25	Schizophrenia;
BRCA	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg24069376	chr3:38537580	EXOG	0.41	11.43	0.41	1.19e-27	Electrocardiographic conduction measures;
BRCA	cis	rs9807989	0.507	rs6755905	chr2:103048207	C/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.38	0.31	3.39e-16	Asthma;
BRCA	cis	rs922182	0.967	rs17788704	chr15:64277097	A/G	cg24729988	chr15:64271149	DAPK2	-0.52	-11.45	-0.41	9.64e-28	Blood protein levels;
BRCA	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg13877915	chr19:58951672	ZNF132	0.45	10.73	0.39	8.17e-25	Uric acid clearance;
BRCA	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11644478	chr21:40555479	PSMG1	-0.67	-14.34	-0.49	1.22e-40	Cognitive function;
BRCA	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-9.61	-0.36	1.69e-20	Menopause (age at onset);
BRCA	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg05313129	chr8:58192883	C8orf71	-0.46	-9.67	-0.36	1.01e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg06627628	chr2:24431161	ITSN2	-0.65	-12.46	-0.44	4.49e-32	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg18154014	chr19:37997991	ZNF793	0.48	9.45	0.35	6.34e-20	Coronary artery calcification;
BRCA	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg23950597	chr19:37808831	NA	-0.62	-11.5	-0.41	6.08e-28	Coronary artery calcification;
BRCA	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.6	-0.39	2.71e-24	Mean corpuscular volume;
BRCA	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg24006582	chr15:45444508	DUOX1	0.53	10.34	0.38	2.93e-23	Uric acid levels;
BRCA	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg25358565	chr5:93447407	FAM172A	1.11	17.79	0.58	8.16e-58	Diabetic retinopathy;
BRCA	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.3	-0.35	2.15e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg23708337	chr7:1209742	NA	0.55	8.21	0.31	1.23e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7589728	0.925	rs80065975	chr2:88502758	G/A	cg04511125	chr2:88470314	THNSL2	0.72	9.96	0.37	8.05e-22	Plasma clusterin levels;
BRCA	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg04362960	chr10:104952993	NT5C2	0.44	10.03	0.37	4.39e-22	Arsenic metabolism;
BRCA	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg03676636	chr4:99064102	C4orf37	0.24	8.27	0.31	7.91e-16	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.38	0.49	8.24e-41	Exhaled nitric oxide output;
BRCA	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.46	10.82	0.39	3.76e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07308232	chr7:1071921	C7orf50	-0.41	-8.39	-0.31	3.23e-16	Longevity;Endometriosis;
BRCA	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg02743256	chr7:2109353	MAD1L1	-0.44	-8.18	-0.31	1.54e-15	Bipolar disorder;
BRCA	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg24130564	chr14:104152367	KLC1	-0.37	-8.27	-0.31	7.75e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg18032046	chr6:28092343	ZSCAN16	0.5	8.01	0.3	5.63e-15	Depression;
BRCA	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg13010199	chr12:38710504	ALG10B	0.54	11.84	0.42	2.28e-29	Heart rate;
BRCA	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg10978503	chr1:24200527	CNR2	0.52	13.86	0.48	2.1e-38	Immature fraction of reticulocytes;
BRCA	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg05082376	chr22:42548792	NA	-0.32	-7.91	-0.3	1.16e-14	Cognitive function;
BRCA	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	19.78	0.62	2.65e-68	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7809950	0.678	rs2237660	chr7:106862963	T/A	cg23024343	chr7:107201750	COG5	-0.44	-8.88	-0.33	6.49e-18	Coronary artery disease;
BRCA	cis	rs4891159	0.790	rs59762437	chr18:74153146	G/A	cg24786174	chr18:74118243	ZNF516	-0.76	-17.92	-0.58	1.67e-58	Longevity;
BRCA	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg00074818	chr8:8560427	CLDN23	0.39	8.55	0.32	9.04e-17	Obesity-related traits;
BRCA	cis	rs4074536	0.574	rs4338353	chr1:116293646	A/C	cg21648376	chr1:116311395	CASQ2	-0.49	-8.63	-0.32	5e-17	QRS duration;
BRCA	cis	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg08807101	chr21:30365312	RNF160	0.37	8.19	0.31	1.39e-15	Pancreatic cancer;
BRCA	trans	rs9409565	0.516	rs114766729	chr9:97069901	C/T	cg05679027	chr9:99775184	HIATL2	0.37	8.32	0.31	5.34e-16	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs11190604	0.767	rs10883484	chr10:102174803	G/C	cg07080220	chr10:102295463	HIF1AN	0.49	10.0	0.37	5.91e-22	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.49	0.32	1.42e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg20587970	chr11:113659929	NA	-1.24	-22.67	-0.67	5.77e-84	Hip circumference adjusted for BMI;
BRCA	cis	rs17270561	0.636	rs11794	chr6:25701718	G/A	cg16482183	chr6:26056742	HIST1H1C	0.46	8.81	0.33	1.18e-17	Iron status biomarkers;
BRCA	trans	rs7786808	0.579	rs55701656	chr7:158188812	G/A	cg02030672	chr11:45687055	CHST1	0.48	10.53	0.38	4.92e-24	Obesity-related traits;
BRCA	trans	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg25214090	chr10:38739885	LOC399744	0.5	10.08	0.37	2.84e-22	Corneal astigmatism;
BRCA	cis	rs883565	0.792	rs784490	chr3:39173530	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	0.43	9.26	0.34	3.07e-19	Handedness;
BRCA	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg27129171	chr3:47204927	SETD2	-0.72	-17.65	-0.57	4.35e-57	Colorectal cancer;
BRCA	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg03929089	chr4:120376271	NA	0.49	8.2	0.31	1.36e-15	Axial length;
BRCA	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg24011408	chr12:48396354	COL2A1	-0.45	-10.12	-0.37	2.06e-22	Plateletcrit;
BRCA	cis	rs7131987	0.934	rs7316004	chr12:29411698	C/T	cg09582351	chr12:29534625	ERGIC2	-0.39	-9.37	-0.35	1.26e-19	QT interval;
BRCA	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	10.74	0.39	7.25e-25	Height;
BRCA	cis	rs290268	1.000	rs290271	chr9:93551619	G/A	cg02608019	chr9:93564028	SYK	0.55	11.98	0.43	5.83e-30	Platelet count;
BRCA	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-10.77	-0.39	5.57e-25	Type 2 diabetes;
BRCA	cis	rs9815354	0.556	rs55953604	chr3:42004428	A/G	cg03022575	chr3:42003672	ULK4	0.65	9.47	0.35	5.34e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs9381107	1.000	rs11754173	chr6:9455664	T/G	cg14735645	chr6:9486422	NA	-0.45	-7.95	-0.3	8.22e-15	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	15.99	0.53	1.15e-48	Platelet count;
BRCA	cis	rs11955398	0.585	rs1456743	chr5:60007421	T/A	cg02684056	chr5:59996105	DEPDC1B	-0.37	-9.04	-0.34	1.91e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs9462846	0.919	rs6936722	chr6:42891311	A/G	cg05552183	chr6:42928497	GNMT	-0.43	-8.01	-0.3	5.52e-15	Blood protein levels;
BRCA	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-16.54	-0.55	1.95e-51	Colorectal cancer;
BRCA	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg23625390	chr15:77176239	SCAPER	-0.51	-11.91	-0.43	1.08e-29	Blood metabolite levels;
BRCA	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg17470723	chr8:74884337	TCEB1	0.4	8.72	0.33	2.46e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11051970	0.611	rs56146365	chr12:32529634	A/G	cg24626660	chr12:32551988	NA	0.28	8.05	0.3	4.17e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs9309473	0.687	rs6747145	chr2:73609177	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-12.52	-0.44	2.64e-32	Metabolite levels;
BRCA	trans	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-12.91	-0.45	4.58e-34	Brugada syndrome;
BRCA	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg21573476	chr21:45109991	RRP1B	0.33	8.87	0.33	7.19e-18	Mean corpuscular volume;
BRCA	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-15.84	-0.53	6.87e-48	Morning vs. evening chronotype;
BRCA	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-13.79	-0.48	4.9e-38	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-16.3	-0.54	3.16e-50	Parkinson's disease;
BRCA	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	17.81	0.58	6.47e-58	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg07148914	chr20:33460835	GGT7	0.46	9.76	0.36	4.67e-21	Height;
BRCA	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.36	0.35	1.38e-19	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs6594713	0.756	rs6872490	chr5:112784592	T/C	cg12552261	chr5:112820674	MCC	0.47	8.7	0.33	2.73e-17	Brain cytoarchitecture;
BRCA	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.44	-0.38	1.18e-23	Tonsillectomy;
BRCA	trans	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg25214090	chr10:38739885	LOC399744	0.55	12.6	0.45	1.2e-32	Corneal astigmatism;
BRCA	cis	rs586533	0.813	rs665986	chr11:99503013	A/G	cg22878054	chr11:99397252	CNTN5	0.32	8.12	0.31	2.45e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1011018	0.628	rs7798740	chr7:139462162	T/C	cg03224163	chr7:139420300	HIPK2	-0.59	-8.83	-0.33	1.01e-17	Systolic blood pressure;
BRCA	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg11266682	chr4:10021025	SLC2A9	0.48	12.56	0.44	1.71e-32	Bone mineral density;
BRCA	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg03188948	chr7:1209495	NA	0.47	9.18	0.34	5.7e-19	Longevity;Endometriosis;
BRCA	cis	rs897080	0.515	rs4953088	chr2:44564518	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.57	-10.57	-0.39	3.64e-24	Height;
BRCA	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg12310025	chr6:25882481	NA	-0.51	-12.16	-0.43	9.04e-31	Blood metabolite levels;
BRCA	trans	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg26043149	chr18:55253948	FECH	-0.41	-9.06	-0.34	1.6e-18	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	14.3	0.49	2.01e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7178424	0.967	rs893156	chr15:62378892	G/A	cg00456672	chr15:62358751	C2CD4A	-0.36	-8.23	-0.31	1.05e-15	Height;
BRCA	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg27129171	chr3:47204927	SETD2	-0.69	-16.28	-0.54	4.01e-50	Colorectal cancer;
BRCA	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.46	-9.62	-0.36	1.52e-20	Iron status biomarkers;
BRCA	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg13010199	chr12:38710504	ALG10B	0.41	8.36	0.31	3.82e-16	Bladder cancer;
BRCA	trans	rs2204008	0.743	rs11495614	chr12:38156358	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.31	-0.35	2.06e-19	Bladder cancer;
BRCA	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18876405	chr7:65276391	NA	0.55	13.35	0.47	4.99e-36	Aortic root size;
BRCA	cis	rs17253792	0.915	rs77161327	chr14:56178565	A/G	cg01858014	chr14:56050164	KTN1	-0.67	-8.24	-0.31	9.82e-16	Putamen volume;
BRCA	cis	rs4919087	1.000	rs7067835	chr10:99074649	T/C	cg25902810	chr10:99078978	FRAT1	0.52	11.25	0.41	6.4e-27	Monocyte count;
BRCA	cis	rs6064559	0.685	rs1062601	chr20:56137834	A/G	cg16101800	chr20:56136569	PCK1	-0.47	-12.34	-0.44	1.63e-31	Hemoglobin concentration;
BRCA	cis	rs1691799	0.899	rs1168304	chr12:66738667	A/C	cg16791601	chr12:66731901	HELB	-0.64	-17.29	-0.56	3.01e-55	White blood cell count (basophil);
BRCA	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg00071950	chr4:10020882	SLC2A9	0.54	13.1	0.46	6.59e-35	Bone mineral density;
BRCA	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg02551604	chr5:131831745	NA	-0.4	-14.95	-0.51	1.56e-43	Asthma (sex interaction);
BRCA	cis	rs807669	0.525	rs2282684	chr22:19184244	C/T	cg02655711	chr22:19163373	SLC25A1	0.45	10.12	0.37	1.95e-22	Metabolite levels;
BRCA	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.01	0.34	2.33e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg14061069	chr19:46274453	DMPK	-0.49	-12.19	-0.43	6.82e-31	Coronary artery disease;
BRCA	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg08885076	chr2:99613938	TSGA10	-0.59	-13.21	-0.46	2.12e-35	Chronic sinus infection;
BRCA	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg26384229	chr12:38710491	ALG10B	0.65	15.74	0.53	2.09e-47	Bladder cancer;
BRCA	cis	rs9359856	0.564	rs6914142	chr6:90398903	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.66	-8.09	-0.3	2.99e-15	Bipolar disorder;
BRCA	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-12.38	-0.44	1.09e-31	Morning vs. evening chronotype;
BRCA	cis	rs7091068	0.518	rs1409337	chr10:95439822	T/C	cg20715218	chr10:95462985	C10orf4	0.47	9.94	0.37	9.77e-22	Urinary tract infection frequency;
BRCA	cis	rs6840360	1.000	rs6535819	chr4:152651503	A/G	cg22705602	chr4:152727874	NA	-0.31	-7.92	-0.3	1.05e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs6973256	0.865	rs62470059	chr7:133334195	T/C	cg07491979	chr7:133331646	EXOC4	-0.39	-8.87	-0.33	7.49e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs17401966	0.522	rs4845930	chr1:10319049	G/A	cg03954927	chr1:10346856	KIF1B	0.34	10.21	0.37	8.96e-23	Hepatocellular carcinoma;
BRCA	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.45	-0.44	5.34e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg19920283	chr7:105172520	RINT1	0.58	9.33	0.35	1.72e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.66	-11.77	-0.42	4.57e-29	Iron status biomarkers;
BRCA	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.6	-0.32	6.33e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7635838	0.686	rs347588	chr3:11287504	C/T	cg00170343	chr3:11313890	ATG7	0.43	8.49	0.32	1.43e-16	HDL cholesterol;
BRCA	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03264133	chr6:25882463	NA	-0.53	-11.99	-0.43	4.97e-30	Blood metabolite levels;
BRCA	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg02503808	chr4:7069936	GRPEL1	0.79	18.31	0.59	1.66e-60	Monocyte percentage of white cells;
BRCA	cis	rs7537052	0.669	rs4652903	chr1:36642858	C/T	cg24686825	chr1:36642396	MAP7D1	-0.53	-12.07	-0.43	2.35e-30	Schizophrenia;
BRCA	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg13010199	chr12:38710504	ALG10B	0.49	9.48	0.35	4.85e-20	Morning vs. evening chronotype;
BRCA	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11764359	chr7:65958608	NA	0.75	16.78	0.55	1.26e-52	Aortic root size;
BRCA	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg16049864	chr8:95962084	TP53INP1	0.48	10.9	0.4	1.68e-25	Type 2 diabetes;
BRCA	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.77	-12.14	-0.43	1.13e-30	Platelet count;
BRCA	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg01181863	chr3:195395398	SDHAP2	-0.5	-8.37	-0.31	3.64e-16	Pancreatic cancer;
BRCA	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.56	-0.32	8.69e-17	Aortic root size;
BRCA	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg04362960	chr10:104952993	NT5C2	-0.34	-8.01	-0.3	5.26e-15	Waist circumference;Hip circumference;
BRCA	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg24558204	chr6:135376177	HBS1L	0.59	15.82	0.53	8.45e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg26384229	chr12:38710491	ALG10B	0.66	13.95	0.48	8.57e-39	Morning vs. evening chronotype;
BRCA	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.74e-16	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg03433033	chr1:76189801	ACADM	0.71	14.08	0.49	2.02e-39	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg08601574	chr20:25228251	PYGB	-0.34	-8.18	-0.31	1.58e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg23289794	chr7:2394357	EIF3B	-0.64	-11.99	-0.43	5.32e-30	Multiple sclerosis;
BRCA	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg15556689	chr8:8085844	FLJ10661	-0.33	-8.95	-0.33	3.94e-18	Neuroticism;
BRCA	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg15704280	chr7:45808275	SEPT13	0.53	8.9	0.33	5.69e-18	Axial length;
BRCA	cis	rs6121246	0.633	rs6060986	chr20:30426297	G/A	cg21427119	chr20:30132790	HM13	-0.36	-8.18	-0.31	1.49e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg04362960	chr10:104952993	NT5C2	0.43	10.51	0.38	6.22e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg04691961	chr3:161091175	C3orf57	-0.58	-15.15	-0.51	1.58e-44	Morning vs. evening chronotype;
BRCA	cis	rs7127900	0.583	rs11043142	chr11:2234042	A/G	cg25635251	chr11:2234043	NA	0.46	12.42	0.44	6.99e-32	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
BRCA	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	8.06	0.3	3.82e-15	Tonsillectomy;
BRCA	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg03676636	chr4:99064102	C4orf37	0.25	8.42	0.32	2.46e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs858239	1.000	rs199348	chr7:23293098	C/A	cg23682824	chr7:23144976	KLHL7	0.33	8.42	0.32	2.4e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg18402987	chr7:1209562	NA	0.48	9.19	0.34	5.29e-19	Longevity;Endometriosis;
BRCA	cis	rs8048589	0.558	rs34565142	chr16:12231347	C/T	cg02910054	chr16:12241554	SNX29	0.39	7.83	0.3	2.02e-14	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
BRCA	trans	rs9951602	0.512	rs61021837	chr18:76648210	A/C	cg02800362	chr5:177631904	HNRNPAB	0.77	18.06	0.58	3.34e-59	Obesity-related traits;
BRCA	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg18854424	chr1:2615690	NA	0.31	7.97	0.3	7.13e-15	Ulcerative colitis;
BRCA	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg24879335	chr3:133465180	TF	-0.33	-11.38	-0.41	1.82e-27	Iron status biomarkers (transferrin levels);
BRCA	cis	rs6445967	0.530	rs12490706	chr3:58408247	C/T	cg23715586	chr3:58305044	RPP14	-0.36	-7.89	-0.3	1.34e-14	Platelet count;
BRCA	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg01579765	chr21:45077557	HSF2BP	-0.44	-12.06	-0.43	2.55e-30	Mean corpuscular volume;
BRCA	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.28	-0.34	2.6e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg17063962	chr7:91808500	NA	-0.51	-11.72	-0.42	7.25e-29	Breast cancer;
BRCA	cis	rs6684514	1.000	rs12142808	chr1:156230546	G/A	cg16558208	chr1:156270281	VHLL	0.37	8.18	0.31	1.53e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg11502198	chr6:26597334	ABT1	0.48	9.53	0.35	3.25e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs6815814	0.950	rs5743557	chr4:38806827	G/A	cg06935464	chr4:38784597	TLR10	0.51	8.42	0.32	2.52e-16	Breast cancer;
BRCA	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg08508325	chr11:3079039	CARS	0.38	13.43	0.47	2.16e-36	Longevity;
BRCA	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.68	-0.42	1.08e-28	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-9.95	-0.37	8.93e-22	Aortic root size;
BRCA	cis	rs9329289	0.510	rs12356215	chr10:2545390	C/G	cg15501526	chr10:2543763	NA	0.47	10.83	0.39	3.3e-25	Age-related hearing impairment;
BRCA	cis	rs13046373	0.535	rs1395775	chr21:32025065	G/A	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.26	0.34	3.07e-19	HDL cholesterol;
BRCA	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg12140854	chr5:148520817	ABLIM3	0.42	8.87	0.33	7.44e-18	Breast cancer;
BRCA	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg20848291	chr7:100343083	ZAN	0.36	8.13	0.31	2.17e-15	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg04944784	chr2:26401820	FAM59B	-0.85	-13.17	-0.46	3.18e-35	Gut microbiome composition (summer);
BRCA	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg27661571	chr11:113659931	NA	-0.83	-12.37	-0.44	1.19e-31	Hip circumference adjusted for BMI;
BRCA	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg06636001	chr8:8085503	FLJ10661	0.49	10.07	0.37	2.99e-22	Triglycerides;
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg09033563	chr22:24373618	LOC391322	0.5	10.71	0.39	9.93e-25	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg23422044	chr7:1970798	MAD1L1	-0.56	-9.32	-0.35	1.85e-19	Neuroticism;
BRCA	cis	rs1568889	1.000	rs6484346	chr11:28040767	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.84	0.51	5.04e-43	Bipolar disorder;
BRCA	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg00383909	chr3:49044727	WDR6	0.43	9.37	0.35	1.22e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18876405	chr7:65276391	NA	0.7	18.69	0.59	1.72e-62	Aortic root size;
BRCA	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg15212455	chr7:39170539	POU6F2	-0.4	-9.21	-0.34	4.56e-19	IgG glycosylation;
BRCA	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg01741372	chr11:783889	NA	-0.46	-11.14	-0.4	1.81e-26	Breast cancer;
BRCA	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg26384229	chr12:38710491	ALG10B	0.41	9.27	0.34	2.71e-19	Morning vs. evening chronotype;
BRCA	cis	rs9341808	0.718	rs10943696	chr6:80901272	C/G	cg08355045	chr6:80787529	NA	0.39	9.96	0.37	7.9e-22	Sitting height ratio;
BRCA	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	16.33	0.54	2.46e-50	Platelet count;
BRCA	trans	rs2797160	1.000	rs2797161	chr6:126010789	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.35	8.01	0.3	5.47e-15	Endometrial cancer;
BRCA	cis	rs10779751	0.770	rs12075896	chr1:11200350	C/A	cg08854313	chr1:11322531	MTOR	-0.73	-14.46	-0.5	3.45e-41	Body mass index;
BRCA	cis	rs4660306	0.961	rs2152077	chr1:45986670	G/T	cg24296786	chr1:45957014	TESK2	0.43	9.15	0.34	7.54e-19	Homocysteine levels;
BRCA	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.09	0.46	7.48e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	15.26	0.52	4.71e-45	Platelet count;
BRCA	cis	rs684232	0.835	rs1833459	chr17:562244	C/T	cg15660573	chr17:549704	VPS53	-0.37	-7.86	-0.3	1.65e-14	Prostate cancer;
BRCA	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.12	-0.34	1e-18	Bipolar disorder;
BRCA	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg22903471	chr2:27725779	GCKR	-0.36	-8.69	-0.32	3.15e-17	Menopause (age at onset);
BRCA	cis	rs3916	0.794	rs10431384	chr12:121127347	C/T	cg21892295	chr12:121157589	UNC119B	0.36	10.52	0.38	5.4e-24	Urinary metabolites (H-NMR features);
BRCA	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-10.84	-0.39	2.94e-25	Mean corpuscular volume;
BRCA	cis	rs698833	0.926	rs1065786	chr2:44660616	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.49	-9.87	-0.36	1.78e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs911555	0.755	rs2756122	chr14:103983033	C/G	cg12935359	chr14:103987150	CKB	-0.55	-12.26	-0.44	3.6e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs2559856	0.904	rs2695283	chr12:102089391	G/C	cg12213457	chr12:102090980	CHPT1	-0.36	-7.81	-0.3	2.32e-14	Blood protein levels;
BRCA	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02176678	chr2:219576539	TTLL4	0.46	11.92	0.43	9.84e-30	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7246657	0.663	rs4803287	chr19:38079435	A/G	cg23950597	chr19:37808831	NA	-0.49	-8.35	-0.31	4.23e-16	Coronary artery calcification;
BRCA	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-12.17	-0.43	8.34e-31	Morning vs. evening chronotype;
BRCA	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg20203395	chr5:56204925	C5orf35	-0.5	-10.38	-0.38	1.93e-23	Initial pursuit acceleration;
BRCA	trans	rs5756813	0.635	rs6000899	chr22:38203796	C/T	cg19894588	chr14:64061835	NA	-0.55	-11.56	-0.42	3.43e-28	Optic cup area;Vertical cup-disc ratio;
BRCA	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00149659	chr3:10157352	C3orf10	0.71	12.26	0.44	3.67e-31	Alzheimer's disease;
BRCA	cis	rs701145	0.585	rs1727893	chr3:153849866	A/C	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.22e-14	Coronary artery disease;
BRCA	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg20290983	chr6:43655470	MRPS18A	1.12	41.79	0.86	5.88e-185	IgG glycosylation;
BRCA	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26314531	chr2:26401878	FAM59B	0.9	16.24	0.54	6.54e-50	Gut microbiome composition (summer);
BRCA	cis	rs6546550	0.743	rs6731941	chr2:70018496	A/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-8.58	-0.32	7.41e-17	Prevalent atrial fibrillation;
BRCA	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg23950597	chr19:37808831	NA	-0.72	-12.52	-0.44	2.58e-32	Coronary artery calcification;
BRCA	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-11.88	-0.43	1.49e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg17063962	chr7:91808500	NA	-0.54	-12.45	-0.44	5.37e-32	Breast cancer;
BRCA	cis	rs698833	0.852	rs698823	chr2:44720947	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	8.89	0.33	6.27e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.12	-0.34	1e-18	Bipolar disorder;
BRCA	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.08	0.74	1.26e-113	Chronic sinus infection;
BRCA	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24549020	chr5:56110836	MAP3K1	0.64	12.87	0.45	7.13e-34	Initial pursuit acceleration;
BRCA	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.04	21.27	0.64	2.69e-76	Gut microbiome composition (summer);
BRCA	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg05313129	chr8:58192883	C8orf71	-0.46	-9.48	-0.35	4.96e-20	Developmental language disorder (linguistic errors);
BRCA	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg26384229	chr12:38710491	ALG10B	0.67	14.25	0.49	3.21e-40	Morning vs. evening chronotype;
BRCA	cis	rs2625529	0.730	rs7403191	chr15:72160964	C/T	cg16672083	chr15:72433130	SENP8	-0.72	-16.92	-0.56	2.49e-53	Red blood cell count;
BRCA	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg20503657	chr10:835505	NA	0.95	14.44	0.5	4.23e-41	Eosinophil percentage of granulocytes;
BRCA	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg09469691	chr10:81107165	PPIF	0.51	10.61	0.39	2.54e-24	Height;
BRCA	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18404041	chr3:52824283	ITIH1	-0.41	-12.06	-0.43	2.43e-30	Bipolar disorder;
BRCA	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg18357645	chr12:58087776	OS9	0.47	13.55	0.47	5.98e-37	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg04315214	chr1:2043799	PRKCZ	0.58	16.45	0.55	5.83e-51	Height;
BRCA	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg05340658	chr4:99064831	C4orf37	-0.48	-11.18	-0.4	1.29e-26	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg03929089	chr4:120376271	NA	0.61	10.56	0.39	3.97e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.58	-10.31	-0.38	3.8e-23	Gut microbiome composition (summer);
BRCA	cis	rs7809950	1.000	rs4727680	chr7:107087407	T/G	cg23024343	chr7:107201750	COG5	-0.4	-9.28	-0.34	2.65e-19	Coronary artery disease;
BRCA	cis	rs7011049	1.000	rs72640848	chr8:53836225	A/G	cg26025543	chr8:53854495	NA	0.54	9.68	0.36	8.84e-21	Systolic blood pressure;
BRCA	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.45	8.07	0.3	3.37e-15	Schizophrenia;
BRCA	cis	rs13046373	0.535	rs8129571	chr21:31980646	G/A	cg06468780	chr21:31798236	KRTAP13-3	0.36	8.9	0.33	5.59e-18	HDL cholesterol;
BRCA	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	10.59	0.39	2.96e-24	Height;
BRCA	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	27.91	0.74	1.14e-112	Chronic sinus infection;
BRCA	cis	rs3767633	0.925	rs2499855	chr1:161929761	C/T	cg09175582	chr1:161736000	ATF6	0.54	8.74	0.33	1.98e-17	IgG glycosylation;
BRCA	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg20933634	chr6:27740509	NA	0.48	9.62	0.36	1.49e-20	Parkinson's disease;
BRCA	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg08885076	chr2:99613938	TSGA10	-0.6	-13.44	-0.47	1.91e-36	Chronic sinus infection;
BRCA	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.13	0.31	2.28e-15	Total cholesterol levels;
BRCA	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg06046430	chr4:77819534	ANKRD56	0.61	13.69	0.48	1.39e-37	Emphysema distribution in smoking;
BRCA	cis	rs12545109	0.800	rs1467125	chr8:57418638	C/T	cg09654669	chr8:57350985	NA	-0.42	-8.22	-0.31	1.15e-15	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg04691961	chr3:161091175	C3orf57	-0.59	-13.97	-0.48	7.07e-39	Morning vs. evening chronotype;
BRCA	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.84	-0.36	2.21e-21	Bladder cancer;
BRCA	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg19257562	chr1:2043853	PRKCZ	-0.34	-9.07	-0.34	1.46e-18	Height;
BRCA	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26314531	chr2:26401878	FAM59B	-0.65	-11.11	-0.4	2.38e-26	Gut microbiome composition (summer);
BRCA	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-13.37	-0.47	4.13e-36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg09537434	chr19:41945824	ATP5SL	1.0	23.79	0.69	4.53e-90	Height;
BRCA	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.54	-0.47	6.75e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	7.87	0.3	1.49e-14	Schizophrenia;
BRCA	cis	rs6442522	0.733	rs4143273	chr3:15501808	C/T	cg16303742	chr3:15540471	COLQ	-0.33	-7.84	-0.3	1.91e-14	Uric acid levels;
BRCA	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg22920501	chr2:26401640	FAM59B	-0.94	-16.36	-0.54	1.65e-50	Gut microbiome composition (summer);
BRCA	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg13010199	chr12:38710504	ALG10B	0.42	9.03	0.34	2.09e-18	Morning vs. evening chronotype;
BRCA	cis	rs4889855	0.505	rs12952775	chr17:78607820	A/G	cg16591659	chr17:78472290	NA	-0.31	-8.0	-0.3	5.96e-15	Fractional excretion of uric acid;
BRCA	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg05665937	chr4:1216051	CTBP1	0.38	7.99	0.3	6.33e-15	Obesity-related traits;
BRCA	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.56	13.75	0.48	7.52e-38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg24450063	chr1:156163899	SLC25A44	0.94	18.49	0.59	1.82e-61	Testicular germ cell tumor;
BRCA	trans	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg15556689	chr8:8085844	FLJ10661	-0.32	-8.28	-0.31	7.29e-16	Triglycerides;
BRCA	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg18964960	chr10:1102726	WDR37	0.63	8.77	0.33	1.62e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg22532475	chr10:104410764	TRIM8	-0.32	-8.01	-0.3	5.28e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.6	-0.32	6.05e-17	Total body bone mineral density;
BRCA	cis	rs9814567	0.574	rs7650509	chr3:134170971	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.38	11.38	0.41	1.98e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs36051895	0.659	rs62541539	chr9:5038180	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-8.62	-0.32	5.24e-17	Pediatric autoimmune diseases;
BRCA	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	18.46	0.59	2.66e-61	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	trans	rs2736337	0.530	rs2003422	chr8:11303137	G/C	cg15556689	chr8:8085844	FLJ10661	0.33	8.18	0.31	1.56e-15	Rheumatoid arthritis;
BRCA	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg06494592	chr3:125709126	NA	-0.54	-8.67	-0.32	3.54e-17	Blood pressure (smoking interaction);
BRCA	trans	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg07211511	chr3:129823064	LOC729375	-0.62	-11.45	-0.41	9.31e-28	Blood pressure (smoking interaction);
BRCA	cis	rs2806561	0.754	rs10917344	chr1:23342193	C/G	cg19743168	chr1:23544995	NA	-0.42	-9.89	-0.36	1.53e-21	Height;
BRCA	cis	rs9986765	0.609	rs73452600	chr7:142828104	C/A	cg22531018	chr7:142981779	TMEM139	0.65	10.25	0.38	6.42e-23	Cancer;Dermatomyositis;
BRCA	cis	rs7572733	0.515	rs12619300	chr2:198786490	A/C	cg00792783	chr2:198669748	PLCL1	-0.46	-9.98	-0.37	7.05e-22	Dermatomyositis;
BRCA	cis	rs10992471	0.603	rs10992349	chr9:95233887	T/C	cg14631576	chr9:95140430	CENPP	-0.38	-9.27	-0.34	2.93e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs8028182	0.636	rs11636031	chr15:75815758	T/C	cg20655648	chr15:75932815	IMP3	0.42	8.06	0.3	3.87e-15	Sudden cardiac arrest;
BRCA	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	17.12	0.56	2.22e-54	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7586879	1.000	rs7608185	chr2:25115432	G/C	cg01884057	chr2:25150051	NA	0.33	8.35	0.31	4.28e-16	Body mass index;
BRCA	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg05896524	chr21:47604654	C21orf56	0.5	9.67	0.36	9.66e-21	Testicular germ cell tumor;
BRCA	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg08999081	chr20:33150536	PIGU	0.36	9.27	0.34	2.78e-19	Coronary artery disease;
BRCA	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08859206	chr1:53392774	SCP2	0.54	11.88	0.43	1.47e-29	Monocyte count;
BRCA	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.42	-7.87	-0.3	1.5e-14	Renal function-related traits (BUN);
BRCA	cis	rs427394	0.664	rs274722	chr5:6718668	C/T	cg10857441	chr5:6722123	POLS	-0.32	-10.95	-0.4	1.08e-25	Menopause (age at onset);
BRCA	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	14.13	0.49	1.18e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg00071950	chr4:10020882	SLC2A9	0.42	9.02	0.34	2.21e-18	Blood metabolite levels;
BRCA	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg12072164	chr19:44306565	LYPD5	0.37	8.71	0.33	2.63e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs6782228	0.585	rs9841161	chr3:128331870	A/G	cg16766828	chr3:128327626	NA	-0.42	-9.23	-0.34	3.82e-19	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg05623727	chr3:50126028	RBM5	-0.41	-9.9	-0.36	1.3e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg06453172	chr10:134556979	INPP5A	-0.6	-11.77	-0.42	4.54e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs1476670	0.710	rs2485993	chr1:44503040	C/T	cg09470012	chr1:44509516	NA	-0.44	-9.54	-0.35	2.86e-20	Eotaxin levels;
BRCA	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	12.76	0.45	2.31e-33	Axial length;
BRCA	cis	rs7092929	0.689	rs964162	chr10:3535233	C/T	cg14308648	chr10:3568949	NA	0.4	8.77	0.33	1.56e-17	Coronary artery calcification;
BRCA	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg13010199	chr12:38710504	ALG10B	-0.52	-10.49	-0.38	7.48e-24	Bladder cancer;
BRCA	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-14.8	-0.51	7.97e-43	Total cholesterol levels;
BRCA	cis	rs4363385	0.747	rs4845332	chr1:152982632	C/T	cg24667326	chr1:152973720	SPRR3	-0.35	-9.87	-0.36	1.81e-21	Inflammatory skin disease;
BRCA	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg21770322	chr7:97807741	LMTK2	0.4	10.38	0.38	1.96e-23	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18876405	chr7:65276391	NA	-0.48	-10.46	-0.38	9.72e-24	Aortic root size;
BRCA	trans	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg04455712	chr21:45112962	RRP1B	-0.36	-8.79	-0.33	1.35e-17	Mean corpuscular volume;
BRCA	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-8.93	-0.33	4.55e-18	Schizophrenia;
BRCA	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg02951883	chr7:2050386	MAD1L1	-0.39	-8.7	-0.33	2.9e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.56	8.77	0.33	1.6e-17	Lung function (FEV1/FVC);
BRCA	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg27147174	chr7:100797783	AP1S1	-0.54	-10.84	-0.39	2.87e-25	Life satisfaction;
BRCA	cis	rs1030877	0.960	rs3792050	chr2:105902255	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.67	-15.99	-0.53	1.15e-48	Obesity-related traits;
BRCA	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg06784218	chr1:46089804	CCDC17	0.44	10.65	0.39	1.65e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-10.27	-0.38	5.17e-23	Longevity;Endometriosis;
BRCA	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg24110177	chr3:50126178	RBM5	0.5	14.23	0.49	4.17e-40	Body mass index;
BRCA	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg21475434	chr5:93447410	FAM172A	0.65	8.65	0.32	4e-17	Diabetic retinopathy;
BRCA	cis	rs3768617	0.811	rs61808068	chr1:182979377	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.88	0.36	1.55e-21	Fuchs's corneal dystrophy;
BRCA	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg06115741	chr20:33292138	TP53INP2	-0.5	-11.27	-0.41	5.51e-27	Coronary artery disease;
BRCA	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg05729581	chr11:3078854	CARS	-0.34	-8.31	-0.31	5.79e-16	Longevity;
BRCA	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.28	0.34	2.56e-19	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.56	-14.29	-0.49	2.19e-40	Electrocardiographic conduction measures;
BRCA	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg18446336	chr7:2847575	GNA12	-0.41	-9.3	-0.35	2.17e-19	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
BRCA	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg11057378	chr10:81107060	PPIF	0.39	8.87	0.33	7.03e-18	Height;
BRCA	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	11.69	0.42	9.87e-29	Schizophrenia;
BRCA	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg19183879	chr15:85880815	NA	0.32	7.87	0.3	1.48e-14	Coronary artery disease;
BRCA	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg20701182	chr2:24300061	SF3B14	0.58	9.02	0.34	2.15e-18	Lymphocyte counts;
BRCA	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.64	-17.83	-0.58	5.23e-58	Schizophrenia;
BRCA	cis	rs7523050	0.643	rs7522324	chr1:109399644	T/C	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg14847009	chr1:175162515	KIAA0040	0.25	9.63	0.36	1.38e-20	Alcohol dependence;
BRCA	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg02574844	chr11:5959923	NA	-0.42	-8.17	-0.31	1.61e-15	DNA methylation (variation);
BRCA	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2806561	1.000	rs681753	chr1:23515216	T/C	cg19743168	chr1:23544995	NA	0.43	10.59	0.39	2.92e-24	Height;
BRCA	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg23131131	chr22:24373011	LOC391322	-0.46	-10.71	-0.39	1e-24	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1403694	0.695	rs3821815	chr3:186434262	A/G	cg12454167	chr3:186435060	KNG1	0.3	8.16	0.31	1.74e-15	Blood protein levels;
BRCA	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs9788721	0.806	rs4887056	chr15:78734585	A/G	cg18825076	chr15:78729989	IREB2	-0.4	-8.28	-0.31	7.31e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg02403541	chr12:121454288	C12orf43	-0.51	-9.68	-0.36	9.26e-21	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
BRCA	trans	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg06636001	chr8:8085503	FLJ10661	0.47	9.01	0.34	2.38e-18	Neuroticism;
BRCA	cis	rs11608355	0.545	rs918107	chr12:109904198	C/T	cg05360138	chr12:110035743	NA	-0.71	-13.07	-0.46	9.4e-35	Neuroticism;
BRCA	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg20203395	chr5:56204925	C5orf35	0.5	10.31	0.38	3.66e-23	Initial pursuit acceleration;
BRCA	cis	rs8032158	1.000	rs8026172	chr15:56125182	T/A	cg02198044	chr15:56286336	NEDD4	-0.38	-9.04	-0.34	1.8e-18	Keloid;
BRCA	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	14.07	0.49	2.42e-39	Lymphocyte counts;
BRCA	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00149659	chr3:10157352	C3orf10	0.79	13.72	0.48	9.53e-38	Alzheimer's disease;
BRCA	cis	rs4862307	0.836	rs4862304	chr4:184996607	C/T	cg06737308	chr4:185021514	ENPP6	0.41	9.27	0.34	2.82e-19	Serum dimethylarginine levels (asymmetric/symetric ratio);
BRCA	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.77	-15.92	-0.53	2.71e-48	HIV-1 control;
BRCA	cis	rs1511802	0.501	rs7683132	chr4:187116039	A/G	cg24794857	chr4:187113578	CYP4V2	0.36	7.91	0.3	1.12e-14	Blood protein levels;
BRCA	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.69	-15.62	-0.53	7.93e-47	Axial length;
BRCA	cis	rs61990749	0.544	rs2544566	chr14:78181738	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.64	10.06	0.37	3.36e-22	Fibroblast growth factor basic levels;
BRCA	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg25237894	chr2:233734115	C2orf82	-0.4	-11.55	-0.42	3.53e-28	Coronary artery disease;
BRCA	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg21385522	chr1:16154831	NA	0.88	16.45	0.55	5.94e-51	Dilated cardiomyopathy;
BRCA	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	11.91	0.43	1.13e-29	Height;
BRCA	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg00383909	chr3:49044727	WDR6	0.93	15.37	0.52	1.34e-45	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg11584989	chr19:19387371	SF4	0.63	13.52	0.47	7.85e-37	Bipolar disorder;
BRCA	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13732083	chr21:47605072	C21orf56	0.37	7.95	0.3	8.68e-15	Testicular germ cell tumor;
BRCA	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg05025164	chr4:1340916	KIAA1530	0.43	9.62	0.36	1.53e-20	Longevity;
BRCA	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg16743903	chr16:89593216	SPG7	0.4	9.7	0.36	7.37e-21	Multiple myeloma (IgH translocation);
BRCA	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg03676636	chr4:99064102	C4orf37	0.23	8.26	0.31	8.59e-16	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg04842962	chr6:43655489	MRPS18A	1.11	38.51	0.84	1.1e-168	IgG glycosylation;
BRCA	cis	rs13064411	0.866	rs35278902	chr3:113239021	A/G	cg18753928	chr3:113234510	CCDC52	-0.59	-9.62	-0.36	1.55e-20	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs4363385	0.818	rs2070964	chr1:153004213	C/T	cg25856811	chr1:152973957	SPRR3	-0.31	-8.12	-0.31	2.32e-15	Inflammatory skin disease;
BRCA	trans	rs1459104	1.000	rs35317943	chr11:55274857	C/T	cg15704280	chr7:45808275	SEPT13	0.65	8.14	0.31	2.12e-15	Body mass index;
BRCA	cis	rs7178424	0.764	rs11634163	chr15:62330633	C/T	cg00456672	chr15:62358751	C2CD4A	-0.41	-9.02	-0.34	2.14e-18	Height;
BRCA	cis	rs3916	0.955	rs2066938	chr12:121160615	A/G	cg21892295	chr12:121157589	UNC119B	-0.36	-9.72	-0.36	6.33e-21	Urinary metabolites (H-NMR features);
BRCA	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg09307838	chr4:120376055	NA	0.72	15.37	0.52	1.39e-45	Corneal astigmatism;
BRCA	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg25767906	chr1:53392781	SCP2	0.52	10.98	0.4	8.37e-26	Monocyte count;
BRCA	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg15145296	chr3:125709740	NA	-0.5	-8.57	-0.32	7.55e-17	Blood pressure (smoking interaction);
BRCA	cis	rs4588572	0.643	rs6453396	chr5:77785387	T/C	cg11547950	chr5:77652471	NA	-0.48	-8.44	-0.32	2.05e-16	Triglycerides;
BRCA	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg19257562	chr1:2043853	PRKCZ	0.31	8.48	0.32	1.59e-16	Height;
BRCA	cis	rs700651	0.789	rs1978889	chr2:198889366	G/A	cg00792783	chr2:198669748	PLCL1	0.38	8.74	0.33	2.06e-17	Intracranial aneurysm;
BRCA	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	16.6	0.55	9.86e-52	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-10.94	-0.4	1.14e-25	Colorectal cancer;
BRCA	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.49	0.38	7.52e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg11663144	chr21:46675770	NA	-0.62	-14.29	-0.49	2.23e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg26384229	chr12:38710491	ALG10B	0.68	14.37	0.49	9.31e-41	Morning vs. evening chronotype;
BRCA	cis	rs36051895	0.626	rs10283564	chr9:5075628	C/G	cg02405213	chr9:5042618	JAK2	-0.55	-9.73	-0.36	5.89e-21	Pediatric autoimmune diseases;
BRCA	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg08885076	chr2:99613938	TSGA10	0.41	9.63	0.36	1.4e-20	Chronic sinus infection;
BRCA	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg17971929	chr21:40555470	PSMG1	-0.48	-10.56	-0.39	3.96e-24	Menarche (age at onset);
BRCA	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.5	0.32	1.33e-16	Aortic root size;
BRCA	cis	rs3857067	0.806	rs6532471	chr4:95108584	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.34	-0.35	1.56e-19	QT interval;
BRCA	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg11812906	chr14:75593930	NEK9	-0.62	-14.2	-0.49	5.56e-40	Height;
BRCA	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg19678392	chr7:94953810	PON1	-0.42	-9.11	-0.34	1.03e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.75	-0.33	1.96e-17	Resting heart rate;
BRCA	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	15.16	0.51	1.39e-44	Platelet count;
BRCA	cis	rs701145	0.585	rs1727946	chr3:153826470	C/T	cg17054900	chr3:154042577	DHX36	0.53	9.04	0.34	1.88e-18	Coronary artery disease;
BRCA	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.06	-28.2	-0.74	2.79e-114	Ulcerative colitis;
BRCA	cis	rs2835872	0.758	rs1709817	chr21:39036349	T/A	cg06728970	chr21:39037746	KCNJ6	0.45	12.85	0.45	9.07e-34	Electroencephalographic traits in alcoholism;
BRCA	cis	rs6598955	0.543	rs4585968	chr1:26535146	G/A	cg04990556	chr1:26633338	UBXN11	0.7	11.69	0.42	9.64e-29	Obesity-related traits;
BRCA	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg05863683	chr7:1912471	MAD1L1	0.38	8.42	0.32	2.55e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-10.58	-0.39	3.19e-24	IgG glycosylation;
BRCA	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg13628971	chr7:2884303	GNA12	0.38	8.52	0.32	1.17e-16	Height;
BRCA	cis	rs6066825	0.644	rs6125442	chr20:47331210	C/G	cg18078177	chr20:47281410	PREX1	0.39	9.52	0.35	3.58e-20	Colorectal cancer;
BRCA	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.61	-0.32	5.7e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs1459104	1.000	rs1974931	chr11:55198460	A/G	cg15704280	chr7:45808275	SEPT13	0.65	8.16	0.31	1.76e-15	Body mass index;
BRCA	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg12444411	chr7:2802554	GNA12	-0.31	-7.91	-0.3	1.14e-14	Height;
BRCA	cis	rs36051895	0.589	rs7038763	chr9:5076399	T/C	cg02405213	chr9:5042618	JAK2	-0.52	-10.09	-0.37	2.59e-22	Pediatric autoimmune diseases;
BRCA	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.32	-7.81	-0.3	2.33e-14	Total body bone mineral density;
BRCA	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-10.47	-0.38	9.18e-24	Retinal vascular caliber;
BRCA	cis	rs4845875	0.626	rs6540999	chr1:11833366	A/G	cg24844545	chr1:11908347	NPPA	0.31	7.85	0.3	1.8e-14	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-9.6	-0.36	1.78e-20	Mood instability;
BRCA	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.23e-23	Motion sickness;
BRCA	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.59	-13.46	-0.47	1.49e-36	Longevity;Endometriosis;
BRCA	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg01475377	chr6:109611718	NA	-0.52	-12.99	-0.46	2.19e-34	Reticulocyte fraction of red cells;
BRCA	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09256448	chr16:638327	NA	0.3	7.88	0.3	1.37e-14	Height;
BRCA	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg00383909	chr3:49044727	WDR6	0.78	13.01	0.46	1.69e-34	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs7766436	0.885	rs12111199	chr6:22578106	C/T	cg13666174	chr6:22585274	NA	-0.49	-11.29	-0.41	4.4e-27	Coronary artery disease;
BRCA	cis	rs897080	0.515	rs2616449	chr2:44597262	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	9.64	0.36	1.28e-20	Height;
BRCA	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.69	0.32	3.15e-17	Rheumatoid arthritis;
BRCA	cis	rs7246657	0.722	rs1975937	chr19:38091932	A/T	cg14683738	chr19:37701593	ZNF585B	0.46	7.89	0.3	1.33e-14	Coronary artery calcification;
BRCA	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.51	-0.47	9.38e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.64	0.39	1.93e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03517284	chr6:25882590	NA	-0.5	-10.12	-0.37	1.91e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs17601876	0.778	rs11632926	chr15:51564226	G/A	cg19946085	chr15:51559439	CYP19A1	-0.38	-11.12	-0.4	2.3e-26	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs701145	0.585	rs1713839	chr3:153829105	A/G	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.2e-14	Coronary artery disease;
BRCA	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.38	0.38	2.01e-23	Cognitive ability;
BRCA	cis	rs965469	0.779	rs57373308	chr20:3314715	G/C	cg25506879	chr20:3388711	C20orf194	-0.43	-8.55	-0.32	9.25e-17	IFN-related cytopenia;
BRCA	trans	rs3857536	0.776	rs6941904	chr6:66931042	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.08	-0.3	3.22e-15	Blood trace element (Cu levels);
BRCA	cis	rs16958440	0.867	rs77615793	chr18:44684464	C/G	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	trans	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-7.86	-0.3	1.65e-14	Menarche (age at onset);
BRCA	cis	rs1043763	0.826	rs4075625	chr12:122610593	A/T	cg14400030	chr12:122498111	BCL7A	-0.62	-13.86	-0.48	2.27e-38	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
BRCA	cis	rs3857067	0.740	rs6532470	chr4:95108211	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.34	-0.35	1.56e-19	QT interval;
BRCA	cis	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg06521331	chr12:34319734	NA	-0.44	-8.06	-0.3	3.7e-15	Resting heart rate;
BRCA	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg11752832	chr7:134001865	SLC35B4	0.43	9.75	0.36	5.02e-21	Mean platelet volume;
BRCA	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg02297831	chr4:17616191	MED28	0.38	8.81	0.33	1.15e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg01620082	chr3:125678407	NA	-0.7	-8.74	-0.33	2e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg22920501	chr2:26401640	FAM59B	-0.65	-11.32	-0.41	3.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26314531	chr2:26401878	FAM59B	-0.63	-10.83	-0.39	3.28e-25	Gut microbiome composition (summer);
BRCA	trans	rs9409565	0.826	rs2769813	chr9:97151194	C/T	cg05679027	chr9:99775184	HIATL2	0.42	9.23	0.34	3.86e-19	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg26384229	chr12:38710491	ALG10B	0.67	15.92	0.53	2.53e-48	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg26769984	chr7:1090371	C7orf50	0.64	11.34	0.41	2.67e-27	Bronchopulmonary dysplasia;
BRCA	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg03351412	chr1:154909251	PMVK	0.61	14.21	0.49	5.26e-40	Prostate cancer;
BRCA	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10802521	chr3:52805072	NEK4	0.34	9.42	0.35	8.39e-20	Bipolar disorder;
BRCA	trans	rs1997103	0.705	rs56301138	chr7:55396555	G/T	cg20935933	chr6:143382018	AIG1	0.6	11.52	0.41	4.77e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg16606324	chr3:10149918	C3orf24	0.46	7.96	0.3	7.96e-15	Alzheimer's disease;
BRCA	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg20290983	chr6:43655470	MRPS18A	1.11	41.43	0.85	3.52e-183	IgG glycosylation;
BRCA	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg12935359	chr14:103987150	CKB	-0.52	-12.39	-0.44	9.56e-32	Intelligence (multi-trait analysis);
BRCA	trans	rs3857536	0.706	rs7749120	chr6:66889832	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-9.67	-0.36	1.01e-20	Blood trace element (Cu levels);
BRCA	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11764359	chr7:65958608	NA	-0.78	-17.68	-0.57	3.13e-57	Aortic root size;
BRCA	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg13256891	chr4:100009986	ADH5	0.53	12.29	0.44	2.71e-31	Alcohol dependence;
BRCA	cis	rs7254827	1.000	rs4808567	chr19:17215381	C/T	cg19418318	chr19:17219073	MYO9B	-0.49	-10.21	-0.37	8.7e-23	Mean platelet volume;
BRCA	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.23	0.38	7.64e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs524281	0.861	rs10750780	chr11:65974592	G/A	cg16950941	chr11:66035639	RAB1B	-0.38	-8.05	-0.3	3.97e-15	Electroencephalogram traits;
BRCA	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg08885076	chr2:99613938	TSGA10	-0.59	-13.08	-0.46	8e-35	Chronic sinus infection;
BRCA	cis	rs332507	0.830	rs1846892	chr3:124399293	A/G	cg05980111	chr3:124395277	KALRN	0.36	8.39	0.32	3.03e-16	Plateletcrit;
BRCA	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg17971929	chr21:40555470	PSMG1	0.79	18.87	0.6	1.9e-63	Cognitive function;
BRCA	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg08885076	chr2:99613938	TSGA10	-0.49	-9.69	-0.36	8.33e-21	Chronic sinus infection;
BRCA	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg27490568	chr2:178487706	NA	-0.54	-8.58	-0.32	7.16e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7539409	0.651	rs969724	chr1:84300712	T/G	cg10977910	chr1:84465055	TTLL7	0.7	10.59	0.39	2.94e-24	Alzheimer's disease;
BRCA	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	18.8	0.6	4.08e-63	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg01324343	chr3:183735012	ABCC5	0.49	11.21	0.41	9.36e-27	Anterior chamber depth;
BRCA	cis	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg09307838	chr4:120376055	NA	0.46	9.63	0.36	1.42e-20	Diastolic blood pressure;
BRCA	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg18132916	chr6:79620363	NA	0.47	10.44	0.38	1.15e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs9309711	0.736	rs13409102	chr2:3496321	G/A	cg10845886	chr2:3471009	TTC15	-0.67	-13.12	-0.46	5.44e-35	Neurofibrillary tangles;
BRCA	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg26168224	chr5:2018326	NA	0.64	17.74	0.57	1.49e-57	Gut microbiome composition (winter);
BRCA	cis	rs9427116	0.502	rs9427104	chr1:154589232	C/T	cg17218026	chr1:154582156	ADAR	0.28	8.47	0.32	1.74e-16	Blood protein levels;
BRCA	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.58	0.65	5.31e-78	Lymphocyte percentage of white cells;
BRCA	cis	rs3768617	0.903	rs10911251	chr1:183081194	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.49	11.29	0.41	4.51e-27	Fuchs's corneal dystrophy;
BRCA	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08704250	chr15:31115839	NA	-0.42	-11.03	-0.4	5.21e-26	Huntington's disease progression;
BRCA	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.43	9.48	0.35	5.05e-20	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.43	-0.32	2.31e-16	Total body bone mineral density;
BRCA	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg25237894	chr2:233734115	C2orf82	0.39	11.16	0.4	1.59e-26	Coronary artery disease;
BRCA	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.77	0.67	1.63e-84	Chronic sinus infection;
BRCA	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.17	0.49	7.85e-40	Motion sickness;
BRCA	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg18351406	chr4:77819688	ANKRD56	0.58	12.68	0.45	5.06e-33	Emphysema distribution in smoking;
BRCA	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg11752832	chr7:134001865	SLC35B4	0.52	13.55	0.47	6.19e-37	Mean platelet volume;
BRCA	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg16179182	chr5:140090404	VTRNA1-1	0.43	10.14	0.37	1.68e-22	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg23262073	chr20:60523788	NA	-0.4	-8.89	-0.33	6.37e-18	Body mass index;
BRCA	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21659725	chr3:3221576	CRBN	-0.71	-21.91	-0.65	8.31e-80	Intelligence (multi-trait analysis);
BRCA	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg24631222	chr15:78858424	CHRNA5	0.46	9.68	0.36	8.67e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg08917208	chr2:24149416	ATAD2B	1.12	15.97	0.53	1.45e-48	Lymphocyte counts;
BRCA	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg02176678	chr2:219576539	TTLL4	0.44	11.53	0.42	4.3e-28	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1400816	0.850	rs6433313	chr2:172657696	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.5	-7.94	-0.3	9.31e-15	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs4880487	0.888	rs67456501	chr10:1252400	G/A	cg03183215	chr10:1252341	ADARB2	-0.39	-8.8	-0.33	1.32e-17	Migraine;
BRCA	cis	rs61931739	0.500	rs11836207	chr12:34315177	G/A	cg06521331	chr12:34319734	NA	-0.67	-13.9	-0.48	1.42e-38	Morning vs. evening chronotype;
BRCA	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg23231163	chr10:75533350	FUT11	-0.33	-8.65	-0.32	4.07e-17	Inflammatory bowel disease;
BRCA	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-12.58	-0.45	1.38e-32	Alzheimer's disease;
BRCA	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg14863265	chr7:2801509	GNA12	-0.45	-9.76	-0.36	4.72e-21	Height;
BRCA	cis	rs11858210	1	rs11858210	chr15:79078358	G/A	cg04896959	chr15:78267971	NA	0.37	8.55	0.32	9.24e-17	Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs6545883	0.894	rs2694643	chr2:61604383	A/G	cg15711740	chr2:61764176	XPO1	-0.5	-12.2	-0.43	6.39e-31	Tuberculosis;
BRCA	cis	rs588177	0.613	rs3782101	chr11:64131280	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	0.33	8.21	0.31	1.18e-15	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	trans	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.54	-0.35	3.06e-20	Bladder cancer;
BRCA	cis	rs1476670	0.690	rs6677372	chr1:44505789	G/A	cg09470012	chr1:44509516	NA	0.37	8.31	0.31	5.67e-16	Eotaxin levels;
BRCA	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.57	10.18	0.37	1.13e-22	Gut microbiome composition (summer);
BRCA	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg04414720	chr1:150670196	GOLPH3L	0.36	8.12	0.31	2.4e-15	Tonsillectomy;
BRCA	cis	rs7552167	0.925	rs3932666	chr1:24511566	G/A	cg01960748	chr1:24522592	NA	-0.62	-10.17	-0.37	1.23e-22	Psoriasis vulgaris;
BRCA	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg21644426	chr2:191273491	MFSD6	0.44	11.39	0.41	1.7e-27	Pulse pressure;
BRCA	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg06698575	chr12:117470875	NA	-0.46	-8.29	-0.31	6.64e-16	Subcortical brain region volumes;Hippocampal volume;
BRCA	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	13.53	0.47	7.65e-37	Mood instability;
BRCA	cis	rs9807989	0.507	rs1592459	chr2:103031569	A/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.37	0.31	3.62e-16	Asthma;
BRCA	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg09021430	chr5:549028	NA	-0.65	-23.19	-0.68	9.09e-87	Obesity-related traits;
BRCA	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg27170947	chr2:26402098	FAM59B	0.98	17.2	0.56	9.41e-55	Gut microbiome composition (summer);
BRCA	cis	rs977987	0.806	rs8050769	chr16:75388434	C/T	cg03315344	chr16:75512273	CHST6	0.51	11.91	0.43	1.16e-29	Dupuytren's disease;
BRCA	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-12.8	-0.45	1.48e-33	Systolic blood pressure;
BRCA	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg24692254	chr21:30365293	RNF160	0.79	22.11	0.66	6.61e-81	Dental caries;
BRCA	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg05665937	chr4:1216051	CTBP1	0.37	7.82	0.3	2.25e-14	Obesity-related traits;
BRCA	cis	rs17401966	0.838	rs12120191	chr1:10345772	A/G	cg03954927	chr1:10346856	KIF1B	0.44	13.99	0.48	5.28e-39	Hepatocellular carcinoma;
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg03188948	chr7:1209495	NA	0.59	11.15	0.4	1.65e-26	Longevity;Endometriosis;
BRCA	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-9.13	-0.34	8.73e-19	Fear of minor pain;
BRCA	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	8.6	0.32	6.13e-17	Rheumatoid arthritis;
BRCA	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg26384229	chr12:38710491	ALG10B	0.58	13.11	0.46	5.78e-35	Morning vs. evening chronotype;
BRCA	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg06238570	chr21:40685208	BRWD1	-0.39	-8.03	-0.3	4.59e-15	Menarche (age at onset);
BRCA	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08564027	chr20:61660810	NA	0.85	22.6	0.67	1.54e-83	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg13010199	chr12:38710504	ALG10B	0.43	9.08	0.34	1.35e-18	Morning vs. evening chronotype;
BRCA	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	10.17	0.37	1.24e-22	Lung cancer in ever smokers;
BRCA	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg27170947	chr2:26402098	FAM59B	-0.66	-11.24	-0.41	7.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.28	-0.31	7.06e-16	Aortic root size;
BRCA	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg06453172	chr10:134556979	INPP5A	-0.53	-11.27	-0.41	5.55e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-11.01	-0.4	6.16e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg23625390	chr15:77176239	SCAPER	-0.57	-14.85	-0.51	4.61e-43	Blood metabolite levels;
BRCA	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg24531977	chr5:56204891	C5orf35	-0.63	-12.58	-0.45	1.39e-32	Type 2 diabetes;
BRCA	cis	rs919433	0.648	rs3097384	chr2:198278834	T/A	cg00792783	chr2:198669748	PLCL1	0.38	8.56	0.32	8.15e-17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg17410650	chr12:54324560	NA	-0.42	-10.33	-0.38	3.08e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
BRCA	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	9.62	0.36	1.52e-20	Bipolar disorder;
BRCA	cis	rs6121246	0.559	rs6060919	chr20:30331922	A/T	cg13852791	chr20:30311386	BCL2L1	0.96	23.39	0.68	6.61e-88	Mean corpuscular hemoglobin;
BRCA	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg06046430	chr4:77819534	ANKRD56	0.58	12.94	0.46	3.41e-34	Emphysema distribution in smoking;
BRCA	cis	rs1863824	0.625	rs12354988	chr10:88155204	G/A	cg07322936	chr10:88137208	NA	-0.44	-8.74	-0.33	2.07e-17	Schizophrenia;
BRCA	cis	rs36051895	0.589	rs17492549	chr9:5202830	A/C	cg02405213	chr9:5042618	JAK2	-0.43	-8.02	-0.3	5.09e-15	Pediatric autoimmune diseases;
BRCA	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg23711669	chr6:146136114	FBXO30	0.72	17.51	0.57	2.19e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs250677	0.522	rs11954893	chr5:148392362	A/G	cg12140854	chr5:148520817	ABLIM3	-0.42	-8.53	-0.32	1.06e-16	Breast cancer;
BRCA	trans	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg02030672	chr11:45687055	CHST1	0.47	10.63	0.39	2.04e-24	Obesity-related traits;
BRCA	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg16482183	chr6:26056742	HIST1H1C	0.5	10.29	0.38	4.31e-23	Height;
BRCA	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.09	0.49	1.88e-39	Eye color traits;
BRCA	cis	rs6558530	0.587	rs6986102	chr8:1700640	C/G	cg19131313	chr8:1704013	NA	-0.4	-8.03	-0.3	4.85e-15	Systolic blood pressure;
BRCA	cis	rs4722585	0.605	rs3753098	chr7:26198040	C/T	cg07876897	chr7:26191696	NFE2L3	-0.42	-9.18	-0.34	5.97e-19	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
BRCA	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg27535305	chr1:53392650	SCP2	-0.4	-10.0	-0.37	5.49e-22	Monocyte count;
BRCA	trans	rs11227306	0.934	rs11227315	chr11:65590389	C/A	cg17712092	chr4:129076599	LARP1B	0.43	8.77	0.33	1.67e-17	DNA methylation (variation);
BRCA	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg12165864	chr7:66369176	NA	-0.44	-9.9	-0.36	1.33e-21	Corneal structure;
BRCA	cis	rs829883	0.659	rs11109521	chr12:98930809	C/A	cg25150519	chr12:98850993	NA	-0.5	-9.1	-0.34	1.1e-18	Colorectal adenoma (advanced);
BRCA	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg22467129	chr15:76604101	ETFA	-0.49	-10.62	-0.39	2.22e-24	Blood metabolite levels;
BRCA	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg24642844	chr7:1081250	C7orf50	-0.89	-16.0	-0.53	1.07e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg23711669	chr6:146136114	FBXO30	0.68	15.51	0.52	2.88e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg18446336	chr7:2847575	GNA12	-0.35	-8.25	-0.31	8.91e-16	Height;
BRCA	cis	rs3820928	0.874	rs4234063	chr2:227828335	A/T	cg11843606	chr2:227700838	RHBDD1	0.39	8.64	0.32	4.4e-17	Pulmonary function;
BRCA	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg05279229	chr7:1896384	MAD1L1	-0.42	-8.35	-0.31	4.15e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs9329289	0.610	rs10903783	chr10:2540623	C/T	cg15501526	chr10:2543763	NA	0.44	10.19	0.37	1.04e-22	Age-related hearing impairment;
BRCA	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg04586622	chr2:25135609	ADCY3	0.46	11.66	0.42	1.3e-28	Body mass index;
BRCA	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.36	0.31	3.79e-16	Tonsillectomy;
BRCA	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg15017067	chr4:17643749	FAM184B	0.29	8.93	0.33	4.39e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg11645453	chr3:52864694	ITIH4	-0.37	-9.76	-0.36	4.58e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6484504	0.532	rs11031342	chr11:31309818	G/A	cg06552810	chr11:31128660	NA	-0.4	-8.89	-0.33	6.19e-18	Red blood cell count;
BRCA	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg13319975	chr6:146136371	FBXO30	0.42	9.39	0.35	1.02e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2415984	0.600	rs72672853	chr14:46932920	T/G	cg14871534	chr14:47121158	RPL10L	-0.37	-8.82	-0.33	1.12e-17	Number of children ever born;
BRCA	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg25036284	chr2:26402008	FAM59B	-0.64	-10.69	-0.39	1.22e-24	Gut microbiome composition (summer);
BRCA	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg08917208	chr2:24149416	ATAD2B	0.57	9.07	0.34	1.43e-18	Lymphocyte counts;
BRCA	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg10253484	chr15:75165896	SCAMP2	-0.59	-11.45	-0.41	9.57e-28	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	9.14	0.34	7.92e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs6479891	1.000	rs9415701	chr10:65151509	T/C	cg14819942	chr15:35414228	NA	0.36	8.77	0.33	1.57e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs1267303	0.675	rs1267312	chr1:46986748	C/G	cg25110126	chr1:46999211	NA	-0.5	-9.53	-0.35	3.34e-20	Monobrow;
BRCA	cis	rs7707921	0.767	rs862245	chr5:81585737	A/C	cg15871215	chr5:81402204	ATG10	-0.35	-8.18	-0.31	1.52e-15	Breast cancer;
BRCA	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg14689365	chr7:158441557	NCAPG2	-0.42	-8.51	-0.32	1.2e-16	Height;
BRCA	cis	rs10754283	0.967	rs10922679	chr1:90100925	T/C	cg21401794	chr1:90099060	LRRC8C	0.46	11.31	0.41	3.76e-27	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg09436375	chr6:42928200	GNMT	-0.29	-10.67	-0.39	1.46e-24	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg12311346	chr5:56204834	C5orf35	-0.78	-15.35	-0.52	1.67e-45	Initial pursuit acceleration;
BRCA	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg13319975	chr6:146136371	FBXO30	0.39	9.02	0.34	2.21e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg21361702	chr7:150065534	REPIN1	0.46	8.15	0.31	1.91e-15	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs4074536	0.622	rs10754365	chr1:116325219	T/C	cg21648376	chr1:116311395	CASQ2	-0.54	-8.81	-0.33	1.2e-17	QRS duration;
BRCA	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg27661571	chr11:113659931	NA	-0.81	-11.96	-0.43	6.92e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg22920501	chr2:26401640	FAM59B	0.94	16.34	0.54	1.98e-50	Gut microbiome composition (summer);
BRCA	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg23711669	chr6:146136114	FBXO30	0.72	17.29	0.56	3.25e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg16414030	chr3:133502952	NA	-0.48	-11.15	-0.4	1.69e-26	Iron status biomarkers;
BRCA	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-9.49	-0.35	4.68e-20	Menopause (age at onset);
BRCA	cis	rs9341808	0.538	rs688867	chr6:80939228	A/G	cg08355045	chr6:80787529	NA	0.32	7.83	0.3	1.99e-14	Sitting height ratio;
BRCA	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg23711669	chr6:146136114	FBXO30	0.73	17.65	0.57	4.45e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.63	13.13	0.46	5.15e-35	Monocyte percentage of white cells;
BRCA	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg18753928	chr3:113234510	CCDC52	-0.58	-12.22	-0.44	5.01e-31	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg11752832	chr7:134001865	SLC35B4	0.53	13.58	0.47	4.23e-37	Mean platelet volume;
BRCA	cis	rs9790314	0.779	rs1609688	chr3:160877096	T/G	cg04691961	chr3:161091175	C3orf57	-0.49	-10.86	-0.39	2.38e-25	Morning vs. evening chronotype;
BRCA	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.45	-10.07	-0.37	3.15e-22	Height;
BRCA	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg06937882	chr20:24974362	C20orf3	0.46	9.24	0.34	3.72e-19	Blood protein levels;
BRCA	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg24006582	chr15:45444508	DUOX1	-0.55	-11.4	-0.41	1.58e-27	Uric acid levels;
BRCA	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg27129171	chr3:47204927	SETD2	0.6	13.06	0.46	1.01e-34	Colorectal cancer;
BRCA	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg02297831	chr4:17616191	MED28	0.37	8.58	0.32	6.97e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg02176678	chr2:219576539	TTLL4	0.38	10.2	0.37	9.8e-23	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs58235267	0.553	rs1025132	chr2:63360639	G/A	cg17519650	chr2:63277830	OTX1	0.4	8.42	0.32	2.55e-16	Prostate-specific antigen levels (conditioned on lead SNPs);
BRCA	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg16850897	chr7:100343110	ZAN	-0.59	-12.54	-0.44	2.18e-32	Other erythrocyte phenotypes;
BRCA	cis	rs4974559	0.739	rs6599298	chr4:1298122	A/G	cg02980000	chr4:1222292	CTBP1	0.81	13.38	0.47	3.78e-36	Systolic blood pressure;
BRCA	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg13334819	chr7:99746414	C7orf59	0.39	9.01	0.34	2.32e-18	Coronary artery disease;
BRCA	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg01689657	chr7:91764605	CYP51A1	0.23	8.32	0.31	5.44e-16	Breast cancer;
BRCA	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg02403541	chr12:121454288	C12orf43	0.54	10.04	0.37	4.14e-22	N-glycan levels;
BRCA	cis	rs3936840	0.539	rs3742441	chr14:102970581	C/G	cg18135206	chr14:102964638	TECPR2	0.45	8.61	0.32	5.48e-17	Plateletcrit;
BRCA	cis	rs11051970	0.879	rs10844201	chr12:32575029	A/G	cg02745156	chr12:32552066	NA	0.28	9.0	0.34	2.64e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs6484504	0.576	rs208088	chr11:31192686	T/C	cg14844989	chr11:31128820	NA	-0.44	-9.52	-0.35	3.45e-20	Red blood cell count;
BRCA	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg23978390	chr7:1156363	C7orf50	0.35	8.17	0.31	1.7e-15	Longevity;Endometriosis;
BRCA	cis	rs490234	0.841	rs829314	chr9:128415506	A/T	cg14078157	chr9:128172775	NA	0.33	7.87	0.3	1.47e-14	Mean arterial pressure;
BRCA	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg12193833	chr17:30244370	NA	-0.56	-8.23	-0.31	1.03e-15	Hip circumference adjusted for BMI;
BRCA	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg26384229	chr12:38710491	ALG10B	0.75	16.64	0.55	6.07e-52	Morning vs. evening chronotype;
BRCA	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg08755490	chr11:65554678	OVOL1	0.52	10.88	0.4	2.11e-25	Acne (severe);
BRCA	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg22105103	chr4:187893119	NA	0.41	13.27	0.46	1.16e-35	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg08645402	chr16:4508243	NA	0.38	8.99	0.34	2.74e-18	Schizophrenia;
BRCA	cis	rs6121246	0.559	rs6087779	chr20:30370566	T/C	cg13852791	chr20:30311386	BCL2L1	0.96	23.37	0.68	8.7e-88	Mean corpuscular hemoglobin;
BRCA	cis	rs35740288	0.571	rs11633790	chr15:86326370	G/A	cg20737812	chr15:86336631	KLHL25	-0.39	-9.27	-0.34	2.73e-19	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-16.92	-0.56	2.36e-53	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg21573476	chr21:45109991	RRP1B	-0.46	-12.0	-0.43	4.65e-30	Mean corpuscular volume;
BRCA	trans	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg00953403	chr17:74099816	EXOC7	0.44	8.3	0.31	6.09e-16	Psychosis in Alzheimer's disease;
BRCA	cis	rs10129255	0.530	rs11624912	chr14:107129907	A/G	cg07958169	chr14:107095056	NA	-0.38	-8.02	-0.3	4.93e-15	Kawasaki disease;
BRCA	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg08885076	chr2:99613938	TSGA10	0.45	10.64	0.39	1.8e-24	Chronic sinus infection;
BRCA	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg04450456	chr4:17643702	FAM184B	0.37	11.05	0.4	4.1e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13046373	0.507	rs8133828	chr21:32033046	C/G	cg14062083	chr21:31802829	KRTAP13-4	0.35	9.01	0.34	2.42e-18	HDL cholesterol;
BRCA	trans	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg11693508	chr17:37793320	STARD3	0.47	9.79	0.36	3.43e-21	Neuroticism;
BRCA	cis	rs9329289	0.510	rs10903785	chr10:2550063	C/T	cg15501526	chr10:2543763	NA	0.46	10.65	0.39	1.69e-24	Age-related hearing impairment;
BRCA	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg17143192	chr8:8559678	CLDN23	0.56	10.96	0.4	1.01e-25	Obesity-related traits;
BRCA	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg17063962	chr7:91808500	NA	0.53	12.57	0.45	1.52e-32	Breast cancer;
BRCA	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg23533926	chr12:111358616	MYL2	-0.43	-9.06	-0.34	1.6e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg02951883	chr7:2050386	MAD1L1	-0.38	-8.49	-0.32	1.4e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs4908768	0.501	rs7551849	chr1:8539463	A/G	cg20416874	chr1:8611966	RERE	-0.29	-8.45	-0.32	1.93e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg05623727	chr3:50126028	RBM5	-0.49	-11.71	-0.42	7.95e-29	Body mass index;
BRCA	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg04166393	chr7:2884313	GNA12	0.41	8.74	0.33	1.98e-17	Height;
BRCA	cis	rs4363385	0.818	rs4452994	chr1:152986871	G/A	cg24667326	chr1:152973720	SPRR3	-0.32	-8.91	-0.33	5.26e-18	Inflammatory skin disease;
BRCA	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg24692254	chr21:30365293	RNF160	-0.58	-14.53	-0.5	1.62e-41	Dental caries;
BRCA	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg09307838	chr4:120376055	NA	0.64	13.92	0.48	1.13e-38	Corneal astigmatism;
BRCA	trans	rs9409565	0.762	rs60964095	chr9:97175774	G/T	cg05679027	chr9:99775184	HIATL2	-0.42	-9.27	-0.34	2.71e-19	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs7523050	0.908	rs12036331	chr1:109398707	A/T	cg08274380	chr1:109419600	GPSM2	0.75	11.68	0.42	1.05e-28	Fat distribution (HIV);
BRCA	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg22920501	chr2:26401640	FAM59B	-0.65	-11.32	-0.41	3.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs6740322	0.696	rs10188539	chr2:43484675	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.75	-14.51	-0.5	1.92e-41	Coronary artery disease;
BRCA	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg07917127	chr4:99064746	C4orf37	0.42	7.97	0.3	7.51e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg02153584	chr22:29168773	CCDC117	0.52	10.8	0.39	4.38e-25	Lymphocyte counts;
BRCA	cis	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg07460842	chr6:66804631	NA	-0.62	-13.48	-0.47	1.22e-36	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg05714579	chr10:131428358	MGMT	0.53	12.05	0.43	2.88e-30	Response to temozolomide;
BRCA	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg09307838	chr4:120376055	NA	0.72	15.26	0.52	4.91e-45	Corneal astigmatism;
BRCA	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	10.01	0.37	5.19e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg06784218	chr1:46089804	CCDC17	0.5	12.02	0.43	3.88e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	12.98	0.46	2.22e-34	Colorectal cancer;
BRCA	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg23711669	chr6:146136114	FBXO30	0.8	19.0	0.6	4e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg20887711	chr4:1340912	KIAA1530	0.64	13.84	0.48	2.78e-38	Longevity;
BRCA	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg00012203	chr2:219082015	ARPC2	0.61	12.84	0.45	9.89e-34	Colorectal cancer;
BRCA	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.2e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.05	15.99	0.53	1.18e-48	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg05283184	chr6:79620031	NA	-0.44	-11.54	-0.42	4e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs2425143	1.000	rs11907811	chr20:34428078	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.81	-0.33	1.19e-17	Blood protein levels;
BRCA	cis	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg07460842	chr6:66804631	NA	1.03	28.26	0.75	1.26e-114	Exhaled nitric oxide output;
BRCA	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg23711669	chr6:146136114	FBXO30	0.71	17.11	0.56	2.46e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg00071950	chr4:10020882	SLC2A9	0.6	14.67	0.5	3.44e-42	Bone mineral density;
BRCA	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg14349672	chr11:133703707	NA	-0.44	-9.7	-0.36	7.89e-21	Childhood ear infection;
BRCA	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg21280719	chr6:42927975	GNMT	-0.31	-13.09	-0.46	7.62e-35	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg05347473	chr6:146136440	FBXO30	0.42	8.3	0.31	6.2e-16	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg20290983	chr6:43655470	MRPS18A	0.94	22.31	0.66	5.5e-82	IgG glycosylation;
BRCA	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19748678	chr4:122722346	EXOSC9	0.71	15.18	0.51	1.18e-44	Type 2 diabetes;
BRCA	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg13385521	chr17:29058706	SUZ12P	0.63	8.58	0.32	7.12e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg27432699	chr2:27873401	GPN1	0.47	10.09	0.37	2.63e-22	Oral cavity cancer;
BRCA	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-11.12	-0.4	2.21e-26	Gut microbiome composition (summer);
BRCA	trans	rs8073060	0.586	rs8074800	chr17:33979148	A/G	cg19694781	chr19:47549865	TMEM160	0.99	22.28	0.66	8.71e-82	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg21970626	chr13:21893289	NA	-0.43	-8.91	-0.33	5.33e-18	White matter hyperintensity burden;
BRCA	cis	rs6028335	0.610	rs12624839	chr20:37573816	G/A	cg16355469	chr20:37678765	NA	0.44	8.07	0.3	3.62e-15	Alcohol and nicotine co-dependence;
BRCA	trans	rs2840044	1.000	rs9891800	chr17:33895015	G/C	cg19694781	chr19:47549865	TMEM160	0.46	10.92	0.4	1.37e-25	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg08508325	chr11:3079039	CARS	-0.43	-15.72	-0.53	2.64e-47	Longevity;
BRCA	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00339695	chr16:24857497	SLC5A11	0.34	8.17	0.31	1.69e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg24531977	chr5:56204891	C5orf35	-0.53	-10.86	-0.39	2.56e-25	Coronary artery disease;
BRCA	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14240646	chr10:27532245	ACBD5	-0.68	-10.46	-0.38	9.55e-24	Breast cancer;
BRCA	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.43	11.87	0.43	1.63e-29	Response to bleomycin (chromatid breaks);
BRCA	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg26384229	chr12:38710491	ALG10B	0.75	17.26	0.56	4.56e-55	Bladder cancer;
BRCA	cis	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg07460842	chr6:66804631	NA	0.6	10.39	0.38	1.79e-23	Type 2 diabetes;
BRCA	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg10932868	chr11:921992	NA	0.49	12.5	0.44	3.11e-32	Alzheimer's disease (late onset);
BRCA	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg13395646	chr4:1353034	KIAA1530	-0.5	-9.12	-0.34	9.35e-19	Obesity-related traits;
BRCA	cis	rs8038465	0.662	rs57771618	chr15:73967578	T/C	cg15420318	chr15:73925796	NPTN	0.39	8.47	0.32	1.7e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg05313129	chr8:58192883	C8orf71	-0.46	-9.59	-0.35	1.91e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg27433088	chr4:174089019	GALNT7	0.28	7.83	0.3	2.02e-14	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg13852791	chr20:30311386	BCL2L1	0.84	16.5	0.55	3.24e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg24675658	chr1:53192096	ZYG11B	-0.52	-11.39	-0.41	1.77e-27	Monocyte count;
BRCA	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	9.63	0.36	1.38e-20	Personality dimensions;
BRCA	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg15839431	chr19:19639596	YJEFN3	-0.41	-9.13	-0.34	9.05e-19	Bipolar disorder;
BRCA	cis	rs4948102	0.731	rs4689	chr7:56067016	G/T	cg09872392	chr7:56161020	PHKG1	-0.39	-8.83	-0.33	9.76e-18	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg18230493	chr5:56204884	C5orf35	-0.73	-14.29	-0.49	2.21e-40	Initial pursuit acceleration;
BRCA	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg03877680	chr5:178157825	ZNF354A	0.83	16.86	0.55	4.73e-53	Neutrophil percentage of white cells;
BRCA	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22601191	chr20:60968625	CABLES2	-0.32	-7.99	-0.3	6.37e-15	Colorectal cancer;
BRCA	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg13770153	chr20:60521292	NA	-0.43	-9.51	-0.35	3.76e-20	Body mass index;
BRCA	cis	rs8017423	0.630	rs4904678	chr14:90821670	T/C	cg04374321	chr14:90722782	PSMC1	-0.49	-11.96	-0.43	6.75e-30	Mortality in heart failure;
BRCA	cis	rs10465746	0.725	rs1359331	chr1:84360301	C/A	cg10977910	chr1:84465055	TTLL7	0.6	12.8	0.45	1.53e-33	Obesity-related traits;
BRCA	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11644478	chr21:40555479	PSMG1	-0.51	-10.75	-0.39	6.88e-25	Menarche (age at onset);
BRCA	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.45	-9.19	-0.34	5.35e-19	Tonsillectomy;
BRCA	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-13.59	-0.47	4.05e-37	Migraine;Coronary artery disease;
BRCA	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg09537434	chr19:41945824	ATP5SL	-1.0	-23.64	-0.68	3e-89	Height;
BRCA	cis	rs7903847	0.620	rs2297988	chr10:99118382	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.06	-0.3	3.74e-15	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg20476274	chr7:133979776	SLC35B4	0.7	21.36	0.65	8.17e-77	Mean platelet volume;
BRCA	cis	rs9420	0.528	rs11229077	chr11:57399072	A/G	cg19752551	chr11:57585705	CTNND1	0.37	9.42	0.35	8.33e-20	Schizophrenia;
BRCA	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	9.15	0.34	7.33e-19	Educational attainment;
BRCA	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12756686	chr19:29218302	NA	0.57	10.98	0.4	8.46e-26	Methadone dose in opioid dependence;
BRCA	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg22974920	chr21:40686053	BRWD1	-0.36	-8.15	-0.31	1.99e-15	Menarche (age at onset);
BRCA	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg08807101	chr21:30365312	RNF160	-0.49	-10.97	-0.4	9.31e-26	Cognitive test performance;
BRCA	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg02544614	chr20:61657117	NA	0.28	8.16	0.31	1.75e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-11.93	-0.43	9.38e-30	Morning vs. evening chronotype;
BRCA	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg10224037	chr5:178157518	ZNF354A	0.79	18.23	0.58	4.46e-60	Neutrophil percentage of white cells;
BRCA	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-20.03	-0.62	1.28e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg00339695	chr16:24857497	SLC5A11	0.34	7.84	0.3	1.83e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs4423214	0.840	rs1792226	chr11:71176574	C/T	cg05163923	chr11:71159392	DHCR7	-0.57	-11.6	-0.42	2.31e-28	Vitamin D levels;
BRCA	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg10495392	chr1:46806563	NSUN4	0.44	8.15	0.31	1.97e-15	Menopause (age at onset);
BRCA	trans	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg25214090	chr10:38739885	LOC399744	0.36	8.12	0.31	2.48e-15	Diastolic blood pressure;
BRCA	trans	rs11039798	0.698	rs6485805	chr11:48101723	C/T	cg15704280	chr7:45808275	SEPT13	0.56	7.89	0.3	1.36e-14	Axial length;
BRCA	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg04586622	chr2:25135609	ADCY3	-0.47	-12.08	-0.43	2.17e-30	Body mass index;
BRCA	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg11366901	chr6:160182831	ACAT2	0.69	13.46	0.47	1.54e-36	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24229701	chr12:130821962	PIWIL1	0.39	8.91	0.33	5.31e-18	Menopause (age at onset);
BRCA	cis	rs9487051	0.768	rs437779	chr6:109527691	T/G	cg21918786	chr6:109611834	NA	-0.34	-9.0	-0.34	2.53e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11890956	chr21:40555474	PSMG1	1.04	29.38	0.76	1.05e-120	Cognitive function;
BRCA	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg26373071	chr5:1325741	CLPTM1L	0.45	10.58	0.39	3.32e-24	Lung cancer;
BRCA	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg19717773	chr7:2847554	GNA12	0.42	9.42	0.35	7.91e-20	Height;
BRCA	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.65	0.42	1.37e-28	Tonsillectomy;
BRCA	trans	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.34	-0.38	2.79e-23	Total cholesterol levels;
BRCA	cis	rs332507	0.830	rs3772789	chr3:124395607	A/G	cg05980111	chr3:124395277	KALRN	0.38	8.58	0.32	6.93e-17	Plateletcrit;
BRCA	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg18850127	chr7:39170497	POU6F2	0.54	11.9	0.43	1.27e-29	IgG glycosylation;
BRCA	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg18252515	chr7:66147081	NA	-0.94	-10.48	-0.38	8.39e-24	Diabetic kidney disease;
BRCA	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg24690094	chr11:67383802	NA	-0.53	-11.14	-0.4	1.77e-26	Mean corpuscular volume;
BRCA	cis	rs495337	0.720	rs6125819	chr20:48545710	T/C	cg17835207	chr20:48524531	SPATA2	-0.69	-16.8	-0.55	1.04e-52	Psoriasis;
BRCA	cis	rs9463078	0.770	rs9296453	chr6:45227432	C/T	cg25276700	chr6:44698697	NA	-0.35	-7.93	-0.3	1.01e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg19920283	chr7:105172520	RINT1	0.59	9.39	0.35	1.03e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg13010199	chr12:38710504	ALG10B	-0.38	-8.7	-0.33	2.89e-17	Morning vs. evening chronotype;
BRCA	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg20933634	chr6:27740509	NA	0.45	9.0	0.34	2.5e-18	Parkinson's disease;
BRCA	cis	rs1865721	1.000	rs3813080	chr18:73186227	C/T	cg26385618	chr18:73139727	C18orf62	-0.41	-9.29	-0.34	2.46e-19	Intelligence;
BRCA	cis	rs26949	0.503	rs1867702	chr5:59897983	T/C	cg02684056	chr5:59996105	DEPDC1B	0.35	8.34	0.31	4.61e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg19622623	chr12:86230825	RASSF9	-0.33	-9.38	-0.35	1.14e-19	Major depressive disorder;
BRCA	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	8.57	0.32	7.63e-17	Rheumatoid arthritis;
BRCA	cis	rs1691799	0.899	rs1168306	chr12:66738900	A/G	cg16791601	chr12:66731901	HELB	-0.64	-17.33	-0.57	2.02e-55	White blood cell count (basophil);
BRCA	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg10876282	chr6:28092338	ZSCAN16	0.41	8.0	0.3	5.69e-15	Parkinson's disease;
BRCA	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg08807892	chr2:162101083	NA	0.49	9.78	0.36	3.7e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.41	0.35	8.87e-20	Morning vs. evening chronotype;
BRCA	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg27129171	chr3:47204927	SETD2	-0.67	-15.32	-0.52	2.3e-45	QT interval;
BRCA	cis	rs7555523	0.887	rs4269750	chr1:165711510	C/T	cg24409356	chr1:165738333	TMCO1	0.51	8.21	0.31	1.23e-15	Intraocular pressure;Glaucoma (high intraocular pressure);
BRCA	cis	rs208520	0.690	rs851465	chr6:66840293	G/A	cg07460842	chr6:66804631	NA	-1.02	-20.15	-0.62	2.95e-70	Exhaled nitric oxide output;
BRCA	cis	rs2764980	1.000	rs11251794	chr10:3283931	C/T	cg11630169	chr10:3283847	NA	-0.41	-9.37	-0.35	1.18e-19	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	trans	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg26248373	chr2:1572462	NA	-0.65	-15.81	-0.53	9.41e-48	IgG glycosylation;
BRCA	cis	rs939658	0.805	rs35318825	chr15:79447098	C/A	cg17916960	chr15:79447300	NA	-0.48	-12.22	-0.44	5.09e-31	Refractive error;
BRCA	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg27279351	chr12:120934652	DYNLL1	0.51	12.19	0.43	6.77e-31	High light scatter reticulocyte count;
BRCA	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	18.19	0.58	7e-60	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.4	2.18e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs198389	0.589	rs535107	chr1:11889468	C/T	cg24844545	chr1:11908347	NPPA	0.34	8.93	0.33	4.57e-18	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
BRCA	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.57	10.74	0.39	7.28e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.39	-8.3	-0.31	6.24e-16	IgG glycosylation;
BRCA	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16680214	chr1:154839983	KCNN3	-0.4	-11.1	-0.4	2.61e-26	Prostate cancer;
BRCA	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg12011299	chr4:100065546	ADH4	-0.48	-10.64	-0.39	1.94e-24	Smoking initiation;
BRCA	cis	rs752010	0.655	rs10890145	chr1:42086290	A/G	cg06885757	chr1:42089581	HIVEP3	0.3	10.7	0.39	1.06e-24	Lupus nephritis in systemic lupus erythematosus;
BRCA	trans	rs6479891	1.000	rs6479891	chr10:65006456	C/T	cg14819942	chr15:35414228	NA	0.33	7.94	0.3	8.97e-15	Arthritis (juvenile idiopathic);
BRCA	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg06115741	chr20:33292138	TP53INP2	0.39	8.73	0.33	2.17e-17	Coronary artery disease;
BRCA	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg09060608	chr5:178986726	RUFY1	0.62	16.03	0.54	7.32e-49	Lung cancer;
BRCA	cis	rs35995292	0.534	rs2008199	chr7:38939678	T/C	cg19327137	chr7:38886074	VPS41	0.4	13.2	0.46	2.26e-35	Subjective well-being (multi-trait analysis);
BRCA	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.52	10.09	0.37	2.68e-22	Height;
BRCA	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.89	-0.36	1.54e-21	IgG glycosylation;
BRCA	cis	rs208520	0.661	rs704519	chr6:66801136	T/C	cg07460842	chr6:66804631	NA	-1.0	-19.95	-0.62	3.32e-69	Exhaled nitric oxide output;
BRCA	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg25554036	chr4:6271136	WFS1	0.42	9.91	0.37	1.19e-21	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7587476	0.906	rs16852750	chr2:215646683	A/G	cg04004882	chr2:215674386	BARD1	0.59	10.38	0.38	1.97e-23	Neuroblastoma;
BRCA	trans	rs1493916	0.837	rs9949631	chr18:31410567	G/A	cg27147174	chr7:100797783	AP1S1	-0.42	-8.48	-0.32	1.55e-16	Life satisfaction;
BRCA	trans	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg03929089	chr4:120376271	NA	0.51	7.85	0.3	1.75e-14	Intraocular pressure;
BRCA	cis	rs6942756	0.806	rs6467240	chr7:128984018	T/C	cg02491457	chr7:128862824	NA	-0.58	-12.25	-0.44	3.93e-31	White matter hyperintensity burden;
BRCA	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.33	-0.31	5.11e-16	Bipolar disorder;
BRCA	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg15017067	chr4:17643749	FAM184B	0.29	8.98	0.33	3.08e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg11693508	chr17:37793320	STARD3	0.53	8.98	0.33	3.03e-18	Neuroticism;
BRCA	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.1	0.31	2.78e-15	Uric acid levels;
BRCA	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg02822958	chr2:46747628	ATP6V1E2	-0.5	-9.9	-0.36	1.33e-21	HDL cholesterol;
BRCA	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg12386194	chr3:101231763	SENP7	0.46	9.79	0.36	3.57e-21	Colorectal cancer;
BRCA	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg01483505	chr11:975446	AP2A2	0.33	9.05	0.34	1.7e-18	Alzheimer's disease (late onset);
BRCA	cis	rs2882667	0.898	rs12719519	chr5:138375687	G/A	cg04439458	chr5:138467593	SIL1	-0.32	-8.94	-0.33	4.18e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.62	-0.32	5.35e-17	Total body bone mineral density;
BRCA	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg00814883	chr7:100076585	TSC22D4	-0.54	-10.6	-0.39	2.74e-24	Platelet count;
BRCA	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg11833968	chr6:79620685	NA	-0.44	-9.95	-0.37	9.12e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg00677455	chr12:58241039	CTDSP2	0.57	13.56	0.47	5.32e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg12193833	chr17:30244370	NA	-0.56	-8.77	-0.33	1.58e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-14.76	-0.5	1.21e-42	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg07549590	chr16:15018862	NA	-0.49	-12.27	-0.44	3.16e-31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg25319279	chr11:5960081	NA	-0.4	-7.9	-0.3	1.23e-14	DNA methylation (variation);
BRCA	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg23950597	chr19:37808831	NA	-0.61	-11.53	-0.41	4.51e-28	Coronary artery calcification;
BRCA	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg14847009	chr1:175162515	KIAA0040	0.25	9.52	0.35	3.52e-20	Alcohol dependence;
BRCA	cis	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-10.56	-0.39	4.07e-24	Resting heart rate;
BRCA	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.43	8.27	0.31	7.97e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs9409565	0.821	rs7858082	chr9:97063929	T/A	cg05679027	chr9:99775184	HIATL2	0.41	9.08	0.34	1.33e-18	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg15395560	chr15:45543142	SLC28A2	-0.29	-7.82	-0.3	2.22e-14	Uric acid levels;
BRCA	cis	rs9309473	1.000	rs6711033	chr2:73746643	T/C	cg20560298	chr2:73613845	ALMS1	-0.41	-10.15	-0.37	1.54e-22	Metabolite levels;
BRCA	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg26398791	chr1:38455867	SF3A3	-0.4	-8.27	-0.31	7.58e-16	Coronary artery disease;
BRCA	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23583168	chr7:148888333	NA	0.95	24.57	0.7	2.32e-94	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	16.92	0.56	2.48e-53	Intelligence (multi-trait analysis);
BRCA	cis	rs11229555	0.645	rs7947248	chr11:58197750	C/T	cg15696309	chr11:58395628	NA	-0.52	-10.83	-0.39	3.19e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg06784218	chr1:46089804	CCDC17	-0.44	-10.47	-0.38	8.95e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.52	11.68	0.42	1.02e-28	Multiple sclerosis;
BRCA	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg11814155	chr7:99998594	ZCWPW1	0.42	8.0	0.3	5.84e-15	Platelet count;
BRCA	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.3	-7.95	-0.3	8.36e-15	Total body bone mineral density;
BRCA	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg25036284	chr2:26402008	FAM59B	-0.88	-15.06	-0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	trans	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-10.07	-0.37	2.96e-22	Brugada syndrome;
BRCA	cis	rs17604090	0.818	rs73090342	chr7:29687540	T/C	cg19413766	chr7:29689036	LOC646762	-0.59	-8.17	-0.31	1.67e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs909002	0.849	rs10914453	chr1:32075036	A/G	cg13919466	chr1:32135498	COL16A1	-0.26	-8.74	-0.33	2e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg09537434	chr19:41945824	ATP5SL	-1.0	-23.92	-0.69	8.58e-91	Height;
BRCA	trans	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg15704280	chr7:45808275	SEPT13	0.55	8.25	0.31	9.34e-16	Axial length;
BRCA	cis	rs143626010	1	rs143626010	chr16:28539398	GTGTA/G	cg16576597	chr16:28551801	NUPR1	0.35	9.41	0.35	8.46e-20	Mosquito bite size;
BRCA	trans	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg25214090	chr10:38739885	LOC399744	0.37	8.73	0.33	2.16e-17	Diastolic blood pressure;
BRCA	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg01475735	chr3:40494733	NA	-0.39	-7.98	-0.3	6.97e-15	Renal cell carcinoma;
BRCA	trans	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17712092	chr4:129076599	LARP1B	0.56	13.49	0.47	1.07e-36	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.5	0.5	2.04e-41	Colorectal cancer;
BRCA	trans	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg16011800	chr17:1958478	HIC1	0.51	8.4	0.32	2.95e-16	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs870825	0.655	rs12502771	chr4:185635834	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.58e-56	Blood protein levels;
BRCA	cis	rs7809950	1.000	rs2712189	chr7:107195747	G/A	cg23024343	chr7:107201750	COG5	-0.4	-9.08	-0.34	1.32e-18	Coronary artery disease;
BRCA	cis	rs4363385	0.747	rs4568784	chr1:152972694	G/A	cg24667326	chr1:152973720	SPRR3	-0.35	-9.71	-0.36	7.26e-21	Inflammatory skin disease;
BRCA	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.75e-66	Aortic root size;
BRCA	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.9e-22	Bladder cancer;
BRCA	cis	rs4363385	0.747	rs4314835	chr1:152984901	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-9.2	-0.34	5.11e-19	Inflammatory skin disease;
BRCA	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg06191203	chr2:152266755	RIF1	-0.42	-12.15	-0.43	1.02e-30	Lung cancer;
BRCA	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg27170947	chr2:26402098	FAM59B	-0.87	-16.7	-0.55	3.29e-52	Gut microbiome composition (summer);
BRCA	trans	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-7.81	-0.3	2.32e-14	Corneal astigmatism;
BRCA	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg18867708	chr6:26865862	GUSBL1	0.42	8.27	0.31	7.7e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6840360	0.615	rs9996320	chr4:152610587	T/G	cg22705602	chr4:152727874	NA	-0.37	-10.16	-0.37	1.37e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.51	-0.32	1.28e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.53	11.89	0.43	1.37e-29	Colorectal cancer;
BRCA	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg12011299	chr4:100065546	ADH4	-0.38	-11.0	-0.4	7.09e-26	Alcohol dependence;
BRCA	cis	rs4900538	0.928	rs1190551	chr14:102911508	A/G	cg18135206	chr14:102964638	TECPR2	-1.06	-29.82	-0.76	4.06e-123	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs1371614	0.632	rs7599286	chr2:27152398	T/C	cg00617064	chr2:27272375	NA	-0.31	-7.98	-0.3	6.97e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg00717180	chr2:96193071	NA	-0.38	-10.14	-0.37	1.71e-22	Height;
BRCA	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-8.85	-0.33	8.79e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-13.6	-0.47	3.46e-37	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs9359856	0.564	rs72915903	chr6:90420190	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.65	-8.15	-0.31	1.94e-15	Bipolar disorder;
BRCA	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg04944784	chr2:26401820	FAM59B	0.82	11.19	0.4	1.11e-26	Gut microbiome composition (summer);
BRCA	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg19920283	chr7:105172520	RINT1	0.58	9.39	0.35	1.01e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg27535305	chr1:53392650	SCP2	-0.49	-11.92	-0.43	9.67e-30	Monocyte count;
BRCA	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.29	-0.34	2.38e-19	Bipolar disorder;
BRCA	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg12573674	chr2:1569213	NA	-0.49	-9.34	-0.35	1.58e-19	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg19338460	chr6:170058176	WDR27	-0.44	-7.83	-0.3	1.99e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg26408565	chr15:76604113	ETFA	0.45	9.68	0.36	9.08e-21	Blood metabolite levels;
BRCA	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.5	0.63	3.81e-72	Chronic sinus infection;
BRCA	cis	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg26695010	chr11:65641043	EFEMP2	0.37	7.98	0.3	6.86e-15	Eosinophil percentage of white cells;
BRCA	cis	rs10046574	0.831	rs7780345	chr7:135137731	T/C	cg27474649	chr7:135195673	CNOT4	0.61	8.64	0.32	4.59e-17	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9811920	0.535	rs704572	chr3:99482314	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.4	-9.24	-0.34	3.56e-19	Axial length;
BRCA	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg02951883	chr7:2050386	MAD1L1	-0.48	-11.4	-0.41	1.57e-27	Schizophrenia;
BRCA	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg03354898	chr7:1950403	MAD1L1	-0.5	-10.48	-0.38	7.95e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg23950597	chr19:37808831	NA	-0.74	-13.0	-0.46	1.93e-34	Coronary artery calcification;
BRCA	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-8.1	-0.31	2.84e-15	Depression;
BRCA	trans	rs629535	0.665	rs2433331	chr8:70041943	T/C	cg21567404	chr3:27674614	NA	0.99	21.48	0.65	1.92e-77	Dupuytren's disease;
BRCA	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg17470723	chr8:74884337	TCEB1	0.4	8.68	0.32	3.22e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4663866	0.901	rs71426512	chr2:239187128	C/T	cg16914508	chr2:239161102	PER2	0.7	9.49	0.35	4.42e-20	Irritable bowel syndrome;
BRCA	trans	rs1493916	0.777	rs1941685	chr18:31304318	G/T	cg27147174	chr7:100797783	AP1S1	-0.42	-8.41	-0.32	2.72e-16	Life satisfaction;
BRCA	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.18	0.46	2.94e-35	Electroencephalogram traits;
BRCA	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg08975724	chr8:8085496	FLJ10661	0.54	11.13	0.4	1.94e-26	Neuroticism;
BRCA	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-9.06	-0.34	1.53e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4711336	0.809	rs749338	chr6:33653448	A/G	cg14003231	chr6:33640908	ITPR3	-0.36	-9.18	-0.34	6.15e-19	Height;
BRCA	cis	rs4642101	0.628	rs1003080	chr3:12811628	C/T	cg24848339	chr3:12840334	CAND2	-0.36	-9.54	-0.35	2.84e-20	QRS complex (12-leadsum);
BRCA	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg11833968	chr6:79620685	NA	-0.42	-9.35	-0.35	1.46e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24531977	chr5:56204891	C5orf35	-0.87	-19.01	-0.6	3.29e-64	Initial pursuit acceleration;
BRCA	cis	rs9811920	0.683	rs793439	chr3:99637783	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.47	11.22	0.41	8.46e-27	Axial length;
BRCA	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-9.85	-0.36	2.07e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.16	0.37	1.4e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg19784903	chr17:45786737	TBKBP1	0.33	7.98	0.3	6.69e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs8028182	0.636	rs12708520	chr15:75830539	C/T	cg20655648	chr15:75932815	IMP3	0.42	8.27	0.31	8e-16	Sudden cardiac arrest;
BRCA	cis	rs4930561	0.765	rs34493482	chr11:67969508	T/C	cg16338278	chr11:67432957	ALDH3B2	0.44	8.97	0.33	3.37e-18	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.32	10.27	0.38	5.1e-23	Bipolar disorder;
BRCA	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.03	22.67	0.67	5.83e-84	Gut microbiome composition (summer);
BRCA	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg00106254	chr7:1943704	MAD1L1	-0.4	-10.71	-0.39	9.92e-25	Bipolar disorder and schizophrenia;
BRCA	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg07148914	chr20:33460835	GGT7	-0.42	-8.95	-0.33	3.92e-18	Height;
BRCA	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg24006582	chr15:45444508	DUOX1	-0.55	-11.32	-0.41	3.19e-27	Uric acid levels;
BRCA	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg17691542	chr6:26056736	HIST1H1C	0.49	9.99	0.37	6.38e-22	Height;
BRCA	cis	rs752010	0.695	rs10789407	chr1:42106538	G/T	cg06885757	chr1:42089581	HIVEP3	0.23	8.35	0.31	4.34e-16	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26314531	chr2:26401878	FAM59B	-0.88	-15.31	-0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg11764359	chr7:65958608	NA	0.63	10.84	0.39	2.88e-25	Aortic root size;
BRCA	cis	rs12612619	0.579	rs41448746	chr2:27080706	A/G	cg08802533	chr2:27073253	DPYSL5	-0.29	-7.87	-0.3	1.55e-14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs17401966	0.838	rs4529713	chr1:10307295	A/G	cg03954927	chr1:10346856	KIF1B	0.43	13.72	0.48	1.01e-37	Hepatocellular carcinoma;
BRCA	cis	rs3784262	0.643	rs8030766	chr15:58369209	A/G	cg12031962	chr15:58353849	ALDH1A2	0.37	9.19	0.34	5.52e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg23711669	chr6:146136114	FBXO30	-0.71	-16.77	-0.55	1.44e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg21064579	chr19:49206444	FUT2	0.32	8.02	0.3	4.92e-15	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
BRCA	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg19077165	chr18:44547161	KATNAL2	0.38	8.1	0.31	2.88e-15	Personality dimensions;
BRCA	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.96	0.3	7.77e-15	Depression;
BRCA	cis	rs1003719	0.688	rs2835662	chr21:38568967	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.73	-0.5	1.77e-42	Eye color traits;
BRCA	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg16850897	chr7:100343110	ZAN	-0.57	-10.66	-0.39	1.57e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.66	-0.61	1.21e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg00321850	chr1:175162397	KIAA0040	0.41	11.39	0.41	1.65e-27	Alcohol dependence;
BRCA	cis	rs495337	0.760	rs2769982	chr20:48524827	C/T	cg17835207	chr20:48524531	SPATA2	0.67	16.76	0.55	1.59e-52	Psoriasis;
BRCA	cis	rs7975161	0.565	rs4545635	chr12:104636844	A/C	cg25273343	chr12:104657179	TXNRD1	-0.63	-9.75	-0.36	4.9e-21	Toenail selenium levels;
BRCA	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg08470875	chr2:26401718	FAM59B	0.71	11.35	0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs897080	0.515	rs786617	chr2:44593158	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	11.04	0.4	4.53e-26	Height;
BRCA	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg26408565	chr15:76604113	ETFA	-0.48	-10.32	-0.38	3.37e-23	Blood metabolite levels;
BRCA	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-12.95	-0.46	3.28e-34	Blood metabolite levels;
BRCA	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg24803719	chr17:45855879	NA	-0.32	-8.4	-0.32	2.93e-16	IgG glycosylation;
BRCA	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11890956	chr21:40555474	PSMG1	1.04	29.55	0.76	1.3e-121	Cognitive function;
BRCA	cis	rs6598955	0.543	rs61608823	chr1:26555090	G/A	cg12744634	chr1:26560303	CCDC21	0.3	7.88	0.3	1.46e-14	Obesity-related traits;
BRCA	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg24692254	chr21:30365293	RNF160	0.78	21.75	0.65	6.72e-79	Dental caries;
BRCA	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg07414643	chr4:187882934	NA	-0.26	-9.15	-0.34	7.66e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg04990556	chr1:26633338	UBXN11	0.54	8.78	0.33	1.52e-17	Obesity-related traits;
BRCA	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg20207973	chr22:38506712	BAIAP2L2	0.31	7.86	0.3	1.66e-14	Cutaneous nevi;
BRCA	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg20476274	chr7:133979776	SLC35B4	0.62	18.01	0.58	6.11e-59	Mean platelet volume;
BRCA	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg12573674	chr2:1569213	NA	-0.58	-12.54	-0.44	2.11e-32	IgG glycosylation;
BRCA	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	13.9	0.48	1.5e-38	Coronary artery disease;
BRCA	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg23950597	chr19:37808831	NA	-0.65	-11.1	-0.4	2.75e-26	Coronary artery calcification;
BRCA	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg05283184	chr6:79620031	NA	-0.43	-11.22	-0.41	8.77e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg05283184	chr6:79620031	NA	-0.36	-8.32	-0.31	5.43e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs897984	0.542	rs11864839	chr16:31095251	G/C	cg02466173	chr16:30829666	NA	-0.44	-9.87	-0.36	1.81e-21	Dementia with Lewy bodies;
BRCA	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	19.56	0.61	4.15e-67	Electrocardiographic conduction measures;
BRCA	trans	rs1459104	0.706	rs35228933	chr11:55027673	G/A	cg15704280	chr7:45808275	SEPT13	0.7	8.64	0.32	4.37e-17	Body mass index;
BRCA	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg25767906	chr1:53392781	SCP2	0.34	7.9	0.3	1.18e-14	Monocyte count;
BRCA	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg12698349	chr2:225449008	CUL3	0.61	13.46	0.47	1.49e-36	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs6450176	1.000	rs3776718	chr5:53298714	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.62	-15.07	-0.51	3.71e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg23649088	chr2:200775458	C2orf69	0.61	10.53	0.38	5.32e-24	Schizophrenia;
BRCA	cis	rs7254827	0.737	rs12973050	chr19:17174261	G/C	cg19418318	chr19:17219073	MYO9B	-0.48	-10.03	-0.37	4.26e-22	Mean platelet volume;
BRCA	trans	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg19862616	chr7:65841803	NCRNA00174	0.86	28.66	0.75	8.26e-117	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10129255	0.518	rs10136903	chr14:107187105	T/C	cg07958169	chr14:107095056	NA	-0.39	-8.29	-0.31	6.7e-16	Kawasaki disease;
BRCA	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg26384229	chr12:38710491	ALG10B	0.69	16.21	0.54	9.67e-50	Bladder cancer;
BRCA	cis	rs7646881	0.767	rs73015669	chr3:158456318	C/A	cg19483011	chr3:158453295	NA	-0.47	-8.3	-0.31	6.28e-16	Tetralogy of Fallot;
BRCA	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg24578937	chr1:2090814	PRKCZ	0.38	11.67	0.42	1.14e-28	Height;
BRCA	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg20307385	chr11:47447363	PSMC3	-0.4	-8.48	-0.32	1.52e-16	Subjective well-being;
BRCA	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg16325326	chr1:53192061	ZYG11B	-0.71	-18.74	-0.6	8.49e-63	Monocyte count;
BRCA	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg20307385	chr11:47447363	PSMC3	-0.82	-20.74	-0.63	1.95e-73	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg19077165	chr18:44547161	KATNAL2	-0.59	-13.39	-0.47	3.24e-36	Personality dimensions;
BRCA	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg24675658	chr1:53192096	ZYG11B	0.83	18.88	0.6	1.69e-63	Monocyte count;
BRCA	cis	rs4494114	0.967	rs9438980	chr1:39355371	A/G	cg25970120	chr1:39325951	RRAGC	-0.37	-7.92	-0.3	1.03e-14	Blood protein levels;
BRCA	cis	rs4363385	0.747	rs2339494	chr1:152975143	G/C	cg21543102	chr1:152974771	SPRR3	-0.3	-8.31	-0.31	5.88e-16	Inflammatory skin disease;
BRCA	cis	rs11051970	0.879	rs2651379	chr12:32581778	A/G	cg02745156	chr12:32552066	NA	0.27	8.93	0.33	4.43e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	trans	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg19862616	chr7:65841803	NCRNA00174	0.86	28.4	0.75	2.15e-115	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6772849	0.896	rs4857859	chr3:128348014	G/T	cg16766828	chr3:128327626	NA	-0.39	-8.74	-0.33	2.11e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06221963	chr1:154839813	KCNN3	-0.56	-15.69	-0.53	3.45e-47	Prostate cancer;
BRCA	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.7	14.78	0.5	9.37e-43	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	14.3	0.49	1.97e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs16958440	1.000	rs16958432	chr18:44631773	G/A	cg17192377	chr18:44677553	HDHD2	0.67	9.75	0.36	4.96e-21	Sitting height ratio;
BRCA	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg10523679	chr1:76189770	ACADM	0.77	15.59	0.52	1.18e-46	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9649465	1.000	rs11770041	chr7:123365788	C/T	cg04330084	chr7:123175371	IQUB	-0.33	-9.08	-0.34	1.33e-18	Migraine;
BRCA	cis	rs6973256	0.897	rs7777805	chr7:133337074	T/C	cg07491979	chr7:133331646	EXOC4	-0.39	-8.9	-0.33	5.64e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs12410462	0.792	rs994666	chr1:227651454	C/T	cg04117972	chr1:227635322	NA	-0.46	-8.31	-0.31	5.86e-16	Major depressive disorder;
BRCA	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg24558204	chr6:135376177	HBS1L	0.47	12.75	0.45	2.45e-33	Red blood cell count;
BRCA	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.31	-8.06	-0.3	3.69e-15	Crohn's disease;
BRCA	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg03877680	chr5:178157825	ZNF354A	0.84	17.0	0.56	9.13e-54	Neutrophil percentage of white cells;
BRCA	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.5	-10.76	-0.39	6.5e-25	Longevity;Endometriosis;
BRCA	cis	rs2386661	0.522	rs11258033	chr10:5644372	C/T	cg17085576	chr10:5658249	NA	0.31	8.04	0.3	4.39e-15	Breast cancer;
BRCA	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg25817165	chr18:72167213	CNDP2	-0.77	-14.27	-0.49	2.52e-40	Refractive error;
BRCA	cis	rs2806561	0.808	rs2235546	chr1:23409538	A/G	cg19743168	chr1:23544995	NA	0.38	8.37	0.31	3.73e-16	Height;
BRCA	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.36	-8.36	-0.31	3.82e-16	Bipolar disorder;
BRCA	trans	rs3960554	0.808	rs78587454	chr7:75688672	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	11.98	0.43	5.53e-30	Eotaxin levels;
BRCA	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.54	0.55	1.95e-51	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs78707713	0.841	rs76628955	chr10:71208625	C/T	cg12610070	chr10:71211762	TSPAN15	-0.32	-8.19	-0.31	1.45e-15	Venous thromboembolism;
BRCA	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg09307838	chr4:120376055	NA	0.64	13.17	0.46	3.09e-35	Corneal astigmatism;
BRCA	cis	rs1476670	0.710	rs4660763	chr1:44503576	T/C	cg09470012	chr1:44509516	NA	0.42	9.46	0.35	5.76e-20	Eotaxin levels;
BRCA	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg22681709	chr2:178499509	PDE11A	-0.39	-8.46	-0.32	1.82e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg21475434	chr5:93447410	FAM172A	0.69	8.94	0.33	4.08e-18	Diabetic retinopathy;
BRCA	cis	rs7301826	1.000	rs10744482	chr12:131298195	C/T	cg11011512	chr12:131303247	STX2	0.4	9.98	0.37	6.6e-22	Plasma plasminogen activator levels;
BRCA	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.94	-0.51	1.6e-43	Total cholesterol levels;
BRCA	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg11266682	chr4:10021025	SLC2A9	0.43	11.36	0.41	2.19e-27	Bone mineral density;
BRCA	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	9.97	0.37	7.08e-22	Aortic root size;
BRCA	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.41	-8.44	-0.32	2.06e-16	Response to bleomycin (chromatid breaks);
BRCA	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg27129171	chr3:47204927	SETD2	-0.68	-15.8	-0.53	9.76e-48	Colorectal cancer;
BRCA	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg05347473	chr6:146136440	FBXO30	-0.43	-8.58	-0.32	7.4e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2806561	0.828	rs944509	chr1:23542242	C/T	cg19743168	chr1:23544995	NA	-0.47	-11.69	-0.42	9.82e-29	Height;
BRCA	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.05	0.49	2.82e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg21573476	chr21:45109991	RRP1B	-0.34	-8.98	-0.33	3e-18	Mean corpuscular volume;
BRCA	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7481584	0.581	rs420127	chr11:3077990	C/T	cg08508325	chr11:3079039	CARS	0.29	8.67	0.32	3.67e-17	Calcium levels;
BRCA	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20891558	chr2:74357851	NA	0.6	12.0	0.43	4.43e-30	Gestational age at birth (maternal effect);
BRCA	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08564027	chr20:61660810	NA	0.84	22.49	0.66	6.16e-83	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs25645	0.502	rs8065126	chr17:38099035	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.46	10.1	0.37	2.29e-22	Myeloid white cell count;
BRCA	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg13385794	chr1:248469461	NA	0.27	7.89	0.3	1.32e-14	Common traits (Other);
BRCA	trans	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg06521331	chr12:34319734	NA	-0.44	-8.51	-0.32	1.24e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg04450456	chr4:17643702	FAM184B	-0.34	-9.65	-0.36	1.18e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg23533926	chr12:111358616	MYL2	0.42	8.79	0.33	1.38e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg18200150	chr17:30822561	MYO1D	0.35	8.91	0.33	5.17e-18	Schizophrenia;
BRCA	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg00409905	chr10:38381863	ZNF37A	-0.48	-9.98	-0.37	6.6e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg19743168	chr1:23544995	NA	0.46	11.24	0.41	7.16e-27	Height;
BRCA	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg05234568	chr11:5960015	NA	-0.51	-9.93	-0.37	1.04e-21	DNA methylation (variation);
BRCA	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs12200560	0.505	rs211172	chr6:97070691	C/A	cg06623918	chr6:96969491	KIAA0776	0.52	12.25	0.44	3.94e-31	Coronary heart disease;
BRCA	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg16145915	chr7:1198662	ZFAND2A	0.41	9.22	0.34	4.41e-19	Longevity;Endometriosis;
BRCA	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.33	9.04	0.34	1.86e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg08754654	chr5:154026448	NA	0.43	9.87	0.36	1.72e-21	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10754283	0.967	rs1317864	chr1:90105448	A/G	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.2e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg00677455	chr12:58241039	CTDSP2	0.62	15.19	0.52	9.72e-45	Multiple sclerosis;
BRCA	cis	rs7818345	1.000	rs12675717	chr8:19293177	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.05	0.3	4.19e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs34779708	0.931	rs2001893	chr10:35300623	G/A	cg03585969	chr10:35415529	CREM	0.45	9.47	0.35	5.36e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6840258	1.000	rs17012234	chr4:87911691	A/C	cg08197287	chr4:87952173	AFF1	0.42	8.3	0.31	6.03e-16	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg04025307	chr7:1156635	C7orf50	0.43	10.46	0.38	9.9899999999999993e-24	Longevity;Endometriosis;
BRCA	cis	rs9649465	1.000	rs55633050	chr7:123388474	A/G	cg04330084	chr7:123175371	IQUB	-0.3	-8.27	-0.31	7.83e-16	Migraine;
BRCA	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg26384229	chr12:38710491	ALG10B	0.55	14.03	0.49	3.44e-39	Morning vs. evening chronotype;
BRCA	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg13010199	chr12:38710504	ALG10B	0.51	10.04	0.37	3.97e-22	Morning vs. evening chronotype;
BRCA	cis	rs6920965	0.509	rs654213	chr6:126149127	C/T	cg05901451	chr6:126070800	HEY2	0.36	8.75	0.33	1.95e-17	High light scatter reticulocyte count;
BRCA	cis	rs7617773	0.780	rs13081169	chr3:48356797	G/A	cg11946769	chr3:48343235	NME6	0.69	14.01	0.48	4.54e-39	Coronary artery disease;
BRCA	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg25838465	chr1:92012736	NA	0.48	9.86	0.36	1.9e-21	Eosinophil percentage of white cells;
BRCA	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg03433033	chr1:76189801	ACADM	0.76	17.13	0.56	2.14e-54	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7827545	1.000	rs7832857	chr8:135565477	A/G	cg17885191	chr8:135476712	NA	0.47	9.19	0.34	5.3e-19	Hypertension (SNP x SNP interaction);
BRCA	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg14664628	chr15:75095509	CSK	-0.91	-26.0	-0.72	3.38e-102	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg13319975	chr6:146136371	FBXO30	-0.62	-14.53	-0.5	1.61e-41	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.5	8.94	0.33	4.19e-18	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.29	-0.35	2.32e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.09	-0.3	3.1e-15	Aortic root size;
BRCA	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg16606324	chr3:10149918	C3orf24	0.58	10.28	0.38	4.75e-23	Alzheimer's disease;
BRCA	trans	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg25214090	chr10:38739885	LOC399744	0.56	12.83	0.45	1.04e-33	Corneal astigmatism;
BRCA	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg06784218	chr1:46089804	CCDC17	0.5	12.02	0.43	3.67e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg06115741	chr20:33292138	TP53INP2	0.5	11.38	0.41	1.84e-27	Coronary artery disease;
BRCA	cis	rs6546550	1.000	rs6546550	chr2:70038232	C/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-10.2	-0.37	9.51e-23	Prevalent atrial fibrillation;
BRCA	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	8.34	0.31	4.51e-16	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	trans	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg25214090	chr10:38739885	LOC399744	0.54	12.64	0.45	7.8e-33	Corneal astigmatism;
BRCA	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg07636037	chr3:49044803	WDR6	0.97	28.33	0.75	5.26e-115	Parkinson's disease;
BRCA	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg11189052	chr15:85197271	WDR73	0.44	9.04	0.34	1.91e-18	Schizophrenia;
BRCA	cis	rs7523050	0.730	rs12734623	chr1:109442654	A/G	cg08274380	chr1:109419600	GPSM2	1.19	16.9	0.56	3.19e-53	Fat distribution (HIV);
BRCA	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg21856205	chr7:94953877	PON1	-0.37	-7.89	-0.3	1.36e-14	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs1113500	0.966	rs11185249	chr1:108611646	C/A	cg06207961	chr1:108661230	NA	0.44	10.54	0.38	4.57e-24	Growth-regulated protein alpha levels;
BRCA	cis	rs2463822	0.614	rs117699706	chr11:62161659	T/C	cg06239285	chr11:62104954	ASRGL1	-0.67	-9.12	-0.34	9.83e-19	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg09525523	chr12:16064153	DERA	0.32	8.03	0.3	4.82e-15	Mosquito bite size;
BRCA	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg23708337	chr7:1209742	NA	0.63	8.86	0.33	8.16e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4742903	0.527	rs10991114	chr9:106885616	A/G	cg14250997	chr9:106856677	SMC2	0.29	8.57	0.32	7.68e-17	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.02e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7300001	0.667	rs7302198	chr12:110506280	T/C	cg12870014	chr12:110450643	ANKRD13A	0.59	8.05	0.3	3.99e-15	Headache;
BRCA	cis	rs74181299	0.819	rs2723087	chr2:65298282	T/A	cg05010058	chr2:65284262	CEP68	0.3	8.27	0.31	7.74e-16	Pulse pressure;
BRCA	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg02659138	chr7:134003124	SLC35B4	0.32	9.8	0.36	3.24e-21	Mean platelet volume;
BRCA	cis	rs1829883	0.583	rs115209822	chr5:98915203	G/A	cg08333243	chr5:99726346	NA	0.35	8.01	0.3	5.39e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg11822812	chr5:140052017	DND1	-0.29	-8.05	-0.3	4.14e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg18016565	chr1:150552671	MCL1	-0.37	-8.56	-0.32	8.12e-17	Tonsillectomy;
BRCA	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg03146154	chr1:46216737	IPP	0.53	11.89	0.43	1.37e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10503871	0.967	rs4403367	chr8:30439724	A/G	cg26383811	chr8:30366931	RBPMS	0.33	8.91	0.33	5.24e-18	Metabolite levels  (X-11787);
BRCA	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg01528321	chr10:82214614	TSPAN14	0.79	16.67	0.55	4.64e-52	Post bronchodilator FEV1;
BRCA	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg03146154	chr1:46216737	IPP	-0.51	-11.13	-0.4	2.06e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg02743256	chr7:2109353	MAD1L1	-0.45	-8.0	-0.3	5.82e-15	Neuroticism;
BRCA	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.0	-0.34	2.48e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6910061	0.830	rs9468408	chr6:11093745	C/T	cg27233058	chr6:11094804	LOC221710	0.5	8.43	0.32	2.33e-16	Diabetic kidney disease;
BRCA	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg14675211	chr2:100938903	LONRF2	0.45	10.36	0.38	2.46e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg11812906	chr14:75593930	NEK9	-0.61	-13.69	-0.48	1.38e-37	Height;
BRCA	cis	rs2882667	0.858	rs4643949	chr5:138372345	C/T	cg04439458	chr5:138467593	SIL1	-0.32	-8.8	-0.33	1.3e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24549020	chr5:56110836	MAP3K1	0.67	13.67	0.48	1.63e-37	Initial pursuit acceleration;
BRCA	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg13073564	chr4:8508604	NA	-0.43	-11.9	-0.43	1.21e-29	Response to antineoplastic agents;
BRCA	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg18105134	chr13:113819100	PROZ	-0.63	-14.22	-0.49	4.32e-40	Platelet distribution width;
BRCA	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg10523679	chr1:76189770	ACADM	0.58	11.0	0.4	6.66e-26	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	8.98	0.33	2.89e-18	Iron status biomarkers;
BRCA	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg07636037	chr3:49044803	WDR6	0.58	8.27	0.31	7.6e-16	Menarche (age at onset);
BRCA	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg16405210	chr4:1374714	KIAA1530	0.85	17.48	0.57	3.11e-56	Longevity;
BRCA	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg06618935	chr21:46677482	NA	-0.36	-8.11	-0.31	2.68e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg12639453	chr1:2035780	PRKCZ	-0.28	-8.04	-0.3	4.31e-15	Height;
BRCA	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	10.58	0.39	3.2e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6750047	0.585	rs168054	chr2:38260282	C/G	cg07380506	chr2:38303506	CYP1B1	-0.42	-9.62	-0.36	1.48e-20	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs2282802	0.685	rs62385161	chr5:139635747	T/C	cg26211634	chr5:139558579	C5orf32	0.35	8.22	0.31	1.17e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18876405	chr7:65276391	NA	0.52	12.56	0.44	1.77e-32	Aortic root size;
BRCA	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg24397884	chr7:158709396	WDR60	-0.95	-22.78	-0.67	1.46e-84	Height;
BRCA	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg25036284	chr2:26402008	FAM59B	0.96	16.09	0.54	3.8e-49	Gut microbiome composition (summer);
BRCA	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg18811423	chr2:55921094	PNPT1	0.68	20.87	0.64	3.62e-74	Metabolic syndrome;
BRCA	cis	rs698833	0.509	rs4952709	chr2:44519142	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	8.55	0.32	9.05e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs9487051	0.698	rs4301336	chr6:109650140	A/T	cg01475377	chr6:109611718	NA	0.46	10.0	0.37	5.48e-22	Reticulocyte fraction of red cells;
BRCA	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08280861	chr8:58055591	NA	0.52	8.47	0.32	1.71e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2282802	0.660	rs2436390	chr5:139586501	G/A	cg26211634	chr5:139558579	C5orf32	-0.34	-8.14	-0.31	2.13e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9807989	0.507	rs3213732	chr2:102998279	A/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.41	0.32	2.59e-16	Asthma;
BRCA	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg10978503	chr1:24200527	CNR2	0.44	11.68	0.42	1.04e-28	Immature fraction of reticulocytes;
BRCA	cis	rs9467773	0.587	rs10946813	chr6:26345141	A/G	cg09904177	chr6:26538194	HMGN4	0.31	8.39	0.31	3.21e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-9.73	-0.36	5.71e-21	IgG glycosylation;
BRCA	trans	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg06521331	chr12:34319734	NA	-0.49	-9.07	-0.34	1.51e-18	Bladder cancer;
BRCA	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg23711669	chr6:146136114	FBXO30	0.64	14.59	0.5	8.29e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg24250549	chr1:154909240	PMVK	0.67	17.32	0.57	2.23e-55	Prostate cancer;
BRCA	trans	rs7200543	1.000	rs55727637	chr16:15145252	C/T	cg24683922	chr1:11983373	KIAA2013	-0.36	-8.35	-0.31	4.25e-16	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.9	-0.3	1.2e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.45	-0.41	1e-27	Mean corpuscular volume;
BRCA	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.27	8.86	0.33	7.79e-18	Systemic lupus erythematosus;
BRCA	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03264133	chr6:25882463	NA	-0.43	-9.38	-0.35	1.08e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.54	-0.32	9.97e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1891275	0.508	rs2096079	chr10:93496667	C/G	cg07889827	chr10:93443413	NA	-0.41	-11.09	-0.4	2.95e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg23285459	chr7:2802560	GNA12	-0.35	-8.48	-0.32	1.57e-16	Height;
BRCA	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.47	-0.32	1.71e-16	Total body bone mineral density;
BRCA	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg12311346	chr5:56204834	C5orf35	0.56	11.79	0.42	3.62e-29	Initial pursuit acceleration;
BRCA	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg08885076	chr2:99613938	TSGA10	-0.6	-13.41	-0.47	2.63e-36	Chronic sinus infection;
BRCA	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24549020	chr5:56110836	MAP3K1	0.61	12.69	0.45	4.51e-33	Initial pursuit acceleration;
BRCA	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg16586182	chr3:47516702	SCAP	0.65	15.06	0.51	4.49e-44	Colorectal cancer;
BRCA	trans	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg06521331	chr12:34319734	NA	-0.52	-9.28	-0.34	2.67e-19	Bladder cancer;
BRCA	cis	rs644148	0.693	rs2686772	chr19:44999729	T/C	cg15540054	chr19:45004280	ZNF180	-0.51	-10.07	-0.37	3.03e-22	Personality dimensions;
BRCA	cis	rs11608355	0.545	rs11612500	chr12:109897136	T/C	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg18252515	chr7:66147081	NA	-0.87	-12.08	-0.43	2.13e-30	Diabetic kidney disease;
BRCA	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg05347473	chr6:146136440	FBXO30	0.42	8.42	0.32	2.39e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg12193833	chr17:30244370	NA	-0.55	-8.77	-0.33	1.62e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg27170947	chr2:26402098	FAM59B	0.97	17.16	0.56	1.38e-54	Gut microbiome composition (summer);
BRCA	trans	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18876405	chr7:65276391	NA	0.43	8.48	0.32	1.53e-16	Corneal structure;
BRCA	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg18512352	chr11:47633146	NA	-0.34	-8.3	-0.31	6.07e-16	Subjective well-being;
BRCA	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00166722	chr3:10149974	C3orf24	0.55	10.74	0.39	7.48e-25	Alzheimer's disease;
BRCA	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-12.56	-0.44	1.73e-32	Personality dimensions;
BRCA	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg03188948	chr7:1209495	NA	0.85	11.6	0.42	2.26e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg20712883	chr12:51590929	POU6F1	0.4	7.96	0.3	7.84e-15	Cisplatin-induced ototoxicity;
BRCA	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg11752832	chr7:134001865	SLC35B4	0.43	9.51	0.35	3.84e-20	Mean platelet volume;
BRCA	cis	rs9815354	0.627	rs115971784	chr3:42016146	T/C	cg03022575	chr3:42003672	ULK4	0.75	9.65	0.36	1.17e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14442939	chr10:27389572	ANKRD26	0.7	11.01	0.4	6.19e-26	Breast cancer;
BRCA	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg21427119	chr20:30132790	HM13	-0.41	-8.75	-0.33	1.93e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13732083	chr21:47605072	C21orf56	0.37	7.98	0.3	7e-15	Testicular germ cell tumor;
BRCA	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg09021430	chr5:549028	NA	-0.68	-14.24	-0.49	3.68e-40	Lung disease severity in cystic fibrosis;
BRCA	cis	rs10949834	0.504	rs13238778	chr7:73567709	G/A	cg07137043	chr7:73588983	EIF4H	-0.66	-10.48	-0.38	8.24e-24	Verbal memory performance (residualized delayed recall change);
BRCA	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg11764359	chr7:65958608	NA	0.68	15.21	0.52	8.16e-45	Aortic root size;
BRCA	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.49	0.38	7.36e-24	Motion sickness;
BRCA	trans	rs8073060	0.586	rs225294	chr17:33925762	G/A	cg19694781	chr19:47549865	TMEM160	-1.01	-21.06	-0.64	3.73e-75	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs754466	0.606	rs56402185	chr10:79585848	G/A	cg17075019	chr10:79541650	NA	-0.81	-21.33	-0.64	1.23e-76	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg05025164	chr4:1340916	KIAA1530	0.37	8.34	0.31	4.58e-16	Longevity;
BRCA	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg20991723	chr1:152506922	NA	0.39	9.01	0.34	2.44e-18	Hair morphology;
BRCA	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10802521	chr3:52805072	NEK4	-0.33	-8.48	-0.32	1.61e-16	Bipolar disorder;
BRCA	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg12564285	chr5:131593104	PDLIM4	0.34	7.87	0.3	1.52e-14	Breast cancer;
BRCA	cis	rs400736	0.671	rs2131630	chr1:7990367	G/A	cg25007680	chr1:8021821	PARK7	-0.42	-10.44	-0.38	1.11e-23	Response to antidepressants and depression;
BRCA	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg27535305	chr1:53392650	SCP2	0.33	8.11	0.31	2.57e-15	Monocyte count;
BRCA	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs10504073	0.647	rs56057508	chr8:49982793	G/T	cg00325661	chr8:49890786	NA	0.42	12.08	0.43	2.18e-30	Blood metabolite ratios;
BRCA	cis	rs10267417	0.603	rs6960607	chr7:19869407	A/G	cg05791153	chr7:19748676	TWISTNB	0.46	8.96	0.33	3.59e-18	Night sleep phenotypes;
BRCA	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg05083358	chr7:2394359	EIF3B	-0.49	-7.89	-0.3	1.29e-14	Multiple sclerosis;
BRCA	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg23708337	chr7:1209742	NA	0.6	8.31	0.31	5.89e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10129255	0.500	rs10131875	chr14:107201036	T/C	cg07958169	chr14:107095056	NA	-0.39	-8.45	-0.32	1.89e-16	Kawasaki disease;
BRCA	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg12756686	chr19:29218302	NA	0.47	8.32	0.31	5.17e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25427524	chr10:38739819	LOC399744	-0.73	-18.04	-0.58	4.15e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg08422745	chr4:174089978	GALNT7	0.79	14.78	0.5	9.57e-43	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg04450456	chr4:17643702	FAM184B	0.37	10.91	0.4	1.54e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.78e-21	Total body bone mineral density;
BRCA	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg05340658	chr4:99064831	C4orf37	0.69	17.44	0.57	5.19e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg23422044	chr7:1970798	MAD1L1	-0.54	-11.91	-0.43	1.11e-29	Bipolar disorder;
BRCA	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg14675211	chr2:100938903	LONRF2	0.52	11.59	0.42	2.46e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg16230307	chr14:35515116	FAM177A1	0.62	13.76	0.48	6.46e-38	Psoriasis;
BRCA	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-11.7	-0.42	8.77e-29	Longevity;Endometriosis;
BRCA	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg27661571	chr11:113659931	NA	-0.71	-10.93	-0.4	1.31e-25	Hip circumference adjusted for BMI;
BRCA	cis	rs11229555	0.645	rs35279927	chr11:58212129	G/T	cg15696309	chr11:58395628	NA	-0.45	-9.64	-0.36	1.27e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg10224037	chr5:178157518	ZNF354A	0.79	17.62	0.57	6.43e-57	Neutrophil percentage of white cells;
BRCA	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.35	0.49	1.13e-40	Motion sickness;
BRCA	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg14689365	chr7:158441557	NCAPG2	0.41	8.71	0.33	2.53e-17	Height;
BRCA	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg24531977	chr5:56204891	C5orf35	-0.55	-11.38	-0.41	1.87e-27	Coronary artery disease;
BRCA	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg23018236	chr17:30244563	NA	-0.63	-9.46	-0.35	5.68e-20	Hip circumference adjusted for BMI;
BRCA	trans	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg13565492	chr6:43139072	SRF	-0.79	-11.12	-0.4	2.25e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-11.2	-0.41	1.05e-26	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3845702	0.736	rs1904850	chr2:180852767	A/G	cg01881094	chr2:180872142	CWC22	-1.02	-18.38	-0.59	6.81e-61	Schizophrenia;
BRCA	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg06115741	chr20:33292138	TP53INP2	0.5	11.12	0.4	2.28e-26	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	8.91	0.33	5.31e-18	Motion sickness;
BRCA	cis	rs2859741	1.000	rs4653239	chr1:37509872	C/G	cg09363841	chr1:37513479	NA	0.65	16.06	0.54	5.02e-49	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
BRCA	cis	rs9814567	0.964	rs6805388	chr3:134173534	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-16.73	-0.55	2.31e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	9.85	0.36	2.06e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.39	10.26	0.38	5.81e-23	IgG glycosylation;
BRCA	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg05729581	chr11:3078854	CARS	-0.36	-8.82	-0.33	1.12e-17	Longevity;
BRCA	trans	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg15704280	chr7:45808275	SEPT13	0.59	8.84	0.33	9.53e-18	Axial length;
BRCA	cis	rs6083	0.536	rs4528512	chr15:58852226	A/T	cg05156742	chr15:59063176	FAM63B	0.4	8.67	0.32	3.5e-17	Schizophrenia;
BRCA	cis	rs11971779	0.941	rs1127424	chr7:139107660	A/G	cg07862535	chr7:139043722	LUC7L2	0.52	12.86	0.45	7.86e-34	Diisocyanate-induced asthma;
BRCA	cis	rs3772130	1.000	rs13083794	chr3:121464928	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.55	9.61	0.36	1.57e-20	Cognitive performance;
BRCA	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg03929089	chr4:120376271	NA	0.6	10.38	0.38	2.02e-23	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg27129171	chr3:47204927	SETD2	-0.68	-16.18	-0.54	1.29e-49	Colorectal cancer;
BRCA	trans	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg20587970	chr11:113659929	NA	0.89	12.97	0.46	2.67e-34	Hip circumference adjusted for BMI;
BRCA	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.64	-15.15	-0.51	1.59e-44	Axial length;
BRCA	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg00666640	chr1:248458726	OR2T12	0.3	8.44	0.32	2.09e-16	Common traits (Other);
BRCA	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.32	-0.31	5.19e-16	Monocyte percentage of white cells;
BRCA	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24308560	chr3:49941425	MST1R	0.39	8.48	0.32	1.55e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	18.86	0.6	2.15e-63	Alzheimer's disease;
BRCA	cis	rs3772130	0.962	rs1920320	chr3:121547527	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.64	0.39	1.94e-24	Cognitive performance;
BRCA	trans	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.86	-0.36	1.86e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	14.36	0.49	9.69e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs17401966	1.000	rs35837142	chr1:10322358	C/G	cg15208524	chr1:10270712	KIF1B	0.4	8.47	0.32	1.72e-16	Hepatocellular carcinoma;
BRCA	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg08859206	chr1:53392774	SCP2	-0.52	-11.34	-0.41	2.72e-27	Monocyte count;
BRCA	cis	rs6893300	0.857	rs62406181	chr5:179171803	G/A	cg14593053	chr5:179126677	CANX	-0.35	-7.95	-0.3	8.56e-15	Resting heart rate;
BRCA	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11890956	chr21:40555474	PSMG1	-0.84	-21.45	-0.65	2.87e-77	Cognitive function;
BRCA	cis	rs9815354	0.812	rs73081383	chr3:41920614	A/G	cg03022575	chr3:42003672	ULK4	0.69	9.49	0.35	4.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg20307385	chr11:47447363	PSMC3	0.74	16.8	0.55	9.88e-53	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.08e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.66	-14.12	-0.49	1.31e-39	Hip circumference adjusted for BMI;
BRCA	cis	rs2304069	0.644	rs216131	chr5:149431223	C/T	cg12661370	chr5:149340060	SLC26A2	0.54	8.12	0.31	2.4e-15	HIV-1 control;
BRCA	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.14	0.49	1.04e-39	Eye color traits;
BRCA	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg03213289	chr20:61660250	NA	0.61	16.28	0.54	4.14e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.38	-8.77	-0.33	1.67e-17	Colorectal cancer;
BRCA	cis	rs9462027	0.628	rs66506671	chr6:34777149	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.89	-0.3	1.33e-14	Systemic lupus erythematosus;
BRCA	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg13047869	chr3:10149882	C3orf24	0.5	9.48	0.35	4.92e-20	Alzheimer's disease;
BRCA	cis	rs6763687	0.823	rs12632949	chr3:171802458	C/T	cg16233210	chr3:171778391	FNDC3B	0.41	9.67	0.36	9.65e-21	Red cell distribution width;
BRCA	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg13010199	chr12:38710504	ALG10B	0.48	9.26	0.34	3.1e-19	Morning vs. evening chronotype;
BRCA	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.35	-11.16	-0.4	1.5e-26	Homoarginine levels;
BRCA	cis	rs858239	0.932	rs1728320	chr7:23319789	T/G	cg23682824	chr7:23144976	KLHL7	0.33	8.45	0.32	1.93e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-10.79	-0.39	4.85e-25	Mean corpuscular volume;
BRCA	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg23231163	chr10:75533350	FUT11	0.34	8.98	0.33	2.9e-18	Inflammatory bowel disease;
BRCA	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg13319975	chr6:146136371	FBXO30	-0.35	-8.25	-0.31	9.4e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9790314	0.812	rs2004862	chr3:161135638	C/T	cg04691961	chr3:161091175	C3orf57	-0.49	-11.86	-0.42	1.91e-29	Morning vs. evening chronotype;
BRCA	cis	rs1941023	0.584	rs4938941	chr11:60173360	C/T	cg08716584	chr11:60157161	MS4A7	0.42	9.66	0.36	1.05e-20	Congenital heart disease (maternal effect);
BRCA	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg18806716	chr10:30721971	MAP3K8	-0.61	-14.19	-0.49	6.04e-40	Inflammatory bowel disease;
BRCA	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.74	16.17	0.54	1.52e-49	Cognitive ability;
BRCA	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.42	8.31	0.31	5.77e-16	Monocyte percentage of white cells;
BRCA	cis	rs870825	0.655	rs35764203	chr4:185639078	C/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.27	0.56	3.85e-55	Blood protein levels;
BRCA	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-20.0	-0.62	1.69e-69	Gut microbiome composition (summer);
BRCA	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg11812906	chr14:75593930	NEK9	-0.54	-11.73	-0.42	6.38e-29	Height;
BRCA	cis	rs9462027	0.628	rs9462009	chr6:34716330	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.0	-0.3	5.67e-15	Systemic lupus erythematosus;
BRCA	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg08917208	chr2:24149416	ATAD2B	1.08	15.26	0.52	4.69e-45	Lymphocyte counts;
BRCA	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.61	9.75	0.36	5.14e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.53	0.5	1.53e-41	Motion sickness;
BRCA	cis	rs7147624	1.000	rs2898816	chr14:66008160	T/C	cg03016385	chr14:66212404	NA	-0.59	-8.59	-0.32	6.75e-17	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg00106254	chr7:1943704	MAD1L1	0.39	9.54	0.35	2.89e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs427394	0.802	rs274694	chr5:6734079	A/G	cg10857441	chr5:6722123	POLS	-0.33	-10.91	-0.4	1.61e-25	Menopause (age at onset);
BRCA	cis	rs3008870	0.585	rs2815382	chr1:67515228	G/A	cg02640540	chr1:67518911	SLC35D1	0.41	8.92	0.33	4.69e-18	Lymphocyte percentage of white cells;
BRCA	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg09307838	chr4:120376055	NA	0.59	12.83	0.45	1.11e-33	Corneal astigmatism;
BRCA	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg22907277	chr7:1156413	C7orf50	0.58	8.91	0.33	5.37e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg13628971	chr7:2884303	GNA12	-0.53	-11.47	-0.41	7.9e-28	Height;
BRCA	cis	rs7178424	0.764	rs35967150	chr15:62324471	G/A	cg00456672	chr15:62358751	C2CD4A	-0.39	-8.56	-0.32	8.18e-17	Height;
BRCA	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg22920501	chr2:26401640	FAM59B	-0.65	-11.23	-0.41	8.19e-27	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg05340658	chr4:99064831	C4orf37	0.67	16.74	0.55	1.9e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg04025307	chr7:1156635	C7orf50	0.75	19.49	0.61	9.61e-67	Longevity;Endometriosis;
BRCA	cis	rs887829	0.531	rs4338954	chr2:234593931	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.36	-0.31	3.84e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg06618935	chr21:46677482	NA	-0.38	-8.56	-0.32	8.68e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23583168	chr7:148888333	NA	-0.86	-20.12	-0.62	4.19e-70	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04565464	chr8:145669602	NFKBIL2	0.37	8.85	0.33	8.54e-18	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2820292	0.804	rs2644120	chr1:201882277	C/G	cg11586189	chr1:201857591	SHISA4	0.28	7.9	0.3	1.23e-14	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
BRCA	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg00074818	chr8:8560427	CLDN23	0.39	8.43	0.32	2.34e-16	Obesity-related traits;
BRCA	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg02403541	chr12:121454288	C12orf43	-0.51	-9.68	-0.36	9.26e-21	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
BRCA	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg05283184	chr6:79620031	NA	-0.43	-11.0	-0.4	6.58e-26	Intelligence (multi-trait analysis);
BRCA	trans	rs4650994	1.000	rs10913568	chr1:178513411	C/T	cg05059571	chr16:84539110	KIAA1609	-0.43	-9.67	-0.36	9.66e-21	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs78707713	0.841	rs10998780	chr10:71201735	A/T	cg12610070	chr10:71211762	TSPAN15	-0.33	-8.42	-0.32	2.4e-16	Venous thromboembolism;
BRCA	cis	rs7580658	0.545	rs12477559	chr2:127951797	C/T	cg16751203	chr2:127950803	CYP27C1	0.28	7.92	0.3	1.09e-14	Protein C levels;
BRCA	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	15.26	0.52	4.8e-45	Mean corpuscular hemoglobin;
BRCA	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg12292205	chr6:26970375	C6orf41	0.58	12.99	0.46	2.15e-34	Schizophrenia;
BRCA	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-17.95	-0.58	1.26e-58	Gut microbiome composition (summer);
BRCA	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg23033748	chr14:75592666	NEK9	-0.43	-10.19	-0.37	1.07e-22	Height;
BRCA	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg17788362	chr6:86352627	SYNCRIP	0.4	8.07	0.3	3.53e-15	Smooth-surface caries;
BRCA	cis	rs7020830	0.858	rs7856690	chr9:37127545	A/T	cg14294708	chr9:37120828	ZCCHC7	1.04	30.31	0.77	9.8e-126	Schizophrenia;
BRCA	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.0	22.33	0.66	4.28e-82	Lymphocyte percentage of white cells;
BRCA	cis	rs13046373	0.507	rs2832959	chr21:31982934	C/T	cg27071517	chr21:31768726	KRTAP13-1	0.29	7.88	0.3	1.37e-14	HDL cholesterol;
BRCA	cis	rs4302748	0.908	rs4723482	chr7:36192249	G/A	cg24442661	chr7:36192818	EEPD1	0.51	9.18	0.34	5.74e-19	Platelet count;
BRCA	cis	rs2289583	0.642	rs55798479	chr15:75392210	C/T	cg14664628	chr15:75095509	CSK	0.4	9.21	0.34	4.79e-19	Systemic lupus erythematosus;
BRCA	trans	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg11693508	chr17:37793320	STARD3	0.52	9.19	0.34	5.41e-19	Neuroticism;
BRCA	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	15.09	0.51	3.14e-44	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4891159	0.548	rs689902	chr18:74119969	C/T	cg24786174	chr18:74118243	ZNF516	-0.84	-25.89	-0.72	1.22e-101	Longevity;
BRCA	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg16006841	chr5:176797999	RGS14	0.72	11.12	0.4	2.15e-26	Urate levels in lean individuals;
BRCA	cis	rs1568889	0.838	rs7131053	chr11:28143312	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.51	0.63	3.25e-72	Bipolar disorder;
BRCA	cis	rs10463316	0.894	rs7703283	chr5:150764904	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.4	-0.32	2.96e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg00012203	chr2:219082015	ARPC2	-0.52	-10.4	-0.38	1.58e-23	Colorectal cancer;
BRCA	trans	rs1459104	0.925	rs12576020	chr11:55221500	G/A	cg15704280	chr7:45808275	SEPT13	0.67	8.35	0.31	4.13e-16	Body mass index;
BRCA	cis	rs7394190	0.748	rs1057410	chr10:75574079	G/A	cg07699608	chr10:75541558	CHCHD1	0.65	9.76	0.36	4.46e-21	Incident atrial fibrillation;
BRCA	trans	rs75804782	0.521	rs55713398	chr2:239419933	A/G	cg01134436	chr17:81009848	B3GNTL1	0.68	8.73	0.33	2.26e-17	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs9986765	0.737	rs10274253	chr7:142810265	G/C	cg21852589	chr7:142981689	TMEM139	0.65	10.38	0.38	1.99e-23	Cancer;Dermatomyositis;
BRCA	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg08847533	chr14:75593920	NEK9	-0.79	-19.07	-0.6	1.52e-64	Height;
BRCA	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg01579765	chr21:45077557	HSF2BP	0.33	8.35	0.31	4.28e-16	Mean corpuscular volume;
BRCA	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg07741184	chr6:167504864	NA	0.35	10.15	0.37	1.57e-22	Crohn's disease;
BRCA	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg01819863	chr10:32635814	EPC1	1.16	20.18	0.62	1.86e-70	Sexual dysfunction (female);
BRCA	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22590775	chr19:49891494	CCDC155	0.49	8.72	0.33	2.44e-17	Multiple sclerosis;
BRCA	cis	rs12618769	0.597	rs3769743	chr2:99063653	C/T	cg10123293	chr2:99228465	UNC50	0.4	8.17	0.31	1.71e-15	Bipolar disorder;
BRCA	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg03709012	chr19:19516395	GATAD2A	0.81	18.95	0.6	7.16e-64	Tonsillectomy;
BRCA	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg26031613	chr14:104095156	KLC1	-0.41	-8.12	-0.31	2.45e-15	Schizophrenia;
BRCA	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg11833968	chr6:79620685	NA	-0.46	-10.29	-0.38	4.47e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg20607798	chr8:58055168	NA	0.47	8.25	0.31	9.1e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.75	-0.36	5.06e-21	IgG glycosylation;
BRCA	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg22601191	chr20:60968625	CABLES2	0.42	9.95	0.37	9.04e-22	Colorectal cancer;
BRCA	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg07493874	chr5:1342172	CLPTM1L	-0.46	-12.63	-0.45	8.1e-33	Lung cancer;
BRCA	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21659725	chr3:3221576	CRBN	-0.5	-12.81	-0.45	1.31e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs7818345	0.967	rs4549789	chr8:19284015	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.32	8.2	0.31	1.35e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg13387374	chr1:19411106	UBR4	-0.58	-12.81	-0.45	1.34e-33	Brain structure;
BRCA	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21659725	chr3:3221576	CRBN	0.38	9.26	0.34	2.96e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-14.18	-0.49	6.82e-40	Platelet count;
BRCA	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06108461	chr20:60628389	TAF4	-0.86	-16.26	-0.54	5.49e-50	Body mass index;
BRCA	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg09904177	chr6:26538194	HMGN4	0.57	18.5	0.59	1.62e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs1506636	1.000	rs7357252	chr7:123369856	C/T	cg03229431	chr7:123269106	ASB15	-0.61	-13.88	-0.48	1.77e-38	Plateletcrit;Platelet count;
BRCA	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	15.0	0.51	8.65e-44	Hypertriglyceridemia;
BRCA	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18402987	chr7:1209562	NA	0.44	9.21	0.34	4.77e-19	Longevity;Endometriosis;
BRCA	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg17063962	chr7:91808500	NA	0.5	11.42	0.41	1.32e-27	Breast cancer;
BRCA	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg09307838	chr4:120376055	NA	-0.76	-16.42	-0.54	8.19e-51	Corneal astigmatism;
BRCA	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg12310025	chr6:25882481	NA	-0.51	-12.13	-0.43	1.32e-30	Blood metabolite levels;
BRCA	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.43	9.56	0.35	2.43e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg12310025	chr6:25882481	NA	-0.54	-12.31	-0.44	2.07e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg26384229	chr12:38710491	ALG10B	0.76	16.91	0.56	2.6e-53	Bladder cancer;
BRCA	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-11.62	-0.42	1.91e-28	Gut microbiome composition (summer);
BRCA	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg09307838	chr4:120376055	NA	0.64	13.92	0.48	1.13e-38	Corneal astigmatism;
BRCA	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg05527609	chr1:210001259	C1orf107	-0.73	-17.79	-0.58	8.04e-58	Orofacial clefts;
BRCA	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg17063962	chr7:91808500	NA	0.55	12.36	0.44	1.24e-31	Breast cancer;
BRCA	cis	rs6499188	0.522	rs8046299	chr16:68672346	G/A	cg02972257	chr16:68554789	NA	-0.47	-8.96	-0.33	3.49e-18	Ulcerative colitis;
BRCA	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg22029157	chr1:209979665	IRF6	0.54	11.09	0.4	3.01e-26	Cleft lip with or without cleft palate;
BRCA	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18876405	chr7:65276391	NA	-0.51	-11.49	-0.41	6.61e-28	Aortic root size;
BRCA	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg27170947	chr2:26402098	FAM59B	-0.93	-16.98	-0.56	1.25e-53	Gut microbiome composition (summer);
BRCA	cis	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg17469321	chr7:55412551	NA	0.49	9.31	0.35	1.98e-19	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg13126279	chr21:47581558	C21orf56	-0.38	-8.3	-0.31	6.03e-16	Testicular germ cell tumor;
BRCA	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg03146154	chr1:46216737	IPP	0.45	9.99	0.37	6.35e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg12386194	chr3:101231763	SENP7	0.45	9.53	0.35	3.27e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg00383909	chr3:49044727	WDR6	0.58	11.05	0.4	4.4e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg08422745	chr4:174089978	GALNT7	-0.81	-18.01	-0.58	5.69e-59	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg24578937	chr1:2090814	PRKCZ	-0.37	-11.8	-0.42	3.21e-29	Height;
BRCA	cis	rs7178424	0.935	rs8034216	chr15:62287528	A/G	cg00456672	chr15:62358751	C2CD4A	0.42	9.59	0.35	1.98e-20	Height;
BRCA	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg06627628	chr2:24431161	ITSN2	-0.79	-14.73	-0.5	1.73e-42	Asthma;
BRCA	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg12179176	chr11:130786555	SNX19	0.73	18.19	0.58	6.95e-60	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg07460842	chr6:66804631	NA	-0.56	-10.14	-0.37	1.62e-22	Blood trace element (Cu levels);
BRCA	trans	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg15704280	chr7:45808275	SEPT13	0.59	8.8	0.33	1.26e-17	Axial length;
BRCA	cis	rs727479	0.543	rs3759811	chr15:51529265	A/G	cg19946085	chr15:51559439	CYP19A1	-0.28	-8.02	-0.3	5.02e-15	Estradiol levels;
BRCA	cis	rs1018836	0.923	rs62526886	chr8:91627676	G/A	cg16814680	chr8:91681699	NA	-0.6	-12.83	-0.45	1.05e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg03146154	chr1:46216737	IPP	0.51	11.25	0.41	6.28e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg13010199	chr12:38710504	ALG10B	0.51	9.99	0.37	6.28e-22	Morning vs. evening chronotype;
BRCA	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg17554472	chr22:41940697	POLR3H	-0.42	-7.9	-0.3	1.22e-14	Vitiligo;
BRCA	cis	rs9790314	0.612	rs9875200	chr3:160733708	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-9.13	-0.34	8.97e-19	Morning vs. evening chronotype;
BRCA	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg09904177	chr6:26538194	HMGN4	0.55	17.67	0.57	3.26e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg24642439	chr20:33292090	TP53INP2	-0.44	-8.7	-0.33	2.78e-17	Height;
BRCA	cis	rs17384381	1.000	rs35193119	chr1:85859265	T/C	cg16011679	chr1:85725395	C1orf52	0.53	8.18	0.31	1.51e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg06092702	chr1:163392909	NA	0.35	9.27	0.34	2.82e-19	Motion sickness;
BRCA	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.98	-15.18	-0.51	1.09e-44	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7737355	0.947	rs10054733	chr5:130989426	C/T	cg06307176	chr5:131281290	NA	0.53	10.34	0.38	2.81e-23	Life satisfaction;
BRCA	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg06108461	chr20:60628389	TAF4	-0.79	-17.05	-0.56	5.51e-54	Body mass index;
BRCA	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg27478167	chr7:817139	HEATR2	-0.48	-9.96	-0.37	8.3e-22	Cerebrospinal P-tau181p levels;
BRCA	trans	rs6479891	1.000	rs12413415	chr10:64919511	T/C	cg14819942	chr15:35414228	NA	0.35	8.63	0.32	5.03e-17	Arthritis (juvenile idiopathic);
BRCA	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg23533926	chr12:111358616	MYL2	-0.41	-8.59	-0.32	6.69e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg14784868	chr12:69753453	YEATS4	0.48	9.59	0.35	2e-20	Response to diuretic therapy;
BRCA	cis	rs7395581	0.877	rs10838690	chr11:47335075	A/G	cg25783544	chr11:47291846	MADD	0.42	9.55	0.35	2.78e-20	HDL cholesterol;
BRCA	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg05347473	chr6:146136440	FBXO30	0.38	7.86	0.3	1.61e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2882667	1.000	rs10064201	chr5:138309405	C/T	cg04439458	chr5:138467593	SIL1	-0.36	-9.66	-0.36	1.02e-20	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.7	-0.77	7.24e-128	Schizophrenia;
BRCA	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg01877450	chr7:97915802	BRI3	-0.39	-8.92	-0.33	5.01e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.78	-0.5	9.3e-43	Chronic sinus infection;
BRCA	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg07169764	chr2:136633963	MCM6	1.1	22.03	0.66	1.84e-80	Corneal structure;
BRCA	trans	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-10.55	-0.39	4.34e-24	Neuroticism;
BRCA	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg26597838	chr10:835615	NA	0.81	14.47	0.5	2.94e-41	Eosinophil percentage of granulocytes;
BRCA	cis	rs73086581	0.786	rs6037705	chr20:3952830	G/C	cg02187196	chr20:3869020	PANK2	0.45	8.27	0.31	7.94e-16	Response to antidepressants in depression;
BRCA	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	5.1e-16	Tonsillectomy;
BRCA	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg13395646	chr4:1353034	KIAA1530	-0.49	-9.03	-0.34	2e-18	Obesity-related traits;
BRCA	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg16606324	chr3:10149918	C3orf24	0.54	10.48	0.38	8.25e-24	Alzheimer's disease;
BRCA	cis	rs701145	0.537	rs1713847	chr3:153791107	C/A	cg17054900	chr3:154042577	DHX36	0.53	9.19	0.34	5.62e-19	Coronary artery disease;
BRCA	cis	rs6840360	0.554	rs58751443	chr4:152709905	A/G	cg22705602	chr4:152727874	NA	-0.4	-10.77	-0.39	5.74e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs13046373	0.535	rs7281767	chr21:32022062	T/C	cg16431978	chr21:31797932	KRTAP13-3	0.35	8.98	0.33	3.03e-18	HDL cholesterol;
BRCA	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	17.83	0.58	5.12e-58	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	13.27	0.46	1.14e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.69	-16.47	-0.55	4.78e-51	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	12.76	0.45	2.26e-33	Colorectal cancer;
BRCA	cis	rs17641971	0.684	rs4873094	chr8:49989578	G/T	cg00325661	chr8:49890786	NA	0.39	10.81	0.39	4.14e-25	Blood metabolite levels;
BRCA	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg07636037	chr3:49044803	WDR6	0.55	8.7	0.33	2.75e-17	Menarche (age at onset);
BRCA	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg20387954	chr3:183756860	HTR3D	0.45	10.03	0.37	4.19e-22	Anterior chamber depth;
BRCA	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg17971929	chr21:40555470	PSMG1	-0.47	-10.39	-0.38	1.87e-23	Menarche (age at onset);
BRCA	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg21475434	chr5:93447410	FAM172A	0.66	8.47	0.32	1.67e-16	Diabetic retinopathy;
BRCA	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24549020	chr5:56110836	MAP3K1	0.66	13.46	0.47	1.47e-36	Initial pursuit acceleration;
BRCA	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg12310025	chr6:25882481	NA	0.42	9.73	0.36	6.08e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.747	rs4240867	chr1:152954921	A/G	cg21543102	chr1:152974771	SPRR3	0.3	8.86	0.33	8.13e-18	Inflammatory skin disease;
BRCA	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg03146154	chr1:46216737	IPP	-0.44	-9.78	-0.36	3.68e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.95	-0.43	7.49e-30	Total cholesterol levels;
BRCA	cis	rs7727544	0.545	rs10074490	chr5:131340032	C/T	cg14196790	chr5:131705035	SLC22A5	0.31	8.0	0.3	5.93e-15	Blood metabolite levels;
BRCA	trans	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg07817883	chr1:32538562	TMEM39B	0.55	8.84	0.33	9.31e-18	Monocyte percentage of white cells;
BRCA	cis	rs2625529	0.824	rs4777480	chr15:72328997	A/C	cg16672083	chr15:72433130	SENP8	-0.84	-17.84	-0.58	4.44e-58	Red blood cell count;
BRCA	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	-0.44	-8.77	-0.33	1.55e-17	Tonsillectomy;
BRCA	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.58	0.35	2.16e-20	Menopause (age at onset);
BRCA	trans	rs7980799	0.935	rs4931717	chr12:33521151	A/G	cg26384229	chr12:38710491	ALG10B	0.4	8.41	0.32	2.73e-16	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg18479299	chr3:125709523	NA	-0.53	-8.14	-0.31	2.03e-15	Blood pressure (smoking interaction);
BRCA	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.47	10.89	0.4	1.91e-25	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg06640241	chr16:89574553	SPG7	0.59	12.97	0.46	2.54e-34	Multiple myeloma (IgH translocation);
BRCA	cis	rs11250464	0.724	rs4614361	chr10:1410394	A/G	cg08668359	chr10:1443807	ADARB2	0.41	8.16	0.31	1.79e-15	Radiation response;
BRCA	cis	rs868036	0.957	rs9920662	chr15:68104297	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	9.46	0.35	5.8e-20	Restless legs syndrome;
BRCA	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg09307838	chr4:120376055	NA	0.63	13.26	0.46	1.29e-35	Corneal astigmatism;
BRCA	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21659725	chr3:3221576	CRBN	-0.47	-9.94	-0.37	9.53e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg06671706	chr8:8559999	CLDN23	0.45	8.76	0.33	1.69e-17	Obesity-related traits;
BRCA	cis	rs17384381	1.000	rs12140457	chr1:85860170	G/A	cg16011679	chr1:85725395	C1orf52	0.53	8.15	0.31	1.86e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2652834	1.000	rs2729780	chr15:63404639	C/G	cg05507819	chr15:63340323	TPM1	0.45	8.34	0.31	4.49e-16	HDL cholesterol;
BRCA	cis	rs6977660	0.619	rs10263780	chr7:19778086	A/G	cg07541023	chr7:19748670	TWISTNB	-0.55	-9.88	-0.36	1.65e-21	Thyroid stimulating hormone;
BRCA	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.51	8.32	0.31	5.45e-16	Lung function (FEV1/FVC);
BRCA	cis	rs11634851	1.000	rs11638879	chr15:81030214	A/G	cg03950166	chr15:80988613	FAM108C1	0.35	7.84	0.3	1.91e-14	Systolic blood pressure;
BRCA	cis	rs1882538	0.596	rs10281827	chr7:133081810	A/G	cg10665199	chr7:133106180	EXOC4	0.46	9.9	0.36	1.33e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs977987	0.835	rs8046109	chr16:75360096	A/G	cg03315344	chr16:75512273	CHST6	0.54	12.78	0.45	1.73e-33	Dupuytren's disease;
BRCA	trans	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg25214090	chr10:38739885	LOC399744	0.43	10.17	0.37	1.3e-22	Corneal astigmatism;
BRCA	cis	rs57590327	0.528	rs13086292	chr3:81705368	G/A	cg07356753	chr3:81810745	GBE1	-0.43	-9.85	-0.36	2.16e-21	Extraversion;
BRCA	cis	rs16958440	1.000	rs62096478	chr18:44662409	A/G	cg17192377	chr18:44677553	HDHD2	0.69	10.1	0.37	2.41e-22	Sitting height ratio;
BRCA	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg25664220	chr3:72788482	NA	-0.53	-10.88	-0.4	2.13e-25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg21132104	chr15:45694354	SPATA5L1	0.75	16.9	0.56	2.9e-53	Homoarginine levels;
BRCA	trans	rs11088226	0.581	rs2016103	chr21:33878030	G/A	cg09050820	chr6:167586206	TCP10L2	0.38	7.85	0.3	1.72e-14	Gastritis;
BRCA	cis	rs13040088	0.872	rs2295481	chr20:61574727	C/T	cg23096297	chr20:61557774	DIDO1	0.9	17.35	0.57	1.55e-55	Menopause (age at onset);
BRCA	cis	rs16854884	0.586	rs7611326	chr3:143736374	C/T	cg06585982	chr3:143692056	C3orf58	0.51	10.64	0.39	1.89e-24	Economic and political preferences (feminism/equality);
BRCA	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg08601574	chr20:25228251	PYGB	0.41	9.61	0.36	1.64e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg01483505	chr11:975446	AP2A2	0.3	8.01	0.3	5.5e-15	Alzheimer's disease (late onset);
BRCA	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg17470723	chr8:74884337	TCEB1	0.41	8.82	0.33	1.06e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs503734	0.521	rs348884	chr3:100975293	C/G	cg27318481	chr3:100970896	IMPG2	-0.41	-9.88	-0.36	1.66e-21	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10416265	0.528	rs3786932	chr19:33620488	T/A	cg17764715	chr19:33622953	WDR88	0.51	8.13	0.31	2.26e-15	Bone properties (heel);
BRCA	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg27490568	chr2:178487706	NA	0.5	8.27	0.31	7.6e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs897984	0.542	rs8061047	chr16:31068960	T/C	cg02466173	chr16:30829666	NA	-0.43	-9.64	-0.36	1.29e-20	Dementia with Lewy bodies;
BRCA	cis	rs7927771	0.524	rs11039377	chr11:47789776	C/T	cg20307385	chr11:47447363	PSMC3	0.42	9.54	0.35	2.88e-20	Subjective well-being;
BRCA	cis	rs1595825	0.891	rs77946222	chr2:198533251	C/T	cg19156104	chr2:198669113	PLCL1	-0.46	-8.59	-0.32	6.88e-17	Ulcerative colitis;
BRCA	trans	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg23711669	chr6:146136114	FBXO30	0.74	17.75	0.57	1.29e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg17509989	chr5:176798049	RGS14	0.94	19.57	0.61	3.37e-67	Urinary electrolytes (magnesium/calcium ratio);
BRCA	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg02476566	chr12:106696527	TCP11L2	0.5	9.39	0.35	1e-19	Tourette syndrome;
BRCA	cis	rs7131987	0.903	rs11050163	chr12:29420398	C/T	cg09582351	chr12:29534625	ERGIC2	-0.39	-9.49	-0.35	4.67e-20	QT interval;
BRCA	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18876405	chr7:65276391	NA	-0.55	-12.95	-0.46	3.03e-34	Aortic root size;
BRCA	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg06238570	chr21:40685208	BRWD1	-0.4	-8.24	-0.31	9.95e-16	Menarche (age at onset);
BRCA	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg20503657	chr10:835505	NA	0.9	13.51	0.47	9.42e-37	Eosinophil percentage of granulocytes;
BRCA	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-10.35	-0.38	2.58e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg18016565	chr1:150552671	MCL1	0.35	8.24	0.31	1.01e-15	Tonsillectomy;
BRCA	trans	rs11989744	0.597	rs11135768	chr8:23573278	A/G	cg03492747	chr16:86543808	FOXF1	0.43	10.68	0.39	1.34e-24	Waist-hip ratio;
BRCA	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03517284	chr6:25882590	NA	-0.51	-11.52	-0.41	5.1e-28	Blood metabolite levels;
BRCA	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg18016565	chr1:150552671	MCL1	-0.39	-8.85	-0.33	8.88e-18	Tonsillectomy;
BRCA	cis	rs7264396	0.887	rs224362	chr20:34062642	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-8.43	-0.32	2.22e-16	Total cholesterol levels;
BRCA	cis	rs6087990	0.806	rs910085	chr20:31383353	T/G	cg13636640	chr20:31349939	DNMT3B	0.65	20.7	0.63	3.29e-73	Ulcerative colitis;
BRCA	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg00857998	chr1:205179979	DSTYK	0.44	8.33	0.31	4.82e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs6882046	0.513	rs628158	chr5:88041781	G/A	cg22951263	chr5:87985283	NA	-0.38	-10.65	-0.39	1.75e-24	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
BRCA	cis	rs3125734	0.572	rs7896627	chr10:64046354	T/G	cg19640130	chr10:64028056	RTKN2	-0.33	-9.05	-0.34	1.64e-18	Rheumatoid arthritis;
BRCA	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg22906224	chr7:99728672	NA	0.43	7.93	0.3	9.58e-15	Coronary artery disease;
BRCA	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.4	-8.7	-0.33	2.82e-17	Menarche (age at onset);
BRCA	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg06671706	chr8:8559999	CLDN23	0.45	8.63	0.32	4.86e-17	Obesity-related traits;
BRCA	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg21573476	chr21:45109991	RRP1B	-0.35	-9.24	-0.34	3.62e-19	Mean corpuscular volume;
BRCA	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg08888203	chr3:10149979	C3orf24	0.65	11.97	0.43	6.05e-30	Alzheimer's disease;
BRCA	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg21918786	chr6:109611834	NA	-0.48	-14.03	-0.49	3.57e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg07148914	chr20:33460835	GGT7	0.49	10.33	0.38	3.06e-23	Height;
BRCA	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg20946044	chr11:1010712	AP2A2	-0.37	-7.93	-0.3	9.63e-15	Alzheimer's disease (late onset);
BRCA	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg25664220	chr3:72788482	NA	-0.55	-11.84	-0.42	2.31e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs877529	0.967	rs139410	chr22:39552597	A/G	cg18708252	chr22:39545030	CBX7	-0.31	-8.17	-0.31	1.62e-15	Multiple myeloma;
BRCA	trans	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg13010199	chr12:38710504	ALG10B	0.42	7.92	0.3	1.05e-14	Resting heart rate;
BRCA	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.27	8.77	0.33	1.61e-17	Electroencephalogram traits;
BRCA	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg03146154	chr1:46216737	IPP	-0.44	-9.78	-0.36	3.68e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg03146154	chr1:46216737	IPP	0.48	10.73	0.39	8.59e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg22535103	chr8:58192502	C8orf71	-0.54	-9.18	-0.34	6.01e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs1691799	0.867	rs1168344	chr12:66758213	G/A	cg16791601	chr12:66731901	HELB	-0.66	-17.99	-0.58	7.66e-59	White blood cell count (basophil);
BRCA	cis	rs7809950	0.773	rs62483722	chr7:107186349	C/T	cg23024343	chr7:107201750	COG5	-0.39	-8.96	-0.33	3.55e-18	Coronary artery disease;
BRCA	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg13852791	chr20:30311386	BCL2L1	0.95	22.78	0.67	1.47e-84	Mean corpuscular hemoglobin;
BRCA	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg21535247	chr6:8435926	SLC35B3	0.41	9.34	0.35	1.59e-19	Motion sickness;
BRCA	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.83	-0.39	3.35e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg24399712	chr22:39784796	NA	0.58	12.22	0.44	5.36e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs6545883	0.894	rs778157	chr2:61554289	C/G	cg15711740	chr2:61764176	XPO1	-0.51	-12.98	-0.46	2.26e-34	Tuberculosis;
BRCA	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg23625390	chr15:77176239	SCAPER	-0.54	-12.75	-0.45	2.58e-33	Blood metabolite levels;
BRCA	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg00701064	chr4:6280414	WFS1	0.7	19.41	0.61	2.52e-66	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg09307838	chr4:120376055	NA	0.58	12.69	0.45	4.73e-33	Corneal astigmatism;
BRCA	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg21782813	chr7:2030301	MAD1L1	0.42	11.41	0.41	1.46e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg08807101	chr21:30365312	RNF160	-0.43	-9.19	-0.34	5.26e-19	Dental caries;
BRCA	trans	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg25214090	chr10:38739885	LOC399744	0.43	10.02	0.37	4.62e-22	Educational attainment;
BRCA	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg06064525	chr11:970664	AP2A2	-0.33	-9.65	-0.36	1.2e-20	Alzheimer's disease (late onset);
BRCA	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.56	-8.69	-0.33	2.95e-17	HIV-1 control;
BRCA	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.03	0.49	3.53e-39	Motion sickness;
BRCA	cis	rs858239	0.539	rs4377861	chr7:23185969	C/T	cg23682824	chr7:23144976	KLHL7	0.37	9.48	0.35	4.86e-20	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.73	-21.29	-0.64	1.91e-76	Schizophrenia;
BRCA	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg17063962	chr7:91808500	NA	-0.53	-12.33	-0.44	1.78e-31	Breast cancer;
BRCA	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg06238570	chr21:40685208	BRWD1	-0.41	-8.36	-0.31	4.05e-16	Menarche (age at onset);
BRCA	cis	rs7903847	0.642	rs9888117	chr10:99159963	C/G	cg20016023	chr10:99160130	RRP12	-0.24	-7.95	-0.3	8.22e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg11833968	chr6:79620685	NA	-0.42	-9.24	-0.34	3.68e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg03676636	chr4:99064102	C4orf37	0.21	7.94	0.3	9.23e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs113835537	0.529	rs79798028	chr11:66199362	T/G	cg24851651	chr11:66362959	CCS	0.42	8.05	0.3	4.1e-15	Airway imaging phenotypes;
BRCA	cis	rs290268	0.874	rs290988	chr9:93562955	C/G	cg02608019	chr9:93564028	SYK	0.55	12.23	0.44	4.54e-31	Platelet count;
BRCA	cis	rs28374715	0.532	rs11854820	chr15:41676526	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.09	-24.82	-0.7	9.65e-96	Ulcerative colitis;
BRCA	cis	rs67981189	0.513	rs2526856	chr14:71412717	A/G	cg15816911	chr14:71606274	NA	0.38	8.26	0.31	8.59e-16	Schizophrenia;
BRCA	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg16586182	chr3:47516702	SCAP	-0.55	-12.44	-0.44	5.89e-32	Colorectal cancer;
BRCA	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.39	10.31	0.38	3.7e-23	IgG glycosylation;
BRCA	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg27366882	chr3:133540807	NA	-0.34	-8.26	-0.31	8.3e-16	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.18	-0.34	6e-19	Bipolar disorder;
BRCA	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.47	0.38	8.99e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg24060327	chr5:131705240	SLC22A5	0.6	11.36	0.41	2.32e-27	Acylcarnitine levels;
BRCA	cis	rs2554380	0.943	rs2585061	chr15:84347751	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.32	-7.87	-0.3	1.56e-14	Height;
BRCA	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.42	-8.55	-0.32	8.75e-17	Monocyte percentage of white cells;
BRCA	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-8.4	-0.32	2.95e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs1997103	1.000	rs1997098	chr7:55405594	G/T	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.64	-15.02	-0.51	6.91e-44	Ulcerative colitis;
BRCA	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg23033748	chr14:75592666	NEK9	-0.42	-10.03	-0.37	4.54e-22	Height;
BRCA	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.31	-7.85	-0.3	1.79e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7301826	0.967	rs4759790	chr12:131296390	T/G	cg11011512	chr12:131303247	STX2	0.42	10.78	0.39	4.99e-25	Plasma plasminogen activator levels;
BRCA	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.58e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg00074818	chr8:8560427	CLDN23	0.36	8.0	0.3	5.98e-15	Obesity-related traits;
BRCA	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.93	-26.13	-0.72	6.44e-103	Birth weight;
BRCA	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	ch.11.42038R	chr11:967971	AP2A2	0.52	16.55	0.55	1.84e-51	Alzheimer's disease (late onset);
BRCA	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg14675211	chr2:100938903	LONRF2	0.46	10.58	0.39	3.25e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs7178375	0.607	rs7171212	chr15:31207711	C/T	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.59	-8.26	-0.31	8.56e-16	Hypertriglyceridemia;
BRCA	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg17724175	chr1:150552817	MCL1	0.26	8.52	0.32	1.12e-16	Tonsillectomy;
BRCA	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg05754148	chr16:3507555	NAT15	0.55	8.14	0.31	2.02e-15	Tuberculosis;
BRCA	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg00071950	chr4:10020882	SLC2A9	0.63	15.59	0.52	1.14e-46	Bone mineral density;
BRCA	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg23649088	chr2:200775458	C2orf69	0.62	10.87	0.39	2.3e-25	Schizophrenia;
BRCA	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg13550731	chr2:172543902	DYNC1I2	0.94	32.19	0.79	7.76e-136	Schizophrenia;
BRCA	cis	rs7631605	0.905	rs7639327	chr3:37099788	A/G	cg15934958	chr3:37212084	LRRFIP2	0.47	10.8	0.39	4.28e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs11958404	0.932	rs12517979	chr5:157428918	T/C	cg05962755	chr5:157440814	NA	0.55	10.4	0.38	1.66e-23	IgG glycosylation;
BRCA	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.65	-0.45	6.63e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg07636037	chr3:49044803	WDR6	0.98	29.08	0.75	4.44e-119	Parkinson's disease;
BRCA	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.96	-0.3	7.72e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg18357645	chr12:58087776	OS9	0.35	9.33	0.35	1.73e-19	Multiple sclerosis;
BRCA	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08219700	chr8:58056026	NA	0.47	8.44	0.32	2.14e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg25817165	chr18:72167213	CNDP2	-0.71	-12.85	-0.45	8.76e-34	Refractive error;
BRCA	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg20203395	chr5:56204925	C5orf35	-0.5	-10.23	-0.38	7.23e-23	Initial pursuit acceleration;
BRCA	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg24562669	chr7:97807699	LMTK2	0.45	12.23	0.44	4.67e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.51	-9.42	-0.35	7.89e-20	Gut microbiome composition (summer);
BRCA	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg26818010	chr10:134567672	INPP5A	0.39	9.24	0.34	3.65e-19	Migraine;
BRCA	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg04553112	chr3:125709451	NA	-0.56	-8.53	-0.32	1.08e-16	Blood pressure (smoking interaction);
BRCA	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg24060327	chr5:131705240	SLC22A5	-0.62	-11.67	-0.42	1.14e-28	Blood metabolite levels;
BRCA	cis	rs17741873	0.836	rs12221230	chr10:75604972	T/C	cg07699608	chr10:75541558	CHCHD1	0.56	8.81	0.33	1.16e-17	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs117623576	0.941	rs7098334	chr10:32418501	G/T	cg03047570	chr10:32398778	NA	-0.58	-8.92	-0.33	4.87e-18	Anti-saccade response;
BRCA	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg10596483	chr8:143751796	JRK	0.39	8.25	0.31	8.98e-16	Schizophrenia;
BRCA	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg12935359	chr14:103987150	CKB	-0.59	-13.52	-0.47	7.94e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.48	-0.32	1.52e-16	Total body bone mineral density;
BRCA	cis	rs7020830	0.571	rs7031314	chr9:37376122	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.87	-16.63	-0.55	7.39e-52	Schizophrenia;
BRCA	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg12379764	chr21:47803548	PCNT	-0.38	-8.08	-0.3	3.33e-15	Testicular germ cell tumor;
BRCA	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	11.09	0.4	2.82e-26	Bone mineral density;
BRCA	trans	rs8002861	0.967	rs9533691	chr13:44482208	A/G	cg17145862	chr1:211918768	LPGAT1	0.69	18.01	0.58	5.82e-59	Leprosy;
BRCA	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.3	0.41	4.02e-27	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg14863265	chr7:2801509	GNA12	-0.42	-9.64	-0.36	1.31e-20	Height;
BRCA	cis	rs13102973	1.000	rs13112665	chr4:135898581	C/A	cg14419869	chr4:135874104	NA	0.54	11.15	0.4	1.64e-26	Subjective well-being;
BRCA	cis	rs17741873	0.779	rs4746154	chr10:75629396	G/A	cg07699608	chr10:75541558	CHCHD1	0.55	8.4	0.32	2.78e-16	Paclitaxel disposition in epithelial ovarian cancer;
BRCA	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg08859206	chr1:53392774	SCP2	-0.44	-8.81	-0.33	1.16e-17	Monocyte count;
BRCA	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg04944784	chr2:26401820	FAM59B	-0.97	-16.48	-0.55	4.21e-51	Gut microbiome composition (summer);
BRCA	cis	rs7631605	0.935	rs2302504	chr3:37116386	A/C	cg15934958	chr3:37212084	LRRFIP2	-0.41	-9.71	-0.36	6.71e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg16339924	chr4:17578868	LAP3	0.67	16.2	0.54	1.04e-49	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg22713356	chr15:30763199	NA	1.09	21.63	0.65	3.04e-78	Uric acid levels;
BRCA	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg00814883	chr7:100076585	TSC22D4	-0.49	-10.26	-0.38	5.9e-23	Platelet count;
BRCA	cis	rs9583531	0.843	rs7999702	chr13:111382264	A/C	cg24331049	chr13:111365604	ING1	-0.65	-14.1	-0.49	1.58e-39	Coronary artery disease;
BRCA	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.76	10.38	0.38	1.98e-23	Initial pursuit acceleration;
BRCA	cis	rs1506636	0.886	rs6466878	chr7:123272278	T/C	cg03229431	chr7:123269106	ASB15	-0.68	-15.83	-0.53	7.21e-48	Plateletcrit;Platelet count;
BRCA	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg11814155	chr7:99998594	ZCWPW1	0.56	9.49	0.35	4.41e-20	Platelet count;
BRCA	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.8	-0.42	3.43e-29	Response to antipsychotic treatment;
BRCA	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg24450063	chr1:156163899	SLC25A44	1.08	33.77	0.8	3.07e-144	Testicular germ cell tumor;
BRCA	cis	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg21775007	chr8:11205619	TDH	-0.5	-10.39	-0.38	1.87e-23	Triglycerides;
BRCA	cis	rs1669338	0.507	rs4685609	chr3:3202279	T/C	cg16797762	chr3:3221439	CRBN	-0.65	-9.95	-0.37	8.55e-22	White matter integrity;
BRCA	cis	rs7394190	0.748	rs11000773	chr10:75534115	G/T	cg07699608	chr10:75541558	CHCHD1	0.65	9.64	0.36	1.26e-20	Incident atrial fibrillation;
BRCA	cis	rs16854884	0.770	rs13091882	chr3:143818661	C/T	cg06585982	chr3:143692056	C3orf58	0.41	7.96	0.3	7.68e-15	Economic and political preferences (feminism/equality);
BRCA	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.78	0.67	1.54e-84	Chronic sinus infection;
BRCA	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg00101154	chr16:420108	MRPL28	-0.48	-11.73	-0.42	6.43e-29	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs730775	0.505	rs325001	chr6:44270936	A/G	cg21130236	chr6:44246755	TMEM151B	0.29	8.26	0.31	8.34e-16	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg25838465	chr1:92012736	NA	-0.68	-19.97	-0.62	2.66e-69	Breast cancer;
BRCA	cis	rs6484504	0.600	rs366758	chr11:31222499	A/C	cg26647111	chr11:31128758	NA	-0.44	-9.67	-0.36	9.59e-21	Red blood cell count;
BRCA	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg05985134	chr18:33552581	C18orf21	0.64	12.25	0.44	3.81e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg23711669	chr6:146136114	FBXO30	-0.71	-16.94	-0.56	2e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11955398	0.647	rs57521726	chr5:59984897	A/T	cg02684056	chr5:59996105	DEPDC1B	0.39	9.02	0.34	2.25e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-10.1	-0.37	2.36e-22	Triglycerides;
BRCA	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg05025164	chr4:1340916	KIAA1530	0.37	8.34	0.31	4.66e-16	Longevity;
BRCA	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg04990556	chr1:26633338	UBXN11	-0.74	-18.31	-0.59	1.61e-60	Obesity-related traits;
BRCA	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg04450456	chr4:17643702	FAM184B	0.39	11.62	0.42	1.95e-28	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg23018236	chr17:30244563	NA	-0.62	-10.04	-0.37	3.95e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg24631222	chr15:78858424	CHRNA5	0.36	7.82	0.3	2.2e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs9837602	0.592	rs629120	chr3:99425767	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-9.46	-0.35	5.69e-20	Breast cancer;
BRCA	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg08917208	chr2:24149416	ATAD2B	1.1	15.53	0.52	2.12e-46	Lymphocyte counts;
BRCA	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg20503657	chr10:835505	NA	1.04	18.27	0.59	2.66e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.8	0.36	3.32e-21	Bipolar disorder;
BRCA	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	14.01	0.48	4.36e-39	Ileal carcinoids;
BRCA	cis	rs34779708	0.801	rs12246600	chr10:35538121	A/C	cg03585969	chr10:35415529	CREM	0.46	9.32	0.35	1.94e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg26513180	chr16:89883248	FANCA	-0.59	-13.22	-0.46	1.87e-35	Vitiligo;
BRCA	cis	rs7408868	1.000	rs2074618	chr19:15276143	C/T	cg14696996	chr19:15285081	NOTCH3	0.98	14.37	0.49	8.85e-41	Pulse pressure;
BRCA	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg24642439	chr20:33292090	TP53INP2	0.69	15.98	0.53	1.29e-48	Coronary artery disease;
BRCA	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg08645402	chr16:4508243	NA	0.36	8.28	0.31	6.96e-16	Schizophrenia;
BRCA	trans	rs629535	0.590	rs62513426	chr8:70136843	T/G	cg21567404	chr3:27674614	NA	-0.96	-17.52	-0.57	2.06e-56	Dupuytren's disease;
BRCA	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg05729581	chr11:3078854	CARS	-0.34	-7.93	-0.3	9.96e-15	Longevity;
BRCA	cis	rs6910061	1.000	rs6456868	chr6:11115183	G/A	cg27233058	chr6:11094804	LOC221710	0.53	9.43	0.35	7.64e-20	Diabetic kidney disease;
BRCA	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg05347473	chr6:146136440	FBXO30	0.59	11.32	0.41	3.19e-27	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4302748	0.862	rs35940984	chr7:36187333	C/G	cg24442661	chr7:36192818	EEPD1	0.46	8.8	0.33	1.27e-17	Platelet count;
BRCA	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.04	0.3	4.26e-15	Menarche (age at onset);
BRCA	cis	rs66530629	0.958	rs55965563	chr1:25050829	G/A	cg01905478	chr1:25040257	NA	0.36	8.29	0.31	6.5e-16	Plateletcrit;
BRCA	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg24879335	chr3:133465180	TF	0.33	11.07	0.4	3.57e-26	Iron status biomarkers;
BRCA	cis	rs6723226	0.804	rs17428810	chr2:32736043	T/C	cg02381751	chr2:32503542	YIPF4	-0.62	-12.32	-0.44	1.87e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18876405	chr7:65276391	NA	-0.63	-15.5	-0.52	3.05e-46	Aortic root size;
BRCA	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg21252483	chr19:49399788	TULP2	-0.4	-9.08	-0.34	1.39e-18	Red cell distribution width;
BRCA	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg09307838	chr4:120376055	NA	0.61	12.31	0.44	2.09e-31	Corneal astigmatism;
BRCA	cis	rs7727544	0.625	rs3864277	chr5:131420249	G/A	cg14196790	chr5:131705035	SLC22A5	0.37	9.09	0.34	1.25e-18	Blood metabolite levels;
BRCA	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg08888203	chr3:10149979	C3orf24	0.61	13.03	0.46	1.34e-34	Alzheimer's disease;
BRCA	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.81	0.55	9.16e-53	Axial length;
BRCA	cis	rs897984	0.609	rs17839567	chr16:31057945	A/G	cg02466173	chr16:30829666	NA	-0.41	-9.27	-0.34	2.86e-19	Dementia with Lewy bodies;
BRCA	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg03188948	chr7:1209495	NA	0.78	8.05	0.3	3.95e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg18131467	chr2:239335373	ASB1	0.86	21.85	0.65	1.88e-79	Multiple system atrophy;
BRCA	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg07148914	chr20:33460835	GGT7	-0.43	-9.31	-0.35	2.09e-19	Height;
BRCA	cis	rs12618769	0.597	rs17031139	chr2:99036530	A/G	cg10123293	chr2:99228465	UNC50	-0.39	-7.97	-0.3	7.3e-15	Bipolar disorder;
BRCA	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg09307838	chr4:120376055	NA	0.62	13.47	0.47	1.37e-36	Corneal astigmatism;
BRCA	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11764359	chr7:65958608	NA	-0.76	-17.43	-0.57	5.6e-56	Aortic root size;
BRCA	trans	rs4650994	1.000	rs6660445	chr1:178528871	C/T	cg05059571	chr16:84539110	KIAA1609	-0.41	-9.22	-0.34	4.12e-19	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs12711979	0.740	rs6711964	chr2:3820916	A/T	cg17052675	chr2:3827356	NA	-0.48	-14.31	-0.49	1.8e-40	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11890956	chr21:40555474	PSMG1	1.04	29.28	0.76	3.45e-120	Cognitive function;
BRCA	trans	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.37	8.43	0.32	2.23e-16	Corneal astigmatism;
BRCA	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg10057126	chr4:77819792	ANKRD56	0.67	15.52	0.52	2.43e-46	Emphysema distribution in smoking;
BRCA	cis	rs2652822	0.935	rs12148069	chr15:63443792	A/T	cg02713581	chr15:63449717	RPS27L	0.49	9.87	0.36	1.71e-21	Metabolic traits;
BRCA	trans	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg17830980	chr10:43048298	ZNF37B	-0.37	-8.87	-0.33	7.12e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg00071950	chr4:10020882	SLC2A9	0.64	16.26	0.54	5.02e-50	Bone mineral density;
BRCA	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg04989706	chr14:50066350	PPIL5	-0.48	-9.32	-0.35	1.93e-19	Carotid intima media thickness;
BRCA	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg00814883	chr7:100076585	TSC22D4	-0.52	-11.91	-0.43	1.13e-29	Platelet count;
BRCA	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg11266682	chr4:10021025	SLC2A9	0.47	12.31	0.44	2.18e-31	Bone mineral density;
BRCA	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.73	-0.33	2.24e-17	Total body bone mineral density;
BRCA	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11644478	chr21:40555479	PSMG1	0.73	14.23	0.49	4.27e-40	Cognitive function;
BRCA	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg11663144	chr21:46675770	NA	-0.39	-8.19	-0.31	1.41e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg13385794	chr1:248469461	NA	0.28	7.8	0.3	2.44e-14	Common traits (Other);
BRCA	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.31	0.31	5.91e-16	Axial length;
BRCA	cis	rs7247513	1.000	rs2042947	chr19:12693103	A/G	cg01871581	chr19:12707946	ZNF490	-0.71	-16.68	-0.55	4.23e-52	Bipolar disorder;
BRCA	cis	rs6942756	0.531	rs9649530	chr7:128927406	G/A	cg02491457	chr7:128862824	NA	0.45	9.42	0.35	8.13e-20	White matter hyperintensity burden;
BRCA	cis	rs250677	0.522	rs10040798	chr5:148367324	A/G	cg12140854	chr5:148520817	ABLIM3	0.41	8.26	0.31	8.63e-16	Breast cancer;
BRCA	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.61	-16.79	-0.55	1.06e-52	Schizophrenia;
BRCA	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18404041	chr3:52824283	ITIH1	-0.52	-15.44	-0.52	5.83e-46	Bipolar disorder;
BRCA	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg02038168	chr22:39784481	NA	-0.42	-8.66	-0.32	3.87e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs41005	1.000	rs193929	chr2:8107620	G/T	cg03155496	chr2:8117019	LOC339788	0.57	15.65	0.53	5.6e-47	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14829155	chr15:31115871	NA	0.55	13.76	0.48	6.77e-38	Huntington's disease progression;
BRCA	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.75	-0.55	1.78e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1577917	0.958	rs3900313	chr6:86537154	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.54	-0.42	4.21e-28	Response to antipsychotic treatment;
BRCA	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.57	0.55	1.53e-51	Alzheimer's disease (late onset);
BRCA	trans	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.62	-0.36	1.48e-20	Extrinsic epigenetic age acceleration;
BRCA	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21582582	chr3:182698605	DCUN1D1	0.4	10.41	0.38	1.49e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs10883723	0.962	rs11191294	chr10:104225837	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	17.02	0.56	7.45e-54	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-9.65	-0.36	1.17e-20	Alzheimer's disease (late onset);
BRCA	cis	rs999943	0.846	rs999942	chr6:33624902	G/C	cg14003231	chr6:33640908	ITPR3	0.67	15.1	0.51	2.67e-44	Obesity (extreme);
BRCA	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg06212747	chr3:49208901	KLHDC8B	0.45	9.37	0.35	1.28e-19	Parkinson's disease;
BRCA	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg03929089	chr4:120376271	NA	0.47	7.93	0.3	1.01e-14	Axial length;
BRCA	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg23788917	chr6:8435910	SLC35B3	-0.47	-10.34	-0.38	2.79e-23	Motion sickness;
BRCA	cis	rs13095912	0.962	rs11916386	chr3:185308069	G/T	cg11274856	chr3:185301563	NA	0.34	8.5	0.32	1.36e-16	Systolic blood pressure;
BRCA	trans	rs3960554	0.808	rs2302434	chr7:75630183	C/T	cg19862616	chr7:65841803	NCRNA00174	0.55	11.58	0.42	2.72e-28	Eotaxin levels;
BRCA	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg06784218	chr1:46089804	CCDC17	0.51	12.14	0.43	1.14e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg07169764	chr2:136633963	MCM6	1.23	23.94	0.69	6.72e-91	Corneal structure;
BRCA	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19346786	chr7:2764209	NA	-0.32	-9.34	-0.35	1.55e-19	Height;
BRCA	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	8.76	0.33	1.79e-17	Iron status biomarkers;
BRCA	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	12.79	0.45	1.65e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.82	0.3	2.21e-14	Aortic root size;
BRCA	cis	rs12545109	0.800	rs1371936	chr8:57422715	A/G	cg09654669	chr8:57350985	NA	-0.42	-8.07	-0.3	3.57e-15	Obesity-related traits;
BRCA	cis	rs2742417	0.603	rs2742371	chr3:45782763	G/A	cg04837898	chr3:45731254	SACM1L	-0.38	-7.81	-0.3	2.31e-14	Response to anti-depressant treatment in major depressive disorder;
BRCA	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06123940	chr18:29597493	RNF125	-0.5	-7.87	-0.3	1.55e-14	Response to platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.28	-7.99	-0.3	6.24e-15	Personality dimensions;
BRCA	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg10253484	chr15:75165896	SCAMP2	-0.59	-11.35	-0.41	2.41e-27	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg07741184	chr6:167504864	NA	0.33	9.88	0.36	1.64e-21	Primary biliary cholangitis;
BRCA	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg09658497	chr7:2847517	GNA12	-0.4	-8.55	-0.32	9e-17	Height;
BRCA	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.97	-0.3	7.52e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs71636778	0.543	rs75305560	chr1:27242521	T/G	cg12203394	chr1:27248618	NUDC	0.6	9.46	0.35	5.7e-20	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	trans	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg26043149	chr18:55253948	FECH	-0.4	-8.87	-0.33	7.43e-18	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12493885	0.818	rs1521324	chr3:153758863	G/T	cg17054900	chr3:154042577	DHX36	-0.5	-8.55	-0.32	8.73e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	7.93	0.3	9.75e-15	Tonsillectomy;
BRCA	cis	rs17253792	0.822	rs10139905	chr14:56170031	T/C	cg01858014	chr14:56050164	KTN1	-0.59	-9.11	-0.34	1.05e-18	Putamen volume;
BRCA	cis	rs877282	0.891	rs10904557	chr10:797490	C/T	cg17470449	chr10:769945	NA	-0.52	-9.11	-0.34	1.09e-18	Uric acid levels;
BRCA	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.36	12.07	0.43	2.39e-30	Bipolar disorder;
BRCA	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg05868516	chr6:26286170	HIST1H4H	0.42	8.65	0.32	4.09e-17	Educational attainment;
BRCA	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg20307385	chr11:47447363	PSMC3	0.72	16.44	0.55	6.91e-51	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg08885076	chr2:99613938	TSGA10	-0.6	-13.44	-0.47	1.91e-36	Chronic sinus infection;
BRCA	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg08470875	chr2:26401718	FAM59B	-0.51	-8.52	-0.32	1.15e-16	Gut microbiome composition (summer);
BRCA	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg20887711	chr4:1340912	KIAA1530	0.4	9.69	0.36	7.97e-21	Longevity;
BRCA	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22455342	chr2:225449267	CUL3	0.41	9.75	0.36	4.83e-21	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg18279126	chr7:2041391	MAD1L1	0.39	9.01	0.34	2.45e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs16854884	0.586	rs7650172	chr3:143729408	G/C	cg06585982	chr3:143692056	C3orf58	0.5	10.63	0.39	2.09e-24	Economic and political preferences (feminism/equality);
BRCA	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg00852783	chr1:26633632	UBXN11	0.51	11.01	0.4	6.2e-26	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg23711669	chr6:146136114	FBXO30	0.79	18.69	0.59	1.59e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.84	-0.42	2.17e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs867371	0.964	rs7169961	chr15:82478929	C/T	cg00614314	chr15:82944287	LOC80154	0.42	8.89	0.33	6.09e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs7246657	0.722	rs4802029	chr19:38055612	A/T	cg18154014	chr19:37997991	ZNF793	0.48	9.13	0.34	8.69e-19	Coronary artery calcification;
BRCA	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.47	-10.58	-0.39	3.1e-24	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-13.58	-0.47	4.34e-37	Morning vs. evening chronotype;
BRCA	cis	rs7631605	0.905	rs9852378	chr3:37038771	C/T	cg15934958	chr3:37212084	LRRFIP2	0.41	9.57	0.35	2.38e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg07080220	chr10:102295463	HIF1AN	0.64	15.0	0.51	8.72e-44	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg01819863	chr10:32635814	EPC1	1.17	20.75	0.63	1.69e-73	Sexual dysfunction (female);
BRCA	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg22601191	chr20:60968625	CABLES2	0.46	10.68	0.39	1.28e-24	Colorectal cancer;
BRCA	cis	rs1003719	0.646	rs2835672	chr21:38581234	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-14.51	-0.5	1.83e-41	Eye color traits;
BRCA	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg05347473	chr6:146136440	FBXO30	0.42	8.34	0.31	4.69e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9682041	0.932	rs7631221	chr3:170069893	A/G	cg11886554	chr3:170076028	SKIL	0.59	11.47	0.41	7.68e-28	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	-0.61	-13.55	-0.47	5.7e-37	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg08601574	chr20:25228251	PYGB	0.34	8.31	0.31	5.58e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.31	-0.38	3.83e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg10978503	chr1:24200527	CNR2	-0.44	-11.85	-0.42	1.99e-29	Immature fraction of reticulocytes;
BRCA	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg14829155	chr15:31115871	NA	-0.41	-9.17	-0.34	6.27e-19	Huntington's disease progression;
BRCA	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg08313168	chr12:7315531	NA	0.5	8.09	0.3	2.95e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03517284	chr6:25882590	NA	-0.46	-10.44	-0.38	1.11e-23	Blood metabolite levels;
BRCA	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs365132	0.875	rs353494	chr5:176431759	C/G	cg16309518	chr5:176445507	NA	-0.4	-9.72	-0.36	6.26e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg13010199	chr12:38710504	ALG10B	-0.37	-8.06	-0.3	3.69e-15	Bladder cancer;
BRCA	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.87	0.3	1.47e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg13010199	chr12:38710504	ALG10B	0.52	10.59	0.39	2.93e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6005807	0.719	rs73430189	chr22:29004881	C/A	cg12565055	chr22:29076175	TTC28	0.48	8.79	0.33	1.41e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.91	-0.3	1.14e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.44	0.38	1.15e-23	Motion sickness;
BRCA	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.24	-0.31	9.74e-16	Axial length;
BRCA	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg24642439	chr20:33292090	TP53INP2	0.42	8.81	0.33	1.19e-17	Height;
BRCA	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.57	-0.61	3.58e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7246657	0.525	rs10405238	chr19:37488055	T/G	cg23950597	chr19:37808831	NA	-0.6	-9.37	-0.35	1.21e-19	Coronary artery calcification;
BRCA	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg23711669	chr6:146136114	FBXO30	0.79	19.0	0.6	3.6e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg27535305	chr1:53392650	SCP2	-0.37	-9.32	-0.35	1.84e-19	Monocyte count;
BRCA	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg17971929	chr21:40555470	PSMG1	0.7	14.66	0.5	3.71e-42	Cognitive function;
BRCA	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.48	-0.38	7.75e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17253792	0.822	rs80085988	chr14:56096173	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	11.37	0.41	2.13e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg24977027	chr2:88469347	THNSL2	0.56	9.38	0.35	1.12e-19	Plasma clusterin levels;
BRCA	trans	rs1997103	1.000	rs10278894	chr7:55404748	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.63	0.42	1.73e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg03806693	chr22:41940476	POLR3H	-0.95	-13.81	-0.48	3.68e-38	Vitiligo;
BRCA	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	14.1	0.49	1.66e-39	Personality dimensions;
BRCA	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg05729581	chr11:3078854	CARS	-0.33	-8.28	-0.31	7.23e-16	Longevity;
BRCA	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg05340658	chr4:99064831	C4orf37	0.66	15.53	0.52	2.29e-46	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.64	0.55	6.71e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2882667	0.898	rs10038121	chr5:138389602	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-8.97	-0.33	3.32e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg00631329	chr6:26305371	NA	-0.42	-12.56	-0.44	1.73e-32	Educational attainment;
BRCA	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.05	-19.05	-0.6	1.99e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg27624424	chr6:160112604	SOD2	0.41	8.02	0.3	5.06e-15	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs3820928	0.874	rs4423583	chr2:227874957	A/G	cg11843606	chr2:227700838	RHBDD1	0.37	8.06	0.3	3.67e-15	Pulmonary function;
BRCA	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.83	16.78	0.55	1.21e-52	HIV-1 control;
BRCA	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	19.97	0.62	2.68e-69	Nonalcoholic fatty liver disease;
BRCA	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.64	0.55	6.19e-52	Hypertriglyceridemia;
BRCA	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg20203395	chr5:56204925	C5orf35	0.41	9.17	0.34	6.43e-19	Initial pursuit acceleration;
BRCA	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.39	-8.39	-0.32	3.03e-16	IgG glycosylation;
BRCA	cis	rs2463822	1.000	rs2463821	chr11:62111662	T/C	cg06239285	chr11:62104954	ASRGL1	0.63	9.02	0.34	2.14e-18	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg21143896	chr7:2802374	GNA12	-0.38	-9.28	-0.34	2.65e-19	Height;
BRCA	cis	rs2882667	0.587	rs6596450	chr5:138146520	G/A	cg04439458	chr5:138467593	SIL1	0.31	7.83	0.3	2.03e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg09307838	chr4:120376055	NA	0.68	13.45	0.47	1.81e-36	Corneal astigmatism;
BRCA	cis	rs2617583	0.935	rs1354139	chr5:1451782	T/C	cg07151155	chr5:1473589	LPCAT1	-0.39	-8.55	-0.32	8.8e-17	Breast cancer;
BRCA	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.31	10.05	0.37	3.54e-22	Electroencephalogram traits;
BRCA	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg00106254	chr7:1943704	MAD1L1	-0.3	-8.15	-0.31	1.87e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg08917208	chr2:24149416	ATAD2B	1.05	14.21	0.49	5.26e-40	Lymphocyte counts;
BRCA	cis	rs698813	0.543	rs12468824	chr2:44482448	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.54	0.32	9.69e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg08514558	chr10:81106712	PPIF	0.38	8.73	0.33	2.3e-17	Height;
BRCA	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg14983838	chr19:29218262	NA	0.55	10.78	0.39	5.09e-25	Methadone dose in opioid dependence;
BRCA	trans	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.4	8.49	0.32	1.4e-16	Mean corpuscular volume;
BRCA	cis	rs7254114	0.578	rs7246614	chr19:11310538	C/T	cg06870470	chr19:11315767	DOCK6	-0.36	-8.16	-0.31	1.74e-15	Immature fraction of reticulocytes;
BRCA	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03264133	chr6:25882463	NA	-0.4	-9.22	-0.34	4.39e-19	Height;
BRCA	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg00666640	chr1:248458726	OR2T12	0.35	8.94	0.33	4.31e-18	Common traits (Other);
BRCA	cis	rs965469	0.779	rs6037546	chr20:3298697	G/T	cg25506879	chr20:3388711	C20orf194	-0.43	-8.73	-0.33	2.23e-17	IFN-related cytopenia;
BRCA	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg02569458	chr12:86230093	RASSF9	0.32	8.01	0.3	5.6e-15	Major depressive disorder;
BRCA	cis	rs7520050	0.966	rs11211199	chr1:46287869	T/C	cg24296786	chr1:45957014	TESK2	0.44	10.03	0.37	4.21e-22	Red blood cell count;Reticulocyte count;
BRCA	cis	rs710865	0.519	rs10753518	chr1:19483593	T/C	cg13387374	chr1:19411106	UBR4	0.43	9.62	0.36	1.45e-20	Brain structure;
BRCA	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.55	9.15	0.34	7.53e-19	Renal function-related traits (BUN);
BRCA	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg18232548	chr7:50535776	DDC	-0.55	-13.75	-0.48	7.53e-38	Systemic sclerosis;
BRCA	cis	rs1882538	0.538	rs9649587	chr7:133104569	A/C	cg10665199	chr7:133106180	EXOC4	0.46	10.03	0.37	4.48e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	21.77	0.65	5.24e-79	Chronic sinus infection;
BRCA	cis	rs9790314	0.690	rs1599389	chr3:160836006	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-11.39	-0.41	1.79e-27	Morning vs. evening chronotype;
BRCA	trans	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg06521331	chr12:34319734	NA	0.46	8.91	0.33	5.31e-18	Morning vs. evening chronotype;
BRCA	cis	rs12545109	0.800	rs2118260	chr8:57393481	T/C	cg09654669	chr8:57350985	NA	-0.42	-8.03	-0.3	4.6e-15	Obesity-related traits;
BRCA	cis	rs9300255	0.544	rs1727309	chr12:123658258	A/G	cg00376283	chr12:123451042	ABCB9	0.51	9.89	0.36	1.47e-21	Neutrophil percentage of white cells;
BRCA	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg24069376	chr3:38537580	EXOG	0.4	11.35	0.41	2.4200000000000002e-27	Electrocardiographic conduction measures;
BRCA	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg24069376	chr3:38537580	EXOG	-0.32	-9.07	-0.34	1.47e-18	Electrocardiographic conduction measures;
BRCA	cis	rs758324	0.947	rs7708140	chr5:131252396	A/G	cg06307176	chr5:131281290	NA	0.55	11.72	0.42	7.37e-29	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	20.21	0.62	1.36e-70	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg12219531	chr12:120966889	COQ5	0.54	11.37	0.41	2.11e-27	High light scatter reticulocyte count;
BRCA	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.75	-0.39	7.02e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	19.57	0.61	3.74e-67	Platelet count;
BRCA	cis	rs3784262	0.967	rs35511675	chr15:58266978	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.49	-13.02	-0.46	1.57e-34	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg05347473	chr6:146136440	FBXO30	-0.43	-8.46	-0.32	1.84e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg04851639	chr8:1020857	NA	-0.32	-8.82	-0.33	1.05e-17	Schizophrenia;
BRCA	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg00071950	chr4:10020882	SLC2A9	0.43	9.84	0.36	2.35e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6429082	0.608	rs4659836	chr1:235564412	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.52	-12.2	-0.43	6.42e-31	Adiposity;
BRCA	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg10978503	chr1:24200527	CNR2	0.52	13.84	0.48	2.7e-38	Immature fraction of reticulocytes;
BRCA	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	14.46	0.5	3.22e-41	Motion sickness;
BRCA	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg16109817	chr1:16162209	FLJ37453	-0.29	-8.24	-0.31	1.01e-15	Systolic blood pressure;
BRCA	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg23358479	chr7:1110784	C7orf50	-0.48	-8.17	-0.31	1.68e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2625529	0.642	rs2200056	chr15:72302667	T/C	cg16672083	chr15:72433130	SENP8	-0.87	-18.02	-0.58	5.19e-59	Red blood cell count;
BRCA	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs3771570	0.901	rs55811034	chr2:242406245	C/T	cg21155796	chr2:242212141	HDLBP	0.61	9.44	0.35	7.03e-20	Prostate cancer;
BRCA	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg11057378	chr10:81107060	PPIF	0.41	9.53	0.35	3.23e-20	Height;
BRCA	cis	rs7572263	0.724	rs35551278	chr2:209056128	A/G	cg23998903	chr2:209048830	C2orf80	-0.42	-8.5	-0.32	1.3e-16	Glioma;Non-glioblastoma glioma;
BRCA	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg20476274	chr7:133979776	SLC35B4	0.66	19.06	0.6	1.83e-64	Mean platelet volume;
BRCA	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg07080220	chr10:102295463	HIF1AN	0.63	14.54	0.5	1.32e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2882667	0.652	rs6596463	chr5:138444926	A/G	cg04439458	chr5:138467593	SIL1	-0.36	-10.01	-0.37	5.19e-22	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg03709012	chr19:19516395	GATAD2A	0.81	18.82	0.6	3.53e-63	Tonsillectomy;
BRCA	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.78	0.36	3.87e-21	Menopause (age at onset);
BRCA	cis	rs4409675	0.576	rs7536088	chr1:28234325	A/G	cg23691781	chr1:28212827	C1orf38	0.3	9.08	0.34	1.33e-18	Corneal astigmatism;
BRCA	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg18898632	chr2:242989856	NA	-0.5	-8.35	-0.31	4.1e-16	Obesity-related traits;
BRCA	cis	rs4911259	0.552	rs13042651	chr20:31467423	C/T	cg13636640	chr20:31349939	DNMT3B	-0.45	-11.86	-0.42	1.78e-29	Inflammatory bowel disease;
BRCA	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.57	8.41	0.32	2.78e-16	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg23625390	chr15:77176239	SCAPER	-0.57	-14.8	-0.51	7.8e-43	Blood metabolite levels;
BRCA	cis	rs9359856	0.510	rs74437492	chr6:90338728	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.72	-10.84	-0.39	2.89e-25	Bipolar disorder;
BRCA	cis	rs10411936	0.692	rs3810196	chr19:16601154	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.45	9.59	0.35	1.9e-20	White blood cell count;Multiple sclerosis;
BRCA	cis	rs17401966	0.838	rs35759975	chr1:10474430	A/T	cg03954927	chr1:10346856	KIF1B	0.43	13.27	0.46	1.12e-35	Hepatocellular carcinoma;
BRCA	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg25036284	chr2:26402008	FAM59B	-0.78	-11.85	-0.42	2.08e-29	Gut microbiome composition (summer);
BRCA	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg04455712	chr21:45112962	RRP1B	0.35	8.84	0.33	8.98e-18	Mean corpuscular volume;
BRCA	cis	rs965469	1.000	rs6051672	chr20:3224819	C/T	cg25506879	chr20:3388711	C20orf194	-0.54	-10.27	-0.38	5.37e-23	IFN-related cytopenia;
BRCA	trans	rs79911532	0.515	rs115332207	chr7:75635405	G/A	cg19862616	chr7:65841803	NCRNA00174	0.64	9.15	0.34	7.7e-19	Mononucleosis;
BRCA	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg11764359	chr7:65958608	NA	0.75	16.17	0.54	1.47e-49	Aortic root size;
BRCA	cis	rs2835872	0.733	rs1787400	chr21:39038217	G/C	cg06728970	chr21:39037746	KCNJ6	0.45	12.72	0.45	3.39e-33	Electroencephalographic traits in alcoholism;
BRCA	cis	rs4919087	0.962	rs10786324	chr10:99054387	A/G	cg25902810	chr10:99078978	FRAT1	0.45	9.48	0.35	4.99e-20	Monocyte count;
BRCA	cis	rs7903847	0.642	rs10882926	chr10:99160690	C/T	cg08345082	chr10:99160200	RRP12	0.29	8.52	0.32	1.14e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs17092148	0.887	rs2378199	chr20:33186480	T/C	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.76	-0.39	6.22e-25	Neuroticism;
BRCA	cis	rs12545109	0.879	rs2576580	chr8:57365828	G/C	cg09654669	chr8:57350985	NA	-0.46	-8.66	-0.32	3.82e-17	Obesity-related traits;
BRCA	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	14.29	0.49	2.11e-40	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs11785693	0.862	rs17435835	chr8:5000713	C/T	cg26367366	chr8:4980734	NA	-0.66	-11.75	-0.42	5.29e-29	Neuroticism (multi-trait analysis);Neuroticism;
BRCA	trans	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg25214090	chr10:38739885	LOC399744	0.57	12.38	0.44	1.06e-31	Corneal astigmatism;
BRCA	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg04511125	chr2:88470314	THNSL2	-0.53	-10.92	-0.4	1.37e-25	Response to metformin (IC50);
BRCA	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg21475434	chr5:93447410	FAM172A	0.69	8.62	0.32	5.3e-17	Diabetic retinopathy;
BRCA	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.6	-0.36	1.78e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	11.32	0.41	3.23e-27	Height;
BRCA	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18876405	chr7:65276391	NA	0.54	12.47	0.44	4.31e-32	Aortic root size;
BRCA	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-11.91	-0.43	1.13e-29	Total cholesterol levels;
BRCA	cis	rs9309473	1.000	rs6710438	chr2:73820108	C/G	cg20560298	chr2:73613845	ALMS1	0.4	9.73	0.36	6e-21	Metabolite levels;
BRCA	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg25036284	chr2:26402008	FAM59B	-0.64	-10.47	-0.38	8.65e-24	Gut microbiome composition (summer);
BRCA	cis	rs1971762	0.563	rs10747679	chr12:54077750	C/T	cg23533419	chr12:54090519	NA	-0.33	-8.37	-0.31	3.69e-16	Height;
BRCA	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg20887711	chr4:1340912	KIAA1530	0.38	8.85	0.33	8.47e-18	Longevity;
BRCA	cis	rs73001065	0.892	rs58542926	chr19:19379549	C/T	cg03709012	chr19:19516395	GATAD2A	0.81	7.94	0.3	8.96e-15	LDL cholesterol;
BRCA	trans	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.37	-8.11	-0.31	2.62e-15	Mean corpuscular volume;
BRCA	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11644478	chr21:40555479	PSMG1	-0.66	-14.24	-0.49	3.69e-40	Cognitive function;
BRCA	cis	rs9443189	0.570	rs529383	chr6:76297847	T/G	cg01950844	chr6:76311363	SENP6	0.74	10.02	0.37	4.85e-22	Prostate cancer;
BRCA	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.03	-0.56	6.83e-54	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.46	9.73	0.36	5.96e-21	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg14349672	chr11:133703707	NA	0.4	8.68	0.32	3.26e-17	Childhood ear infection;
BRCA	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg00105475	chr2:10696890	NA	0.44	10.41	0.38	1.56e-23	Prostate cancer;
BRCA	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg06784218	chr1:46089804	CCDC17	0.45	10.81	0.39	3.92e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	cg06064525	chr11:970664	AP2A2	-0.31	-9.0	-0.34	2.54e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07636037	chr3:49044803	WDR6	0.75	16.49	0.55	3.8e-51	Menarche (age at onset);
BRCA	cis	rs12791968	0.765	rs12226848	chr11:45009204	C/T	cg11846598	chr11:44996168	LOC221122	-0.46	-8.34	-0.31	4.42e-16	Inhibitory control;
BRCA	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.51	0.44	2.74e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg08000102	chr2:233561755	GIGYF2	0.62	13.46	0.47	1.49e-36	Coronary artery disease;
BRCA	cis	rs1691799	0.867	rs1027401	chr12:66760892	C/G	cg16791601	chr12:66731901	HELB	-0.65	-17.38	-0.57	1.03e-55	White blood cell count (basophil);
BRCA	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.64	-0.5	4.62e-42	Chronic sinus infection;
BRCA	trans	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.48	-0.35	4.76e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg08917208	chr2:24149416	ATAD2B	1.03	13.88	0.48	1.83e-38	Lymphocyte counts;
BRCA	cis	rs1577917	1.000	rs7766645	chr6:86622238	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-11.28	-0.41	5.11e-27	Response to antipsychotic treatment;
BRCA	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg11584989	chr19:19387371	SF4	0.6	13.54	0.47	6.49e-37	Bipolar disorder;
BRCA	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg02951883	chr7:2050386	MAD1L1	0.58	15.2	0.52	9.01e-45	Bipolar disorder and schizophrenia;
BRCA	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	11.68	0.42	1.03e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg24558204	chr6:135376177	HBS1L	-0.6	-16.41	-0.54	9.53e-51	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg16590910	chr6:42928470	GNMT	-0.41	-8.86	-0.33	7.79e-18	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg00409905	chr10:38381863	ZNF37A	-0.48	-10.16	-0.37	1.4e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	18.11	0.58	1.89e-59	Menopause (age at onset);
BRCA	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg00106254	chr7:1943704	MAD1L1	-0.32	-7.92	-0.3	1.03e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs1451375	0.572	rs896309	chr7:50545022	A/G	cg18232548	chr7:50535776	DDC	-0.42	-8.94	-0.33	4.2e-18	Malaria;
BRCA	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg24692254	chr21:30365293	RNF160	0.69	18.42	0.59	4.02e-61	Dental caries;
BRCA	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg22907277	chr7:1156413	C7orf50	0.46	10.3	0.38	3.93e-23	Longevity;Endometriosis;
BRCA	cis	rs6973256	0.897	rs1014442	chr7:133349281	A/T	cg07491979	chr7:133331646	EXOC4	-0.39	-9.0	-0.34	2.5e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs13046373	0.535	rs35909098	chr21:32021649	C/T	cg06468780	chr21:31798236	KRTAP13-3	0.34	8.39	0.31	3.16e-16	HDL cholesterol;
BRCA	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.85	17.74	0.57	1.51e-57	IgG glycosylation;
BRCA	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-16.27	-0.54	4.64e-50	Alzheimer's disease (late onset);
BRCA	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	11.64	0.42	1.61e-28	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg08645402	chr16:4508243	NA	0.37	8.91	0.33	5.42e-18	Schizophrenia;
BRCA	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs6840360	0.571	rs10007653	chr4:152524055	A/G	cg22705602	chr4:152727874	NA	-0.33	-8.43	-0.32	2.35e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2882667	0.654	rs2351247	chr5:138185145	A/G	cg04439458	chr5:138467593	SIL1	0.33	8.26	0.31	8.09e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs367943	1.000	rs460079	chr5:112800525	G/A	cg12552261	chr5:112820674	MCC	-0.55	-11.72	-0.42	6.92e-29	Type 2 diabetes;
BRCA	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg17971929	chr21:40555470	PSMG1	0.8	18.66	0.59	2.21e-62	Cognitive function;
BRCA	cis	rs9682041	0.627	rs10936625	chr3:170094908	G/T	cg11886554	chr3:170076028	SKIL	-0.48	-10.16	-0.37	1.35e-22	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	trans	rs9784649	0.641	rs72755823	chr5:25075537	T/C	cg11038491	chr20:34638489	LOC647979	-0.57	-10.22	-0.37	8.48e-23	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg13010199	chr12:38710504	ALG10B	0.35	8.22	0.31	1.12e-15	Morning vs. evening chronotype;
BRCA	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg23711669	chr6:146136114	FBXO30	0.81	19.41	0.61	2.43e-66	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08045932	chr20:61659980	NA	0.5	11.43	0.41	1.2100000000000001e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg22800045	chr5:56110881	MAP3K1	-0.42	-8.32	-0.31	5.35e-16	Initial pursuit acceleration;
BRCA	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg24562669	chr7:97807699	LMTK2	0.47	12.62	0.45	8.93e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7572733	0.515	rs1836234	chr2:198882873	T/G	cg00792783	chr2:198669748	PLCL1	0.38	8.74	0.33	2.06e-17	Dermatomyositis;
BRCA	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg08470875	chr2:26401718	FAM59B	-0.73	-11.73	-0.42	6.39e-29	Gut microbiome composition (summer);
BRCA	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg06784218	chr1:46089804	CCDC17	0.5	12.18	0.43	7.68e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg21782813	chr7:2030301	MAD1L1	0.32	8.87	0.33	7.26e-18	Schizophrenia;
BRCA	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg02659138	chr7:134003124	SLC35B4	0.34	10.72	0.39	9.27e-25	Mean platelet volume;
BRCA	cis	rs524281	0.814	rs10896093	chr11:65958411	C/G	cg16950941	chr11:66035639	RAB1B	-0.37	-7.84	-0.3	1.93e-14	Electroencephalogram traits;
BRCA	cis	rs724568	0.546	rs737359	chr2:67950714	A/G	cg17945962	chr2:67939740	NA	0.38	9.99	0.37	6.38e-22	Major depressive disorder (broad);
BRCA	cis	rs7572733	0.555	rs2164071	chr2:198915467	T/C	cg00792783	chr2:198669748	PLCL1	0.39	8.75	0.33	1.95e-17	Dermatomyositis;
BRCA	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-9.05	-0.34	1.75e-18	Eosinophil percentage of white cells;
BRCA	cis	rs2580764	0.516	rs2860453	chr2:55270485	T/G	cg09592903	chr2:55203963	RTN4	0.38	9.7	0.36	7.68e-21	Mean platelet volume;
BRCA	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.66	0.32	3.82e-17	Rheumatoid arthritis;
BRCA	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg06115741	chr20:33292138	TP53INP2	0.36	8.01	0.3	5.64e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs9400271	0.527	rs4945829	chr6:109638828	T/C	cg01475377	chr6:109611718	NA	0.37	8.22	0.31	1.16e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24110177	chr3:50126178	RBM5	0.41	11.34	0.41	2.87e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21385522	chr1:16154831	NA	-0.52	-10.22	-0.37	8.51e-23	Dilated cardiomyopathy;
BRCA	cis	rs6942756	1.000	rs12112374	chr7:128950071	A/G	cg02491457	chr7:128862824	NA	-0.7	-13.76	-0.48	6.11e-38	White matter hyperintensity burden;
BRCA	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-11.45	-0.41	9.67e-28	Pulmonary function;
BRCA	cis	rs12541635	0.934	rs62527361	chr8:107021574	T/A	cg10147462	chr8:107024639	NA	0.35	9.47	0.35	5.49e-20	Age of smoking initiation;
BRCA	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg06784218	chr1:46089804	CCDC17	0.5	11.82	0.42	2.71e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg09904177	chr6:26538194	HMGN4	0.56	18.42	0.59	4.47e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs9815354	0.767	rs73830585	chr3:42003698	T/A	cg03022575	chr3:42003672	ULK4	0.74	10.27	0.38	5.43e-23	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs6542838	0.611	rs17758170	chr2:99531842	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-9.0	-0.34	2.54e-18	Fear of minor pain;
BRCA	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.48	8.75	0.33	1.9e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2387326	0.671	rs12268728	chr10:129945897	G/A	cg16087940	chr10:129947807	NA	-0.46	-8.23	-0.31	1.05e-15	Select biomarker traits;
BRCA	trans	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg26043149	chr18:55253948	FECH	-0.4	-8.99	-0.34	2.68e-18	Bone mineral density;
BRCA	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21659725	chr3:3221576	CRBN	-0.48	-12.25	-0.44	3.94e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.49	-0.32	1.4e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4908768	0.539	rs922366	chr1:8653733	C/A	cg20416874	chr1:8611966	RERE	-0.29	-8.11	-0.31	2.6e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs701145	0.585	rs921318	chr3:153856775	T/G	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.22e-14	Coronary artery disease;
BRCA	cis	rs7246657	0.722	rs1564206	chr19:38040076	C/T	cg23950597	chr19:37808831	NA	-0.5	-8.64	-0.32	4.57e-17	Coronary artery calcification;
BRCA	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg09184832	chr6:79620586	NA	-0.5	-11.06	-0.4	4.05e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	9.14	0.34	7.92e-19	Platelet count;
BRCA	trans	rs7248779	0.512	rs7250002	chr19:2413188	A/G	cg25835954	chr13:50160062	RCBTB1	0.45	8.77	0.33	1.65e-17	Cortisol levels (saliva);
BRCA	cis	rs7072216	0.806	rs9804285	chr10:100169472	C/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.72	-0.36	6.22e-21	Metabolite levels;
BRCA	cis	rs17401966	0.522	rs17396973	chr1:10334924	C/T	cg03954927	chr1:10346856	KIF1B	0.34	10.39	0.38	1.81e-23	Hepatocellular carcinoma;
BRCA	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-10.89	-0.4	1.82e-25	Oral cavity cancer;
BRCA	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.62	10.08	0.37	2.94e-22	Renal function-related traits (BUN);
BRCA	cis	rs9462846	1.000	rs9471950	chr6:42869040	G/A	cg02353165	chr6:42928485	GNMT	0.49	8.67	0.32	3.44e-17	Blood protein levels;
BRCA	cis	rs12050794	0.671	rs8192362	chr15:72519858	G/A	cg16672083	chr15:72433130	SENP8	0.63	14.89	0.51	3.03e-43	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-8.3	-0.31	6.2e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg22800045	chr5:56110881	MAP3K1	0.64	12.31	0.44	2.05e-31	Initial pursuit acceleration;
BRCA	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.58	9.89	0.36	1.49e-21	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg00814883	chr7:100076585	TSC22D4	-0.47	-10.54	-0.38	4.62e-24	Platelet count;
BRCA	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.65	-0.32	4.03e-17	Total body bone mineral density;
BRCA	cis	rs2336384	1.000	rs4846083	chr1:12045555	G/T	cg13216073	chr1:12042593	MFN2	0.45	9.81	0.36	3.05e-21	Platelet count;
BRCA	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22455342	chr2:225449267	CUL3	-0.34	-8.54	-0.32	1e-16	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg11645453	chr3:52864694	ITIH4	0.49	11.81	0.42	2.96e-29	Schizophrenia;
BRCA	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg21045802	chr8:109455806	TTC35	0.35	7.89	0.3	1.28e-14	Dupuytren's disease;
BRCA	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg04978709	chr7:75101039	POM121C	0.35	9.44	0.35	7.07e-20	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.37	-9.04	-0.34	1.84e-18	Lung cancer;
BRCA	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg18252515	chr7:66147081	NA	-1.06	-15.56	-0.52	1.52e-46	Diabetic kidney disease;
BRCA	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.32	-0.35	1.92e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4948102	0.732	rs6951810	chr7:56076598	T/C	cg09872392	chr7:56161020	PHKG1	-0.39	-8.69	-0.33	2.95e-17	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg16586182	chr3:47516702	SCAP	-0.55	-12.6	-0.45	1.14e-32	Colorectal cancer;
BRCA	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.4	9.63	0.36	1.43e-20	Eosinophil percentage of white cells;
BRCA	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11644478	chr21:40555479	PSMG1	-0.5	-10.58	-0.39	3.24e-24	Menarche (age at onset);
BRCA	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	17.64	0.57	5.13e-57	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	14.11	0.49	1.45e-39	Platelet count;
BRCA	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg25237894	chr2:233734115	C2orf82	-0.45	-14.1	-0.49	1.69e-39	Coronary artery disease;
BRCA	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26314531	chr2:26401878	FAM59B	0.65	11.02	0.4	5.49e-26	Gut microbiome composition (summer);
BRCA	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	12.24	0.44	4.41e-31	Lung cancer in ever smokers;
BRCA	trans	rs66887589	0.776	rs10518337	chr4:120574874	A/C	cg25214090	chr10:38739885	LOC399744	-0.35	-7.81	-0.3	2.29e-14	Diastolic blood pressure;
BRCA	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg05340658	chr4:99064831	C4orf37	-0.68	-17.3	-0.56	2.89e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg11502198	chr6:26597334	ABT1	0.63	10.45	0.38	1.04e-23	Small cell lung carcinoma;
BRCA	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg18132916	chr6:79620363	NA	-0.49	-11.22	-0.41	8.78e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg23422044	chr7:1970798	MAD1L1	-0.61	-13.41	-0.47	2.52e-36	Bipolar disorder;
BRCA	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg27347728	chr4:17578864	LAP3	0.45	8.82	0.33	1.07e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs4650994	0.507	rs56229230	chr1:178526563	G/A	cg05059571	chr16:84539110	KIAA1609	-0.58	-12.94	-0.46	3.38e-34	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg10223061	chr2:219282414	VIL1	0.3	8.57	0.32	8.07e-17	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	8.78	0.33	1.45e-17	Mean corpuscular volume;
BRCA	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg04058563	chr4:185651563	MLF1IP	0.37	9.21	0.34	4.66e-19	Kawasaki disease;
BRCA	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg20573242	chr4:122745356	CCNA2	-0.43	-8.98	-0.33	3.05e-18	Type 2 diabetes;
BRCA	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg15704280	chr7:45808275	SEPT13	0.57	9.73	0.36	6.09e-21	Axial length;
BRCA	trans	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	-0.35	-7.95	-0.3	8.49e-15	Corneal astigmatism;
BRCA	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.43	-0.38	1.21e-23	Aortic root size;
BRCA	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg12310025	chr6:25882481	NA	0.42	9.32	0.35	1.85e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg17971929	chr21:40555470	PSMG1	-0.47	-9.99	-0.37	6.13e-22	Menarche (age at onset);
BRCA	cis	rs36051895	0.658	rs72699568	chr9:5007138	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-8.71	-0.33	2.62e-17	Pediatric autoimmune diseases;
BRCA	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg05552183	chr6:42928497	GNMT	0.68	15.52	0.52	2.41e-46	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.41	9.25	0.34	3.41e-19	Fear of minor pain;
BRCA	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg17063962	chr7:91808500	NA	-0.55	-12.73	-0.45	2.88e-33	Breast cancer;
BRCA	cis	rs13046373	0.535	rs1605428	chr21:32028976	T/C	cg24082983	chr21:31802169	KRTAP13-4	0.34	8.21	0.31	1.21e-15	HDL cholesterol;
BRCA	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg26248373	chr2:1572462	NA	-0.63	-14.39	-0.49	7e-41	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg13010199	chr12:38710504	ALG10B	0.56	12.42	0.44	7.15e-32	Heart rate;
BRCA	cis	rs8044868	0.541	rs7202268	chr16:72086746	A/G	cg16558253	chr16:72132732	DHX38	-0.45	-10.81	-0.39	3.83e-25	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	cis	rs4363385	0.747	rs2879488	chr1:152975241	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-9.29	-0.34	2.4e-19	Inflammatory skin disease;
BRCA	cis	rs10504073	0.647	rs10808745	chr8:49989037	G/A	cg00325661	chr8:49890786	NA	0.44	12.48	0.44	3.72e-32	Blood metabolite ratios;
BRCA	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.39e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg01200585	chr1:228362443	C1orf69	-0.37	-8.16	-0.31	1.82e-15	Diastolic blood pressure;
BRCA	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg01689657	chr7:91764605	CYP51A1	0.22	8.15	0.31	1.88e-15	Breast cancer;
BRCA	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg11764359	chr7:65958608	NA	0.64	11.46	0.41	8.75e-28	Aortic root size;
BRCA	cis	rs12579753	0.917	rs7954438	chr12:82184419	T/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-8.37	-0.31	3.52e-16	Resting heart rate;
BRCA	cis	rs897080	0.515	rs786401	chr2:44712069	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	9.11	0.34	1.07e-18	Height;
BRCA	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg17691542	chr6:26056736	HIST1H1C	0.47	9.74	0.36	5.58e-21	Height;
BRCA	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg09184832	chr6:79620586	NA	-0.53	-12.16	-0.43	9.15e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg00071950	chr4:10020882	SLC2A9	0.54	13.29	0.47	8.88e-36	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg25358565	chr5:93447407	FAM172A	-1.21	-18.88	-0.6	1.65e-63	Diabetic retinopathy;
BRCA	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg22676075	chr6:135203613	NA	0.41	8.3	0.31	6.14e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg26384229	chr12:38710491	ALG10B	0.41	9.02	0.34	2.15e-18	Morning vs. evening chronotype;
BRCA	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg16558253	chr16:72132732	DHX38	-0.4	-9.6	-0.36	1.72e-20	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	cis	rs1568889	1.000	rs12790932	chr11:28046189	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	14.95	0.51	1.41e-43	Bipolar disorder;
BRCA	cis	rs220324	0.688	rs56326363	chr21:43560295	G/A	cg09727148	chr21:43560719	UMODL1	0.5	8.88	0.33	6.65e-18	Idiopathic osteonecrosis of the femoral head;
BRCA	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg06784218	chr1:46089804	CCDC17	0.5	12.1	0.43	1.76e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs911119	0.955	rs35610040	chr20:23616469	T/C	cg16589663	chr20:23618590	CST3	0.47	8.72	0.33	2.36e-17	Chronic kidney disease;
BRCA	cis	rs7635838	0.654	rs346083	chr3:11280017	T/C	cg00170343	chr3:11313890	ATG7	0.44	8.35	0.31	4.32e-16	HDL cholesterol;
BRCA	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg00531865	chr16:30841666	NA	-0.51	-11.82	-0.42	2.65e-29	Multiple myeloma;
BRCA	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.54	11.05	0.4	4.21e-26	Monocyte percentage of white cells;
BRCA	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg23711669	chr6:146136114	FBXO30	0.64	15.31	0.52	2.69e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg22800045	chr5:56110881	MAP3K1	-0.58	-9.93	-0.37	1.04e-21	Initial pursuit acceleration;
BRCA	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg20701182	chr2:24300061	SF3B14	0.7	13.21	0.46	2.15e-35	Lymphocyte counts;
BRCA	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7766436	0.767	rs6909574	chr6:22606773	A/G	cg13666174	chr6:22585274	NA	-0.37	-9.47	-0.35	5.15e-20	Coronary artery disease;
BRCA	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9486719	0.741	rs2049927	chr6:96848958	C/G	cg06623918	chr6:96969491	KIAA0776	-0.69	-11.88	-0.43	1.55e-29	Migraine;Coronary artery disease;
BRCA	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.54	-11.14	-0.4	1.78e-26	Rheumatoid arthritis;
BRCA	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26168224	chr5:2018326	NA	-0.58	-13.96	-0.48	7.46e-39	Gut microbiome composition (winter);
BRCA	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02176678	chr2:219576539	TTLL4	-0.54	-13.53	-0.47	7.3e-37	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10465746	0.780	rs2147392	chr1:84404154	C/A	cg10977910	chr1:84465055	TTLL7	0.57	11.78	0.42	4.09e-29	Obesity-related traits;
BRCA	cis	rs9487051	0.834	rs351728	chr6:109549099	T/C	cg21918786	chr6:109611834	NA	-0.33	-8.46	-0.32	1.83e-16	Reticulocyte fraction of red cells;
BRCA	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg12927641	chr6:109611667	NA	-0.4	-10.43	-0.38	1.3e-23	Reticulocyte fraction of red cells;
BRCA	cis	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg13789015	chr9:136890014	NCRNA00094	0.54	11.25	0.41	6.49e-27	Platelet distribution width;
BRCA	cis	rs7512552	0.839	rs11587116	chr1:150451898	A/T	cg15654264	chr1:150340011	RPRD2	0.37	8.15	0.31	1.97e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs1997103	1.000	rs4628219	chr7:55410449	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg00701064	chr4:6280414	WFS1	0.69	18.05	0.58	3.51e-59	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs10493773	0.618	rs34746573	chr1:86075360	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.43	-8.15	-0.31	1.86e-15	Urate levels in overweight individuals;
BRCA	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25427524	chr10:38739819	LOC399744	-0.68	-16.42	-0.54	8.28e-51	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg04989706	chr14:50066350	PPIL5	-0.5	-9.88	-0.36	1.55e-21	Carotid intima media thickness;
BRCA	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg02176678	chr2:219576539	TTLL4	0.43	11.43	0.41	1.12e-27	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9341808	0.718	rs9343971	chr6:80882056	C/T	cg08355045	chr6:80787529	NA	0.39	9.99	0.37	6.17e-22	Sitting height ratio;
BRCA	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg03477792	chr4:77819574	ANKRD56	0.66	16.13	0.54	2.43e-49	Emphysema distribution in smoking;
BRCA	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.88	0.62	8.32e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.61	-15.84	-0.53	6.8e-48	Colorectal cancer;
BRCA	cis	rs858239	0.600	rs7341483	chr7:23127657	G/T	cg23682824	chr7:23144976	KLHL7	-0.44	-11.7	-0.42	8.36e-29	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg25214090	chr10:38739885	LOC399744	0.37	8.21	0.31	1.21e-15	Diastolic blood pressure;
BRCA	trans	rs4714291	0.963	rs1923466	chr6:39965946	A/C	cg02267698	chr19:7991119	CTXN1	0.41	8.05	0.3	4.07e-15	Strep throat;
BRCA	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg27490568	chr2:178487706	NA	0.48	8.07	0.3	3.58e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs3099143	1.000	rs2629034	chr15:77042240	G/A	cg21673338	chr15:77095150	SCAPER	-0.53	-9.67	-0.36	1.02e-20	Recalcitrant atopic dermatitis;
BRCA	cis	rs12760731	0.641	rs11590951	chr1:178322757	C/T	cg00404053	chr1:178313656	RASAL2	0.63	8.7	0.33	2.75e-17	Obesity-related traits;
BRCA	cis	rs10129255	0.500	rs6576225	chr14:107186359	G/C	cg07958169	chr14:107095056	NA	-0.4	-8.67	-0.32	3.43e-17	Kawasaki disease;
BRCA	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg24675658	chr1:53192096	ZYG11B	0.55	12.61	0.45	1.01e-32	Monocyte count;
BRCA	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg04267008	chr7:1944627	MAD1L1	-0.46	-9.6	-0.35	1.79e-20	Schizophrenia;
BRCA	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg05025164	chr4:1340916	KIAA1530	0.39	8.11	0.31	2.63e-15	Obesity-related traits;
BRCA	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg03146154	chr1:46216737	IPP	0.46	10.2	0.37	9.95e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.63	0.39	2.04e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg22189786	chr22:42395067	WBP2NL	0.43	8.66	0.32	3.99e-17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg12826209	chr6:26865740	GUSBL1	0.61	8.07	0.3	3.52e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg24558204	chr6:135376177	HBS1L	0.59	15.85	0.53	5.69e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs28374715	0.662	rs72737793	chr15:41516823	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.83	-17.17	-0.56	1.25e-54	Ulcerative colitis;
BRCA	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg05347473	chr6:146136440	FBXO30	0.4	7.86	0.3	1.59e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg18904891	chr8:8559673	CLDN23	0.64	12.34	0.44	1.59e-31	Obesity-related traits;
BRCA	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg21573476	chr21:45109991	RRP1B	-0.35	-9.0	-0.34	2.46e-18	Mean corpuscular volume;
BRCA	trans	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg07211511	chr3:129823064	LOC729375	-0.62	-10.85	-0.39	2.79e-25	Blood pressure (smoking interaction);
BRCA	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	9.86	0.36	1.98e-21	Menarche (age at onset);
BRCA	trans	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-16.03	-0.54	7.07e-49	Obesity-related traits;
BRCA	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg02931644	chr1:25747376	RHCE	0.41	11.51	0.41	5.27e-28	Erythrocyte sedimentation rate;
BRCA	cis	rs3125734	0.608	rs7905731	chr10:64018472	T/C	cg09941381	chr10:64027924	RTKN2	-0.27	-7.83	-0.3	2.06e-14	Rheumatoid arthritis;
BRCA	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.25	0.38	6.21e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.24	8.03	0.3	4.65e-15	Electroencephalogram traits;
BRCA	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg01236616	chr12:121019343	POP5	-1.18	-26.44	-0.72	1.27e-104	Type 1 diabetes nephropathy;
BRCA	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg18404041	chr3:52824283	ITIH1	-0.35	-9.31	-0.35	1.94e-19	Schizophrenia;
BRCA	cis	rs7903847	0.642	rs10882913	chr10:99141845	C/T	cg08345082	chr10:99160200	RRP12	-0.3	-8.66	-0.32	3.88e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg13010199	chr12:38710504	ALG10B	0.51	10.37	0.38	2.25e-23	Bladder cancer;
BRCA	cis	rs11997175	0.624	rs4355732	chr8:33676920	A/C	ch.8.33884649F	chr8:33765107	NA	0.4	9.21	0.34	4.59e-19	Body mass index;
BRCA	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.14	-0.31	2.03e-15	Bipolar disorder and schizophrenia;
BRCA	trans	rs6479891	1.000	rs72837056	chr10:65260478	T/G	cg14819942	chr15:35414228	NA	0.35	8.59	0.32	6.62e-17	Arthritis (juvenile idiopathic);
BRCA	trans	rs877282	0.682	rs2265092	chr10:780293	C/T	cg22713356	chr15:30763199	NA	-0.8	-16.05	-0.54	5.6e-49	Uric acid levels;
BRCA	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg01028140	chr2:1542097	TPO	-0.7	-13.93	-0.48	1.03e-38	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4363385	0.747	rs6678107	chr1:152966818	T/G	cg21543102	chr1:152974771	SPRR3	-0.3	-8.64	-0.32	4.51e-17	Inflammatory skin disease;
BRCA	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg05340658	chr4:99064831	C4orf37	0.58	11.65	0.42	1.44e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg18351406	chr4:77819688	ANKRD56	0.61	13.39	0.47	3.13e-36	Emphysema distribution in smoking;
BRCA	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21659725	chr3:3221576	CRBN	0.46	11.67	0.42	1.12e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs1562242	0.653	rs2441112	chr5:57601615	T/C	cg09002358	chr5:57541568	NA	0.68	11.88	0.43	1.43e-29	Educational attainment (years of education);
BRCA	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg23992470	chr4:843637	GAK	0.57	8.53	0.32	1.05e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg12160578	chr15:63334699	TPM1	-0.42	-8.4	-0.32	2.89e-16	Platelet count;
BRCA	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg23229984	chr5:148520753	ABLIM3	0.36	9.03	0.34	1.96e-18	Breast cancer;
BRCA	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg13385521	chr17:29058706	SUZ12P	0.63	8.57	0.32	7.5e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg21226059	chr5:178986404	RUFY1	0.38	9.2	0.34	5.12e-19	Lung cancer;
BRCA	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg22834771	chr12:69754056	YEATS4	-0.42	-10.43	-0.38	1.27e-23	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7572733	0.534	rs700681	chr2:198711502	C/A	cg00792783	chr2:198669748	PLCL1	0.47	10.11	0.37	2.17e-22	Dermatomyositis;
BRCA	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg23711669	chr6:146136114	FBXO30	0.64	14.35	0.49	1.13e-40	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.43	-0.44	6.2e-32	Chronic sinus infection;
BRCA	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.67	-0.61	9.89e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg20203395	chr5:56204925	C5orf35	-0.5	-10.16	-0.37	1.37e-22	Initial pursuit acceleration;
BRCA	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.7	-0.36	7.54e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.83	-0.39	3.35e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs13095912	0.962	rs6785918	chr3:185330631	A/G	cg11274856	chr3:185301563	NA	0.36	9.02	0.34	2.18e-18	Systolic blood pressure;
BRCA	trans	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.7	-0.36	7.7e-21	Bladder cancer;
BRCA	cis	rs4662945	0.603	rs2406981	chr2:130305487	A/G	cg05962382	chr2:130345044	NA	-0.35	-8.41	-0.32	2.67e-16	Response to cytidine analogues (gemcitabine);
BRCA	trans	rs877282	0.945	rs34367686	chr10:791868	G/C	cg22713356	chr15:30763199	NA	1.42	28.55	0.75	3.22e-116	Uric acid levels;
BRCA	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg24879335	chr3:133465180	TF	0.25	7.81	0.3	2.42e-14	Iron status biomarkers;
BRCA	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg23950597	chr19:37808831	NA	-0.74	-12.28	-0.44	2.93e-31	Coronary artery calcification;
BRCA	cis	rs41005	1.000	rs798449	chr2:8106533	G/A	cg03155496	chr2:8117019	LOC339788	0.56	14.67	0.5	3.34e-42	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg26384229	chr12:38710491	ALG10B	0.74	17.56	0.57	1.27e-56	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg04756594	chr16:24857601	SLC5A11	0.34	8.36	0.31	3.78e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg13385521	chr17:29058706	SUZ12P	0.63	8.57	0.32	7.5e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.66	13.45	0.47	1.79e-36	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7707921	0.752	rs2897554	chr5:81276241	C/T	cg15871215	chr5:81402204	ATG10	0.36	9.0	0.34	2.65e-18	Breast cancer;
BRCA	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24531977	chr5:56204891	C5orf35	-0.87	-18.79	-0.6	4.98e-63	Initial pursuit acceleration;
BRCA	trans	rs6600671	0.934	rs11249429	chr1:121291080	C/T	cg00646200	chr1:148855367	NA	-0.33	-8.57	-0.32	7.77e-17	Hip geometry;
BRCA	cis	rs7737355	1.000	rs40396	chr5:130708044	C/G	cg06307176	chr5:131281290	NA	-0.45	-8.82	-0.33	1.06e-17	Life satisfaction;
BRCA	cis	rs4908760	0.899	rs6577496	chr1:8581227	C/A	cg20416874	chr1:8611966	RERE	-0.29	-8.31	-0.31	5.59e-16	Vitiligo;
BRCA	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.22	0.34	4.17e-19	Tonsillectomy;
BRCA	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg17845761	chr1:175162550	KIAA0040	-0.26	-9.9	-0.36	1.41e-21	Alcohol dependence;
BRCA	trans	rs12543645	0.609	rs35112858	chr8:10277269	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	8.35	0.31	4.19e-16	Schizophrenia;
BRCA	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg00105475	chr2:10696890	NA	0.44	10.41	0.38	1.51e-23	Prostate cancer;
BRCA	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg03453431	chr7:157225567	NA	-0.46	-9.19	-0.34	5.36e-19	Epstein-Barr virus copy number in lymphoblastoid cell lines;
BRCA	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21659725	chr3:3221576	CRBN	-0.35	-8.7	-0.33	2.74e-17	Body mass index;
BRCA	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.31	-7.88	-0.3	1.37e-14	Total body bone mineral density;
BRCA	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg11764359	chr7:65958608	NA	-0.66	-12.11	-0.43	1.53e-30	Aortic root size;
BRCA	cis	rs9788682	0.747	rs28480606	chr15:78762313	A/G	cg24631222	chr15:78858424	CHRNA5	0.47	9.32	0.35	1.86e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.99e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.84	-27.35	-0.73	1.32e-109	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg22800045	chr5:56110881	MAP3K1	0.65	12.32	0.44	1.9e-31	Initial pursuit acceleration;
BRCA	cis	rs2191566	0.576	rs382255	chr19:44494156	T/C	cg20607764	chr19:44506953	ZNF230	0.36	7.87	0.3	1.5e-14	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs12791968	0.765	rs11038250	chr11:45009114	A/G	cg11846598	chr11:44996168	LOC221122	-0.45	-8.3	-0.31	6.23e-16	Inhibitory control;
BRCA	trans	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.25	0.31	9.3e-16	Corneal astigmatism;
BRCA	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.62	-0.39	2.19e-24	Bipolar disorder;
BRCA	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.56	-0.32	8.45e-17	Total body bone mineral density;
BRCA	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg26769984	chr7:1090371	C7orf50	0.48	9.0	0.34	2.57e-18	Bronchopulmonary dysplasia;
BRCA	trans	rs11039798	0.925	rs12277669	chr11:48925316	A/T	cg15704280	chr7:45808275	SEPT13	0.6	8.89	0.33	6.42e-18	Axial length;
BRCA	trans	rs1493916	0.748	rs4799355	chr18:31313124	G/T	cg27147174	chr7:100797783	AP1S1	-0.4	-8.07	-0.3	3.51e-15	Life satisfaction;
BRCA	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg07741184	chr6:167504864	NA	-0.29	-8.68	-0.32	3.38e-17	Primary biliary cholangitis;
BRCA	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg18252515	chr7:66147081	NA	1.06	15.97	0.53	1.49e-48	Diabetic kidney disease;
BRCA	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.65	-0.45	6.63e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg11366901	chr6:160182831	ACAT2	0.86	16.91	0.56	2.81e-53	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00149659	chr3:10157352	C3orf10	1.07	18.1	0.58	2.08e-59	Alzheimer's disease;
BRCA	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg27129171	chr3:47204927	SETD2	0.7	16.82	0.55	8.15e-53	Colorectal cancer;
BRCA	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg13010199	chr12:38710504	ALG10B	0.57	12.57	0.45	1.55e-32	Heart rate;
BRCA	cis	rs7043114	0.525	rs7020874	chr9:95112560	G/A	cg14631576	chr9:95140430	CENPP	-0.34	-8.38	-0.31	3.29e-16	Height;
BRCA	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	7.95	0.3	8.39e-15	Total cholesterol levels;
BRCA	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg24531977	chr5:56204891	C5orf35	0.71	15.41	0.52	8.27e-46	Initial pursuit acceleration;
BRCA	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11764359	chr7:65958608	NA	0.79	19.19	0.6	3.68e-65	Aortic root size;
BRCA	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg06627628	chr2:24431161	ITSN2	0.49	10.3	0.38	3.96e-23	Asthma;
BRCA	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg25036284	chr2:26402008	FAM59B	-0.79	-12.32	-0.44	2e-31	Gut microbiome composition (summer);
BRCA	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg07414643	chr4:187882934	NA	-0.25	-8.19	-0.31	1.41e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11955398	0.625	rs34395679	chr5:59954716	A/G	cg02684056	chr5:59996105	DEPDC1B	0.37	8.59	0.32	6.44e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-9.87	-0.36	1.73e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1476670	0.661	rs10157253	chr1:44505646	C/G	cg09470012	chr1:44509516	NA	0.38	8.57	0.32	7.64e-17	Eotaxin levels;
BRCA	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg23711669	chr6:146136114	FBXO30	-0.7	-16.55	-0.55	1.88e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg12436631	chr1:155007014	DCST1;DCST2	-0.26	-7.94	-0.3	9.17e-15	Prostate cancer;
BRCA	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.52	8.54	0.32	1.02e-16	Renal function-related traits (BUN);
BRCA	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg25036284	chr2:26402008	FAM59B	0.88	15.06	0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg01877450	chr7:97915802	BRI3	-0.37	-8.55	-0.32	9.02e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg24069376	chr3:38537580	EXOG	0.34	9.41	0.35	8.96e-20	Electrocardiographic conduction measures;
BRCA	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg09904177	chr6:26538194	HMGN4	0.43	12.65	0.45	6.53e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.44	0.38	1.1e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg07169764	chr2:136633963	MCM6	-1.25	-28.96	-0.75	1.95e-118	Corneal structure;
BRCA	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg04117972	chr1:227635322	NA	0.52	9.28	0.34	2.55e-19	Major depressive disorder;
BRCA	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg10820045	chr2:198174542	NA	-0.38	-7.87	-0.3	1.49e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg04166393	chr7:2884313	GNA12	0.48	9.01	0.34	2.43e-18	Height;
BRCA	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg06784218	chr1:46089804	CCDC17	0.5	12.02	0.43	3.67e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4808199	0.843	rs10402308	chr19:19657500	G/A	cg03709012	chr19:19516395	GATAD2A	0.89	17.39	0.57	9.16e-56	Nonalcoholic fatty liver disease;
BRCA	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.58	-11.25	-0.41	6.79e-27	Multiple sclerosis;
BRCA	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24549020	chr5:56110836	MAP3K1	-0.39	-8.07	-0.3	3.48e-15	Initial pursuit acceleration;
BRCA	cis	rs13095912	0.752	rs13061708	chr3:185339984	T/C	cg11274856	chr3:185301563	NA	0.54	12.88	0.45	6.28e-34	Systolic blood pressure;
BRCA	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg11845111	chr2:191398756	TMEM194B	-0.69	-13.21	-0.46	2.07e-35	Diastolic blood pressure;
BRCA	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg21770322	chr7:97807741	LMTK2	0.42	11.31	0.41	3.74e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7973719	0.868	rs6486910	chr12:7356479	G/A	cg07052231	chr12:7363540	PEX5	0.36	8.17	0.31	1.63e-15	IgG glycosylation;
BRCA	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg18252515	chr7:66147081	NA	-0.9	-12.87	-0.45	7.11e-34	Diabetic kidney disease;
BRCA	cis	rs758324	0.947	rs1948704	chr5:131171653	A/G	cg06307176	chr5:131281290	NA	0.53	10.32	0.38	3.41e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg02556042	chr12:117471086	NA	0.57	9.9	0.36	1.4e-21	Subcortical brain region volumes;Hippocampal volume;
BRCA	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-15.39	-0.52	1.12e-45	Height;
BRCA	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg00012203	chr2:219082015	ARPC2	-0.4	-7.86	-0.3	1.61e-14	Ulcerative colitis;
BRCA	cis	rs2580764	0.565	rs35631428	chr2:55244438	G/A	cg09592903	chr2:55203963	RTN4	-0.33	-8.58	-0.32	7.37e-17	Mean platelet volume;
BRCA	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.43	0.54	7.24e-51	Hypertriglyceridemia;
BRCA	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.48	0.32	1.55e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7131987	0.801	rs962866	chr12:29434147	A/G	cg09582351	chr12:29534625	ERGIC2	-0.42	-10.06	-0.37	3.5e-22	QT interval;
BRCA	cis	rs4742903	0.933	rs10820608	chr9:106890840	A/G	cg21169611	chr9:106856078	SMC2	0.37	9.69	0.36	7.94e-21	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-10.96	-0.4	9.86e-26	Personality dimensions;
BRCA	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg08859206	chr1:53392774	SCP2	-0.52	-11.17	-0.4	1.4e-26	Monocyte count;
BRCA	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14442939	chr10:27389572	ANKRD26	-0.69	-9.28	-0.34	2.68e-19	Breast cancer;
BRCA	cis	rs9649465	1.000	rs6950659	chr7:123361910	C/T	cg04330084	chr7:123175371	IQUB	-0.31	-8.44	-0.32	2.13e-16	Migraine;
BRCA	cis	rs870825	0.929	rs871254	chr4:185589226	G/C	cg04058563	chr4:185651563	MLF1IP	0.68	11.41	0.41	1.46e-27	Blood protein levels;
BRCA	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg04586622	chr2:25135609	ADCY3	0.46	11.63	0.42	1.74e-28	Body mass index;
BRCA	cis	rs9986765	1.000	rs10243198	chr7:142822210	C/T	cg15652212	chr7:142981776	TMEM139	0.58	10.0	0.37	5.72e-22	Cancer;Dermatomyositis;
BRCA	cis	rs2625529	0.761	rs4776582	chr15:72207520	A/T	cg16672083	chr15:72433130	SENP8	-0.83	-17.19	-0.56	9.91e-55	Red blood cell count;
BRCA	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg24562669	chr7:97807699	LMTK2	-0.43	-11.56	-0.42	3.36e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1506636	0.511	rs62484466	chr7:123174880	T/A	cg03229431	chr7:123269106	ASB15	0.51	10.95	0.4	1.08e-25	Plateletcrit;Platelet count;
BRCA	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-9.69	-0.36	8.4e-21	Menopause (age at onset);
BRCA	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg11845111	chr2:191398756	TMEM194B	-0.82	-14.64	-0.5	4.79e-42	Diastolic blood pressure;
BRCA	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg07148914	chr20:33460835	GGT7	-0.42	-9.1	-0.34	1.16e-18	Height;
BRCA	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg22705602	chr4:152727874	NA	-0.37	-10.07	-0.37	3.1e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs3772130	0.962	rs35679661	chr3:121484763	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.56	9.81	0.36	3.02e-21	Cognitive performance;
BRCA	cis	rs6878727	0.665	rs319628	chr5:123674135	C/T	cg01806427	chr5:123737813	NA	-0.36	-8.15	-0.31	1.97e-15	Breast cancer;
BRCA	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg00686598	chr14:53173677	PSMC6	1.23	16.73	0.55	2.26e-52	Alzheimer's disease (late onset);
BRCA	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.45	-10.17	-0.37	1.23e-22	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg05868516	chr6:26286170	HIST1H4H	0.5	11.39	0.41	1.66e-27	Educational attainment;
BRCA	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg02297831	chr4:17616191	MED28	0.37	8.73	0.33	2.19e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	20.25	0.63	7.78e-71	Electrocardiographic conduction measures;
BRCA	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg26384229	chr12:38710491	ALG10B	0.48	12.36	0.44	1.26e-31	Morning vs. evening chronotype;
BRCA	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg09537434	chr19:41945824	ATP5SL	0.57	10.55	0.39	4.38e-24	Colorectal cancer;
BRCA	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27286337	chr10:134555280	INPP5A	0.79	12.53	0.44	2.23e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.56	-0.32	8.25e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg12011299	chr4:100065546	ADH4	0.48	10.81	0.39	4.06e-25	Smoking initiation;
BRCA	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.53	7.89	0.3	1.31e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg14820908	chr5:178986412	RUFY1	0.36	8.11	0.31	2.63e-15	Lung cancer;
BRCA	trans	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg05347473	chr6:146136440	FBXO30	0.4	8.11	0.31	2.64e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg24642439	chr20:33292090	TP53INP2	-0.5	-10.99	-0.4	7.73e-26	Glomerular filtration rate (creatinine);
BRCA	cis	rs7131987	0.903	rs2216853	chr12:29413248	C/G	cg09582351	chr12:29534625	ERGIC2	-0.39	-9.37	-0.35	1.26e-19	QT interval;
BRCA	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg24562669	chr7:97807699	LMTK2	0.44	11.75	0.42	5.51e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2415984	0.622	rs1761026	chr14:46930139	T/C	cg14871534	chr14:47121158	RPL10L	0.34	8.39	0.31	3.22e-16	Number of children ever born;
BRCA	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg08132940	chr7:1081526	C7orf50	-0.59	-8.84	-0.33	9.29e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg05340658	chr4:99064831	C4orf37	0.59	12.67	0.45	5.43e-33	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-9.12	-0.34	9.58e-19	Neuroticism;
BRCA	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg07148914	chr20:33460835	GGT7	0.37	8.45	0.32	1.98e-16	Height;
BRCA	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg09307838	chr4:120376055	NA	0.59	12.91	0.45	4.81e-34	Corneal astigmatism;
BRCA	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg23649088	chr2:200775458	C2orf69	0.56	8.18	0.31	1.56e-15	Schizophrenia;
BRCA	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.7	-11.89	-0.43	1.33e-29	Platelet count;
BRCA	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.96	-0.3	7.64e-15	Depression;
BRCA	cis	rs7586879	1.000	rs10207698	chr2:25117672	C/T	cg01884057	chr2:25150051	NA	0.33	8.27	0.31	7.99e-16	Body mass index;
BRCA	cis	rs3916	0.955	rs34030695	chr12:121156496	G/A	cg21892295	chr12:121157589	UNC119B	-0.38	-9.89	-0.36	1.54e-21	Urinary metabolites (H-NMR features);
BRCA	trans	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg06521331	chr12:34319734	NA	-0.51	-9.34	-0.35	1.53e-19	Heart rate;
BRCA	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.42	8.46	0.32	1.78e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg13385794	chr1:248469461	NA	0.28	7.8	0.3	2.44e-14	Common traits (Other);
BRCA	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18404041	chr3:52824283	ITIH1	-0.28	-8.41	-0.32	2.7e-16	Electroencephalogram traits;
BRCA	cis	rs7809950	0.678	rs2301801	chr7:106870746	T/C	cg23024343	chr7:107201750	COG5	-0.47	-9.32	-0.35	1.84e-19	Coronary artery disease;
BRCA	cis	rs4363385	0.588	rs11205180	chr1:153022070	A/G	cg25856811	chr1:152973957	SPRR3	-0.31	-7.91	-0.3	1.13e-14	Inflammatory skin disease;
BRCA	cis	rs9341808	0.500	rs2322629	chr6:80811540	C/T	cg08355045	chr6:80787529	NA	0.39	9.82	0.36	2.75e-21	Sitting height ratio;
BRCA	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg03733263	chr8:22462867	KIAA1967	1.03	23.83	0.69	2.59e-90	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-9.74	-0.36	5.28e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg00947319	chr17:47005597	UBE2Z	-0.29	-7.81	-0.3	2.39e-14	Type 2 diabetes;
BRCA	cis	rs2294693	0.945	rs9369252	chr6:40986028	C/T	cg14769373	chr6:40998127	UNC5CL	0.38	7.94	0.3	9.22e-15	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.55	-9.88	-0.36	1.58e-21	Body mass index;
BRCA	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	9.0	0.34	2.46e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs507080	0.663	rs7926970	chr11:118559881	T/G	cg08498647	chr11:118550644	TREH	-0.38	-8.3	-0.31	6e-16	Serum metabolite levels;
BRCA	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg11266682	chr4:10021025	SLC2A9	0.42	11.03	0.4	5.24e-26	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4722166	0.532	rs6461662	chr7:22757089	C/T	cg05472934	chr7:22766657	IL6	0.43	10.76	0.39	6.5e-25	Lung cancer;
BRCA	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg08000102	chr2:233561755	GIGYF2	0.62	13.66	0.48	1.88e-37	Coronary artery disease;
BRCA	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23583168	chr7:148888333	NA	-0.73	-15.72	-0.53	2.43e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg19729930	chr2:74357872	NA	0.41	9.3	0.35	2.21e-19	Gestational age at birth (maternal effect);
BRCA	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.61	0.32	5.85e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg04691961	chr3:161091175	C3orf57	-0.38	-8.09	-0.3	3.07e-15	Parkinson's disease;
BRCA	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg22907277	chr7:1156413	C7orf50	0.53	8.75	0.33	1.94e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg03146154	chr1:46216737	IPP	-0.45	-10.13	-0.37	1.84e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9462027	0.628	rs2814969	chr6:34713399	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.01	-0.3	5.42e-15	Systemic lupus erythematosus;
BRCA	cis	rs2011503	0.597	rs8103992	chr19:19665643	A/C	cg11584989	chr19:19387371	SF4	-0.48	-10.56	-0.39	3.8e-24	Bipolar disorder;
BRCA	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.85	18.66	0.59	2.23e-62	Smoking behavior;
BRCA	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-11.43	-0.41	1.15e-27	Putamen volume;
BRCA	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04267008	chr7:1944627	MAD1L1	-0.54	-12.14	-0.43	1.16e-30	Bipolar disorder and schizophrenia;
BRCA	cis	rs1569175	0.522	rs10221945	chr2:200875847	T/C	cg23649088	chr2:200775458	C2orf69	-0.53	-7.91	-0.3	1.11e-14	Response to treatment for acute lymphoblastic leukemia;
BRCA	cis	rs1568889	1.000	rs34667360	chr11:28055650	T/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	13.49	0.47	1.16e-36	Bipolar disorder;
BRCA	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg09754948	chr16:28834200	ATXN2L	0.46	8.45	0.32	2.02e-16	Tonsillectomy;Mean corpuscular volume;
BRCA	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg18154014	chr19:37997991	ZNF793	0.62	11.64	0.42	1.52e-28	Coronary artery calcification;
BRCA	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg18758796	chr5:131593413	PDLIM4	0.34	8.98	0.33	3.12e-18	Breast cancer;
BRCA	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	9.91	0.37	1.21e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11890956	chr21:40555474	PSMG1	0.85	22.14	0.66	4.58e-81	Cognitive function;
BRCA	cis	rs6088813	1.000	rs4911494	chr20:33971914	C/T	cg14752227	chr20:34000481	UQCC	-0.41	-8.65	-0.32	4.1e-17	Height;
BRCA	cis	rs7249921	0.728	rs1627280	chr19:35652248	C/T	cg15419183	chr19:35660584	FXYD5	0.41	9.6	0.35	1.83e-20	Platelet count;
BRCA	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg14196790	chr5:131705035	SLC22A5	0.33	8.74	0.33	2.04e-17	Breast cancer;
BRCA	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg14675211	chr2:100938903	LONRF2	0.52	11.5	0.41	5.78e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg26384229	chr12:38710491	ALG10B	0.82	21.6	0.65	4.01e-78	Heart rate;
BRCA	trans	rs7746199	0.736	rs34038546	chr6:27607660	C/A	cg01620082	chr3:125678407	NA	-0.91	-10.26	-0.38	5.96e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.51	-0.44	2.8099999999999997e-32	Type 2 diabetes;
BRCA	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg23950597	chr19:37808831	NA	-0.72	-12.58	-0.45	1.42e-32	Coronary artery calcification;
BRCA	cis	rs10242455	0.702	rs3528	chr7:99055940	T/C	cg18809830	chr7:99032528	PTCD1	-0.57	-8.45	-0.32	1.98e-16	Blood metabolite levels;
BRCA	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg02175503	chr12:58329896	NA	0.81	21.06	0.64	3.42e-75	Intelligence (multi-trait analysis);
BRCA	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg14683738	chr19:37701593	ZNF585B	0.44	7.89	0.3	1.3e-14	Coronary artery calcification;
BRCA	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg14458575	chr2:238380390	NA	0.52	8.19	0.31	1.37e-15	Prostate cancer;
BRCA	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.31	9.91	0.37	1.23e-21	Electroencephalogram traits;
BRCA	cis	rs6840360	0.533	rs13145446	chr4:152729035	G/A	cg22705602	chr4:152727874	NA	0.38	9.86	0.36	1.91e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1020064	0.636	rs1529974	chr2:105927996	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.41	7.93	0.3	1.02e-14	AIDS;
BRCA	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.02	15.24	0.52	5.52e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg08859206	chr1:53392774	SCP2	0.45	10.08	0.37	2.81e-22	Monocyte count;
BRCA	cis	rs61863818	0.709	rs10786343	chr10:99159465	C/A	cg20016023	chr10:99160130	RRP12	-0.26	-8.36	-0.31	3.84e-16	Monocyte percentage of white cells;
BRCA	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18404041	chr3:52824283	ITIH1	0.38	11.79	0.42	3.72e-29	Bipolar disorder;
BRCA	cis	rs7254827	0.737	rs16981571	chr19:17158694	A/G	cg19418318	chr19:17219073	MYO9B	0.48	10.19	0.37	1.05e-22	Mean platelet volume;
BRCA	cis	rs11997175	0.583	rs4386938	chr8:33673156	A/G	ch.8.33884649F	chr8:33765107	NA	0.35	8.28	0.31	7.42e-16	Body mass index;
BRCA	cis	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.47	-0.41	7.68e-28	Morning vs. evening chronotype;
BRCA	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg23711669	chr6:146136114	FBXO30	0.64	14.96	0.51	1.28e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12618769	0.597	rs3769737	chr2:99088873	C/G	cg10123293	chr2:99228465	UNC50	-0.42	-8.13	-0.31	2.22e-15	Bipolar disorder;
BRCA	cis	rs4780401	0.609	rs4780399	chr16:11828701	A/T	cg01061890	chr16:11836724	TXNDC11	-0.56	-12.95	-0.46	3.16e-34	Rheumatoid arthritis;
BRCA	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg12379764	chr21:47803548	PCNT	-0.35	-7.82	-0.3	2.15e-14	Testicular germ cell tumor;
BRCA	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	13.06	0.46	1.02e-34	Coronary artery disease;
BRCA	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg03929089	chr4:120376271	NA	0.57	9.25	0.34	3.33e-19	Axial length;
BRCA	cis	rs2742234	0.955	rs1800861	chr10:43613843	G/T	cg02780029	chr10:43622663	RET	-0.41	-10.09	-0.37	2.51e-22	Hirschsprung disease;
BRCA	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.57	13.57	0.47	4.88e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs17270561	0.609	rs760698	chr6:25685889	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	8.85	0.33	8.49e-18	Iron status biomarkers;
BRCA	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11764359	chr7:65958608	NA	-0.73	-16.1	-0.54	3.4e-49	Aortic root size;
BRCA	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-12.23	-0.44	4.82e-31	Gut microbiome composition (summer);
BRCA	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg16850897	chr7:100343110	ZAN	0.37	8.53	0.32	1.03e-16	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
BRCA	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.66	-0.5	3.76e-42	Chronic sinus infection;
BRCA	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg04842962	chr6:43655489	MRPS18A	1.12	38.9	0.84	1.18e-170	IgG glycosylation;
BRCA	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26314531	chr2:26401878	FAM59B	-0.79	-12.57	-0.45	1.53e-32	Gut microbiome composition (summer);
BRCA	cis	rs10739663	0.520	rs3122937	chr9:128154808	A/G	cg14078157	chr9:128172775	NA	-0.43	-10.18	-0.37	1.21e-22	Resting heart rate;
BRCA	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg26384229	chr12:38710491	ALG10B	0.59	13.54	0.47	6.37e-37	Morning vs. evening chronotype;
BRCA	cis	rs36051895	0.589	rs2224571	chr9:5196253	A/C	cg02405213	chr9:5042618	JAK2	-0.46	-8.67	-0.32	3.63e-17	Pediatric autoimmune diseases;
BRCA	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg16230307	chr14:35515116	FAM177A1	0.73	14.74	0.5	1.59e-42	Psoriasis;
BRCA	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	14.31	0.49	1.62e-40	Platelet count;
BRCA	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.34	-9.26	-0.34	2.94e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs6750047	0.647	rs62136320	chr2:38275953	T/G	cg07380506	chr2:38303506	CYP1B1	0.48	10.53	0.38	4.98e-24	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.13	0.34	8.89e-19	Tonsillectomy;
BRCA	cis	rs16854884	0.632	rs60505453	chr3:143643864	C/G	cg06585982	chr3:143692056	C3orf58	0.42	8.48	0.32	1.53e-16	Economic and political preferences (feminism/equality);
BRCA	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg18446336	chr7:2847575	GNA12	-0.35	-7.94	-0.3	9.17e-15	Height;
BRCA	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.22	7.87	0.3	1.49e-14	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4363385	0.818	rs10788853	chr1:153002231	C/T	cg24667326	chr1:152973720	SPRR3	-0.33	-8.81	-0.33	1.19e-17	Inflammatory skin disease;
BRCA	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg05283184	chr6:79620031	NA	-0.43	-10.89	-0.4	1.9e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs2742417	0.603	rs2742372	chr3:45783472	T/C	cg04837898	chr3:45731254	SACM1L	-0.38	-7.81	-0.3	2.31e-14	Response to anti-depressant treatment in major depressive disorder;
BRCA	trans	rs800082	0.698	rs800077	chr3:144349940	A/G	cg24215973	chr2:240111563	HDAC4	-0.64	-14.75	-0.5	1.41e-42	Smoking behavior;
BRCA	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	8.78	0.33	1.53e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2404602	0.591	rs11635162	chr15:76951105	C/T	cg23625390	chr15:77176239	SCAPER	-0.52	-11.02	-0.4	5.68e-26	Blood metabolite levels;
BRCA	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.03	16.04	0.54	6.9e-49	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg21905437	chr5:178450457	ZNF879	0.51	10.14	0.37	1.73e-22	Pubertal anthropometrics;
BRCA	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg17911788	chr17:44343683	NA	-0.46	-8.23	-0.31	1.05e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
BRCA	cis	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg21775007	chr8:11205619	TDH	-0.62	-12.17	-0.43	8.92e-31	Retinal vascular caliber;
BRCA	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg08807101	chr21:30365312	RNF160	0.43	9.1	0.34	1.12e-18	Pancreatic cancer;
BRCA	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg07636037	chr3:49044803	WDR6	0.42	8.63	0.32	5.02e-17	Resting heart rate;
BRCA	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18876405	chr7:65276391	NA	0.62	15.35	0.52	1.76e-45	Aortic root size;
BRCA	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg10223061	chr2:219282414	VIL1	0.31	8.89	0.33	6.35e-18	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs4409675	0.576	rs3766396	chr1:28221554	C/T	cg23691781	chr1:28212827	C1orf38	-0.32	-10.66	-0.39	1.6e-24	Corneal astigmatism;
BRCA	cis	rs12545109	0.765	rs1960727	chr8:57411368	G/A	cg09654669	chr8:57350985	NA	-0.4	-7.81	-0.3	2.32e-14	Obesity-related traits;
BRCA	cis	rs17092148	1.000	rs6088603	chr20:33370945	A/G	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.26	-0.41	5.82e-27	Neuroticism;
BRCA	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.55	9.39	0.35	1.07e-19	Renal function-related traits (BUN);
BRCA	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg25457927	chr22:38595422	NA	0.3	11.33	0.41	2.9e-27	Cutaneous nevi;
BRCA	cis	rs6066825	0.590	rs6063307	chr20:47304045	A/G	cg18078177	chr20:47281410	PREX1	0.39	9.88	0.36	1.65e-21	Colorectal cancer;
BRCA	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg08888203	chr3:10149979	C3orf24	0.58	12.28	0.44	2.89e-31	Alzheimer's disease;
BRCA	trans	rs629535	0.862	rs2472141	chr8:70054216	T/C	cg21567404	chr3:27674614	NA	1.0	20.93	0.64	1.77e-74	Dupuytren's disease;
BRCA	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.34	0.35	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1557765	0.527	rs11024272	chr11:17395760	T/C	cg04705435	chr11:17411270	KCNJ11	0.34	7.9	0.3	1.19e-14	Body mass index;Social communication problems;
BRCA	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2425143	1.000	rs6060578	chr20:34305445	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.03	-0.34	2.03e-18	Blood protein levels;
BRCA	trans	rs11165623	0.564	rs7525803	chr1:97000791	T/C	cg10631902	chr5:14652156	NA	-0.43	-12.14	-0.43	1.11e-30	Hip circumference;Waist circumference;
BRCA	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg20587970	chr11:113659929	NA	-1.37	-24.72	-0.7	3.4e-95	Hip circumference adjusted for BMI;
BRCA	cis	rs7523273	0.597	rs2724374	chr1:207941191	G/T	cg22525895	chr1:207977042	MIR29B2	0.4	8.31	0.31	5.96e-16	Schizophrenia;
BRCA	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg08847533	chr14:75593920	NEK9	0.92	23.71	0.68	1.28e-89	Height;
BRCA	cis	rs2625529	0.652	rs8040216	chr15:72255249	C/T	cg16672083	chr15:72433130	SENP8	0.66	15.65	0.53	6e-47	Red blood cell count;
BRCA	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg00684032	chr4:1343700	KIAA1530	0.38	9.23	0.34	3.82e-19	Obesity-related traits;
BRCA	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg13902645	chr11:5959945	NA	0.65	15.23	0.52	6.33e-45	DNA methylation (variation);
BRCA	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-12.27	-0.44	3.13e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg16590910	chr6:42928470	GNMT	0.36	7.83	0.3	2.11e-14	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg24562669	chr7:97807699	LMTK2	0.45	12.03	0.43	3.58e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9381107	0.932	rs13198509	chr6:9479610	C/T	cg14735645	chr6:9486422	NA	-0.46	-8.1	-0.31	2.85e-15	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-12.8	-0.45	1.42e-33	Bipolar disorder;
BRCA	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg20307385	chr11:47447363	PSMC3	0.86	26.38	0.72	2.51e-104	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs6142102	0.625	rs6141436	chr20:32554571	T/A	cg24642439	chr20:33292090	TP53INP2	0.39	7.82	0.3	2.22e-14	Skin pigmentation;
BRCA	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg00012203	chr2:219082015	ARPC2	0.47	9.11	0.34	1.09e-18	Colorectal cancer;
BRCA	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg03929089	chr4:120376271	NA	0.64	12.62	0.45	9.66e-33	Coronary artery disease;
BRCA	cis	rs72781680	0.784	rs12616678	chr2:24181159	G/T	cg08917208	chr2:24149416	ATAD2B	0.62	10.39	0.38	1.76e-23	Lymphocyte counts;
BRCA	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	14.72	0.5	1.86e-42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1832871	0.672	rs9457345	chr6:158743098	A/G	cg07165851	chr6:158734300	TULP4	0.62	12.46	0.44	4.65e-32	Height;
BRCA	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27286337	chr10:134555280	INPP5A	0.59	11.33	0.41	3.16e-27	Migraine;
BRCA	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.53	-0.32	1.06e-16	Monocyte percentage of white cells;
BRCA	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	17.09	0.56	3.46e-54	Alzheimer's disease;
BRCA	cis	rs4566357	0.557	rs2272201	chr2:227912551	T/A	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.08	-0.3	3.32e-15	Coronary artery disease;
BRCA	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg21045802	chr8:109455806	TTC35	0.35	7.89	0.3	1.3e-14	Dupuytren's disease;
BRCA	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	11.33	0.41	2.92e-27	Mean platelet volume;
BRCA	cis	rs735860	0.726	rs209510	chr6:53202035	T/C	cg10236188	chr6:53219634	NA	0.38	7.92	0.3	1.05e-14	Glaucoma;
BRCA	cis	rs2115536	0.730	rs4573897	chr15:80187225	G/A	cg02196730	chr15:80188777	MTHFS	0.36	7.95	0.3	8.27e-15	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
BRCA	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg00757033	chr12:89920650	WDR51B	-0.51	-10.39	-0.38	1.74e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.25	0.34	3.24e-19	Tonsillectomy;
BRCA	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg00383909	chr3:49044727	WDR6	0.89	12.7	0.45	3.96e-33	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.43	-8.79	-0.33	1.42e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg23978390	chr7:1156363	C7orf50	0.33	7.98	0.3	6.64e-15	Longevity;Endometriosis;
BRCA	cis	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg05901451	chr6:126070800	HEY2	0.4	9.73	0.36	6.12e-21	Endometrial cancer;
BRCA	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7246657	0.663	rs4803287	chr19:38079435	A/G	cg18154014	chr19:37997991	ZNF793	0.5	9.38	0.35	1.11e-19	Coronary artery calcification;
BRCA	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg16339924	chr4:17578868	LAP3	-0.57	-13.28	-0.47	9.97e-36	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs813218	0.584	rs1718240	chr3:99536937	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.4	-8.47	-0.32	1.66e-16	Orofacial clefts;
BRCA	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg16586182	chr3:47516702	SCAP	-0.56	-12.53	-0.44	2.3e-32	QT interval;
BRCA	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg08917208	chr2:24149416	ATAD2B	0.89	12.98	0.46	2.32e-34	Lymphocyte counts;
BRCA	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg01877450	chr7:97915802	BRI3	-0.39	-8.97	-0.33	3.34e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-8.98	-0.33	3.09e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4074536	0.574	rs10737732	chr1:116288774	G/A	cg21648376	chr1:116311395	CASQ2	-0.49	-8.71	-0.33	2.5e-17	QRS duration;
BRCA	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg07636037	chr3:49044803	WDR6	0.99	29.67	0.76	2.75e-122	Parkinson's disease;
BRCA	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg03929089	chr4:120376271	NA	-0.68	-13.52	-0.47	8.34e-37	Coronary artery disease;
BRCA	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.73	-0.33	2.24e-17	Total body bone mineral density;
BRCA	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.36	12.45	0.44	5.41e-32	Electroencephalogram traits;
BRCA	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg25237894	chr2:233734115	C2orf82	0.39	11.41	0.41	1.45e-27	Coronary artery disease;
BRCA	cis	rs9287719	0.578	rs7598541	chr2:10700516	G/A	cg00105475	chr2:10696890	NA	0.47	10.26	0.38	5.63e-23	Prostate cancer;
BRCA	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg02175503	chr12:58329896	NA	0.45	8.61	0.32	5.56e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs698833	0.710	rs1441048	chr2:44511929	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	9.46	0.35	5.9e-20	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs2797160	1.000	rs1739367	chr6:126004720	G/T	cg05901451	chr6:126070800	HEY2	-0.39	-9.49	-0.35	4.46e-20	Endometrial cancer;
BRCA	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-11.74	-0.42	6.16e-29	Hemoglobin concentration;
BRCA	cis	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg06521331	chr12:34319734	NA	-0.58	-11.65	-0.42	1.47e-28	Morning vs. evening chronotype;
BRCA	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg23711669	chr6:146136114	FBXO30	-0.62	-14.17	-0.49	7.79e-40	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17253792	0.822	rs77599953	chr14:56058905	C/T	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.87	-0.36	1.83e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs925228	0.504	rs7568176	chr2:24313758	T/A	cg20701182	chr2:24300061	SF3B14	-0.53	-8.56	-0.32	8.43e-17	Reticulocyte fraction of red cells;Reticulocyte count;
BRCA	cis	rs9341808	0.718	rs12208016	chr6:80823563	G/A	cg08355045	chr6:80787529	NA	0.37	9.37	0.35	1.24e-19	Sitting height ratio;
BRCA	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.47	-9.47	-0.35	5.18e-20	Bipolar disorder;
BRCA	cis	rs16976116	0.901	rs1061821	chr15:55496111	T/C	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4363385	0.747	rs4255332	chr1:152958745	G/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.78	-0.33	1.54e-17	Inflammatory skin disease;
BRCA	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg26384229	chr12:38710491	ALG10B	0.66	15.38	0.52	1.21e-45	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg16586182	chr3:47516702	SCAP	0.65	15.14	0.51	1.86e-44	Colorectal cancer;
BRCA	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg14019146	chr3:50243930	SLC38A3	0.61	14.96	0.51	1.4e-43	Intelligence (multi-trait analysis);
BRCA	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.66	-16.69	-0.55	3.67e-52	Multiple sclerosis;
BRCA	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg02297831	chr4:17616191	MED28	0.4	8.67	0.32	3.67e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-13.14	-0.46	4.59e-35	Lymphocyte counts;
BRCA	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.66	0.39	1.63e-24	Tonsillectomy;
BRCA	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00149659	chr3:10157352	C3orf10	0.79	13.72	0.48	9.42e-38	Alzheimer's disease;
BRCA	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg14228332	chr4:119757509	SEC24D	0.68	8.1	0.31	2.78e-15	Cannabis dependence symptom count;
BRCA	cis	rs2742417	0.603	rs2742395	chr3:45758595	A/G	cg04837898	chr3:45731254	SACM1L	-0.43	-8.66	-0.32	3.79e-17	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg18753928	chr3:113234510	CCDC52	-0.58	-12.18	-0.43	7.72e-31	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs61990749	0.597	rs2112136	chr14:78248952	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.46	7.83	0.3	2.01e-14	Fibroblast growth factor basic levels;
BRCA	cis	rs360798	0.532	rs13013218	chr2:63011671	C/T	cg17519650	chr2:63277830	OTX1	-0.37	-8.24	-0.31	9.75e-16	Coronary artery disease;
BRCA	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg00071950	chr4:10020882	SLC2A9	0.59	14.32	0.49	1.53e-40	Bone mineral density;
BRCA	cis	rs6121246	0.542	rs75694362	chr20:30450708	T/C	cg13852791	chr20:30311386	BCL2L1	0.67	8.95	0.33	3.82e-18	Mean corpuscular hemoglobin;
BRCA	trans	rs4596713	0.507	rs10869975	chr9:71795034	C/T	cg16512924	chr15:28394682	HERC2	-0.46	-11.14	-0.4	1.79e-26	Headache;
BRCA	cis	rs738322	0.804	rs4821743	chr22:38514906	A/G	cg25457927	chr22:38595422	NA	-0.31	-10.86	-0.39	2.51e-25	Cutaneous nevi;
BRCA	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg02734326	chr4:10020555	SLC2A9	0.42	9.07	0.34	1.43e-18	Bone mineral density;
BRCA	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg01579765	chr21:45077557	HSF2BP	0.41	10.74	0.39	7.46e-25	Mean corpuscular volume;
BRCA	cis	rs977987	0.778	rs1109341	chr16:75445605	G/A	cg03315344	chr16:75512273	CHST6	0.52	12.42	0.44	7.05e-32	Dupuytren's disease;
BRCA	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	16.64	0.55	6.55e-52	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg23711669	chr6:146136114	FBXO30	0.75	17.42	0.57	6.43e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12545109	0.800	rs1595940	chr8:57398309	T/C	cg09654669	chr8:57350985	NA	-0.41	-7.93	-0.3	1e-14	Obesity-related traits;
BRCA	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg16230307	chr14:35515116	FAM177A1	0.72	14.67	0.5	3.48e-42	Psoriasis;
BRCA	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg22907277	chr7:1156413	C7orf50	0.49	10.98	0.4	7.84e-26	Longevity;Endometriosis;
BRCA	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12379764	chr21:47803548	PCNT	0.39	8.56	0.32	8.18e-17	Testicular germ cell tumor;
BRCA	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02176678	chr2:219576539	TTLL4	-0.51	-12.82	-0.45	1.19e-33	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1003719	0.680	rs2154537	chr21:38502012	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.15	-0.49	9.86e-40	Eye color traits;
BRCA	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.06	-0.43	2.48e-30	Developmental language disorder (linguistic errors);
BRCA	cis	rs6446731	0.593	rs7656026	chr4:3273625	G/C	cg08886695	chr4:3369023	RGS12	-0.38	-9.89	-0.36	1.49e-21	Mean platelet volume;
BRCA	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg03146154	chr1:46216737	IPP	-0.5	-11.01	-0.4	6.25e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg12463550	chr7:65579703	CRCP	-0.38	-8.21	-0.31	1.26e-15	Aortic root size;
BRCA	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg23625390	chr15:77176239	SCAPER	-0.55	-13.15	-0.46	4.02e-35	Blood metabolite levels;
BRCA	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg11645453	chr3:52864694	ITIH4	-0.38	-9.93	-0.37	1.05e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	trans	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg23762105	chr12:34175262	ALG10	0.34	8.0	0.3	5.92e-15	Morning vs. evening chronotype;
BRCA	trans	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg19862616	chr7:65841803	NCRNA00174	0.85	28.37	0.75	3.22e-115	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2637266	1.000	rs7080883	chr10:78361200	A/G	cg18941641	chr10:78392320	NA	0.35	7.84	0.3	1.83e-14	Pulmonary function;
BRCA	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg09307838	chr4:120376055	NA	0.69	14.07	0.49	2.31e-39	Corneal astigmatism;
BRCA	trans	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-19.39	-0.61	3.14e-66	Exhaled nitric oxide output;
BRCA	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg05347473	chr6:146136440	FBXO30	0.39	7.94	0.3	9.39e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg12641515	chr19:46296257	DMWD	-0.55	-12.23	-0.44	4.66e-31	Coronary artery disease;
BRCA	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	14.84	0.51	5.07e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	cis	rs1451375	0.617	rs10267323	chr7:50591424	A/G	cg18232548	chr7:50535776	DDC	0.44	9.36	0.35	1.33e-19	Malaria;
BRCA	cis	rs6788895	1.000	rs79709238	chr3:150488477	A/C	cg09723797	chr3:150481914	SIAH2	0.71	8.59	0.32	6.53e-17	Breast cancer;
BRCA	cis	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg06521331	chr12:34319734	NA	-0.57	-10.68	-0.39	1.32e-24	Morning vs. evening chronotype;
BRCA	cis	rs6120849	0.754	rs7268266	chr20:33581889	T/C	cg24642439	chr20:33292090	TP53INP2	0.59	10.18	0.37	1.18e-22	Protein C levels;
BRCA	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg05973401	chr12:123451056	ABCB9	0.41	7.94	0.3	9.17e-15	Neutrophil percentage of white cells;
BRCA	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg18758796	chr5:131593413	PDLIM4	0.32	8.52	0.32	1.12e-16	Breast cancer;
BRCA	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg20203395	chr5:56204925	C5orf35	-0.52	-10.92	-0.4	1.42e-25	Initial pursuit acceleration;
BRCA	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg24675658	chr1:53192096	ZYG11B	0.84	18.94	0.6	7.77e-64	Monocyte count;
BRCA	cis	rs17253792	0.915	rs77252471	chr14:56178075	C/T	cg01858014	chr14:56050164	KTN1	-0.67	-8.51	-0.32	1.22e-16	Putamen volume;
BRCA	cis	rs1864400	0.605	rs12360493	chr10:43718613	A/G	cg15436174	chr10:43711423	RASGEF1A	0.43	9.06	0.34	1.57e-18	Hirschsprung disease;
BRCA	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-11.62	-0.42	1.89e-28	Lymphocyte counts;
BRCA	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-11.7	-0.42	8.44e-29	Longevity;Endometriosis;
BRCA	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg08917208	chr2:24149416	ATAD2B	1.04	14.64	0.5	4.66e-42	Lymphocyte counts;
BRCA	cis	rs1635	0.655	rs723476	chr6:28305104	C/T	cg15743358	chr6:28303923	ZNF323	-0.75	-8.75	-0.33	1.94e-17	Schizophrenia;
BRCA	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg14926445	chr8:58193284	C8orf71	-0.44	-8.26	-0.31	8.5e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg09594475	chr20:60884601	LAMA5	0.5	11.02	0.4	5.44e-26	Pelvic organ prolapse;
BRCA	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg14349672	chr11:133703707	NA	-0.43	-9.62	-0.36	1.56e-20	Childhood ear infection;
BRCA	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.37	7.93	0.3	9.7e-15	Cognitive ability;
BRCA	cis	rs6594499	0.872	rs10045255	chr5:110438357	C/T	cg04022379	chr5:110408740	TSLP	-0.35	-7.97	-0.3	7.07e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.6	0.57	7.88e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs919433	0.680	rs2565160	chr2:198286474	A/G	cg00792783	chr2:198669748	PLCL1	0.38	8.52	0.32	1.15e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs2637266	0.967	rs7900230	chr10:78366879	A/G	cg18941641	chr10:78392320	NA	0.35	7.82	0.3	2.18e-14	Pulmonary function;
BRCA	cis	rs68170813	0.559	rs5002976	chr7:107050620	C/G	cg02696742	chr7:106810147	HBP1	-0.53	-8.07	-0.3	3.44e-15	Coronary artery disease;
BRCA	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-10.41	-0.38	1.48e-23	Retinal vascular caliber;
BRCA	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg11301795	chr4:187892539	NA	-0.27	-8.81	-0.33	1.17e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg18252515	chr7:66147081	NA	-0.88	-12.64	-0.45	7.81e-33	Diabetic kidney disease;
BRCA	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg26395211	chr5:140044315	WDR55	0.37	8.43	0.32	2.36e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20916646	chr4:852691	GAK	0.5	10.99	0.4	7.26e-26	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
BRCA	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.38	8.21	0.31	1.24e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg25036284	chr2:26402008	FAM59B	0.9	15.64	0.53	6.69e-47	Gut microbiome composition (summer);
BRCA	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg26818010	chr10:134567672	INPP5A	0.37	8.72	0.33	2.47e-17	Migraine;
BRCA	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11890956	chr21:40555474	PSMG1	-0.62	-13.82	-0.48	3.3e-38	Menarche (age at onset);
BRCA	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.54	13.59	0.47	3.96e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg03676636	chr4:99064102	C4orf37	0.24	8.27	0.31	7.91e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	-0.4	-9.19	-0.34	5.23e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02018176	chr4:1364513	KIAA1530	0.38	7.97	0.3	7.33e-15	Longevity;
BRCA	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg07636037	chr3:49044803	WDR6	0.55	8.7	0.33	2.75e-17	Menarche (age at onset);
BRCA	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	13.9	0.48	1.45e-38	Alzheimer's disease;
BRCA	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg11814155	chr7:99998594	ZCWPW1	0.43	8.29	0.31	6.45e-16	Platelet count;
BRCA	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg05868516	chr6:26286170	HIST1H4H	0.41	8.12	0.31	2.45e-15	Educational attainment;
BRCA	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	18.03	0.58	4.69e-59	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg00105475	chr2:10696890	NA	0.44	10.25	0.38	6.03e-23	Prostate cancer;
BRCA	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg13114125	chr14:105738426	BRF1	0.48	10.55	0.39	4.36e-24	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.15	0.31	1.99e-15	Axial length;
BRCA	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg14530993	chr4:882597	GAK	0.53	9.78	0.36	3.71e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.818	rs61811862	chr1:152995668	G/A	cg25856811	chr1:152973957	SPRR3	-0.31	-8.09	-0.3	3.09e-15	Inflammatory skin disease;
BRCA	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg05623727	chr3:50126028	RBM5	0.39	8.52	0.32	1.15e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs17601876	0.814	rs3889391	chr15:51558422	G/A	cg19946085	chr15:51559439	CYP19A1	-0.36	-9.84	-0.36	2.31e-21	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg16179182	chr5:140090404	VTRNA1-1	0.43	10.12	0.37	2.05e-22	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg05863683	chr7:1912471	MAD1L1	0.43	9.31	0.35	2.09e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs4423214	0.840	rs1619577	chr11:71181485	C/T	cg05163923	chr11:71159392	DHCR7	-0.57	-11.6	-0.42	2.28e-28	Vitamin D levels;
BRCA	cis	rs2637266	1.000	rs12258924	chr10:78364758	G/A	cg18941641	chr10:78392320	NA	0.35	7.82	0.3	2.18e-14	Pulmonary function;
BRCA	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18876405	chr7:65276391	NA	-0.62	-15.33	-0.52	2.13e-45	Aortic root size;
BRCA	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg15556689	chr8:8085844	FLJ10661	0.43	11.74	0.42	5.79e-29	Mood instability;
BRCA	cis	rs698813	0.637	rs7579841	chr2:44498887	T/A	cg00619915	chr2:44497795	NA	-0.37	-7.9	-0.3	1.26e-14	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs1863824	0.625	rs10887598	chr10:88166160	T/A	cg07322936	chr10:88137208	NA	-0.47	-9.41	-0.35	8.52e-20	Schizophrenia;
BRCA	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	14.0	0.48	4.71e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg10664184	chr19:17420304	DDA1	0.32	8.96	0.33	3.52e-18	Systemic lupus erythematosus;
BRCA	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.54	-0.32	9.95e-17	Monocyte percentage of white cells;
BRCA	cis	rs4363385	0.747	rs1415962	chr1:152958731	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.88	-0.33	6.84e-18	Inflammatory skin disease;
BRCA	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg05340658	chr4:99064831	C4orf37	0.44	10.13	0.37	1.74e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg07606381	chr6:8435919	SLC35B3	-0.65	-14.19	-0.49	6.03e-40	Motion sickness;
BRCA	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg01874867	chr7:94954059	PON1	-0.4	-8.07	-0.3	3.47e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg13565492	chr6:43139072	SRF	-0.89	-16.02	-0.54	8.62e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg14683738	chr19:37701593	ZNF585B	0.45	8.02	0.3	4.94e-15	Coronary artery calcification;
BRCA	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg04455712	chr21:45112962	RRP1B	-0.36	-8.79	-0.33	1.35e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.39	-0.38	1.77e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs600806	0.815	rs4970758	chr1:109979617	A/G	cg20591472	chr1:110008990	SYPL2	0.32	7.89	0.3	1.34e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs7020830	0.830	rs308499	chr9:37348059	C/G	cg14294708	chr9:37120828	ZCCHC7	1.04	29.82	0.76	4.03e-123	Schizophrenia;
BRCA	cis	rs7246657	0.654	rs10407568	chr19:38123009	A/T	cg23950597	chr19:37808831	NA	-0.5	-8.59	-0.32	6.86e-17	Coronary artery calcification;
BRCA	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.66	0.32	3.82e-17	Rheumatoid arthritis;
BRCA	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-14.46	-0.5	3.2e-41	Bipolar disorder and schizophrenia;
BRCA	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg23711669	chr6:146136114	FBXO30	0.77	17.96	0.58	1.11e-58	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-13.64	-0.47	2.41e-37	Obesity-related traits;
BRCA	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg26395211	chr5:140044315	WDR55	0.37	8.67	0.32	3.68e-17	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-10.02	-0.37	4.58e-22	Retinal vascular caliber;
BRCA	cis	rs870825	0.929	rs1405940	chr4:185591481	A/G	cg20176042	chr4:185552304	CASP3	-0.6	-8.29	-0.31	6.72e-16	Blood protein levels;
BRCA	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg02551604	chr5:131831745	NA	-0.4	-14.11	-0.49	1.57e-39	Asthma (sex interaction);
BRCA	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-16.88	-0.56	4.06e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1577917	0.545	rs9344548	chr6:86487337	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.34	9.18	0.34	5.93e-19	Response to antipsychotic treatment;
BRCA	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg18252515	chr7:66147081	NA	1.07	15.89	0.53	3.53e-48	Diabetic kidney disease;
BRCA	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg21770322	chr7:97807741	LMTK2	-0.41	-10.87	-0.39	2.32e-25	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	10.82	0.39	3.76e-25	Platelet count;
BRCA	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg22834771	chr12:69754056	YEATS4	-0.39	-9.64	-0.36	1.29e-20	Blood protein levels;
BRCA	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg24397884	chr7:158709396	WDR60	-0.98	-24.63	-0.7	1.1e-94	Height;
BRCA	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.6	-11.5	-0.41	5.73e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	10.27	0.38	5.12e-23	Lung function (FEV1/FVC);
BRCA	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg12386194	chr3:101231763	SENP7	0.7	13.18	0.46	2.87e-35	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg26116260	chr4:7069785	GRPEL1	0.94	27.52	0.74	1.3800000000000001e-110	Monocyte percentage of white cells;
BRCA	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg08999081	chr20:33150536	PIGU	-0.33	-8.66	-0.32	3.94e-17	Glomerular filtration rate (creatinine);
BRCA	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg06636001	chr8:8085503	FLJ10661	0.53	9.99	0.37	6.06e-22	Retinal vascular caliber;
BRCA	cis	rs724568	0.546	rs1367457	chr2:67951861	C/T	cg14046302	chr2:67939758	NA	0.38	10.25	0.38	6.56e-23	Major depressive disorder (broad);
BRCA	cis	rs9837602	1.000	rs1688771	chr3:99503359	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.59	-10.77	-0.39	5.51e-25	Breast cancer;
BRCA	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg22906224	chr7:99728672	NA	0.46	8.72	0.33	2.31e-17	Coronary artery disease;
BRCA	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg21775007	chr8:11205619	TDH	0.62	12.82	0.45	1.21e-33	Retinal vascular caliber;
BRCA	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg18132916	chr6:79620363	NA	-0.48	-11.06	-0.4	4.06e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26818010	chr10:134567672	INPP5A	-0.66	-14.4	-0.49	6.53e-41	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6546550	0.935	rs13392884	chr2:70036711	A/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-10.23	-0.38	7.56e-23	Prevalent atrial fibrillation;
BRCA	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg26031613	chr14:104095156	KLC1	0.44	8.7	0.33	2.83e-17	Schizophrenia;
BRCA	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	14.13	0.49	1.16e-39	Hip circumference adjusted for BMI;
BRCA	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg27129171	chr3:47204927	SETD2	0.71	17.08	0.56	3.77e-54	Colorectal cancer;
BRCA	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg12062639	chr20:23401060	NAPB	0.94	13.43	0.47	2.23e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg07080220	chr10:102295463	HIF1AN	0.59	13.98	0.48	5.78e-39	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs490234	0.966	rs829312	chr9:128377873	C/T	cg14078157	chr9:128172775	NA	-0.33	-7.95	-0.3	8.25e-15	Mean arterial pressure;
BRCA	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg05234568	chr11:5960015	NA	-0.52	-10.29	-0.38	4.3e-23	DNA methylation (variation);
BRCA	cis	rs11958404	0.932	rs59246968	chr5:157418180	T/C	cg05962755	chr5:157440814	NA	0.47	9.28	0.34	2.58e-19	IgG glycosylation;
BRCA	cis	rs9837602	0.810	rs9854260	chr3:99850212	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	9.32	0.35	1.84e-19	Breast cancer;
BRCA	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	13.44	0.47	1.87e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11644478	chr21:40555479	PSMG1	-0.51	-10.82	-0.39	3.75e-25	Menarche (age at onset);
BRCA	cis	rs490234	0.702	rs10986788	chr9:128303942	G/C	cg14078157	chr9:128172775	NA	-0.51	-11.39	-0.41	1.73e-27	Mean arterial pressure;
BRCA	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg19920283	chr7:105172520	RINT1	0.58	9.14	0.34	7.99e-19	Bipolar disorder (body mass index interaction);
BRCA	trans	rs4714291	0.925	rs847755	chr6:40030378	T/C	cg02267698	chr19:7991119	CTXN1	0.41	7.85	0.3	1.74e-14	Strep throat;
BRCA	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg18404041	chr3:52824283	ITIH1	-0.53	-16.39	-0.54	1.19e-50	Bipolar disorder;
BRCA	cis	rs2880765	0.743	rs8032488	chr15:86012768	T/C	cg10818794	chr15:86012489	AKAP13	-0.3	-8.26	-0.31	8.35e-16	Coronary artery disease;
BRCA	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg15133208	chr4:90757351	SNCA	-0.41	-8.13	-0.31	2.27e-15	Neuroticism;
BRCA	cis	rs3125734	0.633	rs4979774	chr10:63967795	A/T	cg09941381	chr10:64027924	RTKN2	-0.28	-8.5	-0.32	1.37e-16	Rheumatoid arthritis;
BRCA	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg23625390	chr15:77176239	SCAPER	-0.54	-12.62	-0.45	9.28e-33	Blood metabolite levels;
BRCA	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg25811766	chr13:21894605	NA	-0.55	-9.0	-0.34	2.54e-18	White matter hyperintensity burden;
BRCA	cis	rs7267979	0.932	rs13040655	chr20:25582197	C/T	cg08601574	chr20:25228251	PYGB	0.34	7.93	0.3	9.9e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.57	-0.39	3.71e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs34779708	0.966	rs4934736	chr10:35496868	G/A	cg03585969	chr10:35415529	CREM	0.49	10.38	0.38	2.0500000000000001e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg23711669	chr6:146136114	FBXO30	0.72	16.64	0.55	6.64e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs965469	0.947	rs6051773	chr20:3330382	C/G	cg25506879	chr20:3388711	C20orf194	-0.53	-10.5	-0.38	6.58e-24	IFN-related cytopenia;
BRCA	cis	rs10267417	0.557	rs10249101	chr7:19895397	T/G	cg05791153	chr7:19748676	TWISTNB	0.45	8.86	0.33	7.98e-18	Night sleep phenotypes;
BRCA	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg18904891	chr8:8559673	CLDN23	0.64	14.35	0.49	1.16e-40	Obesity-related traits;
BRCA	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.78e-21	Total body bone mineral density;
BRCA	cis	rs6973256	0.583	rs2345943	chr7:133340630	A/G	cg07491979	chr7:133331646	EXOC4	-0.36	-8.2	-0.31	1.32e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs490234	0.702	rs4838277	chr9:128367886	C/T	cg14078157	chr9:128172775	NA	-0.5	-11.06	-0.4	4.01e-26	Mean arterial pressure;
BRCA	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.15	-0.37	1.55e-22	Mean corpuscular volume;
BRCA	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg00106254	chr7:1943704	MAD1L1	0.37	10.17	0.37	1.3e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.41	-8.92	-0.33	4.91e-18	Personality dimensions;
BRCA	cis	rs13046373	0.535	rs8129571	chr21:31980646	G/A	cg16812893	chr21:31813075	KRTAP15-1	0.38	9.72	0.36	6.22e-21	HDL cholesterol;
BRCA	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg22875332	chr1:76189707	ACADM	0.57	10.86	0.39	2.56e-25	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11764359	chr7:65958608	NA	-0.75	-17.53	-0.57	1.81e-56	Aortic root size;
BRCA	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.4	8.38	0.31	3.4e-16	Total cholesterol levels;
BRCA	cis	rs7580658	0.521	rs35577992	chr2:127941324	C/T	cg16751203	chr2:127950803	CYP27C1	0.29	8.11	0.31	2.63e-15	Protein C levels;
BRCA	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg22467129	chr15:76604101	ETFA	-0.4	-9.09	-0.34	1.28e-18	Blood metabolite levels;
BRCA	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.35	-0.35	1.46e-19	Bipolar disorder;
BRCA	cis	rs3925075	1.000	rs4889543	chr16:31340216	C/T	cg02846316	chr16:31340340	ITGAM	0.54	13.32	0.47	6.97e-36	IgA nephropathy;
BRCA	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg06766960	chr11:133703094	NA	0.61	13.14	0.46	4.29e-35	Childhood ear infection;
BRCA	cis	rs9287719	0.614	rs6711473	chr2:10723374	T/C	cg00105475	chr2:10696890	NA	0.41	9.17	0.34	6.17e-19	Prostate cancer;
BRCA	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg22535103	chr8:58192502	C8orf71	-0.43	-8.87	-0.33	7.02e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg05234568	chr11:5960015	NA	-0.49	-9.68	-0.36	8.89e-21	DNA methylation (variation);
BRCA	trans	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg19862616	chr7:65841803	NCRNA00174	0.81	25.64	0.71	3.13e-100	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg26384229	chr12:38710491	ALG10B	0.59	13.53	0.47	7.42e-37	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg23649088	chr2:200775458	C2orf69	-0.57	-8.58	-0.32	7.12e-17	Schizophrenia;
BRCA	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg00106254	chr7:1943704	MAD1L1	-0.39	-9.31	-0.35	1.96e-19	Bipolar disorder and schizophrenia;
BRCA	trans	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg02030672	chr11:45687055	CHST1	0.36	7.98	0.3	6.79e-15	Obesity-related traits;
BRCA	trans	rs11088226	0.681	rs11700670	chr21:33938615	T/C	cg09050820	chr6:167586206	TCP10L2	0.77	13.24	0.46	1.49e-35	Gastritis;
BRCA	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg04944784	chr2:26401820	FAM59B	1.0	16.5	0.55	3.29e-51	Gut microbiome composition (summer);
BRCA	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg19729930	chr2:74357872	NA	0.6	15.01	0.51	7.62e-44	Gestational age at birth (maternal effect);
BRCA	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-11.56	-0.42	3.49e-28	Type 2 diabetes;
BRCA	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11644478	chr21:40555479	PSMG1	-0.5	-10.74	-0.39	7.25e-25	Menarche (age at onset);
BRCA	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.71	-0.42	7.63e-29	Bipolar disorder;
BRCA	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg00666640	chr1:248458726	OR2T12	0.35	9.16	0.34	6.75e-19	Common traits (Other);
BRCA	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg07636037	chr3:49044803	WDR6	0.97	28.36	0.75	3.74e-115	Parkinson's disease;
BRCA	cis	rs7131987	0.621	rs57803026	chr12:29497506	G/A	cg09582351	chr12:29534625	ERGIC2	-0.48	-10.85	-0.39	2.8e-25	QT interval;
BRCA	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg13628971	chr7:2884303	GNA12	0.4	9.09	0.34	1.25e-18	Height;
BRCA	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg00686598	chr14:53173677	PSMC6	1.17	15.83	0.53	7.63e-48	Alzheimer's disease (late onset);
BRCA	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.27	-0.34	2.9e-19	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-12.21	-0.43	5.68e-31	Gut microbiome composition (summer);
BRCA	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg21138405	chr5:131827807	IRF1	-0.4	-12.91	-0.45	4.83e-34	Asthma (sex interaction);
BRCA	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg06159980	chr1:16340746	HSPB7	-0.39	-8.87	-0.33	7.26e-18	Dilated cardiomyopathy;
BRCA	cis	rs13102973	0.666	rs2042650	chr4:135897082	T/C	cg14419869	chr4:135874104	NA	-0.46	-9.04	-0.34	1.82e-18	Subjective well-being;
BRCA	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg10223061	chr2:219282414	VIL1	-0.27	-7.92	-0.3	1.04e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24549020	chr5:56110836	MAP3K1	0.59	12.01	0.43	4.38e-30	Initial pursuit acceleration;
BRCA	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	8.22	0.31	1.13e-15	Personality dimensions;
BRCA	cis	rs2816062	0.813	rs2816053	chr1:18895819	A/G	cg18795169	chr1:18902165	NA	-0.94	-27.92	-0.74	9.35e-113	Urate levels in lean individuals;
BRCA	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	19.7	0.61	7.03e-68	Alzheimer's disease;
BRCA	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg03433033	chr1:76189801	ACADM	0.75	16.9	0.56	3.13e-53	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs13102973	0.867	rs4543187	chr4:135906850	G/A	cg14419869	chr4:135874104	NA	0.45	8.98	0.33	3.05e-18	Subjective well-being;
BRCA	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	13.49	0.47	1.19e-36	Colorectal cancer;
BRCA	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg24803719	chr17:45855879	NA	-0.31	-7.99	-0.3	6.54e-15	IgG glycosylation;
BRCA	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg05340658	chr4:99064831	C4orf37	0.68	16.9	0.56	3.04e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6964833	1.000	rs4717907	chr7:74086493	C/T	cg07504079	chr7:72649617	NCF1B	-0.5	-10.03	-0.37	4.56e-22	Menarche (age at onset);
BRCA	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg02640540	chr1:67518911	SLC35D1	0.51	11.18	0.4	1.27e-26	Lymphocyte percentage of white cells;
BRCA	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-9.5	-0.35	4.21e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg11822812	chr5:140052017	DND1	-0.31	-8.47	-0.32	1.69e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6782228	0.606	rs2253144	chr3:128329920	C/T	cg16766828	chr3:128327626	NA	0.41	9.34	0.35	1.52e-19	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.3	8.23	0.31	1.04e-15	Response to antipsychotic treatment;
BRCA	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg12310025	chr6:25882481	NA	0.43	10.63	0.39	2.07e-24	Blood metabolite levels;
BRCA	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.13	0.49	1.19e-39	Motion sickness;
BRCA	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg01884057	chr2:25150051	NA	0.34	9.12	0.34	9.39e-19	Body mass index;
BRCA	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg00321850	chr1:175162397	KIAA0040	-0.41	-11.46	-0.41	9.01e-28	Alcohol dependence;
BRCA	cis	rs7617773	0.817	rs3731513	chr3:48219537	A/G	cg11946769	chr3:48343235	NME6	0.68	13.86	0.48	2.3e-38	Coronary artery disease;
BRCA	cis	rs672059	1.000	rs1760621	chr1:183156006	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.44	0.32	2.1e-16	Hypertriglyceridemia;
BRCA	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24549020	chr5:56110836	MAP3K1	0.59	12.17	0.43	8.89e-31	Initial pursuit acceleration;
BRCA	cis	rs17604090	1.000	rs67970052	chr7:29655038	C/T	cg19413766	chr7:29689036	LOC646762	-0.61	-8.11	-0.31	2.64e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg13047869	chr3:10149882	C3orf24	0.51	10.72	0.39	8.72e-25	Alzheimer's disease;
BRCA	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.44	-11.02	-0.4	5.57e-26	Coronary artery disease;
BRCA	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.66	14.11	0.49	1.57e-39	Lymphocyte counts;
BRCA	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg25554036	chr4:6271136	WFS1	0.42	10.16	0.37	1.35e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.22	0.49	4.64e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10802521	chr3:52805072	NEK4	-0.33	-8.55	-0.32	8.89e-17	Bipolar disorder;
BRCA	cis	rs1005224	0.853	rs9323616	chr14:76151697	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.35	-8.26	-0.31	8.29e-16	Large artery stroke;
BRCA	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg13010199	chr12:38710504	ALG10B	0.51	10.32	0.38	3.41e-23	Bladder cancer;
BRCA	cis	rs9942416	0.660	rs61173369	chr5:74997995	A/G	cg19683494	chr5:74908142	NA	0.46	8.69	0.33	3.05e-17	Age-related disease endophenotypes;
BRCA	cis	rs7617773	0.744	rs2125482	chr3:48323133	T/G	cg11946769	chr3:48343235	NME6	0.62	13.25	0.46	1.4e-35	Coronary artery disease;
BRCA	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg26608667	chr7:1196370	ZFAND2A	0.44	10.75	0.39	6.66e-25	Longevity;Endometriosis;
BRCA	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg17366294	chr4:99064904	C4orf37	0.5	11.14	0.4	1.76e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7809950	0.723	rs62483633	chr7:106876644	T/G	cg23024343	chr7:107201750	COG5	-0.47	-9.39	-0.35	1.07e-19	Coronary artery disease;
BRCA	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-11.21	-0.41	9.48e-27	Gut microbiome composition (summer);
BRCA	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.29	-0.34	2.43e-19	Alzheimer's disease (late onset);
BRCA	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg07606381	chr6:8435919	SLC35B3	0.66	14.53	0.5	1.47e-41	Motion sickness;
BRCA	cis	rs4363385	0.818	rs561143	chr1:153010734	C/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg13010199	chr12:38710504	ALG10B	0.49	9.42	0.35	7.88e-20	Morning vs. evening chronotype;
BRCA	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg19628046	chr18:33552617	C18orf21	-0.57	-11.47	-0.41	8.35e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg23719950	chr11:63933701	MACROD1	-0.54	-8.79	-0.33	1.36e-17	Mean platelet volume;
BRCA	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg12927641	chr6:109611667	NA	-0.38	-9.2	-0.34	5.21e-19	Reticulocyte fraction of red cells;
BRCA	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.66	-13.53	-0.47	7.74e-37	Personality dimensions;
BRCA	cis	rs7903847	0.642	rs11817852	chr10:99158426	C/T	cg08345082	chr10:99160200	RRP12	-0.31	-8.89	-0.33	6.36e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg08000102	chr2:233561755	GIGYF2	0.63	13.78	0.48	4.93e-38	Coronary artery disease;
BRCA	trans	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg23762105	chr12:34175262	ALG10	-0.4	-9.79	-0.36	3.41e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.06	0.74	1.58e-113	Chronic sinus infection;
BRCA	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg06917634	chr15:78832804	PSMA4	-0.54	-11.46	-0.41	8.84e-28	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.68	-0.42	1.08e-28	Gut microbiome composition (summer);
BRCA	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg06618935	chr21:46677482	NA	-0.36	-8.25	-0.31	9.36e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs897984	0.645	rs58726213	chr16:31044683	A/G	cg00531865	chr16:30841666	NA	-0.42	-10.03	-0.37	4.42e-22	Dementia with Lewy bodies;
BRCA	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	16.36	0.54	1.75e-50	Colorectal cancer;
BRCA	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg21747090	chr2:27597821	SNX17	-0.43	-9.4	-0.35	9.48e-20	Total body bone mineral density;
BRCA	cis	rs6088813	0.925	rs4353719	chr20:33977349	G/A	cg14752227	chr20:34000481	UQCC	-0.43	-9.11	-0.34	1.08e-18	Height;
BRCA	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg08805041	chr16:621841	PIGQ	-0.31	-8.37	-0.31	3.53e-16	Height;
BRCA	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	14.4	0.5	6.06e-41	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs6484504	0.600	rs1323738	chr11:31344898	T/C	cg06552810	chr11:31128660	NA	0.39	8.54	0.32	9.97e-17	Red blood cell count;
BRCA	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg05714579	chr10:131428358	MGMT	0.59	14.72	0.5	1.95e-42	Response to temozolomide;
BRCA	trans	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.39	-8.98	-0.33	2.9e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs6138458	1.000	rs227630	chr20:24913584	A/G	cg06937882	chr20:24974362	C20orf3	-0.44	-8.41	-0.32	2.76e-16	Blood protein levels;
BRCA	cis	rs2041840	0.538	rs2372999	chr2:37573587	T/C	cg25727520	chr2:37576821	QPCT	-0.28	-7.82	-0.3	2.21e-14	Chronic lymphocytic leukemia;
BRCA	cis	rs6444746	1.000	rs4687454	chr3:193491392	C/G	cg22553634	chr3:193489233	NA	0.52	8.86	0.33	8.13e-18	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
BRCA	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg14349672	chr11:133703707	NA	-0.42	-9.15	-0.34	7.38e-19	Childhood ear infection;
BRCA	cis	rs7737355	1.000	rs27663	chr5:130741438	T/G	cg06307176	chr5:131281290	NA	-0.48	-9.34	-0.35	1.54e-19	Life satisfaction;
BRCA	cis	rs8028182	0.636	rs8023815	chr15:75814704	G/A	cg20655648	chr15:75932815	IMP3	0.42	8.06	0.3	3.87e-15	Sudden cardiac arrest;
BRCA	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.99	-22.35	-0.66	3.35e-82	Lymphocyte percentage of white cells;
BRCA	trans	rs12517041	1.000	rs6880744	chr5:23299825	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.44	-8.07	-0.3	3.61e-15	Calcium levels;
BRCA	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-11.14	-0.4	1.91e-26	Mean corpuscular volume;
BRCA	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-9.39	-0.35	1.03e-19	Schizophrenia;
BRCA	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg20283391	chr11:68216788	NA	-0.39	-7.99	-0.3	6.4e-15	Total body bone mineral density;
BRCA	trans	rs6076960	0.811	rs6053960	chr20:6176778	T/C	cg17788362	chr6:86352627	SYNCRIP	0.4	8.83	0.33	9.88e-18	Smooth-surface caries;
BRCA	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg21535247	chr6:8435926	SLC35B3	0.42	9.42	0.35	7.86e-20	Motion sickness;
BRCA	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-23.75	-0.68	7.01e-90	Gut microbiome composition (summer);
BRCA	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	9.08	0.34	1.28e-18	Bipolar disorder;
BRCA	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg11598736	chr3:195384522	SDHAP2	-0.69	-12.19	-0.43	6.75e-31	Lung disease severity in cystic fibrosis;
BRCA	cis	rs9443189	0.570	rs504323	chr6:76294965	A/G	cg01950844	chr6:76311363	SENP6	-0.73	-10.02	-0.37	4.94e-22	Prostate cancer;
BRCA	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.37	0.57	1.28e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg18132916	chr6:79620363	NA	-0.48	-10.89	-0.4	1.89e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg01324343	chr3:183735012	ABCC5	-0.68	-16.24	-0.54	6.25e-50	Anterior chamber depth;
BRCA	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg16434002	chr17:42200994	HDAC5	0.3	8.77	0.33	1.66e-17	Total body bone mineral density;
BRCA	cis	rs7408868	0.908	rs1044006	chr19:15285052	T/C	cg14696996	chr19:15285081	NOTCH3	1.0	14.69	0.5	2.67e-42	Pulse pressure;
BRCA	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.02	-0.43	3.93e-30	Response to antipsychotic treatment;
BRCA	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg17366294	chr4:99064904	C4orf37	0.42	9.94	0.37	9.99e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg06618935	chr21:46677482	NA	-0.37	-8.01	-0.3	5.27e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.64	-0.39	1.88e-24	Bipolar disorder;
BRCA	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg24812749	chr6:127587940	RNF146	-0.82	-16.89	-0.56	3.26e-53	Breast cancer;
BRCA	cis	rs12949688	0.967	rs12451748	chr17:55822171	T/C	cg12582317	chr17:55822272	NA	0.32	7.93	0.3	9.97e-15	Schizophrenia;
BRCA	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg21747090	chr2:27597821	SNX17	-0.45	-9.65	-0.36	1.2e-20	Total body bone mineral density;
BRCA	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg04944784	chr2:26401820	FAM59B	-0.95	-16.25	-0.54	5.83e-50	Gut microbiome composition (summer);
BRCA	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-11.98	-0.43	5.47e-30	Alzheimer's disease;
BRCA	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg06238570	chr21:40685208	BRWD1	-0.46	-9.26	-0.34	3.17e-19	Cognitive function;
BRCA	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg04362960	chr10:104952993	NT5C2	0.43	10.5	0.38	6.62e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	trans	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg23762105	chr12:34175262	ALG10	0.37	8.53	0.32	1.08e-16	Morning vs. evening chronotype;
BRCA	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg00825309	chr19:58991885	ZNF446	-0.63	-14.03	-0.49	3.51e-39	Uric acid clearance;
BRCA	cis	rs4908768	0.501	rs1463051	chr1:8596893	A/T	cg20416874	chr1:8611966	RERE	0.28	8.31	0.31	5.95e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg02659138	chr7:134003124	SLC35B4	0.31	9.68	0.36	8.67e-21	Mean platelet volume;
BRCA	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg07636037	chr3:49044803	WDR6	0.43	8.71	0.33	2.67e-17	Resting heart rate;
BRCA	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	10.74	0.39	7.69e-25	Platelet count;
BRCA	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg02734326	chr4:10020555	SLC2A9	0.39	8.51	0.32	1.21e-16	Bone mineral density;
BRCA	cis	rs6684428	0.706	rs12119904	chr1:56327241	G/T	cg11651538	chr1:56320950	NA	-0.44	-7.82	-0.3	2.13e-14	Airflow obstruction;
BRCA	cis	rs858239	0.539	rs28716381	chr7:23189015	G/A	cg23682824	chr7:23144976	KLHL7	0.42	10.97	0.4	9.04e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg01689657	chr7:91764605	CYP51A1	0.23	8.46	0.32	1.79e-16	Breast cancer;
BRCA	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg17173187	chr15:85201210	NMB	-0.42	-9.15	-0.34	7.76e-19	Schizophrenia;
BRCA	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg25767906	chr1:53392781	SCP2	-0.39	-8.79	-0.33	1.41e-17	Monocyte count;
BRCA	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-13.5	-0.47	1.01e-36	Migraine;Coronary artery disease;
BRCA	trans	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.66	-0.36	1.04e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg21798802	chr22:38057573	PDXP	0.31	8.57	0.32	7.9e-17	Fat distribution (HIV);
BRCA	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg03213289	chr20:61660250	NA	-0.6	-14.76	-0.5	1.25e-42	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11890956	chr21:40555474	PSMG1	1.04	29.41	0.76	7.29e-121	Cognitive function;
BRCA	cis	rs4308124	0.679	rs7600458	chr2:111963590	G/C	cg04571233	chr2:111982156	NA	-0.45	-9.66	-0.36	1.04e-20	Vitiligo;
BRCA	cis	rs4853036	1.000	rs3816491	chr2:70048534	A/G	cg02498382	chr2:70120550	SNRNP27	0.47	8.59	0.32	6.42e-17	Colorectal or endometrial cancer;
BRCA	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-18.12	-0.58	1.55e-59	Extrinsic epigenetic age acceleration;
BRCA	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.2	-0.34	5.04e-19	Bipolar disorder;
BRCA	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg11764359	chr7:65958608	NA	-0.77	-18.03	-0.58	4.5e-59	Aortic root size;
BRCA	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg02659138	chr7:134003124	SLC35B4	0.34	10.79	0.39	4.94e-25	Mean platelet volume;
BRCA	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg08514558	chr10:81106712	PPIF	0.4	9.23	0.34	4e-19	Height;
BRCA	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg24110177	chr3:50126178	RBM5	0.47	12.11	0.43	1.5e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.4	-10.46	-0.38	9.6e-24	IgG glycosylation;
BRCA	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00149659	chr3:10157352	C3orf10	0.71	12.33	0.44	1.69e-31	Alzheimer's disease;
BRCA	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg01324343	chr3:183735012	ABCC5	0.66	15.71	0.53	2.76e-47	Anterior chamber depth;
BRCA	cis	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.18	-0.37	1.21e-22	Morning vs. evening chronotype;
BRCA	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg11814155	chr7:99998594	ZCWPW1	0.44	8.23	0.31	1.09e-15	Platelet count;
BRCA	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg23711669	chr6:146136114	FBXO30	0.67	15.48	0.52	3.8e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-10.78	-0.39	5.15e-25	Total cholesterol levels;
BRCA	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg18904891	chr8:8559673	CLDN23	0.59	11.51	0.41	5.28e-28	Obesity-related traits;
BRCA	trans	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.21	0.37	8.72e-23	Mean corpuscular volume;
BRCA	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg08470875	chr2:26401718	FAM59B	-0.5	-8.17	-0.31	1.65e-15	Gut microbiome composition (summer);
BRCA	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-9.23	-0.34	3.84e-19	Tonsillectomy;
BRCA	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	10.48	0.38	8.14e-24	Mean corpuscular volume;
BRCA	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg25110126	chr1:46999211	NA	-0.51	-9.76	-0.36	4.73e-21	Monobrow;
BRCA	cis	rs12545109	0.800	rs2670028	chr8:57423673	G/A	cg09654669	chr8:57350985	NA	-0.39	-8.21	-0.31	1.18e-15	Obesity-related traits;
BRCA	trans	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.73	-16.03	-0.54	7.41e-49	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg26373071	chr5:1325741	CLPTM1L	0.48	11.26	0.41	5.98e-27	Lung cancer;
BRCA	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-12.84	-0.45	1.02e-33	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs1003719	0.715	rs2835647	chr21:38546773	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.36	-0.49	1e-40	Eye color traits;
BRCA	cis	rs2625529	0.627	rs11858015	chr15:72552492	G/A	cg16672083	chr15:72433130	SENP8	-0.83	-17.14	-0.56	1.84e-54	Red blood cell count;
BRCA	cis	rs11229555	1.000	rs12799215	chr11:58405674	C/T	cg15696309	chr11:58395628	NA	-0.52	-11.51	-0.41	5.29e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-9.34	-0.35	1.55e-19	Menopause (age at onset);
BRCA	cis	rs1468333	1.000	rs3777113	chr5:137493897	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.42	8.95	0.33	3.79e-18	Resting heart rate;
BRCA	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08109568	chr15:31115862	NA	-0.45	-10.66	-0.39	1.62e-24	Huntington's disease progression;
BRCA	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg09455208	chr3:40491958	NA	0.47	11.39	0.41	1.72e-27	Renal cell carcinoma;
BRCA	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg03929089	chr4:120376271	NA	-0.45	-8.28	-0.31	7.16e-16	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg17420585	chr12:42539391	GXYLT1	-0.38	-8.06	-0.3	3.77e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg07460842	chr6:66804631	NA	-1.0	-19.52	-0.61	6.74e-67	Exhaled nitric oxide output;
BRCA	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg04248312	chr19:17393744	ANKLE1	-0.93	-21.66	-0.65	1.9e-78	Systemic lupus erythematosus;
BRCA	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.81	0.36	2.92e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs2070433	0.500	rs2070435	chr21:47961711	C/T	cg12379764	chr21:47803548	PCNT	0.46	10.16	0.37	1.39e-22	Lymphocyte counts;
BRCA	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg24250549	chr1:154909240	PMVK	0.65	16.41	0.54	9.35e-51	Prostate cancer;
BRCA	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg06623918	chr6:96969491	KIAA0776	-0.88	-24.29	-0.69	8.24e-93	Headache;
BRCA	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg13114125	chr14:105738426	BRF1	-0.53	-11.07	-0.4	3.42e-26	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs9420	0.961	rs11605731	chr11:57524089	C/G	cg19752551	chr11:57585705	CTNND1	-0.51	-12.58	-0.45	1.37e-32	Schizophrenia;
BRCA	cis	rs10740039	0.768	rs10761549	chr10:62461660	A/G	cg02922035	chr10:62493342	NA	0.42	8.05	0.3	4.06e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg00012203	chr2:219082015	ARPC2	-0.57	-12.03	-0.43	3.43e-30	Colorectal cancer;
BRCA	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	19.55	0.61	4.35e-67	Electrocardiographic conduction measures;
BRCA	cis	rs924607	0.583	rs12516251	chr5:608939	C/T	cg07001201	chr5:642380	CEP72	0.44	9.18	0.34	5.95e-19	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
BRCA	cis	rs7072216	0.763	rs10883090	chr10:100167236	G/C	cg26618903	chr10:100175079	PYROXD2	-0.31	-8.97	-0.33	3.17e-18	Metabolite levels;
BRCA	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg00814883	chr7:100076585	TSC22D4	-0.55	-10.6	-0.39	2.8e-24	Platelet count;
BRCA	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.35	-0.44	1.36e-31	Bipolar disorder;
BRCA	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg05347473	chr6:146136440	FBXO30	0.46	9.03	0.34	2.02e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg24829409	chr8:58192753	C8orf71	-0.57	-11.79	-0.42	3.6e-29	Developmental language disorder (linguistic errors);
BRCA	cis	rs7178424	0.870	rs8034914	chr15:62250430	C/T	cg00456672	chr15:62358751	C2CD4A	0.42	9.74	0.36	5.61e-21	Height;
BRCA	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg18016565	chr1:150552671	MCL1	0.33	7.89	0.3	1.35e-14	Melanoma;
BRCA	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11764359	chr7:65958608	NA	0.76	16.83	0.55	7.34e-53	Aortic root size;
BRCA	cis	rs9400271	0.609	rs9386783	chr6:109588644	G/T	cg01475377	chr6:109611718	NA	-0.44	-10.41	-0.38	1.56e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs4908768	0.501	rs4351668	chr1:8535818	C/T	cg20416874	chr1:8611966	RERE	-0.29	-8.31	-0.31	5.55e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.33	10.81	0.39	4.08e-25	Bipolar disorder;
BRCA	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03264133	chr6:25882463	NA	0.49	10.99	0.4	7.69e-26	Blood metabolite levels;
BRCA	cis	rs7246967	0.673	rs12985495	chr19:22930378	A/G	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	11.17	0.4	1.43e-26	Platelet count;
BRCA	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg24006582	chr15:45444508	DUOX1	-0.53	-11.02	-0.4	5.69e-26	Uric acid levels;
BRCA	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg03060546	chr3:49711283	APEH	0.46	9.79	0.36	3.46e-21	Resting heart rate;
BRCA	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg01689657	chr7:91764605	CYP51A1	-0.22	-7.85	-0.3	1.74e-14	Breast cancer;
BRCA	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg24069376	chr3:38537580	EXOG	-0.3	-8.45	-0.32	2.04e-16	Electrocardiographic conduction measures;
BRCA	cis	rs7598759	0.548	rs11686485	chr2:232360697	C/T	cg19187155	chr2:232395269	NMUR1	0.7	16.92	0.56	2.48e-53	Noise-induced hearing loss;
BRCA	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg22467129	chr15:76604101	ETFA	-0.49	-10.67	-0.39	1.44e-24	Blood metabolite levels;
BRCA	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg26608667	chr7:1196370	ZFAND2A	0.41	9.95	0.37	8.43e-22	Longevity;Endometriosis;
BRCA	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg05707623	chr12:122985044	ZCCHC8	0.41	8.51	0.32	1.21e-16	Body mass index;
BRCA	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-13.43	-0.47	2.13e-36	Calcium levels;
BRCA	trans	rs4650994	0.544	rs6682815	chr1:178501109	T/C	cg05059571	chr16:84539110	KIAA1609	-0.48	-10.89	-0.4	1.93e-25	HDL cholesterol levels;HDL cholesterol;
BRCA	trans	rs1493916	0.837	rs1493908	chr18:31411700	G/A	cg27147174	chr7:100797783	AP1S1	-0.42	-8.52	-0.32	1.17e-16	Life satisfaction;
BRCA	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	8.31	0.31	5.63e-16	Educational attainment;
BRCA	cis	rs11605924	0.819	rs12805422	chr11:45839889	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.44	-9.65	-0.36	1.15e-20	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg10556349	chr10:835070	NA	0.73	9.88	0.36	1.6e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg05340658	chr4:99064831	C4orf37	0.65	16.05	0.54	5.84e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg26031613	chr14:104095156	KLC1	-0.43	-8.59	-0.32	6.54e-17	Schizophrenia;
BRCA	cis	rs586533	0.881	rs683623	chr11:99501419	C/G	cg22878054	chr11:99397252	CNTN5	0.32	8.11	0.31	2.53e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06022373	chr22:39101656	GTPBP1	-0.72	-17.71	-0.57	2.2e-57	Menopause (age at onset);
BRCA	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg26031613	chr14:104095156	KLC1	1.01	27.75	0.74	8.32e-112	Body mass index;
BRCA	cis	rs507080	0.922	rs525485	chr11:118555754	C/T	cg08498647	chr11:118550644	TREH	-0.38	-8.31	-0.31	5.6e-16	Serum metabolite levels;
BRCA	cis	rs6700896	0.931	rs1938498	chr1:66098653	T/C	cg04111102	chr1:66153794	NA	0.33	8.23	0.31	1.04e-15	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg23711669	chr6:146136114	FBXO30	0.75	17.32	0.57	2.29e-55	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg26384229	chr12:38710491	ALG10B	0.68	14.09	0.49	1.77e-39	Morning vs. evening chronotype;
BRCA	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg18479299	chr3:125709523	NA	-0.54	-8.39	-0.32	3.1e-16	Blood pressure (smoking interaction);
BRCA	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg23933602	chr10:16859644	RSU1	0.6	9.18	0.34	6.14e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg10950524	chr7:2139216	MAD1L1	0.27	7.88	0.3	1.42e-14	Schizophrenia;
BRCA	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg11366901	chr6:160182831	ACAT2	0.78	14.99	0.51	9.39e-44	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg18305652	chr10:134549665	INPP5A	0.49	12.09	0.43	1.83e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2839186	0.584	rs2032111	chr21:47904569	G/A	cg12379764	chr21:47803548	PCNT	-0.41	-8.84	-0.33	9.51e-18	Testicular germ cell tumor;
BRCA	cis	rs365132	0.818	rs251843	chr5:176476106	A/G	cg16309518	chr5:176445507	NA	-0.39	-9.6	-0.35	1.85e-20	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs16867321	0.639	rs13028421	chr2:181444035	G/T	cg23363182	chr2:181467187	NA	0.47	10.26	0.38	5.8e-23	Obesity;
BRCA	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg04586622	chr2:25135609	ADCY3	0.46	11.66	0.42	1.3e-28	Body mass index;
BRCA	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg09537434	chr19:41945824	ATP5SL	-1.02	-23.73	-0.68	9.65e-90	Height;
BRCA	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg20891283	chr12:69753455	YEATS4	0.56	13.64	0.47	2.38e-37	Blood protein levels;
BRCA	cis	rs4409675	0.548	rs1000432	chr1:28225119	T/C	cg23691781	chr1:28212827	C1orf38	0.32	10.66	0.39	1.53e-24	Corneal astigmatism;
BRCA	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg02820040	chr2:241836501	C2orf54	0.52	9.99	0.37	6.42e-22	Urinary metabolites;
BRCA	trans	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.39	8.48	0.32	1.56e-16	Aortic root size;
BRCA	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.83e-15	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-15.12	-0.51	2.31e-44	Obesity-related traits;
BRCA	cis	rs10465746	0.780	rs1952065	chr1:84464205	T/C	cg10977910	chr1:84465055	TTLL7	0.57	11.85	0.42	1.95e-29	Obesity-related traits;
BRCA	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg21918786	chr6:109611834	NA	-0.44	-11.88	-0.43	1.46e-29	Reticulocyte fraction of red cells;
BRCA	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-13.48	-0.47	1.21e-36	Bipolar disorder and schizophrenia;
BRCA	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.45	0.35	6.14e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	trans	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg07211511	chr3:129823064	LOC729375	-0.54	-9.57	-0.35	2.35e-20	Blood pressure (smoking interaction);
BRCA	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg12310025	chr6:25882481	NA	-0.41	-9.68	-0.36	9.32e-21	Height;
BRCA	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg18016565	chr1:150552671	MCL1	0.35	8.23	0.31	1.08e-15	Tonsillectomy;
BRCA	cis	rs2882667	0.858	rs11948429	chr5:138458584	G/A	cg04439458	chr5:138467593	SIL1	-0.41	-10.51	-0.38	6.16e-24	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.96	0.58	1.14e-58	Fuchs's corneal dystrophy;
BRCA	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg26695010	chr11:65641043	EFEMP2	-0.35	-8.37	-0.31	3.6e-16	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg07080220	chr10:102295463	HIF1AN	0.63	13.16	0.46	3.59e-35	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg21475434	chr5:93447410	FAM172A	0.72	9.19	0.34	5.29e-19	Diabetic retinopathy;
BRCA	cis	rs3925075	1.000	rs4506917	chr16:31347350	T/G	cg02846316	chr16:31340340	ITGAM	0.54	13.29	0.47	9.24e-36	IgA nephropathy;
BRCA	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21659725	chr3:3221576	CRBN	0.36	8.69	0.33	2.94e-17	Body mass index;
BRCA	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22509189	chr2:225307070	NA	-0.46	-9.84	-0.36	2.31e-21	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs870825	0.929	rs55880126	chr4:185591237	T/G	cg04058563	chr4:185651563	MLF1IP	0.88	14.47	0.5	3.03e-41	Blood protein levels;
BRCA	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg20007245	chr22:24372913	LOC391322	0.5	10.69	0.39	1.16e-24	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.34	-0.38	2.72e-23	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg21535247	chr6:8435926	SLC35B3	0.41	9.36	0.35	1.36e-19	Motion sickness;
BRCA	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg05347473	chr6:146136440	FBXO30	-0.4	-7.85	-0.3	1.74e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg25358565	chr5:93447407	FAM172A	-0.65	-11.23	-0.41	7.98e-27	Diabetic retinopathy;
BRCA	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg25019033	chr10:957182	NA	-0.41	-7.9	-0.3	1.25e-14	Eosinophil percentage of granulocytes;
BRCA	trans	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-21.31	-0.64	1.47e-76	Exhaled nitric oxide output;
BRCA	cis	rs17253792	0.822	rs76264681	chr14:56060447	T/C	cg01858014	chr14:56050164	KTN1	-0.75	-10.35	-0.38	2.64e-23	Putamen volume;
BRCA	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.83	16.74	0.55	1.95e-52	HIV-1 control;
BRCA	cis	rs2346177	0.846	rs62138876	chr2:46650672	C/A	cg02822958	chr2:46747628	ATP6V1E2	0.4	8.25	0.31	9.27e-16	HDL cholesterol;
BRCA	cis	rs9682041	0.627	rs4955722	chr3:170102959	G/T	cg11886554	chr3:170076028	SKIL	0.51	10.13	0.37	1.76e-22	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs16958440	0.867	rs59217333	chr18:44694844	A/C	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	14.77	0.5	1.1e-42	Motion sickness;
BRCA	cis	rs365132	0.967	rs11740768	chr5:176339499	G/A	cg16309518	chr5:176445507	NA	-0.52	-13.34	-0.47	5.56e-36	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs7903847	0.642	rs11189177	chr10:99141663	C/T	cg20016023	chr10:99160130	RRP12	-0.27	-8.62	-0.32	5.46e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg11584989	chr19:19387371	SF4	-0.6	-13.51	-0.47	9.58e-37	Bipolar disorder;
BRCA	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg13319975	chr6:146136371	FBXO30	0.61	13.98	0.48	6.18e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17641971	0.599	rs2385230	chr8:50015755	A/G	cg00325661	chr8:49890786	NA	0.35	9.96	0.37	7.87e-22	Blood metabolite levels;
BRCA	cis	rs9341808	0.718	rs2143887	chr6:80917287	T/C	cg08355045	chr6:80787529	NA	0.39	9.98	0.37	6.58e-22	Sitting height ratio;
BRCA	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg01483505	chr11:975446	AP2A2	0.35	9.42	0.35	8.01e-20	Alzheimer's disease (late onset);
BRCA	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg07636037	chr3:49044803	WDR6	0.5	8.23	0.31	1.02e-15	Menarche (age at onset);
BRCA	cis	rs4965272	1.000	rs4965274	chr15:100584971	G/T	cg27344315	chr15:100560801	ADAMTS17	0.38	8.16	0.31	1.76e-15	Gastroesophageal reflux disease;
BRCA	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg22800045	chr5:56110881	MAP3K1	0.52	10.07	0.37	3.19e-22	Type 2 diabetes;
BRCA	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg15145296	chr3:125709740	NA	-0.56	-8.92	-0.33	5.06e-18	Blood pressure (smoking interaction);
BRCA	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg27661571	chr11:113659931	NA	-0.83	-12.3	-0.44	2.31e-31	Hip circumference adjusted for BMI;
BRCA	cis	rs7560272	0.501	rs2272178	chr2:73977609	C/T	cg20560298	chr2:73613845	ALMS1	0.35	8.96	0.33	3.56e-18	Schizophrenia;
BRCA	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	-0.66	-16.84	-0.55	6.09e-53	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg26384229	chr12:38710491	ALG10B	-0.62	-16.22	-0.54	7.9e-50	Heart rate;
BRCA	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-11.47	-0.41	8.06e-28	Platelet count;
BRCA	trans	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg25214090	chr10:38739885	LOC399744	0.44	10.29	0.38	4.34e-23	Corneal astigmatism;
BRCA	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg01420254	chr6:26195488	NA	0.59	9.16	0.34	6.84e-19	Gout;Renal underexcretion gout;
BRCA	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.28	0.56	3.49e-55	Bladder cancer;
BRCA	cis	rs11229555	0.609	rs12286421	chr11:58174898	A/G	cg15696309	chr11:58395628	NA	-0.45	-9.77	-0.36	4.3e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg05896524	chr21:47604654	C21orf56	-0.49	-9.65	-0.36	1.19e-20	Testicular germ cell tumor;
BRCA	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg23649088	chr2:200775458	C2orf69	0.48	9.65	0.36	1.13e-20	Osteoporosis;
BRCA	cis	rs9462027	0.628	rs9469891	chr6:34767396	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.83	-0.3	1.98e-14	Systemic lupus erythematosus;
BRCA	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.75	-12.95	-0.46	3.01e-34	Platelet count;
BRCA	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg02153584	chr22:29168773	CCDC117	0.51	10.69	0.39	1.14e-24	Lymphocyte counts;
BRCA	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg22705602	chr4:152727874	NA	-0.33	-8.32	-0.31	5.25e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs27434	0.583	rs34756	chr5:96152383	C/T	cg16492584	chr5:96139282	ERAP1	0.49	12.3	0.44	2.34e-31	Ankylosing spondylitis;
BRCA	cis	rs7607369	0.536	rs6436091	chr2:219669141	T/C	cg02176678	chr2:219576539	TTLL4	-0.38	-10.16	-0.37	1.45e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg13319975	chr6:146136371	FBXO30	-0.41	-9.39	-0.35	1e-19	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg07817883	chr1:32538562	TMEM39B	0.46	8.58	0.32	7.17e-17	Monocyte percentage of white cells;
BRCA	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26314531	chr2:26401878	FAM59B	0.61	10.65	0.39	1.68e-24	Gut microbiome composition (summer);
BRCA	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg26384229	chr12:38710491	ALG10B	-0.43	-9.84	-0.36	2.2e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg26384229	chr12:38710491	ALG10B	0.75	16.26	0.54	5.37e-50	Bladder cancer;
BRCA	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg25482853	chr8:67687455	SGK3	1.05	16.94	0.56	1.94e-53	Lung disease severity in cystic fibrosis;
BRCA	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00475322	chr7:917719	C7orf20	0.45	11.51	0.41	5.37e-28	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-14.56	-0.5	1.07e-41	Hemoglobin concentration;
BRCA	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg22875332	chr1:76189707	ACADM	0.68	14.38	0.49	7.71e-41	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9682041	0.808	rs9880558	chr3:170067771	A/G	cg11886554	chr3:170076028	SKIL	-0.61	-11.92	-0.43	1.04e-29	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg10253484	chr15:75165896	SCAMP2	-0.51	-9.68	-0.36	9.16e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	trans	rs4714291	0.963	rs1721411	chr6:40102390	T/G	cg02267698	chr19:7991119	CTXN1	0.42	8.24	0.31	9.61e-16	Strep throat;
BRCA	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-12.28	-0.44	2.76e-31	Response to antipsychotic treatment;
BRCA	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg13010199	chr12:38710504	ALG10B	0.37	8.81	0.33	1.19e-17	Morning vs. evening chronotype;
BRCA	cis	rs2625529	0.730	rs6494975	chr15:72177825	T/A	cg16672083	chr15:72433130	SENP8	0.69	16.34	0.54	2e-50	Red blood cell count;
BRCA	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg13010199	chr12:38710504	ALG10B	0.5	10.22	0.37	8.43e-23	Bladder cancer;
BRCA	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg08975724	chr8:8085496	FLJ10661	0.39	8.47	0.32	1.65e-16	Joint mobility (Beighton score);
BRCA	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.71	-16.63	-0.55	7.03e-52	Axial length;
BRCA	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg17691542	chr6:26056736	HIST1H1C	0.67	13.75	0.48	7.21e-38	Height;
BRCA	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg06784218	chr1:46089804	CCDC17	0.49	11.56	0.42	3.44e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.47	-0.52	4.17e-46	Chronic sinus infection;
BRCA	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg17971929	chr21:40555470	PSMG1	0.6	13.8	0.48	4.09e-38	Cognitive function;
BRCA	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg18811423	chr2:55921094	PNPT1	0.72	22.78	0.67	1.58e-84	Metabolic syndrome;
BRCA	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.5	0.32	1.34e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs34779708	0.966	rs1213392	chr10:35430285	C/T	cg03585969	chr10:35415529	CREM	0.46	9.71	0.36	7.1e-21	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1595825	0.891	rs73054808	chr2:198602283	C/T	cg19156104	chr2:198669113	PLCL1	-0.44	-8.02	-0.3	5.18e-15	Ulcerative colitis;
BRCA	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg22920501	chr2:26401640	FAM59B	0.75	10.79	0.39	4.93e-25	Gut microbiome composition (summer);
BRCA	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08219700	chr8:58056026	NA	0.45	8.16	0.31	1.77e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg02466173	chr16:30829666	NA	-0.49	-10.03	-0.37	4.33e-22	Multiple myeloma;
BRCA	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg24558204	chr6:135376177	HBS1L	-0.46	-12.57	-0.45	1.53e-32	Red blood cell count;
BRCA	trans	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg15704280	chr7:45808275	SEPT13	0.59	8.85	0.33	8.61e-18	Axial length;
BRCA	cis	rs5167	0.504	rs7246900	chr19:45454236	G/A	cg20090143	chr19:45452003	APOC2	0.27	7.94	0.3	8.85e-15	Blood protein levels;
BRCA	cis	rs6433895	0.710	rs56692685	chr2:182012093	A/G	cg00481216	chr2:181971175	NA	0.42	7.96	0.3	7.8e-15	Lymphocyte counts;
BRCA	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg07606381	chr6:8435919	SLC35B3	0.64	14.15	0.49	1.01e-39	Motion sickness;
BRCA	cis	rs10463316	0.894	rs7707745	chr5:150765198	G/T	cg03212797	chr5:150827313	SLC36A1	-0.4	-8.07	-0.3	3.43e-15	Metabolite levels (Pyroglutamine);
BRCA	trans	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg06521331	chr12:34319734	NA	-0.52	-9.41	-0.35	8.45e-20	Bladder cancer;
BRCA	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg16405210	chr4:1374714	KIAA1530	-0.91	-22.88	-0.67	4.49e-85	Longevity;
BRCA	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg18270830	chr10:32634957	EPC1	0.58	10.03	0.37	4.37e-22	Sexual dysfunction (female);
BRCA	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg18964960	chr10:1102726	WDR37	-0.51	-9.13	-0.34	8.55e-19	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs17401966	0.931	rs17410217	chr1:10371854	A/G	cg03954927	chr1:10346856	KIF1B	0.48	14.9	0.51	2.64e-43	Hepatocellular carcinoma;
BRCA	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	8.11	0.31	2.68e-15	Aortic root size;
BRCA	cis	rs1691799	0.867	rs1183274	chr12:66732057	C/G	cg16791601	chr12:66731901	HELB	-0.65	-17.57	-0.57	1.16e-56	White blood cell count (basophil);
BRCA	cis	rs7246657	0.525	rs1667357	chr19:37484352	T/C	cg23950597	chr19:37808831	NA	-0.52	-8.28	-0.31	7.37e-16	Coronary artery calcification;
BRCA	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08219700	chr8:58056026	NA	0.61	9.75	0.36	4.97e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg10862848	chr6:42927986	GNMT	-0.36	-15.05	-0.51	5.11e-44	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.65	0.5	4.14e-42	Personality dimensions;
BRCA	trans	rs6479891	0.818	rs9299455	chr10:65073601	A/G	cg14819942	chr15:35414228	NA	-0.34	-8.43	-0.32	2.36e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg16586182	chr3:47516702	SCAP	-0.44	-8.9	-0.33	5.79e-18	Birth weight;
BRCA	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12826209	chr6:26865740	GUSBL1	0.6	10.45	0.38	1.09e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg10253484	chr15:75165896	SCAMP2	-0.55	-11.5	-0.41	5.72e-28	Breast cancer;
BRCA	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg22535103	chr8:58192502	C8orf71	-0.45	-8.97	-0.33	3.26e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	9.99	0.37	6.19e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.88	-0.77	8.37e-129	Schizophrenia;
BRCA	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg07884673	chr3:53033167	SFMBT1	-0.73	-9.95	-0.37	9.05e-22	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg18154014	chr19:37997991	ZNF793	-0.48	-9.06	-0.34	1.6e-18	Coronary artery calcification;
BRCA	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.5e-19	Menopause (age at onset);
BRCA	cis	rs1865721	1.000	rs7244787	chr18:73195162	T/C	cg26385618	chr18:73139727	C18orf62	-0.39	-8.98	-0.33	2.9e-18	Intelligence;
BRCA	cis	rs3771570	0.901	rs9052	chr2:242434809	G/T	cg21155796	chr2:242212141	HDLBP	0.45	7.85	0.3	1.77e-14	Prostate cancer;
BRCA	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg23950597	chr19:37808831	NA	-0.72	-12.64	-0.45	7.28e-33	Coronary artery calcification;
BRCA	cis	rs208520	1.000	rs208521	chr6:66953625	C/T	cg07460842	chr6:66804631	NA	-0.86	-14.26	-0.49	2.84e-40	Exhaled nitric oxide output;
BRCA	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.96	0.3	7.77e-15	Depression;
BRCA	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg02733842	chr7:1102375	C7orf50	-0.83	-13.95	-0.48	8.85e-39	Bronchopulmonary dysplasia;
BRCA	cis	rs3820928	0.935	rs12151597	chr2:227859224	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.3	-0.31	6e-16	Pulmonary function;
BRCA	cis	rs9560113	1.000	rs60374273	chr13:112179206	A/T	cg10483660	chr13:112241077	NA	0.31	7.84	0.3	1.91e-14	Menarche (age at onset);
BRCA	trans	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg25214090	chr10:38739885	LOC399744	0.45	10.28	0.38	4.68e-23	Corneal astigmatism;
BRCA	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg16262614	chr3:133464971	TF	0.25	7.99	0.3	6.32e-15	Iron status biomarkers (transferrin levels);
BRCA	cis	rs11622475	1.000	rs1187446	chr14:104409896	C/T	cg12183467	chr14:104352244	NA	-0.51	-10.6	-0.39	2.67e-24	Bipolar disorder;
BRCA	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg12219531	chr12:120966889	COQ5	0.53	11.53	0.42	4.47e-28	High light scatter reticulocyte count;
BRCA	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.99	-0.37	6.41e-22	Mean corpuscular volume;
BRCA	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg04362960	chr10:104952993	NT5C2	0.45	10.44	0.38	1.2e-23	Arsenic metabolism;
BRCA	cis	rs17641971	0.783	rs2385127	chr8:49975746	C/T	cg00325661	chr8:49890786	NA	0.32	8.61	0.32	5.74e-17	Blood metabolite levels;
BRCA	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg08514558	chr10:81106712	PPIF	0.41	9.48	0.35	4.71e-20	Height;
BRCA	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.0	-0.34	2.59e-18	Menopause (age at onset);
BRCA	cis	rs600806	0.751	rs1933182	chr1:109999838	A/C	cg20591472	chr1:110008990	SYPL2	0.33	8.3	0.31	6.14e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24110177	chr3:50126178	RBM5	-0.36	-9.67	-0.36	9.69e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs931812	0.757	rs4734015	chr8:101909258	C/G	cg20993868	chr7:22813445	NA	0.44	13.3	0.47	8.67e-36	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg01884057	chr2:25150051	NA	0.32	8.52	0.32	1.17e-16	Body mass index;
BRCA	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.87	0.3	1.5e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg09754948	chr16:28834200	ATXN2L	0.47	9.17	0.34	6.53e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg23711669	chr6:146136114	FBXO30	-0.76	-17.6	-0.57	8.28e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3099143	1.000	rs3110378	chr15:77127983	G/A	cg21673338	chr15:77095150	SCAPER	-0.53	-9.51	-0.35	3.9e-20	Recalcitrant atopic dermatitis;
BRCA	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg20701182	chr2:24300061	SF3B14	0.66	9.71	0.36	7.01e-21	Lymphocyte counts;
BRCA	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-10.19	-0.37	1.09e-22	Heart rate;
BRCA	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg22705602	chr4:152727874	NA	-0.31	-8.01	-0.3	5.64e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs13102973	1.000	rs4401503	chr4:135905125	G/A	cg14419869	chr4:135874104	NA	0.47	9.71	0.36	7.1e-21	Subjective well-being;
BRCA	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg02228329	chr11:64053129	BAD;GPR137	0.54	11.88	0.43	1.45e-29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.01	0.34	2.33e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg13660082	chr14:53194042	PSMC6	-0.59	-9.26	-0.34	3.18e-19	Alzheimer's disease (late onset);
BRCA	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg22920501	chr2:26401640	FAM59B	-0.81	-13.14	-0.46	4.44e-35	Gut microbiome composition (summer);
BRCA	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg03929089	chr4:120376271	NA	0.49	8.08	0.3	3.31e-15	Axial length;
BRCA	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.49	-0.32	1.4e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg26408565	chr15:76604113	ETFA	-0.47	-10.15	-0.37	1.51e-22	Blood metabolite levels;
BRCA	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg11941060	chr3:133502564	NA	0.33	7.84	0.3	1.84e-14	Alcohol consumption (transferrin glycosylation);
BRCA	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg14349672	chr11:133703707	NA	0.4	9.13	0.34	8.86e-19	Childhood ear infection;
BRCA	cis	rs2882667	0.652	rs700622	chr5:138098551	T/C	cg04439458	chr5:138467593	SIL1	0.34	8.41	0.32	2.59e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-13.29	-0.47	9.55e-36	Platelet count;
BRCA	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.46	-0.38	9.46e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs10189230	0.904	rs13029372	chr2:222348434	A/G	cg14652038	chr2:222343519	EPHA4	0.48	13.28	0.47	1.03e-35	Urate levels in lean individuals;
BRCA	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg13256891	chr4:100009986	ADH5	-0.53	-9.98	-0.37	6.61e-22	Alcohol dependence;
BRCA	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.49	-8.91	-0.33	5.32e-18	Schizophrenia;
BRCA	cis	rs9596863	1.000	rs7995218	chr13:54427874	C/G	ch.13.53330881F	chr13:54432880	NA	0.52	7.93	0.3	1.01e-14	Epilepsy and lamotrigine-induced maculopapular eruptions;
BRCA	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg01877450	chr7:97915802	BRI3	-0.37	-8.57	-0.32	7.96e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg25237894	chr2:233734115	C2orf82	0.39	11.45	0.41	9.43e-28	Coronary artery disease;
BRCA	cis	rs7737355	0.755	rs12519233	chr5:130960093	C/A	cg06307176	chr5:131281290	NA	0.52	10.22	0.37	8.24e-23	Life satisfaction;
BRCA	cis	rs6484504	0.625	rs6484501	chr11:31373100	G/T	cg14844989	chr11:31128820	NA	0.46	9.59	0.35	1.88e-20	Red blood cell count;
BRCA	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg14004847	chr7:1930337	MAD1L1	-0.4	-7.91	-0.3	1.15e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs6545883	0.894	rs6734628	chr2:61451260	T/C	cg15711740	chr2:61764176	XPO1	0.5	12.07	0.43	2.36e-30	Tuberculosis;
BRCA	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg24101359	chr6:42928495	GNMT	0.53	12.25	0.44	4.05e-31	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg11789530	chr4:8429930	ACOX3	0.59	14.56	0.5	1.07e-41	Response to antineoplastic agents;
BRCA	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg11584989	chr19:19387371	SF4	0.63	13.46	0.47	1.53e-36	Bipolar disorder;
BRCA	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg17845761	chr1:175162550	KIAA0040	-0.26	-9.71	-0.36	6.87e-21	Alcohol dependence;
BRCA	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07343612	chr16:622815	PIGQ	-0.67	-21.31	-0.64	1.52e-76	Height;
BRCA	cis	rs12618769	0.597	rs3754884	chr2:99125376	C/T	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs7975161	0.630	rs4964257	chr12:104633262	T/C	cg25273343	chr12:104657179	TXNRD1	-0.61	-9.53	-0.35	3.31e-20	Toenail selenium levels;
BRCA	cis	rs752010	0.695	rs10890156	chr1:42108090	T/C	cg06885757	chr1:42089581	HIVEP3	0.22	8.19	0.31	1.44e-15	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.55	8.81	0.33	1.19e-17	Platelet count;
BRCA	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11644478	chr21:40555479	PSMG1	-0.68	-15.35	-0.52	1.74e-45	Cognitive function;
BRCA	cis	rs16854884	0.837	rs7644767	chr3:143803092	C/G	cg06585982	chr3:143692056	C3orf58	0.39	7.82	0.3	2.23e-14	Economic and political preferences (feminism/equality);
BRCA	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.19	0.49	6.63e-40	Motion sickness;
BRCA	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg20203395	chr5:56204925	C5orf35	-0.49	-9.91	-0.36	1.25e-21	Initial pursuit acceleration;
BRCA	cis	rs4363385	0.747	rs4255332	chr1:152958745	G/C	cg24667326	chr1:152973720	SPRR3	-0.33	-9.29	-0.34	2.45e-19	Inflammatory skin disease;
BRCA	cis	rs13046373	0.507	rs2832969	chr21:32019627	A/G	cg06468780	chr21:31798236	KRTAP13-3	0.34	8.41	0.32	2.77e-16	HDL cholesterol;
BRCA	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg04317338	chr11:64019027	PLCB3	0.55	9.51	0.35	3.67e-20	Mean platelet volume;
BRCA	cis	rs2742234	0.666	rs715106	chr10:43616751	C/A	cg02780029	chr10:43622663	RET	-0.37	-8.28	-0.31	7.47e-16	Hirschsprung disease;
BRCA	cis	rs1712517	0.835	rs2506961	chr10:105007926	G/T	cg05636881	chr10:105038444	INA	-0.39	-9.04	-0.34	1.83e-18	Migraine;
BRCA	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.82	0.3	2.12e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg27211696	chr2:191398769	TMEM194B	-0.47	-10.74	-0.39	7.67e-25	Pulse pressure;
BRCA	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.56	-0.32	8.25e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12760731	0.565	rs12403070	chr1:178094429	A/G	cg00404053	chr1:178313656	RASAL2	0.66	8.07	0.3	3.41e-15	Obesity-related traits;
BRCA	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg08917208	chr2:24149416	ATAD2B	1.07	14.55	0.5	1.2e-41	Birth weight;
BRCA	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.85	13.4	0.47	2.88e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg11663144	chr21:46675770	NA	-0.64	-15.2	-0.52	8.76e-45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg01939980	chr4:1354348	KIAA1530	0.38	9.2	0.34	5.04e-19	Obesity-related traits;
BRCA	cis	rs13046373	0.505	rs2832962	chr21:32008332	T/C	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.26	0.31	8.49e-16	HDL cholesterol;
BRCA	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05901451	chr6:126070800	HEY2	-0.55	-14.74	-0.5	1.6e-42	Brugada syndrome;
BRCA	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg20573242	chr4:122745356	CCNA2	0.42	10.34	0.38	2.87e-23	Type 2 diabetes;
BRCA	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg16576597	chr16:28551801	NUPR1	0.32	8.64	0.32	4.6e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg25358565	chr5:93447407	FAM172A	0.69	12.04	0.43	3.26e-30	Diabetic retinopathy;
BRCA	cis	rs735860	0.712	rs6909592	chr6:53163090	C/G	cg10236188	chr6:53219634	NA	0.4	8.61	0.32	5.5e-17	Glaucoma;
BRCA	cis	rs2637266	1.000	rs2395387	chr10:78357029	T/C	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	13.69	0.48	1.37e-37	Eosinophil percentage of white cells;
BRCA	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg01657329	chr11:68192670	LRP5	0.36	8.13	0.31	2.27e-15	Bone mineral density (spine);
BRCA	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg04362960	chr10:104952993	NT5C2	0.42	9.92	0.37	1.16e-21	Arsenic metabolism;
BRCA	cis	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05901451	chr6:126070800	HEY2	0.38	9.28	0.34	2.56e-19	Endometrial cancer;
BRCA	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.32	-0.31	5.2e-16	Aortic root size;
BRCA	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23583168	chr7:148888333	NA	0.78	19.25	0.61	1.84e-65	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg06521331	chr12:34319734	NA	-0.52	-9.45	-0.35	6.17e-20	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg26384229	chr12:38710491	ALG10B	0.47	10.43	0.38	1.26e-23	Morning vs. evening chronotype;
BRCA	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg01689657	chr7:91764605	CYP51A1	-0.23	-8.23	-0.31	1.05e-15	Breast cancer;
BRCA	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg08313168	chr12:7315531	NA	0.5	8.04	0.3	4.5e-15	Lung disease severity in cystic fibrosis;
BRCA	trans	rs6479891	1.000	rs6479894	chr10:65098741	T/C	cg14819942	chr15:35414228	NA	-0.34	-8.48	-0.32	1.54e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs911119	1.000	rs6114208	chr20:23621734	C/G	cg16589663	chr20:23618590	CST3	0.47	8.83	0.33	1.02e-17	Chronic kidney disease;
BRCA	cis	rs17095355	0.818	rs12573187	chr10:111856077	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.42	-8.78	-0.33	1.54e-17	Biliary atresia;
BRCA	cis	rs4948102	0.691	rs10435504	chr7:56059591	G/C	cg09872392	chr7:56161020	PHKG1	-0.4	-9.08	-0.34	1.39e-18	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs4988958	0.565	rs6732138	chr2:103009662	G/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.51	0.32	1.21e-16	Asthma (childhood onset);
BRCA	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.22	0.41	8.79e-27	Bipolar disorder;
BRCA	cis	rs30380	0.587	rs151940	chr5:96147777	T/C	cg16492584	chr5:96139282	ERAP1	-0.47	-10.84	-0.39	3.14e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg21782813	chr7:2030301	MAD1L1	0.31	8.91	0.33	5.44e-18	Schizophrenia;
BRCA	trans	rs208520	0.837	rs208467	chr6:66914837	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.48	-0.55	3.88e-51	Exhaled nitric oxide output;
BRCA	cis	rs10504073	0.669	rs62507253	chr8:50028836	C/T	cg00325661	chr8:49890786	NA	0.44	12.11	0.43	1.6e-30	Blood metabolite ratios;
BRCA	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg13393036	chr8:95962371	TP53INP1	0.34	8.32	0.31	5.28e-16	Type 2 diabetes;
BRCA	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg24562669	chr7:97807699	LMTK2	0.44	11.55	0.42	3.55e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg05283184	chr6:79620031	NA	-0.44	-11.2	-0.41	1.07e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg05623727	chr3:50126028	RBM5	0.48	11.85	0.42	2.06e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg14675211	chr2:100938903	LONRF2	0.45	10.19	0.37	1.06e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-12.09	-0.43	1.97e-30	Developmental language disorder (linguistic errors);
BRCA	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg04691961	chr3:161091175	C3orf57	-0.42	-10.26	-0.38	5.91e-23	Morning vs. evening chronotype;
BRCA	cis	rs10267417	0.589	rs6960989	chr7:19869349	G/A	cg05791153	chr7:19748676	TWISTNB	0.51	9.75	0.36	5.1e-21	Night sleep phenotypes;
BRCA	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.71	0.42	8.19e-29	Tonsillectomy;
BRCA	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg01884057	chr2:25150051	NA	0.36	9.45	0.35	6.38e-20	Body mass index;
BRCA	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00166722	chr3:10149974	C3orf24	0.6	12.19	0.43	6.74e-31	Alzheimer's disease;
BRCA	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	8.8	0.33	1.28e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18876405	chr7:65276391	NA	-0.55	-13.26	-0.46	1.29e-35	Aortic root size;
BRCA	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-7.96	-0.3	8.15e-15	Total body bone mineral density;
BRCA	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg13319975	chr6:146136371	FBXO30	0.61	13.93	0.48	1.09e-38	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg26898376	chr11:64110657	CCDC88B	0.39	8.24	0.31	9.99e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg24549020	chr5:56110836	MAP3K1	0.4	8.43	0.32	2.32e-16	Coronary artery disease;
BRCA	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg06627628	chr2:24431161	ITSN2	-0.79	-14.97	-0.51	1.26e-43	Asthma;
BRCA	cis	rs11083475	0.714	rs7248584	chr19:39258110	C/T	cg07403899	chr19:39283540	NA	-0.23	-7.86	-0.3	1.68e-14	Heart rate;
BRCA	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg00677455	chr12:58241039	CTDSP2	-0.6	-14.99	-0.51	9.76e-44	Multiple sclerosis;
BRCA	cis	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg21775007	chr8:11205619	TDH	-0.51	-10.24	-0.38	6.79e-23	Triglycerides;
BRCA	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg24848339	chr3:12840334	CAND2	-0.44	-11.49	-0.41	6.57e-28	QRS complex (12-leadsum);
BRCA	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg05985134	chr18:33552581	C18orf21	0.64	11.75	0.42	5.31e-29	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg00024416	chr22:24240387	NA	0.34	8.48	0.32	1.51e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg08422745	chr4:174089978	GALNT7	0.81	18.13	0.58	1.34e-59	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg25174290	chr11:3078921	CARS	0.44	13.09	0.46	7.09e-35	Longevity;
BRCA	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00149659	chr3:10157352	C3orf10	0.79	13.66	0.48	1.77e-37	Alzheimer's disease;
BRCA	cis	rs2014572	0.933	rs8109882	chr19:57755618	C/G	cg24459738	chr19:57751996	ZNF805	-0.34	-8.09	-0.3	2.94e-15	Hyperactive-impulsive symptoms;
BRCA	cis	rs4363385	0.747	rs4323653	chr1:152983359	T/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.17	-0.34	6.54e-19	Inflammatory skin disease;
BRCA	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.58e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7072216	0.763	rs733345	chr10:100164215	G/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-8.5	-0.32	1.38e-16	Metabolite levels;
BRCA	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg00012203	chr2:219082015	ARPC2	-0.41	-7.88	-0.3	1.4e-14	Ulcerative colitis;
BRCA	cis	rs10504073	0.584	rs7818507	chr8:49918423	G/T	cg00325661	chr8:49890786	NA	0.47	13.78	0.48	4.99e-38	Blood metabolite ratios;
BRCA	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg08470875	chr2:26401718	FAM59B	-0.71	-11.35	-0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs897080	0.515	rs1067345	chr2:44618897	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	10.0	0.37	5.46e-22	Height;
BRCA	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg22800045	chr5:56110881	MAP3K1	0.42	8.58	0.32	6.92e-17	Coronary artery disease;
BRCA	cis	rs4285028	0.948	rs6790281	chr3:121665543	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.6	-10.91	-0.4	1.59e-25	Multiple sclerosis;
BRCA	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg25174290	chr11:3078921	CARS	0.43	12.86	0.45	7.94e-34	Longevity;
BRCA	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg04691961	chr3:161091175	C3orf57	0.6	14.78	0.5	9.57e-43	Morning vs. evening chronotype;
BRCA	cis	rs35740288	0.539	rs4843100	chr15:86339210	G/C	cg20737812	chr15:86336631	KLHL25	-0.39	-8.79	-0.33	1.36e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	trans	rs61931739	0.635	rs10772123	chr12:33975557	C/T	cg26384229	chr12:38710491	ALG10B	0.4	9.03	0.34	2.08e-18	Morning vs. evening chronotype;
BRCA	cis	rs6714710	0.603	rs11678591	chr2:98541001	T/C	cg26665480	chr2:98280029	ACTR1B	0.57	13.39	0.47	3.18e-36	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg04267008	chr7:1944627	MAD1L1	-0.5	-10.61	-0.39	2.44e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg20607287	chr7:12443886	VWDE	-0.57	-8.01	-0.3	5.27e-15	Coronary artery disease;
BRCA	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg06346307	chr22:19949965	COMT	0.27	7.81	0.3	2.31e-14	Blood metabolite levels;
BRCA	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg21366198	chr4:185655624	MLF1IP	-0.43	-10.41	-0.38	1.51e-23	Kawasaki disease;
BRCA	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg08885076	chr2:99613938	TSGA10	0.46	10.71	0.39	9.65e-25	Chronic sinus infection;
BRCA	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg23950597	chr19:37808831	NA	-0.62	-11.37	-0.41	2.02e-27	Coronary artery calcification;
BRCA	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg13334819	chr7:99746414	C7orf59	-0.39	-9.56	-0.35	2.46e-20	Coronary artery disease;
BRCA	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-9.98	-0.37	6.78e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2014572	0.967	rs7259978	chr19:57756129	C/T	cg24459738	chr19:57751996	ZNF805	-0.33	-7.98	-0.3	6.73e-15	Hyperactive-impulsive symptoms;
BRCA	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg16606324	chr3:10149918	C3orf24	0.55	10.84	0.39	2.97e-25	Alzheimer's disease;
BRCA	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11890956	chr21:40555474	PSMG1	1.06	31.86	0.78	4.18e-134	Cognitive function;
BRCA	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	14.06	0.49	2.65e-39	Lymphocyte counts;
BRCA	cis	rs1003719	0.591	rs1053984	chr21:38574018	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-13.7	-0.48	1.2e-37	Eye color traits;
BRCA	cis	rs6484504	0.553	rs413067	chr11:31223497	T/C	cg26647111	chr11:31128758	NA	-0.44	-9.63	-0.36	1.33e-20	Red blood cell count;
BRCA	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg16325326	chr1:53192061	ZYG11B	-0.56	-12.76	-0.45	2.14e-33	Monocyte count;
BRCA	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg27588902	chr6:42928151	GNMT	-0.3	-10.11	-0.37	2.12e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	8.31	0.31	5.68e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg06060754	chr5:176797920	RGS14	0.56	10.78	0.39	5.2e-25	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.39	9.02	0.34	2.2e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.39	-10.15	-0.37	1.54e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg07741184	chr6:167504864	NA	0.27	8.0	0.3	5.67e-15	Crohn's disease;
BRCA	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-9.05	-0.34	1.65e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg02734326	chr4:10020555	SLC2A9	-0.37	-7.89	-0.3	1.31e-14	Bone mineral density;
BRCA	cis	rs701145	0.585	rs357487	chr3:153885199	G/C	cg17054900	chr3:154042577	DHX36	0.57	9.53	0.35	3.22e-20	Coronary artery disease;
BRCA	cis	rs11190604	0.767	rs3829162	chr10:102172752	T/G	cg07080220	chr10:102295463	HIF1AN	0.5	10.27	0.38	5.32e-23	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg16339924	chr4:17578868	LAP3	-0.58	-13.53	-0.47	7.28e-37	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	11.2	0.41	1.01e-26	Type 2 diabetes;
BRCA	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg12292205	chr6:26970375	C6orf41	-0.56	-12.34	-0.44	1.59e-31	Schizophrenia;
BRCA	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg02951883	chr7:2050386	MAD1L1	-0.6	-15.06	-0.51	4.41e-44	Bipolar disorder and schizophrenia;
BRCA	cis	rs4862307	0.762	rs28584149	chr4:184996482	C/T	cg06737308	chr4:185021514	ENPP6	0.41	9.08	0.34	1.36e-18	Serum dimethylarginine levels (asymmetric/symetric ratio);
BRCA	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg26838691	chr2:24397539	C2orf84	0.47	8.51	0.32	1.28e-16	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg20476274	chr7:133979776	SLC35B4	0.6	14.82	0.51	6.17e-43	Mean platelet volume;
BRCA	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg08999081	chr20:33150536	PIGU	0.47	12.93	0.46	3.78e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	10.93	0.4	1.26e-25	Rheumatoid arthritis;
BRCA	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	15.11	0.51	2.51e-44	Mean corpuscular hemoglobin;
BRCA	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.47	0.38	9.16e-24	IgG glycosylation;
BRCA	cis	rs3106136	0.527	rs2865345	chr4:95156565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-9.92	-0.37	1.12e-21	Capecitabine sensitivity;
BRCA	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg26384229	chr12:38710491	ALG10B	0.58	13.17	0.46	3.41e-35	Morning vs. evening chronotype;
BRCA	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg18402987	chr7:1209562	NA	0.84	11.92	0.43	9.85e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7617773	0.817	rs4131362	chr3:48329036	A/C	cg11946769	chr3:48343235	NME6	0.62	13.51	0.47	9.47e-37	Coronary artery disease;
BRCA	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg04025307	chr7:1156635	C7orf50	0.46	11.24	0.41	6.84e-27	Longevity;Endometriosis;
BRCA	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11890956	chr21:40555474	PSMG1	-0.82	-19.27	-0.61	1.43e-65	Cognitive function;
BRCA	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs2304069	0.909	rs30831	chr5:149359053	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.79	-15.76	-0.53	1.66e-47	HIV-1 control;
BRCA	trans	rs1493916	0.601	rs7237379	chr18:31322540	C/T	cg15819921	chr19:927150	ARID3A	0.47	9.08	0.34	1.39e-18	Life satisfaction;
BRCA	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg04455712	chr21:45112962	RRP1B	0.38	10.09	0.37	2.53e-22	Mean corpuscular volume;
BRCA	cis	rs7301826	0.651	rs10848206	chr12:131281471	G/C	cg11011512	chr12:131303247	STX2	0.5	12.92	0.46	4.19e-34	Plasma plasminogen activator levels;
BRCA	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.6	-0.32	6.09e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg09455208	chr3:40491958	NA	-0.46	-11.2	-0.41	1.06e-26	Renal cell carcinoma;
BRCA	cis	rs4812048	0.793	rs6070693	chr20:57589516	C/T	cg14073986	chr20:57617431	SLMO2	0.62	8.71	0.33	2.54e-17	Mean platelet volume;
BRCA	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.71	-13.35	-0.47	4.82e-36	Alzheimer's disease;
BRCA	trans	rs208520	0.874	rs208517	chr6:66947040	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.45	-0.55	5.68e-51	Exhaled nitric oxide output;
BRCA	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.7	-14.84	-0.51	5.18e-43	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	trans	rs7939886	0.688	rs11227290	chr11:55896577	A/G	cg15704280	chr7:45808275	SEPT13	0.61	7.9	0.3	1.21e-14	Myopia (pathological);
BRCA	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg25237894	chr2:233734115	C2orf82	-0.4	-11.7	-0.42	8.58e-29	Coronary artery disease;
BRCA	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-10.1	-0.37	2.41e-22	Schizophrenia;
BRCA	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg01262667	chr19:19385393	TM6SF2	0.41	10.64	0.39	1.95e-24	Tonsillectomy;
BRCA	cis	rs61990749	0.597	rs7142390	chr14:78232880	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.64	9.47	0.35	5.52e-20	Fibroblast growth factor basic levels;
BRCA	cis	rs9463078	0.774	rs4510673	chr6:45350107	A/G	cg25276700	chr6:44698697	NA	0.35	8.08	0.3	3.28e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg08917208	chr2:24149416	ATAD2B	0.98	14.9	0.51	2.63e-43	Lymphocyte counts;
BRCA	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg08847533	chr14:75593920	NEK9	0.8	19.8	0.62	2.21e-68	Height;
BRCA	cis	rs3761847	0.508	rs4837813	chr9:123934463	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	8.4	0.32	2.9e-16	Rheumatoid arthritis;
BRCA	cis	rs9612	0.950	rs346546	chr19:44256910	T/C	cg08581076	chr19:44259116	C19orf61	0.52	9.64	0.36	1.31e-20	Exhaled nitric oxide output;
BRCA	cis	rs2839627	0.561	rs2839601	chr21:44317381	A/G	cg03543861	chr21:44258195	NA	0.39	7.95	0.3	8.74e-15	Information processing speed;
BRCA	cis	rs752010	0.841	rs58737163	chr1:42079821	G/T	cg06885757	chr1:42089581	HIVEP3	0.23	8.46	0.32	1.87e-16	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg25767906	chr1:53392781	SCP2	0.52	11.04	0.4	4.71e-26	Monocyte count;
BRCA	cis	rs4800452	0.956	rs4369779	chr18:20735408	T/C	cg26136497	chr18:20735537	CABLES1	-0.44	-10.86	-0.39	2.41e-25	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg16482183	chr6:26056742	HIST1H1C	0.53	11.49	0.41	6.29e-28	Height;
BRCA	cis	rs2637030	0.559	rs256107	chr5:52873776	C/T	cg06476337	chr5:52856530	NDUFS4	0.37	8.39	0.31	3.15e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	trans	rs4698048	0.506	rs2080072	chr4:10235622	G/C	cg26043149	chr18:55253948	FECH	-0.54	-12.75	-0.45	2.59e-33	Skin aging (microtopography measurement);
BRCA	cis	rs9400271	0.632	rs9398192	chr6:109587236	C/T	cg21918786	chr6:109611834	NA	-0.32	-8.02	-0.3	5.08e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.31	0.31	5.79e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-9.44	-0.35	6.8e-20	Retinal vascular caliber;
BRCA	cis	rs3845702	0.736	rs12465592	chr2:180862654	C/G	cg01881094	chr2:180872142	CWC22	1.01	17.22	0.56	6.97e-55	Schizophrenia;
BRCA	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	19.13	0.6	7.84e-65	Platelet count;
BRCA	cis	rs4233366	0.585	rs3924264	chr1:161178684	C/T	cg13853198	chr1:161185092	FCER1G	-0.25	-8.78	-0.33	1.53e-17	Asthma;
BRCA	cis	rs654950	0.934	rs654220	chr1:42002556	A/T	cg06885757	chr1:42089581	HIVEP3	-0.28	-9.95	-0.37	8.87e-22	Airway imaging phenotypes;
BRCA	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg26384229	chr12:38710491	ALG10B	0.43	10.43	0.38	1.27e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg07423050	chr13:99094983	FARP1	-0.59	-16.02	-0.54	8.26e-49	Neuroticism;
BRCA	trans	rs800082	0.501	rs9873732	chr3:144191665	C/T	cg24215973	chr2:240111563	HDAC4	0.35	8.06	0.3	3.89e-15	Smoking behavior;
BRCA	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.48e-23	Motion sickness;
BRCA	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg12564285	chr5:131593104	PDLIM4	0.43	11.04	0.4	4.77e-26	Acylcarnitine levels;
BRCA	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg08999081	chr20:33150536	PIGU	-0.46	-12.55	-0.44	1.87e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg23711669	chr6:146136114	FBXO30	-0.68	-15.72	-0.53	2.47e-47	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg25817165	chr18:72167213	CNDP2	-0.74	-14.41	-0.5	6.03e-41	Refractive error;
BRCA	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg04586622	chr2:25135609	ADCY3	0.44	11.13	0.4	2.05e-26	Body mass index;
BRCA	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg24531977	chr5:56204891	C5orf35	0.61	12.54	0.44	2.04e-32	Type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg14675211	chr2:100938903	LONRF2	0.44	10.04	0.37	3.94e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.34	-0.35	1.6e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg06713675	chr4:122721982	EXOSC9	-0.53	-12.41	-0.44	7.92e-32	Type 2 diabetes;
BRCA	cis	rs7178424	0.875	rs28513564	chr15:62232360	C/T	cg00456672	chr15:62358751	C2CD4A	-0.44	-9.73	-0.36	5.83e-21	Height;
BRCA	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-15.43	-0.52	7.17e-46	Total cholesterol levels;
BRCA	cis	rs16854884	0.586	rs13081286	chr3:143723757	A/T	cg06585982	chr3:143692056	C3orf58	0.47	10.09	0.37	2.62e-22	Economic and political preferences (feminism/equality);
BRCA	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg11502198	chr6:26597334	ABT1	0.48	9.65	0.36	1.13e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg27211696	chr2:191398769	TMEM194B	0.47	7.93	0.3	9.91e-15	Diastolic blood pressure;
BRCA	cis	rs4363385	0.818	rs11205175	chr1:153001296	A/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.38	-0.31	3.47e-16	Inflammatory skin disease;
BRCA	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg13010199	chr12:38710504	ALG10B	-0.44	-8.74	-0.33	1.98e-17	Heart rate;
BRCA	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.6	-0.32	6.16e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs9503598	0.610	rs1328687	chr6:3468377	A/C	cg00476032	chr6:3446245	SLC22A23	0.38	9.18	0.34	5.81e-19	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg10932868	chr11:921992	NA	0.4	9.74	0.36	5.43e-21	Alzheimer's disease (late onset);
BRCA	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg13736514	chr6:26305472	NA	-0.46	-14.8	-0.51	8.07e-43	Educational attainment;
BRCA	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg10729496	chr3:10149963	C3orf24	0.41	7.9	0.3	1.21e-14	Alzheimer's disease;
BRCA	cis	rs13102973	1.000	rs4569802	chr4:135905371	A/C	cg14419869	chr4:135874104	NA	0.47	9.71	0.36	6.77e-21	Subjective well-being;
BRCA	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg26608667	chr7:1196370	ZFAND2A	0.42	10.04	0.37	3.92e-22	Longevity;Endometriosis;
BRCA	cis	rs757081	0.667	rs1987694	chr11:17107648	G/C	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.57	-0.32	7.52e-17	Systolic blood pressure;
BRCA	cis	rs3857067	0.806	rs34396894	chr4:95097600	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.36	-0.35	1.32e-19	QT interval;
BRCA	cis	rs9469890	0.604	rs11758426	chr6:34503338	A/G	cg14254433	chr6:34482411	PACSIN1	-0.45	-9.47	-0.35	5.31e-20	Pubertal anthropometrics;Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg20607798	chr8:58055168	NA	0.47	8.09	0.3	3.07e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg08738300	chr3:44038990	NA	0.45	8.69	0.32	3.15e-17	Coronary artery disease;
BRCA	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg05347473	chr6:146136440	FBXO30	-0.56	-10.25	-0.38	6.43e-23	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg27661571	chr11:113659931	NA	-0.73	-11.22	-0.41	8.26e-27	Hip circumference adjusted for BMI;
BRCA	cis	rs9393777	0.502	rs3823427	chr6:27256346	G/C	cg12292205	chr6:26970375	C6orf41	-0.61	-10.1	-0.37	2.42e-22	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.06	0.3	3.79e-15	Corneal astigmatism;
BRCA	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00166722	chr3:10149974	C3orf24	0.56	10.94	0.4	1.22e-25	Alzheimer's disease;
BRCA	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg05340658	chr4:99064831	C4orf37	0.45	10.36	0.38	2.44e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg00106254	chr7:1943704	MAD1L1	-0.32	-8.12	-0.31	2.42e-15	Schizophrenia;
BRCA	cis	rs490234	0.702	rs13284572	chr9:128258270	T/C	cg14078157	chr9:128172775	NA	-0.53	-11.75	-0.42	5.48e-29	Mean arterial pressure;
BRCA	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg02297831	chr4:17616191	MED28	0.36	8.39	0.32	3.12e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg19077165	chr18:44547161	KATNAL2	-0.58	-12.89	-0.45	5.75e-34	Personality dimensions;
BRCA	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg26384229	chr12:38710491	ALG10B	0.68	14.28	0.49	2.34e-40	Morning vs. evening chronotype;
BRCA	cis	rs36051895	0.659	rs61284219	chr9:5062816	C/A	cg02405213	chr9:5042618	JAK2	-0.5	-9.67	-0.36	1.01e-20	Pediatric autoimmune diseases;
BRCA	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg19257562	chr1:2043853	PRKCZ	-0.35	-9.81	-0.36	2.95e-21	Height;
BRCA	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	8.19	0.31	1.41e-15	Menarche (age at onset);
BRCA	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.82	-0.42	2.58e-29	Bipolar disorder;
BRCA	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg03433033	chr1:76189801	ACADM	-0.48	-9.93	-0.37	1.02e-21	Daytime sleep phenotypes;
BRCA	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.35	-7.95	-0.3	8.2e-15	Tonsillectomy;
BRCA	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	11.99	0.43	5.35e-30	Personality dimensions;
BRCA	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg27446573	chr6:127587934	RNF146	0.9	21.49	0.65	1.64e-77	Breast cancer;
BRCA	cis	rs365132	0.902	rs353489	chr5:176461974	T/C	cg16309518	chr5:176445507	NA	-0.51	-12.95	-0.46	3.19e-34	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs74181299	0.684	rs12713532	chr2:65356552	G/C	cg05010058	chr2:65284262	CEP68	-0.3	-8.19	-0.31	1.39e-15	Pulse pressure;
BRCA	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg08213375	chr14:104286397	PPP1R13B	-0.64	-17.82	-0.58	5.84e-58	Schizophrenia;
BRCA	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06022373	chr22:39101656	GTPBP1	0.75	18.38	0.59	7.21e-61	Menopause (age at onset);
BRCA	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg17971929	chr21:40555470	PSMG1	-0.49	-10.72	-0.39	9.04e-25	Menarche (age at onset);
BRCA	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg18357645	chr12:58087776	OS9	0.43	12.07	0.43	2.32e-30	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.63	13.68	0.48	1.46e-37	Lymphocyte percentage of white cells;
BRCA	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg08085267	chr17:45401833	C17orf57	0.6	12.31	0.44	2.17e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg08645402	chr16:4508243	NA	0.41	9.67	0.36	1.01e-20	Schizophrenia;
BRCA	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg03433033	chr1:76189801	ACADM	0.7	16.08	0.54	3.97e-49	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg18705301	chr15:41695430	NDUFAF1	1.04	23.42	0.68	4.62e-88	Ulcerative colitis;
BRCA	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	trans	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04565464	chr8:145669602	NFKBIL2	0.41	9.33	0.35	1.66e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs600806	0.778	rs2043059	chr1:109991009	C/A	cg20591472	chr1:110008990	SYPL2	0.32	8.07	0.3	3.58e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	15.97	0.53	1.54e-48	Platelet count;
BRCA	cis	rs1506636	0.854	rs6466879	chr7:123276197	G/A	cg03229431	chr7:123269106	ASB15	-0.66	-15.3	-0.52	2.84e-45	Plateletcrit;Platelet count;
BRCA	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg01874867	chr7:94954059	PON1	-0.4	-8.13	-0.31	2.25e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04267008	chr7:1944627	MAD1L1	0.49	10.99	0.4	7.37e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg10223061	chr2:219282414	VIL1	-0.27	-7.92	-0.3	1.04e-14	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	trans	rs66887589	1.000	rs66887589	chr4:120509279	T/C	cg25214090	chr10:38739885	LOC399744	-0.35	-7.89	-0.3	1.29e-14	Diastolic blood pressure;
BRCA	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg26031613	chr14:104095156	KLC1	-0.45	-8.84	-0.33	9.49e-18	Schizophrenia;
BRCA	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg23711669	chr6:146136114	FBXO30	-0.67	-15.46	-0.52	5.04e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.18	-0.34	6e-19	Bipolar disorder;
BRCA	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.53	-0.35	3.1e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg07988820	chr12:82153109	PPFIA2	-0.67	-11.22	-0.41	8.64e-27	Resting heart rate;
BRCA	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg00012203	chr2:219082015	ARPC2	-0.4	-7.83	-0.3	2.1e-14	Ulcerative colitis;
BRCA	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg10818794	chr15:86012489	AKAP13	-0.41	-11.07	-0.4	3.46e-26	Coronary artery disease;
BRCA	cis	rs870825	0.616	rs4615214	chr4:185624129	G/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg18404041	chr3:52824283	ITIH1	0.35	8.94	0.33	4.17e-18	Schizophrenia;
BRCA	cis	rs919433	0.927	rs6759834	chr2:198204860	C/T	cg00792783	chr2:198669748	PLCL1	-0.38	-8.04	-0.3	4.42e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	trans	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg21659725	chr3:3221576	CRBN	-0.45	-9.61	-0.36	1.65e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg04565464	chr8:145669602	NFKBIL2	0.44	10.59	0.39	3.02e-24	Schizophrenia;
BRCA	cis	rs877282	0.583	rs11595057	chr10:819203	A/C	cg15764593	chr10:829463	NA	-0.5	-8.26	-0.31	8.13e-16	Uric acid levels;
BRCA	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg08470875	chr2:26401718	FAM59B	0.72	11.85	0.42	2.09e-29	Gut microbiome composition (summer);
BRCA	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg17063962	chr7:91808500	NA	0.57	12.96	0.46	2.76e-34	Breast cancer;
BRCA	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.18	-0.43	7.96e-31	Total cholesterol levels;
BRCA	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24549020	chr5:56110836	MAP3K1	0.59	12.05	0.43	2.86e-30	Initial pursuit acceleration;
BRCA	cis	rs4948102	0.599	rs2230197	chr7:56126360	T/C	cg09872392	chr7:56161020	PHKG1	-0.5	-12.51	-0.44	2.78e-32	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg06636001	chr8:8085503	FLJ10661	-0.73	-16.34	-0.54	2.1e-50	Neuroticism;
BRCA	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg17420585	chr12:42539391	GXYLT1	-0.49	-10.54	-0.38	4.52e-24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg11833968	chr6:79620685	NA	-0.44	-9.91	-0.37	1.23e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1997103	1.000	rs1997098	chr7:55405594	G/T	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4363385	0.693	rs821755	chr1:153036245	G/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.24	-0.31	9.7e-16	Inflammatory skin disease;
BRCA	cis	rs3784262	1.000	rs4646638	chr15:58248783	C/T	cg12031962	chr15:58353849	ALDH1A2	0.46	12.5	0.44	3.05e-32	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg08888203	chr3:10149979	C3orf24	0.69	14.76	0.5	1.22e-42	Alzheimer's disease;
BRCA	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg25427524	chr10:38739819	LOC399744	-0.59	-11.21	-0.41	9.06e-27	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3784262	0.679	rs11071365	chr15:58334126	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.55	-13.88	-0.48	1.72e-38	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg26818010	chr10:134567672	INPP5A	-0.72	-15.21	-0.52	7.79e-45	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.35	-9.06	-0.34	1.62e-18	Total body bone mineral density;
BRCA	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg17211192	chr8:82754475	SNX16	-0.54	-11.56	-0.42	3.52e-28	Diastolic blood pressure;
BRCA	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg24642439	chr20:33292090	TP53INP2	0.7	15.9	0.53	3.15e-48	Coronary artery disease;
BRCA	cis	rs10193935	0.901	rs222463	chr2:42644080	A/G	cg27598129	chr2:42591480	NA	-0.81	-13.38	-0.47	3.6e-36	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-9.38	-0.35	1.16e-19	Morning vs. evening chronotype;
BRCA	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg13271783	chr10:134563150	INPP5A	-0.48	-9.58	-0.35	2.06e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.37	0.38	2.23e-23	Motion sickness;
BRCA	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg22875332	chr1:76189707	ACADM	0.69	14.77	0.5	1.08e-42	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4853036	1.000	rs62134006	chr2:70050641	T/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-8.97	-0.33	3.22e-18	Colorectal or endometrial cancer;
BRCA	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg19683494	chr5:74908142	NA	-0.62	-9.7	-0.36	7.66e-21	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
BRCA	cis	rs2282802	0.660	rs4463213	chr5:139545748	G/A	cg26211634	chr5:139558579	C5orf32	-0.34	-8.05	-0.3	3.94e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03517284	chr6:25882590	NA	0.67	15.2	0.52	9.32e-45	Blood metabolite levels;
BRCA	cis	rs495337	0.760	rs471054	chr20:48513236	C/T	cg17835207	chr20:48524531	SPATA2	-0.67	-15.82	-0.53	7.95e-48	Psoriasis;
BRCA	trans	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.53	12.77	0.45	2.1e-33	Brugada syndrome;
BRCA	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	8.63	0.32	4.93e-17	Mean platelet volume;
BRCA	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg06935464	chr4:38784597	TLR10	0.51	8.25	0.31	9.26e-16	Breast cancer;
BRCA	cis	rs17253792	0.915	rs17832389	chr14:56185836	A/G	cg01858014	chr14:56050164	KTN1	-0.66	-8.26	-0.31	8.58e-16	Putamen volume;
BRCA	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg16576597	chr16:28551801	NUPR1	0.36	9.68	0.36	8.82e-21	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg21770322	chr7:97807741	LMTK2	0.45	11.72	0.42	7.35e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.69	0.39	1.15e-24	Tonsillectomy;
BRCA	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.72e-15	Prostate cancer;
BRCA	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg18016565	chr1:150552671	MCL1	-0.37	-8.56	-0.32	8.12e-17	Tonsillectomy;
BRCA	cis	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.69	-0.33	3.09e-17	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4308124	0.708	rs2137168	chr2:111986509	C/T	cg04571233	chr2:111982156	NA	-0.46	-9.25	-0.34	3.21e-19	Vitiligo;
BRCA	cis	rs727479	0.502	rs10046	chr15:51502986	G/A	cg19946085	chr15:51559439	CYP19A1	-0.3	-8.32	-0.31	5.5e-16	Estradiol levels;
BRCA	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg01475377	chr6:109611718	NA	0.53	13.49	0.47	1.16e-36	Reticulocyte fraction of red cells;
BRCA	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	21.05	0.64	3.91e-75	Smoking behavior;
BRCA	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.74	0.55	2.09e-52	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs11229555	0.834	rs7925560	chr11:58263036	G/A	cg15696309	chr11:58395628	NA	-0.54	-11.65	-0.42	1.45e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18404041	chr3:52824283	ITIH1	-0.38	-11.76	-0.42	5.03e-29	Bipolar disorder;
BRCA	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg03433033	chr1:76189801	ACADM	-0.47	-8.98	-0.33	3.1e-18	Daytime sleep phenotypes;
BRCA	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg19318889	chr4:1322082	MAEA	0.49	10.54	0.38	4.74e-24	Longevity;
BRCA	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg11663144	chr21:46675770	NA	-0.62	-14.33	-0.49	1.41e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg03806693	chr22:41940476	POLR3H	-0.55	-10.39	-0.38	1.84e-23	Neuroticism;
BRCA	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg18232548	chr7:50535776	DDC	-0.5	-12.42	-0.44	6.83e-32	Response to zileuton treatment in asthma (FEV1 change interaction);
BRCA	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg00666640	chr1:248458726	OR2T12	0.31	8.27	0.31	7.63e-16	Common traits (Other);
BRCA	cis	rs1614887	1	rs1614887	chr6:26393021	A/G	cg09904177	chr6:26538194	HMGN4	0.41	11.23	0.41	8.14e-27	Intelligence (multi-trait analysis);Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6142102	0.649	rs4911382	chr20:32553095	C/T	cg24642439	chr20:33292090	TP53INP2	0.39	7.82	0.3	2.17e-14	Skin pigmentation;
BRCA	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.46	8.02	0.3	5.09e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6963495	0.649	rs1706888	chr7:105149176	A/G	cg19920283	chr7:105172520	RINT1	0.43	8.93	0.33	4.67e-18	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg10523679	chr1:76189770	ACADM	0.67	13.31	0.47	7.77e-36	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11608355	0.515	rs1045582	chr12:109915727	G/T	cg05360138	chr12:110035743	NA	0.72	13.15	0.46	4.04e-35	Neuroticism;
BRCA	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.23e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11764359	chr7:65958608	NA	0.75	16.57	0.55	1.37e-51	Aortic root size;
BRCA	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg14196790	chr5:131705035	SLC22A5	0.3	7.85	0.3	1.73e-14	Blood metabolite levels;
BRCA	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg10978503	chr1:24200527	CNR2	-0.44	-10.12	-0.37	2.07e-22	Immature fraction of reticulocytes;
BRCA	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.54e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs9467711	0.591	rs13196552	chr6:25974204	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.58	9.13	0.34	9e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.56	8.12	0.31	2.43e-15	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg08422745	chr4:174089978	GALNT7	-0.82	-18.11	-0.58	1.87e-59	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs1011018	0.628	rs56079671	chr7:139466379	G/A	cg03224163	chr7:139420300	HIPK2	-0.58	-8.68	-0.32	3.41e-17	Systolic blood pressure;
BRCA	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg11584989	chr19:19387371	SF4	0.3	7.85	0.3	1.71e-14	Tonsillectomy;
BRCA	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.43	-9.15	-0.34	7.87e-19	IgG glycosylation;
BRCA	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg13010199	chr12:38710504	ALG10B	0.5	9.68	0.36	9.21e-21	Morning vs. evening chronotype;
BRCA	trans	rs12517041	1.000	rs10520888	chr5:23280539	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.44	-8.06	-0.3	3.89e-15	Calcium levels;
BRCA	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00802000	chr16:706648	WDR90	-0.41	-9.6	-0.36	1.73e-20	Height;
BRCA	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg12016809	chr21:47604291	C21orf56	-0.39	-8.12	-0.31	2.37e-15	Testicular germ cell tumor;
BRCA	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg03676636	chr4:99064102	C4orf37	0.21	7.98	0.3	6.8e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg13402656	chr8:1511478	DLGAP2	-0.49	-11.94	-0.43	8.26e-30	Lung cancer;
BRCA	cis	rs7520050	0.931	rs11211224	chr1:46384388	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.76	0.36	4.46e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg11663144	chr21:46675770	NA	-0.61	-13.91	-0.48	1.22e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.97	-0.3	7.43e-15	Aortic root size;
BRCA	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg17691542	chr6:26056736	HIST1H1C	0.54	11.35	0.41	2.55e-27	Height;
BRCA	cis	rs2625529	0.652	rs8028115	chr15:72339503	C/T	cg16672083	chr15:72433130	SENP8	0.65	15.47	0.52	4.46e-46	Red blood cell count;
BRCA	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg09904177	chr6:26538194	HMGN4	0.56	18.26	0.59	3.11e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-14.97	-0.51	1.13e-43	Total cholesterol levels;
BRCA	trans	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg15704280	chr7:45808275	SEPT13	-0.49	-8.2	-0.31	1.36e-15	Axial length;
BRCA	cis	rs672059	1.000	rs546183	chr1:183157753	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.56	0.32	8.08e-17	Hypertriglyceridemia;
BRCA	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg08601574	chr20:25228251	PYGB	-0.33	-7.97	-0.3	7.24e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg21775007	chr8:11205619	TDH	-0.48	-9.68	-0.36	8.68e-21	Subjective well-being;
BRCA	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.56	-14.12	-0.49	1.41e-39	Electrocardiographic conduction measures;
BRCA	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.87e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg05623727	chr3:50126028	RBM5	-0.41	-9.6	-0.35	1.8e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03264133	chr6:25882463	NA	0.42	8.84	0.33	9.1e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs8114671	0.647	rs6060268	chr20:33734293	T/C	cg24642439	chr20:33292090	TP53INP2	0.4	8.6	0.32	5.93e-17	Height;
BRCA	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13136331	0.840	rs13113106	chr4:88704009	T/G	cg22416721	chr4:88570574	DMP1	0.46	10.2	0.37	9.71e-23	Sitting height ratio;
BRCA	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.61	8.47	0.32	1.68e-16	Putamen volume;
BRCA	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg00071950	chr4:10020882	SLC2A9	0.55	13.8	0.48	4.22e-38	Bone mineral density;
BRCA	cis	rs6450176	0.625	rs56193151	chr5:53287790	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-15.64	-0.53	6.06e-47	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.01	14.94	0.51	1.75e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg26384229	chr12:38710491	ALG10B	0.45	10.5	0.38	6.5e-24	Morning vs. evening chronotype;
BRCA	cis	rs2294693	0.945	rs9369255	chr6:40989503	T/C	cg14418226	chr6:40996092	UNC5CL	0.45	8.03	0.3	4.75e-15	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs586533	0.758	rs1690819	chr11:99496535	A/G	cg22878054	chr11:99397252	CNTN5	0.32	7.85	0.3	1.8e-14	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.18	-17.87	-0.58	3.08e-58	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs1003719	0.614	rs1053808	chr21:38525356	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.58	-13.42	-0.47	2.43e-36	Eye color traits;
BRCA	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg23625390	chr15:77176239	SCAPER	-0.55	-12.86	-0.45	8.09e-34	Blood metabolite levels;
BRCA	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08704250	chr15:31115839	NA	-0.35	-9.04	-0.34	1.78e-18	Huntington's disease progression;
BRCA	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.1e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg24692254	chr21:30365293	RNF160	-0.46	-10.34	-0.38	2.86e-23	Pancreatic cancer;
BRCA	cis	rs2625529	0.878	rs4777478	chr15:72279085	T/C	cg16672083	chr15:72433130	SENP8	-0.86	-17.75	-0.57	1.34e-57	Red blood cell count;
BRCA	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg02175503	chr12:58329896	NA	0.56	13.08	0.46	8.38e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg08213375	chr14:104286397	PPP1R13B	0.66	18.72	0.6	1.09e-62	Schizophrenia;
BRCA	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg02891314	chr5:179741120	GFPT2	-0.7	-14.41	-0.5	5.5e-41	Height;
BRCA	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg15997130	chr1:24165203	NA	-0.47	-12.59	-0.45	1.29e-32	Immature fraction of reticulocytes;
BRCA	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg09184832	chr6:79620586	NA	-0.51	-11.3	-0.41	3.9e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg05340658	chr4:99064831	C4orf37	0.68	16.88	0.56	3.89e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs977987	0.806	rs4146809	chr16:75415775	A/G	cg03315344	chr16:75512273	CHST6	-0.54	-13.0	-0.46	1.81e-34	Dupuytren's disease;
BRCA	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	20.19	0.62	1.8e-70	Electrocardiographic conduction measures;
BRCA	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-15.75	-0.53	1.79e-47	Chronic sinus infection;
BRCA	trans	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg01620082	chr3:125678407	NA	-0.92	-10.33	-0.38	2.97e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs11997175	0.766	rs7387133	chr8:33727045	C/G	ch.8.33884649F	chr8:33765107	NA	-0.37	-8.92	-0.33	4.76e-18	Body mass index;
BRCA	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg05623727	chr3:50126028	RBM5	-0.43	-10.51	-0.38	6.07e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg14926445	chr8:58193284	C8orf71	-0.44	-8.43	-0.32	2.32e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2629540	0.580	rs2930796	chr10:126485684	A/G	cg08799069	chr10:126477246	METTL10	0.46	8.31	0.31	5.95e-16	Cocaine dependence;
BRCA	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	10.96	0.4	9.76e-26	Bipolar disorder;
BRCA	trans	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg01620082	chr3:125678407	NA	-0.85	-9.88	-0.36	1.6e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs72781680	0.716	rs2551326	chr2:23982378	T/C	cg08917208	chr2:24149416	ATAD2B	0.63	9.98	0.37	6.5600000000000005e-22	Lymphocyte counts;
BRCA	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg10523679	chr1:76189770	ACADM	-0.45	-8.59	-0.32	6.59e-17	Daytime sleep phenotypes;
BRCA	cis	rs858239	0.932	rs1637190	chr7:23269065	A/G	cg23682824	chr7:23144976	KLHL7	0.35	8.96	0.33	3.44e-18	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg07828340	chr4:882639	GAK	1.07	14.36	0.49	9.99e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs7827545	1.000	rs4909909	chr8:135564627	T/C	cg17885191	chr8:135476712	NA	0.47	9.19	0.34	5.3e-19	Hypertension (SNP x SNP interaction);
BRCA	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg00071950	chr4:10020882	SLC2A9	0.65	16.08	0.54	4.3e-49	Bone mineral density;
BRCA	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg03733263	chr8:22462867	KIAA1967	-0.85	-17.5	-0.57	2.54e-56	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs13064411	0.735	rs6438157	chr3:113207316	G/T	cg18753928	chr3:113234510	CCDC52	-0.59	-12.52	-0.44	2.53e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs4321325	0.536	rs10198483	chr2:127934102	G/A	cg11380483	chr2:127933992	NA	0.53	12.45	0.44	5.03e-32	Protein C levels;
BRCA	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19346786	chr7:2764209	NA	-0.3	-9.4	-0.35	9.79e-20	Height;
BRCA	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	9.51	0.35	3.8e-20	Lung cancer in ever smokers;
BRCA	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg26384229	chr12:38710491	ALG10B	0.43	9.86	0.36	1.99e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg22920501	chr2:26401640	FAM59B	0.94	16.57	0.55	1.46e-51	Gut microbiome composition (summer);
BRCA	cis	rs6750047	1.000	rs6750047	chr2:38276549	A/G	cg07380506	chr2:38303506	CYP1B1	0.42	9.62	0.36	1.5e-20	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg26913058	chr16:419975	MRPL28	-0.32	-7.87	-0.3	1.51e-14	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-10.56	-0.39	4.01e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg15145296	chr3:125709740	NA	-0.54	-8.57	-0.32	7.5e-17	Blood pressure (smoking interaction);
BRCA	cis	rs7394190	0.748	rs4114992	chr10:75566829	A/G	cg07699608	chr10:75541558	CHCHD1	0.62	9.44	0.35	6.91e-20	Incident atrial fibrillation;
BRCA	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg19729930	chr2:74357872	NA	0.6	14.49	0.5	2.49e-41	Gestational age at birth (maternal effect);
BRCA	trans	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg23762105	chr12:34175262	ALG10	0.34	7.9	0.3	1.25e-14	Morning vs. evening chronotype;
BRCA	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.18	0.31	1.49e-15	Axial length;
BRCA	cis	rs8044868	0.530	rs12918956	chr16:72224335	A/G	cg23815491	chr16:72088622	HP	-0.32	-8.27	-0.31	7.65e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg20587970	chr11:113659929	NA	-1.2	-22.12	-0.66	5.89e-81	Hip circumference adjusted for BMI;
BRCA	cis	rs911119	0.913	rs6048928	chr20:23585988	A/G	cg16589663	chr20:23618590	CST3	0.45	8.28	0.31	7.17e-16	Chronic kidney disease;
BRCA	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg06238570	chr21:40685208	BRWD1	-0.46	-9.16	-0.34	6.94e-19	Cognitive function;
BRCA	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg23711669	chr6:146136114	FBXO30	0.72	17.35	0.57	1.59e-55	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.46	-8.83	-0.33	1e-17	Monocyte count;
BRCA	cis	rs72781680	0.784	rs72798406	chr2:24180144	T/C	cg08917208	chr2:24149416	ATAD2B	0.62	10.37	0.38	2.18e-23	Lymphocyte counts;
BRCA	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-9.75	-0.36	4.79e-21	Bladder cancer;
BRCA	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg22951483	chr13:113628068	MCF2L	-0.37	-8.24	-0.31	9.61e-16	Systolic blood pressure;
BRCA	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.2	0.49	5.86e-40	Motion sickness;
BRCA	cis	rs724568	0.546	rs10191089	chr2:67941210	C/T	cg14046302	chr2:67939758	NA	-0.4	-10.95	-0.4	1.08e-25	Major depressive disorder (broad);
BRCA	cis	rs5167	0.504	rs7246900	chr19:45454236	G/A	cg10169327	chr19:45448959	APOC2	0.31	7.84	0.3	1.85e-14	Blood protein levels;
BRCA	cis	rs8032158	0.927	rs7179116	chr15:56174827	A/G	cg02198044	chr15:56286336	NEDD4	-0.38	-9.14	-0.34	8.39e-19	Keloid;
BRCA	cis	rs68170813	0.559	rs77727587	chr7:106815754	C/G	cg02696742	chr7:106810147	HBP1	-0.54	-8.8	-0.33	1.3e-17	Coronary artery disease;
BRCA	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg17372223	chr3:52568218	NT5DC2	0.34	7.97	0.3	7.48e-15	Electroencephalogram traits;
BRCA	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg14019146	chr3:50243930	SLC38A3	-0.39	-9.56	-0.35	2.53e-20	Body mass index;
BRCA	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg03060546	chr3:49711283	APEH	0.47	10.13	0.37	1.84e-22	Resting heart rate;
BRCA	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg17845761	chr1:175162550	KIAA0040	0.28	10.56	0.39	3.89e-24	Alcohol dependence;
BRCA	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg24803719	chr17:45855879	NA	-0.31	-8.06	-0.3	3.76e-15	IgG glycosylation;
BRCA	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg02544614	chr20:61657117	NA	0.29	8.14	0.31	2.09e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11890956	chr21:40555474	PSMG1	0.66	14.4	0.5	6.08e-41	Cognitive function;
BRCA	cis	rs6484504	0.652	rs485265	chr11:31407788	G/A	cg06552810	chr11:31128660	NA	0.39	8.42	0.32	2.4e-16	Red blood cell count;
BRCA	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg20908204	chr19:46285434	DMPK	0.29	8.99	0.34	2.68e-18	Coronary artery disease;
BRCA	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.76e-35	Aortic root size;
BRCA	cis	rs1568889	1.000	rs12800354	chr11:28047723	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	13.41	0.47	2.64e-36	Bipolar disorder;
BRCA	cis	rs7617773	0.747	rs34076262	chr3:48370416	C/T	cg11946769	chr3:48343235	NME6	0.67	13.66	0.48	1.88e-37	Coronary artery disease;
BRCA	cis	rs965469	1.000	rs6037560	chr20:3323055	T/C	cg25506879	chr20:3388711	C20orf194	-0.55	-10.72	-0.39	8.86e-25	IFN-related cytopenia;
BRCA	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg26384229	chr12:38710491	ALG10B	0.69	15.69	0.53	3.64e-47	Bladder cancer;
BRCA	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg23719950	chr11:63933701	MACROD1	-0.58	-9.47	-0.35	5.18e-20	Mean platelet volume;
BRCA	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg13010199	chr12:38710504	ALG10B	0.44	8.93	0.33	4.46e-18	Bladder cancer;
BRCA	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs919433	0.713	rs55642934	chr2:198491110	C/T	cg00792783	chr2:198669748	PLCL1	0.36	8.08	0.3	3.27e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg22105103	chr4:187893119	NA	-0.36	-11.7	-0.42	8.31e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg17691542	chr6:26056736	HIST1H1C	0.53	10.32	0.38	3.45e-23	Height;
BRCA	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg20283391	chr11:68216788	NA	-0.49	-9.52	-0.35	3.55e-20	Total body bone mineral density (age 0-15);
BRCA	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg11663144	chr21:46675770	NA	-0.61	-14.21	-0.49	5.05e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-9.14	-0.34	8.23e-19	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.64	-0.39	1.82e-24	Bipolar disorder;
BRCA	cis	rs6580649	0.943	rs3803183	chr12:48398080	T/A	cg24011408	chr12:48396354	COL2A1	0.52	8.85	0.33	8.55e-18	Lung cancer;
BRCA	cis	rs3750965	0.575	rs3892895	chr11:68884755	A/G	cg06818126	chr11:68850279	TPCN2	0.35	8.93	0.33	4.58e-18	Hair color;
BRCA	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg03425785	chr20:62221387	GMEB2	0.51	8.29	0.31	6.8e-16	Glioblastoma;
BRCA	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg15704280	chr7:45808275	SEPT13	0.8	19.2	0.6	3.31e-65	Coronary artery disease;
BRCA	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-12.7	-0.45	4.24e-33	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg22920501	chr2:26401640	FAM59B	-0.65	-11.41	-0.41	1.45e-27	Gut microbiome composition (summer);
BRCA	trans	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg06521331	chr12:34319734	NA	-0.54	-10.34	-0.38	2.7e-23	Bladder cancer;
BRCA	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.41	-0.47	2.55e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs7677751	0.806	rs17084051	chr4:55087581	C/A	cg17187183	chr4:55093834	PDGFRA	0.44	9.21	0.34	4.62e-19	Corneal astigmatism;
BRCA	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg07148914	chr20:33460835	GGT7	0.47	9.97	0.37	7.37e-22	Height;
BRCA	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg17366294	chr4:99064904	C4orf37	0.42	9.69	0.36	8.26e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg03433033	chr1:76189801	ACADM	0.86	22.18	0.66	2.75e-81	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-10.47	-0.38	8.45e-24	Blood metabolite levels;
BRCA	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.43	12.7	0.45	4.07e-33	Response to antipsychotic treatment;
BRCA	cis	rs2795502	0.630	rs4948698	chr10:43539459	A/G	cg08461752	chr10:43522343	NA	0.5	9.57	0.35	2.3e-20	Blood protein levels;
BRCA	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg16325326	chr1:53192061	ZYG11B	0.8	22.04	0.66	1.62e-80	Monocyte count;
BRCA	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.61	-12.75	-0.45	2.45e-33	Lymphocyte counts;
BRCA	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg23601416	chr22:19950040	COMT	0.34	11.08	0.4	3.14e-26	Blood metabolite levels;
BRCA	cis	rs708547	0.647	rs4864609	chr4:57878141	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.38	9.82	0.36	2.67e-21	Response to bleomycin (chromatid breaks);
BRCA	cis	rs3125734	0.572	rs3864794	chr10:64041956	A/C	cg09941381	chr10:64027924	RTKN2	-0.28	-7.94	-0.3	8.89e-15	Rheumatoid arthritis;
BRCA	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.06	15.87	0.53	4.42e-48	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.02	18.08	0.58	2.69e-59	Gut microbiome composition (summer);
BRCA	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg26384229	chr12:38710491	ALG10B	0.66	15.45	0.52	5.71e-46	Bladder cancer;
BRCA	cis	rs9790314	0.812	rs2004862	chr3:161135638	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-11.14	-0.4	1.8e-26	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg24829409	chr8:58192753	C8orf71	-0.47	-9.11	-0.34	1.01e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg06636001	chr8:8085503	FLJ10661	0.56	11.07	0.4	3.47e-26	Neuroticism;
BRCA	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg26384229	chr12:38710491	ALG10B	0.7	15.94	0.53	1.97e-48	Bladder cancer;
BRCA	cis	rs6973256	0.828	rs10247014	chr7:133431038	A/C	cg07491979	chr7:133331646	EXOC4	0.39	8.56	0.32	8.73e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs4730250	0.707	rs257375	chr7:106799043	A/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.41	-0.32	2.7e-16	Osteoarthritis;
BRCA	trans	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg21659725	chr3:3221576	CRBN	-0.46	-9.91	-0.36	1.27e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg18252515	chr7:66147081	NA	1.06	16.03	0.54	7.81e-49	Diabetic kidney disease;
BRCA	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg14675211	chr2:100938903	LONRF2	0.52	11.62	0.42	1.9e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	12.63	0.45	8.71e-33	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.91	0.3	1.16e-14	Endometrial cancer;
BRCA	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg26384229	chr12:38710491	ALG10B	0.42	9.36	0.35	1.34e-19	Morning vs. evening chronotype;
BRCA	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg03264133	chr6:25882463	NA	-0.37	-8.1	-0.31	2.85e-15	Height;
BRCA	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.37	0.35	1.22e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg06521331	chr12:34319734	NA	-0.61	-11.11	-0.4	2.37e-26	Morning vs. evening chronotype;
BRCA	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg14440974	chr22:39074834	NA	0.41	9.26	0.34	3.1e-19	Menopause (age at onset);
BRCA	cis	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.42	-0.32	2.51e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4974559	0.501	rs1250129	chr4:1254930	C/T	cg02980000	chr4:1222292	CTBP1	0.6	10.07	0.37	3.12e-22	Systolic blood pressure;
BRCA	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg02176678	chr2:219576539	TTLL4	0.39	10.43	0.38	1.31e-23	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs507080	0.922	rs546890	chr11:118557198	T/C	cg08498647	chr11:118550644	TREH	-0.38	-8.26	-0.31	8.53e-16	Serum metabolite levels;
BRCA	cis	rs6545883	0.929	rs7561229	chr2:61737990	A/T	cg15711740	chr2:61764176	XPO1	-0.55	-14.14	-0.49	1.12e-39	Tuberculosis;
BRCA	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.59	0.39	2.87e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg21427119	chr20:30132790	HM13	-0.39	-8.27	-0.31	7.68e-16	Monocyte count;
BRCA	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg25358565	chr5:93447407	FAM172A	1.21	18.4	0.59	5.64e-61	Diabetic retinopathy;
BRCA	cis	rs12367572	0.620	rs1857925	chr12:45344385	T/C	cg04608330	chr12:45269318	NELL2	-0.41	-8.53	-0.32	1.06e-16	Gut microbiome composition (summer);
BRCA	cis	rs9400271	0.632	rs9372205	chr6:109588401	A/T	cg01475377	chr6:109611718	NA	-0.44	-10.4	-0.38	1.59e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs12464559	0.522	rs4316939	chr2:152525120	C/T	cg01189475	chr2:152685088	ARL5A	-0.52	-8.0	-0.3	5.81e-15	Response to cognitive-behavioural therapy in anxiety disorder;
BRCA	cis	rs4285028	0.948	rs12637351	chr3:121694412	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.62	0.39	2.33e-24	Multiple sclerosis;
BRCA	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg10645314	chr2:3704589	ALLC	0.43	8.33	0.31	5.04e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg03585969	chr10:35415529	CREM	0.56	11.37	0.41	2.03e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg26031613	chr14:104095156	KLC1	-0.6	-12.71	-0.45	3.69e-33	Body mass index;
BRCA	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.66	-0.32	3.95e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg06784218	chr1:46089804	CCDC17	0.45	10.84	0.39	2.92e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11249608	0.789	rs1969025	chr5:178425192	A/G	cg21905437	chr5:178450457	ZNF879	0.4	8.4	0.32	2.99e-16	Pubertal anthropometrics;
BRCA	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11890956	chr21:40555474	PSMG1	0.85	22.01	0.66	2.45e-80	Cognitive function;
BRCA	cis	rs858239	0.509	rs6975524	chr7:23186452	T/C	cg23682824	chr7:23144976	KLHL7	0.41	10.64	0.39	1.8e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs250677	0.559	rs17109198	chr5:148369712	C/T	cg12140854	chr5:148520817	ABLIM3	-0.41	-8.19	-0.31	1.38e-15	Breast cancer;
BRCA	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg00701064	chr4:6280414	WFS1	0.71	19.54	0.61	5.18e-67	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg12935359	chr14:103987150	CKB	-0.46	-10.38	-0.38	1.96e-23	Body mass index;
BRCA	cis	rs6598955	0.543	rs57564009	chr1:26557618	A/T	cg04990556	chr1:26633338	UBXN11	0.7	11.87	0.42	1.69e-29	Obesity-related traits;
BRCA	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03517284	chr6:25882590	NA	0.46	10.51	0.38	6.27e-24	Blood metabolite levels;
BRCA	cis	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg20368463	chr18:77673604	PQLC1	-0.36	-9.15	-0.34	7.8e-19	Schizophrenia;
BRCA	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.4	-8.6	-0.32	5.94e-17	Longevity;Endometriosis;
BRCA	cis	rs11997175	0.583	rs67830367	chr8:33833788	G/C	ch.8.33884649F	chr8:33765107	NA	0.35	7.89	0.3	1.29e-14	Body mass index;
BRCA	cis	rs925228	0.504	rs7568272	chr2:24313785	T/C	cg20701182	chr2:24300061	SF3B14	-0.52	-8.49	-0.32	1.49e-16	Reticulocyte fraction of red cells;Reticulocyte count;
BRCA	cis	rs3125734	0.653	rs1007976	chr10:63970144	C/T	cg09941381	chr10:64027924	RTKN2	0.29	8.57	0.32	7.83e-17	Rheumatoid arthritis;
BRCA	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg11584989	chr19:19387371	SF4	0.65	14.16	0.49	8.89e-40	Bipolar disorder;
BRCA	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg12483005	chr1:23474871	LUZP1	0.37	8.01	0.3	5.33e-15	Height;
BRCA	cis	rs12618769	0.597	rs55978998	chr2:99049014	A/G	cg10123293	chr2:99228465	UNC50	0.41	8.21	0.31	1.24e-15	Bipolar disorder;
BRCA	cis	rs2710642	0.777	rs2539987	chr2:63142864	A/G	cg17519650	chr2:63277830	OTX1	0.37	8.13	0.31	2.2e-15	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg17691542	chr6:26056736	HIST1H1C	0.53	11.14	0.4	1.79e-26	Height;
BRCA	cis	rs4566357	0.615	rs6436644	chr2:227914275	T/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.36	-0.35	1.32e-19	Coronary artery disease;
BRCA	cis	rs7246657	0.722	rs8100646	chr19:38107943	T/C	cg14683738	chr19:37701593	ZNF585B	0.47	8.18	0.31	1.53e-15	Coronary artery calcification;
BRCA	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.43	-0.35	7.61e-20	Alzheimer's disease;
BRCA	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg04733989	chr22:42467013	NAGA	-0.37	-8.22	-0.31	1.15e-15	Cognitive function;
BRCA	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	11.14	0.4	1.81e-26	Monocyte percentage of white cells;
BRCA	cis	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.36	-0.41	2.3e-27	Morning vs. evening chronotype;
BRCA	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg06115741	chr20:33292138	TP53INP2	0.39	8.71	0.33	2.5e-17	Coronary artery disease;
BRCA	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.49	10.87	0.4	2.24e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-11.94	-0.43	7.99e-30	Gut microbiome composition (summer);
BRCA	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11764359	chr7:65958608	NA	0.79	18.45	0.59	3.04e-61	Aortic root size;
BRCA	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg24110177	chr3:50126178	RBM5	-0.44	-9.79	-0.36	3.61e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.87	-0.3	1.53e-14	Corneal astigmatism;
BRCA	trans	rs208520	0.690	rs207112	chr6:66792092	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.23	-0.64	4.44e-76	Exhaled nitric oxide output;
BRCA	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-12.91	-0.45	4.95e-34	Schizophrenia;
BRCA	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	8.76	0.33	1.79e-17	Iron status biomarkers;
BRCA	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.48	-10.07	-0.37	3.06e-22	Longevity;Endometriosis;
BRCA	cis	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg21775007	chr8:11205619	TDH	-0.39	-7.82	-0.3	2.19e-14	Triglycerides;
BRCA	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	22.95	0.67	1.88e-85	Platelet count;
BRCA	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg03146154	chr1:46216737	IPP	0.46	10.32	0.38	3.49e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg06640241	chr16:89574553	SPG7	-0.53	-10.98	-0.4	8.24e-26	Multiple myeloma (IgH translocation);
BRCA	cis	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.14	-0.4	1.81e-26	Morning vs. evening chronotype;
BRCA	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg22455342	chr2:225449267	CUL3	0.33	8.87	0.33	7.14e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11764359	chr7:65958608	NA	-0.76	-17.41	-0.57	7.52e-56	Aortic root size;
BRCA	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg11062466	chr8:58055876	NA	0.57	9.5	0.35	4.18e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg06671706	chr8:8559999	CLDN23	0.45	8.63	0.32	4.86e-17	Obesity-related traits;
BRCA	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg12011299	chr4:100065546	ADH4	0.48	10.87	0.4	2.26e-25	Smoking initiation;
BRCA	cis	rs939658	0.935	rs12903747	chr15:79449627	A/C	cg17916960	chr15:79447300	NA	0.39	9.84	0.36	2.23e-21	Refractive error;
BRCA	cis	rs9790314	0.715	rs898681	chr3:160773098	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-9.01	-0.34	2.32e-18	Morning vs. evening chronotype;
BRCA	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg01939980	chr4:1354348	KIAA1530	0.38	9.1	0.34	1.1e-18	Obesity-related traits;
BRCA	trans	rs526821	0.595	rs4938937	chr11:55305507	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-8.21	-0.31	1.26e-15	Pediatric bone mineral density (spine);
BRCA	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg08601574	chr20:25228251	PYGB	0.37	8.89	0.33	6.14e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11229555	0.645	rs11229457	chr11:58207203	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	17.15	0.56	1.62e-54	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08045932	chr20:61659980	NA	0.49	11.21	0.41	9.2e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs35000415	0.515	rs13240595	chr7:128731777	C/A	cg02365945	chr7:128766374	LOC407835	-0.5	-7.87	-0.3	1.55e-14	Systemic lupus erythematosus;
BRCA	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg15934090	chr1:100435551	SLC35A3	0.35	8.15	0.31	1.91e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg02176678	chr2:219576539	TTLL4	-0.46	-12.46	-0.44	4.79e-32	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg16576597	chr16:28551801	NUPR1	0.28	7.9	0.3	1.26e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg07828340	chr4:882639	GAK	0.83	10.03	0.37	4.31e-22	Parkinson's disease;
BRCA	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg04455712	chr21:45112962	RRP1B	0.44	11.96	0.43	6.83e-30	Mean corpuscular volume;
BRCA	cis	rs9815354	0.680	rs73073250	chr3:42016559	G/T	cg03022575	chr3:42003672	ULK4	0.75	9.65	0.36	1.17e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg22907277	chr7:1156413	C7orf50	0.62	10.73	0.39	8.53e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9287719	0.578	rs13425171	chr2:10731966	C/G	cg00105475	chr2:10696890	NA	0.47	10.54	0.38	4.68e-24	Prostate cancer;
BRCA	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.6	0.39	2.68e-24	Motion sickness;
BRCA	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19748678	chr4:122722346	EXOSC9	0.72	15.64	0.53	6.4e-47	Type 2 diabetes;
BRCA	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg07169764	chr2:136633963	MCM6	1.07	21.61	0.65	3.66e-78	Corneal structure;
BRCA	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.66e-15	Menopause (age at onset);
BRCA	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg05985134	chr18:33552581	C18orf21	0.67	12.8	0.45	1.42e-33	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg25358565	chr5:93447407	FAM172A	1.2	18.59	0.59	5.22e-62	Diabetic retinopathy;
BRCA	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg25809561	chr17:30822961	MYO1D	0.4	9.52	0.35	3.4e-20	Schizophrenia;
BRCA	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg02951883	chr7:2050386	MAD1L1	-0.38	-9.19	-0.34	5.5e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg14558114	chr2:88469736	THNSL2	0.6	8.89	0.33	6.31e-18	Plasma clusterin levels;
BRCA	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg13047869	chr3:10149882	C3orf24	0.6	12.81	0.45	1.29e-33	Alzheimer's disease;
BRCA	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg07636037	chr3:49044803	WDR6	0.56	9.16	0.34	7.19e-19	Menarche (age at onset);
BRCA	trans	rs208520	0.661	rs704519	chr6:66801136	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-20.96	-0.64	1.29e-74	Exhaled nitric oxide output;
BRCA	cis	rs3760982	0.585	rs11083724	chr19:44298988	A/G	cg11993925	chr19:44307056	LYPD5	0.38	8.98	0.33	3e-18	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-9.46	-0.35	5.62e-20	Mean corpuscular volume;
BRCA	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg01874867	chr7:94954059	PON1	-0.39	-8.07	-0.3	3.4e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg20701182	chr2:24300061	SF3B14	0.58	9.0	0.34	2.58e-18	Lymphocyte counts;
BRCA	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg24296786	chr1:45957014	TESK2	-0.56	-12.68	-0.45	5.03e-33	High light scatter reticulocyte count;
BRCA	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg25342872	chr17:79175132	AZI1	-0.38	-9.26	-0.34	3.18e-19	Frontotemporal dementia;
BRCA	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg03354898	chr7:1950403	MAD1L1	0.4	8.96	0.33	3.57e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg06627628	chr2:24431161	ITSN2	-0.78	-14.67	-0.5	3.27e-42	Asthma;
BRCA	cis	rs739496	0.542	rs7316698	chr12:111790511	C/T	cg10833066	chr12:111807467	FAM109A	0.35	8.1	0.31	2.77e-15	Platelet count;
BRCA	cis	rs7301016	0.846	rs7302094	chr12:62967430	C/T	cg01804193	chr12:63026212	NA	0.47	8.56	0.32	8.12e-17	IgG glycosylation;
BRCA	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.32	-0.31	5.19e-16	Axial length;
BRCA	cis	rs2274273	0.901	rs8011288	chr14:55735112	C/T	cg04306507	chr14:55594613	LGALS3	0.29	8.08	0.3	3.29e-15	Protein biomarker;
BRCA	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg22920501	chr2:26401640	FAM59B	-0.66	-11.51	-0.41	5.23e-28	Gut microbiome composition (summer);
BRCA	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg11993925	chr19:44307056	LYPD5	0.37	8.76	0.33	1.79e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg03477792	chr4:77819574	ANKRD56	0.66	15.57	0.52	1.47e-46	Emphysema distribution in smoking;
BRCA	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	6.95e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg19920283	chr7:105172520	RINT1	0.59	9.53	0.35	3.29e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	12.31	0.44	2.07e-31	Lung cancer in ever smokers;
BRCA	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	17.72	0.57	1.83e-57	Electrocardiographic conduction measures;
BRCA	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-9.52	-0.35	3.4e-20	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg03433033	chr1:76189801	ACADM	0.69	13.86	0.48	2.27e-38	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-11.12	-0.4	2.2e-26	Schizophrenia;
BRCA	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg04553112	chr3:125709451	NA	-0.59	-9.23	-0.34	3.86e-19	Blood pressure (smoking interaction);
BRCA	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg14784868	chr12:69753453	YEATS4	0.68	19.81	0.62	1.79e-68	Blood protein levels;
BRCA	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.41	0.59	4.72e-61	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg17366294	chr4:99064904	C4orf37	0.41	9.64	0.36	1.23e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3862030	0.694	rs2025712	chr10:104230064	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.14	-0.43	1.12e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg08213375	chr14:104286397	PPP1R13B	0.52	11.47	0.41	7.91e-28	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg26384229	chr12:38710491	ALG10B	0.72	16.05	0.54	5.93e-49	Morning vs. evening chronotype;
BRCA	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg24562669	chr7:97807699	LMTK2	0.44	11.7	0.42	8.61e-29	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs11976180	1.000	rs2371244	chr7:143757611	A/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.44	-8.09	-0.3	2.97e-15	Obesity-related traits;
BRCA	cis	rs367943	0.608	rs4705463	chr5:112980273	C/G	cg12552261	chr5:112820674	MCC	0.37	8.03	0.3	4.77e-15	Type 2 diabetes;
BRCA	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg06238570	chr21:40685208	BRWD1	0.43	8.78	0.33	1.51e-17	Cognitive function;
BRCA	cis	rs28735056	1.000	rs28865701	chr18:77620911	A/G	cg03682112	chr18:77623598	KCNG2	-0.37	-8.62	-0.32	5.3e-17	Schizophrenia;
BRCA	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg17143192	chr8:8559678	CLDN23	0.55	10.48	0.38	8.13e-24	Obesity-related traits;
BRCA	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg03213289	chr20:61660250	NA	0.63	16.54	0.55	2.05e-51	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07080220	chr10:102295463	HIF1AN	0.49	11.34	0.41	2.78e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2742234	0.590	rs2503864	chr10:43666767	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.54	-10.93	-0.4	1.28e-25	Hirschsprung disease;
BRCA	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg22633769	chr20:60982531	CABLES2	0.44	7.94	0.3	8.85e-15	Colorectal cancer;
BRCA	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg25358565	chr5:93447407	FAM172A	1.21	19.0	0.6	3.95e-64	Diabetic retinopathy;
BRCA	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg21798802	chr22:38057573	PDXP	0.49	13.18	0.46	2.91e-35	Fat distribution (HIV);
BRCA	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg13319975	chr6:146136371	FBXO30	-0.37	-8.44	-0.32	2.09e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg24558204	chr6:135376177	HBS1L	0.47	12.8	0.45	1.49e-33	Red blood cell count;
BRCA	cis	rs4713675	0.565	rs942640	chr6:33686442	G/T	cg14003231	chr6:33640908	ITPR3	0.35	8.7	0.33	2.91e-17	Plateletcrit;
BRCA	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg03585969	chr10:35415529	CREM	0.5	10.46	0.38	9.76e-24	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs3960554	0.808	rs111764601	chr7:75706141	T/C	cg19862616	chr7:65841803	NCRNA00174	0.61	12.5	0.44	3.23e-32	Eotaxin levels;
BRCA	cis	rs10129255	0.536	rs6576223	chr14:107184687	C/T	cg07958169	chr14:107095056	NA	-0.39	-8.41	-0.32	2.66e-16	Kawasaki disease;
BRCA	cis	rs4642101	0.561	rs9812144	chr3:12805910	G/A	cg24848339	chr3:12840334	CAND2	0.38	9.25	0.34	3.44e-19	QRS complex (12-leadsum);
BRCA	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg00105475	chr2:10696890	NA	-0.38	-8.75	-0.33	1.89e-17	Prostate cancer;
BRCA	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-10.46	-0.38	1e-23	Longevity;Endometriosis;
BRCA	cis	rs4853036	0.951	rs10165061	chr2:70146363	C/T	cg02498382	chr2:70120550	SNRNP27	-0.51	-10.07	-0.37	3.17e-22	Colorectal or endometrial cancer;
BRCA	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19346786	chr7:2764209	NA	-0.31	-8.92	-0.33	4.73e-18	Height;
BRCA	cis	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg19338460	chr6:170058176	WDR27	-0.74	-9.66	-0.36	1.08e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs7715806	0.500	rs17563700	chr5:74986045	A/G	cg19683494	chr5:74908142	NA	0.52	8.46	0.32	1.87e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg15839431	chr19:19639596	YJEFN3	-0.4	-8.83	-0.33	1.02e-17	Bipolar disorder;
BRCA	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg16482183	chr6:26056742	HIST1H1C	0.37	7.82	0.3	2.23e-14	Height;
BRCA	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg21475434	chr5:93447410	FAM172A	0.67	8.73	0.33	2.21e-17	Diabetic retinopathy;
BRCA	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg27170947	chr2:26402098	FAM59B	0.97	17.18	0.56	1.18e-54	Gut microbiome composition (summer);
BRCA	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg18016565	chr1:150552671	MCL1	0.34	8.07	0.3	3.57e-15	Tonsillectomy;
BRCA	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg20587970	chr11:113659929	NA	-1.35	-24.3	-0.69	7.04e-93	Hip circumference adjusted for BMI;
BRCA	cis	rs495337	1.000	rs4810998	chr20:48580010	G/C	cg17835207	chr20:48524531	SPATA2	-0.61	-14.14	-0.49	1.12e-39	Psoriasis;
BRCA	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.63	0.32	4.73e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6430585	0.527	rs62168792	chr2:136415217	A/G	cg07169764	chr2:136633963	MCM6	1.0	19.54	0.61	5.29e-67	Corneal structure;
BRCA	cis	rs897984	0.683	rs729482	chr16:31016970	T/C	cg02466173	chr16:30829666	NA	-0.43	-9.19	-0.34	5.62e-19	Dementia with Lewy bodies;
BRCA	cis	rs4363385	0.720	rs1611764	chr1:152957887	G/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.44	-0.32	2.09e-16	Inflammatory skin disease;
BRCA	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.09	-40.16	-0.85	6.44e-177	Myeloid white cell count;
BRCA	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg13770153	chr20:60521292	NA	-0.44	-9.93	-0.37	1.06e-21	Body mass index;
BRCA	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-11.17	-0.4	1.34e-26	Gut microbiome composition (summer);
BRCA	cis	rs2425143	1.000	rs1118233	chr20:34228349	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.64	-0.32	4.53e-17	Blood protein levels;
BRCA	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg00677455	chr12:58241039	CTDSP2	0.63	14.18	0.49	7.02e-40	Multiple sclerosis;
BRCA	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg02176678	chr2:219576539	TTLL4	0.4	10.88	0.4	2.09e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs3917254	0.543	rs6752379	chr2:102746705	G/A	cg22835712	chr2:102737379	NA	-0.53	-9.33	-0.35	1.65e-19	Blood protein levels;
BRCA	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg08992911	chr2:238395768	MLPH	0.57	9.41	0.35	9e-20	Prostate cancer;
BRCA	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00149659	chr3:10157352	C3orf10	0.8	13.78	0.48	5.12e-38	Alzheimer's disease;
BRCA	cis	rs11229555	0.645	rs10896814	chr11:58430699	T/C	cg15696309	chr11:58395628	NA	-0.43	-8.96	-0.33	3.4e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg04691961	chr3:161091175	C3orf57	-0.38	-8.95	-0.33	3.84e-18	Morning vs. evening chronotype;
BRCA	cis	rs3099143	1.000	rs7174048	chr15:77165416	T/C	cg21673338	chr15:77095150	SCAPER	0.53	9.5	0.35	4.3e-20	Recalcitrant atopic dermatitis;
BRCA	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg10932868	chr11:921992	NA	0.39	9.41	0.35	9.17e-20	Alzheimer's disease (late onset);
BRCA	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-10.48	-0.38	8.33e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs225245	0.817	rs225299	chr17:33922742	T/C	cg19694781	chr19:47549865	TMEM160	-0.32	-7.81	-0.3	2.38e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs700590	0.515	rs62380364	chr5:88107337	C/A	cg22951263	chr5:87985283	NA	-0.35	-8.89	-0.33	6.39e-18	Educational attainment (years of education);
BRCA	cis	rs6496044	0.568	rs1982742	chr15:86068750	A/G	cg10818794	chr15:86012489	AKAP13	-0.29	-8.0	-0.3	5.67e-15	Interstitial lung disease;
BRCA	trans	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg06606381	chr12:133084897	FBRSL1	-0.71	-7.96	-0.3	7.63e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg15605315	chr1:45957053	TESK2	0.47	9.49	0.35	4.47e-20	High light scatter reticulocyte count;
BRCA	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg24642439	chr20:33292090	TP53INP2	0.42	8.87	0.33	7.22e-18	Height;
BRCA	cis	rs7537052	0.669	rs2296263	chr1:36641729	C/T	cg24686825	chr1:36642396	MAP7D1	-0.53	-12.07	-0.43	2.35e-30	Schizophrenia;
BRCA	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg22834771	chr12:69754056	YEATS4	-0.37	-8.9	-0.33	5.66e-18	Blood protein levels;
BRCA	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg00677455	chr12:58241039	CTDSP2	-0.59	-13.03	-0.46	1.38e-34	Multiple sclerosis;
BRCA	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg13047869	chr3:10149882	C3orf24	0.59	12.55	0.44	1.94e-32	Alzheimer's disease;
BRCA	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg13628971	chr7:2884303	GNA12	0.49	9.56	0.35	2.54e-20	Height;
BRCA	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg18132916	chr6:79620363	NA	-0.5	-11.4	-0.41	1.62e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg14863265	chr7:2801509	GNA12	-0.48	-10.46	-0.38	9.32e-24	Height;
BRCA	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg24069376	chr3:38537580	EXOG	0.34	9.28	0.34	2.49e-19	Electrocardiographic conduction measures;
BRCA	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg24399712	chr22:39784796	NA	-0.58	-13.4	-0.47	2.79e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg05714579	chr10:131428358	MGMT	0.5	11.06	0.4	3.8e-26	Response to temozolomide;
BRCA	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg10729496	chr3:10149963	C3orf24	0.49	9.41	0.35	8.99e-20	Alzheimer's disease;
BRCA	trans	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs3767633	0.925	rs10753666	chr1:161861147	C/G	cg09175582	chr1:161736000	ATF6	0.53	8.67	0.32	3.69e-17	IgG glycosylation;
BRCA	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg14036092	chr11:66035641	RAB1B	0.39	10.77	0.39	5.9e-25	Gout;
BRCA	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.68	-0.42	1.08e-28	Gut microbiome composition (summer);
BRCA	trans	rs6479891	1.000	rs7087279	chr10:65291936	T/A	cg14819942	chr15:35414228	NA	-0.32	-8.17	-0.31	1.66e-15	Arthritis (juvenile idiopathic);
BRCA	cis	rs10193935	0.901	rs62142596	chr2:42529339	C/T	cg27598129	chr2:42591480	NA	-0.65	-10.94	-0.4	1.19e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1113500	0.933	rs4590700	chr1:108638344	G/T	cg06207961	chr1:108661230	NA	0.45	11.09	0.4	2.84e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs919433	0.713	rs2045245	chr2:198485341	A/C	cg00792783	chr2:198669748	PLCL1	0.37	8.35	0.31	4.25e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs9790314	0.638	rs62280303	chr3:160647891	G/A	cg03342759	chr3:160939853	NMD3	0.45	8.73	0.33	2.19e-17	Morning vs. evening chronotype;
BRCA	cis	rs1865721	1.000	rs17283454	chr18:73186619	G/A	cg26385618	chr18:73139727	C18orf62	-0.4	-9.16	-0.34	6.89e-19	Intelligence;
BRCA	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg11062466	chr8:58055876	NA	-0.49	-8.48	-0.32	1.53e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs55883249	1.000	rs62119423	chr2:9726601	C/T	cg23886495	chr2:9695866	ADAM17	0.56	7.97	0.3	7.16e-15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
BRCA	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg13770153	chr20:60521292	NA	-0.34	-7.96	-0.3	8.08e-15	Body mass index;
BRCA	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg01939980	chr4:1354348	KIAA1530	0.29	7.97	0.3	7.57e-15	Longevity;
BRCA	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg20283391	chr11:68216788	NA	-0.45	-9.32	-0.35	1.81e-19	Total body bone mineral density;
BRCA	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg26516362	chr5:178986906	RUFY1	-0.43	-12.33	-0.44	1.71e-31	Lung cancer;
BRCA	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg23625390	chr15:77176239	SCAPER	-0.55	-13.15	-0.46	3.96e-35	Blood metabolite levels;
BRCA	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg00321850	chr1:175162397	KIAA0040	-0.42	-11.63	-0.42	1.79e-28	Alcohol dependence;
BRCA	trans	rs1493916	0.748	rs7230463	chr18:31309133	G/C	cg27147174	chr7:100797783	AP1S1	-0.43	-8.84	-0.33	9.26e-18	Life satisfaction;
BRCA	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg17063962	chr7:91808500	NA	0.57	12.51	0.44	2.88e-32	Breast cancer;
BRCA	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg09307838	chr4:120376055	NA	0.63	12.73	0.45	3.08e-33	Corneal astigmatism;
BRCA	trans	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg25214090	chr10:38739885	LOC399744	-0.46	-9.84	-0.36	2.35e-21	Corneal astigmatism;
BRCA	trans	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	16.03	0.54	7.38e-49	Exhaled nitric oxide levels;
BRCA	cis	rs921968	0.565	rs6757772	chr2:219618497	T/G	cg02176678	chr2:219576539	TTLL4	-0.41	-11.07	-0.4	3.65e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.77	12.91	0.45	4.89e-34	Schizophrenia;
BRCA	trans	rs1493916	0.837	rs9945976	chr18:31409314	C/T	cg15819921	chr19:927150	ARID3A	-0.41	-8.07	-0.3	3.37e-15	Life satisfaction;
BRCA	cis	rs4285028	0.747	rs9820511	chr3:121361345	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.69	-13.56	-0.47	5.51e-37	Multiple sclerosis;
BRCA	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg06623918	chr6:96969491	KIAA0776	0.87	24.33	0.69	5.11e-93	Headache;
BRCA	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg26384229	chr12:38710491	ALG10B	0.59	13.61	0.47	3.04e-37	Morning vs. evening chronotype;
BRCA	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg22491629	chr6:157744540	C6orf35	-0.61	-11.1	-0.4	2.56e-26	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg24296786	chr1:45957014	TESK2	-0.46	-10.6	-0.39	2.74e-24	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7395581	0.959	rs7120118	chr11:47286290	T/C	cg25783544	chr11:47291846	MADD	0.42	9.34	0.35	1.61e-19	HDL cholesterol;
BRCA	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg12011299	chr4:100065546	ADH4	0.39	10.27	0.38	5.43e-23	Alcohol dependence;
BRCA	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg16339924	chr4:17578868	LAP3	0.62	15.44	0.52	5.95e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg12386194	chr3:101231763	SENP7	0.67	13.29	0.47	8.98e-36	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg07169764	chr2:136633963	MCM6	0.99	20.24	0.63	9.27e-71	Mosquito bite size;
BRCA	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg27336068	chr10:1336103	ADARB2	-0.29	-7.99	-0.3	6.44e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-9.55	-0.35	2.63e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	13.03	0.46	1.46e-34	Migraine;Coronary artery disease;
BRCA	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg24562669	chr7:97807699	LMTK2	0.45	12.01	0.43	4.11e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg09021430	chr5:549028	NA	-0.67	-15.45	-0.52	5.36e-46	Lung disease severity in cystic fibrosis;
BRCA	cis	rs61990749	0.597	rs12896026	chr14:78244436	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.57	9.27	0.34	2.92e-19	Fibroblast growth factor basic levels;
BRCA	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg18279126	chr7:2041391	MAD1L1	0.37	8.21	0.31	1.22e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs27434	0.583	rs34762	chr5:96153966	A/G	cg16492584	chr5:96139282	ERAP1	-0.51	-12.82	-0.45	1.2e-33	Ankylosing spondylitis;
BRCA	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg23229984	chr5:148520753	ABLIM3	0.36	8.89	0.33	6.37e-18	Breast cancer;
BRCA	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg08999081	chr20:33150536	PIGU	-0.44	-11.91	-0.43	1.09e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg18758796	chr5:131593413	PDLIM4	0.36	9.47	0.35	5.21e-20	Breast cancer;
BRCA	cis	rs9420	0.961	rs12805841	chr11:57443842	G/A	cg19752551	chr11:57585705	CTNND1	-0.51	-12.51	-0.44	2.91e-32	Schizophrenia;
BRCA	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg11663144	chr21:46675770	NA	-0.51	-10.16	-0.37	1.46e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg24642439	chr20:33292090	TP53INP2	0.54	11.73	0.42	6.53e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	10.01	0.37	5.17e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg20587970	chr11:113659929	NA	-1.2	-22.15	-0.66	4.31e-81	Hip circumference adjusted for BMI;
BRCA	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg14844989	chr11:31128820	NA	-0.44	-9.78	-0.36	3.87e-21	Red blood cell count;
BRCA	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.62	10.33	0.38	3.17e-23	Alzheimer's disease;
BRCA	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg18016565	chr1:150552671	MCL1	0.35	8.23	0.31	1.08e-15	Tonsillectomy;
BRCA	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.93	-15.24	-0.52	5.85e-45	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10802521	chr3:52805072	NEK4	-0.34	-9.41	-0.35	8.52e-20	Bipolar disorder;
BRCA	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10802521	chr3:52805072	NEK4	-0.33	-9.13	-0.34	8.81e-19	Bipolar disorder;
BRCA	cis	rs7572733	0.515	rs1401096	chr2:198823828	A/G	cg00792783	chr2:198669748	PLCL1	0.45	9.9	0.36	1.36e-21	Dermatomyositis;
BRCA	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg18357645	chr12:58087776	OS9	0.46	13.45	0.47	1.66e-36	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg04315214	chr1:2043799	PRKCZ	-0.44	-11.91	-0.43	1.16e-29	Height;
BRCA	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.37	-8.45	-0.32	1.91e-16	Longevity;Endometriosis;
BRCA	trans	rs4650994	0.935	rs4652306	chr1:178528206	T/C	cg05059571	chr16:84539110	KIAA1609	-0.41	-9.22	-0.34	4.12e-19	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg01579765	chr21:45077557	HSF2BP	-0.44	-12.0	-0.43	4.63e-30	Mean corpuscular volume;
BRCA	cis	rs4423214	0.798	rs1894100	chr11:71130343	G/T	cg05163923	chr11:71159392	DHCR7	-0.53	-10.34	-0.38	2.79e-23	Vitamin D levels;
BRCA	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg12373951	chr3:133503437	NA	0.45	10.43	0.38	1.27e-23	Iron status biomarkers;
BRCA	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	19.79	0.62	2.41e-68	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-13.73	-0.48	8.62e-38	Migraine;Coronary artery disease;
BRCA	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00149659	chr3:10157352	C3orf10	0.71	12.33	0.44	1.69e-31	Alzheimer's disease;
BRCA	cis	rs829883	0.664	rs1096148	chr12:98851005	A/G	cg25150519	chr12:98850993	NA	0.68	16.4	0.54	1.01e-50	Colorectal adenoma (advanced);
BRCA	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2120243	0.874	rs2316709	chr3:157150247	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	9.51	0.35	3.96e-20	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg22535103	chr8:58192502	C8orf71	-0.49	-8.6	-0.32	5.95e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg02527881	chr3:46936655	PTH1R	0.4	10.22	0.37	8.23e-23	Birth weight;
BRCA	cis	rs35110281	0.600	rs914198	chr21:45117456	A/C	cg04455712	chr21:45112962	RRP1B	0.43	11.25	0.41	6.33e-27	Mean corpuscular volume;
BRCA	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.45	0.41	9.34e-28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs67981189	0.593	rs2810101	chr14:71429827	G/C	cg15816911	chr14:71606274	NA	-0.36	-8.25	-0.31	8.79e-16	Schizophrenia;
BRCA	cis	rs13082711	0.522	rs640065	chr3:27363937	A/T	cg02860705	chr3:27208620	NA	0.39	7.92	0.3	1.05e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	9.91	0.37	1.21e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7677751	0.806	rs4864862	chr4:55100489	G/A	cg17187183	chr4:55093834	PDGFRA	0.43	8.84	0.33	9.59e-18	Corneal astigmatism;
BRCA	cis	rs16958440	0.867	rs80064497	chr18:44669653	A/G	cg17192377	chr18:44677553	HDHD2	0.99	13.87	0.48	1.94e-38	Sitting height ratio;
BRCA	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg24549020	chr5:56110836	MAP3K1	0.39	8.18	0.31	1.54e-15	Coronary artery disease;
BRCA	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg19717773	chr7:2847554	GNA12	0.41	9.23	0.34	3.88e-19	Height;
BRCA	trans	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg15704280	chr7:45808275	SEPT13	-0.84	-20.44	-0.63	7.5e-72	Height;
BRCA	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg27279351	chr12:120934652	DYNLL1	0.56	13.4	0.47	3.06e-36	High light scatter reticulocyte count;
BRCA	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.56	12.27	0.44	3.24e-31	Chronic sinus infection;
BRCA	cis	rs9790314	0.663	rs9811594	chr3:160745935	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-9.09	-0.34	1.22e-18	Morning vs. evening chronotype;
BRCA	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg16473166	chr22:50639996	SELO	0.52	11.72	0.42	7.26e-29	Obesity-related traits;
BRCA	cis	rs300703	0.542	rs300691	chr2:180171	C/A	cg21211680	chr2:198530	NA	-0.37	-8.18	-0.31	1.59e-15	Blood protein levels;
BRCA	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.56	8.71	0.33	2.65e-17	HIV-1 control;
BRCA	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg18811423	chr2:55921094	PNPT1	0.75	25.14	0.71	1.71e-97	Metabolic syndrome;
BRCA	cis	rs66731853	0.769	rs530104	chr1:20895721	A/G	cg04087271	chr1:20915334	CDA	-0.47	-9.43	-0.35	7.72e-20	Mean corpuscular volume;
BRCA	cis	rs11051970	0.636	rs1128591	chr12:32569351	T/C	cg02745156	chr12:32552066	NA	0.25	8.38	0.31	3.42e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg09307838	chr4:120376055	NA	0.75	16.2	0.54	1.03e-49	Corneal astigmatism;
BRCA	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg23018236	chr17:30244563	NA	-0.58	-9.59	-0.35	1.96e-20	Hip circumference adjusted for BMI;
BRCA	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg25767906	chr1:53392781	SCP2	-0.39	-8.92	-0.33	4.93e-18	Monocyte count;
BRCA	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg22467129	chr15:76604101	ETFA	-0.47	-10.57	-0.39	3.6e-24	Blood metabolite levels;
BRCA	cis	rs1511802	0.666	rs4862662	chr4:187118662	A/C	cg24794857	chr4:187113578	CYP4V2	-0.36	-7.92	-0.3	1.03e-14	Blood protein levels;
BRCA	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg04705435	chr11:17411270	KCNJ11	0.43	9.33	0.35	1.66e-19	Type 2 diabetes;
BRCA	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg21045802	chr8:109455806	TTC35	0.36	8.11	0.31	2.65e-15	Dupuytren's disease;
BRCA	cis	rs13102973	0.863	rs11099307	chr4:135908104	T/C	cg14419869	chr4:135874104	NA	0.45	9.0	0.34	2.46e-18	Subjective well-being;
BRCA	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg06697600	chr4:7070879	GRPEL1	-0.55	-10.99	-0.4	7.36e-26	Monocyte percentage of white cells;
BRCA	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg13628971	chr7:2884303	GNA12	0.57	11.99	0.43	5.13e-30	Height;
BRCA	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg13397359	chr6:42928475	GNMT	0.75	19.37	0.61	3.96e-66	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg02951883	chr7:2050386	MAD1L1	0.39	8.11	0.31	2.62e-15	Neuroticism;
BRCA	cis	rs11229555	0.645	rs12803648	chr11:58177561	G/T	cg15696309	chr11:58395628	NA	-0.45	-9.68	-0.36	9.19e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg07741184	chr6:167504864	NA	0.33	9.87	0.36	1.8e-21	Primary biliary cholangitis;
BRCA	cis	rs2108225	0.934	rs2283045	chr7:107440714	G/A	cg18560240	chr7:107437656	SLC26A3	-0.55	-11.58	-0.42	2.84e-28	Ulcerative colitis;
BRCA	cis	rs1420338	0.967	rs10272282	chr7:34172073	C/T	cg01275685	chr7:34179230	BMPER	-0.46	-9.95	-0.37	8.47e-22	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs10465746	0.746	rs12749350	chr1:84456948	T/A	cg10977910	chr1:84465055	TTLL7	0.57	12.01	0.43	4.32e-30	Obesity-related traits;
BRCA	trans	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg16141378	chr3:129829833	LOC729375	0.31	8.08	0.3	3.16e-15	Mood instability;
BRCA	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg26031613	chr14:104095156	KLC1	-0.45	-8.84	-0.33	9.49e-18	Schizophrenia;
BRCA	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15506890	chr2:3487001	NA	-0.53	-11.75	-0.42	5.53e-29	Neurofibrillary tangles;
BRCA	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	11.19	0.4	1.15e-26	Rheumatoid arthritis;
BRCA	cis	rs751728	0.689	rs3763257	chr6:33773696	T/A	cg25922239	chr6:33757077	LEMD2	0.52	11.64	0.42	1.52e-28	Crohn's disease;
BRCA	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg18252515	chr7:66147081	NA	-0.53	-10.92	-0.4	1.37e-25	Corneal structure;
BRCA	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.61	-13.96	-0.48	7.68e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1018836	0.923	rs10956749	chr8:91621573	G/A	cg16814680	chr8:91681699	NA	-0.6	-12.8	-0.45	1.46e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg10223061	chr2:219282414	VIL1	0.3	8.57	0.32	7.87e-17	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg03146154	chr1:46216737	IPP	0.54	12.0	0.43	4.61e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg27588902	chr6:42928151	GNMT	-0.3	-10.04	-0.37	4.18e-22	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg17691542	chr6:26056736	HIST1H1C	0.49	10.41	0.38	1.51e-23	Height;
BRCA	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg22800045	chr5:56110881	MAP3K1	0.62	11.73	0.42	6.59e-29	Initial pursuit acceleration;
BRCA	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg01689657	chr7:91764605	CYP51A1	0.23	7.81	0.3	2.36e-14	Breast cancer;
BRCA	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-21.07	-0.64	2.96e-75	Gut microbiome composition (summer);
BRCA	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg12432903	chr7:1882776	MAD1L1	0.45	8.03	0.3	4.55e-15	Bipolar disorder;
BRCA	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	14.03	0.49	3.44e-39	Lymphocyte counts;
BRCA	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.37	-8.83	-0.33	1e-17	Tonsillectomy;
BRCA	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg14558114	chr2:88469736	THNSL2	-0.41	-8.97	-0.33	3.25e-18	Response to metformin (IC50);
BRCA	cis	rs311392	1.000	rs454064	chr8:55088336	C/T	cg11783602	chr8:55087084	NA	-0.33	-9.59	-0.35	1.94e-20	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs7572733	0.534	rs13026569	chr2:198783330	C/G	cg00792783	chr2:198669748	PLCL1	-0.46	-9.98	-0.37	7.05e-22	Dermatomyositis;
BRCA	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg24324837	chr19:49891574	CCDC155	0.57	10.38	0.38	1.9e-23	Multiple sclerosis;
BRCA	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.53	-11.93	-0.43	9.31e-30	Personality dimensions;
BRCA	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-11.59	-0.42	2.42e-28	Gut microbiome composition (summer);
BRCA	cis	rs11955398	0.716	rs12515025	chr5:59999437	G/A	cg02684056	chr5:59996105	DEPDC1B	0.39	9.35	0.35	1.42e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs4423214	0.879	rs1792284	chr11:71134966	A/G	cg05163923	chr11:71159392	DHCR7	0.55	10.91	0.4	1.6e-25	Vitamin D levels;
BRCA	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg25801113	chr15:45476975	SHF	-0.33	-8.31	-0.31	5.63e-16	Uric acid levels;
BRCA	cis	rs1568889	1.000	rs34337978	chr11:28136746	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	13.49	0.47	1.18e-36	Bipolar disorder;
BRCA	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg21535247	chr6:8435926	SLC35B3	0.42	9.64	0.36	1.22e-20	Motion sickness;
BRCA	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs12618769	0.597	rs3769724	chr2:99105981	C/T	cg10123293	chr2:99228465	UNC50	0.42	8.22	0.31	1.18e-15	Bipolar disorder;
BRCA	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg25457927	chr22:38595422	NA	-0.32	-11.87	-0.43	1.63e-29	Cutaneous nevi;
BRCA	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg14196790	chr5:131705035	SLC22A5	-0.38	-10.22	-0.37	8.5e-23	Breast cancer;
BRCA	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg23711669	chr6:146136114	FBXO30	0.63	14.12	0.49	1.38e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4363385	0.747	rs946100	chr1:152971663	C/T	cg21543102	chr1:152974771	SPRR3	0.29	8.19	0.31	1.42e-15	Inflammatory skin disease;
BRCA	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg01483505	chr11:975446	AP2A2	0.3	8.21	0.31	1.18e-15	Alzheimer's disease (late onset);
BRCA	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg11166453	chr1:247681781	NA	0.41	9.3	0.35	2.23e-19	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg22496339	chr2:162101262	NA	0.44	9.04	0.34	1.9e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg05347473	chr6:146136440	FBXO30	0.56	10.79	0.39	4.63e-25	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg06521331	chr12:34319734	NA	-0.63	-11.57	-0.42	2.98e-28	Morning vs. evening chronotype;
BRCA	cis	rs490234	0.775	rs12341245	chr9:128340941	C/T	cg14078157	chr9:128172775	NA	-0.46	-10.5	-0.38	6.48e-24	Mean arterial pressure;
BRCA	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg13010199	chr12:38710504	ALG10B	0.54	11.79	0.42	3.61e-29	Heart rate;
BRCA	cis	rs12760731	0.777	rs6701080	chr1:178382261	A/C	cg00404053	chr1:178313656	RASAL2	0.7	8.36	0.31	3.81e-16	Obesity-related traits;
BRCA	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg15605315	chr1:45957053	TESK2	0.5	10.31	0.38	3.72e-23	High light scatter reticulocyte count;
BRCA	cis	rs17641971	0.862	rs341829	chr8:50005758	T/C	cg00325661	chr8:49890786	NA	-0.29	-7.83	-0.3	2.06e-14	Blood metabolite levels;
BRCA	cis	rs1975974	0.872	rs66502681	chr17:21722119	T/A	cg18423549	chr17:21743878	NA	-0.53	-11.27	-0.41	5.49e-27	Psoriasis;
BRCA	cis	rs61935443	0.614	rs11107787	chr12:95311669	C/T	cg21533806	chr12:95267307	NA	0.46	8.17	0.31	1.65e-15	Schizophrenia;
BRCA	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10802521	chr3:52805072	NEK4	-0.34	-9.16	-0.34	7e-19	Bipolar disorder;
BRCA	cis	rs11920090	0.858	rs10513688	chr3:170727218	G/A	cg09710316	chr3:170744871	SLC2A2	0.52	8.97	0.33	3.39e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs2625529	0.824	rs2306488	chr15:72292115	A/G	cg16672083	chr15:72433130	SENP8	-0.86	-17.68	-0.57	3.02e-57	Red blood cell count;
BRCA	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	11.82	0.42	2.77e-29	Hip circumference adjusted for BMI;
BRCA	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg13175981	chr1:150552382	MCL1	0.48	10.62	0.39	2.16e-24	Tonsillectomy;
BRCA	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg04398451	chr17:18023971	MYO15A	-0.52	-11.34	-0.41	2.69e-27	Total body bone mineral density;
BRCA	cis	rs6987853	0.787	rs12677427	chr8:42414226	T/A	cg09913449	chr8:42400586	C8orf40	0.42	9.38	0.35	1.11e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs13046373	0.535	rs2832964	chr21:32014012	A/C	cg22337977	chr21:31811175	KRTAP15-1	0.33	7.83	0.3	2e-14	HDL cholesterol;
BRCA	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	13.2	0.46	2.36e-35	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg03146154	chr1:46216737	IPP	0.45	9.95	0.37	8.9e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6973256	0.897	rs10954422	chr7:133327587	G/A	cg07491979	chr7:133331646	EXOC4	-0.39	-8.84	-0.33	9.14e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.41	-9.04	-0.34	1.91e-18	Longevity;Endometriosis;
BRCA	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg05535760	chr7:792225	HEATR2	0.7	12.34	0.44	1.65e-31	Cerebrospinal P-tau181p levels;
BRCA	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg15103426	chr22:29168792	CCDC117	-0.51	-11.95	-0.43	7.84e-30	Lymphocyte counts;
BRCA	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg24130564	chr14:104152367	KLC1	-0.36	-8.2	-0.31	1.33e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6815814	0.861	rs10034903	chr4:38784678	C/G	cg06935464	chr4:38784597	TLR10	0.48	9.52	0.35	3.58e-20	Breast cancer;
BRCA	cis	rs6005807	0.719	rs73430168	chr22:28985428	C/T	cg12565055	chr22:29076175	TTC28	0.51	9.49	0.35	4.32e-20	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs2710642	0.962	rs1828398	chr2:63034870	A/G	cg17519650	chr2:63277830	OTX1	-0.38	-8.4	-0.32	2.91e-16	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg26597838	chr10:835615	NA	-0.99	-15.4	-0.52	9.31e-46	Eosinophil percentage of granulocytes;
BRCA	cis	rs870825	0.655	rs7675046	chr4:185652201	G/A	cg04058563	chr4:185651563	MLF1IP	-0.73	-15.84	-0.53	6.2e-48	Blood protein levels;
BRCA	cis	rs9816226	0.618	rs1516728	chr3:185829891	A/T	cg00760338	chr3:185826511	ETV5	0.56	12.28	0.44	2.8e-31	Obesity;Body mass index;
BRCA	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg13010199	chr12:38710504	ALG10B	-0.39	-8.83	-0.33	1.04e-17	Morning vs. evening chronotype;
BRCA	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg12193833	chr17:30244370	NA	-0.6	-9.04	-0.34	1.89e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs7586879	0.796	rs916486	chr2:25082629	C/A	cg04586622	chr2:25135609	ADCY3	0.37	8.99	0.34	2.74e-18	Body mass index;
BRCA	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg02176678	chr2:219576539	TTLL4	0.42	11.39	0.41	1.76e-27	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27286337	chr10:134555280	INPP5A	0.67	12.12	0.43	1.43e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs698833	0.892	rs2603257	chr2:44731588	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	10.03	0.37	4.51e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg18904891	chr8:8559673	CLDN23	0.55	10.84	0.39	3.09e-25	Obesity-related traits;
BRCA	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg06115741	chr20:33292138	TP53INP2	-0.49	-11.04	-0.4	4.9e-26	Coronary artery disease;
BRCA	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.57	-0.35	2.31e-20	Total body bone mineral density;
BRCA	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg06766960	chr11:133703094	NA	-0.45	-10.26	-0.38	5.88e-23	Childhood ear infection;
BRCA	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg10253484	chr15:75165896	SCAMP2	-0.49	-9.62	-0.36	1.46e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg20607798	chr8:58055168	NA	0.48	8.43	0.32	2.29e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9487051	0.768	rs351752	chr6:109536034	C/A	cg01475377	chr6:109611718	NA	-0.42	-10.54	-0.38	4.75e-24	Reticulocyte fraction of red cells;
BRCA	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.2	-0.41	1.02e-26	Schizophrenia;
BRCA	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg10523679	chr1:76189770	ACADM	-0.54	-10.06	-0.37	3.44e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg17063962	chr7:91808500	NA	0.5	11.32	0.41	3.27e-27	Breast cancer;
BRCA	cis	rs11229555	0.645	rs1986404	chr11:58194614	T/C	cg15696309	chr11:58395628	NA	-0.52	-10.87	-0.4	2.25e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg17063962	chr7:91808500	NA	0.6	14.47	0.5	2.89e-41	Breast cancer;
BRCA	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg25358565	chr5:93447407	FAM172A	1.19	18.88	0.6	1.53e-63	Diabetic retinopathy;
BRCA	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg26647111	chr11:31128758	NA	-0.45	-9.78	-0.36	3.99e-21	Red blood cell count;
BRCA	cis	rs4891159	0.548	rs2554830	chr18:74127702	A/G	cg24786174	chr18:74118243	ZNF516	0.84	25.79	0.71	4.4e-101	Longevity;
BRCA	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.36	-0.38	2.26e-23	Psoriasis;
BRCA	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.72	0.36	6.31e-21	Menopause (age at onset);
BRCA	cis	rs524281	0.861	rs10896094	chr11:65959206	C/T	cg16950941	chr11:66035639	RAB1B	-0.38	-7.96	-0.3	7.71e-15	Electroencephalogram traits;
BRCA	cis	rs35740288	0.862	rs11637444	chr15:86311188	G/A	cg20737812	chr15:86336631	KLHL25	-0.33	-8.1	-0.31	2.7e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08219700	chr8:58056026	NA	0.54	8.85	0.33	8.66e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg12419862	chr22:24373484	LOC391322	0.64	12.78	0.45	1.77e-33	Urinary 1,3-butadiene metabolite levels in smokers;
BRCA	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg20019365	chr2:219134978	PNKD;AAMP	0.44	9.24	0.34	3.51e-19	Ulcerative colitis;
BRCA	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.95	0.46	3.16e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs11608355	0.545	rs6606721	chr12:109891999	G/A	cg05360138	chr12:110035743	NA	0.71	13.18	0.46	2.85e-35	Neuroticism;
BRCA	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	8.33	0.31	4.96e-16	Schizophrenia;
BRCA	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	13.24	0.46	1.63e-35	Bone mineral density;
BRCA	trans	rs526821	0.595	rs629948	chr11:55356448	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-8.08	-0.3	3.19e-15	Pediatric bone mineral density (spine);
BRCA	cis	rs7246967	0.673	rs3853649	chr19:22880460	C/G	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.26	-0.41	5.68e-27	Morning vs. evening chronotype;
BRCA	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg11764359	chr7:65958608	NA	-0.68	-15.39	-0.52	1.07e-45	Aortic root size;
BRCA	cis	rs4722585	0.533	rs3753097	chr7:26198207	A/G	cg07876897	chr7:26191696	NFE2L3	0.41	8.78	0.33	1.48e-17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
BRCA	cis	rs7903847	0.642	rs7074511	chr10:99140177	G/A	cg20016023	chr10:99160130	RRP12	-0.27	-8.59	-0.32	6.68e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg26608667	chr7:1196370	ZFAND2A	0.38	9.18	0.34	5.92e-19	Longevity;Endometriosis;
BRCA	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg05623727	chr3:50126028	RBM5	0.41	9.7	0.36	7.31e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg25036284	chr2:26402008	FAM59B	0.88	15.06	0.51	4.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg13010199	chr12:38710504	ALG10B	-0.44	-10.29	-0.38	4.39e-23	Heart rate;
BRCA	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-10.14	-0.37	1.67e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg04545296	chr12:48745243	ZNF641	0.25	8.18	0.31	1.52e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg17063962	chr7:91808500	NA	0.53	12.59	0.45	1.21e-32	Breast cancer;
BRCA	cis	rs4302748	0.909	rs1882062	chr7:36188719	C/T	cg24442661	chr7:36192818	EEPD1	0.47	8.59	0.32	6.56e-17	Platelet count;
BRCA	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg02820040	chr2:241836501	C2orf54	-0.53	-10.19	-0.37	1.03e-22	Urinary metabolites;
BRCA	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg11502198	chr6:26597334	ABT1	0.47	9.44	0.35	6.67e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-15.45	-0.52	5.35e-46	Total cholesterol levels;
BRCA	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg20703242	chr1:230279135	GALNT2	0.46	10.22	0.37	8.51e-23	Coronary artery disease;
BRCA	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.75e-16	Menopause (age at onset);
BRCA	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg03934865	chr2:198174659	NA	-0.45	-9.89	-0.36	1.52e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs887829	0.588	rs4663969	chr2:234655313	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.35	-9.33	-0.35	1.73e-19	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.94e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg16576597	chr16:28551801	NUPR1	0.29	8.24	0.31	1e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg21427119	chr20:30132790	HM13	-0.42	-8.85	-0.33	8.22e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs68170813	0.559	rs12538769	chr7:106984288	C/T	cg02696742	chr7:106810147	HBP1	-0.56	-8.92	-0.33	4.72e-18	Coronary artery disease;
BRCA	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg25801113	chr15:45476975	SHF	-0.34	-8.14	-0.31	2.08e-15	Uric acid levels;
BRCA	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg07274523	chr3:49395745	GPX1	0.46	7.88	0.3	1.38e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs7939886	0.920	rs7115395	chr11:55877116	G/A	cg15704280	chr7:45808275	SEPT13	0.61	7.98	0.3	6.74e-15	Myopia (pathological);
BRCA	trans	rs7395662	0.786	rs12791074	chr11:49005023	G/A	cg00717180	chr2:96193071	NA	-0.31	-8.65	-0.32	4.19e-17	HDL cholesterol;
BRCA	trans	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg00953403	chr17:74099816	EXOC7	-0.52	-9.7	-0.36	7.7e-21	Psychosis in Alzheimer's disease;
BRCA	cis	rs1829883	0.798	rs2049313	chr5:98802976	T/G	cg08333243	chr5:99726346	NA	-0.35	-7.82	-0.3	2.24e-14	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.69	0.55	3.69e-52	Colorectal cancer;
BRCA	cis	rs6942756	0.774	rs2694574	chr7:128908963	A/G	cg02491457	chr7:128862824	NA	0.58	12.28	0.44	2.74e-31	White matter hyperintensity burden;
BRCA	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.97	21.57	0.65	6.18e-78	Lymphocyte percentage of white cells;
BRCA	cis	rs1143633	0.530	rs4538207	chr2:113701863	G/T	cg12858261	chr2:113808755	IL1F8	0.35	7.86	0.3	1.59e-14	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs68170813	0.559	rs7794965	chr7:106826439	A/G	cg02696742	chr7:106810147	HBP1	0.52	8.87	0.33	7.14e-18	Coronary artery disease;
BRCA	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg19920283	chr7:105172520	RINT1	0.59	9.54	0.35	2.83e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs13064411	0.696	rs7619913	chr3:113017503	A/G	cg18753928	chr3:113234510	CCDC52	-0.45	-8.35	-0.31	4.19e-16	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg27478167	chr7:817139	HEATR2	0.5	9.71	0.36	7.05e-21	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg09877947	chr5:131593287	PDLIM4	0.36	7.84	0.3	1.91e-14	Breast cancer;
BRCA	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-18.04	-0.58	4.35e-59	Morning vs. evening chronotype;
BRCA	cis	rs3857067	0.772	rs4438731	chr4:95091384	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-9.35	-0.35	1.41e-19	QT interval;
BRCA	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg08742575	chr21:47604166	C21orf56	0.41	8.3	0.31	5.98e-16	Testicular germ cell tumor;
BRCA	cis	rs12611088	0.602	rs6509092	chr19:44022305	A/T	cg13740135	chr19:44006432	PHLDB3	-0.3	-7.88	-0.3	1.39e-14	Plasma amyloid beta peptide concentrations (ABx-42);
BRCA	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg11833968	chr6:79620685	NA	-0.44	-9.86	-0.36	2e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08219700	chr8:58056026	NA	0.46	8.3	0.31	6.17e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11890956	chr21:40555474	PSMG1	1.05	30.2	0.77	3.5e-125	Cognitive function;
BRCA	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19346786	chr7:2764209	NA	-0.29	-8.8	-0.33	1.25e-17	Height;
BRCA	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg00750074	chr16:89608354	SPG7	0.3	8.23	0.31	1.06e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs11874712	1.000	rs8088881	chr18:43664970	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.18	0.31	1.57e-15	Migraine - clinic-based;
BRCA	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg10223061	chr2:219282414	VIL1	-0.28	-8.16	-0.31	1.78e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg18132916	chr6:79620363	NA	-0.47	-10.71	-0.39	9.62e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg13852791	chr20:30311386	BCL2L1	-0.75	-12.38	-0.44	1.03e-31	Mean corpuscular hemoglobin;
BRCA	cis	rs733175	0.855	rs6853437	chr4:10005435	A/G	cg00071950	chr4:10020882	SLC2A9	-0.4	-8.46	-0.32	1.79e-16	Psychosis and Alzheimer's disease;
BRCA	cis	rs365132	0.905	rs353463	chr5:176403170	A/C	cg16309518	chr5:176445507	NA	-0.4	-9.78	-0.36	3.77e-21	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs73001065	0.901	rs73004926	chr19:19671266	C/T	cg03709012	chr19:19516395	GATAD2A	0.85	9.47	0.35	5.14e-20	LDL cholesterol;
BRCA	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg14019146	chr3:50243930	SLC38A3	-0.56	-11.43	-0.41	1.2100000000000001e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg23625390	chr15:77176239	SCAPER	0.52	12.79	0.45	1.62e-33	Blood metabolite levels;
BRCA	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.01	0.37	5.33e-22	Bladder cancer;
BRCA	cis	rs4953076	0.573	rs2053456	chr2:44448632	G/A	cg04920474	chr2:44395004	PPM1B	0.5	10.0	0.37	5.77e-22	Height;
BRCA	cis	rs4722166	0.598	rs4722178	chr7:22798650	T/C	cg05472934	chr7:22766657	IL6	0.39	9.65	0.36	1.15e-20	Lung cancer;
BRCA	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg01877450	chr7:97915802	BRI3	0.39	8.71	0.33	2.68e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.76	-19.03	-0.6	2.58e-64	Systemic lupus erythematosus;
BRCA	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg11645453	chr3:52864694	ITIH4	0.47	10.97	0.4	8.77e-26	Schizophrenia;
BRCA	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg18225595	chr11:63971243	STIP1	0.42	10.62	0.39	2.31e-24	Platelet count;
BRCA	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.72	-15.45	-0.52	5.26e-46	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-12.76	-0.45	2.31e-33	Bipolar disorder;
BRCA	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.89	-17.62	-0.57	6.1e-57	Body mass index;
BRCA	cis	rs7523273	0.597	rs11118612	chr1:207979577	T/A	cg22525895	chr1:207977042	MIR29B2	-0.41	-8.57	-0.32	7.67e-17	Schizophrenia;
BRCA	cis	rs10189230	0.967	rs10498113	chr2:222352629	C/T	cg14652038	chr2:222343519	EPHA4	0.46	12.85	0.45	9.04e-34	Urate levels in lean individuals;
BRCA	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg00339695	chr16:24857497	SLC5A11	-0.53	-11.3	-0.41	3.87e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18876405	chr7:65276391	NA	0.55	13.29	0.47	9.4e-36	Aortic root size;
BRCA	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg25036284	chr2:26402008	FAM59B	-0.61	-10.28	-0.38	4.8e-23	Gut microbiome composition (summer);
BRCA	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg09911534	chr15:67153556	NA	-0.5	-10.16	-0.37	1.44e-22	Lung cancer (smoking interaction);
BRCA	cis	rs4363385	0.791	rs3120744	chr1:153010330	G/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.05e-17	Inflammatory skin disease;
BRCA	cis	rs1003719	0.628	rs2835635	chr21:38528866	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.58	-13.72	-0.48	1e-37	Eye color traits;
BRCA	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg24060327	chr5:131705240	SLC22A5	-0.41	-7.84	-0.3	1.84e-14	Acylcarnitine levels;
BRCA	cis	rs1113500	0.814	rs1592282	chr1:108601365	T/C	cg06207961	chr1:108661230	NA	0.34	8.13	0.31	2.27e-15	Growth-regulated protein alpha levels;
BRCA	cis	rs12541635	0.677	rs1429681	chr8:107048808	A/C	cg10147462	chr8:107024639	NA	0.4	10.68	0.39	1.33e-24	Age of smoking initiation;
BRCA	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg14926445	chr8:58193284	C8orf71	-0.46	-8.7	-0.33	2.73e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg18305652	chr10:134549665	INPP5A	0.51	13.27	0.46	1.18e-35	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg21252483	chr19:49399788	TULP2	-0.51	-10.82	-0.39	3.49e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	cg01483505	chr11:975446	AP2A2	0.31	8.41	0.32	2.65e-16	Alzheimer's disease (late onset);
BRCA	cis	rs9487051	0.676	rs9386774	chr6:109561646	C/T	cg21918786	chr6:109611834	NA	-0.32	-8.25	-0.31	9.15e-16	Reticulocyte fraction of red cells;
BRCA	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.45	-8.81	-0.33	1.22e-17	Lung cancer in ever smokers;
BRCA	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg11301795	chr4:187892539	NA	-0.31	-10.26	-0.38	6.01e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22509189	chr2:225307070	NA	0.47	9.94	0.37	9.63e-22	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg05340658	chr4:99064831	C4orf37	0.62	15.07	0.51	3.71e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg21573476	chr21:45109991	RRP1B	-0.41	-10.56	-0.39	3.83e-24	Mean corpuscular volume;
BRCA	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg14675211	chr2:100938903	LONRF2	0.5	11.42	0.41	1.35e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs870825	0.929	rs10027213	chr4:185579871	C/G	cg04058563	chr4:185651563	MLF1IP	0.67	12.07	0.43	2.41e-30	Blood protein levels;
BRCA	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg05863683	chr7:1912471	MAD1L1	0.39	8.05	0.3	4.01e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg00852783	chr1:26633632	UBXN11	-0.46	-8.1	-0.31	2.88e-15	Obesity-related traits;
BRCA	trans	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-10.4	-0.38	1.65e-23	Blood trace element (Cu levels);
BRCA	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.67	-10.86	-0.39	2.42e-25	Alzheimer's disease;
BRCA	cis	rs600806	0.850	rs10858095	chr1:109962642	G/C	cg20591472	chr1:110008990	SYPL2	0.34	8.46	0.32	1.88e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg12863693	chr15:85201151	NMB	-0.36	-8.39	-0.32	3.11e-16	P wave terminal force;
BRCA	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg01262667	chr19:19385393	TM6SF2	0.41	10.75	0.39	6.82e-25	Tonsillectomy;
BRCA	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18876405	chr7:65276391	NA	0.56	13.43	0.47	2.22e-36	Aortic root size;
BRCA	cis	rs6700896	0.931	rs7531867	chr1:66107546	A/G	cg04111102	chr1:66153794	NA	-0.34	-8.53	-0.32	1.03e-16	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg00530320	chr1:46809349	NSUN4	0.47	9.3	0.35	2.21e-19	Menopause (age at onset);
BRCA	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg04362960	chr10:104952993	NT5C2	0.46	10.7	0.39	1.13e-24	Arsenic metabolism;
BRCA	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	19.45	0.61	1.5e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1003719	0.680	rs3992	chr21:38505969	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.19	-0.49	6.29e-40	Eye color traits;
BRCA	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg22875332	chr1:76189707	ACADM	-0.52	-10.14	-0.37	1.6400000000000001e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs3772130	1.000	rs2070180	chr3:121351338	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.52	-9.14	-0.34	8.05e-19	Cognitive performance;
BRCA	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg03433033	chr1:76189801	ACADM	-0.46	-9.6	-0.36	1.71e-20	Daytime sleep phenotypes;
BRCA	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg13736514	chr6:26305472	NA	-0.35	-11.82	-0.42	2.62e-29	Educational attainment;
BRCA	cis	rs1568889	0.838	rs4614434	chr11:28302234	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	19.55	0.61	4.51e-67	Bipolar disorder;
BRCA	cis	rs2066819	1.000	rs41392645	chr12:56696742	A/G	cg26714650	chr12:56694279	CS	-1.18	-15.85	-0.53	5.52e-48	Psoriasis vulgaris;
BRCA	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg24531977	chr5:56204891	C5orf35	-0.45	-9.27	-0.34	2.72e-19	Coronary artery disease;
BRCA	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg15704280	chr7:45808275	SEPT13	-0.53	-10.61	-0.39	2.56e-24	HDL cholesterol;
BRCA	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg21475434	chr5:93447410	FAM172A	0.63	8.4	0.32	2.94e-16	Diabetic retinopathy;
BRCA	cis	rs7975161	0.640	rs10778323	chr12:104746075	A/G	cg25273343	chr12:104657179	TXNRD1	0.48	9.84	0.36	2.24e-21	Toenail selenium levels;
BRCA	cis	rs3820928	0.874	rs1917123	chr2:227889783	T/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.49	-0.32	1.48e-16	Pulmonary function;
BRCA	trans	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg26043149	chr18:55253948	FECH	-0.39	-8.88	-0.33	6.72e-18	Bone mineral density;
BRCA	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg20307385	chr11:47447363	PSMC3	0.37	7.92	0.3	1.07e-14	Subjective well-being;
BRCA	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	17.56	0.57	1.33e-56	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg00071950	chr4:10020882	SLC2A9	0.66	16.76	0.55	1.6e-52	Bone mineral density;
BRCA	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.35	7.83	0.3	2.11e-14	Endometrial cancer;
BRCA	trans	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.0	0.3	5.96e-15	Corneal astigmatism;
BRCA	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg11502198	chr6:26597334	ABT1	0.58	12.51	0.44	2.71e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg05347473	chr6:146136440	FBXO30	0.39	8.06	0.3	3.81e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg08508325	chr11:3079039	CARS	-0.46	-16.5	-0.55	3.33e-51	Longevity;
BRCA	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	14.18	0.49	7.01e-40	Colorectal cancer;
BRCA	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg04450456	chr4:17643702	FAM184B	0.37	10.65	0.39	1.73e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg07636037	chr3:49044803	WDR6	0.98	29.58	0.76	8.59e-122	Parkinson's disease;
BRCA	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.47	-9.37	-0.35	1.25e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg03676636	chr4:99064102	C4orf37	0.23	8.26	0.31	8.09e-16	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21659725	chr3:3221576	CRBN	-0.47	-10.03	-0.37	4.52e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg26384229	chr12:38710491	ALG10B	0.74	17.23	0.56	6.19e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2882667	0.898	rs6882583	chr5:138385796	C/T	cg04439458	chr5:138467593	SIL1	-0.32	-8.83	-0.33	9.64e-18	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg04586622	chr2:25135609	ADCY3	0.39	9.47	0.35	5.45e-20	Body mass index in non-asthmatics;
BRCA	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05025164	chr4:1340916	KIAA1530	-0.63	-12.74	-0.45	2.61e-33	Obesity-related traits;
BRCA	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg06784218	chr1:46089804	CCDC17	0.45	10.91	0.4	1.54e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11644478	chr21:40555479	PSMG1	0.85	19.84	0.62	1.29e-68	Cognitive function;
BRCA	trans	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg25835954	chr13:50160062	RCBTB1	0.45	8.74	0.33	1.97e-17	Cortisol levels (saliva);
BRCA	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg02403541	chr12:121454288	C12orf43	-0.64	-12.39	-0.44	9.5e-32	N-glycan levels;
BRCA	cis	rs7011049	1.000	rs11985185	chr8:53834494	T/C	cg26025543	chr8:53854495	NA	0.54	9.86	0.36	1.85e-21	Systolic blood pressure;
BRCA	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg12927641	chr6:109611667	NA	-0.42	-11.09	-0.4	2.8e-26	Reticulocyte fraction of red cells;
BRCA	cis	rs12612619	0.732	rs11126857	chr2:27297757	G/A	cg00617064	chr2:27272375	NA	0.31	8.19	0.31	1.4e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.08	-0.4	3.36e-26	Extrinsic epigenetic age acceleration;
BRCA	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.64	-0.39	1.82e-24	Retinal vascular caliber;
BRCA	cis	rs701145	0.938	rs355778	chr3:154030349	C/T	cg17054900	chr3:154042577	DHX36	0.68	11.88	0.43	1.56e-29	Coronary artery disease;
BRCA	cis	rs6598955	0.543	rs60433268	chr1:26548055	A/C	cg04990556	chr1:26633338	UBXN11	0.7	12.12	0.43	1.45e-30	Obesity-related traits;
BRCA	trans	rs7200543	1.000	rs1135999	chr16:15131962	A/G	cg24683922	chr1:11983373	KIAA2013	-0.39	-8.71	-0.33	2.69e-17	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.8	-0.33	1.23e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09263875	chr16:632152	PIGQ	0.72	21.62	0.65	3.1e-78	Height;
BRCA	cis	rs4363385	0.818	rs6661791	chr1:152994113	G/A	cg25856811	chr1:152973957	SPRR3	-0.31	-8.34	-0.31	4.69e-16	Inflammatory skin disease;
BRCA	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg27432699	chr2:27873401	GPN1	0.44	9.29	0.34	2.39e-19	Oral cavity cancer;
BRCA	cis	rs11229555	0.645	rs11229428	chr11:58180382	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.61	-0.36	1.64e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs4942242	0.663	rs17460812	chr13:44215504	A/G	cg19169023	chr15:41853346	TYRO3	-0.56	-11.42	-0.41	1.3e-27	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg16606324	chr3:10149918	C3orf24	0.5	10.02	0.37	4.84e-22	Alzheimer's disease;
BRCA	cis	rs13064411	0.696	rs9860549	chr3:113148368	G/A	cg18753928	chr3:113234510	CCDC52	-0.43	-8.51	-0.32	1.2e-16	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg08997352	chr12:9597637	DDX12	-0.54	-10.21	-0.37	8.78e-23	Breast size;
BRCA	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg16576597	chr16:28551801	NUPR1	0.29	8.15	0.31	1.91e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs12949688	0.967	rs1990231	chr17:55821002	G/C	cg12582317	chr17:55822272	NA	0.32	7.93	0.3	9.68e-15	Schizophrenia;
BRCA	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg04362960	chr10:104952993	NT5C2	0.44	10.01	0.37	5.03e-22	Arsenic metabolism;
BRCA	trans	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg01620082	chr3:125678407	NA	-0.92	-10.33	-0.38	3.07e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg16339924	chr4:17578868	LAP3	0.62	15.4	0.52	1e-45	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg16230307	chr14:35515116	FAM177A1	0.73	15.28	0.52	3.85e-45	Psoriasis;
BRCA	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg02574844	chr11:5959923	NA	0.47	10.04	0.37	3.93e-22	DNA methylation (variation);
BRCA	cis	rs9815354	0.812	rs60659106	chr3:41949569	G/C	cg03022575	chr3:42003672	ULK4	0.68	9.48	0.35	4.82e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg18479299	chr3:125709523	NA	-0.54	-8.36	-0.31	4.05e-16	Blood pressure (smoking interaction);
BRCA	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	14.55	0.5	1.2e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-10.96	-0.4	9.57e-26	Personality dimensions;
BRCA	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04824913	chr4:887549	GAK	-0.75	-15.54	-0.52	1.94e-46	Systemic sclerosis;
BRCA	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	17.07	0.56	4.05e-54	Smoking behavior;
BRCA	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg20476274	chr7:133979776	SLC35B4	0.65	19.39	0.61	3.04e-66	Mean platelet volume;
BRCA	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg04586622	chr2:25135609	ADCY3	0.44	11.36	0.41	2.32e-27	Body mass index in non-asthmatics;
BRCA	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.65	0.55	5.42e-52	Alzheimer's disease (late onset);
BRCA	cis	rs10911363	0.573	rs2761580	chr1:183516989	A/T	cg09173681	chr1:183549694	NCF2	0.53	10.78	0.39	5.31e-25	Systemic lupus erythematosus;
BRCA	cis	rs6121246	0.559	rs6119650	chr20:30258480	C/A	cg13852791	chr20:30311386	BCL2L1	0.95	22.81	0.67	1.1e-84	Mean corpuscular hemoglobin;
BRCA	cis	rs710865	0.516	rs12062540	chr1:19529204	A/G	cg13387374	chr1:19411106	UBR4	0.39	8.51	0.32	1.28e-16	Brain structure;
BRCA	cis	rs939658	0.683	rs1434459	chr15:79465210	T/C	cg17916960	chr15:79447300	NA	-0.38	-9.39	-0.35	1.05e-19	Refractive error;
BRCA	cis	rs2559856	0.967	rs7970837	chr12:102081576	A/G	cg12213457	chr12:102090980	CHPT1	-0.37	-8.09	-0.3	3.01e-15	Blood protein levels;
BRCA	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11764359	chr7:65958608	NA	-0.77	-17.87	-0.58	3.29e-58	Aortic root size;
BRCA	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg13010199	chr12:38710504	ALG10B	-0.56	-12.19	-0.43	7.11e-31	Heart rate;
BRCA	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg19077165	chr18:44547161	KATNAL2	-0.59	-13.29	-0.47	9.5e-36	Personality dimensions;
BRCA	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg21143896	chr7:2802374	GNA12	-0.31	-7.97	-0.3	7.58e-15	Height;
BRCA	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg20628663	chr10:43360327	NA	0.65	13.24	0.46	1.62e-35	Blood protein levels;
BRCA	cis	rs34779708	0.649	rs34421369	chr10:35550275	G/C	cg03585969	chr10:35415529	CREM	0.43	8.64	0.32	4.39e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg05340658	chr4:99064831	C4orf37	-0.42	-9.03	-0.34	1.98e-18	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9443645	0.527	rs1413969	chr6:79790982	A/G	cg18132916	chr6:79620363	NA	-0.4	-8.42	-0.32	2.47e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.53	-0.44	2.28e-32	Bipolar disorder;
BRCA	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg11366901	chr6:160182831	ACAT2	0.78	14.98	0.51	1.12e-43	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg01256987	chr12:42539512	GXYLT1	-0.42	-8.01	-0.3	5.64e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02176678	chr2:219576539	TTLL4	-0.46	-12.03	-0.43	3.46e-30	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21659725	chr3:3221576	CRBN	-0.47	-11.85	-0.42	2e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs2073300	1.000	rs6137966	chr20:23444359	A/T	cg12062639	chr20:23401060	NAPB	0.89	10.63	0.39	2.06e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2019216	0.542	rs8073228	chr17:21909838	C/G	cg22648282	chr17:21454238	C17orf51	-0.42	-9.79	-0.36	3.49e-21	Pelvic organ prolapse;
BRCA	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.56	-0.35	2.4e-20	Neuroticism;
BRCA	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	9.7	0.36	7.89e-21	Aortic root size;
BRCA	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	25.53	0.71	1.19e-99	Platelet count;
BRCA	trans	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Educational attainment;
BRCA	cis	rs6087990	0.865	rs6058859	chr20:31335157	A/G	cg13636640	chr20:31349939	DNMT3B	0.7	20.34	0.63	2.73e-71	Ulcerative colitis;
BRCA	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-12.72	-0.45	3.39e-33	Chronic sinus infection;
BRCA	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.64	-0.39	1.9e-24	Personality dimensions;
BRCA	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg14530993	chr4:882597	GAK	0.53	9.31	0.35	2.05e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs36051895	0.664	rs3780377	chr9:5110899	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-8.78	-0.33	1.55e-17	Pediatric autoimmune diseases;
BRCA	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg14458575	chr2:238380390	NA	0.72	15.59	0.52	1.16e-46	Prostate cancer;
BRCA	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg13010199	chr12:38710504	ALG10B	0.5	9.57	0.35	2.29e-20	Morning vs. evening chronotype;
BRCA	cis	rs10871290	1.000	rs10871290	chr16:74472696	C/T	cg01733217	chr16:74700730	RFWD3	-0.49	-11.72	-0.42	7.33e-29	Breast cancer;
BRCA	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-9.44	-0.35	7.1e-20	Menopause (age at onset);
BRCA	cis	rs4862307	0.514	rs7696176	chr4:185014390	A/G	cg06737308	chr4:185021514	ENPP6	0.51	12.48	0.44	4.02e-32	Serum dimethylarginine levels (asymmetric/symetric ratio);
BRCA	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg22875332	chr1:76189707	ACADM	-0.69	-15.05	-0.51	4.97e-44	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg23018236	chr17:30244563	NA	-0.68	-10.6	-0.39	2.7e-24	Hip circumference adjusted for BMI;
BRCA	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg21918786	chr6:109611834	NA	-0.46	-13.03	-0.46	1.37e-34	Reticulocyte fraction of red cells;
BRCA	cis	rs7818345	0.904	rs11780388	chr8:19271554	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.31	8.12	0.31	2.45e-15	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs9462027	0.506	rs6934662	chr6:34759884	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.97	-0.3	7.34e-15	Systemic lupus erythematosus;
BRCA	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg04455712	chr21:45112962	RRP1B	0.36	9.43	0.35	7.57e-20	Mean corpuscular volume;
BRCA	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg27336068	chr10:1336103	ADARB2	-0.29	-7.99	-0.3	6.44e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg16230307	chr14:35515116	FAM177A1	0.75	15.03	0.51	5.98e-44	Psoriasis;
BRCA	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.01	-22.16	-0.66	3.76e-81	Gut microbiome composition (summer);
BRCA	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-14.92	-0.51	2.09e-43	Bipolar disorder and schizophrenia;
BRCA	cis	rs6545883	0.868	rs778755	chr2:61781037	A/G	cg15711740	chr2:61764176	XPO1	0.48	11.8	0.42	3.15e-29	Tuberculosis;
BRCA	cis	rs6815814	0.950	rs66819621	chr4:38819403	A/G	cg02016764	chr4:38805732	TLR1	-0.57	-8.32	-0.31	5.23e-16	Breast cancer;
BRCA	trans	rs72766638	0.895	rs55924785	chr9:136929586	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.68	-9.9	-0.36	1.39e-21	Mosquito bite size;
BRCA	cis	rs8028182	0.636	rs7171507	chr15:75737287	T/C	cg20655648	chr15:75932815	IMP3	0.41	8.03	0.3	4.8e-15	Sudden cardiac arrest;
BRCA	trans	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.01	29.36	0.76	1.31e-120	Exhaled nitric oxide output;
BRCA	cis	rs7246657	0.722	rs2291002	chr19:38033926	G/A	cg18154014	chr19:37997991	ZNF793	0.48	9.17	0.34	6.65e-19	Coronary artery calcification;
BRCA	trans	rs8073060	0.586	rs6505485	chr17:33996102	C/T	cg19694781	chr19:47549865	TMEM160	-0.99	-18.78	-0.6	5.3e-63	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-8.0	-0.3	6.01e-15	Coronary artery disease;
BRCA	cis	rs3820928	1.000	rs7561378	chr2:227772248	T/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.41	-0.32	2.72e-16	Pulmonary function;
BRCA	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg27129171	chr3:47204927	SETD2	0.73	17.83	0.58	5.34e-58	Colorectal cancer;
BRCA	cis	rs9420	0.961	rs11570190	chr11:57560452	A/C	cg19752551	chr11:57585705	CTNND1	-0.5	-12.27	-0.44	3.21e-31	Schizophrenia;
BRCA	cis	rs965469	0.947	rs6037529	chr20:3261006	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-10.15	-0.37	1.57e-22	IFN-related cytopenia;
BRCA	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg06532163	chr17:45867833	NA	0.38	7.91	0.3	1.17e-14	IgG glycosylation;
BRCA	trans	rs61931739	0.591	rs1608907	chr12:33945435	A/G	cg26384229	chr12:38710491	ALG10B	0.39	8.87	0.33	7.17e-18	Morning vs. evening chronotype;
BRCA	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11764359	chr7:65958608	NA	0.62	13.51	0.47	8.69e-37	Calcium levels;
BRCA	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1953600	0.837	rs2573352	chr10:81939813	T/C	cg04850286	chr10:81895943	PLAC9	0.32	9.05	0.34	1.75e-18	Sarcoidosis;
BRCA	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg08885076	chr2:99613938	TSGA10	0.47	10.93	0.4	1.31e-25	Chronic sinus infection;
BRCA	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg23358479	chr7:1110784	C7orf50	-0.47	-7.9	-0.3	1.26e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs28374715	0.662	rs8038983	chr15:41473316	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.87	-18.05	-0.58	3.56e-59	Ulcerative colitis;
BRCA	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15378786	chr11:17036137	PLEKHA7	0.89	25.61	0.71	4.72e-100	Coronary artery disease;
BRCA	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.58	-0.32	7.04e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg24812749	chr6:127587940	RNF146	0.88	20.66	0.63	4.91e-73	Breast cancer;
BRCA	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg07262247	chr5:131593730	PDLIM4	0.36	8.58	0.32	7.25e-17	Acylcarnitine levels;
BRCA	trans	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs10267417	0.603	rs10266969	chr7:19903452	G/A	cg07541023	chr7:19748670	TWISTNB	0.45	8.23	0.31	1.09e-15	Night sleep phenotypes;
BRCA	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg08999081	chr20:33150536	PIGU	0.45	12.54	0.44	2.02e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg08085267	chr17:45401833	C17orf57	0.61	12.51	0.44	2.72e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg12365402	chr11:9010492	NRIP3	-0.42	-9.91	-0.37	1.22e-21	Hemoglobin concentration;
BRCA	cis	rs11608355	0.545	rs6606723	chr12:109905044	C/G	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs7011049	1.000	rs11997774	chr8:53833370	T/A	cg26025543	chr8:53854495	NA	0.55	9.94	0.37	9.57e-22	Systolic blood pressure;
BRCA	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg15605315	chr1:45957053	TESK2	-0.42	-8.47	-0.32	1.66e-16	High light scatter reticulocyte count;
BRCA	cis	rs17253792	0.822	rs10147688	chr14:56054642	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.57	7.98	0.3	6.98e-15	Putamen volume;
BRCA	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.39	-9.25	-0.34	3.34e-19	Alzheimer's disease (late onset);
BRCA	cis	rs55882075	0.967	rs62404346	chr5:179141391	A/C	cg14593053	chr5:179126677	CANX	0.38	9.43	0.35	7.55e-20	Monocyte percentage of white cells;
BRCA	cis	rs738321	0.671	rs3761446	chr22:38595483	G/A	cg25457927	chr22:38595422	NA	-0.41	-13.87	-0.48	1.99e-38	Breast cancer;
BRCA	cis	rs12579753	0.827	rs7311917	chr12:82187551	G/T	cg07988820	chr12:82153109	PPFIA2	-0.51	-8.89	-0.33	6.18e-18	Resting heart rate;
BRCA	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg13010199	chr12:38710504	ALG10B	0.48	9.45	0.35	6.55e-20	Morning vs. evening chronotype;
BRCA	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.46	-11.45	-0.41	9.87e-28	Longevity;Endometriosis;
BRCA	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg12591125	chr7:1885375	MAD1L1	0.51	8.99	0.34	2.82e-18	Bipolar disorder;
BRCA	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg07549590	chr16:15018862	NA	-0.35	-8.61	-0.32	5.77e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	trans	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg26043149	chr18:55253948	FECH	1.08	23.16	0.68	1.29e-86	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg17724175	chr1:150552817	MCL1	-0.29	-9.99	-0.37	6.33e-22	Urate levels;
BRCA	cis	rs2625529	0.730	rs2929528	chr15:72269337	C/A	cg16672083	chr15:72433130	SENP8	0.73	17.34	0.57	1.65e-55	Red blood cell count;
BRCA	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg15556689	chr8:8085844	FLJ10661	-0.34	-9.03	-0.34	1.95e-18	Neuroticism;
BRCA	cis	rs290268	0.845	rs290266	chr9:93537952	T/A	cg02608019	chr9:93564028	SYK	0.48	9.94	0.37	9.45e-22	Platelet count;
BRCA	cis	rs72928364	1.000	rs17398684	chr3:100695342	G/A	cg10123952	chr3:100791384	NA	0.53	7.85	0.3	1.71e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs72781680	0.716	rs2675363	chr2:24080003	G/C	cg08917208	chr2:24149416	ATAD2B	0.59	10.15	0.37	1.51e-22	Lymphocyte counts;
BRCA	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg11663144	chr21:46675770	NA	-0.58	-13.7	-0.48	1.26e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg08999081	chr20:33150536	PIGU	0.46	12.85	0.45	8.9e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs2652834	0.851	rs4468558	chr15:63346681	T/C	cg05507819	chr15:63340323	TPM1	0.53	9.5	0.35	4.01e-20	HDL cholesterol;
BRCA	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18404041	chr3:52824283	ITIH1	-0.42	-12.26	-0.44	3.51e-31	Bipolar disorder;
BRCA	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg11663144	chr21:46675770	NA	-0.6	-13.87	-0.48	2.05e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	14.78	0.5	9.71e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs9318086	0.712	rs9318100	chr13:24442482	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.29	-8.33	-0.31	4.93e-16	Myopia (pathological);
BRCA	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.6	13.65	0.48	2.05e-37	Eosinophil percentage of white cells;
BRCA	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg23711669	chr6:146136114	FBXO30	0.76	17.27	0.56	3.82e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6484504	0.512	rs7940020	chr11:31366453	T/G	cg26647111	chr11:31128758	NA	0.45	9.64	0.36	1.25e-20	Red blood cell count;
BRCA	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-8.16	-0.31	1.84e-15	Blood pressure (smoking interaction);
BRCA	trans	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg06521331	chr12:34319734	NA	-0.53	-10.08	-0.37	2.83e-22	Bladder cancer;
BRCA	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	13.76	0.48	6.14e-38	Mood instability;
BRCA	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg15383120	chr6:291909	DUSP22	0.53	11.3	0.41	4.09e-27	Menopause (age at onset);
BRCA	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg19156104	chr2:198669113	PLCL1	-0.44	-8.27	-0.31	7.89e-16	Ulcerative colitis;
BRCA	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.75	-0.36	5.08e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs4594175	0.926	rs11157800	chr14:51615502	A/T	cg23942311	chr14:51606299	NA	0.32	8.11	0.31	2.53e-15	Cancer;
BRCA	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	17.68	0.57	3.2e-57	Fuchs's corneal dystrophy;
BRCA	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg13385521	chr17:29058706	SUZ12P	0.76	10.09	0.37	2.66e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-11.43	-0.41	1.14e-27	Alzheimer's disease;
BRCA	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg09904177	chr6:26538194	HMGN4	0.47	14.72	0.5	1.82e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg18305652	chr10:134549665	INPP5A	0.5	11.47	0.41	8.02e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg11845111	chr2:191398756	TMEM194B	-0.77	-14.87	-0.51	3.74e-43	Diastolic blood pressure;
BRCA	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg20701182	chr2:24300061	SF3B14	0.56	8.67	0.32	3.58e-17	Lymphocyte counts;
BRCA	cis	rs12760731	0.565	rs12027723	chr1:178090271	A/T	cg00404053	chr1:178313656	RASAL2	0.67	8.02	0.3	5.06e-15	Obesity-related traits;
BRCA	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.39	-8.96	-0.33	3.42e-18	Alzheimer's disease (late onset);
BRCA	cis	rs4285028	0.747	rs9852845	chr3:121390618	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-13.88	-0.48	1.71e-38	Multiple sclerosis;
BRCA	trans	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg25214090	chr10:38739885	LOC399744	0.45	10.38	0.38	2.04e-23	Corneal astigmatism;
BRCA	trans	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.66	-15.01	-0.51	8e-44	Blood trace element (Cu levels);
BRCA	cis	rs778371	0.723	rs34707169	chr2:233699459	C/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-17.0	-0.56	9.22e-54	Schizophrenia;
BRCA	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	15.45	0.52	5.47e-46	Coronary artery disease;
BRCA	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08219700	chr8:58056026	NA	0.59	9.83	0.36	2.59e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs6429082	0.806	rs2382570	chr1:235570523	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.34	-8.13	-0.31	2.27e-15	Adiposity;
BRCA	cis	rs524281	0.861	rs2177053	chr11:65966145	A/C	cg16950941	chr11:66035639	RAB1B	-0.38	-8.11	-0.31	2.68e-15	Electroencephalogram traits;
BRCA	cis	rs10046574	0.519	rs11505985	chr7:135210197	G/T	cg27474649	chr7:135195673	CNOT4	0.64	10.75	0.39	6.98e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg05868516	chr6:26286170	HIST1H4H	0.5	11.28	0.41	4.88e-27	Educational attainment;
BRCA	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.66	10.78	0.39	5.15e-25	Renal function-related traits (BUN);
BRCA	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg24562669	chr7:97807699	LMTK2	0.61	18.04	0.58	4.12e-59	Breast cancer;
BRCA	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg20891283	chr12:69753455	YEATS4	0.73	22.1	0.66	7.57e-81	Blood protein levels;
BRCA	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg11168104	chr5:1857477	NA	-0.35	-9.29	-0.34	2.44e-19	Cardiovascular disease risk factors;
BRCA	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11890956	chr21:40555474	PSMG1	1.06	31.86	0.78	4.18e-134	Cognitive function;
BRCA	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg04362960	chr10:104952993	NT5C2	0.46	10.35	0.38	2.54e-23	Arsenic metabolism;
BRCA	cis	rs586533	0.881	rs637006	chr11:99495383	A/G	cg22878054	chr11:99397252	CNTN5	0.31	7.81	0.3	2.39e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-13.44	-0.47	1.99e-36	Bladder cancer;
BRCA	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs9487051	0.768	rs437779	chr6:109527691	T/G	cg01475377	chr6:109611718	NA	-0.42	-10.48	-0.38	7.98e-24	Reticulocyte fraction of red cells;
BRCA	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02187348	chr16:89574699	SPG7	-0.48	-11.77	-0.42	4.44e-29	Multiple myeloma (IgH translocation);
BRCA	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg08917208	chr2:24149416	ATAD2B	0.56	8.64	0.32	4.37e-17	Lymphocyte counts;
BRCA	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.3	-8.05	-0.3	3.96e-15	Type 2 diabetes;
BRCA	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg17063962	chr7:91808500	NA	0.58	13.72	0.48	9.56e-38	Breast cancer;
BRCA	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg10495392	chr1:46806563	NSUN4	0.46	8.46	0.32	1.82e-16	Menopause (age at onset);
BRCA	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.35	0.49	1.13e-40	Motion sickness;
BRCA	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.35	-0.31	4.34e-16	Colorectal cancer;
BRCA	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-15.85	-0.53	5.83e-48	Heart rate;
BRCA	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.25	7.91	0.3	1.16e-14	Cardiac Troponin-T levels;
BRCA	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg08755490	chr11:65554678	OVOL1	0.52	10.88	0.4	2.11e-25	Acne (severe);
BRCA	cis	rs3125734	0.608	rs7094950	chr10:64019744	T/C	cg19640130	chr10:64028056	RTKN2	-0.31	-8.91	-0.33	5.23e-18	Rheumatoid arthritis;
BRCA	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.43	-9.06	-0.34	1.62e-18	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs7833986	0.501	rs72653990	chr8:57037115	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	13.06	0.46	9.86e-35	Height;
BRCA	trans	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg13010199	chr12:38710504	ALG10B	0.4	8.16	0.31	1.74e-15	Morning vs. evening chronotype;
BRCA	trans	rs1997103	1.000	rs1965556	chr7:55403584	C/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs9473147	0.516	rs10948367	chr6:47585615	A/G	cg12968598	chr6:47444699	CD2AP	0.43	9.29	0.35	2.29e-19	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs72781680	0.664	rs2712076	chr2:23993366	T/C	cg08917208	chr2:24149416	ATAD2B	0.65	10.42	0.38	1.42e-23	Lymphocyte counts;
BRCA	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.57	-11.85	-0.42	1.95e-29	Lymphocyte counts;
BRCA	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg13334819	chr7:99746414	C7orf59	-0.4	-9.56	-0.35	2.46e-20	Coronary artery disease;
BRCA	cis	rs3862030	0.720	rs3740414	chr10:104232809	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.14	-0.43	1.18e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	8.78	0.33	1.53e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg16606324	chr3:10149918	C3orf24	0.56	11.14	0.4	1.82e-26	Alzheimer's disease;
BRCA	cis	rs2882667	0.654	rs825760	chr5:138139974	G/T	cg04439458	chr5:138467593	SIL1	0.35	8.4	0.32	2.98e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg02659138	chr7:134003124	SLC35B4	0.33	10.32	0.38	3.35e-23	Mean platelet volume;
BRCA	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg04756594	chr16:24857601	SLC5A11	-0.55	-12.43	-0.44	6.24e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg25358565	chr5:93447407	FAM172A	-0.52	-9.57	-0.35	2.29e-20	Diabetic retinopathy;
BRCA	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.84	-0.3	1.85e-14	Aortic root size;
BRCA	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg03709012	chr19:19516395	GATAD2A	0.81	18.85	0.6	2.32e-63	Tonsillectomy;
BRCA	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg10295955	chr4:187884368	NA	-0.96	-27.8	-0.74	4.23e-112	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.6	-13.2	-0.46	2.49e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2656056	1	rs2656056	chr15:78722519	T/C	cg24631222	chr15:78858424	CHRNA5	-0.49	-9.62	-0.36	1.52e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
BRCA	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg07606381	chr6:8435919	SLC35B3	-0.65	-14.25	-0.49	3.18e-40	Motion sickness;
BRCA	cis	rs3824867	0.920	rs4752836	chr11:47465095	T/C	cg20307385	chr11:47447363	PSMC3	0.51	11.52	0.41	4.99e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11890956	chr21:40555474	PSMG1	1.04	29.41	0.76	7.29e-121	Cognitive function;
BRCA	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24110177	chr3:50126178	RBM5	-0.41	-11.17	-0.4	1.39e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.39	8.22	0.31	1.14e-15	Multiple sclerosis;
BRCA	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg09754948	chr16:28834200	ATXN2L	0.46	8.45	0.32	2.02e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg23711669	chr6:146136114	FBXO30	0.71	17.09	0.56	3.21e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg24829409	chr8:58192753	C8orf71	-0.45	-8.73	-0.33	2.17e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6740322	0.901	rs2163228	chr2:43549246	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-11.37	-0.41	2.09e-27	Coronary artery disease;
BRCA	cis	rs6910061	1.000	rs28860023	chr6:11106765	G/A	cg27233058	chr6:11094804	LOC221710	0.53	9.35	0.35	1.45e-19	Diabetic kidney disease;
BRCA	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg23711669	chr6:146136114	FBXO30	0.79	19.28	0.61	1.26e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs66887589	0.777	rs10015883	chr4:120268146	A/G	cg09307838	chr4:120376055	NA	0.44	9.48	0.35	4.77e-20	Diastolic blood pressure;
BRCA	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.49	-0.32	1.4e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	11.18	0.4	1.23e-26	Height;
BRCA	cis	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg05901451	chr6:126070800	HEY2	0.4	9.69	0.36	8.1e-21	Endometrial cancer;
BRCA	trans	rs6479891	1.000	rs10437345	chr10:65202946	C/T	cg14819942	chr15:35414228	NA	-0.3	-7.9	-0.3	1.25e-14	Arthritis (juvenile idiopathic);
BRCA	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11764359	chr7:65958608	NA	0.8	19.53	0.61	6.05e-67	Aortic root size;
BRCA	trans	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg18876405	chr7:65276391	NA	-0.39	-7.82	-0.3	2.22e-14	Corneal structure;
BRCA	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg13010199	chr12:38710504	ALG10B	0.51	10.46	0.38	9.29e-24	Bladder cancer;
BRCA	cis	rs11608355	0.545	rs11613023	chr12:109898047	T/C	cg05360138	chr12:110035743	NA	0.71	13.11	0.46	6.34e-35	Neuroticism;
BRCA	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.42	-0.35	8.38e-20	Total body bone mineral density;
BRCA	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-8.13	-0.31	2.3e-15	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg12193833	chr17:30244370	NA	-0.57	-8.43	-0.32	2.29e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs4478137	1.000	rs4478137	chr4:164238385	G/A	cg06758707	chr4:164254230	NPY1R	0.59	12.7	0.45	4.19e-33	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg06937882	chr20:24974362	C20orf3	-0.48	-9.46	-0.35	5.84e-20	Blood protein levels;
BRCA	cis	rs13046373	0.535	rs7281489	chr21:31978125	C/T	cg27071517	chr21:31768726	KRTAP13-1	0.29	7.95	0.3	8.62e-15	HDL cholesterol;
BRCA	cis	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg06521331	chr12:34319734	NA	0.53	10.32	0.38	3.44e-23	Morning vs. evening chronotype;
BRCA	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg00990874	chr7:1149470	C7orf50	-0.63	-13.33	-0.47	6.13e-36	Bronchopulmonary dysplasia;
BRCA	cis	rs1577917	0.876	rs12212808	chr6:86533972	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.54	-0.42	4.21e-28	Response to antipsychotic treatment;
BRCA	cis	rs701145	0.537	rs2695845	chr3:153881836	G/A	cg17054900	chr3:154042577	DHX36	0.56	9.42	0.35	7.83e-20	Coronary artery disease;
BRCA	cis	rs1371614	0.588	rs11126784	chr2:27169842	C/A	cg00617064	chr2:27272375	NA	-0.31	-8.24	-0.31	1.01e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11764359	chr7:65958608	NA	-0.7	-15.03	-0.51	5.83e-44	Aortic root size;
BRCA	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12756686	chr19:29218302	NA	0.55	11.43	0.41	1.2e-27	Methadone dose in opioid dependence;
BRCA	trans	rs6479891	0.841	rs7085869	chr10:65070163	C/T	cg14819942	chr15:35414228	NA	-0.34	-8.43	-0.32	2.36e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.21e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg06115741	chr20:33292138	TP53INP2	0.5	11.22	0.41	8.66e-27	Coronary artery disease;
BRCA	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg21770322	chr7:97807741	LMTK2	0.42	11.28	0.41	4.79e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg20283391	chr11:68216788	NA	-0.46	-9.04	-0.34	1.89e-18	Total body bone mineral density;
BRCA	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg12311346	chr5:56204834	C5orf35	-0.79	-15.59	-0.53	1.08e-46	Initial pursuit acceleration;
BRCA	cis	rs600806	0.850	rs4970752	chr1:109930852	C/T	cg20591472	chr1:110008990	SYPL2	0.33	8.17	0.31	1.65e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg26384229	chr12:38710491	ALG10B	0.74	17.32	0.57	2.11e-55	Drug-induced liver injury (flucloxacillin);
BRCA	trans	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	9.93	0.37	1.06e-21	Personality dimensions;
BRCA	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.52	-0.61	6.85e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-14.27	-0.49	2.7e-40	Platelet count;
BRCA	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg12863693	chr15:85201151	NMB	-0.34	-8.33	-0.31	5.03e-16	P wave terminal force;
BRCA	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg19000871	chr14:103996768	TRMT61A	-0.35	-8.04	-0.3	4.21e-15	Coronary artery disease;
BRCA	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27286337	chr10:134555280	INPP5A	0.63	11.3	0.41	4.09e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg02248941	chr16:2239361	CASKIN1	-0.44	-11.06	-0.4	3.88e-26	Height;
BRCA	trans	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg25214090	chr10:38739885	LOC399744	0.53	11.71	0.42	7.51e-29	Corneal astigmatism;
BRCA	cis	rs9462027	0.628	rs7741437	chr6:34737553	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-8.01	-0.3	5.4e-15	Systemic lupus erythematosus;
BRCA	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg02493740	chr2:85810744	VAMP5	0.55	11.3	0.41	3.92e-27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg03929089	chr4:120376271	NA	-0.71	-13.99	-0.48	5.59e-39	Height;
BRCA	cis	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg06521331	chr12:34319734	NA	-0.55	-10.01	-0.37	4.99e-22	Morning vs. evening chronotype;
BRCA	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg09184832	chr6:79620586	NA	-0.51	-11.2	-0.41	9.93e-27	Intelligence (multi-trait analysis);
BRCA	trans	rs800082	0.690	rs6440260	chr3:144289214	C/A	cg24215973	chr2:240111563	HDAC4	-0.42	-10.13	-0.37	1.77e-22	Smoking behavior;
BRCA	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg13047869	chr3:10149882	C3orf24	0.53	11.01	0.4	5.91e-26	Alzheimer's disease;
BRCA	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg02261765	chr11:831170	EFCAB4A	-0.41	-8.92	-0.33	4.8e-18	Mean platelet volume;
BRCA	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg12863693	chr15:85201151	NMB	-0.37	-8.84	-0.33	8.93e-18	P wave terminal force;
BRCA	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg03146154	chr1:46216737	IPP	-0.5	-11.13	-0.4	1.98e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg18252515	chr7:66147081	NA	-0.84	-12.15	-0.43	1.0500000000000001e-30	Diabetic kidney disease;
BRCA	cis	rs4363385	0.747	rs1415960	chr1:152973571	G/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.29	-0.31	6.49e-16	Inflammatory skin disease;
BRCA	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg03433033	chr1:76189801	ACADM	-0.76	-16.87	-0.56	4.13e-53	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.73e-18	Motion sickness;
BRCA	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-10.74	-0.39	7.59e-25	Alzheimer's disease;
BRCA	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.28	-0.38	4.86e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg17691542	chr6:26056736	HIST1H1C	0.55	11.8	0.42	3.17e-29	Height;
BRCA	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg27446573	chr6:127587934	RNF146	0.88	20.71	0.63	2.59e-73	Breast cancer;
BRCA	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.58e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg00105475	chr2:10696890	NA	0.44	10.26	0.38	5.78e-23	Prostate cancer;
BRCA	trans	rs8002861	0.935	rs9533678	chr13:44463409	C/T	cg17145862	chr1:211918768	LPGAT1	0.73	19.6	0.61	2.43e-67	Leprosy;
BRCA	cis	rs10751667	0.560	rs10902267	chr11:1007831	T/C	ch.11.42038R	chr11:967971	AP2A2	0.47	14.24	0.49	3.59e-40	Alzheimer's disease (late onset);
BRCA	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg11845111	chr2:191398756	TMEM194B	-0.35	-7.91	-0.3	1.14e-14	Pulse pressure;
BRCA	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08704250	chr15:31115839	NA	-0.36	-9.07	-0.34	1.42e-18	Huntington's disease progression;
BRCA	cis	rs6088813	0.961	rs2425062	chr20:33923566	A/G	cg14752227	chr20:34000481	UQCC	0.41	8.76	0.33	1.76e-17	Height;
BRCA	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-10.09	-0.37	2.61e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg08601574	chr20:25228251	PYGB	0.41	9.57	0.35	2.2e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-13.46	-0.47	1.49e-36	Bladder cancer;
BRCA	cis	rs4285028	0.948	rs34543553	chr3:121675637	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.82	-0.39	3.64e-25	Multiple sclerosis;
BRCA	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg24634471	chr8:143751801	JRK	-0.48	-9.99	-0.37	6.09e-22	Schizophrenia;
BRCA	cis	rs9462027	0.588	rs13215181	chr6:34759881	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.92	-0.3	1.07e-14	Systemic lupus erythematosus;
BRCA	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	11.61	0.42	2e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg13319975	chr6:146136371	FBXO30	-0.36	-8.19	-0.31	1.39e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs57143961	1	rs57143961	chr19:16533225	C/CT	cg10248733	chr19:16607483	C19orf44;CALR3	-0.62	-10.62	-0.39	2.16e-24	Lymphocyte percentage of white cells;
BRCA	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg11301795	chr4:187892539	NA	0.31	10.19	0.37	1.1e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2742417	0.609	rs11709306	chr3:45773732	G/A	cg04837898	chr3:45731254	SACM1L	-0.38	-7.82	-0.3	2.24e-14	Response to anti-depressant treatment in major depressive disorder;
BRCA	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg01475377	chr6:109611718	NA	-0.6	-16.64	-0.55	6.41e-52	Reticulocyte fraction of red cells;
BRCA	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-14.01	-0.48	4.47e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3772130	0.923	rs13434284	chr3:121482842	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.75	0.39	7.12e-25	Cognitive performance;
BRCA	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg16606324	chr3:10149918	C3orf24	0.49	9.66	0.36	1.06e-20	Alzheimer's disease;
BRCA	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg08000102	chr2:233561755	GIGYF2	0.62	13.48	0.47	1.3e-36	Coronary artery disease;
BRCA	cis	rs9337951	0.579	rs2505083	chr10:30335122	C/T	cg00730780	chr10:30316187	KIAA1462	0.42	8.74	0.33	2.08e-17	Pulse pressure;Coronary artery disease;
BRCA	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03264133	chr6:25882463	NA	-0.53	-11.42	-0.41	1.25e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg25237894	chr2:233734115	C2orf82	0.3	8.68	0.32	3.17e-17	Coronary artery disease;
BRCA	cis	rs10046574	0.561	rs11505984	chr7:135208359	G/A	cg27474649	chr7:135195673	CNOT4	0.65	10.84	0.39	2.91e-25	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs6977660	0.652	rs10249291	chr7:19844448	C/G	cg07541023	chr7:19748670	TWISTNB	0.71	11.09	0.4	2.95e-26	Thyroid stimulating hormone;
BRCA	cis	rs6977660	0.714	rs7798760	chr7:19803487	T/C	cg05791153	chr7:19748676	TWISTNB	0.57	10.52	0.38	5.76e-24	Thyroid stimulating hormone;
BRCA	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg05623727	chr3:50126028	RBM5	-0.49	-11.8	-0.42	3.31e-29	Body mass index;
BRCA	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	10.47	0.38	8.71e-24	Height;
BRCA	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.89	0.33	6.08e-18	Ovarian reserve;
BRCA	cis	rs9420	0.961	rs79260745	chr11:57612960	T/C	cg19752551	chr11:57585705	CTNND1	-0.51	-12.6	-0.45	1.16e-32	Schizophrenia;
BRCA	cis	rs13082711	0.555	rs73038733	chr3:27263537	C/G	cg02860705	chr3:27208620	NA	0.55	10.85	0.39	2.74e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs6088813	1.000	rs6088812	chr20:33974163	T/A	cg14752227	chr20:34000481	UQCC	-0.41	-8.65	-0.32	4.1e-17	Height;
BRCA	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg14458575	chr2:238380390	NA	0.54	8.09	0.3	3.03e-15	Prostate cancer;
BRCA	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg12292205	chr6:26970375	C6orf41	-0.65	-10.69	-0.39	1.18e-24	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs804292	0.695	rs804279	chr8:11623889	A/T	cg26752888	chr8:11627280	NEIL2	0.58	11.98	0.43	5.61e-30	Alcohol dependence;Nicotine use;
BRCA	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg05283184	chr6:79620031	NA	-0.43	-11.0	-0.4	6.58e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg25801113	chr15:45476975	SHF	0.31	7.83	0.3	2e-14	Uric acid levels;
BRCA	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg05707623	chr12:122985044	ZCCHC8	0.45	8.8	0.33	1.29e-17	Body mass index;
BRCA	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg06115741	chr20:33292138	TP53INP2	-0.38	-8.34	-0.31	4.45e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs3820928	0.804	rs4675125	chr2:227802499	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.72	-0.33	2.42e-17	Pulmonary function;
BRCA	cis	rs858239	0.539	rs6461694	chr7:23187779	G/A	cg23682824	chr7:23144976	KLHL7	0.37	9.64	0.36	1.27e-20	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs11051970	0.679	rs2651377	chr12:32556919	A/C	cg24626660	chr12:32551988	NA	0.32	9.43	0.35	7.74e-20	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg25809561	chr17:30822961	MYO1D	0.4	9.42	0.35	8.38e-20	Schizophrenia;
BRCA	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg03146154	chr1:46216737	IPP	-0.48	-10.79	-0.39	4.61e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg23762105	chr12:34175262	ALG10	0.34	8.0	0.3	5.92e-15	Morning vs. evening chronotype;
BRCA	cis	rs6987853	0.787	rs2923405	chr8:42448126	T/G	cg09913449	chr8:42400586	C8orf40	0.38	7.92	0.3	1.03e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg25237894	chr2:233734115	C2orf82	-0.45	-14.15	-0.49	1.02e-39	Coronary artery disease;
BRCA	cis	rs1371614	0.632	rs3820823	chr2:27164806	C/T	cg00617064	chr2:27272375	NA	-0.31	-8.23	-0.31	1.03e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.41	-0.32	2.59e-16	Colorectal cancer;
BRCA	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg26384229	chr12:38710491	ALG10B	0.67	14.01	0.48	4.18e-39	Morning vs. evening chronotype;
BRCA	trans	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg06521331	chr12:34319734	NA	-0.48	-8.78	-0.33	1.47e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg04602696	chr16:88846723	FAM38A	-0.44	-11.59	-0.42	2.5e-28	Glycated hemoglobin levels;
BRCA	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15541040	chr2:3486749	NA	-0.47	-10.55	-0.39	4.34e-24	Neurofibrillary tangles;
BRCA	trans	rs783540	0.592	rs2567632	chr15:83284804	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.32	-8.77	-0.33	1.66e-17	Schizophrenia;
BRCA	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-12.29	-0.44	2.59e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs4363385	0.720	rs1970328	chr1:152975829	A/G	cg25856811	chr1:152973957	SPRR3	-0.35	-9.29	-0.34	2.4e-19	Inflammatory skin disease;
BRCA	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-9.27	-0.34	2.92e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs11191205	0.644	rs7874	chr10:103361088	C/T	cg15320455	chr10:103880129	LDB1	0.46	7.97	0.3	7.25e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg14728415	chr7:32535168	LSM5;AVL9	0.41	8.71	0.33	2.63e-17	Cognitive ability;
BRCA	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	18.9	0.6	1.21e-63	Smoking behavior;
BRCA	cis	rs12600053	0.687	rs8063190	chr16:84849280	C/T	cg09249803	chr16:84846936	NA	0.38	8.88	0.33	6.77e-18	Asthma (childhood onset);
BRCA	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-15.19	-0.52	1.02e-44	Total cholesterol levels;
BRCA	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg15352829	chr14:105391018	PLD4	-0.39	-12.46	-0.44	4.79e-32	Rheumatoid arthritis;
BRCA	cis	rs6138458	0.701	rs6050255	chr20:25007089	A/G	cg26195577	chr20:24973756	C20orf3	0.61	14.45	0.5	3.84e-41	Blood protein levels;
BRCA	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg25019033	chr10:957182	NA	-0.41	-7.95	-0.3	8.62e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs2997447	0.655	rs11247852	chr1:26383125	C/G	cg19633962	chr1:26362018	EXTL1	0.53	9.21	0.34	4.59e-19	QRS complex (12-leadsum);
BRCA	trans	rs9944715	0.954	rs4542747	chr18:43802169	C/T	cg01718231	chr17:29326311	RNF135	-0.4	-8.08	-0.3	3.23e-15	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.42	9.01	0.34	2.31e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs6028335	0.674	rs61213966	chr20:37621906	A/G	cg16355469	chr20:37678765	NA	0.5	9.03	0.34	1.97e-18	Alcohol and nicotine co-dependence;
BRCA	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg09658497	chr7:2847517	GNA12	-0.41	-8.67	-0.32	3.51e-17	Height;
BRCA	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg14530993	chr4:882597	GAK	0.6	9.78	0.36	3.96e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg12573674	chr2:1569213	NA	-0.58	-12.65	-0.45	6.98e-33	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg07636037	chr3:49044803	WDR6	0.97	28.33	0.75	5.26e-115	Parkinson's disease;
BRCA	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg07988820	chr12:82153109	PPFIA2	-0.59	-9.51	-0.35	3.9e-20	Resting heart rate;
BRCA	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-15.89	-0.53	3.76e-48	Heart rate;
BRCA	cis	rs4363385	0.693	rs581447	chr1:153033269	A/G	cg24667326	chr1:152973720	SPRR3	-0.31	-8.2	-0.31	1.28e-15	Inflammatory skin disease;
BRCA	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	12.02	0.43	3.77e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg21132104	chr15:45694354	SPATA5L1	0.7	15.39	0.52	1.14e-45	Homoarginine levels;
BRCA	cis	rs6834538	0.964	rs2087110	chr4:113411791	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.36	8.31	0.31	5.7e-16	Free thyroxine concentration;
BRCA	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg25664220	chr3:72788482	NA	-0.5	-10.64	-0.39	1.86e-24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3818285	0.504	rs1973972	chr10:111651133	A/T	cg00817464	chr10:111662876	XPNPEP1	0.33	8.9	0.33	5.81e-18	Superior crus of antihelix expression;
BRCA	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg21475434	chr5:93447410	FAM172A	0.66	8.55	0.32	8.79e-17	Diabetic retinopathy;
BRCA	cis	rs34779708	0.966	rs1148245	chr10:35511894	C/T	cg03585969	chr10:35415529	CREM	0.44	9.14	0.34	8.21e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12425451	0.544	rs3741951	chr12:3147080	A/G	cg05389053	chr12:3131226	TEAD4	0.42	8.22	0.31	1.16e-15	Narcolepsy with cataplexy;
BRCA	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11764359	chr7:65958608	NA	0.77	17.36	0.57	1.4e-55	Aortic root size;
BRCA	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg15017067	chr4:17643749	FAM184B	0.31	9.57	0.35	2.29e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg16386425	chr10:429943	DIP2C	-0.42	-8.91	-0.33	5.27e-18	Psychosis in Alzheimer's disease;
BRCA	cis	rs7246657	0.722	rs35863684	chr19:38109777	C/T	cg18154014	chr19:37997991	ZNF793	0.5	9.67	0.36	9.8e-21	Coronary artery calcification;
BRCA	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06634786	chr22:41940651	POLR3H	0.51	9.4	0.35	9.28e-20	Vitiligo;
BRCA	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-11.12	-0.4	2.21e-26	Morning vs. evening chronotype;
BRCA	cis	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg06521331	chr12:34319734	NA	-0.62	-12.13	-0.43	1.24e-30	Morning vs. evening chronotype;
BRCA	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.44	-10.36	-0.38	2.44e-23	Lymphocyte counts;
BRCA	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg12310025	chr6:25882481	NA	0.51	12.0	0.43	4.48e-30	Blood metabolite levels;
BRCA	trans	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg26384229	chr12:38710491	ALG10B	0.56	12.16	0.43	9.46e-31	Morning vs. evening chronotype;
BRCA	cis	rs7945718	0.934	rs10831907	chr11:12790875	C/T	cg25843174	chr11:12811716	TEAD1	-0.24	-9.18	-0.34	5.72e-19	Educational attainment (years of education);
BRCA	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.32	-9.01	-0.34	2.3e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-10.66	-0.39	1.56e-24	Total cholesterol levels;
BRCA	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg06714761	chr1:201096289	NA	0.29	7.83	0.3	2.05e-14	Permanent tooth development;
BRCA	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg23625390	chr15:77176239	SCAPER	-0.54	-12.55	-0.44	1.98e-32	Blood metabolite levels;
BRCA	cis	rs1843834	0.898	rs2015099	chr2:225519915	T/C	cg22455342	chr2:225449267	CUL3	0.35	8.57	0.32	7.7e-17	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs2012796	1.000	rs12436146	chr14:81821282	A/G	cg02996355	chr14:81879375	NA	0.49	9.75	0.36	4.77e-21	Night sleep phenotypes;
BRCA	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg19628046	chr18:33552617	C18orf21	0.56	11.5	0.41	6.2e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs17253792	0.659	rs34330219	chr14:56017375	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-7.99	-0.3	6.09e-15	Putamen volume;
BRCA	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg02659138	chr7:134003124	SLC35B4	0.34	10.78	0.39	5.39e-25	Mean platelet volume;
BRCA	cis	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg06521331	chr12:34319734	NA	-0.52	-10.17	-0.37	1.3e-22	Morning vs. evening chronotype;
BRCA	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg13770153	chr20:60521292	NA	-0.45	-10.81	-0.39	4.09e-25	Body mass index;
BRCA	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg14458575	chr2:238380390	NA	0.57	12.95	0.46	3.02e-34	Prostate cancer;
BRCA	cis	rs1030877	0.515	rs920217	chr2:105904662	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.64	-12.29	-0.44	2.52e-31	Obesity-related traits;
BRCA	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg13319975	chr6:146136371	FBXO30	-0.36	-8.38	-0.31	3.25e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.51	0.35	3.93e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.42	0.5	4.89e-41	Personality dimensions;
BRCA	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg04705435	chr11:17411270	KCNJ11	0.44	9.4	0.35	9.82e-20	Type 2 diabetes;
BRCA	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.9	-29.3	-0.76	2.97e-120	Schizophrenia;
BRCA	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg17691542	chr6:26056736	HIST1H1C	0.76	13.47	0.47	1.44e-36	Iron status biomarkers;
BRCA	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg27588902	chr6:42928151	GNMT	-0.31	-10.32	-0.38	3.3e-23	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg17143192	chr8:8559678	CLDN23	0.53	10.23	0.38	7.52e-23	Obesity-related traits;
BRCA	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.39	-0.44	9.32e-32	Chronic sinus infection;
BRCA	cis	rs9341808	0.754	rs978814	chr6:80959912	G/T	cg08355045	chr6:80787529	NA	0.37	9.53	0.35	3.26e-20	Sitting height ratio;
BRCA	cis	rs332507	0.673	rs2242426	chr3:124398031	A/G	cg05980111	chr3:124395277	KALRN	0.36	8.4	0.32	2.92e-16	Plateletcrit;
BRCA	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg11752832	chr7:134001865	SLC35B4	0.49	11.02	0.4	5.53e-26	Mean platelet volume;
BRCA	cis	rs3818285	0.679	rs552419	chr10:111630883	G/T	cg00817464	chr10:111662876	XPNPEP1	0.46	15.14	0.51	1.78e-44	Superior crus of antihelix expression;
BRCA	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10802521	chr3:52805072	NEK4	-0.33	-9.02	-0.34	2.22e-18	Bipolar disorder;
BRCA	trans	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.37	-9.05	-0.34	1.73e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9438901	0.655	rs609320	chr1:25717365	C/G	cg12421513	chr1:25599066	RHD	-0.47	-7.95	-0.3	8.26e-15	Red cell distribution width;
BRCA	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg21475434	chr5:93447410	FAM172A	0.67	8.74	0.33	2.02e-17	Diabetic retinopathy;
BRCA	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg23422044	chr7:1970798	MAD1L1	0.69	15.25	0.52	5.16e-45	Bipolar disorder;
BRCA	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg02297831	chr4:17616191	MED28	0.34	8.07	0.3	3.6e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7903847	0.642	rs2275089	chr10:99141205	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.66	-0.32	3.88e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg16325326	chr1:53192061	ZYG11B	0.79	20.91	0.64	2.3e-74	Monocyte count;
BRCA	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.13	-0.4	1.98e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs938554	0.513	rs3733588	chr4:9997303	A/G	cg00071950	chr4:10020882	SLC2A9	-0.38	-8.09	-0.3	3.1e-15	Blood metabolite levels;
BRCA	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg24069376	chr3:38537580	EXOG	-0.33	-9.43	-0.35	7.22e-20	Electrocardiographic conduction measures;
BRCA	cis	rs7246657	0.678	rs2972446	chr19:38129893	G/A	cg14683738	chr19:37701593	ZNF585B	-0.46	-7.91	-0.3	1.16e-14	Coronary artery calcification;
BRCA	cis	rs752010	0.841	rs7519983	chr1:42083369	C/T	cg06885757	chr1:42089581	HIVEP3	0.24	9.25	0.34	3.19e-19	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11764359	chr7:65958608	NA	0.8	19.51	0.61	7.85e-67	Aortic root size;
BRCA	cis	rs7677751	0.848	rs7673625	chr4:55088586	C/T	cg17187183	chr4:55093834	PDGFRA	0.44	9.2	0.34	5.19e-19	Corneal astigmatism;
BRCA	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg24558204	chr6:135376177	HBS1L	0.46	12.59	0.45	1.23e-32	Red blood cell count;
BRCA	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg13902645	chr11:5959945	NA	-0.47	-10.08	-0.37	2.94e-22	DNA methylation (variation);
BRCA	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg21475434	chr5:93447410	FAM172A	0.67	8.74	0.33	2.02e-17	Diabetic retinopathy;
BRCA	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg17143192	chr8:8559678	CLDN23	0.57	11.08	0.4	3.3e-26	Obesity-related traits;
BRCA	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07308232	chr7:1071921	C7orf50	-0.38	-7.87	-0.3	1.48e-14	Longevity;Endometriosis;
BRCA	cis	rs17384381	0.906	rs2300639	chr1:85823676	T/A	cg16011679	chr1:85725395	C1orf52	0.53	8.05	0.3	4e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	10.97	0.4	9.02e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg18402987	chr7:1209562	NA	0.42	8.02	0.3	5.22e-15	Longevity;Endometriosis;
BRCA	cis	rs7572733	0.576	rs6734781	chr2:198759973	G/A	cg00792783	chr2:198669748	PLCL1	0.46	10.07	0.37	3.08e-22	Dermatomyositis;
BRCA	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-11.17	-0.4	1.37e-26	Mood instability;
BRCA	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg02631126	chr6:28058918	ZSCAN12L1	-0.27	-7.85	-0.3	1.71e-14	Depression;
BRCA	cis	rs877282	1.000	rs11253367	chr10:773389	G/A	cg17470449	chr10:769945	NA	0.52	9.74	0.36	5.5e-21	Uric acid levels;
BRCA	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg11789530	chr4:8429930	ACOX3	0.57	14.54	0.5	1.42e-41	Response to antineoplastic agents;
BRCA	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg00409905	chr10:38381863	ZNF37A	0.57	12.55	0.44	1.91e-32	Extrinsic epigenetic age acceleration;
BRCA	cis	rs367615	0.918	rs4270746	chr5:108876839	T/C	cg17395555	chr5:108820864	NA	0.37	9.42	0.35	8.11e-20	Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg08085267	chr17:45401833	C17orf57	0.67	14.76	0.5	1.17e-42	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg07606381	chr6:8435919	SLC35B3	0.64	14.21	0.49	4.83e-40	Motion sickness;
BRCA	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg00701064	chr4:6280414	WFS1	0.68	17.67	0.57	3.6e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg00277334	chr10:82204260	NA	-0.85	-24.9	-0.7	3.41e-96	Post bronchodilator FEV1;
BRCA	cis	rs4812048	0.689	rs151360	chr20:57613373	T/C	cg14073986	chr20:57617431	SLMO2	0.49	8.33	0.31	4.99e-16	Mean platelet volume;
BRCA	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg07636037	chr3:49044803	WDR6	0.94	27.36	0.73	1.12e-109	Parkinson's disease;
BRCA	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg09307838	chr4:120376055	NA	0.64	14.08	0.49	1.96e-39	Corneal astigmatism;
BRCA	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03452623	chr4:187889614	NA	-0.28	-9.53	-0.35	3.31e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	11.15	0.4	1.72e-26	Platelet count;
BRCA	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-8.78	-0.33	1.51e-17	Response to antipsychotic treatment;
BRCA	trans	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.32	0.38	3.23e-23	Mean corpuscular volume;
BRCA	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg23711669	chr6:146136114	FBXO30	0.77	17.96	0.58	1.11e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-12.42	-0.44	6.72e-32	Total cholesterol levels;
BRCA	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg13256891	chr4:100009986	ADH5	0.55	10.27	0.38	5.22e-23	Smoking initiation;
BRCA	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.03	-0.54	7.47e-49	Alzheimer's disease (late onset);
BRCA	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25427524	chr10:38739819	LOC399744	-0.69	-16.76	-0.55	1.62e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg12483005	chr1:23474871	LUZP1	0.46	10.35	0.38	2.53e-23	Height;
BRCA	cis	rs1865721	0.728	rs8087297	chr18:73136221	T/A	cg26385618	chr18:73139727	C18orf62	-0.43	-10.54	-0.38	4.63e-24	Intelligence;
BRCA	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg11657440	chr19:46296263	DMWD	-0.57	-13.53	-0.47	7.15e-37	Coronary artery disease;
BRCA	cis	rs6545883	0.542	rs7584500	chr2:61692115	T/C	cg15711740	chr2:61764176	XPO1	-0.32	-7.81	-0.3	2.29e-14	Tuberculosis;
BRCA	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	13.05	0.46	1.08e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs921968	0.565	rs35594672	chr2:219589280	T/A	cg02176678	chr2:219576539	TTLL4	-0.4	-10.97	-0.4	8.94e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.53	0.38	5.1900000000000004e-24	Motion sickness;
BRCA	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg18479299	chr3:125709523	NA	-0.54	-8.36	-0.31	4.05e-16	Blood pressure (smoking interaction);
BRCA	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg24692254	chr21:30365293	RNF160	-0.46	-10.25	-0.38	6.51e-23	Dental caries;
BRCA	trans	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04565464	chr8:145669602	NFKBIL2	0.43	9.82	0.36	2.6e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs9649465	1.000	rs4588795	chr7:123349924	A/G	cg04330084	chr7:123175371	IQUB	0.3	8.36	0.31	3.85e-16	Migraine;
BRCA	cis	rs10242455	0.702	rs73403247	chr7:99088730	G/A	cg18809830	chr7:99032528	PTCD1	-0.62	-8.68	-0.32	3.31e-17	Blood metabolite levels;
BRCA	cis	rs490234	0.871	rs4837019	chr9:128276081	C/G	cg14078157	chr9:128172775	NA	-0.4	-9.25	-0.34	3.23e-19	Mean arterial pressure;
BRCA	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg18016565	chr1:150552671	MCL1	-0.36	-8.14	-0.31	2e-15	Tonsillectomy;
BRCA	cis	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg02751453	chr18:77725136	HSBP1L1	0.36	8.87	0.33	7e-18	Opioid sensitivity;
BRCA	trans	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.25	0.31	9.3e-16	Corneal astigmatism;
BRCA	cis	rs909002	0.849	rs1464306	chr1:32076261	T/C	cg13919466	chr1:32135498	COL16A1	-0.26	-8.75	-0.33	1.94e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-14.5	-0.5	2.16e-41	Monocyte count;
BRCA	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg26384229	chr12:38710491	ALG10B	0.84	21.62	0.65	3.14e-78	Heart rate;
BRCA	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg18196295	chr10:418757	DIP2C	0.49	11.87	0.43	1.6800000000000001e-29	Psychosis in Alzheimer's disease;
BRCA	trans	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg14791747	chr16:20752902	THUMPD1	0.4	9.35	0.35	1.51e-19	Cognitive test performance;
BRCA	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg07414643	chr4:187882934	NA	0.28	9.67	0.36	9.82e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg21573476	chr21:45109991	RRP1B	-0.34	-8.78	-0.33	1.44e-17	Mean corpuscular volume;
BRCA	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-8.37	-0.31	3.51e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg00071950	chr4:10020882	SLC2A9	0.38	8.05	0.3	4.18e-15	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs10089	0.953	rs10223203	chr5:127527646	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.6	-13.68	-0.48	1.46e-37	Ileal carcinoids;
BRCA	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.51	-0.38	6.16e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	12.84	0.45	9.45e-34	Lung cancer in ever smokers;
BRCA	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg24558204	chr6:135376177	HBS1L	0.48	13.24	0.46	1.53e-35	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	16.65	0.55	5.52e-52	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg06521331	chr12:34319734	NA	-0.54	-10.97	-0.4	9.24e-26	Morning vs. evening chronotype;
BRCA	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg04374321	chr14:90722782	PSMC1	-0.41	-8.44	-0.32	2.16e-16	Gut microbiota (bacterial taxa);
BRCA	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg26597838	chr10:835615	NA	0.89	13.85	0.48	2.47e-38	Eosinophil percentage of granulocytes;
BRCA	cis	rs2455799	0.613	rs7617039	chr3:15800740	A/G	cg16303742	chr3:15540471	COLQ	0.35	8.09	0.3	3.01e-15	Mean platelet volume;
BRCA	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.55	11.85	0.42	1.95e-29	Monocyte percentage of white cells;
BRCA	trans	rs1994135	0.594	rs10772096	chr12:33732869	A/G	cg26384229	chr12:38710491	ALG10B	0.39	8.84	0.33	8.9e-18	Resting heart rate;
BRCA	trans	rs4596713	0.508	rs12056979	chr9:71778946	A/G	cg16512924	chr15:28394682	HERC2	0.45	10.58	0.39	3.12e-24	Headache;
BRCA	cis	rs1971762	0.542	rs12303370	chr12:54091807	A/C	cg23533419	chr12:54090519	NA	-0.32	-8.12	-0.31	2.49e-15	Height;
BRCA	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.08	-0.3	3.3e-15	Total body bone mineral density;
BRCA	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.35	0.57	1.6e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11025559	0.643	rs11025570	chr11:20481109	T/A	cg19653624	chr11:20408972	PRMT3	-0.46	-8.98	-0.33	3e-18	Pursuit maintenance gain;
BRCA	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.5	-9.49	-0.35	4.43e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13126279	chr21:47581558	C21orf56	0.48	10.68	0.39	1.25e-24	Testicular germ cell tumor;
BRCA	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14442939	chr10:27389572	ANKRD26	0.69	11.43	0.41	1.2e-27	Breast cancer;
BRCA	cis	rs12618769	0.601	rs56118505	chr2:99139832	T/G	cg10123293	chr2:99228465	UNC50	0.41	7.91	0.3	1.14e-14	Bipolar disorder;
BRCA	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg26384229	chr12:38710491	ALG10B	0.74	17.53	0.57	1.85e-56	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg22800045	chr5:56110881	MAP3K1	0.68	12.93	0.46	3.81e-34	Initial pursuit acceleration;
BRCA	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs1003719	0.715	rs1981432	chr21:38541356	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.31	-0.49	1.67e-40	Eye color traits;
BRCA	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06028605	chr16:24865363	SLC5A11	0.44	9.77	0.36	4.08e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs912057	0.901	rs744056	chr6:6733540	A/G	cg06612196	chr6:6737390	NA	0.44	9.82	0.36	2.63e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06108461	chr20:60628389	TAF4	-0.8	-17.52	-0.57	2.09e-56	Body mass index;
BRCA	trans	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg26043149	chr18:55253948	FECH	-0.37	-8.12	-0.31	2.34e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.41	-0.35	9.07e-20	Alzheimer's disease;
BRCA	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg01262667	chr19:19385393	TM6SF2	0.39	8.37	0.31	3.7e-16	Nonalcoholic fatty liver disease;
BRCA	cis	rs9341808	0.527	rs7453746	chr6:80810013	T/G	cg08355045	chr6:80787529	NA	0.43	11.36	0.41	2.38e-27	Sitting height ratio;
BRCA	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg26031613	chr14:104095156	KLC1	-0.43	-8.41	-0.32	2.62e-16	Schizophrenia;
BRCA	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg14019146	chr3:50243930	SLC38A3	0.39	9.5	0.35	4.19e-20	Intelligence (multi-trait analysis);
BRCA	trans	rs1459104	0.866	rs28873990	chr11:54812748	G/A	cg15704280	chr7:45808275	SEPT13	0.63	8.25	0.31	8.87e-16	Body mass index;
BRCA	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.71	14.46	0.5	3.31e-41	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11764359	chr7:65958608	NA	-0.73	-16.06	-0.54	4.98e-49	Aortic root size;
BRCA	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	8.19	0.31	1.47e-15	Personality dimensions;
BRCA	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg26818010	chr10:134567672	INPP5A	-0.64	-13.44	-0.47	1.96e-36	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08564027	chr20:61660810	NA	0.85	22.66	0.67	6.95e-84	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg05340658	chr4:99064831	C4orf37	0.5	11.58	0.42	2.87e-28	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg26446133	chr18:72167187	CNDP2	-0.75	-14.61	-0.5	6.08e-42	Refractive error;
BRCA	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg00225070	chr15:80189496	MTHFS	0.41	10.04	0.37	3.87e-22	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
BRCA	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg00383909	chr3:49044727	WDR6	0.92	15.55	0.52	1.69e-46	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs926392	0.589	rs2019032	chr20:37680326	C/A	cg16355469	chr20:37678765	NA	0.51	12.31	0.44	2.15e-31	Dialysis-related mortality;
BRCA	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg27398817	chr8:82754497	SNX16	0.34	7.89	0.3	1.35e-14	Diastolic blood pressure;
BRCA	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg25809561	chr17:30822961	MYO1D	-0.43	-9.68	-0.36	8.92e-21	Schizophrenia;
BRCA	cis	rs4363385	0.747	rs6665575	chr1:152960506	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.52	-0.32	1.13e-16	Inflammatory skin disease;
BRCA	trans	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.72	-0.36	6.43e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9341808	0.718	rs9352803	chr6:80864667	G/T	cg08355045	chr6:80787529	NA	0.37	9.34	0.35	1.63e-19	Sitting height ratio;
BRCA	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	11.95	0.43	7.75e-30	Personality dimensions;
BRCA	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24110177	chr3:50126178	RBM5	0.53	15.55	0.52	1.82e-46	Body mass index;
BRCA	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg06159980	chr1:16340746	HSPB7	-0.38	-8.82	-0.33	1.11e-17	Dilated cardiomyopathy;
BRCA	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg17135325	chr3:160939158	NMD3	0.41	7.93	0.3	1.01e-14	Parkinson's disease;
BRCA	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg24101359	chr6:42928495	GNMT	0.63	15.5	0.52	3.2e-46	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-8.93	-0.33	4.67e-18	Alzheimer's disease;
BRCA	cis	rs78761021	0.867	rs8077150	chr17:9788769	C/T	cg26853458	chr17:9805074	RCVRN	0.37	8.36	0.31	4.06e-16	Type 2 diabetes;
BRCA	trans	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg02030672	chr11:45687055	CHST1	-0.4	-9.01	-0.34	2.42e-18	Obesity-related traits;
BRCA	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg08422745	chr4:174089978	GALNT7	-0.8	-18.4	-0.59	5.71e-61	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-9.28	-0.34	2.56e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7572733	0.534	rs2060488	chr2:198751637	T/G	cg00792783	chr2:198669748	PLCL1	0.47	10.25	0.38	6.42e-23	Dermatomyositis;
BRCA	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg15448220	chr1:150897856	SETDB1	0.35	7.9	0.3	1.26e-14	Melanoma;
BRCA	cis	rs7131987	0.683	rs12366505	chr12:29474110	C/T	cg09582351	chr12:29534625	ERGIC2	-0.43	-9.85	-0.36	2.03e-21	QT interval;
BRCA	cis	rs6694270	0.913	rs3935030	chr1:19116956	C/T	cg19637330	chr1:19110922	NA	-0.49	-8.86	-0.33	8.01e-18	Drug-induced liver injury (nitrofurantoin);
BRCA	cis	rs16858210	0.520	rs34190894	chr3:183550412	A/T	cg03417191	chr3:183542750	MAP6D1	-0.68	-10.61	-0.39	2.5300000000000002e-24	Menopause (age at onset);
BRCA	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg16339924	chr4:17578868	LAP3	0.66	16.7	0.55	3.21e-52	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6788895	1.000	rs74950732	chr3:150482621	C/T	cg09723797	chr3:150481914	SIAH2	0.72	8.6	0.32	6.26e-17	Breast cancer;
BRCA	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg11502198	chr6:26597334	ABT1	0.56	12.02	0.43	3.88e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg00383909	chr3:49044727	WDR6	0.98	15.72	0.53	2.59e-47	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg07080220	chr10:102295463	HIF1AN	0.48	10.21	0.37	8.66e-23	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.36	-0.41	2.25e-27	Gut microbiome composition (summer);
BRCA	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg22951483	chr13:113628068	MCF2L	-0.34	-8.02	-0.3	5.04e-15	Systolic blood pressure;
BRCA	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg05791153	chr7:19748676	TWISTNB	0.58	10.59	0.39	2.98e-24	Thyroid stimulating hormone;
BRCA	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.59	-0.39	3.05e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7011049	1.000	rs72648409	chr8:53857307	T/C	cg26025543	chr8:53854495	NA	0.55	9.5	0.35	4.24e-20	Systolic blood pressure;
BRCA	cis	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg26695010	chr11:65641043	EFEMP2	0.37	8.13	0.31	2.31e-15	Eosinophil percentage of white cells;
BRCA	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg06784218	chr1:46089804	CCDC17	0.5	11.67	0.42	1.14e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg03929089	chr4:120376271	NA	-0.66	-12.09	-0.43	1.9e-30	Coronary artery disease;
BRCA	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg14036092	chr11:66035641	RAB1B	0.4	10.76	0.39	6.55e-25	Gout;
BRCA	cis	rs12760731	0.565	rs12406779	chr1:178088936	C/G	cg00404053	chr1:178313656	RASAL2	0.66	8.07	0.3	3.41e-15	Obesity-related traits;
BRCA	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg19508488	chr2:152266495	RIF1	0.49	10.65	0.39	1.73e-24	Lung cancer;
BRCA	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg09754948	chr16:28834200	ATXN2L	0.45	8.92	0.33	5.02e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg14664628	chr15:75095509	CSK	-0.95	-28.82	-0.75	1.21e-117	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	trans	rs3960554	0.932	rs60717745	chr7:75846083	C/G	cg19862616	chr7:65841803	NCRNA00174	0.59	11.0	0.4	6.51e-26	Eotaxin levels;
BRCA	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	10.41	0.38	1.45e-23	Height;
BRCA	trans	rs8002861	0.935	rs9525865	chr13:44459647	A/T	cg17145862	chr1:211918768	LPGAT1	0.73	19.38	0.61	3.68e-66	Leprosy;
BRCA	cis	rs9837602	0.935	rs56233205	chr3:99821679	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	8.69	0.33	3.01e-17	Breast cancer;
BRCA	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.85	0.45	8.83e-34	Bipolar disorder;
BRCA	cis	rs16976116	0.803	rs28590021	chr15:55490993	C/T	cg11288833	chr15:55489084	RSL24D1	0.47	10.61	0.39	2.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg06618935	chr21:46677482	NA	-0.35	-7.85	-0.3	1.75e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg06046430	chr4:77819534	ANKRD56	0.58	12.69	0.45	4.5e-33	Emphysema distribution in smoking;
BRCA	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg19318889	chr4:1322082	MAEA	0.57	11.78	0.42	4.14e-29	Longevity;
BRCA	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-8.81	-0.33	1.2e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg11890956	chr21:40555474	PSMG1	-0.55	-11.8	-0.42	3.26e-29	Menarche (age at onset);
BRCA	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07343612	chr16:622815	PIGQ	-0.66	-21.19	-0.64	6.61e-76	Height;
BRCA	cis	rs17253792	0.822	rs75763956	chr14:56071176	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.59	8.12	0.31	2.46e-15	Putamen volume;
BRCA	cis	rs3099143	1.000	rs3099142	chr15:77104909	C/T	cg21673338	chr15:77095150	SCAPER	-0.53	-9.4	-0.35	9.79e-20	Recalcitrant atopic dermatitis;
BRCA	cis	rs495337	0.736	rs967305	chr20:48459946	G/C	cg17835207	chr20:48524531	SPATA2	0.5	10.94	0.4	1.22e-25	Psoriasis;
BRCA	cis	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg04990556	chr1:26633338	UBXN11	0.55	9.24	0.34	3.56e-19	Obesity-related traits;
BRCA	cis	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg09307838	chr4:120376055	NA	0.44	9.63	0.36	1.43e-20	Diastolic blood pressure;
BRCA	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg20673091	chr1:2541236	MMEL1	0.33	8.51	0.32	1.27e-16	Ulcerative colitis;
BRCA	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg26384229	chr12:38710491	ALG10B	0.57	13.16	0.46	3.66e-35	Morning vs. evening chronotype;
BRCA	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-18.03	-0.58	4.83e-59	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg25214090	chr10:38739885	LOC399744	0.55	12.05	0.43	2.91e-30	Corneal astigmatism;
BRCA	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg13010199	chr12:38710504	ALG10B	0.51	10.02	0.37	4.91e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2425143	0.818	rs11167280	chr20:34560526	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-7.97	-0.3	7.08e-15	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg05340658	chr4:99064831	C4orf37	-0.68	-17.22	-0.56	7.01e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs501916	0.554	rs10851460	chr15:48092994	A/G	cg16110827	chr15:48056943	SEMA6D	0.38	8.04	0.3	4.3e-15	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg00277334	chr10:82204260	NA	-0.42	-8.23	-0.31	1.04e-15	Post bronchodilator FEV1;
BRCA	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg20290983	chr6:43655470	MRPS18A	0.8	21.08	0.64	2.58e-75	IgG glycosylation;
BRCA	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg22705602	chr4:152727874	NA	-0.36	-8.84	-0.33	9.35e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg13047869	chr3:10149882	C3orf24	-0.52	-11.14	-0.4	1.83e-26	Alzheimer's disease;
BRCA	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg23422044	chr7:1970798	MAD1L1	-0.71	-12.67	-0.45	5.67e-33	Bipolar disorder;
BRCA	cis	rs3008870	0.816	rs1118392	chr1:67366549	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.75	-16.4	-0.54	1e-50	Lymphocyte percentage of white cells;
BRCA	cis	rs9318086	0.648	rs35449605	chr13:24472582	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.32	8.97	0.33	3.24e-18	Myopia (pathological);
BRCA	cis	rs9420	0.961	rs7938083	chr11:57493622	C/A	cg19752551	chr11:57585705	CTNND1	-0.48	-11.43	-0.41	1.17e-27	Schizophrenia;
BRCA	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg03060546	chr3:49711283	APEH	0.6	9.83	0.36	2.5e-21	Menarche (age at onset);
BRCA	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg26384229	chr12:38710491	ALG10B	0.68	14.12	0.49	1.32e-39	Morning vs. evening chronotype;
BRCA	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg18252515	chr7:66147081	NA	1.04	15.68	0.53	4.14e-47	Diabetic kidney disease;
BRCA	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg06115741	chr20:33292138	TP53INP2	0.35	7.89	0.3	1.29e-14	Glomerular filtration rate (creatinine);
BRCA	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.08e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7809950	0.817	rs62483725	chr7:107201575	G/A	cg23024343	chr7:107201750	COG5	-0.48	-9.92	-0.37	1.1e-21	Coronary artery disease;
BRCA	trans	rs208520	0.837	rs208488	chr6:66926902	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.36	-0.54	1.72e-50	Exhaled nitric oxide output;
BRCA	cis	rs2594989	1.000	rs346081	chr3:11329085	A/G	cg01796438	chr3:11312864	ATG7	-0.53	-8.38	-0.31	3.29e-16	Circulating chemerin levels;
BRCA	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg01304814	chr3:48885189	PRKAR2A	0.57	7.97	0.3	7.2e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.56	-0.35	2.56e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.17	0.31	1.68e-15	Depression;
BRCA	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg13047869	chr3:10149882	C3orf24	0.53	11.24	0.41	6.83e-27	Alzheimer's disease;
BRCA	cis	rs698833	0.892	rs1067403	chr2:44675851	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	9.21	0.34	4.79e-19	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs6840360	0.533	rs4696297	chr4:152725838	T/G	cg22705602	chr4:152727874	NA	0.39	10.37	0.38	2.19e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg02574844	chr11:5959923	NA	-0.44	-8.6	-0.32	5.99e-17	DNA methylation (variation);
BRCA	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg12062639	chr20:23401060	NAPB	0.87	10.46	0.38	9.93e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg05283184	chr6:79620031	NA	-0.42	-10.63	-0.39	1.99e-24	Intelligence (multi-trait analysis);
BRCA	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg04842962	chr6:43655489	MRPS18A	1.12	38.27	0.83	1.8e-167	IgG glycosylation;
BRCA	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg22800045	chr5:56110881	MAP3K1	-0.47	-9.35	-0.35	1.47e-19	Initial pursuit acceleration;
BRCA	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-12.95	-0.46	3.16e-34	Migraine;Coronary artery disease;
BRCA	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg16339924	chr4:17578868	LAP3	0.76	18.15	0.58	1.04e-59	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6942756	0.806	rs2694572	chr7:128911721	A/G	cg02491457	chr7:128862824	NA	0.57	12.07	0.43	2.25e-30	White matter hyperintensity burden;
BRCA	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg09904177	chr6:26538194	HMGN4	0.46	12.7	0.45	4.04e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.84	0.39	3.02e-25	Bipolar disorder;
BRCA	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-13.19	-0.46	2.49e-35	Bone mineral density;
BRCA	cis	rs12618769	0.543	rs72819971	chr2:99034846	T/G	cg10123293	chr2:99228465	UNC50	0.4	7.96	0.3	7.97e-15	Bipolar disorder;
BRCA	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.62	-0.42	1.85e-28	Response to antipsychotic treatment;
BRCA	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg22705602	chr4:152727874	NA	-0.37	-10.14	-0.37	1.7e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-9.44	-0.35	6.71e-20	Personality dimensions;
BRCA	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.5	0.32	1.34e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2985684	0.894	rs10147029	chr14:50020232	G/T	cg04989706	chr14:50066350	PPIL5	0.51	10.17	0.37	1.33e-22	Carotid intima media thickness;
BRCA	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	13.95	0.48	8.22e-39	Alzheimer's disease;
BRCA	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg25427524	chr10:38739819	LOC399744	-0.6	-10.51	-0.38	6.1e-24	Obesity (extreme);
BRCA	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg24069376	chr3:38537580	EXOG	0.31	8.2	0.31	1.28e-15	Electrocardiographic conduction measures;
BRCA	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg04166393	chr7:2884313	GNA12	0.48	9.17	0.34	6.17e-19	Height;
BRCA	cis	rs870825	0.616	rs2141258	chr4:185609576	A/C	cg04058563	chr4:185651563	MLF1IP	-0.68	-13.29	-0.47	8.77e-36	Blood protein levels;
BRCA	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg14675211	chr2:100938903	LONRF2	0.42	9.35	0.35	1.4e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-15.41	-0.52	8.48e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg12573674	chr2:1569213	NA	-0.55	-11.95	-0.43	7.83e-30	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs10504073	0.626	rs6472220	chr8:50008477	C/A	cg00325661	chr8:49890786	NA	0.38	11.26	0.41	5.75e-27	Blood metabolite ratios;
BRCA	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg20476274	chr7:133979776	SLC35B4	0.6	16.15	0.54	1.82e-49	Mean platelet volume;
BRCA	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg05347473	chr6:146136440	FBXO30	0.42	8.4	0.32	2.93e-16	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.5	0.35	4.18e-20	Morning vs. evening chronotype;
BRCA	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-12.42	-0.44	6.83e-32	Platelet count;
BRCA	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21659725	chr3:3221576	CRBN	-0.46	-9.58	-0.35	2.13e-20	Educational attainment;
BRCA	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg12927641	chr6:109611667	NA	-0.4	-10.39	-0.38	1.75e-23	Reticulocyte fraction of red cells;
BRCA	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg18132916	chr6:79620363	NA	-0.45	-10.17	-0.37	1.24e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06022373	chr22:39101656	GTPBP1	0.74	17.05	0.56	5.08e-54	Menopause (age at onset);
BRCA	cis	rs367943	0.698	rs10046061	chr5:112976533	A/G	cg12552261	chr5:112820674	MCC	0.37	7.87	0.3	1.5e-14	Type 2 diabetes;
BRCA	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-14.89	-0.51	2.92e-43	Chronic sinus infection;
BRCA	cis	rs2625529	0.824	rs16956328	chr15:72143855	A/T	cg16672083	chr15:72433130	SENP8	-0.83	-17.22	-0.56	7.53e-55	Red blood cell count;
BRCA	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg20607287	chr7:12443886	VWDE	-0.57	-8.03	-0.3	4.69e-15	Coronary artery disease;
BRCA	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg22920501	chr2:26401640	FAM59B	0.76	10.92	0.4	1.44e-25	Gut microbiome composition (summer);
BRCA	cis	rs600806	0.888	rs3879450	chr1:109909149	C/T	cg20591472	chr1:110008990	SYPL2	0.32	8.06	0.3	3.71e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7580658	0.545	rs13006847	chr2:127952263	C/T	cg16751203	chr2:127950803	CYP27C1	-0.28	-8.27	-0.31	7.95e-16	Protein C levels;
BRCA	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg12011299	chr4:100065546	ADH4	0.48	10.8	0.39	4.39e-25	Smoking initiation;
BRCA	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11764359	chr7:65958608	NA	-0.8	-19.57	-0.61	3.39e-67	Aortic root size;
BRCA	trans	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-15.56	-0.52	1.65e-46	Obesity-related traits;
BRCA	cis	rs6446731	0.593	rs6446728	chr4:3275650	A/G	cg08886695	chr4:3369023	RGS12	-0.38	-9.92	-0.37	1.1e-21	Mean platelet volume;
BRCA	cis	rs4588572	0.644	rs10805920	chr5:77698222	G/A	cg11547950	chr5:77652471	NA	-0.43	-8.36	-0.31	4.01e-16	Triglycerides;
BRCA	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg18132916	chr6:79620363	NA	-0.38	-7.82	-0.3	2.2e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs1865721	0.771	rs6566093	chr18:73136682	T/C	cg26385618	chr18:73139727	C18orf62	-0.43	-10.64	-0.39	1.88e-24	Intelligence;
BRCA	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.64	-0.36	1.27e-20	Alcohol dependence;
BRCA	cis	rs2463822	1.000	rs1881534	chr11:62085083	A/G	cg06239285	chr11:62104954	ASRGL1	0.61	8.89	0.33	6.39e-18	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg10556349	chr10:835070	NA	0.67	9.67	0.36	9.78e-21	Eosinophil percentage of granulocytes;
BRCA	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg02221750	chr19:17393354	ANKLE1	-0.65	-12.55	-0.44	1.92e-32	Systemic lupus erythematosus;
BRCA	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-10.85	-0.39	2.73e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg05714579	chr10:131428358	MGMT	-0.71	-17.98	-0.58	8.32e-59	Response to temozolomide;
BRCA	cis	rs9463078	0.874	rs2093903	chr6:45177482	A/C	cg25276700	chr6:44698697	NA	-0.36	-8.02	-0.3	5.18e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg05564831	chr3:52568323	NT5DC2	0.34	8.08	0.3	3.32e-15	Electroencephalogram traits;
BRCA	cis	rs12530845	0.830	rs73721678	chr7:135355710	T/G	cg23117316	chr7:135346802	PL-5283	-0.41	-9.5	-0.35	3.99e-20	Red blood cell traits;
BRCA	cis	rs12612619	0.732	rs12616092	chr2:27217228	G/A	cg00617064	chr2:27272375	NA	-0.32	-8.51	-0.32	1.25e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.33	-7.83	-0.3	1.98e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg01119278	chr6:110721349	DDO	-0.43	-10.46	-0.38	9.28e-24	Platelet distribution width;
BRCA	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7814319	0.899	rs1878638	chr8:97258719	C/T	cg20787634	chr8:97240163	UQCRB	-0.51	-11.83	-0.42	2.4e-29	Lung function (FVC);
BRCA	trans	rs208520	0.690	rs207114	chr6:66791703	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-20.76	-0.63	1.55e-73	Exhaled nitric oxide output;
BRCA	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.46	-0.35	5.87e-20	Alzheimer's disease;
BRCA	trans	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg25214090	chr10:38739885	LOC399744	0.38	8.73	0.33	2.24e-17	Diastolic blood pressure;
BRCA	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg26597838	chr10:835615	NA	0.8	14.26	0.49	3.06e-40	Eosinophil percentage of granulocytes;
BRCA	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.51	0.35	3.82e-20	Morning vs. evening chronotype;
BRCA	cis	rs2346177	0.875	rs4413204	chr2:46647092	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.38	7.85	0.3	1.72e-14	HDL cholesterol;
BRCA	cis	rs56399783	0.808	rs73049331	chr7:2799911	C/T	cg19731401	chr7:2775893	GNA12	0.49	7.9	0.3	1.23e-14	Childhood ear infection;
BRCA	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg04586622	chr2:25135609	ADCY3	0.43	10.68	0.39	1.29e-24	Body mass index;
BRCA	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25427524	chr10:38739819	LOC399744	-0.65	-15.66	-0.53	5.1e-47	Extrinsic epigenetic age acceleration;
BRCA	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-9.74	-0.36	5.28e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18404041	chr3:52824283	ITIH1	-0.38	-11.52	-0.41	5.06e-28	Electroencephalogram traits;
BRCA	cis	rs953387	1.000	rs4954392	chr2:136901607	A/G	cg05194412	chr2:137003533	NA	-0.37	-8.39	-0.32	3.07e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13732083	chr21:47605072	C21orf56	0.39	7.98	0.3	6.74e-15	Testicular germ cell tumor;
BRCA	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg17724175	chr1:150552817	MCL1	0.25	8.42	0.32	2.44e-16	Tonsillectomy;
BRCA	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg18230493	chr5:56204884	C5orf35	0.62	13.27	0.46	1.14e-35	Initial pursuit acceleration;
BRCA	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11644478	chr21:40555479	PSMG1	0.82	18.57	0.59	7.21e-62	Cognitive function;
BRCA	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.67	-0.61	9.89e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg24562669	chr7:97807699	LMTK2	-0.52	-13.1	-0.46	6.61e-35	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7551345	0.803	rs7513300	chr1:31698466	C/T	cg19084893	chr1:31688959	NA	-0.46	-10.04	-0.37	4.13e-22	Schizophrenia;
BRCA	cis	rs1577917	0.958	rs2660576	chr6:86651603	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.39	-0.41	1.76e-27	Response to antipsychotic treatment;
BRCA	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.91	-0.3	1.18e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00149659	chr3:10157352	C3orf10	1.03	17.8	0.58	7.26e-58	Alzheimer's disease;
BRCA	trans	rs11088226	0.801	rs2833886	chr21:33923872	C/A	cg09050820	chr6:167586206	TCP10L2	0.57	10.8	0.39	4.2e-25	Gastritis;
BRCA	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	13.98	0.48	6.35e-39	Calcium levels;
BRCA	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg12011299	chr4:100065546	ADH4	-0.51	-11.76	-0.42	5.05e-29	Alcohol dependence;
BRCA	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.74	16.0	0.53	9.97e-49	Lymphocyte counts;
BRCA	cis	rs11971779	0.715	rs6943973	chr7:139029893	G/C	cg07862535	chr7:139043722	LUC7L2	0.39	10.46	0.38	9.65e-24	Diisocyanate-induced asthma;
BRCA	trans	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg15556689	chr8:8085844	FLJ10661	-0.34	-7.88	-0.3	1.45e-14	Triglycerides;
BRCA	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg08885076	chr2:99613938	TSGA10	0.42	9.73	0.36	5.81e-21	Chronic sinus infection;
BRCA	cis	rs4887140	1.000	rs4887140	chr15:74046663	G/T	cg11789681	chr15:74046708	NA	0.55	9.03	0.34	2.07e-18	Glucose homeostasis traits;
BRCA	cis	rs4240897	0.935	rs1474868	chr1:12044164	A/G	cg13216073	chr1:12042593	MFN2	-0.55	-13.38	-0.47	3.71e-36	Tuberculosis;
BRCA	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg22431228	chr1:16359049	CLCNKA	-0.44	-9.82	-0.36	2.75e-21	Dilated cardiomyopathy;
BRCA	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg00666640	chr1:248458726	OR2T12	0.3	8.59	0.32	6.48e-17	Common traits (Other);
BRCA	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg17366294	chr4:99064904	C4orf37	0.42	9.78	0.36	3.87e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg12444411	chr7:2802554	GNA12	-0.36	-8.96	-0.33	3.52e-18	Height;
BRCA	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.82	0.3	2.21e-14	Aortic root size;
BRCA	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	8.02e-19	Lymphocyte counts;
BRCA	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg24324837	chr19:49891574	CCDC155	0.47	7.94	0.3	9.35e-15	Multiple sclerosis;
BRCA	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg10553204	chr2:20871195	GDF7	0.28	7.92	0.3	1.05e-14	Abdominal aortic aneurysm;
BRCA	cis	rs701145	0.585	rs1713853	chr3:153795595	A/G	cg17054900	chr3:154042577	DHX36	0.54	9.14	0.34	8.17e-19	Coronary artery disease;
BRCA	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg19622623	chr12:86230825	RASSF9	-0.33	-9.35	-0.35	1.47e-19	Major depressive disorder;
BRCA	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg02176678	chr2:219576539	TTLL4	-0.44	-11.63	-0.42	1.7e-28	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs883565	1.000	rs883565	chr3:39055317	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	0.38	7.81	0.3	2.42e-14	Handedness;
BRCA	cis	rs11249608	0.636	rs6868893	chr5:178449826	C/A	cg21905437	chr5:178450457	ZNF879	0.52	10.65	0.39	1.7e-24	Pubertal anthropometrics;
BRCA	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg15704280	chr7:45808275	SEPT13	0.84	18.84	0.6	2.54e-63	Height;
BRCA	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-13.5	-0.47	1.05e-36	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg11707556	chr5:10655725	ANKRD33B	0.44	9.75	0.36	5.06e-21	Coronary artery disease;
BRCA	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg23018236	chr17:30244563	NA	-0.71	-11.07	-0.4	3.42e-26	Hip circumference adjusted for BMI;
BRCA	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg16339924	chr4:17578868	LAP3	0.58	14.13	0.49	1.17e-39	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg16606324	chr3:10149918	C3orf24	0.55	10.84	0.39	2.97e-25	Alzheimer's disease;
BRCA	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg07741184	chr6:167504864	NA	0.28	8.19	0.31	1.44e-15	Crohn's disease;
BRCA	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg26031613	chr14:104095156	KLC1	-0.45	-8.75	-0.33	1.94e-17	Schizophrenia;
BRCA	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.36	0.44	1.23e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg20701182	chr2:24300061	SF3B14	0.57	8.93	0.33	4.55e-18	Lymphocyte counts;
BRCA	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.18	0.34	6.13e-19	Tonsillectomy;
BRCA	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18876405	chr7:65276391	NA	0.62	15.02	0.51	6.87e-44	Aortic root size;
BRCA	cis	rs17641971	0.662	rs2385229	chr8:50003869	T/C	cg00325661	chr8:49890786	NA	0.35	10.1	0.37	2.38e-22	Blood metabolite levels;
BRCA	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.45	0.38	1.08e-23	Motion sickness;
BRCA	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg06784218	chr1:46089804	CCDC17	0.45	10.85	0.39	2.66e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.87	17.77	0.58	9.98e-58	Platelet distribution width;
BRCA	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.59	12.53	0.44	2.3e-32	Lymphocyte counts;
BRCA	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg16586182	chr3:47516702	SCAP	0.62	14.4	0.49	6.48e-41	Colorectal cancer;
BRCA	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg12573674	chr2:1569213	NA	-0.43	-8.12	-0.31	2.37e-15	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-9.55	-0.35	2.62e-20	Tonsillectomy;
BRCA	cis	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.75	-0.33	1.93e-17	Resting heart rate;
BRCA	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.97	-0.37	7.48e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg13852791	chr20:30311386	BCL2L1	0.94	22.77	0.67	1.79e-84	Mean corpuscular hemoglobin;
BRCA	cis	rs490234	0.812	rs12351825	chr9:128265736	T/C	cg14078157	chr9:128172775	NA	-0.48	-10.96	-0.4	1.03e-25	Mean arterial pressure;
BRCA	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg13397359	chr6:42928475	GNMT	0.63	14.24	0.49	3.48e-40	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg08508325	chr11:3079039	CARS	-0.4	-14.23	-0.49	3.97e-40	Longevity;
BRCA	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg03146154	chr1:46216737	IPP	-0.44	-9.49	-0.35	4.59e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2108225	0.872	rs4618632	chr7:107440952	T/G	cg18560240	chr7:107437656	SLC26A3	-0.54	-11.23	-0.41	7.92e-27	Ulcerative colitis;
BRCA	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.5	-0.61	8.18e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg02896835	chr1:92012615	NA	-0.6	-15.79	-0.53	1.11e-47	Breast cancer;
BRCA	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18876405	chr7:65276391	NA	-0.51	-11.74	-0.42	5.96e-29	Aortic root size;
BRCA	cis	rs10193935	0.901	rs222464	chr2:42643889	C/T	cg27598129	chr2:42591480	NA	-0.88	-14.36	-0.49	9.66e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg27087555	chr16:88793112	FAM38A	-1.3	-16.55	-0.55	1.93e-51	Plateletcrit;
BRCA	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg10792982	chr14:105748885	BRF1	0.49	11.29	0.41	4.54e-27	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09256448	chr16:638327	NA	0.31	8.51	0.32	1.27e-16	Height;
BRCA	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg03711944	chr11:47377212	SPI1	-0.42	-10.08	-0.37	2.79e-22	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg01877450	chr7:97915802	BRI3	-0.38	-8.61	-0.32	5.73e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6545883	0.895	rs2177961	chr2:61560264	T/C	cg15711740	chr2:61764176	XPO1	0.53	13.45	0.47	1.7e-36	Tuberculosis;
BRCA	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg09307838	chr4:120376055	NA	0.75	16.18	0.54	1.37e-49	Corneal astigmatism;
BRCA	cis	rs1865760	0.541	rs1436309	chr6:25970109	T/A	cg17691542	chr6:26056736	HIST1H1C	0.5	10.38	0.38	1.89e-23	Height;
BRCA	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg20848291	chr7:100343083	ZAN	-0.62	-13.01	-0.46	1.76e-34	Other erythrocyte phenotypes;
BRCA	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg21535247	chr6:8435926	SLC35B3	0.42	9.5	0.35	4.14e-20	Motion sickness;
BRCA	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg04586622	chr2:25135609	ADCY3	0.46	11.49	0.41	6.43e-28	Body mass index;
BRCA	cis	rs858239	0.601	rs10278776	chr7:23169759	C/T	cg23682824	chr7:23144976	KLHL7	0.45	11.96	0.43	7.05e-30	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg12641515	chr19:46296257	DMWD	-0.57	-12.56	-0.44	1.73e-32	Coronary artery disease;
BRCA	cis	rs1971762	0.563	rs11170645	chr12:54079080	G/T	cg23533419	chr12:54090519	NA	-0.32	-8.11	-0.31	2.62e-15	Height;
BRCA	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg13010199	chr12:38710504	ALG10B	-0.35	-7.93	-0.3	9.69e-15	Morning vs. evening chronotype;
BRCA	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.02	14.89	0.51	2.87e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg06636001	chr8:8085503	FLJ10661	0.54	10.08	0.37	2.73e-22	Retinal vascular caliber;
BRCA	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-12.26	-0.44	3.51e-31	Tonsillectomy;
BRCA	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.17	-0.34	6.4e-19	Total body bone mineral density;
BRCA	cis	rs68170813	0.559	rs10953532	chr7:106881808	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.44	-0.32	2.13e-16	Coronary artery disease;
BRCA	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg04450456	chr4:17643702	FAM184B	0.36	10.47	0.38	8.41e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9487051	0.768	rs9398188	chr6:109526615	G/A	cg21918786	chr6:109611834	NA	-0.34	-8.97	-0.33	3.22e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg15017067	chr4:17643749	FAM184B	0.29	9.01	0.34	2.29e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs13095912	0.889	rs34765114	chr3:185335156	T/A	cg11274856	chr3:185301563	NA	0.36	9.01	0.34	2.32e-18	Systolic blood pressure;
BRCA	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-13.45	-0.47	1.65e-36	Morning vs. evening chronotype;
BRCA	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg23950597	chr19:37808831	NA	-0.72	-12.58	-0.45	1.42e-32	Coronary artery calcification;
BRCA	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg12641515	chr19:46296257	DMWD	-0.56	-12.52	-0.44	2.54e-32	Coronary artery disease;
BRCA	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-11.43	-0.41	1.2e-27	Chronic sinus infection;
BRCA	cis	rs7520050	0.966	rs7522601	chr1:46419021	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.76	0.36	4.47e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9309473	0.607	rs6716776	chr2:73587713	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-12.64	-0.45	7.83e-33	Metabolite levels;
BRCA	cis	rs4853036	0.904	rs2278934	chr2:70121197	T/C	cg02498382	chr2:70120550	SNRNP27	-0.54	-10.72	-0.39	8.68e-25	Colorectal or endometrial cancer;
BRCA	cis	rs6598955	0.543	rs112752634	chr1:26534217	G/A	cg12744634	chr1:26560303	CCDC21	0.32	8.64	0.32	4.46e-17	Obesity-related traits;
BRCA	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg13550731	chr2:172543902	DYNC1I2	0.93	30.86	0.77	9.53e-129	Schizophrenia;
BRCA	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	10.49	0.38	7.14e-24	Personality dimensions;
BRCA	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.97	0.33	3.39e-18	Ovarian reserve;
BRCA	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs208520	0.874	rs208512	chr6:66943869	C/G	cg07460842	chr6:66804631	NA	-0.82	-14.66	-0.5	3.52e-42	Exhaled nitric oxide output;
BRCA	trans	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg01620082	chr3:125678407	NA	-0.57	-8.08	-0.3	3.19e-15	Depression;
BRCA	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18876405	chr7:65276391	NA	0.7	18.55	0.59	9.27e-62	Aortic root size;
BRCA	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg13770153	chr20:60521292	NA	-0.43	-9.51	-0.35	3.76e-20	Body mass index;
BRCA	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg22189786	chr22:42395067	WBP2NL	0.43	8.75	0.33	1.91e-17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.42e-34	Alzheimer's disease (late onset);
BRCA	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg18252515	chr7:66147081	NA	-0.9	-12.92	-0.46	4.23e-34	Diabetic kidney disease;
BRCA	cis	rs10789491	1.000	rs4553120	chr1:47165729	C/T	cg15501359	chr1:47185051	KIAA0494	0.66	18.42	0.59	4.08e-61	Response to hepatitis C treatment;
BRCA	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg27661571	chr11:113659931	NA	-0.7	-10.89	-0.4	1.93e-25	Hip circumference adjusted for BMI;
BRCA	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg24803719	chr17:45855879	NA	-0.31	-8.1	-0.31	2.77e-15	IgG glycosylation;
BRCA	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	9.55	0.35	2.68e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg16576597	chr16:28551801	NUPR1	0.31	8.48	0.32	1.51e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs11191270	1.000	rs11191270	chr10:104124605	C/T	cg15320455	chr10:103880129	LDB1	0.5	8.18	0.31	1.5e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs68170813	0.599	rs6466162	chr7:106902625	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-8.97	-0.33	3.36e-18	Coronary artery disease;
BRCA	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg05863683	chr7:1912471	MAD1L1	0.38	8.23	0.31	1.02e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-8.96	-0.33	3.47e-18	Aortic root size;
BRCA	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg27170947	chr2:26402098	FAM59B	0.98	17.25	0.56	4.73e-55	Gut microbiome composition (summer);
BRCA	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.76	-0.57	1.24e-57	Chronic sinus infection;
BRCA	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-10.86	-0.39	2.43e-25	Schizophrenia;
BRCA	cis	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.4	1.52e-26	Morning vs. evening chronotype;
BRCA	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg07148914	chr20:33460835	GGT7	0.36	8.01	0.3	5.34e-15	Height;
BRCA	cis	rs4566357	0.615	rs4675139	chr2:227908527	G/A	cg05526886	chr2:227700861	RHBDD1	-0.38	-7.99	-0.3	6.19e-15	Coronary artery disease;
BRCA	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg03354898	chr7:1950403	MAD1L1	-0.59	-14.23	-0.49	3.9e-40	Bipolar disorder and schizophrenia;
BRCA	cis	rs7011049	1.000	rs4521776	chr8:53838833	G/C	cg26025543	chr8:53854495	NA	0.56	9.66	0.36	1.11e-20	Systolic blood pressure;
BRCA	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg08999081	chr20:33150536	PIGU	-0.33	-8.48	-0.32	1.56e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs2625529	0.627	rs12898585	chr15:72473928	T/C	cg16672083	chr15:72433130	SENP8	-0.75	-16.05	-0.54	6.09e-49	Red blood cell count;
BRCA	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.98	-0.33	3.09e-18	Mood instability;
BRCA	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15664640	chr17:80829946	TBCD	0.4	10.74	0.39	7.73e-25	Breast cancer;
BRCA	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg03929089	chr4:120376271	NA	0.49	8.21	0.31	1.24e-15	Axial length;
BRCA	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg04450456	chr4:17643702	FAM184B	-0.34	-10.01	-0.37	5.44e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9815354	0.812	rs17218103	chr3:41943724	A/G	cg03022575	chr3:42003672	ULK4	0.68	9.48	0.35	4.82e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06108461	chr20:60628389	TAF4	-0.99	-21.98	-0.66	3.68e-80	Body mass index;
BRCA	cis	rs66887589	0.934	rs56843000	chr4:120516597	T/C	cg09307838	chr4:120376055	NA	-0.44	-9.18	-0.34	5.72e-19	Diastolic blood pressure;
BRCA	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg00677455	chr12:58241039	CTDSP2	0.62	13.95	0.48	8.34e-39	Multiple sclerosis;
BRCA	cis	rs4363385	0.747	rs1415971	chr1:152965779	T/G	cg25856811	chr1:152973957	SPRR3	-0.35	-9.44	-0.35	7.12e-20	Inflammatory skin disease;
BRCA	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg06212747	chr3:49208901	KLHDC8B	0.51	8.0	0.3	5.96e-15	Menarche (age at onset);
BRCA	cis	rs6545883	0.718	rs2694624	chr2:61672313	C/A	cg15711740	chr2:61764176	XPO1	-0.53	-13.52	-0.47	8.07e-37	Tuberculosis;
BRCA	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg08508325	chr11:3079039	CARS	0.27	7.89	0.3	1.3e-14	Calcium levels;
BRCA	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg08885076	chr2:99613938	TSGA10	0.45	10.61	0.39	2.51e-24	Chronic sinus infection;
BRCA	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-11.55	-0.42	3.66e-28	Schizophrenia;
BRCA	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg13319975	chr6:146136371	FBXO30	-0.37	-8.56	-0.32	8.41e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18876405	chr7:65276391	NA	-0.63	-15.57	-0.52	1.36e-46	Aortic root size;
BRCA	cis	rs847851	0.630	rs9462021	chr6:34758640	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.88	-0.3	1.42e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg02466173	chr16:30829666	NA	-0.55	-11.65	-0.42	1.43e-28	Multiple myeloma;
BRCA	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg17063962	chr7:91808500	NA	0.58	13.58	0.47	4.22e-37	Breast cancer;
BRCA	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg10057126	chr4:77819792	ANKRD56	0.58	12.78	0.45	1.79e-33	Emphysema distribution in smoking;
BRCA	cis	rs812925	0.519	rs2922089	chr2:61625129	T/G	cg15711740	chr2:61764176	XPO1	0.33	8.1	0.31	2.86e-15	Immature fraction of reticulocytes;
BRCA	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg22705602	chr4:152727874	NA	-0.37	-10.08	-0.37	2.9e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7631605	0.905	rs9869432	chr3:37196601	A/G	cg15934958	chr3:37212084	LRRFIP2	0.39	8.82	0.33	1.11e-17	Cerebrospinal P-tau181p levels;
BRCA	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg12311346	chr5:56204834	C5orf35	-0.81	-16.05	-0.54	5.76e-49	Initial pursuit acceleration;
BRCA	trans	rs9951602	0.541	rs7243702	chr18:76645637	G/A	cg02800362	chr5:177631904	HNRNPAB	0.77	17.67	0.57	3.29e-57	Obesity-related traits;
BRCA	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg13628971	chr7:2884303	GNA12	0.47	9.82	0.36	2.8e-21	Height;
BRCA	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg03585969	chr10:35415529	CREM	0.48	10.22	0.37	8.56e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs11249608	0.548	rs10479519	chr5:178450693	T/C	cg21905437	chr5:178450457	ZNF879	0.53	11.12	0.4	2.22e-26	Pubertal anthropometrics;
BRCA	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	trans	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.9	0.3	1.22e-14	Corneal astigmatism;
BRCA	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.19e-40	Motion sickness;
BRCA	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg11502198	chr6:26597334	ABT1	0.58	12.64	0.45	7.69e-33	Intelligence (multi-trait analysis);
BRCA	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg05623727	chr3:50126028	RBM5	0.42	10.02	0.37	4.59e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg25036284	chr2:26402008	FAM59B	-0.66	-10.91	-0.4	1.6e-25	Gut microbiome composition (summer);
BRCA	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.3	-0.31	6.14e-16	Breast cancer;
BRCA	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg22920501	chr2:26401640	FAM59B	-0.91	-16.48	-0.55	3.91e-51	Gut microbiome composition (summer);
BRCA	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg10820045	chr2:198174542	NA	-0.39	-9.07	-0.34	1.42e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg02176678	chr2:219576539	TTLL4	0.4	10.88	0.4	2.13e-25	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg16230307	chr14:35515116	FAM177A1	0.73	15.18	0.51	1.16e-44	Psoriasis;
BRCA	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.57	-0.61	3.58e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg08847533	chr14:75593920	NEK9	-0.87	-21.97	-0.66	3.87e-80	Height;
BRCA	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg21535247	chr6:8435926	SLC35B3	0.38	8.74	0.33	2.11e-17	Motion sickness;
BRCA	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg13256891	chr4:100009986	ADH5	0.54	10.01	0.37	5.06e-22	Smoking initiation;
BRCA	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00166722	chr3:10149974	C3orf24	0.55	10.74	0.39	7.48e-25	Alzheimer's disease;
BRCA	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.61	-0.32	5.8e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg17366294	chr4:99064904	C4orf37	0.53	11.22	0.41	8.92e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.54	-0.32	9.81e-17	Electroencephalogram traits;
BRCA	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11890956	chr21:40555474	PSMG1	-0.83	-21.15	-0.64	1.19e-75	Cognitive function;
BRCA	cis	rs6815814	0.950	rs55830619	chr4:38807364	G/A	cg06935464	chr4:38784597	TLR10	0.5	8.36	0.31	4.02e-16	Breast cancer;
BRCA	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-11.17	-0.4	1.39e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg11366901	chr6:160182831	ACAT2	0.83	16.28	0.54	4.3e-50	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	11.64	0.42	1.51e-28	Rheumatoid arthritis;
BRCA	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10802521	chr3:52805072	NEK4	-0.31	-7.95	-0.3	8.27e-15	Bipolar disorder;
BRCA	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-13.83	-0.48	3.01e-38	Morning vs. evening chronotype;
BRCA	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg25427524	chr10:38739819	LOC399744	-0.58	-10.0	-0.37	5.82e-22	Obesity (extreme);
BRCA	cis	rs11249608	0.636	rs13359549	chr5:178449178	T/A	cg21905437	chr5:178450457	ZNF879	0.5	10.61	0.39	2.55e-24	Pubertal anthropometrics;
BRCA	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg17757837	chr7:157058334	UBE3C	-0.72	-17.81	-0.58	6.54e-58	Body mass index;
BRCA	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg04267008	chr7:1944627	MAD1L1	-0.48	-10.13	-0.37	1.86e-22	Schizophrenia;
BRCA	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg24562669	chr7:97807699	LMTK2	0.44	11.84	0.42	2.19e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg18154014	chr19:37997991	ZNF793	0.62	11.63	0.42	1.75e-28	Coronary artery calcification;
BRCA	cis	rs9807989	0.507	rs4851577	chr2:103028921	T/C	cg03938978	chr2:103052716	IL18RAP	0.29	8.37	0.31	3.62e-16	Asthma;
BRCA	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.56	-0.47	5.53e-37	Developmental language disorder (linguistic errors);
BRCA	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg15556689	chr8:8085844	FLJ10661	0.38	9.95	0.37	8.97e-22	Neuroticism;
BRCA	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg07741184	chr6:167504864	NA	0.27	8.02	0.3	5.15e-15	Crohn's disease;
BRCA	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.14	-0.31	2.11e-15	Total body bone mineral density;
BRCA	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg25427524	chr10:38739819	LOC399744	0.58	13.07	0.46	8.93e-35	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10242455	0.557	rs2404487	chr7:99038057	G/A	cg18809830	chr7:99032528	PTCD1	-0.63	-8.98	-0.33	3.13e-18	Blood metabolite levels;
BRCA	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg20701182	chr2:24300061	SF3B14	0.59	9.19	0.34	5.66e-19	Lymphocyte counts;
BRCA	cis	rs16866061	1.000	rs17480230	chr2:225399864	G/A	cg12698349	chr2:225449008	CUL3	0.79	20.56	0.63	1.72e-72	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.73	0.6	9.84e-63	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg24692254	chr21:30365293	RNF160	-0.62	-15.86	-0.53	5.22e-48	Dental caries;
BRCA	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg21475434	chr5:93447410	FAM172A	0.67	8.6	0.32	6.25e-17	Diabetic retinopathy;
BRCA	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg05283184	chr6:79620031	NA	-0.42	-10.8	-0.39	4.41e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-12.32	-0.44	1.93e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg22903471	chr2:27725779	GCKR	-0.38	-9.29	-0.35	2.33e-19	Total body bone mineral density;
BRCA	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg04545296	chr12:48745243	ZNF641	-0.25	-8.34	-0.31	4.66e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg22713356	chr15:30763199	NA	1.3	24.75	0.7	2.51e-95	Uric acid levels;
BRCA	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.44	-0.32	2.14e-16	Total body bone mineral density;
BRCA	cis	rs9807989	0.507	rs3755266	chr2:103042712	G/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.39	0.31	3.2e-16	Asthma;
BRCA	cis	rs72627509	0.904	rs58408429	chr4:57769824	T/C	cg26694713	chr4:57773883	REST	0.48	9.34	0.35	1.58e-19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	16.95	0.56	1.65e-53	Platelet count;
BRCA	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.54	-9.76	-0.36	4.35e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg06453172	chr10:134556979	INPP5A	-0.54	-11.54	-0.42	3.92e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.61	-13.87	-0.48	1.89e-38	Ulcerative colitis;
BRCA	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg11752832	chr7:134001865	SLC35B4	0.53	13.59	0.47	3.95e-37	Mean platelet volume;
BRCA	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg03433033	chr1:76189801	ACADM	-0.51	-10.82	-0.39	3.72e-25	Daytime sleep phenotypes;
BRCA	cis	rs9443189	0.570	rs567903	chr6:76327851	C/T	cg01950844	chr6:76311363	SENP6	0.85	13.75	0.48	7.02e-38	Prostate cancer;
BRCA	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.57	-0.61	3.58e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.63	0.42	1.63e-28	Homoarginine levels;
BRCA	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg00106254	chr7:1943704	MAD1L1	-0.44	-11.85	-0.42	2e-29	Bipolar disorder and schizophrenia;
BRCA	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg08601574	chr20:25228251	PYGB	-0.34	-8.06	-0.3	3.75e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7011049	1.000	rs79169015	chr8:53843908	C/T	cg26025543	chr8:53854495	NA	0.56	9.66	0.36	1.11e-20	Systolic blood pressure;
BRCA	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg20019720	chr6:154832845	CNKSR3	0.52	10.31	0.38	3.64e-23	Lipoprotein (a) levels;
BRCA	cis	rs8028182	0.636	rs7163451	chr15:75861076	G/T	cg20655648	chr15:75932815	IMP3	0.45	8.82	0.33	1.06e-17	Sudden cardiac arrest;
BRCA	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.36	-0.47	4.23e-36	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6066835	1.000	rs4431002	chr20:47316585	C/T	cg18078177	chr20:47281410	PREX1	0.64	7.92	0.3	1.08e-14	Multiple myeloma;
BRCA	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg17173187	chr15:85201210	NMB	-0.43	-8.9	-0.33	5.66e-18	Schizophrenia;
BRCA	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.15	-48.94	-0.89	2.43e-218	Myeloid white cell count;
BRCA	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg21132104	chr15:45694354	SPATA5L1	0.65	13.37	0.47	3.98e-36	Homoarginine levels;
BRCA	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4853036	1.000	rs6718012	chr2:70078258	T/C	cg02498382	chr2:70120550	SNRNP27	-0.5	-9.1	-0.34	1.16e-18	Colorectal or endometrial cancer;
BRCA	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg03433033	chr1:76189801	ACADM	0.73	18.53	0.59	1.12e-61	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs3862030	0.720	rs11191295	chr10:104231054	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-12.14	-0.43	1.12e-30	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg05340658	chr4:99064831	C4orf37	-0.54	-10.69	-0.39	1.21e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13102973	0.965	rs4864244	chr4:135866959	A/G	cg14419869	chr4:135874104	NA	0.58	12.96	0.46	2.87e-34	Subjective well-being;
BRCA	cis	rs9314323	0.592	rs12165	chr8:26269412	C/T	cg11498726	chr8:26250323	BNIP3L	-0.4	-10.14	-0.37	1.7e-22	Red cell distribution width;
BRCA	cis	rs1018836	0.669	rs6471243	chr8:91656967	C/T	cg16814680	chr8:91681699	NA	0.82	20.32	0.63	3.36e-71	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs943466	1.000	rs11754690	chr6:33744157	G/A	cg25922239	chr6:33757077	LEMD2	-0.39	-7.84	-0.3	1.85e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs528301	0.868	rs542883	chr2:45143382	C/G	cg02372786	chr2:45167549	SIX3	-0.52	-11.87	-0.43	1.67e-29	Alcohol and nicotine co-dependence;
BRCA	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	8.29	0.31	6.67e-16	Breast cancer;
BRCA	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg19077165	chr18:44547161	KATNAL2	-0.52	-11.32	-0.41	3.43e-27	Personality dimensions;
BRCA	cis	rs9976767	0.637	rs9325635	chr21:43823289	G/A	cg23042151	chr21:43824109	UBASH3A	-0.28	-8.7	-0.33	2.7e-17	Type 1 diabetes;
BRCA	cis	rs12618769	0.652	rs72823801	chr2:99235055	A/G	cg10123293	chr2:99228465	UNC50	0.4	7.93	0.3	9.65e-15	Bipolar disorder;
BRCA	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-13.03	-0.46	1.44e-34	Monocyte count;
BRCA	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-9.12	-0.34	9.31e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17253792	0.598	rs35830444	chr14:56017350	T/C	cg01858014	chr14:56050164	KTN1	-0.61	-7.99	-0.3	6.09e-15	Putamen volume;
BRCA	cis	rs2336384	1.000	rs6668386	chr1:12047233	T/C	cg13216073	chr1:12042593	MFN2	0.44	9.41	0.35	8.81e-20	Platelet count;
BRCA	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg09184832	chr6:79620586	NA	-0.55	-12.1	-0.43	1.76e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs10899021	1.000	rs11236193	chr11:74368307	T/C	cg25880958	chr11:74394337	NA	-0.53	-8.07	-0.3	3.37e-15	Response to metformin (IC50);
BRCA	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg26384229	chr12:38710491	ALG10B	0.66	15.43	0.52	6.85e-46	Bladder cancer;
BRCA	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg02951883	chr7:2050386	MAD1L1	-0.39	-8.75	-0.33	1.95e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.42	-9.66	-0.36	1.1e-20	Longevity;Endometriosis;
BRCA	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg24642844	chr7:1081250	C7orf50	-0.56	-11.39	-0.41	1.8e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7178424	1.000	rs1436963	chr15:62374593	C/T	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.3	-0.31	6.42e-16	Height;
BRCA	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-8.82	-0.33	1.07e-17	Personality dimensions;
BRCA	cis	rs559928	0.947	rs12417275	chr11:64143774	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	9.65	0.36	1.21e-20	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	trans	rs1941687	0.583	rs8091977	chr18:31359414	T/C	cg27147174	chr7:100797783	AP1S1	-0.42	-8.36	-0.31	3.85e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21659725	chr3:3221576	CRBN	0.48	12.39	0.44	9.4e-32	Intelligence (multi-trait analysis);
BRCA	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg12219531	chr12:120966889	COQ5	0.55	11.44	0.41	1.07e-27	High light scatter reticulocyte count;
BRCA	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg18225595	chr11:63971243	STIP1	0.42	10.64	0.39	1.8e-24	Platelet count;
BRCA	cis	rs3815700	1.000	rs8108840	chr19:33094452	A/C	cg02997394	chr19:33096574	ANKRD27	0.66	11.09	0.4	2.89e-26	Eosinophilic esophagitis;
BRCA	cis	rs9837602	0.935	rs9810235	chr3:99736538	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	11.1	0.4	2.74e-26	Breast cancer;
BRCA	cis	rs3772130	0.961	rs13072618	chr3:121391833	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	9.38	0.35	1.16e-19	Cognitive performance;
BRCA	trans	rs9951602	0.512	rs9958376	chr18:76655167	G/T	cg02800362	chr5:177631904	HNRNPAB	0.78	18.13	0.58	1.44e-59	Obesity-related traits;
BRCA	cis	rs11945232	0.929	rs28736552	chr4:88356111	T/C	cg23841344	chr4:88312519	HSD17B11	-0.46	-9.2	-0.34	4.98e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg06453172	chr10:134556979	INPP5A	0.59	12.64	0.45	7.68e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11764359	chr7:65958608	NA	-0.75	-16.53	-0.55	2.26e-51	Aortic root size;
BRCA	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18876405	chr7:65276391	NA	-0.7	-18.44	-0.59	3.26e-61	Aortic root size;
BRCA	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg14664628	chr15:75095509	CSK	-0.53	-12.59	-0.45	1.25e-32	Breast cancer;
BRCA	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg22963979	chr7:1858916	MAD1L1	-0.4	-8.54	-0.32	9.75e-17	Bipolar disorder and schizophrenia;
BRCA	trans	rs8073060	0.586	rs225288	chr17:33929291	G/A	cg19694781	chr19:47549865	TMEM160	-1.06	-21.28	-0.64	2.4e-76	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg01939980	chr4:1354348	KIAA1530	0.38	8.92	0.33	4.8e-18	Obesity-related traits;
BRCA	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24531977	chr5:56204891	C5orf35	-0.88	-18.88	-0.6	1.53e-63	Initial pursuit acceleration;
BRCA	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg26384229	chr12:38710491	ALG10B	0.85	22.92	0.67	2.58e-85	Heart rate;
BRCA	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-8.44	-0.32	2.09e-16	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg25214090	chr10:38739885	LOC399744	0.43	10.0	0.37	5.45e-22	Educational attainment;
BRCA	cis	rs7715806	0.500	rs72633982	chr5:75001321	C/T	cg19683494	chr5:74908142	NA	0.53	8.61	0.32	5.76e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-15.65	-0.53	5.73e-47	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg07606381	chr6:8435919	SLC35B3	0.66	14.55	0.5	1.27e-41	Motion sickness;
BRCA	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.83	12.84	0.45	9.76e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1950500	0.545	rs1950501	chr14:24806800	C/G	cg16194253	chr14:24768981	DHRS1;C14orf21	0.39	8.05	0.3	4e-15	Height;
BRCA	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg15605315	chr1:45957053	TESK2	-0.44	-8.74	-0.33	2.08e-17	High light scatter reticulocyte count;
BRCA	trans	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg25214090	chr10:38739885	LOC399744	0.56	12.45	0.44	5.14e-32	Corneal astigmatism;
BRCA	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg27170947	chr2:26402098	FAM59B	0.71	13.07	0.46	9.11e-35	Gut microbiome composition (summer);
BRCA	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg19539972	chr4:7069911	GRPEL1	0.68	16.79	0.55	1.12e-52	Monocyte percentage of white cells;
BRCA	cis	rs7523050	0.730	rs72984628	chr1:109460808	G/A	cg08274380	chr1:109419600	GPSM2	0.96	14.13	0.49	1.19e-39	Fat distribution (HIV);
BRCA	cis	rs751728	0.664	rs4711349	chr6:33740592	C/T	cg25922239	chr6:33757077	LEMD2	0.52	13.18	0.46	2.84e-35	Crohn's disease;
BRCA	cis	rs10267417	0.657	rs7800274	chr7:19871184	G/T	cg07541023	chr7:19748670	TWISTNB	0.51	9.14	0.34	8.14e-19	Night sleep phenotypes;
BRCA	cis	rs17401966	1.000	rs12129035	chr1:10291166	G/A	cg03954927	chr1:10346856	KIF1B	0.44	13.05	0.46	1.08e-34	Hepatocellular carcinoma;
BRCA	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg05623727	chr3:50126028	RBM5	-0.37	-8.06	-0.3	3.86e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg18016565	chr1:150552671	MCL1	0.35	8.23	0.31	1.08e-15	Tonsillectomy;
BRCA	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg22189786	chr22:42395067	WBP2NL	0.43	8.64	0.32	4.43e-17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg18402987	chr7:1209562	NA	0.85	12.04	0.43	2.97e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg13906792	chr15:75199810	C15orf17	-0.39	-9.17	-0.34	6.5e-19	Breast cancer;
BRCA	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg07080220	chr10:102295463	HIF1AN	0.44	9.77	0.36	4.16e-21	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs13046373	0.535	rs2832970	chr21:32020767	T/C	cg24082983	chr21:31802169	KRTAP13-4	0.32	8.16	0.31	1.74e-15	HDL cholesterol;
BRCA	cis	rs113835537	0.529	rs7950790	chr11:66258053	G/A	cg24851651	chr11:66362959	CCS	0.41	7.91	0.3	1.16e-14	Airway imaging phenotypes;
BRCA	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-16.23	-0.54	7.7e-50	Alzheimer's disease (late onset);
BRCA	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.66	-13.1	-0.46	6.65e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg00071950	chr4:10020882	SLC2A9	0.47	11.35	0.41	2.48e-27	Bone mineral density;
BRCA	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-11.92	-0.43	1.05e-29	Bipolar disorder;
BRCA	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-10.53	-0.38	5.26e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg22535103	chr8:58192502	C8orf71	-0.44	-8.83	-0.33	9.86e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1506636	0.889	rs619075	chr7:123426317	A/T	cg03229431	chr7:123269106	ASB15	0.61	13.53	0.47	7.36e-37	Plateletcrit;Platelet count;
BRCA	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg14019146	chr3:50243930	SLC38A3	-0.42	-10.18	-0.37	1.18e-22	Body mass index;
BRCA	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	19.23	0.61	2.28e-65	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11644478	chr21:40555479	PSMG1	0.5	10.2	0.37	9.6e-23	Cognitive function;
BRCA	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg13010199	chr12:38710504	ALG10B	0.55	11.89	0.43	1.39e-29	Heart rate;
BRCA	cis	rs1003719	0.715	rs2835642	chr21:38539066	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.36	-0.49	1e-40	Eye color traits;
BRCA	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg02261765	chr11:831170	EFCAB4A	-0.39	-8.48	-0.32	1.53e-16	Mean platelet volume;
BRCA	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg06627628	chr2:24431161	ITSN2	-0.85	-15.66	-0.53	5.08e-47	Asthma;
BRCA	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg09654669	chr8:57350985	NA	-0.39	-8.74	-0.33	2.11e-17	Obesity-related traits;
BRCA	cis	rs7520050	0.902	rs4626927	chr1:46248645	C/T	cg24296786	chr1:45957014	TESK2	0.44	10.01	0.37	5.02e-22	Red blood cell count;Reticulocyte count;
BRCA	cis	rs10267417	0.603	rs10258555	chr7:19868344	T/G	cg05791153	chr7:19748676	TWISTNB	0.51	9.81	0.36	3.01e-21	Night sleep phenotypes;
BRCA	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg01802117	chr1:53393560	SCP2	-0.35	-8.17	-0.31	1.68e-15	Monocyte count;
BRCA	cis	rs9287719	0.649	rs10202370	chr2:10727043	T/C	cg00105475	chr2:10696890	NA	0.41	9.2	0.34	5.17e-19	Prostate cancer;
BRCA	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg12698349	chr2:225449008	CUL3	0.85	29.62	0.76	5.2e-122	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg26408565	chr15:76604113	ETFA	-0.47	-9.97	-0.37	7.26e-22	Blood metabolite levels;
BRCA	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	8.73	0.33	2.15e-17	Personality dimensions;
BRCA	trans	rs62578126	0.695	rs10760444	chr9:129396434	C/T	cg12286636	chr12:27933133	KLHDC5	0.38	9.67	0.36	1.02e-20	Eyebrow thickness;
BRCA	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	14.47	0.5	2.94e-41	Ileal carcinoids;
BRCA	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg02951883	chr7:2050386	MAD1L1	-0.48	-11.13	-0.4	2.09e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs311392	0.967	rs4255114	chr8:55089450	G/A	cg11783602	chr8:55087084	NA	-0.32	-9.49	-0.35	4.38e-20	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03517284	chr6:25882590	NA	0.48	10.84	0.39	3.03e-25	Blood metabolite levels;
BRCA	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg07051648	chr19:49177693	NTN5;SEC1	-0.43	-8.04	-0.3	4.44e-15	Dietary macronutrient intake;
BRCA	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg25427524	chr10:38739819	LOC399744	0.58	13.15	0.46	3.86e-35	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2051211	0.947	rs73065216	chr3:38524194	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.53	-10.36	-0.38	2.27e-23	QRS duration;
BRCA	cis	rs11608355	0.545	rs2302707	chr12:109893797	G/A	cg05360138	chr12:110035743	NA	0.71	13.18	0.46	2.85e-35	Neuroticism;
BRCA	cis	rs738322	0.805	rs2016755	chr22:38539604	A/G	cg20207973	chr22:38506712	BAIAP2L2	0.32	8.1	0.31	2.75e-15	Cutaneous nevi;
BRCA	cis	rs6570726	0.526	rs72994723	chr6:145722948	G/A	cg23711669	chr6:146136114	FBXO30	-0.44	-9.59	-0.35	1.9e-20	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg15704280	chr7:45808275	SEPT13	0.59	8.79	0.33	1.39e-17	Axial length;
BRCA	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg00383909	chr3:49044727	WDR6	0.73	12.69	0.45	4.51e-33	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11905131	chr22:24372483	LOC391322	-0.52	-11.79	-0.42	3.57e-29	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7072216	0.763	rs7910014	chr10:100172110	C/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.68	-0.36	9.24e-21	Metabolite levels;
BRCA	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-11.34	-0.41	2.75e-27	Menarche (age at onset);
BRCA	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.62	14.05	0.49	3.01e-39	Colorectal cancer;
BRCA	cis	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg07460842	chr6:66804631	NA	0.62	11.13	0.4	2.1e-26	Type 2 diabetes;
BRCA	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg05623727	chr3:50126028	RBM5	-0.51	-12.7	-0.45	3.97e-33	Body mass index;
BRCA	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg11812906	chr14:75593930	NEK9	-0.63	-14.62	-0.5	5.46e-42	Height;
BRCA	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg17330251	chr7:94953956	PON1	-0.42	-8.79	-0.33	1.39e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.99	0.37	6.2e-22	Bipolar disorder;
BRCA	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14829155	chr15:31115871	NA	-0.43	-10.14	-0.37	1.72e-22	Huntington's disease progression;
BRCA	cis	rs9309473	0.606	rs77962988	chr2:73886090	T/C	cg20560298	chr2:73613845	ALMS1	-0.44	-7.98	-0.3	6.64e-15	Metabolite levels;
BRCA	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg12483005	chr1:23474871	LUZP1	0.44	9.81	0.36	2.84e-21	Height;
BRCA	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.81	0.3	2.37e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6815814	0.898	rs1873195	chr4:38891173	C/T	cg02016764	chr4:38805732	TLR1	-0.49	-8.19	-0.31	1.41e-15	Breast cancer;
BRCA	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg04511125	chr2:88470314	THNSL2	0.79	11.39	0.41	1.74e-27	Plasma clusterin levels;
BRCA	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg11814155	chr7:99998594	ZCWPW1	0.48	8.59	0.32	6.58e-17	Platelet count;
BRCA	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg06784218	chr1:46089804	CCDC17	0.45	10.76	0.39	6.28e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	10.34	0.38	2.79e-23	Retinal vascular caliber;
BRCA	trans	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-14.06	-0.49	2.67e-39	Brugada syndrome;
BRCA	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg27478167	chr7:817139	HEATR2	-0.43	-9.22	-0.34	4.38e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs6545883	0.860	rs777589	chr2:61425621	T/C	cg15711740	chr2:61764176	XPO1	-0.52	-13.25	-0.46	1.42e-35	Tuberculosis;
BRCA	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	7.9	0.3	1.19e-14	Axial length;
BRCA	cis	rs198389	0.589	rs198391	chr1:11876417	C/T	cg06193043	chr1:11908199	NPPA	0.31	7.93	0.3	9.46e-15	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
BRCA	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg13319975	chr6:146136371	FBXO30	0.41	9.25	0.34	3.38e-19	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	8.05	0.3	4.12e-15	Retinal vascular caliber;
BRCA	trans	rs4714291	0.925	rs847750	chr6:40074250	G/A	cg02267698	chr19:7991119	CTXN1	0.42	8.17	0.31	1.64e-15	Strep throat;
BRCA	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19626725	chr5:178986131	RUFY1	0.35	10.66	0.39	1.5e-24	Lung cancer;
BRCA	cis	rs11920090	0.858	rs66683764	chr3:170720960	A/G	cg09710316	chr3:170744871	SLC2A2	0.58	9.65	0.36	1.19e-20	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg08999081	chr20:33150536	PIGU	-0.44	-11.97	-0.43	6.38e-30	Glomerular filtration rate (creatinine);
BRCA	trans	rs1973993	0.561	rs4127308	chr1:96990754	G/C	cg10631902	chr5:14652156	NA	-0.39	-9.87	-0.36	1.82e-21	Weight;
BRCA	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg05343316	chr1:45956843	TESK2	0.66	13.63	0.47	2.51e-37	Platelet count;
BRCA	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg17330251	chr7:94953956	PON1	0.43	9.19	0.34	5.61e-19	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs3857536	0.719	rs9363555	chr6:66930332	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.1	-0.31	2.78e-15	Blood trace element (Cu levels);
BRCA	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-10.45	-0.38	1.09e-23	Schizophrenia;
BRCA	cis	rs977987	0.778	rs4888400	chr16:75425596	G/C	cg03315344	chr16:75512273	CHST6	0.52	12.32	0.44	1.83e-31	Dupuytren's disease;
BRCA	cis	rs7617773	0.963	rs12494304	chr3:48178029	C/T	cg11946769	chr3:48343235	NME6	-0.39	-8.47	-0.32	1.69e-16	Coronary artery disease;
BRCA	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10802521	chr3:52805072	NEK4	-0.34	-9.3	-0.35	2.22e-19	Bipolar disorder;
BRCA	trans	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg05926928	chr17:57297772	GDPD1	0.52	10.61	0.39	2.41e-24	Schizophrenia;
BRCA	cis	rs4466137	0.903	rs3734092	chr5:83016743	C/T	cg16102102	chr5:83017553	HAPLN1	-0.92	-18.5	-0.59	1.69e-61	Prostate cancer;
BRCA	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-12.8	-0.45	1.41e-33	Alzheimer's disease;
BRCA	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06002616	chr8:101225028	SPAG1	-0.34	-8.28	-0.31	7.37e-16	Atrioventricular conduction;
BRCA	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg06238570	chr21:40685208	BRWD1	-0.46	-9.06	-0.34	1.61e-18	Cognitive function;
BRCA	cis	rs3772130	0.962	rs4280673	chr3:121526107	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.58	10.91	0.4	1.63e-25	Cognitive performance;
BRCA	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03517284	chr6:25882590	NA	0.67	15.19	0.52	1.01e-44	Blood metabolite levels;
BRCA	cis	rs3771570	1.000	rs73004354	chr2:242356239	G/T	cg21155796	chr2:242212141	HDLBP	0.61	9.26	0.34	3.11e-19	Prostate cancer;
BRCA	cis	rs1829883	0.835	rs2461972	chr5:98776454	G/A	cg08333243	chr5:99726346	NA	-0.35	-7.82	-0.3	2.23e-14	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs367943	1.000	rs348956	chr5:112821464	C/T	cg12552261	chr5:112820674	MCC	0.55	12.1	0.43	1.66e-30	Type 2 diabetes;
BRCA	cis	rs11874712	1.000	rs7244950	chr18:43676523	G/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.05	0.3	4.16e-15	Migraine - clinic-based;
BRCA	cis	rs61990749	0.597	rs176955	chr14:78181220	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	9.73	0.36	5.8e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg06623918	chr6:96969491	KIAA0776	0.72	12.33	0.44	1.69e-31	Migraine;Coronary artery disease;
BRCA	cis	rs68170813	0.559	rs6964966	chr7:106933099	C/G	cg02696742	chr7:106810147	HBP1	-0.53	-8.7	-0.33	2.87e-17	Coronary artery disease;
BRCA	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-20.02	-0.62	1.37e-69	Lymphocyte percentage of white cells;
BRCA	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg14036092	chr11:66035641	RAB1B	0.38	10.13	0.37	1.88e-22	Gout;
BRCA	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	18.79	0.6	4.58e-63	Smoking behavior;
BRCA	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg04733989	chr22:42467013	NAGA	-0.41	-8.84	-0.33	9.17e-18	Cognitive function;
BRCA	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg00666640	chr1:248458726	OR2T12	-0.34	-9.38	-0.35	1.09e-19	Common traits (Other);
BRCA	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg18850127	chr7:39170497	POU6F2	0.54	11.82	0.42	2.62e-29	IgG glycosylation;
BRCA	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg17366294	chr4:99064904	C4orf37	0.41	9.73	0.36	6e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2073300	1.000	rs34449811	chr20:23443771	T/C	cg12062639	chr20:23401060	NAPB	0.89	10.63	0.39	2.06e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	14.13	0.49	1.25e-39	Lymphocyte counts;
BRCA	cis	rs55665837	1.000	rs10047429	chr11:14439032	C/T	cg19336497	chr11:14380999	RRAS2	-0.36	-9.48	-0.35	4.83e-20	Vitamin D levels;
BRCA	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08280861	chr8:58055591	NA	-0.55	-8.81	-0.33	1.2e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg05340658	chr4:99064831	C4orf37	0.45	10.42	0.38	1.42e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	14.03	0.49	3.61e-39	Motion sickness;
BRCA	cis	rs6543140	0.964	rs2310301	chr2:103072935	C/T	cg04239558	chr2:103089729	SLC9A4	0.34	9.56	0.35	2.4e-20	Blood protein levels;
BRCA	cis	rs2464469	0.654	rs4646570	chr15:58343146	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.35	-9.01	-0.34	2.29e-18	Barrett's esophagus  or Esophageal adenocarcinoma;
BRCA	cis	rs7520050	0.902	rs9429088	chr1:46497500	T/A	cg24296786	chr1:45957014	TESK2	0.4	8.84	0.33	9.43e-18	Red blood cell count;Reticulocyte count;
BRCA	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg10932868	chr11:921992	NA	0.5	12.85	0.45	8.49e-34	Alzheimer's disease (late onset);
BRCA	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg07828340	chr4:882639	GAK	0.86	10.44	0.38	1.15e-23	Parkinson's disease;
BRCA	cis	rs41005	0.597	rs35400177	chr2:8101757	C/T	cg03155496	chr2:8117019	LOC339788	-0.5	-11.91	-0.43	1.13e-29	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg09307838	chr4:120376055	NA	0.61	11.2	0.41	1.06e-26	Corneal astigmatism;
BRCA	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg00701064	chr4:6280414	WFS1	0.66	15.68	0.53	4.11e-47	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg19847866	chr10:1019161	NA	0.49	10.2	0.37	9.8e-23	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg18016565	chr1:150552671	MCL1	-0.37	-8.5	-0.32	1.3e-16	Tonsillectomy;
BRCA	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg04450456	chr4:17643702	FAM184B	0.42	12.73	0.45	2.88e-33	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs16867321	0.950	rs1919152	chr2:181507765	C/T	cg23363182	chr2:181467187	NA	-0.44	-8.19	-0.31	1.42e-15	Obesity;
BRCA	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-12.1	-0.43	1.65e-30	Gut microbiome composition (summer);
BRCA	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.45	8.63	0.32	4.99e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg19743168	chr1:23544995	NA	0.45	11.12	0.4	2.31e-26	Height;
BRCA	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg03605463	chr16:89740564	NA	-0.63	-11.28	-0.41	4.99e-27	Vitiligo;
BRCA	cis	rs7072216	0.690	rs113195335	chr10:100175532	A/C	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.7	-0.36	7.5e-21	Metabolite levels;
BRCA	cis	rs17092148	1.000	rs17092148	chr20:33435161	A/C	cg16810054	chr20:33298113	TP53INP2	-0.45	-10.02	-0.37	4.59e-22	Neuroticism;
BRCA	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-10.01	-0.37	5.32e-22	Heart rate;
BRCA	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.36	12.32	0.44	1.94e-31	Bipolar disorder;
BRCA	cis	rs67981189	0.865	rs2810117	chr14:71391025	T/C	cg15816911	chr14:71606274	NA	-0.37	-8.25	-0.31	9.29e-16	Schizophrenia;
BRCA	cis	rs7918232	0.567	rs4749215	chr10:27312005	T/C	cg14442939	chr10:27389572	ANKRD26	0.46	8.52	0.32	1.12e-16	Breast cancer;
BRCA	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg19622623	chr12:86230825	RASSF9	-0.34	-9.43	-0.35	7.52e-20	Major depressive disorder;
BRCA	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	9.34	0.35	1.53e-19	Parkinson's disease;
BRCA	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.45	-0.38	1.05e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6435161	1.000	rs6435161	chr2:203519783	T/G	cg18429434	chr2:203499731	FAM117B	-0.44	-8.76	-0.33	1.78e-17	Total cholesterol levels;
BRCA	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.14	0.37	1.68e-22	Aortic root size;
BRCA	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg02176678	chr2:219576539	TTLL4	-0.48	-12.9	-0.45	5.31e-34	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg04362960	chr10:104952993	NT5C2	0.43	10.51	0.38	6.22e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs28374715	0.662	rs11852419	chr15:41456374	A/T	cg18705301	chr15:41695430	NDUFAF1	0.71	14.43	0.5	4.72e-41	Ulcerative colitis;
BRCA	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg23711669	chr6:146136114	FBXO30	-0.77	-17.93	-0.58	1.6e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg18129178	chr5:148520854	ABLIM3	-0.58	-11.65	-0.42	1.44e-28	Breast cancer;
BRCA	cis	rs10465746	0.570	rs11163887	chr1:84474718	C/T	cg10977910	chr1:84465055	TTLL7	0.55	11.38	0.41	1.85e-27	Obesity-related traits;
BRCA	cis	rs75229567	0.717	rs17107156	chr12:70234066	A/G	cg10114359	chr12:70132523	RAB3IP	-0.59	-8.65	-0.32	4.3e-17	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
BRCA	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg05340658	chr4:99064831	C4orf37	-0.43	-9.81	-0.36	2.98e-21	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4671400	0.571	rs12615222	chr2:61494895	C/T	cg15711740	chr2:61764176	XPO1	0.4	7.9	0.3	1.19e-14	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg10253484	chr15:75165896	SCAMP2	-0.5	-9.79	-0.36	3.53e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs7246657	0.722	rs2927742	chr19:38133618	T/C	cg14683738	chr19:37701593	ZNF585B	-0.46	-7.84	-0.3	1.96e-14	Coronary artery calcification;
BRCA	cis	rs10504073	0.584	rs17642664	chr8:49942945	A/G	cg00325661	chr8:49890786	NA	0.47	13.74	0.48	8.37e-38	Blood metabolite ratios;
BRCA	trans	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg04702396	chr17:15466718	FAM18B2	0.4	7.81	0.3	2.35e-14	Educational attainment (years of education);
BRCA	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg13047869	chr3:10149882	C3orf24	0.58	12.2	0.43	6.43e-31	Alzheimer's disease;
BRCA	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg19077165	chr18:44547161	KATNAL2	0.55	12.19	0.43	6.77e-31	Personality dimensions;
BRCA	cis	rs55882075	0.537	rs62406698	chr5:179110429	C/T	cg14593053	chr5:179126677	CANX	0.4	9.9	0.36	1.35e-21	Monocyte percentage of white cells;
BRCA	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg27279351	chr12:120934652	DYNLL1	0.52	12.24	0.44	4.28e-31	High light scatter reticulocyte count;
BRCA	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg14530993	chr4:882597	GAK	-0.53	-9.88	-0.36	1.65e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg00106254	chr7:1943704	MAD1L1	-0.43	-10.51	-0.38	6.14e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02475777	chr4:1388615	CRIPAK	0.67	13.04	0.46	1.3e-34	Longevity;
BRCA	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.35	8.35	0.31	4.1e-16	Tonsillectomy;
BRCA	trans	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.13	0.31	2.16e-15	Corneal astigmatism;
BRCA	cis	rs13315871	0.929	rs7643185	chr3:58311158	A/C	cg12435725	chr3:58293450	RPP14	0.47	7.91	0.3	1.13e-14	Cholesterol, total;
BRCA	cis	rs9790314	0.589	rs9790132	chr3:160627289	A/T	cg03342759	chr3:160939853	NMD3	0.42	8.11	0.31	2.63e-15	Morning vs. evening chronotype;
BRCA	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg25457927	chr22:38595422	NA	-0.32	-11.87	-0.43	1.63e-29	Cutaneous nevi;
BRCA	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.26	0.31	8.36e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg19336497	chr11:14380999	RRAS2	0.3	7.98	0.3	6.72e-15	Mitochondrial DNA levels;
BRCA	cis	rs870825	0.698	rs72703549	chr4:185623963	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.52	7.98	0.3	6.57e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg05347473	chr6:146136440	FBXO30	-0.64	-12.53	-0.44	2.25e-32	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg11833968	chr6:79620685	NA	-0.45	-10.03	-0.37	4.43e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.31	0.49	1.76e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs61990749	0.597	rs72685264	chr14:78152998	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.62	-9.53	-0.35	3.28e-20	Fibroblast growth factor basic levels;
BRCA	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg22713356	chr15:30763199	NA	1.29	24.0	0.69	3.29e-91	Uric acid levels;
BRCA	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg05340658	chr4:99064831	C4orf37	0.67	16.62	0.55	8.44e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2625529	0.824	rs12595464	chr15:72294398	C/T	cg16672083	chr15:72433130	SENP8	-0.85	-17.53	-0.57	1.89e-56	Red blood cell count;
BRCA	cis	rs2742234	0.541	rs61268333	chr10:43721370	G/A	cg02780029	chr10:43622663	RET	0.35	7.86	0.3	1.69e-14	Hirschsprung disease;
BRCA	cis	rs9831754	0.865	rs9842838	chr3:78387904	A/C	cg06138941	chr3:78371609	NA	-0.76	-16.49	-0.55	3.72e-51	Calcium levels;
BRCA	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg23978390	chr7:1156363	C7orf50	0.5	11.61	0.42	2.16e-28	Longevity;Endometriosis;
BRCA	cis	rs4919087	0.923	rs11189037	chr10:98974707	C/G	cg25902810	chr10:99078978	FRAT1	0.43	8.8	0.33	1.26e-17	Monocyte count;
BRCA	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg02493740	chr2:85810744	VAMP5	-0.53	-11.07	-0.4	3.46e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.45	-10.36	-0.38	2.37e-23	Schizophrenia;
BRCA	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg00717180	chr2:96193071	NA	-0.31	-8.71	-0.33	2.6e-17	HDL cholesterol;
BRCA	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	8.12	0.31	2.49e-15	Uric acid levels;
BRCA	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg00147160	chr1:26503991	CNKSR1	0.28	9.42	0.35	7.8e-20	Height;
BRCA	trans	rs9409565	0.826	rs9409778	chr9:97242839	G/A	cg05679027	chr9:99775184	HIATL2	-0.42	-9.23	-0.34	3.89e-19	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg22903471	chr2:27725779	GCKR	-0.38	-9.15	-0.34	7.38e-19	Menopause (age at onset);
BRCA	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	ch.11.42038R	chr11:967971	AP2A2	0.58	19.04	0.6	2.45e-64	Alzheimer's disease (late onset);
BRCA	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg03929089	chr4:120376271	NA	-0.66	-12.87	-0.45	7.18e-34	Coronary artery disease;
BRCA	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg24642439	chr20:33292090	TP53INP2	0.68	15.5	0.52	2.97e-46	Coronary artery disease;
BRCA	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg12011299	chr4:100065546	ADH4	0.48	10.94	0.4	1.21e-25	Smoking initiation;
BRCA	cis	rs4363385	0.747	rs6668215	chr1:152964498	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.25	-0.34	3.44e-19	Inflammatory skin disease;
BRCA	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg17640201	chr16:30407289	ZNF48	-0.67	-13.51	-0.47	8.79e-37	Tonsillectomy;
BRCA	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg08085267	chr17:45401833	C17orf57	-0.69	-15.2	-0.52	8.76e-45	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg22705602	chr4:152727874	NA	0.38	10.57	0.39	3.57e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	12.38	0.44	1.05e-31	Lung cancer in ever smokers;
BRCA	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg11663144	chr21:46675770	NA	-0.5	-10.03	-0.37	4.51e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs501916	0.602	rs472081	chr15:48058652	G/T	cg16110827	chr15:48056943	SEMA6D	-0.42	-9.13	-0.34	9.06e-19	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs1577917	1.000	rs1911552	chr6:86638024	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-11.54	-0.42	4.14e-28	Response to antipsychotic treatment;
BRCA	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg27398817	chr8:82754497	SNX16	-0.37	-8.57	-0.32	7.68e-17	Diastolic blood pressure;
BRCA	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg09307838	chr4:120376055	NA	0.7	14.24	0.49	3.67e-40	Corneal astigmatism;
BRCA	cis	rs34779708	0.736	rs34195979	chr10:35549817	T/C	cg03585969	chr10:35415529	CREM	0.43	8.71	0.33	2.56e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg14186256	chr22:23484241	RTDR1	0.76	22.75	0.67	2.33e-84	Bone mineral density;
BRCA	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.81	-0.45	1.36e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs68170813	0.559	rs75007274	chr7:106814543	G/A	cg02696742	chr7:106810147	HBP1	-0.54	-8.72	-0.33	2.4e-17	Coronary artery disease;
BRCA	trans	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.15	0.31	1.96e-15	Mean corpuscular volume;
BRCA	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg18132916	chr6:79620363	NA	-0.4	-7.98	-0.3	6.92e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-8.83	-0.33	9.91e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs3824867	0.920	rs7126210	chr11:47460306	A/G	cg20307385	chr11:47447363	PSMC3	0.51	11.31	0.41	3.56e-27	Mean corpuscular hemoglobin;
BRCA	cis	rs10779751	1.000	rs11121704	chr1:11293959	A/G	cg08854313	chr1:11322531	MTOR	-0.79	-16.59	-0.55	1.12e-51	Body mass index;
BRCA	trans	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg25042112	chr7:64838748	ZNF92	0.45	8.37	0.31	3.68e-16	Pain;
BRCA	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	11.14	0.4	1.9e-26	IgG glycosylation;
BRCA	cis	rs2880765	0.743	rs6416598	chr15:86011848	G/A	cg10818794	chr15:86012489	AKAP13	-0.31	-8.48	-0.32	1.59e-16	Coronary artery disease;
BRCA	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06028605	chr16:24865363	SLC5A11	0.43	9.68	0.36	8.76e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-8.8	-0.33	1.26e-17	Alzheimer's disease (late onset);
BRCA	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg15934090	chr1:100435551	SLC35A3	0.35	8.11	0.31	2.6e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg13854012	chr2:162103682	NA	-0.39	-8.7	-0.33	2.92e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg00852783	chr1:26633632	UBXN11	0.49	10.37	0.38	2.24e-23	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg12179176	chr11:130786555	SNX19	0.62	14.51	0.5	1.95e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
BRCA	cis	rs6121246	0.559	rs6060599	chr20:30257754	T/G	cg13852791	chr20:30311386	BCL2L1	0.95	22.95	0.67	1.76e-85	Mean corpuscular hemoglobin;
BRCA	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg10495392	chr1:46806563	NSUN4	0.44	8.15	0.31	1.97e-15	Menopause (age at onset);
BRCA	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg21475434	chr5:93447410	FAM172A	0.68	8.55	0.32	8.84e-17	Diabetic retinopathy;
BRCA	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21659725	chr3:3221576	CRBN	0.5	12.87	0.45	7.57e-34	Intelligence (multi-trait analysis);
BRCA	cis	rs791888	0.929	rs791887	chr10:89411554	A/G	cg13926569	chr10:89418898	PAPSS2	-0.35	-8.03	-0.3	4.66e-15	Magnesium levels;
BRCA	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg13852791	chr20:30311386	BCL2L1	0.84	18.04	0.58	3.93e-59	Mean corpuscular hemoglobin;
BRCA	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg26516362	chr5:178986906	RUFY1	0.44	11.78	0.42	3.98e-29	Lung cancer;
BRCA	cis	rs13046373	0.535	rs2832957	chr21:31973140	C/T	cg22337977	chr21:31811175	KRTAP15-1	0.34	8.16	0.31	1.8e-15	HDL cholesterol;
BRCA	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg11062466	chr8:58055876	NA	0.42	8.02	0.3	5.19e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg26248373	chr2:1572462	NA	-0.49	-10.42	-0.38	1.41e-23	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg13736514	chr6:26305472	NA	-0.46	-14.83	-0.51	5.92e-43	Educational attainment;
BRCA	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg15352829	chr14:105391018	PLD4	-0.38	-12.35	-0.44	1.35e-31	Rheumatoid arthritis;
BRCA	trans	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	14.6	0.5	6.91e-42	Exhaled nitric oxide output;
BRCA	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg25358565	chr5:93447407	FAM172A	1.14	18.39	0.59	6.32e-61	Diabetic retinopathy;
BRCA	cis	rs495337	0.736	rs595777	chr20:48474819	C/G	cg17835207	chr20:48524531	SPATA2	-0.5	-11.06	-0.4	3.87e-26	Psoriasis;
BRCA	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg06784218	chr1:46089804	CCDC17	0.45	10.77	0.39	5.62e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9815354	0.812	rs11129935	chr3:41985203	A/C	cg03022575	chr3:42003672	ULK4	0.7	9.76	0.36	4.45e-21	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg20587970	chr11:113659929	NA	-1.35	-24.23	-0.69	1.81e-92	Hip circumference adjusted for BMI;
BRCA	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05665937	chr4:1216051	CTBP1	0.52	11.3	0.41	4.08e-27	Obesity-related traits;
BRCA	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21659725	chr3:3221576	CRBN	0.7	20.95	0.64	1.37e-74	Intelligence (multi-trait analysis);
BRCA	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.69	0.55	3.53e-52	Colorectal cancer;
BRCA	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07930192	chr7:1003750	NA	0.4	8.69	0.33	3.03e-17	Longevity;Endometriosis;
BRCA	cis	rs2797160	1.000	rs1777194	chr6:126004883	G/A	cg05901451	chr6:126070800	HEY2	-0.39	-9.42	-0.35	7.86e-20	Endometrial cancer;
BRCA	cis	rs12541635	0.966	rs4734128	chr8:107026913	G/A	cg10147462	chr8:107024639	NA	0.36	9.75	0.36	5.03e-21	Age of smoking initiation;
BRCA	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg15704280	chr7:45808275	SEPT13	0.77	15.91	0.53	2.93e-48	Coronary artery disease;
BRCA	trans	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg13565492	chr6:43139072	SRF	-0.87	-15.16	-0.51	1.39e-44	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	-0.37	-8.18	-0.31	1.49e-15	Multiple sclerosis;
BRCA	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.54e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs877282	1.000	rs877281	chr10:771557	T/G	cg17470449	chr10:769945	NA	0.5	8.88	0.33	6.84e-18	Uric acid levels;
BRCA	trans	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg26043149	chr18:55253948	FECH	0.36	7.81	0.3	2.29e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9427116	0.502	rs903323	chr1:154572228	A/G	cg17218026	chr1:154582156	ADAR	-0.27	-8.37	-0.31	3.56e-16	Blood protein levels;
BRCA	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg25036284	chr2:26402008	FAM59B	-0.89	-15.1	-0.51	2.72e-44	Gut microbiome composition (summer);
BRCA	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg17211192	chr8:82754475	SNX16	-0.49	-11.16	-0.4	1.48e-26	Diastolic blood pressure;
BRCA	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	12.4	0.44	8.43e-32	Hip circumference adjusted for BMI;
BRCA	cis	rs9611519	1.000	rs4820433	chr22:41607065	C/G	cg03806693	chr22:41940476	POLR3H	-0.42	-8.08	-0.3	3.27e-15	Neuroticism;
BRCA	cis	rs8014204	0.816	rs28426374	chr14:75346740	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.41	-8.22	-0.31	1.14e-15	Caffeine consumption;
BRCA	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg03433033	chr1:76189801	ACADM	-0.38	-8.01	-0.3	5.62e-15	Daytime sleep phenotypes;
BRCA	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26384229	chr12:38710491	ALG10B	0.75	16.59	0.55	1.17e-51	Morning vs. evening chronotype;
BRCA	cis	rs34779708	0.801	rs12098720	chr10:35538683	G/A	cg03585969	chr10:35415529	CREM	0.45	9.22	0.34	4.14e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs17253792	0.822	rs45501402	chr14:56140115	C/T	cg01858014	chr14:56050164	KTN1	-0.75	-9.37	-0.35	1.25e-19	Putamen volume;
BRCA	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg20887711	chr4:1340912	KIAA1530	0.4	9.71	0.36	7.07e-21	Longevity;
BRCA	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg18016565	chr1:150552671	MCL1	0.35	8.29	0.31	6.92e-16	Tonsillectomy;
BRCA	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7246967	0.551	rs34907478	chr19:22928831	T/C	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs10504073	0.584	rs12546490	chr8:49932841	C/T	cg00325661	chr8:49890786	NA	0.5	14.18	0.49	6.82e-40	Blood metabolite ratios;
BRCA	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg02733842	chr7:1102375	C7orf50	-0.8	-13.59	-0.47	3.74e-37	Bronchopulmonary dysplasia;
BRCA	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.69	-14.01	-0.48	4.52e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs12541635	0.966	rs62527363	chr8:107024258	A/G	cg10147462	chr8:107024639	NA	0.37	10.37	0.38	2.09e-23	Age of smoking initiation;
BRCA	cis	rs6740322	0.857	rs11690012	chr2:43542480	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-12.45	-0.44	5.24e-32	Coronary artery disease;
BRCA	cis	rs4566357	0.595	rs10206912	chr2:227921095	A/T	cg05526886	chr2:227700861	RHBDD1	-0.42	-8.66	-0.32	3.76e-17	Coronary artery disease;
BRCA	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.64	10.42	0.38	1.43e-23	Renal function-related traits (BUN);
BRCA	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.43	-9.28	-0.34	2.58e-19	IgG glycosylation;
BRCA	cis	rs12474201	0.832	rs4953419	chr2:46989869	T/G	cg06386533	chr2:46925753	SOCS5	0.84	18.37	0.59	8.21e-61	Height;
BRCA	trans	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg27600084	chr12:12264075	NA	0.35	8.19	0.31	1.44e-15	Breast size;
BRCA	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.16	0.4	1.48e-26	Bipolar disorder;
BRCA	cis	rs8017423	0.608	rs12589866	chr14:90820977	T/C	cg04374321	chr14:90722782	PSMC1	-0.5	-12.16	-0.43	9.29e-31	Mortality in heart failure;
BRCA	cis	rs7246657	0.551	rs10407224	chr19:37651470	G/T	cg18154014	chr19:37997991	ZNF793	0.53	8.62	0.32	5.35e-17	Coronary artery calcification;
BRCA	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg00071950	chr4:10020882	SLC2A9	0.49	11.35	0.41	2.59e-27	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs4774830	0.744	rs2288346	chr15:56139153	T/C	cg05129572	chr15:56138634	NEDD4	-0.6	-8.46	-0.32	1.76e-16	Delta-5 desaturase activity;
BRCA	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.75	-0.42	5.46e-29	Alcohol dependence;
BRCA	cis	rs4363385	0.747	rs946097	chr1:152974732	A/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.54	-0.35	2.94e-20	Inflammatory skin disease;
BRCA	trans	rs6828577	0.729	rs35604604	chr4:119421152	C/A	cg26518628	chr1:97050305	NA	-0.46	-9.48	-0.35	4.74e-20	Perioperative myocardial infarction in coronary artery bypass surgery;
BRCA	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.88	0.43	1.44e-29	Homoarginine levels;
BRCA	trans	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.33	-9.01	-0.34	2.28e-18	Response to antipsychotic treatment;
BRCA	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg12219531	chr12:120966889	COQ5	0.55	11.44	0.41	1.11e-27	High light scatter reticulocyte count;
BRCA	cis	rs6088813	1.000	rs6088816	chr20:33982435	G/A	cg14752227	chr20:34000481	UQCC	-0.41	-8.85	-0.33	8.21e-18	Height;
BRCA	cis	rs11690935	0.589	rs62183782	chr2:172865009	T/A	cg13550731	chr2:172543902	DYNC1I2	0.49	12.09	0.43	1.91e-30	Schizophrenia;
BRCA	cis	rs17092148	0.945	rs6087622	chr20:33310471	A/G	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.3	-0.41	4.18e-27	Neuroticism;
BRCA	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	11.07	0.4	3.51e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg07148914	chr20:33460835	GGT7	0.38	8.62	0.32	5.21e-17	Height;
BRCA	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg27478167	chr7:817139	HEATR2	-0.57	-11.58	-0.42	2.69e-28	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12612619	0.732	rs11687536	chr2:27199754	C/T	cg00617064	chr2:27272375	NA	0.31	8.06	0.3	3.77e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs9297145	0.761	rs62473005	chr7:98742510	G/C	cg05967295	chr7:98741636	SMURF1	0.95	17.22	0.56	6.85e-55	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.6	0.55	9.62e-52	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg09436375	chr6:42928200	GNMT	-0.3	-10.99	-0.4	7.31e-26	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs977987	0.806	rs35263058	chr16:75391937	T/C	cg03315344	chr16:75512273	CHST6	0.53	12.65	0.45	6.77e-33	Dupuytren's disease;
BRCA	cis	rs965469	1.000	rs2236118	chr20:3302058	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-10.23	-0.37	7.84e-23	IFN-related cytopenia;
BRCA	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	17.94	0.58	1.39e-58	Colorectal cancer;
BRCA	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg27446573	chr6:127587934	RNF146	0.78	17.43	0.57	5.9e-56	Breast cancer;
BRCA	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg05283184	chr6:79620031	NA	-0.45	-11.48	-0.41	7.5e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18404041	chr3:52824283	ITIH1	0.43	12.79	0.45	1.56e-33	Bipolar disorder;
BRCA	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg24296786	chr1:45957014	TESK2	-0.39	-8.13	-0.31	2.17e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg00757033	chr12:89920650	WDR51B	0.54	11.08	0.4	3.21e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs3815700	1.000	rs2287670	chr19:33095057	G/A	cg02997394	chr19:33096574	ANKRD27	0.69	11.47	0.41	7.98e-28	Eosinophilic esophagitis;
BRCA	cis	rs2742234	0.504	rs7093409	chr10:43740067	A/G	cg02780029	chr10:43622663	RET	0.35	7.83	0.3	2.01e-14	Hirschsprung disease;
BRCA	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg24675658	chr1:53192096	ZYG11B	0.65	15.48	0.52	3.75e-46	Monocyte count;
BRCA	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19717773	chr7:2847554	GNA12	-0.41	-7.97	-0.3	7.1e-15	Height;
BRCA	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg13852791	chr20:30311386	BCL2L1	0.84	16.5	0.55	3.24e-51	Mean corpuscular hemoglobin;
BRCA	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg13010199	chr12:38710504	ALG10B	0.51	10.0	0.37	5.91e-22	Morning vs. evening chronotype;
BRCA	cis	rs4853036	0.629	rs13388084	chr2:70017663	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.87	-0.3	1.55e-14	Colorectal or endometrial cancer;
BRCA	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26384229	chr12:38710491	ALG10B	0.74	16.62	0.55	8.14e-52	Morning vs. evening chronotype;
BRCA	trans	rs17685	0.535	rs6953065	chr7:75601169	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.37	-8.97	-0.33	3.29e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs12681287	0.547	rs6471360	chr8:87513469	C/T	cg27223183	chr8:87520930	FAM82B	0.45	8.76	0.33	1.68e-17	Caudate activity during reward;
BRCA	cis	rs67981189	0.574	rs2810118	chr14:71388575	A/G	cg15816911	chr14:71606274	NA	-0.37	-8.45	-0.32	2e-16	Schizophrenia;
BRCA	cis	rs2249625	0.584	rs2463744	chr6:72875936	C/T	cg18830697	chr6:72922368	RIMS1	-0.64	-14.66	-0.5	3.57e-42	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	trans	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg26043149	chr18:55253948	FECH	1.1	23.64	0.68	2.83e-89	Gout;Urate levels;Serum uric acid levels;
BRCA	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg00953403	chr17:74099816	EXOC7	-0.52	-9.73	-0.36	5.79e-21	Psychosis in Alzheimer's disease;
BRCA	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg25173405	chr17:45401733	C17orf57	-0.49	-9.68	-0.36	9.34e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg15839431	chr19:19639596	YJEFN3	0.41	9.14	0.34	8.24e-19	Bipolar disorder;
BRCA	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg16414030	chr3:133502952	NA	-0.47	-10.95	-0.4	1.12e-25	Iron status biomarkers;
BRCA	cis	rs11608355	0.545	rs7969313	chr12:109907303	A/G	cg05360138	chr12:110035743	NA	0.7	12.83	0.45	1.09e-33	Neuroticism;
BRCA	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg14993813	chr1:46806288	NSUN4	0.47	9.22	0.34	4.1e-19	Menopause (age at onset);
BRCA	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg00701064	chr4:6280414	WFS1	0.68	17.62	0.57	5.86e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg13770153	chr20:60521292	NA	-0.42	-9.27	-0.34	2.73e-19	Body mass index;
BRCA	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg18132916	chr6:79620363	NA	-0.49	-11.13	-0.4	1.95e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg03060546	chr3:49711283	APEH	-0.61	-12.39	-0.44	9.33e-32	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg23033748	chr14:75592666	NEK9	-0.36	-8.51	-0.32	1.21e-16	Height;
BRCA	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg23711669	chr6:146136114	FBXO30	0.79	18.93	0.6	9.16e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12579753	0.810	rs10862350	chr12:82156202	G/A	cg07988820	chr12:82153109	PPFIA2	-0.44	-8.18	-0.31	1.54e-15	Resting heart rate;
BRCA	cis	rs701145	0.585	rs1727944	chr3:153826603	A/C	cg17054900	chr3:154042577	DHX36	-0.53	-9.06	-0.34	1.51e-18	Coronary artery disease;
BRCA	cis	rs2505998	0.833	rs2565203	chr10:43603735	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.44	-8.56	-0.32	8.21e-17	Hirschsprung disease;
BRCA	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg17366294	chr4:99064904	C4orf37	0.54	11.58	0.42	2.76e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs13046373	0.535	rs1354866	chr21:31981559	A/T	cg16812893	chr21:31813075	KRTAP15-1	0.38	9.64	0.36	1.32e-20	HDL cholesterol;
BRCA	cis	rs534126	0.744	rs10248147	chr7:142941023	C/G	cg21852589	chr7:142981689	TMEM139	-0.43	-10.13	-0.37	1.84e-22	Cancer;
BRCA	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg22875332	chr1:76189707	ACADM	0.62	11.47	0.41	7.96e-28	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.55	7.99	0.3	6.45e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.66	10.4	0.38	1.6e-23	Schizophrenia;
BRCA	cis	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg22455342	chr2:225449267	CUL3	0.35	8.59	0.32	6.59e-17	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.12	0.43	1.37e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg26384229	chr12:38710491	ALG10B	0.57	12.2	0.43	6.52e-31	Morning vs. evening chronotype;
BRCA	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg11266682	chr4:10021025	SLC2A9	-0.44	-11.66	-0.42	1.34e-28	Bone mineral density;
BRCA	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg18252515	chr7:66147081	NA	-1.07	-15.7	-0.53	3.09e-47	Diabetic kidney disease;
BRCA	trans	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Educational attainment;
BRCA	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18876405	chr7:65276391	NA	-0.5	-11.14	-0.4	1.82e-26	Aortic root size;
BRCA	cis	rs17401966	0.838	rs35759975	chr1:10474430	A/T	cg19773385	chr1:10388646	KIF1B	-0.37	-7.97	-0.3	7.1e-15	Hepatocellular carcinoma;
BRCA	cis	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg06521331	chr12:34319734	NA	-0.61	-11.15	-0.4	1.73e-26	Morning vs. evening chronotype;
BRCA	cis	rs1953600	0.870	rs2573353	chr10:81940917	A/C	cg04850286	chr10:81895943	PLAC9	-0.31	-8.94	-0.33	4e-18	Sarcoidosis;
BRCA	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.77	-0.36	4.22e-21	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg26384229	chr12:38710491	ALG10B	0.51	11.03	0.4	4.98e-26	Morning vs. evening chronotype;
BRCA	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg08807101	chr21:30365312	RNF160	-0.44	-9.35	-0.35	1.42e-19	Pancreatic cancer;
BRCA	cis	rs8038465	0.615	rs62004616	chr15:73961176	C/T	cg15420318	chr15:73925796	NPTN	0.41	9.16	0.34	7.03e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg20290983	chr6:43655470	MRPS18A	0.82	22.18	0.66	2.91e-81	IgG glycosylation;
BRCA	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg00101154	chr16:420108	MRPL28	-0.45	-10.56	-0.39	4.02e-24	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18876405	chr7:65276391	NA	-0.51	-11.86	-0.42	1.77e-29	Aortic root size;
BRCA	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg18230493	chr5:56204884	C5orf35	-0.74	-14.89	-0.51	2.85e-43	Initial pursuit acceleration;
BRCA	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg19784903	chr17:45786737	TBKBP1	0.34	8.15	0.31	1.86e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg21252483	chr19:49399788	TULP2	-0.41	-9.26	-0.34	3.11e-19	Red cell distribution width;
BRCA	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg17691542	chr6:26056736	HIST1H1C	0.53	11.44	0.41	1.05e-27	Height;
BRCA	cis	rs1997103	1.000	rs6948112	chr7:55411302	G/A	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.67	-16.41	-0.54	9.66e-51	Ulcerative colitis;
BRCA	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg20848291	chr7:100343083	ZAN	0.46	10.13	0.37	1.81e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg08601574	chr20:25228251	PYGB	0.41	9.54	0.35	2.85e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg18230493	chr5:56204884	C5orf35	0.55	11.07	0.4	3.47e-26	Coronary artery disease;
BRCA	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg10223061	chr2:219282414	VIL1	-0.27	-7.89	-0.3	1.36e-14	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg17420585	chr12:42539391	GXYLT1	-0.38	-8.12	-0.31	2.35e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg09359103	chr1:154839909	KCNN3	-0.58	-15.09	-0.51	3.28e-44	Prostate cancer;
BRCA	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg22907277	chr7:1156413	C7orf50	0.59	9.1	0.34	1.11e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg05340658	chr4:99064831	C4orf37	0.66	16.14	0.54	2.18e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11644478	chr21:40555479	PSMG1	-0.55	-11.79	-0.42	3.59e-29	Menarche (age at onset);
BRCA	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg18904891	chr8:8559673	CLDN23	0.63	12.34	0.44	1.55e-31	Obesity-related traits;
BRCA	cis	rs1035491	0.574	rs10461497	chr5:63942398	A/G	cg01791865	chr5:63954708	NA	0.33	8.44	0.32	2.16e-16	Body mass index;
BRCA	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.92	0.56	2.52e-53	Hypertriglyceridemia;
BRCA	cis	rs6723226	0.521	rs1991626	chr2:32602450	G/A	cg02381751	chr2:32503542	YIPF4	-0.46	-9.49	-0.35	4.64e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs12042938	1.000	rs4366301	chr1:231806286	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.37	-8.16	-0.31	1.84e-15	Neuranatomic and neurocognitive phenotypes;
BRCA	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg07395648	chr5:131743802	NA	-0.37	-7.95	-0.3	8.72e-15	Acylcarnitine levels;
BRCA	cis	rs877282	0.945	rs11253388	chr10:787852	A/G	cg17470449	chr10:769945	NA	0.51	8.63	0.32	4.87e-17	Uric acid levels;
BRCA	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg18512352	chr11:47633146	NA	-0.34	-8.24	-0.31	1e-15	Subjective well-being;
BRCA	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg06627628	chr2:24431161	ITSN2	0.51	8.22	0.31	1.11e-15	Lymphocyte counts;
BRCA	cis	rs193541	0.632	rs2910135	chr5:122229790	C/T	cg19412675	chr5:122181750	SNX24	0.33	7.9	0.3	1.2e-14	Glucose homeostasis traits;
BRCA	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg24558204	chr6:135376177	HBS1L	-0.42	-10.93	-0.4	1.32e-25	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	trans	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg21659725	chr3:3221576	CRBN	-0.45	-9.61	-0.36	1.69e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs4908768	0.501	rs11121186	chr1:8540341	G/A	cg20416874	chr1:8611966	RERE	-0.27	-7.97	-0.3	7.25e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs495337	0.736	rs627898	chr20:48480254	A/C	cg17835207	chr20:48524531	SPATA2	-0.5	-11.0	-0.4	6.92e-26	Psoriasis;
BRCA	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg06784218	chr1:46089804	CCDC17	-0.47	-10.55	-0.39	4.12e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.46	-0.32	1.86e-16	Breast cancer;
BRCA	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg04691961	chr3:161091175	C3orf57	-0.47	-11.15	-0.4	1.72e-26	Morning vs. evening chronotype;
BRCA	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.58	-0.61	3.27e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs3857536	0.706	rs7755994	chr6:66891747	T/C	cg07460842	chr6:66804631	NA	-0.46	-8.86	-0.33	8.14e-18	Blood trace element (Cu levels);
BRCA	cis	rs10129255	0.518	rs8009612	chr14:107185749	G/T	cg07958169	chr14:107095056	NA	-0.4	-8.67	-0.32	3.43e-17	Kawasaki disease;
BRCA	cis	rs4363385	0.818	rs10888525	chr1:153000215	G/A	cg24667326	chr1:152973720	SPRR3	-0.33	-9.01	-0.34	2.29e-18	Inflammatory skin disease;
BRCA	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8044868	0.586	rs7200854	chr16:72083318	G/A	cg16558253	chr16:72132732	DHX38	-0.45	-10.76	-0.39	6.27e-25	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
BRCA	cis	rs4671400	0.571	rs28480287	chr2:61489289	G/C	cg15711740	chr2:61764176	XPO1	0.39	7.9	0.3	1.21e-14	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.55	-12.74	-0.45	2.65e-33	Age at first birth;
BRCA	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg23711669	chr6:146136114	FBXO30	0.79	18.95	0.6	6.68e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7131987	0.801	rs6487804	chr12:29454934	G/A	cg09582351	chr12:29534625	ERGIC2	-0.46	-11.03	-0.4	5.22e-26	QT interval;
BRCA	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-13.0	-0.46	1.92e-34	Migraine;Coronary artery disease;
BRCA	cis	rs929596	0.556	rs10202865	chr2:234587707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.37	-9.07	-0.34	1.51e-18	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg26384229	chr12:38710491	ALG10B	-0.44	-10.07	-0.37	3.11e-22	Bladder cancer;
BRCA	cis	rs490234	0.588	rs35278449	chr9:128172963	C/G	cg14078157	chr9:128172775	NA	-0.55	-12.03	-0.43	3.54e-30	Mean arterial pressure;
BRCA	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg08807101	chr21:30365312	RNF160	0.52	12.92	0.46	4.15e-34	Dental caries;
BRCA	cis	rs586533	0.881	rs612614	chr11:99504950	T/C	cg22878054	chr11:99397252	CNTN5	0.32	8.12	0.31	2.44e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs953387	1.000	rs12616955	chr2:136902666	C/T	cg05194412	chr2:137003533	NA	-0.37	-8.51	-0.32	1.26e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-8.36	-0.31	3.94e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.34	-8.69	-0.33	3.1e-17	Total body bone mineral density;
BRCA	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg03146154	chr1:46216737	IPP	0.52	11.61	0.42	2.16e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg12310025	chr6:25882481	NA	-0.5	-11.91	-0.43	1.13e-29	Blood metabolite levels;
BRCA	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18876405	chr7:65276391	NA	-0.67	-16.99	-0.56	1.04e-53	Aortic root size;
BRCA	cis	rs4363385	0.747	rs1415960	chr1:152973571	G/T	cg25856811	chr1:152973957	SPRR3	-0.35	-9.27	-0.34	2.84e-19	Inflammatory skin disease;
BRCA	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg07148914	chr20:33460835	GGT7	-0.42	-9.1	-0.34	1.16e-18	Height;
BRCA	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg17892150	chr10:133769511	PPP2R2D	0.66	14.42	0.5	5.19e-41	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	13.29	0.47	9.64e-36	Lung cancer in ever smokers;
BRCA	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg24069376	chr3:38537580	EXOG	0.41	11.96	0.43	6.63e-30	Electrocardiographic conduction measures;
BRCA	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg19508488	chr2:152266495	RIF1	-0.49	-10.48	-0.38	7.71e-24	Lung cancer;
BRCA	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg09307838	chr4:120376055	NA	0.7	14.57	0.5	9.78e-42	Corneal astigmatism;
BRCA	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.34	-9.5	-0.35	4.15e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	11.89	0.43	1.4e-29	Personality dimensions;
BRCA	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	11.61	0.42	2e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg12193833	chr17:30244370	NA	0.51	8.41	0.32	2.64e-16	Hip circumference adjusted for BMI;
BRCA	cis	rs17406451	0.587	rs6544646	chr2:43576997	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.41	-8.84	-0.33	9.29e-18	Mitochondrial DNA levels;
BRCA	cis	rs7677751	0.806	rs7681399	chr4:55090886	T/G	cg17187183	chr4:55093834	PDGFRA	0.44	9.14	0.34	7.9e-19	Corneal astigmatism;
BRCA	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg09904177	chr6:26538194	HMGN4	0.47	14.7	0.5	2.27e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs28735056	0.967	rs623546	chr18:77595228	C/T	cg20368463	chr18:77673604	PQLC1	-0.34	-7.97	-0.3	7.21e-15	Schizophrenia;
BRCA	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg00173435	chr12:106696525	TCP11L2	0.55	9.75	0.36	4.89e-21	Tourette syndrome;
BRCA	cis	rs919433	0.713	rs6714697	chr2:198484486	C/T	cg00792783	chr2:198669748	PLCL1	0.35	8.16	0.31	1.82e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg22875332	chr1:76189707	ACADM	0.64	11.42	0.41	1.32e-27	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.59	10.15	0.37	1.51e-22	Gut microbiome composition (summer);
BRCA	cis	rs4363385	0.818	rs532743	chr1:153011758	T/G	cg25856811	chr1:152973957	SPRR3	-0.33	-8.56	-0.32	8.51e-17	Inflammatory skin disease;
BRCA	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.38	0.49	7.79e-41	Motion sickness;
BRCA	cis	rs4363385	0.747	rs1413849	chr1:152970233	C/A	cg21543102	chr1:152974771	SPRR3	-0.29	-8.06	-0.3	3.69e-15	Inflammatory skin disease;
BRCA	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg22903471	chr2:27725779	GCKR	-0.38	-9.22	-0.34	4.15e-19	Total body bone mineral density;
BRCA	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg23791538	chr6:167370224	RNASET2	0.49	12.5	0.44	3.14e-32	Crohn's disease;
BRCA	cis	rs939658	0.967	rs7171067	chr15:79452727	G/T	cg17916960	chr15:79447300	NA	0.42	10.48	0.38	7.75e-24	Refractive error;
BRCA	trans	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.61	13.75	0.48	7.14e-38	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg25809561	chr17:30822961	MYO1D	-0.4	-9.52	-0.35	3.52e-20	Schizophrenia;
BRCA	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg25767906	chr1:53392781	SCP2	0.39	8.18	0.31	1.58e-15	Monocyte count;
BRCA	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-10.5	-0.38	6.85e-24	Personality dimensions;
BRCA	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg04362960	chr10:104952993	NT5C2	0.94	14.57	0.5	1.05e-41	Arsenic metabolism;
BRCA	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg05372495	chr19:1063624	ABCA7	-0.42	-8.71	-0.33	2.61e-17	Alzheimer's disease (late onset);
BRCA	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg17830980	chr10:43048298	ZNF37B	-0.54	-13.03	-0.46	1.32e-34	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg17971929	chr21:40555470	PSMG1	-0.49	-10.92	-0.4	1.48e-25	Menarche (age at onset);
BRCA	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg14820908	chr5:178986412	RUFY1	-0.34	-8.54	-0.32	9.6e-17	Lung cancer;
BRCA	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24531977	chr5:56204891	C5orf35	-0.86	-17.83	-0.58	4.82e-58	Initial pursuit acceleration;
BRCA	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg01028140	chr2:1542097	TPO	-0.81	-15.85	-0.53	5.82e-48	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08280861	chr8:58055591	NA	0.56	9.09	0.34	1.21e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.36	8.25	0.31	9.3e-16	Corneal astigmatism;
BRCA	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg23796481	chr11:64053134	BAD;GPR137	0.49	10.26	0.38	5.58e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg15556689	chr8:8085844	FLJ10661	0.45	11.55	0.42	3.88e-28	Retinal vascular caliber;
BRCA	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11644478	chr21:40555479	PSMG1	0.85	19.35	0.61	5.16e-66	Cognitive function;
BRCA	cis	rs1506636	0.720	rs2456552	chr7:123441400	A/G	cg03229431	chr7:123269106	ASB15	0.41	9.68	0.36	8.66e-21	Plateletcrit;Platelet count;
BRCA	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg06784218	chr1:46089804	CCDC17	-0.52	-12.34	-0.44	1.49e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg25237894	chr2:233734115	C2orf82	0.39	11.32	0.41	3.5e-27	Coronary artery disease;
BRCA	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	11.64	0.42	1.51e-28	Neuroticism;
BRCA	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg08601574	chr20:25228251	PYGB	0.35	8.47	0.32	1.63e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-11.44	-0.41	1.08e-27	Gut microbiome composition (summer);
BRCA	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg22906224	chr7:99728672	NA	-0.43	-8.04	-0.3	4.29e-15	Coronary artery disease;
BRCA	cis	rs7766436	0.885	rs1418311	chr6:22594964	T/G	cg13666174	chr6:22585274	NA	-0.49	-11.49	-0.41	6.42e-28	Coronary artery disease;
BRCA	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.73e-18	Motion sickness;
BRCA	cis	rs796364	0.662	rs11687313	chr2:201146399	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-8.07	-0.3	3.51e-15	Schizophrenia;
BRCA	cis	rs7903847	0.642	rs11814021	chr10:99158386	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.74	-0.33	2.09e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg18876405	chr7:65276391	NA	0.7	18.33	0.59	1.2e-60	Aortic root size;
BRCA	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24531977	chr5:56204891	C5orf35	-0.88	-19.02	-0.6	2.94e-64	Initial pursuit acceleration;
BRCA	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23583168	chr7:148888333	NA	-0.84	-19.93	-0.62	4.16e-69	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12667521	chr19:29218732	NA	0.47	8.75	0.33	1.93e-17	Methadone dose in opioid dependence;
BRCA	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	15.14	0.51	1.89e-44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1018836	0.828	rs12548806	chr8:91564256	C/T	cg16814680	chr8:91681699	NA	-0.59	-12.7	-0.45	4.24e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg11502198	chr6:26597334	ABT1	0.49	9.89	0.36	1.5e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1635	0.655	rs73742541	chr6:28310615	T/C	cg15743358	chr6:28303923	ZNF323	-0.76	-8.85	-0.33	8.47e-18	Schizophrenia;
BRCA	cis	rs1997103	1.000	rs6593233	chr7:55406200	C/T	cg17469321	chr7:55412551	NA	-0.5	-9.63	-0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg08470875	chr2:26401718	FAM59B	-0.72	-12.01	-0.43	4.01e-30	Gut microbiome composition (summer);
BRCA	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg12573674	chr2:1569213	NA	-0.49	-9.28	-0.34	2.57e-19	Placebo response in major depressive disorder (% change in symptom score);
BRCA	trans	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.49	0.5	2.5e-41	Exhaled nitric oxide output;
BRCA	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08219700	chr8:58056026	NA	0.45	8.1	0.31	2.86e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.8e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg13256891	chr4:100009986	ADH5	0.53	9.76	0.36	4.38e-21	Smoking initiation;
BRCA	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg07636037	chr3:49044803	WDR6	-0.58	-8.06	-0.3	3.81e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs17604090	0.887	rs7795109	chr7:29666244	G/A	cg19413766	chr7:29689036	LOC646762	-0.52	-8.12	-0.31	2.32e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs501916	0.761	rs589889	chr15:48019016	C/G	cg16110827	chr15:48056943	SEMA6D	-0.39	-8.6	-0.32	6.08e-17	Inflammatory bowel disease;Ulcerative colitis;
BRCA	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg17063962	chr7:91808500	NA	0.5	11.72	0.42	6.9e-29	Breast cancer;
BRCA	cis	rs12711979	0.765	rs13028529	chr2:3825467	C/T	cg17052675	chr2:3827356	NA	-0.47	-13.98	-0.48	6.28e-39	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18876405	chr7:65276391	NA	-0.49	-10.78	-0.39	5.16e-25	Aortic root size;
BRCA	trans	rs9944715	0.911	rs12969147	chr18:43806524	G/A	cg01718231	chr17:29326311	RNF135	-0.4	-8.09	-0.3	3.1e-15	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg05863683	chr7:1912471	MAD1L1	0.38	8.02	0.3	5.08e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg00800038	chr16:89945340	TCF25	-0.71	-10.85	-0.39	2.82e-25	Skin colour saturation;
BRCA	cis	rs7523050	0.730	rs12726126	chr1:109436128	A/G	cg08274380	chr1:109419600	GPSM2	1.18	16.83	0.55	6.67e-53	Fat distribution (HIV);
BRCA	cis	rs751728	0.605	rs1535950	chr6:33785827	A/G	cg25922239	chr6:33757077	LEMD2	0.43	9.78	0.36	3.97e-21	Crohn's disease;
BRCA	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.7	0.36	7.74e-21	Menopause (age at onset);
BRCA	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg22705602	chr4:152727874	NA	-0.33	-8.32	-0.31	5.25e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1018836	0.923	rs6986689	chr8:91626709	A/C	cg16814680	chr8:91681699	NA	-0.6	-12.78	-0.45	1.84e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg10295955	chr4:187884368	NA	-0.99	-32.04	-0.79	4.48e-135	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg07080220	chr10:102295463	HIF1AN	0.61	14.23	0.49	4.12e-40	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4944092	0.793	rs94111	chr11:75915139	A/G	cg04588336	chr11:75916460	WNT11	-0.54	-13.66	-0.48	1.94e-37	PR interval;
BRCA	cis	rs586533	0.801	rs651048	chr11:99496234	C/T	cg22878054	chr11:99397252	CNTN5	0.32	8.0	0.3	5.88e-15	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg01620082	chr3:125678407	NA	-0.86	-9.95	-0.37	8.92e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg11366901	chr6:160182831	ACAT2	0.82	16.14	0.54	2.12e-49	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.32	-9.0	-0.34	2.62e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg03188948	chr7:1209495	NA	0.55	10.48	0.38	7.88e-24	Longevity;Endometriosis;
BRCA	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00149659	chr3:10157352	C3orf10	0.81	14.21	0.49	5.29e-40	Alzheimer's disease;
BRCA	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg15395560	chr15:45543142	SLC28A2	-0.3	-7.85	-0.3	1.79e-14	Uric acid levels;
BRCA	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-14.94	-0.51	1.73e-43	Morning vs. evening chronotype;
BRCA	cis	rs2637266	0.935	rs2583058	chr10:78396018	T/A	cg18941641	chr10:78392320	NA	0.38	8.67	0.32	3.69e-17	Pulmonary function;
BRCA	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18404041	chr3:52824283	ITIH1	-0.38	-11.76	-0.42	5.03e-29	Bipolar disorder;
BRCA	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg21747090	chr2:27597821	SNX17	-0.43	-9.31	-0.35	2.1e-19	Total body bone mineral density;
BRCA	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg17063962	chr7:91808500	NA	-0.55	-12.68	-0.45	5.25e-33	Breast cancer;
BRCA	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	17.2	0.56	9.22e-55	Platelet count;
BRCA	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg06784218	chr1:46089804	CCDC17	0.5	12.08	0.43	2.02e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg23533926	chr12:111358616	MYL2	-0.41	-8.51	-0.32	1.2e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9473147	0.543	rs9349407	chr6:47453378	C/G	cg12968598	chr6:47444699	CD2AP	0.46	9.76	0.36	4.54e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg27170947	chr2:26402098	FAM59B	-0.66	-11.39	-0.41	1.75e-27	Gut microbiome composition (summer);
BRCA	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24110177	chr3:50126178	RBM5	-0.54	-16.05	-0.54	5.57e-49	Body mass index;
BRCA	cis	rs13161895	1.000	rs12656814	chr5:179471556	G/A	cg02702477	chr5:179499311	RNF130	0.46	8.53	0.32	1.03e-16	LDL cholesterol;
BRCA	cis	rs778371	1.000	rs11535	chr2:233743532	G/C	cg08000102	chr2:233561755	GIGYF2	-0.78	-17.25	-0.56	4.95e-55	Schizophrenia;
BRCA	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg09184832	chr6:79620586	NA	-0.51	-11.2	-0.4	1.09e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	14.52	0.5	1.73e-41	Platelet count;
BRCA	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg01448562	chr3:133502909	NA	-0.41	-9.41	-0.35	9.13e-20	Iron status biomarkers;
BRCA	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.03	-18.48	-0.59	2e-61	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg13010199	chr12:38710504	ALG10B	0.4	8.11	0.31	2.66e-15	Morning vs. evening chronotype;
BRCA	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg23422044	chr7:1970798	MAD1L1	-0.44	-9.01	-0.34	2.4e-18	Neuroticism;
BRCA	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg00825309	chr19:58991885	ZNF446	-0.58	-12.95	-0.46	3.25e-34	Uric acid clearance;
BRCA	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-16.23	-0.54	7.7e-50	Alzheimer's disease (late onset);
BRCA	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg24088639	chr11:34937564	PDHX;APIP	0.4	9.23	0.34	4.05e-19	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg04705435	chr11:17411270	KCNJ11	0.45	10.15	0.37	1.54e-22	Type 2 diabetes;
BRCA	cis	rs6450176	1.000	rs6886510	chr5:53303127	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.6	14.59	0.5	8.3e-42	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs12541635	1.000	rs1896918	chr8:107090500	G/A	cg10147462	chr8:107024639	NA	-0.3	-8.29	-0.31	6.64e-16	Age of smoking initiation;
BRCA	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.23	-0.41	7.94e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg12011299	chr4:100065546	ADH4	0.49	10.95	0.4	1.12e-25	Smoking initiation;
BRCA	cis	rs34779708	0.931	rs17583009	chr10:35320915	T/C	cg03585969	chr10:35415529	CREM	0.55	11.39	0.41	1.72e-27	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg22117172	chr7:91764530	CYP51A1	0.24	8.2	0.31	1.29e-15	Breast cancer;
BRCA	cis	rs9463078	0.547	rs9472336	chr6:44710392	G/A	cg25276700	chr6:44698697	NA	0.36	8.18	0.31	1.56e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg27478167	chr7:817139	HEATR2	-0.55	-11.03	-0.4	5.31e-26	Cerebrospinal P-tau181p levels;
BRCA	cis	rs35306767	0.668	rs35657988	chr10:1103590	A/G	cg20503657	chr10:835505	NA	0.61	10.08	0.37	2.78e-22	Eosinophil percentage of granulocytes;
BRCA	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg13010199	chr12:38710504	ALG10B	0.52	10.55	0.39	4.1e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4363385	0.747	rs2339495	chr1:152975116	A/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.32	-0.31	5.23e-16	Inflammatory skin disease;
BRCA	cis	rs13082711	0.555	rs7627508	chr3:27252495	A/C	cg02860705	chr3:27208620	NA	0.58	11.76	0.42	4.86e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg07395648	chr5:131743802	NA	0.35	7.94	0.3	9.19e-15	Blood metabolite levels;
BRCA	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg09307838	chr4:120376055	NA	0.61	12.35	0.44	1.42e-31	Corneal astigmatism;
BRCA	cis	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg06521331	chr12:34319734	NA	-0.5	-10.15	-0.37	1.51e-22	Morning vs. evening chronotype;
BRCA	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg13385521	chr17:29058706	SUZ12P	0.77	12.03	0.43	3.31e-30	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs10411936	0.712	rs10414751	chr19:16591695	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.47	9.74	0.36	5.51e-21	White blood cell count;Multiple sclerosis;
BRCA	cis	rs9469890	0.604	rs11756280	chr6:34503439	T/C	cg14254433	chr6:34482411	PACSIN1	-0.44	-9.07	-0.34	1.44e-18	Pubertal anthropometrics;Coronary artery disease;
BRCA	cis	rs1198430	1.000	rs946268	chr1:23747766	A/G	cg19827787	chr1:23763612	ASAP3	0.37	10.11	0.37	2.16e-22	Total cholesterol levels;
BRCA	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg04842962	chr6:43655489	MRPS18A	1.12	37.64	0.83	2.89e-164	IgG glycosylation;
BRCA	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg24848339	chr3:12840334	CAND2	0.44	11.59	0.42	2.62e-28	QRS complex (12-leadsum);
BRCA	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.41	8.74	0.33	2.07e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg19077165	chr18:44547161	KATNAL2	-0.59	-13.09	-0.46	7.3e-35	Personality dimensions;
BRCA	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg13397359	chr6:42928475	GNMT	0.68	16.45	0.55	5.8e-51	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs1003719	0.667	rs13050226	chr21:38457708	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.51	10.85	0.39	2.78e-25	Eye color traits;
BRCA	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg25206134	chr2:45395956	NA	0.54	8.9	0.33	5.78e-18	Bipolar disorder;
BRCA	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg00701064	chr4:6280414	WFS1	0.68	17.76	0.57	1.17e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg23950597	chr19:37808831	NA	-0.71	-12.56	-0.44	1.71e-32	Coronary artery calcification;
BRCA	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	7.98	0.3	6.81e-15	Diabetic retinopathy;
BRCA	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18876405	chr7:65276391	NA	0.58	13.86	0.48	2.32e-38	Aortic root size;
BRCA	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg26408565	chr15:76604113	ETFA	-0.39	-8.56	-0.32	8.47e-17	Blood metabolite levels;
BRCA	cis	rs35306767	0.807	rs1013505	chr10:953273	C/T	cg26597838	chr10:835615	NA	1.02	17.17	0.56	1.33e-54	Eosinophil percentage of granulocytes;
BRCA	cis	rs6032067	0.561	rs2741502	chr20:43936265	C/T	cg06407657	chr20:43937138	MATN4;RBPJL	0.28	8.0	0.3	6.07e-15	Blood protein levels;
BRCA	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg21747090	chr2:27597821	SNX17	-0.44	-9.57	-0.35	2.23e-20	Total body bone mineral density;
BRCA	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg14926445	chr8:58193284	C8orf71	-0.44	-8.4	-0.32	2.81e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.56	-0.52	1.55e-46	Chronic sinus infection;
BRCA	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg09184832	chr6:79620586	NA	-0.52	-11.31	-0.41	3.56e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg08999081	chr20:33150536	PIGU	0.47	12.59	0.45	1.3e-32	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.48e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	14.24	0.49	3.61e-40	Ileal carcinoids;
BRCA	trans	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg07211511	chr3:129823064	LOC729375	-0.5	-9.3	-0.35	2.17e-19	Blood pressure (smoking interaction);
BRCA	cis	rs6545883	0.931	rs9807965	chr2:61732159	T/C	cg15711740	chr2:61764176	XPO1	-0.52	-13.15	-0.46	3.83e-35	Tuberculosis;
BRCA	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00166722	chr3:10149974	C3orf24	0.59	11.67	0.42	1.22e-28	Alzheimer's disease;
BRCA	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.37e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg07080220	chr10:102295463	HIF1AN	0.61	13.88	0.48	1.76e-38	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg04025307	chr7:1156635	C7orf50	0.58	10.22	0.37	8.3e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg15556689	chr8:8085844	FLJ10661	0.48	11.69	0.42	9.95e-29	Red cell distribution width;
BRCA	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26314531	chr2:26401878	FAM59B	-0.66	-11.23	-0.41	7.76e-27	Gut microbiome composition (summer);
BRCA	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg05623727	chr3:50126028	RBM5	0.44	8.33	0.31	5.01e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg18064842	chr5:14874549	NA	0.46	12.44	0.44	5.84e-32	Blood metabolite levels;
BRCA	cis	rs7267979	0.844	rs2424703	chr20:25270124	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.28	7.86	0.3	1.66e-14	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg10169327	chr19:45448959	APOC2	0.31	7.81	0.3	2.31e-14	Blood protein levels;
BRCA	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg17420585	chr12:42539391	GXYLT1	-0.38	-8.11	-0.31	2.59e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.46	8.03	0.3	4.58e-15	Mean platelet volume;
BRCA	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg27170947	chr2:26402098	FAM59B	-0.64	-11.4	-0.41	1.49e-27	Gut microbiome composition (summer);
BRCA	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg01802117	chr1:53393560	SCP2	-0.36	-8.39	-0.31	3.15e-16	Monocyte count;
BRCA	cis	rs8114671	0.647	rs6060267	chr20:33734012	A/G	cg07148914	chr20:33460835	GGT7	0.35	7.92	0.3	1.08e-14	Height;
BRCA	cis	rs4908768	0.501	rs7518608	chr1:8557320	C/G	cg20416874	chr1:8611966	RERE	-0.29	-8.21	-0.31	1.22e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg22907277	chr7:1156413	C7orf50	0.59	9.18	0.34	5.82e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.86	16.25	0.54	5.61e-50	Lymphocyte percentage of white cells;
BRCA	trans	rs2262909	0.962	rs55728714	chr19:22262899	A/G	cg17074339	chr11:11642133	GALNTL4	0.42	8.15	0.31	1.93e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg08847533	chr14:75593920	NEK9	-0.81	-19.85	-0.62	1.08e-68	Height;
BRCA	cis	rs2425143	1.000	rs79035779	chr20:34343004	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.16	-0.34	6.69e-19	Blood protein levels;
BRCA	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg14926445	chr8:58193284	C8orf71	-0.46	-8.83	-0.33	1.01e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs12200560	0.505	rs211166	chr6:97068598	T/C	cg06623918	chr6:96969491	KIAA0776	0.53	12.71	0.45	3.61e-33	Coronary heart disease;
BRCA	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11890956	chr21:40555474	PSMG1	1.09	33.48	0.8	1.04e-142	Cognitive function;
BRCA	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24229701	chr12:130821962	PIWIL1	0.38	8.59	0.32	6.73e-17	Menopause (age at onset);
BRCA	cis	rs701145	0.585	rs1727957	chr3:153870407	G/A	cg17054900	chr3:154042577	DHX36	0.55	9.29	0.35	2.32e-19	Coronary artery disease;
BRCA	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg20307385	chr11:47447363	PSMC3	0.39	8.41	0.32	2.75e-16	Subjective well-being;
BRCA	cis	rs6723226	0.593	rs176401	chr2:32636511	A/T	cg02381751	chr2:32503542	YIPF4	-0.69	-14.83	-0.51	5.82e-43	Intelligence (multi-trait analysis);
BRCA	cis	rs912057	0.671	rs1024246	chr6:6743505	A/T	cg06612196	chr6:6737390	NA	0.46	10.85	0.39	2.86e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs2282802	0.685	rs4913079	chr5:139683029	A/G	cg26211634	chr5:139558579	C5orf32	0.34	8.2	0.31	1.35e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11764359	chr7:65958608	NA	-0.77	-17.87	-0.58	3.29e-58	Aortic root size;
BRCA	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg03709012	chr19:19516395	GATAD2A	-0.8	-18.12	-0.58	1.59e-59	Tonsillectomy;
BRCA	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg22563815	chr15:78856949	CHRNA5	-0.36	-8.62	-0.32	5.39e-17	Sudden cardiac arrest;
BRCA	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg09307838	chr4:120376055	NA	0.64	13.92	0.48	1.13e-38	Corneal astigmatism;
BRCA	cis	rs4363385	0.747	rs885096	chr1:152971313	T/C	cg21543102	chr1:152974771	SPRR3	-0.29	-8.22	-0.31	1.17e-15	Inflammatory skin disease;
BRCA	cis	rs17767294	0.614	rs72854506	chr6:28252497	T/C	cg08851530	chr6:28072375	NA	1.14	10.34	0.38	2.73e-23	Parkinson's disease;
BRCA	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.19e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg16584290	chr5:462447	EXOC3	0.53	14.97	0.51	1.18e-43	Cystic fibrosis severity;
BRCA	cis	rs72634258	0.554	rs4908704	chr1:7918904	A/G	cg26816564	chr1:7831052	VAMP3	0.54	10.71	0.39	9.93e-25	Inflammatory bowel disease;
BRCA	cis	rs10129255	0.500	rs6576230	chr14:107186778	C/A	cg07958169	chr14:107095056	NA	-0.4	-8.67	-0.32	3.43e-17	Kawasaki disease;
BRCA	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.37	-8.52	-0.32	1.18e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg11814155	chr7:99998594	ZCWPW1	0.45	8.1	0.31	2.86e-15	Platelet count;
BRCA	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs17253792	0.915	rs79894275	chr14:56180285	C/T	cg01858014	chr14:56050164	KTN1	-0.67	-8.24	-0.31	9.82e-16	Putamen volume;
BRCA	cis	rs61990749	0.597	rs10136053	chr14:78155205	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.64	-10.16	-0.37	1.4e-22	Fibroblast growth factor basic levels;
BRCA	cis	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.33	3.03e-18	Resting heart rate;
BRCA	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg01028140	chr2:1542097	TPO	-0.62	-11.77	-0.42	4.54e-29	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4478858	0.709	rs7514640	chr1:31752316	G/A	cg00250761	chr1:31883323	NA	-0.32	-8.33	-0.31	4.93e-16	Alcohol dependence;
BRCA	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg01858014	chr14:56050164	KTN1	-0.77	-11.27	-0.41	5.52e-27	Putamen volume;
BRCA	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg17366294	chr4:99064904	C4orf37	0.42	9.76	0.36	4.44e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.98	-21.61	-0.65	3.57e-78	Lymphocyte percentage of white cells;
BRCA	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg24558204	chr6:135376177	HBS1L	0.59	15.94	0.53	2.02e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.94	-19.93	-0.62	4.02e-69	Gut microbiome composition (summer);
BRCA	cis	rs9443645	0.527	rs12194642	chr6:79538791	G/A	cg09184832	chr6:79620586	NA	-0.41	-8.04	-0.3	4.5e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs34779708	0.733	rs12254018	chr10:35550641	T/A	cg03585969	chr10:35415529	CREM	0.43	8.64	0.32	4.64e-17	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg01802117	chr1:53393560	SCP2	-0.36	-8.38	-0.31	3.43e-16	Monocyte count;
BRCA	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg17971929	chr21:40555470	PSMG1	0.79	18.79	0.6	4.9e-63	Cognitive function;
BRCA	cis	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg22729335	chr19:2427816	TIMM13	1.0	25.41	0.71	5.84e-99	Cortisol levels (saliva);
BRCA	trans	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg23762105	chr12:34175262	ALG10	0.34	7.81	0.3	2.34e-14	Morning vs. evening chronotype;
BRCA	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg01028140	chr2:1542097	TPO	-0.57	-11.83	-0.42	2.35e-29	IgG glycosylation;
BRCA	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg04362960	chr10:104952993	NT5C2	0.44	10.77	0.39	5.57e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-10.55	-0.39	4.09e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs877282	0.945	rs11253398	chr10:790012	T/C	cg17470449	chr10:769945	NA	0.51	8.62	0.32	5.29e-17	Uric acid levels;
BRCA	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	16.31	0.54	3.05e-50	Platelet count;
BRCA	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	14.96	0.51	1.38e-43	Hypertriglyceridemia;
BRCA	cis	rs4363385	0.510	rs6661063	chr1:153036048	C/A	cg25856811	chr1:152973957	SPRR3	-0.31	-7.93	-0.3	1e-14	Inflammatory skin disease;
BRCA	cis	rs1577917	1.000	rs16876529	chr6:86591202	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-11.92	-0.43	9.73e-30	Response to antipsychotic treatment;
BRCA	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	10.46	0.38	9.47e-24	Triglycerides;
BRCA	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg00599163	chr2:162100495	NA	0.27	8.93	0.33	4.59e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs2120243	0.782	rs7609926	chr3:157149160	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	9.49	0.35	4.61e-20	Hepatocellular carcinoma in hepatitis B infection;
BRCA	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26314531	chr2:26401878	FAM59B	0.96	16.36	0.54	1.59e-50	Gut microbiome composition (summer);
BRCA	cis	rs11893307	0.566	rs13412750	chr2:191634958	C/T	cg05765582	chr2:191677683	NA	0.45	8.08	0.3	3.16e-15	Mean platelet volume;
BRCA	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg06784218	chr1:46089804	CCDC17	-0.53	-12.64	-0.45	7.87e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.28	7.96	0.3	7.77e-15	Depression;
BRCA	trans	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg06521331	chr12:34319734	NA	-0.5	-9.25	-0.34	3.41e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.43	8.43	0.32	2.38e-16	Lymphocyte counts;
BRCA	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.4	-8.36	-0.31	3.84e-16	Ulcerative colitis;
BRCA	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.16	0.34	7.11e-19	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.78	-0.33	1.47e-17	Bladder cancer;
BRCA	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg03433033	chr1:76189801	ACADM	0.73	18.53	0.59	1.12e-61	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg23791538	chr6:167370224	RNASET2	0.51	13.03	0.46	1.33e-34	Crohn's disease;
BRCA	cis	rs11920090	0.932	rs12495622	chr3:170684878	A/G	cg09710316	chr3:170744871	SLC2A2	0.41	7.93	0.3	9.56e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs4363385	0.693	rs608509	chr1:153034650	G/C	cg24667326	chr1:152973720	SPRR3	-0.31	-8.24	-0.31	9.68e-16	Inflammatory skin disease;
BRCA	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg22705602	chr4:152727874	NA	0.33	8.46	0.32	1.86e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26314531	chr2:26401878	FAM59B	-0.88	-15.31	-0.52	2.56e-45	Gut microbiome composition (summer);
BRCA	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.51	-11.62	-0.42	1.85e-28	Longevity;Endometriosis;
BRCA	cis	rs4566357	0.615	rs2272204	chr2:227915601	G/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-9.58	-0.35	2.16e-20	Coronary artery disease;
BRCA	cis	rs2464469	0.526	rs11071363	chr15:58333961	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-9.67	-0.36	9.65e-21	Barrett's esophagus  or Esophageal adenocarcinoma;
BRCA	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.36	7.95	0.3	8.38e-15	Electroencephalogram traits;
BRCA	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg11645453	chr3:52864694	ITIH4	-0.37	-9.73	-0.36	5.9e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	-0.39	-9.3	-0.35	2.26e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg26608667	chr7:1196370	ZFAND2A	0.45	10.01	0.37	5.21e-22	Longevity;Endometriosis;
BRCA	cis	rs7246967	0.673	rs2194112	chr19:22926189	A/C	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs829883	0.872	rs1641641	chr12:98896018	A/C	cg25150519	chr12:98850993	NA	0.59	11.9	0.43	1.19e-29	Colorectal adenoma (advanced);
BRCA	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg17063962	chr7:91808500	NA	0.52	12.28	0.44	2.75e-31	Breast cancer;
BRCA	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg15549821	chr19:49342101	PLEKHA4	0.62	10.33	0.38	3.07e-23	Red cell distribution width;
BRCA	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg08888203	chr3:10149979	C3orf24	0.68	14.44	0.5	4.29e-41	Alzheimer's disease;
BRCA	cis	rs4800452	0.956	rs7235010	chr18:20724810	G/A	cg26136497	chr18:20735537	CABLES1	-0.38	-9.4	-0.35	9.77e-20	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
BRCA	cis	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-8.85	-0.33	8.3e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg00852783	chr1:26633632	UBXN11	-0.48	-10.09	-0.37	2.56e-22	Obesity-related traits;
BRCA	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg18678763	chr11:4115507	RRM1	-0.38	-8.58	-0.32	7.01e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
BRCA	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.65	0.39	1.73e-24	Motion sickness;
BRCA	cis	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg19338460	chr6:170058176	WDR27	0.47	8.25	0.31	9.14e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs6844506	0.565	rs10008153	chr4:185227184	C/T	cg12654155	chr4:185238627	NA	-0.42	-8.75	-0.33	1.88e-17	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
BRCA	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg13319975	chr6:146136371	FBXO30	0.34	8.02	0.3	5.07e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg14343924	chr8:8086146	FLJ10661	0.43	9.14	0.34	8.44e-19	Mood instability;
BRCA	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg27432699	chr2:27873401	GPN1	0.47	9.88	0.36	1.66e-21	Oral cavity cancer;
BRCA	cis	rs7520050	0.966	rs2486447	chr1:46545724	G/A	cg24296786	chr1:45957014	TESK2	0.43	9.77	0.36	4.17e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg22705602	chr4:152727874	NA	-0.38	-10.38	-0.38	2.01e-23	Intelligence (multi-trait analysis);
BRCA	trans	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg25214090	chr10:38739885	LOC399744	0.51	10.47	0.38	8.45e-24	Corneal astigmatism;
BRCA	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	8.52	0.32	1.11e-16	Schizophrenia;
BRCA	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg23708337	chr7:1209742	NA	0.68	10.25	0.38	6.32e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.57	0.35	2.35e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg27129171	chr3:47204927	SETD2	0.66	15.67	0.53	4.58e-47	Colorectal cancer;
BRCA	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg00701064	chr4:6280414	WFS1	0.69	18.98	0.6	4.71e-64	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7799006	0.606	rs7792045	chr7:2316852	C/T	cg08027265	chr7:2291960	NA	-0.45	-11.74	-0.42	6.08e-29	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg11814155	chr7:99998594	ZCWPW1	0.43	8.07	0.3	3.38e-15	Platelet count;
BRCA	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21582582	chr3:182698605	DCUN1D1	0.38	10.03	0.37	4.41e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-10.63	-0.39	2.03e-24	Response to antipsychotic treatment;
BRCA	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-19.86	-0.62	1e-68	Systemic lupus erythematosus;
BRCA	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.17	-0.34	6.46e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg06784218	chr1:46089804	CCDC17	0.51	12.17	0.43	8.34e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg06784218	chr1:46089804	CCDC17	0.49	11.62	0.42	1.96e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg19678392	chr7:94953810	PON1	-0.42	-8.54	-0.32	1e-16	Yu-Zhi constitution type in type 2 diabetes;
BRCA	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg15704280	chr7:45808275	SEPT13	0.69	14.09	0.49	1.88e-39	Coronary artery disease;
BRCA	cis	rs17685	0.753	rs869804	chr7:75688954	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-8.95	-0.33	3.76e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs11718455	0.767	rs6785433	chr3:43964265	A/G	cg08738300	chr3:44038990	NA	0.48	8.85	0.33	8.61e-18	Coronary artery disease;
BRCA	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.37	-12.76	-0.45	2.2e-33	Electroencephalogram traits;
BRCA	cis	rs36051895	0.626	rs10283563	chr9:5075603	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-9.64	-0.36	1.22e-20	Pediatric autoimmune diseases;
BRCA	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg01939980	chr4:1354348	KIAA1530	0.3	7.81	0.3	2.29e-14	Obesity-related traits;
BRCA	trans	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg25214090	chr10:38739885	LOC399744	0.53	11.96	0.43	7.08e-30	Corneal astigmatism;
BRCA	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg01256987	chr12:42539512	GXYLT1	0.46	9.11	0.34	1.04e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs6545883	0.965	rs6734830	chr2:61731112	G/A	cg15711740	chr2:61764176	XPO1	-0.52	-13.14	-0.46	4.2e-35	Tuberculosis;
BRCA	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg08601574	chr20:25228251	PYGB	0.33	8.03	0.3	4.73e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-8.8	-0.33	1.26e-17	Alzheimer's disease (late onset);
BRCA	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg02079420	chr8:82753780	SNX16	-0.31	-8.32	-0.31	5.45e-16	Diastolic blood pressure;
BRCA	cis	rs9796	0.621	rs557864	chr15:41471358	T/C	cg18705301	chr15:41695430	NDUFAF1	0.37	7.92	0.3	1.03e-14	Menopause (age at onset);
BRCA	cis	rs11997175	0.583	rs7829680	chr8:33794207	C/T	ch.8.33884649F	chr8:33765107	NA	-0.36	-8.36	-0.31	4.05e-16	Body mass index;
BRCA	cis	rs13040088	1.000	rs13040088	chr20:61549202	A/G	cg23096297	chr20:61557774	DIDO1	0.91	18.93	0.6	8.83e-64	Menopause (age at onset);
BRCA	cis	rs6032067	0.673	rs991048	chr20:43898227	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.34	-8.31	-0.31	5.95e-16	Blood protein levels;
BRCA	cis	rs4074536	0.614	rs4075008	chr1:116298064	C/A	cg21648376	chr1:116311395	CASQ2	-0.45	-7.99	-0.3	6.11e-15	QRS duration;
BRCA	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg12573674	chr2:1569213	NA	-0.58	-12.86	-0.45	8.4e-34	IgG glycosylation;
BRCA	cis	rs7254827	0.737	rs62126021	chr19:17159723	C/G	cg19418318	chr19:17219073	MYO9B	-0.48	-10.08	-0.37	2.82e-22	Mean platelet volume;
BRCA	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00149659	chr3:10157352	C3orf10	1.07	18.1	0.58	2.08e-59	Alzheimer's disease;
BRCA	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	8.03	0.3	4.62e-15	Tonsillectomy;
BRCA	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg10932868	chr11:921992	NA	0.49	12.38	0.44	1.09e-31	Alzheimer's disease (late onset);
BRCA	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg26384229	chr12:38710491	ALG10B	0.75	17.0	0.56	9.05e-54	Bladder cancer;
BRCA	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg01236616	chr12:121019343	POP5	1.21	27.84	0.74	2.68e-112	Type 1 diabetes nephropathy;
BRCA	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg18252515	chr7:66147081	NA	-1.04	-15.49	-0.52	3.67e-46	Diabetic kidney disease;
BRCA	cis	rs9649465	0.542	rs616297	chr7:123426949	A/G	cg03229431	chr7:123269106	ASB15	0.43	9.73	0.36	6.01e-21	Migraine;
BRCA	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg18230493	chr5:56204884	C5orf35	-0.72	-14.34	-0.49	1.2e-40	Initial pursuit acceleration;
BRCA	cis	rs7927771	0.524	rs11039392	chr11:47798753	A/G	cg20307385	chr11:47447363	PSMC3	0.42	9.54	0.35	2.88e-20	Subjective well-being;
BRCA	cis	rs12973672	1.000	rs2280747	chr19:35770064	C/T	cg12095397	chr19:35769544	USF2	0.38	8.41	0.32	2.58e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	trans	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	10.37	0.38	2.16e-23	Mean corpuscular volume;
BRCA	cis	rs3771570	0.901	rs62190415	chr2:242426692	A/G	cg21155796	chr2:242212141	HDLBP	0.56	9.4	0.35	9.57e-20	Prostate cancer;
BRCA	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.65	17.01	0.56	8.71e-54	Colorectal cancer;
BRCA	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08109568	chr15:31115862	NA	-0.45	-10.4	-0.38	1.58e-23	Huntington's disease progression;
BRCA	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg12826209	chr6:26865740	GUSBL1	0.56	9.25	0.34	3.41e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs1568889	1.000	rs7931847	chr11:28175245	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	13.35	0.47	4.92e-36	Bipolar disorder;
BRCA	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.33	-0.44	1.69e-31	Chronic sinus infection;
BRCA	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg11366901	chr6:160182831	ACAT2	0.85	16.31	0.54	3.02e-50	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg11752832	chr7:134001865	SLC35B4	0.44	9.61	0.36	1.6e-20	Mean platelet volume;
BRCA	cis	rs7927771	0.542	rs11039336	chr11:47706141	A/G	cg20307385	chr11:47447363	PSMC3	-0.39	-9.06	-0.34	1.57e-18	Subjective well-being;
BRCA	cis	rs7809615	0.901	rs13243267	chr7:99053314	C/G	cg12290671	chr7:99195819	NA	0.5	8.81	0.33	1.18e-17	Blood metabolite ratios;
BRCA	cis	rs13053817	1.000	rs71329486	chr22:29831208	G/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.47	-8.95	-0.33	3.85e-18	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.39	9.39	0.35	1e-19	Tonsillectomy;
BRCA	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg25173405	chr17:45401733	C17orf57	-0.53	-11.22	-0.41	8.92e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.87	0.56	4.51e-53	Colorectal cancer;
BRCA	cis	rs7520050	0.933	rs9787208	chr1:46314616	C/A	cg24296786	chr1:45957014	TESK2	0.41	9.35	0.35	1.5e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1538970	0.924	rs4660851	chr1:45843810	A/T	cg05343316	chr1:45956843	TESK2	0.53	11.04	0.4	4.84e-26	Platelet count;
BRCA	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-12.82	-0.45	1.21e-33	Gut microbiome composition (summer);
BRCA	cis	rs36051895	0.632	rs7036536	chr9:5181610	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-9.37	-0.35	1.22e-19	Pediatric autoimmune diseases;
BRCA	cis	rs8170	0.603	rs7249329	chr19:17423373	G/T	cg04749549	chr19:17459798	NA	-0.36	-9.67	-0.36	9.58e-21	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
BRCA	cis	rs7766436	0.848	rs6931450	chr6:22582076	T/C	cg13666174	chr6:22585274	NA	-0.49	-11.6	-0.42	2.25e-28	Coronary artery disease;
BRCA	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg14440974	chr22:39074834	NA	-0.39	-8.75	-0.33	1.87e-17	Menopause (age at onset);
BRCA	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12379764	chr21:47803548	PCNT	-0.6	-12.01	-0.43	4.12e-30	Testicular germ cell tumor;
BRCA	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11644478	chr21:40555479	PSMG1	0.84	19.24	0.61	2.1e-65	Cognitive function;
BRCA	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg03954927	chr1:10346856	KIF1B	0.45	12.58	0.45	1.33e-32	Hepatocellular carcinoma;
BRCA	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21659725	chr3:3221576	CRBN	0.51	12.07	0.43	2.37e-30	Resting heart rate;
BRCA	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg12386194	chr3:101231763	SENP7	0.46	9.92	0.37	1.18e-21	Colorectal cancer;
BRCA	cis	rs877282	0.853	rs12763400	chr10:763617	C/T	cg17470449	chr10:769945	NA	0.47	7.92	0.3	1.08e-14	Uric acid levels;
BRCA	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg11833968	chr6:79620685	NA	-0.38	-8.54	-0.32	1.01e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.22	0.31	1.17e-15	Tonsillectomy;
BRCA	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23583168	chr7:148888333	NA	-0.79	-18.85	-0.6	2.3e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg06494592	chr3:125709126	NA	-0.5	-8.53	-0.32	1.06e-16	Blood pressure (smoking interaction);
BRCA	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg24531977	chr5:56204891	C5orf35	-0.41	-8.41	-0.32	2.64e-16	Coronary artery disease;
BRCA	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg18758796	chr5:131593413	PDLIM4	-0.34	-8.72	-0.33	2.37e-17	Breast cancer;
BRCA	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg19318889	chr4:1322082	MAEA	0.35	8.04	0.3	4.48e-15	Longevity;
BRCA	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg08888203	chr3:10149979	C3orf24	0.67	14.07	0.49	2.42e-39	Alzheimer's disease;
BRCA	cis	rs7116495	0.609	rs2503	chr11:71719403	C/T	cg26138937	chr11:71823887	C11orf51	1.05	10.16	0.37	1.39e-22	Severe influenza A (H1N1) infection;
BRCA	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg06784218	chr1:46089804	CCDC17	0.51	12.36	0.44	1.28e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg17063962	chr7:91808500	NA	-0.54	-12.61	-0.45	1.01e-32	Breast cancer;
BRCA	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg26384229	chr12:38710491	ALG10B	0.59	13.61	0.47	3.04e-37	Morning vs. evening chronotype;
BRCA	trans	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg26384229	chr12:38710491	ALG10B	0.49	10.53	0.38	5.18e-24	Resting heart rate;
BRCA	cis	rs8028182	0.577	rs8023268	chr15:75814672	A/T	cg20655648	chr15:75932815	IMP3	0.42	8.06	0.3	3.87e-15	Sudden cardiac arrest;
BRCA	cis	rs6815814	0.851	rs17582921	chr4:38892649	T/C	cg02016764	chr4:38805732	TLR1	-0.54	-8.69	-0.33	3.02e-17	Breast cancer;
BRCA	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg23950597	chr19:37808831	NA	-0.62	-11.45	-0.41	9.99e-28	Coronary artery calcification;
BRCA	cis	rs7523273	0.548	rs2724381	chr1:207949017	T/C	cg22525895	chr1:207977042	MIR29B2	0.47	11.98	0.43	5.36e-30	Schizophrenia;
BRCA	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg15145296	chr3:125709740	NA	-0.53	-9.12	-0.34	9.63e-19	Blood pressure (smoking interaction);
BRCA	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	11.15	0.4	1.68e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.39	-8.46	-0.32	1.82e-16	IgG glycosylation;
BRCA	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.58	-11.53	-0.42	4.45e-28	Lymphocyte counts;
BRCA	cis	rs11080107	0.542	rs894606	chr17:27909352	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.39	9.06	0.34	1.63e-18	Coronary artery disease;
BRCA	cis	rs586533	0.846	rs1690816	chr11:99496849	C/T	cg22878054	chr11:99397252	CNTN5	0.31	7.81	0.3	2.39e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1506403	0.685	rs1994497	chr7:142816927	A/G	cg15652212	chr7:142981776	TMEM139	0.44	8.48	0.32	1.53e-16	Cancer;
BRCA	cis	rs6545883	1.000	rs778762	chr2:61782921	G/T	cg15711740	chr2:61764176	XPO1	-0.55	-14.06	-0.49	2.58e-39	Tuberculosis;
BRCA	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg23533926	chr12:111358616	MYL2	-0.42	-8.75	-0.33	1.93e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg24692254	chr21:30365293	RNF160	0.65	14.49	0.5	2.46e-41	Selective IgA deficiency;
BRCA	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-12.02	-0.43	3.84e-30	Gut microbiome composition (summer);
BRCA	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg21252483	chr19:49399788	TULP2	-0.51	-10.86	-0.39	2.46e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs76419734	0.510	rs17036102	chr4:106603098	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.54	-12.16	-0.43	9.21e-31	Post bronchodilator FEV1;
BRCA	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	11.35	0.41	2.54e-27	Systemic lupus erythematosus;
BRCA	cis	rs9287719	0.601	rs12692412	chr2:10720054	A/G	cg00105475	chr2:10696890	NA	-0.47	-10.42	-0.38	1.41e-23	Prostate cancer;
BRCA	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg23285459	chr7:2802560	GNA12	-0.38	-9.63	-0.36	1.42e-20	Height;
BRCA	trans	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg25214090	chr10:38739885	LOC399744	0.49	11.45	0.41	1e-27	Corneal astigmatism;
BRCA	cis	rs2415984	0.622	rs12437018	chr14:46937149	A/G	cg14871534	chr14:47121158	RPL10L	-0.33	-8.03	-0.3	4.67e-15	Number of children ever born;
BRCA	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg16339924	chr4:17578868	LAP3	-0.55	-13.23	-0.46	1.78e-35	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg18479299	chr3:125709523	NA	-0.56	-9.14	-0.34	8.19e-19	Blood pressure (smoking interaction);
BRCA	cis	rs36051895	0.622	rs12335546	chr9:5072182	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-9.9	-0.36	1.35e-21	Pediatric autoimmune diseases;
BRCA	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.48	-0.32	1.54e-16	Glomerular filtration rate (creatinine);
BRCA	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg17845761	chr1:175162550	KIAA0040	-0.25	-9.57	-0.35	2.36e-20	Alcohol dependence;
BRCA	cis	rs911119	1.000	rs6036478	chr20:23611359	C/A	cg16589663	chr20:23618590	CST3	0.45	8.47	0.32	1.72e-16	Chronic kidney disease;
BRCA	cis	rs9811920	0.809	rs4928150	chr3:99685991	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.57	13.86	0.48	2.15e-38	Axial length;
BRCA	cis	rs9807989	0.507	rs11465721	chr2:103063240	T/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.33	0.31	4.8e-16	Asthma;
BRCA	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs9815354	0.812	rs73069213	chr3:41940590	G/A	cg03022575	chr3:42003672	ULK4	0.68	9.48	0.35	4.82e-20	Pulse pressure;Diastolic blood pressure;
BRCA	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg13010199	chr12:38710504	ALG10B	0.49	9.55	0.35	2.82e-20	Morning vs. evening chronotype;
BRCA	cis	rs897984	0.609	rs12445650	chr16:31044897	G/A	cg02466173	chr16:30829666	NA	-0.42	-9.39	-0.35	1.04e-19	Dementia with Lewy bodies;
BRCA	cis	rs4561483	0.771	rs7202234	chr16:11942322	A/G	cg08843971	chr16:11963173	GSPT1	0.42	9.04	0.34	1.8e-18	Testicular germ cell tumor;
BRCA	trans	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg25214090	chr10:38739885	LOC399744	0.46	10.55	0.39	4.16e-24	Corneal astigmatism;
BRCA	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.55	8.42	0.32	2.56e-16	Gut microbiome composition (summer);
BRCA	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.51	-10.21	-0.37	8.76e-23	Body mass index;
BRCA	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	14.09	0.49	1.82e-39	Alzheimer's disease;
BRCA	cis	rs2882667	0.654	rs2940595	chr5:138101037	A/G	cg04439458	chr5:138467593	SIL1	0.31	7.87	0.3	1.47e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs17253792	0.822	rs13379343	chr14:56050205	G/A	cg01858014	chr14:56050164	KTN1	-0.77	-11.27	-0.41	5.52e-27	Putamen volume;
BRCA	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.37	-8.28	-0.31	7.14e-16	Axial length;
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg23131131	chr22:24373011	LOC391322	0.46	10.64	0.39	1.91e-24	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6446731	0.593	rs6446726	chr4:3274214	T/C	cg08886695	chr4:3369023	RGS12	-0.38	-9.92	-0.37	1.1e-21	Mean platelet volume;
BRCA	cis	rs1403694	0.695	rs5029969	chr3:186434405	G/T	cg12454167	chr3:186435060	KNG1	0.29	7.92	0.3	1.05e-14	Blood protein levels;
BRCA	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg16339924	chr4:17578868	LAP3	0.68	16.58	0.55	1.32e-51	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7092929	0.723	rs7082020	chr10:3535672	T/C	cg14308648	chr10:3568949	NA	0.4	8.74	0.33	2.04e-17	Coronary artery calcification;
BRCA	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11764359	chr7:65958608	NA	0.73	16.44	0.55	6.54e-51	Aortic root size;
BRCA	cis	rs7760949	0.852	rs9464423	chr6:13931851	A/G	cg27413430	chr6:13925136	RNF182	0.47	9.3	0.35	2.2e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg25486957	chr4:152246857	NA	-0.36	-7.9	-0.3	1.26e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs4722404	0.560	rs6975818	chr7:3115520	C/G	cg19214707	chr7:3157722	NA	-0.36	-7.94	-0.3	9e-15	Atopic dermatitis;
BRCA	cis	rs2882667	1.000	rs10515505	chr5:138313146	A/G	cg04439458	chr5:138467593	SIL1	-0.34	-9.23	-0.34	4.07e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-11.85	-0.42	1.95e-29	Longevity;
BRCA	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	11.37	0.41	2.16e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7072216	0.691	rs3829853	chr10:100171174	A/G	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.71	-0.36	7.24e-21	Metabolite levels;
BRCA	cis	rs7766436	0.767	rs13200993	chr6:22612912	C/T	cg13666174	chr6:22585274	NA	-0.36	-9.15	-0.34	7.28e-19	Coronary artery disease;
BRCA	cis	rs3820928	0.874	rs2272198	chr2:227893017	A/G	cg11843606	chr2:227700838	RHBDD1	0.38	8.47	0.32	1.66e-16	Pulmonary function;
BRCA	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg13319975	chr6:146136371	FBXO30	0.41	9.25	0.34	3.19e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11249608	0.548	rs11958355	chr5:178451640	T/C	cg21905437	chr5:178450457	ZNF879	0.54	11.31	0.41	3.58e-27	Pubertal anthropometrics;
BRCA	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg24060327	chr5:131705240	SLC22A5	-0.54	-9.65	-0.36	1.14e-20	Breast cancer;
BRCA	trans	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg25214090	chr10:38739885	LOC399744	0.45	10.4	0.38	1.71e-23	Corneal astigmatism;
BRCA	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg26031613	chr14:104095156	KLC1	-0.53	-9.5	-0.35	3.97e-20	Reticulocyte count;
BRCA	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg04842962	chr6:43655489	MRPS18A	1.12	38.92	0.84	9.43e-171	IgG glycosylation;
BRCA	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg10518572	chr11:65560635	OVOL1	-0.28	-8.11	-0.31	2.52e-15	Acne (severe);
BRCA	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg02574844	chr11:5959923	NA	-0.44	-8.63	-0.32	4.74e-17	DNA methylation (variation);
BRCA	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg01819863	chr10:32635814	EPC1	1.15	20.15	0.62	2.94e-70	Sexual dysfunction (female);
BRCA	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg20387954	chr3:183756860	HTR3D	-0.43	-10.07	-0.37	3.03e-22	Anterior chamber depth;
BRCA	cis	rs7567389	0.704	rs4662714	chr2:127995213	A/G	cg09760422	chr2:128146352	NA	-0.4	-8.59	-0.32	6.5e-17	Self-rated health;
BRCA	cis	rs7587476	0.906	rs3768713	chr2:215637505	G/A	cg04004882	chr2:215674386	BARD1	0.59	10.36	0.38	2.31e-23	Neuroblastoma;
BRCA	cis	rs6009527	0.711	rs8141990	chr22:49570455	T/G	cg12746016	chr22:49560550	NA	0.41	9.67	0.36	9.92e-21	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
BRCA	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03517284	chr6:25882590	NA	-0.96	-24.94	-0.7	2.04e-96	Urate levels;
BRCA	cis	rs11984145	1.000	rs73121396	chr7:38870102	G/A	cg19327137	chr7:38886074	VPS41	0.49	8.55	0.32	9.39e-17	Cognitive performance;
BRCA	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg20503657	chr10:835505	NA	1.33	22.01	0.66	2.37e-80	Eosinophil percentage of granulocytes;
BRCA	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	10.65	0.39	1.72e-24	Platelet count;
BRCA	cis	rs13315871	0.929	rs79813245	chr3:58318475	G/A	cg20936604	chr3:58311152	NA	-0.65	-8.24	-0.31	9.48e-16	Cholesterol, total;
BRCA	trans	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg25214090	chr10:38739885	LOC399744	0.46	10.61	0.39	2.52e-24	Corneal astigmatism;
BRCA	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-13.51	-0.47	8.9e-37	Migraine;Coronary artery disease;
BRCA	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.48	-10.37	-0.38	2.21e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3768617	0.811	rs34721094	chr1:183051521	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.46	10.09	0.37	2.5e-22	Fuchs's corneal dystrophy;
BRCA	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg03433033	chr1:76189801	ACADM	-0.47	-9.69	-0.36	8.06e-21	Daytime sleep phenotypes;
BRCA	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg13073564	chr4:8508604	NA	-0.42	-10.82	-0.39	3.7e-25	Response to antineoplastic agents;
BRCA	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg20307385	chr11:47447363	PSMC3	0.74	16.8	0.55	9.88e-53	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs4780401	0.609	rs8055247	chr16:11827543	G/A	cg01061890	chr16:11836724	TXNDC11	-0.54	-12.54	-0.44	2.03e-32	Rheumatoid arthritis;
BRCA	cis	rs7766436	0.583	rs988972	chr6:22558502	A/C	cg13666174	chr6:22585274	NA	-0.39	-7.81	-0.3	2.29e-14	Coronary artery disease;
BRCA	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18876405	chr7:65276391	NA	-0.51	-11.65	-0.42	1.38e-28	Aortic root size;
BRCA	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24308560	chr3:49941425	MST1R	-0.4	-8.56	-0.32	8.62e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.38	-8.31	-0.31	5.79e-16	Tonsillectomy;
BRCA	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08704250	chr15:31115839	NA	0.48	12.94	0.46	3.34e-34	Huntington's disease progression;
BRCA	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	19.85	0.62	1.16e-68	Platelet count;
BRCA	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	13.21	0.46	2.18e-35	Bone mineral density;
BRCA	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg12373951	chr3:133503437	NA	0.53	12.6	0.45	1.12e-32	Iron status biomarkers;
BRCA	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08219700	chr8:58056026	NA	0.46	8.39	0.32	3.01e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	14.43	0.5	4.46e-41	Personality dimensions;
BRCA	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg17366294	chr4:99064904	C4orf37	0.44	10.22	0.37	8.18e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.82	0.62	1.64e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs28374715	0.662	rs28493087	chr15:41486504	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.87	-18.08	-0.58	2.61e-59	Ulcerative colitis;
BRCA	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg18479299	chr3:125709523	NA	-0.57	-9.13	-0.34	9.11e-19	Blood pressure (smoking interaction);
BRCA	cis	rs897984	0.806	rs1458202	chr16:30953202	A/G	cg00531865	chr16:30841666	NA	-0.38	-8.96	-0.33	3.65e-18	Dementia with Lewy bodies;
BRCA	cis	rs11677370	0.533	rs12711971	chr2:3820821	G/C	cg17052675	chr2:3827356	NA	-0.61	-15.54	-0.52	2.01e-46	Type 2 diabetes;
BRCA	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg09624528	chr10:1369823	ADARB2	0.46	9.04	0.34	1.88e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg07169764	chr2:136633963	MCM6	0.95	19.1	0.6	1.05e-64	Corneal structure;
BRCA	cis	rs1941023	0.584	rs6591578	chr11:60158649	G/A	cg08716584	chr11:60157161	MS4A7	-0.41	-9.25	-0.34	3.26e-19	Congenital heart disease (maternal effect);
BRCA	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-8.5	-0.32	1.31e-16	Schizophrenia;
BRCA	cis	rs7586879	1.000	rs12713419	chr2:25121853	G/A	cg01884057	chr2:25150051	NA	0.33	8.57	0.32	7.98e-17	Body mass index;
BRCA	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.03	14.39	0.49	7.02e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12579753	0.872	rs7956132	chr12:82178709	A/G	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.9	-0.3	1.21e-14	Resting heart rate;
BRCA	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg23711669	chr6:146136114	FBXO30	0.64	14.97	0.51	1.25e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8032158	1.000	rs8032158	chr15:56194877	T/C	cg02198044	chr15:56286336	NEDD4	-0.37	-8.98	-0.33	2.91e-18	Keloid;
BRCA	cis	rs73001065	0.818	rs16996185	chr19:19720788	G/T	cg03709012	chr19:19516395	GATAD2A	-0.73	-9.48	-0.35	4.92e-20	LDL cholesterol;
BRCA	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg03709012	chr19:19516395	GATAD2A	0.81	19.11	0.6	9.59e-65	Tonsillectomy;
BRCA	cis	rs10208940	0.920	rs35005506	chr2:68814238	A/T	cg12452813	chr2:68675892	NA	0.49	8.52	0.32	1.15e-16	Urate levels in lean individuals;
BRCA	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg16606324	chr3:10149918	C3orf24	0.56	10.97	0.4	9.33e-26	Alzheimer's disease;
BRCA	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg03711944	chr11:47377212	SPI1	-0.43	-11.16	-0.4	1.45e-26	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg18129178	chr5:148520854	ABLIM3	-0.56	-11.56	-0.42	3.34e-28	Breast cancer;
BRCA	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-15.95	-0.53	1.82e-48	Chronic sinus infection;
BRCA	cis	rs2882667	0.690	rs1039788	chr5:138171501	G/A	cg04439458	chr5:138467593	SIL1	0.31	7.81	0.3	2.44e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.61	9.59	0.35	2e-20	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg17971929	chr21:40555470	PSMG1	0.79	18.73	0.6	1.05e-62	Cognitive function;
BRCA	trans	rs2122469	0.655	rs17603934	chr8:20576344	A/G	cg19996406	chr8:8318774	NA	-0.35	-7.92	-0.3	1.06e-14	Serum tamsulosin hydrochloride concentration;
BRCA	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.1	-0.31	2.71e-15	Total body bone mineral density;
BRCA	cis	rs6723226	0.764	rs176403	chr2:32637864	C/A	cg02381751	chr2:32503542	YIPF4	-0.73	-16.36	-0.54	1.56e-50	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg09184832	chr6:79620586	NA	-0.52	-11.46	-0.41	8.98e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.37e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg24060327	chr5:131705240	SLC22A5	-0.49	-10.19	-0.37	1.09e-22	Blood metabolite levels;
BRCA	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg13010199	chr12:38710504	ALG10B	0.44	8.95	0.33	3.88e-18	Bladder cancer;
BRCA	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg06623918	chr6:96969491	KIAA0776	0.74	12.98	0.46	2.34e-34	Migraine;Coronary artery disease;
BRCA	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg09307838	chr4:120376055	NA	0.63	13.63	0.47	2.45e-37	Corneal astigmatism;
BRCA	cis	rs7737355	0.853	rs1468453	chr5:130587459	A/C	cg06307176	chr5:131281290	NA	0.45	8.8	0.33	1.3e-17	Life satisfaction;
BRCA	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg22800045	chr5:56110881	MAP3K1	0.66	12.28	0.44	2.9e-31	Initial pursuit acceleration;
BRCA	cis	rs7617773	0.643	rs78159520	chr3:48349023	T/C	cg11946769	chr3:48343235	NME6	0.7	14.26	0.49	2.94e-40	Coronary artery disease;
BRCA	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-12.05	-0.43	2.92e-30	Triglycerides;
BRCA	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg01191920	chr7:158217561	PTPRN2	-0.34	-7.9	-0.3	1.23e-14	Obesity-related traits;
BRCA	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.59	-12.31	-0.44	2.1e-31	Lymphocyte counts;
BRCA	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg09307838	chr4:120376055	NA	0.66	14.22	0.49	4.76e-40	Corneal astigmatism;
BRCA	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg26384229	chr12:38710491	ALG10B	0.64	16.76	0.55	1.55e-52	Heart rate;
BRCA	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	8.02	0.3	4.97e-15	Uric acid levels;
BRCA	cis	rs16866061	0.962	rs3845840	chr2:225359100	G/A	cg12698349	chr2:225449008	CUL3	0.77	21.13	0.64	1.54e-75	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg25554036	chr4:6271136	WFS1	0.44	10.46	0.38	9.8599999999999993e-24	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs977987	0.872	rs10781976	chr16:75314838	G/T	cg03315344	chr16:75512273	CHST6	0.5	11.48	0.41	7.19e-28	Dupuytren's disease;
BRCA	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg11578532	chr1:161008127	TSTD1	0.3	9.49	0.35	4.66e-20	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg20933634	chr6:27740509	NA	0.47	9.34	0.35	1.64e-19	Parkinson's disease;
BRCA	cis	rs28735056	0.967	rs61090726	chr18:77631219	A/G	cg20368463	chr18:77673604	PQLC1	-0.34	-8.0	-0.3	5.75e-15	Schizophrenia;
BRCA	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg04691961	chr3:161091175	C3orf57	-0.42	-10.17	-0.37	1.23e-22	Morning vs. evening chronotype;
BRCA	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg04586622	chr2:25135609	ADCY3	0.46	11.66	0.42	1.26e-28	Body mass index;
BRCA	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	8.77	0.33	1.6e-17	Multiple sclerosis;
BRCA	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.33	7.87	0.3	1.57e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg25358565	chr5:93447407	FAM172A	1.19	18.53	0.59	1.06e-61	Diabetic retinopathy;
BRCA	cis	rs7523273	0.606	rs2796268	chr1:207925192	G/A	cg22525895	chr1:207977042	MIR29B2	0.46	11.69	0.42	9.35e-29	Schizophrenia;
BRCA	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg08885076	chr2:99613938	TSGA10	0.44	10.21	0.37	8.7e-23	Chronic sinus infection;
BRCA	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg08917208	chr2:24149416	ATAD2B	0.67	10.91	0.4	1.57e-25	Lymphocyte counts;
BRCA	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg09754948	chr16:28834200	ATXN2L	0.45	8.9	0.33	5.81e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.18	0.54	1.27e-49	Alzheimer's disease (late onset);
BRCA	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg16482183	chr6:26056742	HIST1H1C	0.49	10.06	0.37	3.33e-22	Height;
BRCA	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.5	11.94	0.43	8.09e-30	Response to bleomycin (chromatid breaks);
BRCA	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg26384229	chr12:38710491	ALG10B	0.78	18.28	0.59	2.32e-60	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7560272	0.501	rs4852978	chr2:73943110	G/A	cg20560298	chr2:73613845	ALMS1	0.34	8.59	0.32	6.44e-17	Schizophrenia;
BRCA	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.49	-10.01	-0.37	5.08e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg12160578	chr15:63334699	TPM1	-0.46	-9.06	-0.34	1.62e-18	Platelet count;
BRCA	trans	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-12.91	-0.45	4.97e-34	Brugada syndrome;
BRCA	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg16405210	chr4:1374714	KIAA1530	-0.61	-13.72	-0.48	9.35e-38	Longevity;
BRCA	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg18404041	chr3:52824283	ITIH1	-0.3	-8.03	-0.3	4.74e-15	Schizophrenia;
BRCA	cis	rs6430585	0.527	rs6753232	chr2:136436317	C/T	cg07169764	chr2:136633963	MCM6	-0.93	-17.58	-0.57	9.57e-57	Corneal structure;
BRCA	trans	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg02030672	chr11:45687055	CHST1	0.39	8.19	0.31	1.46e-15	Obesity-related traits;
BRCA	trans	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.32	-8.37	-0.31	3.74e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs36051895	0.632	rs1581927	chr9:5177462	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-9.06	-0.34	1.52e-18	Pediatric autoimmune diseases;
BRCA	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03576123	chr11:487126	PTDSS2	1.16	17.31	0.57	2.38e-55	Body mass index;
BRCA	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg13319975	chr6:146136371	FBXO30	-0.37	-8.56	-0.32	8.47e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs68170813	0.559	rs2107319	chr7:106863744	T/C	cg02696742	chr7:106810147	HBP1	-0.48	-8.44	-0.32	2.06e-16	Coronary artery disease;
BRCA	cis	rs858239	0.571	rs2390755	chr7:23190716	A/T	cg23682824	chr7:23144976	KLHL7	0.42	11.04	0.4	4.49e-26	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg05985134	chr18:33552581	C18orf21	0.65	12.41	0.44	7.63e-32	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg15395560	chr15:45543142	SLC28A2	0.3	8.37	0.31	3.69e-16	Uric acid levels;
BRCA	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg16506815	chr2:162101123	NA	-0.44	-9.45	-0.35	6.14e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	21.92	0.66	7.61e-80	Platelet count;
BRCA	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-11.48	-0.41	7.32e-28	Pulmonary function;
BRCA	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.19	0.4	1.17e-26	Bipolar disorder;
BRCA	trans	rs6479891	1.000	rs12416349	chr10:65277543	C/T	cg14819942	chr15:35414228	NA	0.35	8.51	0.32	1.28e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg23625390	chr15:77176239	SCAPER	0.39	9.06	0.34	1.61e-18	Blood metabolite levels;
BRCA	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg25036284	chr2:26402008	FAM59B	-0.89	-15.18	-0.51	1.1e-44	Gut microbiome composition (summer);
BRCA	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg26528668	chr16:1614120	IFT140	0.38	8.6	0.32	6.27e-17	Coronary artery disease;
BRCA	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02176678	chr2:219576539	TTLL4	-0.54	-13.54	-0.47	6.76e-37	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg12386194	chr3:101231763	SENP7	0.62	11.97	0.43	6.48e-30	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg02951883	chr7:2050386	MAD1L1	0.39	8.07	0.3	3.57e-15	Neuroticism;
BRCA	cis	rs922182	0.538	rs16947599	chr15:64260944	C/T	cg24729988	chr15:64271149	DAPK2	-0.6	-15.21	-0.52	8.08e-45	Blood protein levels;
BRCA	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg10523679	chr1:76189770	ACADM	0.91	22.02	0.66	2.26e-80	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg11584989	chr19:19387371	SF4	0.66	14.26	0.49	2.94e-40	Bipolar disorder;
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg03188948	chr7:1209495	NA	0.53	9.72	0.36	6.17e-21	Longevity;Endometriosis;
BRCA	trans	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg26384229	chr12:38710491	ALG10B	0.58	13.17	0.46	3.35e-35	Morning vs. evening chronotype;
BRCA	cis	rs67981189	0.896	rs3814871	chr14:71444788	G/A	cg15816911	chr14:71606274	NA	0.35	7.9	0.3	1.25e-14	Schizophrenia;
BRCA	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.63	13.38	0.47	3.75e-36	Lymphocyte counts;
BRCA	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.81	-0.33	1.2e-17	Total body bone mineral density;
BRCA	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00166722	chr3:10149974	C3orf24	0.65	11.23	0.41	7.83e-27	Alzheimer's disease;
BRCA	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-15.84	-0.53	6.63e-48	Systemic lupus erythematosus;
BRCA	cis	rs367943	0.649	rs255866	chr5:112748532	A/T	cg12552261	chr5:112820674	MCC	0.36	7.87	0.3	1.51e-14	Type 2 diabetes;
BRCA	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg03609598	chr5:56110824	MAP3K1	-0.49	-8.03	-0.3	4.74e-15	Initial pursuit acceleration;
BRCA	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg05985134	chr18:33552581	C18orf21	0.64	12.16	0.43	9.02e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.49	-0.41	6.35e-28	Morning vs. evening chronotype;
BRCA	cis	rs67981189	0.835	rs2526855	chr14:71413346	T/C	cg15816911	chr14:71606274	NA	-0.36	-8.02	-0.3	5.17e-15	Schizophrenia;
BRCA	cis	rs2282802	0.685	rs12188849	chr5:139621570	G/A	cg26211634	chr5:139558579	C5orf32	0.35	8.62	0.32	5.12e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg02753203	chr1:228287806	NA	-0.59	-12.59	-0.45	1.29e-32	Diastolic blood pressure;
BRCA	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-9.38	-0.35	1.14e-19	Total body bone mineral density;
BRCA	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg04691961	chr3:161091175	C3orf57	-0.38	-8.86	-0.33	7.65e-18	Morning vs. evening chronotype;
BRCA	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg15395560	chr15:45543142	SLC28A2	0.28	7.95	0.3	8.52e-15	Uric acid levels;
BRCA	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-8.47	-0.32	1.73e-16	Total body bone mineral density;
BRCA	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg18016565	chr1:150552671	MCL1	0.36	8.72	0.33	2.47e-17	Tonsillectomy;
BRCA	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg08807101	chr21:30365312	RNF160	-0.59	-15.06	-0.51	4.22e-44	Dental caries;
BRCA	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.58	9.21	0.34	4.81e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	10.14	0.37	1.69e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6842047	0.563	rs6843711	chr4:187212953	T/C	cg14349977	chr4:187219430	NA	-0.61	-7.97	-0.3	7.05e-15	Blood protein levels;
BRCA	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11890956	chr21:40555474	PSMG1	-0.85	-21.99	-0.66	3.23e-80	Cognitive function;
BRCA	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg15485101	chr11:133734466	NA	-0.4	-9.62	-0.36	1.56e-20	Childhood ear infection;
BRCA	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	10.81	0.39	3.99e-25	Rheumatoid arthritis;
BRCA	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg27446573	chr6:127587934	RNF146	0.86	18.16	0.58	1.02e-59	Breast cancer;
BRCA	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18876405	chr7:65276391	NA	0.5	11.01	0.4	6.2e-26	Aortic root size;
BRCA	cis	rs7552167	0.925	rs11249021	chr1:24512881	G/T	cg01960748	chr1:24522592	NA	-0.63	-10.93	-0.4	1.3e-25	Psoriasis vulgaris;
BRCA	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg26874164	chr19:58962979	ZNF324B	0.44	9.3	0.35	2.28e-19	Uric acid clearance;
BRCA	cis	rs11969893	0.649	rs1321204	chr6:101468591	A/G	cg12253828	chr6:101329408	ASCC3	0.76	9.9	0.36	1.37e-21	Economic and political preferences (immigration/crime);
BRCA	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg08888203	chr3:10149979	C3orf24	0.68	14.5	0.5	2.22e-41	Alzheimer's disease;
BRCA	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg01877450	chr7:97915802	BRI3	-0.36	-8.19	-0.31	1.45e-15	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21582582	chr3:182698605	DCUN1D1	0.39	10.16	0.37	1.38e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.67	-13.85	-0.48	2.45e-38	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs9811920	0.809	rs793475	chr3:99543764	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.55	-12.96	-0.46	2.9e-34	Axial length;
BRCA	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03923535	chr7:1197113	ZFAND2A	0.52	11.18	0.4	1.31e-26	Longevity;Endometriosis;
BRCA	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg22713356	chr15:30763199	NA	1.41	27.93	0.74	8.83e-113	Uric acid levels;
BRCA	cis	rs12612619	0.732	rs2289360	chr2:27302165	T/C	cg00617064	chr2:27272375	NA	-0.33	-8.68	-0.32	3.32e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg24675658	chr1:53192096	ZYG11B	0.55	11.33	0.41	3.17e-27	Monocyte count;
BRCA	cis	rs7631605	0.905	rs931721	chr3:37211972	T/C	cg15934958	chr3:37212084	LRRFIP2	0.42	9.87	0.36	1.69e-21	Cerebrospinal P-tau181p levels;
BRCA	trans	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg06521331	chr12:34319734	NA	-0.53	-9.51	-0.35	3.7e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2070433	1.000	rs2070433	chr21:47961386	G/A	cg12379764	chr21:47803548	PCNT	0.51	9.35	0.35	1.4e-19	Lymphocyte counts;
BRCA	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg07148914	chr20:33460835	GGT7	0.38	8.58	0.32	7.26e-17	Height;
BRCA	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg08132940	chr7:1081526	C7orf50	-0.6	-9.02	-0.34	2.25e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg05507819	chr15:63340323	TPM1	0.43	9.27	0.34	2.88e-19	Platelet count;
BRCA	cis	rs6005807	0.719	rs12166245	chr22:28999890	C/T	cg12565055	chr22:29076175	TTC28	0.5	9.38	0.35	1.17e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	trans	rs1997103	1.000	rs10228182	chr7:55406695	A/T	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg05313129	chr8:58192883	C8orf71	-0.42	-8.85	-0.33	8.51e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg16586182	chr3:47516702	SCAP	0.65	15.13	0.51	1.93e-44	Colorectal cancer;
BRCA	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.9e-18	Motion sickness;
BRCA	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg17063962	chr7:91808500	NA	-0.53	-12.29	-0.44	2.63e-31	Breast cancer;
BRCA	cis	rs17401966	0.800	rs12122029	chr1:10339822	G/A	cg03954927	chr1:10346856	KIF1B	0.43	13.78	0.48	5.32e-38	Hepatocellular carcinoma;
BRCA	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	17.42	0.57	6.88e-56	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg24558204	chr6:135376177	HBS1L	0.59	15.86	0.53	5.13e-48	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg04362960	chr10:104952993	NT5C2	0.43	9.74	0.36	5.33e-21	Arsenic metabolism;
BRCA	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg06627628	chr2:24431161	ITSN2	-0.52	-8.55	-0.32	9.28e-17	Lymphocyte counts;
BRCA	cis	rs922182	0.557	rs2004231	chr15:64195769	C/T	cg24729988	chr15:64271149	DAPK2	0.45	9.34	0.35	1.62e-19	Blood protein levels;
BRCA	cis	rs929596	0.606	rs10178992	chr2:234657877	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-10.79	-0.39	4.79e-25	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs12612619	0.732	rs10432697	chr2:27272052	T/C	cg00617064	chr2:27272375	NA	-0.32	-8.46	-0.32	1.83e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	trans	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg25214090	chr10:38739885	LOC399744	0.56	12.91	0.45	4.95e-34	Corneal astigmatism;
BRCA	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.97	-0.37	7.48e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	trans	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg25214090	chr10:38739885	LOC399744	0.55	12.36	0.44	1.33e-31	Corneal astigmatism;
BRCA	cis	rs7646881	0.812	rs7624408	chr3:158460058	G/A	cg19483011	chr3:158453295	NA	-0.46	-8.05	-0.3	4.08e-15	Tetralogy of Fallot;
BRCA	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	12.76	0.45	2.24e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.81	-0.3	2.42e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg18016565	chr1:150552671	MCL1	0.34	7.95	0.3	8.56e-15	Melanoma;
BRCA	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg05985134	chr18:33552581	C18orf21	0.71	13.49	0.47	1.16e-36	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg22974920	chr21:40686053	BRWD1	-0.41	-9.06	-0.34	1.58e-18	Cognitive function;
BRCA	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-10.52	-0.38	5.4e-24	IgG glycosylation;
BRCA	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	9.94	0.37	9.51e-22	Neuroticism;
BRCA	trans	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg26384229	chr12:38710491	ALG10B	0.47	9.93	0.37	1.07e-21	Resting heart rate;
BRCA	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-9.05	-0.34	1.66e-18	Fear of minor pain;
BRCA	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg26384229	chr12:38710491	ALG10B	0.41	9.26	0.34	2.97e-19	Morning vs. evening chronotype;
BRCA	cis	rs6750047	0.585	rs4670234	chr2:38272477	C/T	cg07380506	chr2:38303506	CYP1B1	0.48	10.57	0.39	3.52e-24	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	10.96	0.4	1e-25	Rheumatoid arthritis;
BRCA	cis	rs1953600	0.870	rs12770550	chr10:81953451	G/T	cg04850286	chr10:81895943	PLAC9	0.32	8.96	0.33	3.45e-18	Sarcoidosis;
BRCA	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg21854759	chr1:92012499	NA	0.39	8.9	0.33	5.54e-18	Breast cancer;
BRCA	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	14.1	0.49	1.71e-39	Personality dimensions;
BRCA	cis	rs10193935	0.901	rs222468	chr2:42642531	C/T	cg27598129	chr2:42591480	NA	-0.76	-13.01	-0.46	1.66e-34	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg16586182	chr3:47516702	SCAP	0.53	11.57	0.42	3.09e-28	Colorectal cancer;
BRCA	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03188948	chr7:1209495	NA	0.68	14.5	0.5	2.24e-41	Longevity;Endometriosis;
BRCA	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg10932868	chr11:921992	NA	0.5	12.8	0.45	1.56e-33	Alzheimer's disease (late onset);
BRCA	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg01529538	chr14:23388837	RBM23	0.42	11.47	0.41	8.31e-28	Cognitive ability (multi-trait analysis);
BRCA	cis	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg20368463	chr18:77673604	PQLC1	-0.42	-10.65	-0.39	1.71e-24	Schizophrenia;
BRCA	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg08888203	chr3:10149979	C3orf24	0.57	12.08	0.43	2.15e-30	Alzheimer's disease;
BRCA	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg11502198	chr6:26597334	ABT1	0.47	9.43	0.35	7.5599999999999994e-20	Intelligence (multi-trait analysis);
BRCA	trans	rs1459104	1.000	rs35097999	chr11:55048103	C/T	cg03929089	chr4:120376271	NA	0.64	7.81	0.3	2.44e-14	Body mass index;
BRCA	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs36051895	0.695	rs10974916	chr9:5017350	G/A	cg02405213	chr9:5042618	JAK2	-0.45	-8.38	-0.31	3.45e-16	Pediatric autoimmune diseases;
BRCA	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg10495392	chr1:46806563	NSUN4	0.45	8.17	0.31	1.7e-15	Menopause (age at onset);
BRCA	cis	rs2882667	0.690	rs288021	chr5:138224283	C/T	cg04439458	chr5:138467593	SIL1	-0.34	-8.4	-0.32	2.91e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg00701064	chr4:6280414	WFS1	0.68	17.68	0.57	3.11e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7246967	0.673	rs12974988	chr19:22925965	G/T	cg23217946	chr19:22817039	ZNF492	0.5	9.19	0.34	5.61e-19	Bronchopulmonary dysplasia;
BRCA	trans	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg25214090	chr10:38739885	LOC399744	0.53	12.03	0.43	3.51e-30	Corneal astigmatism;
BRCA	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06481639	chr22:41940642	POLR3H	0.48	7.92	0.3	1.03e-14	Vitiligo;
BRCA	cis	rs3892630	0.817	rs35408716	chr19:33187961	A/C	cg22980127	chr19:33182716	NUDT19	0.9	18.06	0.58	3.08e-59	Red blood cell traits;
BRCA	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	11.85	0.42	2.03e-29	Lung cancer in ever smokers;
BRCA	cis	rs1829883	0.898	rs2963578	chr5:98785417	C/T	cg08333243	chr5:99726346	NA	-0.34	-7.88	-0.3	1.45e-14	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs1941023	0.584	rs2197236	chr11:60168859	T/C	cg08716584	chr11:60157161	MS4A7	-0.42	-9.73	-0.36	5.83e-21	Congenital heart disease (maternal effect);
BRCA	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg04546413	chr19:29218101	NA	0.49	8.43	0.32	2.21e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg10523679	chr1:76189770	ACADM	0.74	16.98	0.56	1.25e-53	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg21535247	chr6:8435926	SLC35B3	0.42	9.5	0.35	4.14e-20	Motion sickness;
BRCA	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	27.6	0.74	5.62e-111	Chronic sinus infection;
BRCA	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg24642439	chr20:33292090	TP53INP2	0.43	9.11	0.34	1.07e-18	Height;
BRCA	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg00277334	chr10:82204260	NA	-0.42	-8.08	-0.3	3.14e-15	Post bronchodilator FEV1;
BRCA	cis	rs7944584	0.632	rs7116451	chr11:47322327	G/A	cg20307385	chr11:47447363	PSMC3	0.57	11.66	0.42	1.27e-28	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs813218	0.584	rs793469	chr3:99537305	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-8.82	-0.33	1.07e-17	Orofacial clefts;
BRCA	cis	rs7000551	0.532	rs4872486	chr8:22256359	G/T	cg12081754	chr8:22256438	SLC39A14	0.78	15.94	0.53	2.18e-48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg23719950	chr11:63933701	MACROD1	-0.55	-9.19	-0.34	5.65e-19	Mean platelet volume;
BRCA	cis	rs6878727	0.962	rs10045630	chr5:123736235	C/T	cg01806427	chr5:123737813	NA	0.42	9.31	0.35	2.08e-19	Breast cancer;
BRCA	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	20.93	0.64	1.71e-74	Lymphocyte percentage of white cells;
BRCA	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-16.73	-0.55	2.24e-52	Axial length;
BRCA	cis	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.33	-0.31	4.99e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg02743256	chr7:2109353	MAD1L1	-0.45	-8.08	-0.3	3.31e-15	Bipolar disorder;
BRCA	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg19196401	chr6:110721138	DDO	-0.4	-10.08	-0.37	2.92e-22	Platelet distribution width;
BRCA	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00166722	chr3:10149974	C3orf24	0.66	13.26	0.46	1.33e-35	Alzheimer's disease;
BRCA	cis	rs9790314	0.747	rs9990242	chr3:160838461	T/C	cg04691961	chr3:161091175	C3orf57	-0.46	-9.89	-0.36	1.44e-21	Morning vs. evening chronotype;
BRCA	cis	rs6815814	0.950	rs5743557	chr4:38806827	G/A	cg02016764	chr4:38805732	TLR1	-0.6	-9.56	-0.35	2.42e-20	Breast cancer;
BRCA	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	11.22	0.41	8.98e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg03060546	chr3:49711283	APEH	-0.53	-10.51	-0.38	6.38e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-12.95	-0.46	3.16e-34	Migraine;Coronary artery disease;
BRCA	cis	rs738322	0.533	rs5756934	chr22:38547279	G/A	cg25457927	chr22:38595422	NA	-0.37	-13.18	-0.46	2.8e-35	Cutaneous nevi;
BRCA	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs55665837	1.000	rs10832268	chr11:14465068	C/A	cg19336497	chr11:14380999	RRAS2	-0.37	-9.77	-0.36	4.22e-21	Vitamin D levels;
BRCA	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg12292205	chr6:26970375	C6orf41	0.58	12.87	0.45	7.13e-34	Schizophrenia;
BRCA	cis	rs312274	0.550	rs10879360	chr12:41313575	A/C	cg17827154	chr12:41323612	CNTN1	-0.42	-10.51	-0.38	6.02e-24	Metabolite levels  (X-11787);
BRCA	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg26384229	chr12:38710491	ALG10B	0.75	16.26	0.54	5.37e-50	Bladder cancer;
BRCA	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg23711669	chr6:146136114	FBXO30	0.75	17.37	0.57	1.18e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-10.96	-0.4	9.9e-26	Calcium levels;
BRCA	trans	rs4650994	1.000	rs12138561	chr1:178518784	G/T	cg05059571	chr16:84539110	KIAA1609	-0.43	-9.61	-0.36	1.6e-20	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs11955398	0.584	rs62372964	chr5:59885798	C/A	cg02684056	chr5:59996105	DEPDC1B	0.35	8.33	0.31	4.78e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg14530993	chr4:882597	GAK	0.57	10.16	0.37	1.36e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg19920283	chr7:105172520	RINT1	0.59	9.4	0.35	9.51e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	8.7	0.33	2.75e-17	Platelet count;
BRCA	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg03929089	chr4:120376271	NA	-0.48	-9.02	-0.34	2.1e-18	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.06	0.54	5.01e-49	Colorectal cancer;
BRCA	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg08888203	chr3:10149979	C3orf24	0.67	14.07	0.49	2.26e-39	Alzheimer's disease;
BRCA	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.09	-38.64	-0.84	2.5e-169	Myeloid white cell count;
BRCA	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg05340658	chr4:99064831	C4orf37	0.62	14.89	0.51	2.75e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.52	-0.32	1.18e-16	Total body bone mineral density;
BRCA	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg05623727	chr3:50126028	RBM5	-0.39	-9.04	-0.34	1.89e-18	Menarche (age at onset);
BRCA	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg14349672	chr11:133703707	NA	-0.41	-9.15	-0.34	7.55e-19	Childhood ear infection;
BRCA	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg12935359	chr14:103987150	CKB	-0.56	-13.13	-0.46	4.85e-35	Body mass index;
BRCA	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg05347473	chr6:146136440	FBXO30	0.4	8.12	0.31	2.48e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg03146154	chr1:46216737	IPP	0.52	11.59	0.42	2.54e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg21545522	chr1:205238299	TMCC2	0.4	8.79	0.33	1.39e-17	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg11941060	chr3:133502564	NA	-0.59	-14.24	-0.49	3.47e-40	Iron status biomarkers;
BRCA	trans	rs3857536	0.776	rs9342535	chr6:66932963	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.11	-0.31	2.53e-15	Blood trace element (Cu levels);
BRCA	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg03060546	chr3:49711283	APEH	0.61	10.33	0.38	3.17e-23	Menarche (age at onset);
BRCA	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-9.97	-0.37	7.37e-22	Alzheimer's disease (late onset);
BRCA	cis	rs1003719	0.591	rs13046303	chr21:38551976	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.57	-13.08	-0.46	8.12e-35	Eye color traits;
BRCA	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.97	-20.82	-0.64	6.59e-74	Lymphocyte percentage of white cells;
BRCA	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg08888203	chr3:10149979	C3orf24	0.64	11.9	0.43	1.24e-29	Alzheimer's disease;
BRCA	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg02659138	chr7:134003124	SLC35B4	0.33	10.38	0.38	1.95e-23	Mean platelet volume;
BRCA	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.22	-0.31	1.13e-15	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg25319279	chr11:5960081	NA	-0.41	-7.91	-0.3	1.17e-14	DNA methylation (variation);
BRCA	cis	rs9403521	1.000	rs9390126	chr6:143980432	A/G	cg18240653	chr6:144019428	PHACTR2	-0.41	-8.18	-0.31	1.48e-15	Obesity-related traits;
BRCA	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-10.0	-0.37	5.53e-22	Alzheimer's disease (late onset);
BRCA	cis	rs7607369	0.536	rs12623740	chr2:219665715	T/A	cg02176678	chr2:219576539	TTLL4	-0.37	-9.42	-0.35	8.09e-20	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	cis	rs829883	0.902	rs1620317	chr12:98890566	T/C	cg25150519	chr12:98850993	NA	0.59	11.88	0.43	1.52e-29	Colorectal adenoma (advanced);
BRCA	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg25358565	chr5:93447407	FAM172A	1.24	19.13	0.6	7.41e-65	Diabetic retinopathy;
BRCA	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg17971929	chr21:40555470	PSMG1	0.52	11.64	0.42	1.49e-28	Cognitive function;
BRCA	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg25036284	chr2:26402008	FAM59B	0.59	9.8	0.36	3.35e-21	Gut microbiome composition (summer);
BRCA	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg24110177	chr3:50126178	RBM5	-0.4	-10.32	-0.38	3.38e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06221963	chr1:154839813	KCNN3	-0.57	-16.07	-0.54	4.89e-49	Prostate cancer;
BRCA	cis	rs4595586	0.756	rs1400283	chr12:39364596	G/C	cg26384229	chr12:38710491	ALG10B	0.39	8.59	0.32	6.65e-17	Morning vs. evening chronotype;
BRCA	cis	rs9788682	0.747	rs2568499	chr15:78722359	T/C	cg24631222	chr15:78858424	CHRNA5	-0.49	-9.6	-0.36	1.75e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-9.93	-0.37	1.01e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg27129171	chr3:47204927	SETD2	0.75	19.53	0.61	5.98e-67	Colorectal cancer;
BRCA	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00166722	chr3:10149974	C3orf24	0.64	12.62	0.45	9.76e-33	Alzheimer's disease;
BRCA	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg14440974	chr22:39074834	NA	-0.38	-9.09	-0.34	1.24e-18	Menopause (age at onset);
BRCA	cis	rs11608355	0.545	rs1073779	chr12:109894721	C/T	cg05360138	chr12:110035743	NA	0.71	13.18	0.46	2.85e-35	Neuroticism;
BRCA	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg22064581	chr6:34113293	NA	0.34	8.16	0.31	1.83e-15	Mosquito bite size;
BRCA	trans	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg26043149	chr18:55253948	FECH	0.4	8.73	0.33	2.17e-17	Bone mineral density;
BRCA	cis	rs17401966	0.838	rs55676616	chr1:10290126	T/C	cg03954927	chr1:10346856	KIF1B	0.43	13.68	0.48	1.56e-37	Hepatocellular carcinoma;
BRCA	trans	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.51	-0.35	3.7e-20	Bladder cancer;
BRCA	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-9.98	-0.37	6.55e-22	IgG glycosylation;
BRCA	cis	rs17253792	0.822	rs10135426	chr14:56054644	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.57	7.98	0.3	6.98e-15	Putamen volume;
BRCA	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg24675658	chr1:53192096	ZYG11B	0.64	14.15	0.49	9.68e-40	Monocyte count;
BRCA	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg14582100	chr15:45693742	SPATA5L1	0.3	8.96	0.33	3.63e-18	Homoarginine levels;
BRCA	cis	rs1865760	0.688	rs9379814	chr6:25979869	C/T	cg17691542	chr6:26056736	HIST1H1C	0.49	10.16	0.37	1.38e-22	Height;
BRCA	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg22467129	chr15:76604101	ETFA	-0.49	-10.83	-0.39	3.42e-25	Blood metabolite levels;
BRCA	trans	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	20.89	0.64	3.01e-74	Exhaled nitric oxide output;
BRCA	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg13385794	chr1:248469461	NA	0.28	7.81	0.3	2.28e-14	Common traits (Other);
BRCA	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.31	9.56	0.35	2.59e-20	Bipolar disorder;
BRCA	cis	rs7301016	0.846	rs11174571	chr12:63022329	C/T	cg01804193	chr12:63026212	NA	0.47	8.31	0.31	5.61e-16	IgG glycosylation;
BRCA	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg17063962	chr7:91808500	NA	-0.54	-12.92	-0.45	4.51e-34	Breast cancer;
BRCA	trans	rs4650994	0.525	rs2761463	chr1:178557137	T/C	cg05059571	chr16:84539110	KIAA1609	0.57	12.78	0.45	1.82e-33	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg13852791	chr20:30311386	BCL2L1	0.89	20.13	0.62	3.67e-70	Mean corpuscular hemoglobin;
BRCA	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg08885076	chr2:99613938	TSGA10	-0.59	-13.08	-0.46	8e-35	Chronic sinus infection;
BRCA	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg11189052	chr15:85197271	WDR73	-0.42	-8.82	-0.33	1.09e-17	Schizophrenia;
BRCA	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg25554036	chr4:6271136	WFS1	0.43	10.02	0.37	4.67e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	trans	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg25042112	chr7:64838748	ZNF92	-0.45	-8.46	-0.32	1.84e-16	Pain;
BRCA	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-9.5	-0.35	3.97e-20	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg15704280	chr7:45808275	SEPT13	0.56	8.04	0.3	4.24e-15	Intraocular pressure;
BRCA	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.48	10.38	0.38	2.01e-23	Cognitive ability;
BRCA	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.35	-8.01	-0.3	5.59e-15	Bipolar disorder;
BRCA	cis	rs11920090	0.932	rs2292621	chr3:170723668	C/T	cg09710316	chr3:170744871	SLC2A2	0.41	7.93	0.3	1.02e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg02493740	chr2:85810744	VAMP5	-0.56	-11.31	-0.41	3.8e-27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs9815354	0.812	rs77732985	chr3:41945872	G/A	cg03022575	chr3:42003672	ULK4	0.68	9.49	0.35	4.64e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs11690935	0.549	rs62183819	chr2:172904520	G/T	cg13550731	chr2:172543902	DYNC1I2	0.58	14.51	0.5	1.86e-41	Schizophrenia;
BRCA	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	14.46	0.5	3.43e-41	Alzheimer's disease;
BRCA	cis	rs12681288	0.676	rs34282191	chr8:991290	G/A	cg04851639	chr8:1020857	NA	-0.36	-9.96	-0.37	7.9e-22	Schizophrenia;
BRCA	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.5	-0.32	1.31e-16	Menopause (age at onset);
BRCA	cis	rs870825	0.860	rs60022249	chr4:185600772	T/C	cg04058563	chr4:185651563	MLF1IP	0.65	11.26	0.41	5.77e-27	Blood protein levels;
BRCA	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.72	-0.5	1.95e-42	Chronic sinus infection;
BRCA	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg23711669	chr6:146136114	FBXO30	-0.72	-17.06	-0.56	4.95e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg14196790	chr5:131705035	SLC22A5	0.43	11.2	0.41	1.04e-26	Blood metabolite levels;
BRCA	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg03433033	chr1:76189801	ACADM	-0.6	-12.27	-0.44	3.15e-31	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg22105103	chr4:187893119	NA	0.41	13.28	0.47	1.03e-35	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg03709012	chr19:19516395	GATAD2A	1.1	21.37	0.65	7.05e-77	Nonalcoholic fatty liver disease;
BRCA	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg05283184	chr6:79620031	NA	-0.35	-8.21	-0.31	1.27e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg03060546	chr3:49711283	APEH	0.47	10.11	0.37	2.25e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
BRCA	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg06484146	chr7:12443880	VWDE	-0.72	-9.97	-0.37	7.58e-22	Coronary artery disease;
BRCA	cis	rs2882667	0.654	rs7709770	chr5:138149339	A/G	cg04439458	chr5:138467593	SIL1	0.36	8.64	0.32	4.57e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4919694	1.000	rs58700372	chr10:104800205	T/C	cg04362960	chr10:104952993	NT5C2	0.94	14.5	0.5	2.26e-41	Arsenic metabolism;
BRCA	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg08885076	chr2:99613938	TSGA10	0.46	10.93	0.4	1.36e-25	Chronic sinus infection;
BRCA	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11890956	chr21:40555474	PSMG1	-0.8	-18.85	-0.6	2.33e-63	Cognitive function;
BRCA	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.04	0.34	1.92e-18	Tonsillectomy;
BRCA	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg11764359	chr7:65958608	NA	-0.65	-11.91	-0.43	1.15e-29	Aortic root size;
BRCA	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26714650	chr12:56694279	CS	1.11	14.9	0.51	2.46e-43	Psoriasis vulgaris;
BRCA	cis	rs6546550	0.901	rs3771531	chr2:70164034	T/C	cg02498382	chr2:70120550	SNRNP27	-0.51	-11.14	-0.4	1.76e-26	Prevalent atrial fibrillation;
BRCA	cis	rs9359856	0.564	rs76069351	chr6:90425043	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.69	-8.22	-0.31	1.15e-15	Bipolar disorder;
BRCA	cis	rs7524258	0.903	rs4908450	chr1:7292756	T/C	cg07173049	chr1:7289937	CAMTA1	0.55	13.54	0.47	6.48e-37	Tourette's syndrome or obsessive-compulsive disorder;
BRCA	cis	rs2015599	0.549	rs3782508	chr12:29451379	T/G	cg09582351	chr12:29534625	ERGIC2	-0.34	-7.82	-0.3	2.21e-14	Mean platelet volume;Platelet count;
BRCA	cis	rs778371	0.723	rs6739794	chr2:233576165	G/A	cg08000102	chr2:233561755	GIGYF2	0.82	20.01	0.62	1.6e-69	Schizophrenia;
BRCA	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg26248373	chr2:1572462	NA	-0.51	-9.82	-0.36	2.63e-21	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.51	-9.88	-0.36	1.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs11971779	0.715	rs7787398	chr7:139061846	A/G	cg07862535	chr7:139043722	LUC7L2	0.4	10.75	0.39	7.08e-25	Diisocyanate-induced asthma;
BRCA	cis	rs4363385	0.818	rs407448	chr1:153007504	C/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.55	-0.32	9.31e-17	Inflammatory skin disease;
BRCA	cis	rs9790314	0.690	rs6783085	chr3:160830929	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-11.33	-0.41	3.02e-27	Morning vs. evening chronotype;
BRCA	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg27170947	chr2:26402098	FAM59B	-0.64	-11.25	-0.41	6.3100000000000004e-27	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg25036284	chr2:26402008	FAM59B	-0.88	-15.49	-0.52	3.43e-46	Gut microbiome composition (summer);
BRCA	cis	rs113835537	0.529	rs11227509	chr11:66281194	T/C	cg24851651	chr11:66362959	CCS	0.44	8.29	0.31	6.92e-16	Airway imaging phenotypes;
BRCA	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg05623727	chr3:50126028	RBM5	0.39	8.3	0.31	6.09e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg09184832	chr6:79620586	NA	-0.48	-10.35	-0.38	2.54e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6763687	0.637	rs7620170	chr3:171808897	A/G	cg16233210	chr3:171778391	FNDC3B	0.37	8.77	0.33	1.61e-17	Red cell distribution width;
BRCA	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg24848339	chr3:12840334	CAND2	0.49	13.14	0.46	4.22e-35	QRS complex (12-leadsum);
BRCA	cis	rs2882667	0.690	rs288041	chr5:138204011	T/C	cg04439458	chr5:138467593	SIL1	-0.31	-7.94	-0.3	8.86e-15	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg11266682	chr4:10021025	SLC2A9	0.41	10.82	0.39	3.7e-25	Bone mineral density;
BRCA	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg12311346	chr5:56204834	C5orf35	-0.83	-16.32	-0.54	2.49e-50	Initial pursuit acceleration;
BRCA	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg19052272	chr2:3704530	ALLC	0.48	10.35	0.38	2.58e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
BRCA	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18876405	chr7:65276391	NA	0.52	12.19	0.43	7e-31	Aortic root size;
BRCA	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg00717180	chr2:96193071	NA	-0.38	-10.2	-0.37	9.48e-23	HDL cholesterol;
BRCA	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27286337	chr10:134555280	INPP5A	0.8	12.94	0.46	3.49e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	8.51	0.32	1.21e-16	Rheumatoid arthritis;
BRCA	cis	rs490234	0.934	rs7865246	chr9:128269511	T/C	cg14078157	chr9:128172775	NA	-0.33	-7.91	-0.3	1.13e-14	Mean arterial pressure;
BRCA	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg12564285	chr5:131593104	PDLIM4	0.37	9.98	0.37	6.59e-22	Breast cancer;
BRCA	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg07169764	chr2:136633963	MCM6	1.06	19.98	0.62	2.22e-69	Corneal structure;
BRCA	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg15208524	chr1:10270712	KIF1B	-0.38	-8.11	-0.31	2.56e-15	Hepatocellular carcinoma;
BRCA	cis	rs10504073	0.669	rs341801	chr8:50037784	A/G	cg00325661	chr8:49890786	NA	0.38	10.87	0.39	2.36e-25	Blood metabolite ratios;
BRCA	cis	rs2625529	0.689	rs10851847	chr15:72111760	T/C	cg16672083	chr15:72433130	SENP8	-0.65	-15.31	-0.52	2.61e-45	Red blood cell count;
BRCA	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg23711669	chr6:146136114	FBXO30	0.65	14.66	0.5	3.86e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2011503	0.739	rs10412176	chr19:19689164	T/C	cg15839431	chr19:19639596	YJEFN3	0.38	8.44	0.32	2.07e-16	Bipolar disorder;
BRCA	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	9.23	0.34	3.96e-19	Mean platelet volume;
BRCA	cis	rs7599312	0.963	rs6735267	chr2:213403863	C/T	cg20637307	chr2:213403960	ERBB4	0.49	9.86	0.36	1.91e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1577917	0.804	rs2786854	chr6:86668740	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.33	-8.92	-0.33	5.04e-18	Response to antipsychotic treatment;
BRCA	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg05347473	chr6:146136440	FBXO30	-0.4	-8.01	-0.3	5.45e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.54	11.53	0.41	4.62e-28	Lymphocyte counts;
BRCA	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22509189	chr2:225307070	NA	-0.46	-9.93	-0.37	1.07e-21	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	1.0	26.91	0.73	3.15e-107	Body mass index (adult);
BRCA	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	14.08	0.49	2.02e-39	Platelet count;
BRCA	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg21918786	chr6:109611834	NA	-0.46	-12.9	-0.45	5.56e-34	Reticulocyte fraction of red cells;
BRCA	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg02493740	chr2:85810744	VAMP5	-0.54	-11.23	-0.41	8.17e-27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs312273	0.589	rs278919	chr12:41378355	C/T	cg17827154	chr12:41323612	CNTN1	0.39	10.28	0.38	4.91e-23	Bipolar disorder;
BRCA	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg17971929	chr21:40555470	PSMG1	-0.49	-10.88	-0.4	2.11e-25	Menarche (age at onset);
BRCA	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	9.38	0.35	1.16e-19	Rheumatoid arthritis;
BRCA	trans	rs208520	0.802	rs208516	chr6:66946119	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.45	-0.55	5.68e-51	Exhaled nitric oxide output;
BRCA	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg04450456	chr4:17643702	FAM184B	0.4	11.92	0.43	1.03e-29	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg05255149	chr17:80675120	FN3KRP	-0.44	-9.2	-0.34	4.94e-19	Breast cancer;
BRCA	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg05623727	chr3:50126028	RBM5	0.42	9.73	0.36	6.07e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-8.75	-0.33	1.94e-17	Longevity;Endometriosis;
BRCA	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg09469691	chr10:81107165	PPIF	0.5	10.16	0.37	1.4e-22	Height;
BRCA	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08280861	chr8:58055591	NA	0.52	8.51	0.32	1.25e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2625529	0.557	rs1000281	chr15:72553422	A/G	cg16672083	chr15:72433130	SENP8	0.6	14.45	0.5	3.84e-41	Red blood cell count;
BRCA	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg23708337	chr7:1209742	NA	0.54	8.83	0.33	1.02e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs67460515	0.529	rs11712713	chr3:160852471	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-11.9	-0.43	1.29e-29	Parkinson's disease;
BRCA	cis	rs897984	0.609	rs11862744	chr16:31057800	G/A	cg02466173	chr16:30829666	NA	-0.42	-9.36	-0.35	1.39e-19	Dementia with Lewy bodies;
BRCA	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg11846333	chr4:119757529	SEC24D	0.59	7.82	0.3	2.22e-14	Cannabis dependence symptom count;
BRCA	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg08601574	chr20:25228251	PYGB	-0.35	-8.56	-0.32	8.27e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg00852783	chr1:26633632	UBXN11	-0.46	-8.09	-0.3	2.9e-15	Obesity-related traits;
BRCA	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg24829409	chr8:58192753	C8orf71	-0.47	-9.01	-0.34	2.32e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg00074818	chr8:8560427	CLDN23	0.39	8.53	0.32	1.08e-16	Obesity-related traits;
BRCA	cis	rs6484504	0.600	rs2761593	chr11:31326752	G/T	cg26647111	chr11:31128758	NA	0.42	9.28	0.34	2.68e-19	Red blood cell count;
BRCA	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg06623918	chr6:96969491	KIAA0776	0.73	12.95	0.46	3.16e-34	Migraine;Coronary artery disease;
BRCA	cis	rs6740322	1.000	rs11693666	chr2:43562479	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.64	11.87	0.42	1.6800000000000001e-29	Coronary artery disease;
BRCA	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06022373	chr22:39101656	GTPBP1	0.74	17.59	0.57	9.13e-57	Menopause (age at onset);
BRCA	cis	rs877529	0.932	rs139403	chr22:39547021	G/A	cg12193277	chr22:39547181	CBX7	0.48	13.12	0.46	5.53e-35	Multiple myeloma;
BRCA	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.46	-8.18	-0.31	1.49e-15	Menarche (age at onset);
BRCA	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg15704280	chr7:45808275	SEPT13	-0.54	-10.37	-0.38	2.22e-23	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg20701182	chr2:24300061	SF3B14	0.58	8.98	0.33	2.93e-18	Lymphocyte counts;
BRCA	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg06238570	chr21:40685208	BRWD1	0.41	8.35	0.31	4.16e-16	Menarche (age at onset);
BRCA	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11644478	chr21:40555479	PSMG1	0.84	19.05	0.6	2.07e-64	Cognitive function;
BRCA	cis	rs7809950	1.000	rs7778270	chr7:107224667	A/G	cg23024343	chr7:107201750	COG5	0.41	9.06	0.34	1.57e-18	Coronary artery disease;
BRCA	cis	rs870825	1.000	rs72689245	chr4:185579788	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	13.73	0.48	8.52e-38	Blood protein levels;
BRCA	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg21775007	chr8:11205619	TDH	0.62	12.61	0.45	1.01e-32	Retinal vascular caliber;
BRCA	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg06618935	chr21:46677482	NA	-0.37	-7.94	-0.3	9e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9875589	0.957	rs60060718	chr3:13950333	G/A	cg19554555	chr3:13937349	NA	0.43	8.95	0.33	3.88e-18	Ovarian reserve;
BRCA	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg01206211	chr2:36825736	FEZ2	-0.49	-12.81	-0.45	1.33e-33	Height;
BRCA	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.64	0.36	1.29e-20	Morning vs. evening chronotype;
BRCA	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg25554036	chr4:6271136	WFS1	0.36	8.73	0.33	2.28e-17	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.39	-9.08	-0.34	1.3e-18	Longevity;Endometriosis;
BRCA	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg18132916	chr6:79620363	NA	-0.49	-11.12	-0.4	2.19e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.9	0.62	6.05e-69	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10044254	0.563	rs12152734	chr5:15694406	A/G	cg07238450	chr5:15720153	FBXL7	-0.39	-8.18	-0.31	1.57e-15	Asthma (corticosteroid response);
BRCA	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg08601574	chr20:25228251	PYGB	0.34	8.15	0.31	1.86e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg05347473	chr6:146136440	FBXO30	-0.61	-11.92	-0.43	1.06e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08219700	chr8:58056026	NA	0.44	7.91	0.3	1.12e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg14004847	chr7:1930337	MAD1L1	-0.38	-8.09	-0.3	3.03e-15	Schizophrenia;
BRCA	trans	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg25206134	chr2:45395956	NA	0.52	8.76	0.33	1.7e-17	Bipolar disorder;
BRCA	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg23029597	chr12:123009494	RSRC2	0.63	12.15	0.43	1.0500000000000001e-30	Body mass index;
BRCA	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg18301423	chr5:131593218	PDLIM4	0.32	8.2	0.31	1.28e-15	Breast cancer;
BRCA	cis	rs12760731	0.668	rs73037529	chr1:178410203	A/T	cg00404053	chr1:178313656	RASAL2	0.61	7.92	0.3	1.09e-14	Obesity-related traits;
BRCA	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24308560	chr3:49941425	MST1R	0.39	8.27	0.31	7.64e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.74	0.36	5.54e-21	Menopause (age at onset);
BRCA	cis	rs4478858	0.684	rs2062951	chr1:31762981	T/C	cg00250761	chr1:31883323	NA	-0.32	-8.33	-0.31	4.93e-16	Alcohol dependence;
BRCA	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	15.16	0.51	1.39e-44	Hip circumference adjusted for BMI;
BRCA	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	13.18	0.46	2.94e-35	Electroencephalogram traits;
BRCA	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg23533926	chr12:111358616	MYL2	-0.41	-8.53	-0.32	1.05e-16	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg02733842	chr7:1102375	C7orf50	-0.52	-9.71	-0.36	6.69e-21	Bronchopulmonary dysplasia;
BRCA	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg21905437	chr5:178450457	ZNF879	0.52	10.79	0.39	4.69e-25	Pubertal anthropometrics;
BRCA	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg04450456	chr4:17643702	FAM184B	0.39	11.54	0.42	4.04e-28	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg24675658	chr1:53192096	ZYG11B	0.72	17.19	0.56	1.06e-54	Monocyte count;
BRCA	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.4	8.62	0.32	5.27e-17	Cognitive ability;
BRCA	cis	rs6910061	0.830	rs10946959	chr6:11096401	G/A	cg27233058	chr6:11094804	LOC221710	0.5	8.42	0.32	2.44e-16	Diabetic kidney disease;
BRCA	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg20701182	chr2:24300061	SF3B14	0.7	13.39	0.47	3.24e-36	Lymphocyte counts;
BRCA	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg00383909	chr3:49044727	WDR6	0.63	11.36	0.41	2.33e-27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.57	0.39	3.62e-24	Motion sickness;
BRCA	cis	rs9309711	0.961	rs11678655	chr2:3476234	T/G	cg10845886	chr2:3471009	TTC15	-0.76	-16.3	-0.54	3.21e-50	Neurofibrillary tangles;
BRCA	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg18132916	chr6:79620363	NA	-0.39	-8.02	-0.3	5e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg26384229	chr12:38710491	ALG10B	0.76	16.93	0.56	2.12e-53	Bladder cancer;
BRCA	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	11.7	0.42	8.76e-29	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg18904891	chr8:8559673	CLDN23	-0.57	-11.28	-0.41	4.94e-27	Obesity-related traits;
BRCA	cis	rs9837602	0.745	rs792834	chr3:99476121	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-10.6	-0.39	2.62e-24	Breast cancer;
BRCA	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg13256891	chr4:100009986	ADH5	-0.52	-9.74	-0.36	5.46e-21	Alcohol dependence;
BRCA	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg07169764	chr2:136633963	MCM6	-0.88	-17.61	-0.57	7.22e-57	Corneal structure;
BRCA	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg05340658	chr4:99064831	C4orf37	0.7	17.61	0.57	7.25e-57	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs977987	0.778	rs62059846	chr16:75430809	T/A	cg03315344	chr16:75512273	CHST6	0.52	12.24	0.44	4.23e-31	Dupuytren's disease;
BRCA	cis	rs868036	1.000	rs4325504	chr15:68055570	A/G	cg05925327	chr15:68127851	NA	0.34	8.54	0.32	9.66e-17	Restless legs syndrome;
BRCA	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg14844989	chr11:31128820	NA	-0.45	-9.75	-0.36	4.79e-21	Bone mineral density (spine);
BRCA	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg11845111	chr2:191398756	TMEM194B	0.78	14.55	0.5	1.3e-41	Diastolic blood pressure;
BRCA	cis	rs7903847	0.642	rs7078004	chr10:99140511	A/G	cg20016023	chr10:99160130	RRP12	-0.27	-8.59	-0.32	6.78e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.52	-19.98	-0.62	2.43e-69	Diastolic blood pressure;
BRCA	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg08999081	chr20:33150536	PIGU	0.37	8.92	0.33	4.74e-18	Coronary artery disease;
BRCA	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19626725	chr5:178986131	RUFY1	0.32	9.6	0.35	1.83e-20	Lung cancer;
BRCA	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.73	0.39	8.52e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg03146154	chr1:46216737	IPP	0.46	10.22	0.37	7.99e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg07636037	chr3:49044803	WDR6	-0.39	-8.13	-0.31	2.17e-15	Resting heart rate;
BRCA	cis	rs4771122	0.697	rs1475220	chr13:28037448	G/C	cg22138327	chr13:27999177	GTF3A	-0.44	-8.57	-0.32	7.91e-17	Body mass index;
BRCA	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.43	8.3	0.31	6.18e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.74	0.39	7.82e-25	Tonsillectomy;
BRCA	cis	rs96067	0.711	rs272833	chr1:36622870	C/G	cg24686825	chr1:36642396	MAP7D1	-0.56	-11.28	-0.41	4.88e-27	Corneal structure;
BRCA	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg12310025	chr6:25882481	NA	0.51	12.0	0.43	4.71e-30	Blood metabolite levels;
BRCA	cis	rs17601876	0.807	rs4545755	chr15:51549044	G/A	cg19946085	chr15:51559439	CYP19A1	-0.36	-9.42	-0.35	7.82e-20	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg00105475	chr2:10696890	NA	0.42	9.61	0.36	1.65e-20	Prostate cancer;
BRCA	cis	rs4285028	0.747	rs11916169	chr3:121403211	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.83	-16.05	-0.54	5.97e-49	Multiple sclerosis;
BRCA	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12923728	chr3:195709715	SDHAP1	-0.59	-12.6	-0.45	1.14e-32	Pancreatic cancer;
BRCA	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.61	-0.32	5.77e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9314323	0.524	rs7816609	chr8:26202482	A/C	cg11498726	chr8:26250323	BNIP3L	-0.37	-8.43	-0.32	2.29e-16	Red cell distribution width;
BRCA	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg16006841	chr5:176797999	RGS14	-0.7	-10.97	-0.4	9.1e-26	Urate levels in lean individuals;
BRCA	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg20476274	chr7:133979776	SLC35B4	0.51	11.82	0.42	2.82e-29	Mean platelet volume;
BRCA	cis	rs847577	0.677	rs951988	chr7:97762474	C/G	cg24562669	chr7:97807699	LMTK2	-0.49	-13.2	-0.46	2.47e-35	Breast cancer;
BRCA	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg08085267	chr17:45401833	C17orf57	-0.6	-12.11	-0.43	1.48e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg06484146	chr7:12443880	VWDE	-0.74	-10.57	-0.39	3.58e-24	Coronary artery disease;
BRCA	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-13.59	-0.47	3.87e-37	Gut microbiome composition (summer);
BRCA	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg01475377	chr6:109611718	NA	-0.53	-14.11	-0.49	1.54e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs3925075	0.525	rs2011491	chr16:31280255	G/A	cg02846316	chr16:31340340	ITGAM	0.43	8.78	0.33	1.55e-17	IgA nephropathy;
BRCA	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	11.05	0.4	4.26e-26	Platelet count;
BRCA	cis	rs1832871	0.599	rs1539312	chr6:158743188	G/A	cg07215822	chr6:158701037	NA	0.47	9.55	0.35	2.8e-20	Height;
BRCA	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg15556689	chr8:8085844	FLJ10661	0.37	8.73	0.33	2.23e-17	Retinal vascular caliber;
BRCA	cis	rs55788414	0.932	rs9936302	chr16:81190790	C/T	cg06400318	chr16:81190750	PKD1L2	-1.01	-16.84	-0.55	6.04e-53	Left ventricular obstructive tract defect (maternal effect);
BRCA	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02018176	chr4:1364513	KIAA1530	-0.38	-8.18	-0.31	1.52e-15	Longevity;
BRCA	cis	rs4363385	0.818	rs558363	chr1:153010431	C/T	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg13010199	chr12:38710504	ALG10B	-0.55	-12.38	-0.44	1.09e-31	Heart rate;
BRCA	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg06618935	chr21:46677482	NA	-0.37	-8.11	-0.31	2.59e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs36051895	0.623	rs1555476	chr9:5233054	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-8.12	-0.31	2.41e-15	Pediatric autoimmune diseases;
BRCA	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg05340658	chr4:99064831	C4orf37	0.62	14.74	0.5	1.55e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.3	0.38	4.03e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg12573674	chr2:1569213	NA	-0.57	-12.88	-0.45	6.39e-34	IgG glycosylation;
BRCA	cis	rs6738485	0.861	rs13014335	chr2:106802805	A/G	cg16099169	chr2:106886729	NA	-0.4	-8.19	-0.31	1.45e-15	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
BRCA	cis	rs965469	0.779	rs6051836	chr20:3386482	C/T	cg25506879	chr20:3388711	C20orf194	-0.43	-8.41	-0.32	2.58e-16	IFN-related cytopenia;
BRCA	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg22467129	chr15:76604101	ETFA	-0.49	-10.66	-0.39	1.51e-24	Blood metabolite levels;
BRCA	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg23285459	chr7:2802560	GNA12	-0.32	-8.57	-0.32	7.76e-17	Height;
BRCA	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg14844989	chr11:31128820	NA	-0.45	-9.59	-0.35	1.8899999999999998e-20	Red blood cell count;
BRCA	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg18225595	chr11:63971243	STIP1	0.4	9.93	0.37	1.05e-21	Platelet count;
BRCA	cis	rs2455799	0.573	rs2455812	chr3:15734096	C/G	cg16303742	chr3:15540471	COLQ	-0.37	-9.05	-0.34	1.65e-18	Mean platelet volume;
BRCA	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg14186256	chr22:23484241	RTDR1	-0.71	-18.03	-0.58	4.53e-59	Bone mineral density;
BRCA	trans	rs75804782	0.521	rs72982596	chr2:239454919	G/C	cg01134436	chr17:81009848	B3GNTL1	0.63	8.36	0.31	3.83e-16	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.56	-10.09	-0.37	2.67e-22	Renal function-related traits (BUN);
BRCA	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg03433033	chr1:76189801	ACADM	0.69	13.77	0.48	5.96e-38	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg05340658	chr4:99064831	C4orf37	-0.61	-13.9	-0.48	1.39e-38	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.4	-8.21	-0.31	1.25e-15	Menopause (age at onset);
BRCA	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg00990874	chr7:1149470	C7orf50	-0.52	-9.4	-0.35	9.72e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs11030122	0.702	rs66503725	chr11:3980998	G/A	cg18678763	chr11:4115507	RRM1	-0.35	-7.89	-0.3	1.27e-14	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs1941023	0.584	rs950803	chr11:60152563	A/T	cg08716584	chr11:60157161	MS4A7	0.41	9.75	0.36	5.08e-21	Congenital heart disease (maternal effect);
BRCA	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11644478	chr21:40555479	PSMG1	0.82	18.54	0.59	1.05e-61	Cognitive function;
BRCA	cis	rs2294693	0.945	rs9381023	chr6:40983281	C/T	cg14418226	chr6:40996092	UNC5CL	-0.44	-7.89	-0.3	1.32e-14	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg22535103	chr8:58192502	C8orf71	-0.48	-9.34	-0.35	1.59e-19	Developmental language disorder (linguistic errors);
BRCA	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg21775007	chr8:11205619	TDH	-0.39	-8.07	-0.3	3.57e-15	Neuroticism;
BRCA	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1577917	0.545	rs1335443	chr6:86478737	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.36	-9.72	-0.36	6.31e-21	Response to antipsychotic treatment;
BRCA	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	16.75	0.55	1.82e-52	Mean corpuscular hemoglobin;
BRCA	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg02574844	chr11:5959923	NA	-0.43	-8.42	-0.32	2.55e-16	DNA methylation (variation);
BRCA	cis	rs922182	0.633	rs16947621	chr15:64271660	C/G	cg24729988	chr15:64271149	DAPK2	0.64	16.79	0.55	1.16e-52	Blood protein levels;
BRCA	trans	rs7939886	0.920	rs7112964	chr11:55866408	T/C	cg15704280	chr7:45808275	SEPT13	0.6	7.88	0.3	1.38e-14	Myopia (pathological);
BRCA	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg24562669	chr7:97807699	LMTK2	0.46	12.47	0.44	4.14e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs79146658	0.736	rs4894060	chr2:179751817	T/A	cg17765952	chr2:179737173	CCDC141	-0.45	-7.84	-0.3	1.9e-14	Diastolic blood pressure;
BRCA	cis	rs490234	0.756	rs1398142	chr9:128226712	C/A	cg14078157	chr9:128172775	NA	-0.36	-8.43	-0.32	2.25e-16	Mean arterial pressure;
BRCA	cis	rs36051895	0.564	rs7874624	chr9:5179865	A/G	cg02405213	chr9:5042618	JAK2	-0.48	-9.36	-0.35	1.31e-19	Pediatric autoimmune diseases;
BRCA	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg15017067	chr4:17643749	FAM184B	0.35	10.83	0.39	3.2e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.57	0.35	2.32e-20	Morning vs. evening chronotype;
BRCA	cis	rs11585357	0.895	rs2977305	chr1:17613737	A/T	cg19159961	chr1:17633534	PADI4	-0.5	-8.65	-0.32	4.1e-17	Hair shape;
BRCA	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg08000102	chr2:233561755	GIGYF2	0.75	15.26	0.52	4.73e-45	Schizophrenia;
BRCA	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg24296786	chr1:45957014	TESK2	0.43	8.66	0.32	3.96e-17	Homocysteine levels;
BRCA	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg25767906	chr1:53392781	SCP2	-0.36	-8.13	-0.31	2.16e-15	Monocyte count;
BRCA	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.59	-0.47	3.72e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg14228332	chr4:119757509	SEC24D	-0.65	-7.98	-0.3	6.55e-15	Cannabis dependence symptom count;
BRCA	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg22676075	chr6:135203613	NA	0.44	8.71	0.33	2.6e-17	High light scatter reticulocyte percentage of red cells;
BRCA	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	20.23	0.62	1.01e-70	Platelet count;
BRCA	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg08999081	chr20:33150536	PIGU	-0.31	-7.85	-0.3	1.79e-14	Glomerular filtration rate (creatinine);
BRCA	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg02574844	chr11:5959923	NA	-0.43	-8.44	-0.32	2.08e-16	DNA methylation (variation);
BRCA	cis	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg05084668	chr3:125655381	ALG1L	-0.63	-11.89	-0.43	1.42e-29	Blood pressure (smoking interaction);
BRCA	cis	rs17401966	0.540	rs7546368	chr1:10418826	G/A	cg03954927	chr1:10346856	KIF1B	0.35	10.72	0.39	9.15e-25	Hepatocellular carcinoma;
BRCA	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg16230307	chr14:35515116	FAM177A1	0.72	14.94	0.51	1.73e-43	Psoriasis;
BRCA	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg25237894	chr2:233734115	C2orf82	-0.3	-8.91	-0.33	5.32e-18	Coronary artery disease;
BRCA	cis	rs870825	0.616	rs4623060	chr4:185642943	A/G	cg04058563	chr4:185651563	MLF1IP	0.76	16.78	0.55	1.26e-52	Blood protein levels;
BRCA	cis	rs10499694	0.933	rs12538938	chr7:50592313	A/G	cg18232548	chr7:50535776	DDC	-0.39	-9.39	-0.35	1.04e-19	Body mass index;
BRCA	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg13010199	chr12:38710504	ALG10B	0.45	8.99	0.34	2.73e-18	Morning vs. evening chronotype;
BRCA	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.89e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs175714	0.845	rs175706	chr14:75976200	G/A	cg01624173	chr14:75981868	NA	0.34	9.31	0.35	2e-19	Lymphocyte counts;
BRCA	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg23950597	chr19:37808831	NA	-0.64	-11.72	-0.42	6.91e-29	Coronary artery calcification;
BRCA	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg05535760	chr7:792225	HEATR2	-0.72	-11.55	-0.42	3.73e-28	Cerebrospinal P-tau181p levels;
BRCA	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg23229984	chr5:148520753	ABLIM3	0.36	8.74	0.33	2.06e-17	Breast cancer;
BRCA	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.53	8.89	0.33	6.37e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg21724239	chr8:58056113	NA	0.65	10.15	0.37	1.52e-22	Developmental language disorder (linguistic errors);
BRCA	cis	rs11231017	0.507	rs11231025	chr11:62073305	C/G	cg23876832	chr11:62092739	NA	0.32	8.09	0.3	2.92e-15	HIV-1 viral setpoint;
BRCA	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg11764359	chr7:65958608	NA	0.67	15.05	0.51	4.64e-44	Aortic root size;
BRCA	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg08885076	chr2:99613938	TSGA10	0.41	9.63	0.36	1.4e-20	Chronic sinus infection;
BRCA	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg20469991	chr17:27169893	C17orf63	-0.45	-8.76	-0.33	1.75e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs10044254	0.614	rs13358928	chr5:15737539	G/T	cg07238450	chr5:15720153	FBXL7	-0.38	-8.02	-0.3	5.21e-15	Asthma (corticosteroid response);
BRCA	cis	rs17401966	0.838	rs946502	chr1:10309279	G/C	cg03954927	chr1:10346856	KIF1B	0.44	13.78	0.48	5.01e-38	Hepatocellular carcinoma;
BRCA	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.42	8.86	0.33	7.99e-18	Cognitive ability;
BRCA	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg20933634	chr6:27740509	NA	0.48	9.49	0.35	4.58e-20	Parkinson's disease;
BRCA	cis	rs16958440	0.867	rs74411203	chr18:44677466	G/A	cg17192377	chr18:44677553	HDHD2	0.99	13.58	0.47	4.48e-37	Sitting height ratio;
BRCA	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.18	0.31	1.52e-15	Breast cancer;
BRCA	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg01420254	chr6:26195488	NA	0.54	8.43	0.32	2.24e-16	Gout;Renal underexcretion gout;
BRCA	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-21.3	-0.64	1.76e-76	Height;
BRCA	trans	rs4596713	0.507	rs10115283	chr9:71801162	T/G	cg16512924	chr15:28394682	HERC2	0.45	10.64	0.39	1.82e-24	Headache;
BRCA	cis	rs2742234	0.590	rs2075912	chr10:43622217	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.53	-10.75	-0.39	6.99e-25	Hirschsprung disease;
BRCA	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg00071950	chr4:10020882	SLC2A9	0.39	8.3	0.31	6.16e-16	Blood metabolite levels;
BRCA	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.55	9.29	0.34	2.43e-19	Renal function-related traits (BUN);
BRCA	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.6	0.39	2.83e-24	Motion sickness;
BRCA	trans	rs11039798	1.000	rs7125559	chr11:48984207	C/G	cg15704280	chr7:45808275	SEPT13	0.6	8.84	0.33	8.93e-18	Axial length;
BRCA	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-8.08	-0.3	3.35e-15	Triglycerides;
BRCA	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg04455712	chr21:45112962	RRP1B	0.42	10.86	0.39	2.47e-25	Mean corpuscular volume;
BRCA	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-8.98	-0.33	3.08e-18	Alzheimer's disease (late onset);
BRCA	cis	rs524281	0.861	rs7931544	chr11:65917034	C/T	cg16950941	chr11:66035639	RAB1B	-0.37	-7.86	-0.3	1.6e-14	Electroencephalogram traits;
BRCA	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10150615	chr22:24372951	LOC391322	-0.43	-9.76	-0.36	4.55e-21	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs11676348	0.776	rs11690316	chr2:219017462	A/G	cg00012203	chr2:219082015	ARPC2	-0.46	-8.9	-0.33	5.73e-18	Ulcerative colitis;
BRCA	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-11.12	-0.4	2.2e-26	Schizophrenia;
BRCA	cis	rs13046373	0.535	rs1395778	chr21:31985502	G/C	cg16812893	chr21:31813075	KRTAP15-1	0.37	9.09	0.34	1.26e-18	HDL cholesterol;
BRCA	cis	rs13064411	0.696	rs7631082	chr3:113208913	C/G	cg18753928	chr3:113234510	CCDC52	-0.59	-12.52	-0.44	2.53e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs2882667	0.690	rs13158360	chr5:138258177	G/A	cg04439458	chr5:138467593	SIL1	-0.31	-7.89	-0.3	1.29e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg17971929	chr21:40555470	PSMG1	0.58	9.01	0.34	2.36e-18	Cognitive function;
BRCA	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg03929089	chr4:120376271	NA	0.64	12.64	0.45	7.27e-33	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg03676636	chr4:99064102	C4orf37	0.21	8.02	0.3	5.17e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24531977	chr5:56204891	C5orf35	-0.88	-18.13	-0.58	1.46e-59	Initial pursuit acceleration;
BRCA	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg24296786	chr1:45957014	TESK2	0.65	16.08	0.54	4.27e-49	High light scatter reticulocyte count;
BRCA	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-11.19	-0.4	1.18e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03517284	chr6:25882590	NA	0.68	15.76	0.53	1.56e-47	Blood metabolite levels;
BRCA	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg22705602	chr4:152727874	NA	-0.31	-8.06	-0.3	3.68e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg06618935	chr21:46677482	NA	-0.36	-7.98	-0.3	6.64e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg23978390	chr7:1156363	C7orf50	0.5	11.58	0.42	2.69e-28	Longevity;Endometriosis;
BRCA	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg03433033	chr1:76189801	ACADM	-0.49	-10.37	-0.38	2.17e-23	Daytime sleep phenotypes;
BRCA	cis	rs9287719	0.649	rs10929683	chr2:10732208	C/T	cg00105475	chr2:10696890	NA	-0.42	-9.24	-0.34	3.6e-19	Prostate cancer;
BRCA	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg27446573	chr6:127587934	RNF146	0.7	15.78	0.53	1.27e-47	Breast cancer;
BRCA	cis	rs1997103	0.906	rs6593231	chr7:55402914	T/A	cg17469321	chr7:55412551	NA	0.51	9.72	0.36	6.37e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg06046430	chr4:77819534	ANKRD56	0.61	13.51	0.47	9.58e-37	Emphysema distribution in smoking;
BRCA	cis	rs4948102	0.731	rs10229446	chr7:56064262	A/G	cg09872392	chr7:56161020	PHKG1	0.38	8.67	0.32	3.69e-17	Plasma homocysteine levels (post-methionine load test);
BRCA	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.25	-20.33	-0.63	3.09e-71	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg15017067	chr4:17643749	FAM184B	-0.27	-8.24	-0.31	1e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg04944784	chr2:26401820	FAM59B	-0.88	-15.84	-0.53	6.35e-48	Gut microbiome composition (summer);
BRCA	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg21475434	chr5:93447410	FAM172A	0.69	9.09	0.34	1.27e-18	Diabetic retinopathy;
BRCA	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17971929	chr21:40555470	PSMG1	-0.56	-13.46	-0.47	1.52e-36	Cognitive function;
BRCA	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg14061069	chr19:46274453	DMPK	-0.5	-12.44	-0.44	5.54e-32	Coronary artery disease;
BRCA	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg08885076	chr2:99613938	TSGA10	0.46	10.77	0.39	5.97e-25	Chronic sinus infection;
BRCA	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg26384229	chr12:38710491	ALG10B	0.75	17.26	0.56	4.56e-55	Bladder cancer;
BRCA	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.31	8.46	0.32	1.8e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs9649465	0.902	rs10253850	chr7:123273095	T/C	cg04330084	chr7:123175371	IQUB	-0.32	-8.77	-0.33	1.56e-17	Migraine;
BRCA	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg16584290	chr5:462447	EXOC3	-0.51	-14.31	-0.49	1.69e-40	Cystic fibrosis severity;
BRCA	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-10.1	-0.37	2.28e-22	Neuroticism;
BRCA	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg01475377	chr6:109611718	NA	-0.55	-15.03	-0.51	6.34e-44	Reticulocyte fraction of red cells;
BRCA	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg01689657	chr7:91764605	CYP51A1	0.23	8.43	0.32	2.29e-16	Breast cancer;
BRCA	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg24562669	chr7:97807699	LMTK2	0.47	12.44	0.44	5.97e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.84	-0.3	1.86e-14	Aortic root size;
BRCA	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg05793240	chr7:2802953	GNA12	-0.33	-8.05	-0.3	4.05e-15	Height;
BRCA	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24308560	chr3:49941425	MST1R	0.38	8.14	0.31	2.07e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.747	rs885096	chr1:152971313	T/C	cg25856811	chr1:152973957	SPRR3	-0.34	-8.98	-0.33	3.11e-18	Inflammatory skin disease;
BRCA	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-10.09	-0.37	2.58e-22	Resting heart rate;
BRCA	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg12564285	chr5:131593104	PDLIM4	0.37	9.51	0.35	3.72e-20	Acylcarnitine levels;
BRCA	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg07741184	chr6:167504864	NA	0.27	8.1	0.31	2.78e-15	Crohn's disease;
BRCA	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26314531	chr2:26401878	FAM59B	0.93	14.02	0.49	3.95e-39	Gut microbiome composition (summer);
BRCA	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg08822215	chr16:89438651	ANKRD11	-0.38	-8.13	-0.31	2.15e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11764359	chr7:65958608	NA	0.74	16.67	0.55	4.38e-52	Aortic root size;
BRCA	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg17691542	chr6:26056736	HIST1H1C	0.51	10.13	0.37	1.88e-22	Iron status biomarkers;
BRCA	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg00409905	chr10:38381863	ZNF37A	-0.48	-9.96	-0.37	7.79e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg25554036	chr4:6271136	WFS1	0.43	10.13	0.37	1.82e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs11608355	0.515	rs35691047	chr12:109932585	C/T	cg05360138	chr12:110035743	NA	0.74	13.68	0.48	1.56e-37	Neuroticism;
BRCA	cis	rs12760731	0.668	rs72482621	chr1:178410442	C/T	cg00404053	chr1:178313656	RASAL2	0.62	8.13	0.31	2.26e-15	Obesity-related traits;
BRCA	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.49	-11.93	-0.43	9e-30	Longevity;Endometriosis;
BRCA	cis	rs701145	0.585	rs896013	chr3:153863873	A/G	cg12800244	chr3:153838788	SGEF	0.58	8.15	0.31	1.9e-15	Coronary artery disease;
BRCA	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.41	9.78	0.36	3.93e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4862307	0.836	rs13107384	chr4:185004073	C/T	cg06737308	chr4:185021514	ENPP6	-0.37	-8.14	-0.31	2.09e-15	Serum dimethylarginine levels (asymmetric/symetric ratio);
BRCA	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg11663144	chr21:46675770	NA	-0.54	-12.85	-0.45	8.64e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg03146154	chr1:46216737	IPP	0.46	10.03	0.37	4.21e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg25036284	chr2:26402008	FAM59B	-0.63	-10.95	-0.4	1.12e-25	Gut microbiome composition (summer);
BRCA	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05890377	chr2:74357713	NA	0.59	12.05	0.43	2.7e-30	Gestational age at birth (maternal effect);
BRCA	cis	rs7633857	0.512	rs13098529	chr3:160657053	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-10.83	-0.39	3.37e-25	Educational attainment (years of education);
BRCA	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06022373	chr22:39101656	GTPBP1	0.73	17.6	0.57	7.85e-57	Menopause (age at onset);
BRCA	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.31	-0.35	2.04e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6594499	0.542	rs7722241	chr5:110460747	T/A	cg04022379	chr5:110408740	TSLP	0.36	8.17	0.31	1.71e-15	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.68	0.39	1.35e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17023223	0.537	rs12081198	chr1:119686104	A/C	cg05756136	chr1:119680316	WARS2	-0.41	-7.88	-0.3	1.41e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21659725	chr3:3221576	CRBN	0.49	11.06	0.4	3.9e-26	Resting heart rate;
BRCA	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.24	-0.31	9.74e-16	Axial length;
BRCA	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg21724239	chr8:58056113	NA	-0.58	-9.19	-0.34	5.66e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs57590327	0.508	rs7621968	chr3:81951460	A/G	cg07356753	chr3:81810745	GBE1	-0.4	-9.47	-0.35	5.32e-20	Extraversion;
BRCA	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg06766960	chr11:133703094	NA	-0.64	-13.21	-0.46	2.05e-35	Childhood ear infection;
BRCA	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.16	-48.97	-0.89	1.81e-218	Myeloid white cell count;
BRCA	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg15556689	chr8:8085844	FLJ10661	0.37	9.09	0.34	1.19e-18	Retinal vascular caliber;
BRCA	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.53	0.35	3.28e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs250677	0.522	rs12520924	chr5:148349149	C/T	cg12140854	chr5:148520817	ABLIM3	0.41	8.23	0.31	1.04e-15	Breast cancer;
BRCA	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg09307838	chr4:120376055	NA	0.73	15.87	0.53	4.5e-48	Corneal astigmatism;
BRCA	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg04166393	chr7:2884313	GNA12	0.4	8.57	0.32	7.91e-17	Height;
BRCA	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg17410650	chr12:54324560	NA	-0.43	-10.73	-0.39	8.16e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
BRCA	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26314531	chr2:26401878	FAM59B	-0.66	-10.72	-0.39	8.78e-25	Gut microbiome composition (summer);
BRCA	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg26384229	chr12:38710491	ALG10B	0.85	23.28	0.68	2.68e-87	Heart rate;
BRCA	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg25036284	chr2:26402008	FAM59B	0.94	15.84	0.53	6.66e-48	Gut microbiome composition (summer);
BRCA	cis	rs737008	0.500	rs7189239	chr16:11402515	T/C	cg00044050	chr16:11439710	C16orf75	0.48	11.63	0.42	1.65e-28	Obesity-related traits;
BRCA	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg21475434	chr5:93447410	FAM172A	0.67	9.17	0.34	6.36e-19	Diabetic retinopathy;
BRCA	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg04414720	chr1:150670196	GOLPH3L	0.35	7.87	0.3	1.55e-14	Tonsillectomy;
BRCA	cis	rs2386661	0.547	rs4747358	chr10:5650193	A/G	cg17085576	chr10:5658249	NA	0.36	8.81	0.33	1.19e-17	Breast cancer;
BRCA	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.22e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg00071950	chr4:10020882	SLC2A9	0.55	13.5	0.47	1.03e-36	Bone mineral density;
BRCA	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg20503657	chr10:835505	NA	0.95	14.77	0.5	1.14e-42	Eosinophil percentage of granulocytes;
BRCA	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.53	-10.12	-0.37	1.92e-22	Body mass index;
BRCA	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-12.65	-0.45	6.99e-33	Total cholesterol levels;
BRCA	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg01689657	chr7:91764605	CYP51A1	0.22	8.17	0.31	1.69e-15	Breast cancer;
BRCA	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.91	-0.4	1.53e-25	Personality dimensions;
BRCA	cis	rs9682041	0.877	rs10804841	chr3:170072031	T/A	cg11886554	chr3:170076028	SKIL	0.53	10.76	0.39	6.06e-25	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg16586182	chr3:47516702	SCAP	0.52	11.45	0.41	9.32e-28	Colorectal cancer;
BRCA	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11764359	chr7:65958608	NA	-0.75	-16.63	-0.55	7.22e-52	Aortic root size;
BRCA	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26306683	chr17:18585705	ZNF286B	0.38	9.51	0.35	3.7799999999999997e-20	Educational attainment (years of education);
BRCA	cis	rs7737355	0.947	rs9327620	chr5:130996451	A/G	cg06307176	chr5:131281290	NA	0.53	10.31	0.38	3.63e-23	Life satisfaction;
BRCA	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg13010199	chr12:38710504	ALG10B	0.51	10.15	0.37	1.53e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-9.41	-0.35	8.95e-20	Schizophrenia;
BRCA	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-8.4	-0.32	2.9e-16	Monocyte percentage of white cells;
BRCA	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	18.2	0.58	6.2e-60	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg05340658	chr4:99064831	C4orf37	0.49	10.75	0.39	6.73e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg20607798	chr8:58055168	NA	0.48	8.43	0.32	2.29e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs698833	0.886	rs17580226	chr2:44570776	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	10.6	0.39	2.61e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg08470875	chr2:26401718	FAM59B	0.71	11.64	0.42	1.57e-28	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	10.13	0.37	1.88e-22	Aortic root size;
BRCA	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg17330251	chr7:94953956	PON1	-0.41	-8.58	-0.32	7.06e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs701145	0.938	rs355773	chr3:154036657	A/G	cg17054900	chr3:154042577	DHX36	-0.66	-11.62	-0.42	1.88e-28	Coronary artery disease;
BRCA	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg11584989	chr19:19387371	SF4	0.6	12.46	0.44	4.54e-32	Bipolar disorder;
BRCA	cis	rs7131987	0.650	rs10843382	chr12:29451721	G/A	cg09582351	chr12:29534625	ERGIC2	-0.47	-10.87	-0.39	2.36e-25	QT interval;
BRCA	trans	rs3960554	0.808	rs78340819	chr7:75673833	C/G	cg19862616	chr7:65841803	NCRNA00174	0.59	12.53	0.44	2.26e-32	Eotaxin levels;
BRCA	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg05340658	chr4:99064831	C4orf37	0.62	14.66	0.5	3.8e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs250677	0.522	rs2895837	chr5:148357535	C/T	cg12140854	chr5:148520817	ABLIM3	0.41	8.34	0.31	4.52e-16	Breast cancer;
BRCA	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg26384229	chr12:38710491	ALG10B	0.74	17.23	0.56	6.19e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.08	0.4	3.21e-26	Bipolar disorder;
BRCA	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08859206	chr1:53392774	SCP2	0.66	13.73	0.48	9.31e-38	Monocyte count;
BRCA	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11644478	chr21:40555479	PSMG1	-0.69	-14.91	-0.51	2.28e-43	Cognitive function;
BRCA	cis	rs897080	0.515	rs1067362	chr2:44660112	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	8.08	0.3	3.33e-15	Height;
BRCA	cis	rs13082711	0.520	rs2724494	chr3:27563920	C/A	cg02860705	chr3:27208620	NA	0.43	8.55	0.32	8.9e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg00852783	chr1:26633632	UBXN11	0.56	13.61	0.47	3.2e-37	Obesity-related traits;
BRCA	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg05283184	chr6:79620031	NA	-0.43	-11.02	-0.4	5.89e-26	Intelligence (multi-trait analysis);
BRCA	trans	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg26043149	chr18:55253948	FECH	0.38	8.35	0.31	4.17e-16	Bone mineral density;
BRCA	trans	rs6479891	1.000	rs9415680	chr10:65020890	A/G	cg14819942	chr15:35414228	NA	-0.34	-8.53	-0.32	1.03e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs2797160	1.000	rs2797154	chr6:126005197	A/G	cg05901451	chr6:126070800	HEY2	-0.39	-9.49	-0.35	4.46e-20	Endometrial cancer;
BRCA	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03264133	chr6:25882463	NA	-0.41	-9.53	-0.35	3.13e-20	Height;
BRCA	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.78	-0.36	3.67e-21	Depressive symptoms (multi-trait analysis);
BRCA	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg13010199	chr12:38710504	ALG10B	0.48	9.23	0.34	3.94e-19	Morning vs. evening chronotype;
BRCA	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg12935359	chr14:103987150	CKB	0.61	14.06	0.49	2.59e-39	Intelligence (multi-trait analysis);
BRCA	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.96	0.37	8.25e-22	Bipolar disorder;
BRCA	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg08885076	chr2:99613938	TSGA10	-0.52	-11.86	-0.42	1.85e-29	Chronic sinus infection;
BRCA	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg18446336	chr7:2847575	GNA12	-0.34	-7.94	-0.3	8.8e-15	Height;
BRCA	trans	rs3857536	0.813	rs7766786	chr6:66932889	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.11	-0.31	2.53e-15	Blood trace element (Cu levels);
BRCA	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg18230493	chr5:56204884	C5orf35	-0.74	-14.96	-0.51	1.3e-43	Initial pursuit acceleration;
BRCA	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06108461	chr20:60628389	TAF4	-1.01	-22.73	-0.67	2.96e-84	Body mass index;
BRCA	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.8	15.64	0.53	6.64e-47	HIV-1 control;
BRCA	cis	rs12474201	0.822	rs897530	chr2:46948150	C/G	cg06386533	chr2:46925753	SOCS5	0.83	17.95	0.58	1.25e-58	Height;
BRCA	cis	rs17092148	0.945	rs6060034	chr20:33351864	T/C	cg16810054	chr20:33298113	TP53INP2	-0.5	-11.26	-0.41	5.82e-27	Neuroticism;
BRCA	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg11632617	chr15:75315747	PPCDC	0.4	8.7	0.33	2.83e-17	Blood trace element (Zn levels);
BRCA	cis	rs858239	0.796	rs433395	chr7:23401955	G/T	cg23682824	chr7:23144976	KLHL7	0.34	8.58	0.32	7.35e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.19	0.68	8.5e-87	Chronic sinus infection;
BRCA	cis	rs9649465	0.967	rs598115	chr7:123402603	C/G	cg04330084	chr7:123175371	IQUB	0.32	8.72	0.33	2.31e-17	Migraine;
BRCA	cis	rs10504073	0.669	rs4493917	chr8:50015846	C/T	cg00325661	chr8:49890786	NA	0.44	12.52	0.44	2.54e-32	Blood metabolite ratios;
BRCA	trans	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-14.17	-0.49	7.78e-40	Brugada syndrome;
BRCA	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg09184832	chr6:79620586	NA	0.49	10.68	0.39	1.25e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg25767906	chr1:53392781	SCP2	-0.45	-10.06	-0.37	3.34e-22	Monocyte count;
BRCA	cis	rs9796	0.621	rs1659227	chr15:41472398	G/A	cg18705301	chr15:41695430	NDUFAF1	0.37	7.99	0.3	6.42e-15	Menopause (age at onset);
BRCA	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.52	8.33	0.31	4.95e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.35	0.35	1.43e-19	Morning vs. evening chronotype;
BRCA	cis	rs4631830	0.863	rs3101227	chr10:51520203	C/A	cg20129853	chr10:51489980	NA	-0.3	-8.12	-0.31	2.42e-15	Prostate-specific antigen levels;
BRCA	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.43	10.12	0.37	1.95e-22	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2425143	1.000	rs733609	chr20:34393074	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.99	-0.34	2.73e-18	Blood protein levels;
BRCA	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg23711669	chr6:146136114	FBXO30	-0.62	-14.03	-0.49	3.52e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg13010199	chr12:38710504	ALG10B	0.51	10.01	0.37	5e-22	Morning vs. evening chronotype;
BRCA	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg03433033	chr1:76189801	ACADM	0.75	16.46	0.55	5.41e-51	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg24011408	chr12:48396354	COL2A1	-0.43	-9.41	-0.35	8.59e-20	Plateletcrit;
BRCA	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg02734326	chr4:10020555	SLC2A9	0.4	8.84	0.33	9.02e-18	Bone mineral density;
BRCA	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg01689657	chr7:91764605	CYP51A1	0.22	8.05	0.3	3.98e-15	Breast cancer;
BRCA	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg24848339	chr3:12840334	CAND2	0.43	11.14	0.4	1.78e-26	P wave duration;
BRCA	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg15704280	chr7:45808275	SEPT13	-0.72	-14.33	-0.49	1.39e-40	Coronary artery disease;
BRCA	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11764359	chr7:65958608	NA	-0.77	-17.65	-0.57	4.23e-57	Aortic root size;
BRCA	cis	rs1904096	0.506	rs10034781	chr4:95169682	A/C	cg11021082	chr4:95130006	SMARCAD1	0.39	8.19	0.31	1.4e-15	Type 2 diabetes;
BRCA	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg22535103	chr8:58192502	C8orf71	-0.58	-13.12	-0.46	5.72e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg00701064	chr4:6280414	WFS1	0.68	17.68	0.57	3.11e-57	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-11.94	-0.43	7.99e-30	Gut microbiome composition (summer);
BRCA	cis	rs10504073	0.527	rs118032023	chr8:49926296	A/T	cg00325661	chr8:49890786	NA	0.47	13.78	0.48	4.99e-38	Blood metabolite ratios;
BRCA	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg08000102	chr2:233561755	GIGYF2	0.63	14.03	0.49	3.74e-39	Coronary artery disease;
BRCA	cis	rs4285028	0.747	rs9838301	chr3:121375144	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-13.77	-0.48	5.65e-38	Multiple sclerosis;
BRCA	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg05519781	chr21:40033154	ERG	0.43	9.25	0.34	3.37e-19	Coronary artery disease;
BRCA	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.77	-0.42	4.23e-29	Glomerular filtration rate (creatinine);
BRCA	trans	rs8073060	0.586	rs11080356	chr17:33895309	T/C	cg19694781	chr19:47549865	TMEM160	1.01	21.86	0.65	1.58e-79	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.61	0.32	5.85e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.71	9.92	0.37	1.19e-21	Initial pursuit acceleration;
BRCA	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23583168	chr7:148888333	NA	-0.97	-25.73	-0.71	9.71e-101	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg17063962	chr7:91808500	NA	-0.55	-12.54	-0.44	2.13e-32	Breast cancer;
BRCA	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg11584989	chr19:19387371	SF4	0.64	13.48	0.47	1.25e-36	Bipolar disorder;
BRCA	cis	rs921968	0.565	rs2272188	chr2:219612282	C/T	cg02176678	chr2:219576539	TTLL4	0.41	11.17	0.4	1.36e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7520050	0.966	rs12410071	chr1:46358886	T/C	cg24296786	chr1:45957014	TESK2	0.43	9.66	0.36	1.06e-20	Red blood cell count;Reticulocyte count;
BRCA	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg10578991	chr7:12443926	VWDE	-0.54	-7.96	-0.3	7.88e-15	Coronary artery disease;
BRCA	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg25809561	chr17:30822961	MYO1D	0.4	9.52	0.35	3.36e-20	Schizophrenia;
BRCA	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg18478394	chr8:109455254	TTC35	0.27	7.84	0.3	1.86e-14	Dupuytren's disease;
BRCA	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21659725	chr3:3221576	CRBN	-0.48	-10.21	-0.37	9.33e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	12.97	0.46	2.51e-34	Bipolar disorder;
BRCA	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg26384229	chr12:38710491	ALG10B	0.78	18.13	0.58	1.41e-59	Bladder cancer;
BRCA	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.39	0.57	9.59e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.56	-12.7	-0.45	4.13e-33	Ileal carcinoids;
BRCA	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.56	-12.62	-0.45	9.61e-33	Longevity;Endometriosis;
BRCA	cis	rs4919694	1.000	rs77827514	chr10:104822009	C/T	cg04362960	chr10:104952993	NT5C2	0.95	14.72	0.5	1.85e-42	Arsenic metabolism;
BRCA	cis	rs10484885	0.824	rs72919981	chr6:90528977	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.77	-9.79	-0.36	3.51e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14442939	chr10:27389572	ANKRD26	-0.68	-10.76	-0.39	6.52e-25	Breast cancer;
BRCA	cis	rs2629540	0.731	rs11245341	chr10:126408777	G/C	cg08799069	chr10:126477246	METTL10	0.47	9.51	0.35	3.93e-20	Cocaine dependence;
BRCA	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg02980000	chr4:1222292	CTBP1	-0.44	-8.72	-0.33	2.47e-17	Obesity-related traits;
BRCA	cis	rs78707713	0.560	rs35060419	chr10:71229539	A/G	cg12610070	chr10:71211762	TSPAN15	-0.32	-9.95	-0.37	8.77e-22	Venous thromboembolism;
BRCA	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg04691961	chr3:161091175	C3orf57	-0.58	-15.15	-0.51	1.58e-44	Morning vs. evening chronotype;
BRCA	trans	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.0	0.3	5.82e-15	Mean corpuscular volume;
BRCA	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg13319975	chr6:146136371	FBXO30	0.39	9.12	0.34	9.44e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8038465	0.615	rs62004618	chr15:73962164	A/G	cg15420318	chr15:73925796	NPTN	0.42	9.33	0.35	1.67e-19	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg26838691	chr2:24397539	C2orf84	-0.46	-8.58	-0.32	7.39e-17	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg24130564	chr14:104152367	KLC1	-0.39	-8.84	-0.33	8.97e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-10.45	-0.38	1.01e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.75	-12.86	-0.45	8.08e-34	Gut microbiome composition (summer);
BRCA	cis	rs9487051	0.735	rs351745	chr6:109529169	C/T	cg01475377	chr6:109611718	NA	0.47	11.86	0.42	1.84e-29	Reticulocyte fraction of red cells;
BRCA	cis	rs1506636	0.962	rs7811830	chr7:123320183	G/C	cg03229431	chr7:123269106	ASB15	-0.62	-14.07	-0.49	2.4e-39	Plateletcrit;Platelet count;
BRCA	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg24692254	chr21:30365293	RNF160	-0.6	-15.71	-0.53	2.77e-47	Dental caries;
BRCA	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg08885076	chr2:99613938	TSGA10	0.45	10.48	0.38	7.93e-24	Chronic sinus infection;
BRCA	trans	rs78049276	0.736	rs6842241	chr4:148400819	C/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.42	-8.06	-0.3	3.88e-15	Pulse pressure;
BRCA	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	8.91	0.33	5.22e-18	Iron status biomarkers;
BRCA	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg23649088	chr2:200775458	C2orf69	-0.55	-9.85	-0.36	2.09e-21	LDL cholesterol to HDL cholesterol ratio;
BRCA	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg17135325	chr3:160939158	NMD3	0.44	8.47	0.32	1.74e-16	Parkinson's disease;
BRCA	cis	rs8010715	0.848	rs8009511	chr14:24593980	G/A	cg23112188	chr14:24563095	PCK2	-0.33	-8.28	-0.31	7.35e-16	IgG glycosylation;
BRCA	cis	rs6005807	0.719	rs12169071	chr22:29033210	C/G	cg12565055	chr22:29076175	TTC28	0.49	9.36	0.35	1.35e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs9880211	0.800	rs9873536	chr3:136474267	A/G	cg21827317	chr3:136751795	NA	-0.45	-7.81	-0.3	2.28e-14	Body mass index;Height;
BRCA	cis	rs17253792	0.822	rs79022053	chr14:56071721	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.6	8.13	0.31	2.23e-15	Putamen volume;
BRCA	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg06191203	chr2:152266755	RIF1	-0.27	-8.11	-0.31	2.62e-15	Lung cancer;
BRCA	cis	rs9986765	1.000	rs28672333	chr7:142826798	G/A	cg21852589	chr7:142981689	TMEM139	0.56	9.68	0.36	9.12e-21	Cancer;Dermatomyositis;
BRCA	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg13010199	chr12:38710504	ALG10B	-0.42	-9.89	-0.36	1.52e-21	Heart rate;
BRCA	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg22974920	chr21:40686053	BRWD1	0.37	8.43	0.32	2.26e-16	Cognitive function;
BRCA	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg25036284	chr2:26402008	FAM59B	-0.64	-10.97	-0.4	8.71e-26	Gut microbiome composition (summer);
BRCA	cis	rs11779988	0.545	rs436506	chr8:17798243	A/G	cg01800426	chr8:17659068	MTUS1	0.42	8.26	0.31	8.27e-16	Breast cancer;
BRCA	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg07148914	chr20:33460835	GGT7	0.48	10.33	0.38	3e-23	Height;
BRCA	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg03161606	chr19:29218774	NA	0.44	7.89	0.3	1.33e-14	Methadone dose in opioid dependence;
BRCA	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg03709012	chr19:19516395	GATAD2A	0.74	16.3	0.54	3.28e-50	Tonsillectomy;
BRCA	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg21770322	chr7:97807741	LMTK2	0.42	11.27	0.41	5.33e-27	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg15556689	chr8:8085844	FLJ10661	-0.36	-9.33	-0.35	1.7e-19	Triglycerides;
BRCA	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg06002616	chr8:101225028	SPAG1	0.35	8.69	0.33	3.04e-17	Atrioventricular conduction;
BRCA	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg05457628	chr5:178986728	RUFY1	-0.39	-9.07	-0.34	1.44e-18	Lung cancer;
BRCA	cis	rs3815700	0.920	rs10424732	chr19:33096487	C/T	cg02997394	chr19:33096574	ANKRD27	0.68	11.25	0.41	6.55e-27	Eosinophilic esophagitis;
BRCA	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg03709012	chr19:19516395	GATAD2A	1.0	18.84	0.6	2.65e-63	Nonalcoholic fatty liver disease;
BRCA	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg05347473	chr6:146136440	FBXO30	0.4	7.94	0.3	9.04e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6714710	0.603	rs2044458	chr2:98377512	A/T	cg26665480	chr2:98280029	ACTR1B	0.56	13.05	0.46	1.11e-34	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs1568889	1.000	rs1464897	chr11:28034844	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	14.58	0.5	8.73e-42	Bipolar disorder;
BRCA	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg19284575	chr1:160991224	F11R	-0.45	-8.14	-0.31	2.14e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7572263	0.724	rs12986551	chr2:209052303	T/C	cg23998903	chr2:209048830	C2orf80	-0.42	-8.68	-0.32	3.16e-17	Glioma;Non-glioblastoma glioma;
BRCA	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg00484396	chr16:3507460	NAT15	0.42	8.52	0.32	1.12e-16	Tuberculosis;
BRCA	cis	rs754466	0.606	rs10824581	chr10:79599501	A/G	cg17075019	chr10:79541650	NA	-0.82	-19.6	-0.61	2.45e-67	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg02659138	chr7:134003124	SLC35B4	-0.32	-10.2	-0.37	9.66e-23	Mean platelet volume;
BRCA	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg08885076	chr2:99613938	TSGA10	0.46	10.9	0.4	1.66e-25	Chronic sinus infection;
BRCA	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18876405	chr7:65276391	NA	0.62	15.18	0.51	1.09e-44	Aortic root size;
BRCA	cis	rs9487051	0.768	rs12176068	chr6:109521629	C/T	cg21918786	chr6:109611834	NA	-0.35	-9.24	-0.34	3.73e-19	Reticulocyte fraction of red cells;
BRCA	trans	rs208520	0.955	rs208532	chr6:66961280	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-14.55	-0.5	1.17e-41	Exhaled nitric oxide output;
BRCA	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg22105103	chr4:187893119	NA	0.38	11.76	0.42	5.02e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg11632617	chr15:75315747	PPCDC	-0.38	-8.39	-0.32	3.01e-16	Blood trace element (Zn levels);
BRCA	cis	rs6973256	0.865	rs1133540	chr7:133346380	C/T	cg07491979	chr7:133331646	EXOC4	-0.39	-8.94	-0.33	4.2e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs13095912	0.752	rs9758141	chr3:185315085	A/T	cg11274856	chr3:185301563	NA	0.55	13.27	0.46	1.08e-35	Systolic blood pressure;
BRCA	cis	rs7246657	0.722	rs12979640	chr19:38179156	T/C	cg18154014	chr19:37997991	ZNF793	-0.46	-8.79	-0.33	1.34e-17	Coronary artery calcification;
BRCA	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	9.9	0.36	1.3e-21	Triglycerides;
BRCA	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg17691542	chr6:26056736	HIST1H1C	0.64	11.21	0.41	9.32e-27	Iron status biomarkers;
BRCA	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg11814155	chr7:99998594	ZCWPW1	0.43	8.07	0.3	3.38e-15	Platelet count;
BRCA	cis	rs6594713	0.717	rs17331844	chr5:112914426	G/T	cg12552261	chr5:112820674	MCC	0.48	8.22	0.31	1.18e-15	Brain cytoarchitecture;
BRCA	cis	rs4631830	0.600	rs11004324	chr10:51496623	G/T	cg20129853	chr10:51489980	NA	-0.31	-7.84	-0.3	1.87e-14	Prostate-specific antigen levels;
BRCA	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25427524	chr10:38739819	LOC399744	-0.7	-16.88	-0.56	4.06e-53	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg26513180	chr16:89883248	FANCA	-0.57	-13.03	-0.46	1.45e-34	Vitiligo;
BRCA	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg06808227	chr14:105710500	BRF1	-0.8	-15.93	-0.53	2.39e-48	Mean platelet volume;Platelet distribution width;
BRCA	trans	rs12310956	0.510	rs2054867	chr12:33835462	C/G	cg26384229	chr12:38710491	ALG10B	-0.41	-9.59	-0.35	2e-20	Morning vs. evening chronotype;
BRCA	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.62	-12.11	-0.43	1.52e-30	Body mass index (adult);
BRCA	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg09307838	chr4:120376055	NA	0.64	13.8	0.48	4.09e-38	Corneal astigmatism;
BRCA	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg23625390	chr15:77176239	SCAPER	0.54	13.77	0.48	5.76e-38	Blood metabolite levels;
BRCA	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.84	0.39	3.02e-25	Bipolar disorder;
BRCA	cis	rs1030877	0.889	rs2576746	chr2:105909559	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.71	17.42	0.57	6.66e-56	Obesity-related traits;
BRCA	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg23711669	chr6:146136114	FBXO30	-0.71	-16.79	-0.55	1.13e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg18357645	chr12:58087776	OS9	0.44	12.49	0.44	3.5e-32	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs7586879	0.828	rs4077677	chr2:25122798	G/C	cg04586622	chr2:25135609	ADCY3	0.4	9.55	0.35	2.77e-20	Body mass index;
BRCA	cis	rs1127311	0.905	rs6702449	chr1:154583210	A/C	cg17218026	chr1:154582156	ADAR	0.28	8.68	0.32	3.27e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
BRCA	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg22920501	chr2:26401640	FAM59B	-0.65	-11.32	-0.41	3.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs4285028	0.948	rs71329246	chr3:121680170	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.58	-10.71	-0.39	1.03e-24	Multiple sclerosis;
BRCA	cis	rs11955398	0.585	rs4524466	chr5:60020078	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.37	-8.94	-0.33	4.21e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7072216	0.763	rs6584204	chr10:100173580	C/G	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.63	-0.36	1.35e-20	Metabolite levels;
BRCA	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.77	12.51	0.44	2.7e-32	Platelet count;
BRCA	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg09754948	chr16:28834200	ATXN2L	0.47	8.6	0.32	6.33e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg07817883	chr1:32538562	TMEM39B	0.5	8.96	0.33	3.63e-18	Monocyte percentage of white cells;
BRCA	trans	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg21659725	chr3:3221576	CRBN	-0.48	-8.87	-0.33	7.34e-18	Menarche (age at onset);
BRCA	cis	rs858239	0.600	rs7789237	chr7:23124713	T/G	cg23682824	chr7:23144976	KLHL7	0.45	11.83	0.42	2.53e-29	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg22535103	chr8:58192502	C8orf71	-0.47	-8.34	-0.31	4.47e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg20607798	chr8:58055168	NA	-0.54	-8.3	-0.31	6.13e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg25173405	chr17:45401733	C17orf57	0.49	10.18	0.37	1.21e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs72960926	0.744	rs72964214	chr6:74864851	T/C	cg03266952	chr6:74778945	NA	-0.67	-8.02	-0.3	5.06e-15	Metabolite levels (MHPG);
BRCA	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.24	-0.38	6.96e-23	Mean corpuscular volume;
BRCA	trans	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	16.05	0.54	5.66e-49	Exhaled nitric oxide levels;
BRCA	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg08601574	chr20:25228251	PYGB	-0.35	-8.56	-0.32	8.27e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg14847009	chr1:175162515	KIAA0040	-0.25	-9.45	-0.35	6.06e-20	Alcohol dependence;
BRCA	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg05985134	chr18:33552581	C18orf21	0.69	13.25	0.46	1.44e-35	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-9.5	-0.35	4.21e-20	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs701145	0.556	rs355787	chr3:153994502	T/C	cg16511985	chr3:153974050	SGEF	0.46	10.62	0.39	2.21e-24	Coronary artery disease;
BRCA	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00908189	chr16:619842	PIGQ	0.7	17.69	0.57	2.7e-57	Height;
BRCA	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg11822812	chr5:140052017	DND1	0.29	7.99	0.3	6.23e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg14784868	chr12:69753453	YEATS4	0.68	19.91	0.62	5.54e-69	Blood protein levels;
BRCA	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg08067268	chr2:26466485	HADHB;HADHA	0.59	10.15	0.37	1.51e-22	Gut microbiome composition (summer);
BRCA	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg08470875	chr2:26401718	FAM59B	-0.5	-8.17	-0.31	1.65e-15	Gut microbiome composition (summer);
BRCA	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg06115741	chr20:33292138	TP53INP2	0.51	11.32	0.41	3.29e-27	Coronary artery disease;
BRCA	cis	rs12579753	0.917	rs12366599	chr12:82212112	C/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.99	-0.3	6.3e-15	Resting heart rate;
BRCA	cis	rs6973256	0.897	rs1041621	chr7:133353965	A/G	cg07491979	chr7:133331646	EXOC4	0.4	9.11	0.34	1.06e-18	Intelligence (multi-trait analysis);
BRCA	trans	rs7939886	0.920	rs1552151	chr11:55780951	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-8.08	-0.3	3.18e-15	Myopia (pathological);
BRCA	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02176678	chr2:219576539	TTLL4	0.42	10.98	0.4	8.25e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs897080	0.515	rs1067366	chr2:44655094	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	9.16	0.34	7.05e-19	Height;
BRCA	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.49	-10.6	-0.39	2.75e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg12165864	chr7:66369176	NA	-0.45	-10.29	-0.38	4.56e-23	Corneal structure;
BRCA	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg04455712	chr21:45112962	RRP1B	0.41	11.18	0.4	1.28e-26	Mean corpuscular volume;
BRCA	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg24209194	chr3:40518798	ZNF619	0.38	7.85	0.3	1.74e-14	Renal cell carcinoma;
BRCA	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg13385521	chr17:29058706	SUZ12P	0.6	8.4	0.32	2.98e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg05985134	chr18:33552581	C18orf21	0.64	11.51	0.41	5.2e-28	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs6433895	0.667	rs35702511	chr2:182018106	G/A	cg00481216	chr2:181971175	NA	0.43	8.06	0.3	3.8e-15	Lymphocyte counts;
BRCA	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg08508325	chr11:3079039	CARS	-0.44	-15.71	-0.53	2.97e-47	Longevity;
BRCA	cis	rs2742234	0.578	rs2742241	chr10:43625223	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.51	-10.46	-0.38	9.22e-24	Hirschsprung disease;
BRCA	cis	rs921968	0.565	rs62191658	chr2:219630294	A/G	cg02176678	chr2:219576539	TTLL4	-0.41	-11.0	-0.4	6.78e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7586879	0.828	rs9631061	chr2:25109804	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.55	0.35	2.71e-20	Body mass index;
BRCA	cis	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg06521331	chr12:34319734	NA	-0.52	-10.17	-0.37	1.26e-22	Morning vs. evening chronotype;
BRCA	trans	rs2797160	0.967	rs1954360	chr6:126001064	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.35	-7.83	-0.3	2.07e-14	Endometrial cancer;
BRCA	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg16230307	chr14:35515116	FAM177A1	0.73	14.7	0.5	2.46e-42	Psoriasis;
BRCA	cis	rs3820928	1.000	rs2163041	chr2:227772480	T/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.41	-0.32	2.72e-16	Pulmonary function;
BRCA	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.69	0.55	3.67e-52	Hypertriglyceridemia;
BRCA	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg18016565	chr1:150552671	MCL1	0.34	7.9	0.3	1.23e-14	Melanoma;
BRCA	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg11645453	chr3:52864694	ITIH4	0.34	8.79	0.33	1.39e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08045932	chr20:61659980	NA	0.48	11.27	0.41	5.19e-27	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10802521	chr3:52805072	NEK4	-0.31	-8.44	-0.32	2.08e-16	Electroencephalogram traits;
BRCA	cis	rs495337	0.720	rs6067274	chr20:48544386	G/A	cg17835207	chr20:48524531	SPATA2	-0.69	-16.8	-0.55	1.04e-52	Psoriasis;
BRCA	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	12.86	0.45	8.33e-34	Bone mineral density;
BRCA	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24549020	chr5:56110836	MAP3K1	-0.58	-10.61	-0.39	2.48e-24	Initial pursuit acceleration;
BRCA	trans	rs1459104	1.000	rs34391788	chr11:55271721	C/A	cg15704280	chr7:45808275	SEPT13	0.65	8.14	0.31	2.12e-15	Body mass index;
BRCA	cis	rs4671400	0.571	rs62152270	chr2:61494260	C/A	cg15711740	chr2:61764176	XPO1	0.4	7.94	0.3	8.94e-15	3-hydroxypropylmercapturic acid levels in smokers;
BRCA	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg16586182	chr3:47516702	SCAP	0.51	11.18	0.4	1.21e-26	Colorectal cancer;
BRCA	cis	rs9811920	0.625	rs7631174	chr3:99913902	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.38	8.62	0.32	5.11e-17	Axial length;
BRCA	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg08085267	chr17:45401833	C17orf57	0.58	12.1	0.43	1.68e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg01448562	chr3:133502909	NA	-0.64	-15.27	-0.52	4.38e-45	Iron status biomarkers;
BRCA	cis	rs3820928	0.874	rs4461255	chr2:227846524	C/T	cg11843606	chr2:227700838	RHBDD1	0.38	8.51	0.32	1.27e-16	Pulmonary function;
BRCA	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14240646	chr10:27532245	ACBD5	0.64	9.5	0.35	4.29e-20	Breast cancer;
BRCA	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg13073564	chr4:8508604	NA	0.31	7.81	0.3	2.33e-14	Response to antineoplastic agents;
BRCA	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.6	-14.38	-0.49	7.77e-41	Hemoglobin concentration;
BRCA	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg24112000	chr20:60950667	NA	-0.52	-9.81	-0.36	2.91e-21	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs6138458	1.000	rs227627	chr20:24912107	T/C	cg06937882	chr20:24974362	C20orf3	-0.44	-8.39	-0.31	3.15e-16	Blood protein levels;
BRCA	cis	rs4363385	0.747	rs1577965	chr1:152968294	T/C	cg24667326	chr1:152973720	SPRR3	-0.35	-9.66	-0.36	1.03e-20	Inflammatory skin disease;
BRCA	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.9	0.33	5.7e-18	Tonsillectomy;
BRCA	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg13010199	chr12:38710504	ALG10B	0.5	10.3	0.38	4.14e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg26408565	chr15:76604113	ETFA	-0.39	-8.41	-0.32	2.66e-16	Blood metabolite levels;
BRCA	cis	rs7737355	1.000	rs12719444	chr5:130607378	C/T	cg06307176	chr5:131281290	NA	0.46	8.81	0.33	1.19e-17	Life satisfaction;
BRCA	cis	rs3784262	0.669	rs12915989	chr15:58315736	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-10.12	-0.37	2.03e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs16958440	0.737	rs16958699	chr18:44654846	T/C	cg17192377	chr18:44677553	HDHD2	0.68	10.01	0.37	5.3e-22	Sitting height ratio;
BRCA	cis	rs8054556	0.633	rs12928610	chr16:30016022	C/T	cg06326092	chr16:30034487	C16orf92	0.36	9.19	0.34	5.38e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg18904891	chr8:8559673	CLDN23	0.65	13.06	0.46	1.02e-34	Obesity-related traits;
BRCA	cis	rs7560272	0.512	rs12998980	chr2:73930726	A/C	cg20560298	chr2:73613845	ALMS1	0.35	9.05	0.34	1.75e-18	Schizophrenia;
BRCA	cis	rs1595825	0.891	rs78835808	chr2:198669110	G/A	cg19156104	chr2:198669113	PLCL1	-0.48	-8.58	-0.32	7.39e-17	Ulcerative colitis;
BRCA	trans	rs75804782	0.521	rs56340711	chr2:239440080	A/T	cg01134436	chr17:81009848	B3GNTL1	0.69	8.99	0.34	2.69e-18	Morning vs. evening chronotype;Chronotype;
BRCA	trans	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg26043149	chr18:55253948	FECH	-0.4	-9.01	-0.34	2.28e-18	Bone mineral density;
BRCA	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.13	0.37	1.82e-22	Aortic root size;
BRCA	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11644478	chr21:40555479	PSMG1	-0.52	-10.97	-0.4	9.31e-26	Menarche (age at onset);
BRCA	cis	rs13064411	0.696	rs36054418	chr3:113204762	G/T	cg18753928	chr3:113234510	CCDC52	-0.59	-12.52	-0.44	2.53e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.88	-19.17	-0.6	4.81e-65	Cognitive ability;
BRCA	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11644478	chr21:40555479	PSMG1	0.87	20.89	0.64	2.94e-74	Cognitive function;
BRCA	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg26384229	chr12:38710491	ALG10B	0.66	15.19	0.52	1.03e-44	Bladder cancer;
BRCA	trans	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg26043149	chr18:55253948	FECH	0.4	8.86	0.33	7.83e-18	Bone mineral density;
BRCA	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg17691542	chr6:26056736	HIST1H1C	0.48	9.55	0.35	2.75e-20	Iron status biomarkers;
BRCA	cis	rs672059	1.000	rs547905	chr1:183157924	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.38	8.64	0.32	4.62e-17	Hypertriglyceridemia;
BRCA	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg03146154	chr1:46216737	IPP	-0.45	-9.49	-0.35	4.35e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24531977	chr5:56204891	C5orf35	-0.86	-18.03	-0.58	4.63e-59	Initial pursuit acceleration;
BRCA	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg01097406	chr16:89675127	NA	0.52	9.31	0.35	1.97e-19	Vitiligo;
BRCA	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg24069376	chr3:38537580	EXOG	0.41	11.94	0.43	8.01e-30	Electrocardiographic conduction measures;
BRCA	cis	rs6867032	0.527	rs13162781	chr5:2012235	C/T	cg26168224	chr5:2018326	NA	0.44	11.91	0.43	1.13e-29	Gut microbiome composition (winter);
BRCA	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03713592	chr11:72463424	ARAP1	1.14	16.86	0.55	5.06e-53	Type 2 diabetes;
BRCA	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg06784218	chr1:46089804	CCDC17	0.49	11.82	0.42	2.75e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg11845111	chr2:191398756	TMEM194B	-0.71	-13.61	-0.47	3.01e-37	Diastolic blood pressure;
BRCA	cis	rs1557765	0.527	rs10832782	chr11:17397273	G/C	cg15432903	chr11:17409602	KCNJ11	0.41	8.78	0.33	1.46e-17	Body mass index;Social communication problems;
BRCA	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.97	0.3	7.09e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.62	0.36	1.54e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7246657	0.722	rs10402671	chr19:38117086	C/T	cg23950597	chr19:37808831	NA	-0.49	-8.51	-0.32	1.28e-16	Coronary artery calcification;
BRCA	cis	rs35740288	0.929	rs1978391	chr15:86311695	A/G	cg20737812	chr15:86336631	KLHL25	0.34	8.5	0.32	1.31e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg18196295	chr10:418757	DIP2C	0.49	10.45	0.38	1.08e-23	Psychosis in Alzheimer's disease;
BRCA	cis	rs12618769	0.652	rs3769708	chr2:99187650	T/C	cg10123293	chr2:99228465	UNC50	0.43	8.55	0.32	9.39e-17	Bipolar disorder;
BRCA	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.32	0.57	2.24e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11644478	chr21:40555479	PSMG1	0.85	19.82	0.62	1.71e-68	Cognitive function;
BRCA	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg08917208	chr2:24149416	ATAD2B	0.52	8.21	0.31	1.21e-15	Lymphocyte counts;
BRCA	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg13010199	chr12:38710504	ALG10B	0.54	11.98	0.43	5.39e-30	Heart rate;
BRCA	cis	rs332507	0.830	rs35816663	chr3:124405513	G/T	cg05980111	chr3:124395277	KALRN	0.37	8.65	0.32	4.31e-17	Plateletcrit;
BRCA	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg17971929	chr21:40555470	PSMG1	-0.48	-10.5	-0.38	6.57e-24	Menarche (age at onset);
BRCA	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg17143192	chr8:8559678	CLDN23	0.56	10.93	0.4	1.29e-25	Obesity-related traits;
BRCA	trans	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.37	-9.05	-0.34	1.73e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs13064411	0.696	rs6808394	chr3:113122524	T/G	cg18753928	chr3:113234510	CCDC52	-0.51	-9.53	-0.35	3.14e-20	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg23229984	chr5:148520753	ABLIM3	0.32	7.89	0.3	1.29e-14	Breast cancer;
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18402987	chr7:1209562	NA	0.51	9.81	0.36	3.02e-21	Longevity;Endometriosis;
BRCA	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg23625390	chr15:77176239	SCAPER	0.39	9.25	0.34	3.3e-19	Blood metabolite levels;
BRCA	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.5	-0.32	1.38e-16	Monocyte percentage of white cells;
BRCA	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg13256891	chr4:100009986	ADH5	0.5	10.33	0.38	3.21e-23	Alcohol dependence;
BRCA	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg11657440	chr19:46296263	DMWD	-0.57	-13.82	-0.48	3.25e-38	Coronary artery disease;
BRCA	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-8.33	-0.31	5.02e-16	Monocyte percentage of white cells;
BRCA	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg14829155	chr15:31115871	NA	0.41	9.99	0.37	6.26e-22	Huntington's disease progression;
BRCA	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg26168224	chr5:2018326	NA	0.65	18.95	0.6	7.32e-64	Gut microbiome composition (winter);
BRCA	trans	rs11088226	0.681	rs1015047	chr21:33949423	A/G	cg09050820	chr6:167586206	TCP10L2	0.86	15.87	0.53	4.7e-48	Gastritis;
BRCA	trans	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg26043149	chr18:55253948	FECH	0.41	8.83	0.33	9.63e-18	Bone mineral density;
BRCA	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg24060327	chr5:131705240	SLC22A5	-0.6	-11.43	-0.41	1.16e-27	Breast cancer;
BRCA	cis	rs7903847	0.642	rs11189175	chr10:99139609	T/C	cg08345082	chr10:99160200	RRP12	-0.29	-8.62	-0.32	5.4e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-10.78	-0.39	5.36e-25	Response to bleomycin (chromatid breaks);
BRCA	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg03146154	chr1:46216737	IPP	-0.45	-9.89	-0.36	1.53e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg27624424	chr6:160112604	SOD2	0.39	8.26	0.31	8.65e-16	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg05340658	chr4:99064831	C4orf37	0.49	10.73	0.39	8.4e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.32	-8.56	-0.32	8.25e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10493773	0.962	rs6698578	chr1:86236676	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.47	-9.72	-0.36	6.14e-21	Urate levels in overweight individuals;
BRCA	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg16576597	chr16:28551801	NUPR1	0.3	8.19	0.31	1.38e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.41	-0.35	8.45e-20	Bladder cancer;
BRCA	trans	rs61931739	0.635	rs6488185	chr12:33933127	G/C	cg26384229	chr12:38710491	ALG10B	0.4	8.97	0.33	3.18e-18	Morning vs. evening chronotype;
BRCA	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.43	-8.35	-0.31	4.34e-16	Iron status biomarkers;
BRCA	trans	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	14.54	0.5	1.32e-41	Exhaled nitric oxide levels;
BRCA	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg17971929	chr21:40555470	PSMG1	0.79	18.51	0.59	1.46e-61	Cognitive function;
BRCA	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18357526	chr6:26021779	HIST1H4A	0.5	9.29	0.35	2.35e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg21138405	chr5:131827807	IRF1	0.39	12.9	0.45	5.51e-34	Asthma (sex interaction);
BRCA	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	11.33	0.41	2.92e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-8.63	-0.32	4.87e-17	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	15.81	0.53	9.4e-48	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg22800045	chr5:56110881	MAP3K1	0.66	12.38	0.44	1.06e-31	Initial pursuit acceleration;
BRCA	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg13010199	chr12:38710504	ALG10B	0.54	11.47	0.41	8.32e-28	Heart rate;
BRCA	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg15556689	chr8:8085844	FLJ10661	-0.31	-8.24	-0.31	9.63e-16	Joint mobility (Beighton score);
BRCA	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	8.12	0.31	2.43e-15	Personality dimensions;
BRCA	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	18.21	0.58	5.13e-60	Platelet count;
BRCA	cis	rs9341808	0.718	rs3812121	chr6:80968727	A/G	cg08355045	chr6:80787529	NA	0.38	9.64	0.36	1.24e-20	Sitting height ratio;
BRCA	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg17425144	chr1:10567563	PEX14	0.55	13.84	0.48	2.83e-38	Prostate cancer;
BRCA	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg07080220	chr10:102295463	HIF1AN	0.63	14.95	0.51	1.42e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg20503657	chr10:835505	NA	1.04	18.24	0.59	3.93e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg05863683	chr7:1912471	MAD1L1	0.44	9.45	0.35	6.29e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs12530845	0.887	rs59400686	chr7:135360029	A/G	cg23117316	chr7:135346802	PL-5283	-0.42	-9.58	-0.35	2.03e-20	Red blood cell traits;
BRCA	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg01689657	chr7:91764605	CYP51A1	0.22	8.11	0.31	2.58e-15	Breast cancer;
BRCA	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg23711669	chr6:146136114	FBXO30	0.74	17.76	0.57	1.14e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-11.4	-0.41	1.61e-27	Morning vs. evening chronotype;
BRCA	cis	rs11112613	0.713	rs68053161	chr12:105950035	G/C	cg03607813	chr12:105948248	NA	0.6	11.21	0.41	9.41e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs12760731	0.720	rs12022646	chr1:178355821	A/G	cg00404053	chr1:178313656	RASAL2	0.62	8.06	0.3	3.74e-15	Obesity-related traits;
BRCA	cis	rs2637266	0.935	rs2583057	chr10:78396019	C/T	cg18941641	chr10:78392320	NA	0.36	8.31	0.31	5.79e-16	Pulmonary function;
BRCA	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg21132104	chr15:45694354	SPATA5L1	0.75	16.9	0.56	2.9e-53	Homoarginine levels;
BRCA	trans	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg06521331	chr12:34319734	NA	0.45	8.91	0.33	5.31e-18	Morning vs. evening chronotype;
BRCA	cis	rs4285028	0.747	rs1574133	chr3:121468794	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-13.85	-0.48	2.56e-38	Multiple sclerosis;
BRCA	cis	rs365132	1.000	rs2292255	chr5:176334195	C/T	cg16309518	chr5:176445507	NA	-0.51	-13.26	-0.46	1.3e-35	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs3771570	0.901	rs869943	chr2:242431585	C/G	cg21155796	chr2:242212141	HDLBP	0.63	9.7	0.36	7.62e-21	Prostate cancer;
BRCA	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg22800045	chr5:56110881	MAP3K1	0.66	12.28	0.44	2.9e-31	Initial pursuit acceleration;
BRCA	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.74	0.67	2.6e-84	Chronic sinus infection;
BRCA	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.41	8.62	0.32	5.45e-17	Total cholesterol levels;
BRCA	cis	rs9309473	0.607	rs7604588	chr2:73571417	C/T	cg20560298	chr2:73613845	ALMS1	-0.42	-11.27	-0.41	5.44e-27	Metabolite levels;
BRCA	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.58	0.55	1.25e-51	Hypertriglyceridemia;
BRCA	cis	rs10949834	0.504	rs77541100	chr7:73555605	C/T	cg07137043	chr7:73588983	EIF4H	-0.62	-9.42	-0.35	7.84e-20	Verbal memory performance (residualized delayed recall change);
BRCA	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg18200150	chr17:30822561	MYO1D	0.36	9.08	0.34	1.37e-18	Schizophrenia;
BRCA	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg02073558	chr3:44770973	ZNF501	0.38	8.0	0.3	5.75e-15	Depressive symptoms;
BRCA	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.39	-9.63	-0.36	1.35e-20	Bipolar disorder;
BRCA	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg02297831	chr4:17616191	MED28	-0.35	-8.02	-0.3	5.22e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.39	0.31	3.21e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.52	-0.52	2.52e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg22875332	chr1:76189707	ACADM	-0.51	-9.8	-0.36	3.14e-21	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg00814883	chr7:100076585	TSC22D4	-0.51	-11.66	-0.42	1.24e-28	Platelet count;
BRCA	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg24690094	chr11:67383802	NA	-0.54	-11.46	-0.41	8.69e-28	Mean corpuscular volume;
BRCA	cis	rs3125734	0.633	rs10761616	chr10:64009076	G/A	cg19640130	chr10:64028056	RTKN2	-0.34	-9.7	-0.36	7.4e-21	Rheumatoid arthritis;
BRCA	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11764359	chr7:65958608	NA	0.61	13.42	0.47	2.37e-36	Aortic root size;
BRCA	cis	rs10267417	0.603	rs10263094	chr7:19872801	C/T	cg07541023	chr7:19748670	TWISTNB	0.49	8.72	0.33	2.42e-17	Night sleep phenotypes;
BRCA	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg23285459	chr7:2802560	GNA12	-0.36	-9.08	-0.34	1.29e-18	Height;
BRCA	cis	rs2625529	0.824	rs2415130	chr15:72242554	G/A	cg16672083	chr15:72433130	SENP8	-0.77	-16.36	-0.54	1.71e-50	Red blood cell count;
BRCA	cis	rs1190552	0.846	rs3742437	chr14:102965047	G/A	cg18135206	chr14:102964638	TECPR2	0.46	9.02	0.34	2.1e-18	Blood protein levels;
BRCA	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg27029518	chr18:72166324	CNDP2	-0.31	-8.85	-0.33	8.44e-18	Refractive error;
BRCA	cis	rs2712184	0.935	rs2541387	chr2:217666174	A/C	cg05032264	chr2:217675019	NA	-0.43	-10.63	-0.39	2.04e-24	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs2046867	0.818	rs17010195	chr3:72872852	A/G	cg25664220	chr3:72788482	NA	0.43	9.79	0.36	3.37e-21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	17.02	0.56	7.12e-54	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	15.63	0.53	7.54e-47	Smoking behavior;
BRCA	cis	rs10056811	0.527	rs55798253	chr5:74380957	A/G	cg19683494	chr5:74908142	NA	0.56	8.33	0.31	4.84e-16	Coronary artery disease;
BRCA	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21659725	chr3:3221576	CRBN	-0.71	-21.67	-0.65	1.76e-78	Intelligence (multi-trait analysis);
BRCA	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg25206134	chr2:45395956	NA	-0.48	-8.23	-0.31	1.08e-15	Bipolar disorder;
BRCA	cis	rs897984	0.762	rs1870293	chr16:30970941	T/C	cg02466173	chr16:30829666	NA	0.47	10.47	0.38	9.03e-24	Dementia with Lewy bodies;
BRCA	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11890956	chr21:40555474	PSMG1	1.06	31.69	0.78	3.73e-133	Cognitive function;
BRCA	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg15934090	chr1:100435551	SLC35A3	0.36	8.43	0.32	2.38e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.11	0.37	2.24e-22	Aortic root size;
BRCA	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	14.53	0.5	1.53e-41	Motion sickness;
BRCA	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg27433088	chr4:174089019	GALNT7	0.34	9.06	0.34	1.6e-18	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg03929089	chr4:120376271	NA	0.55	9.26	0.34	2.97e-19	Axial length;
BRCA	cis	rs9612	0.718	rs346535	chr19:44251425	C/T	cg08581076	chr19:44259116	C19orf61	0.43	7.85	0.3	1.72e-14	Exhaled nitric oxide output;
BRCA	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg14675211	chr2:100938903	LONRF2	0.49	11.2	0.4	1.07e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-13.27	-0.46	1.12e-35	Response to antipsychotic treatment;
BRCA	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg04362960	chr10:104952993	NT5C2	0.39	9.31	0.35	2.03e-19	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg23033748	chr14:75592666	NEK9	-0.37	-8.82	-0.33	1.11e-17	Height;
BRCA	cis	rs11958404	0.932	rs72816543	chr5:157416464	A/G	cg05962755	chr5:157440814	NA	0.54	9.96	0.37	8.27e-22	IgG glycosylation;
BRCA	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.06	-0.3	3.74e-15	Prostate cancer;
BRCA	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	13.99	0.48	5.5e-39	Motion sickness;
BRCA	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	18.8	0.6	4.37e-63	Smoking behavior;
BRCA	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg12863693	chr15:85201151	NMB	0.45	8.19	0.31	1.44e-15	Schizophrenia;
BRCA	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg11502198	chr6:26597334	ABT1	0.48	9.53	0.35	3.21e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	16.52	0.55	2.63e-51	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg04586622	chr2:25135609	ADCY3	0.46	11.66	0.42	1.28e-28	Body mass index;
BRCA	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg21770322	chr7:97807741	LMTK2	0.41	11.03	0.4	5.14e-26	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg12311346	chr5:56204834	C5orf35	-0.77	-14.92	-0.51	2.1e-43	Type 2 diabetes;
BRCA	cis	rs7809950	0.678	rs2107317	chr7:106899685	T/C	cg23024343	chr7:107201750	COG5	-0.44	-8.69	-0.33	2.96e-17	Coronary artery disease;
BRCA	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg06618935	chr21:46677482	NA	-0.37	-7.99	-0.3	6.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg20503657	chr10:835505	NA	0.99	17.46	0.57	4.23e-56	Eosinophil percentage of granulocytes;
BRCA	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-14.03	-0.49	3.69e-39	Migraine;Coronary artery disease;
BRCA	trans	rs7980799	0.649	rs1994135	chr12:33682405	T/C	cg26384229	chr12:38710491	ALG10B	0.39	8.74	0.33	2.02e-17	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg04025307	chr7:1156635	C7orf50	0.59	9.37	0.35	1.26e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.42	-9.36	-0.35	1.39e-19	Coronary artery disease;
BRCA	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg13852791	chr20:30311386	BCL2L1	0.96	23.2	0.68	7.58e-87	Mean corpuscular hemoglobin;
BRCA	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	21.16	0.64	9.69e-76	Lymphocyte percentage of white cells;
BRCA	cis	rs6878727	0.665	rs2633536	chr5:123667422	A/T	cg01806427	chr5:123737813	NA	-0.37	-8.27	-0.31	7.92e-16	Breast cancer;
BRCA	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.52	-0.32	1.11e-16	Monocyte percentage of white cells;
BRCA	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11644478	chr21:40555479	PSMG1	-0.49	-10.49	-0.38	7.48e-24	Menarche (age at onset);
BRCA	cis	rs4664304	0.620	rs2136977	chr2:160722850	C/T	cg14819504	chr2:160761413	LY75	0.34	8.51	0.32	1.22e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg24803719	chr17:45855879	NA	-0.31	-8.32	-0.31	5.38e-16	IgG glycosylation;
BRCA	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg09754948	chr16:28834200	ATXN2L	0.45	8.9	0.33	5.77e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg03146154	chr1:46216737	IPP	-0.44	-9.78	-0.36	3.68e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.35	-7.87	-0.3	1.57e-14	Bipolar disorder;
BRCA	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.72	0.36	6.4e-21	Bipolar disorder;
BRCA	cis	rs10992471	0.528	rs7031567	chr9:95241363	A/G	cg14631576	chr9:95140430	CENPP	-0.34	-8.51	-0.32	1.27e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs7147624	1.000	rs7147624	chr14:65865625	G/T	cg03016385	chr14:66212404	NA	0.52	8.02	0.3	5.04e-15	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg00149659	chr3:10157352	C3orf10	0.69	12.27	0.44	3.05e-31	Alzheimer's disease;
BRCA	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-11.04	-0.4	4.72e-26	Mean corpuscular volume;
BRCA	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg17420585	chr12:42539391	GXYLT1	-0.48	-10.31	-0.38	3.67e-23	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg17971929	chr21:40555470	PSMG1	0.78	18.39	0.59	6.48e-61	Cognitive function;
BRCA	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg25427524	chr10:38739819	LOC399744	-0.54	-9.97	-0.37	7.53e-22	Obesity (extreme);
BRCA	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg24642439	chr20:33292090	TP53INP2	-0.55	-11.84	-0.42	2.31e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg00277334	chr10:82204260	NA	-0.85	-25.02	-0.7	7.78e-97	Post bronchodilator FEV1;
BRCA	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg07929629	chr2:241523174	NA	0.49	10.32	0.38	3.36e-23	Bipolar disorder;
BRCA	cis	rs312274	0.550	rs11178856	chr12:41267456	A/G	cg17827154	chr12:41323612	CNTN1	-0.36	-9.01	-0.34	2.39e-18	Metabolite levels  (X-11787);
BRCA	cis	rs34779708	0.931	rs11010082	chr10:35351155	A/G	cg03585969	chr10:35415529	CREM	0.45	9.44	0.35	6.86e-20	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg20701182	chr2:24300061	SF3B14	0.58	9.05	0.34	1.68e-18	Lymphocyte counts;
BRCA	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg05313129	chr8:58192883	C8orf71	-0.45	-9.39	-0.35	1.06e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs1635	0.655	rs1416919	chr6:28302884	T/G	cg15743358	chr6:28303923	ZNF323	-0.75	-8.56	-0.32	8.52e-17	Schizophrenia;
BRCA	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg20607798	chr8:58055168	NA	0.47	8.29	0.31	6.44e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	25.91	0.72	1.01e-101	Chronic sinus infection;
BRCA	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg24130564	chr14:104152367	KLC1	0.35	7.96	0.3	8.02e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs11112613	0.713	rs73184082	chr12:105951748	T/C	cg03607813	chr12:105948248	NA	0.55	10.39	0.38	1.81e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg19920283	chr7:105172520	RINT1	0.59	9.39	0.35	1.03e-19	Bipolar disorder (body mass index interaction);
BRCA	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg25237894	chr2:233734115	C2orf82	-0.31	-8.78	-0.33	1.49e-17	Schizophrenia;
BRCA	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg26373071	chr5:1325741	CLPTM1L	0.49	12.16	0.43	9.58e-31	Lung cancer;
BRCA	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.83	-0.58	5.25e-58	Chronic sinus infection;
BRCA	cis	rs701145	0.585	rs365119	chr3:153916502	A/T	cg17054900	chr3:154042577	DHX36	0.57	9.59	0.35	1.96e-20	Coronary artery disease;
BRCA	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.5	-9.71	-0.36	7.18e-21	Body mass index;
BRCA	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg12615879	chr12:58013172	SLC26A10	0.32	9.05	0.34	1.66e-18	Multiple sclerosis;
BRCA	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg04691961	chr3:161091175	C3orf57	-0.58	-15.0	-0.51	8.21e-44	Morning vs. evening chronotype;
BRCA	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg00071950	chr4:10020882	SLC2A9	0.45	10.93	0.4	1.26e-25	Bone mineral density;
BRCA	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg09904177	chr6:26538194	HMGN4	0.47	14.7	0.5	2.27e-42	Intelligence (multi-trait analysis);
BRCA	trans	rs8002861	0.781	rs3816311	chr13:44453783	G/A	cg17145862	chr1:211918768	LPGAT1	0.66	16.49	0.55	3.56e-51	Leprosy;
BRCA	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg05347473	chr6:146136440	FBXO30	0.4	8.03	0.3	4.71e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg24069376	chr3:38537580	EXOG	0.31	8.72	0.33	2.4e-17	Electrocardiographic conduction measures;
BRCA	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	11.18	0.4	1.23e-26	Personality dimensions;
BRCA	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg24006582	chr15:45444508	DUOX1	-0.55	-11.28	-0.41	4.73e-27	Uric acid levels;
BRCA	cis	rs4588572	0.643	rs10068686	chr5:77795220	C/T	cg11547950	chr5:77652471	NA	-0.5	-9.14	-0.34	7.95e-19	Triglycerides;
BRCA	cis	rs977987	0.585	rs62059845	chr16:75430713	A/G	cg03315344	chr16:75512273	CHST6	0.52	12.24	0.44	4.23e-31	Dupuytren's disease;
BRCA	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg05347473	chr6:146136440	FBXO30	0.38	7.83	0.3	1.97e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs8028182	0.636	rs62027181	chr15:75839952	A/G	cg20655648	chr15:75932815	IMP3	0.44	8.65	0.32	4.14e-17	Sudden cardiac arrest;
BRCA	cis	rs897984	0.609	rs55979739	chr16:31049155	A/G	cg02466173	chr16:30829666	NA	-0.44	-9.85	-0.36	2.08e-21	Dementia with Lewy bodies;
BRCA	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg11502198	chr6:26597334	ABT1	0.56	12.01	0.43	4.06e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs10193935	1.000	rs13386385	chr2:42436928	G/T	cg27598129	chr2:42591480	NA	-0.97	-15.28	-0.52	3.74e-45	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg06784218	chr1:46089804	CCDC17	0.51	12.22	0.44	5.44e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3099143	1.000	rs3106378	chr15:77110524	A/C	cg21673338	chr15:77095150	SCAPER	-0.54	-9.33	-0.35	1.67e-19	Recalcitrant atopic dermatitis;
BRCA	trans	rs9409565	0.513	rs16912862	chr9:97050005	A/G	cg05679027	chr9:99775184	HIATL2	-0.36	-8.38	-0.31	3.47e-16	Colorectal cancer (alcohol consumption interaction);
BRCA	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg08917208	chr2:24149416	ATAD2B	0.94	14.13	0.49	1.25e-39	Lymphocyte counts;
BRCA	cis	rs11608355	0.515	rs12822282	chr12:109923207	G/A	cg05360138	chr12:110035743	NA	0.74	13.54	0.47	6.41e-37	Neuroticism;
BRCA	cis	rs17604090	0.793	rs73687726	chr7:29688773	T/C	cg19413766	chr7:29689036	LOC646762	-0.51	-8.2	-0.31	1.33e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg19717773	chr7:2847554	GNA12	-0.5	-11.84	-0.42	2.24e-29	Height;
BRCA	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-8.24	-0.31	9.74e-16	Axial length;
BRCA	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	8.02e-19	Lymphocyte counts;
BRCA	cis	rs17253792	0.822	rs28392709	chr14:56093685	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs7131987	0.903	rs2194518	chr12:29419460	C/T	cg09582351	chr12:29534625	ERGIC2	-0.51	-11.73	-0.42	6.21e-29	QT interval;
BRCA	cis	rs3784262	0.631	rs4646566	chr15:58348173	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.75	-0.36	4.82e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg18016565	chr1:150552671	MCL1	0.36	8.09	0.3	3.07e-15	Melanoma;
BRCA	cis	rs7635838	0.619	rs347616	chr3:11277927	G/A	cg00170343	chr3:11313890	ATG7	0.44	8.42	0.32	2.43e-16	HDL cholesterol;
BRCA	cis	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg09307838	chr4:120376055	NA	0.55	11.39	0.41	1.64e-27	Corneal astigmatism;
BRCA	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg00376283	chr12:123451042	ABCB9	0.51	11.48	0.41	7.05e-28	Neutrophil percentage of white cells;
BRCA	cis	rs977987	0.778	rs8057849	chr16:75443816	T/C	cg03315344	chr16:75512273	CHST6	0.53	12.52	0.44	2.66e-32	Dupuytren's disease;
BRCA	cis	rs67478160	0.506	rs6575998	chr14:104250417	A/G	cg26031613	chr14:104095156	KLC1	-0.5	-10.09	-0.37	2.69e-22	Schizophrenia;
BRCA	trans	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg23762105	chr12:34175262	ALG10	0.35	7.86	0.3	1.69e-14	Morning vs. evening chronotype;
BRCA	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg18806716	chr10:30721971	MAP3K8	0.58	13.42	0.47	2.25e-36	Inflammatory bowel disease;
BRCA	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg21573476	chr21:45109991	RRP1B	-0.41	-11.19	-0.4	1.11e-26	Mean corpuscular volume;
BRCA	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11644478	chr21:40555479	PSMG1	0.67	15.32	0.52	2.27e-45	Cognitive function;
BRCA	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg10932868	chr11:921992	NA	0.48	12.49	0.44	3.31e-32	Alzheimer's disease (late onset);
BRCA	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg18016565	chr1:150552671	MCL1	0.35	8.06	0.3	3.74e-15	Melanoma;
BRCA	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.38	8.69	0.33	2.92e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg26384229	chr12:38710491	ALG10B	-0.4	-9.38	-0.35	1.15e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18131467	chr2:239335373	ASB1	-0.94	-33.3	-0.8	8.82e-142	Multiple system atrophy;
BRCA	trans	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg25214090	chr10:38739885	LOC399744	0.53	12.04	0.43	2.97e-30	Corneal astigmatism;
BRCA	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg24829409	chr8:58192753	C8orf71	-0.42	-8.36	-0.31	3.89e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg05729581	chr11:3078854	CARS	-0.34	-8.06	-0.3	3.78e-15	Longevity;
BRCA	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg03354898	chr7:1950403	MAD1L1	-0.45	-8.62	-0.32	5.1e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.54	11.88	0.43	1.45e-29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs12618769	0.597	rs17446058	chr2:99164160	A/G	cg10123293	chr2:99228465	UNC50	0.41	8.02	0.3	4.94e-15	Bipolar disorder;
BRCA	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.38	8.71	0.33	2.58e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg23711669	chr6:146136114	FBXO30	0.72	14.71	0.5	2.22e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.18	-0.31	1.53e-15	Aortic root size;
BRCA	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg04450456	chr4:17643702	FAM184B	0.42	12.5	0.44	3.05e-32	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs3784262	0.512	rs4646571	chr15:58343137	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.5	-12.36	-0.44	1.22e-31	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs11229555	0.645	rs11229462	chr11:58209931	A/T	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg18230493	chr5:56204884	C5orf35	0.61	12.87	0.45	7.3e-34	Initial pursuit acceleration;
BRCA	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg23711669	chr6:146136114	FBXO30	0.74	17.38	0.57	1.13e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17253792	0.822	rs13379342	chr14:56050452	A/G	cg01858014	chr14:56050164	KTN1	-0.77	-11.27	-0.41	5.52e-27	Putamen volume;
BRCA	cis	rs17253792	0.822	rs17253723	chr14:56154015	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-9.53	-0.35	3.34e-20	Putamen volume;
BRCA	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.44	9.24	0.34	3.51e-19	Monocyte percentage of white cells;
BRCA	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	18.43	0.59	3.97e-61	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7020830	0.898	rs495863	chr9:37346955	T/C	cg14294708	chr9:37120828	ZCCHC7	1.07	32.6	0.79	4.74e-138	Schizophrenia;
BRCA	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg13319975	chr6:146136371	FBXO30	-0.42	-9.68	-0.36	8.78e-21	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13102973	0.864	rs7697346	chr4:135899283	G/A	cg14419869	chr4:135874104	NA	0.47	9.5	0.35	4.18e-20	Subjective well-being;
BRCA	cis	rs7523273	0.606	rs1962149	chr1:207956559	G/A	cg22525895	chr1:207977042	MIR29B2	-0.54	-13.47	-0.47	1.38e-36	Schizophrenia;
BRCA	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg16006841	chr5:176797999	RGS14	0.69	11.18	0.4	1.2e-26	Urate levels in lean individuals;
BRCA	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg11764359	chr7:65958608	NA	-0.63	-14.06	-0.49	2.65e-39	Aortic root size;
BRCA	cis	rs3780378	0.967	rs7852988	chr9:5010751	C/A	cg02405213	chr9:5042618	JAK2	-0.44	-8.94	-0.33	4.08e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg09915433	chr19:53449742	NA	-0.71	-15.73	-0.53	2.29e-47	Psoriasis;
BRCA	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg02503808	chr4:7069936	GRPEL1	0.8	18.41	0.59	4.58e-61	Monocyte percentage of white cells;
BRCA	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg17063962	chr7:91808500	NA	0.52	12.4	0.44	8.5e-32	Breast cancer;
BRCA	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg16482183	chr6:26056742	HIST1H1C	0.76	13.58	0.47	4.48e-37	Iron status biomarkers;
BRCA	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg04362960	chr10:104952993	NT5C2	-0.44	-10.04	-0.37	4.18e-22	Arsenic metabolism;
BRCA	cis	rs7903847	0.642	rs11189191	chr10:99148796	T/C	cg20016023	chr10:99160130	RRP12	-0.26	-7.82	-0.3	2.2e-14	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs36051895	0.658	rs10974910	chr9:5010091	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-9.01	-0.34	2.39e-18	Pediatric autoimmune diseases;
BRCA	cis	rs9837602	1.000	rs793496	chr3:99507254	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-10.9	-0.4	1.8e-25	Breast cancer;
BRCA	cis	rs7561273	0.609	rs2160943	chr2:24288775	G/A	cg04809136	chr2:24300158	SF3B14	-0.4	-9.28	-0.34	2.62e-19	Quantitative traits;
BRCA	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg14993813	chr1:46806288	NSUN4	0.47	9.17	0.34	6.65e-19	Menopause (age at onset);
BRCA	cis	rs4074536	0.536	rs10754348	chr1:116290564	C/G	cg21648376	chr1:116311395	CASQ2	-0.49	-8.71	-0.33	2.5e-17	QRS duration;
BRCA	cis	rs2880765	0.743	rs7168345	chr15:86013601	A/G	cg10818794	chr15:86012489	AKAP13	0.3	8.25	0.31	9.39e-16	Coronary artery disease;
BRCA	trans	rs7246760	0.867	rs16981648	chr19:9804424	A/C	cg02900749	chr2:68251473	NA	-0.48	-7.84	-0.3	1.89e-14	Pursuit maintenance gain;
BRCA	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.96	14.43	0.5	4.63e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7575217	0.654	rs62155196	chr2:101701022	A/G	cg23907051	chr2:101730305	TBC1D8	0.2	7.85	0.3	1.75e-14	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg13736514	chr6:26305472	NA	-0.36	-12.25	-0.44	3.73e-31	Educational attainment;
BRCA	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg03188948	chr7:1209495	NA	0.68	11.16	0.4	1.47e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.5	-12.64	-0.45	7.76e-33	Longevity;Endometriosis;
BRCA	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.48	0.38	7.92e-24	Motion sickness;
BRCA	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg05896524	chr21:47604654	C21orf56	0.5	10.28	0.38	4.83e-23	Testicular germ cell tumor;
BRCA	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg18252515	chr7:66147081	NA	-0.95	-13.46	-0.47	1.56e-36	Diabetic kidney disease;
BRCA	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg05535760	chr7:792225	HEATR2	0.68	11.89	0.43	1.41e-29	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg05340658	chr4:99064831	C4orf37	0.55	10.7	0.39	1.07e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17253792	0.731	rs74829671	chr14:56112759	G/C	cg01858014	chr14:56050164	KTN1	-0.76	-10.55	-0.39	4.43e-24	Putamen volume;
BRCA	cis	rs2742234	0.541	rs4648313	chr10:43716739	G/A	cg15436174	chr10:43711423	RASGEF1A	0.53	10.6	0.39	2.8e-24	Hirschsprung disease;
BRCA	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg16482183	chr6:26056742	HIST1H1C	0.59	10.27	0.38	5.25e-23	Iron status biomarkers;
BRCA	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.25	8.14	0.31	2.08e-15	Cardiac Troponin-T levels;
BRCA	cis	rs2171564	0.791	rs9826586	chr3:112441312	C/T	cg06685282	chr3:112453648	NA	0.34	8.02	0.3	5.07e-15	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs4566357	0.595	rs1320406	chr2:227920474	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-9.64	-0.36	1.31e-20	Coronary artery disease;
BRCA	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.66	-0.61	1.21e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-13.44	-0.47	2e-36	Morning vs. evening chronotype;
BRCA	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg10792982	chr14:105748885	BRF1	0.48	11.12	0.4	2.17e-26	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.8	-0.36	3.32e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.08	0.37	2.81e-22	Bladder cancer;
BRCA	cis	rs13082711	0.911	rs35262121	chr3:27508277	G/A	cg02860705	chr3:27208620	NA	0.53	10.45	0.38	1.06e-23	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg19077165	chr18:44547161	KATNAL2	-0.54	-11.75	-0.42	5.56e-29	Personality dimensions;
BRCA	cis	rs273218	1.000	rs273218	chr5:53380555	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.44	8.9	0.33	5.71e-18	Migraine;
BRCA	trans	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg25214090	chr10:38739885	LOC399744	0.57	13.01	0.46	1.79e-34	Corneal astigmatism;
BRCA	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	7.91	0.3	1.11e-14	Menarche (age at onset);
BRCA	trans	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg01620082	chr3:125678407	NA	-0.57	-8.21	-0.31	1.21e-15	Depression;
BRCA	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg16386425	chr10:429943	DIP2C	-0.41	-8.68	-0.32	3.18e-17	Psychosis in Alzheimer's disease;
BRCA	cis	rs9462027	0.727	rs3798352	chr6:34734809	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.27	-8.06	-0.3	3.7e-15	Systemic lupus erythematosus;
BRCA	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg22189786	chr22:42395067	WBP2NL	0.43	8.67	0.32	3.67e-17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs9902453	0.726	rs3115092	chr17:28036350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	14.62	0.5	5.74e-42	Coffee consumption (cups per day);
BRCA	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg20476274	chr7:133979776	SLC35B4	0.68	20.43	0.63	9.26e-72	Mean platelet volume;
BRCA	cis	rs3762637	0.941	rs9837149	chr3:122230845	G/C	cg24169773	chr3:122142474	KPNA1	-0.43	-8.03	-0.3	4.75e-15	LDL cholesterol levels;
BRCA	cis	rs13064411	0.696	rs35860985	chr3:113209828	C/T	cg18753928	chr3:113234510	CCDC52	-0.59	-12.52	-0.44	2.53e-32	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg20587970	chr11:113659929	NA	-1.24	-22.68	-0.67	5.38e-84	Hip circumference adjusted for BMI;
BRCA	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg23533926	chr12:111358616	MYL2	-0.43	-8.97	-0.33	3.19e-18	Extrinsic epigenetic age acceleration;
BRCA	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg23505145	chr19:12996616	KLF1	0.56	12.69	0.45	4.46e-33	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	21.05	0.64	3.87e-75	Exhaled nitric oxide output;
BRCA	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg22920501	chr2:26401640	FAM59B	-0.91	-16.27	-0.54	4.46e-50	Gut microbiome composition (summer);
BRCA	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg24578937	chr1:2090814	PRKCZ	0.59	18.6	0.59	5.12e-62	Height;
BRCA	cis	rs11674184	0.714	rs9789525	chr2:11724580	G/T	cg07314298	chr2:11723111	GREB1	-0.78	-19.38	-0.61	3.48e-66	Endometriosis;
BRCA	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg04450456	chr4:17643702	FAM184B	-0.29	-8.35	-0.31	4.4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg18305652	chr10:134549665	INPP5A	0.49	11.09	0.4	2.96e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.61	-13.9	-0.48	1.47e-38	Ulcerative colitis;
BRCA	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06022373	chr22:39101656	GTPBP1	0.71	17.29	0.56	3.28e-55	Menopause (age at onset);
BRCA	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	0.4	8.58	0.32	7.2e-17	IgG glycosylation;
BRCA	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg08859206	chr1:53392774	SCP2	-0.49	-10.83	-0.39	3.38e-25	Monocyte count;
BRCA	cis	rs7246657	0.722	rs2287229	chr19:38188652	G/A	cg14683738	chr19:37701593	ZNF585B	-0.47	-8.04	-0.3	4.29e-15	Coronary artery calcification;
BRCA	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg27286337	chr10:134555280	INPP5A	-0.84	-20.56	-0.63	1.82e-72	Migraine;
BRCA	trans	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg25042112	chr7:64838748	ZNF92	-0.45	-8.34	-0.31	4.45e-16	Pain;
BRCA	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg22920501	chr2:26401640	FAM59B	-0.81	-13.18	-0.46	2.83e-35	Gut microbiome composition (summer);
BRCA	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.33	-8.03	-0.3	4.68e-15	Personality dimensions;
BRCA	cis	rs36052053	0.908	rs13203987	chr6:109585240	G/A	cg12927641	chr6:109611667	NA	-0.51	-7.84	-0.3	1.89e-14	Red cell distribution width;
BRCA	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg11822812	chr5:140052017	DND1	-0.29	-7.84	-0.3	1.91e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00149659	chr3:10157352	C3orf10	0.76	13.09	0.46	7.1e-35	Alzheimer's disease;
BRCA	cis	rs9644630	0.841	rs3185	chr8:19328959	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.34	-8.03	-0.3	4.54e-15	Oropharynx cancer;
BRCA	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg25344623	chr2:136566232	LCT	-0.35	-8.77	-0.33	1.55e-17	Mosquito bite size;
BRCA	trans	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg16011800	chr17:1958478	HIC1	-0.54	-8.82	-0.33	1.05e-17	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg22974920	chr21:40686053	BRWD1	-0.35	-8.07	-0.3	3.38e-15	Menarche (age at onset);
BRCA	cis	rs10493773	1.000	rs10493774	chr1:86137963	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.47	-9.78	-0.36	3.85e-21	Urate levels in overweight individuals;
BRCA	cis	rs12618769	0.597	rs72821930	chr2:99127525	C/T	cg10123293	chr2:99228465	UNC50	0.42	8.37	0.31	3.7e-16	Bipolar disorder;
BRCA	cis	rs35740288	0.571	rs11631009	chr15:86318653	G/A	cg20737812	chr15:86336631	KLHL25	-0.39	-8.6	-0.32	6.38e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	trans	rs11227306	0.934	rs2303384	chr11:65640204	C/T	cg17712092	chr4:129076599	LARP1B	-0.38	-8.19	-0.31	1.42e-15	DNA methylation (variation);
BRCA	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg06627628	chr2:24431161	ITSN2	-0.59	-7.81	-0.3	2.31e-14	Lymphocyte counts;
BRCA	trans	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-21.1	-0.64	2.17e-75	Exhaled nitric oxide output;
BRCA	cis	rs17401966	0.838	rs11121551	chr1:10435170	T/C	cg03954927	chr1:10346856	KIF1B	0.44	13.85	0.48	2.48e-38	Hepatocellular carcinoma;
BRCA	trans	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.65	-17.59	-0.57	8.92e-57	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg05340658	chr4:99064831	C4orf37	0.63	15.14	0.51	1.82e-44	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg25482853	chr8:67687455	SGK3	0.79	13.2	0.46	2.48e-35	Obesity-related traits;
BRCA	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg23033748	chr14:75592666	NEK9	-0.43	-10.61	-0.39	2.43e-24	Height;
BRCA	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg03060546	chr3:49711283	APEH	-0.53	-10.58	-0.39	3.33e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg00383909	chr3:49044727	WDR6	0.88	12.66	0.45	5.95e-33	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03264133	chr6:25882463	NA	-0.49	-10.33	-0.38	3.15e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs1506636	0.539	rs17701547	chr7:123383461	A/G	cg03229431	chr7:123269106	ASB15	-0.5	-8.27	-0.31	7.64e-16	Plateletcrit;Platelet count;
BRCA	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg13770153	chr20:60521292	NA	-0.42	-9.41	-0.35	8.91e-20	Body mass index;
BRCA	trans	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	10.22	0.37	8.53e-23	Mean corpuscular volume;
BRCA	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg23625390	chr15:77176239	SCAPER	-0.46	-11.18	-0.4	1.2e-26	Blood metabolite levels;
BRCA	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.52	0.32	1.13e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg18753928	chr3:113234510	CCDC52	-0.58	-12.31	-0.44	2.2e-31	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg10560079	chr2:191398806	TMEM194B	-0.65	-11.98	-0.43	5.89e-30	Diastolic blood pressure;
BRCA	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.36	9.3	0.35	2.16e-19	IgG glycosylation;
BRCA	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg09754948	chr16:28834200	ATXN2L	-0.46	-9.23	-0.34	4.06e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg03060546	chr3:49711283	APEH	0.6	9.96	0.37	8.39e-22	Menarche (age at onset);
BRCA	cis	rs654950	0.934	rs638859	chr1:42001444	A/G	cg06885757	chr1:42089581	HIVEP3	0.27	9.31	0.35	2.06e-19	Airway imaging phenotypes;
BRCA	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg16606324	chr3:10149918	C3orf24	0.53	10.45	0.38	1.04e-23	Alzheimer's disease;
BRCA	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg20283391	chr11:68216788	NA	-0.43	-8.67	-0.32	3.64e-17	Total body bone mineral density;
BRCA	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg07148914	chr20:33460835	GGT7	0.37	8.47	0.32	1.75e-16	Height;
BRCA	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.23	-0.41	7.77e-27	Schizophrenia;
BRCA	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg15704280	chr7:45808275	SEPT13	0.52	9.05	0.34	1.64e-18	Axial length;
BRCA	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23583168	chr7:148888333	NA	-0.82	-18.75	-0.6	7.72e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6750047	0.625	rs336036	chr2:38261143	C/T	cg07380506	chr2:38303506	CYP1B1	-0.4	-9.18	-0.34	5.84e-19	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg05623727	chr3:50126028	RBM5	0.43	8.35	0.31	4.15e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg01939980	chr4:1354348	KIAA1530	0.34	7.86	0.3	1.61e-14	Obesity-related traits;
BRCA	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	12.14	0.43	1.12e-30	Lung cancer in ever smokers;
BRCA	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.27	-0.38	5.49e-23	Psoriasis;
BRCA	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg03342759	chr3:160939853	NMD3	0.64	13.68	0.48	1.51e-37	Morning vs. evening chronotype;
BRCA	cis	rs1883415	0.534	rs2817208	chr6:24481373	T/A	cg20631270	chr6:24437470	GPLD1	0.4	8.23	0.31	1.04e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg14036092	chr11:66035641	RAB1B	0.39	10.23	0.38	7.55e-23	Gout;
BRCA	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-10.38	-0.38	1.97e-23	Personality dimensions;
BRCA	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs2652834	0.950	rs4774474	chr15:63405580	C/G	cg05507819	chr15:63340323	TPM1	0.44	8.46	0.32	1.89e-16	HDL cholesterol;
BRCA	cis	rs4711336	1.000	rs764752	chr6:33658066	G/C	cg14003231	chr6:33640908	ITPR3	0.32	7.86	0.3	1.69e-14	Height;
BRCA	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg04944784	chr2:26401820	FAM59B	-0.86	-13.03	-0.46	1.41e-34	Gut microbiome composition (summer);
BRCA	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.52	8.64	0.32	4.42e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-10.1	-0.37	2.36e-22	Joint mobility (Beighton score);
BRCA	cis	rs17253792	0.545	rs12883972	chr14:56018020	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-7.99	-0.3	6.09e-15	Putamen volume;
BRCA	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs9815354	0.812	rs73079360	chr3:41888372	T/A	cg03022575	chr3:42003672	ULK4	0.68	9.46	0.35	5.93e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg08917208	chr2:24149416	ATAD2B	0.52	8.28	0.31	7.42e-16	Asthma;
BRCA	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg25019033	chr10:957182	NA	-0.41	-7.88	-0.3	1.37e-14	Eosinophil percentage of granulocytes;
BRCA	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-10.83	-0.39	3.3e-25	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg04450456	chr4:17643702	FAM184B	0.33	9.62	0.36	1.44e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg18806716	chr10:30721971	MAP3K8	-0.42	-9.94	-0.37	9.6e-22	Inflammatory bowel disease;
BRCA	cis	rs9463078	0.817	rs3799967	chr6:44798701	A/G	cg25276700	chr6:44698697	NA	-0.36	-8.34	-0.31	4.53e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.75	-0.33	1.96e-17	Resting heart rate;
BRCA	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg04398451	chr17:18023971	MYO15A	-0.84	-20.12	-0.62	4.05e-70	Total body bone mineral density;
BRCA	cis	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg06521331	chr12:34319734	NA	-0.65	-11.93	-0.43	9.53e-30	Morning vs. evening chronotype;
BRCA	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-8.31	-0.31	5.8e-16	Monocyte percentage of white cells;
BRCA	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg14061069	chr19:46274453	DMPK	0.64	18.05	0.58	3.55e-59	Coronary artery disease;
BRCA	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg02659138	chr7:134003124	SLC35B4	0.32	10.02	0.37	4.85e-22	Mean platelet volume;
BRCA	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg06784218	chr1:46089804	CCDC17	-0.44	-10.42	-0.38	1.32e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.42	-9.36	-0.35	1.3e-19	Longevity;Endometriosis;
BRCA	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg24531977	chr5:56204891	C5orf35	-0.41	-8.32	-0.31	5.17e-16	Breast cancer;Breast cancer (early onset);
BRCA	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg26384229	chr12:38710491	ALG10B	0.58	13.18	0.46	3.06e-35	Morning vs. evening chronotype;
BRCA	cis	rs6782228	0.675	rs9841987	chr3:128385142	G/T	cg16766828	chr3:128327626	NA	-0.43	-9.47	-0.35	5.35e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs7520050	0.966	rs12139630	chr1:46350935	A/G	cg24296786	chr1:45957014	TESK2	0.43	9.78	0.36	3.7e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg20476274	chr7:133979776	SLC35B4	0.6	16.64	0.55	6.38e-52	Mean platelet volume;
BRCA	cis	rs3857067	0.804	rs6821438	chr4:95091911	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-9.43	-0.35	7.73e-20	QT interval;
BRCA	cis	rs13064411	0.518	rs7623919	chr3:113219160	A/G	cg18753928	chr3:113234510	CCDC52	-0.41	-9.19	-0.34	5.49e-19	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg15839431	chr19:19639596	YJEFN3	-0.39	-8.51	-0.32	1.22e-16	Bipolar disorder;
BRCA	trans	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg25214090	chr10:38739885	LOC399744	0.51	11.59	0.42	2.45e-28	Corneal astigmatism;
BRCA	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg07080220	chr10:102295463	HIF1AN	0.61	14.51	0.5	1.97e-41	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg22467129	chr15:76604101	ETFA	-0.39	-8.77	-0.33	1.57e-17	Blood metabolite levels;
BRCA	cis	rs2637266	0.967	rs10400134	chr10:78365158	G/C	cg18941641	chr10:78392320	NA	0.34	7.81	0.3	2.33e-14	Pulmonary function;
BRCA	cis	rs7301826	0.627	rs34103763	chr12:131290149	G/A	cg11011512	chr12:131303247	STX2	-0.45	-11.27	-0.41	5.43e-27	Plasma plasminogen activator levels;
BRCA	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg03188948	chr7:1209495	NA	0.49	10.11	0.37	2.16e-22	Longevity;Endometriosis;
BRCA	cis	rs12210905	0.688	rs75968505	chr6:27476996	T/C	cg08851530	chr6:28072375	NA	0.81	8.01	0.3	5.53e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg03462622	chr3:195777018	TFRC	-0.38	-8.63	-0.32	4.83e-17	Mean corpuscular volume;
BRCA	cis	rs2425143	1.000	rs6060639	chr20:34438183	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.54	-0.32	9.92e-17	Blood protein levels;
BRCA	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.45	-9.81	-0.36	2.87e-21	Longevity;Endometriosis;
BRCA	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-8.86	-0.33	7.73e-18	Personality dimensions;
BRCA	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.62	10.14	0.37	1.72e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2625529	0.617	rs2957365	chr15:72348106	C/T	cg16672083	chr15:72433130	SENP8	0.67	16.04	0.54	6.33e-49	Red blood cell count;
BRCA	cis	rs7715811	0.913	rs73749951	chr5:13762514	G/A	cg07548982	chr5:13769939	DNAH5	-0.37	-7.99	-0.3	6.53e-15	Subclinical atherosclerosis traits (other);
BRCA	cis	rs754466	0.580	rs2579177	chr10:79529245	C/T	cg17075019	chr10:79541650	NA	-0.77	-18.39	-0.59	6.09e-61	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs1973993	0.567	rs2800433	chr1:96998126	T/A	cg10631902	chr5:14652156	NA	0.48	14.7	0.5	2.28e-42	Weight;
BRCA	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg20701182	chr2:24300061	SF3B14	0.58	9.04	0.34	1.86e-18	Lymphocyte counts;
BRCA	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg24675658	chr1:53192096	ZYG11B	-0.68	-15.37	-0.52	1.3e-45	Monocyte count;
BRCA	cis	rs7178424	0.846	rs13379492	chr15:62184636	T/A	cg00456672	chr15:62358751	C2CD4A	-0.41	-9.16	-0.34	6.87e-19	Height;
BRCA	cis	rs6088813	0.883	rs2425061	chr20:33915571	A/G	cg14752227	chr20:34000481	UQCC	0.4	8.42	0.32	2.46e-16	Height;
BRCA	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg15556689	chr8:8085844	FLJ10661	-0.34	-8.37	-0.31	3.56e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg22920501	chr2:26401640	FAM59B	-0.63	-10.9	-0.4	1.73e-25	Gut microbiome composition (summer);
BRCA	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg08917208	chr2:24149416	ATAD2B	1.05	14.21	0.49	5.24e-40	Lymphocyte counts;
BRCA	trans	rs10242455	0.702	rs73403290	chr7:99157828	C/T	cg09045935	chr12:6379348	NA	0.84	8.15	0.31	1.99e-15	Blood metabolite levels;
BRCA	cis	rs4887140	0.717	rs9920840	chr15:74054462	A/G	cg11789681	chr15:74046708	NA	0.53	7.95	0.3	8.69e-15	Glucose homeostasis traits;
BRCA	cis	rs754466	0.580	rs11002293	chr10:79537965	C/T	cg17075019	chr10:79541650	NA	-0.83	-20.39	-0.63	1.53e-71	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs12517041	1.000	rs10054160	chr5:23297609	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg13010199	chr12:38710504	ALG10B	0.51	10.44	0.38	1.14e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg10729496	chr3:10149963	C3orf24	0.41	7.88	0.3	1.44e-14	Alzheimer's disease;
BRCA	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	ch.11.42038R	chr11:967971	AP2A2	0.52	16.65	0.55	5.42e-52	Alzheimer's disease (late onset);
BRCA	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.19e-47	Alzheimer's disease (late onset);
BRCA	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg19628046	chr18:33552617	C18orf21	0.54	11.31	0.41	3.83e-27	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs6088813	1.000	rs6141548	chr20:33971085	A/G	cg14752227	chr20:34000481	UQCC	-0.41	-8.65	-0.32	4.09e-17	Height;
BRCA	cis	rs6545883	0.655	rs11893880	chr2:61422019	C/T	cg15711740	chr2:61764176	XPO1	-0.47	-11.73	-0.42	6.56e-29	Tuberculosis;
BRCA	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg20476274	chr7:133979776	SLC35B4	-0.59	-14.81	-0.51	6.92e-43	Mean platelet volume;
BRCA	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg26031613	chr14:104095156	KLC1	0.75	16.54	0.55	2.08e-51	Body mass index;
BRCA	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg00071950	chr4:10020882	SLC2A9	0.43	10.03	0.37	4.31e-22	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg10560079	chr2:191398806	TMEM194B	0.73	13.49	0.47	1.19e-36	Diastolic blood pressure;
BRCA	cis	rs7927771	0.689	rs10734557	chr11:47380061	A/C	cg20307385	chr11:47447363	PSMC3	0.41	8.67	0.32	3.6e-17	Subjective well-being;
BRCA	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.73	-15.66	-0.53	4.96e-47	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs66887589	0.720	rs11724758	chr4:120239878	G/A	cg09307838	chr4:120376055	NA	0.47	10.19	0.37	1.07e-22	Diastolic blood pressure;
BRCA	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.46	10.36	0.38	2.42e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7904368	0.806	rs7899923	chr10:16857394	G/A	cg23933602	chr10:16859644	RSU1	0.55	8.56	0.32	8.37e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg18479299	chr3:125709523	NA	-0.53	-8.14	-0.31	2.03e-15	Blood pressure (smoking interaction);
BRCA	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg26536863	chr7:158807979	LOC154822	0.36	8.17	0.31	1.61e-15	Facial morphology (factor 20);
BRCA	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg10862848	chr6:42927986	GNMT	-0.35	-14.56	-0.5	1.08e-41	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg20469991	chr17:27169893	C17orf63	0.41	8.26	0.31	8.57e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	16.92	0.56	2.51e-53	Intelligence (multi-trait analysis);
BRCA	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.65	13.31	0.47	7.49e-36	Lymphocyte counts;
BRCA	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg17724175	chr1:150552817	MCL1	0.25	8.37	0.31	3.69e-16	Melanoma;
BRCA	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.66	-12.3	-0.44	2.46e-31	Alzheimer's disease;
BRCA	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg06627628	chr2:24431161	ITSN2	0.7	13.66	0.48	1.79e-37	Asthma;
BRCA	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.57	11.67	0.42	1.13e-28	IgG glycosylation;
BRCA	cis	rs4077515	0.874	rs10781505	chr9:139271355	C/T	cg14019695	chr9:139328340	INPP5E	-0.3	-7.83	-0.3	2.04e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg06238570	chr21:40685208	BRWD1	-0.39	-8.03	-0.3	4.66e-15	Menarche (age at onset);
BRCA	cis	rs877282	0.891	rs34652870	chr10:772218	T/C	cg17470449	chr10:769945	NA	0.5	8.9	0.33	5.64e-18	Uric acid levels;
BRCA	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg12219531	chr12:120966889	COQ5	0.55	11.43	0.41	1.17e-27	High light scatter reticulocyte count;
BRCA	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.84	0.36	2.34e-21	Bipolar disorder;
BRCA	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg05527609	chr1:210001259	C1orf107	0.61	13.17	0.46	3.38e-35	Orofacial clefts;
BRCA	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07636037	chr3:49044803	WDR6	-0.74	-16.07	-0.54	4.89e-49	Menarche (age at onset);
BRCA	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-14.11	-0.49	1.44e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs11051970	0.879	rs2728669	chr12:32590651	C/T	cg24626660	chr12:32551988	NA	0.3	8.48	0.32	1.52e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg08755490	chr11:65554678	OVOL1	0.54	11.17	0.4	1.34e-26	Acne (severe);
BRCA	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg00383909	chr3:49044727	WDR6	0.98	15.72	0.53	2.59e-47	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02176678	chr2:219576539	TTLL4	0.46	12.16	0.43	9.47e-31	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg26384229	chr12:38710491	ALG10B	0.44	10.54	0.38	4.74e-24	Morning vs. evening chronotype;
BRCA	cis	rs7586879	0.964	rs11688665	chr2:25121168	G/T	cg01884057	chr2:25150051	NA	0.35	8.72	0.33	2.32e-17	Body mass index;
BRCA	cis	rs9768139	0.658	rs896778	chr7:158113270	A/G	cg24154853	chr7:158122151	PTPRN2	0.34	7.98	0.3	6.65e-15	Calcium levels;
BRCA	cis	rs61935443	0.673	rs11107770	chr12:95275147	C/T	cg21533806	chr12:95267307	NA	-0.47	-9.07	-0.34	1.4e-18	Schizophrenia;
BRCA	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	9.93	0.37	1.04e-21	Aortic root size;
BRCA	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	14.3	0.49	1.97e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7715806	0.500	rs2307112	chr5:75003413	A/C	cg19683494	chr5:74908142	NA	0.5	8.08	0.3	3.23e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg22907277	chr7:1156413	C7orf50	0.38	8.19	0.31	1.48e-15	Longevity;Endometriosis;
BRCA	cis	rs929596	0.639	rs2070959	chr2:234602191	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-9.37	-0.35	1.19e-19	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-8.52	-0.32	1.15e-16	Aortic root size;
BRCA	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23583168	chr7:148888333	NA	-0.82	-18.41	-0.59	4.68e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7809950	1.000	rs2712191	chr7:107182724	C/G	cg23024343	chr7:107201750	COG5	-0.4	-9.18	-0.34	6.12e-19	Coronary artery disease;
BRCA	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs1371614	0.523	rs12468721	chr2:27183751	G/A	cg00617064	chr2:27272375	NA	0.31	8.04	0.3	4.34e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-12.39	-0.44	9.86e-32	Morning vs. evening chronotype;
BRCA	trans	rs11246602	1	rs11246602	chr11:51512090	T/C	cg15704280	chr7:45808275	SEPT13	0.66	8.48	0.32	1.56e-16	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.48	9.14	0.34	8.42e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg02016764	chr4:38805732	TLR1	-0.54	-8.84	-0.33	9.38e-18	Breast cancer;
BRCA	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg11266682	chr4:10021025	SLC2A9	0.43	11.37	0.41	2.02e-27	Bone mineral density;
BRCA	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06108461	chr20:60628389	TAF4	-0.92	-19.95	-0.62	3.37e-69	Body mass index;
BRCA	cis	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-9.08	-0.34	1.37e-18	IgG glycosylation;
BRCA	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg02734326	chr4:10020555	SLC2A9	0.38	8.13	0.31	2.21e-15	Bone mineral density;
BRCA	cis	rs9462846	0.919	rs9462851	chr6:42890602	A/G	cg05552183	chr6:42928497	GNMT	0.44	8.17	0.31	1.6e-15	Blood protein levels;
BRCA	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-9.26	-0.34	3.1400000000000002e-19	Bone mineral density;
BRCA	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg22029157	chr1:209979665	IRF6	0.41	8.01	0.3	5.25e-15	Cleft lip with or without cleft palate;
BRCA	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05890377	chr2:74357713	NA	0.49	12.12	0.43	1.46e-30	Gestational age at birth (maternal effect);
BRCA	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg06115741	chr20:33292138	TP53INP2	-0.4	-8.59	-0.32	6.71e-17	Coronary artery disease;
BRCA	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	18.33	0.59	1.25e-60	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs7408868	0.563	rs11085949	chr19:15296917	G/T	cg14696996	chr19:15285081	NOTCH3	0.81	12.23	0.44	4.8e-31	Pulse pressure;
BRCA	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg13047869	chr3:10149882	C3orf24	0.59	12.55	0.44	1.94e-32	Alzheimer's disease;
BRCA	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg17145862	chr1:211918768	LPGAT1	0.63	14.71	0.5	2.04e-42	Leprosy;
BRCA	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	18.25	0.59	3.31e-60	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs6543140	0.964	rs2080288	chr2:103022166	G/A	cg04239558	chr2:103089729	SLC9A4	0.33	9.29	0.35	2.31e-19	Blood protein levels;
BRCA	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg09307838	chr4:120376055	NA	0.64	13.92	0.48	1.13e-38	Corneal astigmatism;
BRCA	cis	rs13053817	1.000	rs13055707	chr22:29851172	G/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.47	-9.04	-0.34	1.81e-18	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg21535247	chr6:8435926	SLC35B3	0.4	9.09	0.34	1.28e-18	Motion sickness;
BRCA	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg17802220	chr15:77601643	NA	0.46	10.29	0.38	4.38e-23	Type 2 diabetes;
BRCA	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg01256987	chr12:42539512	GXYLT1	-0.47	-9.33	-0.35	1.67e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs7395581	0.959	rs901746	chr11:47260319	A/G	cg25783544	chr11:47291846	MADD	0.37	8.17	0.31	1.68e-15	HDL cholesterol;
BRCA	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.85	-0.36	2.08e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg06935464	chr4:38784597	TLR10	0.51	8.2	0.31	1.32e-15	Breast cancer;
BRCA	cis	rs2066819	1.000	rs118130855	chr12:56677979	T/A	cg26734620	chr12:56694298	CS	0.88	10.19	0.37	1.08e-22	Psoriasis vulgaris;
BRCA	cis	rs11955398	0.625	rs10805370	chr5:59984244	A/T	cg02684056	chr5:59996105	DEPDC1B	0.39	9.02	0.34	2.25e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	ch.11.42038R	chr11:967971	AP2A2	0.52	16.68	0.55	4.14e-52	Alzheimer's disease (late onset);
BRCA	cis	rs77633900	0.614	rs2170998	chr15:77007159	C/T	cg21673338	chr15:77095150	SCAPER	0.51	9.83	0.36	2.45e-21	Non-glioblastoma glioma;Glioma;
BRCA	cis	rs7975161	0.579	rs7962423	chr12:104710910	G/A	cg25273343	chr12:104657179	TXNRD1	-0.56	-8.98	-0.33	2.92e-18	Toenail selenium levels;
BRCA	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg27129171	chr3:47204927	SETD2	0.68	16.54	0.55	2.06e-51	Colorectal cancer;
BRCA	cis	rs7766436	0.583	rs62389420	chr6:22557720	G/A	cg13666174	chr6:22585274	NA	-0.39	-7.91	-0.3	1.13e-14	Coronary artery disease;
BRCA	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-45.93	-0.88	1.27e-204	Myeloid white cell count;
BRCA	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-13.22	-0.46	1.86e-35	Gut microbiome composition (summer);
BRCA	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg11764359	chr7:65958608	NA	0.67	15.04	0.51	5.51e-44	Aortic root size;
BRCA	cis	rs7520050	0.966	rs785489	chr1:46576390	A/G	cg24296786	chr1:45957014	TESK2	0.41	9.12	0.34	9.96e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs6433857	0.536	rs1901750	chr2:181350739	C/T	cg23363182	chr2:181467187	NA	-0.37	-7.88	-0.3	1.42e-14	Body mass index;
BRCA	cis	rs329648	0.667	rs11223616	chr11:133772838	C/T	cg18057887	chr11:133800913	IGSF9B	0.4	8.2	0.31	1.37e-15	Parkinson's disease;
BRCA	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg11814155	chr7:99998594	ZCWPW1	0.47	8.5	0.32	1.34e-16	Platelet count;
BRCA	cis	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg21775007	chr8:11205619	TDH	-0.45	-8.81	-0.33	1.14e-17	Neuroticism;
BRCA	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg20887711	chr4:1340912	KIAA1530	-0.6	-12.9	-0.45	5.24e-34	Obesity-related traits;
BRCA	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg23505145	chr19:12996616	KLF1	0.57	12.57	0.45	1.49e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg22105103	chr4:187893119	NA	0.38	11.89	0.43	1.3e-29	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-15.58	-0.52	1.22e-46	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	12.08	0.43	2.01e-30	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.62	13.9	0.48	1.45e-38	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs1891275	0.515	rs1418161	chr10:93484655	C/G	cg07889827	chr10:93443413	NA	-0.4	-10.92	-0.4	1.39e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg01262667	chr19:19385393	TM6SF2	-0.42	-10.94	-0.4	1.16e-25	Tonsillectomy;
BRCA	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg25173405	chr17:45401733	C17orf57	0.49	9.94	0.37	9.55e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg13902645	chr11:5959945	NA	-0.55	-11.19	-0.4	1.17e-26	DNA methylation (variation);
BRCA	cis	rs6687430	0.543	rs7512495	chr1:10631237	C/T	cg17425144	chr1:10567563	PEX14	0.55	12.29	0.44	2.51e-31	Hand grip strength;
BRCA	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg00383909	chr3:49044727	WDR6	0.98	15.74	0.53	2.1e-47	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs9443189	0.527	rs775059	chr6:76370130	G/T	cg01950844	chr6:76311363	SENP6	0.83	13.39	0.47	3.38e-36	Prostate cancer;
BRCA	cis	rs1163251	0.837	rs592762	chr1:120247355	A/G	cg19096424	chr1:120255104	PHGDH	0.45	10.44	0.38	1.2e-23	Blood metabolite levels;
BRCA	trans	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg02030672	chr11:45687055	CHST1	0.39	8.3	0.31	6.43e-16	Obesity-related traits;
BRCA	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg13902645	chr11:5959945	NA	-0.54	-10.91	-0.4	1.58e-25	DNA methylation (variation);
BRCA	cis	rs10924970	0.967	rs10754589	chr1:235439755	T/C	cg26050004	chr1:235667680	B3GALNT2	0.35	8.69	0.33	3.01e-17	Asthma;
BRCA	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg12219531	chr12:120966889	COQ5	0.55	11.61	0.42	2.02e-28	High light scatter reticulocyte count;
BRCA	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.71	11.94	0.43	8.59e-30	Schizophrenia;
BRCA	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg18811423	chr2:55921094	PNPT1	0.78	26.76	0.73	2.14e-106	Metabolic syndrome;
BRCA	trans	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg25214090	chr10:38739885	LOC399744	0.56	12.39	0.44	9.8e-32	Corneal astigmatism;
BRCA	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs11608355	0.545	rs7315846	chr12:109908617	T/C	cg05360138	chr12:110035743	NA	0.71	13.05	0.46	1.11e-34	Neuroticism;
BRCA	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg06784218	chr1:46089804	CCDC17	0.45	10.91	0.4	1.58e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4268898	0.932	rs7577964	chr2:24598279	A/G	cg06627628	chr2:24431161	ITSN2	0.45	9.39	0.35	1.08e-19	Asthma;
BRCA	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg20891558	chr2:74357851	NA	0.56	11.91	0.43	1.12e-29	Gestational age at birth (maternal effect);
BRCA	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg08997352	chr12:9597637	DDX12	-0.57	-11.35	-0.41	2.6e-27	Breast size;
BRCA	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg21475434	chr5:93447410	FAM172A	0.68	8.66	0.32	3.96e-17	Diabetic retinopathy;
BRCA	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg22705602	chr4:152727874	NA	0.38	10.4	0.38	1.66e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs672059	0.967	rs657901	chr1:183163411	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.37	0.31	3.6e-16	Hypertriglyceridemia;
BRCA	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-9.45	-0.35	6.41e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg20503657	chr10:835505	NA	0.92	15.43	0.52	6.6e-46	Eosinophil percentage of granulocytes;
BRCA	cis	rs2882667	0.931	rs13153618	chr5:138352776	C/A	cg04439458	chr5:138467593	SIL1	-0.34	-9.37	-0.35	1.27e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs2197308	0.813	rs11504316	chr12:38219320	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.67	-0.36	1.02e-20	Morning vs. evening chronotype;
BRCA	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg09537434	chr19:41945824	ATP5SL	0.63	13.25	0.46	1.38e-35	Migraine;Coronary artery disease;
BRCA	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.65	-9.9	-0.36	1.3e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg00409905	chr10:38381863	ZNF37A	-0.49	-10.48	-0.38	8.07e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg20487152	chr13:99095054	FARP1	0.33	8.78	0.33	1.51e-17	Neuroticism;
BRCA	cis	rs698833	0.798	rs1067391	chr2:44639434	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	10.15	0.37	1.51e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg05340658	chr4:99064831	C4orf37	0.56	11.1	0.4	2.59e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.44	-0.41	1.11e-27	Personality dimensions;
BRCA	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg21573476	chr21:45109991	RRP1B	-0.35	-9.52	-0.35	3.6e-20	Mean corpuscular volume;
BRCA	cis	rs939658	0.805	rs59104559	chr15:79438784	A/G	cg17916960	chr15:79447300	NA	-0.43	-11.02	-0.4	5.66e-26	Refractive error;
BRCA	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg23711669	chr6:146136114	FBXO30	0.79	19.28	0.61	1.28e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7633770	0.786	rs1402148	chr3:46678295	C/T	cg11219411	chr3:46661640	NA	0.61	15.66	0.53	5.12e-47	Coronary artery disease;
BRCA	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.33	-10.21	-0.37	8.77e-23	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg03340356	chr1:67600835	NA	0.35	7.84	0.3	1.88e-14	Psoriasis;
BRCA	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.58	-11.46	-0.41	9.1e-28	Lymphocyte counts;
BRCA	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg07549590	chr16:15018862	NA	0.33	8.27	0.31	7.81e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.55	-0.42	3.59e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg22764044	chr5:178986830	RUFY1	0.46	12.4	0.44	8.53e-32	Lung cancer;
BRCA	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.61	-12.69	-0.45	4.34e-33	Lymphocyte counts;
BRCA	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	11.0	0.4	6.87e-26	Rheumatoid arthritis;
BRCA	cis	rs7178424	1.000	rs11633500	chr15:62372475	A/G	cg00456672	chr15:62358751	C2CD4A	-0.36	-8.24	-0.31	9.42e-16	Height;
BRCA	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg04450456	chr4:17643702	FAM184B	0.37	10.86	0.39	2.57e-25	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.39	8.4	0.32	2.82e-16	Mean corpuscular volume;
BRCA	cis	rs507080	0.922	rs561845	chr11:118558827	A/G	cg09144398	chr11:118550485	TREH	-0.37	-8.96	-0.33	3.5e-18	Serum metabolite levels;
BRCA	cis	rs9287719	0.649	rs10183359	chr2:10733044	G/A	cg00105475	chr2:10696890	NA	0.41	9.23	0.34	3.83e-19	Prostate cancer;
BRCA	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg24642439	chr20:33292090	TP53INP2	-0.55	-11.83	-0.42	2.57e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.32	-7.89	-0.3	1.31e-14	Total body bone mineral density;
BRCA	cis	rs1568889	1.000	rs11826837	chr11:28322566	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.61	-13.45	-0.47	1.74e-36	Bipolar disorder;
BRCA	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg05834845	chr3:195489306	MUC4	0.55	8.22	0.31	1.14e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg23711669	chr6:146136114	FBXO30	0.64	14.85	0.51	4.4e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg20607798	chr8:58055168	NA	0.47	8.04	0.3	4.43e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23221052	chr5:179740743	GFPT2	-0.67	-14.09	-0.49	1.93e-39	Height;
BRCA	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg08888203	chr3:10149979	C3orf24	0.63	11.56	0.42	3.44e-28	Alzheimer's disease;
BRCA	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg24675658	chr1:53192096	ZYG11B	-0.68	-15.46	-0.52	4.76e-46	Monocyte count;
BRCA	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg21918786	chr6:109611834	NA	-0.44	-11.95	-0.43	7.83e-30	Reticulocyte fraction of red cells;
BRCA	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg04362960	chr10:104952993	NT5C2	0.46	10.74	0.39	7.57e-25	Arsenic metabolism;
BRCA	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.41	-8.7	-0.33	2.74e-17	Bipolar disorder;
BRCA	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg18446336	chr7:2847575	GNA12	-0.35	-8.25	-0.31	9.28e-16	Height;
BRCA	cis	rs12612619	0.732	rs6547401	chr2:27284845	A/G	cg00617064	chr2:27272375	NA	-0.32	-8.39	-0.32	3.05e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs10821556	1	rs10821556	chr9:136942136	C/A	cg13758054	chr9:136930777	BRD3	0.29	8.4	0.32	2.9e-16	Mean platelet volume;
BRCA	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	11.72	0.42	6.96e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg07460842	chr6:66804631	NA	0.97	19.47	0.61	1.26e-66	Exhaled nitric oxide output;
BRCA	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21659725	chr3:3221576	CRBN	0.7	20.95	0.64	1.37e-74	Intelligence (multi-trait analysis);
BRCA	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg13010199	chr12:38710504	ALG10B	0.44	8.61	0.32	5.71e-17	Morning vs. evening chronotype;
BRCA	cis	rs12541635	0.966	rs6987512	chr8:106998770	C/T	cg10147462	chr8:107024639	NA	0.37	10.15	0.37	1.5e-22	Age of smoking initiation;
BRCA	cis	rs11227306	0.934	rs11227315	chr11:65590389	C/A	cg00576331	chr11:65640516	EFEMP2	-0.38	-7.89	-0.3	1.32e-14	DNA methylation (variation);
BRCA	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.92	0.33	4.98e-18	Motion sickness;
BRCA	trans	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-14.12	-0.49	1.27e-39	Brugada syndrome;
BRCA	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.42	-0.38	1.38e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02176678	chr2:219576539	TTLL4	0.46	12.11	0.43	1.52e-30	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg15017067	chr4:17643749	FAM184B	0.3	8.52	0.32	1.15e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg23711669	chr6:146136114	FBXO30	0.77	17.96	0.58	1.11e-58	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg24803719	chr17:45855879	NA	0.3	7.91	0.3	1.14e-14	IgG glycosylation;
BRCA	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg07636037	chr3:49044803	WDR6	0.76	15.38	0.52	1.27e-45	Menarche (age at onset);
BRCA	cis	rs400736	0.602	rs10864330	chr1:8168564	C/T	cg25007680	chr1:8021821	PARK7	-0.35	-8.68	-0.32	3.37e-17	Response to antidepressants and depression;
BRCA	cis	rs9807989	0.507	rs3732124	chr2:103018052	A/G	cg03938978	chr2:103052716	IL18RAP	-0.3	-8.76	-0.33	1.79e-17	Asthma;
BRCA	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg24110177	chr3:50126178	RBM5	-0.45	-9.67	-0.36	1.01e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	8.98	0.33	2.96e-18	Tonsillectomy;
BRCA	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.63	10.21	0.37	9.1e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs57590327	0.555	rs3943556	chr3:81738892	G/C	cg07356753	chr3:81810745	GBE1	-0.47	-11.19	-0.4	1.09e-26	Extraversion;
BRCA	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg21573476	chr21:45109991	RRP1B	-0.47	-11.68	-0.42	1.02e-28	Mean corpuscular volume;
BRCA	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg03146154	chr1:46216737	IPP	0.45	9.9	0.36	1.36e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg16325326	chr1:53192061	ZYG11B	0.96	27.09	0.73	3.27e-108	Monocyte count;
BRCA	trans	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg15556689	chr8:8085844	FLJ10661	0.31	8.04	0.3	4.5e-15	Neuroticism;
BRCA	cis	rs2882667	0.898	rs10045761	chr5:138397289	G/A	cg04439458	chr5:138467593	SIL1	-0.35	-9.45	-0.35	6.18e-20	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg22875332	chr1:76189707	ACADM	-0.68	-14.53	-0.5	1.62e-41	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1018836	0.923	rs13268594	chr8:91588545	G/T	cg16814680	chr8:91681699	NA	-0.57	-12.27	-0.44	3.19e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	trans	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg25214090	chr10:38739885	LOC399744	0.48	10.7	0.39	1.1e-24	Corneal astigmatism;
BRCA	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg21427119	chr20:30132790	HM13	-0.4	-8.43	-0.32	2.34e-16	Mean corpuscular hemoglobin;
BRCA	cis	rs490234	0.934	rs4837018	chr9:128275991	A/G	cg14078157	chr9:128172775	NA	-0.33	-8.04	-0.3	4.47e-15	Mean arterial pressure;
BRCA	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg22535103	chr8:58192502	C8orf71	-0.45	-9.05	-0.34	1.65e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-15.97	-0.53	1.42e-48	Total cholesterol levels;
BRCA	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg08000102	chr2:233561755	GIGYF2	-0.62	-13.57	-0.47	5.01e-37	Coronary artery disease;
BRCA	cis	rs868036	0.958	rs3784709	chr15:68072275	C/T	cg08079166	chr15:68083412	MAP2K5	0.33	8.51	0.32	1.21e-16	Restless legs syndrome;
BRCA	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg03929089	chr4:120376271	NA	0.57	9.47	0.35	5.22e-20	Axial length;
BRCA	cis	rs7953508	0.506	rs930316	chr12:93967035	A/G	cg18151635	chr12:93972918	NA	-0.46	-9.27	-0.34	2.83e-19	Pubertal anthropometrics;
BRCA	trans	rs4650994	0.544	rs11579513	chr1:178496092	T/C	cg05059571	chr16:84539110	KIAA1609	-0.49	-11.06	-0.4	4.05e-26	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg01028140	chr2:1542097	TPO	-0.57	-11.74	-0.42	5.83e-29	IgG glycosylation;
BRCA	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg18196295	chr10:418757	DIP2C	0.39	8.78	0.33	1.46e-17	Psychosis in Alzheimer's disease;
BRCA	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg00814883	chr7:100076585	TSC22D4	-0.52	-11.77	-0.42	4.38e-29	Platelet count;
BRCA	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg05340658	chr4:99064831	C4orf37	0.48	11.13	0.4	2.08e-26	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg17724175	chr1:150552817	MCL1	0.27	8.83	0.33	9.73e-18	Tonsillectomy;
BRCA	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-11.37	-0.41	2.14e-27	Gut microbiome composition (summer);
BRCA	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-17.03	-0.56	6.87e-54	Chronic sinus infection;
BRCA	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg13010199	chr12:38710504	ALG10B	-0.37	-8.84	-0.33	9e-18	Morning vs. evening chronotype;
BRCA	trans	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg13565492	chr6:43139072	SRF	-0.84	-11.44	-0.41	1.02e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg21573476	chr21:45109991	RRP1B	-0.32	-8.15	-0.31	1.94e-15	Mean corpuscular volume;
BRCA	cis	rs600806	0.815	rs10858097	chr1:109967324	C/A	cg20591472	chr1:110008990	SYPL2	0.32	7.99	0.3	6.35e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs11690935	0.531	rs62183800	chr2:172867273	C/T	cg13550731	chr2:172543902	DYNC1I2	0.49	12.11	0.43	1.55e-30	Schizophrenia;
BRCA	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11764359	chr7:65958608	NA	0.79	19.35	0.61	5.48e-66	Aortic root size;
BRCA	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	14.92	0.51	1.98e-43	Hip circumference adjusted for BMI;
BRCA	cis	rs1003719	0.708	rs2000417	chr21:38502868	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.19	-0.49	6.29e-40	Eye color traits;
BRCA	trans	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.84	-0.3	1.96e-14	Corneal astigmatism;
BRCA	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.06	0.74	1.58e-113	Chronic sinus infection;
BRCA	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg22563815	chr15:78856949	CHRNA5	-0.35	-8.39	-0.31	3.18e-16	Sudden cardiac arrest;
BRCA	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg02415014	chr8:143852576	LYNX1	-0.33	-8.27	-0.31	7.65e-16	Urinary tract infection frequency;
BRCA	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.53	0.57	1.78e-56	Fuchs's corneal dystrophy;
BRCA	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.01	-0.34	2.31e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg06808227	chr14:105710500	BRF1	-0.8	-16.15	-0.54	1.82e-49	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg02466173	chr16:30829666	NA	-0.54	-11.61	-0.42	2.07e-28	Multiple myeloma;
BRCA	cis	rs9309473	0.554	rs4330127	chr2:73581320	A/T	cg20560298	chr2:73613845	ALMS1	-0.42	-10.91	-0.4	1.53e-25	Metabolite levels;
BRCA	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg03709012	chr19:19516395	GATAD2A	0.75	17.13	0.56	2.09e-54	Tonsillectomy;
BRCA	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg05535760	chr7:792225	HEATR2	-0.77	-11.66	-0.42	1.22e-28	Cerebrospinal P-tau181p levels;
BRCA	cis	rs11229555	0.645	rs10466679	chr11:58188257	T/C	cg15696309	chr11:58395628	NA	-0.44	-9.41	-0.35	8.7e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg25457927	chr22:38595422	NA	-0.32	-11.87	-0.43	1.63e-29	Cutaneous nevi;
BRCA	trans	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg15704280	chr7:45808275	SEPT13	0.56	8.74	0.33	2.02e-17	Intraocular pressure;
BRCA	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg10792982	chr14:105748885	BRF1	0.5	11.67	0.42	1.15e-28	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg00530320	chr1:46809349	NSUN4	0.5	9.94	0.37	9.36e-22	Menopause (age at onset);
BRCA	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-7.92	-0.3	1.07e-14	Ulcerative colitis;
BRCA	trans	rs1459104	1.000	rs2903534	chr11:55054044	A/G	cg03929089	chr4:120376271	NA	0.65	7.9	0.3	1.19e-14	Body mass index;
BRCA	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	17.27	0.56	4.14e-55	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg26587870	chr6:27730563	NA	-0.54	-8.14	-0.31	2.11e-15	Depression;
BRCA	cis	rs6761276	0.649	rs3811055	chr2:113831182	A/T	cg12858261	chr2:113808755	IL1F8	0.43	8.53	0.32	1.1e-16	Protein quantitative trait loci;
BRCA	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	10.64	0.39	1.94e-24	Motion sickness;
BRCA	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg11189052	chr15:85197271	WDR73	-0.35	-8.29	-0.31	6.86e-16	P wave terminal force;
BRCA	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg25036284	chr2:26402008	FAM59B	-0.63	-10.95	-0.4	1.05e-25	Gut microbiome composition (summer);
BRCA	cis	rs6087990	0.735	rs2065576	chr20:31389009	C/T	cg13636640	chr20:31349939	DNMT3B	0.62	17.13	0.56	2.03e-54	Ulcerative colitis;
BRCA	cis	rs9790314	0.723	rs10936223	chr3:160884313	C/A	cg03342759	chr3:160939853	NMD3	-0.58	-13.09	-0.46	7.66e-35	Morning vs. evening chronotype;
BRCA	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18404041	chr3:52824283	ITIH1	-0.44	-12.92	-0.46	4.26e-34	Bipolar disorder;
BRCA	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg26384229	chr12:38710491	ALG10B	0.76	16.99	0.56	1.04e-53	Morning vs. evening chronotype;
BRCA	cis	rs4853036	1.000	rs11903034	chr2:70060278	T/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-9.12	-0.34	9.96e-19	Colorectal or endometrial cancer;
BRCA	cis	rs586533	0.881	rs676086	chr11:99506539	T/C	cg22878054	chr11:99397252	CNTN5	0.32	8.13	0.31	2.3e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.26	0.31	8.13e-16	Cognitive ability;
BRCA	cis	rs12210905	0.687	rs12191649	chr6:27421208	A/T	cg08851530	chr6:28072375	NA	0.81	7.89	0.3	1.3e-14	Hip circumference adjusted for BMI;
BRCA	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg24154853	chr7:158122151	PTPRN2	0.35	8.16	0.31	1.73e-15	Calcium levels;
BRCA	cis	rs9300255	0.544	rs1716174	chr12:123660717	T/C	cg00376283	chr12:123451042	ABCB9	0.51	9.74	0.36	5.37e-21	Neutrophil percentage of white cells;
BRCA	cis	rs919433	0.617	rs700642	chr2:198600730	G/T	cg00792783	chr2:198669748	PLCL1	-0.47	-10.16	-0.37	1.45e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg24829409	chr8:58192753	C8orf71	-0.61	-12.58	-0.45	1.41e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22307029	chr19:49891270	CCDC155	0.47	7.91	0.3	1.15e-14	Multiple sclerosis;
BRCA	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg25554036	chr4:6271136	WFS1	-0.41	-9.91	-0.37	1.19e-21	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.9	0.33	5.55e-18	Motion sickness;
BRCA	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg26168224	chr5:2018326	NA	-0.56	-14.49	-0.5	2.52e-41	Gut microbiome composition (winter);
BRCA	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg24450063	chr1:156163899	SLC25A44	0.93	17.51	0.57	2.29e-56	Testicular germ cell tumor;
BRCA	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg01579765	chr21:45077557	HSF2BP	0.36	9.58	0.35	2.08e-20	Mean corpuscular volume;
BRCA	cis	rs13190036	0.591	rs78523677	chr5:176551103	C/A	cg06733329	chr5:176740039	MXD3	0.4	7.97	0.3	7.47e-15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.46	-9.24	-0.34	3.48e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs367943	0.799	rs10478135	chr5:112976905	C/A	cg12552261	chr5:112820674	MCC	0.51	9.89	0.36	1.48e-21	Type 2 diabetes;
BRCA	cis	rs61990749	0.597	rs8016447	chr14:78222068	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.63	9.73	0.36	5.64e-21	Fibroblast growth factor basic levels;
BRCA	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg26384229	chr12:38710491	ALG10B	0.67	15.18	0.51	1.13e-44	Bladder cancer;
BRCA	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11890956	chr21:40555474	PSMG1	1.06	30.81	0.77	1.95e-128	Cognitive function;
BRCA	cis	rs250677	0.522	rs6872172	chr5:148359529	G/C	cg12140854	chr5:148520817	ABLIM3	0.41	8.32	0.31	5.16e-16	Breast cancer;
BRCA	trans	rs12517041	1.000	rs2356713	chr5:23284777	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.9	-0.3	1.19e-14	Calcium levels;
BRCA	trans	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.3	-0.35	2.25e-19	Bladder cancer;
BRCA	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg26384229	chr12:38710491	ALG10B	0.8	19.69	0.61	7.86e-68	Heart rate;
BRCA	trans	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17712092	chr4:129076599	LARP1B	0.54	13.2	0.46	2.27e-35	Eosinophil percentage of white cells;
BRCA	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg11789530	chr4:8429930	ACOX3	-0.69	-17.98	-0.58	8.05e-59	Response to antineoplastic agents;
BRCA	cis	rs7809950	0.817	rs10224503	chr7:107075569	A/C	cg23024343	chr7:107201750	COG5	-0.49	-10.74	-0.39	7.33e-25	Coronary artery disease;
BRCA	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-8.07	-0.3	3.56e-15	Aortic root size;
BRCA	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.36	11.2	0.41	1.05e-26	Bipolar disorder;
BRCA	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7617773	0.963	rs9822496	chr3:48181333	T/C	cg11946769	chr3:48343235	NME6	0.39	8.72	0.33	2.48e-17	Coronary artery disease;
BRCA	cis	rs11051970	0.879	rs2651362	chr12:32587851	G/C	cg02745156	chr12:32552066	NA	0.27	8.87	0.33	7.25e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs30380	0.632	rs27045	chr5:96138861	C/T	cg16492584	chr5:96139282	ERAP1	-0.47	-11.25	-0.41	6.42e-27	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.42	-0.32	2.54e-16	Monocyte percentage of white cells;
BRCA	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg07414643	chr4:187882934	NA	0.28	9.61	0.36	1.65e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs758324	0.812	rs30159	chr5:131306535	T/C	cg06307176	chr5:131281290	NA	-0.41	-8.5	-0.32	1.38e-16	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg08888203	chr3:10149979	C3orf24	0.67	13.93	0.48	9.94e-39	Alzheimer's disease;
BRCA	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg27661571	chr11:113659931	NA	-0.73	-11.22	-0.41	8.26e-27	Hip circumference adjusted for BMI;
BRCA	cis	rs7394190	0.748	rs2075641	chr10:75562108	G/A	cg07699608	chr10:75541558	CHCHD1	0.69	10.37	0.38	2.17e-23	Incident atrial fibrillation;
BRCA	cis	rs4891159	0.724	rs690639	chr18:74108957	C/T	cg24786174	chr18:74118243	ZNF516	0.73	18.01	0.58	6.04e-59	Longevity;
BRCA	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg01420254	chr6:26195488	NA	0.55	8.56	0.32	8.23e-17	Gout;Renal underexcretion gout;
BRCA	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11644478	chr21:40555479	PSMG1	0.77	16.62	0.55	8.14e-52	Cognitive function;
BRCA	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg08847533	chr14:75593920	NEK9	-0.93	-23.37	-0.68	8.68e-88	Height;
BRCA	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg18963800	chr10:38644991	HSD17B7P2	-0.4	-7.91	-0.3	1.12e-14	Extrinsic epigenetic age acceleration;
BRCA	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg08888203	chr3:10149979	C3orf24	0.56	11.7	0.42	9.05e-29	Alzheimer's disease;
BRCA	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14240646	chr10:27532245	ACBD5	-0.64	-9.38	-0.35	1.16e-19	Breast cancer;
BRCA	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg06494592	chr3:125709126	NA	-0.53	-8.22	-0.31	1.17e-15	Blood pressure (smoking interaction);
BRCA	cis	rs3767633	0.925	rs6427639	chr1:161866372	C/A	cg09175582	chr1:161736000	ATF6	0.52	8.43	0.32	2.32e-16	IgG glycosylation;
BRCA	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	14.13	0.49	1.26e-39	Eye color traits;
BRCA	cis	rs2516839	0.517	rs1556257	chr1:161051134	A/G	cg11161846	chr1:160990452	F11R	-0.36	-8.33	-0.31	5.04e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg12751644	chr20:60527061	NA	-0.33	-7.91	-0.3	1.1e-14	Body mass index;
BRCA	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.21	-0.37	9.22e-23	Psoriasis;
BRCA	cis	rs509477	1.000	rs7245165	chr18:32567007	C/A	cg00449728	chr18:32561817	MAPRE2	0.34	8.01	0.3	5.55e-15	Cerebrospinal fluid AB1-42 levels;
BRCA	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg01256987	chr12:42539512	GXYLT1	0.56	11.54	0.42	4.05e-28	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg26446133	chr18:72167187	CNDP2	-0.79	-19.96	-0.62	2.82e-69	Refractive error;
BRCA	cis	rs11690935	0.921	rs6710698	chr2:172596078	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.93	-32.26	-0.79	3.31e-136	Schizophrenia;
BRCA	cis	rs997295	0.554	rs4261477	chr15:68073968	G/T	cg08079166	chr15:68083412	MAP2K5	0.31	8.37	0.31	3.66e-16	Motion sickness;
BRCA	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.84	0.36	2.34e-21	Bipolar disorder;
BRCA	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg25703541	chr22:24373054	LOC391322	0.73	16.91	0.56	2.69e-53	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	12.06	0.43	2.65e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.6	-10.56	-0.39	3.91e-24	Birth weight;
BRCA	trans	rs9393777	0.778	rs66841633	chr6:27382386	G/T	cg01620082	chr3:125678407	NA	-0.7	-9.15	-0.34	7.58e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg26031613	chr14:104095156	KLC1	-0.57	-9.67	-0.36	1e-20	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.36	-8.18	-0.31	1.59e-15	Colorectal cancer;
BRCA	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg21132104	chr15:45694354	SPATA5L1	0.73	15.67	0.53	4.65e-47	Homoarginine levels;
BRCA	cis	rs61990749	0.597	rs117131659	chr14:78131126	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.58	-8.92	-0.33	4.88e-18	Fibroblast growth factor basic levels;
BRCA	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg24531977	chr5:56204891	C5orf35	-0.41	-8.37	-0.31	3.55e-16	Coronary artery disease;
BRCA	trans	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg15556689	chr8:8085844	FLJ10661	-0.34	-8.93	-0.33	4.47e-18	Neuroticism;
BRCA	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21659725	chr3:3221576	CRBN	0.46	11.55	0.42	3.53e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg24642439	chr20:33292090	TP53INP2	0.42	8.24	0.31	9.43e-16	Height;
BRCA	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.07	-27.73	-0.74	1.05e-111	Ulcerative colitis;
BRCA	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-13.4	-0.47	3e-36	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1691799	0.899	rs1168325	chr12:66728234	C/G	cg16791601	chr12:66731901	HELB	-0.65	-17.34	-0.57	1.74e-55	White blood cell count (basophil);
BRCA	cis	rs1555322	0.530	rs2425043	chr20:33868702	T/C	cg17927777	chr20:33865990	NA	0.42	7.91	0.3	1.11e-14	Attention deficit hyperactivity disorder;
BRCA	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06636551	chr8:101224915	SPAG1	0.49	11.6	0.42	2.33e-28	Atrioventricular conduction;
BRCA	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	9.12	0.34	1.01e-18	Height;
BRCA	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	12.96	0.46	2.77e-34	Bipolar disorder;
BRCA	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg06970220	chr1:156163860	SLC25A44	0.4	9.58	0.35	2.04e-20	Testicular germ cell tumor;
BRCA	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.58	0.35	2.14e-20	Morning vs. evening chronotype;
BRCA	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg00750074	chr16:89608354	SPG7	-0.34	-9.17	-0.34	6.46e-19	Multiple myeloma (IgH translocation);
BRCA	trans	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg13010199	chr12:38710504	ALG10B	0.4	8.09	0.3	3.05e-15	Morning vs. evening chronotype;
BRCA	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg07308232	chr7:1071921	C7orf50	-0.36	-7.87	-0.3	1.5e-14	Longevity;Endometriosis;
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg04234412	chr22:24373322	LOC391322	0.81	23.1	0.67	2.64e-86	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6545883	0.894	rs2121661	chr2:61561658	A/G	cg15711740	chr2:61764176	XPO1	0.53	13.55	0.47	6.11e-37	Tuberculosis;
BRCA	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg06636001	chr8:8085503	FLJ10661	0.49	9.52	0.35	3.53e-20	Neuroticism;
BRCA	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg24642439	chr20:33292090	TP53INP2	0.43	9.19	0.34	5.32e-19	Height;
BRCA	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.73	-0.36	5.75e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	10.75	0.39	7.02e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11644478	chr21:40555479	PSMG1	-0.68	-14.87	-0.51	3.75e-43	Cognitive function;
BRCA	cis	rs796364	0.525	rs10931895	chr2:201143242	C/T	cg23649088	chr2:200775458	C2orf69	0.45	7.94	0.3	8.82e-15	Schizophrenia;
BRCA	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg02269571	chr22:50332266	NA	-0.53	-9.8	-0.36	3.19e-21	Schizophrenia;
BRCA	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.72	16.81	0.55	9.16e-53	Axial length;
BRCA	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.56	-14.93	-0.51	1.85e-43	Longevity;Endometriosis;
BRCA	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25427524	chr10:38739819	LOC399744	-0.69	-16.64	-0.55	6.29e-52	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg23711669	chr6:146136114	FBXO30	0.8	19.0	0.6	3.6e-64	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg11247378	chr22:39784982	NA	-0.63	-15.43	-0.52	6.89e-46	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg25036284	chr2:26402008	FAM59B	0.96	16.04	0.54	6.76e-49	Gut microbiome composition (summer);
BRCA	cis	rs1568889	1.000	rs12791341	chr11:28335452	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	13.1	0.46	6.59e-35	Bipolar disorder;
BRCA	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg16606324	chr3:10149918	C3orf24	0.57	11.19	0.4	1.16e-26	Alzheimer's disease;
BRCA	cis	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg06521331	chr12:34319734	NA	-0.63	-11.57	-0.42	2.98e-28	Morning vs. evening chronotype;
BRCA	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg24069376	chr3:38537580	EXOG	-0.4	-11.37	-0.41	2.08e-27	Electrocardiographic conduction measures;
BRCA	cis	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.19	-0.31	1.4e-15	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7818345	0.967	rs13258090	chr8:19285726	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.32	-8.41	-0.32	2.62e-16	Language performance in older adults (adjusted for episodic memory);
BRCA	cis	rs6546550	0.901	rs6736408	chr2:70137774	C/T	cg02498382	chr2:70120550	SNRNP27	-0.53	-11.62	-0.42	1.93e-28	Prevalent atrial fibrillation;
BRCA	trans	rs2048656	0.600	rs1976671	chr8:9679634	A/G	cg06636001	chr8:8085503	FLJ10661	0.39	7.93	0.3	9.47e-15	Schizophrenia;
BRCA	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.48	0.38	8.08e-24	Motion sickness;
BRCA	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg26248373	chr2:1572462	NA	-0.48	-9.57	-0.35	2.24e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4919694	0.572	rs12243903	chr10:104906992	T/C	cg04362960	chr10:104952993	NT5C2	0.72	12.66	0.45	6.05e-33	Arsenic metabolism;
BRCA	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.3	-7.81	-0.3	2.4e-14	Response to antipsychotic treatment;
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg20007245	chr22:24372913	LOC391322	0.76	18.56	0.59	8.28e-62	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.38	8.51	0.32	1.25e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1506403	0.685	rs1994497	chr7:142816927	A/G	cg22531018	chr7:142981779	TMEM139	0.45	8.59	0.32	6.48e-17	Cancer;
BRCA	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg19077165	chr18:44547161	KATNAL2	-0.58	-12.89	-0.45	5.75e-34	Personality dimensions;
BRCA	cis	rs10851411	0.697	rs11636209	chr15:42788107	A/G	cg21293051	chr15:42870591	STARD9	0.52	8.71	0.33	2.66e-17	Glucose homeostasis traits;
BRCA	trans	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg17675199	chr6:35436792	RPL10A	-0.29	-7.81	-0.3	2.37e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs644148	0.836	rs2571112	chr19:45000319	T/A	cg15540054	chr19:45004280	ZNF180	-0.57	-12.3	-0.44	2.36e-31	Personality dimensions;
BRCA	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11644478	chr21:40555479	PSMG1	-0.54	-11.53	-0.42	4.36e-28	Menarche (age at onset);
BRCA	trans	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.93	0.46	3.84e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg18230493	chr5:56204884	C5orf35	-0.61	-13.2	-0.46	2.42e-35	Initial pursuit acceleration;
BRCA	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.59	0.32	6.84e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg04267008	chr7:1944627	MAD1L1	0.45	10.13	0.37	1.89e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs11585357	0.947	rs3003441	chr1:17611869	C/T	cg19159961	chr1:17633534	PADI4	-0.5	-8.9	-0.33	5.6e-18	Hair shape;
BRCA	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg13114125	chr14:105738426	BRF1	-0.48	-10.06	-0.37	3.29e-22	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg15103426	chr22:29168792	CCDC117	0.54	12.72	0.45	3.37e-33	Lymphocyte counts;
BRCA	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg08601574	chr20:25228251	PYGB	-0.4	-9.53	-0.35	3.15e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg00012203	chr2:219082015	ARPC2	-0.4	-7.84	-0.3	1.92e-14	Ulcerative colitis;
BRCA	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	12.29	0.44	2.67e-31	Lung cancer in ever smokers;
BRCA	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg13256891	chr4:100009986	ADH5	0.46	9.58	0.35	2.16e-20	Alcohol dependence;
BRCA	cis	rs17253792	0.545	rs17745459	chr14:56008549	T/A	cg01858014	chr14:56050164	KTN1	-0.61	-7.83	-0.3	1.99e-14	Putamen volume;
BRCA	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26314531	chr2:26401878	FAM59B	0.94	16.39	0.54	1.24e-50	Gut microbiome composition (summer);
BRCA	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg08601574	chr20:25228251	PYGB	0.34	8.15	0.31	1.86e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg09163369	chr1:210001066	C1orf107	-0.49	-9.35	-0.35	1.41e-19	Orofacial clefts;
BRCA	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg11814155	chr7:99998594	ZCWPW1	0.48	8.79	0.33	1.36e-17	Platelet count;
BRCA	cis	rs312274	0.550	rs66578805	chr12:41264460	A/G	cg17827154	chr12:41323612	CNTN1	-0.36	-9.0	-0.34	2.48e-18	Metabolite levels  (X-11787);
BRCA	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg17366294	chr4:99064904	C4orf37	0.54	11.57	0.42	2.97e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg23711669	chr6:146136114	FBXO30	0.64	14.89	0.51	2.93e-43	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg25214090	chr10:38739885	LOC399744	0.55	11.7	0.42	8.57e-29	Corneal astigmatism;
BRCA	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.7e-23	Motion sickness;
BRCA	cis	rs977987	0.806	rs11640674	chr16:75394944	A/G	cg03315344	chr16:75512273	CHST6	0.52	12.41	0.44	8.12e-32	Dupuytren's disease;
BRCA	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg04553112	chr3:125709451	NA	-0.55	-8.27	-0.31	7.6e-16	Blood pressure (smoking interaction);
BRCA	trans	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.62	11.38	0.41	1.94e-27	Type 2 diabetes;
BRCA	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg18811423	chr2:55921094	PNPT1	0.71	22.76	0.67	1.91e-84	Metabolic syndrome;
BRCA	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg16482183	chr6:26056742	HIST1H1C	0.49	10.01	0.37	5.07e-22	Iron status biomarkers;
BRCA	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg25208724	chr1:156163844	SLC25A44	1.06	34.16	0.8	2.58e-146	Testicular germ cell tumor;
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg26608667	chr7:1196370	ZFAND2A	0.34	7.8	0.3	2.44e-14	Longevity;Endometriosis;
BRCA	trans	rs9650657	0.803	rs13276026	chr8:10609955	G/A	cg06636001	chr8:8085503	FLJ10661	-0.4	-8.46	-0.32	1.84e-16	Neuroticism;
BRCA	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	10.78	0.39	5.39e-25	Parkinson's disease;
BRCA	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg23708337	chr7:1209742	NA	0.64	8.74	0.33	2.05e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.38	-8.18	-0.31	1.5e-15	Alzheimer's disease (late onset);
BRCA	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg15556689	chr8:8085844	FLJ10661	-0.35	-9.28	-0.34	2.57e-19	Triglycerides;
BRCA	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg00012203	chr2:219082015	ARPC2	0.62	12.94	0.46	3.55e-34	Colorectal cancer;
BRCA	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-11.03	-0.4	5.27e-26	Chronic sinus infection;
BRCA	cis	rs2882667	0.690	rs7714455	chr5:138153970	T/G	cg04439458	chr5:138467593	SIL1	0.33	8.31	0.31	5.8e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10411936	0.720	rs7252649	chr19:16582785	G/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.46	9.65	0.36	1.19e-20	White blood cell count;Multiple sclerosis;
BRCA	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg14963724	chr18:72166303	CNDP2	-0.34	-9.44	-0.35	6.73e-20	Refractive error;
BRCA	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05025164	chr4:1340916	KIAA1530	-0.76	-14.93	-0.51	1.83e-43	Longevity;
BRCA	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg04362960	chr10:104952993	NT5C2	-0.34	-8.08	-0.3	3.17e-15	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs6684514	1.000	rs12141236	chr1:156302575	A/C	cg16558208	chr1:156270281	VHLL	0.35	8.08	0.3	3.34e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg03433033	chr1:76189801	ACADM	0.67	14.21	0.49	5.11e-40	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9807989	0.501	rs11903946	chr2:103005330	A/G	cg03938978	chr2:103052716	IL18RAP	0.29	8.42	0.32	2.39e-16	Asthma;
BRCA	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg23711669	chr6:146136114	FBXO30	0.64	14.85	0.51	4.32e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg09904177	chr6:26538194	HMGN4	0.43	12.0	0.43	4.58e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg13010199	chr12:38710504	ALG10B	0.44	10.86	0.39	2.47e-25	Heart rate;
BRCA	cis	rs7072216	0.770	rs1061123	chr10:100176997	A/G	cg26618903	chr10:100175079	PYROXD2	-0.27	-8.11	-0.31	2.62e-15	Metabolite levels;
BRCA	cis	rs6084875	0.733	rs6052854	chr20:4742399	A/G	cg05143360	chr20:4741328	NA	0.36	8.13	0.31	2.27e-15	Systemic lupus erythematosus;
BRCA	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24308560	chr3:49941425	MST1R	-0.39	-8.11	-0.31	2.66e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.7	-11.51	-0.41	5.66e-28	Red cell distribution width;
BRCA	cis	rs9463078	0.764	rs10948187	chr6:44921320	A/G	cg25276700	chr6:44698697	NA	0.35	8.19	0.31	1.39e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs1865721	1.000	rs72977888	chr18:73195250	C/T	cg26385618	chr18:73139727	C18orf62	-0.39	-9.02	-0.34	2.26e-18	Intelligence;
BRCA	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04267008	chr7:1944627	MAD1L1	0.57	13.1	0.46	6.58e-35	Bipolar disorder and schizophrenia;
BRCA	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.33	9.24	0.34	3.64e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs13046373	0.508	rs1507393	chr21:31992779	A/G	cg24082983	chr21:31802169	KRTAP13-4	0.33	8.18	0.31	1.58e-15	HDL cholesterol;
BRCA	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg15133208	chr4:90757351	SNCA	-0.39	-7.92	-0.3	1.04e-14	Neuroticism;
BRCA	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg13902645	chr11:5959945	NA	-0.44	-8.58	-0.32	7.32e-17	DNA methylation (variation);
BRCA	cis	rs1568889	1.000	rs35343234	chr11:28034379	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	12.98	0.46	2.38e-34	Bipolar disorder;
BRCA	cis	rs9463078	0.838	rs1924662	chr6:45140332	T/A	cg25276700	chr6:44698697	NA	-0.36	-8.14	-0.31	2.04e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg24112000	chr20:60950667	NA	-0.45	-8.04	-0.3	4.5e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg17366294	chr4:99064904	C4orf37	0.45	10.81	0.39	3.9e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9394841	0.692	rs2395795	chr6:41802354	G/A	cg08135965	chr6:41755394	TOMM6	0.47	7.82	0.3	2.15e-14	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs6433857	0.536	rs1971135	chr2:181351508	G/A	cg23363182	chr2:181467187	NA	-0.38	-7.93	-0.3	9.89e-15	Body mass index;
BRCA	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg06115741	chr20:33292138	TP53INP2	0.52	11.69	0.42	9.91e-29	Coronary artery disease;
BRCA	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg00031303	chr3:195681400	NA	0.49	9.48	0.35	4.92e-20	Pancreatic cancer;
BRCA	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg26195577	chr20:24973756	C20orf3	1.03	28.97	0.75	1.65e-118	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.39	0.57	9.59e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2425143	1.000	rs7273668	chr20:34442731	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.54	-0.32	9.92e-17	Blood protein levels;
BRCA	cis	rs7552167	0.925	rs11249020	chr1:24512804	A/G	cg01960748	chr1:24522592	NA	-0.61	-10.08	-0.37	2.81e-22	Psoriasis vulgaris;
BRCA	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg18154014	chr19:37997991	ZNF793	0.48	9.55	0.35	2.65e-20	Coronary artery calcification;
BRCA	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg04545296	chr12:48745243	ZNF641	0.25	8.3	0.31	6.07e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs77972916	0.536	rs11679731	chr2:43589064	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-10.4	-0.38	1.59e-23	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-11.99	-0.43	5.2e-30	Bipolar disorder;
BRCA	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg21782813	chr7:2030301	MAD1L1	-0.34	-10.0	-0.37	5.7e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs28735056	0.592	rs2277725	chr18:77694168	A/C	cg20368463	chr18:77673604	PQLC1	-0.49	-12.12	-0.43	1.34e-30	Schizophrenia;
BRCA	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18876405	chr7:65276391	NA	0.61	15.13	0.51	2.06e-44	Aortic root size;
BRCA	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg05985134	chr18:33552581	C18orf21	0.63	12.3	0.44	2.32e-31	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg06623918	chr6:96969491	KIAA0776	0.89	25.79	0.71	4.53e-101	Headache;
BRCA	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg01475735	chr3:40494733	NA	-0.43	-7.91	-0.3	1.13e-14	Renal cell carcinoma;
BRCA	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg23422044	chr7:1970798	MAD1L1	-0.44	-9.4	-0.35	9.18e-20	Neuroticism;
BRCA	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	18.35	0.59	9.61e-61	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg17063962	chr7:91808500	NA	0.53	12.21	0.43	6e-31	Breast cancer;
BRCA	trans	rs10805346	0.501	rs4604059	chr4:10115065	C/T	cg26043149	chr18:55253948	FECH	-0.44	-10.32	-0.38	3.36e-23	Urate levels in overweight individuals;Urate levels in obese individuals;
BRCA	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	23.03	0.67	6.4e-86	Platelet count;
BRCA	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg16586182	chr3:47516702	SCAP	-0.55	-12.23	-0.44	4.63e-31	Colorectal cancer;
BRCA	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg06636001	chr8:8085503	FLJ10661	0.52	10.09	0.37	2.51e-22	Neuroticism;
BRCA	cis	rs2304069	0.909	rs30831	chr5:149359053	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.53	-8.33	-0.31	4.99e-16	HIV-1 control;
BRCA	trans	rs1974653	0.781	rs175162	chr22:20113253	A/C	cg20152630	chr19:46405944	MYPOP	0.37	8.33	0.31	5.01e-16	Schizophrenia;
BRCA	trans	rs877282	0.685	rs56234340	chr10:781339	A/G	cg22713356	chr15:30763199	NA	1.15	22.49	0.66	5.94e-83	Uric acid levels;
BRCA	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg18230493	chr5:56204884	C5orf35	-0.72	-14.12	-0.49	1.41e-39	Initial pursuit acceleration;
BRCA	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-9.48	-0.35	4.98e-20	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg06623918	chr6:96969491	KIAA0776	0.72	12.8	0.45	1.51e-33	Migraine;Coronary artery disease;
BRCA	cis	rs1953600	1.000	rs2573346	chr10:81918041	G/A	cg04850286	chr10:81895943	PLAC9	-0.35	-10.1	-0.37	2.35e-22	Sarcoidosis;
BRCA	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg03146154	chr1:46216737	IPP	0.44	9.8	0.36	3.15e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg00757033	chr12:89920650	WDR51B	0.43	9.26	0.34	3.07e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg01475377	chr6:109611718	NA	-0.51	-12.67	-0.45	5.32e-33	Reticulocyte fraction of red cells;
BRCA	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.6	12.51	0.44	2.94e-32	Lymphocyte counts;
BRCA	cis	rs870825	0.929	rs72689254	chr4:185589941	C/T	cg04058563	chr4:185651563	MLF1IP	0.69	11.72	0.42	7.1e-29	Blood protein levels;
BRCA	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg12661370	chr5:149340060	SLC26A2	0.55	7.96	0.3	7.94e-15	HIV-1 control;
BRCA	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg17135325	chr3:160939158	NMD3	0.39	7.82	0.3	2.14e-14	Parkinson's disease;
BRCA	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg05340658	chr4:99064831	C4orf37	0.67	16.49	0.55	3.48e-51	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11051970	0.879	rs2728682	chr12:32580193	G/A	cg02745156	chr12:32552066	NA	0.27	8.9	0.33	5.93e-18	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg18357645	chr12:58087776	OS9	0.48	13.8	0.48	3.98e-38	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs11718455	0.653	rs28533958	chr3:43974179	C/A	cg08738300	chr3:44038990	NA	0.49	9.03	0.34	1.95e-18	Coronary artery disease;
BRCA	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg03676636	chr4:99064102	C4orf37	0.21	7.99	0.3	6.19e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.42	-0.61	2.35e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs1829883	0.835	rs10068675	chr5:98890617	C/G	cg08333243	chr5:99726346	NA	-0.36	-8.35	-0.31	4.27e-16	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	ch.11.42038R	chr11:967971	AP2A2	0.51	16.26	0.54	5.44e-50	Alzheimer's disease (late onset);
BRCA	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg23033748	chr14:75592666	NEK9	0.34	8.02	0.3	5e-15	Height;
BRCA	trans	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	14.75	0.5	1.34e-42	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs7789940	1.000	rs17149161	chr7:75978229	C/A	cg10167463	chr7:75959203	YWHAG	-0.44	-8.86	-0.33	8.13e-18	Multiple sclerosis;
BRCA	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg11693508	chr17:37793320	STARD3	0.53	10.18	0.37	1.14e-22	Bipolar disorder;
BRCA	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg03929089	chr4:120376271	NA	0.79	17.0	0.56	9.17e-54	Height;
BRCA	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg12386194	chr3:101231763	SENP7	0.46	9.79	0.36	3.64e-21	Colorectal cancer;
BRCA	cis	rs1451375	1.000	rs2329342	chr7:50624971	A/G	cg18232548	chr7:50535776	DDC	-0.44	-10.23	-0.38	7.59e-23	Malaria;
BRCA	cis	rs34779708	0.931	rs35388511	chr10:35296616	A/G	cg03585969	chr10:35415529	CREM	0.49	10.21	0.37	9.07e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	trans	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.23	0.31	1.08e-15	Mean corpuscular volume;
BRCA	cis	rs870825	0.616	rs4594761	chr4:185643002	A/C	cg04058563	chr4:185651563	MLF1IP	0.77	17.2	0.56	9.11e-55	Blood protein levels;
BRCA	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg03342759	chr3:160939853	NMD3	-0.8	-18.84	-0.6	2.5e-63	Parkinson's disease;
BRCA	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg23711669	chr6:146136114	FBXO30	0.75	17.29	0.56	3.24e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9790314	0.613	rs4679666	chr3:160629025	C/G	cg03342759	chr3:160939853	NMD3	0.42	8.44	0.32	2.18e-16	Morning vs. evening chronotype;
BRCA	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg01528321	chr10:82214614	TSPAN14	0.69	14.59	0.5	7.96e-42	Post bronchodilator FEV1;
BRCA	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg21918786	chr6:109611834	NA	0.48	13.73	0.48	9.13e-38	Reticulocyte fraction of red cells;
BRCA	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg05083358	chr7:2394359	EIF3B	-0.51	-7.93	-0.3	1e-14	Multiple sclerosis;
BRCA	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.54	-9.77	-0.36	4.32e-21	Renal function-related traits (BUN);
BRCA	cis	rs2012796	0.661	rs59969857	chr14:81841579	A/G	cg02996355	chr14:81879375	NA	0.53	10.94	0.4	1.16e-25	Night sleep phenotypes;
BRCA	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg26373071	chr5:1325741	CLPTM1L	0.49	12.26	0.44	3.51e-31	Lung cancer;
BRCA	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.32	-7.9	-0.3	1.21e-14	Response to antipsychotic treatment;
BRCA	cis	rs4363385	0.747	rs6668696	chr1:152964910	A/G	cg24667326	chr1:152973720	SPRR3	-0.33	-9.33	-0.35	1.74e-19	Inflammatory skin disease;
BRCA	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.46	8.88	0.33	6.85e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg17470723	chr8:74884337	TCEB1	0.41	8.81	0.33	1.16e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs921968	0.565	rs755112	chr2:219606052	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-11.05	-0.4	4.43e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	11.37	0.41	2.05e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg27170947	chr2:26402098	FAM59B	-0.65	-11.62	-0.42	1.85e-28	Gut microbiome composition (summer);
BRCA	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg27170947	chr2:26402098	FAM59B	0.97	16.99	0.56	1.05e-53	Gut microbiome composition (summer);
BRCA	cis	rs9837602	0.935	rs4928149	chr3:99685686	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-10.64	-0.39	1.95e-24	Breast cancer;
BRCA	cis	rs7246657	0.639	rs3112434	chr19:38198148	G/T	cg23950597	chr19:37808831	NA	0.51	8.58	0.32	7.23e-17	Coronary artery calcification;
BRCA	cis	rs477692	0.673	rs10764889	chr10:131341521	G/A	cg24747557	chr10:131355152	MGMT	-0.37	-8.91	-0.33	5.46e-18	Response to temozolomide;
BRCA	cis	rs6973256	0.865	rs4728295	chr7:133322680	A/T	cg07491979	chr7:133331646	EXOC4	-0.38	-8.74	-0.33	2.05e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs13102973	0.899	rs4541577	chr4:135901087	G/T	cg14419869	chr4:135874104	NA	0.47	9.55	0.35	2.68e-20	Subjective well-being;
BRCA	cis	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg07460842	chr6:66804631	NA	0.88	14.23	0.49	4.1e-40	Exhaled nitric oxide output;
BRCA	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg11235426	chr6:292522	DUSP22	0.57	12.05	0.43	2.77e-30	Menopause (age at onset);
BRCA	cis	rs12612619	0.557	rs1368888	chr2:27068577	G/C	cg08802533	chr2:27073253	DPYSL5	-0.29	-7.82	-0.3	2.16e-14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg22713356	chr15:30763199	NA	1.3	24.11	0.69	7.71e-92	Uric acid levels;
BRCA	cis	rs13315871	0.929	rs11720747	chr3:58267833	G/A	cg20936604	chr3:58311152	NA	-0.65	-8.03	-0.3	4.73e-15	Cholesterol, total;
BRCA	cis	rs10193935	0.892	rs7574609	chr2:42388468	C/A	cg27598129	chr2:42591480	NA	-0.87	-14.49	-0.5	2.32e-41	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1874326	0.545	rs4574789	chr7:138109427	C/A	cg18008034	chr7:138118925	NA	-0.45	-9.24	-0.34	3.74e-19	Quantitative traits;
BRCA	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg13550731	chr2:172543902	DYNC1I2	0.93	31.76	0.78	1.53e-133	Schizophrenia;
BRCA	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg23018236	chr17:30244563	NA	-0.64	-10.29	-0.38	4.42e-23	Hip circumference adjusted for BMI;
BRCA	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.37	8.11	0.31	2.55e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1451375	0.785	rs6593010	chr7:50629888	A/G	cg18232548	chr7:50535776	DDC	0.41	9.89	0.36	1.48e-21	Malaria;
BRCA	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09256448	chr16:638327	NA	0.3	7.97	0.3	7.21e-15	Height;
BRCA	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg03188948	chr7:1209495	NA	0.45	8.79	0.33	1.39e-17	Longevity;Endometriosis;
BRCA	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg10932868	chr11:921992	NA	0.47	12.11	0.43	1.62e-30	Alzheimer's disease (late onset);
BRCA	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.31	-7.83	-0.3	1.98e-14	Response to antipsychotic treatment;
BRCA	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03264133	chr6:25882463	NA	0.73	16.47	0.55	4.7e-51	Blood metabolite levels;
BRCA	cis	rs7246657	0.551	rs28462002	chr19:37634462	A/G	cg18154014	chr19:37997991	ZNF793	0.54	9.01	0.34	2.38e-18	Coronary artery calcification;
BRCA	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	14.04	0.49	3.14e-39	Colorectal cancer;
BRCA	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg00409905	chr10:38381863	ZNF37A	0.51	10.96	0.4	9.92e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs943466	0.614	rs4713677	chr6:33731225	C/G	cg25922239	chr6:33757077	LEMD2	-0.33	-8.14	-0.31	2.06e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg18404041	chr3:52824283	ITIH1	0.42	12.96	0.46	2.75e-34	Bipolar disorder;
BRCA	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg23533926	chr12:111358616	MYL2	-0.41	-8.59	-0.32	6.59e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg04944784	chr2:26401820	FAM59B	-0.64	-10.13	-0.37	1.77e-22	Gut microbiome composition (summer);
BRCA	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg06970220	chr1:156163860	SLC25A44	0.39	9.58	0.35	2.08e-20	Testicular germ cell tumor;
BRCA	trans	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg25214090	chr10:38739885	LOC399744	0.37	8.6	0.32	6.29e-17	Diastolic blood pressure;
BRCA	cis	rs698833	0.828	rs6748528	chr2:44517752	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	10.63	0.39	2.07e-24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.29	0.44	2.59e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-12.19	-0.43	7.39e-31	Tonsillectomy;
BRCA	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	trans	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg06521331	chr12:34319734	NA	-0.49	-8.88	-0.33	6.67e-18	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg12386194	chr3:101231763	SENP7	-0.48	-9.99	-0.37	5.94e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg12365402	chr11:9010492	NRIP3	-0.37	-8.67	-0.32	3.51e-17	Hemoglobin concentration;
BRCA	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-9.77	-0.36	4.07e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	13.19	0.46	2.74e-35	Colorectal cancer;
BRCA	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg03808351	chr9:123631620	PHF19	0.61	12.65	0.45	6.8e-33	Birth weight;
BRCA	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.9	-0.45	5.34e-34	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10465746	0.967	rs11576870	chr1:84333301	G/A	cg10977910	chr1:84465055	TTLL7	0.5	10.17	0.37	1.29e-22	Obesity-related traits;
BRCA	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg15704280	chr7:45808275	SEPT13	-0.71	-13.41	-0.47	2.65e-36	Coronary artery disease;
BRCA	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.57	10.29	0.38	4.57e-23	Gut microbiome composition (summer);
BRCA	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg00745463	chr17:30367425	LRRC37B	-0.62	-9.88	-0.36	1.64e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	14.19	0.49	6.4e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg01579765	chr21:45077557	HSF2BP	0.33	8.35	0.31	4.28e-16	Mean corpuscular hemoglobin;
BRCA	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg14829155	chr15:31115871	NA	0.43	9.93	0.37	1.03e-21	Huntington's disease progression;
BRCA	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg06937882	chr20:24974362	C20orf3	-0.48	-9.46	-0.35	5.84e-20	Blood protein levels;
BRCA	cis	rs11603020	0.950	rs28362951	chr11:57372526	A/G	cg19752551	chr11:57585705	CTNND1	-0.43	-10.08	-0.37	2.88e-22	Blood protein levels;
BRCA	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg02176678	chr2:219576539	TTLL4	0.43	11.37	0.41	2.12e-27	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg17724175	chr1:150552817	MCL1	0.25	8.19	0.31	1.45e-15	Tonsillectomy;
BRCA	cis	rs7766436	0.767	rs13215709	chr6:22604121	A/G	cg13666174	chr6:22585274	NA	-0.36	-9.38	-0.35	1.16e-19	Coronary artery disease;
BRCA	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg24558204	chr6:135376177	HBS1L	0.59	16.02	0.54	8.77e-49	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg20307385	chr11:47447363	PSMC3	0.4	9.08	0.34	1.39e-18	Subjective well-being;
BRCA	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg22029157	chr1:209979665	IRF6	0.43	8.19	0.31	1.42e-15	Cleft lip with or without cleft palate;
BRCA	cis	rs701145	0.643	rs7647694	chr3:153851535	C/G	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.82e-18	Coronary artery disease;
BRCA	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg23711669	chr6:146136114	FBXO30	0.63	13.84	0.48	2.81e-38	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs312274	0.609	rs1584096	chr12:41200529	C/A	cg17827154	chr12:41323612	CNTN1	0.36	8.71	0.33	2.65e-17	Metabolite levels  (X-11787);
BRCA	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18876405	chr7:65276391	NA	0.62	15.35	0.52	1.6e-45	Aortic root size;
BRCA	cis	rs912057	0.601	rs1294413	chr6:6739924	C/A	cg06612196	chr6:6737390	NA	0.57	13.62	0.47	2.95e-37	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs6684514	1.000	rs12040868	chr1:156284803	G/T	cg16558208	chr1:156270281	VHLL	0.37	8.39	0.32	3.05e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs6782228	0.675	rs9813845	chr3:128399623	G/C	cg16766828	chr3:128327626	NA	-0.41	-9.15	-0.34	7.41e-19	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg01657329	chr11:68192670	LRP5	0.39	8.66	0.32	3.83e-17	Bone mineral density (spine);
BRCA	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg15490075	chr13:100150979	NA	-0.54	-9.67	-0.36	9.74e-21	Obesity-related traits;
BRCA	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg26384229	chr12:38710491	ALG10B	0.74	17.6	0.57	7.83e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26818010	chr10:134567672	INPP5A	-0.71	-14.83	-0.51	5.36e-43	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.67	-0.36	9.51e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg09754948	chr16:28834200	ATXN2L	0.46	9.18	0.34	6.07e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg18132916	chr6:79620363	NA	-0.4	-8.09	-0.3	2.92e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg06784218	chr1:46089804	CCDC17	0.5	12.08	0.43	2.02e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	10.69	0.39	1.17e-24	Motion sickness;
BRCA	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	8.58	0.32	6.96e-17	Rheumatoid arthritis;
BRCA	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg24060327	chr5:131705240	SLC22A5	-0.61	-11.54	-0.42	4.19e-28	Acylcarnitine levels;
BRCA	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.06e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.79	-0.42	3.67e-29	Mean corpuscular volume;
BRCA	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg24642844	chr7:1081250	C7orf50	-0.69	-13.1	-0.46	6.97e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg25214090	chr10:38739885	LOC399744	-0.39	-8.97	-0.33	3.15e-18	Corneal astigmatism;
BRCA	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg10820045	chr2:198174542	NA	-0.46	-10.82	-0.39	3.67e-25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs1865721	0.771	rs7236311	chr18:73137450	A/G	cg26385618	chr18:73139727	C18orf62	-0.43	-10.68	-0.39	1.36e-24	Intelligence;
BRCA	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.68e-18	Motion sickness;
BRCA	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg00105475	chr2:10696890	NA	0.44	10.21	0.37	9.03e-23	Prostate cancer;
BRCA	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg22875332	chr1:76189707	ACADM	0.69	14.76	0.5	1.23e-42	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-9.48	-0.35	4.76e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg26384229	chr12:38710491	ALG10B	0.74	17.19	0.56	9.72e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg01689657	chr7:91764605	CYP51A1	0.23	8.14	0.31	2.07e-15	Breast cancer;
BRCA	cis	rs870825	0.587	rs35377170	chr4:185639728	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.43	0.57	5.93e-56	Blood protein levels;
BRCA	cis	rs701145	0.585	rs1727884	chr3:153838368	A/C	cg17054900	chr3:154042577	DHX36	0.54	9.04	0.34	1.82e-18	Coronary artery disease;
BRCA	trans	rs11976180	1.000	rs2951353	chr7:143761116	G/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.46	-8.43	-0.32	2.37e-16	Obesity-related traits;
BRCA	cis	rs919433	0.617	rs700643	chr2:198601370	A/G	cg00792783	chr2:198669748	PLCL1	0.46	9.99	0.37	6.18e-22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg24692254	chr21:30365293	RNF160	-0.64	-17.58	-0.57	9.87e-57	Dental caries;
BRCA	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10802521	chr3:52805072	NEK4	-0.31	-8.48	-0.32	1.59e-16	Electroencephalogram traits;
BRCA	trans	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg25214090	chr10:38739885	LOC399744	0.51	11.53	0.41	4.57e-28	Corneal astigmatism;
BRCA	trans	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg15704280	chr7:45808275	SEPT13	0.6	8.88	0.33	6.87e-18	Axial length;
BRCA	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg05623727	chr3:50126028	RBM5	0.42	9.84	0.36	2.37e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.62	9.95	0.37	8.58e-22	Renal function-related traits (BUN);
BRCA	cis	rs11887277	0.507	rs1368892	chr2:27054551	A/G	cg12368169	chr2:27073192	DPYSL5	-0.27	-8.06	-0.3	3.73e-15	Obesity-related traits;
BRCA	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg25358565	chr5:93447407	FAM172A	0.69	11.95	0.43	7.36e-30	Diabetic retinopathy;
BRCA	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg20933634	chr6:27740509	NA	-0.48	-9.47	-0.35	5.12e-20	Parkinson's disease;
BRCA	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg14196790	chr5:131705035	SLC22A5	0.42	10.59	0.39	3.01e-24	Blood metabolite levels;
BRCA	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg00814883	chr7:100076585	TSC22D4	-0.52	-11.92	-0.43	1.04e-29	Platelet count;
BRCA	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	14.07	0.49	2.35e-39	Hip circumference adjusted for BMI;
BRCA	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg03425785	chr20:62221387	GMEB2	0.51	8.25	0.31	8.77e-16	Glioblastoma;
BRCA	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.61	0.39	2.38e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg20203395	chr5:56204925	C5orf35	-0.5	-10.11	-0.37	2.13e-22	Initial pursuit acceleration;
BRCA	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg00012203	chr2:219082015	ARPC2	-0.52	-10.51	-0.38	6.09e-24	Pyoderma gangrenosum in inflammatory bowel disease;
BRCA	cis	rs11690935	0.921	rs7594711	chr2:172895637	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.9	-25.88	-0.72	1.55e-101	Schizophrenia;
BRCA	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg08975724	chr8:8085496	FLJ10661	0.43	8.04	0.3	4.22e-15	Retinal vascular caliber;
BRCA	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.98	-0.48	6.13e-39	Extrinsic epigenetic age acceleration;
BRCA	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	13.91	0.48	1.3e-38	Lymphocyte counts;
BRCA	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg12011299	chr4:100065546	ADH4	0.42	10.52	0.38	5.65e-24	Alcohol dependence;
BRCA	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11644478	chr21:40555479	PSMG1	-0.68	-15.56	-0.52	1.65e-46	Cognitive function;
BRCA	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg05283184	chr6:79620031	NA	-0.41	-10.49	-0.38	7.56e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg11822812	chr5:140052017	DND1	-0.32	-8.69	-0.33	3.01e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg12386194	chr3:101231763	SENP7	0.46	9.88	0.36	1.6e-21	Colorectal cancer;
BRCA	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.47	8.13	0.31	2.26e-15	Mean platelet volume;
BRCA	cis	rs12986413	1.000	rs12459350	chr19:2176586	A/G	cg09261902	chr19:2140048	AP3D1	0.39	10.2	0.37	9.68e-23	Height;
BRCA	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg14582100	chr15:45693742	SPATA5L1	0.36	11.49	0.41	6.44e-28	Homoarginine levels;
BRCA	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg18279126	chr7:2041391	MAD1L1	0.37	8.02	0.3	5.24e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	16.9	0.56	2.9e-53	Alzheimer's disease;
BRCA	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg08000102	chr2:233561755	GIGYF2	0.63	14.03	0.49	3.74e-39	Coronary artery disease;
BRCA	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg00677455	chr12:58241039	CTDSP2	0.63	15.75	0.53	1.84e-47	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg03188948	chr7:1209495	NA	0.68	11.55	0.42	3.6e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs812925	0.519	rs10199672	chr2:61627634	T/G	cg15711740	chr2:61764176	XPO1	0.32	8.01	0.3	5.31e-15	Immature fraction of reticulocytes;
BRCA	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	8.35	0.31	4.12e-16	Iron status biomarkers;
BRCA	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2882667	0.598	rs10078179	chr5:138256099	G/C	cg04439458	chr5:138467593	SIL1	-0.31	-7.83	-0.3	2.08e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg12011299	chr4:100065546	ADH4	0.51	11.78	0.42	4.02e-29	Alcohol dependence;
BRCA	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg08859206	chr1:53392774	SCP2	-0.4	-7.83	-0.3	2.1e-14	Monocyte count;
BRCA	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12756686	chr19:29218302	NA	0.6	12.4	0.44	8.6e-32	Methadone dose in opioid dependence;
BRCA	cis	rs7091068	0.707	rs829107	chr10:95418102	C/T	cg20715218	chr10:95462985	C10orf4	-0.52	-7.91	-0.3	1.12e-14	Urinary tract infection frequency;
BRCA	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg22875332	chr1:76189707	ACADM	-0.54	-10.17	-0.37	1.32e-22	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.19	-0.43	7.27e-31	Breast cancer;
BRCA	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg04414720	chr1:150670196	GOLPH3L	0.37	8.44	0.32	2.06e-16	Urate levels;
BRCA	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	9.82	0.36	2.67e-21	Sum eosinophil basophil counts;Eosinophil counts;
BRCA	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg08422745	chr4:174089978	GALNT7	-0.75	-15.34	-0.52	1.81e-45	Dementia and core Alzheimer's disease neuropathologic changes;
BRCA	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg04362960	chr10:104952993	NT5C2	0.43	9.74	0.36	5.33e-21	Arsenic metabolism;
BRCA	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg06212747	chr3:49208901	KLHDC8B	0.54	11.59	0.42	2.64e-28	Menarche (age at onset);
BRCA	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg02743256	chr7:2109353	MAD1L1	-0.45	-8.4	-0.32	2.8e-16	Bipolar disorder;
BRCA	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg14582100	chr15:45693742	SPATA5L1	0.36	11.54	0.42	4.09e-28	Homoarginine levels;
BRCA	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.32	-7.94	-0.3	9.18e-15	Total body bone mineral density;
BRCA	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg18232548	chr7:50535776	DDC	-0.51	-12.65	-0.45	6.79e-33	Systemic sclerosis;
BRCA	cis	rs13064411	0.542	rs2399477	chr3:113222998	A/G	cg18753928	chr3:113234510	CCDC52	-0.45	-9.69	-0.36	8.07e-21	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg23950597	chr19:37808831	NA	-0.63	-10.94	-0.4	1.15e-25	Coronary artery calcification;
BRCA	cis	rs16866061	1.000	rs72972378	chr2:225372562	A/G	cg12698349	chr2:225449008	CUL3	0.77	21.11	0.64	1.92e-75	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg18230493	chr5:56204884	C5orf35	-0.4	-8.06	-0.3	3.86e-15	Coronary artery disease;
BRCA	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg04944784	chr2:26401820	FAM59B	0.98	14.38	0.49	7.93e-41	Gut microbiome composition (summer);
BRCA	cis	rs733592	0.894	rs886589	chr12:48477197	C/T	cg24011408	chr12:48396354	COL2A1	-0.45	-9.72	-0.36	6.38e-21	Plateletcrit;
BRCA	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg23711669	chr6:146136114	FBXO30	0.71	17.08	0.56	3.5e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs911555	0.547	rs8006994	chr14:103841296	C/T	cg12935359	chr14:103987150	CKB	-0.5	-10.68	-0.39	1.31e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg23982607	chr1:1823379	GNB1	0.34	8.24	0.31	1.01e-15	Body mass index;
BRCA	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg13628971	chr7:2884303	GNA12	0.45	9.01	0.34	2.42e-18	Height;
BRCA	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg03433033	chr1:76189801	ACADM	0.75	16.43	0.55	7.14e-51	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg03213289	chr20:61660250	NA	0.62	16.18	0.54	1.29e-49	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4363385	0.747	rs1413849	chr1:152970233	C/A	cg24667326	chr1:152973720	SPRR3	-0.34	-9.36	-0.35	1.36e-19	Inflammatory skin disease;
BRCA	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg05347473	chr6:146136440	FBXO30	0.43	8.55	0.32	8.98e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg07308232	chr7:1071921	C7orf50	-0.5	-10.57	-0.39	3.71e-24	Longevity;Endometriosis;
BRCA	trans	rs3858145	0.588	rs736535	chr10:70043916	G/A	cg04882175	chr6:131122610	NA	-0.34	-7.85	-0.3	1.74e-14	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
BRCA	cis	rs782590	0.870	rs2586950	chr2:55868966	T/G	cg18811423	chr2:55921094	PNPT1	0.68	20.03	0.62	1.19e-69	Metabolic syndrome;
BRCA	cis	rs4363385	0.747	rs1984198	chr1:152958584	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.78	-0.33	1.54e-17	Inflammatory skin disease;
BRCA	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg07741184	chr6:167504864	NA	0.27	7.96	0.3	7.76e-15	Crohn's disease;
BRCA	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.82	-0.36	2.67e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1030877	0.960	rs3792049	chr2:105901908	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.66	-15.75	-0.53	1.72e-47	Obesity-related traits;
BRCA	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg08807101	chr21:30365312	RNF160	-0.39	-8.3	-0.31	5.97e-16	Pancreatic cancer;
BRCA	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg14829155	chr15:31115871	NA	-0.42	-9.67	-0.36	9.95e-21	Huntington's disease progression;
BRCA	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg03711944	chr11:47377212	SPI1	-0.39	-9.25	-0.34	3.28e-19	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg00376283	chr12:123451042	ABCB9	0.51	11.17	0.4	1.36e-26	Neutrophil percentage of white cells;
BRCA	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg11266682	chr4:10021025	SLC2A9	-0.38	-9.93	-0.37	1.02e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.37	-7.83	-0.3	2.02e-14	Longevity;Endometriosis;
BRCA	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg10978503	chr1:24200527	CNR2	-0.43	-9.48	-0.35	5.04e-20	Immature fraction of reticulocytes;
BRCA	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg08601574	chr20:25228251	PYGB	0.37	8.89	0.33	6.14e-18	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg25358565	chr5:93447407	FAM172A	1.16	18.84	0.6	2.51e-63	Diabetic retinopathy;
BRCA	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg22907277	chr7:1156413	C7orf50	0.6	9.01	0.34	2.28e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-13.89	-0.48	1.61e-38	Blood metabolite levels;
BRCA	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg12826209	chr6:26865740	GUSBL1	0.64	8.39	0.31	3.22e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg03060546	chr3:49711283	APEH	-0.59	-11.93	-0.43	9.23e-30	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs1973993	0.691	rs553785	chr1:96895325	G/A	cg10631902	chr5:14652156	NA	0.59	21.2	0.64	6.24e-76	Weight;
BRCA	cis	rs4664304	0.620	rs4665125	chr2:160714314	C/G	cg18514922	chr2:160761262	LY75	0.34	7.84	0.3	1.94e-14	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg06623918	chr6:96969491	KIAA0776	0.74	13.05	0.46	1.17e-34	Migraine;Coronary artery disease;
BRCA	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-10.15	-0.37	1.52e-22	Body mass index;
BRCA	trans	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-10.39	-0.38	1.75e-23	Blood trace element (Cu levels);
BRCA	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg02659138	chr7:134003124	SLC35B4	0.4	11.58	0.42	2.86e-28	Mean platelet volume;
BRCA	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg18904891	chr8:8559673	CLDN23	0.59	11.5	0.41	5.78e-28	Obesity-related traits;
BRCA	trans	rs3960554	0.808	rs4728587	chr7:75803132	C/T	cg19862616	chr7:65841803	NCRNA00174	0.59	11.91	0.43	1.13e-29	Eotaxin levels;
BRCA	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg03433033	chr1:76189801	ACADM	-0.49	-10.34	-0.38	2.72e-23	Daytime sleep phenotypes;
BRCA	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	18.24	0.59	3.77e-60	Platelet count;
BRCA	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.6	13.7	0.48	1.26e-37	Eosinophil percentage of white cells;
BRCA	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg05347473	chr6:146136440	FBXO30	0.41	7.97	0.3	7.18e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg17063962	chr7:91808500	NA	0.54	12.71	0.45	3.83e-33	Breast cancer;
BRCA	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg18964960	chr10:1102726	WDR37	0.59	8.0	0.3	5.81e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs2249625	0.874	rs2463745	chr6:72876135	A/G	cg18830697	chr6:72922368	RIMS1	-0.37	-8.0	-0.3	5.84e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg09455208	chr3:40491958	NA	-0.48	-11.9	-0.43	1.25e-29	Renal cell carcinoma;
BRCA	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg01884057	chr2:25150051	NA	0.32	8.45	0.32	2.01e-16	Body mass index;
BRCA	cis	rs6460942	0.915	rs10488158	chr7:12508894	C/T	cg06484146	chr7:12443880	VWDE	-0.74	-10.35	-0.38	2.64e-23	Coronary artery disease;
BRCA	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	9.84	0.36	2.36e-21	Bipolar disorder;
BRCA	cis	rs534126	0.778	rs6464540	chr7:142954903	G/A	cg21852589	chr7:142981689	TMEM139	0.44	10.06	0.37	3.23e-22	Cancer;
BRCA	trans	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.9	0.3	1.22e-14	Corneal astigmatism;
BRCA	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg00666640	chr1:248458726	OR2T12	0.32	8.83	0.33	9.7e-18	Common traits (Other);
BRCA	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	17.99	0.58	7.86e-59	Platelet count;
BRCA	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11644478	chr21:40555479	PSMG1	0.82	18.77	0.6	6.19e-63	Cognitive function;
BRCA	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-11.63	-0.42	1.67e-28	Morning vs. evening chronotype;
BRCA	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg06115741	chr20:33292138	TP53INP2	-0.39	-8.54	-0.32	9.69e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg22535103	chr8:58192502	C8orf71	-0.46	-9.04	-0.34	1.87e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg06521331	chr12:34319734	NA	-0.52	-10.29	-0.38	4.53e-23	Morning vs. evening chronotype;
BRCA	cis	rs7011049	1.000	rs72640849	chr8:53836430	A/T	cg26025543	chr8:53854495	NA	0.55	9.76	0.36	4.4e-21	Systolic blood pressure;
BRCA	trans	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.66	-0.36	1.07e-20	Bladder cancer;
BRCA	cis	rs6981523	0.553	rs11989369	chr8:11055385	A/G	cg21775007	chr8:11205619	TDH	0.46	8.48	0.32	1.51e-16	Neuroticism;
BRCA	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg03433033	chr1:76189801	ACADM	0.73	18.53	0.59	1.16e-61	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.47	8.36	0.31	4.07e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg22875332	chr1:76189707	ACADM	0.69	14.74	0.5	1.58e-42	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg17173187	chr15:85201210	NMB	0.42	8.85	0.33	8.83e-18	Schizophrenia;
BRCA	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg09307838	chr4:120376055	NA	0.72	15.18	0.51	1.14e-44	Corneal astigmatism;
BRCA	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.2	0.49	5.6e-40	Motion sickness;
BRCA	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-8.05	-0.3	3.94e-15	Axial length;
BRCA	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg05457628	chr5:178986728	RUFY1	0.53	11.94	0.43	8.53e-30	Lung cancer;
BRCA	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg09526685	chr4:187126073	CYP4V2	0.89	10.08	0.37	2.77e-22	Blood protein levels;
BRCA	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.34	-0.38	2.7e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6910061	0.956	rs9468419	chr6:11102576	T/C	cg27233058	chr6:11094804	LOC221710	0.53	9.36	0.35	1.33e-19	Diabetic kidney disease;
BRCA	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	14.38	0.49	8.14e-41	Colorectal cancer;
BRCA	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23583168	chr7:148888333	NA	-0.75	-17.46	-0.57	3.96e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.42	0.47	2.35e-36	Colorectal cancer;
BRCA	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg06238570	chr21:40685208	BRWD1	-0.39	-7.88	-0.3	1.47e-14	Menarche (age at onset);
BRCA	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg21138405	chr5:131827807	IRF1	0.4	12.97	0.46	2.5e-34	Asthma (sex interaction);
BRCA	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg05868516	chr6:26286170	HIST1H4H	0.43	8.87	0.33	7.16e-18	Educational attainment;
BRCA	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg10523679	chr1:76189770	ACADM	0.62	10.83	0.39	3.39e-25	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs11229555	0.645	rs12290089	chr11:58176849	A/G	cg15696309	chr11:58395628	NA	-0.45	-9.77	-0.36	4.3e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.49	10.4	0.38	1.69e-23	Height;
BRCA	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg26384229	chr12:38710491	ALG10B	0.52	10.93	0.4	1.33e-25	Resting heart rate;
BRCA	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg17330251	chr7:94953956	PON1	-0.41	-8.58	-0.32	7.06e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs4919087	0.892	rs10786319	chr10:99008951	T/C	cg25902810	chr10:99078978	FRAT1	0.37	8.08	0.3	3.25e-15	Monocyte count;
BRCA	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg14458575	chr2:238380390	NA	0.54	8.64	0.32	4.4e-17	Prostate cancer;
BRCA	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg13010199	chr12:38710504	ALG10B	-0.36	-7.83	-0.3	2.1e-14	Morning vs. evening chronotype;
BRCA	cis	rs829883	0.932	rs249840	chr12:98871993	T/C	cg25150519	chr12:98850993	NA	0.58	11.84	0.42	2.14e-29	Colorectal adenoma (advanced);
BRCA	trans	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg06521331	chr12:34319734	NA	-0.51	-9.4	-0.35	9.41e-20	Bladder cancer;
BRCA	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg17127132	chr2:85788382	GGCX	0.36	8.11	0.31	2.51e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg08601574	chr20:25228251	PYGB	0.35	8.47	0.32	1.74e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg09436375	chr6:42928200	GNMT	-0.3	-10.99	-0.4	7.32e-26	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg24829409	chr8:58192753	C8orf71	-0.53	-11.02	-0.4	5.69e-26	Developmental language disorder (linguistic errors);
BRCA	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg26384229	chr12:38710491	ALG10B	0.68	14.28	0.49	2.34e-40	Morning vs. evening chronotype;
BRCA	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.29	0.31	6.45e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs17023223	0.508	rs12096448	chr1:119683390	G/A	cg05756136	chr1:119680316	WARS2	-0.41	-7.81	-0.3	2.31e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	19.86	0.62	9.79e-69	Smoking behavior;
BRCA	cis	rs2835872	0.869	rs73203821	chr21:39046744	C/T	cg06728970	chr21:39037746	KCNJ6	-0.34	-8.29	-0.31	6.72e-16	Electroencephalographic traits in alcoholism;
BRCA	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg08027265	chr7:2291960	NA	-0.37	-8.52	-0.32	1.14e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs7827545	1.000	rs6578232	chr8:135565690	G/A	cg17885191	chr8:135476712	NA	0.47	9.19	0.34	5.3e-19	Hypertension (SNP x SNP interaction);
BRCA	cis	rs5771069	0.896	rs137862	chr22:50446550	C/A	cg03721641	chr22:50451245	IL17REL	0.32	9.91	0.37	1.24e-21	Ulcerative colitis;
BRCA	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18876405	chr7:65276391	NA	-0.7	-17.96	-0.58	1.05e-58	Aortic root size;
BRCA	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg21573476	chr21:45109991	RRP1B	0.3	7.83	0.3	2e-14	Mean corpuscular volume;
BRCA	trans	rs75804782	0.521	rs72993044	chr2:239397949	C/T	cg01134436	chr17:81009848	B3GNTL1	0.69	8.75	0.33	1.91e-17	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg16325326	chr1:53192061	ZYG11B	-0.65	-16.23	-0.54	7.41e-50	Monocyte count;
BRCA	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg24558204	chr6:135376177	HBS1L	0.43	11.91	0.43	1.11e-29	Red blood cell count;
BRCA	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg24642439	chr20:33292090	TP53INP2	0.42	8.99	0.34	2.82e-18	Height;
BRCA	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg01028140	chr2:1542097	TPO	-0.57	-12.03	-0.43	3.57e-30	IgG glycosylation;
BRCA	trans	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.78	-0.33	1.47e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg04450456	chr4:17643702	FAM184B	0.33	9.61	0.36	1.68e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26314531	chr2:26401878	FAM59B	-0.66	-11.25	-0.41	6.5e-27	Gut microbiome composition (summer);
BRCA	cis	rs2964802	0.505	rs13159419	chr5:10824302	C/A	cg14521931	chr5:10832172	NA	-0.58	-12.7	-0.45	4.12e-33	Major depressive disorder;Recurrent major depressive disorder;
BRCA	cis	rs11051970	0.704	rs2733694	chr12:32555230	A/G	cg02745156	chr12:32552066	NA	0.25	8.49	0.32	1.48e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg24829409	chr8:58192753	C8orf71	-0.42	-8.54	-0.32	9.73e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.51	-11.28	-0.41	5.09e-27	Longevity;Endometriosis;
BRCA	cis	rs72772090	0.539	rs11738810	chr5:96119055	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-12.18	-0.43	7.64e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg21747090	chr2:27597821	SNX17	-0.43	-9.43	-0.35	7.24e-20	Total body bone mineral density;
BRCA	cis	rs11971779	0.688	rs1862880	chr7:139020100	T/C	cg07862535	chr7:139043722	LUC7L2	0.44	11.62	0.42	1.81e-28	Diisocyanate-induced asthma;
BRCA	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg24829409	chr8:58192753	C8orf71	-0.6	-12.52	-0.44	2.53e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs7178424	1.000	rs11635977	chr15:62370484	T/C	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.2	-0.31	1.29e-15	Height;
BRCA	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg20203395	chr5:56204925	C5orf35	-0.51	-10.71	-0.39	1.02e-24	Initial pursuit acceleration;
BRCA	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-9.56	-0.35	2.42e-20	Height;
BRCA	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg23649088	chr2:200775458	C2orf69	-0.42	-9.06	-0.34	1.58e-18	QT interval;
BRCA	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	19.61	0.61	2.24e-67	Platelet count;
BRCA	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg21770322	chr7:97807741	LMTK2	0.45	11.92	0.43	9.83e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7264396	0.623	rs2425127	chr20:34332037	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.16	-0.43	9.24e-31	Total cholesterol levels;
BRCA	cis	rs9463078	0.774	rs9296457	chr6:45264687	A/G	cg25276700	chr6:44698697	NA	-0.36	-8.03	-0.3	4.54e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg08807101	chr21:30365312	RNF160	0.57	12.35	0.44	1.46e-31	Selective IgA deficiency;
BRCA	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-13.64	-0.47	2.21e-37	Morning vs. evening chronotype;
BRCA	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	14.36	0.49	9.66e-41	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg21770322	chr7:97807741	LMTK2	0.66	19.85	0.62	1.18e-68	Breast cancer;
BRCA	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg18252515	chr7:66147081	NA	-1.07	-15.92	-0.53	2.69e-48	Diabetic kidney disease;
BRCA	cis	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-8.47	-0.32	1.74e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg25554036	chr4:6271136	WFS1	0.42	9.99	0.37	6.36e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg02403541	chr12:121454288	C12orf43	0.53	9.98	0.37	7.06e-22	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
BRCA	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg21361702	chr7:150065534	REPIN1	-0.5	-10.39	-0.38	1.73e-23	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs910873	0.505	rs6087607	chr20:33197489	A/G	cg16810054	chr20:33298113	TP53INP2	-0.49	-10.52	-0.38	5.51e-24	Melanoma;
BRCA	cis	rs7640424	0.620	rs34910554	chr3:107816733	C/T	cg09227934	chr3:107805635	CD47	-0.43	-8.14	-0.31	2.08e-15	Body mass index;
BRCA	trans	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg13565492	chr6:43139072	SRF	-0.79	-10.98	-0.4	8.18e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg15556689	chr8:8085844	FLJ10661	-0.42	-11.61	-0.42	2.16e-28	Mood instability;
BRCA	cis	rs11920090	0.932	rs2292620	chr3:170724036	T/C	cg09710316	chr3:170744871	SLC2A2	0.55	9.6	0.35	1.8e-20	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg01689657	chr7:91764605	CYP51A1	0.23	8.15	0.31	1.89e-15	Breast cancer;
BRCA	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.56	-0.52	1.55e-46	Chronic sinus infection;
BRCA	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg12863693	chr15:85201151	NMB	0.57	12.39	0.44	9.96e-32	Schizophrenia;
BRCA	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.14	-0.31	2.1e-15	Depression;
BRCA	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg10729496	chr3:10149963	C3orf24	0.48	9.0	0.34	2.49e-18	Alzheimer's disease;
BRCA	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg14004847	chr7:1930337	MAD1L1	0.46	9.96	0.37	7.96e-22	Bipolar disorder and schizophrenia;
BRCA	trans	rs783540	0.934	rs36109438	chr15:83264459	T/G	cg18393722	chr15:85113863	UBE2QP1	-0.26	-8.2	-0.31	1.37e-15	Schizophrenia;
BRCA	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg04166393	chr7:2884313	GNA12	0.39	8.46	0.32	1.8e-16	Height;
BRCA	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-13.45	-0.47	1.66e-36	Personality dimensions;
BRCA	cis	rs13046373	0.505	rs2832962	chr21:32008332	T/C	cg06468780	chr21:31798236	KRTAP13-3	0.34	8.29	0.31	6.81e-16	HDL cholesterol;
BRCA	cis	rs881375	0.967	rs1548783	chr9:123658639	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.21	0.31	1.2e-15	Rheumatoid arthritis;
BRCA	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg01528321	chr10:82214614	TSPAN14	0.81	17.1	0.56	2.94e-54	Post bronchodilator FEV1;
BRCA	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg16606324	chr3:10149918	C3orf24	0.55	10.85	0.39	2.84e-25	Alzheimer's disease;
BRCA	cis	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg00852783	chr1:26633632	UBXN11	-0.46	-8.09	-0.3	2.9e-15	Obesity-related traits;
BRCA	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg11663144	chr21:46675770	NA	-0.62	-14.84	-0.51	5.12e-43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg25319279	chr11:5960081	NA	0.48	10.46	0.38	9.97e-24	DNA methylation (variation);
BRCA	cis	rs919433	0.617	rs13018267	chr2:198545592	G/C	cg00792783	chr2:198669748	PLCL1	-0.45	-9.75	-0.36	4.88e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg00012203	chr2:219082015	ARPC2	-0.42	-8.13	-0.31	2.2e-15	Ulcerative colitis;
BRCA	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	11.91	0.43	1.13e-29	Height;
BRCA	trans	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	13.45	0.47	1.78e-36	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-7.96	-0.3	8.12e-15	Homocysteine levels;
BRCA	cis	rs672059	1.000	rs1760624	chr1:183158552	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.37	8.56	0.32	8.26e-17	Hypertriglyceridemia;
BRCA	cis	rs7903847	0.642	rs11814021	chr10:99158386	A/G	cg20016023	chr10:99160130	RRP12	-0.26	-8.32	-0.31	5.39e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg18279126	chr7:2041391	MAD1L1	0.38	7.92	0.3	1.06e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs10848704	0.956	rs10848703	chr12:2882250	C/T	cg19995117	chr12:2880862	NA	0.47	11.26	0.41	5.99e-27	Quantitative traits;
BRCA	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg23649088	chr2:200775458	C2orf69	0.6	8.94	0.33	4.14e-18	Schizophrenia;
BRCA	cis	rs312273	0.806	rs10879396	chr12:41340667	A/G	cg17827154	chr12:41323612	CNTN1	-0.43	-11.15	-0.4	1.63e-26	Bipolar disorder;
BRCA	cis	rs775227	0.574	rs36108475	chr3:113038406	C/T	cg18753928	chr3:113234510	CCDC52	-0.57	-9.49	-0.35	4.41e-20	Dental caries;
BRCA	trans	rs637571	0.565	rs633800	chr11:65638719	G/A	cg17712092	chr4:129076599	LARP1B	-0.6	-13.95	-0.48	8.5e-39	Eosinophil percentage of white cells;
BRCA	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg06671706	chr8:8559999	CLDN23	0.45	8.76	0.33	1.75e-17	Obesity-related traits;
BRCA	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	trans	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg26384229	chr12:38710491	ALG10B	0.57	12.26	0.44	3.38e-31	Morning vs. evening chronotype;
BRCA	cis	rs2882667	0.690	rs10044401	chr5:138237557	A/G	cg04439458	chr5:138467593	SIL1	-0.34	-8.36	-0.31	4.05e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10501293	0.917	rs10838003	chr11:43071988	T/A	cg03447554	chr11:43094025	NA	0.45	8.6	0.32	6.32e-17	Cognitive performance;
BRCA	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.89	0.36	1.53e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22590775	chr19:49891494	CCDC155	0.47	8.27	0.31	7.62e-16	Multiple sclerosis;
BRCA	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg27446573	chr6:127587934	RNF146	0.9	21.24	0.64	3.9e-76	Breast cancer;
BRCA	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg24848339	chr3:12840334	CAND2	0.46	12.16	0.43	9.6e-31	QRS complex (12-leadsum);
BRCA	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.91	-0.3	1.15e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11102986	0.607	rs10776909	chr9:137288746	T/C	cg00753924	chr9:137298813	RXRA	-0.59	-9.84	-0.36	2.23e-21	Intelligence;
BRCA	cis	rs9644630	1.000	rs9644631	chr8:19370830	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.4	9.26	0.34	2.99e-19	Oropharynx cancer;
BRCA	cis	rs778371	0.676	rs7560115	chr2:233709465	T/G	cg08000102	chr2:233561755	GIGYF2	-0.77	-16.3	-0.54	3.3e-50	Schizophrenia;
BRCA	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	11.24	0.41	7.45e-27	IgG glycosylation;
BRCA	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg26597838	chr10:835615	NA	0.93	14.38	0.49	7.94e-41	Eosinophil percentage of granulocytes;
BRCA	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg03609598	chr5:56110824	MAP3K1	-0.47	-7.93	-0.3	9.55e-15	Initial pursuit acceleration;
BRCA	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg23950597	chr19:37808831	NA	-0.62	-11.59	-0.42	2.48e-28	Coronary artery calcification;
BRCA	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg18196295	chr10:418757	DIP2C	-0.5	-11.27	-0.41	5.44e-27	Psychosis in Alzheimer's disease;
BRCA	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg08888203	chr3:10149979	C3orf24	0.62	12.78	0.45	1.79e-33	Alzheimer's disease;
BRCA	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg12437481	chr16:420112	MRPL28	-0.56	-11.32	-0.41	3.44e-27	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs758324	0.648	rs31473	chr5:131404446	A/T	cg06307176	chr5:131281290	NA	-0.38	-8.23	-0.31	1.09e-15	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs698833	0.962	rs786406	chr2:44735953	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.49	-9.61	-0.36	1.64e-20	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs13102973	0.829	rs13126756	chr4:135900185	G/A	cg14419869	chr4:135874104	NA	0.47	9.47	0.35	5.45e-20	Subjective well-being;
BRCA	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg18867708	chr6:26865862	GUSBL1	0.42	8.24	0.31	9.97e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9309711	0.772	rs9309715	chr2:3492318	C/G	cg16153549	chr2:3496821	NA	0.43	10.13	0.37	1.85e-22	Neurofibrillary tangles;
BRCA	cis	rs1499972	0.941	rs62264766	chr3:117641227	A/G	cg07612923	chr3:117604196	NA	0.6	8.1	0.31	2.82e-15	Schizophrenia;
BRCA	cis	rs6545883	0.894	rs4672423	chr2:61435275	C/T	cg15711740	chr2:61764176	XPO1	0.52	13.21	0.46	2.17e-35	Tuberculosis;
BRCA	trans	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg25214090	chr10:38739885	LOC399744	0.42	9.85	0.36	2.11e-21	Corneal astigmatism;
BRCA	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg20607798	chr8:58055168	NA	0.47	8.26	0.31	8.19e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-8.69	-0.33	2.93e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg20503657	chr10:835505	NA	1.04	18.24	0.59	3.93e-60	Eosinophil percentage of granulocytes;
BRCA	cis	rs13082711	0.911	rs923940	chr3:27459341	C/G	cg02860705	chr3:27208620	NA	0.51	9.99	0.37	6.32e-22	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg06636001	chr8:8085503	FLJ10661	0.68	15.58	0.52	1.22e-46	Mood instability;
BRCA	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg05863683	chr7:1912471	MAD1L1	0.37	8.3	0.31	6.18e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg13660082	chr14:53194042	PSMC6	0.54	8.67	0.32	3.58e-17	Alzheimer's disease (late onset);
BRCA	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.34	7.95	0.3	8.64e-15	Coronary artery disease;
BRCA	cis	rs72772090	0.522	rs111977797	chr5:96016167	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-8.12	-0.31	2.41e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs113835537	0.529	rs74869459	chr11:66296569	T/C	cg24851651	chr11:66362959	CCS	0.47	8.82	0.33	1.1e-17	Airway imaging phenotypes;
BRCA	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg14458575	chr2:238380390	NA	0.59	13.46	0.47	1.55e-36	Prostate cancer;
BRCA	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.89e-18	Motion sickness;
BRCA	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg01620082	chr3:125678407	NA	-0.98	-11.27	-0.41	5.59e-27	Depression;
BRCA	cis	rs7646881	0.812	rs59192661	chr3:158459027	T/C	cg19483011	chr3:158453295	NA	-0.45	-7.95	-0.3	8.22e-15	Tetralogy of Fallot;
BRCA	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg22980127	chr19:33182716	NUDT19	0.9	17.6	0.57	7.68e-57	Red blood cell traits;
BRCA	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-9.53	-0.35	3.1e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs68170813	0.559	rs9641378	chr7:106868003	T/C	cg02696742	chr7:106810147	HBP1	-0.51	-8.51	-0.32	1.28e-16	Coronary artery disease;
BRCA	cis	rs6495367	1.000	rs4778882	chr15:79382019	A/G	cg17916960	chr15:79447300	NA	0.38	9.07	0.34	1.4e-18	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs72772090	0.710	rs17400741	chr5:96066576	C/G	cg24982541	chr5:96078678	CAST	-0.46	-7.94	-0.3	9.29e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg12935359	chr14:103987150	CKB	0.65	15.04	0.51	5.37e-44	Intelligence (multi-trait analysis);
BRCA	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05901451	chr6:126070800	HEY2	-0.69	-19.23	-0.61	2.23e-65	Brugada syndrome;
BRCA	cis	rs2625529	0.652	rs2929525	chr15:72287856	G/A	cg16672083	chr15:72433130	SENP8	0.7	16.71	0.55	2.89e-52	Red blood cell count;
BRCA	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg11843238	chr5:131593191	PDLIM4	-0.4	-9.82	-0.36	2.63e-21	Acylcarnitine levels;
BRCA	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	18.28	0.59	2.39e-60	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs312274	0.609	rs10879259	chr12:41222390	A/G	cg17827154	chr12:41323612	CNTN1	0.38	9.29	0.35	2.32e-19	Metabolite levels  (X-11787);
BRCA	cis	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg06521331	chr12:34319734	NA	-0.52	-10.27	-0.38	5.25e-23	Morning vs. evening chronotype;
BRCA	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg20307385	chr11:47447363	PSMC3	-0.45	-9.02	-0.34	2.13e-18	Subjective well-being;
BRCA	cis	rs61990749	0.500	rs8011337	chr14:78272626	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.67	10.47	0.38	8.51e-24	Fibroblast growth factor basic levels;
BRCA	cis	rs2066819	1.000	rs11171803	chr12:56718422	T/C	cg26734620	chr12:56694298	CS	0.9	10.37	0.38	2.09e-23	Psoriasis vulgaris;
BRCA	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.08	0.62	6.44e-70	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg26384229	chr12:38710491	ALG10B	0.66	13.9	0.48	1.49e-38	Morning vs. evening chronotype;
BRCA	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg16230307	chr14:35515116	FAM177A1	0.67	13.99	0.48	5.68e-39	Psoriasis;
BRCA	trans	rs11165623	0.564	rs9887887	chr1:96996930	A/G	cg10631902	chr5:14652156	NA	-0.43	-12.06	-0.43	2.43e-30	Hip circumference;Waist circumference;
BRCA	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg02753203	chr1:228287806	NA	-0.6	-13.03	-0.46	1.4e-34	Diastolic blood pressure;
BRCA	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05890377	chr2:74357713	NA	0.57	11.76	0.42	4.9e-29	Gestational age at birth (maternal effect);
BRCA	trans	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg11693508	chr17:37793320	STARD3	0.42	8.82	0.33	1.11e-17	Bipolar disorder;
BRCA	cis	rs701145	0.585	rs7612886	chr3:153821176	T/A	cg17054900	chr3:154042577	DHX36	0.53	9.04	0.34	1.88e-18	Coronary artery disease;
BRCA	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22307029	chr19:49891270	CCDC155	0.5	9.18	0.34	6.11e-19	Multiple sclerosis;
BRCA	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg07741184	chr6:167504864	NA	0.36	10.37	0.38	2.2e-23	Crohn's disease;
BRCA	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.68	16.31	0.54	2.98e-50	Ileal carcinoids;
BRCA	cis	rs10845606	0.781	rs7972866	chr12:12828320	C/T	cg04607235	chr12:12878440	APOLD1	-0.44	-7.94	-0.3	9.34e-15	Systemic lupus erythematosus;
BRCA	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.71	11.32	0.41	3.49e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11764359	chr7:65958608	NA	-0.8	-19.12	-0.6	8.59e-65	Aortic root size;
BRCA	cis	rs7590368	1.000	rs2884289	chr2:10959724	G/A	cg15705551	chr2:10952987	PDIA6	0.44	8.14	0.31	2.02e-15	Educational attainment (years of education);
BRCA	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg15819921	chr19:927150	ARID3A	-0.52	-9.64	-0.36	1.26e-20	Life satisfaction;
BRCA	cis	rs7043114	0.525	rs7047089	chr9:95117980	C/T	cg14631576	chr9:95140430	CENPP	-0.34	-8.33	-0.31	4.92e-16	Height;
BRCA	cis	rs2731664	0.792	rs163199	chr5:176890067	A/G	cg23176889	chr5:176863531	GRK6	-0.62	-17.03	-0.56	6.51e-54	Intelligence (multi-trait analysis);
BRCA	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-9.02	-0.34	2.13e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg25214090	chr10:38739885	LOC399744	0.55	12.62	0.45	8.93e-33	Corneal astigmatism;
BRCA	cis	rs7520050	0.966	rs6661910	chr1:46290632	A/T	cg24296786	chr1:45957014	TESK2	0.43	9.77	0.36	4.07e-21	Red blood cell count;Reticulocyte count;
BRCA	trans	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg05926928	chr17:57297772	GDPD1	-0.66	-9.83	-0.36	2.49e-21	Opioid sensitivity;
BRCA	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg22800045	chr5:56110881	MAP3K1	0.67	12.82	0.45	1.22e-33	Initial pursuit acceleration;
BRCA	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg03351412	chr1:154909251	PMVK	0.6	13.88	0.48	1.72e-38	Prostate cancer;
BRCA	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.32	0.31	5.44e-16	Rheumatoid arthritis;
BRCA	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg14019146	chr3:50243930	SLC38A3	-0.4	-9.85	-0.36	2.18e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs3892630	0.620	rs10413279	chr19:33182746	A/G	cg22980127	chr19:33182716	NUDT19	0.97	23.7	0.68	1.39e-89	Red blood cell traits;
BRCA	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg16586182	chr3:47516702	SCAP	0.65	15.04	0.51	5.26e-44	Colorectal cancer;
BRCA	cis	rs899997	0.773	rs62010525	chr15:78968310	C/G	cg04896959	chr15:78267971	NA	-0.47	-9.57	-0.35	2.36e-20	Coronary artery disease or large artery stroke;
BRCA	cis	rs12612619	0.704	rs7602823	chr2:27309406	G/A	cg00617064	chr2:27272375	NA	0.33	8.41	0.32	2.66e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.31	8.58	0.32	7.29e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-8.96	-0.33	3.61e-18	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg18357645	chr12:58087776	OS9	0.48	13.82	0.48	3.37e-38	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15541040	chr2:3486749	NA	-0.46	-10.21	-0.37	8.86e-23	Neurofibrillary tangles;
BRCA	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	16.37	0.54	1.4e-50	Platelet count;
BRCA	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg13010199	chr12:38710504	ALG10B	0.42	8.95	0.33	3.69e-18	Morning vs. evening chronotype;
BRCA	trans	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg21659725	chr3:3221576	CRBN	-0.53	-9.35	-0.35	1.44e-19	Menarche (age at onset);
BRCA	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.53	11.84	0.42	2.27e-29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
BRCA	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-8.53	-0.32	1.02e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00166722	chr3:10149974	C3orf24	0.6	12.19	0.43	6.74e-31	Alzheimer's disease;
BRCA	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19346786	chr7:2764209	NA	-0.34	-9.98	-0.37	6.97e-22	Height;
BRCA	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg09455208	chr3:40491958	NA	0.52	11.84	0.42	2.27e-29	Renal cell carcinoma;
BRCA	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg25554036	chr4:6271136	WFS1	0.38	9.01	0.34	2.43e-18	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg04842962	chr6:43655489	MRPS18A	1.11	36.98	0.83	6.17e-161	IgG glycosylation;
BRCA	cis	rs10492096	0.947	rs61918022	chr12:6614521	C/T	cg13857086	chr12:6580257	VAMP1	0.43	8.43	0.32	2.35e-16	Hip geometry;
BRCA	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg15704280	chr7:45808275	SEPT13	0.53	8.97	0.33	3.33e-18	Axial length;
BRCA	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg27446573	chr6:127587934	RNF146	0.69	14.84	0.51	4.96e-43	Breast cancer;
BRCA	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg11764359	chr7:65958608	NA	0.75	17.49	0.57	2.93e-56	Aortic root size;
BRCA	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg11189052	chr15:85197271	WDR73	0.44	8.94	0.33	4.28e-18	Schizophrenia;
BRCA	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg14675211	chr2:100938903	LONRF2	-0.42	-9.53	-0.35	3.2e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg12011299	chr4:100065546	ADH4	0.42	10.89	0.4	1.89e-25	Alcohol dependence;
BRCA	cis	rs483180	0.511	rs496195	chr1:120207182	A/G	cg19096424	chr1:120255104	PHGDH	-0.42	-9.3	-0.35	2.12e-19	Macular telangiectasia type 2;
BRCA	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg11645453	chr3:52864694	ITIH4	0.36	9.46	0.35	5.87e-20	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg11822812	chr5:140052017	DND1	-0.31	-8.52	-0.32	1.15e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg13010199	chr12:38710504	ALG10B	0.51	10.57	0.39	3.5e-24	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9470366	0.527	rs4711456	chr6:36632482	C/T	cg08179530	chr6:36648295	CDKN1A	-0.55	-12.53	-0.44	2.31e-32	QRS duration;
BRCA	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg11266682	chr4:10021025	SLC2A9	0.37	9.7	0.36	7.66e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg27661571	chr11:113659931	NA	-0.74	-11.34	-0.41	2.71e-27	Hip circumference adjusted for BMI;
BRCA	cis	rs11585357	0.895	rs2501795	chr1:17633499	A/G	cg08277548	chr1:17600880	PADI3	-0.57	-10.0	-0.37	5.59e-22	Hair shape;
BRCA	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg01877450	chr7:97915802	BRI3	-0.39	-8.98	-0.33	3.1e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6066835	1.000	rs6066831	chr20:47354131	C/A	cg18078177	chr20:47281410	PREX1	0.69	8.6	0.32	6.2e-17	Multiple myeloma;
BRCA	cis	rs4845875	0.626	rs1889292	chr1:11840943	T/C	cg24844545	chr1:11908347	NPPA	0.33	8.25	0.31	9.01e-16	Midregional pro atrial natriuretic peptide levels;
BRCA	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg06623918	chr6:96969491	KIAA0776	0.71	12.68	0.45	5.23e-33	Migraine;Coronary artery disease;
BRCA	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.82	13.04	0.46	1.24e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs7246657	0.653	rs10402050	chr19:37688958	A/T	cg18154014	chr19:37997991	ZNF793	0.56	9.34	0.35	1.63e-19	Coronary artery calcification;
BRCA	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg23711669	chr6:146136114	FBXO30	0.64	14.99	0.51	9.22e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg05623727	chr3:50126028	RBM5	0.41	9.93	0.37	1.05e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg04455712	chr21:45112962	RRP1B	0.36	9.31	0.35	1.98e-19	Mean corpuscular volume;
BRCA	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg25319279	chr11:5960081	NA	-0.43	-8.41	-0.32	2.62e-16	DNA methylation (variation);
BRCA	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg21535247	chr6:8435926	SLC35B3	0.41	9.34	0.35	1.54e-19	Motion sickness;
BRCA	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	13.54	0.47	6.48e-37	Motion sickness;
BRCA	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg26384229	chr12:38710491	ALG10B	0.76	16.84	0.55	5.89e-53	Bladder cancer;
BRCA	trans	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.36	-8.05	-0.3	3.93e-15	Corneal astigmatism;
BRCA	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.15	0.37	1.53e-22	Bladder cancer;
BRCA	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-9.69	-0.36	8.4e-21	Menopause (age at onset);
BRCA	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg07741184	chr6:167504864	NA	-0.31	-9.13	-0.34	8.91e-19	Crohn's disease;
BRCA	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg03146154	chr1:46216737	IPP	0.51	11.11	0.4	2.32e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg09719594	chr16:21412588	NA	-0.32	-7.82	-0.3	2.19e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs887829	0.570	rs6753320	chr2:234595615	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.32	8.15	0.31	1.9e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs877529	0.967	rs12158877	chr22:39549426	T/G	cg12193277	chr22:39547181	CBX7	0.47	12.67	0.45	5.71e-33	Multiple myeloma;
BRCA	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg16482183	chr6:26056742	HIST1H1C	0.74	12.96	0.46	2.9e-34	Iron status biomarkers;
BRCA	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg18806716	chr10:30721971	MAP3K8	0.38	9.1	0.34	1.18e-18	Inflammatory bowel disease;
BRCA	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg14863265	chr7:2801509	GNA12	-0.42	-9.19	-0.34	5.48e-19	Height;
BRCA	cis	rs10463316	0.894	rs6579875	chr5:150782574	C/T	cg03212797	chr5:150827313	SLC36A1	-0.39	-7.85	-0.3	1.79e-14	Metabolite levels (Pyroglutamine);
BRCA	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	12.57	0.45	1.6e-32	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-31.68	-0.78	3.91e-133	Schizophrenia;
BRCA	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11644478	chr21:40555479	PSMG1	-0.66	-14.66	-0.5	3.85e-42	Cognitive function;
BRCA	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg02891314	chr5:179741120	GFPT2	-0.67	-13.25	-0.46	1.44e-35	Height;
BRCA	cis	rs4409675	0.576	rs12070659	chr1:28227175	G/A	cg23691781	chr1:28212827	C1orf38	0.32	10.71	0.39	9.82e-25	Corneal astigmatism;
BRCA	cis	rs2742234	0.910	rs2505505	chr10:43648221	G/T	cg02780029	chr10:43622663	RET	-0.4	-10.08	-0.37	2.94e-22	Hirschsprung disease;
BRCA	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg04414720	chr1:150670196	GOLPH3L	0.36	8.17	0.31	1.6e-15	Tonsillectomy;
BRCA	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg06606381	chr12:133084897	FBRSL1	-0.85	-8.85	-0.33	8.54e-18	Depression;
BRCA	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg19622623	chr12:86230825	RASSF9	-0.33	-9.32	-0.35	1.83e-19	Major depressive disorder;
BRCA	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	8.35	0.31	4.09e-16	Axial length;
BRCA	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg21918786	chr6:109611834	NA	-0.48	-13.98	-0.48	6.15e-39	Reticulocyte fraction of red cells;
BRCA	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg09307838	chr4:120376055	NA	0.75	16.17	0.54	1.48e-49	Corneal astigmatism;
BRCA	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg09307838	chr4:120376055	NA	0.64	13.64	0.47	2.27e-37	Corneal astigmatism;
BRCA	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12311346	chr5:56204834	C5orf35	0.9	16.93	0.56	2.27e-53	Initial pursuit acceleration;
BRCA	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg12219531	chr12:120966889	COQ5	0.53	11.21	0.41	9.63e-27	High light scatter reticulocyte count;
BRCA	trans	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg11693508	chr17:37793320	STARD3	0.41	8.55	0.32	8.77e-17	Neuroticism;
BRCA	trans	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	14.82	0.51	6.58e-43	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg09307838	chr4:120376055	NA	0.46	9.5	0.35	3.99e-20	Diastolic blood pressure;
BRCA	cis	rs9811920	0.666	rs793456	chr3:99525631	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.52	-12.3	-0.44	2.38e-31	Axial length;
BRCA	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	11.77	0.42	4.24e-29	Schizophrenia;
BRCA	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg00814883	chr7:100076585	TSC22D4	-0.47	-10.6	-0.39	2.63e-24	Platelet count;
BRCA	cis	rs4363385	0.667	rs399550	chr1:153049917	T/C	cg25856811	chr1:152973957	SPRR3	-0.31	-8.01	-0.3	5.53e-15	Inflammatory skin disease;
BRCA	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg18795169	chr1:18902165	NA	-0.9	-26.49	-0.72	6.1e-105	Urate levels in lean individuals;
BRCA	cis	rs34779708	0.966	rs11010135	chr10:35518063	A/G	cg03585969	chr10:35415529	CREM	0.53	10.37	0.38	2.17e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg01475377	chr6:109611718	NA	0.6	16.65	0.55	5.51e-52	Reticulocyte fraction of red cells;
BRCA	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg24977027	chr2:88469347	THNSL2	0.56	9.54	0.35	2.92e-20	Plasma clusterin levels;
BRCA	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg12751644	chr20:60527061	NA	-0.39	-8.32	-0.31	5.28e-16	Obesity-related traits;
BRCA	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg03146154	chr1:46216737	IPP	0.49	10.79	0.39	4.77e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg13114125	chr14:105738426	BRF1	-0.53	-11.07	-0.4	3.42e-26	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg04317338	chr11:64019027	PLCB3	0.53	9.42	0.35	8.34e-20	Mean platelet volume;
BRCA	cis	rs55665837	1.000	rs12295888	chr11:14450531	T/C	cg19336497	chr11:14380999	RRAS2	-0.36	-9.47	-0.35	5.33e-20	Vitamin D levels;
BRCA	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg03433033	chr1:76189801	ACADM	-0.49	-10.21	-0.37	9.23e-23	Daytime sleep phenotypes;
BRCA	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	15.9	0.53	3.13e-48	Bone mineral density;
BRCA	cis	rs2404602	0.735	rs2461870	chr15:76813920	T/G	cg23625390	chr15:77176239	SCAPER	-0.49	-12.69	-0.45	4.43e-33	Blood metabolite levels;
BRCA	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	9.44	0.35	6.94e-20	Tonsillectomy;
BRCA	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg09184832	chr6:79620586	NA	-0.51	-11.12	-0.4	2.32e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs13631	0.928	rs9411308	chr9:140000115	C/T	cg14289826	chr9:140003911	NA	0.53	13.96	0.48	7.92e-39	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg13902645	chr11:5959945	NA	-0.52	-10.56	-0.39	3.93e-24	DNA methylation (variation);
BRCA	cis	rs1420338	0.967	rs10271544	chr7:34147159	C/T	cg01275685	chr7:34179230	BMPER	-0.52	-11.58	-0.42	2.87e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg26031613	chr14:104095156	KLC1	0.5	9.09	0.34	1.28e-18	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-8.09	-0.3	3.04e-15	Prostate cancer;
BRCA	cis	rs1371614	0.577	rs877274	chr2:27140099	A/C	cg12368169	chr2:27073192	DPYSL5	-0.29	-8.73	-0.33	2.13e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs2463822	0.764	rs7125402	chr11:62097259	C/T	cg06239285	chr11:62104954	ASRGL1	0.66	11.05	0.4	4.1e-26	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.97	-0.37	7.49e-22	Alzheimer's disease;
BRCA	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg17420585	chr12:42539391	GXYLT1	-0.38	-8.06	-0.3	3.77e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg13010199	chr12:38710504	ALG10B	0.53	11.62	0.42	1.8e-28	Heart rate;
BRCA	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg25358565	chr5:93447407	FAM172A	1.14	18.05	0.58	3.61e-59	Diabetic retinopathy;
BRCA	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg02297831	chr4:17616191	MED28	0.37	8.49	0.32	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg03060546	chr3:49711283	APEH	-0.48	-9.56	-0.35	2.39e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs931812	0.895	rs7831714	chr8:101913987	C/T	cg20993868	chr7:22813445	NA	0.52	14.16	0.49	8.26e-40	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs4363385	0.818	rs4576617	chr1:152985729	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.41	-0.32	2.64e-16	Inflammatory skin disease;
BRCA	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11644478	chr21:40555479	PSMG1	-0.75	-16.32	-0.54	2.56e-50	Cognitive function;
BRCA	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.39	8.4	0.32	2.86e-16	IgG glycosylation;
BRCA	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03264133	chr6:25882463	NA	-0.41	-9.19	-0.34	5.63e-19	Height;
BRCA	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg08859206	chr1:53392774	SCP2	-0.51	-11.21	-0.41	9.64e-27	Monocyte count;
BRCA	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg03146154	chr1:46216737	IPP	0.45	10.08	0.37	2.88e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg14675211	chr2:100938903	LONRF2	0.43	9.56	0.35	2.46e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15501526	chr10:2543763	NA	0.58	14.31	0.49	1.7e-40	Age-related hearing impairment;
BRCA	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg02196655	chr2:10830764	NOL10	-0.3	-7.93	-0.3	9.52e-15	Prostate cancer;
BRCA	cis	rs9837602	0.872	rs1489816	chr3:99769088	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-10.94	-0.4	1.14e-25	Breast cancer;
BRCA	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg21138405	chr5:131827807	IRF1	0.4	12.97	0.46	2.67e-34	Asthma (sex interaction);
BRCA	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	11.54	0.42	4.18e-28	Rheumatoid arthritis;
BRCA	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	0.56	9.5	0.35	4.16e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg09307838	chr4:120376055	NA	-0.7	-14.2	-0.49	5.79e-40	Corneal astigmatism;
BRCA	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg13880726	chr7:1868755	MAD1L1	0.51	10.2	0.37	9.77e-23	Bipolar disorder and schizophrenia;
BRCA	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg07741184	chr6:167504864	NA	0.33	9.76	0.36	4.48e-21	Primary biliary cholangitis;
BRCA	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg23711669	chr6:146136114	FBXO30	-0.72	-14.58	-0.5	8.51e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19748678	chr4:122722346	EXOSC9	0.75	16.19	0.54	1.21e-49	Type 2 diabetes;
BRCA	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg27478167	chr7:817139	HEATR2	0.58	11.62	0.42	1.87e-28	Cerebrospinal P-tau181p levels;
BRCA	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-9.62	-0.36	1.48e-20	Menopause (age at onset);
BRCA	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	18.9	0.6	1.21e-63	Smoking behavior;
BRCA	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.64	-16.56	-0.55	1.55e-51	Longevity;Endometriosis;
BRCA	trans	rs4650994	0.525	rs4457535	chr1:178497186	C/T	cg05059571	chr16:84539110	KIAA1609	0.49	11.27	0.41	5.6e-27	HDL cholesterol levels;HDL cholesterol;
BRCA	cis	rs11971779	0.680	rs11772026	chr7:139052589	T/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.24	0.38	6.65e-23	Diisocyanate-induced asthma;
BRCA	cis	rs2882667	0.690	rs288018	chr5:138192416	G/A	cg04439458	chr5:138467593	SIL1	0.35	8.57	0.32	7.79e-17	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.51	0.57	2.31e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	ch.11.42038R	chr11:967971	AP2A2	0.46	13.86	0.48	2.2e-38	Alzheimer's disease (late onset);
BRCA	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg21385522	chr1:16154831	NA	-0.62	-11.39	-0.41	1.69e-27	Dilated cardiomyopathy;
BRCA	cis	rs9831754	1.000	rs9855903	chr3:78347988	C/A	cg06138941	chr3:78371609	NA	-0.81	-17.48	-0.57	3.45e-56	Calcium levels;
BRCA	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg04025307	chr7:1156635	C7orf50	0.52	9.99	0.37	6.34e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-10.23	-0.38	7.53e-23	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg18252515	chr7:66147081	NA	-1.07	-15.92	-0.53	2.69e-48	Diabetic kidney disease;
BRCA	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg14675211	chr2:100938903	LONRF2	0.52	11.67	0.42	1.16e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg01292856	chr11:65242576	NA	0.36	9.04	0.34	1.85e-18	Bone mineral density;
BRCA	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg04287289	chr16:89883240	FANCA	-0.65	-14.49	-0.5	2.51e-41	Vitiligo;
BRCA	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg05552183	chr6:42928497	GNMT	0.69	15.48	0.52	3.7e-46	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg15704280	chr7:45808275	SEPT13	0.54	8.2	0.31	1.31e-15	Intraocular pressure;
BRCA	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg13010199	chr12:38710504	ALG10B	0.51	10.18	0.37	1.22e-22	Bladder cancer;
BRCA	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg20283391	chr11:68216788	NA	-0.44	-8.95	-0.33	3.75e-18	Total body bone mineral density;
BRCA	cis	rs27434	0.607	rs26654	chr5:96140367	C/T	cg16492584	chr5:96139282	ERAP1	-0.51	-13.2	-0.46	2.3e-35	Ankylosing spondylitis;
BRCA	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.7	0.55	3.14e-52	Hypertriglyceridemia;
BRCA	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg23029597	chr12:123009494	RSRC2	0.58	11.48	0.41	7.41e-28	Body mass index;
BRCA	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.63	0.32	4.82e-17	Motion sickness;
BRCA	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg22535103	chr8:58192502	C8orf71	-0.51	-10.92	-0.4	1.37e-25	Developmental language disorder (linguistic errors);
BRCA	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg00631329	chr6:26305371	NA	-0.44	-12.92	-0.46	4.11e-34	Educational attainment;
BRCA	cis	rs11677370	0.574	rs10190477	chr2:3862738	A/G	cg17052675	chr2:3827356	NA	0.52	12.48	0.44	3.65e-32	Type 2 diabetes;
BRCA	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg00666640	chr1:248458726	OR2T12	0.3	8.39	0.31	3.15e-16	Common traits (Other);
BRCA	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg09904177	chr6:26538194	HMGN4	0.55	17.67	0.57	3.26e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg09307838	chr4:120376055	NA	0.6	12.94	0.46	3.6e-34	Corneal astigmatism;
BRCA	cis	rs11252926	0.797	rs61837235	chr10:489363	G/A	cg08603382	chr10:743973	NA	-0.45	-8.34	-0.31	4.54e-16	Psychosis in Alzheimer's disease;
BRCA	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg22153463	chr1:85462885	MCOLN2	-0.6	-10.72	-0.39	9.34e-25	Serum sulfate level;
BRCA	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg23229984	chr5:148520753	ABLIM3	0.36	8.87	0.33	7.15e-18	Breast cancer;
BRCA	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg00745463	chr17:30367425	LRRC37B	-0.54	-8.87	-0.33	7.06e-18	Hip circumference adjusted for BMI;
BRCA	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg01620082	chr3:125678407	NA	-0.86	-10.28	-0.38	4.77e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs4077515	0.934	rs10781507	chr9:139272058	A/G	cg14019695	chr9:139328340	INPP5E	0.32	7.96	0.3	7.73e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-11.13	-0.4	1.98e-26	Extrinsic epigenetic age acceleration;
BRCA	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg27478167	chr7:817139	HEATR2	-0.54	-11.0	-0.4	6.94e-26	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7072216	0.655	rs3830025	chr10:100176104	A/G	cg26618903	chr10:100175079	PYROXD2	-0.32	-8.93	-0.33	4.6e-18	Metabolite levels;
BRCA	trans	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg13010199	chr12:38710504	ALG10B	0.36	7.87	0.3	1.52e-14	Morning vs. evening chronotype;
BRCA	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg17971929	chr21:40555470	PSMG1	-0.64	-14.9	-0.51	2.57e-43	Cognitive function;
BRCA	cis	rs7903847	0.619	rs76094900	chr10:99158164	G/A	cg08345082	chr10:99160200	RRP12	-0.31	-9.08	-0.34	1.29e-18	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs1997103	0.954	rs56030000	chr7:55405750	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.39	2.34e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	20.88	0.64	3.29e-74	Chronic sinus infection;
BRCA	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg00666640	chr1:248458726	OR2T12	0.32	8.95	0.33	3.99e-18	Common traits (Other);
BRCA	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.5	-0.44	3.1e-32	Type 2 diabetes;
BRCA	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg11168104	chr5:1857477	NA	-0.35	-9.33	-0.35	1.67e-19	Cardiovascular disease risk factors;
BRCA	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg05313129	chr8:58192883	C8orf71	-0.48	-9.87	-0.36	1.8e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg16339924	chr4:17578868	LAP3	0.59	14.44	0.5	4.24e-41	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7729447	0.813	rs4867121	chr5:32692548	T/C	cg16267343	chr5:32710456	NPR3	0.42	8.54	0.32	9.71e-17	Blood pressure;
BRCA	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg26384229	chr12:38710491	ALG10B	0.76	16.99	0.56	1.09e-53	Bladder cancer;
BRCA	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg27446573	chr6:127587934	RNF146	0.86	19.7	0.61	7.62e-68	Breast cancer;
BRCA	cis	rs1400816	0.850	rs6433315	chr2:172686290	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.55	-8.46	-0.32	1.77e-16	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg09904177	chr6:26538194	HMGN4	0.47	14.71	0.5	2.02e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.05	22.15	0.66	4.01e-81	Gut microbiome composition (summer);
BRCA	cis	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg07460842	chr6:66804631	NA	0.93	18.55	0.59	8.93e-62	Exhaled nitric oxide output;
BRCA	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg11663144	chr21:46675770	NA	-0.56	-13.38	-0.47	3.43e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg18252515	chr7:66147081	NA	-1.08	-16.09	-0.54	3.78e-49	Diabetic kidney disease;
BRCA	cis	rs490234	0.841	rs490333	chr9:128354569	T/C	cg14078157	chr9:128172775	NA	0.34	7.88	0.3	1.41e-14	Mean arterial pressure;
BRCA	cis	rs9815354	0.556	rs113213296	chr3:41873097	G/A	cg03022575	chr3:42003672	ULK4	0.69	9.47	0.35	5.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg22638593	chr5:131593259	PDLIM4	-0.34	-8.59	-0.32	6.59e-17	Acylcarnitine levels;
BRCA	cis	rs17767294	0.614	rs72845061	chr6:27653261	G/A	cg08851530	chr6:28072375	NA	0.95	8.95	0.33	3.95e-18	Parkinson's disease;
BRCA	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.77	12.95	0.46	3.07e-34	Schizophrenia;
BRCA	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg22800045	chr5:56110881	MAP3K1	0.46	9.1	0.34	1.14e-18	Initial pursuit acceleration;
BRCA	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.5	-10.61	-0.39	2.37e-24	Longevity;Endometriosis;
BRCA	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg08514558	chr10:81106712	PPIF	0.37	8.77	0.33	1.58e-17	Height;
BRCA	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00149659	chr3:10157352	C3orf10	0.79	13.72	0.48	9.42e-38	Alzheimer's disease;
BRCA	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg18279126	chr7:2041391	MAD1L1	-0.39	-9.05	-0.34	1.72e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs7903847	0.642	rs10786344	chr10:99165975	T/C	cg08345082	chr10:99160200	RRP12	-0.3	-8.78	-0.33	1.44e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg20701182	chr2:24300061	SF3B14	0.58	9.2	0.34	5.02e-19	Lymphocyte counts;
BRCA	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg11752832	chr7:134001865	SLC35B4	0.49	12.1	0.43	1.76e-30	Mean platelet volume;
BRCA	cis	rs4363385	0.510	rs6686526	chr1:153044996	T/C	cg25856811	chr1:152973957	SPRR3	-0.32	-7.83	-0.3	2.11e-14	Inflammatory skin disease;
BRCA	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-9.36	-0.35	1.34e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs36051895	0.664	rs10815157	chr9:5108771	C/G	cg02405213	chr9:5042618	JAK2	-0.48	-9.1	-0.34	1.12e-18	Pediatric autoimmune diseases;
BRCA	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg09065629	chr16:1709722	CRAMP1L	0.36	8.32	0.31	5.17e-16	Coronary artery disease;
BRCA	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg00105475	chr2:10696890	NA	0.44	10.44	0.38	1.2e-23	Prostate cancer;
BRCA	cis	rs919433	0.963	rs12469546	chr2:198178826	T/C	cg10820045	chr2:198174542	NA	-0.38	-7.9	-0.3	1.25e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs12986413	0.781	rs2864419	chr19:2183175	A/C	cg09261902	chr19:2140048	AP3D1	-0.39	-9.99	-0.37	6.26e-22	Height;
BRCA	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg05340658	chr4:99064831	C4orf37	0.45	10.24	0.38	7.17e-23	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2712184	0.756	rs715049	chr2:217657102	C/T	cg05032264	chr2:217675019	NA	-0.38	-9.14	-0.34	7.89e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg12564285	chr5:131593104	PDLIM4	0.39	9.64	0.36	1.24e-20	Acylcarnitine levels;
BRCA	trans	rs9784649	1.000	rs56156666	chr5:24999440	A/T	cg08600765	chr20:34638493	LOC647979	-0.52	-8.65	-0.32	4e-17	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg20503657	chr10:835505	NA	0.85	15.1	0.51	2.69e-44	Eosinophil percentage of granulocytes;
BRCA	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg14582100	chr15:45693742	SPATA5L1	0.36	11.73	0.42	6.29e-29	Homoarginine levels;
BRCA	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg18478394	chr8:109455254	TTC35	0.3	8.61	0.32	5.65e-17	Dupuytren's disease;
BRCA	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg18904891	chr8:8559673	CLDN23	0.56	11.01	0.4	6.42e-26	Obesity-related traits;
BRCA	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg25182066	chr10:30743637	MAP3K8	0.34	8.21	0.31	1.21e-15	Inflammatory bowel disease;
BRCA	cis	rs3820928	1.000	rs2396433	chr2:227772502	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.41	-0.32	2.72e-16	Pulmonary function;
BRCA	cis	rs877282	1.000	rs12773872	chr10:771939	T/C	cg17470449	chr10:769945	NA	0.5	8.9	0.33	5.64e-18	Uric acid levels;
BRCA	cis	rs4363385	0.747	rs4845508	chr1:152968421	G/C	cg24667326	chr1:152973720	SPRR3	-0.36	-9.89	-0.36	1.54e-21	Inflammatory skin disease;
BRCA	cis	rs77861329	1.000	rs164639	chr3:52210872	A/G	cg08692210	chr3:52188851	WDR51A	-0.67	-11.37	-0.41	1.99e-27	Macrophage inflammatory protein 1b levels;
BRCA	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	-0.4	-8.84	-0.33	9.57e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs858239	0.539	rs6965833	chr7:23192366	T/C	cg23682824	chr7:23144976	KLHL7	0.41	10.89	0.4	1.84e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs10754283	0.840	rs6428560	chr1:90102462	A/T	cg21401794	chr1:90099060	LRRC8C	0.47	11.3	0.41	3.96e-27	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs67460515	0.563	rs13085336	chr3:160880599	G/A	cg03342759	chr3:160939853	NMD3	-0.7	-14.6	-0.5	7.51e-42	Parkinson's disease;
BRCA	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg10578991	chr7:12443926	VWDE	-0.57	-8.06	-0.3	3.71e-15	Coronary artery disease;
BRCA	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05901451	chr6:126070800	HEY2	-0.54	-14.24	-0.49	3.76e-40	Brugada syndrome;
BRCA	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg04450456	chr4:17643702	FAM184B	0.39	11.59	0.42	2.58e-28	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs34779708	0.931	rs10466072	chr10:35402756	C/T	cg03585969	chr10:35415529	CREM	0.44	9.34	0.35	1.54e-19	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs903263	0.512	rs1325602	chr1:84505777	C/T	cg10977910	chr1:84465055	TTLL7	0.46	9.05	0.34	1.74e-18	Breast cancer (male);
BRCA	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg16102102	chr5:83017553	HAPLN1	0.77	16.39	0.54	1.18e-50	Prostate cancer;
BRCA	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.76	-0.33	1.81e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7119038	0.509	rs10790261	chr11:118579747	C/T	cg19308663	chr11:118741387	NA	-0.39	-8.46	-0.32	1.77e-16	Sjögren's syndrome;
BRCA	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg26384229	chr12:38710491	ALG10B	0.66	15.19	0.52	1.03e-44	Bladder cancer;
BRCA	cis	rs7631605	0.935	rs7639375	chr3:37107022	C/A	cg15934958	chr3:37212084	LRRFIP2	0.41	9.51	0.35	3.69e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg01483505	chr11:975446	AP2A2	-0.33	-8.97	-0.33	3.14e-18	Alzheimer's disease (late onset);
BRCA	trans	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.06	-0.64	3.72e-75	Exhaled nitric oxide output;
BRCA	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg07884673	chr3:53033167	SFMBT1	0.72	8.94	0.33	4.2e-18	Immune reponse to smallpox (secreted IL-2);
BRCA	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg10495392	chr1:46806563	NSUN4	0.45	8.27	0.31	7.52e-16	Menopause (age at onset);
BRCA	trans	rs9329221	0.686	rs60755617	chr8:10243327	T/G	cg15556689	chr8:8085844	FLJ10661	0.38	8.88	0.33	6.53e-18	Neuroticism;
BRCA	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg00530320	chr1:46809349	NSUN4	0.48	9.42	0.35	8.17e-20	Menopause (age at onset);
BRCA	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg00105475	chr2:10696890	NA	0.44	10.36	0.38	2.45e-23	Prostate cancer;
BRCA	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg23711669	chr6:146136114	FBXO30	0.65	15.3	0.52	2.96e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.4	0.32	2.9e-16	Aortic root size;
BRCA	cis	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg04990556	chr1:26633338	UBXN11	-0.51	-8.85	-0.33	8.49e-18	Obesity-related traits;
BRCA	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg25767906	chr1:53392781	SCP2	-0.37	-8.62	-0.32	5.27e-17	Monocyte count;
BRCA	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03934478	chr11:495069	RNH1	0.79	11.76	0.42	5.06e-29	Body mass index;
BRCA	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg23625390	chr15:77176239	SCAPER	0.44	10.97	0.4	9.14e-26	Blood metabolite levels;
BRCA	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-9.33	-0.35	1.75e-19	Menopause (age at onset);
BRCA	cis	rs10504073	0.669	rs818559	chr8:50035806	C/T	cg00325661	chr8:49890786	NA	0.38	10.92	0.4	1.42e-25	Blood metabolite ratios;
BRCA	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg22903471	chr2:27725779	GCKR	-0.38	-9.4	-0.35	9.77e-20	Total body bone mineral density;
BRCA	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg21747090	chr2:27597821	SNX17	-0.43	-9.43	-0.35	7.24e-20	Total body bone mineral density;
BRCA	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg21699342	chr2:239360505	ASB1	0.53	13.95	0.48	8.34e-39	Multiple system atrophy;
BRCA	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13012494	chr21:47604986	C21orf56	0.42	8.89	0.33	6.4e-18	Testicular germ cell tumor;
BRCA	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	9.39	0.35	1.03e-19	Iron status biomarkers;
BRCA	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	6.95e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg07423050	chr13:99094983	FARP1	-0.45	-9.37	-0.35	1.26e-19	Longevity;
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg03188948	chr7:1209495	NA	0.53	9.95	0.37	8.57e-22	Longevity;Endometriosis;
BRCA	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg25554036	chr4:6271136	WFS1	0.43	10.04	0.37	3.93e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.3	0.49	1.92e-40	Motion sickness;
BRCA	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.62	-0.32	5.37e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6772849	0.930	rs9868579	chr3:128351054	C/T	cg16766828	chr3:128327626	NA	0.39	8.62	0.32	5.26e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg11764359	chr7:65958608	NA	-0.61	-13.29	-0.47	9.53e-36	Aortic root size;
BRCA	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg15556689	chr8:8085844	FLJ10661	-0.3	-7.98	-0.3	7e-15	Neuroticism;
BRCA	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg00147160	chr1:26503991	CNKSR1	0.28	9.22	0.34	4.34e-19	Height;
BRCA	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg02820040	chr2:241836501	C2orf54	-0.54	-10.23	-0.38	7.52e-23	Urinary metabolites;
BRCA	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg13852791	chr20:30311386	BCL2L1	0.85	16.95	0.56	1.63e-53	Mean corpuscular hemoglobin;
BRCA	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg11833968	chr6:79620685	NA	-0.46	-10.41	-0.38	1.49e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.59	0.39	2.87e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg00409905	chr10:38381863	ZNF37A	0.49	10.62	0.39	2.17e-24	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	11.37	0.41	2.13e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4588572	0.688	rs2362829	chr5:77724036	T/A	cg11547950	chr5:77652471	NA	-0.45	-8.55	-0.32	9.08e-17	Triglycerides;
BRCA	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-16.96	-0.56	1.52e-53	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg01579765	chr21:45077557	HSF2BP	-0.44	-11.68	-0.42	1.07e-28	Mean corpuscular volume;
BRCA	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg26248373	chr2:1572462	NA	-0.63	-14.52	-0.5	1.68e-41	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg11663144	chr21:46675770	NA	-0.53	-12.45	-0.44	5.15e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.18	-0.34	6e-19	Bipolar disorder;
BRCA	trans	rs9944715	1.000	rs9951624	chr18:43840829	A/G	cg01718231	chr17:29326311	RNF135	-0.46	-9.13	-0.34	8.8e-19	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.7	-0.5	2.35e-42	Chronic sinus infection;
BRCA	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg09877947	chr5:131593287	PDLIM4	0.34	7.95	0.3	8.7e-15	Blood metabolite levels;
BRCA	cis	rs77972916	0.611	rs11693190	chr2:43602415	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-10.59	-0.39	2.85e-24	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs35123781	0.696	rs904612	chr5:139070952	G/A	cg10513866	chr5:139070639	NA	0.44	9.62	0.36	1.44e-20	Schizophrenia;
BRCA	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg26597838	chr10:835615	NA	0.8	14.69	0.5	2.59e-42	Eosinophil percentage of granulocytes;
BRCA	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg10523679	chr1:76189770	ACADM	-0.71	-13.09	-0.46	7.79e-35	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg24596788	chr1:163392923	NA	-0.4	-10.59	-0.39	2.85e-24	Motion sickness;
BRCA	cis	rs7520050	0.933	rs6680211	chr1:46315007	C/G	cg24296786	chr1:45957014	TESK2	0.41	9.35	0.35	1.5e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg25358565	chr5:93447407	FAM172A	1.17	17.4	0.57	8.11e-56	Diabetic retinopathy;
BRCA	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	14.31	0.49	1.68e-40	Calcium levels;
BRCA	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.56e-19	Morning vs. evening chronotype;
BRCA	cis	rs867371	0.929	rs1501371	chr15:82460440	A/C	cg00614314	chr15:82944287	LOC80154	0.43	8.96	0.33	3.59e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg05863683	chr7:1912471	MAD1L1	0.36	8.04	0.3	4.49e-15	Bipolar disorder and schizophrenia;
BRCA	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21659725	chr3:3221576	CRBN	0.71	21.65	0.65	2.21e-78	Intelligence (multi-trait analysis);
BRCA	trans	rs9944715	1.000	rs8094070	chr18:43849640	G/A	cg01718231	chr17:29326311	RNF135	-0.47	-9.2	-0.34	4.96e-19	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs7851660	0.901	rs2401639	chr9:100607837	T/C	cg13688889	chr9:100608707	NA	-0.35	-8.56	-0.32	8.52e-17	Strep throat;
BRCA	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg17366294	chr4:99064904	C4orf37	0.52	9.72	0.36	6.3e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg14983838	chr19:29218262	NA	0.54	10.09	0.37	2.65e-22	Methadone dose in opioid dependence;
BRCA	trans	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.45	-9.55	-0.35	2.71e-20	Mean corpuscular volume;
BRCA	cis	rs55728055	0.661	rs1018488	chr22:31992376	A/G	cg01338084	chr22:32026380	PISD	0.85	8.37	0.31	3.62e-16	Age-related hearing impairment;
BRCA	cis	rs6545883	0.929	rs2592352	chr2:61665336	C/T	cg15711740	chr2:61764176	XPO1	-0.56	-14.22	-0.49	4.62e-40	Tuberculosis;
BRCA	cis	rs701145	0.585	rs2689330	chr3:153929990	T/C	cg17054900	chr3:154042577	DHX36	0.57	9.59	0.35	1.96e-20	Coronary artery disease;
BRCA	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-25.62	-0.71	4.13e-100	Chronic sinus infection;
BRCA	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg12573674	chr2:1569213	NA	-0.62	-14.09	-0.49	1.83e-39	IgG glycosylation;
BRCA	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg24848339	chr3:12840334	CAND2	0.49	13.29	0.47	9.14e-36	QRS complex (12-leadsum);
BRCA	trans	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg25214090	chr10:38739885	LOC399744	-0.54	-11.82	-0.42	2.73e-29	Corneal astigmatism;
BRCA	cis	rs2540552	0.620	rs2540571	chr7:91206783	C/T	cg15143024	chr7:91199642	NA	-0.46	-11.34	-0.41	2.76e-27	IgG glycosylation;
BRCA	cis	rs11690935	0.632	rs12052246	chr2:172895606	G/T	cg13550731	chr2:172543902	DYNC1I2	0.57	14.48	0.5	2.75e-41	Schizophrenia;
BRCA	cis	rs12618769	0.543	rs3769728	chr2:99103001	G/A	cg10123293	chr2:99228465	UNC50	0.42	8.18	0.31	1.53e-15	Bipolar disorder;
BRCA	cis	rs887829	0.570	rs7563561	chr2:234598991	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.31	-7.82	-0.3	2.18e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg00042356	chr1:8021962	PARK7	-0.51	-8.13	-0.31	2.24e-15	Inflammatory bowel disease;
BRCA	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg09307838	chr4:120376055	NA	0.7	14.18	0.49	7.37e-40	Corneal astigmatism;
BRCA	trans	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg25214090	chr10:38739885	LOC399744	-0.46	-9.84	-0.36	2.29e-21	Corneal astigmatism;
BRCA	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1568889	0.838	rs11030206	chr11:28099747	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.11	0.62	4.67e-70	Bipolar disorder;
BRCA	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg21280719	chr6:42927975	GNMT	-0.31	-13.09	-0.46	7.62e-35	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg18252515	chr7:66147081	NA	-0.98	-13.81	-0.48	3.74e-38	Diabetic kidney disease;
BRCA	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg18132916	chr6:79620363	NA	-0.47	-10.59	-0.39	3.01e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.95	-0.37	8.91e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	ch.11.42038R	chr11:967971	AP2A2	0.52	16.68	0.55	4.17e-52	Alzheimer's disease (late onset);
BRCA	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg11843238	chr5:131593191	PDLIM4	0.36	7.97	0.3	7.15e-15	Breast cancer;
BRCA	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg08885076	chr2:99613938	TSGA10	0.44	10.29	0.38	4.44e-23	Chronic sinus infection;
BRCA	cis	rs6142102	0.961	rs6119447	chr20:32668576	A/G	cg24642439	chr20:33292090	TP53INP2	0.4	7.86	0.3	1.59e-14	Skin pigmentation;
BRCA	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg08999081	chr20:33150536	PIGU	-0.44	-12.28	-0.44	2.85e-31	Glomerular filtration rate (creatinine);
BRCA	cis	rs3784262	0.692	rs12907125	chr15:58282621	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.85	-0.36	2.02e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs2386661	0.547	rs11259582	chr10:5646767	C/T	cg17085576	chr10:5658249	NA	-0.33	-8.18	-0.31	1.5e-15	Breast cancer;
BRCA	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg05472934	chr7:22766657	IL6	0.5	12.99	0.46	2.02e-34	Lung cancer;
BRCA	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg09455208	chr3:40491958	NA	-0.48	-11.8	-0.42	3.16e-29	Renal cell carcinoma;
BRCA	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00934597	chr7:893267	UNC84A	-0.52	-11.53	-0.41	4.59e-28	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	10.74	0.39	7.19e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg11502198	chr6:26597334	ABT1	0.48	9.67	0.36	1.02e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg22920501	chr2:26401640	FAM59B	-0.81	-13.17	-0.46	3.36e-35	Gut microbiome composition (summer);
BRCA	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.92e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg07080220	chr10:102295463	HIF1AN	0.63	14.82	0.51	6.32e-43	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	8.5	0.32	1.33e-16	Mean platelet volume;
BRCA	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24308560	chr3:49941425	MST1R	-0.4	-8.57	-0.32	7.82e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.4	10.69	0.39	1.24e-24	IgG glycosylation;
BRCA	cis	rs7178424	1.000	rs893158	chr15:62378608	G/A	cg00456672	chr15:62358751	C2CD4A	-0.35	-8.29	-0.31	6.74e-16	Height;
BRCA	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12292205	chr6:26970375	C6orf41	-0.48	-8.25	-0.31	8.81e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg11584989	chr19:19387371	SF4	0.55	12.25	0.44	3.95e-31	Bipolar disorder;
BRCA	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg12310025	chr6:25882481	NA	-0.68	-16.23	-0.54	7.51e-50	Intelligence (multi-trait analysis);
BRCA	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg15819921	chr19:927150	ARID3A	0.5	9.6	0.36	1.72e-20	Life satisfaction;
BRCA	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-11.23	-0.41	7.96e-27	Longevity;Endometriosis;
BRCA	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg14196790	chr5:131705035	SLC22A5	0.4	10.04	0.37	3.84e-22	Blood metabolite levels;
BRCA	cis	rs67460515	0.596	rs4856700	chr3:160922951	A/C	cg17135325	chr3:160939158	NMD3	0.45	8.43	0.32	2.25e-16	Parkinson's disease;
BRCA	cis	rs7809615	0.901	rs6947974	chr7:99156506	G/A	cg12290671	chr7:99195819	NA	-0.5	-8.7	-0.33	2.82e-17	Blood metabolite ratios;
BRCA	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.68	14.66	0.5	3.6e-42	HIV-1 control;
BRCA	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg21395723	chr22:39101663	GTPBP1	-0.37	-7.99	-0.3	6.53e-15	Menopause (age at onset);
BRCA	trans	rs1941687	0.509	rs6507060	chr18:31322278	C/T	cg27147174	chr7:100797783	AP1S1	0.46	9.13	0.34	8.99e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.43	0.35	7.15e-20	Bipolar disorder;
BRCA	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg22508957	chr16:3507546	NAT15	0.47	11.42	0.41	1.31e-27	Tuberculosis;
BRCA	cis	rs4949448	1.000	rs4949448	chr1:32062066	A/C	cg13919466	chr1:32135498	COL16A1	0.26	8.24	0.31	9.57e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26314531	chr2:26401878	FAM59B	-0.63	-10.78	-0.39	5.13e-25	Gut microbiome composition (summer);
BRCA	cis	rs12618769	0.597	rs961242	chr2:99138979	G/A	cg10123293	chr2:99228465	UNC50	0.41	8.24	0.31	9.93e-16	Bipolar disorder;
BRCA	cis	rs600231	0.508	rs35292734	chr11:65227700	C/T	cg01292856	chr11:65242576	NA	0.65	14.2	0.49	5.92e-40	Bone mineral density;
BRCA	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg23711669	chr6:146136114	FBXO30	0.71	17.08	0.56	3.5e-54	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg04455712	chr21:45112962	RRP1B	0.36	8.6	0.32	5.94e-17	Mean corpuscular volume;
BRCA	cis	rs9487051	0.839	rs13196590	chr6:109561918	T/C	cg01475377	chr6:109611718	NA	-0.41	-9.63	-0.36	1.36e-20	Reticulocyte fraction of red cells;
BRCA	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	17.13	0.56	2.16e-54	Fuchs's corneal dystrophy;
BRCA	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03264133	chr6:25882463	NA	-0.52	-11.75	-0.42	5.15e-29	Blood metabolite levels;
BRCA	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18876405	chr7:65276391	NA	0.55	13.2	0.46	2.49e-35	Aortic root size;
BRCA	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.53	10.73	0.39	7.97e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg25173405	chr17:45401733	C17orf57	0.49	9.94	0.37	9.55e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.37	-8.73	-0.33	2.19e-17	Longevity;Endometriosis;
BRCA	cis	rs912057	0.671	rs1294433	chr6:6745163	G/A	cg06612196	chr6:6737390	NA	0.46	10.68	0.39	1.32e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg09035930	chr12:129282057	SLC15A4	0.58	17.38	0.57	1.09e-55	Systemic lupus erythematosus;
BRCA	cis	rs10489202	0.608	rs6657019	chr1:168079669	T/C	cg24449463	chr1:168025552	DCAF6	-0.46	-15.1	-0.51	2.77e-44	Schizophrenia;
BRCA	cis	rs365132	0.791	rs55954117	chr5:176454075	A/G	cg16309518	chr5:176445507	NA	-0.39	-9.29	-0.34	2.45e-19	Menarche and menopause (age at onset);Menopause (age at onset);
BRCA	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	cis	rs2255932	1.000	rs2662767	chr3:183212393	A/G	cg12326526	chr3:183209927	KLHL6	0.46	7.84	0.3	1.87e-14	Interleukin-1-beta levels;
BRCA	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.82	16.66	0.55	5.33e-52	HIV-1 control;
BRCA	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg24060327	chr5:131705240	SLC22A5	0.65	12.88	0.45	6.76e-34	Blood metabolite levels;
BRCA	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg10523679	chr1:76189770	ACADM	0.75	15.64	0.53	6.6e-47	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg22974920	chr21:40686053	BRWD1	-0.39	-8.57	-0.32	7.74e-17	Cognitive function;
BRCA	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg18225595	chr11:63971243	STIP1	0.47	11.17	0.4	1.36e-26	Platelet count;
BRCA	cis	rs4478858	0.647	rs11581476	chr1:31717675	C/T	cg00250761	chr1:31883323	NA	-0.31	-8.16	-0.31	1.74e-15	Alcohol dependence;
BRCA	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-11.14	-0.4	1.77e-26	Personality dimensions;
BRCA	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg04025307	chr7:1156635	C7orf50	0.58	9.08	0.34	1.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2599510	0.811	rs176413	chr2:32646847	G/A	cg02381751	chr2:32503542	YIPF4	-0.42	-8.35	-0.31	4.28e-16	Interleukin-18 levels;
BRCA	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg24531977	chr5:56204891	C5orf35	0.71	15.53	0.52	2.24e-46	Initial pursuit acceleration;
BRCA	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg04166393	chr7:2884313	GNA12	0.48	9.08	0.34	1.35e-18	Height;
BRCA	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg04990556	chr1:26633338	UBXN11	-0.47	-9.26	-0.34	2.98e-19	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs3820928	0.874	rs1917125	chr2:227798981	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-8.84	-0.33	9.34e-18	Pulmonary function;
BRCA	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg05665937	chr4:1216051	CTBP1	-0.38	-8.26	-0.31	8.12e-16	Obesity-related traits;
BRCA	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg11764359	chr7:65958608	NA	0.41	7.86	0.3	1.7e-14	Aortic root size;
BRCA	trans	rs7939886	0.920	rs17150095	chr11:55902900	A/G	cg15704280	chr7:45808275	SEPT13	0.63	7.84	0.3	1.88e-14	Myopia (pathological);
BRCA	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	20.53	0.63	2.65e-72	Platelet count;
BRCA	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg08798685	chr6:27730294	NA	-0.41	-8.03	-0.3	4.78e-15	Parkinson's disease;
BRCA	cis	rs10193935	1.000	rs62144748	chr2:42419468	C/T	cg27598129	chr2:42591480	NA	-0.93	-15.0	-0.51	8.94e-44	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	13.16	0.46	3.58e-35	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg25042112	chr7:64838748	ZNF92	0.46	8.34	0.31	4.53e-16	Pain;
BRCA	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-11.27	-0.41	5.62e-27	Personality dimensions;
BRCA	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg23649088	chr2:200775458	C2orf69	0.53	8.9	0.33	5.71e-18	Schizophrenia;
BRCA	cis	rs12318506	1.000	rs12318506	chr12:75718423	G/T	cg04728562	chr12:75699417	CAPS2	-0.64	-9.2	-0.34	5.1e-19	Coronary artery calcification;
BRCA	cis	rs60843830	0.550	rs300751	chr2:209063	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	9.71	0.36	7.13e-21	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	10.89	0.4	1.82e-25	Rheumatoid arthritis;
BRCA	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg05552183	chr6:42928497	GNMT	0.68	15.39	0.52	1.11e-45	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.82	-0.36	2.81e-21	Hip circumference adjusted for BMI;
BRCA	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg25801113	chr15:45476975	SHF	-0.34	-8.33	-0.31	4.87e-16	Uric acid levels;
BRCA	cis	rs73086581	1.000	rs56069856	chr20:3965709	A/C	cg02187196	chr20:3869020	PANK2	0.53	9.48	0.35	4.73e-20	Response to antidepressants in depression;
BRCA	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg24578937	chr1:2090814	PRKCZ	0.58	17.86	0.58	3.76e-58	Height;
BRCA	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg23711669	chr6:146136114	FBXO30	0.74	16.67	0.55	4.5e-52	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6594713	0.679	rs9326890	chr5:112859994	C/T	cg12552261	chr5:112820674	MCC	0.48	8.03	0.3	4.85e-15	Brain cytoarchitecture;
BRCA	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg11663144	chr21:46675770	NA	-0.62	-14.32	-0.49	1.53e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7572733	0.534	rs1518365	chr2:198809410	T/C	cg00792783	chr2:198669748	PLCL1	0.45	9.94	0.37	9.5e-22	Dermatomyositis;
BRCA	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg17640201	chr16:30407289	ZNF48	-0.74	-16.02	-0.54	8.68e-49	Tonsillectomy;
BRCA	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg24069376	chr3:38537580	EXOG	-0.29	-7.97	-0.3	7.27e-15	Electrocardiographic conduction measures;
BRCA	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg20476274	chr7:133979776	SLC35B4	0.61	15.06	0.51	4.51e-44	Mean platelet volume;
BRCA	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg20701182	chr2:24300061	SF3B14	0.58	9.04	0.34	1.86e-18	Lymphocyte counts;
BRCA	cis	rs3761847	0.593	rs10985140	chr9:123822837	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	8.34	0.31	4.5e-16	Rheumatoid arthritis;
BRCA	cis	rs6120849	0.901	rs6060270	chr20:33736814	G/T	cg24642439	chr20:33292090	TP53INP2	0.48	8.52	0.32	1.18e-16	Protein C levels;
BRCA	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23583168	chr7:148888333	NA	-0.86	-20.12	-0.62	4.19e-70	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg04944784	chr2:26401820	FAM59B	-0.92	-15.22	-0.52	7.33e-45	Gut microbiome composition (summer);
BRCA	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg15839431	chr19:19639596	YJEFN3	0.41	8.96	0.33	3.58e-18	Bipolar disorder;
BRCA	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08564027	chr20:61660810	NA	0.85	22.97	0.67	1.42e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg01017244	chr2:74357527	NA	0.6	12.4	0.44	8.95e-32	Gestational age at birth (maternal effect);
BRCA	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg23033748	chr14:75592666	NEK9	-0.33	-7.9	-0.3	1.26e-14	Height;
BRCA	trans	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	27.56	0.74	8.71e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg03433033	chr1:76189801	ACADM	0.58	11.29	0.41	4.65e-27	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg22681709	chr2:178499509	PDE11A	0.42	9.01	0.34	2.29e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg12365402	chr11:9010492	NRIP3	-0.39	-9.05	-0.34	1.69e-18	Hemoglobin concentration;
BRCA	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.77	17.11	0.56	2.51e-54	Lymphocyte counts;
BRCA	cis	rs57590327	0.555	rs7634258	chr3:81799100	T/C	cg07356753	chr3:81810745	GBE1	-0.47	-11.24	-0.41	7.08e-27	Extraversion;
BRCA	cis	rs6545883	0.524	rs2463101	chr2:61574422	G/C	cg15711740	chr2:61764176	XPO1	0.33	8.03	0.3	4.65e-15	Tuberculosis;
BRCA	cis	rs7246657	0.639	rs12459015	chr19:38083189	T/A	cg23950597	chr19:37808831	NA	-0.5	-8.64	-0.32	4.63e-17	Coronary artery calcification;
BRCA	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.77	12.65	0.45	6.99e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg05926928	chr17:57297772	GDPD1	1.0	13.63	0.47	2.68e-37	Opioid sensitivity;
BRCA	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg10556349	chr10:835070	NA	0.63	8.79	0.33	1.36e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg08000102	chr2:233561755	GIGYF2	0.63	13.88	0.48	1.8e-38	Coronary artery disease;
BRCA	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg02503808	chr4:7069936	GRPEL1	0.8	18.42	0.59	4.24e-61	Monocyte percentage of white cells;
BRCA	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg15556689	chr8:8085844	FLJ10661	0.38	8.84	0.33	9.02e-18	Retinal vascular caliber;
BRCA	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.44	-9.39	-0.35	1.01e-19	Bipolar disorder;
BRCA	trans	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.09	0.3	3e-15	Corneal astigmatism;
BRCA	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg02297831	chr4:17616191	MED28	0.37	8.5	0.32	1.34e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	8.43	0.32	2.27e-16	Rheumatoid arthritis;
BRCA	cis	rs73198271	0.562	rs3827810	chr8:8659040	T/G	cg01851573	chr8:8652454	MFHAS1	0.49	7.98	0.3	6.91e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
BRCA	cis	rs427394	0.582	rs274667	chr5:6710771	A/G	cg10857441	chr5:6722123	POLS	0.3	9.51	0.35	3.72e-20	Menopause (age at onset);
BRCA	cis	rs28735056	0.967	rs4799092	chr18:77608203	C/G	cg20368463	chr18:77673604	PQLC1	-0.35	-8.2	-0.31	1.32e-15	Schizophrenia;
BRCA	cis	rs68170813	0.559	rs4730231	chr7:106942039	G/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.72	-0.33	2.33e-17	Coronary artery disease;
BRCA	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg06636001	chr8:8085503	FLJ10661	0.7	15.87	0.53	4.66e-48	Mood instability;
BRCA	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg24578937	chr1:2090814	PRKCZ	0.58	17.99	0.58	7.63e-59	Height;
BRCA	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg06784218	chr1:46089804	CCDC17	-0.53	-12.75	-0.45	2.45e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	28.06	0.74	1.58e-113	Chronic sinus infection;
BRCA	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg13047869	chr3:10149882	C3orf24	0.61	13.07	0.46	9.09e-35	Alzheimer's disease;
BRCA	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-10.78	-0.39	5.15e-25	Longevity;Endometriosis;
BRCA	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg03806693	chr22:41940476	POLR3H	1.09	19.35	0.61	5.17e-66	Vitiligo;
BRCA	cis	rs10129255	0.500	rs2105991	chr14:107138039	C/G	cg07958169	chr14:107095056	NA	-0.38	-8.15	-0.31	1.97e-15	Kawasaki disease;
BRCA	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg02403541	chr12:121454288	C12orf43	0.53	9.96	0.37	7.72e-22	N-glycan levels;
BRCA	cis	rs3820928	0.874	rs6707265	chr2:227849255	T/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.29	-0.31	6.71e-16	Pulmonary function;
BRCA	cis	rs9308433	0.505	rs6695148	chr1:214497861	G/T	cg06198575	chr1:214491504	SMYD2	0.57	12.27	0.44	3.04e-31	IgG glycosylation;
BRCA	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg13010199	chr12:38710504	ALG10B	0.5	9.98	0.37	6.83e-22	Bladder cancer;
BRCA	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08219700	chr8:58056026	NA	0.44	8.0	0.3	5.74e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs4566357	0.615	rs10184991	chr2:227916533	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-9.55	-0.35	2.65e-20	Coronary artery disease;
BRCA	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg17366294	chr4:99064904	C4orf37	0.45	10.64	0.39	1.81e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg23285459	chr7:2802560	GNA12	-0.33	-8.04	-0.3	4.28e-15	Height;
BRCA	cis	rs4642101	0.824	rs3889515	chr3:12844112	G/C	cg24848339	chr3:12840334	CAND2	0.41	10.6	0.39	2.8e-24	QRS complex (12-leadsum);
BRCA	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg08132940	chr7:1081526	C7orf50	-0.6	-8.85	-0.33	8.67e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19346786	chr7:2764209	NA	-0.32	-9.12	-0.34	9.99e-19	Height;
BRCA	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.79	-13.67	-0.48	1.6e-37	Smoking behavior;
BRCA	cis	rs4363385	0.818	rs559236	chr1:153010510	T/C	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	trans	rs8002861	0.935	rs1822969	chr13:44418164	G/A	cg17145862	chr1:211918768	LPGAT1	0.68	17.84	0.58	4.6e-58	Leprosy;
BRCA	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg21856205	chr7:94953877	PON1	-0.37	-7.93	-0.3	9.67e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.87	0.56	4.51e-53	Colorectal cancer;
BRCA	cis	rs10267417	0.603	rs10224041	chr7:19903837	T/C	cg07541023	chr7:19748670	TWISTNB	0.45	8.23	0.31	1.09e-15	Night sleep phenotypes;
BRCA	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.75	-0.33	1.82e-17	Colorectal cancer;
BRCA	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg00990874	chr7:1149470	C7orf50	-0.6	-12.02	-0.43	3.95e-30	Bronchopulmonary dysplasia;
BRCA	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg07636037	chr3:49044803	WDR6	-0.58	-8.0	-0.3	6e-15	Cognitive function;
BRCA	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.84	-0.3	1.86e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg09307838	chr4:120376055	NA	0.69	13.91	0.48	1.24e-38	Corneal astigmatism;
BRCA	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-13.44	-0.47	1.91e-36	Bladder cancer;
BRCA	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg00631329	chr6:26305371	NA	-0.57	-15.8	-0.53	1.09e-47	Educational attainment;
BRCA	cis	rs11971779	0.793	rs11543827	chr7:139032693	G/A	cg07862535	chr7:139043722	LUC7L2	0.45	12.05	0.43	2.88e-30	Diisocyanate-induced asthma;
BRCA	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg05347473	chr6:146136440	FBXO30	-0.4	-7.85	-0.3	1.74e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg01579765	chr21:45077557	HSF2BP	0.34	9.13	0.34	8.7e-19	Mean corpuscular volume;
BRCA	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg18850127	chr7:39170497	POU6F2	0.48	10.86	0.39	2.48e-25	IgG glycosylation;
BRCA	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	12.46	0.44	4.75e-32	Platelet count;
BRCA	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.3e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg24250549	chr1:154909240	PMVK	0.71	18.24	0.59	3.82e-60	Prostate cancer;
BRCA	cis	rs7191700	0.509	rs416603	chr16:11364079	A/T	cg00044050	chr16:11439710	C16orf75	-0.35	-8.44	-0.32	2.09e-16	Multiple sclerosis;
BRCA	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg20607798	chr8:58055168	NA	-0.46	-8.02	-0.3	5.07e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg14675211	chr2:100938903	LONRF2	0.52	12.14	0.43	1.12e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg21747090	chr2:27597821	SNX17	-0.37	-8.0	-0.3	5.8e-15	Total body bone mineral density;
BRCA	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg22705602	chr4:152727874	NA	-0.34	-8.54	-0.32	9.91e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg06115741	chr20:33292138	TP53INP2	-0.36	-7.95	-0.3	8.64e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg13319975	chr6:146136371	FBXO30	0.36	8.07	0.3	3.51e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7246657	0.663	rs9304568	chr19:38054508	C/A	cg14683738	chr19:37701593	ZNF585B	0.47	8.07	0.3	3.58e-15	Coronary artery calcification;
BRCA	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-16.81	-0.55	9.2e-53	Migraine;Coronary artery disease;
BRCA	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg13866156	chr1:1669148	SLC35E2	0.49	10.28	0.38	4.69e-23	Body mass index;
BRCA	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg09904177	chr6:26538194	HMGN4	0.47	14.7	0.5	2.33e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg07080220	chr10:102295463	HIF1AN	0.62	13.79	0.48	4.48e-38	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs312273	0.806	rs10879417	chr12:41347940	T/C	cg17827154	chr12:41323612	CNTN1	-0.42	-10.98	-0.4	8.04e-26	Bipolar disorder;
BRCA	cis	rs4077515	0.839	rs3812563	chr9:139271106	A/G	cg14019695	chr9:139328340	INPP5E	0.31	8.1	0.31	2.73e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs74417235	0.528	rs9324789	chr5:154074362	C/T	cg08754654	chr5:154026448	NA	-0.35	-9.06	-0.34	1.59e-18	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
BRCA	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg01884057	chr2:25150051	NA	0.32	8.46	0.32	1.88e-16	Body mass index in non-asthmatics;
BRCA	cis	rs4561483	0.832	rs33645	chr16:11985201	T/C	cg08843971	chr16:11963173	GSPT1	-0.53	-12.02	-0.43	3.95e-30	Testicular germ cell tumor;
BRCA	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg18279126	chr7:2041391	MAD1L1	0.4	8.88	0.33	6.47e-18	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs13046373	0.535	rs13051135	chr21:32005278	G/A	cg16431978	chr21:31797932	KRTAP13-3	0.36	9.02	0.34	2.22e-18	HDL cholesterol;
BRCA	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg03929089	chr4:120376271	NA	-0.67	-13.39	-0.47	3.19e-36	Height;
BRCA	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13012494	chr21:47604986	C21orf56	0.41	8.4	0.32	2.81e-16	Testicular germ cell tumor;
BRCA	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg11584989	chr19:19387371	SF4	0.3	7.85	0.3	1.71e-14	Tonsillectomy;
BRCA	cis	rs9359856	0.623	rs1179907	chr6:90324849	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.53	-8.65	-0.32	4.01e-17	Bipolar disorder;
BRCA	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg06212747	chr3:49208901	KLHDC8B	0.48	9.72	0.36	6.24e-21	Parkinson's disease;
BRCA	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg05340658	chr4:99064831	C4orf37	0.62	14.8	0.51	8.06e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1691799	0.899	rs903589	chr12:66745835	C/T	cg16791601	chr12:66731901	HELB	-0.63	-17.05	-0.56	5.45e-54	White blood cell count (basophil);
BRCA	cis	rs2481665	0.772	rs6661862	chr1:62534854	A/C	cg18591186	chr1:62594603	INADL	0.54	11.72	0.42	7.14e-29	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	8.48	0.32	1.53e-16	Rheumatoid arthritis;
BRCA	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg18252515	chr7:66147081	NA	1.06	15.89	0.53	3.65e-48	Diabetic kidney disease;
BRCA	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg06618935	chr21:46677482	NA	-0.38	-8.51	-0.32	1.28e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg12311346	chr5:56204834	C5orf35	-0.82	-16.27	-0.54	4.48e-50	Initial pursuit acceleration;
BRCA	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg19338460	chr6:170058176	WDR27	-0.45	-7.85	-0.3	1.72e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-8.0	-0.3	5.94e-15	Ulcerative colitis;
BRCA	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12667521	chr19:29218732	NA	0.47	7.89	0.3	1.35e-14	Methadone dose in opioid dependence;
BRCA	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.8	14.01	0.48	4.26e-39	Platelet count;
BRCA	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg01884057	chr2:25150051	NA	0.3	7.82	0.3	2.21e-14	Body mass index;
BRCA	cis	rs4664304	1.000	rs6735923	chr2:160769588	A/G	cg02280532	chr2:160761244	LY75	-0.4	-8.77	-0.33	1.6e-17	Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg26384229	chr12:38710491	ALG10B	-0.56	-12.0	-0.43	4.67e-30	Morning vs. evening chronotype;
BRCA	cis	rs220324	0.688	rs2236703	chr21:43562525	G/A	cg09727148	chr21:43560719	UMODL1	0.48	8.33	0.31	4.88e-16	Idiopathic osteonecrosis of the femoral head;
BRCA	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.55	-0.39	4.32e-24	Bipolar disorder;
BRCA	cis	rs3771570	1.000	rs73004382	chr2:242382192	C/T	cg21155796	chr2:242212141	HDLBP	0.61	9.34	0.35	1.6e-19	Prostate cancer;
BRCA	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11644478	chr21:40555479	PSMG1	-0.49	-10.42	-0.38	1.34e-23	Menarche (age at onset);
BRCA	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	22.69	0.67	4.49e-84	Platelet count;
BRCA	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02475777	chr4:1388615	CRIPAK	0.61	12.01	0.43	4.01e-30	Longevity;
BRCA	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg23229984	chr5:148520753	ABLIM3	0.35	8.18	0.31	1.56e-15	Breast cancer;
BRCA	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg06784218	chr1:46089804	CCDC17	-0.51	-12.23	-0.44	4.9e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg20887711	chr4:1340912	KIAA1530	0.36	8.53	0.32	1.03e-16	Longevity;
BRCA	trans	rs75804782	0.641	rs2340870	chr2:239356026	C/T	cg01134436	chr17:81009848	B3GNTL1	0.77	9.91	0.36	1.25e-21	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs17601876	0.679	rs11636403	chr15:51548744	A/G	cg19946085	chr15:51559439	CYP19A1	0.32	8.37	0.31	3.65e-16	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.68e-18	Motion sickness;
BRCA	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg10523679	chr1:76189770	ACADM	-0.57	-10.61	-0.39	2.5e-24	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg20019720	chr6:154832845	CNKSR3	0.52	10.31	0.38	3.64e-23	Lipoprotein (a) levels;
BRCA	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg13010199	chr12:38710504	ALG10B	0.44	9.22	0.34	4.31e-19	Morning vs. evening chronotype;
BRCA	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg26874164	chr19:58962979	ZNF324B	0.42	9.17	0.34	6.23e-19	Uric acid clearance;
BRCA	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	13.73	0.48	8.4e-38	Lymphocyte counts;
BRCA	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg25237894	chr2:233734115	C2orf82	0.4	11.42	0.41	1.32e-27	Coronary artery disease;
BRCA	trans	rs877282	0.945	rs11599043	chr10:777972	C/T	cg22713356	chr15:30763199	NA	1.27	24.67	0.7	6.18e-95	Uric acid levels;
BRCA	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg07148914	chr20:33460835	GGT7	-0.42	-8.99	-0.34	2.74e-18	Height;
BRCA	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg20701182	chr2:24300061	SF3B14	0.58	9.14	0.34	7.93e-19	Lymphocyte counts;
BRCA	cis	rs9815354	0.767	rs73087378	chr3:41936827	G/A	cg03022575	chr3:42003672	ULK4	0.68	9.48	0.35	4.71e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs10193935	0.901	rs10189710	chr2:42573102	C/G	cg27598129	chr2:42591480	NA	-0.86	-14.02	-0.49	3.82e-39	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00475322	chr7:917719	C7orf20	0.48	12.85	0.45	9.04e-34	Perceived unattractiveness to mosquitoes;
BRCA	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg17366294	chr4:99064904	C4orf37	0.44	10.43	0.38	1.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg09184832	chr6:79620586	NA	-0.46	-10.07	-0.37	2.95e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg05573699	chr3:52720067	GNL3;PBRM1	-0.33	-7.81	-0.3	2.41e-14	Electroencephalogram traits;
BRCA	cis	rs17604090	0.775	rs76480599	chr7:29689180	A/G	cg19413766	chr7:29689036	LOC646762	-0.5	-7.95	-0.3	8.71e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	trans	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-16.22	-0.54	8.55e-50	Obesity-related traits;
BRCA	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.67	15.55	0.52	1.82e-46	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs9463078	0.547	rs4714819	chr6:44735285	G/C	cg25276700	chr6:44698697	NA	0.39	9.12	0.34	9.57e-19	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg06064525	chr11:970664	AP2A2	-0.33	-9.93	-0.37	1.03e-21	Alzheimer's disease (late onset);
BRCA	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg04756594	chr16:24857601	SLC5A11	0.54	12.08	0.43	2.11e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg17211192	chr8:82754475	SNX16	-0.64	-11.87	-0.43	1.67e-29	Diastolic blood pressure;
BRCA	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	8.68	0.32	3.27e-17	Multiple sclerosis;
BRCA	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-13.37	-0.47	3.82e-36	Bipolar disorder and schizophrenia;
BRCA	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg06238570	chr21:40685208	BRWD1	0.4	8.16	0.31	1.78e-15	Menarche (age at onset);
BRCA	trans	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg15556689	chr8:8085844	FLJ10661	-0.36	-9.54	-0.35	3.02e-20	Triglycerides;
BRCA	cis	rs1712517	0.873	rs1891292	chr10:105001510	A/G	cg05636881	chr10:105038444	INA	-0.4	-9.35	-0.35	1.43e-19	Migraine;
BRCA	cis	rs56399783	0.901	rs56007918	chr7:2826205	A/G	cg19731401	chr7:2775893	GNA12	0.51	8.28	0.31	7.2e-16	Childhood ear infection;
BRCA	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06636551	chr8:101224915	SPAG1	-0.38	-8.62	-0.32	5.27e-17	Atrioventricular conduction;
BRCA	cis	rs7520050	0.966	rs12409773	chr1:46358831	A/G	cg24296786	chr1:45957014	TESK2	0.43	9.66	0.36	1.06e-20	Red blood cell count;Reticulocyte count;
BRCA	trans	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg06521331	chr12:34319734	NA	-0.46	-8.53	-0.32	1.08e-16	Bladder cancer;
BRCA	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg08213375	chr14:104286397	PPP1R13B	0.64	18.05	0.58	3.53e-59	Schizophrenia;
BRCA	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg25124228	chr12:125621409	AACS	-0.48	-10.91	-0.4	1.61e-25	Post bronchodilator FEV1/FVC ratio;
BRCA	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg19183879	chr15:85880815	NA	-0.33	-8.03	-0.3	4.84e-15	Coronary artery disease;
BRCA	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.78	-0.36	3.67e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9815354	0.812	rs17283243	chr3:41914792	C/T	cg03022575	chr3:42003672	ULK4	0.69	9.49	0.35	4.43e-20	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.46	-8.06	-0.3	3.7e-15	Body mass index (adult);
BRCA	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg13852791	chr20:30311386	BCL2L1	0.86	16.53	0.55	2.2e-51	Mean corpuscular hemoglobin;
BRCA	cis	rs2625529	0.878	rs16956302	chr15:72136243	C/T	cg16672083	chr15:72433130	SENP8	-0.83	-16.87	-0.56	4.44e-53	Red blood cell count;
BRCA	cis	rs16976116	0.951	rs3809540	chr15:55489412	A/C	cg11288833	chr15:55489084	RSL24D1	0.48	11.04	0.4	4.83e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg27588902	chr6:42928151	GNMT	-0.31	-10.24	-0.38	7.05e-23	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs11997175	0.583	rs34540455	chr8:33799300	C/T	ch.8.33884649F	chr8:33765107	NA	0.36	8.48	0.32	1.62e-16	Body mass index;
BRCA	cis	rs1451375	0.959	rs1451373	chr7:50622606	A/G	cg18232548	chr7:50535776	DDC	0.43	9.97	0.37	7.51e-22	Malaria;
BRCA	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg01689657	chr7:91764605	CYP51A1	0.21	7.82	0.3	2.26e-14	Breast cancer;
BRCA	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg07262247	chr5:131593730	PDLIM4	0.36	8.58	0.32	7.25e-17	Acylcarnitine levels;
BRCA	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08219700	chr8:58056026	NA	0.45	8.29	0.31	6.75e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.66e-18	Motion sickness;
BRCA	cis	rs2637266	0.967	rs6480826	chr10:78356154	A/G	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.38e-14	Pulmonary function;
BRCA	cis	rs10080237	0.564	rs2490224	chr6:80809833	G/A	cg08355045	chr6:80787529	NA	0.42	11.04	0.4	4.88e-26	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
BRCA	cis	rs7760949	0.889	rs9475816	chr6:13935425	T/C	cg27413430	chr6:13925136	RNF182	0.46	9.24	0.34	3.66e-19	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-15.79	-0.53	1.13e-47	Obesity-related traits;
BRCA	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg26384229	chr12:38710491	ALG10B	0.57	13.42	0.47	2.45e-36	Bladder cancer;
BRCA	cis	rs713587	0.521	rs6545766	chr2:25077856	C/T	cg04586622	chr2:25135609	ADCY3	0.4	10.1	0.37	2.28e-22	Body mass index in non-asthmatics;
BRCA	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.38	-0.31	3.45e-16	Bipolar disorder;
BRCA	cis	rs1712517	0.873	rs1712510	chr10:105009086	A/G	cg05636881	chr10:105038444	INA	-0.39	-9.04	-0.34	1.83e-18	Migraine;
BRCA	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg09307838	chr4:120376055	NA	0.74	15.87	0.53	4.38e-48	Corneal astigmatism;
BRCA	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.19	-19.2	-0.6	3.13e-65	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03264133	chr6:25882463	NA	0.73	16.65	0.55	5.4e-52	Blood metabolite levels;
BRCA	cis	rs9309711	0.922	rs13399524	chr2:3480206	C/G	cg10845886	chr2:3471009	TTC15	-0.73	-16.03	-0.54	7.33e-49	Neurofibrillary tangles;
BRCA	cis	rs6138458	0.961	rs227625	chr20:24911618	T/C	cg06937882	chr20:24974362	C20orf3	-0.44	-8.36	-0.31	3.95e-16	Blood protein levels;
BRCA	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19748678	chr4:122722346	EXOSC9	0.74	15.94	0.53	2.18e-48	Type 2 diabetes;
BRCA	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.02	0.48	4.03e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg23260525	chr10:116636907	FAM160B1	0.3	7.81	0.3	2.42e-14	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg03146154	chr1:46216737	IPP	0.45	9.95	0.37	8.9e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg27661571	chr11:113659931	NA	-0.57	-7.84	-0.3	1.84e-14	Hip circumference adjusted for BMI;
BRCA	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg01877450	chr7:97915802	BRI3	-0.39	-8.8	-0.33	1.3e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.0	22.78	0.67	1.56e-84	Lymphocyte percentage of white cells;
BRCA	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13012494	chr21:47604986	C21orf56	0.45	9.41	0.35	8.83e-20	Testicular germ cell tumor;
BRCA	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg18512352	chr11:47633146	NA	-0.32	-7.97	-0.3	7.41e-15	Subjective well-being;
BRCA	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg05340658	chr4:99064831	C4orf37	0.62	14.78	0.5	9.85e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg18016565	chr1:150552671	MCL1	-0.41	-9.45	-0.35	6.49e-20	Lymphocyte counts;
BRCA	cis	rs56399783	0.901	rs55767077	chr7:2774608	C/T	cg19731401	chr7:2775893	GNA12	0.52	8.28	0.31	7.04e-16	Childhood ear infection;
BRCA	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg20045696	chr14:77926864	AHSA1	-0.42	-7.94	-0.3	8.8e-15	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
BRCA	cis	rs9309473	0.500	rs11688718	chr2:73760939	C/T	cg20560298	chr2:73613845	ALMS1	-0.42	-11.36	-0.41	2.29e-27	Metabolite levels;
BRCA	cis	rs586533	0.881	rs1790265	chr11:99511987	A/G	cg22878054	chr11:99397252	CNTN5	0.31	7.84	0.3	1.85e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg01420254	chr6:26195488	NA	0.59	9.01	0.34	2.36e-18	Gout;Renal underexcretion gout;
BRCA	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg19077165	chr18:44547161	KATNAL2	0.64	14.56	0.5	1.17e-41	Personality dimensions;
BRCA	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg02659138	chr7:134003124	SLC35B4	0.34	10.72	0.39	9.33e-25	Mean platelet volume;
BRCA	cis	rs2594989	1.000	rs346082	chr3:11329216	C/G	cg01796438	chr3:11312864	ATG7	-0.55	-8.27	-0.31	7.57e-16	Circulating chemerin levels;
BRCA	cis	rs2880765	0.743	rs6497194	chr15:86014116	C/T	cg10818794	chr15:86012489	AKAP13	-0.3	-8.3	-0.31	6.38e-16	Coronary artery disease;
BRCA	cis	rs6867032	0.527	rs13190594	chr5:2012474	T/C	cg26168224	chr5:2018326	NA	0.46	12.47	0.44	4.23e-32	Gut microbiome composition (winter);
BRCA	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg05279229	chr7:1896384	MAD1L1	-0.4	-8.05	-0.3	4e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-9.57	-0.35	2.32e-20	Menopause (age at onset);
BRCA	cis	rs6545883	0.965	rs9989775	chr2:61761774	A/G	cg15711740	chr2:61764176	XPO1	-0.55	-14.14	-0.49	1.11e-39	Tuberculosis;
BRCA	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg17366294	chr4:99064904	C4orf37	0.46	10.9	0.4	1.66e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.56	0.42	3.32e-28	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs8058578	0.832	rs35969813	chr16:30714417	T/C	cg02466173	chr16:30829666	NA	-0.5	-10.24	-0.38	7.18e-23	Multiple myeloma;
BRCA	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.76	12.41	0.44	8.15e-32	Platelet count;
BRCA	cis	rs870825	0.616	rs9631782	chr4:185626379	A/G	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg16322792	chr1:120165303	ZNF697	0.57	15.34	0.52	1.82e-45	Systemic lupus erythematosus;
BRCA	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg06636001	chr8:8085503	FLJ10661	0.68	15.42	0.52	7.42e-46	Mood instability;
BRCA	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg25036284	chr2:26402008	FAM59B	-0.68	-11.02	-0.4	5.67e-26	Gut microbiome composition (summer);
BRCA	cis	rs36051895	0.695	rs1327494	chr9:4999303	A/G	cg02405213	chr9:5042618	JAK2	-0.51	-9.06	-0.34	1.58e-18	Pediatric autoimmune diseases;
BRCA	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-10.28	-0.38	4.95e-23	Bipolar disorder;
BRCA	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg24296786	chr1:45957014	TESK2	0.6	14.64	0.5	4.77e-42	High light scatter reticulocyte count;
BRCA	trans	rs587242	0.910	rs6671342	chr1:97000957	T/G	cg10631902	chr5:14652156	NA	0.37	8.9	0.33	5.81e-18	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
BRCA	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-15.73	-0.53	2.29e-47	Electrocardiographic conduction measures;
BRCA	trans	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg26384229	chr12:38710491	ALG10B	0.51	10.82	0.39	3.73e-25	Morning vs. evening chronotype;
BRCA	cis	rs7827545	1.000	rs4909911	chr8:135565255	G/A	cg17885191	chr8:135476712	NA	0.47	9.19	0.34	5.3e-19	Hypertension (SNP x SNP interaction);
BRCA	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	15.63	0.53	6.83e-47	Colorectal cancer;
BRCA	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg20991723	chr1:152506922	NA	0.37	8.29	0.31	6.78e-16	Hair morphology;
BRCA	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.37	0.57	1.19e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg00677455	chr12:58241039	CTDSP2	0.69	16.01	0.54	8.97e-49	Intelligence (multi-trait analysis);
BRCA	trans	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg19862616	chr7:65841803	NCRNA00174	0.79	25.02	0.7	8.03e-97	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs96067	0.805	rs12033825	chr1:36600311	C/T	cg24686825	chr1:36642396	MAP7D1	-0.48	-8.84	-0.33	9.11e-18	Corneal structure;
BRCA	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg08999081	chr20:33150536	PIGU	0.5	14.12	0.49	1.29e-39	Coronary artery disease;
BRCA	trans	rs78049276	0.562	rs55965782	chr4:148378442	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	-0.45	-8.35	-0.31	4.14e-16	Pulse pressure;
BRCA	cis	rs4363385	0.720	rs1338178	chr1:152981550	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.1	-0.34	1.11e-18	Inflammatory skin disease;
BRCA	cis	rs1971762	0.563	rs10219725	chr12:54080865	T/G	cg23533419	chr12:54090519	NA	-0.34	-8.48	-0.32	1.57e-16	Height;
BRCA	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg02951883	chr7:2050386	MAD1L1	-0.38	-8.42	-0.32	2.45e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg24578937	chr1:2090814	PRKCZ	-0.49	-15.96	-0.53	1.67e-48	Height;
BRCA	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.68	-0.36	9.36e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg23625390	chr15:77176239	SCAPER	0.4	9.31	0.35	1.98e-19	Blood metabolite levels;
BRCA	cis	rs2075371	0.871	rs418135	chr7:133949898	A/G	cg20476274	chr7:133979776	SLC35B4	0.59	15.64	0.53	6.64e-47	Mean platelet volume;
BRCA	cis	rs4389656	0.826	rs395939	chr5:6734245	T/C	cg10857441	chr5:6722123	POLS	-0.25	-7.86	-0.3	1.66e-14	Coronary artery disease;
BRCA	cis	rs897080	0.515	rs1067358	chr2:44662183	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	8.96	0.33	3.66e-18	Height;
BRCA	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-9.11	-0.34	1.07e-18	Tonsillectomy;
BRCA	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-13.77	-0.48	5.9e-38	Bipolar disorder and schizophrenia;
BRCA	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg22875332	chr1:76189707	ACADM	0.81	19.69	0.61	8.33e-68	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.06	-25.81	-0.71	3.64e-101	Ulcerative colitis;
BRCA	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg20503657	chr10:835505	NA	0.93	16.59	0.55	1.17e-51	Eosinophil percentage of granulocytes;
BRCA	cis	rs7011049	1.000	rs72643590	chr8:53849595	A/G	cg26025543	chr8:53854495	NA	0.55	9.57	0.35	2.31e-20	Systolic blood pressure;
BRCA	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.41	-7.83	-0.3	2.07e-14	Colorectal cancer;
BRCA	trans	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg25214090	chr10:38739885	LOC399744	0.44	10.29	0.38	4.34e-23	Corneal astigmatism;
BRCA	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.74e-16	Menopause (age at onset);
BRCA	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg11764359	chr7:65958608	NA	-0.67	-12.33	-0.44	1.73e-31	Aortic root size;
BRCA	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg03711944	chr11:47377212	SPI1	-0.31	-8.09	-0.3	3.11e-15	Neuroticism;Neuroticism (multi-trait analysis);
BRCA	cis	rs7953508	0.506	rs2053196	chr12:93962959	T/C	cg18151635	chr12:93972918	NA	-0.47	-9.5	-0.35	4.12e-20	Pubertal anthropometrics;
BRCA	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg09904177	chr6:26538194	HMGN4	-0.56	-18.28	-0.59	2.19e-60	Intelligence (multi-trait analysis);
BRCA	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.57	13.66	0.48	1.96e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs11051970	0.659	rs950082	chr12:32588414	G/T	cg02745156	chr12:32552066	NA	0.27	8.21	0.31	1.27e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg19539972	chr4:7069911	GRPEL1	0.7	16.92	0.56	2.33e-53	Monocyte percentage of white cells;
BRCA	cis	rs4906332	0.834	rs12882130	chr14:103878774	C/G	cg04998671	chr14:104000505	TRMT61A	-0.37	-8.1	-0.31	2.77e-15	Coronary artery disease;
BRCA	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.55	8.33	0.31	4.93e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg18404041	chr3:52824283	ITIH1	-0.31	-8.18	-0.31	1.48e-15	Bipolar disorder;
BRCA	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg27129171	chr3:47204927	SETD2	0.77	19.95	0.62	3.42e-69	Colorectal cancer;
BRCA	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.91	-0.33	5.1e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-9.75	-0.36	5.06e-21	IgG glycosylation;
BRCA	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg21573476	chr21:45109991	RRP1B	-0.35	-9.19	-0.34	5.47e-19	Mean corpuscular volume;
BRCA	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg08885076	chr2:99613938	TSGA10	-0.52	-11.73	-0.42	6.2e-29	Chronic sinus infection;
BRCA	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg27535305	chr1:53392650	SCP2	-0.37	-9.11	-0.34	1.05e-18	Monocyte count;
BRCA	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg12863693	chr15:85201151	NMB	-0.36	-8.66	-0.32	3.71e-17	P wave terminal force;
BRCA	cis	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg06521331	chr12:34319734	NA	-0.65	-11.92	-0.43	1.03e-29	Morning vs. evening chronotype;
BRCA	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg25237894	chr2:233734115	C2orf82	0.4	11.5	0.41	6.01e-28	Coronary artery disease;
BRCA	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg10820045	chr2:198174542	NA	-0.45	-10.47	-0.38	8.77e-24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.8	-18.59	-0.59	5.42e-62	Platelet count;
BRCA	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg26031613	chr14:104095156	KLC1	0.72	15.33	0.52	2.01e-45	Body mass index;
BRCA	cis	rs7352944	0.686	rs6125877	chr20:48658312	G/T	cg17835207	chr20:48524531	SPATA2	0.4	8.93	0.33	4.55e-18	Psoriasis;
BRCA	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.81	0.51	7.41e-43	Colorectal cancer;
BRCA	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg13047869	chr3:10149882	C3orf24	0.58	12.2	0.43	6.43e-31	Alzheimer's disease;
BRCA	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg16482183	chr6:26056742	HIST1H1C	0.54	11.18	0.4	1.23e-26	Height;
BRCA	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg26384229	chr12:38710491	ALG10B	0.67	14.29	0.49	2.1e-40	Morning vs. evening chronotype;
BRCA	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg04450456	chr4:17643702	FAM184B	0.38	11.4	0.41	1.63e-27	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg08885076	chr2:99613938	TSGA10	-0.59	-13.08	-0.46	8e-35	Chronic sinus infection;
BRCA	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg11366901	chr6:160182831	ACAT2	0.69	13.05	0.46	1.14e-34	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs870825	0.616	rs1401362	chr4:185643775	G/A	cg04058563	chr4:185651563	MLF1IP	0.77	17.2	0.56	9.11e-55	Blood protein levels;
BRCA	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-15.27	-0.52	4.31e-45	Systemic lupus erythematosus;
BRCA	trans	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg07211511	chr3:129823064	LOC729375	-0.65	-7.82	-0.3	2.19e-14	Blood pressure (smoking interaction);
BRCA	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.66	10.65	0.39	1.71e-24	Renal function-related traits (BUN);
BRCA	cis	rs35123781	0.696	rs4912756	chr5:139070780	A/T	cg10513866	chr5:139070639	NA	0.44	9.76	0.36	4.65e-21	Schizophrenia;
BRCA	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.13	-0.34	9.19e-19	Bipolar disorder;
BRCA	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03264133	chr6:25882463	NA	-0.48	-10.78	-0.39	5.01e-25	Blood metabolite levels;
BRCA	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg08470875	chr2:26401718	FAM59B	-0.63	-9.41	-0.35	8.56e-20	Gut microbiome composition (summer);
BRCA	trans	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg06521331	chr12:34319734	NA	-0.51	-9.81	-0.36	2.93e-21	Bladder cancer;
BRCA	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg03433033	chr1:76189801	ACADM	0.76	16.93	0.56	2.05e-53	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg23711669	chr6:146136114	FBXO30	-0.71	-16.44	-0.55	6.34e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg21775007	chr8:11205619	TDH	-0.57	-12.88	-0.45	6.51e-34	Retinal vascular caliber;
BRCA	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.62	-0.36	1.51e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg17366294	chr4:99064904	C4orf37	0.42	9.92	0.37	1.13e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg11189052	chr15:85197271	WDR73	-0.38	-9.06	-0.34	1.61e-18	P wave terminal force;
BRCA	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg23711669	chr6:146136114	FBXO30	0.65	15.23	0.52	6.75e-45	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	12.61	0.45	9.85e-33	Electrocardiographic conduction measures;
BRCA	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg18154014	chr19:37997991	ZNF793	0.48	9.11	0.34	1.05e-18	Coronary artery calcification;
BRCA	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	9.31	0.35	1.97e-19	Height;
BRCA	cis	rs7760949	0.889	rs9475795	chr6:13931270	A/C	cg27413430	chr6:13925136	RNF182	0.46	9.34	0.35	1.51e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg06766960	chr11:133703094	NA	-0.61	-12.92	-0.46	4.14e-34	Childhood ear infection;
BRCA	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.62	0.45	8.94e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	8.11	0.31	2.56e-15	Corneal astigmatism;
BRCA	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg10253484	chr15:75165896	SCAMP2	-0.53	-10.12	-0.37	2.04e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg26384229	chr12:38710491	ALG10B	0.75	16.58	0.55	1.31e-51	Morning vs. evening chronotype;
BRCA	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.53	-9.02	-0.34	2.11e-18	Body mass index (adult);
BRCA	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07636037	chr3:49044803	WDR6	0.77	16.73	0.55	2.36e-52	Menarche (age at onset);
BRCA	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.37e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg03188948	chr7:1209495	NA	0.9	14.22	0.49	4.57e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10503871	0.657	rs13248936	chr8:30316162	C/T	cg26383811	chr8:30366931	RBPMS	-0.3	-8.18	-0.31	1.52e-15	Metabolite levels  (X-11787);
BRCA	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg10224037	chr5:178157518	ZNF354A	0.76	16.28	0.54	4.27e-50	Neutrophil percentage of white cells;
BRCA	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.44	-8.15	-0.31	1.9e-15	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg20469991	chr17:27169893	C17orf63	-0.44	-8.77	-0.33	1.57e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg08132940	chr7:1081526	C7orf50	-0.53	-8.21	-0.31	1.24e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.48	-0.32	1.51e-16	Breast cancer;
BRCA	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg08000102	chr2:233561755	GIGYF2	-0.62	-13.39	-0.47	3.37e-36	Coronary artery disease;
BRCA	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg11247378	chr22:39784982	NA	0.62	13.69	0.48	1.34e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-10.17	-0.37	1.23e-22	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg25214090	chr10:38739885	LOC399744	0.5	11.47	0.41	8.07e-28	Corneal astigmatism;
BRCA	cis	rs8005677	1.000	rs4982710	chr14:23398902	C/T	cg01529538	chr14:23388837	RBM23	0.41	11.12	0.4	2.25e-26	Cognitive ability (multi-trait analysis);
BRCA	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg26384229	chr12:38710491	ALG10B	0.76	17.17	0.56	1.31e-54	Bladder cancer;
BRCA	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg21475434	chr5:93447410	FAM172A	0.66	8.49	0.32	1.43e-16	Diabetic retinopathy;
BRCA	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg18404041	chr3:52824283	ITIH1	-0.3	-7.82	-0.3	2.26e-14	Schizophrenia;
BRCA	trans	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.35	-7.92	-0.3	1.07e-14	Corneal astigmatism;
BRCA	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg21770322	chr7:97807741	LMTK2	0.45	11.96	0.43	6.82e-30	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11764359	chr7:65958608	NA	0.62	13.55	0.47	6.08e-37	Aortic root size;
BRCA	cis	rs11585357	0.947	rs6684387	chr1:17611519	T/C	cg19159961	chr1:17633534	PADI4	-0.5	-8.97	-0.33	3.35e-18	Hair shape;
BRCA	cis	rs1003719	0.715	rs1981433	chr21:38542223	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.36	-0.49	1e-40	Eye color traits;
BRCA	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg11789530	chr4:8429930	ACOX3	0.59	14.72	0.5	1.85e-42	Response to antineoplastic agents;
BRCA	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg05863683	chr7:1912471	MAD1L1	0.36	8.27	0.31	7.51e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg25208724	chr1:156163844	SLC25A44	1.0	32.71	0.79	1.26e-138	Testicular germ cell tumor;
BRCA	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.88	-0.33	6.93e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg17507749	chr15:85114479	UBE2QP1	0.57	10.79	0.39	4.64e-25	Schizophrenia;
BRCA	cis	rs3849570	0.961	rs3821548	chr3:81758728	C/G	cg07356753	chr3:81810745	GBE1	-0.45	-10.96	-0.4	1.01e-25	Waist circumference;Body mass index;
BRCA	cis	rs11690935	0.632	rs62183783	chr2:172865775	A/G	cg13550731	chr2:172543902	DYNC1I2	0.51	12.6	0.45	1.2e-32	Schizophrenia;
BRCA	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	23.2	0.68	7.62e-87	Chronic sinus infection;
BRCA	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg18132916	chr6:79620363	NA	-0.4	-8.11	-0.31	2.65e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.88	0.43	1.57e-29	Tonsillectomy;
BRCA	cis	rs6728642	1.000	rs80303184	chr2:98024633	G/A	cg26665480	chr2:98280029	ACTR1B	-0.68	-7.9	-0.3	1.21e-14	Bipolar disorder lithium response (continuous) or schizophrenia;
BRCA	cis	rs738322	0.836	rs4821741	chr22:38514745	A/G	cg20207973	chr22:38506712	BAIAP2L2	0.39	9.84	0.36	2.19e-21	Cutaneous nevi;
BRCA	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg13010199	chr12:38710504	ALG10B	-0.41	-8.75	-0.33	1.94e-17	Morning vs. evening chronotype;
BRCA	cis	rs595018	0.505	rs11230501	chr11:60598075	G/A	cg07268726	chr11:60701918	TMEM132A	-0.48	-7.99	-0.3	6.12e-15	Wegener's granulomatosis;
BRCA	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg25036284	chr2:26402008	FAM59B	-0.64	-10.59	-0.39	3.03e-24	Gut microbiome composition (summer);
BRCA	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.37	8.37	0.31	3.58e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg18357645	chr12:58087776	OS9	0.4	11.63	0.42	1.74e-28	Rheumatoid arthritis;
BRCA	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	8.65e-21	Menopause (age at onset);
BRCA	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg08738300	chr3:44038990	NA	0.44	8.55	0.32	9.12e-17	Coronary artery disease;
BRCA	cis	rs16910800	0.731	rs59845980	chr11:23191511	T/G	cg20040320	chr11:23191996	NA	-0.59	-10.23	-0.38	7.61e-23	Cancer;
BRCA	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg04455712	chr21:45112962	RRP1B	0.38	9.76	0.36	4.61e-21	Mean corpuscular volume;
BRCA	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg22974920	chr21:40686053	BRWD1	-0.36	-8.05	-0.3	4.14e-15	Menarche (age at onset);
BRCA	cis	rs2282802	0.685	rs10077671	chr5:139689505	C/T	cg26211634	chr5:139558579	C5orf32	0.33	8.0	0.3	5.84e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg20203395	chr5:56204925	C5orf35	-0.5	-10.6	-0.39	2.71e-24	Initial pursuit acceleration;
BRCA	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg09307838	chr4:120376055	NA	0.69	13.72	0.48	1.03e-37	Corneal astigmatism;
BRCA	cis	rs11030122	0.661	rs4910877	chr11:4062153	A/G	cg18678763	chr11:4115507	RRM1	-0.34	-8.19	-0.31	1.45e-15	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03264133	chr6:25882463	NA	-0.48	-11.1	-0.4	2.77e-26	Blood metabolite levels;
BRCA	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13012494	chr21:47604986	C21orf56	0.43	8.94	0.33	3.99e-18	Testicular germ cell tumor;
BRCA	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg02153584	chr22:29168773	CCDC117	0.54	11.19	0.4	1.09e-26	Lymphocyte counts;
BRCA	cis	rs2108225	0.714	rs10953548	chr7:107436232	G/A	cg18560240	chr7:107437656	SLC26A3	-0.57	-12.04	-0.43	2.98e-30	Ulcerative colitis;
BRCA	trans	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	28.47	0.75	9.74e-116	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg02176678	chr2:219576539	TTLL4	-0.44	-11.58	-0.42	2.7e-28	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	10.18	0.37	1.2e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs12618769	0.625	rs3769736	chr2:99089119	C/T	cg10123293	chr2:99228465	UNC50	0.42	8.24	0.31	1.01e-15	Bipolar disorder;
BRCA	cis	rs9381107	0.932	rs9369200	chr6:9453471	C/T	cg14735645	chr6:9486422	NA	-0.45	-7.95	-0.3	8.56e-15	Nonsyndromic cleft lip with cleft palate;
BRCA	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg02574844	chr11:5959923	NA	-0.42	-8.16	-0.31	1.79e-15	DNA methylation (variation);
BRCA	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg13393036	chr8:95962371	TP53INP1	-0.3	-8.06	-0.3	3.7e-15	Type 2 diabetes;
BRCA	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg20701182	chr2:24300061	SF3B14	0.66	9.71	0.36	6.96e-21	Lymphocyte counts;
BRCA	cis	rs17401966	0.838	rs12141246	chr1:10327407	A/T	cg03954927	chr1:10346856	KIF1B	0.43	13.57	0.47	5.02e-37	Hepatocellular carcinoma;
BRCA	cis	rs72766638	0.848	rs11789898	chr9:136925663	A/C	cg13789015	chr9:136890014	NCRNA00094	-0.56	-9.04	-0.34	1.82e-18	Mosquito bite size;
BRCA	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg07636037	chr3:49044803	WDR6	0.4	8.16	0.31	1.74e-15	Resting heart rate;
BRCA	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg00277334	chr10:82204260	NA	-0.43	-8.47	-0.32	1.74e-16	Post bronchodilator FEV1;
BRCA	cis	rs7737355	0.947	rs31258	chr5:130824536	G/A	cg06307176	chr5:131281290	NA	0.52	10.4	0.38	1.71e-23	Life satisfaction;
BRCA	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg00814883	chr7:100076585	TSC22D4	-0.52	-11.99	-0.43	4.88e-30	Platelet count;
BRCA	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	14.28	0.49	2.48e-40	Electrocardiographic conduction measures;
BRCA	cis	rs2555155	1.000	rs11604149	chr11:6519642	G/A	cg18103150	chr11:6518907	DNHD1	-0.34	-7.91	-0.3	1.17e-14	DNA methylation (variation);
BRCA	cis	rs479844	0.617	rs12146493	chr11:65547333	G/A	cg08755490	chr11:65554678	OVOL1	0.46	8.8	0.33	1.31e-17	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
BRCA	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	12.89	0.45	5.95e-34	Ileal carcinoids;
BRCA	cis	rs6496044	0.634	rs4843066	chr15:86062911	C/T	cg10818794	chr15:86012489	AKAP13	-0.29	-8.01	-0.3	5.46e-15	Interstitial lung disease;
BRCA	cis	rs1420338	0.933	rs10228731	chr7:34150782	G/T	cg01275685	chr7:34179230	BMPER	-0.46	-10.24	-0.38	6.69e-23	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00166722	chr3:10149974	C3orf24	0.65	11.23	0.41	7.83e-27	Alzheimer's disease;
BRCA	cis	rs9875589	0.509	rs6768383	chr3:14076952	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.34	8.98	0.33	2.93e-18	Ovarian reserve;
BRCA	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.46	8.15	0.31	1.9e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg20933634	chr6:27740509	NA	0.44	8.47	0.32	1.63e-16	Parkinson's disease;
BRCA	cis	rs72928364	1.000	rs79265689	chr3:100621684	C/A	cg10123952	chr3:100791384	NA	0.54	8.07	0.3	3.62e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg21856205	chr7:94953877	PON1	-0.51	-12.48	-0.44	3.9e-32	Paraoxonase activity;
BRCA	cis	rs10911363	0.573	rs2702181	chr1:183516985	T/A	cg09173681	chr1:183549694	NCF2	0.6	11.94	0.43	8.21e-30	Systemic lupus erythematosus;
BRCA	cis	rs4466137	0.953	rs974023	chr5:83014848	T/C	cg15083037	chr5:83017644	HAPLN1	-0.54	-10.86	-0.39	2.45e-25	Prostate cancer;
BRCA	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg23533926	chr12:111358616	MYL2	-0.43	-8.96	-0.33	3.42e-18	Extrinsic epigenetic age acceleration;
BRCA	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg09307838	chr4:120376055	NA	0.75	16.19	0.54	1.12e-49	Corneal astigmatism;
BRCA	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg00277334	chr10:82204260	NA	-0.43	-8.48	-0.32	1.53e-16	Post bronchodilator FEV1;
BRCA	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg17971929	chr21:40555470	PSMG1	-0.47	-10.43	-0.38	1.28e-23	Menarche (age at onset);
BRCA	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-8.44	-0.32	2.21e-16	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.35	-8.75	-0.33	1.84e-17	Total body bone mineral density;
BRCA	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg02640540	chr1:67518911	SLC35D1	-0.42	-8.96	-0.33	3.44e-18	Lymphocyte percentage of white cells;
BRCA	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg06238570	chr21:40685208	BRWD1	-0.4	-8.18	-0.31	1.55e-15	Menarche (age at onset);
BRCA	cis	rs66887589	0.967	rs3775842	chr4:120427732	G/A	cg09307838	chr4:120376055	NA	0.45	9.38	0.35	1.1e-19	Diastolic blood pressure;
BRCA	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.68	0.36	9.37e-21	Bipolar disorder;
BRCA	cis	rs701145	0.537	rs1713832	chr3:153835833	C/T	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.2e-14	Coronary artery disease;
BRCA	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.43	0.38	1.24e-23	Motion sickness;
BRCA	trans	rs11088226	0.846	rs2154501	chr21:33926451	G/A	cg09050820	chr6:167586206	TCP10L2	0.57	10.82	0.39	3.76e-25	Gastritis;
BRCA	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg09537434	chr19:41945824	ATP5SL	-0.98	-23.22	-0.68	6.18e-87	Height;
BRCA	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg16482183	chr6:26056742	HIST1H1C	0.51	10.44	0.38	1.12e-23	Height;
BRCA	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg24642844	chr7:1081250	C7orf50	-0.58	-12.06	-0.43	2.43e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.02e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs7973719	0.865	rs1057225	chr12:7363574	C/G	cg07052231	chr12:7363540	PEX5	0.36	8.16	0.31	1.74e-15	IgG glycosylation;
BRCA	cis	rs7131987	0.903	rs11050162	chr12:29420054	T/G	cg09582351	chr12:29534625	ERGIC2	-0.48	-11.73	-0.42	6.3e-29	QT interval;
BRCA	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg01262667	chr19:19385393	TM6SF2	0.39	7.86	0.3	1.62e-14	Nonalcoholic fatty liver disease;
BRCA	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04530015	chr2:215796436	ABCA12	0.39	8.74	0.33	2.06e-17	Neuroblastoma (high-risk);
BRCA	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg12573674	chr2:1569213	NA	-0.58	-12.65	-0.45	6.98e-33	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg20283391	chr11:68216788	NA	-0.39	-7.81	-0.3	2.38e-14	Total body bone mineral density;
BRCA	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg03477792	chr4:77819574	ANKRD56	0.64	15.41	0.52	8.45e-46	Emphysema distribution in smoking;
BRCA	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg11764359	chr7:65958608	NA	0.61	13.16	0.46	3.58e-35	Aortic root size;
BRCA	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg03474202	chr17:45855739	NA	-0.46	-12.02	-0.43	3.9e-30	IgG glycosylation;
BRCA	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.81	0.39	3.9e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg13906792	chr15:75199810	C15orf17	-0.33	-7.82	-0.3	2.11e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
BRCA	cis	rs73086581	1.000	rs6052218	chr20:3970212	A/G	cg02187196	chr20:3869020	PANK2	0.51	9.22	0.34	4.42e-19	Response to antidepressants in depression;
BRCA	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.4	0.35	9.51e-20	Morning vs. evening chronotype;
BRCA	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.42	9.08	0.34	1.39e-18	Iron status biomarkers;
BRCA	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg13319975	chr6:146136371	FBXO30	0.6	13.61	0.47	3.32e-37	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg19920283	chr7:105172520	RINT1	0.65	12.98	0.46	2.34e-34	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg20090143	chr19:45452003	APOC2	0.27	8.04	0.3	4.44e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00684032	chr4:1343700	KIAA1530	0.43	10.44	0.38	1.16e-23	Obesity-related traits;
BRCA	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg22535103	chr8:58192502	C8orf71	0.58	10.52	0.38	5.36e-24	Developmental language disorder (linguistic errors);
BRCA	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg26195577	chr20:24973756	C20orf3	1.03	28.97	0.75	1.65e-118	Blood protein levels;
BRCA	trans	rs1997103	0.954	rs1997099	chr7:55405540	T/C	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.04e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg04944784	chr2:26401820	FAM59B	-0.95	-16.17	-0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16744531	chr19:17905626	B3GNT3	0.55	11.91	0.43	1.11e-29	Tumor biomarkers;
BRCA	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.45	-10.24	-0.38	6.82e-23	Reticulocyte count;
BRCA	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg26395211	chr5:140044315	WDR55	0.38	8.72	0.33	2.44e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg22705602	chr4:152727874	NA	-0.32	-7.95	-0.3	8.32e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg18230493	chr5:56204884	C5orf35	0.61	13.0	0.46	1.93e-34	Initial pursuit acceleration;
BRCA	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	trans	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg17712092	chr4:129076599	LARP1B	-0.48	-10.53	-0.38	4.9e-24	Breast cancer;
BRCA	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg11766577	chr21:47581405	C21orf56	0.5	10.71	0.39	1.02e-24	Testicular germ cell tumor;
BRCA	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg04455712	chr21:45112962	RRP1B	-0.41	-10.75	-0.39	7.07e-25	Mean corpuscular volume;
BRCA	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07930192	chr7:1003750	NA	-0.47	-10.61	-0.39	2.51e-24	Longevity;Endometriosis;
BRCA	cis	rs16976116	0.901	rs2899581	chr15:55491643	T/C	cg11288833	chr15:55489084	RSL24D1	0.47	10.57	0.39	3.49e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3784262	0.669	rs12595180	chr15:58332541	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.37	-9.94	-0.37	9.69e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs11955398	0.716	rs2409792	chr5:59998236	A/G	cg02684056	chr5:59996105	DEPDC1B	0.39	9.26	0.34	2.94e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.34	-0.44	1.64e-31	Developmental language disorder (linguistic errors);
BRCA	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg05340658	chr4:99064831	C4orf37	0.66	16.1	0.54	3.26e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35110281	0.667	rs914197	chr21:45117439	A/G	cg21573476	chr21:45109991	RRP1B	-0.39	-10.23	-0.38	7.64e-23	Mean corpuscular volume;
BRCA	cis	rs77741769	0.529	rs3213572	chr12:121205078	A/G	cg02419362	chr12:121203948	SPPL3	-0.36	-8.32	-0.31	5.3e-16	Mean corpuscular volume;
BRCA	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg23625390	chr15:77176239	SCAPER	0.51	12.6	0.45	1.12e-32	Blood metabolite levels;
BRCA	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg07080220	chr10:102295463	HIF1AN	0.44	9.78	0.36	3.69e-21	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg24642844	chr7:1081250	C7orf50	-0.59	-12.22	-0.44	5.22e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19346786	chr7:2764209	NA	-0.29	-8.87	-0.33	7.08e-18	Height;
BRCA	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg26384229	chr12:38710491	ALG10B	0.67	14.03	0.49	3.66e-39	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.85	0.3	1.78e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs36051895	0.559	rs1590268	chr9:5209433	T/A	cg02405213	chr9:5042618	JAK2	-0.43	-8.29	-0.31	6.61e-16	Pediatric autoimmune diseases;
BRCA	cis	rs2070488	0.662	rs7373930	chr3:38454931	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.52	11.44	0.41	1.09e-27	Electrocardiographic conduction measures;
BRCA	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg03709012	chr19:19516395	GATAD2A	0.71	15.53	0.52	2.28e-46	Tonsillectomy;
BRCA	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	8.02	0.3	5.24e-15	Multiple sclerosis;
BRCA	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg23711669	chr6:146136114	FBXO30	-0.65	-14.97	-0.51	1.19e-43	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.17	-49.4	-0.89	2.16e-220	Myeloid white cell count;
BRCA	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.44	-9.87	-0.36	1.83e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2712184	0.967	rs1014680	chr2:217672824	A/G	cg05032264	chr2:217675019	NA	0.44	10.77	0.39	5.94e-25	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
BRCA	cis	rs9837602	1.000	rs704582	chr3:99571926	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.58	10.97	0.4	9.25e-26	Breast cancer;
BRCA	trans	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg19862616	chr7:65841803	NCRNA00174	0.81	25.64	0.71	3.13e-100	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs2742234	0.590	rs2435383	chr10:43675671	T/C	cg02780029	chr10:43622663	RET	-0.35	-7.96	-0.3	7.99e-15	Hirschsprung disease;
BRCA	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-10.73	-0.39	8.59e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs3771570	1.000	rs60604866	chr2:242352257	A/G	cg21155796	chr2:242212141	HDLBP	0.59	8.97	0.33	3.19e-18	Prostate cancer;
BRCA	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	ch.11.42038R	chr11:967971	AP2A2	0.52	16.63	0.55	7.59e-52	Alzheimer's disease (late onset);
BRCA	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg27446573	chr6:127587934	RNF146	0.9	21.34	0.65	1.05e-76	Breast cancer;
BRCA	cis	rs7827545	1.000	rs7008158	chr8:135565982	T/C	cg17885191	chr8:135476712	NA	0.47	9.19	0.34	5.3e-19	Hypertension (SNP x SNP interaction);
BRCA	cis	rs1003719	0.715	rs2835658	chr21:38565201	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.42	-0.5	4.91e-41	Eye color traits;
BRCA	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg11584989	chr19:19387371	SF4	0.63	13.18	0.46	3.04e-35	Bipolar disorder;
BRCA	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg20007245	chr22:24372913	LOC391322	-0.57	-12.78	-0.45	1.88e-33	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs6484504	0.576	rs208083	chr11:31196880	C/T	cg06552810	chr11:31128660	NA	-0.39	-8.7	-0.33	2.76e-17	Red blood cell count;
BRCA	cis	rs7833986	0.501	rs72653948	chr8:56955689	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.66	12.58	0.45	1.35e-32	Height;
BRCA	cis	rs7520050	0.966	rs10890363	chr1:46356148	C/T	cg24296786	chr1:45957014	TESK2	-0.43	-9.58	-0.35	2.1e-20	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg25237894	chr2:233734115	C2orf82	0.39	11.31	0.41	3.6e-27	Coronary artery disease;
BRCA	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.44	13.01	0.46	1.78e-34	Response to antipsychotic treatment;
BRCA	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg10729496	chr3:10149963	C3orf24	0.49	9.01	0.34	2.35e-18	Alzheimer's disease;
BRCA	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg11764359	chr7:65958608	NA	0.64	11.46	0.41	8.75e-28	Aortic root size;
BRCA	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg21427119	chr20:30132790	HM13	-0.42	-8.89	-0.33	6.37e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg04944784	chr2:26401820	FAM59B	0.96	16.87	0.56	4.16e-53	Gut microbiome composition (summer);
BRCA	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg13010199	chr12:38710504	ALG10B	-0.39	-8.36	-0.31	3.88e-16	Bladder cancer;
BRCA	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24229701	chr12:130821962	PIWIL1	0.39	8.95	0.33	3.76e-18	Menopause (age at onset);
BRCA	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-12.89	-0.45	6.01e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-7.93	-0.3	9.87e-15	Aortic root size;
BRCA	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg00409905	chr10:38381863	ZNF37A	0.48	9.55	0.35	2.64e-20	Extrinsic epigenetic age acceleration;
BRCA	cis	rs3818285	0.504	rs7100154	chr10:111650150	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.32	-8.48	-0.32	1.61e-16	Superior crus of antihelix expression;
BRCA	cis	rs2731664	0.721	rs2450333	chr5:176899546	G/A	cg23176889	chr5:176863531	GRK6	-0.59	-15.55	-0.52	1.8e-46	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg14863265	chr7:2801509	GNA12	-0.43	-9.24	-0.34	3.72e-19	Height;
BRCA	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg04362960	chr10:104952993	NT5C2	0.44	9.79	0.36	3.4e-21	Arsenic metabolism;
BRCA	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg00666640	chr1:248458726	OR2T12	0.33	9.04	0.34	1.85e-18	Common traits (Other);
BRCA	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg23231163	chr10:75533350	FUT11	-0.33	-8.65	-0.32	4.1e-17	Inflammatory bowel disease;
BRCA	cis	rs2625529	0.689	rs12898868	chr15:72112918	A/G	cg16672083	chr15:72433130	SENP8	0.63	14.74	0.5	1.59e-42	Red blood cell count;
BRCA	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.71	16.83	0.55	7.02e-53	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg14835575	chr10:16859367	RSU1	0.66	14.11	0.49	1.5e-39	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg09904177	chr6:26538194	HMGN4	0.55	17.63	0.57	5.85e-57	Intelligence (multi-trait analysis);
BRCA	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg21132104	chr15:45694354	SPATA5L1	0.7	15.45	0.52	5.52e-46	Homoarginine levels;
BRCA	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11764359	chr7:65958608	NA	0.77	17.32	0.57	2.26e-55	Aortic root size;
BRCA	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.46	-9.98	-0.37	6.81e-22	Multiple sclerosis;
BRCA	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-10.4	-0.38	1.63e-23	Bladder cancer;
BRCA	cis	rs735860	0.712	rs3736732	chr6:53160383	G/T	cg10236188	chr6:53219634	NA	-0.41	-8.77	-0.33	1.64e-17	Glaucoma;
BRCA	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg01528321	chr10:82214614	TSPAN14	0.85	18.93	0.6	8.63e-64	Post bronchodilator FEV1;
BRCA	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19346786	chr7:2764209	NA	0.32	9.77	0.36	4.33e-21	Height;
BRCA	cis	rs56399783	0.901	rs73033403	chr7:2877941	G/A	cg19731401	chr7:2775893	GNA12	0.54	8.25	0.31	9.25e-16	Childhood ear infection;
BRCA	cis	rs4722166	0.532	rs4719712	chr7:22755807	C/T	cg05472934	chr7:22766657	IL6	0.43	10.62	0.39	2.26e-24	Lung cancer;
BRCA	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	10.75	0.39	7.02e-25	Bone mineral density;
BRCA	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg21856205	chr7:94953877	PON1	-0.37	-8.03	-0.3	4.74e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg07537917	chr2:241836409	C2orf54	-0.43	-10.45	-0.38	1.04e-23	Urinary metabolites;
BRCA	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06108461	chr20:60628389	TAF4	0.91	16.91	0.56	2.66e-53	Body mass index;
BRCA	cis	rs490234	0.702	rs1891035	chr9:128258684	T/C	cg14078157	chr9:128172775	NA	-0.53	-11.75	-0.42	5.48e-29	Mean arterial pressure;
BRCA	trans	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg26043149	chr18:55253948	FECH	0.41	9.09	0.34	1.28e-18	Bone mineral density;
BRCA	cis	rs7520050	0.966	rs12561806	chr1:46396776	C/T	cg24296786	chr1:45957014	TESK2	0.44	9.8	0.36	3.19e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg08888203	chr3:10149979	C3orf24	0.65	13.64	0.47	2.35e-37	Alzheimer's disease;
BRCA	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-14.19	-0.49	6.54e-40	Morning vs. evening chronotype;
BRCA	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg26384229	chr12:38710491	ALG10B	0.73	17.15	0.56	1.68e-54	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg03676636	chr4:99064102	C4orf37	0.24	8.26	0.31	8.47e-16	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg24812749	chr6:127587940	RNF146	0.66	14.88	0.51	3.15e-43	Breast cancer;
BRCA	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	20.85	0.64	4.81e-74	Electrocardiographic conduction measures;
BRCA	cis	rs3820928	0.874	rs9288618	chr2:227872617	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.37	-0.31	3.61e-16	Pulmonary function;
BRCA	cis	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg06521331	chr12:34319734	NA	-0.56	-10.84	-0.39	2.95e-25	Morning vs. evening chronotype;
BRCA	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg08888203	chr3:10149979	C3orf24	0.59	12.1	0.43	1.67e-30	Alzheimer's disease;
BRCA	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg24642439	chr20:33292090	TP53INP2	0.43	9.11	0.34	1.03e-18	Height;
BRCA	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	11.1	0.4	2.69e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03517284	chr6:25882590	NA	0.69	15.83	0.53	7.39e-48	Blood metabolite levels;
BRCA	cis	rs9815354	0.904	rs73081347	chr3:41903582	T/C	cg03022575	chr3:42003672	ULK4	0.71	9.74	0.36	5.4e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs4268898	0.735	rs12469585	chr2:24489054	A/T	cg06627628	chr2:24431161	ITSN2	0.41	8.63	0.32	4.96e-17	Asthma;
BRCA	cis	rs911119	0.955	rs12625716	chr20:23606845	A/G	cg16589663	chr20:23618590	CST3	-0.43	-8.05	-0.3	4.04e-15	Chronic kidney disease;
BRCA	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg25801113	chr15:45476975	SHF	0.31	8.05	0.3	4.02e-15	Uric acid levels;
BRCA	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg13175981	chr1:150552382	MCL1	0.41	9.04	0.34	1.79e-18	Tonsillectomy;
BRCA	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg09455208	chr3:40491958	NA	0.41	9.77	0.36	4.33e-21	Renal cell carcinoma;
BRCA	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg13319975	chr6:146136371	FBXO30	0.43	10.01	0.37	5.43e-22	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7119038	0.509	rs10892256	chr11:118578705	G/A	cg19308663	chr11:118741387	NA	0.38	8.53	0.32	1.1e-16	Sjögren's syndrome;
BRCA	cis	rs7577696	0.524	rs61399065	chr2:32208554	G/A	cg02381751	chr2:32503542	YIPF4	-0.43	-8.03	-0.3	4.82e-15	Inflammatory biomarkers;
BRCA	cis	rs2559856	0.967	rs7970837	chr12:102081576	A/G	cg12924262	chr12:102091054	CHPT1	0.36	8.16	0.31	1.82e-15	Blood protein levels;
BRCA	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.44	-0.32	2.15e-16	Colorectal cancer;
BRCA	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	12.26	0.44	3.39e-31	Hip circumference adjusted for BMI;
BRCA	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.36	0.49	1e-40	Motion sickness;
BRCA	trans	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg25214090	chr10:38739885	LOC399744	0.44	9.98	0.37	6.57e-22	Corneal astigmatism;
BRCA	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg02951883	chr7:2050386	MAD1L1	-0.38	-9.11	-0.34	1.06e-18	Bipolar disorder and schizophrenia;
BRCA	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25373794	chr1:162760220	HSD17B7	-0.41	-8.06	-0.3	3.89e-15	Breast cancer;
BRCA	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg10523679	chr1:76189770	ACADM	0.71	13.01	0.46	1.74e-34	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg08847533	chr14:75593920	NEK9	-0.85	-21.31	-0.64	1.61e-76	Height;
BRCA	cis	rs1710278	0.904	rs1278261	chr10:127746275	C/G	cg22975853	chr10:127789788	ADAM12	0.3	7.91	0.3	1.17e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
BRCA	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg24006582	chr15:45444508	DUOX1	-0.55	-11.31	-0.41	3.61e-27	Uric acid levels;
BRCA	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg20701182	chr2:24300061	SF3B14	0.58	9.11	0.34	1.04e-18	Lymphocyte counts;
BRCA	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.57	0.35	2.29e-20	Morning vs. evening chronotype;
BRCA	trans	rs853679	0.546	rs2232423	chr6:28366151	A/G	cg06606381	chr12:133084897	FBRSL1	-0.9	-8.84	-0.33	9.38e-18	Depression;
BRCA	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg20887711	chr4:1340912	KIAA1530	0.45	10.52	0.38	5.44e-24	Longevity;
BRCA	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg10556349	chr10:835070	NA	0.59	8.09	0.3	3.05e-15	Eosinophil percentage of granulocytes;
BRCA	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.74	-18.14	-0.58	1.29e-59	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.47	8.36	0.31	4.07e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs13102973	0.864	rs7442176	chr4:135899575	C/A	cg14419869	chr4:135874104	NA	-0.52	-10.64	-0.39	1.87e-24	Subjective well-being;
BRCA	cis	rs4363385	0.818	rs6587719	chr1:152993409	G/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.36	-0.31	3.81e-16	Inflammatory skin disease;
BRCA	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg06640241	chr16:89574553	SPG7	-0.52	-11.1	-0.4	2.66e-26	Multiple myeloma (IgH translocation);
BRCA	cis	rs9815354	0.812	rs73071330	chr3:41810553	T/G	cg03022575	chr3:42003672	ULK4	0.72	9.84	0.36	2.33e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-10.81	-0.39	4.05e-25	Total cholesterol levels;
BRCA	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg06627628	chr2:24431161	ITSN2	-0.78	-14.9	-0.51	2.64e-43	Asthma;
BRCA	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg04450456	chr4:17643702	FAM184B	0.36	10.6	0.39	2.63e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg12386194	chr3:101231763	SENP7	0.41	8.81	0.33	1.19e-17	Colorectal cancer;
BRCA	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg17971929	chr21:40555470	PSMG1	-0.48	-10.73	-0.39	8.59e-25	Menarche (age at onset);
BRCA	cis	rs12711979	1.000	rs6542655	chr2:3872434	T/C	cg17052675	chr2:3827356	NA	-0.43	-11.55	-0.42	3.63e-28	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg11812906	chr14:75593930	NEK9	-0.58	-13.02	-0.46	1.49e-34	Height;
BRCA	cis	rs4423214	0.840	rs1792227	chr11:71177412	A/G	cg05163923	chr11:71159392	DHCR7	-0.57	-11.6	-0.42	2.31e-28	Vitamin D levels;
BRCA	cis	rs17092148	0.887	rs6059919	chr20:33151545	G/T	cg16810054	chr20:33298113	TP53INP2	-0.48	-10.31	-0.38	3.66e-23	Neuroticism;
BRCA	cis	rs28493229	0.522	rs17713068	chr19:41270055	A/C	cg21869046	chr19:41225005	ITPKC	0.38	9.74	0.36	5.4e-21	Kawasaki disease;
BRCA	cis	rs7639513	0.590	rs3729931	chr3:12626516	A/G	cg23032965	chr3:12705835	RAF1	-0.59	-12.53	-0.44	2.32e-32	Itch intensity from mosquito bite;
BRCA	cis	rs12612619	0.732	rs7585410	chr2:27202120	A/G	cg00617064	chr2:27272375	NA	-0.32	-8.37	-0.31	3.53e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg09754948	chr16:28834200	ATXN2L	0.45	8.9	0.33	5.77e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg08885076	chr2:99613938	TSGA10	-0.52	-11.8	-0.42	3.27e-29	Chronic sinus infection;
BRCA	cis	rs870825	0.616	rs7678949	chr4:185635018	G/C	cg04058563	chr4:185651563	MLF1IP	0.78	17.56	0.57	1.28e-56	Blood protein levels;
BRCA	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	14.9	0.51	2.58e-43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.62	-14.06	-0.49	2.6e-39	Platelet count;
BRCA	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg06784218	chr1:46089804	CCDC17	0.44	10.65	0.39	1.65e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-12.33	-0.44	1.69e-31	Chronic sinus infection;
BRCA	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg23649088	chr2:200775458	C2orf69	0.62	10.94	0.4	1.21e-25	Schizophrenia;
BRCA	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.71	0.36	7.2e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg24803719	chr17:45855879	NA	-0.32	-8.35	-0.31	4.14e-16	IgG glycosylation;
BRCA	cis	rs9420	0.961	rs499188	chr11:57434122	C/A	cg19752551	chr11:57585705	CTNND1	-0.41	-10.38	-0.38	1.92e-23	Schizophrenia;
BRCA	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-11.68	-0.42	1.06e-28	Hemoglobin concentration;
BRCA	cis	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-9.41	-0.35	8.79e-20	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-8.03	-0.3	4.53e-15	Corneal astigmatism;
BRCA	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	11.32	0.41	3.23e-27	Monocyte percentage of white cells;
BRCA	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg17971929	chr21:40555470	PSMG1	0.74	15.42	0.52	7.52e-46	Cognitive function;
BRCA	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg12573674	chr2:1569213	NA	-0.56	-12.07	-0.43	2.35e-30	IgG glycosylation;
BRCA	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.28	9.08	0.34	1.28e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg07148914	chr20:33460835	GGT7	0.44	9.61	0.36	1.63e-20	Height;
BRCA	trans	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg25214090	chr10:38739885	LOC399744	0.46	10.68	0.39	1.28e-24	Corneal astigmatism;
BRCA	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg08392591	chr16:89556376	ANKRD11	0.47	11.25	0.41	6.25e-27	Multiple myeloma (IgH translocation);
BRCA	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg14092571	chr14:90743983	NA	-0.38	-9.55	-0.35	2.73e-20	Mortality in heart failure;
BRCA	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg22800045	chr5:56110881	MAP3K1	0.65	12.21	0.43	5.84e-31	Initial pursuit acceleration;
BRCA	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg12311346	chr5:56204834	C5orf35	-0.73	-14.67	-0.5	3.42e-42	Initial pursuit acceleration;
BRCA	cis	rs2694528	0.686	rs6864253	chr5:59862743	A/G	cg11474532	chr5:59995715	DEPDC1B	0.63	9.46	0.35	5.7e-20	Parkinson's disease;
BRCA	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg11812906	chr14:75593930	NEK9	-0.6	-14.03	-0.49	3.71e-39	Height;
BRCA	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	12.7	0.45	3.91e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg25214090	chr10:38739885	LOC399744	0.53	11.71	0.42	7.51e-29	Corneal astigmatism;
BRCA	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg23625390	chr15:77176239	SCAPER	0.48	11.45	0.41	9.27e-28	Blood metabolite levels;
BRCA	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg20203395	chr5:56204925	C5orf35	0.39	8.57	0.32	8.02e-17	Initial pursuit acceleration;
BRCA	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg10253484	chr15:75165896	SCAMP2	0.61	12.03	0.43	3.51e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14240646	chr10:27532245	ACBD5	-0.63	-9.93	-0.37	1.05e-21	Breast cancer;
BRCA	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg25554036	chr4:6271136	WFS1	0.38	8.61	0.32	5.8e-17	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs1538970	0.962	rs3219489	chr1:45797505	C/G	cg05343316	chr1:45956843	TESK2	0.52	9.7	0.36	7.47e-21	Platelet count;
BRCA	cis	rs6987853	0.736	rs6991995	chr8:42436219	A/C	cg09913449	chr8:42400586	C8orf40	0.42	9.27	0.34	2.81e-19	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg26384229	chr12:38710491	ALG10B	0.69	16.06	0.54	5.54e-49	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg20302533	chr7:39170763	POU6F2	0.38	8.06	0.3	3.78e-15	IgG glycosylation;
BRCA	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg18016565	chr1:150552671	MCL1	0.35	8.25	0.31	9.22e-16	Tonsillectomy;
BRCA	cis	rs6545883	0.826	rs777590	chr2:61417145	C/G	cg15711740	chr2:61764176	XPO1	-0.52	-13.11	-0.46	5.93e-35	Tuberculosis;
BRCA	cis	rs7246657	0.722	rs1975937	chr19:38091932	A/T	cg18154014	chr19:37997991	ZNF793	0.49	9.35	0.35	1.42e-19	Coronary artery calcification;
BRCA	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg08508325	chr11:3079039	CARS	-0.41	-14.29	-0.49	2.15e-40	Longevity;
BRCA	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.58	10.28	0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg04362960	chr10:104952993	NT5C2	-0.35	-8.08	-0.3	3.36e-15	Waist circumference;Hip circumference;
BRCA	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.69	16.09	0.54	3.63e-49	Axial length;
BRCA	trans	rs2270927	0.510	rs7730153	chr5:75579762	A/G	cg13563193	chr19:33072644	PDCD5	-0.77	-9.55	-0.35	2.71e-20	Mean corpuscular volume;
BRCA	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.32	-7.98	-0.3	6.6e-15	Total body bone mineral density;
BRCA	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg14683738	chr19:37701593	ZNF585B	-0.48	-8.37	-0.31	3.73e-16	Coronary artery calcification;
BRCA	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg01858014	chr14:56050164	KTN1	-0.76	-10.46	-0.38	9.82e-24	Putamen volume;
BRCA	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11890956	chr21:40555474	PSMG1	-0.81	-19.26	-0.61	1.65e-65	Cognitive function;
BRCA	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	8.89	0.33	6.45e-18	Iron status biomarkers;
BRCA	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.32	10.13	0.37	1.84e-22	Bipolar disorder;
BRCA	trans	rs75804782	0.521	rs72993074	chr2:239413582	T/G	cg01134436	chr17:81009848	B3GNTL1	0.67	8.56	0.32	8.1e-17	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs944002	1.000	rs2297067	chr14:103566785	A/G	cg01104208	chr14:103566172	C14orf73	0.45	8.83	0.33	1.02e-17	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;
BRCA	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg27147174	chr7:100797783	AP1S1	-0.54	-10.87	-0.4	2.35e-25	Life satisfaction;
BRCA	cis	rs56399783	0.901	rs12540539	chr7:2873294	C/T	cg19731401	chr7:2775893	GNA12	0.54	8.25	0.31	9.25e-16	Childhood ear infection;
BRCA	cis	rs9649465	0.967	rs11765790	chr7:123293152	A/C	cg04330084	chr7:123175371	IQUB	-0.31	-8.48	-0.32	1.51e-16	Migraine;
BRCA	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11644478	chr21:40555479	PSMG1	-0.51	-10.84	-0.39	3.1e-25	Menarche (age at onset);
BRCA	trans	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-13.94	-0.48	9.76e-39	Obesity-related traits;
BRCA	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg15448220	chr1:150897856	SETDB1	0.35	7.82	0.3	2.21e-14	Melanoma;
BRCA	cis	rs400736	0.602	rs11121090	chr1:8168634	A/G	cg25007680	chr1:8021821	PARK7	0.35	8.78	0.33	1.55e-17	Response to antidepressants and depression;
BRCA	cis	rs3815700	1.000	rs7248273	chr19:33096816	C/T	cg02997394	chr19:33096574	ANKRD27	0.66	10.2	0.37	1.01e-22	Eosinophilic esophagitis;
BRCA	trans	rs1973993	0.561	rs3862908	chr1:96987042	G/A	cg10631902	chr5:14652156	NA	-0.39	-9.83	-0.36	2.46e-21	Weight;
BRCA	trans	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.71	-0.36	6.9e-21	Bladder cancer;
BRCA	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg18758796	chr5:131593413	PDLIM4	0.34	8.76	0.33	1.72e-17	Breast cancer;
BRCA	cis	rs7593730	0.537	rs6711375	chr2:161090873	G/A	cg22609984	chr2:161126801	NA	0.39	8.59	0.32	6.56e-17	Type 2 diabetes;
BRCA	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg23711669	chr6:146136114	FBXO30	0.64	14.65	0.5	4.06e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg26587870	chr6:27730563	NA	-0.39	-8.31	-0.31	5.84e-16	Parkinson's disease;
BRCA	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.12	-0.43	1.38e-30	Total cholesterol levels;
BRCA	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg03146154	chr1:46216737	IPP	-0.43	-9.08	-0.34	1.39e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.49	8.7	0.33	2.9e-17	Mean platelet volume;
BRCA	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg00031303	chr3:195681400	NA	0.72	12.11	0.43	1.57e-30	Pancreatic cancer;
BRCA	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg10636054	chr15:40330586	SRP14	0.84	12.29	0.44	2.62e-31	Corneal curvature;
BRCA	cis	rs7131987	0.641	rs2015599	chr12:29435480	G/A	cg09582351	chr12:29534625	ERGIC2	-0.34	-8.37	-0.31	3.63e-16	QT interval;
BRCA	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.36	8.18	0.31	1.53e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4953318	0.894	rs10495928	chr2:46353166	A/G	cg12428440	chr2:46370979	PRKCE	0.4	9.44	0.35	6.98e-20	Red blood cell count;Hematocrit;Red blood cell traits;
BRCA	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	11.95	0.43	7.69e-30	Tonsillectomy;
BRCA	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg00530320	chr1:46809349	NSUN4	0.49	9.78	0.36	3.91e-21	Menopause (age at onset);
BRCA	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg19318889	chr4:1322082	MAEA	0.58	12.1	0.43	1.71e-30	Longevity;
BRCA	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.39	-10.12	-0.37	2e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg03060546	chr3:49711283	APEH	-0.53	-10.54	-0.38	4.55e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg05347473	chr6:146136440	FBXO30	-0.59	-11.22	-0.41	8.96e-27	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7707921	0.846	rs4293895	chr5:81425592	T/C	cg15871215	chr5:81402204	ATG10	-0.41	-8.73	-0.33	2.15e-17	Breast cancer;
BRCA	cis	rs6763687	0.856	rs9862371	chr3:171803226	G/T	cg16233210	chr3:171778391	FNDC3B	-0.43	-10.28	-0.38	4.88e-23	Red cell distribution width;
BRCA	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg14530993	chr4:882597	GAK	0.57	10.19	0.37	1.09e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg02574844	chr11:5959923	NA	-0.42	-8.84	-0.33	9.53e-18	DNA methylation (variation);
BRCA	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	14.08	0.49	1.97e-39	Hip circumference adjusted for BMI;
BRCA	cis	rs3784262	0.631	rs4646560	chr15:58353546	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-10.27	-0.38	5.35e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg06547715	chr2:218990976	CXCR2	0.32	7.89	0.3	1.3e-14	Ulcerative colitis;
BRCA	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-10.53	-0.38	5.29e-24	Heart rate;
BRCA	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.57	9.85	0.36	2.04e-21	Gut microbiome composition (summer);
BRCA	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg20587970	chr11:113659929	NA	-1.34	-24.68	-0.7	5.51e-95	Hip circumference adjusted for BMI;
BRCA	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg25358565	chr5:93447407	FAM172A	1.17	18.68	0.59	1.81e-62	Diabetic retinopathy;
BRCA	trans	rs12517041	1.000	rs4701363	chr5:23301008	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.83	-0.3	2.03e-14	Calcium levels;
BRCA	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg01877450	chr7:97915802	BRI3	0.39	8.13	0.31	2.23e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg15112475	chr7:1198522	ZFAND2A	-0.38	-8.89	-0.33	6.26e-18	Longevity;Endometriosis;
BRCA	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.43	-11.13	-0.4	1.99e-26	Schizophrenia;
BRCA	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg14196790	chr5:131705035	SLC22A5	0.5	13.19	0.46	2.56e-35	Blood metabolite levels;
BRCA	cis	rs71636778	0.722	rs116491347	chr1:27172684	C/T	cg12203394	chr1:27248618	NUDC	0.53	8.52	0.32	1.17e-16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg01181863	chr3:195395398	SDHAP2	-0.46	-8.16	-0.31	1.73e-15	Pancreatic cancer;
BRCA	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg16586182	chr3:47516702	SCAP	0.44	8.9	0.33	5.67e-18	Birth weight;
BRCA	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg09307838	chr4:120376055	NA	0.69	14.25	0.49	3.17e-40	Corneal astigmatism;
BRCA	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg16584290	chr5:462447	EXOC3	0.54	15.14	0.51	1.72e-44	Cystic fibrosis severity;
BRCA	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg18904891	chr8:8559673	CLDN23	0.61	12.08	0.43	2.19e-30	Obesity-related traits;
BRCA	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg01777586	chr17:80163174	CCDC57	0.39	8.03	0.3	4.64e-15	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg06808227	chr14:105710500	BRF1	-0.79	-16.39	-0.54	1.17e-50	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-11.36	-0.41	2.19e-27	Mood instability;
BRCA	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg13256891	chr4:100009986	ADH5	0.53	9.84	0.36	2.22e-21	Smoking initiation;
BRCA	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.94	20.32	0.63	3.65e-71	Gut microbiome composition (summer);
BRCA	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg10253484	chr15:75165896	SCAMP2	-0.53	-9.92	-0.37	1.1e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg13256891	chr4:100009986	ADH5	0.54	10.01	0.37	5.06e-22	Alcohol dependence;
BRCA	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg21573476	chr21:45109991	RRP1B	-0.36	-9.14	-0.34	8.31e-19	Mean corpuscular volume;
BRCA	cis	rs3768617	0.811	rs10911232	chr1:183052533	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	9.34	0.35	1.52e-19	Fuchs's corneal dystrophy;
BRCA	cis	rs910873	0.505	rs6059961	chr20:33231490	T/C	cg16810054	chr20:33298113	TP53INP2	-0.47	-10.19	-0.37	1.1e-22	Melanoma;
BRCA	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg22705602	chr4:152727874	NA	-0.32	-8.0	-0.3	6.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg10223061	chr2:219282414	VIL1	0.29	8.04	0.3	4.22e-15	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	15.12	0.51	2.34e-44	Platelet count;
BRCA	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg26384229	chr12:38710491	ALG10B	0.69	16.07	0.54	4.72e-49	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg09789173	chr7:4769017	FOXK1	-0.49	-11.43	-0.41	1.2e-27	Mosquito bite size;
BRCA	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg07395648	chr5:131743802	NA	-0.36	-7.89	-0.3	1.28e-14	Breast cancer;
BRCA	cis	rs7267979	0.714	rs6115107	chr20:25237390	A/G	cg08601574	chr20:25228251	PYGB	0.34	8.1	0.3	2.89e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg24558204	chr6:135376177	HBS1L	0.44	12.19	0.43	7.21e-31	Red blood cell count;
BRCA	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	8.35	0.31	4.13e-16	Rheumatoid arthritis;
BRCA	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg22713356	chr15:30763199	NA	1.17	24.0	0.69	3.28e-91	Uric acid levels;
BRCA	trans	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg23762105	chr12:34175262	ALG10	0.38	8.65	0.32	4.26e-17	Morning vs. evening chronotype;
BRCA	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg07606381	chr6:8435919	SLC35B3	0.65	14.41	0.5	5.45e-41	Motion sickness;
BRCA	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-12.42	-0.44	7.23e-32	Response to antipsychotic treatment;
BRCA	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg23933602	chr10:16859644	RSU1	0.55	8.99	0.33	2.88e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
BRCA	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg14863265	chr7:2801509	GNA12	-0.45	-9.67	-0.36	9.74e-21	Height;
BRCA	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.37	0.57	1.21e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg18351406	chr4:77819688	ANKRD56	0.61	13.39	0.47	3.29e-36	Emphysema distribution in smoking;
BRCA	cis	rs943466	1.000	rs61394483	chr6:33751945	G/A	cg25922239	chr6:33757077	LEMD2	-0.38	-7.84	-0.3	1.9e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
BRCA	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg00105475	chr2:10696890	NA	0.44	10.41	0.38	1.56e-23	Prostate cancer;
BRCA	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg12863693	chr15:85201151	NMB	-0.38	-9.01	-0.34	2.42e-18	P wave terminal force;
BRCA	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	12.75	0.45	2.5e-33	Lung cancer in ever smokers;
BRCA	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	18.57	0.59	7.01e-62	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03264133	chr6:25882463	NA	-0.67	-14.93	-0.51	1.83e-43	Intelligence (multi-trait analysis);
BRCA	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg07169764	chr2:136633963	MCM6	1.28	28.78	0.75	1.99e-117	Corneal structure;
BRCA	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg18512352	chr11:47633146	NA	-0.34	-8.24	-0.31	9.79e-16	Subjective well-being;
BRCA	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-13.42	-0.47	2.45e-36	Personality dimensions;
BRCA	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg12935359	chr14:103987150	CKB	0.62	14.43	0.5	4.64e-41	Intelligence (multi-trait analysis);
BRCA	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg03146154	chr1:46216737	IPP	0.54	12.12	0.43	1.45e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg15662616	chr7:148823355	ZNF425;ZNF398	0.45	10.13	0.37	1.75e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	trans	rs9944715	1.000	rs6507693	chr18:43829137	G/A	cg01718231	chr17:29326311	RNF135	-0.46	-9.26	-0.34	3.18e-19	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.48e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg08807101	chr21:30365312	RNF160	0.5	11.12	0.4	2.18e-26	Cognitive test performance;
BRCA	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg06784218	chr1:46089804	CCDC17	0.51	12.17	0.43	8.34e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg15704280	chr7:45808275	SEPT13	0.74	15.07	0.51	3.94e-44	Coronary artery disease;
BRCA	trans	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.39	7.99	0.3	6.22e-15	Menarche (age at onset);
BRCA	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg26384229	chr12:38710491	ALG10B	0.67	14.17	0.49	7.99e-40	Morning vs. evening chronotype;
BRCA	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.46	-10.97	-0.4	9.35e-26	Coronary artery disease;
BRCA	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg21475434	chr5:93447410	FAM172A	-0.69	-8.69	-0.33	3.01e-17	Diabetic retinopathy;
BRCA	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg04414720	chr1:150670196	GOLPH3L	0.35	7.84	0.3	1.88e-14	Tonsillectomy;
BRCA	cis	rs3784262	0.669	rs4646554	chr15:58355437	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-10.46	-0.38	9.33e-24	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg03433033	chr1:76189801	ACADM	-0.69	-12.68	-0.45	4.97e-33	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg17470723	chr8:74884337	TCEB1	-0.41	-8.53	-0.32	1.09e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg16606324	chr3:10149918	C3orf24	0.49	9.81	0.36	2.97e-21	Alzheimer's disease;
BRCA	cis	rs1011018	0.628	rs10268753	chr7:139419888	C/T	cg03224163	chr7:139420300	HIPK2	-0.53	-8.85	-0.33	8.73e-18	Systolic blood pressure;
BRCA	trans	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg26043149	chr18:55253948	FECH	0.43	9.24	0.34	3.53e-19	Bone mineral density;
BRCA	cis	rs2625529	0.775	rs2723342	chr15:72107699	G/C	cg16672083	chr15:72433130	SENP8	-0.79	-15.65	-0.53	5.92e-47	Red blood cell count;
BRCA	trans	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg13565492	chr6:43139072	SRF	-0.5	-8.47	-0.32	1.73e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg13256891	chr4:100009986	ADH5	0.47	9.03	0.34	2.09e-18	Alcohol dependence;
BRCA	cis	rs13095912	0.785	rs4686682	chr3:185307402	C/T	cg11274856	chr3:185301563	NA	0.54	13.1	0.46	6.59e-35	Systolic blood pressure;
BRCA	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg06627628	chr2:24431161	ITSN2	-0.84	-15.45	-0.52	5.22e-46	Asthma;
BRCA	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.11	32.35	0.79	9.94e-137	Cognitive ability;
BRCA	cis	rs3768617	1.000	rs2027077	chr1:183073453	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.47	10.33	0.38	3.14e-23	Fuchs's corneal dystrophy;
BRCA	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg15605315	chr1:45957053	TESK2	0.49	10.15	0.37	1.56e-22	High light scatter reticulocyte count;
BRCA	cis	rs3784262	0.669	rs7180059	chr15:58288172	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.87	-0.36	1.75e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg22875332	chr1:76189707	ACADM	0.65	11.79	0.42	3.61e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.76	14.45	0.5	3.6e-41	Platelet distribution width;
BRCA	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	19.43	0.61	2.03e-66	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg18132916	chr6:79620363	NA	-0.5	-11.39	-0.41	1.68e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs220324	0.688	rs4283513	chr21:43566409	G/T	cg09727148	chr21:43560719	UMODL1	0.44	7.92	0.3	1.09e-14	Idiopathic osteonecrosis of the femoral head;
BRCA	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.09	0.34	1.28e-18	Tonsillectomy;
BRCA	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg24562669	chr7:97807699	LMTK2	0.46	11.8	0.42	3.21e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg23096020	chr7:158799433	NA	0.37	8.98	0.33	2.94e-18	Facial morphology (factor 20);
BRCA	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg13385794	chr1:248469461	NA	0.28	7.81	0.3	2.28e-14	Common traits (Other);
BRCA	cis	rs922182	0.904	rs9972469	chr15:64283793	C/A	cg24729988	chr15:64271149	DAPK2	0.44	9.54	0.35	3.05e-20	Blood protein levels;
BRCA	cis	rs11083475	0.599	rs7250443	chr19:39267345	T/C	cg07905965	chr19:39260460	NA	0.47	10.5	0.38	6.86e-24	Heart rate;
BRCA	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-10.1	-0.37	2.42e-22	IgG glycosylation;
BRCA	cis	rs9287719	0.614	rs10929678	chr2:10723095	T/C	cg00105475	chr2:10696890	NA	0.47	10.42	0.38	1.35e-23	Prostate cancer;
BRCA	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg25174290	chr11:3078921	CARS	0.47	14.29	0.49	2.19e-40	Longevity;
BRCA	cis	rs6973256	0.897	rs10266435	chr7:133346081	C/T	cg07491979	chr7:133331646	EXOC4	-0.39	-8.55	-0.32	8.74e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-12.15	-0.43	1.0500000000000001e-30	Brugada syndrome;
BRCA	cis	rs17401966	0.838	rs10864449	chr1:10296922	A/T	cg03954927	chr1:10346856	KIF1B	0.44	13.94	0.48	9.07e-39	Hepatocellular carcinoma;
BRCA	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg17063962	chr7:91808500	NA	0.54	12.26	0.44	3.55e-31	Breast cancer;
BRCA	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.51	-13.1	-0.46	6.43e-35	Colorectal cancer;
BRCA	cis	rs3784262	0.565	rs12914414	chr15:58318757	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-9.51	-0.35	3.82e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	cis	rs4700695	0.719	rs27082	chr5:65436152	A/C	cg21114390	chr5:65439923	SFRS12	-0.54	-10.13	-0.37	1.9e-22	Facial morphology (factor 19);
BRCA	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-14.89	-0.51	2.92e-43	Chronic sinus infection;
BRCA	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-9.87	-0.36	1.73e-21	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.47	0.57	3.9e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg18252515	chr7:66147081	NA	-0.99	-13.97	-0.48	6.87e-39	Diabetic kidney disease;
BRCA	cis	rs9443645	0.527	rs1413968	chr6:79791042	A/G	cg18132916	chr6:79620363	NA	-0.4	-8.42	-0.32	2.47e-16	Intelligence (multi-trait analysis);
BRCA	trans	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-15.49	-0.52	3.38e-46	Obesity-related traits;
BRCA	cis	rs9470366	0.848	rs66761782	chr6:36636080	T/C	cg08179530	chr6:36648295	CDKN1A	0.55	10.76	0.39	6.32e-25	QRS duration;
BRCA	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10819733	chr22:24237672	NA	0.31	8.2	0.31	1.36e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	11.14	0.4	1.83e-26	Schizophrenia;
BRCA	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg01802117	chr1:53393560	SCP2	-0.39	-8.57	-0.32	7.79e-17	Monocyte count;
BRCA	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-8.09	-0.3	3.04e-15	Prostate cancer;
BRCA	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg04398451	chr17:18023971	MYO15A	-0.57	-11.37	-0.41	1.99e-27	Total body bone mineral density;
BRCA	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg13298116	chr11:62369859	EML3;MTA2	0.54	13.5	0.47	9.84e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	20.35	0.63	2.32e-71	Platelet count;
BRCA	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18876405	chr7:65276391	NA	-0.51	-11.54	-0.42	3.95e-28	Aortic root size;
BRCA	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.25	-0.38	6.29e-23	Psoriasis;
BRCA	cis	rs220324	0.618	rs9975331	chr21:43559892	T/C	cg09727148	chr21:43560719	UMODL1	0.49	8.39	0.32	3.01e-16	Idiopathic osteonecrosis of the femoral head;
BRCA	cis	rs6942756	0.531	rs7811141	chr7:128908273	C/G	cg02491457	chr7:128862824	NA	0.44	9.21	0.34	4.5e-19	White matter hyperintensity burden;
BRCA	cis	rs4774830	0.744	rs12438427	chr15:56295062	A/T	cg24530489	chr15:56299380	NA	0.82	9.61	0.36	1.68e-20	Delta-5 desaturase activity;
BRCA	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg18753928	chr3:113234510	CCDC52	-0.58	-12.22	-0.44	5.01e-31	Response to simvastatin treatment (PCSK9 protein level change);
BRCA	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg17063962	chr7:91808500	NA	0.56	12.77	0.45	2.03e-33	Breast cancer;
BRCA	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg05207973	chr5:176823642	SLC34A1	0.35	7.84	0.3	1.89e-14	Urinary electrolytes (magnesium/calcium ratio);
BRCA	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-8.63	-0.32	5.04e-17	Morning vs. evening chronotype;
BRCA	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg05064044	chr6:292385	DUSP22	0.63	13.0	0.46	1.82e-34	Menopause (age at onset);
BRCA	cis	rs290268	0.585	rs290992	chr9:93561309	C/T	cg02608019	chr9:93564028	SYK	-0.43	-9.09	-0.34	1.27e-18	Platelet count;
BRCA	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg18512352	chr11:47633146	NA	-0.37	-9.1	-0.34	1.1e-18	Subjective well-being;
BRCA	cis	rs2463822	0.844	rs72923263	chr11:62161170	C/G	cg06239285	chr11:62104954	ASRGL1	-0.67	-9.12	-0.34	9.83e-19	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg13010199	chr12:38710504	ALG10B	0.45	8.92	0.33	4.88e-18	Morning vs. evening chronotype;
BRCA	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg18446336	chr7:2847575	GNA12	-0.36	-8.04	-0.3	4.51e-15	Height;
BRCA	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg22105103	chr4:187893119	NA	0.42	13.29	0.47	9.52e-36	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg19774624	chr17:42201019	HDAC5	0.43	10.44	0.38	1.12e-23	Total body bone mineral density;
BRCA	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg15556689	chr8:8085844	FLJ10661	-0.3	-7.86	-0.3	1.65e-14	Retinal vascular caliber;
BRCA	cis	rs1874326	0.524	rs6947999	chr7:138109868	A/G	cg18008034	chr7:138118925	NA	-0.45	-9.28	-0.34	2.54e-19	Quantitative traits;
BRCA	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg25358565	chr5:93447407	FAM172A	1.21	18.8	0.6	4.09e-63	Diabetic retinopathy;
BRCA	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg06212747	chr3:49208901	KLHDC8B	0.47	9.62	0.36	1.51e-20	Parkinson's disease;
BRCA	trans	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg25214090	chr10:38739885	LOC399744	0.51	11.5	0.41	5.81e-28	Corneal astigmatism;
BRCA	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18404041	chr3:52824283	ITIH1	-0.42	-12.61	-0.45	9.81e-33	Bipolar disorder;
BRCA	cis	rs6450176	1.000	rs6450175	chr5:53297824	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-15.18	-0.51	1.2e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs1355223	0.506	rs12294339	chr11:34860199	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-8.92	-0.33	4.96e-18	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg05347473	chr6:146136440	FBXO30	-0.42	-8.36	-0.31	3.91e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg24069376	chr3:38537580	EXOG	-0.3	-8.62	-0.32	5.19e-17	Electrocardiographic conduction measures;
BRCA	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06544989	chr22:39130855	UNC84B	0.35	8.35	0.31	4.14e-16	Menopause (age at onset);
BRCA	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg00376283	chr12:123451042	ABCB9	0.49	11.26	0.41	5.96e-27	Neutrophil percentage of white cells;
BRCA	cis	rs9815354	0.812	rs17284472	chr3:41996304	A/G	cg03022575	chr3:42003672	ULK4	-0.61	-8.96	-0.33	3.6e-18	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg16405210	chr4:1374714	KIAA1530	-0.93	-22.1	-0.66	7.49e-81	Longevity;
BRCA	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg16482183	chr6:26056742	HIST1H1C	0.45	8.72	0.33	2.48e-17	Iron status biomarkers;
BRCA	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.4	9.33	0.35	1.73e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs6684514	0.922	rs12037778	chr1:156284864	A/G	cg16558208	chr1:156270281	VHLL	0.36	8.45	0.32	1.99e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg02551604	chr5:131831745	NA	-0.36	-9.81	-0.36	2.95e-21	Asthma (sex interaction);
BRCA	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg25173405	chr17:45401733	C17orf57	-0.53	-11.32	-0.41	3.23e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs495337	0.965	rs6122848	chr20:48546557	A/G	cg17835207	chr20:48524531	SPATA2	-0.69	-16.79	-0.55	1.13e-52	Psoriasis;
BRCA	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg07952391	chr2:88470173	THNSL2	0.68	9.27	0.34	2.76e-19	Plasma clusterin levels;
BRCA	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg13319975	chr6:146136371	FBXO30	0.34	7.9	0.3	1.22e-14	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg26384229	chr12:38710491	ALG10B	0.46	10.49	0.38	7.34e-24	Morning vs. evening chronotype;
BRCA	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.52	-0.32	1.1e-16	Breast cancer;
BRCA	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg20573242	chr4:122745356	CCNA2	0.49	10.92	0.4	1.43e-25	Type 2 diabetes;
BRCA	cis	rs11051970	0.679	rs2931554	chr12:32556162	G/A	cg24626660	chr12:32551988	NA	0.32	9.43	0.35	7.74e-20	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg17971929	chr21:40555470	PSMG1	0.74	15.72	0.53	2.49e-47	Cognitive function;
BRCA	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.83	16.68	0.55	4.06e-52	HIV-1 control;
BRCA	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg27279351	chr12:120934652	DYNLL1	0.57	13.34	0.47	5.7e-36	High light scatter reticulocyte count;
BRCA	cis	rs72772090	0.908	rs72772091	chr5:96040122	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.51	-11.29	-0.41	4.54e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg05347473	chr6:146136440	FBXO30	0.43	8.44	0.32	2.08e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08219700	chr8:58056026	NA	0.45	8.34	0.31	4.68e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg25036284	chr2:26402008	FAM59B	-0.7	-11.33	-0.41	3.16e-27	Gut microbiome composition (summer);
BRCA	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg15934090	chr1:100435551	SLC35A3	0.36	8.49	0.32	1.46e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg06521331	chr12:34319734	NA	-0.48	-8.66	-0.32	3.96e-17	Resting heart rate;
BRCA	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.57	8.23	0.31	1.07e-15	Yeast infection;
BRCA	cis	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.72	0.33	2.46e-17	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11644478	chr21:40555479	PSMG1	0.65	14.42	0.5	5.28e-41	Cognitive function;
BRCA	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg27661571	chr11:113659931	NA	-0.53	-8.93	-0.33	4.64e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg01733217	chr16:74700730	RFWD3	0.74	19.11	0.6	9.49e-65	Testicular germ cell tumor;
BRCA	cis	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	10.45	0.38	1.06e-23	Lymphocyte counts;Red cell distribution width;
BRCA	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.41	-9.83	-0.36	2.41e-21	Alzheimer's disease (late onset);
BRCA	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	11.29	0.41	4.53e-27	Height;
BRCA	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20891558	chr2:74357851	NA	0.48	11.87	0.42	1.73e-29	Gestational age at birth (maternal effect);
BRCA	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg04374321	chr14:90722782	PSMC1	-0.74	-20.17	-0.62	2.34e-70	Mortality in heart failure;
BRCA	cis	rs35995292	0.534	rs11980627	chr7:38907533	T/C	cg19327137	chr7:38886074	VPS41	0.4	13.57	0.47	5.07e-37	Subjective well-being (multi-trait analysis);
BRCA	cis	rs965469	1.000	rs6051753	chr20:3315513	G/A	cg25506879	chr20:3388711	C20orf194	-0.56	-10.89	-0.4	1.93e-25	IFN-related cytopenia;
BRCA	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg17063962	chr7:91808500	NA	-0.52	-11.91	-0.43	1.17e-29	Breast cancer;
BRCA	cis	rs12711979	0.740	rs6715434	chr2:3820862	T/G	cg17052675	chr2:3827356	NA	-0.48	-14.31	-0.49	1.8e-40	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg24562669	chr7:97807699	LMTK2	0.44	11.79	0.42	3.53e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7178375	0.607	rs7171212	chr15:31207711	C/T	cg03767031	chr15:31195708	MTMR15	0.61	8.11	0.31	2.64e-15	Hypertriglyceridemia;
BRCA	trans	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg25214090	chr10:38739885	LOC399744	0.44	9.93	0.37	1.08e-21	Corneal astigmatism;
BRCA	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg12751644	chr20:60527061	NA	-0.33	-7.91	-0.3	1.1e-14	Body mass index;
BRCA	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg00071950	chr4:10020882	SLC2A9	0.55	13.2	0.46	2.4e-35	Bone mineral density;
BRCA	trans	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg19862616	chr7:65841803	NCRNA00174	0.86	28.7	0.75	5.2e-117	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6782228	0.606	rs1697	chr3:128356852	C/T	cg16766828	chr3:128327626	NA	-0.43	-9.7	-0.36	7.92e-21	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg16384552	chr7:74938386	SPDYE8P	-0.51	-11.09	-0.4	2.94e-26	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg13010199	chr12:38710504	ALG10B	0.47	9.03	0.34	2.04e-18	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg20607798	chr8:58055168	NA	0.58	9.27	0.34	2.73e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg10792982	chr14:105748885	BRF1	-0.46	-11.03	-0.4	4.9e-26	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs9644630	0.965	rs10105097	chr8:19364883	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.37	-8.52	-0.32	1.19e-16	Oropharynx cancer;
BRCA	cis	rs8017423	0.647	rs4900037	chr14:90821478	A/G	cg04374321	chr14:90722782	PSMC1	0.5	12.17	0.43	8.48e-31	Mortality in heart failure;
BRCA	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg00852783	chr1:26633632	UBXN11	-0.49	-10.62	-0.39	2.31e-24	Obesity-related traits;
BRCA	cis	rs9420	0.961	rs7116341	chr11:57481155	G/A	cg19752551	chr11:57585705	CTNND1	-0.51	-12.49	-0.44	3.34e-32	Schizophrenia;
BRCA	cis	rs6977660	0.943	rs10254261	chr7:19846001	A/G	cg07541023	chr7:19748670	TWISTNB	-0.4	-7.82	-0.3	2.21e-14	Thyroid stimulating hormone;
BRCA	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.5	-0.47	1.02e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg08493051	chr2:3487164	NA	0.42	9.0	0.34	2.57e-18	Neurofibrillary tangles;
BRCA	cis	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg05901451	chr6:126070800	HEY2	0.39	9.6	0.36	1.76e-20	Endometrial cancer;
BRCA	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	9.45	0.35	6.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg12573674	chr2:1569213	NA	-0.45	-8.63	-0.32	4.93e-17	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11905131	chr22:24372483	LOC391322	0.54	12.01	0.43	4.04e-30	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg04553112	chr3:125709451	NA	-0.55	-8.34	-0.31	4.41e-16	Blood pressure (smoking interaction);
BRCA	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg20701182	chr2:24300061	SF3B14	0.55	8.51	0.32	1.21e-16	Lymphocyte counts;
BRCA	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.87	-0.48	1.9e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg03188948	chr7:1209495	NA	0.68	11.26	0.41	5.97e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	7.93	0.3	9.86e-15	Glomerular filtration rate;
BRCA	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg14036092	chr11:66035641	RAB1B	0.39	10.73	0.39	7.91e-25	Gout;
BRCA	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19748678	chr4:122722346	EXOSC9	0.74	15.94	0.53	2.16e-48	Type 2 diabetes;
BRCA	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg23625390	chr15:77176239	SCAPER	0.4	9.37	0.35	1.24e-19	Blood metabolite levels;
BRCA	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg16339924	chr4:17578868	LAP3	0.62	15.4	0.52	9.27e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs73242632	1.000	rs56798906	chr4:57875725	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	0.69	8.27	0.31	8.02e-16	Congenital heart disease (maternal effect);
BRCA	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg06713675	chr4:122721982	EXOSC9	-0.54	-12.38	-0.44	1.06e-31	Type 2 diabetes;
BRCA	cis	rs6429082	0.715	rs9793740	chr1:235595590	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.54	-12.82	-0.45	1.22e-33	Adiposity;
BRCA	cis	rs4363385	0.597	rs55667413	chr1:152976849	G/T	cg25856811	chr1:152973957	SPRR3	-0.34	-9.08	-0.34	1.31e-18	Inflammatory skin disease;
BRCA	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-16.84	-0.55	6e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg20129853	chr10:51489980	NA	-0.32	-8.54	-0.32	9.98e-17	Prostate-specific antigen levels;
BRCA	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg15997130	chr1:24165203	NA	0.44	11.49	0.41	6.91e-28	Immature fraction of reticulocytes;
BRCA	cis	rs738321	0.790	rs4820317	chr22:38543287	T/C	cg25457927	chr22:38595422	NA	-0.33	-11.52	-0.41	4.89e-28	Breast cancer;
BRCA	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg02734326	chr4:10020555	SLC2A9	0.39	8.48	0.32	1.61e-16	Bone mineral density;
BRCA	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.88	-0.3	1.43e-14	Electroencephalogram traits;
BRCA	cis	rs6066825	0.644	rs1040559	chr20:47314445	A/G	cg18078177	chr20:47281410	PREX1	0.42	10.27	0.38	5.11e-23	Colorectal cancer;
BRCA	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-9.82	-0.36	2.61e-21	Blood metabolite levels;
BRCA	cis	rs28735056	1.000	rs4798923	chr18:77629373	G/A	cg20368463	chr18:77673604	PQLC1	-0.34	-8.19	-0.31	1.41e-15	Schizophrenia;
BRCA	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg20587970	chr11:113659929	NA	-0.64	-11.06	-0.4	3.94e-26	Hip circumference adjusted for BMI;
BRCA	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg03213289	chr20:61660250	NA	0.62	16.32	0.54	2.77e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs965469	1.000	rs2281503	chr20:3263636	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-10.2	-0.37	9.47e-23	IFN-related cytopenia;
BRCA	cis	rs34779708	0.931	rs7079205	chr10:35324619	C/T	cg03585969	chr10:35415529	CREM	0.5	10.23	0.38	7.21e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs13082711	0.595	rs13075389	chr3:27339586	C/T	cg02860705	chr3:27208620	NA	0.76	13.96	0.48	7.59e-39	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
BRCA	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg26587870	chr6:27730563	NA	-0.41	-8.71	-0.33	2.57e-17	Parkinson's disease;
BRCA	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg02931644	chr1:25747376	RHCE	0.47	13.1	0.46	6.75e-35	Erythrocyte sedimentation rate;
BRCA	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg11879182	chr18:77439856	CTDP1	0.65	13.92	0.48	1.21e-38	Monocyte count;
BRCA	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg11822812	chr5:140052017	DND1	-0.3	-8.23	-0.31	1.07e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	11.7	0.42	8.69e-29	Tonsillectomy;
BRCA	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21659725	chr3:3221576	CRBN	-0.72	-21.74	-0.65	6.94e-79	Intelligence (multi-trait analysis);
BRCA	cis	rs7246657	0.722	rs10403173	chr19:38078680	G/A	cg18154014	chr19:37997991	ZNF793	0.48	9.16	0.34	7.24e-19	Coronary artery calcification;
BRCA	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg22800045	chr5:56110881	MAP3K1	0.6	10.81	0.39	4.01e-25	Initial pursuit acceleration;
BRCA	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.4	8.02	0.3	4.99e-15	Ulcerative colitis;Inflammatory bowel disease;
BRCA	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg22875332	chr1:76189707	ACADM	-0.68	-14.0	-0.48	4.91e-39	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12541635	1.000	rs1896919	chr8:107090357	C/G	cg10147462	chr8:107024639	NA	-0.3	-8.29	-0.31	6.64e-16	Age of smoking initiation;
BRCA	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.65	0.39	1.73e-24	Motion sickness;
BRCA	cis	rs4363385	0.693	rs4845331	chr1:152982623	A/G	cg21543102	chr1:152974771	SPRR3	-0.29	-8.36	-0.31	3.82e-16	Inflammatory skin disease;
BRCA	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg05283184	chr6:79620031	NA	-0.45	-11.41	-0.41	1.4e-27	Intelligence (multi-trait analysis);
BRCA	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.41	9.01	0.34	2.29e-18	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs495337	0.699	rs6020075	chr20:48448695	A/G	cg17835207	chr20:48524531	SPATA2	0.49	10.82	0.39	3.59e-25	Psoriasis;
BRCA	trans	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg25214090	chr10:38739885	LOC399744	0.35	8.2	0.31	1.36e-15	Diastolic blood pressure;
BRCA	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg15017067	chr4:17643749	FAM184B	0.28	8.4	0.32	2.91e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9359856	0.510	rs6937789	chr6:90468775	C/G	cg13799429	chr6:90582589	CASP8AP2	0.7	10.57	0.39	3.41e-24	Bipolar disorder;
BRCA	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg22920501	chr2:26401640	FAM59B	-0.81	-13.17	-0.46	3.22e-35	Gut microbiome composition (summer);
BRCA	trans	rs6076960	0.652	rs3852945	chr20:6254118	T/C	cg21095983	chr6:86352623	SYNCRIP	0.35	8.2	0.31	1.36e-15	Smooth-surface caries;
BRCA	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg23231163	chr10:75533350	FUT11	-0.34	-8.98	-0.33	2.92e-18	Inflammatory bowel disease;
BRCA	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg20283391	chr11:68216788	NA	-0.44	-8.6	-0.32	6.13e-17	Total body bone mineral density;
BRCA	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg01181863	chr3:195395398	SDHAP2	0.49	9.84	0.36	2.36e-21	Bronchopulmonary dysplasia;
BRCA	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04876069	chr12:132293656	NA	-0.45	-9.77	-0.36	4.04e-21	Migraine;
BRCA	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg17294928	chr15:75287854	SCAMP5	-0.75	-16.77	-0.55	1.44e-52	Blood trace element (Zn levels);
BRCA	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg19156104	chr2:198669113	PLCL1	-0.44	-8.13	-0.31	2.26e-15	Ulcerative colitis;
BRCA	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11764359	chr7:65958608	NA	0.8	19.33	0.61	6.8e-66	Aortic root size;
BRCA	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg16482183	chr6:26056742	HIST1H1C	0.49	10.2	0.37	1.01e-22	Height;
BRCA	trans	rs1973993	0.537	rs1988854	chr1:96989786	A/G	cg10631902	chr5:14652156	NA	-0.39	-9.82	-0.36	2.62e-21	Weight;
BRCA	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg17330251	chr7:94953956	PON1	-0.45	-10.29	-0.38	4.31e-23	Paraoxonase activity;
BRCA	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg27165867	chr14:105738592	BRF1	-0.36	-8.37	-0.31	3.53e-16	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.46	-8.84	-0.33	9.17e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs1325195	0.879	rs2791940	chr1:179115485	C/T	cg11624085	chr17:8464688	MYH10	0.26	7.86	0.3	1.65e-14	IgE grass sensitization;
BRCA	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg01579765	chr21:45077557	HSF2BP	-0.45	-12.19	-0.43	7.28e-31	Mean corpuscular volume;
BRCA	cis	rs1401999	0.898	rs6443928	chr3:183729487	C/T	cg20387954	chr3:183756860	HTR3D	0.47	10.7	0.39	1.09e-24	Anterior chamber depth;
BRCA	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg26769984	chr7:1090371	C7orf50	-0.69	-13.56	-0.47	5.41e-37	Bronchopulmonary dysplasia;
BRCA	cis	rs34779708	0.931	rs4934700	chr10:35310842	A/G	cg03585969	chr10:35415529	CREM	0.56	11.59	0.42	2.46e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6545883	0.929	rs9679557	chr2:61709349	C/A	cg15711740	chr2:61764176	XPO1	-0.55	-13.86	-0.48	2.21e-38	Tuberculosis;
BRCA	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11644478	chr21:40555479	PSMG1	-0.5	-10.67	-0.39	1.46e-24	Menarche (age at onset);
BRCA	trans	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg06521331	chr12:34319734	NA	-0.47	-8.56	-0.32	8.19e-17	Bladder cancer;
BRCA	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg25809561	chr17:30822961	MYO1D	0.4	9.56	0.35	2.4e-20	Schizophrenia;
BRCA	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg06784218	chr1:46089804	CCDC17	0.5	11.9	0.43	1.24e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-22.92	-0.67	2.73e-85	Monocyte count;
BRCA	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg27541892	chr1:1571801	CDK11B	-0.35	-7.84	-0.3	1.85e-14	Body mass index;
BRCA	cis	rs9473147	0.516	rs7754282	chr6:47502024	C/G	cg12968598	chr6:47444699	CD2AP	-0.44	-9.63	-0.36	1.4e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg06521331	chr12:34319734	NA	-0.59	-11.56	-0.42	3.37e-28	Morning vs. evening chronotype;
BRCA	cis	rs858239	0.539	rs6955726	chr7:23186691	A/G	cg23682824	chr7:23144976	KLHL7	0.41	10.64	0.39	1.8e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7843479	0.965	rs2291317	chr8:21827162	C/T	cg17168535	chr8:21777572	XPO7	0.46	10.38	0.38	1.9e-23	Mean corpuscular volume;
BRCA	cis	rs7903847	0.642	rs10882913	chr10:99141845	C/T	cg20016023	chr10:99160130	RRP12	-0.27	-8.62	-0.32	5.46e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs62458065	0.513	rs10268803	chr7:32547835	A/G	cg20159608	chr7:32802032	NA	-0.5	-9.61	-0.36	1.65e-20	Metabolite levels (HVA/MHPG ratio);
BRCA	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg03188948	chr7:1209495	NA	0.44	8.13	0.31	2.29e-15	Longevity;Endometriosis;
BRCA	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg08975724	chr8:8085496	FLJ10661	0.54	12.22	0.44	5.06e-31	Mood instability;
BRCA	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg25358565	chr5:93447407	FAM172A	1.21	18.8	0.6	4.09e-63	Diabetic retinopathy;
BRCA	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg00105475	chr2:10696890	NA	0.44	10.25	0.38	6.46e-23	Prostate cancer;
BRCA	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg08355456	chr11:67383691	NA	-0.42	-8.64	-0.32	4.46e-17	Mean corpuscular volume;
BRCA	trans	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-15.46	-0.52	5.17e-46	Obesity-related traits;
BRCA	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg20991723	chr1:152506922	NA	0.38	8.67	0.32	3.47e-17	Hair morphology;
BRCA	cis	rs30380	0.632	rs26498	chr5:96138812	C/T	cg16492584	chr5:96139282	ERAP1	0.46	10.92	0.4	1.44e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg06784218	chr1:46089804	CCDC17	0.5	11.98	0.43	5.89e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs11976180	1.000	rs2951360	chr7:143757349	C/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.47	-8.65	-0.32	4.09e-17	Obesity-related traits;
BRCA	cis	rs6450176	0.625	rs3776726	chr5:53290052	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-15.17	-0.51	1.22e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.2	-0.31	1.33e-15	Bipolar disorder;
BRCA	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg18232548	chr7:50535776	DDC	0.44	9.08	0.34	1.39e-18	Malaria;
BRCA	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg08999081	chr20:33150536	PIGU	-0.47	-12.85	-0.45	9.11e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08564027	chr20:61660810	NA	0.84	22.84	0.67	7.41e-85	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.84	0.39	3.12e-25	Type 2 diabetes;
BRCA	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg13010199	chr12:38710504	ALG10B	0.44	8.95	0.33	3.78e-18	Bladder cancer;
BRCA	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg21479132	chr6:26055353	NA	0.57	7.97	0.3	7.48e-15	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg20203395	chr5:56204925	C5orf35	-0.49	-10.25	-0.38	6.14e-23	Initial pursuit acceleration;
BRCA	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg14343924	chr8:8086146	FLJ10661	-0.4	-8.29	-0.31	6.8e-16	Mood instability;
BRCA	trans	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg25214090	chr10:38739885	LOC399744	0.56	12.26	0.44	3.41e-31	Corneal astigmatism;
BRCA	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	13.28	0.46	1.06e-35	Schizophrenia;
BRCA	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg12386194	chr3:101231763	SENP7	0.41	8.77	0.33	1.63e-17	Colorectal cancer;
BRCA	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.05	-0.34	1.65e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg01689657	chr7:91764605	CYP51A1	0.22	8.22	0.31	1.17e-15	Breast cancer;
BRCA	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg01420254	chr6:26195488	NA	0.55	8.52	0.32	1.1e-16	Gout;Renal underexcretion gout;
BRCA	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg16325326	chr1:53192061	ZYG11B	0.76	17.2	0.56	9.15e-55	Monocyte count;
BRCA	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg25457927	chr22:38595422	NA	-0.32	-11.87	-0.43	1.63e-29	Cutaneous nevi;
BRCA	cis	rs9394841	0.667	rs9367112	chr6:41769920	T/C	cg08135965	chr6:41755394	TOMM6	0.5	8.13	0.31	2.18e-15	Mean corpuscular hemoglobin;Red cell distribution width;
BRCA	cis	rs7246967	0.673	rs73028776	chr19:22813740	A/C	cg23217946	chr19:22817039	ZNF492	0.47	8.43	0.32	2.22e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg04362960	chr10:104952993	NT5C2	0.44	10.81	0.39	4.09e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs1368882	1.000	rs1368882	chr1:55107019	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.42	-9.11	-0.34	1.09e-18	Non-substance related behavioral disinhibition;
BRCA	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg17724175	chr1:150552817	MCL1	0.25	8.14	0.31	2.07e-15	Tonsillectomy;
BRCA	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22307029	chr19:49891270	CCDC155	0.62	11.3	0.41	4.17e-27	Multiple sclerosis;
BRCA	cis	rs7178424	0.774	rs7172145	chr15:62239697	C/T	cg00456672	chr15:62358751	C2CD4A	0.41	9.94	0.37	9.45e-22	Height;
BRCA	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-12.42	-0.44	6.78e-32	Morning vs. evening chronotype;
BRCA	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg21770322	chr7:97807741	LMTK2	0.43	11.49	0.41	6.49e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg07460842	chr6:66804631	NA	-1.0	-19.98	-0.62	2.38e-69	Exhaled nitric oxide output;
BRCA	cis	rs7319311	1.000	rs7319311	chr13:111030578	A/G	cg05272587	chr13:111038400	COL4A2	0.34	7.85	0.3	1.8e-14	Bipolar disorder and schizophrenia;
BRCA	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg03433033	chr1:76189801	ACADM	-0.41	-8.35	-0.31	4.3e-16	Daytime sleep phenotypes;
BRCA	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.6	9.7	0.36	7.48e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs868036	1.000	rs7168156	chr15:68102933	T/C	cg08079166	chr15:68083412	MAP2K5	0.35	9.46	0.35	5.8e-20	Restless legs syndrome;
BRCA	cis	rs6942756	1.000	rs7778277	chr7:128978805	C/T	cg02491457	chr7:128862824	NA	-0.71	-14.05	-0.49	3e-39	White matter hyperintensity burden;
BRCA	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg19678392	chr7:94953810	PON1	-0.42	-9.02	-0.34	2.22e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg19508488	chr2:152266495	RIF1	0.37	8.08	0.3	3.16e-15	Lung cancer;
BRCA	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-12.61	-0.45	9.81e-33	Bipolar disorder;
BRCA	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg04013093	chr6:42928303	GNMT	-0.28	-8.79	-0.33	1.4e-17	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg18446336	chr7:2847575	GNA12	-0.37	-8.62	-0.32	5.08e-17	Height;
BRCA	trans	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-20.82	-0.64	6.89e-74	Exhaled nitric oxide output;
BRCA	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.53	0.32	1.06e-16	Rheumatoid arthritis;
BRCA	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg26384229	chr12:38710491	ALG10B	-0.54	-13.43	-0.47	2.18e-36	Morning vs. evening chronotype;
BRCA	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg25358565	chr5:93447407	FAM172A	1.19	18.82	0.6	3.54e-63	Diabetic retinopathy;
BRCA	trans	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg06521331	chr12:34319734	NA	-0.51	-9.75	-0.36	4.86e-21	Bladder cancer;
BRCA	trans	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04565464	chr8:145669602	NFKBIL2	0.4	9.68	0.36	8.96e-21	Bipolar disorder and schizophrenia;
BRCA	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg13319975	chr6:146136371	FBXO30	-0.41	-9.28	-0.34	2.63e-19	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg15704280	chr7:45808275	SEPT13	-0.75	-15.36	-0.52	1.55e-45	Coronary artery disease;
BRCA	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg04511125	chr2:88470314	THNSL2	-0.5	-10.42	-0.38	1.36e-23	Response to metformin (IC50);
BRCA	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	11.33	0.41	2.95e-27	Electroencephalogram traits;
BRCA	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg12432903	chr7:1882776	MAD1L1	0.45	8.14	0.31	2.08e-15	Bipolar disorder;
BRCA	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.57	-11.8	-0.42	3.39e-29	Blood metabolite levels;
BRCA	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg03146154	chr1:46216737	IPP	0.46	10.07	0.37	3.14e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18402987	chr7:1209562	NA	0.62	13.53	0.47	7.67e-37	Longevity;Endometriosis;
BRCA	cis	rs11112613	0.775	rs61200462	chr12:105969271	G/A	cg03607813	chr12:105948248	NA	0.58	9.73	0.36	5.87e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18876405	chr7:65276391	NA	0.62	15.18	0.51	1.09e-44	Aortic root size;
BRCA	cis	rs11051970	0.879	rs2651362	chr12:32587851	G/C	cg24626660	chr12:32551988	NA	0.29	8.36	0.31	4e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-17.3	-0.56	2.75e-55	Schizophrenia;
BRCA	cis	rs4908768	0.520	rs6681362	chr1:8658527	T/G	cg20416874	chr1:8611966	RERE	-0.29	-8.2	-0.31	1.27e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg08999081	chr20:33150536	PIGU	0.45	12.54	0.44	2.02e-32	Glomerular filtration rate (creatinine);
BRCA	cis	rs1003719	1.000	rs2154536	chr21:38492147	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	14.17	0.49	7.99e-40	Eye color traits;
BRCA	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.59	-9.84	-0.36	2.38e-21	Body mass index (adult);
BRCA	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.99	-0.3	6.45e-15	Prostate cancer;
BRCA	cis	rs7975161	1.000	rs7975161	chr12:104645405	C/T	cg25273343	chr12:104657179	TXNRD1	0.51	11.02	0.4	5.73e-26	Toenail selenium levels;
BRCA	cis	rs9942416	0.660	rs111937612	chr5:74979631	C/T	cg19683494	chr5:74908142	NA	0.48	8.95	0.33	3.81e-18	Age-related disease endophenotypes;
BRCA	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.65	0.55	5.99e-52	Colorectal cancer;
BRCA	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.58	0.42	2.86e-28	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.59	-10.38	-0.38	1.89e-23	Gut microbiome composition (summer);
BRCA	cis	rs4253311	0.544	rs4253244	chr4:187153775	C/A	cg24794857	chr4:187113578	CYP4V2	0.39	8.16	0.31	1.73e-15	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
BRCA	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.82	0.3	2.22e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg03676636	chr4:99064102	C4orf37	0.21	8.05	0.3	4.14e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.46	-13.34	-0.47	5.46e-36	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg09436375	chr6:42928200	GNMT	-0.3	-10.85	-0.39	2.84e-25	Plasma homocysteine levels (post-methionine load test);
BRCA	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg18225595	chr11:63971243	STIP1	0.5	8.7	0.33	2.79e-17	Mean platelet volume;
BRCA	cis	rs6942756	0.744	rs2718088	chr7:128927020	C/A	cg02491457	chr7:128862824	NA	0.56	11.72	0.42	7.37e-29	White matter hyperintensity burden;
BRCA	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg12193833	chr17:30244370	NA	-0.54	-8.66	-0.32	3.95e-17	Hip circumference adjusted for BMI;
BRCA	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg02659138	chr7:134003124	SLC35B4	0.33	10.13	0.37	1.75e-22	Mean platelet volume;
BRCA	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.07e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.16	-0.34	6.76e-19	Total body bone mineral density;
BRCA	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs35110281	0.667	rs4818859	chr21:45117120	G/A	cg01579765	chr21:45077557	HSF2BP	-0.43	-11.59	-0.42	2.62e-28	Mean corpuscular volume;
BRCA	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg13334819	chr7:99746414	C7orf59	-0.42	-9.92	-0.37	1.16e-21	Coronary artery disease;
BRCA	cis	rs3771570	1.000	rs73020143	chr2:242261240	T/A	cg21155796	chr2:242212141	HDLBP	0.6	9.38	0.35	1.09e-19	Prostate cancer;
BRCA	cis	rs1371614	0.635	rs10175737	chr2:27139747	C/A	cg00617064	chr2:27272375	NA	0.3	7.88	0.3	1.41e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg25358565	chr5:93447407	FAM172A	1.14	18.39	0.59	6.32e-61	Diabetic retinopathy;
BRCA	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg11502198	chr6:26597334	ABT1	0.56	11.95	0.43	7.45e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs34779708	0.868	rs2384352	chr10:35492832	A/G	cg03585969	chr10:35415529	CREM	0.48	9.84	0.36	2.2e-21	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg03060546	chr3:49711283	APEH	-0.51	-10.46	-0.38	9.45e-24	Educational attainment (college completion);
BRCA	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg22029157	chr1:209979665	IRF6	0.55	11.24	0.41	6.82e-27	Cleft lip with or without cleft palate;
BRCA	cis	rs6763687	0.765	rs4894799	chr3:171795540	G/A	cg16233210	chr3:171778391	FNDC3B	0.36	8.05	0.3	3.95e-15	Red cell distribution width;
BRCA	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg01579765	chr21:45077557	HSF2BP	-0.44	-11.66	-0.42	1.29e-28	Mean corpuscular volume;
BRCA	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg21699342	chr2:239360505	ASB1	0.5	11.52	0.41	5.08e-28	Multiple system atrophy;
BRCA	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-12.9	-0.45	5.18e-34	Bipolar disorder and schizophrenia;
BRCA	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.12	-0.31	2.37e-15	Total body bone mineral density;
BRCA	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg05872129	chr22:39784769	NA	-0.56	-11.75	-0.42	5.42e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg13628971	chr7:2884303	GNA12	0.57	11.91	0.43	1.11e-29	Height;
BRCA	cis	rs7336332	0.569	rs7988412	chr13:28000282	C/T	cg22138327	chr13:27999177	GTF3A	0.6	12.17	0.43	8.24e-31	Weight;
BRCA	cis	rs997295	0.554	rs7180312	chr15:68105256	G/A	cg08079166	chr15:68083412	MAP2K5	0.31	8.33	0.31	5.03e-16	Motion sickness;
BRCA	cis	rs3849570	0.643	rs10779986	chr3:81970818	C/G	cg07356753	chr3:81810745	GBE1	0.36	8.42	0.32	2.57e-16	Waist circumference;Body mass index;
BRCA	trans	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.28	-0.64	2.26e-76	Exhaled nitric oxide output;
BRCA	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg10295955	chr4:187884368	NA	0.93	26.88	0.73	4.81e-107	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg23109721	chr2:106886537	NA	-0.47	-8.47	-0.32	1.63e-16	Facial morphology (factor 23);
BRCA	cis	rs6714710	0.627	rs6748124	chr2:98519014	T/C	cg26665480	chr2:98280029	ACTR1B	0.57	13.39	0.47	3.3e-36	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs7572733	0.555	rs11903129	chr2:198918591	A/T	cg00792783	chr2:198669748	PLCL1	0.39	8.81	0.33	1.14e-17	Dermatomyositis;
BRCA	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg24812749	chr6:127587940	RNF146	0.88	20.63	0.63	7.68e-73	Breast cancer;
BRCA	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg04362960	chr10:104952993	NT5C2	0.44	10.77	0.39	5.48e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs4845570	0.850	rs4618976	chr1:151766588	A/G	cg07092448	chr1:151763213	TDRKH	0.88	18.98	0.6	5.07e-64	Coronary artery disease;
BRCA	cis	rs919433	0.647	rs2045242	chr2:198507649	G/A	cg00792783	chr2:198669748	PLCL1	0.4	9.05	0.34	1.69e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg21573476	chr21:45109991	RRP1B	-0.34	-9.07	-0.34	1.4e-18	Mean corpuscular volume;
BRCA	cis	rs701145	0.585	rs1713807	chr3:153883344	C/T	cg17054900	chr3:154042577	DHX36	0.56	9.47	0.35	5.3e-20	Coronary artery disease;
BRCA	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg00717180	chr2:96193071	NA	-0.39	-10.42	-0.38	1.39e-23	Height;
BRCA	cis	rs600231	0.508	rs17146964	chr11:65249145	C/T	cg01292856	chr11:65242576	NA	-0.66	-14.93	-0.51	1.92e-43	Bone mineral density;
BRCA	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg21385522	chr1:16154831	NA	0.47	8.37	0.31	3.62e-16	Dilated cardiomyopathy;
BRCA	trans	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.36	-0.38	2.35e-23	Morning vs. evening chronotype;
BRCA	cis	rs427394	0.632	rs169285	chr5:6736587	G/C	cg10857441	chr5:6722123	POLS	-0.31	-9.97	-0.37	7.32e-22	Menopause (age at onset);
BRCA	cis	rs11051970	0.566	rs2651372	chr12:32583199	A/G	cg24626660	chr12:32551988	NA	0.27	8.15	0.31	1.91e-15	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03934478	chr11:495069	RNH1	-0.8	-11.97	-0.43	5.91e-30	Body mass index;
BRCA	cis	rs1506636	1.000	rs10225428	chr7:123357646	A/G	cg03229431	chr7:123269106	ASB15	-0.6	-13.53	-0.47	7.28e-37	Plateletcrit;Platelet count;
BRCA	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg11663144	chr21:46675770	NA	-0.59	-13.76	-0.48	6.24e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg22800045	chr5:56110881	MAP3K1	0.69	13.38	0.47	3.5e-36	Initial pursuit acceleration;
BRCA	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg06671706	chr8:8559999	CLDN23	0.45	8.64	0.32	4.57e-17	Obesity-related traits;
BRCA	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg06606381	chr12:133084897	FBRSL1	-0.77	-8.04	-0.3	4.34e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg07460842	chr6:66804631	NA	-1.0	-19.97	-0.62	2.6e-69	Exhaled nitric oxide output;
BRCA	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.58	-0.32	7.19e-17	Total body bone mineral density;
BRCA	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg17509989	chr5:176798049	RGS14	-0.74	-11.79	-0.42	3.79e-29	Urate levels in lean individuals;
BRCA	cis	rs9815354	1.000	rs56158380	chr3:41885588	G/A	cg03022575	chr3:42003672	ULK4	0.49	7.99	0.3	6.4e-15	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg13752114	chr3:195489708	MUC4	0.55	8.76	0.33	1.81e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	9.53	0.35	3.19e-20	Rheumatoid arthritis;
BRCA	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg14349672	chr11:133703707	NA	-0.39	-9.06	-0.34	1.58e-18	Childhood ear infection;
BRCA	trans	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg25214090	chr10:38739885	LOC399744	0.44	10.29	0.38	4.34e-23	Corneal astigmatism;
BRCA	trans	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.37	8.25	0.31	8.73e-16	Endometrial cancer;
BRCA	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg26384229	chr12:38710491	ALG10B	0.59	13.52	0.47	8.1e-37	Morning vs. evening chronotype;
BRCA	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg08807101	chr21:30365312	RNF160	-0.43	-9.12	-0.34	9.51e-19	Dental caries;
BRCA	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.64	9.83	0.36	2.59e-21	Lung function (FEV1/FVC);
BRCA	cis	rs61990749	0.597	rs10136053	chr14:78155205	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.44	-7.89	-0.3	1.28e-14	Fibroblast growth factor basic levels;
BRCA	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.9	0.3	1.25e-14	Depression;
BRCA	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg04362960	chr10:104952993	NT5C2	0.46	10.7	0.39	1.08e-24	Arsenic metabolism;
BRCA	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg04511125	chr2:88470314	THNSL2	0.94	13.51	0.47	9.42e-37	Plasma clusterin levels;
BRCA	trans	rs11976180	1.000	rs2961132	chr7:143768128	A/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.45	-8.2	-0.31	1.32e-15	Obesity-related traits;
BRCA	trans	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	10.52	0.38	5.58e-24	Type 2 diabetes;
BRCA	cis	rs4478858	0.735	rs6425736	chr1:31784376	T/A	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg16576597	chr16:28551801	NUPR1	0.31	8.57	0.32	7.87e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs7677751	0.806	rs7689569	chr4:55096398	G/A	cg17187183	chr4:55093834	PDGFRA	0.45	8.86	0.33	8.09e-18	Corneal astigmatism;
BRCA	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg23708337	chr7:1209742	NA	0.56	12.12	0.43	1.36e-30	Longevity;Endometriosis;
BRCA	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg01528321	chr10:82214614	TSPAN14	0.68	14.57	0.5	9.95e-42	Post bronchodilator FEV1;
BRCA	cis	rs13046373	0.535	rs1354866	chr21:31981559	A/T	cg16431978	chr21:31797932	KRTAP13-3	0.36	9.15	0.34	7.46e-19	HDL cholesterol;
BRCA	trans	rs1997103	1.000	rs6954474	chr7:55404847	A/G	cg20935933	chr6:143382018	AIG1	0.6	11.56	0.42	3.34e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	trans	rs61931739	0.927	rs1906135	chr12:34038103	C/A	cg26384229	chr12:38710491	ALG10B	-0.42	-9.38	-0.35	1.09e-19	Morning vs. evening chronotype;
BRCA	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg18479299	chr3:125709523	NA	-0.54	-8.43	-0.32	2.33e-16	Blood pressure (smoking interaction);
BRCA	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-11.48	-0.41	7.3e-28	Personality dimensions;
BRCA	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11644478	chr21:40555479	PSMG1	-0.5	-10.65	-0.39	1.66e-24	Menarche (age at onset);
BRCA	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg23711669	chr6:146136114	FBXO30	0.61	13.95	0.48	8.19e-39	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9463078	0.625	rs1891412	chr6:44760642	T/C	cg25276700	chr6:44698697	NA	0.35	8.26	0.31	8.64e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	12.71	0.45	3.82e-33	Multiple sclerosis;
BRCA	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg09462578	chr12:12878428	APOLD1	-0.68	-11.7	-0.42	8.62e-29	Systemic lupus erythematosus;
BRCA	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg08885076	chr2:99613938	TSGA10	-0.55	-12.8	-0.45	1.52e-33	Chronic sinus infection;
BRCA	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg06212747	chr3:49208901	KLHDC8B	0.46	9.35	0.35	1.41e-19	Parkinson's disease;
BRCA	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg05340658	chr4:99064831	C4orf37	0.44	10.13	0.37	1.74e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.36	-9.63	-0.36	1.4e-20	Total body bone mineral density;
BRCA	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg10978503	chr1:24200527	CNR2	-0.52	-14.09	-0.49	1.79e-39	Immature fraction of reticulocytes;
BRCA	cis	rs7000551	0.725	rs4871998	chr8:22308150	A/T	cg12081754	chr8:22256438	SLC39A14	0.41	8.22	0.31	1.1e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	trans	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	8.77	0.33	1.64e-17	Mean corpuscular volume;
BRCA	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg21770322	chr7:97807741	LMTK2	0.56	16.02	0.54	8.01e-49	Breast cancer;
BRCA	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-10.51	-0.38	6.17e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg13010199	chr12:38710504	ALG10B	0.51	10.07	0.37	2.99e-22	Bladder cancer;
BRCA	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.52	-10.79	-0.39	4.75e-25	Chronic sinus infection;
BRCA	cis	rs4728302	0.869	rs13233715	chr7:133617471	C/T	cg07491979	chr7:133331646	EXOC4	0.36	7.84	0.3	1.95e-14	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg00677455	chr12:58241039	CTDSP2	0.62	15.3	0.52	2.86e-45	Multiple sclerosis;
BRCA	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	trans	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg05926928	chr17:57297772	GDPD1	0.47	9.11	0.34	1.04e-18	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
BRCA	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-11.58	-0.42	2.68e-28	Morning vs. evening chronotype;
BRCA	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg25036284	chr2:26402008	FAM59B	-0.62	-10.23	-0.38	7.22e-23	Gut microbiome composition (summer);
BRCA	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs2559856	1.000	rs10778139	chr12:102083202	C/T	cg12924262	chr12:102091054	CHPT1	-0.35	-7.91	-0.3	1.13e-14	Blood protein levels;
BRCA	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.44	-11.29	-0.41	4.4e-27	Schizophrenia;
BRCA	cis	rs2014572	0.967	rs10412975	chr19:57770554	C/A	cg24459738	chr19:57751996	ZNF805	-0.36	-8.4	-0.32	2.99e-16	Hyperactive-impulsive symptoms;
BRCA	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg24110177	chr3:50126178	RBM5	0.5	14.17	0.49	7.91e-40	Body mass index;
BRCA	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg05340658	chr4:99064831	C4orf37	0.68	17.05	0.56	5.48e-54	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.45	-8.63	-0.32	4.85e-17	Monocyte count;
BRCA	cis	rs1011018	0.628	rs17177103	chr7:139449161	G/A	cg03224163	chr7:139420300	HIPK2	-0.6	-8.97	-0.33	3.36e-18	Systolic blood pressure;
BRCA	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg09455208	chr3:40491958	NA	-0.39	-9.11	-0.34	1.02e-18	Renal cell carcinoma;
BRCA	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.23	-0.54	7.7e-50	Alzheimer's disease (late onset);
BRCA	trans	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg25517755	chr10:38738941	LOC399744	-0.38	-7.9	-0.3	1.26e-14	Corneal astigmatism;
BRCA	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg08975724	chr8:8085496	FLJ10661	0.43	8.88	0.33	6.65e-18	Retinal vascular caliber;
BRCA	trans	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg13010199	chr12:38710504	ALG10B	0.38	8.37	0.31	3.62e-16	Morning vs. evening chronotype;
BRCA	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg20887711	chr4:1340912	KIAA1530	0.34	7.89	0.3	1.29e-14	Obesity-related traits;
BRCA	cis	rs2516839	0.517	rs1556257	chr1:161051134	A/G	cg04981885	chr1:160991156	F11R	-0.48	-8.7	-0.33	2.84e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg05294307	chr14:35346193	BAZ1A	-0.61	-10.38	-0.38	1.91e-23	Psoriasis;
BRCA	cis	rs2304069	0.695	rs6866298	chr5:149439588	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.63	13.02	0.46	1.55e-34	HIV-1 control;
BRCA	cis	rs4478858	0.684	rs7515988	chr1:31731061	C/T	cg00250761	chr1:31883323	NA	0.32	8.48	0.32	1.55e-16	Alcohol dependence;
BRCA	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.69	-0.36	7.96e-21	Alzheimer's disease;
BRCA	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.97	0.3	7.09e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg13319975	chr6:146136371	FBXO30	-0.35	-7.98	-0.3	6.95e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs113835537	0.529	rs2277302	chr11:66240882	T/C	cg24851651	chr11:66362959	CCS	0.42	8.06	0.3	3.76e-15	Airway imaging phenotypes;
BRCA	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.02	-0.3	5.22e-15	Depression;
BRCA	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg13010199	chr12:38710504	ALG10B	0.5	10.36	0.38	2.35e-23	Bladder cancer;
BRCA	cis	rs9790314	0.663	rs9860360	chr3:160747963	G/A	cg03342759	chr3:160939853	NMD3	-0.46	-8.7	-0.33	2.86e-17	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.86	0.3	1.67e-14	Corneal astigmatism;
BRCA	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-13.3	-0.47	8.04e-36	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg23018236	chr17:30244563	NA	-0.61	-10.02	-0.37	4.87e-22	Hip circumference adjusted for BMI;
BRCA	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg05340658	chr4:99064831	C4orf37	0.67	16.85	0.55	5.47e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg06784218	chr1:46089804	CCDC17	-0.53	-12.92	-0.45	4.51e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	trans	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg17675199	chr6:35436792	RPL10A	-0.3	-7.88	-0.3	1.36e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs13394619	1.000	rs4669752	chr2:11727988	G/C	cg07314298	chr2:11723111	GREB1	-0.53	-11.83	-0.42	2.45e-29	Endometriosis;
BRCA	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg13010199	chr12:38710504	ALG10B	0.5	10.43	0.38	1.31e-23	Bladder cancer;
BRCA	cis	rs921968	0.565	rs6708192	chr2:219592227	A/G	cg02176678	chr2:219576539	TTLL4	-0.38	-10.43	-0.38	1.28e-23	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg25214090	chr10:38739885	LOC399744	-0.56	-12.67	-0.45	5.87e-33	Corneal astigmatism;
BRCA	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg21535247	chr6:8435926	SLC35B3	0.42	9.49	0.35	4.56e-20	Motion sickness;
BRCA	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg17063962	chr7:91808500	NA	0.53	12.65	0.45	7.05e-33	Breast cancer;
BRCA	cis	rs1011018	0.628	rs1106768	chr7:139473564	C/A	cg03224163	chr7:139420300	HIPK2	-0.59	-8.92	-0.33	5.04e-18	Systolic blood pressure;
BRCA	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg04362960	chr10:104952993	NT5C2	0.43	10.38	0.38	1.95e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.4	0.38	1.65e-23	Motion sickness;
BRCA	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	12.69	0.45	4.46e-33	Lymphocyte counts;
BRCA	cis	rs7729447	0.813	rs7715571	chr5:32690010	A/C	cg16267343	chr5:32710456	NPR3	0.45	9.48	0.35	4.98e-20	Blood pressure;
BRCA	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07308232	chr7:1071921	C7orf50	-0.43	-9.21	-0.34	4.51e-19	Longevity;Endometriosis;
BRCA	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg03585969	chr10:35415529	CREM	-0.49	-10.28	-0.38	4.9e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg11663144	chr21:46675770	NA	-0.61	-14.18	-0.49	6.95e-40	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg25664220	chr3:72788482	NA	-0.5	-10.8	-0.39	4.38e-25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg00409905	chr10:38381863	ZNF37A	0.45	9.18	0.34	5.8e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6580649	0.831	rs1635528	chr12:48395900	C/T	cg24011408	chr12:48396354	COL2A1	0.52	8.81	0.33	1.19e-17	Lung cancer;
BRCA	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	trans	rs2048656	0.600	rs1976671	chr8:9679634	A/G	cg15556689	chr8:8085844	FLJ10661	0.32	8.38	0.31	3.32e-16	Schizophrenia;
BRCA	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11764359	chr7:65958608	NA	0.62	13.52	0.47	8.65e-37	Calcium levels;
BRCA	cis	rs654351	0.541	rs556554	chr6:10388774	T/C	cg17959970	chr6:10383164	NA	-0.41	-8.55	-0.32	8.77e-17	Squamous cell lung carcinoma;
BRCA	cis	rs9470361	0.506	rs4568449	chr6:36621143	A/G	cg08179530	chr6:36648295	CDKN1A	0.39	8.46	0.32	1.87e-16	QRS complex (Cornell);QRS duration;Left ventricular fractional shortening;
BRCA	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg00717180	chr2:96193071	NA	-0.32	-9.08	-0.34	1.34e-18	Coronary artery disease;
BRCA	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg01475377	chr6:109611718	NA	-0.6	-16.68	-0.55	3.8e-52	Reticulocyte fraction of red cells;
BRCA	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg26384229	chr12:38710491	ALG10B	0.76	17.28	0.56	3.49e-55	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs459482	1.000	rs459498	chr21:42795027	G/A	cg14166395	chr21:42792516	MX1	0.51	11.68	0.42	1.02e-28	IgG glycosylation;
BRCA	cis	rs311392	0.902	rs423150	chr8:55092804	C/T	cg11783602	chr8:55087084	NA	-0.31	-9.07	-0.34	1.49e-18	Pelvic organ prolapse (moderate/severe);
BRCA	cis	rs17620991	1.000	rs17688571	chr7:40862763	C/T	cg05119115	chr7:40866195	C7orf10	0.53	8.28	0.31	7.14e-16	Alcohol dependence;
BRCA	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.47	9.4	0.35	9.51e-20	Tonsillectomy;
BRCA	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs16866061	0.890	rs72972401	chr2:225404668	T/C	cg12698349	chr2:225449008	CUL3	0.78	21.23	0.64	4.04e-76	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg13010199	chr12:38710504	ALG10B	-0.41	-8.37	-0.31	3.63e-16	Bladder cancer;
BRCA	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11764359	chr7:65958608	NA	-0.76	-16.82	-0.55	7.85e-53	Aortic root size;
BRCA	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg02659138	chr7:134003124	SLC35B4	-0.35	-10.9	-0.4	1.7e-25	Mean platelet volume;
BRCA	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg00277334	chr10:82204260	NA	-0.4	-7.94	-0.3	9.04e-15	Post bronchodilator FEV1;
BRCA	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg14784868	chr12:69753453	YEATS4	0.68	19.87	0.62	8.39e-69	Blood protein levels;
BRCA	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18876405	chr7:65276391	NA	0.48	10.75	0.39	7.14e-25	Aortic root size;
BRCA	cis	rs17604090	1.000	rs114892953	chr7:29676298	G/A	cg19413766	chr7:29689036	LOC646762	-0.64	-8.76	-0.33	1.77e-17	Facial emotion recognition;Facial emotion recognition (sad faces);
BRCA	cis	rs1997103	0.954	rs10246216	chr7:55390479	C/T	cg17469321	chr7:55412551	NA	0.52	9.82	0.36	2.79e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg25358565	chr5:93447407	FAM172A	-0.67	-11.7	-0.42	8.73e-29	Diabetic retinopathy;
BRCA	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23583168	chr7:148888333	NA	-0.81	-18.71	-0.59	1.32e-62	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18404041	chr3:52824283	ITIH1	-0.42	-12.47	-0.44	4.36e-32	Bipolar disorder;
BRCA	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg09624528	chr10:1369823	ADARB2	0.41	8.47	0.32	1.67e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
BRCA	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg06627628	chr2:24431161	ITSN2	-0.53	-8.67	-0.32	3.68e-17	Lymphocyte counts;
BRCA	cis	rs7589728	1.000	rs6720809	chr2:88528943	T/C	cg04511125	chr2:88470314	THNSL2	0.71	10.4	0.38	1.67e-23	Plasma clusterin levels;
BRCA	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08704250	chr15:31115839	NA	-0.35	-8.75	-0.33	1.92e-17	Huntington's disease progression;
BRCA	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg17971929	chr21:40555470	PSMG1	-0.49	-10.86	-0.39	2.48e-25	Menarche (age at onset);
BRCA	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-12.51	-0.44	2.93e-32	Bone mineral density;
BRCA	cis	rs10046574	0.831	rs7780028	chr7:135092556	A/G	cg27474649	chr7:135195673	CNOT4	0.58	8.24	0.31	1e-15	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg23625390	chr15:77176239	SCAPER	-0.54	-12.39	-0.44	9.98e-32	Blood metabolite levels;
BRCA	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg03188948	chr7:1209495	NA	0.84	11.6	0.42	2.4e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg23978390	chr7:1156363	C7orf50	0.4	9.05	0.34	1.64e-18	Longevity;Endometriosis;
BRCA	cis	rs9487051	0.773	rs421790	chr6:109543428	T/A	cg01475377	chr6:109611718	NA	-0.42	-9.79	-0.36	3.63e-21	Reticulocyte fraction of red cells;
BRCA	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg07395648	chr5:131743802	NA	0.37	8.5	0.32	1.38e-16	Breast cancer;Mosquito bite size;
BRCA	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg08999081	chr20:33150536	PIGU	0.47	13.11	0.46	6.3e-35	Glomerular filtration rate (creatinine);
BRCA	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg13256891	chr4:100009986	ADH5	-0.52	-9.75	-0.36	4.74e-21	Alcohol dependence;
BRCA	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg05535760	chr7:792225	HEATR2	0.71	12.93	0.46	3.86e-34	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg05340658	chr4:99064831	C4orf37	0.7	17.51	0.57	2.34e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1710278	0.505	rs2138278	chr10:127742664	A/G	cg22975853	chr10:127789788	ADAM12	0.33	8.15	0.31	1.9e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
BRCA	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg26384229	chr12:38710491	ALG10B	0.72	17.02	0.56	7.88e-54	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg25237894	chr2:233734115	C2orf82	0.4	11.51	0.41	5.56e-28	Coronary artery disease;
BRCA	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.53	-16.8	-0.55	9.57e-53	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg15212455	chr7:39170539	POU6F2	0.44	9.69	0.36	8.13e-21	IgG glycosylation;
BRCA	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg10351095	chr21:47802916	PCNT	0.42	9.19	0.34	5.58e-19	Testicular germ cell tumor;
BRCA	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.55	-0.32	8.94e-17	Monocyte percentage of white cells;
BRCA	cis	rs7617773	0.817	rs9311421	chr3:48293078	G/A	cg11946769	chr3:48343235	NME6	0.56	12.31	0.44	2.02e-31	Coronary artery disease;
BRCA	cis	rs9324022	0.929	rs1004574	chr14:101178067	C/G	cg18089426	chr14:101175970	NA	0.64	12.37	0.44	1.13e-31	Plateletcrit;
BRCA	trans	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg26384229	chr12:38710491	ALG10B	0.47	10.13	0.37	1.77e-22	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.13	-0.34	8.85e-19	Bipolar disorder;
BRCA	trans	rs629535	0.773	rs655299	chr8:70074534	C/T	cg21567404	chr3:27674614	NA	1.01	21.1	0.64	2.2100000000000001e-75	Dupuytren's disease;
BRCA	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg01874867	chr7:94954059	PON1	-0.39	-8.04	-0.3	4.23e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg05084668	chr3:125655381	ALG1L	-0.46	-8.05	-0.3	4.01e-15	Blood pressure (smoking interaction);
BRCA	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.48	9.54	0.35	2.93e-20	Tonsillectomy;
BRCA	cis	rs2463822	1.000	rs2513071	chr11:62098387	A/C	cg06239285	chr11:62104954	ASRGL1	0.66	11.05	0.4	4.1e-26	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs1003719	0.680	rs7275984	chr21:38505696	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.19	-0.49	6.29e-40	Eye color traits;
BRCA	cis	rs965469	1.000	rs6139103	chr20:3361140	T/C	cg25506879	chr20:3388711	C20orf194	-0.56	-10.8	-0.39	4.53e-25	IFN-related cytopenia;
BRCA	cis	rs4363385	0.747	rs4845334	chr1:152982998	T/A	cg24667326	chr1:152973720	SPRR3	-0.35	-9.91	-0.37	1.21e-21	Inflammatory skin disease;
BRCA	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg10223061	chr2:219282414	VIL1	0.3	8.79	0.33	1.42e-17	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg14456004	chr13:21872349	NA	1.03	20.39	0.63	1.45e-71	White matter hyperintensity burden;
BRCA	cis	rs2294693	0.947	rs4714417	chr6:40987782	A/G	cg14418226	chr6:40996092	UNC5CL	0.45	8.25	0.31	9.28e-16	Gastric cancer;Non-cardia gastric cancer;
BRCA	trans	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	14.41	0.5	5.62e-41	Exhaled nitric oxide output;
BRCA	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg23708337	chr7:1209742	NA	0.64	8.93	0.33	4.47e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg11663144	chr21:46675770	NA	-0.49	-9.79	-0.36	3.41e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9308433	0.643	rs7412913	chr1:214463228	G/A	cg06198575	chr1:214491504	SMYD2	0.49	10.29	0.38	4.37e-23	IgG glycosylation;
BRCA	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg05347473	chr6:146136440	FBXO30	0.38	7.87	0.3	1.57e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.38	-0.31	3.38e-16	Bipolar disorder;
BRCA	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg26031613	chr14:104095156	KLC1	0.44	8.73	0.33	2.14e-17	Schizophrenia;
BRCA	cis	rs870825	0.616	rs7680835	chr4:185652992	C/G	cg04058563	chr4:185651563	MLF1IP	-0.73	-15.84	-0.53	6.2e-48	Blood protein levels;
BRCA	cis	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg05084668	chr3:125655381	ALG1L	-0.61	-9.14	-0.34	7.94e-19	Blood pressure (smoking interaction);
BRCA	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg05283184	chr6:79620031	NA	0.39	10.03	0.37	4.43e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg05340658	chr4:99064831	C4orf37	0.43	10.1	0.37	2.4e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg10932868	chr11:921992	NA	0.47	12.11	0.43	1.62e-30	Alzheimer's disease (late onset);
BRCA	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg11764359	chr7:65958608	NA	0.64	11.45	0.41	1.01e-27	Aortic root size;
BRCA	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg24812749	chr6:127587940	RNF146	0.82	18.9	0.6	1.35e-63	Breast cancer;
BRCA	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg22535103	chr8:58192502	C8orf71	-0.47	-9.36	-0.35	1.34e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs10779751	0.770	rs1417131	chr1:11191922	T/C	cg08854313	chr1:11322531	MTOR	-0.7	-13.62	-0.47	2.76e-37	Body mass index;
BRCA	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	12.14	0.43	1.19e-30	Coronary artery disease;
BRCA	cis	rs350251	0.934	rs350209	chr16:12212818	G/C	cg06014057	chr16:12226852	SNX29	0.3	7.93	0.3	1e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs867371	0.762	rs12905578	chr15:82581264	T/G	cg00614314	chr15:82944287	LOC80154	-0.47	-9.63	-0.36	1.32e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs2625529	0.617	rs62023343	chr15:72174963	C/A	cg16672083	chr15:72433130	SENP8	0.65	15.63	0.53	7.49e-47	Red blood cell count;
BRCA	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg17366294	chr4:99064904	C4orf37	0.43	10.18	0.37	1.22e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg11764359	chr7:65958608	NA	0.66	11.64	0.42	1.58e-28	Aortic root size;
BRCA	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg16386425	chr10:429943	DIP2C	-0.41	-8.68	-0.32	3.18e-17	Psychosis in Alzheimer's disease;
BRCA	cis	rs6815814	0.950	rs66979032	chr4:38814700	A/G	cg02016764	chr4:38805732	TLR1	-0.59	-8.76	-0.33	1.73e-17	Breast cancer;
BRCA	cis	rs9837602	1.000	rs923470	chr3:99757792	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.16	0.4	1.5e-26	Breast cancer;
BRCA	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg20476274	chr7:133979776	SLC35B4	0.67	19.69	0.61	8.47e-68	Mean platelet volume;
BRCA	cis	rs6546550	0.901	rs12232914	chr2:70117176	C/T	cg02498382	chr2:70120550	SNRNP27	-0.52	-11.62	-0.42	1.88e-28	Prevalent atrial fibrillation;
BRCA	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg13047869	chr3:10149882	C3orf24	0.55	10.19	0.37	1.03e-22	Alzheimer's disease;
BRCA	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg01262667	chr19:19385393	TM6SF2	0.41	10.68	0.39	1.28e-24	Tonsillectomy;
BRCA	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	9.95	0.37	8.86e-22	Aortic root size;
BRCA	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-9.14	-0.34	8.3e-19	IgG glycosylation;
BRCA	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.34	0.49	1.19e-40	Motion sickness;
BRCA	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.05	0.3	4.1e-15	Menarche (age at onset);
BRCA	cis	rs4363385	0.747	rs2879489	chr1:152970465	A/G	cg24667326	chr1:152973720	SPRR3	-0.34	-9.42	-0.35	8.42e-20	Inflammatory skin disease;
BRCA	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.35	9.85	0.36	2.09e-21	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg07810366	chr2:100720526	AFF3	-0.3	-7.94	-0.3	9.4e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	trans	rs3960554	0.529	rs7793844	chr7:75883147	C/T	cg19862616	chr7:65841803	NCRNA00174	0.45	10.39	0.38	1.74e-23	Eotaxin levels;
BRCA	cis	rs4363385	0.765	rs3806221	chr1:153002555	G/T	cg24667326	chr1:152973720	SPRR3	-0.32	-8.81	-0.33	1.17e-17	Inflammatory skin disease;
BRCA	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg05082376	chr22:42548792	NA	0.36	8.52	0.32	1.11e-16	Cognitive function;
BRCA	cis	rs4474465	1.000	rs7395344	chr11:78202388	A/G	cg27205649	chr11:78285834	NARS2	-0.27	-8.08	-0.3	3.15e-15	Alzheimer's disease (survival time);
BRCA	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg26769984	chr7:1090371	C7orf50	0.45	9.64	0.36	1.22e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg23422044	chr7:1970798	MAD1L1	-0.45	-9.55	-0.35	2.66e-20	Neuroticism;
BRCA	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg22431228	chr1:16359049	CLCNKA	-0.43	-9.71	-0.36	6.72e-21	Systolic blood pressure;
BRCA	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg07810366	chr2:100720526	AFF3	0.33	8.27	0.31	7.5e-16	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
BRCA	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.41	-7.93	-0.3	9.58e-15	Huntington's disease progression;
BRCA	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	8.25	0.31	9.02e-16	Uric acid levels;
BRCA	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg03433033	chr1:76189801	ACADM	-0.38	-7.87	-0.3	1.5e-14	Daytime sleep phenotypes;
BRCA	cis	rs3780378	0.840	rs10119004	chr9:5071049	C/T	cg02405213	chr9:5042618	JAK2	-0.41	-8.13	-0.31	2.16e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg03676636	chr4:99064102	C4orf37	0.2	7.93	0.3	9.65e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9682041	0.627	rs6786374	chr3:170105233	A/G	cg11886554	chr3:170076028	SKIL	-0.47	-9.52	-0.35	3.41e-20	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg06238570	chr21:40685208	BRWD1	-0.42	-8.52	-0.32	1.15e-16	Cognitive function;
BRCA	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg17063962	chr7:91808500	NA	0.54	12.91	0.45	4.89e-34	Breast cancer;
BRCA	cis	rs965469	0.947	rs6139087	chr20:3329062	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-10.5	-0.38	6.58e-24	IFN-related cytopenia;
BRCA	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.37	-9.37	-0.35	1.24e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs587242	0.910	rs6593608	chr1:96987688	C/T	cg10631902	chr5:14652156	NA	0.36	8.63	0.32	4.78e-17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
BRCA	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg17927777	chr20:33865990	NA	-0.48	-9.32	-0.35	1.89e-19	Attention deficit hyperactivity disorder;
BRCA	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	23.23	0.68	4.96e-87	Platelet count;
BRCA	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg03146154	chr1:46216737	IPP	0.53	11.85	0.42	2e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg00677455	chr12:58241039	CTDSP2	0.63	15.54	0.52	2.07e-46	Multiple sclerosis;
BRCA	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.13	0.37	1.79e-22	Bipolar disorder;
BRCA	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07308232	chr7:1071921	C7orf50	-0.39	-8.15	-0.31	1.9e-15	Longevity;Endometriosis;
BRCA	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-12.87	-0.45	7.43e-34	Mood instability;
BRCA	cis	rs12541635	0.677	rs1496181	chr8:107027141	C/T	cg10147462	chr8:107024639	NA	0.37	9.93	0.37	1.05e-21	Age of smoking initiation;
BRCA	cis	rs10046574	0.561	rs56014861	chr7:135203027	A/T	cg27474649	chr7:135195673	CNOT4	0.66	11.04	0.4	4.84e-26	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	20.11	0.62	4.48e-70	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs4566357	0.615	rs1800517	chr2:227915832	G/A	cg05526886	chr2:227700861	RHBDD1	-0.39	-8.22	-0.31	1.13e-15	Coronary artery disease;
BRCA	cis	rs795544	0.554	rs12186615	chr5:13783861	T/C	cg07548982	chr5:13769939	DNAH5	-0.38	-7.92	-0.3	1.06e-14	Corneal astigmatism;
BRCA	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg26384229	chr12:38710491	ALG10B	0.58	13.27	0.46	1.1e-35	Morning vs. evening chronotype;
BRCA	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg03709012	chr19:19516395	GATAD2A	0.91	17.44	0.57	5.35e-56	Nonalcoholic fatty liver disease;
BRCA	trans	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg26384229	chr12:38710491	ALG10B	0.57	12.15	0.43	1.03e-30	Morning vs. evening chronotype;
BRCA	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg13385521	chr17:29058706	SUZ12P	0.76	11.17	0.4	1.41e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg18016565	chr1:150552671	MCL1	-0.41	-9.47	-0.35	5.55e-20	Tonsillectomy;
BRCA	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	14.95	0.51	1.56e-43	Hip circumference adjusted for BMI;
BRCA	cis	rs12760731	0.565	rs34303391	chr1:178178126	T/A	cg00404053	chr1:178313656	RASAL2	0.64	7.93	0.3	9.88e-15	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg05340658	chr4:99064831	C4orf37	0.62	14.74	0.5	1.55e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11229555	0.645	rs11229442	chr11:58196790	C/T	cg15696309	chr11:58395628	NA	-0.45	-9.72	-0.36	6.4e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs9612	1.000	rs346523	chr19:44260681	A/C	cg08581076	chr19:44259116	C19orf61	0.53	9.72	0.36	6.46e-21	Exhaled nitric oxide output;
BRCA	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00149659	chr3:10157352	C3orf10	0.82	14.28	0.49	2.33e-40	Alzheimer's disease;
BRCA	cis	rs16958440	1.000	rs16958701	chr18:44655241	T/C	cg17192377	chr18:44677553	HDHD2	0.68	10.01	0.37	5.3e-22	Sitting height ratio;
BRCA	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	8.19	0.31	1.44e-15	Menarche (age at onset);
BRCA	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg14675211	chr2:100938903	LONRF2	0.52	12.01	0.43	4.37e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg03676636	chr4:99064102	C4orf37	0.2	7.86	0.3	1.68e-14	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs12517041	1.000	rs1428619	chr5:23282426	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.32	-0.31	5.27e-16	Calcium levels;
BRCA	cis	rs66530629	0.958	rs1002707	chr1:25051102	C/T	cg01905478	chr1:25040257	NA	0.37	8.28	0.31	7.38e-16	Plateletcrit;
BRCA	cis	rs6772849	0.930	rs4857916	chr3:128376014	C/G	cg16766828	chr3:128327626	NA	-0.39	-8.72	-0.33	2.43e-17	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs78707713	0.560	rs61848436	chr10:71247714	C/T	cg12610070	chr10:71211762	TSPAN15	-0.32	-10.17	-0.37	1.31e-22	Venous thromboembolism;
BRCA	cis	rs9503598	0.636	rs7745968	chr6:3467745	G/T	cg00476032	chr6:3446245	SLC22A23	0.39	9.42	0.35	8.43e-20	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
BRCA	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg23950597	chr19:37808831	NA	-0.72	-12.56	-0.44	1.72e-32	Coronary artery calcification;
BRCA	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg27446573	chr6:127587934	RNF146	0.67	15.06	0.51	4.47e-44	Breast cancer;
BRCA	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg10295955	chr4:187884368	NA	-0.95	-28.09	-0.74	1.17e-113	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.45	7.91	0.3	1.15e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2806561	0.729	rs649664	chr1:23324263	C/T	cg19743168	chr1:23544995	NA	-0.39	-9.42	-0.35	8.09e-20	Height;
BRCA	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg03676636	chr4:99064102	C4orf37	0.2	7.93	0.3	9.65e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.39	-8.36	-0.31	4e-16	Alzheimer's disease (late onset);
BRCA	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg15145296	chr3:125709740	NA	-0.53	-8.38	-0.31	3.25e-16	Blood pressure (smoking interaction);
BRCA	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.46	8.02	0.3	5.09e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21659725	chr3:3221576	CRBN	0.52	13.44	0.47	1.88e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg08917208	chr2:24149416	ATAD2B	0.89	12.98	0.46	2.32e-34	Lymphocyte counts;
BRCA	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.07	15.91	0.53	2.86e-48	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg12310025	chr6:25882481	NA	-0.42	-9.65	-0.36	1.19e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg20476274	chr7:133979776	SLC35B4	0.67	19.69	0.61	7.98e-68	Mean platelet volume;
BRCA	cis	rs939658	0.805	rs35602654	chr15:79417527	T/A	cg17916960	chr15:79447300	NA	-0.45	-11.06	-0.4	3.71e-26	Refractive error;
BRCA	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg18301423	chr5:131593218	PDLIM4	0.32	7.85	0.3	1.78e-14	Acylcarnitine levels;
BRCA	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg26838691	chr2:24397539	C2orf84	-0.48	-8.67	-0.32	3.46e-17	Venous thromboembolism (SNP x SNP interaction);
BRCA	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg14784868	chr12:69753453	YEATS4	0.44	11.53	0.42	4.41e-28	Blood protein levels;
BRCA	cis	rs17601876	0.814	rs34712049	chr15:51560064	C/T	cg19946085	chr15:51559439	CYP19A1	-0.38	-10.64	-0.39	1.9e-24	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg12927641	chr6:109611667	NA	-0.39	-9.54	-0.35	2.95e-20	Reticulocyte fraction of red cells;
BRCA	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-10.74	-0.39	7.54e-25	IgG glycosylation;
BRCA	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg02297831	chr4:17616191	MED28	0.36	8.47	0.32	1.67e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg04944784	chr2:26401820	FAM59B	0.67	11.03	0.4	4.93e-26	Gut microbiome composition (summer);
BRCA	cis	rs1420338	0.933	rs62451689	chr7:34178719	C/T	cg01275685	chr7:34179230	BMPER	-0.52	-11.54	-0.42	3.96e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg11266682	chr4:10021025	SLC2A9	0.48	12.9	0.45	5.2e-34	Bone mineral density;
BRCA	trans	rs7181230	1.000	rs28587891	chr15:40365106	T/A	cg22705835	chr10:65332833	REEP3	-0.41	-9.72	-0.36	6.45e-21	Dehydroepiandrosterone sulphate levels;
BRCA	trans	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg25214090	chr10:38739885	LOC399744	0.51	11.02	0.4	5.39e-26	Corneal astigmatism;
BRCA	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.02	-0.34	2.13e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg15017067	chr4:17643749	FAM184B	0.32	10.0	0.37	5.88e-22	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.35	-0.41	2.58e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg25358565	chr5:93447407	FAM172A	1.25	18.92	0.6	1.03e-63	Diabetic retinopathy;
BRCA	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg00701064	chr4:6280414	WFS1	0.67	17.55	0.57	1.46e-56	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg04398451	chr17:18023971	MYO15A	0.57	12.08	0.43	2.01e-30	Total body bone mineral density;
BRCA	cis	rs897984	0.542	rs59061704	chr16:31062704	G/C	cg02466173	chr16:30829666	NA	-0.42	-9.31	-0.35	1.98e-19	Dementia with Lewy bodies;
BRCA	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg27170947	chr2:26402098	FAM59B	0.95	16.36	0.54	1.59e-50	Gut microbiome composition (summer);
BRCA	cis	rs17253792	0.598	rs12880362	chr14:56017929	G/C	cg01858014	chr14:56050164	KTN1	-0.61	-7.99	-0.3	6.09e-15	Putamen volume;
BRCA	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19748678	chr4:122722346	EXOSC9	0.74	15.94	0.53	2.18e-48	Type 2 diabetes;
BRCA	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg04944784	chr2:26401820	FAM59B	-0.73	-11.6	-0.42	2.19e-28	Gut microbiome composition (summer);
BRCA	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	14.08	0.49	2.16e-39	Motion sickness;
BRCA	cis	rs9790314	0.663	rs4679924	chr3:160661862	T/C	cg03342759	chr3:160939853	NMD3	0.43	8.19	0.31	1.4e-15	Morning vs. evening chronotype;
BRCA	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg22535103	chr8:58192502	C8orf71	-0.51	-11.88	-0.43	1.49e-29	Developmental language disorder (linguistic errors);
BRCA	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.61	9.5	0.35	4.1e-20	Mean platelet volume;
BRCA	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg25358565	chr5:93447407	FAM172A	1.21	18.17	0.58	9.14e-60	Diabetic retinopathy;
BRCA	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg03676636	chr4:99064102	C4orf37	0.21	7.96	0.3	7.83e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.09	0.4	2.95e-26	Bipolar disorder;
BRCA	cis	rs751728	0.638	rs4713686	chr6:33787506	C/T	cg15252951	chr6:33757062	LEMD2	0.36	8.31	0.31	5.67e-16	Crohn's disease;
BRCA	cis	rs17401966	1.000	rs7520935	chr1:10354271	G/T	cg15208524	chr1:10270712	KIF1B	0.37	8.05	0.3	4.08e-15	Hepatocellular carcinoma;
BRCA	cis	rs1451375	0.617	rs745043	chr7:50543955	T/G	cg18232548	chr7:50535776	DDC	-0.41	-8.64	-0.32	4.56e-17	Malaria;
BRCA	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg26384229	chr12:38710491	ALG10B	0.82	21.74	0.65	7.44e-79	Heart rate;
BRCA	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg21252483	chr19:49399788	TULP2	-0.51	-11.08	-0.4	3.1e-26	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs11955398	0.585	rs1117677	chr5:60034675	T/G	cg02684056	chr5:59996105	DEPDC1B	-0.38	-9.06	-0.34	1.6e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg21475434	chr5:93447410	FAM172A	0.65	8.65	0.32	4e-17	Diabetic retinopathy;
BRCA	cis	rs3772130	0.961	rs34667636	chr3:121353291	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	9.45	0.35	6.12e-20	Cognitive performance;
BRCA	cis	rs2742234	0.590	rs2435377	chr10:43683600	A/G	cg15436174	chr10:43711423	RASGEF1A	0.55	11.38	0.41	1.84e-27	Hirschsprung disease;
BRCA	trans	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg25214090	chr10:38739885	LOC399744	0.56	12.25	0.44	3.83e-31	Corneal astigmatism;
BRCA	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg22508957	chr16:3507546	NAT15	-0.58	-8.61	-0.32	5.8e-17	Tuberculosis;
BRCA	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg20607798	chr8:58055168	NA	0.53	8.41	0.32	2.62e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg10729496	chr3:10149963	C3orf24	0.47	7.84	0.3	1.9e-14	Alzheimer's disease;
BRCA	cis	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg05901451	chr6:126070800	HEY2	-0.41	-10.03	-0.37	4.36e-22	Endometrial cancer;
BRCA	trans	rs8073060	0.544	rs2626626	chr17:34026717	A/G	cg19694781	chr19:47549865	TMEM160	-1.06	-20.95	-0.64	1.39e-74	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg14343924	chr8:8086146	FLJ10661	0.41	8.55	0.32	9.4e-17	Mood instability;
BRCA	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg06784218	chr1:46089804	CCDC17	0.46	10.92	0.4	1.49e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg09165964	chr15:75287851	SCAMP5	0.85	19.34	0.61	6.07e-66	Blood trace element (Zn levels);
BRCA	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg24675658	chr1:53192096	ZYG11B	-0.66	-14.3	-0.49	1.81e-40	Monocyte count;
BRCA	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg15017067	chr4:17643749	FAM184B	0.27	8.07	0.3	3.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg04362960	chr10:104952993	NT5C2	0.44	9.98	0.37	7.02e-22	Arsenic metabolism;
BRCA	trans	rs2270927	0.510	rs4352583	chr5:75576716	A/G	cg13563193	chr19:33072644	PDCD5	0.77	9.45	0.35	6.13e-20	Mean corpuscular volume;
BRCA	cis	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg07460842	chr6:66804631	NA	-0.95	-17.73	-0.57	1.73e-57	Exhaled nitric oxide output;
BRCA	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg22906224	chr7:99728672	NA	-0.41	-8.23	-0.31	1.07e-15	Coronary artery disease;
BRCA	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg24130564	chr14:104152367	KLC1	-0.35	-7.92	-0.3	1.06e-14	Body mass index;
BRCA	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg20573242	chr4:122745356	CCNA2	0.46	10.19	0.37	1.09e-22	Type 2 diabetes;
BRCA	cis	rs1468333	0.724	rs12514307	chr5:137612143	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.38	7.97	0.3	7.33e-15	Resting heart rate;
BRCA	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg08601574	chr20:25228251	PYGB	-0.34	-8.2	-0.31	1.31e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.64e-24	Motion sickness;
BRCA	cis	rs507080	0.922	rs558907	chr11:118558455	A/G	cg09144398	chr11:118550485	TREH	-0.38	-8.97	-0.33	3.15e-18	Serum metabolite levels;
BRCA	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg24558204	chr6:135376177	HBS1L	0.45	12.33	0.44	1.66e-31	Red blood cell count;
BRCA	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	10.67	0.39	1.45e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2625529	0.824	rs35112434	chr15:72448326	G/T	cg16672083	chr15:72433130	SENP8	-0.87	-18.09	-0.58	2.27e-59	Red blood cell count;
BRCA	cis	rs7677751	0.806	rs7682912	chr4:55085620	T/G	cg17187183	chr4:55093834	PDGFRA	0.46	9.01	0.34	2.33e-18	Corneal astigmatism;
BRCA	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg11833968	chr6:79620685	NA	-0.4	-9.15	-0.34	7.38e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg16414030	chr3:133502952	NA	-0.42	-9.25	-0.34	3.43e-19	Iron status biomarkers;
BRCA	cis	rs9649213	0.614	rs59120980	chr7:98017730	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.58	-15.87	-0.53	4.83e-48	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg00080972	chr5:178986291	RUFY1	0.5	13.05	0.46	1.15e-34	Lung cancer;
BRCA	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg15556689	chr8:8085844	FLJ10661	0.32	8.55	0.32	9.04e-17	Neuroticism;
BRCA	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg17366294	chr4:99064904	C4orf37	0.44	10.45	0.38	1.08e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg04553112	chr3:125709451	NA	-0.56	-8.49	-0.32	1.46e-16	Blood pressure (smoking interaction);
BRCA	cis	rs9560113	1.000	rs9555809	chr13:112181401	T/C	cg10483660	chr13:112241077	NA	0.32	7.99	0.3	6.49e-15	Menarche (age at onset);
BRCA	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg21573476	chr21:45109991	RRP1B	-0.36	-9.49	-0.35	4.48e-20	Mean corpuscular volume;
BRCA	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	10.46	0.38	9.94e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs4363385	0.720	rs1984197	chr1:152962915	C/G	cg21543102	chr1:152974771	SPRR3	-0.28	-8.15	-0.31	1.9e-15	Inflammatory skin disease;
BRCA	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg21747090	chr2:27597821	SNX17	-0.43	-9.43	-0.35	7.24e-20	Total body bone mineral density;
BRCA	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg11764359	chr7:65958608	NA	0.65	11.2	0.41	1.03e-26	Aortic root size;
BRCA	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-17.65	-0.57	4.47e-57	Chronic sinus infection;
BRCA	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg00106254	chr7:1943704	MAD1L1	-0.39	-9.52	-0.35	3.47e-20	Bipolar disorder and schizophrenia;
BRCA	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg14829155	chr15:31115871	NA	-0.42	-9.78	-0.36	3.74e-21	Huntington's disease progression;
BRCA	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg01877450	chr7:97915802	BRI3	-0.39	-8.8	-0.33	1.25e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9581857	0.547	rs76435345	chr13:28107638	G/A	cg22138327	chr13:27999177	GTF3A	0.55	7.87	0.3	1.47e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
BRCA	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg25358565	chr5:93447407	FAM172A	1.16	18.09	0.58	2.26e-59	Diabetic retinopathy;
BRCA	cis	rs877529	1.000	rs139404	chr22:39547201	C/T	cg12193277	chr22:39547181	CBX7	0.47	13.09	0.46	7.28e-35	Multiple myeloma;
BRCA	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg22676075	chr6:135203613	NA	-0.4	-8.21	-0.31	1.26e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	8.71	0.33	2.67e-17	Tonsillectomy;
BRCA	cis	rs6087990	0.806	rs2424918	chr20:31382770	C/T	cg13636640	chr20:31349939	DNMT3B	0.64	20.32	0.63	3.35e-71	Ulcerative colitis;
BRCA	cis	rs6545883	0.868	rs7594191	chr2:61840018	A/G	cg15711740	chr2:61764176	XPO1	0.48	12.14	0.43	1.15e-30	Tuberculosis;
BRCA	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg02297831	chr4:17616191	MED28	0.37	8.01	0.3	5.43e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg02493740	chr2:85810744	VAMP5	-0.54	-11.17	-0.4	1.44e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.37	8.2	0.31	1.29e-15	Cognitive ability;
BRCA	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg08470875	chr2:26401718	FAM59B	-0.5	-8.16	-0.31	1.85e-15	Gut microbiome composition (summer);
BRCA	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06108461	chr20:60628389	TAF4	-0.64	-13.49	-0.47	1.13e-36	Body mass index;
BRCA	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg15017067	chr4:17643749	FAM184B	0.29	8.84	0.33	8.94e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10248839	0.518	rs34011864	chr7:29698499	G/A	cg19413766	chr7:29689036	LOC646762	-0.58	-9.19	-0.34	5.33e-19	Facial emotion recognition (angry faces);
BRCA	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg09021430	chr5:549028	NA	-0.68	-14.24	-0.49	3.76e-40	Lung disease severity in cystic fibrosis;
BRCA	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg23173402	chr1:227635558	NA	-0.45	-8.33	-0.31	4.89e-16	Major depressive disorder;
BRCA	trans	rs1941687	0.563	rs9947894	chr18:31328720	G/T	cg15819921	chr19:927150	ARID3A	0.45	8.49	0.32	1.43e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg10636054	chr15:40330586	SRP14	0.89	13.01	0.46	1.77e-34	Corneal curvature;
BRCA	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.38	8.34	0.31	4.57e-16	Cognitive ability;
BRCA	trans	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg26043149	chr18:55253948	FECH	-0.39	-8.57	-0.32	8.06e-17	Bone mineral density;
BRCA	cis	rs11191270	0.554	rs11191275	chr10:104142800	C/T	cg15320455	chr10:103880129	LDB1	0.75	11.06	0.4	4.04e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg04944784	chr2:26401820	FAM59B	-1.02	-17.0	-0.56	9.06e-54	Gut microbiome composition (summer);
BRCA	cis	rs10789491	0.953	rs1866770	chr1:47182468	G/T	cg15501359	chr1:47185051	KIAA0494	0.66	18.2	0.58	6.28e-60	Response to hepatitis C treatment;
BRCA	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg03676636	chr4:99064102	C4orf37	0.2	7.87	0.3	1.55e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	18.27	0.59	2.5e-60	Platelet count;
BRCA	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-14.14	-0.49	1.05e-39	Morning vs. evening chronotype;
BRCA	cis	rs6684514	1.000	rs10752615	chr1:156248609	T/C	cg16558208	chr1:156270281	VHLL	0.35	7.95	0.3	8.56e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg11645453	chr3:52864694	ITIH4	0.47	10.86	0.39	2.42e-25	Schizophrenia;
BRCA	cis	rs10733682	0.659	rs13292976	chr9:129467340	C/T	cg00232160	chr9:129468157	NA	0.39	9.07	0.34	1.44e-18	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg06238570	chr21:40685208	BRWD1	-0.46	-9.03	-0.34	1.94e-18	Cognitive function;
BRCA	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg18811423	chr2:55921094	PNPT1	-0.51	-13.01	-0.46	1.68e-34	Metabolic syndrome;
BRCA	cis	rs4975616	0.807	rs28379291	chr5:1313701	A/G	cg26373071	chr5:1325741	CLPTM1L	-0.44	-10.33	-0.38	3.1e-23	Lung cancer;
BRCA	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	14.95	0.51	1.5e-43	Hip circumference adjusted for BMI;
BRCA	cis	rs4588572	0.644	rs6870646	chr5:77741082	G/A	cg11547950	chr5:77652471	NA	-0.42	-8.04	-0.3	4.5e-15	Triglycerides;
BRCA	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg13010199	chr12:38710504	ALG10B	0.42	9.01	0.34	2.29e-18	Morning vs. evening chronotype;
BRCA	cis	rs9831754	0.704	rs7647185	chr3:78468807	T/C	cg06138941	chr3:78371609	NA	-0.61	-12.92	-0.46	4.17e-34	Calcium levels;
BRCA	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.96	-0.33	3.42e-18	Bipolar disorder and schizophrenia;
BRCA	trans	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg11693508	chr17:37793320	STARD3	0.52	9.14	0.34	7.91e-19	Neuroticism;
BRCA	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg17971929	chr21:40555470	PSMG1	0.79	18.61	0.59	4.55e-62	Cognitive function;
BRCA	cis	rs4891159	0.824	rs17059362	chr18:74144307	G/A	cg24786174	chr18:74118243	ZNF516	-0.77	-18.16	-0.58	1.02e-59	Longevity;
BRCA	cis	rs912057	0.526	rs1294400	chr6:6733421	A/G	cg06612196	chr6:6737390	NA	-0.57	-14.13	-0.49	1.22e-39	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg24642439	chr20:33292090	TP53INP2	-0.71	-16.39	-0.54	1.13e-50	Coronary artery disease;
BRCA	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-11.77	-0.42	4.53e-29	Gut microbiome composition (summer);
BRCA	trans	rs4596713	0.568	rs7048937	chr9:71746253	A/G	cg16512924	chr15:28394682	HERC2	-0.4	-9.61	-0.36	1.65e-20	Headache;
BRCA	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg00631329	chr6:26305371	NA	0.49	13.3	0.47	8.69e-36	Mosquito bite size;
BRCA	cis	rs2354432	1.000	rs2354432	chr1:146693229	C/T	cg25205988	chr1:146714368	CHD1L	0.95	16.12	0.54	2.57e-49	Mitochondrial DNA levels;
BRCA	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg08508325	chr11:3079039	CARS	0.28	8.51	0.32	1.19e-16	Calcium levels;
BRCA	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg17830980	chr10:43048298	ZNF37B	-0.54	-13.02	-0.46	1.52e-34	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4285028	0.948	rs12488334	chr3:121702526	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.59	-10.85	-0.39	2.68e-25	Multiple sclerosis;
BRCA	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-14.26	-0.49	2.79e-40	Total cholesterol levels;
BRCA	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.49	-9.33	-0.35	1.76e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg04990556	chr1:26633338	UBXN11	0.54	8.93	0.33	4.42e-18	Obesity-related traits;
BRCA	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg18230493	chr5:56204884	C5orf35	-0.42	-8.73	-0.33	2.23e-17	Coronary artery disease;
BRCA	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg13319975	chr6:146136371	FBXO30	-0.45	-10.29	-0.38	4.53e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11608355	0.545	rs12818120	chr12:109901916	C/T	cg05360138	chr12:110035743	NA	0.71	13.0	0.46	1.93e-34	Neuroticism;
BRCA	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	15.14	0.51	1.79e-44	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg01448562	chr3:133502909	NA	-0.63	-14.96	-0.51	1.35e-43	Iron status biomarkers;
BRCA	cis	rs6684514	0.845	rs12138564	chr1:156291600	G/T	cg16558208	chr1:156270281	VHLL	0.35	7.97	0.3	7.18e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs2070488	0.804	rs1870914	chr3:38494220	T/C	cg24069376	chr3:38537580	EXOG	0.35	9.74	0.36	5.34e-21	Electrocardiographic conduction measures;
BRCA	cis	rs6815814	0.898	rs115807384	chr4:38851585	A/C	cg02016764	chr4:38805732	TLR1	-0.52	-7.92	-0.3	1.07e-14	Breast cancer;
BRCA	cis	rs919433	0.617	rs700638	chr2:198588950	A/C	cg00792783	chr2:198669748	PLCL1	0.42	9.16	0.34	7.2e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.52	9.91	0.36	1.25e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg06521331	chr12:34319734	NA	-0.45	-8.4	-0.32	2.91e-16	Bladder cancer;
BRCA	cis	rs2625529	0.617	rs7175792	chr15:72431883	C/G	cg16672083	chr15:72433130	SENP8	-0.67	-16.3	-0.54	3.41e-50	Red blood cell count;
BRCA	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg25036284	chr2:26402008	FAM59B	0.89	15.61	0.53	8.74e-47	Gut microbiome composition (summer);
BRCA	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg13256891	chr4:100009986	ADH5	0.51	10.63	0.39	2.03e-24	Alcohol dependence;
BRCA	cis	rs829883	0.934	rs1641642	chr12:98898726	A/G	cg25150519	chr12:98850993	NA	0.6	12.04	0.43	3.07e-30	Colorectal adenoma (advanced);
BRCA	cis	rs6878727	0.589	rs190464	chr5:123668730	T/C	cg01806427	chr5:123737813	NA	-0.37	-8.26	-0.31	8.69e-16	Breast cancer;
BRCA	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg21475434	chr5:93447410	FAM172A	0.67	8.57	0.32	8.02e-17	Diabetic retinopathy;
BRCA	cis	rs1799922	0.693	rs1688932	chr7:128421135	A/G	cg02354431	chr7:128423266	NA	0.36	9.51	0.35	3.76e-20	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
BRCA	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg16322792	chr1:120165303	ZNF697	0.58	15.27	0.52	4.29e-45	Systemic lupus erythematosus;
BRCA	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg01324343	chr3:183735012	ABCC5	-0.74	-11.55	-0.42	3.54e-28	Body mass index;
BRCA	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg13319975	chr6:146136371	FBXO30	0.34	7.83	0.3	2.03e-14	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg03188948	chr7:1209495	NA	0.47	8.8	0.33	1.32e-17	Longevity;Endometriosis;
BRCA	cis	rs13046373	0.535	rs1395778	chr21:31985502	G/C	cg06468780	chr21:31798236	KRTAP13-3	0.34	8.37	0.31	3.67e-16	HDL cholesterol;
BRCA	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22307029	chr19:49891270	CCDC155	0.58	10.44	0.38	1.18e-23	Multiple sclerosis;
BRCA	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg05340658	chr4:99064831	C4orf37	0.57	10.99	0.4	7.15e-26	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg23533926	chr12:111358616	MYL2	-0.42	-8.77	-0.33	1.62e-17	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4363385	0.617	rs5010885	chr1:152973141	C/T	cg25856811	chr1:152973957	SPRR3	-0.35	-9.28	-0.34	2.55e-19	Inflammatory skin disease;
BRCA	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg20307385	chr11:47447363	PSMC3	-0.42	-8.65	-0.32	4.01e-17	Subjective well-being;
BRCA	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg18876405	chr7:65276391	NA	0.54	12.22	0.44	5.13e-31	Calcium levels;
BRCA	cis	rs72781680	0.716	rs2712079	chr2:24082061	G/A	cg08917208	chr2:24149416	ATAD2B	0.59	10.15	0.37	1.51e-22	Lymphocyte counts;
BRCA	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-11.49	-0.41	6.64e-28	Longevity;Endometriosis;
BRCA	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.77	12.63	0.45	8.45e-33	Platelet count;
BRCA	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-9.47	-0.35	5.5e-20	Height;
BRCA	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg20701182	chr2:24300061	SF3B14	0.6	9.39	0.35	1.02e-19	Lymphocyte counts;
BRCA	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg03354898	chr7:1950403	MAD1L1	-0.4	-8.34	-0.31	4.42e-16	Bipolar disorder and schizophrenia;
BRCA	trans	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg05926928	chr17:57297772	GDPD1	1.0	13.58	0.47	4.5e-37	Opioid sensitivity;
BRCA	cis	rs6942407	0.546	rs3747807	chr7:86800351	A/G	cg02420886	chr7:86849541	C7orf23	0.52	7.88	0.3	1.44e-14	Food allergy;
BRCA	cis	rs6142102	0.625	rs1883707	chr20:32552587	A/G	cg24642439	chr20:33292090	TP53INP2	-0.4	-7.96	-0.3	7.79e-15	Skin pigmentation;
BRCA	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg20469991	chr17:27169893	C17orf63	-0.45	-8.78	-0.33	1.51e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs4908768	0.539	rs6663123	chr1:8642931	T/C	cg20416874	chr1:8611966	RERE	-0.28	-8.16	-0.31	1.83e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg10495392	chr1:46806563	NSUN4	0.46	8.43	0.32	2.32e-16	Menopause (age at onset);
BRCA	cis	rs11920090	0.789	rs73169742	chr3:170756779	C/T	cg09710316	chr3:170744871	SLC2A2	0.57	8.96	0.33	3.51e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs7178424	0.777	rs8033816	chr15:62233167	A/G	cg00456672	chr15:62358751	C2CD4A	-0.38	-9.29	-0.35	2.33e-19	Height;
BRCA	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19717773	chr7:2847554	GNA12	-0.43	-9.4	-0.35	9.87e-20	Height;
BRCA	trans	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg06521331	chr12:34319734	NA	-0.45	-8.59	-0.32	6.74e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.47	-11.25	-0.41	6.51e-27	IgG glycosylation;
BRCA	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08045932	chr20:61659980	NA	0.5	11.54	0.42	3.98e-28	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-16.75	-0.55	1.78e-52	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg27170947	chr2:26402098	FAM59B	0.69	11.58	0.42	2.77e-28	Gut microbiome composition (summer);
BRCA	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11764359	chr7:65958608	NA	-0.79	-18.83	-0.6	2.83e-63	Aortic root size;
BRCA	cis	rs1143633	0.662	rs12990810	chr2:113642532	G/T	cg12858261	chr2:113808755	IL1F8	-0.45	-9.18	-0.34	5.99e-19	Allergic disease (asthma, hay fever or eczema);
BRCA	trans	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg21659725	chr3:3221576	CRBN	-0.48	-8.87	-0.33	7.34e-18	Menarche (age at onset);
BRCA	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg27446573	chr6:127587934	RNF146	0.89	21.1	0.64	2.1e-75	Breast cancer;
BRCA	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg05347473	chr6:146136440	FBXO30	0.41	8.05	0.3	4.05e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg21905437	chr5:178450457	ZNF879	0.52	10.79	0.39	4.73e-25	Pubertal anthropometrics;
BRCA	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00149659	chr3:10157352	C3orf10	0.78	13.55	0.47	5.8e-37	Alzheimer's disease;
BRCA	cis	rs12200560	0.505	rs59296768	chr6:97075535	C/T	cg06623918	chr6:96969491	KIAA0776	0.53	12.73	0.45	3.02e-33	Coronary heart disease;
BRCA	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg22920501	chr2:26401640	FAM59B	-0.65	-11.32	-0.41	3.23e-27	Gut microbiome composition (summer);
BRCA	cis	rs1997103	0.906	rs2177806	chr7:55402609	A/T	cg17469321	chr7:55412551	NA	0.51	9.72	0.36	6.37e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	10.84	0.39	2.95e-25	Rheumatoid arthritis;
BRCA	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg20307385	chr11:47447363	PSMC3	0.79	18.93	0.6	9.01e-64	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg04455712	chr21:45112962	RRP1B	0.41	10.76	0.39	6.02e-25	Mean corpuscular volume;
BRCA	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg25173405	chr17:45401733	C17orf57	0.52	11.22	0.41	8.53e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9612	0.718	rs173202	chr19:44253588	C/T	cg08581076	chr19:44259116	C19orf61	0.45	8.3	0.31	6.19e-16	Exhaled nitric oxide output;
BRCA	cis	rs7799006	0.606	rs12669625	chr7:2315950	C/T	cg08027265	chr7:2291960	NA	-0.46	-11.97	-0.43	6.04e-30	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs7945718	0.935	rs1609442	chr11:12795418	T/A	cg25843174	chr11:12811716	TEAD1	0.24	9.35	0.35	1.47e-19	Educational attainment (years of education);
BRCA	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00166722	chr3:10149974	C3orf24	0.59	11.45	0.41	1e-27	Alzheimer's disease;
BRCA	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg01181863	chr3:195395398	SDHAP2	-0.54	-9.26	-0.34	3.09e-19	Pancreatic cancer;
BRCA	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg24642439	chr20:33292090	TP53INP2	0.53	11.49	0.41	6.44e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg14784868	chr12:69753453	YEATS4	0.47	9.28	0.34	2.67e-19	Response to diuretic therapy;
BRCA	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-12.94	-0.46	3.67e-34	Response to antipsychotic treatment;
BRCA	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg10295955	chr4:187884368	NA	0.97	31.28	0.78	5.38e-131	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.42	-9.34	-0.35	1.5700000000000001e-19	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	trans	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.35	-7.83	-0.3	2.07e-14	Endometrial cancer;
BRCA	cis	rs4363385	0.818	rs678960	chr1:153011621	G/A	cg21543102	chr1:152974771	SPRR3	-0.28	-7.83	-0.3	2.09e-14	Inflammatory skin disease;
BRCA	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11890956	chr21:40555474	PSMG1	0.98	23.1	0.67	2.86e-86	Cognitive function;
BRCA	cis	rs6484504	0.600	rs2761593	chr11:31326752	G/T	cg14844989	chr11:31128820	NA	0.44	9.64	0.36	1.22e-20	Red blood cell count;
BRCA	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.49	8.62	0.32	5.17e-17	Mean platelet volume;
BRCA	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.3	0.31	6.41e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg02773041	chr1:40204384	PPIE	0.47	9.98	0.37	7.06e-22	Blood protein levels;
BRCA	cis	rs9513627	0.573	rs7325697	chr13:100117793	A/G	cg25919922	chr13:100150906	NA	0.55	8.87	0.33	7.35e-18	Obesity-related traits;
BRCA	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg15556689	chr8:8085844	FLJ10661	-0.38	-9.75	-0.36	4.8e-21	Triglycerides;
BRCA	cis	rs586533	0.881	rs629701	chr11:99503431	C/G	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.31	2.76e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	13.49	0.47	1.12e-36	Personality dimensions;
BRCA	cis	rs312273	0.693	rs11179168	chr12:41345882	A/C	cg17827154	chr12:41323612	CNTN1	-0.39	-10.04	-0.37	4.08e-22	Bipolar disorder;
BRCA	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-10.25	-0.38	6.13e-23	Neuroticism;
BRCA	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg20891283	chr12:69753455	YEATS4	0.84	28.41	0.75	1.93e-115	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs1997103	1.000	rs11238364	chr7:55407632	G/T	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg05457628	chr5:178986728	RUFY1	0.57	14.13	0.49	1.15e-39	Lung cancer;
BRCA	cis	rs6815814	0.861	rs73142654	chr4:38785697	T/A	cg06935464	chr4:38784597	TLR10	0.49	9.9	0.36	1.35e-21	Breast cancer;
BRCA	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg04944784	chr2:26401820	FAM59B	0.99	16.56	0.55	1.61e-51	Gut microbiome composition (summer);
BRCA	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.25	0.31	9.38e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs459571	0.959	rs408307	chr9:136892523	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.71	13.62	0.47	2.98e-37	Platelet distribution width;
BRCA	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg11693508	chr17:37793320	STARD3	0.57	10.76	0.39	6.54e-25	Bipolar disorder;
BRCA	trans	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg23762105	chr12:34175262	ALG10	-0.41	-10.19	-0.37	1.1e-22	Morning vs. evening chronotype;
BRCA	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg24562669	chr7:97807699	LMTK2	0.47	12.33	0.44	1.78e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg10876282	chr6:28092338	ZSCAN16	0.41	7.93	0.3	9.66e-15	Parkinson's disease;
BRCA	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07080220	chr10:102295463	HIF1AN	0.49	11.36	0.41	2.23e-27	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.34	-8.57	-0.32	7.75e-17	Total body bone mineral density;
BRCA	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg11764359	chr7:65958608	NA	0.67	15.04	0.51	5.33e-44	Aortic root size;
BRCA	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.84	-0.33	9.59e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg03585969	chr10:35415529	CREM	0.56	11.55	0.42	3.74e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg22875332	chr1:76189707	ACADM	0.79	18.87	0.6	1.86e-63	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg23029597	chr12:123009494	RSRC2	-0.62	-12.43	-0.44	6.52e-32	Body mass index;
BRCA	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg03806693	chr22:41940476	POLR3H	-1.17	-22.48	-0.66	6.33e-83	Vitiligo;
BRCA	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg04362960	chr10:104952993	NT5C2	0.45	10.2	0.37	9.66e-23	Arsenic metabolism;
BRCA	cis	rs919433	0.679	rs6757632	chr2:198530266	C/T	cg00792783	chr2:198669748	PLCL1	0.39	9.01	0.34	2.27e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg04414720	chr1:150670196	GOLPH3L	0.36	8.3	0.31	6.38e-16	Tonsillectomy;
BRCA	cis	rs1371614	0.635	rs6706127	chr2:27140741	C/T	cg12368169	chr2:27073192	DPYSL5	-0.29	-8.73	-0.33	2.13e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs752010	0.523	rs943376	chr1:42122117	A/G	cg06885757	chr1:42089581	HIVEP3	0.29	9.82	0.36	2.77e-21	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg16586182	chr3:47516702	SCAP	-0.57	-12.54	-0.44	2.04e-32	Colorectal cancer;
BRCA	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-13.23	-0.46	1.66e-35	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg24920358	chr1:40204285	PPIE	0.34	7.87	0.3	1.47e-14	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.19e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2963155	0.518	rs853176	chr5:142636456	A/G	cg17617527	chr5:142782415	NR3C1	-0.52	-8.22	-0.31	1.12e-15	Breast cancer;
BRCA	trans	rs1997103	1.000	rs6951294	chr7:55400835	C/T	cg20935933	chr6:143382018	AIG1	0.6	11.42	0.41	1.32e-27	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs858239	0.539	rs7791200	chr7:23182121	A/T	cg23682824	chr7:23144976	KLHL7	0.41	10.66	0.39	1.52e-24	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg20933634	chr6:27740509	NA	0.44	8.43	0.32	2.27e-16	Parkinson's disease;
BRCA	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg03474202	chr17:45855739	NA	0.41	10.34	0.38	2.73e-23	IgG glycosylation;
BRCA	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg10057126	chr4:77819792	ANKRD56	0.68	15.42	0.52	7.78e-46	Emphysema distribution in smoking;
BRCA	cis	rs10754283	1.000	rs10754283	chr1:90112431	G/T	cg21401794	chr1:90099060	LRRC8C	0.46	11.12	0.4	2.31e-26	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.58	-12.74	-0.45	2.65e-33	Platelet count;
BRCA	trans	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg06521331	chr12:34319734	NA	-0.47	-8.68	-0.32	3.27e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs7572733	0.555	rs7561950	chr2:198754244	C/T	cg00792783	chr2:198669748	PLCL1	0.47	10.08	0.37	2.94e-22	Dermatomyositis;
BRCA	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg18270830	chr10:32634957	EPC1	0.58	10.04	0.37	4.01e-22	Sexual dysfunction (female);
BRCA	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg18904891	chr8:8559673	CLDN23	0.64	12.52	0.44	2.6e-32	Obesity-related traits;
BRCA	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.51	-14.97	-0.51	1.25e-43	Lung cancer;
BRCA	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.27	-7.98	-0.3	6.92e-15	Personality dimensions;
BRCA	cis	rs3772130	1.000	rs34086988	chr3:121352745	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	9.58	0.35	2.15e-20	Cognitive performance;
BRCA	cis	rs10851411	0.518	rs17767264	chr15:42886656	C/T	cg21293051	chr15:42870591	STARD9	0.56	9.26	0.34	3.01e-19	Glucose homeostasis traits;
BRCA	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07308232	chr7:1071921	C7orf50	0.44	9.39	0.35	1.08e-19	Longevity;Endometriosis;
BRCA	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10802521	chr3:52805072	NEK4	-0.32	-8.33	-0.31	5.11e-16	Bipolar disorder;
BRCA	cis	rs6714710	0.603	rs6746768	chr2:98466647	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	13.44	0.47	1.84e-36	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg13789015	chr9:136890014	NCRNA00094	0.58	12.2	0.43	6.37e-31	Platelet distribution width;
BRCA	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.31	-0.38	3.85e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg13010199	chr12:38710504	ALG10B	0.5	10.0	0.37	5.52e-22	Bladder cancer;
BRCA	cis	rs56399783	0.901	rs73051415	chr7:2850643	C/T	cg19731401	chr7:2775893	GNA12	0.5	7.88	0.3	1.36e-14	Childhood ear infection;
BRCA	cis	rs1127311	0.901	rs11264223	chr1:154565519	G/A	cg17218026	chr1:154582156	ADAR	0.28	8.29	0.31	6.73e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
BRCA	trans	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.32	7.82	0.3	2.18e-14	Corneal astigmatism;
BRCA	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.38	-8.56	-0.32	8.35e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4588572	0.643	rs1019803	chr5:77739154	A/G	cg11547950	chr5:77652471	NA	-0.47	-8.42	-0.32	2.41e-16	Triglycerides;
BRCA	cis	rs2625529	0.938	rs2742323	chr15:72116778	A/T	cg16672083	chr15:72433130	SENP8	0.82	17.0	0.56	9.56e-54	Red blood cell count;
BRCA	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.56	8.44	0.32	2.13e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg02931644	chr1:25747376	RHCE	-0.42	-11.79	-0.42	3.63e-29	Erythrocyte sedimentation rate;
BRCA	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg23711669	chr6:146136114	FBXO30	0.77	17.59	0.57	8.37e-57	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs459571	0.959	rs465724	chr9:136910097	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.71	-13.94	-0.48	9.39e-39	Platelet distribution width;
BRCA	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg04944784	chr2:26401820	FAM59B	-0.69	-11.45	-0.41	9.33e-28	Gut microbiome composition (summer);
BRCA	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12292205	chr6:26970375	C6orf41	-0.47	-7.96	-0.3	7.59e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg06627628	chr2:24431161	ITSN2	0.5	10.36	0.38	2.28e-23	Asthma;
BRCA	cis	rs2505998	0.796	rs2505537	chr10:43592158	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.43	-8.53	-0.32	1.05e-16	Hirschsprung disease;
BRCA	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04267008	chr7:1944627	MAD1L1	-0.52	-12.07	-0.43	2.21e-30	Bipolar disorder and schizophrenia;
BRCA	cis	rs6782228	0.585	rs3122175	chr3:128361276	C/T	cg16766828	chr3:128327626	NA	-0.43	-9.64	-0.36	1.22e-20	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
BRCA	cis	rs738321	0.694	rs4821749	chr22:38542074	A/G	cg20207973	chr22:38506712	BAIAP2L2	0.38	9.23	0.34	3.81e-19	Breast cancer;
BRCA	trans	rs3857536	0.785	rs2157964	chr6:66938419	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.21e-15	Blood trace element (Cu levels);
BRCA	cis	rs9329289	0.547	rs4366414	chr10:2561529	C/G	cg15501526	chr10:2543763	NA	-0.42	-9.0	-0.34	2.6e-18	Age-related hearing impairment;
BRCA	cis	rs3772130	0.583	rs58088236	chr3:121561765	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	14.39	0.49	7.2e-41	Cognitive performance;
BRCA	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg13271783	chr10:134563150	INPP5A	-0.45	-9.3	-0.35	2.15e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg18225595	chr11:63971243	STIP1	0.54	9.74	0.36	5.22e-21	Mean platelet volume;
BRCA	trans	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg26043149	chr18:55253948	FECH	-0.42	-9.29	-0.34	2.47e-19	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg12011299	chr4:100065546	ADH4	-0.52	-15.0	-0.51	8.9e-44	Alcohol dependence;
BRCA	cis	rs4423214	0.559	rs7949129	chr11:71193135	G/C	cg05163923	chr11:71159392	DHCR7	-0.48	-8.47	-0.32	1.7e-16	Vitamin D levels;
BRCA	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg00857998	chr1:205179979	DSTYK	0.41	8.12	0.31	2.39e-15	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.41	-9.09	-0.34	1.2e-18	Personality dimensions;
BRCA	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg26874164	chr19:58962979	ZNF324B	0.44	9.3	0.35	2.23e-19	Uric acid clearance;
BRCA	trans	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-7.93	-0.3	9.81e-15	Corneal astigmatism;
BRCA	cis	rs68170813	0.559	rs78079372	chr7:106934548	T/G	cg02696742	chr7:106810147	HBP1	-0.52	-8.99	-0.33	2.84e-18	Coronary artery disease;
BRCA	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-13.51	-0.47	9e-37	Morning vs. evening chronotype;
BRCA	cis	rs9420	0.528	rs11229080	chr11:57399511	T/C	cg19752551	chr11:57585705	CTNND1	-0.38	-9.45	-0.35	6.29e-20	Schizophrenia;
BRCA	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg14689365	chr7:158441557	NCAPG2	-0.44	-8.97	-0.33	3.39e-18	Height;
BRCA	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg16586182	chr3:47516702	SCAP	-0.61	-14.24	-0.49	3.69e-40	Colorectal cancer;
BRCA	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg08601574	chr20:25228251	PYGB	0.35	8.41	0.32	2.72e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg04362960	chr10:104952993	NT5C2	0.43	10.36	0.38	2.38e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-9.66	-0.36	1.05e-20	Fear of minor pain;
BRCA	trans	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg25214090	chr10:38739885	LOC399744	-0.56	-12.96	-0.46	2.89e-34	Corneal astigmatism;
BRCA	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg10523679	chr1:76189770	ACADM	-0.53	-9.82	-0.36	2.67e-21	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg26384229	chr12:38710491	ALG10B	0.47	10.52	0.38	5.39e-24	Morning vs. evening chronotype;
BRCA	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-9.58	-0.35	2.12e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg03342759	chr3:160939853	NMD3	-0.8	-18.89	-0.6	1.45e-63	Parkinson's disease;
BRCA	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg09455208	chr3:40491958	NA	0.4	9.59	0.35	1.9e-20	Renal cell carcinoma;
BRCA	cis	rs1691799	0.899	rs1168315	chr12:66746694	A/G	cg16791601	chr12:66731901	HELB	-0.69	-19.69	-0.61	8.5e-68	White blood cell count (basophil);
BRCA	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg26384229	chr12:38710491	ALG10B	-0.43	-9.76	-0.36	4.45e-21	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	14.78	0.5	9.45e-43	Colorectal cancer;
BRCA	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg04518342	chr5:131593106	PDLIM4	0.36	9.1	0.34	1.17e-18	Breast cancer;
BRCA	cis	rs72781680	0.821	rs72796361	chr2:24160689	A/T	cg08917208	chr2:24149416	ATAD2B	0.64	10.71	0.39	9.64e-25	Lymphocyte counts;
BRCA	trans	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg25214090	chr10:38739885	LOC399744	0.51	11.61	0.42	2.02e-28	Corneal astigmatism;
BRCA	cis	rs73086581	0.838	rs11906481	chr20:4028706	C/T	cg02187196	chr20:3869020	PANK2	0.53	9.56	0.35	2.54e-20	Response to antidepressants in depression;
BRCA	cis	rs1577917	0.771	rs3812133	chr6:86354411	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.35	-7.83	-0.3	2.11e-14	Response to antipsychotic treatment;
BRCA	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg22800045	chr5:56110881	MAP3K1	0.45	9.17	0.34	6.29e-19	Initial pursuit acceleration;
BRCA	trans	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg02030672	chr11:45687055	CHST1	0.39	8.28	0.31	7.49e-16	Obesity-related traits;
BRCA	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg09904177	chr6:26538194	HMGN4	0.54	17.26	0.56	4.65e-55	Intelligence (multi-trait analysis);
BRCA	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.63	-0.32	4.68e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg19318889	chr4:1322082	MAEA	-0.49	-10.39	-0.38	1.84e-23	Longevity;
BRCA	cis	rs34779708	0.931	rs2384287	chr10:35340559	A/G	cg03585969	chr10:35415529	CREM	0.49	10.26	0.38	5.74e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg19077165	chr18:44547161	KATNAL2	-0.5	-10.53	-0.38	5.18e-24	Personality dimensions;
BRCA	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg18129178	chr5:148520854	ABLIM3	-0.6	-12.19	-0.43	6.89e-31	Breast cancer;
BRCA	cis	rs10754283	0.967	rs6663363	chr1:90116854	A/G	cg21401794	chr1:90099060	LRRC8C	0.45	10.87	0.39	2.38e-25	Amyotrophic lateral sclerosis (sporadic);
BRCA	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg16405210	chr4:1374714	KIAA1530	0.65	13.92	0.48	1.12e-38	Obesity-related traits;
BRCA	cis	rs7633857	0.512	rs733948	chr3:160652784	C/G	cg03342759	chr3:160939853	NMD3	-0.51	-10.89	-0.4	1.98e-25	Educational attainment (years of education);
BRCA	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-10.36	-0.38	2.26e-23	Blood metabolite levels;
BRCA	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.31	-8.53	-0.32	1.05e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg07262247	chr5:131593730	PDLIM4	-0.38	-9.17	-0.34	6.47e-19	Acylcarnitine levels;
BRCA	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	19.78	0.62	2.8e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6005807	0.719	rs58049055	chr22:29007850	A/G	cg12565055	chr22:29076175	TTC28	0.5	9.42	0.35	7.86e-20	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.35	-0.31	4.34e-16	Colorectal cancer;
BRCA	cis	rs9790314	0.686	rs2306061	chr3:160787502	C/T	cg03342759	chr3:160939853	NMD3	-0.46	-8.99	-0.34	2.82e-18	Morning vs. evening chronotype;
BRCA	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.46	-0.32	1.87e-16	Monocyte percentage of white cells;
BRCA	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.36	-8.17	-0.31	1.64e-15	Colorectal cancer;
BRCA	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg23649088	chr2:200775458	C2orf69	-0.63	-10.03	-0.37	4.38e-22	Schizophrenia;
BRCA	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg13010199	chr12:38710504	ALG10B	0.51	10.01	0.37	5.33e-22	Bladder cancer;
BRCA	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg11062466	chr8:58055876	NA	0.41	7.96	0.3	7.98e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs17095355	1.000	rs11194923	chr10:111695762	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.39	-10.13	-0.37	1.88e-22	Biliary atresia;
BRCA	cis	rs10411936	0.682	rs8103805	chr19:16598433	T/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.47	9.7	0.36	7.58e-21	White blood cell count;Multiple sclerosis;
BRCA	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg22676075	chr6:135203613	NA	0.42	8.4	0.32	2.81e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
BRCA	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg05340658	chr4:99064831	C4orf37	-0.46	-10.57	-0.39	3.47e-24	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg02527881	chr3:46936655	PTH1R	-0.37	-9.21	-0.34	4.47e-19	Colorectal cancer;
BRCA	cis	rs7520050	1.000	rs12410070	chr1:46358882	T/C	cg24296786	chr1:45957014	TESK2	0.43	9.66	0.36	1.06e-20	Red blood cell count;Reticulocyte count;
BRCA	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg26149184	chr10:133730230	NA	0.4	8.2	0.31	1.37e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	trans	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg25482853	chr8:67687455	SGK3	0.78	13.4	0.47	2.8e-36	Obesity-related traits;
BRCA	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.67	-9.72	-0.36	6.19e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg13010199	chr12:38710504	ALG10B	-0.39	-8.45	-0.32	2e-16	Bladder cancer;
BRCA	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg26384229	chr12:38710491	ALG10B	-0.4	-9.32	-0.35	1.87e-19	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg03425785	chr20:62221387	GMEB2	0.53	8.6	0.32	6.12e-17	Glioblastoma;
BRCA	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.33	-9.29	-0.35	2.32e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.93	0.46	3.84e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.6	-11.1	-0.4	2.59e-26	Lung cancer in ever smokers;
BRCA	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06108461	chr20:60628389	TAF4	-0.64	-13.33	-0.47	6.24e-36	Body mass index;
BRCA	cis	rs9790314	0.779	rs12493960	chr3:160899772	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-11.19	-0.4	1.14e-26	Morning vs. evening chronotype;
BRCA	cis	rs9462027	0.628	rs11757370	chr6:34760736	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.88	-0.3	1.44e-14	Systemic lupus erythematosus;
BRCA	cis	rs6694270	0.913	rs11261069	chr1:19117300	C/G	cg19637330	chr1:19110922	NA	-0.44	-8.27	-0.31	7.88e-16	Drug-induced liver injury (nitrofurantoin);
BRCA	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg13397359	chr6:42928475	GNMT	0.76	19.52	0.61	6.66e-67	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-12.82	-0.45	1.22e-33	Blood metabolite levels;
BRCA	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg12437481	chr16:420112	MRPL28	0.46	11.47	0.41	8.29e-28	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg10523679	chr1:76189770	ACADM	-0.62	-11.45	-0.41	1.01e-27	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg17971929	chr21:40555470	PSMG1	0.77	17.79	0.58	8.63e-58	Cognitive function;
BRCA	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.84	0.39	2.89e-25	Bipolar disorder;
BRCA	cis	rs7255436	0.928	rs7250870	chr19:8453682	C/T	cg10811474	chr19:8428787	ANGPTL4	-0.31	-7.96	-0.3	8.04e-15	HDL cholesterol;
BRCA	cis	rs586533	0.846	rs592217	chr11:99498738	C/T	cg22878054	chr11:99397252	CNTN5	0.32	8.1	0.3	2.89e-15	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03517284	chr6:25882590	NA	-0.48	-10.01	-0.37	5.21e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9682041	0.696	rs35177863	chr3:170090006	A/G	cg11886554	chr3:170076028	SKIL	0.51	10.19	0.37	1.03e-22	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg01236616	chr12:121019343	POP5	-1.22	-23.92	-0.69	9.07e-91	Type 1 diabetes nephropathy;
BRCA	cis	rs6138458	0.620	rs2151462	chr20:24911823	T/C	cg26195577	chr20:24973756	C20orf3	0.98	24.72	0.7	3.46e-95	Blood protein levels;
BRCA	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.59	-0.39	3.04e-24	Personality dimensions;
BRCA	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg01475377	chr6:109611718	NA	-0.52	-13.46	-0.47	1.47e-36	Reticulocyte fraction of red cells;
BRCA	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg14926445	chr8:58193284	C8orf71	-0.44	-8.41	-0.32	2.72e-16	Developmental language disorder (linguistic errors);
BRCA	trans	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.85	-0.33	8.51e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg21573476	chr21:45109991	RRP1B	-0.39	-10.36	-0.38	2.26e-23	Mean corpuscular volume;
BRCA	trans	rs783540	0.934	rs4779050	chr15:83368738	T/G	cg18393722	chr15:85113863	UBE2QP1	0.28	8.69	0.33	3.03e-17	Schizophrenia;
BRCA	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg13567636	chr1:160991154	F11R	-0.47	-9.2	-0.34	5.05e-19	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg16584290	chr5:462447	EXOC3	0.53	14.91	0.51	2.41e-43	Cystic fibrosis severity;
BRCA	cis	rs10465746	0.780	rs2389648	chr1:84403031	C/T	cg10977910	chr1:84465055	TTLL7	0.58	12.02	0.43	3.77e-30	Obesity-related traits;
BRCA	cis	rs427394	0.593	rs880993	chr5:6732120	C/G	cg10857441	chr5:6722123	POLS	-0.31	-9.91	-0.37	1.23e-21	Menopause (age at onset);
BRCA	cis	rs7474896	0.537	rs2505255	chr10:38359642	C/A	cg25427524	chr10:38739819	LOC399744	-0.57	-10.62	-0.39	2.19e-24	Obesity (extreme);
BRCA	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg22676075	chr6:135203613	NA	0.47	9.97	0.37	7.16e-22	High light scatter reticulocyte percentage of red cells;
BRCA	trans	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg02030672	chr11:45687055	CHST1	0.45	10.27	0.38	5.16e-23	Obesity-related traits;
BRCA	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06108461	chr20:60628389	TAF4	-0.98	-22.16	-0.66	3.66e-81	Body mass index;
BRCA	cis	rs9287719	0.649	rs10207885	chr2:10733188	C/T	cg00105475	chr2:10696890	NA	0.42	9.39	0.35	1.06e-19	Prostate cancer;
BRCA	cis	rs4363385	0.747	rs946099	chr1:152971618	A/G	cg24667326	chr1:152973720	SPRR3	-0.35	-9.84	-0.36	2.31e-21	Inflammatory skin disease;
BRCA	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg13047869	chr3:10149882	C3orf24	0.59	12.34	0.44	1.6e-31	Alzheimer's disease;
BRCA	cis	rs7020830	0.931	rs3802422	chr9:37097172	G/A	cg14294708	chr9:37120828	ZCCHC7	1.16	40.89	0.85	1.52e-180	Schizophrenia;
BRCA	cis	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg07460842	chr6:66804631	NA	0.88	14.2	0.49	5.86e-40	Exhaled nitric oxide output;
BRCA	cis	rs1595825	0.838	rs7603283	chr2:198517592	A/G	cg19156104	chr2:198669113	PLCL1	-0.43	-8.2	-0.31	1.28e-15	Ulcerative colitis;
BRCA	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg20991723	chr1:152506922	NA	0.38	8.71	0.33	2.52e-17	Hair morphology;
BRCA	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg18225595	chr11:63971243	STIP1	-0.41	-10.25	-0.38	6.39e-23	Platelet count;
BRCA	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg24692254	chr21:30365293	RNF160	0.46	10.16	0.37	1.39e-22	Pancreatic cancer;
BRCA	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg14266287	chr2:239334506	ASB1	-0.34	-8.24	-0.31	1.01e-15	Multiple system atrophy;
BRCA	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg27398817	chr8:82754497	SNX16	-0.47	-9.04	-0.34	1.85e-18	Diastolic blood pressure;
BRCA	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg22535103	chr8:58192502	C8orf71	-0.45	-8.94	-0.33	4.17e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs12579753	0.597	rs2244802	chr12:82153749	C/G	cg07988820	chr12:82153109	PPFIA2	0.41	7.99	0.3	6.18e-15	Resting heart rate;
BRCA	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg09307838	chr4:120376055	NA	0.7	14.19	0.49	5.99e-40	Corneal astigmatism;
BRCA	trans	rs6479891	1.000	rs4745706	chr10:65159580	T/C	cg14819942	chr15:35414228	NA	0.35	8.67	0.32	3.63e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg06618935	chr21:46677482	NA	-0.37	-7.99	-0.3	6.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.6	-12.36	-0.44	1.25e-31	Lymphocyte counts;
BRCA	cis	rs1904096	0.513	rs2632405	chr4:95152215	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-10.04	-0.37	4.03e-22	Type 2 diabetes;
BRCA	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.34	-9.31	-0.35	1.97e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg21475434	chr5:93447410	FAM172A	0.69	9.09	0.34	1.2e-18	Diabetic retinopathy;
BRCA	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg12564285	chr5:131593104	PDLIM4	0.36	9.77	0.36	4.02e-21	Breast cancer;
BRCA	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg06064525	chr11:970664	AP2A2	-0.28	-8.23	-0.31	1.04e-15	Alzheimer's disease (late onset);
BRCA	cis	rs2387326	0.671	rs12256275	chr10:129947139	T/C	cg16087940	chr10:129947807	NA	-0.47	-8.32	-0.31	5.44e-16	Select biomarker traits;
BRCA	trans	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	13.25	0.46	1.4e-35	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg05623727	chr3:50126028	RBM5	0.44	8.49	0.32	1.46e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg04450456	chr4:17643702	FAM184B	0.41	12.33	0.44	1.67e-31	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10267417	0.603	rs13307910	chr7:19858392	C/T	cg05791153	chr7:19748676	TWISTNB	0.48	9.46	0.35	5.96e-20	Night sleep phenotypes;
BRCA	cis	rs1375194	0.582	rs13391166	chr2:33805314	C/T	cg04131969	chr2:33951647	MYADML	0.44	8.48	0.32	1.57e-16	Response to antidepressants in depression;
BRCA	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.94e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11603020	1.000	rs11603020	chr11:57374332	C/T	cg19752551	chr11:57585705	CTNND1	0.42	9.98	0.37	6.6e-22	Blood protein levels;
BRCA	cis	rs6546550	0.935	rs10202159	chr2:70062454	G/T	cg02498382	chr2:70120550	SNRNP27	-0.49	-10.29	-0.38	4.38e-23	Prevalent atrial fibrillation;
BRCA	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg17366294	chr4:99064904	C4orf37	0.44	10.38	0.38	1.98e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-15.94	-0.53	2.15e-48	Alzheimer's disease (late onset);
BRCA	cis	rs3820928	0.874	rs4675130	chr2:227827740	G/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.6	-0.32	6.23e-17	Pulmonary function;
BRCA	cis	rs977987	0.788	rs7184525	chr16:75437186	A/G	cg03315344	chr16:75512273	CHST6	0.52	12.26	0.44	3.43e-31	Dupuytren's disease;
BRCA	cis	rs4363385	0.747	rs885096	chr1:152971313	T/C	cg24667326	chr1:152973720	SPRR3	-0.34	-9.42	-0.35	8e-20	Inflammatory skin disease;
BRCA	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg23978390	chr7:1156363	C7orf50	0.47	11.01	0.4	6.28e-26	Longevity;Endometriosis;
BRCA	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.32	-7.94	-0.3	9.1e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs12367572	1.000	rs12367572	chr12:45290466	C/T	cg04608330	chr12:45269318	NELL2	0.63	13.43	0.47	2.12e-36	Gut microbiome composition (summer);
BRCA	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.8	12.12	0.43	1.37e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg21573476	chr21:45109991	RRP1B	-0.35	-9.16	-0.34	7.14e-19	Mean corpuscular volume;
BRCA	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg23711669	chr6:146136114	FBXO30	0.72	16.53	0.55	2.2e-51	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.81	0.3	2.32e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs1577917	0.883	rs9450375	chr6:86756629	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.33	8.82	0.33	1.06e-17	Response to antipsychotic treatment;
BRCA	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.05	-30.14	-0.77	7.83e-125	Cognitive ability;
BRCA	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg25173405	chr17:45401733	C17orf57	-0.52	-11.12	-0.4	2.26e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	trans	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg25214090	chr10:38739885	LOC399744	0.43	9.81	0.36	2.9e-21	Corneal astigmatism;
BRCA	cis	rs9359856	0.564	rs56084221	chr6:90365349	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.64	-8.54	-0.32	9.91e-17	Bipolar disorder;
BRCA	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg06115741	chr20:33292138	TP53INP2	0.41	9.18	0.34	6.11e-19	Coronary artery disease;
BRCA	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg13010199	chr12:38710504	ALG10B	0.48	9.46	0.35	5.66e-20	Morning vs. evening chronotype;
BRCA	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg18132916	chr6:79620363	NA	-0.44	-10.06	-0.37	3.3e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg20607798	chr8:58055168	NA	0.48	8.39	0.32	3.08e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg22117172	chr7:91764530	CYP51A1	0.23	8.01	0.3	5.3e-15	Breast cancer;
BRCA	cis	rs7246967	0.611	rs2194113	chr19:22958075	C/T	cg23217946	chr19:22817039	ZNF492	0.5	9.11	0.34	1.04e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs6005807	0.719	rs12169460	chr22:29042079	A/G	cg12565055	chr22:29076175	TTC28	0.5	9.36	0.35	1.32e-19	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg16482183	chr6:26056742	HIST1H1C	0.75	14.65	0.5	4.12e-42	Iron status biomarkers;
BRCA	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg04545296	chr12:48745243	ZNF641	0.25	8.31	0.31	5.74e-16	Hemoglobin concentration;Red blood cell count;Hematocrit;
BRCA	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg21770322	chr7:97807741	LMTK2	0.44	11.86	0.42	1.77e-29	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg20573242	chr4:122745356	CCNA2	0.47	10.57	0.39	3.63e-24	Type 2 diabetes;
BRCA	cis	rs4930561	0.714	rs1540209	chr11:67928520	A/C	cg04465784	chr11:67976953	SUV420H1	-0.28	-9.26	-0.34	3.17e-19	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03517284	chr6:25882590	NA	-0.46	-9.67	-0.36	9.59e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11764359	chr7:65958608	NA	0.8	19.21	0.61	2.94e-65	Aortic root size;
BRCA	cis	rs6840360	0.593	rs1429559	chr4:152681952	A/G	cg22705602	chr4:152727874	NA	-0.38	-10.39	-0.38	1.81e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7590368	0.961	rs12474895	chr2:10957848	A/C	cg15705551	chr2:10952987	PDIA6	0.44	8.14	0.31	2.1e-15	Educational attainment (years of education);
BRCA	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	ch.11.42038R	chr11:967971	AP2A2	0.52	16.68	0.55	4.09e-52	Alzheimer's disease (late onset);
BRCA	trans	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg25214090	chr10:38739885	LOC399744	0.51	11.61	0.42	2e-28	Corneal astigmatism;
BRCA	cis	rs897984	0.806	rs8050588	chr16:30937799	G/A	cg00531865	chr16:30841666	NA	-0.41	-9.7	-0.36	7.77e-21	Dementia with Lewy bodies;
BRCA	cis	rs7617773	0.817	rs9818937	chr3:48325281	G/A	cg11946769	chr3:48343235	NME6	0.63	13.47	0.47	1.45e-36	Coronary artery disease;
BRCA	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg03877680	chr5:178157825	ZNF354A	0.79	14.75	0.5	1.38e-42	Neutrophil percentage of white cells;
BRCA	cis	rs4974559	0.947	rs28509315	chr4:1358107	C/T	cg02980000	chr4:1222292	CTBP1	0.77	12.64	0.45	7.38e-33	Systolic blood pressure;
BRCA	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18876405	chr7:65276391	NA	-0.5	-10.98	-0.4	8.51e-26	Aortic root size;
BRCA	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg04117972	chr1:227635322	NA	-0.46	-8.39	-0.31	3.13e-16	Major depressive disorder;
BRCA	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.35	-0.31	4.34e-16	Colorectal cancer;
BRCA	cis	rs6066835	1.000	rs4516495	chr20:47316482	A/G	cg18078177	chr20:47281410	PREX1	0.61	7.95	0.3	8.49e-15	Multiple myeloma;
BRCA	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg07080220	chr10:102295463	HIF1AN	0.6	13.28	0.47	1.03e-35	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.16	-48.97	-0.89	1.81e-218	Myeloid white cell count;
BRCA	cis	rs56804039	1.000	rs34154295	chr8:8383477	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.19	-0.34	5.54e-19	Cervical cancer;
BRCA	cis	rs752010	0.967	rs10890151	chr1:42101843	C/A	cg06885757	chr1:42089581	HIVEP3	0.23	8.4	0.32	2.93e-16	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	8.08	0.3	3.14e-15	Schizophrenia;
BRCA	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.34	9.4	0.35	9.78e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg20607798	chr8:58055168	NA	0.61	9.77	0.36	4.27e-21	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg25214090	chr10:38739885	LOC399744	0.53	11.98	0.43	5.76e-30	Corneal astigmatism;
BRCA	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-12.14	-0.43	1.21e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.75	-0.33	1.93e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	10.73	0.39	7.99e-25	Height;
BRCA	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg09307838	chr4:120376055	NA	0.74	15.99	0.53	1.14e-48	Corneal astigmatism;
BRCA	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg16950941	chr11:66035639	RAB1B	0.45	12.09	0.43	1.95e-30	Gout;
BRCA	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg23711669	chr6:146136114	FBXO30	0.75	17.25	0.56	4.8e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9463078	0.702	rs929614	chr6:44771934	C/A	cg25276700	chr6:44698697	NA	-0.39	-8.97	-0.33	3.16e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs1011018	0.628	rs79125145	chr7:139451168	C/T	cg03224163	chr7:139420300	HIPK2	-0.6	-9.15	-0.34	7.69e-19	Systolic blood pressure;
BRCA	cis	rs36051895	0.530	rs4425810	chr9:5222208	A/G	cg02405213	chr9:5042618	JAK2	-0.42	-7.93	-0.3	9.78e-15	Pediatric autoimmune diseases;
BRCA	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09256448	chr16:638327	NA	0.3	8.09	0.3	3.01e-15	Height;
BRCA	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-13.52	-0.47	8.28e-37	Developmental language disorder (linguistic errors);
BRCA	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg26373071	chr5:1325741	CLPTM1L	0.48	11.33	0.41	3.05e-27	Lung cancer;
BRCA	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg09654669	chr8:57350985	NA	-0.39	-8.52	-0.32	1.1e-16	Obesity-related traits;
BRCA	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.35	8.94	0.33	4.02e-18	Resting heart rate;
BRCA	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.49	9.77	0.36	4.01e-21	Birth weight;
BRCA	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-15.72	-0.53	2.66e-47	Electrocardiographic conduction measures;
BRCA	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg15934090	chr1:100435551	SLC35A3	0.36	8.43	0.32	2.38e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg18402987	chr7:1209562	NA	0.47	9.0	0.34	2.52e-18	Longevity;Endometriosis;
BRCA	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08219700	chr8:58056026	NA	0.44	7.98	0.3	6.64e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg07460842	chr6:66804631	NA	-1.18	-38.99	-0.84	3.98e-171	Exhaled nitric oxide output;
BRCA	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg15212455	chr7:39170539	POU6F2	0.4	8.72	0.33	2.33e-17	IgG glycosylation;
BRCA	trans	rs10242455	0.702	rs59240302	chr7:99072991	C/G	cg09045935	chr12:6379348	NA	0.87	8.57	0.32	7.88e-17	Blood metabolite levels;
BRCA	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24531977	chr5:56204891	C5orf35	-0.88	-19.04	-0.6	2.35e-64	Initial pursuit acceleration;
BRCA	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.65	-0.32	4.29e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs701145	0.537	rs357479	chr3:153891489	A/G	cg17054900	chr3:154042577	DHX36	0.56	9.48	0.35	4.82e-20	Coronary artery disease;
BRCA	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg00530320	chr1:46809349	NSUN4	0.49	9.68	0.36	8.65e-21	Menopause (age at onset);
BRCA	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.53	-0.32	1.07e-16	Total body bone mineral density;
BRCA	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg21475434	chr5:93447410	FAM172A	-0.63	-8.05	-0.3	3.98e-15	Diabetic retinopathy;
BRCA	cis	rs858239	0.600	rs6461690	chr7:23135534	A/G	cg23682824	chr7:23144976	KLHL7	0.45	11.89	0.43	1.36e-29	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg02297831	chr4:17616191	MED28	0.36	8.51	0.32	1.2e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18876405	chr7:65276391	NA	0.55	13.16	0.46	3.77e-35	Aortic root size;
BRCA	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg12311346	chr5:56204834	C5orf35	-0.79	-15.4	-0.52	9.6e-46	Initial pursuit acceleration;
BRCA	trans	rs629535	0.734	rs659430	chr8:70009988	A/G	cg21567404	chr3:27674614	NA	0.7	15.2	0.52	9.14e-45	Dupuytren's disease;
BRCA	cis	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg07460842	chr6:66804631	NA	0.59	10.16	0.37	1.4e-22	Type 2 diabetes;
BRCA	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg21366198	chr4:185655624	MLF1IP	-0.43	-10.39	-0.38	1.83e-23	Kawasaki disease;
BRCA	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg20503657	chr10:835505	NA	0.65	11.19	0.4	1.17e-26	Eosinophil percentage of granulocytes;
BRCA	cis	rs2580764	0.573	rs13387751	chr2:55227375	C/G	cg09592903	chr2:55203963	RTN4	-0.41	-10.52	-0.38	5.35e-24	Mean platelet volume;
BRCA	cis	rs921968	0.565	rs13412324	chr2:219620521	T/C	cg02176678	chr2:219576539	TTLL4	-0.41	-11.06	-0.4	3.87e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs870825	0.616	rs10006828	chr4:185651416	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	17.79	0.58	7.74e-58	Blood protein levels;
BRCA	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg21573476	chr21:45109991	RRP1B	-0.36	-9.11	-0.34	1.04e-18	Mean corpuscular volume;
BRCA	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg16049864	chr8:95962084	TP53INP1	0.48	10.56	0.39	4.05e-24	Type 2 diabetes;
BRCA	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg11645453	chr3:52864694	ITIH4	0.48	11.88	0.43	1.47e-29	Schizophrenia;
BRCA	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	8.22	0.31	1.16e-15	Axial length;
BRCA	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg23029597	chr12:123009494	RSRC2	0.62	12.11	0.43	1.53e-30	Body mass index;
BRCA	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	ch.11.42038R	chr11:967971	AP2A2	0.5	15.79	0.53	1.21e-47	Alzheimer's disease (late onset);
BRCA	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg21518248	chr2:162101506	NA	0.53	11.28	0.41	5.07e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.31	-8.3	-0.31	6.13e-16	Cognitive function;
BRCA	cis	rs10162002	1.000	rs73449251	chr13:24042272	C/T	cg00158254	chr13:24040743	NA	0.58	9.4	0.35	9.33e-20	Hypothyroidism;
BRCA	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg19539972	chr4:7069911	GRPEL1	-0.7	-16.58	-0.55	1.28e-51	Monocyte percentage of white cells;
BRCA	trans	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg09719594	chr16:21412588	NA	-0.34	-8.27	-0.31	7.88e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	14.29	0.49	2.19e-40	Motion sickness;
BRCA	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg02773041	chr1:40204384	PPIE	0.45	9.6	0.36	1.71e-20	Blood protein levels;
BRCA	cis	rs2625529	0.775	rs4777477	chr15:72269612	G/A	cg16672083	chr15:72433130	SENP8	-0.85	-17.65	-0.57	4.2e-57	Red blood cell count;
BRCA	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg23950597	chr19:37808831	NA	-0.62	-11.36	-0.41	2.26e-27	Coronary artery calcification;
BRCA	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18404041	chr3:52824283	ITIH1	-0.37	-11.33	-0.41	3.04e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs2580764	0.598	rs7340476	chr2:55227346	G/C	cg09592903	chr2:55203963	RTN4	-0.41	-10.52	-0.38	5.35e-24	Mean platelet volume;
BRCA	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24110177	chr3:50126178	RBM5	0.4	11.25	0.41	6.55e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs6142102	0.961	rs6057957	chr20:32549858	T/G	cg24642439	chr20:33292090	TP53INP2	0.43	8.15	0.31	1.97e-15	Skin pigmentation;
BRCA	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg05283184	chr6:79620031	NA	-0.36	-8.23	-0.31	1.02e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg04362960	chr10:104952993	NT5C2	0.42	10.1	0.37	2.41e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.35	0.31	4.24e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7903847	0.667	rs3818787	chr10:99145179	T/C	cg08345082	chr10:99160200	RRP12	-0.28	-8.39	-0.32	3.05e-16	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs6772849	0.930	rs1962040	chr3:128324161	G/A	cg16766828	chr3:128327626	NA	-0.41	-8.93	-0.33	4.32e-18	Monocyte percentage of white cells;Monocyte count;
BRCA	cis	rs77972916	0.505	rs1322	chr2:43521167	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-11.04	-0.4	4.71e-26	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg26248373	chr2:1572462	NA	-0.63	-14.52	-0.5	1.68e-41	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.44	-8.57	-0.32	8e-17	Alzheimer's disease (late onset);
BRCA	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg08017756	chr2:100939284	LONRF2	-0.31	-7.99	-0.3	6.51e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg13010199	chr12:38710504	ALG10B	0.51	10.01	0.37	5.33e-22	Bladder cancer;
BRCA	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-8.59	-0.32	6.86e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg14784868	chr12:69753453	YEATS4	0.78	25.12	0.7	2.27e-97	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.08	-24.99	-0.7	1.08e-96	Ulcerative colitis;
BRCA	cis	rs13046373	0.535	rs1961491	chr21:31973685	C/T	cg16812893	chr21:31813075	KRTAP15-1	0.39	9.77	0.36	4.14e-21	HDL cholesterol;
BRCA	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.52	13.29	0.47	8.81e-36	Schizophrenia;
BRCA	cis	rs2742234	0.590	rs2257767	chr10:43657811	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.56	-11.35	-0.41	2.4e-27	Hirschsprung disease;
BRCA	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg21535247	chr6:8435926	SLC35B3	0.39	8.89	0.33	6.32e-18	Motion sickness;
BRCA	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg26384229	chr12:38710491	ALG10B	0.51	13.55	0.47	5.82e-37	Morning vs. evening chronotype;
BRCA	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg17063962	chr7:91808500	NA	-0.53	-11.57	-0.42	2.94e-28	Breast cancer;
BRCA	trans	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-10.79	-0.39	4.88e-25	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg13010199	chr12:38710504	ALG10B	-0.44	-9.42	-0.35	8.05e-20	Morning vs. evening chronotype;
BRCA	cis	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05901451	chr6:126070800	HEY2	-0.39	-9.56	-0.35	2.45e-20	Endometrial cancer;
BRCA	cis	rs965469	1.000	rs6037532	chr20:3267911	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-10.23	-0.38	7.7e-23	IFN-related cytopenia;
BRCA	cis	rs4742903	1.000	rs3780535	chr9:106894211	A/C	cg14250997	chr9:106856677	SMC2	0.35	11.22	0.41	8.33e-27	High-grade serous ovarian cancer;Breast cancer;
BRCA	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg05025164	chr4:1340916	KIAA1530	0.6	12.18	0.43	7.92e-31	Longevity;
BRCA	cis	rs912057	0.609	rs1294431	chr6:6745003	G/C	cg06612196	chr6:6737390	NA	0.46	10.81	0.39	4.12e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
BRCA	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.48	-11.13	-0.4	2.04e-26	IgG glycosylation;
BRCA	trans	rs6011368	0.840	rs2427638	chr20:62900717	C/T	cg13869341	chr1:15865	WASH5P	0.45	10.12	0.37	1.91e-22	Clozapine-induced cytotoxicity;
BRCA	cis	rs6893300	0.506	rs35320050	chr5:179131013	C/T	cg14593053	chr5:179126677	CANX	0.48	12.91	0.45	4.59e-34	Resting heart rate;
BRCA	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg15790184	chr11:494944	RNH1	0.64	9.95	0.37	8.42e-22	Body mass index;
BRCA	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg01877450	chr7:97915802	BRI3	-0.38	-8.75	-0.33	1.94e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg16606324	chr3:10149918	C3orf24	0.58	10.08	0.37	2.93e-22	Alzheimer's disease;
BRCA	cis	rs897080	0.515	rs1067357	chr2:44663064	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	9.15	0.34	7.72e-19	Height;
BRCA	cis	rs7520050	0.966	rs785488	chr1:46576095	G/A	cg24296786	chr1:45957014	TESK2	0.41	9.12	0.34	9.96e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2742234	0.541	rs1254959	chr10:43700979	C/G	cg15436174	chr10:43711423	RASGEF1A	0.57	11.53	0.41	4.62e-28	Hirschsprung disease;
BRCA	cis	rs9942416	0.660	rs10462356	chr5:74987108	C/T	cg19683494	chr5:74908142	NA	0.48	9.0	0.34	2.66e-18	Age-related disease endophenotypes;
BRCA	cis	rs1568889	0.838	rs1525717	chr11:28081205	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.46	0.63	6.26e-72	Bipolar disorder;
BRCA	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg23711669	chr6:146136114	FBXO30	-0.71	-16.94	-0.56	2e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg04362960	chr10:104952993	NT5C2	-0.43	-9.69	-0.36	8.33e-21	Arsenic metabolism;
BRCA	cis	rs6565681	1.000	rs4889848	chr17:78354661	C/T	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.5	-8.39	-0.32	3.1e-16	Moyamoya disease;
BRCA	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23708337	chr7:1209742	NA	0.53	10.66	0.39	1.58e-24	Longevity;Endometriosis;
BRCA	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08109568	chr15:31115862	NA	0.44	8.83	0.33	1.04e-17	Huntington's disease progression;
BRCA	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg08896387	chr1:24191740	FUCA1	-0.24	-7.9	-0.3	1.21e-14	Immature fraction of reticulocytes;
BRCA	trans	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg06521331	chr12:34319734	NA	-0.44	-8.58	-0.32	7.23e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg15103426	chr22:29168792	CCDC117	0.52	12.04	0.43	3.24e-30	Lymphocyte counts;
BRCA	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	22.74	0.67	2.6e-84	Chronic sinus infection;
BRCA	trans	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04565464	chr8:145669602	NFKBIL2	0.43	9.56	0.35	2.53e-20	Schizophrenia;
BRCA	cis	rs2836633	0.895	rs991816	chr21:40042150	C/A	cg05519781	chr21:40033154	ERG	0.37	7.89	0.3	1.33e-14	Coronary artery disease;
BRCA	cis	rs6005807	0.582	rs8136767	chr22:29008626	G/A	cg12565055	chr22:29076175	TTC28	0.5	9.41	0.35	8.9e-20	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
BRCA	cis	rs6545883	0.860	rs4671399	chr2:61458518	C/T	cg15711740	chr2:61764176	XPO1	0.51	13.06	0.46	1.06e-34	Tuberculosis;
BRCA	trans	rs800082	0.839	rs62275528	chr3:144293687	T/C	cg24215973	chr2:240111563	HDAC4	-0.35	-7.82	-0.3	2.18e-14	Smoking behavior;
BRCA	trans	rs7200543	1.000	rs4985154	chr16:15131642	G/C	cg24683922	chr1:11983373	KIAA2013	-0.39	-8.71	-0.33	2.69e-17	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg03342759	chr3:160939853	NMD3	-0.72	-17.97	-0.58	9.09e-59	Morning vs. evening chronotype;
BRCA	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg18806716	chr10:30721971	MAP3K8	-0.56	-13.43	-0.47	2.21e-36	Inflammatory bowel disease;
BRCA	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg08888203	chr3:10149979	C3orf24	0.55	8.64	0.32	4.65e-17	Alzheimer's disease;
BRCA	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg17971929	chr21:40555470	PSMG1	0.5	11.25	0.41	6.35e-27	Menarche (age at onset);
BRCA	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg20607798	chr8:58055168	NA	0.48	8.43	0.32	2.29e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs17253792	0.822	rs79022053	chr14:56071721	A/G	cg01858014	chr14:56050164	KTN1	-0.78	-11.08	-0.4	3.12e-26	Putamen volume;
BRCA	trans	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg21659725	chr3:3221576	CRBN	-0.45	-10.01	-0.37	5.41e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg01065977	chr19:18549689	ISYNA1	-0.28	-8.35	-0.31	4.25e-16	Breast cancer;
BRCA	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg18230493	chr5:56204884	C5orf35	-0.73	-14.68	-0.5	2.87e-42	Initial pursuit acceleration;
BRCA	trans	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg21775007	chr8:11205619	TDH	0.41	8.45	0.32	2e-16	Mood instability;
BRCA	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg15556689	chr8:8085844	FLJ10661	0.36	8.68	0.32	3.29e-17	Neuroticism;
BRCA	cis	rs5167	0.504	rs3760627	chr19:45457180	T/C	cg20090143	chr19:45452003	APOC2	0.27	8.08	0.3	3.25e-15	Blood protein levels;
BRCA	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg05775895	chr3:12838266	CAND2	0.37	8.33	0.31	4.79e-16	QRS complex (12-leadsum);
BRCA	cis	rs4363385	0.720	rs1611754	chr1:152956415	A/T	cg25856811	chr1:152973957	SPRR3	-0.33	-8.88	-0.33	6.88e-18	Inflammatory skin disease;
BRCA	cis	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-9.76	-0.36	4.63e-21	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.36	7.83	0.3	1.98e-14	Electroencephalogram traits;
BRCA	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg20991723	chr1:152506922	NA	0.36	8.13	0.31	2.24e-15	Hair morphology;
BRCA	cis	rs701145	0.585	rs357468	chr3:153898560	A/G	cg17054900	chr3:154042577	DHX36	0.53	9.34	0.35	1.62e-19	Coronary artery disease;
BRCA	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg13319975	chr6:146136371	FBXO30	-0.41	-9.38	-0.35	1.12e-19	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg27490568	chr2:178487706	NA	-0.57	-9.23	-0.34	3.99e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg26384229	chr12:38710491	ALG10B	0.75	16.65	0.55	6.01e-52	Morning vs. evening chronotype;
BRCA	trans	rs3960554	0.741	rs28446604	chr7:75662518	C/T	cg19862616	chr7:65841803	NCRNA00174	0.58	12.21	0.43	6.03e-31	Eotaxin levels;
BRCA	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg11214544	chr1:2391121	NA	-0.35	-8.53	-0.32	1.05e-16	Schizophrenia;
BRCA	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	12.9	0.45	5.17e-34	Menarche (age at onset);
BRCA	cis	rs367943	0.637	rs6859521	chr5:113007423	C/T	cg12552261	chr5:112820674	MCC	0.39	7.87	0.3	1.49e-14	Type 2 diabetes;
BRCA	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.58	-0.61	3.27e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg18964960	chr10:1102726	WDR37	0.6	8.36	0.31	3.84e-16	Eosinophil percentage of granulocytes;
BRCA	trans	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.38	8.07	0.3	3.48e-15	Mean corpuscular volume;
BRCA	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg00677455	chr12:58241039	CTDSP2	-0.35	-7.9	-0.3	1.24e-14	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg00012203	chr2:219082015	ARPC2	-0.7	-15.98	-0.53	1.29e-48	Colorectal cancer;
BRCA	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg21770322	chr7:97807741	LMTK2	0.45	11.81	0.42	2.94e-29	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg19862616	chr7:65841803	NCRNA00174	0.83	27.23	0.73	5.66e-109	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg17691542	chr6:26056736	HIST1H1C	0.74	14.71	0.5	2.08e-42	Iron status biomarkers;
BRCA	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg20362242	chr5:692897	TPPP	0.53	7.97	0.3	7.21e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg18964960	chr10:1102726	WDR37	0.62	8.38	0.31	3.32e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.85	12.47	0.44	4.18e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22307029	chr19:49891270	CCDC155	0.58	9.35	0.35	1.45e-19	Multiple sclerosis;
BRCA	cis	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg07460842	chr6:66804631	NA	0.62	11.18	0.4	1.27e-26	Type 2 diabetes;
BRCA	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg00531865	chr16:30841666	NA	0.39	9.28	0.34	2.6e-19	Dementia with Lewy bodies;
BRCA	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	12.81	0.45	1.37e-33	Height;
BRCA	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	15.64	0.53	6.08e-47	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg15664640	chr17:80829946	TBCD	-0.4	-10.33	-0.38	3.21e-23	Breast cancer;
BRCA	cis	rs6426558	0.537	rs2670462	chr1:227432923	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.43	-8.91	-0.33	5.33e-18	Neutrophil percentage of white cells;
BRCA	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24110177	chr3:50126178	RBM5	0.35	9.65	0.36	1.19e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg26373071	chr5:1325741	CLPTM1L	0.5	12.35	0.44	1.36e-31	Lung cancer;
BRCA	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg01819863	chr10:32635814	EPC1	1.17	20.65	0.63	5.58e-73	Sexual dysfunction (female);
BRCA	cis	rs1904096	0.506	rs2632412	chr4:95149319	A/C	cg11021082	chr4:95130006	SMARCAD1	0.41	8.48	0.32	1.51e-16	Type 2 diabetes;
BRCA	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg08514558	chr10:81106712	PPIF	0.4	9.36	0.35	1.38e-19	Height;
BRCA	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg23625390	chr15:77176239	SCAPER	-0.56	-14.23	-0.49	4.3e-40	Blood metabolite levels;
BRCA	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg08601574	chr20:25228251	PYGB	-0.37	-8.82	-0.33	1.08e-17	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-11.53	-0.42	4.34e-28	Mean corpuscular volume;
BRCA	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg23505145	chr19:12996616	KLF1	0.54	12.3	0.44	2.43e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg00531865	chr16:30841666	NA	-0.57	-13.24	-0.46	1.58e-35	Multiple myeloma;
BRCA	cis	rs11779988	0.545	rs422746	chr8:17784486	C/A	cg01800426	chr8:17659068	MTUS1	-0.4	-8.36	-0.31	4.03e-16	Breast cancer;
BRCA	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08048268	chr3:133502702	NA	-0.33	-8.35	-0.31	4.32e-16	Iron status biomarkers;
BRCA	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg13010199	chr12:38710504	ALG10B	0.49	9.57	0.35	2.24e-20	Morning vs. evening chronotype;
BRCA	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	14.06	0.49	2.67e-39	Mean corpuscular hemoglobin;
BRCA	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg17063962	chr7:91808500	NA	-0.52	-12.4	-0.44	9e-32	Breast cancer;
BRCA	cis	rs360798	0.512	rs12989754	chr2:63020970	A/G	cg17519650	chr2:63277830	OTX1	-0.37	-8.06	-0.3	3.72e-15	Coronary artery disease;
BRCA	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9815354	0.812	rs17218441	chr3:41987044	A/G	cg03022575	chr3:42003672	ULK4	0.7	9.76	0.36	4.45e-21	Pulse pressure;Diastolic blood pressure;
BRCA	cis	rs921968	0.591	rs3731877	chr2:219602499	G/C	cg02176678	chr2:219576539	TTLL4	-0.41	-11.04	-0.4	4.59e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs57590327	0.555	rs3821551	chr3:81710179	A/T	cg07356753	chr3:81810745	GBE1	-0.44	-10.0	-0.37	5.8e-22	Extraversion;
BRCA	cis	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg07460842	chr6:66804631	NA	-0.95	-17.64	-0.57	4.66e-57	Exhaled nitric oxide output;
BRCA	cis	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg26306683	chr17:18585705	ZNF286B	-0.32	-8.26	-0.31	8.28e-16	Educational attainment (years of education);
BRCA	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg20476274	chr7:133979776	SLC35B4	0.61	15.05	0.51	5.07e-44	Mean platelet volume;
BRCA	cis	rs72928364	1.000	rs67946790	chr3:100688682	T/A	cg10123952	chr3:100791384	NA	0.53	7.89	0.3	1.3e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg23173402	chr1:227635558	NA	0.54	9.7	0.36	7.72e-21	Major depressive disorder;
BRCA	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg13271783	chr10:134563150	INPP5A	-0.5	-9.52	-0.35	3.56e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	trans	rs2262909	0.962	rs390730	chr19:22233509	C/A	cg17074339	chr11:11642133	GALNTL4	-0.41	-8.02	-0.3	4.97e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg03709012	chr19:19516395	GATAD2A	0.9	17.31	0.57	2.34e-55	Nonalcoholic fatty liver disease;
BRCA	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg16325326	chr1:53192061	ZYG11B	0.58	12.72	0.45	3.3e-33	Monocyte count;
BRCA	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg07988820	chr12:82153109	PPFIA2	-0.69	-11.62	-0.42	1.98e-28	Resting heart rate;
BRCA	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg13271783	chr10:134563150	INPP5A	-0.5	-9.31	-0.35	1.98e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg25173405	chr17:45401733	C17orf57	-0.51	-10.59	-0.39	2.89e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	17.01	0.56	8.75e-54	Alzheimer's disease;
BRCA	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg23505145	chr19:12996616	KLF1	0.56	12.69	0.45	4.46e-33	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg26384229	chr12:38710491	ALG10B	0.58	13.39	0.47	3.21e-36	Morning vs. evening chronotype;
BRCA	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-12.55	-0.44	1.86e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg00383909	chr3:49044727	WDR6	0.62	10.12	0.37	1.92e-22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg20476274	chr7:133979776	SLC35B4	0.62	17.99	0.58	7.18e-59	Mean platelet volume;
BRCA	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg15819921	chr19:927150	ARID3A	-0.48	-9.38	-0.35	1.18e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg01324343	chr3:183735012	ABCC5	0.83	20.95	0.64	1.44e-74	Anterior chamber depth;
BRCA	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg01528321	chr10:82214614	TSPAN14	0.92	20.17	0.62	2.1e-70	Post bronchodilator FEV1;
BRCA	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg03060546	chr3:49711283	APEH	-0.53	-8.88	-0.33	6.58e-18	Menarche (age at onset);
BRCA	cis	rs4919087	0.923	rs11189038	chr10:98974765	A/T	cg25902810	chr10:99078978	FRAT1	0.43	8.8	0.33	1.26e-17	Monocyte count;
BRCA	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg11502198	chr6:26597334	ABT1	0.48	9.67	0.36	9.58e-21	Intelligence (multi-trait analysis);
BRCA	trans	rs7980799	0.649	rs12819439	chr12:33684509	A/C	cg26384229	chr12:38710491	ALG10B	0.52	10.98	0.4	8.47e-26	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg21427119	chr20:30132790	HM13	-0.43	-8.81	-0.33	1.22e-17	Mean corpuscular hemoglobin;
BRCA	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg17330251	chr7:94953956	PON1	-0.42	-8.58	-0.32	7.37e-17	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg13770153	chr20:60521292	NA	0.84	22.16	0.66	3.49e-81	Obesity-related traits;
BRCA	cis	rs7737355	1.000	rs248652	chr5:130654837	A/T	cg06307176	chr5:131281290	NA	-0.46	-8.98	-0.33	2.98e-18	Life satisfaction;
BRCA	cis	rs939658	0.805	rs11634903	chr15:79436192	C/T	cg17916960	chr15:79447300	NA	0.43	10.62	0.39	2.2e-24	Refractive error;
BRCA	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg02527881	chr3:46936655	PTH1R	0.34	8.54	0.32	1.01e-16	Colorectal cancer;
BRCA	trans	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg06521331	chr12:34319734	NA	0.48	9.37	0.35	1.27e-19	Morning vs. evening chronotype;
BRCA	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-11.27	-0.41	5.36e-27	IgG glycosylation;
BRCA	trans	rs867371	0.502	rs28610286	chr15:82525655	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.32	-8.58	-0.32	7.37e-17	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg16482183	chr6:26056742	HIST1H1C	0.45	8.77	0.33	1.6e-17	Iron status biomarkers;
BRCA	trans	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.94	-0.3	9.1e-15	Corneal astigmatism;
BRCA	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-8.35	-0.31	4.3e-16	Alzheimer's disease (late onset);
BRCA	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.59e-19	Morning vs. evening chronotype;
BRCA	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	13.12	0.46	5.29e-35	Lung cancer in ever smokers;
BRCA	cis	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg06521331	chr12:34319734	NA	-0.61	-11.1	-0.4	2.65e-26	Morning vs. evening chronotype;
BRCA	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg25358565	chr5:93447407	FAM172A	1.14	18.59	0.59	5.23e-62	Diabetic retinopathy;
BRCA	cis	rs919433	0.679	rs61155920	chr2:198528881	C/T	cg00792783	chr2:198669748	PLCL1	0.39	9.03	0.34	2.08e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg23029597	chr12:123009494	RSRC2	0.58	11.43	0.41	1.2100000000000001e-27	Body mass index;
BRCA	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.62	0.55	8.2e-52	Alzheimer's disease (late onset);
BRCA	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg16606324	chr3:10149918	C3orf24	0.45	8.0	0.3	5.81e-15	Alzheimer's disease;
BRCA	cis	rs12347191	0.500	rs1912998	chr9:100621386	T/C	cg13688889	chr9:100608707	NA	-0.49	-9.96	-0.37	8.33e-22	Orofacial clefts;
BRCA	cis	rs9790314	0.663	rs778642	chr3:160705819	A/G	cg03342759	chr3:160939853	NMD3	-0.46	-8.96	-0.33	3.52e-18	Morning vs. evening chronotype;
BRCA	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-9.64	-0.36	1.29e-20	HDL cholesterol;
BRCA	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.66	-9.58	-0.35	2.1e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg21782813	chr7:2030301	MAD1L1	0.39	11.38	0.41	1.91e-27	Bipolar disorder and schizophrenia;
BRCA	cis	rs867371	1.000	rs13380317	chr15:82506790	A/G	cg00614314	chr15:82944287	LOC80154	-0.41	-8.8	-0.33	1.22e-17	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-11.76	-0.42	4.64e-29	Mood instability;
BRCA	cis	rs4363385	0.791	rs11205177	chr1:153002502	G/A	cg24667326	chr1:152973720	SPRR3	-0.32	-8.82	-0.33	1.08e-17	Inflammatory skin disease;
BRCA	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg05343316	chr1:45956843	TESK2	-0.56	-11.45	-0.41	9.91e-28	Platelet count;
BRCA	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg14820908	chr5:178986412	RUFY1	0.38	9.41	0.35	8.87e-20	Lung cancer;
BRCA	cis	rs2404602	0.552	rs11636612	chr15:76959530	C/T	cg23625390	chr15:77176239	SCAPER	-0.54	-11.2	-0.41	1.05e-26	Blood metabolite levels;
BRCA	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg19077165	chr18:44547161	KATNAL2	0.55	12.19	0.43	6.77e-31	Personality dimensions;
BRCA	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg24130564	chr14:104152367	KLC1	-0.34	-7.87	-0.3	1.47e-14	Body mass index;
BRCA	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03517284	chr6:25882590	NA	-0.52	-11.8	-0.42	3.32e-29	Blood metabolite levels;
BRCA	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg01420254	chr6:26195488	NA	-0.55	-8.07	-0.3	3.46e-15	Gout;Renal underexcretion gout;
BRCA	cis	rs13102973	0.899	rs13126625	chr4:135900322	C/T	cg14419869	chr4:135874104	NA	0.47	9.48	0.35	4.96e-20	Subjective well-being;
BRCA	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg06671706	chr8:8559999	CLDN23	0.43	8.29	0.31	6.45e-16	Obesity-related traits;
BRCA	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-10.16	-0.37	1.38e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4919694	1.000	rs12245779	chr10:104645944	C/A	cg04362960	chr10:104952993	NT5C2	0.95	14.86	0.51	4.07e-43	Arsenic metabolism;
BRCA	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg09307838	chr4:120376055	NA	0.73	16.02	0.54	7.93e-49	Corneal astigmatism;
BRCA	trans	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg06521331	chr12:34319734	NA	-0.47	-8.73	-0.33	2.14e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-9.95	-0.37	9.06e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg07945448	chr16:4304224	NA	0.49	10.12	0.37	1.92e-22	Prostate-specific antigen levels;
BRCA	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-12.78	-0.45	1.75e-33	Total cholesterol levels;
BRCA	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14442939	chr10:27389572	ANKRD26	-0.7	-12.82	-0.45	1.24e-33	Breast cancer;
BRCA	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg26384229	chr12:38710491	ALG10B	0.57	13.08	0.46	8.05e-35	Morning vs. evening chronotype;
BRCA	trans	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg25214090	chr10:38739885	LOC399744	0.56	12.39	0.44	9.8e-32	Corneal astigmatism;
BRCA	cis	rs9834373	0.553	rs12491264	chr3:78497118	T/C	cg06138941	chr3:78371609	NA	-0.35	-8.54	-0.32	9.73e-17	Protein quantitative trait loci;
BRCA	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg08917208	chr2:24149416	ATAD2B	0.94	14.07	0.49	2.42e-39	Lymphocyte counts;
BRCA	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg04362960	chr10:104952993	NT5C2	0.43	10.24	0.38	6.79e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg24006582	chr15:45444508	DUOX1	-0.53	-10.92	-0.4	1.44e-25	Uric acid levels;
BRCA	cis	rs6820391	0.781	rs1369354	chr4:54447974	G/T	cg04173182	chr4:54446035	LNX1	0.51	11.57	0.42	3.2e-28	Cervical artery dissection;
BRCA	cis	rs600231	0.542	rs34527830	chr11:65240863	G/A	cg01292856	chr11:65242576	NA	0.65	14.83	0.51	5.53e-43	Bone mineral density;
BRCA	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg00409905	chr10:38381863	ZNF37A	0.46	9.45	0.35	6.04e-20	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg15212455	chr7:39170539	POU6F2	0.38	8.52	0.32	1.14e-16	IgG glycosylation;
BRCA	cis	rs2625529	0.617	rs3784313	chr15:72187519	G/T	cg16672083	chr15:72433130	SENP8	0.66	15.74	0.53	2.07e-47	Red blood cell count;
BRCA	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg05872129	chr22:39784769	NA	-0.45	-9.97	-0.37	7.67e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg05535760	chr7:792225	HEATR2	0.72	13.22	0.46	1.82e-35	Cerebrospinal P-tau181p levels;
BRCA	cis	rs10493773	1.000	rs10493773	chr1:86125753	C/T	cg17807903	chr1:86174739	ZNHIT6	0.46	9.46	0.35	5.94e-20	Urate levels in overweight individuals;
BRCA	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg26031613	chr14:104095156	KLC1	-0.54	-9.44	-0.35	6.92e-20	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg25554036	chr4:6271136	WFS1	0.42	9.99	0.37	6.36e-22	Type 2 diabetes and other traits;Type 2 diabetes;
BRCA	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.92	0.4	1.44e-25	Bipolar disorder;
BRCA	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg04691961	chr3:161091175	C3orf57	-0.59	-14.06	-0.49	2.44e-39	Morning vs. evening chronotype;
BRCA	cis	rs4285028	0.747	rs12634032	chr3:121524575	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.9	-16.34	-0.54	1.98e-50	Multiple sclerosis;
BRCA	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.9	-0.33	5.94e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg08470875	chr2:26401718	FAM59B	-0.62	-10.53	-0.38	4.96e-24	Gut microbiome composition (summer);
BRCA	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg26384229	chr12:38710491	ALG10B	0.58	13.26	0.46	1.22e-35	Morning vs. evening chronotype;
BRCA	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg24642439	chr20:33292090	TP53INP2	0.43	8.86	0.33	8.02e-18	Height;
BRCA	cis	rs240110	0.539	rs6919745	chr6:101338978	T/C	cg09795085	chr6:101329169	ASCC3	0.39	8.08	0.3	3.32e-15	Neuroticism;
BRCA	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg02734326	chr4:10020555	SLC2A9	0.41	8.92	0.33	4.71e-18	Bone mineral density;
BRCA	trans	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg17830980	chr10:43048298	ZNF37B	-0.37	-7.84	-0.3	1.94e-14	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg17211192	chr8:82754475	SNX16	-0.6	-11.54	-0.42	4.05e-28	Diastolic blood pressure;
BRCA	cis	rs12612619	0.732	rs1440044	chr2:27226954	A/G	cg00617064	chr2:27272375	NA	-0.31	-8.06	-0.3	3.74e-15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs11718455	0.767	rs4682924	chr3:43992760	G/A	cg08738300	chr3:44038990	NA	0.48	8.87	0.33	7.13e-18	Coronary artery disease;
BRCA	cis	rs2992756	0.663	rs3007734	chr1:18803022	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.38	-7.81	-0.3	2.28e-14	Breast cancer;
BRCA	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg16423285	chr20:60520624	NA	0.61	13.2	0.46	2.44e-35	Obesity-related traits;
BRCA	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg18479299	chr3:125709523	NA	-0.54	-8.46	-0.32	1.84e-16	Blood pressure (smoking interaction);
BRCA	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg00149659	chr3:10157352	C3orf10	1.08	18.11	0.58	1.73e-59	Alzheimer's disease;
BRCA	trans	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg06521331	chr12:34319734	NA	-0.45	-8.4	-0.32	2.92e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.57	10.57	0.39	3.59e-24	Height;
BRCA	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg06937882	chr20:24974362	C20orf3	-0.48	-9.47	-0.35	5.48e-20	Blood protein levels;
BRCA	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-8.58	-0.32	6.92e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	14.22	0.49	4.65e-40	Motion sickness;
BRCA	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg08992911	chr2:238395768	MLPH	0.54	8.34	0.31	4.44e-16	Prostate cancer;
BRCA	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23583168	chr7:148888333	NA	0.95	24.48	0.7	7.11e-94	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg07395648	chr5:131743802	NA	0.38	9.42	0.35	8.26e-20	Blood metabolite levels;
BRCA	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	30.18	0.77	5e-125	Chronic sinus infection;
BRCA	cis	rs757081	0.667	rs644419	chr11:17212375	C/T	cg15432903	chr11:17409602	KCNJ11	0.45	8.5	0.32	1.32e-16	Systolic blood pressure;
BRCA	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg23711669	chr6:146136114	FBXO30	0.64	15.08	0.51	3.35e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg12935359	chr14:103987150	CKB	0.58	13.31	0.47	7.29e-36	Intelligence (multi-trait analysis);
BRCA	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg06115741	chr20:33292138	TP53INP2	0.39	8.68	0.32	3.35e-17	Glomerular filtration rate (creatinine);
BRCA	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg18129178	chr5:148520854	ABLIM3	-0.59	-11.89	-0.43	1.37e-29	Breast cancer;
BRCA	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg14844989	chr11:31128820	NA	0.45	9.64	0.36	1.32e-20	Red blood cell count;
BRCA	cis	rs9309711	0.772	rs9309714	chr2:3491830	G/C	cg10845886	chr2:3471009	TTC15	-0.77	-16.25	-0.54	5.66e-50	Neurofibrillary tangles;
BRCA	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.75	-23.42	-0.68	5.06e-88	Longevity;Endometriosis;
BRCA	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg17691542	chr6:26056736	HIST1H1C	0.48	9.55	0.35	2.75e-20	Iron status biomarkers;
BRCA	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02475777	chr4:1388615	CRIPAK	-0.67	-13.11	-0.46	5.99e-35	Longevity;
BRCA	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg18876405	chr7:65276391	NA	0.49	10.62	0.39	2.16e-24	Aortic root size;
BRCA	cis	rs701145	0.537	rs1358403	chr3:153862757	C/T	cg12800244	chr3:153838788	SGEF	0.62	7.83	0.3	2.1e-14	Coronary artery disease;
BRCA	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.26	0.38	5.81e-23	Bipolar disorder;
BRCA	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.29	-8.11	-0.31	2.64e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs8002861	0.641	rs4942252	chr13:44443039	C/T	cg17145862	chr1:211918768	LPGAT1	0.47	10.69	0.39	1.16e-24	Leprosy;
BRCA	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg20503657	chr10:835505	NA	1.02	17.74	0.57	1.5e-57	Eosinophil percentage of granulocytes;
BRCA	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.39	-8.4	-0.32	2.87e-16	Longevity;Endometriosis;
BRCA	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg25173405	chr17:45401733	C17orf57	-0.57	-12.26	-0.44	3.51e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg09998033	chr7:158218633	PTPRN2	-0.33	-7.91	-0.3	1.15e-14	Obesity-related traits;
BRCA	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.48	-10.72	-0.39	9.21e-25	Type 2 diabetes;
BRCA	cis	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg07460842	chr6:66804631	NA	0.72	12.01	0.43	4.37e-30	Exhaled nitric oxide output;
BRCA	cis	rs2016266	0.806	rs11170494	chr12:53665164	C/A	cg26875137	chr12:53738046	NA	0.35	9.46	0.35	5.82e-20	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs870825	0.860	rs72703519	chr4:185602707	G/A	cg04058563	chr4:185651563	MLF1IP	0.65	11.26	0.41	5.77e-27	Blood protein levels;
BRCA	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg26248373	chr2:1572462	NA	-0.5	-9.62	-0.36	1.49e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg09877947	chr5:131593287	PDLIM4	0.46	11.17	0.4	1.37e-26	Acylcarnitine levels;
BRCA	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-15.67	-0.53	4.38e-47	Systemic lupus erythematosus;
BRCA	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg15556689	chr8:8085844	FLJ10661	-0.31	-8.18	-0.31	1.48e-15	Mood instability;
BRCA	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07636037	chr3:49044803	WDR6	0.74	15.91	0.53	3.01e-48	Menarche (age at onset);
BRCA	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg12437481	chr16:420112	MRPL28	-0.47	-11.84	-0.42	2.18e-29	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03517284	chr6:25882590	NA	-0.36	-8.42	-0.32	2.42e-16	Height;
BRCA	cis	rs6032067	0.561	rs2741502	chr20:43936265	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	0.31	8.13	0.31	2.29e-15	Blood protein levels;
BRCA	trans	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg25214090	chr10:38739885	LOC399744	0.55	12.18	0.43	7.52e-31	Corneal astigmatism;
BRCA	cis	rs877282	0.838	rs34912955	chr10:772222	T/C	cg17470449	chr10:769945	NA	0.5	8.9	0.33	5.64e-18	Uric acid levels;
BRCA	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg08999081	chr20:33150536	PIGU	-0.46	-12.76	-0.45	2.3e-33	Glomerular filtration rate (creatinine);
BRCA	cis	rs858239	0.539	rs4365988	chr7:23190871	T/C	cg23682824	chr7:23144976	KLHL7	0.41	10.95	0.4	1.1e-25	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg17366294	chr4:99064904	C4orf37	0.44	10.49	0.38	7.52e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4478137	0.839	rs3967763	chr4:164239273	G/C	cg06758707	chr4:164254230	NPY1R	0.57	12.46	0.44	4.7e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg10495392	chr1:46806563	NSUN4	0.44	8.18	0.31	1.49e-15	Menopause (age at onset);
BRCA	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11764359	chr7:65958608	NA	-0.61	-13.45	-0.47	1.72e-36	Calcium levels;
BRCA	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.09	0.34	1.21e-18	Tonsillectomy;
BRCA	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg23711669	chr6:146136114	FBXO30	-0.79	-19.16	-0.6	5.32e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg14196790	chr5:131705035	SLC22A5	0.4	10.15	0.37	1.51e-22	Blood metabolite levels;
BRCA	trans	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg06521331	chr12:34319734	NA	0.52	9.99	0.37	6.45e-22	Bladder cancer;
BRCA	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg17143192	chr8:8559678	CLDN23	0.57	11.25	0.41	6.26e-27	Obesity-related traits;
BRCA	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg05283184	chr6:79620031	NA	0.41	10.12	0.37	2.06e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg03342759	chr3:160939853	NMD3	-0.61	-13.44	-0.47	1.83e-36	Morning vs. evening chronotype;
BRCA	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg08085267	chr17:45401833	C17orf57	0.6	12.4	0.44	8.84e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.42	-8.47	-0.32	1.63e-16	Lymphocyte percentage of white cells;
BRCA	cis	rs13102973	0.899	rs4643872	chr4:135901432	A/G	cg14419869	chr4:135874104	NA	0.45	9.02	0.34	2.21e-18	Subjective well-being;
BRCA	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	8.25	0.31	9.17e-16	Uric acid levels;
BRCA	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.54	13.28	0.47	1.01e-35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg00495681	chr13:53174319	NA	-0.39	-8.11	-0.31	2.6e-15	Lewy body disease;
BRCA	cis	rs752010	0.619	rs10789406	chr1:42105182	G/T	cg06885757	chr1:42089581	HIVEP3	-0.25	-9.08	-0.34	1.31e-18	Lupus nephritis in systemic lupus erythematosus;
BRCA	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-10.57	-0.39	3.49e-24	Monocyte count;
BRCA	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg04546413	chr19:29218101	NA	0.5	8.62	0.32	5.46e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
BRCA	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg11657440	chr19:46296263	DMWD	-0.54	-12.71	-0.45	3.84e-33	Coronary artery disease;
BRCA	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.7	-12.12	-0.43	1.4e-30	Platelet count;
BRCA	cis	rs62229266	0.771	rs2835232	chr21:37393427	G/A	cg12218747	chr21:37451666	NA	-0.34	-8.08	-0.3	3.21e-15	Mitral valve prolapse;
BRCA	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg23708337	chr7:1209742	NA	0.6	8.31	0.31	5.89e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg00757033	chr12:89920650	WDR51B	0.53	10.64	0.39	1.92e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	trans	rs877282	0.583	rs10904564	chr10:819459	C/G	cg22713356	chr15:30763199	NA	1.03	16.73	0.55	2.29e-52	Uric acid levels;
BRCA	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg05340658	chr4:99064831	C4orf37	0.59	12.81	0.45	1.29e-33	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg04455712	chr21:45112962	RRP1B	0.39	9.82	0.36	2.78e-21	Mean corpuscular volume;
BRCA	cis	rs708547	0.647	rs1277308	chr4:57897864	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.4	10.4	0.38	1.64e-23	Response to bleomycin (chromatid breaks);
BRCA	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-10.47	-0.38	9e-24	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg00339695	chr16:24857497	SLC5A11	0.53	11.22	0.41	8.77e-27	Intelligence (multi-trait analysis);
BRCA	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.53	-0.35	3.1e-20	Total body bone mineral density;
BRCA	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg11266682	chr4:10021025	SLC2A9	0.44	11.54	0.42	4.15e-28	Bone mineral density;
BRCA	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg11262906	chr1:85462892	MCOLN2	-0.47	-8.98	-0.33	3.08e-18	Serum sulfate level;
BRCA	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.43	9.6	0.36	1.77e-20	Multiple sclerosis;
BRCA	cis	rs4363385	0.747	rs946101	chr1:152972032	C/T	cg25856811	chr1:152973957	SPRR3	0.34	9.5	0.35	4.3e-20	Inflammatory skin disease;
BRCA	cis	rs2130392	0.886	rs2077205	chr4:185637418	C/T	cg21366198	chr4:185655624	MLF1IP	-0.4	-9.55	-0.35	2.79e-20	Kawasaki disease;
BRCA	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	9.08	0.34	1.33e-18	Personality dimensions;
BRCA	cis	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-8.29	-0.31	6.64e-16	Coffee consumption;Coffee consumption (cups per day);
BRCA	trans	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.74	0.39	7.43e-25	Type 2 diabetes;
BRCA	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg16576597	chr16:28551801	NUPR1	0.29	8.2	0.31	1.29e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs250677	0.522	rs1432801	chr5:148390979	T/C	cg18129178	chr5:148520854	ABLIM3	-0.55	-10.56	-0.39	3.75e-24	Breast cancer;
BRCA	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg24069376	chr3:38537580	EXOG	-0.33	-9.35	-0.35	1.5e-19	Electrocardiographic conduction measures;
BRCA	cis	rs1997103	1.000	rs10252413	chr7:55396740	C/G	cg17469321	chr7:55412551	NA	0.51	9.67	0.36	9.47e-21	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11764359	chr7:65958608	NA	0.75	16.82	0.55	8.27e-53	Aortic root size;
BRCA	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg13047869	chr3:10149882	C3orf24	0.59	12.37	0.44	1.16e-31	Alzheimer's disease;
BRCA	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg08917208	chr2:24149416	ATAD2B	0.55	8.55	0.32	8.75e-17	Lymphocyte counts;
BRCA	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	8.08	0.3	3.17e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg21427119	chr20:30132790	HM13	-0.43	-9.29	-0.35	2.34e-19	Mean corpuscular hemoglobin;
BRCA	trans	rs12517041	1.000	rs4701219	chr5:23284067	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.32	-0.31	5.27e-16	Calcium levels;
BRCA	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg11941060	chr3:133502564	NA	-0.5	-11.89	-0.43	1.35e-29	Iron status biomarkers;
BRCA	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg11502198	chr6:26597334	ABT1	0.48	9.58	0.35	2.09e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs1506636	0.512	rs1035015	chr7:123309842	G/C	cg03229431	chr7:123269106	ASB15	0.5	8.26	0.31	8.4e-16	Plateletcrit;Platelet count;
BRCA	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg23788917	chr6:8435910	SLC35B3	0.48	10.49	0.38	7.17e-24	Motion sickness;
BRCA	cis	rs4478137	0.824	rs10857353	chr4:164215835	A/G	cg06758707	chr4:164254230	NPY1R	-0.54	-11.64	-0.42	1.53e-28	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs4363385	0.747	rs4240867	chr1:152954921	A/G	cg24667326	chr1:152973720	SPRR3	0.34	10.05	0.37	3.61e-22	Inflammatory skin disease;
BRCA	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19717773	chr7:2847554	GNA12	-0.41	-8.47	-0.32	1.71e-16	Height;
BRCA	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg17063962	chr7:91808500	NA	0.54	12.72	0.45	3.47e-33	Breast cancer;
BRCA	cis	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.48	9.14	0.34	8.42e-19	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg23978390	chr7:1156363	C7orf50	0.41	9.8	0.36	3.31e-21	Longevity;Endometriosis;
BRCA	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	13.98	0.48	6.08e-39	Motion sickness;
BRCA	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg22907277	chr7:1156413	C7orf50	0.5	10.74	0.39	7.77e-25	Longevity;Endometriosis;
BRCA	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	10.56	0.39	3.88e-24	Iron status biomarkers;
BRCA	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg13319975	chr6:146136371	FBXO30	0.34	8.04	0.3	4.43e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg01236616	chr12:121019343	POP5	-1.23	-27.99	-0.74	4.13e-113	Type 1 diabetes nephropathy;
BRCA	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg20469991	chr17:27169893	C17orf63	0.44	8.73	0.33	2.3e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
BRCA	cis	rs4930561	0.765	rs1894204	chr11:67929671	C/T	cg16338278	chr11:67432957	ALDH3B2	0.44	9.1	0.34	1.14e-18	Breast cancer in childhood cancer survivors;IgG glycosylation;
BRCA	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg17366294	chr4:99064904	C4orf37	0.47	10.97	0.4	8.76e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg15698299	chr3:52233019	ALAS1	0.36	8.31	0.31	5.53e-16	Electroencephalogram traits;
BRCA	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg19678392	chr7:94953810	PON1	-0.42	-8.93	-0.33	4.37e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg24069376	chr3:38537580	EXOG	0.4	11.59	0.42	2.43e-28	Electrocardiographic conduction measures;
BRCA	cis	rs4853036	1.000	rs13025205	chr2:70044159	C/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-8.89	-0.33	6.1e-18	Colorectal or endometrial cancer;
BRCA	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg04362960	chr10:104952993	NT5C2	0.42	10.08	0.37	2.8e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
BRCA	cis	rs55665837	1.000	rs11023216	chr11:14437153	G/A	cg19336497	chr11:14380999	RRAS2	-0.36	-9.49	-0.35	4.37e-20	Vitamin D levels;
BRCA	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg09367891	chr1:107599246	PRMT6	0.51	9.47	0.35	5.52e-20	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg09754948	chr16:28834200	ATXN2L	0.47	8.87	0.33	7.16e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	trans	rs2018683	0.707	rs917219	chr7:28975343	A/G	cg19402173	chr7:128379420	CALU	-0.44	-10.56	-0.39	3.94e-24	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
BRCA	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-8.14	-0.31	2.1e-15	Depression;
BRCA	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg18479299	chr3:125709523	NA	-0.54	-8.34	-0.31	4.59e-16	Blood pressure (smoking interaction);
BRCA	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg07636037	chr3:49044803	WDR6	0.8	20.78	0.64	1.14e-73	Menarche (age at onset);
BRCA	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg19717773	chr7:2847554	GNA12	-0.42	-9.51	-0.35	3.75e-20	Height;
BRCA	cis	rs8048589	0.515	rs4780412	chr16:12232409	A/G	cg02910054	chr16:12241554	SNX29	0.44	9.3	0.35	2.13e-19	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
BRCA	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg23505145	chr19:12996616	KLF1	0.56	12.69	0.45	4.46e-33	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg22189786	chr22:42395067	WBP2NL	0.43	8.66	0.32	3.99e-17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
BRCA	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg24846343	chr22:24311635	DDTL	-0.49	-12.11	-0.43	1.63e-30	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08280861	chr8:58055591	NA	-0.54	-8.58	-0.32	7.39e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.92	0.33	4.98e-18	Motion sickness;
BRCA	trans	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg26043149	chr18:55253948	FECH	-0.37	-8.17	-0.31	1.59e-15	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg19628046	chr18:33552617	C18orf21	0.55	10.58	0.39	3.18e-24	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg26395211	chr5:140044315	WDR55	0.35	7.89	0.3	1.36e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11764359	chr7:65958608	NA	0.8	19.21	0.6	3.07e-65	Aortic root size;
BRCA	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11644478	chr21:40555479	PSMG1	0.48	10.15	0.37	1.56e-22	Menarche (age at onset);
BRCA	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg09904177	chr6:26538194	HMGN4	0.56	18.46	0.59	2.5e-61	Intelligence (multi-trait analysis);
BRCA	cis	rs9682041	0.696	rs11709437	chr3:170085568	T/G	cg11886554	chr3:170076028	SKIL	0.52	10.27	0.38	5.42e-23	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
BRCA	cis	rs312274	0.546	rs11178979	chr12:41299357	A/G	cg17827154	chr12:41323612	CNTN1	-0.45	-11.25	-0.41	6.48e-27	Metabolite levels  (X-11787);
BRCA	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg18402987	chr7:1209562	NA	0.84	12.05	0.43	2.92e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg05347473	chr6:146136440	FBXO30	0.42	8.16	0.31	1.84e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg08888203	chr3:10149979	C3orf24	0.65	13.7	0.48	1.2e-37	Alzheimer's disease;
BRCA	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg24747557	chr10:131355152	MGMT	0.37	9.13	0.34	8.71e-19	Response to temozolomide;
BRCA	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg08798685	chr6:27730294	NA	-0.72	-8.9	-0.33	5.88e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg10523679	chr1:76189770	ACADM	0.76	15.95	0.53	1.76e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg15819921	chr19:927150	ARID3A	-0.47	-8.98	-0.33	2.89e-18	Life satisfaction;
BRCA	cis	rs17092148	0.887	rs2144956	chr20:33145868	G/A	cg16810054	chr20:33298113	TP53INP2	-0.45	-10.08	-0.37	2.93e-22	Neuroticism;
BRCA	cis	rs17253792	0.822	rs76055105	chr14:56069127	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-10.5	-0.38	6.49e-24	Putamen volume;
BRCA	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg02659138	chr7:134003124	SLC35B4	0.4	11.57	0.42	3.18e-28	Mean platelet volume;
BRCA	cis	rs700651	0.754	rs1518367	chr2:198807015	T/A	cg00792783	chr2:198669748	PLCL1	0.44	9.75	0.36	4.75e-21	Intracranial aneurysm;
BRCA	cis	rs9788721	0.836	rs72738732	chr15:78752188	C/G	cg18825076	chr15:78729989	IREB2	-0.45	-8.76	-0.33	1.71e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
BRCA	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg06618935	chr21:46677482	NA	-0.38	-8.56	-0.32	8.68e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg26384229	chr12:38710491	ALG10B	0.76	17.07	0.56	4.41e-54	Morning vs. evening chronotype;
BRCA	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg08807101	chr21:30365312	RNF160	0.57	12.37	0.44	1.2e-31	Selective IgA deficiency;
BRCA	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-9.15	-0.34	7.34e-19	Bipolar disorder;
BRCA	cis	rs11112613	0.713	rs12307351	chr12:105955634	T/A	cg03607813	chr12:105948248	NA	0.6	10.46	0.38	9.53e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
BRCA	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg09307838	chr4:120376055	NA	0.65	13.19	0.46	2.55e-35	Corneal astigmatism;
BRCA	cis	rs812925	0.537	rs2593620	chr2:61613261	A/G	cg15711740	chr2:61764176	XPO1	0.32	7.9	0.3	1.2e-14	Immature fraction of reticulocytes;
BRCA	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07080220	chr10:102295463	HIF1AN	0.49	11.15	0.4	1.7e-26	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs847577	0.575	rs41278842	chr7:97815999	A/G	cg21770322	chr7:97807741	LMTK2	-0.46	-11.99	-0.43	5.09e-30	Breast cancer;
BRCA	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24308560	chr3:49941425	MST1R	0.39	8.48	0.32	1.56e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg14675211	chr2:100938903	LONRF2	0.47	10.19	0.37	1.09e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg12573674	chr2:1569213	NA	-0.62	-14.09	-0.49	1.83e-39	IgG glycosylation;
BRCA	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg02297831	chr4:17616191	MED28	0.35	8.14	0.31	2.1e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03264133	chr6:25882463	NA	0.49	10.98	0.4	8.45e-26	Blood metabolite levels;
BRCA	cis	rs7586879	0.719	rs7565468	chr2:25130092	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.53	0.35	3.3e-20	Body mass index;
BRCA	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg00750074	chr16:89608354	SPG7	-0.38	-10.31	-0.38	3.68e-23	Multiple myeloma (IgH translocation);
BRCA	cis	rs10463316	0.894	rs7727926	chr5:150767216	G/A	cg03212797	chr5:150827313	SLC36A1	-0.43	-8.32	-0.31	5.17e-16	Metabolite levels (Pyroglutamine);
BRCA	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.53	-13.35	-0.47	4.72e-36	Urate levels in overweight individuals;
BRCA	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-14.36	-0.49	1.03e-40	Personality dimensions;
BRCA	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.63	-0.61	1.73e-67	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04565464	chr8:145669602	NFKBIL2	-0.36	-9.12	-0.34	9.89e-19	Bipolar disorder and schizophrenia;
BRCA	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-8.31	-0.31	5.65e-16	Aortic root size;
BRCA	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-12.11	-0.43	1.52e-30	Bipolar disorder;
BRCA	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg03877680	chr5:178157825	ZNF354A	0.78	14.61	0.5	6.26e-42	Neutrophil percentage of white cells;
BRCA	cis	rs9810890	1.000	rs73196988	chr3:128453467	G/A	cg15033153	chr3:128514015	RAB7A	0.7	8.08	0.3	3.34e-15	Dental caries;
BRCA	cis	rs12618769	0.570	rs17032866	chr2:99132415	A/G	cg10123293	chr2:99228465	UNC50	0.41	8.24	0.31	9.93e-16	Bipolar disorder;
BRCA	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03264133	chr6:25882463	NA	0.49	10.97	0.4	9.32e-26	Blood metabolite levels;
BRCA	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg04842962	chr6:43655489	MRPS18A	1.12	37.97	0.83	5.95e-166	IgG glycosylation;
BRCA	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg15549821	chr19:49342101	PLEKHA4	-0.71	-11.43	-0.41	1.2100000000000001e-27	Red cell distribution width;
BRCA	cis	rs2294693	0.945	rs9349175	chr6:40982401	T/C	cg14418226	chr6:40996092	UNC5CL	0.44	7.97	0.3	7.14e-15	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg04450456	chr4:17643702	FAM184B	0.32	9.34	0.35	1.5700000000000001e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg24642439	chr20:33292090	TP53INP2	0.42	8.82	0.33	1.1e-17	Height;
BRCA	trans	rs12517041	1.000	rs7737671	chr5:23288400	C/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-8.36	-0.31	4.04e-16	Calcium levels;
BRCA	cis	rs1547553	1	rs1547553	chr18:77926197	C/A	cg14906638	chr18:78001859	PARD6G	-0.58	-9.7	-0.36	7.75e-21	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg23289794	chr7:2394357	EIF3B	-0.66	-12.14	-0.43	1.2e-30	Multiple sclerosis;
BRCA	cis	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg08807101	chr21:30365312	RNF160	-0.47	-8.01	-0.3	5.52e-15	Cognitive test performance;
BRCA	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg21475434	chr5:93447410	FAM172A	0.69	8.69	0.33	2.92e-17	Diabetic retinopathy;
BRCA	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg23422044	chr7:1970798	MAD1L1	-0.47	-9.9	-0.36	1.38e-21	Bipolar disorder;
BRCA	cis	rs9790314	0.690	rs7633857	chr3:160844942	C/G	cg03342759	chr3:160939853	NMD3	-0.53	-11.33	-0.41	3.02e-27	Morning vs. evening chronotype;
BRCA	trans	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg15556689	chr8:8085844	FLJ10661	0.33	8.49	0.32	1.5e-16	Neuroticism;
BRCA	cis	rs12545109	0.959	rs12547974	chr8:57314785	G/T	cg09654669	chr8:57350985	NA	-0.38	-8.05	-0.3	4.1e-15	Obesity-related traits;
BRCA	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg03188948	chr7:1209495	NA	0.69	11.62	0.42	1.85e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23583168	chr7:148888333	NA	-0.82	-18.94	-0.6	7.99e-64	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.31	-8.08	-0.3	3.26e-15	Total body bone mineral density;
BRCA	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.61	-10.46	-0.38	9.79e-24	Lung function (FEV1/FVC);
BRCA	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	12.51	0.44	2.82e-32	Electroencephalogram traits;
BRCA	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg11502198	chr6:26597334	ABT1	0.54	11.45	0.41	9.26e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg01448562	chr3:133502909	NA	-0.72	-17.58	-0.57	1.01e-56	Iron status biomarkers;
BRCA	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg17366294	chr4:99064904	C4orf37	0.45	10.72	0.39	8.75e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg22906224	chr7:99728672	NA	0.45	8.59	0.32	6.5e-17	Coronary artery disease;
BRCA	cis	rs870825	0.655	rs35397385	chr4:185639095	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	17.27	0.56	3.85e-55	Blood protein levels;
BRCA	cis	rs2882667	0.931	rs10075893	chr5:138355871	A/G	cg04439458	chr5:138467593	SIL1	0.34	9.33	0.35	1.75e-19	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs6088813	1.000	rs6142374	chr20:33985568	C/T	cg14752227	chr20:34000481	UQCC	-0.43	-9.08	-0.34	1.39e-18	Height;
BRCA	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	12.02	0.43	3.86e-30	Tonsillectomy;
BRCA	cis	rs877282	0.898	rs12354872	chr10:763362	G/A	cg17470449	chr10:769945	NA	0.47	7.92	0.3	1.08e-14	Uric acid levels;
BRCA	cis	rs911119	0.908	rs12624424	chr20:23601878	C/T	cg16589663	chr20:23618590	CST3	0.44	8.13	0.31	2.31e-15	Chronic kidney disease;
BRCA	trans	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.62	-14.19	-0.49	6.18e-40	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs2070997	0.816	rs9695008	chr9:133720877	C/T	cg11464064	chr9:133710261	ABL1	0.58	9.24	0.34	3.58e-19	Response to amphetamines;
BRCA	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg18252515	chr7:66147081	NA	-0.93	-13.3	-0.47	8.69e-36	Diabetic kidney disease;
BRCA	cis	rs6066825	0.555	rs6019378	chr20:47309716	C/T	cg18078177	chr20:47281410	PREX1	0.39	9.58	0.35	2.02e-20	Colorectal cancer;
BRCA	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg03060546	chr3:49711283	APEH	-0.57	-11.4	-0.41	1.61e-27	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.23e-24	Motion sickness;
BRCA	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.21	-0.34	4.59e-19	Menopause (age at onset);
BRCA	cis	rs9487051	0.768	rs12176068	chr6:109521629	C/T	cg01475377	chr6:109611718	NA	-0.45	-11.4	-0.41	1.58e-27	Reticulocyte fraction of red cells;
BRCA	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.05	-19.05	-0.6	1.99e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg18129178	chr5:148520854	ABLIM3	-0.63	-12.33	-0.44	1.69e-31	Breast cancer;
BRCA	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg05729581	chr11:3078854	CARS	-0.35	-8.77	-0.33	1.65e-17	Longevity;
BRCA	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg08132940	chr7:1081526	C7orf50	-0.6	-8.74	-0.33	2.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg13866156	chr1:1669148	SLC35E2	0.41	8.92	0.33	4.86e-18	Body mass index;
BRCA	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.04	-0.34	1.79e-18	Total body bone mineral density;
BRCA	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg21045802	chr8:109455806	TTC35	0.35	8.08	0.3	3.19e-15	Dupuytren's disease;
BRCA	trans	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg26384229	chr12:38710491	ALG10B	0.51	11.2	0.41	1.05e-26	Morning vs. evening chronotype;
BRCA	trans	rs11088226	1.000	rs11701627	chr21:33927794	T/A	cg09050820	chr6:167586206	TCP10L2	0.5	8.8	0.33	1.26e-17	Gastritis;
BRCA	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg15704280	chr7:45808275	SEPT13	0.58	9.84	0.36	2.22e-21	Axial length;
BRCA	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg05340658	chr4:99064831	C4orf37	0.67	16.84	0.55	6e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24531977	chr5:56204891	C5orf35	-0.8	-16.77	-0.55	1.32e-52	Initial pursuit acceleration;
BRCA	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10802521	chr3:52805072	NEK4	-0.32	-8.38	-0.31	3.4e-16	Bipolar disorder;
BRCA	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11645453	chr3:52864694	ITIH4	-0.47	-11.59	-0.42	2.61e-28	Schizophrenia;
BRCA	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg08999081	chr20:33150536	PIGU	0.46	12.92	0.46	4.19e-34	Glomerular filtration rate (creatinine);
BRCA	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg24531977	chr5:56204891	C5orf35	-0.41	-8.45	-0.32	1.93e-16	Coronary artery disease;
BRCA	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.63	-0.32	4.88e-17	Breast cancer;
BRCA	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.47	-11.16	-0.4	1.49e-26	IgG glycosylation;
BRCA	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.52	-0.52	2.52e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs41005	1.000	rs42357	chr2:8110896	C/T	cg03155496	chr2:8117019	LOC339788	0.57	15.39	0.52	1.08e-45	Response to anti-TNF therapy in rheumatoid arthritis;
BRCA	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg04166393	chr7:2884313	GNA12	0.51	9.65	0.36	1.18e-20	Height;
BRCA	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg03433033	chr1:76189801	ACADM	0.71	13.13	0.46	5.04e-35	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg24130564	chr14:104152367	KLC1	-0.34	-7.88	-0.3	1.45e-14	Body mass index;
BRCA	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg27490568	chr2:178487706	NA	0.5	8.4	0.32	2.91e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg12373951	chr3:133503437	NA	0.44	10.28	0.38	4.83e-23	Iron status biomarkers;
BRCA	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg14784868	chr12:69753453	YEATS4	0.68	19.81	0.62	1.79e-68	Blood protein levels;
BRCA	cis	rs977987	0.806	rs72787160	chr16:75445162	G/C	cg03315344	chr16:75512273	CHST6	0.53	12.46	0.44	4.72e-32	Dupuytren's disease;
BRCA	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.43	-0.41	1.22e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs4594175	1.000	rs4594175	chr14:51606541	C/A	cg23942311	chr14:51606299	NA	0.34	8.66	0.32	3.85e-17	Cancer;
BRCA	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg05623727	chr3:50126028	RBM5	0.44	10.44	0.38	1.14e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-9.24	-0.34	3.51e-19	Fear of minor pain;
BRCA	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg15819921	chr19:927150	ARID3A	-0.48	-9.38	-0.35	1.15e-19	Life satisfaction;
BRCA	cis	rs9309473	0.519	rs6746971	chr2:73669462	A/G	cg20560298	chr2:73613845	ALMS1	-0.41	-11.22	-0.41	8.42e-27	Metabolite levels;
BRCA	cis	rs1030877	0.515	rs17030766	chr2:105911905	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.54	-9.85	-0.36	2.18e-21	Obesity-related traits;
BRCA	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg05340658	chr4:99064831	C4orf37	0.68	17.04	0.56	6.18e-54	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg05234568	chr11:5960015	NA	-0.42	-8.8	-0.33	1.29e-17	DNA methylation (variation);
BRCA	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg10729496	chr3:10149963	C3orf24	0.48	9.16	0.34	6.82e-19	Alzheimer's disease;
BRCA	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg03676636	chr4:99064102	C4orf37	0.2	7.89	0.3	1.33e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg16414030	chr3:133502952	NA	-0.47	-10.82	-0.39	3.73e-25	Iron status biomarkers;
BRCA	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg08822215	chr16:89438651	ANKRD11	0.38	8.24	0.31	9.99e-16	Multiple myeloma (IgH translocation);
BRCA	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg03188948	chr7:1209495	NA	-0.47	-8.63	-0.32	5.02e-17	Longevity;Endometriosis;
BRCA	cis	rs495337	0.706	rs671130	chr20:48477458	G/A	cg17835207	chr20:48524531	SPATA2	-0.5	-11.06	-0.4	3.87e-26	Psoriasis;
BRCA	cis	rs7617773	0.817	rs936426	chr3:48215253	C/T	cg11946769	chr3:48343235	NME6	0.6	13.33	0.47	5.79e-36	Coronary artery disease;
BRCA	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.59	9.24	0.34	3.63e-19	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg05729581	chr11:3078854	CARS	-0.33	-8.02	-0.3	5e-15	Longevity;
BRCA	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg17211192	chr8:82754475	SNX16	-0.52	-11.94	-0.43	8.29e-30	Diastolic blood pressure;
BRCA	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	16.93	0.56	2.15e-53	Platelet count;
BRCA	cis	rs700651	0.821	rs700663	chr2:198670478	T/A	cg00792783	chr2:198669748	PLCL1	0.47	10.27	0.38	5.27e-23	Intracranial aneurysm;
BRCA	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg11266682	chr4:10021025	SLC2A9	0.42	11.2	0.41	1.03e-26	Bone mineral density;
BRCA	cis	rs9462846	1.000	rs9462846	chr6:42861581	A/C	cg02353165	chr6:42928485	GNMT	0.48	8.61	0.32	5.61e-17	Blood protein levels;
BRCA	cis	rs17228212	1.000	rs10152307	chr15:67444498	C/T	cg26876701	chr15:67458665	SMAD3	-0.47	-9.19	-0.34	5.52e-19	Coronary heart disease;
BRCA	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg05347473	chr6:146136440	FBXO30	0.41	8.03	0.3	4.76e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg15395560	chr15:45543142	SLC28A2	0.3	8.32	0.31	5.52e-16	Uric acid levels;
BRCA	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg03213289	chr20:61660250	NA	0.62	15.95	0.53	1.88e-48	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg25358565	chr5:93447407	FAM172A	1.21	19.85	0.62	1.16e-68	Diabetic retinopathy;
BRCA	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.6	19.45	0.61	1.5e-66	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-12.72	-0.45	3.52e-33	Gut microbiome composition (summer);
BRCA	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.66	-16.3	-0.54	3.49e-50	Longevity;Endometriosis;
BRCA	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg08470875	chr2:26401718	FAM59B	-0.71	-11.35	-0.41	2.41e-27	Gut microbiome composition (summer);
BRCA	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	11.03	0.4	4.9e-26	Bipolar disorder;
BRCA	cis	rs360798	0.532	rs7573756	chr2:62990637	G/A	cg17519650	chr2:63277830	OTX1	-0.36	-7.89	-0.3	1.33e-14	Coronary artery disease;
BRCA	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg17971929	chr21:40555470	PSMG1	-0.47	-10.26	-0.38	5.89e-23	Menarche (age at onset);
BRCA	cis	rs68170813	0.559	rs4730226	chr7:106887274	A/C	cg02696742	chr7:106810147	HBP1	-0.52	-8.47	-0.32	1.67e-16	Coronary artery disease;
BRCA	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg16486109	chr11:613632	IRF7	0.41	8.77	0.33	1.65e-17	Systemic lupus erythematosus;
BRCA	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-12.9	-0.45	5.18e-34	Response to antipsychotic treatment;
BRCA	cis	rs3092073	0.819	rs3848715	chr20:44564682	G/A	cg17986701	chr20:44574422	PCIF1	-0.32	-7.84	-0.3	1.85e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2580764	0.598	rs2580772	chr2:55218805	G/T	cg09592903	chr2:55203963	RTN4	0.4	10.17	0.37	1.25e-22	Mean platelet volume;
BRCA	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	25.27	0.71	3.16e-98	Body mass index (adult);
BRCA	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg08992911	chr2:238395768	MLPH	0.49	8.16	0.31	1.82e-15	Prostate cancer;
BRCA	cis	rs9811920	0.683	rs7650727	chr3:99688976	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-11.09	-0.4	2.87e-26	Axial length;
BRCA	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg15017067	chr4:17643749	FAM184B	-0.29	-8.72	-0.33	2.44e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg10556349	chr10:835070	NA	0.63	8.68	0.32	3.23e-17	Eosinophil percentage of granulocytes;
BRCA	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg07148914	chr20:33460835	GGT7	0.38	8.57	0.32	7.57e-17	Height;
BRCA	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.03	-0.37	4.35e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg23711669	chr6:146136114	FBXO30	0.64	15.14	0.51	1.72e-44	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.27	7.95	0.3	8.6e-15	Depression;
BRCA	cis	rs26949	0.526	rs10058456	chr5:60037941	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.34	-7.89	-0.3	1.32e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs16958440	1.000	rs62096474	chr18:44647504	G/A	cg17192377	chr18:44677553	HDHD2	0.67	9.8	0.36	3.16e-21	Sitting height ratio;
BRCA	cis	rs12220238	1.000	rs10824129	chr10:76008855	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.5	8.32	0.31	5.44e-16	Soluble interleukin-2 receptor subunit alpha;
BRCA	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg15704280	chr7:45808275	SEPT13	0.59	10.5	0.38	6.77e-24	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs6121246	0.559	rs6060932	chr20:30350545	A/G	cg21427119	chr20:30132790	HM13	-0.36	-8.12	-0.31	2.35e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	17.09	0.56	3.15e-54	Platelet count;
BRCA	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg23711669	chr6:146136114	FBXO30	-0.8	-19.22	-0.61	2.46e-65	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg04455712	chr21:45112962	RRP1B	0.44	12.14	0.43	1.13e-30	Mean corpuscular volume;
BRCA	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg04450456	chr4:17643702	FAM184B	0.37	10.67	0.39	1.39e-24	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03352830	chr11:487213	PTDSS2	0.75	11.75	0.42	5.39e-29	Body mass index;
BRCA	cis	rs9463078	0.774	rs6458441	chr6:45327401	G/T	cg25276700	chr6:44698697	NA	0.35	7.88	0.3	1.42e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg19920283	chr7:105172520	RINT1	0.59	9.4	0.35	9.51e-20	Bipolar disorder (body mass index interaction);
BRCA	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg04234412	chr22:24373322	LOC391322	0.62	15.29	0.52	3.18e-45	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs858239	0.600	rs10256524	chr7:23144947	T/C	cg23682824	chr7:23144976	KLHL7	0.46	12.23	0.44	4.72e-31	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg04450456	chr4:17643702	FAM184B	-0.33	-9.37	-0.35	1.24e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg11887960	chr12:57824829	NA	0.54	8.6	0.32	6.25e-17	Lung disease severity in cystic fibrosis;
BRCA	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg04944784	chr2:26401820	FAM59B	-1.01	-16.81	-0.55	8.38e-53	Gut microbiome composition (summer);
BRCA	cis	rs4845570	1.000	rs6673002	chr1:151743275	G/T	cg07092448	chr1:151763213	TDRKH	0.85	17.12	0.56	2.34e-54	Coronary artery disease;
BRCA	cis	rs10254118	0.757	rs7788086	chr7:133135206	C/T	cg10665199	chr7:133106180	EXOC4	0.48	10.15	0.37	1.53e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg12863693	chr15:85201151	NMB	-0.36	-8.51	-0.32	1.21e-16	P wave terminal force;
BRCA	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg06238570	chr21:40685208	BRWD1	-0.39	-7.94	-0.3	9.01e-15	Menarche (age at onset);
BRCA	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg25036284	chr2:26402008	FAM59B	0.94	13.9	0.48	1.37e-38	Gut microbiome composition (summer);
BRCA	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	14.33	0.49	1.3e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg03433033	chr1:76189801	ACADM	-0.46	-9.39	-0.35	1.01e-19	Daytime sleep phenotypes;
BRCA	trans	rs970548	0.657	rs11239572	chr10:46088061	C/T	cg20477318	chr10:51623047	TIMM23	-0.44	-7.85	-0.3	1.77e-14	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
BRCA	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg22307297	chr20:60903441	LAMA5	0.37	10.02	0.37	4.92e-22	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.49	10.99	0.4	7.21e-26	Cognitive ability;
BRCA	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg11502198	chr6:26597334	ABT1	0.48	9.53	0.35	3.23e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02176678	chr2:219576539	TTLL4	0.54	13.61	0.47	3.15e-37	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10193935	0.786	rs13399052	chr2:42385151	G/A	cg27598129	chr2:42591480	NA	-0.86	-14.67	-0.5	3.26e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg22705602	chr4:152727874	NA	-0.32	-7.88	-0.3	1.44e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg08000102	chr2:233561755	GIGYF2	-0.6	-13.31	-0.47	7.7e-36	Coronary artery disease;
BRCA	cis	rs12541635	0.966	rs55729609	chr8:107056034	A/C	cg10147462	chr8:107024639	NA	0.37	9.74	0.36	5.53e-21	Age of smoking initiation;
BRCA	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg25358565	chr5:93447407	FAM172A	1.14	18.03	0.58	4.84e-59	Diabetic retinopathy;
BRCA	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg24829409	chr8:58192753	C8orf71	-0.48	-8.02	-0.3	5.2e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg00530320	chr1:46809349	NSUN4	0.49	9.75	0.36	5.11e-21	Menopause (age at onset);
BRCA	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-9.18	-0.34	5.87e-19	IgG glycosylation;
BRCA	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.66	-15.95	-0.53	1.91e-48	Ulcerative colitis;
BRCA	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg05340658	chr4:99064831	C4orf37	0.63	14.73	0.5	1.74e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.34	-0.38	2.73e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.44	-0.38	1.1e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg08477640	chr19:41863820	B9D2	0.52	9.97	0.37	7.58e-22	Colorectal cancer;
BRCA	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg04317338	chr11:64019027	PLCB3	0.54	9.59	0.35	1.99e-20	Mean platelet volume;
BRCA	cis	rs7809950	0.954	rs2520242	chr7:107136320	G/T	cg23024343	chr7:107201750	COG5	0.41	9.43	0.35	7.5e-20	Coronary artery disease;
BRCA	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	21.81	0.65	2.95e-79	Platelet count;
BRCA	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.16	-0.31	1.79e-15	Prostate cancer;
BRCA	trans	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg07211511	chr3:129823064	LOC729375	-0.62	-11.06	-0.4	3.89e-26	Blood pressure (smoking interaction);
BRCA	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	10.89	0.4	1.85e-25	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg09307838	chr4:120376055	NA	0.69	14.08	0.49	2.13e-39	Corneal astigmatism;
BRCA	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg18446336	chr7:2847575	GNA12	0.39	9.29	0.34	2.36e-19	Height;
BRCA	cis	rs13053817	1.000	rs71324766	chr22:29839659	A/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.51	-9.52	-0.35	3.61e-20	Carotid atherosclerosis in HIV infection;
BRCA	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg22496339	chr2:162101262	NA	0.58	13.08	0.46	8.37e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
BRCA	cis	rs13136331	0.680	rs2732208	chr4:88650530	C/T	cg22416721	chr4:88570574	DMP1	-0.57	-13.12	-0.46	5.17e-35	Sitting height ratio;
BRCA	cis	rs7474896	0.559	rs2738185	chr10:38247736	G/A	cg25427524	chr10:38739819	LOC399744	0.52	9.61	0.36	1.68e-20	Obesity (extreme);
BRCA	trans	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg06521331	chr12:34319734	NA	-0.46	-8.57	-0.32	8.05e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00149659	chr3:10157352	C3orf10	0.78	13.55	0.47	6.28e-37	Alzheimer's disease;
BRCA	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg12219531	chr12:120966889	COQ5	0.54	11.42	0.41	1.31e-27	High light scatter reticulocyte count;
BRCA	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg20701182	chr2:24300061	SF3B14	0.59	9.19	0.34	5.66e-19	Lymphocyte counts;
BRCA	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg15083037	chr5:83017644	HAPLN1	-0.52	-10.52	-0.38	5.73e-24	Prostate cancer;
BRCA	cis	rs68170813	0.559	rs77150993	chr7:106817100	G/T	cg02696742	chr7:106810147	HBP1	-0.53	-8.49	-0.32	1.47e-16	Coronary artery disease;
BRCA	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	9.59	0.35	1.86e-20	Neuroticism;
BRCA	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg16482183	chr6:26056742	HIST1H1C	0.5	10.34	0.38	2.88e-23	Height;
BRCA	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg12011299	chr4:100065546	ADH4	-0.51	-11.73	-0.42	6.44e-29	Alcohol dependence;
BRCA	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg13010199	chr12:38710504	ALG10B	0.5	9.57	0.35	2.29e-20	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-11.12	-0.4	2.2e-26	Schizophrenia;
BRCA	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg21138405	chr5:131827807	IRF1	0.4	12.97	0.46	2.65e-34	Asthma (sex interaction);
BRCA	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg06494592	chr3:125709126	NA	-0.53	-8.23	-0.31	1.05e-15	Blood pressure (smoking interaction);
BRCA	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg05283184	chr6:79620031	NA	-0.35	-8.15	-0.31	1.9e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg02734326	chr4:10020555	SLC2A9	0.4	8.84	0.33	9.03e-18	Bone mineral density;
BRCA	cis	rs735860	0.687	rs2294852	chr6:53157214	C/G	cg10236188	chr6:53219634	NA	-0.4	-8.55	-0.32	9.02e-17	Glaucoma;
BRCA	cis	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg08807101	chr21:30365312	RNF160	-0.46	-7.94	-0.3	9e-15	Cognitive test performance;
BRCA	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-17.07	-0.56	4.02e-54	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg04455712	chr21:45112962	RRP1B	-0.39	-10.37	-0.38	2.13e-23	Mean corpuscular volume;
BRCA	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg16132339	chr22:24313637	DDTL;DDT	-0.37	-8.03	-0.3	4.68e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg11789530	chr4:8429930	ACOX3	-0.53	-12.3	-0.44	2.44e-31	Response to antineoplastic agents;
BRCA	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.4	9.62	0.36	1.51e-20	Eosinophil percentage of white cells;
BRCA	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.39	8.5	0.32	1.33e-16	Cognitive ability;
BRCA	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.77e-24	Motion sickness;
BRCA	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg04691961	chr3:161091175	C3orf57	-0.54	-12.32	-0.44	1.83e-31	Morning vs. evening chronotype;
BRCA	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	13.53	0.47	7.69e-37	Mean platelet volume;
BRCA	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg26031613	chr14:104095156	KLC1	-0.55	-9.87	-0.36	1.69e-21	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg04166393	chr7:2884313	GNA12	0.42	9.09	0.34	1.23e-18	Height;
BRCA	cis	rs867371	1.000	rs13380319	chr15:82506867	G/T	cg00614314	chr15:82944287	LOC80154	0.42	8.9	0.33	5.82e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg11941060	chr3:133502564	NA	0.47	11.5	0.41	5.85e-28	Iron status biomarkers;
BRCA	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-7.9	-0.3	1.19e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs2455601	0.744	rs11042133	chr11:8966511	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-8.46	-0.32	1.78e-16	Schizophrenia;
BRCA	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg06064525	chr11:970664	AP2A2	-0.49	-16.53	-0.55	2.2e-51	Alzheimer's disease (late onset);
BRCA	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg26384229	chr12:38710491	ALG10B	-0.45	-10.23	-0.38	7.69e-23	Bladder cancer;
BRCA	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg23708337	chr7:1209742	NA	0.49	8.1	0.31	2.8e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs6484504	0.532	rs1475558	chr11:31263428	A/G	cg14844989	chr11:31128820	NA	-0.43	-9.4	-0.35	9.95e-20	Red blood cell count;
BRCA	cis	rs10465746	0.682	rs882897	chr1:84426049	A/T	cg10977910	chr1:84465055	TTLL7	0.57	11.94	0.43	8.09e-30	Obesity-related traits;
BRCA	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.66	0.36	1.06e-20	Bipolar disorder;
BRCA	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg09537434	chr19:41945824	ATP5SL	-0.99	-23.27	-0.68	3.29e-87	Height;
BRCA	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg14926445	chr8:58193284	C8orf71	-0.44	-8.58	-0.32	7.45e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.03	-0.3	4.72e-15	Extrinsic epigenetic age acceleration;
BRCA	trans	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg06521331	chr12:34319734	NA	-0.46	-8.52	-0.32	1.16e-16	Bladder cancer;
BRCA	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg13628971	chr7:2884303	GNA12	0.39	8.61	0.32	5.5e-17	Height;
BRCA	cis	rs7851660	0.967	rs1443434	chr9:100617479	G/T	cg13688889	chr9:100608707	NA	-0.36	-8.7	-0.33	2.78e-17	Strep throat;
BRCA	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg18252515	chr7:66147081	NA	-1.07	-15.92	-0.53	2.69e-48	Diabetic kidney disease;
BRCA	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg13047869	chr3:10149882	C3orf24	0.51	9.64	0.36	1.25e-20	Alzheimer's disease;
BRCA	cis	rs68170813	0.559	rs6947675	chr7:106817184	T/C	cg02696742	chr7:106810147	HBP1	-0.54	-8.91	-0.33	5.32e-18	Coronary artery disease;
BRCA	cis	rs4363385	0.818	rs684305	chr1:153006242	G/A	cg25856811	chr1:152973957	SPRR3	-0.32	-8.49	-0.32	1.49e-16	Inflammatory skin disease;
BRCA	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg22153463	chr1:85462885	MCOLN2	-0.64	-11.75	-0.42	5.41e-29	Serum sulfate level;
BRCA	cis	rs7903847	0.642	rs1537646	chr10:99149922	T/C	cg20016023	chr10:99160130	RRP12	-0.27	-8.64	-0.32	4.5e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg05025164	chr4:1340916	KIAA1530	0.77	15.38	0.52	1.16e-45	Longevity;
BRCA	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg16472389	chr18:74514291	NA	0.47	10.12	0.37	1.98e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
BRCA	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg14829155	chr15:31115871	NA	0.42	10.09	0.37	2.53e-22	Huntington's disease progression;
BRCA	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg08392591	chr16:89556376	ANKRD11	-0.34	-7.99	-0.3	6.43e-15	Multiple myeloma (IgH translocation);
BRCA	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.82	0.39	3.64e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs7493	0.901	rs13226149	chr7:95025600	G/A	cg19678392	chr7:94953810	PON1	-0.4	-8.17	-0.31	1.65e-15	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs7520050	0.966	rs1085243	chr1:46544768	C/T	cg24296786	chr1:45957014	TESK2	0.41	9.19	0.34	5.42e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-11.58	-0.42	2.72e-28	Monocyte percentage of white cells;
BRCA	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg26384229	chr12:38710491	ALG10B	0.77	17.07	0.56	4.14e-54	Morning vs. evening chronotype;
BRCA	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg26818010	chr10:134567672	INPP5A	-0.78	-15.37	-0.52	1.39e-45	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs7474896	0.559	rs1735641	chr10:38184852	C/A	cg25427524	chr10:38739819	LOC399744	0.55	9.72	0.36	6.48e-21	Obesity (extreme);
BRCA	cis	rs4363385	0.818	rs2651413	chr1:153012068	T/A	cg25856811	chr1:152973957	SPRR3	-0.33	-8.58	-0.32	7.47e-17	Inflammatory skin disease;
BRCA	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg03585969	chr10:35415529	CREM	0.56	11.68	0.42	1.08e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg01483505	chr11:975446	AP2A2	0.33	8.9	0.33	5.62e-18	Alzheimer's disease (late onset);
BRCA	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg05347473	chr6:146136440	FBXO30	-0.43	-8.57	-0.32	7.79e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg18252515	chr7:66147081	NA	-0.42	-9.15	-0.34	7.85e-19	Corneal structure;
BRCA	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg06191203	chr2:152266755	RIF1	-0.34	-9.0	-0.34	2.46e-18	Squamous cell lung carcinoma;
BRCA	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.62	-14.36	-0.49	9.47e-41	Ulcerative colitis;
BRCA	cis	rs2882667	0.515	rs13161286	chr5:138484105	A/G	cg04439458	chr5:138467593	SIL1	-0.46	-11.1	-0.4	2.69e-26	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs10129255	0.500	rs4774008	chr14:107137290	A/T	cg07958169	chr14:107095056	NA	-0.43	-9.09	-0.34	1.2e-18	Kawasaki disease;
BRCA	cis	rs3812565	0.506	rs8413	chr9:139323311	T/C	cg14169450	chr9:139327907	INPP5E	0.51	12.08	0.43	2.16e-30	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg06784218	chr1:46089804	CCDC17	0.5	12.02	0.43	3.67e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.71	12.05	0.43	2.89e-30	Schizophrenia;
BRCA	cis	rs4953318	0.619	rs12105417	chr2:46361255	A/C	cg12428440	chr2:46370979	PRKCE	0.49	10.69	0.39	1.14e-24	Red blood cell count;Hematocrit;Red blood cell traits;
BRCA	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg15212455	chr7:39170539	POU6F2	0.43	9.55	0.35	2.68e-20	IgG glycosylation;
BRCA	cis	rs7707921	0.881	rs7733122	chr5:81351443	C/T	cg15871215	chr5:81402204	ATG10	-0.39	-8.2	-0.31	1.32e-15	Breast cancer;
BRCA	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	9.86	0.36	1.94e-21	Aortic root size;
BRCA	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg05985134	chr18:33552581	C18orf21	0.61	11.01	0.4	6.47e-26	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg18225595	chr11:63971243	STIP1	0.5	8.89	0.33	6.26e-18	Mean platelet volume;
BRCA	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.88	-0.3	1.4e-14	Electroencephalogram traits;
BRCA	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg04362960	chr10:104952993	NT5C2	0.45	10.38	0.38	1.89e-23	Arsenic metabolism;
BRCA	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg14019146	chr3:50243930	SLC38A3	0.34	7.89	0.3	1.31e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.61	-10.54	-0.38	4.62e-24	Body mass index (adult);
BRCA	cis	rs6570726	0.516	rs10457779	chr6:145736663	C/T	cg23711669	chr6:146136114	FBXO30	0.46	9.51	0.35	3.72e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg25204440	chr1:209979598	IRF6	0.42	8.25	0.31	8.77e-16	Cleft lip with or without cleft palate;
BRCA	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	8.99	0.34	2.67e-18	Personality dimensions;
BRCA	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.49	8.09	0.3	2.96e-15	Renal function-related traits (BUN);
BRCA	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg01017244	chr2:74357527	NA	0.57	13.29	0.47	9e-36	Gestational age at birth (maternal effect);
BRCA	trans	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg26043149	chr18:55253948	FECH	0.39	8.38	0.31	3.34e-16	Bone mineral density;
BRCA	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg18252515	chr7:66147081	NA	-0.9	-12.92	-0.46	4.23e-34	Diabetic kidney disease;
BRCA	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg05340658	chr4:99064831	C4orf37	0.48	11.17	0.4	1.35e-26	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg01620082	chr3:125678407	NA	-0.83	-10.07	-0.37	2.97e-22	Depression;
BRCA	cis	rs701145	0.537	rs357471	chr3:153896403	C/T	cg17054900	chr3:154042577	DHX36	0.57	9.56	0.35	2.56e-20	Coronary artery disease;
BRCA	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12923728	chr3:195709715	SDHAP1	-0.6	-13.12	-0.46	5.69e-35	Pancreatic cancer;
BRCA	cis	rs9473147	0.503	rs2171086	chr6:47590104	C/T	cg12968598	chr6:47444699	CD2AP	0.44	9.63	0.36	1.38e-20	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg16386425	chr10:429943	DIP2C	-0.44	-9.36	-0.35	1.33e-19	Psychosis in Alzheimer's disease;
BRCA	cis	rs4363385	0.747	rs6671524	chr1:152974247	C/G	cg25856811	chr1:152973957	SPRR3	-0.35	-9.33	-0.35	1.69e-19	Inflammatory skin disease;
BRCA	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg06970220	chr1:156163860	SLC25A44	0.35	8.87	0.33	7.14e-18	Testicular germ cell tumor;
BRCA	cis	rs7246967	0.673	rs34126042	chr19:22909218	G/A	cg23217946	chr19:22817039	ZNF492	0.5	9.12	0.34	9.65e-19	Bronchopulmonary dysplasia;
BRCA	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg27446573	chr6:127587934	RNF146	0.69	15.82	0.53	8.25e-48	Breast cancer;
BRCA	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg21475434	chr5:93447410	FAM172A	-0.66	-8.58	-0.32	7.39e-17	Diabetic retinopathy;
BRCA	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.29	8.9	0.33	5.67e-18	Bipolar disorder;
BRCA	cis	rs34779708	0.733	rs4391768	chr10:35547595	A/G	cg03585969	chr10:35415529	CREM	0.44	9.1	0.34	1.17e-18	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs6942756	1.000	rs6971917	chr7:128976919	G/A	cg02491457	chr7:128862824	NA	-0.71	-14.05	-0.49	3e-39	White matter hyperintensity burden;
BRCA	cis	rs4853036	1.000	rs12614581	chr2:70079400	C/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-9.04	-0.34	1.85e-18	Colorectal or endometrial cancer;
BRCA	trans	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg25206134	chr2:45395956	NA	0.5	7.94	0.3	8.92e-15	Neuroticism;
BRCA	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.07	0.3	3.55e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg04691961	chr3:161091175	C3orf57	-0.58	-13.51	-0.47	9.25e-37	Morning vs. evening chronotype;
BRCA	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg19508488	chr2:152266495	RIF1	-0.51	-10.37	-0.38	2.1e-23	Lung cancer;
BRCA	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	14.55	0.5	1.27e-41	Motion sickness;
BRCA	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.7	-11.47	-0.41	7.65e-28	Red cell distribution width;
BRCA	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.27	-0.31	7.85e-16	Bipolar disorder;
BRCA	cis	rs2882667	0.690	rs185956	chr5:138230263	A/G	cg04439458	chr5:138467593	SIL1	-0.34	-8.28	-0.31	7.37e-16	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.42	9.69	0.36	7.95e-21	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs7833986	1.000	rs36088882	chr8:57092914	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.46	8.22	0.31	1.12e-15	Height;
BRCA	cis	rs7572733	0.534	rs1401091	chr2:198790423	T/G	cg00792783	chr2:198669748	PLCL1	-0.46	-10.01	-0.37	5.34e-22	Dermatomyositis;
BRCA	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg21535247	chr6:8435926	SLC35B3	0.41	9.28	0.34	2.61e-19	Motion sickness;
BRCA	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg13010199	chr12:38710504	ALG10B	0.5	9.83	0.36	2.4e-21	Morning vs. evening chronotype;
BRCA	cis	rs68170813	0.523	rs12535093	chr7:107020182	C/T	cg02696742	chr7:106810147	HBP1	-0.5	-8.43	-0.32	2.38e-16	Coronary artery disease;
BRCA	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg11752832	chr7:134001865	SLC35B4	0.52	13.46	0.47	1.53e-36	Mean platelet volume;
BRCA	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg06085985	chr11:830527	EFCAB4A	-0.41	-8.99	-0.33	2.87e-18	Mean platelet volume;
BRCA	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg02544614	chr20:61657117	NA	0.28	8.04	0.3	4.32e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg07636037	chr3:49044803	WDR6	-0.53	-11.64	-0.42	1.49e-28	Resting heart rate;
BRCA	cis	rs16854884	0.584	rs34372603	chr3:143738249	T/C	cg06585982	chr3:143692056	C3orf58	0.42	8.93	0.33	4.41e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs965469	1.000	rs6051764	chr20:3321807	A/G	cg25506879	chr20:3388711	C20orf194	0.5	9.87	0.36	1.81e-21	IFN-related cytopenia;
BRCA	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg23625390	chr15:77176239	SCAPER	0.44	11.17	0.4	1.35e-26	Blood metabolite levels;
BRCA	cis	rs1635	0.826	rs4711167	chr6:28294888	C/T	cg15743358	chr6:28303923	ZNF323	0.7	7.96	0.3	8.09e-15	Schizophrenia;
BRCA	cis	rs11051970	0.636	rs2651368	chr12:32561506	T/C	cg24626660	chr12:32551988	NA	0.31	9.26	0.34	2.98e-19	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs2354432	0.607	rs10900350	chr1:146828017	T/G	cg25205988	chr1:146714368	CHD1L	0.88	12.48	0.44	3.69e-32	Mitochondrial DNA levels;
BRCA	cis	rs1113500	1.000	rs1113500	chr1:108595442	G/T	cg06207961	chr1:108661230	NA	-0.44	-10.46	-0.38	9.38e-24	Growth-regulated protein alpha levels;
BRCA	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.66	-14.28	-0.49	2.27e-40	Lung cancer;
BRCA	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg19628046	chr18:33552617	C18orf21	0.52	10.7	0.39	1.12e-24	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg21535247	chr6:8435926	SLC35B3	-0.37	-8.24	-0.31	9.62e-16	Motion sickness;
BRCA	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg04944784	chr2:26401820	FAM59B	0.95	16.17	0.54	1.43e-49	Gut microbiome composition (summer);
BRCA	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.59	-0.32	6.46e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-8.87	-0.33	7.01e-18	Mean corpuscular volume;
BRCA	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg13319975	chr6:146136371	FBXO30	-0.61	-13.7	-0.48	1.28e-37	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg11189052	chr15:85197271	WDR73	-0.33	-7.99	-0.3	6.37e-15	P wave terminal force;
BRCA	cis	rs965469	0.779	rs2236088	chr20:3256342	T/C	cg25506879	chr20:3388711	C20orf194	-0.45	-9.1	-0.34	1.12e-18	IFN-related cytopenia;
BRCA	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg03060546	chr3:49711283	APEH	0.55	10.57	0.39	3.69e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg15819921	chr19:927150	ARID3A	-0.48	-9.17	-0.34	6.67e-19	Life satisfaction;
BRCA	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg24558204	chr6:135376177	HBS1L	0.46	12.39	0.44	9.78e-32	Red blood cell count;
BRCA	cis	rs9400271	0.632	rs949882	chr6:109586062	A/G	cg01475377	chr6:109611718	NA	0.42	10.16	0.37	1.43e-22	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg06808227	chr14:105710500	BRF1	-0.74	-15.16	-0.51	1.39e-44	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs4535700	0.501	rs57251705	chr7:55981083	A/G	cg09872392	chr7:56161020	PHKG1	0.35	8.04	0.3	4.43e-15	Macular telangiectasia type 2;
BRCA	cis	rs11051970	0.879	rs2651363	chr12:32587550	G/T	cg02745156	chr12:32552066	NA	-0.26	-8.6	-0.32	6.07e-17	Response to tocilizumab in rheumatoid arthritis;
BRCA	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg21427119	chr20:30132790	HM13	0.42	8.92	0.33	4.92e-18	Mean corpuscular hemoglobin;
BRCA	cis	rs838147	0.760	rs12979144	chr19:49237547	G/A	cg13540341	chr19:49222985	MAMSTR	0.34	9.18	0.34	5.71e-19	Dietary macronutrient intake;
BRCA	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg26597838	chr10:835615	NA	1.02	17.81	0.58	6.25e-58	Eosinophil percentage of granulocytes;
BRCA	trans	rs2235573	0.625	rs8142174	chr22:38427963	C/T	cg19894588	chr14:64061835	NA	0.33	7.96	0.3	7.76e-15	Glioblastoma;Glioma;
BRCA	cis	rs9790314	0.638	rs6441339	chr3:160619683	T/G	cg03342759	chr3:160939853	NMD3	0.44	8.86	0.33	7.58e-18	Morning vs. evening chronotype;
BRCA	trans	rs3858145	0.588	rs76854765	chr10:70037456	C/T	cg04882175	chr6:131122610	NA	-0.34	-8.23	-0.31	1.08e-15	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
BRCA	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg00031303	chr3:195681400	NA	-0.4	-8.44	-0.32	2.11e-16	Bronchopulmonary dysplasia;
BRCA	cis	rs6687430	0.562	rs12139169	chr1:10635328	C/T	cg17425144	chr1:10567563	PEX14	0.5	11.61	0.42	2.18e-28	Hand grip strength;
BRCA	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.71	18.88	0.6	1.66e-63	Chronic sinus infection;
BRCA	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	13.21	0.46	2.18e-35	Neuroticism;
BRCA	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg16414030	chr3:133502952	NA	-0.47	-11.1	-0.4	2.73e-26	Iron status biomarkers;
BRCA	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg17724175	chr1:150552817	MCL1	0.25	8.33	0.31	4.95e-16	Tonsillectomy;
BRCA	cis	rs11971779	0.680	rs7799598	chr7:139051833	C/T	cg07862535	chr7:139043722	LUC7L2	0.38	10.28	0.38	4.63e-23	Diisocyanate-induced asthma;
BRCA	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg19156104	chr2:198669113	PLCL1	0.45	8.32	0.31	5.29e-16	Ulcerative colitis;
BRCA	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	8.46	0.32	1.76e-16	Educational attainment;
BRCA	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg06917634	chr15:78832804	PSMA4	-0.57	-12.79	-0.45	1.65e-33	Sudden cardiac arrest;
BRCA	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg14675211	chr2:100938903	LONRF2	0.46	10.46	0.38	9.25e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg03188948	chr7:1209495	NA	0.86	11.78	0.42	3.91e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18402987	chr7:1209562	NA	0.65	14.8	0.51	7.44e-43	Longevity;Endometriosis;
BRCA	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg27284194	chr4:1044797	NA	0.43	9.24	0.34	3.55e-19	Recombination rate (males);
BRCA	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg10523679	chr1:76189770	ACADM	-0.76	-16.11	-0.54	2.86e-49	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg08508325	chr11:3079039	CARS	0.28	8.46	0.32	1.77e-16	Calcium levels;
BRCA	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18404041	chr3:52824283	ITIH1	-0.41	-12.17	-0.43	8.58e-31	Bipolar disorder;
BRCA	cis	rs7927771	0.524	rs7129797	chr11:47667167	G/C	cg20307385	chr11:47447363	PSMC3	0.42	9.51	0.35	3.9e-20	Subjective well-being;
BRCA	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg17063962	chr7:91808500	NA	-0.55	-12.09	-0.43	1.9e-30	Breast cancer;
BRCA	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg04944784	chr2:26401820	FAM59B	0.8	11.11	0.4	2.45e-26	Gut microbiome composition (summer);
BRCA	cis	rs9942416	0.601	rs40059	chr5:74964582	A/G	cg19683494	chr5:74908142	NA	-0.45	-8.42	-0.32	2.57e-16	Age-related disease endophenotypes;
BRCA	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-13.11	-0.46	6.35e-35	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg08000102	chr2:233561755	GIGYF2	0.62	13.46	0.47	1.48e-36	Coronary artery disease;
BRCA	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg14863265	chr7:2801509	GNA12	-0.45	-9.6	-0.36	1.74e-20	Height;
BRCA	cis	rs7590720	1.000	rs4674051	chr2:216907512	G/C	cg12620499	chr2:216877984	MREG	0.79	22.46	0.66	8.6e-83	Alcohol dependence;
BRCA	trans	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	14.63	0.5	5.38e-42	Spherical equivalent (joint analysis main effects and education interaction);
BRCA	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg02196655	chr2:10830764	NOL10	-0.3	-8.03	-0.3	4.84e-15	Prostate cancer;
BRCA	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg23711669	chr6:146136114	FBXO30	0.75	17.43	0.57	6.04e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22307029	chr19:49891270	CCDC155	0.53	8.83	0.33	1.04e-17	Multiple sclerosis;
BRCA	cis	rs2806561	1.000	rs2806558	chr1:23503456	T/C	cg19743168	chr1:23544995	NA	0.4	9.6	0.36	1.74e-20	Height;
BRCA	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24531977	chr5:56204891	C5orf35	0.99	20.06	0.62	8.25e-70	Initial pursuit acceleration;
BRCA	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg14993813	chr1:46806288	NSUN4	-0.48	-9.17	-0.34	6.63e-19	Menopause (age at onset);
BRCA	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg24069376	chr3:38537580	EXOG	0.31	8.7	0.33	2.85e-17	Electrocardiographic conduction measures;
BRCA	cis	rs9811920	0.898	rs7636776	chr3:99840446	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.53	12.53	0.44	2.29e-32	Axial length;
BRCA	cis	rs7766436	0.767	rs7764914	chr6:22601548	T/G	cg13666174	chr6:22585274	NA	-0.37	-9.48	-0.35	4.99e-20	Coronary artery disease;
BRCA	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg05340658	chr4:99064831	C4orf37	-0.44	-10.19	-0.37	1.06e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14829155	chr15:31115871	NA	0.51	13.06	0.46	9.68e-35	Huntington's disease progression;
BRCA	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.37	-9.53	-0.35	3.1e-20	Total body bone mineral density;
BRCA	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg08885076	chr2:99613938	TSGA10	-0.52	-11.8	-0.42	3.27e-29	Chronic sinus infection;
BRCA	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg18252515	chr7:66147081	NA	-0.88	-12.63	-0.45	8.19e-33	Diabetic kidney disease;
BRCA	cis	rs11920090	0.932	rs2292622	chr3:170723664	A/G	cg09710316	chr3:170744871	SLC2A2	0.41	7.89	0.3	1.31e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
BRCA	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg08822215	chr16:89438651	ANKRD11	-0.4	-8.58	-0.32	6.96e-17	Multiple myeloma (IgH translocation);
BRCA	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-9.96	-0.37	7.99e-22	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11644478	chr21:40555479	PSMG1	0.84	19.34	0.61	6.13e-66	Cognitive function;
BRCA	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg20891283	chr12:69753455	YEATS4	0.73	21.96	0.66	4.86e-80	Blood protein levels;
BRCA	trans	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg26384229	chr12:38710491	ALG10B	0.51	11.03	0.4	4.98e-26	Morning vs. evening chronotype;
BRCA	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-11.12	-0.4	2.2e-26	Schizophrenia;
BRCA	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08219700	chr8:58056026	NA	0.45	8.35	0.31	4.18e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs9790314	0.637	rs778643	chr3:160706041	G/A	cg03342759	chr3:160939853	NMD3	-0.46	-8.84	-0.33	9.06e-18	Morning vs. evening chronotype;
BRCA	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg03146154	chr1:46216737	IPP	-0.5	-11.01	-0.4	6.25e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg08213375	chr14:104286397	PPP1R13B	0.64	18.2	0.58	6.11e-60	Schizophrenia;
BRCA	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg24558204	chr6:135376177	HBS1L	-0.44	-12.13	-0.43	1.23e-30	Red blood cell count;
BRCA	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg24829409	chr8:58192753	C8orf71	-0.48	-9.25	-0.34	3.23e-19	Developmental language disorder (linguistic errors);
BRCA	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg14863265	chr7:2801509	GNA12	-0.48	-10.57	-0.39	3.71e-24	Height;
BRCA	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03517284	chr6:25882590	NA	-0.52	-10.59	-0.39	3.05e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11764359	chr7:65958608	NA	-0.76	-16.79	-0.55	1.17e-52	Aortic root size;
BRCA	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg04455712	chr21:45112962	RRP1B	0.4	10.44	0.38	1.19e-23	Mean corpuscular volume;
BRCA	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg22875332	chr1:76189707	ACADM	0.8	19.06	0.6	1.81e-64	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg05425664	chr17:57184151	TRIM37	0.39	9.59	0.35	1.97e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg16482183	chr6:26056742	HIST1H1C	0.56	11.86	0.42	1.79e-29	Height;
BRCA	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg14558114	chr2:88469736	THNSL2	0.63	9.13	0.34	8.88e-19	Plasma clusterin levels;
BRCA	cis	rs2073300	1.000	rs6132626	chr20:23444672	T/C	cg12062639	chr20:23401060	NAPB	0.89	10.63	0.39	2.06e-24	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs12711979	0.509	rs13000873	chr2:3823705	T/C	cg17052675	chr2:3827356	NA	-0.7	-23.81	-0.69	3.44e-90	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs6740322	0.895	rs10172375	chr2:43572047	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-12.36	-0.44	1.32e-31	Coronary artery disease;
BRCA	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg16339924	chr4:17578868	LAP3	0.63	15.75	0.53	1.77e-47	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	5.83e-21	Developmental language disorder (linguistic errors);
BRCA	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg17830980	chr10:43048298	ZNF37B	-0.56	-13.72	-0.48	9.54e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06028605	chr16:24865363	SLC5A11	0.46	10.09	0.37	2.6e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs7072216	0.727	rs7901577	chr10:100164442	A/G	cg26618903	chr10:100175079	PYROXD2	-0.31	-8.67	-0.32	3.68e-17	Metabolite levels;
BRCA	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg20290983	chr6:43655470	MRPS18A	0.94	21.38	0.65	6.59e-77	IgG glycosylation;
BRCA	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	8.03	0.3	4.62e-15	Tonsillectomy;
BRCA	cis	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.28	-0.41	5.11e-27	Morning vs. evening chronotype;
BRCA	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.35	-8.5	-0.32	1.31e-16	Total body bone mineral density;
BRCA	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg00277334	chr10:82204260	NA	-0.49	-10.31	-0.38	3.77e-23	Post bronchodilator FEV1;
BRCA	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-9.11	-0.34	1.01e-18	Educational attainment;
BRCA	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg23719950	chr11:63933701	MACROD1	0.57	9.75	0.36	4.94e-21	Mean platelet volume;
BRCA	trans	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.35	8.0	0.3	5.99e-15	Corneal astigmatism;
BRCA	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg03711944	chr11:47377212	SPI1	-0.4	-9.64	-0.36	1.27e-20	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg24112000	chr20:60950667	NA	0.52	11.2	0.41	1.01e-26	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
BRCA	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg24846343	chr22:24311635	DDTL	-0.58	-14.86	-0.51	4.11e-43	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg13010199	chr12:38710504	ALG10B	0.49	9.62	0.36	1.5e-20	Morning vs. evening chronotype;
BRCA	trans	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg01620082	chr3:125678407	NA	-0.7	-8.26	-0.31	8.19e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg09307838	chr4:120376055	NA	-0.44	-9.08	-0.34	1.3e-18	Diastolic blood pressure;
BRCA	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg21138405	chr5:131827807	IRF1	-0.39	-12.6	-0.45	1.12e-32	Asthma (sex interaction);
BRCA	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg21535247	chr6:8435926	SLC35B3	0.42	9.52	0.35	3.54e-20	Motion sickness;
BRCA	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg24562669	chr7:97807699	LMTK2	0.46	12.18	0.43	7.51e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6750047	0.932	rs2116232	chr2:38268718	C/A	cg07380506	chr2:38303506	CYP1B1	0.42	9.79	0.36	3.48e-21	Cutaneous malignant melanoma;Melanoma;
BRCA	cis	rs7520050	0.808	rs11211195	chr1:46282295	T/C	cg24296786	chr1:45957014	TESK2	0.44	9.83	0.36	2.51e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9473147	0.516	rs6931478	chr6:47461913	C/A	cg12968598	chr6:47444699	CD2AP	0.44	9.7	0.36	7.62e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs2455799	0.574	rs2455800	chr3:15701589	T/G	cg16303742	chr3:15540471	COLQ	-0.35	-8.49	-0.32	1.4e-16	Mean platelet volume;
BRCA	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg04025307	chr7:1156635	C7orf50	-0.55	-12.69	-0.45	4.5e-33	Longevity;Endometriosis;
BRCA	cis	rs16866061	1.000	rs72974205	chr2:225408468	C/T	cg12698349	chr2:225449008	CUL3	0.79	20.58	0.63	1.38e-72	Acute graft versus host disease in bone marrow transplantation (recipient effect);
BRCA	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg22920501	chr2:26401640	FAM59B	0.9	13.73	0.48	9.17e-38	Gut microbiome composition (summer);
BRCA	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg03864215	chr11:17408437	KCNJ11	-0.27	-7.98	-0.3	7e-15	Type 2 diabetes;
BRCA	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg18132916	chr6:79620363	NA	-0.48	-10.93	-0.4	1.31e-25	Intelligence (multi-trait analysis);
BRCA	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg26384229	chr12:38710491	ALG10B	0.69	14.64	0.5	4.65e-42	Morning vs. evening chronotype;
BRCA	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg12564285	chr5:131593104	PDLIM4	0.38	9.67	0.36	1e-20	Acylcarnitine levels;
BRCA	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	11.99	0.43	5.21e-30	Hip circumference adjusted for BMI;
BRCA	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg05347473	chr6:146136440	FBXO30	0.4	7.94	0.3	9.43e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	19.85	0.62	1.19e-68	Exhaled nitric oxide output;
BRCA	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg01191920	chr7:158217561	PTPRN2	-0.45	-10.42	-0.38	1.4e-23	Obesity-related traits;
BRCA	cis	rs929596	0.517	rs1875263	chr2:234625622	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-10.87	-0.4	2.2e-25	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs7631605	0.608	rs62239460	chr3:37442910	A/G	cg15934958	chr3:37212084	LRRFIP2	0.38	7.85	0.3	1.77e-14	Cerebrospinal P-tau181p levels;
BRCA	trans	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg26384229	chr12:38710491	ALG10B	0.44	10.72	0.39	8.67e-25	Morning vs. evening chronotype;
BRCA	trans	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg26043149	chr18:55253948	FECH	-0.36	-7.92	-0.3	1.05e-14	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs586533	0.813	rs1790262	chr11:99495651	T/A	cg22878054	chr11:99397252	CNTN5	0.31	7.81	0.3	2.39e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg00666640	chr1:248458726	OR2T12	0.3	8.42	0.32	2.5e-16	Common traits (Other);
BRCA	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg09307838	chr4:120376055	NA	0.61	11.98	0.43	5.74e-30	Corneal astigmatism;
BRCA	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	10.07	0.37	3.06e-22	Bipolar disorder;
BRCA	cis	rs12530845	0.887	rs73725434	chr7:135313657	T/C	cg23117316	chr7:135346802	PL-5283	-0.35	-8.37	-0.31	3.66e-16	Red blood cell traits;
BRCA	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24531977	chr5:56204891	C5orf35	0.71	15.67	0.53	4.4e-47	Initial pursuit acceleration;
BRCA	cis	rs11971779	0.838	rs58074268	chr7:139108925	C/T	cg07862535	chr7:139043722	LUC7L2	0.43	11.54	0.42	3.99e-28	Diisocyanate-induced asthma;
BRCA	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.38	8.33	0.31	4.85e-16	Cognitive ability;
BRCA	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-16.94	-0.56	2e-53	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg01877450	chr7:97915802	BRI3	-0.39	-8.86	-0.33	7.95e-18	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg23708337	chr7:1209742	NA	0.48	8.15	0.31	1.94e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4363385	0.818	rs1750309	chr1:153013630	G/C	cg24667326	chr1:152973720	SPRR3	-0.32	-8.51	-0.32	1.22e-16	Inflammatory skin disease;
BRCA	cis	rs3772130	0.961	rs11716984	chr3:121362407	A/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.54	9.5	0.35	4.22e-20	Cognitive performance;
BRCA	cis	rs7833986	0.501	rs9650314	chr8:56903610	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	12.57	0.45	1.6e-32	Height;
BRCA	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg01877450	chr7:97915802	BRI3	-0.38	-8.56	-0.32	8.45e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs6973256	0.897	rs763644	chr7:133343349	G/C	cg07491979	chr7:133331646	EXOC4	-0.39	-9.03	-0.34	2.04e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.65	-14.59	-0.5	7.82e-42	Multiple sclerosis;
BRCA	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26314531	chr2:26401878	FAM59B	-0.65	-11.19	-0.4	1.1e-26	Gut microbiome composition (summer);
BRCA	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00149659	chr3:10157352	C3orf10	0.72	12.57	0.45	1.49e-32	Alzheimer's disease;
BRCA	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg13736514	chr6:26305472	NA	-0.37	-12.59	-0.45	1.29e-32	Educational attainment;
BRCA	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18876405	chr7:65276391	NA	0.52	11.65	0.42	1.43e-28	Aortic root size;
BRCA	cis	rs2882667	0.824	rs1560656	chr5:138470789	A/G	cg04439458	chr5:138467593	SIL1	0.42	10.74	0.39	7.69e-25	Age-related hearing impairment (SNP x SNP interaction);
BRCA	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03452623	chr4:187889614	NA	-0.32	-10.37	-0.38	2.09e-23	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6120849	0.901	rs6088735	chr20:33745676	C/T	cg24642439	chr20:33292090	TP53INP2	0.47	8.45	0.32	1.99e-16	Protein C levels;
BRCA	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.35	-0.41	2.61e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg09184832	chr6:79620586	NA	-0.5	-11.04	-0.4	4.73e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs1451375	1.000	rs10247443	chr7:50620586	G/A	cg18232548	chr7:50535776	DDC	0.44	10.21	0.37	8.96e-23	Malaria;
BRCA	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg14683738	chr19:37701593	ZNF585B	0.45	8.03	0.3	4.85e-15	Coronary artery calcification;
BRCA	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg06060754	chr5:176797920	RGS14	0.67	10.47	0.38	9.09e-24	Urate levels in lean individuals;
BRCA	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg18512352	chr11:47633146	NA	0.32	7.91	0.3	1.13e-14	Subjective well-being;
BRCA	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg00684032	chr4:1343700	KIAA1530	-0.34	-8.83	-0.33	1.03e-17	Obesity-related traits;
BRCA	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	10.04	0.37	3.92e-22	Bipolar disorder;
BRCA	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23583168	chr7:148888333	NA	-0.76	-17.35	-0.57	1.58e-55	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg25358565	chr5:93447407	FAM172A	1.17	18.51	0.59	1.52e-61	Diabetic retinopathy;
BRCA	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg26248373	chr2:1572462	NA	-0.49	-9.59	-0.35	1.96e-20	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg07460842	chr6:66804631	NA	-0.84	-15.05	-0.51	5.01e-44	Exhaled nitric oxide levels;
BRCA	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg09263875	chr16:632152	PIGQ	0.73	21.27	0.64	2.61e-76	Height;
BRCA	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg18964960	chr10:1102726	WDR37	0.66	9.21	0.34	4.67e-19	Eosinophil percentage of granulocytes;
BRCA	cis	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.35	-7.94	-0.3	9.03e-15	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs1691799	0.867	rs1168333	chr12:66761377	G/A	cg16791601	chr12:66731901	HELB	-0.59	-15.64	-0.53	6.15e-47	White blood cell count (basophil);
BRCA	cis	rs7520050	0.966	rs785520	chr1:46568836	T/C	cg24296786	chr1:45957014	TESK2	0.41	9.14	0.34	8.37e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg06238570	chr21:40685208	BRWD1	-0.45	-8.98	-0.33	3.03e-18	Cognitive function;
BRCA	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-9.54	-0.35	3.04e-20	Alzheimer's disease (late onset);
BRCA	cis	rs7607369	0.536	rs11892469	chr2:219669488	A/T	cg02176678	chr2:219576539	TTLL4	-0.38	-10.14	-0.37	1.65e-22	Red blood cell count;Amyotrophic lateral sclerosis;
BRCA	trans	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg21659725	chr3:3221576	CRBN	-0.49	-8.5	-0.32	1.31e-16	Menarche (age at onset);
BRCA	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg20887711	chr4:1340912	KIAA1530	0.41	9.97	0.37	7.71e-22	Longevity;
BRCA	trans	rs1829883	0.841	rs2948730	chr5:98723663	G/A	cg08333243	chr5:99726346	NA	0.34	8.46	0.32	1.77e-16	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg05347473	chr6:146136440	FBXO30	0.43	8.58	0.32	7.42e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg01877450	chr7:97915802	BRI3	-0.39	-8.6	-0.32	6e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	26.68	0.73	5.88e-106	Chronic sinus infection;
BRCA	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg17063962	chr7:91808500	NA	0.52	12.12	0.43	1.37e-30	Breast cancer;
BRCA	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg13319975	chr6:146136371	FBXO30	-0.38	-8.58	-0.32	7.02e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg04362960	chr10:104952993	NT5C2	0.94	14.64	0.5	4.47e-42	Arsenic metabolism;
BRCA	trans	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg25214090	chr10:38739885	LOC399744	0.53	11.98	0.43	5.63e-30	Corneal astigmatism;
BRCA	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg01483505	chr11:975446	AP2A2	0.33	9.0	0.34	2.53e-18	Alzheimer's disease (late onset);
BRCA	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg14004847	chr7:1930337	MAD1L1	-0.39	-8.2	-0.31	1.34e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg01877450	chr7:97915802	BRI3	-0.38	-8.62	-0.32	5.33e-17	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.61	-12.82	-0.45	1.23e-33	Lymphocyte counts;
BRCA	cis	rs4074536	0.536	rs6670402	chr1:116289786	G/C	cg21648376	chr1:116311395	CASQ2	-0.49	-8.71	-0.33	2.5e-17	QRS duration;
BRCA	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.49	9.92	0.37	1.11e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19626725	chr5:178986131	RUFY1	-0.36	-11.19	-0.4	1.11e-26	Lung cancer;
BRCA	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg12011299	chr4:100065546	ADH4	0.33	8.83	0.33	9.94e-18	Alcohol dependence;
BRCA	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg23711669	chr6:146136114	FBXO30	-0.76	-17.5	-0.57	2.51e-56	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs698833	0.886	rs4953091	chr2:44565266	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	-0.53	-10.83	-0.39	3.35e-25	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs243505	0.559	rs10215794	chr7:148478895	C/G	cg09806900	chr7:148480153	CUL1	0.56	11.19	0.4	1.19e-26	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3768617	0.591	rs9787073	chr1:182974328	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.51	11.84	0.42	2.15e-29	Fuchs's corneal dystrophy;
BRCA	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg13902645	chr11:5959945	NA	-0.51	-11.97	-0.43	6.39e-30	DNA methylation (variation);
BRCA	cis	rs16857609	0.600	rs10932715	chr2:218259783	A/G	cg15335768	chr2:218268053	DIRC3	-0.42	-9.71	-0.36	7.21e-21	Breast cancer;Breast cancer (estrogen-receptor negative);
BRCA	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg21535247	chr6:8435926	SLC35B3	0.4	8.94	0.33	4.14e-18	Motion sickness;
BRCA	cis	rs3125734	0.633	rs4979774	chr10:63967795	A/T	cg19640130	chr10:64028056	RTKN2	-0.3	-8.66	-0.32	3.86e-17	Rheumatoid arthritis;
BRCA	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.58	0.55	1.28e-51	Hypertriglyceridemia;
BRCA	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg05347473	chr6:146136440	FBXO30	0.46	9.0	0.34	2.59e-18	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg20503657	chr10:835505	NA	1.0	17.49	0.57	2.89e-56	Eosinophil percentage of granulocytes;
BRCA	trans	rs75804782	0.630	rs55708222	chr2:239287693	C/T	cg01134436	chr17:81009848	B3GNTL1	0.74	7.95	0.3	8.66e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs6430585	0.527	rs12465544	chr2:136451676	C/T	cg07169764	chr2:136633963	MCM6	1.0	19.33	0.61	6.52e-66	Corneal structure;
BRCA	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg26384229	chr12:38710491	ALG10B	-0.86	-23.31	-0.68	1.96e-87	Heart rate;
BRCA	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg08601574	chr20:25228251	PYGB	0.35	8.39	0.31	3.21e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs9807989	0.507	rs2041739	chr2:102994333	A/G	cg03938978	chr2:103052716	IL18RAP	-0.29	-8.34	-0.31	4.4e-16	Asthma;
BRCA	cis	rs4478137	0.931	rs4057797	chr4:164245053	T/A	cg06758707	chr4:164254230	NPY1R	0.56	12.25	0.44	3.81e-31	Subjective well-being (multi-trait analysis);Subjective well-being;
BRCA	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg02079420	chr8:82753780	SNX16	0.34	7.94	0.3	9.33e-15	Diastolic blood pressure;
BRCA	trans	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg06521331	chr12:34319734	NA	-0.47	-8.69	-0.33	2.99e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08219700	chr8:58056026	NA	0.54	9.01	0.34	2.27e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs3771570	1.000	rs62186422	chr2:242249499	A/G	cg21155796	chr2:242212141	HDLBP	0.61	9.63	0.36	1.42e-20	Prostate cancer;
BRCA	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg01475377	chr6:109611718	NA	-0.59	-16.46	-0.55	5.05e-51	Reticulocyte fraction of red cells;
BRCA	trans	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg06636001	chr8:8085503	FLJ10661	0.49	10.58	0.39	3.27e-24	Retinal vascular caliber;
BRCA	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	9.79	0.36	3.52e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-11.72	-0.42	7.26e-29	Response to antipsychotic treatment;
BRCA	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-10.21	-0.37	9.22e-23	Psoriasis;
BRCA	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg26149184	chr10:133730230	NA	0.4	8.2	0.31	1.37e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
BRCA	cis	rs7246657	0.722	rs954504	chr19:38045394	A/G	cg23950597	chr19:37808831	NA	-0.5	-8.62	-0.32	5.36e-17	Coronary artery calcification;
BRCA	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.56	-8.01	-0.3	5.62e-15	Schizophrenia;
BRCA	cis	rs1829883	0.626	rs2548089	chr5:98910440	A/C	cg08333243	chr5:99726346	NA	0.36	8.49	0.32	1.49e-16	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs7178424	1.000	rs11071649	chr15:62312297	A/G	cg00456672	chr15:62358751	C2CD4A	-0.38	-8.69	-0.33	3.04e-17	Height;
BRCA	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg01448562	chr3:133502909	NA	0.37	8.42	0.32	2.4e-16	Iron status biomarkers;
BRCA	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg13256891	chr4:100009986	ADH5	0.38	8.07	0.3	3.39e-15	Alcohol dependence;
BRCA	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg18232548	chr7:50535776	DDC	-0.53	-13.52	-0.47	8.44e-37	Systemic sclerosis;
BRCA	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg18132916	chr6:79620363	NA	-0.46	-10.31	-0.38	3.58e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg23711669	chr6:146136114	FBXO30	0.78	18.48	0.59	2.19e-61	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg01256987	chr12:42539512	GXYLT1	-0.46	-9.21	-0.34	4.74e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg26384229	chr12:38710491	ALG10B	0.74	17.32	0.57	2.11e-55	Bladder cancer;
BRCA	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg15145296	chr3:125709740	NA	-0.56	-8.93	-0.33	4.5e-18	Blood pressure (smoking interaction);
BRCA	cis	rs4363385	0.747	rs1999886	chr1:152955522	T/C	cg25856811	chr1:152973957	SPRR3	-0.33	-8.79	-0.33	1.42e-17	Inflammatory skin disease;
BRCA	cis	rs4478858	0.698	rs10914370	chr1:31854955	T/C	cg00250761	chr1:31883323	NA	-0.32	-8.42	-0.32	2.56e-16	Alcohol dependence;
BRCA	cis	rs3820928	1.000	rs4675120	chr2:227774888	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.46	-0.32	1.8e-16	Pulmonary function;
BRCA	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	16.92	0.56	2.43e-53	Multiple sclerosis;
BRCA	cis	rs6977660	1.000	rs10260360	chr7:19792824	T/C	cg05791153	chr7:19748676	TWISTNB	0.43	8.48	0.32	1.51e-16	Thyroid stimulating hormone;
BRCA	cis	rs4853036	0.903	rs13021969	chr2:70117602	T/C	cg02498382	chr2:70120550	SNRNP27	-0.54	-10.67	-0.39	1.49e-24	Colorectal or endometrial cancer;
BRCA	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg26384229	chr12:38710491	ALG10B	0.67	15.23	0.52	6.4e-45	Bladder cancer;
BRCA	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg10862848	chr6:42927986	GNMT	-0.36	-15.05	-0.51	5.13e-44	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg13175981	chr1:150552382	MCL1	0.41	9.04	0.34	1.79e-18	Tonsillectomy;
BRCA	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24110177	chr3:50126178	RBM5	-0.39	-10.7	-0.39	1.08e-24	Intelligence (multi-trait analysis);
BRCA	cis	rs4728302	0.559	rs7779409	chr7:133158475	A/G	cg10665199	chr7:133106180	EXOC4	0.47	10.1	0.37	2.29e-22	Intelligence;Intelligence (multi-trait analysis);
BRCA	cis	rs4363385	0.667	rs73014331	chr1:152964533	A/G	cg21543102	chr1:152974771	SPRR3	-0.3	-8.32	-0.31	5.29e-16	Inflammatory skin disease;
BRCA	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	10.12	0.37	1.94e-22	Eosinophil percentage of white cells;
BRCA	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg20503657	chr10:835505	NA	1.04	15.8	0.53	9.87e-48	Eosinophil percentage of granulocytes;
BRCA	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg09467607	chr2:36825704	FEZ2	-0.62	-15.26	-0.52	4.57e-45	Height;
BRCA	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg18357645	chr12:58087776	OS9	0.36	10.08	0.37	2.81e-22	Multiple sclerosis;
BRCA	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg06092702	chr1:163392909	NA	-0.36	-9.66	-0.36	1.06e-20	Motion sickness;
BRCA	cis	rs10193935	0.792	rs2053349	chr2:42516205	G/A	cg27598129	chr2:42591480	NA	-0.66	-11.14	-0.4	1.88e-26	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs6479891	0.915	rs7091664	chr10:65101800	G/A	cg14819942	chr15:35414228	NA	-0.34	-8.48	-0.32	1.54e-16	Arthritis (juvenile idiopathic);
BRCA	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg01689657	chr7:91764605	CYP51A1	0.25	8.61	0.32	5.78e-17	Breast cancer;
BRCA	cis	rs6815814	0.950	rs113465719	chr4:38808045	A/T	cg02016764	chr4:38805732	TLR1	-0.6	-9.49	-0.35	4.33e-20	Breast cancer;
BRCA	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.32	-8.55	-0.32	8.91e-17	Crohn's disease;
BRCA	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	17.27	0.56	3.83e-55	Alzheimer's disease;
BRCA	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg13010199	chr12:38710504	ALG10B	0.48	9.91	0.37	1.23e-21	Bladder cancer;
BRCA	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02475777	chr4:1388615	CRIPAK	-0.52	-10.15	-0.37	1.56e-22	Obesity-related traits;
BRCA	cis	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg06521331	chr12:34319734	NA	-0.62	-11.17	-0.4	1.44e-26	Morning vs. evening chronotype;
BRCA	trans	rs7939886	0.920	rs1482009	chr11:55884690	T/G	cg15704280	chr7:45808275	SEPT13	0.62	7.96	0.3	7.6e-15	Myopia (pathological);
BRCA	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg15595755	chr5:1867978	NA	0.33	7.96	0.3	8.02e-15	Cardiovascular disease risk factors;
BRCA	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg03188948	chr7:1209495	NA	0.5	9.28	0.34	2.5e-19	Longevity;Endometriosis;
BRCA	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg04691961	chr3:161091175	C3orf57	-0.62	-15.07	-0.51	3.8e-44	Morning vs. evening chronotype;
BRCA	trans	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg26384229	chr12:38710491	ALG10B	0.6	12.16	0.43	9.04e-31	Resting heart rate;
BRCA	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg20503657	chr10:835505	NA	1.3	21.72	0.65	9.26e-79	Eosinophil percentage of granulocytes;
BRCA	cis	rs897984	0.542	rs35713203	chr16:31090407	G/C	cg00531865	chr16:30841666	NA	-0.38	-8.76	-0.33	1.76e-17	Dementia with Lewy bodies;
BRCA	cis	rs3106136	0.546	rs2632417	chr4:95137542	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.08	-0.37	2.82e-22	Capecitabine sensitivity;
BRCA	cis	rs2637266	1.000	rs2395390	chr10:78357734	C/G	cg18941641	chr10:78392320	NA	0.35	7.82	0.3	2.23e-14	Pulmonary function;
BRCA	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg24060327	chr5:131705240	SLC22A5	0.48	10.06	0.37	3.27e-22	Blood metabolite levels;
BRCA	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg20607798	chr8:58055168	NA	0.47	8.07	0.3	3.41e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg14675211	chr2:100938903	LONRF2	0.52	12.07	0.43	2.29e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg20573242	chr4:122745356	CCNA2	0.45	9.89	0.36	1.49e-21	Type 2 diabetes;
BRCA	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg11645453	chr3:52864694	ITIH4	0.47	10.73	0.39	8.52e-25	Schizophrenia;
BRCA	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg07636037	chr3:49044803	WDR6	0.58	9.29	0.35	2.3e-19	Menarche (age at onset);
BRCA	cis	rs312274	0.588	rs11179030	chr12:41309245	G/A	cg17827154	chr12:41323612	CNTN1	-0.45	-11.21	-0.41	9.82e-27	Metabolite levels  (X-11787);
BRCA	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg07234876	chr8:600039	NA	-0.75	-9.28	-0.34	2.69e-19	IgG glycosylation;
BRCA	cis	rs495337	0.760	rs4810994	chr20:48571673	C/T	cg17835207	chr20:48524531	SPATA2	-0.67	-16.84	-0.55	6.21e-53	Psoriasis;
BRCA	cis	rs7520050	0.966	rs10890352	chr1:46283628	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.85	0.36	2.07e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs9300255	0.566	rs1716169	chr12:123716930	A/T	cg00376283	chr12:123451042	ABCB9	0.51	10.1	0.37	2.36e-22	Neutrophil percentage of white cells;
BRCA	cis	rs6121246	0.559	rs6060933	chr20:30351903	C/T	cg13852791	chr20:30311386	BCL2L1	0.96	23.37	0.68	8.7e-88	Mean corpuscular hemoglobin;
BRCA	cis	rs4363385	0.720	rs6665527	chr1:152967009	C/A	cg25856811	chr1:152973957	SPRR3	-0.36	-9.43	-0.35	7.23e-20	Inflammatory skin disease;
BRCA	cis	rs2191566	1.000	rs10418363	chr19:44525463	A/G	cg20607764	chr19:44506953	ZNF230	-0.42	-9.37	-0.35	1.27e-19	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg21475434	chr5:93447410	FAM172A	0.61	8.19	0.31	1.43e-15	Diabetic retinopathy;
BRCA	cis	rs7178424	0.875	rs17271193	chr15:62165168	A/G	cg00456672	chr15:62358751	C2CD4A	-0.39	-8.82	-0.33	1.12e-17	Height;
BRCA	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.32	10.89	0.4	1.96e-25	Systemic lupus erythematosus;
BRCA	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg11266682	chr4:10021025	SLC2A9	0.4	10.53	0.38	5.26e-24	Bone mineral density;
BRCA	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg02753203	chr1:228287806	NA	-0.57	-11.93	-0.43	9.2e-30	Diastolic blood pressure;
BRCA	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg11707556	chr5:10655725	ANKRD33B	0.42	9.39	0.35	1.06e-19	Coronary artery disease;
BRCA	cis	rs858239	0.632	rs1985769	chr7:23122506	T/G	cg23682824	chr7:23144976	KLHL7	0.45	11.83	0.42	2.53e-29	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs1371614	0.632	rs6547318	chr2:27153481	A/C	cg00617064	chr2:27272375	NA	-0.31	-7.9	-0.3	1.26e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg21045802	chr8:109455806	TTC35	0.34	7.87	0.3	1.52e-14	Dupuytren's disease;
BRCA	cis	rs7903847	0.642	rs11189200	chr10:99156273	C/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.72	-0.33	2.41e-17	Granulocyte percentage of myeloid white cells;
BRCA	trans	rs2840044	1.000	rs11656138	chr17:33910218	T/C	cg19694781	chr19:47549865	TMEM160	0.45	10.47	0.38	8.73e-24	Response to radiotherapy in cancer (late toxicity);
BRCA	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg15557168	chr22:42548783	NA	-0.32	-8.81	-0.33	1.16e-17	Cognitive function;
BRCA	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg23719950	chr11:63933701	MACROD1	-0.58	-9.87	-0.36	1.79e-21	Mean platelet volume;
BRCA	trans	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.38	8.57	0.32	8e-17	Corneal astigmatism;
BRCA	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21659725	chr3:3221576	CRBN	-0.33	-7.86	-0.3	1.66e-14	Body mass index;
BRCA	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg03433033	chr1:76189801	ACADM	-0.46	-9.58	-0.35	2.1e-20	Daytime sleep phenotypes;
BRCA	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-9.0	-0.34	2.53e-18	Monocyte percentage of white cells;
BRCA	cis	rs11997175	0.624	rs4621768	chr8:33677452	T/C	ch.8.33884649F	chr8:33765107	NA	0.4	9.19	0.34	5.56e-19	Body mass index;
BRCA	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg03213289	chr20:61660250	NA	0.61	16.28	0.54	4.14e-50	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs3784262	0.528	rs17820966	chr15:58336662	A/G	cg12031962	chr15:58353849	ALDH1A2	0.37	9.93	0.37	1.06e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
BRCA	trans	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.27	0.31	7.89e-16	Aortic root size;
BRCA	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg09436375	chr6:42928200	GNMT	-0.29	-10.79	-0.39	4.82e-25	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs78707713	0.511	rs28697194	chr10:71215483	T/C	cg12610070	chr10:71211762	TSPAN15	-0.33	-11.49	-0.41	6.43e-28	Venous thromboembolism;
BRCA	trans	rs1200821	0.641	rs11011162	chr10:37674483	G/C	cg25427524	chr10:38739819	LOC399744	0.38	8.16	0.31	1.83e-15	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22307029	chr19:49891270	CCDC155	0.65	11.42	0.41	1.3e-27	Multiple sclerosis;
BRCA	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-12.7	-0.45	4.14e-33	Bipolar disorder;
BRCA	cis	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg21775007	chr8:11205619	TDH	-0.51	-9.49	-0.35	4.46e-20	Triglycerides;
BRCA	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg23711669	chr6:146136114	FBXO30	0.77	18.52	0.59	1.33e-61	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11622475	1.000	rs12889168	chr14:104481957	A/T	cg12183467	chr14:104352244	NA	-0.46	-9.52	-0.35	3.5e-20	Bipolar disorder;
BRCA	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg13256891	chr4:100009986	ADH5	0.54	10.14	0.37	1.65e-22	Smoking initiation;
BRCA	cis	rs243505	0.964	rs243517	chr7:148425915	T/A	cg09806900	chr7:148480153	CUL1	-0.4	-8.35	-0.31	4.36e-16	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg27572855	chr1:25598939	RHD	0.47	13.11	0.46	6.08e-35	Erythrocyte sedimentation rate;
BRCA	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg08601574	chr20:25228251	PYGB	0.35	8.49	0.32	1.48e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs896543	0.657	rs10179774	chr2:237487588	C/T	cg25295825	chr2:237489920	CXCR7	0.49	9.75	0.36	5.06e-21	Alcohol dependence (age at onset);
BRCA	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg14829155	chr15:31115871	NA	0.42	10.04	0.37	4.07e-22	Huntington's disease progression;
BRCA	cis	rs8038465	0.622	rs17185294	chr15:73858415	C/T	cg15420318	chr15:73925796	NPTN	-0.44	-9.76	-0.36	4.67e-21	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs12618769	0.597	rs3769723	chr2:99105988	A/G	cg10123293	chr2:99228465	UNC50	0.42	8.43	0.32	2.38e-16	Bipolar disorder;
BRCA	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg05340658	chr4:99064831	C4orf37	0.69	17.46	0.57	4.29e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.58	-14.19	-0.49	6.18e-40	Longevity;Endometriosis;
BRCA	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg22535103	chr8:58192502	C8orf71	-0.6	-13.12	-0.46	5.64e-35	Developmental language disorder (linguistic errors);
BRCA	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg00857998	chr1:205179979	DSTYK	0.45	8.42	0.32	2.42e-16	Mean corpuscular volume;Mean platelet volume;
BRCA	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg18225595	chr11:63971243	STIP1	-0.4	-9.96	-0.37	7.91e-22	Platelet count;
BRCA	cis	rs1832871	0.619	rs827861	chr6:158710074	C/A	cg07215822	chr6:158701037	NA	-0.51	-10.56	-0.39	3.93e-24	Height;
BRCA	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg03342759	chr3:160939853	NMD3	-0.77	-18.35	-0.59	9.86e-61	Parkinson's disease;
BRCA	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg21475434	chr5:93447410	FAM172A	0.73	9.13	0.34	8.89e-19	Diabetic retinopathy;
BRCA	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg05340658	chr4:99064831	C4orf37	-0.44	-10.13	-0.37	1.89e-22	Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs75804782	0.641	rs56000747	chr2:239318541	T/G	cg01134436	chr17:81009848	B3GNTL1	0.78	9.84	0.36	2.34e-21	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg27366882	chr3:133540807	NA	-0.33	-7.99	-0.3	6.23e-15	Alcohol consumption (transferrin glycosylation);
BRCA	trans	rs8073060	0.586	rs226084	chr17:34019582	T/A	cg19694781	chr19:47549865	TMEM160	-1.07	-21.69	-0.65	1.28e-78	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.41	0.38	1.48e-23	Motion sickness;
BRCA	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-13.14	-0.46	4.54e-35	Blood metabolite levels;
BRCA	trans	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg26384229	chr12:38710491	ALG10B	0.57	12.26	0.44	3.38e-31	Morning vs. evening chronotype;
BRCA	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg05665937	chr4:1216051	CTBP1	-0.39	-8.4	-0.32	2.92e-16	Obesity-related traits;
BRCA	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg07080220	chr10:102295463	HIF1AN	0.59	14.28	0.49	2.31e-40	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg22535103	chr8:58192502	C8orf71	-0.45	-9.05	-0.34	1.65e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7523050	0.643	rs35050241	chr1:109404876	T/C	cg08274380	chr1:109419600	GPSM2	0.98	14.02	0.49	3.82e-39	Fat distribution (HIV);
BRCA	cis	rs56399783	0.614	rs11772508	chr7:2771504	A/C	cg19731401	chr7:2775893	GNA12	-0.5	-8.14	-0.31	2.1e-15	Childhood ear infection;
BRCA	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg10253484	chr15:75165896	SCAMP2	0.51	9.76	0.36	4.66e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg12062639	chr20:23401060	NAPB	0.96	13.42	0.47	2.43e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	11.35	0.41	2.45e-27	Personality dimensions;
BRCA	cis	rs2797685	0.755	rs41402249	chr1:7822723	C/G	cg04725166	chr1:7887271	PER3	0.48	8.85	0.33	8.3e-18	Crohn's disease;
BRCA	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg17366294	chr4:99064904	C4orf37	0.44	10.49	0.38	7.52e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg19847866	chr10:1019161	NA	-0.51	-10.27	-0.38	5.12e-23	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs56399783	0.901	rs73051444	chr7:2866529	G/A	cg19731401	chr7:2775893	GNA12	0.51	8.4	0.32	2.97e-16	Childhood ear infection;
BRCA	cis	rs6545883	0.560	rs11677776	chr2:61503113	T/C	cg15711740	chr2:61764176	XPO1	0.33	8.17	0.31	1.65e-15	Tuberculosis;
BRCA	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg11822812	chr5:140052017	DND1	0.31	8.4	0.32	2.86e-16	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg24675658	chr1:53192096	ZYG11B	-0.52	-11.18	-0.4	1.3e-26	Monocyte count;
BRCA	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg05313129	chr8:58192883	C8orf71	-0.47	-9.73	-0.36	6.11e-21	Developmental language disorder (linguistic errors);
BRCA	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.03	-22.26	-0.66	1.07e-81	Ulcerative colitis;
BRCA	trans	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg25214090	chr10:38739885	LOC399744	0.46	10.6	0.39	2.61e-24	Corneal astigmatism;
BRCA	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg05347473	chr6:146136440	FBXO30	-0.43	-8.76	-0.33	1.79e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-10.35	-0.38	2.58e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg03462622	chr3:195777018	TFRC	-0.38	-8.62	-0.32	5.42e-17	Mean corpuscular volume;
BRCA	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg04944784	chr2:26401820	FAM59B	-0.69	-11.47	-0.41	8.14e-28	Gut microbiome composition (summer);
BRCA	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.55	8.26	0.31	8.57e-16	Platelet count;
BRCA	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg25036284	chr2:26402008	FAM59B	-0.8	-12.52	-0.44	2.6e-32	Gut microbiome composition (summer);
BRCA	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.41	0.35	8.46e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.85	-0.33	8.45e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs4363385	0.720	rs9325996	chr1:152965347	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-9.36	-0.35	1.35e-19	Inflammatory skin disease;
BRCA	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08564027	chr20:61660810	NA	0.85	22.82	0.67	9.28e-85	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs965469	0.846	rs7271575	chr20:3333877	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-10.5	-0.38	6.58e-24	IFN-related cytopenia;
BRCA	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg05340658	chr4:99064831	C4orf37	0.69	17.38	0.57	1.11e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6060717	0.536	rs17431878	chr20:34502107	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.14	-0.31	2.02e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs7246657	0.722	rs2972458	chr19:38135403	T/C	cg18154014	chr19:37997991	ZNF793	-0.49	-9.34	-0.35	1.59e-19	Coronary artery calcification;
BRCA	cis	rs240110	0.539	rs6934256	chr6:101338728	G/A	cg09795085	chr6:101329169	ASCC3	0.4	8.13	0.31	2.17e-15	Neuroticism;
BRCA	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg04691961	chr3:161091175	C3orf57	-0.4	-9.88	-0.36	1.61e-21	Morning vs. evening chronotype;
BRCA	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	18.27	0.59	2.7e-60	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg17366294	chr4:99064904	C4orf37	0.46	10.87	0.39	2.33e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.48	-0.47	1.31e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs4953076	0.573	rs7595470	chr2:44402467	A/G	cg04920474	chr2:44395004	PPM1B	0.49	9.89	0.36	1.45e-21	Height;
BRCA	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg17063962	chr7:91808500	NA	0.53	12.58	0.45	1.42e-32	Breast cancer;
BRCA	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.74	16.31	0.54	2.89e-50	Lymphocyte counts;
BRCA	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg19077165	chr18:44547161	KATNAL2	0.39	8.3	0.31	6.39e-16	Educational attainment;
BRCA	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg00321850	chr1:175162397	KIAA0040	-0.4	-11.26	-0.41	6.13e-27	Alcohol dependence;
BRCA	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg26384229	chr12:38710491	ALG10B	0.42	9.34	0.35	1.54e-19	Morning vs. evening chronotype;
BRCA	cis	rs4409675	0.576	rs6565	chr1:28213157	T/C	cg23691781	chr1:28212827	C1orf38	0.33	11.27	0.41	5.37e-27	Corneal astigmatism;
BRCA	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-13.53	-0.47	7.4e-37	Bipolar disorder and schizophrenia;
BRCA	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg11752832	chr7:134001865	SLC35B4	0.52	13.5	0.47	1.06e-36	Mean platelet volume;
BRCA	trans	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg06521331	chr12:34319734	NA	0.46	9.03	0.34	2.02e-18	Bladder cancer;
BRCA	cis	rs10045504	0.502	rs17456198	chr5:38732005	A/G	cg15396434	chr5:38725168	NA	-0.55	-10.54	-0.38	4.81e-24	Night sleep phenotypes;
BRCA	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg18811423	chr2:55921094	PNPT1	-0.51	-12.5	-0.44	2.99e-32	Metabolic syndrome;
BRCA	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg08859206	chr1:53392774	SCP2	-0.4	-8.67	-0.32	3.41e-17	Monocyte count;
BRCA	cis	rs28830936	1.000	rs4924570	chr15:41974660	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.33	-9.17	-0.34	6.18e-19	Diastolic blood pressure;
BRCA	cis	rs7927771	0.542	rs10769300	chr11:47865560	C/T	cg20307385	chr11:47447363	PSMC3	0.42	9.49	0.35	4.65e-20	Subjective well-being;
BRCA	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg17971929	chr21:40555470	PSMG1	0.79	18.52	0.59	1.31e-61	Cognitive function;
BRCA	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg11843238	chr5:131593191	PDLIM4	-0.34	-7.81	-0.3	2.34e-14	Breast cancer;
BRCA	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg05347473	chr6:146136440	FBXO30	0.41	8.07	0.3	3.41e-15	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg03060546	chr3:49711283	APEH	-0.46	-10.08	-0.37	2.89e-22	Resting heart rate;
BRCA	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14240646	chr10:27532245	ACBD5	0.64	9.43	0.35	7.69e-20	Breast cancer;
BRCA	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg10011062	chr15:43941034	CATSPER2	-0.53	-7.87	-0.3	1.52e-14	Lung cancer in ever smokers;
BRCA	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	9.26	0.34	2.99e-19	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg06627628	chr2:24431161	ITSN2	-0.55	-8.91	-0.33	5.12e-18	Lymphocyte counts;
BRCA	trans	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg23762105	chr12:34175262	ALG10	0.35	7.95	0.3	8.49e-15	Morning vs. evening chronotype;
BRCA	cis	rs12612619	0.579	rs6722906	chr2:27080035	C/A	cg12368169	chr2:27073192	DPYSL5	-0.33	-10.05	-0.37	3.66e-22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs17401966	1.000	rs3753037	chr1:10355834	C/T	cg15208524	chr1:10270712	KIF1B	0.37	8.25	0.31	9e-16	Hepatocellular carcinoma;
BRCA	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg15557168	chr22:42548783	NA	0.3	8.41	0.32	2.58e-16	Cognitive function;
BRCA	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg18196295	chr10:418757	DIP2C	0.38	8.83	0.33	9.96e-18	Psychosis in Alzheimer's disease;
BRCA	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.99	0.34	2.76e-18	Platelet count;
BRCA	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.49	-0.32	1.48e-16	Monocyte percentage of white cells;
BRCA	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg04025307	chr7:1156635	C7orf50	0.58	9.64	0.36	1.28e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-13.31	-0.47	7.8e-36	Extrinsic epigenetic age acceleration;
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.45	-9.92	-0.37	1.12e-21	Longevity;Endometriosis;
BRCA	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg14349672	chr11:133703707	NA	-0.42	-9.2	-0.34	4.99e-19	Childhood ear infection;
BRCA	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.28e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.14	0.34	8.4e-19	Tonsillectomy;
BRCA	cis	rs12431939	1.000	rs58225416	chr14:51662196	C/T	cg23942311	chr14:51606299	NA	-0.43	-8.04	-0.3	4.5e-15	Cancer;
BRCA	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg05340658	chr4:99064831	C4orf37	0.69	17.45	0.57	4.94e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	11.74	0.42	6.14e-29	Glomerular filtration rate (creatinine);
BRCA	cis	rs600806	0.888	rs3879449	chr1:109904971	A/T	cg20591472	chr1:110008990	SYPL2	0.32	8.12	0.31	2.4e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs586533	0.758	rs1690818	chr11:99496554	C/T	cg22878054	chr11:99397252	CNTN5	0.32	7.85	0.3	1.8e-14	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11644478	chr21:40555479	PSMG1	0.83	18.38	0.59	7.03e-61	Cognitive function;
BRCA	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-12.08	-0.43	2.06e-30	Total cholesterol levels;
BRCA	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.45	10.36	0.38	2.36e-23	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs524281	0.692	rs10791845	chr11:65834340	C/G	cg16950941	chr11:66035639	RAB1B	0.4	8.86	0.33	7.79e-18	Electroencephalogram traits;
BRCA	cis	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg09307838	chr4:120376055	NA	0.43	9.2	0.34	4.85e-19	Educational attainment;
BRCA	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg11764359	chr7:65958608	NA	0.63	10.74	0.39	7.39e-25	Aortic root size;
BRCA	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg09455208	chr3:40491958	NA	0.41	9.53	0.35	3.32e-20	Renal cell carcinoma;
BRCA	cis	rs3820928	0.874	rs10210997	chr2:227859108	C/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-8.58	-0.32	7.03e-17	Pulmonary function;
BRCA	trans	rs7980799	0.711	rs1482993	chr12:33594515	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-10.99	-0.4	7.31e-26	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs7246657	0.722	rs2972458	chr19:38135403	T/C	cg23950597	chr19:37808831	NA	0.51	8.83	0.33	9.83e-18	Coronary artery calcification;
BRCA	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-11.16	-0.4	1.59e-26	Neuroticism;
BRCA	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg27129171	chr3:47204927	SETD2	-0.71	-17.4	-0.57	8.85e-56	Colorectal cancer;
BRCA	cis	rs6815814	0.950	rs3924112	chr4:38795810	C/T	cg06935464	chr4:38784597	TLR10	0.51	8.24	0.31	9.92e-16	Breast cancer;
BRCA	cis	rs6545883	0.708	rs2518936	chr2:61792342	T/C	cg15711740	chr2:61764176	XPO1	-0.48	-11.68	-0.42	1.04e-28	Tuberculosis;
BRCA	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-13.58	-0.47	4.27e-37	Morning vs. evening chronotype;
BRCA	cis	rs3820928	0.874	rs7594505	chr2:227878562	C/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-8.38	-0.31	3.33e-16	Pulmonary function;
BRCA	cis	rs2710642	0.821	rs56373728	chr2:63095792	G/A	cg17519650	chr2:63277830	OTX1	0.39	8.59	0.32	6.7e-17	LDL cholesterol levels;LDL cholesterol;
BRCA	cis	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg07460842	chr6:66804631	NA	0.86	15.39	0.52	1.02e-45	Exhaled nitric oxide levels;
BRCA	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg12219531	chr12:120966889	COQ5	0.55	11.43	0.41	1.17e-27	High light scatter reticulocyte count;
BRCA	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg26248373	chr2:1572462	NA	-0.46	-8.63	-0.32	4.73e-17	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-15.51	-0.52	2.78e-46	Chronic sinus infection;
BRCA	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07080220	chr10:102295463	HIF1AN	0.49	11.15	0.4	1.7e-26	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs12367572	0.601	rs1495036	chr12:45410643	T/C	cg04608330	chr12:45269318	NELL2	-0.45	-9.87	-0.36	1.7e-21	Gut microbiome composition (summer);
BRCA	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	12.85	0.45	9.05e-34	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs7766436	0.885	rs4711020	chr6:22582920	A/G	cg13666174	chr6:22585274	NA	-0.49	-11.63	-0.42	1.65e-28	Coronary artery disease;
BRCA	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg12062639	chr20:23401060	NAPB	0.96	13.42	0.47	2.36e-36	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	cis	rs9486719	0.857	rs13208321	chr6:96860354	C/T	cg06623918	chr6:96969491	KIAA0776	-0.55	-11.64	-0.42	1.61e-28	Migraine;Coronary artery disease;
BRCA	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg00686598	chr14:53173677	PSMC6	1.2	16.3	0.54	3.21e-50	Alzheimer's disease (late onset);
BRCA	cis	rs909002	0.789	rs3817398	chr1:32119431	C/T	cg01639898	chr1:32083012	HCRTR1	-0.29	-8.68	-0.32	3.27e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg26395211	chr5:140044315	WDR55	0.37	8.56	0.32	8.62e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.38	-7.97	-0.3	7.58e-15	Bipolar disorder;
BRCA	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-12.55	-0.44	1.94e-32	Bipolar disorder and schizophrenia;
BRCA	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	-0.39	-9.06	-0.34	1.6e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg26608667	chr7:1196370	ZFAND2A	0.44	10.62	0.39	2.23e-24	Longevity;Endometriosis;
BRCA	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.46	-11.18	-0.4	1.26e-26	IgG glycosylation;
BRCA	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg15704280	chr7:45808275	SEPT13	-0.88	-23.34	-0.68	1.33e-87	Coronary artery disease;
BRCA	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.37	7.98	0.3	6.79e-15	Total cholesterol levels;
BRCA	cis	rs6815814	0.950	rs5743571	chr4:38805489	C/T	cg02016764	chr4:38805732	TLR1	-0.61	-9.73	-0.36	5.9e-21	Breast cancer;
BRCA	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg02773041	chr1:40204384	PPIE	-0.43	-9.44	-0.35	6.62e-20	Blood protein levels;
BRCA	cis	rs1941023	0.503	rs7952244	chr11:60132164	G/A	cg08716584	chr11:60157161	MS4A7	-0.44	-10.23	-0.38	7.45e-23	Congenital heart disease (maternal effect);
BRCA	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg24829409	chr8:58192753	C8orf71	-0.46	-8.01	-0.3	5.36e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs34779708	0.931	rs4934704	chr10:35332164	C/T	cg03585969	chr10:35415529	CREM	0.48	10.12	0.37	1.98e-22	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg16339924	chr4:17578868	LAP3	0.6	14.83	0.51	5.67e-43	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg16606324	chr3:10149918	C3orf24	0.5	9.56	0.35	2.53e-20	Alzheimer's disease;
BRCA	cis	rs9811920	0.625	rs9868170	chr3:99914139	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.38	8.59	0.32	6.63e-17	Axial length;
BRCA	trans	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg07817883	chr1:32538562	TMEM39B	-0.44	-8.57	-0.32	8.06e-17	Monocyte percentage of white cells;
BRCA	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.49e-52	Hypertriglyceridemia;
BRCA	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.95	-0.3	8.35e-15	Prostate cancer;
BRCA	trans	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg26384229	chr12:38710491	ALG10B	0.53	10.98	0.4	7.86e-26	Resting heart rate;
BRCA	cis	rs4478858	0.735	rs6425737	chr1:31790288	T/C	cg00250761	chr1:31883323	NA	-0.33	-8.54	-0.32	9.88e-17	Alcohol dependence;
BRCA	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg20703242	chr1:230279135	GALNT2	0.47	10.36	0.38	2.45e-23	Coronary artery disease;
BRCA	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-14.17	-0.49	7.7e-40	Hemoglobin concentration;
BRCA	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg17691542	chr6:26056736	HIST1H1C	0.49	9.99	0.37	6.29e-22	Iron status biomarkers;
BRCA	cis	rs4891159	0.548	rs690082	chr18:74116668	C/T	cg24786174	chr18:74118243	ZNF516	0.84	26.02	0.72	2.36e-102	Longevity;
BRCA	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg03433033	chr1:76189801	ACADM	0.76	17.32	0.57	2.15e-55	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-10.28	-0.38	4.63e-23	Schizophrenia;
BRCA	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.58	9.78	0.36	3.95e-21	Gut microbiome composition (summer);
BRCA	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg00383909	chr3:49044727	WDR6	0.6	10.99	0.4	7.78e-26	Cognitive function;
BRCA	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg15934090	chr1:100435551	SLC35A3	0.36	8.15	0.31	1.89e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg18351406	chr4:77819688	ANKRD56	0.61	13.71	0.48	1.08e-37	Emphysema distribution in smoking;
BRCA	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-11.87	-0.42	1.6800000000000001e-29	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
BRCA	cis	rs897080	0.552	rs1067369	chr2:44652654	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	9.47	0.35	5.51e-20	Height;
BRCA	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg02551604	chr5:131831745	NA	-0.4	-14.95	-0.51	1.56e-43	Asthma (sex interaction);
BRCA	trans	rs6479891	1.000	rs9415696	chr10:65134348	A/T	cg14819942	chr15:35414228	NA	0.35	8.65	0.32	4.02e-17	Arthritis (juvenile idiopathic);
BRCA	trans	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg19676328	chr12:49525230	TUBA1B	-0.51	-11.45	-0.41	9.44e-28	Total cholesterol levels;
BRCA	cis	rs4478858	0.735	rs34960310	chr1:31816197	A/G	cg00250761	chr1:31883323	NA	-0.33	-8.53	-0.32	1.02e-16	Alcohol dependence;
BRCA	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg15704280	chr7:45808275	SEPT13	0.63	11.24	0.41	6.97e-27	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs3845702	0.736	rs72962517	chr2:180861452	G/A	cg01881094	chr2:180872142	CWC22	1.01	17.22	0.56	6.97e-55	Schizophrenia;
BRCA	cis	rs9487051	0.698	rs35757653	chr6:109644599	A/C	cg01475377	chr6:109611718	NA	-0.49	-10.13	-0.37	1.76e-22	Reticulocyte fraction of red cells;
BRCA	cis	rs9463078	0.774	rs9357484	chr6:45265882	C/A	cg25276700	chr6:44698697	NA	-0.35	-7.99	-0.3	6.29e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
BRCA	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10150615	chr22:24372951	LOC391322	-0.47	-10.71	-0.39	1.01e-24	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg26043149	chr18:55253948	FECH	0.39	8.71	0.33	2.61e-17	Bone mineral density;
BRCA	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.54e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg11645453	chr3:52864694	ITIH4	-0.38	-10.07	-0.37	3.01e-22	Red blood cell count;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg01262667	chr19:19385393	TM6SF2	-0.41	-10.57	-0.39	3.52e-24	Tonsillectomy;
BRCA	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.83	0.39	3.19e-25	Bipolar disorder;
BRCA	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg02659138	chr7:134003124	SLC35B4	0.34	10.73	0.39	8.25e-25	Mean platelet volume;
BRCA	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11644478	chr21:40555479	PSMG1	0.82	18.67	0.59	2.13e-62	Cognitive function;
BRCA	cis	rs11955398	0.625	rs12655515	chr5:59974098	G/C	cg02684056	chr5:59996105	DEPDC1B	0.39	9.06	0.34	1.55e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg06766960	chr11:133703094	NA	-0.61	-12.74	-0.45	2.64e-33	Childhood ear infection;
BRCA	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg05340658	chr4:99064831	C4orf37	0.66	16.19	0.54	1.17e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg17507749	chr15:85114479	UBE2QP1	0.56	9.2	0.34	5.16e-19	Schizophrenia;
BRCA	cis	rs1941023	0.606	rs7926219	chr11:60180335	C/T	cg08716584	chr11:60157161	MS4A7	-0.36	-8.46	-0.32	1.89e-16	Congenital heart disease (maternal effect);
BRCA	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg21535247	chr6:8435926	SLC35B3	-0.4	-8.98	-0.33	3.03e-18	Motion sickness;
BRCA	cis	rs1113500	0.933	rs10494089	chr1:108626695	T/G	cg06207961	chr1:108661230	NA	0.45	11.04	0.4	4.5e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs7254827	0.737	rs16981567	chr19:17152552	C/T	cg19418318	chr19:17219073	MYO9B	0.47	9.84	0.36	2.36e-21	Mean platelet volume;
BRCA	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg25427524	chr10:38739819	LOC399744	0.52	9.67	0.36	9.73e-21	Obesity (extreme);
BRCA	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg19913688	chr11:428466	ANO9	-0.67	-9.76	-0.36	4.67e-21	Body mass index;
BRCA	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg05340658	chr4:99064831	C4orf37	0.58	11.84	0.42	2.15e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2147904	0.933	rs783621	chr1:42368035	A/G	cg16685388	chr1:42384056	HIVEP3	0.34	9.69	0.36	8.49e-21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
BRCA	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg03433033	chr1:76189801	ACADM	-0.71	-14.12	-0.49	1.37e-39	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7043114	0.525	rs7853859	chr9:95151377	A/G	cg14631576	chr9:95140430	CENPP	-0.33	-8.17	-0.31	1.71e-15	Height;
BRCA	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.43	12.45	0.44	5.33e-32	Total body bone mineral density;
BRCA	cis	rs9400271	0.632	rs9386784	chr6:109591208	C/A	cg21918786	chr6:109611834	NA	-0.32	-8.08	-0.3	3.17e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
BRCA	cis	rs4363385	0.747	rs6684188	chr1:152974285	A/G	cg25856811	chr1:152973957	SPRR3	-0.35	-9.3	-0.35	2.23e-19	Inflammatory skin disease;
BRCA	cis	rs9296092	0.560	rs7765393	chr6:33525598	A/T	cg13560919	chr6:33536144	NA	-0.85	-18.96	-0.6	5.84e-64	Age at smoking initiation in chronic obstructive pulmonary disease;
BRCA	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg04691961	chr3:161091175	C3orf57	-0.6	-14.18	-0.49	7.02e-40	Morning vs. evening chronotype;
BRCA	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg12292205	chr6:26970375	C6orf41	-0.54	-11.88	-0.43	1.45e-29	Intelligence (multi-trait analysis);
BRCA	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg16405210	chr4:1374714	KIAA1530	-0.93	-22.13	-0.66	5.35e-81	Longevity;
BRCA	cis	rs870825	0.616	rs28660669	chr4:185623312	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	17.4	0.57	8.51e-56	Blood protein levels;
BRCA	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg26384229	chr12:38710491	ALG10B	0.76	17.14	0.56	1.77e-54	Bladder cancer;
BRCA	cis	rs524281	0.861	rs12226649	chr11:65842047	T/C	cg16950941	chr11:66035639	RAB1B	-0.38	-7.87	-0.3	1.58e-14	Electroencephalogram traits;
BRCA	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg16482183	chr6:26056742	HIST1H1C	0.55	11.44	0.41	1.11e-27	Height;
BRCA	cis	rs7395581	0.959	rs2013867	chr11:47260272	A/G	cg25783544	chr11:47291846	MADD	0.4	8.96	0.33	3.54e-18	HDL cholesterol;
BRCA	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg21747090	chr2:27597821	SNX17	-0.43	-9.43	-0.35	7.24e-20	Total body bone mineral density;
BRCA	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg04025307	chr7:1156635	C7orf50	0.62	15.69	0.53	3.5e-47	Longevity;Endometriosis;
BRCA	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg23285459	chr7:2802560	GNA12	-0.35	-8.52	-0.32	1.16e-16	Height;
BRCA	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg25319279	chr11:5960081	NA	-0.43	-8.38	-0.31	3.28e-16	DNA methylation (variation);
BRCA	cis	rs2070433	0.539	rs2839312	chr21:47958225	T/C	cg12379764	chr21:47803548	PCNT	0.56	11.99	0.43	5.14e-30	Lymphocyte counts;
BRCA	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg24069376	chr3:38537580	EXOG	-0.41	-11.73	-0.42	6.34e-29	Electrocardiographic conduction measures;
BRCA	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg06618935	chr21:46677482	NA	-0.38	-8.39	-0.32	3.11e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg24642439	chr20:33292090	TP53INP2	0.43	9.12	0.34	1.01e-18	Height;
BRCA	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg15556689	chr8:8085844	FLJ10661	-0.38	-9.45	-0.35	6.15e-20	Retinal vascular caliber;
BRCA	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg04691961	chr3:161091175	C3orf57	-0.44	-10.58	-0.39	3.26e-24	Morning vs. evening chronotype;
BRCA	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.59	-14.52	-0.5	1.7e-41	Colorectal cancer;
BRCA	cis	rs7631605	0.836	rs4678938	chr3:37181015	G/C	cg15934958	chr3:37212084	LRRFIP2	0.39	9.21	0.34	4.48e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs524281	0.861	rs10896080	chr11:65876796	G/A	cg16950941	chr11:66035639	RAB1B	-0.39	-8.2	-0.31	1.35e-15	Electroencephalogram traits;
BRCA	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg24006582	chr15:45444508	DUOX1	-0.55	-11.28	-0.41	4.73e-27	Uric acid levels;
BRCA	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.93	-0.3	9.52e-15	Prostate cancer;
BRCA	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.49	-10.62	-0.39	2.25e-24	Longevity;Endometriosis;
BRCA	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg06618935	chr21:46677482	NA	-0.37	-7.99	-0.3	6.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9811920	0.535	rs704577	chr3:99487375	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-9.8	-0.36	3.35e-21	Axial length;
BRCA	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.43	-10.23	-0.38	7.73e-23	IgG glycosylation;
BRCA	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg08859206	chr1:53392774	SCP2	0.43	8.58	0.32	7.2e-17	Monocyte count;
BRCA	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg20129853	chr10:51489980	NA	-0.32	-8.4	-0.32	2.98e-16	Prostate-specific antigen levels;
BRCA	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg14196790	chr5:131705035	SLC22A5	0.35	9.29	0.34	2.43e-19	Breast cancer;
BRCA	cis	rs3824867	0.770	rs11820680	chr11:47452744	C/T	cg20307385	chr11:47447363	PSMC3	-0.51	-11.48	-0.41	6.99e-28	Mean corpuscular hemoglobin;
BRCA	cis	rs965469	0.779	rs6037566	chr20:3331414	A/C	cg25506879	chr20:3388711	C20orf194	-0.43	-8.74	-0.33	2.11e-17	IFN-related cytopenia;
BRCA	trans	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.35	-7.88	-0.3	1.41e-14	Endometrial cancer;
BRCA	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg08859206	chr1:53392774	SCP2	-0.51	-11.07	-0.4	3.55e-26	Monocyte count;
BRCA	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg24562669	chr7:97807699	LMTK2	0.46	12.44	0.44	5.67e-32	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18876405	chr7:65276391	NA	0.58	14.01	0.48	4.47e-39	Aortic root size;
BRCA	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg03146154	chr1:46216737	IPP	0.46	10.04	0.37	3.97e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	18.9	0.6	1.21e-63	Smoking behavior;
BRCA	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21659725	chr3:3221576	CRBN	0.49	11.64	0.42	1.62e-28	Resting heart rate;
BRCA	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg16606324	chr3:10149918	C3orf24	0.56	11.15	0.4	1.74e-26	Alzheimer's disease;
BRCA	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg21535247	chr6:8435926	SLC35B3	0.39	8.85	0.33	8.55e-18	Motion sickness;
BRCA	cis	rs7598759	0.712	rs12991636	chr2:232333666	T/C	cg19187155	chr2:232395269	NMUR1	0.39	8.2	0.31	1.33e-15	Noise-induced hearing loss;
BRCA	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg09537434	chr19:41945824	ATP5SL	-0.61	-12.81	-0.45	1.37e-33	Migraine;Coronary artery disease;
BRCA	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg05731713	chr7:157510257	PTPRN2	0.39	10.0	0.37	5.7e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs9811920	0.809	rs13059754	chr3:99678490	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.55	-13.49	-0.47	1.14e-36	Axial length;
BRCA	cis	rs6120849	0.754	rs3818253	chr20:33596876	C/T	cg24642439	chr20:33292090	TP53INP2	0.58	10.08	0.37	2.95e-22	Protein C levels;
BRCA	cis	rs897984	0.542	rs7294	chr16:31102321	A/G	cg02466173	chr16:30829666	NA	0.45	10.31	0.38	3.79e-23	Dementia with Lewy bodies;
BRCA	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg10845886	chr2:3471009	TTC15	-0.54	-12.22	-0.44	5.48e-31	Neurofibrillary tangles;
BRCA	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg12751644	chr20:60527061	NA	0.39	8.39	0.32	3.06e-16	Obesity-related traits;
BRCA	cis	rs1113500	0.862	rs3853494	chr1:108637334	G/A	cg06207961	chr1:108661230	NA	0.45	11.07	0.4	3.47e-26	Growth-regulated protein alpha levels;
BRCA	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.52	11.05	0.4	4.16e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs12200560	0.505	rs211182	chr6:97074513	G/A	cg06623918	chr6:96969491	KIAA0776	0.53	12.69	0.45	4.72e-33	Coronary heart disease;
BRCA	trans	rs8073060	0.572	rs1634683	chr17:33941560	G/C	cg19694781	chr19:47549865	TMEM160	-1.01	-20.54	-0.63	2.33e-72	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23583168	chr7:148888333	NA	-0.73	-15.84	-0.53	6.47e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs4808199	0.895	rs8105094	chr19:19374061	C/T	cg03709012	chr19:19516395	GATAD2A	0.95	15.92	0.53	2.49e-48	Nonalcoholic fatty liver disease;
BRCA	cis	rs7246657	0.551	rs12972146	chr19:37626095	G/T	cg18154014	chr19:37997991	ZNF793	0.51	8.21	0.31	1.2e-15	Coronary artery calcification;
BRCA	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-8.17	-0.31	1.61e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18876405	chr7:65276391	NA	0.62	15.26	0.52	4.8e-45	Aortic root size;
BRCA	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg06484146	chr7:12443880	VWDE	-0.75	-10.62	-0.39	2.31e-24	Coronary artery disease;
BRCA	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg27661571	chr11:113659931	NA	-0.73	-11.16	-0.4	1.58e-26	Hip circumference adjusted for BMI;
BRCA	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg08807101	chr21:30365312	RNF160	-0.39	-8.49	-0.32	1.4e-16	Pancreatic cancer;
BRCA	cis	rs7264396	1.000	rs224434	chr20:34153856	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-9.41	-0.35	8.86e-20	Total cholesterol levels;
BRCA	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.43	-0.38	1.3e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.32	-8.18	-0.31	1.52e-15	Total body bone mineral density;
BRCA	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.4	-0.32	2.87e-16	Monocyte percentage of white cells;
BRCA	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg00990874	chr7:1149470	C7orf50	-0.6	-12.52	-0.44	2.49e-32	Bronchopulmonary dysplasia;
BRCA	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-12.53	-0.44	2.33e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg10792982	chr14:105748885	BRF1	0.5	11.39	0.41	1.67e-27	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs7178572	0.568	rs12914345	chr15:77670401	A/C	cg22256960	chr15:77711686	NA	-0.4	-8.66	-0.32	3.78e-17	Type 2 diabetes;
BRCA	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg26597838	chr10:835615	NA	1.31	21.35	0.65	9.17e-77	Eosinophil percentage of granulocytes;
BRCA	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg21535247	chr6:8435926	SLC35B3	0.4	9.05	0.34	1.66e-18	Motion sickness;
BRCA	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg07148914	chr20:33460835	GGT7	-0.36	-7.89	-0.3	1.35e-14	Glomerular filtration rate (creatinine);
BRCA	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg26528668	chr16:1614120	IFT140	0.38	8.55	0.32	9.08e-17	Coronary artery disease;
BRCA	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg00376283	chr12:123451042	ABCB9	-0.49	-11.21	-0.41	9.52e-27	Neutrophil percentage of white cells;
BRCA	cis	rs290268	0.838	rs1319677	chr9:93565999	A/G	cg02608019	chr9:93564028	SYK	0.55	12.26	0.44	3.35e-31	Platelet count;
BRCA	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.57	13.62	0.47	2.81e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	trans	rs1493916	0.837	rs2172626	chr18:31410478	C/T	cg27147174	chr7:100797783	AP1S1	-0.42	-8.48	-0.32	1.55e-16	Life satisfaction;
BRCA	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg10518572	chr11:65560635	OVOL1	-0.28	-8.13	-0.31	2.19e-15	Acne (severe);
BRCA	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg06627628	chr2:24431161	ITSN2	0.76	14.61	0.5	6.62e-42	Asthma;
BRCA	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg06937882	chr20:24974362	C20orf3	-0.48	-9.46	-0.35	5.84e-20	Blood protein levels;
BRCA	cis	rs2580764	0.598	rs6726158	chr2:55239202	G/T	cg09592903	chr2:55203963	RTN4	-0.34	-8.75	-0.33	1.92e-17	Mean platelet volume;
BRCA	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.47	-9.7	-0.36	7.75e-21	Body mass index;
BRCA	cis	rs2463822	1.000	rs951677	chr11:62107249	G/C	cg06239285	chr11:62104954	ASRGL1	0.65	9.73	0.36	5.86e-21	Chronic obstructive pulmonary disease-related biomarkers;
BRCA	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	11.23	0.41	7.92e-27	Glomerular filtration rate (creatinine);
BRCA	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg05283184	chr6:79620031	NA	-0.35	-8.08	-0.3	3.18e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg05340658	chr4:99064831	C4orf37	0.62	14.95	0.51	1.57e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg00757033	chr12:89920650	WDR51B	0.53	10.71	0.39	1.02e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-10.4	-0.38	1.61e-23	Mean corpuscular volume;
BRCA	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg18811423	chr2:55921094	PNPT1	0.72	23.02	0.67	7.54e-86	Metabolic syndrome;
BRCA	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg03060546	chr3:49711283	APEH	-0.59	-10.21	-0.37	9.07e-23	Menarche (age at onset);
BRCA	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg02951883	chr7:2050386	MAD1L1	-0.49	-10.55	-0.39	4.1e-24	Bipolar disorder and schizophrenia;
BRCA	cis	rs143000161	1	rs143000161	chr2:165710540	A/T	cg03182029	chr2:165697222	COBLL1	0.54	10.11	0.37	2.13e-22	Heschl's gyrus morphology;
BRCA	cis	rs6429082	0.818	rs291383	chr1:235643100	G/A	cg26050004	chr1:235667680	B3GALNT2	0.57	14.15	0.49	9.77e-40	Adiposity;
BRCA	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg19284575	chr1:160991224	F11R	-0.45	-8.14	-0.31	2.14e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.37	-9.67	-0.36	9.78e-21	Total body bone mineral density;
BRCA	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg07169764	chr2:136633963	MCM6	-1.27	-26.18	-0.72	3.38e-103	Corneal structure;
BRCA	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg14784868	chr12:69753453	YEATS4	0.68	19.79	0.62	2.42e-68	Blood protein levels;
BRCA	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg25237894	chr2:233734115	C2orf82	0.39	11.0	0.4	6.9e-26	Coronary artery disease;
BRCA	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg21573476	chr21:45109991	RRP1B	-0.36	-9.39	-0.35	1.01e-19	Mean corpuscular volume;
BRCA	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.38	8.14	0.31	2.04e-15	Total cholesterol levels;
BRCA	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg03929089	chr4:120376271	NA	0.8	18.63	0.59	3.48e-62	Coronary artery disease;
BRCA	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-10.0	-0.37	5.53e-22	Alzheimer's disease (late onset);
BRCA	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg19010396	chr19:19431384	KIAA0892;SF4	0.45	9.05	0.34	1.71e-18	Tonsillectomy;
BRCA	cis	rs9811920	0.535	rs792837	chr3:99477182	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-9.96	-0.37	8.22e-22	Axial length;
BRCA	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-9.21	-0.34	4.59e-19	Menopause (age at onset);
BRCA	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-18.56	-0.59	7.46e-62	Total body bone mineral density;
BRCA	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg02476566	chr12:106696527	TCP11L2	-0.51	-9.6	-0.36	1.71e-20	Tourette syndrome;
BRCA	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg24069376	chr3:38537580	EXOG	0.31	8.69	0.32	3.14e-17	Electrocardiographic conduction measures;
BRCA	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.63	13.86	0.48	2.15e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg26384229	chr12:38710491	ALG10B	-0.55	-13.85	-0.48	2.47e-38	Morning vs. evening chronotype;
BRCA	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-10.0	-0.37	5.49e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.38	10.59	0.39	2.87e-24	Response to antipsychotic treatment;
BRCA	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg10932868	chr11:921992	NA	-0.49	-12.61	-0.45	1.03e-32	Alzheimer's disease (late onset);
BRCA	trans	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg25517755	chr10:38738941	LOC399744	-0.38	-7.93	-0.3	9.81e-15	Corneal astigmatism;
BRCA	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg00012203	chr2:219082015	ARPC2	0.5	10.2	0.37	9.9e-23	Colorectal cancer;
BRCA	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22307029	chr19:49891270	CCDC155	0.54	9.11	0.34	1.06e-18	Multiple sclerosis;
BRCA	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg23285459	chr7:2802560	GNA12	-0.36	-8.79	-0.33	1.34e-17	Height;
BRCA	cis	rs13046373	0.535	rs7281767	chr21:32022062	T/C	cg24082983	chr21:31802169	KRTAP13-4	0.32	8.16	0.31	1.74e-15	HDL cholesterol;
BRCA	trans	rs4596713	0.507	rs10217120	chr9:71794919	A/G	cg16512924	chr15:28394682	HERC2	0.45	10.79	0.39	4.85e-25	Headache;
BRCA	cis	rs2249625	0.874	rs2496534	chr6:72922550	C/T	cg18830697	chr6:72922368	RIMS1	-0.38	-7.94	-0.3	9.15e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
BRCA	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11890956	chr21:40555474	PSMG1	-0.61	-13.77	-0.48	5.95e-38	Menarche (age at onset);
BRCA	trans	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg25214090	chr10:38739885	LOC399744	0.54	12.22	0.44	5.01e-31	Corneal astigmatism;
BRCA	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg26384229	chr12:38710491	ALG10B	0.67	13.9	0.48	1.47e-38	Morning vs. evening chronotype;
BRCA	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg03146154	chr1:46216737	IPP	-0.45	-10.13	-0.37	1.84e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24549020	chr5:56110836	MAP3K1	0.41	8.58	0.32	7.34e-17	Initial pursuit acceleration;
BRCA	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg00990874	chr7:1149470	C7orf50	-0.54	-9.66	-0.36	1.05e-20	Bronchopulmonary dysplasia;
BRCA	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg19784903	chr17:45786737	TBKBP1	0.36	8.51	0.32	1.26e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg09307838	chr4:120376055	NA	0.64	13.76	0.48	6.34e-38	Educational attainment;
BRCA	cis	rs698833	0.886	rs8886	chr2:44547909	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.53	-10.81	-0.39	3.8e-25	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg12310025	chr6:25882481	NA	-0.35	-8.42	-0.32	2.45e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs10484885	0.648	rs2777848	chr6:90535993	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.88	-17.42	-0.57	6.58e-56	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs77972916	0.536	rs62137421	chr2:43594091	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-10.88	-0.4	2.06e-25	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg25036284	chr2:26402008	FAM59B	0.61	10.42	0.38	1.38e-23	Gut microbiome composition (summer);
BRCA	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.32	7.94	0.3	9.11e-15	IgG glycosylation;
BRCA	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg11366901	chr6:160182831	ACAT2	0.83	16.08	0.54	4e-49	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10802521	chr3:52805072	NEK4	-0.32	-8.56	-0.32	8.48e-17	Electroencephalogram traits;
BRCA	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.83	-14.24	-0.49	3.66e-40	Alzheimer's disease;
BRCA	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg18129178	chr5:148520854	ABLIM3	-0.55	-11.09	-0.4	2.8e-26	Breast cancer;
BRCA	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg04691961	chr3:161091175	C3orf57	-0.51	-12.67	-0.45	5.78e-33	Morning vs. evening chronotype;
BRCA	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg12140854	chr5:148520817	ABLIM3	-0.43	-9.2	-0.34	4.85e-19	Breast cancer;
BRCA	cis	rs733175	0.904	rs3775944	chr4:10019974	G/T	cg00071950	chr4:10020882	SLC2A9	0.41	7.91	0.3	1.17e-14	Psychosis and Alzheimer's disease;
BRCA	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg05804949	chr7:23719620	C7orf46	0.37	7.85	0.3	1.76e-14	Schizophrenia;
BRCA	cis	rs9392556	0.765	rs613709	chr6:4120683	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.38	-8.02	-0.3	4.96e-15	Blood metabolite levels;
BRCA	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11764359	chr7:65958608	NA	-0.77	-17.55	-0.57	1.38e-56	Aortic root size;
BRCA	trans	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg19862616	chr7:65841803	NCRNA00174	0.81	25.64	0.71	3.13e-100	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg24006582	chr15:45444508	DUOX1	-0.55	-11.32	-0.41	3.43e-27	Uric acid levels;
BRCA	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg13010199	chr12:38710504	ALG10B	0.44	8.5	0.32	1.31e-16	Morning vs. evening chronotype;
BRCA	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg22906224	chr7:99728672	NA	0.42	7.8	0.3	2.44e-14	Coronary artery disease;
BRCA	cis	rs7520050	0.966	rs7515491	chr1:46355079	A/G	cg24296786	chr1:45957014	TESK2	0.4	9.15	0.34	7.45e-19	Red blood cell count;Reticulocyte count;
BRCA	cis	rs3812565	0.506	rs8413	chr9:139323311	T/C	cg14019695	chr9:139328340	INPP5E	0.45	11.83	0.42	2.37e-29	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg05340658	chr4:99064831	C4orf37	0.59	11.9	0.43	1.29e-29	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg18402987	chr7:1209562	NA	0.48	9.13	0.34	8.57e-19	Longevity;Endometriosis;
BRCA	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.32	8.36	0.31	3.8e-16	Monocyte percentage of white cells;
BRCA	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg15556689	chr8:8085844	FLJ10661	0.41	11.9	0.43	1.21e-29	Mood instability;
BRCA	cis	rs921968	0.565	rs13408305	chr2:219628183	G/A	cg02176678	chr2:219576539	TTLL4	-0.41	-11.01	-0.4	6.4e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs13046373	0.507	rs11088139	chr21:31978884	T/G	cg22337977	chr21:31811175	KRTAP15-1	0.35	8.36	0.31	4.03e-16	HDL cholesterol;
BRCA	trans	rs330048	0.545	rs11774353	chr8:9153127	C/T	cg08975724	chr8:8085496	FLJ10661	0.47	9.4	0.35	9.32e-20	Systemic lupus erythematosus;
BRCA	trans	rs1973993	0.691	rs1980684	chr1:96890636	A/G	cg10631902	chr5:14652156	NA	0.57	19.73	0.62	5.29e-68	Weight;
BRCA	cis	rs501916	0.634	rs1045688	chr15:48065487	A/G	cg16110827	chr15:48056943	SEMA6D	0.41	8.42	0.32	2.5e-16	Inflammatory bowel disease;Ulcerative colitis;
BRCA	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21659725	chr3:3221576	CRBN	-0.49	-10.3	-0.38	3.95e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg01448562	chr3:133502909	NA	-0.76	-19.03	-0.6	2.57e-64	Iron status biomarkers;
BRCA	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg13010199	chr12:38710504	ALG10B	0.44	8.95	0.33	3.88e-18	Bladder cancer;
BRCA	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11644478	chr21:40555479	PSMG1	0.67	15.13	0.51	1.9e-44	Cognitive function;
BRCA	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg11584989	chr19:19387371	SF4	0.6	12.31	0.44	2.03e-31	Bipolar disorder;
BRCA	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26818010	chr10:134567672	INPP5A	0.79	16.1	0.54	3.43e-49	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs4812048	0.846	rs151361	chr20:57614002	A/G	cg14073986	chr20:57617431	SLMO2	0.43	8.26	0.31	8.13e-16	Mean platelet volume;
BRCA	cis	rs895636	0.519	rs4953155	chr2:45189496	A/T	cg16198908	chr2:45192207	NA	-0.37	-8.06	-0.3	3.63e-15	Metabolite levels;Fasting plasma glucose;
BRCA	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg19628046	chr18:33552617	C18orf21	0.53	10.37	0.38	2.07e-23	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg06636001	chr8:8085503	FLJ10661	0.6	13.27	0.46	1.18e-35	Mood instability;
BRCA	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-15.66	-0.53	5.27e-47	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2066819	0.892	rs112931321	chr12:56667894	C/T	cg26714650	chr12:56694279	CS	-1.19	-15.69	-0.53	3.47e-47	Psoriasis vulgaris;
BRCA	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05901451	chr6:126070800	HEY2	0.69	20.02	0.62	1.39e-69	Brugada syndrome;
BRCA	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg03954927	chr1:10346856	KIF1B	0.44	13.98	0.48	5.84e-39	Hepatocellular carcinoma;
BRCA	cis	rs2012796	0.956	rs7146802	chr14:81820515	A/G	cg02996355	chr14:81879375	NA	0.51	9.82	0.36	2.77e-21	Night sleep phenotypes;
BRCA	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg11366901	chr6:160182831	ACAT2	0.83	16.08	0.54	4e-49	Age-related macular degeneration (geographic atrophy);
BRCA	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg00105475	chr2:10696890	NA	0.44	10.41	0.38	1.51e-23	Prostate cancer;
BRCA	cis	rs34779708	0.900	rs73262807	chr10:35496386	C/T	cg03585969	chr10:35415529	CREM	0.49	10.38	0.38	2.0500000000000001e-23	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg00409905	chr10:38381863	ZNF37A	-0.47	-9.92	-0.37	1.16e-21	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2425143	0.643	rs6058324	chr20:34388789	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.07	-0.34	1.48e-18	Blood protein levels;
BRCA	cis	rs11955398	0.585	rs1117674	chr5:60035007	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.37	-8.95	-0.33	3.75e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs7944584	1.000	rs7944584	chr11:47336320	A/T	cg20307385	chr11:47447363	PSMC3	0.62	12.14	0.43	1.18e-30	Fasting blood glucose;Fasting blood glucose (BMI interaction);
BRCA	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg23096020	chr7:158799433	NA	0.45	10.46	0.38	9.91e-24	Facial morphology (factor 20);
BRCA	cis	rs4631830	0.600	rs11004324	chr10:51496623	G/T	cg16070123	chr10:51489643	NA	-0.37	-8.11	-0.31	2.63e-15	Prostate-specific antigen levels;
BRCA	cis	rs7520050	0.966	rs11211234	chr1:46438787	C/A	cg24296786	chr1:45957014	TESK2	0.44	9.76	0.36	4.56e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg07395648	chr5:131743802	NA	-0.4	-9.92	-0.37	1.1e-21	Blood metabolite levels;
BRCA	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg14004847	chr7:1930337	MAD1L1	-0.41	-8.11	-0.31	2.66e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.5	9.4	0.35	9.96e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg25173405	chr17:45401733	C17orf57	-0.5	-10.5	-0.38	6.69e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg27489772	chr12:121021490	NA	0.45	8.02	0.3	5.07e-15	Type 1 diabetes nephropathy;
BRCA	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-10.28	-0.38	4.68e-23	Reticulocyte count;
BRCA	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg15017067	chr4:17643749	FAM184B	-0.29	-8.57	-0.32	7.96e-17	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	11.58	0.42	2.86e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg25358565	chr5:93447407	FAM172A	-0.5	-8.88	-0.33	6.68e-18	Diabetic retinopathy;
BRCA	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg14036092	chr11:66035641	RAB1B	0.39	10.56	0.39	4e-24	Gout;
BRCA	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10802521	chr3:52805072	NEK4	0.32	8.01	0.3	5.51e-15	Bipolar disorder;
BRCA	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg24692254	chr21:30365293	RNF160	-0.64	-16.62	-0.55	7.79e-52	Dental caries;
BRCA	cis	rs3818285	0.515	rs4918471	chr10:111660500	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.37	-9.79	-0.36	3.54e-21	Superior crus of antihelix expression;
BRCA	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.43	-0.41	1.22e-27	Extrinsic epigenetic age acceleration;
BRCA	cis	rs2130392	1.000	rs3796689	chr4:185649866	C/A	cg04058563	chr4:185651563	MLF1IP	0.39	9.56	0.35	2.52e-20	Kawasaki disease;
BRCA	cis	rs10193935	0.901	rs13384404	chr2:42601147	G/T	cg27598129	chr2:42591480	NA	-0.86	-14.34	-0.49	1.24e-40	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg20587970	chr11:113659929	NA	1.13	21.13	0.64	1.56e-75	Hip circumference adjusted for BMI;
BRCA	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.92	18.66	0.59	2.4e-62	Body mass index;
BRCA	cis	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg21775007	chr8:11205619	TDH	-0.47	-9.81	-0.36	2.86e-21	Triglycerides;
BRCA	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg06547715	chr2:218990976	CXCR2	0.32	8.01	0.3	5.29e-15	Ulcerative colitis;
BRCA	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg27170947	chr2:26402098	FAM59B	0.93	16.76	0.55	1.67e-52	Gut microbiome composition (summer);
BRCA	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg25110126	chr1:46999211	NA	0.74	13.82	0.48	3.45e-38	Monobrow;
BRCA	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.35	0.57	1.52e-55	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-13.19	-0.46	2.72e-35	Bladder cancer;
BRCA	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.69	0.39	1.22e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg22920501	chr2:26401640	FAM59B	-0.9	-16.11	-0.54	3.04e-49	Gut microbiome composition (summer);
BRCA	cis	rs16976116	0.901	rs1061870	chr15:55496769	G/T	cg11288833	chr15:55489084	RSL24D1	0.47	10.67	0.39	1.37e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03452623	chr4:187889614	NA	0.35	11.52	0.41	4.77e-28	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg12591125	chr7:1885375	MAD1L1	0.46	7.85	0.3	1.8e-14	Bipolar disorder;
BRCA	cis	rs6973256	0.897	rs9656422	chr7:133324665	C/T	cg07491979	chr7:133331646	EXOC4	-0.38	-8.74	-0.33	2.03e-17	Intelligence (multi-trait analysis);
BRCA	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg00080972	chr5:178986291	RUFY1	0.37	8.43	0.32	2.37e-16	Lung cancer;
BRCA	trans	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg26043149	chr18:55253948	FECH	-0.38	-8.34	-0.31	4.43e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs877282	0.945	rs10904555	chr10:787740	C/A	cg17470449	chr10:769945	NA	0.51	8.63	0.32	4.87e-17	Uric acid levels;
BRCA	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg16230307	chr14:35515116	FAM177A1	0.73	15.16	0.51	1.44e-44	Psoriasis;
BRCA	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg20848291	chr7:100343083	ZAN	0.64	13.62	0.47	2.83e-37	Other erythrocyte phenotypes;
BRCA	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-9.18	-0.34	6.07e-19	Chronic sinus infection;
BRCA	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08219700	chr8:58056026	NA	0.54	8.9	0.33	5.58e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg27478167	chr7:817139	HEATR2	0.44	9.59	0.35	1.95e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg20790798	chr5:1857306	NA	-0.39	-9.16	-0.34	6.78e-19	Cardiovascular disease risk factors;
BRCA	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-16.24	-0.54	6.41e-50	Morning vs. evening chronotype;
BRCA	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg23625390	chr15:77176239	SCAPER	-0.51	-11.94	-0.43	8.44e-30	Blood metabolite levels;
BRCA	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg15017067	chr4:17643749	FAM184B	0.34	10.35	0.38	2.6e-23	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-10.75	-0.39	7.18e-25	Bipolar disorder;
BRCA	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg05340658	chr4:99064831	C4orf37	0.69	17.41	0.57	7.61e-56	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg13010199	chr12:38710504	ALG10B	0.43	9.11	0.34	1.04e-18	Morning vs. evening chronotype;
BRCA	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-9.82	-0.36	2.79e-21	Monocyte percentage of white cells;
BRCA	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg06138931	chr13:21896616	NA	-0.5	-8.63	-0.32	4.68e-17	White matter hyperintensity burden;
BRCA	cis	rs2880765	0.835	rs4281668	chr15:86047286	C/T	cg10818794	chr15:86012489	AKAP13	-0.29	-7.82	-0.3	2.13e-14	Coronary artery disease;
BRCA	cis	rs17253792	0.822	rs11546	chr14:56146357	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-10.26	-0.38	5.89e-23	Putamen volume;
BRCA	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg21361702	chr7:150065534	REPIN1	0.51	10.44	0.38	1.13e-23	Blood protein levels;Circulating chemerin levels;
BRCA	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg05535760	chr7:792225	HEATR2	-0.71	-11.42	-0.41	1.24e-27	Cerebrospinal P-tau181p levels;
BRCA	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21659725	chr3:3221576	CRBN	-0.35	-8.07	-0.3	3.45e-15	Body mass index;
BRCA	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg16325326	chr1:53192061	ZYG11B	-0.56	-11.53	-0.42	4.35e-28	Monocyte count;
BRCA	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg07395648	chr5:131743802	NA	0.38	8.23	0.31	1.02e-15	Breast cancer;
BRCA	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg26597838	chr10:835615	NA	0.52	9.16	0.34	6.78e-19	Response to angiotensin II receptor blocker therapy;
BRCA	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg18252515	chr7:66147081	NA	1.06	16.03	0.54	7.81e-49	Diabetic kidney disease;
BRCA	cis	rs858239	0.698	rs858295	chr7:23245569	A/G	cg23682824	chr7:23144976	KLHL7	0.31	7.96	0.3	7.66e-15	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	15.9	0.53	3.34e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg14993813	chr1:46806288	NSUN4	-0.49	-9.61	-0.36	1.69e-20	Menopause (age at onset);
BRCA	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg03146154	chr1:46216737	IPP	-0.5	-11.22	-0.41	8.47e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg02659138	chr7:134003124	SLC35B4	-0.29	-8.83	-0.33	1e-17	Mean platelet volume;
BRCA	cis	rs7617773	0.817	rs13094727	chr3:48323489	G/A	cg11946769	chr3:48343235	NME6	0.67	13.65	0.48	2.04e-37	Coronary artery disease;
BRCA	cis	rs2016266	0.896	rs3741663	chr12:53664015	G/A	cg26875137	chr12:53738046	NA	0.35	9.54	0.35	2.94e-20	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-9.79	-0.36	3.4e-21	Height;
BRCA	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06544989	chr22:39130855	UNC84B	0.37	9.13	0.34	8.96e-19	Menopause (age at onset);
BRCA	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-11.3	-0.41	3.86e-27	Bone mineral density;
BRCA	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg10932868	chr11:921992	NA	0.49	12.38	0.44	1.09e-31	Alzheimer's disease (late onset);
BRCA	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg13256891	chr4:100009986	ADH5	0.54	9.98	0.37	7.03e-22	Smoking initiation;
BRCA	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg05347473	chr6:146136440	FBXO30	0.41	8.06	0.3	3.74e-15	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs3857536	0.740	rs7745163	chr6:66889936	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-9.67	-0.36	1.01e-20	Blood trace element (Cu levels);
BRCA	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg01528321	chr10:82214614	TSPAN14	0.72	16.16	0.54	1.66e-49	Post bronchodilator FEV1;
BRCA	trans	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg06521331	chr12:34319734	NA	0.47	9.3	0.35	2.26e-19	Bladder cancer;
BRCA	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg01065977	chr19:18549689	ISYNA1	-0.29	-8.78	-0.33	1.46e-17	Breast cancer;
BRCA	cis	rs2066819	1.000	rs17118403	chr12:56630067	C/T	cg26734620	chr12:56694298	CS	0.86	9.88	0.36	1.64e-21	Psoriasis vulgaris;
BRCA	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg03474202	chr17:45855739	NA	-0.47	-12.55	-0.44	1.8e-32	IgG glycosylation;
BRCA	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.59	12.98	0.46	2.31e-34	Hemoglobin concentration;
BRCA	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.97	21.93	0.66	6.99e-80	Smoking behavior;
BRCA	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg16325326	chr1:53192061	ZYG11B	0.71	17.04	0.56	5.67e-54	Monocyte count;
BRCA	cis	rs2505998	1.000	rs2435357	chr10:43582056	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.41	-7.94	-0.3	9.29e-15	Hirschsprung disease;
BRCA	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.44	0.38	1.12e-23	Motion sickness;
BRCA	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg12573674	chr2:1569213	NA	-0.61	-13.42	-0.47	2.46e-36	Placebo response in major depressive disorder (% change in symptom score);
BRCA	trans	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-12.2	-0.43	6.38e-31	Initial pursuit acceleration in psychotic disorders;
BRCA	cis	rs3771570	1.000	rs62186400	chr2:242226700	A/G	cg21155796	chr2:242212141	HDLBP	0.6	9.49	0.35	4.51e-20	Prostate cancer;
BRCA	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg22974920	chr21:40686053	BRWD1	0.4	9.03	0.34	1.99e-18	Cognitive function;
BRCA	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03264133	chr6:25882463	NA	-0.54	-11.46	-0.41	8.77e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs7677751	0.767	rs6554158	chr4:55066077	G/A	cg17187183	chr4:55093834	PDGFRA	0.4	8.2	0.31	1.34e-15	Corneal astigmatism;
BRCA	trans	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-20.07	-0.62	7.65e-70	Exhaled nitric oxide output;
BRCA	trans	rs7178375	0.941	rs4779796	chr15:31208050	C/T	cg04373760	chr16:53404718	NA	0.47	8.85	0.33	8.41e-18	Hypertriglyceridemia;
BRCA	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg15448220	chr1:150897856	SETDB1	0.37	8.25	0.31	8.72e-16	Melanoma;
BRCA	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg09582351	chr12:29534625	ERGIC2	-0.41	-9.62	-0.36	1.51e-20	QT interval;
BRCA	cis	rs3772130	0.962	rs9848027	chr3:121551227	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	10.64	0.39	1.94e-24	Cognitive performance;
BRCA	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg02187348	chr16:89574699	SPG7	0.46	11.03	0.4	5.04e-26	Multiple myeloma (IgH translocation);
BRCA	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg03929089	chr4:120376271	NA	-0.66	-12.93	-0.46	3.9e-34	Coronary artery disease;
BRCA	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg08392591	chr16:89556376	ANKRD11	0.52	12.66	0.45	6.47e-33	Multiple myeloma (IgH translocation);
BRCA	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg21143896	chr7:2802374	GNA12	0.34	8.52	0.32	1.11e-16	Height;
BRCA	cis	rs921968	0.565	rs6436086	chr2:219640125	T/C	cg02176678	chr2:219576539	TTLL4	-0.41	-11.04	-0.4	4.9e-26	Mean corpuscular hemoglobin concentration;
BRCA	trans	rs75804782	0.630	rs79693451	chr2:239296473	A/G	cg01134436	chr17:81009848	B3GNTL1	0.76	7.94	0.3	9.25e-15	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-9.74	-0.36	5.28e-21	Glomerular filtration rate in chronic kidney disease;
BRCA	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg07148914	chr20:33460835	GGT7	0.38	8.62	0.32	5.15e-17	Height;
BRCA	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22857025	chr5:266934	NA	-1.04	-19.98	-0.62	2.21e-69	Breast cancer;
BRCA	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg12072164	chr19:44306565	LYPD5	0.36	8.7	0.33	2.75e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg11584989	chr19:19387371	SF4	0.62	13.31	0.47	7.53e-36	Bipolar disorder;
BRCA	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg18154014	chr19:37997991	ZNF793	0.48	9.41	0.35	8.49e-20	Coronary artery calcification;
BRCA	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-9.72	-0.36	6.22e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg13319975	chr6:146136371	FBXO30	-0.4	-8.69	-0.33	3.01e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-11.76	-0.42	4.84e-29	Developmental language disorder (linguistic errors);
BRCA	trans	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg25214090	chr10:38739885	LOC399744	0.43	10.0	0.37	5.45e-22	Corneal astigmatism;
BRCA	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg05340658	chr4:99064831	C4orf37	0.49	10.73	0.39	8.14e-25	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6878727	0.815	rs9885338	chr5:123725320	G/A	cg01806427	chr5:123737813	NA	0.42	9.58	0.35	2.09e-20	Breast cancer;
BRCA	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg00106254	chr7:1943704	MAD1L1	0.39	10.12	0.37	2.04e-22	Bipolar disorder and schizophrenia;
BRCA	cis	rs17209837	0.607	rs10452936	chr7:87094306	C/A	cg00919237	chr7:87102261	ABCB4	-0.53	-10.2	-0.37	9.44e-23	Gallbladder cancer;
BRCA	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg02711726	chr17:80685570	FN3KRP	0.68	16.5	0.55	3.31e-51	Glycated hemoglobin levels;
BRCA	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg08645402	chr16:4508243	NA	0.37	8.64	0.32	4.52e-17	Schizophrenia;
BRCA	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	12.48	0.44	3.99e-32	Coronary artery disease;
BRCA	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg05340658	chr4:99064831	C4orf37	0.51	9.75	0.36	5.14e-21	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17509989	chr5:176798049	RGS14	0.67	13.13	0.46	5.08e-35	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs2777491	0.574	rs11635906	chr15:41779260	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-25.06	-0.7	4.72e-97	Ulcerative colitis;
BRCA	cis	rs2522056	1.000	rs7730247	chr5:131781288	A/C	cg24060327	chr5:131705240	SLC22A5	0.44	7.82	0.3	2.26e-14	Lymphocyte counts;Fibrinogen;
BRCA	trans	rs208520	1.000	rs208537	chr6:66963544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-14.55	-0.5	1.24e-41	Exhaled nitric oxide output;
BRCA	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg26384229	chr12:38710491	ALG10B	0.74	17.65	0.57	4.53e-57	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg20933634	chr6:27740509	NA	0.43	8.42	0.32	2.57e-16	Parkinson's disease;
BRCA	cis	rs870825	0.616	rs28666955	chr4:185631338	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	17.14	0.56	1.9e-54	Blood protein levels;
BRCA	cis	rs1691799	0.899	rs1168351	chr12:66752505	A/G	cg16791601	chr12:66731901	HELB	-0.67	-18.63	-0.59	3.23e-62	White blood cell count (basophil);
BRCA	cis	rs12618769	0.652	rs3769698	chr2:99233894	T/C	cg10123293	chr2:99228465	UNC50	0.42	8.41	0.32	2.65e-16	Bipolar disorder;
BRCA	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.13	-18.74	-0.6	8.96e-63	Hemostatic factors and hematological phenotypes;
BRCA	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg13010199	chr12:38710504	ALG10B	-0.38	-8.74	-0.33	2e-17	Morning vs. evening chronotype;
BRCA	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg01262667	chr19:19385393	TM6SF2	0.4	10.49	0.38	7.35e-24	Tonsillectomy;
BRCA	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg13010199	chr12:38710504	ALG10B	0.35	8.02	0.3	4.98e-15	Morning vs. evening chronotype;
BRCA	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.66	-12.91	-0.45	4.93e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg07460842	chr6:66804631	NA	-1.13	-35.7	-0.82	2.49e-154	Exhaled nitric oxide output;
BRCA	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg12463550	chr7:65579703	CRCP	0.37	7.87	0.3	1.56e-14	Aortic root size;
BRCA	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.26	8.14	0.31	2.05e-15	Cardiac Troponin-T levels;
BRCA	cis	rs8022179	0.580	rs6575979	chr14:103841018	A/G	cg12935359	chr14:103987150	CKB	-0.47	-9.43	-0.35	7.15e-20	Monocyte count;
BRCA	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg17420585	chr12:42539391	GXYLT1	-0.49	-10.61	-0.39	2.54e-24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.32	-7.98	-0.3	6.81e-15	Total body bone mineral density;
BRCA	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11644478	chr21:40555479	PSMG1	0.83	19.15	0.6	6.37e-65	Cognitive function;
BRCA	cis	rs1568889	1.000	rs33937991	chr11:28045260	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	14.66	0.5	3.59e-42	Bipolar disorder;
BRCA	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.53	7.89	0.3	1.31e-14	Cerebrospinal P-tau181p levels;
BRCA	cis	rs701145	0.585	rs62276841	chr3:153783645	C/T	cg17054900	chr3:154042577	DHX36	-0.53	-9.19	-0.34	5.48e-19	Coronary artery disease;
BRCA	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg18230493	chr5:56204884	C5orf35	-0.57	-12.26	-0.44	3.37e-31	Coronary artery disease;
BRCA	cis	rs12711979	0.765	rs7559461	chr2:3818623	G/A	cg17052675	chr2:3827356	NA	-0.48	-14.1	-0.49	1.76e-39	Itch intensity from mosquito bite adjusted by bite size;
BRCA	trans	rs12517041	1.000	rs1428624	chr5:23290393	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.45	-8.13	-0.31	2.16e-15	Calcium levels;
BRCA	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg09184832	chr6:79620586	NA	-0.41	-8.25	-0.31	9.35e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs490234	0.552	rs2841327	chr9:128156503	G/A	cg14078157	chr9:128172775	NA	-0.43	-10.23	-0.38	7.21e-23	Mean arterial pressure;
BRCA	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00802000	chr16:706648	WDR90	-0.41	-9.65	-0.36	1.16e-20	Height;
BRCA	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg11764359	chr7:65958608	NA	-0.68	-15.39	-0.52	1.07e-45	Aortic root size;
BRCA	cis	rs7646881	0.812	rs59957986	chr3:158458913	G/A	cg19483011	chr3:158453295	NA	-0.45	-7.97	-0.3	7.58e-15	Tetralogy of Fallot;
BRCA	cis	rs495337	1.000	rs1056198	chr20:48556229	C/T	cg17835207	chr20:48524531	SPATA2	-0.58	-13.13	-0.46	5e-35	Psoriasis;
BRCA	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg04727924	chr7:799746	HEATR2	-0.55	-10.72	-0.39	9.37e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.72	-19.81	-0.62	1.94e-68	Electrocardiographic conduction measures;
BRCA	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg14019146	chr3:50243930	SLC38A3	0.64	15.96	0.53	1.67e-48	Intelligence (multi-trait analysis);
BRCA	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg26248373	chr2:1572462	NA	-0.51	-10.19	-0.37	1.11e-22	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs6684514	1.000	rs67034206	chr1:156270260	C/T	cg16558208	chr1:156270281	VHLL	0.36	8.43	0.32	2.35e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg06115741	chr20:33292138	TP53INP2	-0.37	-8.15	-0.31	1.89e-15	Glomerular filtration rate (creatinine);
BRCA	cis	rs929596	0.556	rs10168416	chr2:234597087	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-9.57	-0.35	2.29e-20	Total bilirubin levels in HIV-1 infection;
BRCA	cis	rs11971779	0.650	rs10085842	chr7:139064582	A/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.21	0.37	9.03e-23	Diisocyanate-induced asthma;
BRCA	cis	rs1577917	1.000	rs2816815	chr6:86691656	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-11.23	-0.41	7.63e-27	Response to antipsychotic treatment;
BRCA	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg15017067	chr4:17643749	FAM184B	0.29	8.85	0.33	8.48e-18	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg11833968	chr6:79620685	NA	-0.44	-9.81	-0.36	2.92e-21	Intelligence (multi-trait analysis);
BRCA	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-11.85	-0.42	1.96e-29	Pulmonary function;
BRCA	cis	rs7809950	1.000	rs3801944	chr7:107255548	T/C	cg23024343	chr7:107201750	COG5	0.36	8.24	0.31	1e-15	Coronary artery disease;
BRCA	cis	rs10193935	0.901	rs7594010	chr2:42534896	C/T	cg27598129	chr2:42591480	NA	-0.95	-14.79	-0.5	8.83e-43	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	11.37	0.41	2.13e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4363385	0.818	rs4845514	chr1:153000820	T/C	cg25856811	chr1:152973957	SPRR3	-0.32	-8.4	-0.32	2.84e-16	Inflammatory skin disease;
BRCA	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-12.82	-0.45	1.24e-33	Blood metabolite levels;
BRCA	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg07952391	chr2:88470173	THNSL2	0.64	8.61	0.32	5.56e-17	Plasma clusterin levels;
BRCA	cis	rs7408868	1.000	rs10418305	chr19:15278808	C/G	cg14696996	chr19:15285081	NOTCH3	1.0	14.52	0.5	1.76e-41	Pulse pressure;
BRCA	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg17366294	chr4:99064904	C4orf37	0.41	9.64	0.36	1.23e-20	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg09307838	chr4:120376055	NA	0.66	14.21	0.49	4.94e-40	Corneal astigmatism;
BRCA	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg09184832	chr6:79620586	NA	-0.54	-11.94	-0.43	8.48e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs701145	0.585	rs1727884	chr3:153838368	A/C	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.22e-14	Coronary artery disease;
BRCA	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg14196790	chr5:131705035	SLC22A5	0.44	10.69	0.39	1.18e-24	Breast cancer;Mosquito bite size;
BRCA	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	16.64	0.55	6.17e-52	Colorectal cancer;
BRCA	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18404041	chr3:52824283	ITIH1	-0.38	-11.76	-0.42	4.7e-29	Bipolar disorder;
BRCA	trans	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg01620082	chr3:125678407	NA	-0.63	-8.39	-0.32	3.12e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	9.02	0.34	2.15e-18	Schizophrenia;
BRCA	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg11752832	chr7:134001865	SLC35B4	0.53	13.8	0.48	4.03e-38	Mean platelet volume;
BRCA	cis	rs17818399	0.510	rs1451153	chr2:46799852	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.53	11.12	0.4	2.27e-26	Height;
BRCA	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg18301423	chr5:131593218	PDLIM4	0.35	8.75	0.33	1.93e-17	Acylcarnitine levels;
BRCA	cis	rs12431939	1.000	rs67113863	chr14:51653103	G/C	cg23942311	chr14:51606299	NA	-0.44	-8.2	-0.31	1.36e-15	Cancer;
BRCA	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.41	8.79	0.33	1.33e-17	Alzheimer's disease (late onset);
BRCA	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.5	-11.16	-0.4	1.58e-26	IgG glycosylation;
BRCA	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg17063962	chr7:91808500	NA	0.52	12.42	0.44	6.92e-32	Breast cancer;
BRCA	cis	rs2742234	0.590	rs2503863	chr10:43667398	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.55	-11.04	-0.4	4.86e-26	Hirschsprung disease;
BRCA	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-10.14	-0.37	1.7e-22	Schizophrenia;
BRCA	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg26384229	chr12:38710491	ALG10B	0.42	9.45	0.35	6.27e-20	Morning vs. evening chronotype;
BRCA	cis	rs11874712	1.000	rs8089150	chr18:43674300	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.34	8.05	0.3	4.16e-15	Migraine - clinic-based;
BRCA	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg06108461	chr20:60628389	TAF4	-0.71	-14.9	-0.51	2.59e-43	Body mass index;
BRCA	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg03676636	chr4:99064102	C4orf37	0.2	7.9	0.3	1.2e-14	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1904096	0.506	rs13434570	chr4:95168019	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.44	-10.2	-0.37	9.63e-23	Type 2 diabetes;
BRCA	cis	rs17023223	0.537	rs10923767	chr1:119732347	C/T	cg05756136	chr1:119680316	WARS2	-0.42	-8.16	-0.31	1.72e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
BRCA	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg05472934	chr7:22766657	IL6	0.48	12.45	0.44	5.29e-32	Lung cancer;
BRCA	cis	rs6960043	0.818	rs10238625	chr7:15054232	A/G	cg19272540	chr7:15055459	NA	0.22	8.02	0.3	4.93e-15	Type 2 diabetes;
BRCA	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg15605315	chr1:45957053	TESK2	0.46	9.38	0.35	1.18e-19	High light scatter reticulocyte count;
BRCA	cis	rs1691799	0.899	rs1177555	chr12:66727568	A/G	cg16791601	chr12:66731901	HELB	-0.65	-17.46	-0.57	4.37e-56	White blood cell count (basophil);
BRCA	cis	rs870825	0.616	rs4519834	chr4:185633865	A/G	cg04058563	chr4:185651563	MLF1IP	-0.79	-18.1	-0.58	2.04e-59	Blood protein levels;
BRCA	trans	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg25214090	chr10:38739885	LOC399744	0.54	11.83	0.42	2.49e-29	Corneal astigmatism;
BRCA	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg00530320	chr1:46809349	NSUN4	0.48	9.66	0.36	1.1e-20	Menopause (age at onset);
BRCA	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg04851639	chr8:1020857	NA	-0.39	-11.21	-0.41	9.63e-27	Schizophrenia;
BRCA	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	17.72	0.57	1.83e-57	Electrocardiographic conduction measures;
BRCA	cis	rs6717918	0.620	rs7570112	chr2:233150452	A/G	ch.2.233013039R	chr2:233304795	NA	0.45	9.39	0.35	1.02e-19	Height;
BRCA	cis	rs698833	1.000	rs698833	chr2:44735438	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	9.54	0.35	3.07e-20	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg04450456	chr4:17643702	FAM184B	0.37	11.01	0.4	6.09e-26	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs79387448	0.638	rs116055209	chr2:103032189	C/T	cg09003973	chr2:102972529	NA	0.59	8.8	0.33	1.22e-17	Gut microbiota (bacterial taxa);
BRCA	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	13.49	0.47	1.16e-36	Colorectal cancer;
BRCA	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.57	-9.79	-0.36	3.54e-21	Gut microbiome composition (summer);
BRCA	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg24812749	chr6:127587940	RNF146	0.87	19.64	0.61	1.51e-67	Breast cancer;
BRCA	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	11.12	0.4	2.27e-26	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
BRCA	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.53	8.05	0.3	4.13e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-7.85	-0.3	1.77e-14	Breast cancer;
BRCA	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg09307838	chr4:120376055	NA	0.69	14.08	0.49	2.13e-39	Corneal astigmatism;
BRCA	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg18016565	chr1:150552671	MCL1	-0.44	-9.76	-0.36	4.62e-21	Tonsillectomy;
BRCA	trans	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04565464	chr8:145669602	NFKBIL2	0.38	8.77	0.33	1.61e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg03709012	chr19:19516395	GATAD2A	0.8	18.47	0.59	2.3e-61	Tonsillectomy;
BRCA	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg25358565	chr5:93447407	FAM172A	1.14	18.59	0.59	5.23e-62	Diabetic retinopathy;
BRCA	cis	rs7714584	1.000	rs11957134	chr5:150230950	A/G	cg22134413	chr5:150180641	NA	-0.67	-10.35	-0.38	2.66e-23	Crohn's disease;
BRCA	cis	rs887829	0.507	rs10929301	chr2:234663649	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.3	-7.89	-0.3	1.3e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	cis	rs6066825	0.644	rs6095248	chr20:47320932	A/G	cg18078177	chr20:47281410	PREX1	0.41	10.1	0.37	2.46e-22	Colorectal cancer;
BRCA	cis	rs760805	1.000	rs61774728	chr1:25258867	G/C	cg22509179	chr1:25234806	RUNX3	-0.57	-14.68	-0.5	2.96e-42	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs2011503	0.739	rs4808973	chr19:19725456	A/G	cg15839431	chr19:19639596	YJEFN3	0.35	7.99	0.3	6.13e-15	Bipolar disorder;
BRCA	cis	rs9308433	0.529	rs867444	chr1:214502160	T/C	cg06198575	chr1:214491504	SMYD2	0.53	11.62	0.42	1.94e-28	IgG glycosylation;
BRCA	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg15934090	chr1:100435551	SLC35A3	0.36	8.38	0.31	3.28e-16	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg20203395	chr5:56204925	C5orf35	-0.5	-10.64	-0.39	1.83e-24	Initial pursuit acceleration;
BRCA	cis	rs68170813	0.559	rs4730232	chr7:106942382	G/C	cg02696742	chr7:106810147	HBP1	-0.53	-8.55	-0.32	9.34e-17	Coronary artery disease;
BRCA	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg08807101	chr21:30365312	RNF160	0.74	18.87	0.6	1.91e-63	Dental caries;
BRCA	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.28	0.31	7.49e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg03146154	chr1:46216737	IPP	-0.49	-10.8	-0.39	4.37e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg21573476	chr21:45109991	RRP1B	-0.35	-9.5	-0.35	4.07e-20	Mean corpuscular volume;
BRCA	cis	rs9790314	0.582	rs13071909	chr3:160604864	A/G	cg03342759	chr3:160939853	NMD3	0.43	8.29	0.31	6.73e-16	Morning vs. evening chronotype;
BRCA	cis	rs3820928	0.874	rs4144328	chr2:227790187	A/C	cg05526886	chr2:227700861	RHBDD1	-0.38	-7.89	-0.3	1.36e-14	Pulmonary function;
BRCA	cis	rs17401966	0.627	rs35859381	chr1:10466040	G/A	cg19773385	chr1:10388646	KIF1B	-0.37	-7.95	-0.3	8.73e-15	Hepatocellular carcinoma;
BRCA	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg24011408	chr12:48396354	COL2A1	0.42	8.26	0.31	8.12e-16	Bipolar disorder and schizophrenia;
BRCA	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-10.5	-0.38	6.58e-24	Daytime sleep phenotypes;
BRCA	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg05347473	chr6:146136440	FBXO30	0.42	8.45	0.32	2.03e-16	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-12.6	-0.45	1.13e-32	Developmental language disorder (linguistic errors);
BRCA	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	8.28	0.31	7.36e-16	Tonsillectomy;
BRCA	cis	rs5167	0.504	rs892101	chr19:45455458	G/A	cg10169327	chr19:45448959	APOC2	0.31	7.94	0.3	9.02e-15	Blood protein levels;
BRCA	trans	rs6479891	1.000	rs4746119	chr10:65129917	T/C	cg14819942	chr15:35414228	NA	0.35	8.6	0.32	6e-17	Arthritis (juvenile idiopathic);
BRCA	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg04025307	chr7:1156635	C7orf50	0.58	9.08	0.34	1.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg02743256	chr7:2109353	MAD1L1	-0.46	-8.12	-0.31	2.36e-15	Neuroticism;
BRCA	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg08392591	chr16:89556376	ANKRD11	0.53	13.02	0.46	1.54e-34	Multiple myeloma (IgH translocation);
BRCA	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg01448562	chr3:133502909	NA	-0.61	-14.38	-0.49	7.95e-41	Iron status biomarkers;
BRCA	cis	rs6001027	0.517	rs2284060	chr22:38543453	A/G	cg25457927	chr22:38595422	NA	-0.27	-9.73	-0.36	6.12e-21	Melanoma;
BRCA	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19626725	chr5:178986131	RUFY1	-0.35	-10.89	-0.4	1.89e-25	Lung cancer;
BRCA	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06558623	chr16:89946397	TCF25	0.65	11.86	0.42	1.8e-29	Skin colour saturation;
BRCA	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg27286337	chr10:134555280	INPP5A	-0.85	-21.57	-0.65	6.32e-78	Migraine;
BRCA	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.23e-24	Motion sickness;
BRCA	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.34	-0.35	1.55e-19	Morning vs. evening chronotype;
BRCA	cis	rs919433	0.679	rs10931788	chr2:198531084	A/G	cg00792783	chr2:198669748	PLCL1	0.39	9.01	0.34	2.27e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg00677455	chr12:58241039	CTDSP2	-0.35	-7.84	-0.3	1.95e-14	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs9837602	0.935	rs9875640	chr3:99729091	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	10.56	0.39	4.06e-24	Breast cancer;
BRCA	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg26384229	chr12:38710491	ALG10B	0.68	14.54	0.5	1.35e-41	Morning vs. evening chronotype;
BRCA	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg17366294	chr4:99064904	C4orf37	0.43	9.98	0.37	6.6e-22	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	19.59	0.61	2.64e-67	Platelet count;
BRCA	cis	rs9837602	0.938	rs9815439	chr3:99785206	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	10.52	0.38	5.73e-24	Breast cancer;
BRCA	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg07395648	chr5:131743802	NA	-0.37	-9.18	-0.34	5.75e-19	Blood metabolite levels;
BRCA	cis	rs367943	0.637	rs6891711	chr5:113009026	G/T	cg12552261	chr5:112820674	MCC	-0.39	-8.32	-0.31	5.19e-16	Type 2 diabetes;
BRCA	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03576123	chr11:487126	PTDSS2	-1.2	-18.77	-0.6	6.11e-63	Body mass index;
BRCA	cis	rs6684514	1.000	rs12038203	chr1:156248265	C/T	cg16558208	chr1:156270281	VHLL	0.35	7.95	0.3	8.56e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs6714710	0.603	rs116309486	chr2:98493359	A/G	cg26665480	chr2:98280029	ACTR1B	0.6	13.75	0.48	6.79e-38	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg10523679	chr1:76189770	ACADM	0.88	20.7	0.63	2.98e-73	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11890956	chr21:40555474	PSMG1	-0.82	-19.5	-0.61	8.45e-67	Cognitive function;
BRCA	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg26587870	chr6:27730563	NA	-0.39	-8.26	-0.31	8.11e-16	Parkinson's disease;
BRCA	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-11.49	-0.41	6.42e-28	Extrinsic epigenetic age acceleration;
BRCA	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg04455712	chr21:45112962	RRP1B	0.43	10.6	0.39	2.83e-24	Mean corpuscular volume;
BRCA	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg06552810	chr11:31128660	NA	-0.4	-8.88	-0.33	6.88e-18	Red blood cell count;
BRCA	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg26597838	chr10:835615	NA	0.89	13.86	0.48	2.29e-38	Eosinophil percentage of granulocytes;
BRCA	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg05519781	chr21:40033154	ERG	0.44	9.43	0.35	7.2e-20	Coronary artery disease;
BRCA	cis	rs7267979	0.932	rs1985737	chr20:25591468	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.29	8.21	0.31	1.21e-15	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg00757033	chr12:89920650	WDR51B	0.54	11.08	0.4	3.21e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg10495392	chr1:46806563	NSUN4	0.45	8.47	0.32	1.74e-16	Menopause (age at onset);
BRCA	trans	rs629535	0.814	rs604254	chr8:70059164	A/G	cg21567404	chr3:27674614	NA	0.99	20.81	0.64	7.73e-74	Dupuytren's disease;
BRCA	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg17971929	chr21:40555470	PSMG1	-0.48	-10.57	-0.39	3.68e-24	Menarche (age at onset);
BRCA	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg12935359	chr14:103987150	CKB	-0.58	-13.15	-0.46	3.79e-35	Intelligence (multi-trait analysis);
BRCA	cis	rs858239	0.720	rs10227559	chr7:23272144	G/A	cg23682824	chr7:23144976	KLHL7	0.35	8.71	0.33	2.57e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.82	-12.32	-0.44	1.86e-31	Platelet count;
BRCA	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg21699342	chr2:239360505	ASB1	0.53	14.2	0.49	5.48e-40	Multiple system atrophy;
BRCA	cis	rs2637030	0.559	rs372006	chr5:52875859	T/A	cg06476337	chr5:52856530	NDUFS4	0.38	8.62	0.32	5.24e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg07080220	chr10:102295463	HIF1AN	0.5	10.35	0.38	2.59e-23	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg00666640	chr1:248458726	OR2T12	0.3	8.57	0.32	7.54e-17	Common traits (Other);
BRCA	cis	rs78487399	0.908	rs55855805	chr2:43808490	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-7.99	-0.3	6.36e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
BRCA	cis	rs7587476	0.626	rs4672729	chr2:215643483	A/G	cg04004882	chr2:215674386	BARD1	-0.4	-8.22	-0.31	1.14e-15	Neuroblastoma;
BRCA	cis	rs3849570	0.883	rs28435942	chr3:81679692	C/T	cg07356753	chr3:81810745	GBE1	-0.45	-10.63	-0.39	2.04e-24	Waist circumference;Body mass index;
BRCA	cis	rs2797160	0.967	rs1739368	chr6:126011079	C/T	cg05901451	chr6:126070800	HEY2	0.4	9.65	0.36	1.14e-20	Endometrial cancer;
BRCA	cis	rs7178424	1.000	rs62008532	chr15:62365877	T/C	cg00456672	chr15:62358751	C2CD4A	-0.42	-9.43	-0.35	7.5599999999999994e-20	Height;
BRCA	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg23625390	chr15:77176239	SCAPER	-0.52	-12.26	-0.44	3.45e-31	Blood metabolite levels;
BRCA	cis	rs477692	0.569	rs1771448	chr10:131296201	A/G	cg05714579	chr10:131428358	MGMT	-0.45	-10.19	-0.37	1.09e-22	Response to temozolomide;
BRCA	cis	rs877529	0.967	rs139407	chr22:39552075	G/A	cg18708252	chr22:39545030	CBX7	-0.32	-8.19	-0.31	1.45e-15	Multiple myeloma;
BRCA	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06544989	chr22:39130855	UNC84B	0.34	7.94	0.3	9.19e-15	Menopause (age at onset);
BRCA	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg05340658	chr4:99064831	C4orf37	0.5	10.99	0.4	7.52e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00166722	chr3:10149974	C3orf24	0.65	12.8	0.45	1.54e-33	Alzheimer's disease;
BRCA	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18876405	chr7:65276391	NA	-0.5	-11.67	-0.42	1.19e-28	Aortic root size;
BRCA	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg00254258	chr1:3105189	PRDM16	0.44	10.38	0.38	1.89e-23	Migraine;
BRCA	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg25358565	chr5:93447407	FAM172A	0.69	11.91	0.43	1.14e-29	Diabetic retinopathy;
BRCA	cis	rs7766436	0.727	rs6908574	chr6:22610165	T/C	cg13666174	chr6:22585274	NA	-0.36	-9.25	-0.34	3.28e-19	Coronary artery disease;
BRCA	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg10556349	chr10:835070	NA	0.58	8.32	0.31	5.15e-16	Eosinophil percentage of granulocytes;
BRCA	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg05343316	chr1:45956843	TESK2	0.7	14.72	0.5	2e-42	Platelet count;
BRCA	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg03433033	chr1:76189801	ACADM	-0.47	-9.86	-0.36	1.94e-21	Daytime sleep phenotypes;
BRCA	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg11062466	chr8:58055876	NA	0.41	7.99	0.3	6.47e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs7975161	0.506	rs7953434	chr12:104622101	T/G	cg25273343	chr12:104657179	TXNRD1	-0.6	-10.33	-0.38	2.98e-23	Toenail selenium levels;
BRCA	cis	rs9807989	0.524	rs2110662	chr2:103020139	A/T	cg03938978	chr2:103052716	IL18RAP	0.29	8.51	0.32	1.25e-16	Asthma;
BRCA	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23583168	chr7:148888333	NA	-0.78	-18.85	-0.6	2.33e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.5	8.77	0.33	1.61e-17	Body mass index (adult);
BRCA	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg20503657	chr10:835505	NA	0.85	15.42	0.52	7.78e-46	Eosinophil percentage of granulocytes;
BRCA	trans	rs8002861	0.935	rs9567299	chr13:44456969	G/A	cg17145862	chr1:211918768	LPGAT1	0.73	19.3	0.61	1.01e-65	Leprosy;
BRCA	trans	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg21659725	chr3:3221576	CRBN	-0.47	-8.46	-0.32	1.86e-16	Menarche (age at onset);
BRCA	cis	rs1003719	0.715	rs7282195	chr21:38508619	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.61	-14.19	-0.49	6.29e-40	Eye color traits;
BRCA	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg01256987	chr12:42539512	GXYLT1	-0.48	-9.24	-0.34	3.52e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg03146154	chr1:46216737	IPP	0.52	11.77	0.42	4.62e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4237845	0.844	rs7306124	chr12:58303349	A/T	cg00677455	chr12:58241039	CTDSP2	0.43	10.0	0.37	5.45e-22	Intelligence (multi-trait analysis);
BRCA	cis	rs7729447	0.841	rs10941021	chr5:32691144	C/T	cg16267343	chr5:32710456	NPR3	0.43	8.95	0.33	3.91e-18	Blood pressure;
BRCA	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg25237894	chr2:233734115	C2orf82	0.4	11.38	0.41	1.84e-27	Coronary artery disease;
BRCA	trans	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	29.89	0.76	1.81e-123	Colorectal cancer;
BRCA	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg14664628	chr15:75095509	CSK	-0.86	-23.07	-0.67	4.09e-86	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg14784868	chr12:69753453	YEATS4	0.79	25.23	0.71	5.18e-98	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.53	-13.2	-0.46	2.36e-35	Urate levels in overweight individuals;
BRCA	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg14004847	chr7:1930337	MAD1L1	-0.42	-8.81	-0.33	1.22e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg18252515	chr7:66147081	NA	-0.81	-11.28	-0.41	5.12e-27	Diabetic kidney disease;
BRCA	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg23711669	chr6:146136114	FBXO30	0.74	17.77	0.58	1.06e-57	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg17691542	chr6:26056736	HIST1H1C	0.71	14.12	0.49	1.38e-39	Iron status biomarkers;
BRCA	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg10253484	chr15:75165896	SCAMP2	0.5	9.52	0.35	3.64e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
BRCA	cis	rs11030122	0.702	rs10835340	chr11:3960420	A/G	cg18678763	chr11:4115507	RRM1	0.36	8.21	0.31	1.27e-15	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg11266682	chr4:10021025	SLC2A9	0.46	12.19	0.43	7.08e-31	Bone mineral density;
BRCA	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22307029	chr19:49891270	CCDC155	0.53	8.9	0.33	5.51e-18	Multiple sclerosis;
BRCA	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg11189052	chr15:85197271	WDR73	-0.36	-8.62	-0.32	5.42e-17	P wave terminal force;
BRCA	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	16.8	0.55	9.46e-53	Hypertriglyceridemia;
BRCA	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	14.69	0.5	2.56e-42	Colorectal cancer;
BRCA	cis	rs6484504	0.625	rs10835766	chr11:31374329	C/A	cg26647111	chr11:31128758	NA	0.42	9.33	0.35	1.72e-19	Red blood cell count;
BRCA	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg10556349	chr10:835070	NA	0.75	10.1	0.37	2.41e-22	Eosinophil percentage of granulocytes;
BRCA	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg09754948	chr16:28834200	ATXN2L	0.46	9.12	0.34	9.55e-19	Cognitive ability (multi-trait analysis);Cognitive ability;
BRCA	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg24829409	chr8:58192753	C8orf71	-0.46	-7.86	-0.3	1.67e-14	Developmental language disorder (linguistic errors);
BRCA	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-9.0	-0.34	2.53e-18	Alzheimer's disease (late onset);
BRCA	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg21226059	chr5:178986404	RUFY1	0.4	10.43	0.38	1.21e-23	Lung cancer;
BRCA	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg17640201	chr16:30407289	ZNF48	-0.74	-15.9	-0.53	3.17e-48	Tonsillectomy;
BRCA	cis	rs17401966	1.000	rs58549151	chr1:10314657	A/C	cg15208524	chr1:10270712	KIF1B	0.39	8.43	0.32	2.24e-16	Hepatocellular carcinoma;
BRCA	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg09085632	chr11:111637200	PPP2R1B	0.75	14.71	0.5	2.12e-42	Primary sclerosing cholangitis;
BRCA	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg18301423	chr5:131593218	PDLIM4	0.33	8.69	0.33	3.08e-17	Breast cancer;
BRCA	cis	rs7255436	0.928	rs7250870	chr19:8453682	C/T	cg10174797	chr19:8464628	RAB11B	0.37	9.37	0.35	1.22e-19	HDL cholesterol;
BRCA	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg05283184	chr6:79620031	NA	-0.43	-11.1	-0.4	2.77e-26	Intelligence (multi-trait analysis);
BRCA	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg17366294	chr4:99064904	C4orf37	0.45	10.58	0.39	3.37e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2051211	0.895	rs2300670	chr3:38555815	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.48	-9.45	-0.35	6.2e-20	QRS duration;
BRCA	cis	rs2677744	0.626	rs12915155	chr15:91490894	G/T	cg23684204	chr15:91497937	RCCD1	0.45	9.08	0.34	1.32e-18	Attention deficit hyperactivity disorder;
BRCA	trans	rs9951602	1.000	rs9949784	chr18:76649994	A/G	cg02800362	chr5:177631904	HNRNPAB	0.75	13.03	0.46	1.3600000000000001e-34	Obesity-related traits;
BRCA	cis	rs12791968	0.765	rs12794846	chr11:44998943	C/T	cg11846598	chr11:44996168	LOC221122	0.46	8.33	0.31	4.84e-16	Inhibitory control;
BRCA	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg23950597	chr19:37808831	NA	-0.74	-13.09	-0.46	7.77e-35	Coronary artery calcification;
BRCA	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg20991723	chr1:152506922	NA	0.39	8.99	0.33	2.83e-18	Hair morphology;
BRCA	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21659725	chr3:3221576	CRBN	0.53	13.67	0.48	1.61e-37	Intelligence (multi-trait analysis);
BRCA	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg26384229	chr12:38710491	ALG10B	0.66	15.11	0.51	2.4e-44	Bladder cancer;
BRCA	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.47	-7.9	-0.3	1.25e-14	HIV-1 control;
BRCA	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg01448562	chr3:133502909	NA	0.58	13.76	0.48	6.36e-38	Iron status biomarkers;
BRCA	cis	rs6121246	0.559	rs6087771	chr20:30306724	A/G	cg13852791	chr20:30311386	BCL2L1	0.97	23.69	0.68	1.64e-89	Mean corpuscular hemoglobin;
BRCA	cis	rs698813	0.572	rs6544749	chr2:44478077	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	8.28	0.31	7.36e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg17143192	chr8:8559678	CLDN23	0.57	11.17	0.4	1.35e-26	Obesity-related traits;
BRCA	cis	rs7246657	0.524	rs10411251	chr19:37428755	C/T	cg14683738	chr19:37701593	ZNF585B	0.57	9.34	0.35	1.6e-19	Coronary artery calcification;
BRCA	cis	rs6066835	1.000	rs6066830	chr20:47353897	C/T	cg18078177	chr20:47281410	PREX1	0.69	8.6	0.32	6.2e-17	Multiple myeloma;
BRCA	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg04414720	chr1:150670196	GOLPH3L	0.34	7.83	0.3	2.03e-14	Urate levels;
BRCA	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg05340658	chr4:99064831	C4orf37	0.69	17.49	0.57	3.01e-56	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg00106254	chr7:1943704	MAD1L1	-0.44	-11.03	-0.4	5.02e-26	Bipolar disorder and schizophrenia;
BRCA	cis	rs78456975	0.739	rs11896906	chr2:1519550	A/G	cg26248373	chr2:1572462	NA	-0.52	-10.58	-0.39	3.38e-24	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs708547	1.000	rs708547	chr4:57821309	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.48	11.06	0.4	4.05e-26	Response to bleomycin (chromatid breaks);
BRCA	cis	rs67079557	1	rs67079557	chr15:75930300	ATAATAAG/A	cg20655648	chr15:75932815	IMP3	0.51	9.91	0.36	1.26e-21	Breast cancer;
BRCA	cis	rs6815814	0.950	rs5743593	chr4:38802913	A/G	cg02016764	chr4:38805732	TLR1	-0.61	-9.75	-0.36	5.03e-21	Breast cancer;
BRCA	cis	rs4363385	0.818	rs4845522	chr1:153011099	C/T	cg24667326	chr1:152973720	SPRR3	-0.34	-9.3	-0.35	2.17e-19	Inflammatory skin disease;
BRCA	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg04362960	chr10:104952993	NT5C2	0.42	9.63	0.36	1.34e-20	Arsenic metabolism;
BRCA	cis	rs4285028	0.747	rs9817818	chr3:121466826	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-13.87	-0.48	2.07e-38	Multiple sclerosis;
BRCA	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg26384229	chr12:38710491	ALG10B	0.84	21.88	0.65	1.18e-79	Heart rate;
BRCA	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg21535247	chr6:8435926	SLC35B3	0.39	8.95	0.33	3.68e-18	Motion sickness;
BRCA	cis	rs12612619	0.732	rs7560144	chr2:27280460	A/G	cg00617064	chr2:27272375	NA	-0.33	-8.87	-0.33	7.31e-18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
BRCA	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg21918786	chr6:109611834	NA	-0.49	-14.24	-0.49	3.6e-40	Reticulocyte fraction of red cells;
BRCA	cis	rs870825	0.860	rs72689284	chr4:185596680	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	14.29	0.49	2.16e-40	Blood protein levels;
BRCA	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg05340658	chr4:99064831	C4orf37	0.66	16.1	0.54	3.26e-49	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg26395211	chr5:140044315	WDR55	0.37	8.61	0.32	5.55e-17	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg16482183	chr6:26056742	HIST1H1C	0.53	11.42	0.41	1.3e-27	Height;
BRCA	cis	rs4285028	0.948	rs7615571	chr3:121665950	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.58	-10.77	-0.39	5.85e-25	Multiple sclerosis;
BRCA	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg04842962	chr6:43655489	MRPS18A	1.12	38.72	0.84	9.92e-170	IgG glycosylation;
BRCA	cis	rs698833	0.532	rs698809	chr2:44702978	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.47	-8.6	-0.32	6.2e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg12935359	chr14:103987150	CKB	-0.61	-13.96	-0.48	7.3e-39	Intelligence (multi-trait analysis);
BRCA	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg07080220	chr10:102295463	HIF1AN	0.65	15.51	0.52	2.69e-46	Palmitoleic acid (16:1n-7) levels;
BRCA	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg24130564	chr14:104152367	KLC1	-0.34	-7.84	-0.3	1.86e-14	Body mass index;
BRCA	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-8.15	-0.31	1.99e-15	HDL cholesterol;
BRCA	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg04166393	chr7:2884313	GNA12	0.52	9.93	0.37	1.01e-21	Height;
BRCA	cis	rs250677	0.522	rs10040598	chr5:148365720	C/A	cg12140854	chr5:148520817	ABLIM3	0.41	8.34	0.31	4.44e-16	Breast cancer;
BRCA	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg03433033	chr1:76189801	ACADM	0.88	27.72	0.74	1.13e-111	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs7149337	0.837	rs10132658	chr14:51677599	C/T	cg23942311	chr14:51606299	NA	0.43	12.13	0.43	1.26e-30	Cancer;
BRCA	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg23711669	chr6:146136114	FBXO30	0.73	17.3	0.56	2.77e-55	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.6	13.68	0.48	1.54e-37	Colorectal cancer;
BRCA	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg20203395	chr5:56204925	C5orf35	-0.5	-10.16	-0.37	1.36e-22	Initial pursuit acceleration;
BRCA	trans	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg06521331	chr12:34319734	NA	-0.48	-8.79	-0.33	1.39e-17	Bladder cancer;
BRCA	cis	rs7582720	0.887	rs72934589	chr2:204017937	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	12.75	0.45	2.48e-33	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
BRCA	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg14844989	chr11:31128820	NA	-0.45	-9.65	-0.36	1.14e-20	Red blood cell count;
BRCA	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.57	8.35	0.31	4.08e-16	Cerebrospinal P-tau181p levels;
BRCA	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg12483005	chr1:23474871	LUZP1	0.45	10.13	0.37	1.83e-22	Height;
BRCA	trans	rs8073060	0.586	rs225278	chr17:33974170	C/T	cg19694781	chr19:47549865	TMEM160	-1.04	-21.19	-0.64	6.54e-76	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
BRCA	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg02196655	chr2:10830764	NOL10	-0.3	-7.99	-0.3	6.39e-15	Prostate cancer;
BRCA	cis	rs6460942	0.597	rs13227809	chr7:12525557	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-7.8	-0.3	2.45e-14	Coronary artery disease;
BRCA	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg14266287	chr2:239334506	ASB1	-0.34	-8.24	-0.31	1.01e-15	Multiple system atrophy;
BRCA	cis	rs829883	0.659	rs11109510	chr12:98911382	A/G	cg25150519	chr12:98850993	NA	-0.51	-9.37	-0.35	1.2e-19	Colorectal adenoma (advanced);
BRCA	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg04944784	chr2:26401820	FAM59B	-0.66	-11.28	-0.41	4.88e-27	Gut microbiome composition (summer);
BRCA	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19346786	chr7:2764209	NA	-0.34	-10.01	-0.37	5.15e-22	Height;
BRCA	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg24812749	chr6:127587940	RNF146	0.88	20.78	0.63	1.21e-73	Breast cancer;
BRCA	cis	rs6977660	1.000	rs57916046	chr7:19800542	T/C	cg05791153	chr7:19748676	TWISTNB	0.47	9.11	0.34	1.06e-18	Thyroid stimulating hormone;
BRCA	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-10.17	-0.37	1.26e-22	Joint mobility (Beighton score);
BRCA	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg22961513	chr11:14280813	SPON1	0.31	7.91	0.3	1.11e-14	Mitochondrial DNA levels;
BRCA	cis	rs7191700	0.601	rs243329	chr16:11352313	A/T	cg00044050	chr16:11439710	C16orf75	0.38	9.05	0.34	1.74e-18	Multiple sclerosis;
BRCA	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	12.03	0.43	3.4e-30	Coronary artery disease;
BRCA	trans	rs7980799	0.649	rs2389215	chr12:33649457	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-9.63	-0.36	1.4e-20	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg00383909	chr3:49044727	WDR6	0.92	13.01	0.46	1.72e-34	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.61	-13.87	-0.48	1.89e-38	Ulcerative colitis;
BRCA	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.71	-0.53	2.9e-47	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	trans	rs75804782	0.572	rs74979875	chr2:239302568	G/A	cg01134436	chr17:81009848	B3GNTL1	0.74	7.87	0.3	1.49e-14	Morning vs. evening chronotype;Chronotype;
BRCA	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg18252515	chr7:66147081	NA	-0.82	-11.98	-0.43	5.61e-30	Diabetic kidney disease;
BRCA	cis	rs6684514	0.922	rs12047994	chr1:156284535	C/A	cg16558208	chr1:156270281	VHLL	0.36	8.43	0.32	2.35e-16	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
BRCA	cis	rs3780378	0.870	rs2149556	chr9:5059440	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-8.88	-0.33	6.86e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
BRCA	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg18876405	chr7:65276391	NA	-0.47	-9.37	-0.35	1.23e-19	Aortic root size;
BRCA	trans	rs3857536	0.776	rs4710316	chr6:66935097	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-8.13	-0.31	2.24e-15	Blood trace element (Cu levels);
BRCA	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg03717367	chr9:139980219	LOC100289341;MAN1B1	-0.36	-8.62	-0.32	5.3e-17	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs243505	0.898	rs243542	chr7:148403194	G/A	cg09806900	chr7:148480153	CUL1	-0.39	-8.09	-0.3	3.11e-15	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs877282	0.842	rs35872126	chr10:764545	G/A	cg17470449	chr10:769945	NA	0.47	7.96	0.3	8.16e-15	Uric acid levels;
BRCA	cis	rs2637266	1.000	rs2395389	chr10:78357701	C/T	cg18941641	chr10:78392320	NA	0.35	7.82	0.3	2.23e-14	Pulmonary function;
BRCA	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.51	-11.3	-0.41	4.05e-27	IgG glycosylation;
BRCA	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg08917208	chr2:24149416	ATAD2B	1.06	14.87	0.51	3.6e-43	Lymphocyte counts;
BRCA	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg02527881	chr3:46936655	PTH1R	-0.4	-9.54	-0.35	2.91e-20	Birth weight;
BRCA	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg11645453	chr3:52864694	ITIH4	-0.47	-11.54	-0.42	4.2e-28	Schizophrenia;
BRCA	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21659725	chr3:3221576	CRBN	-0.71	-21.71	-0.65	1.02e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.28	8.15	0.31	1.9e-15	Parkinson's disease;
BRCA	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg27446573	chr6:127587934	RNF146	0.9	21.49	0.65	1.64e-77	Breast cancer;
BRCA	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg05283184	chr6:79620031	NA	-0.41	-10.78	-0.39	5.22e-25	Intelligence (multi-trait analysis);
BRCA	cis	rs1568889	0.838	rs12273631	chr11:28042135	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	20.33	0.63	2.95e-71	Bipolar disorder;
BRCA	cis	rs10992471	0.603	rs1121978	chr9:95140351	T/G	cg14631576	chr9:95140430	CENPP	-0.4	-9.71	-0.36	6.96e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg23950597	chr19:37808831	NA	-0.74	-13.06	-0.46	1.05e-34	Coronary artery calcification;
BRCA	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg15145296	chr3:125709740	NA	-0.55	-8.81	-0.33	1.13e-17	Blood pressure (smoking interaction);
BRCA	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	20.06	0.62	8.66e-70	Allergic disease (asthma, hay fever or eczema);
BRCA	cis	rs7178424	0.742	rs12908081	chr15:62162264	C/T	cg00456672	chr15:62358751	C2CD4A	-0.37	-8.9	-0.33	5.79e-18	Height;
BRCA	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg17623882	chr6:41773611	USP49	-0.37	-10.1	-0.37	2.44e-22	Menarche (age at onset);
BRCA	cis	rs4908768	0.539	rs1318218	chr1:8658712	T/C	cg20416874	chr1:8611966	RERE	-0.29	-8.2	-0.31	1.27e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
BRCA	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	13.86	0.48	2.21e-38	Lymphocyte counts;
BRCA	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg20887711	chr4:1340912	KIAA1530	0.71	15.53	0.52	2.16e-46	Longevity;
BRCA	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.01	14.96	0.51	1.29e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg19862616	chr7:65841803	NCRNA00174	0.83	27.56	0.74	8.71e-111	Coffee consumption;Coffee consumption (cups per day);
BRCA	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg00852783	chr1:26633632	UBXN11	0.52	12.36	0.44	1.29e-31	Obesity-related traits;
BRCA	cis	rs7851660	0.967	rs7860598	chr9:100600702	G/A	cg13688889	chr9:100608707	NA	-0.36	-8.61	-0.32	5.84e-17	Strep throat;
BRCA	cis	rs941764	0.965	rs941765	chr14:91841358	G/C	cg10511902	chr14:91842949	CCDC88C	0.54	13.97	0.48	6.65e-39	Breast cancer;
BRCA	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg08738300	chr3:44038990	NA	0.45	8.71	0.33	2.55e-17	Coronary artery disease;
BRCA	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg00277334	chr10:82204260	NA	-0.59	-13.4	-0.47	2.77e-36	Post bronchodilator FEV1;
BRCA	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg16339924	chr4:17578868	LAP3	0.62	15.43	0.52	6.61e-46	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs858239	0.712	rs200717	chr7:23392271	A/G	cg23682824	chr7:23144976	KLHL7	0.33	8.36	0.31	3.83e-16	Cerebrospinal fluid biomarker levels;
BRCA	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg00106254	chr7:1943704	MAD1L1	0.32	8.62	0.32	5.08e-17	Schizophrenia;
BRCA	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06108461	chr20:60628389	TAF4	-0.78	-17.05	-0.56	5.54e-54	Body mass index;
BRCA	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06022373	chr22:39101656	GTPBP1	0.75	18.41	0.59	4.74e-61	Menopause (age at onset);
BRCA	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11890956	chr21:40555474	PSMG1	-0.83	-20.56	-0.63	1.72e-72	Cognitive function;
BRCA	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02176678	chr2:219576539	TTLL4	0.46	11.88	0.43	1.57e-29	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-10.55	-0.39	4.14e-24	Personality dimensions;
BRCA	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg26384229	chr12:38710491	ALG10B	0.87	23.71	0.68	1.15e-89	Heart rate;
BRCA	cis	rs11608355	0.545	rs11066782	chr12:109910552	C/T	cg05360138	chr12:110035743	NA	0.71	13.09	0.46	7.36e-35	Neuroticism;
BRCA	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg17691542	chr6:26056736	HIST1H1C	0.51	10.43	0.38	1.29e-23	Height;
BRCA	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg01448562	chr3:133502909	NA	-0.41	-9.48	-0.35	4.87e-20	Iron status biomarkers;
BRCA	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg18357645	chr12:58087776	OS9	-0.33	-8.0	-0.3	5.66e-15	Multiple sclerosis;
BRCA	cis	rs9420	0.961	rs12807250	chr11:57600285	C/T	cg19752551	chr11:57585705	CTNND1	-0.51	-12.68	-0.45	4.94e-33	Schizophrenia;
BRCA	cis	rs367943	1.000	rs2248930	chr5:112811119	G/T	cg12552261	chr5:112820674	MCC	-0.56	-12.28	-0.44	2.97e-31	Type 2 diabetes;
BRCA	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.37	-8.27	-0.31	7.69e-16	Longevity;Endometriosis;
BRCA	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.56	-9.04	-0.34	1.88e-18	Platelet count;
BRCA	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg26446133	chr18:72167187	CNDP2	-0.75	-14.38	-0.49	7.57e-41	Refractive error;
BRCA	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg15934090	chr1:100435551	SLC35A3	-0.33	-7.98	-0.3	6.82e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg12373951	chr3:133503437	NA	0.46	10.84	0.39	2.95e-25	Iron status biomarkers;
BRCA	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-19.8	-0.62	2.12e-68	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg23625390	chr15:77176239	SCAPER	-0.52	-10.94	-0.4	1.21e-25	Blood metabolite levels;
BRCA	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg27446573	chr6:127587934	RNF146	0.7	15.98	0.53	1.35e-48	Breast cancer;
BRCA	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg12193833	chr17:30244370	NA	-0.61	-9.25	-0.34	3.3e-19	Hip circumference adjusted for BMI;
BRCA	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-11.83	-0.42	2.48e-29	Mood instability;
BRCA	cis	rs7091068	0.522	rs866674	chr10:95487515	A/G	cg20715218	chr10:95462985	C10orf4	0.48	9.17	0.34	6.54e-19	Urinary tract infection frequency;
BRCA	cis	rs56399783	0.614	rs73047368	chr7:2766396	G/T	cg23627948	chr7:2760692	NA	0.54	8.84	0.33	8.98e-18	Childhood ear infection;
BRCA	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg01256987	chr12:42539512	GXYLT1	0.43	8.06	0.3	3.76e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.37	-8.35	-0.31	4.34e-16	Colorectal cancer;
BRCA	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg18154014	chr19:37997991	ZNF793	0.47	9.31	0.35	1.99e-19	Coronary artery calcification;
BRCA	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	9.61	0.36	1.7e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs708547	0.533	rs3806746	chr4:57773330	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.42	8.1	0.31	2.83e-15	Response to bleomycin (chromatid breaks);
BRCA	trans	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg25214090	chr10:38739885	LOC399744	0.57	13.01	0.46	1.79e-34	Corneal astigmatism;
BRCA	cis	rs7246967	0.611	rs62120457	chr19:22958519	A/G	cg23217946	chr19:22817039	ZNF492	0.5	9.1	0.34	1.14e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11764359	chr7:65958608	NA	0.8	19.1	0.6	1.14e-64	Aortic root size;
BRCA	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg26384229	chr12:38710491	ALG10B	-0.48	-11.36	-0.41	2.26e-27	Morning vs. evening chronotype;
BRCA	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-7.89	-0.3	1.32e-14	Homocysteine levels;
BRCA	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg22920501	chr2:26401640	FAM59B	-0.9	-14.24	-0.49	3.68e-40	Gut microbiome composition (summer);
BRCA	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg00383909	chr3:49044727	WDR6	0.52	10.07	0.37	3.08e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	8.3	0.31	6.15e-16	Educational attainment;
BRCA	cis	rs6088813	1.000	rs6087702	chr20:33995945	T/A	cg14752227	chr20:34000481	UQCC	-0.39	-8.41	-0.32	2.76e-16	Height;
BRCA	cis	rs11696845	0.776	rs6073538	chr20:43379264	A/C	cg25301532	chr20:43378953	KCNK15	0.45	10.73	0.39	8.29e-25	Obesity-related traits;
BRCA	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg11062466	chr8:58055876	NA	0.52	8.9	0.33	5.5e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs7072216	0.763	rs2274245	chr10:100175082	C/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-9.72	-0.36	6.33e-21	Metabolite levels;
BRCA	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.54	-13.39	-0.47	3.18e-36	Urate levels in overweight individuals;
BRCA	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg07636037	chr3:49044803	WDR6	-0.58	-7.94	-0.3	8.9e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg17063962	chr7:91808500	NA	0.54	12.32	0.44	1.86e-31	Breast cancer;
BRCA	cis	rs1971762	0.563	rs4759284	chr12:54079491	G/A	cg23533419	chr12:54090519	NA	-0.33	-8.3	-0.31	6.05e-16	Height;
BRCA	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.57	9.85	0.36	2.04e-21	Gut microbiome composition (summer);
BRCA	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg27535305	chr1:53392650	SCP2	-0.37	-9.32	-0.35	1.85e-19	Monocyte count;
BRCA	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08564027	chr20:61660810	NA	0.89	23.44	0.68	3.86e-88	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg03711944	chr11:47377212	SPI1	-0.38	-8.78	-0.33	1.48e-17	Diastolic blood pressure;Systolic blood pressure;
BRCA	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg26597838	chr10:835615	NA	1.02	17.81	0.58	6.47e-58	Eosinophil percentage of granulocytes;
BRCA	cis	rs7640424	0.819	rs179046	chr3:107840773	A/C	cg09227934	chr3:107805635	CD47	-0.4	-8.38	-0.31	3.38e-16	Body mass index;
BRCA	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg13852791	chr20:30311386	BCL2L1	0.82	15.58	0.52	1.24e-46	Mean corpuscular hemoglobin;
BRCA	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg08917208	chr2:24149416	ATAD2B	0.55	8.35	0.31	4.17e-16	Lymphocyte counts;
BRCA	cis	rs778371	0.723	rs283470	chr2:233656918	G/A	cg08000102	chr2:233561755	GIGYF2	0.82	19.95	0.62	3.33e-69	Schizophrenia;
BRCA	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg15242686	chr22:24348715	GSTTP1	0.34	8.38	0.31	3.41e-16	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.63	10.18	0.37	1.2e-22	Renal function-related traits (BUN);
BRCA	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg09904177	chr6:26538194	HMGN4	0.47	14.71	0.5	2.11e-42	Intelligence (multi-trait analysis);
BRCA	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg02016764	chr4:38805732	TLR1	-0.6	-9.25	-0.34	3.22e-19	Breast cancer;
BRCA	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-15.64	-0.53	6.7e-47	Extrinsic epigenetic age acceleration;
BRCA	cis	rs36051895	0.632	rs117896567	chr9:5141281	C/G	cg02405213	chr9:5042618	JAK2	-0.51	-9.5	-0.35	4.07e-20	Pediatric autoimmune diseases;
BRCA	cis	rs13095912	0.512	rs115865582	chr3:185308598	A/C	cg11274856	chr3:185301563	NA	0.53	12.6	0.45	1.12e-32	Systolic blood pressure;
BRCA	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg27170947	chr2:26402098	FAM59B	-0.92	-16.52	-0.55	2.6e-51	Gut microbiome composition (summer);
BRCA	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg08807101	chr21:30365312	RNF160	-0.6	-15.0	-0.51	8.49e-44	Dental caries;
BRCA	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg00631329	chr6:26305371	NA	-0.43	-12.88	-0.45	6.55e-34	Educational attainment;
BRCA	cis	rs7572733	0.534	rs700670	chr2:198687284	T/C	cg00792783	chr2:198669748	PLCL1	0.47	10.24	0.38	7.08e-23	Dermatomyositis;
BRCA	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg23788917	chr6:8435910	SLC35B3	0.48	10.39	0.38	1.77e-23	Motion sickness;
BRCA	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg03433033	chr1:76189801	ACADM	0.76	17.21	0.56	8.42e-55	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg00383909	chr3:49044727	WDR6	0.45	9.47	0.35	5.21e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
BRCA	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02353165	chr6:42928485	GNMT	0.76	18.78	0.6	5.32e-63	Alzheimer's disease in APOE e4+ carriers;
BRCA	trans	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg15934090	chr1:100435551	SLC35A3	0.35	7.93	0.3	9.76e-15	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15664640	chr17:80829946	TBCD	-0.43	-11.6	-0.42	2.36e-28	Breast cancer;
BRCA	cis	rs11229555	0.874	rs10896787	chr11:58285494	G/T	cg15696309	chr11:58395628	NA	-0.54	-11.47	-0.41	7.94e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs812925	0.519	rs1186696	chr2:61660483	A/C	cg15711740	chr2:61764176	XPO1	-0.33	-7.98	-0.3	6.78e-15	Immature fraction of reticulocytes;
BRCA	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.37	9.67	0.36	1.02e-20	IgG glycosylation;
BRCA	trans	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-21.06	-0.64	3.5e-75	Exhaled nitric oxide output;
BRCA	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.6	9.05	0.34	1.69e-18	Lung function (FEV1/FVC);
BRCA	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg08313168	chr12:7315531	NA	0.5	7.98	0.3	6.91e-15	Lung disease severity in cystic fibrosis;
BRCA	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg06484146	chr7:12443880	VWDE	-0.62	-8.47	-0.32	1.69e-16	Coronary artery disease;
BRCA	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg17971929	chr21:40555470	PSMG1	0.79	18.37	0.59	7.78e-61	Cognitive function;
BRCA	cis	rs57590327	0.555	rs3772884	chr3:81802720	G/T	cg07356753	chr3:81810745	GBE1	-0.44	-10.52	-0.38	5.75e-24	Extraversion;
BRCA	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg27129171	chr3:47204927	SETD2	0.71	17.05	0.56	5.37e-54	Colorectal cancer;
BRCA	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11644478	chr21:40555479	PSMG1	0.84	18.75	0.6	8.13e-63	Cognitive function;
BRCA	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.93	-31.07	-0.78	7.64e-130	Schizophrenia;
BRCA	trans	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-10.15	-0.37	1.58e-22	Morning vs. evening chronotype;
BRCA	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg08807101	chr21:30365312	RNF160	-0.57	-14.02	-0.49	3.76e-39	Dental caries;
BRCA	cis	rs7520050	0.966	rs6672898	chr1:46290588	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.9	0.36	1.38e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs6714710	0.603	rs4311104	chr2:98424802	A/G	cg26665480	chr2:98280029	ACTR1B	0.58	13.62	0.47	2.86e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs887829	0.570	rs10168333	chr2:234596988	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.33	-8.36	-0.31	3.83e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
BRCA	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg03929089	chr4:120376271	NA	0.7	14.24	0.49	3.5e-40	Coronary artery disease;
BRCA	cis	rs10924970	0.625	rs12730441	chr1:235498059	G/T	cg26050004	chr1:235667680	B3GALNT2	0.36	8.39	0.32	3.03e-16	Asthma;
BRCA	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg04450456	chr4:17643702	FAM184B	0.32	9.35	0.35	1.44e-19	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg09307838	chr4:120376055	NA	0.64	14.08	0.49	1.96e-39	Corneal astigmatism;
BRCA	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14240646	chr10:27532245	ACBD5	-0.6	-9.29	-0.35	2.35e-19	Breast cancer;
BRCA	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg05340658	chr4:99064831	C4orf37	0.67	16.38	0.54	1.38e-50	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-11.99	-0.43	4.87e-30	Morning vs. evening chronotype;
BRCA	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg16950941	chr11:66035639	RAB1B	0.46	12.17	0.43	8.49e-31	Gout;
BRCA	trans	rs1997103	1.000	rs2331064	chr7:55408610	C/G	cg20935933	chr6:143382018	AIG1	0.6	11.61	0.42	2.11e-28	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg00666640	chr1:248458726	OR2T12	0.32	8.83	0.33	9.7e-18	Common traits (Other);
BRCA	cis	rs10465746	0.967	rs11163876	chr1:84440605	T/C	cg10977910	chr1:84465055	TTLL7	0.51	10.36	0.38	2.4e-23	Obesity-related traits;
BRCA	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg23625390	chr15:77176239	SCAPER	0.51	12.33	0.44	1.81e-31	Blood metabolite levels;
BRCA	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11644478	chr21:40555479	PSMG1	-0.76	-16.66	-0.55	5.06e-52	Cognitive function;
BRCA	cis	rs12711979	0.765	rs6715805	chr2:3821117	T/C	cg17052675	chr2:3827356	NA	-0.48	-14.31	-0.49	1.8e-40	Itch intensity from mosquito bite adjusted by bite size;
BRCA	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg27478167	chr7:817139	HEATR2	-0.44	-9.55	-0.35	2.7e-20	Cerebrospinal P-tau181p levels;
BRCA	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	14.22	0.49	4.38e-40	Ileal carcinoids;
BRCA	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg19622623	chr12:86230825	RASSF9	-0.34	-9.42	-0.35	8.17e-20	Major depressive disorder;
BRCA	cis	rs26949	0.504	rs10054744	chr5:60040047	C/G	cg02684056	chr5:59996105	DEPDC1B	-0.33	-7.87	-0.3	1.56e-14	Intelligence (multi-trait analysis);
BRCA	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg08067268	chr2:26466485	HADHB;HADHA	0.57	9.81	0.36	3e-21	Gut microbiome composition (summer);
BRCA	cis	rs12541635	0.966	rs2217391	chr8:107063126	A/G	cg10147462	chr8:107024639	NA	0.35	9.71	0.36	7.11e-21	Age of smoking initiation;
BRCA	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26314531	chr2:26401878	FAM59B	-0.66	-11.25	-0.41	6.63e-27	Gut microbiome composition (summer);
BRCA	cis	rs3125734	0.534	rs10821973	chr10:64052337	G/A	cg09941381	chr10:64027924	RTKN2	-0.29	-8.04	-0.3	4.43e-15	Rheumatoid arthritis;
BRCA	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg03060546	chr3:49711283	APEH	0.56	9.84	0.36	2.26e-21	Menarche (age at onset);
BRCA	trans	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg14791747	chr16:20752902	THUMPD1	0.39	9.27	0.34	2.92e-19	Cognitive test performance;
BRCA	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg01028140	chr2:1542097	TPO	-0.58	-11.82	-0.42	2.63e-29	Placebo response in major depressive disorder (% change in symptom score);
BRCA	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg17366294	chr4:99064904	C4orf37	0.46	11.02	0.4	5.61e-26	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10992471	0.630	rs10992322	chr9:95159196	A/G	cg14631576	chr9:95140430	CENPP	-0.32	-8.07	-0.3	3.54e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg15448220	chr1:150897856	SETDB1	0.36	8.26	0.31	8.31e-16	Melanoma;
BRCA	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg26116260	chr4:7069785	GRPEL1	0.95	27.85	0.74	2.18e-112	Monocyte percentage of white cells;
BRCA	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10802521	chr3:52805072	NEK4	-0.33	-9.12	-0.34	9.27e-19	Bipolar disorder;
BRCA	cis	rs490234	0.902	rs10739663	chr9:128278739	A/G	cg14078157	chr9:128172775	NA	-0.33	-7.87	-0.3	1.55e-14	Mean arterial pressure;
BRCA	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-10.23	-0.38	7.63e-23	Neuroticism;
BRCA	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg08017756	chr2:100939284	LONRF2	-0.31	-7.97	-0.3	7.58e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs30380	1.000	rs30378	chr5:96121994	A/G	cg16492584	chr5:96139282	ERAP1	-0.31	-7.95	-0.3	8.37e-15	Cerebrospinal fluid biomarker levels;
BRCA	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21659725	chr3:3221576	CRBN	0.42	10.37	0.38	2.2e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg23649088	chr2:200775458	C2orf69	0.49	9.98	0.37	7.05e-22	Osteoporosis;
BRCA	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg22920501	chr2:26401640	FAM59B	-0.91	-16.04	-0.54	6.5e-49	Gut microbiome composition (summer);
BRCA	trans	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.45	-8.91	-0.33	5.2e-18	Menarche (age at onset);
BRCA	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg21775007	chr8:11205619	TDH	0.61	12.17	0.43	8.35e-31	Retinal vascular caliber;
BRCA	cis	rs6763687	0.637	rs747612	chr3:171822023	G/A	cg16233210	chr3:171778391	FNDC3B	0.4	9.28	0.34	2.53e-19	Red cell distribution width;
BRCA	cis	rs7809950	0.953	rs2520267	chr7:107187497	T/C	cg23024343	chr7:107201750	COG5	-0.39	-8.96	-0.33	3.55e-18	Coronary artery disease;
BRCA	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg17143192	chr8:8559678	CLDN23	0.55	10.39	0.38	1.79e-23	Obesity-related traits;
BRCA	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg07169764	chr2:136633963	MCM6	1.27	26.71	0.73	3.86e-106	Corneal structure;
BRCA	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg21064579	chr19:49206444	FUT2	0.32	7.98	0.3	7.05e-15	Dietary macronutrient intake;
BRCA	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg21475434	chr5:93447410	FAM172A	-0.63	-7.9	-0.3	1.22e-14	Diabetic retinopathy;
BRCA	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg21280719	chr6:42927975	GNMT	-0.31	-12.81	-0.45	1.35e-33	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	18.14	0.58	1.24e-59	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg15691649	chr6:25882328	NA	-0.45	-8.58	-0.32	7.41e-17	Urate levels;
BRCA	trans	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.34	7.9	0.3	1.22e-14	Corneal astigmatism;
BRCA	cis	rs9790314	0.631	rs9867582	chr3:160797405	A/G	cg03342759	chr3:160939853	NMD3	-0.49	-10.06	-0.37	3.44e-22	Morning vs. evening chronotype;
BRCA	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	18.4	0.59	5.58e-61	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-13.34	-0.47	5.49e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg11752832	chr7:134001865	SLC35B4	0.53	13.77	0.48	5.95e-38	Mean platelet volume;
BRCA	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg09417038	chr21:47716443	C21orf57	0.33	8.54	0.32	9.51e-17	Testicular germ cell tumor;
BRCA	trans	rs1974653	0.781	rs4476436	chr22:20082961	T/C	cg20152630	chr19:46405944	MYPOP	0.37	8.31	0.31	5.53e-16	Schizophrenia;
BRCA	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg02403541	chr12:121454288	C12orf43	0.64	12.33	0.44	1.75e-31	N-glycan levels;
BRCA	cis	rs7131987	0.834	rs7139273	chr12:29434650	T/C	cg09582351	chr12:29534625	ERGIC2	-0.42	-10.06	-0.37	3.5e-22	QT interval;
BRCA	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg18357645	chr12:58087776	OS9	0.46	13.25	0.46	1.38e-35	Celiac disease or Rheumatoid arthritis;
BRCA	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg13047869	chr3:10149882	C3orf24	0.58	12.2	0.43	6.43e-31	Alzheimer's disease;
BRCA	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg22764044	chr5:178986830	RUFY1	-0.36	-9.4	-0.35	9.94e-20	Lung cancer;
BRCA	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	22.11	0.66	6.54e-81	Gut microbiome composition (summer);
BRCA	cis	rs1476670	0.710	rs751442	chr1:44509551	A/C	cg09470012	chr1:44509516	NA	0.44	9.75	0.36	5.06e-21	Eotaxin levels;
BRCA	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-13.12	-0.46	5.66e-35	Chronic sinus infection;
BRCA	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg26384229	chr12:38710491	ALG10B	0.66	15.43	0.52	6.85e-46	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg14186256	chr22:23484241	RTDR1	0.73	21.27	0.64	2.55e-76	Bone mineral density;
BRCA	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg19318889	chr4:1322082	MAEA	0.53	11.17	0.4	1.44e-26	Longevity;
BRCA	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg17971929	chr21:40555470	PSMG1	-0.6	-13.25	-0.46	1.42e-35	Cognitive function;
BRCA	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg18225595	chr11:63971243	STIP1	0.4	9.91	0.37	1.2e-21	Platelet count;
BRCA	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-16.27	-0.54	4.64e-50	Alzheimer's disease (late onset);
BRCA	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.82	12.93	0.46	3.84e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs977987	0.806	rs1549306	chr16:75415341	A/G	cg03315344	chr16:75512273	CHST6	0.54	12.95	0.46	3.26e-34	Dupuytren's disease;
BRCA	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg24675658	chr1:53192096	ZYG11B	0.63	14.98	0.51	1.02e-43	Monocyte count;
BRCA	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg15017067	chr4:17643749	FAM184B	0.31	9.53	0.35	3.27e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-12.21	-0.44	5.58e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg05665937	chr4:1216051	CTBP1	-0.4	-8.53	-0.32	1.06e-16	Obesity-related traits;
BRCA	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg12463550	chr7:65579703	CRCP	-0.37	-8.04	-0.3	4.41e-15	Aortic root size;
BRCA	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg19678392	chr7:94953810	PON1	-0.43	-9.08	-0.34	1.38e-18	Yu-Zhi constitution type in type 2 diabetes;
BRCA	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg09307838	chr4:120376055	NA	0.75	16.65	0.55	5.56e-52	Corneal astigmatism;
BRCA	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg15017067	chr4:17643749	FAM184B	0.31	9.64	0.36	1.27e-20	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg14829155	chr15:31115871	NA	-0.44	-10.1	-0.37	2.42e-22	Huntington's disease progression;
BRCA	cis	rs218264	0.592	rs34534202	chr4:55368913	C/G	cg17105814	chr4:55365203	NA	-0.4	-8.32	-0.31	5.41e-16	Hemoglobin concentration;Hematocrit;
BRCA	cis	rs4566357	0.615	rs10198214	chr2:227913314	A/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-9.4	-0.35	9.56e-20	Coronary artery disease;
BRCA	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.7	13.1	0.46	6.81e-35	Lung function (FEV1/FVC);
BRCA	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	14.94	0.51	1.73e-43	Platelet count;
BRCA	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-10.59	-0.39	2.84e-24	Gut microbiome composition (summer);
BRCA	cis	rs12541635	0.677	rs4734892	chr8:106990088	G/C	cg10147462	chr8:107024639	NA	0.4	10.42	0.38	1.34e-23	Age of smoking initiation;
BRCA	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-12.77	-0.45	1.92e-33	Blood metabolite levels;
BRCA	cis	rs3799378	0.582	rs1796518	chr6:26388672	C/T	cg09904177	chr6:26538194	HMGN4	-0.33	-8.23	-0.31	1.04e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11764359	chr7:65958608	NA	0.62	13.65	0.48	1.99e-37	Aortic root size;
BRCA	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg08999081	chr20:33150536	PIGU	0.44	11.95	0.43	7.25e-30	Coronary artery disease;
BRCA	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg27446573	chr6:127587934	RNF146	0.69	15.82	0.53	8.25e-48	Breast cancer;
BRCA	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.27	-0.31	7.98e-16	Total body bone mineral density;
BRCA	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg23719950	chr11:63933701	MACROD1	0.55	8.74	0.33	2.03e-17	Mean platelet volume;
BRCA	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg24642439	chr20:33292090	TP53INP2	0.41	8.12	0.31	2.32e-15	Height;
BRCA	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg00071950	chr4:10020882	SLC2A9	0.51	12.05	0.43	2.81e-30	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg04362960	chr10:104952993	NT5C2	0.39	9.31	0.35	2.05e-19	Immature fraction of reticulocytes;Schizophrenia;
BRCA	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg18404041	chr3:52824283	ITIH1	-0.39	-10.7	-0.39	1.09e-24	Bipolar disorder;
BRCA	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg14440974	chr22:39074834	NA	-0.39	-9.17	-0.34	6.68e-19	Menopause (age at onset);
BRCA	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg13319975	chr6:146136371	FBXO30	-0.38	-8.72	-0.33	2.43e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1997103	1.000	rs2140915	chr7:55410699	G/C	cg17469321	chr7:55412551	NA	0.5	9.63	0.36	1.41e-20	QRS interval (sulfonylurea treatment interaction);
BRCA	cis	rs1595825	0.891	rs16824264	chr2:198675917	T/C	cg19156104	chr2:198669113	PLCL1	-0.42	-7.97	-0.3	7.13e-15	Ulcerative colitis;
BRCA	cis	rs6942756	1.000	rs6942756	chr7:128886821	T/G	cg02491457	chr7:128862824	NA	-0.72	-14.17	-0.49	8.16e-40	White matter hyperintensity burden;
BRCA	cis	rs921968	0.565	rs6436081	chr2:219637884	A/G	cg02176678	chr2:219576539	TTLL4	-0.42	-11.2	-0.41	1.02e-26	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs10193935	0.818	rs2374428	chr2:42667961	T/C	cg27598129	chr2:42591480	NA	0.79	13.3	0.47	8.46e-36	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg17366294	chr4:99064904	C4orf37	0.42	9.71	0.36	6.85e-21	Colonoscopy-negative controls vs population controls;
BRCA	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg27661571	chr11:113659931	NA	-0.76	-11.6	-0.42	2.29e-28	Hip circumference adjusted for BMI;
BRCA	cis	rs13190036	1.000	rs13167431	chr5:176621075	G/C	cg06733329	chr5:176740039	MXD3	0.46	8.22	0.31	1.12e-15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
BRCA	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg20129853	chr10:51489980	NA	-0.32	-8.39	-0.32	3.07e-16	Prostate-specific antigen levels;
BRCA	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg03923535	chr7:1197113	ZFAND2A	0.5	10.19	0.37	1.1e-22	Longevity;Endometriosis;
BRCA	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg24069376	chr3:38537580	EXOG	0.32	9.06	0.34	1.6e-18	Electrocardiographic conduction measures;
BRCA	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg11062466	chr8:58055876	NA	0.5	8.76	0.33	1.7e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg25036284	chr2:26402008	FAM59B	0.77	10.65	0.39	1.79e-24	Gut microbiome composition (summer);
BRCA	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	9.01	0.34	2.41e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
BRCA	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11764359	chr7:65958608	NA	0.75	16.57	0.55	1.37e-51	Aortic root size;
BRCA	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg09555818	chr19:45449301	APOC2	0.47	12.22	0.44	5.19e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg00383909	chr3:49044727	WDR6	0.99	15.08	0.51	3.48e-44	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs9420	0.961	rs708228	chr11:57585662	C/T	cg19752551	chr11:57585705	CTNND1	-0.51	-12.56	-0.45	1.68e-32	Schizophrenia;
BRCA	trans	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg18876405	chr7:65276391	NA	0.43	8.45	0.32	1.96e-16	Corneal structure;
BRCA	cis	rs7043114	0.525	rs7850432	chr9:95130510	G/A	cg14631576	chr9:95140430	CENPP	-0.34	-8.38	-0.31	3.32e-16	Height;
BRCA	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg06640241	chr16:89574553	SPG7	0.8	19.79	0.62	2.32e-68	Multiple myeloma (IgH translocation);
BRCA	cis	rs10503871	0.685	rs7824823	chr8:30322735	G/T	cg26383811	chr8:30366931	RBPMS	-0.32	-8.76	-0.33	1.7e-17	Metabolite levels  (X-11787);
BRCA	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg00990874	chr7:1149470	C7orf50	0.53	9.81	0.36	2.93e-21	Bronchopulmonary dysplasia;
BRCA	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg03929089	chr4:120376271	NA	-0.46	-9.29	-0.34	2.4e-19	HDL cholesterol;
BRCA	cis	rs17095355	0.579	rs72828224	chr10:111702047	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.38	-9.97	-0.37	7.39e-22	Biliary atresia;
BRCA	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg03146154	chr1:46216737	IPP	-0.54	-12.02	-0.43	3.92e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg14683738	chr19:37701593	ZNF585B	0.44	7.91	0.3	1.14e-14	Coronary artery calcification;
BRCA	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg23750338	chr8:142222470	SLC45A4	0.41	10.13	0.37	1.84e-22	Immature fraction of reticulocytes;
BRCA	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg22681709	chr2:178499509	PDE11A	-0.41	-8.86	-0.33	7.65e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg02734326	chr4:10020555	SLC2A9	0.37	8.13	0.31	2.3e-15	Bone mineral density;
BRCA	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.41	-9.12	-0.34	9.28e-19	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg24296786	chr1:45957014	TESK2	0.45	10.35	0.38	2.6e-23	Red blood cell count;Reticulocyte count;
BRCA	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg04586622	chr2:25135609	ADCY3	0.47	11.89	0.43	1.4e-29	Body mass index in non-asthmatics;
BRCA	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	11.1	0.4	2.62e-26	Bipolar disorder;
BRCA	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg18876405	chr7:65276391	NA	0.68	17.92	0.58	1.82e-58	Aortic root size;
BRCA	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg04450456	chr4:17643702	FAM184B	-0.3	-8.5	-0.32	1.38e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.57	-13.22	-0.46	1.9e-35	Mean platelet volume;
BRCA	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg18806716	chr10:30721971	MAP3K8	-0.41	-9.51	-0.35	3.81e-20	Inflammatory bowel disease;
BRCA	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	14.3	0.49	1.81e-40	Hip circumference adjusted for BMI;
BRCA	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-19.14	-0.6	6.81e-65	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.64	13.99	0.48	5.47e-39	Lymphocyte percentage of white cells;
BRCA	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg21252483	chr19:49399788	TULP2	-0.5	-10.68	-0.39	1.26e-24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
BRCA	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg02574844	chr11:5959923	NA	-0.4	-8.05	-0.3	4.19e-15	DNA methylation (variation);
BRCA	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg18230493	chr5:56204884	C5orf35	-0.68	-13.41	-0.47	2.57e-36	Initial pursuit acceleration;
BRCA	cis	rs11955398	0.716	rs1379114	chr5:59997798	A/G	cg02684056	chr5:59996105	DEPDC1B	0.39	9.35	0.35	1.42e-19	Intelligence (multi-trait analysis);
BRCA	cis	rs6687430	0.526	rs12127400	chr1:10613660	C/T	cg17425144	chr1:10567563	PEX14	0.57	13.36	0.47	4.64e-36	Hand grip strength;
BRCA	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg13047869	chr3:10149882	C3orf24	0.59	12.55	0.44	1.94e-32	Alzheimer's disease;
BRCA	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg23711669	chr6:146136114	FBXO30	0.78	18.44	0.59	3.27e-61	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg24296786	chr1:45957014	TESK2	-0.39	-8.01	-0.3	5.38e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7523050	0.643	rs12741194	chr1:109400390	T/C	cg08274380	chr1:109419600	GPSM2	0.98	13.97	0.48	7.02e-39	Fat distribution (HIV);
BRCA	cis	rs9392556	0.829	rs649725	chr6:4109593	A/C	cg08342332	chr6:4079704	C6orf201;C6orf146	0.37	8.16	0.31	1.84e-15	Blood metabolite levels;
BRCA	cis	rs208520	0.690	rs851459	chr6:66813989	A/G	cg07460842	chr6:66804631	NA	-1.0	-19.98	-0.62	2.38e-69	Exhaled nitric oxide output;
BRCA	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06634786	chr22:41940651	POLR3H	-0.59	-10.44	-0.38	1.12e-23	Vitiligo;
BRCA	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg03161606	chr19:29218774	NA	0.45	8.18	0.31	1.57e-15	Methadone dose in opioid dependence;
BRCA	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-9.44	-0.35	6.86e-20	Personality dimensions;
BRCA	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	18.86	0.6	2.15e-63	Alzheimer's disease;
BRCA	cis	rs9420	1.000	rs543725	chr11:57483039	A/T	cg19752551	chr11:57585705	CTNND1	-0.42	-10.74	-0.39	7.56e-25	Schizophrenia;
BRCA	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg04989706	chr14:50066350	PPIL5	-0.47	-9.21	-0.34	4.76e-19	Carotid intima media thickness;
BRCA	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.37	-0.31	3.51e-16	Menopause (age at onset);
BRCA	cis	rs10193935	0.901	rs10169971	chr2:42602189	G/A	cg27598129	chr2:42591480	NA	-0.97	-15.46	-0.52	4.85e-46	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10193935	0.901	rs12619348	chr2:42625586	C/T	cg27598129	chr2:42591480	NA	-0.8	-13.32	-0.47	6.82e-36	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg06784218	chr1:46089804	CCDC17	-0.52	-12.42	-0.44	7.05e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.77	0.55	1.34e-52	Hypertriglyceridemia;
BRCA	trans	rs459571	0.959	rs461462	chr9:136911272	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-14.62	-0.5	5.64e-42	Platelet distribution width;
BRCA	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.34	-7.94	-0.3	8.82e-15	Bipolar disorder;
BRCA	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19346786	chr7:2764209	NA	-0.31	-8.95	-0.33	3.94e-18	Height;
BRCA	cis	rs7927771	0.524	rs4752860	chr11:47705015	C/A	cg20307385	chr11:47447363	PSMC3	-0.39	-9.06	-0.34	1.57e-18	Subjective well-being;
BRCA	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12826209	chr6:26865740	GUSBL1	0.58	10.45	0.38	1.03e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg17691542	chr6:26056736	HIST1H1C	0.45	8.73	0.33	2.17e-17	Iron status biomarkers;
BRCA	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	-0.49	-9.93	-0.37	1.07e-21	Tonsillectomy;
BRCA	cis	rs3824344	0.507	rs10814501	chr9:37019304	C/T	cg14294708	chr9:37120828	ZCCHC7	0.42	8.56	0.32	8.24e-17	Intelligence;
BRCA	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg19628046	chr18:33552617	C18orf21	0.55	10.58	0.39	3.18e-24	Endometriosis;Drug-induced torsades de pointes;
BRCA	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg16339924	chr4:17578868	LAP3	-0.55	-13.59	-0.47	3.81e-37	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs11971779	0.774	rs6467838	chr7:139043501	A/G	cg07862535	chr7:139043722	LUC7L2	0.38	10.37	0.38	2.13e-23	Diisocyanate-induced asthma;
BRCA	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg12648201	chr2:27665141	KRTCAP3	-0.36	-8.84	-0.33	9.56e-18	Total body bone mineral density;
BRCA	trans	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg04565464	chr8:145669602	NFKBIL2	0.37	8.17	0.31	1.71e-15	Bipolar disorder and schizophrenia;
BRCA	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg00814883	chr7:100076585	TSC22D4	-0.49	-9.61	-0.36	1.69e-20	Platelet count;
BRCA	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg00677455	chr12:58241039	CTDSP2	-0.44	-10.15	-0.37	1.58e-22	Intelligence (multi-trait analysis);
BRCA	trans	rs6561151	0.681	rs17065161	chr13:44443723	A/T	cg12856521	chr11:46389249	DGKZ	0.56	10.52	0.38	5.62e-24	Crohn's disease;
BRCA	cis	rs16854884	0.657	rs4611822	chr3:143735544	C/T	cg06585982	chr3:143692056	C3orf58	0.43	9.01	0.34	2.29e-18	Economic and political preferences (feminism/equality);
BRCA	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24549020	chr5:56110836	MAP3K1	0.65	13.07	0.46	9.15e-35	Initial pursuit acceleration;
BRCA	trans	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg17675199	chr6:35436792	RPL10A	-0.29	-7.93	-0.3	9.46e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs10992471	0.528	rs1924244	chr9:95224952	A/G	cg14631576	chr9:95140430	CENPP	-0.35	-8.67	-0.32	3.6e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
BRCA	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg27446573	chr6:127587934	RNF146	0.68	15.54	0.52	1.94e-46	Breast cancer;
BRCA	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.48	-9.34	-0.35	1.63e-19	Body mass index;
BRCA	cis	rs13046373	0.535	rs13051135	chr21:32005278	G/A	cg06468780	chr21:31798236	KRTAP13-3	0.33	8.32	0.31	5.43e-16	HDL cholesterol;
BRCA	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg08601574	chr20:25228251	PYGB	0.36	8.37	0.31	3.65e-16	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs921968	0.565	rs1554622	chr2:219606218	T/G	cg02176678	chr2:219576539	TTLL4	-0.42	-11.23	-0.41	7.69e-27	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg00745463	chr17:30367425	LRRC37B	-0.56	-9.29	-0.34	2.36e-19	Hip circumference adjusted for BMI;
BRCA	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-10.28	-0.38	4.93e-23	Reticulocyte count;
BRCA	cis	rs870825	0.929	rs72689256	chr4:185590174	C/T	cg04058563	chr4:185651563	MLF1IP	0.69	11.83	0.42	2.39e-29	Blood protein levels;
BRCA	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.61	-0.32	5.53e-17	Total body bone mineral density;
BRCA	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg14582100	chr15:45693742	SPATA5L1	0.36	11.85	0.42	1.99e-29	Homoarginine levels;
BRCA	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg23505145	chr19:12996616	KLF1	0.54	12.33	0.44	1.69e-31	Prostate cancer (SNP x SNP interaction);
BRCA	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg04756594	chr16:24857601	SLC5A11	-0.44	-8.44	-0.32	2.13e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
BRCA	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg03709012	chr19:19516395	GATAD2A	0.71	15.15	0.51	1.54e-44	Tonsillectomy;
BRCA	cis	rs751728	0.638	rs4713686	chr6:33787506	C/T	cg25922239	chr6:33757077	LEMD2	0.45	10.05	0.37	3.65e-22	Crohn's disease;
BRCA	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00908189	chr16:619842	PIGQ	0.7	17.63	0.57	5.55e-57	Height;
BRCA	cis	rs666930	0.967	rs637868	chr1:120257110	A/G	cg19096424	chr1:120255104	PHGDH	0.37	8.69	0.33	3.06e-17	Breast cancer;
BRCA	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.57	-10.18	-0.37	1.13e-22	Gut microbiome composition (summer);
BRCA	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg17971929	chr21:40555470	PSMG1	0.77	16.61	0.55	9.04e-52	Cognitive function;
BRCA	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18404041	chr3:52824283	ITIH1	-0.37	-11.3	-0.41	4.19e-27	Electroencephalogram traits;
BRCA	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg13047869	chr3:10149882	C3orf24	0.57	10.45	0.38	1.05e-23	Alzheimer's disease;
BRCA	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg08999081	chr20:33150536	PIGU	0.35	9.08	0.34	1.31e-18	Coronary artery disease;
BRCA	cis	rs919433	0.679	rs55656916	chr2:198519628	T/C	cg00792783	chr2:198669748	PLCL1	0.41	9.05	0.34	1.76e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg24006582	chr15:45444508	DUOX1	-0.55	-11.31	-0.41	3.61e-27	Uric acid levels;
BRCA	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	13.64	0.47	2.22e-37	Lymphocyte counts;
BRCA	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	10.66	0.39	1.6e-24	Rheumatoid arthritis;
BRCA	trans	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	20.76	0.63	1.49e-73	Exhaled nitric oxide output;
BRCA	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-13.86	-0.48	2.11e-38	Extrinsic epigenetic age acceleration;
BRCA	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg03676636	chr4:99064102	C4orf37	0.21	8.0	0.3	5.69e-15	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs7572733	0.534	rs700662	chr2:198668751	T/C	cg00792783	chr2:198669748	PLCL1	0.47	10.32	0.38	3.34e-23	Dermatomyositis;
BRCA	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	21.47	0.65	2.06e-77	Chronic sinus infection;
BRCA	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg11941060	chr3:133502564	NA	-0.51	-12.4	-0.44	8.56e-32	Iron status biomarkers;
BRCA	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg08847533	chr14:75593920	NEK9	0.84	21.44	0.65	3.24e-77	Height;
BRCA	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg16405210	chr4:1374714	KIAA1530	0.44	9.94	0.37	9.57e-22	Obesity-related traits;
BRCA	trans	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.33	7.81	0.3	2.3e-14	Corneal astigmatism;
BRCA	cis	rs911119	0.913	rs6048923	chr20:23578206	C/T	cg16589663	chr20:23618590	CST3	0.43	7.88	0.3	1.43e-14	Chronic kidney disease;
BRCA	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg11062466	chr8:58055876	NA	0.41	7.97	0.3	7.11e-15	Developmental language disorder (linguistic errors);
BRCA	cis	rs6723226	1.000	rs6723226	chr2:32849207	C/T	cg02381751	chr2:32503542	YIPF4	0.46	9.54	0.35	2.87e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	9.92	0.37	1.1e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
BRCA	cis	rs9337951	0.636	rs2487928	chr10:30323892	C/T	cg00730780	chr10:30316187	KIAA1462	-0.44	-9.39	-0.35	1.01e-19	Pulse pressure;Coronary artery disease;
BRCA	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg07423050	chr13:99094983	FARP1	-0.43	-10.43	-0.38	1.22e-23	Longevity;
BRCA	trans	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-14.04	-0.49	3.23e-39	Brugada syndrome;
BRCA	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-12.87	-0.45	7.32e-34	Chronic sinus infection;
BRCA	cis	rs7124681	0.584	rs4752792	chr11:47815702	G/A	cg20307385	chr11:47447363	PSMC3	-0.4	-9.37	-0.35	1.18e-19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
BRCA	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13732083	chr21:47605072	C21orf56	-0.37	-7.87	-0.3	1.54e-14	Testicular germ cell tumor;
BRCA	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.81	12.49	0.44	3.53e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg05665937	chr4:1216051	CTBP1	0.37	7.9	0.3	1.19e-14	Obesity-related traits;
BRCA	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg24692254	chr21:30365293	RNF160	-0.5	-11.01	-0.4	6.14e-26	Pancreatic cancer;
BRCA	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg16590910	chr6:42928470	GNMT	0.36	7.84	0.3	1.94e-14	Alzheimer's disease in APOE e4+ carriers;
BRCA	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg23131131	chr22:24373011	LOC391322	0.45	10.44	0.38	1.12e-23	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs9944715	0.954	rs9807157	chr18:43817755	T/C	cg01718231	chr17:29326311	RNF135	-0.46	-9.07	-0.34	1.51e-18	Red cell distribution width;Mean corpuscular volume;
BRCA	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg19336497	chr11:14380999	RRAS2	-0.48	-11.96	-0.43	6.84e-30	Sense of smell;
BRCA	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg15105969	chr2:36825350	FEZ2	0.45	8.56	0.32	8.69e-17	Height;
BRCA	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg17366294	chr4:99064904	C4orf37	0.44	10.36	0.38	2.29e-23	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8114671	0.967	rs2378337	chr20:33771435	G/A	cg07148914	chr20:33460835	GGT7	0.38	8.01	0.3	5.27e-15	Height;
BRCA	cis	rs9290065	0.519	rs1562465	chr3:160701442	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-9.95	-0.37	9.17e-22	Kawasaki disease;
BRCA	trans	rs783540	0.542	rs62009945	chr15:83299956	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.32	-8.12	-0.31	2.42e-15	Schizophrenia;
BRCA	cis	rs17253792	0.915	rs28663681	chr14:56178820	A/T	cg01858014	chr14:56050164	KTN1	-0.68	-8.53	-0.32	1.02e-16	Putamen volume;
BRCA	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11644478	chr21:40555479	PSMG1	-0.68	-15.35	-0.52	1.74e-45	Cognitive function;
BRCA	cis	rs6714710	0.603	rs7583868	chr2:98588372	C/A	cg26665480	chr2:98280029	ACTR1B	0.59	13.66	0.48	1.89e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs7474896	0.537	rs2749589	chr10:38266870	C/T	cg25427524	chr10:38739819	LOC399744	0.51	9.28	0.34	2.55e-19	Obesity (extreme);
BRCA	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg03146154	chr1:46216737	IPP	-0.51	-11.06	-0.4	3.95e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg26384229	chr12:38710491	ALG10B	0.42	9.33	0.35	1.73e-19	Morning vs. evening chronotype;
BRCA	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg25358565	chr5:93447407	FAM172A	1.21	19.73	0.62	5.16e-68	Diabetic retinopathy;
BRCA	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg10560079	chr2:191398806	TMEM194B	-0.74	-13.55	-0.47	6.03e-37	Diastolic blood pressure;
BRCA	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg02527881	chr3:46936655	PTH1R	0.36	9.05	0.34	1.77e-18	Colorectal cancer;
BRCA	cis	rs758324	0.947	rs58016983	chr5:131235275	T/C	cg06307176	chr5:131281290	NA	-0.57	-11.98	-0.43	5.62e-30	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs9487051	0.646	rs11153165	chr6:109622159	G/A	cg01475377	chr6:109611718	NA	-0.4	-8.85	-0.33	8.5e-18	Reticulocyte fraction of red cells;
BRCA	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg04362960	chr10:104952993	NT5C2	0.45	10.6	0.39	2.68e-24	Arsenic metabolism;
BRCA	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02176678	chr2:219576539	TTLL4	-0.52	-13.23	-0.46	1.77e-35	Mean corpuscular hemoglobin concentration;
BRCA	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg04727924	chr7:799746	HEATR2	-0.54	-10.74	-0.39	7.86e-25	Cerebrospinal P-tau181p levels;
BRCA	cis	rs35995292	0.517	rs6948026	chr7:38920854	A/G	cg19327137	chr7:38886074	VPS41	0.38	12.68	0.45	4.91e-33	Subjective well-being (multi-trait analysis);
BRCA	cis	rs1568889	1.000	rs11604085	chr11:28141002	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	13.49	0.47	1.18e-36	Bipolar disorder;
BRCA	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg17691542	chr6:26056736	HIST1H1C	0.45	8.72	0.33	2.35e-17	Iron status biomarkers;
BRCA	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-11.46	-0.41	8.4e-28	Pulmonary function;
BRCA	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg01483505	chr11:975446	AP2A2	0.3	8.17	0.31	1.61e-15	Alzheimer's disease (late onset);
BRCA	cis	rs3845702	0.736	rs6722147	chr2:180829704	G/A	cg01881094	chr2:180872142	CWC22	-1.02	-17.15	-0.56	1.67e-54	Schizophrenia;
BRCA	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg20701182	chr2:24300061	SF3B14	0.63	8.92	0.33	4.85e-18	Lymphocyte counts;
BRCA	trans	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg01620082	chr3:125678407	NA	-0.69	-8.53	-0.32	1.04e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg05340658	chr4:99064831	C4orf37	0.58	11.24	0.41	7.41e-27	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs10193935	0.901	rs9789740	chr2:42486799	A/G	cg27598129	chr2:42591480	NA	-0.94	-14.7	-0.5	2.32e-42	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6910061	0.830	rs13214911	chr6:11103690	C/A	cg27233058	chr6:11094804	LOC221710	0.51	8.54	0.32	1.01e-16	Diabetic kidney disease;
BRCA	cis	rs919433	0.680	rs3792159	chr2:198403697	A/G	cg00792783	chr2:198669748	PLCL1	-0.37	-8.34	-0.31	4.59e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs1113500	0.965	rs10881495	chr1:108610986	C/A	cg06207961	chr1:108661230	NA	0.44	10.4	0.38	1.69e-23	Growth-regulated protein alpha levels;
BRCA	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg03462622	chr3:195777018	TFRC	-0.38	-8.61	-0.32	5.5e-17	Mean corpuscular volume;
BRCA	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg07952391	chr2:88470173	THNSL2	0.58	8.06	0.3	3.84e-15	Plasma clusterin levels;
BRCA	cis	rs36051895	0.659	rs2149555	chr9:5053743	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-9.54	-0.35	3e-20	Pediatric autoimmune diseases;
BRCA	cis	rs10046574	0.831	rs76054058	chr7:135093486	G/C	cg27474649	chr7:135195673	CNOT4	0.59	8.29	0.31	6.82e-16	Peripheral arterial disease (traffic-related air pollution interaction);
BRCA	trans	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg25214090	chr10:38739885	LOC399744	0.45	10.28	0.38	4.83e-23	Corneal astigmatism;
BRCA	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg03709012	chr19:19516395	GATAD2A	-0.8	-18.5	-0.59	1.68e-61	Tonsillectomy;
BRCA	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.61	8.47	0.32	1.71e-16	Putamen volume;
BRCA	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg23708337	chr7:1209742	NA	0.7	11.05	0.4	4.23e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg07460842	chr6:66804631	NA	0.99	26.66	0.73	7.26e-106	Exhaled nitric oxide output;
BRCA	cis	rs7095944	0.614	rs10901817	chr10:126443404	A/T	cg08799069	chr10:126477246	METTL10	-0.4	-9.49	-0.35	4.41e-20	Asthma;
BRCA	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg18154014	chr19:37997991	ZNF793	0.57	11.25	0.41	6.39e-27	Coronary artery calcification;
BRCA	cis	rs12618769	0.652	rs72821965	chr2:99188783	T/C	cg10123293	chr2:99228465	UNC50	0.42	8.52	0.32	1.19e-16	Bipolar disorder;
BRCA	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00166722	chr3:10149974	C3orf24	0.66	13.21	0.46	2.15e-35	Alzheimer's disease;
BRCA	cis	rs2637266	0.967	rs12246436	chr10:78352914	C/T	cg18941641	chr10:78392320	NA	0.35	7.81	0.3	2.29e-14	Pulmonary function;
BRCA	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07636037	chr3:49044803	WDR6	-0.79	-20.43	-0.63	8.72e-72	Menarche (age at onset);
BRCA	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg03060546	chr3:49711283	APEH	-0.57	-7.85	-0.3	1.79e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	ch.11.42038R	chr11:967971	AP2A2	0.52	16.51	0.55	2.86e-51	Alzheimer's disease (late onset);
BRCA	cis	rs2880765	0.835	rs4514633	chr15:86041017	T/G	cg10818794	chr15:86012489	AKAP13	-0.3	-8.43	-0.32	2.36e-16	Coronary artery disease;
BRCA	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg07828340	chr4:882639	GAK	1.03	12.29	0.44	2.47e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs12467847	1.000	rs12467847	chr2:113691404	A/G	cg12858261	chr2:113808755	IL1F8	0.36	7.88	0.3	1.45e-14	Response to amphetamines;
BRCA	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.26	8.35	0.31	4.37e-16	Electroencephalogram traits;
BRCA	cis	rs701145	0.537	rs446144	chr3:153922154	T/C	cg17054900	chr3:154042577	DHX36	0.51	8.9	0.33	5.93e-18	Coronary artery disease;
BRCA	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg21573476	chr21:45109991	RRP1B	-0.49	-12.43	-0.44	6.48e-32	Mean corpuscular volume;
BRCA	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	8.76	0.33	1.79e-17	Rheumatoid arthritis;
BRCA	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg02012338	chr4:187126139	CYP4V2	0.88	10.12	0.37	2.01e-22	Blood protein levels;
BRCA	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg06494592	chr3:125709126	NA	-0.54	-8.4	-0.32	2.85e-16	Blood pressure (smoking interaction);
BRCA	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19346786	chr7:2764209	NA	-0.37	-11.15	-0.4	1.67e-26	Height;
BRCA	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.58	9.93	0.37	1.03e-21	Gut microbiome composition (summer);
BRCA	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg13319975	chr6:146136371	FBXO30	0.41	9.5	0.35	3.98e-20	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg26516362	chr5:178986906	RUFY1	0.33	7.92	0.3	1.05e-14	Lung cancer;
BRCA	cis	rs1975991	0.521	rs1383059	chr3:187964407	T/C	cg15417654	chr3:187959138	LPP	0.36	9.22	0.34	4.1e-19	White matter integrity (bipolar disorder risk interaction);
BRCA	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-9.93	-0.37	1.09e-21	Mean corpuscular volume;
BRCA	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.38	9.21	0.34	4.71e-19	Tonsillectomy;
BRCA	cis	rs67460515	0.596	rs35127376	chr3:160927289	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-15.04	-0.51	5.48e-44	Parkinson's disease;
BRCA	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg09307838	chr4:120376055	NA	0.74	16.17	0.54	1.53e-49	Corneal astigmatism;
BRCA	cis	rs4478858	0.735	rs1566961	chr1:31772450	G/A	cg00250761	chr1:31883323	NA	-0.32	-8.25	-0.31	9.14e-16	Alcohol dependence;
BRCA	cis	rs897984	0.542	rs750952	chr16:31093954	C/T	cg02466173	chr16:30829666	NA	-0.45	-10.19	-0.37	1.07e-22	Dementia with Lewy bodies;
BRCA	cis	rs867371	1.000	rs7166570	chr15:82466221	C/T	cg00614314	chr15:82944287	LOC80154	0.42	8.86	0.33	7.7e-18	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg21724239	chr8:58056113	NA	0.58	9.49	0.35	4.59e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg25237894	chr2:233734115	C2orf82	0.39	11.3	0.41	4.07e-27	Coronary artery disease;
BRCA	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg20701182	chr2:24300061	SF3B14	0.6	9.39	0.35	1.02e-19	Lymphocyte counts;
BRCA	cis	rs939658	1.000	rs17175798	chr15:79463960	A/G	cg17916960	chr15:79447300	NA	0.44	11.02	0.4	5.8e-26	Refractive error;
BRCA	cis	rs6088813	1.000	rs62211529	chr20:33959315	T/C	cg14752227	chr20:34000481	UQCC	-0.43	-9.15	-0.34	7.71e-19	Height;
BRCA	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.44	-9.8	-0.36	3.24e-21	Longevity;Endometriosis;
BRCA	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.33	10.36	0.38	2.27e-23	Bipolar disorder;
BRCA	cis	rs698813	0.604	rs7565928	chr2:44489956	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	8.52	0.32	1.11e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
BRCA	cis	rs9527	0.590	rs7089680	chr10:104802071	C/T	cg04362960	chr10:104952993	NT5C2	-0.43	-9.8	-0.36	3.09e-21	Arsenic metabolism;
BRCA	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-8.62	-0.32	5.3e-17	Developmental language disorder (linguistic errors);
BRCA	trans	rs12517041	0.935	rs4701359	chr5:23284257	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.91	-0.3	1.12e-14	Calcium levels;
BRCA	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg09307838	chr4:120376055	NA	0.69	14.0	0.48	4.65e-39	Corneal astigmatism;
BRCA	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	ch.11.42038R	chr11:967971	AP2A2	0.5	15.66	0.53	4.83e-47	Alzheimer's disease (late onset);
BRCA	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg26116260	chr4:7069785	GRPEL1	-0.59	-8.93	-0.33	4.43e-18	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg10523679	chr1:76189770	ACADM	-0.47	-9.04	-0.34	1.91e-18	Daytime sleep phenotypes;
BRCA	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-8.8	-0.33	1.31e-17	Monocyte percentage of white cells;
BRCA	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg05294307	chr14:35346193	BAZ1A	-0.61	-10.56	-0.39	3.85e-24	Psoriasis;
BRCA	cis	rs1994135	0.715	rs10506110	chr12:33708552	A/C	cg06521331	chr12:34319734	NA	-0.46	-8.15	-0.31	1.89e-15	Resting heart rate;
BRCA	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg22920501	chr2:26401640	FAM59B	-0.87	-15.03	-0.51	6.18e-44	Gut microbiome composition (summer);
BRCA	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg07148914	chr20:33460835	GGT7	0.47	10.0	0.37	5.78e-22	Height;
BRCA	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg27446573	chr6:127587934	RNF146	0.88	20.18	0.62	1.94e-70	Breast cancer;
BRCA	cis	rs4302748	0.774	rs58840739	chr7:36181940	C/T	cg24442661	chr7:36192818	EEPD1	0.46	8.74	0.33	2.11e-17	Platelet count;
BRCA	cis	rs1843834	0.838	rs6436506	chr2:225558242	T/C	cg22455342	chr2:225449267	CUL3	0.33	8.02	0.3	5.09e-15	IgE levels in asthmatics (D.p. specific);
BRCA	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-12.15	-0.43	1.08e-30	Morning vs. evening chronotype;
BRCA	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg21399703	chr1:247681439	NA	0.43	9.45	0.35	6.56e-20	Acute lymphoblastic leukemia (childhood);
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg03923535	chr7:1197113	ZFAND2A	0.49	9.74	0.36	5.5e-21	Longevity;Endometriosis;
BRCA	cis	rs7903847	0.596	rs9787426	chr10:99155327	A/G	cg08345082	chr10:99160200	RRP12	-0.3	-8.72	-0.33	2.41e-17	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs9341808	0.667	rs806783	chr6:80942943	A/C	cg08355045	chr6:80787529	NA	-0.33	-7.94	-0.3	8.92e-15	Sitting height ratio;
BRCA	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg23788917	chr6:8435910	SLC35B3	0.48	10.46	0.38	9.59e-24	Motion sickness;
BRCA	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg22903471	chr2:27725779	GCKR	-0.4	-9.76	-0.36	4.52e-21	Total body bone mineral density;
BRCA	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg23260525	chr10:116636907	FAM160B1	0.32	8.47	0.32	1.67e-16	Bipolar disorder or attention deficit hyperactivity disorder;
BRCA	cis	rs1506636	1.000	rs615410	chr7:123437765	T/C	cg03229431	chr7:123269106	ASB15	0.56	12.39	0.44	9.78e-32	Plateletcrit;Platelet count;
BRCA	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.6	9.58	0.35	2.15e-20	Renal function-related traits (BUN);
BRCA	cis	rs9811920	0.809	rs793464	chr3:99626028	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	13.52	0.47	8.15e-37	Axial length;
BRCA	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-8.32	-0.31	5.43e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	8.82	0.33	1.09e-17	Iron status biomarkers;
BRCA	trans	rs641862	1	rs641862	chr13:110790232	C/T	cg22783940	chr13:114251672	TFDP1	0.63	7.83	0.3	1.98e-14	Obesity-related traits;
BRCA	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg22535103	chr8:58192502	C8orf71	-0.6	-13.01	-0.46	1.63e-34	Developmental language disorder (linguistic errors);
BRCA	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.33	8.18	0.31	1.51e-15	Personality dimensions;
BRCA	cis	rs9473147	0.543	rs4711880	chr6:47480676	A/G	cg12968598	chr6:47444699	CD2AP	0.46	9.86	0.36	1.85e-21	Platelet distribution width;Mean platelet volume;
BRCA	cis	rs2108225	0.934	rs2190392	chr7:107452685	T/C	cg18560240	chr7:107437656	SLC26A3	-0.51	-10.25	-0.38	6.52e-23	Ulcerative colitis;
BRCA	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg19077165	chr18:44547161	KATNAL2	0.43	9.18	0.34	6.1e-19	Educational attainment;
BRCA	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg07645718	chr20:61493192	TCFL5	0.65	8.48	0.32	1.52e-16	Obesity-related traits;
BRCA	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg11584989	chr19:19387371	SF4	0.3	7.9	0.3	1.24e-14	Tonsillectomy;
BRCA	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg22980127	chr19:33182716	NUDT19	0.9	20.52	0.63	2.99e-72	Red blood cell traits;
BRCA	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg05340658	chr4:99064831	C4orf37	0.5	11.59	0.42	2.56e-28	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	14.02	0.48	4.03e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
BRCA	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07636037	chr3:49044803	WDR6	-0.73	-15.76	-0.53	1.62e-47	Menarche (age at onset);
BRCA	trans	rs2736345	0.788	rs998683	chr8:11353000	A/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-8.55	-0.32	8.81e-17	Sjögren's syndrome;Systemic lupus erythematosus;
BRCA	trans	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg05039488	chr6:79577232	IRAK1BP1	0.36	7.99	0.3	6.53e-15	Endometrial cancer;
BRCA	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.38	-8.48	-0.32	1.57e-16	Colorectal cancer;
BRCA	trans	rs911555	0.755	rs975892	chr14:103883349	A/T	cg17675199	chr6:35436792	RPL10A	0.3	8.07	0.3	3.49e-15	Intelligence (multi-trait analysis);
BRCA	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg20290983	chr6:43655470	MRPS18A	0.97	22.15	0.66	4.37e-81	IgG glycosylation;
BRCA	cis	rs4363385	0.655	rs11205163	chr1:152983677	C/T	cg21543102	chr1:152974771	SPRR3	-0.29	-8.19	-0.31	1.41e-15	Inflammatory skin disease;
BRCA	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg00484396	chr16:3507460	NAT15	0.57	8.4	0.32	2.82e-16	Tuberculosis;
BRCA	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	14.09	0.49	1.82e-39	Ileal carcinoids;
BRCA	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg27446573	chr6:127587934	RNF146	0.67	15.1	0.51	2.8e-44	Breast cancer;
BRCA	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00149659	chr3:10157352	C3orf10	0.76	13.06	0.46	9.78e-35	Alzheimer's disease;
BRCA	cis	rs4363385	0.747	rs4240867	chr1:152954921	A/G	cg25856811	chr1:152973957	SPRR3	0.32	8.95	0.33	3.82e-18	Inflammatory skin disease;
BRCA	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.53	-0.32	1.06e-16	Triglycerides;
BRCA	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.3	-7.87	-0.3	1.58e-14	Total body bone mineral density;
BRCA	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-16.15	-0.54	1.89e-49	Alzheimer's disease (late onset);
BRCA	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg26031613	chr14:104095156	KLC1	0.68	13.88	0.48	1.76e-38	Body mass index;
BRCA	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg21496419	chr19:44306685	LYPD5	0.39	8.21	0.31	1.22e-15	Breast cancer (estrogen-receptor negative);Breast cancer;
BRCA	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg25173405	chr17:45401733	C17orf57	0.48	9.84	0.36	2.24e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
BRCA	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg09035930	chr12:129282057	SLC15A4	0.49	13.79	0.48	4.53e-38	Systemic lupus erythematosus;
BRCA	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg15556689	chr8:8085844	FLJ10661	-0.3	-8.19	-0.31	1.38e-15	Retinal vascular caliber;
BRCA	cis	rs7246657	0.678	rs2972446	chr19:38129893	G/A	cg23950597	chr19:37808831	NA	0.51	8.84	0.33	9.4e-18	Coronary artery calcification;
BRCA	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg27129171	chr3:47204927	SETD2	-0.65	-14.4	-0.49	6.44e-41	Birth weight;
BRCA	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	25.91	0.72	1.01e-101	Chronic sinus infection;
BRCA	trans	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg25214090	chr10:38739885	LOC399744	0.44	10.29	0.38	4.34e-23	Corneal astigmatism;
BRCA	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg21475434	chr5:93447410	FAM172A	0.68	8.6	0.32	6.23e-17	Diabetic retinopathy;
BRCA	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg13319975	chr6:146136371	FBXO30	-0.39	-8.8	-0.33	1.3e-17	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg09307838	chr4:120376055	NA	0.69	14.25	0.49	3.17e-40	Corneal astigmatism;
BRCA	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.55	13.23	0.46	1.73e-35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
BRCA	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-15.96	-0.53	1.69e-48	Total cholesterol levels;
BRCA	trans	rs12517041	0.935	rs10062553	chr5:23294800	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.94	-0.3	9.15e-15	Calcium levels;
BRCA	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	22.89	0.67	3.9e-85	Chronic sinus infection;
BRCA	cis	rs6901250	0.851	rs168128	chr6:117166865	A/G	cg12892004	chr6:117198278	RFX6	-0.5	-11.5	-0.41	5.96e-28	C-reactive protein levels;
BRCA	cis	rs1011018	0.590	rs74620925	chr7:139470733	C/T	cg03224163	chr7:139420300	HIPK2	-0.59	-8.94	-0.33	4.16e-18	Systolic blood pressure;
BRCA	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.57	0.39	3.41e-24	Tonsillectomy;
BRCA	cis	rs701145	0.938	rs1086106	chr3:154084032	C/T	cg17054900	chr3:154042577	DHX36	0.68	11.72	0.42	7.27e-29	Coronary artery disease;
BRCA	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg13010199	chr12:38710504	ALG10B	0.49	9.41	0.35	9.16e-20	Morning vs. evening chronotype;
BRCA	cis	rs6714710	0.603	rs35424768	chr2:98395653	A/C	cg26665480	chr2:98280029	ACTR1B	0.58	13.59	0.47	4.06e-37	Posterior cortical atrophy and Alzheimer's disease;
BRCA	cis	rs7408868	1.000	rs7249525	chr19:15277309	G/A	cg14696996	chr19:15285081	NOTCH3	1.02	14.79	0.5	9.21e-43	Pulse pressure;
BRCA	cis	rs3849570	0.643	rs11705789	chr3:81969196	G/T	cg07356753	chr3:81810745	GBE1	-0.33	-7.89	-0.3	1.35e-14	Waist circumference;Body mass index;
BRCA	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg08807101	chr21:30365312	RNF160	-0.61	-15.64	-0.53	6.71e-47	Dental caries;
BRCA	trans	rs35847492	1.000	rs17730481	chr8:9276163	A/G	cg15556689	chr8:8085844	FLJ10661	-0.36	-8.39	-0.32	3.08e-16	Neuroticism;
BRCA	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg10818794	chr15:86012489	AKAP13	-0.3	-8.5	-0.32	1.34e-16	Coronary artery disease;
BRCA	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg10729496	chr3:10149963	C3orf24	0.48	8.91	0.33	5.33e-18	Alzheimer's disease;
BRCA	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg23711669	chr6:146136114	FBXO30	0.64	14.77	0.5	1.09e-42	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs727479	0.543	rs6493489	chr15:51514203	C/T	cg19946085	chr15:51559439	CYP19A1	-0.29	-7.86	-0.3	1.6e-14	Estradiol levels;
BRCA	cis	rs965469	0.724	rs6037527	chr20:3254412	T/G	cg25506879	chr20:3388711	C20orf194	-0.45	-9.1	-0.34	1.12e-18	IFN-related cytopenia;
BRCA	cis	rs7091068	0.522	rs11187621	chr10:95483074	T/C	cg20715218	chr10:95462985	C10orf4	0.48	9.15	0.34	7.34e-19	Urinary tract infection frequency;
BRCA	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg22875332	chr1:76189707	ACADM	0.69	14.48	0.5	2.59e-41	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg08885076	chr2:99613938	TSGA10	-0.59	-13.21	-0.46	2.12e-35	Chronic sinus infection;
BRCA	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg06115741	chr20:33292138	TP53INP2	0.35	7.89	0.3	1.29e-14	Glomerular filtration rate (creatinine);
BRCA	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg07148914	chr20:33460835	GGT7	0.38	8.52	0.32	1.14e-16	Height;
BRCA	trans	rs6479901	0.512	rs7100372	chr10:65064244	T/C	cg14819942	chr15:35414228	NA	-0.35	-8.56	-0.32	8.37e-17	Intelligence (multi-trait analysis);
BRCA	trans	rs877282	0.891	rs34383514	chr10:800181	T/C	cg22713356	chr15:30763199	NA	1.4	28.4	0.75	2.36e-115	Uric acid levels;
BRCA	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	17.08	0.56	3.51e-54	Platelet count;
BRCA	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	8.33	0.31	4.94e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg03709012	chr19:19516395	GATAD2A	-0.75	-16.65	-0.55	5.94e-52	Tonsillectomy;
BRCA	cis	rs9487051	0.803	rs11153161	chr6:109541774	A/G	cg01475377	chr6:109611718	NA	-0.42	-9.79	-0.36	3.55e-21	Reticulocyte fraction of red cells;
BRCA	trans	rs7395662	0.853	rs35255233	chr11:48442870	T/A	cg00717180	chr2:96193071	NA	-0.28	-7.83	-0.3	2.05e-14	HDL cholesterol;
BRCA	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg24088639	chr11:34937564	PDHX;APIP	0.41	9.21	0.34	4.66e-19	Systemic lupus erythematosus and Systemic sclerosis;
BRCA	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg02551604	chr5:131831745	NA	-0.4	-14.95	-0.51	1.56e-43	Asthma (sex interaction);
BRCA	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg03354898	chr7:1950403	MAD1L1	0.38	8.57	0.32	7.99e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg26893861	chr17:41843967	DUSP3	-1.06	-29.73	-0.76	1.27e-122	Triglycerides;
BRCA	cis	rs4891159	0.790	rs7241485	chr18:74122325	C/T	cg24786174	chr18:74118243	ZNF516	-0.78	-18.83	-0.6	2.97e-63	Longevity;
BRCA	cis	rs698833	0.537	rs698826	chr2:44728418	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	8.76	0.33	1.81e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.32	-8.18	-0.31	1.49e-15	Personality dimensions;
BRCA	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg02297831	chr4:17616191	MED28	0.36	8.42	0.32	2.43e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-16.03	-0.54	7.33e-49	Alzheimer's disease (late onset);
BRCA	cis	rs11051970	0.879	rs2088806	chr12:32592125	C/T	cg24626660	chr12:32551988	NA	0.29	8.3	0.31	6.16e-16	Response to tocilizumab in rheumatoid arthritis;
BRCA	trans	rs931812	0.757	rs4734014	chr8:101908844	A/G	cg20993868	chr7:22813445	NA	0.44	13.33	0.47	5.96e-36	Attention deficit hyperactivity disorder and conduct disorder;
BRCA	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg01877450	chr7:97915802	BRI3	-0.38	-8.63	-0.32	4.87e-17	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg06521331	chr12:34319734	NA	-0.46	-9.05	-0.34	1.75e-18	Bladder cancer;
BRCA	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11644478	chr21:40555479	PSMG1	0.84	19.08	0.6	1.5e-64	Cognitive function;
BRCA	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg15839431	chr19:19639596	YJEFN3	-0.36	-8.08	-0.3	3.2e-15	Bipolar disorder;
BRCA	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg09367891	chr1:107599246	PRMT6	0.42	8.22	0.31	1.11e-15	Facial morphology (factor 21, depth of nasal alae);
BRCA	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg14004847	chr7:1930337	MAD1L1	-0.45	-8.59	-0.32	6.73e-17	Bipolar disorder and schizophrenia;
BRCA	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05535760	chr7:792225	HEATR2	0.83	14.42	0.5	4.97e-41	Cerebrospinal P-tau181p levels;
BRCA	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg21775007	chr8:11205619	TDH	-0.62	-13.41	-0.47	2.64e-36	Retinal vascular caliber;
BRCA	cis	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg07460842	chr6:66804631	NA	0.98	19.59	0.61	2.75e-67	Exhaled nitric oxide output;
BRCA	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.35	7.85	0.3	1.71e-14	Coronary artery disease;
BRCA	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg03146154	chr1:46216737	IPP	0.53	11.89	0.43	1.37e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg00757033	chr12:89920650	WDR51B	0.53	10.74	0.39	7.86e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
BRCA	cis	rs7646881	0.812	rs7636023	chr3:158460059	T/C	cg19483011	chr3:158453295	NA	-0.46	-8.05	-0.3	4.08e-15	Tetralogy of Fallot;
BRCA	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg13852791	chr20:30311386	BCL2L1	0.82	15.98	0.53	1.31e-48	Mean corpuscular hemoglobin;
BRCA	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg20503657	chr10:835505	NA	0.95	14.77	0.5	1.14e-42	Eosinophil percentage of granulocytes;
BRCA	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg18850127	chr7:39170497	POU6F2	0.48	10.13	0.37	1.81e-22	IgG glycosylation;
BRCA	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg13628971	chr7:2884303	GNA12	0.47	9.97	0.37	7.71e-22	Height;
BRCA	cis	rs593982	1.000	rs470360	chr11:65500530	T/C	cg08755490	chr11:65554678	OVOL1	1.27	29.33	0.76	1.95e-120	Atopic dermatitis;
BRCA	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-17.41	-0.57	7.87e-56	Body mass index;
BRCA	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg01689657	chr7:91764605	CYP51A1	0.22	7.92	0.3	1.09e-14	Breast cancer;
BRCA	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	14.05	0.49	2.94e-39	Lymphocyte percentage of white cells;
BRCA	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg09307838	chr4:120376055	NA	0.58	10.81	0.39	3.98e-25	Corneal astigmatism;
BRCA	cis	rs6964587	0.621	rs39744	chr7:92043016	A/G	cg17063962	chr7:91808500	NA	0.48	10.93	0.4	1.25e-25	Breast cancer;
BRCA	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg04455712	chr21:45112962	RRP1B	0.4	10.4	0.38	1.58e-23	Mean corpuscular volume;
BRCA	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg06064525	chr11:970664	AP2A2	-0.33	-9.52	-0.35	3.48e-20	Alzheimer's disease (late onset);
BRCA	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg18252515	chr7:66147081	NA	-0.86	-12.38	-0.44	1.04e-31	Diabetic kidney disease;
BRCA	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.49	-11.16	-0.4	1.46e-26	Longevity;Endometriosis;
BRCA	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg14820908	chr5:178986412	RUFY1	0.37	9.24	0.34	3.7e-19	Lung cancer;
BRCA	cis	rs10851411	0.697	rs113979838	chr15:42792353	T/C	cg21293051	chr15:42870591	STARD9	0.51	8.37	0.31	3.54e-16	Glucose homeostasis traits;
BRCA	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	8.25	0.31	9.02e-16	Uric acid levels;
BRCA	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg00071950	chr4:10020882	SLC2A9	0.56	13.89	0.48	1.6e-38	Bone mineral density;
BRCA	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg16606324	chr3:10149918	C3orf24	0.57	10.04	0.37	3.9e-22	Alzheimer's disease;
BRCA	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.58	10.28	0.38	4.65e-23	Gut microbiome composition (summer);
BRCA	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.39	8.29	0.31	6.64e-16	Total cholesterol levels;
BRCA	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg09033563	chr22:24373618	LOC391322	-0.39	-8.08	-0.3	3.13e-15	Liver enzyme levels (gamma-glutamyl transferase);
BRCA	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-9.28	-0.34	2.51e-19	Triglycerides;
BRCA	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.39	-8.33	-0.31	4.81e-16	Longevity;Endometriosis;
BRCA	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg03433033	chr1:76189801	ACADM	-0.6	-11.81	-0.42	3.05e-29	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg21427119	chr20:30132790	HM13	-0.35	-7.95	-0.3	8.73e-15	Mean corpuscular hemoglobin;
BRCA	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-8.44	-0.32	2.15e-16	Schizophrenia;
BRCA	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg08847533	chr14:75593920	NEK9	-0.83	-20.65	-0.63	5.59e-73	Height;
BRCA	cis	rs12618769	0.597	rs55934321	chr2:99099417	G/A	cg10123293	chr2:99228465	UNC50	0.42	8.18	0.31	1.53e-15	Bipolar disorder;
BRCA	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg26061582	chr7:22766209	IL6	0.35	8.06	0.3	3.7e-15	Lung cancer;
BRCA	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg10523679	chr1:76189770	ACADM	-0.76	-15.83	-0.53	7.67e-48	Blood metabolite levels;Acylcarnitine levels;
BRCA	cis	rs867371	1.000	rs7180584	chr15:82455834	A/G	cg00614314	chr15:82944287	LOC80154	0.44	9.12	0.34	9.52e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
BRCA	cis	rs666930	0.519	rs483180	chr1:120267505	C/G	cg19096424	chr1:120255104	PHGDH	-0.62	-13.44	-0.47	2e-36	Breast cancer;
BRCA	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg24296786	chr1:45957014	TESK2	-0.39	-8.06	-0.3	3.84e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg21724239	chr8:58056113	NA	0.6	9.63	0.36	1.35e-20	Developmental language disorder (linguistic errors);
BRCA	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg11062466	chr8:58055876	NA	0.5	8.77	0.33	1.63e-17	Developmental language disorder (linguistic errors);
BRCA	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	22.2	0.66	2.32e-81	Platelet count;
BRCA	cis	rs7249921	0.833	rs6510469	chr19:35672008	G/T	cg15419183	chr19:35660584	FXYD5	0.46	10.34	0.38	2.72e-23	Platelet count;
BRCA	cis	rs9790314	0.730	rs4856705	chr3:161100219	T/G	cg03342759	chr3:160939853	NMD3	-0.55	-11.98	-0.43	5.68e-30	Morning vs. evening chronotype;
BRCA	cis	rs3849570	0.695	rs6792696	chr3:81874009	G/A	cg07356753	chr3:81810745	GBE1	-0.4	-9.56	-0.35	2.6e-20	Waist circumference;Body mass index;
BRCA	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg14675211	chr2:100938903	LONRF2	0.52	11.82	0.42	2.63e-29	Intelligence (multi-trait analysis);
BRCA	trans	rs9951602	0.512	rs4799247	chr18:76653449	G/A	cg02800362	chr5:177631904	HNRNPAB	0.77	18.23	0.58	4.25e-60	Obesity-related traits;
BRCA	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg16576597	chr16:28551801	NUPR1	0.34	8.58	0.32	6.98e-17	Body mass index;
BRCA	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13732083	chr21:47605072	C21orf56	0.37	7.86	0.3	1.61e-14	Testicular germ cell tumor;
BRCA	cis	rs17601876	0.843	rs28490942	chr15:51559845	G/C	cg19946085	chr15:51559439	CYP19A1	-0.38	-11.58	-0.42	2.72e-28	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg20991723	chr1:152506922	NA	0.39	8.95	0.33	3.69e-18	Hair morphology;
BRCA	trans	rs12517041	1.000	rs1593967	chr5:23313900	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-7.84	-0.3	1.84e-14	Calcium levels;
BRCA	cis	rs812925	0.512	rs7558954	chr2:61384906	T/C	cg15711740	chr2:61764176	XPO1	-0.32	-8.0	-0.3	5.8e-15	Immature fraction of reticulocytes;
BRCA	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg05340658	chr4:99064831	C4orf37	0.68	16.94	0.56	1.9e-53	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-13.95	-0.48	8.14e-39	Bipolar disorder and schizophrenia;
BRCA	cis	rs9807989	0.524	rs6543126	chr2:103027104	G/A	cg03938978	chr2:103052716	IL18RAP	0.29	8.21	0.31	1.2e-15	Asthma;
BRCA	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	10.71	0.39	1.01e-24	Bipolar disorder;
BRCA	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg02297831	chr4:17616191	MED28	0.36	8.42	0.32	2.43e-16	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg13385794	chr1:248469461	NA	0.27	7.89	0.3	1.32e-14	Common traits (Other);
BRCA	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg21573476	chr21:45109991	RRP1B	-0.36	-9.55	-0.35	2.67e-20	Mean corpuscular volume;
BRCA	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg17691542	chr6:26056736	HIST1H1C	0.52	10.45	0.38	1.08e-23	Height;
BRCA	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21659725	chr3:3221576	CRBN	-0.71	-21.71	-0.65	1.04e-78	Intelligence (multi-trait analysis);
BRCA	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	8.09	0.3	2.91e-15	Tonsillectomy;
BRCA	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-30.51	-0.77	8.1e-127	Schizophrenia;
BRCA	cis	rs136211	0.619	rs9607337	chr22:36758849	A/T	cg21778268	chr22:36877729	TXN2	-0.36	-8.26	-0.31	8.2e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-9.7	-0.36	7.72e-21	Resting heart rate;
BRCA	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg26031613	chr14:104095156	KLC1	-0.42	-8.49	-0.32	1.5e-16	Schizophrenia;
BRCA	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.43	8.26	0.31	8.1e-16	Resistin levels;
BRCA	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg06212747	chr3:49208901	KLHDC8B	0.44	9.29	0.35	2.32e-19	Menarche (age at onset);
BRCA	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg22705602	chr4:152727874	NA	-0.32	-8.24	-0.31	9.68e-16	Intelligence (multi-trait analysis);
BRCA	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg21573476	chr21:45109991	RRP1B	-0.37	-9.64	-0.36	1.32e-20	Mean corpuscular volume;
BRCA	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg01579765	chr21:45077557	HSF2BP	0.37	9.89	0.36	1.51e-21	Mean corpuscular volume;
BRCA	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.53	10.29	0.38	4.45e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	cis	rs9900497	0.536	rs4646785	chr17:19651902	A/G	cg22552966	chr17:19620595	SLC47A2	-0.32	-8.06	-0.3	3.63e-15	Response to paliperidone in schizophrenia (CGI-S score);
BRCA	cis	rs911555	0.576	rs8015723	chr14:103895909	A/G	cg12935359	chr14:103987150	CKB	0.53	11.66	0.42	1.26e-28	Intelligence (multi-trait analysis);
BRCA	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg22980127	chr19:33182716	NUDT19	0.89	17.96	0.58	1.09e-58	Red blood cell traits;
BRCA	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg12826209	chr6:26865740	GUSBL1	-0.54	-9.11	-0.34	1.01e-18	Intelligence (multi-trait analysis);
BRCA	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	18.33	0.59	1.25e-60	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
BRCA	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg14675211	chr2:100938903	LONRF2	0.43	9.53	0.35	3.14e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg19773385	chr1:10388646	KIF1B	-0.38	-8.14	-0.31	2.12e-15	Hepatocellular carcinoma;
BRCA	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-10.4	-0.38	1.67e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg08859206	chr1:53392774	SCP2	0.42	8.31	0.31	5.65e-16	Monocyte count;
BRCA	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.68	-0.5	3.02e-42	Chronic sinus infection;
BRCA	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg24060327	chr5:131705240	SLC22A5	-0.63	-12.26	-0.44	3.58e-31	Acylcarnitine levels;
BRCA	cis	rs6484504	0.576	rs158136	chr11:31220712	C/T	cg14844989	chr11:31128820	NA	-0.45	-9.62	-0.36	1.51e-20	Red blood cell count;
BRCA	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-8.3	-0.31	6.07e-16	Monocyte percentage of white cells;
BRCA	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-10.6	-0.39	2.68e-24	Lymphocyte counts;
BRCA	trans	rs7980799	0.649	rs2220059	chr12:33648630	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-9.67	-0.36	9.67e-21	Heart rate;Heart rate variability traits (RMSSD);
BRCA	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-11.56	-0.42	3.28e-28	Lymphocyte counts;
BRCA	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg04842962	chr6:43655489	MRPS18A	1.11	38.55	0.84	7e-169	IgG glycosylation;
BRCA	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg18279126	chr7:2041391	MAD1L1	0.39	8.98	0.33	3.1e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs11249608	0.548	rs62393074	chr5:178450476	G/C	cg21905437	chr5:178450457	ZNF879	0.53	11.1	0.4	2.76e-26	Pubertal anthropometrics;
BRCA	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg01483505	chr11:975446	AP2A2	0.33	8.95	0.33	3.8e-18	Alzheimer's disease (late onset);
BRCA	cis	rs738322	0.555	rs5750547	chr22:38546700	A/G	cg25457927	chr22:38595422	NA	0.35	12.89	0.45	5.72e-34	Cutaneous nevi;
BRCA	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.34	9.41	0.35	8.46e-20	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg11584989	chr19:19387371	SF4	0.63	13.52	0.47	7.85e-37	Bipolar disorder;
BRCA	cis	rs427394	0.659	rs187295	chr5:6734326	C/T	cg10857441	chr5:6722123	POLS	-0.3	-9.53	-0.35	3.34e-20	Menopause (age at onset);
BRCA	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg27446573	chr6:127587934	RNF146	0.9	21.07	0.64	2.99e-75	Breast cancer;
BRCA	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg27347728	chr4:17578864	LAP3	0.43	8.04	0.3	4.27e-15	Parasitemia in Tripanosoma cruzi seropositivity;
BRCA	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07988820	chr12:82153109	PPFIA2	-0.67	-11.92	-0.43	1.03e-29	Resting heart rate;
BRCA	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg02951883	chr7:2050386	MAD1L1	-0.54	-12.27	-0.44	3.31e-31	Bipolar disorder and schizophrenia;
BRCA	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg21535247	chr6:8435926	SLC35B3	0.39	8.88	0.33	6.9e-18	Motion sickness;
BRCA	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-8.6	-0.32	6.33e-17	Monocyte percentage of white cells;
BRCA	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-8.41	-0.32	2.77e-16	Monocyte percentage of white cells;
BRCA	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.83	0.55	7.34e-53	Colorectal cancer;
BRCA	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.4	-10.45	-0.38	1.08e-23	Intelligence (multi-trait analysis);
BRCA	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg04691961	chr3:161091175	C3orf57	-0.4	-9.28	-0.34	2.7e-19	Morning vs. evening chronotype;
BRCA	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg08975724	chr8:8085496	FLJ10661	0.38	7.84	0.3	1.84e-14	Neuroticism;
BRCA	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg13114125	chr14:105738426	BRF1	-0.53	-11.06	-0.4	3.95e-26	Mean platelet volume;Platelet distribution width;
BRCA	cis	rs6878727	0.665	rs161012	chr5:123674990	C/T	cg01806427	chr5:123737813	NA	-0.36	-8.15	-0.31	1.97e-15	Breast cancer;
BRCA	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-10.43	-0.38	1.23e-23	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg17366294	chr4:99064904	C4orf37	0.44	10.46	0.38	9.87e-24	Colonoscopy-negative controls vs population controls;
BRCA	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg11941060	chr3:133502564	NA	-0.49	-11.68	-0.42	1.11e-28	Iron status biomarkers;
BRCA	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg11941060	chr3:133502564	NA	-0.5	-11.91	-0.43	1.16e-29	Iron status biomarkers;
BRCA	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg13010199	chr12:38710504	ALG10B	0.51	10.07	0.37	2.99e-22	Bladder cancer;
BRCA	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg16325326	chr1:53192061	ZYG11B	0.58	13.04	0.46	1.24e-34	Monocyte count;
BRCA	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg08470875	chr2:26401718	FAM59B	-0.78	-12.17	-0.43	8.7e-31	Gut microbiome composition (summer);
BRCA	cis	rs7631605	0.905	rs6786906	chr3:37226016	T/C	cg15934958	chr3:37212084	LRRFIP2	0.39	9.26	0.34	3.01e-19	Cerebrospinal P-tau181p levels;
BRCA	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg06159980	chr1:16340746	HSPB7	-0.38	-8.83	-0.33	1.01e-17	Dilated cardiomyopathy;
BRCA	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg23788917	chr6:8435910	SLC35B3	0.48	10.36	0.38	2.42e-23	Motion sickness;
BRCA	cis	rs7903847	0.642	rs7903562	chr10:99154782	T/C	cg20016023	chr10:99160130	RRP12	-0.25	-8.18	-0.31	1.56e-15	Granulocyte percentage of myeloid white cells;
BRCA	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg08601574	chr20:25228251	PYGB	0.41	9.35	0.35	1.43e-19	Liver enzyme levels (alkaline phosphatase);
BRCA	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg22961513	chr11:14280813	SPON1	0.32	8.07	0.3	3.44e-15	Mitochondrial DNA levels;
BRCA	cis	rs6752107	0.935	rs1596017	chr2:234147930	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	10.45	0.38	1.09e-23	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg04362960	chr10:104952993	NT5C2	0.45	10.39	0.38	1.84e-23	Arsenic metabolism;
BRCA	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-10.46	-0.38	9.35e-24	Neuroticism;
BRCA	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg13175981	chr1:150552382	MCL1	0.54	11.86	0.42	1.83e-29	Tonsillectomy;
BRCA	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg17143192	chr8:8559678	CLDN23	0.57	11.1	0.4	2.61e-26	Obesity-related traits;
BRCA	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg17830980	chr10:43048298	ZNF37B	-0.53	-12.79	-0.45	1.66e-33	Extrinsic epigenetic age acceleration;
BRCA	cis	rs698833	0.852	rs2241869	chr2:44549229	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.5	-9.93	-0.37	1.02e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
BRCA	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg23442198	chr4:187126114	CYP4V2	0.94	11.58	0.42	2.71e-28	Blood protein levels;
BRCA	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-10.34	-0.38	2.72e-23	Schizophrenia;
BRCA	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg04691961	chr3:161091175	C3orf57	-0.4	-9.23	-0.34	3.79e-19	Morning vs. evening chronotype;
BRCA	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg23719950	chr11:63933701	MACROD1	-0.54	-9.02	-0.34	2.09e-18	Mean platelet volume;
BRCA	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-10.07	-0.37	3.08e-22	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11644478	chr21:40555479	PSMG1	-0.44	-8.62	-0.32	5.08e-17	Menarche (age at onset);
BRCA	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg26608667	chr7:1196370	ZFAND2A	0.42	9.14	0.34	7.87e-19	Longevity;Endometriosis;
BRCA	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg03060546	chr3:49711283	APEH	0.59	10.21	0.37	9.07e-23	Menarche (age at onset);
BRCA	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	9.83	0.36	2.45e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
BRCA	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg17691542	chr6:26056736	HIST1H1C	0.6	11.68	0.42	1.08e-28	Height;
BRCA	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.4	-8.87	-0.33	7.35e-18	Alzheimer's disease (late onset);
BRCA	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18876405	chr7:65276391	NA	-0.64	-15.66	-0.53	5.03e-47	Aortic root size;
BRCA	cis	rs9868809	0.772	rs34096717	chr3:48719453	A/C	cg00383909	chr3:49044727	WDR6	0.57	9.81	0.36	2.85e-21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg04455712	chr21:45112962	RRP1B	0.4	10.67	0.39	1.45e-24	Mean corpuscular volume;
BRCA	cis	rs2637030	0.559	rs2607501	chr5:52989545	A/T	cg06476337	chr5:52856530	NDUFS4	0.37	8.41	0.32	2.76e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
BRCA	cis	rs6840258	0.825	rs72667751	chr4:87936379	C/T	cg08197287	chr4:87952173	AFF1	-0.42	-8.34	-0.31	4.6e-16	Mean corpuscular volume;Basophil percentage of granulocytes;
BRCA	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg23708337	chr7:1209742	NA	0.64	8.93	0.33	4.47e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-8.04	-0.3	4.24e-15	Extrinsic epigenetic age acceleration;
BRCA	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.81	12.03	0.43	3.33e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
BRCA	trans	rs7200543	1.000	rs1121	chr16:15131076	G/A	cg24683922	chr1:11983373	KIAA2013	-0.39	-8.72	-0.33	2.45e-17	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
BRCA	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21659725	chr3:3221576	CRBN	0.7	20.96	0.64	1.24e-74	Intelligence (multi-trait analysis);
BRCA	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg09455208	chr3:40491958	NA	0.4	9.58	0.35	2.14e-20	Renal cell carcinoma;
BRCA	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	11.5	0.41	5.88e-28	Crohn's disease;Inflammatory bowel disease;
BRCA	trans	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	14.54	0.5	1.32e-41	Exhaled nitric oxide levels;
BRCA	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg27102117	chr16:15229624	NA	0.41	9.68	0.36	9.29e-21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg20628663	chr10:43360327	NA	-0.69	-13.51	-0.47	9.07e-37	Blood protein levels;
BRCA	cis	rs2658782	0.901	rs11604909	chr11:93218355	C/G	cg15737290	chr11:93063684	CCDC67	0.49	9.17	0.34	6.55e-19	Pulmonary function decline;
BRCA	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg19508488	chr2:152266495	RIF1	0.43	9.39	0.35	1.01e-19	Lung cancer;
BRCA	cis	rs6815814	0.950	rs5743566	chr4:38805942	G/C	cg06935464	chr4:38784597	TLR10	0.51	8.49	0.32	1.46e-16	Breast cancer;
BRCA	cis	rs13136331	0.680	rs2732208	chr4:88650530	C/T	cg12990093	chr4:88570587	DMP1	-0.39	-7.84	-0.3	1.84e-14	Sitting height ratio;
BRCA	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg23033748	chr14:75592666	NEK9	-0.42	-10.28	-0.38	4.63e-23	Height;
BRCA	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-1.02	-17.54	-0.57	1.66e-56	Platelet count;
BRCA	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19717773	chr7:2847554	GNA12	-0.46	-9.66	-0.36	1.04e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
BRCA	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.55	17.83	0.58	4.99e-58	Neurocognitive impairment in HIV-1 infection (dichotomous);
BRCA	trans	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg26043149	chr18:55253948	FECH	-0.39	-8.29	-0.31	6.5e-16	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg08917208	chr2:24149416	ATAD2B	0.9	12.92	0.46	4.27e-34	Lymphocyte counts;
BRCA	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg00745463	chr17:30367425	LRRC37B	-0.54	-8.88	-0.33	6.88e-18	Hip circumference adjusted for BMI;
BRCA	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.87	0.56	4.51e-53	Colorectal cancer;
BRCA	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	18.03	0.58	4.67e-59	Age-related macular degeneration (geographic atrophy);
BRCA	trans	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg06521331	chr12:34319734	NA	-0.46	-8.56	-0.32	8.29e-17	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg26384229	chr12:38710491	ALG10B	0.76	17.18	0.56	1.18e-54	Bladder cancer;
BRCA	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20891558	chr2:74357851	NA	0.53	12.68	0.45	5.17e-33	Gestational age at birth (maternal effect);
BRCA	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-11.65	-0.42	1.42e-28	Glomerular filtration rate (creatinine);
BRCA	cis	rs1568889	1.000	rs35697240	chr11:28287342	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	13.04	0.46	1.24e-34	Bipolar disorder;
BRCA	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg02493740	chr2:85810744	VAMP5	-0.56	-11.36	-0.41	2.28e-27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
BRCA	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg12437481	chr16:420112	MRPL28	-0.4	-8.73	-0.33	2.19e-17	Bone mineral density (spine);Bone mineral density;
BRCA	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg07493874	chr5:1342172	CLPTM1L	0.51	14.61	0.5	6.06e-42	Lung cancer;
BRCA	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg26031613	chr14:104095156	KLC1	-0.54	-9.08	-0.34	1.3e-18	Schizophrenia;Autism spectrum disorder or schizophrenia;
BRCA	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-13.45	-0.47	1.72e-36	Developmental language disorder (linguistic errors);
BRCA	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg11764359	chr7:65958608	NA	-0.68	-15.38	-0.52	1.14e-45	Aortic root size;
BRCA	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg20701182	chr2:24300061	SF3B14	0.63	8.91	0.33	5.3e-18	Lymphocyte counts;
BRCA	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg08501292	chr6:25962987	TRIM38	0.59	8.28	0.31	6.98e-16	Autism spectrum disorder or schizophrenia;
BRCA	cis	rs4664304	0.620	rs2729705	chr2:160710922	T/C	cg14819504	chr2:160761413	LY75	-0.34	-8.3	-0.31	6.24e-16	Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg12365402	chr11:9010492	NRIP3	-0.36	-8.35	-0.31	4.3e-16	Hemoglobin concentration;
BRCA	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg11502198	chr6:26597334	ABT1	0.44	8.22	0.31	1.1e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs7408868	0.831	rs7245850	chr19:15274585	A/C	cg14696996	chr19:15285081	NOTCH3	0.99	14.37	0.49	8.85e-41	Pulse pressure;
BRCA	trans	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg06521331	chr12:34319734	NA	-0.46	-8.5	-0.32	1.33e-16	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg06521331	chr12:34319734	NA	-0.61	-11.07	-0.4	3.68e-26	Morning vs. evening chronotype;
BRCA	cis	rs4363385	0.818	rs546666	chr1:153015385	A/G	cg25856811	chr1:152973957	SPRR3	-0.32	-8.46	-0.32	1.88e-16	Inflammatory skin disease;
BRCA	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-9.18	-0.34	5.94e-19	Systolic blood pressure;
BRCA	cis	rs8028182	0.636	rs8036758	chr15:75817562	G/A	cg20655648	chr15:75932815	IMP3	0.42	8.03	0.3	4.78e-15	Sudden cardiac arrest;
BRCA	cis	rs17818399	0.926	rs7590693	chr2:46823992	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.48	9.23	0.34	3.77e-19	Height;
BRCA	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg24829409	chr8:58192753	C8orf71	-0.46	-8.86	-0.33	7.63e-18	Developmental language disorder (linguistic errors);
BRCA	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.67	15.11	0.51	2.58e-44	Breast cancer;
BRCA	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg01884057	chr2:25150051	NA	0.34	8.85	0.33	8.67e-18	Body mass index;
BRCA	cis	rs7520050	0.931	rs6698247	chr1:46371486	C/T	cg24296786	chr1:45957014	TESK2	0.43	9.85	0.36	2.18e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg14675211	chr2:100938903	LONRF2	0.43	9.58	0.35	2.06e-20	Intelligence (multi-trait analysis);
BRCA	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	24.5	0.7	5.31e-94	Platelet count;
BRCA	cis	rs2294693	0.945	rs9349175	chr6:40982401	T/C	cg14769373	chr6:40998127	UNC5CL	-0.38	-7.86	-0.3	1.68e-14	Gastric cancer;Non-cardia gastric cancer;
BRCA	cis	rs919433	0.963	rs4850429	chr2:198178409	A/G	cg10820045	chr2:198174542	NA	0.4	8.41	0.32	2.71e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
BRCA	cis	rs10899021	0.920	rs76121309	chr11:74343921	A/T	cg25880958	chr11:74394337	NA	-0.65	-8.45	-0.32	1.99e-16	Response to metformin (IC50);
BRCA	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg16482183	chr6:26056742	HIST1H1C	0.49	9.66	0.36	1.1e-20	Iron status biomarkers;
BRCA	cis	rs2629540	0.889	rs4962696	chr10:126445630	A/G	cg08799069	chr10:126477246	METTL10	-0.54	-11.69	-0.42	9.55e-29	Cocaine dependence;
BRCA	cis	rs10779751	0.726	rs1205593	chr1:11252716	T/C	cg08854313	chr1:11322531	MTOR	0.72	14.05	0.49	2.8e-39	Body mass index;
BRCA	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg15556689	chr8:8085844	FLJ10661	0.51	14.44	0.5	3.93e-41	Mood instability;
BRCA	trans	rs629535	0.773	rs681534	chr8:70056964	A/C	cg21567404	chr3:27674614	NA	1.0	21.33	0.64	1.25e-76	Dupuytren's disease;
BRCA	cis	rs7520050	0.933	rs4504835	chr1:46455571	G/A	cg24296786	chr1:45957014	TESK2	0.44	9.81	0.36	2.95e-21	Red blood cell count;Reticulocyte count;
BRCA	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg23711669	chr6:146136114	FBXO30	0.78	18.56	0.59	7.74e-62	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg03146154	chr1:46216737	IPP	0.52	11.73	0.42	6.24e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg24977027	chr2:88469347	THNSL2	0.43	8.04	0.3	4.34e-15	Plasma clusterin levels;
BRCA	cis	rs9462027	0.628	rs9462023	chr6:34769410	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.26	-7.83	-0.3	1.98e-14	Systemic lupus erythematosus;
BRCA	cis	rs752010	1.000	rs752010	chr1:42093015	C/T	cg06885757	chr1:42089581	HIVEP3	0.27	9.65	0.36	1.12e-20	Lupus nephritis in systemic lupus erythematosus;
BRCA	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg13010199	chr12:38710504	ALG10B	-0.41	-8.75	-0.33	1.94e-17	Morning vs. evening chronotype;
BRCA	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg23625390	chr15:77176239	SCAPER	0.38	9.14	0.34	8.08e-19	Blood metabolite levels;
BRCA	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg08798685	chr6:27730294	NA	0.42	8.1	0.31	2.82e-15	Parkinson's disease;
BRCA	cis	rs758324	0.704	rs40401	chr5:131396478	C/T	cg06307176	chr5:131281290	NA	-0.41	-8.64	-0.32	4.59e-17	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg11764359	chr7:65958608	NA	0.64	11.47	0.41	7.88e-28	Aortic root size;
BRCA	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg12501888	chr15:85177176	SCAND2	-0.37	-9.31	-0.35	1.95e-19	P wave terminal force;
BRCA	cis	rs6582630	0.538	rs12305104	chr12:38336353	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-9.45	-0.35	6.24e-20	Drug-induced liver injury (flucloxacillin);
BRCA	cis	rs72781680	0.821	rs72796401	chr2:24180078	T/A	cg08917208	chr2:24149416	ATAD2B	0.62	10.44	0.38	1.18e-23	Lymphocyte counts;
BRCA	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg00321850	chr1:175162397	KIAA0040	0.43	12.31	0.44	2.06e-31	Alcohol dependence;
BRCA	cis	rs6545883	0.894	rs778158	chr2:61555421	A/G	cg15711740	chr2:61764176	XPO1	0.52	13.15	0.46	3.91e-35	Tuberculosis;
BRCA	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	9.09	0.34	1.28e-18	Tonsillectomy;
BRCA	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-11.68	-0.42	1.01e-28	Cleft plate (environmental tobacco smoke interaction);
BRCA	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg00106254	chr7:1943704	MAD1L1	-0.38	-8.85	-0.33	8.52e-18	Bipolar disorder and schizophrenia;
BRCA	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg00383909	chr3:49044727	WDR6	0.74	12.31	0.44	2.06e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
BRCA	cis	rs7246657	0.653	rs4805207	chr19:37673733	G/A	cg18154014	chr19:37997991	ZNF793	0.55	9.25	0.34	3.46e-19	Coronary artery calcification;
BRCA	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg12564285	chr5:131593104	PDLIM4	0.34	9.1	0.34	1.17e-18	Blood metabolite levels;
BRCA	cis	rs10899021	1.000	rs10899025	chr11:74367040	G/A	cg25880958	chr11:74394337	NA	-0.51	-8.0	-0.3	5.96e-15	Response to metformin (IC50);
BRCA	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg21573476	chr21:45109991	RRP1B	-0.32	-8.19	-0.31	1.44e-15	Mean corpuscular volume;
BRCA	trans	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	8.26	0.31	8.36e-16	Aortic root size;
BRCA	trans	rs208520	0.690	rs207107	chr6:66794385	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-21.23	-0.64	4.44e-76	Exhaled nitric oxide output;
BRCA	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-14.72	-0.5	1.95e-42	Chronic sinus infection;
BRCA	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg16325326	chr1:53192061	ZYG11B	0.86	23.92	0.69	8.86e-91	Monocyte count;
BRCA	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg08213375	chr14:104286397	PPP1R13B	0.64	18.28	0.59	2.23e-60	Schizophrenia;
BRCA	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg15083037	chr5:83017644	HAPLN1	-0.38	-8.56	-0.32	8.13e-17	Prostate cancer;
BRCA	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg20302533	chr7:39170763	POU6F2	0.38	7.87	0.3	1.54e-14	IgG glycosylation;
BRCA	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg23711669	chr6:146136114	FBXO30	-0.7	-16.23	-0.54	7.19e-50	Lobe attachment (rater-scored or self-reported);
BRCA	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-8.97	-0.33	3.16e-18	Tonsillectomy;
BRCA	cis	rs7246967	0.551	rs3925175	chr19:22880958	G/A	cg23217946	chr19:22817039	ZNF492	0.48	8.93	0.33	4.47e-18	Bronchopulmonary dysplasia;
BRCA	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg01324343	chr3:183735012	ABCC5	0.85	21.76	0.65	5.82e-79	Anterior chamber depth;
BRCA	cis	rs757081	0.667	rs12577525	chr11:17260116	G/A	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.68	-0.32	3.25e-17	Systolic blood pressure;
BRCA	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	16.19	0.54	1.13e-49	Platelet count;
BRCA	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg14963724	chr18:72166303	CNDP2	-0.34	-7.89	-0.3	1.29e-14	Refractive error;
BRCA	trans	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg25214090	chr10:38739885	LOC399744	-0.43	-9.9	-0.36	1.39e-21	Corneal astigmatism;
BRCA	cis	rs7091068	0.550	rs7079013	chr10:95487878	A/C	cg20715218	chr10:95462985	C10orf4	0.53	10.91	0.4	1.58e-25	Urinary tract infection frequency;
BRCA	trans	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg25214090	chr10:38739885	LOC399744	0.45	10.11	0.37	2.1e-22	Corneal astigmatism;
BRCA	cis	rs1509123	0.609	rs7224971	chr17:6713999	A/T	cg12642237	chr17:6703447	TEKT1	0.85	11.1	0.4	2.77e-26	Blood metabolite levels;
BRCA	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg19318889	chr4:1322082	MAEA	0.34	7.91	0.3	1.12e-14	Longevity;
BRCA	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg01256987	chr12:42539512	GXYLT1	-0.43	-8.28	-0.31	7.25e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
BRCA	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg20607798	chr8:58055168	NA	0.53	8.4	0.32	2.85e-16	Developmental language disorder (linguistic errors);
BRCA	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg03585969	chr10:35415529	CREM	0.56	11.5	0.41	5.77e-28	Inflammatory bowel disease;Crohn's disease;
BRCA	cis	rs12973672	1.000	rs8101606	chr19:35774556	A/C	cg12095397	chr19:35769544	USF2	0.38	8.4	0.32	2.81e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg26384229	chr12:38710491	ALG10B	0.73	15.99	0.53	1.2e-48	Morning vs. evening chronotype;
BRCA	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg06784218	chr1:46089804	CCDC17	0.5	12.03	0.43	3.45e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
BRCA	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg26408565	chr15:76604113	ETFA	0.5	11.5	0.41	5.9e-28	Blood metabolite levels;
BRCA	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	11.35	0.41	2.62e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
BRCA	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg03733263	chr8:22462867	KIAA1967	0.75	16.75	0.55	1.8e-52	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
BRCA	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg05707623	chr12:122985044	ZCCHC8	0.46	9.57	0.35	2.25e-20	Body mass index;
BRCA	cis	rs2014572	0.967	rs10413671	chr19:57763489	G/A	cg24459738	chr19:57751996	ZNF805	-0.36	-8.55	-0.32	8.76e-17	Hyperactive-impulsive symptoms;
BRCA	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg11271282	chr2:238384023	NA	0.47	8.81	0.33	1.15e-17	Prostate cancer;
BRCA	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg20307385	chr11:47447363	PSMC3	0.42	9.69	0.36	8.54e-21	Subjective well-being;
BRCA	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-9.51	-0.35	3.8e-20	Depressive symptoms (multi-trait analysis);
BRCA	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg01119278	chr6:110721349	DDO	0.42	9.92	0.37	1.13e-21	Platelet distribution width;
BRCA	cis	rs1420338	0.967	rs9655014	chr7:34148632	T/C	cg01275685	chr7:34179230	BMPER	-0.47	-10.26	-0.38	5.71e-23	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
BRCA	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg23029597	chr12:123009494	RSRC2	-0.63	-12.7	-0.45	4.06e-33	Body mass index;
BRCA	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-9.22	-0.34	4.13e-19	Eosinophil percentage of white cells;
BRCA	cis	rs6450176	1.000	rs5024170	chr5:53300827	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.62	-15.07	-0.51	3.83e-44	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
BRCA	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-10.31	-0.38	3.63e-23	Morning vs. evening chronotype;
BRCA	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg17385448	chr1:15911702	AGMAT	0.37	7.81	0.3	2.35e-14	Systolic blood pressure;
BRCA	cis	rs7707921	0.801	rs862243	chr5:81586829	C/G	cg15871215	chr5:81402204	ATG10	0.35	8.29	0.31	6.7e-16	Breast cancer;
BRCA	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00149659	chr3:10157352	C3orf10	0.67	10.24	0.38	6.96e-23	Alzheimer's disease;
BRCA	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	11.18	0.4	1.22e-26	Bipolar disorder;
BRCA	cis	rs9868809	1.000	rs2310997	chr3:48678011	G/C	cg00383909	chr3:49044727	WDR6	0.55	8.1	0.31	2.8e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
BRCA	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg25801113	chr15:45476975	SHF	0.31	8.05	0.3	4.16e-15	Uric acid levels;
BRCA	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg03354898	chr7:1950403	MAD1L1	-0.45	-9.02	-0.34	2.17e-18	Bipolar disorder and schizophrenia;
BRCA	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg20290983	chr6:43655470	MRPS18A	1.11	40.6	0.85	4.27e-179	IgG glycosylation;
BRCA	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	ch.11.42038R	chr11:967971	AP2A2	0.52	16.51	0.55	2.86e-51	Alzheimer's disease (late onset);
BRCA	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.93	0.37	1.07e-21	Bladder cancer;
BRCA	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg16482183	chr6:26056742	HIST1H1C	0.49	9.7	0.36	7.4e-21	Iron status biomarkers;
BRCA	cis	rs758324	0.947	rs9327622	chr5:131125080	T/A	cg06307176	chr5:131281290	NA	0.53	10.26	0.38	5.85e-23	Alzheimer's disease in APOE e4- carriers;
BRCA	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg20607287	chr7:12443886	VWDE	-0.58	-8.32	-0.31	5.34e-16	Coronary artery disease;
BRCA	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg11584989	chr19:19387371	SF4	0.31	8.0	0.3	5.7e-15	Tonsillectomy;
BRCA	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-10.28	-0.38	4.77e-23	Heart rate;
BRCA	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg03213289	chr20:61660250	NA	0.63	16.52	0.55	2.52e-51	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg13010199	chr12:38710504	ALG10B	0.43	9.08	0.34	1.35e-18	Morning vs. evening chronotype;
BRCA	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	16.64	0.55	6.67e-52	Hypertriglyceridemia;
BRCA	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-9.71	-0.36	7.18e-21	Body mass index;
BRCA	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg12863693	chr15:85201151	NMB	-0.34	-8.14	-0.31	2.12e-15	P wave terminal force;
BRCA	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg10011062	chr15:43941034	CATSPER2	-0.53	-7.81	-0.3	2.27e-14	Lung cancer in ever smokers;
BRCA	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	25.08	0.7	3.78e-97	Platelet count;
BRCA	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg02734326	chr4:10020555	SLC2A9	0.41	8.83	0.33	9.65e-18	Bone mineral density;
BRCA	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg22676075	chr6:135203613	NA	-0.38	-7.85	-0.3	1.71e-14	Red blood cell count;
BRCA	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg08017756	chr2:100939284	LONRF2	-0.31	-7.96	-0.3	8.17e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg17143192	chr8:8559678	CLDN23	0.52	10.08	0.37	2.88e-22	Obesity-related traits;
BRCA	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg23202291	chr11:1979235	NA	0.37	7.92	0.3	1.03e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
BRCA	cis	rs6878727	0.562	rs2633528	chr5:123641078	G/A	cg01806427	chr5:123737813	NA	-0.36	-8.0	-0.3	5.94e-15	Breast cancer;
BRCA	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-8.63	-0.32	4.8e-17	Monocyte percentage of white cells;
BRCA	cis	rs4631830	0.720	rs11004422	chr10:51498336	A/G	cg16070123	chr10:51489643	NA	0.35	7.85	0.3	1.73e-14	Prostate-specific antigen levels;
BRCA	trans	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.43	0.44	6.65e-32	Exhaled nitric oxide output;
BRCA	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg20848291	chr7:100343083	ZAN	-0.6	-11.41	-0.41	1.48e-27	Mean corpuscular hemoglobin;Mean corpuscular volume;
BRCA	cis	rs2625529	0.652	rs2957750	chr15:72332258	C/T	cg16672083	chr15:72433130	SENP8	0.67	16.06	0.54	5.26e-49	Red blood cell count;
BRCA	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg23029597	chr12:123009494	RSRC2	-0.65	-13.04	-0.46	1.3e-34	Body mass index;
BRCA	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg26031613	chr14:104095156	KLC1	-0.42	-8.45	-0.32	1.94e-16	Schizophrenia;
BRCA	cis	rs10924970	0.625	rs10925482	chr1:235499263	C/T	cg26050004	chr1:235667680	B3GALNT2	0.36	8.45	0.32	1.99e-16	Asthma;
BRCA	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03264133	chr6:25882463	NA	0.72	16.88	0.56	4e-53	Blood metabolite levels;
BRCA	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg13334819	chr7:99746414	C7orf59	-0.34	-8.11	-0.31	2.68e-15	Coronary artery disease;
BRCA	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.26	8.64	0.32	4.65e-17	Electroencephalogram traits;
BRCA	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00152838	chr16:24741724	TNRC6A	-0.36	-7.98	-0.3	6.88e-15	Intelligence (multi-trait analysis);
BRCA	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.37	-7.95	-0.3	8.63e-15	Aortic root size;
BRCA	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg24069376	chr3:38537580	EXOG	0.3	8.38	0.31	3.39e-16	Electrocardiographic conduction measures;
BRCA	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21659725	chr3:3221576	CRBN	-0.47	-12.16	-0.43	9.18e-31	Intelligence (multi-trait analysis);
BRCA	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg07148914	chr20:33460835	GGT7	-0.42	-9.1	-0.34	1.16e-18	Height;
BRCA	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg15605315	chr1:45957053	TESK2	0.46	9.45	0.35	6.53e-20	High light scatter reticulocyte count;
BRCA	cis	rs701145	0.585	rs12493885	chr3:153839866	G/C	cg12800244	chr3:153838788	SGEF	0.63	7.9	0.3	1.22e-14	Coronary artery disease;
BRCA	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg13271783	chr10:134563150	INPP5A	0.46	9.37	0.35	1.19e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
BRCA	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg11941060	chr3:133502564	NA	0.59	13.93	0.48	9.86e-39	Iron status biomarkers;
BRCA	cis	rs12210905	0.688	rs72841376	chr6:27456321	G/A	cg08851530	chr6:28072375	NA	0.81	8.01	0.3	5.42e-15	Hip circumference adjusted for BMI;
BRCA	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg11301795	chr4:187892539	NA	-0.31	-10.15	-0.37	1.55e-22	Lobe attachment (rater-scored or self-reported);
BRCA	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-9.98	-0.37	6.84e-22	Neuroticism;
BRCA	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg21770322	chr7:97807741	LMTK2	0.42	11.3	0.41	4e-27	Prostate cancer (SNP x SNP interaction);
BRCA	trans	rs9951602	0.512	rs12607938	chr18:76651887	A/C	cg02800362	chr5:177631904	HNRNPAB	0.77	18.38	0.59	6.87e-61	Obesity-related traits;
BRCA	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg14675211	chr2:100938903	LONRF2	0.52	11.96	0.43	7.15e-30	Intelligence (multi-trait analysis);
BRCA	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg20607798	chr8:58055168	NA	0.47	8.25	0.31	9.1e-16	Developmental language disorder (linguistic errors);